Serotonin B-TRIVIAL 
receptor O 
2A O 
( O 
HTR2A O 
) O 
gene O 
polymorphism O 
predicts O 
treatment O 
response O 
to O 
venlafaxine B-TRIVIAL 
XR I-TRIVIAL 
in O 
generalized O 
anxiety O 
disorder O 
. O 

anxiety O 
disorder O 
( O 
GAD O 
) O 
is O 
a O 
chronic O 
psychiatric O 
disorder O 
with O 
significant O 
morbidity O 
and O 
mortality O 
. O 
Antidepressant O 
drugs O 
are O 
the O 
preferred O 
choice O 
for O 
treatment O 
; O 
however O 
, O 
treatment O 
response O 
is O 
often O 
variable O 
. O 
Several O 
studies O 
in O 
major O 
depression O 
have O 
implicated O 
a O 
role O 
of O 
the O 
serotonin B-TRIVIAL 
receptor O 
gene O 
( O 
HTR2A O 
) O 
in O 
treatment O 
response O 
to O 
antidepressants O 
. O 
We O 
tested O 
the O 
hypothesis O 
that O 
the O 
genetic O 
polymorphism O 
rs7997012 O 
in O 
the O 
HTR2A O 
gene O 
predicts O 
treatment O 
outcome O 
in O 
GAD O 
patients O 
treated O 
with O 
venlafaxine B-TRIVIAL 
XR I-TRIVIAL 
. O 
Treatment O 
response O 
was O 
assessed O 
in O 
156 O 
patients O 
that O 
participated O 
in O 
a O 
6-month O 
open O 
- O 
label O 
clinical O 
trial O 
of O 
venlafaxine B-TRIVIAL 
XR I-TRIVIAL 
for O 
GAD O 
. O 
Primary O 
analysis O 
included O 
Hamilton O 
Anxiety O 
Scale O 
( O 
HAM-A O 
) O 
reduction O 
at O 
6 O 
months O 
. O 
Secondary O 
outcome O 
measure O 
was O 
the O 
Clinical O 
Global O 
Impression O 
of O 
Improvement O 
( O 
CGI-I O 
) O 
score O 
at O 
6 O 
months O 
. O 
Genotype O 
and O 
allele O 
frequencies O 
were O 
compared O 
between O 
groups O 
using O 
χ(2) O 
contingency O 
analysis O 
. O 
The O 
frequency O 
of O 
the O 
G-allele O 
differed O 
significantly O 
between O 
responders O 
( O 
70% O 
) O 
and O 
nonresponders O 
( O 
56% O 
) O 
at O 
6 O 
months O 
( O 
P=0.05 O 
) O 
using O 
the O 
HAM-A O 
scale O 
as O 
outcome O 
measure O 
. O 
Similarly O 
, O 
using O 
the O 
CGI-I O 
as O 
outcome O 
, O 
the O 
G-allele O 
was O 
significantly O 
associated O 
with O 
improvement O 
( O 
P=0.01 O 
) O 
. O 
Assuming O 
a O 
dominant O 
effect O 
of O 
the O 
G-allele O 
, O 
improvement O 
differed O 
significantly O 
between O 
groups O 
( O 
P=0.001 O 
, O 
odds O 
ratio=4.72 O 
) O 
. O 
Similar O 
trends O 
were O 
observed O 
for O 
remission O 
although O 
not O 
statistically O 
significant O 
. O 
We O 
show O 
for O 
the O 
first O 
time O 
a O 
pharmacogenetic O 
effect O 
of O 
the O 
HTR2A O 
rs7997012 O 
variant O 
in O 
anxiety O 
disorders O 
, O 
suggesting O 
that O 
pharmacogenetic O 
effects O 
cross O 
diagnostic O 
categories O 
. O 
Our O 
data O 
document O 
that O 
individuals O 
with O 
the O 
HTR2A O 
rs7997012 O 
single O 
nucleotide O 
polymorphism O 
G-allele O 
have O 
better O 
treatment O 
outcome O 
over O 
time O 
. O 
Future O 
studies O 
with O 
larger O 
sample O 
sizes O 
are O 
necessary O 
to O 
further O 
characterize O 
this O 
effect O 
in O 
treatment O 
response O 
to O 
antidepressants O 
in O 
GAD O 
. O 

children O 
are O 
exposed O 
to O 
environmental O 
pollutants O 
via O 
the O 
placenta O 
, O 
and O 
there O 
is O 
a O 
causal O 
relationship O 
between O 
maternal O 
intake O 
of O 
pollutants O 
and O 
fetal O 
exposure O 
. O 
Placental O 
examination O 
is O 
an O 
effective O 
way O 
for O 
acquiring O 
data O 
for O 
estimating O 
fetal O 
exposure O 
. O 
We O 
analyzed O 
the O 
concentrations O 
of O 
104 O 
congeners O 
of O 
persistent O 
organic O 
pollutants O 
, O 
seven O 
organotin O 
compounds O 
, O 
five O 
heavy O 
metals O 
, O 
and O 
methylmercury B-SYSTEMATIC 
in O 
130 O 
randomly O 
selected O 
placentas O 
. O 
Additionally O 
, O 
we O 
examined O 
similarities O 
between O 
pollutant O 
concentrations O 
by O 
analyzing O 
correlations O 
between O 
their O 
placental O 
concentrations O 
. O 
Our O 
results O 
yield O 
new O 
information O 
for O 
conducting O 
contaminant O 
risk O 
assessments O 
for O 
the O 
prenatal O 
period O 
. O 
Out O 
of O 
the O 
117 O 
individual O 
persistent O 
organic O 
pollutants O 
or O 
metals O 
assayed O 
, O 
46 O 
could O 
be O 
detected O 
in O 
more O 
than O 
half O 
of O 
the O 
placentas O 
. O 
Moreover O 
, O 
dichlorodiphenyldichloroethylene B-SYSTEMATIC 
( O 
p,p'-DDE B-SYSTEMATIC 
) O 
was O 
found O 
in O 
all O 
placentas O 
. O 
The O 
data O 
indicates O 
that O 
fetal O 
exposure O 
to O 
dioxins B-FAMILY 
and O 
furans B-FAMILY 
( O 
PCDD B-ABBREVIATION 
/ O 
Fs O 
) O 
, O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
( O 
PCBs B-ABBREVIATION 
) O 
, O 
p,p'-DDE B-SYSTEMATIC 
, O 
and O 
methylmercury B-SYSTEMATIC 
depends O 
on O 
the O 
mother's O 
parity O 
, O 
and O 
age O 
. O 
We O 
also O 
conclude O 
that O 
sources O 
of O 
the O 
above O 
four O 
pollutants O 
are O 
similar O 
but O 
differ O 
from O 
the O 
sources O 
of O 
polybrominated B-FAMILY 
diphenyl I-FAMILY 
ethers I-FAMILY 
. O 

fish O 
ingredient O 
N3-docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
22 O 
: O 
6 O 
n-3 O 
( O 
DHA B-ABBREVIATION 
) O 
stimulates O 
brain O 
development O 
. O 
On O 
the O 
other O 
hand O 
methylmercury B-SYSTEMATIC 
( O 
MeHg B-FORMULA 
) O 
in O 
fish O 
disturbs O 
the O 
developing O 
central O 
nervous O 
system O 
. O 
In O 
this O 
Context O 
the O 
IQ O 
score O 
in O 
children O 
is O 
considered O 
as O 
an O 
aggregate O 
measure O 
of O 
in O 
utero O 
brain O 
development O 
. O 
To O 
determine O 
the O 
effect O 
of O 
DHA B-ABBREVIATION 
exposure O 
on O 
prenatal O 
neurodevelopment O 
the O 
maternal O 
DHA B-ABBREVIATION 
intake O 
during O 
pregnancy O 
was O 
compared O 
with O 
its O 
epidemiologically O 
observed O 
effect O 
on O 
the O 
IQ O 
score O 
of O 
children O 
. O 
For O 
MeHg B-FORMULA 
the O 
maternal O 
intake O 
was O 
converted O 
into O 
its O 
accumulation O 
in O 
the O 
maternal O 
body O 
. O 
The O 
maternal O 
body O 
burden O 
then O 
was O 
compared O 
with O 
its O 
epidemiologically O 
observed O 
relationship O 
with O 
the O 
IQ O 
score O 
. O 
Taking O 
the O 
MeHg B-FORMULA 
and O 
DHA B-ABBREVIATION 
content O 
of O 
33 O 
fish O 
species O 
the O 
net O 
effect O 
of O 
these O 
compounds O 
on O 
the O 
IQ O 
score O 
was O 
quantified O 
. O 
For O 
most O 
fish O 
species O 
the O 
adverse O 
effect O 
of O 
MeHg B-FORMULA 
on O 
the O 
IQ O 
score O 
exceeded O 
the O 
beneficial O 
effect O 
of O 
DHA B-ABBREVIATION 
. O 
In O 
the O 
case O 
of O 
long O 
- O 
living O 
predators O 
a O 
negative O 
effect O 
up O 
to O 
10 O 
points O 
on O 
the O 
IQ O 
score O 
was O 
found O 
. O 
The O 
results O 
of O 
this O 
study O 
indicate O 
that O 
food O 
interventions O 
aiming O 
at O 
the O 
beneficial O 
effects O 
of O 
fish O 
consumption O 
should O 
focus O 
on O 
fish O 
species O 
with O 
a O 
high O 
DHA B-ABBREVIATION 
content O 
, O 
while O 
avoiding O 
fish O 
species O 
with O 
a O 
high O 
MeHg B-FORMULA 
content O 
. O 

harmful O 
effects O 
of O 
folkloric O 
uses O 
of O 
Nigerian O 
bonny O 
light O 
crude O 
oil O 
( O 
BLCO O 
) O 
in O 
ailments O 
management O 
may O 
outweigh O 
the O 
expected O 
beneficial O 
effects O 
. O 
We O 
investigated O 
the O 
levels O 
of O 
heavy O 
metal O 
concentrations O 
in O 
the O 
tissues O 
as O 
well O 
as O 
the O 
effect O 
of O 
BLCO O 
on O 
the O 
antioxidant O 
status O 
of O 
erythrocytes O 
of O 
rats O 
after O 
oral O 
exposure O 
to O 
0 O 
, O 
200 O 
and O 
800 O 
mg O 
/ O 
kg O 
BLCO O 
for O 
7 O 
days O 
. O 
Analysis O 
of O 
heavy O 
metal O 
concentrations O 
in O 
BLCO O 
showed O 
that O 
Zn B-FORMULA 
> O 
Fe B-FORMULA 
> O 
Pb B-FORMULA 
> O 
Cu B-FORMULA 
> O 
Ni B-FORMULA 
. O 
The O 
trend O 
of O 
accumulation O 
of O 
the O 
metals O 
in O 
the O 
tissues O 
is O 
blood- O 
Fe B-FORMULA 
> O 
Pb B-FORMULA 
> O 
Zn B-FORMULA 
whereas O 
Cu B-FORMULA 
and O 
Ni B-FORMULA 
levels O 
were O 
not O 
affected O 
; O 
Liver- O 
Ni B-FORMULA 
> O 
Zn B-FORMULA 
> O 
Fe B-FORMULA 
> O 
Cu B-FORMULA 
> O 
Pb B-FORMULA 
and O 
Testes- O 
Ni B-FORMULA 
> O 
Cu B-FORMULA 
> O 
Pb B-FORMULA 
> O 
Zn B-FORMULA 
> O 
Fe B-FORMULA 
. O 
The O 
order O 
of O 
concentration O 
of O 
the O 
metals O 
in O 
the O 
tissues O 
is O 
as O 
follows O 
: O 
iron B-SYSTEMATIC 
-blood O 
> O 
liver O 
> O 
testes O 
; O 
zinc B-SYSTEMATIC 
-liver O 
> O 
blood O 
> O 
testes O 
; O 
lead O 
- O 
blood O 
> O 
liver O 
> O 
testes O 
; O 
copper B-SYSTEMATIC 
-testes O 
> O 
liver O 
> O 
blood O 
; O 
nickel B-SYSTEMATIC 
-liver O 
> O 
testes O 
> O 
blood O 
. O 
Activities O 
of O 
the O 
antioxidant O 
enzymes O 
of O 
erythrocytes O 
such O 
as O 
superoxide B-TRIVIAL 
dismutase O 
, O 
catalase O 
, O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
increased O 
significantly O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
with O 
significant O 
elevation O 
in O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
and O 
malondialdehyde B-TRIVIAL 
levels O 
, O 
whereas O 
glutathione B-TRIVIAL 
level O 
was O 
not O 
significantly O 
decreased O 
in O 
BLCO O 
- O 
treated O 
animals O 
. O 
Collectively O 
, O 
the O 
results O 
showed O 
that O 
BLCO O 
induces O 
oxidative O 
damage O 
to O 
erythrocytes O 
of O 
rats O 
. O 

flower O 
volatile O 
compounds O 
( O 
FVCs O 
) O 
of O 
two O 
tetraploid O 
Freesia O 
hybrida O 
( O 
pink O 
- O 
yellow O 
and O 
yellow O 
) O 
cultivars O 
and O 
their O 
cut O 
flowers O 
were O 
analysed O 
by O 
headspace O 
solid O 
- O 
phase O 
microextraction O 
combined O 
with O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
. O 
Twelve O 
FVCs O 
were O 
identified O 
in O 
the O 
pink O 
- O 
yellow O 
cultivar O 
, O 
with O 
linalool B-TRIVIAL 
as O 
the O 
major O 
compound O 
; O 
30 O 
FVCs O 
were O 
identified O 
in O 
the O 
yellow O 
cultivar O 
, O 
with O 
linalool B-TRIVIAL 
and O 
terpineol B-TRIVIAL 
as O 
the O 
two O 
major O 
compounds O 
. O 
The O 
FVCs O 
( O 
> O 
1% O 
) O 
of O 
the O 
two O 
cut O 
flower O 
cultivars O 
were O 
very O 
similar O 
to O 
that O 
of O 
the O 
un O 
- O 
cut O 
flowers O 
, O 
and O 
no O 
significant O 
difference O 
was O 
observed O 
. O 

organic O 
compounds O 
of O 
Schenella O 
pityophilus O 
have O 
been O 
identified O 
via O 
solid O 
- O 
phase O 
microextraction O 
- O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
analysis O 
. O 
Ten O 
compounds O 
have O 
been O 
identified O 
, O 
in O 
which O 
3-methylthio-1-propene B-SYSTEMATIC 
was O 
the O 
most O 
significant O 
component O 
. O 
Some O 
other O 
components O 
were O 
previously O 
identified O 
in O 
Tuber O 
aestivum O 
and O 
Tuber O 
melanosporum O 
. O 

and O 
tetronic B-FAMILY 
acids I-FAMILY 
from O 
Penicillium O 
griseoroseum O 
. O 

our O 
continuous O 
studies O 
on O 
the O 
chemistry O 
of O 
the O 
endophytic O 
fungus O 
Penicillium O 
griseoroseum O 
, O 
an O 
endophyte O 
isolated O 
from O 
fruits O 
of O 
Coffea O 
arabica O 
, O 
we O 
isolated O 
clavatol B-TRIVIAL 
, O 
a O 
dimethylated B-FAMILY 
tetraketide I-FAMILY 
, O 
and O 
its O 
dimer O 
which O 
appears O 
to O 
be O 
a O 
novel O 
natural O 
compound O 
. O 
The O 
studies O 
also O 
resulted O 
in O 
the O 
identification O 
of O 
two O 
known O 
tetronic B-FAMILY 
acids I-FAMILY 
, O 
viridicatic B-TRIVIAL 
acid I-TRIVIAL 
and O 
terrestric B-TRIVIAL 
acid I-TRIVIAL 
, O 
found O 
in O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
and O 
n-butanol B-SYSTEMATIC 
extracts O 
. O 
Spectroscopic O 
studies O 
using O 
1-D O 
and O 
2-D O 
NMR O 
and O 
MS O 
/ O 
MS O 
analysis O 
were O 
performed O 
to O 
determine O 
the O 
structures O 
of O 
these O 
compounds O 
, O 
first O 
reported O 
by O 
this O 
Penicillium O 
. O 
Two O 
other O 
tetronic B-FAMILY 
acids I-FAMILY 
congeners O 
were O 
identified O 
through O 
HPLC O 
/ O 
MS O 
/ O 
MS O 
studies O 
, O 
based O 
on O 
fragmentation O 
pattern O 
of O 
ions O 
produced O 
from O 
ionised O 
tetronic B-FAMILY 
acids I-FAMILY 
, O 
and O 
UV O 
light O 
absorptions O 
. O 

essential O 
oils O 
obtained O 
by O 
hydrodistillation O 
from O 
the O 
leaves O 
of O 
Tabernaemontana O 
catharinensis O 
had O 
their O 
composition O 
analysed O 
by O 
GC-MS O 
. O 
A O 
total O 
of O 
18 O 
substances O 
were O 
identified O 
, O 
consisting O 
of O 
a O 
complex O 
mixture O 
of O 
sesquiterpenes B-FAMILY 
( O 
83.52% O 
) O 
, O 
monoterpenes B-FAMILY 
( O 
5.46% O 
) O 
and O 
triterpenes B-FAMILY 
( O 
4.56% O 
) O 
. O 
The O 
main O 
components O 
in O 
the O 
oil O 
were O 
β-caryophyllene B-TRIVIAL 
( O 
56.87% O 
) O 
, O 
α-cadinol B-TRIVIAL 
( O 
12.52% O 
) O 
, O 
8S,13-cedran- B-SYSTEMATIC 
diol I-SYSTEMATIC 
( O 
5.41% O 
) O 
, O 
α-terpineol B-TRIVIAL 
( O 
3.99% O 
) O 
, O 
β-eudesmol B-TRIVIAL 
( O 
2.54% O 
) O 
, O 
caryophyllene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
2.51% O 
) O 
and O 
ethyl B-SYSTEMATIC 
iso-allocholate I-SYSTEMATIC 
( O 
2.03% O 
) O 
along O 
with O 
β-cubebene B-TRIVIAL 
, O 
γ-cadinene B-TRIVIAL 
, O 
cubenol B-TRIVIAL 
, O 
1,8-cineol B-TRIVIAL 
, O 
o-cymene B-TRIVIAL 
, O 
curcumenol B-TRIVIAL 
, O 
spathulenol B-TRIVIAL 
, O 
friedeline B-TRIVIAL 
and O 
β-sitosterol B-TRIVIAL 
as O 
minor O 
constituents O 
. O 
An O 
antioxidant O 
property O 
was O 
tested O 
with O 
the O 
oil O 
obtained O 
by O 
means O 
of O 
1,1-diphenyl-2-picrylhydrazyl B-SYSTEMATIC 
assay O 
; O 
the O 
oil O 
presented O 
interesting O 
radical O 
scavenging O 
activity O 
. O 
To O 
the O 
best O 
of O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
study O 
of O 
the O 
composition O 
and O 
antioxidant O 
activity O 
of O 
essential O 
oil O 
from O 
the O 
T O 
. O 
catharinensis O 
collected O 
from O 
Brazil O 
. O 

tea O 
extract O 
alleviates O 
arsenic B-SYSTEMATIC 
-induced O 
biochemical O 
toxicity O 
and O 
lipid O 
peroxidation O 
in O 
rats O 
. O 

present O 
work O 
was O 
undertaken O 
to O 
evaluate O 
the O 
protective O 
effect O 
of O 
an O 
aqueous O 
extract O 
of O 
green O 
tea O 
( O 
GT O 
, O 
Camellia O 
sinensis O 
) O 
leaves O 
against O 
arsenic B-SYSTEMATIC 
( O 
NaAsO2 B-FORMULA 
)-induced O 
biochemical O 
toxicity O 
and O 
lipid O 
peroxidation O 
production O 
in O 
experimental O 
rats O 
. O 
The O 
treatment O 
with O 
arsenic B-SYSTEMATIC 
exhibited O 
a O 
significant O 
increase O 
in O 
some O 
serum O 
hepatic O 
and O 
renal O 
biochemical O 
parameters O 
( O 
alanine B-TRIVIAL 
aminotransferase O 
, O 
aspartate B-TRIVIAL 
aminotransferase O 
, O 
alkaline O 
phosphatase O 
, O 
total O 
protein O 
, O 
albumin O 
, O 
bilirubin B-TRIVIAL 
, O 
cholesterol B-TRIVIAL 
, O 
urea B-TRIVIAL 
and O 
creatinine B-TRIVIAL 
) O 
. O 
But O 
the O 
co O 
- O 
administration O 
of O 
GT O 
has O 
increased O 
the O 
level O 
of O 
plasmatic O 
concentration O 
of O 
biochemical O 
parameters O 
. O 
Exposure O 
of O 
rats O 
to O 
arsenic B-SYSTEMATIC 
caused O 
also O 
a O 
significant O 
increase O 
in O 
liver O 
, O 
kidney O 
and O 
testicular O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
reactive O 
substances O 
compared O 
to O 
control O 
. O 
However O 
, O 
the O 
co O 
- O 
administration O 
of O 
GT O 
was O 
effective O 
in O 
reducing O 
its O 
level O 
. O 
To O 
conclude O 
, O 
our O 
data O 
suggest O 
that O 
arsenic B-SYSTEMATIC 
exposure O 
enhanced O 
an O 
oxidative O 
stress O 
by O 
disturbing O 
the O 
tissue O 
antioxidant O 
defense O 
system O 
, O 
but O 
the O 
GT O 
co O 
- O 
administration O 
alleviates O 
the O 
toxicity O 
induced O 
by O 
arsenic B-SYSTEMATIC 
exposure O 
. O 

in O 
carbohydrate B-FAMILY 
metabolism O 
, O 
oxidative O 
stress O 
and O 
loss O 
of O 
cortisol B-TRIVIAL 
secretion O 
in O 
adrenocortica O 
l O 
cells O 
of O 
Oreochromis O 
niloticus O 
exposed O 
in O 
vitro O 
to O 
endosulfan B-TRIVIAL 
. O 

effects O 
of O 
endosulfan B-TRIVIAL 
, O 
an O 
organochlorine B-FAMILY 
pesticide O 
regularly O 
used O 
in O 
Niger O 
Delta O 
ecological O 
zone O 
, O 
were O 
examined O 
and O 
also O 
its O 
effects O 
on O 
various O 
biochemical O 
parameters O 
in O 
the O 
serum O 
of O 
Oreochromis O 
niloticus O 
, O 
a O 
dominant O 
fish O 
species O 
in O 
Nigeria O 
. O 
One O 
hundred O 
and O 
fifty O 
juveniles O 
of O 
O O 
. O 
niloticus O 
were O 
used O 
for O 
the O 
toxicity O 
study O 
. O 
Lethal O 
concentration O 
of O 
50% O 
mortality O 
of O 
sample O 
( O 
LC50 O 
) O 
was O 
determined O 
using O 
semi-static O 
method O 
. O 
From O 
the O 
result O 
of O 
the O 
LC50 O 
determination O 
, O 
lower O 
concentrations O 
of O 
endosulfan B-TRIVIAL 
were O 
prepared O 
for O 
sublethal O 
test O 
. O 
Five O 
fish O 
per O 
test O 
concentration O 
in O 
three O 
replicates O 
were O 
exposed O 
to O 
varying O 
concentrations O 
of O 
endosulfan B-TRIVIAL 
. O 
Glucose B-TRIVIAL 
level O 
and O 
the O 
enzyme O 
activities O 
were O 
measured O 
spectrophotometrically O 
at O 
the O 
end O 
of O 
28 O 
days O 
of O 
exposure O 
. O 
Glucose B-TRIVIAL 
levels O 
and O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
activities O 
were O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
higher O 
than O 
the O 
control O 
and O 
the O 
concentrations O 
increased O 
with O 
increasing O 
concentration O 
of O 
the O 
toxicant O 
and O 
exposure O 
duration O 
. O 
Cortisol B-TRIVIAL 
secretion O 
was O 
significantly O 
( O 
p O 
= O 
0.05 O 
) O 
lower O 
in O 
the O 
treated O 
fish O 
than O 
the O 
control O 
. O 
These O 
findings O 
indicated O 
that O 
endosulfan B-TRIVIAL 
altered O 
all O 
the O 
investigated O 
parameters O 
, O 
which O 
is O 
an O 
indication O 
of O 
their O 
suitability O 
as O 
markers O 
for O 
fish O 
and O 
other O 
aquatic O 
organism O 
toxicity O 
study O 
. O 

of O 
aflatoxin B-TRIVIAL 
M1 I-TRIVIAL 
in O 
milk O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
in O 
Mashhad O 
( O 
north O 
east O 
of O 
Iran O 
) O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
aflatoxin B-TRIVIAL 
M1 I-TRIVIAL 
( O 
AFM1 B-ABBREVIATION 
) O 
contamination O 
in O 
milk O 
samples O 
in O 
Mashhad O 
in O 
Iran O 
. O 
A O 
total O 
of O 
60 O 
milk O 
samples O 
were O 
collected O 
from O 
retail O 
stores O 
of O 
five O 
regions O 
in O 
June O 
2011 O 
. O 
The O 
occurrence O 
and O 
concentration O 
range O 
of O 
AFM1 B-ABBREVIATION 
in O 
the O 
samples O 
were O 
investigated O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
method O 
. O 
AFM1 B-ABBREVIATION 
was O 
found O 
in O 
100% O 
of O 
the O 
examined O 
milk O 
samples O 
by O 
average O 
concentration O 
of O 
16.16 O 
ng O 
/ O 
L O 
and O 
the O 
contamination O 
level O 
ranging O 
between O 
2 O 
and O 
64 O 
ng O 
/ O 
L O 
. O 
The O 
concentration O 
of O 
AFM1 B-ABBREVIATION 
in O 
all O 
the O 
samples O 
was O 
lower O 
than O 
the O 
Iranian O 
national O 
standard O 
and O 
Food O 
and O 
Drug O 
Administration O 
limit O 
( O 
500 O 
ng O 
/ O 
L O 
) O 
, O 
and O 
only O 
in O 
one O 
( O 
1.6% O 
) O 
of O 
the O 
samples O 
, O 
the O 
concentration O 
of O 
AFM1 B-ABBREVIATION 
was O 
greater O 
than O 
the O 
maximum O 
tolerance O 
limit O 
( O 
50 O 
ng O 
/ O 
L O 
) O 
accepted O 
by O 
European O 
Union O 
and O 
Codex O 
Alimentarius O 
Commission O 
. O 
Statistical O 
evaluation O 
showed O 
no O 
significant O 
difference O 
between O 
the O 
mean O 
concentrations O 
of O 
AFM1 B-ABBREVIATION 
in O 
milk O 
samples O 
taken O 
from O 
different O 
regions O 
( O 
p O 
> O 
0.05 O 
) O 
. O 

distribution O 
of O 
metabotropic O 
glutamate B-TRIVIAL 
2 O 
and O 
3 O 
receptors O 
: O 
transgenic O 
mice O 
and O 
[³H]LY459477 B-SYSTEMATIC 
autoradiography O 
. O 

II O 
metabotropic O 
glutamate B-TRIVIAL 
( O 
mGlu O 
) O 
receptor O 
agonists O 
were O 
efficacious O 
in O 
randomized O 
clinical O 
research O 
trials O 
for O 
schizophrenia O 
and O 
generalized O 
anxiety O 
disorder O 
. O 
The O 
regional O 
quantification O 
of O 
mGlu(2) O 
and O 
mGlu(3) O 
receptors O 
remains O 
unknown O 
. O 
A O 
selective O 
and O 
structurally O 
novel O 
mGlu(2 O 
/ O 
3 O 
) O 
receptor O 
agonist O 
, O 
2-amino-4-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-amino-4-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
LY459477 B-IDENTIFIER 
) O 
was O 
tritiated O 
and O 
the O 
distribution O 
of O 
mGlu(2) O 
and O 
mGlu(3) O 
receptors O 
was O 
studied O 
in O 
transgenic O 
mice O 
lacking O 
either O 
mGlu(2) O 
, O 
mGlu(3) O 
or O 
both O 
receptors O 
. O 
LY459477 B-IDENTIFIER 
is O 
an O 
agonist O 
with O 
1-2 O 
nM O 
potency O 
for O 
rodent O 
and O 
human O 
mGlu(2) O 
and O 
mGlu(3) O 
receptors O 
. O 
The O 
functional O 
selectivity O 
of O 
LY459477 B-IDENTIFIER 
was O 
demonstrated O 
by O 
over O 
640-fold O 
selectivity O 
and O 
the O 
displacement O 
binding O 
selectivity O 
was O 
greater O 
than O 
320-fold O 
for O 
all O 
glutamate B-TRIVIAL 
receptors O 
except O 
mGlu(6) O 
( O 
∼230-fold O 
) O 
. O 
More O 
than O 
1000-fold O 
selectivity O 
was O 
demonstrated O 
for O 
all O 
non- O 
glutamate B-TRIVIAL 
receptors O 
known O 
to O 
be O 
targeted O 
by O 
antipsychotic O 
drugs O 
. O 
Like O 
atypical O 
antipsychotic O 
drugs O 
, O 
LY459477 B-IDENTIFIER 
reversed O 
in O 
vitro O 
electrophysiological O 
effects O 
of O 
a O 
serotonergic O 
hallucinogen O 
and O 
behavioral O 
effects O 
of O 
phencyclidine B-TRIVIAL 
or O 
amphetamine B-TRIVIAL 
. O 
There O 
was O 
virtually O 
no O 
binding O 
of O 
[(3)H]LY459477 B-SYSTEMATIC 
to O 
any O 
brain O 
region O 
in O 
mice O 
with O 
a O 
deletion O 
of O 
both O 
mGlu(2) O 
and O 
mGlu(3) O 
receptors O 
. O 
Regions O 
enriched O 
in O 
mGlu(2) O 
receptors O 
included O 
the O 
medial O 
prefrontal O 
cortex O 
, O 
select O 
hippocampal O 
regions O 
, O 
the O 
medial O 
mammillary O 
nucleus O 
, O 
the O 
medial O 
habenula O 
, O 
and O 
the O 
cerebellar O 
granular O 
cell O 
layer O 
. O 
Regions O 
enriched O 
in O 
mGlu(3) O 
receptors O 
were O 
the O 
dorsolateral O 
entorhinal O 
cortex O 
, O 
the O 
hippocampal O 
CA1 O 
field O 
, O 
the O 
piriform O 
cortex O 
, O 
the O 
substantia O 
nigra O 
, O 
the O 
thalamic O 
reticular O 
nucleus O 
, O 
and O 
primary O 
sensory O 
thalamic O 
nuclei O 
. O 
These O 
findings O 
suggest O 
[(3)H]LY459477 B-SYSTEMATIC 
should O 
be O 
a O 
useful O 
tool O 
to O 
further O 
define O 
the O 
role O 
of O 
mGlu(2) O 
and O 
mGlu(3) O 
receptors O 
throughout O 
the O 
brain O 
with O 
respect O 
to O 
major O 
neuropsychiatric O 
syndromes O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

, O 
in O 
vitro O 
and O 
in O 
vivo O 
evaluation O 
of O 
transdermal O 
patches O 
containing O 
risperidone B-TRIVIAL 
. O 

efficacy O 
of O 
oral O 
risperidone B-TRIVIAL 
treatment O 
in O 
prevention O 
of O 
schizophrenia O 
is O 
well O 
known O 
. O 
However O 
, O 
oral O 
side O 
effects O 
and O 
patient O 
compliance O 
is O 
always O 
a O 
problem O 
for O 
schizophrenics O 
. O 
In O 
this O 
study O 
, O 
risperidone B-TRIVIAL 
was O 
formulated O 
into O 
matrix O 
transdermal O 
patches O 
to O 
overcome O 
these O 
problems O 
. O 
The O 
formulation O 
factors O 
for O 
such O 
patches O 
, O 
including O 
eudragit B-FAMILY 
RL I-FAMILY 
100 I-FAMILY 
and O 
eudragit B-FAMILY 
RS I-FAMILY 
100 I-FAMILY 
as O 
matrix O 
forming O 
polymers O 
, O 
olive O 
oil O 
, O 
groundnut O 
oil O 
and O 
jojoba O 
oil O 
in O 
different O 
concentrations O 
as O 
enhancers O 
and O 
amount O 
of O 
drug O 
loaded O 
were O 
investigated O 
. O 
The O 
transdermal O 
patches O 
containing O 
risperidone B-TRIVIAL 
were O 
prepared O 
by O 
solvent O 
casting O 
method O 
and O 
characterized O 
for O 
physicochemical O 
and O 
in O 
vitro O 
permeation O 
studies O 
through O 
excised O 
rat O 
skin O 
. O 
Among O 
the O 
tested O 
preparations O 
, O 
formulations O 
with O 
20% O 
risperidone B-TRIVIAL 
, O 
3 O 
: O 
2 O 
ERL B-FAMILY 
100 I-FAMILY 
and O 
ERS B-FAMILY 
100 I-FAMILY 
as O 
polymers O 
, O 
mixture O 
of O 
olive O 
oil O 
and O 
jojoba O 
oil O 
as O 
enhancer O 
, O 
exhibited O 
greatest O 
cumulative O 
amount O 
of O 
drug O 
permeated O 
( O 
1.87 O 
± O 
0.09 O 
mg O 
/ O 
cm(2) O 
) O 
in O 
72 O 
h O 
, O 
so O 
batch O 
ROJ O 
was O 
concluded O 
as O 
optimized O 
formulation O 
and O 
assessed O 
for O 
pharmacokinetic O 
, O 
pharmacodynamic O 
and O 
skin O 
irritation O 
potential O 
. O 
The O 
pharmacokinetic O 
characteristics O 
of O 
the O 
optimized O 
risperidone B-TRIVIAL 
patch O 
were O 
determined O 
using O 
rabbits O 
, O 
while O 
orally O 
administered O 
risperidone B-TRIVIAL 
in O 
solution O 
was O 
used O 
for O 
comparison O 
. O 
The O 
calculated O 
relative O 
bioavailability O 
of O 
risperidone B-TRIVIAL 
transdermal O 
patch O 
was O 
115.20% O 
with O 
prolonged O 
release O 
of O 
drug O 
. O 
Neuroleptic O 
efficacy O 
of O 
transdermal O 
formulation O 
was O 
assessed O 
by O 
rota O 
- O 
rod O 
and O 
grip O 
test O 
in O 
comparison O 
with O 
control O 
and O 
marketed O 
oral O 
formulations O 
with O 
no O 
skin O 
irritation O 
. O 
This O 
suggests O 
the O 
transdermal O 
application O 
of O 
risperidone B-TRIVIAL 
holds O 
promise O 
for O 
improved O 
bioavailability O 
and O 
better O 
management O 
of O 
schizophrenia O 
in O 
long O 
- O 
term O 
basis O 
. O 

composition O 
of O 
essential O 
oil O 
of O 
the O 
seeds O 
of O 
Artemisia O 
annua O 
L O 
. O 
was O 
analysed O 
by O 
GC-MS O 
. O 
Overall O 
, O 
16 O 
volatile O 
components O 
were O 
identified O 
on O 
the O 
basis O 
of O 
their O 
mass O 
spectra O 
characteristics O 
and O 
retention O 
indices O 
representing O 
95.5% O 
of O 
the O 
total O 
oil O 
. O 
Trans-3(10)-caren-4-ol B-SYSTEMATIC 
( O 
22.3% O 
) O 
, O 
artemisia B-TRIVIAL 
ketone I-TRIVIAL 
( O 
18.6% O 
) O 
, O 
1,8-cineole B-SYSTEMATIC 
( O 
14.9% O 
) O 
, O 
δ-selinene B-TRIVIAL 
( O 
13.0% O 
) O 
and O 
α-pinene B-TRIVIAL 
( O 
8.2% O 
) O 
were O 
the O 
major O 
compounds O 
. O 
Oxygenated O 
monoterpenes B-FAMILY 
were O 
the O 
main O 
compounds O 
with O 
51.6% O 
followed O 
by O 
sesquiterpene B-FAMILY 
hydrocarbons I-FAMILY 
( O 
13.3% O 
) O 
, O 
monoterpene B-FAMILY 
hydrocarbons I-FAMILY 
( O 
9.9% O 
) O 
and O 
other O 
compounds O 
( O 
8.3% O 
) O 
. O 
The O 
essential O 
oil O 
was O 
highly O 
active O 
against O 
Escherichia O 
coli O 
and O 
Enterococcus O 
faecalis O 
. O 

and O 
survival O 
of O 
an O 
organism O 
depend O 
on O 
its O 
ability O 
to O 
mount O 
a O 
successful O 
stress O 
response O 
when O 
challenged O 
by O 
exposure O 
to O 
damaging O 
agents O 
. O 
We O 
hypothesized O 
that O 
co O 
- O 
exposure O 
to O 
contaminants O 
may O 
exacerbate O 
oxidative O 
stress O 
in O 
hypoxia O 
- O 
challenged O 
benthic O 
animals O 
compromising O 
their O 
ability O 
to O 
recover O 
upon O 
reoxygenation O 
. O 
This O 
was O 
tested O 
using O 
the O 
amphipod O 
Monoporeia O 
affinis O 
exposed O 
to O 
hypoxia O 
followed O 
by O 
reoxygenation O 
in O 
sediments O 
collected O 
in O 
polluted O 
and O 
pristine O 
areas O 
. O 
In O 
both O 
sediment O 
types O 
, O 
oxygen B-SYSTEMATIC 
radical O 
absorbance O 
capacity O 
( O 
ORAC O 
) O 
and O 
antioxidant O 
enzyme O 
activities O 
[ O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
and O 
catalase O 
( O 
CAT O 
) O 
] O 
increased O 
during O 
hypoxia O 
, O 
suggesting O 
that O 
M O 
. O 
affinis O 
has O 
a O 
strategy O 
of O 
preparation O 
for O 
oxidative O 
stress O 
that O 
facilitates O 
recovery O 
after O 
a O 
hypoxic O 
episode O 
. O 
Exposure O 
to O 
contaminants O 
altered O 
this O 
anticipatory O 
response O 
as O 
indicated O 
by O 
higher O 
baselines O 
of O 
ORAC O 
and O 
SOD O 
during O 
hypoxia O 
and O 
no O 
response O 
upon O 
reoxygenation O 
. O 
This O 
coincided O 
with O 
significantly O 
elevated O 
oxidative O 
damage O 
evidenced O 
by O 
a O 
marked O 
reduction O 
in O 
glutathione B-TRIVIAL 
redox O 
status O 
( O 
ratio O 
of O 
reduced B-ABBREVIATION 
GSH I-ABBREVIATION 
/ O 
oxidized B-ABBREVIATION 
GSSG I-ABBREVIATION 
) O 
and O 
an O 
increase O 
in O 
lipid O 
peroxidation O 
( O 
TBARS O 
levels O 
) O 
. O 
Moreover O 
, O 
RNA O 
: O 
DNA O 
ratio O 
, O 
a O 
proxy O 
for O 
protein O 
synthetic O 
activity O 
, O 
decreased O 
in O 
concert O 
with O 
increased O 
TBARS O 
, O 
indicating O 
a O 
linkage O 
between O 
oxidative O 
damage O 
and O 
fitness O 
. O 
Finally O 
, O 
inhibited O 
acetylcholinesterase O 
( O 
AChE O 
) O 
activity O 
in O 
animals O 
exposed O 
to O 
contaminated O 
sediments O 
suggested O 
a O 
neurotoxic O 
impact O 
, O 
whereas O 
significant O 
correlations O 
between O 
AChE O 
and O 
oxidative O 
biomarkers O 
may O 
indicate O 
connections O 
with O 
redox O 
state O 
regulation O 
. O 
The O 
oxidative O 
responses O 
in O 
pristine O 
sediments O 
suggested O 
a O 
typical O 
scenario O 
of O 
ROS O 
production O 
and O 
removal O 
, O 
with O 
no O 
apparent O 
oxidative O 
damage O 
. O 
By O 
contrast O 
, O 
co O 
- O 
exposure O 
to O 
contaminants O 
caused O 
greater O 
increase O 
in O 
antioxidants O 
, O 
lipid O 
peroxidation O 
, O 
and O 
slowed O 
recovery O 
from O 
hypoxia O 
as O 
indicated O 
by O 
CAT O 
, O 
GSH B-ABBREVIATION 
/ O 
GSSG B-ABBREVIATION 
, O 
TBARS O 
and O 
AChE O 
responses O 
. O 
These O 
results O 
support O 
the O 
hypothesized O 
potential O 
of O 
xenobiotics O 
to O 
hamper O 
ability O 
of O 
animals O 
to O 
cope O 
with O 
fluctuating O 
hypoxia O 
. O 
They O 
also O 
emphasize O 
the O 
importance O 
of O 
understanding O 
interactions O 
between O 
antioxidant O 
responses O 
to O 
different O 
stressors O 
and O 
physiological O 
mechanisms O 
of O 
oxidative O 
damage O 
. O 

determination O 
of O 
glucoraphanin B-TRIVIAL 
and O 
sulforaphane B-TRIVIAL 
in O 
Brassica O 
oleracea O 
seeds O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
with O 
evaporative O 
light O 
- O 
scattering O 
detector O 
. O 

this O 
article O 
, O 
a O 
novel O 
and O 
efficient O 
analysis O 
method O 
is O 
described O 
to O 
simultaneously O 
and O 
quantitatively O 
determine O 
glucoraphanin B-TRIVIAL 
and O 
its O 
major O 
degradation O 
product O 
sulforaphane B-TRIVIAL 
by O 
reversed O 
- O 
phase O 
high O 
- O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
coupled O 
with O 
an O 
evaporative O 
light O 
- O 
scattering O 
detector O 
( O 
ELSD O 
) O 
. O 
This O 
method O 
was O 
validated O 
according O 
to O 
the O 
regulatory O 
guidelines O 
with O 
respect O 
to O 
precision O 
, O 
accuracy O 
and O 
linearity O 
. O 
The O 
HPLC-ELSD O 
method O 
was O 
successfully O 
used O 
to O 
assess O 
the O 
contents O 
of O 
glucoraphanin B-TRIVIAL 
and O 
sulforaphane B-TRIVIAL 
in O 
varieties O 
of O 
Brassica O 
oleracea O 
seeds O 
. O 
The O 
developed O 
analytical O 
method O 
not O 
only O 
avoids O 
the O 
underestimation O 
of O 
total O 
glucoraphanin B-TRIVIAL 
content O 
, O 
but O 
also O 
provides O 
a O 
reduction O 
in O 
analysis O 
time O 
and O 
good O 
efficiency O 
and O 
sensitivity O 
compared O 
to O 
with O 
conventional O 
HPLC O 
methods O 
. O 

/ O 
Thr B-FORMULA 
protein O 
phosphatase O 
1 O 
( O 
PP1 O 
) O 
is O 
a O 
single O 
- O 
domain O 
hub O 
protein O 
with O 
nearly O 
200 O 
validated O 
interactors O 
in O 
vertebrates O 
. O 
PP1-interacting O 
proteins O 
( O 
PIPs O 
) O 
are O 
ubiquitously O 
expressed O 
but O 
show O 
an O 
exceptional O 
diversity O 
in O 
brain O 
, O 
testis O 
and O 
white O 
blood O 
cells O 
. O 
The O 
binding O 
of O 
PIPs O 
is O 
mainly O 
mediated O 
by O 
short O 
motifs O 
that O 
dock O 
to O 
surface O 
grooves O 
of O 
PP1 O 
. O 
Although O 
PIPs O 
often O 
contain O 
variants O 
of O 
the O 
same O 
PP1 O 
binding O 
motifs O 
, O 
they O 
differ O 
in O 
the O 
number O 
and O 
combination O 
of O 
docking O 
sites O 
. O 
This O 
molecular O 
- O 
lego O 
strategy O 
for O 
binding O 
to O 
PP1 O 
creates O 
holoenzymes O 
with O 
unique O 
properties O 
. O 
The O 
PP1 O 
binding O 
code O 
can O 
be O 
described O 
as O 
specific O 
, O 
universal O 
, O 
degenerate O 
, O 
nonexclusive O 
and O 
dynamic O 
. O 
PIPs O 
control O 
associated O 
PP1 O 
by O 
interference O 
with O 
substrate O 
recruitment O 
or O 
access O 
to O 
the O 
active O 
site O 
. O 
In O 
addition O 
, O 
some O 
PIPs O 
have O 
a O 
subcellular O 
targeting O 
domain O 
that O 
promotes O 
dephosphorylation O 
by O 
increasing O 
the O 
local O 
concentration O 
of O 
PP1 O 
. O 
The O 
diversity O 
of O 
the O 
PP1 O 
interactome O 
and O 
the O 
properties O 
of O 
the O 
PP1 O 
binding O 
code O 
account O 
for O 
the O 
exquisite O 
specificity O 
of O 
PP1 O 
in O 
vivo O 
. O 

a O 
new O 
metabolite O 
obtained O 
from O 
Serratia O 
marcescens O 
, O 
a O 
bacterium O 
isolated O 
from O 
the O 
microflora O 
associated O 
with O 
banana O 
plantations O 
. O 

cultures O 
of O 
Serratia O 
marcescens O 
, O 
an O 
enterobacteria O 
isolated O 
from O 
the O 
microflora O 
associated O 
with O 
banana O 
plantations O 
incubated O 
at O 
27°C O 
in O 
a O 
yeast- O 
calcium B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
- O 
dextrose B-TRIVIAL 
solid O 
medium O 
( O 
10 O 
g O 
of O 
yeast O 
extract O 
, O 
20 O 
g O 
dextrose B-TRIVIAL 
, O 
15 O 
g O 
bacteriological O 
agar O 
, O 
20 O 
g O 
calcium B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
and O 
1000 O 
mL O 
distilled O 
water O 
) O 
were O 
extracted O 
with O 
chloroform B-TRIVIAL 
and O 
purified O 
by O 
column O 
chromatography O 
, O 
we O 
obtained O 
a O 
new O 
colourless O 
bacterial O 
metabolite O 
which O 
according O 
to O 
spectroscopic O 
data O 
proved O 
to O 
be O 
serratin B-TRIVIAL 
. O 

this O 
study O 
, O 
we O 
report O 
the O 
isolation O 
and O 
identification O 
of O 
several O 
compounds O 
present O 
in O 
the O 
polar O 
fraction O 
of O 
Stachys O 
germanica O 
L O 
. O 
subsp O 
. O 
salviifolia O 
( O 
Ten O 
. O 
) O 
Gams O 
, O 
collected O 
in O 
the O 
protected O 
area O 
of O 
Majella O 
National O 
Park O 
. O 
In O 
particular O 
, O 
we O 
have O 
isolated O 
and O 
identified O 
harpagide B-TRIVIAL 
, O 
7-β-hydroxy-harpagide B-SYSTEMATIC 
, O 
ajugol B-TRIVIAL 
, O 
5-allosyloxy-aucubin B-SYSTEMATIC 
, O 
verbascoside B-TRIVIAL 
and O 
, O 
for O 
the O 
first O 
time O 
in O 
this O 
genus O 
, O 
arbutin B-TRIVIAL 
. O 

and O 
pharmacodynamic O 
evaluation O 
of O 
floating O 
microspheres O 
of O 
metformin B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
. O 

hydrochloride I-SYSTEMATIC 
( O 
MH O 
) O 
, O 
a O 
biguanide B-TRIVIAL 
antidiabetic O 
, O 
is O 
the O 
drug O 
of O 
choice O 
in O 
obese O 
patients O 
. O 
It O 
is O 
well O 
absorbed O 
from O 
the O 
upper O 
part O 
of O 
gastrointestinal O 
tract O 
and O 
has O 
oral O 
bioavailability O 
of O 
50% O 
to O 
60% O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
formulate O 
MH O 
into O 
floating O 
microspheres O 
in O 
order O 
to O 
increase O 
its O 
residence O 
time O 
at O 
the O 
site O 
of O 
absorption O 
and O 
thus O 
improve O 
its O 
bioavailability O 
; O 
and O 
to O 
extend O 
the O 
duration O 
of O 
action O 
along O 
with O 
possibilities O 
of O 
dose O 
reduction O 
. O 
Microspheres O 
were O 
prepared O 
by O 
emulsion O 
solvent O 
evaporation O 
method O 
and O 
evaluated O 
for O 
particle O 
size O 
, O 
entrapment O 
efficiency O 
, O 
buoyancy O 
, O 
and O 
in O 
vitro O 
release O 
; O 
and O 
further O 
characterized O 
by O 
powder O 
X-ray O 
diffraction O 
, O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
, O 
scanning O 
electron O 
microscopy O 
, O 
and O 
differential O 
scanning O 
calorimetry O 
. O 
The O 
pharmacokinetic O 
and O 
pharmacodynamic O 
evaluation O 
of O 
selected O 
formulation O 
was O 
carried O 
out O 
in O 
male O 
Wistar O 
diabetic O 
rats O 
. O 
The O 
data O 
was O 
statistically O 
analyzed O 
by O 
unpaired O 
t-test O 
. O 
A O 
3.5-fold O 
increase O 
in O 
relative O 
bioavailability O 
was O 
observed O 
. O 
The O 
prolongation O 
of O 
half O 
- O 
life O 
( O 
t(1 O 
/ O 
2 O 
) O 
) O 
from O 
4.5 O 
± O 
2.41 O 
h O 
to O 
14.12 O 
± O 
4.81 O 
h O 
indicated O 
extended O 
duration O 
of O 
action O 
. O 
Oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
( O 
OGTT O 
) O 
was O 
analyzed O 
by O 
one O 
- O 
way O 
analysis O 
of O 
variance O 
followed O 
by O 
Dunnet O 
multiple O 
comparison O 
test O 
, O 
a O 
significant O 
decrease O 
( O 
p O 
< O 
0.05 O 
) O 
in O 
the O 
blood O 
glucose B-TRIVIAL 
levels O 
was O 
observed O 
when O 
formulations O 
were O 
compared O 
with O 
control O 
rats O 
. O 
Hence O 
, O 
MH O 
floating O 
microspheres O 
were O 
tested O 
at O 
50 O 
mg O 
/ O 
kg O 
and O 
100 O 
mg O 
/ O 
kg O 
body O 
weight O 
, O 
OGTT O 
data O 
showed O 
nonsignificant O 
difference O 
( O 
p O 
> O 
0.05 O 
) O 
. O 
In O 
conclusion O 
, O 
an O 
effective O 
oral O 
antidiabetics O 
treatment O 
can O 
be O 
achieved O 
by O 
formulating O 
MH O 
into O 
floating O 
microspheres O 
which O 
results O 
in O 
increase O 
in O 
bioavailability O 
along O 
with O 
extended O 
duration O 
of O 
action O 
resulting O 
in O 
possible O 
reduction O 
in O 
dose O 
. O 

evidence O 
of O 
functional O 
inhibitory O 
metabotrophic O 
glutamate B-TRIVIAL 
receptors O 
on O 
mouse O 
arousal O 
- O 
related O 
cholinergic O 
laterodorsal O 
tegmental O 
neurons O 
. O 

neurons O 
of O 
the O 
pontine O 
laterodorsal O 
tegmentum O 
( O 
LDT O 
) O 
are O 
importantly O 
involved O 
in O 
neurobiological O 
mechanisms O 
governing O 
states O 
of O 
arousal O 
such O 
as O 
sleep O 
and O 
wakefulness O 
as O 
well O 
as O 
other O 
appetitive O 
behaviors O 
, O 
such O 
as O 
drug O 
- O 
seeking O 
. O 
Accordingly O 
, O 
mechanisms O 
controlling O 
their O 
excitability O 
are O 
important O 
to O 
elucidate O 
if O 
we O 
are O 
to O 
understand O 
how O 
these O 
LDT O 
neurons O 
generate O 
arousal O 
states O 
. O 
Glutamate B-TRIVIAL 
mediates O 
the O 
vast O 
majority O 
of O 
excitatory O 
synaptic O 
transmission O 
in O 
the O 
vertebrate O 
CNS O 
and O 
while O 
presence O 
of O 
glutamate B-TRIVIAL 
input O 
in O 
the O 
LDT O 
has O 
been O 
shown O 
and O 
ionotropic O 
responses O 
to O 
glutamate B-TRIVIAL 
have O 
been O 
reported O 
in O 
the O 
LDT O 
, O 
characterization O 
of O 
metabotropic O 
responses O 
is O 
lacking O 
. O 
Therefore O 
, O 
electrophysiological O 
responses O 
and O 
changes O 
in O 
levels O 
of O 
intracellular O 
Ca(2+) B-FORMULA 
in O 
mouse O 
cholinergic O 
LDT O 
neurons O 
following O 
application O 
of O 
specific O 
mGluR O 
agonists O 
and O 
antagonists O 
were O 
examined O 
. O 
Unexpectedly O 
, O 
both O 
the O 
mGluR(5)specific O 
agonist O 
, O 
CHPG B-ABBREVIATION 
, O 
and O 
the O 
group O 
II O 
mGluR O 
( O 
mGlu(2 O 
/ O 
3 O 
) O 
) O 
agonist O 
, O 
LY379268 B-IDENTIFIER 
( O 
LY O 
) O 
, O 
induced O 
a O 
TTX B-ABBREVIATION 
-insensitive O 
outward O 
current O 
/ O 
hyperpolarization O 
. O 
Both O 
outward O 
currents O 
were O 
significantly O 
reduced O 
by O 
the O 
mGluR O 
antagonist O 
MCPG B-ABBREVIATION 
and O 
the O 
CHPG B-ABBREVIATION 
-induced O 
current O 
was O 
blocked O 
by O 
the O 
specific O 
mGluR(5) O 
antagonist O 
MTEP B-ABBREVIATION 
. O 
Concurrent O 
Ca(2+) B-FORMULA 
imaging O 
revealed O 
that O 
while O 
CHPG B-ABBREVIATION 
actions O 
did O 
include O 
release O 
of O 
Ca(2+) B-FORMULA 
from O 
CPA B-ABBREVIATION 
/ O 
thapsigargin B-TRIVIAL 
-sensitive O 
intracellular O 
stores O 
, O 
actions O 
of O 
LY O 
did O 
not O 
. O 
Both O 
CHPG B-ABBREVIATION 
- O 
and O 
LY-induced O 
outward O 
currents O 
were O 
mediated O 
by O 
a O 
TEA B-ABBREVIATION 
-sensitive O 
potassium B-SYSTEMATIC 
conductance O 
. O 
The O 
large O 
- O 
conductance O 
, O 
Ca(2+) B-FORMULA 
-dependent O 
potassium B-SYSTEMATIC 
( O 
BK O 
) O 
channel O 
blocker O 
, O 
iberiotoxin O 
, O 
attenuated O 
CHPG B-ABBREVIATION 
actions O 
. O 
Consistent O 
with O 
actions O 
on O 
the O 
BK O 
conductance O 
, O 
CHPG B-ABBREVIATION 
enhanced O 
the O 
amplitude O 
of O 
the O 
fast O 
component O 
of O 
the O 
after O 
hyperpolarizing O 
potential O 
, O 
concurrent O 
with O 
a O 
reduction O 
in O 
the O 
firing O 
rate O 
. O 
We O 
conclude O 
that O 
stimulation O 
of O 
mGluR(5) O 
and O 
group O 
II O 
( O 
mGluR(2 O 
/ O 
3 O 
) O 
) O 
elicits O 
postsynaptically O 
- O 
mediated O 
outward O 
currents O 
/ O 
hyperpolarizations O 
in O 
cholinergic O 
LDT O 
neurons O 
. O 
Effects O 
of O 
glutamatergic O 
input O 
would O 
be O 
, O 
thus O 
, O 
expected O 
not O 
only O 
to O 
be O 
excitation O 
via O 
stimulation O 
of O 
ionotropic O 
glutamate B-TRIVIAL 
receptors O 
and O 
mGluR(1) O 
, O 
but O 
also O 
inhibition O 
via O 
actions O 
at O 
mGluR(5) O 
and O 
mGluR(2 O 
/ O 
3 O 
) O 
on O 
these O 
neurons O 
. O 
As O 
these O 
two O 
processes O 
counteract O 
each O 
other O 
, O 
these O 
surprising O 
findings O 
necessitate O 
revision O 
of O 
predictions O 
regarding O 
the O 
net O 
level O 
of O 
excitation O 
generated O 
by O 
glutamate B-TRIVIAL 
input O 
to O 
cholinergic O 
LDT O 
cells O 
and O 
, O 
by O 
extension O 
, O 
the O 
functional O 
outcome O 
of O 
glutamate B-TRIVIAL 
transmission O 
on O 
processes O 
which O 
these O 
neurons O 
regulate O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

are O 
few O 
effective O 
treatments O 
for O 
metastatic O 
melanoma O 
. O 
Checkpoint O 
kinase O 
1 O 
( O 
Chk1 O 
) O 
inhibitors O 
are O 
being O 
trialled O 
for O 
their O 
efficacy O 
in O 
enhancing O 
conventional O 
chemotherapeutic O 
agents O 
, O 
but O 
their O 
effectiveness O 
as O 
single O 
agents O 
is O 
not O 
known O 
. O 
We O 
have O 
examined O 
the O 
effectiveness O 
of O 
two O 
novel O 
Chk1 O 
selective O 
inhibitors O 
, O 
AR323 B-NO_CLASS 
and O 
AR678 B-NO_CLASS 
, O 
in O 
a O 
panel O 
of O 
melanoma O 
cell O 
lines O 
and O 
normal O 
cell O 
types O 
. O 
We O 
demonstrate O 
that O 
these O 
drugs O 
display O 
single O 
- O 
agent O 
activity O 
, O 
with O 
IC50s O 
in O 
the O 
low O 
nanomolar O 
range O 
. O 
The O 
drugs O 
produce O 
cytotoxic O 
effects O 
in O 
cell O 
lines O 
that O 
are O 
most O 
sensitive O 
to O 
these O 
drugs O 
, O 
whereas O 
normal O 
cells O 
are O 
only O 
sensitive O 
to O 
these O 
drugs O 
at O 
the O 
higher O 
concentrations O 
where O 
they O 
have O 
cytostatic O 
activity O 
. O 
The O 
cytotoxic O 
effect O 
is O 
the O 
consequence O 
of O 
inhibition O 
of O 
S-phase O 
Chk1 O 
, O 
which O 
drives O 
cells O 
prematurely O 
from O 
late O 
S O 
phase O 
into O 
an O 
aberrant O 
mitosis O 
and O 
results O 
in O 
either O 
failure O 
of O 
cytokinesis O 
or O 
cell O 
death O 
through O 
an O 
apoptotic O 
mechanism O 
. O 
The O 
sensitivity O 
to O 
the O 
Chk1 O 
inhibitors O 
was O 
correlated O 
with O 
the O 
level O 
of O 
endogenous O 
DNA O 
damage O 
indicating O 
replicative O 
stress O 
. O 
Chk1 O 
inhibitors O 
are O 
viable O 
single O 
- O 
agent O 
therapies O 
that O 
target O 
melanoma O 
cells O 
with O 
high O 
levels O 
of O 
endogenous O 
DNA O 
damage O 
. O 
This O 
sensitivity O 
suggests O 
that O 
Chk1 O 
is O 
a O 
critical O 
component O 
of O 
an O 
adaptation O 
to O 
replicative O 
stress O 
in O 
these O 
cells O 
. O 
It O 
also O 
suggests O 
that O 
markers O 
of O 
DNA O 
damage O 
may O 
be O 
useful O 
in O 
identifying O 
the O 
melanomas O 
and O 
potentially O 
other O 
tumour O 
types O 
that O 
are O 
more O 
likely O 
to O 
be O 
sensitive O 
to O 
Chk1 O 
inhibitors O 
as O 
single O 
agents O 
. O 

- O 
growth O 
Marchantia O 
paleacea O 
calluses O 
were O 
induced O 
on O 
MSK2 O 
medium O 
through O 
surface O 
sterilisation O 
of O 
the O 
capsula O 
. O 
Ten O 
known O 
compounds O 
including O 
two O 
steroids B-FAMILY 
( O 
1-2 O 
) O 
, O 
six O 
bibenzyls B-FAMILY 
( O 
3 O 
, O 
5-9 O 
) O 
, O 
a O 
flavonoid B-FAMILY 
( O 
10 O 
) O 
, O 
and O 
a O 
terpenoid B-FAMILY 
( O 
4 O 
) O 
were O 
isolated O 
from O 
these O 
calluses O 
. O 
The O 
allelopathic O 
effect O 
of O 
the O 
six O 
bibenzyls B-FAMILY 
was O 
assessed O 
in O 
Arabidopsis O 
thaliana O 
. O 
Results O 
revealed O 
that O 
bibenzyls B-FAMILY 
could O 
inhibit O 
seedling O 
growth O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 

and O 
in O 
vitro O 
/ O 
in O 
vivo O 
evaluation O 
of O 
a O 
ketoprofen B-TRIVIAL 
orally O 
disintegrating O 
/ O 
sustained O 
release O 
tablet O 
. O 

: O 
Orally O 
disintegrating O 
tablets O 
( O 
ODTs O 
) O 
with O 
sustained O 
release O 
profiles O 
are O 
a O 
new O 
generation O 
of O 
ODTs O 
called O 
orally O 
disintegrating O 
/ O 
sustained O 
release O 
tablets O 
( O 
ODSRTs O 
) O 
, O 
which O 
are O 
convenient O 
in O 
use O 
and O 
able O 
to O 
slowly O 
release O 
drugs O 
to O 
maintain O 
effective O 
blood O 
concentrations O 
over O 
a O 
prolonged O 
period O 
of O 
time O 
. O 
Ketoprofen B-TRIVIAL 
, O 
one O 
of O 
non-steroidal O 
anti-inflammatory O 
drugs O 
, O 
is O 
an O 
ideal O 
model O 
drug O 
for O 
ODSRTs O 
. O 
Methods O 
: O 
We O 
designed O 
a O 
simple O 
two O 
- O 
step O 
process O 
to O 
develop O 
novel O 
ketoprofen B-TRIVIAL 
orally O 
disintegrating O 
/ O 
sustained O 
release O 
tablets O 
( O 
KODSRTs O 
) O 
. O 
Firstly O 
, O 
sustained O 
release O 
ketoprofen B-TRIVIAL 
fine O 
granules O 
were O 
developed O 
by O 
spray O 
drying O 
the O 
aqueous O 
dispersions O 
composed O 
of O 
Eudragit B-TRIVIAL 
RS-30D I-TRIVIAL 
, O 
Starch O 
1500 O 
and O 
PEG B-ABBREVIATION 
PEG B-TRIVIAL 
6000 I-TRIVIAL 
. O 
The O 
optimal O 
parameters O 
of O 
spray O 
drying O 
were O 
100°C O 
for O 
inlet O 
air O 
temperature O 
and O 
1.5 O 
mL O 
/ O 
min O 
for O 
feed O 
rate O 
. O 
Subsequently O 
, O 
the O 
obtained O 
granules O 
were O 
directly O 
compressed O 
into O 
KODSRTs O 
after O 
mixing O 
with O 
lactose B-TRIVIAL 
, O 
mannitol B-TRIVIAL 
and O 
a O 
superdisintegrant O 
, O 
crosslinked O 
polyvinylpyrrolidone B-SYSTEMATIC 
( O 
PVPP B-ABBREVIATION 
) O 
. O 
The O 
characteristics O 
of O 
KODSRTs O 
, O 
especially O 
their O 
potential O 
for O 
extended O 
drug O 
release O 
, O 
were O 
evaluated O 
. O 
Results O 
: O 
Results O 
of O 
an O 
in O 
vitro O 
release O 
test O 
demonstrated O 
that O 
KODSRTs O 
could O 
slowly O 
release O 
ketoprofen B-TRIVIAL 
for O 
24 O 
h O 
after O 
disintegrating O 
within O 
30 O 
s O 
. O 
Extended O 
release O 
properties O 
of O 
KODSRTs O 
were O 
decided O 
by O 
the O 
ketoprofen B-TRIVIAL 
sustained O 
release O 
fine O 
granules O 
in O 
tablets O 
. O 
Besides O 
, O 
the O 
disintegration O 
time O 
of O 
KODSRTs O 
depended O 
on O 
the O 
percentage O 
of O 
PVPP B-ABBREVIATION 
in O 
tablets O 
. O 
In O 
vivo O 
pharmacokinetic O 
studies O 
in O 
beagles O 
also O 
showed O 
that O 
KODSRTs O 
possessed O 
a O 
significantly O 
extended O 
release O 
profile O 
compared O 
with O 
ketoprofen B-TRIVIAL 
normal O 
capsules O 
. O 
Conclusion O 
: O 
KODSRTs O 
were O 
successfully O 
prepared O 
using O 
a O 
simple O 
two O 
- O 
step O 
process O 
: O 
spray O 
drying O 
and O 
direct O 
compression O 
. O 

receptor O 
tyrosine B-TRIVIAL 
kinase O 
Axl O 
is O 
an O 
essential O 
regulator O 
of O 
prostate O 
cancer O 
proliferation O 
and O 
tumor O 
growth O 
and O 
represents O 
a O 
new O 
therapeutic O 
target O 
. O 

of O 
the O 
receptor O 
tyrosine B-TRIVIAL 
kinase O 
Axl O 
has O 
been O 
implicated O 
in O 
the O 
progression O 
of O 
several O 
human O 
cancers O 
. O 
However O 
, O 
the O 
role O 
of O 
Axl O 
in O 
prostate O 
cancer O 
remains O 
poorly O 
understood O 
, O 
and O 
the O 
therapeutic O 
efficacy O 
of O 
Axl O 
targeting O 
remains O 
untested O 
. O 
In O 
this O 
report O 
we O 
identified O 
Axl O 
as O 
a O 
new O 
therapeutic O 
target O 
for O 
prostate O 
cancer O 
. O 
Axl O 
is O 
consistently O 
overexpressed O 
in O 
prostate O 
cancer O 
cell O 
lines O 
and O 
human O 
prostate O 
tumors O 
. O 
Interestingly O 
, O 
the O 
blockage O 
of O 
Axl O 
gene O 
expression O 
strongly O 
inhibits O 
proliferation O 
, O 
migration O 
, O 
invasion O 
and O 
tumor O 
growth O 
. O 
Furthermore O 
, O 
inhibition O 
of O 
Axl O 
expression O 
by O 
small O 
interfering O 
RNA O 
regulates O 
a O 
transcriptional O 
program O 
of O 
genes O 
involved O 
in O 
cell O 
survival O 
, O 
strikingly O 
all O 
connected O 
to O 
the O 
nuclear O 
factor-κB O 
pathway O 
. O 
Additionally O 
, O 
blockage O 
of O 
Axl O 
expression O 
leads O 
to O 
inhibition O 
of O 
Akt O 
, O 
IKKα O 
and O 
IκBα O 
phosphorylation O 
, O 
increasing O 
IκBα O 
expression O 
and O 
stability O 
. O 
Furthermore O 
, O 
induction O 
of O 
Akt O 
phosphorylation O 
by O 
insulin O 
- O 
like O 
growth O 
factor O 
1 O 
in O 
Axl O 
knockdown O 
cells O 
restores O 
Akt O 
activity O 
and O 
proliferation O 
. O 
Taken O 
together O 
, O 
our O 
results O 
establish O 
an O 
unambiguous O 
role O 
for O 
Axl O 
in O 
prostate O 
cancer O 
tumorigenesis O 
with O 
implications O 
for O 
prostate O 
cancer O 
treatment O 
. O 

K-ras O 
expression O 
is O 
associated O 
with O 
derangement O 
of O 
the O 
cAMP B-ABBREVIATION 
/ O 
PKA O 
pathway O 
and O 
forskolin B-TRIVIAL 
-reversible O 
alterations O 
of O 
mitochondrial O 
dynamics O 
and O 
respiration O 
. O 

Warburg O 
effect O 
in O 
cancer O 
cells O 
has O 
been O 
proposed O 
to O 
involve O 
several O 
mechanisms O 
, O 
including O 
adaptation O 
to O 
hypoxia O 
, O 
oncogenes O 
activation O 
or O 
loss O 
of O 
oncosuppressors O 
and O 
impaired O 
mitochondrial O 
function O 
. O 
In O 
previous O 
papers O 
, O 
it O 
has O 
been O 
shown O 
that O 
K-ras O 
transformed O 
mouse O 
cells O 
are O 
much O 
more O 
sensitive O 
as O 
compared O 
with O 
normal O 
cells O 
to O 
glucose B-TRIVIAL 
withdrawal O 
( O 
undergoing O 
apoptosis O 
) O 
and O 
present O 
a O 
high O 
glycolytic O 
rate O 
and O 
a O 
strong O 
reduction O 
of O 
mitochondrial O 
complex O 
I O 
. O 
Recent O 
observations O 
suggest O 
that O 
transformed O 
cells O 
have O 
a O 
derangement O 
in O 
the O 
cyclic B-SYSTEMATIC 
adenosine I-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
/ O 
cAMP B-ABBREVIATION 
-dependent O 
protein O 
kinase O 
( O 
cAMP B-ABBREVIATION 
/ O 
PKA O 
) O 
pathway O 
, O 
which O 
is O 
known O 
to O 
regulate O 
several O 
mitochondrial O 
functions O 
. O 
Herein O 
, O 
the O 
derangement O 
of O 
the O 
cAMP B-ABBREVIATION 
/ O 
PKA O 
pathway O 
and O 
its O 
impact O 
on O 
transformation O 
- O 
linked O 
changes O 
of O 
mitochondrial O 
functions O 
is O 
investigated O 
. O 
Exogenous O 
stimulation O 
of O 
PKA O 
activity O 
, O 
achieved O 
by O 
forskolin B-TRIVIAL 
treatment O 
, O 
protected O 
K-ras-transformed O 
cells O 
from O 
apoptosis O 
induced O 
by O 
glucose B-TRIVIAL 
deprivation O 
, O 
enhanced O 
complex O 
I O 
activity O 
, O 
intracellular O 
adenosine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
( O 
ATP B-ABBREVIATION 
) O 
levels O 
, O 
mitochondrial O 
fusion O 
and O 
decreased O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
levels O 
. O 
Several O 
of O 
these O 
effects O 
were O 
almost O 
completely O 
prevented O 
by O 
inhibiting O 
the O 
PKA O 
activity O 
. O 
Short O 
- O 
time O 
treatment O 
with O 
compounds O 
favoring O 
mitochondrial O 
fusion O 
strongly O 
decreased O 
the O 
cellular O 
ROS O 
levels O 
especially O 
in O 
transformed O 
cells O 
. O 
These O 
findings O 
support O 
the O 
notion O 
that O 
glucose B-TRIVIAL 
shortage O 
- O 
induced O 
apoptosis O 
, O 
specific O 
of O 
K-ras-transformed O 
cells O 
, O 
is O 
associated O 
to O 
a O 
derangement O 
of O 
PKA O 
signaling O 
that O 
leads O 
to O 
mitochondrial O 
complex O 
I O 
decrease O 
, O 
reduction O 
of O 
ATP B-ABBREVIATION 
formation O 
, O 
prevalence O 
of O 
mitochondrial O 
fission O 
over O 
fusion O 
, O 
and O 
thereby O 
opening O 
new O 
approaches O 
for O 
development O 
of O 
anticancer O 
drugs O 
. O 

new O 
chromone B-TRIVIAL 
from O 
the O 
leaves O 
of O 
Melaleuca O 
cajuputi O 
Powell O 
. O 

new O 
chromone B-TRIVIAL 
, O 
5,7-dihydroxy-2 B-SYSTEMATIC 
-(hydroxymethyl)-6,8-dimethyl-chromen-4-one I-SYSTEMATIC 
, O 
named O 
melachromone B-TRIVIAL 
, O 
together O 
with O 
12 O 
known O 
compounds O 
, O 
including O 
chromones B-FAMILY 
, O 
anthraquinone B-SYSTEMATIC 
, O 
flavonoids B-FAMILY 
, O 
flavonoid B-FAMILY 
glycosides I-FAMILY 
, O 
benzene B-SYSTEMATIC 
derivatives O 
, O 
ellagic B-FAMILY 
acids I-FAMILY 
and O 
terpenes B-FAMILY 
, O 
were O 
isolated O 
from O 
the O 
leaves O 
of O 
Melaleuca O 
cajuputi O 
Powell O 
. O 
Their O 
structures O 
were O 
characterised O 
by O 
spectroscopic O 
methods O 
. O 

glutamate B-TRIVIAL 
receptors O 
( O 
mGlus O 
) O 
are O 
a O 
group O 
of O 
Family O 
C O 
Seven O 
Transmembrane O 
Spanning O 
Receptors O 
( O 
7TMRs O 
) O 
that O 
play O 
important O 
roles O 
in O 
modulating O 
signaling O 
transduction O 
, O 
particularly O 
within O 
the O 
central O 
nervous O 
system O 
. O 
mGlu(4) O 
belongs O 
to O 
a O 
subfamily O 
of O 
mGlus O 
that O 
is O 
predominantly O 
coupled O 
to O 
G(i O 
/ O 
o O 
) O 
G O 
proteins O 
. O 
We O 
now O 
report O 
that O 
the O 
ubiquitous O 
autacoid O 
and O 
neuromodulator O 
, O 
histamine B-TRIVIAL 
, O 
induces O 
substantial O 
glutamate B-TRIVIAL 
-activated O 
calcium B-SYSTEMATIC 
mobilization O 
in O 
mGlu(4)-expressing O 
cells O 
, O 
an O 
effect O 
which O 
is O 
observed O 
in O 
the O 
absence O 
of O 
co O 
- O 
expressed O 
chimeric O 
G O 
proteins O 
. O 
This O 
strong O 
induction O 
of O 
calcium B-SYSTEMATIC 
signaling O 
downstream O 
of O 
glutamate B-TRIVIAL 
activation O 
of O 
mGlu(4) O 
depends O 
upon O 
the O 
presence O 
of O 
H(1) O 
histamine B-TRIVIAL 
receptors O 
. O 
Interestingly O 
, O 
the O 
potentiating O 
effect O 
of O 
histamine B-TRIVIAL 
activation O 
does O 
not O 
extend O 
to O 
other O 
mGlu(4) O 
- O 
mediated O 
signaling O 
events O 
downstream O 
of O 
G(i O 
/ O 
o O 
) O 
G O 
proteins O 
, O 
such O 
as O 
cAMP B-ABBREVIATION 
inhibition O 
, O 
suggesting O 
that O 
the O 
presence O 
of O 
G(q) O 
coupled O 
receptors O 
such O 
as O 
H(1) O 
may O 
bias O 
normal O 
mGlu(4) O 
- O 
mediated O 
G(i O 
/ O 
o O 
) O 
signaling O 
events O 
. O 
When O 
the O 
activity O 
induced O 
by O 
small O 
molecule O 
positive O 
allosteric O 
modulators O 
of O 
mGlu(4) O 
is O 
assessed O 
, O 
the O 
potentiated O 
signaling O 
of O 
mGlu(4) O 
is O 
further O 
biased O 
by O 
histamine B-TRIVIAL 
toward O 
calcium B-SYSTEMATIC 
-dependent O 
pathways O 
. O 
These O 
results O 
suggest O 
that O 
G(i O 
/ O 
o)-coupled O 
mGlus O 
may O 
induce O 
substantial O 
, O 
and O 
potentially O 
unexpected O 
, O 
calcium B-SYSTEMATIC 
-mediated O 
signaling O 
events O 
if O 
stimulation O 
occurs O 
concomitantly O 
with O 
activation O 
of O 
G(q) O 
receptors O 
. O 
Additionally O 
, O 
our O 
results O 
suggest O 
that O 
signaling O 
induced O 
by O 
small O 
molecule O 
positive O 
allosteric O 
modulators O 
may O 
be O 
substantially O 
biased O 
when O 
G(q) O 
receptors O 
are O 
co O 
- O 
activated O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

new O 
triterpenoid B-FAMILY 
saponins I-FAMILY 
from O 
the O 
husks O 
of O 
Xanthoceras O 
sorbifolia O 
. O 

new O 
oleanane B-TRIVIAL 
triterpenoid B-FAMILY 
saponins I-FAMILY 
, O 
xanthohuskisides B-FAMILY 
A O 
( O 
1 O 
) O 
and O 
B O 
( O 
2 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
husks O 
of O 
Xanthoceras O 
sorbifolia O 
. O 
The O 
structures O 
of O 
these O 
two O 
compounds O 
were O 
established O 
as O 
3-O-β-D-glucopyranosyl B-SYSTEMATIC 
( I-SYSTEMATIC 
1→6)-[β-D-glucopyranosyl I-SYSTEMATIC 
(1→2)]-β-D-glucopyranosyl I-SYSTEMATIC 
, I-SYSTEMATIC 
28-O-β-D-glucopyranosyl I-SYSTEMATIC 
( I-SYSTEMATIC 
1→6)-[α-L-rhamnopyranosyl I-SYSTEMATIC 
(1→2)]-β-D-glucopyranosyl I-SYSTEMATIC 
16-deoxybarringtogenol I-SYSTEMATIC 
C I-SYSTEMATIC 
( O 
1 O 
) O 
and O 
3-O-β-D-glucopyranosyl B-SYSTEMATIC 
( I-SYSTEMATIC 
1→6)-[β-D-glucopyranosyl I-SYSTEMATIC 
(1→2)]-β-D-glucopyranosyl I-SYSTEMATIC 
, I-SYSTEMATIC 
28-O-β-D-glucopyranosyl I-SYSTEMATIC 
(1→6)-β-D-glucopyranosyl I-SYSTEMATIC 
16-deoxybarringtogenol I-SYSTEMATIC 
C I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
respectively O 
, O 
based O 
on O 
the O 
analysis O 
on O 
their O 
spectral O 
data O 
including O 
NMR O 
and O 
HR-ESI-MS O 
. O 
The O 
growth O 
inhibitory O 
activities O 
of O 
compounds O 
1 O 
and O 
2 O 
were O 
assayed O 
, O 
and O 
2 O 
showed O 
moderate O 
activity O 
against O 
U937 O 
cell O 
line O 
with O 
the O 
IG(50) O 
value O 
of O 
82.85 O 
± O 
1.58 O 
µM O 
. O 

epidermal O 
growth O 
factor O 
receptor O 
( O 
EGFR O 
) O 
is O 
a O 
central O 
regulator O 
of O 
tumor O 
progression O 
in O 
human O 
cancers O 
. O 
Cetuximab O 
is O 
an O 
anti-EGFR O 
antibody O 
that O 
has O 
been O 
approved O 
for O 
use O 
in O 
oncology O 
. O 
Previously O 
we O 
investigated O 
mechanisms O 
of O 
resistance O 
to O 
cetuximab O 
using O 
a O 
model O 
derived O 
from O 
the O 
non-small O 
cell O 
lung O 
cancer O 
line O 
NCI-H226 O 
. O 
We O 
demonstrated O 
that O 
cetuximab O 
- O 
resistant O 
clones O 
(Ctx(R)) O 
had O 
increased O 
nuclear O 
localization O 
of O 
the O 
EGFR O 
. O 
This O 
process O 
was O 
mediated O 
by O 
Src O 
family O 
kinases O 
( O 
SFKs O 
) O 
, O 
and O 
nuclear O 
EGFR O 
had O 
a O 
role O 
in O 
resistance O 
to O 
cetuximab O 
. O 
To O 
better O 
understand O 
SFK O 
- O 
mediated O 
nuclear O 
translocation O 
of O 
EGFR O 
, O 
we O 
investigated O 
which O 
SFK O 
member(s) O 
controlled O 
this O 
process O 
as O 
well O 
as O 
the O 
EGFR O 
tyrosine B-TRIVIAL 
residues O 
that O 
are O 
involved O 
. O 
Analyses O 
of O 
mRNA O 
and O 
protein O 
expression O 
indicated O 
upregulation O 
of O 
the O 
SFK O 
members O 
Yes O 
( O 
v-Yes-1 O 
yamaguchi O 
sarcoma O 
viral O 
oncogene O 
) O 
and O 
Lyn O 
( O 
v-yes-1 O 
Yamaguchi O 
sarcoma O 
viral O 
- O 
related O 
oncogene O 
homolog O 
) O 
in O 
all O 
Ctx O 
( O 
R O 
) O 
clones O 
. O 
Further O 
, O 
immunoprecipitation O 
analysis O 
revealed O 
that O 
EGFR O 
interacts O 
with O 
Yes O 
and O 
Lyn O 
in O 
Ctx O 
( O 
R O 
) O 
clones O 
, O 
but O 
not O 
in O 
cetuximab O 
- O 
sensitive O 
(Ctx(S)) O 
parental O 
cells O 
. O 
Using O 
RNAi O 
interference O 
, O 
we O 
found O 
that O 
knockdown O 
of O 
either O 
Yes O 
or O 
Lyn O 
led O 
to O 
loss O 
of O 
EGFR O 
translocation O 
to O 
the O 
nucleus O 
. O 
Conversely O 
, O 
overexpression O 
of O 
Yes O 
or O 
Lyn O 
in O 
low O 
nuclear O 
EGFR-expressing O 
Ctx(S) O 
parental O 
cells O 
led O 
to O 
increased O 
nuclear O 
EGFR O 
. O 
Chromatin O 
immunoprecipitation O 
( O 
ChIP O 
) O 
assays O 
confirmed O 
nuclear O 
EGFR O 
complexes O 
associated O 
with O 
the O 
promoter O 
of O 
the O 
known O 
EGFR O 
target O 
genes O 
B-Myb O 
and O 
iNOS O 
. O 
Further O 
, O 
all O 
Ctx O 
( O 
R O 
) O 
clones O 
exhibited O 
upregulation O 
of O 
B-Myb O 
and O 
iNOS O 
at O 
the O 
mRNA O 
and O 
protein O 
levels O 
. O 
siRNAs O 
directed O 
at O 
Yes O 
or O 
Lyn O 
led O 
to O 
decreased O 
binding O 
of O 
EGFR O 
complexes O 
to O 
the O 
B-Myb O 
and O 
iNOS O 
promoters O 
based O 
on O 
ChIP O 
analyses O 
. O 
SFKs O 
have O 
been O 
shown O 
to O 
phosphorylate O 
EGFR O 
on O 
tyrosines O 
845 O 
and O 
1101 O 
( O 
Y845 O 
and O 
Y1101 O 
) O 
, O 
and O 
mutation O 
of O 
Y1101 O 
, O 
but O 
not O 
Y845 O 
, O 
impaired O 
nuclear O 
entry O 
of O 
the O 
EGFR O 
. O 
Taken O 
together O 
, O 
our O 
findings O 
demonstrate O 
that O 
Yes O 
and O 
Lyn O 
phosphorylate O 
EGFR O 
at O 
Y1101 O 
, O 
which O 
influences O 
EGFR O 
nuclear O 
translocation O 
in O 
this O 
model O 
of O 
cetuximab O 
resistance O 
. O 

of O 
sinensetin B-TRIVIAL 
on O 
lipid O 
metabolism O 
in O 
mature O 
3T3-L1 O 
adipocytes O 
. O 

is O 
a O 
rare O 
polymethoxylated B-TRIVIAL 
flavone I-TRIVIAL 
found O 
in O 
certain O 
citrus O 
fruits O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
sinensetin B-TRIVIAL 
on O 
lipid O 
metabolism O 
in O 
mature O 
3T3-L1 O 
adipocytes O 
. O 
Sinensetin B-TRIVIAL 
decreased O 
the O 
expression O 
of O 
sterol B-FAMILY 
regulatory O 
element O 
- O 
binding O 
protein O 
1c O 
( O 
SREBP1c O 
) O 
, O 
suggesting O 
its O 
antiadipogeneic O 
property O 
via O 
downreguation O 
of O 
SREBP1c O 
. O 
Also O 
, O 
sinensetin B-TRIVIAL 
increased O 
the O 
phosphorylation O 
of O 
protein O 
kinase O 
A O 
and O 
hormone O 
- O 
sensitive O 
lipase O 
, O 
indicating O 
its O 
lipolytic O 
property O 
via O 
a O 
cAMP B-ABBREVIATION 
-mediated O 
signaling O 
pathway O 
. O 
Moreover O 
, O 
sinensetin B-TRIVIAL 
inhibited O 
insulin O 
- O 
stimulated O 
glucose B-TRIVIAL 
uptake O 
by O 
decreasing O 
the O 
phosphorylation O 
of O 
insulin O 
receptor O 
substrate O 
and O 
Akt O 
. O 
Furthermore O 
, O 
sinensetin B-TRIVIAL 
increased O 
the O 
phosphorylation O 
of O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
and O 
acetyl-CoA B-SYSTEMATIC 
carboxylase O 
. O 
It O 
also O 
upregulated O 
mRNA O 
expression O 
of O 
carnitine B-TRIVIAL 
palmitoyltransferase-1a O 
, O 
suggesting O 
that O 
sinensetin B-TRIVIAL 
enhances O 
fatty O 
acid O 
β-oxidation O 
through O 
the O 
AMPK O 
pathway O 
. O 
Taken O 
together O 
, O 
these O 
results O 
suggest O 
that O 
sinensetin B-TRIVIAL 
may O 
have O 
potential O 
as O 
a O 
natural O 
agent O 
for O 
prevention O 
/ O 
improvement O 
of O 
obesity O 
. O 

factors O 
are O 
vital O 
not O 
only O 
to O 
support O 
neuronal O 
development O 
but O 
also O 
to O 
protect O 
mature O 
neurons O 
from O 
atrophy O 
in O 
neurodegenerative O 
diseases O 
. O 
As O 
an O 
effort O 
to O 
explore O 
natural O 
sources O 
that O 
possess O 
neurotrophic O 
activity O 
, O 
we O 
screened O 
common O 
marine O 
algae O 
for O 
their O 
neuritogenic O 
activity O 
in O 
the O 
developing O 
rat O 
hippocampal O 
neurons O 
in O 
culture O 
. O 
Of O 
the O 
22 O 
seaweed O 
species O 
examined O 
, O 
ethanol B-SYSTEMATIC 
extracts O 
of O 
Gelidium O 
amansii O 
( O 
GAE O 
) O 
exhibited O 
potent O 
neuritogenic O 
activity O 
, O 
followed O 
by O 
Undaria O 
pinnatifida O 
and O 
Sargassum O 
fulvellum O 
extracts O 
. O 
The O 
effects O 
of O 
GAE O 
were O 
dose O 
dependent O 
with O 
an O 
optimum O 
concentration O 
of O 
15 O 
µg O 
/ O 
mL O 
. O 
The O 
GAE O 
significantly O 
promoted O 
the O 
initial O 
neuronal O 
differentiation O 
from O 
the O 
stage O 
I O 
into O 
the O 
stage O 
II O 
and O 
increased O 
the O 
indices O 
of O 
axonal O 
and O 
dendritic O 
development O 
such O 
as O 
the O 
length O 
, O 
the O 
numbers O 
of O 
primary O 
processes O 
, O 
and O 
branching O 
frequencies O 
by O 
a O 
minimum O 
of O 
twofold O 
compared O 
with O 
the O 
vehicle O 
control O 
. O 
These O 
results O 
show O 
that O 
marine O 
algae O 
are O 
promising O 
candidates O 
for O 
neurotrophic O 
potentials O 
. O 

immunosuppressive O 
cyclomyrsinol B-FAMILY 
diterpenes I-FAMILY 
from O 
Euphorbia O 
kopetdaghi O 
Prokh O 
. O 

: O 
chloroform B-TRIVIAL 
( O 
1 O 
: O 
2 O 
) O 
extracts O 
of O 
the O 
aerial O 
parts O 
of O 
Euphorbia O 
kopetdaghi O 
Prokh O 
. O 
( O 
Euphorbiaceae O 
) O 
were O 
investigated O 
for O 
its O 
diterpenoids B-FAMILY 
and O 
afforded O 
three O 
new O 
five O 
- O 
membered O 
ring O 
, O 
pentacyclic B-FAMILY 
myrisinane I-FAMILY 
polyester I-FAMILY 
comprised O 
of O 
3,5,10-O-triacetyl-8-O-isobutanoyl-14-O-benzoylcyclomyrsinol B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
3,5,10,14-O-tetraacetyl-8-O-(2'-methyl B-SYSTEMATIC 
butanoyl)-cyclomyrsinol I-SYSTEMATIC 
( O 
2 O 
) O 
and O 
3,5,10,14-O-tetracetyl-8-O-isobutanoylcyclomyrsinol B-SYSTEMATIC 
( O 
3 O 
) O 
. O 
The O 
structures O 
were O 
elucidated O 
based O 
on O 
(13)C B-FORMULA 
- O 
and O 
(1)H B-FORMULA 
-NMR O 
as O 
well O 
as O 
2D-NMR O 
, O 
IR O 
and O 
different O 
MS O 
spectra O 
and O 
the O 
immunomodulation O 
activity O 
for O 
compound O 
1 O 
was O 
evaluated O 
through O 
lymphocyte O 
proliferation O 
assay O 
, O 
IL-2 O 
assay O 
, O 
oxidative O 
burst O 
of O 
phagocytic O 
leukocytes O 
and O 
through O 
their O 
cytotoxicity O 
on O 
two O 
cell O 
lines O 
. O 
Compound O 
1 O 
showed O 
significant O 
suppressive O 
activity O 
against O 
phytohemagglutinin O 
- O 
activated O 
T-cell O 
proliferation O 
with O 
an O 
IC(50) O 
of O 
1.83 O 
µg O 
mL(-1) O 
, O 
IL-2 O 
suppressive O 
activity O 
with O 
an O 
IC(50) O 
of O 
19 O 
µg O 
mL(-1) O 
and O 
oxidative O 
burst O 
suppressive O 
activity O 
with O 
an O 
IC(50) O 
of O 
1.6 O 
µg O 
mL(-1) O 
and O 
ignorable O 
cytotoxic O 
effect O 
on O 
the O 
CC-1 O 
rat O 
hepatocyte O 
and O 
3T3-L1 O 
mouse O 
fibroblast O 
cell O 
- O 
lines O 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
examine O 
the O 
molecular O 
and O 
organism O 
reaction O 
of O 
rainbow O 
trout O 
, O 
Oncorhynchus O 
mykiss O 
, O 
to O 
the O 
combined O 
impact O 
of O 
two O 
environmental O 
stressors O 
. O 
The O 
two O 
stressors O 
were O 
the O 
myxozoan O 
parasite O 
, O 
Tetracapsuloides O 
bryosalmonae O 
, O 
which O 
is O 
the O 
etiological O 
agent O 
of O 
proliferative O 
kidney O 
disease O 
( O 
PKD O 
) O 
and O 
a O 
natural O 
stressor O 
to O 
salmonid O 
populations O 
, O 
and O 
17β-estradiol B-SYSTEMATIC 
( O 
E2 O 
) O 
as O 
prototype O 
of O 
estrogen B-FAMILY 
-active O 
chemical O 
stressors O 
in O 
the O 
aquatic O 
environment O 
. O 
Both O 
stressors O 
, O 
the O 
parasite O 
and O 
estrogenic O 
contaminants O 
, O 
co O 
- O 
exist O 
in O 
Swiss O 
rivers O 
and O 
are O 
discussed O 
as O 
factors O 
contributing O 
to O 
the O 
decline O 
of O 
Swiss O 
brown O 
trout O 
populations O 
over O 
the O 
last O 
decades O 
. O 
Using O 
a O 
microarray O 
approach O 
contrasting O 
parasite O 
- O 
infected O 
and O 
non-infected O 
rainbow O 
trout O 
at O 
low O 
or O 
high O 
estrogen B-FAMILY 
levels O 
, O 
it O 
was O 
observed O 
that O 
molecular O 
response O 
patterns O 
under O 
joint O 
exposure O 
differed O 
from O 
those O 
to O 
the O 
single O 
stressors O 
. O 
More O 
specifically O 
, O 
three O 
major O 
response O 
patterns O 
were O 
present O 
: O 
(i) O 
expression O 
responses O 
of O 
gene O 
transcripts O 
to O 
one O 
stressor O 
are O 
weakened O 
by O 
the O 
presence O 
of O 
the O 
second O 
stressor O 
; O 
(ii) O 
expression O 
responses O 
of O 
gene O 
transcripts O 
to O 
one O 
stressor O 
are O 
enhanced O 
by O 
the O 
presence O 
of O 
the O 
second O 
stressor O 
; O 
(iii) O 
expression O 
responses O 
of O 
gene O 
transcripts O 
at O 
joint O 
treatment O 
are O 
dominated O 
by O 
one O 
of O 
the O 
two O 
stressors O 
. O 
Organism O 
- O 
level O 
responses O 
to O 
concurrent O 
E2 O 
and O 
parasite O 
treatment O 
- O 
assessed O 
through O 
measuring O 
parasite O 
loads O 
in O 
the O 
fish O 
host O 
and O 
cumulative O 
mortalities O 
of O 
trout O 
- O 
were O 
dominated O 
by O 
the O 
pathogen O 
, O 
with O 
no O 
modulating O 
influence O 
of O 
E2 O 
. O 
The O 
findings O 
reveal O 
function- O 
and O 
level O 
- O 
specific O 
responses O 
of O 
rainbow O 
trout O 
to O 
stressor O 
combinations O 
, O 
which O 
are O 
only O 
partly O 
predictable O 
from O 
the O 
response O 
to O 
the O 
single O 
stressors O 
. O 

composition O 
of O 
essential O 
oils O 
isolated O 
from O 
leaves O 
of O 
11 O 
natural O 
populations O 
of O 
Cupressus O 
atlantica O 
, O 
an O 
endemic O 
and O 
endangered O 
coniferous O 
species O 
from O 
Morocco O 
, O 
was O 
investigated O 
by O 
GC-MS O 
. O 
In O 
total O 
, O 
42 O 
essential O 
oil O 
components O 
were O 
identified O 
, O 
accounting O 
for O 
73.1-97.7% O 
of O 
the O 
total O 
oil O 
. O 
Monoterpene B-FAMILY 
( O 
25.2-84.9% O 
) O 
and O 
sesquiterpene B-FAMILY 
hydrocarbons I-FAMILY 
( O 
12.2-46.8% O 
) O 
were O 
the O 
principal O 
subclasses O 
of O 
compounds O 
, O 
with O 
α-pinene B-TRIVIAL 
( O 
15-65.4% O 
) O 
, O 
germacrene B-TRIVIAL 
D I-TRIVIAL 
( O 
5.9-30.5% O 
) O 
, O 
δ-3-carene B-SYSTEMATIC 
( O 
2-16.6% O 
) O 
and O 
γ-cadinene B-TRIVIAL 
( O 
1.3-9.8% O 
) O 
as O 
the O 
main O 
constituents O 
. O 
The O 
results O 
of O 
the O 
oil O 
composition O 
were O 
analysed O 
by O 
hierarchical O 
cluster O 
and O 
principal O 
component O 
analysis O 
that O 
established O 
three O 
main O 
groups O 
of O 
essential O 
oils O 
. O 
These O 
oils O 
were O 
differentiated O 
by O 
the O 
content O 
of O 
the O 
major O 
constituents O 
( O 
α-pinene B-TRIVIAL 
, O 
germacrene B-TRIVIAL 
D I-TRIVIAL 
, O 
δ-3-carene B-SYSTEMATIC 
and O 
γ-cadinene B-TRIVIAL 
) O 
, O 
geographical O 
location O 
and O 
climatic O 
characteristics O 
. O 

phosphatase O 
type O 
2A O 
( O 
PP2A O 
) O 
enzymes O 
constitute O 
a O 
large O 
family O 
of O 
Ser B-FORMULA 
/ O 
Thr B-FORMULA 
phosphatases O 
with O 
multiple O 
functions O 
in O 
cellular O 
signaling O 
and O 
physiology O 
. O 
The O 
composition O 
of O 
heterotrimeric O 
PP2A O 
holoenzymes O 
, O 
resulting O 
from O 
the O 
combinatorial O 
assembly O 
of O 
a O 
catalytic O 
C O 
subunit O 
, O 
a O 
structural O 
A O 
subunit O 
, O 
and O 
regulatory O 
B O 
- O 
type O 
subunit O 
, O 
provides O 
the O 
essential O 
determinants O 
for O 
substrate O 
specificity O 
, O 
subcellular O 
targeting O 
, O 
and O 
fine O 
- O 
tuning O 
of O 
phosphatase O 
activity O 
, O 
largely O 
explaining O 
why O 
PP2A O 
is O 
functionally O 
involved O 
in O 
so O 
many O 
diverse O 
physiological O 
processes O 
, O 
sometimes O 
in O 
seemingly O 
opposing O 
ways O 
. O 
In O 
this O 
review O 
, O 
we O 
highlight O 
how O 
PP2A O 
holoenzyme O 
biogenesis O 
and O 
enzymatic O 
activity O 
are O 
controlled O 
by O 
a O 
sophisticatedly O 
coordinated O 
network O 
of O 
five O 
PP2A O 
modulators O 
, O 
consisting O 
of O 
α4 O 
, O 
phosphatase O 
2A O 
phosphatase O 
activator O 
( O 
PTPA O 
) O 
, O 
leucine B-SYSTEMATIC 
carboxyl I-SYSTEMATIC 
methyl I-SYSTEMATIC 
transferase O 
1 O 
( O 
LCMT1 O 
) O 
, O 
PP2A O 
methyl B-SYSTEMATIC 
esterase O 
1 O 
( O 
PME-1 O 
) O 
and O 
, O 
potentially O 
, O 
target O 
of O 
rapamycin B-TRIVIAL 
signaling O 
pathway O 
regulator O 
- O 
like O 
1 O 
( O 
TIPRL1 O 
) O 
, O 
which O 
serve O 
to O 
prevent O 
promiscuous O 
phosphatase O 
activity O 
until O 
the O 
holoenzyme O 
is O 
completely O 
assembled O 
. O 
Likewise O 
, O 
these O 
modulators O 
may O 
come O 
into O 
play O 
when O 
PP2A O 
holoenzymes O 
are O 
disassembled O 
following O 
particular O 
cellular O 
stresses O 
. O 
Malfunctioning O 
of O 
these O 
cellular O 
control O 
mechanisms O 
contributes O 
to O 
human O 
disease O 
. O 
The O 
potential O 
therapeutic O 
benefits O 
or O 
pitfalls O 
of O 
interfering O 
with O 
these O 
regulatory O 
mechanisms O 
will O 
be O 
briefly O 
discussed O 
. O 

disease O 
( O 
AD O 
) O 
is O 
characterized O 
by O 
signs O 
of O 
major O 
oxidative O 
stress O 
and O 
the O 
loss O 
of O 
cholinergic O 
cells O 
. O 
The O 
present O 
study O 
was O 
designed O 
to O 
investigate O 
the O 
role O 
of O 
the O 
total O 
alkaloidal O 
extract O 
from O 
Murraya O 
koenigii O 
( O 
MKA O 
) O 
leaves O 
on O 
age O 
related O 
oxidative O 
stress O 
and O 
the O 
cholinergic O 
pathway O 
in O 
aged O 
mice O 
. O 
Ascorbic B-TRIVIAL 
acid I-TRIVIAL 
( O 
100 O 
mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
was O 
used O 
as O 
a O 
standard O 
drug O 
. O 
The O 
MKA O 
improved O 
the O 
level O 
of O 
protective O 
antioxidants O 
such O 
as O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
, O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
, O 
glutathione B-TRIVIAL 
reductase O 
( O 
GRD O 
) O 
, O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
and O 
catalase O 
( O 
CAT O 
) O 
in O 
brain O 
homogenate O 
at O 
higher O 
doses O 
( O 
20 O 
and O 
40 O 
mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
. O 
Moreover O 
, O 
a O 
dose O 
dependent O 
decline O 
was O 
noted O 
in O 
lipid O 
peroxidation O 
( O 
LPO O 
) O 
and O 
the O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
assay O 
( O 
NO O 
) O 
at O 
all O 
doses O 
of O 
MKA O 
( O 
10 O 
, O 
20 O 
and O 
40 O 
mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
. O 
Interestingly O 
, O 
significant O 
progress O 
was O 
noted O 
with O 
the O 
supplementation O 
of O 
MKA O 
by O 
an O 
improvement O 
of O 
the O 
acetylcholine B-SYSTEMATIC 
( O 
ACh B-ABBREVIATION 
) O 
levels O 
and O 
a O 
reduction O 
in O 
the O 
acetylcholinesterase O 
( O 
AChE O 
) O 
activity O 
in O 
aged O 
mouse O 
brain O 
. O 
In O 
addition O 
, O 
a O 
significant O 
elevation O 
of O 
serum O 
albumin O 
( O 
ALBU O 
) O 
, O 
alkaline O 
phosphatase O 
( O 
ALP O 
) O 
, O 
alanine B-TRIVIAL 
transaminase O 
( O 
ALT O 
) O 
, O 
aspartate B-TRIVIAL 
transaminase O 
( O 
AST O 
) O 
and O 
total O 
protein O 
as O 
well O 
as O 
a O 
decline O 
in O 
creatinine B-TRIVIAL 
, O 
total O 
cholesterol B-TRIVIAL 
, O 
urea B-SYSTEMATIC 
nitrogen I-SYSTEMATIC 
and O 
glucose B-TRIVIAL 
levels O 
with O 
MKA O 
also O 
ameliorated O 
the O 
hepatic O 
and O 
renal O 
functions O 
in O 
normal O 
ageing O 
process O 
. O 
The O 
results O 
showed O 
the O 
possible O 
utility O 
of O 
Murraya O 
koenigii O 
leaves O 
in O 
neuroprotection O 
against O 
neurodegenerative O 
disorders O 
such O 
as O 
Alzheimer's O 
disease O 
. O 

reduces O 
high O 
- O 
fat O 
diet O 
- O 
induced O 
fat O 
accumulation O 
in O 
the O 
liver O 
by O 
regulating O 
lipid O 
metabolism O 
genes O 
. O 

understand O 
the O 
molecular O 
mechanisms O 
underlying O 
the O 
influence O 
of O 
quercetin B-TRIVIAL 
on O 
the O 
physiological O 
effects O 
of O 
hyperlipidemia O 
, O 
we O 
investigated O 
its O 
role O 
in O 
the O 
prevention O 
of O 
high O 
- O 
fat O 
diet O 
(HFD)-induced O 
obesity O 
and O 
found O 
that O 
it O 
regulated O 
hepatic O 
gene O 
expression O 
related O 
to O 
lipid O 
metabolism O 
. O 
Quercetin B-TRIVIAL 
supplementation O 
in O 
mice O 
significantly O 
reduced O 
the O 
HFD-induced O 
gains O 
in O 
body O 
weight O 
, O 
liver O 
weight O 
, O 
and O 
white O 
adipose O 
tissue O 
weight O 
compared O 
with O 
the O 
mice O 
fed O 
only O 
with O 
HFD O 
. O 
It O 
also O 
significantly O 
reduced O 
HFD-induced O 
increases O 
in O 
serum O 
lipids O 
, O 
including O 
cholesterol B-TRIVIAL 
, O 
triglyceride B-FAMILY 
, O 
and O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
-reactive O 
substance O 
( O 
TBARS O 
) O 
. O 
Consistent O 
with O 
the O 
reduced O 
liver O 
weight O 
and O 
white O 
adipose O 
tissue O 
weight O 
, O 
hepatic O 
lipid O 
accumulation O 
and O 
the O 
size O 
of O 
lipid O 
droplets O 
in O 
the O 
epididymal O 
fat O 
pads O 
were O 
also O 
reduced O 
by O 
quercetin B-TRIVIAL 
supplementation O 
. O 
To O 
further O 
investigate O 
how O 
quercetin B-TRIVIAL 
may O 
reduce O 
obesity O 
, O 
we O 
analyzed O 
lipid O 
metabolism O 
- O 
related O 
genes O 
in O 
the O 
liver O 
. O 
Quercetin B-TRIVIAL 
supplementation O 
altered O 
expression O 
profiles O 
of O 
several O 
lipid O 
metabolism O 
- O 
related O 
genes O 
, O 
including O 
Fnta O 
, O 
Pon1 O 
, O 
Pparg O 
, O 
Aldh1b1 O 
, O 
Apoa4 O 
, O 
Abcg5 O 
, O 
Gpam O 
, O 
Acaca O 
, O 
Cd36 O 
, O 
Fdft1 O 
, O 
and O 
Fasn O 
, O 
relative O 
to O 
those O 
in O 
HFD O 
control O 
mice O 
. O 
The O 
expression O 
patterns O 
of O 
these O 
genes O 
observed O 
by O 
quantitative O 
reverse O 
transcriptase O 
- O 
polymerase O 
chain O 
reaction O 
were O 
confirmed O 
by O 
immunoblot O 
assays O 
. O 
Collectively O 
, O 
our O 
results O 
indicate O 
that O 
quercetin B-TRIVIAL 
prevents O 
HFD-induced O 
obesity O 
in O 
C57B1 O 
/ O 
6 O 
mice O 
, O 
and O 
its O 
anti-obesity O 
effects O 
may O 
be O 
related O 
to O 
the O 
regulation O 
of O 
lipogenesis O 
at O 
the O 
level O 
of O 
transcription O 
. O 

orellana O 
L O 
. O 
, O 
urucum O 
, O 
or O 
urucu O 
, O 
a O 
native O 
tropical O 
tree O 
of O 
Central O 
and O 
South O 
American O 
rain O 
forests O 
is O 
used O 
to O 
treat O 
various O 
diseases O 
in O 
popular O 
medicine O 
. O 
In O 
Ceará O 
, O 
Northeast O 
of O 
Brazil O 
, O 
the O 
seeds O 
of O 
urucum O 
have O 
been O 
used O 
for O 
the O 
treatment O 
of O 
high O 
lipid O 
blood O 
levels O 
. O 
The O 
present O 
study O 
investigated O 
the O 
effects O 
of O 
the O 
aqueous O 
extract O 
from O 
Bixa O 
orellana O 
seeds O 
( O 
AEBO O 
) O 
in O 
mice O 
with O 
hyperlipidemia O 
induced O 
by O 
tyloxapol B-FAMILY 
, O 
fructose B-TRIVIAL 
and O 
ethanol B-SYSTEMATIC 
. O 
In O 
hyperlipidemia O 
induced O 
by O 
Triton B-TRIVIAL 
WR1339 I-TRIVIAL 
, O 
400 O 
and O 
800 O 
mg O 
/ O 
kg O 
AEBO O 
reduced O 
triglycerides B-FAMILY 
( O 
TG O 
) O 
serum O 
levels O 
at O 
24 O 
h O 
and O 
48 O 
h O 
. O 
In O 
the O 
study O 
of O 
hypertriglyceridemia O 
induced O 
by O 
fructose B-TRIVIAL 
, O 
AEBO O 
in O 
doses O 
of O 
400 O 
mg O 
/ O 
kg O 
and O 
800 O 
mg O 
/ O 
kg O 
reduced O 
TG O 
levels O 
by O 
48.2% O 
and O 
48.7% O 
, O 
respectively O 
. O 
Finally O 
, O 
the O 
ethanol B-SYSTEMATIC 
experimental O 
model O 
with O 
400 O 
mg O 
/ O 
kg O 
AEBO O 
promoted O 
a O 
reduction O 
of O 
33.6% O 
of O 
TG O 
levels O 
, O 
while O 
the O 
800 O 
mg O 
/ O 
kg O 
concentration O 
reduced O 
hypertriglyceridemia O 
in O 
62.2% O 
. O 
In O 
conclusion O 
, O 
the O 
aqueous O 
extract O 
of O 
the O 
seeds O 
of O 
Bixa O 
orellana O 
was O 
capable O 
of O 
reversing O 
the O 
hypertriglyceridemia O 
induced O 
by O 
Triton B-TRIVIAL 
, O 
fructose B-TRIVIAL 
and O 
ethanol B-SYSTEMATIC 
, O 
demonstrating O 
a O 
hypolipidemic O 
effect O 
. O 
However O 
, O 
further O 
studies O 
are O 
necessary O 
to O 
discover O 
the O 
precise O 
mechanism O 
of O 
action O 
. O 

, O 
a O 
novel O 
hexadienamide B-SYSTEMATIC 
from O 
Thai O 
soil O 
actinomycetes O 
. O 

new O 
hexadienamide O 
derivative O 
named O 
sarmentosamide B-TRIVIAL 
( O 
1 O 
) O 
was O 
identified O 
from O 
the O 
culture O 
of O 
Streptomyces O 
sp O 
. O 
SBI108 O 
isolated O 
from O 
Thai O 
soil O 
under O 
an O 
herb O 
. O 
The O 
structure O 
was O 
elucidated O 
on O 
the O 
basis O 
of O 
spectroscopic O 
data O 
, O 
and O 
the O 
absolute O 
configuration O 
was O 
determined O 
by O 
chemical O 
degradation O 
. O 

cancer O 
is O 
one O 
of O 
the O 
major O 
causes O 
of O 
cancer O 
mortality O 
worldwide O 
. O 
The O 
analysed O 
feeds O 
, O 
containing O 
non-genetically O 
modified O 
( O 
GM O 
) O 
soybean O 
and O 
Roundup O 
Ready O 
soybean O 
, O 
showed O 
a O 
different O 
polyphenolic B-FAMILY 
content O 
and O 
lipophilic O 
composition O 
. O 
Non-GM O 
soybean O 
extract O 
possessed O 
twice O 
the O 
polyphenolic B-FAMILY 
content O 
of O 
GM O 
soybean O 
and O 
the O 
highest O 
number O 
of O 
sterols B-FAMILY 
. O 
Among O 
them O 
, O 
γ-sitosterol B-TRIVIAL 
was O 
found O 
to O 
be O 
the O 
major O 
constituent O 
. O 
Methanolic O 
extract O 
of O 
non-GM O 
soybean O 
extract O 
was O 
more O 
potent O 
than O 
GM O 
soybean O 
extract O 
against O 
colon O 
carcinoma O 
cell O 
line O 
LoVo O 
using O 
MTT B-ABBREVIATION 
assay O 
, O 
while O 
the O 
second O 
one O 
showed O 
a O 
slightly O 
higher O 
anti-inflammatory O 
activity O 
. O 
The O 
findings O 
add O 
to O 
epidemiological O 
evidence O 
for O 
the O 
therapeutic O 
effects O 
of O 
soy O 
foods O 
in O 
colorectal O 
carcinoma O 
. O 

of O 
a O 
p-hydroxyphenyl B-SYSTEMATIC 
anhydride I-SYSTEMATIC 
from O 
the O 
leaves O 
of O 
Diphysa O 
carthagenensisw O 
. O 

( O 
1 O 
) O 
, O 
a O 
new O 
p-hydroxyphenyl B-SYSTEMATIC 
anhydride I-SYSTEMATIC 
, O 
and O 
vitexin B-TRIVIAL 
( O 
2 O 
) O 
were O 
isolated O 
from O 
the O 
leaves O 
of O 
Diphysa O 
carthagenensis O 
. O 
The O 
structure O 
of O 
the O 
new O 
metabolite O 
was O 
characterised O 
as O 
4-(4-hydroxy-phenyl)-3H-pyran-2,6-dione B-SYSTEMATIC 
using O 
1D O 
and O 
2D O 
NMR O 
spectroscopy O 
. O 

synaptic O 
plasticity O 
in O 
neurodegenerative O 
diseases O 
could O 
prevent O 
neuronal O 
degeneration O 
, O 
as O 
well O 
as O 
motor O 
and O 
cognitive O 
disorders O 
. O 
In O 
Parkinson's O 
disease O 
, O 
synaptic O 
plasticity O 
at O 
corticostriatal O 
synapses O 
is O 
altered O 
. O 
Dendrites O 
of O 
striatal O 
medium O 
spiny O 
neurons O 
( O 
MSNs O 
) O 
receive O 
dopaminergic O 
inputs O 
from O 
the O 
substantia O 
nigra O 
and O 
glutamatergic O 
cortical O 
afferents O 
. O 
Because O 
both O 
glutamate B-TRIVIAL 
and O 
dopamine B-TRIVIAL 
are O 
required O 
to O 
induce O 
and O 
sustain O 
MSNs O 
plasticity O 
, O 
the O 
particular O 
molecular O 
mechanisms O 
involved O 
at O 
this O 
synaptic O 
triad O 
are O 
difficult O 
to O 
understand O 
. O 
In O 
the O 
present O 
work O 
, O 
we O 
established O 
a O 
convenient O 
in O 
vitro O 
model O 
of O 
the O 
corticostriatal O 
synapse O 
to O 
study O 
synaptic O 
plasticity O 
. O 
We O 
focused O 
on O 
long O 
- O 
term O 
depression O 
involving O 
group O 
I O 
metabotropic O 
glutamate B-TRIVIAL 
( O 
mGlu O 
) O 
receptors O 
. O 
We O 
found O 
that O 
in O 
striatal O 
neurons O 
co O 
- O 
cultured O 
with O 
cortical O 
neurons O 
, O 
the O 
absence O 
of O 
dopaminergic O 
stimuli O 
favored O 
the O 
excess O 
of O 
glutamatergic O 
drive O 
from O 
cortical O 
neuron O 
terminals O 
, O 
thus O 
resulting O 
in O 
a O 
constitutive O 
depression O 
of O 
the O 
corticostriatal O 
glutamatergic O 
transmission O 
. O 
Indeed O 
, O 
concomitant O 
blockade O 
of O 
group O 
I O 
mGlu O 
receptors O 
and O 
activation O 
of O 
dopaminergic O 
receptors O 
stably O 
reduced O 
the O 
depression O 
of O 
the O 
synaptic O 
transmission O 
. O 
Thus O 
the O 
dependence O 
on O 
glutamate B-TRIVIAL 
and O 
dopamine B-TRIVIAL 
balance O 
of O 
the O 
corticostriatal O 
synapse O 
responsiveness O 
validates O 
the O 
accuracy O 
of O 
this O 
manageable O 
in O 
vitro O 
model O 
to O 
depict O 
the O 
molecular O 
pathways O 
involved O 
in O 
the O 
plasticity O 
at O 
corticostriatal O 
synapses O 
and O 
to O 
test O 
restorative O 
therapeutic O 
approaches O 
in O 
Parkinson's O 
disease O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

this O 
study O 
copper B-SYSTEMATIC 
, O 
nickel B-SYSTEMATIC 
, O 
lead O 
, O 
cadmium B-SYSTEMATIC 
, O 
arsenic B-SYSTEMATIC 
, O 
chromium B-SYSTEMATIC 
and O 
vanadium B-SYSTEMATIC 
content O 
was O 
measured O 
in O 
the O 
muscles O 
and O 
gills O 
of O 
24 O 
fishes O 
( O 
Sarda O 
sarda O 
, O 
Sardinella O 
aurita O 
and O 
Lepidopus O 
caudatus O 
) O 
caught O 
in O 
the O 
Strait O 
of O 
Messina O 
, O 
by O 
inductively O 
coupled O 
plasma O 
- O 
optical O 
emission O 
spectroscopy O 
with O 
microwave O 
digestion O 
techniques O 
. O 
In O 
general O 
, O 
it O 
was O 
found O 
that O 
arsenic B-SYSTEMATIC 
was O 
higher O 
than O 
other O 
analytes O 
in O 
all O 
fish O 
species O 
, O 
particularly O 
its O 
content O 
was O 
much O 
higher O 
in O 
S O 
. O 
aurita O 
than O 
in O 
the O 
other O 
two O 
exemplary O 
species O 
. O 
Lead O 
and O 
cadmium B-SYSTEMATIC 
were O 
always O 
detected O 
with O 
values O 
below O 
the O 
legal O 
limits O 
( O 
CE O 
no O 
. O 
1881 O 
/ O 
2006 O 
and O 
subsequent O 
modification O 
CE O 
no O 
. O 
629 O 
/ O 
2008 O 
) O 
. O 

new O 
abietane B-FAMILY 
diterpenoid I-FAMILY 
from O 
Salvia O 
xanthocheila O 
Boiss O 
. O 

the O 
chloroform B-TRIVIAL 
extract O 
of O 
aerial O 
part O 
of O 
Salvia O 
xanthocheila O 
Boiss O 
. O 
one O 
new O 
abietane B-FAMILY 
diterpenoid I-FAMILY 
, O 
xantoquinone B-TRIVIAL 
( O 
5α,6α-dimethoxy-7,11,14-trioxoabieta-8,12-diene B-SYSTEMATIC 
) O 
and O 
one O 
known O 
oleanene B-FAMILY 
triterpenoid I-FAMILY 
namely O 
1β,3β-dihydroxy-12-oleanene B-SYSTEMATIC 
were O 
isolated O 
. O 
The O 
structure O 
of O 
the O 
new O 
terpenoid B-FAMILY 
was O 
elucidated O 
by O 
comprehensive O 
spectroscopic O 
analysis O 
including O 
electron O 
ionisation O 
- O 
mass O 
spectra O 
, O 
(1)H B-FORMULA 
NMR O 
, O 
(13)C B-FORMULA 
NMR O 
, O 
distortionless O 
enchancement O 
by O 
polarisation O 
transfer O 
, O 
H B-FORMULA 
, O 
H B-FORMULA 
correlation O 
spectroscopy O 
, O 
heteronuclear O 
multiple O 
- O 
quantum O 
coherence O 
and O 
heteronuclear O 
multiple O 
- O 
bond O 
correlation O 
. O 

new O 
amide B-FAMILY 
and O 
a O 
new O 
monoterpene B-FAMILY 
from O 
the O 
seeds O 
of O 
Clausena O 
lansium O 
. O 

new O 
amide B-FAMILY 
( O 
2 O 
) O 
and O 
a O 
new O 
monoterpene B-FAMILY 
( O 
6 O 
) O 
were O 
isolated O 
from O 
the O 
seeds O 
of O 
Clausena O 
lansium O 
together O 
with O 
four O 
known O 
ones O 
( O 
1 O 
, O 
3-5 O 
) O 
. O 
The O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
elucidated O 
by O 
extensive O 
spectroscopic O 
analyses O 
. O 
The O 
absolute O 
configurations O 
of O 
1 O 
, O 
2 O 
and O 
6 O 
were O 
determined O 
by O 
optical O 
rotation O 
and O 
the O 
modified O 
Mosher's O 
method O 
. O 

triterpenoids B-FAMILY 
from O 
Morus O 
alba O 
L O 
. O 
stem O 
bark O 
. O 

lupeol B-TRIVIAL 
-type O 
pentacyclic B-FAMILY 
triterpenoids I-FAMILY 
characterised O 
as O 
lup-20(29)-en-3β-ol-27-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
moruslupenoic B-TRIVIAL 
acid I-TRIVIAL 
A I-TRIVIAL 
) O 
and O 
lup-12 B-SYSTEMATIC 
, I-SYSTEMATIC 
20(29)-dien-3β-ol-26-oic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
moruslupenoic B-TRIVIAL 
acid I-TRIVIAL 
B I-TRIVIAL 
) O 
and O 
lanst-5 B-SYSTEMATIC 
, I-SYSTEMATIC 
24-dien-3β-yl I-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
moruslanosteryl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
) O 
along O 
with O 
the O 
known O 
triterpenoidal O 
phytoconstituents O 
α-amyrin B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
β-amyrin-β-D-glucopyranoside B-TRIVIAL 
and O 
betulinic B-TRIVIAL 
acid I-TRIVIAL 
have O 
been O 
isolated O 
from O 
the O 
stem O 
bark O 
of O 
Morus O 
alba O 
L O 
. O 
( O 
Moraceae O 
) O 
. O 
The O 
structures O 
of O 
the O 
isolated O 
phytoconstituents O 
were O 
established O 
on O 
the O 
basis O 
of O 
spectral O 
data O 
analysis O 
and O 
chemical O 
means O 
. O 

between O 
L-DOPA B-ABBREVIATION 
and O 
a O 
novel O 
positive O 
allosteric O 
modulator O 
of O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
4 O 
: O 
implications O 
for O 
Parkinson's O 
disease O 
treatment O 
and O 
dyskinesia O 
. O 

III O 
metabotropic O 
glutamate B-TRIVIAL 
( O 
mGlu O 
) O 
receptors O 
are O 
localized O 
in O 
presynaptic O 
terminals O 
within O 
basal O 
ganglia O 
( O 
BG O 
) O 
circuitry O 
that O 
become O 
hyperactive O 
due O 
to O 
dopamine B-TRIVIAL 
depletion O 
in O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
. O 
For O 
this O 
reason O 
, O 
group O 
III O 
mGlu O 
receptors O 
, O 
in O 
particular O 
mGlu4 O 
, O 
have O 
been O 
considered O 
as O 
key O 
strategic O 
targets O 
for O 
non-dopaminergic O 
pharmacological O 
treatments O 
aimed O 
at O 
modulating O 
these O 
synapses O 
, O 
without O 
producing O 
the O 
well O 
known O 
side-effects O 
of O 
l-DOPA B-ABBREVIATION 
, O 
in O 
particular O 
the O 
highly O 
disabling O 
l-DOPA B-ABBREVIATION 
-induced O 
dyskinesia O 
( O 
LID O 
) O 
. O 
Herein O 
we O 
add O 
physiological O 
and O 
functional O 
support O 
to O 
this O 
hypothesis O 
using O 
Lu B-IDENTIFIER 
AF21934 I-IDENTIFIER 
, O 
a O 
novel O 
selective O 
and O 
brain O 
- O 
penetrant O 
mGlu4 O 
receptor O 
positive O 
allosteric O 
modulator O 
( O 
PAM O 
) O 
tool O 
compound O 
. O 
By O 
in O 
vitro O 
electrophysiological O 
recordings O 
we O 
demonstrate O 
that O 
Lu B-IDENTIFIER 
AF21934 I-IDENTIFIER 
inhibits O 
corticostriatal O 
synaptic O 
transmission O 
and O 
enhances O 
the O 
effect O 
of O 
the O 
orthosteric O 
mGlu4 O 
receptor O 
- O 
preferred O 
agonist O 
LSP1-2111 B-IDENTIFIER 
. O 
In O 
naïve O 
rats O 
, O 
Lu B-IDENTIFIER 
AF21934 I-IDENTIFIER 
dose O 
- O 
dependently O 
( O 
10 O 
and O 
30 O 
mg O 
/ O 
kg O 
) O 
alleviated O 
haloperidol B-TRIVIAL 
-induced O 
catalepsy O 
. O 
In O 
hemiparkinsonian O 
rats O 
( O 
unilateral O 
6-hydroxydopamine B-SYSTEMATIC 
lesion O 
of O 
the O 
substantia O 
nigra O 
pars O 
compacta O 
) O 
, O 
Lu B-IDENTIFIER 
AF21934 I-IDENTIFIER 
alone O 
did O 
not O 
affect O 
akinesia O 
at O 
the O 
doses O 
tested O 
( O 
10 O 
and O 
30 O 
mg O 
/ O 
kg O 
) O 
. O 
However O 
, O 
when O 
Lu B-IDENTIFIER 
AF21934 I-IDENTIFIER 
was O 
combined O 
with O 
sub O 
- O 
threshold O 
doses O 
of O 
l-DOPA B-ABBREVIATION 
( O 
1 O 
and O 
5 O 
mg O 
/ O 
kg O 
) O 
, O 
it O 
acted O 
synergistically O 
in O 
alleviating O 
akinesia O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
and O 
, O 
notably O 
, O 
also O 
reduced O 
the O 
incidence O 
of O 
LID O 
but O 
not O 
its O 
severity O 
. O 
Interestingly O 
, O 
these O 
effects O 
occurred O 
at O 
Lu B-IDENTIFIER 
AF21934 I-IDENTIFIER 
brain O 
free O 
concentrations O 
that O 
showed O 
functional O 
activity O 
in O 
in O 
vitro O 
screens O 
( O 
calcium B-SYSTEMATIC 
flux O 
and O 
electrophysiology O 
assays O 
) O 
. O 
These O 
results O 
support O 
the O 
potential O 
for O 
antiparkinsonian O 
clinical O 
use O 
of O 
a O 
combined O 
treatment O 
consisting O 
in O 
l-DOPA B-ABBREVIATION 
and O 
a O 
mGlu4 O 
receptor O 
PAM O 
to O 
reduce O 
efficacious O 
l-DOPA B-ABBREVIATION 
doses O 
( O 
generally O 
known O 
as O 
l-DOPA B-ABBREVIATION 
sparing O 
) O 
, O 
while O 
maintaining O 
the O 
same O 
benefit O 
on O 
PD O 
motor O 
troubles O 
, O 
and O 
at O 
the O 
same O 
time O 
minimizing O 
the O 
development O 
of O 
LID O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

triterpenoids B-FAMILY 
from O 
the O 
stem O 
bark O 
of O 
Hypodaphnis O 
zenkeri O 
. O 

new O 
pentacyclic B-FAMILY 
triterpenoid I-FAMILY 
and O 
three O 
new O 
derivatives O 
based O 
on O 
the O 
taraxer-14-ene B-TRIVIAL 
skeleton O 
with O 
a O 
C-28 O 
attached O 
a O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
group O 
have O 
been O 
isolated O 
from O 
the O 
stem O 
bark O 
of O 
Hypodaphnis O 
zenkeri O 
, O 
together O 
with O 
six O 
known O 
compounds O 
. O 
The O 
new O 
product O 
was O 
identified O 
as O 
2α,3α-dihydroxytaraxer-14-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
1 O 
) O 
. O 
Its O 
derivatives O 
, O 
2α,3α-diacetyltaraxer-14-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
2α,3α-di-O-carbonyl-2α,3α-dihydroxytaraxer-14-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
3 O 
) O 
and O 
2α,3α-dipropionyltaraxer-14-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
4 O 
) O 
were O 
obtained O 
by O 
semisynthesis O 
. O 
The O 
known O 
compounds O 
were O 
identified O 
as O 
3β-hydroxytaraxer-14-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
or O 
aleuritolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
5 O 
) O 
( O 
McPhail O 
, O 
A.T O 
. O 
, O 
McPhail O 
, O 
D.R O 
. O 
, O 
Wani O 
, O 
M.C O 
. O 
, O 
Wall O 
, O 
M.E O 
. O 
& O 
A.W O 
. O 
, O 
Nicholas O 
, O 
A.W O 
. O 
( O 
1989 O 
) O 
. O 
Identity O 
of O 
maprounic B-TRIVIAL 
acid I-TRIVIAL 
with O 
aleuritolic B-TRIVIAL 
acid I-TRIVIAL 
. O 
Revision O 
of O 
the O 
structure O 
of O 
maprounic B-TRIVIAL 
acid I-TRIVIAL 
: O 
X-ray O 
crystal O 
structure O 
of O 
p-bromobenzyl B-SYSTEMATIC 
acetylmaprounate I-SYSTEMATIC 
. O 
Journal O 
Natural O 
Products O 
, O 
52 O 
, O 
212 O 
) O 
, O 
3α-hydroxytaraxer-14-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
or O 
isoaleuritolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
6 O 
) O 
, O 
3α-acetyltaraxer-14-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
acetate I-SYSTEMATIC 
or O 
aleuritolic B-TRIVIAL 
acid I-TRIVIAL 
acetate I-TRIVIAL 
( O 
7 O 
) O 
( O 
Chaudhuri O 
, O 
S.K O 
. O 
, O 
Fullas O 
, O 
F O 
. O 
, O 
Brown O 
, O 
D.M O 
. O 
, O 
Wani O 
, O 
M.C O 
. O 
, O 
Wall O 
, O 
M.E O 
. O 
, O 
Cai O 
, O 
L O 
. O 
, O 
… O 
Kinghorn O 
, O 
A.D O 
. O 
( O 
1995 O 
) O 
. O 
Isolation O 
and O 
structural O 
elucidation O 
of O 
pentacyclic O 
triterpenoids O 
from O 
Maprounea O 
africana O 
. O 
Journal O 
of O 
Natural O 
Products O 
, O 
58 O 
, O 
1-9 O 
) O 
, O 
3-oxo-taraxer-14-ene B-SYSTEMATIC 
or O 
taraxerone B-TRIVIAL 
( O 
8 O 
) O 
β-sitosterol B-TRIVIAL 
( O 
9 O 
) O 
and O 
stigmasterol B-TRIVIAL 
( O 
10 O 
) O 
( O 
Kamboj O 
& O 
Saluja O 
, O 
2011 O 
) O 
, O 
together O 
with O 
fatty O 
acids O 
. O 
Their O 
structures O 
were O 
established O 
on O 
the O 
basis O 
of O 
spectroscopic O 
studies O 
and O 
chemical O 
transformations O 
. O 

new O 
flavonol B-TRIVIAL 
from O 
Oxytropis O 
ochrocephala O 
Bunge O 
. O 

new O 
acylated B-FAMILY 
flavonoid I-FAMILY 
, O 
3-O-rhamnocitrin-6-O-benzoyl-β-D-glucopyranoside B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
together O 
with O 
five O 
known O 
flavonoids B-FAMILY 
, O 
rhamnocitrin B-TRIVIAL 
( O 
2 O 
) O 
, O 
pratensein B-TRIVIAL 
( O 
3 O 
) O 
, O 
(3R)-7,3'-dihydroxy-2',4'-dimethoxyisoflavan B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
(3R)-7,2'-dihydroxy-3',4'-dimethoxyisoflavan B-SYSTEMATIC 
( O 
5 O 
) O 
and O 
isoliquiritigenin B-TRIVIAL 
( O 
6 O 
) O 
, O 
was O 
isolated O 
from O 
Oxytropis O 
ochrocephala O 
Bunge O 
. O 
The O 
structural O 
elucidation O 
of O 
the O 
isolated O 
compounds O 
was O 
primarily O 
based O 
on O 
HRESIMS O 
, O 
IR O 
and O 
1-D- O 
and O 
2-D-NMR O 
analyses O 
. O 

infusion O 
of O 
20-hydroxyecdysone B-SYSTEMATIC 
increased O 
mass O 
of O 
triceps O 
brachii O 
in O 
C57BL O 
/ O 
6 O 
mice O 
. O 

have O 
been O 
attributed O 
with O 
numerous O 
pharmacological O 
properties O 
in O 
animals O 
, O 
including O 
increasing O 
muscle O 
mass O 
, O 
and O 
20-hydroxyecdysone B-SYSTEMATIC 
( O 
20E O 
) O 
is O 
one O 
of O 
the O 
most O 
abundant O 
phytoecdysteroids B-FAMILY 
produced O 
by O 
plants O 
. O 
In O 
this O 
study O 
, O 
the O 
physiological O 
and O 
gene O 
expression O 
effects O 
of O 
20E O 
were O 
analyzed O 
in O 
C57BL O 
/ O 
6 O 
mice O 
given O 
a O 
continuous O 
infusion O 
of O 
saline O 
or O 
20E O 
( O 
5 O 
mg O 
/ O 
kg O 
/ O 
day O 
) O 
for O 
5 O 
or O 
15 O 
days O 
using O 
subcutaneously O 
implanted O 
Alzet O 
® O 
osmotic O 
pumps O 
. O 
The O 
masses O 
of O 
the O 
total O 
body O 
, O 
muscle O 
groups O 
and O 
organs O 
were O 
determined O 
. O 
There O 
was O 
a O 
significant O 
increase O 
( O 
p O 
= O 
0.01 O 
) O 
in O 
the O 
mass O 
of O 
triceps O 
brachii O 
in O 
mice O 
treated O 
with O 
20E O 
for O 
5 O 
days O 
( O 
115 O 
± O 
8 O 
mg O 
) O 
compared O 
with O 
mice O 
treated O 
with O 
saline O 
for O 
5 O 
days O 
( O 
88 O 
± O 
3 O 
mg O 
) O 
, O 
however O 
, O 
there O 
were O 
no O 
differences O 
in O 
the O 
other O 
measured O 
parameters O 
. O 
To O 
determine O 
potential O 
mechanisms O 
of O 
20E O 
in O 
skeletal O 
muscle O 
, O 
Illumina's O 
Mouse O 
Whole O 
Genome-6 O 
v2.0 O 
Expression O 
BeadChips O 
were O 
used O 
to O 
evaluate O 
changes O 
in O 
gene O 
expression O 
of O 
the O 
triceps O 
brachii O 
after O 
20E O 
infusion O 
. O 
Ingenuity O 
Pathways O 
Analysis O 
was O 
used O 
to O 
identify O 
genes O 
with O 
the O 
most O 
evidence O 
for O 
differential O 
expression O 
, O 
of O 
which O 
, O 
16 O 
genes O 
involved O 
in O 
the O 
skeletal O 
and O 
muscular O 
system O 
were O 
identified O 
. O 
Overall O 
, O 
the O 
data O 
suggest O 
that O 
20E O 
does O 
not O 
have O 
potent O 
anabolic O 
properties O 
, O 
however O 
, O 
a O 
muscle O 
- O 
specific O 
increase O 
was O 
observed O 
and O 
genes O 
were O 
identified O 
to O 
provide O 
an O 
explanation O 
for O 
the O 
muscle O 
accretion O 
. O 

and O 
antihyperlipidemic O 
activities O 
of O 
ethanolic O 
extract O 
of O 
Zygophyllum O 
album O 
in O 
streptozotocin B-TRIVIAL 
-induced O 
diabetic O 
mice O 
. O 

album O 
has O 
been O 
mentioned O 
in O 
Tunisian O 
system O 
of O 
folk O 
medicine O 
to O 
be O 
of O 
value O 
in O 
the O 
treatment O 
of O 
diabetes O 
mellitus O 
. O 
The O 
present O 
study O 
was O 
designed O 
to O 
investigate O 
the O 
possible O 
antihyperglycemic O 
effects O 
of O 
ethanolic O 
extracts O 
of O 
the O 
whole O 
plant O 
of O 
Z O 
. O 
album O 
on O 
blood O 
glucose B-TRIVIAL 
, O 
plasma O 
insulin O 
, O 
serum O 
lipids O 
and O 
hepatic O 
glycogen O 
and O 
metabolism O 
enzymes O 
of O 
carbohydrate B-FAMILY 
in O 
streptozotocin B-TRIVIAL 
( O 
STZ B-ABBREVIATION 
)-induced O 
diabetic O 
mice O 
. O 
Administration O 
of O 
the O 
ethanolic O 
extract O 
from O 
plant O 
( O 
100 O 
and O 
300 O 
mg O 
/ O 
kg O 
body O 
weight O 
) O 
for O 
14 O 
days O 
resulted O 
in O 
significant O 
reduction O 
in O 
plasma O 
glucose B-TRIVIAL 
, O 
cholesterol B-TRIVIAL 
, O 
triglycerides B-FAMILY 
, O 
low O 
- O 
density O 
lipoprotein O 
, O 
very O 
- O 
low O 
- O 
density O 
liprotein O 
, O 
hepatic O 
glucokinase O 
and O 
glycogen O 
in O 
STZ B-ABBREVIATION 
diabetic O 
mice O 
. O 
In O 
addition O 
to O 
that O 
, O 
significant O 
increase O 
in O 
plasma O 
high O 
- O 
density O 
lipoprotein O 
, O 
hepatic O 
phosphofructokinase O 
and O 
glucose-6 B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
dehydrogenase O 
was O 
observed O 
in O 
STZ B-ABBREVIATION 
diabetic O 
mice O 
. O 
After O 
administration O 
of O 
the O 
ethanolic O 
extract O 
, O 
the O 
increased O 
level O 
of O 
plasma O 
insulin O 
is O 
not O 
significant O 
in O 
diabetic O 
mice O 
. O 
In O 
conclusion O 
, O 
the O 
present O 
results O 
showed O 
that O 
the O 
ethanolic O 
extract O 
of O 
Z O 
. O 
album O 
possesses O 
significant O 
antihyperglycemic O 
and O 
antihyperlipidemic O 
effects O 
in O 
experimental O 
model O 
of O 
diabetes O 
mellitus O 
. O 

of O 
BCS O 
Class O 
II O 
drugs O 
are O 
produced O 
in O 
wet O 
stirred O 
media O 
mills O 
operating O 
in O 
batch O 
or O 
recirculation O 
mode O 
with O 
the O 
goal O 
of O 
resolving O 
the O 
poor O 
water O 
- O 
solubility O 
issue O 
. O 
Scant O 
information O 
is O 
available O 
regarding O 
the O 
continuous O 
production O 
of O 
drug O 
nanoparticles O 
via O 
wet O 
media O 
milling O 
. O 
Griseofulvin B-TRIVIAL 
and O 
Naproxen B-TRIVIAL 
were O 
milled O 
in O 
both O 
recirculation O 
mode O 
and O 
multi O 
- O 
pass O 
continuous O 
mode O 
to O 
study O 
the O 
breakage O 
dynamics O 
and O 
to O 
determine O 
the O 
effects O 
of O 
suspension O 
flow O 
rate O 
. O 
The O 
evolution O 
of O 
the O 
median O 
particle O 
size O 
was O 
measured O 
and O 
described O 
by O 
an O 
empirical O 
breakage O 
model O 
. O 
We O 
found O 
that O 
these O 
two O 
operation O 
modes O 
could O 
produce O 
drug O 
nanosuspensions O 
with O 
similar O 
particle O 
size O 
distributions O 
( O 
PSDs O 
) O 
. O 
A O 
reduced O 
suspension O 
flow O 
rate O 
slowed O 
the O 
breakage O 
rate O 
and O 
led O 
to O 
a O 
wider O 
PSD O 
and O 
more O 
differentiation O 
between O 
the O 
two O 
operation O 
modes O 
. O 
The O 
latter O 
part O 
of O 
this O 
study O 
focused O 
on O 
the O 
roles O 
of O 
stabilizers O 
( O 
hydroxypropyl B-SYSTEMATIC 
cellulose O 
and O 
sodium B-SYSTEMATIC 
lauryl I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
) O 
and O 
elucidation O 
of O 
the O 
so O 
- O 
called O 
Rehbinder O 
effect O 
( O 
reduction O 
in O 
particle O 
strength O 
due O 
to O 
adsorbed O 
stabilizers O 
such O 
as O 
polymers O 
and O 
surfactants O 
) O 
. O 
Milling O 
the O 
drugs O 
in O 
the O 
absence O 
of O 
the O 
stabilizers O 
produced O 
primary O 
nanoparticles O 
and O 
their O 
aggregates O 
, O 
while O 
milling O 
with O 
the O 
stabilizers O 
produced O 
smaller O 
primary O 
nanoparticles O 
with O 
minimal O 
aggregation O 
. O 
Using O 
laser O 
diffraction O 
, O 
BET O 
nitrogen B-SYSTEMATIC 
adsorption O 
, O 
scanning O 
electron O 
microscopy O 
imaging O 
, O 
and O 
a O 
microhydrodynamic O 
analysis O 
of O 
milling O 
, O 
this O 
study O 
, O 
for O 
the O 
first O 
time O 
, O 
provides O 
sufficient O 
evidence O 
for O 
the O 
existence O 
of O 
the O 
Rehbinder O 
effect O 
during O 
the O 
milling O 
of O 
drugs O 
. O 
Not O 
only O 
do O 
the O 
polymers O 
and O 
surfactants O 
allow O 
proper O 
stabilization O 
of O 
the O 
nanoparticles O 
in O 
the O 
suspensions O 
, O 
but O 
they O 
also O 
do O 
facilitate O 
drug O 
particle O 
breakage O 
. O 

of O 
the O 
cell O 
adhesion O 
protein O 
E-cadherin O 
increases O 
the O 
invasive O 
capability O 
of O 
ovarian O 
cancer O 
cells O 
. O 
We O 
have O 
previously O 
shown O 
that O 
epidermal O 
growth O 
factor O 
( O 
EGF O 
) O 
downregulates O 
E-cadherin O 
and O 
induces O 
ovarian O 
cancer O 
cell O 
invasion O 
through O 
the O 
H(2)O(2) B-FORMULA 
/ O 
p38 O 
MAPK O 
- O 
mediated O 
upregulation O 
of O 
the O 
E-cadherin O 
transcriptional O 
repressor O 
Snail O 
. O 
However O 
, O 
the O 
molecular O 
mechanisms O 
underlying O 
the O 
EGF-induced O 
downregulation O 
of O 
E-cadherin O 
are O 
not O 
fully O 
understood O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
demonstrated O 
that O 
treatment O 
of O 
two O 
ovarian O 
cancer O 
cell O 
lines O 
, O 
SKOV3 O 
and O 
OVCAR5 O 
, O 
with O 
EGF O 
induced O 
the O 
expression O 
of O 
the O 
transcription O 
factor O 
Egr-1 O 
, O 
and O 
this O 
induction O 
was O 
abolished O 
by O 
small O 
interfering O 
RNA O 
( O 
siRNA O 
) O 
- O 
mediated O 
depletion O 
of O 
the O 
EGF O 
receptor O 
. O 
EGF-induced O 
Egr-1 O 
expression O 
required O 
the O 
activation O 
of O 
the O 
ERK1 O 
/ O 
2 O 
and O 
PI3K O 
/ O 
Akt O 
signaling O 
pathways O 
and O 
was O 
unrelated O 
to O 
EGF-induced O 
H(2)O(2) B-FORMULA 
production O 
and O 
activation O 
of O 
the O 
p38 O 
MAPK O 
pathway O 
. O 
Moreover O 
, O 
depletion O 
of O 
Egr-1 O 
with O 
siRNA O 
abolished O 
the O 
EGF-induced O 
downregulation O 
of O 
E-cadherin O 
and O 
increased O 
cell O 
invasion O 
. O 
Interestingly O 
, O 
siRNA O 
depletion O 
of O 
Egr-1 O 
attenuated O 
the O 
EGF-induced O 
expression O 
of O 
Slug O 
, O 
but O 
not O 
that O 
of O 
Snail O 
. O 
Moreover O 
, O 
chromatin O 
immunoprecipitation O 
( O 
ChIP O 
) O 
analysis O 
showed O 
that O 
Slug O 
is O 
a O 
target O 
gene O 
of O 
Egr-1 O 
. O 
These O 
results O 
provide O 
evidence O 
that O 
Egr-1 O 
is O 
a O 
mediator O 
that O 
is O 
involved O 
in O 
the O 
EGF-induced O 
downregulation O 
of O 
E-cadherin O 
and O 
increased O 
cell O 
invasion O 
. O 
Our O 
results O 
also O 
demonstrate O 
that O 
EGF O 
activates O 
two O 
independent O 
signaling O 
pathways O 
, O 
which O 
are O 
the O 
H(2)O(2) B-FORMULA 
/ O 
p38 O 
MAPK O 
- O 
mediated O 
upregulation O 
of O 
Snail O 
expression O 
and O 
the O 
Egr-1 O 
- O 
mediated O 
upregulation O 
of O 
Slug O 
expression O 
. O 
These O 
two O 
signaling O 
pathways O 
contribute O 
to O 
the O 
EGF-induced O 
downregulation O 
of O 
E-cadherin O 
, O 
which O 
subsequently O 
increases O 
the O 
invasive O 
capability O 
of O 
ovarian O 
cancer O 
cells O 
. O 

objective O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
immunomodulatory O 
effects O 
of O 
the O 
purified O 
Ganoderma O 
atrum O 
polysaccharide O 
( O 
PSG-1 O 
) O 
on O 
murine O 
macrophage O 
cell O 
line O 
RAW264.7 O 
. O 
Phagocytotic O 
assay O 
by O 
fluorescein B-TRIVIAL 
isothiocyanate I-TRIVIAL 
-dextran O 
internalization O 
showed O 
that O 
PSG-1 O 
stimulated O 
the O 
phagocytosis O 
of O 
macrophages O 
. O 
G. O 
atrum O 
polysaccharide O 
increased O 
the O 
production O 
of O 
NO B-FORMULA 
, O 
and O 
the O 
level O 
of O 
mRNA O 
expression O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
in O 
a O 
dose O 
- O 
response O 
manner O 
. O 
G. O 
atrum O 
polysaccharide O 
also O 
dose O 
- O 
dependently O 
induced O 
the O 
release O 
of O 
TNF-α O 
and O 
interleukin-1β O 
. O 
Generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
was O 
promoted O 
by O 
PSG-1 O 
, O 
as O 
determined O 
by O 
flow O 
cytometry O 
. O 
Moreover O 
, O 
PSG-1 O 
induced O 
nuclear O 
factor-κB O 
activation O 
by O 
elevation O 
of O 
p65 O 
nuclear O 
translocation O 
, O 
suggesting O 
that O 
PSG-1 O 
probably O 
stimulated O 
macrophage O 
activities O 
by O 
activating O 
the O 
nuclear O 
factor-κB O 
pathway O 
. O 

of O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
-induced O 
red O 
blood O 
cells O 
lysis O 
by O 
Ilex O 
paraguariensis O 
aqueous O 
extract O 
: O 
participation O 
of O 
phenolic B-FAMILY 
and O 
xanthine B-TRIVIAL 
compounds O 
. O 

fresh O 
leaves O 
and O 
stems O 
of O 
Ilex O 
paraguariensis O 
( O 
Aquifoliaceae O 
) O 
are O 
employed O 
to O 
prepare O 
the O 
commercial O 
product O 
used O 
in O 
North O 
- O 
eastern O 
Argentina O 
, O 
Southern O 
Brazil O 
and O 
Eastern O 
Paraguay O 
named O 
yerba O 
maté O 
. O 
The O 
presence O 
of O 
polyphenols B-FAMILY 
and O 
xanthines B-FAMILY 
, O 
which O 
present O 
antioxidant O 
activity O 
, O 
has O 
been O 
described O 
in O 
I O 
. O 
paraguariensis O 
. O 
In O 
living O 
organism O 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
can O 
cause O 
tissue O 
damage O 
affecting O 
erythrocyte O 
membranes O 
leading O 
to O 
hemolysis O 
. O 
The O 
aim O 
of O 
this O 
work O 
was O 
to O 
evaluate O 
the O 
protective O 
effect O 
of O 
an O 
aqueous O 
extract O 
of O 
I O 
. O 
paraguariensis O 
( O 
green O 
leaves O 
) O 
on O 
the O 
hemolysis O 
of O 
red O 
blood O 
cells O 
induced O 
by O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
and O 
to O 
correlate O 
this O 
activity O 
with O 
the O 
enzymatic O 
activity O 
related O 
to O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
metabolism O 
. O 
The O 
antioxidant O 
activity O 
of O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
and O 
caffeine B-TRIVIAL 
was O 
also O 
analysed O 
to O 
evaluate O 
their O 
contribution O 
to O 
the O 
activity O 
of O 
the O 
crude O 
extract O 
. O 
The O 
extract O 
as O 
well O 
as O 
the O 
isolated O 
compounds O 
protected O 
red O 
blood O 
cells O 
from O 
hemolysis O 
. O 
This O 
effect O 
was O 
related O 
to O 
a O 
catalase O 
- O 
like O 
activity O 
. O 
This O 
study O 
could O 
contribute O 
to O 
the O 
knowledge O 
of O 
the O 
antioxidant O 
activity O 
of O 
I O 
. O 
paraguariensis O 
in O 
view O 
of O 
the O 
great O 
quantities O 
of O 
yerba O 
maté O 
consumed O 
by O 
the O 
population O 
. O 

has O 
shown O 
an O 
efficacy O 
in O 
preventing O 
and O 
managing O 
various O 
health O 
conditions O 
. O 
This O 
study O 
aimed O 
to O 
evaluate O 
the O 
effect O 
of O 
the O 
fermented O 
ginseng O 
extract O 
( O 
FGE O 
) O 
in O 
type O 
2 O 
diabetes O 
mellitus O 
murine O 
model O 
. O 
FGE O 
was O 
provided O 
to O 
male O 
C57BL O 
/ O 
ksJ-db O 
/ O 
db O 
mice O 
for O 
8 O 
weeks O 
at O 
0.1% O 
( O 
w O 
/ O 
w O 
) O 
dose O 
in O 
contrast O 
to O 
water O 
for O 
the O 
control O 
group O 
. O 
Potential O 
anti-diabetic O 
mechanisms O 
were O 
investigated O 
with O 
blood O 
glucose O 
, O 
serum O 
insulin O 
, O 
serum O 
adiponectin O 
, O 
hemoglobin O 
A1c O 
( O 
HbA1c O 
) O 
, O 
glucose B-TRIVIAL 
tolerance O 
, O 
insulin O 
secretion O 
assay O 
, O 
quantitative O 
real O 
- O 
time O 
polymerase O 
chain O 
reaction O 
, O 
and O 
hematoxylin B-TRIVIAL 
- O 
eosin B-FAMILY 
staining O 
. O 
Compared O 
with O 
the O 
control O 
group O 
, O 
the O 
FGE O 
group O 
had O 
lower O 
levels O 
of O 
blood O 
glucose B-TRIVIAL 
after O 
6 O 
and O 
9 O 
h O 
fasting O 
, O 
HbA1c O 
, O 
and O 
the O 
area O 
under O 
the O 
curve O 
in O 
an O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
and O 
higher O 
levels O 
of O 
adiponectin O 
and O 
serum O 
insulin O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
FGE O 
group O 
had O 
higher O 
levels O 
of O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
gamma O 
2 O 
and O 
glucose B-TRIVIAL 
transporter O 
protein O 
2 O 
mRNAs O 
, O 
a O 
lower O 
level O 
of O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
( O 
p O 
< O 
0.05 O 
) O 
, O 
and O 
less O 
lymphocytes O 
in O 
pancreas O 
than O 
the O 
control O 
group O 
had O 
. O 
The O 
FGE O 
exerted O 
anti-diabetic O 
effects O 
in O 
type O 
2 O 
diabetic O 
mice O 
. O 

outermost O 
layer O 
of O 
skin O 
, O 
stratum O 
corneum O 
, O 
being O 
lipophilic O 
limits O 
the O 
passive O 
transport O 
of O 
hydrophilic O 
and O 
large O 
molecular O 
weight O 
drugs O 
. O 
Microfabrication O 
technology O 
has O 
been O 
adapted O 
to O 
fabricate O 
micron O 
scale O 
needles O 
, O 
which O 
are O 
minimally O 
invasive O 
, O 
yet O 
able O 
to O 
deliver O 
the O 
drugs O 
across O 
this O 
barrier O 
layer O 
. O 
In O 
this O 
study O 
, O 
we O 
fabricated O 
microneedles O 
from O 
a O 
biocompatible O 
polymer O 
, O 
namely O 
, O 
poly B-FAMILY 
( I-FAMILY 
ethylene I-FAMILY 
glycol I-FAMILY 
) I-FAMILY 
diacrylate I-FAMILY 
. O 
A O 
simple O 
lithographical O 
approach O 
was O 
developed O 
for O 
microneedle O 
array O 
fabrication O 
. O 
Several O 
factors O 
including O 
polymerization O 
time O 
, O 
ultraviolet O 
light O 
intensity O 
and O 
distance O 
from O 
light O 
source O 
were O 
studied O 
for O 
their O 
effects O 
on O 
microneedle O 
formation O 
. O 
The O 
microneedle O 
length O 
and O 
tip O 
diameter O 
can O 
be O 
controlled O 
by O 
varying O 
these O 
factors O 
. O 
The O 
microneedles O 
were O 
shown O 
to O 
be O 
able O 
to O 
penetrate O 
cadaver O 
pig O 
skin O 
. O 
Model O 
drug O 
rhodamine B-TRIVIAL 
B I-TRIVIAL 
was O 
encapsulated O 
in O 
the O 
range O 
of O 
50 O 
µg O 
to O 
450 O 
µg O 
per O 
microneedle O 
array O 
. O 
The O 
fabricated O 
microneedles O 
containing O 
rhodamine B-TRIVIAL 
B I-TRIVIAL 
increased O 
the O 
permeability O 
by O 
four O 
times O 
than O 
the O 
control O 
. O 
Altogether O 
, O 
we O 
demonstrated O 
that O 
the O 
microneedle O 
arrays O 
can O 
be O 
fabricated O 
through O 
a O 
simple O 
single O 
- O 
step O 
process O 
and O 
needles O 
were O 
mechanically O 
strong O 
to O 
penetrate O 
skin O 
, O 
increasing O 
the O 
permeability O 
of O 
encapsulated O 
drug O 
through O 
skin O 
. O 

of O 
estradiol B-TRIVIAL 
in O 
adult O 
neurogenesis O 
and O 
brain O 
repair O 
in O 
zebrafish O 
. O 

brain O 
of O 
the O 
adult O 
teleost O 
fish O 
exhibits O 
intense O 
neurogenic O 
activity O 
and O 
an O 
outstanding O 
capability O 
for O 
brain O 
repair O 
. O 
Remarkably O 
, O 
the O 
brain O 
estrogen B-FAMILY 
-synthesizing O 
enzyme O 
, O 
aromatase O 
B O 
, O 
is O 
strongly O 
expressed O 
, O 
particularly O 
in O 
adult O 
fishes O 
, O 
in O 
radial O 
glial O 
cells O 
, O 
which O 
act O 
as O 
progenitors O 
. O 
Using O 
zebrafish O 
, O 
we O 
tested O 
the O 
hypothesis O 
that O 
estrogens B-FAMILY 
affect O 
adult O 
neurogenesis O 
and O 
brain O 
regeneration O 
by O 
modulating O 
the O 
neurogenic O 
activity O 
of O 
radial O 
glial O 
cells O 
. O 
To O 
investigate O 
this O 
, O 
the O 
estrogenic O 
environment O 
was O 
modified O 
through O 
inhibition O 
of O 
aromatase O 
activity O 
, O 
blockade O 
of O 
nuclear O 
estrogen B-FAMILY 
receptors O 
, O 
or O 
estrogenic O 
treatments O 
. O 
Estrogens O 
significantly O 
decreased O 
cell O 
proliferation O 
and O 
migration O 
at O 
the O 
olfactory O 
bulbs O 
/ O 
telencephalon O 
junction O 
and O 
in O 
the O 
mediobasal O 
hypothalamus O 
. O 
It O 
also O 
appears O 
that O 
cell O 
survival O 
is O 
reduced O 
at O 
the O 
olfactory O 
bulbs O 
/ O 
telencephalon O 
junction O 
. O 
We O 
also O 
developed O 
a O 
model O 
of O 
telencephalic O 
lesion O 
to O 
assess O 
the O 
role O 
of O 
aromatase O 
and O 
estrogens B-FAMILY 
in O 
brain O 
repair O 
. O 
Proliferation O 
increased O 
rapidly O 
immediately O 
after O 
the O 
lesion O 
in O 
the O 
parenchyma O 
of O 
the O 
injured O 
telencephalon O 
, O 
while O 
proliferation O 
at O 
the O 
ventricular O 
surface O 
appeared O 
after O 
48 O 
h O 
and O 
peaked O 
at O 
7 O 
days O 
. O 
At O 
this O 
time O 
, O 
most O 
proliferative O 
cells O 
express O 
Sox2 O 
, O 
however O 
, O 
none O 
of O 
these O 
Sox2 O 
positive O 
cells O 
correspond O 
to O 
aromatase O 
B-positive O 
radial O 
glial O 
cells O 
. O 
Interestingly O 
, O 
aromatase O 
B O 
expression O 
was O 
significantly O 
reduced O 
48 O 
h O 
and O 
7 O 
days O 
after O 
the O 
injury O 
, O 
but O 
surprisingly O 
, O 
at O 
72 O 
h O 
after O 
lesion O 
, O 
aromatase O 
B O 
expression O 
appeared O 
de O 
novo O 
expressed O 
in O 
parenchyma O 
cells O 
, O 
suggesting O 
a O 
role O 
for O 
this O 
ectopic O 
expression O 
of O 
aromatase O 
in O 
brain O 
repair O 
mechanisms O 
. O 
Altogether O 
these O 
data O 
suggest O 
that O 
estrogens B-FAMILY 
modulate O 
adult O 
, O 
but O 
not O 
reparative O 
neurogenesis O 
, O 
in O 
zebrafish O 
. O 

objective O 
of O 
this O 
study O 
was O 
to O 
improve O 
the O 
dissolution O 
rate O 
and O 
to O 
enhance O 
the O 
stability O 
of O 
a O 
poorly O 
water O 
- O 
soluble O 
and O 
low O 
glass O 
- O 
trasition O 
temperature O 
(T(g)) O 
model O 
drug O 
, O 
fenofibrate B-TRIVIAL 
, O 
in O 
low O 
molecular O 
weight O 
grades O 
of O 
hydroxypropylcellulose O 
matrices O 
produced O 
by O 
hot O 
- O 
melt O 
extrusion O 
( O 
HME O 
) O 
. O 
Percent O 
drug O 
loading O 
had O 
a O 
significant O 
effect O 
on O 
the O 
extrudability O 
of O 
the O 
formulations O 
. O 
Dissolution O 
rate O 
of O 
fenofibrate B-TRIVIAL 
from O 
melt O 
extruded O 
pellets O 
was O 
faster O 
than O 
that O 
of O 
the O 
pure O 
drug O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Incorporation O 
of O 
sugars B-FAMILY 
within O 
the O 
formulation O 
further O 
increased O 
the O 
fenofibrate B-TRIVIAL 
release O 
rates O 
. O 
Differential O 
scanning O 
calorimetry O 
results O 
revealed O 
that O 
the O 
crystalline O 
drug O 
was O 
converted O 
into O 
an O 
amorphous O 
form O 
during O 
the O 
HME O 
process O 
. O 
Fenofibrate B-TRIVIAL 
is O 
prone O 
to O 
recrystallization O 
due O 
to O 
its O 
low O 
T(g) O 
. O 
Various O 
polymers O 
were O 
evaluated O 
as O 
stabilizing O 
agents O 
among O 
which O 
polyvinylpyrrolidone B-SYSTEMATIC 
17PF O 
and O 
amino B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
copolymer O 
exhibited O 
a O 
significant O 
inhibitory O 
effect O 
on O 
fenofibrate B-TRIVIAL 
recrystallization O 
in O 
the O 
hot O 
- O 
melt O 
extrudates O 
. O 
Subsequently O 
immediate O 
- O 
release O 
fenofibrate B-TRIVIAL 
tablets O 
were O 
successfully O 
developed O 
and O 
complete O 
drug O 
release O 
was O 
achieved O 
within O 
5 O 
min O 
. O 
The O 
dissolution O 
profile O 
was O 
comparable O 
to O 
that O 
of O 
a O 
currently O 
marketed O 
formulation O 
. O 
The O 
hot O 
- O 
melt O 
extruded O 
fenofibrate B-TRIVIAL 
tablets O 
were O 
stable O 
, O 
and O 
exhibited O 
an O 
unchanged O 
drug O 
release O 
profile O 
after O 
3-month O 
storage O 
at O 
40°C O 
/ O 
75% O 
RH O 
. O 

Hippo O 
signaling O 
pathway O 
regulates O 
cellular O 
proliferation O 
and O 
survival O 
, O 
thus O 
exerting O 
profound O 
effects O 
on O 
normal O 
cell O 
fate O 
and O 
tumorigenesis O 
. O 
The O 
pivotal O 
effector O 
of O 
this O 
pathway O 
is O 
YAP O 
, O 
a O 
transcriptional O 
co O 
- O 
activator O 
amplified O 
in O 
mouse O 
and O 
human O 
cancers O 
where O 
it O 
promotes O 
epithelial O 
- O 
to O 
- O 
mesenchymal O 
transition O 
and O 
malignant O 
transformation O 
. O 
Here O 
, O 
we O 
report O 
a O 
novel O 
regulatory O 
mechanism O 
for O 
the O 
YAP O 
oncogenic O 
function O 
via O 
direct O 
interaction O 
with O 
non-receptor O 
tyrosine B-TRIVIAL 
phosphatase O 
14 O 
( O 
PTPN14 O 
) O 
through O 
the O 
WW O 
domain O 
of O 
YAP O 
and O 
the O 
PPxY O 
domain O 
of O 
PTPN14 O 
. O 
We O 
also O 
found O 
that O 
YAP O 
is O 
a O 
direct O 
substrate O 
of O 
PTPN14 O 
. O 
In O 
addition O 
, O 
luciferase O 
reporter O 
assay O 
showed O 
that O 
the O 
inhibition O 
of O 
the O 
YAP O 
transcriptional O 
co O 
- O 
activator O 
function O 
by O 
PTPN14 O 
is O 
mediated O 
through O 
their O 
protein O 
interactions O 
and O 
may O 
result O 
from O 
an O 
increase O 
in O 
the O 
inactive O 
cytoplasmic O 
form O 
of O 
YAP O 
. O 
Last O 
, O 
knockdown O 
of O 
PTPN14 O 
induces O 
the O 
nuclear O 
retention O 
of O 
YAP O 
and O 
increases O 
the O 
YAP-dependent O 
cell O 
migration O 
. O 
In O 
summary O 
, O 
our O 
results O 
indicate O 
a O 
potential O 
regulatory O 
role O 
of O 
PTPN14 O 
on O 
YAP O 
and O 
demonstrate O 
a O 
novel O 
mechanism O 
in O 
YAP O 
regulation O 
. O 

aggressiveness O 
of O 
glioblastoma O 
multiforme O 
( O 
GBM O 
) O 
is O 
defined O 
by O 
local O 
invasion O 
and O 
resistance O 
to O 
therapy O 
. O 
Within O 
established O 
GBM O 
, O 
a O 
subpopulation O 
of O 
tumor O 
- O 
initiating O 
cells O 
with O 
stem O 
- O 
like O 
properties O 
( O 
GBM O 
stem O 
cells O 
, O 
GSCs O 
) O 
is O 
believed O 
to O 
underlie O 
resistance O 
to O 
therapy O 
. O 
The O 
metabolic O 
pathway O 
autophagy O 
has O 
been O 
implicated O 
in O 
the O 
regulation O 
of O 
survival O 
in O 
GBM O 
. O 
However O 
, O 
the O 
status O 
of O 
autophagy O 
in O 
GBM O 
and O 
its O 
role O 
in O 
the O 
cancer O 
stem O 
cell O 
fraction O 
is O 
currently O 
unclear O 
. O 
We O 
found O 
that O 
a O 
number O 
of O 
autophagy O 
regulators O 
are O 
highly O 
expressed O 
in O 
GBM O 
tumors O 
carrying O 
a O 
mesenchymal O 
signature O 
, O 
which O 
defines O 
aggressiveness O 
and O 
invasion O 
, O 
and O 
are O 
associated O 
with O 
components O 
of O 
the O 
MAPK O 
pathway O 
. O 
This O 
autophagy O 
signature O 
included O 
the O 
autophagy O 
- O 
associated O 
genes O 
DRAM1 O 
and O 
SQSTM1 O 
, O 
which O 
encode O 
a O 
key O 
regulator O 
of O 
selective O 
autophagy O 
, O 
p62 O 
. O 
High O 
levels O 
of O 
DRAM1 O 
were O 
associated O 
with O 
shorter O 
overall O 
survival O 
in O 
GBM O 
patients O 
. O 
In O 
GSCs O 
, O 
DRAM1 O 
and O 
SQSTM1 O 
expression O 
correlated O 
with O 
activation O 
of O 
MAPK O 
and O 
expression O 
of O 
the O 
mesenchymal O 
marker O 
c-MET O 
. O 
DRAM1 O 
knockdown O 
decreased O 
p62 O 
localization O 
to O 
autophagosomes O 
and O 
its O 
autophagy O 
- O 
mediated O 
degradation O 
, O 
thus O 
suggesting O 
a O 
role O 
for O 
DRAM1 O 
in O 
p62 O 
- O 
mediated O 
autophagy O 
. O 
In O 
contrast O 
, O 
autophagy O 
induced O 
by O 
starvation O 
or O 
inhibition O 
of O 
mTOR O 
/ O 
PI-3K O 
was O 
not O 
affected O 
by O 
either O 
DRAM1 O 
or O 
p62 O 
downregulation O 
. O 
Functionally O 
, O 
DRAM1 O 
and O 
p62 O 
regulate O 
cell O 
motility O 
and O 
invasion O 
in O 
GSCs O 
. O 
This O 
was O 
associated O 
with O 
alterations O 
of O 
energy O 
metabolism O 
, O 
in O 
particular O 
reduced O 
ATP B-ABBREVIATION 
and O 
lactate B-FAMILY 
levels O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
shed O 
new O 
light O 
on O 
the O 
role O 
of O 
autophagy O 
in O 
GBM O 
and O 
reveal O 
a O 
novel O 
function O 
of O 
the O 
autophagy O 
regulators O 
DRAM1 O 
and O 
p62 O 
in O 
control O 
of O 
migration O 
/ O 
invasion O 
in O 
cancer O 
stem O 
cells O 
. O 

II O 
metabotropic O 
glutamate B-TRIVIAL 
( O 
mGlu O 
) O 
receptors O 
are O 
known O 
to O 
induce O 
a O 
long O 
- O 
term O 
depression O 
( O 
LTD O 
) O 
of O 
synaptic O 
transmission O 
in O 
many O 
brain O 
regions O 
including O 
the O 
amygdala O 
. O 
However O 
the O 
roles O 
of O 
the O 
individual O 
receptor O 
subtypes O 
, O 
mGlu2 O 
and O 
mGlu3 O 
, O 
in O 
LTD O 
are O 
not O 
well O 
understood O 
. O 
In O 
particular O 
, O 
it O 
is O 
unclear O 
whether O 
activation O 
of O 
mGlu3 O 
receptors O 
is O 
sufficient O 
to O 
induce O 
LTD O 
at O 
synapses O 
in O 
the O 
CNS O 
. O 
In O 
the O 
present O 
study O 
, O 
advantage O 
was O 
taken O 
of O 
a O 
Wistar O 
rat O 
strain O 
not O 
expressing O 
mGlu2 O 
receptors O 
( O 
Ceolin O 
et O 
al O 
. O 
, O 
2011 O 
) O 
to O 
investigate O 
the O 
function O 
of O 
mGlu3 O 
receptors O 
in O 
the O 
amygdala O 
. O 
In O 
this O 
preparation O 
, O 
the O 
group O 
II O 
agonist O 
, O 
DCG-IV O 
induced O 
an O 
LTD O 
of O 
the O 
cortical O 
, O 
but O 
not O 
the O 
intra O 
- O 
nuclear O 
, O 
synaptic O 
input O 
to O 
the O 
lateral O 
amygdala O 
. O 
This O 
LTD O 
was O 
concentration O 
dependent O 
and O 
was O 
blocked O 
by O 
the O 
group O 
II O 
mGlu O 
receptor O 
antagonist O 
, O 
LY341495 B-IDENTIFIER 
. O 
To O 
investigate O 
further O 
the O 
role O 
of O 
mGlu3 O 
receptors O 
, O 
we O 
used O 
LY395756 B-IDENTIFIER 
( O 
an O 
mGlu2 O 
agonist O 
and O 
mGlu3 O 
antagonist O 
) O 
, O 
which O 
acts O 
as O 
a O 
pure O 
mGlu3 O 
receptor O 
antagonist O 
in O 
this O 
rat O 
strain O 
. O 
This O 
compound O 
alone O 
had O 
no O 
effect O 
on O 
basal O 
synaptic O 
transmission O 
, O 
but O 
blocked O 
the O 
LTD O 
induced O 
by O 
DCG-IV O 
. O 
Furthermore O 
, O 
we O 
found O 
that O 
DCG-IV O 
also O 
induces O 
LTD O 
in O 
mGlu2 O 
receptor O 
knock O 
- O 
out O 
( O 
KO O 
) O 
mice O 
to O 
a O 
similar O 
extent O 
as O 
in O 
wild O 
- O 
type O 
mice O 
. O 
This O 
confirms O 
that O 
the O 
activation O 
of O 
mGlu3 O 
receptors O 
alone O 
is O 
sufficient O 
to O 
induce O 
LTD O 
at O 
this O 
amygdala O 
synapse O 
. O 
To O 
address O 
whether O 
mGlu2 O 
activation O 
alone O 
is O 
also O 
sufficient O 
to O 
induce O 
LTD O 
at O 
this O 
synapse O 
we O 
used O 
LY541850 B-IDENTIFIER 
( O 
the O 
active O 
enantiomer O 
of O 
LY395756 B-IDENTIFIER 
) O 
in O 
wild O 
- O 
type O 
mice O 
. O 
LY541850 B-IDENTIFIER 
induced O 
a O 
substantial O 
LTD O 
showing O 
that O 
either O 
receptor O 
alone O 
is O 
capable O 
of O 
inducing O 
LTD O 
in O 
this O 
pathway O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

of O 
water O 
extracts O 
from O 
edible O 
myrtaceae O 
plants O 
on O 
uptake O 
of O 
2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose B-SYSTEMATIC 
in O 
TNF-α O 
- O 
treated O 
FL83B O 
mouse O 
hepatocytes O 
. O 

study O 
investigated O 
the O 
glucose B-TRIVIAL 
uptake O 
activity O 
of O 
the O 
water O 
extracts O 
from O 
the O 
leaves O 
and O 
fruit O 
of O 
edible O 
Myrtaceae O 
plants O 
, O 
including O 
guava O 
( O 
Psidium O 
guajava O 
Linn O 
. O 
) O 
, O 
wax O 
apples O 
[ O 
Syzygium O 
samarangense O 
( O 
Blume O 
) O 
Merr O 
. O 
and O 
L.M O 
. O 
Perry O 
] O 
, O 
Pu-Tau O 
[ O 
Syzygium O 
jambo O 
( O 
L O 
. O 
) O 
Alston O 
] O 
, O 
and O 
Kan-Shi O 
Pu-Tau O 
( O 
Syzygium O 
cumini O 
Linn O 
. O 
) O 
in O 
FL83B O 
mouse O 
hepatocytes O 
. O 
The O 
fluorescent O 
dye O 
2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucos B-SYSTEMATIC 
e O 
was O 
used O 
to O 
estimate O 
the O 
uptake O 
ability O 
of O 
the O 
cells O 
. O 
Glucose O 
uptake O 
test O 
showed O 
that O 
pink O 
wax O 
apple O 
fruit O 
extract O 
( O 
PWFE O 
) O 
exhibits O 
the O 
highest O 
glucos B-TRIVIAL 
e O 
uptake O 
activity O 
, O 
at O 
an O 
increment O 
of O 
21% O 
in O 
the O 
insulin O 
- O 
resistant O 
FL83B O 
mouse O 
hepatocytes O 
as O 
compared O 
with O 
the O 
TNF-α O 
- O 
treated O 
control O 
group O 
. O 
Vescalagin O 
was O 
isolated O 
using O 
column O 
chromatography O 
of O 
PWFE O 
. O 
This O 
compound O 
, O 
at O 
the O 
concentration O 
of O 
6.25 O 
µg O 
/ O 
mL O 
, O 
exhibits O 
the O 
same O 
glucos B-TRIVIAL 
e O 
uptake O 
improvement O 
in O 
insulin O 
- O 
resistant O 
cells O 
as O 
PWFE O 
at O 
a O 
100-µg O 
/ O 
mL O 
dose O 
. O 
We O 
postulate O 
that O 
vescalagi B-TRIVIAL 
n O 
is O 
an O 
active O 
component O 
in O 
PWFE O 
that O 
may O 
alleviate O 
the O 
insulin O 
resistance O 
in O 
mouse O 
hepatocytes O 
. O 

new O 
C- O 
15 O 
enolic B-FAMILY 
acyl I-FAMILY 
phragmalin I-FAMILY 
-type O 
limonoids B-FAMILY 
from O 
Chukrasia O 
tabularis O 
var O 
. O 
velutina O 
. O 

new O 
C- O 
15 O 
enolic B-FAMILY 
acyl I-FAMILY 
phragmalin I-FAMILY 
-type O 
limonoid B-FAMILY 
orthoesters I-FAMILY 
, O 
chukvelutilide B-TRIVIAL 
G I-TRIVIAL 
( O 
1 O 
) O 
and O 
chukrasine B-TRIVIAL 
F I-TRIVIAL 
( O 
2 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
stem O 
barks O 
of O 
Chukrasia O 
tabularis O 
var O 
. O 
velutina O 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
their O 
extensive O 
high O 
resolution O 
- O 
electrospray O 
ionization O 
mass O 
spectrometry O 
( O 
HR-ESI-MS O 
) O 
, O 
one- O 
and O 
two O 
- O 
dimensional O 
spectroscopic O 
analysis O 
, O 
including O 
heteronuclear O 
single O 
quantum O 
coherence O 
( O 
HSQC O 
) O 
, O 
HMBC O 
and O 
NOESY O 
experiments O 
. O 

new O 
xanthone B-TRIVIAL 
from O 
the O 
bark O 
of O 
Calophyllum O 
thorelii O 
. O 

new O 
xanthone B-TRIVIAL 
, O 
calothorexanthone B-TRIVIAL 
, O 
together O 
with O 
five O 
known O 
compounds O 
, O 
garbogiol B-TRIVIAL 
, O 
1,4,8-trihydroxyxanthone B-SYSTEMATIC 
, O 
δ-tocotrienol B-TRIVIAL 
, O 
1,7-dihydroxyxanthone B-SYSTEMATIC 
and O 
globuxanthone B-TRIVIAL 
, O 
was O 
isolated O 
from O 
a O 
petroleum O 
ether O 
extract O 
of O 
the O 
bark O 
of O 
Calophyllum O 
thorelii O 
. O 
Their O 
structures O 
were O 
established O 
on O 
the O 
basis O 
of O 
spectroscopic O 
methods O 
, O 
mainly O 
one- O 
and O 
two O 
- O 
dimensional O 
NMR O 
. O 
Antioxidant O 
activity O 
of O 
the O 
isolated O 
compounds O 
was O 
tested O 
using O 
DPPH B-ABBREVIATION 
free O 
radical O 
scavenging O 
assay O 
and O 
some O 
exhibited O 
remarkable O 
effects O 
with O 
IC50 O 
of O 
13.63-17.46 O 
µg O 
mL(-1) O 
. O 

and O 
cyclodextrin O 
assisted O 
dissolution O 
rate O 
enhancement O 
of O 
itraconazolium B-SYSTEMATIC 
dinitrate I-SYSTEMATIC 
salt O 
. O 

poor O 
solubility O 
of O 
itraconazole B-TRIVIAL 
( O 
ITR B-ABBREVIATION 
) O 
results O 
in O 
its O 
variable O 
oral O 
absorption O 
and O 
bioavailability O 
and O 
has O 
also O 
proven O 
to O 
be O 
a O 
major O 
setback O 
in O 
developing O 
an O 
efficient O 
oral O 
delivery O 
system O 
. O 
To O 
improve O 
its O 
solubility O 
and O 
dissolution O 
profile O 
, O 
itraconazolium B-SYSTEMATIC 
dinitrate I-SYSTEMATIC 
salt O 
( O 
ITRDNT B-ABBREVIATION 
) O 
was O 
prepared O 
and O 
characterized O 
using O 
various O 
spectral O 
and O 
thermal O 
techniques O 
. O 
The O 
morphology O 
of O 
the O 
salt O 
was O 
studied O 
using O 
optical O 
and O 
scanning O 
electron O 
microscopy O 
( O 
SEM O 
) O 
. O 
Broth O 
microdilution O 
assay O 
demonstrated O 
antifungal O 
efficacy O 
of O 
ITRDNT B-ABBREVIATION 
similar O 
to O 
ITR B-ABBREVIATION 
against O 
four O 
different O 
fungal O 
strains O 
namely O 
, O 
Asparagillus O 
fumigatus O 
, O 
Microsporum O 
canis O 
, O 
Microsporum O 
gypsum O 
and O 
Trichophyton O 
rubrum O 
. O 
The O 
salt O 
exhibited O 
better O 
solubility O 
profile O 
than O 
ITR B-ABBREVIATION 
in O 
water O 
and O 
a O 
number O 
of O 
pharmaceutical O 
solvents O 
. O 
Dissolution O 
studies O 
revealed O 
the O 
total O 
amount O 
of O 
drug O 
released O 
from O 
ITRDNT B-ABBREVIATION 
in O 
3 O 
h O 
was O 
four O 
times O 
greater O 
than O 
that O 
of O 
ITR B-ABBREVIATION 
. O 
To O 
further O 
improve O 
dissolution O 
characteristics O 
, O 
the O 
physical O 
mixtures O 
of O 
ITR B-ABBREVIATION 
and O 
ITRDNT B-ABBREVIATION 
with O 
two O 
cyclodextrins O 
, O 
β-cyclodextrin B-TRIVIAL 
( O 
β-CD B-ABBREVIATION 
) O 
and O 
HP-β-cyclodextrin B-TRIVIAL 
( O 
HP-β-CD B-ABBREVIATION 
) O 
were O 
prepared O 
and O 
their O 
molar O 
ratios O 
were O 
optimized O 
. O 
It O 
was O 
observed O 
that O 
about O 
75% O 
of O 
drug O 
was O 
released O 
in O 
30 O 
min O 
from O 
1 O 
: O 
3 O 
molar O 
ratio O 
of O 
ITRDNT B-ABBREVIATION 
and O 
HP-β-CD B-ABBREVIATION 
physical O 
mixture O 
, O 
which O 
was O 
distinctly O 
higher O 
than O 
ITR B-ABBREVIATION 
commercial O 
capsules O 
( O 
70% O 
) O 
. O 
Owing O 
to O 
its O 
facile O 
and O 
economical O 
preparation O 
and O 
substantially O 
better O 
in O 
vitro O 
release O 
profile O 
, O 
the O 
ITRDNT B-ABBREVIATION 
and O 
its O 
CD O 
physical O 
mixtures O 
could O 
be O 
better O 
and O 
cost O 
effective O 
alternatives O 
to O 
ITR B-ABBREVIATION 
and O 
commercial O 
ITR B-ABBREVIATION 
capsules O 
. O 

Vitamin B-FAMILY 
E I-FAMILY 
" O 
fortified O 
parenteral O 
lipid O 
emulsions O 
: O 
Plackett-Burman O 
screening O 
of O 
primary O 
process O 
and O 
composition O 
parameters O 
. O 

objective O 
of O 
this O 
study O 
was O 
to O 
screen O 
the O 
effect O 
of O 
eight O 
formulations O 
and O 
process O 
parameters O 
on O 
the O 
physical O 
attributes O 
and O 
stability O 
of O 
" O 
Vitamin B-FAMILY 
E I-FAMILY 
" O 
-rich O 
parenteral O 
lipid O 
emulsions O 
. O 
Screening O 
was O 
performed O 
using O 
a O 
12-run O 
, O 
8-factor O 
, O 
2-level O 
Plackett-Burman O 
design O 
. O 
This O 
design O 
was O 
employed O 
to O 
construct O 
polynomial O 
equations O 
that O 
identified O 
the O 
magnitude O 
and O 
direction O 
of O 
the O 
linear O 
effect O 
of O 
homogenization O 
pressure O 
, O 
number O 
of O 
homogenization O 
cycles O 
, O 
primary O 
and O 
secondary O 
emulsifiers O 
, O 
pre O 
- O 
homogenization O 
temperature O 
, O 
oil O 
loading O 
, O 
and O 
ratio O 
of O 
vitamin B-FAMILY 
E I-FAMILY 
to O 
medium O 
- O 
chain O 
triglycerides B-FAMILY 
( O 
MCT O 
) O 
in O 
the O 
oil O 
phase O 
on O 
particle O 
size O 
, O 
polydispersity O 
index O 
, O 
short O 
- O 
term O 
stability O 
, O 
and O 
outlet O 
temperature O 
of O 
manufactured O 
emulsions O 
. O 
The O 
viscosity O 
of O 
vitamin B-FAMILY 
E I-FAMILY 
was O 
reduced O 
from O 
3700 O 
( O 
100% O 
) O 
to O 
64 O 
mPa.s O 
( O 
30% O 
) O 
by O 
MCT O 
addition O 
. O 
As O 
viscosity O 
is O 
critical O 
for O 
efficient O 
emulsification O 
, O 
vitamin O 
/ O 
MCT O 
ratio O 
was O 
the O 
most O 
significant O 
contributor O 
for O 
the O 
stability O 
of O 
emulsions O 
. O 
Particle O 
size O 
increased O 
from O 
236 O 
to O 
388 O 
nm O 
, O 
and O 
percentage O 
vitamin O 
remaining O 
emulsified O 
after O 
48 O 
h O 
dropped O 
from O 
100 O 
to O 
73% O 
with O 
increase O 
in O 
vitamin O 
/ O 
MCT O 
ratio O 
from O 
30 O 
/ O 
70 O 
to O 
70 O 
/ O 
30 O 
. O 
Significant O 
decrease O 
in O 
particle O 
size O 
and O 
PI O 
, O 
and O 
an O 
increase O 
in O 
outlet O 
temperature O 
were O 
also O 
observed O 
with O 
increase O 
in O 
homogenization O 
pressure O 
and O 
number O 
of O 
homogenization O 
cycles O 
. O 
Emulsifiers O 
and O 
oil O 
loading O 
, O 
however O 
, O 
had O 
insignificant O 
effect O 
on O 
the O 
responses O 
. O 
Overall O 
, O 
stable O 
submicron O 
emulsions O 
at O 
vitamin O 
/ O 
MCT O 
ratio O 
of O 
30 O 
/ O 
70 O 
could O 
be O 
prepared O 
at O 
25000 O 
psi O 
and O 
25 O 
cycles O 
in O 
ambient O 
conditions O 
. O 
The O 
identification O 
of O 
these O 
parameters O 
by O 
a O 
well O 
- O 
constructed O 
design O 
demonstrated O 
the O 
utility O 
of O 
screening O 
studies O 
in O 
the O 
" O 
Quality O 
by O 
Design O 
" O 
approach O 
to O 
pharmaceutical O 
product O 
development O 
. O 

studies O 
suggest O 
that O 
a O 
variety O 
of O 
prenatal O 
stressors O 
are O 
related O 
to O 
high O 
risk O 
for O 
cognitive O 
and O 
behavioral O 
abnormalities O 
associated O 
with O 
psychiatric O 
illness O 
( O 
Markham O 
and O 
Koenig O 
, O 
2011 O 
) O 
. O 
Recently O 
, O 
a O 
downregulation O 
in O 
the O 
expression O 
of O 
GABAergic O 
genes O 
( O 
i.e O 
. O 
, O 
glutamic B-TRIVIAL 
acid I-TRIVIAL 
decarboxylase O 
67 O 
and O 
reelin O 
) O 
associated O 
with O 
DNA O 
methyltransferase O 
( O 
DNMT O 
) O 
overexpression O 
in O 
GABAergic O 
neurons O 
has O 
been O 
regarded O 
as O 
a O 
characteristic O 
phenotypic O 
component O 
of O 
the O 
neuropathology O 
of O 
psychotic O 
disorders O 
( O 
Guidotti O 
et O 
al., O 
2011 O 
) O 
. O 
Here O 
, O 
we O 
characterized O 
mice O 
exposed O 
to O 
prenatal O 
restraint O 
stress O 
( O 
PRS O 
) O 
in O 
order O 
to O 
study O 
neurochemical O 
and O 
behavioral O 
abnormalities O 
related O 
to O 
development O 
of O 
schizophrenia O 
in O 
the O 
adult O 
. O 
Offspring O 
born O 
from O 
non-stressed O 
mothers O 
( O 
control O 
mice O 
) O 
showed O 
high O 
levels O 
of O 
DNMT1 O 
and O 
3a O 
mRNA O 
expression O 
in O 
the O 
frontal O 
cortex O 
at O 
birth O 
, O 
but O 
these O 
levels O 
progressively O 
decreased O 
at O 
post O 
- O 
natal O 
days O 
( O 
PND O 
) O 
7 O 
, O 
14 O 
, O 
and O 
60 O 
. O 
Offspring O 
born O 
from O 
stressed O 
mothers O 
( O 
PRS O 
mice O 
) O 
showed O 
increased O 
levels O 
of O 
DNMTs O 
compared O 
to O 
controls O 
at O 
all O 
time O 
- O 
points O 
studied O 
including O 
at O 
birth O 
and O 
at O 
PND O 
60 O 
. O 
Using O 
GAD67-GFP O 
transgenic O 
mice O 
, O 
we O 
established O 
that O 
, O 
in O 
both O 
control O 
and O 
PRS O 
mice O 
, O 
high O 
levels O 
of O 
DNMT1 O 
and O 
3a O 
were O 
preferentially O 
expressed O 
in O 
GABAergic O 
neurons O 
of O 
frontal O 
cortex O 
and O 
hippocampus O 
. O 
Importantly O 
, O 
the O 
overexpression O 
of O 
DNMT O 
in O 
GABAergic O 
neurons O 
was O 
associated O 
with O 
a O 
decrease O 
in O 
reelin O 
and O 
GAD67 O 
expression O 
in O 
PRS O 
mice O 
in O 
early O 
and O 
adult O 
life O 
. O 
PRS O 
mice O 
also O 
showed O 
an O 
increased O 
binding O 
of O 
DNMT1 O 
and O 
MeCP2 O 
, O 
and O 
an O 
increase O 
in O 
5-methylcytosine B-SYSTEMATIC 
and O 
5-hydroxymethylcytosine B-SYSTEMATIC 
in O 
specific O 
CpG B-ABBREVIATION 
-rich O 
regions O 
of O 
the O 
reelin O 
and O 
GAD67 O 
promoters O 
. O 
Thus O 
, O 
the O 
epigenetic O 
changes O 
in O 
PRS O 
mice O 
are O 
similar O 
to O 
changes O 
observed O 
in O 
the O 
post O 
- O 
mortem O 
brains O 
of O 
psychiatric O 
patients O 
. O 
Behaviorally O 
, O 
adult O 
PRS O 
mice O 
showed O 
hyperactivity O 
and O 
deficits O 
in O 
social O 
interaction O 
, O 
prepulse O 
inhibition O 
, O 
and O 
fear O 
conditioning O 
that O 
were O 
corrected O 
by O 
administration O 
of O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
( O 
a O 
histone O 
deacetylase O 
inhibitor O 
) O 
or O 
clozapine B-TRIVIAL 
( O 
an O 
atypical O 
antipsychotic O 
with O 
DNA-demethylation O 
activity O 
) O 
. O 
Taken O 
together O 
, O 
these O 
data O 
show O 
that O 
prenatal O 
stress O 
in O 
mice O 
induces O 
abnormalities O 
in O 
the O 
DNA O 
methylation O 
network O 
and O 
in O 
behaviors O 
indicative O 
of O 
a O 
schizophrenia O 
- O 
like O 
phenotype O 
. O 
Thus O 
, O 
PRS O 
mice O 
may O 
be O 
a O 
valid O 
model O 
for O 
the O 
investigation O 
of O 
new O 
drugs O 
for O 
schizophrenia O 
treatment O 
targeting O 
DNA O 
methylation O 
. O 
This O 
article O 
is O 
part O 
of O 
the O 
Special O 
Issue O 
entitled O 
' O 
Neurodevelopmental O 
Disorders' O 
. O 

mGlu7 O 
receptors O 
control O 
GABA B-ABBREVIATION 
release O 
in O 
mouse O 
hippocampus O 
. O 

functional O 
role O 
of O 
presynaptic O 
release O 
- O 
regulating O 
metabotropic O 
glutamate B-TRIVIAL 
type O 
7 O 
( O 
mGlu7 O 
) O 
receptors O 
in O 
hippocampal O 
GABAergic O 
terminals O 
was O 
investigated O 
. O 
Mouse O 
hippocampal O 
synaptosomes O 
were O 
preloaded O 
with O 
[(3)H]D-γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
[(3)H]GABA B-FORMULA 
) O 
and O 
then O 
exposed O 
in O 
superfusion O 
to O 
12 O 
mM O 
KCl B-FORMULA 
. O 
The O 
K(+) B-FORMULA 
-evoked O 
[(3)H]GABA B-FORMULA 
release O 
was O 
inhibited O 
by O 
the O 
mGlu7 O 
allosteric O 
agonist O 
N,N'-dibenzyhydryl-ethane-1,2-diamine B-SYSTEMATIC 
dihydrochloride I-SYSTEMATIC 
( O 
AMN082 B-IDENTIFIER 
, O 
0.001-10 O 
μM O 
) O 
, O 
as O 
well O 
as O 
by O 
the O 
group O 
III O 
mGlu O 
receptor O 
agonist O 
l-(+)-2-amino-4-phosphonobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
[ O 
(l)-AP4 B-IDENTIFIER 
, O 
0.01-1 O 
mM O 
] O 
. O 
The O 
mGlu8 O 
receptor O 
agonist O 
(S)-3,4-dicarboxyphenylglycine B-SYSTEMATIC 
[ O 
(S)-3,4-DCPG B-SYSTEMATIC 
, O 
10-100 O 
nM O 
] O 
was O 
ineffective O 
. O 
AMN082 B-IDENTIFIER 
and O 
(l)-AP4 B-IDENTIFIER 
-induced O 
effects O 
were O 
recovered O 
by O 
the O 
mGlu7 O 
negative O 
allosteric O 
modulator O 
( O 
NAM O 
) O 
6-(4-methoxyphenyl)-5-methyl-3-(4-pyridinyl)-isoxazolo[4,5-c]pyridin-4(5H)-one B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
MMPIP B-ABBREVIATION 
) O 
. O 
AMN082 B-IDENTIFIER 
also O 
inhibited O 
in O 
a O 
MMPIP B-ABBREVIATION 
-sensitive O 
manner O 
the O 
K(+) B-FORMULA 
-evoked O 
release O 
of O 
endogenous O 
GABA B-ABBREVIATION 
. O 
AMN082 B-IDENTIFIER 
and O 
the O 
adenylyl O 
cyclase O 
( O 
AC O 
) O 
inhibitor O 
MDL-12,330A B-IDENTIFIER 
reduced O 
[(3)H]GABA B-FORMULA 
exocytosis O 
in O 
a O 
8-Br-cAMP B-SYSTEMATIC 
-sensitive O 
. O 
AMN082 B-IDENTIFIER 
-inhibitory O 
effect O 
was O 
additive O 
to O 
that O 
caused O 
by O 
(-)baclofen B-TRIVIAL 
, O 
but O 
insensitive O 
to O 
the O 
GABA B-ABBREVIATION 
( O 
B O 
) O 
antagonist O 
3-[[(3,4-Dichlorophenyl)methyl]amino]propyl B-SYSTEMATIC 
] I-SYSTEMATIC 
diethoxymethyl I-SYSTEMATIC 
) I-SYSTEMATIC 
phosphinic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
CGP52432 B-IDENTIFIER 
) O 
. O 
Conversely O 
, O 
(-)baclofen B-TRIVIAL 
-induced O 
inhibition O 
of O 
GABA B-ABBREVIATION 
exocytosis O 
was O 
insensitive O 
to O 
MMPIP B-ABBREVIATION 
. O 
Finally O 
, O 
the O 
forskolin B-TRIVIAL 
-evoked O 
[(3)H]GABA B-FORMULA 
release O 
was O 
reduced O 
by O 
AMN082 B-IDENTIFIER 
or O 
(-)baclofen B-TRIVIAL 
but O 
abolished O 
when O 
the O 
two O 
agonists O 
were O 
added O 
concomitantly O 
. O 
Mouse O 
hippocampal O 
synaptosomal O 
plasmamembranes O 
posses O 
mGlu7 O 
receptor O 
proteins O 
; O 
confocal O 
microscopy O 
analysis O 
unveiled O 
that O 
mGlu7 O 
proteins O 
colocalize O 
with O 
syntaxin-1A O 
( O 
Stx-1A O 
) O 
, O 
with O 
vesicular O 
GABA B-ABBREVIATION 
transporter O 
( O 
VGAT O 
) O 
- O 
proteins O 
and O 
with O 
GABA B-ABBREVIATION 
( O 
B O 
) O 
receptor O 
subunit O 
proteins O 
. O 
We O 
propose O 
that O 
presynaptic O 
inhibitory O 
mGlu7 O 
heteroreceptors O 
, O 
negatively O 
coupled O 
to O 
AC-dependent O 
intraterminal O 
pathway O 
, O 
exist O 
in O 
mouse O 
hippocampal O 
GABA B-ABBREVIATION 
-containing O 
terminals O 
, O 
where O 
they O 
colocalize O 
, O 
but O 
do O 
not O 
functionally O 
cross O 
- O 
talk O 
, O 
with O 
GABA B-ABBREVIATION 
( O 
B O 
) O 
autoreceptors O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate O 
Receptors' O 
. O 

new O 
method O 
for O 
preparing O 
pentacyclic B-FAMILY 
triterpene I-FAMILY 
rich O 
Centella O 
asiatica O 
extracts O 
. O 

study O 
evaluated O 
microwave O 
- O 
assisted O 
extraction O 
( O 
MAE O 
) O 
for O 
four O 
pentacyclic B-FAMILY 
triterpenes I-FAMILY 
as O 
well O 
as O 
developed O 
a O 
method O 
for O 
preparing O 
a O 
pentacyclic B-FAMILY 
triterpenene I-FAMILY 
rich O 
extract O 
from O 
Centella O 
asiatica O 
. O 
MAE O 
was O 
capable O 
of O 
increasing O 
the O 
yield O 
of O 
the O 
pentacyclic B-FAMILY 
triterpenes I-FAMILY 
up O 
to O 
twice O 
that O 
produced O 
by O 
the O 
heat O 
reflux O 
method O 
, O 
and O 
it O 
was O 
also O 
much O 
less O 
time O 
consuming O 
. O 
The O 
optimal O 
conditions O 
of O 
MAE O 
employed O 
were O 
extraction O 
with O 
absolute O 
ethanol B-SYSTEMATIC 
as O 
solvent O 
, O 
an O 
irradiation O 
power O 
of O 
600 O 
W O 
, O 
at O 
75°C O 
, O 
four O 
irradiation O 
cycles O 
and O 
four O 
extraction O 
times O 
. O 
Here O 
, O 
we O 
provide O 
a O 
simple O 
method O 
for O 
the O 
preparation O 
of O 
the O 
pentacyclic B-FAMILY 
triterpene I-FAMILY 
rich O 
C O 
. O 
asiatica O 
extracts O 
, O 
which O 
contained O 
not O 
less O 
than O 
65% O 
w O 
/ O 
w O 
total O 
pentacyclic B-FAMILY 
triterpenes I-FAMILY 
. O 
The O 
method O 
involved O 
a O 
macroporous O 
resin O 
( O 
Diaion O 
® O 
HP-20 O 
) O 
column O 
eluted O 
with O 
ethanol B-SYSTEMATIC 
and O 
a O 
decolourisation O 
step O 
with O 
activated O 
charcoal O 
. O 

interplay O 
between O 
cardiac O 
sarcoplasmic O 
Ca(2+) B-FORMULA 
ATPase O 
and O 
phospholamban O 
is O 
a O 
key O 
regulating O 
factor O 
of O 
contraction O 
and O 
relaxation O 
in O 
the O 
cardiac O 
muscle O 
. O 
In O 
heart O 
failure O 
, O 
aberrations O 
in O 
the O 
inhibition O 
of O 
sarcoplasmic O 
Ca(2+) B-FORMULA 
ATPase O 
by O 
phospholamban O 
are O 
associated O 
with O 
anomalies O 
in O 
cardiac O 
functions O 
. O 
In O 
experimental O 
heart O 
failure O 
models O 
, O 
modulation O 
of O 
the O 
interaction O 
between O 
these O 
two O 
proteins O 
has O 
been O 
shown O 
to O 
be O 
a O 
potential O 
therapeutic O 
approach O 
. O 
The O 
aim O 
of O 
our O 
research O 
was O 
to O 
find O 
molecules O 
able O 
to O 
interfere O 
with O 
the O 
inhibitory O 
activity O 
of O 
phospholamban O 
on O 
sarcoplasmic O 
Ca(2+) B-FORMULA 
ATPase O 
. O 
For O 
this O 
purpose O 
, O 
a O 
portion O 
of O 
phospholamban O 
was O 
synthesized O 
and O 
used O 
as O 
target O 
for O 
a O 
phage O 
- O 
display O 
peptide O 
library O 
screening O 
. O 
The O 
cyclic O 
peptide O 
C-Y-W-E-L-E-W-L-P-C-A O 
was O 
found O 
to O 
bind O 
to O 
phospholamban O 
( O 
1-36 O 
) O 
with O 
high O 
specificity O 
. O 
Its O 
functional O 
activity O 
was O 
tested O 
in O 
Ca(2+) B-FORMULA 
uptake O 
assays O 
utilizing O 
preparations O 
from O 
cardiac O 
sarcoplasmic O 
reticulum O 
. O 
By O 
synthesizing O 
and O 
testing O 
a O 
series O 
of O 
alanine B-TRIVIAL 
point O 
- O 
mutated O 
cyclic O 
peptides O 
, O 
we O 
identified O 
which O 
amino B-FAMILY 
acid I-FAMILY 
was O 
important O 
for O 
the O 
inhibition O 
of O 
the O 
phospholamban O 
function O 
. O 
The O 
structures O 
of O 
active O 
and O 
inactive O 
alanine B-TRIVIAL 
-mutated O 
cyclic O 
peptides O 
, O 
and O 
of O 
phospholamban O 
( O 
1-36 O 
) O 
, O 
were O 
determined O 
by O 
NMR O 
. O 
This O 
structure O 
- O 
activity O 
analysis O 
allowed O 
building O 
a O 
model O 
of O 
phospholamban O 
-cyclic O 
peptide O 
complex O 
. O 
Thereafter O 
, O 
a O 
simple O 
pharmacophore O 
was O 
defined O 
and O 
used O 
for O 
the O 
design O 
of O 
small O 
molecules O 
. O 
Finally O 
, O 
examples O 
of O 
such O 
molecules O 
were O 
synthesized O 
and O 
characterized O 
as O 
phospholamban O 
inhibitors O 
. O 

oils O 
are O 
composed O 
of O 
multiple O 
components O 
. O 
It O 
is O 
thought O 
that O 
the O 
effect O 
of O 
essential O 
oils O 
is O 
due O 
to O 
specific O 
component O 
ratios O 
, O 
which O 
may O 
differ O 
from O 
the O 
original O 
ratio O 
when O 
the O 
essential O 
oil O 
is O 
absorbed O 
. O 
However O 
, O 
very O 
little O 
detailed O 
research O 
exists O 
in O 
this O 
area O 
. O 
We O 
studied O 
the O 
distribution O 
of O 
essential O 
oil O 
components O 
after O 
inhalation O 
of O 
single O 
and O 
mixed O 
components O 
in O 
mice O 
. O 
This O 
research O 
was O 
done O 
using O 
four O 
main O 
components O 
of O 
Alpinia O 
zerumbet O 
( O 
Pers O 
. O 
) O 
B O 
. O 
L O 
. O 
Burtt O 
. O 
and O 
R O 
. O 
M O 
. O 
Sm O 
. O 
: O 
α-pinen B-TRIVIAL 
e O 
, O 
p-cymen B-TRIVIAL 
e O 
, O 
1,8-cineol B-SYSTEMATIC 
e O 
, O 
and O 
limonen B-TRIVIAL 
e O 
. O 
After O 
inhalation O 
of O 
single O 
or O 
mixed O 
components O 
for O 
90 O 
min O 
, O 
component O 
levels O 
in O 
the O 
brain O 
and O 
liver O 
of O 
mice O 
were O 
measured O 
. O 
The O 
results O 
indicated O 
that O 
the O 
amount O 
of O 
α-pinen B-TRIVIAL 
e O 
in O 
the O 
brain O 
and O 
liver O 
was O 
twofold O 
greater O 
after O 
mixed O 
- O 
component O 
inhalation O 
than O 
that O 
after O 
single O 
- O 
component O 
inhalation O 
. O 
In O 
a O 
comparison O 
of O 
the O 
components O 
of O 
the O 
mixed O 
inhalation O 
, O 
the O 
ratio O 
of O 
α-pinen B-TRIVIAL 
e O 
increased O 
to O 
about O 
three O 
times O 
that O 
of O 
1,8-cineol B-SYSTEMATIC 
e O 
. O 
It O 
is O 
thought O 
that O 
the O 
absorption O 
via O 
the O 
nasal O 
mucus O 
greatly O 
influences O 
this O 
phenomenon O 
. O 
The O 
results O 
of O 
this O 
investigation O 
of O 
the O 
bodily O 
distribution O 
of O 
essential O 
oil O 
volatile O 
components O 
may O 
provide O 
clues O 
for O 
elucidating O 
their O 
action O 
. O 

effects O 
of O 
p-coumaric B-TRIVIAL 
acid I-TRIVIAL 
in O 
human O 
endothelial O 
cells O 
. O 

acid I-TRIVIAL 
, O 
a O 
hydroxy B-SYSTEMATIC 
derivative O 
of O 
cinnamic B-TRIVIAL 
acid I-TRIVIAL 
, O 
has O 
been O 
known O 
to O 
possess O 
antioxidant O 
and O 
anticancer O 
activities O 
. O 
Despite O 
its O 
potential O 
contribution O 
to O 
chemopreventive O 
effects O 
, O 
the O 
mechanism O 
by O 
which O 
p-coumaric B-TRIVIAL 
acid I-TRIVIAL 
exerts O 
its O 
antiangiogenic O 
actions O 
remains O 
elusive O 
. O 
In O 
this O 
study O 
, O 
we O 
revealed O 
that O 
p-coumaric B-TRIVIAL 
acid I-TRIVIAL 
inhibited O 
the O 
sprouting O 
of O 
endothelial O 
cells O 
in O 
rat O 
aortic O 
rings O 
and O 
inhibited O 
the O 
tube O 
formation O 
and O 
migration O 
of O 
endothelial O 
cells O 
. O 
We O 
observed O 
that O 
p-coumaric B-TRIVIAL 
acid I-TRIVIAL 
could O 
downregulate O 
mRNA O 
expression O 
levels O 
of O 
the O 
key O 
angiogenic O 
factors O 
vascular O 
endothelial O 
growth O 
factor O 
and O 
basic O 
fibroblast O 
growth O 
factor O 
. O 
Also O 
, O 
we O 
demonstrated O 
that O 
p-coumaric B-TRIVIAL 
acid I-TRIVIAL 
inhibited O 
both O 
the O 
AKT O 
and O 
ERK O 
signaling O 
pathways O 
, O 
which O 
are O 
known O 
to O 
be O 
crucial O 
for O 
angiogenesis O 
. O 
Using O 
a O 
mouse O 
model O 
, O 
we O 
also O 
showed O 
that O 
p-coumaric B-TRIVIAL 
acid I-TRIVIAL 
effectively O 
suppressed O 
tumor O 
growth O 
in O 
vivo O 
by O 
lowering O 
hemoglobin O 
contents O 
. O 
Collectively O 
, O 
these O 
findings O 
indicate O 
that O 
p-coumaric B-TRIVIAL 
acid I-TRIVIAL 
possesses O 
potent O 
anticancer O 
properties O 
due O 
to O 
the O 
inhibition O 
of O 
angiogenesis O 
in O 
vivo O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

acid I-FAMILY 
composition O 
of O 
selected O 
macrophytes O 
. O 

content O 
of O 
total O 
lipids O 
and O 
the O 
fatty B-FAMILY 
acid I-FAMILY 
( O 
FA O 
) O 
profile O 
were O 
determined O 
for O 
eight O 
macroalgae O 
( O 
Cystoseira O 
abies O 
- O 
marina O 
, O 
Fucus O 
spiralis O 
, O 
Chaetomorpha O 
pachynema O 
, O 
Codium O 
elisabethae O 
, O 
Porphyra O 
sp O 
. O 
, O 
Osmundea O 
pinnatifida O 
, O 
Pterocladiella O 
capillacea O 
and O 
Sphaeroccoccus O 
coronopifolius O 
) O 
. O 
Total O 
lipids O 
were O 
extracted O 
using O 
a O 
solvent O 
mixture O 
of O 
methanol B-SYSTEMATIC 
/ O 
chloroform B-TRIVIAL 
( O 
2 O 
/ O 
1 O 
, O 
v O 
/ O 
v O 
) O 
and O 
further O 
derivatised O 
to O 
FA B-FAMILY 
methyl I-FAMILY 
esters I-FAMILY 
( O 
FAME B-ABBREVIATION 
) O 
. O 
The O 
analyses O 
of O 
FAME B-ABBREVIATION 
samples O 
were O 
performed O 
by O 
gas O 
chromatography O 
coupled O 
to O 
a O 
flame O 
ionisation O 
detector O 
. O 
The O 
total O 
lipid O 
content O 
ranged O 
from O 
0.06 O 
to O 
3.54 O 
g O 
( O 
per O 
100 O 
g O 
) O 
. O 
The O 
most O 
abundant O 
saturated O 
FA O 
were O 
palmitic B-TRIVIAL 
( O 
C16 B-FORMULA 
: I-FORMULA 
0 I-FORMULA 
) O 
and O 
myristic B-TRIVIAL 
( O 
C14 B-FORMULA 
: I-FORMULA 
0 I-FORMULA 
) O 
, O 
while O 
oleic B-TRIVIAL 
( O 
C18 B-FORMULA 
: I-FORMULA 
1 I-FORMULA 
n-9 O 
) O 
was O 
the O 
dominant O 
monounsaturated B-FAMILY 
acid I-FAMILY 
. O 
All O 
seaweeds O 
contained O 
linoleic B-TRIVIAL 
FA I-TRIVIAL 
( O 
C18 B-FORMULA 
: I-FORMULA 
2 I-FORMULA 
n-6 O 
) O 
. O 
The O 
α-linolenic B-TRIVIAL 
( O 
C18 B-FORMULA 
: I-FORMULA 
3 I-FORMULA 
n-3 O 
) O 
and O 
eicosapentaenoic B-SYSTEMATIC 
( O 
20 O 
: O 
5 O 
n-3 O 
) O 
acids O 
were O 
present O 
only O 
in O 
Porphyra O 
sp O 
. O 
( O 
3.34% O 
± O 
0.13 O 
) O 
and O 
C O 
. O 
pachynema O 
( O 
0.47% O 
± O 
0.12 O 
) O 
, O 
respectively O 
. O 
The O 
n-6 O 
/ O 
n-3 O 
and O 
h/ O 
H B-FORMULA 
ratios O 
were O 
low O 
, O 
suggesting O 
a O 
high O 
nutritional O 
value O 
of O 
the O 
algae O 
studied O 
. O 

in O 
solubility O 
and O 
bioavailability O 
of O 
puerarin B-TRIVIAL 
by O 
mechanochemical O 
preparation O 
. O 

efficient O 
and O 
solvent-free O 
procedure O 
was O 
developed O 
to O 
improve O 
the O 
solubility O 
and O 
bioavailability O 
of O 
the O 
poorly O 
water O 
- O 
soluble O 
drug O 
puerarin B-TRIVIAL 
by O 
mechanochemical O 
technology O 
. O 
The O 
stable O 
inclusion O 
complex O 
of O 
puerarin B-TRIVIAL 
and O 
2-hydroxypropyl-β-cyclodextrin B-SYSTEMATIC 
( O 
HPCD B-ABBREVIATION 
) O 
was O 
prepared O 
by O 
a O 
ball O 
mill O 
under O 
the O 
following O 
conditions O 
: O 
equimolar O 
ratio O 
of O 
puerarin O 
to O 
HPCD B-ABBREVIATION 
; O 
rotational O 
speed O 
of O 
250 O 
rpm O 
; O 
milling O 
time O 
of O 
90 O 
min O 
; O 
steel O 
balls O 
of O 
22 O 
mm O 
diameter O 
. O 
The O 
solid O 
complex O 
was O 
characterized O 
by O 
scanning O 
electron O 
microscopy O 
( O 
SEM O 
) O 
, O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
, O 
powder O 
X-ray O 
diffractometry O 
( O 
XRD O 
) O 
, O 
and O 
fourier O 
transformation O 
- O 
infrared O 
spectroscopy O 
( O 
FT-IR O 
) O 
. O 
Mechanochemical O 
action O 
could O 
result O 
in O 
enhanced O 
molecular O 
encapsulation O 
, O 
homogeneous O 
distribution O 
and O 
amorphization O 
of O 
the O 
drug O 
. O 
In O 
comparison O 
to O 
puerarin B-TRIVIAL 
, O 
a O 
1.64-fold O 
increase O 
in O 
absolute O 
bioavailability O 
was O 
obtained O 
. O 
The O 
solubility O 
of O 
the O 
inclusion O 
complex O 
was O 
25.33-fold O 
higher O 
and O 
the O 
drug O 
release O 
amount O 
reached O 
79.44% O 
at O 
15 O 
min O 
, O 
2.76-fold O 
higher O 
. O 

and O 
evaluation O 
of O 
a O 
self O 
- O 
microemulsifying O 
drug O 
delivery O 
system O 
for O 
apigenin B-TRIVIAL 
. O 

of O 
this O 
study O 
was O 
to O 
prepare O 
, O 
characterize O 
and O 
evaluate O 
a O 
self O 
- O 
microemulsifying O 
drug O 
delivery O 
system O 
( O 
SMEDDS O 
) O 
with O 
the O 
aim O 
to O 
improve O 
the O 
solubility O 
and O 
dissolution O 
of O 
apigenin B-TRIVIAL 
. O 
Ternary O 
phase O 
diagrams O 
were O 
constructed O 
in O 
order O 
to O 
obtain O 
the O 
most O 
efficient O 
self O 
- O 
emulsification O 
region O 
, O 
and O 
the O 
formulation O 
of O 
apigenin B-TRIVIAL 
loaded O 
SMEDDS O 
was O 
optimized O 
by O 
a O 
simplex O 
lattice O 
experiment O 
design O 
. O 
The O 
optimal O 
formulation O 
of O 
SMEDDS O 
obtained O 
was O 
comprised O 
of O 
60% O 
Cremophor(®)EL O 
, O 
30% O 
Transcutol B-TRIVIAL 
(®)HP O 
and O 
10% O 
Capryol B-TRIVIAL 
™ O 
90 O 
. O 
The O 
equilibrium O 
solubility O 
of O 
apigenin B-TRIVIAL 
in O 
SMEDDS O 
was O 
about O 
15 O 
mg O 
/ O 
g O 
, O 
and O 
it O 
could O 
increase O 
the O 
solubility O 
of O 
apigenin B-TRIVIAL 
in O 
water O 
for O 
about O 
7500 O 
folds O 
. O 
Apigenin B-TRIVIAL 
loaded O 
SMEDDS O 
could O 
turn O 
into O 
microemulsion O 
when O 
diluted O 
with O 
distilled O 
water O 
and O 
the O 
droplets O 
were O 
spherical O 
under O 
transmission O 
electron O 
microscope O 
( O 
TEM O 
) O 
, O 
the O 
average O 
particle O 
size O 
was O 
17.1 O 
nm O 
and O 
zeta O 
potential O 
-5.18 O 
mV O 
. O 
In O 
vitro O 
dissolution O 
studies O 
showed O 
about O 
95% O 
of O 
apigenin B-TRIVIAL 
was O 
released O 
within O 
10 O 
min O 
. O 
All O 
of O 
the O 
results O 
showed O 
that O 
SMEDDS O 
could O 
enhance O 
the O 
solubility O 
and O 
dissolution O 
of O 
apigenin B-TRIVIAL 
, O 
and O 
would O 
be O 
a O 
potential O 
carrier O 
to O 
improve O 
the O 
oral O 
absorption O 
of O 
apigenin B-TRIVIAL 
, O 
a O 
poorly O 
water O 
soluble O 
drug O 
. O 

of O 
liver O 
function O 
in O 
humans O 
using O 
a O 
mixture O 
of O 
schisandra O 
fruit O 
extract O 
and O 
sesamin B-TRIVIAL 
. O 

was O 
a O 
randomized O 
, O 
parallel O 
, O 
and O 
placebo O 
- O 
controlled O 
study O 
. O 
Forty O 
subjects O 
were O 
divided O 
into O 
a O 
test O 
group O 
and O 
a O 
placebo O 
group O 
. O 
The O 
study O 
was O 
focused O 
on O 
the O 
potential O 
effects O 
of O 
a O 
mixture O 
of O 
Schisandra O 
fruit O 
extract O 
and O 
sesamin B-TRIVIAL 
( O 
hereinafter O 
called O 
' O 
SCH B-ABBREVIATION 
' O 
) O 
in O 
the O 
subjects O 
with O 
borderline O 
high O 
levels O 
( O 
40-60 O 
U O 
/ O 
L O 
) O 
of O 
alanine B-TRIVIAL 
aminotransferase O 
( O 
ALT O 
) O 
or O 
aspartate B-TRIVIAL 
aminotransferase O 
( O 
AST O 
) O 
. O 
Twenty O 
subjects O 
taking O 
SCH B-ABBREVIATION 
( O 
four O 
tablets O 
per O 
day O 
) O 
and O 
20 O 
subjects O 
taking O 
a O 
placebo O 
( O 
four O 
tablets O 
per O 
day O 
) O 
were O 
studied O 
. O 
The O 
effects O 
of O 
SCH B-ABBREVIATION 
on O 
ALT O 
, O 
AST O 
, O 
total O 
bilirubin B-TRIVIAL 
, O 
direct O 
bilirubin B-TRIVIAL 
, O 
free O 
radical O 
levels O 
, O 
total O 
antioxidant O 
status O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
, O 
glutathione B-TRIVIAL 
reductase O 
, O 
and O 
the O 
lag O 
time O 
for O 
low O 
- O 
density O 
lipoprotein O 
oxidation O 
were O 
determined O 
. O 
The O 
total O 
test O 
period O 
was O 
5 O 
months O 
. O 
Intervention O 
of O 
SCH B-ABBREVIATION 
clearly O 
reduced O 
the O 
levels O 
of O 
ALT O 
and O 
AST O 
, O 
but O 
it O 
made O 
no O 
change O 
in O 
the O 
total O 
bilirubin B-TRIVIAL 
and O 
direct O 
bilirubin B-TRIVIAL 
. O 
Intake O 
of O 
SCH B-ABBREVIATION 
also O 
greatly O 
increased O 
the O 
antioxidant O 
capacity O 
and O 
decreased O 
the O 
values O 
of O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
reactive O 
substances O 
, O 
total O 
free O 
radicals O 
, O 
and O 
superoxide B-TRIVIAL 
anion O 
radicals O 
in O 
the O 
plasma O 
. O 
The O 
activities O 
of O 
glutathione B-TRIVIAL 
peroxidase O 
and O 
reductase O 
in O 
the O 
erythrocytes O 
were O 
significantly O 
increased O 
. O 
In O 
addition O 
, O 
the O 
lag O 
time O 
for O 
low O 
- O 
density O 
lipoprotein O 
oxidation O 
, O 
an O 
inflammatory O 
marker O 
, O 
was O 
evidently O 
increased O 
. O 
Fatty O 
liver O 
was O 
found O 
to O 
have O 
been O 
significantly O 
improved O 
in O 
this O 
study O 
. O 
SCH B-ABBREVIATION 
proved O 
to O 
have O 
the O 
effects O 
of O 
antioxidation O 
and O 
improving O 
liver O 
function O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

solid O 
tumors O 
are O 
characterized O 
by O 
a O 
metabolic O 
shift O 
from O 
glucose B-TRIVIAL 
oxidation O 
to O 
glycolysis O 
, O 
in O 
part O 
due O 
to O 
actively O 
suppressed O 
mitochondrial O 
function O 
, O 
a O 
state O 
that O 
favors O 
resistance O 
to O 
apoptosis O 
. O 
Suppressed O 
mitochondrial O 
function O 
may O 
also O 
contribute O 
to O 
the O 
activation O 
of O 
hypoxia O 
- O 
inducible O 
factor O 
1α O 
( O 
HIF1α O 
) O 
and O 
angiogenesis O 
. O 
We O 
have O 
previously O 
shown O 
that O 
the O 
inhibitor O 
of O 
pyruvate B-TRIVIAL 
dehydrogenase O 
kinase O 
( O 
PDK O 
) O 
dichloroacetate B-SYSTEMATIC 
( O 
DCA B-ABBREVIATION 
) O 
activates O 
glucose B-TRIVIAL 
oxidation O 
and O 
induces O 
apoptosis O 
in O 
cancer O 
cells O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
We O 
hypothesized O 
that O 
DCA B-ABBREVIATION 
will O 
also O 
reverse O 
the O 
' O 
pseudohypoxic O 
' O 
mitochondrial O 
signals O 
that O 
lead O 
to O 
HIF1α O 
activation O 
in O 
cancer O 
, O 
even O 
in O 
the O 
absence O 
of O 
hypoxia O 
and O 
inhibit O 
cancer O 
angiogenesis O 
. O 
We O 
show O 
that O 
inhibition O 
of O 
PDKII O 
inhibits O 
HIF1α O 
in O 
cancer O 
cells O 
using O 
several O 
techniques O 
, O 
including O 
HIF1α O 
luciferase O 
reporter O 
assays O 
. O 
Using O 
pharmacologic O 
and O 
molecular O 
approaches O 
that O 
suppress O 
the O 
prolyl B-TRIVIAL 
-hydroxylase O 
( O 
PHD O 
) O 
- O 
mediated O 
inhibition O 
of O 
HIF1α O 
, O 
we O 
show O 
that O 
DCA B-ABBREVIATION 
inhibits O 
HIF1α O 
by O 
both O 
a O 
PHD-dependent O 
mechanism O 
( O 
that O 
involves O 
a O 
DCA B-ABBREVIATION 
-induced O 
increase O 
in O 
the O 
production O 
of O 
mitochondria O 
- O 
derived O 
α-ketoglutarate B-TRIVIAL 
) O 
and O 
a O 
PHD O 
- O 
independent O 
mechanism O 
, O 
involving O 
activation O 
of O 
p53 O 
via O 
mitochondrial O 
- O 
derived O 
H(2)O(2) B-FORMULA 
, O 
as O 
well O 
as O 
activation O 
of O 
GSK3β O 
. O 
Effective O 
inhibition O 
of O 
HIF1α O 
is O 
shown O 
by O 
a O 
decrease O 
in O 
the O 
expression O 
of O 
several O 
HIF1α O 
regulated O 
gene O 
products O 
as O 
well O 
as O 
inhibition O 
of O 
angiogenesis O 
in O 
vitro O 
in O 
matrigel O 
assays O 
. O 
More O 
importantly O 
, O 
in O 
rat O 
xenotransplant O 
models O 
of O 
non-small O 
cell O 
lung O 
cancer O 
and O 
breast O 
cancer O 
, O 
we O 
show O 
effective O 
inhibition O 
of O 
angiogenesis O 
and O 
tumor O 
perfusion O 
in O 
vivo O 
, O 
assessed O 
by O 
contrast O 
- O 
enhanced O 
ultrasonography O 
, O 
nuclear O 
imaging O 
techniques O 
and O 
histology O 
. O 
This O 
work O 
suggests O 
that O 
mitochondria O 
- O 
targeting O 
metabolic O 
modulators O 
that O 
increase O 
pyruvate B-TRIVIAL 
dehydrogenase O 
activity O 
, O 
in O 
addition O 
to O 
the O 
recently O 
described O 
pro O 
- O 
apoptotic O 
and O 
anti-proliferative O 
effects O 
, O 
suppress O 
angiogenesis O 
as O 
well O 
, O 
normalizing O 
the O 
pseudo O 
- O 
hypoxic O 
signals O 
that O 
lead O 
to O 
normoxic O 
HIF1α O 
activation O 
in O 
solid O 
tumors O 
. O 

marrow O 
macrophages O 
( O 
BMMs O 
) O 
share O 
common O 
progenitors O 
with O 
osteoclasts O 
and O 
are O 
critical O 
components O 
of O 
bone O 
- O 
tumor O 
microenvironment O 
; O 
however O 
, O 
their O 
function O 
in O 
prostate O 
tumor O 
growth O 
in O 
the O 
skeleton O 
has O 
not O 
been O 
explored O 
. O 
BMMs O 
are O 
the O 
major O 
source O 
of O 
inflammatory O 
factors O 
and O 
proteases O 
, O 
including O 
cysteine B-TRIVIAL 
protease O 
cathepsin O 
K O 
( O 
CTSK O 
) O 
. O 
In O 
this O 
study O 
, O 
utilizing O 
mice O 
deficient O 
in O 
CTSK O 
, O 
we O 
demonstrate O 
the O 
critical O 
involvement O 
of O 
this O 
potent O 
collagenase O 
in O 
tumor O 
progression O 
in O 
bone O 
. O 
We O 
present O 
the O 
evidence O 
that O 
tumor O 
growth O 
and O 
progression O 
in O 
the O 
bone O 
are O 
impaired O 
in O 
the O 
absence O 
of O 
CTSK O 
. O 
Most O 
importantly O 
, O 
we O 
show O 
for O 
the O 
first O 
time O 
that O 
BMM-supplied O 
CTSK O 
may O 
be O 
involved O 
in O 
CCL2- O 
and O 
COX-2-driven O 
pathways O 
that O 
contribute O 
to O 
tumor O 
progression O 
in O 
bone O 
. O 
Together O 
, O 
our O 
data O 
unravel O 
novel O 
roles O 
for O 
CTSK O 
in O 
macrophage O 
- O 
regulated O 
processes O 
, O 
and O 
provide O 
evidence O 
for O 
close O 
interplay O 
between O 
inflammatory O 
, O 
osteolytic O 
and O 
tumor O 
cell O 
- O 
driven O 
events O 
in O 
the O 
bone O 
- O 
tumor O 
microenvironment O 
. O 

non-ionic O 
surfactant O 
based O 
self O 
- O 
nanoemulsifying O 
drug O 
delivery O 
system O 
( O 
SNEDDS O 
) O 
was O 
formulated O 
and O 
characterised O 
for O 
poor O 
water O 
soluble O 
drug O 
, O 
Atorvastatin B-SYSTEMATIC 
calcium I-SYSTEMATIC 
. O 
Capmul O 
MCM O 
oil O 
showing O 
highest O 
solubility O 
for O 
Atorvastatin B-SYSTEMATIC 
calcium I-SYSTEMATIC 
was O 
selected O 
as O 
oil O 
phase O 
. O 
Self O 
- O 
nanoemulsifying O 
capacity O 
of O 
Cremophor O 
RH O 
40 O 
, O 
Cremophor O 
EL O 
, O 
Tween B-TRIVIAL 
20 I-TRIVIAL 
, O 
Tween B-TRIVIAL 
60 I-TRIVIAL 
, O 
Tween B-TRIVIAL 
80 I-TRIVIAL 
and O 
Labrasol O 
were O 
tested O 
for O 
the O 
selected O 
oil O 
. O 
In O 
vitro O 
dissolution O 
studies O 
were O 
performed O 
and O 
were O 
characterized O 
by O 
t85% O 
and O 
dissolution O 
efficiency O 
( O 
DE O 
) O 
. O 
Cytotoxicity O 
of O 
the O 
formulations O 
and O 
permeation O 
enhancement O 
of O 
the O 
drug O 
across O 
caco-2 O 
cell O 
monolayer O 
was O 
assessed O 
. O 
Capmul O 
MCM O 
was O 
found O 
to O 
be O 
better O 
nanoemulsified O 
in O 
decreasing O 
order O 
of O 
Cremophor O 
RH O 
40 O 
> O 
Cremophor O 
EL O 
> O 
Tween B-TRIVIAL 
20 I-TRIVIAL 
> O 
Tween B-TRIVIAL 
60 I-TRIVIAL 
> O 
Tween B-TRIVIAL 
80 I-TRIVIAL 
. O 
Values O 
of O 
droplet O 
size O 
( O 
range O 
11-83 O 
nm O 
) O 
, O 
polydispersity O 
index O 
( O 
range O 
0.07-0.65 O 
) O 
; O 
zeta O 
potential O 
( O 
range O 
-3.97 O 
to O 
-19 O 
) O 
and O 
cloud O 
point O 
( O 
60-85°C O 
) O 
before O 
and O 
after O 
drug O 
loading O 
proves O 
the O 
uniformity O 
and O 
stability O 
of O 
the O 
formulations O 
. O 
SNEDDS O 
formulated O 
with O 
Tween B-TRIVIAL 
20 I-TRIVIAL 
surfactant O 
showed O 
enhanced O 
dissolution O 
with O 
t85% O 
and O 
DE O 
values O 
at O 
10 O 
min O 
and O 
78.7 O 
, O 
respectively O 
. O 
None O 
of O 
the O 
formulation O 
showed O 
cytotoxicity O 
at O 
the O 
concentration O 
tested O 
. O 
Tween B-TRIVIAL 
20 I-TRIVIAL 
based O 
SNEDDS O 
enhanced O 
permeation O 
of O 
the O 
drug O 
as O 
compared O 
with O 
pure O 
drug O 
across O 
cell O 
lines O 
. O 
It O 
can O 
be O 
concluded O 
that O 
SNEDDS O 
can O 
be O 
formulated O 
by O 
using O 
single O 
non-ionic O 
surfactant O 
system O 
for O 
enhance O 
dissolution O 
and O 
absorption O 
of O 
poorly O 
soluble O 
drug O 
, O 
Atorvastatin B-SYSTEMATIC 
calcium I-SYSTEMATIC 
. O 

the O 
light O 
influence O 
astaxanthin B-TRIVIAL 
production O 
in O 
Xanthophyllomyces O 
dendrorhous O 
? O 

( O 
C40H52O4 B-FORMULA 
) O 
is O 
an O 
important O 
natural O 
pigment O 
that O 
has O 
considerable O 
promising O 
applications O 
in O 
human O 
health O 
. O 
Until O 
now O 
, O 
many O 
efforts O 
were O 
made O 
aimed O 
to O 
develop O 
economically O 
sustainable O 
bioprocesses O 
alternative O 
to O 
the O 
chemical O 
synthesis O 
, O 
to O 
satisfy O 
the O 
increasing O 
demand O 
of O 
this O 
ketocarotenoid O 
from O 
feed O 
, O 
food O 
and O 
cosmetic O 
industries O 
. O 
The O 
extraction O 
of O 
natural O 
astaxanthin B-TRIVIAL 
from O 
the O 
yeast O 
Xanthophyllomyces O 
dendrorhous O 
till O 
now O 
seems O 
to O 
be O 
rather O 
expensive O 
if O 
compared O 
with O 
chemically O 
synthesized O 
astaxanthin B-TRIVIAL 
. O 
In O 
this O 
article O 
, O 
astaxanthin B-TRIVIAL 
production O 
by O 
Xanthophyllomyces O 
dendrorhous O 
under O 
two O 
different O 
conditions O 
was O 
studied O 
: O 
a O 
first O 
effort O 
was O 
made O 
using O 
a O 
conventional O 
reactor O 
while O 
a O 
second O 
using O 
an O 
enlightened O 
one O 
. O 
This O 
research O 
was O 
aimed O 
also O 
to O 
optimise O 
astaxanthin B-TRIVIAL 
production O 
by O 
testing O 
the O 
influence O 
of O 
the O 
light O 
and O 
of O 
some O 
nutrient O 
sources O 
. O 
From O 
fermentation O 
tests O 
, O 
an O 
astaxanthin B-TRIVIAL 
yield O 
ranging O 
about O 
970 O 
µg O 
g(-1) O 
was O 
obtained O 
after O 
fed O 
batch O 
cultivation O 
in O 
the O 
conventional O 
reactor O 
. O 
In O 
the O 
enlightened O 
reactor O 
lower O 
values O 
, O 
about O 
930 O 
µg O 
g(-1) O 
, O 
were O 
found O 
. O 

triggers O 
apoptosis O 
and O 
cell O 
- O 
cycle O 
arrest O 
of O 
SGC7901 O 
cells O 
. O 

, O 
a O 
flavonoid B-FAMILY 
compound O 
, O 
has O 
shown O 
to O 
be O 
of O 
chemopreventive O 
potential O 
against O 
many O 
cancers O 
. O 
However O 
, O 
its O 
efficacy O 
against O 
gastric O 
cancer O 
has O 
not O 
been O 
well O 
elucidated O 
. O 
Here O 
, O 
we O 
assessed O 
the O 
activity O 
of O 
Silibinin B-TRIVIAL 
on O 
apoptosis O 
and O 
cell O 
- O 
cycle O 
arrest O 
in O 
human O 
gastric O 
cells O 
culture O 
system O 
using O 
SGC-7901 O 
as O 
the O 
model O 
. O 
Silibinin B-TRIVIAL 
treatment O 
could O 
inhibit O 
the O 
cell O 
growth O 
and O 
cause O 
a O 
prominent O 
G2 O 
phase O 
arrest O 
and O 
apoptosis O 
in O 
dose- O 
and O 
time O 
- O 
dependent O 
manner O 
. O 
In O 
mechanistic O 
studies O 
, O 
Silibinin B-TRIVIAL 
decreased O 
the O 
protein O 
level O 
of O 
p34cdc2 O 
, O 
which O 
might O 
be O 
the O 
possible O 
molecular O 
mechanism O 
of O 
Silibinin B-TRIVIAL 
efficacy O 
on O 
the O 
growth O 
inhibition O 
in O 
SGC-7901 O 
cells O 
. O 
In O 
addition O 
, O 
Silibinin B-TRIVIAL 
caused O 
an O 
increase O 
in O 
p53 O 
and O 
p21 O 
protein O 
level O 
as O 
well O 
as O 
mRNA O 
levels O 
. O 
Interestingly O 
, O 
Silibinin B-TRIVIAL 
-induced O 
apoptosis O 
in O 
SGC-7901 O 
cells O 
was O 
independent O 
of O 
caspases O 
activation O 
. O 
These O 
results O 
indicated O 
that O 
Silibinin B-TRIVIAL 
is O 
a O 
cell O 
- O 
cycle O 
regulator O 
and O 
apoptosis O 
inducer O 
in O 
human O 
gastric O 
carcinoma O 
SGC-7901 O 
cells O 
and O 
might O 
be O 
used O 
as O 
a O 
candidate O 
chemopreventive O 
agent O 
for O 
gastric O 
carcinoma O 
prevention O 
and O 
intervention O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

new O 
alkaloid B-FAMILY 
galactosides I-FAMILY 
from O 
the O 
kernel O 
of O 
Prinsepia O 
uniflora O 
. O 

new O 
alkaloid B-FAMILY 
galactosides I-FAMILY 
have O 
been O 
isolated O 
from O 
the O 
kernel O 
of O 
Prinsepia O 
uniflora O 
. O 
Their O 
structures O 
were O 
elucidated O 
as O 
5-[(α-D-galactopyranosyloxy) B-SYSTEMATIC 
methyl]-1H-pyrrole-2-carbaldehyde I-SYSTEMATIC 
( O 
1 O 
) O 
and O 
6-[(α-D-galactopyranosyloxy) B-SYSTEMATIC 
methyl]-3-pyridinol I-SYSTEMATIC 
( O 
2 O 
) O 
by O 
various O 
spectroscopic O 
means O 
including O 
HR-ESI-MS O 
, O 
IR O 
, O 
1D O 
and O 
2D O 
NMR O 
. O 
The O 
determined O 
structures O 
were O 
characterized O 
with O 
a O 
unit O 
of O 
galactose B-TRIVIAL 
which O 
is O 
rarely O 
seen O 
in O 
the O 
previously O 
isolated O 
pyrrole B-SYSTEMATIC 
and O 
pyridinol B-SYSTEMATIC 
compounds O 
. O 

depressive O 
disorder O 
is O 
among O 
the O 
most O 
prevalent O 
forms O 
of O 
mental O 
illness O 
. O 
All O 
currently O 
available O 
antidepressant O 
medications O 
have O 
stemmed O 
from O 
study O 
of O 
the O 
mechanisms O 
of O 
serendipitously O 
discovered O 
drugs O 
, O 
and O 
only O 
30-50% O 
of O 
patients O 
exhibit O 
remission O 
and O 
frequently O 
at O 
least O 
3-4 O 
weeks O 
are O 
required O 
for O 
manifestation O 
of O 
significant O 
therapeutic O 
effects O 
. O 
To O 
overcome O 
these O 
drawbacks O 
, O 
discovering O 
novel O 
neuronal O 
mechanisms O 
of O 
pathophysiology O 
of O 
depression O 
as O 
well O 
as O 
more O 
effective O 
treatments O 
are O 
necessary O 
. O 
This O 
review O 
focuses O 
on O 
the O 
metabotropic O 
glutamate B-TRIVIAL 
( O 
mGlu O 
) O 
receptors O 
and O 
their O 
potential O 
for O 
drug O 
targets O 
for O 
the O 
treatment O 
of O 
depression O 
. O 
In O 
particular O 
, O 
accumulating O 
evidence O 
has O 
indicated O 
the O 
potential O 
importance O 
and O 
usefulness O 
of O 
agents O 
acting O 
on O 
mGlu2 O 
/ O 
3 O 
and O 
mGlu5 O 
receptors O 
. O 
Preclinical O 
and O 
clinical O 
evidence O 
of O 
mGlu2 O 
/ O 
3 O 
receptor O 
ligands O 
and O 
mGlu5 O 
receptor O 
antagonists O 
are O 
described O 
. O 
Moreover O 
, O 
their O 
potential O 
in O 
clinic O 
will O 
be O 
discussed O 
in O 
the O 
context O 
of O 
neuronal O 
mechanisms O 
of O 
ketamine B-TRIVIAL 
, O 
an O 
agent O 
recently O 
demonstrated O 
a O 
robust O 
effect O 
for O 
patients O 
with O 
treatment-resistant O 
depression O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

to O 
the O 
increasing O 
prevalence O 
of O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
, O 
the O 
emergent O 
trend O 
towards O 
diagnosis O 
in O 
younger O 
patients O 
and O 
the O 
progressive O 
nature O 
of O 
this O 
disease O 
, O 
many O 
more O 
patients O 
than O 
before O 
now O 
require O 
insulin O 
to O 
maintain O 
glycaemic O 
control O 
. O 
However O 
, O 
there O 
is O 
a O 
degree O 
of O 
inertia O 
among O 
physicians O 
and O 
patients O 
regarding O 
the O 
initiation O 
and O 
intensification O 
of O 
insulin O 
therapy O 
, O 
in O 
part O 
due O 
to O 
concerns O 
about O 
the O 
associated O 
weight O 
gain O 
and O 
increased O 
risk O 
of O 
hypoglycaemia O 
. O 
Glucagon O 
- O 
like O 
peptide-1 O 
receptor O 
agonists O 
( O 
GLP-1RAs O 
) O 
increase O 
insulin O 
release O 
and O 
suppress O 
glucagon O 
secretion O 
in O 
a O 
glucose B-TRIVIAL 
-dependent O 
manner O 
, O 
thus O 
conferring O 
glycaemic O 
control O 
with O 
a O 
low O 
incidence O 
of O 
hypoglycaemia O 
. O 
GLP-1RAs O 
also O 
promote O 
weight O 
loss O 
, O 
and O 
have O 
beneficial O 
effects O 
on O 
markers O 
of O 
β O 
cell O 
function O 
, O 
lipid O 
levels O 
, O 
blood O 
pressure O 
and O 
cardiovascular O 
risk O 
markers O 
. O 
However O 
, O 
the O 
durability O 
of O 
their O 
effectiveness O 
is O 
unknown O 
and O 
, O 
compared O 
with O 
insulin O 
, O 
the O 
antihyperglycaemic O 
efficacy O 
of O 
GLP-1RAs O 
is O 
limited O 
. O 
The O 
combination O 
of O 
a O 
GLP-1RA O 
and O 
insulin O 
might O 
thus O 
be O 
highly O 
effective O 
for O 
optimal O 
glucose B-TRIVIAL 
control O 
, O 
ameliorating O 
the O 
adverse O 
effects O 
typically O 
associated O 
with O 
insulin O 
. O 
Data O 
from O 
clinical O 
studies O 
support O 
the O 
therapeutic O 
potential O 
of O 
GLP-1RA-insulin O 
combination O 
therapy O 
, O 
typically O 
showing O 
beneficial O 
effects O 
on O 
glycaemic O 
control O 
and O 
body O 
weight O 
, O 
with O 
a O 
low O 
incidence O 
of O 
hypoglycaemia O 
and O 
, O 
in O 
established O 
insulin O 
therapy O 
, O 
facilitating O 
reductions O 
in O 
insulin O 
dose O 
. O 
In O 
this O 
review O 
, O 
the O 
physiological O 
and O 
pharmacological O 
rationale O 
for O 
using O 
GLP-1RA O 
and O 
insulin O 
therapies O 
in O 
combination O 
is O 
discussed O 
, O 
and O 
data O 
from O 
clinical O 
studies O 
that O 
have O 
assessed O 
the O 
efficacy O 
and O 
safety O 
of O 
this O 
treatment O 
strategy O 
are O 
outlined O 
. O 

III O 
and O 
subtype O 
4 O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
agonists O 
: O 
discovery O 
and O 
pathophysiological O 
applications O 
in O 
Parkinson's O 
disease O 
. O 

the O 
balance O 
between O 
excitatory O 
and O 
inhibitory O 
circuits O 
in O 
the O 
basal O 
ganglia O 
, O 
following O 
the O 
loss O 
of O 
dopaminergic O 
( O 
DA O 
) O 
neurons O 
of O 
the O 
substantia O 
nigra O 
pars O 
compacta O 
, O 
represents O 
a O 
major O 
challenge O 
to O 
treat O 
patients O 
affected O 
by O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
. O 
The O 
imbalanced O 
situation O 
in O 
favor O 
of O 
excitation O 
in O 
the O 
disease O 
state O 
may O 
also O 
accelerate O 
excitotoxic O 
processes O 
, O 
thereby O 
representing O 
a O 
potential O 
target O 
for O 
neuroprotective O 
therapies O 
. O 
Reducing O 
the O 
excitatory O 
action O 
of O 
glutamate B-TRIVIAL 
, O 
the O 
major O 
excitatory O 
neurotransmitter O 
in O 
the O 
basal O 
ganglia O 
, O 
should O 
lead O 
to O 
symptomatic O 
improvement O 
for O 
PD O 
patients O 
and O 
may O 
promote O 
the O 
survival O 
of O 
DA O 
neurons O 
. O 
Recent O 
studies O 
have O 
focused O 
on O 
the O 
modulatory O 
action O 
of O 
metabotropic O 
glutamate B-TRIVIAL 
( O 
mGlu O 
) O 
receptors O 
on O 
neurodegenerative O 
diseases O 
including O 
PD O 
. O 
Group O 
III O 
mGlu O 
receptors O 
, O 
including O 
subtypes O 
4 O 
, O 
7 O 
and O 
8 O 
, O 
are O 
largely O 
expressed O 
in O 
the O 
basal O 
ganglia O 
. O 
Recent O 
studies O 
highlight O 
the O 
use O 
of O 
selective O 
mGlu4 O 
receptor O 
positive O 
allosteric O 
modulators O 
( O 
PAMs O 
) O 
for O 
the O 
treatment O 
of O 
PD O 
. O 
Here O 
we O 
review O 
the O 
effects O 
of O 
newly O 
- O 
designed O 
group-III O 
orthosteric O 
agonists O 
on O 
neuroprotection O 
, O 
neurorestoration O 
and O 
reduction O 
of O 
l-DOPA B-ABBREVIATION 
induced O 
dyskinesia O 
in O 
animal O 
models O 
of O 
PD O 
. O 
The O 
combination O 
of O 
orthosteric O 
mGlu4 O 
receptor O 
selective O 
agonists O 
with O 
PAMs O 
may O 
open O 
new O 
avenues O 
for O 
the O 
symptomatic O 
treatment O 
of O 
PD O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

lipid O 
nanoparticles O 
and O 
nanosuspension O 
of O 
adefovir B-TRIVIAL 
dipivoxil I-TRIVIAL 
for O 
bioavailability O 
improvement O 
: O 
formulation O 
, O 
characterization O 
, O 
pharmacokinetic O 
and O 
biodistribution O 
studies O 
. O 

present O 
study O 
was O 
aimed O 
at O 
developing O 
colloidal O 
formulations O 
like O 
solid O 
lipid O 
nanoparticles O 
( O 
SLN O 
) O 
and O 
nanosuspension O 
( O 
NS O 
) O 
for O 
improving O 
bioavailability O 
of O 
adefovir B-TRIVIAL 
dipivoxil I-TRIVIAL 
( O 
AD O 
) O 
, O 
a O 
nucleoside B-FAMILY 
reverse O 
transcriptase O 
inhibitor O 
which O 
displays O 
poor O 
oral O 
bioavailability O 
. O 
SLNs O 
were O 
prepared O 
by O 
solvent O 
injection O 
method O 
while O 
NS O 
was O 
prepared O 
by O 
pearl O 
milling O 
method O 
. O 
The O 
prepared O 
formulations O 
were O 
characterized O 
for O 
physicochemical O 
parameters O 
such O 
as O 
particle O 
size O 
, O 
ζ O 
potential O 
, O 
drug O 
content O 
, O 
X-ray O 
Diffraction O 
( O 
XRD O 
) O 
, O 
Differential O 
Scanning O 
Calorimetry O 
( O 
DSC O 
) O 
. O 
Pharmacokinetic O 
and O 
biodistribution O 
studies O 
were O 
performed O 
in O 
mice O 
to O 
evaluate O 
in O 
vivo O 
fate O 
of O 
the O 
formulations O 
. O 
The O 
SLNs O 
showed O 
particle O 
size O 
of O 
267 O 
± O 
18 O 
nm O 
and O 
entrapment O 
efficiency O 
of O 
73.5 O 
± O 
2.12% O 
. O 
The O 
particle O 
size O 
obtained O 
for O 
NS O 
was O 
393 O 
± O 
13 O 
nm O 
against O 
710 O 
± O 
70 O 
μm O 
for O 
bulk O 
drug O 
, O 
which O 
led O 
to O 
significant O 
improvement O 
in O 
saturation O 
solubility O 
. O 
DSC O 
and O 
XRD O 
studies O 
of O 
NS O 
and O 
SLN O 
showed O 
reduction O 
in O 
crystallinity O 
while O 
in O 
vitro O 
studies O 
showed O 
improved O 
dissolution O 
rate O 
in O 
both O 
cases O 
. O 
Pharmacokinetics O 
studies O 
of O 
orally O 
administered O 
formulations O 
in O 
mice O 
exhibited O 
higher O 
plasma O 
concentration O 
compared O 
to O 
plain O 
drug O 
. O 
Biodistribution O 
studies O 
showed O 
higher O 
accumulation O 
of O 
drug O 
in O 
liver O 
, O 
kidneys O 
, O 
intestine O 
and O 
stomach O 
. O 
The O 
higher O 
concentration O 
of O 
AD O 
in O 
liver O 
after O 
24 O 
hr O 
highlights O 
its O 
potential O 
advantage O 
for O 
effective O 
treatment O 
of O 
chronic O 
hepatitis O 
infection O 
. O 
The O 
relative O 
bioavailability O 
for O 
adefovir B-TRIVIAL 
NS O 
and O 
SLN O 
were O 
52.46% O 
and O 
78.23% O 
respectively O 
compared O 
to O 
34.34% O 
bioavailability O 
obtained O 
after O 
administration O 
of O 
adefovir B-TRIVIAL 
micro O 
suspension O 
( O 
AMS O 
) O 
, O 
indicating O 
suitability O 
of O 
both O 
nanoparticulate O 
formulations O 
for O 
improving O 
bioavailability O 
. O 
SLNs O 
were O 
found O 
to O 
performed O 
better O 
as O 
compared O 
to O 
NS O 
for O 
improving O 
the O 
bioavailability O 
of O 
AD O 
. O 

new O 
bromobenzyl B-SYSTEMATIC 
methyl I-SYSTEMATIC 
sulphoxide I-SYSTEMATIC 
from O 
marine O 
red O 
alga O 
Symphyocladia O 
latiuscula O 
. O 

new O 
bromophenol B-SYSTEMATIC 
, O 
2,3,6-tribromo-4,5-dihydroxybenzyl B-SYSTEMATIC 
methyl I-SYSTEMATIC 
sulphoxide I-SYSTEMATIC 
, O 
was O 
isolated O 
from O 
the O 
EtOH B-FORMULA 
extract O 
of O 
the O 
marine O 
alga O 
Symphyocladia O 
latiuscula O 
. O 
Its O 
structure O 
was O 
confirmed O 
by O 
spectroscopic O 
methods O 
( O 
1D- O 
and O 
2D-NMR O 
, O 
HR-ESI-MS O 
) O 
. O 
This O 
new O 
bromophenol B-SYSTEMATIC 
showed O 
moderate O 
antifungal O 
activity O 
against O 
Candida O 
albicans O 
with O 
MIC O 
value O 
of O 
37.5 O 
µg O 
mL(-1) O 
. O 

, O 
a O 
new O 
component O 
of O 
the O 
flavonoid B-FAMILY 
pattern O 
of O 
Olea O 
europaea O 
L O 
. O 
and O 
its O 
anti-inflammatory O 
activity O 
. O 

of O 
Olea O 
europaea O 
, O 
cultivar O 
Nocellara O 
del O 
Belice O 
, O 
were O 
examined O 
with O 
respect O 
to O 
the O 
medium O 
- O 
polar O 
fraction O 
, O 
obtained O 
by O 
an O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extraction O 
of O 
the O 
whole O 
extract O 
. O 
In O 
the O 
medium O 
polar O 
fraction O 
, O 
we O 
isolated O 
the O 
two O 
hydroxy-phenyl-ethyl B-FAMILY 
alcohols I-FAMILY 
( O 
hydroxyl-tyrosol B-SYSTEMATIC 
and O 
tyrosol B-TRIVIAL 
) O 
that O 
are O 
the O 
main O 
component O 
of O 
olives O 
. O 
In O 
addition O 
, O 
we O 
isolated O 
a O 
flavonoidic B-FAMILY 
compound O 
, O 
aromadendrine B-TRIVIAL 
, O 
a O 
dihydroflavonol B-SYSTEMATIC 
yet O 
known O 
but O 
quite O 
rare O 
in O 
nature O 
. O 
It O 
is O 
the O 
first O 
time O 
that O 
aromadendrine B-TRIVIAL 
is O 
isolated O 
in O 
O O 
. O 
europaea O 
and O 
we O 
studied O 
the O 
aromadendrine B-TRIVIAL 
biological O 
activity O 
. O 
In O 
particular O 
, O 
the O 
ability O 
of O 
aromadendrine B-TRIVIAL 
to O 
reduce O 
the O 
inflammation O 
induced O 
in O 
normal O 
keratinocytes O 
using O 
an O 
in O 
vitro O 
cell O 
model O 
was O 
evaluated O 
. O 
The O 
results O 
of O 
the O 
present O 
research O 
indicate O 
aromadendrine B-TRIVIAL 
as O 
a O 
novel O 
component O 
in O 
O O 
. O 
europaea O 
with O 
effective O 
activity O 
against O 
skin O 
inflammation O 
. O 

ion O 
- O 
exchange O 
fiber O 
complex O 
: O 
improved O 
dissolution O 
and O 
gastric O 
tolerance O 
based O 
on O 
ion O 
exchange O 
. O 

purpose O 
of O 
the O 
present O 
study O 
is O 
to O 
develop O 
a O 
novel O 
method O 
to O 
improve O 
the O 
dissolution O 
of O 
water O 
- O 
insoluble O 
drug O 
ibuprofen B-TRIVIAL 
and O 
the O 
gastric O 
tolerance O 
of O 
this O 
non-steroidal O 
anti-inflammatory O 
drug O 
which O 
has O 
potentially O 
serious O 
gastrointestinal O 
side O 
effects O 
. O 
This O 
method O 
is O 
based O 
on O 
ion O 
exchange O 
of O 
ion O 
- O 
exchange O 
fibers O 
. O 
Water O 
- O 
insoluble O 
drug O 
ibuprofen B-TRIVIAL 
was O 
dispersed O 
in O 
deionized O 
water O 
, O 
and O 
then O 
the O 
ion O 
- O 
exchange O 
fibers O 
in O 
OH(-) B-FORMULA 
type O 
was O 
immersed O 
in O 
it O 
. O 
Ibuprofen B-TRIVIAL 
and O 
the O 
active O 
groups O 
of O 
the O 
ion O 
- O 
exchange O 
fibers O 
combined O 
into O 
ion O 
pairs O 
based O 
on O 
the O 
acid O 
- O 
base O 
reaction O 
. O 
This O 
drug O 
carrier O 
did O 
not O 
release O 
drugs O 
in O 
deionized O 
water O 
, O 
but O 
in O 
water O 
solution O 
containing O 
other O 
ions O 
it O 
would O 
release O 
the O 
drugs O 
into O 
the O 
solution O 
by O 
ion O 
exchange O 
. O 
Confirmed O 
by O 
the O 
X-ray O 
diffraction O 
and O 
the O 
scanning O 
electron O 
microscopy O 
, O 
the O 
ibuprofen B-TRIVIAL 
combined O 
onto O 
the O 
ion O 
- O 
exchange O 
fibers O 
was O 
in O 
a O 
highly O 
molecular O 
level O 
dispersed O 
state O 
. O 
The O 
improved O 
dissolution O 
of O 
ibuprofen B-TRIVIAL 
ion O 
- O 
exchange O 
fiber O 
complexes O 
is O 
likely O 
to O 
originate O 
from O 
this O 
ibuprofen B-TRIVIAL 
' O 
s O 
highly O 
dispersed O 
state O 
. O 
Due O 
to O 
this O 
, O 
ibuprofen B-TRIVIAL 
' O 
s O 
highly O 
dispersed O 
state O 
, O 
ibuprofen B-TRIVIAL 
ion O 
- O 
exchange O 
fiber O 
complexes O 
significantly O 
decreases O 
the O 
gastrointestinal O 
side O 
effects O 
of O 
ibuprofen B-TRIVIAL 
by O 
avoiding O 
the O 
solid O 
ibuprofen B-TRIVIAL 
' O 
s O 
educing O 
. O 
The O 
present O 
study O 
showed O 
that O 
ibuprofen B-TRIVIAL 
ion O 
- O 
exchange O 
fiber O 
complexes O 
have O 
the O 
two O 
- O 
fold O 
advantages O 
. O 
One O 
is O 
to O 
improve O 
the O 
dissolution O 
of O 
ibuprofen B-TRIVIAL 
. O 
The O 
other O 
is O 
to O 
decrease O 
the O 
ibuprofen B-TRIVIAL 
' O 
s O 
gastrointestinal O 
toxicity O 
. O 

modern O 
approach O 
for O 
controlled O 
transdermal O 
delivery O 
of O 
diflunisal B-TRIVIAL 
: O 
optimization O 
and O 
in O 
vivo O 
evaluation O 
. O 

purpose O 
of O 
the O 
present O 
work O 
was O 
to O 
elaborate O 
an O 
optimized O 
transdermal O 
therapeutic O 
system O 
for O 
diflunisal B-TRIVIAL 
. O 
Selection O 
of O 
suitable O 
ingredients O 
was O 
done O 
via O 
solubility O 
and O 
phase O 
behavior O 
studies O 
. O 
Composition O 
of O 
microemulsion O 
( O 
ME O 
) O 
systems O 
consisting O 
of O 
butyl B-SYSTEMATIC 
lactate I-SYSTEMATIC 
, O 
Brij B-TRIVIAL 
( O 
® O 
) O 
97 O 
, O 
Transcutol B-TRIVIAL 
( O 
® O 
) O 
and O 
water O 
was O 
optimized O 
using O 
augmented O 
simplex O 
lattice O 
mixture O 
design O 
. O 
The O 
independent O 
variables O 
selected O 
were O 
the O 
percentages O 
of O 
butyl B-SYSTEMATIC 
lactate I-SYSTEMATIC 
, O 
surfactant O 
mixture O 
and O 
water O 
. O 
The O 
dependent O 
variables O 
were O 
refractive O 
index O 
, O 
pH O 
, O 
conductivity O 
, O 
viscosity O 
, O 
drug O 
solubility O 
in O 
the O 
ME O 
formulation O 
and O 
the O 
ex O 
vivo O 
skin O 
permeation O 
flux O 
. O 
Mathematical O 
equations O 
and O 
response O 
surface O 
plots O 
were O 
used O 
to O 
relate O 
the O 
dependent O 
and O 
independent O 
variables O 
. O 
The O 
statistical O 
validity O 
of O 
the O 
polynomials O 
was O 
established O 
. O 
Optimized O 
formulation O 
factors O 
were O 
selected O 
by O 
desirability O 
approach O 
. O 
The O 
optimized O 
ME O 
formulation O 
was O 
converted O 
into O 
gel O 
using O 
Carbomer B-FAMILY 
( O 
® O 
) O 
934 O 
. O 
The O 
microemulsion O 
based O 
gel O 
( O 
MBG O 
) O 
showed O 
better O 
spreadability O 
and O 
5.07-fold O 
increase O 
in O 
the O 
transdermal O 
flux O 
than O 
Carbomer B-FAMILY 
( O 
® O 
) O 
934 O 
gel O 
. O 
The O 
in O 
vivo O 
antihyperalgesia O 
assay O 
performed O 
on O 
mice O 
showed O 
significant O 
reduction O 
of O 
the O 
licking O 
time O 
in O 
the O 
treated O 
group O 
compared O 
to O 
the O 
control O 
group O 
. O 
This O 
demonstrated O 
the O 
reliability O 
of O 
the O 
simplex O 
lattice O 
statistical O 
design O 
for O 
predicting O 
optimum O 
ME O 
formulation O 
. O 
The O 
developed O 
MBG O 
proved O 
its O 
in O 
vivo O 
efficiency O 
for O 
transdermal O 
delivery O 
of O 
diflunisal B-TRIVIAL 
. O 

study O 
aimed O 
to O 
evaluate O 
the O 
antimicrobial O 
effects O 
, O 
the O 
radical O 
scavenging O 
activity O 
( O 
by O 
DPPH B-ABBREVIATION 
and O 
ABTS B-ABBREVIATION 
tests O 
) O 
and O 
the O 
antioxidant O 
capacity O 
( O 
by O 
β-carotene B-TRIVIAL 
bleaching O 
test O 
) O 
of O 
Betula O 
aetnensis O 
leaves O 
extract O 
. O 
The O 
antimicrobial O 
activity O 
was O 
tested O 
against O 
14 O 
Gram O 
- O 
positive O 
clinical O 
strains O 
, O 
2 O 
ATCC O 
Gram O 
- O 
positive O 
strains O 
, O 
10 O 
Gram O 
- O 
negative O 
clinical O 
strains O 
and O 
4 O 
Gram O 
- O 
negative O 
ATCC O 
strains O 
. O 
Streptococcus O 
pyogenes O 
Ery-S O 
and O 
Ery-R1 O 
were O 
the O 
most O 
sensitive O 
. O 
Betula O 
aetnensis O 
was O 
considerably O 
active O 
against O 
three O 
bacterial O 
strains O 
, O 
namely O 
Haemophilus O 
influenzae O 
ATCC O 
49247 O 
, O 
Amp-R1 O 
and O 
Moraxella O 
catarrhalis O 
ATCC O 
25238 O 
. O 
Standard O 
ATCC O 
strains O 
of O 
Gram O 
- O 
positive O 
bacteria O 
were O 
more O 
sensitive O 
than O 
Gram O 
- O 
negative O 
. O 
Betula O 
aetnensis O 
showed O 
also O 
an O 
interesting O 
reducing O 
power O 
with O 
TEAC O 
values O 
of O 
9.7 O 
and O 
a O 
good O 
inhibition O 
of O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
oxidation O 
with O 
an O 
IC50 O 
value O 
of O 
22 O 
µg O 
mL(-1) O 
after O 
30 O 
min O 
of O 
incubation O 
. O 
The O 
total O 
phenol B-SYSTEMATIC 
and O 
flavonoid B-FAMILY 
contents O 
were O 
determined O 
with O 
the O 
purpose O 
to O 
evaluate O 
the O 
relationship O 
with O 
the O 
observed O 
bioactivities O 
. O 

C-E I-MULTIPLE 
, O 
new O 
apotirucallane B-FAMILY 
triterpenoids I-FAMILY 
from O 
the O 
stem O 
bark O 
of O 
Feroniella O 
lucida O 
. O 

- O 
directed O 
isolation O 
of O 
Feroniella O 
lucida O 
stem O 
bark O 
yielded O 
three O 
new O 
apotirucallane B-FAMILY 
triterpenoids I-FAMILY 
named O 
feroniellides B-MULTIPLE 
C-E I-MULTIPLE 
. O 
The O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
established O 
by O 
extensive O 
analysis O 
of O 
spectroscopic O 
data O 
. O 
Of O 
triterpenoids B-FAMILY 
examined O 
, O 
feroniellides B-MULTIPLE 
D I-MULTIPLE 
and I-MULTIPLE 
E I-MULTIPLE 
revealed O 
anticancer O 
activity O 
against O 
KB O 
and O 
HeLa O 
cells O 
with O 
IC50 O 
values O 
in O 
range O 
of O 
3.4-14.2 O 
µg O 
mL(-1) O 
, O 
which O 
are O 
significantly O 
more O 
potent O 
than O 
feroniellides B-MULTIPLE 
A-C I-MULTIPLE 
( O 
IC50 O 
25.5-60.0 O 
µg O 
mL(-1) O 
) O 
. O 
The O 
present O 
investigation O 
suggests O 
that O 
an O 
isovalerate B-TRIVIAL 
moiety O 
in O 
feroniellides B-MULTIPLE 
D I-MULTIPLE 
and I-MULTIPLE 
E I-MULTIPLE 
is O 
possibly O 
associated O 
with O 
exerting O 
cytotoxicity O 
against O 
cancer O 
cells O 
. O 

chloride B-SYSTEMATIC 
cotransporters O 
NKCC1 O 
and O 
KCC2 O 
as O 
potential O 
targets O 
for O 
novel O 
antiepileptic O 
and O 
antiepileptogenic O 
treatments O 
. O 

cortical O 
and O 
hippocampal O 
neurons O 
, O 
cation- O 
chloride B-SYSTEMATIC 
cotransporters O 
( O 
CCCs O 
) O 
control O 
the O 
reversal O 
potential O 
( O 
EGABA O 
) O 
of O 
GABAA O 
receptor O 
- O 
mediated O 
current O 
and O 
voltage O 
responses O 
and O 
, O 
consequently O 
, O 
they O 
modulate O 
the O 
efficacy O 
of O 
GABAergic O 
inhibition O 
. O 
Two O 
members O 
of O 
the O 
CCC O 
family O 
, O 
KCC2 O 
( O 
the O 
major O 
neuron O 
- O 
specific O 
K-Cl O 
cotransporter O 
; O 
KCC O 
isoform O 
2 O 
) O 
and O 
NKCC1 O 
( O 
the O 
Na-K-2Cl O 
cotransporter O 
isoform O 
1 O 
which O 
is O 
expressed O 
in O 
both O 
neurons O 
and O 
glial O 
cells O 
) O 
have O 
attracted O 
much O 
interest O 
in O 
studies O 
on O 
GABAergic O 
signaling O 
under O 
both O 
normal O 
and O 
pathophysiological O 
conditions O 
, O 
such O 
as O 
epilepsy O 
. O 
There O 
is O 
tentative O 
evidence O 
that O 
loop O 
diuretic O 
compounds O 
such O 
as O 
furosemide O 
and O 
bumetanide O 
may O 
have O 
clinically O 
relevant O 
antiepileptic O 
actions O 
, O 
especially O 
when O 
administered O 
in O 
combination O 
with O 
conventional O 
GABA-mimetic O 
drugs O 
such O 
as O 
phenobarbital O 
. O 
Furosemide O 
is O 
a O 
non-selective O 
inhibitor O 
of O 
CCCs O 
while O 
at O 
low O 
concentrations O 
bumetanide O 
is O 
selective O 
for O 
NKCCs O 
. O 
Search O 
for O 
novel O 
antiepileptic O 
drugs O 
( O 
AEDs O 
) O 
is O 
highly O 
motivated O 
especially O 
for O 
the O 
treatment O 
of O 
neonatal O 
seizures O 
which O 
are O 
often O 
resistant O 
to O 
, O 
or O 
even O 
aggravated O 
by O 
conventional O 
AEDs O 
. O 
This O 
review O 
shows O 
that O 
the O 
antiepileptic O 
effects O 
of O 
loop O 
diuretics O 
described O 
in O 
the O 
pertinent O 
literature O 
are O 
based O 
on O 
widely O 
heterogeneous O 
mechanisms O 
ranging O 
from O 
actions O 
on O 
both O 
neuronal O 
NKCC1 O 
and O 
KCC2 O 
to O 
modulation O 
of O 
the O 
brain O 
extracellular O 
volume O 
fraction O 
. O 
A O 
promising O 
strategy O 
for O 
the O 
development O 
of O 
novel O 
CCC-blocking O 
AEDs O 
is O 
based O 
on O 
prodrugs O 
that O 
are O 
activated O 
following O 
their O 
passage O 
across O 
the O 
blood O 
- O 
brain O 
barrier O 
. O 
This O 
article O 
is O 
part O 
of O 
the O 
Special O 
Issue O 
entitled O 
' O 
New O 
Targets O 
and O 
Approaches O 
to O 
the O 
Treatment O 
of O 
Epilepsy O 
' O 
. O 

FC I-TRIVIAL 
( O 
GFC B-ABBREVIATION 
) O 
, O 
a O 
natural O 
prenylated B-SYSTEMATIC 
benzophenone I-SYSTEMATIC 
, O 
was O 
extracted O 
from O 
Platonia O 
insignis O 
Mart O 
. O 
( O 
Clusiaceae O 
) O 
, O 
a O 
native O 
plant O 
commonly O 
known O 
as O 
bacuri O 
and O 
used O 
in O 
traditional O 
Brazilian O 
medicine O 
for O 
the O 
treatment O 
of O 
skin O 
diseases O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
cytotoxic O 
and O 
leishmanicidal O 
effects O 
of O 
GFC B-ABBREVIATION 
using O 
in O 
vitro O 
models O 
. O 
The O 
experimental O 
data O 
demonstrated O 
that O 
the O 
polyisoprenylated B-FAMILY 
benzophenone I-FAMILY 
GFC I-FAMILY 
possesses O 
cytotoxic O 
and O 
leishmanicidal O 
activities O 
. O 

new O 
acylated B-FAMILY 
flavone I-FAMILY 
glycoside I-FAMILY 
with O 
antioxidant O 
and O 
radical O 
scavenging O 
activities O 
from O 
Teucrium O 
polium O 
leaves O 
. O 

antioxidant O 
properties O 
of O 
six O 
flavones B-FAMILY 
from O 
Teucrium O 
polium O 
L O 
. O 
, O 
one O 
of O 
them O 
isolated O 
for O 
the O 
first O 
time O 
, O 
have O 
been O 
established O 
through O 
the O 
determination O 
of O 
their O 
abilities O 
to O 
inhibit O 
free O 
radicals O 
using O 
DPPH B-ABBREVIATION 
, O 
ABTS B-ABBREVIATION 
radicals O 
and O 
ORAC O 
test O 
. O 
The O 
structure O 
of O 
the O 
new O 
metabolite O 
has O 
been O 
elucidated O 
by O 
1-D O 
( O 
1H B-FORMULA 
, O 
13C B-FORMULA 
and O 
DEPT O 
) O 
and O 
2-D O 
( O 
COSY O 
, O 
TOCSY O 
, O 
HSQC O 
, O 
CIGAR O 
) O 
NMR O 
experiments O 
and O 
by O 
ESI O 
Q-TOF O 
HRMS O 
analysis O 
. O 
Flavones B-FAMILY 
1-3 O 
presented O 
an O 
efficacious O 
activity O 
towards O 
the O 
stable O 
DPPH B-ABBREVIATION 
radical O 
. O 
Analogously O 
, O 
compounds O 
2 O 
and O 
3 O 
resulted O 
significantly O 
active O 
also O 
versus O 
ABTS B-ABBREVIATION 
cation O 
radical O 
. O 
On O 
the O 
basis O 
of O 
the O 
comparable O 
bioactivity O 
of O 
luteolin B-TRIVIAL 
-based O 
compounds O 
, O 
the O 
presence O 
of O 
an O 
ortho-dihydroxy B-SYSTEMATIC 
substitution O 
in O 
the O 
flavone B-TRIVIAL 
B-ring O 
is O 
supposed O 
to O 
be O 
the O 
structural O 
feature O 
responsible O 
for O 
the O 
antioxidant O 
activity O 
. O 

study O 
is O 
designed O 
to O 
examine O 
the O 
chemical O 
composition O 
and O 
antioxidant O 
activity O 
of O 
the O 
essential O 
oil O 
of O 
Vitex O 
megapotamica O 
. O 
Gas O 
chromatography O 
- O 
mass O 
spectrometry O 
analysis O 
resulted O 
in O 
the O 
detection O 
of O 
27 O 
components O 
, O 
representing O 
92.36% O 
of O 
the O 
total O 
oil O 
composition O 
. O 
The O 
main O 
components O 
in O 
the O 
oil O 
were O 
butylated B-SYSTEMATIC 
hydroxytoluene I-SYSTEMATIC 
( O 
BHT B-ABBREVIATION 
) O 
( O 
34.17% O 
) O 
, O 
phytol B-TRIVIAL 
( O 
12.66% O 
) O 
, O 
α-caryophyllene B-TRIVIAL 
( O 
11.84% O 
) O 
, O 
δ-elemene B-TRIVIAL 
( O 
10.65% O 
) O 
, O 
β-caryophyllene B-TRIVIAL 
( O 
7.82% O 
) O 
, O 
γ-elemene B-TRIVIAL 
( O 
4.24% O 
) O 
and O 
germacrene B-TRIVIAL 
D I-TRIVIAL 
( O 
2.82% O 
) O 
. O 
The O 
antioxidant O 
activity O 
of O 
the O 
oil O 
was O 
evaluated O 
in O 
terms O 
of O 
their O 
free O 
- O 
radical O 
scavenging O 
activity O 
against O 
1,1-diphenyl-2-picrylhydrazyl B-SYSTEMATIC 
. O 
The O 
oil O 
showed O 
percentage O 
inhibition O 
of O 
35.62% O 
and O 
75.25% O 
at O 
concentrations O 
of O 
76 O 
and O 
101.6 O 
mg O 
mL(-1) O 
, O 
respectively O 
. O 
BHT B-ABBREVIATION 
( O 
36.30% O 
) O 
was O 
also O 
determined O 
by O 
HPLC-DAD O 
in O 
the O 
hexane B-SYSTEMATIC 
fraction O 
from O 
the O 
leaves O 
. O 
To O 
the O 
best O 
of O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
study O 
of O 
the O 
composition O 
and O 
antioxidant O 
activity O 
of O 
the O 
essential O 
oil O 
of O 
the O 
species O 
V O 
. O 
megapotamica O 
. O 

activity O 
of O 
an O 
aqueous O 
extract O 
of O 
Prasaplai O 
, O 
a O 
Thai O 
traditional O 
medicine O 
, O 
was O 
studied O 
on O 
the O 
isolated O 
rat O 
uterus O 
in O 
the O 
oestrus O 
stage O 
. O 
The O 
results O 
showed O 
that O 
the O 
extract O 
inhibited O 
the O 
contraction O 
induced O 
by O 
a O 
submaximal O 
dose O 
of O 
acetylcholine B-SYSTEMATIC 
(2.04×10(-4) O 
mg O 
mL(-1)) O 
, O 
oxytocin B-TRIVIAL 
( O 
1.54×10(-4) O 
mg O 
mL(-1) O 
) O 
and O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
( O 
PGE2 B-ABBREVIATION 
) O 
(6.00×10(-4) O 
mg O 
mL(-1)) O 
. O 
The O 
inhibition O 
was O 
concentration O 
- O 
dependent O 
and O 
reversible O 
by O 
tissue O 
washing O 
. O 
The O 
IC50 O 
of O 
Prasaplai O 
extracts O 
expressed O 
as O 
milligram O 
of O 
powdered O 
preparation O 
per O 
millilitre O 
of O 
perfusion O 
solution O 
for O 
acetylcholine B-SYSTEMATIC 
, O 
oxytocin B-TRIVIAL 
and O 
PGE2 B-ABBREVIATION 
were O 
11.7 O 
, O 
10 O 
and O 
5.75 O 
mg O 
mL(-1) O 
, O 
respectively O 
. O 
These O 
data O 
reveal O 
that O 
Prasaplai O 
has O 
an O 
antispasmodic O 
effect O 
against O 
uterine O 
contraction O 
by O 
different O 
mechanisms O 
and O 
corroborate O 
the O 
traditional O 
use O 
in O 
the O 
treatment O 
of O 
dysmenorrhoea O 
. O 
Oral O 
administration O 
of O 
single O 
dose O 
of O 
the O 
water O 
extract O 
, O 
calculated O 
as O 
powdered O 
Prasaplai O 
up O 
to O 
20 O 
g O 
kg(-1) O 
in O 
rats O 
, O 
showed O 
no O 
sign O 
and O 
symptom O 
of O 
acute O 
toxicity O 
, O 
and O 
no O 
rat O 
died O 
even O 
at O 
the O 
maximum O 
dose O 
. O 

new O 
caryolane B-FAMILY 
sesquiterpene I-FAMILY 
from O 
Heteropappus O 
altaicus O 
( O 
Willd O 
. O 
) O 
Novopokr O 
. O 

new O 
caryolane B-FAMILY 
sesquiterpene I-FAMILY 
, O 
1β-methoxycaryol-9-one B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
along O 
with O 
eight O 
known O 
compounds O 
( O 
2-9 O 
) O 
, O 
was O 
isolated O 
from O 
the O 
whole O 
plant O 
of O 
Heteropappus O 
altaicus O 
. O 
The O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
comprehensive O 
1D- O 
and O 
2D-NMR O 
analysis O 
and O 
high O 
- O 
resolution O 
mass O 
spectrometry O 
. O 
The O 
13C B-FORMULA 
-NMR O 
data O 
of O 
compound O 
2 O 
are O 
reported O 
for O 
the O 
first O 
time O 
. O 

antileishmanial O 
prenyloxy-naphthoquinone B-SYSTEMATIC 
from O 
roots O 
of O 
Plumbago O 
zeylanica O 
. O 

donovani O 
, O 
an O 
obligate O 
intracellular O 
parasite O 
of O 
genus O 
Leishmania O 
causes O 
visceral O 
leishmaniasis O 
that O 
affects O 
millions O 
of O 
people O 
worldwide O 
, O 
especially O 
in O 
the O 
Indian O 
subcontinent O 
and O 
East O 
Africa O 
. O 
Generic O 
pentavalent O 
antimonials O 
have O 
been O 
the O 
mainstay O 
for O 
therapy O 
in O 
the O 
endemic O 
regions O 
due O 
to O 
efficacy O 
and O 
cost O 
effectiveness O 
but O 
the O 
growing O 
incidence O 
of O 
their O 
resistance O 
has O 
seriously O 
hampered O 
their O 
use O 
. O 
This O 
study O 
discloses O 
strong O 
in O 
vitro O 
antileishmanial O 
activity O 
of O 
2-methyl-5 B-SYSTEMATIC 
-(3'-methyl-but-2'-enyloxy)-[1,4]naphthoquinone I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
a O 
prenyloxy-naphthoquinone B-SYSTEMATIC 
isolated O 
and O 
characterised O 
from O 
roots O 
of O 
the O 
plant O 
Plumbago O 
zeylanica O 
( O 
family-Plumbaginaceae O 
) O 
. O 
The O 
observed O 
EC50 O 
for O 
the O 
compound O 
1 O 
against O 
promastigote O 
and O 
amastigote O 
forms O 
of O 
L O 
. O 
donovani O 
was O 
significantly O 
( O 
p O 
< O 
0.001 O 
) O 
lower O 
than O 
miltefosine B-TRIVIAL 
, O 
a O 
reference O 
drug O 
. O 
In O 
context O 
to O 
limited O 
treatment O 
options O 
and O 
growing O 
resistance O 
for O 
available O 
drugs O 
, O 
compound O 
1 O 
offers O 
a O 
greater O 
prospect O 
towards O 
antileishmanial O 
drug O 
discovery O 
and O 
development O 
. O 

and O 
structure O 
determination O 
of O 
new O 
siderophore O 
tsukubachelin B-TRIVIAL 
B I-TRIVIAL 
from O 
Streptomyces O 
sp O 
. O 
TM-74 O 
. O 

new O 
siderophore O 
tsukubachelin B-TRIVIAL 
B I-TRIVIAL 
( O 
1 O 
) O 
was O 
isolated O 
from O 
the O 
iron B-SYSTEMATIC 
-deficient O 
culture O 
medium O 
of O 
the O 
newly O 
isolated O 
strain O 
Streptomyces O 
sp O 
. O 
TM-74 O 
. O 
The O 
chemical O 
structure O 
of O 
tsukubachelin B-TRIVIAL 
B I-TRIVIAL 
( O 
1 O 
) O 
was O 
established O 
via O 
interpretation O 
of O 
2D O 
nuclear O 
magnetic O 
resonance O 
and O 
electrospray O 
ionization O 
- O 
mass O 
spectroscopic O 
data O 
. O 
The O 
structure O 
of O 
tsukubachelin B-TRIVIAL 
B I-TRIVIAL 
( O 
1 O 
) O 
comprises O 
6 O 
mol O 
of O 
amino B-FAMILY 
acids I-FAMILY 
, O 
including O 
2 O 
mol O 
of O 
serine B-TRIVIAL 
and O 
1 O 
mol O 
each O 
of O 
ornithine B-TRIVIAL 
, O 
N-α-methyl-N-δ-hydroxy-N-δ- B-SYSTEMATIC 
formylornithine I-SYSTEMATIC 
, O 
N-α-methyl-N-δ-hydroxyornithine B-SYSTEMATIC 
, O 
and O 
cyclic B-SYSTEMATIC 
N-hydroxyornithine I-SYSTEMATIC 
. O 

describe O 
the O 
2-year O 
follow O 
- O 
up O 
of O 
an O 
open O 
- O 
label O 
trial O 
( O 
CT-AMT-011-01 O 
) O 
of O 
AAV1-LPL(S447X) O 
gene O 
therapy O 
for O 
lipoprotein O 
lipase O 
( O 
LPL O 
) O 
deficiency O 
( O 
LPLD O 
) O 
, O 
an O 
orphan O 
disease O 
associated O 
with O 
chylomicronemia O 
, O 
severe O 
hypertriglyceridemia O 
, O 
metabolic O 
complications O 
and O 
potentially O 
life O 
- O 
threatening O 
pancreatitis O 
. O 
The O 
LPL(S447X) O 
gene O 
variant O 
, O 
in O 
an O 
adeno O 
- O 
associated O 
viral O 
vector O 
of O 
serotype O 
1 O 
( O 
alipogene O 
tiparvovec O 
) O 
, O 
was O 
administered O 
to O 
14 O 
adult O 
LPLD O 
patients O 
with O 
a O 
prior O 
history O 
of O 
pancreatitis O 
. O 
Primary O 
objectives O 
were O 
to O 
assess O 
the O 
long O 
- O 
term O 
safety O 
of O 
alipogene O 
tiparvovec O 
and O 
achieve O 
a O 
40% O 
reduction O 
in O 
fasting O 
median O 
plasma O 
triglyceride B-FAMILY 
( O 
TG O 
) O 
at O 
3-12 O 
weeks O 
compared O 
with O 
baseline O 
. O 
Cohorts O 
1 O 
( O 
n=2 O 
) O 
and O 
2 O 
( O 
n=4 O 
) O 
received O 
3 O 
× O 
10(11) O 
gc O 
kg(-1) O 
, O 
and O 
cohort O 
3 O 
( O 
n=8 O 
) O 
received O 
1 O 
× O 
10(12) O 
gc O 
kg(-1) O 
. O 
Cohorts O 
2 O 
and O 
3 O 
also O 
received O 
immunosuppressants O 
from O 
the O 
time O 
of O 
alipogene O 
tiparvovec O 
administration O 
and O 
continued O 
for O 
12 O 
weeks O 
. O 
Alipogene O 
tiparvovec O 
was O 
well O 
tolerated O 
, O 
without O 
emerging O 
safety O 
concerns O 
for O 
2 O 
years O 
. O 
Half O 
of O 
the O 
patients O 
demonstrated O 
a O 
40% O 
reduction O 
in O 
fasting O 
TG O 
between O 
3 O 
and O 
12 O 
weeks O 
. O 
TG O 
subsequently O 
returned O 
to O 
baseline O 
, O 
although O 
sustained O 
LPL(S447X) O 
expression O 
and O 
long O 
- O 
term O 
changes O 
in O 
TG-rich O 
lipoprotein O 
characteristics O 
were O 
noted O 
independently O 
of O 
the O 
effect O 
on O 
fasting O 
plasma O 
TG O 
. O 

Activity O 
of O 
Swertiamarin B-TRIVIAL 
is O 
due O 
to O 
an O 
Active O 
Metabolite O 
, O 
Gentianine B-TRIVIAL 
, O 
that O 
Upregulates O 
PPAR-γ O 
Gene O 
Expression O 
in O 
3T3-L1 O 
cells O 
. O 

have O 
previously O 
shown O 
the O 
anti-diabetic O 
effects O 
of O 
swertiamarin B-TRIVIAL 
; O 
however O 
, O 
pharmacokinetic O 
analysis O 
showed O 
that O 
swertiamarin B-TRIVIAL 
had O 
a O 
plasma O 
half O 
- O 
life O 
of O 
1.3 O 
h O 
. O 
Gentianine B-TRIVIAL 
is O 
an O 
active O 
metabolite O 
of O 
swertiamarin B-TRIVIAL 
that O 
possesses O 
a O 
pharmacophoric O 
moiety O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
explore O 
the O 
possibility O 
whether O 
the O 
anti-diabetic O 
effect O 
of O 
swertiamarin B-TRIVIAL 
is O 
due O 
to O 
gentianine B-TRIVIAL 
. O 
Swertiamarin B-TRIVIAL 
treatment O 
had O 
no O 
significant O 
effect O 
on O 
adipogenesis O 
, O 
or O 
the O 
mRNA O 
expression O 
of O 
PPAR-γ O 
and O 
GLUT-4 O 
; O 
however O 
, O 
there O 
was O 
a O 
significant O 
increase O 
in O 
the O 
mRNA O 
expression O 
of O 
adiponectin O 
. O 
On O 
the O 
other O 
hand O 
, O 
treatment O 
with O 
gentianine B-TRIVIAL 
significantly O 
increased O 
adipogenesis O 
, O 
which O 
was O 
associated O 
with O 
a O 
significant O 
increase O 
in O 
the O 
mRNA O 
expression O 
of O 
PPAR-γ O 
, O 
GLUT-4 O 
and O 
adiponectin O 
. O 
These O 
findings O 
suggest O 
, O 
for O 
the O 
first O 
time O 
, O 
that O 
the O 
anti-diabetic O 
effect O 
of O 
swertiamarin B-TRIVIAL 
is O 
due O 
to O 
gentianine B-TRIVIAL 
, O 
an O 
active O 
metabolite O 
of O 
swertiamarin B-TRIVIAL 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

treatment O 
with O 
selective O 
I2- O 
imidazoline B-SYSTEMATIC 
receptor O 
ligands O 
decreases O 
the O 
content O 
of O 
pro O 
- O 
apoptotic O 
markers O 
in O 
rat O 
brain O 
. O 

I(2)- O 
imidazoline B-SYSTEMATIC 
receptor O 
ligands O 
induce O 
neuroprotection O 
through O 
various O 
molecular O 
mechanisms O 
including O 
blockade O 
of O 
N-methyl-D-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
receptors O 
. O 
To O 
investigate O 
new O 
neuroprotective O 
mechanisms O 
associated O 
with O 
I(2)- O 
imidazoline B-SYSTEMATIC 
receptors O 
, O 
the O 
effects O 
of O 
selective O 
( O 
2-styryl-2-imidazoline B-SYSTEMATIC 
( O 
LSL B-IDENTIFIER 
61122 I-IDENTIFIER 
) O 
, O 
2-(2-benzofuranyl)-2-imidazoline B-SYSTEMATIC 
( O 
2-BFI B-SYSTEMATIC 
) O 
, O 
2-(4,5-dihydroimidazol-2-yl) B-SYSTEMATIC 
quinoline I-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
BU-224 B-IDENTIFIER 
) O 
) O 
and O 
non-selective O 
( O 
idazoxan B-TRIVIAL 
) O 
I(2)-drugs O 
on O 
canonical O 
apoptotic O 
pathways O 
were O 
assessed O 
in O 
rat O 
brain O 
cortex O 
. O 
The O 
acute O 
treatment O 
with O 
LSL B-IDENTIFIER 
61122 I-IDENTIFIER 
( O 
10 O 
mg O 
/ O 
kg O 
) O 
reduced O 
the O 
content O 
of O 
mitochondrial O 
( O 
pro O 
- O 
apoptotic O 
) O 
Bax O 
( O 
-33% O 
) O 
and O 
cytochrome O 
c O 
( O 
-31% O 
) O 
, O 
which O 
was O 
prevented O 
by O 
idazoxan B-TRIVIAL 
, O 
an O 
I(2)-receptor O 
antagonist O 
. O 
The O 
sustained O 
stimulation O 
of O 
I(2)- O 
imidazoline B-SYSTEMATIC 
receptors O 
with O 
selective O 
drugs O 
( O 
10 O 
mg O 
/ O 
kg O 
, O 
every O 
12 O 
h O 
for O 
seven O 
days O 
) O 
was O 
associated O 
with O 
down O 
- O 
regulation O 
of O 
key O 
components O 
of O 
the O 
extrinsic O 
( O 
Fas O 
receptor O 
: O 
-20% O 
; O 
Fas O 
associated O 
protein O 
with O 
death O 
domain O 
( O 
FADD O 
) O 
adaptor O 
: O 
-47-54% O 
) O 
and O 
/ O 
or O 
intrinsic O 
( O 
Bax O 
: O 
-20-23% O 
; O 
cytochrome O 
c O 
: O 
-22-28% O 
) O 
apoptotic O 
signalling O 
and O 
/ O 
or O 
up O 
- O 
regulation O 
of O 
survival O 
anti-apoptotic O 
factors O 
( O 
p- O 
Ser B-FORMULA 
194 O 
FADD O 
/ O 
FADD O 
ratio O 
: O 
+ O 
1.6-2.5-fold O 
; O 
and O 
/ O 
or O 
Bcl-2 O 
/ O 
Bax O 
ratio O 
: O 
+ O 
1.5-fold O 
) O 
, O 
which O 
in O 
the O 
long O 
- O 
term O 
could O 
dampen O 
cell O 
death O 
in O 
the O 
brain O 
. O 
Similar O 
chronic O 
treatments O 
with O 
LSL B-IDENTIFIER 
60101 I-IDENTIFIER 
( O 
the O 
imidazole B-SYSTEMATIC 
analogue O 
of O 
2-BFI B-SYSTEMATIC 
) O 
and O 
idazoxan B-TRIVIAL 
( O 
a O 
mixed O 
I(2) O 
/ O 
α(2) O 
- O 
ligand O 
) O 
did O 
not O 
induce O 
significant O 
alterations O 
of O 
pro- O 
or O 
anti-apoptotic O 
proteins O 
. O 
The O 
disclosed O 
anti-apoptotic O 
mechanisms O 
of O 
selective O 
I(2)- O 
imidazoline B-SYSTEMATIC 
drugs O 
may O 
work O 
in O 
concert O 
with O 
other O 
molecular O 
mechanisms O 
of O 
neuroprotection O 
( O 
e.g O 
. O 
blockade O 
of O 
NMDA O 
receptors O 
) O 
that O 
are O 
engaged O 
by O 
I(2) O 
- O 
ligands O 
. O 

new O 
furolactone B-FAMILY 
-type O 
lignan B-FAMILY 
from O 
Lycium O 
chinense O 
. O 

phytochemical O 
investigation O 
of O 
extracts O 
from O 
the O 
root O 
barks O 
of O 
Lycium O 
chinense O 
yielded O 
a O 
new O 
furolactone O 
- O 
type O 
lignan O 
, O 
lyciumin B-TRIVIAL 
( O 
1 O 
) O 
. O 
Its O 
structure O 
and O 
absolute O 
configurations O 
were O 
established O 
on O 
the O 
basis O 
of O 
spectral O 
data O 
, O 
particularly O 
by O 
the O 
use O 
of O 
1D O 
NMR O 
, O 
2D O 
shift O 
- O 
correlated O 
NMR O 
pulse O 
sequences O 
( O 
(1)H B-FORMULA 
- O 
(1)H B-FORMULA 
COSY O 
, O 
HSQC O 
, O 
HMBC O 
and O 
ROESY O 
) O 
and O 
CD O 
spectra O 
. O 

of O 
serotonin B-TRIVIAL 
2A O 
receptors O 
facilitates O 
consolidation O 
and O 
extinction O 
of O 
fear O 
memory O 
in O 
C57BL O 
/ O 
6J O 
mice O 
. O 

fear O 
is O 
a O 
hallmark O 
of O 
several O 
emotional O 
and O 
mental O 
disorders O 
such O 
as O 
phobias O 
and O 
panic O 
disorders O 
. O 
Considerable O 
attention O 
is O 
focused O 
on O 
defining O 
the O 
neurobiological O 
mechanisms O 
of O 
the O 
extinction O 
of O 
conditioned O 
fear O 
memory O 
in O 
an O 
effort O 
to O 
identify O 
mechanisms O 
that O 
may O 
hold O 
clinical O 
significance O 
for O 
remediating O 
aberrant O 
fear O 
memory O 
. O 
Serotonin B-TRIVIAL 
modulates O 
the O 
acquisition O 
and O 
retention O 
of O 
conditioned O 
emotional O 
memory O 
, O 
and O 
the O 
serotonin B-TRIVIAL 
2A O 
receptor O 
( O 
5HT2AR O 
) O 
may O 
be O 
one O 
of O 
the O 
postsynaptic O 
targets O 
mediating O 
such O 
effects O 
. O 
Here O 
we O 
tested O 
the O 
hypothesis O 
that O 
the O 
5HT2AR O 
regulates O 
the O 
consolidation O 
and O 
extinction O 
of O 
fear O 
memory O 
in O 
male O 
C57BL O 
/ O 
6J O 
mice O 
. O 
The O 
influence O 
of O 
5HT2ARs O 
on O 
memory O 
consolidation O 
was O 
further O 
confirmed O 
with O 
a O 
novel O 
object O 
recognition O 
task O 
. O 
With O 
a O 
trace O 
fear O 
conditioning O 
paradigm O 
, O 
administration O 
of O 
the O 
5HT2AR O 
agonist O 
TCB-2 B-IDENTIFIER 
( O 
1 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
before O 
the O 
extinction O 
test O 
facilitated O 
the O 
acquisition O 
of O 
extinction O 
of O 
fear O 
memory O 
as O 
compared O 
to O 
vehicle O 
treatment O 
. O 
In O 
contrast O 
, O 
administration O 
of O 
the O 
5HT2AR O 
antagonist O 
MDL B-IDENTIFIER 
11939 I-IDENTIFIER 
( O 
0.5 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
delayed O 
the O 
acquisition O 
of O 
extinction O 
of O 
fear O 
memory O 
. O 
Further O 
, O 
the O 
post O 
- O 
conditioning O 
administration O 
of O 
TCB-2 B-IDENTIFIER 
enhanced O 
contextual O 
and O 
cued O 
fear O 
memory O 
, O 
possibly O 
by O 
facilitating O 
the O 
consolidation O 
of O 
fear O 
memory O 
. O 
Administration O 
of O 
TCB-2 B-IDENTIFIER 
also O 
facilitated O 
the O 
acquisition O 
of O 
extinction O 
of O 
fear O 
memory O 
in O 
delay O 
fear O 
conditioned O 
mice O 
. O 
Stimulation O 
or O 
blockade O 
of O 
5HT2ARs O 
did O 
not O 
affect O 
the O 
encoding O 
or O 
retrieval O 
of O 
conditioned O 
fear O 
memory O 
. O 
Finally O 
, O 
administration O 
of O 
TCB-2 B-IDENTIFIER 
right O 
after O 
training O 
in O 
an O 
object O 
recognition O 
task O 
enhanced O 
the O 
consolidation O 
of O 
object O 
memory O 
. O 
These O 
results O 
suggest O 
that O 
stimulation O 
of O 
5HT2ARs O 
facilitates O 
the O 
consolidation O 
and O 
extinction O 
of O 
trace O 
and O 
delay O 
cued O 
fear O 
memory O 
and O 
the O 
consolidation O 
of O 
object O 
memory O 
. O 
Blocking O 
the O 
5HT2AR O 
impairs O 
the O 
acquisition O 
of O 
fear O 
memory O 
extinction O 
. O 
The O 
results O 
support O 
the O 
view O 
that O 
serotonergic O 
activation O 
of O 
the O 
5HT2AR O 
provides O 
an O 
important O 
modulatory O 
influence O 
on O 
circuits O 
engaged O 
during O 
extinction O 
learning O 
. O 
Taken O 
together O 
these O 
results O 
suggest O 
that O 
the O 
5HT2AR O 
may O 
be O 
a O 
potential O 
therapeutic O 
target O 
for O 
enhancing O 
hippocampal O 
and O 
amygdala O 
- O 
dependent O 
memory O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

disorders O 
are O 
characterized O 
by O 
persistent O 
, O 
excessive O 
fear O 
. O 
Therapeutic O 
interventions O 
that O 
reverse O 
deficits O 
in O 
fear O 
extinction O 
represent O 
a O 
tractable O 
approach O 
to O 
treating O 
these O 
disorders O 
. O 
We O 
previously O 
reported O 
that O 
129S1 O 
/ O 
SvImJ O 
( O 
S1 O 
) O 
mice O 
show O 
no O 
extinction O 
learning O 
following O 
normal O 
fear O 
conditioning O 
. O 
We O 
now O 
demonstrate O 
that O 
weak O 
fear O 
conditioning O 
does O 
permit O 
fear O 
reduction O 
during O 
massed O 
extinction O 
training O 
in O 
S1 O 
mice O 
, O 
but O 
reveals O 
specific O 
deficiency O 
in O 
extinction O 
memory O 
consolidation O 
/ O 
retrieval O 
. O 
Rescue O 
of O 
this O 
impaired O 
extinction O 
consolidation O 
/ O 
retrieval O 
was O 
achieved O 
with O 
d-cycloserine B-TRIVIAL 
( O 
N-methly-d-aspartate B-SYSTEMATIC 
partial O 
agonist O 
) O 
or O 
MS-275 B-IDENTIFIER 
( O 
histone O 
deacetylase O 
( O 
HDAC O 
) O 
inhibitor O 
) O 
, O 
applied O 
after O 
extinction O 
training O 
. O 
We O 
next O 
examined O 
the O 
ability O 
of O 
different O 
drugs O 
and O 
non-pharmacological O 
manipulations O 
to O 
rescue O 
the O 
extreme O 
fear O 
extinction O 
deficit O 
in O 
S1 O 
following O 
normal O 
fear O 
conditioning O 
with O 
the O 
ultimate O 
aim O 
to O 
produce O 
low O 
fear O 
levels O 
in O 
extinction O 
retrieval O 
tests O 
. O 
Results O 
showed O 
that O 
deep O 
brain O 
stimulation O 
( O 
DBS O 
) O 
by O 
applying O 
high O 
frequency O 
stimulation O 
to O 
the O 
nucleus O 
accumbens O 
( O 
ventral O 
striatum O 
) O 
during O 
extinction O 
training O 
, O 
indeed O 
significantly O 
reduced O 
fear O 
during O 
extinction O 
retrieval O 
compared O 
to O 
sham O 
stimulation O 
controls O 
. O 
Rescue O 
of O 
both O 
impaired O 
extinction O 
acquisition O 
and O 
deficient O 
extinction O 
consolidation O 
/ O 
retrieval O 
was O 
achieved O 
with O 
prior O 
extinction O 
training O 
administration O 
of O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
( O 
a O 
GABAergic O 
enhancer O 
and O 
HDAC O 
inhibitor O 
) O 
or O 
AMN082 B-IDENTIFIER 
[ O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
7 O 
( O 
mGlu7 O 
) O 
agonist O 
] O 
, O 
while O 
MS-275 B-IDENTIFIER 
or O 
PEPA B-ABBREVIATION 
( O 
AMPA B-ABBREVIATION 
receptor O 
potentiator O 
) O 
failed O 
to O 
affect O 
extinction O 
acquisition O 
in O 
S1 O 
mice O 
. O 
Collectively O 
, O 
these O 
data O 
identify O 
potential O 
beneficial O 
effects O 
of O 
DBS O 
and O 
various O 
drug O 
treatments O 
, O 
including O 
those O 
with O 
HDAC O 
inhibiting O 
or O 
mGlu7 O 
agonism O 
properties O 
, O 
as O 
adjuncts O 
to O 
overcome O 
treatment O 
resistance O 
in O 
exposure O 
- O 
based O 
therapies O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

of O 
high O 
salt O 
toxicity O 
- O 
induced O 
oxidative O 
damage O 
by O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
pretreatment O 
in O 
two O 
wheat O 
cultivars O 
. O 

of O 
exogenous O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
( O 
SA O 
) O 
in O 
the O 
antioxidative O 
response O 
to O 
salt O 
toxicity O 
of O 
two O 
wheat O 
( O 
Triticum O 
aestivum O 
) O 
cultivars O 
( O 
Gerek-79 O 
and O 
Bezostaya O 
) O 
was O 
investigated O 
. O 
Hydroponic O 
growth O 
environment O 
of O 
10-day O 
wheat O 
seedlings O 
grown O 
under O 
normal O 
conditions O 
( O 
22 O 
/ O 
20°C O 
) O 
was O 
adjusted O 
to O 
0 O 
, O 
0.25 O 
, O 
0.5 O 
and O 
0.75 O 
M O 
of O 
salt O 
( O 
NaCl B-FORMULA 
) O 
, O 
and O 
then O 
freshly O 
prepared O 
SA O 
solutions O 
( O 
0 O 
, O 
0.01 O 
and O 
0.1 O 
mM O 
) O 
were O 
once O 
sprayed O 
on O 
leaves O 
of O 
the O 
same O 
seedlings O 
. O 
Activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
peroxidase O 
( O 
POX O 
) O 
and O 
catalase O 
( O 
CAT O 
) O 
were O 
determined O 
in O 
fresh O 
leaves O 
obtained O 
from O 
15-day O 
seedlings O 
. O 
Treatment O 
with O 
SA O 
alone O 
increased O 
all O 
the O 
antioxidant O 
activities O 
in O 
Gerek-79 O 
. O 
However O 
, O 
the O 
same O 
treatments O 
with O 
SA O 
decreased O 
the O 
activities O 
of O 
CAT O 
and O 
SOD O 
in O 
Bezostaya O 
, O 
while O 
increased O 
that O 
of O 
POX O 
. O 
Salt O 
applications O 
alone O 
increased O 
the O 
activities O 
of O 
POX O 
and O 
SOD O 
, O 
while O 
decreased O 
that O 
of O 
CAT O 
in O 
Bezostaya O 
. O 
The O 
same O 
salt O 
applications O 
increased O 
the O 
POX O 
activity O 
, O 
while O 
decreased O 
the O 
activities O 
of O 
CAT O 
and O 
SOD O 
in O 
Gerek-79 O 
. O 
In O 
plants O 
under O 
saline O 
conditions O 
, O 
except O 
0.75 O 
M O 
NaCl B-FORMULA 
, O 
treatments O 
with O 
SA O 
increased O 
the O 
activities O 
of O 
CAT O 
, O 
POX O 
and O 
SOD O 
in O 
both O 
the O 
varieties O 
compared O 
with O 
plants O 
applied O 
salt O 
alone O 
. O 
In O 
plants O 
applied O 
with O 
0.75 O 
M O 
NaCl B-FORMULA 
, O 
however O 
, O 
treatments O 
with O 
SA O 
decreased O 
CAT O 
activity O 
. O 
Results O 
showed O 
that O 
salt O 
toxicity O 
caused O 
a O 
derangement O 
in O 
the O 
regulation O 
of O 
antioxidant O 
enzyme O 
activities O 
by O 
decreasing O 
CAT O 
activity O 
especially O 
in O 
both O 
the O 
varieties O 
, O 
but O 
treatments O 
with O 
SA O 
could O 
turn O 
back O 
the O 
derangement O 
in O 
the O 
antioxidative O 
enzymes O 
caused O 
by O 
salt O 
toxicity O 
. O 
SA O 
can O 
involve O 
in O 
increasing O 
salt O 
tolerance O 
by O 
regulating O 
the O 
activities O 
of O 
antioxidant O 
enzymes O 
in O 
wheat O 
cultivars O 
exposed O 
to O 
salt O 
toxicity O 
. O 

for O 
the O 
development O 
of O 
cosmetics O 
with O 
PLGA B-ABBREVIATION 
nanospheres O 
. O 

optimized O 
preparation O 
of O 
Poly-(lactide-co B-FAMILY 
- I-FAMILY 
glycolic I-FAMILY 
acid I-FAMILY 
) I-FAMILY 
( O 
PLGA B-ABBREVIATION 
) O 
nanospheres O 
containing O 
ubiquinone O 
( O 
UQ O 
) O 
for O 
cosmetic O 
products O 
was O 
pursued O 
. O 
By O 
investigating O 
various O 
conditions O 
for O 
the O 
preparation O 
of O 
UQ/ O 
PLGA B-ABBREVIATION 
nanospheres O 
such O 
as O 
the O 
molecular O 
weight O 
of O 
PLGA B-ABBREVIATION 
, O 
PLGA B-ABBREVIATION 
concentration O 
, O 
and O 
UQ O 
concentration O 
, O 
UQ/ O 
PLGA B-ABBREVIATION 
nanospheres O 
with O 
increased O 
stability O 
and O 
slower O 
drug O 
release O 
at O 
a O 
higher O 
drug O 
loading O 
efficiency O 
were O 
prepared O 
. O 
Permeation O 
tests O 
on O 
the O 
prepared O 
nanospheres O 
using O 
iontophoresis O 
via O 
electric O 
dermal O 
administration O 
on O 
membrane O 
filters O 
( O 
200 O 
nm O 
pore O 
size O 
) O 
and O 
hairless O 
mouse O 
skin O 
samples O 
were O 
also O 
carried O 
out O 
. O 
After O 
iontophoresis O 
, O 
the O 
nanospheres O 
choked O 
the O 
membrane O 
filter O 
and O 
remained O 
on O 
the O 
horny O 
layer O 
of O 
the O 
hairless O 
mouse O 
skin O 
, O 
even O 
after O 
washing O 
. O 
Therefore O 
, O 
the O 
prepared O 
UQ/ O 
PLGA B-ABBREVIATION 
nanospheres O 
and O 
the O 
established O 
iontophoresis O 
technique O 
with O 
the O 
PLGA B-ABBREVIATION 
nanospheres O 
in O 
the O 
present O 
study O 
can O 
be O 
applied O 
to O 
the O 
future O 
development O 
of O 
cosmetics O 
. O 

in O 
prenatal O 
and O 
postnatal O 
organs O 
in O 
rats O 
. O 

can O 
be O 
transferred O 
to O 
fetus O 
in O 
utero O 
through O 
placenta O 
and O 
to O 
infant O 
ex O 
utero O 
by O 
breast O 
feeding O 
. O 
In O 
this O 
study O 
, O 
we O 
characterized O 
the O 
pharmacokinetics O 
of O 
melamine B-TRIVIAL 
in O 
prenatal O 
and O 
postnatal O 
organs O 
in O 
rats O 
. O 
Single O 
bolus O 
of O 
melamine B-TRIVIAL 
was O 
administered O 
to O 
pregnant O 
rats O 
at O 
different O 
gestational O 
stages O 
and O 
to O 
infants O 
at O 
different O 
postnatal O 
stages O 
. O 
Distribution O 
of O 
melamine B-TRIVIAL 
in O 
maternal O 
serum O 
was O 
about O 
30% O 
higher O 
in O 
late O 
pregnancy O 
than O 
that O 
in O 
early O 
pregnancy O 
; O 
and O 
it O 
was O 
2 O 
folds O 
higher O 
in O 
postnatal O 
serum O 
in O 
early O 
infants O 
in O 
young O 
adulthood O 
. O 
Distribution O 
of O 
melamine B-TRIVIAL 
in O 
all O 
postnatal O 
organs O 
was O 
higher O 
than O 
that O 
in O 
prenatal O 
organs O 
. O 
Postnatal O 
kidneys O 
in O 
early O 
infants O 
had O 
the O 
highest O 
maximum O 
concentration O 
and O 
the O 
lowest O 
clearance O 
of O 
melamine B-TRIVIAL 
than O 
the O 
other O 
postnatal O 
organs O 
. O 
It O 
may O 
relate O 
to O 
the O 
high O 
vulnerability O 
to O 
the O 
toxicity O 
of O 
melamine B-TRIVIAL 
in O 
this O 
population O 
. O 

GABA B-ABBREVIATION 
( O 
A O 
) O 
α5 O 
positive O 
allosteric O 
modulators O 
improve O 
cognitive O 
function O 
in O 
aged O 
rats O 
with O 
memory O 
impairment O 
. O 

condition O 
of O 
excess O 
activity O 
in O 
the O 
hippocampal O 
formation O 
is O 
observed O 
in O 
the O 
aging O 
brain O 
and O 
in O 
conditions O 
that O 
confer O 
additional O 
risk O 
during O 
aging O 
for O 
Alzheimer's O 
disease O 
. O 
Compounds O 
that O 
act O 
as O 
positive O 
allosteric O 
modulators O 
at O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
α5 O 
receptors O 
might O 
be O 
useful O 
in O 
targeting O 
this O 
condition O 
because O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
α5 O 
receptors O 
mediate O 
tonic O 
inhibition O 
of O 
principal O 
neurons O 
in O 
the O 
affected O 
network O 
. O 
While O 
agents O 
to O 
improve O 
cognitive O 
function O 
in O 
the O 
past O 
focused O 
on O 
inverse O 
agonists O 
, O 
which O 
are O 
negative O 
allosteric O 
modulators O 
at O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
α5 O 
receptors O 
, O 
research O 
supporting O 
that O 
approach O 
used O 
only O 
young O 
animals O 
and O 
predated O 
current O 
evidence O 
for O 
excessive O 
hippocampal O 
activity O 
in O 
age O 
- O 
related O 
conditions O 
of O 
cognitive O 
impairment O 
. O 
Here O 
, O 
we O 
used O 
two O 
compounds O 
, O 
Compound O 
44 O 
[ O 
6,6-dimethyl-3-(3-hydroxypropyl)thio-1-(thiazol-2-yl)-6,7-dihydro-2-benzothiophen-4(5H)-one B-SYSTEMATIC 
] O 
and O 
Compound O 
6 O 
[ O 
methyl B-SYSTEMATIC 
3,5-diphenylpyridazine-4-carboxylate I-SYSTEMATIC 
] O 
, O 
with O 
functional O 
activity O 
as O 
potentiators O 
of O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
at O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
α5 O 
receptors O 
, O 
to O 
test O 
their O 
ability O 
to O 
improve O 
hippocampal O 
- O 
dependent O 
memory O 
in O 
aged O 
rats O 
with O 
identified O 
cognitive O 
impairment O 
. O 
Improvement O 
was O 
obtained O 
in O 
aged O 
rats O 
across O 
protocols O 
differing O 
in O 
motivational O 
and O 
performance O 
demands O 
and O 
across O 
varying O 
retention O 
intervals O 
. O 
Significant O 
memory O 
improvement O 
occurred O 
after O 
either O 
intracereboventricular O 
infusion O 
with O 
Compound O 
44 O 
( O 
100 O 
μg O 
) O 
in O 
a O 
water O 
maze O 
task O 
or O 
systemic O 
administration O 
with O 
Compound O 
6 O 
( O 
3 O 
mg O 
/ O 
kg O 
) O 
in O 
a O 
radial O 
arm O 
maze O 
task O 
. O 
Furthermore O 
, O 
systemic O 
administration O 
improved O 
behavioral O 
performance O 
at O 
dosing O 
shown O 
to O 
provide O 
drug O 
exposure O 
in O 
the O 
brain O 
and O 
in O 
vivo O 
receptor O 
occupancy O 
in O 
the O 
hippocampus O 
. O 
These O 
data O 
suggest O 
a O 
novel O 
approach O 
to O 
improve O 
neural O 
network O 
function O 
in O 
clinical O 
conditions O 
of O 
excess O 
hippocampal O 
activity O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

annua O 
is O 
a O 
Chinese O 
antimalarial O 
herb O 
that O 
has O 
been O 
used O 
for O 
more O 
than O 
2000 O 
years O 
. O 
The O 
maternal O 
and O 
foetal O 
safety O 
of O 
the O 
ethanolic O 
leaf O 
extract O 
of O 
therapeutically O 
active O 
Artemisia O 
annua O 
( O 
EAA O 
) O 
, O 
with O 
previously O 
determined O 
artemisinin O 
yield O 
of O 
1.098% O 
was O 
evaluated O 
in O 
Wistar O 
rats O 
. O 
Twenty O 
pregnant O 
rats O 
, O 
divided O 
into O 
four O 
study O 
groups O 
of O 
saline O 
treated O 
( O 
control O 
) O 
, O 
and O 
test O 
groups O 
administered O 
orally O 
with O 
100 O 
, O 
200 O 
and O 
300 O 
mg O 
/ O 
kg O 
body O 
weights O 
of O 
EAA O 
, O 
respectively O 
, O 
from O 
gestation O 
days O 
( O 
GD O 
) O 
8 O 
to O 
19 O 
. O 
Following O 
overnight O 
fast O 
, O 
animals O 
were O 
sacrificed O 
on O 
GD O 
20 O 
, O 
and O 
maternal O 
blood O 
was O 
collected O 
to O 
evaluate O 
biochemical O 
and O 
haematological O 
markers O 
. O 
Foetuses O 
were O 
carefully O 
removed O 
, O 
weighed O 
, O 
and O 
observed O 
for O 
any O 
possible O 
malformation O 
. O 
Biochemical O 
and O 
haematological O 
studies O 
revealed O 
that O 
EAA O 
did O 
not O 
result O 
in O 
maternal O 
hepatotoxicity O 
, O 
haematotoxicity O 
, O 
and O 
hyperlipidemia O 
. O 
While O 
litter O 
size O 
significantly O 
decreased O 
( O 
p O 
< O 
0.05 O 
) O 
at O 
100 O 
mg O 
/ O 
kg O 
EAA O 
, O 
maternal O 
estrogen B-FAMILY 
levels O 
decreased O 
in O 
all O 
the O 
EAA O 
- O 
treated O 
groups O 
. O 
Non-viable O 
( O 
21% O 
) O 
and O 
malformed O 
( O 
31% O 
) O 
foetuses O 
were O 
observed O 
at O 
the O 
300 O 
mg O 
/ O 
kg O 
dose O 
of O 
EAA O 
, O 
which O 
implies O 
that O 
although O 
consumption O 
of O 
the O 
leaf O 
extract O 
may O 
not O 
predispose O 
users O 
to O 
hepatotoxicity O 
, O 
haematotoxicity O 
, O 
and O 
hyperlipidemia O 
, O 
it O 
should O 
be O 
taken O 
with O 
caution O 
during O 
pregnancy O 
due O 
to O 
possible O 
risk O 
of O 
embryotoxicity O 
at O 
concentrations O 
higher O 
than O 
the O 
therapeutic O 
dose O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

facilitates O 
memory O 
consolidation O 
in O 
perceptual O 
learning O 
. O 

learning O 
is O 
a O 
special O 
type O 
of O 
non-declarative O 
learning O 
that O 
involves O 
experience O 
- O 
dependent O 
plasticity O 
in O 
sensory O 
cortices O 
. O 
The O 
cholinergic O 
system O 
is O 
known O 
to O 
modulate O 
declarative O 
learning O 
. O 
In O 
particular O 
, O 
reduced O 
levels O 
or O 
efficacy O 
of O 
the O 
neurotransmitter O 
acetylcholine B-SYSTEMATIC 
were O 
found O 
to O 
facilitate O 
declarative O 
memory O 
consolidation O 
. O 
However O 
, O 
little O 
is O 
known O 
about O 
the O 
role O 
of O 
the O 
cholinergic O 
system O 
in O 
memory O 
consolidation O 
of O 
non-declarative O 
learning O 
. O 
Here O 
we O 
compared O 
two O 
groups O 
of O 
non-smoking O 
men O 
who O 
learned O 
a O 
visual O 
texture O 
discrimination O 
task O 
( O 
TDT O 
) O 
. O 
One O 
group O 
received O 
chewing O 
tobacco O 
containing O 
nicotine B-TRIVIAL 
for O 
1 O 
h O 
directly O 
following O 
the O 
TDT O 
training O 
. O 
The O 
other O 
group O 
received O 
a O 
similar O 
tasting O 
control O 
substance O 
without O 
nicotine B-TRIVIAL 
. O 
Electroencephalographic O 
recordings O 
during O 
substance O 
consumption O 
showed O 
reduced O 
alpha O 
activity O 
and O 
P300 O 
latencies O 
in O 
the O 
nicotine B-TRIVIAL 
group O 
compared O 
to O 
the O 
control O 
group O 
. O 
When O 
re O 
- O 
tested O 
on O 
the O 
TDT O 
the O 
following O 
day O 
, O 
both O 
groups O 
responded O 
more O 
accurately O 
and O 
more O 
rapidly O 
than O 
during O 
training O 
. O 
These O 
improvements O 
were O 
specific O 
to O 
the O 
retinal O 
location O 
and O 
orientation O 
of O 
the O 
texture O 
elements O 
of O 
the O 
TDT O 
suggesting O 
that O 
learning O 
involved O 
early O 
visual O 
cortex O 
. O 
A O 
group O 
comparison O 
showed O 
that O 
learning O 
effects O 
were O 
more O 
pronounced O 
in O 
the O 
nicotine B-TRIVIAL 
group O 
than O 
in O 
the O 
control O 
group O 
. O 
These O 
findings O 
suggest O 
that O 
oral O 
consumption O 
of O 
nicotine B-TRIVIAL 
enhances O 
the O 
efficacy O 
of O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
. O 
Our O 
findings O 
further O 
suggest O 
that O 
enhanced O 
efficacy O 
of O 
the O 
cholinergic O 
system O 
facilitates O 
memory O 
consolidation O 
in O 
perceptual O 
learning O 
( O 
and O 
possibly O 
other O 
types O 
of O 
non-declarative O 
learning O 
) O 
. O 
In O 
that O 
regard O 
acetylcholine B-SYSTEMATIC 
seems O 
to O 
affect O 
consolidation O 
processes O 
in O 
perceptual O 
learning O 
in O 
a O 
different O 
manner O 
than O 
in O 
declarative O 
learning O 
. O 
Alternatively O 
, O 
our O 
findings O 
might O 
reflect O 
dose O 
- O 
dependent O 
cholinergic O 
modulation O 
of O 
memory O 
consolidation O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

volatile O 
composition O 
of O 
10 O 
endemic O 
Cephalaria O 
( O 
Dipsacaceae O 
) O 
species O 
( O 
Cephalaria O 
gazipashensis O 
, O 
Cephalaria O 
lycica O 
, O 
Cephalaria O 
paphlagonica O 
, O 
Cephalaria O 
elmaliensis O 
, O 
Cephalaria O 
stellipilis O 
, O 
Cephalaria O 
scoparia O 
, O 
Cephalaria O 
isaurica O 
, O 
Cephalaria O 
cilicica O 
, O 
Cephalaria O 
elazigensis O 
var O 
. O 
purpurea O 
and O 
Cephalaria O 
davisiana O 
) O 
was O 
investigated O 
. O 
The O 
essential O 
oil O 
mixtures O 
were O 
obtained O 
by O 
steam O 
distillation O 
in O 
a O 
Clevenger O 
- O 
type O 
apparatus O 
. O 
Twenty O 
- O 
eight O 
components O 
were O 
identified O 
by O 
GC-FID O 
and O 
GC-MS O 
techniques O 
. O 
While O 
total O 
volatile O 
percentages O 
ranged O 
from O 
68.99% O 
to O 
84.57% O 
, O 
the O 
total O 
essential O 
oil O 
yields O 
ranged O 
between O 
38.15% O 
and O 
64.05% O 
. O 
Geraniol B-TRIVIAL 
, O 
α-cedrene B-TRIVIAL 
and O 
p-cymene B-TRIVIAL 
were O 
determined O 
as O 
the O 
main O 
components O 
. O 
Geraniol B-TRIVIAL 
was O 
detected O 
as O 
a O 
major O 
component O 
in O 
C O 
. O 
cilicica O 
( O 
14.64% O 
) O 
, O 
and O 
α-cedrene B-TRIVIAL 
was O 
detected O 
as O 
a O 
major O 
component O 
with O 
26.03% O 
for O 
C O 
. O 
lycica O 
, O 
16.93% O 
for O 
C O 
. O 
scoparia O 
, O 
13.01% O 
for O 
C O 
. O 
davisiana O 
and O 
10.94% O 
for O 
C O 
. O 
paphlagonica O 
. O 
Cephalaria O 
scoparia O 
, O 
C O 
. O 
davisiana O 
and O 
C O 
. O 
gazipashensis O 
have O 
considerable O 
amount O 
of O 
p-cymene B-TRIVIAL 
as O 
12.86% O 
, O 
12.70% O 
and O 
11.16% O 
, O 
respectively O 
. O 
This O 
was O 
the O 
first O 
essential O 
oil O 
report O 
concerning O 
the O 
Cephalaria O 
genus O 
. O 

and O 
its O 
Effects O 
on O 
the O 
Re-emergence O 
of O 
Colon O 
Cancer O 
Stem O 
Cells O 
. O 

studies O 
indicate O 
that O 
auraptene B-TRIVIAL 
( O 
7-geranyloxycoumarin B-SYSTEMATIC 
, O 
AUR B-ABBREVIATION 
) O 
, O 
a O 
geranyloxycoumarin B-SYSTEMATIC 
extracted O 
from O 
fruits O 
of O 
edible O 
plants O 
belonging O 
to O 
the O 
Rutaceae O 
family O 
, O 
may O 
represent O 
a O 
novel O 
lead O 
compound O 
for O 
dietary O 
colon O 
cancer O 
chemoprevention O 
in O 
rodents O 
. O 
As O 
a O 
continuation O 
of O 
studies O 
aimed O 
to O 
better O 
depict O 
the O 
pharmacological O 
effects O 
and O 
mechanism O 
of O 
action O 
of O 
the O 
title O 
natural O 
compound O 
, O 
the O 
current O 
investigation O 
was O 
undertaken O 
to O 
determine O 
whether O 
AUR B-ABBREVIATION 
would O 
be O 
able O 
to O 
prevent O 
the O 
growth O 
and O 
sphere O 
( O 
surrogate O 
tumors O 
) O 
formation O 
of O 
FOLFOX-resistant O 
colon O 
cancer O 
cells O 
that O 
are O 
highly O 
enriched O 
in O 
cancer O 
stem O 
cells O 
( O 
CSCs O 
) O 
. O 
Our O 
results O 
demonstrate O 
that O 
AUR B-ABBREVIATION 
at O 
a O 
concentration O 
of O 
10 O 
μM O 
was O 
able O 
to O 
inhibit O 
the O 
growth O 
and O 
formation O 
of O 
colonospheres O 
of O 
FOLFOX-resistant O 
colon O 
cancer O 
HT-29 O 
cells O 
in O 
vitro O 
. O 
The O 
corresponding O 
parental O 
cells O 
were O 
also O 
similarly O 
affected O 
by O 
AUR B-ABBREVIATION 
at O 
the O 
same O 
concentration O 
level O 
. O 
The O 
reduction O 
in O 
the O 
growth O 
and O 
colonospheres O 
formation O 
in O 
FOLFOX-resistant O 
HT-29 O 
was O 
also O 
associated O 
with O 
a O 
concomitant O 
decrease O 
in O 
phospho B-SYSTEMATIC 
-epidermal O 
growth O 
factor O 
receptor O 
. O 
These O 
findings O 
suggest O 
that O 
AUR B-ABBREVIATION 
could O 
prevent O 
the O 
re O 
- O 
emergence O 
of O 
CSCs O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

usambarense O 
( O 
Engl O 
. O 
) O 
Kokwaro O 
has O 
traditionally O 
been O 
used O 
for O 
the O 
treatment O 
of O 
malaria O 
, O 
upper O 
respiratory O 
tract O 
infections O 
, O 
cough O 
, O 
rheumatism O 
, O 
tooth O 
decay O 
and O 
sore O 
gums O 
in O 
Kenya O 
and O 
other O 
African O 
countries O 
. O 
Dried O 
ground O 
parts O 
of O 
Z O 
. O 
usambarense O 
were O 
extracted O 
by O 
maceration O 
using O 
methanol B-SYSTEMATIC 
( O 
MeOH B-FORMULA 
) O 
at O 
room O 
temperature O 
, O 
extract O 
was O 
dried O 
and O 
reconstituted O 
in O 
70% O 
aq O 
. O 
MeOH B-FORMULA 
and O 
partitioned O 
against O 
n-hexane B-SYSTEMATIC 
and O 
chloroform B-TRIVIAL 
( O 
CHCl3 B-FORMULA 
) O 
to O 
obtain O 
MeOH B-FORMULA 
, O 
n-hexane B-SYSTEMATIC 
and O 
CHCl3 B-FORMULA 
extracts O 
. O 
All O 
extracts O 
were O 
assessed O 
for O 
cytotoxicity O 
against O 
two O 
breast O 
cancer O 
cell O 
lines O 
, O 
MDA-MB-231 O 
and O 
MCF-7 O 
, O 
and O 
the O 
brain O 
tumour O 
cell O 
line O 
U251 O 
by O 
the O 
MTT B-ABBREVIATION 
assay O 
. O 
The O 
free O 
- O 
radical O 
scavenging O 
activity O 
of O 
the O 
extracts O 
was O 
also O 
determined O 
by O 
the O 
2,2-diphenyl-1-picryhydrazyl B-SYSTEMATIC 
( O 
DPPH B-ABBREVIATION 
) O 
assay O 
. O 
In O 
the O 
DPPH B-ABBREVIATION 
assay O 
, O 
the O 
MeOH B-FORMULA 
extract O 
was O 
found O 
to O 
be O 
the O 
most O 
active O 
free O 
- O 
radical O 
scavenger O 
with O 
a O 
RC50 O 
value O 
of O 
41.1 O 
× O 
10(-3) O 
mg O 
/ O 
mL O 
. O 
It O 
also O 
displayed O 
significant O 
cytotoxicity O 
against O 
the O 
MCF-7 O 
cell O 
line O 
( O 
IC50 O 
42.9 O 
µg O 
/ O 
mL O 
) O 
and O 
appeared O 
to O 
have O 
induced O 
cell O 
death O 
through O 
apoptosis O 
. O 
None O 
of O 
the O 
test O 
extracts O 
showed O 
any O 
activity O 
against O 
the O 
U251 O 
cell O 
line O 
at O 
test O 
concentrations O 
. O 
The O 
present O 
findings O 
demonstrated O 
that O 
Z O 
. O 
usambarense O 
could O 
be O 
a O 
potential O 
source O 
for O 
new O 
cytotoxic O 
compounds O 
for O 
possible O 
anticancer O 
drug O 
development O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

peptide O 
cation O 
- O 
radical O 
electronic O 
states O 
by O 
thioxoamide B-SYSTEMATIC 
groups O 
: O 
formation O 
, O 
dissociations O 
, O 
and O 
energetics O 
of O 
thioxopeptide O 
cation O 
- O 
radicals O 
. O 

Gly-thio-Lys B-SYSTEMATIC 
( O 
GtK B-ABBREVIATION 
) O 
, O 
Ala-thio-Lys B-SYSTEMATIC 
( O 
AtK B-ABBREVIATION 
) O 
, O 
and O 
Ala-thio-Arg B-SYSTEMATIC 
( O 
AtR B-ABBREVIATION 
) O 
in O 
which O 
the O 
amide B-FAMILY 
group O 
has O 
been O 
modified O 
to O 
a O 
thioxoamide B-SYSTEMATIC 
were O 
made O 
into O 
dications O 
by O 
electrospray O 
ionization O 
and O 
converted O 
to O 
cation O 
- O 
radicals O 
, O 
( O 
GtK B-ABBREVIATION 
+ O 
2H B-FORMULA 
)(+• O 
) O 
, O 
( O 
AtK B-ABBREVIATION 
+ O 
2H B-FORMULA 
)(+• O 
) O 
, O 
and O 
( O 
AtR B-ABBREVIATION 
+ O 
2H B-FORMULA 
)(+• O 
) O 
, O 
by O 
electron O 
transfer O 
dissociation O 
( O 
ETD O 
) O 
tandem O 
mass O 
spectrometry O 
using O 
fluoranthene B-SYSTEMATIC 
anion I-SYSTEMATIC 
- I-SYSTEMATIC 
radical I-SYSTEMATIC 
as O 
an O 
electron O 
donor O 
. O 
The O 
common O 
and O 
dominant O 
dissociation O 
of O 
these O 
cation O 
- O 
radicals O 
was O 
the O 
loss O 
of O 
a O 
hydrogen B-SYSTEMATIC 
atom O 
. O 
The O 
dissociation O 
products O 
were O 
characterized O 
by O 
collision O 
- O 
induced O 
dissociation O 
( O 
CID O 
) O 
multistage O 
tandem O 
mass O 
spectrometry O 
up O 
to O 
CID-MS(5) O 
. O 
The O 
ground O 
electronic O 
states O 
of O 
several O 
( O 
GtK B-ABBREVIATION 
+ O 
2H B-FORMULA 
)(+• O 
) O 
, O 
( O 
AtK B-ABBREVIATION 
+ O 
2H B-FORMULA 
)(+• O 
) O 
, O 
and O 
( O 
AtR B-ABBREVIATION 
+ O 
2H B-FORMULA 
)(+• O 
) O 
conformers O 
were O 
explored O 
by O 
extensive O 
ab O 
initio O 
and O 
density O 
functional O 
theory O 
calculations O 
of O 
the O 
potential O 
energy O 
surface O 
. O 
In O 
silico O 
electron O 
transfer O 
to O 
the O 
precursor O 
dications O 
, O 
( O 
GtK B-ABBREVIATION 
+ O 
2H B-FORMULA 
)(2+ O 
) O 
, O 
( O 
AtK B-ABBREVIATION 
+ O 
2H B-FORMULA 
)(2+ O 
) O 
, O 
and O 
( O 
AtR B-ABBREVIATION 
+ O 
2H B-FORMULA 
)(2+ O 
) O 
, O 
formed O 
zwitterionic O 
intermediates O 
containing O 
thioenol B-SYSTEMATIC 
anion I-SYSTEMATIC 
- I-SYSTEMATIC 
radical I-SYSTEMATIC 
and O 
ammonium B-SYSTEMATIC 
cation I-SYSTEMATIC 
groups O 
that O 
were O 
local O 
energy O 
minima O 
on O 
the O 
potential O 
energy O 
surface O 
of O 
the O 
ground O 
electronic O 
state O 
. O 
The O 
zwitterions O 
underwent O 
facile O 
isomerization O 
by O 
N B-FORMULA 
-terminal O 
ammonium B-SYSTEMATIC 
proton O 
migration O 
to O 
the O 
thioenol B-SYSTEMATIC 
anion I-SYSTEMATIC 
- I-SYSTEMATIC 
radical I-SYSTEMATIC 
group O 
forming O 
aminothioketyl B-SYSTEMATIC 
intermediates O 
. O 
Combined O 
potential O 
energy O 
mapping O 
and O 
RRKM O 
calculations O 
of O 
dissociation O 
rate O 
constants O 
identified O 
N-C(α) B-FORMULA 
bond O 
cleavages O 
as O 
the O 
most O 
favorable O 
dissociation O 
pathways O 
, O 
in O 
a O 
stark O 
contrast O 
to O 
the O 
experimental O 
results O 
. O 
This O 
discrepancy O 
is O 
interpreted O 
as O 
being O 
due O 
to O 
the O 
population O 
upon O 
electron O 
transfer O 
of O 
low O 
- O 
lying O 
excited O 
electronic O 
states O 
that O 
promote O 
loss O 
of O 
hydrogen B-SYSTEMATIC 
atoms O 
. O 
For O 
( O 
GtK B-ABBREVIATION 
+ O 
2H B-FORMULA 
)(+• O 
) O 
, O 
these O 
excited O 
states O 
were O 
characterized O 
by O 
time O 
- O 
dependent O 
density O 
functional O 
theory O 
as O 
A-C O 
states O 
that O 
had O 
large O 
components O 
of O 
Rydberg O 
- O 
like O 
3s O 
molecular O 
orbitals O 
at O 
the O 
N B-FORMULA 
-terminal O 
and O 
lysine B-TRIVIAL 
ammonium B-SYSTEMATIC 
groups O 
that O 
are O 
conducive O 
to O 
hydrogen B-SYSTEMATIC 
atom O 
loss O 
. O 

this O 
multicenter O 
, O 
double O 
- O 
blind O 
, O 
placebo O 
- O 
controlled O 
, O 
randomized O 
, O 
four O 
way O 
cross O 
- O 
over O 
proof O 
- O 
of O 
- O 
mechanism O 
study O 
, O 
we O 
tested O 
the O 
effect O 
of O 
the O 
positive O 
allosteric O 
α7 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
nAChR O 
) O 
modulator O 
JNJ-39393406 B-IDENTIFIER 
in O 
a O 
key O 
translational O 
assay O 
( O 
sensory O 
P50 O 
gating O 
) O 
in O 
39 O 
regularly O 
smoking O 
male O 
patients O 
with O 
schizophrenia O 
. O 
All O 
patients O 
were O 
clinically O 
stable O 
and O 
JNJ-39393406 B-IDENTIFIER 
was O 
administered O 
as O 
an O 
adjunct O 
treatment O 
to O 
antipsychotics O 
. O 
No O 
indication O 
was O 
found O 
that O 
JNJ-39393406 B-IDENTIFIER 
has O 
the O 
potential O 
to O 
reverse O 
basic O 
deficits O 
of O 
information O 
processing O 
in O 
schizophrenia O 
( O 
sensory O 
P50 O 
gating O 
) O 
or O 
has O 
a O 
significant O 
effect O 
on O 
other O 
tested O 
electrophysiological O 
markers O 
( O 
MMN O 
, O 
P300 O 
and O 
quantitative O 
resting O 
EEG O 
) O 
. O 
Sensitivity O 
analyses O 
including O 
severity O 
of O 
disease O 
, O 
baseline O 
P50 O 
gating O 
, O 
medication O 
and O 
gene O 
variants O 
of O 
the O 
CHRNA7 O 
gene O 
did O 
not O 
reveal O 
any O 
subgroups O 
with O 
consistent O 
significant O 
effects O 
. O 
It O 
is O 
discussed O 
that O 
potential O 
positive O 
effects O 
in O 
subgroups O 
not O 
present O 
or O 
not O 
large O 
enough O 
in O 
the O 
current O 
study O 
or O 
upon O 
chronic O 
dosing O 
are O 
possible O 
, O 
but O 
unlikely O 
to O 
be O 
developed O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

of O 
collisional O 
and O 
vibrational O 
velocity O 
on O 
proton O 
and O 
deuteron B-SYSTEMATIC 
transfer O 
in O 
the O 
reaction O 
of O 
HOD+ B-FORMULA 
with O 
CO B-FORMULA 
. O 

of O 
HOD(+) B-FORMULA 
with O 
CO B-FORMULA 
was O 
studied O 
over O 
the O 
collision O 
energy O 
(E(col)) O 
range O 
between O 
0.18 O 
and O 
2.87 O 
eV O 
, O 
for O 
HOD(+) B-FORMULA 
in O 
its O 
ground O 
state O 
and O 
with O 
one O 
quantum O 
in O 
each O 
of O 
its O 
vibrational O 
modes O 
: O 
( O 
1 O 
) O 
-- O 
predominantly O 
OH B-FORMULA 
stretch O 
; O 
( O 
10 O 
) O 
-- O 
bend O 
, O 
and O 
( O 
100 O 
) O 
-- O 
predominately O 
OD B-FORMULA 
stretch O 
. O 
In O 
addition O 
to O 
integral O 
cross O 
sections O 
, O 
product O 
recoil O 
velocity O 
distributions O 
were O 
also O 
measured O 
for O 
each O 
initial O 
condition O 
. O 
The O 
dominant O 
reactions O 
are O 
near O 
- O 
thermoneutral O 
proton O 
and O 
deuteron B-SYSTEMATIC 
transfer O 
, O 
generating O 
HCO(+) B-FORMULA 
and O 
DCO(+) B-FORMULA 
product O 
ions O 
by O 
a O 
predominantly O 
direct O 
mechanism O 
. O 
The O 
HCO(+) B-FORMULA 
and O 
DCO(+) B-FORMULA 
channels O 
occur O 
with O 
a O 
combined O 
efficiency O 
of O 
76% O 
for O 
ground O 
state O 
HOD(+) B-FORMULA 
at O 
our O 
lowest O 
E(col) O 
, O 
increasing O 
to O 
94% O 
for O 
E(col) O 
around O 
0.33 O 
eV O 
, O 
then O 
falling O 
at O 
high O 
E(col) O 
to O 
~40% O 
. O 
The O 
HCO(+) B-FORMULA 
and O 
DCO(+) B-FORMULA 
channels O 
have O 
a O 
complicated O 
dependence O 
on O 
the O 
HOD(+) B-FORMULA 
vibrational O 
state O 
. O 
Excitation O 
of O 
the O 
OH B-FORMULA 
or O 
OD B-FORMULA 
stretch O 
modes O 
enhances O 
H(+) B-FORMULA 
or O 
D(+) B-FORMULA 
transfer O 
, O 
respectively O 
, O 
and O 
inhibits O 
D(+) B-FORMULA 
or O 
H(+) B-FORMULA 
transfer O 
. O 
Bend O 
excitation O 
preferentially O 
enhances O 
H(+) B-FORMULA 
transfer O 
, O 
with O 
no O 
effect O 
on O 
D(+) B-FORMULA 
transfer O 
. O 
There O 
is O 
no O 
coupling O 
of O 
energy O 
initially O 
in O 
any O 
HOD(+) B-FORMULA 
vibrational O 
mode O 
to O 
recoil O 
velocity O 
of O 
either O 
of O 
the O 
product O 
ions O 
, O 
even O 
at O 
low O 
E(col) O 
where O 
vibrational O 
excitation O 
doubles O 
or O 
triples O 
the O 
energy O 
available O 
to O 
products O 
. O 
The O 
results O 
suggest O 
that O 
transfer O 
of O 
H B-FORMULA 
or O 
D B-FORMULA 
atoms O 
is O 
enhanced O 
if O 
the O 
atom O 
in O 
question O 
has O 
a O 
high O 
vibrational O 
velocity O 
, O 
and O 
that O 
this O 
effect O 
offsets O 
what O 
is O 
otherwise O 
a O 
general O 
inhibition O 
of O 
reactivity O 
by O 
added O 
energy O 
. O 
HOCO(+) B-FORMULA 
+ O 
D B-FORMULA 
and O 
DOCO(+) B-FORMULA 
+ O 
H B-FORMULA 
products O 
are O 
also O 
observed O 
, O 
but O 
as O 
minor O 
channels O 
despite O 
being O 
barrierless O 
and O 
exoergic O 
. O 
These O 
channels O 
appear O 
to O 
be O 
complex O 
mediated O 
at O 
low O 
E(col) O 
, O 
essentially O 
vanish O 
at O 
intermediate O 
E(col) O 
, O 
then O 
reappear O 
with O 
a O 
direct O 
reaction O 
mechanism O 
at O 
high O 
E(col) O 
. O 

functional O 
theory O 
study O 
on O 
the O 
reaction O 
mechanism O 
of O 
synthesizing O 
1,3-dimethyl-2-imidazolidinone B-SYSTEMATIC 
by O 
urea B-TRIVIAL 
method O 
. O 

report O 
a O 
first O 
- O 
principles O 
density O 
functional O 
theory O 
investigation O 
on O 
tailoring O 
the O 
fundamental O 
reaction O 
mechanism O 
of O 
synthesizing O 
1,3-dimethyl-2-imidazolidinone B-SYSTEMATIC 
( O 
DMI B-ABBREVIATION 
) O 
through O 
the O 
urea B-TRIVIAL 
method O 
with O 
water O 
serving O 
as O 
both O 
solvent O 
and O 
catalyst O 
. O 
The O 
nucleophilic O 
cyclization O 
reaction O 
is O 
implemented O 
by O 
two O 
ammonia B-SYSTEMATIC 
removal O 
steps O 
. O 
One O 
- O 
NH B-FORMULA 
group O 
of O 
dimethylethylenediamine B-SYSTEMATIC 
( O 
DMEDA B-ABBREVIATION 
) O 
first O 
attacks O 
the O 
carbon B-SYSTEMATIC 
atom O 
of O 
urea B-TRIVIAL 
, O 
eliminating O 
one O 
- O 
NH3 B-FORMULA 
group O 
and O 
forming O 
an O 
intermediate O 
state O 
CH3NHC2H4N(CH3)CONH2 B-FORMULA 
( O 
IMI O 
) O 
. O 
IMI O 
subsequently O 
undergoes O 
the O 
cyclization O 
process O 
through O 
a O 
secondary B-FAMILY 
ammonia I-FAMILY 
removal O 
via O 
similar O 
manner O 
. O 
Without O 
water O 
, O 
the O 
two O 
ammonia B-SYSTEMATIC 
removal O 
steps O 
are O 
both O 
slightly O 
exothermic O 
with O 
high O 
activation O 
barriers O 
( O 
~50 O 
kcal O 
mol(-1) O 
) O 
. O 
As O 
water O 
participated O 
in O 
the O 
reaction O 
, O 
the O 
kinetics O 
of O 
the O 
two O 
steps O 
can O 
be O 
significantly O 
improved O 
, O 
respectively O 
. O 
The O 
role O 
that O 
water O 
plays O 
, O 
beside O 
as O 
solvent O 
, O 
more O 
importantly O 
, O 
is O 
to O 
serve O 
as O 
a O 
proton O 
exchange O 
bridge O 
. O 
Due O 
to O 
the O 
spatial O 
configuration O 
, O 
the O 
direct O 
proton O 
migration O 
from O 
the O 
N B-FORMULA 
atoms O 
of O 
ethylenediamine B-SYSTEMATIC 
to O 
urea B-TRIVIAL 
is O 
difficult O 
to O 
occur O 
. O 
The O 
water O 
bridge O 
facilitates O 
the O 
proton O 
migration O 
by O 
shortening O 
the O 
migration O 
distance O 
. O 
As O 
a O 
consequence O 
, O 
the O 
activation O 
barriers O 
are O 
considerably O 
lowered O 
down O 
to O 
~30 O 
kcal O 
mol(-1) O 
, O 
indicating O 
a O 
strong O 
catalytic O 
effect O 
from O 
water O 
. O 
In O 
contrast O 
, O 
the O 
three O 
possible O 
side O 
reactions O 
of O 
IM O 
(I) O 
, O 
even O 
catalyzed O 
by O 
water O 
, O 
have O 
higher O 
activation O 
barriers O 
due O 
to O 
strong O 
steric O 
inhibitive O 
effect O 
and O 
consequently O 
become O 
difficult O 
to O 
occur O 
at O 
the O 
same O 
condition O 
. O 
The O 
current O 
computational O 
understanding O 
on O 
the O 
prototypical O 
reaction O 
to O 
DMI B-ABBREVIATION 
can O 
be O 
extended O 
to O 
guide O 
developing O 
more O 
efficient O 
routes O 
to O 
synthesize O 
imidazolidinone B-SYSTEMATIC 
derivatives O 
through O 
the O 
urea B-TRIVIAL 
method O 
. O 

impairments O 
are O 
found O 
in O 
a O 
range O 
of O 
neurodegenerative O 
and O 
neuropsychiatric O 
disorders O 
. O 
However O 
, O 
the O 
development O 
of O 
procognitive O 
enhancers O 
to O 
alleviate O 
these O 
impairments O 
has O 
been O 
hindered O 
by O 
a O 
lack O 
of O 
comprehensive O 
hypotheses O 
regarding O 
the O 
circuitry O 
mediating O 
the O 
targeted O 
attentional O 
functions O 
. O 
Here O 
we O 
discuss O 
the O 
role O 
of O 
the O 
cortical O 
cholinergic O 
system O 
in O 
mediating O 
cue O 
detection O 
and O 
attentional O 
control O 
and O 
propose O 
two O 
target O 
mechanisms O 
for O 
cognition O 
enhancers O 
: O 
stimulation O 
of O 
prefrontal O 
α4β2* O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
nAChR O 
) O 
for O 
the O 
enhancement O 
of O 
cue O 
detection O 
and O 
augmentation O 
of O 
tonic O 
acetylcholine B-SYSTEMATIC 
levels O 
for O 
the O 
enhancement O 
of O 
attentional O 
control O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

selective O 
dopamine B-TRIVIAL 
reuptake O 
inhibitor O 
improves O 
prefrontal O 
cortex O 
- O 
dependent O 
cognitive O 
function O 
: O 
potential O 
relevance O 
to O 
attention O 
deficit O 
hyperactivity O 
disorder O 
. O 

used O 
to O 
treat O 
attention O 
deficit O 
hyperactivity O 
disorder O 
( O 
ADHD O 
) O 
improve O 
prefrontal O 
cortex O 
(PFC)-dependent O 
cognitive O 
function O 
. O 
The O 
majority O 
of O 
ADHD O 
- O 
related O 
treatments O 
act O 
either O 
as O 
dual O 
norepinephrine B-TRIVIAL 
( O 
NE O 
) O 
and O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
reuptake O 
inhibitors O 
( O 
psychostimulants O 
) O 
or O 
selective O 
NE O 
reuptake O 
inhibitors O 
( O 
SNRIs O 
) O 
. O 
Certain O 
benztropine B-TRIVIAL 
analogs O 
act O 
as O 
highly O 
selective O 
DA O 
reuptake O 
inhibitors O 
while O 
lacking O 
the O 
reinforcing O 
actions O 
, O 
and O 
thus O 
abuse O 
potential O 
, O 
of O 
psychostimulants O 
. O 
To O 
assess O 
the O 
potential O 
use O 
of O 
these O 
compounds O 
in O 
the O 
treatment O 
of O 
ADHD O 
, O 
we O 
examined O 
the O 
effects O 
of O 
a O 
well O 
- O 
characterized O 
benztropine B-TRIVIAL 
analog O 
, O 
AHN B-IDENTIFIER 
2-005 I-IDENTIFIER 
, O 
on O 
performance O 
of O 
rats O 
in O 
a O 
PFC-dependent O 
delayed O 
- O 
alternation O 
task O 
of O 
spatial O 
working O 
memory O 
. O 
Similar O 
to O 
that O 
seen O 
with O 
all O 
drugs O 
currently O 
approved O 
for O 
ADHD O 
, O 
AHN B-IDENTIFIER 
2-005 I-IDENTIFIER 
dose O 
- O 
dependently O 
improved O 
performance O 
in O 
this O 
task O 
. O 
Clinically O 
- O 
relevant O 
doses O 
of O 
psychostimulants O 
and O 
SNRIs O 
elevate O 
NE O 
and O 
DA O 
preferentially O 
in O 
the O 
PFC O 
. O 
Despite O 
the O 
selectivity O 
of O 
this O 
compound O 
for O 
the O 
DA O 
transporter O 
, O 
additional O 
microdialysis O 
studies O 
demonstrated O 
that O 
a O 
cognition O 
- O 
enhancing O 
dose O 
of O 
AHN B-IDENTIFIER 
2-005 I-IDENTIFIER 
that O 
lacked O 
locomotor O 
activating O 
effects O 
increased O 
extracellular O 
levels O 
of O 
both O 
DA O 
and O 
NE O 
in O 
the O 
PFC O 
. O 
AHN B-IDENTIFIER 
2-005 I-IDENTIFIER 
produced O 
a O 
larger O 
increase O 
in O 
extracellular O 
DA O 
in O 
the O 
nucleus O 
accumbens O 
, O 
although O 
the O 
magnitude O 
of O 
this O 
was O 
well O 
below O 
that O 
seen O 
with O 
motor O 
activating O 
doses O 
of O 
psychostimulants O 
. O 
Collectively O 
, O 
these O 
observations O 
suggest O 
that O 
benztropine B-TRIVIAL 
analogs O 
may O 
be O 
efficacious O 
in O 
the O 
treatment O 
of O 
ADHD O 
or O 
other O 
disorders O 
associated O 
with O 
PFC O 
dysfunction O 
. O 
These O 
studies O 
provide O 
a O 
strong O 
rationale O 
for O 
future O 
research O 
focused O 
on O 
the O 
neural O 
mechanisms O 
contributing O 
to O 
the O 
cognition O 
- O 
enhancing O 
actions O 
and O 
the O 
potential O 
clinical O 
utility O 
of O 
AHN B-IDENTIFIER 
2-005 I-IDENTIFIER 
and O 
related O 
compounds O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

NMDA B-ABBREVIATION 
receptor O 
as O 
a O 
target O 
for O 
cognitive O 
enhancement O 
. O 

receptors O 
( O 
NMDARs O 
) O 
play O 
an O 
important O 
role O 
in O 
neural O 
plasticity O 
including O 
long O 
- O 
term O 
potentiation O 
and O 
long O 
- O 
term O 
depression O 
, O 
which O 
are O 
likely O 
to O 
explain O 
their O 
importance O 
for O 
learning O 
and O 
memory O 
. O 
Cognitive O 
decline O 
is O 
a O 
major O 
problem O 
facing O 
an O 
ageing O 
human O 
population O 
, O 
so O 
much O 
so O 
that O 
its O 
reversal O 
has O 
become O 
an O 
important O 
goal O 
for O 
scientific O 
research O 
and O 
pharmaceutical O 
development O 
. O 
Enhancement O 
of O 
NMDAR O 
function O 
is O 
a O 
core O 
strategy O 
toward O 
this O 
goal O 
. O 
In O 
this O 
review O 
we O 
indicate O 
some O 
of O 
the O 
major O 
ways O 
of O 
potentiating O 
NMDAR O 
function O 
by O 
both O 
direct O 
and O 
indirect O 
modulation O 
. O 
There O 
is O 
good O 
evidence O 
that O 
both O 
positive O 
and O 
negative O 
modulation O 
can O 
enhance O 
function O 
suggesting O 
that O 
a O 
subtle O 
approach O 
correcting O 
imbalances O 
in O 
particular O 
clinical O 
situations O 
will O 
be O 
required O 
. O 
Excessive O 
activation O 
and O 
the O 
resultant O 
deleterious O 
effects O 
will O 
need O 
to O 
be O 
carefully O 
avoided O 
. O 
Finally O 
we O 
describe O 
some O 
novel O 
positive O 
allosteric O 
modulators O 
of O 
NMDARs O 
, O 
with O 
some O 
subunit O 
selectivity O 
, O 
and O 
show O 
initial O 
evidence O 
of O 
their O 
ability O 
to O 
affect O 
NMDAR O 
mediated O 
events O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
assess O 
the O 
relationship O 
between O 
urinary O 
Smad1 O 
and O 
glomerular O 
hyperfiltration O 
( O 
GHF O 
) O 
in O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
, O 
and O 
to O 
explore O 
the O 
factors O 
related O 
to O 
the O 
urinary O 
Smad1 O 
in O 
T2DM O 
. O 
The O 
reference O 
value O 
of O 
the O 
estimated O 
glomerular O 
filtration O 
rate O 
( O 
eGFR O 
) O 
was O 
determined O 
in O 
248 O 
healthy O 
individuals O 
. O 
30 O 
patients O 
with O 
GHF O 
, O 
58 O 
patients O 
with O 
norm-GFR O 
T2DM O 
, O 
and O 
24 O 
healthy O 
patients O 
who O 
served O 
as O 
controls O 
were O 
recruited O 
. O 
Urinary O 
Smad1 O 
, O 
fasting O 
plasma O 
glucose B-TRIVIAL 
( O 
FPG O 
) O 
, O 
fasting O 
serum O 
C- O 
Peptide O 
( O 
C-P O 
) O 
, O 
hemoglobin O 
A1C O 
( O 
HbA1c O 
) O 
, O 
cystatin O 
C O 
, O 
and O 
other O 
chemistry O 
laboratory O 
parameters O 
of O 
T2DM O 
participants O 
and O 
controls O 
were O 
measured O 
. O 
Patients O 
with O 
GHF O 
had O 
higher O 
levels O 
of O 
urinary O 
Smad1 O 
than O 
the O 
control O 
group O 
, O 
and O 
those O 
with O 
norm-GFR O 
. O 
For O 
T2DM O 
patients O 
with O 
body O 
mass O 
index O 
, O 
age O 
, O 
and O 
gender O 
adjustments O 
, O 
urinary O 
Smad1 O 
was O 
positively O 
correlated O 
with O 
FPG O 
, O 
HbA1C O 
, O 
and O 
eGFR O 
, O 
but O 
negatively O 
correlated O 
with O 
fasting O 
serum O 
C-P O 
. O 
Multivariate O 
linear O 
regression O 
analysis O 
demonstrated O 
that O 
eGFR O 
, O 
HbA1C O 
, O 
and O 
fasting O 
serum O 
C-P O 
were O 
independently O 
associated O 
with O 
urinary O 
Smad1 O 
. O 
High O 
levels O 
of O 
urinary O 
Smad1 O 
were O 
found O 
in O 
GHF O 
patients O 
with O 
T2DM O 
, O 
which O 
may O 
be O 
another O 
potential O 
mechanism O 
of O 
GHF O 
in O 
relation O 
to O 
diabetic O 
nephropathy O 
. O 

in O 
Pressure-Induced O 
Structural O 
Transformations O 
of O 
CdSe B-FORMULA 
/ O 
ZnS B-FORMULA 
Core O 
/ O 
Shell O 
Nanocrystals O 
. O 

kinetics O 
and O 
thermodynamics O 
of O 
structural O 
transformations O 
under O 
pressure O 
depend O 
strongly O 
on O 
particle O 
size O 
due O 
to O 
the O 
influence O 
of O 
surface O 
free O 
energy O 
. O 
By O 
suitable O 
design O 
of O 
surface O 
structure O 
, O 
composition O 
, O 
and O 
passivation O 
it O 
is O 
possible O 
, O 
in O 
principle O 
, O 
to O 
prepare O 
nanocrystals O 
in O 
structures O 
inaccessible O 
to O 
bulk O 
materials O 
. O 
However O 
, O 
few O 
realizations O 
of O 
such O 
extreme O 
size O 
- O 
dependent O 
behavior O 
exist O 
. O 
Here O 
, O 
we O 
show O 
with O 
molecular O 
dynamics O 
computer O 
simulation O 
that O 
in O 
a O 
model O 
of O 
CdSe B-FORMULA 
/ O 
ZnS B-FORMULA 
core O 
/ O 
shell O 
nanocrystals O 
the O 
core O 
high O 
- O 
pressure O 
structure O 
can O 
be O 
made O 
metastable O 
under O 
ambient O 
conditions O 
by O 
tuning O 
the O 
thickness O 
of O 
the O 
shell O 
. O 
In O 
nanocrystals O 
with O 
thick O 
shells O 
, O 
we O 
furthermore O 
observe O 
a O 
wurtzite B-TRIVIAL 
to O 
NiAs B-FORMULA 
transformation O 
, O 
which O 
does O 
not O 
occur O 
in O 
the O 
pure O 
bulk O 
materials O 
. O 
These O 
phenomena O 
are O 
linked O 
to O 
a O 
fundamental O 
change O 
in O 
the O 
atomistic O 
transformation O 
mechanism O 
from O 
heterogeneous O 
nucleation O 
at O 
the O 
surface O 
to O 
homogeneous O 
nucleation O 
in O 
the O 
crystal O 
core O 
. O 

involvement O 
in O 
the O 
amelioration O 
of O 
behavioral O 
abnormalities O 
in O 
dopamine B-TRIVIAL 
transporter O 
knockout O 
mice O 
by O 
nicotine B-TRIVIAL 
. O 

transporter O 
knockout O 
( O 
DAT O 
KO O 
) O 
mice O 
exhibit O 
elevated O 
extracellular O 
dopamine B-TRIVIAL 
levels O 
in O 
brain O 
regions O 
that O 
include O 
the O 
striatum O 
and O 
the O 
nucleus O 
accumbens O 
, O 
but O 
not O 
the O 
prefrontal O 
cortex O 
. O 
DAT O 
KO O 
mice O 
model O 
some O 
aspects O 
of O 
psychiatric O 
disorders O 
, O 
including O 
schizophrenia O 
. O 
Smoking O 
is O 
more O 
common O 
in O 
patients O 
with O 
schizophrenia O 
, O 
suggesting O 
that O 
nicotine O 
might O 
ameliorate O 
aspects O 
of O 
the O 
behavioral O 
abnormalities O 
and O 
/ O 
or O 
treatment O 
side O 
effects O 
seen O 
in O 
these O 
individuals O 
. O 
We O 
report O 
nicotine B-TRIVIAL 
-induced O 
normalization O 
of O 
effects O 
on O 
locomotion O 
and O 
prepulse O 
inhibition O 
of O 
acoustic O 
startle O 
( O 
PPI O 
) O 
in O 
DAT O 
KO O 
mice O 
that O 
require O 
intact O 
serotonin B-TRIVIAL 
5-HT1A O 
systems O 
. O 
First O 
, O 
we O 
observed O 
that O 
the O 
marked O 
hyperactivity O 
displayed O 
by O 
DAT O 
KO O 
mice O 
was O 
reduced O 
by O 
administration O 
of O 
nicotine B-TRIVIAL 
. O 
This O 
nicotine B-TRIVIAL 
effect O 
was O 
blocked O 
by O 
pretreatment O 
with O 
the O 
non-specific O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
( O 
nACh O 
) O 
receptor O 
antagonist O 
mecamylamine B-TRIVIAL 
, O 
or O 
the O 
5-HT1A O 
antagonist O 
WAY100635 B-IDENTIFIER 
. O 
Secondly O 
, O 
we O 
examined O 
the O 
effects O 
of O 
nicotine B-TRIVIAL 
on O 
PPI O 
in O 
DAT O 
KO O 
mice O 
. O 
Treatment O 
with O 
nicotine B-TRIVIAL 
significantly O 
ameliorated O 
the O 
PPI O 
deficits O 
observed O 
in O 
DAT O 
KO O 
mice O 
. O 
The O 
ameliorating O 
action O 
of O 
nicotine B-TRIVIAL 
on O 
PPI O 
deficits O 
in O 
DAT O 
KO O 
mice O 
was O 
blocked O 
by O 
mecamylamine B-TRIVIAL 
, O 
the O 
α₇ O 
nACh O 
receptor O 
antagonist O 
methyllycaconitine B-TRIVIAL 
or O 
WAY100635 B-IDENTIFIER 
, O 
while O 
the O 
α₄β₂ O 
nACh O 
receptor O 
antagonist O 
dihydro-β-erythroidinehydrobromide B-SYSTEMATIC 
( O 
DHβE B-ABBREVIATION 
) O 
produced O 
only O 
a O 
non-significant O 
trend O 
toward O 
attenuation O 
of O 
nicotine B-TRIVIAL 
effects O 
. O 
Finally O 
, O 
we O 
observed O 
that O 
administration O 
of O 
the O 
5-HT1A O 
receptor O 
agonist O 
8-OH-DPAT B-SYSTEMATIC 
also O 
ameliorated O 
the O 
deficit O 
in O 
PPI O 
observed O 
in O 
DAT O 
KO O 
mice O 
. O 
This O 
amelioration O 
was O 
antagonized O 
by O 
pretreatment O 
with O 
WAY100635 B-IDENTIFIER 
. O 
These O 
data O 
support O 
the O 
idea O 
that O 
nicotine B-TRIVIAL 
might O 
ameliorate O 
some O 
of O 
the O 
cognitive O 
dysfunctions O 
found O 
in O 
schizophrenia O 
in O 
a O 
5-HT1A-dependent O 
fashion O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

new O 
diterpenes B-FAMILY 
from O 
Caesalpinia O 
minax O 
Hance O 
. O 

new O 
cassane B-TRIVIAL 
-type O 
diterpenes B-FAMILY 
, O 
Caesalpinolide B-TRIVIAL 
F I-TRIVIAL 
( O 
1 O 
) O 
and O 
Caesalpinolide B-TRIVIAL 
G I-TRIVIAL 
( O 
2 O 
) O 
were O 
isolated O 
from O 
Caesalpinia O 
minax O 
Hance O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
1D O 
and O 
2D O 
NMR O 
, O 
MS O 
and O 
CD O 
analysis O 
. O 
Compounds O 
1 O 
and O 
2 O 
were O 
tested O 
against O 
colon O 
carcinoma O 
( O 
HCT-8 O 
) O 
and O 
breast O 
cancer O 
( O 
MCF-7 O 
) O 
human O 
cancer O 
cell O 
lines O 
, O 
and O 
showed O 
mild O 
cytotoxicity O 
activities O 
. O 

of O 
diiosononyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
and O 
its O 
effects O 
on O 
sexual O 
development O 
of O 
the O 
male O 
fetus O 
following O 
repeated O 
dosing O 
in O 
pregnant O 
rats O 
. O 

Sprague-Dawley O 
rats O 
received O 
50 O 
, O 
250 O 
, O 
and O 
500 O 
mg O 
/ O 
kg O 
/ O 
day O 
diisononyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DiNP B-ABBREVIATION 
) O 
from O 
GD O 
12 O 
to O 
19 O 
via O 
corn O 
oil O 
gavage O 
to O 
study O 
the O 
dose O 
response O 
for O 
effects O 
on O 
fetal O 
male O 
rat O 
sexual O 
development O 
as O 
well O 
as O 
metabolite O 
disposition O 
in O 
the O 
dam O 
and O 
fetus O 
. O 
Monoisononyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
MiNP B-ABBREVIATION 
) O 
, O 
mono(carboxy-isooctyl) B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
MCiOP B-ABBREVIATION 
) O 
, O 
mono(hydroxyl-isononyl) B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
MHiNP B-ABBREVIATION 
) O 
, O 
mono(oxo-isononyl) B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
MOiNP B-ABBREVIATION 
) O 
, O 
and O 
monoisononyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
glucuronide I-SYSTEMATIC 
( O 
MiNP-G B-ABBREVIATION 
) O 
were O 
found O 
in O 
all O 
measured O 
tissues O 
. O 
MCiOP B-ABBREVIATION 
was O 
the O 
major O 
metabolite O 
, O 
followed O 
in O 
decreasing O 
order O 
by O 
MiNP B-ABBREVIATION 
, O 
MHiNP B-ABBREVIATION 
, O 
MOiNP B-ABBREVIATION 
, O 
and O 
MiNP-G B-ABBREVIATION 
. O 
Percentage O 
of O 
dose O 
absorbed O 
decreased O 
at O 
750 O 
mg O 
/ O 
kg O 
/ O 
day O 
. O 
Testosterone B-TRIVIAL 
concentration O 
in O 
the O 
fetal O 
testes O 
was O 
reduced O 
at O 
250 O 
and O 
750 O 
mg O 
/ O 
kg O 
/ O 
day O 
. O 
Multinucleated O 
germ O 
cells O 
were O 
increased O 
in O 
the O 
testes O 
of O 
rats O 
at O 
250 O 
and O 
750 O 
mg O 
/ O 
kg O 
/ O 
day O 
. O 
The O 
no O 
observed O 
effect O 
level O 
( O 
NOEL O 
) O 
for O 
this O 
study O 
was O 
50 O 
mg O 
/ O 
kg O 
/ O 
day O 
based O 
on O 
increased O 
MNGs O 
and O 
reduced O 
testes O 
testosterone B-TRIVIAL 
concentration O 
in O 
the O 
fetal O 
rat O 
. O 

prediction O 
of O 
CYP2B6 O 
induction O 
by O 
estradiol B-TRIVIAL 
during O 
pregnancy O 
: O 
potential O 
explanation O 
for O 
increased O 
methadone B-TRIVIAL 
clearance O 
during O 
pregnancy O 
. O 

is O 
considerable O 
evidence O 
that O 
pregnancy O 
changes O 
the O 
disposition O 
of O 
drugs O 
in O 
an O 
enzyme- O 
and O 
gestational O 
stage O 
- O 
specific O 
manner O 
. O 
On O 
the O 
basis O 
of O 
probe O 
drug O 
studies O 
, O 
the O 
activity O 
of O 
CYP3A4 O 
and O 
CYP2D6 O 
increases O 
and O 
CYP1A2 O 
decreases O 
during O 
human O 
pregnancy O 
. O 
However O 
, O 
no O 
studies O 
of O 
CYP2B6 O 
activity O 
during O 
human O 
pregnancy O 
have O 
been O 
conducted O 
. O 
In O 
rodent O 
models O 
and O 
in O 
HepG2 O 
cells O 
, O 
CYP2B O 
enzymes O 
have O 
been O 
shown O 
to O 
be O 
regulated O 
by O 
estradiol B-TRIVIAL 
. O 
Because O 
estradiol B-TRIVIAL 
concentrations O 
increase O 
by O 
∼50-fold O 
during O 
human O 
pregnancy O 
, O 
it O 
was O 
hypothesized O 
that O 
the O 
increasing O 
estradiol B-TRIVIAL 
concentrations O 
during O 
human O 
pregnancy O 
would O 
result O 
in O 
induction O 
of O 
CYP2B6 O 
activity O 
. O 
Hepatocytes O 
from O 
three O 
female O 
donors O 
were O 
treated O 
with O 
estradiol B-TRIVIAL 
, O 
and O 
the O 
EC(50) O 
and O 
E(max) O 
were O 
measured O 
for O 
CYP2B6 O 
mRNA O 
and O 
bupropion B-TRIVIAL 
hydroxylation O 
activity O 
. O 
The O 
measured O 
values O 
were O 
used O 
to O 
predict O 
the O 
magnitude O 
of O 
CYP2B6 O 
induction O 
during O 
human O 
pregnancy O 
. O 
At O 
100 O 
nM O 
total O 
estradiol B-TRIVIAL 
, O 
a O 
concentration O 
achievable O 
during O 
the O 
third O 
trimester O 
of O 
pregnancy O 
, O 
CYP2B6 O 
activity O 
was O 
predicted O 
to O 
increase O 
by O 
1.5-3-fold O 
, O 
based O 
on O 
increased O 
CYP2B6 O 
activity O 
and O 
mRNA O 
. O 
When O 
the O 
E(max) O 
and O 
EC(50) O 
values O 
were O 
compared O 
with O 
those O 
for O 
carbamazepine B-TRIVIAL 
and O 
rifampin B-TRIVIAL 
, O 
estradiol B-TRIVIAL 
was O 
found O 
to O 
be O 
as O 
potent O 
an O 
inducer O 
of O 
CYP2B6 O 
as O 
rifampin B-TRIVIAL 
and O 
carbamazepine B-TRIVIAL 
. O 
These O 
data O 
suggest O 
that O 
, O 
during O 
human O 
pregnancy O 
, O 
the O 
increasing O 
estradiol B-TRIVIAL 
concentrations O 
will O 
result O 
in O 
increased O 
clearance O 
of O 
drugs O 
that O 
have O 
CYP2B6 O 
- O 
mediated O 
clearance O 
pathways O 
. O 
This O 
could O 
in O 
part O 
explain O 
the O 
observed O 
increase O 
in O 
methadone B-TRIVIAL 
clearance O 
during O 
pregnancy O 
. O 

synapse O 
is O 
a O 
crowded O 
area O 
. O 
In O 
the O 
last O 
years O 
, O 
the O 
concept O 
that O 
proteins O 
can O 
be O 
organized O 
in O 
different O 
membrane O 
domains O 
according O 
to O 
their O 
structure O 
has O 
emerged O 
. O 
Cholesterol B-TRIVIAL 
-rich O 
membrane O 
domains O 
, O 
or O 
lipid O 
rafts O 
, O 
form O 
an O 
organized O 
portion O 
of O 
the O 
membrane O 
that O 
is O 
thought O 
to O 
concentrate O 
signaling O 
molecules O 
. O 
Accumulating O 
evidence O 
has O 
shown O 
that O 
both O 
the O 
pre O 
- O 
synaptic O 
and O 
post O 
- O 
synaptic O 
sites O 
are O 
highly O 
enriched O 
in O 
lipid O 
rafts O 
, O 
which O 
are O 
likely O 
to O 
organize O 
and O 
maintain O 
synaptic O 
proteins O 
in O 
their O 
precise O 
localization O 
. O 
Here O 
we O 
review O 
recent O 
studies O 
highlighting O 
the O 
importance O 
of O 
lipid O 
rafts O 
for O 
synaptic O 
function O 
and O 
plasticity O 
, O 
as O 
well O 
as O 
their O 
relevance O 
for O 
age O 
or O 
disease O 
- O 
related O 
cognitive O 
impairment O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

of O 
clopidogrel B-TRIVIAL 
and O 
clarithromycin B-TRIVIAL 
on O 
the O 
disposition O 
of O 
sibutramine B-TRIVIAL 
and O 
its O 
active O 
metabolites O 
M1 O 
and O 
M2 O 
in O 
relation O 
to O 
CYP2B6*6 O 
polymorphism O 
. O 

concentrations O 
of O 
sibutramine B-TRIVIAL 
and O 
its O 
two O 
active O 
metabolites O 
after O 
single O 
oral O 
dose O 
of O 
sibutramine B-TRIVIAL 
were O 
determined O 
in O 
Korean O 
healthy O 
male O 
subjects O 
with O 
different O 
CYP2B6 O 
genotypes O 
( O 
CYP2B6*1 O 
/ O 
*1 O 
, O 
*1 O 
/ O 
*6 O 
and O 
*6 O 
/ O 
*6 O 
) O 
, O 
either O 
alone O 
or O 
after O 
four O 
- O 
day O 
pretreatment O 
with O 
clopidogrel B-TRIVIAL 
or O 
clarithromycin B-TRIVIAL 
. O 
The O 
pretreatment O 
with O 
clopidogrel B-TRIVIAL 
and O 
clarithromycin B-TRIVIAL 
raised O 
the O 
mean O 
area O 
under O 
the O 
concentration O 
- O 
time O 
curve O 
( O 
AUC O 
) O 
of O 
sibutramine B-TRIVIAL 
by O 
163% O 
and O 
255% O 
, O 
respectively O 
. O 
Co-administration O 
of O 
clarithromycin B-TRIVIAL 
, O 
combined O 
with O 
CYP2B6*6 O 
/ O 
*6 O 
genotype O 
, O 
led O 
to O 
highest O 
concentration O 
of O 
sibutramine B-TRIVIAL 
. O 
The O 
molar O 
sum O 
AUC O 
( O 
M1 O 
+ O 
M2 O 
) O 
was O 
raised O 
by O 
35% O 
in O 
the O 
clopidogrel B-TRIVIAL 
phase O 
but O 
not O 
significantly O 
affected O 
by O 
clarithromycin B-TRIVIAL 
or O 
CYP2B6 O 
genotype O 
. O 
The O 
CYP2B6*6 O 
/ O 
*6 O 
subjects O 
in O 
the O 
clopidogrel B-TRIVIAL 
phase O 
showed O 
the O 
highest O 
molar O 
AUC O 
( O 
M1 O 
+ O 
M2 O 
) O 
among O 
three O 
genotype O 
groups O 
throughout O 
the O 
three O 
phases O 
. O 
The O 
exposure O 
of O 
sibutramine B-TRIVIAL 
and O 
its O 
metabolites O 
seemed O 
to O 
be O 
associated O 
with O 
the O 
CYP2B6 O 
genotype O 
. O 
The O 
treatment O 
of O 
clopidogrel B-TRIVIAL 
significantly O 
altered O 
the O 
disposition O 
of O 
active O 
metabolites O 
as O 
well O 
as O 
sibutramine B-TRIVIAL 
, O 
but O 
clarithromycin B-TRIVIAL 
only O 
affects O 
the O 
disposition O 
of O 
sibutramine B-TRIVIAL 
. O 
These O 
results O 
suggest O 
that O 
the O 
perturbation O 
of O 
CYP2B6 O 
activity O 
may O 
contribute O 
to O 
the O 
inter O 
- O 
individual O 
variation O 
of O 
sibutramine B-TRIVIAL 
drug O 
responses O 
although O 
the O 
clinical O 
relevance O 
is O 
remained O 
to O 
be O 
established O 
. O 

cell O 
hyperplasia O 
and O 
Leydig O 
cell O 
tumours O 
of O 
the O 
ovary O 
are O 
rare O 
. O 
We O 
present O 
two O 
cases O 
in O 
which O 
patients O 
had O 
increased O 
blood O 
levels O 
of O 
testosterone B-TRIVIAL 
and O 
frank O 
hirsutism O 
. O 
Imaging O 
showed O 
minimal O 
abnormalities O 
. O 
After O 
adrenal O 
disease O 
had O 
been O 
ruled O 
out O 
, O 
they O 
underwent O 
a O 
bilateral O 
oophorectomy O 
. O 
One O 
case O 
showed O 
a O 
Leydig O 
cell O 
hyperplasia O 
, O 
the O 
other O 
a O 
Leydig O 
cell O 
tumour O 
. O 
An O 
androgen B-FAMILY 
producing O 
tumour O 
should O 
be O 
excluded O 
in O 
every O 
woman O 
with O 
evidence O 
of O 
hirsutism O 
or O 
frank O 
virilization O 
and O 
markedly O 
elevated O 
testosterone B-TRIVIAL 
levels O 
. O 
Adrenal O 
disease O 
with O 
androgen B-FAMILY 
hypersecretion O 
can O 
be O 
suspected O 
by O 
detailed O 
clinical O 
, O 
laboratory O 
and O 
radiologic O 
imaging O 
. O 
Although O 
DHEAS B-ABBREVIATION 
has O 
a O 
good O 
sensitivity O 
in O 
the O 
detection O 
of O 
adrenal O 
origin O 
of O 
hyperandrogenism O 
( O 
and O 
hence O 
a O 
good O 
negative O 
predictive O 
value O 
) O 
it O 
is O 
not O 
specific O 
( O 
specificity O 
ranging O 
from O 
85 O 
to O 
98% O 
) O 
. O 
Imaging O 
of O 
the O 
ovaries O 
can O 
be O 
helpful O 
but O 
does O 
not O 
rule O 
out O 
ovarian O 
disease O 
if O 
normal O 
. O 
Indeed O 
, O 
diffuse O 
stromal O 
Leydig O 
cell O 
hyperplasia O 
and O 
Leydig O 
cell O 
tumours O 
( O 
usually O 
small O 
) O 
may O 
escape O 
imaging O 
and O 
in O 
some O 
cases O 
diagnosis O 
can O 
only O 
be O 
made O 
on O 
pathology O 
. O 
As O 
these O 
clinical O 
entities O 
represent O 
a O 
diagnostic O 
and O 
therapeutic O 
challenge O 
, O 
oophorectomy O 
should O 
be O 
considered O 
in O 
postmenopausal O 
women O 
with O 
hirsutism O 
and O 
elevated O 
testosterone B-TRIVIAL 
levels O 
, O 
after O 
the O 
exclusion O 
of O 
adrenal O 
causes O 
. O 
The O 
procedure O 
is O 
relatively O 
safe O 
and O 
effective O 
. O 
Follow O 
- O 
up O 
remains O 
indicated O 
. O 

- O 
specific O 
regulation O 
of O 
cytochromes O 
P450 O 
expression O 
by O 
estradiol B-TRIVIAL 
and O 
progesterone B-TRIVIAL 
. O 

from O 
clinical O 
studies O 
suggest O 
that O 
pregnancy O 
alters O 
hepatic O 
drug O 
metabolism O 
in O 
a O 
cytochrome O 
P450 O 
( O 
P450 O 
) O 
isoform O 
- O 
specific O 
manner O 
, O 
and O 
rising O 
concentrations O 
of O 
female O 
hormones O 
are O 
potentially O 
responsible O 
for O 
the O 
changes O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
comprehensively O 
characterize O 
the O 
effects O 
of O 
estrogen B-FAMILY 
and O 
progesterone B-TRIVIAL 
on O 
the O 
expression O 
and O 
activity O 
of O 
major O 
drug O 
- O 
metabolizing O 
P450s O 
. O 
To O 
this O 
end O 
, O 
primary O 
human O 
hepatocytes O 
were O 
treated O 
with O 
estradiol B-TRIVIAL 
and O 
progesterone B-TRIVIAL 
, O 
and O 
mRNA O 
expression O 
and O 
activity O 
levels O 
of O 
10 O 
different O 
P450 O 
isoforms O 
were O 
determined O 
. O 
The O 
results O 
showed O 
that O 
estradiol B-TRIVIAL 
enhances O 
CYP2A6 O 
, O 
CYP2B6 O 
, O 
and O 
CYP3A4 O 
expression O 
, O 
whereas O 
progesterone B-TRIVIAL 
induces O 
CYP2A6 O 
, O 
CYP2B6 O 
, O 
CYP2C8 O 
, O 
CYP3A4 O 
, O 
and O 
CYP3A5 O 
expression O 
. O 
The O 
induction O 
was O 
mainly O 
observed O 
when O 
the O 
average O 
hormone O 
concentrations O 
were O 
at O 
the O 
levels O 
reached O 
during O 
pregnancy O 
, O 
suggesting O 
that O 
these O 
effects O 
are O 
likely O 
pregnancy O 
- O 
specific O 
. O 
Estradiol B-TRIVIAL 
also O 
increased O 
enzyme O 
activities O 
of O 
CYP2C9 O 
and O 
CYP2E1 O 
without O 
affecting O 
the O 
mRNA O 
expression O 
levels O 
by O 
unknown O 
mechanisms O 
. O 
Taken O 
together O 
, O 
our O 
results O 
show O 
differential O 
effects O 
of O 
estrogen B-FAMILY 
and O 
progesterone B-TRIVIAL 
on O 
P450 O 
expression O 
, O 
suggesting O 
involvement O 
of O 
different O 
regulatory O 
mechanisms O 
in O 
female O 
hormone O 
- O 
mediated O 
P450 O 
regulation O 
. O 
Our O 
findings O 
potentially O 
provide O 
a O 
basis O 
in O 
mechanistic O 
understanding O 
for O 
altered O 
drug O 
metabolism O 
during O 
pregnancy O 
. O 

induces O 
death O 
receptor O 
and O 
mitochondria O 
- O 
mediated O 
apoptosis O 
in O 
human O 
cervical O 
cancer O 
( O 
SiHa O 
) O 
cells O 
. O 

cancer O 
is O 
the O 
second O 
most O 
common O 
female O 
cancer O 
worldwide O 
, O 
and O 
it O 
remains O 
a O 
challenge O 
to O 
manage O 
preinvasive O 
and O 
invasive O 
lesions O 
. O 
Fruit O 
- O 
based O 
cancer O 
prevention O 
entities O 
, O 
such O 
as O 
flavonoid B-FAMILY 
and O 
their O 
derivatives O 
, O 
have O 
demonstrated O 
a O 
marked O 
ability O 
to O 
inhibit O 
preclinical O 
models O 
of O 
epithelial O 
cancer O 
cell O 
growth O 
and O 
tumor O 
formation O 
. O 
Here O 
, O 
we O 
extend O 
the O 
role O 
of O 
naringin B-TRIVIAL 
-mediated O 
chemoprevention O 
to O 
that O 
of O 
cervical O 
carcinogenesis O 
. O 
The O 
present O 
study O 
sought O 
to O 
investigate O 
the O 
therapeutic O 
potential O 
effect O 
of O 
naringin B-TRIVIAL 
on O 
apoptosis O 
in O 
human O 
cervical O 
SiHa O 
cancer O 
cells O 
. O 
Viability O 
of O 
SiHa O 
cells O 
was O 
evaluated O 
by O 
the O 
MTT B-ABBREVIATION 
assay O 
, O 
apoptosis O 
and O 
mitochondrial O 
transmembrane O 
potential O 
by O 
flow O 
cytometry O 
, O 
and O 
pro O 
- O 
apoptotic O 
related O 
genes O 
by O 
Real O 
- O 
time O 
quantitative O 
PCR O 
. O 
Naringin B-TRIVIAL 
showed O 
a O 
50% O 
inhibition O 
of O 
SiHa O 
human O 
cervical O 
cancer O 
cells O 
at O 
a O 
concentration O 
of O 
750μM O 
. O 
SiHa O 
cells O 
exhibited O 
apoptotic O 
cell O 
death O 
, O 
intranucleosomal O 
DNA O 
fragmentation O 
, O 
morphological O 
changes O 
and O 
decline O 
in O 
the O 
mitochondrial O 
transmembrane O 
potential O 
. O 
In O 
addition O 
, O 
administration O 
of O 
naringin B-TRIVIAL 
increased O 
the O 
expression O 
of O 
caspases O 
, O 
p53 O 
and O 
Bax O 
, O 
Fas O 
death O 
receptor O 
and O 
its O 
adaptor O 
protein O 
FADD O 
. O 
These O 
results O 
suggest O 
that O 
the O 
induction O 
of O 
apoptosis O 
by O 
naringin B-TRIVIAL 
is O 
through O 
both O 
death O 
- O 
receptor O 
and O 
mitochondrial O 
pathways O 
. O 
Taken O 
together O 
, O 
our O 
results O 
suggest O 
that O 
naringin B-TRIVIAL 
might O 
be O 
an O 
effective O 
agent O 
to O 
treat O 
human O 
cervical O 
cancer O 
. O 

A O 
, O 
a O 
stimulator O 
of O 
follicle O 
- O 
stimulating O 
hormone O 
secretion O 
from O 
the O 
pituitary O 
, O 
acts O 
as O 
a O 
neurotrophic O 
and O 
neuroprotective O 
factor O 
in O 
the O 
central O 
nervous O 
system O 
. O 
Activin O 
receptor O 
- O 
interacting O 
protein O 
1 O 
( O 
ARIP1 O 
) O 
has O 
been O 
identified O 
as O 
a O 
cytoplasmic O 
protein O 
that O 
interacts O 
with O 
the O 
type O 
II O 
receptor O 
of O 
activin O 
( O 
ActRII O 
) O 
. O 
However O 
, O 
the O 
distribution O 
pattern O 
and O 
function O 
of O 
ARIP1 O 
are O 
not O 
well O 
characterised O 
in O 
the O 
brain O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
confirmed O 
the O 
existence O 
of O 
mRNA O 
and O 
protein O 
of O 
ARIP1 O 
in O 
the O 
mouse O 
brain O 
, O 
and O 
found O 
that O 
ARIP1 O 
was O 
mainly O 
localised O 
at O 
the O 
hippocampus O 
and O 
hypothalamus O 
in O 
the O 
cerebrum O 
, O 
granular O 
layers O 
in O 
the O 
cerebellum O 
( O 
especially O 
in O 
Purkinje O 
cells O 
of O 
the O 
cerebellum O 
) O 
and O 
choroid O 
epithelial O 
cells O 
by O 
immunohistochemical O 
staining O 
. O 
Furthermore O 
, O 
in O 
contrast O 
to O 
the O 
significant O 
increase O 
of O 
activin O 
A O 
mRNA O 
, O 
ARIP1 O 
mRNA O 
and O 
protein O 
expression O 
decreased O 
in O 
the O 
mechanically O 
lesioned O 
brain O 
of O 
the O 
mouse O 
. O 
Using O 
neuroblastoma O 
- O 
derived O 
Neuro-2a O 
cells O 
to O 
investigate O 
the O 
function O 
of O 
ARIP1 O 
, O 
we O 
found O 
that O 
overexpression O 
of O 
ARIP1 O 
down O 
- O 
regulated O 
the O 
activin O 
A-induced O 
signal O 
transduction O 
and O 
significantly O 
decreased O 
the O 
voltage O 
- O 
gated O 
Na(+) B-FORMULA 
current O 
( O 
I( O 
Na B-FORMULA 
) O 
) O 
. O 
These O 
data O 
indicate O 
that O 
ARIP1 O 
is O 
a O 
key O 
molecule O 
for O 
the O 
regulation O 
of O 
the O 
action O 
of O 
activin O 
in O 
neurones O 
, O 
and O 
also O 
that O 
decreased O 
ARIP1 O 
expression O 
in O 
the O 
lesioned O 
brain O 
may O 
be O 
beneficial O 
to O 
the O 
neurotrophic O 
and O 
neuroprotective O 
roles O 
of O 
activin O 
A O 
in O 
recovery O 
after O 
brain O 
injury O 
. O 

aim O 
of O 
the O 
study O 
was O 
to O 
evaluate O 
patients O 
with O 
Cushing's O 
syndrome O 
the O 
coronary O 
flow O 
reserve O 
( O 
CFR O 
) O 
, O 
an O 
index O 
of O 
coronary O 
microvascular O 
function O 
. O 
Fifteen O 
newly O 
diagnosed O 
patients O 
with O 
Cushing's O 
syndrome O 
( O 
1 O 
male O 
/ O 
14 O 
females O 
; O 
mean O 
age O 
45 O 
± O 
11 O 
years O 
) O 
, O 
were O 
selected O 
for O 
having O 
no O 
clinical O 
evidence O 
of O 
ischemic O 
heart O 
disease O 
. O 
Twelve O 
patients O 
had O 
pituitary O 
- O 
dependent O 
Cushing's O 
disease O 
and O 
three O 
had O 
an O 
adrenal O 
adenoma O 
. O 
Fifteen O 
subjects O 
matched O 
for O 
age O 
, O 
sex O 
, O 
and O 
major O 
cardiovascular O 
risk O 
factors O 
were O 
used O 
as O 
controls O 
. O 
Coronary O 
flow O 
velocity O 
in O 
the O 
left O 
anterior O 
descending O 
coronary O 
artery O 
was O 
investigated O 
by O 
transthoracic O 
Doppler O 
echocardiography O 
at O 
rest O 
and O 
during O 
adenosine B-TRIVIAL 
infusion O 
. O 
CFR O 
was O 
obtained O 
as O 
the O 
ratio O 
hyperemic O 
/ O 
resting O 
diastolic O 
flow O 
velocity O 
. O 
A O 
reduced O 
coronary O 
reserve O 
( O 
hyperemic O 
/ O 
resting O 
ratio O 
≤ O 
2.5 O 
) O 
was O 
found O 
in O 
5 O 
/ O 
15 O 
Cushing O 
patients O 
and O 
4 O 
/ O 
15 O 
controls O 
. O 
In O 
all O 
patients O 
with O 
abnormal O 
CFR O 
, O 
epicardial O 
coronary O 
stenosis O 
was O 
excluded O 
by O 
multi O 
- O 
slice O 
computed O 
tomographic O 
coronary O 
angiography O 
. O 
CFR O 
was O 
inversely O 
related O 
to O 
urinary O 
cortisol B-TRIVIAL 
in O 
patients O 
with O 
endogenous O 
hypercortisolism O 
( O 
Spearman's O 
rho O 
= O 
-0.57 O 
, O 
P O 
= O 
0.03 O 
) O 
, O 
while O 
no O 
correlation O 
was O 
found O 
in O 
controls O 
. O 
Coronary O 
microvascular O 
function O 
, O 
as O 
assessed O 
by O 
CFR O 
, O 
is O 
pathologically O 
reduced O 
in O 
a O 
considerable O 
number O 
of O 
patients O 
with O 
Cushing's O 
syndrome O 
without O 
clinical O 
symptoms O 
of O 
ischemic O 
heart O 
disease O 
and O 
in O 
the O 
absence O 
of O 
epicardial O 
coronary O 
artery O 
lesions O 
, O 
as O 
well O 
as O 
in O 
controls O 
matched O 
for O 
cardiovascular O 
risk O 
factors O 
. O 
The O 
presence O 
of O 
comorbidities O 
can O 
explain O 
this O 
early O 
coronary O 
abnormality O 
in O 
both O 
patients O 
and O 
controls O 
. O 
Whether O 
urinary O 
cortisol B-TRIVIAL 
may O 
be O 
a O 
predictor O 
of O 
coronary O 
microvascular O 
function O 
in O 
the O 
setting O 
of O 
patients O 
with O 
Cushing's O 
syndrome O 
, O 
needs O 
further O 
investigation O 
. O 

rosette O 
cooling O 
cell O 
: O 
more O 
effective O 
container O 
for O 
solubilization O 
of O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
under O 
probe O 
- O 
type O 
ultrasonic O 
irradiation O 
. O 

- O 
type O 
ultrasonication O 
has O 
been O 
employed O 
for O 
surfactant O 
- O 
aided O 
solubilization O 
, O 
or O 
individualization O 
, O 
of O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWNTs O 
) O 
. O 
The O 
resulting O 
solution O 
can O 
be O 
used O 
not O 
only O 
for O 
spectroscopic O 
analyses O 
such O 
as O 
absorption O 
, O 
photoluminescence O 
, O 
and O 
circular O 
dichroism O 
, O 
but O 
also O 
for O 
separation O 
by O 
density O 
gradient O 
ultracentrifugation O 
, O 
dielectrophoresis O 
, O 
chromatography O 
, O 
and O 
polymer O 
wrapping O 
. O 
In O 
spite O 
of O 
its O 
importance O 
, O 
the O 
sonochemical O 
processing O 
of O 
SWNTs O 
has O 
not O 
been O 
considered O 
seriously O 
. O 
Herein O 
, O 
we O 
report O 
on O 
a O 
more O 
efficient O 
cooling O 
cell O 
for O 
probe O 
- O 
type O 
ultrasonication O 
. O 
As O 
compared O 
with O 
a O 
conventional O 
cylindrical O 
cell O 
, O 
the O 
concentration O 
of O 
the O 
SWNTs O 
solubilized O 
in O 
water O 
was O 
found O 
to O 
be O 
almost O 
double O 
in O 
a O 
rosette O 
cooling O 
cell O 
after O 
ultracentrifugation O 
. O 
The O 
efficiency O 
of O 
a O 
rosette O 
cell O 
can O 
be O 
attributed O 
to O 
the O 
higher O 
efficiency O 
in O 
circulation O 
and O 
cooling O 
of O 
the O 
SWNT O 
dispersion O 
as O 
well O 
as O 
enhancement O 
of O 
the O 
cavitation O 
process O 
. O 

characterization O 
of O 
the O 
novel O 
TAZ O 
modulator O 
TM-25659 B-IDENTIFIER 
using O 
a O 
multicompartment O 
kinetic O 
model O 
in O 
rats O 
and O 
a O 
possibility O 
of O 
its O 
drug O 
- O 
drug O 
interactions O 
in O 
humans O 
. O 

study O 
evaluated O 
the O 
pharmacokinetics O 
of O 
the O 
novel O 
TAZ O 
modulator O 
TM-25659 B-IDENTIFIER 
in O 
rats O 
following O 
intravenous O 
and O 
oral O 
administration O 
at O 
dose O 
ranges O 
of O 
0.5-5 O 
mg O 
/ O 
kg O 
and O 
2-10 O 
mg O 
/ O 
kg O 
, O 
respectively O 
. O 
Plasma O 
protein O 
binding O 
, O 
plasma O 
stability O 
, O 
liver O 
microsomal O 
stability O 
, O 
CYP O 
inhibition O 
, O 
and O 
transport O 
in O 
Caco-2 O 
cells O 
were O 
also O 
evaluated O 
. O 
After O 
intravenous O 
injection O 
, O 
systemic O 
clearance O 
, O 
steady O 
- O 
state O 
volumes O 
of O 
distribution O 
, O 
and O 
half O 
- O 
life O 
were O 
dose O 
- O 
independent O 
, O 
with O 
values O 
ranging O 
from O 
0.434-0.890 O 
mL O 
· O 
h(-1) O 
· O 
kg(-1) O 
, O 
2.02-4.22 O 
mL O 
/ O 
kg O 
, O 
and O 
4.60-7.40 O 
h O 
, O 
respectively O 
. O 
Mean O 
absolute O 
oral O 
bioavailability O 
was O 
50.9% O 
and O 
was O 
not O 
dose O 
dependent O 
. O 
Recovery O 
of O 
TM-25659 B-IDENTIFIER 
was O 
43.6% O 
in O 
bile O 
and O 
< O 
1% O 
in O 
urine O 
. O 
In O 
pharmacokinetic O 
modeling O 
studies O 
, O 
the O 
three O 
- O 
compartment O 
( O 
3C O 
) O 
model O 
was O 
appropriate O 
for O 
understanding O 
these O 
parameters O 
in O 
rats O 
. O 
TM-25659 B-IDENTIFIER 
was O 
stable O 
in O 
plasma O 
. O 
Plasma O 
protein O 
binding O 
was O 
approximately O 
99.2% O 
, O 
and O 
was O 
concentration O 
- O 
independent O 
. O 
TM-25659 B-IDENTIFIER 
showed O 
high O 
permeation O 
of O 
Caco-2 O 
cells O 
and O 
did O 
not O 
appear O 
to O 
inhibit O 
CYP450 O 
. O 
TM-25659 B-IDENTIFIER 
was O 
metabolized O 
in O 
phase O 
I O 
and O 
II O 
steps O 
in O 
rat O 
liver O 
microsomes O 
. O 
In O 
conclusion O 
, O 
the O 
pharmacokinetics O 
of O 
TM-25659 B-IDENTIFIER 
was O 
characterized O 
for O 
intravenous O 
and O 
oral O 
administration O 
at O 
doses O 
of O 
0.5-5 O 
and O 
2-10 O 
mg O 
/ O 
kg O 
, O 
respectively O 
. O 
TM-25659 B-IDENTIFIER 
was O 
eliminated O 
primarily O 
by O 
hepatic O 
metabolism O 
and O 
urinary O 
excretion O 
. O 

functional O 
study O 
on O 
the O 
adsorption O 
of O 
the O 
drug O 
isoniazid B-TRIVIAL 
onto O 
pristine O 
and O 
B B-FORMULA 
-doped O 
single O 
wall O 
carbon B-SYSTEMATIC 
nanotubes O 
. O 

current O 
study O 
explores O 
a O 
new O 
strategy O 
to O 
incorporate O 
single O 
wall O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWNTs O 
) O 
/ O 
doped O 
SWNTs O 
as O 
carrier O 
modules O 
in O 
target O 
- O 
specific O 
administration O 
of O 
antitubercular O 
chemotherapeutics O 
through O 
covalent O 
and O 
noncovalent O 
functionalization O 
onto O 
the O 
nanotube O 
sidewall O 
. O 
Density O 
functional O 
studies O 
illustrate O 
that O 
noncovalent O 
functionalization O 
of O 
isoniazid B-TRIVIAL 
( O 
INH B-ABBREVIATION 
) O 
is O 
preferred O 
over O 
covalent O 
attachment O 
, O 
exhibiting O 
low O 
adsorption O 
energy O 
values O 
, O 
HOMO-LUMO O 
gap O 
and O 
comparison O 
of O 
quantum O 
molecular O 
descriptors O 
performed O 
in O 
( O 
5,5 O 
) O 
and O 
( O 
9,0 O 
) O 
SWNT O 
systems O 
. O 
Substitution O 
doping O 
of O 
boron B-SYSTEMATIC 
facilitates O 
the O 
adsorption O 
of O 
INH B-ABBREVIATION 
onto O 
the O 
otherwise O 
inert O 
nanotube O 
. O 
Frontier O 
orbital O 
analysis O 
reveals O 
reorientation O 
of O 
electronic O 
charge O 
in O 
the O 
nanotubes O 
after O 
functionalization O 
, O 
the O 
effect O 
being O 
more O 
pronounced O 
in O 
the O 
case O 
of O 
doped O 
nanotubes O 
. O 
The O 
charge O 
transfer O 
is O 
significant O 
in O 
covalent O 
functionalization O 
of O 
INH B-ABBREVIATION 
via O 
the O 
B B-FORMULA 
-dopant O 
atom O 
, O 
whereas O 
in O 
noncovalent O 
functionalization O 
a O 
small O 
amount O 
of O 
charge O 
transfer O 
is O 
noted O 
. O 
Solvation O 
studies O 
demonstrate O 
the O 
dissolution O 
of O 
INH B-ABBREVIATION 
in O 
B B-FORMULA 
-doped O 
( O 
5,5 O 
) O 
and O 
( O 
9,0 O 
) O 
SWNTs O 
to O 
be O 
higher O 
compared O 
to O 
pristine O 
nanotube- O 
INH B-ABBREVIATION 
complexes O 
. O 
Functionalization O 
of O 
nanotubes O 
via O 
covalent O 
and O 
noncovalent O 
means O 
can O 
foster O 
pioneering O 
prospects O 
especially O 
for O 
experimental O 
studies O 
in O 
this O 
area O 
of O 
research O 
. O 

by O 
chrysin B-TRIVIAL 
, O 
apigenin B-TRIVIAL 
, O 
and O 
luteolin B-TRIVIAL 
against O 
oxidative O 
stress O 
is O 
mediated O 
by O 
the O 
Nrf2-dependent O 
up O 
- O 
regulation O 
of O 
heme B-FAMILY 
oxygenase O 
1 O 
and O 
glutamate B-TRIVIAL 
cysteine B-TRIVIAL 
ligase O 
in O 
rat O 
primary O 
hepatocytes O 
. O 

, O 
apigenin B-TRIVIAL 
, O 
and O 
luteolin B-TRIVIAL 
are O 
flavones B-FAMILY 
that O 
differ O 
in O 
their O 
number O 
of O 
hydroxyl B-SYSTEMATIC 
groups O 
in O 
the O 
B O 
ring O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
protection O 
by O 
chrysin B-TRIVIAL 
, O 
apigenin B-TRIVIAL 
, O 
and O 
luteolin B-TRIVIAL 
against O 
tert-butyl B-SYSTEMATIC 
hydroperoxide I-SYSTEMATIC 
( O 
tBHP B-ABBREVIATION 
)-induced O 
oxidative O 
stress O 
and O 
the O 
possible O 
mechanisms O 
involved O 
in O 
rat O 
primary O 
hepatocytes O 
. O 
Chrysin B-TRIVIAL 
, O 
apigenin B-TRIVIAL 
, O 
and O 
luteolin B-TRIVIAL 
dose O 
- O 
dependently O 
up O 
- O 
regulated O 
the O 
protein O 
expression O 
of O 
heme B-FAMILY 
oxygenase O 
1 O 
( O 
HO-1 O 
) O 
and O 
glutamate B-TRIVIAL 
cysteine B-TRIVIAL 
ligase O 
( O 
GCL O 
) O 
catalytic O 
( O 
GCLC O 
) O 
and O 
modifier O 
subunit O 
( O 
GCLM O 
) O 
and O 
increased O 
the O 
intracellular O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
content O 
and O 
the O 
ratio O 
of O 
GSH B-ABBREVIATION 
to O 
oxidized B-ABBREVIATION 
GSH I-ABBREVIATION 
. O 
Among O 
the O 
flavones O 
studied O 
, O 
chrysin B-TRIVIAL 
showed O 
the O 
greatest O 
induction O 
of O 
HO-1 O 
, O 
GCLC O 
, O 
and O 
GCLM O 
protein O 
expression O 
and O 
GSH B-ABBREVIATION 
content O 
. O 
Cellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
production O 
induced O 
by O 
tBHP B-ABBREVIATION 
was O 
attenuated O 
by O 
pretreatment O 
with O 
chrysin B-TRIVIAL 
, O 
apigenin B-TRIVIAL 
, O 
and O 
luteolin B-TRIVIAL 
( O 
P O 
< O 
0.05 O 
) O 
, O 
and O 
this O 
protection O 
was O 
reversed O 
by O 
the O 
GCL O 
inhibitor O 
l-buthionine-S-sulfoximine B-SYSTEMATIC 
and O 
the O 
HO-1 O 
inhibitor O 
zinc B-SYSTEMATIC 
protoporphyrin I-SYSTEMATIC 
. O 
Chrysin B-TRIVIAL 
, O 
apigenin B-TRIVIAL 
, O 
and O 
luteolin B-TRIVIAL 
activated O 
extracellular O 
signal O 
- O 
regulated O 
protein O 
kinase O 
2 O 
( O 
ERK2 O 
) O 
, O 
nuclear O 
factor O 
erythroid O 
2- O 
related O 
factor O 
2 O 
( O 
Nrf2 O 
) O 
nuclear O 
translocation O 
, O 
nuclear O 
Nrf2-antioxidant O 
responsive O 
element O 
( O 
ARE O 
) O 
binding O 
activity O 
, O 
and O 
ARE-dependent O 
luciferase O 
activity O 
. O 
Both O 
ERK2 O 
and O 
Nrf2 O 
siRNAs O 
attenuated O 
chrysin B-TRIVIAL 
-induced O 
HO-1 O 
, O 
GCLC O 
, O 
and O 
GCLM O 
protein O 
expression O 
. O 
Taken O 
together O 
, O 
these O 
results O 
suggest O 
that O 
chrysin B-TRIVIAL 
, O 
apigenin B-TRIVIAL 
, O 
and O 
luteolin B-TRIVIAL 
inhibit O 
tBHP B-ABBREVIATION 
-induced O 
oxidative O 
stress O 
by O 
up O 
- O 
regulating O 
HO-1 O 
, O 
GCLC O 
, O 
and O 
GCLM O 
gene O 
transcription O 
via O 
the O 
ERK2 O 
/ O 
Nrf2 O 
/ O 
ARE O 
signaling O 
pathways O 
in O 
rat O 
primary O 
hepatocytes O 
. O 

in O 
plasma O 
protein O 
binding O 
properties O 
of O 
propranolol B-TRIVIAL 
and O 
flurbiprofen B-TRIVIAL 
during O 
development O 
of O 
adjuvant O 
- O 
induced O 
arthritis O 
in O 
rats O 
. O 

- O 
induced O 
arthritis O 
( O 
AA O 
) O 
in O 
the O 
rat O 
is O 
used O 
as O 
a O 
model O 
for O 
rheumatoid O 
arthritis O 
. O 
In O 
AA O 
rats O 
, O 
the O 
pharmacokinetics O 
of O 
various O 
drugs O 
is O 
affected O 
due O 
to O 
the O 
alterations O 
of O 
plasma O 
protein O 
binding O 
of O 
drugs O 
. O 
We O 
choose O 
propranolol B-TRIVIAL 
( O 
PL O 
) O 
and O 
flurbiprofen B-TRIVIAL 
( O 
FP O 
) O 
as O 
model O 
basic O 
and O 
acidic O 
drugs O 
, O 
respectively O 
, O 
and O 
investigated O 
the O 
effect O 
of O 
AA O 
induction O 
on O 
their O 
plasma O 
protein O 
binding O 
at O 
each O 
developing O 
stage O 
of O 
inflammation O 
. O 
The O 
plasma O 
protein O 
binding O 
of O 
PL O 
and O 
FP O 
was O 
dramatically O 
changed O 
due O 
to O 
reduced O 
albumin O 
and O 
increased O 
α₁-acid O 
glycoprotein O 
levels O 
for O 
at O 
least O 
21 O 
days O 
after O 
adjuvant O 
treatment O 
. O 
Moreover O 
, O 
we O 
illustrated O 
the O 
differences O 
in O 
protein O 
binding O 
in O 
AA O 
between O 
both O 
the O 
drugs O 
in O 
each O 
developing O 
stage O 
of O 
inflammation O 
. O 
These O 
results O 
suggest O 
that O 
the O 
changed O 
plasma O 
protein O 
levels O 
in O 
AA O 
rats O 
accompanying O 
the O 
altered O 
protein O 
binding O 
of O 
drugs O 
affect O 
the O 
pharmacokinetics O 
of O 
drugs O 
which O 
extensively O 
bind O 
to O 
plasma O 
protein O 
under O 
inflammatory O 
condition O 
. O 

of O 
10 O 
ginsenosides B-FAMILY 
in O 
Panax O 
ginseng O 
of O 
different O 
harvest O 
times O 
based O 
on O 
HPLC O 
fingerprints O 
and O 
principal O 
component O 
analysis O 
. O 

combinative O 
method O 
of O 
HPLC O 
fingerprinting O 
and O 
quantitative O 
determination O 
was O 
successfully O 
applied O 
to O 
monitor O 
dynamic O 
accumulation O 
of O 
ginsenosides B-FAMILY 
in O 
five O 
- O 
year O 
- O 
old O 
Panax O 
ginseng O 
roots O 
from O 
different O 
harvest O 
times O 
. O 
The O 
optimal O 
chromatographic O 
conditions O 
were O 
achieved O 
on O 
a O 
C18 O 
column O 
with O 
gradient O 
elution O 
using O 
acetonitrile O 
and O 
1 O 
mmol O 
· O 
L(-1) O 
KH2PO4 B-FORMULA 
buffer O 
solution O 
at O 
203 O 
nm O 
. O 
The O 
result O 
indicated O 
that O 
the O 
contents O 
of O 
total O 
ginsenosides B-FAMILY 
showed O 
significant O 
variations O 
, O 
and O 
a O 
decrease O 
tendency O 
appeared O 
in O 
the O 
growth O 
period O 
of O 
the O 
fifth O 
year O 
. O 

large O 
proportion O 
of O 
the O 
population O 
carries O 
restorative O 
dental O 
fillings O 
containing O 
either O 
classic O 
Hg B-FORMULA 
-based O 
amalgams B-FAMILY 
and O 
/ O 
or O 
the O 
more O 
frequently O 
used O 
methacrylates B-FAMILY 
. O 
Both O 
Hg B-FORMULA 
- O 
and O 
resin O 
- O 
based O 
materials O 
have O 
been O 
shown O 
to O 
be O 
released O 
into O 
the O 
buccal O 
cavity O 
and O 
to O 
be O 
spread O 
systemically O 
. O 
In O 
addition O 
, O 
they O 
induce O 
toxic O 
and O 
genotoxic O 
alterations O 
in O 
experimental O 
test O 
systems O 
. O 
Using O 
the O 
comet O 
assay O 
, O 
we O 
previously O 
demonstrated O 
that O 
circulating O 
lymphocytes O 
of O 
subjects O 
with O 
dental O 
fillings O 
have O 
an O 
increased O 
DNA O 
damage O 
. O 
Here O 
, O 
we O 
analyzed O 
the O 
oral O 
mucosa O 
cells O 
of O 
63 O 
young O 
subjects O 
of O 
both O 
genders O 
, O 
by O 
using O 
both O 
the O 
comet O 
assay O 
and O 
the O 
micronucleus O 
( O 
MN O 
) O 
test O 
and O 
by O 
monitoring O 
cell O 
death O 
markers O 
. O 
The O 
results O 
obtained O 
show O 
that O 
both O 
amalgams B-FAMILY 
and O 
resin O 
- O 
based O 
composite O 
fillings O 
can O 
induce O 
genotoxic O 
damage O 
in O 
human O 
oral O 
mucosa O 
cells O 
, O 
as O 
convincingly O 
and O 
dose O 
- O 
dependently O 
inferred O 
from O 
the O 
results O 
of O 
the O 
MN O 
test O 
and O 
, O 
more O 
marginally O 
, O 
from O 
comet O 
assay O 
data O 
. O 
Lifestyle O 
variables O 
, O 
also O 
including O 
alcohol B-FAMILY 
intake O 
and O 
smoking O 
habits O 
, O 
did O 
not O 
affect O 
the O 
genotoxic O 
response O 
and O 
did O 
not O 
act O 
as O 
confounding O 
factors O 
. O 
Thus O 
, O 
we O 
provide O 
unequivocal O 
evidence O 
for O 
the O 
genotoxicity O 
of O 
both O 
amalgams B-FAMILY 
and O 
resin O 
- O 
based O 
dental O 
fillings O 
in O 
humans O 
not O 
only O 
by O 
testing O 
circulating O 
lymphocytes O 
but O 
also O 
by O 
analyzing O 
oral O 
mucosa O 
cells O 
. O 
These O 
findings O 
are O 
of O 
particular O 
relevance O 
due O 
to O 
the O 
circumstance O 
that O 
subjects O 
with O 
restorative O 
materials O 
are O 
exposed O 
continuously O 
and O 
for O 
long O 
periods O 
of O 
time O 
. O 

and O 
antioxidant O 
activity O 
of O 
thymoquinone B-TRIVIAL 
in O 
a O 
rat O 
model O 
of O 
acute O 
bacterial O 
prostatitis O 
. O 

plays O 
a O 
major O 
role O 
in O 
morbidity O 
and O 
mortality O 
related O 
to O 
prostate O 
diseases O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
detect O 
whether O 
thymoquinone B-TRIVIAL 
( O 
TQ O 
) O 
could O 
ameliorate O 
oxidative O 
damage O 
and O 
the O 
proliferative O 
response O 
induced O 
by O 
Escherichia O 
coli O 
( O 
E O 
. O 
coli O 
) O 
in O 
rats O 
. O 
A O 
total O 
of O 
42 O 
adult O 
male O 
Wistar O 
rats O 
were O 
used O 
. O 
The O 
rats O 
were O 
randomly O 
divided O 
into O 
seven O 
groups O 
( O 
three O 
treatment O 
groups O 
, O 
three O 
infected O 
groups O 
and O 
one O 
control O 
group O 
) O 
. O 
Control O 
group O 
received O 
saline O 
and O 
was O 
killed O 
24 O 
h O 
after O 
saline O 
administration O 
. O 
Infected O 
rats O 
were O 
killed O 
after O 
24 O 
, O 
48 O 
and O 
72 O 
h O 
following O 
direct O 
injection O 
of O 
E O 
. O 
coli O 
into O 
the O 
prostate O 
. O 
Treatment O 
groups O 
were O 
administered O 
with O 
10 O 
mg O 
/ O 
kg O 
dose O 
of O 
TQ O 
intraperitoneally O 
following O 
E O 
. O 
coli O 
injection O 
and O 
after O 
24 O 
and O 
48 O 
h O 
following O 
E O 
. O 
coli O 
injection O 
. O 
The O 
rats O 
were O 
killed O 
at O 
24 O 
, O 
48 O 
and O 
72 O 
h O 
after O 
the O 
first O 
drug O 
administration O 
. O 
Each O 
group O 
was O 
compared O 
with O 
each O 
other O 
and O 
with O 
the O 
control O 
group O 
. O 
In O 
addition O 
, O 
infected O 
groups O 
were O 
compared O 
with O 
treatment O 
groups O 
. O 
Our O 
findings O 
show O 
that O 
the O 
treatment O 
with O 
TQ O 
has O 
a O 
protective O 
effect O 
against O 
bacterial O 
prostatitis O 
- O 
induced O 
tissue O 
injury O 
. O 
Increase O 
in O 
malondialdehyde B-TRIVIAL 
levels O 
and O 
histological O 
damage O 
caused O 
by O 
E O 
. O 
coli O 
were O 
improved O 
markedly O 
with O 
TQ O 
treatment O 
. O 
TQ O 
treatment O 
particularly O 
increased O 
the O 
activity O 
of O 
glutathione B-TRIVIAL 
peroxidase O 
and O 
decreased O 
the O 
activities O 
of O 
catalase O 
and O 
superoxide B-TRIVIAL 
dismutase O 
. O 
These O 
observations O 
might O 
be O 
attributed O 
, O 
at O 
least O 
in O 
part O 
, O 
to O 
the O 
antioxidant O 
effect O 
of O 
TQ O 
and O 
suggest O 
that O 
it O 
could O 
be O 
a O 
clinically O 
valuable O 
agent O 
in O 
the O 
prevention O 
of O 
acute O 
prostatitis O 
caused O 
by O 
E O 
. O 
coli O 
. O 

of O 
methyleugenol B-SYSTEMATIC 
in O 
F344 O 
rats O 
and O 
B6C3F₁ O 
mice O 
. O 

. O 
Methyleugenol B-TRIVIAL 
( O 
MEG B-ABBREVIATION 
) O 
has O 
been O 
used O 
as O 
a O 
flavouring O 
agent O 
in O 
food O 
, O 
as O 
a O 
fragrance O 
in O 
cosmetic O 
products O 
, O 
and O 
as O 
an O 
insect O 
attractant O 
. O 
MEG B-ABBREVIATION 
was O 
carcinogenic O 
in O 
both O 
rats O 
and O 
mice O 
following O 
gavage O 
administration O 
. O 
In O 
this O 
study O 
we O 
investigated O 
plasma O 
toxicokinetics O 
of O 
MEG B-ABBREVIATION 
in O 
F344 O 
rats O 
and O 
B6C3F₁ O 
mice O 
of O 
both O 
sexes O 
following O 
single O 
gavage O 
( O 
37 O 
, O 
75 O 
, O 
or O 
150 O 
mg O 
/ O 
kg O 
) O 
and O 
intravenous O 
(IV) O 
( O 
37 O 
mg O 
/ O 
kg O 
) O 
administration O 
. O 
2 O 
. O 
Following O 
IV O 
administration O 
, O 
MEG B-ABBREVIATION 
was O 
rapidly O 
distributed O 
and O 
cleared O 
from O 
the O 
systemic O 
circulation O 
in O 
both O 
species O 
and O 
sexes O 
. O 
Absorption O 
of O 
MEG B-ABBREVIATION 
was O 
rapid O 
following O 
gavage O 
administration O 
with O 
secondary O 
peaks O 
in O 
the O 
plasma O 
MEG B-ABBREVIATION 
concentration O 
- O 
versus O 
- O 
time O 
profiles O 
. O 
C(max) O 
and O 
AUC(T) O 
increased O 
and O 
the O 
clearance O 
decreased O 
greater O 
than O 
proportional O 
to O 
the O 
dose O 
in O 
rats O 
and O 
mice O 
of O 
both O 
sexes O 
. O 
In O 
general O 
, O 
rats O 
had O 
higher O 
internal O 
exposure O 
to O 
MEG B-ABBREVIATION 
than O 
mice O 
. O 
3 O 
. O 
The O 
results O 
for O 
AUC(T) O 
and O 
clearance O 
suggest O 
that O 
perhaps O 
the O 
metabolism O 
of O 
MEG B-ABBREVIATION 
is O 
saturated O 
at O 
higher O 
doses O 
tested O 
in O 
this O 
study O 
. O 
Absolute O 
bioavailability O 
following O 
gavage O 
administration O 
of O 
37 O 
mg O 
/ O 
kg O 
was O 
low O 
in O 
both O 
rats O 
( O 
~4% O 
) O 
and O 
mice O 
( O 
7-9% O 
) O 
of O 
both O 
sexes O 
indicating O 
extensive O 
first O 
- O 
pass O 
metabolism O 
. O 
There O 
was O 
no O 
sex O 
difference O 
in O 
plasma O 
toxicokinetics O 
of O 
MEG B-ABBREVIATION 
following O 
gavage O 
administration O 
both O 
in O 
rats O 
and O 
mice O 
. O 

trends O 
of O 
1 B-SYSTEMATIC 
, I-SYSTEMATIC 
3-diphenyl-2-propen-1-one I-SYSTEMATIC 
derivatives O 
. O 

( O 
1 B-SYSTEMATIC 
, I-SYSTEMATIC 
3-Diphenyl-2-propen-1-one I-SYSTEMATIC 
) O 
are O 
constituted O 
by O 
a O 
three O 
carbon B-SYSTEMATIC 
α B-FAMILY 
, I-FAMILY 
β- I-FAMILY 
unsaturated I-FAMILY 
carbonyl I-FAMILY 
system O 
. O 
The O 
biosynthesis O 
of O 
flavonoids B-FAMILY 
and O 
isoflavonoids B-FAMILY 
is O 
initiated O 
by O 
chalcones B-FAMILY 
. O 
Notable O 
pharmacological O 
activities O 
of O 
chalcones B-FAMILY 
and O 
its O 
derivatives O 
include O 
anti-inflammatory O 
, O 
antifungal O 
, O 
antibacterial O 
, O 
antimalarial O 
, O 
antituberculosis O 
, O 
antitumor O 
, O 
antimicrobial O 
and O 
antiviral O 
effects O 
respectively O 
. O 
Owing O 
to O 
simplicity O 
of O 
the O 
chemical O 
structures O 
and O 
a O 
huge O 
variety O 
of O 
pharmacological O 
actions O 
exhibited O 
, O 
the O 
entities O 
derived O 
from O 
chalcones B-FAMILY 
are O 
subjected O 
to O 
extensive O 
consideration O 
. O 
This O 
review O 
article O 
is O 
an O 
effort O 
to O 
sum O 
up O 
the O 
anti-inflammatory O 
activities O 
of O 
chalcone B-FAMILY 
derived O 
chemical O 
entities O 
. O 
Effect O 
of O 
chalcones B-FAMILY 
on O 
lipid O 
peroxidation O 
, O 
heme B-FAMILY 
oxygenase O 
1(HO-1) O 
, O 
cyclooxygenase O 
( O 
COX O 
) O 
, O 
interleukin O 
5 O 
( O 
IL-5 O 
) O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
and O 
expression O 
of O 
cell O 
adhesion O 
molecules O 
( O 
CAM O 
) O 
is O 
summarized O 
stepwise O 
. O 

in O 
Cancer O 
: O 
Understanding O 
their O 
Role O 
in O 
Terms O 
of O 
QSAR O 
. O 
II O 
Part O 
. O 

are O 
a O 
group O 
of O 
plant O 
- O 
derived O 
polyphenolic B-FAMILY 
compounds O 
belonging O 
to O 
the O 
flavonoids B-FAMILY 
family O 
and O 
possess O 
a O 
wide O 
variety O 
of O 
cytoprotective O 
and O 
modulatory O 
functions O 
. O 
In O 
this O 
research O 
we O 
tried O 
to O 
review O 
the O 
anticancer O 
effect O 
of O 
chalcones B-FAMILY 
derivatives O 
and O 
to O 
evaluate O 
new O 
QSARs O 
which O 
will O 
help O 
in O 
the O 
understanding O 
of O 
the O 
role O 
of O 
chalcones B-FAMILY 
and O 
of O 
their O 
analogs O 
on O 
cancer O 
. O 
Simultaneously O 
a O 
comparative O 
study O 
will O 
be O 
presented O 
. O 
Our O 
QSAR O 
results O 
reveal O 
that O 
: O 
1 O 
) O 
the O 
clog O 
P O 
( O 
hydrophobicity O 
/ O 
hydrophilicity O 
) O 
parameter O 
plays O 
an O 
important O 
part O 
in O 
three O 
QSAR O 
relationships O 
( O 
linear O 
model O 
) O 
, O 
2 O 
) O 
the O 
steric O 
factors O 
such O 
as O 
molar O 
volume O 
MgVol O 
, O 
molar O 
refractivity O 
CMR O 
or O 
the O 
substituents O 
molar O 
refractivity O 
MR O 
( O 
linear O 
) O 
are O 
important O 
. O 
Electronic O 
effects O 
are O 
comparatively O 
unimportant O 
. O 
These O 
results O 
compared O 
to O 
our O 
previous O 
findings O 
on O 
the O 
QSAR O 
of O 
anti-proliferative O 
chalcones B-FAMILY 
support O 
primarily O 
the O 
role O 
of O 
bulk O 
. O 

information O 
regulator O 
2 O 
( O 
Sir2 O 
) O 
enzymes O 
or O 
sirtuins O 
are O 
a O 
family O 
of O 
evolutionarily O 
conserved O 
intracellular O 
protein O 
deacetylases O 
that O 
can O 
catalyze O 
the O 
acetyl B-SYSTEMATIC 
group O 
removal O 
from O 
the O 
specific O 
Nε-acetyl-lysine B-SYSTEMATIC 
( O 
AcK O 
) O 
side O 
chains O 
on O 
a O 
variety O 
of O 
proteins O 
from O 
all O 
kingdoms O 
of O 
life O 
. O 
Yeast O 
Sir2 O 
was O 
the O 
first O 
sirtuin O 
identified O 
, O 
and O 
so O 
far O 
seven O 
sirtuins O 
( O 
i.e O 
. O 
SIRT1-7 O 
) O 
have O 
been O 
found O 
in O 
mammals O 
including O 
humans O 
. O 
The O 
sirtuin O 
- O 
catalyzed O 
deacetylation O 
reaction O 
has O 
captured O 
tremendous O 
interest O 
during O 
the O 
past O 
a O 
few O 
years O 
because O 
of O 
(i) O 
its O 
increasingly O 
demonstrated O 
importance O 
in O 
many O 
crucial O 
biological O 
processes O 
such O 
as O 
gene O 
transcription O 
, O 
metabolism O 
, O 
and O 
aging O 
, O 
and O 
thus O 
its O 
therapeutic O 
potential O 
for O 
metabolic O 
and O 
age O 
- O 
related O 
diseases O 
and O 
cancer O 
, O 
and O 
(ii) O 
its O 
unique O 
deacetylation O 
chemistry O 
. O 
Specifically O 
, O 
the O 
sirtuin O 
- O 
catalyzed O 
AcK O 
side O 
chain O 
deacetylation O 
is O 
not O 
merely O 
an O 
amide B-FAMILY 
hydrolysis O 
reaction O 
, O 
instead O 
is O 
coupled O 
to O 
the O 
nicotinamide B-TRIVIAL 
cleavage O 
from O 
β-nicotinamide B-TRIVIAL 
adenine I-TRIVIAL 
dinucleotide I-TRIVIAL 
( O 
β-NAD B-ABBREVIATION 
+ O 
or O 
NAD B-ABBREVIATION 
+ O 
) O 
with O 
the O 
generation O 
of O 
three O 
enzymatic O 
products O 
, O 
i.e O 
. O 
the O 
deacetylated O 
protein O 
species O 
, O 
nicotinamide O 
, O 
and O 
2'-O-acetyl-ADP-ribose B-SYSTEMATIC 
( O 
2'-O-AADPR B-SYSTEMATIC 
) O 
. O 
Here O 
the O 
author O 
would O 
like O 
to O 
review O 
the O 
past O 
endeavors O 
on O 
developing O 
mechanism O 
- O 
based O 
sirtuin O 
modulators O 
( O 
inhibitors O 
and O 
activators O 
) O 
. O 
The O 
first O 
part O 
of O 
this O 
article O 
will O 
provide O 
an O 
updated O 
mechanistic O 
picture O 
of O 
the O 
sirtuin O 
- O 
catalyzed O 
deacetylation O 
reaction O 
. O 
The O 
second O 
part O 
will O 
be O 
focused O 
on O 
how O 
the O 
mechanistic O 
knowledge O 
has O 
been O 
exploited O 
for O 
the O 
design O 
of O 
effective O 
sirtuin O 
modulators O 
. O 

( O 
TZDs B-FAMILY 
) O 
affect O 
osteoblast O 
viability O 
and O 
biomarkers O 
independently O 
of O 
the O 
TZD B-ABBREVIATION 
effects O 
on O 
aromatase O 
. O 

( O 
TZDs B-FAMILY 
) O 
are O 
insulin O 
sensitizers O 
used O 
for O 
treatment O 
of O 
diabetes O 
. O 
We O 
have O 
previously O 
reported O 
that O 
TZDs B-FAMILY 
reduce O 
estrogen B-FAMILY 
synthesis O 
by O 
inhibiting O 
aromatase O 
activity O 
in O 
human O 
granulosa O 
cells O 
( O 
HGC O 
) O 
. O 
Multiple O 
clinical O 
trials O 
demonstrated O 
that O 
TZDs B-FAMILY 
increase O 
the O 
risk O 
of O 
fractures O 
in O 
postmenopausal O 
women O 
with O 
type O 
2 O 
diabetes O 
. O 
We O 
studied O 
mouse O 
osteoblasts O 
alone O 
or O 
in O 
a O 
co O 
- O 
culture O 
with O 
HGC O 
to O 
determine O 
whether O 
TZD B-ABBREVIATION 
inhibition O 
of O 
aromatase O 
plays O 
a O 
role O 
in O 
their O 
effects O 
on O 
bone O 
metabolism O 
. O 
Mouse O 
osteoblasts O 
were O 
cultured O 
with O 
and O 
without O 
HGC O 
, O 
and O 
incubated O 
in O 
a O 
medium O 
with O 
or O 
without O 
testosterone B-TRIVIAL 
, O 
pioglitazone B-TRIVIAL 
or O 
rosiglitazone B-TRIVIAL 
. O 
Cell O 
growth O 
, O 
oleic O 
acid O 
uptake O 
, O 
alkaline O 
phosphatase O 
activity O 
, O 
and O 
osteocalcin O 
production O 
were O 
measured O 
. O 
TZDs B-FAMILY 
inhibited O 
estradiol B-TRIVIAL 
production O 
by O 
up O 
to O 
84% O 
in O 
HGC O 
/ O 
mouse O 
osteoblast O 
co O 
- O 
cultures O 
. O 
TZDs B-FAMILY 
induced O 
mouse O 
osteoblast O 
death O 
and O 
increased O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
uptake O 
. O 
TZDs B-FAMILY 
also O 
inhibited O 
alkaline O 
phosphatase O 
activity O 
( O 
58-75% O 
, O 
p O 
< O 
0.046 O 
) O 
and O 
osteocalcin O 
production O 
( O 
52-75% O 
, O 
p O 
< O 
0.031 O 
) O 
. O 
For O 
all O 
the O 
parameters O 
, O 
there O 
were O 
no O 
significant O 
differences O 
between O 
the O 
osteoblast O 
cultures O 
alone O 
and O 
the O 
HCG O 
/ O 
osteoblast O 
co O 
- O 
cultures O 
. O 
TZD B-ABBREVIATION 
effects O 
on O 
osteoblast O 
viability O 
, O 
oleic O 
acid O 
uptake O 
, O 
alkaline O 
phosphatase O 
and O 
osteocalcin O 
production O 
are O 
independent O 
of O 
their O 
effects O 
on O 
aromatase O 
. O 

alloferon B-TRIVIAL 
analogues O 
: O 
synthesis O 
and O 
antiviral O 
properties O 
. O 

have O 
extended O 
our O 
study O 
on O 
structure O 
/ O 
activity O 
relationship O 
studies O 
of O 
insect O 
peptide O 
alloferon B-TRIVIAL 
( O 
H-His-Gly-Val-Ser-Gly-His-Gly-Gln-His-Gly-Val-His-Gly-OH B-FORMULA 
) O 
by O 
evaluating O 
the O 
antiviral O 
effects O 
of O 
new O 
alloferon B-TRIVIAL 
analogues O 
. O 
We O 
synthesized O 
18 O 
alloferon B-TRIVIAL 
analogues O 
: O 
12 O 
peptides O 
with O 
sequences O 
shortened O 
from O 
N B-FORMULA 
- O 
or O 
C B-FORMULA 
-terminus O 
and O 
6 O 
N B-FORMULA 
-terminally O 
modified O 
analogues O 
H-X(1)- O 
Gly-Val-Ser-Gly-His-Gly-Gln-His-Gly-Val-His-Gly-OH B-FORMULA 
, O 
where O 
X(1) O 
= O 
Phe B-FORMULA 
( O 
13 O 
) O 
, O 
Tyr B-FORMULA 
( O 
14 O 
) O 
, O 
Trp B-FORMULA 
( O 
15 O 
) O 
, O 
Phg O 
( O 
16 O 
) O 
, O 
Phe(p-Cl) B-FORMULA 
( O 
17 O 
) O 
, O 
and O 
Phe(p-OMe) B-FORMULA 
( O 
18 O 
) O 
. O 
We O 
found O 
that O 
most O 
of O 
the O 
evaluated O 
peptides O 
inhibit O 
the O 
replication O 
of O 
Human O 
Herpesviruses O 
or O 
Coxsackievirus O 
B2 O 
in O 
Vero O 
, O 
HEp-2 O 
and O 
LLC-MK(2) O 
cells O 
. O 
Our O 
results O 
indicate O 
that O 
the O 
compound O 
[3-13]-alloferon B-TRIVIAL 
( O 
1 O 
) O 
exhibits O 
the O 
strongest O 
antiviral O 
activity O 
( O 
IC(50) O 
= O 
38 O 
μM O 
) O 
among O 
the O 
analyzed O 
compound O 
. O 
Moreover O 
, O 
no O 
cytotoxic O 
activity O 
against O 
the O 
investigated O 
cell O 
lines O 
was O 
observed O 
for O 
all O 
studied O 
peptides O 
at O 
concentration O 
165 O 
μM O 
or O 
higher O 
. O 

synthesis O 
of O 
hierarchical O 
ZnO B-FORMULA 
nanostructures O 
. O 

work O 
is O 
about O 
fabrication O 
of O 
ZnO B-FORMULA 
nanostructures O 
( O 
ZnO B-FORMULA 
-NS O 
) O 
via O 
a O 
simple O 
sonochemical O 
method O 
. O 
The O 
chemicals O 
used O 
for O 
the O 
synthesis O 
of O 
various O 
shaped O 
ZnO B-FORMULA 
are O 
Zn B-FORMULA 
salt O 
, O 
sodium B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
and O 
ammonia B-SYSTEMATIC 
solution I-SYSTEMATIC 
without O 
other O 
structure O 
directing O 
agent O 
or O 
surfactant O 
needed O 
. O 
This O 
method O 
is O 
feasible O 
and O 
green O 
, O 
as O 
it O 
does O 
not O 
require O 
high O 
temperature O 
and O 
/ O 
or O 
highly O 
toxic O 
chemicals O 
. O 
The O 
shape O 
of O 
the O 
ZnO B-FORMULA 
-NS O 
can O 
be O 
tuned O 
by O 
adjusting O 
the O 
ultrasound O 
energy O 
dissipated O 
via O 
varying O 
the O 
ultrasonication O 
time O 
from O 
5 O 
to O 
60 O 
min O 
. O 
It O 
was O 
found O 
that O 
uniform O 
ZnO B-FORMULA 
nanorods O 
with O 
diameter O 
around O 
50 O 
nm O 
were O 
formed O 
after O 
15 O 
min O 
of O 
ultrasonication O 
while O 
flowerlike O 
ZnO B-FORMULA 
-NS O 
was O 
formed O 
after O 
30 O 
min O 
. O 
This O 
method O 
produces O 
high O 
quality O 
ZnO B-FORMULA 
-NS O 
with O 
controllable O 
shapes O 
, O 
uniformity O 
, O 
and O 
purity O 
. O 

and O 
subjective O 
cognitive O 
enhancing O 
effects O 
of O 
mixed O 
amphetamine B-TRIVIAL 
salts O 
in O 
healthy O 
people O 
. O 

such O 
as O 
mixed O 
amphetamine B-TRIVIAL 
salts O 
( O 
MAS O 
, O 
brand O 
name O 
Adderall B-TRIVIAL 
) O 
are O 
widely O 
used O 
for O 
cognitive O 
enhancement O 
by O 
healthy O 
young O 
people O 
, O 
yet O 
laboratory O 
research O 
on O 
effectiveness O 
has O 
yielded O 
variable O 
results O 
. O 
The O 
present O 
study O 
assessed O 
the O 
effects O 
of O 
MAS O 
in O 
healthy O 
young O 
adults O 
with O 
an O 
adequately O 
powered O 
double O 
- O 
blind O 
cross O 
- O 
over O 
placebo O 
- O 
controlled O 
trial O 
. O 
We O 
examined O 
effects O 
in O 
13 O 
measures O 
of O 
cognitive O 
ability O 
including O 
episodic O 
memory O 
, O 
working O 
memory O 
, O 
inhibitory O 
control O 
, O 
convergent O 
creativity O 
, O 
intelligence O 
and O 
scholastic O 
achievement O 
, O 
with O 
the O 
goals O 
of O 
determining O 
( O 
1 O 
) O 
whether O 
the O 
drug O 
is O 
at O 
least O 
moderately O 
enhancing O 
( O 
Cohen's O 
d O 
> O 
= O 
0.5 O 
) O 
to O 
some O 
or O 
all O 
cognitive O 
abilities O 
tested O 
, O 
( O 
2 O 
) O 
whether O 
its O 
effects O 
on O 
cognition O 
are O 
moderated O 
by O 
baseline O 
ability O 
or O 
COMT O 
genotype O 
, O 
and O 
( O 
3 O 
) O 
whether O 
it O 
induces O 
an O 
illusory O 
perception O 
of O 
cognitive O 
enhancement O 
. O 
The O 
results O 
did O 
not O 
reveal O 
enhancement O 
of O 
any O 
cognitive O 
abilities O 
by O 
MAS O 
for O 
participants O 
in O 
general O 
. O 
There O 
was O 
a O 
suggestion O 
of O 
moderation O 
of O 
enhancement O 
by O 
baseline O 
ability O 
and O 
COMT O 
genotype O 
in O 
a O 
minority O 
of O 
tasks O 
, O 
with O 
MAS O 
enhancing O 
lower O 
ability O 
participants O 
on O 
word O 
recall O 
, O 
embedded O 
figures O 
and O 
Raven's O 
Progressive O 
Matrices O 
. O 
Despite O 
the O 
lack O 
of O 
enhancement O 
observed O 
for O 
most O 
measures O 
and O 
most O 
participants O 
, O 
participants O 
nevertheless O 
believed O 
their O 
performance O 
was O 
more O 
enhanced O 
by O 
the O 
active O 
capsule O 
than O 
by O 
placebo O 
. O 
We O 
conclude O 
that O 
MAS O 
has O 
no O 
more O 
than O 
small O 
effects O 
on O 
cognition O 
in O 
healthy O 
young O 
adults O 
, O 
although O 
users O 
may O 
perceive O 
the O 
drug O 
as O 
enhancing O 
their O 
cognition O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

D I-FAMILY 
binding O 
protein O 
is O 
a O 
key O 
determinant O 
of O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
levels O 
in O 
infants O 
and O 
toddlers O 
. O 

25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
( O 
25-OHD B-SYSTEMATIC 
) O 
levels O 
vary O 
among O 
human O 
populations O 
. O 
Only O 
limited O 
information O 
regarding O 
determinants O 
of O 
these O 
measures O 
is O 
available O 
for O 
infants O 
and O 
children O 
, O 
particularly O 
in O 
minority O 
groups O 
at O 
greatest O 
risk O 
for O 
vitamin B-FAMILY 
D I-FAMILY 
deficiency O 
. O 
We O 
identified O 
demographic O 
determinants O 
of O 
circulating O 
25-OHD B-SYSTEMATIC 
in O 
a O 
large O 
cohort O 
of O 
minority O 
children O 
, O 
and O 
now O 
extend O 
our O 
studies O 
to O 
examine O 
potential O 
roles O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
binding O 
protein O 
( O 
DBP O 
) O 
as O 
a O 
determinant O 
of O 
25-OHD B-SYSTEMATIC 
levels O 
. O 
Serum O 
DBP O 
level O 
and O 
common O 
single O 
nucleotide B-FAMILY 
polymorphisms O 
( O 
SNPs O 
) O 
at O 
positions O 
432 O 
and O 
436 O 
in O 
the O 
GC O 
gene O 
, O 
encoding O 
DBP O 
, O 
were O 
examined O 
. O 
We O 
confirmed O 
self O 
- O 
reported O 
ancestry O 
using O 
ancestry O 
informative O 
markers O 
( O 
AIMs O 
) O 
, O 
and O 
included O 
quantitative O 
AIMs O 
scores O 
in O 
the O 
analysis O 
. O 
The O 
multivariate O 
model O 
incorporated O 
previously O 
identified O 
demographic O 
and O 
nutritional O 
determinants O 
of O 
25-OHD B-SYSTEMATIC 
in O 
this O 
cohort O 
, O 
as O 
well O 
as O 
GC O 
SNPs O 
and O 
circulating O 
DBP O 
. O 
Genetic O 
variants O 
in O 
GC O 
differed O 
by O 
self O 
- O 
reported O 
ancestry O 
. O 
The O 
1f O 
allele O 
( O 
D432 O 
/ O 
T436 O 
) O 
was O 
enriched O 
in O 
African O 
Americans O 
, O 
occurring O 
in O 
71% O 
. O 
Homozygosity O 
for O 
the O 
1f O 
allele O 
( O 
DDTT O 
) O 
occurred O 
in O 
53% O 
of O 
African O 
Americans O 
but O 
only O 
6% O 
of O 
Caucasians O 
and O 
13% O 
of O 
Hispanics O 
. O 
Circulating O 
DBP O 
was O 
significantly O 
correlated O 
with O 
25-OHD B-SYSTEMATIC 
. O 
GC O 
SNPs O 
were O 
associated O 
with O 
both O 
circulating O 
DBP O 
and O 
25-OHD B-SYSTEMATIC 
. O 
It O 
appears O 
that O 
progressive O 
substitution O 
of O 
lysine B-TRIVIAL 
for O 
threonine B-TRIVIAL 
at O 
the O 
436 O 
position O 
results O 
in O 
lower O 
circulating O 
25-OHD B-SYSTEMATIC 
. O 
Multivariate O 
analysis O 
revealed O 
that O 
genetic O 
variance O 
in O 
GC O 
significantly O 
contributes O 
to O 
circulating O 
DBP O 
as O 
well O 
as O 
25-OHD B-SYSTEMATIC 
. O 
Moreover O 
, O 
the O 
effect O 
of O 
GC O 
SNPs O 
on O 
25-OHD B-SYSTEMATIC 
are O 
evident O 
after O 
adjusting O 
for O 
their O 
effects O 
on O 
circulating O 
DBP O 
. O 
Thus O 
in O 
young O 
children O 
genetic O 
variance O 
of O 
the O 
common O 
GC O 
T436K O 
SNP O 
affects O 
circulating O 
levels O 
of O 
the O 
DBP O 
protein O 
, O 
which O 
in O 
turn O 
affects O 
circulating O 
25-OHD B-SYSTEMATIC 
. O 
However O 
, O 
the O 
GC O 
genotype O 
also O 
affects O 
circulating O 
25-OHD B-SYSTEMATIC 
independently O 
of O 
its O 
effect O 
on O 
circulating O 
DBP O 
. O 
These O 
findings O 
provide O 
data O 
that O 
may O 
be O 
important O 
in O 
the O 
interpretation O 
of O 
vitamin O 
D O 
status O 
in O 
children O 
of O 
varying O 
ancestral O 
backgrounds O 
. O 

the O 
chemical O 
reactivity O 
of O 
an O 
ultimate O 
carcinogen O 
be O 
related O 
to O 
its O 
carcinogenicity O 
? O 
An O 
application O 
to O 
propylene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
. O 

this O 
article O 
we O 
report O 
calculations O 
of O 
the O 
activation O 
free O 
energy O 
for O 
a O 
chemical O 
reaction O 
between O 
propylene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
DNA O 
, O 
in O 
particular O 
with O 
the O 
guanine B-TRIVIAL 
at O 
the O 
N7 O 
position O 
. O 
Calculations O 
were O 
performed O 
using O 
Hartree-Fock O 
and O 
MP2 O 
methods O 
in O 
conjunction O 
with O 
flexible O 
basis O 
sets O 
. O 
The O 
effects O 
of O 
solvation O 
were O 
considered O 
using O 
the O 
Langevin O 
dipoles O 
and O 
solvent O 
reaction O 
field O 
methods O 
. O 
The O 
calculated O 
activation O 
free O 
energies O 
are O 
in O 
good O 
agreement O 
with O 
the O 
experimental O 
value O 
of O 
25.36 O 
kcal O 
/ O 
mol O 
. O 
Moreover O 
, O 
the O 
reactivities O 
of O 
a O 
series O 
of O 
ultimate O 
carcinogens O 
of O 
the O 
epoxy B-SYSTEMATIC 
type O 
toward O 
DNA O 
are O 
shown O 
to O 
be O 
related O 
to O 
their O 
carcinogenicities O 
. O 
Higher O 
reactivity O 
is O 
generally O 
associated O 
with O 
higher O 
carcinogenicity O 
, O 
although O 
transport O 
properties O 
, O 
reactions O 
with O 
ultimate O 
carcinogen O 
scavengers O 
, O 
and O 
the O 
DNA O 
correction O 
mechanism O 
are O 
also O 
very O 
important O 
. O 
It O 
is O 
very O 
likely O 
that O 
the O 
window O 
of O 
reactivity O 
rather O 
than O 
a O 
high O 
reactivity O 
value O 
is O 
the O 
relevant O 
measure O 
of O 
carcinogenicity O 
, O 
since O 
highly O 
reactive O 
ultimate O 
carcinogens O 
interact O 
with O 
water O 
and O 
proteins O 
before O 
they O 
reach O 
DNA O 
. O 

role O 
of O 
long O 
chain O 
omega-3 B-FAMILY 
polyunsaturated I-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
in O 
reducing O 
lipid O 
peroxidation O 
among O 
elderly O 
patients O 
with O 
mild O 
cognitive O 
impairment O 
: O 
a O 
case O 
- O 
control O 
study O 
. O 

present O 
work O 
explores O 
the O 
effect O 
of O 
dietary O 
omega-3 B-FAMILY 
polyunsaturated I-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
PUFAs B-ABBREVIATION 
) O 
intake O 
on O 
lipid O 
peroxidation O 
among O 
mild O 
cognitive O 
impairment O 
( O 
MCI O 
) O 
patients O 
. O 
The O 
plasma O 
lipid O 
hydroperoxide B-FAMILY 
( O 
LPO O 
) O 
levels O 
in O 
67 O 
MCI O 
patients O 
were O 
compared O 
to O 
those O 
of O 
134 O 
healthy O 
elderly O 
controls O 
. O 
Omega-3 B-FAMILY 
PUFA I-FAMILY 
intake O 
was O 
assessed O 
using O 
an O 
interviewer O 
- O 
administered O 
food O 
frequency O 
questionnaire O 
. O 
Apolipoprotein O 
E O 
genotyping O 
was O 
performed O 
using O 
polymerase O 
chain O 
reaction O 
and O 
restriction O 
enzyme O 
digestion O 
. O 
The O 
association O 
between O 
various O 
confounders O 
and O 
lipid O 
peroxidation O 
was O 
evaluated O 
using O 
regression O 
analysis O 
. O 
The O 
influence O 
of O 
docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DHA B-ABBREVIATION 
) O 
and O 
eicosapentaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
EPA B-ABBREVIATION 
) O 
intake O 
on O 
LPO O 
level O 
was O 
investigated O 
. O 
The O 
results O 
revealed O 
that O 
LPO O 
levels O 
were O 
significantly O 
higher O 
in O 
the O 
MCI O 
group O 
than O 
in O 
the O 
control O 
group O 
. O 
Inverse O 
correlations O 
were O 
found O 
between O 
DHA B-ABBREVIATION 
and O 
EPA B-ABBREVIATION 
intake O 
and O 
LPO O 
level O 
among O 
the O 
MCI O 
group O 
. O 
LPO O 
levels O 
decreased O 
significantly O 
with O 
increasing O 
DHA B-ABBREVIATION 
and O 
EPA B-ABBREVIATION 
intake O 
. O 
In O 
summary O 
, O 
the O 
findings O 
revealed O 
that O 
DHA B-ABBREVIATION 
and O 
EPA B-ABBREVIATION 
can O 
play O 
a O 
role O 
in O 
alleviating O 
oxidative O 
stress O 
and O 
reducing O 
the O 
risk O 
of O 
neurodegenerative O 
diseases O 
. O 

resistance O 
- O 
associated O 
proteins O 
are O 
involved O 
in O 
the O 
transport O 
of O 
the O 
glutathione B-TRIVIAL 
conjugates O 
of O 
the O 
ultimate O 
carcinogen O 
of O 
benzo[a]pyrene B-SYSTEMATIC 
in O 
human O 
Caco-2 O 
cells O 
. O 

wide O 
variety O 
of O 
contaminants O 
are O 
ingested O 
through O 
food O 
, O 
among O 
them O 
the O 
pro O 
- O 
carcinogenic O 
polycyclic O 
aromatic O 
hydrocarbon O 
benzo[a]pyrene B-SYSTEMATIC 
( O 
BP O 
) O 
that O 
is O 
resorbed O 
and O 
partially O 
metabolized O 
in O 
the O 
enterocytes O 
of O 
the O 
small O 
intestine O 
. O 
Previous O 
in O 
vitro O 
studies O 
have O 
revealed O 
that O 
BP B-FAMILY 
phenols I-FAMILY 
are O 
excreted O 
as O 
Phase O 
II O 
metabolites O 
including O 
glucuronides O 
and O 
sulfates B-FAMILY 
. O 
This O 
export O 
is O 
mediated O 
by O 
the O 
breast O 
cancer O 
resistance O 
protein O 
( O 
ABCG2 O 
) O 
. O 
The O 
ultimate O 
carcinogenic O 
Phase O 
I O 
BP O 
metabolite O 
anti- O 
BP-7,8-dihydrodiol-9,10-epoxide B-SYSTEMATIC 
( O 
BPDE B-ABBREVIATION 
) O 
can O 
be O 
detoxified O 
by O 
glutathione B-TRIVIAL 
conjugate O 
formation O 
catalyzed O 
by O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferases O 
. O 
In O 
the O 
present O 
study O 
, O 
differentiated O 
human O 
intestinal O 
Caco-2 O 
cells O 
were O 
used O 
as O 
a O 
model O 
for O 
the O 
human O 
small O 
intestine O 
to O 
investigate O 
the O 
detoxification O 
of O 
BPDE B-ABBREVIATION 
and O 
excretion O 
of O 
stereoisomeric O 
glutathione B-TRIVIAL 
conjugates O 
in O 
the O 
presence O 
of O 
an O 
inhibitor O 
of O 
the O 
glutathione B-TRIVIAL 
-cleaving O 
enzyme O 
γ-glutamyl O 
transpeptidase O 
at O 
the O 
cell O 
surface O 
. O 
The O 
results O 
indicate O 
that O 
the O 
glutathione B-TRIVIAL 
conjugates O 
of O 
BPDE B-ABBREVIATION 
are O 
formed O 
and O 
excreted O 
mainly O 
to O 
the O 
apical O 
and O 
to O 
a O 
minor O 
extent O 
to O 
the O 
basolateral O 
side O 
of O 
polarized O 
Caco-2 O 
monolayers O 
. O 
Inhibition O 
studies O 
revealed O 
that O 
the O 
multidrug O 
resistance O 
- O 
associated O 
proteins O 
( O 
ABCCs O 
) O 
are O 
involved O 
in O 
the O 
transport O 
of O 
BPDE B-TRIVIAL 
glutathione I-TRIVIAL 
conjugates O 
. O 
Stable O 
ABCC1 O 
, O 
ABCC2 O 
and O 
ABCC3 O 
knockdown O 
cell O 
lines O 
were O 
generated O 
, O 
thus O 
making O 
it O 
possible O 
to O 
demonstrate O 
that O 
ABCC1 O 
mediates O 
the O 
basolateral O 
and O 
ABCC2 O 
the O 
apical O 
excretion O 
of O 
BPDE B-TRIVIAL 
glutathione I-TRIVIAL 
conjugates O 
. O 
In O 
conclusion O 
, O 
the O 
ultimate O 
carcinogen O 
BPDE B-ABBREVIATION 
is O 
detoxified O 
via O 
glutathione B-TRIVIAL 
conjugation O 
and O 
subsequently O 
excreted O 
by O 
Caco-2 O 
cells O 
in O 
both O 
apical O 
and O 
basolateral O 
directions O 
. O 
This O 
finding O 
is O 
equivalent O 
to O 
a O 
transport O 
into O 
feces O 
as O 
well O 
as O 
blood O 
system O 
in O 
the O 
in O 
vivo O 
situation O 
. O 

supplementation O 
increases O 
urinary O 
noradrenaline B-TRIVIAL 
and O 
testicular O 
testosterone B-TRIVIAL 
levels O 
and O 
decreases O 
plasma O 
corticosterone B-TRIVIAL 
level O 
in O 
rats O 
fed O 
high O 
- O 
protein O 
diet O 
. O 

effects O 
of O 
oleuropein B-TRIVIAL 
, O 
a O 
phenolic B-FAMILY 
compound O 
in O 
extra O 
virgin O 
olive O 
oil O 
, O 
on O 
protein O 
metabolism O 
were O 
investigated O 
by O 
measuring O 
testicular O 
testosterone B-TRIVIAL 
and O 
plasma O 
corticosterone B-TRIVIAL 
levels O 
in O 
rats O 
fed O 
diets O 
with O 
different O 
protein O 
levels O 
. O 
In O 
Experiment O 
1 O 
, O 
rats O 
were O 
fed O 
experimental O 
diets O 
with O 
different O 
protein O 
levels O 
( O 
40 O 
, O 
25 O 
and O 
10 O 
g O 
/ O 
100 O 
g O 
casein O 
) O 
with O 
or O 
without O 
0.1 O 
g O 
/ O 
100 O 
g O 
oleuropein B-TRIVIAL 
. O 
After O 
28 O 
days O 
of O 
feeding O 
, O 
the O 
testosterone B-TRIVIAL 
level O 
in O 
the O 
testis O 
was O 
significantly O 
higher O 
and O 
the O 
plasma O 
corticosterone B-TRIVIAL 
level O 
was O 
significantly O 
lower O 
in O 
rats O 
fed O 
the O 
40% O 
casein O 
diet O 
with O 
oleuropein B-TRIVIAL 
than O 
in O 
those O 
fed O 
the O 
same O 
diet O 
without O 
oleuropein B-TRIVIAL 
. O 
The O 
urinary O 
noradrenaline B-TRIVIAL 
level O 
, O 
nitrogen B-SYSTEMATIC 
balance O 
and O 
hepatic O 
arginase O 
activity O 
were O 
significantly O 
higher O 
in O 
rats O 
fed O 
the O 
40% O 
casein O 
diet O 
with O 
oleuropein B-TRIVIAL 
supplementation O 
than O 
in O 
those O 
fed O 
the O 
40% O 
casein O 
diet O 
without O 
oleuropein B-TRIVIAL 
supplementation O 
. O 
In O 
Experiment O 
2 O 
, O 
the O 
effects O 
of O 
oleuropein B-TRIVIAL 
aglycone O 
( O 
a O 
major O 
phenolic B-FAMILY 
compound O 
in O 
extra O 
virgin O 
olive O 
oil O 
and O 
the O 
absorbed O 
form O 
of O 
oleuropein B-TRIVIAL 
ingested O 
in O 
the O 
gastrointestinal O 
tracts O 
) O 
on O 
the O 
secretion O 
of O 
luteinizing O 
hormone O 
( O 
LH O 
) O 
from O 
the O 
pituitary O 
gland O 
, O 
which O 
regulates O 
testosterone B-TRIVIAL 
production O 
in O 
the O 
testis O 
, O 
were O 
investigated O 
in O 
anesthetized O 
rats O 
. O 
Plasma O 
LH O 
level O 
increased O 
dose O 
dependently O 
after O 
the O 
administration O 
of O 
oleuropein B-TRIVIAL 
aglycone O 
( O 
P O 
< O 
0.001 O 
, O 
r=0.691 O 
) O 
. O 
These O 
findings O 
suggest O 
that O 
dietary O 
supplementation O 
with O 
0.1 O 
g O 
/ O 
100 O 
g O 
oleuropein B-TRIVIAL 
alters O 
the O 
levels O 
of O 
hormones O 
associated O 
with O 
protein O 
anabolism O 
by O 
increasing O 
urinary O 
noradrenaline B-TRIVIAL 
and O 
testicular O 
testosterone B-TRIVIAL 
levels O 
and O 
decreasing O 
plasma O 
corticosterone B-TRIVIAL 
level O 
in O 
rats O 
fed O 
a O 
high O 
- O 
protein O 
diet O 
. O 

rat O 
hepatocytes O 
are O 
widely O 
used O 
to O 
assess O 
the O 
metabolism O 
and O 
toxicity O 
of O 
xenobiotics O 
. O 
The O 
choice O 
of O 
digestion O 
enzyme O 
used O 
to O 
prepare O 
the O 
cells O 
has O 
been O 
shown O 
previously O 
to O 
influence O 
their O 
metabolic O 
capability O 
. O 
This O 
study O 
investigates O 
the O 
effect O 
of O 
the O 
digestion O 
enzyme O 
( O 
collagenase O 
II O 
, O 
collagenase O 
A O 
/ O 
trypsin O 
inhibitor O 
, O 
or O 
collagenase O 
plus O 
dispase O 
) O 
on O 
the O 
uptake O 
of O 
xenobiotics O 
into O 
, O 
and O 
efflux O 
from O 
, O 
hepatocytes O 
. O 
The O 
choice O 
of O 
digestion O 
enzymes O 
used O 
in O 
this O 
study O 
does O 
not O 
affect O 
uptake O 
of O 
either O 
pravastatin B-TRIVIAL 
( O 
an O 
organic O 
anion O 
probe O 
substrate O 
for O 
Oatp O 
transporter O 
) O 
or O 
metformin B-TRIVIAL 
( O 
an O 
organic O 
cation O 
probe O 
substrate O 
for O 
Oct O 
transporter O 
) O 
. O 
With O 
regard O 
to O 
efflux O 
transporters O 
, O 
hepatocyte O 
differentiation O 
was O 
better O 
maintained O 
when O 
cells O 
were O 
isolated O 
using O 
collagenase O 
II O 
alone O 
. O 

: O 
The O 
suitability O 
of O 
the O 
rabbit O 
as O 
an O 
animal O 
model O 
for O 
the O 
primary O 
screening O 
and O 
selection O 
of O 
the O 
pilot O 
scale O 
batches O 
during O 
the O 
early O 
stages O 
of O 
the O 
formulation O 
development O 
was O 
studied O 
. O 
Materials O 
and O 
methods O 
: O 
Three O 
modified O 
- O 
release O 
formulations O 
of O 
aminophylline B-TRIVIAL 
consisted O 
of O 
Carbopol B-TRIVIAL 
® O 
971P O 
/ O 
HPMC O 
K4M O 
( O 
F-I O 
) O 
, O 
and O 
HPMC O 
K100M O 
( O 
F-II O 
) O 
or O 
HPMC O 
K4M O 
( O 
F-III O 
) O 
were O 
used O 
. O 
Commercial O 
products O 
were O 
Aminofilin B-TRIVIAL 
retard O 
350 O 
mg O 
tablets O 
, O 
Srbolek O 
, O 
Serbia O 
( O 
R-I O 
) O 
and O 
Phyllocontin B-TRIVIAL 
( O 
® O 
) O 
350 O 
, O 
tablets O 
Purdue O 
Frederic O 
, O 
Canada O 
( O 
R-II O 
) O 
. O 
Results O 
: O 
Calculated O 
release O 
rate O 
constants O 
and O 
the O 
ƒ2 O 
values O 
between O 
R-I O 
/ O 
F-I O 
( O 
84.1 O 
) O 
and O 
R-II O 
/ O 
F-III O 
( O 
83.4 O 
) O 
indicated O 
similar O 
in O 
vitro O 
release O 
while O 
the O 
coefficient O 
n O 
showed O 
presence O 
of O 
different O 
mechanisms O 
of O 
release O 
from O 
Anomalous O 
transport O 
, O 
Fickian O 
diffusion O 
to O 
Case-II O 
transport O 
. O 
Higher O 
Tmax O 
, O 
was O 
found O 
in O 
the O 
rabbits O 
, O 
dosed O 
with O 
F-II O 
( O 
12 O 
h O 
) O 
, O 
F-III O 
( O 
10.5 O 
h O 
) O 
, O 
and O 
R-II O 
( O 
15 O 
h O 
) O 
formulation O 
. O 
The O 
highest O 
Cmax O 
( O 
9.22 O 
mg O 
/ O 
L O 
) O 
was O 
obtained O 
with O 
F-II O 
, O 
similar O 
lower O 
values O 
was O 
seen O 
for O 
F-I O 
and O 
F-III O 
, O 
while O 
commercial O 
products O 
showed O 
the O 
lowest O 
values O 
R-I O 
( O 
5.58 O 
mg O 
/ O 
L O 
) O 
and O 
R-II O 
( O 
4.18 O 
mg O 
/ O 
L O 
) O 
. O 
Higher O 
AUC O 
values O 
were O 
detected O 
for O 
all O 
three O 
formulations O 
( O 
from O 
115.9 O 
to O 
204.06 O 
mgh O 
/ O 
L O 
) O 
in O 
relation O 
to O 
commercial O 
products O 
( O 
105.33 O 
and O 
113.25 O 
mgh O 
/ O 
L O 
) O 
. O 
Discussion O 
and O 
conclusion O 
: O 
The O 
results O 
demonstrated O 
a O 
good O 
correlation O 
of O 
Level O 
A O 
( O 
r(2) O 
= O 
0.97 O 
) O 
for O 
the O 
two O 
formulations O 
( O 
F-I O 
, O 
F-III O 
) O 
and O 
commercial O 
product O 
( O 
R-I O 
) O 
indicates O 
that O 
there O 
is O 
a O 
reasonable O 
assumption O 
that O 
the O 
rabbit O 
might O 
be O 
use O 
as O 
a O 
model O 
for O 
the O 
preliminary O 
comparison O 
of O 
scale O 
up O 
formulations O 
in O 
the O 
early O 
stages O 
of O 
the O 
product O 
development O 
. O 

of O 
lead O 
and O 
mercuric B-SYSTEMATIC 
ions O 
on O 
the O 
interleukin-2-dependent O 
proliferation O 
and O 
survival O 
of O 
T O 
cells O 
. O 

and O 
lead O 
are O 
widespread O 
in O 
the O 
environment O 
, O 
causing O 
chronic O 
exposure O 
of O 
a O 
large O 
population O 
to O 
low O 
concentrations O 
of O 
these O 
metals O 
. O 
While O 
several O 
studies O 
demonstrated O 
that O 
low O 
levels O 
of O 
both O 
metals O 
affect O 
the O 
immune O 
system O 
, O 
little O 
is O 
known O 
about O 
underlying O 
molecular O 
mechanisms O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
impact O 
of O 
mercuric B-SYSTEMATIC 
( O 
Hg(2+) B-FORMULA 
) O 
and O 
lead O 
( O 
Pb(2+) B-FORMULA 
) O 
ions O 
on O 
T O 
cells O 
. O 
Up O 
to O 
100 O 
μM O 
Pb(NO(3))(2) B-FORMULA 
had O 
no O 
effect O 
on O 
cellular O 
viability O 
and O 
proliferation O 
. O 
In O 
contrast O 
, O 
HgCl(2) B-FORMULA 
caused O 
a O 
concentration O 
- O 
dependent O 
decline O 
of O 
viable O 
leukocytes O 
and O 
especially O 
of O 
activated O 
T O 
cells O 
. O 
Additionally O 
, O 
Hg(2+) B-FORMULA 
induced O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
generation O 
accompanied O 
by O 
the O 
loss O 
of O 
mitochondrial O 
transmembrane O 
potential O 
, O 
measured O 
by O 
Dihydrorhodamine B-SYSTEMATIC 
and O 
Rhodamine-123 B-TRIVIAL 
, O 
respectively O 
. O 
The O 
antioxidant O 
N-acetylcysteine B-SYSTEMATIC 
partially O 
reversed O 
the O 
toxic O 
effects O 
of O 
Hg(2+) B-FORMULA 
, O 
pointing O 
to O 
an O 
involvement O 
of O 
ROS O 
. O 
The O 
major O 
cytokine O 
controlling O 
T-cell O 
survival O 
and O 
proliferation O 
is O 
interleukin O 
(IL)-2 O 
. O 
Hg(2+) B-FORMULA 
had O 
no O 
effect O 
on O 
the O 
secretion O 
of O 
IL-2 O 
, O 
but O 
on O 
IL-2 O 
mediated O 
signal O 
transduction O 
pathways O 
, O 
reducing O 
phosphorylation O 
of O 
the O 
downstream O 
kinases O 
ERK1 O 
/ O 
2 O 
and O 
AKT O 
. O 
Moreover O 
, O 
Hg(2+) B-FORMULA 
led O 
to O 
an O 
arrest O 
of O 
the O 
cells O 
in O 
the O 
S O 
phase O 
of O 
the O 
cell O 
cycle O 
. O 
Taken O 
together O 
, O 
these O 
data O 
fit O 
a O 
model O 
in O 
which O 
Hg(2+) B-FORMULA 
disrupts O 
mitochondria O 
, O 
and O 
the O 
resulting O 
release O 
of O 
ROS O 
inhibits O 
IL-2-dependent O 
signal O 
transduction O 
, O 
reducing O 
proliferation O 
and O 
survival O 
of O 
T O 
cells O 
. O 

are O 
acidic O 
, O 
low O 
molecular O 
weight O 
metalloproteinases O 
( O 
Mr O 
of O 
23074.31 O 
Da O 
colombienase-1 O 
and O 
23078.8 O 
Da O 
colombienase-2 O 
; O 
pI O 
of O 
6 O 
and O 
6.2 O 
, O 
respectively O 
) O 
isolated O 
from O 
Bothrops O 
colombiensis O 
snake O 
venom O 
. O 
The O 
chromatographic O 
profile O 
in O 
RP-HPLC O 
and O 
its O 
partial O 
sequence O 
confirmed O 
its O 
high O 
homogeneity O 
. O 
Both O 
colombienases O 
present O 
fibrino(geno)lytic O 
activity O 
, O 
but O 
did O 
not O 
show O 
any O 
hemorrhagic O 
, O 
amidolytic O 
, O 
plasminogen O 
activator O 
or O 
coagulant O 
activities O 
, O 
and O 
no O 
effect O 
on O 
platelet O 
aggregation O 
induced O 
by O 
collagen O 
or O 
ADP B-ABBREVIATION 
. O 
Both O 
enzymes O 
were O 
strongly O 
active O 
on O 
fibrinogen O 
Aα O 
chains O 
followed O 
by O 
the O 
Bβ O 
chains O 
, O 
and O 
colombienases-2 O 
, O 
at O 
high O 
doses O 
, O 
also O 
degraded O 
the O 
γ O 
chains O 
. O 
This O 
activity O 
was O 
stable O 
at O 
temperatures O 
ranging O 
between O 
4 O 
and O 
37 O 
°C O 
, O 
with O 
a O 
maximum O 
activity O 
at O 
25 O 
°C O 
, O 
and O 
at O 
pHs O 
between O 
7 O 
and O 
9 O 
. O 
The O 
homology O 
demonstrated O 
by O 
the O 
comparison O 
of O 
sequences O 
, O 
with O 
zinc B-SYSTEMATIC 
-dependent O 
metalloproteinases O 
, O 
as O 
well O 
as O 
the O 
metal O 
chelant O 
effects O 
on O 
, O 
confirmed O 
that O 
the O 
colombienases O 
were O 
metalloproteinases O 
, O 
particularly O 
to O 
α-fibrinogenases O 
belonging O 
to O 
the O 
P-I O 
class O 
of O 
SVPMs O 
( O 
20-30 O 
kDa O 
) O 
, O 
which O 
contain O 
only O 
the O 
single O 
- O 
domain O 
proteins O 
. O 
The O 
biological O 
characteristics O 
of O 
the O 
colombienases O 
confer O 
a O 
therapeutic O 
potential O 
, O 
since O 
they O 
contain O 
a O 
high O 
fibrino(geno)lytic O 
activity O 
, O 
devoid O 
of O 
hemorrhagic O 
activity O 
. O 
These O 
metalloproteinases O 
might O 
be O 
explored O 
as O 
thrombolytic O 
agents O 
given O 
that O 
they O 
dissolve O 
fibrin O 
clots O 
or O 
prevent O 
their O 
formation O 
. O 

nerve O 
agents O 
irreversibly O 
inhibit O 
cholinesterases O 
. O 
Phosphylation O 
of O 
the O 
catalytic O 
serine B-TRIVIAL 
can O 
be O 
reversed O 
by O 
the O 
mean O 
of O 
powerful O 
nucleophiles O 
like O 
oximes B-FAMILY 
. O 
But O 
the O 
phosphyl O 
adduct O 
can O 
undergo O 
a O 
rapid O 
spontaneous O 
reaction O 
leading O 
to O 
an O 
aged O 
enzyme O 
, O 
i.e O 
. O 
, O 
a O 
conjugated O 
enzyme O 
that O 
is O 
no O 
longer O 
reactivable O 
by O 
oximes B-FAMILY 
. O 
One O 
strategy O 
to O 
regain O 
reactivability O 
is O 
to O 
alkylate O 
the O 
phosphylic O 
adduct O 
. O 
Specific O 
alkylating O 
molecules O 
were O 
synthesized O 
and O 
the O 
crystal O 
structures O 
of O 
the O 
complexes O 
they O 
form O 
with O 
soman B-TRIVIAL 
-aged O 
human O 
butyrylcholinesterase O 
were O 
solved O 
. O 
Although O 
the O 
compounds O 
bind O 
in O 
the O 
active O 
site O 
gorge O 
of O 
the O 
aged O 
enzyme O 
, O 
the O 
orientation O 
of O 
the O 
alkylating O 
function O 
appears O 
to O 
be O 
unsuitable O 
for O 
efficient O 
alkylation O 
of O 
the O 
phosphylic O 
adduct O 
. O 
However O 
, O 
these O 
crystal O 
structures O 
provide O 
key O 
information O 
to O 
design O 
efficient O 
alkylators O 
of O 
aged O 
- O 
butyrylcholinesterase O 
and O 
specific O 
reactivators O 
of O 
butyrylcholinesterase O 
. O 

anticholinesterase O 
( O 
antiChE O 
) O 
organophosphorus B-FAMILY 
( O 
OP O 
) O 
and O 
methylcarbamate B-SYSTEMATIC 
( O 
MC O 
) O 
insecticides O 
have O 
been O 
used O 
very O 
effectively O 
as O 
contact O 
and O 
systemic O 
plant O 
protectants O 
for O 
seven O 
decades O 
. O 
About O 
90 O 
of O 
these O 
compounds O 
are O 
still O 
in O 
use O 
- O 
the O 
largest O 
number O 
for O 
any O 
insecticide O 
chemotype O 
or O 
mode O 
of O 
action O 
. O 
In O 
both O 
insects O 
and O 
mammals O 
, O 
AChE O 
inhibition O 
and O 
acetylcholine B-SYSTEMATIC 
accumulation O 
leads O 
to O 
excitation O 
and O 
death O 
. O 
The O 
cholinergic O 
system O 
of O 
insects O 
is O 
located O 
centrally O 
( O 
where O 
it O 
is O 
protected O 
from O 
ionized O 
OPs O 
and O 
MCs O 
) O 
but O 
not O 
at O 
the O 
neuromuscular O 
junction O 
. O 
Structural O 
differences O 
between O 
insect O 
and O 
mammalian O 
AChE O 
are O 
also O 
evident O 
in O 
their O 
genomics O 
, O 
amino B-FAMILY 
acid I-FAMILY 
sequences O 
and O 
active O 
site O 
conformations O 
. O 
Species O 
selectivity O 
is O 
determined O 
in O 
part O 
by O 
inhibitor O 
and O 
target O 
site O 
specificity O 
. O 
Pest O 
population O 
selection O 
with O 
OPs O 
and O 
MCs O 
has O 
resulted O 
in O 
a O 
multitude O 
of O 
modified O 
AChEs O 
of O 
altered O 
inhibitor O 
specificity O 
some O 
conferring O 
insecticide O 
resistance O 
and O 
others O 
enhancing O 
sensitivity O 
. O 
Much O 
of O 
the O 
success O 
of O 
antiChE O 
insecticides O 
results O 
from O 
a O 
suitable O 
balance O 
of O 
bioactivation O 
and O 
detoxification O 
by O 
families O 
of O 
CYP450 O 
oxidases O 
, O 
hydrolases O 
, O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferases O 
and O 
others O 
. O 
Known O 
inhibitors O 
for O 
these O 
enzymes O 
block O 
detoxification O 
and O 
enhance O 
potency O 
which O 
is O 
particularly O 
important O 
in O 
resistant O 
strains O 
. O 
The O 
current O 
market O 
for O 
OPs O 
and O 
MCs O 
of O 
19% O 
of O 
worldwide O 
insecticide O 
sales O 
is O 
only O 
half O 
of O 
that O 
of O 
10years O 
ago O 
for O 
several O 
reasons O 
: O 
there O 
have O 
been O 
no O 
major O 
new O 
compounds O 
for O 
30years O 
; O 
resistance O 
has O 
eroded O 
their O 
effectiveness O 
; O 
human O 
toxicity O 
problems O 
are O 
still O 
encountered O 
; O 
the O 
patents O 
have O 
expired O 
reducing O 
the O 
incentive O 
to O 
update O 
registration O 
packages O 
; O 
alternative O 
chemotypes O 
or O 
control O 
methods O 
have O 
been O 
developed O 
. O 
Despite O 
this O 
decline O 
, O 
they O 
still O 
play O 
a O 
major O 
role O 
in O 
pest O 
control O 
and O 
the O 
increasing O 
knowledge O 
on O 
their O 
target O 
sites O 
and O 
metabolism O 
may O 
make O 
it O 
possible O 
to O 
redesign O 
the O 
inhibitors O 
for O 
insensitive O 
AChEs O 
and O 
to O 
target O 
new O 
sites O 
in O 
the O 
cholinergic O 
system O 
. O 
The O 
OPs O 
and O 
MCs O 
are O 
down O 
but O 
not O 
out O 
. O 

and O 
metabolism O 
of O 
[¹⁴C]PTZ601 B-SYSTEMATIC 
in O 
healthy O 
volunteers O 
. O 

. O 
Six O 
healthy O 
male O 
subjects O 
were O 
given O 
a O 
single O 
dose O 
of O 
500 O 
mg O 
of O 
[14C]PTZ601 B-SYSTEMATIC 
( O 
mean O 
radioactivity O 
79.2 O 
μCi O 
) O 
by O 
intravenous O 
(IV) O 
infusion O 
over O 
1 O 
h O 
, O 
and O 
observed O 
for O 
5 O 
days O 
post O 
- O 
dose O 
during O 
which O 
pharmacokinetic O 
( O 
PK O 
) O 
samples O 
were O 
collected O 
. O 
Plasma O 
PTZ601 B-IDENTIFIER 
concentrations O 
and O 
metabolite O 
identification O 
were O 
determined O 
using O 
LC-MS O 
/ O 
MS O 
; O 
PK O 
parameters O 
were O 
estimated O 
by O 
non-compartmental O 
analysis O 
. O 
Excretion O 
and O 
mass O 
balance O 
were O 
determined O 
with O 
liquid O 
scintillation O 
analysis O 
and O 
metabolites O 
profiling O 
was O 
characterized O 
by O 
HPLC O 
online O 
radiochemical O 
detection O 
. O 
2 O 
. O 
The O 
disposition O 
of O 
PTZ601 B-IDENTIFIER 
was O 
best O 
described O 
by O 
a O 
fast O 
absorption O 
, O 
followed O 
by O 
a O 
biphasic O 
elimination O 
phase O 
. O 
Peak O 
PTZ601 B-IDENTIFIER 
plasma O 
concentrations O 
were O 
reached O 
within O 
0.5-1 O 
h O 
. O 
The O 
mean O 
elimination O 
half O 
- O 
life O 
was O 
1.6 O 
h O 
and O 
clearance O 
was O 
13 O 
L O 
/ O 
h O 
. O 
3 O 
. O 
Recovery O 
of O 
the O 
radioactivity O 
dose O 
was O 
complete O 
( O 
mean O 
92% O 
) O 
. O 
The O 
main O 
route O 
of O 
excretion O 
( O 
parent O 
and O 
metabolites O 
) O 
was O 
the O 
renal O 
route O 
, O 
as O 
urine O 
accounted O 
for O 
69-77% O 
, O 
while O 
feces O 
only O 
13-22% O 
, O 
of O 
the O 
total O 
radioactivity O 
. O 
4 O 
. O 
The O 
majority O 
of O 
the O 
drug O 
was O 
excreted O 
in O 
urine O 
as O 
multiple O 
open O 
ring O 
metabolites O 
: O 
M17.3 O 
( O 
oxidative O 
ring O 
- O 
opened O 
product O 
) O 
and O 
M22.2 O 
( O 
di B-TRIVIAL 
- I-TRIVIAL 
cysteine I-TRIVIAL 
conjugate O 
of O 
17.3 O 
) O 
; O 
unchanged O 
PTZ601 B-IDENTIFIER 
in O 
urine O 
contributed O 
to O 
15% O 
of O 
radioactivity O 
. O 
The O 
major O 
metabolites O 
detected O 
in O 
plasma O 
were O 
M17.3 O 
, O 
M12.8 O 
( O 
acetylated O 
M17.3 O 
) O 
, O 
M22.2 O 
, O 
and O 
M41.4 O 
( O 
methylated O 
M17.3 O 
) O 
. O 
5 O 
. O 
PTZ601 B-IDENTIFIER 
was O 
well O 
tolerated O 
. O 

corticosterone B-TRIVIAL 
administration O 
reduces O 
dendritic O 
complexity O 
and O 
increases O 
the O 
density O 
of O 
mushroom O 
spines O 
of O 
hippocampal O 
CA3 O 
arbours O 
in O 
dams O 
. O 

depression O 
( O 
PPD O 
) O 
affects O 
approximately O 
15% O 
of O 
mothers O 
after O 
giving O 
birth O 
. O 
A O 
complete O 
understanding O 
of O 
depression O 
during O 
the O 
postpartum O 
period O 
has O 
yet O 
to O 
be O 
established O 
, O 
although O 
disruptions O 
in O 
the O 
hypothalamic O 
- O 
pituitary O 
- O 
adrenal O 
axis O 
and O 
stress O 
during O 
the O 
postpartum O 
may O 
be O 
involved O 
. O 
To O 
model O 
these O 
components O 
in O 
rats O 
, O 
we O 
administered O 
high O 
corticosterone B-TRIVIAL 
( O 
CORT B-ABBREVIATION 
) O 
postpartum O 
, O 
which O 
increases O 
immobility O 
in O 
the O 
forced O 
swim O 
test O 
( O 
FST O 
) O 
, O 
and O 
reduces O 
maternal O 
care O 
, O 
body O 
weight O 
and O 
hippocampal O 
cell O 
proliferation O 
in O 
dams O 
. O 
The O 
hippocampus O 
is O 
altered O 
in O 
response O 
to O 
chronic O 
stress O 
, O 
exposure O 
to O 
high O 
glucocorticoids O 
and O 
in O 
major O 
depression O 
in O 
humans O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
examined O 
whether O 
high O 
CORT B-ABBREVIATION 
reduced O 
dendritic O 
complexity O 
and O 
spines O 
in O 
the O 
CA3 O 
region O 
of O 
the O 
hippocampus O 
. O 
Additionally O 
, O 
housing O 
complexity O 
was O 
manipulated O 
so O 
that O 
dams O 
and O 
litters O 
were O 
housed O 
either O 
with O 
tubes O 
( O 
complex O 
) O 
or O 
without O 
tubes O 
( O 
impoverished O 
) O 
to O 
investigate O 
the O 
consequences O 
of O 
new O 
animal O 
care O 
regulations O 
. O 
Dams O 
received O 
40 O 
mg O 
/ O 
kg O 
/ O 
day O 
of O 
CORT B-ABBREVIATION 
or O 
oil O 
starting O 
on O 
day O 
2 O 
postpartum O 
for O 
23 O 
days O 
. O 
Maternal O 
behaviours O 
were O 
assessed O 
on O 
postpartum O 
days O 
2-8 O 
and O 
dams O 
were O 
tested O 
using O 
the O 
FST O 
on O 
days O 
21 O 
and O 
22 O 
. O 
Dams O 
were O 
killed O 
on O 
day O 
24 O 
and O 
brains O 
were O 
processed O 
for O 
Golgi O 
impregnation O 
. O 
Pyramidal O 
cells O 
in O 
the O 
CA3 O 
subfield O 
were O 
traced O 
using O 
a O 
camera O 
lucida O 
and O 
analysed O 
for O 
branch O 
points O 
and O 
dendritic O 
complexity O 
, O 
as O 
well O 
as O 
spine O 
density O 
and O 
type O 
on O 
both O 
basal O 
and O 
apical O 
arbours O 
. O 
As O 
previously O 
established O 
, O 
high O 
CORT B-ABBREVIATION 
postpartum O 
reduced O 
maternal O 
care O 
and O 
increased O 
immobility O 
in O 
the O 
FST O 
, O 
which O 
is O 
a O 
measure O 
of O 
depressive O 
- O 
like O 
behaviour O 
. O 
High O 
CORT B-ABBREVIATION 
postpartum O 
reduced O 
the O 
complexity O 
of O 
basal O 
arbours O 
and O 
increased O 
mushroom O 
spines O 
on O 
both O 
apical O 
and O 
basal O 
dendrites O 
. O 
Housing O 
complexity O 
had O 
no O 
effect O 
on O 
spines O 
of O 
CA3 O 
pyramidal O 
cells O 
but O 
modest O 
effects O 
on O 
cell O 
morphology O 
. O 
These O 
data O 
show O 
that O 
chronic O 
high O 
CORT B-ABBREVIATION 
in O 
postpartum O 
females O 
alters O 
hippocampal O 
morphology O 
and O 
may O 
provide O 
insight O 
regarding O 
the O 
neurobiological O 
consequences O 
of O 
high O 
stress O 
or O 
CORT B-ABBREVIATION 
during O 
the O 
postpartum O 
period O 
, O 
as O 
well O 
as O 
be O 
relevant O 
for O 
postpartum O 
stress O 
or O 
depression O 
. O 

of O 
anti- O 
cocaine B-TRIVIAL 
vaccine O 
and O 
viral O 
gene O 
transfer O 
of O 
cocaine B-TRIVIAL 
hydrolase O 
in O 
mice O 
on O 
cocaine B-TRIVIAL 
toxicity O 
including O 
motor O 
strength O 
and O 
liver O 
damage O 
. O 

developing O 
an O 
vivo O 
drug O 
- O 
interception O 
therapy O 
to O 
treat O 
cocaine B-TRIVIAL 
abuse O 
and O 
hinder O 
relapse O 
into O 
drug O 
seeking O 
provoked O 
by O 
re O 
- O 
encounter O 
with O 
cocaine B-TRIVIAL 
, O 
two O 
promising O 
agents O 
are O 
: O 
( O 
1 O 
) O 
a O 
cocaine B-TRIVIAL 
hydrolase O 
enzyme O 
( O 
CocH O 
) O 
derived O 
from O 
human O 
butyrylcholinesterase O 
and O 
delivered O 
by O 
gene O 
transfer O 
; O 
( O 
2 O 
) O 
an O 
anti- O 
cocaine B-TRIVIAL 
antibody O 
elicited O 
by O 
vaccination O 
. O 
Recent O 
behavioral O 
experiments O 
showed O 
that O 
antibody O 
and O 
enzyme O 
work O 
in O 
a O 
complementary O 
fashion O 
to O 
reduce O 
cocaine B-TRIVIAL 
-stimulated O 
locomotor O 
activity O 
in O 
rats O 
and O 
mice O 
. O 
Our O 
present O 
goal O 
was O 
to O 
test O 
protection O 
against O 
liver O 
damage O 
and O 
muscle O 
weakness O 
in O 
mice O 
challenged O 
with O 
massive O 
doses O 
of O 
cocaine B-TRIVIAL 
at O 
or O 
near O 
the O 
LD50 O 
level O 
( O 
100-120mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
. O 
We O 
found O 
that O 
, O 
when O 
the O 
interceptor O 
proteins O 
were O 
combined O 
at O 
doses O 
that O 
were O 
only O 
modestly O 
protective O 
in O 
isolation O 
( O 
enzyme O 
, O 
1mg O 
/ O 
kg O 
; O 
antibody O 
, O 
8mg O 
/ O 
kg O 
) O 
, O 
they O 
provided O 
complete O 
protection O 
of O 
liver O 
tissue O 
and O 
motor O 
function O 
. O 
When O 
the O 
enzyme O 
levels O 
were O 
∼400-fold O 
higher O 
, O 
after O 
in O 
vivo O 
transduction O 
by O 
adeno O 
- O 
associated O 
viral O 
vector O 
, O 
similar O 
protection O 
was O 
observed O 
from O 
CocH O 
alone O 
. O 

prolyl B-TRIVIAL 
-isomerase O 
Pin1 O 
activates O 
the O 
mitochondrial O 
death O 
program O 
of O 
p53 O 
. O 

response O 
to O 
intense O 
stress O 
, O 
the O 
tumor O 
protein O 
p53 O 
( O 
p53 O 
) O 
tumor O 
suppressor O 
rapidly O 
mounts O 
a O 
direct O 
mitochondrial O 
death O 
program O 
that O 
precedes O 
transcription O 
- O 
mediated O 
apoptosis O 
. O 
By O 
eliminating O 
severely O 
damaged O 
cells O 
, O 
this O 
pathway O 
contributes O 
to O 
tumor O 
suppression O 
as O 
well O 
as O 
to O 
cancer O 
cell O 
killing O 
induced O 
by O 
both O 
genotoxic O 
drugs O 
and O 
non-genotoxic O 
p53-reactivating O 
molecules O 
. O 
Here O 
we O 
have O 
explored O 
the O 
role O 
had O 
in O 
this O 
pathway O 
by O 
the O 
prolyl B-TRIVIAL 
-isomerase O 
Pin1 O 
( O 
peptidylprolyl O 
cis O 
/ O 
trans O 
isomerase O 
, O 
NIMA-interacting O 
1 O 
) O 
, O 
a O 
crucial O 
transducer O 
of O 
p53's O 
phosphorylation O 
into O 
conformational O 
changes O 
unleashing O 
its O 
pro O 
- O 
apoptotic O 
activity O 
. O 
We O 
show O 
that O 
Pin1 O 
promotes O 
stress O 
- O 
induced O 
localization O 
of O 
p53 O 
to O 
mitochondria O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
In O 
particular O 
, O 
we O 
demonstrate O 
that O 
upon O 
stress O 
- O 
induced O 
phosphorylation O 
of O 
p53 O 
on O 
Ser B-FORMULA 
46 O 
by O 
homeodomain O 
interacting O 
protein O 
kinase O 
2 O 
, O 
Pin1 O 
stimulates O 
its O 
mitochondrial O 
trafficking O 
signal O 
, O 
that O 
is O 
, O 
monoubiquitination O 
. O 
This O 
pathway O 
is O 
induced O 
also O 
by O 
the O 
p53-activating O 
molecule O 
RITA O 
, O 
and O 
we O 
demonstrate O 
the O 
strong O 
requirement O 
of O 
Pin1 O 
for O 
the O 
induction O 
of O 
mitochondrial O 
apoptosis O 
by O 
this O 
compound O 
. O 
These O 
findings O 
have O 
significant O 
implications O 
for O 
treatment O 
of O 
p53-expressing O 
tumors O 
and O 
for O 
prospective O 
use O 
of O 
p53-activating O 
compounds O 
in O 
clinics O 
. O 

nanotube O 
functionalization O 
with O 
carboxylic B-SYSTEMATIC 
derivatives O 
: O 
a O 
DFT O 
study O 
. O 

functionalization O 
of O 
a O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
( O 
CNT O 
) O 
with O 
different O 
carboxylic B-SYSTEMATIC 
derivatives O 
including O 
- O 
COOX B-FAMILY 
( O 
X= O 
H B-FORMULA 
, O 
CH3 B-FORMULA 
, O 
CH2NH2 B-FORMULA 
, O 
CH3Ph B-FORMULA 
, O 
CH2NO2 B-FORMULA 
, O 
and O 
CH2CN B-FORMULA 
) O 
has O 
been O 
theoretically O 
investigated O 
in O 
terms O 
of O 
geometric O 
, O 
energetic O 
, O 
and O 
electronic O 
properties O 
. O 
Reaction O 
energies O 
have O 
been O 
calculated O 
to O 
be O 
in O 
the O 
range O 
of O 
-0.23 O 
to O 
-7.07 O 
eV O 
. O 
The O 
results O 
reveal O 
that O 
the O 
reaction O 
energy O 
is O 
increased O 
by O 
increasing O 
the O 
electron O 
withdrawing O 
character O 
of O 
the O 
functional O 
groups O 
so O 
that O 
the O 
relative O 
magnitude O 
order O 
is O 
- O 
CH2NO2 B-FORMULA 
> O 
- O 
CH2CN B-FORMULA 
> O 
- O 
H B-FORMULA 
> O 
- O 
CH2Ph B-FORMULA 
> O 
- O 
CH3 B-FORMULA 
> O 
- O 
CH2NH2 B-FORMULA 
. O 
The O 
chemical O 
functionalization O 
leads O 
to O 
an O 
increase O 
in O 
HOMO O 
/ O 
LUMO O 
energy O 
gap O 
of O 
CNT O 
by O 
about O 
0.32 O 
to O 
0.35 O 
eV O 
( O 
except O 
for O 
- O 
H B-FORMULA 
) O 
. O 
LUMO O 
, O 
HOMO O 
, O 
and O 
Fermi O 
level O 
of O 
the O 
CNT O 
are O 
shifted O 
to O 
lower O 
energies O 
especially O 
in O 
the O 
case O 
of O 
- O 
CH2NO2 B-FORMULA 
and O 
- O 
CH2CN B-FORMULA 
functional O 
groups O 
. O 
Therefore O 
, O 
it O 
leads O 
to O 
an O 
increment O 
in O 
work O 
function O 
of O 
the O 
tube O 
, O 
impeding O 
the O 
field O 
electron O 
emission O 
. O 

promoted O 
one O 
- O 
pot O 
synthesis O 
of O 
2-amino-4,8-dihydropyrano[3,2-b]pyran-3-carbonitrile B-SYSTEMATIC 
scaffolds O 
in O 
aqueous O 
media O 
: O 
a O 
complementary O 
' O 
green O 
chemistry O 
' O 
tool O 
to O 
organic O 
synthesis O 
. O 

green O 
and O 
simple O 
approach O 
to O 
assembling O 
of O 
2-amino-4,8-dihydropyrano[3,2-b]pyran-3-carbonitrile B-SYSTEMATIC 
scaffolds O 
via O 
three O 
- O 
component O 
reaction O 
of O 
kojic B-TRIVIAL 
acid I-TRIVIAL 
, O 
malononitrile B-TRIVIAL 
, O 
and O 
aromatic B-FAMILY 
aldehydes I-FAMILY 
in O 
aqueous O 
media O 
under O 
ultrasound O 
irradiation O 
is O 
described O 
. O 
The O 
combinatorial O 
synthesis O 
was O 
achieved O 
for O 
this O 
methodology O 
with O 
applying O 
ultrasound O 
irradiation O 
while O 
making O 
use O 
of O 
water O 
as O 
green O 
solvent O 
. O 
In O 
comparison O 
to O 
conventional O 
methods O 
, O 
experimental O 
simplicity O 
, O 
good O 
functional O 
group O 
tolerance O 
, O 
excellent O 
yields O 
, O 
short O 
routine O 
, O 
and O 
selectivity O 
without O 
the O 
need O 
for O 
a O 
transition B-FAMILY 
metal I-FAMILY 
or O 
base O 
catalyst O 
are O 
prominent O 
features O 
of O 
this O 
green O 
procedure O 
. O 

transplantation O 
approaches O 
to O 
retinal B-TRIVIAL 
ganglion O 
cell O 
neuroprotection O 
in O 
glaucoma O 
. O 

is O 
a O 
complex O 
neurodegenerative O 
disease O 
that O 
involves O 
interactions O 
among O 
multiple O 
signaling O 
pathways O 
, O 
ultimately O 
leading O 
to O 
progressive O 
retinal B-TRIVIAL 
ganglion O 
cell O 
( O 
RGC O 
) O 
death O 
. O 
The O 
development O 
of O 
neuroprotective O 
approaches O 
to O 
glaucoma O 
therapy O 
could O 
preserve O 
vision O 
by O 
modulating O 
these O 
pathologic O 
pathways O 
or O 
by O 
acting O 
directly O 
on O 
RGCs O 
to O 
attenuate O 
cell O 
death O 
and O 
maintain O 
function O 
. O 
Intraocular O 
cell O 
transplantation O 
is O 
being O 
evaluated O 
as O 
one O 
approach O 
to O 
achieve O 
sustained O 
RGC O 
neuroprotection O 
. O 
Unlike O 
traditional O 
pharmacological O 
approaches O 
, O 
transplanted O 
cells O 
might O 
be O 
capable O 
of O 
simultaneously O 
targeting O 
multiple O 
pro O 
- O 
survival O 
pathways O 
via O 
local O 
delivery O 
of O 
secreted O 
factors O 
and O 
/ O 
or O 
via O 
modulation O 
of O 
the O 
intraocular O 
microenvironment O 
. O 
Elucidating O 
the O 
mechanisms O 
by O 
which O 
different O 
cell O 
types O 
attenuate O 
RGC O 
death O 
in O 
models O 
of O 
glaucoma O 
may O 
uncover O 
additional O 
novel O 
mechanisms O 
of O 
neuroprotection O 
. O 
In O 
this O 
review O 
, O 
we O 
will O 
discuss O 
the O 
rationale O 
for O 
transplantation O 
- O 
based O 
approaches O 
to O 
neuroprotection O 
for O 
glaucoma O 
and O 
explore O 
the O 
various O 
mechanisms O 
of O 
action O 
proposed O 
to O 
account O 
for O 
RGC O 
neuroprotection O 
achieved O 
by O 
two O 
distinct O 
cell O 
classes O 
that O 
have O 
been O 
studied O 
most O 
extensively O 
for O 
this O 
purpose O 
: O 
glial O 
cells O 
and O 
mesenchymal O 
stem O 
cells O 
. O 

and O 
autism O 
: O 
a O 
spectrum O 
of O 
opportunities O 
. O 

rodents O 
, O 
insufficient O 
adenosine B-TRIVIAL 
produces O 
behavioral O 
and O 
physiological O 
symptoms O 
consistent O 
with O 
several O 
comorbidities O 
of O 
autism O 
. O 
In O 
rodents O 
and O 
humans O 
, O 
stimuli O 
postulated O 
to O 
increase O 
adenosine B-TRIVIAL 
can O 
ameliorate O 
these O 
comorbidities O 
. O 
Because O 
adenosine B-TRIVIAL 
is O 
a O 
broad O 
homeostatic O 
regulator O 
of O 
cell O 
function O 
and O 
nervous O 
system O 
activity O 
, O 
increasing O 
adenosine B-TRIVIAL 
' O 
s O 
influence O 
might O 
be O 
a O 
new O 
therapeutic O 
target O 
for O 
autism O 
with O 
multiple O 
beneficial O 
effects O 
. O 
This O 
article O 
is O 
part O 
of O 
the O 
Special O 
Issue O 
entitled O 
' O 
Neurodevelopmental O 
Disorders' O 
. O 

syndrome O 
( O 
RTT O 
) O 
is O 
a O 
pervasive O 
developmental O 
disorder O 
, O 
primarily O 
affecting O 
girls O 
with O 
a O 
prevalence O 
of O 
1 O 
in O 
every O 
10000 O 
births O 
; O 
it O 
represents O 
the O 
second O 
most O 
common O 
cause O 
of O 
intellectual O 
disability O 
in O 
females O 
. O 
Mutations O 
in O 
the O 
gene O 
encoding O 
methyl B-SYSTEMATIC 
- O 
CpG B-ABBREVIATION 
-binding O 
protein O 
2 O 
( O 
MECP2 O 
) O 
have O 
been O 
identified O 
as O 
clear O 
etiological O 
factors O 
in O 
more O 
than O 
90% O 
of O 
classical O 
RTT O 
cases O 
. O 
Whereas O 
the O 
mechanisms O 
leading O 
to O 
the O 
severe O 
, O 
progressive O 
and O 
specific O 
neurological O 
dysfunctions O 
when O 
this O 
gene O 
is O 
mutated O 
still O 
remain O 
to O 
be O 
elucidated O 
, O 
a O 
series O 
of O 
different O 
mouse O 
models O 
have O 
been O 
generated O 
, O 
bearing O 
different O 
Mecp2 O 
mutation O 
. O 
Neurobehavioural O 
analysis O 
in O 
these O 
mouse O 
lines O 
have O 
been O 
carried O 
out O 
and O 
phenotyping O 
analysis O 
can O 
be O 
now O 
utilised O 
to O 
preclinically O 
evaluate O 
the O 
effects O 
of O 
potential O 
RTT O 
treatments O 
. O 
This O 
review O 
summarizes O 
the O 
different O 
results O 
achieved O 
in O 
this O 
research O 
field O 
taking O 
into O 
account O 
different O 
key O 
targets O 
identified O 
to O 
ameliorate O 
RTT O 
phenotype O 
in O 
mouse O 
models O 
, O 
including O 
those O 
not O 
directly O 
downstream O 
of O 
MeCP2 O 
and O 
those O 
limited O 
to O 
the O 
early O 
phases O 
of O 
postnatal O 
development O 
. O 
This O 
article O 
is O 
part O 
of O 
the O 
Special O 
Issue O 
entitled O 
' O 
Neurodevelopmental O 
Disorders' O 
. O 

evidence O 
shows O 
a O 
strong O 
, O 
bidirectional O 
comorbidity O 
between O 
depression O 
and O 
epilepsy O 
that O 
is O 
associated O 
with O 
decreased O 
quality O 
of O 
life O 
and O 
responsivity O 
to O 
pharmacotherapies O 
. O 
At O 
present O 
, O 
the O 
neurobiological O 
underpinnings O 
of O 
this O 
comorbidity O 
remain O 
hazy O 
. O 
To O 
complicate O 
matters O 
, O 
anticonvulsant O 
drugs O 
can O 
cause O 
mood O 
disturbances O 
, O 
while O 
antidepressant O 
drugs O 
can O 
lower O 
seizure O 
threshold O 
, O 
making O 
it O 
difficult O 
to O 
treat O 
patients O 
suffering O 
from O 
both O 
depression O 
and O 
epilepsy O 
. O 
Animal O 
models O 
have O 
been O 
created O 
to O 
untangle O 
the O 
mechanisms O 
behind O 
the O 
relationship O 
between O 
these O 
disorders O 
and O 
to O 
serve O 
as O 
screening O 
tools O 
for O 
new O 
therapies O 
targeted O 
to O 
treat O 
both O 
simultaneously O 
. O 
These O 
animal O 
models O 
are O 
based O 
on O 
chemical O 
interventions O 
( O 
e.g O 
. O 
pentylenetetrazol B-TRIVIAL 
, O 
kainic B-TRIVIAL 
acid I-TRIVIAL 
, O 
pilocarpine B-TRIVIAL 
) O 
, O 
electrical O 
stimulations O 
( O 
e.g O 
. O 
kindling O 
, O 
electroshock O 
) O 
, O 
and O 
genetic O 
/ O 
selective O 
breeding O 
paradigms O 
( O 
e.g O 
. O 
genetically O 
epilepsy O 
- O 
prone O 
rats O 
( O 
GEPRs O 
) O 
, O 
genetic O 
absence O 
epilepsy O 
rat O 
from O 
Strasbourg O 
( O 
GAERS O 
) O 
, O 
WAG O 
/ O 
Rij O 
rats O 
, O 
swim O 
lo O 
- O 
active O 
rats O 
( O 
SwLo O 
) O 
) O 
. O 
Studies O 
on O 
these O 
animal O 
models O 
point O 
to O 
some O 
potential O 
mechanisms O 
that O 
could O 
explain O 
epilepsy O 
and O 
depression O 
comorbidity O 
, O 
such O 
as O 
various O 
components O 
of O 
the O 
dopaminergic O 
, O 
noradrenergic O 
, O 
serotonergic O 
, O 
and O 
GABAergic O 
systems O 
, O 
as O 
well O 
as O 
key O 
brain O 
regions O 
, O 
like O 
the O 
amygdala O 
and O 
hippocampus O 
. O 
These O 
models O 
have O 
also O 
been O 
used O 
to O 
screen O 
possible O 
therapies O 
. O 
The O 
purpose O 
of O 
the O 
present O 
review O 
is O 
to O 
highlight O 
the O 
importance O 
of O 
animal O 
models O 
in O 
research O 
on O 
comorbid O 
epilepsy O 
and O 
depression O 
and O 
to O 
explore O 
the O 
contributions O 
of O 
these O 
models O 
to O 
our O 
understanding O 
of O 
the O 
mechanisms O 
and O 
potential O 
treatments O 
for O 
these O 
disorders O 
. O 

plays O 
an O 
important O 
role O 
in O 
the O 
genesis O 
and O 
progression O 
of O 
diabetes O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
effect O 
of O 
resistance O 
training O 
on O 
serum O 
levels O 
of O 
some O 
inflammatory O 
markers O 
associated O 
with O 
diabetes O 
mellitus O 
. O 
Twenty O 
- O 
four O 
male O 
Wistar O 
rats O 
( O 
290 O 
± O 
19 O 
g O 
) O 
were O 
randomly O 
divided O 
into O 
three O 
groups O 
: O 
non-diabetic O 
control O 
( O 
non-DC O 
) O 
, O 
diabetic O 
control O 
( O 
DC O 
) O 
, O 
and O 
diabetic O 
trained O 
( O 
DT O 
) O 
. O 
Animals O 
in O 
DT O 
group O 
were O 
subjected O 
to O 
a O 
resistance O 
training O 
program O 
with O 
the O 
use O 
of O 
a O 
ladder O 
( O 
3 O 
days O 
/ O 
week O 
, O 
for O 
4 O 
weeks O 
) O 
. O 
Body O 
weight O 
, O 
serum O 
high O 
sensitivity O 
C-reactive O 
protein O 
( O 
hs-CRP O 
) O 
, O 
interleukin O 
(IL)-6 O 
, O 
tumor O 
necrosis O 
factor O 
(TNF)-α O 
, O 
fasting O 
glucose B-TRIVIAL 
, O 
and O 
insulin O 
were O 
measured O 
. O 
Four O 
weeks O 
of O 
resistance O 
training O 
decreased O 
serum O 
levels O 
of O 
TNF-α O 
, O 
hs-CRP O 
, O 
and O 
IL-6 O 
in O 
diabetic O 
rats O 
when O 
compared O 
with O 
DC O 
animals O 
. O 
We O 
conclude O 
that O 
resistance O 
training O 
with O 
appropriate O 
intensity O 
, O 
duration O 
, O 
and O 
recovery O 
between O 
exercise O 
bouts O 
has O 
marked O 
anti-inflammatory O 
effects O 
on O 
diabetic O 
rats O 
. O 
This O 
may O 
be O 
an O 
efficient O 
strategy O 
to O 
protect O 
against O 
some O 
diabetic O 
complications O 
. O 

the O 
Galβ1-4Gal O 
epitope O 
is O 
rarely O 
found O 
in O 
mammalian O 
glycans O 
, O 
it O 
has O 
been O 
found O 
in O 
glycans O 
of O 
various O 
species O 
of O 
non-mammalian O 
vertebrates O 
, O 
such O 
as O 
fish O 
, O 
amphibians O 
and O 
birds O 
. O 
Although O 
glycans O 
containing O 
Galβ1-4Gal O 
in O 
these O 
vertebrates O 
were O 
detected O 
by O 
precise O 
structural O 
analysis O 
of O 
the O 
glycans O 
using O 
mass O 
spectrometry O 
and O 
/ O 
or O 
NMR O 
spectrometry O 
, O 
there O 
are O 
no O 
convenient O 
methods O 
to O 
detect O 
Galβ1-4Gal O 
from O 
various O 
samples O 
. O 
To O 
analyze O 
systematically O 
the O 
distribution O 
of O 
Galβ1-4Gal O 
in O 
nature O 
, O 
we O 
generated O 
mouse O 
monoclonal O 
antibodies O 
( O 
mAbs O 
) O 
specific O 
for O 
Galβ1-4Gal O 
using O 
extracts O 
of O 
medaka O 
eggs O 
as O 
an O 
immunogen O 
. O 
Four O 
mAbs O 
( O 
two O 
immunoglobulin O 
(Ig)Ms O 
and O 
two O 
IgG1s O 
) O 
were O 
obtained O 
by O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
- O 
based O 
screening O 
. O 
The O 
specificities O 
of O 
these O 
mAbs O 
were O 
evaluated O 
by O 
frontal O 
affinity O 
chromatography O 
using O 
142 O 
kinds O 
of O 
2-aminopyridine B-SYSTEMATIC 
(PA)-derivatized O 
oligosaccharides O 
. O 
While O 
all O 
mAbs O 
interacted O 
with O 
( O 
Galβ1-4Gal O 
) O 
- O 
containing O 
oligosaccharides O 
at O 
their O 
non-reducing O 
termini O 
with O 
dissociation O 
constants O 
(K(d)) O 
ranging O 
from O 
1 O 
x O 
10⁻⁵ O 
to O 
2.8 O 
x O 
10⁻⁴ O 
M O 
, O 
no O 
apparent O 
interaction O 
was O 
observed O 
with O 
any O 
other O 
glycans O 
. O 
The O 
number O 
of O 
branches O 
containing O 
Galβ1-4Gal O 
on O 
N B-FORMULA 
-glycans O 
did O 
not O 
significantly O 
affect O 
K(d) O 
of O 
mAbs O 
of O 
IgG1 O 
subclasses O 
, O 
but O 
those O 
of O 
IgM O 
mAbs O 
were O 
decreased O 
by O 
∼1 O 
order O 
of O 
magnitude O 
, O 
in O 
increments O 
of O 
the O 
number O 
of O 
branches O 
present O 
. O 
Using O 
the O 
mAbs O 
, O 
we O 
established O 
that O 
Galβ1-4Gal O 
is O 
also O 
expressed O 
on O 
glycoproteins O 
in O 
various O 
tissues O 
from O 
the O 
African O 
clawed O 
frog O 
. O 
Immunohistochemical O 
staining O 
of O 
medaka O 
sections O 
revealed O 
that O 
Galβ1-4Gal O 
epitopes O 
were O 
expressed O 
in O 
the O 
endothelium O 
, O 
epithelium O 
and O 
epidermis O 
, O 
which O 
directly O 
contact O 
the O 
external O 
environment O 
or O 
invading O 
organisms O 
. O 
Thus O 
, O 
these O 
mAbs O 
are O 
useful O 
for O 
systematically O 
investigating O 
the O 
species O 
- O 
specific O 
expression O 
of O 
glycans O 
, O 
which O 
may O 
act O 
as O 
a O 
barrier O 
against O 
infection O 
. O 

induces O 
apoptosis O 
in O 
neuroblastoma O 
cells O 
by O 
raising O 
the O 
intracellular O 
copper B-SYSTEMATIC 
level O 
, O 
triggering O 
cytochrome O 
c O 
release O 
and O 
caspase O 
activation O 
. O 

are O 
nitrogen B-SYSTEMATIC 
- O 
and O 
sulfur B-SYSTEMATIC 
-containing O 
compounds O 
commonly O 
used O 
in O 
pharmacology O 
, O 
medicine O 
and O 
agriculture O 
. O 
The O 
molecular O 
effects O 
of O 
dithiocarbamates B-FAMILY 
on O 
neuronal O 
cell O 
systems O 
are O 
not O 
fully O 
understood O 
, O 
especially O 
in O 
terms O 
of O 
their O 
ability O 
to O 
accumulate O 
copper B-SYSTEMATIC 
ions O 
inside O 
the O 
cell O 
. O 
In O 
this O 
work O 
, O 
the O 
molecular O 
effects O 
of O 
N,N-diethyldithiocarbamate B-SYSTEMATIC 
( O 
DEDTC B-ABBREVIATION 
) O 
were O 
studied O 
in O 
human O 
SH-SY5Y O 
neuroblastoma O 
cells O 
to O 
determine O 
the O 
role O 
of O 
copper B-SYSTEMATIC 
in O 
the O 
DEDTC B-ABBREVIATION 
toxicity O 
and O 
the O 
pathway O 
trigged O 
in O 
cell O 
by O 
the O 
complex O 
Cu-DEDTC B-FORMULA 
. O 
From O 
concentration O 
- O 
dependent O 
studies O 
, O 
we O 
found O 
that O 
5 O 
μM O 
of O 
this O 
compound O 
induced O 
a O 
drastic O 
decrease O 
in O 
viable O 
cells O 
with O 
a O 
concomitant O 
accumulation O 
in O 
intracellular O 
copper B-SYSTEMATIC 
resulted O 
from O 
complexation O 
with O 
DEDTC B-ABBREVIATION 
, O 
measured O 
by O 
atomic O 
absorption O 
spectroscopy O 
. O 
The O 
mechanism O 
of O 
DEDTC B-ABBREVIATION 
-induced O 
apoptosis O 
in O 
neuronal O 
model O 
cells O 
is O 
thought O 
to O 
occur O 
through O 
the O 
death O 
receptor O 
signaling O 
triggered O 
by O 
DEDTC-copper B-SYSTEMATIC 
complex O 
in O 
low O 
concentration O 
that O 
is O 
associated O 
with O 
the O 
activation O 
of O 
caspase O 
8 O 
. O 
Our O 
results O 
indicated O 
that O 
the O 
mechanism O 
of O 
cell O 
death O 
involves O 
cytochrome O 
c O 
release O 
forming O 
the O 
apoptosome O 
together O 
with O 
Apaf-1 O 
and O 
caspase O 
9 O 
, O 
converting O 
the O 
caspase O 
9 O 
into O 
its O 
active O 
form O 
, O 
allowing O 
it O 
to O 
activate O 
caspase O 
3 O 
as O 
observed O 
by O 
immunofluorescence O 
. O 
This O 
pathway O 
is O 
induced O 
by O 
the O 
cytotoxic O 
effects O 
that O 
occur O 
when O 
DEDTC B-ABBREVIATION 
forms O 
a O 
complex O 
with O 
the O 
copper B-SYSTEMATIC 
ions O 
present O 
in O 
the O 
culture O 
medium O 
and O 
transports O 
them O 
into O 
the O 
cell O 
, O 
suggesting O 
that O 
the O 
DEDTC B-ABBREVIATION 
by O 
itself O 
was O 
not O 
able O 
to O 
cause O 
cell O 
death O 
and O 
the O 
major O 
effect O 
is O 
from O 
its O 
copper B-SYSTEMATIC 
-complex O 
in O 
neuroblastoma O 
cells O 
. O 
The O 
present O 
study O 
suggests O 
a O 
role O 
for O 
the O 
influence O 
of O 
copper B-SYSTEMATIC 
by O 
low O 
concentrations O 
of O 
DEDTC B-ABBREVIATION 
in O 
the O 
extracellular O 
media O 
, O 
the O 
absorption O 
and O 
accumulation O 
of O 
copper B-SYSTEMATIC 
in O 
the O 
cell O 
and O 
apoptotic O 
events O 
, O 
induced O 
by O 
the O 
cytotoxic O 
effects O 
that O 
occur O 
when O 
DEDTC B-ABBREVIATION 
forms O 
a O 
complex O 
with O 
the O 
copper B-SYSTEMATIC 
ions O 
. O 

nanoparticle O 
- O 
induced O 
cytotoxicity O 
in O 
rat O 
brain O 
endothelial O 
cell O 
culture O 
. O 

nanoparticles O 
( O 
AgNPs O 
) O 
are O 
among O 
the O 
most O 
widely O 
commercialised O 
engineered O 
nanomaterials O 
, O 
because O 
of O 
their O 
antimicrobial O 
properties O 
. O 
They O 
are O 
already O 
commonly O 
used O 
in O 
medical O 
devices O 
, O 
household O 
products O 
and O 
industry O 
. O 
Concerns O 
have O 
been O 
raised O 
about O 
potential O 
adverse O 
health O 
effects O 
due O 
to O 
increasing O 
dispersion O 
of O 
AgNPs O 
in O 
the O 
environment O 
. O 
The O 
present O 
study O 
examined O 
the O 
cytotoxic O 
effects O 
of O 
spherical O 
, O 
citrate B-FAMILY 
-coated O 
AgNPs O 
( O 
10 O 
, O 
50 O 
and O 
100 O 
nm O 
) O 
in O 
rat O 
brain O 
endothelial O 
( O 
RBE4 O 
) O 
cells O 
and O 
investigated O 
whether O 
the O 
observed O 
effects O 
can O 
be O 
explained O 
by O 
the O 
intrinsic O 
toxicity O 
of O 
the O 
particles O 
or O 
the O 
silver B-SYSTEMATIC 
ions O 
released O 
from O 
the O 
particles O 
. O 
The O 
results O 
indicated O 
that O 
exposure O 
of O 
RBE4 O 
cells O 
to O 
AgNPs O 
lead O 
to O 
significant O 
reduction O 
in O 
dye O 
uptake O 
as O 
measured O 
with O 
the O 
Neutral B-TRIVIAL 
red I-TRIVIAL 
( O 
NR O 
) O 
assay O 
. O 
The O 
effect O 
was O 
found O 
to O 
be O 
related O 
to O 
particle O 
size O 
, O 
surface O 
area O 
, O 
dose O 
and O 
exposure O 
time O 
. O 
In O 
contrast O 
, O 
silver B-SYSTEMATIC 
ions O 
increased O 
NR O 
uptake O 
( O 
ca O 
. O 
10% O 
) O 
in O 
RBE4 O 
cells O 
after O 
1h O 
, O 
while O 
a O 
reduction O 
in O 
NR O 
uptake O 
was O 
observed O 
after O 
24h O 
exposure O 
at O 
high O 
concentrations O 
( O 
20-30 O 
μM O 
) O 
. O 
Colony O 
formation O 
, O 
as O 
an O 
indicator O 
of O 
proliferation O 
ability O 
, O 
was O 
completely O 
inhibited O 
by O 
AgNPs O 
at O 
concentrations O 
higher O 
than O 
1 O 
μg O 
/ O 
ml O 
. O 
Silver B-SYSTEMATIC 
ions O 
had O 
less O 
effect O 
on O 
the O 
colony O 
formation O 
of O 
RBE4 O 
cells O 
than O 
AgNPs O 
. O 

temporal O 
increase O 
of O 
hepatic O 
Hsp70 O 
in O 
ApoE O 
knockout O 
mice O 
after O 
prenatal O 
arsenic B-SYSTEMATIC 
exposure O 
. O 

arsenic B-SYSTEMATIC 
exposure O 
accelerates O 
atherosclerosis O 
in O 
ApoE(- O 
/ O 
- O 
) O 
mice O 
by O 
unknown O 
mechanism O 
. O 
Arsenic B-SYSTEMATIC 
is O 
a O 
hepatotoxicant O 
, O 
and O 
liver O 
disease O 
increases O 
atherosclerosis O 
risk O 
. O 
Prenatal O 
arsenic B-SYSTEMATIC 
exposure O 
may O 
predispose O 
to O 
liver O 
disease O 
by O 
priming O 
for O 
susceptibility O 
to O 
other O 
environmental O 
insults O 
. O 
Earlier O 
microarray O 
analyses O 
showed O 
prenatal O 
arsenic B-SYSTEMATIC 
exposure O 
increased O 
Hsc70 O 
( O 
HspA8 O 
) O 
and O 
Hsp70 O 
( O 
HspA1a O 
) O 
mRNAs O 
in O 
livers O 
of O 
10-week- O 
old O 
mice O 
. O 
We O 
determined O 
effects O 
of O 
prenatal O 
arsenic B-SYSTEMATIC 
exposure O 
on O 
hepatic O 
Hsp70 O 
and O 
Hsc70 O 
expression O 
by O 
Western O 
blot O 
and O 
on O 
DNA O 
methylation O 
by O 
methyl B-SYSTEMATIC 
acceptance O 
assay O 
during O 
prenatal O 
and O 
postnatal O 
development O 
. O 
Pregnant O 
ApoE(- O 
/ O 
- O 
) O 
mice O 
were O 
given O 
drinking O 
water O 
containing O 
85 O 
mg O 
/ O 
l O 
NaAsO(2) B-FORMULA 
( O 
49 O 
ppm O 
arsenic B-SYSTEMATIC 
) O 
from O 
gestation O 
day O 
( O 
GD O 
) O 
8 O 
to O 
18 O 
. O 
Hsp70 O 
and O 
Hsc70 O 
expression O 
and O 
DNA O 
methylation O 
were O 
determined O 
in O 
GD18 O 
fetuses O 
and O 
3- O 
, O 
10- O 
, O 
and O 
24-week- O 
old O 
mice O 
. O 
Hsc70 O 
expression O 
was O 
unchanged O 
at O 
all O 
ages O 
. O 
Hsp70 O 
induction O 
was O 
observed O 
at O 
3 O 
and O 
10 O 
weeks O 
, O 
but O 
was O 
unchanged O 
in O 
GD18 O 
fetuses O 
and O 
24-week O 
livers O 
of O 
mice O 
. O 
Global O 
DNA O 
methylation O 
increased O 
with O 
age O 
; O 
arsenic B-SYSTEMATIC 
had O 
no O 
effects O 
. O 
Bisulfite B-SYSTEMATIC 
sequencing O 
of O 
DNA O 
from O 
livers O 
of O 
10-week- O 
old O 
mice O 
showed O 
Hsp70 O 
promoter O 
region O 
methylation O 
was O 
unchanged O 
, O 
but O 
methylation O 
was O 
increased O 
within O 
the O 
transcribed O 
region O 
. O 
Hsf1 O 
and O 
Nrf2 O 
nuclear O 
translocation O 
were O 
investigated O 
as O 
potential O 
mechanisms O 
of O 
Hsp70 O 
induction O 
and O 
found O 
unaltered O 
. O 
Putative O 
binding O 
sites O 
were O 
identified O 
in O 
HSP70 O 
for O 
in O 
utero O 
arsenic B-SYSTEMATIC 
exposure O 
- O 
suppressed O 
microRNAs O 
suggesting O 
a O 
possible O 
mechanism O 
. O 
Thus O 
, O 
prenatal O 
arsenic B-SYSTEMATIC 
exposure O 
causes O 
delayed O 
temporal O 
hepatic O 
Hsp70 O 
induction O 
, O 
suggesting O 
a O 
transient O 
state O 
of O 
stress O 
in O 
livers O 
which O 
can O 
predispose O 
the O 
mice O 
to O 
developing O 
liver O 
disease O 
. O 

profile O 
of O 
small O 
- O 
molecule O 
IAP O 
antagonist O 
GDC-0152 B-IDENTIFIER 
is O 
linked O 
to O 
TNF-α O 
pharmacology O 
. O 

- O 
of O 
- O 
apoptosis O 
( O 
IAP O 
) O 
proteins O 
suppress O 
apoptosis O 
and O 
are O 
overexpressed O 
in O 
a O 
variety O 
of O 
cancers O 
. O 
Small O 
- O 
molecule O 
IAP O 
antagonists O 
are O 
currently O 
being O 
tested O 
in O 
clinical O 
trials O 
as O 
novel O 
cancer O 
therapeutics O 
. O 
GDC-0152 B-IDENTIFIER 
is O 
a O 
small O 
- O 
molecule O 
drug O 
that O 
triggers O 
tumor O 
cell O 
apoptosis O 
by O 
selectively O 
antagonizing O 
IAPs O 
. O 
GDC-0152 B-IDENTIFIER 
induces O 
NF-κB O 
transcriptional O 
activity O 
leading O 
to O 
expression O 
of O 
several O 
chemokines O 
and O 
cytokines O 
, O 
of O 
which O 
tumor O 
necrosis O 
factor O 
alpha O 
( O 
TNF-α O 
) O 
is O 
the O 
most O 
important O 
for O 
single O 
- O 
agent O 
tumor O 
activity O 
. O 
TNF-α O 
is O 
a O 
pleiotropic O 
cytokine O 
that O 
drives O 
a O 
variety O 
of O 
cellular O 
responses O 
, O 
comprising O 
inflammation O 
, O 
proliferation O 
, O 
and O 
cell O 
survival O 
or O 
death O 
depending O 
on O 
the O 
cellular O 
context O 
. O 
As O 
malignant O 
and O 
normal O 
cells O 
produce O 
TNF-α O 
upon O 
IAP O 
antagonism O 
, O 
increased O 
TNF-α O 
could O 
drive O 
both O 
efficacy O 
and O 
toxicity O 
. O 
The O 
toxicity O 
profile O 
of O 
GDC-0152 B-IDENTIFIER 
in O 
dogs O 
and O 
rats O 
was O 
characterized O 
after O 
iv O 
dose O 
administration O 
once O 
every O 
2 O 
weeks O 
for O 
four O 
doses O 
. O 
Findings O 
in O 
both O 
species O 
consisted O 
of O 
a O 
dose O 
- O 
related O 
, O 
acute O 
, O 
systemic O 
inflammatory O 
response O 
, O 
and O 
hepatic O 
injury O 
. O 
Laboratory O 
findings O 
included O 
elevated O 
plasma O 
cytokines O 
, O 
an O 
inflammatory O 
leukogram O 
, O 
and O 
increased O 
liver O 
transaminases O 
with O 
histopathological O 
findings O 
of O 
inflammatory O 
infiltrates O 
and O 
apoptosis O 
/ O 
necrosis O 
in O 
multiple O 
tissues O 
; O 
a O 
toxicology O 
profile O 
consistent O 
with O 
TNF-α O 
- O 
mediated O 
toxicity O 
. O 
Dogs O 
exhibited O 
more O 
severe O 
findings O 
than O 
rats O 
, O 
and O 
humans O 
did O 
not O 
exhibit O 
these O 
findings O 
, O 
at O 
comparable O 
exposures O 
across O 
species O 
. O 
Furthermore O 
, O 
elevations O 
in O 
blood O 
neutrophil O 
count O 
, O 
serum O 
monocyte O 
chemoattractant O 
protein-1 O 
, O 
and O 
other O 
markers O 
of O 
inflammation O 
corresponded O 
to O 
GDC-0152 B-IDENTIFIER 
exposure O 
and O 
toxicity O 
and O 
thus O 
may O 
have O 
utility O 
as O 
safety O 
biomarkers O 
. O 

of O 
interleukin-6-regulated O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
in O 
hemorrhagic O 
cystitis O 
and O 
impaired O 
bladder O 
contractions O 
in O 
young O 
rats O 
induced O 
by O 
acrolein B-TRIVIAL 
, O 
a O 
urinary O 
metabolite O 
of O 
cyclophosphamide B-TRIVIAL 
. O 

cystitis O 
is O 
a O 
common O 
complication O 
in O 
children O 
receiving O 
cyclophosphamide B-TRIVIAL 
, O 
a O 
chemotherapeutic O 
alkylating O 
agent O 
. O 
Acrolein B-TRIVIAL 
is O 
a O 
urinary O 
metabolite O 
from O 
cyclophosphamide B-TRIVIAL 
and O 
can O 
induce O 
hemorrhagic O 
cystitis O 
. O 
Here O 
, O 
we O 
investigated O 
the O 
effects O 
and O 
mechanisms O 
of O 
acrolein B-TRIVIAL 
by O 
intravesical O 
instillation O 
on O 
urinary O 
bladder O 
muscle O 
contractions O 
and O 
pathological O 
alterations O 
in O 
rats O 
. O 
Acrolein B-TRIVIAL 
instillation O 
significantly O 
increased O 
the O 
muscle O 
contractions O 
of O 
rat O 
bladder O 
detrusor O 
after O 
1 O 
and O 
6 O 
h O 
but O 
markedly O 
decreased O 
detrusor O 
contractions O 
after O 
24 O 
h O 
. O 
Acrolein B-TRIVIAL 
increased O 
phosphorylated O 
protein O 
kinase O 
C O 
( O 
pan-PKC O 
) O 
expressions O 
in O 
bladders O 
after O 
1 O 
and O 
6 O 
h O 
but O 
inhibited O 
it O 
after O 
24 O 
h O 
. O 
Inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
synthase O 
( O 
iNOS O 
) O 
protein O 
expressions O 
were O 
markedly O 
induced O 
in O 
bladders O 
24 O 
h O 
after O 
acrolein B-TRIVIAL 
treatment O 
. O 
Twenty O 
- O 
four O 
- O 
hour O 
acrolein B-TRIVIAL 
instillation O 
increased O 
the O 
levels O 
of O 
nitrite B-SYSTEMATIC 
/ O 
nitrate B-SYSTEMATIC 
and O 
interleukin-6 O 
( O 
IL-6 O 
) O 
in O 
the O 
urinary O 
bladder O 
. O 
The O 
iNOS O 
inhibitors O 
significantly O 
inhibited O 
the O 
acrolein B-TRIVIAL 
-increased O 
nitrite B-SYSTEMATIC 
/ O 
nitrate B-SYSTEMATIC 
levels O 
, O 
but O 
not O 
IL-6 O 
levels O 
. O 
IL-6-neutralizing O 
antibodies O 
effectively O 
inhibited O 
the O 
acrolein B-TRIVIAL 
-increased O 
NOx O 
levels O 
. O 
The O 
increased O 
detrusor O 
contractions O 
by O 
1-h O 
acrolein B-TRIVIAL 
treatment O 
were O 
significantly O 
reversed O 
by O 
the O 
PKC O 
inhibitor O 
RO32-0432 B-IDENTIFIER 
, O 
and O 
the O 
decreased O 
detrusor O 
contractions O 
by O 
24-h O 
acrolein B-TRIVIAL 
treatment O 
were O 
significantly O 
reversed O 
by O 
the O 
iNOS O 
inhibitor O 
and O 
IL-6-neutralizing O 
antibody O 
. O 
Both O 
the O 
iNOS O 
inhibitor O 
and O 
IL-6-neutralizing O 
antibody O 
effectively O 
reversed O 
the O 
increased O 
iNOS O 
expression O 
, O 
decreased O 
PKC O 
phosphorylation O 
, O 
increased O 
bladder O 
weight O 
, O 
and O 
hemorrhagic O 
cystitis O 
in O 
rats O 
24 O 
h O 
after O 
acrolein B-TRIVIAL 
treatment O 
. O 
Taken O 
together O 
, O 
these O 
results O 
suggest O 
that O 
an O 
IL-6-regulated O 
iNOS/ O 
NO B-FORMULA 
signaling O 
pathway O 
participates O 
in O 
the O 
acrolein B-TRIVIAL 
-triggered O 
detrusor O 
contraction O 
inhibition O 
and O 
hemorrhagic O 
cystitis O 
. O 
These O 
findings O 
may O 
help O 
us O 
to O 
find O 
a O 
new O 
strategy O 
to O 
treat O 
cyclophosphamide B-TRIVIAL 
-induced O 
hemorrhagic O 
cystitis O 
. O 

novel O 
reproductive O 
peptide O 
, O 
phoenixin B-NO_CLASS 
. O 

anterior O 
pituitary O 
function O 
is O 
essential O 
for O 
fertility O 
. O 
Release O 
from O 
the O 
gland O 
of O 
the O 
reproductive O 
hormones O 
luteinising O 
hormone O 
and O 
follicle O 
- O 
stimulating O 
hormone O 
is O 
regulated O 
primarily O 
by O 
hypothalamically O 
- O 
derived O 
gonadotrophin B-TRIVIAL 
- I-TRIVIAL 
releasing I-TRIVIAL 
hormone I-TRIVIAL 
( O 
GnRH B-ABBREVIATION 
) O 
, O 
although O 
other O 
releasing O 
factors O 
( O 
RF O 
) O 
have O 
been O 
postulated O 
to O 
exist O 
. O 
Using O 
a O 
bioinformatic O 
approach O 
, O 
we O 
have O 
identified O 
a O 
novel O 
peptide O 
, O 
phoenixin B-NO_CLASS 
, O 
that O 
regulates O 
pituitary O 
gonadotrophin O 
secretion O 
by O 
modulating O 
the O 
expression O 
of O 
the O 
GnRH B-ABBREVIATION 
receptor O 
, O 
an O 
action O 
with O 
physiologically O 
relevant O 
consequences O 
. O 
Compromise O 
of O 
phoenixin B-NO_CLASS 
in O 
vivo O 
using O 
small O 
interfering O 
RNA O 
resulted O 
in O 
the O 
delayed O 
appearance O 
of O 
oestrus O 
and O 
a O 
reduction O 
in O 
GnRH B-ABBREVIATION 
receptor O 
expression O 
in O 
the O 
pituitary O 
. O 
Phoenixin B-NO_CLASS 
may O 
represent O 
a O 
new O 
class O 
of O 
hypothalamically O 
- O 
derived O 
pituitary O 
priming O 
factors O 
that O 
sensitise O 
the O 
pituitary O 
to O 
the O 
action O 
of O 
other O 
RFs O 
, O 
rather O 
than O 
directly O 
stimulating O 
the O 
fusion O 
of O 
secretary O 
vesicles O 
to O 
pituitary O 
membranes O 
. O 

and O 
aligned O 
carbon B-SYSTEMATIC 
nanotube/ O 
titania B-TRIVIAL 
core O 
/ O 
shell O 
films O 
for O 
flexible O 
TCO-free O 
photoelectrodes O 
. O 

nanotube O 
( O 
CNT O 
) O 
/ O 
semiconducting O 
oxide B-SYSTEMATIC 
hybrids O 
are O 
an O 
ideal O 
architecture O 
for O 
light O 
- O 
harvesting O 
devices O 
, O 
in O 
which O 
the O 
CNTs O 
are O 
expected O 
to O 
not O 
only O 
act O 
as O 
a O 
scaffold O 
but O 
also O 
provide O 
fast O 
transport O 
paths O 
for O 
photogenerated O 
charges O 
in O 
the O 
oxide B-SYSTEMATIC 
. O 
However O 
, O 
the O 
current O 
potential O 
of O 
CNTs O 
for O 
charge O 
transport O 
is O 
largely O 
suppressed O 
due O 
to O 
the O 
nanotubes O 
not O 
being O 
interconnected O 
but O 
isolated O 
by O 
the O 
low O 
conductive O 
oxide B-SYSTEMATIC 
coatings O 
. O 
Herein O 
, O 
a O 
flexible O 
and O 
conductive O 
CNT/ O 
TiO(2) B-FORMULA 
core O 
/ O 
shell O 
heterostructure O 
film O 
is O 
reported O 
, O 
with O 
aligned O 
and O 
interconnected O 
CNTs O 
wrapped O 
in O 
a O 
continuous O 
TiO(2) B-FORMULA 
coating O 
. O 
Without O 
using O 
additional O 
transparent O 
conducting O 
oxide B-SYSTEMATIC 
( O 
TCO O 
) O 
substrates O 
, O 
this O 
unique O 
feature O 
of O 
the O 
film O 
boosts O 
the O 
incident O 
photon O 
- O 
to O 
- O 
electron O 
conversion O 
efficiency O 
to O 
32% O 
, O 
outperforming O 
TiO(2) B-FORMULA 
nanoparticle O 
electrodes O 
fabricated O 
on O 
TCO O 
substrates O 
. O 
Moreover O 
, O 
the O 
film O 
shows O 
high O 
structural O 
stability O 
and O 
can O 
generate O 
a O 
stable O 
photocurrent O 
even O 
after O 
being O 
bent O 
hundreds O 
of O 
times O 
. O 

core O 
cysteines B-FAMILY 
, O 
( O 
C909 O 
) O 
of O 
islet O 
antigen-2 O 
and O 
( O 
C945 O 
) O 
of O 
islet O 
antigen-2β O 
, O 
are O 
crucial O 
to O 
autoantibody O 
binding O 
in O 
type O 
1 O 
diabetes O 
. O 

are O 
thought O 
integral O 
to O 
conformational O 
epitopes O 
of O 
islet O 
antigen-2 O 
( O 
IA-2 O 
) O 
autoantibodies O 
( O 
IA-2A O 
) O 
, O 
possibly O 
through O 
disulfide B-SYSTEMATIC 
bond O 
formation O 
. O 
We O 
therefore O 
investigated O 
which O 
cysteines B-FAMILY 
are O 
critical O 
to O 
IA-2A O 
binding O 
in O 
patients O 
with O 
newly O 
diagnosed O 
type O 
1 O 
diabetes O 
. O 
All O 
10 O 
cysteines B-FAMILY 
in O 
the O 
intracellular O 
domain O 
of O 
IA-2 O 
were O 
modified O 
to O 
serine B-TRIVIAL 
by O 
site O 
- O 
directed O 
mutagenesis O 
, O 
and O 
the O 
effects O 
of O 
these O 
changes O 
on O 
autoantibody O 
binding O 
in O 
comparison O 
with O 
wild O 
- O 
type O 
control O 
were O 
investigated O 
by O 
radiobinding O 
assay O 
. O 
Mutation O 
of O 
the O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
( O 
PTP O 
) O 
core O 
cysteine B-TRIVIAL 
( O 
C909 O 
) O 
in O 
IA-2 O 
caused O 
large O 
reductions O 
in O 
autoantibody O 
binding O 
. O 
In O 
contrast O 
, O 
little O 
or O 
no O 
reduction O 
in O 
binding O 
was O 
seen O 
following O 
substitution O 
of O 
the O 
other O 
cysteines B-FAMILY 
. O 
Modification O 
of O 
the O 
core O 
cysteine B-TRIVIAL 
( O 
C945 O 
) O 
in O 
IA-2β O 
also O 
greatly O 
reduced O 
autoantibody O 
binding O 
. O 
Lysine B-TRIVIAL 
substitution O 
of O 
glutamate B-TRIVIAL 
-836 O 
in O 
IA-2 O 
or O 
glutamate B-TRIVIAL 
-872 O 
in O 
IA-2β O 
resulted O 
in O 
modest O 
reductions O 
in O 
binding O 
and O 
identified O 
a O 
second O 
epitope O 
region O 
. O 
Binding O 
to O 
IA-2 O 
PTP O 
and O 
IA-2β O 
PTP O 
was O 
almost O 
abolished O 
by O 
mutation O 
of O 
both O 
the O 
core O 
cysteine B-TRIVIAL 
and O 
these O 
glutamates B-FAMILY 
. O 
The O 
core O 
cysteine B-TRIVIAL 
is O 
key O 
to O 
the O 
major O 
PTP O 
conformational O 
epitope O 
, O 
but O 
disulfide O 
bonding O 
contributes O 
little O 
to O 
IA-2A O 
epitope O 
integrity O 
. O 
In O 
most O 
patients O 
, O 
at O 
disease O 
onset O 
, O 
> O 
90% O 
of O 
antibodies O 
binding O 
to O 
the O 
PTP O 
domain O 
of O 
IA-2 O 
recognize O 
just O 
two O 
epitope O 
regions O 
. O 

of O 
oestrogen B-FAMILY 
receptors O 
on O 
the O 
modulation O 
of O 
NADPH B-ABBREVIATION 
-diaphorase O 
- O 
positive O 
cell O 
number O 
in O 
supraoptic O 
and O 
paraventricular O 
nuclei O 
of O 
ovariectomised O 
female O 
rats O 
. O 

of O 
the O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
producing O 
system O 
( O 
demonstrated O 
via O 
the O 
NADPH B-ABBREVIATION 
-diaphorase O 
histochemical O 
reaction O 
) O 
by O 
oestradiol B-TRIVIAL 
has O 
been O 
established O 
in O 
several O 
structures O 
of O 
the O 
rat O 
brain O 
. O 
The O 
present O 
study O 
aimed O 
to O 
explore O 
the O 
possible O 
regulation O 
of O 
NADPH B-ABBREVIATION 
-diaphorase O 
activity O 
by O 
oestradiol B-TRIVIAL 
in O 
neurones O 
of O 
the O 
supraoptic O 
( O 
SON O 
) O 
and O 
paraventricular O 
( O 
PVN O 
) O 
nuclei O 
and O 
the O 
role O 
of O 
oestrogen B-FAMILY 
receptors O 
( O 
ERα O 
and O 
ERβ O 
) O 
in O 
this O 
regulation O 
. O 
Adult O 
ovariectomised O 
rats O 
were O 
divided O 
into O 
six O 
groups O 
and O 
injected O 
either O 
with O 
vehicle O 
or O 
a O 
single O 
dose O 
of O 
oestradiol B-TRIVIAL 
, O 
a O 
selective O 
ERα O 
agonist- O 
PPT B-ABBREVIATION 
[ O 
4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol B-SYSTEMATIC 
] O 
, O 
a O 
selective O 
ERβ O 
agonist- O 
DPN B-ABBREVIATION 
[ O 
2,3-bis(4-hydroxyphenyl)-propionitrile B-SYSTEMATIC 
] O 
, O 
a O 
selective O 
ERα O 
antagonist- O 
MPP B-ABBREVIATION 
[ O 
1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol B-SYSTEMATIC 
]- O 
1H-pyrazole B-SYSTEMATIC 
dihydrochloride I-SYSTEMATIC 
] O 
or O 
a O 
selective O 
ERβ O 
antagonist- O 
PHTPP B-ABBREVIATION 
( O 
4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol B-SYSTEMATIC 
) O 
. O 
The O 
number O 
of O 
NADPH B-ABBREVIATION 
-diaphorase O 
positive O 
elements O 
in O 
the O 
SON O 
and O 
the O 
PVN O 
was O 
modulated O 
by O 
both O 
ERs O 
but O 
, O 
depending O 
on O 
the O 
nucleus O 
, O 
ERα O 
and O 
ERβ O 
ligands O 
induced O 
different O 
effects O 
. O 
These O 
results O 
suggest O 
that O 
the O 
regulation O 
of O 
nitrergic O 
system O 
by O 
ERs O 
may O 
play O 
a O 
role O 
in O 
the O 
control O 
of O 
oestrogen B-FAMILY 
-dependent O 
physiological O 
mechanisms O 
regulated O 
by O 
the O 
SON O 
and O 
the O 
PVN O 
. O 

research O 
is O 
needed O 
to O 
discover O 
pharmacological O 
targets O 
and O 
treatments O 
for O 
the O 
diagnostic O 
behavioral O 
domains O 
of O 
autism O 
spectrum O 
disorders O 
. O 
Animal O 
models O 
with O 
phenotypic O 
relevance O 
to O 
diagnostic O 
criteria O 
offer O 
clear O 
experimental O 
strategies O 
to O 
test O 
the O 
efficacy O 
and O 
safety O 
of O 
novel O 
treatments O 
. O 
Antagonists O 
of O 
mGluR5 O 
receptors O 
are O 
in O 
clinical O 
trials O 
for O 
Fragile O 
X O 
syndrome O 
and O 
under O 
investigation O 
for O 
the O 
treatment O 
of O 
autism O 
spectrum O 
disorders O 
. O 
However O 
, O 
in O 
preclinical O 
studies O 
of O 
mGluR5 O 
compounds O 
tested O 
in O 
our O 
laboratory O 
and O 
others O 
, O 
increased O 
locomotion O 
following O 
mGluR5 O 
modulation O 
has O 
been O 
observed O 
. O 
Understanding O 
the O 
influence O 
of O 
general O 
activity O 
on O 
sociability O 
and O 
repetitive O 
behaviors O 
will O 
increase O 
the O 
accuracy O 
of O 
interpretations O 
of O 
positive O 
outcomes O 
measured O 
from O 
pharmacological O 
treatment O 
that O 
produces O 
locomotor O 
activating O 
or O 
sedating O 
effects O 
. O 
In O 
the O 
present O 
studies O 
, O 
dose O 
- O 
response O 
curves O 
for O 
d-amphetamine B-TRIVIAL 
( O 
AMPH B-ABBREVIATION 
)-induced O 
hyperlocomotion O 
were O 
similar O 
in O 
standard O 
B6 O 
mice O 
and O 
in O 
the O 
BTBR O 
mouse O 
model O 
of O 
autism O 
. O 
AMPH B-ABBREVIATION 
produced O 
significant O 
, O 
robust O 
reductions O 
in O 
the O 
high O 
level O 
of O 
repetitive O 
self O 
- O 
grooming O 
that O 
characterizes O 
BTBR O 
, O 
and O 
also O 
reduced O 
the O 
low O 
baseline O 
grooming O 
in O 
B6 O 
, O 
indicating O 
that O 
AMPH B-ABBREVIATION 
-induced O 
hyperlocomotion O 
competes O 
with O 
time O 
spent O 
engaged O 
in O 
self O 
- O 
grooming O 
. O 
We O 
then O 
tested O 
AMPH B-ABBREVIATION 
in O 
B6 O 
and O 
BTBR O 
on O 
the O 
3-chambered O 
social O 
approach O 
task O 
. O 
One O 
component O 
of O 
sociability O 
, O 
the O 
time O 
spent O 
in O 
the O 
chamber O 
with O 
the O 
novel O 
mouse O 
, O 
in O 
B6 O 
mice O 
was O 
reduced O 
, O 
while O 
the O 
sniffing O 
time O 
component O 
of O 
sociability O 
in O 
BTBR O 
mice O 
was O 
enhanced O 
. O 
This O 
finding O 
replicated O 
across O 
multiple O 
cohorts O 
treated O 
with O 
AMPH B-ABBREVIATION 
and O 
saline O 
vehicle O 
. O 
In-depth O 
analysis O 
revealed O 
that O 
AMPH B-ABBREVIATION 
increased O 
the O 
number O 
and O 
decreased O 
the O 
duration O 
of O 
sniffing O 
bouts O 
in O 
BTBR O 
, O 
suggesting O 
BTBR O 
treated O 
with O 
AMPH B-ABBREVIATION 
mostly O 
engaged O 
in O 
brief O 
sniffs O 
rather O 
than O 
true O 
social O 
interactions O 
with O 
the O 
novel O 
mouse O 
during O 
the O 
social O 
approach O 
task O 
. O 
Our O 
data O 
suggest O 
that O 
compounds O 
with O 
stimulant O 
properties O 
may O 
have O 
some O 
direct O 
benefits O 
on O 
reducing O 
repetitive O 
behaviors O 
in O 
autism O 
spectrum O 
disorders O 
, O 
particularly O 
in O 
the O 
subset O 
of O 
autistic O 
individuals O 
with O 
hyperactivity O 
. O 
This O 
article O 
is O 
part O 
of O 
the O 
Special O 
Issue O 
entitled O 
' O 
Neurodevelopmental O 
Disorders' O 
. O 

receptor-α O 
is O 
required O 
for O 
the O 
osteogenic O 
response O 
to O 
mechanical O 
loading O 
in O 
a O 
ligand O 
- O 
independent O 
manner O 
involving O 
its O 
activation O 
function O 
1 O 
but O 
not O 
2 O 
. O 

receptor-α O 
( O 
ERα O 
) O 
is O 
crucial O 
for O 
the O 
adaptive O 
response O 
of O 
bone O 
to O 
loading O 
but O 
the O 
role O 
of O 
endogenous O 
estradiol B-TRIVIAL 
( O 
E2 O 
) O 
for O 
this O 
response O 
is O 
unclear O 
. O 
To O 
determine O 
in O 
vivo O 
the O 
ligand O 
dependency O 
and O 
relative O 
roles O 
of O 
different O 
ERα O 
domains O 
for O 
the O 
osteogenic O 
response O 
to O 
mechanical O 
loading O 
, O 
gene O 
- O 
targeted O 
mouse O 
models O 
with O 
( O 
1 O 
) O 
a O 
complete O 
ERα O 
inactivation O 
( O 
ERα(- O 
/ O 
- O 
) O 
) O 
, O 
( O 
2 O 
) O 
specific O 
inactivation O 
of O 
activation O 
function O 
1 O 
( O 
AF-1 O 
) O 
in O 
ERα O 
( O 
ERαAF-1(0) O 
) O 
, O 
or O 
( O 
3 O 
) O 
specific O 
inactivation O 
of O 
ERαAF-2 O 
( O 
ERαAF-2(0) O 
) O 
were O 
subjected O 
to O 
axial O 
loading O 
of O 
tibia O 
, O 
in O 
the O 
presence O 
or O 
absence O 
( O 
ovariectomy O 
[ O 
ovx O 
] O 
) O 
of O 
endogenous O 
E2 O 
. O 
Loading O 
increased O 
the O 
cortical O 
bone O 
area O 
in O 
the O 
tibia O 
mainly O 
as O 
a O 
result O 
of O 
an O 
increased O 
periosteal O 
bone O 
formation O 
rate O 
( O 
BFR O 
) O 
and O 
this O 
osteogenic O 
response O 
was O 
similar O 
in O 
gonadal O 
intact O 
and O 
ovx O 
mice O 
, O 
demonstrating O 
that O 
E2 O 
( O 
ligand O 
) O 
is O 
not O 
required O 
for O 
this O 
response O 
. O 
Female O 
ERα(- O 
/ O 
- O 
) O 
mice O 
displayed O 
a O 
severely O 
reduced O 
osteogenic O 
response O 
to O 
loading O 
with O 
changes O 
in O 
cortical O 
area O 
( O 
-78% O 
± O 
15% O 
, O 
p O 
< O 
0.01 O 
) O 
and O 
periosteal O 
BFR O 
( O 
-81% O 
± O 
9% O 
, O 
p O 
< O 
0.01 O 
) O 
being O 
significantly O 
lower O 
than O 
in O 
wild O 
- O 
type O 
( O 
WT O 
) O 
mice O 
. O 
ERαAF-1(0) O 
mice O 
also O 
displayed O 
a O 
reduced O 
response O 
to O 
mechanical O 
loading O 
compared O 
with O 
WT O 
mice O 
( O 
cortical O 
area O 
-40% O 
± O 
11% O 
, O 
p O 
< O 
0.05 O 
and O 
periosteal O 
BFR O 
-41% O 
± O 
8% O 
, O 
p O 
< O 
0.01 O 
) O 
, O 
whereas O 
the O 
periosteal O 
osteogenic O 
response O 
to O 
loading O 
was O 
unaffected O 
in O 
ERαAF-2(0) O 
mice O 
. O 
Mechanical O 
loading O 
of O 
transgenic O 
estrogen B-FAMILY 
response O 
element O 
(ERE)-luciferase O 
reporter O 
mice O 
did O 
not O 
increase O 
luciferase O 
expression O 
in O 
cortical O 
bone O 
, O 
suggesting O 
that O 
the O 
loading O 
response O 
does O 
not O 
involve O 
classical O 
genomic O 
ERE O 
- O 
mediated O 
pathways O 
. O 
In O 
conclusion O 
, O 
ERα O 
is O 
required O 
for O 
the O 
osteogenic O 
response O 
to O 
mechanical O 
loading O 
in O 
a O 
ligand O 
- O 
independent O 
manner O 
involving O 
AF-1 O 
but O 
not O 
AF-2 O 
. O 

is O 
a O 
risk O 
factor O 
for O 
numerous O 
metabolic O 
disorders O 
. O 
Recently O 
, O 
natural O 
compounds O 
that O 
may O 
be O 
beneficial O 
for O 
improving O 
obesity O 
have O 
received O 
increasing O 
attention O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
whether O 
red O 
and O 
green O 
tomato O 
extracts O 
attenuate O 
high O 
- O 
fat O 
- O 
diet O 
- O 
induced O 
obesity O 
in O 
C57BL O 
/ O 
6 O 
mice O 
. O 
The O 
mice O 
were O 
maintained O 
on O 
a O 
normal O 
diet O 
( O 
ND O 
) O 
or O 
high O 
- O 
fat O 
diet O 
( O 
HFD O 
) O 
for O 
4 O 
weeks O 
and O 
then O 
fed O 
ND O 
, O 
HFD O 
, O 
HFD O 
plus O 
2% O 
red O 
tomato O 
extract O 
( O 
RTE O 
) O 
or O 
HFD O 
plus O 
2% O 
green O 
tomato O 
extract O 
( O 
GTE O 
) O 
for O 
13 O 
weeks O 
. O 
The O 
weekly O 
food O 
intakes O 
among O 
the O 
groups O 
were O 
not O 
significantly O 
different O 
. O 
Body O 
weight O 
of O 
mice O 
fed O 
HFD O 
plus O 
GTE O 
was O 
significantly O 
decreased O 
to O 
the O 
level O 
of O 
mice O 
fed O 
ND O 
, O 
but O 
the O 
body O 
weight O 
was O 
only O 
slightly O 
reduced O 
in O 
mice O 
fed O 
HFD O 
plus O 
RTE O 
. O 
Epididymal O 
adipose O 
tissue O 
and O 
liver O 
weights O 
were O 
significantly O 
decreased O 
in O 
mice O 
fed O 
HFD O 
plus O 
GTE O 
compared O 
to O 
those O 
in O 
HFD O 
. O 
Serum O 
total O 
cholesterol B-TRIVIAL 
and O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
levels O 
in O 
mice O 
fed O 
GTE O 
were O 
modestly O 
reduced O 
, O 
and O 
liver O 
total O 
cholesterol B-TRIVIAL 
level O 
was O 
strongly O 
decreased O 
in O 
HFD O 
plus O 
GTE-fed O 
mice O 
compared O 
to O 
that O 
in O 
HFD-fed O 
mice O 
. O 
Adenosine B-SYSTEMATIC 
- I-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
and O 
acetyl-CoA B-SYSTEMATIC 
carboxylase O 
phosphorylation O 
in O 
liver O 
from O 
HFD O 
plus O 
GTE-fed O 
mice O 
was O 
significantly O 
elevated O 
, O 
and O 
HMG-CoA B-ABBREVIATION 
reductase O 
expression O 
was O 
also O 
significantly O 
decreased O 
. O 
GTE O 
strongly O 
decreased O 
the O 
expression O 
of O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
gamma O 
, O 
CCAAT O 
/ O 
enhancer O 
- O 
binding O 
protein O 
alpha O 
and O 
perilipin O 
in O 
the O 
adipose O 
tissue O 
of O 
mice O 
fed O 
HFD O 
plus O 
GTE O 
. O 
Our O 
results O 
indicate O 
that O 
the O 
antiobesity O 
effects O 
of O 
GTE O 
may O 
be O 
associated O 
with O 
activation O 
of O 
the O 
AMPK O 
pathway O 
. O 

systemic O 
fibrosis O 
- O 
like O 
effects O 
of O 
magnetic O 
resonance O 
imaging O 
contrast O 
agents O 
in O 
rats O 
with O 
adenine B-TRIVIAL 
-induced O 
renal O 
failure O 
. O 

systemic O 
fibrosis O 
( O 
NSF O 
) O 
is O 
a O 
scleroderma O 
- O 
like O 
disease O 
associated O 
with O 
prior O 
administration O 
of O 
certain O 
gadolinium B-SYSTEMATIC 
chelates O 
( O 
GCs O 
) O 
. O 
NSF O 
occurs O 
in O 
patients O 
with O 
severe O 
renal O 
failure O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
set O 
up O 
a O 
rat O 
model O 
of O 
GC-associated O 
NSF O 
to O 
elucidate O 
the O 
mechanism O 
of O 
this O 
devastating O 
disease O 
. O 
Firstly O 
, O 
after O 
characterization O 
of O 
the O 
model O 
, O 
male O 
Wistar O 
rats O 
received O 
a O 
0.75% O 
adenine B-TRIVIAL 
-enriched O 
diet O 
for O 
8 O 
, O 
14 O 
, O 
or O 
16 O 
days O 
to O 
obtain O 
various O 
degrees O 
of O 
renal O 
failure O 
. O 
Rats O 
received O 
five O 
consecutive O 
daily O 
iv O 
injections O 
of O 
saline O 
or O 
gadodiamide B-TRIVIAL 
( O 
2.5 O 
mmol O 
/ O 
kg O 
/ O 
day O 
) O 
. O 
Secondly O 
, O 
the O 
safety O 
profile O 
and O 
in O 
vivo O 
propensity O 
to O 
dissociate O 
of O 
all O 
categories O 
of O 
marketed O 
GCs O 
( O 
gadoterate B-TRIVIAL 
, O 
gadobutrol B-TRIVIAL 
, O 
gadobenate B-TRIVIAL 
, O 
gadopentetate B-TRIVIAL 
, O 
and O 
gadodiamide B-TRIVIAL 
) O 
were O 
compared O 
in O 
rats O 
receiving O 
adenine B-TRIVIAL 
-enriched O 
diet O 
for O 
16 O 
days O 
. O 
Serial O 
skin O 
biopsies O 
were O 
performed O 
for O 
blinded O 
histopathological O 
study O 
. O 
Total O 
Gd B-FORMULA 
concentration O 
in O 
tissues O 
was O 
measured O 
by O 
Inductively O 
Coupled O 
Plasma O 
Mass O 
Spectrometry O 
. O 
Relaxometry O 
was O 
used O 
to O 
evaluate O 
the O 
presence O 
of O 
dissociated O 
Gd B-FORMULA 
in O 
skin O 
and O 
bone O 
. O 
Gadodiamide B-TRIVIAL 
-induced O 
high O 
mortality O 
and O 
skin O 
lesions O 
( O 
dermal O 
fibrosis O 
, O 
calcification O 
, O 
and O 
inflammation O 
) O 
were O 
related O 
to O 
adenine B-TRIVIAL 
diet O 
duration O 
. O 
No O 
skin O 
lesions O 
were O 
observed O 
with O 
other O 
molecules O 
. O 
Unlike O 
macrocyclic O 
GCs O 
, O 
gadodiamide B-TRIVIAL 
, O 
gadopentetate B-TRIVIAL 
, O 
and O 
gadobenate B-TRIVIAL 
gradually O 
increased O 
the O 
r(1) O 
relaxivity O 
value O 
, O 
consistent O 
with O 
in O 
vivo O 
dissociation O 
and O 
release O 
of O 
soluble O 
Gd B-FORMULA 
( O 
or O 
, O 
in O 
the O 
case O 
of O 
gadobenate B-TRIVIAL 
, O 
the O 
consequence O 
of O 
protein O 
binding O 
) O 
. O 
Gadodiamide B-TRIVIAL 
-induced O 
cutaneous O 
and O 
systemic O 
toxicity O 
depended O 
on O 
baseline O 
renal O 
function O 
. O 
We O 
demonstrate O 
in O 
vivo O 
dissociation O 
of O 
linear O 
GCs O 
, O 
gadodiamide B-TRIVIAL 
, O 
and O 
gadopentetate B-TRIVIAL 
, O 
whereas O 
macrocyclic O 
agents O 
remained O 
stable O 
over O 
the O 
study O 
period O 
. O 

of O 
ozone B-TRIVIAL 
and O 
particulate O 
matter O 
on O 
cardiac O 
mechanics O 
: O 
role O 
of O 
the O 
atrial O 
natriuretic O 
peptide O 
gene O 
. O 

positive O 
association O 
between O 
air O 
pollution O 
exposure O 
and O 
increased O 
human O 
risk O 
of O 
chronic O 
heart O 
disease O 
progression O 
is O 
well O 
established O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
test O 
two O 
hypotheses O 
: O 
( O 
1 O 
) O 
the O 
cardiac O 
compensatory O 
changes O 
in O 
response O 
to O 
air O 
pollution O 
are O 
dependent O 
on O 
its O 
composition O 
and O 
( O 
2 O 
) O 
specific O 
cardiac O 
adaptations O 
are O 
regulated O 
by O 
atrial O 
natriuretic O 
peptide O 
( O 
ANP O 
) O 
. O 
We O 
address O 
these O 
hypotheses O 
by O 
initially O 
examining O 
the O 
exposure O 
effects O 
of O 
ozone B-TRIVIAL 
( O 
O(3) B-FORMULA 
) O 
and O 
/ O 
or O 
particulate O 
matter O 
( O 
PM O 
) O 
on O 
cardiac O 
function O 
in O 
C57Bl O 
/ O 
6J O 
( O 
B6 O 
) O 
mice O 
. O 
Subsequently O 
, O 
the O 
results O 
are O 
compared O 
with O 
cardiac O 
functional O 
changes O 
to O 
the O 
same O 
exposures O 
in O 
Nppa O 
( O 
the O 
precursor O 
gene O 
for O 
ANP O 
) O 
knockout O 
( O 
KO O 
) O 
mice O 
. O 
Separate O 
groups O 
of O 
mice O 
underwent O 
3 O 
consecutive O 
days O 
of O 
the O 
same O 
exposure O 
sequence O 
for O 
3h O 
each O 
consisting O 
of O 
the O 
following O 
: O 
( O 
1 O 
) O 
6h O 
of O 
filtered O 
air O 
( O 
FAFA O 
) O 
, O 
( O 
2 O 
) O 
O(3) B-FORMULA 
then O 
FA O 
( O 
O(3) B-FORMULA 
FA O 
) O 
, O 
( O 
3 O 
) O 
FA O 
then O 
carbon B-TRIVIAL 
black I-TRIVIAL 
( O 
FACB O 
) O 
, O 
or O 
( O 
4 O 
) O 
O(3) B-FORMULA 
then O 
CB O 
. O 
Cardiac O 
function O 
was O 
assessed O 
using O 
a O 
conductance O 
catheter O 
to O 
generate O 
cardiac O 
pressure O 
- O 
volume O 
loops O 
8-10h O 
following O 
each O 
exposure O 
sequence O 
. O 
As O 
compared O 
with O 
FAFA O 
, O 
each O 
sequence O 
led O 
to O 
a O 
substantial O 
drop O 
( O 
as O 
much O 
as O 
33% O 
) O 
in O 
stroke O 
volume O 
and O 
cardiac O 
output O 
. O 
However O 
, O 
these O 
losses O 
of O 
cardiac O 
function O 
occurred O 
by O 
different O 
compensatory O 
mechanisms O 
dependent O 
on O 
the O 
pollutant O 
composition O 
. O 
For O 
example O 
, O 
O(3) B-FORMULA 
FA O 
exposure O 
led O 
to O 
reductions O 
in O 
both O 
end O 
- O 
systolic O 
and O 
end O 
- O 
diastolic O 
left O 
ventricular O 
( O 
LV O 
) O 
volumes O 
, O 
whereas O 
FACB O 
exposure O 
led O 
an O 
increase O 
in O 
end O 
- O 
diastolic O 
LV O 
volume O 
. O 
These O 
same O 
cardiac O 
compensatory O 
changes O 
were O 
largely O 
abolished O 
in O 
Nppa O 
KO O 
mice O 
following O 
O(3) B-FORMULA 
FA O 
or O 
FACB O 
exposure O 
. O 
These O 
results O 
suggest O 
that O 
cardiac O 
functional O 
changes O 
in O 
response O 
to O 
air O 
pollution O 
exposure O 
are O 
strongly O 
dependent O 
on O 
the O 
pollutant O 
constituents O 
, O 
especially O 
related O 
to O 
O(3) B-FORMULA 
and O 
/ O 
or O 
PM O 
. O 
Furthermore O 
, O 
ANP O 
regulation O 
appears O 
to O 
be O 
crucial O 
to O 
these O 
cardiac O 
compensatory O 
mechanisms O 
induced O 
by O 
air O 
pollution O 
. O 

organophosphorous B-FAMILY 
( O 
OP O 
) O 
agents O 
, O 
such O 
as O 
VX O 
, O 
are O 
hazardous O 
by O 
absorption O 
through O 
the O 
skin O 
and O 
are O 
resistant O 
to O 
conventional O 
pharmacological O 
antidotal O 
treatments O 
. O 
The O 
residence O 
time O 
of O 
a O 
stoichiometric O 
bioscavenger O 
, O 
human O 
butyrylcholinesterase O 
( O 
huBuChE O 
) O 
, O 
in O 
the O 
plasma O 
more O 
closely O 
matches O 
that O 
of O 
VX O 
than O 
do O 
the O 
residence O 
times O 
of O 
conventional O 
therapy O 
drugs O 
( O 
oxime B-SYSTEMATIC 
, O 
anti-muscarinic O 
, O 
anticonvulsant O 
) O 
. O 
Intramuscular O 
( O 
i.m O 
. O 
) O 
huBuChE O 
afforded O 
almost O 
complete O 
protection O 
when O 
administered O 
prior O 
to O 
the O 
onset O 
of O 
observable O 
cholinergic O 
signs O 
of O 
VX O 
poisoning O 
, O 
but O 
once O 
signs O 
of O 
poisoning O 
became O 
evident O 
the O 
efficacy O 
of O 
i.m O 
. O 
huBuChE O 
decreased O 
. O 
A O 
combination O 
of O 
nerve O 
agent O 
therapy O 
drugs O 
( O 
oxime B-SYSTEMATIC 
, O 
anti-muscarinic O 
, O 
anticonvulsant O 
) O 
with O 
huBuChE O 
( O 
i.m O 
. O 
) O 
protected O 
100% O 
( O 
8 O 
/ O 
8 O 
) O 
of O 
guinea O 
- O 
pigs O 
from O 
a O 
lethal O 
dose O 
of O 
VX O 
( O 
0.74mg O 
/ O 
kg O 
) O 
to O 
48h O 
, O 
even O 
when O 
administered O 
on O 
signs O 
of O 
poisoning O 
. O 
Survival O 
was O 
presumed O 
to O 
be O 
due O 
to O 
immediate O 
alleviation O 
of O 
the O 
cholinergic O 
crisis O 
by O 
the O 
conventional O 
pharmacological O 
treatment O 
drugs O 
, O 
in O 
conjunction O 
with O 
bioscavenger O 
that O 
prevented O 
further O 
absorbed O 
agent O 
reaching O 
the O 
AChE O 
targets O 
. O 
Evidence O 
to O 
support O 
this O 
proposed O 
mechanism O 
of O 
action O 
was O 
obtained O 
from O 
PKPD O 
experiments O 
in O 
which O 
multiple O 
blood O 
samples O 
and O 
microdialysate O 
samples O 
were O 
collected O 
from O 
individual O 
conscious O 
ambulatory O 
animals O 
. O 
Plasma O 
concentrations O 
of O 
intramuscularly O 
- O 
administered O 
atropine B-TRIVIAL 
, O 
diazepam B-TRIVIAL 
and O 
HI-6 B-IDENTIFIER 
reached O 
a O 
peak O 
within O 
15min O 
and O 
were O 
eliminated O 
rapidly O 
within O 
4h O 
. O 
Plasma O 
concentrations O 
of O 
huBuChE O 
administered O 
by O 
the O 
i.m O 
. O 
route O 
took O 
approximately O 
24h O 
to O 
reach O 
a O 
peak O 
, O 
but O 
were O 
well O 
- O 
maintained O 
over O 
the O 
subsequent O 
7days O 
. O 
Thus O 
, O 
the O 
pharmacological O 
therapy O 
rapidly O 
treated O 
the O 
initial O 
signs O 
of O 
poisoning O 
, O 
whilst O 
the O 
bioscavenger O 
provided O 
prolonged O 
protection O 
by O 
neutralising O 
further O 
nerve O 
agent O 
entering O 
the O 
bloodstream O 
and O 
preventing O 
it O 
from O 
reaching O 
the O 
target O 
organs O 
. O 

overcome O 
the O 
limitations O 
of O 
in O 
vitro O 
exposure O 
of O 
submerged O 
lung O 
cells O 
to O 
nanoparticles O 
( O 
NPs O 
) O 
, O 
we O 
validated O 
an O 
integrated O 
low O 
flow O 
system O 
capable O 
of O 
generating O 
and O 
depositing O 
airborne O 
NPs O 
directly O 
onto O 
cells O 
at O 
an O 
air O 
- O 
liquid O 
interface O 
( O 
ALI O 
) O 
. O 
The O 
in O 
vitro O 
exposure O 
system O 
was O 
shown O 
to O 
provide O 
uniform O 
and O 
controlled O 
dosing O 
of O 
particles O 
with O 
70.3% O 
efficiency O 
to O 
epithelial O 
cells O 
grown O 
on O 
transwells O 
. O 
This O 
system O 
delivered O 
a O 
continuous O 
airborne O 
exposure O 
of O 
NPs O 
to O 
lung O 
cells O 
without O 
loss O 
of O 
cell O 
viability O 
in O 
repeated O 
4h O 
exposure O 
periods O 
. O 
We O 
sequentially O 
exposed O 
cells O 
to O 
air O 
- O 
delivered O 
copper B-SYSTEMATIC 
( O 
Cu B-FORMULA 
) O 
NPs O 
in O 
vitro O 
to O 
compare O 
toxicity O 
results O 
to O 
our O 
prior O 
in O 
vivo O 
inhalation O 
studies O 
. O 
The O 
evaluation O 
of O 
cellular O 
dosimetry O 
indicated O 
that O 
a O 
large O 
amount O 
of O 
Cu B-FORMULA 
was O 
taken O 
up O 
, O 
dissolved O 
and O 
released O 
into O 
the O 
basolateral O 
medium O 
( O 
62% O 
of O 
total O 
mass O 
) O 
. O 
Exposure O 
to O 
Cu B-FORMULA 
NPs O 
decreased O 
cell O 
viability O 
to O 
73% O 
( O 
p O 
< O 
0.01 O 
) O 
and O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
elevated O 
levels O 
of O 
lactate B-FAMILY 
dehydrogenase O 
, O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
and O 
interleukin-8 O 
that O 
mirrored O 
our O 
findings O 
from O 
subacute O 
in O 
vivo O 
inhalation O 
studies O 
in O 
mice O 
. O 
Our O 
results O 
show O 
that O 
this O 
exposure O 
system O 
is O 
useful O 
for O 
screening O 
of O 
NP O 
toxicity O 
in O 
a O 
manner O 
that O 
represents O 
cellular O 
responses O 
of O 
the O 
pulmonary O 
epithelium O 
in O 
vivo O 
. O 

- O 
assisted O 
coating O 
of O 
silk O 
yarn O 
with O 
sphere O 
- O 
like O 
Mn3O4 B-FORMULA 
nanoparticles O 
. O 

growth O 
of O 
sphere O 
- O 
like O 
trimanganese B-SYSTEMATIC 
tetraoxide I-SYSTEMATIC 
( O 
Mn(3)O(4) B-FORMULA 
) O 
nanoparticles O 
on O 
silk O 
fiber O 
was O 
achieved O 
by O 
sequential O 
dipping O 
in O 
an O 
alternating O 
bath O 
of O 
potassium B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
and O 
manganese B-SYSTEMATIC 
(II) I-SYSTEMATIC 
nitrate I-SYSTEMATIC 
under O 
ultrasound O 
irradiation O 
. O 
Some O 
parameters O 
such O 
as O 
the O 
effect O 
of O 
pH O 
, O 
numerous O 
sequential O 
dipping O 
and O 
ultrasonic O 
irradiation O 
on O 
growth O 
of O 
the O 
nanoparticles O 
have O 
been O 
studied O 
. O 
The O 
samples O 
were O 
characterized O 
with O 
powder O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
, O 
scanning O 
electron O 
microscopy O 
( O 
SEM O 
) O 
and O 
wavelength O 
dispersive O 
X-ray O 
( O 
WDX O 
) O 
. O 

PARP O 
inhibitor O 
PJ34 B-IDENTIFIER 
modifies O 
proliferation O 
, O 
NIS O 
expression O 
and O 
epigenetic O 
marks O 
in O 
thyroid O 
cancer O 
cell O 
lines O 
. O 

PARP-1 O 
is O 
supposed O 
to O 
be O 
part O 
of O 
a O 
multimeric O 
repressor O 
of O 
sodium B-SYSTEMATIC 
iodide I-SYSTEMATIC 
symporter O 
( O 
NIS O 
) O 
expression O 
, O 
in O 
this O 
study O 
the O 
effect O 
of O 
the O 
PARP O 
inhibitor O 
PJ34 B-IDENTIFIER 
on O 
several O 
properties O 
of O 
thyroid O 
cancer O 
cell O 
lines O 
was O 
investigated O 
. O 
In O 
TPC1 O 
, O 
BCPAP O 
, O 
FRO O 
, O 
WRO O 
cell O 
lines O 
PJ34 B-IDENTIFIER 
induced O 
a O 
strong O 
increase O 
in O 
NIS O 
mRNA O 
levels O 
. O 
In O 
BCPAP O 
and O 
TPC1 O 
cells O 
also O 
significant O 
increase O 
of O 
radio B-SYSTEMATIC 
- I-SYSTEMATIC 
iodine I-SYSTEMATIC 
uptake O 
was O 
induced O 
. O 
Accordingly O 
, O 
in O 
transfection O 
experiments O 
performed O 
in O 
TPC1 O 
cells O 
, O 
treatment O 
with O 
PJ34 B-IDENTIFIER 
increased O 
NIS O 
promoter O 
activity O 
without O 
affecting O 
PARP-1 O 
binding O 
to O 
the O 
promoter O 
sequence O 
. O 
We O 
also O 
investigated O 
the O 
epigenetic O 
status O 
of O 
NIS O 
promoter O 
after O 
PJ34 B-IDENTIFIER 
treatment O 
in O 
TPC1 O 
cell O 
line O 
: O 
in O 
addition O 
to O 
an O 
increase O 
of O 
histone O 
modification O 
activation O 
marks O 
( O 
H3K9K14ac O 
, O 
H3K4me3 O 
) O 
, O 
surprisingly O 
we O 
observed O 
also O 
an O 
increase O 
of O 
H3K27me3 O 
, O 
a O 
classical O 
repressive O 
mark O 
. O 
Our O 
data O 
demonstrate O 
that O 
in O 
various O 
thyroid O 
cancer O 
cell O 
lines O 
PARP O 
inhibition O 
increases O 
NIS O 
gene O 
expression O 
through O 
a O 
particular O 
modulation O 
of O 
transcriptional O 
regulatory O 
mechanisms O 
. O 
Therefore O 
, O 
we O 
suggest O 
that O 
PARP O 
inhibitors O 
may O 
deserve O 
future O 
investigations O 
as O 
tools O 
for O 
medical O 
treatment O 
of O 
thyroid O 
cancer O 
. O 

receptor O 
signaling O 
mediates O 
the O 
expression O 
of O 
protein O 
inhibitor O 
of O 
activated O 
STAT1 O 
( O 
PIAS1 O 
) O 
in O 
rat O 
hippocampus O 
. O 

inhibitor O 
of O 
activated O 
STAT1 O 
( O 
PIAS1 O 
) O 
was O 
shown O 
to O 
play O 
an O 
important O 
role O 
in O 
inflammation O 
and O 
innate O 
immune O 
response O 
, O 
but O 
how O 
PIAS1 O 
is O 
regulated O 
is O 
not O 
known O 
. O 
We O 
have O 
recently O 
demonstrated O 
that O 
PIAS1 O 
enhances O 
spatial O 
learning O 
and O 
memory O 
performance O 
in O 
rats O 
. O 
In O 
this O 
study O 
, O 
we O 
examined O 
the O 
signaling O 
pathway O 
and O 
neural O 
mechanism O 
that O 
regulate O 
PIAS1 O 
expression O 
in O 
the O 
brain O 
by O 
using O 
pharmacological O 
and O 
molecular O 
approaches O 
. O 
Our O 
results O 
revealed O 
that O 
pias1 O 
gene O 
expression O 
is O 
rapidly O 
induced O 
upon O 
NMDA B-ABBREVIATION 
receptor O 
activation O 
in O 
rat O 
hippocampus O 
, O 
but O 
this O 
effect O 
is O 
blocked O 
by O 
transfection O 
of O 
sub O 
- O 
threshold O 
concentrations O 
of O 
ERK1 O 
siRNA O 
/ O 
ERK2 O 
siRNA O 
or O 
CREB O 
siRNA O 
. O 
Pias1 O 
gene O 
expression O 
is O 
similarly O 
induced O 
by O 
overexpression O 
of O 
the O 
ERK1 O 
/ O 
ERK2 O 
plasmids O 
in O 
rat O 
hippocampus O 
, O 
and O 
this O 
effect O 
is O 
also O 
blocked O 
by O 
sub O 
- O 
threshold O 
concentration O 
of O 
CREB O 
siRNA O 
transfection O 
. O 
On O 
the O 
other O 
hand O 
, O 
transfection O 
of O 
ERK1 O 
siRNA O 
/ O 
ERK2 O 
siRNA O 
or O 
CREB O 
siRNA O 
at O 
a O 
higher O 
concentration O 
is O 
sufficient O 
to O 
down O 
- O 
regulate O 
PIAS1 O 
expression O 
. O 
Inhibition O 
of O 
PI-3 O 
kinase O 
signaling O 
and O 
CaMKII O 
signaling O 
, O 
which O 
both O 
result O 
in O 
CREB O 
inactivation O 
, O 
similarly O 
decreases O 
PIAS1 O 
expression O 
. O 
But O 
NMDA B-ABBREVIATION 
and O 
MK-801 B-IDENTIFIER 
do O 
not O 
affect O 
the O 
expression O 
of O 
IL-6 O 
and O 
TNFα O 
. O 
NMDA B-ABBREVIATION 
also O 
did O 
not O 
affect O 
the O 
expression O 
of O 
PIAS2 O 
, O 
PIAS3 O 
and O 
PIAS4 O 
. O 
Further O 
, O 
pias1 O 
mRNA O 
has O 
a O 
similar O 
degradation O 
rate O 
to O 
that O 
of O 
the O 
zif268 O 
gene O 
. O 
These O 
results O 
together O 
suggest O 
that O 
pias1 O 
may O 
function O 
as O 
an O 
immediate O 
early O 
gene O 
in O 
an O 
activity O 
- O 
dependent O 
manner O 
and O 
PIAS1 O 
expression O 
is O 
regulated O 
by O 
the O 
NMDA B-ABBREVIATION 
-MAPK O 
/ O 
ERK-CREB O 
signaling O 
pathway O 
implicated O 
in O 
neuronal O 
plasticity O 
. O 

suggests O 
that O 
depression O 
is O 
associated O 
with O 
an O 
increase O 
in O 
the O 
high O 
- O 
affinity O 
conformation O 
of O 
the O 
α2-adrenoceptors O 
in O 
human O 
brain O 
. O 
Such O 
enhanced O 
α2-adrenoceptor O 
activity O 
could O 
explain O 
the O 
deficit O 
in O 
central O 
noradrenergic O 
transmission O 
described O 
in O 
the O 
aetiology O 
of O 
depression O 
. O 
Thus O 
, O 
administration O 
of O 
α2-adrenoceptor O 
antagonists O 
augments O 
noradrenaline B-TRIVIAL 
levels O 
and O 
provides O 
an O 
effective O 
therapeutic O 
approach O 
for O 
the O 
treatment O 
of O 
depressive O 
disorders O 
. O 
In O 
previous O 
studies O 
, O 
we O 
have O 
characterized O 
three O 
new O 
synthesized O 
guanidine B-TRIVIAL 
and O 
2-aminoimidazoline B-SYSTEMATIC 
aromatic O 
derivatives O 
( O 
8b O 
, O 
17b O 
and O 
20b O 
) O 
as O 
α2-adrenoceptor O 
antagonists O 
that O 
are O 
able O 
to O 
increase O 
extracellular O 
concentration O 
of O 
noradrenaline B-TRIVIAL 
in O 
rat O 
brain O 
. O 
The O 
purpose O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
the O 
in O 
vivo O 
antidepressant O 
- O 
like O 
properties O 
of O 
these O 
three O 
new O 
α2-adrenoceptor O 
antagonists O 
. O 
For O 
that O 
aim O 
, O 
compounds O 
were O 
tested O 
on O 
the O 
tail O 
suspension O 
test O 
( O 
TST O 
) O 
and O 
forced O 
swim O 
test O 
( O 
FST O 
) O 
, O 
two O 
classically O 
widely O 
- O 
used O 
behavioural O 
paradigms O 
for O 
the O 
evaluation O 
of O 
antidepressant O 
- O 
like O 
activity O 
. O 
Compound O 
8b O 
significantly O 
reduced O 
the O 
immobility O 
time O 
at O 
10 O 
, O 
20 O 
and O 
40 O 
mg O 
/ O 
kg O 
doses O 
in O 
both O 
TST O 
and O 
FST O 
. O 
Compound O 
17b O 
reduced O 
the O 
immobility O 
time O 
at O 
40 O 
mg O 
/ O 
kg O 
in O 
both O 
TST O 
and O 
FST O 
. O 
Compound O 
20b O 
showed O 
a O 
significant O 
decrease O 
in O 
the O 
immobility O 
time O 
at O 
20 O 
mg O 
/ O 
kg O 
in O 
the O 
TST O 
. O 
As O 
drugs O 
of O 
reference O 
, O 
fluoxetine B-TRIVIAL 
induced O 
a O 
significant O 
antidepressant O 
- O 
like O 
effect O 
in O 
both O 
TST O 
and O 
FST O 
, O 
while O 
mirtazapine B-TRIVIAL 
induced O 
a O 
significant O 
antidepressant O 
- O 
like O 
effect O 
only O 
in O 
the O 
FST O 
. O 
Additionally O 
, O 
none O 
of O 
the O 
tested O 
compounds O 
increased O 
locomotor O 
activity O 
or O 
displayed O 
anxiolytic O 
- O 
like O 
properties O 
. O 
These O 
results O 
suggest O 
that O 
these O 
new O 
synthesized O 
α2-adrenoceptor O 
antagonists O 
may O 
be O 
useful O 
as O 
potential O 
antidepressant O 
drugs O 
. O 

- O 
fat O 
feeding O 
or O 
CNS O 
leptin O 
overexpression O 
in O 
chow O 
- O 
fed O 
rats O 
results O 
in O 
a O 
region O 
- O 
specific O 
cellular O 
leptin O 
resistance O 
in O 
medial O 
basal O 
hypothalamic O 
regions O 
and O 
the O 
ventral O 
tegmental O 
area O 
( O 
VTA O 
) O 
. O 
The O 
present O 
investigation O 
examined O 
the O 
effects O 
of O 
targeted O 
chronic O 
leptin O 
overexpression O 
in O 
the O 
VTA O 
as O 
compared O 
with O 
the O 
medial O 
basal O 
hypothalamus O 
on O 
long O 
- O 
term O 
body O 
weight O 
homeostasis O 
. O 
The O 
study O 
also O 
examined O 
if O 
this O 
targeted O 
intervention O 
conserves O 
regional O 
leptin O 
sensitivity O 
or O 
results O 
in O 
localized O 
leptin O 
resistance O 
. O 
Cellular O 
leptin O 
resistance O 
was O 
assessed O 
by O 
leptin O 
- O 
stimulated O 
phosphorylation O 
of O 
signal O 
transducers O 
and O 
activators O 
of O 
transcription O 
3 O 
( O 
STAT3 O 
) O 
. O 
Tyrosine B-TRIVIAL 
hydroxylase O 
was O 
measured O 
in O 
hypothalamus O 
and O 
VTA O 
along O 
with O 
brown O 
adipose O 
tissue O 
uncoupling O 
protein O 
1 O 
. O 
Leptin O 
overexpression O 
in O 
VTA O 
tempered O 
HF-induced O 
obesity O 
, O 
but O 
to O 
a O 
slightly O 
lesser O 
extent O 
than O 
that O 
with O 
leptin O 
overexpression O 
in O 
the O 
hypothalamus O 
. O 
Moreover O 
, O 
the O 
overexpression O 
of O 
leptin O 
in O 
the O 
VTA O 
stimulated O 
cellular O 
STAT3 O 
phosphorylation O 
in O 
several O 
regions O 
of O 
the O 
medial O 
basal O 
hypothalamus O 
, O 
whereas O 
verexpression O 
in O 
the O 
hypothalamus O 
did O 
not O 
activate O 
STAT3 O 
signaling O 
in O 
the O 
VTA O 
. O 
This O 
unidirectional O 
trans-stimulation O 
did O 
not O 
appear O 
to O 
involve O 
migration O 
of O 
either O 
the O 
vector O 
or O 
the O 
gene O 
product O 
. O 
Long O 
- O 
term O 
leptin O 
overexpression O 
in O 
either O 
the O 
medial O 
basal O 
hypothalamus O 
or O 
VTA O 
caused O 
desensitization O 
of O 
leptin O 
signaling O 
in O 
the O 
treated O 
region O 
and O 
cross O 
- O 
desensitization O 
of O 
leptin O 
signaling O 
in O 
the O 
untreated O 
region O 
. O 
These O 
results O 
demonstrate O 
a O 
role O 
of O 
leptin O 
receptors O 
in O 
the O 
VTA O 
in O 
long O 
- O 
term O 
body O 
weight O 
regulation O 
, O 
but O 
the O 
trans-activation O 
of O 
the O 
hypothalamus O 
following O 
VTA O 
leptin O 
stimulation O 
suggests O 
that O 
an O 
integrative O 
response O 
involving O 
both O 
brain O 
regions O 
may O 
account O 
for O 
the O 
observed O 
physiological O 
outcomes O 
. O 

liver O 
prolidase O 
, O 
a O 
metal O 
- O 
dependent O 
dipeptidase O 
, O 
is O 
being O 
tested O 
as O 
a O 
potential O 
catalytic O 
bioscavenger O 
against O 
organophosphorus B-FAMILY 
( O 
OP O 
) O 
chemical O 
warfare O 
nerve O 
agents O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
determine O 
whether O 
persistent O 
and O 
high O 
- O 
levels O 
of O 
biologically O 
active O 
and O 
intact O 
recombinant O 
human O 
( O 
rHu O 
) O 
prolidase O 
could O 
be O 
introduced O 
in O 
vivo O 
in O 
mice O 
using O 
adenovirus O 
( O 
Ad O 
) O 
. O 
Here O 
, O 
we O 
report O 
that O 
a O 
single O 
intravenous O 
injection O 
of O 
Ad O 
containing O 
the O 
prolidase O 
gene O 
with O 
a O 
6× O 
histidine B-TRIVIAL 
-tag O 
( O 
Ad-prolidase O 
) O 
introduced O 
high O 
- O 
levels O 
of O 
rHu O 
prolidase O 
in O 
the O 
circulation O 
of O 
mice O 
which O 
peaked O 
on O 
days O 
5-7 O 
at O 
159±129U O 
/ O 
mL O 
. O 
This O 
level O 
of O 
prolidase O 
is O 
∼120 O 
times O 
greater O 
than O 
that O 
of O 
the O 
enzyme O 
level O 
in O 
mice O 
injected O 
with O 
Ad-null O 
virus O 
. O 
To O 
determine O 
if O 
all O 
of O 
Ad-prolidase O 
- O 
produced O 
rHu O 
prolidase O 
was O 
exported O 
into O 
the O 
circulation O 
, O 
enzyme O 
activity O 
was O 
measured O 
in O 
a O 
variety O 
of O 
tissues O 
. O 
Liver O 
contained O 
the O 
highest O 
levels O 
of O 
rHu O 
prolidase O 
on O 
day O 
7 O 
( O 
5647±454U O 
/ O 
g O 
) O 
compared O 
to O 
blood O 
or O 
any O 
other O 
tissue O 
. O 
Recombinant O 
Hu O 
prolidase O 
hydrolyzed O 
DFP O 
, O 
a O 
simulant O 
of O 
OP O 
nerve O 
agents O 
, O 
in O 
vitro O 
. O 
In O 
vivo O 
, O 
prolidase O 
overexpression O 
extended O 
the O 
survival O 
of O 
4 O 
out O 
of O 
6 O 
mice O 
by O 
4-8h O 
against O 
exposure O 
to O 
two O 
1× O 
LD50 O 
doses O 
of O 
DFP O 
. O 
In O 
contrast O 
, O 
overexpression O 
of O 
mouse O 
butyrylcholinesterase O 
( O 
BChE O 
) O 
, O 
a O 
proven O 
stoichiometric O 
bioscavenger O 
of O 
OP O 
compounds O 
, O 
protected O 
5 O 
out O 
of O 
6 O 
mice O 
from O 
DFP O 
lethality O 
and O 
surviving O 
mice O 
showed O 
no O 
symptoms O 
of O 
DFP O 
toxicity O 
. O 
In O 
conclusion O 
, O 
the O 
results O 
suggest O 
that O 
gene O 
delivery O 
using O 
Ad O 
is O 
capable O 
of O 
introducing O 
persistent O 
and O 
high O 
levels O 
of O 
human O 
liver O 
prolidase O 
in O 
vivo O 
. O 
The O 
gene O 
- O 
delivered O 
prolidase O 
hydrolyzed O 
DFP O 
in O 
vitro O 
but O 
provided O 
only O 
modest O 
protection O 
in O 
vivo O 
in O 
mice O 
, O 
delaying O 
the O 
death O 
of O 
the O 
animals O 
by O 
only O 
4-8h O 
. O 

2-ethyl I-SYSTEMATIC 
hexyl I-SYSTEMATIC 
phthalate I-SYSTEMATIC 
affects O 
differentiation O 
and O 
matrix O 
mineralization O 
of O 
rat O 
calvarial O 
osteoblasts O 
-- O 
in O 
vitro O 
. O 

hexyl I-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DEHP B-ABBREVIATION 
) O 
, O 
an O 
industrial O 
plasticizer O 
and O 
a O 
ubiquitous O 
environmental O 
contaminant O 
, O 
is O 
an O 
established O 
endocrine O 
disruptor O 
( O 
ED O 
) O 
. O 
Increasing O 
evidences O 
indicate O 
that O 
some O 
EDs O 
interfere O 
with O 
osteoblast O 
differentiation O 
and O 
function O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
DEHP B-ABBREVIATION 
on O 
the O 
expression O 
of O 
cell O 
cycle O 
proteins O 
, O 
differentiation O 
markers O 
, O 
Runx2 O 
and O 
its O 
co O 
- O 
activator O 
TAZ O 
in O 
osteoblasts O 
derived O 
from O 
neonatal O 
rat O 
calvaria O 
. O 
A O 
significant O 
decrease O 
in O 
protein O 
levels O 
of O 
cyclin O 
D1 O 
and O 
CDK-2 O 
was O 
found O 
at O 
high O 
dosage O 
of O 
DEHP B-ABBREVIATION 
( O 
100 O 
μM O 
) O 
after O 
24h O 
treatment O 
. O 
DEHP B-ABBREVIATION 
treatment O 
caused O 
a O 
significant O 
decrease O 
in O 
ALP O 
mRNA O 
. O 
While O 
DEHP B-ABBREVIATION 
treatment O 
significantly O 
decreased O 
the O 
TAZ O 
at O 
mRNA O 
and O 
protein O 
levels O 
, O 
it O 
decreased O 
only O 
the O 
Runx2protein O 
levels O 
. O 
Histochemical O 
localization O 
of O 
ALP O 
, O 
collagen O 
and O 
mineralized O 
nodules O 
studied O 
from O 
cells O 
treated O 
with O 
DEHP B-ABBREVIATION 
( O 
10 O 
and O 
100 O 
μM O 
) O 
for O 
21 O 
days O 
revealed O 
a O 
drastic O 
decrease O 
in O 
collagen O 
, O 
ALP O 
and O 
mineralization O 
. O 
In O 
conclusion O 
, O 
DEHP B-ABBREVIATION 
affected O 
differentiation O 
of O 
neonatal O 
rat O 
calvarial O 
osteoblasts O 
and O 
mineralization O 
of O 
matrix O 
secreted O 
by O 
these O 
cells O 
. O 

B O 
activated O 
1,25(OH)(2)D B-SYSTEMATIC 
affects O 
the O 
level O 
of O 
fibroblast O 
growth O 
factor-23 O 
in O 
human O 
. O 

growth O 
factor O 
23 O 
( O 
FGF-23 O 
) O 
is O 
known O 
as O 
a O 
phosphaturic O 
factor O 
regulating O 
phosphate B-SYSTEMATIC 
homeostasis O 
. O 
Several O 
studies O 
suggest O 
that O 
dietary O 
phosphate B-SYSTEMATIC 
, O 
serum O 
phosphate B-SYSTEMATIC 
and O 
1,25-dihydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
[ O 
1,25(OH)(2)D B-SYSTEMATIC 
] O 
are O 
candidate O 
regulators O 
of O 
FGF-23 O 
. O 
While O 
the O 
human O 
studies O 
, O 
which O 
modulated O 
the O 
dietary O 
or O 
serum O 
phosphate B-SYSTEMATIC 
showed O 
in O 
rather O 
controversial O 
results O 
, O 
manipulation O 
of O 
the O 
active O 
vitamin B-FAMILY 
D I-FAMILY 
definitely O 
affected O 
FGF-23 O 
in O 
animals O 
. O 
This O 
study O 
was O 
conducted O 
to O 
elucidate O 
the O 
relationship O 
between O 
active O 
vitamin B-FAMILY 
D I-FAMILY 
directly O 
stimulated O 
by O 
ultraviolet O 
B O 
( O 
UVB O 
) O 
exposure O 
and O 
FGF-23 O 
level O 
in O 
human O 
. O 
Ten O 
healthy O 
young O 
adults O 
were O 
recruited O 
to O 
get O 
the O 
UVB O 
exposure O 
thrice O 
a O 
week O 
at O 
sub O 
- O 
minimal O 
erythemal O 
dose O 
with O 
gradual O 
increment O 
by O 
10% O 
only O 
for O 
4 O 
weeks O 
. O 
Serum O 
calcium B-SYSTEMATIC 
, O 
phosphate B-SYSTEMATIC 
, O 
mineral O 
- O 
related O 
hormones O 
and O 
bone O 
turnover O 
markers O 
were O 
analyzed O 
before O 
and O 
after O 
the O 
UVB O 
exposure O 
every O 
4 O 
week O 
for O 
12 O 
whole O 
weeks O 
. O 
Twenty B-SYSTEMATIC 
five I-SYSTEMATIC 
- I-SYSTEMATIC 
hydroxyvitamin I-SYSTEMATIC 
D I-SYSTEMATIC 
[ O 
25(OH)D B-SYSTEMATIC 
] O 
increased O 
by O 
115% O 
( O 
19.8 O 
ng O 
/ O 
mL O 
to O 
40.5 O 
ng O 
/ O 
mL O 
, O 
p O 
< O 
0.001 O 
) O 
after O 
4 O 
weeks O 
of O 
UVB O 
exposure O 
. O 
While O 
1,25(OH)(2)D B-SYSTEMATIC 
increased O 
by O 
75% O 
( O 
49.9 O 
pg O 
/ O 
mL O 
to O 
64.4 O 
pg O 
/ O 
mL O 
, O 
p O 
< O 
0.001 O 
) O 
then O 
both O 
level O 
decreased O 
after O 
4 O 
weeks O 
of O 
withdrawal O 
. O 
C-telopeptide O 
peaked O 
at O 
2nd O 
week O 
then O 
decreased O 
, O 
while O 
osteocalcin O 
increased O 
gradually O 
. O 
FGF-23 O 
started O 
to O 
increase O 
from O 
the O 
4th O 
week O 
of O 
UVB O 
exposure O 
then O 
significantly O 
at O 
the O 
4th O 
week O 
after O 
withdrawal O 
of O 
UVB O 
( O 
27.8 O 
pg O 
/ O 
mL O 
to O 
41.4 O 
pg O 
/ O 
mL O 
, O 
p O 
< O 
0.05 O 
) O 
. O 
UVB O 
exposure O 
effectively O 
increased O 
1,25(OH)(2)D B-SYSTEMATIC 
with O 
delayed O 
stimulatory O 
effect O 
on O 
FGF-23 O 
. O 
This O 
result O 
could O 
support O 
the O 
regulatory O 
loop O 
of O 
1,25(OH)(2)D B-SYSTEMATIC 
and O 
FGF-23 O 
in O 
human O 
, O 
FGF-23 O 
regulation O 
by O 
1,25(OH)(2)D B-SYSTEMATIC 
. O 

receptor O 
antagonist O 
a438079 O 
protects O 
against O 
acetaminophen B-TRIVIAL 
-induced O 
liver O 
injury O 
by O 
inhibiting O 
p450 O 
isoenzymes O 
, O 
not O 
by O 
inflammasome O 
activation O 
. O 

( O 
APAP B-ABBREVIATION 
) O 
overdose O 
is O 
the O 
most O 
frequent O 
cause O 
of O 
acute O 
liver O 
failure O 
in O 
the O 
western O 
world O 
. O 
Controversy O 
exists O 
regarding O 
the O 
hypothesis O 
that O 
the O 
hepatocyte O 
injury O 
is O 
amplified O 
by O 
a O 
sterile O 
inflammatory O 
response O 
, O 
rather O 
than O 
being O 
the O 
result O 
of O 
intracellular O 
mechanisms O 
alone O 
. O 
A O 
recent O 
study O 
suggested O 
that O 
the O 
purinergic O 
receptor O 
antagonist O 
A438079 B-IDENTIFIER 
protects O 
against O 
APAP B-ABBREVIATION 
-induced O 
liver O 
injury O 
by O 
preventing O 
the O 
activation O 
of O 
the O 
Nalp3 O 
inflammasome O 
in O 
Kupffer O 
cells O 
and O 
thereby O 
preventing O 
inflammatory O 
injury O 
. O 
To O 
test O 
the O 
hypothesis O 
that O 
A438079 B-IDENTIFIER 
actually O 
affects O 
the O 
intracellular O 
signaling O 
events O 
in O 
hepatocytes O 
, O 
C57Bl O 
/ O 
6 O 
mice O 
were O 
treated O 
with O 
APAP B-ABBREVIATION 
( O 
300 O 
mg O 
/ O 
kg O 
) O 
and O 
A438079 B-IDENTIFIER 
( O 
80 O 
mg O 
/ O 
kg O 
) O 
or O 
saline O 
and O 
GSH B-ABBREVIATION 
depletion O 
, O 
protein O 
adduct O 
formation O 
, O 
c-jun- O 
N B-FORMULA 
-terminal O 
kinase O 
( O 
JNK O 
) O 
activation O 
, O 
oxidant O 
stress O 
, O 
and O 
liver O 
cell O 
necrosis O 
were O 
determined O 
between O 
0 O 
and O 
6 O 
h O 
after O 
APAP B-ABBREVIATION 
administration O 
. O 
APAP B-ABBREVIATION 
caused O 
rapid O 
GSH B-ABBREVIATION 
depletion O 
, O 
extensive O 
protein O 
adduct O 
formation O 
in O 
liver O 
homogenates O 
and O 
in O 
mitochondria O 
, O 
JNK O 
phosphorylation O 
and O 
mitochondrial O 
translocation O 
of O 
phospho-JNK O 
within O 
2 O 
h O 
, O 
oxidant O 
stress O 
, O 
and O 
extensive O 
centrilobular O 
necrosis O 
at O 
6 O 
h O 
. O 
A438079 B-IDENTIFIER 
significantly O 
attenuated O 
GSH B-ABBREVIATION 
depletion O 
, O 
which O 
resulted O 
in O 
a O 
50% O 
reduction O 
of O 
total O 
liver O 
and O 
mitochondrial O 
protein O 
adducts O 
and O 
substantial O 
reduction O 
of O 
JNK O 
activation O 
, O 
mitochondrial O 
P-JNK O 
translocation O 
, O 
oxidant O 
stress O 
, O 
and O 
liver O 
injury O 
. O 
The O 
same O 
results O 
were O 
obtained O 
using O 
primary O 
mouse O 
hepatocytes O 
. O 
A438079 B-IDENTIFIER 
did O 
not O 
directly O 
affect O 
JNK O 
activation O 
induced O 
by O 
tert-butyl B-SYSTEMATIC 
hydroperoxide I-SYSTEMATIC 
and O 
GSH B-ABBREVIATION 
depletion O 
. O 
However O 
, O 
A438079 B-IDENTIFIER 
dose O 
- O 
dependently O 
inhibited O 
hepatic O 
P450 O 
enzyme O 
activity O 
. O 
Thus O 
, O 
the O 
protective O 
effect O 
of O 
A438079 B-IDENTIFIER 
against O 
APAP B-ABBREVIATION 
hepatotoxicity O 
in O 
vivo O 
can O 
be O 
explained O 
by O 
its O 
effect O 
on O 
metabolic O 
activation O 
and O 
cell O 
death O 
pathways O 
in O 
hepatocytes O 
without O 
involvement O 
of O 
the O 
Nalp3 O 
inflammasome O 
. O 

roles O 
of O 
single O 
- O 
wall O 
carbon B-SYSTEMATIC 
nanotubes O 
in O 
ultrasonication O 
- O 
induced O 
DNA O 
base O 
damage O 
. O 

overall O 
level O 
of O 
ultrasonication O 
- O 
induced O 
DNA O 
damage O 
is O 
reduced O 
in O 
the O 
presence O 
of O 
single O 
- O 
wall O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWCNTs O 
) O 
, O 
particularly O 
for O 
DNA O 
lesions O 
formed O 
by O 
one O 
- O 
electron O 
reduction O 
of O 
intermediate O 
radicals O 
. O 
The O 
protective O 
role O 
of O 
SWCNTs O 
observed O 
in O 
this O 
work O 
suggests O 
a O 
contrary O 
view O 
to O 
the O 
general O 
idea O 
that O 
carbon B-SYSTEMATIC 
nanotubes O 
have O 
damaging O 
effects O 
on O 
biomolecules O 
. O 

grafting O 
to O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
: O 
effect O 
of O 
chain O 
length O 
on O 
solubility O 
, O 
graft O 
density O 
and O 
mechanical O 
properties O 
of O 
macroscopic O 
structures O 
. O 

- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
are O 
grafted O 
with O 
polystyrene B-SYSTEMATIC 
chains O 
employing O 
a O 
graft O 
- O 
to O 
protocol O 
. O 
Thermogravimetric O 
analysis O 
allows O 
calculation O 
of O 
the O 
grafted O 
chain O 
density O 
and O 
average O 
interchain O 
separation O 
on O 
the O 
nanotube O 
surface O 
as O 
a O 
function O 
of O 
molecular O 
weight O 
. O 
The O 
separation O 
scales O 
with O 
molecular O 
weight O 
as O 
a O 
power O 
law O 
with O 
an O 
exponent O 
of O 
ca O 
. O 
0.588 O 
, O 
showing O 
the O 
grafted O 
chains O 
to O 
be O 
in O 
a O 
swollen O 
random O 
walk O 
conformation O 
. O 
This O 
implies O 
that O 
chain O 
packing O 
is O 
controlled O 
by O 
coil O 
size O 
in O 
solution O 
. O 
In O 
addition O 
, O 
the O 
dispersed O 
concentration O 
of O 
functionalized O 
nanotubes O 
scales O 
with O 
the O 
size O 
of O 
the O 
steric O 
potential O 
barrier O 
that O 
prevents O 
aggregation O 
of O 
polymer O 
functionalized O 
nanotubes O 
. O 
It O 
is O 
also O 
shown O 
that O 
the O 
molecular O 
weight O 
of O 
the O 
grafted O 
chains O 
significantly O 
affects O 
the O 
mechanical O 
properties O 
of O 
nanotube O 
films O 
. O 

A I-TRIVIAL 
-stimulated O 
Ca2+ B-FORMULA 
entry O 
, O 
ceramide B-FAMILY 
formation O 
and O 
suicidal O 
death O 
of O 
erythrocytes O 
. O 

A I-TRIVIAL 
, O 
a O 
triterpenoid B-FAMILY 
component O 
from O 
Withania O 
somnifera O 
, O 
counteracts O 
malignancy O 
, O 
an O 
effect O 
attributed O 
to O 
stimulation O 
of O 
apoptosis O 
. O 
Withaferin B-TRIVIAL 
A I-TRIVIAL 
is O 
partially O 
effective O 
through O 
induction O 
of O 
oxidative O 
stress O 
, O 
altered O 
gene O 
expression O 
and O 
mitochondrial O 
depolarization O 
. O 
Erythrocytes O 
lack O 
mitochondria O 
and O 
nuclei O 
but O 
may O 
enter O 
apoptosis O 
- O 
like O 
eryptosis O 
, O 
a O 
suicidal O 
cell O 
death O 
characterized O 
by O 
cell O 
shrinkage O 
and O 
cell O 
membrane O 
scrambling O 
with O 
phosphatidylserine B-FAMILY 
exposure O 
at O 
the O 
cell O 
surface O 
. O 
Triggers O 
of O 
eryptosis O 
include O 
increase O 
of O 
cytosolic O 
Ca(2+) B-FORMULA 
-activity O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
following O 
activation O 
of O 
oxidant O 
- O 
sensitive O 
Ca(2+) B-FORMULA 
-permeable O 
cation O 
channels O 
, O 
ceramide B-FAMILY 
formation O 
and O 
/ O 
or O 
ATP B-ABBREVIATION 
-depletion O 
. O 
The O 
present O 
study O 
explored O 
, O 
whether O 
withaferin B-TRIVIAL 
A I-TRIVIAL 
triggers O 
eryptosis O 
. O 
To O 
this O 
end O 
, O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
was O 
estimated O 
from O 
Fluo3 B-TRIVIAL 
-fluorescence O 
, O 
cell O 
volume O 
from O 
forward O 
scatter O 
, O 
phosphatidylserine B-FAMILY 
exposure O 
from O 
annexin-V O 
- O 
binding O 
, O 
hemolysis O 
from O 
hemoglobin O 
release O 
, O 
oxidative O 
stress O 
from O 
DCFDA B-ABBREVIATION 
-fluorescence O 
and O 
ceramide B-FAMILY 
abundance O 
utilizing O 
antibodies O 
. O 
A O 
48 O 
h O 
exposure O 
to O 
withaferin B-TRIVIAL 
A I-TRIVIAL 
significantly O 
decreased O 
forward O 
scatter O 
( O 
at O 
≥ O 
10 O 
μM O 
withaferin B-TRIVIAL 
concentration O 
) O 
and O 
increased O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
( O 
≥ O 
5 O 
μM O 
) O 
, O 
ROS O 
- O 
formation O 
( O 
≥ O 
10 O 
μM O 
) O 
ceramide B-FAMILY 
-formation O 
( O 
≥ O 
10 O 
μM O 
) O 
as O 
well O 
as O 
annexin-V O 
- O 
binding O 
( O 
≥ O 
5 O 
μM O 
) O 
. O 
Withaferin B-TRIVIAL 
A I-TRIVIAL 
treatment O 
was O 
followed O 
by O 
slight O 
but O 
significant O 
increase O 
of O 
hemolysis O 
. O 
Extracellular O 
Ca(2+) B-FORMULA 
removal O 
, O 
amiloride B-TRIVIAL 
, O 
and O 
the O 
antioxidant O 
N-acetyl-l-cysteine B-SYSTEMATIC 
significantly O 
blunted O 
withaferin B-TRIVIAL 
A I-TRIVIAL 
-triggered O 
annexin-V O 
- O 
binding O 
. O 
The O 
present O 
observations O 
reveal O 
that O 
withaferin B-TRIVIAL 
A I-TRIVIAL 
triggers O 
suicidal O 
erythrocyte O 
death O 
despite O 
the O 
absence O 
of O 
gene O 
expression O 
and O 
key O 
elements O 
of O 
apoptosis O 
such O 
as O 
mitochondria O 
. O 

microbiota O 
of O 
Westerners O 
is O 
significantly O 
reduced O 
in O 
comparison O 
to O 
rural O 
individuals O 
living O 
a O 
similar O 
lifestyle O 
to O 
our O 
Paleolithic O 
forefathers O 
but O 
also O 
to O 
that O 
of O 
other O 
free O 
- O 
living O 
primates O 
such O 
as O 
the O 
chimpanzee O 
. O 
The O 
great O 
majority O 
of O 
ingredients O 
in O 
the O 
industrially O 
produced O 
foods O 
consumed O 
in O 
the O 
West O 
are O 
absorbed O 
in O 
the O 
upper O 
part O 
of O 
small O 
intestine O 
and O 
thus O 
of O 
limited O 
benefit O 
to O 
the O 
microbiota O 
. O 
Lack O 
of O 
proper O 
nutrition O 
for O 
microbiota O 
is O 
a O 
major O 
factor O 
under O 
- O 
pinning O 
dysfunctional O 
microbiota O 
, O 
dysbiosis O 
, O 
chronically O 
elevated O 
inflammation O 
, O 
and O 
the O 
production O 
and O 
leakage O 
of O 
endotoxins O 
through O 
the O 
various O 
tissue O 
barriers O 
. O 
Furthermore O 
, O 
the O 
over O 
- O 
comsumption O 
of O 
insulinogenic O 
foods O 
and O 
proteotoxins O 
, O 
such O 
as O 
advanced O 
glycation O 
and O 
lipoxidation O 
molecules O 
, O 
gluten O 
and O 
zein O 
, O 
and O 
a O 
reduced O 
intake O 
of O 
fruit O 
and O 
vegetables O 
, O 
are O 
key O 
factors O 
behind O 
the O 
commonly O 
observed O 
elevated O 
inflammation O 
and O 
the O 
endemic O 
of O 
obesity O 
and O 
chronic O 
diseases O 
, O 
factors O 
which O 
are O 
also O 
likely O 
to O 
be O 
detrimental O 
to O 
microbiota O 
. O 
As O 
a O 
consequence O 
of O 
this O 
lifestyle O 
and O 
the O 
associated O 
eating O 
habits O 
, O 
most O 
barriers O 
, O 
including O 
the O 
gut O 
, O 
the O 
airways O 
, O 
the O 
skin O 
, O 
the O 
oral O 
cavity O 
, O 
the O 
vagina O 
, O 
the O 
placenta O 
, O 
the O 
blood O 
- O 
brain O 
barrier O 
, O 
etc O 
. O 
, O 
are O 
increasingly O 
permeable O 
. O 
Attempts O 
to O 
recondition O 
these O 
barriers O 
through O 
the O 
use O 
of O 
so O 
called O 
' O 
probiotics O 
' O 
, O 
normally O 
applied O 
to O 
the O 
gut O 
, O 
are O 
rarely O 
successful O 
, O 
and O 
sometimes O 
fail O 
, O 
as O 
they O 
are O 
usually O 
applied O 
as O 
adjunctive O 
treatments O 
, O 
e.g O 
. O 
in O 
parallel O 
with O 
heavy O 
pharmaceutical O 
treatment O 
, O 
not O 
rarely O 
consisting O 
in O 
antibiotics O 
and O 
chemotherapy O 
. O 
It O 
is O 
increasingly O 
observed O 
that O 
the O 
majority O 
of O 
pharmaceutical O 
drugs O 
, O 
even O 
those O 
believed O 
to O 
have O 
minimal O 
adverse O 
effects O 
, O 
such O 
as O 
proton O 
pump O 
inhibitors O 
and O 
anti-hypertensives O 
, O 
in O 
fact O 
adversely O 
affect O 
immune O 
development O 
and O 
functions O 
and O 
are O 
most O 
likely O 
also O 
deleterious O 
to O 
microbiota O 
. O 
Equally O 
, O 
it O 
appears O 
that O 
probiotic O 
treatment O 
is O 
not O 
compatible O 
with O 
pharmacological O 
treatments O 
. O 
Eco O 
- O 
biological O 
treatments O 
, O 
with O 
plant O 
- O 
derived O 
substances O 
, O 
or O 
phytochemicals O 
, O 
e.g O 
. O 
curcumin B-TRIVIAL 
and O 
resveratrol B-TRIVIAL 
, O 
and O 
pre- O 
, O 
pro- O 
and O 
syn-biotics O 
offers O 
similar O 
effects O 
as O 
use O 
of O 
biologicals O 
, O 
although O 
milder O 
but O 
also O 
free O 
from O 
adverse O 
effects O 
. O 
Such O 
treatments O 
should O 
be O 
tried O 
as O 
alternative O 
therapies O 
; O 
mainly O 
, O 
to O 
begin O 
with O 
, O 
for O 
disease O 
prevention O 
but O 
also O 
in O 
early O 
cases O 
of O 
chronic O 
diseases O 
. O 
Pharmaceutical O 
treatment O 
has O 
, O 
thus O 
far O 
, O 
failed O 
to O 
inhibit O 
the O 
tsunami O 
of O 
endemic O 
diseases O 
spreading O 
around O 
the O 
world O 
, O 
and O 
no O 
new O 
tools O 
are O 
in O 
sight O 
. O 
Dramatic O 
alterations O 
, O 
in O 
direction O 
of O 
a O 
paleolithic O 
- O 
like O 
lifestyle O 
and O 
food O 
habits O 
, O 
seem O 
to O 
be O 
the O 
only O 
alternatives O 
with O 
the O 
potential O 
to O 
control O 
the O 
present O 
escalating O 
crisis O 
. O 
The O 
present O 
review O 
focuses O 
on O 
human O 
studies O 
, O 
especially O 
those O 
of O 
clinical O 
relevance O 
. O 

methylcarbamates I-FAMILY 
: O 
Potency O 
and O 
selectivity O 
towards O 
wild O 
- O 
type O 
and O 
carbamate B-FAMILY 
-insensitive O 
( O 
G119S O 
) O 
Anopheles O 
gambiae O 
acetylcholinesterase O 
, O 
and O 
toxicity O 
to O 
G3 O 
strain O 
An O 
. O 
gambiae O 
. O 

carbamates B-FAMILY 
that O 
are O 
highly O 
selective O 
for O 
inhibition O 
of O 
Anopheles O 
gambiae O 
acetylcholinesterase O 
( O 
AChE O 
) O 
over O 
the O 
human O 
enzyme O 
might O 
be O 
useful O 
in O 
continuing O 
efforts O 
to O 
limit O 
malaria O 
transmission O 
. O 
In O 
this O 
report O 
we O 
assessed O 
34 O 
synthesized O 
and O 
commercial O 
carbamates B-FAMILY 
for O 
their O 
selectivity O 
to O 
inhibit O 
the O 
AChEs O 
found O 
in O 
carbamate B-FAMILY 
-susceptible O 
( O 
G3 O 
) O 
and O 
carbamate B-FAMILY 
-resistant O 
( O 
Akron O 
) O 
An O 
. O 
gambiae O 
, O 
relative O 
to O 
human O 
AChE O 
. O 
Excellent O 
correspondence O 
is O 
seen O 
between O 
inhibition O 
potencies O 
measured O 
with O 
carbamate B-FAMILY 
-susceptible O 
mosquito O 
homogenate O 
and O 
purified O 
recombinant O 
wild O 
- O 
type O 
( O 
WT O 
) O 
An O 
. O 
gambiae O 
AChE O 
( O 
AgAChE O 
) O 
. O 
Similarly O 
, O 
excellent O 
correspondence O 
is O 
seen O 
between O 
inhibition O 
potencies O 
measured O 
with O 
carbamate B-FAMILY 
-resistant O 
mosquito O 
homogenate O 
and O 
purified O 
recombinant O 
G119S O 
AgAChE O 
, O 
consistent O 
with O 
our O 
earlier O 
finding O 
that O 
the O 
Akron O 
strain O 
carries O 
the O 
G119S O 
mutation O 
. O 
Although O 
high O 
( O 
100- O 
to O 
500-fold O 
) O 
WT O 
An O 
. O 
gambiae O 
vs O 
human O 
selectivity O 
is O 
observed O 
for O 
several O 
compounds O 
, O 
none O 
of O 
the O 
carbamates B-FAMILY 
tested O 
potently O 
inhibits O 
the O 
G119S O 
mutant O 
enzyme O 
. O 
Finally O 
, O 
we O 
describe O 
a O 
predictive O 
model O 
for O 
WT O 
An O 
. O 
gambiae O 
tarsal O 
contact O 
toxicity O 
of O 
the O 
carbamates B-FAMILY 
that O 
relies O 
on O 
inhibition O 
potency O 
, O 
molecular O 
volume O 
, O 
and O 
polar O 
surface O 
area O 
. O 

- O 
linked O 
hypophosphatemia O 
( O 
XLH O 
/ O 
HYP)-with O 
renal O 
phosphate B-SYSTEMATIC 
wasting O 
, O 
hypophosphatemia O 
, O 
osteomalacia O 
, O 
and O 
tooth O 
abscesses O 
- O 
is O 
caused O 
by O 
mutations O 
in O 
the O 
zinc B-SYSTEMATIC 
-metallopeptidase O 
PHEX O 
gene O 
( O 
phosphate B-SYSTEMATIC 
-regulating O 
gene O 
with O 
homologies O 
to O 
endopeptidase O 
on O 
the O 
X O 
chromosome O 
) O 
. O 
PHEX O 
is O 
highly O 
expressed O 
by O 
mineralized O 
tissue O 
cells O 
. O 
Inactivating O 
mutations O 
in O 
PHEX O 
lead O 
to O 
distal O 
renal O 
effects O 
( O 
implying O 
accumulation O 
of O 
a O 
secreted O 
, O 
circulating O 
phosphaturic O 
factor O 
) O 
and O 
accumulation O 
in O 
bone O 
and O 
teeth O 
of O 
mineralization O 
- O 
inhibiting O 
, O 
acidic O 
serine B-TRIVIAL 
- O 
and O 
aspartate B-TRIVIAL 
-rich O 
motif O 
( O 
ASARM O 
) O 
- O 
containing O 
peptides O 
, O 
which O 
are O 
proteolytically O 
derived O 
from O 
the O 
mineral O 
- O 
binding O 
matrix O 
proteins O 
of O 
the O 
SIBLING O 
family O 
( O 
small O 
, O 
integrin O 
- O 
binding O 
ligand O 
N B-FORMULA 
-linked O 
glycoproteins O 
) O 
. O 
Although O 
the O 
latter O 
observation O 
suggests O 
a O 
local O 
, O 
direct O 
matrix O 
effect O 
for O 
PHEX O 
, O 
its O 
physiologically O 
relevant O 
substrate O 
protein(s) O 
have O 
not O 
been O 
identified O 
. O 
Here O 
, O 
we O 
investigated O 
two O 
SIBLING O 
proteins O 
containing O 
the O 
ASARM O 
motif O 
- O 
osteopontin O 
( O 
OPN O 
) O 
and O 
bone O 
sialoprotein O 
(BSP)-as O 
potential O 
substrates O 
for O 
PHEX O 
. O 
Using O 
cleavage O 
assays O 
, O 
gel O 
electrophoresis O 
, O 
and O 
mass O 
spectrometry O 
, O 
we O 
report O 
that O 
OPN O 
is O 
a O 
full O 
- O 
length O 
protein O 
substrate O 
for O 
PHEX O 
. O 
Degradation O 
of O 
OPN O 
was O 
essentially O 
complete O 
, O 
including O 
hydrolysis O 
of O 
the O 
ASARM O 
motif O 
, O 
resulting O 
in O 
only O 
very O 
small O 
residual O 
fragments O 
. O 
Western O 
blotting O 
of O 
Hyp O 
( O 
the O 
murine O 
homolog O 
of O 
human O 
XLH O 
) O 
mouse O 
bone O 
extracts O 
having O 
no O 
PHEX O 
activity O 
clearly O 
showed O 
accumulation O 
of O 
an O 
∼35 O 
kDa O 
OPN O 
fragment O 
that O 
was O 
not O 
present O 
in O 
wild O 
- O 
type O 
mouse O 
bone O 
. O 
Immunohistochemistry O 
and O 
immunogold O 
labeling O 
( O 
electron O 
microscopy O 
) O 
for O 
OPN O 
in O 
Hyp O 
bone O 
likewise O 
showed O 
an O 
accumulation O 
of O 
OPN O 
and O 
/ O 
or O 
its O 
fragments O 
compared O 
with O 
normal O 
wild O 
- O 
type O 
bone O 
. O 
Incubation O 
of O 
Hyp O 
mouse O 
bone O 
extracts O 
with O 
PHEX O 
resulted O 
in O 
the O 
complete O 
degradation O 
of O 
these O 
fragments O 
. O 
In O 
conclusion O 
, O 
these O 
results O 
identify O 
full O 
- O 
length O 
OPN O 
and O 
its O 
fragments O 
as O 
novel O 
, O 
physiologically O 
relevant O 
substrates O 
for O 
PHEX O 
, O 
suggesting O 
that O 
accumulation O 
of O 
mineralization O 
- O 
inhibiting O 
OPN O 
fragments O 
may O 
contribute O 
to O 
the O 
mineralization O 
defect O 
seen O 
in O 
the O 
osteomalacic O 
bone O 
characteristic O 
of O 
XLH O 
/ O 
HYP O 
. O 

acid I-TRIVIAL 
but O 
not O 
D-cycloserine B-TRIVIAL 
facilitates O 
sleep O 
- O 
dependent O 
offline O 
learning O 
of O 
extinction O 
and O 
habituation O 
of O 
conditioned O 
fear O 
in O 
humans O 
. O 

effectiveness O 
of O 
D-cycloserine B-TRIVIAL 
( O 
DCS B-ABBREVIATION 
) O 
, O 
an O 
N-methyl-D-aspartate B-SYSTEMATIC 
glutamate I-SYSTEMATIC 
receptor O 
partial O 
agonist O 
, O 
and O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
( O 
VPA B-ABBREVIATION 
) O 
, O 
a O 
histone O 
deacetylase O 
inhibitor O 
, O 
in O 
facilitating O 
the O 
extinction O 
of O 
fear O 
- O 
conditioned O 
memory O 
has O 
been O 
explored O 
in O 
humans O 
and O 
animals O 
. O 
Here O 
, O 
we O 
confirmed O 
whether O 
DCS B-ABBREVIATION 
( O 
100 O 
mg O 
) O 
and O 
VPA B-ABBREVIATION 
( O 
400 O 
mg O 
) O 
act O 
in O 
off O 
- O 
line O 
learning O 
processes O 
during O 
sleep O 
or O 
waking O 
, O 
for O 
further O 
clinical O 
application O 
to O 
anxiety O 
disorders O 
and O 
posttraumatic O 
stress O 
disorder O 
( O 
PTSD O 
) O 
. O 
We O 
performed O 
a O 
randomized O 
, O 
blind O 
, O 
placebo O 
- O 
controlled O 
clinical O 
trial O 
in O 
90 O 
healthy O 
adults O 
. O 
Visual O 
cues O 
and O 
electric O 
shocks O 
were O 
used O 
as O 
the O 
conditioned O 
stimulus O 
( O 
CS O 
) O 
and O 
unconditioned O 
stimulus O 
( O 
US O 
) O 
, O 
respectively O 
. O 
The O 
extinction O 
effect O 
was O 
observed O 
not O 
in O 
simple O 
recall O 
after O 
the O 
extinction O 
of O 
coupled O 
CS-US O 
, O 
but O 
was O 
observed O 
in O 
the O 
post O 
- O 
re O 
- O 
exposure O 
phase O 
after O 
unexpected O 
re O 
- O 
exposure O 
to O 
reinstatement O 
CS-US O 
coupling O 
. O 
Newly O 
acquired O 
conditioned O 
fear O 
was O 
also O 
eliminated O 
or O 
habituated O 
by O 
DCS B-ABBREVIATION 
and O 
VPA B-ABBREVIATION 
administration O 
, O 
in O 
line O 
with O 
previous O 
findings O 
. O 
Furthermore O 
, O 
VPA B-ABBREVIATION 
facilitated O 
the O 
off O 
- O 
line O 
learning O 
process O 
of O 
conditioned O 
fear O 
extinction O 
and O 
habituation O 
during O 
sleep O 
, O 
while O 
DCS B-ABBREVIATION 
facilitated O 
this O 
process O 
during O 
waking O 
. O 
These O 
novel O 
findings O 
suggest O 
that O 
DCS B-ABBREVIATION 
and O 
VPA B-ABBREVIATION 
might O 
enhance O 
exposure O 
- O 
based O 
cognitive O 
therapy O 
for O 
anxiety O 
disorders O 
and O 
PTSD O 
by O 
reducing O 
the O 
vulnerability O 
to O 
reinstatement O 
and O 
preventing O 
relapses O 
of O 
fear O 
- O 
conditioned O 
responses O 
, O 
and O 
provide O 
evidence O 
for O 
a O 
peculiarity O 
of O 
the O 
sleep O 
- O 
dependent O 
off O 
- O 
line O 
learning O 
process O 
for O 
conditioned O 
fear O 
extinction O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

effects O 
of O 
caffeine B-TRIVIAL 
on O 
attention O 
: O 
a O 
comparison O 
of O 
non-consumers O 
and O 
withdrawn O 
consumers O 
. O 

the O 
large O 
number O 
of O 
studies O 
on O 
caffeine B-TRIVIAL 
and O 
attention O 
, O 
interpretation O 
is O 
often O 
difficult O 
because O 
of O 
methodological O 
weaknesses O 
. O 
In O 
the O 
present O 
study O 
, O 
use O 
of O 
a O 
small O 
battery O 
of O 
tests O 
with O 
four O 
key O 
outcome O 
measures O 
, O 
combined O 
with O 
an O 
appropriate O 
sample O 
size O 
, O 
addresses O 
many O 
of O 
these O 
problems O 
. O 
This O 
methodology O 
was O 
used O 
to O 
examine O 
whether O 
effects O 
of O 
caffeine B-TRIVIAL 
( O 
a O 
dose O 
of O 
2 O 
mg O 
/ O 
kg O 
) O 
could O 
be O 
explained O 
in O 
terms O 
of O 
reversal O 
of O 
the O 
effects O 
of O 
caffeine B-TRIVIAL 
withdrawal O 
. O 
This O 
was O 
achieved O 
by O 
examining O 
effects O 
in O 
non-consumers O 
( O 
N O 
= O 
35 O 
) O 
, O 
who O 
could O 
not O 
be O 
withdrawn O 
, O 
and O 
also O 
in O 
a O 
group O 
of O 
consumers O 
( O 
N O 
= O 
35 O 
) O 
who O 
had O 
undergone O 
withdrawal O 
for O 
a O 
week O 
and O 
no O 
longer O 
reported O 
symptoms O 
of O 
withdrawal O 
. O 
The O 
results O 
showed O 
no O 
effect O 
of O 
short O 
- O 
term O 
withdrawal O 
on O 
the O 
performance O 
measures O 
, O 
even O 
though O 
subjective O 
reports O 
showed O 
an O 
increase O 
in O 
symptoms O 
after O 
withdrawal O 
. O 
In O 
contrast O 
, O 
the O 
caffeine B-TRIVIAL 
challenge O 
carried O 
out O 
on O 
Day O 
8 O 
showed O 
that O 
ingestion O 
of O 
caffeine B-TRIVIAL 
was O 
associated O 
with O 
faster O 
simple O 
reaction O 
time O 
, O 
fewer O 
long O 
responses O 
, O 
greater O 
detection O 
of O 
targets O 
in O 
the O 
cognitive O 
vigilance O 
task O 
, O 
and O 
faster O 
encoding O 
of O 
new O 
information O 
. O 
These O 
results O 
suggest O 
that O 
it O 
is O 
important O 
to O 
continue O 
to O 
investigate O 
mechanisms O 
underlying O 
these O 
effects O 
of O 
caffeine B-TRIVIAL 
and O 
to O 
further O 
evaluate O 
the O 
practical O 
implications O 
of O 
such O 
effects O 
. O 

potential O 
of O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
in O 
the O 
rat O 
brain O 
striatum O 
and O 
hippocampus O 
. O 

has O 
recently O 
been O 
reported O 
that O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
( O 
Fe(3)O(4) B-FORMULA 
-NPs O 
, O 
30 O 
nm O 
) O 
have O 
the O 
ability O 
to O 
translocate O 
directly O 
from O 
the O 
olfactory O 
nerve O 
to O 
the O 
brain O 
. O 
The O 
striatum O 
and O 
hippocampus O 
are O 
important O 
structures O 
in O 
the O 
brain O 
and O 
are O 
associated O 
with O 
the O 
development O 
of O 
Parkinson's O 
and O 
Alzheimer's O 
diseases O 
. O 
Therefore O 
, O 
it O 
is O 
critical O 
to O 
evaluate O 
Fe(3)O(4) B-FORMULA 
-NPs O 
and O 
their O 
potential O 
to O 
confer O 
striatum O 
and O 
hippocampus O 
neurotoxicity O 
. O 
This O 
study O 
focuses O 
on O 
the O 
effects O 
of O 
Fe(3)O(4) B-FORMULA 
-NPs O 
on O 
the O 
striatum O 
and O 
hippocampus O 
, O 
including O 
oxidative O 
injury O 
and O 
the O 
accumulation O 
and O 
retention O 
of O 
Fe(3)O(4) B-FORMULA 
-NPs O 
. O 
This O 
study O 
also O 
explores O 
the O 
molecular O 
mechanism O 
of O 
oxidative O 
damage O 
in O 
dopaminergic O 
neurons O 
; O 
we O 
were O 
able O 
to O 
assess O 
the O 
neurotoxic O 
effects O 
of O 
Fe(3)O(4) B-FORMULA 
-NPs O 
by O 
incubating O 
dopaminergic O 
neurons O 
with O 
radioactive O 
Fe(3)O(4) B-FORMULA 
-NPs O 
. O 
A O 
regional O 
distribution O 
of O 
Fe(3)O(4) B-FORMULA 
-NPs O 
was O 
observed O 
in O 
rat O 
brains O 
after O 
the O 
particles O 
were O 
intranasally O 
instilled O 
for O 
seven O 
days O 
. O 
The O 
particles O 
were O 
found O 
to O 
be O 
deposited O 
at O 
particularly O 
high O 
concentrations O 
in O 
the O 
rat O 
striata O 
and O 
hippocampi O 
. O 
Over O 
half O 
of O 
the O 
Fe(3)O(4) B-FORMULA 
-NPs O 
were O 
retained O 
in O 
the O 
striata O 
for O 
a O 
minimum O 
of O 
14 O 
days O 
, O 
and O 
may O 
have O 
induced O 
oxidative O 
damage O 
to O 
the O 
region O 
. O 
However O 
, O 
no O 
injuries O 
were O 
observed O 
in O 
the O 
hippocampi O 
. O 
These O 
in O 
vitro O 
studies O 
demonstrate O 
that O 
Fe(3)O(4) B-FORMULA 
-NPs O 
may O 
decrease O 
neuron O 
viability O 
, O 
trigger O 
oxidative O 
stress O 
, O 
and O 
activate O 
JNK- O 
and O 
p53 O 
- O 
mediated O 
pathways O 
to O 
regulate O 
the O 
cell O 
cycle O 
and O 
apoptosis O 
. O 
These O 
results O 
also O 
suggest O 
that O 
environmental O 
exposure O 
to O 
Fe(3)O(4) B-FORMULA 
-NPs O 
may O 
play O 
a O 
role O 
in O 
the O 
development O 
of O 
neurodegenerative O 
diseases O 
. O 

of O 
apoptosis O 
in O 
human O 
ovarian O 
cancer O 
cells O 
by O 
new O 
anticancer O 
compounds O 
, O 
epothilone B-MULTIPLE 
A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
. O 

are O 
a O 
new O 
group O 
of O 
compounds O 
with O 
action O 
mechanisms O 
similar O 
to O 
taxanes B-FAMILY 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
compare O 
the O 
effects O 
of O 
epothilone B-TRIVIAL 
A I-TRIVIAL 
( O 
Epo B-ABBREVIATION 
A I-ABBREVIATION 
) O 
and O 
epothilone B-TRIVIAL 
B I-TRIVIAL 
( O 
Epo B-ABBREVIATION 
B I-ABBREVIATION 
) O 
on O 
ovarian O 
cancer O 
cell O 
line O 
SKOV-3 O 
with O 
those O 
of O 
paclitaxel B-TRIVIAL 
( O 
PTX B-ABBREVIATION 
) O 
, O 
a O 
classic O 
taxane B-FAMILY 
. O 
We O 
evaluate O 
glycoprotein O 
P O 
( O 
P-gp O 
) O 
activity O 
in O 
the O 
ovarian O 
cancer O 
cell O 
line O 
. O 
Apoptotic O 
and O 
necrotic O 
cell O 
levels O 
were O 
measured O 
by O 
double O 
staining O 
with O 
Hoechst B-TRIVIAL 
33258 I-TRIVIAL 
and O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
( O 
PI O 
) O 
as O 
well O 
as O 
Annexin O 
V O 
staining O 
. O 
The O 
production O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
and O 
changes O 
in O 
mitochondrial O 
membrane O 
potential O 
( O 
ΔΨm O 
) O 
in O 
cells O 
exposed O 
to O 
Epo B-ABBREVIATION 
A I-ABBREVIATION 
, O 
Epo B-ABBREVIATION 
B I-ABBREVIATION 
and O 
PTX B-ABBREVIATION 
were O 
studied O 
using O 
specific O 
fluorescence O 
probes O 
, O 
DCFH(2)-DA B-ABBREVIATION 
( O 
2',7'-dichlorodihydrofluorescein B-SYSTEMATIC 
diacetate I-SYSTEMATIC 
) O 
and O 
JC-1 B-IDENTIFIER 
( O 
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine B-SYSTEMATIC 
) O 
. O 
The O 
cytotoxic O 
activity O 
of O 
the O 
drugs O 
was O 
determined O 
by O 
the O 
MTT B-ABBREVIATION 
( O 
3-(4,5-dimethylthiazol-2-yl)-2,5 B-SYSTEMATIC 
diphenyltetrazolium I-SYSTEMATIC 
bromide I-SYSTEMATIC 
) O 
test O 
. O 
All O 
probes O 
were O 
analyzed O 
in O 
both O 
the O 
presence O 
and O 
absence O 
of O 
the O 
antioxidant O 
N-acetylcysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
. O 
The O 
results O 
obtained O 
demonstrated O 
that O 
the O 
antiproliferative O 
capacity O 
of O 
Epo B-ABBREVIATION 
A I-ABBREVIATION 
and O 
Epo B-ABBREVIATION 
B I-ABBREVIATION 
in O 
SKOV-3 O 
cell O 
line O 
( O 
measured O 
as O 
IC(50) O 
after O 
72 O 
h O 
continuous O 
treatment O 
) O 
was O 
six O 
and O 
five O 
times O 
greater O 
than O 
that O 
of O 
PTX B-ABBREVIATION 
' O 
s O 
respectively O 
. O 
Epothilones B-FAMILY 
induced O 
timecourse O 
- O 
dependent O 
apoptosis O 
and O 
necrosis O 
. O 
Apoptotic O 
and O 
necrotic O 
events O 
were O 
partially O 
blocked O 
by O 
NAC B-ABBREVIATION 
, O 
indicating O 
ROS O 
played O 
a O 
substantial O 
role O 
in O 
epothilone B-FAMILY 
-induced O 
apoptosis O 
. O 
Cell O 
death O 
was O 
also O 
associated O 
with O 
a O 
decrease O 
in O 
mitochondrial O 
membrane O 
potential O 
, O 
which O 
was O 
more O 
pronounced O 
after O 
treatment O 
with O 
epothilones B-FAMILY 
as O 
compared O 
to O 
paclitaxel B-TRIVIAL 
. O 

oral O 
bioavailability O 
of O 
isradipine B-TRIVIAL 
via O 
proniosomal O 
systems O 
. O 

objective O 
of O 
the O 
present O 
research O 
was O 
to O 
develop O 
a O 
proniosomal O 
formulation O 
of O 
isradipine B-TRIVIAL 
and O 
to O 
evaluate O 
the O 
influence O 
of O 
proniosomal O 
systems O 
on O 
the O 
oral O 
bioavailability O 
of O 
the O 
drug O 
in O 
albino O 
Wistar O 
rats O 
. O 
Proniosomes O 
were O 
prepared O 
by O 
film O 
deposition O 
on O 
carrier's O 
method O 
using O 
various O 
molar O 
ratios O 
of O 
nonionic O 
surfactants O 
such O 
as O 
span20 B-TRIVIAL 
, O 
span40 B-TRIVIAL 
, O 
span60 B-TRIVIAL 
, O 
and O 
span80 B-TRIVIAL 
with O 
cholesterol B-TRIVIAL 
as O 
membrane O 
stabilizing O 
agent O 
and O 
dicetylphosphate B-SYSTEMATIC 
as O 
a O 
charge O 
inducer O 
. O 
The O 
formation O 
of O 
niosomes O 
and O 
surface O 
morphology O 
of O 
proniosome O 
formulations O 
were O 
studied O 
by O 
optical O 
and O 
scanning O 
electron O 
microscopy O 
( O 
SEM O 
) O 
, O 
respectively O 
. O 
The O 
prepared O 
proniosomes O 
have O 
shown O 
higher O 
dissolution O 
of O 
isradipine B-TRIVIAL 
compared O 
with O 
pure O 
drug O 
powder O 
. O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
, O 
differential O 
scanning O 
calorimetry O 
, O 
and O 
powder O 
X-ray O 
diffractometry O 
studies O 
were O 
performed O 
to O 
understand O 
the O 
solid O 
state O 
properties O 
of O 
the O 
drug O 
. O 
Ex O 
vivo O 
permeation O 
enhancement O 
assessed O 
from O 
flux O 
, O 
permeability O 
coefficient O 
, O 
and O 
enhancement O 
ratio O 
were O 
significantly O 
higher O 
for O 
proniosomes O 
compared O 
with O 
control O 
. O 
The O 
pharmacokinetic O 
parameters O 
were O 
evaluated O 
in O 
male O 
albino O 
Wistar O 
rats O 
and O 
a O 
significant O 
enhancement O 
in O 
the O 
bioavailability O 
( O 
2.3-fold O 
) O 
was O 
observed O 
from O 
optimized O 
proniosome O 
formulation O 
compared O 
with O 
control O 
( O 
oral O 
suspension O 
) O 
. O 
The O 
stability O 
study O 
reveals O 
that O 
the O 
proniosome O 
formulations O 
are O 
stable O 
when O 
stored O 
at O 
4°C O 
. O 

of O 
β-cyclodextrin B-TRIVIAL 
inclusion O 
complex O 
and O 
self O 
- O 
microemulsifying O 
drug O 
delivery O 
system O 
for O 
photostability O 
and O 
enhanced O 
oral O 
bioavailability O 
of O 
methotrexate B-TRIVIAL 
: O 
novel O 
technique O 
. O 

the O 
present O 
study O 
, O 
we O 
prepared O 
an O 
inclusion O 
complex O 
of O 
methotrexate B-TRIVIAL 
( O 
MTX B-ABBREVIATION 
) O 
with O 
β-cyclodextrin B-TRIVIAL 
( O 
β-CD B-ABBREVIATION 
) O 
in O 
order O 
to O 
decrease O 
its O 
photosensitivity O 
and O 
enhance O 
its O 
aqueous O 
solubility O 
. O 
Then O 
we O 
incorporated O 
this O 
inclusion O 
complex O 
in O 
a O 
self O 
- O 
microemulsifying O 
drug O 
delivery O 
system O 
( O 
SMEDDS O 
) O 
overall O 
to O 
increase O 
its O 
oral O 
bioavailability O 
. O 
The O 
inclusion O 
complex O 
has O 
been O 
prepared O 
by O 
freeze O 
drying O 
method O 
and O 
characterized O 
by O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
, O 
ultraviolet O 
( O 
UV O 
) O 
, O 
and O 
infrared O 
( O 
IR O 
) O 
spectroscopy O 
assays O 
. O 
The O 
proper O 
molecular O 
ratio O 
of O 
MTX B-ABBREVIATION 
/ O 
β-CD B-ABBREVIATION 
was O 
found O 
to O 
be O 
of O 
1 O 
: O 
7 O 
, O 
and O 
the O 
water O 
- O 
solubility O 
of O 
MTX B-ABBREVIATION 
was O 
increased O 
in O 
an O 
average O 
of O 
10-fold O 
. O 
The O 
photostability O 
studies O 
showed O 
that O 
the O 
MTX B-ABBREVIATION 
became O 
stable O 
on O 
exposure O 
to O 
light O 
. O 
Construction O 
of O 
pseudoternary O 
diagrams O 
were O 
investigated O 
to O 
prepare O 
a O 
MTX B-ABBREVIATION 
/ O 
β-CD B-ABBREVIATION 
inclusion O 
complex O 
loaded O 
SMEDDS O 
which O 
was O 
characterized O 
by O 
measuring O 
the O 
particle O 
size O 
and O 
the O 
zeta-potential O 
. O 
The O 
optimum O 
formulation O 
of O 
SMEDDS O 
was O 
a O 
system O 
consisting O 
of O 
ethyl B-SYSTEMATIC 
oleate I-SYSTEMATIC 
, O 
tween B-FAMILY 
80 I-FAMILY 
, O 
and O 
propylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
with O 
a O 
mean O 
droplet O 
size O 
of O 
39.42 O 
nm O 
. O 
In O 
vitro O 
drug O 
release O 
in O 
different O 
pH O 
media O 
showed O 
that O 
the O 
release O 
profile O 
of O 
MTX B-ABBREVIATION 
from O 
the O 
MTX B-ABBREVIATION 
/ O 
β-CD B-ABBREVIATION 
loaded O 
SMEDDS O 
was O 
influenced O 
by O 
the O 
pH O 
of O 
the O 
release O 
medium O 
and O 
presented O 
the O 
characteristics O 
of O 
a O 
sustained O 
release O 
profile O 
. O 
Finally O 
, O 
in O 
- O 
vivo O 
studies O 
showed O 
an O 
enhancement O 
of O 
the O 
bioavailability O 
of O 
MTX B-ABBREVIATION 
from O 
the O 
MTX B-ABBREVIATION 
/ O 
β-CD B-ABBREVIATION 
loaded O 
SMEDDS O 
form O 
of O 
1.57-fold O 
. O 
We O 
concluded O 
that O 
the O 
β-CD B-ABBREVIATION 
inclusion O 
complex O 
loaded O 
SMEDDS O 
improved O 
the O 
chemical O 
and O 
physiological O 
properties O 
of O 
MTX B-ABBREVIATION 
and O 
could O 
be O 
a O 
promising O 
means O 
for O 
the O 
delivery O 
of O 
MTX B-ABBREVIATION 
and O 
other O 
unstable O 
and O 
lipophilic O 
drugs O 
by O 
oral O 
route O 
. O 

proteomic O 
analyses O 
of O 
snake O 
venoms O 
show O 
that O 
metalloproteinases O 
represent O 
major O 
components O 
in O 
most O 
of O 
the O 
Crotalid O 
and O 
Viperid O 
venoms O 
. O 
In O 
this O 
chapter O 
we O 
discuss O 
the O 
multiple O 
activities O 
of O 
the O 
SVMPs O 
. O 
In O 
addition O 
to O 
hemorrhagic O 
activity O 
, O 
members O 
of O 
the O 
SVMP O 
family O 
also O 
have O 
fibrin(ogen)olytic O 
activity O 
, O 
act O 
as O 
prothrombin O 
activators O 
, O 
activate O 
blood O 
coagulation O 
factor O 
X O 
, O 
possess O 
apoptotic O 
activity O 
, O 
inhibit O 
platelet O 
aggregation O 
, O 
are O 
pro O 
- O 
inflammatory O 
and O 
inactivate O 
blood O 
serine O 
proteinase O 
inhibitors O 
. O 
Clearly O 
the O 
SVMPs O 
have O 
multiple O 
functions O 
in O 
addition O 
to O 
their O 
well O 
- O 
known O 
hemorrhagic O 
activity O 
. O 
The O 
realization O 
that O 
there O 
are O 
structural O 
variations O 
in O 
the O 
SVMPs O 
and O 
the O 
early O 
studies O 
that O 
led O 
to O 
their O 
classification O 
represents O 
an O 
important O 
event O 
in O 
our O 
understanding O 
of O 
the O 
structural O 
forms O 
of O 
the O 
SVMPs O 
. O 
The O 
SVMPs O 
were O 
subdivided O 
into O 
the O 
P-I O 
, O 
P-II O 
and O 
P-III O 
protein O 
classes O 
. O 
The O 
noticeable O 
characteristic O 
that O 
distinguished O 
the O 
different O 
classes O 
was O 
their O 
size O 
( O 
molecular O 
weight O 
) O 
differences O 
and O 
domain O 
structure O 
: O 
Class O 
I O 
( O 
P-I O 
) O 
, O 
the O 
small O 
SVMPs O 
, O 
have O 
molecular O 
masses O 
of O 
20-30 O 
kDa O 
, O 
contain O 
only O 
a O 
pro O 
domain O 
and O 
the O 
proteinase O 
domain O 
; O 
Class O 
II O 
( O 
P-II O 
) O 
, O 
the O 
medium O 
size O 
SVMPs O 
, O 
molecular O 
masses O 
of O 
30-60 O 
kDa O 
, O 
contain O 
the O 
pro O 
domain O 
, O 
proteinase O 
domain O 
and O 
disintegrin O 
domain O 
; O 
Class O 
III O 
( O 
P-III O 
) O 
, O 
the O 
large O 
SVMPs O 
, O 
have O 
molecular O 
masses O 
of O 
60-100 O 
kDa O 
, O 
contain O 
pro O 
, O 
proteinase O 
, O 
disintegrin O 
- O 
like O 
and O 
cysteine B-TRIVIAL 
-rich O 
domain O 
structure O 
. O 
Another O 
significant O 
advance O 
in O 
the O 
SVMP O 
field O 
was O 
the O 
characterization O 
of O 
the O 
crystal O 
structure O 
of O 
the O 
first O 
P-I O 
class O 
SVMP O 
. O 
The O 
structures O 
of O 
other O 
P-I O 
SVMPs O 
soon O 
followed O 
and O 
the O 
structures O 
of O 
P-III O 
SVMPs O 
have O 
also O 
been O 
determined O 
. O 
The O 
active O 
site O 
of O 
the O 
metalloproteinase O 
domain O 
has O 
a O 
consensus O 
HEXXHXXGXXHD O 
sequence O 
and O 
a O 
Met B-FORMULA 
-turn O 
. O 
The O 
" O 
Met B-FORMULA 
-turn O 
" O 
structure O 
contains O 
a O 
conserved O 
Met B-FORMULA 
residue O 
that O 
forms O 
a O 
hydrophobic O 
basement O 
for O 
the O 
three O 
zinc B-SYSTEMATIC 
-binding O 
histidines B-FAMILY 
in O 
the O 
consensus O 
sequence O 
. O 

induces O 
autophagy O 
in O 
MDA-MB-231 O 
cells O 
by O 
regulating O 
MAPK-mTOR O 
pathway O 
. O 

studies O 
have O 
demonstrated O 
that O 
wogonoside B-TRIVIAL 
, O 
a O 
bioactive O 
flavonoid B-FAMILY 
extracted O 
from O 
the O 
root O 
of O 
Scutellaria O 
baicalensis O 
Gerogi O 
, O 
has O 
anti-inflammatory O 
and O 
anti-angiogenic O 
activities O 
. O 
In O 
this O 
study O 
, O 
we O 
evaluated O 
wogonoside B-TRIVIAL 
-induced O 
autophagy O 
on O 
human O 
breast O 
MDA-MB-231 O 
cells O 
. O 
We O 
report O 
that O 
wogonoside B-TRIVIAL 
triggered O 
the O 
formation O 
of O 
microtubule O 
- O 
associated O 
protein O 
- O 
light O 
chain O 
3 O 
( O 
MAP-LC3 O 
) O 
positive O 
autophagosomes O 
and O 
the O 
accumulation O 
of O 
acidic O 
vesicular O 
and O 
autolysosomes O 
in O 
MDA-MB-231 O 
cells O 
. O 
In O 
addition O 
, O 
cells O 
treated O 
by O 
wogonoside B-TRIVIAL 
developed O 
autophagosome O 
- O 
like O 
characteristics O 
, O 
including O 
single O 
and O 
double O 
membrane O 
vacuoles O 
containing O 
intact O 
and O 
degraded O 
cellular O 
debris O 
. O 
The O 
results O 
showed O 
that O 
wogonoside B-TRIVIAL 
promotes O 
the O 
expression O 
of O 
LC3-II O 
and O 
Beclin-1 O 
. O 
Furthermore O 
, O 
wogonoside B-TRIVIAL 
inhibited O 
cell O 
growth O 
of O 
MDA-MB-231 O 
cells O 
in O 
a O 
concentration- O 
and O 
time O 
- O 
dependent O 
manner O 
, O 
which O 
was O 
associated O 
with O 
wogonoside B-TRIVIAL 
-induced O 
autophagy O 
. O 
Wogonoside B-TRIVIAL 
also O 
suppressed O 
the O 
activation O 
of O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
( O 
mTOR O 
) O 
and O 
p70-S6 O 
kinase O 
( O 
p70S6K O 
) O 
by O 
regulating O 
the O 
expression O 
of O 
the O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
( O 
ERK1 O 
/ O 
2 O 
) O 
and O 
p38 O 
involved O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
signaling O 
pathway O 
. O 
Taken O 
together O 
, O 
these O 
results O 
suggest O 
that O 
wogonoside B-TRIVIAL 
partially O 
inhibits O 
MDA-MB-231 O 
cell O 
growth O 
by O 
inducing O 
autophagy O 
through O 
the O 
MAPK-mTOR O 
pathway O 
and O 
may O 
be O 
a O 
promising O 
anti-tumor O 
agent O 
. O 

may O 
induce O 
colon O 
carcinogenesis O 
through O 
oxidative O 
or O 
alkylating O 
DNA O 
damage O 
. O 
However O 
, O 
diet O 
may O 
also O 
contain O 
anticarcinogenic O 
compounds O 
that O 
contribute O 
to O 
cancer O 
prevention O 
. O 
DNA O 
damage O 
prevention O 
and O 
/ O 
or O 
induction O 
of O 
repair O 
are O 
two O 
important O 
mechanisms O 
involved O 
in O 
cancer O 
chemoprevention O 
by O 
dietary O 
compounds O 
. O 
Hypericum O 
sps O 
. O 
are O 
widely O 
used O 
in O 
traditional O 
medicine O 
to O 
prepare O 
infusions O 
due O 
to O 
their O 
beneficial O 
digestive O 
and O 
neurologic O 
effects O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
potential O 
of O 
water O 
extracts O 
from O 
three O 
Hypericum O 
sps O 
. O 
and O 
some O 
of O 
their O 
main O 
phenolic B-FAMILY 
compounds O 
to O 
prevent O 
and O 
repair O 
oxidative O 
and O 
alkylating O 
DNA O 
damage O 
in O 
colon O 
cells O 
. O 
The O 
results O 
showed O 
that O 
water O 
extracts O 
of O 
Hypericum O 
perforatum O 
, O 
Hypericum O 
androsaemum O 
, O 
Hypericum O 
undulatum O 
, O 
quercetin B-TRIVIAL 
and O 
rutin B-TRIVIAL 
have O 
protective O 
effect O 
against O 
oxidative O 
DNA O 
damage O 
in O 
HT29 O 
cells O 
. O 
Protective O 
effect O 
was O 
also O 
observed O 
against O 
alkylating O 
DNA O 
damage O 
induced O 
by O 
methyl-methanesulfonate B-SYSTEMATIC 
, O 
except O 
for O 
H O 
. O 
androsaemum O 
. O 
With O 
regard O 
to O 
alkylating O 
damage O 
repair O 
H O 
. O 
perforatum O 
, O 
H O 
. O 
androsaemum O 
and O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
increased O 
repair O 
of O 
alkylating O 
DNA O 
damage O 
by O 
base O 
excision O 
repair O 
pathway O 
. O 
No O 
effect O 
was O 
observed O 
on O 
nucleotide B-FAMILY 
excision O 
repair O 
pathway O 
. O 
Antigenotoxic O 
effects O 
of O 
Hypericum O 
sps O 
. O 
may O 
contribute O 
to O 
colon O 
cancer O 
prevention O 
and O 
the O 
high O 
amount O 
of O 
phenolic B-FAMILY 
compounds O 
present O 
in O 
Hypericum O 
sps O 
. O 
play O 
an O 
important O 
role O 
in O 
DNA O 
protective O 
effects O 
. O 

disturbance O 
and O 
clustering O 
in O 
the O 
NaCl B-FORMULA 
water O 
solutions O 
. O 

clustering O 
and O 
the O 
solvation O 
properties O 
in O 
the O 
NaCl B-FORMULA 
solutions O 
are O 
explored O 
by O 
molecular O 
dynamics O 
simulations O 
with O 
several O 
popular O 
force O 
fields O 
. O 
The O 
existence O 
of O 
ions O 
has O 
a O 
negligible O 
disturbance O 
to O 
the O 
hydrogen B-SYSTEMATIC 
bond O 
structures O 
and O 
rotational O 
mobility O 
of O 
water O 
beyond O 
the O 
first O 
ion O 
solvation O 
shells O 
, O 
which O 
is O 
suggested O 
by O 
the O 
local O 
hydrogen B-SYSTEMATIC 
bond O 
structures O 
and O 
the O 
rotation O 
times O 
of O 
water O 
. O 
The O 
potential O 
of O 
mean O 
force O 
( O 
PMF O 
) O 
of O 
ion O 
pair O 
in O 
the O 
dilute O 
solution O 
presents O 
a O 
consistent O 
view O 
with O 
the O 
populations O 
of O 
ion O 
clusters O 
in O 
the O 
electrolyte O 
solutions O 
. O 
The O 
aggregation O 
level O 
of O 
ions O 
is O 
sensitive O 
to O 
the O 
force O 
field O 
used O 
in O 
the O 
simulations O 
. O 
The O 
ion O 
- O 
ion O 
interaction O 
potential O 
plays O 
an O 
important O 
role O 
in O 
the O 
forming O 
of O 
the O 
contact O 
ion O 
pair O 
. O 
The O 
entropy O 
of O 
water O 
increases O 
as O 
the O 
ion O 
pair O 
approaches O 
each O 
other O 
and O 
the O 
association O 
of O 
ion O 
pair O 
is O 
driven O 
by O 
the O 
increment O 
of O 
water O 
entropy O 
according O 
to O 
the O 
results O 
from O 
the O 
selected O 
force O 
fields O 
. O 
The O 
kinetic O 
transition O 
from O 
the O 
single O 
solvent O 
separated O 
state O 
to O 
the O 
contact O 
ion O 
pair O 
is O 
controlled O 
by O 
the O 
enthalpy O 
loss O 
of O 
solution O 
. O 

effect O 
of O 
varying O 
the O 
surfactant O 
and O 
solvent O 
medium O 
on O 
the O 
dynamics O 
of O 
spin O 
- O 
lattice O 
relaxation O 
in O 
photoexcited O 
Fe3O4 B-FORMULA 
nanocrystals O 
has O 
been O 
investigated O 
by O 
measuring O 
the O 
time O 
- O 
dependent O 
magnetization O 
employing O 
pump O 
- O 
probe O 
transient O 
Faraday O 
rotation O 
technique O 
. O 
The O 
variation O 
of O 
the O 
surfactants O 
having O 
surface O 
- O 
binding O 
functional O 
groups O 
modified O 
not O 
only O 
the O 
static O 
magnetization O 
but O 
also O 
the O 
dynamics O 
of O 
the O 
recovery O 
of O 
the O 
magnetization O 
occurring O 
via O 
spin O 
- O 
lattice O 
relaxation O 
in O 
the O 
photoexcited O 
Fe3O4 B-FORMULA 
nanocrystals O 
. O 
The O 
variation O 
of O 
the O 
polarity O 
and O 
size O 
of O 
the O 
solvent O 
molecules O 
can O 
also O 
influence O 
the O 
spin O 
- O 
lattice O 
relaxation O 
dynamics O 
. O 
However O 
, O 
the O 
effect O 
is O 
limited O 
to O 
the O 
nanocrystals O 
having O 
sufficiently O 
permeable O 
surfactant O 
layer O 
, O 
where O 
the O 
small O 
solvent O 
molecules O 
( O 
e.g O 
. O 
, O 
water O 
) O 
can O 
access O 
the O 
surface O 
and O 
dynamically O 
modify O 
the O 
ligand O 
field O 
on O 
the O 
surface O 
. O 

metastases O 
( O 
PM O 
) O 
from O 
thyroid O 
cancer O 
are O 
rare O 
, O 
but O 
their O 
management O 
can O 
represent O 
a O 
difficult O 
challenge O 
for O 
the O 
endocrinologist O 
. O 
Our O 
aim O 
was O 
to O 
review O 
all O 
reported O 
cases O 
of O 
PM O 
from O 
thyroid O 
cancer O 
. O 
PubMed O 
was O 
consulted O 
and O 
19 O 
papers O 
reporting O 
20 O 
cases O 
were O 
found O 
. O 
We O 
moreover O 
discuss O 
two O 
of O 
our O 
own O 
cases O 
, O 
which O 
had O 
come O 
to O 
our O 
attention O 
within O 
a O 
few O 
months O 
of O 
one O 
another O 
. O 
Eleven O 
cases O 
were O 
follicular O 
cancer O 
, O 
eight O 
cases O 
were O 
papillary O 
cancer O 
, O 
two O 
cases O 
were O 
medullary O 
cancer O 
, O 
and O 
one O 
case O 
was O 
an O 
insular O 
cancer O 
. O 
In O 
nine O 
cases O 
, O 
PM O 
was O 
the O 
first O 
sign O 
of O 
the O 
disease O 
. O 
Cranial O 
nerve O 
involvement O 
was O 
the O 
most O 
common O 
sign O 
of O 
its O 
presence O 
, O 
and O 
no O 
neuroradiological O 
imaging O 
could O 
lead O 
to O 
a O 
sure O 
diagnosis O 
of O 
PM O 
. O 
Neurosurgical O 
intervention O 
was O 
performed O 
in O 
almost O 
all O 
cases O 
, O 
and O 
post O 
- O 
surgical O 
treatment O 
comprised O 
radioiodine B-SYSTEMATIC 
, O 
external O 
beam O 
radiotherapy O 
, O 
and O 
radiosurgery O 
. O 
Prognosis O 
was O 
poor O 
for O 
larger O 
metastases O 
, O 
cranial O 
nerve O 
palsy O 
disappeared O 
in O 
only O 
one O 
case O 
, O 
and O 
in O 
only O 
one O 
case O 
of O 
intrasellar O 
metastasis O 
was O 
the O 
disease O 
cured O 
. O 
PM O 
from O 
thyroid O 
cancer O 
are O 
rare O 
, O 
but O 
are O 
burdened O 
by O 
a O 
poor O 
prognosis O 
. O 
An O 
early O 
diagnosis O 
appears O 
important O 
, O 
and O 
a O 
comprehensive O 
strategy O 
for O 
treatment O 
( O 
neurosurgery O 
, O 
radioiodine B-SYSTEMATIC 
, O 
external O 
radiotherapy O 
, O 
and O 
radiosurgery O 
) O 
appears O 
advisable O 
. O 

novel O 
, O 
potent O 
, O 
and O 
selective O 
inhibitor O 
of O 
cardiac O 
late O 
sodium B-SYSTEMATIC 
current O 
suppresses O 
experimental O 
arrhythmias O 
. O 

of O 
cardiac O 
late O 
sodium B-SYSTEMATIC 
current O 
( O 
late O 
I( O 
Na B-FORMULA 
) O 
) O 
is O 
a O 
strategy O 
to O 
suppress O 
arrhythmias O 
and O 
sodium B-SYSTEMATIC 
-dependent O 
calcium B-SYSTEMATIC 
overload O 
associated O 
with O 
myocardial O 
ischemia O 
and O 
heart O 
failure O 
. O 
Current O 
inhibitors O 
of O 
late O 
I( O 
Na B-FORMULA 
) O 
are O 
unselective O 
and O 
can O 
be O 
proarrhythmic O 
. O 
This O 
study O 
introduces O 
GS967 B-IDENTIFIER 
( O 
6-[4-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine B-SYSTEMATIC 
) O 
, O 
a O 
potent O 
and O 
selective O 
inhibitor O 
of O 
late O 
I( O 
Na B-FORMULA 
) O 
, O 
and O 
demonstrates O 
its O 
effectiveness O 
to O 
suppress O 
ventricular O 
arrhythmias O 
. O 
The O 
effects O 
of O 
GS967 B-IDENTIFIER 
on O 
rabbit O 
ventricular O 
myocyte O 
ion O 
channel O 
currents O 
and O 
action O 
potentials O 
were O 
determined O 
. O 
Anti-arrhythmic O 
actions O 
of O 
GS967 B-IDENTIFIER 
were O 
characterized O 
in O 
ex O 
vivo O 
and O 
in O 
vivo O 
rabbit O 
models O 
of O 
reduced O 
repolarization O 
reserve O 
and O 
ischemia O 
. O 
GS967 B-IDENTIFIER 
inhibited O 
Anemonia O 
sulcata O 
toxin O 
II O 
(ATX-II)-induced O 
late O 
I( O 
Na B-FORMULA 
) O 
in O 
ventricular O 
myocytes O 
and O 
isolated O 
hearts O 
with O 
IC(50) O 
values O 
of O 
0.13 O 
and O 
0.21 O 
µM O 
, O 
respectively O 
. O 
Reduction O 
of O 
peak O 
I( O 
Na B-FORMULA 
) O 
by O 
GS967 B-IDENTIFIER 
was O 
minimal O 
at O 
a O 
holding O 
potential O 
of O 
-120 O 
mV O 
but O 
increased O 
at O 
-80 O 
mV O 
. O 
GS967 B-IDENTIFIER 
did O 
not O 
prolong O 
action O 
potential O 
duration O 
or O 
the O 
QRS O 
interval O 
. O 
GS967 B-IDENTIFIER 
prevented O 
and O 
reversed O 
proarrhythmic O 
effects O 
( O 
afterdepolarizations O 
and O 
torsades O 
de O 
pointes O 
) O 
of O 
the O 
late O 
I( O 
Na B-FORMULA 
) O 
enhancer O 
ATX-II O 
and O 
the O 
I( O 
Kr B-FORMULA 
) O 
inhibitor O 
E-4031 B-IDENTIFIER 
in O 
isolated O 
ventricular O 
myocytes O 
and O 
hearts O 
. O 
GS967 B-IDENTIFIER 
significantly O 
attenuated O 
the O 
proarrhythmic O 
effects O 
of O 
methoxamine B-TRIVIAL 
+ O 
clofilium B-TRIVIAL 
and O 
suppressed O 
ischemia O 
- O 
induced O 
arrhythmias O 
. O 
GS967 B-IDENTIFIER 
was O 
more O 
potent O 
and O 
effective O 
to O 
reduce O 
late O 
I( O 
Na B-FORMULA 
) O 
and O 
arrhythmias O 
than O 
either O 
flecainide B-TRIVIAL 
or O 
ranolazine B-TRIVIAL 
. O 
Results O 
of O 
all O 
studies O 
and O 
assays O 
of O 
binding O 
and O 
activity O 
of O 
GS967 B-IDENTIFIER 
at O 
numerous O 
receptors O 
, O 
transporters O 
, O 
and O 
enzymes O 
indicated O 
that O 
GS967 B-IDENTIFIER 
selectively O 
inhibited O 
late O 
I( O 
Na B-FORMULA 
) O 
. O 
In O 
summary O 
, O 
GS967 B-IDENTIFIER 
selectively O 
suppressed O 
late O 
I( O 
Na B-FORMULA 
) O 
and O 
prevented O 
and O 
/ O 
or O 
reduced O 
the O 
incidence O 
of O 
experimentally O 
induced O 
arrhythmias O 
in O 
rabbit O 
myocytes O 
and O 
hearts O 
. O 

ability O 
of O 
small O 
interfering O 
RNAs O 
( O 
siRNAs O 
) O 
to O 
potently O 
but O 
reversibly O 
silence O 
genes O 
in O 
vivo O 
has O 
made O 
them O 
particularly O 
well O 
suited O 
as O 
a O 
new O 
class O 
of O 
drugs O 
that O 
interfere O 
with O 
disease O 
- O 
causing O 
or O 
disease O 
- O 
promoting O 
genes O 
. O 
However O 
, O 
the O 
largest O 
remaining O 
hurdle O 
for O 
the O 
widespread O 
use O 
of O 
this O 
technology O 
in O 
skin O 
is O 
the O 
lack O 
of O 
an O 
effective O 
delivery O 
system O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
nanodispersed O 
systems O 
in O 
liquid O 
crystalline O 
phases O 
that O 
deliver O 
siRNA O 
into O 
the O 
skin O 
. O 
The O 
proposed O 
systems O 
present O 
important O 
properties O 
for O 
the O 
delivery O 
of O 
macromolecules O 
in O 
a O 
biological O 
medium O 
, O 
as O 
they O 
are O 
formed O 
by O 
substances O 
that O 
have O 
absorption O 
- O 
enhancing O 
and O 
fusogenic O 
effects O 
; O 
additionally O 
, O 
they O 
facilitate O 
entrapment O 
by O 
cellular O 
membranes O 
due O 
to O 
their O 
nano O 
- O 
scale O 
structure O 
. O 
The O 
cationic O 
polymer O 
polyethylenimine B-SYSTEMATIC 
( O 
PEI B-ABBREVIATION 
) O 
or O 
the O 
cationic O 
lipid O 
oleylamine B-SYSTEMATIC 
( O 
OAM B-ABBREVIATION 
) O 
were O 
added O 
to O 
monoolein B-TRIVIAL 
( O 
MO O 
) O 
- O 
based O 
systems O 
in O 
different O 
concentrations O 
, O 
and O 
after O 
dispersion O 
in O 
aqueous O 
medium O 
, O 
liquid O 
crystalline O 
phase O 
nanodispersions O 
were O 
obtained O 
and O 
characterized O 
by O 
their O 
physicochemical O 
properties O 
. O 
Then O 
, O 
in O 
vitro O 
penetration O 
studies O 
using O 
diffusion O 
cell O 
and O 
pig O 
ear O 
skin O 
were O 
carried O 
out O 
to O 
evaluate O 
the O 
effect O 
of O 
the O 
nanodispersions O 
on O 
the O 
skin O 
penetration O 
of O 
siRNA O 
; O 
based O 
on O 
these O 
results O 
, O 
the O 
nanodispersions O 
containing O 
MO O 
/ O 
OA/ O 
PEI B-ABBREVIATION 
/ O 
aqueous O 
phase O 
( O 
8 O 
: O 
2 O 
: O 
5 O 
: O 
85 O 
, O 
w O 
/ O 
w O 
/ O 
w O 
/ O 
w O 
) O 
and O 
MO O 
/ O 
OA/ O 
OAM B-ABBREVIATION 
/ O 
aqueous O 
phase O 
( O 
8 O 
: O 
2 O 
: O 
2 O 
: O 
88 O 
, O 
w O 
/ O 
w O 
/ O 
w O 
/ O 
w O 
) O 
were O 
selected O 
. O 
These O 
systems O 
were O 
investigated O 
in O 
vivo O 
for O 
skin O 
penetration O 
, O 
skin O 
irritation O 
, O 
and O 
the O 
ability O 
to O 
knockdown O 
glyceraldehyde B-SYSTEMATIC 
3-phosphate I-SYSTEMATIC 
dehydrogenase O 
( O 
GAPDH O 
) O 
protein O 
levels O 
in O 
animal O 
models O 
. O 
The O 
results O 
showed O 
that O 
the O 
studied O 
nanodispersions O 
may O 
represent O 
a O 
promising O 
new O 
non-viral O 
vehicle O 
and O 
can O 
be O 
considered O 
highly O 
advantageous O 
in O 
the O 
treatment O 
of O 
skin O 
disorders O 
; O 
they O 
were O 
effective O 
in O 
optimizing O 
the O 
skin O 
penetration O 
of O 
siRNA O 
and O 
reducing O 
the O 
levels O 
of O 
the O 
model O 
protein O 
GAPDH O 
without O 
causing O 
skin O 
irritation O 
. O 

and O 
liver O 
toxicity O 
of O 
the O 
herb O 
tarragon O 
( O 
Artemisia O 
dracunculus O 
) O 
were O 
evaluated O 
using O 
single O 
cell O 
gel O 
( O 
comet O 
) O 
electrophoresis O 
. O 
Ten O 
microlitres O 
aliquots O 
of O 
peripheral O 
venous O 
human O 
blood O 
were O 
incubated O 
with O 
tarragon O 
extract O 
, O 
saline O 
, O 
or O 
the O 
mutagen O 
sodium B-SYSTEMATIC 
dichromate I-SYSTEMATIC 
. O 
Cell O 
suspensions O 
dispersed O 
in O 
low O 
- O 
melting O 
agarose O 
were O 
electrophoresed O 
in O 
ethidium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
. O 
The O 
resulting O 
DNA O 
migration O 
trails O 
were O 
obtained O 
using O 
fluorescent O 
microscopy O 
at O 
400× O 
magnification O 
, O 
and O 
graded O 
according O 
to O 
the O 
mutagenicity O 
index O 
( O 
MI O 
) O 
for O 
each O 
cell O 
incubation O 
condition O 
. O 
The O 
in O 
vivo O 
liver O 
toxicity O 
of O 
Artemisia O 
dracunculus O 
was O 
assessed O 
in O 
the O 
blood O 
of O 
mice O 
treated O 
orally O 
with O 
the O 
extract O 
of O 
the O 
herb O 
, O 
using O 
alanine B-TRIVIAL 
aminotransferase O 
( O 
ALT O 
) O 
and O 
aspartate B-TRIVIAL 
aminotransferase O 
( O 
AST O 
) O 
as O 
liver O 
function O 
indicators O 
. O 
Liver O 
morphology O 
was O 
assessed O 
using O 
hematoxylin B-TRIVIAL 
and O 
eosin B-FAMILY 
( O 
HE O 
) O 
staining O 
of O 
liver O 
tissue O 
. O 
The O 
present O 
study O 
demonstrated O 
a O 
direct O 
correlation O 
between O 
tarragon O 
extract O 
dosage O 
and O 
three O 
major O 
outcome O 
variables O 
: O 
MI O 
; O 
serum O 
liver O 
enzyme O 
activity O 
; O 
and O 
liver O 
histopathology O 
. O 
These O 
outcomes O 
are O 
possibly O 
due O 
to O 
the O 
presence O 
in O 
tarragon O 
of O 
methylchavicol B-SYSTEMATIC 
and O 
other O 
genotoxic O 
compounds O 
. O 
These O 
findings O 
provide O 
a O 
preliminary O 
guide O 
for O 
risk O 
assessment O 
of O 
tarragon O 
in O 
diet O 
and O 
in O 
possible O 
therapeutic O 
applications O 
. O 

aggressive O 
treatment O 
with O 
radiation O 
and O 
chemotherapy O 
, O 
recurrence O 
of O 
glioblastoma O 
multiforme O 
( O 
GBM O 
) O 
is O 
inevitable O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
show O 
that O 
the O 
blood O 
- O 
brain O 
barrier O 
( O 
BBB O 
) O 
, O 
through O 
a O 
combination O 
of O 
tight O 
junctions O 
and O 
active O 
efflux O 
transporters O 
in O 
the O 
brain O 
microvasculature O 
, O 
can O 
significantly O 
restrict O 
delivery O 
of O 
molecularly O 
targeted O 
agents O 
to O 
invasive O 
glioma O 
cells O 
. O 
Transgenic O 
mice O 
lacking O 
P-glycoprotein O 
( O 
P-gp O 
) O 
and O 
breast O 
cancer O 
resistance O 
protein O 
( O 
Bcrp O 
) O 
were O 
used O 
to O 
study O 
efflux O 
of O 
erlotinib B-TRIVIAL 
at O 
the O 
BBB O 
. O 
A O 
U87 O 
rat O 
xenograft O 
model O 
of O 
GBM O 
was O 
used O 
to O 
investigate O 
the O 
regional O 
distribution O 
of O 
erlotinib B-TRIVIAL 
to O 
the O 
tumor O 
, O 
and O 
brain O 
regions O 
surrounding O 
the O 
tumor O 
. O 
The O 
effect O 
of O 
concurrent O 
administration O 
of O 
elacridar B-TRIVIAL 
on O 
regional O 
tumor O 
distribution O 
of O 
erlotinib B-TRIVIAL 
was O 
evaluated O 
. O 
We O 
show O 
that O 
erlotinib B-TRIVIAL 
transport O 
across O 
an O 
intact O 
BBB O 
is O 
significantly O 
restricted O 
due O 
to O 
P-gp- O 
and O 
Bcrp O 
- O 
mediated O 
efflux O 
transport O 
. O 
We O 
then O 
show O 
that O 
the O 
BBB O 
is O 
sufficiently O 
intact O 
in O 
areas O 
of O 
brain O 
adjacent O 
to O 
the O 
tumor O 
core O 
to O 
significantly O 
restrict O 
erlotinib B-TRIVIAL 
delivery O 
. O 
Inhibition O 
of O 
P-gp O 
and O 
Bcrp O 
by O 
the O 
dual O 
inhibitor O 
elacridar B-TRIVIAL 
dramatically O 
increased O 
erlotinib B-TRIVIAL 
delivery O 
to O 
the O 
tumor O 
core O 
, O 
rim O 
, O 
and O 
normal O 
brain O 
. O 
These O 
results O 
provide O 
conclusive O 
evidence O 
of O 
the O 
impact O 
that O 
active O 
efflux O 
at O 
the O 
BBB O 
has O 
on O 
the O 
delivery O 
of O 
molecularly O 
targeted O 
therapy O 
to O 
different O 
tumor O 
regions O 
in O 
glioma O 
. O 
These O 
data O 
also O 
support O 
the O 
possibility O 
that O 
the O 
repeated O 
failure O 
of O 
clinical O 
trials O 
of O 
new O 
drugs O 
for O 
gliomas O 
may O 
be O 
in O 
part O 
due O 
to O 
a O 
failure O 
to O 
achieve O 
effective O 
concentrations O 
in O 
invasive O 
tumor O 
cells O 
that O 
reside O 
behind O 
an O 
intact O 
BBB O 
. O 

profiles O 
of O 
olive O 
fruits O 
( O 
Olea O 
europaea O 
L O 
. O 
) O 
and O 
oils O 
from O 
Ayvalık O 
, O 
Domat O 
and O 
Gemlik O 
varieties O 
at O 
different O 
ripening O 
stages O 
. O 

compounds O 
in O 
olive O 
fruit O 
and O 
oils O 
obtained O 
from O 
Ayvalık O 
, O 
Domat O 
and O 
Gemlik O 
olive O 
varieties O 
collected O 
at O 
different O 
ripening O 
periods O 
were O 
evaluated O 
by O 
High O 
Performance O 
Liquid O 
Chromatography O 
( O 
HPLC O 
) O 
. O 
Gallic B-TRIVIAL 
acid I-TRIVIAL 
and O 
p-cumaric B-TRIVIAL 
acid I-TRIVIAL 
were O 
identified O 
for O 
Ayvalık O 
and O 
Domat O 
at O 
each O 
period O 
of O 
ripening O 
, O 
respectively O 
. O 
In O 
addition O 
, O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
, O 
p-cumaric B-TRIVIAL 
acid I-TRIVIAL 
, O 
sinapinic B-MULTIPLE 
and I-MULTIPLE 
apigenin I-MULTIPLE 
acids I-MULTIPLE 
were O 
detected O 
in O 
Gemlik O 
olive O 
fruit O 
. O 
Hydroxytyrosol B-SYSTEMATIC 
, O 
rutin B-TRIVIAL 
, O 
oleoropein B-TRIVIAL 
, O 
luteolin B-TRIVIAL 
, O 
tyrosol B-TRIVIAL 
, O 
vanilic B-TRIVIAL 
acid I-TRIVIAL 
and O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
in O 
Ayvalık O 
olive O 
fruit O 
in O 
all O 
ripening O 
periods O 
were O 
determined O 
. O 
The O 
tyrasol B-TRIVIAL 
contents O 
varied O 
between O 
0.18 O 
to O 
1.57mg O 
/ O 
kg O 
. O 
Luteolin B-TRIVIAL 
contents O 
of O 
olive O 
oils O 
ranged O 
at O 
the O 
levels O 
between O 
0.12 O 
to O 
2.28mg O 
/ O 
kg O 
. O 
In O 
contrast O 
, O 
oils O 
had O 
the O 
lowest O 
syringic B-MULTIPLE 
, I-MULTIPLE 
p-cumaric I-MULTIPLE 
, I-MULTIPLE 
chlorogenic I-MULTIPLE 
and I-MULTIPLE 
ferulic I-MULTIPLE 
acids I-MULTIPLE 
. O 
Vanillic B-TRIVIAL 
acid I-TRIVIAL 
contents O 
of O 
oils O 
ranged O 
between O 
0.08 O 
to O 
2.38mg O 
/ O 
kg O 
. O 

objective O 
of O 
this O 
research O 
was O 
to O 
optimize O 
the O 
vacuum O 
- O 
drying O 
of O 
frozen O 
sour O 
cherries O 
in O 
order O 
to O 
preserve O 
health O 
- O 
beneficial O 
phytochemicals O 
, O 
as O 
well O 
as O 
textural O 
characteristics O 
. O 
Investigated O 
range O 
of O 
temperature O 
was O 
46-74°C O 
and O 
, O 
of O 
pressure O 
, O 
17-583mbar O 
, O 
in O 
a O 
new O 
design O 
of O 
vacuum O 
- O 
dryer O 
equipment O 
. O 
The O 
total O 
solids O 
, O 
a(w) O 
value O 
, O 
total O 
phenolics B-FAMILY 
, O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
, O 
antioxidant O 
activity O 
, O 
anthocyanin B-FAMILY 
content O 
, O 
total O 
colour O 
change O 
and O 
firmness O 
were O 
used O 
as O 
quality O 
indicators O 
of O 
dried O 
sour O 
cherry O 
. O 
Within O 
the O 
experimental O 
range O 
of O 
studied O 
variables O 
, O 
the O 
optimum O 
conditions O 
of O 
54.03°C O 
and O 
148.16mbar O 
were O 
established O 
for O 
vacuum O 
drying O 
of O 
sour O 
cherry O 
. O 
Separate O 
validation O 
experiments O 
were O 
conducted O 
, O 
under O 
optimum O 
conditions O 
, O 
to O 
verify O 
predictions O 
and O 
adequacy O 
of O 
the O 
second O 
- O 
order O 
polynomial O 
models O 
. O 
Under O 
these O 
optimal O 
conditions O 
, O 
the O 
predicted O 
amount O 
of O 
total O 
phenolics B-FAMILY 
was O 
744mg O 
CAE O 
/ O 
100 O 
dw O 
, O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
1.44mg O 
/ O 
100g O 
per O 
dry O 
weight O 
( O 
g O 
dw O 
) O 
, O 
anthocyanin B-FAMILY 
content O 
125mg O 
/ O 
100g O 
dw O 
, O 
IC(50) O 
3.23mg O 
/ O 
ml O 
, O 
total O 
solids O 
70.72% O 
, O 
a(w) O 
value O 
0.646 O 
, O 
total O 
colour O 
change O 
52.61 O 
and O 
firmness O 
3395.4g O 
. O 
The O 
investigated O 
parameters O 
had O 
a O 
significant O 
effect O 
on O 
the O 
quality O 
of O 
the O 
dried O 
sour O 
cherries O 
. O 

of O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
in O 
cocoa O 
by O 
- O 
products O 
and O 
determination O 
of O 
its O 
reduction O 
during O 
chocolate O 
manufacture O 
. O 

work O 
reports O 
an O 
investigation O 
carried O 
out O 
to O 
assess O 
the O 
natural O 
occurrence O 
of O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
in O 
168 O 
samples O 
from O 
different O 
fractions O 
obtained O 
during O 
the O 
technological O 
processing O 
of O 
cocoa O 
( O 
shell O 
, O 
nibs O 
, O 
liquor O 
, O 
butter O 
, O 
cake O 
and O 
cocoa O 
powder O 
) O 
and O 
the O 
reduction O 
of O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
during O 
chocolate O 
manufacture O 
. O 
Ochratoxin B-TRIVIAL 
A I-TRIVIAL 
analyses O 
were O 
performed O 
with O 
immunoaffinity O 
columns O 
and O 
detection O 
by O 
high O 
performance O 
liquid O 
chromatography O 
. O 
Concerning O 
the O 
natural O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
contamination O 
in O 
cocoa O 
by O 
- O 
products O 
, O 
the O 
highest O 
levels O 
of O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
were O 
found O 
in O 
the O 
shell O 
, O 
cocoa O 
powder O 
and O 
cocoa O 
cake O 
. O 
The O 
cocoa O 
butter O 
was O 
the O 
least O 
contaminated O 
, O 
showing O 
that O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
seems O 
to O 
remain O 
in O 
the O 
defatted O 
cocoa O 
solids O 
. O 
Under O 
the O 
technological O 
conditions O 
applied O 
during O 
the O 
manufacture O 
of O 
chocolate O 
in O 
this O 
study O 
and O 
the O 
level O 
of O 
contamination O 
present O 
in O 
the O 
cocoa O 
beans O 
, O 
this O 
experiment O 
demonstrated O 
that O 
93.6% O 
of O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
present O 
in O 
the O 
beans O 
was O 
reduced O 
during O 
the O 
chocolate O 
producing O 
. O 

improve O 
the O 
yield O 
of O 
Maillard O 
peptides O 
, O 
a O 
microbial O 
transglutaminase O 
( O 
MTGase O 
) O 
was O 
used O 
to O 
increase O 
the O 
content O 
of O 
1000-5000Da O 
peptides O 
in O 
soybean O 
protein O 
hydrolysates O 
by O 
using O 
a O 
cross O 
- O 
linking O 
reaction O 
. O 
The O 
sensory O 
characteristics O 
and O 
antioxidant O 
activities O 
of O 
corresponding O 
Maillard O 
Reaction O 
Products O 
( O 
MSPC O 
) O 
was O 
then O 
evaluated O 
. O 
After O 
cross O 
- O 
linking O 
treatment O 
the O 
content O 
of O 
1000-5000Da O 
peptides O 
in O 
protein O 
hydrolysates O 
and O 
the O 
yield O 
of O 
Maillard O 
peptides O 
increased O 
by O 
21.19% O 
and O 
8.71% O 
, O 
respectively O 
, O 
which O 
contributed O 
to O 
the O 
improved O 
mouthfulness O 
of O 
MSPC O 
. O 
The O 
bitter O 
amino B-FAMILY 
acids I-FAMILY 
were O 
significantly O 
decreased O 
and O 
the O 
umami O 
acids O 
were O 
markedly O 
increased O 
in O 
MSPC O 
. O 
Volatile O 
compounds O 
identified O 
by O 
GC-MS O 
analysis O 
showed O 
that O 
the O 
content O 
of O 
the O 
important O 
meaty O 
flavour O 
compounds O 
( O 
such O 
as O 
2-methyl-3-furanthiol B-SYSTEMATIC 
, O 
bis(2-methyl-3-furyl)disulfide B-SYSTEMATIC 
) O 
of O 
MSPC O 
were O 
dramatically O 
higher O 
than O 
that O 
of O 
MRPs O 
from O 
uncross O 
- O 
linking O 
peptides O 
. O 
Combined O 
with O 
sensory O 
evaluation O 
, O 
it O 
was O 
confirmed O 
that O 
MTGase O 
cross O 
- O 
linking O 
improved O 
the O 
flavour O 
Characteristics O 
and O 
did O 
not O 
affect O 
the O 
antioxidant O 
activity O 
of O 
MSPC O 
. O 

and O 
gold O 
kiwifruit O 
peel O 
ethanol B-SYSTEMATIC 
extracts O 
potentiate O 
pentobarbital B-TRIVIAL 
-induced O 
sleep O 
in O 
mice O 
via O 
a O 
GABAergic O 
mechanism O 
. O 

is O 
one O 
of O 
the O 
most O 
popular O 
fruits O 
worldwide O 
, O 
and O 
it O 
has O 
various O 
biological O 
properties O 
, O 
including O 
antioxidant O 
, O 
anti-allergic O 
, O 
and O 
cardiovascular O 
protective O 
effects O 
. O 
The O 
peel O 
of O 
kiwifruit O 
, O 
which O 
is O 
a O 
by O 
- O 
product O 
of O 
processing O 
, O 
is O 
a O 
good O 
source O 
of O 
flavonoids B-FAMILY 
; O 
however O 
, O 
its O 
bioactivity O 
has O 
not O 
been O 
widely O 
investigated O 
. O 
In O 
this O 
study O 
, O 
we O 
evaluated O 
the O 
hypnotic O 
effects O 
of O 
green O 
( O 
GRPE O 
, O 
Actinidia O 
deliciosa O 
) O 
and O 
gold O 
( O 
GOPE O 
, O 
Actinidia O 
chinensis O 
) O 
kiwifruit O 
peel O 
ethanol B-SYSTEMATIC 
extracts O 
and O 
their O 
solvent O 
fractions O 
, O 
and O 
the O 
possible O 
underlying O 
mechanisms O 
. O 
Oral O 
GRPE O 
and O 
GOPE O 
administration O 
( O 
125-1000mg O 
/ O 
kg O 
) O 
produced O 
a O 
dose O 
- O 
dependent O 
decrease O 
in O 
sleep O 
latency O 
and O 
an O 
increase O 
in O 
sleep O 
duration O 
in O 
pentobarbital B-TRIVIAL 
-treated O 
mice O 
. O 
Among O 
three O 
different O 
solvent O 
fractions O 
of O 
GRPE O 
and O 
GOPE O 
, O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
EA O 
) O 
fractions O 
had O 
the O 
greatest O 
effect O 
on O 
sleep O 
duration O 
at O 
250mg O 
/ O 
kg O 
. O 
The O 
total O 
flavonoid B-FAMILY 
contents O 
of O 
solvent O 
fractions O 
were O 
proportional O 
to O 
sleep O 
duration O 
. O 
Like O 
diazepam O 
( O 
a O 
GABA B-ABBREVIATION 
(A)- O 
benzodiazepine B-FAMILY 
( O 
BZD B-ABBREVIATION 
) O 
receptor O 
agonist O 
) O 
, O 
the O 
hypnotic O 
effects O 
of O 
GRPE O 
, O 
GOPE O 
, O 
and O 
their O 
EA O 
fractions O 
were O 
fully O 
inhibited O 
by O 
flumazenil B-TRIVIAL 
( O 
a O 
GABA B-ABBREVIATION 
(A)- O 
BZD B-ABBREVIATION 
receptor O 
antagonist O 
) O 
. O 
These O 
results O 
suggest O 
that O 
potentiation O 
effects O 
of O 
GRPE O 
and O 
GOPE O 
on O 
pentobarbital B-TRIVIAL 
-induced O 
sleep O 
in O 
mice O 
may O 
be O 
modulated O 
by O 
a O 
GABAergic O 
mechanism O 
. O 

investigation O 
into O 
the O 
supramolecular O 
structure O 
, O 
solubility O 
, O 
stability O 
and O 
antioxidant O 
activity O 
of O 
rutin B-TRIVIAL 
/ O 
cyclodextrin O 
inclusion O 
complex O 
. O 

formation O 
of O 
supramolecular O 
inclusion O 
complexes O 
between O 
rutin B-TRIVIAL 
and O 
four O 
cyclodextrins O 
, O 
namely O 
β-cyclodextrin B-TRIVIAL 
( O 
β-CD B-ABBREVIATION 
) O 
, O 
(2-hydroxypropyl)-α-cyclodextrin B-SYSTEMATIC 
( O 
HP-α-CD B-ABBREVIATION 
) O 
, O 
(2-hydroxypropyl)-β-cyclodextrin B-SYSTEMATIC 
( O 
HP-β-CD B-ABBREVIATION 
) O 
and O 
(2-hydroxypropyl)-γ-cyclodextrin B-SYSTEMATIC 
( O 
HP-γ-CD B-ABBREVIATION 
) O 
, O 
and O 
the O 
effects O 
of O 
the O 
complexation O 
on O 
the O 
stability O 
and O 
antioxidant O 
activity O 
of O 
rutin B-TRIVIAL 
were O 
investigated O 
. O 
Results O 
from O 
phase O 
- O 
solubility O 
studies O 
showed O 
that O 
rutin B-TRIVIAL 
formed O 
1 O 
: O 
1 O 
stoichiometric O 
inclusion O 
complexes O 
with O 
HP-α-CD B-ABBREVIATION 
, O 
β-CD B-ABBREVIATION 
, O 
HP-β-CD B-ABBREVIATION 
and O 
HP-γ-CD B-ABBREVIATION 
; O 
the O 
complexes O 
formed O 
with O 
HP-γ-CD B-ABBREVIATION 
and O 
HP-β-CD B-ABBREVIATION 
had O 
the O 
greatest O 
stability O 
constants O 
, O 
followed O 
by O 
β-CD B-ABBREVIATION 
and O 
HP-α-CD B-ABBREVIATION 
. O 
Thermodynamic O 
studies O 
demonstrate O 
that O 
the O 
inclusion O 
of O 
rutin B-TRIVIAL 
into O 
HP-β-CD B-ABBREVIATION 
was O 
an O 
exothermic O 
process O 
which O 
occurred O 
spontaneously O 
. O 
Two O 
- O 
dimensional O 
rotating O 
- O 
frame O 
nuclear O 
Overhauser O 
effect O 
spectroscopy O 
( O 
2D O 
ROESY O 
) O 
(1)H B-FORMULA 
NMR O 
analyses O 
show O 
that O 
the O 
A O 
ring O 
of O 
rutin B-TRIVIAL 
was O 
the O 
part O 
of O 
the O 
molecule O 
that O 
most O 
likely O 
inserted O 
into O 
the O 
cavity O 
of O 
HP-β-CD B-ABBREVIATION 
, O 
thus O 
forming O 
a O 
supramolecular O 
inclusion O 
complex O 
. O 
Formation O 
of O 
such O 
an O 
inclusion O 
complex O 
conferred O 
moderate O 
degrees O 
of O 
protection O 
to O 
rutin B-TRIVIAL 
from O 
degradation O 
by O 
heat O 
and O 
UV O 
radiation O 
during O 
storage O 
, O 
and O 
significantly O 
enhanced O 
its O 
antioxidant O 
capacity O 
as O 
determined O 
by O 
three O 
different O 
procedures O 
. O 

nanosised O 
oxygen B-SYSTEMATIC 
scavenger O 
: O 
preparation O 
and O 
antioxidant O 
application O 
to O 
roasted O 
sunflower O 
seeds O 
and O 
walnuts O 
. O 

novel O 
oxygen B-SYSTEMATIC 
scavenger O 
using O 
iron O 
nanoparticle O 
was O 
produced O 
and O 
evaluated O 
as O 
a O 
potential O 
oxygen B-SYSTEMATIC 
scavenger O 
. O 
Iron O 
nanoparticle O 
was O 
prepared O 
by O 
liquid O 
phase O 
reduction O 
method O 
in O 
microemulsion O 
systems O 
. O 
The O 
absorption O 
capacity O 
of O 
different O 
kinds O 
of O 
oxygen B-SYSTEMATIC 
scavengers O 
was O 
measured O 
as O 
a O 
function O 
of O 
time O 
, O 
and O 
the O 
absorption O 
rate O 
constant O 
was O 
evaluated O 
at O 
25°C O 
. O 
The O 
absorption O 
kinetic O 
analysis O 
showed O 
that O 
the O 
absorption O 
process O 
followed O 
a O 
first O 
- O 
order O 
reaction O 
. O 
The O 
absorption O 
rate O 
constant O 
of O 
nanosised O 
and O 
conventional O 
oxygen B-SYSTEMATIC 
scavenger O 
were O 
0.45±0.044h(-1) O 
and O 
0.05±0.006h(-1) O 
, O 
respectively O 
. O 
Successful O 
application O 
of O 
the O 
nanosised O 
oxygen B-SYSTEMATIC 
scavenger O 
on O 
roasted O 
sunflower O 
seed O 
and O 
walnut O 
demonstrated O 
its O 
ability O 
to O 
inhibit O 
lipid O 
oxidation O 
in O 
lipid O 
- O 
containing O 
food O 
. O 
Roasted O 
nut O 
treated O 
with O 
nanosised O 
oxygen B-SYSTEMATIC 
scavenger O 
possessed O 
the O 
lowest O 
PV O 
and O 
AnV O 
in O 
all O 
treatments O 
after O 
120 O 
days O 
of O 
storage O 
. O 
Therefore O 
, O 
it O 
has O 
the O 
potential O 
for O 
broad O 
application O 
as O 
an O 
active O 
packaging O 
in O 
a O 
variety O 
of O 
oxygen B-SYSTEMATIC 
-sensitive O 
foods O 
. O 

effect O 
of O 
infection O 
of O 
Citrus O 
sinensis O 
( O 
var O 
. O 
Navelina O 
) O 
fruits O 
with O 
Penicillium O 
digitatum O 
was O 
studied O 
at O 
gene O 
expression O 
and O 
metabolite O 
levels O 
. O 
In O 
this O 
study O 
, O 
expression O 
of O 
genes O 
involved O 
in O 
the O 
phenylpropanoid O 
pathway O 
was O 
studied O 
in O 
the O 
flavedo O 
( O 
outer O 
coloured O 
part O 
of O 
the O 
peel O 
) O 
and O 
albedo O 
( O 
inner O 
white O 
part O 
) O 
in O 
response O 
to O 
pathogen O 
infection O 
. O 
Results O 
of O 
the O 
time O 
- O 
course O 
experiment O 
showed O 
that O 
maximal O 
expression O 
of O 
10 O 
out O 
of O 
17 O 
phenylpropanoid O 
genes O 
analysed O 
occurred O 
at O 
48h O 
post O 
- O 
inoculation O 
, O 
when O 
decay O 
symptoms O 
started O 
to O 
appear O 
, O 
and O 
mRNA O 
levels O 
either O 
kept O 
constant O 
or O 
decreased O 
after O 
72h O 
post O 
- O 
inoculation O 
. O 
To O 
further O 
investigate O 
the O 
putative O 
involvement O 
of O 
the O 
phenylpropanoid O 
pathway O 
in O 
the O 
defence O 
of O 
citrus O 
fruit O 
, O 
changes O 
in O 
the O 
metabolic O 
profile O 
of O 
both O 
tissues O 
infected O 
with O 
P O 
. O 
digitatum O 
was O 
studied O 
by O 
means O 
of O 
HPLC-PDA-FD O 
. O 
Metabolite O 
accumulation O 
levels O 
along O 
the O 
time O 
course O 
suggest O 
that O 
flavanones B-FAMILY 
, O 
flavones B-FAMILY 
, O 
polymethoxylated B-FAMILY 
flavones I-FAMILY 
and O 
scoparone B-TRIVIAL 
are O 
induced O 
in O 
citrus O 
fruit O 
in O 
response O 
to O 
P O 
. O 
digitatum O 
infection O 
, O 
although O 
with O 
different O 
trends O 
depending O 
on O 
the O 
tissue O 
. O 

vivo O 
effects O 
of O 
cannabinoid O 
( O 
CB O 
) O 
agonists O 
are O 
often O 
assessed O 
using O 
four O 
well O 
- O 
established O 
measures O 
: O 
locomotor O 
activity O 
, O 
hypothermia O 
, O 
cataleptic O 
- O 
like O 
effects O 
, O 
and O 
analgesia O 
. O 
The O 
present O 
studies O 
demonstrate O 
that O 
doses O 
of O 
CB O 
agonists O 
that O 
produce O 
these O 
effects O 
also O 
reliably O 
increase O 
diuresis O 
. O 
Diuretic O 
effects O 
of O 
several O 
CB O 
agonists O 
were O 
measured O 
in O 
female O 
rats O 
over O 
2 O 
hours O 
immediately O 
after O 
drug O 
injection O 
, O 
and O 
results O 
were O 
compared O 
with O 
hypothermic O 
effects O 
. O 
Direct O 
- O 
acting O 
CB1 O 
agonists O 
, O 
including O 
Δ(9)-tetrahydrocannabinol B-SYSTEMATIC 
, O 
WIN B-IDENTIFIER 
55212 I-IDENTIFIER 
[ O 
R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone B-SYSTEMATIC 
mesylate I-SYSTEMATIC 
] O 
, O 
AM2389 B-IDENTIFIER 
[ O 
9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol B-SYSTEMATIC 
] O 
, O 
and O 
AM4054 B-IDENTIFIER 
[ O 
9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol B-SYSTEMATIC 
] O 
, O 
produced O 
dose O 
- O 
dependent O 
increases O 
in O 
diuresis O 
and O 
decreases O 
in O 
colonic O 
temperature O 
, O 
with O 
slightly O 
lower O 
ED(50) O 
values O 
for O 
diuresis O 
than O 
for O 
hypothermia O 
. O 
The O 
highest O 
doses O 
of O 
cannabinoid O 
drugs O 
yielded O 
, O 
on O 
average O 
, O 
26-32 O 
g O 
/ O 
kg O 
urine O 
; O 
comparable O 
effects O 
were O 
obtained O 
with O 
10 O 
mg O 
/ O 
kg O 
furosemide B-TRIVIAL 
and O 
3 O 
mg O 
/ O 
kg O 
trans-(-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide B-SYSTEMATIC 
( O 
U50-488 B-IDENTIFIER 
) O 
. O 
Methanandamide B-TRIVIAL 
( O 
10 O 
mg O 
/ O 
kg O 
) O 
had O 
lesser O 
effect O 
than O 
other O 
CB O 
agonists O 
, O 
and O 
the O 
CB2 O 
agonist O 
AM1241 B-IDENTIFIER 
[ O 
1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole B-SYSTEMATIC 
] O 
, O 
the O 
anandamide B-TRIVIAL 
transport O 
inhibitor O 
AM404 B-IDENTIFIER 
, O 
and O 
the O 
CB O 
antagonist O 
rimonabant B-TRIVIAL 
did O 
not O 
have O 
diuretic O 
effects O 
. O 
In O 
further O 
studies O 
, O 
the O 
diuretic O 
effects O 
of O 
the O 
CB1 O 
agonist O 
AM4054 B-IDENTIFIER 
were O 
similar O 
in O 
male O 
and O 
female O 
rats O 
, O 
displayed O 
a O 
relatively O 
rapid O 
onset O 
to O 
action O 
, O 
and O 
were O 
dose O 
- O 
dependently O 
antagonized O 
by O 
30 O 
minutes O 
pretreatment O 
with O 
rimonabant B-TRIVIAL 
, O 
but O 
not O 
by O 
the O 
vanilloid B-FAMILY 
receptor O 
type O 
I O 
antagonist O 
capsazepine B-TRIVIAL 
, O 
nor O 
were O 
the O 
effects O 
of O 
WIN B-IDENTIFIER 
55212 I-IDENTIFIER 
antagonized O 
by O 
the O 
CB2 O 
antagonist O 
AM630 B-IDENTIFIER 
[ O 
(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) B-SYSTEMATIC 
methanone I-SYSTEMATIC 
) I-SYSTEMATIC 
] O 
. O 
These O 
data O 
indicate O 
that O 
cannabinoids O 
have O 
robust O 
diuretic O 
effects O 
in O 
rats O 
that O 
are O 
mediated O 
via O 
CB1 O 
receptor O 
mechanisms O 
. O 

of O 
carbonyl B-FAMILY 
reducing O 
enzymes O 
in O 
the O 
phase O 
I O 
biotransformation O 
of O 
the O 
non-steroidal O 
anti-inflammatory O 
drug O 
nabumetone B-TRIVIAL 
in O 
vitro O 
. O 

. O 
Nabumetone B-TRIVIAL 
is O 
a O 
clinically O 
used O 
non-steroidal O 
anti-inflammatory O 
drug O 
, O 
its O 
biotransformation O 
includes O 
major O 
active O 
metabolite O 
6-methoxy-2-naphtylacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
another O 
three O 
phase O 
I O 
as O 
well O 
as O 
corresponding O 
phase O 
II O 
metabolites O 
which O 
are O 
regarded O 
as O 
inactive O 
. O 
One O 
important O 
biotransformation O 
pathway O 
is O 
carbonyl B-FAMILY 
reduction O 
, O 
which O 
leads O 
to O 
the O 
phase O 
I O 
metabolite O 
, O 
reduced O 
nabumetone B-TRIVIAL 
. O 
2 O 
. O 
The O 
aim O 
of O 
this O 
study O 
is O 
the O 
determination O 
of O 
the O 
role O 
of O 
a O 
particular O 
human O 
liver O 
subcellular O 
fraction O 
in O 
the O 
nabumetone B-TRIVIAL 
reduction O 
and O 
the O 
identification O 
of O 
participating O 
carbonyl B-FAMILY 
reducing O 
enzymes O 
along O 
with O 
their O 
stereospecificities O 
. O 
3 O 
. O 
Both O 
subcellular O 
fractions O 
take O 
part O 
in O 
the O 
carbonyl B-FAMILY 
reduction O 
of O 
nabumetone B-TRIVIAL 
and O 
the O 
reduction O 
is O 
at O 
least O 
in O 
vitro O 
the O 
main O 
biotransformation O 
pathway O 
. O 
The O 
activities O 
of O 
eight O 
cytosolic O 
carbonyl B-FAMILY 
reducing O 
enzymes O 
-- O 
CBR1 O 
, O 
CBR3 O 
, O 
AKR1B1 O 
, O 
AKR1B10 O 
, O 
AKR1C1-4 O 
-- O 
toward O 
nabumetone B-TRIVIAL 
were O 
tested O 
. O 
Except O 
for O 
CBR3 O 
, O 
all O 
tested O 
reductases O 
transform O 
nabumetone B-TRIVIAL 
to O 
its O 
reduced O 
metabolite O 
. O 
AKR1C4 O 
and O 
AKR1C3 O 
have O 
the O 
highest O 
intrinsic O 
clearances O 
. O 
4 O 
. O 
The O 
stereospecificity O 
of O 
the O 
majority O 
of O 
the O 
tested O 
enzymes O 
is O 
shifted O 
to O 
the O 
production O 
of O 
an O 
(+)-enantiomer O 
of O 
reduced O 
nabumetone B-TRIVIAL 
; O 
only O 
AKR1C1 O 
and O 
AKR1C4 O 
produce O 
predominantly O 
an O 
(-)-enantiomer O 
. O 
This O 
project O 
provides O 
for O 
the O 
first O 
time O 
evidence O 
that O 
seven O 
specific O 
carbonyl B-FAMILY 
reducing O 
enzymes O 
participate O 
in O 
nabumetone B-TRIVIAL 
metabolism O 
. O 

of O 
gemifloxacin B-TRIVIAL 
, O 
a O 
4th O 
generation O 
quinolone B-FAMILY 
antibiotic O 
, O 
in O 
the O 
Caco-2 O 
and O 
engineered O 
MDCKII O 
cells O 
, O 
and O 
potential O 
involvement O 
of O 
efflux O 
transporters O 
in O 
the O 
intestinal O 
absorption O 
of O 
the O 
drug O 
. O 

oral O 
( O 
po O 
) O 
bioavailability O 
of O 
gemifloxacin B-TRIVIAL 
mesylate I-TRIVIAL 
in O 
rats O 
and O 
its O 
possible O 
association O 
with O 
efflux O 
transporters O 
was O 
investigated O 
. O 
The O 
apparent O 
permeabilities O 
( O 
Papp O 
) O 
of O 
gemifloxacin B-TRIVIAL 
across O 
the O 
Caco-2 O 
cell O 
monolayer O 
were O 
1.2 O 
± O 
0.09 O 
× O 
10(-5) O 
cm O 
/ O 
s O 
for O 
apical O 
to O 
basal O 
( O 
absorptive O 
) O 
transport O 
, O 
and O 
2.13 O 
± O 
0.6 O 
× O 
10(-5) O 
cm O 
/ O 
s O 
for O 
basal O 
to O 
apical O 
( O 
secretory O 
) O 
transport O 
for O 
a O 
5-500 O 
μM O 
concentration O 
range O 
, O 
suggesting O 
the O 
involvement O 
of O 
a O 
carrier O 
- O 
mediated O 
efflux O 
in O 
the O 
secretory O 
transport O 
. O 
The O 
secretory O 
transport O 
in O 
Caco-2 O 
cells O 
was O 
significantly O 
decreased O 
by O 
MRP2 O 
( O 
MK571 B-IDENTIFIER 
) O 
and O 
BCRP O 
( O 
Ko143 B-IDENTIFIER 
) O 
inhibitors O 
. O 
The O 
secretory O 
transport O 
was O 
distinct O 
in O 
MDCKII O 
/ O 
P-gp O 
, O 
MDCKII O 
/ O 
MRP2 O 
and O 
MDCKII O 
/ O 
BCRP O 
cells O 
, O 
and O 
the O 
affinity O 
was O 
highest O 
for O 
MRP2 O 
, O 
followed O 
by O 
BCRP O 
and O 
P-gp O 
. O 
The O 
efflux O 
was O 
significantly O 
decreased O 
by O 
verapamil B-TRIVIAL 
and O 
Ko143 B-IDENTIFIER 
, O 
but O 
not O 
significantly O 
by O 
MK571 B-IDENTIFIER 
. O 
The O 
comparative O 
po O 
bioavailability O 
in O 
rats O 
was O 
increased O 
by O 
the O 
preadministration O 
of O 
Ko143 B-IDENTIFIER 
( O 
four O 
- O 
fold O 
) O 
, O 
MK571 B-IDENTIFIER 
( O 
two O 
- O 
fold O 
) O 
and O 
verapamil B-TRIVIAL 
( O 
two O 
- O 
fold O 
) O 
. O 
Efflux O 
transporters O 
appeared O 
to O 
significantly O 
limit O 
the O 
bioavailability O 
of O 
gemifloxacin B-TRIVIAL 
in O 
rats O 
, O 
suggesting O 
their O 
possible O 
contribution O 
to O 
the O 
low O 
bioavailability O 
of O 
the O 
drug O 
in O 
the O 
human O 
( O 
70% O 
) O 
. O 

phase O 
I O 
, O 
open O 
- O 
label O 
, O 
single O 
- O 
dose O 
, O 
mass O 
balance O 
study O 
of O 
14C-labeled B-SYSTEMATIC 
abiraterone I-SYSTEMATIC 
acetate I-SYSTEMATIC 
in O 
healthy O 
male O 
subjects O 
. O 

. O 
Metabolic O 
disposition O 
of O 
(14)C-abiraterone B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
AA O 
) O 
, O 
a O 
prodrug O 
of O 
abiraterone B-TRIVIAL 
was O 
assessed O 
in O 
a O 
phase O 
I O 
, O 
open O 
- O 
label O 
, O 
single O 
- O 
dose O 
( O 
1000 O 
mg O 
, O 
approximately O 
100 O 
μCi O 
) O 
study O 
in O 
healthy O 
males O 
( O 
18-55 O 
years O 
, O 
N O 
= O 
8 O 
) O 
. O 
Blood O 
, O 
urine O 
, O 
and O 
faecal O 
samples O 
were O 
obtained O 
at O 
specified O 
timepoints O 
for O 
determination O 
of O 
abiraterone B-TRIVIAL 
concentrations O 
in O 
the O 
plasma O 
, O 
total O 
radioactivity O 
( O 
TR O 
) O 
, O 
and O 
the O 
metabolite O 
profile O 
. O 
2 O 
. O 
Most O 
plasma O 
AA O 
concentrations O 
were O 
below O 
the O 
limit O 
of O 
quantification O 
. O 
The O 
mean O 
maximum O 
plasma O 
concentration O 
( O 
Cmax O 
) O 
of O 
abiraterone B-TRIVIAL 
was O 
10.4 O 
ng O 
/ O 
mL O 
, O 
mean O 
area O 
under O 
the O 
plasma O 
concentration O 
- O 
time O 
curve O 
( O 
AUC O 
) O 
from O 
0 O 
to O 
the O 
last O 
measurable O 
plasma O 
concentration O 
( O 
AUC0-last O 
) O 
was O 
74.8 O 
ng·h O 
/ O 
mL O 
. O 
The O 
exposures O 
for O 
TR O 
in O 
plasma O 
( O 
Cmax O 
= O 
3429 O 
ng·eq O 
/ O 
mL O 
; O 
AUC0-last O 
= O 
26683 O 
ng O 
eq·h O 
/ O 
mL O 
) O 
and O 
whole O 
blood O 
( O 
Cmax O 
= O 
1836 O 
ng·eq O 
/ O 
mL O 
; O 
AUC0-last O 
= O 
12162 O 
ng·eq·h O 
/ O 
mL O 
) O 
were O 
> O 
300-fold O 
higher O 
than O 
abiraterone B-TRIVIAL 
exposure O 
in O 
plasma O 
. O 
The O 
majority O 
of O 
TR O 
resided O 
in O 
the O 
plasma O 
compartment O 
of O 
blood O 
. O 
3 O 
. O 
Main O 
circulating O 
metabolites O 
were O 
abiraterone B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
and O 
N-oxide B-SYSTEMATIC 
abiraterone I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
. O 
The O 
main O 
metabolite O 
excreted O 
in O 
urine O 
was O 
N-oxide B-SYSTEMATIC 
abiraterone I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
4.22% O 
of O 
TR O 
) O 
. O 
Major O 
components O 
of O 
TR O 
in O 
faeces O 
were O 
unchanged O 
AA O 
( O 
55.3% O 
of O 
TR O 
) O 
and O 
abiraterone B-TRIVIAL 
( O 
22.3% O 
of O 
TR O 
) O 
. O 
Mean O 
recovery O 
of O 
TR O 
in O 
faeces O 
was O 
87.9% O 
, O 
indicating O 
faeces O 
as O 
primary O 
route O 
of O 
excretion O 
. O 

of O 
GABA B-ABBREVIATION 
synthesis O 
in O 
the O 
prefrontal O 
cortex O 
increases O 
locomotor O 
activity O 
but O 
does O 
not O 
affect O 
attention O 
in O 
the O 
5-choice O 
serial O 
reaction O 
time O 
task O 
. O 

deficits O 
are O 
a O 
core O 
cognitive O 
symptom O 
of O 
schizophrenia O 
; O 
the O 
neuropathology O 
underlying O 
these O 
deficits O 
is O 
not O 
known O 
. O 
Attention O 
is O 
regulated O 
, O 
at O 
least O 
in O 
part O 
, O 
by O 
the O 
prefrontal O 
cortex O 
( O 
PFC O 
) O 
, O 
a O 
brain O 
area O 
in O 
which O 
pathology O 
of O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
) O 
neurons O 
has O 
been O 
consistently O 
observed O 
in O 
post O 
- O 
mortem O 
analysis O 
of O 
the O 
brains O 
of O 
people O 
with O 
schizophrenia O 
. O 
Specifically O 
, O 
expression O 
of O 
the O 
67-kD O 
isoform O 
of O 
the O 
GABA B-ABBREVIATION 
synthesis O 
enzyme O 
glutamic B-TRIVIAL 
acid I-TRIVIAL 
decarboxylase O 
( O 
GAD67 O 
) O 
is O 
reduced O 
in O 
parvalbumin O 
- O 
containing O 
fast O 
- O 
spiking O 
GABA B-ABBREVIATION 
interneurons O 
. O 
Thus O 
it O 
is O 
hypothesized O 
that O 
reduced O 
cortical O 
GABA B-ABBREVIATION 
synthesis O 
and O 
release O 
may O 
contribute O 
to O 
the O 
attention O 
deficits O 
in O 
schizophrenia O 
. O 
Here O 
the O 
effect O 
of O 
reducing O 
cortical O 
GABA B-ABBREVIATION 
synthesis O 
with O 
l-allylglycine B-TRIVIAL 
( O 
LAG B-ABBREVIATION 
) O 
on O 
attention O 
was O 
tested O 
using O 
three O 
different O 
versions O 
of O 
the O 
5-choice O 
serial O 
reaction O 
time O 
task O 
( O 
5CSRTT O 
) O 
. O 
Because O 
5CSRTT O 
performance O 
can O 
be O 
affected O 
by O 
locomotor O 
activity O 
, O 
we O 
also O 
measured O 
this O 
behavior O 
in O 
an O 
open O 
field O 
. O 
Finally O 
, O 
the O 
expression O 
of O 
Fos O 
protein O 
was O 
used O 
as O 
an O 
indirect O 
measure O 
of O 
reduced O 
GABA B-ABBREVIATION 
synthesis O 
. O 
Intra O 
- O 
cortical O 
LAG B-ABBREVIATION 
( O 
10 O 
μg O 
/ O 
0.5 O 
μl O 
/ O 
side O 
) O 
infusions O 
increased O 
Fos O 
expression O 
and O 
resulted O 
in O 
hyperactivity O 
in O 
the O 
open O 
field O 
. O 
Intra O 
- O 
cortical O 
LAG B-ABBREVIATION 
infusions O 
did O 
not O 
affect O 
attention O 
in O 
any O 
version O 
of O 
the O 
5CSRTT O 
. O 
These O 
results O 
suggest O 
that O 
a O 
general O 
decrease O 
in O 
GABA B-ABBREVIATION 
synthesis O 
is O 
not O 
sufficient O 
to O 
cause O 
attention O 
deficits O 
. O 
It O 
remains O 
to O 
be O 
tested O 
whether O 
a O 
selective O 
decrease O 
in O 
GABA B-ABBREVIATION 
synthesis O 
in O 
parvalbumin O 
- O 
containing O 
GABA B-ABBREVIATION 
neurons O 
could O 
cause O 
attention O 
deficits O 
. O 
Decreased O 
cortical O 
GABA B-ABBREVIATION 
synthesis O 
did O 
increase O 
locomotor O 
activity O 
; O 
this O 
may O 
reflect O 
the O 
positive O 
symptoms O 
of O 
schizophrenia O 
. O 

confers O 
neuronal O 
protection O 
against O 
excitotoxic O 
injury O 
by O 
down O 
- O 
regulating O 
GluN2B O 
- O 
containing O 
NMDA B-ABBREVIATION 
receptors O 
. O 

( O 
CYT B-ABBREVIATION 
) O 
, O 
one O 
of O 
the O 
principal O 
bioactive O 
components O 
derived O 
from O 
the O 
seeds O 
of O 
Cytisus O 
laborinum O 
L O 
, O 
has O 
been O 
widely O 
used O 
for O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
diseases O 
treatment O 
. O 
The O 
present O 
study O 
investigated O 
the O 
protective O 
effect O 
of O 
CYT B-ABBREVIATION 
on O 
cultured O 
cortical O 
neural O 
injury O 
induced O 
by O 
N-methyl-d-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
. O 
Our O 
data O 
showed O 
that O 
CYT B-ABBREVIATION 
conferred O 
protective O 
effect O 
against O 
loss O 
of O 
cellular O 
viability O 
induced O 
by O 
brief O 
exposure O 
to O 
200 O 
μM O 
NMDA B-ABBREVIATION 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 
CYT B-ABBREVIATION 
significantly O 
inhibited O 
the O 
neuronal O 
apoptosis O 
induced O 
by O 
NMDA B-ABBREVIATION 
exposure O 
by O 
reversing O 
intracellular O 
Ca(2+) B-FORMULA 
overload O 
and O 
balancing O 
Bcl-2 O 
and O 
Bax O 
expression O 
levels O 
. O 
Furthermore O 
, O 
CYT B-ABBREVIATION 
significantly O 
reversed O 
the O 
up O 
- O 
regulation O 
of O 
GluN2B O 
- O 
containing O 
NMDA B-ABBREVIATION 
receptors O 
by O 
exposure O 
to O 
NMDA B-ABBREVIATION 
, O 
but O 
it O 
did O 
not O 
affect O 
the O 
level O 
of O 
GluN2A O 
- O 
containing O 
NMDA B-ABBREVIATION 
receptors O 
. O 
These O 
findings O 
suggest O 
that O 
CYT B-ABBREVIATION 
protects O 
cortical O 
neurons O 
, O 
at O 
least O 
partially O 
, O 
by O 
inhibiting O 
the O 
level O 
of O 
GluN2B O 
- O 
containing O 
NMDA B-ABBREVIATION 
receptors O 
and O 
regulating O 
Bcl-2 O 
family O 
. O 

of O 
neurite O 
outgrowth O 
and O 
alteration O 
of O 
cytoskeletal O 
gene O 
expression O 
by O 
sodium B-SYSTEMATIC 
arsenite I-SYSTEMATIC 
. O 

compounds O 
that O 
are O 
often O 
found O 
in O 
drinking O 
water O 
increase O 
the O 
risk O 
of O 
developmental O 
brain O 
disorders O 
. O 
In O 
this O 
study O 
, O 
we O 
performed O 
live O 
imaging O 
analyses O 
of O 
Neuro-2a O 
cells O 
expressing O 
SCAT3 O 
, O 
a O 
caspase-3 O 
cleavage O 
peptide O 
sequence O 
linking O 
two O 
fluorescent O 
proteins O 
; O 
enhanced O 
cyan O 
fluorescence O 
protein O 
( O 
ECFP O 
) O 
and O 
Venus O 
, O 
to O 
determine O 
whether O 
sodium B-SYSTEMATIC 
arsenite I-SYSTEMATIC 
( O 
NaAsO(2) B-FORMULA 
; O 
0 O 
, O 
1 O 
, O 
5 O 
, O 
or O 
10 O 
μM O 
) O 
affects O 
both O 
neurite O 
outgrowth O 
and O 
/ O 
or O 
induces O 
apoptosis O 
with O 
the O 
same O 
doses O 
and O 
in O 
the O 
same O 
cell O 
cultures O 
. O 
We O 
observed O 
that O 
the O 
area O 
ratio O 
of O 
neurite O 
to O 
cell O 
body O 
in O 
SCAT3-expressing O 
cells O 
was O 
significantly O 
reduced O 
by O 
5 O 
and O 
10 O 
μM O 
NaAsO(2) B-FORMULA 
, O 
but O 
not O 
by O 
1 O 
μM O 
, O 
although O 
the O 
emission O 
ratio O 
of O 
ECFP O 
to O 
Venus O 
, O 
an O 
endpoint O 
of O 
caspase-3 O 
activity O 
, O 
was O 
not O 
changed O 
. O 
However O 
, O 
cytological O 
assay O 
using O 
apoptotic O 
and O 
necrotic O 
markers O 
resulted O 
in O 
that O 
apoptosis O 
, O 
but O 
not O 
necrosis O 
, O 
was O 
significantly O 
induced O 
in O 
Neuro-2a O 
cells O 
when O 
NaAsO(2) B-FORMULA 
exposure O 
continued O 
after O 
the O 
significant O 
effects O 
of O 
NaAsO(2) B-FORMULA 
on O 
neurite O 
outgrowth O 
were O 
found O 
by O 
live O 
imaging O 
. O 
These O 
results O 
suggested O 
that O 
neurite O 
outgrowth O 
was O 
suppressed O 
by O 
NaAsO(2) B-FORMULA 
prior O 
to O 
NaAsO(2) B-FORMULA 
-induced O 
apoptosis O 
. O 
Next O 
, O 
we O 
examined O 
the O 
effects O 
of O 
NaAsO(2) B-FORMULA 
on O 
cytoskeletal O 
gene O 
expression O 
in O 
Neuro-2a O 
cells O 
. O 
NaAsO(2) B-FORMULA 
increased O 
the O 
mRNA O 
levels O 
of O 
the O 
light O 
and O 
medium O 
subunits O 
of O 
neurofilament O 
and O 
decreased O 
the O 
mRNA O 
levels O 
of O 
tau O 
and O 
tubulin O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
; O 
no O 
significant O 
effect O 
was O 
found O 
in O 
the O 
mRNA O 
levels O 
of O 
the O 
heavy O 
subunit O 
of O 
neurofilament O 
, O 
microtubule O 
- O 
associated O 
protein O 
2 O 
, O 
or O 
actin O 
. O 
The O 
changes O 
in O 
cytoskeletal O 
gene O 
expression O 
are O 
likely O 
responsible O 
for O 
the O 
inhibitory O 
effects O 
of O 
NaAsO(2) B-FORMULA 
on O 
neurite O 
outgrowth O 
. O 

of O 
triethylenetetramine B-SYSTEMATIC 
and O 
1,12-diamino-3,6,9-triazadodecane B-SYSTEMATIC 
by O 
the O 
spermidine B-TRIVIAL 
/ O 
spermine B-TRIVIAL 
-N(1)-acetyltransferase O 
and O 
thialysine B-SYSTEMATIC 
acetyltransferase O 
. O 

( O 
TETA B-ABBREVIATION 
; O 
Syprine B-TRIVIAL 
; O 
Merck O 
Rahway O 
, O 
NJ O 
) O 
, O 
a O 
drug O 
for O 
Wilson's O 
disease O 
, O 
is O 
a O 
copper B-SYSTEMATIC 
chelator O 
and O 
a O 
charge O 
- O 
deficient O 
analog O 
of O 
polyamine B-FAMILY 
spermidine B-TRIVIAL 
. O 
We O 
recently O 
showed O 
that O 
TETA B-ABBREVIATION 
is O 
metabolized O 
in O 
vitro O 
by O 
polyamine B-FAMILY 
catabolic O 
enzyme O 
spermidine B-TRIVIAL 
/ O 
spermine B-TRIVIAL 
-N(1)-acetyltransferase O 
( O 
SSAT1 O 
) O 
and O 
by O 
thialysine B-SYSTEMATIC 
acetyltransferase O 
( O 
SSAT2 O 
) O 
to O 
its O 
monoacetylated O 
derivative O 
( O 
MAT O 
) O 
. O 
The O 
acetylation O 
of O 
TETA B-ABBREVIATION 
is O 
increased O 
in O 
SSAT1-overexpressing O 
mice O 
compared O 
with O 
wild O 
- O 
type O 
mice O 
. O 
However O 
, O 
SSAT1-deficient O 
mice O 
metabolize O 
TETA B-ABBREVIATION 
at O 
the O 
same O 
rate O 
as O 
the O 
wild O 
- O 
type O 
mice O 
, O 
indicating O 
the O 
existence O 
of O 
another O 
N-acetylase O 
respons O 
2ible O 
for O 
its O 
metabolism O 
in O 
mice O 
. O 
Here O 
, O 
we O 
show O 
that O 
siRNA O 
- O 
mediated O 
knockdown O 
of O 
SSAT2 O 
in O 
HEPG2 O 
cells O 
and O 
in O 
primary O 
hepatocytes O 
from O 
the O 
SSAT1-deficient O 
or O 
wild O 
- O 
type O 
mice O 
reduced O 
the O 
metabolism O 
of O 
TETA B-ABBREVIATION 
to O 
MAT O 
. O 
By O 
contrast O 
, O 
1,12-diamino-3,6,9-triazadodecane B-SYSTEMATIC 
( O 
SpmTrien B-TRIVIAL 
) O 
, O 
a O 
charge O 
- O 
deficient O 
spermine B-TRIVIAL 
analog O 
, O 
was O 
an O 
extremely O 
poor O 
substrate O 
of O 
human O 
recombinant O 
SSAT2 O 
and O 
was O 
metabolized O 
by O 
SSAT1 O 
in O 
HEPG2 O 
cells O 
and O 
in O 
wild O 
- O 
type O 
primary O 
hepatocytes O 
. O 
Thus O 
, O 
despite O 
the O 
similar O 
structures O 
of O 
TETA B-ABBREVIATION 
and O 
SpmTrien B-TRIVIAL 
, O 
SSAT2 O 
is O 
the O 
main O 
acetylator O 
of O 
TETA B-ABBREVIATION 
, O 
whereas O 
SpmTrien B-TRIVIAL 
is O 
primarily O 
acetylated O 
by O 
SSAT1 O 
. O 

between O 
excitons O 
of O 
CdSe B-FORMULA 
nanocrystal O 
quantum O 
dots O 
( O 
NQDs O 
) O 
and O 
surface O 
plasmon O 
polaritons O 
( O 
SPPs O 
) O 
of O 
an O 
Ag B-FORMULA 
film O 
attached O 
to O 
a O 
prism O 
have O 
been O 
studied O 
by O 
steady O 
- O 
state O 
and O 
transient O 
reflectivity O 
measurements O 
in O 
the O 
Kretschmann O 
geometry O 
. O 
In O 
these O 
experiments O 
, O 
the O 
angle O 
of O 
incidence O 
of O 
the O 
probe O 
beam O 
selects O 
hybrid O 
exciton O 
/ O 
SPP O 
states O 
with O 
different O 
wavevectors O 
and O 
exciton O 
/ O 
SPP O 
compositions O 
. O 
The O 
dynamics O 
measured O 
in O 
the O 
transient O 
reflectivity O 
experiments O 
are O 
sensitive O 
to O 
the O 
composition O 
of O 
the O 
hybrid O 
states O 
. O 
Specifically O 
, O 
fast O 
dynamics O 
are O 
observed O 
at O 
probe O 
wavevectors O 
where O 
the O 
lower O 
hybrid O 
state O 
has O 
predominant O 
SPP O 
character O 
. O 
In O 
contrast O 
, O 
at O 
probe O 
wavevectors O 
where O 
the O 
lower O 
hybrid O 
state O 
is O 
predominantly O 
excitonic O 
, O 
the O 
dynamics O 
are O 
similar O 
to O 
that O 
measured O 
for O 
CdSe B-FORMULA 
NQDs O 
on O 
glass O 
. O 

regulation O 
of O 
sulfotransferase O 
1A1 O 
and O 
2A1 O 
expression O 
in O 
rat O 
brain O 
sections O 
. O 

catalyzed O 
sulfation O 
regulates O 
the O 
biological O 
activities O 
of O 
various O 
neurotransmitters O 
/ O 
hormones O 
and O 
detoxifies O 
xenobiotics O 
. O 
Rat O 
sulfotransferase O 
rSULT1A1 O 
catalyzes O 
the O 
sulfation O 
of O 
neurotransmitters O 
and O 
xenobiotic O 
phenolic B-FAMILY 
compounds O 
. O 
rSULT2A1 O 
catalyzes O 
the O 
sulfation O 
of O 
hydroxysteroids B-FAMILY 
and O 
xenobiotic O 
alcoholic B-FAMILY 
compounds O 
. O 
In O 
this O 
work O 
, O 
Western O 
blot O 
and O 
real O 
- O 
time O 
RT-PCR O 
were O 
used O 
to O 
investigate O 
the O 
effect O 
of O 
methamphetamine B-TRIVIAL 
on O 
rSULT1A1 O 
and O 
rSULT2A1 O 
protein O 
and O 
mRNA O 
expression O 
in O 
rat O 
cerebellum O 
, O 
frontal O 
cortex O 
, O 
hippocampus O 
, O 
and O 
striatum O 
. O 
After O 
1-day O 
treatment O 
, O 
significant O 
induction O 
of O 
rSULT1A1 O 
was O 
observed O 
only O 
in O 
the O 
cerebellum O 
; O 
rSULT2A1 O 
was O 
induced O 
significantly O 
in O 
the O 
cerebellum O 
, O 
frontal O 
cortex O 
, O 
and O 
hippocampus O 
. O 
After O 
7 O 
days O 
of O 
exposure O 
, O 
rSULT1A1 O 
was O 
induced O 
in O 
the O 
cerebellum O 
, O 
frontal O 
cortex O 
, O 
and O 
hippocampus O 
, O 
while O 
rSULT2A1 O 
was O 
induced O 
significantly O 
in O 
all O 
four O 
regions O 
. O 
Western O 
blot O 
results O 
agreed O 
with O 
the O 
real O 
- O 
time O 
RT-PCR O 
results O 
, O 
suggesting O 
that O 
the O 
induction O 
occurred O 
at O 
the O 
gene O 
transcriptional O 
level O 
. O 
Results O 
indicate O 
that O 
rSULT1A1 O 
and O 
rSULT2A1 O 
are O 
expressed O 
in O 
rat O 
frontal O 
cortex O 
, O 
cerebellum O 
, O 
striatum O 
, O 
and O 
hippocampus O 
. O 
rSULT1A1 O 
and O 
rSULT2A1are O 
inducible O 
by O 
methamphetamine B-TRIVIAL 
in O 
rat O 
brain O 
sections O 
in O 
a O 
time O 
dependable O 
manner O 
. O 
rSULT2A1 O 
is O 
more O 
inducible O 
than O 
rSULT1A1 O 
by O 
methamphetamine B-TRIVIAL 
in O 
rat O 
brain O 
sections O 
. O 
Induction O 
activity O 
of O 
methamphetamine B-TRIVIAL 
is O 
in O 
the O 
order O 
of O 
cerebellum O 
> O 
frontal O 
cortex O 
, O 
hippocampus O 
> O 
striatum O 
. O 
These O 
results O 
suggest O 
that O 
the O 
physiological O 
functions O 
of O 
rSULT1A1 O 
and O 
rSULT2A1 O 
in O 
different O 
brain O 
regions O 
can O 
be O 
affected O 
by O 
methamphetamine B-TRIVIAL 
. O 

review O 
the O 
specific O 
approaches O 
for O 
lung O 
tissue O 
slices O 
preparation O 
and O 
incubation O 
systems O 
and O 
the O 
research O 
application O 
fields O 
in O 
which O 
lung O 
slices O 
proved O 
to O 
be O 
a O 
very O 
efficient O 
alternative O 
to O 
animal O 
experimentation O 
for O 
biomechanical O 
, O 
physiological O 
, O 
pharmacological O 
and O 
toxicological O 
approaches O 
. O 
2.Focus O 
is O 
made O 
on O 
air O 
- O 
liquid O 
interface O 
dynamic O 
organ O 
culture O 
systems O 
that O 
allow O 
direct O 
tissue O 
exposure O 
to O 
complex O 
aerosol O 
and O 
that O 
best O 
mimic O 
in O 
vivo O 
lung O 
tissue O 
physiology O 
. O 
3.A O 
compilation O 
of O 
research O 
applications O 
in O 
the O 
fields O 
of O 
vascular O 
and O 
airway O 
reactivity O 
, O 
mucociliary O 
transport O 
, O 
polyamine B-FAMILY 
transport O 
, O 
xenobiotic O 
biotransformation O 
, O 
chemicals O 
toxicology O 
and O 
complex O 
aerosols O 
supports O 
the O 
concept O 
that O 
precision O 
cut O 
lung O 
slices O 
are O 
a O 
very O 
efficient O 
tool O 
maintaining O 
highly O 
differentiated O 
functions O 
similar O 
to O 
in O 
vivo O 
lung O 
organ O 
when O 
kept O 
under O 
dynamic O 
organ O 
culture O 
. O 
They O 
also O 
have O 
been O 
successfully O 
used O 
for O 
lung O 
gene O 
transfer O 
efficiency O 
assessment O 
, O 
for O 
lung O 
viral O 
infection O 
efficiency O 
assessment O 
, O 
for O 
studies O 
of O 
tissue O 
preservation O 
media O 
and O 
tissue O 
post O 
- O 
conditioning O 
to O 
optimize O 
lung O 
tissue O 
viability O 
before O 
grafting O 
. O 
4.Taken O 
all O 
together O 
, O 
the O 
reviewed O 
studies O 
point O 
to O 
a O 
great O 
interest O 
for O 
precision O 
cut O 
lung O 
slices O 
as O 
an O 
efficient O 
and O 
valuable O 
alternative O 
to O 
in O 
vivo O 
lung O 
organ O 
experimentation O 
. O 

products O 
as O 
sources O 
of O 
new O 
fungicides O 
(I) O 
: O 
synthesis O 
and O 
antifungal O 
activity O 
of O 
acetophenone B-TRIVIAL 
derivatives O 
against O 
phytopathogenic O 
fungi O 
. O 

series O 
of O 
45 O 
acetophenone B-TRIVIAL 
derivatives O 
bearing O 
various O 
alkyl B-FAMILY 
or O 
benzyl B-SYSTEMATIC 
substituents O 
were O 
conveniently O 
synthesized O 
and O 
their O 
structures O 
characterized O 
by O 
(1)H B-FORMULA 
and O 
(13)C B-FORMULA 
NMR O 
spectroscopy O 
, O 
HRMS O 
and O 
single O 
- O 
crystal O 
X-ray O 
analysis O 
. O 
Their O 
in O 
vitro O 
antifungal O 
activities O 
against O 
a O 
panel O 
of O 
phytopathogenic O 
fungi O 
were O 
evaluated O 
by O 
mycelial O 
growth O 
rate O 
assay O 
. O 
Of O 
them O 
, O 
12 O 
derivatives O 
( O 
e.g O 
. O 
, O 
3a-c O 
, O 
4c O 
and O 
4e O 
) O 
exhibited O 
more O 
potent O 
antifungal O 
effects O 
on O 
some O 
phytopathogens O 
than O 
a O 
commercial O 
fungicide O 
hymexazol B-TRIVIAL 
as O 
positive O 
control O 
. O 
In O 
particular O 
, O 
compound O 
3b O 
with O 
IC50 O 
values O 
of O 
10-19 O 
μg O 
/ O 
mL O 
was O 
found O 
to O 
be O 
the O 
most O 
active O 
in O 
this O 
series O 
and O 
might O 
be O 
a O 
potential O 
lead O 
structure O 
for O 
further O 
optimization O 
. O 
The O 
preliminary O 
structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
studies O 
of O 
a O 
series O 
of O 
acetophenones B-FAMILY 
are O 
also O 
discussed O 
. O 

human O 
epidermal O 
growth O 
factor O 
receptor O 
2 O 
( O 
HER2 O 
, O 
also O 
known O 
as O 
erbB2 O 
) O 
gene O 
is O 
involved O 
in O 
signal O 
transduction O 
for O 
cell O 
growth O 
and O 
differentiation O 
. O 
It O 
is O 
a O 
cell O 
surface O 
receptor O 
tyrosine B-TRIVIAL 
kinase O 
and O 
a O 
proto O 
- O 
oncogene O 
. O 
Overexpression O 
of O 
HER2 O 
is O 
of O 
clinical O 
relevance O 
in O 
breast O 
cancer O 
due O 
to O 
its O 
prognostic O 
value O 
correlating O 
elevated O 
expression O 
with O 
worsening O 
clinical O 
outcome O 
. O 
At O 
the O 
same O 
time O 
, O 
HER2 O 
assessment O 
is O 
also O 
of O 
importance O 
because O 
successful O 
anti-tumor O 
treatment O 
with O 
Herceptin O 
® O 
is O 
strongly O 
correlated O 
with O 
HER2 O 
overexpression O 
in O 
the O 
tumor O 
( O 
approximately O 
30% O 
of O 
all O 
breast O 
tumors O 
overexpress O 
HER2 O 
) O 
. O 
In O 
a O 
comprehensive O 
national O 
study O 
, O 
Wolff O 
et O 
al O 
. O 
[ O 
1 O 
] O 
state O 
that O 
" O 
Approximately O 
20% O 
of O 
current O 
HER2 O 
testing O 
may O 
be O 
inaccurate O 
" O 
which O 
underscores O 
the O 
importance O 
of O 
developing O 
more O 
accurate O 
methods O 
to O 
determine O 
HER2 O 
status O 
. O 
Droplet O 
Digital O 
™ O 
PCR O 
( O 
ddPCR O 
™ O 
) O 
has O 
the O 
potential O 
to O 
improve O 
upon O 
HER2 O 
measurements O 
due O 
to O 
its O 
ability O 
to O 
quantitate O 
DNA O 
and O 
RNA O 
targets O 
with O 
high O 
precision O 
and O 
accuracy O 
. O 
Here O 
we O 
present O 
a O 
study O 
which O 
investigates O 
whether O 
ddPCR O 
can O 
be O 
used O 
to O 
assess O 
HER2 O 
transcript O 
levels O 
in O 
formalin B-TRIVIAL 
-fixed O 
paraffin O 
embedded O 
( O 
FFPE O 
) O 
human O 
breast O 
tumors O 
and O 
whether O 
these O 
ddPCR O 
measurements O 
agree O 
with O 
prior O 
assessments O 
of O 
these O 
same O 
samples O 
by O 
pathologists O 
using O 
immunohistochemistry O 
( O 
IHC O 
) O 
and O 
in O 
some O 
cases O 
fluorescence O 
in O 
situ O 
hybridization O 
( O 
FISH O 
) O 
. O 
We O 
also O 
determined O 
the O 
copy O 
number O 
of O 
HER2 O 
in O 
these O 
samples O 
as O 
compared O 
to O 
the O 
CEP17 O 
reference O 
gene O 
. O 
Results O 
: O 
Clinical O 
FFPE O 
samples O 
were O 
successfully O 
studied O 
using O 
ddPCR O 
and O 
compared O 
to O 
results O 
from O 
standard O 
FISH O 
and O 
IHC O 
methodology O 
. O 
The O 
results O 
demonstrate O 
that O 
ddPCR O 
can O 
rank O 
order O 
the O 
samples O 
in O 
complete O 
agreement O 
with O 
the O 
current O 
standard O 
methods O 
and O 
that O 
ddPCR O 
has O 
the O 
added O 
benefit O 
of O 
providing O 
quantitative O 
results O 
, O 
rather O 
than O 
relying O 
on O 
the O 
expert O 
skill O 
of O 
a O 
seasoned O 
pathologist O 
for O 
determination O 
. O 

[Lp(a)] O 
resembles O 
low O 
- O 
density O 
lipoprotein O 
( O 
LDL O 
) O 
, O 
with O 
an O 
LDL O 
lipid O 
core O 
and O 
apolipoprotein O 
B O 
( O 
apoB O 
) O 
, O 
but O 
contains O 
a O 
unique O 
apolipoprotein O 
, O 
apo(a) O 
. O 
Elevated O 
Lp(a) O 
is O 
an O 
independent O 
risk O 
factor O 
for O 
coronary O 
and O 
peripheral O 
vascular O 
diseases O 
. O 
The O 
size O 
and O 
concentration O 
of O 
plasma O 
Lp(a) O 
are O 
related O 
to O 
the O 
synthetic O 
rate O 
, O 
not O 
the O 
catabolic O 
rate O 
, O 
and O 
are O 
highly O 
variable O 
with O 
small O 
isoforms O 
associated O 
with O 
high O 
concentrations O 
and O 
pathogenic O 
risk O 
. O 
Apo(a) O 
is O 
synthesized O 
in O 
the O 
liver O 
, O 
although O 
assembly O 
of O 
apo(a) O 
and O 
LDL O 
may O 
occur O 
in O 
the O 
hepatocytes O 
or O 
plasma O 
. O 
While O 
the O 
uptake O 
and O 
clearance O 
site O 
of O 
Lp(a) O 
is O 
poorly O 
delineated O 
, O 
the O 
kidney O 
is O 
the O 
site O 
of O 
apo(a) O 
fragment O 
excretion O 
. O 
The O 
structure O 
of O 
apo(a) O 
has O 
high O 
homology O 
to O 
plasminogen O 
, O 
the O 
zymogen O 
for O 
plasmin O 
and O 
the O 
primary O 
clot O 
lysis O 
enzyme O 
. O 
Apo(a) O 
interferes O 
with O 
plasminogen O 
binding O 
to O 
C B-FORMULA 
-terminal O 
lysines O 
of O 
cell O 
surface O 
and O 
extracellular O 
matrix O 
proteins O 
. O 
Lp(a) O 
and O 
apo(a) O 
inhibit O 
fibrinolysis O 
and O 
accumulate O 
in O 
the O 
vascular O 
wall O 
in O 
atherosclerotic O 
lesions O 
. O 
The O 
pathogenic O 
role O 
of O 
Lp(a) O 
is O 
not O 
known O 
. O 
Small O 
isoforms O 
and O 
high O 
concentrations O 
of O 
Lp(a) O 
are O 
found O 
in O 
healthy O 
octogenarians O 
that O 
suggest O 
Lp(a) O 
may O 
also O 
have O 
a O 
physiological O 
role O 
. O 
Studies O 
of O 
Lp(a) O 
function O 
have O 
been O 
limited O 
since O 
it O 
is O 
not O 
found O 
in O 
commonly O 
studied O 
small O 
mammals O 
. O 
An O 
important O 
aspect O 
of O 
Lp(a) O 
metabolism O 
is O 
the O 
modification O 
of O 
circulating O 
Lp(a) O 
, O 
which O 
has O 
the O 
potential O 
to O 
alter O 
the O 
functions O 
of O 
Lp(a) O 
. O 
There O 
are O 
no O 
therapeutic O 
drugs O 
that O 
selectively O 
target O 
elevated O 
Lp(a) O 
, O 
but O 
a O 
number O 
of O 
possible O 
agents O 
are O 
being O 
considered O 
. O 
Recently O 
, O 
new O 
modifiers O 
of O 
apo(a) O 
synthesis O 
have O 
been O 
identified O 
. O 
This O 
review O 
reports O 
the O 
regulation O 
of O 
Lp(a) O 
metabolism O 
and O 
potential O 
sites O 
for O 
therapeutic O 
targets O 
. O 

activity O 
of O 
apoptosis O 
signal O 
- O 
regulating O 
kinase O 
1 O 
( O 
ASK1 O 
) O 
is O 
associated O 
with O 
a O 
number O 
of O 
human O 
disorders O 
and O 
the O 
inhibitors O 
of O 
ASK1 O 
may O 
become O 
important O 
compounds O 
for O 
pharmaceutical O 
application O 
. O 
Here O 
we O 
report O 
novel O 
ASK1 O 
inhibitor O 
scaffold O 
, O 
namely O 
5-(5-Phenyl-furan-2-ylmethylene)-2-thioxo-thiazolidin-4-one B-SYSTEMATIC 
, O 
that O 
has O 
been O 
identified O 
using O 
virtual O 
screening O 
and O 
biochemical O 
tests O 
. O 
A O 
series O 
of O 
derivatives O 
has O 
been O 
synthesized O 
and O 
evaluated O 
in O 
vitro O 
towards O 
human O 
protein O 
kinase O 
ASK1 O 
. O 
It O 
was O 
revealed O 
that O 
the O 
most O 
active O 
compounds O 
4-((5Z)-5-{[5-(4-bromophenyl)-2-furyl]methylene}-4-oxo-2-thioxo-1,3-thiazolidin-3-yl)butanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
6-((5Z)-5-{[5-(4-bromophenyl)-2-furyl]methylene}-4-oxo-2-thioxo-1,3-thiazolidin-3-yl)hexanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
inhibit O 
ASK1 O 
with O 
IC50 O 
of O 
0.2 O 
μM O 
. O 
Structure O 
- O 
activity O 
relationships O 
of O 
33 O 
derivatives O 
of O 
5-(5-Phenyl-furan-2-ylmethylene)-2-thioxo-thiazolidin-4-one B-SYSTEMATIC 
have O 
been O 
studied O 
and O 
binding O 
mode O 
of O 
this O 
chemical O 
class O 
has O 
been O 
predicted O 
. O 

and O 
characterization O 
of O 
novel O 
catalytic O 
bioscavengers O 
of O 
organophosphorus B-FAMILY 
nerve O 
agents O 
. O 

an O 
effort O 
to O 
discover O 
novel O 
catalytic O 
bioscavengers O 
of O 
organophosphorus B-FAMILY 
( O 
OP O 
) O 
nerve O 
agents O 
, O 
cell O 
lysates O 
from O 
a O 
diverse O 
set O 
of O 
bacterial O 
strains O 
were O 
screened O 
for O 
their O 
capacity O 
to O 
hydrolyze O 
the O 
OP O 
nerve O 
agents O 
VX O 
, O 
VR O 
, O 
and O 
soman B-TRIVIAL 
( O 
GD O 
) O 
. O 
The O 
library O 
of O 
bacterial O 
strains O 
was O 
identified O 
using O 
both O 
random O 
and O 
rational O 
approaches O 
. O 
Specifically O 
, O 
two O 
representative O 
strains O 
from O 
eight O 
categories O 
of O 
extremophiles O 
were O 
chosen O 
at O 
random O 
. O 
For O 
the O 
rational O 
approach O 
, O 
the O 
protein O 
sequence O 
of O 
organophosphorus B-FAMILY 
hydrolase O 
( O 
OPH O 
) O 
from O 
Brevundimonas O 
diminuta O 
was O 
searched O 
against O 
a O 
non-redundant O 
protein O 
database O 
using O 
the O 
Basic O 
Local O 
Alignment O 
Search O 
Tool O 
to O 
find O 
regions O 
of O 
local O 
similarity O 
between O 
sequences O 
. O 
Over O 
15 O 
protein O 
sequences O 
with O 
significant O 
sequence O 
similarity O 
to O 
OPH O 
were O 
identified O 
from O 
a O 
variety O 
of O 
bacterial O 
strains O 
. O 
Some O 
of O 
these O 
matches O 
were O 
based O 
on O 
predicted O 
protein O 
structures O 
derived O 
from O 
bacterial O 
genome O 
sequences O 
rather O 
than O 
from O 
bona O 
fide O 
proteins O 
isolated O 
from O 
bacteria O 
. O 
Of O 
the O 
25 O 
strains O 
selected O 
for O 
nerve O 
agent O 
testing O 
, O 
three O 
bacterial O 
strains O 
had O 
measurable O 
levels O 
of O 
OP O 
hydrolase O 
activity O 
. O 
These O 
strains O 
are O 
Ammoniphilus O 
oxalaticus O 
, O 
Haloarcula O 
sp O 
. O 
, O 
and O 
Micromonospora O 
aurantiaca O 
. O 
Lysates O 
from O 
A O 
. O 
oxalaticus O 
had O 
detectable O 
hydrolysis O 
of O 
VR O 
; O 
Haloarcula O 
sp O 
. O 
had O 
appreciable O 
hydrolysis O 
of O 
VX O 
and O 
VR O 
, O 
whereas O 
lysates O 
from O 
M O 
. O 
aurantiaca O 
had O 
detectable O 
hydrolysis O 
of O 
VR O 
and O 
GD O 
. O 

proliferator O 
- O 
activated O 
receptor-β O 
/ O 
δ O 
( O 
PPARδ O 
) O 
is O 
a O 
ubiquitously O 
expressed O 
, O 
ligand O 
- O 
activated O 
transcriptional O 
factor O 
that O 
performs O 
diverse O 
critical O 
functions O 
in O 
normal O 
cells O 
( O 
e.g O 
. O 
, O 
fatty B-FAMILY 
acid I-FAMILY 
metabolism O 
, O 
obesity O 
, O 
apoptosis O 
, O 
and O 
inflammation O 
) O 
. O 
Various O 
studies O 
in O 
humans O 
have O 
found O 
that O 
PPARδ O 
is O 
upregulated O 
in O 
primary O 
colorectal O 
cancers O 
; O 
however O 
, O 
these O 
findings O 
have O 
been O 
challenged O 
by O 
those O 
of O 
other O 
reports O 
. O 
Similarly O 
, O 
various O 
in O 
vitro O 
and O 
in O 
vivo O 
mechanistic O 
pre O 
- O 
clinical O 
models O 
have O 
yielded O 
data O 
demonstrating O 
that O 
PPARδ O 
promotes O 
colonic O 
tumorigenesis O 
, O 
but O 
other O 
models O 
have O 
yielded O 
data O 
that O 
contradicts O 
this O 
notion O 
. O 
Definitive O 
studies O 
are O 
therefore O 
needed O 
to O 
establish O 
the O 
exact O 
role O 
of O 
PPARδ O 
in O 
human O 
colorectal O 
tumorigenesis O 
and O 
to O 
provide O 
a O 
theoretical O 
basis O 
for O 
PPARδ O 
therapeutic O 
targeting O 
. O 

cell O 
- O 
protective O 
function O 
of O 
two O 
resveratrol B-TRIVIAL 
( B-SYSTEMATIC 
trans-3,5,4'-trihydroxystilbene I-SYSTEMATIC 
) I-SYSTEMATIC 
glucosides I-SYSTEMATIC 
against O 
oxidative O 
stress O 
. O 

( O 
trans-3,5,4'-trihydroxystilbene B-SYSTEMATIC 
; O 
RSV B-ABBREVIATION 
) O 
, O 
a O 
natural O 
polyphenol B-FAMILY 
, O 
exerts O 
a O 
beneficial O 
effect O 
on O 
health O 
and O 
diseases O 
. O 
RSV B-ABBREVIATION 
targets O 
and O 
activates O 
the O 
NAD(+) B-ABBREVIATION 
-dependent O 
protein O 
deacetylase O 
SIRT1 O 
; O 
in O 
turn O 
, O 
SIRT1 O 
induces O 
an O 
intracellular O 
antioxidative O 
mechanism O 
by O 
inducing O 
mitochondrial O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD2 O 
) O 
. O 
Most O 
RSV O 
found O 
in O 
plants O 
is O 
glycosylated O 
, O 
and O 
the O 
effect O 
of O 
these O 
glycosylated O 
forms O 
on O 
SIRT1 O 
has O 
not O 
been O 
studied O 
. O 
In O 
this O 
study O 
, O 
we O 
compared O 
the O 
effects O 
of O 
RSV B-ABBREVIATION 
and O 
two O 
glycosyl B-FAMILY 
RSVs I-FAMILY 
, O 
resveratrol-3-O-β-d-glucoside B-SYSTEMATIC 
( O 
3G-RSV B-SYSTEMATIC 
; O 
polydatin B-TRIVIAL 
/ O 
piceid B-TRIVIAL 
) O 
and O 
resveratrol-4'-O-β-d-glucoside B-SYSTEMATIC 
( O 
4'G-RSV B-SYSTEMATIC 
) O 
, O 
at O 
the O 
cellular O 
level O 
. O 
In O 
oxygen O 
radical O 
absorbance O 
capacity O 
and O 
2,2-diphenyl-1-picrylhydrazyl B-SYSTEMATIC 
radical O 
scavenging O 
assays O 
, O 
the O 
antioxidant O 
activity O 
of O 
3G-RSV B-SYSTEMATIC 
was O 
comparable O 
to O 
that O 
of O 
RSV B-ABBREVIATION 
, O 
whereas O 
the O 
radical O 
- O 
scavenging O 
efficiency O 
of O 
4'G-RSV B-SYSTEMATIC 
was O 
less O 
than O 
50% O 
of O 
that O 
of O 
RSV B-ABBREVIATION 
. O 
However O 
, O 
4'G-RSV B-SYSTEMATIC 
, O 
but O 
not O 
3G-RSV B-SYSTEMATIC 
, O 
induced O 
SIRT1-dependent O 
histone O 
H3 O 
deacetylation O 
and O 
SOD2 O 
expression O 
in O 
mouse O 
C2C12 O 
skeletal O 
myoblasts O 
; O 
as O 
with O 
RSV B-ABBREVIATION 
, O 
SIRT1 O 
knockdown O 
blunted O 
these O 
effects O 
. O 
RSV B-ABBREVIATION 
and O 
4'G-RSV B-SYSTEMATIC 
, O 
but O 
not O 
3G-RSV B-SYSTEMATIC 
, O 
mitigated O 
oxidative O 
stress O 
- O 
induced O 
cell O 
death O 
in O 
C2C12 O 
cells O 
and O 
primary O 
neonatal O 
rat O 
cardiomyocytes O 
. O 
RSV B-ABBREVIATION 
and O 
4'G-RSV B-SYSTEMATIC 
inhibited O 
C2C12 O 
cell O 
proliferation O 
, O 
but O 
3G-RSV B-SYSTEMATIC 
did O 
not O 
. O 
RSV B-ABBREVIATION 
was O 
found O 
in O 
both O 
the O 
intracellular O 
and O 
extracellular O 
fractions O 
of O 
C2C12 O 
cells O 
that O 
had O 
been O 
incubated O 
with O 
4'G-RSV B-SYSTEMATIC 
, O 
indicating O 
that O 
4'G-RSV B-SYSTEMATIC 
was O 
extracellularly O 
deglycosylated O 
to O 
RSV B-ABBREVIATION 
, O 
which O 
was O 
then O 
taken O 
up O 
by O 
the O 
cells O 
. O 
C2C12 O 
cells O 
did O 
not O 
deglycosylate O 
3G-RSV B-SYSTEMATIC 
. O 
Our O 
results O 
point O 
to O 
4'G-RSV B-SYSTEMATIC 
as O 
a O 
useful O 
RSV B-ABBREVIATION 
prodrug O 
with O 
high O 
water O 
solubility O 
. O 
These O 
data O 
also O 
show O 
that O 
the O 
in O 
vitro O 
antioxidative O 
activity O 
of O 
these O 
molecules O 
did O 
not O 
correlate O 
with O 
their O 
ability O 
to O 
protect O 
cells O 
from O 
oxidative O 
stress O 
- O 
induced O 
apoptosis O 
. O 

and O 
disposition O 
of O 
vilanterol B-TRIVIAL 
, O 
a O 
long O 
- O 
acting O 
β(2)-adrenoceptor O 
agonist O 
for O 
inhalation O 
use O 
in O 
humans O 
. O 

metabolism O 
and O 
disposition O 
of O 
vilanterol B-TRIVIAL 
, O 
a O 
novel O 
long O 
- O 
acting O 
β(2)-adrenoceptor O 
agonist O 
( O 
LABA O 
) O 
for O 
inhalation O 
use O 
, O 
was O 
investigated O 
after O 
oral O 
administration O 
in O 
humans O 
. O 
Single O 
oral O 
administrations O 
of O 
up O 
to O 
500 O 
μg O 
of O 
vilanterol B-TRIVIAL 
were O 
shown O 
to O 
be O 
safe O 
and O 
well O 
tolerated O 
in O 
two O 
clinical O 
studies O 
in O 
healthy O 
men O 
. O 
In O 
a O 
human O 
radiolabel O 
study O 
, O 
six O 
healthy O 
men O 
received O 
a O 
single O 
oral O 
dose O 
of O 
200 O 
μg O 
of O 
[(14)C]vilanterol B-SYSTEMATIC 
( O 
74 O 
kBq O 
) O 
. O 
Plasma O 
, O 
urine O 
, O 
and O 
feces O 
were O 
collected O 
up O 
to O 
168 O 
hours O 
after O 
the O 
dose O 
and O 
were O 
analyzed O 
for O 
vilanterol B-TRIVIAL 
, O 
metabolites O 
, O 
and O 
radioactivity O 
. O 
At O 
least O 
50% O 
of O 
the O 
radioactive O 
dose O 
was O 
orally O 
absorbed O 
. O 
The O 
primary O 
route O 
of O 
excretion O 
of O 
drug O 
- O 
related O 
material O 
was O 
via O 
O B-FORMULA 
-dealkylation O 
to O 
metabolites O 
, O 
which O 
were O 
mainly O 
excreted O 
in O 
urine O 
. O 
Vilanterol B-TRIVIAL 
represented O 
a O 
very O 
small O 
percentage O 
( O 
< O 
0.5% O 
) O 
of O 
the O 
total O 
drug O 
- O 
related O 
material O 
in O 
plasma O 
, O 
indicative O 
of O 
extensive O 
first O 
- O 
pass O 
metabolism O 
. O 
Circulating O 
metabolites O 
resulted O 
mainly O 
from O 
O B-FORMULA 
-dealkylation O 
and O 
exhibited O 
negligible O 
pharmacologic O 
activity O 
. O 
The O 
therapeutic O 
dose O 
level O 
for O 
vilanterol B-TRIVIAL 
is O 
25 O 
μg O 
by O 
the O 
inhalation O 
route O 
. O 
At O 
this O 
low O 
- O 
dose O 
level O 
, O 
the O 
likelihood O 
of O 
pharmacologically O 
inactive O 
metabolites O 
causing O 
unexpected O 
toxicity O 
is O 
negligible O 
. O 
In O 
addition O 
to O 
providing O 
an O 
assessment O 
of O 
the O 
disposition O 
of O 
vilanterol B-TRIVIAL 
in O 
human O 
, O 
this O 
work O 
highlights O 
a O 
number O 
of O 
complexities O 
associated O 
with O 
determining O 
human O 
absorption O 
, O 
distribution O 
, O 
metabolism O 
, O 
and O 
excretion O 
( O 
ADME O 
) O 
for O 
inhaled O 
molecules O 
-- O 
mainly O 
related O 
to O 
the O 
low O 
chemical O 
doses O 
and O 
complications O 
associated O 
with O 
the O 
inhalation O 
route O 
of O 
administration O 
. O 

between O 
photoallergenic O 
and O 
phototoxic O 
reactions O 
induced O 
by O 
low O 
molecular O 
weight O 
compounds O 
represents O 
a O 
current O 
problem O 
. O 
The O 
use O 
of O 
keratinocytes O 
as O 
a O 
potential O 
tool O 
for O 
the O 
detection O 
of O 
photoallergens O 
as O 
opposed O 
to O 
photoirritants O 
is O 
considered O 
an O 
interesting O 
strategy O 
for O 
developing O 
in O 
vitro O 
methods O 
. O 
We O 
have O 
previously O 
demonstrated O 
the O 
possibility O 
to O 
use O 
the O 
human O 
keratinocyte O 
cell O 
line O 
NCTC2455 O 
and O 
the O 
production O 
of O 
interleukin-18 O 
( O 
IL-18 O 
) O 
to O 
screen O 
low O 
molecular O 
weight O 
sensitizers O 
. O 
The O 
purpose O 
of O 
this O 
work O 
was O 
to O 
explore O 
the O 
possibility O 
to O 
use O 
the O 
NCTC2544 O 
assay O 
to O 
identify O 
photoallergens O 
and O 
discriminate O 
from O 
phototoxic O 
chemicals O 
. O 
First O 
, O 
we O 
identified O 
suitable O 
condition O 
of O 
UV-irradiation O 
( O 
3.5 O 
J O 
/ O 
cm(2) O 
) O 
by O 
investigating O 
the O 
effect O 
of O 
UVA O 
irradiation O 
on O 
intracellular O 
IL-18 O 
on O 
untreated O 
or O 
chloropromazine B-SYSTEMATIC 
( O 
a O 
representative O 
phototoxic O 
compound O 
) O 
- O 
treated O 
NCTC2544 O 
cells O 
. O 
Then O 
, O 
the O 
effect O 
of O 
UVA-irradiation O 
over O 
NCTC2544 O 
cells O 
treated O 
with O 
increasing O 
concentrations O 
of O 
15 O 
compounds O 
including O 
photoallergens O 
( O 
benzophenone B-SYSTEMATIC 
, O 
4-ter-butyl-4-methoxy-dibenzoylmethane B-SYSTEMATIC 
, I-SYSTEMATIC 
2-ethylexyl-p-methoxycinnamate I-SYSTEMATIC 
, O 
ketoprofen B-TRIVIAL 
, O 
6-methylcumarin B-SYSTEMATIC 
) O 
; O 
photoirritant O 
and O 
photoallergen O 
( O 
4-aminobenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
chlorpromazine B-TRIVIAL 
, O 
promethazine B-TRIVIAL 
) O 
; O 
photoirritants O 
( O 
acridine B-TRIVIAL 
, O 
ibuprofen B-TRIVIAL 
, O 
8-methoxypsoralen B-SYSTEMATIC 
, O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
) O 
; O 
and O 
negative O 
compounds O 
( O 
lactic B-TRIVIAL 
acid I-TRIVIAL 
, O 
SDS B-ABBREVIATION 
and O 
p-phenilendiamine B-SYSTEMATIC 
) O 
was O 
investigated O 
. O 
Twenty O 
- O 
four O 
hours O 
after O 
exposure O 
, O 
cytotoxicity O 
was O 
evaluated O 
by O 
the O 
MTT B-ABBREVIATION 
assay O 
or O 
LDH O 
leakage O 
, O 
while O 
ELISA O 
was O 
used O 
to O 
measure O 
the O 
production O 
of O 
IL-18 O 
. O 
At O 
the O 
maximal O 
concentration O 
assayed O 
with O 
non-cytotoxic O 
effects O 
( O 
CV80 O 
under O 
irradiated O 
condition O 
) O 
, O 
all O 
tested O 
photoallergens O 
induced O 
a O 
significant O 
and O 
a O 
dose O 
- O 
dependent O 
increase O 
of O 
intracellular O 
IL-18 O 
following O 
UVA O 
irratiation O 
, O 
whereas O 
photoirritants O 
failed O 
. O 
We O 
suggest O 
that O 
this O 
system O 
may O 
be O 
useful O 
for O 
the O 
in O 
vitro O 
evaluation O 
of O 
the O 
photoallergic O 
potential O 
of O 
chemicals O 
. O 

effects O 
of O 
PTH O 
1-34 O 
, O 
PTH O 
1-84 O 
, O 
and O 
zoledronic B-TRIVIAL 
acid I-TRIVIAL 
on O 
bone O 
microarchitecture O 
and O 
estimated O 
strength O 
in O 
postmenopausal O 
women O 
with O 
osteoporosis O 
: O 
an O 
18-month O 
open O 
- O 
labeled O 
observational O 
study O 
using O 
HR-pQCT O 
. O 

the O 
beneficial O 
effects O 
of O 
intermittent O 
treatment O 
with O 
parathyroid O 
hormone O 
( O 
PTH O 
) O 
( O 
intact O 
PTH O 
1-84 O 
or O 
fragment O 
PTH O 
1-34 O 
, O 
teriparatide O 
) O 
on O 
vertebral O 
strength O 
is O 
well O 
documented O 
, O 
treatment O 
may O 
not O 
be O 
equally O 
effective O 
in O 
the O 
peripheral O 
skeleton O 
. O 
We O 
used O 
high O 
- O 
resolution O 
peripheral O 
quantitative O 
computed O 
tomography O 
( O 
HR-pQCT O 
) O 
to O 
detail O 
effects O 
on O 
compartmental O 
geometry O 
, O 
density O 
, O 
and O 
microarchitecture O 
as O 
well O 
as O 
finite O 
element O 
( O 
FE O 
) O 
estimated O 
integral O 
strength O 
at O 
the O 
distal O 
radius O 
and O 
tibia O 
in O 
postmenopausal O 
osteoporotic O 
women O 
treated O 
with O 
PTH O 
1-34 O 
(20 O 
µg O 
sc O 
daily O 
, O 
n O 
= O 
18 O 
) O 
or O 
PTH O 
1-84 O 
(100 O 
µg O 
sc O 
daily O 
, O 
n O 
= O 
20 O 
) O 
for O 
18 O 
months O 
in O 
an O 
open O 
- O 
label O 
, O 
nonrandomized O 
study O 
. O 
A O 
group O 
of O 
postmenopausal O 
osteoporotic O 
women O 
receiving O 
zoledronic B-TRIVIAL 
acid I-TRIVIAL 
( O 
5 O 
mg O 
infusion O 
once O 
yearly O 
, O 
n O 
= O 
33 O 
) O 
was O 
also O 
included O 
. O 
Anabolic O 
therapy O 
increased O 
cortical O 
porosity O 
in O 
radius O 
( O 
PTH O 
1-34 O 
32 O 
± O 
37% O 
, O 
PTH O 
1-84 O 
39 O 
± O 
32% O 
, O 
both O 
p O 
< O 
0.001 O 
) O 
and O 
tibia O 
( O 
PTH O 
1-34 O 
13 O 
± O 
27% O 
, O 
PTH O 
1-84 O 
15 O 
± O 
22% O 
, O 
both O 
p O 
< O 
0.001 O 
) O 
with O 
corresponding O 
declines O 
in O 
cortical O 
density O 
. O 
With O 
PTH O 
1-34 O 
, O 
increases O 
in O 
cortical O 
thickness O 
in O 
radius O 
( O 
2 O 
± O 
3.8% O 
, O 
p O 
< O 
0.05 O 
) O 
and O 
tibia O 
( O 
3.8 O 
± O 
10.4% O 
, O 
p O 
< O 
0.01 O 
) O 
were O 
found O 
. O 
Trabecular O 
number O 
increased O 
in O 
tibia O 
with O 
both O 
PTH O 
1-34 O 
( O 
4.2 O 
± O 
7.1% O 
, O 
p O 
< O 
0.05 O 
) O 
and O 
PTH O 
1-84 O 
( O 
5.3 O 
± O 
8.3% O 
, O 
p O 
< O 
0.01 O 
) O 
. O 
Zoledronic B-TRIVIAL 
acid I-TRIVIAL 
did O 
not O 
impact O 
cortical O 
porosity O 
at O 
either O 
site O 
but O 
increased O 
cortical O 
thickness O 
( O 
3 O 
± O 
3.5% O 
, O 
p O 
< O 
0.01 O 
) O 
, O 
total O 
( O 
2.7 O 
± O 
2.5% O 
, O 
p O 
< O 
0.001 O 
) O 
and O 
cortical O 
density O 
( O 
1.5 O 
± O 
2.0% O 
, O 
p O 
< O 
0.01 O 
) O 
in O 
tibia O 
as O 
well O 
as O 
trabecular O 
volume O 
fraction O 
in O 
radius O 
( O 
2.5 O 
± O 
5.1% O 
, O 
p O 
< O 
0.05 O 
) O 
and O 
tibia O 
( O 
2.2 O 
± O 
2.2% O 
, O 
p O 
< O 
0.01 O 
) O 
. O 
FE O 
estimated O 
bone O 
strength O 
was O 
preserved O 
, O 
but O 
not O 
increased O 
, O 
with O 
PTH O 
1-34 O 
and O 
zoledronic B-TRIVIAL 
acid I-TRIVIAL 
at O 
both O 
sites O 
, O 
whereas O 
it O 
decreased O 
with O 
PTH O 
1-84 O 
in O 
radius O 
( O 
-2.8 O 
± O 
5.8% O 
, O 
p O 
< O 
0.05 O 
) O 
and O 
tibia O 
( O 
-3.9 O 
± O 
4.8% O 
, O 
p O 
< O 
0.001 O 
) O 
. O 
Conclusively O 
, O 
divergent O 
treatment-specific O 
effects O 
in O 
cortical O 
and O 
trabecular O 
bone O 
were O 
observed O 
with O 
anabolic O 
and O 
zoledronic B-TRIVIAL 
acid I-TRIVIAL 
therapy O 
. O 
The O 
finding O 
of O 
decreased O 
estimated O 
strength O 
with O 
PTH O 
1-84 O 
treatment O 
was O 
surprising O 
and O 
warrants O 
confirmation O 
. O 

is O 
a O 
type O 
II O 
transmembrane O 
protein O 
that O 
can O 
act O 
as O 
a O 
receptor O 
for O 
macrophage O 
migration O 
inhibitory O 
factor O 
( O 
MIF O 
) O 
and O 
plays O 
a O 
role O 
in O 
MIF-regulated O 
responses O 
. O 
We O 
reported O 
that O 
MIF O 
inhibited O 
osteoclast O 
formation O 
and O 
MIF O 
knockout O 
( O 
KO O 
) O 
mice O 
had O 
decreased O 
bone O 
mass O 
. O 
We O 
therefore O 
examined O 
if O 
CD74 O 
was O 
involved O 
in O 
the O 
ability O 
of O 
MIF O 
to O 
alter O 
osteoclastogenesis O 
in O 
cultured O 
bone O 
marrow O 
( O 
BM O 
) O 
from O 
wild O 
- O 
type O 
( O 
WT O 
) O 
and O 
CD74-deficient O 
( O 
KO O 
) O 
male O 
mice O 
. O 
We O 
also O 
measured O 
the O 
bone O 
phenotype O 
of O 
CD74 O 
KO O 
male O 
mice O 
. O 
Bone O 
mass O 
in O 
the O 
femur O 
of O 
8-week- O 
old O 
mice O 
was O 
measured O 
by O 
micro O 
- O 
computed O 
tomography O 
and O 
histomorphometry O 
. O 
Bone O 
marrow O 
cells O 
from O 
CD74 O 
KO O 
mice O 
formed O 
15% O 
more O 
osteoclast O 
- O 
like O 
cells O 
( O 
OCLs O 
) O 
with O 
macrophage O 
colony O 
- O 
stimulating O 
factor O 
( O 
M-CSF O 
) O 
and O 
receptor O 
activator O 
of O 
NF-κB O 
ligand O 
( O 
RANKL O 
) O 
( O 
both O 
at O 
30 O 
ng O 
/ O 
mL O 
) O 
compared O 
to O 
WT O 
. O 
Addition O 
of O 
MIF O 
to O 
WT O 
cultures O 
inhibited O 
OCL O 
formation O 
by O 
16% O 
but O 
had O 
no O 
effect O 
on O 
CD74KO O 
cultures O 
. O 
The O 
number O 
of O 
colony O 
forming O 
unit O 
granulocyte O 
- O 
macrophage O 
( O 
CFU-GM O 
) O 
in O 
the O 
bone O 
marrow O 
of O 
CD74 O 
KO O 
mice O 
was O 
26% O 
greater O 
than O 
in O 
WT O 
controls O 
. O 
Trabecular O 
bone O 
volume O 
( O 
TBV O 
) O 
in O 
the O 
femurs O 
of O 
CD74 O 
KO O 
male O 
mice O 
was O 
decreased O 
by O 
26% O 
compared O 
to O 
WT O 
. O 
In O 
addition O 
, O 
cortical O 
area O 
and O 
thickness O 
were O 
decreased O 
by O 
14% O 
and O 
11% O 
, O 
respectively O 
. O 
Histomorphometric O 
analysis O 
demonstrated O 
that O 
tartrate B-TRIVIAL 
-resistant O 
acid O 
phosphatase O 
(TRAP)(+) O 
osteoclast O 
number O 
and O 
area O 
were O 
significantly O 
increased O 
in O 
CD74 O 
KO O 
by O 
35% O 
and O 
43% O 
, O 
respectively O 
compared O 
to O 
WT O 
. O 
Finally O 
, O 
we O 
examined O 
the O 
effect O 
of O 
MIF O 
on O 
RANKL-induced O 
- O 
signaling O 
pathways O 
in O 
bone O 
marrow O 
macrophage O 
( O 
BMM O 
) O 
cultures O 
. O 
MIF O 
treatment O 
decreased O 
RANKL-induced O 
nuclear O 
factor O 
of O 
activated O 
T O 
cells O 
, O 
cytoplasmic O 
1 O 
( O 
NFATc1 O 
) O 
and O 
c-Fos O 
protein O 
in O 
BMM O 
cultures O 
by O 
70% O 
and O 
41% O 
, O 
respectively O 
. O 
Our O 
data O 
demonstrate O 
that O 
CD74 O 
is O 
required O 
for O 
MIF O 
to O 
affect O 
in O 
vitro O 
osteoclastogenesis O 
. O 
Further O 
, O 
the O 
bone O 
phenotype O 
of O 
CD74 O 
KO O 
mice O 
is O 
similar O 
to O 
that O 
of O 
MIF O 
KO O 
mice O 
. O 
MIF O 
treatment O 
of O 
WT O 
cultures O 
suppressed O 
RANKL-induced O 
activator O 
protein O 
1 O 
( O 
AP-1 O 
) O 
expression O 
, O 
which O 
resulted O 
in O 
decreased O 
osteoclast O 
differentiation O 
in O 
vitro O 
. O 
We O 
propose O 
that O 
CD74 O 
plays O 
a O 
critical O 
role O 
in O 
the O 
MIF O 
inhibition O 
of O 
osteoclastogenesis O 
. O 

(IL)-6 O 
is O 
critical O 
for O 
the O 
febrile O 
response O 
to O 
peripheral O 
immune O 
challenge O 
. O 
However O 
, O 
the O 
mechanism O 
by O 
which O 
IL-6 O 
enables O 
fever O 
is O 
still O 
unknown O 
. O 
To O 
characterise O 
the O 
IL-6-dependent O 
fever O 
generating O 
pathway O 
, O 
we O 
used O 
microarray O 
analysis O 
to O 
identify O 
differentially O 
expressed O 
genes O 
in O 
the O 
brain O 
of O 
lipopolysaccharide O 
( O 
LPS O 
) O 
- O 
treated O 
IL-6 O 
wild O 
- O 
type O 
and O 
knockout O 
mice O 
. O 
Mice O 
lacking O 
IL-6 O 
displayed O 
a O 
two O 
- O 
fold O 
lower O 
expression O 
of O 
the O 
lipocalin-2 O 
gene O 
( O 
lcn2 O 
) O 
, O 
and O 
this O 
difference O 
was O 
confirmed O 
by O 
real O 
- O 
time O 
reverse O 
transcriptase O 
- O 
polymerase O 
chain O 
reaction O 
. O 
Conversely O 
, O 
the O 
induction O 
of O 
lipocalin-2 O 
protein O 
was O 
observed O 
in O 
brain O 
vascular O 
cells O 
following O 
i.p O 
. O 
administration O 
of O 
recombinant O 
IL-6 O 
, O 
suggesting O 
a O 
direct O 
relationship O 
between O 
IL-6 O 
and O 
lipocalin-2 O 
. O 
Immunohistochemical O 
analysis O 
also O 
revealed O 
that O 
LPS-induced O 
lipocalin-2 O 
is O 
expressed O 
by O 
brain O 
endothelial O 
cells O 
and O 
is O 
partly O 
co O 
- O 
localised O 
with O 
cyclooxygenase-2 O 
( O 
Cox-2 O 
) O 
, O 
the O 
rate O 
- O 
limiting O 
enzyme O 
for O 
the O 
production O 
of O 
inflammatory O 
induced O 
prostaglandin B-TRIVIAL 
E(2) I-TRIVIAL 
( O 
PGE(2) B-ABBREVIATION 
) O 
, O 
which O 
is O 
the O 
key O 
mediator O 
of O 
fever O 
. O 
The O 
direct O 
role O 
of O 
lipocalin-2 O 
in O 
fever O 
was O 
examined O 
in O 
LPS-challenged O 
lipocalin-2 O 
knockout O 
mice O 
. O 
In O 
both O 
male O 
and O 
female O 
mice O 
, O 
normal O 
fever O 
responses O 
were O 
observed O 
at O 
near O 
- O 
thermoneutral O 
conditions O 
( O 
29-30 O 
°C O 
) O 
but O 
when O 
recorded O 
at O 
normal O 
room O 
temperature O 
( O 
19-20 O 
°C O 
) O 
, O 
the O 
body O 
temperature O 
of O 
lipocalin-2 O 
knockout O 
female O 
mice O 
displayed O 
an O 
attenuated O 
fever O 
response O 
compared O 
to O 
their O 
wild O 
- O 
type O 
littermates O 
. O 
This O 
difference O 
was O 
reflected O 
in O 
significantly O 
attenuated O 
mRNA O 
expression O 
of O 
Cox-2 O 
in O 
the O 
brain O 
of O 
lipocalin-2 O 
knockout O 
female O 
mice O 
, O 
but O 
not O 
of O 
male O 
mice O 
, O 
following O 
challenge O 
with O 
peripheral O 
LPS O 
. O 
Our O 
findings O 
suggest O 
that O 
IL-6 O 
influences O 
the O 
expression O 
of O 
lipocalin-2 O 
, O 
which O 
in O 
turn O 
may O 
be O 
involved O 
in O 
the O 
control O 
of O 
the O 
formation O 
of O 
Cox-2 O 
, O 
and O 
hence O 
central O 
PGE(2) B-ABBREVIATION 
-production O 
. O 
We O 
have O 
thus O 
identified O 
lipocalin-2 O 
as O 
a O 
new O 
factor O 
in O 
the O 
pathway O 
of O 
inflammatory O 
IL-6 O 
signalling O 
. O 
However O 
, O 
the O 
effect O 
of O 
lipocalin-2 O 
on O 
fever O 
is O 
small O 
, O 
being O 
sex O 
- O 
dependent O 
and O 
ambient O 
temperature O 
- O 
specific O 
, O 
and O 
thus O 
lipocalin-2 O 
cannot O 
be O 
considered O 
as O 
a O 
major O 
mediator O 
of O 
the O 
IL-6-dependent O 
fever O 
generating O 
pathway O 
. O 

variation O 
in O 
the O 
metabolism O 
of O 
zoniporide B-TRIVIAL 
by O 
aldehyde B-SYSTEMATIC 
oxidase O 
. O 

. O 
Aldehyde B-SYSTEMATIC 
oxidase O 
( O 
AO O 
) O 
is O 
a O 
cytosolic O 
enzyme O 
that O 
contributes O 
to O 
the O 
Phase O 
I O 
metabolism O 
of O 
xenobiotics O 
in O 
human O 
and O 
preclinical O 
species O 
. O 
2 O 
. O 
Current O 
studies O 
explored O 
in O 
vitro O 
metabolism O 
of O 
zoniporide B-TRIVIAL 
in O 
various O 
animal O 
species O 
and O 
humans O 
using O 
S9 O 
fractions O 
. O 
The O 
animal O 
species O 
included O 
commonly O 
used O 
pharmacology O 
and O 
toxicology O 
models O 
and O 
domestic O 
animals O 
such O 
as O 
the O 
cat O 
, O 
cow O 
or O 
bull O 
, O 
pig O 
and O 
horse O 
. O 
3 O 
. O 
In O 
addition O 
, O 
gender O 
and O 
strain O 
differences O 
in O 
some O 
species O 
were O 
also O 
explored O 
. O 
4 O 
. O 
All O 
animals O 
except O 
the O 
dog O 
and O 
cat O 
converted O 
zoniporide B-TRIVIAL 
to O 
2-oxozoniporide B-SYSTEMATIC 
( O 
M1 O 
) O 
. O 
5 O 
. O 
Michael-Menten O 
kinetic O 
studies O 
were O 
conducted O 
in O 
species O 
that O 
turned O 
over O 
zoniporide B-TRIVIAL 
to O 
M1 O 
. O 
6 O 
. O 
Marked O 
differences O 
in O 
KM O 
, O 
Vmax O 
and O 
Clint O 
were O 
observed O 
in O 
the O 
oxidation O 
of O 
zoniporide B-TRIVIAL 
. O 
7 O 
. O 
Although O 
the O 
KM O 
and O 
Vmax O 
of O 
zoniporide B-TRIVIAL 
oxidation O 
in O 
male O 
and O 
female O 
human O 
S9 O 
was O 
similar O 
, O 
some O 
gender O 
difference O 
was O 
observed O 
in O 
animals O 
especially O 
, O 
in O 
Vmax O 
. O 
8 O 
. O 
The O 
domestic O 
animals O 
also O 
showed O 
marked O 
species O 
differences O 
in O 
the O 
AO O 
activity O 
and O 
affinity O 
toward O 
zoniporide B-TRIVIAL 
. O 

outcome O 
pathways O 
during O 
zebrafish O 
embryogenesis O 
: O 
a O 
case O 
study O 
with O 
paraoxon B-TRIVIAL 
. O 

paraoxon B-TRIVIAL 
as O 
a O 
reference O 
acetylcholinesterase O 
( O 
AChE O 
) O 
inhibitor O 
, O 
the O 
objective O 
of O 
this O 
study O 
was O 
to O 
develop O 
an O 
adverse O 
outcome O 
pathway O 
( O 
AOP O 
) O 
that O 
provided O 
quantitative O 
linkages O 
across O 
levels O 
of O 
biological O 
organization O 
during O 
zebrafish O 
embryogenesis O 
. O 
Within O 
normal O 
zebrafish O 
embryos O 
, O 
we O 
first O 
demonstrated O 
that O 
ache O 
transcripts O 
and O 
AChE O 
activity O 
increased O 
in O 
a O 
stage O 
- O 
dependent O 
manner O 
following O 
segmentation O 
. O 
We O 
then O 
showed O 
that O 
static O 
exposure O 
of O 
embryos O 
to O 
paraoxon B-TRIVIAL 
( O 
31.2-500 O 
nM O 
) O 
from O 
5 O 
to O 
96 O 
hpf O 
resulted O 
in O 
significant O 
stage- O 
and O 
concentration O 
- O 
dependent O 
AChE O 
inhibition O 
, O 
albeit O 
these O 
effects O 
were O 
fully O 
reversible O 
within O 
48 O 
h O 
following O 
transfer O 
to O 
clean O 
water O 
. O 
However O 
, O 
even O 
in O 
the O 
presence O 
of O 
significant O 
AChE O 
inhibition O 
, O 
exposure O 
to O 
non-teratogenic O 
paraoxon B-TRIVIAL 
concentrations O 
( O 
≤ O 
250 O 
nM O 
) O 
did O 
not O 
adversely O 
impact O 
secondary O 
motoneuron O 
development O 
at O 
96 O 
hpf O 
. O 
Therefore O 
, O 
we O 
investigated O 
the O 
potential O 
effects O 
of O 
paraoxon B-TRIVIAL 
exposure O 
on O 
spontaneous O 
tail O 
contractions O 
at O 
26 O 
hpf O 
- O 
an O 
early O 
locomotor O 
behavior O 
that O 
results O 
from O 
innervation O 
of O 
primary O 
( O 
not O 
secondary O 
) O 
motoneuron O 
axons O 
to O 
target O 
axial O 
muscles O 
. O 
Based O 
on O 
these O 
studies O 
, O 
the O 
frequency O 
of O 
spontaneous O 
tail O 
contractions O 
at O 
26 O 
hpf O 
- O 
a O 
developmental O 
stage O 
with O 
minimal O 
AChE O 
expression O 
and O 
activity O 
- O 
was O 
significantly O 
higher O 
following O 
exposure O 
to O 
paraoxon B-TRIVIAL 
concentrations O 
as O 
low O 
as O 
31.2 O 
nM O 
. O 
Overall O 
, O 
our O 
data O 
suggest O 
that O 
( O 
1 O 
) O 
normal O 
AChE O 
activity O 
is O 
not O 
required O 
for O 
secondary O 
motoneuron O 
development O 
and O 
( O 
2 O 
) O 
spontaneous O 
tail O 
contractions O 
at O 
26 O 
hpf O 
are O 
sensitive O 
to O 
paraoxon B-TRIVIAL 
exposure O 
, O 
an O 
effect O 
that O 
may O 
be O 
independent O 
of O 
AChE O 
inhibition O 
. O 
Using O 
a O 
well O 
- O 
studied O 
reference O 
chemical O 
, O 
this O 
study O 
highlights O 
the O 
potential O 
challenges O 
in O 
developing O 
quantitative O 
AOPs O 
to O 
support O 
chemical O 
screening O 
and O 
prioritization O 
strategies O 
. O 

rutile O 
TiO2 B-FORMULA 
flower O 
cluster O 
- O 
based O 
high O 
efficiency O 
dye O 
- O 
sensitized O 
solar O 
cells O 
via O 
direct O 
hydrothermal O 
growth O 
on O 
conducting O 
substrates O 
. O 

- O 
sensitized O 
solar O 
cells O 
( O 
DSSCs O 
) O 
based O 
on O 
hierarchical O 
rutile O 
TiO(2) B-FORMULA 
flower O 
clusters O 
prepared O 
by O 
a O 
facile O 
, O 
one O 
- O 
pot O 
hydrothermal O 
process O 
exhibit O 
a O 
high O 
efficiency O 
. O 
Complex O 
yet O 
appealing O 
rutile O 
TiO(2) B-FORMULA 
flower O 
films O 
are O 
, O 
for O 
the O 
first O 
time O 
, O 
directly O 
hydrothermally O 
grown O 
on O 
a O 
transparent O 
conducting O 
fluorine B-SYSTEMATIC 
- I-SYSTEMATIC 
doped I-SYSTEMATIC 
tin I-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
FTO B-ABBREVIATION 
) O 
substrate O 
. O 
The O 
thickness O 
and O 
density O 
of O 
as-grown O 
flower O 
clusters O 
can O 
be O 
readily O 
tuned O 
by O 
tailoring O 
growth O 
parameters O 
, O 
such O 
as O 
growth O 
time O 
, O 
the O 
addition O 
of O 
cations O 
of O 
different O 
valence O 
and O 
size O 
, O 
initial O 
concentrations O 
of O 
precursor O 
and O 
cation O 
, O 
growth O 
temperature O 
, O 
and O 
acidity O 
. O 
Notably O 
, O 
the O 
small O 
lattice O 
mismatch O 
between O 
the O 
FTO B-ABBREVIATION 
substrate O 
and O 
rutile O 
TiO(2) B-FORMULA 
renders O 
the O 
epitaxial O 
growth O 
of O 
a O 
compact O 
rutile O 
TiO(2) B-FORMULA 
layer O 
on O 
the O 
FTO B-ABBREVIATION 
glass O 
. O 
Intriguingly O 
, O 
these O 
TiO(2) B-FORMULA 
flower O 
clusters O 
can O 
then O 
be O 
exploited O 
as O 
photoanodes O 
to O 
produce O 
DSSCs O 
, O 
yielding O 
a O 
power O 
conversion O 
efficiency O 
of O 
2.94% O 
despite O 
their O 
rutile O 
nature O 
, O 
which O 
is O 
further O 
increased O 
to O 
4.07% O 
upon O 
the O 
TiCl(4) B-FORMULA 
treatment O 
. O 

very O 
- O 
low O 
- O 
density O 
lipoprotein O 
from O 
subjects O 
with O 
impaired O 
glucose B-TRIVIAL 
tolerance O 
accelerates O 
adrenocortical O 
cortisol B-TRIVIAL 
and O 
aldosterone B-TRIVIAL 
synthesis O 
. O 

from O 
their O 
role O 
in O 
cardiovascular O 
homeostasis O 
and O 
immunomodulation O 
, O 
aldosterone B-TRIVIAL 
and O 
cortisol B-TRIVIAL 
are O 
also O 
implicated O 
in O 
the O 
pathogenesis O 
of O 
insulin O 
resistance O 
and O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
. O 
Furthermore O 
, O 
glycoxidative O 
modifications O 
of O 
lipoproteins O 
are O 
increasingly O 
recognized O 
as O 
an O 
etiological O 
factor O 
for O 
increased O 
cardiovascular O 
morbidity O 
and O 
mortality O 
in O 
prediabetic O 
individuals O 
. O 
The O 
causative O 
relationship O 
between O 
in O 
vivo O 
lipoprotein O 
modifications O 
and O 
steroidogenesis O 
in O 
subjects O 
with O 
impaired O 
glucose B-TRIVIAL 
tolerance O 
( O 
IGT O 
) O 
, O 
however O 
, O 
is O 
not O 
well O 
defined O 
. O 
Therefore O 
, O 
we O 
aimed O 
to O 
investigate O 
the O 
impact O 
of O 
in O 
vivo O 
modified O 
lipoproteins O 
on O 
aldosterone B-TRIVIAL 
and O 
cortisol B-TRIVIAL 
release O 
from O 
human O 
adrenocortical O 
H295R O 
cells O 
. O 
Following O 
an O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
, O 
20 O 
individuals O 
with O 
normal O 
glucose B-TRIVIAL 
tolerance O 
( O 
NGT O 
) O 
and O 
20 O 
IGT O 
subjects O 
were O 
randomly O 
selected O 
from O 
the O 
ongoing O 
PRAEDIAS O 
prevention O 
study O 
in O 
our O 
department O 
. O 
Cells O 
were O 
incubated O 
for O 
24 O 
h O 
with O 
lipoproteins O 
isolated O 
from O 
NGT O 
and O 
IGT O 
individuals O 
and O 
aldosterone B-TRIVIAL 
and O 
cortisol B-TRIVIAL 
release O 
was O 
measured O 
in O 
the O 
supernatants O 
. O 
VLDL O 
induced O 
a O 
greater O 
stimulating O 
effect O 
on O 
adrenocortical O 
aldosterone B-TRIVIAL 
and O 
cortisol B-TRIVIAL 
release O 
compared O 
to O 
HDL O 
and O 
LDL O 
. O 
Moreover O 
, O 
IGT-VLDL O 
evoked O 
a O 
significantly O 
higher O 
effect O 
( O 
p O 
< O 
0.05 O 
) O 
on O 
hormone O 
release O 
than O 
NGT-VLDL O 
. O 
Incubation O 
of O 
cells O 
with O 
in O 
vitro O 
modified O 
lipoproteins O 
and O 
specific O 
pharmacological O 
inhibitors O 
suggests O 
that O 
VLDL O 
presumably O 
recruits O 
ERK1 O 
/ O 
2 O 
as O 
one O 
of O 
the O 
downstream O 
effectors O 
of O 
Jak-2 O 
. O 
In O 
summary O 
, O 
in O 
vivo O 
modified O 
VLDL O 
are O 
able O 
to O 
promote O 
prediabetic O 
hormonal O 
dysregulation O 
by O 
modulating O 
adrenocortical O 
steroidogenesis O 
via O 
Jak-2-ERK O 
dependent O 
pathway O 
. O 

melanocortin-4 O 
receptor O 
( O 
MC4R O 
) O 
is O 
well O 
recognized O 
as O 
an O 
important O 
mediator O 
of O 
body O 
weight O 
homeostasis O 
. O 
Activation O 
of O 
MC4R O 
causes O 
dramatic O 
weight O 
loss O 
in O 
rodent O 
models O 
, O 
and O 
mutations O 
in O 
human O 
are O 
associated O 
with O 
obesity O 
. O 
This O 
makes O 
MC4R O 
a O 
logical O 
target O 
for O 
pharmacological O 
therapy O 
for O 
the O 
treatment O 
of O 
obesity O 
. O 
However O 
, O 
previous O 
studies O 
in O 
rodents O 
and O 
humans O 
have O 
observed O 
a O 
broad O 
array O 
of O 
side O 
effects O 
caused O 
by O 
acute O 
treatment O 
with O 
MC4R O 
agonists O 
, O 
including O 
increased O 
heart O 
rate O 
and O 
blood O 
pressure O 
. O 
We O 
demonstrate O 
that O 
treatment O 
with O 
a O 
highly O 
- O 
selective O 
novel O 
MC4R O 
agonist O 
( O 
BIM-22493 B-NO_CLASS 
or O 
RM-493 B-NO_CLASS 
) O 
resulted O 
in O 
transient O 
decreases O 
in O 
food O 
intake O 
( O 
35% O 
) O 
, O 
with O 
persistent O 
weight O 
loss O 
over O 
8 O 
weeks O 
of O 
treatment O 
( O 
13.5% O 
) O 
in O 
a O 
diet O 
- O 
induced O 
obese O 
nonhuman O 
primate O 
model O 
. O 
Consistent O 
with O 
weight O 
loss O 
, O 
these O 
animals O 
significantly O 
decreased O 
adiposity O 
and O 
improved O 
glucose B-TRIVIAL 
tolerance O 
. O 
Importantly O 
, O 
we O 
observed O 
no O 
increases O 
in O 
blood O 
pressure O 
or O 
heart O 
rate O 
with O 
BIM-22493 B-NO_CLASS 
treatment O 
. O 
In O 
contrast O 
, O 
treatment O 
with O 
LY2112688 B-NO_CLASS 
, O 
an O 
MC4R O 
agonist O 
previously O 
shown O 
to O 
increase O 
blood O 
pressure O 
and O 
heart O 
rate O 
in O 
humans O 
, O 
caused O 
increases O 
in O 
blood O 
pressure O 
and O 
heart O 
rate O 
, O 
while O 
modestly O 
decreasing O 
food O 
intake O 
. O 
These O 
studies O 
demonstrate O 
that O 
distinct O 
melanocortin O 
peptide O 
drugs O 
can O 
have O 
widely O 
different O 
efficacies O 
and O 
side O 
effects O 
. O 

fatty B-FAMILY 
acid I-FAMILY 
binding O 
protein O 
: O 
a O 
novel O 
adipokine O 
involved O 
in O 
the O 
pathogenesis O 
of O 
metabolic O 
and O 
vascular O 
disease O 
? O 

fatty B-FAMILY 
acid I-FAMILY 
binding O 
protein O 
( O 
AFABP O 
, O 
also O 
known O 
as O 
aP2 O 
and O 
FABP4 O 
) O 
has O 
recently O 
been O 
introduced O 
as O 
a O 
novel O 
fat O 
- O 
derived O 
circulating O 
protein O 
. O 
AFABP O 
serum O 
concentrations O 
are O 
positively O 
correlated O 
with O 
markers O 
of O 
the O 
metabolic O 
syndrome O 
and O 
vascular O 
disease O 
in O 
various O 
cross O 
- O 
sectional O 
and O 
interventional O 
studies O 
. O 
Furthermore O 
, O 
a O 
small O 
set O 
of O 
prospective O 
studies O 
indicates O 
that O 
high O 
AFABP O 
serum O 
levels O 
at O 
baseline O 
predict O 
the O 
risk O 
for O 
metabolic O 
and O 
vascular O 
morbidity O 
and O 
mortality O 
. O 
Studies O 
in O 
Afabp O 
( O 
also O 
known O 
as O 
Fabp4 O 
) O 
knockout O 
mice O 
and O 
AFABP O 
inhibitor O 
- O 
treated O 
animals O 
suggest O 
that O 
total O 
AFABP O 
promotes O 
insulin O 
resistance O 
, O 
hypertriacylglycerolaemia O 
and O 
atherosclerosis O 
by O 
ligand O 
/ O 
ligand O 
delivery O 
, O 
as O 
well O 
as O 
ligand O 
- O 
independent O 
mechanisms O 
. O 
In O 
contrast O 
, O 
the O 
pathophysiological O 
significance O 
of O 
circulating O 
AFABP O 
and O 
the O 
mechanisms O 
leading O 
to O 
its O 
release O 
remain O 
to O 
be O 
established O 
. O 
The O 
current O 
review O 
summarises O 
recent O 
findings O 
on O 
the O 
regulation O 
and O 
potential O 
role O 
of O 
AFABP O 
in O 
metabolic O 
and O 
vascular O 
disease O 
. O 

sulfate I-SYSTEMATIC 
treatment O 
against O 
sarin B-TRIVIAL 
poisoning O 
: O 
dissociation O 
between O 
overt O 
convulsions O 
and O 
recorded O 
cortical O 
seizure O 
activity O 
. O 

, O 
a O 
potent O 
organophosphate B-FAMILY 
cholinesterase O 
inhibitor O 
, O 
induces O 
an O 
array O 
of O 
toxic O 
effects O 
including O 
convulsions O 
. O 
Many O 
antidotal O 
treatments O 
contain O 
anticonvulsants O 
to O 
block O 
seizure O 
activity O 
and O 
the O 
ensuing O 
brain O 
damage O 
. O 
Magnesium B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
MGS B-ABBREVIATION 
) O 
is O 
used O 
to O 
suppress O 
eclamptic O 
seizures O 
in O 
pregnant O 
women O 
with O 
hypertension O 
and O 
was O 
shown O 
to O 
block O 
kainate B-TRIVIAL 
-induced O 
convulsions O 
. O 
Magnesium B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
was O 
evaluated O 
herein O 
as O 
an O 
anticonvulsant O 
against O 
sarin O 
poisoning O 
and O 
its O 
efficacy O 
was O 
compared O 
with O 
the O 
potent O 
anticonvulsants O 
midazolam B-TRIVIAL 
( O 
MDZ B-ABBREVIATION 
) O 
and O 
caramiphen B-TRIVIAL 
( O 
CRM B-ABBREVIATION 
) O 
. O 
Rats O 
were O 
exposed O 
to O 
a O 
convulsant O 
dose O 
of O 
sarin B-TRIVIAL 
( O 
96 O 
μg O 
/ O 
kg O 
, O 
im O 
) O 
and O 
1 O 
min O 
later O 
treated O 
with O 
the O 
oxime B-SYSTEMATIC 
TMB4 B-TRIVIAL 
and O 
atropine B-TRIVIAL 
to O 
increase O 
survival O 
. O 
Five O 
minutes O 
after O 
initiation O 
of O 
convulsions O 
, O 
MGS B-ABBREVIATION 
, O 
CRM B-ABBREVIATION 
, O 
or O 
MDZ B-ABBREVIATION 
were O 
administered O 
. O 
Attenuation O 
of O 
tonic O 
- O 
clonic O 
convulsions O 
was O 
observed O 
following O 
all O 
these O 
treatments O 
. O 
However O 
, O 
radio O 
- O 
telemetric O 
electro O 
- O 
corticography O 
( O 
ECoG O 
) O 
monitoring O 
demonstrated O 
sustained O 
seizure O 
activity O 
in O 
MGS B-ABBREVIATION 
-injected O 
animals O 
while O 
this O 
activity O 
was O 
completely O 
blocked O 
by O 
MDZ B-ABBREVIATION 
and O 
CRM B-ABBREVIATION 
. O 
This O 
disrupted O 
brain O 
activity O 
was O 
associated O 
with O 
marked O 
increase O 
in O 
brain O 
translocator O 
protein O 
levels O 
, O 
a O 
marker O 
for O 
brain O 
damage O 
, O 
measured O 
1 O 
week O 
following O 
exposure O 
. O 
Additionally O 
, O 
histopathological O 
analyses O 
of O 
MGS B-ABBREVIATION 
-treated O 
group O 
showed O 
typical O 
sarin B-TRIVIAL 
-induced O 
brain O 
injury O 
excluding O 
the O 
hippocampus O 
that O 
was O 
partially O 
protected O 
. O 
Our O 
results O 
clearly O 
show O 
that O 
MGS B-ABBREVIATION 
demonstrated O 
misleading O 
features O 
as O 
an O 
anticonvulsant O 
against O 
sarin B-TRIVIAL 
-induced O 
seizures O 
. O 
This O 
stems O 
from O 
the O 
dissociation O 
observed O 
between O 
overt O 
convulsions O 
and O 
seizure O 
activity O 
. O 
Thus O 
, O 
the O 
presence O 
or O 
absence O 
of O 
motor O 
convulsions O 
may O 
be O 
an O 
unreliable O 
indicator O 
in O 
the O 
assessment O 
of O 
clinical O 
status O 
and O 
in O 
directing O 
adequate O 
antidotal O 
treatments O 
following O 
exposure O 
to O 
nerve O 
agents O 
in O 
battle O 
field O 
or O 
terror O 
attacks O 
. O 

oral O 
dose O 
toxicity O 
studies O 
of O 
melamine B-TRIVIAL 
in O 
rats O 
and O 
monkeys O 
. O 

is O 
an O 
important O 
and O 
widely O 
used O 
organic O 
industrial O 
chemical O 
. O 
Recently O 
, O 
clinical O 
findings O 
of O 
renal O 
failure O 
and O 
kidney O 
stones O 
in O 
infants O 
have O 
been O 
associated O 
with O 
ingestion O 
of O 
melamine B-TRIVIAL 
-contaminated O 
infant O 
formula O 
. O 
To O 
understand O 
the O 
toxicity O 
and O 
clinical O 
outcome O 
of O 
melamine B-TRIVIAL 
exposure O 
, O 
repeated O 
oral O 
dose O 
studies O 
in O 
rats O 
and O 
monkeys O 
were O 
performed O 
to O 
characterize O 
the O 
subchronic O 
toxicity O 
of O 
melamine B-TRIVIAL 
. O 
Assessment O 
of O 
toxicity O 
was O 
based O 
on O 
mortality O 
, O 
clinical O 
signs O 
, O 
body O 
weights O 
, O 
ophthalmic O 
findings O 
, O 
clinical O 
pathology O 
, O 
gross O 
pathology O 
, O 
organ O 
weights O 
, O 
and O 
microscopic O 
observations O 
. O 
The O 
first O 
rat O 
study O 
was O 
intended O 
to O 
be O 
a O 
14-day O 
oral O 
study O 
followed O 
by O 
an O 
8-day O 
recovery O 
period O 
. O 
The O 
dose O 
levels O 
were O 
140 O 
, O 
700 O 
, O 
and O 
1400 O 
mg O 
/ O 
kg O 
/ O 
day O 
( O 
lowered O 
to O 
1000 O 
mg O 
/ O 
kg O 
/ O 
day O 
subsequently O 
due O 
to O 
mortality O 
) O 
. O 
Oral O 
administration O 
of O 
melamine B-TRIVIAL 
at O 
700 O 
mg O 
/ O 
kg O 
/ O 
day O 
for O 
14 O 
consecutive O 
days O 
in O 
rats O 
produced O 
compound O 
- O 
related O 
clinical O 
signs O 
( O 
red O 
urine O 
) O 
, O 
decreased O 
body O 
weights O 
, O 
and O 
changes O 
in O 
clinical O 
pathology O 
( O 
increased O 
serum O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
and O 
creatinine B-TRIVIAL 
) O 
and O 
anatomical O 
pathology O 
( O 
renal O 
tubular O 
cell O 
debris O 
, O 
crystal O 
deposition O 
, O 
and O 
hyperactive O 
regeneration O 
of O 
renal O 
tubular O 
epithelium O 
) O 
. O 
The O 
kidney O 
was O 
identified O 
as O 
the O 
target O 
organ O 
. O 
Oral O 
administration O 
at O 
1400 O 
mg O 
/ O 
kg O 
/ O 
day O 
( O 
subsequently O 
lowered O 
to O 
1000 O 
mg O 
/ O 
kg O 
/ O 
day O 
) O 
resulted O 
in O 
animal O 
death O 
and O 
moribundity O 
. O 
There O 
were O 
no O 
treatment O 
- O 
related O 
findings O 
in O 
the O 
140 O 
mg O 
/ O 
kg O 
/ O 
day O 
group O 
. O 
There O 
were O 
no O 
compound O 
- O 
related O 
findings O 
in O 
the O 
high O 
- O 
dose O 
recovery O 
animals O 
. O 
The O 
second O 
rat O 
study O 
was O 
a O 
5-day O 
oral O 
toxicity O 
study O 
with O 
genomic O 
biomarkers O 
assayed O 
in O 
the O 
kidney O 
tissues O 
. O 
At O 
the O 
top O 
dose O 
of O 
1050 O 
mg O 
/ O 
kg O 
/ O 
day O 
, O 
similar O 
clinical O 
and O 
anatomical O 
pathology O 
findings O 
as O 
described O 
above O 
were O 
observed O 
. O 
The O 
genes O 
measured O 
, O 
Kim-1 O 
, O 
Clu O 
, O 
Spp1 O 
, O 
A2m O 
, O 
Lcn2 O 
, O 
Tcfrsf12a O 
, O 
Gpnmb O 
, O 
and O 
CD44 O 
, O 
were O 
significantly O 
up O 
- O 
regulated O 
( O 
fivefold O 
to O 
550-fold O 
) O 
, O 
while O 
Tff3 O 
was O 
significantly O 
down O 
- O 
regulated O 
( O 
fivefold O 
) O 
. O 
These O 
results O 
indicated O 
that O 
genomic O 
markers O 
could O 
sensitively O 
diagnose O 
melamine B-TRIVIAL 
-induced O 
kidney O 
injury O 
. O 
A O 
3-month O 
oral O 
study O 
with O 
4-week O 
recovery O 
in O 
monkeys O 
was O 
also O 
conducted O 
. O 
In O 
this O 
monkey O 
study O 
, O 
the O 
animals O 
were O 
treated O 
with O 
melamine B-TRIVIAL 
at O 
doses O 
of O 
60 O 
, O 
200 O 
, O 
or O 
700 O 
mg O 
/ O 
kg O 
/ O 
day O 
. O 
The O 
administration O 
of O 
700 O 
mg O 
/ O 
kg O 
/ O 
day O 
melamine B-TRIVIAL 
by O 
nasal O 
- O 
gastric O 
gavage O 
to O 
monkeys O 
resulted O 
in O 
test O 
article O 
- O 
related O 
clinical O 
signs O 
including O 
turbid O 
and O 
whitish O 
urine O 
, O 
urine O 
crystals O 
, O 
red O 
blood O 
cell O 
changes O 
, O 
increased O 
serum O 
alanine B-TRIVIAL 
aminotransferase O 
and O 
kidney O 
and O 
/ O 
or O 
liver O 
weights O 
, O 
and O 
microscopic O 
findings O 
including O 
nephrotoxicity O 
, O 
pericarditis O 
, O 
and O 
increased O 
hematopoiesis O 
. O 
Nephrotoxicity O 
was O 
also O 
noted O 
at O 
200 O 
mg O 
/ O 
kg O 
/ O 
day O 
. O 
It O 
was O 
concluded O 
that O 
the O 
kidney O 
is O 
the O 
primary O 
target O 
organ O 
and O 
the O 
NOAEL O 
was O 
estimated O 
to O 
be O 
140 O 
mg O 
/ O 
kg O 
/ O 
day O 
in O 
rats O 
following O 
a O 
14-day O 
oral O 
administration O 
and O 
60 O 
mg O 
/ O 
kg O 
/ O 
day O 
in O 
the O 
monkey O 
study O 
. O 

and O 
claudin-4 O 
regulate O 
sensitivity O 
to O 
cisplatin B-TRIVIAL 
by O 
controlling O 
expression O 
of O 
the O 
copper B-SYSTEMATIC 
and O 
cisplatin B-TRIVIAL 
influx O 
transporter O 
CTR1 O 
. O 

( O 
CLDN3 O 
) O 
and O 
claudin-4 O 
( O 
CLDN4 O 
) O 
are O 
the O 
major O 
structural O 
molecules O 
that O 
form O 
tight O 
junctions O 
( O 
TJs O 
) O 
between O 
epithelial O 
cells O 
. O 
We O 
found O 
that O 
knockdown O 
of O 
the O 
expression O 
of O 
either O 
CLDN3 O 
or O 
CLDN4 O 
produced O 
marked O 
changes O 
in O 
the O 
phenotype O 
of O 
ovarian O 
cancer O 
cells O 
, O 
including O 
an O 
increase O 
in O 
resistance O 
to O 
cisplatin B-TRIVIAL 
( O 
cDDP O 
) O 
. O 
The O 
effect O 
of O 
CLND3 O 
and O 
CLDN4 O 
on O 
cDDP O 
cytotoxicity O 
, O 
cDDP O 
cellular O 
accumulation O 
, O 
and O 
DNA O 
adduct O 
formation O 
was O 
compared O 
in O 
the O 
CLDN3- O 
and O 
CLDN4-expressing O 
parental O 
human O 
ovarian O 
carcinoma O 
2008 O 
cells O 
and O 
CLDN3 O 
and O 
CLDN4 O 
knockdown O 
sublines O 
( O 
CLDN3KD O 
and O 
CLDN4KD O 
, O 
respectively O 
) O 
. O 
Knockdown O 
of O 
CLDN3 O 
or O 
CLDN4 O 
rendered O 
human O 
ovarian O 
carcinoma O 
2008 O 
cells O 
resistant O 
to O 
cDDP O 
in O 
both O 
in O 
vitro O 
culture O 
and O 
in O 
vivo O 
xenograft O 
model O 
. O 
The O 
net O 
accumulation O 
of O 
platinum B-SYSTEMATIC 
( O 
Pt B-FORMULA 
) O 
and O 
the O 
Pt B-FORMULA 
-DNA O 
adduct O 
levels O 
were O 
reduced O 
in O 
CLDN3KD O 
and O 
CLDN4KD O 
cells O 
. O 
The O 
endogenous O 
mRNA O 
levels O 
of O 
copper B-SYSTEMATIC 
influx O 
transporter O 
CTR1 O 
were O 
found O 
to O 
be O 
significantly O 
reduced O 
in O 
the O 
knockdown O 
cells O 
, O 
and O 
exogenous O 
expression O 
of O 
CTR1 O 
restored O 
their O 
sensitivity O 
to O 
cDDP O 
. O 
Reexpression O 
of O 
an O 
shRNAi-resistant O 
CLDN3 O 
or O 
CLDN4 O 
up O 
- O 
regulated O 
CTR1 O 
levels O 
, O 
reversed O 
the O 
cDDP O 
resistance O 
, O 
and O 
enhanced O 
TJ O 
formation O 
in O 
the O 
knockdown O 
cells O 
. O 
Baseline O 
copper B-SYSTEMATIC 
( O 
Cu B-FORMULA 
) O 
level O 
, O 
Cu B-FORMULA 
uptake O 
, O 
and O 
Cu B-FORMULA 
cytotoxicity O 
were O 
also O 
reduced O 
in O 
CLDN3KD O 
and O 
CLDN4KD O 
cells O 
. O 
Cu B-FORMULA 
-dependent O 
tyrosinase O 
activity O 
was O 
also O 
markedly O 
reduced O 
in O 
both O 
types O 
of O 
CLDN O 
knockdown O 
cells O 
when O 
incubated O 
with O 
the O 
substrate O 
l-DOPA B-ABBREVIATION 
. O 
These O 
results O 
indicate O 
that O 
CLDN3 O 
and O 
CLDN4 O 
affect O 
sensitivity O 
of O 
the O 
ovarian O 
cancer O 
cells O 
to O 
the O 
cytotoxic O 
effect O 
of O 
cDDP O 
by O 
regulating O 
expression O 
of O 
the O 
Cu B-FORMULA 
transporter O 
CTR1 O 
. O 

changes O 
in O 
serotonin B-TRIVIAL 
levels O 
in O 
brain O 
and O 
blood O 
following O 
acute O 
administration O 
of O 
MDMA B-ABBREVIATION 
. O 

studies O 
have O 
demonstrated O 
a O 
similar O 
acute O 
effect O 
of O 
3,4- B-SYSTEMATIC 
methylenedioxymethamphetamine I-SYSTEMATIC 
( O 
MDMA B-ABBREVIATION 
) O 
in O 
blood O 
platelets O 
and O 
brain O 
tissue O 
via O 
action O 
on O 
the O 
serotonin B-TRIVIAL 
transporter O 
. O 
To O 
investigate O 
the O 
validity O 
of O 
blood O 
serotonin B-TRIVIAL 
as O 
a O 
peripheral O 
marker O 
for O 
central O 
serotonin B-TRIVIAL 
in O 
this O 
regard O 
, O 
we O 
administered O 
MDMA B-ABBREVIATION 
( O 
20 O 
mg O 
/ O 
kg O 
i.p O 
. O 
) O 
to O 
rats O 
and O 
observed O 
a O 
parallel O 
decrease O 
in O 
serotonin B-TRIVIAL 
levels O 
in O 
the O 
frontal O 
cortex O 
and O 
blood O 
at O 
2 O 
h O 
( O 
63% O 
and O 
46% O 
respectively O 
) O 
with O 
some O 
recovery O 
evident O 
at O 
8 O 
h O 
( O 
42% O 
and O 
38% O 
) O 
and O 
more O 
so O 
at O 
18 O 
h O 
( O 
19% O 
and O 
24% O 
below O 
control O 
levels O 
) O 
. O 
Administration O 
of O 
a O 
tryptophan B-TRIVIAL 
supplement O 
( O 
82.5 O 
mg O 
/ O 
kg O 
p.o O 
. O 
) O 
to O 
naïve O 
rats O 
produced O 
parallel O 
increases O 
in O 
serotonin B-TRIVIAL 
levels O 
2 O 
h O 
later O 
in O 
the O 
frontal O 
cortex O 
( O 
39% O 
) O 
and O 
blood O 
( O 
26% O 
) O 
. O 
Following O 
MDMA B-ABBREVIATION 
administration O 
, O 
the O 
same O 
dose O 
of O 
tryptophan B-TRIVIAL 
caused O 
a O 
smaller O 
( O 
26% O 
) O 
rise O 
in O 
brain O 
serotonin B-TRIVIAL 
whereas O 
in O 
blood O 
it O 
had O 
no O 
effect O 
. O 
We O 
conclude O 
that O 
blood O 
serotonin B-TRIVIAL 
is O 
a O 
useful O 
marker O 
for O 
brain O 
serotonin B-TRIVIAL 
levels O 
in O 
the O 
rat O 
following O 
acute O 
administration O 
of O 
MDMA B-ABBREVIATION 
and O 
this O 
finding O 
highlights O 
the O 
possible O 
use O 
of O 
platelet O 
serotonin B-TRIVIAL 
as O 
a O 
marker O 
for O 
brain O 
serotonin B-TRIVIAL 
in O 
human O 
studies O 
involving O 
MDMA B-ABBREVIATION 
. O 

the O 
first O 
example O 
of O 
a O 
chemically O 
powered O 
micromotor O 
that O 
harvests O 
its O 
energy O 
from O 
the O 
reactions O 
of O 
three O 
different O 
fuels O 
is O 
presented O 
. O 
The O 
new O 
Al B-FORMULA 
/ O 
Pd B-FORMULA 
Janus O 
microspheres O 
- O 
prepared O 
by O 
depositing O 
a O 
Pd B-FORMULA 
layer O 
on O 
one O 
side O 
of O 
Al B-FORMULA 
microparticles O 
- O 
are O 
propelled O 
efficiently O 
by O 
the O 
thrust O 
of O 
hydrogen B-SYSTEMATIC 
bubbles O 
generated O 
from O 
different O 
reactions O 
of O 
Al B-FORMULA 
in O 
strong O 
acidic O 
and O 
alkaline O 
environments O 
, O 
and O 
by O 
an O 
oxygen B-SYSTEMATIC 
bubble O 
thrust O 
produced O 
at O 
their O 
partial O 
Pd B-FORMULA 
coating O 
in O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
media O 
. O 
High O 
speeds O 
and O 
long O 
lifetimes O 
of O 
200 O 
μm O 
s(-1) O 
and O 
8 O 
min O 
are O 
achieved O 
in O 
strong O 
alkaline O 
media O 
and O 
acidic O 
media O 
, O 
respectively O 
. O 
The O 
ability O 
to O 
autonomously O 
adapt O 
to O 
the O 
presence O 
of O 
a O 
new O 
fuel O 
( O 
surrounding O 
environment O 
) O 
, O 
without O 
compromising O 
the O 
propulsion O 
behavior O 
is O 
illustrated O 
. O 
These O 
data O 
also O 
represent O 
the O 
first O 
example O 
of O 
a O 
chemically O 
powered O 
micromotor O 
that O 
propels O 
autonomously O 
and O 
efficiently O 
in O 
alkaline O 
environments O 
( O 
pH O 
> O 
11 O 
) O 
without O 
additional O 
fuels O 
. O 
The O 
ability O 
to O 
use O 
multiple O 
fuel O 
sources O 
to O 
power O 
the O 
same O 
micromotor O 
offers O 
a O 
broader O 
scope O 
of O 
operation O 
and O 
considerable O 
promise O 
for O 
diverse O 
applications O 
of O 
micromotors O 
in O 
different O 
chemical O 
environments O 
. O 

, O 
a O 
highly O 
selective O 
A1 O 
adenosine B-TRIVIAL 
receptor O 
agonist O 
: O 
evaluation O 
of O 
chronotropic O 
, O 
dromotropic O 
, O 
and O 
hemodynamic O 
effects O 
in O 
rats O 
. O 

pharmacological O 
activation O 
of O 
the O 
adenosine B-TRIVIAL 
1 O 
receptor O 
( O 
A(1)R O 
) O 
is O 
a O 
promising O 
new O 
approach O 
to O 
achieve O 
a O 
potent O 
block O 
of O 
atrioventricular O 
(A-V)-nodal O 
conduction O 
without O 
significant O 
cardiovascular O 
side O 
effects O 
. O 
The O 
purpose O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
the O 
cardiovascular O 
profile O 
of O 
INO-8875 B-IDENTIFIER 
, O 
a O 
highly O 
selective O 
A(1)R O 
agonist O 
, O 
and O 
to O 
compare O 
its O 
properties O 
with O 
N-[3(R)-tetrahydrofuranyl]-6-aminopurine B-SYSTEMATIC 
riboside I-SYSTEMATIC 
( O 
CVT-510 B-IDENTIFIER 
) O 
, O 
which O 
has O 
already O 
been O 
shown O 
to O 
induce O 
negative O 
dromotropic O 
effects O 
with O 
minimal O 
cardiovascular O 
side O 
effects O 
in O 
animals O 
and O 
in O 
clinical O 
studies O 
. O 
Dose O 
- O 
response O 
experiments O 
in O 
the O 
isolated O 
hearts O 
of O 
rats O 
were O 
used O 
to O 
evaluate O 
the O 
functional O 
selectivity O 
of O 
INO-8875 B-IDENTIFIER 
for O 
the O 
slowing O 
of O 
A-V-nodal O 
conduction O 
. O 
Ventilated O 
adult O 
rats O 
were O 
used O 
to O 
study O 
the O 
effects O 
of O 
INO-8875 B-IDENTIFIER 
, O 
in O 
vivo O 
, O 
on O 
arterial O 
blood O 
pressure O 
as O 
well O 
as O 
on O 
supraventricular O 
electrophysiology O 
. O 
Ex O 
vivo O 
, O 
INO-8875 B-IDENTIFIER 
( O 
100 O 
nM O 
to O 
3 O 
μM O 
) O 
progressively O 
prolonged O 
A-V-nodal O 
conduction O 
without O 
reducing O 
left O 
ventricular O 
function O 
or O 
coronary O 
resistance O 
. O 
In O 
vivo O 
, O 
INO-8875 B-IDENTIFIER 
up O 
to O 
a O 
dose O 
of O 
50 O 
μg O 
/ O 
kg O 
did O 
not O 
reduce O 
the O 
carotid O 
arterial O 
blood O 
pressure O 
( O 
n O 
= O 
4 O 
) O 
. O 
INO-8875 B-IDENTIFIER 
( O 
1-50 O 
μg O 
/ O 
kg O 
) O 
and O 
CVT-510 B-IDENTIFIER 
( O 
20 O 
and O 
50 O 
μg O 
/ O 
kg O 
) O 
both O 
induced O 
a O 
dose O 
- O 
dependent O 
decrease O 
in O 
heart O 
rate O 
and O 
atrial O 
refractoriness O 
, O 
as O 
well O 
as O 
slowing O 
of O 
A-V-nodal O 
conduction O 
. O 
However O 
, O 
compared O 
with O 
CVT-510 B-IDENTIFIER 
, O 
the O 
activity O 
of O 
INO-8875 B-IDENTIFIER 
was O 
more O 
pronounced O 
in O 
A-V-nodal O 
function O 
. O 
INO-8875 B-IDENTIFIER 
exhibited O 
a O 
greater O 
duration O 
of O 
action O 
, O 
lasting O 
up O 
to O 
2.5 O 
hours O 
post O 
dosing O 
, O 
whereas O 
the O 
effects O 
of O 
CVT-510 B-IDENTIFIER 
dissipated O 
over O 
1 O 
hour O 
. O 
INO-8875 B-IDENTIFIER 
demonstrates O 
functional O 
properties O 
of O 
a O 
highly O 
selective O 
A(1)R O 
agonist O 
. O 
INO-8875 B-IDENTIFIER 
exhibits O 
an O 
increased O 
dromotropic O 
effect O 
and O 
greater O 
duration O 
of O 
action O 
compared O 
with O 
CVT-510 B-IDENTIFIER 
. O 

mechanisms O 
associated O 
with O 
increased O 
tolerance O 
to O 
the O 
neonicotinoid O 
insecticide O 
imidacloprid B-TRIVIAL 
in O 
the O 
dengue O 
vector O 
Aedes O 
aegypti O 
. O 

are O 
vectors O 
of O 
several O 
major O 
human O 
diseases O 
and O 
their O 
control O 
is O 
mainly O 
based O 
on O 
the O 
use O 
of O 
chemical O 
insecticides O 
. O 
Resistance O 
of O 
mosquitoes O 
to O 
organochlorines B-FAMILY 
, O 
organophosphates B-FAMILY 
, O 
carbamates B-FAMILY 
and O 
pyrethroids B-FAMILY 
led O 
to O 
a O 
regain O 
of O 
interest O 
for O 
the O 
use O 
of O 
neonicotinoid O 
insecticides O 
in O 
vector O 
control O 
. O 
The O 
present O 
study O 
investigated O 
the O 
molecular O 
basis O 
of O 
neonicotinoid O 
resistance O 
in O 
the O 
mosquito O 
Aedes O 
aegypti O 
. O 
A O 
strain O 
susceptible O 
to O 
insecticides O 
was O 
selected O 
at O 
the O 
larval O 
stage O 
with O 
imidacloprid B-TRIVIAL 
. O 
After O 
eight O 
generations O 
of O 
selection O 
, O 
larvae O 
of O 
the O 
selected O 
strain O 
( O 
Imida-R O 
) O 
showed O 
a O 
5.4-fold O 
increased O 
tolerance O 
to O 
imidacloprid B-TRIVIAL 
while O 
adult O 
tolerance O 
level O 
remained O 
low O 
. O 
Imida-R O 
larvae O 
showed O 
significant O 
cross O 
- O 
tolerance O 
to O 
other O 
neonicotinoids O 
but O 
not O 
to O 
pyrethroids B-FAMILY 
, O 
organophosphates B-FAMILY 
and O 
carbamates B-FAMILY 
. O 
Transcriptome O 
profiling O 
identified O 
344 O 
and O 
108 O 
genes O 
differentially O 
transcribed O 
in O 
larvae O 
and O 
adults O 
of O 
the O 
Imida-R O 
strain O 
compared O 
to O 
the O 
parental O 
strain O 
. O 
Most O 
of O 
these O 
genes O 
encode O 
detoxification O 
enzymes O 
, O 
cuticle O 
proteins O 
, O 
hexamerins O 
as O 
well O 
as O 
other O 
proteins O 
involved O 
in O 
cell O 
metabolism O 
. O 
Among O 
detoxification O 
enzymes O 
, O 
cytochrome O 
P450 O 
monooxygenases O 
( O 
CYPs O 
) O 
and O 
glucosyl O 
/ O 
glucuronosyl O 
transferases O 
( O 
UDPGTs O 
) O 
were O 
over O 
- O 
represented O 
. O 
Bioassays O 
with O 
enzyme O 
inhibitors O 
and O 
biochemical O 
assays O 
confirmed O 
the O 
contribution O 
of O 
P450s O 
with O 
an O 
increased O 
capacity O 
of O 
the O 
Imida-R O 
microsomes O 
to O 
metabolize O 
imidacloprid B-TRIVIAL 
in O 
presence O 
of O 
NADPH B-ABBREVIATION 
. O 
Comparison O 
of O 
substrate O 
recognition O 
sites O 
and O 
imidacloprid B-TRIVIAL 
docking O 
models O 
of O 
six O 
CYP6s O 
over O 
- O 
transcribed O 
in O 
the O 
Imida-R O 
strain O 
together O 
with O 
Bemisia O 
tabaci O 
CYP6CM1vQ O 
and O 
Drosophila O 
melanogaster O 
CYP6G1 O 
, O 
both O 
able O 
to O 
metabolize O 
imidacloprid B-TRIVIAL 
, O 
suggested O 
that O 
CYP6BB2 O 
and O 
CYP6N12 O 
are O 
good O 
candidates O 
for O 
imidacloprid B-TRIVIAL 
metabolism O 
in O 
Ae O 
. O 
aegypti O 
. O 
The O 
present O 
study O 
revealed O 
that O 
imidacloprid B-TRIVIAL 
tolerance O 
in O 
mosquitoes O 
can O 
arise O 
after O 
few O 
generations O 
of O 
selection O 
at O 
the O 
larval O 
stage O 
but O 
does O 
not O 
lead O 
to O 
a O 
significant O 
tolerance O 
of O 
adults O 
. O 
As O 
in O 
other O 
insects O 
, O 
P450 O 
- O 
mediated O 
insecticide O 
metabolism O 
appears O 
to O 
play O 
a O 
major O 
role O 
in O 
imidacloprid B-TRIVIAL 
tolerance O 
in O 
mosquitoes O 
. O 

effect O 
of O 
accumulated O 
aluminum B-SYSTEMATIC 
trichloride I-SYSTEMATIC 
on O 
the O 
hepatic O 
microsomal O 
cytochrome O 
P450 O 
enzyme O 
system O 
in O 
rats O 
. O 

( O 
Al B-FORMULA 
) O 
is O 
a O 
low O 
toxicological O 
metal O 
and O 
can O 
accumulate O 
in O 
the O 
liver O 
. O 
The O 
hepatic O 
microsomal O 
cytochrome O 
P450 O 
enzyme O 
system O 
( O 
CYPS O 
) O 
plays O 
important O 
role O 
in O 
the O 
transformation O 
of O 
the O 
toxic O 
materials O 
. O 
It O 
is O 
not O 
clear O 
if O 
the O 
CYPS O 
is O 
affected O 
by O 
Al B-FORMULA 
exposure O 
. O 
Thus O 
, O 
the O 
aim O 
of O 
this O 
study O 
is O 
to O 
investigate O 
the O 
effects O 
of O 
aluminum B-SYSTEMATIC 
trichloride I-SYSTEMATIC 
( O 
AlCl(3) B-FORMULA 
) O 
on O 
CYPS O 
in O 
rats O 
. O 
Forty O 
male O 
Wistar O 
rats O 
( O 
5weeks O 
old O 
) O 
weighing O 
110-120g O 
were O 
randomly O 
allocated O 
and O 
orally O 
exposed O 
to O 
0 O 
, O 
64.18 O 
, O 
128.36 O 
and O 
256.72mg O 
/ O 
kg O 
body O 
weight O 
( O 
BW O 
) O 
AlCl(3) B-FORMULA 
in O 
drinking O 
water O 
for O 
120days O 
. O 
The O 
body O 
weight O 
( O 
BW O 
) O 
of O 
rats O 
, O 
hepatosomatic O 
index O 
( O 
HSI O 
) O 
, O 
hepatic O 
Al B-FORMULA 
content O 
, O 
the O 
concentrations O 
of O 
cytochrome O 
P450 O 
( O 
CYP450 O 
) O 
, O 
cytochrome O 
B5 O 
( O 
B5 O 
) O 
, O 
microsomal O 
protein O 
and O 
the O 
activities O 
of O 
NADPH B-ABBREVIATION 
-cytochrome O 
c O 
reductase O 
( O 
CR O 
) O 
, O 
aminopyrin B-TRIVIAL 
N B-FORMULA 
-demethylase O 
( O 
AND O 
) O 
, O 
erythromycin O 
N B-FORMULA 
-demethylase O 
( O 
ERND O 
) O 
and O 
aniline B-SYSTEMATIC 
-4-hydeoxylase O 
( O 
AH O 
) O 
were O 
assessed O 
at O 
the O 
end O 
of O 
the O 
experiment O 
. O 
The O 
results O 
showed O 
that O 
the O 
increase O 
in O 
Al B-FORMULA 
concentration O 
decreased O 
BW O 
, O 
HIS O 
, O 
concentrations O 
of O 
CYP450 O 
, O 
B5 O 
, O 
microsomal O 
protein O 
and O 
the O 
activity O 
of O 
CR O 
, O 
AND O 
, O 
ERND O 
and O 
AH O 
in O 
hepatic O 
microsomes O 
. O 
The O 
results O 
revealed O 
that O 
exposure O 
to O 
AlCl(3) B-FORMULA 
inhibited O 
the O 
microsomal O 
CYP450 O 
dependent O 
enzyme O 
system O 
of O 
liver O 
. O 
Our O 
findings O 
suggest O 
that O 
long O 
term O 
daily O 
exposure O 
of O 
AlCl(3) B-FORMULA 
exerts O 
the O 
suppressive O 
effects O 
and O 
thus O 
may O 
cause O 
dysfunction O 
of O 
hepatic O 
CYP450 O 
dependent O 
enzyme O 
system O 
of O 
rat O 
. O 

distribution O 
in O 
tissues O 
of O 
free O 
- O 
range O 
chickens O 
near O 
a O 
lead- O 
zinc B-SYSTEMATIC 
mine O 
in O 
Kabwe O 
, O 
Zambia O 
. O 

of O 
Pb B-FORMULA 
, O 
Cd B-FORMULA 
, O 
and O 
other O 
metals O 
in O 
tissues O 
of O 
17 O 
free O 
- O 
range O 
and O 
32 O 
commercial O 
broiler O 
chickens O 
from O 
the O 
Kabwe O 
mining O 
town O 
in O 
Zambia O 
were O 
determined O 
. O 
Mean O 
concentrations O 
of O 
Pb B-FORMULA 
and O 
Cd B-FORMULA 
exceeded O 
maximum O 
levels O 
for O 
human O 
consumption O 
in O 
some O 
organs O 
including O 
muscle O 
( O 
Pb B-FORMULA 
only O 
) O 
in O 
free O 
- O 
range O 
chickens O 
, O 
in O 
contrast O 
to O 
low O 
levels O 
in O 
broiler O 
chickens O 
. O 
Human O 
consumers O 
in O 
Kabwe O 
could O 
be O 
exposed O 
to O 
Pb B-FORMULA 
and O 
Cd B-FORMULA 
in O 
free O 
- O 
range O 
chickens O 
. O 

agents O 
are O 
widely O 
applied O 
for O 
the O 
treatment O 
of O 
gastrointestinal O 
( O 
and O 
systemic O 
) O 
disorders O 
and O 
their O 
role O 
as O 
modulators O 
of O 
host O 
cell O 
responses O 
is O 
relatively O 
well O 
characterized O 
. O 
By O 
contrast O 
, O 
we O 
are O 
only O 
beginning O 
to O 
understand O 
the O 
molecular O 
mechanisms O 
by O 
which O 
health O 
- O 
promoting O 
, O 
probiotic O 
bacteria O 
act O 
as O 
host O 
cell O 
modulators O 
. O 
The O 
last O 
decade O 
has O 
seen O 
a O 
rapid O 
development O 
of O 
the O 
genomics O 
field O 
for O 
the O 
widely O 
applied O 
probiotic O 
genus O 
Lactobacillus O 
, O 
and O 
nowadays O 
dozens O 
of O 
full O 
genome O 
sequences O 
are O 
available O 
, O 
as O 
well O 
as O 
sophisticated O 
post O 
genomic O 
and O 
genetic O 
engineering O 
tools O 
. O 
This O 
development O 
has O 
enabled O 
comparative O 
( O 
functional O 
) O 
genomics O 
approaches O 
to O 
identify O 
the O 
bacterial O 
effector O 
molecules O 
involved O 
in O 
molecular O 
communication O 
with O 
the O 
host O 
system O 
that O 
may O 
underlie O 
the O 
probiotic O 
effects O 
observed O 
. O 
These O 
efforts O 
can O 
also O 
be O 
complemented O 
with O 
dedicated O 
mutagenesis O 
approaches O 
to O 
eliminate O 
or O 
alter O 
these O 
effector O 
molecules O 
, O 
followed O 
by O 
assessment O 
of O 
the O 
host O 
interaction O 
consequences O 
thereof O 
, O 
allowing O 
the O 
elucidation O 
of O 
the O 
molecular O 
mechanisms O 
involved O 
in O 
probiotic O 
health O 
effects O 
. O 
Many O 
of O 
these O 
approaches O 
have O 
pinpointed O 
that O 
the O 
Lactobacillus O 
cell O 
envelope O 
contains O 
several O 
effector O 
molecules O 
that O 
are O 
pivotal O 
in O 
the O 
direct O 
signaling O 
capacity O 
of O 
these O 
bacteria O 
that O 
underlies O 
their O 
immunomodulatory O 
effects O 
, O 
including O 
lipoteichoic O 
acid O 
, O 
peptidoglycan O 
, O 
and O 
(glyco)proteins O 
. O 
Moreover O 
, O 
the O 
cell O 
envelope O 
contains O 
several O 
compounds O 
such O 
as O 
wall O 
teichoic O 
acid O 
and O 
capsular O 
polysaccharides O 
that O 
may O 
not O 
be O 
involved O 
in O 
direct O 
signaling O 
to O 
the O 
host O 
cell O 
, O 
but O 
still O 
affect O 
signaling O 
through O 
shielding O 
of O 
other O 
bacterial O 
effector O 
molecules O 
. O 
Initial O 
structural O 
studies O 
revealed O 
subtle O 
strain- O 
and O 
species O 
- O 
specific O 
biochemical O 
differences O 
in O 
the O 
canonical O 
cell O 
envelope O 
compounds O 
that O 
are O 
involved O 
in O 
these O 
host O 
interactions O 
. O 
These O 
biochemical O 
variations O 
include O 
the O 
degree O 
and O 
positioning O 
of O 
d-alanyl B-TRIVIAL 
and O 
glycosyl B-SYSTEMATIC 
substitution O 
in O 
lipoteichoic O 
acids O 
, O 
and O 
acetylation O 
of O 
peptidoglycan O 
. O 
Furthermore O 
, O 
specific O 
peptides O 
derived O 
from O 
peptidoglycan O 
and O 
envelope O 
associated O 
(glyco)proteins O 
were O 
recently O 
identified O 
as O 
potent O 
immunomodulators O 
. O 
The O 
latter O 
findings O 
are O 
exciting O 
in O 
the O 
light O 
of O 
the O 
possibility O 
of O 
more O 
pharmacological O 
application O 
of O 
these O 
bioactive O 
probiotic O 
molecules O 
, O 
and O 
especially O 
cost O 
- O 
effective O 
production O 
and O 
targeted O 
delivery O 
of O 
bioactive O 
peptides O 
seems O 
to O 
emerge O 
as O 
a O 
feasible O 
strategy O 
to O 
harness O 
this O 
knowledge O 
. O 

graphene B-TRIVIAL 
in O 
biomedicine O 
: O 
theranostic O 
applications O 
. O 

to O 
their O 
unique O 
physical O 
and O 
chemical O 
properties O 
, O 
graphene B-TRIVIAL 
and O 
its O 
derivatives O 
such O 
as O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
GO O 
) O 
, O 
reduced B-SYSTEMATIC 
graphene I-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
RGO B-ABBREVIATION 
) O 
and O 
GO-nanocomposites O 
have O 
attracted O 
tremendous O 
interest O 
in O 
many O 
different O 
fields O 
including O 
biomedicine O 
in O 
recent O 
years O 
. O 
With O 
every O 
atom O 
exposed O 
on O 
its O 
surface O 
, O 
single O 
- O 
layered O 
graphene B-TRIVIAL 
shows O 
ultra O 
- O 
high O 
surface O 
area O 
available O 
for O 
efficient O 
molecular O 
loading O 
and O 
bioconjugation O 
, O 
and O 
has O 
been O 
widely O 
explored O 
as O 
novel O 
nano O 
- O 
carriers O 
for O 
drug O 
and O 
gene O 
delivery O 
. O 
Utilizing O 
the O 
intrinsic O 
near O 
- O 
infrared O 
( O 
NIR O 
) O 
optical O 
absorbance O 
, O 
in O 
vivo O 
graphene B-TRIVIAL 
-based O 
photothermal O 
therapy O 
has O 
been O 
realized O 
, O 
achieving O 
excellent O 
anti-tumor O 
therapeutic O 
efficacy O 
in O 
animal O 
experiments O 
. O 
A O 
variety O 
of O 
inorganic O 
nanoparticles O 
can O 
be O 
grown O 
on O 
the O 
surface O 
of O 
nano- O 
graphene B-TRIVIAL 
, O 
obtaining O 
functional O 
graphene B-TRIVIAL 
-based O 
nanocomposites O 
with O 
interesting O 
optical O 
and O 
magnetic O 
properties O 
useful O 
for O 
multi O 
- O 
modal O 
imaging O 
and O 
imaging O 
- O 
guided O 
cancer O 
therapy O 
. O 
Moreover O 
, O 
significant O 
efforts O 
have O 
also O 
been O 
devoted O 
to O 
study O 
the O 
behaviors O 
and O 
toxicology O 
of O 
functionalized O 
nano- O 
graphene B-TRIVIAL 
in O 
animals O 
. O 
It O 
has O 
been O 
uncovered O 
that O 
both O 
surface O 
chemistry O 
and O 
sizes O 
play O 
key O 
roles O 
in O 
controlling O 
the O 
biodistribution O 
, O 
excretion O 
, O 
and O 
toxicity O 
of O 
nano- O 
graphene B-TRIVIAL 
. O 
Biocompatibly O 
coated O 
nano- O 
graphene B-TRIVIAL 
with O 
ultra O 
- O 
small O 
sizes O 
can O 
be O 
cleared O 
out O 
from O 
body O 
after O 
systemic O 
administration O 
, O 
without O 
rendering O 
noticeable O 
toxicity O 
to O 
the O 
treated O 
mice O 
. O 
In O 
this O 
review O 
article O 
, O 
we O 
will O 
summarize O 
the O 
latest O 
progress O 
in O 
this O 
rapidly O 
growing O 
field O 
, O 
and O 
discuss O 
future O 
prospects O 
and O 
challenges O 
of O 
using O 
graphene B-TRIVIAL 
-based O 
materials O 
for O 
theranostic O 
applications O 
. O 

PFOS B-ABBREVIATION 
exposures O 
induce O 
life O 
stage O 
- O 
specific O 
behavioral O 
deficits O 
in O 
adult O 
zebrafish O 
and O 
produce O 
malformation O 
and O 
behavioral O 
deficits O 
in O 
F1 O 
offspring O 
. O 

sulfonic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
PFOS B-ABBREVIATION 
) O 
is O 
an O 
organic O 
contaminant O 
that O 
is O 
ubiquitous O 
in O 
the O 
environment O 
. O 
Few O 
studies O 
have O 
assessed O 
the O 
behavioral O 
effects O 
of O 
chronic O 
PFOS B-ABBREVIATION 
exposure O 
in O 
aquatic O 
organisms O 
. O 
The O 
present O 
study O 
defined O 
the O 
behavioral O 
effects O 
of O 
varying O 
life O 
span O 
chronic O 
exposures O 
to O 
PFOS B-ABBREVIATION 
in O 
zebrafish O 
. O 
Specifically O 
, O 
zebrafish O 
were O 
exposed O 
to O 
control O 
or O 
0.5 O 
µM O 
PFOS B-ABBREVIATION 
during O 
1 O 
to O 
20 O 
, O 
21 O 
to O 
120 O 
, O 
or O 
1 O 
to O 
120 O 
d O 
postfertilization O 
( O 
dpf O 
) O 
. O 
Exposure O 
to O 
PFOS B-ABBREVIATION 
impaired O 
the O 
adult O 
zebrafish O 
behavior O 
mode O 
under O 
the O 
tapping O 
stimulus O 
. O 
The O 
movement O 
speed O 
of O 
male O 
and O 
female O 
fish O 
exposed O 
for O 
1 O 
to O 
120 O 
dpf O 
was O 
significantly O 
increased O 
compared O 
with O 
control O 
before O 
and O 
after O 
tapping O 
, O 
whereas O 
in O 
the O 
groups O 
exposed O 
for O 
1 O 
to O 
20 O 
and O 
21 O 
to O 
120 O 
dpf O 
, O 
only O 
the O 
males O 
exhibited O 
elevated O 
swim O 
speed O 
before O 
tapping O 
. O 
Residues O 
of O 
PFOS B-ABBREVIATION 
in O 
F1 O 
embryos O 
derived O 
from O 
parental O 
exposure O 
for O 
1 O 
to O 
120 O 
and O 
21 O 
to O 
120 O 
dpf O 
were O 
significantly O 
higher O 
than O 
control O 
, O 
and O 
F1 O 
embryos O 
in O 
these O 
two O 
groups O 
also O 
showed O 
high O 
malformation O 
and O 
mortality O 
. O 
The O 
F1 O 
larvae O 
of O 
parental O 
fish O 
exposed O 
to O 
PFOS B-ABBREVIATION 
for O 
1 O 
to O 
20 O 
or O 
21 O 
to O 
120 O 
dpf O 
exhibited O 
a O 
higher O 
swimming O 
speed O 
than O 
control O 
larvae O 
in O 
a O 
light O 
- O 
to O 
- O 
dark O 
behavior O 
assessment O 
test O 
. O 
The O 
F1 O 
larvae O 
derived O 
from O 
parental O 
fish O 
exposed O 
to O 
PFOS B-ABBREVIATION 
for O 
1 O 
to O 
120 O 
dpf O 
showed O 
a O 
significantly O 
lower O 
speed O 
in O 
the O 
light O 
period O 
and O 
a O 
higher O 
speed O 
in O 
the O 
dark O 
period O 
compared O 
with O 
controls O 
. O 
Although O 
there O 
was O 
little O 
PFOS B-ABBREVIATION 
residue O 
in O 
embryos O 
derived O 
from O 
the O 
1- O 
to O 
20-dpf O 
parental O 
PFOS B-ABBREVIATION 
-exposed O 
group O 
, O 
the O 
adverse O 
behavioral O 
effects O 
on O 
both O 
adult O 
and O 
F1 O 
larvae O 
indicate O 
that O 
exposure O 
during O 
the O 
first O 
21 O 
dpf O 
induces O 
long O 
- O 
term O 
neurobehaviorial O 
toxicity O 
. O 
The O 
authors O 
' O 
findings O 
demonstrate O 
that O 
chronic O 
PFOS B-ABBREVIATION 
exposure O 
during O 
different O 
life O 
stages O 
adversely O 
affects O 
adult O 
behavior O 
and O 
F1 O 
offspring O 
morphology O 
, O 
behavior O 
, O 
and O 
survival O 
. O 

, O 
estimated O 
costs O 
to O 
manage O 
( O 
i.e O 
. O 
, O 
remediate O 
and O 
monitor O 
) O 
contaminated O 
sediments O 
are O 
in O 
the O 
billions O 
of O 
U.S O 
. O 
dollars O 
. O 
Biologically O 
based O 
approaches O 
for O 
assessing O 
the O 
contaminated O 
sediments O 
which O 
pose O 
the O 
greatest O 
ecological O 
risk O 
range O 
from O 
toxicity O 
testing O 
to O 
benthic O 
community O 
analysis O 
. O 
In O 
addition O 
, O 
chemically O 
based O 
sediment O 
quality O 
guidelines O 
( O 
SQGs O 
) O 
provide O 
a O 
relatively O 
inexpensive O 
line O 
of O 
evidence O 
for O 
supporting O 
these O 
assessments O 
. O 
The O 
present O 
study O 
summarizes O 
a O 
mechanistic O 
SQG O 
based O 
on O 
equilibrium O 
partitioning O 
( O 
EqP O 
) O 
, O 
which O 
uses O 
the O 
dissolved O 
concentrations O 
of O 
contaminants O 
in O 
sediment O 
interstitial O 
waters O 
as O 
a O 
surrogate O 
for O 
bioavailable O 
contaminant O 
concentrations O 
. O 
The O 
EqP O 
- O 
based O 
mechanistic O 
SQGs O 
are O 
called O 
equilibrium O 
partitioning O 
sediment O 
benchmarks O 
( O 
ESBs O 
) O 
. O 
Sediment O 
concentrations O 
less O 
than O 
or O 
equal O 
to O 
the O 
ESB O 
values O 
are O 
not O 
expected O 
to O 
result O 
in O 
adverse O 
effects O 
and O 
benthic O 
organisms O 
should O 
be O 
protected O 
, O 
while O 
sediment O 
concentrations O 
above O 
the O 
ESB O 
values O 
may O 
result O 
in O 
adverse O 
effects O 
to O 
benthic O 
organisms O 
. O 
In O 
the O 
present O 
study O 
, O 
ESB O 
values O 
are O 
reported O 
for O 
34 O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbon I-FAMILY 
, O 
32 O 
other O 
organic O 
contaminants O 
, O 
and O 
seven O 
metals O 
( O 
cadmium B-SYSTEMATIC 
, O 
chromium B-SYSTEMATIC 
, O 
copper B-SYSTEMATIC 
, O 
nickel B-SYSTEMATIC 
, O 
lead O 
, O 
silver B-SYSTEMATIC 
, O 
zinc B-SYSTEMATIC 
) O 
. O 
Also O 
included O 
is O 
an O 
overview O 
of O 
EqP O 
theory O 
, O 
ESB O 
derivation O 
, O 
examples O 
of O 
applying O 
ESB O 
values O 
, O 
and O 
considerations O 
when O 
using O 
ESBs O 
. O 
The O 
ESBs O 
are O 
intended O 
as O 
a O 
complement O 
to O 
existing O 
sediment-assessment O 
tools O 
, O 
to O 
assist O 
in O 
determining O 
the O 
extent O 
of O 
sediment O 
contamination O 
, O 
to O 
help O 
identify O 
chemicals O 
causing O 
toxicity O 
, O 
and O 
to O 
serve O 
as O 
targets O 
for O 
pollutant O 
loading O 
control O 
measures O 
. O 

to O 
1,3-dimethylamylamine B-SYSTEMATIC 
-containing O 
products O 
reported O 
to O 
Texas O 
poison O 
centers O 
. O 

( O 
DMAA B-ABBREVIATION 
) O 
is O 
an O 
ingredient O 
in O 
a O 
number O 
of O 
weight O 
loss O 
and O 
exercise O 
performance O 
enhancing O 
products O 
. O 
However O 
, O 
information O 
on O 
the O 
safety O 
of O 
DMAA B-ABBREVIATION 
-containing O 
products O 
is O 
limited O 
. O 
Exposures O 
to O 
DMAA B-ABBREVIATION 
-containing O 
products O 
reported O 
to O 
Texas O 
poison O 
centers O 
during O 
2010-2011 O 
were O 
identified O 
and O 
selected O 
factors O 
were O 
examined O 
. O 
A O 
total O 
of O 
56 O 
exposures O 
were O 
found O 
, O 
of O 
which O 
75.0% O 
were O 
reported O 
during O 
2011 O 
. O 
OxyElite O 
Pro O 
™ O 
was O 
the O 
reported O 
product O 
in O 
80.4% O 
of O 
the O 
exposures O 
. O 
The O 
patients O 
were O 
51.8% O 
male O 
and O 
55.4% O 
age O 
≤ O 
5 O 
years O 
. O 
The O 
patient O 
was O 
managed O 
on O 
site O 
( O 
such O 
as O 
at O 
home O 
) O 
in O 
57.1% O 
of O 
the O 
cases O 
, O 
and O 
the O 
exposure O 
was O 
known O 
or O 
expected O 
to O 
result O 
in O 
an O 
outcome O 
that O 
was O 
classified O 
as O 
not O 
serious O 
in O 
80.4% O 
. O 
The O 
most O 
frequently O 
reported O 
clinical O 
effects O 
were O 
tachycardia O 
( O 
28.6% O 
) O 
, O 
nausea O 
( O 
16.1% O 
) O 
, O 
and O 
vomiting O 
( O 
12.5% O 
) O 
. O 
The O 
most O 
common O 
treatments O 
were O 
dilution O 
( O 
41.1% O 
) O 
, O 
food O 
( O 
19.6% O 
) O 
, O 
and O 
activated O 
charcoal B-TRIVIAL 
( O 
14.3% O 
) O 
. O 
It O 
should O 
be O 
noted O 
that O 
the O 
adverse O 
clinical O 
effects O 
may O 
be O 
due O 
to O 
other O 
ingredients O 
in O 
the O 
DMAA B-ABBREVIATION 
-containing O 
products O 
, O 
such O 
as O 
caffeine B-TRIVIAL 
. O 

do O 
not O 
consume O 
/ O 
do O 
not O 
use O 
concentrations O 
for O 
blended O 
phosphates B-FAMILY 
in O 
drinking O 
water O 
. O 

U.S O 
. O 
Congress O 
[ O 
PL O 
107-188 O 
] O 
amended O 
the O 
Safe O 
Drinking O 
Water O 
Act O 
and O 
required O 
each O 
community O 
water O 
system O 
serving O 
more O 
than O 
3000 O 
people O 
to O 
conduct O 
vulnerability O 
assessments O 
. O 
These O 
assessments O 
address O 
potential O 
circumstances O 
that O 
could O 
compromise O 
the O 
safety O 
and O 
reliability O 
of O 
municipal O 
water O 
. O 
The O 
present O 
evaluation O 
concerns O 
the O 
concentrations O 
of O 
the O 
blended O 
phosphates B-FAMILY 
( O 
also O 
known O 
as O 
polyphosphates B-FAMILY 
, O 
condensed O 
complex O 
phosphates B-FAMILY 
, O 
polyphosphate O 
glassy O 
balls O 
, O 
and O 
pyrophosphates B-FAMILY 
) O 
intended O 
to O 
aid O 
regulatory O 
agencies O 
in O 
decisions O 
to O 
avoid O 
contact O 
with O 
affected O 
water O 
. O 
Polyphosphates B-FAMILY 
are O 
direct O 
food O 
additives O 
and O 
they O 
are O 
used O 
to O 
treat O 
municipal O 
drinking O 
water O 
, O 
but O 
depending O 
upon O 
the O 
concentration O 
and O 
duration O 
of O 
exposure O 
these O 
substances O 
can O 
induce O 
chemical O 
burns O 
. O 
Ingested O 
polyphosphates B-FAMILY 
are O 
degraded O 
by O 
phosphatase O 
enzymes O 
to O 
monophosphates B-FAMILY 
, O 
substances O 
that O 
are O 
over O 
- O 
the O 
- O 
counter O 
bowel O 
purgatives O 
. O 
High O 
oral O 
doses O 
of O 
the O 
monophosphates B-FAMILY 
can O 
induce O 
transient O 
hyperphosphatemia O 
in O 
older O 
and O 
susceptible O 
young O 
people O 
, O 
which O 
can O 
lead O 
to O 
acute O 
phosphate B-SYSTEMATIC 
nephropathy O 
. O 
In O 
some O 
patients O 
, O 
the O 
condition O 
is O 
fatal O 
. O 
Based O 
on O 
the O 
acute O 
diarrhea O 
after O 
the O 
ingestion O 
of O 
a O 
single O 
oral O 
dose O 
of O 
monobasic O 
( O 
NaH2PO(4) B-FORMULA 
) O 
and O 
dibasic O 
( O 
Na2HPO(4) B-FORMULA 
) O 
monophosphates B-FAMILY 
in O 
adults O 
, O 
a O 
do O 
not O 
consume O 
concentration O 
of O 
600 O 
mg O 
PO(4) B-FORMULA 
/L O 
can O 
be O 
derived O 
. O 
Based O 
on O 
mild O 
local O 
irritation O 
after O 
topical O 
application O 
of O 
1.0% O 
sodium B-SYSTEMATIC 
metaphosphate I-SYSTEMATIC 
[ O 
(NaPO(3))6 B-FORMULA 
• I-FORMULA 
H2O I-FORMULA 
] O 
to O 
intact O 
skin O 
of O 
sensitive O 
volunteers O 
, O 
a O 
do O 
not O 
use O 
concentration O 
of O 
8000 O 
mg O 
PO4 B-FORMULA 
/L O 
can O 
be O 
assigned O 
. O 
Given O 
the O 
lack O 
of O 
eye O 
irritation O 
in O 
rabbits O 
after O 
direct O 
instillation O 
of O 
0.2% O 
(NaPO(3))6 B-FORMULA 
• I-FORMULA 
H2O I-FORMULA 
, O 
an O 
acute O 
ocular O 
contact O 
limit O 
of O 
50 O 
mg O 
PO4 B-FORMULA 
/L O 
serves O 
as O 
the O 
overall O 
do O 
not O 
use O 
level O 
. O 

it O 
has O 
been O 
reported O 
that O 
deficiency O 
of O 
toll O 
- O 
like O 
receptor O 
4 O 
( O 
TLR4 O 
) O 
is O 
associated O 
with O 
reduced O 
atherosclerosis O 
in O 
atherosclerosis O 
- O 
prone O 
mice O 
and O 
attenuated O 
pro O 
- O 
inflammatory O 
state O 
in O 
diabetic O 
mice O 
, O 
it O 
remains O 
undetermined O 
whether O 
treatment O 
with O 
a O 
TLR4 O 
antagonist O 
reduces O 
atherosclerosis O 
in O 
nondiabetic O 
or O 
diabetic O 
mice O 
that O 
have O 
TLR4 O 
expression O 
. O 
In O 
this O 
study O 
, O 
we O 
determined O 
the O 
effect O 
of O 
Rhodobacter O 
sphaeroides O 
lipopolysaccharide O 
( O 
Rs-LPS O 
) O 
, O 
an O 
established O 
TLR4 O 
antagonist O 
, O 
on O 
early O 
- O 
stage O 
atherosclerosis O 
in O 
nondiabetic O 
and O 
streptozotocin B-TRIVIAL 
-induced O 
diabetic O 
apolipoprotein O 
E-deficient O 
( O 
Apoe(- O 
/ O 
- O 
) O 
) O 
mice O 
. O 
Analysis O 
of O 
atherosclerotic O 
lesions O 
of O 
both O 
en O 
face O 
aortas O 
and O 
cross O 
sections O 
of O 
aortic O 
roots O 
showed O 
that O 
administration O 
of O 
Rs-LPS O 
in O 
14-week- O 
old O 
diabetic O 
Apoe(- O 
/ O 
- O 
) O 
mice O 
for O 
10 O 
weeks O 
significantly O 
reduced O 
atherosclerotic O 
lesions O 
. O 
Although O 
atherosclerotic O 
lesions O 
in O 
nondiabetic O 
Apoe(- O 
/ O 
- O 
) O 
mice O 
appeared O 
to O 
be O 
decreased O 
by O 
Rs-LPS O 
treatment O 
, O 
the O 
difference O 
was O 
not O 
statistically O 
significant O 
. O 
Metabolic O 
study O 
showed O 
that O 
Rs-LPS O 
significantly O 
lowered O 
serum O 
levels O 
of O 
cholesterol B-TRIVIAL 
and O 
triglycerides B-FAMILY 
in O 
nondiabetic O 
mice O 
but O 
not O 
in O 
diabetic O 
mice O 
. O 
Furthermore O 
, O 
immunohistochemistry O 
studies O 
showed O 
that O 
Rs-LPS O 
inhibited O 
the O 
expression O 
of O 
interleukin O 
6 O 
and O 
matrix O 
metalloproteinase-9 O 
and O 
reduced O 
the O 
content O 
of O 
monocytes O 
and O 
macrophages O 
in O 
atherosclerotic O 
plaques O 
. O 
Taken O 
together O 
, O 
this O 
study O 
demonstrated O 
for O 
the O 
first O 
time O 
that O 
TLR4 O 
antagonist O 
inhibited O 
vascular O 
inflammation O 
and O 
atherogenesis O 
in O 
diabetic O 
Apoe(- O 
/ O 
- O 
) O 
mice O 
and O 
lowered O 
serum O 
cholesterol B-TRIVIAL 
and O 
triglyceride B-FAMILY 
levels O 
in O 
nondiabetic O 
Apoe(- O 
/ O 
- O 
) O 
mice O 
. O 

in O 
synthesis O 
and O 
antitumor O 
activities O 
of O 
estradiol B-TRIVIAL 
-linked O 
platinum B-SYSTEMATIC 
complex O 
. O 

complexes O 
such O 
as O 
cisplatin B-TRIVIAL 
and O 
caboplatin B-TRIVIAL 
are O 
widely O 
used O 
in O 
cancer O 
chemotherapy O 
. O 
However O 
, O 
their O 
clinical O 
applications O 
are O 
substantially O 
limited O 
by O 
unexpected O 
toxic O 
side O 
effects O 
. O 
In O 
this O 
review O 
, O 
we O 
discuss O 
the O 
current O 
progress O 
on O 
the O 
design O 
and O 
synthesis O 
of O 
estradiol B-TRIVIAL 
-linked O 
platinum B-SYSTEMATIC 
complexes O 
as O 
the O 
targeted O 
antitumor O 
drugs O 
. O 
Many O 
of O 
them O 
display O 
a O 
high O 
antitumor O 
activity O 
against O 
the O 
growth O 
of O 
breast O 
cancer O 
cell O 
lines O 
in O 
vitro O 
. O 
The O 
estradiol B-TRIVIAL 
-linked O 
platinum B-SYSTEMATIC 
complexes O 
could O 
be O 
used O 
as O 
target O 
therapeutics O 
for O 
breast O 
cancer O 
. O 

article O 
summarizes O 
the O 
results O 
of O 
using O 
cytokinesis O 
- O 
block O 
micronucleus O 
( O 
CBMN O 
) O 
assay O 
to O 
evaluate O 
the O 
antioxidant O 
potential O 
of O 
heterocyclic O 
compounds O 
. O 
Most O 
studies O 
were O 
carried O 
out O 
with O 
naturally O 
occurring O 
heterocyclic O 
compounds O 
such O 
as O 
plant O 
polyphenols B-FAMILY 
: O 
flavonoids B-FAMILY 
, O 
xanthones B-FAMILY 
, O 
coumarins B-FAMILY 
, O 
and O 
ellagitannins B-FAMILY 
, O 
or O 
plant O 
derived O 
products O 
( O 
juices O 
, O 
extracts O 
, O 
supplements O 
) O 
rich O 
in O 
bioactive O 
heterocyclic O 
compounds O 
. O 
There O 
are O 
also O 
some O 
studies O 
dealing O 
with O 
synthetic O 
heterocyclic O 
antioxidants O 
. O 
CBMN O 
assay O 
is O 
an O 
in O 
vitro O 
study O 
that O 
has O 
been O 
used O 
to O 
evaluate O 
antioxidant O 
and O 
protective O 
effects O 
of O 
heterocyclic O 
compounds O 
on O 
induced O 
chromosome O 
aberration O 
in O 
human O 
lymphocytes O 
. O 

corrupts O 
the O 
antiandrogenic O 
effect O 
of O 
bicalutamide B-TRIVIAL 
but O 
only O 
weakly O 
attenuates O 
the O 
effect O 
of O 
MDV3100 B-IDENTIFIER 
( O 
Enzalutamide B-TRIVIAL 
™ O 
) O 
. O 

cancer O 
growth O 
depends O 
on O 
androgens B-FAMILY 
. O 
Synthetic O 
antiandrogens O 
are O 
used O 
in O 
the O 
cancer O 
treatment O 
. O 
However O 
, O 
antiandrogens O 
, O 
such O 
as O 
bicalutamide B-TRIVIAL 
( O 
BIC B-ABBREVIATION 
) O 
, O 
have O 
a O 
mixed O 
agonist O 
/ O 
antagonist O 
activity O 
. O 
Here O 
we O 
compare O 
the O 
antiandrogenic O 
capacity O 
of O 
BIC B-ABBREVIATION 
to O 
a O 
new O 
antiandrogen O 
, O 
MDV3100 B-IDENTIFIER 
( O 
MDV O 
) O 
or O 
Enzalutamide B-TRIVIAL 
™ O 
. O 
By O 
reconstitution O 
of O 
a O 
hormone O 
- O 
regulated O 
enhancer O 
in O 
Xenopus O 
oocytes O 
we O 
show O 
that O 
both O 
antagonists O 
trigger O 
the O 
androgen B-FAMILY 
receptor O 
( O 
AR O 
) O 
translocation O 
to O 
the O 
nucleus O 
, O 
albeit O 
with O 
a O 
reduced O 
efficiency O 
for O 
MDV O 
. O 
Once O 
in O 
the O 
nucleus O 
, O 
both O 
AR-antagonist O 
complexes O 
can O 
bind O 
sequence O 
specifically O 
to O 
DNA O 
in O 
vivo O 
. O 
The O 
forkhead O 
box O 
transcription O 
factor O 
A O 
( O 
FoxA1 O 
) O 
is O 
a O 
negative O 
prognostic O 
indicator O 
for O 
prostate O 
cancer O 
disease O 
. O 
FoxA1 O 
expression O 
presets O 
the O 
enhancer O 
chromatin O 
and O 
makes O 
the O 
DNA O 
more O 
accessible O 
for O 
AR O 
binding O 
. O 
In O 
this O 
context O 
the O 
BIC B-ABBREVIATION 
-AR O 
antiandrogenic O 
effect O 
is O 
seriously O 
compromised O 
as O 
demonstrated O 
by O 
a O 
significant O 
chromatin O 
remodeling O 
and O 
induction O 
of O 
a O 
robust O 
MMTV O 
transcription O 
whereas O 
the O 
MDV-AR O 
complex O 
displays O 
a O 
more O 
persistent O 
antagonistic O 
character O 
. O 

slowing O 
of O 
network O 
oscillations O 
in O 
mouse O 
neocortex O 
by O 
diazepam B-TRIVIAL 
. O 

have O 
a O 
broad O 
spectrum O 
of O 
clinical O 
applications O 
including O 
sedation O 
, O 
anti-anxiety O 
, O 
and O 
anticonvulsive O 
therapy O 
. O 
At O 
the O 
cellular O 
level O 
, O 
benzodiazepines B-FAMILY 
are O 
allosteric O 
modulators O 
of O 
GABA(A) O 
receptors O 
; O 
they O 
increase O 
the O 
efficacy O 
of O 
inhibition O 
in O 
neuronal O 
networks O 
by O 
prolonging O 
the O 
duration O 
of O 
inhibitory O 
postsynaptic O 
potentials O 
. O 
This O 
mechanism O 
of O 
action O 
predicts O 
that O 
benzodiazepines B-FAMILY 
reduce O 
the O 
frequency O 
of O 
inhibition O 
- O 
driven O 
network O 
oscillations O 
, O 
consistent O 
with O 
observations O 
from O 
human O 
and O 
animal O 
EEG O 
. O 
However O 
, O 
most O 
of O 
existing O 
data O 
are O 
restricted O 
to O 
frequency O 
bands O 
below O 
∼30 O 
Hz O 
. O 
Recent O 
data O 
suggest O 
that O 
faster O 
cortical O 
network O 
rhythms O 
are O 
critically O 
involved O 
in O 
several O 
behavioral O 
and O 
cognitive O 
tasks O 
. O 
We O 
therefore O 
analyzed O 
diazepam B-TRIVIAL 
effects O 
on O 
a O 
large O 
range O 
of O 
cortical O 
network O 
oscillations O 
in O 
freely O 
moving O 
mice O 
, O 
including O 
theta O 
( O 
4-12 O 
Hz O 
) O 
, O 
gamma O 
( O 
40-100 O 
Hz O 
) O 
and O 
fast O 
gamma O 
( O 
120-160 O 
Hz O 
) O 
oscillations O 
. O 
We O 
also O 
investigated O 
diazepam B-TRIVIAL 
effects O 
over O 
the O 
coupling O 
between O 
theta O 
phase O 
and O 
the O 
amplitude O 
fast O 
oscillations O 
. O 
We O 
report O 
that O 
diazepam B-TRIVIAL 
causes O 
a O 
global O 
slowing O 
of O 
oscillatory O 
activity O 
in O 
all O 
frequency O 
domains O 
. O 
Oscillation O 
power O 
was O 
changed O 
differently O 
for O 
each O 
frequency O 
domain O 
, O 
with O 
characteristic O 
differences O 
between O 
active O 
wakefulness O 
, O 
slow O 
- O 
wave O 
sleep O 
and O 
REM O 
sleep O 
. O 
Cross O 
- O 
frequency O 
coupling O 
strength O 
, O 
in O 
contrast O 
, O 
was O 
mostly O 
unaffected O 
by O 
diazepam B-TRIVIAL 
. O 
Such O 
state- O 
and O 
frequency O 
- O 
dependent O 
actions O 
of O 
benzodiazepines B-FAMILY 
on O 
cortical O 
network O 
oscillations O 
may O 
be O 
relevant O 
for O 
their O 
specific O 
cognitive O 
effects O 
. O 
They O 
also O 
underline O 
the O 
strong O 
interaction O 
between O 
local O 
network O 
oscillations O 
and O 
global O 
brain O 
states O 
. O 

role O 
of O 
oxygen B-SYSTEMATIC 
during O 
fracture O 
healing O 
. O 

affects O 
the O 
activity O 
of O 
multiple O 
skeletogenic O 
cells O 
and O 
is O 
involved O 
in O 
many O 
processes O 
that O 
are O 
important O 
for O 
fracture O 
healing O 
. O 
However O 
, O 
the O 
role O 
of O 
oxygen B-SYSTEMATIC 
in O 
fracture O 
healing O 
has O 
not O 
been O 
fully O 
studied O 
. O 
Here O 
we O 
systematically O 
examine O 
the O 
effects O 
of O 
oxygen B-SYSTEMATIC 
tension O 
on O 
fracture O 
healing O 
and O 
test O 
the O 
ability O 
of O 
hyperoxia O 
to O 
rescue O 
healing O 
defects O 
in O 
a O 
mouse O 
model O 
of O 
ischemic O 
fracture O 
healing O 
. O 
Mice O 
with O 
tibia O 
fracture O 
were O 
housed O 
in O 
custom O 
- O 
built O 
gas O 
chambers O 
and O 
groups O 
breathed O 
a O 
constant O 
atmosphere O 
of O 
13% O 
oxygen B-SYSTEMATIC 
( O 
hypoxia O 
) O 
, O 
21% O 
oxygen B-SYSTEMATIC 
( O 
normoxia O 
) O 
, O 
or O 
50% O 
oxygen B-SYSTEMATIC 
( O 
hyperoxia O 
) O 
. O 
The O 
influx O 
of O 
inflammatory O 
cells O 
to O 
the O 
fracture O 
site O 
, O 
stem O 
cell O 
differentiation O 
, O 
tissue O 
vascularization O 
, O 
and O 
fracture O 
healing O 
were O 
analyzed O 
. O 
In O 
addition O 
, O 
the O 
efficacy O 
of O 
hyperoxia O 
( O 
50% O 
oxygen B-SYSTEMATIC 
) O 
as O 
a O 
treatment O 
regimen O 
for O 
fracture O 
nonunion O 
was O 
tested O 
. O 
Hypoxic O 
animals O 
had O 
decreased O 
tissue O 
vascularity O 
, O 
decreased O 
bone O 
formation O 
, O 
and O 
delayed O 
callus O 
remodeling O 
. O 
Hyperoxia O 
increased O 
tissue O 
vascularization O 
, O 
altered O 
fracture O 
healing O 
in O 
un O 
- O 
complicated O 
fractures O 
, O 
and O 
improved O 
bone O 
repair O 
in O 
ischemia O 
- O 
induced O 
delayed O 
fracture O 
union O 
. O 
However O 
, O 
neither O 
hypoxia O 
nor O 
hyperoxia O 
significantly O 
altered O 
chondrogenesis O 
or O 
osteogenesis O 
during O 
early O 
stages O 
of O 
fracture O 
healing O 
, O 
and O 
infiltration O 
of O 
macrophages O 
and O 
neutrophils O 
was O 
not O 
affected O 
by O 
environmental O 
oxygen B-SYSTEMATIC 
after O 
bone O 
injury O 
. O 
In O 
conclusion O 
, O 
our O 
results O 
indicate O 
that O 
environmental O 
oxygen B-SYSTEMATIC 
levels O 
affect O 
tissue O 
vascularization O 
and O 
fracture O 
healing O 
, O 
and O 
that O 
providing O 
oxygen B-SYSTEMATIC 
when O 
fractures O 
are O 
accompanied O 
by O 
ischemia O 
may O 
be O 
beneficial O 
. O 

highly O 
concentrated O 
itraconazole B-TRIVIAL 
nanosuspension O 
for O 
the O 
treatment O 
of O 
bronchopulmonary O 
aspergillosis O 
. O 

fibrosis O 
( O 
CF O 
) O 
patients O 
are O 
suffering O 
from O 
multiple O 
often O 
chronic O 
endobronchial O 
infection O 
. O 
The O 
stiff O 
mucus O 
in O 
these O 
patients O 
represents O 
a O 
compartment O 
, O 
which O 
cannot O 
easily O 
be O 
reached O 
by O 
systemic O 
treatment O 
. O 
While O 
bacterial O 
infections O 
are O 
now O 
successfully O 
treated O 
with O 
repeated O 
inhalation O 
of O 
antibiotics O 
such O 
as O 
tobramycine B-TRIVIAL 
, O 
57% O 
of O 
CF O 
patients O 
are O 
colonized O 
by O 
Aspergillus O 
species O 
. O 
About O 
10-20% O 
of O 
colonized O 
patients O 
develop O 
symptoms O 
of O 
allergic O 
bronchopulmonary O 
aspergillosis O 
( O 
ABPA O 
) O 
. O 
While O 
current O 
standard O 
of O 
treatment O 
of O 
ABPA O 
in O 
CF O 
patients O 
is O 
to O 
suppress O 
the O 
allergy O 
related O 
symptoms O 
by O 
administration O 
of O 
glucocorticoids O 
, O 
itraconazole B-TRIVIAL 
( O 
ITRA B-ABBREVIATION 
) O 
, O 
administered O 
orally O 
at O 
high O 
doses O 
, O 
can O 
alleviate O 
the O 
symptoms O 
of O 
ABPA O 
. O 
However O 
, O 
no O 
inhalable O 
formulation O 
of O 
ITRA B-ABBREVIATION 
is O 
available O 
to O 
enable O 
local O 
treatment O 
of O 
aspergillosis O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
describe O 
an O 
aqueous O 
nanosuspension O 
of O 
ITRA B-ABBREVIATION 
and O 
to O 
characterize O 
the O 
pharmacokinetics O 
after O 
single O 
dose O 
inhalation O 
. O 
Using O 
wet O 
- O 
milling O 
with O 
organic O 
milling O 
beads O 
, O 
a O 
stable O 
nanosuspension O 
with O 
particle O 
size O 
in O 
the O 
range O 
of O 
200nm O 
and O 
an O 
ITRA B-ABBREVIATION 
concentration O 
of O 
20% O 
( O 
v O 
/ O 
w O 
) O 
could O 
be O 
obtained O 
, O 
using O 
polysorbate B-FAMILY 
polysorbate B-TRIVIAL 
80 I-TRIVIAL 
at O 
a O 
concentration O 
of O 
14% O 
relative O 
to O 
ITRA B-ABBREVIATION 
. O 
The O 
suspension O 
was O 
stable O 
if O 
stored O 
at O 
8°C O 
for O 
3 O 
months O 
without O 
particle O 
growth O 
and O 
could O 
be O 
nebulized O 
using O 
standard O 
nebulizer O 
technologies O 
including O 
mesh O 
technology O 
and O 
pressured O 
air O 
nebulizers O 
. O 
A O 
10% O 
suspension O 
was O 
well O 
tolerated O 
upon O 
repeated O 
dose O 
inhalation O 
once O 
daily O 
for O 
7 O 
days O 
at O 
a O 
predicted O 
dose O 
of O 
45mg O 
/ O 
kg O 
in O 
rats O 
. O 
A O 
single O 
dose O 
inhalation O 
at O 
a O 
predicted O 
dose O 
of O 
22.5mg O 
/ O 
kg O 
resulted O 
in O 
maximum O 
lung O 
tissue O 
concentration O 
of O 
21.4μg O 
/ O 
g O 
tissue O 
with O 
a O 
terminal O 
half O 
- O 
life O 
of O 
25.4h O 
. O 
Serum O 
concentrations O 
were O 
lower O 
, O 
with O 
a O 
maximum O 
concentration O 
of O 
104ng O 
/ O 
ml O 
at O 
4h O 
after O 
dosing O 
and O 
a O 
terminal O 
half O 
- O 
life O 
of O 
10.5h O 
. O 
The O 
data O 
indicate O 
that O 
ITRA B-ABBREVIATION 
nanosuspension O 
represents O 
an O 
interesting O 
formulation O 
for O 
inhaled O 
administration O 
in O 
CF O 
patients O 
suffering O 
from O 
ABPA O 
. O 
High O 
and O 
long O 
lasting O 
lung O 
tissue O 
concentrations O 
well O 
above O 
the O 
minimal O 
inhibitory O 
concentration O 
of O 
Aspergillus O 
species O 
enable O 
once O 
daily O 
administration O 
with O 
minimal O 
systemic O 
exposure O 
. O 

of O 
adenosine B-TRIVIAL 
levels O 
during O 
cerebral O 
ischemia O 
. O 

is O 
a O 
neuromodulator O 
with O 
its O 
level O 
increasing O 
up O 
to O 
100-fold O 
during O 
ischemic O 
events O 
, O 
and O 
attenuates O 
the O 
excitotoxic O 
neuronal O 
injury O 
. O 
Adenosine B-TRIVIAL 
is O 
produced O 
both O 
intracellularly O 
and O 
extracellularly O 
, O 
and O 
nucleoside B-FAMILY 
transport O 
proteins O 
transfer O 
adenosine B-TRIVIAL 
across O 
plasma O 
membranes O 
. O 
Adenosine B-TRIVIAL 
levels O 
and O 
receptor O 
- O 
mediated O 
effects O 
of O 
adenosine B-TRIVIAL 
are O 
regulated O 
by O 
intracellular O 
ATP B-ABBREVIATION 
consumption O 
, O 
cellular O 
release O 
of O 
ATP B-ABBREVIATION 
, O 
metabolism O 
of O 
extracellular O 
ATP B-ABBREVIATION 
( O 
and O 
other O 
adenine B-FAMILY 
nucleotides I-FAMILY 
) O 
, O 
adenosine B-TRIVIAL 
influx O 
, O 
adenosine B-TRIVIAL 
efflux O 
and O 
adenosine B-TRIVIAL 
metabolism O 
. O 
Recent O 
studies O 
have O 
used O 
genetically O 
modified O 
mice O 
to O 
investigate O 
the O 
relative O 
contributions O 
of O 
intra- O 
and O 
extracellular O 
pathways O 
for O 
adenosine B-TRIVIAL 
formation O 
. O 
The O 
importance O 
of O 
cortical O 
or O 
hippocampal O 
neurons O 
as O 
a O 
source O 
or O 
a O 
sink O 
of O 
adenosine B-TRIVIAL 
under O 
basal O 
and O 
hypoxic O 
/ O 
ischemic O 
conditions O 
was O 
addressed O 
through O 
the O 
use O 
of O 
transgenic O 
mice O 
expressing O 
human O 
equilibrative O 
nucleoside B-FAMILY 
transporter O 
1 O 
( O 
hENT1 O 
) O 
under O 
the O 
control O 
of O 
a O 
promoter O 
for O 
neuron O 
- O 
specific O 
enolase O 
. O 
From O 
these O 
studies O 
, O 
we O 
conclude O 
that O 
ATP B-ABBREVIATION 
consumption O 
within O 
neurons O 
is O 
the O 
primary O 
source O 
of O 
adenosine B-TRIVIAL 
in O 
neuronal O 
cultures O 
, O 
but O 
not O 
in O 
hippocampal O 
slices O 
or O 
in O 
vivo O 
mice O 
exposed O 
to O 
ischemic O 
conditions O 
. O 

toxicity O 
of O 
the O 
N-hydroxy B-SYSTEMATIC 
and O 
6-hydroxy B-SYSTEMATIC 
metabolites O 
of O 
3,4-dichloropropionanilide B-SYSTEMATIC 
does O 
not O 
depend O 
on O 
calcium B-SYSTEMATIC 
release O 
- O 
activated O 
calcium B-SYSTEMATIC 
channel O 
inhibition O 
. O 

year O 
~1 O 
billion O 
kg O 
of O 
herbicides O 
are O 
used O 
worldwide O 
to O 
control O 
the O 
unwanted O 
growth O 
of O 
plants O 
. O 
In O 
the O 
United O 
States O 
, O 
over O 
a O 
quarter O 
of O 
a O 
billion O 
kg O 
of O 
herbicides O 
are O 
used O 
, O 
representing O 
28% O 
of O 
worldwide O 
use O 
. O 
( O 
Kiely O 
, O 
T O 
. O 
, O 
Donaldson O 
, O 
D O 
. O 
, O 
and O 
Grube O 
, O 
A O 
. O 
[ O 
2004 O 
] O 
. O 
Pesticide O 
Industry O 
Sales O 
and O 
Usage O 
. O 
2000 O 
and O 
2001 O 
Market O 
Estimates O 
. O 
Available O 
at O 
: O 
http O 
: O 
/ O 
/ O 
www.epa.gov O 
/ O 
pesticides O 
/ O 
pestsales O 
/ O 
01pestsales O 
/ O 
market_estimates2001.pdf O 
. O 
Accessed O 
October O 
25 O 
, O 
2012 O 
. O 
) O 
Propanil B-TRIVIAL 
( O 
3,4-dichloropropionanilide B-SYSTEMATIC 
[ O 
DCPA B-ABBREVIATION 
] O 
) O 
is O 
a O 
commonly O 
used O 
herbicide O 
in O 
the O 
United O 
States O 
, O 
with O 
2-4 O 
million O 
kg O 
applied O 
annually O 
to O 
2 O 
million O 
acres O 
of O 
crop O 
land O 
. O 
The O 
immunomodulatory O 
effects O 
of O 
DCPA B-ABBREVIATION 
have O 
been O 
well O 
documented O 
, O 
but O 
limited O 
data O 
are O 
available O 
on O 
the O 
effects O 
of O 
its O 
metabolites O 
. O 
( O 
Salazar O 
, O 
K O 
. O 
D O 
. O 
, O 
Ustyugova O 
, O 
I O 
. O 
V O 
. O 
, O 
Brundage O 
, O 
K O 
. O 
M O 
. O 
, O 
Barnett O 
, O 
J O 
. O 
B O 
. O 
, O 
and O 
Schafer O 
, O 
R O 
. O 
[ O 
2008 O 
] O 
. O 
A O 
review O 
of O 
the O 
immunotoxicity O 
of O 
the O 
pesticide O 
3,4-dichloropropionanalide B-SYSTEMATIC 
. O 
J O 
. O 
Toxicol O 
. O 
Environ O 
. O 
Health O 
B O 
Crit O 
. O 
Rev O 
. O 
11 O 
, O 
630-645 O 
. O 
) O 
In O 
mammals O 
, O 
hepatic O 
enzymes O 
metabolize O 
DCPA B-ABBREVIATION 
, O 
resulting O 
in O 
the O 
production O 
of O 
3,4-dichloroaniline B-SYSTEMATIC 
( O 
DCA B-ABBREVIATION 
) O 
. O 
Further O 
biotransformation O 
of O 
DCA B-ABBREVIATION 
leads O 
to O 
the O 
production O 
of O 
6-hydroxy-3,4-dichloroaniline B-SYSTEMATIC 
( O 
6OH-DCA B-SYSTEMATIC 
) O 
and O 
N-hydroxy-3,4-dichloroaniline B-SYSTEMATIC 
( O 
NOH-DCA B-SYSTEMATIC 
) O 
. O 
We O 
report O 
, O 
for O 
the O 
first O 
time O 
, O 
the O 
immunotoxic O 
effects O 
of O 
DCPA B-ABBREVIATION 
metabolites O 
on O 
T-cell O 
function O 
. O 
Human O 
Jurkat O 
T O 
cells O 
were O 
exposed O 
to O 
varying O 
concentrations O 
of O 
DCPA B-ABBREVIATION 
or O 
its O 
metabolites O 
and O 
assayed O 
for O 
effects O 
on O 
T-cell O 
function O 
. O 
In O 
addition O 
, O 
fluorine B-SYSTEMATIC 
analogs O 
of O 
DCPA B-ABBREVIATION 
and O 
DCA B-ABBREVIATION 
were O 
investigated O 
to O 
determine O 
the O 
relative O 
role O 
of O 
chlorine B-SYSTEMATIC 
substituents O 
on O 
T-cell O 
immunotoxicity O 
. O 
Here O 
we O 
report O 
that O 
exposure O 
of O 
Jurkat O 
T O 
cells O 
to O 
DCPA B-ABBREVIATION 
and O 
DCA B-ABBREVIATION 
alters O 
IL-2 O 
secretion O 
, O 
nuclear O 
factor O 
of O 
activated O 
T O 
cells O 
( O 
NFAT O 
) O 
activity O 
, O 
and O 
calcium B-SYSTEMATIC 
influx O 
. O 
However O 
, O 
exposure O 
to O 
6OH-DCA B-SYSTEMATIC 
and O 
NOH-DCA B-SYSTEMATIC 
reduces O 
IL-2 O 
secretion O 
and O 
NFAT O 
activity O 
but O 
has O 
no O 
effect O 
on O 
calcium B-SYSTEMATIC 
flux O 
. O 
When O 
both O 
chlorines B-FAMILY 
in O 
DCPA B-ABBREVIATION 
and O 
DCA B-ABBREVIATION 
were O 
substituted O 
with O 
fluorines B-FAMILY 
all O 
effects O 
were O 
abrogated O 
. O 
Our O 
data O 
indicate O 
that O 
metabolites O 
of O 
DCPA B-ABBREVIATION 
have O 
differential O 
effects O 
on O 
T-cell O 
function O 
and O 
the O 
presence O 
of O 
chlorines B-FAMILY 
plays O 
an O 
important O 
role O 
in O 
eliciting O 
these O 
effects O 
. O 

and O 
quantification O 
of O 
[(18)F]DPA-714 B-SYSTEMATIC 
, O 
a O 
new O 
TSPO O 
positron O 
emission O 
tomography O 
radioligand O 
. O 

[ O 
N,N-diethyl-2-(2-(4-(2[(18)F]-fluoroethoxy)phenyl)5,7dimethylpyrazolo[1,5a]pyrimidin-3-yl)acetamide B-SYSTEMATIC 
] O 
is O 
a O 
new O 
radioligand O 
currently O 
used O 
for O 
imaging O 
the O 
18-kDa O 
translocator O 
protein O 
in O 
animal O 
models O 
of O 
neuroinflammation O 
and O 
recently O 
in O 
humans O 
. O 
The O 
biodistribution O 
by O 
positron O 
emission O 
tomography O 
( O 
PET O 
) O 
in O 
baboons O 
and O 
the O 
in O 
vitro O 
and O 
in O 
vivo O 
metabolism O 
of O 
[(18)F]DPA-714 B-SYSTEMATIC 
were O 
investigated O 
in O 
rats O 
, O 
baboons O 
, O 
and O 
humans O 
. O 
Whole O 
- O 
body O 
PET O 
experiments O 
showed O 
a O 
high O 
uptake O 
of O 
radioactivity O 
in O 
the O 
kidneys O 
, O 
heart O 
, O 
liver O 
, O 
and O 
gallbladder O 
. O 
The O 
liver O 
was O 
a O 
major O 
route O 
of O 
elimination O 
of O 
[(18)F]DPA-714 B-SYSTEMATIC 
, O 
and O 
urine O 
was O 
a O 
route O 
of O 
excretion O 
for O 
radiometabolites O 
. O 
In O 
rat O 
and O 
baboon O 
plasma O 
, O 
high O 
- O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
metabolic O 
profiles O 
showed O 
three O 
major O 
radiometabolites O 
accounting O 
for O 
85% O 
and O 
89% O 
of O 
total O 
radioactivity O 
at O 
120 O 
minutes O 
after O 
injection O 
, O 
respectively O 
. O 
Rat O 
microsomal O 
incubations O 
and O 
analyses O 
by O 
liquid O 
chromatography O 
- O 
mass O 
spectrometry O 
( O 
LC-MS O 
) O 
identified O 
seven O 
metabolites O 
, O 
characterized O 
as O 
O-deethyl B-SYSTEMATIC 
, O 
hydroxyl B-SYSTEMATIC 
, O 
and O 
N-deethyl B-SYSTEMATIC 
derivatives O 
of O 
nonradioactive O 
DPA-714 B-IDENTIFIER 
, O 
two O 
of O 
them O 
having O 
the O 
same O 
retention O 
times O 
than O 
those O 
detected O 
in O 
rat O 
and O 
baboon O 
plasma O 
. O 
The O 
third O 
plasma O 
radiometabolite O 
was O 
suggested O 
to O 
be O 
a O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
compound O 
that O 
accounted O 
for O 
15% O 
of O 
the O 
rat O 
brain O 
radioactivity O 
. O 
O B-FORMULA 
-deethylation O 
led O 
to O 
a O 
nonradioactive O 
compound O 
and O 
[(18)F]fluoroacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
Human O 
CYP3A4 O 
and O 
CYP2D6 O 
were O 
shown O 
to O 
be O 
involved O 
in O 
the O 
oxidation O 
of O 
the O 
radioligand O 
. O 
Finally O 
an O 
easy O 
, O 
rapid O 
, O 
and O 
accurate O 
method O 
-- O 
indispensable O 
for O 
PET O 
quantitative O 
clinical O 
studies O 
-- O 
for O 
quantifying O 
[(18)F]DPA-714 B-SYSTEMATIC 
by O 
solid O 
- O 
phase O 
extraction O 
was O 
developed O 
. O 
In O 
vivo O 
, O 
an O 
extensive O 
metabolism O 
of O 
[(18)F]DPA-714 B-SYSTEMATIC 
was O 
observed O 
in O 
rats O 
and O 
baboons O 
, O 
identified O 
as O 
[(18)F]deethyl B-SYSTEMATIC 
, O 
[(18)F]hydroxyl B-SYSTEMATIC 
, O 
and O 
[(18)F]carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
derivatives O 
of O 
[(18)F]DPA-714 B-SYSTEMATIC 
. O 
The O 
main O 
route O 
of O 
excretion O 
of O 
the O 
unchanged O 
radioligand O 
in O 
baboons O 
was O 
hepatobiliary O 
while O 
that O 
of O 
radiometabolites O 
was O 
the O 
urinary O 
system O 
. O 

in O 
the O 
vitamin B-FAMILY 
D I-FAMILY 
receptor O 
gene O 
and O 
risk O 
of O 
autoimmune O 
thyroid O 
diseases O 
: O 
a O 
meta-analysis O 
. O 

and O 
genetic O 
factors O 
are O 
thought O 
to O 
be O 
involved O 
in O 
the O 
pathogenesis O 
of O 
autoimmune O 
thyroid O 
diseases O 
( O 
AITD O 
) O 
, O 
which O 
include O 
Graves' O 
disease O 
, O 
Hashimoto's O 
thyroiditis O 
. O 
Polymorphisms O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
receptor O 
( O 
VDR O 
) O 
were O 
implicated O 
in O 
AITDs O 
risk O 
. O 
To O 
date O 
, O 
many O 
studies O 
have O 
evaluated O 
the O 
association O 
between O 
a O 
functional O 
polymorphism O 
in O 
the O 
VDR O 
gene O 
and O 
AITDs O 
risk O 
; O 
however O 
, O 
the O 
result O 
is O 
still O 
ambiguous O 
and O 
inconclusive O 
. O 
To O 
address O 
the O 
association O 
of O 
VDR O 
gene O 
FokI O 
( O 
rs10735810 O 
) O 
, O 
TaqI O 
( O 
rs731236 O 
) O 
, O 
BsmI O 
( O 
rs1544410 O 
) O 
, O 
and O 
ApaI O 
( O 
rs7975232 O 
) O 
polymorphisms O 
with O 
AITD O 
risk O 
by O 
meta-analysis O 
. O 
By O 
searching O 
the O 
relevant O 
literature O 
, O 
a O 
total O 
of O 
eight O 
studies O 
were O 
identified O 
and O 
meta-analyzed O 
. O 
HWE O 
for O 
each O 
study O 
are O 
checked O 
. O 
Crude O 
odds O 
ratios O 
( O 
OR O 
) O 
with O 
95 O 
% O 
confidence O 
intervals O 
( O 
CIs O 
) O 
were O 
used O 
to O 
assess O 
the O 
strength O 
of O 
association O 
in O 
the O 
allele O 
polymorphism O 
, O 
codominant O 
model O 
, O 
dominant O 
model O 
, O 
and O 
recessive O 
model O 
. O 
The O 
result O 
indicates O 
that O 
the O 
BsmI O 
or O 
TaqI O 
polymorphisms O 
is O 
significantly O 
associated O 
with O 
AITD O 
risk O 
( O 
OR O 
= O 
0.801 O 
95 O 
% O 
CI O 
0.705 O 
, O 
0.91 O 
, O 
Pz O 
= O 
0.001 O 
for O 
B O 
vs O 
. O 
b O 
; O 
OR O 
= O 
0.854 O 
, O 
95 O 
% O 
CI O 
0.757 O 
, O 
0.963 O 
, O 
Pz O 
= O 
0.01 O 
for O 
t O 
vs O 
. O 
T O 
) O 
, O 
while O 
the O 
ApaI O 
or O 
FokI O 
polymorphism O 
do O 
not O 
. O 
In O 
the O 
subgroup O 
analysis O 
in O 
Europeans O 
, O 
the O 
decreased O 
risk O 
of O 
AITD O 
remained O 
for O 
the O 
B O 
or O 
t O 
variant O 
. O 
This O 
gene O 
- O 
based O 
analysis O 
indicates O 
that O 
, O 
based O 
on O 
current O 
evidence O 
from O 
published O 
studies O 
, O 
the O 
cumulative O 
effect O 
of O 
BsmI O 
or O 
TaqI O 
polymorphisms O 
in O 
VDR O 
is O 
significantly O 
associated O 
with O 
AITD O 
. O 

of O 
CD4 O 
/ O 
gp120 O 
inhibitors O 
by O 
thermodynamic O 
- O 
guided O 
alanine B-TRIVIAL 
-scanning O 
mutagenesis O 
. O 

protein O 
/ O 
protein O 
interactions O 
usually O 
trigger O 
signalling O 
processes O 
, O 
inhibitors O 
of O 
those O 
interactions O 
must O 
preclude O 
protein O 
binding O 
without O 
eliciting O 
the O 
signalling O 
process O 
themselves O 
. O 
To O 
accomplish O 
those O 
goals O 
, O 
small O 
molecules O 
need O 
to O 
target O 
those O 
protein O 
residues O 
that O 
contribute O 
the O 
most O 
to O 
binding O 
( O 
binding O 
hotspots O 
) O 
without O 
disturbing O 
those O 
residues O 
that O 
initiate O 
signalling O 
processes O 
( O 
allosteric O 
hotspots O 
) O 
. O 
The O 
availability O 
of O 
a O 
blueprint O 
identifying O 
binding O 
and O 
allosteric O 
hotspots O 
will O 
significantly O 
aid O 
inhibitor O 
design O 
and O 
optimization O 
. O 
In O 
this O 
study O 
, O 
we O 
show O 
that O 
in O 
some O 
situations O 
the O 
blueprint O 
can O 
be O 
constructed O 
by O 
combining O 
the O 
standard O 
technique O 
of O 
alanine B-TRIVIAL 
-scanning O 
mutagenesis O 
with O 
isothermal O 
titration O 
calorimetry O 
( O 
ITC O 
) O 
. O 
We O 
demonstrate O 
the O 
approach O 
by O 
developing O 
the O 
combined O 
binding O 
and O 
allosteric O 
hotspots O 
blueprint O 
for O 
CD4 O 
/ O 
gp120 O 
, O 
the O 
initial O 
interaction O 
leading O 
to O 
HIV-1 O 
cell O 
infection O 
. O 
A O 
major O 
finding O 
of O 
these O 
studies O 
is O 
that O 
not O 
all O 
binding O 
hotspots O 
are O 
allosteric O 
hotspots O 
opening O 
the O 
possibility O 
for O 
the O 
rational O 
design O 
of O 
inhibitors O 
and O 
antagonist O 
or O 
agonist O 
modulators O 
. O 

scan O 
of O 
an O 
immunosuppressive O 
peptide O 
( O 
CP O 
) O 
: O 
analysis O 
of O 
structure O 
- O 
function O 
relationships O 
. O 

peptide O 
is O 
a O 
hydrophobic O 
peptide O 
, O 
the O 
sequence O 
of O 
which O 
is O 
derived O 
from O 
the O 
T-cell O 
antigen O 
receptor O 
alpha-chain O 
transmembrane O 
region O 
. O 
Previous O 
studies O 
have O 
shown O 
that O 
core O 
peptide O 
can O 
inhibit O 
T-cell O 
- O 
mediated O 
immune O 
responses O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Here O 
, O 
we O 
report O 
the O 
role O 
each O 
constituent O 
amino B-FAMILY 
acid I-FAMILY 
plays O 
within O 
core O 
peptide O 
using O 
an O 
alanine B-TRIVIAL 
scan O 
and O 
the O 
amino B-FAMILY 
acid I-FAMILY 
effect O 
on O 
function O 
using O 
a O 
biological O 
antigen O 
presentation O 
assay O 
. O 
The O 
biophysical O 
behaviour O 
of O 
these O 
analogues O 
in O 
model O 
membranes O 
was O 
analysed O 
using O 
surface O 
plasmon O 
resonance O 
studies O 
and O 
then O 
binding O 
correlated O 
with O 
T-cell O 
function O 
. O 
Removal O 
of O 
any O 
single O 
hydrophobic O 
amino B-FAMILY 
acid I-FAMILY 
between O 
the O 
two O 
charged O 
amino B-FAMILY 
acids I-FAMILY 
in O 
core O 
peptide O 
( O 
R O 
, O 
K O 
) O 
resulted O 
in O 
lower O 
binding O 
. O 
Changing O 
the O 
overall O 
net O 
charge O 
of O 
core O 
peptide O 
, O 
by O 
removing O 
either O 
of O 
the O 
positively O 
charged O 
residues O 
( O 
R O 
or O 
K O 
) O 
, O 
had O 
varying O 
effects O 
on O 
peptide O 
binding O 
and O 
IL-2 O 
production O 
. O 
There O 
was O 
a O 
direct O 
correlation O 
( O 
ρ O 
= O 
0.718 O 
) O 
between O 
peptide O 
binding O 
to O 
model O 
membranes O 
and O 
peptide O 
ability O 
to O 
inhibit O 
IL-2 O 
. O 
Except O 
for O 
IL-2 O 
inhibition O 
, O 
production O 
of O 
other O 
T-cell O 
cytokines O 
such O 
as O 
GM-CSF O 
, O 
IFN-γ O 
, O 
IL-1α O 
, O 
IL-4 O 
, O 
IL-5 O 
, O 
IL-6 O 
, O 
IL-10 O 
, O 
IL-17 O 
and O 
T-cell O 
antigen O 
receptor O 
alpha-chain O 
was O 
not O 
detected O 
using O 
a O 
fluorescent O 
bead O 
immunoassay O 
. O 
This O 
study O 
provides O 
important O 
structure O 
- O 
function O 
relationships O 
essential O 
for O 
further O 
drug O 
design O 
. O 

probes O 
designed O 
to O 
monitor O 
or O 
perturb O 
signaling O 
events O 
in O 
living O 
cells O 
rely O 
on O 
engineered O 
molecular O 
switches O 
. O 
Here O 
, O 
we O 
show O 
that O 
a O 
kinase O 
- O 
inducible O 
bimolecular O 
switch O 
comprising O 
a O 
kinase O 
- O 
specific O 
substrate O 
and O 
a O 
phosphoamino B-SYSTEMATIC 
acid I-SYSTEMATIC 
binding O 
domain O 
can O 
be O 
used O 
for O 
acute O 
regulation O 
of O 
cellular O 
events O 
. O 
As O 
a O 
proof O 
of O 
concept O 
, O 
we O 
employed O 
a O 
Protein O 
Kinase O 
A O 
(PKA)-dependent O 
switch O 
and O 
coupled O 
it O 
to O 
a O 
lipid O 
phosphatase O 
to O 
manipulate O 
the O 
level O 
of O 
phosphatidylinositol B-TRIVIAL 
4,5-bisphosphate I-TRIVIAL 
( O 
PI(4,5)P(2) B-SYSTEMATIC 
) O 
in O 
living O 
cells O 
. O 
PKA O 
activation O 
results O 
in O 
rapid O 
degradation O 
of O 
PI(4,5)P(2) B-SYSTEMATIC 
. O 
Conversely O 
, O 
when O 
PKA O 
is O 
inhibited O 
, O 
dephosphorylation O 
of O 
the O 
switch O 
leads O 
to O 
the O 
replenishment O 
of O 
PI(4,5)P(2) B-SYSTEMATIC 
. O 
Thus O 
, O 
this O 
strategy O 
can O 
be O 
used O 
for O 
reversibly O 
controlling O 
enzymatic O 
action O 
in O 
living O 
cells O 
. O 
Furthermore O 
, O 
its O 
genetic O 
encodability O 
and O 
modular O 
design O 
should O 
facilitate O 
the O 
adaptation O 
of O 
this O 
approach O 
to O 
control O 
different O 
cellular O 
activities O 
as O 
a O 
function O 
of O 
phosphorylation O 
- O 
dependent O 
input O 
signals O 
, O 
thereby O 
providing O 
versatile O 
tools O 
for O 
potentially O 
perturbing O 
or O 
rewiring O 
signaling O 
pathways O 
. O 

, O 
synthesis O 
, O 
and O 
in O 
vitro O 
evaluation O 
of O 
new O 
amphiphilic O 
cyclodextrin O 
- O 
based O 
nanoparticles O 
for O 
the O 
incorporation O 
and O 
controlled O 
release O 
of O 
acyclovir B-TRIVIAL 
. O 

possesses O 
low O 
solubility O 
in O 
water O 
and O 
in O 
lipid O 
bilayers O 
, O 
so O 
that O 
its O 
dosage O 
forms O 
do O 
not O 
allow O 
suitable O 
drug O 
levels O 
at O 
target O 
sites O 
following O 
oral O 
, O 
local O 
, O 
or O 
parenteral O 
administration O 
. O 
In O 
order O 
to O 
improve O 
this O 
lack O 
of O 
solubility O 
, O 
new O 
cyclodextrin O 
- O 
based O 
amphiphilic O 
derivatives O 
have O 
been O 
designed O 
to O 
form O 
nanoparticles O 
, O 
allowing O 
the O 
efficient O 
encapsulation O 
of O 
this O 
hydrophobic O 
antiviral O 
agent O 
. O 
The O 
present O 
work O 
first O 
describes O 
the O 
synthesis O 
and O 
characterization O 
of O 
five O 
new O 
O-2,O-3 B-MULTIPLE 
permethylated I-MULTIPLE 
O-6 I-MULTIPLE 
alkylthio- I-MULTIPLE 
and I-MULTIPLE 
perfluoroalkyl-propanethio I-MULTIPLE 
- I-MULTIPLE 
amphiphilic I-MULTIPLE 
β-cyclodextrins I-MULTIPLE 
. O 
These O 
derivatives O 
have O 
been O 
obtained O 
with O 
good O 
overall O 
yields O 
. O 
The O 
capacity O 
of O 
these O 
molecules O 
to O 
form O 
nanoparticles O 
in O 
water O 
and O 
to O 
encapsulate O 
acyclovir B-TRIVIAL 
has O 
then O 
been O 
studied O 
. O 
The O 
nanoparticles O 
prepared O 
from O 
the O 
new O 
β-cyclodextrin B-TRIVIAL 
derivatives O 
have O 
been O 
characterized O 
by O 
dynamic O 
light O 
scattering O 
and O 
have O 
an O 
average O 
size O 
of O 
120nm O 
for O 
the O 
fluorinated O 
derivatives O 
and O 
220nm O 
for O 
the O 
hydrogenated O 
analogs O 
. O 
They O 
all O 
allowed O 
high O 
loading O 
and O 
sustained O 
release O 
of O 
acyclovir B-TRIVIAL 
. O 

protects O 
cultured O 
cortical O 
neurons O 
against O 
excitotoxic O 
death O 
. O 

( O 
FTY720 B-IDENTIFIER 
) O 
, O 
a O 
novel O 
drug O 
approved O 
for O 
the O 
treatment O 
of O 
relapsing O 
- O 
remitting O 
multiple O 
sclerosis O 
, O 
activates O 
different O 
sphingosine-1-phosphate B-SYSTEMATIC 
receptor O 
( O 
S1PR O 
) O 
subtypes O 
. O 
Its O 
primary O 
mechanism O 
of O 
action O 
is O 
to O 
reduce O 
the O 
egress O 
of O 
T O 
lymphocytes O 
from O 
secondary O 
lymphoid O 
organs O 
, O 
thus O 
restraining O 
neuroinflammation O 
and O 
autoimmunity O 
. O 
However O 
, O 
recent O 
evidence O 
suggests O 
that O 
the O 
action O 
of O 
FTY720 B-IDENTIFIER 
involves O 
S1PRs O 
expressed O 
by O 
cells O 
resident O 
in O 
the O 
CNS O 
, O 
including O 
neurons O 
. O 
Here O 
, O 
we O 
examined O 
the O 
effect O 
of O 
FTY720 B-IDENTIFIER 
, O 
its O 
active O 
metabolite O 
, O 
FTY720-P B-IDENTIFIER 
, O 
and O 
sphingosine-1-phosphate B-SYSTEMATIC 
( O 
S1P B-ABBREVIATION 
) O 
on O 
neuronal O 
viability O 
using O 
a O 
classical O 
in O 
vitro O 
model O 
of O 
excitotoxic O 
neuronal O 
death O 
. O 
Mixed O 
cultures O 
of O 
mouse O 
cortical O 
cells O 
were O 
challenged O 
with O 
toxic O 
concentrations O 
of O 
N-methyl-d-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
for O 
10 O 
min O 
, O 
and O 
neuronal O 
death O 
was O 
assessed O 
20 O 
h O 
later O 
. O 
FTY720 B-IDENTIFIER 
, O 
FTY720-P B-IDENTIFIER 
, O 
and O 
S1P B-ABBREVIATION 
were O 
all O 
neuroprotective O 
when O 
applied O 
18-20 O 
h O 
prior O 
to O 
the O 
NMDA B-ABBREVIATION 
pulse O 
. O 
Neuroprotection O 
was O 
attenuated O 
by O 
pertussis O 
toxin O 
, O 
and O 
inhibited O 
by O 
the O 
selective O 
type-1 O 
S1PR O 
( O 
S1P1R O 
) O 
antagonist O 
, O 
W146 B-IDENTIFIER 
, O 
and O 
by O 
inhibitors O 
of O 
the O 
mitogen O 
associated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
and O 
the O 
phosphatidylinositol B-TRIVIAL 
-3-kinase O 
( O 
PtdIns-3-K O 
) O 
pathways O 
. O 
Both O 
FTY720 B-IDENTIFIER 
and O 
FTY720-P B-IDENTIFIER 
retained O 
their O 
protective O 
activity O 
in O 
pure O 
cultures O 
of O 
mouse O 
or O 
rat O 
cortical O 
neurons O 
. O 
These O 
data O 
offer O 
the O 
first O 
direct O 
demonstration O 
that O 
FTY720 B-IDENTIFIER 
and O 
its O 
active O 
metabolite O 
protect O 
neurons O 
against O 
excitotoxic O 
death O 
. O 

topography O 
can O 
play O 
a O 
significant O 
role O 
in O 
regulating O 
cellular O 
function O 
and O 
fate O 
. O 
To O 
study O 
cellular O 
responses O 
to O 
biophysical O 
cues O 
, O 
researchers O 
have O 
developed O 
dynamic O 
methods O 
for O 
controlling O 
cell O 
morphology O 
; O 
however O 
, O 
many O 
of O 
these O 
platforms O 
are O 
limited O 
to O 
one O 
transition O 
between O 
two O 
predefined O 
substratum O 
topographies O 
. O 
To O 
afford O 
the O 
user O 
additional O 
control O 
over O 
the O 
presentation O 
of O 
microtopographic O 
cues O 
to O 
cell O 
populations O 
, O 
a O 
photolabile O 
, O 
PEG B-ABBREVIATION 
-based O 
hydrogel O 
system O 
is O 
presented O 
in O 
which O 
precisely O 
engineered O 
topographic O 
cues O 
can O 
be O 
formed O 
in O 
situ O 
by O 
controlled O 
erosion O 
. O 
Here O 
, O 
the O 
ability O 
to O 
produce O 
precisely O 
engineered O 
static O 
microtopographies O 
in O 
the O 
hydrogel O 
surface O 
is O 
first O 
established O 
. O 
Human O 
mesenchymal O 
stem O 
cell O 
( O 
hMSC O 
) O 
response O 
to O 
topographies O 
with O 
features O 
of O 
subcellular O 
dimensions O 
( O 
~5 O 
to O 
40 O 
μm O 
) O 
and O 
with O 
various O 
aspect O 
ratios O 
increasing O 
from O 
1 O 
: O 
1 O 
to O 
infinity O 
( O 
e.g O 
. O 
, O 
channels O 
) O 
are O 
quantified O 
, O 
and O 
the O 
dynamic O 
nature O 
of O 
the O 
culture O 
system O 
is O 
demonstrated O 
by O 
sequentially O 
presenting O 
a O 
series O 
of O 
topographies O 
through O 
in O 
situ O 
modifications O 
and O 
quantifying O 
reversible O 
changes O 
in O 
cell O 
morphology O 
in O 
response O 
to O 
substratum O 
topographies O 
altered O 
in O 
real O 
time O 
. O 

acid O 
modified O 
mesoporous O 
silica B-TRIVIAL 
nanoparticles O 
for O 
targeted O 
drug O 
delivery O 
to O 
CD44-overexpressing O 
cancer O 
cells O 
. O 

this O 
paper O 
, O 
a O 
targeted O 
drug O 
delivery O 
system O 
has O 
been O 
developed O 
based O 
on O 
hyaluronic O 
acid O 
( O 
HA O 
) O 
modified O 
mesoporous O 
silica B-TRIVIAL 
nanoparticles O 
( O 
MSNs O 
) O 
. O 
HA-MSNs O 
possess O 
a O 
specific O 
affinity O 
to O 
CD44 O 
over O 
- O 
expressed O 
on O 
the O 
surface O 
of O 
a O 
specific O 
cancer O 
cell O 
line O 
, O 
HCT-116 O 
( O 
human O 
colon O 
cancer O 
cells O 
) O 
. O 
The O 
cellular O 
uptake O 
performance O 
of O 
fluorescently O 
labelled O 
MSNs O 
with O 
and O 
without O 
HA O 
modification O 
has O 
been O 
evaluated O 
by O 
confocal O 
microscopy O 
and O 
fluorescence O 
- O 
activated O 
cell O 
sorter O 
( O 
FACS O 
) O 
analysis O 
. O 
Compared O 
to O 
bare O 
MSNs O 
, O 
HA-MSNs O 
exhibit O 
a O 
higher O 
cellular O 
uptake O 
via O 
HA O 
receptor O 
mediated O 
endocytosis O 
. O 
An O 
anticancer O 
drug O 
, O 
doxorubicin B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
Dox B-ABBREVIATION 
) O 
, O 
has O 
been O 
loaded O 
into O 
MSNs O 
and O 
HA-MSNs O 
as O 
drug O 
delivery O 
vehicles O 
. O 
Dox B-ABBREVIATION 
loaded O 
HA-MSNs O 
show O 
greater O 
cytotoxicity O 
to O 
HCT-116 O 
cells O 
than O 
free O 
Dox B-ABBREVIATION 
and O 
Dox B-ABBREVIATION 
-MSNs O 
due O 
to O 
the O 
enhanced O 
cell O 
internalization O 
behavior O 
of O 
HA-MSNs O 
. O 
It O 
is O 
expected O 
that O 
HA-MSNs O 
have O 
a O 
great O 
potential O 
in O 
targeted O 
delivery O 
of O 
anticancer O 
drugs O 
to O 
CD44 O 
over O 
- O 
expressing O 
tumors O 
. O 

in O 
vitro O 
model O 
simulating O 
the O 
intestinal O 
barrier O 
for O 
efficacy O 
and O 
drug O 
interaction O 
testing O 
of O 
mycotoxin O 
detoxifying O 
agents O 
was O 
developed O 
using O 
Transwell O 
® O 
cell O 
culture O 
inserts O 
. O 
Intestinal O 
porcine O 
epithelial O 
cells O 
derived O 
from O 
the O 
jejunum O 
of O 
piglets O 
were O 
exposed O 
to O 
DON O 
and O 
a O 
mycotoxin O 
binder O 
( O 
efficacy O 
testing O 
) O 
or O 
exposed O 
to O 
tylosin B-TRIVIAL 
and O 
a O 
mycotoxin O 
binder O 
( O 
drug O 
interaction O 
testing O 
) O 
. O 
Active O 
carbon B-SYSTEMATIC 
and O 
bentonite B-FAMILY 
were O 
used O 
in O 
the O 
efficacy O 
and O 
drug O 
interaction O 
trials O 
, O 
respectively O 
, O 
to O 
validate O 
the O 
developed O 
model O 
. O 
The O 
evaluated O 
parameters O 
were O 
passage O 
of O 
DON B-ABBREVIATION 
and O 
tylosin B-TRIVIAL 
through O 
the O 
epithelial O 
monolayer O 
, O 
the O 
integrity O 
of O 
the O 
monolayer O 
by O 
measurements O 
of O 
the O 
trans-epithelial O 
electrical O 
resistance O 
and O 
the O 
viability O 
of O 
the O 
monolayer O 
using O 
the O 
neutral B-TRIVIAL 
red I-TRIVIAL 
assay O 
. O 
In O 
the O 
efficacy O 
model O 
it O 
was O 
shown O 
that O 
active O 
carbon B-SYSTEMATIC 
effectively O 
bound O 
DON B-ABBREVIATION 
at O 
both O 
non-cytotoxic O 
and O 
cytotoxic O 
concentrations O 
of O 
DON B-ABBREVIATION 
, O 
respectively O 
0.5 O 
and O 
1 O 
μg O 
/ O 
mL O 
. O 
Moreover O 
, O 
the O 
negative O 
effects O 
of O 
DON B-ABBREVIATION 
at O 
cytotoxic O 
concentrations O 
on O 
cellular O 
viability O 
and O 
integrity O 
were O 
completely O 
offset O 
. O 
A O 
commercially O 
available O 
modified O 
gluco-mannan O 
binder O 
was O 
also O 
tested O 
and O 
it O 
was O 
able O 
to O 
partly O 
reduce O 
the O 
negative O 
effects O 
on O 
these O 
latter O 
parameter O 
. O 
Moreover O 
, O 
it O 
reduced O 
the O 
transepithelial O 
passage O 
of O 
DON B-ABBREVIATION 
with O 
37% O 
to O 
57% O 
compared O 
to O 
active O 
carbon B-SYSTEMATIC 
, O 
at O 
both O 
cytotoxic O 
and O 
non-cytotoxic O 
concentrations O 
of O 
DON B-ABBREVIATION 
. O 
In O 
our O 
drug O 
interaction O 
model O 
, O 
the O 
interaction O 
between O 
tylosin B-TRIVIAL 
and O 
mycotoxin O 
binders O 
was O 
investigated O 
as O 
some O 
authors O 
suggest O 
binding O 
of O 
macrolide B-FAMILY 
antibiotics O 
to O 
bentonite B-FAMILY 
clays O 
. O 
Indeed O 
, O 
a O 
bentonite B-FAMILY 
clay O 
showed O 
decreased O 
passage O 
of O 
tylosin B-TRIVIAL 
through O 
the O 
epithelial O 
monolayer O 
, O 
indicating O 
binding O 
of O 
tylosin B-TRIVIAL 
by O 
bentonite B-FAMILY 
. O 
This O 
indicates O 
that O 
the O 
combined O 
use O 
of O 
bentonite B-FAMILY 
and O 
tylosin B-TRIVIAL 
in O 
the O 
feed O 
could O 
lead O 
to O 
therapy O 
failure O 
. O 
The O 
modified O 
gluco-mannan O 
binder O 
did O 
not O 
alter O 
the O 
passage O 
of O 
tylosin B-TRIVIAL 
significantly O 
, O 
indicating O 
safe O 
combined O 
use O 
. O 

arginine B-TRIVIAL 
and O 
GHRP-2 O 
tests O 
as O 
alternatives O 
to O 
the O 
insulin O 
tolerance O 
test O 
for O 
the O 
diagnosis O 
of O 
adult O 
GH O 
deficiency O 
in O 
Japanese O 
patients O 
: O 
a O 
comparison O 
. O 

arginine B-TRIVIAL 
+ O 
GHRH O 
test O 
has O 
been O 
established O 
as O 
an O 
alternative O 
to O 
the O 
insulin O 
tolerance O 
test O 
( O 
ITT O 
) O 
for O 
the O 
diagnosis O 
of O 
adult O 
GH O 
deficiency O 
( O 
AGHD O 
) O 
. O 
However O 
, O 
the O 
glucagon O 
, O 
arginine B-TRIVIAL 
, O 
and O 
GH O 
releasing O 
peptide-2 O 
( O 
GHRP-2 O 
) O 
test O 
are O 
recommended O 
as O 
alternatives O 
in O 
Japan O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
arginine B-TRIVIAL 
and O 
GHRP-2 O 
tests O 
as O 
alternatives O 
to O 
the O 
ITT O 
for O 
the O 
diagnosis O 
of O 
AGHD O 
in O 
a O 
Japanese O 
population O 
. O 
Three O 
stimulation O 
tests O 
( O 
ITT O 
, O 
arginine B-TRIVIAL 
test O 
, O 
and O 
GHRP-2 O 
test O 
) O 
were O 
conducted O 
in O 
71 O 
pre O 
- O 
operative O 
adult O 
patients O 
with O 
pituitary O 
tumors O 
( O 
age O 
, O 
18-65 O 
years O 
) O 
. O 
The O 
peak O 
GH O 
responses O 
to O 
each O 
test O 
were O 
examined O 
. O 
The O 
peak O 
GH O 
responses O 
were O 
significantly O 
lower O 
with O 
the O 
ARG B-FORMULA 
test O 
( O 
median O 
4.43 O 
μg O 
/ O 
L O 
) O 
( O 
p O 
< O 
0.0001 O 
) O 
than O 
with O 
the O 
ITT O 
( O 
median O 
9.38 O 
μg O 
/ O 
L O 
) O 
, O 
and O 
the O 
peak O 
GH O 
responses O 
with O 
the O 
GHRP-2 O 
test O 
( O 
median O 
28.88 O 
μg O 
/ O 
L O 
) O 
were O 
higher O 
( O 
p O 
< O 
0.0001 O 
) O 
. O 
However O 
, O 
among O 
the O 
AGHD O 
patients O 
, O 
there O 
was O 
no O 
significant O 
difference O 
between O 
the O 
peak O 
GH O 
responses O 
to O 
the O 
ARG B-FORMULA 
test O 
and O 
the O 
ITT O 
. O 
The O 
sensitivities O 
and O 
specificities O 
of O 
the O 
ARG B-FORMULA 
/ O 
GHRP-2 O 
tests O 
compared O 
to O 
the O 
ITT O 
for O 
the O 
diagnosis O 
of O 
severe O 
AGHD O 
( O 
peak O 
GH O 
responses O 
to O 
ITT O 
≤ O 
1.8 O 
μg O 
/ O 
L O 
) O 
were O 
93.8% O 
/ O 
81.3% O 
and O 
85.5% O 
/ O 
94.5% O 
, O 
respectively O 
. O 
The O 
arginine B-TRIVIAL 
and O 
GHRP-2 O 
stimulation O 
tests O 
are O 
acceptable O 
alternatives O 
to O 
the O 
ITT O 
for O 
the O 
diagnosis O 
of O 
AGHD O 
in O 
Japanese O 
patients O 
. O 
The O 
method O 
and O 
criterion O 
for O 
the O 
diagnosis O 
of O 
AGHD O 
should O 
be O 
reconsidered O 
and O 
adjusted O 
to O 
each O 
population O 
. O 

preparation O 
of O 
methyl B-SYSTEMATIC 
bis(2,2,2-trifluoroethoxy)-bromophosphonoacetate I-SYSTEMATIC 
for O 
the O 
stereoselective O 
synthesis O 
of O 
(E)-α-bromoacrylates B-FAMILY 
. O 

have O 
established O 
an O 
efficient O 
method O 
for O 
preparing O 
methyl B-SYSTEMATIC 
bis(2,2,2-trifluoroethoxy)bromophosphonoacetate I-SYSTEMATIC 
, O 
which O 
we O 
developed O 
for O 
the O 
stereoselective O 
synthesis O 
of O 
(E)-α-bromoacrylates B-FAMILY 
. O 
This O 
improved O 
method O 
enables O 
the O 
reagent O 
to O 
be O 
prepared O 
reproducibly O 
in O 
one O 
step O 
from O 
methyl B-SYSTEMATIC 
bis(2,2,2-trifluoroethoxy)phosphonoacetate I-SYSTEMATIC 
. O 

- O 
TiO(2) B-FORMULA 
@ O 
MnO(2) B-FORMULA 
// O 
H B-FORMULA 
- O 
TiO(2) B-FORMULA 
@ O 
C B-FORMULA 
core O 
- O 
shell O 
nanowires O 
for O 
high O 
performance O 
and O 
flexible O 
asymmetric O 
supercapacitors O 
. O 

flexible O 
solid O 
- O 
state O 
asymmetric O 
supercapacitor O 
device O 
with O 
H B-FORMULA 
- O 
TiO(2) B-FORMULA 
@ O 
MnO(2) B-FORMULA 
core O 
- O 
shell O 
NWs O 
as O 
the O 
positive O 
electrode O 
and O 
H B-FORMULA 
- O 
TiO(2) B-FORMULA 
@ O 
C B-FORMULA 
core O 
- O 
shell O 
NWs O 
as O 
the O 
negative O 
electrode O 
is O 
developed O 
. O 
This O 
device O 
operates O 
in O 
a O 
1.8 O 
V O 
voltage O 
window O 
and O 
is O 
able O 
to O 
deliver O 
a O 
high O 
specific O 
capacitance O 
of O 
139.6 O 
F O 
g(-1) O 
and O 
maximum O 
volumetric O 
energy O 
density O 
of O 
0.3 O 
mWh O 
cm(-3) O 
with O 
excellent O 
cycling O 
performance O 
and O 
good O 
flexibility O 
. O 

- O 
lethal O 
effects O 
of O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
nanoparticles O 
on O 
the O 
physiology O 
and O 
reproduction O 
of O 
zebrafish O 
. O 

are O 
limited O 
data O 
on O 
the O 
sub O 
- O 
lethal O 
physiological O 
effects O 
of O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
nanoparticles O 
( O 
TiO(2) B-FORMULA 
NPs O 
) O 
in O 
adult O 
fishes O 
, O 
and O 
the O 
consequences O 
of O 
TiO(2) B-FORMULA 
NP O 
exposure O 
on O 
reproductive O 
success O 
are O 
also O 
unclear O 
. O 
This O 
study O 
aimed O 
to O 
examine O 
the O 
sub O 
- O 
lethal O 
effects O 
of O 
a O 
14-d O 
aqueous O 
TiO(2) B-FORMULA 
( O 
TiO(2) B-FORMULA 
NP O 
, O 
0.1 O 
or O 
1 O 
mg O 
l(-1) O 
; O 
TiO(2) B-FORMULA 
bulk O 
, O 
1 O 
mg O 
l(-1) O 
) O 
exposure O 
on O 
the O 
physiology O 
and O 
reproductive O 
health O 
of O 
zebrafish O 
. O 
After O 
the O 
14-d O 
exposure O 
, O 
fish O 
were O 
examined O 
for O 
haematology O 
, O 
whole O 
body O 
electrolyte O 
and O 
trace O 
metal O 
profiles O 
, O 
biochemistry O 
, O 
and O 
histopathology O 
. O 
Then O 
, O 
during O 
a O 
21-d O 
post O 
exposure O 
recovery O 
period O 
, O 
effects O 
of O 
the O 
TiO(2) B-FORMULA 
exposure O 
on O 
reproductive O 
success O 
were O 
evaluated O 
. O 
Whole O 
body O 
Ti B-FORMULA 
concentrations O 
increased O 
significantly O 
in O 
fish O 
exposed O 
to O 
both O 
the O 
1 O 
mg O 
l(-1) O 
TiO(2) B-FORMULA 
NP O 
and O 
bulk O 
TiO(2) B-FORMULA 
compared O 
to O 
controls O 
, O 
but O 
concentrations O 
returned O 
to O 
control O 
levels O 
by O 
the O 
end O 
of O 
the O 
recovery O 
period O 
. O 
No O 
change O 
in O 
erythrocyte O 
counts O 
were O 
observed O 
, O 
but O 
there O 
was O 
a O 
two O 
- O 
fold O 
decline O 
in O 
leukocyte O 
counts O 
in O 
all O 
TiO(2) B-FORMULA 
treatment O 
groups O 
relative O 
to O 
time O 
- O 
matched O 
controls O 
. O 
Whole O 
body O 
electrolyte O 
and O 
trace O 
metal O 
profiles O 
were O 
not O 
affected O 
by O 
exposure O 
to O 
TiO(2) B-FORMULA 
, O 
and O 
there O 
were O 
no O 
changes O 
in O 
Na(+) B-FORMULA 
K(+) B-FORMULA 
-ATPase O 
activity O 
in O 
brain O 
, O 
gill O 
or O 
liver O 
tissues O 
. O 
Total O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
levels O 
in O 
brain O 
, O 
gill O 
and O 
liver O 
tissues O 
were O 
higher O 
in O 
fish O 
exposed O 
to O 
TiO(2) B-FORMULA 
NP O 
( O 
both O 
0.1 O 
and O 
1 O 
mg O 
l(-1) O 
) O 
compared O 
to O 
bulk O 
TiO(2) B-FORMULA 
and O 
control O 
fish O 
. O 
Histological O 
examination O 
of O 
gill O 
, O 
liver O 
, O 
brain O 
and O 
gonad O 
tissues O 
showed O 
little O 
evidence O 
of O 
treatment O 
- O 
related O 
morphological O 
change O 
. O 
At O 
the O 
end O 
of O 
the O 
14-d O 
exposure O 
adult O 
zebrafish O 
were O 
able O 
to O 
reproduce O 
; O 
however O 
, O 
the O 
cumulative O 
number O 
of O 
viable O 
embryos O 
produced O 
was O 
lower O 
in O 
fish O 
exposed O 
to O 
1 O 
mg O 
l(-1) O 
TiO(2) B-FORMULA 
( O 
both O 
NP O 
and O 
bulk O 
) O 
by O 
the O 
end O 
of O 
the O 
21-d O 
recovery O 
period O 
. O 
Overall O 
, O 
this O 
study O 
showed O 
limited O 
toxicity O 
of O 
bulk O 
or O 
nano O 
scale O 
TiO(2) B-FORMULA 
during O 
the O 
exposure O 
; O 
however O 
reproduction O 
was O 
affected O 
in O 
both O 
bulk O 
and O 
NP O 
1 O 
mg O 
l(-1) O 
groups O 
. O 

effects O 
of O 
microcystin-LR B-TRIVIAL 
on O 
the O 
reproductive O 
system O 
of O 
male O 
Rana O 
nigromaculata O 
in O 
vitro O 
. O 

study O 
aims O 
to O 
demonstrate O 
that O 
microcystin-LR B-TRIVIAL 
( O 
MC-LR B-ABBREVIATION 
) O 
has O 
toxic O 
effects O 
on O 
the O 
reproductive O 
system O 
of O 
male O 
Rana O 
nigromaculata O 
in O 
vitro O 
. O 
R O 
. O 
nigromaculata O 
were O 
treated O 
with O 
0 O 
, O 
0.1 O 
, O 
1 O 
, O 
10 O 
, O 
and O 
100 O 
nmol O 
/ O 
L O 
of O 
MC-LR O 
for O 
6 O 
h O 
. O 
Results O 
show O 
that O 
exposure O 
to O 
1 O 
nmol O 
/ O 
L O 
to O 
100 O 
nmol O 
/ O 
L O 
of O 
MC-LR B-ABBREVIATION 
decreased O 
sperm O 
motility O 
and O 
number O 
of O 
sperm O 
cells O 
and O 
increased O 
the O 
sperm O 
abnormality O 
rate O 
, O 
whose O 
values O 
were O 
significantly O 
different O 
from O 
those O 
of O 
the O 
control O 
( O 
P O 
< O 
0.01 O 
) O 
. O 
Moreover O 
, O 
the O 
same O 
dosage O 
of O 
MC-LR B-ABBREVIATION 
increased O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
production O 
and O 
malondialdehyde B-TRIVIAL 
content O 
. O 
At O 
the O 
same O 
time O 
, O 
antioxidant O 
enzyme O 
( O 
catalase O 
and O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
) O 
activity O 
and O 
glutathione B-TRIVIAL 
reduced O 
content O 
rapidly O 
increased O 
, O 
whereas O 
antioxidant O 
enzyme O 
superoxide B-TRIVIAL 
dismutase O 
activity O 
significantly O 
decreased O 
. O 
These O 
results O 
imply O 
that O 
the O 
defense O 
system O 
of O 
the O 
testes O 
quickly O 
responds O 
to O 
oxidative O 
stress O 
. O 
Ultrastructural O 
observation O 
shows O 
distention O 
of O 
the O 
mitochondria O 
, O 
endoplasmic O 
reticulum O 
, O 
and O 
Golgi O 
apparatus O 
and O 
changes O 
in O 
the O 
mitochondrial O 
matrix O 
color O 
, O 
cristae O 
number O 
, O 
and O 
morphology O 
. O 
Moreover O 
, O 
using O 
real O 
- O 
time O 
PCR O 
, O 
increased O 
relative O 
expressions O 
of O 
P450 O 
aromatase O 
and O 
SF-1 O 
genes O 
were O 
observed O 
. O 
The O 
results O 
demonstrate O 
for O 
the O 
first O 
time O 
that O 
MC-LR B-ABBREVIATION 
could O 
induce O 
toxicity O 
in O 
the O 
male O 
reproductive O 
system O 
of O 
R O 
. O 
nigromaculata O 
. O 
The O 
findings O 
in O 
this O 
research O 
will O 
provide O 
more O 
insights O 
into O 
the O 
relationships O 
between O 
aquatic O 
microcystins B-FAMILY 
and O 
amphibians O 
. O 

- O 
promoted O 
coating O 
of O 
silk O 
yarn O 
with O 
different O 
morphology O 
of O 
magnesium B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
nanostructures O 
. O 

growth O 
of O 
magnesium B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
nanostructures O 
on O 
silk O 
yarn O 
was O 
achieved O 
by O 
sequential O 
dipping O 
steps O 
in O 
alternating O 
bath O 
of O 
magnesium B-SYSTEMATIC 
nitrate I-SYSTEMATIC 
and O 
potassium B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
under O 
ultrasound O 
irradiation O 
. O 
The O 
effects O 
of O 
ultrasound O 
irradiation O 
, O 
concentration O 
, O 
pH O 
and O 
sequential O 
dipping O 
steps O 
on O 
growth O 
of O 
the O 
Mg(OH)(2) B-FORMULA 
nanostructures O 
have O 
been O 
studied O 
. O 
Morphology O 
of O 
the O 
nanostructures O 
, O 
depending O 
on O 
pH O 
and O 
with O 
decreasing O 
pH O 
from O 
13 O 
to O 
8 O 
, O 
changed O 
from O 
nanoparticle O 
to O 
nanoneedle O 
. O 
Results O 
show O 
a O 
decrease O 
in O 
the O 
particles O 
size O 
as O 
the O 
concentration O 
and O 
sequential O 
dipping O 
steps O 
increased O 
. O 
The O 
physicochemical O 
properties O 
of O 
the O 
nanostructures O 
were O 
determined O 
by O 
powder O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
, O 
scanning O 
electron O 
microscopy O 
( O 
SEM O 
) O 
and O 
wavelength O 
dispersive O 
X-ray O 
( O 
WDX O 
) O 
. O 

exposure O 
of O 
highly O 
toxic O 
aconitine B-TRIVIAL 
does O 
not O 
significantly O 
impact O 
the O 
activity O 
and O 
expression O 
of O 
cytochrome O 
P450 O 
3A O 
in O 
rats O 
determined O 
by O 
a O 
novel O 
ultra O 
performance O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometric O 
method O 
of O 
a O 
specific O 
probe O 
buspirone B-TRIVIAL 
. O 

species O 
are O 
widely O 
used O 
to O 
treat O 
rheumatism O 
, O 
cardiovascular O 
diseases O 
, O 
and O 
tumors O 
in O 
China O 
and O 
other O 
Asian O 
countries O 
. O 
The O 
herbs O 
are O 
always O 
used O 
with O 
drugs O 
such O 
as O 
paclitaxel B-TRIVIAL 
. O 
Aconitine B-TRIVIAL 
( O 
AC O 
) O 
is O 
one O 
of O 
the O 
main O 
bioactive O 
/ O 
high O 
- O 
toxic O 
alkaloids O 
of O 
Aconitum O 
roots O 
. O 
AC O 
is O 
metabolized O 
by O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
3A O 
. O 
However O 
, O 
whether O 
AC O 
inhibits O 
/ O 
induces O 
CYP3A O 
, O 
which O 
causes O 
drug O 
- O 
drug O 
interaction O 
( O 
DDI O 
) O 
is O 
unclear O 
. O 
Our O 
study O 
aims O 
to O 
explore O 
the O 
potent O 
effects O 
of O 
AC O 
, O 
as O 
a O 
marker O 
component O 
of O 
Aconitum O 
, O 
on O 
CYP3A O 
using O 
the O 
probe O 
buspirone B-TRIVIAL 
in O 
rats O 
. O 
The O 
effects O 
of O 
oral O 
AC O 
on O 
pharmacokinetics O 
of O 
buspirone B-TRIVIAL 
were O 
evaluated O 
. O 
CYP3A O 
activity O 
and O 
protein O 
levels O 
in O 
rat O 
liver O 
microsomes O 
pretreated O 
with O 
oral O 
AC O 
were O 
also O 
measured O 
using O 
in O 
vitro O 
buspirone B-TRIVIAL 
metabolism O 
and O 
Western O 
blot O 
. O 
Buspirone B-TRIVIAL 
and O 
its O 
major O 
metabolites O 
1-(2-pyrimidinyl)piperazine B-SYSTEMATIC 
and O 
6'-hydroxybuspirone B-SYSTEMATIC 
were O 
determined O 
using O 
a O 
newly O 
validated O 
UPLC-MS O 
/ O 
MS O 
method O 
. O 
Single O 
dose O 
and O 
7-day O 
AC O 
administration O 
at O 
0.125mg O 
/ O 
kg O 
had O 
no O 
effect O 
on O 
CYP3A O 
activity O 
since O 
no O 
change O 
in O 
the O 
formation O 
of O 
1-(2-pyrimidinyl)piperazine B-SYSTEMATIC 
and O 
6'-hydroxybuspirone B-SYSTEMATIC 
. O 
CYP3A O 
activity O 
and O 
protein O 
levels O 
in O 
liver O 
microsomes O 
were O 
also O 
not O 
affected O 
by O 
7-day O 
AC O 
pretreatment O 
at O 
0.125mg O 
/ O 
kg O 
. O 
Therefore O 
, O 
AC O 
neither O 
inhibits O 
nor O 
induces O 
CYP3A O 
in O 
rats O 
, O 
indicating O 
AC O 
does O 
not O 
cause O 
CYP3A O 
- O 
related O 
DDI O 
in O 
the O 
liver O 
. O 

the O 
past O 
four O 
decades O 
of O 
cholinesterase O 
( O 
ChE O 
) O 
research O 
, O 
we O 
have O 
seen O 
substantive O 
evolution O 
of O 
the O 
field O 
from O 
one O 
centered O 
around O 
substrate O 
and O 
inhibitor O 
kinetic O 
profiles O 
and O 
compound O 
characterizations O 
to O 
the O 
analysis O 
of O 
ChE O 
structure O 
, O 
first O 
through O 
the O 
gene O 
families O 
and O 
then O 
by O 
X-ray O 
crystallographic O 
determinations O 
of O 
the O 
free O 
enzymes O 
and O 
their O 
complexes O 
and O 
conjugates O 
. O 
Indeed O 
, O 
these O 
endeavors O 
have O 
been O 
facilitated O 
by O 
recombinant O 
DNA O 
technologies O 
, O 
structure O 
determinations O 
and O 
parallel O 
studies O 
in O 
related O 
proteins O 
in O 
the O 
α O 
/ O 
β-hydrolase O 
fold O 
family O 
. O 
This O 
approach O 
has O 
not O 
only O 
contributed O 
to O 
a O 
fundamental O 
understanding O 
of O 
structure O 
and O 
function O 
of O 
a O 
large O 
family O 
of O 
hydrolase O 
- O 
like O 
proteins O 
possessing O 
functions O 
other O 
than O 
catalysis O 
, O 
but O 
also O 
has O 
been O 
used O 
to O 
develop O 
new O 
practical O 
strategies O 
for O 
scavenging O 
and O 
antidotal O 
activity O 
in O 
cases O 
of O 
organophosphate B-FAMILY 
insecticide O 
or O 
nerve O 
agent O 
exposure O 
. O 

volatile O 
organophosphorous B-FAMILY 
nerve O 
agents O 
such O 
as O 
VX O 
, O 
will O 
most O 
likely O 
enter O 
the O 
body O 
via O 
the O 
skin O 
. O 
The O 
pharmacokinetics O 
of O 
drugs O 
such O 
as O 
oximes B-FAMILY 
, O 
atropine B-TRIVIAL 
and O 
diazepam B-TRIVIAL 
, O 
are O 
not O 
aligned O 
with O 
the O 
variable O 
and O 
persistent O 
toxicokinetics O 
of O 
the O 
agent O 
. O 
Repeated O 
administration O 
of O 
these O 
drugs O 
showed O 
to O 
improve O 
treatment O 
efficacy O 
compared O 
to O 
a O 
single O 
injection O 
treatment O 
. O 
Because O 
of O 
the O 
effectiveness O 
of O 
continuous O 
treatment O 
, O 
it O 
was O 
investigated O 
to O 
what O 
extent O 
a O 
subchronic O 
pretreatment O 
with O 
carbamate B-FAMILY 
( O 
pyridostigmine B-TRIVIAL 
or O 
physostigmine B-TRIVIAL 
combined O 
with O 
either O 
procyclidine B-TRIVIAL 
or O 
scopolamine B-TRIVIAL 
) O 
would O 
protect O 
against O 
percutaneous O 
VX O 
exposure O 
. O 
Inclusion O 
of O 
scopolamine B-TRIVIAL 
in O 
the O 
pretreatment O 
prevented O 
seizures O 
in O 
all O 
animals O 
, O 
but O 
none O 
of O 
the O 
pretreatments O 
affected O 
survival O 
time O 
or O 
the O 
onset O 
time O 
of O 
cholinergic O 
signs O 
. O 
These O 
results O 
indicate O 
that O 
percutaneous O 
poisoning O 
with O 
VX O 
requires O 
additional O 
conventional O 
treatment O 
in O 
addition O 
to O 
the O 
current O 
pretreatment O 
regimen O 
. O 
Decontamination O 
of O 
VX-exposed O 
skin O 
is O 
one O 
of O 
the O 
most O 
important O 
countermeasures O 
to O 
mitigate O 
the O 
effects O 
of O 
the O 
exposure O 
. O 
To O 
evaluate O 
the O 
window O 
of O 
opportunity O 
for O 
decontamination O 
, O 
the O 
fielded O 
skin O 
decontaminant O 
Reactive O 
Skin O 
Decontaminant O 
Lotion O 
( O 
RSDL O 
) O 
was O 
tested O 
at O 
different O 
times O 
in O 
hairless O 
guinea O 
pigs O 
percutaneously O 
challenged O 
with O 
4× O 
LD50 O 
VX O 
in O 
IPA B-ABBREVIATION 
. O 
The O 
results O 
showed O 
that O 
RSDL O 
decontamination O 
at O 
15min O 
after O 
exposure O 
could O 
not O 
prevent O 
progressive O 
blood O 
cholinesterase O 
inhibition O 
and O 
therefore O 
would O 
still O 
require O 
additional O 
treatment O 
. O 
A O 
similar O 
decontamination O 
regimen O 
with O 
RSDL O 
at O 
90min O 
showed O 
that O 
it O 
still O 
might O 
effectively O 
increase O 
the O 
time O 
window O 
of O 
opportunity O 
for O 
treatment O 
. O 
In O 
conclusion O 
, O 
the O 
delay O 
in O 
absorption O 
presents O 
a O 
window O 
of O 
opportunity O 
for O 
decontamination O 
and O 
treatment O 
. O 
The O 
continuous O 
release O 
of O 
VX O 
from O 
the O 
skin O 
presents O 
a O 
significant O 
challenge O 
for O 
efficacious O 
therapy O 
, O 
which O 
should O 
ideally O 
consist O 
of O 
thorough O 
decontamination O 
and O 
continuous O 
treatment O 
. O 

discovery O 
of O 
soft O 
, O 
transparent O 
microstructures O 
in O 
dinosaur O 
bone O 
consistent O 
in O 
morphology O 
with O 
osteocytes O 
was O 
controversial O 
. O 
We O 
hypothesize O 
that O 
, O 
if O 
original O 
, O 
these O 
microstructures O 
will O 
have O 
molecular O 
features O 
in O 
common O 
with O 
extant O 
osteocytes O 
. O 
We O 
present O 
immunological O 
and O 
mass O 
spectrometry O 
evidence O 
for O 
preservation O 
of O 
proteins O 
comprising O 
extant O 
osteocytes O 
( O 
Actin O 
, O 
Tubulin O 
, O 
PHEX O 
, O 
Histone O 
H4 O 
) O 
in O 
osteocytes O 
recovered O 
from O 
two O 
non-avian O 
dinosaurs O 
. O 
Furthermore O 
, O 
antibodies O 
to O 
DNA O 
show O 
localized O 
binding O 
to O 
these O 
microstructures O 
, O 
which O 
also O 
react O 
positively O 
with O 
DNA O 
intercalating O 
stains O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
( O 
PI O 
) O 
and O 
4',6'-diamidino-2-phenylindole B-SYSTEMATIC 
dihydrochloride I-SYSTEMATIC 
( O 
DAPI B-ABBREVIATION 
) O 
. O 
Each O 
antibody O 
binds O 
dinosaur O 
cells O 
in O 
patterns O 
similar O 
to O 
extant O 
cells O 
. O 
These O 
data O 
are O 
the O 
first O 
to O 
support O 
preservation O 
of O 
multiple O 
proteins O 
and O 
to O 
present O 
multiple O 
lines O 
of O 
evidence O 
for O 
material O 
consistent O 
with O 
DNA O 
in O 
dinosaurs O 
, O 
supporting O 
the O 
hypothesis O 
that O 
these O 
structures O 
were O 
part O 
of O 
the O 
once O 
living O 
animals O 
. O 
We O 
propose O 
mechanisms O 
for O 
preservation O 
of O 
cells O 
and O 
component O 
molecules O 
, O 
and O 
discuss O 
implications O 
for O 
dinosaurian O 
cellular O 
biology O 
. O 

of O 
amorphization O 
method O 
on O 
telmisartan B-TRIVIAL 
solubility O 
and O 
the O 
tableting O 
process O 
. O 

( O 
TLM B-ABBREVIATION 
) O 
, O 
a O 
poorly O 
water O 
- O 
soluble O 
angiotensin O 
II O 
receptor O 
antagonist O 
in O 
crystalline O 
form O 
, O 
was O 
transformed O 
into O 
the O 
amorphous O 
state O 
by O 
the O 
melt O 
quench O 
technique O 
, O 
as O 
well O 
as O 
a O 
cryogenic O 
grinding O 
method O 
, O 
in O 
order O 
to O 
improve O 
its O 
physiochemical O 
properties O 
. O 
The O 
chemical O 
stability O 
of O 
TLM B-ABBREVIATION 
, O 
that O 
is O 
, O 
the O 
tendency O 
of O 
the O 
material O 
to O 
resist O 
change O 
or O 
decomposition O 
due O 
to O 
internal O 
reaction O 
, O 
or O 
due O 
to O 
the O 
effects O 
of O 
air O 
, O 
heat O 
, O 
light O 
, O 
pressure O 
, O 
etc O 
. O 
, O 
during O 
formation O 
of O 
the O 
amorphous O 
phase O 
was O 
assessed O 
by O 
monitoring O 
high O 
performance O 
liquid O 
chromatography O 
. O 
The O 
existence O 
of O 
the O 
amorphous O 
state O 
was O 
confirmed O 
by O 
differential O 
scanning O 
calorimetry O 
and O 
X-ray O 
powder O 
diffraction O 
. O 
The O 
glass O 
transition O 
occurred O 
at O 
T(g)=401K O 
. O 
In O 
the O 
next O 
stage O 
, O 
the O 
solubility O 
of O 
TLM B-ABBREVIATION 
in O 
0.1M O 
HCl B-FORMULA 
, O 
phosphate O 
buffer O 
, O 
pH=6.8 O 
, O 
and O 
water O 
( O 
25°C O 
and O 
37°C O 
) O 
was O 
determined O 
. O 
Both O 
amorphous O 
forms O 
of O 
TLM B-ABBREVIATION 
( O 
vitrified O 
and O 
cryogrinded O 
) O 
had O 
a O 
higher O 
solubility O 
( O 
μg O 
/ O 
ml O 
) O 
than O 
their O 
crystalline O 
counterpart O 
. O 
An O 
important O 
and O 
interesting O 
problem O 
of O 
the O 
study O 
was O 
to O 
evaluate O 
how O 
the O 
tableting O 
process O 
was O 
affected O 
by O 
the O 
choice O 
of O 
either O 
a O 
crystalline O 
or O 
an O 
amorphous O 
form O 
of O 
TLM B-ABBREVIATION 
. O 
Eight O 
different O 
tablet O 
formulations O 
were O 
evaluated O 
using O 
both O 
the O 
crystalline O 
and O 
the O 
amorphous O 
form O 
of O 
TLM B-ABBREVIATION 
. O 
Measurements O 
of O 
the O 
physical O 
properties O 
and O 
dissolution O 
tests O 
of O 
G4 O 
formulations O 
tablets O 
with O 
telmisartan B-TRIVIAL 
in O 
crystalline O 
and O 
amorphous O 
form O 
after O 
different O 
storage O 
periods O 
were O 
also O 
performed O 
. O 

is O 
behind O 
the O 
non-antibiotic O 
properties O 
of O 
minocycline B-TRIVIAL 
? O 

is O 
a O 
second O 
- O 
generation O 
, O 
semi-synthetic O 
tetracycline B-FAMILY 
that O 
has O 
been O 
in O 
use O 
in O 
therapy O 
for O 
over O 
30 O 
years O 
for O 
its O 
antibiotic O 
properties O 
against O 
both O 
Gram O 
- O 
positive O 
and O 
Gram O 
- O 
negative O 
bacteria O 
. O 
It O 
displays O 
antibiotic O 
activity O 
due O 
to O 
its O 
ability O 
to O 
bind O 
to O 
the O 
30S O 
ribosomal O 
subunit O 
of O 
bacteria O 
and O 
thus O 
inhibit O 
protein O 
synthesis O 
. O 
More O 
recently O 
, O 
it O 
has O 
been O 
described O 
to O 
exert O 
a O 
variety O 
of O 
biological O 
actions O 
beyond O 
its O 
antimicrobial O 
activity O 
, O 
including O 
anti-inflammatory O 
and O 
anti-apoptotic O 
activities O 
, O 
inhibition O 
of O 
proteolysis O 
, O 
as O 
well O 
as O 
suppression O 
of O 
angiogenesis O 
and O 
tumor O 
metastasis O 
, O 
which O 
have O 
been O 
confirmed O 
in O 
different O 
experimental O 
models O 
of O 
non-infectious O 
diseases O 
. O 
There O 
are O 
also O 
many O 
studies O 
that O 
have O 
focused O 
on O 
the O 
mechanisms O 
involved O 
in O 
these O 
non-antibiotic O 
properties O 
of O 
minocycline B-TRIVIAL 
, O 
including O 
anti-oxidant O 
activity O 
, O 
inhibition O 
of O 
several O 
enzyme O 
activities O 
, O 
inhibition O 
of O 
apoptosis O 
and O 
regulation O 
of O 
immune O 
cell O 
activation O 
and O 
proliferation O 
. O 
This O 
review O 
summarizes O 
the O 
current O 
findings O 
in O 
this O 
topic O 
, O 
mainly O 
focusing O 
on O 
the O 
mechanisms O 
underlying O 
the O 
immunomodulatory O 
and O 
anti-inflammatory O 
activities O 
of O 
minocycline B-TRIVIAL 
. O 

current O 
study O 
has O 
determined O 
the O 
ability O 
of O 
(pGlu-Gln)-CCK-8 O 
to O 
counter O 
the O 
development O 
of O 
diet O 
- O 
induced O 
obesity O 
- O 
diabetes O 
and O 
examined O 
persistence O 
of O 
beneficial O 
metabolic O 
effects O 
in O 
high O 
fat O 
and O 
ob O 
/ O 
ob O 
mice O 
, O 
respectively O 
. O 
Twice O 
daily O 
injection O 
of O 
(pGlu-Gln)-CCK-8 O 
in O 
normal O 
mice O 
transferred O 
to O 
a O 
high O 
fat O 
diet O 
reduced O 
energy O 
intake O 
( O 
p O 
< O 
0.001 O 
) O 
, O 
body O 
weight O 
( O 
p O 
< O 
0.01 O 
) O 
, O 
circulating O 
insulin O 
and O 
LDL- O 
cholesterol B-TRIVIAL 
( O 
p O 
< O 
0.001 O 
) O 
and O 
improved O 
insulin O 
sensitivity O 
( O 
p O 
< O 
0.001 O 
) O 
as O 
well O 
as O 
oral O 
and O 
intraperitoneal O 
( O 
p O 
< O 
0.001 O 
) O 
glucose B-TRIVIAL 
tolerance O 
. O 
Energy O 
intake O 
, O 
body O 
weight O 
, O 
circulating O 
insulin O 
and O 
glucose B-TRIVIAL 
tolerance O 
of O 
(pGlu-Gln)-CCK-8 O 
mice O 
were O 
similar O 
to O 
lean O 
controls O 
. O 
In O 
addition O 
, O 
(pGlu-Gln)-CCK-8 O 
prevented O 
the O 
effect O 
of O 
high O 
fat O 
feeding O 
on O 
triacylglycerol B-FAMILY 
accumulation O 
in O 
liver O 
and O 
muscle O 
. O 
Interestingly O 
, O 
(pGlu-Gln)-CCK-8 O 
significantly O 
( O 
p O 
< O 
0.001 O 
) O 
elevated O 
pancreatic O 
glucagon O 
content O 
. O 
Histological O 
examination O 
of O 
the O 
pancreata O 
of O 
(pGlu-Gln)-CCK-8 O 
mice O 
revealed O 
no O 
changes O 
in O 
islet O 
number O 
or O 
size O 
, O 
but O 
there O 
was O 
increased O 
turnover O 
of O 
beta-cells O 
with O 
significantly O 
( O 
p O 
< O 
0.001 O 
) O 
increased O 
numbers O 
of O 
peripherally O 
located O 
alpha-cells O 
, O 
co O 
- O 
expressing O 
both O 
glucagon O 
and O 
GLP-1 O 
. O 
Beneficial O 
metabolic O 
effects O 
were O 
observed O 
similarly O 
in O 
ob O 
/ O 
ob O 
mice O 
treated O 
twice O 
daily O 
with O 
(pGlu-Gln)-CCK-8 O 
for O 
18 O 
days O 
, O 
including O 
significantly O 
reduced O 
energy O 
intake O 
( O 
p O 
< O 
0.05 O 
) O 
, O 
body O 
weight O 
( O 
p O 
< O 
0.05 O 
to O 
p O 
< O 
0.01 O 
) O 
, O 
circulating O 
glucose B-TRIVIAL 
( O 
p O 
< O 
0.05 O 
to O 
p O 
< O 
0.01 O 
) O 
and O 
insulin O 
( O 
p O 
< O 
0.05 O 
to O 
p O 
< O 
0.001 O 
) O 
and O 
improved O 
glucose B-TRIVIAL 
tolerance O 
( O 
p O 
< O 
0.05 O 
) O 
and O 
insulin O 
sensitivity O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
Notably O 
, O 
these O 
beneficial O 
effects O 
were O 
still O 
evident O 
18 O 
days O 
following O 
cessation O 
of O 
treatment O 
. O 
These O 
studies O 
emphasize O 
the O 
potential O 
of O 
(pGlu-Gln)-CCK-8 O 
for O 
the O 
treatment O 
of O 
obesity O 
- O 
diabetes O 
. O 

the O 
brain O 
continues O 
developing O 
in O 
the O 
postnatal O 
period O 
, O 
epidemiological O 
studies O 
on O 
the O 
effects O 
of O 
postnatal O 
exposure O 
to O 
neurotoxic O 
POPs O 
through O 
breast O 
- O 
feeding O 
remain O 
mostly O 
inconclusive O 
. O 
Failure O 
to O 
detect O 
associations O 
between O 
postnatal O 
exposure O 
and O 
health O 
outcomes O 
may O 
stem O 
from O 
the O 
limitations O 
of O 
commonly O 
employed O 
approaches O 
to O 
assess O 
lactational O 
exposure O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
assess O 
whether O 
lactational O 
exposure O 
to O 
polychlorinated B-TRIVIAL 
biphenyl-153 I-TRIVIAL 
( O 
PCB-153 B-ABBREVIATION 
) O 
, O 
dichlorodiphenyldichloroethylene B-SYSTEMATIC 
( O 
DDE B-ABBREVIATION 
) O 
, O 
or O 
hexachlorobenzene B-SYSTEMATIC 
( O 
HCB B-ABBREVIATION 
) O 
as O 
estimated O 
with O 
a O 
physiologically O 
based O 
pharmacokinetic O 
( O 
PBPK O 
) O 
model O 
, O 
is O 
associated O 
with O 
decrements O 
in O 
mental O 
and O 
psychomotor O 
development O 
scores O 
of O 
the O 
Bayley O 
Scales O 
of O 
Infant O 
Development O 
( O 
BSID O 
) O 
test O 
in O 
children O 
aged O 
around O 
14-months O 
of O 
a O 
subsample O 
( O 
N=1175 O 
) O 
of O 
the O 
Spanish O 
INMA O 
birth O 
cohort O 
, O 
and O 
to O 
compare O 
this O 
with O 
the O 
effects O 
of O 
prenatal O 
exposure O 
. O 
Although O 
in O 
the O 
present O 
study O 
population O 
PCB-153 B-ABBREVIATION 
, O 
DDE B-ABBREVIATION 
and O 
HCB B-ABBREVIATION 
exposure O 
increased O 
within O 
the O 
first O 
months O 
of O 
postnatal O 
life O 
, O 
no O 
associations O 
were O 
found O 
between O 
different O 
periods O 
of O 
postnatal O 
exposure O 
to O 
these O 
compounds O 
and O 
mental O 
or O 
psychomotor O 
scores O 
. O 
Increasing O 
prenatal O 
PCB-153 B-ABBREVIATION 
concentrations O 
were O 
associated O 
with O 
worse O 
mental O 
and O 
psychomotor O 
scores O 
, O 
although O 
significance O 
was O 
only O 
reached O 
for O 
psychomotor O 
development O 
( O 
β O 
[95%CI]=-1.36 O 
[ O 
-2.61 O 
, O 
-0.11 O 
] O 
) O 
. O 
Indeed O 
, O 
the O 
association O 
between O 
exposure O 
and O 
effects O 
observed O 
during O 
prenatal O 
life O 
weakened O 
gradually O 
across O 
periods O 
of O 
postnatal O 
life O 
. O 
Results O 
of O 
the O 
present O 
study O 
suggest O 
that O 
, O 
although O 
breastfeeding O 
increases O 
children's O 
blood O 
persistent O 
organic O 
pollutants O 
( O 
POPs O 
) O 
levels O 
during O 
postnatal O 
life O 
, O 
deleterious O 
effects O 
of O 
PCB-153 B-ABBREVIATION 
on O 
neuropsychological O 
development O 
are O 
mainly O 
attributable O 
to O 
prenatal O 
exposure O 
. O 

the O 
recent O 
attention O 
focused O 
on O 
the O 
roles O 
of O 
the O 
nucleotide B-FAMILY 
binding O 
and O 
oligomerization O 
domain O 
- O 
like O 
receptor O 
family O 
pyrin O 
domain O 
- O 
containing O 
3 O 
( O 
NLRP3 O 
) O 
inflammasome O 
in O 
the O 
pathogenesis O 
of O 
type O 
2 O 
diabetes O 
, O 
little O 
is O 
known O 
about O 
the O 
ex O 
vivo O 
profile O 
of O 
inflammasome O 
activation O 
in O 
type O 
2 O 
diabetic O 
patients O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
patterns O 
of O 
NLRP3 O 
inflammasome O 
activation O 
in O 
monocyte O 
- O 
derived O 
macrophages O 
( O 
MDMs O 
) O 
from O 
drug-naïve O 
patients O 
with O 
newly O 
diagnosed O 
type O 
2 O 
diabetes O 
. O 
Type O 
2 O 
diabetic O 
subjects O 
had O 
significantly O 
increased O 
mRNA O 
and O 
protein O 
expression O 
of O 
NLRP3 O 
, O 
apoptosis O 
- O 
associated O 
speck O 
- O 
like O 
protein O 
containing O 
a O 
CARD O 
( O 
ASC O 
) O 
, O 
and O 
proinflammatory O 
cytokines O 
in O 
MDMs O 
cultured O 
with O 
autologous O 
sera O 
compared O 
with O 
healthy O 
controls O 
. O 
Upregulated O 
interleukin O 
(IL)-1β O 
maturation O 
, O 
IL-18 O 
secretion O 
, O 
and O 
caspase-1 O 
cleavage O 
were O 
observed O 
in O 
MDMs O 
from O 
type O 
2 O 
diabetic O 
patients O 
after O 
stimulation O 
with O 
various O 
danger O 
molecules O 
( O 
ATP B-ABBREVIATION 
, O 
high O 
- O 
mobility O 
group O 
protein O 
B1 O 
, O 
free O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
islet O 
amyloid O 
polypeptide O 
, O 
and O 
monosodium B-SYSTEMATIC 
uric I-SYSTEMATIC 
acid I-SYSTEMATIC 
crystals O 
) O 
. O 
Mitochondrial O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
and O 
NLRP3 O 
were O 
required O 
for O 
IL-1β O 
synthesis O 
in O 
MDMs O 
. O 
Finally O 
, O 
2 O 
months O 
of O 
therapy O 
with O 
the O 
antidiabetic O 
drug O 
metformin B-TRIVIAL 
significantly O 
inhibited O 
the O 
maturation O 
of O 
IL-1β O 
in O 
MDMs O 
from O 
patients O 
with O 
type O 
2 O 
diabetes O 
through O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
activation O 
. O 
Taken O 
together O 
, O 
these O 
data O 
suggest O 
that O 
NLRP3 O 
inflammasome O 
activation O 
is O 
elevated O 
in O 
myeloid O 
cells O 
from O 
type O 
2 O 
diabetic O 
patients O 
and O 
that O 
antidiabetic O 
treatment O 
with O 
metformin B-TRIVIAL 
contributes O 
to O 
modulation O 
of O 
inflammasome O 
activation O 
in O 
type O 
2 O 
diabetes O 
. O 

neuropeptide O 
apelin O 
is O 
expressed O 
in O 
hypothalamic O 
paraventricular O 
and O 
supraoptic O 
nuclei O 
and O 
mediates O 
its O 
effects O 
via O 
activation O 
of O 
the O 
apelin O 
receptor O 
( O 
APJ O 
) O 
. O 
Evidence O 
suggests O 
a O 
role O 
for O 
apelin O 
and O 
APJ O 
in O 
mediating O 
the O 
neuroendocrine O 
response O 
to O 
stress O 
. O 
To O 
understand O 
the O 
physiological O 
role O 
of O 
APJ O 
in O 
regulation O 
of O 
the O 
hypothalamic O 
- O 
pituitary O 
- O 
adrenal O 
( O 
HPA O 
) O 
axis O 
, O 
we O 
measured O 
ACTH O 
and O 
corticosterone B-TRIVIAL 
( O 
CORT B-ABBREVIATION 
) O 
plasma O 
levels O 
in O 
male O 
and O 
female O 
mice O 
lacking O 
APJ O 
( O 
APJ O 
knockout O 
, O 
APJ O 
KO O 
) O 
and O 
in O 
wild O 
- O 
type O 
controls O 
, O 
in O 
response O 
to O 
a O 
variety O 
of O 
acute O 
stressors O 
. O 
Exposure O 
to O 
mild O 
restraint O 
, O 
systemic O 
injection O 
of O 
lipopolysaccharide O 
( O 
LPS O 
) O 
, O 
insulin O 
- O 
induced O 
hypoglycaemia O 
and O 
forced O 
swim O 
( O 
FS O 
) O 
stressors O 
, O 
elevated O 
plasma O 
ACTH O 
and O 
CORT B-ABBREVIATION 
levels O 
in O 
wild O 
- O 
type O 
mice O 
. O 
Acute O 
mild O 
restraint O 
significantly O 
increased O 
plasma O 
ACTH O 
and O 
CORT B-ABBREVIATION 
to O 
a O 
similar O 
level O 
in O 
APJ O 
KO O 
mice O 
as O 
in O 
wild O 
- O 
type O 
mice O 
. O 
However O 
, O 
an O 
intact O 
APJ O 
was O 
required O 
for O 
a O 
conventional O 
ACTH O 
, O 
but O 
not O 
CORT B-ABBREVIATION 
, O 
response O 
to O 
LPS O 
administration O 
in O 
male O 
mice O 
and O 
to O 
insulin O 
- O 
induced O 
hypoglycaemia O 
in O 
male O 
and O 
female O 
mice O 
. O 
In O 
contrast O 
, O 
APJ O 
KO O 
mice O 
displayed O 
an O 
impaired O 
CORT B-ABBREVIATION 
response O 
to O 
acute O 
FS O 
stress O 
, O 
regardless O 
of O 
gender O 
. O 
These O 
data O 
indicate O 
that O 
APJ O 
has O 
a O 
role O 
in O 
regulation O 
of O 
the O 
HPA O 
axis O 
response O 
to O 
some O 
acute O 
stressors O 
and O 
has O 
a O 
gender O 
- O 
specific O 
function O 
in O 
peripheral O 
immune O 
activation O 
of O 
the O 
HPA O 
axis O 
. O 

bioavailability O 
and O 
toxicity O 
of O 
permethrin B-TRIVIAL 
and O 
DDT B-ABBREVIATION 
in O 
sediment O 
using O 
matrix O 
solid O 
phase O 
microextraction O 
. O 

solid O 
phase O 
microextraction O 
( O 
matrix-SPME O 
) O 
was O 
evaluated O 
as O 
a O 
surrogate O 
for O 
the O 
absorbed O 
dose O 
in O 
organisms O 
to O 
estimate O 
bioavailability O 
and O 
toxicity O 
of O 
permethrin B-TRIVIAL 
and O 
dichlorodiphenyltrichloroethane B-SYSTEMATIC 
( O 
DDT B-ABBREVIATION 
) O 
in O 
laboratory O 
- O 
spiked O 
sediment O 
. O 
Sediments O 
were O 
incubated O 
for O 
7 O 
, O 
28 O 
, O 
and O 
90 O 
days O 
at O 
room O 
temperature O 
to O 
characterize O 
the O 
effect O 
of O 
aging O 
on O 
bioavailability O 
and O 
toxicity O 
. O 
Sediment O 
toxicity O 
was O 
assessed O 
using O 
two O 
freshwater O 
invertebrates O 
, O 
the O 
midge O 
Chironomus O 
dilutus O 
and O 
amphipod O 
Hyalella O 
azteca O 
. O 
Disposable O 
polydimethylsiloxane B-SYSTEMATIC 
fibers O 
were O 
used O 
to O 
estimate O 
the O 
absorbed O 
dose O 
in O 
organisms O 
and O 
to O 
examine O 
bioavailability O 
and O 
toxicity O 
. O 
The O 
equilibrium O 
fiber O 
concentrations O 
substantially O 
decreased O 
with O 
an O 
increase O 
in O 
sediment O 
aging O 
time O 
, O 
indicating O 
a O 
reduction O 
in O 
bioavailability O 
. O 
Based O 
on O 
median O 
lethal O 
fiber O 
concentrations O 
( O 
fiber O 
LC50 O 
) O 
, O 
toxicity O 
of O 
permethrin B-TRIVIAL 
was O 
not O 
significantly O 
different O 
among O 
the O 
different O 
aging O 
times O 
. O 
Due O 
to O 
the O 
substantial O 
degradation O 
of O 
DDT B-ABBREVIATION 
to O 
dichlorodiphenyldichloroethane B-SYSTEMATIC 
( O 
DDD B-ABBREVIATION 
) O 
in O 
sediment O 
, O 
sediment O 
toxicity O 
to O 
C O 
. O 
dilutus O 
increased O 
, O 
while O 
it O 
decreased O 
for O 
H O 
. O 
azteca O 
with O 
extended O 
aging O 
times O 
. O 
A O 
toxic O 
unit O 
- O 
based O 
fiber O 
LC50 O 
value O 
represented O 
the O 
DDT B-ABBREVIATION 
mixture O 
( O 
DDT B-ABBREVIATION 
and O 
DDD B-ABBREVIATION 
) O 
toxicity O 
for O 
both O 
species O 
. O 
Significant O 
linear O 
relationships O 
were O 
found O 
between O 
organism O 
body O 
residues O 
and O 
the O 
equilibrium O 
fiber O 
concentrations O 
for O 
each O 
compound O 
, O 
across O 
aging O 
times O 
. O 
The O 
study O 
suggested O 
that O 
the O 
matrix-SPME O 
fibers O 
mimicked O 
bioaccumulation O 
in O 
the O 
organisms O 
, O 
and O 
enabled O 
estimation O 
of O 
body O 
residues O 
, O 
and O 
could O 
potentially O 
be O 
used O 
in O 
environmental O 
risk O 
assessment O 
across O 
matrices O 
( O 
e.g O 
. O 
sediment O 
and O 
water O 
) O 
to O 
measure O 
bioavailability O 
and O 
toxicity O 
of O 
hydrophobic O 
pesticides O 
. O 

of O 
DMSA B-ABBREVIATION 
-coated O 
Fe3O4 B-FORMULA 
nanoparticles O 
on O 
the O 
transcription O 
of O 
genes O 
related O 
to O 
iron B-SYSTEMATIC 
and O 
osmosis O 
homeostasis O 
. O 

this O 
article O 
, O 
we O 
checked O 
the O 
effect O 
of O 
2,3-dimercaptosuccinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-coated O 
Fe(3)O(4) B-FORMULA 
nanoparticles O 
on O 
gene O 
expression O 
of O 
mouse O 
macrophage O 
RAW264.7 O 
cells O 
and O 
found O 
that O 
the O 
transcription O 
of O 
several O 
important O 
genes O 
related O 
to O 
intracellular O 
iron B-SYSTEMATIC 
homeostasis O 
were O 
significantly O 
changed O 
. O 
We O 
thus O 
speculated O 
that O 
the O 
cellular O 
iron B-SYSTEMATIC 
homeostasis O 
might O 
be O 
disturbed O 
by O 
this O 
nanoparticle O 
through O 
releasing O 
iron B-SYSTEMATIC 
ion O 
in O 
cells O 
. O 
To O 
verify O 
this O 
speculation O 
, O 
we O 
first O 
confirmed O 
the O 
transcriptional O 
changes O 
of O 
several O 
key O 
iron B-SYSTEMATIC 
homeostasis- O 
related O 
genes O 
, O 
such O 
as O 
Tfrc O 
, O 
Trf O 
, O 
and O 
Lcn2 O 
, O 
using O 
quantitative O 
PCR O 
, O 
and O 
found O 
that O 
an O 
iron B-SYSTEMATIC 
ion O 
chelator O 
, O 
desferrioxamine B-TRIVIAL 
, O 
could O 
alleviate O 
the O 
transcriptional O 
alterations O 
of O 
two O 
typical O 
genes O 
, O 
Tfrc O 
and O 
Lcn2 O 
. O 
Then O 
, O 
we O 
designed O 
and O 
validated O 
a O 
method O 
based O 
on O 
centrifugation O 
for O 
assaying O 
intracellular O 
irons B-FAMILY 
in O 
ion O 
and O 
nanoparticle O 
state O 
. O 
After O 
extensive O 
measures O 
of O 
intracellular O 
iron B-SYSTEMATIC 
in O 
two O 
forms O 
and O 
total O 
iron B-SYSTEMATIC 
, O 
we O 
found O 
that O 
the O 
intracellular O 
iron B-SYSTEMATIC 
ion O 
significantly O 
increased O 
with O 
intracellular O 
total O 
iron B-SYSTEMATIC 
and O 
nanoparticle O 
iron B-SYSTEMATIC 
, O 
demonstrating O 
degradation O 
of O 
this O 
nanoparticle O 
into O 
iron B-SYSTEMATIC 
ion O 
in O 
cells O 
. O 
We O 
next O 
mimicked O 
the O 
intralysosomal O 
environment O 
in O 
vitro O 
and O 
verified O 
that O 
the O 
internalized O 
iron O 
nanoparticle O 
could O 
release O 
iron B-SYSTEMATIC 
ion O 
in O 
lysosome O 
. O 
We O 
found O 
that O 
as O 
another O 
important O 
compensatory O 
response O 
to O 
intracellular O 
overload O 
of O 
iron B-SYSTEMATIC 
ion O 
, O 
cells O 
significantly O 
downregulated O 
the O 
expressions O 
of O 
genes O 
belonging O 
to O 
solute O 
carrier O 
family O 
which O 
are O 
responsible O 
for O 
transferring O 
many O 
organic O 
solutes O 
into O 
cells O 
, O 
such O 
as O 
Slc5a3 O 
and O 
Slc44a1 O 
, O 
in O 
order O 
to O 
prevent O 
more O 
organic O 
solutes O 
into O 
cells O 
and O 
thus O 
lower O 
the O 
intracellular O 
osmosis O 
. O 
Based O 
on O 
these O 
findings O 
, O 
we O 
profiled O 
a O 
map O 
of O 
gene O 
effects O 
after O 
cells O 
were O 
treated O 
with O 
this O 
iron B-SYSTEMATIC 
nanoparticle O 
and O 
concluded O 
that O 
the O 
iron B-SYSTEMATIC 
nanoparticles O 
might O 
be O 
more O 
detrimental O 
to O 
cell O 
than O 
iron B-SYSTEMATIC 
ion O 
due O 
to O 
its O 
intracellular O 
internalization O 
fashion O 
, O 
nonspecific O 
endocytosis O 
. O 

( O 
ColQ O 
) O 
is O 
a O 
specific O 
collagen O 
that O 
anchors O 
acetylcholinesterase O 
( O 
AChE O 
) O 
in O 
the O 
synaptic O 
basal O 
lamina O 
of O 
the O 
neuromuscular O 
junction O 
( O 
NMJ O 
) O 
. O 
Over O 
30 O 
mutations O 
in O 
the O 
COLQ O 
gene O 
have O 
been O 
identified O 
that O 
are O 
responsible O 
for O 
a O 
congenital O 
myasthenic O 
syndrome O 
with O 
AChE O 
deficiency O 
, O 
highlighting O 
the O 
importance O 
of O 
this O 
collagen O 
in O 
the O 
physiology O 
of O 
the O 
NMJ O 
. O 
The O 
anchoring O 
of O 
AChE O 
at O 
the O 
synapse O 
requires O 
the O 
interaction O 
of O 
ColQ O 
with O 
MuSK O 
( O 
Muscle-Specific O 
Kinase O 
) O 
, O 
a O 
tyrosine B-TRIVIAL 
kinase O 
expressed O 
on O 
the O 
muscle O 
membrane O 
that O 
is O 
necessary O 
for O 
the O 
formation O 
and O 
the O 
maintenance O 
of O 
the O 
NMJ O 
. O 
MuSK O 
forms O 
with O 
its O 
co O 
- O 
receptor O 
LRP4 O 
, O 
a O 
member O 
of O 
the O 
Low O 
- O 
density O 
Related O 
Protein O 
family O 
, O 
a O 
receptor O 
complex O 
for O 
agrin O 
and O 
Wnts O 
, O 
representing O 
the O 
core O 
system O 
from O 
which O 
the O 
postsynaptic O 
domain O 
is O 
built O 
, O 
the O 
growth O 
cone O 
attracted O 
and O 
the O 
presynaptic O 
element O 
instructed O 
for O 
some O 
aspects O 
of O 
its O 
differentiation O 
. O 
Therefore O 
, O 
the O 
discovery O 
that O 
ColQ O 
binds O 
to O 
MuSK O 
prompted O 
us O 
to O 
study O 
a O 
possible O 
regulatory O 
function O 
of O 
ColQ O 
during O 
NMJ O 
development O 
. O 
In O 
this O 
review O 
, O 
after O 
a O 
brief O 
survey O 
on O 
ColQ O 
, O 
we O 
summarize O 
our O 
recent O 
data O 
demonstrating O 
that O 
ColQ O 
, O 
in O 
addition O 
to O 
its O 
anchoring O 
role O 
, O 
exerts O 
signaling O 
functions O 
and O 
controls O 
some O 
aspects O 
of O 
postsynaptic O 
differentiation O 
such O 
as O 
the O 
clustering O 
of O 
acetylcholine O 
receptors O 
. O 
Our O 
results O 
also O 
strengthen O 
the O 
hypothesis O 
that O 
the O 
defects O 
observed O 
in O 
synaptic O 
congenital O 
myasthenic O 
syndromes O 
might O 
be O 
linked O 
, O 
at O 
least O 
in O 
part O 
, O 
to O 
alterations O 
of O 
ColQ O 
signaling O 
functions O 
and O 
not O 
only O 
to O 
AChE O 
deficiency O 
. O 
Finally O 
, O 
we O 
discuss O 
future O 
research O 
directions O 
to O 
understand O 
how O 
ColQ O 
may O 
modulate O 
the O 
action O 
of O 
the O 
other O 
ligands O 
of O 
the O 
MuSK O 
/ O 
LRP4 O 
complex O 
and O 
cooperate O 
with O 
them O 
to O 
coordinate O 
the O 
different O 
steps O 
of O 
NMJ O 
formation O 
and O 
maintenance O 
. O 

number O 
of O 
human O 
teratogens O 
elicit O 
their O 
deleterious O 
effects O 
through O 
mechanisms O 
involving O 
the O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
and O 
oxidative O 
stress O 
. O 
However O 
, O 
classic O 
definitions O 
of O 
oxidative O 
stress O 
do O 
not O 
fully O 
coincide O 
with O 
basic O 
fundamental O 
principles O 
of O 
teratology O 
. O 
Newer O 
definitions O 
of O 
oxidative O 
stress O 
focus O 
on O 
the O 
targeted O 
redox O 
modification O 
of O 
cysteine B-TRIVIAL 
/ O 
thiol B-FAMILY 
functional O 
groups O 
found O 
in O 
the O 
regulatory O 
domains O 
of O 
critical O 
signaling O 
pathway O 
proteins O 
, O 
suggesting O 
that O 
the O 
targeted O 
disruption O 
of O 
signaling O 
through O 
specific O 
redox O 
couples O 
may O 
account O 
for O 
the O 
specificity O 
of O 
teratogen O 
- O 
induced O 
malformations O 
which O 
previously O 
could O 
not O 
be O 
rationalized O 
. O 
Here O 
, O 
we O 
review O 
examples O 
of O 
teratogens O 
that O 
induce O 
ROS O 
and O 
oxidative O 
injury O 
, O 
describe O 
oxidative O 
stress O 
- O 
related O 
teratogenic O 
mechanisms O 
, O 
and O 
provide O 
rationale O 
for O 
developmental O 
periods O 
of O 
sensitivity O 
and O 
species O 
susceptibility O 
. O 
Understanding O 
how O 
chemicals O 
disrupt O 
redox O 
status O 
, O 
induce O 
oxidative O 
stress O 
leading O 
to O 
dysmorphogenesis O 
becomes O 
important O 
to O 
identify O 
potential O 
teratogens O 
and O 
develop O 
therapeutic O 
interventions O 
for O 
attenuation O 
of O 
harmful O 
chemical O 
effects O 
in O 
utero O 
following O 
exposure O 
. O 

ester I-SYSTEMATIC 
droplets O 
and O 
steroidogenesis O 
. O 

lipid O 
droplets O 
( O 
LDs O 
) O 
are O 
dynamic O 
organelles O 
that O 
contain O 
a O 
number O 
of O 
associated O 
proteins O 
including O 
perilipin O 
( O 
Plin O 
) O 
and O 
vimentin O 
. O 
Cholesteryl B-SYSTEMATIC 
ester I-SYSTEMATIC 
(CE)-rich O 
LDs O 
normally O 
accumulate O 
in O 
steroidogenic O 
cells O 
and O 
their O 
mobilization O 
is O 
the O 
preferred O 
initial O 
source O 
of O 
cholesterol B-TRIVIAL 
for O 
steroidogenesis O 
. O 
Plin1a O 
, O 
1b O 
and O 
5 O 
were O 
found O 
to O 
preferentially O 
associate O 
with O 
triacylglycerol B-FAMILY 
-rich O 
LDs O 
and O 
Plin1c O 
and O 
Plin4 O 
to O 
associate O 
with O 
CE-rich O 
LDs O 
, O 
but O 
the O 
biological O 
significance O 
of O 
this O 
remains O 
unanswered O 
. O 
Vimentin O 
nan O 
mice O 
were O 
found O 
to O 
have O 
decreased O 
ACTH-stimulated O 
corticosterone B-TRIVIAL 
levels O 
, O 
and O 
decreased O 
progesterone B-TRIVIAL 
levels O 
in O 
females O 
, O 
but O 
normal O 
hCG-stimulated O 
testosterone B-TRIVIAL 
levels O 
in O 
males O 
. O 
Smaller O 
LDs O 
were O 
seen O 
in O 
nan O 
cells O 
. O 
Lipoprotein O 
cholesterol B-TRIVIAL 
delivery O 
to O 
adrenals O 
and O 
ovary O 
was O 
normal O 
, O 
as O 
was O 
the O 
expression O 
of O 
steroidogenic O 
genes O 
; O 
however O 
, O 
the O 
movement O 
of O 
cholesterol B-TRIVIAL 
to O 
mitochondria O 
was O 
reduced O 
in O 
vimentin O 
nan O 
mice O 
. O 
These O 
results O 
suggest O 
that O 
vimentin O 
is O 
important O 
in O 
the O 
maintenance O 
of O 
CE-rich O 
LDs O 
and O 
in O 
the O 
movement O 
of O 
cholesterol B-TRIVIAL 
for O 
steroidogenesis O 
. O 

interactive O 
effects O 
of O 
selenomethionine B-SYSTEMATIC 
and O 
methylmercury B-SYSTEMATIC 
on O 
their O 
absorption O 
, O 
disposition O 
, O 
and O 
elimination O 
in O 
juvenile O 
white O 
sturgeon O 
. O 

( O 
Se B-FORMULA 
) O 
and O 
mercury B-SYSTEMATIC 
( O 
Hg B-FORMULA 
) O 
are O 
prevalent O 
pollutants O 
of O 
industrialized O 
watersheds O 
. O 
However O 
, O 
when O 
co O 
- O 
administered O 
, O 
Se B-FORMULA 
has O 
protective O 
effects O 
on O 
organisms O 
from O 
Hg B-FORMULA 
. O 
The O 
mechanism O 
is O 
not O 
fully O 
understood O 
, O 
but O 
it O 
is O 
thought O 
that O 
Se B-FORMULA 
reduces O 
Hg B-FORMULA 
availability O 
, O 
either O 
by O 
forming O 
biologically O 
inert O 
complexes O 
and O 
/ O 
or O 
associating O 
with O 
selenoproteins O 
. O 
Despite O 
concerns O 
with O 
aquatic O 
contaminations O 
, O 
relatively O 
little O 
information O 
is O 
available O 
on O 
the O 
interaction O 
in O 
aquatic O 
organisms O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
interactive O 
effects O 
of O 
Se B-FORMULA 
and O 
Hg B-FORMULA 
on O 
their O 
absorption O 
, O 
disposition O 
, O 
and O 
elimination O 
were O 
examined O 
in O 
juvenile O 
white O 
sturgeon O 
, O 
a O 
benthic O 
fish O 
species O 
at O 
high O 
risk O 
to O 
exposures O 
of O 
both O 
contaminants O 
. O 
Selenium B-SYSTEMATIC 
and O 
Hg B-FORMULA 
were O 
provided O 
as O 
L-selenomethionine B-TRIVIAL 
( O 
SeMet B-FORMULA 
) O 
and O 
methylmercury B-SYSTEMATIC 
( O 
MeHg B-FORMULA 
) O 
, O 
respectively O 
. O 
Groups O 
of O 
10 O 
sturgeon O 
were O 
orally O 
intubated O 
with O 
a O 
single O 
dose O 
of O 
either O 
0 O 
( O 
control O 
) O 
, O 
SeMet B-FORMULA 
( O 
500 O 
μg O 
Se B-FORMULA 
/ O 
kg O 
body O 
weight O 
; O 
BW O 
) O 
, O 
MeHg B-FORMULA 
( O 
850 O 
μg O 
Hg B-FORMULA 
/ O 
kg O 
BW O 
) O 
, O 
or O 
their O 
combination O 
( O 
Se B-FORMULA 
/ O 
Hg B-FORMULA 
; O 
500 O 
μg O 
Se B-FORMULA 
/ O 
kg O 
and O 
850 O 
μg O 
Hg O 
/ O 
kg O 
BW O 
) O 
. O 
The O 
blood O 
was O 
repeatedly O 
sampled O 
and O 
urine O 
collected O 
from O 
the O 
fish O 
, O 
over O 
a O 
48 O 
h O 
post O 
intubation O 
period O 
. O 
At O 
48 O 
h O 
, O 
the O 
fish O 
were O 
sacrificed O 
for O 
Se B-FORMULA 
and O 
Hg B-FORMULA 
tissue O 
concentration O 
and O 
distribution O 
. O 
The O 
co O 
- O 
administration O 
of O 
SeMet B-FORMULA 
and O 
MeHg B-FORMULA 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
lowered O 
blood O 
concentrations O 
of O 
both O 
Se B-FORMULA 
and O 
Hg B-FORMULA 
and O 
tissue O 
Se B-FORMULA 
concentrations O 
. O 
Similarly O 
, O 
assimilation O 
of O 
Se B-FORMULA 
and O 
Hg B-FORMULA 
was O 
also O 
reduced O 
significantly O 
. O 
The O 
interaction O 
has O 
a O 
more O 
quantitative O 
effect O 
on O 
Se B-FORMULA 
metabolism O 
because O 
the O 
reduction O 
in O 
the O 
overall O 
tissue O 
Se B-FORMULA 
is O 
a O 
consequence O 
of O 
reduced O 
Se B-FORMULA 
absorption O 
at O 
the O 
gut O 
and O 
not O 
from O 
the O 
metabolic O 
effects O 
after O 
absorption O 
. O 
In O 
contrast O 
, O 
given O 
the O 
pulse O 
increase O 
in O 
blood O 
Hg B-FORMULA 
concentration O 
, O 
tissue O 
redistribution O 
, O 
and O 
increased O 
urinary O 
elimination O 
, O 
the O 
interactive O 
effect O 
on O 
tissue O 
Hg B-FORMULA 
concentration O 
is O 
likely O 
to O 
be O 
post O 
- O 
absorption O 
. O 
Even O 
in O 
the O 
absence O 
of O 
exogenous O 
SeMet B-FORMULA 
, O 
Se B-FORMULA 
and O 
Hg B-FORMULA 
co O 
- O 
accumulated O 
in O 
tissue O 
at O 
a O 
Se B-FORMULA 
: O 
Hg B-FORMULA 
molar O 
ratio O 
greater O 
than O 
1 O 
. O 
Thus O 
, O 
similar O 
to O 
mammals O 
, O 
maintaining O 
at O 
least O 
a O 
1 O 
: O 
1 O 
molar O 
ratio O 
of O 
Se B-FORMULA 
and O 
Hg B-FORMULA 
is O 
of O 
great O 
physiological O 
importance O 
in O 
the O 
white O 
sturgeon O 
. O 
Interestingly O 
, O 
SeMet B-FORMULA 
did O 
not O 
divert O 
Hg B-FORMULA 
from O 
the O 
brain O 
. O 
Allocation O 
of O 
Se B-FORMULA 
from O 
the O 
kidneys O 
may O 
have O 
occurred O 
in O 
order O 
to O 
maintain O 
the O 
high O 
Se B-FORMULA 
: O 
Hg B-FORMULA 
molar O 
ratios O 
in O 
the O 
brain O 
of O 
white O 
sturgeon O 
. O 
In O 
the O 
current O 
study O 
, O 
the O 
combined O 
use O 
of O 
kinetic O 
analysis O 
and O 
that O 
of O 
the O 
conventional O 
approach O 
of O 
measuring O 
tissue O 
concentration O 
changes O 
provided O 
a O 
comprehensive O 
understanding O 
of O 
the O 
interactive O 
effect O 
of O 
SeMet B-FORMULA 
and O 
MeHg B-FORMULA 
on O 
their O 
respective O 
metabolic O 
processes O 
in O 
juvenile O 
white O 
sturgeon O 
. O 

charge O 
carrier O 
mobility O 
in O 
two O 
- O 
dimensional O 
high O 
dielectric O 
molybdenum B-SYSTEMATIC 
oxide I-SYSTEMATIC 
. O 

demonstrate O 
that O 
the O 
energy O 
bandgap O 
of O 
layered O 
, O 
high O 
- O 
dielectric O 
α-MoO(3) B-FORMULA 
can O 
be O 
reduced O 
to O 
values O 
viable O 
for O 
the O 
fabrication O 
of O 
2D O 
electronic O 
devices O 
. O 
This O 
is O 
achieved O 
through O 
embedding O 
Coulomb O 
charges O 
within O 
the O 
high O 
dielectric O 
media O 
, O 
advantageously O 
limiting O 
charge O 
scattering O 
. O 
As O 
a O 
result O 
, O 
devices O 
with O 
α-MoO(3) B-FORMULA 
of O 
∼11 O 
nm O 
thickness O 
and O 
carrier O 
mobilities O 
larger O 
than O 
1100 O 
cm(2) O 
V(-1) O 
s(-1) O 
are O 
obtained O 
. O 

of O 
multimeric O 
T O 
cell O 
antigens O 
on O 
carbon B-SYSTEMATIC 
nanotubes O 
: O 
effect O 
on O 
protein O 
structure O 
and O 
antigen O 
- O 
specific O 
T O 
cell O 
stimulation O 
. O 

- O 
specific O 
activation O 
of O 
cytotoxic O 
T O 
cells O 
can O 
be O 
enhanced O 
up O 
to O 
three O 
- O 
fold O 
more O 
than O 
soluble O 
controls O 
when O 
using O 
functionalized O 
bundled O 
carbon B-SYSTEMATIC 
nanotube O 
substrates O 
( O 
( O 
b O 
) O 
CNTs O 
) O 
. O 
To O 
overcome O 
the O 
denaturing O 
effects O 
of O 
direct O 
adsorption O 
on O 
( O 
b O 
) O 
CNTs O 
, O 
a O 
simple O 
but O 
robust O 
method O 
is O 
demonstrated O 
to O 
stabilize O 
the O 
T O 
cell O 
stimulus O 
on O 
carbon B-SYSTEMATIC 
nanotube O 
substrates O 
through O 
non-covalent O 
attachment O 
of O 
the O 
linker O 
neutravidin O 
. O 

anti-inflammatory O 
drugs O 
( O 
NSAIDs O 
) O 
can O 
cause O 
serious O 
gastrointestinal O 
( O 
GI O 
) O 
injury O 
including O 
jejunal O 
/ O 
ileal O 
mucosal O 
ulceration O 
, O 
bleeding O 
, O 
and O 
even O 
perforation O 
in O 
susceptible O 
patients O 
. O 
The O 
underlying O 
mechanisms O 
are O 
largely O 
unknown O 
, O 
but O 
they O 
are O 
distinct O 
from O 
those O 
related O 
to O 
gastric O 
injury O 
. O 
Based O 
on O 
recent O 
insights O 
from O 
experimental O 
models O 
, O 
including O 
genetics O 
and O 
pharmacology O 
in O 
rodents O 
typically O 
exposed O 
to O 
diclofenac B-TRIVIAL 
, O 
indomethacin B-TRIVIAL 
, O 
or O 
naproxen B-TRIVIAL 
, O 
we O 
propose O 
a O 
multiple O 
- O 
hit O 
pathogenesis O 
of O 
NSAID O 
enteropathy O 
. O 
The O 
multiple O 
hits O 
start O 
with O 
an O 
initial O 
pharmacokinetic O 
determinant O 
caused O 
by O 
vectorial O 
hepatobiliary O 
excretion O 
and O 
delivery O 
of O 
glucuronidated O 
NSAID O 
or O 
oxidative O 
metabolite O 
conjugates O 
to O 
the O 
distal O 
small O 
intestinal O 
lumen O 
, O 
where O 
bacterial O 
β-glucuronidase O 
produces O 
critical O 
aglycones O 
. O 
The O 
released O 
aglycones O 
are O 
then O 
taken O 
up O 
by O 
enterocytes O 
and O 
further O 
metabolized O 
by O 
intestinal O 
cytochrome O 
P450s O 
to O 
potentially O 
reactive O 
intermediates O 
. O 
The O 
" O 
first O 
hit O 
" O 
is O 
caused O 
by O 
the O 
NSAID O 
and O 
/ O 
or O 
oxidative O 
metabolites O 
that O 
induce O 
severe O 
endoplasmic O 
reticulum O 
stress O 
or O 
mitochondrial O 
stress O 
and O 
lead O 
to O 
cell O 
death O 
. O 
The O 
" O 
second O 
hit O 
" O 
is O 
created O 
by O 
the O 
significant O 
subsequent O 
inflammatory O 
response O 
that O 
would O 
follow O 
such O 
a O 
first O 
- O 
hit O 
injury O 
. O 
Based O 
on O 
these O 
putative O 
mechanisms O 
, O 
strategies O 
have O 
been O 
developed O 
to O 
protect O 
the O 
enterocytes O 
from O 
being O 
exposed O 
to O 
the O 
parent O 
NSAID O 
and O 
/ O 
or O 
oxidative O 
metabolites O 
. O 
Among O 
these O 
, O 
a O 
novel O 
strategy O 
already O 
demonstrated O 
in O 
a O 
murine O 
model O 
is O 
the O 
selective O 
disruption O 
of O 
bacteria O 
- O 
specific O 
β-glucuronidases O 
with O 
a O 
novel O 
small O 
molecule O 
inhibitor O 
that O 
does O 
not O 
harm O 
the O 
bacteria O 
and O 
that O 
alleviates O 
NSAID-induced O 
enteropathy O 
. O 
Such O 
mechanism O 
- O 
based O 
strategies O 
require O 
further O 
investigation O 
but O 
provide O 
potential O 
avenues O 
for O 
the O 
alleviation O 
of O 
the O 
GI O 
toxicity O 
caused O 
by O 
multiple O 
NSAID O 
hits O 
. O 

lopinavir B-TRIVIAL 
and O 
ritonavir B-TRIVIAL 
alter O 
exogenous O 
and O 
endogenous O 
bile B-FAMILY 
acid I-FAMILY 
disposition O 
in O 
sandwich O 
- O 
cultured O 
rat O 
hepatocytes O 
. O 

of O 
the O 
bile B-FAMILY 
salt I-FAMILY 
export O 
pump O 
( O 
BSEP O 
) O 
can O 
cause O 
intracellular O 
accumulation O 
of O 
bile B-FAMILY 
acids I-FAMILY 
and O 
is O 
a O 
risk O 
factor O 
for O 
drug O 
- O 
induced O 
liver O 
injury O 
in O 
humans O 
. O 
Antiretroviral O 
protease O 
inhibitors O 
lopinavir B-TRIVIAL 
( O 
LPV B-ABBREVIATION 
) O 
and O 
ritonavir B-TRIVIAL 
( O 
RTV B-ABBREVIATION 
) O 
are O 
reported O 
BSEP O 
inhibitors O 
. O 
However O 
, O 
the O 
consequences O 
of O 
LPV B-ABBREVIATION 
and O 
RTV B-ABBREVIATION 
, O 
alone O 
and O 
combined O 
( O 
LPV B-ABBREVIATION 
/r O 
) O 
, O 
on O 
hepatocyte O 
viability O 
, O 
bile B-FAMILY 
acid I-FAMILY 
transport O 
, O 
and O 
endogenous O 
bile B-FAMILY 
acid I-FAMILY 
disposition O 
in O 
rat O 
hepatocytes O 
have O 
not O 
been O 
examined O 
. O 
The O 
effect O 
of O 
LPV B-ABBREVIATION 
, O 
RTV B-ABBREVIATION 
, O 
and O 
LPV B-ABBREVIATION 
/r O 
on O 
cellular O 
viability O 
and O 
the O 
disposition O 
of O 
[(3)H]taurocholic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
TCA B-ABBREVIATION 
) O 
and O 
[(14)C]chenodeoxycholic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
CDCA B-ABBREVIATION 
) O 
was O 
determined O 
in O 
sandwich O 
- O 
cultured O 
rat O 
hepatocytes O 
( O 
SCRH O 
) O 
and O 
suspended O 
rat O 
hepatocytes O 
. O 
Lactate B-TRIVIAL 
dehydrogenase O 
and O 
ATP B-ABBREVIATION 
assays O 
revealed O 
a O 
concentration O 
- O 
dependent O 
effect O 
of O 
LPV B-ABBREVIATION 
and O 
RTV B-ABBREVIATION 
on O 
cellular O 
viability O 
. O 
LPV B-ABBREVIATION 
( O 
5 O 
µM O 
) O 
, O 
alone O 
and O 
combined O 
with O 
5 O 
µM O 
RTV B-ABBREVIATION 
, O 
significantly O 
decreased O 
[(3)H]TCA B-SYSTEMATIC 
accumulation O 
in O 
cells O 
+ O 
bile O 
of O 
SCRHs O 
compared O 
with O 
control O 
. O 
LPV B-ABBREVIATION 
/r O 
significantly O 
increased O 
[(3)H]TCA B-SYSTEMATIC 
cellular O 
accumulation O 
( O 
7.7 O 
± O 
0.1 O 
pmol O 
/ O 
mg O 
of O 
protein O 
) O 
compared O 
with O 
vehicle O 
and O 
5 O 
µM O 
LPV B-ABBREVIATION 
alone O 
( O 
5.1 O 
± O 
0.7 O 
and O 
5 O 
± O 
0.5 O 
pmol O 
/ O 
mg O 
of O 
protein O 
) O 
. O 
The O 
[(3)H]TCA B-SYSTEMATIC 
biliary O 
clearance O 
was O 
reduced O 
significantly O 
by O 
LPV B-ABBREVIATION 
and O 
RTV B-ABBREVIATION 
and O 
further O 
reduced O 
by O 
LPV B-ABBREVIATION 
/r O 
. O 
LPV B-ABBREVIATION 
and O 
RTV B-ABBREVIATION 
did O 
not O 
affect O 
the O 
initial O 
uptake O 
rates O 
of O 
[(3)H]TCA B-SYSTEMATIC 
or O 
[(14)C]CDCA B-SYSTEMATIC 
in O 
suspended O 
rat O 
hepatocytes O 
. O 
LPV B-ABBREVIATION 
( O 
50 O 
µM O 
) O 
, O 
RTV B-ABBREVIATION 
( O 
5 O 
µM O 
) O 
, O 
and O 
LPV B-ABBREVIATION 
/r O 
( O 
5 O 
and O 
50 O 
µM O 
/ O 
5 O 
µM O 
) O 
significantly O 
decreased O 
the O 
accumulation O 
of O 
total O 
measured O 
endogenous O 
bile B-FAMILY 
acids I-FAMILY 
( O 
TCA B-ABBREVIATION 
, O 
glycocholic B-TRIVIAL 
acid I-TRIVIAL 
, O 
taurochenodeoxycholic B-TRIVIAL 
acid I-TRIVIAL 
, O 
glycochenodeoxycholic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
α B-MULTIPLE 
/ I-MULTIPLE 
β-tauromuricholic I-MULTIPLE 
acid I-MULTIPLE 
) O 
in O 
SCRH O 
. O 
Quantification O 
of O 
endogenous O 
bile B-FAMILY 
acids I-FAMILY 
in O 
SCRH O 
may O 
reveal O 
important O 
adaptive O 
responses O 
associated O 
with O 
exposure O 
to O 
known O 
BSEP O 
inhibitors O 
. O 

the O 
dispersion O 
of O 
inorganic O 
nanoparticles O 
within O 
organic O 
matrices O 
is O 
critical O 
to O 
optimizing O 
polymer O 
nanocomposite O 
properties O 
and O 
is O 
intrinsically O 
difficult O 
due O 
to O 
their O 
strong O 
enthalpic O 
incompatibility O 
. O 
Conventional O 
attempts O 
to O 
use O 
polymer O 
brushes O 
to O 
control O 
nanoparticle O 
dispersion O 
are O 
challenged O 
by O 
the O 
need O 
for O 
high O 
graft O 
density O 
to O 
reduce O 
particle O 
core O 
- O 
core O 
attractions O 
and O 
the O 
need O 
for O 
low O 
graft O 
density O 
to O 
reduce O 
the O 
entropic O 
penalty O 
for O 
matrix O 
penetration O 
into O 
the O 
brush O 
. O 
We O 
validated O 
a O 
parametric O 
phase O 
diagram O 
previously O 
reported O 
by O 
Pryamtisyn O 
et O 
al O 
. O 
( O 
Pryamtisyn O 
, O 
V O 
. O 
; O 
Ganesan O 
, O 
V O 
. O 
; O 
Panagiotopoulos O 
, O 
A O 
. O 
Z O 
. O 
; O 
Liu O 
, O 
H O 
. O 
; O 
Kumar O 
, O 
S O 
. O 
K O 
. O 
Modeling O 
the O 
Anisotropic O 
Self-Assembly O 
of O 
Spherical O 
Polymer-Grafted O 
Nanoparticles O 
. O 
J O 
. O 
Chem O 
. O 
Phys.2009 O 
, O 
131 O 
, O 
221102 O 
) O 
for O 
predicting O 
dispersion O 
of O 
monomodal O 
- O 
polymer O 
- O 
brush O 
- O 
modified O 
nanoparticles O 
in O 
polymer O 
matrices O 
. O 
The O 
theoretical O 
calculation O 
successfully O 
predicted O 
the O 
experimental O 
observation O 
that O 
the O 
monomodal- O 
poly(dimethyl B-FAMILY 
siloxane I-FAMILY 
) I-FAMILY 
( O 
PDMS B-ABBREVIATION 
)-brush O 
- O 
grafted O 
TiO(2) B-FORMULA 
nanoparticles O 
can O 
only O 
be O 
well O 
dispersed O 
within O 
a O 
small O 
molecular O 
weight O 
silicone B-FAMILY 
matrix O 
. O 
We O 
further O 
extended O 
the O 
parametric O 
phase O 
diagram O 
to O 
analyze O 
the O 
dispersion O 
behavior O 
of O 
bimodal- O 
PDMS B-ABBREVIATION 
-brush O 
- O 
grafted O 
particles O 
, O 
which O 
is O 
also O 
in O 
good O 
agreement O 
with O 
experimental O 
results O 
. O 
Utilizing O 
a O 
bimodal O 
grafted O 
polymer O 
brush O 
design O 
, O 
with O 
densely O 
grafted O 
short O 
brushes O 
to O 
shield O 
particle O 
surfaces O 
and O 
sparsely O 
grafted O 
long O 
brushes O 
that O 
favor O 
the O 
entanglement O 
with O 
matrix O 
chains O 
, O 
we O 
dispersed O 
TiO(2) B-FORMULA 
nanoparticles O 
in O 
high O 
molecular O 
weight O 
commercial O 
silicone B-FAMILY 
matrices O 
and O 
successfully O 
prepared O 
thick O 
( O 
about O 
5 O 
mm O 
) O 
transparent O 
high O 
- O 
refractive O 
- O 
index O 
TiO(2) B-FORMULA 
/ O 
silicone B-FAMILY 
nanocomposites O 
. O 

complete O 
and O 
reversible O 
charge O 
- O 
selective O 
sequestration O 
of O 
fluorophores O 
by O 
a O 
weak O 
polyelectrolyte O 
brush O 
, O 
poly(2-(dimethylamino)ethylmethacrylate) B-FAMILY 
( O 
PDMAEMA B-ABBREVIATION 
) O 
was O 
demonstrated O 
using O 
fluorescence O 
correlation O 
spectroscopy O 
( O 
FCS O 
) O 
. O 
The O 
chemistry O 
and O 
thickness O 
of O 
the O 
weak O 
polyelectrolyte O 
PDMAEMA B-ABBREVIATION 
was O 
tuned O 
reversibly O 
between O 
neutral O 
and O 
cationic O 
polymer O 
forms O 
. O 
Thus O 
, O 
by O 
switching O 
the O 
pH O 
successively O 
, O 
the O 
brush O 
architecture O 
was O 
tuned O 
to O 
selectively O 
trap O 
and O 
release O 
anionic O 
dye O 
probes O 
while O 
continuously O 
excluding O 
cationic O 
molecules O 
. O 
In O 
addition O 
, O 
line O 
- O 
scan O 
FCS O 
was O 
implemented O 
and O 
applied O 
for O 
the O 
first O 
time O 
to O 
a O 
synthetic O 
polymer O 
system O 
and O 
used O 
to O 
identify O 
a O 
new O 
, O 
slower O 
diffusion O 
time O 
on O 
the O 
order O 
of O 
seconds O 
for O 
the O 
sequestered O 
anionic O 
probe O 
under O 
acidic O 
conditions O 
. O 
These O 
results O 
, O 
which O 
quantify O 
the O 
selective O 
sequestration O 
properties O 
of O 
the O 
PDMAEMA B-ABBREVIATION 
brush O 
, O 
are O 
important O 
because O 
they O 
enable O 
a O 
better O 
understanding O 
of O 
transport O 
in O 
polymers O 
and O 
establish O 
a O 
spectroscopic O 
means O 
of O 
evaluating O 
materials O 
with O 
proposed O 
applications O 
in O 
separations O 
science O 
, O 
charge O 
storage O 
/ O 
release O 
, O 
and O 
environmental O 
remediation O 
. O 

associated O 
protein O 
of O 
mTOR O 
( O 
Raptor O 
) O 
and O 
rapamycin B-TRIVIAL 
-insensitive O 
companion O 
of O 
mTOR O 
( O 
rictor O 
) O 
are O 
two O 
proteins O 
that O 
delineate O 
two O 
different O 
mTOR O 
complexes O 
, O 
mTORC1 O 
and O 
mTORC2 O 
respectively O 
. O 
Recent O 
studies O 
demonstrated O 
the O 
role O 
of O 
rictor O 
in O 
the O 
development O 
and O 
function O 
of O 
β-cells O 
. O 
mTORC1 O 
has O 
long O 
been O 
known O 
to O 
impact O 
β-cell O 
function O 
and O 
development O 
. O 
However O 
, O 
most O 
of O 
the O 
studies O 
evaluating O 
its O 
role O 
used O 
either O 
drug O 
treatment O 
( O 
i.e O 
. O 
rapamycin B-TRIVIAL 
) O 
or O 
modification O 
of O 
expression O 
of O 
proteins O 
known O 
to O 
modulate O 
its O 
activity O 
, O 
and O 
the O 
direct O 
role O 
of O 
raptor O 
in O 
insulin O 
secretion O 
is O 
unclear O 
. O 
In O 
this O 
study O 
, O 
using O 
siRNA O 
, O 
we O 
investigated O 
the O 
role O 
of O 
raptor O 
and O 
rictor O 
in O 
insulin O 
secretion O 
and O 
production O 
in O 
INS-1 O 
cells O 
and O 
the O 
possible O 
cross O 
talk O 
between O 
their O 
respective O 
complexes O 
, O 
mTORC1 O 
and O 
mTORC2 O 
. O 
Reduced O 
expression O 
of O 
raptor O 
is O 
associated O 
with O 
increased O 
glucose B-TRIVIAL 
-stimulated O 
insulin O 
secretion O 
and O 
intracellular O 
insulin O 
content O 
. O 
Downregulation O 
of O 
rictor O 
expression O 
leads O 
to O 
impaired O 
insulin O 
secretion O 
without O 
affecting O 
insulin O 
content O 
and O 
is O 
able O 
to O 
correct O 
the O 
increased O 
insulin O 
secretion O 
mediated O 
by O 
raptor O 
siRNA O 
. O 
Using O 
dominant O 
- O 
negative O 
or O 
constitutively O 
active O 
forms O 
of O 
Akt O 
, O 
we O 
demonstrate O 
that O 
the O 
effect O 
of O 
both O 
raptor O 
and O 
rictor O 
is O 
mediated O 
through O 
alteration O 
of O 
Akt O 
signaling O 
. O 
Our O 
finding O 
shed O 
new O 
light O 
on O 
the O 
mechanism O 
of O 
control O 
of O 
insulin O 
secretion O 
and O 
production O 
by O 
the O 
mTOR O 
, O 
and O 
they O 
provide O 
evidence O 
for O 
antagonistic O 
effect O 
of O 
raptor O 
and O 
rictor O 
on O 
insulin O 
secretion O 
in O 
response O 
to O 
glucose B-TRIVIAL 
by O 
modulating O 
the O 
activity O 
of O 
Akt O 
, O 
whereas O 
only O 
raptor O 
is O 
able O 
to O 
control O 
insulin O 
biosynthesis O 
. O 

sleep O 
apnea O 
( O 
OSA O 
) O 
is O 
associated O 
with O 
cardiovascular O 
complications O 
including O 
hypertension O 
. O 
Previous O 
findings O 
from O 
our O 
laboratory O 
indicate O 
that O 
exposure O 
to O 
intermittent O 
hypoxia O 
( O 
IH O 
) O 
, O 
to O 
mimic O 
sleep O 
apnea O 
, O 
increases O 
blood O 
pressure O 
in O 
rats O 
. O 
IH O 
also O 
increases O 
endothelin-1 O 
( O 
ET-1 O 
) O 
constrictor O 
sensitivity O 
in O 
a O 
protein O 
kinase O 
C O 
( O 
PKC O 
) O 
δ-dependent O 
manner O 
in O 
mesenteric O 
arteries O 
. O 
Because O 
phosphoinositide-dependent O 
kinase-1 O 
( O 
PDK-1 O 
) O 
regulates O 
PKCδ O 
activity O 
, O 
we O 
hypothesized O 
that O 
PDK-1 O 
contributes O 
to O 
the O 
augmented O 
ET-1 O 
constrictor O 
sensitivity O 
and O 
elevated O 
blood O 
pressure O 
following O 
IH O 
. O 
Male O 
Sprague-Dawley O 
rats O 
were O 
exposed O 
to O 
either O 
sham O 
or O 
IH O 
( O 
cycles O 
between O 
21% O 
O(2) B-FORMULA 
/ O 
0% O 
CO(2) B-FORMULA 
and O 
5% O 
O(2) B-FORMULA 
/ O 
5% O 
CO(2) B-FORMULA 
) O 
conditions O 
for O 
7 O 
h O 
/ O 
day O 
for O 
14 O 
or O 
21 O 
days O 
. O 
The O 
contribution O 
of O 
PKCδ O 
and O 
PDK-1 O 
to O 
ET-1 O 
- O 
mediated O 
vasoconstriction O 
was O 
assessed O 
in O 
mesenteric O 
arteries O 
using O 
pharmacological O 
inhibitors O 
. O 
Constrictor O 
sensitivity O 
to O 
ET-1 O 
was O 
enhanced O 
in O 
arteries O 
from O 
IH-exposed O 
rats O 
. O 
Inhibition O 
of O 
PKCδ O 
or O 
PDK-1 O 
blunted O 
ET-1 O 
constriction O 
in O 
arteries O 
from O 
IH O 
but O 
not O 
sham O 
group O 
rats O 
. O 
Western O 
analysis O 
revealed O 
similar O 
levels O 
of O 
total O 
and O 
phosphorylated O 
PDK-1 O 
in O 
arteries O 
from O 
sham O 
and O 
IH O 
group O 
rats O 
but O 
decreased O 
protein O 
- O 
protein O 
interaction O 
between O 
PKCδ O 
and O 
PDK-1 O 
in O 
arteries O 
from O 
IH- O 
compared O 
with O 
sham O 
- O 
exposed O 
rats O 
. O 
Blood O 
pressure O 
was O 
increased O 
in O 
rats O 
exposed O 
to O 
IH O 
, O 
and O 
treatment O 
with O 
the O 
PDK-1 O 
inhibitor O 
OSU-03012 B-IDENTIFIER 
[ O 
2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide B-SYSTEMATIC 
] O 
( O 
33 O 
mg O 
/ O 
day O 
) O 
lowered O 
blood O 
pressure O 
in O 
IH O 
but O 
not O 
sham O 
group O 
rats O 
. O 
Our O 
results O 
suggest O 
that O 
exposure O 
to O 
IH O 
unmasks O 
a O 
role O 
for O 
PDK-1 O 
in O 
regulating O 
ET-1 O 
constrictor O 
sensitivity O 
and O 
blood O 
pressure O 
that O 
is O 
not O 
present O 
under O 
normal O 
conditions O 
. O 
These O 
novel O 
findings O 
suggest O 
that O 
PDK-1 O 
may O 
be O 
a O 
uniquely O 
effective O 
antihypertensive O 
therapy O 
for O 
OSA O 
patients O 
. O 

liver O 
protein O 
sulfhydryl B-FAMILY 
depletion O 
after O 
acetaminophen B-TRIVIAL 
exposure O 
. O 

( O 
APAP B-ABBREVIATION 
)-induced O 
liver O 
injury O 
is O 
the O 
leading O 
cause O 
of O 
acute O 
liver O 
failure O 
in O 
many O 
countries O 
. O 
This O 
study O 
determined O 
the O 
extent O 
of O 
liver O 
protein O 
sulfhydryl B-FAMILY 
depletion O 
not O 
only O 
in O 
whole O 
liver O 
homogenate O 
but O 
also O 
in O 
the O 
zonal O 
pattern O 
of O 
sulfhydryl B-FAMILY 
depletion O 
within O 
the O 
liver O 
lobule O 
. O 
A O 
single O 
oral O 
gavage O 
dose O 
of O 
150 O 
or O 
300 O 
mg O 
/ O 
kg O 
APAP B-ABBREVIATION 
in O 
B6C3F1 O 
mice O 
produced O 
increased O 
serum O 
alanine B-TRIVIAL 
aminotransferase O 
levels O 
, O 
liver O 
necrosis O 
, O 
and O 
glutathione B-TRIVIAL 
depletion O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Free O 
protein O 
sulfhydryls B-FAMILY 
were O 
measured O 
in O 
liver O 
protein O 
homogenates O 
by O 
labeling O 
with O 
maleimide B-SYSTEMATIC 
linked O 
to O 
a O 
near O 
infrared O 
fluorescent O 
dye O 
followed O 
by O 
SDS B-ABBREVIATION 
- O 
polyacrylamide B-SYSTEMATIC 
gel O 
electrophoresis O 
. O 
Global O 
protein O 
sulfhydryl B-FAMILY 
levels O 
were O 
decreased O 
significantly O 
( O 
48.4% O 
) O 
starting O 
at O 
1 O 
hour O 
after O 
the O 
APAP B-ABBREVIATION 
dose O 
and O 
maintained O 
at O 
this O 
reduced O 
level O 
through O 
24 O 
hours O 
. O 
To O 
visualize O 
the O 
specific O 
hepatocytes O 
that O 
had O 
reduced O 
protein O 
sulfhydryl B-FAMILY 
levels O 
, O 
frozen O 
liver O 
sections O 
were O 
labeled O 
with O 
maleimide B-SYSTEMATIC 
linked O 
to O 
horseradish O 
peroxidase O 
. O 
The O 
centrilobular O 
areas O 
exhibited O 
dramatic O 
decreases O 
in O 
free O 
protein O 
sulfhydryls B-FAMILY 
while O 
the O 
periportal O 
regions O 
were O 
essentially O 
spared O 
. O 
These O 
protein O 
sulfhydryl B-FAMILY 
-depleted O 
regions O 
correlated O 
with O 
areas O 
exhibiting O 
histopathologic O 
injury O 
and O 
APAP B-ABBREVIATION 
binding O 
to O 
protein O 
. O 
The O 
majority O 
of O 
protein O 
sulfhydryl B-FAMILY 
depletion O 
was O 
due O 
to O 
reversible O 
oxidation O 
since O 
the O 
global- O 
and O 
lobule O 
- O 
specific O 
effects O 
were O 
essentially O 
reversed O 
when O 
the O 
samples O 
were O 
reduced O 
with O 
tris(2-carboxyethy)phosphine B-SYSTEMATIC 
before O 
maleimide B-SYSTEMATIC 
labeling O 
. O 
These O 
temporal O 
and O 
zonal O 
pattern O 
changes O 
in O 
protein O 
sulfhydryl B-FAMILY 
oxidation O 
shed O 
new O 
light O 
on O 
the O 
importance O 
that O 
changes O 
in O 
protein O 
redox O 
status O 
might O 
play O 
in O 
the O 
pathogenesis O 
of O 
APAP B-ABBREVIATION 
hepatotoxicity O 
. O 

sensitivity O 
of O 
slo1 O 
channel O 
proteins O 
to O 
ethanol B-SYSTEMATIC 
. O 

levels O 
reached O 
in O 
circulation O 
during O 
moderate O 
- O 
to O 
- O 
heavy O 
alcohol B-FAMILY 
intoxication O 
( O 
50-100 O 
mM O 
) O 
modify O 
Ca(2+) B-FORMULA 
- O 
and O 
voltage O 
- O 
gated O 
K(+) B-FORMULA 
( O 
BK O 
) O 
channel O 
steady O 
- O 
state O 
activity O 
, O 
eventually O 
altering O 
both O 
physiology O 
and O 
behavior O 
. O 
Ethanol B-SYSTEMATIC 
action O 
on O 
BK O 
steady O 
- O 
state O 
activity O 
solely O 
requires O 
the O 
channel O 
- O 
forming O 
subunit O 
slo1 O 
within O 
a O 
bare O 
lipid O 
environment O 
. O 
To O 
identify O 
the O 
protein O 
regions O 
that O 
confer O 
ethanol B-SYSTEMATIC 
sensitivity O 
to O 
slo1 O 
, O 
we O 
tested O 
the O 
ethanol B-SYSTEMATIC 
sensitivity O 
of O 
heterologously O 
expressed O 
slo1 O 
and O 
structurally O 
related O 
channels O 
. O 
Ethanol B-SYSTEMATIC 
( O 
50 O 
mM O 
) O 
increased O 
the O 
steady O 
- O 
state O 
activities O 
of O 
mslo1 O 
and O 
Ca(2+) B-FORMULA 
-gated O 
MthK O 
, O 
the O 
latter O 
after O 
channel O 
reconstitution O 
into O 
phospholipid O 
bilayers O 
. O 
In O 
contrast O 
, O 
50-100 O 
mM O 
ethanol B-SYSTEMATIC 
failed O 
to O 
alter O 
the O 
steady O 
- O 
state O 
activities O 
of O 
Na(+) B-FORMULA 
/ O 
Cl(-) B-FORMULA 
-gated O 
rslo2 O 
, O 
H(+) B-FORMULA 
-gated O 
mslo3 O 
, O 
and O 
an O 
mslo1 O 
/ O 
3 O 
chimera O 
engineered O 
by O 
joining O 
the O 
mslo1 O 
region O 
encompassing O 
the O 
N B-FORMULA 
terminus O 
to O 
S6 O 
with O 
the O 
mslo3 O 
cytosolic O 
tail O 
domain O 
( O 
CTD O 
) O 
. O 
Collectively O 
, O 
data O 
indicate O 
that O 
the O 
slo O 
family O 
canonical O 
design O 
, O 
which O 
combines O 
a O 
transmembrane O 
6 O 
( O 
TM6 O 
) O 
voltage O 
- O 
gated O 
K(+) B-FORMULA 
channel O 
( O 
K B-FORMULA 
( O 
V O 
) O 
) O 
core O 
with O 
CTDs O 
that O 
empower O 
the O 
channel O 
with O 
ion O 
- O 
sensing O 
, O 
does O 
not O 
necessarily O 
render O 
ethanol B-SYSTEMATIC 
sensitivity O 
. O 
In O 
addition O 
, O 
the O 
region O 
encompassing O 
the O 
N B-FORMULA 
terminus O 
to O 
the O 
S0-S1 O 
cytosolic O 
loop O 
( O 
missing O 
in O 
MthK O 
) O 
is O 
not O 
necessary O 
for O 
ethanol B-SYSTEMATIC 
action O 
. O 
Moreover O 
, O 
incorporation O 
of O 
both O 
this O 
region O 
and O 
an O 
ion O 
- O 
sensing O 
CTD O 
to O 
TM6 O 
K B-FORMULA 
(V) O 
cores O 
( O 
a O 
design O 
common O 
to O 
mslo1 O 
, O 
mslo3 O 
, O 
and O 
the O 
mslo1 O 
/ O 
mslo3 O 
chimera O 
) O 
is O 
not O 
sufficient O 
for O 
ethanol B-SYSTEMATIC 
sensitivity O 
. O 
Rather O 
, O 
a O 
CTD O 
containing O 
Ca(2+) B-FORMULA 
-sensing O 
regulator O 
of O 
conductance O 
for O 
K(+) B-FORMULA 
domains O 
seems O 
to O 
be O 
critical O 
to O 
bestow O 
K B-FORMULA 
(V) O 
structures O 
, O 
whether O 
of O 
TM2 O 
( O 
MthK O 
) O 
or O 
TM6 O 
( O 
slo1 O 
) O 
, O 
with O 
sensitivity O 
to O 
intoxicating O 
ethanol B-SYSTEMATIC 
levels O 
. O 

of O 
determinants O 
required O 
for O 
agonistic O 
and O 
inverse O 
agonistic O 
ligand O 
properties O 
at O 
the O 
ADP B-ABBREVIATION 
receptor O 
P2Y12 O 
. O 

ADP B-ABBREVIATION 
receptor O 
P2Y(12) O 
belongs O 
to O 
the O 
superfamily O 
of O 
G O 
protein O 
- O 
coupled O 
receptors O 
( O 
GPCRs O 
) O 
, O 
and O 
its O 
activation O 
triggers O 
platelet O 
aggregation O 
. O 
Therefore O 
, O 
potent O 
antagonists O 
, O 
such O 
as O 
clopidogrel B-TRIVIAL 
, O 
are O 
of O 
high O 
clinical O 
relevance O 
in O 
prophylaxis O 
and O 
treatment O 
of O 
thromboembolic O 
events O 
. O 
P2Y(12) O 
displays O 
an O 
elevated O 
basal O 
activity O 
in O 
vitro O 
, O 
and O 
as O 
such O 
, O 
inverse O 
agonists O 
may O 
be O 
therapeutically O 
beneficial O 
compared O 
with O 
antagonists O 
. O 
Only O 
a O 
few O 
inverse O 
agonists O 
of O 
P2Y(12) O 
have O 
been O 
described O 
. O 
To O 
expand O 
this O 
limited O 
chemical O 
space O 
and O 
improve O 
understanding O 
of O 
structural O 
determinants O 
of O 
inverse O 
agonist O 
- O 
receptor O 
interaction O 
, O 
this O 
study O 
screened O 
a O 
purine B-TRIVIAL 
compound O 
library O 
for O 
lead O 
structures O 
using O 
wild O 
- O 
type O 
( O 
WT O 
) O 
human O 
P2Y(12) O 
and O 
28 O 
constitutively O 
active O 
mutants O 
. O 
Results O 
showed O 
that O 
ATP B-ABBREVIATION 
and O 
ATP B-ABBREVIATION 
derivatives O 
are O 
agonists O 
at O 
P2Y(12) O 
. O 
The O 
potency O 
at O 
P2Y(12) O 
was O 
2-(methylthio)-ADP B-SYSTEMATIC 
> O 
2-(methylthio)-ATP B-SYSTEMATIC 
> O 
ADP B-ABBREVIATION 
> O 
ATP B-ABBREVIATION 
. O 
Determinants O 
required O 
for O 
agonistic O 
ligand O 
activity O 
were O 
identified O 
. O 
Molecular O 
docking O 
studies O 
revealed O 
a O 
binding O 
pocket O 
for O 
the O 
ATP B-ABBREVIATION 
derivatives O 
that O 
is O 
bordered O 
by O 
transmembrane O 
helices O 
3 O 
, O 
5 O 
, O 
6 O 
, O 
and O 
7 O 
in O 
human O 
P2Y(12,) O 
with O 
Y(105) O 
, O 
E(188) O 
, O 
R(256) O 
, O 
Y(259) O 
, O 
and O 
K(280) O 
playing O 
a O 
particularly O 
important O 
role O 
in O 
ligand O 
interaction O 
. O 
N-Methyl-anthraniloyl B-SYSTEMATIC 
modification O 
at O 
the O 
3'-OH B-SYSTEMATIC 
of O 
the O 
2'-deoxyribose B-SYSTEMATIC 
leads O 
to O 
ligands O 
( O 
mant-deoxy- O 
ATP B-ABBREVIATION 
[ O 
dATP O 
] O 
, O 
mant-deoxy- O 
ADP B-ABBREVIATION 
) O 
with O 
inverse O 
agonist O 
activity O 
. O 
Inverse O 
agonist O 
activity O 
of O 
mant-dATP O 
was O 
found O 
at O 
the O 
WT O 
human O 
P2Y(12) O 
and O 
half O 
of O 
the O 
constitutive O 
active O 
P2Y(12) O 
mutants O 
. O 
This O 
study O 
showed O 
that O 
, O 
in O 
addition O 
to O 
ADP B-ABBREVIATION 
and O 
ATP B-ABBREVIATION 
, O 
other O 
ATP B-ABBREVIATION 
derivatives O 
are O 
not O 
only O 
ligands O 
of O 
P2Y(12) O 
but O 
also O 
agonists O 
. O 
Modification O 
of O 
the O 
ribose O 
within O 
ATP B-ABBREVIATION 
can O 
result O 
in O 
inverse O 
activity O 
of O 
ATP B-ABBREVIATION 
-derived O 
ligands O 
. O 

evidence O 
supports O 
the O 
assumption O 
that O 
antiserotonergic O 
second O 
- O 
generation O 
antipsychotics O 
( O 
SGA O 
) O 
induce O 
and O 
aggravate O 
obsessive O 
- O 
compulsive O 
symptoms O 
( O 
OCS O 
) O 
in O 
schizophrenia O 
. O 
However O 
, O 
multimodal O 
studies O 
assessing O 
the O 
long O 
- O 
term O 
interaction O 
of O 
pharmacotherapy O 
and O 
psychopathology O 
are O 
missing O 
. O 
Over O 
12 O 
months O 
, O 
we O 
followed O 
- O 
up O 
75 O 
schizophrenia O 
patients O 
who O 
were O 
classified O 
into O 
two O 
groups O 
according O 
to O 
antipsychotic O 
treatment O 
: O 
clozapine B-TRIVIAL 
or O 
olanzapine B-TRIVIAL 
( O 
group O 
I O 
) O 
versus O 
aripiprazole B-TRIVIAL 
or O 
amisulpride B-TRIVIAL 
( O 
group O 
II O 
) O 
. O 
We O 
applied O 
the O 
Yale O 
Brown O 
Obsessive O 
Compulsive O 
Scale O 
( O 
YBOCS O 
) O 
and O 
investigated O 
between O 
- O 
group O 
changes O 
over O 
time O 
as O 
the O 
primary O 
endpoint O 
. O 
Group O 
I O 
showed O 
markedly O 
higher O 
YBOCS O 
scores O 
at O 
both O 
time O 
points O 
. O 
Repeated O 
measure O 
analyses O 
of O 
variance O 
( O 
ANOVAs O 
) O 
revealed O 
significant O 
interaction O 
effects O 
of O 
group O 
and O 
time O 
( O 
per O 
protocol O 
sample O 
( O 
PP O 
) O 
: O 
p=0.006 O 
) O 
. O 
This O 
was O 
due O 
to O 
persistently O 
high O 
OCS O 
severity O 
within O 
group O 
I O 
, O 
and O 
decreasing O 
YBOCS O 
scores O 
within O 
group O 
II O 
. O 
OCS O 
severity O 
correlated O 
significantly O 
with O 
the O 
negative O 
and O 
general O 
psychopathology O 
subscales O 
of O 
the O 
Positive O 
and O 
Negative O 
Syndrome O 
Scale O 
( O 
PANSS O 
) O 
, O 
as O 
well O 
as O 
with O 
depressive O 
symptoms O 
. O 
The O 
progressive O 
differences O 
in O 
OCS O 
severity O 
between O 
our O 
groups O 
support O 
the O 
assumption O 
of O 
differential O 
pharmacodynamic O 
effects O 
on O 
comorbid O 
OCS O 
in O 
schizophrenia O 
. O 
Further O 
studies O 
should O 
address O 
the O 
pathogenetic O 
mechanism O 
, O 
define O 
patients O 
at O 
risk O 
and O 
facilitate O 
early O 
detection O 
as O 
well O 
as O 
therapeutic O 
interventions O 
. O 

this O 
study O 
, O 
we O 
investigated O 
the O 
role O 
of O 
intercellular O 
adhesion O 
molecule-2 O 
( O 
ICAM2 O 
) O 
in O 
the O 
testis O 
. O 
ICAM2 O 
is O 
a O 
cell O 
adhesion O 
protein O 
having O 
important O 
roles O 
in O 
cell O 
migration O 
, O 
especially O 
during O 
inflammation O 
when O 
leukocytes O 
cross O 
the O 
endothelium O 
. O 
Herein O 
, O 
we O 
showed O 
ICAM2 O 
to O 
be O 
expressed O 
by O 
germ O 
and O 
Sertoli O 
cells O 
in O 
the O 
rat O 
testis O 
. O 
When O 
a O 
monospecific O 
antibody O 
was O 
used O 
for O 
immunolocalization O 
experiments O 
, O 
ICAM2 O 
was O 
found O 
to O 
surround O 
the O 
heads O 
of O 
elongating O 
/ O 
elongated O 
spermatids O 
in O 
all O 
stages O 
of O 
the O 
seminiferous O 
epithelial O 
cycle O 
. O 
To O 
determine O 
whether O 
ICAM2 O 
is O 
a O 
constituent O 
of O 
apical O 
ectoplasmic O 
specialization O 
( O 
ES O 
) O 
, O 
co O 
- O 
immunoprecipitation O 
and O 
dual O 
immunofluorescence O 
staining O 
were O 
performed O 
. O 
Interestingly O 
, O 
ICAM2 O 
was O 
found O 
to O 
associate O 
with O 
β1-integrin O 
, O 
nectin-3 O 
, O 
afadin O 
, O 
Src O 
, O 
proline O 
- O 
rich O 
tyrosine B-TRIVIAL 
kinase O 
2 O 
, O 
annexin O 
II O 
, O 
and O 
actin O 
. O 
Following O 
CdCl₂ B-FORMULA 
treatment O 
, O 
ICAM2 O 
was O 
found O 
to O 
be O 
upregulated O 
during O 
restructuring O 
of O 
the O 
seminiferous O 
epithelium O 
, O 
with O 
round O 
spermatids O 
becoming O 
increasingly O 
immunoreactive O 
for O 
ICAM2 O 
by O 
6-16 O 
h O 
. O 
Interestingly O 
, O 
there O 
was O 
a O 
loss O 
in O 
the O 
binding O 
of O 
ICAM2 O 
to O 
actin O 
during O 
CdCl₂ B-FORMULA 
-induced O 
germ O 
cell O 
loss O 
, O 
suggesting O 
that O 
a O 
loss O 
of O 
ICAM2-actin O 
interactions O 
might O 
have O 
facilitated O 
junction O 
restructuring O 
. O 
Taken O 
collectively O 
, O 
these O 
results O 
illustrate O 
that O 
ICAM2 O 
plays O 
an O 
important O 
role O 
in O 
apical O 
ES O 
dynamics O 
during O 
spermatogenesis O 
. O 

targeting O 
G O 
- O 
protein O 
- O 
coupled O 
receptors O 
( O 
GPCRs O 
) O 
make O 
up O 
more O 
than O 
25% O 
of O 
all O 
prescribed O 
medicines O 
. O 
The O 
ability O 
of O 
GPCRs O 
to O 
form O 
heteromers O 
with O 
unique O 
signaling O 
properties O 
suggests O 
an O 
entirely O 
new O 
and O 
unexplored O 
pool O 
of O 
drug O 
targets O 
. O 
However O 
, O 
current O 
in O 
vitro O 
assays O 
are O 
ill O 
equipped O 
to O 
detect O 
heteromer O 
- O 
selective O 
compounds O 
. O 
We O 
have O 
successfully O 
adapted O 
an O 
approach O 
, O 
using O 
fusion O 
proteins O 
of O 
GPCRs O 
and O 
chimeric O 
G O 
proteins O 
, O 
to O 
create O 
an O 
in O 
vitro O 
screening O 
assay O 
( O 
in O 
human O 
embryonic O 
kidney O 
cells O 
) O 
in O 
which O 
only O 
activated O 
heteromers O 
are O 
detectable O 
. O 
Here O 
we O 
show O 
that O 
this O 
assay O 
can O 
demonstrate O 
heteromer O 
- O 
selective O 
G O 
- O 
protein O 
bias O 
as O 
well O 
as O 
measure O 
transinhibition O 
. O 
Using O 
this O 
assay O 
, O 
we O 
reveal O 
that O 
the O 
δ-opioid O 
receptor O 
agonist O 
ADL5859 B-IDENTIFIER 
, O 
which O 
is O 
currently O 
in O 
clinical O 
trials O 
, O 
has O 
a O 
10-fold O 
higher O 
potency O 
against O 
δ-opioid O 
receptor O 
homomers O 
than O 
δ O 
/ O 
μ-opioid O 
receptor O 
heteromers O 
( O 
pEC(50) O 
= O 
6.7 O 
± O 
0.1 O 
versus O 
5.8 O 
± O 
0.2 O 
) O 
. O 
The O 
assay O 
enables O 
the O 
screening O 
of O 
large O 
compound O 
libraries O 
to O 
identify O 
heteromer O 
- O 
selective O 
compounds O 
that O 
could O 
then O 
be O 
used O 
in O 
vivo O 
to O 
determine O 
the O 
functional O 
role O 
of O 
heteromers O 
and O 
develop O 
potential O 
therapeutic O 
agents O 
. O 

new O 
anthraquinone B-SYSTEMATIC 
dimers O 
from O 
the O 
fruit O 
bodies O 
of O 
Bulgaria O 
inquinans O 
. O 

new O 
dimeric O 
anthraquinone B-SYSTEMATIC 
derivatives O 
, O 
bulgareone B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
and O 
bulgareone B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
fruit O 
bodies O 
of O 
Bulgaria O 
inquinans O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
extensive O 
spectroscopic O 
analysis O 
. O 
The O 
in O 
vitro O 
cytotoxic O 
activity O 
of O 
compounds O 
1 O 
and O 
2 O 
was O 
assayed O 
. O 
They O 
displayed O 
inhibitive O 
activities O 
against O 
human O 
cancer O 
cell O 
lines O 
HL60 O 
and O 
K562 O 
. O 

differences O 
in O 
effects O 
of O 
low O 
level O 
domoic B-TRIVIAL 
acid I-TRIVIAL 
exposure O 
. O 

of O 
seafood O 
containing O 
the O 
phytoplankton O 
- O 
derived O 
toxin O 
domoic B-TRIVIAL 
acid I-TRIVIAL 
( O 
DOM B-ABBREVIATION 
) O 
causes O 
neurotoxicity O 
in O 
humans O 
and O 
in O 
animals O 
. O 
It O 
has O 
been O 
reported O 
that O 
DOM B-ABBREVIATION 
-induced O 
symptoms O 
may O 
be O 
more O 
severe O 
in O 
men O 
than O 
women O 
, O 
but O 
to O 
date O 
the O 
effect O 
of O 
sex O 
on O 
DOM B-ABBREVIATION 
-induced O 
effects O 
in O 
adults O 
is O 
not O 
known O 
. O 
We O 
investigated O 
sex O 
differences O 
in O 
DOM B-ABBREVIATION 
-induced O 
effects O 
in O 
adult O 
rats O 
. O 
Since O 
low O 
level O 
exposure O 
is O 
of O 
greatest O 
relevance O 
to O 
human O 
health O 
( O 
due O 
to O 
DOM B-ABBREVIATION 
regulatory O 
limit O 
) O 
, O 
we O 
examined O 
the O 
effects O 
of O 
low O 
level O 
exposure O 
. O 
Adult O 
male O 
and O 
female O 
Sprague O 
Dawley O 
rats O 
were O 
administered O 
a O 
single O 
intraperitoneal O 
injection O 
of O 
DOM B-ABBREVIATION 
( O 
0 O 
, O 
1 O 
, O 
1.8 O 
mg O 
/ O 
kg O 
) O 
. O 
Behaviour O 
was O 
monitored O 
for O 
3h O 
and O 
immunohistochemistry O 
in O 
the O 
dorsal O 
hippocampus O 
and O 
olfactory O 
bulb O 
was O 
also O 
examined O 
. O 
DOM B-ABBREVIATION 
increased O 
locomotor O 
and O 
grooming O 
activity O 
, O 
compared O 
to O 
vehicle O 
group O 
. O 
DOM B-ABBREVIATION 
exposure O 
also O 
significantly O 
increased O 
stereotypic O 
behaviours O 
and O 
decreased O 
phosphorylated B-ABBREVIATION 
cAMP I-ABBREVIATION 
response O 
element O 
- O 
binding O 
protein O 
immunoreactivity O 
( O 
pCREB-IR O 
) O 
. O 
There O 
was O 
no O 
effect O 
of O 
sex O 
on O 
the O 
magnitude O 
of O 
the O 
behavioural O 
responses O 
, O 
but O 
the O 
onset O 
of O 
DOM B-ABBREVIATION 
-induced O 
locomotor O 
activity O 
and O 
ear O 
scratches O 
was O 
quicker O 
in O 
females O 
than O 
in O 
males O 
. O 
Mixed O 
effect O 
modelling O 
revealed O 
the O 
predicted O 
peak O 
in O 
locomotor O 
activity O 
in O 
response O 
to O 
DOM B-ABBREVIATION 
was O 
also O 
quicker O 
in O 
females O 
than O 
in O 
males O 
. O 
Severe O 
toxicity O 
was O 
evident O 
in O 
2 O 
/ O 
7 O 
male O 
rats O 
and O 
0 O 
/ O 
8 O 
female O 
rats O 
dosed O 
with O 
1.8 O 
mg O 
/ O 
kg O 
DOM B-ABBREVIATION 
. O 
These O 
data O 
suggest O 
that O 
males O 
exposed O 
to O 
low O 
level O 
DOM B-ABBREVIATION 
may O 
be O 
more O 
susceptible O 
to O 
severe O 
neurotoxicity O 
, O 
whereas O 
females O 
are O 
affected O 
more O 
quickly O 
. O 
Understanding O 
sex O 
differences O 
in O 
DOM B-ABBREVIATION 
-induced O 
neurotoxicity O 
may O 
contribute O 
to O 
future O 
protective O 
strategies O 
and O 
treatments O 
. O 

study O 
and O 
absolute O 
oral O 
bioavailability O 
of O 
deoxynivalenol B-TRIVIAL 
, O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
and O 
zearalenone B-TRIVIAL 
in O 
broiler O 
chickens O 
. O 

lead O 
to O 
economic O 
losses O 
in O 
animal O 
production O 
. O 
A O 
way O 
to O 
counteract O 
mycotoxicosis O 
is O 
the O 
use O 
of O 
detoxifiers O 
. O 
The O 
European O 
Food O 
Safety O 
Authority O 
stated O 
that O 
the O 
efficacy O 
of O 
detoxifiers O 
should O 
be O 
investigated O 
based O 
on O 
toxicokinetic O 
studies O 
. O 
Little O 
information O 
is O 
available O 
on O 
the O 
absolute O 
oral O 
bioavailability O 
and O 
the O 
toxicokinetic O 
parameters O 
of O 
deoxynivalenol B-TRIVIAL 
, O 
T-2 B-TRIVIAL 
and O 
zearalenone B-TRIVIAL 
in O 
broilers O 
. O 
Toxins O 
were O 
administered O 
intravenously O 
and O 
orally O 
in O 
a O 
two O 
- O 
way O 
cross O 
- O 
over O 
design O 
. O 
For O 
deoxynivalenol B-TRIVIAL 
a O 
bolus O 
of O 
0.75mg O 
/ O 
kg O 
BW O 
was O 
administered O 
, O 
for O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
0.02mg O 
/ O 
kg O 
BW O 
and O 
for O 
zearalenone B-TRIVIAL 
0.3mg O 
/ O 
kg O 
BW O 
. O 
Blood O 
was O 
collected O 
at O 
several O 
time O 
points O 
. O 
Plasma O 
levels O 
of O 
the O 
mycotoxins O 
and O 
their O 
metabolite(s) O 
were O 
quantified O 
using O 
LC-MS O 
/ O 
MS O 
methods O 
and O 
toxicokinetic O 
parameters O 
were O 
analyzed O 
. O 
Deoxynivalenol B-TRIVIAL 
has O 
a O 
low O 
absolute O 
oral O 
bioavailability O 
( O 
19.3% O 
) O 
. O 
For O 
zearalenone B-TRIVIAL 
and O 
T-2 B-TRIVIAL 
no O 
plasma O 
levels O 
above O 
the O 
limit O 
of O 
quantification O 
were O 
observed O 
after O 
an O 
oral O 
bolus O 
. O 
Volumes O 
of O 
distribution O 
were O 
recorded O 
, O 
i.e O 
. O 
4.99 O 
, O 
0.14 O 
and O 
22.26L O 
/ O 
kg O 
for O 
deoxynivalenol B-TRIVIAL 
, O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
and O 
zearalenone B-TRIVIAL 
, O 
respectively O 
. O 
Total O 
body O 
clearance O 
was O 
0.12 O 
, O 
0.03 O 
and O 
0.48L O 
/ O 
minkg O 
for O 
deoxynivalenol B-TRIVIAL 
, O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
and O 
zearalenone B-TRIVIAL 
, O 
respectively O 
. O 
After O 
IV O 
administration O 
, O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
had O 
the O 
shortest O 
elimination O 
half O 
- O 
life O 
( O 
3.9min O 
) O 
, O 
followed O 
by O 
deoxynivalenol B-TRIVIAL 
( O 
27.9min O 
) O 
and O 
zearalenone B-TRIVIAL 
( O 
31.8min O 
) O 
. O 

peel O 
polymethoxylated B-FAMILY 
flavones I-FAMILY 
extract O 
modulates O 
liver O 
and O 
heart O 
function O 
parameters O 
in O 
diet O 
induced O 
hypercholesterolemic O 
rats O 
. O 

primary O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
effects O 
of O 
Ortanique O 
peel O 
polymethoxylated B-FAMILY 
flavones I-FAMILY 
extract O 
( O 
PMF B-ABBREVIATION 
( O 
ort O 
) O 
) O 
on O 
organ O 
function O 
parameters O 
in O 
the O 
serum O 
of O 
hypercholesterolemic O 
and O 
normal O 
rats O 
. O 
Thirty O 
Sprague-Dawley O 
rats O 
were O 
fed O 
high O 
cholesterol B-TRIVIAL 
diets O 
supplemented O 
with O 
1.5% O 
PMF B-ABBREVIATION 
( O 
ort O 
) O 
and O 
niacin O 
respectively O 
for O 
49days O 
. O 
Hypercholesterolemic O 
rats O 
fed O 
PMF B-ABBREVIATION 
( O 
ort O 
) O 
had O 
significant O 
reductions O 
in O 
the O 
activities O 
of O 
aspartate B-TRIVIAL 
aminotransferase O 
and O 
alkaline O 
phosphatase O 
( O 
69.12±3.34 O 
and O 
87.22±8.42U O 
/ O 
L O 
respectively O 
) O 
compared O 
to O 
the O 
untreated O 
hypercholesterolemic O 
group O 
( O 
118.61±4.85 O 
and O 
132.62±10.62U O 
/ O 
L O 
respectively O 
, O 
p O 
< O 
0.05 O 
) O 
. O 
Supplementation O 
of O 
the O 
diet O 
with O 
niacin B-TRIVIAL 
or O 
PMF B-ABBREVIATION 
( O 
ort O 
) O 
resulted O 
in O 
no O 
significant O 
differences O 
in O 
the O 
serum O 
levels O 
of O 
creatinine B-TRIVIAL 
or O 
urea B-TRIVIAL 
in O 
any O 
of O 
the O 
groups O 
. O 
Total O 
bilirubin B-TRIVIAL 
was O 
highest O 
in O 
the O 
untreated O 
hypercholesterolemic O 
group O 
. O 
Supplementation O 
of O 
the O 
diets O 
of O 
hypercholesterolemic O 
rats O 
with O 
PMF B-ABBREVIATION 
( O 
ort O 
) O 
resulted O 
in O 
significant O 
reductions O 
in O 
the O 
activities O 
of O 
serum O 
creatine B-TRIVIAL 
kinase O 
and O 
lactate B-FAMILY 
dehydrogenase O 
( O 
119.3±25.3 O 
; O 
222.5±50.3U O 
/ O 
L O 
, O 
p O 
< O 
0.05 O 
) O 
respectively O 
relative O 
to O 
the O 
untreated O 
hypercholesterolemic O 
group O 
( O 
257.2±48.3 O 
; O 
648.8±103U O 
/ O 
L O 
, O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
results O 
would O 
suggest O 
that O 
PMF B-ABBREVIATION 
( O 
ort O 
) O 
modulates O 
hypercholesterolemia O 
- O 
associated O 
organ O 
injury O 
in O 
rats O 
. O 
PMF B-ABBREVIATION 
( O 
ort O 
) O 
could O 
therefore O 
be O 
a O 
suitable O 
candidate O 
for O 
prophylactic O 
and O 
therapeutic O 
treatment O 
of O 
hypercholesterolemia O 
- O 
associated O 
organ O 
injury O 
. O 

of O 
immunotoxicity O 
and O 
genotoxicity O 
in O 
workers O 
exposed O 
to O 
low O 
concentrations O 
of O 
formaldehyde B-SYSTEMATIC 
. O 

( O 
FA O 
) O 
, O 
which O 
is O 
an O 
important O 
chemical O 
with O 
a O 
wide O 
commercial O 
use O 
, O 
has O 
been O 
classified O 
as O 
carcinogenic O 
to O 
humans O 
by O 
International O 
Research O 
on O 
Cancer O 
( O 
IARC O 
) O 
. O 
The O 
genotoxic O 
and O 
carcinogenic O 
potential O 
of O 
FA O 
has O 
been O 
documented O 
in O 
mammalian O 
cells O 
and O 
in O 
rodents O 
. O 
A O 
recent O 
evaluation O 
by O 
the O 
E.U O 
. O 
Scientific O 
Committee O 
for O 
Occupational O 
Exposure O 
Limits O 
( O 
SCOEL O 
) O 
anticipated O 
that O 
an O 
8-h O 
time O 
- O 
weighted O 
average O 
exposure O 
to O 
0.2 O 
ppm O 
FA O 
would O 
not O 
be O 
irritating O 
and O 
not O 
genotoxic O 
in O 
humans O 
. O 
In O 
order O 
to O 
verify O 
this O 
prediction O 
, O 
a O 
field O 
study O 
was O 
performed O 
that O 
aimed O 
at O 
evaluating O 
immune O 
alterations O 
and O 
genetic O 
damage O 
in O 
peripheral O 
lymphocytes O 
of O 
workers O 
in O 
medium O 
density O 
fiberboard O 
plants O 
exposed O 
to O 
a O 
level O 
of O 
FA O 
equivalent O 
to O 
the O 
OEL O 
recommended O 
by O 
SCOEL O 
( O 
0.2 O 
ppm O 
) O 
. O 
Subsets O 
of O 
peripheral O 
lymphocytes O 
, O 
immunoglobulins O 
( O 
IgG O 
, O 
IgA O 
, O 
IgM O 
) O 
, O 
complement O 
proteins O 
, O 
and O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
( O 
TNF-α O 
) O 
levels O 
were O 
evaluated O 
. O 
DNA O 
damage O 
of O 
the O 
workers O 
was O 
assessed O 
by O 
the O 
Comet O 
assay O 
. O 
The O 
absolute O 
numbers O 
and O 
the O 
percentages O 
of O 
T O 
lymphocytes O 
and O 
of O 
natural O 
killer O 
cells O 
, O 
and O 
the O 
levels O 
of O 
TNF-α O 
were O 
higher O 
than O 
the O 
controls O 
, O 
whereas O 
IgG O 
and O 
IgM O 
levels O 
were O 
found O 
to O 
be O 
lower O 
in O 
workers O 
. O 
Other O 
examined O 
immunological O 
parameters O 
were O 
not O 
different O 
from O 
those O 
of O 
the O 
controls O 
. O 
There O 
was O 
no O 
increased O 
DNA O 
damage O 
in O 
the O 
workers O 
compared O 
to O 
controls O 
. O 

fusion O 
: O 
a O 
mechanism O 
of O 
cisplatin B-TRIVIAL 
-induced O 
resistance O 
in O 
neuroblastoma O 
cells O 
? O 

induces O 
apoptosis O 
through O 
different O 
pathways O 
. O 
The O 
intrinsic O 
apoptotic O 
pathway O 
is O 
mediated O 
by O 
mitochondria O 
, O 
which O 
, O 
as O 
a O 
result O 
of O 
cisplatin B-TRIVIAL 
treatment O 
, O 
undergo O 
morphological O 
alterations O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
cisplatin B-TRIVIAL 
-induced O 
mitochondrial O 
functional O 
and O 
morphological O 
long O 
- O 
term O 
effects O 
in O 
neuroblastoma O 
B50 O 
rat O 
cells O 
. O 
To O 
this O 
purpose O 
, O 
we O 
followed O 
evaluated O 
different O 
several O 
apoptotic O 
markers O 
by O 
means O 
of O 
flow O 
cytometry O 
, O 
confocal O 
and O 
electron O 
microscopy O 
and O 
western O 
blotting O 
techniques O 
. O 
We O 
applied O 
different O 
treatment O 
protocols O 
based O 
on O 
the O 
incubation O 
of O 
the O 
neuroblastoma O 
B50 O 
rat O 
cells O 
with O 
40 O 
μM O 
cisplatin B-TRIVIAL 
: O 
(i) O 
for O 
48 O 
h O 
and O 
harvesting O 
of O 
the O 
cells O 
at O 
the O 
end O 
of O 
the O 
treatment O 
; O 
(ii) O 
further O 
recovery O 
in O 
drug O 
- O 
free O 
medium O 
for O 
7 O 
days O 
post O 
- O 
treatment O 
; O 
(iii) O 
conditions O 
as O 
in O 
(ii) O 
followed O 
by O 
re O 
- O 
seeding O 
in O 
normal O 
medium O 
and O 
growth O 
for O 
a O 
further O 
4 O 
days O 
. O 
We O 
observed O 
apoptosis O 
induction O 
after O 
the O 
first O 
treatment O 
and O 
after O 
the O 
recovery O 
from O 
cell O 
death O 
after O 
long O 
- O 
term O 
culture O 
in O 
drug O 
- O 
free O 
medium O 
. O 
Interestingly O 
, O 
the O 
latter O 
phenomenon O 
was O 
characterized O 
by O 
mitochondrial O 
elongation O 
and O 
mitochondrial O 
protein O 
rearrangement O 
. O 
In O 
recovered O 
and O 
re O 
- O 
seeded O 
cells O 
, O 
mitochondrial O 
equilibrium O 
moved O 
toward O 
fusion O 
, O 
possibly O 
protecting O 
cells O 
from O 
apoptosis O 
. O 

bone O 
mass O 
( O 
HBM O 
) O 
, O 
detected O 
in O 
0.2% O 
of O 
DXA O 
scans O 
, O 
is O 
characterised O 
by O 
a O 
mild O 
skeletal O 
dysplasia O 
largely O 
unexplained O 
by O 
known O 
genetic O 
mutations O 
. O 
We O 
conducted O 
the O 
first O 
systematic O 
assessment O 
of O 
the O 
skeletal O 
phenotype O 
in O 
unexplained O 
HBM O 
using O 
pQCT O 
in O 
our O 
unique O 
HBM O 
population O 
identified O 
from O 
screening O 
routine O 
UK O 
NHS O 
DXA O 
scans O 
. O 
pQCT O 
measurements O 
from O 
the O 
mid O 
and O 
distal O 
tibia O 
and O 
radius O 
in O 
98 O 
HBM O 
cases O 
were O 
compared O 
with O 
(i) O 
65 O 
family O 
controls O 
( O 
constituting O 
unaffected O 
relatives O 
and O 
spouses O 
) O 
, O 
and O 
(ii) O 
692 O 
general O 
population O 
controls O 
. O 
HBM O 
cases O 
had O 
substantially O 
greater O 
trabecular O 
density O 
at O 
the O 
distal O 
tibia O 
( O 
340 O 
[ O 
320 O 
, O 
359 O 
] O 
mg O 
/ O 
cm(3) O 
) O 
, O 
compared O 
to O 
both O 
family O 
( O 
294 O 
[ O 
276 O 
, O 
312 O 
] O 
) O 
and O 
population O 
controls O 
( O 
290 O 
[ O 
281 O 
, O 
299 O 
] O 
) O 
( O 
p O 
< O 
0.001 O 
for O 
both O 
, O 
adjusted O 
for O 
age O 
, O 
gender O 
, O 
weight O 
, O 
height O 
, O 
alcohol O 
, O 
smoking O 
, O 
malignancy O 
, O 
menopause O 
, O 
steroid B-FAMILY 
and O 
estrogen B-FAMILY 
replacement O 
use O 
) O 
. O 
Similar O 
results O 
were O 
obtained O 
at O 
the O 
distal O 
radius O 
. O 
Greater O 
cortical O 
bone O 
mineral O 
density O 
( O 
cBMD O 
) O 
was O 
observed O 
in O 
HBM O 
cases O 
, O 
both O 
at O 
the O 
midtibia O 
and O 
radius O 
( O 
adjusted O 
p O 
< O 
0.001 O 
) O 
. O 
Total O 
bone O 
area O 
( O 
TBA O 
) O 
was O 
higher O 
in O 
HBM O 
cases O 
, O 
at O 
the O 
distal O 
and O 
mid O 
tibia O 
and O 
radius O 
( O 
adjusted O 
p O 
< O 
0.05 O 
versus O 
family O 
controls O 
) O 
, O 
suggesting O 
greater O 
periosteal O 
apposition O 
. O 
Cortical O 
thickness O 
was O 
increased O 
at O 
the O 
mid O 
tibia O 
and O 
radius O 
( O 
adjusted O 
p O 
< O 
0.001 O 
) O 
, O 
implying O 
reduced O 
endosteal O 
expansion O 
. O 
Together O 
, O 
these O 
changes O 
resulted O 
in O 
greater O 
predicted O 
cortical O 
strength O 
( O 
strength O 
strain O 
index O 
[ O 
SSI O 
] O 
) O 
in O 
both O 
tibia O 
and O 
radius O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
We O 
then O 
examined O 
relationships O 
with O 
age O 
; O 
tibial O 
cBMD O 
remained O 
constant O 
with O 
increasing O 
age O 
amongst O 
HBM O 
cases O 
( O 
adjusted O 
β O 
-0.01 O 
[ O 
-0.02 O 
, O 
0.01 O 
] O 
, O 
p=0.41 O 
) O 
, O 
but O 
declined O 
in O 
family O 
controls O 
( O 
-0.05 O 
[ O 
-0.03 O 
, O 
-0.07 O 
] O 
, O 
p O 
< O 
0.001 O 
) O 
interaction O 
p=0.002 O 
; O 
age O 
- O 
related O 
changes O 
in O 
tibial O 
trabecular O 
BMD O 
, O 
CBA O 
and O 
SSI O 
were O 
also O 
divergent O 
. O 
In O 
contrast O 
, O 
at O 
the O 
radius O 
HBM O 
cases O 
and O 
controls O 
showed O 
parallel O 
age O 
- O 
related O 
declines O 
in O 
cBMD O 
and O 
trabecular O 
BMD O 
. O 
HBM O 
is O 
characterised O 
by O 
increased O 
trabecular O 
BMD O 
and O 
by O 
alterations O 
in O 
cortical O 
bone O 
density O 
and O 
structure O 
, O 
leading O 
to O 
substantial O 
increments O 
in O 
predicted O 
cortical O 
bone O 
strength O 
. O 
In O 
contrast O 
to O 
the O 
radius O 
, O 
neither O 
trabecular O 
nor O 
cortical O 
BMD O 
declined O 
with O 
age O 
in O 
the O 
tibia O 
of O 
HBM O 
cases O 
, O 
suggesting O 
attenuation O 
of O 
age O 
- O 
related O 
bone O 
loss O 
in O 
weight O 
- O 
bearing O 
limbs O 
contributes O 
to O 
the O 
observed O 
bone O 
phenotype O 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
use O 
of O 
human O 
intestinal O 
tissue O 
in O 
Ussing O 
chamber O 
to O 
predict O 
oral O 
and O 
colonic O 
drug O 
absorption O 
and O 
intestinal O 
metabolism O 
. O 
Data O 
on O 
viability O 
, O 
correlation O 
between O 
apparent O 
permeability O 
coefficients O 
(P(app)) O 
and O 
fraction O 
absorbed O 
(f(a)) O 
after O 
oral O 
and O 
colonic O 
administration O 
, O 
regional O 
permeability O 
, O 
active O 
uptake O 
and O 
efflux O 
of O 
drugs O 
as O 
well O 
as O 
intestinal O 
metabolism O 
were O 
compiled O 
from O 
experiments O 
using O 
159 O 
human O 
donors O 
. O 
Permeability O 
coefficients O 
for O 
up O 
to O 
28 O 
drugs O 
were O 
determined O 
using O 
one O 
or O 
several O 
of O 
four O 
intestinal O 
regions O 
: O 
duodenum O 
, O 
jejunum O 
, O 
ileum O 
and O 
colon O 
and O 
10 O 
drugs O 
were O 
studied O 
bidirectionally O 
. O 
Viability O 
was O 
monitored O 
simultaneously O 
with O 
transport O 
experiments O 
by O 
recording O 
potential O 
difference O 
( O 
PD O 
) O 
, O 
short O 
- O 
circuit O 
current O 
( O 
SCC O 
) O 
and O 
the O 
resistance O 
( O 
TER O 
) O 
. O 
Intestinal O 
metabolism O 
was O 
studied O 
using O 
testosterone B-TRIVIAL 
and O 
midazolam B-TRIVIAL 
as O 
probe O 
substrates O 
. O 
There O 
was O 
a O 
steep O 
sigmoidal O 
correlation O 
between O 
P(app) O 
in O 
the O 
Ussing O 
chamber O 
, O 
using O 
jejunal O 
segments O 
, O 
and O 
oral O 
f(a) O 
in O 
humans O 
, O 
for O 
a O 
set O 
of O 
25 O 
drugs O 
( O 
R(2) O 
: O 
0.85 O 
, O 
p O 
< O 
0.01 O 
) O 
. O 
A O 
clear O 
sigmoidal O 
relationship O 
was O 
also O 
obtained O 
between O 
P(app) O 
in O 
colonic O 
segments O 
and O 
f(a) O 
after O 
colonic O 
administration O 
in O 
humans O 
for O 
a O 
set O 
of O 
10 O 
drugs O 
( O 
R(2) O 
: O 
0.93 O 
, O 
p O 
< O 
0.05 O 
) O 
. O 
Regional O 
permeability O 
data O 
showed O 
a O 
tendency O 
for O 
highly O 
permeable O 
compounds O 
to O 
have O 
higher O 
or O 
similar O 
P(app) O 
in O 
colon O 
as O 
in O 
the O 
small O 
intestinal O 
segments O 
, O 
while O 
the O 
colonic O 
regions O 
showed O 
a O 
lower O 
P(app) O 
for O 
more O 
polar O 
compounds O 
as O 
well O 
as O 
for O 
d-glucose B-TRIVIAL 
and O 
l-leucine B-TRIVIAL 
. O 
Bidirectional O 
transport O 
( O 
mucosa O 
to O 
serosa O 
and O 
serosa O 
to O 
mucosa O 
direction O 
) O 
in O 
jejunum O 
showed O 
well O 
functioning O 
efflux- O 
and O 
uptake O 
asymmetry O 
. O 
Intestinal O 
metabolic O 
extraction O 
during O 
transport O 
across O 
jejunum O 
segments O 
was O 
found O 
for O 
both O 
testosterone B-TRIVIAL 
and O 
midazolam B-TRIVIAL 
. O 
In O 
conclusion O 
, O 
viable O 
excised O 
human O 
intestine O 
mounted O 
in O 
the O 
Ussing O 
chamber O 
, O 
is O 
a O 
powerful O 
technique O 
for O 
predicting O 
regional O 
fraction O 
absorbed O 
(f(a)) O 
, O 
transporter O 
- O 
mediated O 
uptake O 
or O 
efflux O 
as O 
well O 
as O 
intestinal O 
metabolism O 
of O 
drug O 
candidates O 
in O 
man O 
. O 
Furthermore O 
, O 
a O 
sigmoidal O 
relationship O 
of O 
P(app) O 
vs O 
. O 
f(a) O 
was O 
obtained O 
when O 
permeability O 
data O 
from O 
the O 
present O 
study O 
were O 
merged O 
with O 
data O 
from O 
2 O 
other O 
independent O 
laboratories O 
( O 
R(2) O 
: O 
0.83 O 
, O 
p O 
< O 
0.01 O 
) O 
. O 
The O 
correlation O 
curve O 
reported O 
can O 
be O 
used O 
by O 
any O 
laboratory O 
for O 
predictions O 
of O 
human O 
permeability O 
and O 
f(a)(.) O 
In O 
addition O 
, O 
for O 
the O 
first O 
time O 
a O 
correlation O 
curve O 
between O 
colonic O 
P(app) O 
and O 
human O 
colonic O 
f(a) O 
is O 
reported O 
, O 
which O 
demonstrates O 
the O 
usefulness O 
of O 
this O 
methodology O 
in O 
early O 
assessment O 
of O 
the O 
colonic O 
absorption O 
potential O 
of O 
extended O 
release O 
formulation O 
candidates O 
. O 

P-glycoprotein O 
mediate O 
resistance O 
to O 
nilotinib B-TRIVIAL 
in O 
human O 
leukaemia O 
cells O 
? O 

effect O 
of O 
P-glycoprotein O 
( O 
P-gp O 
, O 
ABCB1 O 
, O 
MDR1 O 
) O 
expression O 
on O 
cell O 
resistance O 
to O 
nilotinib B-TRIVIAL 
was O 
studied O 
in O 
human O 
leukaemia O 
cells O 
. O 
We O 
used O 
K562/ O 
Dox B-ABBREVIATION 
cells O 
overexpressing O 
P-gp O 
and O 
their O 
variants O 
( O 
subclones O 
) O 
with O 
a O 
gradually O 
decreased O 
P-gp O 
expression O 
. O 
These O 
subclones O 
were O 
established O 
by O 
stable O 
transfection O 
of O 
K562/ O 
Dox B-ABBREVIATION 
cells O 
with O 
a O 
plasmid O 
vector O 
expressing O 
shRNA O 
targeting O 
the O 
ABCB1 O 
gene O 
. O 
Functional O 
analysis O 
of O 
P-gp O 
using O 
a O 
specific O 
fluorescent O 
probe O 
indicated O 
gradually O 
decreased O 
dye O 
efflux O 
which O 
was O 
proportional O 
to O 
the O 
P-gp O 
expression O 
. O 
We O 
observed O 
that O 
K562/ O 
Dox B-ABBREVIATION 
cells O 
overexpressing O 
P-gp O 
contained O 
a O 
significantly O 
reduced O 
intracellular O 
level O 
of O 
nilotinib B-TRIVIAL 
when O 
compared O 
to O 
their O 
counter O 
partner O 
K562 O 
cells O 
, O 
which O 
do O 
not O 
express O 
P-gp O 
. O 
This O 
effect O 
was O 
accompanied O 
by O 
a O 
decreased O 
sensitivity O 
of O 
the O 
K562/ O 
Dox B-ABBREVIATION 
cells O 
to O 
nilotinib B-TRIVIAL 
. O 
Importantly O 
, O 
cells O 
with O 
downregulated O 
expression O 
of O 
P-gp O 
gradually O 
lost O 
their O 
ability O 
to O 
decrease O 
the O 
intracellular O 
level O 
of O 
nilotinib B-TRIVIAL 
although O 
they O 
still O 
significantly O 
decreased O 
the O 
intracellular O 
level O 
of O 
daunorubicin B-TRIVIAL 
( O 
DNR B-ABBREVIATION 
) O 
. O 
Accordingly O 
, O 
cells O 
with O 
the O 
reduced O 
expression O 
of O 
P-gp O 
concomitantly O 
failed O 
to O 
provide O 
resistance O 
to O 
nilotinib B-TRIVIAL 
, O 
however O 
, O 
they O 
exhibited O 
a O 
significant O 
resistance O 
to O 
DNR B-ABBREVIATION 
. O 
Taken O 
together O 
, O 
we O 
demonstrated O 
that O 
the O 
conclusion O 
as O 
to O 
whether O 
P-gp O 
is O 
involved O 
in O 
nilotinib B-TRIVIAL 
resistance O 
or O 
not O 
strongly O 
depends O 
on O 
its O 
expression O 
at O 
protein O 
level O 
. O 

of O 
the O 
deleterious O 
effects O 
of O 
chronic O 
dietary O 
HFCS-55 B-TRIVIAL 
intake O 
by O 
PPAR-δ O 
agonism O 
correlates O 
with O 
impaired O 
NLRP3 O 
inflammasome O 
activation O 
. O 

high B-TRIVIAL 
- I-TRIVIAL 
fructose I-TRIVIAL 
corn I-TRIVIAL 
syrup I-TRIVIAL 
( O 
HFCS-55 B-TRIVIAL 
) O 
is O 
the O 
major O 
sweetener O 
in O 
foods O 
and O 
soft O 
- O 
drinks O 
, O 
its O 
potential O 
role O 
in O 
the O 
pathophysiology O 
of O 
diabetes O 
and O 
obesity O 
( O 
" O 
diabesity O 
" O 
) O 
remains O 
unclear O 
. O 
Peroxisome O 
- O 
proliferator O 
activated O 
receptor O 
(PPAR)-δ O 
agonists O 
have O 
never O 
been O 
tested O 
in O 
models O 
of O 
sugar B-FAMILY 
-induced O 
metabolic O 
abnormalities O 
. O 
This O 
study O 
was O 
designed O 
to O 
evaluate O 
(i) O 
the O 
metabolic O 
and O 
renal O 
consequences O 
of O 
HFCS-55 B-TRIVIAL 
administration O 
( O 
15% O 
wt O 
/ O 
vol O 
in O 
drinking O 
water O 
) O 
for O 
30 O 
weeks O 
on O 
male O 
C57Bl6 O 
/ O 
J O 
mice O 
and O 
(ii) O 
the O 
effects O 
of O 
the O 
selective O 
PPAR-δ O 
agonist O 
GW0742 B-IDENTIFIER 
( O 
1 O 
mg O 
/ O 
kg O 
/ O 
day O 
for O 
16 O 
weeks O 
) O 
in O 
this O 
condition O 
. O 
HFCS-55 B-TRIVIAL 
caused O 
(i) O 
hyperlipidemia O 
, O 
(ii) O 
insulin O 
resistance O 
, O 
and O 
(iii) O 
renal O 
injury O 
/ O 
inflammation O 
. O 
In O 
the O 
liver O 
, O 
HFCS-55 B-TRIVIAL 
enhanced O 
the O 
expression O 
of O 
fructokinase O 
resulting O 
in O 
hyperuricemia O 
and O 
caused O 
abnormalities O 
in O 
known O 
insulin O 
- O 
driven O 
signaling O 
events O 
. O 
In O 
the O 
kidney O 
, O 
HFCS-55 B-TRIVIAL 
enhanced O 
the O 
expression O 
of O 
the O 
NLRP3 O 
( O 
nucleotide B-FAMILY 
-binding O 
domain O 
and O 
leucine B-TRIVIAL 
-rich O 
- O 
repeat O 
- O 
protein O 
3 O 
) O 
inflammasome O 
complex O 
, O 
resulting O 
in O 
caspase-1 O 
activation O 
and O 
interleukin-1β O 
production O 
. O 
All O 
of O 
the O 
above O 
effects O 
of O 
HFCS-55 B-TRIVIAL 
were O 
attenuated O 
by O 
the O 
specific O 
PPAR-δ O 
agonist O 
GW0742 B-IDENTIFIER 
. O 
Thus O 
, O 
we O 
demonstrate O 
for O 
the O 
first O 
time O 
that O 
the O 
specific O 
PPAR-δ O 
agonist O 
GW0742 B-IDENTIFIER 
attenuates O 
the O 
metabolic O 
abnormalities O 
and O 
the O 
renal O 
dysfunction O 
/ O 
inflammation O 
caused O 
by O 
chronic O 
HFCS-55 B-TRIVIAL 
exposure O 
by O 
preventing O 
upregulation O 
of O 
fructokinase O 
( O 
liver O 
) O 
and O 
activation O 
of O 
the O 
NLRP3 O 
inflammasome O 
( O 
kidney O 
) O 
. O 

and O 
therapeutic O 
potential O 
of O 
hydrogen B-SYSTEMATIC 
sulfide I-SYSTEMATIC 
and O 
hydrogen B-SYSTEMATIC 
sulfide I-SYSTEMATIC 
-releasing O 
chimeras O 
. O 

sulfide I-SYSTEMATIC 
, O 
H2S B-FORMULA 
, O 
is O 
a O 
colorless O 
gas O 
with O 
a O 
strong O 
odor O 
that O 
until O 
recently O 
was O 
only O 
considered O 
to O 
be O 
a O 
toxic O 
environmental O 
pollutant O 
with O 
little O 
or O 
no O 
physiological O 
significance O 
. O 
However O 
, O 
the O 
past O 
few O 
years O 
have O 
demonstrated O 
its O 
role O 
in O 
many O 
biological O 
systems O 
and O 
it O 
is O 
becoming O 
increasingly O 
clear O 
that O 
H2S B-FORMULA 
is O 
likely O 
to O 
join O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
and O 
carbon B-SYSTEMATIC 
monoxide I-SYSTEMATIC 
( O 
CO B-FORMULA 
) O 
as O 
a O 
major O 
player O 
in O 
mammalian O 
biology O 
. O 
In O 
this O 
review O 
, O 
we O 
have O 
provided O 
an O 
overview O 
of O 
the O 
chemistry O 
and O 
biology O 
of O 
H2S B-FORMULA 
and O 
have O 
summarized O 
the O 
chemistry O 
and O 
biological O 
activity O 
of O 
some O 
natural O 
and O 
synthetic O 
H2S B-FORMULA 
-donating O 
compounds O 
. O 
The O 
naturally O 
occurring O 
compounds O 
discussed O 
include O 
, O 
garlic O 
, O 
sulforaphane B-TRIVIAL 
, O 
erucin B-TRIVIAL 
, O 
and O 
iberin B-TRIVIAL 
. O 
The O 
synthetic O 
H2S B-FORMULA 
donors O 
reviewed O 
include O 
, O 
GYY4137 B-IDENTIFIER 
; O 
cysteine B-TRIVIAL 
analogs O 
; O 
S-propyl B-SYSTEMATIC 
cysteine I-SYSTEMATIC 
, O 
S-allyl B-SYSTEMATIC 
cysteine I-SYSTEMATIC 
, O 
S-propargyl B-SYSTEMATIC 
cysteine I-SYSTEMATIC 
, O 
and O 
N-acetyl B-SYSTEMATIC 
cysteine I-SYSTEMATIC 
. O 
Dithiolethione B-FAMILY 
and O 
its O 
NSAID O 
and O 
other O 
chimeras O 
such O 
as O 
, O 
L-DOPA B-ABBREVIATION 
, O 
sildenafil B-TRIVIAL 
, O 
aspirin B-TRIVIAL 
, O 
diclofenac B-TRIVIAL 
, O 
naproxen B-TRIVIAL 
, O 
ibuprofen B-TRIVIAL 
, O 
indomethacin B-TRIVIAL 
, O 
and O 
mesalamine B-TRIVIAL 
have O 
also O 
been O 
reviewed O 
in O 
detail O 
. O 
The O 
newly O 
reported O 
NOSH-aspirin B-FORMULA 
that O 
releases O 
both O 
NO B-FORMULA 
and O 
H2S B-FORMULA 
has O 
also O 
been O 
discussed O 
. O 

genome O 
of O 
Escherichia O 
coli O 
K12 O 
contains O 
9 O 
open O 
reading O 
frames O 
encoding O 
aldo O 
/ O 
keto O 
reductases O 
( O 
AKRs O 
) O 
that O 
are O 
differentially O 
regulated O 
and O 
sequence O 
diverse O 
. O 
A O 
significant O 
amount O 
of O 
data O 
is O 
available O 
for O 
the O 
E O 
. O 
coli O 
AKRs O 
through O 
the O 
availability O 
of O 
gene O 
knockouts O 
and O 
gene O 
expression O 
studies O 
, O 
which O 
adds O 
to O 
the O 
biochemical O 
and O 
kinetic O 
data O 
. O 
This O 
together O 
with O 
the O 
availability O 
of O 
crystal O 
structures O 
for O 
nearly O 
half O 
of O 
the O 
E O 
. O 
coli O 
AKRs O 
and O 
homologues O 
of O 
several O 
others O 
provides O 
an O 
opportunity O 
to O 
look O 
at O 
the O 
diversity O 
of O 
these O 
representative O 
bacterial O 
AKRs O 
. O 
Based O 
around O 
the O 
common O 
AKR O 
fold O 
of O 
( O 
β O 
/ O 
α)8 O 
barrel O 
with O 
two O 
additional O 
α-helices O 
, O 
the O 
E O 
. O 
coli O 
AKRs O 
have O 
a O 
loop O 
structure O 
that O 
is O 
more O 
diverse O 
than O 
their O 
mammalian O 
counterparts O 
, O 
creating O 
a O 
variety O 
of O 
active O 
site O 
architectures O 
. O 
Nearly O 
half O 
of O 
the O 
AKRs O 
are O 
expected O 
to O 
be O 
monomeric O 
, O 
but O 
there O 
are O 
examples O 
of O 
dimeric O 
, O 
trimeric O 
and O 
octameric O 
enzymes O 
, O 
as O 
well O 
as O 
diversity O 
in O 
specificity O 
for O 
NAD B-ABBREVIATION 
as O 
well O 
as O 
NADP B-ABBREVIATION 
as O 
a O 
cofactor O 
. O 
However O 
in O 
functional O 
assignments O 
and O 
characterisation O 
of O 
enzyme O 
activities O 
there O 
is O 
a O 
paucity O 
of O 
data O 
when O 
compared O 
to O 
the O 
mammalian O 
AKR O 
enzymes O 
. O 

exposure O 
to O 
inorganic O 
arsenic B-SYSTEMATIC 
of O 
the O 
Hong O 
Kong O 
population O 
: O 
results O 
of O 
the O 
first O 
Hong O 
Kong O 
total O 
diet O 
study O 
. O 

arsenic B-SYSTEMATIC 
, O 
a O 
human O 
carcinogen O 
, O 
can O 
be O 
found O 
in O 
the O 
environment O 
and O 
food O 
. O 
In O 
the O 
first O 
Hong O 
Kong O 
Total O 
Diet O 
Study O 
, O 
the O 
dietary O 
exposure O 
of O 
the O 
Hong O 
Kong O 
people O 
, O 
including O 
various O 
age O 
- O 
gender O 
subgroups O 
, O 
to O 
inorganic O 
arsenic B-SYSTEMATIC 
was O 
estimated O 
for O 
assessing O 
the O 
associated O 
health O 
risk O 
. O 
Food O 
samples O 
, O 
which O 
represented O 
the O 
Hong O 
Kong O 
people's O 
diet O 
, O 
were O 
collected O 
and O 
prepared O 
" O 
as O 
consumed O 
" O 
for O 
analysis O 
. O 
Concentrations O 
of O 
inorganic O 
arsenic B-SYSTEMATIC 
, O 
as O 
sum O 
of O 
arsenite B-SYSTEMATIC 
( O 
As B-FORMULA 
(III) I-FORMULA 
) O 
and O 
arsenate B-SYSTEMATIC 
( O 
As B-FORMULA 
(V) I-FORMULA 
) O 
were O 
determined O 
in O 
600 O 
composite O 
samples O 
by O 
using O 
inductively O 
coupled O 
plasma O 
mass O 
spectrometry O 
. O 
The O 
dietary O 
exposures O 
were O 
estimated O 
by O 
combining O 
the O 
analytical O 
results O 
with O 
the O 
local O 
food O 
consumption O 
data O 
of O 
the O 
adult O 
population O 
. O 
The O 
mean O 
and O 
95th O 
percentile O 
of O 
inorganic O 
arsenic B-SYSTEMATIC 
exposures O 
of O 
the O 
Hong O 
Kong O 
people O 
were O 
0.22 O 
and O 
0.38μg O 
/ O 
kg O 
body O 
weight O 
( O 
bw O 
) O 
/ O 
day O 
, O 
respectively O 
. O 
Among O 
the O 
12 O 
age O 
- O 
gender O 
subgroups O 
, O 
the O 
respective O 
exposures O 
ranged O 
from O 
0.19 O 
to O 
0.26μg O 
/ O 
kg O 
bw O 
/ O 
day O 
and O 
from O 
0.33 O 
to O 
0.46μg O 
/ O 
kg O 
bw O 
/ O 
day O 
. O 
The O 
main O 
food O 
category O 
that O 
contributed O 
inorganic O 
arsenic B-SYSTEMATIC 
was O 
" O 
cereals O 
and O 
their O 
products O 
" O 
( O 
53.5% O 
of O 
the O 
total O 
exposure O 
) O 
, O 
particularly O 
rice O 
. O 
Having O 
considered O 
the O 
carcinogenic O 
risk O 
of O 
inorganic O 
arsenic B-SYSTEMATIC 
to O 
humans O 
, O 
it O 
is O 
suggested O 
that O 
efforts O 
should O 
be O 
made O 
to O 
reduce O 
the O 
inorganic O 
arsenic B-SYSTEMATIC 
exposure O 
of O 
the O 
Hong O 
Kong O 
population O 
. O 

two O 
- O 
component O 
system O 
AfsQ1 O 
/ O 
Q2 O 
of O 
Streptomyces O 
coelicolor O 
was O 
identified O 
in O 
our O 
previous O 
work O 
as O 
a O 
pleiotropic O 
regulator O 
for O 
antibiotic O 
biosynthesis O 
and O 
morphological O 
differentiation O 
under O 
the O 
condition O 
of O 
a O 
minimal O 
medium O 
supplemented O 
with O 
75 O 
mM O 
glutamate B-TRIVIAL 
. O 
In O 
this O 
work O 
, O 
we O 
report O 
the O 
dissection O 
of O 
the O 
mechanism O 
underlying O 
the O 
function O 
of O 
AfsQ1 O 
/ O 
Q2 O 
on O 
antibiotic O 
production O 
and O 
also O 
the O 
identification O 
of O 
the O 
AfsQ1 O 
/ O 
Q2 O 
regulon O 
. O 
The O 
results O 
showed O 
that O 
AfsQ1 O 
/ O 
Q2 O 
stimulated O 
antibiotic O 
ACT O 
, O 
RED O 
and O 
CDA O 
production O 
directly O 
through O 
the O 
pathway O 
- O 
specific O 
activator O 
genes O 
actII-ORF4 O 
, O 
redZ O 
and O 
cdaR O 
respectively O 
. O 
In O 
addition O 
, O 
expression O 
of O 
sigQ O 
that O 
encodes O 
a O 
sigma O 
factor O 
and O 
is O 
divergently O 
transcribed O 
from O 
afsQ1 O 
was O 
also O 
subject O 
to O 
direct O 
regulation O 
by O 
AfsQ1 O 
/ O 
Q2 O 
. O 
The O 
precise O 
AfsQ1 O 
binding O 
sites O 
in O 
the O 
upstream O 
regions O 
of O 
these O 
target O 
genes O 
were O 
determined O 
by O 
DNase O 
I O 
footprinting O 
assays O 
coupled O 
with O 
site O 
- O 
directed O 
DNA O 
mutagenesis O 
. O 
By O 
computational O 
prediction O 
and O 
functional O 
analysis O 
, O 
at O 
least O 
17 O 
new O 
AfsQ1 O 
targets O 
were O 
identified O 
, O 
including O 
pstS O 
gene O 
encoding O 
a O 
high O 
- O 
affinity O 
phosphate B-SYSTEMATIC 
-binding O 
protein O 
and O 
two O 
developmental O 
genes O 
whiD O 
, O 
bldM O 
. O 
For O 
the O 
AfsQ1 O 
/ O 
Q2 O 
regulon O 
, O 
an O 
AfsQ1 O 
binding O 
motif O 
comprising O 
the O 
sequence O 
GTnAC-n(6) O 
-GTnAC O 
has O 
been O 
defined O 
. O 
Interestingly O 
, O 
we O 
found O 
from O 
electrophoretic O 
mobility O 
shift O 
assays O 
and O 
transcriptional O 
analysis O 
that O 
AfsQ1 O 
/ O 
Q2 O 
can O 
also O 
function O 
as O 
a O 
repressor O 
for O 
nitrogen B-SYSTEMATIC 
assimilation O 
, O 
and O 
AfsQ1 O 
can O 
compete O 
with O 
GlnR O 
for O 
the O 
promoter O 
regions O 
of O 
glnA O 
and O 
nirB O 
, O 
suggesting O 
the O 
cross O 
- O 
regulation O 
between O 
AfsQ1 O 
/ O 
Q2 O 
and O 
GlnR O 
in O 
nitrogen B-SYSTEMATIC 
metabolism O 
. O 
These O 
findings O 
suggested O 
that O 
AfsQ1 O 
/ O 
Q2 O 
is O 
important O 
not O 
only O 
for O 
antibiotic O 
biosynthesis O 
but O 
also O 
in O 
maintaining O 
the O 
metabolic O 
homeostasis O 
of O 
nutrient O 
utilization O 
under O 
the O 
stress O 
of O 
high O 
concentration O 
of O 
glutamate B-TRIVIAL 
in O 
S. O 
coelicolor O 
. O 

upregulation O 
promotes O 
survival O 
and O 
attenuates O 
doxorubicin B-TRIVIAL 
-induced O 
cardiotoxicity O 
. O 

study O 
evaluated O 
whether O 
the O 
manipulation O 
of O 
autophagy O 
could O 
attenuate O 
the O 
cardiotoxic O 
effects O 
of O 
doxorubicin B-TRIVIAL 
( O 
DXR B-ABBREVIATION 
) O 
in O 
vitro O 
as O 
well O 
as O 
in O 
a O 
tumour O 
- O 
bearing O 
mouse O 
model O 
of O 
acute O 
doxorubicin B-TRIVIAL 
-induced O 
cardiotoxicity O 
. O 
We O 
examined O 
the O 
effect O 
of O 
an O 
increase O 
or O 
inhibition O 
of O 
autophagy O 
in O 
combination O 
with O 
DXR B-ABBREVIATION 
on O 
apoptosis O 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
production O 
and O 
mitochondrial O 
function O 
. O 
H9C2 O 
rat O 
cardiac O 
myoblasts O 
were O 
pre O 
- O 
treated O 
with O 
bafilomycin B-TRIVIAL 
A1 I-TRIVIAL 
( O 
autophagy O 
inhibitor O 
, O 
10 O 
nM O 
) O 
or O 
rapamycin B-TRIVIAL 
( O 
autophagy O 
inducer O 
, O 
50 O 
μM O 
) O 
followed O 
by O 
DXR B-ABBREVIATION 
treatment O 
( O 
3 O 
μM O 
) O 
. O 
The O 
augmentation O 
of O 
autophagy O 
with O 
rapamycin B-TRIVIAL 
in O 
the O 
presence O 
of O 
DXR B-ABBREVIATION 
substantially O 
ameliorated O 
the O 
detrimental O 
effects O 
induced O 
by O 
DXR B-ABBREVIATION 
. O 
This O 
combination O 
treatment O 
demonstrated O 
improved O 
cell O 
viability O 
, O 
decreased O 
apoptosis O 
and O 
ROS O 
production O 
and O 
enhanced O 
mitochondrial O 
function O 
. O 
To O 
corroborate O 
these O 
findings O 
, O 
GFP-LC3 O 
mice O 
were O 
inoculated O 
with O 
a O 
mouse O 
breast O 
cancer O 
cell O 
line O 
( O 
EO771 O 
) O 
. O 
Following O 
the O 
appearance O 
of O 
tumours O 
, O 
animals O 
were O 
either O 
treated O 
with O 
one O 
injection O 
of O 
rapamycin B-TRIVIAL 
( O 
4 O 
mg O 
/ O 
kg O 
) O 
followed O 
by O 
two O 
injections O 
of O 
DXR B-ABBREVIATION 
( O 
10 O 
mg O 
/ O 
kg O 
) O 
. O 
Mice O 
were O 
then O 
sacrificed O 
and O 
their O 
hearts O 
rapidly O 
excised O 
and O 
utilized O 
for O 
biochemical O 
and O 
histological O 
analyses O 
. O 
The O 
combination O 
treatment O 
, O 
rather O 
than O 
the O 
combinants O 
alone O 
, O 
conferred O 
a O 
cardioprotective O 
effect O 
. O 
These O 
hearts O 
expressed O 
down O 
- O 
regulation O 
of O 
the O 
pro O 
- O 
apoptotic O 
protein O 
caspase-3 O 
and O 
cardiomyocyte O 
cross O 
- O 
sectional O 
area O 
was O 
preserved O 
. O 
These O 
results O 
strongly O 
indicate O 
that O 
the O 
co O 
- O 
treatment O 
strategy O 
with O 
rapamycin B-TRIVIAL 
can O 
attenuate O 
the O 
cardiotoxic O 
effects O 
of O 
DXR B-ABBREVIATION 
in O 
a O 
tumour O 
- O 
bearing O 
mouse O 
model O 
. O 

inhibits O 
the O 
adipogenic O 
differentiation O 
of O 
mesenchymal O 
stem O 
cells O 
by O 
down O 
- O 
regulating O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
gamma O 
and O 
CCAAT O 
enhancer O 
- O 
binding O 
proteins O 
. O 

remains O 
a O 
top O 
environmental O 
concern O 
in O 
the O 
United O 
States O 
as O 
well O 
as O 
worldwide O 
because O 
of O 
its O 
global O 
existence O 
and O 
serious O 
health O 
impacts O 
. O 
Apoptotic O 
effect O 
of O 
arsenic B-SYSTEMATIC 
in O 
human O 
mesenchymal O 
stem O 
cells O 
( O 
hMSCs O 
) O 
has O 
been O 
identified O 
in O 
our O 
previous O 
study O 
; O 
the O 
effects O 
of O 
arsenic B-SYSTEMATIC 
on O 
hMSCs O 
remain O 
largely O 
unknown O 
. O 
Here O 
, O 
we O 
report O 
that O 
arsenic B-SYSTEMATIC 
inhibits O 
the O 
adipogenic O 
differentiation O 
of O 
human O 
mesenchymal O 
stem O 
cells O 
( O 
hMSCs O 
) O 
. O 
Arsenic B-SYSTEMATIC 
reduced O 
the O 
formation O 
of O 
lipid O 
droplets O 
and O 
the O 
expression O 
of O 
adipogenesis O 
- O 
related O 
proteins O 
, O 
such O 
as O 
CCAAT O 
enhancer O 
binding O 
protein-(C O 
/ O 
EBPs O 
) O 
, O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
- O 
gamma O 
( O 
PPAR-γ O 
) O 
, O 
and O 
adipocyte O 
fatty B-FAMILY 
acid I-FAMILY 
-binding O 
protein O 
aP2 O 
( O 
aP2 O 
) O 
. O 
Arsenic B-SYSTEMATIC 
mediates O 
this O 
process O 
by O 
sustaining O 
PPAR-γ O 
activity O 
. O 
In O 
addition O 
, O 
inhibition O 
of O 
PPAR-γ O 
activity O 
with O 
T0070907 O 
and O 
up O 
- O 
regulation O 
with O 
its O 
agonist O 
troglitazone B-TRIVIAL 
, O 
showed O 
the O 
direct O 
association O 
of O 
PPAR-γ O 
and O 
arsenic B-SYSTEMATIC 
-mediated O 
inhibition O 
of O 
differentiating O 
hMSCs O 
. O 
Taken O 
together O 
, O 
these O 
results O 
indicate O 
that O 
arsenic B-SYSTEMATIC 
inhibits O 
adipogenic O 
differentiation O 
through O 
PPAR-γ O 
pathway O 
and O 
suggest O 
a O 
novel O 
inhibitory O 
effect O 
of O 
arsenic B-SYSTEMATIC 
on O 
adipogenic O 
differentiation O 
in O 
hMSCs O 
. O 

and O 
chiral O 
recognition O 
of O 
nickel B-SYSTEMATIC 
(II) I-SYSTEMATIC 
macrocyclic O 
complex O 
with O 
(R)-naphthylethyleneamine B-SYSTEMATIC 
pendant O 
groups O 
and O 
its O 
self O 
- O 
assembled O 
framework O 
. O 

novel O 
nickel B-SYSTEMATIC 
(II) I-SYSTEMATIC 
hexaaza I-SYSTEMATIC 
macrocyclic O 
complex O 
, O 
[Ni(L(R,R))](ClO(4))(2) B-FAMILY 
( O 
1 O 
) O 
, O 
containing O 
chiral O 
pendant O 
groups O 
was O 
synthesized O 
by O 
an O 
efficient O 
one O 
- O 
pot O 
template O 
condensation O 
and O 
characterized O 
( O 
L(R,R) O 
═ O 
1,8-di((R)-α-methylnaphthyl)-1,3,6,8,10,13-hexaazacyclotetradecane B-SYSTEMATIC 
) O 
. O 
The O 
crystal O 
structure O 
of O 
compound O 
1 O 
was O 
determined O 
by O 
single O 
- O 
crystal O 
X-ray O 
analysis O 
. O 
The O 
complex O 
was O 
found O 
to O 
have O 
a O 
square O 
- O 
planar O 
coordination O 
environment O 
for O 
the O 
nickel B-SYSTEMATIC 
(II) I-SYSTEMATIC 
ion O 
. O 
Open O 
framework O 
[Ni(L(R,R))](3) B-FAMILY 
[C(6)H(3)(COO)(3)](2) I-FAMILY 
( O 
2 O 
) O 
was O 
constructed O 
from O 
the O 
self O 
- O 
assembly O 
of O 
compound O 
1 O 
with O 
deprotonated O 
1,3,5-benzenetricarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
BTC(3-) B-ABBREVIATION 
. O 
Chiral O 
discrimination O 
of O 
rac-1,1'-bi-2-naphthol B-SYSTEMATIC 
and O 
rac-2,2,2-trifluoro-1-(9-anthryl)ethanol B-SYSTEMATIC 
was O 
performed O 
to O 
determine O 
the O 
chiral O 
recognition O 
ability O 
of O 
the O 
chiral O 
complex O 
( O 
1 O 
) O 
and O 
its O 
self O 
- O 
assembled O 
framework O 
( O 
2 O 
) O 
. O 
Binaphthol B-SYSTEMATIC 
showed O 
a O 
good O 
chiral O 
discrimination O 
on O 
the O 
framework O 
( O 
2 O 
) O 
. O 
The O 
optimum O 
experimental O 
conditions O 
for O 
the O 
chiral O 
discrimination O 
were O 
examined O 
by O 
changing O 
the O 
weight O 
ratio O 
between O 
the O 
macrocyclic O 
complex O 
1 O 
or O 
self O 
- O 
assembled O 
framework O 
2 O 
and O 
racemates O 
. O 
The O 
detailed O 
synthetic O 
procedures O 
, O 
spectroscopic O 
data O 
including O 
single O 
- O 
crystal O 
X-ray O 
analysis O 
, O 
and O 
the O 
results O 
of O 
the O 
chiral O 
recognition O 
for O 
the O 
compounds O 
are O 
described O 
. O 

- O 
temperature O 
electron O 
spin O 
amplifier O 
based O 
on O 
Ga(In)NAs B-FORMULA 
alloys O 
. O 

first O 
experimental O 
demonstration O 
of O 
a O 
spin O 
amplifier O 
at O 
room O 
temperature O 
is O 
presented O 
. O 
An O 
efficient O 
, O 
defect O 
- O 
enabled O 
spin O 
amplifier O 
based O 
on O 
a O 
non-magnetic O 
semiconductor O 
, O 
Ga(In)NAs B-FORMULA 
, O 
is O 
proposed O 
and O 
demonstrated O 
, O 
with O 
a O 
large O 
spin O 
gain O 
( O 
up O 
to O 
2700% O 
at O 
zero O 
field O 
) O 
for O 
conduction O 
electrons O 
and O 
a O 
high O 
cut O 
- O 
off O 
frequency O 
of O 
up O 
to O 
1 O 
GHz O 
. O 

acetate I-SYSTEMATIC 
: O 
X-ray O 
, O 
solvent O 
and O 
computed O 
structures O 
. O 

acetate I-SYSTEMATIC 
( O 
ethyl B-SYSTEMATIC 
ethanoate I-SYSTEMATIC 
) O 
was O 
crystallized O 
in O 
situ O 
and O 
the O 
crystal O 
structure O 
was O 
determined O 
. O 
In O 
the O 
solid O 
, O 
the O 
molecule O 
is O 
flat O 
with O 
trans O 
conformation O 
. O 
The O 
geometric O 
details O 
of O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
as O 
a O 
solvate O 
are O 
analyzed O 
statistically O 
using O 
the O 
Cambridge O 
Structural O 
Database O 
, O 
uncovering O 
a O 
high O 
degree O 
of O 
hidden O 
disorder O 
. O 
Despite O 
the O 
disorder O 
, O 
they O 
exhibit O 
a O 
preference O 
of O 
the O 
trans O 
over O 
the O 
gauche O 
isomer O 
, O 
with O 
a O 
negligible O 
contribution O 
of O 
the O 
cis O 
isomer O 
. O 
These O 
results O 
are O 
compared O 
to O 
ab O 
initio O 
calculations O 
on O 
both O 
solid O 
- O 
state O 
and O 
molecular O 
level O 
. O 
For O 
the O 
molecular O 
structures O 
, O 
the O 
computed O 
energy O 
differences O 
of O 
the O 
isomers O 
match O 
the O 
statistics O 
found O 
as O 
a O 
solvent O 
. O 
Several O 
DFT-D2 O 
methods O 
used O 
to O 
calculate O 
the O 
solid O 
state O 
yield O 
results O 
that O 
differ O 
significantly O 
from O 
the O 
experiment O 
. O 

contaminants O 
are O 
released O 
into O 
aquatic O 
systems O 
intermittently O 
in O 
a O 
series O 
of O 
pulses O 
. O 
Pulse O 
timing O 
and O 
magnitude O 
can O 
vary O 
according O 
to O 
usage O 
, O 
compound O 
- O 
specific O 
physicochemical O 
properties O 
, O 
and O 
use O 
area O 
characteristics O 
. O 
Standard O 
laboratory O 
ecotoxicity O 
tests O 
typically O 
employ O 
continuous O 
exposure O 
concentrations O 
over O 
defined O 
durations O 
and O 
thus O 
may O 
not O 
accurately O 
and O 
realistically O 
reflect O 
the O 
effects O 
of O 
certain O 
compounds O 
on O 
aquatic O 
organisms O 
, O 
resulting O 
in O 
potential O 
over- O 
or O 
underestimation O 
. O 
Consequently O 
, O 
the O 
relative O 
effects O 
of O 
pulsed O 
( O 
2 O 
and O 
4 O 
d O 
) O 
and O 
continuous O 
exposures O 
of O 
the O 
duckweed O 
Lemna O 
minor O 
to O 
isoproturon B-TRIVIAL 
, O 
metsulfuron B-SYSTEMATIC 
- I-SYSTEMATIC 
methyl I-SYSTEMATIC 
, O 
and O 
pentachlorophenol B-SYSTEMATIC 
over O 
a O 
period O 
of O 
42 O 
d O 
were O 
explored O 
in O 
the O 
present O 
study O 
. O 
At O 
the O 
highest O 
test O 
concentrations O 
, O 
exposure O 
of O 
L O 
. O 
minor O 
to O 
pulses O 
of O 
metsulfuron B-SYSTEMATIC 
- I-SYSTEMATIC 
methyl I-SYSTEMATIC 
resulted O 
in O 
effects O 
on O 
growth O 
similar O 
to O 
those O 
of O 
an O 
equivalent O 
continuous O 
exposure O 
. O 
For O 
isoproturon B-TRIVIAL 
, O 
pulsed O 
exposures O 
had O 
a O 
lower O 
impact O 
than O 
a O 
corresponding O 
continuous O 
exposure O 
, O 
whereas O 
the O 
effect O 
of O 
pentachlorophenol B-SYSTEMATIC 
delivered O 
in O 
pulses O 
was O 
greater O 
. O 
These O 
differences O 
may O 
be O 
explained O 
by O 
compound O 
- O 
specific O 
uptake O 
and O 
degradation O 
or O 
dissipation O 
rates O 
in O 
plants O 
and O 
the O 
recovery O 
potential O 
that O 
occurs O 
following O 
pulses O 
for O 
different O 
pesticides O 
. O 
Given O 
these O 
results O 
, O 
use O 
of O 
a O 
simple O 
time O 
- O 
weighted O 
average O 
approach O 
to O 
estimate O 
effects O 
of O 
intermittent O 
exposures O 
from O 
short O 
- O 
term O 
standard O 
toxicity O 
studies O 
may O 
not O 
provide O 
an O 
accurate O 
prediction O 
that O 
reflects O 
realistic O 
exposure O 
scenarios O 
. O 
Development O 
of O 
mechanistic O 
modeling O 
approaches O 
may O 
facilitate O 
better O 
estimates O 
of O 
effects O 
from O 
intermittent O 
exposures O 
. O 

histone O 
variant O 
H2AX O 
is O 
a O 
principal O 
component O 
of O 
chromatin O 
involved O 
in O 
the O 
detection O 
, O 
signaling O 
, O 
and O 
repair O 
of O 
DNA O 
double O 
- O 
strand O 
breaks O 
( O 
DSBs O 
) O 
. O 
H2AX O 
is O 
thought O 
to O 
operate O 
primarily O 
through O 
its O 
C B-FORMULA 
-terminal O 
S139 O 
phosphorylation O 
, O 
which O 
mediates O 
the O 
recruitment O 
of O 
DNA O 
damage O 
response O 
( O 
DDR O 
) O 
factors O 
to O 
chromatin O 
at O 
DSB O 
sites O 
. O 
Here O 
, O 
we O 
describe O 
a O 
comprehensive O 
screen O 
of O 
67 O 
residues O 
in O 
H2AX O 
to O 
determine O 
their O 
contributions O 
to O 
H2AX O 
functions O 
. O 
Our O 
analysis O 
revealed O 
that O 
H2AX O 
is O 
both O 
sumoylated O 
and O 
ubiquitylated O 
. O 
Individual O 
residues O 
defective O 
for O 
sumoylation O 
, O 
ubiquitylation O 
, O 
and O 
S139 O 
phosphorylation O 
in O 
untreated O 
and O 
damaged O 
cells O 
were O 
identified O 
. O 
Specifically O 
, O 
we O 
identified O 
an O 
acidic O 
triad O 
region O 
in O 
both O 
H2A O 
and O 
H2AX O 
that O 
is O 
required O 
in O 
cis O 
for O 
their O 
ubiquitylation O 
. O 
We O 
also O 
report O 
the O 
characterization O 
of O 
a O 
human O 
H2AX O 
knockout O 
cell O 
line O 
, O 
which O 
exhibits O 
DDR O 
defects O 
, O 
including O 
p53 O 
activation O 
, O 
following O 
DNA O 
damage O 
. O 
Collectively O 
, O 
this O 
work O 
constitutes O 
the O 
first O 
genetic O 
complementation O 
system O 
for O 
a O 
histone O 
in O 
human O 
cells O 
. O 
Finally O 
, O 
our O 
data O 
reveal O 
new O 
roles O 
for O 
several O 
residues O 
in O 
H2AX O 
and O 
define O 
distinct O 
functions O 
for O 
H2AX O 
in O 
human O 
cells O 
. O 

search O 
of O 
a O 
next O 
generation O 
molecule O 
to O 
the O 
novel O 
wake O 
- O 
promoting O 
agent O 
modafinil B-TRIVIAL 
, O 
a O 
series O 
of O 
aryl-heteroayl O 
- O 
derived O 
wakefulness O 
enhancing O 
agents O 
( O 
in O 
rats O 
) O 
was O 
developed O 
. O 
From O 
this O 
work O 
, O 
compound O 
16 O 
was O 
separated O 
into O 
its O 
enantiomers O 
to O 
profile O 
them O 
individually O 
. O 

diagnostic O 
use O 
of O 
in O 
vitro O 
molecular O 
assays O 
can O 
be O 
limited O 
by O 
the O 
lack O 
of O 
guidelines O 
for O 
collection O 
, O 
handling O 
, O 
stabilization O 
and O 
storage O 
of O 
patient O 
specimens O 
. O 
One O 
of O 
the O 
major O 
goals O 
of O 
the O 
EC O 
funded O 
project O 
SPIDIA O 
( O 
www.spidia.eu O 
) O 
is O 
to O 
develop O 
evidence O 
- O 
based O 
quality O 
guidelines O 
for O 
the O 
pre O 
- O 
analytical O 
phase O 
of O 
blood O 
samples O 
used O 
for O 
molecular O 
testing O 
which O 
requires O 
intracellular O 
RNA O 
analytes O 
. O 
To O 
this O 
end O 
, O 
a O 
survey O 
and O 
a O 
pan-European O 
external O 
quality O 
assessment O 
( O 
EQA O 
) O 
were O 
implemented O 
. O 
This O 
report O 
is O 
the O 
summary O 
of O 
the O 
results O 
of O 
that O 
trial O 
. O 
With O 
the O 
European O 
Federation O 
of O 
Laboratory O 
Medicine O 
( O 
EFLM O 
) O 
support O 
, O 
124 O 
applications O 
for O 
participation O 
in O 
the O 
trial O 
were O 
received O 
from O 
27 O 
different O 
European O 
countries O 
, O 
and O 
102 O 
laboratories O 
actually O 
participated O 
in O 
the O 
trial O 
. O 
Each O 
participating O 
laboratory O 
described O 
their O 
respective O 
laboratory O 
policies O 
and O 
practices O 
as O 
well O 
as O 
blood O 
collection O 
tubes O 
typically O 
used O 
in O 
performing O 
this O 
type O 
of O 
testing O 
. O 
The O 
participating O 
laboratories O 
received O 
two O 
identical O 
blood O 
specimens O 
: O 
in O 
an O 
EDTA B-ABBREVIATION 
tubes O 
( O 
unstabilized O 
blood O 
; O 
n=67 O 
) O 
or O 
in O 
tubes O 
designed O 
specifically O 
for O 
the O 
stabilization O 
of O 
intracellular O 
RNA O 
in O 
blood O 
( O 
PAXgene O 
® O 
Blood O 
RNA O 
tubes O 
; O 
n=35 O 
) O 
. O 
Laboratories O 
were O 
requested O 
to O 
perform O 
RNA O 
extraction O 
according O 
to O 
the O 
laboratory's O 
own O 
procedure O 
as O 
soon O 
as O 
possible O 
upon O 
receipt O 
of O 
the O 
tubes O 
for O 
one O 
tube O 
and O 
24h O 
after O 
the O 
first O 
extraction O 
for O 
the O 
second O 
tube O 
. O 
Participants O 
( O 
n=93 O 
) O 
returned O 
the O 
two O 
extracted O 
RNAs O 
to O 
SPIDIA O 
facility O 
for O 
analysis O 
, O 
and O 
provided O 
details O 
about O 
the O 
reagents O 
and O 
protocols O 
they O 
used O 
for O 
the O 
extraction O 
. O 
At O 
the O 
SPIDIA O 
facility O 
responsible O 
for O 
coordinating O 
the O 
study O 
, O 
the O 
survey O 
data O 
were O 
classified O 
, O 
and O 
the O 
extracted O 
RNA O 
samples O 
were O 
evaluated O 
for O 
purity O 
, O 
yield O 
, O 
integrity O 
, O 
stability O 
, O 
and O 
the O 
presence O 
of O 
interfering O 
substances O 
affecting O 
RT-qPCR O 
assays O 
. O 
All O 
participants O 
received O 
a O 
report O 
comparing O 
the O 
performance O 
of O 
the O 
RNA O 
they O 
submitted O 
to O 
that O 
of O 
the O 
other O 
participants O 
. O 
All O 
the O 
results O 
obtained O 
by O 
participants O 
for O 
each O 
RNA O 
quality O 
parameter O 
were O 
classified O 
as O 
" O 
in O 
control O 
" O 
, O 
" O 
warning O 
" O 
, O 
" O 
out O 
of O 
control O 
" O 
and O 
" O 
missing O 
" O 
by O 
consensus O 
mean O 
analysis O 
. O 
From O 
the O 
survey O 
data O 
, O 
the O 
most O 
variable O 
parameters O 
were O 
the O 
volume O 
of O 
blood O 
collected O 
and O 
the O 
time O 
and O 
storage O 
temperature O 
between O 
blood O 
collection O 
and O 
RNA O 
extraction O 
. O 
Analyzing O 
the O 
results O 
of O 
quality O 
testing O 
of O 
submitted O 
RNA O 
samples O 
we O 
observed O 
a O 
data O 
distribution O 
of O 
purity O 
, O 
yield O 
, O 
and O 
presence O 
of O 
assay O 
interference O 
in O 
agreement O 
with O 
expected O 
values O 
. O 
The O 
RNA O 
Integrity O 
Number O 
( O 
RIN O 
) O 
values O 
distribution O 
was O 
, O 
on O 
the O 
other O 
hand O 
, O 
much O 
wider O 
than O 
the O 
optimal O 
expected O 
value O 
, O 
which O 
led O 
to O 
an O 
" O 
in O 
control O 
" O 
classification O 
, O 
even O 
for O 
partly O 
degraded O 
RNA O 
samples O 
. O 
On O 
the O 
other O 
hand O 
, O 
RIN O 
values O 
below O 
5 O 
significantly O 
correlated O 
with O 
a O 
reduction O 
of O 
GAPDH O 
expression O 
levels O 
. O 
Furthermore O 
, O 
the O 
distribution O 
of O 
the O 
values O 
of O 
the O 
four O 
transcripts O 
investigated O 
( O 
c-fos O 
, O 
IL-1β O 
, O 
IL-8 O 
, O 
and O 
GAPDH O 
) O 
was O 
wide O 
and O 
the O 
RNA O 
instability O 
between O 
samples O 
separated O 
by O 
24h O 
were O 
similar O 
. O 
Assuming O 
the O 
presence O 
of O 
at O 
least O 
two O 
quality O 
parameters O 
" O 
out O 
of O 
control O 
" O 
as O 
an O 
indication O 
of O 
a O 
critical O 
performance O 
of O 
the O 
laboratory O 
, O 
33% O 
of O 
the O 
laboratories O 
were O 
included O 
in O 
this O 
group O 
. O 
The O 
results O 
of O 
this O 
study O 
will O 
be O 
the O 
basis O 
for O 
implementing O 
a O 
second O 
pan-European O 
EQA O 
and O 
the O 
results O 
of O 
both O 
EQAs O 
will O 
be O 
pooled O 
and O 
will O 
provide O 
the O 
basis O 
for O 
the O 
implementation O 
of O 
evidence O 
- O 
based O 
guidelines O 
for O 
the O 
pre O 
- O 
analytical O 
phase O 
of O 
RNA O 
analysis O 
of O 
blood O 
samples O 
. O 

of O 
efflux O 
mediated O 
antifungal O 
resistance O 
underlies O 
synergistic O 
activity O 
of O 
two O 
monoterpenes B-FAMILY 
with O 
fluconazole B-TRIVIAL 
. O 

( O 
THY B-ABBREVIATION 
) O 
and O 
carvacrol B-TRIVIAL 
( O 
CARV B-ABBREVIATION 
) O 
, O 
the O 
principal O 
chemical O 
components O 
of O 
thyme O 
oil O 
have O 
long O 
been O 
known O 
for O 
their O 
wide O 
use O 
in O 
medicine O 
due O 
to O 
antimicrobial O 
and O 
disinfectant O 
properties O 
. O 
This O 
study O 
, O 
however O 
, O 
draws O 
attention O 
to O 
a O 
possible O 
synergistic O 
antifungal O 
effect O 
of O 
these O 
monoterpenes B-FAMILY 
with O 
azole B-FAMILY 
antimycotic- O 
fluconazole B-TRIVIAL 
. O 
Resistance O 
to O 
azoles B-FAMILY 
in O 
Candida O 
albicans O 
involves O 
over O 
- O 
expression O 
of O 
efflux O 
- O 
pump O 
genes O 
MDR1 O 
, O 
CDR1 O 
, O 
CDR2 O 
or O 
mutations O 
and O 
over O 
- O 
expression O 
of O 
target O 
gene O 
ERG11 O 
. O 
The O 
inhibition O 
of O 
drug O 
efflux O 
pumps O 
is O 
considered O 
a O 
feasible O 
strategy O 
to O 
overcome O 
clinical O 
antifungal O 
resistance O 
. O 
To O 
put O 
forward O 
this O 
approach O 
, O 
we O 
investigated O 
the O 
combination O 
effects O 
of O 
these O 
monoterpenes B-FAMILY 
and O 
FLC B-ABBREVIATION 
against O 
38 O 
clinically O 
obtained O 
FLC B-ABBREVIATION 
-sensitive O 
, O 
and O 
eleven O 
FLC B-ABBREVIATION 
-resistant O 
Candida O 
isolates O 
. O 
Synergism O 
was O 
observed O 
with O 
combinations O 
of O 
THY B-ABBREVIATION 
- O 
FLC B-ABBREVIATION 
and O 
CARV B-ABBREVIATION 
- O 
FLC B-ABBREVIATION 
evaluated O 
by O 
checkerboard O 
microdilution O 
method O 
and O 
nature O 
of O 
the O 
interactions O 
was O 
calculated O 
by O 
FICI O 
. O 
In O 
addition O 
, O 
antifungal O 
activity O 
was O 
assessed O 
using O 
agar O 
- O 
diffusion O 
and O 
time O 
- O 
kill O 
curves O 
. O 
The O 
drug O 
efflux O 
activity O 
was O 
determined O 
using O 
two O 
dyes O 
, O 
Rhodamine6G B-TRIVIAL 
( O 
R6G B-ABBREVIATION 
) O 
and O 
fluorescent O 
Hoechst B-TRIVIAL 
33342 I-TRIVIAL 
. O 
No O 
significant O 
differences O 
were O 
observed O 
in O 
dye O 
uptakes O 
between O 
FLC-susceptible O 
and O 
resistant O 
isolates O 
, O 
incubated O 
in O 
glucose B-TRIVIAL 
free O 
buffer O 
. O 
However O 
, O 
a O 
significantly O 
higher O 
efflux O 
was O 
recorded O 
in O 
FLC B-ABBREVIATION 
-resistant O 
isolates O 
when O 
glucose B-TRIVIAL 
was O 
added O 
. O 
Both O 
monoterpenes B-FAMILY 
inhibited O 
efflux O 
by O 
70-90% O 
, O 
showing O 
their O 
high O 
potency O 
to O 
block O 
drug O 
transporter O 
pumps O 
. O 
Significant O 
differences O 
, O 
in O 
the O 
expression O 
levels O 
of O 
CDR1 O 
and O 
MDR1 O 
, O 
induced O 
by O 
monoterpenes B-FAMILY 
revealed O 
reversal O 
of O 
FLC B-ABBREVIATION 
-resistance O 
. O 
The O 
selectively O 
fungicidal O 
characteristics O 
and O 
ability O 
to O 
restore O 
FLC B-ABBREVIATION 
susceptibility O 
in O 
resistant O 
isolates O 
signify O 
a O 
promising O 
candidature O 
of O 
THY B-ABBREVIATION 
and O 
CARV B-ABBREVIATION 
as O 
antifungal O 
agents O 
in O 
combinational O 
treatments O 
for O 
candidiasis O 
. O 

exposure O 
of O 
red O 
- O 
legged O 
partridges O 
( O 
Alectoris O 
rufa O 
) O 
to O 
seeds O 
coated O 
with O 
imidacloprid B-TRIVIAL 
, O 
thiram B-TRIVIAL 
and O 
difenoconazole B-TRIVIAL 
. O 

coated O 
seeds O 
are O 
commonly O 
used O 
in O 
agriculture O 
, O 
and O 
may O 
be O 
an O 
important O 
source O 
of O 
food O 
for O 
some O 
birds O 
in O 
times O 
of O 
scarcity O 
, O 
as O 
well O 
as O 
a O 
route O 
of O 
pesticide O 
ingestion O 
. O 
We O 
tested O 
the O 
lethal O 
and O 
sub O 
- O 
lethal O 
effects O 
of O 
treated O 
seed O 
ingestion O 
by O 
the O 
red O 
- O 
legged O 
partridge O 
( O 
Alectoris O 
rufa O 
) O 
, O 
a O 
game O 
bird O 
of O 
high O 
socio O 
- O 
economic O 
value O 
in O 
Spain O 
. O 
One O 
year O 
- O 
old O 
partridges O 
( O 
n O 
= O 
42 O 
pairs O 
) O 
were O 
fed O 
for O 
10 O 
days O 
in O 
spring O 
( O 
prior O 
to O 
breeding O 
) O 
with O 
wheat O 
treated O 
with O 
difenoconazole B-TRIVIAL 
( O 
fungicide O 
) O 
, O 
thiram B-TRIVIAL 
( O 
fungicide O 
) O 
or O 
imidacloprid B-TRIVIAL 
( O 
insecticide O 
) O 
, O 
using O 
two O 
doses O 
for O 
each O 
pesticide O 
( O 
the O 
one O 
recommended O 
, O 
and O 
its O 
double O 
to O 
represent O 
potential O 
cases O 
of O 
abuse O 
of O 
pesticides O 
) O 
. O 
We O 
investigated O 
the O 
direct O 
and O 
indirect O 
effects O 
on O 
the O 
body O 
condition O 
, O 
physiology O 
, O 
immunology O 
, O 
coloration O 
and O 
subsequent O 
reproduction O 
of O 
exposed O 
partridges O 
. O 
For O 
the O 
latter O 
, O 
eggs O 
were O 
collected O 
, O 
measured O 
and O 
incubated O 
and O 
the O 
growth O 
and O 
survival O 
of O 
chicks O 
were O 
monitored O 
. O 
Thiram B-TRIVIAL 
and O 
imidacloprid B-TRIVIAL 
at O 
high O 
exposure O 
doses O 
produced O 
mortalities O 
of O 
41.6 O 
and O 
58.3 O 
% O 
, O 
respectively O 
. O 
The O 
first O 
death O 
was O 
observed O 
at O 
day O 
3 O 
for O 
imidacloprid B-TRIVIAL 
and O 
at O 
day O 
7 O 
for O 
thiram B-TRIVIAL 
. O 
Both O 
doses O 
of O 
the O 
three O 
pesticides O 
caused O 
sublethal O 
effects O 
, O 
such O 
as O 
altered O 
biochemical O 
parameters O 
, O 
oxidative O 
stress O 
and O 
reduced O 
carotenoid O 
- O 
based O 
coloration O 
. O 
The O 
high O 
exposure O 
doses O 
of O 
imidacloprid B-TRIVIAL 
and O 
thiram B-TRIVIAL 
also O 
produced O 
a O 
decrease O 
in O 
cellular O 
immune O 
response O 
measured O 
by O 
the O 
phytohemagglutinin O 
test O 
in O 
males O 
. O 
Bearing O 
in O 
mind O 
the O 
limitation O 
of O 
the O 
small O 
number O 
of O 
surviving O 
pairs O 
in O 
some O 
treatments O 
, O 
we O 
found O 
that O 
the O 
three O 
pesticides O 
reduced O 
the O 
size O 
of O 
eggs O 
and O 
imidacloprid B-TRIVIAL 
and O 
difenoconazole B-TRIVIAL 
also O 
reduced O 
the O 
fertilization O 
rate O 
. O 
In O 
addition O 
, O 
both O 
thiram B-TRIVIAL 
and O 
imidacloprid B-TRIVIAL 
reduced O 
chick O 
survival O 
. O 
These O 
experiments O 
highlight O 
that O 
the O 
toxicity O 
of O 
pesticide O 
- O 
treated O 
seeds O 
is O 
a O 
factor O 
to O 
consider O 
in O 
the O 
decline O 
of O 
birds O 
in O 
agricultural O 
environments O 
. O 

role O 
of O 
adenosine B-TRIVIAL 
receptors O 
on O 
amitriptyline B-TRIVIAL 
-induced O 
electrophysiological O 
changes O 
on O 
rat O 
atrium O 
. O 

investigated O 
the O 
role O 
of O 
adenosine B-TRIVIAL 
receptors O 
in O 
amitriptyline B-TRIVIAL 
-induced O 
cardiac O 
action O 
potential O 
( O 
AP O 
) O 
changes O 
in O 
isolated O 
rat O 
atria O 
. O 
In O 
the O 
first O 
group O 
, O 
APs O 
were O 
recorded O 
after O 
cumulative O 
addition O 
of O 
amitriptyline B-TRIVIAL 
( O 
1 O 
μM O 
, O 
10 O 
μM O 
and O 
50 O 
μM O 
) O 
. O 
In O 
other O 
groups O 
, O 
each O 
atrium O 
was O 
incubated O 
with O 
selective O 
adenosine B-TRIVIAL 
A(1) O 
antagonist O 
( O 
8-cyclopentyl-1,3-dipropylxanthine B-SYSTEMATIC 
( O 
DPCPX B-ABBREVIATION 
) O 
, O 
10(-4) O 
M O 
) O 
or O 
selective O 
adenosine B-TRIVIAL 
A(2a) O 
receptor O 
antagonist O 
( O 
8-(3-chlorostyryl) B-SYSTEMATIC 
caffeine I-SYSTEMATIC 
, O 
10(-5) O 
M O 
) O 
before O 
amitriptyline B-TRIVIAL 
administration O 
. O 
Resting O 
membrane O 
potential O 
, O 
AP O 
amplitude O 
( O 
APA O 
) O 
, O 
AP O 
duration O 
at O 
50% O 
and O 
80% O 
of O 
repolarization O 
( O 
APD(50) O 
and O 
APD(80) O 
, O 
respectively O 
) O 
, O 
and O 
the O 
maximum O 
rise O 
and O 
decay O 
slopes O 
of O 
AP O 
were O 
recorded O 
. O 
Amitriptyline B-TRIVIAL 
( O 
50 O 
μM O 
) O 
prolonged O 
the O 
APD(50) O 
and O 
APD(80) O 
( O 
p O 
< O 
0.001 O 
) O 
and O 
the O 
maximum O 
rise O 
slope O 
of O 
AP O 
was O 
reduced O 
by O 
amitriptyline B-TRIVIAL 
( O 
p O 
< O 
0.0001 O 
) O 
. O 
Amitriptyline B-TRIVIAL 
reduced O 
maximum O 
decay O 
slope O 
of O 
AP O 
only O 
at O 
50 O 
μM O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
DPCPX B-ABBREVIATION 
significantly O 
decreased O 
the O 
50-μM O 
amitriptyline B-TRIVIAL 
-induced O 
APD(50) O 
and O 
APD(80) O 
prolongation O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
DPCPX B-ABBREVIATION 
significantly O 
prevented O 
the O 
effects O 
of O 
amitriptyline B-TRIVIAL 
( O 
1 O 
μM O 
and O 
50 O 
μM O 
) O 
on O 
maximum O 
rise O 
slope O 
of O 
AP O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
DPCPX B-ABBREVIATION 
significantly O 
prevented O 
the O 
amitriptyline B-TRIVIAL 
-induced O 
( O 
50 O 
μM O 
) O 
reduction O 
in O 
maximum O 
decay O 
slope O 
of O 
AP O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
The O 
selective O 
adenosine B-TRIVIAL 
A(1) O 
receptor O 
antagonist O 
prevented O 
the O 
electrophysiological O 
effects O 
of O 
amitriptyline B-TRIVIAL 
on O 
atrial O 
AP O 
. O 
A(1) O 
receptor O 
stimulation O 
may O 
be O 
responsible O 
for O 
the O 
cardiovascular O 
toxic O 
effects O 
produced O 
by O 
amitriptyline B-TRIVIAL 
. O 

- O 
agent O 
duloxetine B-TRIVIAL 
ingestions O 
. O 

is O 
a O 
serotonin B-TRIVIAL 
and O 
norepinephrine B-TRIVIAL 
reuptake O 
inhibitor O 
, O 
which O 
is O 
mainly O 
used O 
to O 
treat O 
depression O 
. O 
This O 
retrospective O 
study O 
describes O 
the O 
demographic O 
and O 
clinical O 
effects O 
of O 
duloxetine B-TRIVIAL 
ingestions O 
reported O 
to O 
the O 
National O 
Poison O 
Data O 
System O 
( O 
NPDS O 
) O 
. O 
NPDS O 
data O 
were O 
searched O 
for O 
duloxetine B-TRIVIAL 
exposures O 
between O 
2004 O 
and O 
2010 O 
. O 
A O 
total O 
of O 
11373 O 
patients O 
were O 
included O 
and O 
exposures O 
were O 
divided O 
into O 
three O 
groups O 
of O 
ages O 
≤ O 
6 O 
years O 
old O 
, O 
7-12 O 
years O 
and O 
> O 
12 O 
years O 
. O 
Neurological O 
clinical O 
effects O 
occurred O 
in O 
6.1% O 
of O 
the O 
patients O 
aged O 
≤ O 
6 O 
years O 
, O 
13.0% O 
of O 
the O 
patients O 
aged O 
7-12 O 
years O 
and O 
24.6% O 
of O 
the O 
patients O 
aged O 
> O 
12 O 
years O 
. O 
Cardiovascular O 
effects O 
occurred O 
in O 
1.4% O 
of O 
the O 
patients O 
aged O 
≤ O 
6 O 
years O 
old O 
, O 
2.5% O 
of O 
the O 
patients O 
aged O 
7-12 O 
years O 
and O 
11.6% O 
of O 
the O 
patients O 
aged O 
> O 
12 O 
years O 
. O 
Gastrointestinal O 
effects O 
occurred O 
in O 
4.1% O 
of O 
the O 
patients O 
aged O 
≤ O 
6 O 
years O 
old O 
, O 
16.6% O 
of O 
the O 
patients O 
aged O 
7-12 O 
years O 
and O 
13.8% O 
of O 
the O 
patients O 
aged O 
> O 
12 O 
years O 
. O 
Tachycardia O 
, O 
nausea O 
, O 
vomiting O 
, O 
agitation O 
/ O 
irritability O 
, O 
dizziness O 
/ O 
vertigo O 
and O 
drowsiness O 
were O 
among O 
the O 
most O 
common O 
clinical O 
effects O 
in O 
all O 
three O 
groups O 
. O 
Overall O 
, O 
61.4% O 
of O 
the O 
patients O 
aged O 
≤ O 
6 O 
years O 
and O 
77.5% O 
of O 
the O 
patients O 
aged O 
7-12 O 
years O 
were O 
managed O 
in O 
a O 
non-health O 
care O 
facility O 
, O 
while O 
55.8% O 
of O 
the O 
patients O 
aged O 
> O 
12 O 
years O 
were O 
referred O 
to O 
or O 
already O 
in O 
a O 
health O 
care O 
facility O 
. O 
We O 
conclude O 
that O 
the O 
majority O 
of O 
ingestions O 
are O 
benign O 
in O 
both O 
pediatrics O 
and O 
adults O 
. O 
Most O 
symptomatic O 
patients O 
have O 
neurologic O 
, O 
gastrointestinal O 
and O 
cardiovascular O 
effects O 
. O 
Most O 
pediatric O 
patients O 
will O 
be O 
able O 
to O 
be O 
managed O 
in O 
a O 
non-health O 
care O 
facility O 
. O 

analysis O 
of O 
thioacetamide B-SYSTEMATIC 
-induced O 
electroencephalographic O 
changes O 
in O 
rats O 
. O 

( O 
TAA B-ABBREVIATION 
) O 
is O 
widely O 
used O 
as O 
a O 
model O 
of O 
hepatic O 
encephalopathy O 
( O 
HE O 
) O 
. O 
The O 
aim O 
of O 
our O 
study O 
was O 
to O 
investigate O 
the O 
effects O 
of O 
TAA B-ABBREVIATION 
on O 
electroencephalographic O 
( O 
EEG O 
) O 
changes O 
in O 
rats O 
and O 
to O 
compare O 
them O 
with O 
human O 
HE O 
. O 
Male O 
Wistar O 
rats O 
were O 
divided O 
into O 
groups O 
: O 
( O 
1 O 
) O 
saline O 
- O 
treated O 
group O 
and O 
( O 
2 O 
) O 
TAA B-ABBREVIATION 
-treated O 
groups O 
: O 
TAA B-ABBREVIATION 
( O 
300 O 
) O 
( O 
300 O 
mg O 
/ O 
kg O 
) O 
, O 
TAA B-ABBREVIATION 
( O 
600 O 
) O 
( O 
600 O 
mg O 
/ O 
kg O 
) O 
, O 
and O 
TAA B-ABBREVIATION 
( O 
900 O 
) O 
( O 
900 O 
mg O 
/ O 
kg O 
) O 
. O 
Daily O 
dose O 
of O 
TAA B-ABBREVIATION 
( O 
300 O 
mg O 
/ O 
kg O 
) O 
was O 
administered O 
intraperitoneally O 
once O 
( O 
TAA B-ABBREVIATION 
( O 
300 O 
) O 
) O 
, O 
twice O 
( O 
TAA B-ABBREVIATION 
( O 
600 O 
) O 
) O 
, O 
or O 
thrice O 
( O 
TAA B-ABBREVIATION 
( O 
900 O 
) O 
) O 
in O 
subsequent O 
days O 
. O 
EEG O 
changes O 
were O 
recorded O 
about O 
24 O 
h O 
after O 
the O 
last O 
dose O 
of O 
TAA B-ABBREVIATION 
. O 
Absolute O 
and O 
relative O 
power O 
density O 
in O 
alpha O 
bands O 
were O 
significantly O 
higher O 
in O 
TAA B-ABBREVIATION 
( O 
300 O 
) O 
versus O 
control O 
group O 
. O 
In O 
TAA B-ABBREVIATION 
( O 
300 O 
) O 
, O 
absolute O 
beta O 
power O 
density O 
was O 
higher O 
and O 
relative O 
beta O 
power O 
density O 
was O 
lower O 
versus O 
control O 
group O 
. O 
Absolute O 
alpha O 
, O 
theta O 
, O 
delta O 
, O 
and O 
relative O 
theta O 
power O 
were O 
significantly O 
lower O 
, O 
while O 
relative O 
power O 
in O 
delta O 
band O 
was O 
significantly O 
higher O 
in O 
TAA B-ABBREVIATION 
( O 
900 O 
) O 
versus O 
control O 
group O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
In O 
conclusion O 
, O 
decrease O 
in O 
EEG O 
voltage O 
with O 
an O 
increase O 
in O 
delta O 
relative O 
power O 
, O 
which O 
correspond O 
to O 
the O 
EEG O 
manifestations O 
of O 
severe O 
HE O 
in O 
humans O 
, O 
was O 
observed O 
in O 
TAA B-ABBREVIATION 
( O 
900 O 
) O 
group O 
. O 
Electrical O 
activity O 
in O 
TAA B-ABBREVIATION 
( O 
300 O 
) O 
group O 
correlates O 
with O 
mild O 
HE O 
in O 
humans O 
. O 

protective O 
effect O 
of O 
recombinant O 
human O 
erythropoietin O 
against O 
cisplatin B-TRIVIAL 
-induced O 
renal O 
and O 
hepatic O 
dysfunctions O 
in O 
Wistar O 
rats O 
. O 

( O 
Cisp B-ABBREVIATION 
) O 
is O 
one O 
of O 
the O 
most O 
effective O 
chemotherapeutic O 
drugs O 
. O 
However O 
, O 
the O 
dose O 
of O 
Cisp B-ABBREVIATION 
is O 
greatly O 
limited O 
by O 
its O 
toxicity O 
. O 
Recombinant O 
human O 
erythropoietin O 
( O 
rhEPO O 
) O 
, O 
a O 
hormone O 
that O 
regulates O 
hematopoiesis O 
, O 
has O 
also O 
been O 
shown O 
to O 
exert O 
tissue O 
- O 
protective O 
effects O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
explore O 
the O 
protective O 
effect O 
of O 
rhEPO O 
against O 
Cisp B-ABBREVIATION 
-induced O 
renal O 
and O 
liver O 
dysfunctions O 
. O 
Adult O 
male O 
Wistar O 
rats O 
were O 
divided O 
into O 
six O 
groups O 
of O 
six O 
each O 
: O 
control O 
, O 
rhEPO-alone O 
group O 
, O 
Cisp B-ABBREVIATION 
-alone O 
group O 
and O 
rhEPO O 
+ O 
Cisp B-ABBREVIATION 
group O 
( O 
pretreatment O 
, O 
cotreatment O 
and O 
posttreatment O 
conditions O 
) O 
. O 
Our O 
results O 
showed O 
that O 
Cisp B-ABBREVIATION 
-induced O 
a O 
marked O 
renal O 
and O 
liver O 
failure O 
characterized O 
by O 
a O 
significant O 
decrease O 
in O 
body O 
weight O 
, O 
organ O 
weight O 
and O 
organ O 
ratio O 
and O 
a O 
significant O 
increase O 
in O 
creatinine B-TRIVIAL 
, O 
blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
, O 
alanine B-TRIVIAL 
aminotransferase O 
, O 
aspartate B-TRIVIAL 
aminotransferase O 
, O 
G-glutamyl O 
transferase O 
, O 
alkaline O 
phosphatase O 
, O 
bilirubin B-TRIVIAL 
conjugated O 
and O 
bilirubin B-TRIVIAL 
total O 
levels O 
in O 
serum O 
. O 
Histological O 
examination O 
showed O 
that O 
Cisp B-ABBREVIATION 
caused O 
kidney O 
alterations O 
. O 
rhEPO O 
treatments O 
restored O 
body O 
weight O 
, O 
organ O 
weight O 
and O 
organ O 
ratio O 
as O 
well O 
as O 
serum O 
biochemical O 
parameters O 
changed O 
due O 
to O 
Cisp B-ABBREVIATION 
exposure O 
. O 

of O 
increasing O 
supplementation O 
of O 
magnesium B-SYSTEMATIC 
in O 
diets O 
on O 
productive O 
performance O 
and O 
eggshell O 
quality O 
of O 
aged O 
laying O 
hens O 
. O 

( O 
Mg B-FORMULA 
) O 
concentrations O 
in O 
diets O 
have O 
been O 
associated O 
with O 
performance O 
and O 
eggshell O 
quality O 
of O 
laying O 
hens O 
, O 
but O 
the O 
results O 
have O 
been O 
inconclusive O 
. O 
In O 
this O 
experiment O 
, O 
the O 
effects O 
of O 
increasing O 
concentrations O 
of O 
dietary O 
Mg B-FORMULA 
on O 
productive O 
performance O 
and O 
eggshell O 
quality O 
of O 
aged O 
laying O 
hens O 
were O 
evaluated O 
. O 
A O 
total O 
of O 
640 O 
Hy-Line O 
Brown O 
laying O 
hens O 
of O 
72 O 
weeks O 
of O 
age O 
were O 
randomly O 
allotted O 
to O 
one O 
of O 
four O 
dietary O 
treatments O 
with O 
four O 
replicates O 
per O 
treatment O 
. O 
A O 
commercial O 
- O 
type O 
basal O 
diet O 
containing O 
1.6 O 
g O 
/ O 
kg O 
Mg B-FORMULA 
was O 
prepared O 
, O 
and O 
three O 
additional O 
diets O 
were O 
prepared O 
to O 
contain O 
2.3 O 
, O 
2.6 O 
, O 
or O 
3 O 
g O 
/ O 
kg O 
Mg B-FORMULA 
in O 
diets O 
by O 
adding O 
1 O 
, O 
1.5 O 
, O 
or O 
2 O 
g O 
of O 
MgO B-FORMULA 
to O 
the O 
basal O 
diet O 
. O 
The O 
diets O 
were O 
fed O 
to O 
hens O 
ad O 
libitum O 
for O 
5 O 
weeks O 
. O 
Results O 
indicated O 
that O 
Mg B-FORMULA 
concentrations O 
in O 
eggshells O 
were O 
increased O 
( O 
linear O 
, O 
P O 
< O 
0.01 O 
) O 
with O 
increasing O 
concentrations O 
of O 
Mg B-FORMULA 
in O 
diets O 
. O 
Increasing O 
concentrations O 
of O 
Mg B-FORMULA 
in O 
diets O 
decreased O 
( O 
linear O 
and O 
quadratic O 
, O 
P O 
< O 
0.01 O 
) O 
broken O 
and O 
shell O 
- O 
less O 
egg O 
production O 
, O 
but O 
improved O 
( O 
linear O 
, O 
P O 
< O 
0.05 O 
) O 
eggshell O 
strength O 
. O 
Feed O 
intake O 
was O 
decreased O 
( O 
linear O 
, O 
P O 
< O 
0.05 O 
) O 
with O 
the O 
concentrations O 
of O 
Mg B-FORMULA 
in O 
diets O 
, O 
but O 
hen O 
- O 
day O 
egg O 
production O 
, O 
egg O 
weight O 
, O 
feed O 
conversion O 
ratio O 
, O 
and O 
Haugh O 
unit O 
were O 
not O 
affected O 
by O 
increasing O 
concentrations O 
of O 
Mg B-FORMULA 
in O 
diets O 
. O 
Hunter O 
L* O 
and O 
a* O 
values O 
of O 
eggshell O 
were O 
decreased O 
( O 
linear O 
, O 
P O 
< O 
0.05 O 
) O 
as O 
the O 
concentrations O 
of O 
Mg B-FORMULA 
in O 
diets O 
increased O 
. O 
In O 
conclusion O 
, O 
feeding O 
aged O 
laying O 
hens O 
with O 
diets O 
containing O 
increasing O 
concentrations O 
of O 
Mg B-FORMULA 
up O 
to O 
3 O 
g O 
/ O 
kg O 
improves O 
eggshell O 
strength O 
, O 
but O 
has O 
no O 
detrimental O 
effects O 
on O 
laying O 
performance O 
. O 

insights O 
on O 
the O 
effect O 
of O 
nicotine B-TRIVIAL 
in O 
a O 
murine O 
colitis O 
model O 
. O 

showed O 
that O 
nicotine B-TRIVIAL 
has O 
a O 
positive O 
influence O 
on O 
symptoms O 
of O 
ulcerative O 
colitis O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
explored O 
the O 
effect O 
of O 
nicotine B-TRIVIAL 
treatment O 
using O 
different O 
routes O 
of O 
administration O 
in O 
the O 
dextran O 
sodium B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
DSS O 
) O 
colitis O 
mouse O 
model O 
. O 
We O 
also O 
investigated O 
the O 
effects O 
of O 
cotinine B-TRIVIAL 
, O 
a O 
major O 
metabolite O 
of O 
nicotine B-TRIVIAL 
, O 
in O 
the O 
model O 
. O 
C57BL6 O 
adult O 
male O 
mice O 
were O 
given O 
DSS O 
solution O 
freely O 
in O 
the O 
drinking O 
water O 
for O 
seven O 
consecutive O 
days O 
, O 
and O 
tap O 
water O 
was O 
given O 
thereafter O 
. O 
Disease O 
severity O 
, O 
length O 
of O 
the O 
colon O 
, O 
colon O 
tissue O 
histology O 
, O 
and O 
inflammatory O 
markers O 
, O 
including O 
colonic O 
myeloperoxidase O 
activity O 
and O 
colonic O 
tumor O 
necrosis O 
factor-α O 
levels O 
, O 
were O 
evaluated O 
. O 
The O 
effect O 
of O 
nicotine B-TRIVIAL 
and O 
cotinine B-TRIVIAL 
treatments O 
via O 
various O 
different O 
routes O 
of O 
administration O 
were O 
examined O 
the O 
DSS O 
model O 
. O 
In O 
addition O 
, O 
we O 
measured O 
the O 
plasma O 
levels O 
of O 
nicotine B-TRIVIAL 
and O 
cotinine B-TRIVIAL 
in O 
our O 
treatment O 
protocols O 
. O 
Administration O 
of O 
low O 
, O 
but O 
not O 
high O 
, O 
doses O 
of O 
oral O 
nicotine B-TRIVIAL 
in O 
DSS O 
- O 
treated O 
mice O 
resulted O 
in O 
a O 
significant O 
decrease O 
in O 
disease O 
severity O 
, O 
histologic O 
damage O 
scores O 
, O 
as O 
well O 
as O 
colonic O 
level O 
of O 
tumor O 
necrosis O 
factor-α O 
. O 
However O 
, O 
the O 
anti-inflammatory O 
effect O 
of O 
nicotine B-TRIVIAL 
was O 
not O 
seen O 
after O 
chronic O 
s.c O 
. O 
or O 
minipump O 
infusion O 
of O 
the O 
drug O 
. O 
Differences O 
in O 
plasma O 
levels O 
of O 
nicotine B-TRIVIAL 
and O 
cotinine B-TRIVIAL 
do O 
not O 
seem O 
to O 
account O 
for O 
this O 
lack O 
of O 
effect O 
. O 
Finally O 
, O 
oral O 
cotinine B-TRIVIAL 
alone O 
failed O 
to O 
show O 
a O 
significant O 
effect O 
in O 
the O 
DSS O 
model O 
of O 
colitis O 
. O 
These O 
results O 
highlight O 
that O 
dose O 
and O 
route O 
of O 
administration O 
play O 
a O 
critical O 
role O 
in O 
the O 
protective O 
effect O 
of O 
nicotine B-TRIVIAL 
in O 
the O 
DSS O 
mouse O 
colitis O 
model O 
. O 

receptor O 
CAG O 
repeat O 
length O 
modifies O 
the O 
effect O 
of O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
on O 
receptor O 
activity O 
in O 
human O 
prostate O 
cells O 
. O 

incidence O 
of O 
prostate O 
cancer O 
has O 
been O 
reported O 
in O 
men O 
exposed O 
to O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
. O 
TCDD B-ABBREVIATION 
acts O 
through O 
the O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AhR O 
) O 
, O 
which O 
interacts O 
with O 
the O 
androgen B-FAMILY 
receptor O 
( O 
AR O 
) O 
. O 
The O 
AR O 
gene O 
contains O 
a O 
polymorphic O 
CAG O 
repeat O 
that O 
influences O 
its O 
transcriptional O 
activity O 
. O 
We O 
investigated O 
the O 
influence O 
of O 
TCDD B-ABBREVIATION 
on O 
prostate O 
cancer O 
cells O 
( O 
PC-3 O 
) O 
and O 
non-tumor O 
prostate O 
cells O 
( O 
PNT1A O 
) O 
on O 
5α-dihydrotestosterone B-SYSTEMATIC 
-activated O 
ARs O 
containing O 
CAG O 
repeats O 
within O 
normal O 
length O 
range O 
( O 
16 O 
, O 
22 O 
, O 
and O 
28 O 
) O 
. O 
The O 
AhR O 
target O 
gene O 
CYP1A1 O 
mRNA O 
expression O 
was O 
induced O 
by O 
TCDD B-ABBREVIATION 
, O 
but O 
was O 
not O 
affected O 
by O 
the O 
AR O 
CAG O 
length O 
. O 
TCDD B-ABBREVIATION 
had O 
no O 
effect O 
on O 
AR O 
activity O 
in O 
PC-3 O 
cells O 
, O 
whereas O 
the O 
shortest O 
AR O 
variant O 
was O 
induced O 
by O 
TCDD B-ABBREVIATION 
in O 
PNT1A O 
cells O 
. O 
In O 
conclusion O 
, O 
the O 
CAG O 
length O 
dependent O 
effect O 
of O 
TCDD B-ABBREVIATION 
on O 
AR O 
activity O 
in O 
PNT1A O 
, O 
but O 
not O 
in O 
PC-3 O 
cells O 
, O 
indicates O 
as O 
a O 
cell O 
- O 
specific O 
effect O 
of O 
TCDD B-ABBREVIATION 
on O 
AR O 
activity O 
. O 

affecting O 
the O 
Sequestosome O 
1 O 
( O 
SQSTM1 O 
) O 
gene O 
commonly O 
occur O 
in O 
patients O 
with O 
the O 
skeletal O 
disorder O 
Paget's O 
disease O 
of O 
bone O 
( O 
PDB O 
) O 
, O 
a O 
condition O 
characterised O 
by O 
defective O 
osteoclast O 
differentiation O 
and O 
function O 
. O 
Whilst O 
most O 
mutations O 
cluster O 
within O 
the O 
ubiquitin O 
- O 
associated O 
( O 
UBA O 
) O 
domain O 
of O 
the O 
SQSTM1 O 
protein O 
, O 
and O 
are O 
associated O 
with O 
dysregulated O 
NFκB O 
signalling O 
, O 
several O 
non-UBA O 
domain O 
mutations O 
have O 
also O 
been O 
identified O 
. O 
Keap1 O 
is O 
a O 
SQSTM1-interacting O 
protein O 
that O 
regulates O 
the O 
levels O 
and O 
activity O 
of O 
the O 
Nrf2 O 
transcription O 
factor O 
. O 
This O 
in O 
turn O 
controls O 
the O 
expression O 
of O 
numerous O 
cytoprotective O 
genes O 
that O 
contribute O 
to O 
the O 
cell's O 
capacity O 
to O 
defend O 
itself O 
against O 
chemical O 
and O 
oxidative O 
stress O 
, O 
through O 
binding O 
to O 
the O 
antioxidant O 
response O 
element O 
( O 
ARE O 
) O 
. O 
The O 
PDB-associated O 
S349T O 
mutation O 
maps O 
to O 
the O 
Keap1-interacting O 
region O 
( O 
KIR O 
) O 
of O 
SQSTM1 O 
, O 
however O 
the O 
effects O 
of O 
PDB O 
mutant O 
SQSTM1 O 
on O 
Keap1 O 
function O 
have O 
not O 
been O 
investigated O 
. O 
Here O 
we O 
show O 
that O 
unlike O 
other O 
SQSTM1 O 
mutations O 
, O 
the O 
S349T O 
mutation O 
results O 
in O 
neither O 
impaired O 
ubiquitin O 
- O 
binding O 
function O 
in O 
pull O 
- O 
down O 
assays O 
, O 
nor O 
dysregulated O 
NFκB O 
signalling O 
in O 
luciferase O 
reporter O 
assays O 
. O 
Keap1 O 
is O 
expressed O 
in O 
differentiating O 
osteoclast O 
- O 
like O 
cells O 
and O 
the O 
S349T O 
mutation O 
selectively O 
impairs O 
the O 
SQSTM1-Keap1 O 
interaction O 
in O 
co O 
- O 
immunoprecipitations O 
, O 
which O 
molecular O 
modelling O 
indicates O 
results O 
from O 
effects O 
on O 
critical O 
hydrogen B-SYSTEMATIC 
bonds O 
required O 
to O 
stabilise O 
the O 
KIR-Keap1 O 
complex O 
. O 
Further O 
, O 
S349T O 
mutant O 
SQSTM1 O 
, O 
but O 
not O 
other O 
PDB-associated O 
mutants O 
, O 
showed O 
reduced O 
ability O 
to O 
activate O 
Nrf2 O 
signalling O 
as O 
assessed O 
by O 
ARE-luciferase O 
reporter O 
assays O 
. O 
Thus O 
, O 
SQSTM1 O 
- O 
mediated O 
dysregulation O 
of O 
the O 
Keap1-Nrf2 O 
axis O 
, O 
which O 
could O 
potentially O 
lead O 
to O 
aberrant O 
production O 
of O 
oxidative O 
response O 
genes O 
, O 
may O 
contribute O 
to O 
disease O 
aetiology O 
in O 
a O 
subset O 
of O 
PDB O 
patients O 
. O 

junction O 
( O 
HJ O 
) O 
resolvases O 
are O 
structure O 
- O 
specific O 
endonucleases O 
that O 
cleave O 
four O 
- O 
way O 
DNA O 
junctions O 
( O 
HJs O 
) O 
generated O 
during O 
DNA O 
recombination O 
and O 
repair O 
. O 
Bacterial O 
RuvC O 
, O 
a O 
prototypical O 
HJ O 
resolvase O 
, O 
functions O 
as O 
homodimer O 
and O 
nicks O 
DNA O 
strands O 
precisely O 
across O 
the O 
junction O 
point O 
. O 
To O 
gain O 
insights O 
into O 
the O 
mechanisms O 
underlying O 
symmetrical O 
strand O 
cleavages O 
by O 
RuvC O 
, O 
we O 
performed O 
crystallographic O 
and O 
biochemical O 
analyses O 
of O 
RuvC O 
from O 
Thermus O 
thermophilus O 
( O 
T.th O 
. O 
RuvC O 
) O 
. O 
The O 
crystal O 
structure O 
of O 
T.th O 
. O 
RuvC O 
shows O 
an O 
overall O 
protein O 
fold O 
similar O 
to O 
that O 
of O 
Escherichia O 
coli O 
RuvC O 
, O 
but O 
T.th O 
. O 
RuvC O 
has O 
a O 
more O 
tightly O 
associated O 
dimer O 
interface O 
possibly O 
reflecting O 
its O 
thermostability O 
. O 
The O 
binding O 
mode O 
of O 
a O 
HJ-DNA O 
substrate O 
can O 
be O 
inferred O 
from O 
the O 
shape O 
/ O 
charge O 
complementarity O 
between O 
the O 
T.th O 
. O 
RuvC O 
dimer O 
and O 
HJ-DNA O 
, O 
as O 
well O 
as O 
positions O 
of O 
sulfate B-SYSTEMATIC 
ions O 
bound O 
on O 
the O 
protein O 
surface O 
. O 
Unexpectedly O 
, O 
the O 
structure O 
of O 
T.th O 
. O 
RuvC O 
homodimer O 
refined O 
at O 
1.28 O 
Å O 
resolution O 
shows O 
distinct O 
asymmetry O 
near O 
the O 
dimer O 
interface O 
, O 
in O 
the O 
region O 
harboring O 
catalytically O 
important O 
aromatic O 
residues O 
. O 
The O 
observation O 
suggests O 
that O 
the O 
T.th O 
. O 
RuvC O 
homodimer O 
interconverts O 
between O 
two O 
asymmetric O 
conformations O 
, O 
with O 
alternating O 
subunits O 
switched O 
on O 
for O 
DNA O 
strand O 
cleavage O 
. O 
This O 
model O 
provides O 
a O 
structural O 
basis O 
for O 
the O 
' O 
nick O 
- O 
counter O 
- O 
nick O 
' O 
mechanism O 
in O 
HJ O 
resolution O 
, O 
a O 
mode O 
of O 
HJ O 
processing O 
shared O 
by O 
prokaryotic O 
and O 
eukaryotic O 
HJ O 
resolvases O 
. O 

are O 
often O 
the O 
top O 
predators O 
in O 
marine O 
benthic O 
environments O 
, O 
and O 
trophic O 
transfer O 
is O 
the O 
predominant O 
route O 
by O 
which O 
metals O 
are O 
accumulated O 
in O 
these O 
predators O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
potential O 
influences O 
of O 
prey O 
composition O 
on O 
the O 
trophic O 
transfer O 
, O 
accumulation O 
, O 
subcellular O 
distribution O 
and O 
metallothionein O 
induction O 
of O 
six O 
metals O 
( O 
Ag B-FORMULA 
, O 
As B-FORMULA 
, O 
Cd B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Pb B-FORMULA 
and O 
Zn B-FORMULA 
) O 
in O 
a O 
predator O 
Nassarius O 
siquijorensis O 
were O 
investigated O 
. O 
The O 
snails O 
were O 
fed O 
venerid O 
clams O 
Ruditapes O 
philippinarum O 
, O 
mussels O 
Perna O 
viridis O 
, O 
oysters O 
Crassostrea O 
angulata O 
or O 
barnacles O 
Fistulobalanus O 
albicostatus O 
, O 
each O 
differing O 
greatly O 
in O 
their O 
metal O 
accumulation O 
and O 
handling O 
patterns O 
. O 
N O 
. O 
siquijorensis O 
showed O 
prey O 
- O 
specific O 
bioaccumulation O 
and O 
trophic O 
transfer O 
of O 
the O 
six O 
metals O 
. O 
In O 
general O 
, O 
the O 
body O 
burdens O 
of O 
metals O 
in O 
the O 
viscera O 
and O 
muscles O 
of O 
N O 
. O 
siquijorensis O 
increased O 
with O 
increasing O 
exposure O 
period O 
and O 
metal O 
concentration O 
in O 
the O 
four O 
prey O 
. O 
The O 
calculated O 
trophic O 
transfer O 
factors O 
( O 
TTFs O 
) O 
of O 
the O 
metals O 
in O 
different O 
prey O 
varied O 
and O 
were O 
the O 
highest O 
for O 
clams O 
and O 
mussels O 
prey O 
, O 
indicating O 
that O 
metal O 
bioavailability O 
from O 
these O 
prey O 
was O 
higher O 
than O 
that O 
from O 
barnacles O 
and O 
oysters O 
. O 
All O 
the O 
studied O 
metals O 
except O 
Pb B-FORMULA 
were O 
enriched O 
during O 
transfer O 
to O 
the O 
snails O 
. O 
The O 
subcellular O 
metal O 
distribution O 
in O 
the O 
viscera O 
was O 
affected O 
by O 
prey O 
composition O 
. O 
Exposure O 
to O 
the O 
four O 
natural O 
prey O 
induced O 
MTs O 
, O 
which O 
may O 
be O 
used O 
as O 
a O 
better O 
biomarker O 
for O 
muscle O 
than O 
for O 
viscera O 
for O 
metal O 
stress O 
. O 
Our O 
results O 
imply O 
that O 
metals O 
from O 
different O 
natural O 
prey O 
have O 
different O 
bioavailability O 
and O 
may O 
help O 
better O 
understand O 
the O 
trophic O 
transfer O 
of O 
metals O 
in O 
marine O 
benthic O 
food O 
chain O 
. O 

inhibitory O 
effect O 
of O 
an O 
aqueous O 
extract O 
from O 
spinach O 
on O 
degranulation O 
of O 
RBL-2H3 O 
cells O 
is O 
herein O 
reported O 
. O 
The O 
extract O 
significantly O 
suppressed O 
antigen O 
- O 
induced O 
degranulation O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
without O 
affecting O 
cell O 
viability O 
. O 
Active O 
substances O 
in O 
the O 
extract O 
were O 
heat O 
- O 
stable O 
and O 
trypsin O 
- O 
resistant O 
with O 
molecular O 
weights O 
ranging O 
from O 
500 O 
Da O 
to O 
14 O 
kDa O 
. O 
The O 
extract O 
inhibited O 
elevation O 
of O 
the O 
intracellular O 
Ca(2+) B-FORMULA 
concentration O 
caused O 
by O 
stimulation O 
by O 
antigen O 
, O 
while O 
not O 
suppressing O 
degranulation O 
induced O 
by O 
a O 
calcium B-SYSTEMATIC 
ionophore O 
A23187 B-IDENTIFIER 
. O 
Immunoblot O 
analysis O 
revealed O 
that O 
the O 
inhibitory O 
effect O 
results O 
from O 
downregulation O 
of O 
phosphorylation O 
of O 
both O 
Syk O 
kinase O 
and O 
phosphatidylinositol B-TRIVIAL 
3-kinase O 
in O 
the O 
signalling O 
pathways O 
involved O 
in O 
degranulation O 
caused O 
by O 
the O 
antigen O 
- O 
antibody O 
interaction O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
suggest O 
that O 
aqueous O 
spinach O 
extract O 
has O 
an O 
anti-allergic O 
activity O 
that O 
controls O 
degranulation O 
. O 

profile O 
, O 
antioxidant O 
and O 
antimicrobial O 
activity O 
of O 
bark O 
extracts O 
of O 
Rhamnus O 
alaternus O 
, O 
R O 
. O 
fallax O 
, O 
R O 
. O 
intermedia O 
and O 
R O 
. O 
pumila O 
. O 

quantity O 
of O 
phenols B-FAMILY 
, O 
as O 
well O 
as O 
antioxidant O 
and O 
antimicrobial O 
activities O 
, O 
were O 
investigated O 
in O 
bark O 
of O 
Rhamnus O 
alaternus O 
L O 
. O 
, O 
R O 
. O 
fallax O 
Boiss O 
. O 
, O 
R O 
. O 
intermedia O 
Steud O 
. O 
et O 
Hochst O 
. O 
, O 
and O 
R O 
. O 
pumila O 
Turra O 
from O 
natural O 
stands O 
in O 
Croatia O 
. O 
The O 
most O 
abundant O 
anthraquinones B-FAMILY 
in O 
the O 
investigated O 
extracts O 
were O 
chrysophanol B-TRIVIAL 
in O 
R O 
. O 
alaternus O 
( O 
3.14 O 
mg O 
/ O 
g O 
) O 
, O 
emodin B-TRIVIAL 
in O 
R O 
. O 
pumila O 
( O 
0.339 O 
mg O 
/ O 
g O 
) O 
, O 
and O 
physcion B-TRIVIAL 
in O 
R O 
. O 
fallax O 
( O 
2.7 O 
mg O 
/ O 
g O 
) O 
and O 
R O 
. O 
intermedia O 
( O 
0.285 O 
mg O 
/ O 
g O 
) O 
. O 
The O 
species O 
exhibiting O 
the O 
highest O 
antioxidant O 
activity O 
were O 
R O 
. O 
fallax O 
and O 
R O 
. O 
pumila O 
. O 
A O 
positive O 
correlation O 
was O 
observed O 
between O 
total O 
phenolic B-FAMILY 
and O 
flavonoid B-FAMILY 
levels O 
of O 
the O 
extracts O 
and O 
antioxidant O 
activity O 
in O 
some O 
of O 
the O 
assays O 
. O 
All O 
species O 
showed O 
antimicrobial O 
activity O 
against O 
Staphylococcus O 
aureus O 
, O 
Pseudomonas O 
aeruginosa O 
, O 
Escherichia O 
coli O 
, O 
Candida O 
albicans O 
, O 
Aspergillus O 
niger O 
and O 
Microsporum O 
gypseum O 
with O 
minimal O 
inhibitory O 
concentrations O 
equal O 
to O 
or O 
below O 
2.5 O 
mg O 
/ O 
mL O 
. O 
The O 
results O 
indicate O 
that O 
the O 
investigated O 
Rhamnus O 
species O 
are O 
a O 
source O 
of O 
anthraquinones B-FAMILY 
and O 
other O 
phenols B-FAMILY 
, O 
which O 
act O 
as O 
multifunctional O 
antioxidants O 
with O 
antimicrobial O 
activity O 
. O 

aqueum O 
leaf O 
extract O 
and O 
its O 
bioactive O 
compounds O 
enhances O 
pre O 
- O 
adipocyte O 
differentiation O 
and O 
2-NBDG B-SYSTEMATIC 
uptake O 
in O 
3T3-L1 O 
cells O 
. O 

insulin O 
- O 
like O 
and O 
/ O 
or O 
insulin O 
- O 
sensitising O 
effects O 
of O 
Syzygium O 
aqueum O 
leaf O 
extract O 
and O 
its O 
six O 
bioactive O 
compounds O 
; O 
4-hydroxybenzaldehyde B-SYSTEMATIC 
, O 
myricetin-3-O-rhamnoside B-SYSTEMATIC 
, O 
europetin-3-O-rhamnoside B-SYSTEMATIC 
, O 
phloretin B-TRIVIAL 
, O 
myrigalone-G B-TRIVIAL 
and O 
myrigalone-B B-TRIVIAL 
were O 
investigated O 
in O 
3T3-L1 O 
adipocytes O 
. O 
We O 
observed O 
that O 
, O 
S O 
. O 
aqueum O 
leaf O 
extract O 
( O 
0.04-5 O 
μg O 
/ O 
ml O 
) O 
and O 
its O 
six O 
bioactive O 
compounds O 
( O 
0.08-10 O 
μM O 
) O 
at O 
non-cytotoxic O 
concentrations O 
were O 
effectively O 
enhance O 
adipogenesis O 
, O 
stimulate O 
glucose B-TRIVIAL 
uptake O 
and O 
increase O 
adiponectin O 
secretion O 
in O 
3T3-L1 O 
adipocytes O 
. O 
Clearly O 
, O 
the O 
compounds O 
myricetin-3-O-rhamnoside B-SYSTEMATIC 
and O 
europetin-3-O-rhamnoside B-SYSTEMATIC 
showed O 
insulin O 
- O 
like O 
and O 
insulin O 
- O 
sensitising O 
effects O 
on O 
adipocytes O 
from O 
a O 
concentration O 
of O 
0.08 O 
μM O 
. O 
These O 
compounds O 
were O 
far O 
better O 
than O 
rosiglitazone B-TRIVIAL 
and O 
the O 
other O 
isolated O 
compounds O 
in O 
enhancing O 
adipogenesis O 
, O 
stimulating O 
2-NBDG B-SYSTEMATIC 
uptake O 
and O 
increasing O 
adiponectin O 
secretion O 
at O 
all O 
the O 
concentrations O 
tested O 
. O 
These O 
suggest O 
the O 
antidiabetic O 
potential O 
of O 
S O 
. O 
aqueum O 
leaf O 
extract O 
and O 
its O 
six O 
bioactive O 
compounds O 
. O 
However O 
, O 
further O 
molecular O 
interaction O 
studies O 
to O 
explain O 
the O 
mechanisms O 
of O 
action O 
are O 
highly O 
warranted O 
. O 

improved O 
mass O 
spectrometric O 
method O 
for O 
identification O 
and O 
quantification O 
of O 
phenolic B-FAMILY 
compounds O 
in O 
apple O 
fruits O 
. O 

- O 
nine O 
phenolic B-FAMILY 
compounds O 
were O 
analysed O 
using O 
ultra O 
high O 
performance O 
liquid O 
chromatography O 
( O 
UHPLC O 
) O 
coupled O 
with O 
diode O 
array O 
and O 
accurate O 
mass O 
spectrometry O 
detection O 
using O 
electrospray O 
ionisation O 
( O 
DAD O 
/ O 
ESI-am-MS O 
) O 
. O 
Instrumental O 
parameters O 
such O 
as O 
scan O 
speed O 
, O 
resolution O 
, O 
and O 
mass O 
accuracy O 
were O 
optimised O 
to O 
establish O 
accurate O 
mass O 
measurements O 
. O 
The O 
method O 
was O 
fully O 
validated O 
in O 
terms O 
of O 
model O 
deviation O 
( O 
r(2) O 
> O 
0.999 O 
) O 
, O 
range O 
( O 
typically O 
10-3500 O 
ngg(-1) O 
) O 
, O 
intra O 
/ O 
inter O 
- O 
day O 
precision O 
( O 
< O 
6% O 
and O 
< O 
8% O 
, O 
respectively O 
) O 
and O 
accuracy O 
( O 
typically O 
100 O 
± O 
10% O 
) O 
. O 
The O 
mass O 
accuracy O 
of O 
each O 
selected O 
phenolic B-FAMILY 
compound O 
was O 
below O 
1.5 O 
ppm O 
. O 
The O 
results O 
confirmed O 
that O 
the O 
UHPLC-DAD O 
/ O 
ESI-am-MS O 
method O 
developed O 
here O 
was O 
convenient O 
and O 
reliable O 
for O 
the O 
determination O 
of O 
phenolic B-FAMILY 
compounds O 
in O 
apple O 
extracts O 
. O 

attenuates O 
high O 
glucose B-TRIVIAL 
-induced O 
lipid O 
accumulation O 
in O 
human O 
HepG2 O 
hepatocytes O 
through O 
the O 
activation O 
of O 
LKB1/ O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
- O 
dependent O 
signalling O 
. O 

, O 
an O 
active O 
constituent O 
found O 
in O 
many O 
medicinal O 
plants O 
and O 
certain O 
functional O 
foods O 
, O 
has O 
anti-obesity O 
activity O 
in O 
vivo O 
. O 
The O 
aim O 
of O 
our O 
study O 
was O 
to O 
provide O 
new O 
data O 
on O 
the O 
molecular O 
mechanism(s) O 
underlying O 
the O 
role O 
of O 
phillyrin B-TRIVIAL 
in O 
the O 
prevention O 
of O 
high O 
glucose B-TRIVIAL 
-induced O 
lipid O 
accumulation O 
in O 
human O 
HepG2 O 
hepatocytes O 
. O 
We O 
found O 
that O 
phillyrin B-TRIVIAL 
suppressed O 
high O 
glucose B-TRIVIAL 
-induced O 
lipid O 
accumulation O 
in O 
HepG2 O 
cells O 
. O 
Phillyrin B-TRIVIAL 
strongly O 
inhibited O 
high O 
glucose B-TRIVIAL 
-induced O 
fatty B-FAMILY 
acid I-FAMILY 
synthase O 
( O 
FAS O 
) O 
expression O 
by O 
modulating O 
sterol B-FAMILY 
regulatory O 
element O 
- O 
binding O 
protein-1c O 
( O 
SREBP-1c O 
) O 
activation O 
. O 
Moreover O 
, O 
use O 
of O 
the O 
pharmacological O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
inhibitor O 
compound B-TRIVIAL 
C I-TRIVIAL 
revealed O 
that O 
AMPK O 
is O 
essential O 
for O 
suppressing O 
SREBP-1c O 
expression O 
in O 
phillyrin B-TRIVIAL 
-treated O 
cells O 
. O 
Finally O 
, O 
we O 
found O 
that O 
liver O 
kinase O 
B1 O 
( O 
LKB1 O 
) O 
phosphorylation O 
is O 
required O 
for O 
the O 
phillyrin B-TRIVIAL 
-enhanced O 
activation O 
of O 
AMPK O 
in O 
HepG2 O 
hepatocytes O 
. O 
These O 
results O 
indicate O 
that O 
phillyrin B-TRIVIAL 
prevents O 
lipid O 
accumulation O 
in O 
HepG2 O 
cells O 
by O 
blocking O 
the O 
expression O 
of O 
SREBP-1c O 
and O 
FAS O 
through O 
LKB1 O 
/ O 
AMPK O 
activation O 
, O 
suggesting O 
that O 
phillyrin B-TRIVIAL 
is O 
a O 
novel O 
AMPK O 
activator O 
with O 
a O 
role O 
in O 
the O 
prevention O 
and O 
treatment O 
of O 
obesity O 
. O 

vitro O 
digestion O 
models O 
have O 
been O 
developed O 
to O 
estimate O 
carotenoid O 
bioavailability O 
but O 
most O 
do O 
not O 
consider O 
that O 
their O 
diffusion O 
from O 
fruit O 
matrix O 
to O 
the O 
lipid O 
phase O 
of O 
the O 
bolus O 
could O 
be O 
a O 
limiting O 
step O 
. O 
Therefore O 
we O 
designed O 
a O 
model O 
in O 
which O 
tomato O 
juice O 
is O 
mixed O 
with O 
oil O 
or O 
oil O 
/ O 
water O 
emulsions O 
, O 
and O 
the O 
carotenoids O 
diffusing O 
to O 
oil O 
are O 
measured O 
by O 
spectrometry O 
. O 
Temperature O 
, O 
pH O 
and O 
tomato O 
juice O 
/ O 
peanut O 
oil O 
ratio O 
were O 
evaluated O 
for O 
their O 
influence O 
on O 
carotenoid O 
diffusion O 
. O 
When O 
oil O 
/ O 
tomato O 
ratio O 
was O 
between O 
0.11 O 
and O 
1 O 
, O 
extraction O 
of O 
lycopene B-TRIVIAL 
was O 
limited O 
by O 
the O 
saturation O 
of O 
the O 
oil O 
phase O 
. O 
With O 
a O 
large O 
excess O 
of O 
oil O 
, O 
diffusion O 
was O 
also O 
limited O 
, O 
as O 
only O 
31 O 
± O 
1% O 
of O 
lycopene B-TRIVIAL 
could O 
be O 
extracted O 
from O 
the O 
juice O 
. O 
Diffusion O 
did O 
not O 
vary O 
significantly O 
with O 
pH O 
but O 
doubled O 
when O 
temperature O 
rose O 
from O 
10°C O 
to O 
37°C O 
. O 
When O 
the O 
juice O 
was O 
mixed O 
in O 
an O 
emulsion O 
stabilised O 
with O 
bovine O 
serum O 
albumin O 
or O 
phospholipids O 
the O 
maximum O 
extraction O 
decreased O 
to O 
14.5 O 
± O 
0.2% O 
and O 
18.5 O 
± O 
1.5% O 
respectively O 
, O 
indicating O 
that O 
in O 
addition O 
to O 
the O 
saturation O 
of O 
the O 
oil O 
phase O 
at O 
low O 
oil O 
/ O 
tomato O 
ratio O 
and O 
in O 
addition O 
to O 
intrinsic O 
properties O 
of O 
the O 
tomato O 
juice O 
in O 
non-saturating O 
conditions O 
, O 
lycopene B-TRIVIAL 
diffusion O 
was O 
limited O 
by O 
the O 
structure O 
of O 
the O 
interface O 
in O 
emulsions O 
. O 

( O 
Fortunella O 
margarita O 
Swingle O 
) O 
cultivated O 
in O 
Taiwan O 
are O 
eaten O 
raw O 
or O 
made O 
into O 
candied O 
fruit O 
or O 
fruit O 
tea O 
. O 
For O 
the O 
experiments O 
described O 
in O 
this O 
paper O 
, O 
essential O 
oils O 
were O 
obtained O 
from O 
kumquat O 
peels O 
or O 
whole O 
fruit O 
by O 
cold O 
pressing O 
, O 
steam O 
distillation O 
or O 
heating O 
in O 
water O 
at O 
90°C O 
for O 
15 O 
min O 
followed O 
by O 
steam O 
distillation O 
. O 
The O 
volatile O 
components O 
contained O 
in O 
the O 
essential O 
oils O 
were O 
identified O 
by O 
direct O 
injection O 
( O 
DI O 
) O 
or O 
headspace O 
- O 
solid O 
phase O 
microextraction O 
( O 
HS-SPME O 
) O 
coupled O 
with O 
gas O 
chromatography O 
( O 
GC O 
) O 
. O 
A O 
total O 
of O 
43 O 
compounds O 
were O 
identified O 
, O 
of O 
which O 
37 O 
were O 
verified O 
by O 
DI O 
/ O 
GC O 
and O 
31 O 
by O 
HS-SPME O 
/ O 
GC O 
. O 
Hot O 
water O 
heating O 
increased O 
the O 
yields O 
of O 
essential O 
oils O 
from O 
both O 
peels O 
and O 
whole O 
fruit O 
. O 
The O 
principal O 
constituents O 
of O 
the O 
oils O 
were O 
similar O 
except O 
for O 
the O 
minor O 
compounds O 
, O 
including O 
linalool B-TRIVIAL 
, O 
terpinen-4-ol B-SYSTEMATIC 
and O 
α-terpineol B-TRIVIAL 
, O 
the O 
levels O 
of O 
which O 
increased O 
after O 
steam O 
distillation O 
. O 
The O 
whole O 
fruit O 
also O 
contained O 
higher O 
levels O 
of O 
terpene B-FAMILY 
alcohols I-FAMILY 
. O 

acid I-TRIVIAL 
-induced O 
elicitation O 
of O 
folates O 
in O 
coriander O 
( O 
Coriandrum O 
sativum O 
L O 
. O 
) O 
improves O 
bioaccessibility O 
and O 
reduces O 
pro O 
- O 
oxidant O 
status O 
. O 

of O 
Coriandrum O 
sativum O 
is O 
a O 
rich O 
source O 
of O 
natural O 
folates O 
amenable O 
for O 
enhancement O 
through O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
-mediated O 
elicitation O 
, O 
thereby O 
holding O 
a O 
great O 
promise O 
for O 
natural O 
- O 
mode O 
alleviation O 
of O 
this O 
vitamin B-TRIVIAL 
(B(9)) I-TRIVIAL 
deficiency O 
. O 
In O 
the O 
present O 
study O 
we O 
report O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
-mediated O 
differential O 
elicitation O 
of O 
different O 
forms O 
of O 
folates B-FAMILY 
- O 
5-methyltetrahydrofolate B-SYSTEMATIC 
, O 
5- B-SYSTEMATIC 
formyltetrahydrofolate I-SYSTEMATIC 
and O 
10- B-SYSTEMATIC 
formyltetrahydrofolate I-SYSTEMATIC 
- O 
their O 
stabilities O 
during O 
microwave O 
- O 
drying O 
and O 
bioaccessibilities O 
from O 
fresh O 
and O 
dried O 
foliage O 
. O 
The O 
first O 
two O 
compounds O 
nearly O 
doubled O 
and O 
the O 
third O 
increased O 
sixfold O 
post O 
- O 
elicitation O 
, O 
with O 
all O 
three O 
showing O 
concomitant O 
increase O 
in O 
bioaccessibilities O 
. O 
Although O 
a O 
slight O 
decrease O 
in O 
bioaccessibility O 
was O 
observed O 
in O 
dried O 
foliage O 
, O 
over O 
twofold O 
increase O 
of O 
each O 
form O 
of O 
folate O 
upon O 
elicitation O 
would O 
deliver O 
much O 
higher O 
levels O 
of O 
natural O 
folates O 
from O 
this O 
traditional O 
culinary O 
foliage O 
, O 
which O 
is O 
widely O 
used O 
in O 
many O 
cuisines O 
. O 
Elicitor O 
- O 
mediated O 
folate O 
enhancement O 
also O 
imparted O 
reduction O 
of O 
oxidative O 
status O 
and O 
the O 
enhancement O 
of O 
antioxidant O 
enzyme O 
activities O 
in O 
coriander O 
foliage O 
. O 

- O 
term O 
comparative O 
study O 
of O 
the O 
influence O 
of O 
fried O 
edible O 
oils O 
intake O 
on O 
the O 
metabolism O 
of O 
essential O 
fatty B-FAMILY 
acids I-FAMILY 
in O 
obese O 
individuals O 
. O 

effect O 
of O 
breakfast O 
intake O 
of O 
fried O 
oils O 
containing O 
natural O 
antioxidants O 
or O 
a O 
synthetic O 
autooxidation O 
inhibitor O 
on O 
the O 
metabolism O 
of O 
essential O 
fatty B-FAMILY 
acids I-FAMILY 
focused O 
on O 
obese O 
individuals O 
. O 
Serum O 
levels O 
of O 
eicosanoids B-FAMILY 
were O 
compared O 
in O 
individuals O 
before O 
and O 
after O 
intake O 
of O 
different O 
breakfasts O 
. O 
Univariate O 
descriptive O 
analysis O 
was O 
used O 
to O 
characterise O 
the O 
cohort O 
selected O 
for O 
this O 
study O 
and O 
multivariate O 
analysis O 
to O 
reveal O 
statistical O 
differences O 
of O 
normalised O 
eicosanoids B-FAMILY 
concentrations O 
( O 
determined O 
by O 
solid O 
- O 
phase O 
extraction O 
coupled O 
to O 
LC-MS O 
/ O 
MS O 
) O 
depending O 
on O 
the O 
edible O 
oil O 
used O 
for O 
breakfast O 
preparation O 
. O 
The O 
results O 
showed O 
that O 
the O 
intake O 
of O 
breakfast O 
prepared O 
with O 
pure O 
sunflower O 
oil O 
subjected O 
to O 
deep O 
frying O 
causes O 
an O 
effect O 
over O 
the O 
eicosanoids B-FAMILY 
profile O 
that O 
enables O 
discrimination O 
versus O 
the O 
rest O 
of O 
individuals O 
. O 
The O 
effect O 
was O 
a O 
significant O 
increase O 
in O 
the O 
concentration O 
of O 
hydroxyoctadecadienoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
HODE B-ABBREVIATION 
) O 
metabolites O 
, O 
indicative O 
markers O 
of O 
the O 
intake O 
of O 
fried O 
oils O 
. O 
The O 
concentration O 
of O 
HODE B-ABBREVIATION 
metabolites O 
was O 
lower O 
when O 
the O 
oil O 
contained O 
either O 
natural O 
antioxidants O 
from O 
olive O 
- O 
oil O 
pomace O 
or O 
a O 
synthetic O 
autooxidation O 
inhibitor O 
as O 
dimethylsiloxane B-SYSTEMATIC 
. O 
The O 
comparison O 
of O 
the O 
effect O 
of O 
fried O 
sunflower O 
oils O 
with O 
fried O 
extra O 
virgin O 
olive O 
oil O 
shows O 
the O 
benefits O 
associated O 
to O 
the O 
consumption O 
of O 
the O 
latter O 
. O 

which O 
have O 
been O 
traditionally O 
eaten O 
by O 
the O 
alpine O 
population O 
may O 
provide O 
new O 
opportunities O 
for O 
agricultural O 
development O 
in O 
mountain O 
regions O 
. O 
In O 
this O 
context O 
we O 
have O 
investigated O 
the O 
chemical O 
composition O 
of O 
Phyteuma O 
orbiculare O 
( O 
Campanulaceae O 
) O 
, O 
a O 
perennial O 
herb O 
whose O 
leaves O 
have O 
been O 
eaten O 
as O 
salad O 
by O 
rural O 
populations O 
in O 
Valais O 
( O 
Switzerland O 
) O 
. O 
Extracts O 
of O 
different O 
polarities O 
were O 
subjected O 
to O 
comprehensive O 
metabolite O 
profiling O 
using O 
a O 
dereplication O 
platform O 
combining O 
HPLC-PDA-MS O 
, O 
and O 
offline O 
NMR O 
analysis O 
. O 
Twenty O 
- O 
three O 
compounds O 
, O 
including O 
various O 
phenolic B-FAMILY 
glycosides I-FAMILY 
, O 
a O 
new O 
dimeric O 
phenylpropanoid B-SYSTEMATIC 
glucoside I-SYSTEMATIC 
, O 
saponins B-FAMILY 
, O 
and O 
fatty B-FAMILY 
acids I-FAMILY 
were O 
identified O 
online O 
, O 
or O 
after O 
targeted O 
isolation O 
. O 
Selected O 
phenolic O 
constituents O 
were O 
quantitatively O 
assessed O 
by O 
HPLC-PDA O 
analysis O 
. O 
In O 
addition O 
, O 
substances O 
relevant O 
for O 
nutrition O 
, O 
such O 
as O 
β-carotene B-TRIVIAL 
, O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
minerals O 
were O 
quantified O 
in O 
leaves O 
and O 
flowers O 
. O 
The O 
antioxidant O 
capacity O 
was O 
determined O 
with O 
an O 
ORAC O 
assay O 
, O 
and O 
total O 
phenolic B-FAMILY 
compounds O 
were O 
quantified O 
. O 
Finally O 
, O 
the O 
phytochemical O 
profile O 
was O 
compared O 
to O 
that O 
of O 
the O 
related O 
species O 
P O 
. O 
spicatum O 
, O 
P O 
. O 
hemisphaericum O 
and O 
P O 
. O 
ovatum O 
. O 

induces O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
mediated O 
intrinsic O 
pathway O 
of O 
apoptosis O 
in O 
HepG2 O 
cells O 
. O 

has O 
accumulated O 
concerning O 
the O 
medicinal O 
application O 
of O 
Nelumbo O 
nucifera O 
in O 
the O 
treatment O 
of O 
various O 
diseases O 
. O 
Neferine B-TRIVIAL 
, O 
an O 
alkaloid O 
from O 
N O 
. O 
nucifera O 
was O 
found O 
to O 
exert O 
cytotoxicity O 
on O 
liver O 
cancer O 
cells O 
HepG2 O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
We O 
evaluated O 
its O 
anticancer O 
potential O 
by O 
studying O 
its O 
effect O 
on O 
mitochondrial O 
membrane O 
potential O 
, O 
intracellular O 
calcium B-SYSTEMATIC 
levels O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
, O 
cell O 
membrane O 
integrity O 
, O 
apoptotic O 
body O 
formation O 
and O 
DNA O 
fragmentation O 
in O 
cultured O 
HepG2 O 
cells O 
. O 
The O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
level O 
has O 
been O 
increased O 
upon O 
neferine B-TRIVIAL 
treatment O 
with O 
concomitant O 
decrease O 
in O 
reduced O 
glutathione B-TRIVIAL 
. O 
Our O 
data O 
further O 
indicate O 
reduction O 
of O 
ΔψM O 
and O 
increased O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
during O 
apoptosis O 
induction O 
by O 
neferine B-TRIVIAL 
with O 
increased O 
expression O 
of O 
apoptotic O 
proteins O 
such O 
as O 
Bax O 
, O 
Bad O 
, O 
cleaved O 
forms O 
of O 
caspase O 
3 O 
, O 
caspase O 
9 O 
and O 
PARP O 
, O 
with O 
the O 
downregulation O 
of O 
anti-apoptotic O 
protein O 
Bcl2 O 
in O 
HepG2 O 
cells O 
. O 
Moreover O 
, O 
the O 
expressions O 
of O 
tumour O 
suppressor O 
proteins O 
p53 O 
and O 
PTEN O 
were O 
upregulated O 
along O 
with O 
the O 
downregulation O 
of O 
P-Akt O 
. O 
In O 
addition O 
, O 
expression O 
levels O 
of O 
TNF-α O 
, O 
p38 O 
and O 
ERK1 O 
/ O 
2 O 
MAP O 
kinases O 
were O 
increased O 
upon O 
neferine B-TRIVIAL 
treatment O 
. O 
These O 
results O 
imply O 
that O 
mitochondrial O 
- O 
mediated O 
ROS O 
generation O 
induced O 
by O 
neferine B-TRIVIAL 
leads O 
to O 
caspase O 
- O 
dependent O 
apoptosis O 
in O 
HepG2 O 
cells O 
. O 

and O 
continuous O 
synthesis O 
of O 
lactulose B-TRIVIAL 
from O 
whey O 
lactose B-TRIVIAL 
by O 
immobilized O 
β-galactosidase O 
. O 

this O 
study O 
, O 
lactulose B-TRIVIAL 
synthesis O 
from O 
whey O 
lactose B-TRIVIAL 
was O 
investigated O 
in O 
batch O 
and O 
continuous O 
systems O 
using O 
immobilized O 
β-galactosidase O 
. O 
In O 
the O 
batch O 
system O 
, O 
the O 
optimal O 
concentration O 
of O 
fructose B-TRIVIAL 
for O 
lactulose B-TRIVIAL 
synthesis O 
was O 
20% O 
, O 
and O 
the O 
effect O 
of O 
galactose B-TRIVIAL 
, O 
glucose B-TRIVIAL 
and O 
fructose B-TRIVIAL 
on O 
β-galactosidase O 
activity O 
was O 
determined O 
for O 
hydrolysis O 
of O 
whey O 
lactose B-TRIVIAL 
and O 
the O 
transgalactosylation O 
reaction O 
for O 
lactulose B-TRIVIAL 
synthesis O 
. O 
Galactose B-TRIVIAL 
and O 
fructose B-TRIVIAL 
were O 
competitive O 
inhibitors O 
, O 
and O 
glucose B-TRIVIAL 
acted O 
as O 
a O 
noncompetitive O 
inhibitor O 
. O 
The O 
inhibitory O 
effects O 
of O 
galactose B-TRIVIAL 
and O 
glucose B-TRIVIAL 
were O 
stronger O 
in O 
the O 
transgalactosylation O 
reaction O 
than O 
they O 
were O 
in O 
the O 
hydrolysis O 
reaction O 
. O 
In O 
addition O 
, O 
when O 
immobilized O 
β-galactosidase O 
was O 
reused O 
for O 
lactulose B-TRIVIAL 
synthesis O 
, O 
its O 
catalytic O 
activity O 
was O 
retained O 
to O 
the O 
extent O 
of O 
52.9% O 
after O 
10 O 
reuses O 
. O 
Lactulose B-TRIVIAL 
was O 
synthesized O 
continuously O 
in O 
a O 
packed O 
- O 
bed O 
reactor O 
. O 
We O 
synthesized O 
19.1g O 
/ O 
l O 
lactulose B-TRIVIAL 
during O 
the O 
continuous O 
flow O 
reaction O 
at O 
a O 
flow O 
rate O 
of O 
0.5 O 
ml O 
/ O 
min O 
. O 

and O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
effects O 
upon O 
newborn O 
pathogenic O 
bacteria O 
adhesion O 
: O 
an O 
in O 
vitro O 
study O 
. O 

effect O 
of O 
the O 
main O 
gangliosides O 
( O 
GM(1) O 
, O 
GM(3) O 
, O 
GD(3) O 
) O 
and O 
free O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
( O 
Neu5Ac B-SYSTEMATIC 
) O 
upon O 
the O 
adhesion O 
of O 
pathogenic O 
bacteria O 
implicated O 
in O 
infant O 
diarrhoea O 
is O 
assessed O 
in O 
vitro O 
using O 
the O 
Caco-2 O 
cell O 
line O 
. O 
Concentrations O 
of O 
the O 
bioactive O 
compounds O 
found O 
in O 
the O 
bioaccessible O 
( O 
soluble O 
) O 
fraction O 
of O 
infant O 
formula O 
and O 
human O 
milk O 
are O 
employed O 
. O 
Bacterial O 
adhesion O 
behaviour O 
included O 
enterotoxigenic O 
Escherichia O 
coli O 
( O 
ETEC O 
) O 
, O 
enteropathogenic O 
E.coli O 
( O 
EPEC O 
) O 
, O 
Listeria O 
monocytogenes O 
, O 
Salmonella O 
entericaserovartyphi O 
, O 
Shigella O 
sonnei O 
, O 
Campylobacter O 
jejuni O 
and O 
Helicobacter O 
pylori O 
. O 
Three O 
different O 
approaches O 
were O 
assayed O 
: O 
pre O 
- O 
incubation O 
of O 
bacteria O 
and O 
compounds O 
before O 
addition O 
to O 
cells O 
( O 
competition O 
) O 
; O 
pre O 
- O 
incubation O 
of O 
the O 
cells O 
with O 
compounds O 
( O 
exclusion O 
) O 
; O 
and O 
pre O 
- O 
incubation O 
of O 
cells O 
with O 
bacteria O 
( O 
displacement O 
) O 
. O 
Furthermore O 
, O 
the O 
spatial O 
localization O 
of O 
the O 
most O 
abundant O 
gangliosides O 
, O 
GM(3) O 
and O 
GD(3) O 
, O 
in O 
Caco-2 O 
cells O 
has O 
been O 
determined O 
using O 
confocal O 
microscopy O 
. O 
Results O 
show O 
that O 
GM(3) O 
, O 
GD(3) O 
, O 
GM(1) O 
and O 
Neu5Ac B-SYSTEMATIC 
at O 
the O 
assayed O 
concentrations O 
are O 
able O 
to O 
interfere O 
with O 
the O 
adhesion O 
of O 
several O 
pathogenic O 
bacteria O 
involved O 
in O 
neonatal O 
diseases O 
- O 
the O 
greatest O 
effect O 
corresponding O 
to O 
Neu5Ac B-SYSTEMATIC 
, O 
followed O 
by O 
GD(3) O 
, O 
GM(1) O 
and O 
GM(3) O 
. O 
Gangliosides O 
GM(3) O 
and O 
GD(3) O 
are O 
located O 
in O 
the O 
apical O 
and O 
basolateral O 
membranes O 
of O 
the O 
Caco-2 O 
cells O 
. O 

simple O 
GC-MS O 
method O 
for O 
the O 
screening O 
of O 
betulinic B-MULTIPLE 
, I-MULTIPLE 
corosolic I-MULTIPLE 
, I-MULTIPLE 
maslinic I-MULTIPLE 
, I-MULTIPLE 
oleanolic I-MULTIPLE 
and I-MULTIPLE 
ursolic I-MULTIPLE 
acid I-MULTIPLE 
contents O 
in O 
commercial O 
botanicals O 
used O 
as O 
food O 
supplement O 
ingredients O 
. O 

occurrence O 
of O 
triterpene B-FAMILY 
pentacyclic I-FAMILY 
acids I-FAMILY 
in O 
plants O 
is O 
extensive O 
, O 
but O 
little O 
is O 
known O 
about O 
their O 
availability O 
in O 
commercial O 
extracts O 
. O 
A O 
simple O 
GC-MS O 
method O 
for O 
the O 
simultaneous O 
determination O 
of O 
betulinic B-MULTIPLE 
, I-MULTIPLE 
corosolic I-MULTIPLE 
, I-MULTIPLE 
maslinic I-MULTIPLE 
, I-MULTIPLE 
oleanolic I-MULTIPLE 
and I-MULTIPLE 
ursolic I-MULTIPLE 
acids I-MULTIPLE 
was O 
developed O 
and O 
applied O 
to O 
38 O 
different O 
commercial O 
plant O 
extracts O 
sold O 
as O 
ingredients O 
for O 
dietary O 
supplements O 
. O 
A O 
suitable O 
protocol O 
was O 
set O 
up O 
to O 
perform O 
routine O 
control O 
of O 
a O 
diverse O 
array O 
of O 
samples O 
with O 
different O 
botanical O 
, O 
chemical O 
and O 
physical O 
characteristics O 
. O 
Remarkable O 
quantities O 
of O 
corosolic B-TRIVIAL 
acid I-TRIVIAL 
were O 
found O 
in O 
dried O 
extracts O 
from O 
aerial O 
parts O 
of O 
Lagerstroemia O 
speciosa O 
and O 
Ortosiphon O 
stamineus O 
( O 
14233 O 
and O 
1132 O 
mg O 
/ O 
kg O 
, O 
respectively O 
) O 
, O 
while O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
was O 
abundant O 
in O 
O O 
. O 
stamineus O 
and O 
Crataegus O 
monogyna O 
flowers O 
( O 
2774 O 
and O 
2339 O 
mg O 
/ O 
kg O 
) O 
; O 
ursolic B-TRIVIAL 
was O 
identified O 
in O 
O O 
. O 
stamineus O 
, O 
C O 
. O 
monogyna O 
, O 
L O 
. O 
speciosa O 
and O 
Arctostaphylos O 
uva O 
- O 
ursi O 
leaves O 
( O 
7773 O 
, O 
4165 O 
, O 
2108 O 
and O 
1034 O 
mg O 
/ O 
kg O 
) O 
. O 
Only O 
L O 
. O 
speciosa O 
was O 
rich O 
in O 
maslinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
4958 O 
mg O 
/ O 
kg O 
) O 
, O 
while O 
minor O 
amounts O 
of O 
betulinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
257 O 
and O 
80 O 
mg O 
/ O 
kg O 
) O 
were O 
detected O 
in O 
L O 
. O 
speciosa O 
and O 
C O 
. O 
monogyna O 
extracts O 
. O 
Lower O 
quantities O 
of O 
triterpenic B-FAMILY 
acids I-FAMILY 
were O 
identified O 
in O 
dried O 
extracts O 
of O 
Harpagophyton O 
procumbens O 
root O 
, O 
propolis O 
, O 
Punica O 
granatum O 
root O 
, O 
Styrax O 
benzoin O 
, O 
Vaccinium O 
myrtillus O 
fruits O 
and O 
Vitis O 
vinifera O 
seeds O 
. O 
Decoctions O 
and O 
fluid O 
extracts O 
lacked O 
or O 
contained O 
very O 
low O 
amounts O 
of O 
triterpenic B-FAMILY 
acids I-FAMILY 
. O 
Results O 
are O 
discussed O 
in O 
terms O 
of O 
quality O 
and O 
safety O 
of O 
these O 
ingredients O 
. O 

egg O 
white O 
comprises O 
of O 
a O 
complex O 
mixture O 
of O 
proteins O 
, O 
which O 
greatly O 
differ O 
in O 
their O 
physicochemical O 
characteristics O 
and O 
relative O 
abundance O 
. O 
We O 
aimed O 
to O 
identify O 
potential O 
undiscovered O 
egg O 
allergens O 
within O 
the O 
egg O 
white O 
proteome O 
and O 
investigated O 
the O 
existence O 
of O 
matrix O 
effects O 
on O 
the O 
proteolytic O 
stability O 
and O 
resultant O 
IgE O 
- O 
binding O 
of O 
the O 
allergenic O 
proteins O 
. O 
In O 
addition O 
to O 
the O 
main O 
egg O 
allergens O 
: O 
ovalbumin O 
( O 
OVA O 
) O 
, O 
ovomucoid O 
( O 
OM O 
) O 
and O 
lysozyme O 
( O 
LYS O 
) O 
, O 
two O 
minor O 
egg O 
white O 
proteins O 
, O 
tentatively O 
identified O 
as O 
ovoinhibitor O 
and O 
clusterin O 
, O 
were O 
found O 
to O 
react O 
with O 
serum O 
IgE O 
from O 
egg O 
- O 
allergic O 
patients O 
. O 
Egg O 
white O 
exhibited O 
residual O 
immunoreactivity O 
after O 
gastrointestinal O 
digestion O 
due O 
to O 
the O 
presence O 
of O 
intact O 
OVA O 
and O 
LYS O 
, O 
as O 
well O 
as O 
of O 
several O 
IgE O 
- O 
binding O 
peptides O 
derived O 
from O 
OVA O 
. O 
The O 
presence O 
of O 
egg O 
yolk O 
slightly O 
increased O 
the O 
susceptibility O 
to O 
hydrolysis O 
of O 
egg O 
white O 
proteins O 
and O 
abrogated O 
bile B-FAMILY 
salt I-FAMILY 
-induced O 
precipitation O 
of O 
LYS O 
in O 
the O 
duodenal O 
medium O 
. O 
However O 
, O 
the O 
resultant O 
immunoreactivity O 
against O 
IgE O 
of O 
egg O 
white O 
proteins O 
after O 
in O 
vitro O 
digestion O 
was O 
not O 
significantly O 
modified O 
by O 
the O 
presence O 
of O 
yolk O 
components O 
. O 

on O 
the O 
phase O 
behaviour O 
of O 
a O 
biopolymer O 
mixture O 
has O 
been O 
performed O 
using O 
7.5% O 
( O 
w O 
/ O 
w O 
) O 
gelatin O 
and O 
1.5% O 
( O 
w O 
/ O 
w O 
) O 
agarose O 
in O 
the O 
presence O 
of O 
variable O 
amounts O 
of O 
polydextrose B-FAMILY 
as O 
the O 
co O 
- O 
solute O 
from O 
low O 
to O 
high O 
levels O 
of O 
total O 
solids O 
. O 
Mechanical O 
observation O 
of O 
the O 
system O 
was O 
performed O 
using O 
small O 
deformation O 
dynamic O 
oscillation O 
in O 
shear O 
along O 
with O 
thermal O 
studies O 
using O 
modulated O 
differential O 
scanning O 
calorimetry O 
. O 
Micrographs O 
provided O 
images O 
of O 
the O 
changing O 
morphology O 
of O 
the O 
network O 
with O 
the O 
addition O 
of O 
co O 
- O 
solute O 
. O 
Agarose O 
and O 
gelatin O 
form O 
non-interactive O 
bicontinuous O 
phases O 
in O 
the O 
aqueous O 
environment O 
. O 
Systematic O 
increase O 
in O 
the O 
concentration O 
of O 
polydextrose B-FAMILY 
prevents O 
the O 
formation O 
of O 
a O 
stable O 
agarose O 
network O 
, O 
with O 
the O 
polysaccharide O 
chains O 
dispersing O 
in O 
the O 
high O 
solids O 
environment O 
. O 
Gelatin O 
, O 
on O 
the O 
other O 
hand O 
, O 
retains O 
its O 
conformational O 
stability O 
even O 
at O 
a O 
saturating O 
co O 
- O 
solute O 
environment O 
through O 
enhanced O 
protein O 
structuring O 
. O 
Vitrification O 
studies O 
on O 
the O 
high O 
solids O 
system O 
at O 
subzero O 
temperatures O 
provides O 
information O 
on O 
the O 
structural O 
and O 
molecular O 
relaxation O 
identified O 
as O 
a O 
glass O 
transition O 
phenomenon O 
. O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
was O 
used O 
to O 
analyse O 
potential O 
direct O 
interaction O 
between O 
polymers O 
and O 
co O 
- O 
solute O 
. O 
The O 
extent O 
of O 
amorphicity O 
in O 
the O 
system O 
was O 
confirmed O 
using O 
wide O 
angle O 
X-ray O 
diffraction O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
effect O 
of O 
atmospheric O 
frying O 
followed O 
by O 
drainage O 
under O 
vacuum O 
on O 
the O 
stability O 
of O 
oil O 
, O 
compared O 
to O 
similar O 
frying O 
with O 
drainage O 
at O 
atmospheric O 
pressure O 
. O 
Changes O 
in O 
the O 
oil O 
were O 
assessed O 
by O 
the O 
free O 
fatty B-FAMILY 
acid I-FAMILY 
( O 
FFA O 
) O 
content O 
, O 
p-anisidine B-SYSTEMATIC 
value O 
( O 
AnV O 
) O 
, O 
colour O 
, O 
viscosity O 
, O 
fatty B-FAMILY 
acid I-FAMILY 
profile O 
and O 
concentration O 
of O 
tocols O 
. O 
The O 
rate O 
of O 
FFA O 
formation O 
in O 
the O 
case O 
of O 
vacuum O 
drainage O 
was O 
found O 
to O 
be O 
about O 
half O 
that O 
of O 
atmospheric O 
drainage O 
. O 
Oil O 
deterioration O 
by O 
oxidation O 
and O 
polymerisation O 
was O 
also O 
reduced O 
by O 
the O 
use O 
of O 
vacuum O 
drainage O 
. O 
The O 
AnV O 
of O 
the O 
oil O 
after O 
vacuum O 
drainage O 
was O 
lower O 
by O 
about O 
12% O 
, O 
the O 
total O 
colour O 
difference O 
was O 
improved O 
by O 
14% O 
and O 
viscosity O 
was O 
slightly O 
reduced O 
after O 
5 O 
days O 
of O 
frying O 
, O 
compared O 
to O 
the O 
values O 
for O 
oil O 
that O 
had O 
been O 
drained O 
at O 
atmospheric O 
pressure O 
. O 
There O 
was O 
a O 
reduction O 
in O 
the O 
loss O 
of O 
polyunsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
in O 
the O 
case O 
of O 
vacuum O 
drainage O 
after O 
5 O 
days O 
of O 
frying O 
but O 
differences O 
in O 
retention O 
of O 
tocols O 
were O 
only O 
evident O 
in O 
the O 
first O 
two O 
days O 
of O 
frying O 
. O 

metabolomic O 
approach O 
reveals O 
urinary O 
metabolites O 
linked O 
to O 
steroid B-FAMILY 
biosynthesis O 
pathway O 
after O 
ingestion O 
of O 
citrus O 
juice O 
. O 

juice O 
intake O 
has O 
been O 
highlighted O 
because O 
of O 
its O 
health O 
- O 
promoting O 
effects O 
. O 
LC-MS O 
based O 
metabolomics O 
approaches O 
are O 
applied O 
to O 
obtain O 
a O 
better O 
knowledge O 
on O 
changes O 
in O 
the O 
concentration O 
of O 
metabolites O 
due O 
to O 
its O 
dietary O 
intake O 
and O 
allow O 
a O 
better O 
understanding O 
of O 
involved O 
metabolic O 
pathways O 
. O 
Eight O 
volunteers O 
daily O 
consumed O 
400 O 
mL O 
of O 
juice O 
for O 
four O 
consecutive O 
days O 
and O 
urine O 
samples O 
were O 
collected O 
before O 
intake O 
and O 
24h O 
after O 
each O 
citrus O 
juice O 
intake O 
. O 
Urine O 
samples O 
were O 
analysed O 
by O 
nanoHPLC-q-TOF O 
, O 
followed O 
by O 
principal O 
component O 
analysis O 
( O 
PCA O 
) O 
and O 
Student's O 
t-test O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
PCA O 
showed O 
a O 
separation O 
between O 
two O 
groups O 
( O 
before O 
and O 
after O 
citrus O 
juice O 
consumption O 
) O 
. O 
This O 
approach O 
allowed O 
the O 
identification O 
of O 
four O 
endocrine O 
compounds O 
( O 
tetrahydroaldosterone-3-glucuronide B-SYSTEMATIC 
, O 
cortolone-3-glucuronide B-SYSTEMATIC 
, O 
testosterone B-SYSTEMATIC 
- I-SYSTEMATIC 
glucuronide I-SYSTEMATIC 
and O 
17-hydroxyprogesterone B-SYSTEMATIC 
) O 
, O 
which O 
belonged O 
to O 
the O 
steroid B-FAMILY 
biosynthesis O 
pathway O 
as O 
significant O 
metabolites O 
upregulated O 
by O 
citrus O 
juice O 
intake O 
. O 
Additionally O 
, O 
these O 
results O 
confirmed O 
the O 
importance O 
of O 
using O 
the O 
non-targeted O 
metabolomics O 
technique O 
to O 
identify O 
new O 
endogenous O 
metabolites O 
, O 
up- O 
or O 
down O 
- O 
regulated O 
as O 
a O 
consequence O 
of O 
food O 
intake O 
. O 

of O 
flavonoids B-FAMILY 
and O 
flavonoid B-FAMILY 
rhamnosides I-FAMILY 
from O 
Rhododendron O 
mucronulatum O 
for O 
. O 
albiflorum O 
and O 
their O 
inhibitory O 
activities O 
against O 
aldose B-FAMILY 
reductase O 
. O 

investigate O 
the O 
therapeutic O 
potential O 
of O 
compounds O 
from O 
natural O 
sources O 
, O 
Rhododendron O 
mucronulatum O 
for O 
. O 
albiflorum O 
flowers O 
( O 
RMAF O 
) O 
and O 
R O 
. O 
mucronulatum O 
flowers O 
( O 
RMF O 
) O 
were O 
tested O 
for O 
inhibition O 
of O 
aldose B-FAMILY 
reductase O 
( O 
AR O 
) O 
. O 
The O 
methanol B-SYSTEMATIC 
extracts O 
of O 
RMAF O 
and O 
RMF O 
exhibited O 
AR O 
inhibitory O 
activities O 
( O 
IC(50) O 
values O 
1.07 O 
and O 
1.29 O 
μg O 
/ O 
mL O 
, O 
respectively O 
) O 
. O 
The O 
stepwise O 
polarity O 
fractions O 
of O 
RMAF O 
were O 
tested O 
for O 
in O 
vitro O 
inhibition O 
of O 
AR O 
from O 
rat O 
lenses O 
. O 
Of O 
these O 
, O 
the O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
EtOAc B-FORMULA 
) O 
fraction O 
exhibited O 
AR O 
inhibitory O 
activity O 
( O 
IC(50) O 
0.15 O 
μg O 
/ O 
mL O 
) O 
. O 
A O 
chromatography O 
of O 
the O 
active O 
EtOAc B-FORMULA 
fraction O 
of O 
RMAF O 
led O 
to O 
the O 
isolation O 
of O 
six O 
flavonoids B-FAMILY 
, O 
which O 
were O 
identified O 
by O 
spectroscopic O 
analysis O 
as O 
kaempferol B-TRIVIAL 
( O 
1 O 
) O 
, O 
afzelin B-TRIVIAL 
( O 
2 O 
) O 
, O 
quercetin B-TRIVIAL 
( O 
3 O 
) O 
, O 
quercitrin B-TRIVIAL 
( O 
4 O 
) O 
, O 
myricetin B-TRIVIAL 
( O 
5 O 
) O 
and O 
myricitrin B-TRIVIAL 
( O 
6 O 
) O 
. O 
Compounds O 
1-6 O 
exhibited O 
high O 
AR O 
inhibitory O 
activity O 
, O 
with O 
IC(50) O 
values O 
of O 
0.79 O 
, O 
0.31 O 
, O 
0.48 O 
, O 
0.13 O 
, O 
11.92 O 
and O 
2.67 O 
μg O 
/ O 
mL O 
, O 
respectively O 
. O 
HPLC O 
/ O 
UV O 
analysis O 
revealed O 
that O 
the O 
major O 
flavonoids B-FAMILY 
of O 
RMAF O 
and O 
RMF O 
are O 
quercitrin B-TRIVIAL 
( O 
4 O 
) O 
and O 
myricitrin B-TRIVIAL 
( O 
6 O 
) O 
. O 
Our O 
results O 
suggest O 
that O 
RMAF O 
containing O 
these O 
six O 
flavonoids B-FAMILY 
could O 
be O 
a O 
useful O 
natural O 
source O 
in O 
the O 
development O 
of O 
a O 
novel O 
AR O 
inhibitory O 
agent O 
against O 
diabetic O 
complications O 
. O 

of O 
food O 
grade O 
antioxidant O 
in O 
natural O 
biopolymer O 
by O 
electrospinning O 
technique O 
: O 
a O 
physicochemical O 
study O 
based O 
on O 
zein- O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
system O 
. O 

acid I-TRIVIAL 
was O 
successfully O 
incorporated O 
into O 
zein O 
ultra O 
- O 
fine O 
fibres O 
at O 
different O 
loading O 
amount O 
( O 
5% O 
, O 
10% O 
and O 
20% O 
) O 
in O 
order O 
to O 
develop O 
an O 
encapsulating O 
technology O 
for O 
functional O 
ingredient O 
delivery O 
using O 
electrospinning O 
. O 
The O 
produced O 
fibres O 
exhibit O 
diameters O 
ranging O 
from O 
327 O 
to O 
387 O 
nm O 
. O 
The O 
physical O 
and O 
thermal O 
properties O 
of O 
encapsulated O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
were O 
determined O 
by O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
and O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
; O 
and O 
the O 
interaction O 
between O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
and O 
zein O 
was O 
attested O 
by O 
attenuated O 
total O 
reflection-Fourier O 
transform O 
infrared O 
( O 
ATR-FTIR O 
) O 
. O 
Thermogravimetric O 
analysis O 
( O 
TGA O 
) O 
demonstrated O 
a O 
different O 
thermal O 
stability O 
of O 
the O 
fabricated O 
complex O 
before O 
and O 
after O 
the O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
incorporation O 
. O 
Lastly O 
, O 
the O 
1,1'-diphenyl-2-picrylhydrazyl B-SYSTEMATIC 
( O 
DPPH B-ABBREVIATION 
) O 
assay O 
showed O 
that O 
the O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
had O 
retained O 
its O 
antioxidant O 
activity O 
after O 
incorporation O 
in O 
zein O 
electrospun O 
fibres O 
. O 
Overall O 
, O 
electrospinning O 
technique O 
had O 
shown O 
promising O 
results O 
as O 
an O 
efficient O 
and O 
effective O 
method O 
for O 
the O 
preparation O 
of O 
sub O 
- O 
micron O 
structured O 
encapsulated O 
functional O 
ingredient O 
that O 
may O 
find O 
uses O 
in O 
food O 
industry O 
. O 

( O 
Rosmarinus O 
officinalis O 
L O 
. O 
) O 
has O 
been O 
used O 
in O 
folk O 
medicine O 
to O 
treat O 
headaches O 
, O 
epilepsy O 
, O 
poor O 
circulation O 
, O 
and O 
many O 
other O 
ailments O 
. O 
It O 
was O 
found O 
that O 
rosemary O 
could O 
act O 
as O 
a O 
stimulant O 
and O 
mild O 
analgesic O 
and O 
could O 
reduce O 
inflammation O 
. O 
However O 
, O 
the O 
mechanisms O 
underlying O 
the O 
anti-inflammatory O 
effects O 
of O 
rosemary O 
need O 
more O 
study O 
to O 
be O 
established O 
. O 
Therefore O 
, O 
in O 
this O 
study O 
, O 
the O 
effects O 
of O 
rosemary O 
on O 
the O 
activation O 
of O 
nuclear O 
factor O 
kappa O 
beta O 
( O 
NF-kB O 
) O 
and O 
mitogen O 
- O 
activated O 
protein O 
kinases O 
( O 
MAPKs O 
) O 
, O 
the O 
expression O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
and O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
, O 
and O 
the O 
production O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
, O 
prostaglandin B-TRIVIAL 
E(2) I-TRIVIAL 
( O 
PGE(2) B-ABBREVIATION 
) O 
, O 
and O 
cytokine O 
in O 
lipopolysaccharide O 
(LPS)-stimulated O 
RAW O 
264.7 O 
cells O 
were O 
investigated O 
. O 
A O 
methanol B-SYSTEMATIC 
extract O 
of O 
rosemary O 
and O 
its O 
hexane B-SYSTEMATIC 
fraction O 
reduced O 
NO B-FORMULA 
generation O 
with O 
an O 
IC(50) O 
of O 
2.75 O 
and O 
2.83 O 
μg O 
/ O 
ml O 
, O 
respectively O 
. O 
Also O 
, O 
the O 
methanol B-SYSTEMATIC 
extract O 
and O 
the O 
hexane B-SYSTEMATIC 
fraction O 
inhibited O 
LPS-induced O 
MAPKs O 
and O 
NF-kB O 
activation O 
associated O 
with O 
the O 
inhibition O 
of O 
iNOS O 
or O 
COX-2 O 
expression O 
. O 
LPS-induced O 
production O 
of O 
PGE(2) B-ABBREVIATION 
and O 
tumour O 
necrosis O 
factor O 
- O 
alpha O 
( O 
TNF-α O 
) O 
were O 
blocked O 
by O 
rosemary O 
. O 
Rosemary O 
extract O 
and O 
its O 
hexane B-SYSTEMATIC 
fraction O 
are O 
important O 
for O 
the O 
prevention O 
of O 
phosphorylation O 
of O 
MAPKs O 
, O 
thereby O 
blocking O 
NF-kB O 
activation O 
, O 
which O 
in O 
turn O 
leads O 
to O 
decreased O 
expression O 
of O 
iNOS O 
and O 
COX-2 O 
, O 
thus O 
preventing O 
inflammation O 
. O 

herbal O 
medications O 
may O 
be O 
one O 
answer O 
to O 
the O 
worldwide O 
epidemic O 
of O 
obesity O 
. O 
This O 
study O 
examines O 
the O 
effects O 
of O 
Cassia O 
seed O 
ethanol B-SYSTEMATIC 
extract O 
( O 
CSEE O 
) O 
upon O 
lipid O 
accumulation O 
in O 
white O 
adipose O 
tissue O 
( O 
WAT O 
) O 
. O 
CSEE O 
exhibited O 
a O 
significant O 
concentration O 
- O 
dependent O 
decrease O 
in O 
the O 
intracellular O 
accumulation O 
of O 
trigycerides B-FAMILY 
in O 
3T3-L1 O 
adipocytes O 
. O 
After O 
being O 
fed O 
a O 
high O 
- O 
fat O 
diet O 
( O 
HFD O 
) O 
for O 
2 O 
weeks O 
, O 
rats O 
were O 
fed O 
CSEE O 
( O 
100 O 
, O 
200 O 
or O 
300 O 
mg O 
/ O 
kg O 
) O 
once O 
daily O 
for O 
8 O 
weeks O 
. O 
CSEE O 
caused O 
dose O 
- O 
related O 
reductions O 
in O 
body O 
weight O 
gain O 
( O 
as O 
well O 
as O 
plasma O 
lipid O 
levels O 
and O 
epididymal O 
WAT O 
sizes O 
in O 
HFD-fed O 
rats O 
) O 
. O 
CSEE O 
enhanced O 
the O 
phosphorylation O 
of O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
and O 
its O 
primary O 
downstream O 
targeting O 
enzyme O 
, O 
acetyl-CoA B-SYSTEMATIC 
carboxylase O 
, O 
up O 
- O 
regulated O 
gene O 
expression O 
of O 
carnitine B-TRIVIAL 
palmitoyl B-TRIVIAL 
transferase O 
1 O 
, O 
and O 
down O 
- O 
regulated O 
sterol O 
regulatory O 
element O 
- O 
binding O 
protein O 
1 O 
and O 
fatty B-FAMILY 
acid I-FAMILY 
synthase O 
protein O 
levels O 
in O 
epididymal O 
WAT O 
of O 
HFD-fed O 
rats O 
. O 
CSEE O 
could O 
attenuate O 
lipid O 
accumulation O 
in O 
WAT O 
via O 
AMPK O 
signaling O 
pathway O 
activation O 
. O 

structure O 
and O 
dynamics O 
of O 
the O 
C B-FORMULA 
-terminal O 
domain O 
of O 
R- O 
type O 
lectin O 
from O 
the O 
earthworm O 
Lumbricus O 
terrestris O 
. O 

C B-FORMULA 
-terminal O 
domain O 
( O 
Ch O 
; O 
C-half O 
) O 
of O 
the O 
R- O 
type O 
earthworm O 
29-kDa O 
lectin O 
( O 
EW29 O 
) O 
, O 
isolated O 
from O 
the O 
earthworm O 
Lumbricus O 
terrestris O 
, O 
has O 
two O 
sugar B-FAMILY 
-binding O 
sites O 
, O 
in O 
subdomains O 
α O 
and O 
γ O 
, O 
and O 
the O 
protein O 
uses O 
the O 
two O 
sugar B-FAMILY 
-binding O 
sites O 
for O 
its O 
function O 
as O 
a O 
single O 
domain O 
- O 
type O 
haemagglutinin O 
. O 
Our O 
previous O 
NMR O 
titration O 
experiments O 
showed O 
that O 
the O 
α O 
sugar B-FAMILY 
-binding O 
site O 
is O 
a O 
high O 
- O 
affinity O 
site O 
and O 
the O 
γ O 
sugar B-FAMILY 
-binding O 
site O 
is O 
a O 
low O 
- O 
affinity O 
site O 
. O 
However O 
, O 
it O 
remains O 
unclear O 
why O 
the O 
α O 
sugar B-FAMILY 
-binding O 
site O 
of O 
EW29Ch O 
binds O 
to O 
lactose O 
much O 
more O 
strongly O 
because O 
the O 
crystal O 
structure O 
of O 
lactose B-TRIVIAL 
-bound O 
EW29Ch O 
showed O 
that O 
the O 
interaction O 
between O 
the O 
α O 
sugar B-FAMILY 
-binding O 
site O 
and O 
lactose B-TRIVIAL 
was O 
almost O 
same O 
as O 
that O 
between O 
the O 
γ O 
sugar B-FAMILY 
-binding O 
site O 
and O 
lactose B-TRIVIAL 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
have O 
determined O 
the O 
NMR O 
structure O 
of O 
EW29Ch O 
in O 
the O 
sugar B-FAMILY 
-free O 
state O 
and O 
performed O 
(15)N B-FORMULA 
relaxation O 
experiments O 
for O 
EW29Ch O 
in O 
both O 
the O 
sugar B-FAMILY 
-free O 
state O 
and O 
the O 
lactose B-TRIVIAL 
-bound O 
states O 
. O 
The O 
conformation O 
of O 
EW29Ch O 
in O 
the O 
sugar B-FAMILY 
-free O 
state O 
was O 
similar O 
to O 
that O 
of O 
EW29Ch O 
in O 
complex O 
with O 
lactose O 
. O 
Conformational O 
changes O 
upon O 
binding O 
of O 
lactose O 
were O 
observed O 
only O 
for O 
the O 
α O 
sugar O 
- O 
binding O 
site O 
. O 
By O 
contrast O 
, O 
the O 
(15)N B-FORMULA 
relaxation O 
experiments O 
revealed O 
a O 
conformational O 
exchange O 
at O 
the O 
α O 
sugar B-FAMILY 
-binding O 
site O 
in O 
the O 
sugar B-FAMILY 
-free O 
state O 
, O 
which O 
was O 
suppressed O 
in O 
the O 
lactose B-TRIVIAL 
-bound O 
state O 
. O 
The O 
conformational O 
exchange O 
phenomenon O 
observed O 
for O 
the O 
α O 
sugar B-FAMILY 
-binding O 
site O 
was O 
not O 
observed O 
for O 
the O 
γ O 
sugar B-FAMILY 
-binding O 
site O 
. O 
Differences O 
in O 
the O 
conformational O 
change O 
and O 
the O 
backbone O 
dynamics O 
between O 
subdomains O 
α O 
and O 
γ O 
may O 
be O 
associated O 
with O 
the O 
difference O 
of O 
the O 
sugar B-FAMILY 
-binding O 
modes O 
between O 
the O 
two O 
sugar B-FAMILY 
-binding O 
sites O 
. O 
DATABASE O 
: O 
Structural O 
data O 
for O 
the O 
NMR O 
structure O 
of O 
EW29Ch O 
in O 
the O 
sugar B-FAMILY 
-free O 
state O 
have O 
been O 
deposited O 
in O 
the O 
Protein O 
Data O 
Bank O 
database O 
under O 
accession O 
number O 
2RST O 
. O 

Phellodendron O 
chinensis O 
( O 
CPC O 
) O 
and O 
Cortex O 
Phellodendron O 
amurensis O 
( O 
CPA O 
) O 
derived O 
from O 
the O 
dried O 
bark O 
of O 
Phellodendron O 
chinense O 
Schneid O 
. O 
or O 
Phellodendron O 
amurense O 
Rupr O 
. O 
, O 
respectively O 
, O 
are O 
used O 
interchangeably O 
in O 
clinical O 
practice O 
under O 
the O 
name O 
" O 
Huang O 
Bai O 
" O 
for O 
centuries O 
in O 
Chinese O 
medicine O 
for O 
the O 
treatment O 
of O 
various O 
inflammatory O 
conditions O 
. O 
Previous O 
study O 
in O 
our O 
laboratory O 
demonstrated O 
that O 
CPC O 
and O 
CPA O 
had O 
different O 
anti-diarrheal O 
, O 
anti-bacterial O 
and O 
anti-inflammatory O 
effects O 
. O 
In O 
this O 
present O 
study O 
, O 
we O 
aimed O 
to O 
compare O 
the O 
protective O 
effect O 
of O 
ethanol B-SYSTEMATIC 
extract O 
of O 
Cortex O 
Phellodendri O 
chinensis O 
( O 
ECPC O 
) O 
and O 
Cortex O 
Phellodendri O 
Amurensis O 
( O 
ECPA O 
) O 
against O 
beta-amyloid O 
(Aβ)-induced O 
neurotoxicity O 
in O 
PC12 O 
cells O 
, O 
a O 
typical O 
model O 
of O 
Alzheimer's O 
disease O 
. O 
The O 
results O 
showed O 
that O 
ECPC O 
and O 
ECPA O 
contain O 
four O 
common O 
chemical O 
markers O 
such O 
as O 
berberine B-TRIVIAL 
, O 
but O 
palmatine B-TRIVIAL 
and O 
jatrorrhizin B-TRIVIAL 
were O 
not O 
found O 
in O 
CPC O 
in O 
contrast O 
to O 
the O 
presence O 
in O 
CPA O 
. O 
In O 
addition O 
, O 
both O 
ECPC O 
and O 
ECPA O 
can O 
significantly O 
increase O 
the O 
cell O 
viability O 
in O 
Aβ O 
- O 
treated O 
PC12 O 
cells O 
. O 
Moreover O 
, O 
ECPC O 
and O 
ECPA O 
can O 
markedly O 
elevate O 
the O 
ratio O 
of O 
the O 
protein O 
and O 
mRNA O 
levels O 
of O 
Bcl-2 O 
/ O 
Bax O 
, O 
while O 
remarkably O 
decrease O 
the O 
release O 
of O 
cytochrome O 
c O 
, O 
and O 
the O 
protein O 
and O 
mRNA O 
expression O 
of O 
caspase-3 O 
. O 
Interestingly O 
, O 
ECPA O 
has O 
better O 
protective O 
effect O 
than O 
ECPC O 
against O 
Aβ-induced O 
neurotoxicity O 
in O 
PC12 O 
cells O 
. O 
These O 
results O 
indicate O 
that O 
both O 
ECPC O 
and O 
ECPA O 
have O 
potential O 
protective O 
effect O 
against O 
Aβ-induced O 
neurotoxicity O 
in O 
PC12 O 
cells O 
, O 
and O 
ECPA O 
is O 
more O 
potential O 
of O 
the O 
two O 
species O 
to O 
be O 
used O 
in O 
traditional O 
medicine O 
as O 
a O 
neuroprotective O 
agent O 
for O 
the O 
treatment O 
of O 
AD O 
. O 
The O 
neuroprotective O 
effect O 
of O 
the O 
two O 
species O 
may O 
be O 
mediated O 
, O 
at O 
least O 
in O 
part O 
, O 
via O 
suppressing O 
of O 
the O 
cellular O 
apoptosis O 
. O 

, O 
an O 
active O 
principle O 
of O 
Acorus O 
calamus O 
rhizome O 
, O 
inhibits O 
morphogenesis O 
, O 
biofilm O 
formation O 
and O 
ergosterol B-TRIVIAL 
biosynthesis O 
in O 
Candida O 
albicans O 
. O 

potential O 
of O 
Acorus O 
calamus O 
rhizome O 
and O 
its O 
active O 
principle O 
, O 
β-asarone B-TRIVIAL 
, O 
was O 
evaluated O 
against O 
the O 
human O 
fungal O 
pathogen O 
, O 
Candida O 
albicans O 
. O 
β-Asarone B-TRIVIAL 
exhibited O 
promising O 
growth O 
inhibitory O 
activity O 
at O 
0.5mg O 
/ O 
ml O 
and O 
it O 
was O 
fungicidal O 
at O 
8 O 
mg O 
/ O 
ml O 
. O 
Time O 
dependant O 
kill O 
curve O 
assay O 
showed O 
that O 
MFC O 
of O 
β-asarone B-TRIVIAL 
was O 
highly O 
toxic O 
to O 
C O 
. O 
albicans O 
, O 
killing O 
99.9% O 
inoculum O 
within O 
120 O 
min O 
of O 
exposure O 
. O 
β-Asarone B-TRIVIAL 
caused O 
significant O 
inhibition O 
of O 
C O 
. O 
albicans O 
morphogenesis O 
and O 
biofilm O 
development O 
at O 
sub O 
- O 
inhibitory O 
concentrations O 
. O 
Our O 
data O 
indicate O 
that O 
the O 
growth O 
inhibitory O 
activity O 
of O 
β-asarone B-TRIVIAL 
might O 
be O 
through O 
inhibition O 
of O 
ergosterol B-TRIVIAL 
biosynthesis O 
. O 
Hemolytic O 
assay O 
showed O 
that O 
β-asarone B-TRIVIAL 
is O 
non-toxic O 
, O 
even O 
at O 
concentrations O 
approaching O 
MIC O 
value O 
. O 
Our O 
results O 
suggest O 
that O 
β-asarone B-TRIVIAL 
may O 
be O 
safe O 
as O 
a O 
topical O 
antifungal O 
agent O 
. O 

of O 
novel O 
brain O 
- O 
penetrating O 
oxime B-SYSTEMATIC 
reactivators O 
of O 
acetylcholinesterase O 
inhibited O 
by O 
nerve O 
agent O 
surrogates O 
. O 

critical O 
need O 
for O 
combating O 
the O 
effects O 
of O 
organophosphate B-FAMILY 
( O 
OP O 
) O 
anticholinesterases O 
, O 
such O 
as O 
nerve O 
agents O 
, O 
is O 
the O 
current O 
lack O 
of O 
an O 
effective O 
oxime B-SYSTEMATIC 
reactivator O 
which O 
can O 
penetrate O 
the O 
blood O 
- O 
brain O 
barrier O 
( O 
BBB O 
) O 
, O 
and O 
therefore O 
reactivate O 
inhibited O 
acetylcholinesterase O 
( O 
AChE O 
) O 
in O 
the O 
brain O 
. O 
Our O 
laboratories O 
have O 
synthesized O 
and O 
have O 
initiated O 
testing O 
of O 
novel O 
phenoxyalkyl B-FAMILY 
pyridinium I-FAMILY 
oximes I-FAMILY 
( O 
patent O 
pending O 
) O 
that O 
are O 
more O 
lipophilic O 
than O 
currently O 
approved O 
oximes B-FAMILY 
. O 
This O 
is O 
a O 
preliminary O 
report O 
on O 
these O 
novel O 
oximes B-FAMILY 
which O 
have O 
been O 
tested O 
in O 
vitro O 
in O 
rat O 
brain O 
homogenates O 
with O 
highly O 
relevant O 
surrogates O 
for O 
sarin B-TRIVIAL 
( O 
phthalimidyl B-SYSTEMATIC 
isopropyl I-SYSTEMATIC 
methylphosphonate I-SYSTEMATIC 
; O 
PIMP B-ABBREVIATION 
) O 
and O 
VX O 
( O 
nitrophenyl B-SYSTEMATIC 
ethyl I-SYSTEMATIC 
methylphosphonate I-SYSTEMATIC 
; O 
NEMP B-ABBREVIATION 
) O 
. O 
The O 
oximes B-FAMILY 
demonstrated O 
a O 
range O 
of O 
14-76% O 
reactivation O 
of O 
rat O 
brain O 
AChE O 
in O 
vitro O 
. O 
An O 
in O 
vivo O 
testing O 
paradigm O 
was O 
developed O 
in O 
which O 
the O 
novel O 
oxime B-SYSTEMATIC 
was O 
administered O 
at O 
the O 
time O 
of O 
maximal O 
brain O 
AChE O 
inhibition O 
( O 
about O 
80% O 
) O 
( O 
1h O 
) O 
elicited O 
by O 
nitrophenyl B-SYSTEMATIC 
isopropyl I-SYSTEMATIC 
methylphosphonate I-SYSTEMATIC 
( O 
NIMP B-ABBREVIATION 
; O 
sarin B-TRIVIAL 
surrogate O 
) O 
. O 
This O 
paradigm O 
, O 
with O 
delayed O 
administration O 
of O 
oxime B-SYSTEMATIC 
to O 
a O 
time O 
when O 
brain O 
AChE O 
was O 
starting O 
to O 
recover O 
, O 
was O 
designed O 
to O 
minimize O 
reactivation O 
/ O 
reinhibition O 
of O 
peripheral O 
AChE O 
during O 
the O 
reactivation O 
period O 
which O 
would O 
decrease O 
the O 
availability O 
of O 
the O 
surrogate O 
for O 
entry O 
into O 
the O 
brain O 
; O 
this O 
paradigm O 
will O 
allow O 
proof O 
of O 
concept O 
of O 
BBB O 
penetrability O 
. O 
The O 
initial O 
studies O 
of O 
these O 
oximes B-FAMILY 
in O 
vivo O 
with O 
the O 
sarin B-TRIVIAL 
surrogate O 
NIMP B-ABBREVIATION 
have O 
indicated O 
reactivation O 
of O 
up O 
to O 
about O 
25% O 
at O 
30min O 
after O 
oxime B-SYSTEMATIC 
administration O 
and O 
substantial O 
attenuation O 
of O 
seizure O 
behavior O 
from O 
some O 
of O 
the O 
oximes B-FAMILY 
. O 
Therefore O 
these O 
novel O 
oximes B-FAMILY 
have O 
considerable O 
potential O 
as O 
brain O 
- O 
protecting O 
therapeutics O 
for O 
anticholinesterases O 
. O 

of O 
rat O 
Ctr1 O 
to O 
the O 
uptake O 
and O 
toxicity O 
of O 
copper B-SYSTEMATIC 
and O 
platinum B-SYSTEMATIC 
anticancer O 
drugs O 
in O 
dorsal O 
root O 
ganglion O 
neurons O 
. O 

root O 
ganglion O 
( O 
DRG O 
) O 
neurons O 
are O 
affected O 
by O 
platinum B-SYSTEMATIC 
-induced O 
neurotoxicity O 
and O 
neurodegenerative O 
processes O 
associated O 
with O 
disturbed O 
copper B-SYSTEMATIC 
homeostasis O 
and O 
transport O 
. O 
This O 
study O 
aimed O 
to O 
understand O 
the O 
role O 
of O 
copper B-SYSTEMATIC 
transporter O 
1 O 
( O 
Ctr1 O 
) O 
in O 
the O 
uptake O 
and O 
toxicity O 
of O 
copper B-SYSTEMATIC 
and O 
platinum B-SYSTEMATIC 
drugs O 
in O 
cultured O 
rat O 
DRG O 
neurons O 
, O 
and O 
the O 
functional O 
activities O 
of O 
rat O 
Ctr1 O 
( O 
rCtr1 O 
) O 
as O 
a O 
membrane O 
transporter O 
of O 
copper B-SYSTEMATIC 
and O 
platinum B-SYSTEMATIC 
drugs O 
. O 
Heterologous O 
expression O 
of O 
rCtr1 O 
in O 
HEK293 O 
cells O 
( O 
HEK O 
/ O 
rCtr1 O 
cells O 
) O 
increased O 
the O 
uptake O 
and O 
cytotoxicity O 
of O 
copper B-SYSTEMATIC 
, O 
oxaliplatin B-TRIVIAL 
, O 
cisplatin B-TRIVIAL 
and O 
carboplatin B-TRIVIAL 
, O 
in O 
comparison O 
to O 
isogenic O 
vector O 
- O 
transfected O 
control O 
cells O 
. O 
Cultured O 
rat O 
DRG O 
neurons O 
endogenously O 
expressed O 
rCtr1 O 
protein O 
on O 
their O 
neuronal O 
cell O 
body O 
plasma O 
membranes O 
and O 
cytoplasm O 
, O 
and O 
displayed O 
substantial O 
capacity O 
for O 
taking O 
up O 
copper B-SYSTEMATIC 
, O 
but O 
were O 
resistant O 
to O 
copper B-SYSTEMATIC 
toxicity O 
. O 
The O 
uptake O 
of O 
copper B-SYSTEMATIC 
by O 
both O 
cultured O 
rat O 
DRG O 
neurons O 
and O 
HEK O 
/ O 
rCtr1 O 
cells O 
was O 
saturable O 
and O 
inhibited O 
by O 
cold O 
temperature O 
, O 
silver B-SYSTEMATIC 
and O 
zinc B-SYSTEMATIC 
, O 
consistent O 
with O 
it O 
being O 
mediated O 
by O 
rCtr1 O 
. O 
Cultured O 
rat O 
DRG O 
neurons O 
accumulated O 
platinum B-SYSTEMATIC 
during O 
their O 
exposure O 
to O 
oxaliplatin B-TRIVIAL 
and O 
were O 
sensitive O 
to O 
oxaliplatin B-TRIVIAL 
cytotoxicity O 
. O 
The O 
accumulation O 
of O 
platinum B-SYSTEMATIC 
by O 
both O 
cultured O 
rat O 
DRG O 
neurons O 
and O 
HEK O 
/ O 
rCtr1 O 
cells O 
, O 
during O 
oxaliplatin B-TRIVIAL 
exposure O 
, O 
was O 
saturable O 
and O 
temperature O 
dependent O 
, O 
but O 
was O 
inhibited O 
by O 
copper B-SYSTEMATIC 
only O 
in O 
HEK O 
/ O 
rCtr1 O 
cells O 
. O 
In O 
conclusion O 
, O 
rCtr1 O 
can O 
transport O 
copper B-SYSTEMATIC 
and O 
platinum B-SYSTEMATIC 
drugs O 
, O 
and O 
sensitizes O 
cells O 
to O 
their O 
cytotoxicities O 
. O 
DRG O 
neurons O 
display O 
substantial O 
capacity O 
for O 
accumulating O 
copper B-SYSTEMATIC 
via O 
a O 
transport O 
process O 
mediated O 
by O 
rCtr1 O 
, O 
but O 
appear O 
able O 
to O 
resist O 
copper B-SYSTEMATIC 
toxicity O 
and O 
use O 
alternative O 
mechanisms O 
to O 
take O 
up O 
oxaliplatin B-TRIVIAL 
. O 

of O 
cysteine B-TRIVIAL 
consumption O 
in O 
tamoxifen B-TRIVIAL 
-resistant O 
MCF-7 O 
cells O 
. O 

( O 
TAM B-ABBREVIATION 
) O 
resistance O 
is O 
a O 
main O 
cause O 
of O 
therapeutic O 
failure O 
in O 
breast O 
cancers O 
. O 
Although O 
methionine B-TRIVIAL 
dependency O 
is O 
a O 
phenotypic O 
characteristic O 
of O 
tumor O 
cells O 
, O 
the O 
role O 
of O 
sulfur B-SYSTEMATIC 
amino B-FAMILY 
acid I-FAMILY 
metabolism O 
in O 
chemotherapy O 
resistance O 
remains O 
to O 
be O 
elucidated O 
. O 
This O 
study O 
compared O 
metabolite O 
profiles O 
of O 
sulfur B-SYSTEMATIC 
amino B-FAMILY 
acid I-FAMILY 
metabolism O 
from O 
methionine B-TRIVIAL 
to O 
taurine B-TRIVIAL 
or O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
between O 
normal O 
MCF-7 O 
and O 
TAM B-ABBREVIATION 
-resistant O 
MCF-7 O 
( O 
TAMR-MCF-7 O 
) O 
cells O 
. O 
TAMR-MCF-7 O 
cells O 
showed O 
elevated O 
levels O 
and O 
activities O 
of O 
enzymes O 
involved O 
in O 
both O 
transsulfuration O 
from O 
methionine B-TRIVIAL 
to O 
cysteine B-TRIVIAL 
and O 
metabolism O 
of O 
cysteine B-TRIVIAL 
to O 
GSH B-ABBREVIATION 
and O 
taurine B-TRIVIAL 
. O 
Cysteine B-TRIVIAL 
concentrations O 
in O 
TAMR-MCF-7 O 
cells O 
and O 
medium O 
conditioned O 
by O 
cell O 
culture O 
for O 
42h O 
were O 
markedly O 
decreased O 
, O 
while O 
GSH B-ABBREVIATION 
, O 
hypotaurine B-TRIVIAL 
, O 
and O 
taurine B-TRIVIAL 
concentrations O 
in O 
the O 
medium O 
were O 
increased O 
. O 
These O 
results O 
show O 
that O 
TAMR-MCF-7 O 
cells O 
display O 
enhanced O 
cysteine B-TRIVIAL 
utilization O 
. O 
The O 
addition O 
of O 
propargylglycine B-SYSTEMATIC 
, O 
a O 
specific O 
cystathionine B-TRIVIAL 
γ-lyase O 
inhibitor O 
, O 
and O 
buthionine B-SYSTEMATIC 
sulfoximine I-SYSTEMATIC 
, O 
a O 
specific O 
γ-glutamylcysteine B-SYSTEMATIC 
ligase O 
inhibitor O 
, O 
to O 
TAMR-MCF-7 O 
cells O 
, O 
but O 
not O 
to O 
MCF-7 O 
cells O 
, O 
resulted O 
in O 
cytotoxicity O 
after O 
sulfur B-SYSTEMATIC 
amino B-FAMILY 
acid I-FAMILY 
deprivation O 
. O 
These O 
results O 
suggest O 
that O 
cell O 
viability O 
of O 
TAMR-MCF-7 O 
cells O 
is O 
affected O 
by O 
inhibition O 
of O 
sulfur B-SYSTEMATIC 
amino B-FAMILY 
acid I-FAMILY 
metabolism O 
, O 
particularly O 
cysteine B-TRIVIAL 
synthesis O 
from O 
homocysteine B-TRIVIAL 
and O 
GSH B-ABBREVIATION 
synthesis O 
from O 
cysteine B-TRIVIAL 
. O 
Additionally O 
, O 
the O 
S-adenosylmethionine B-TRIVIAL 
/ O 
S-adenosylhomocysteine B-TRIVIAL 
ratio O 
, O 
an O 
index O 
of O 
transmethylation O 
potential O 
, O 
in O 
TAMR-MCF-7 O 
cells O 
increased O 
to O 
~3.6-fold O 
relative O 
to O 
that O 
in O 
MCF-7 O 
cells O 
, O 
a O 
finding O 
that O 
may O 
result O 
from O 
upregulation O 
of O 
methionine B-TRIVIAL 
adenosyltransferase O 
IIa O 
and O 
S-adenosylhomocysteine B-TRIVIAL 
hydrolase O 
. O 
In O 
conclusion O 
, O 
this O 
study O 
suggests O 
that O 
TAMR-MCF-7 O 
cells O 
display O 
enhanced O 
cysteine B-TRIVIAL 
utilization O 
for O 
synthesis O 
of O 
GSH B-ABBREVIATION 
and O 
taurine B-TRIVIAL 
, O 
and O 
are O 
sensitive O 
to O 
inhibition O 
of O 
cysteine B-TRIVIAL 
metabolism O 
. O 

human O 
butyrylcholinesterase O 
( O 
BChE O 
) O 
activity O 
is O 
less O 
than O 
1% O 
in O 
the O 
serum O 
of O 
silent O 
variant O 
individuals O 
of O 
Vysya O 
community O 
in O 
India O 
. O 
They O 
are O 
homozygous O 
for O 
a O 
point O 
mutation O 
at O 
codon O 
307 O 
( O 
CTT→CCT O 
) O 
resulting O 
in O 
the O 
substitution O 
of O 
leucine B-TRIVIAL 
307 O 
by O 
proline B-TRIVIAL 
. O 
The O 
reason O 
for O 
the O 
disappearance O 
of O 
the O 
protein O 
in O 
the O 
serum O 
has O 
not O 
been O 
explicated O 
till O 
date O 
. O 
Based O 
on O 
this O 
background O 
, O 
we O 
performed O 
molecular O 
dynamics O 
simulation O 
to O 
probe O 
the O 
structural O 
stability O 
of O 
Indian O 
variant O 
( O 
L307P O 
) O 
in O 
comparison O 
with O 
wild O 
and O 
other O 
BChE O 
variants O 
( O 
D70G O 
, O 
E497V O 
, O 
V142M O 
) O 
having O 
differential O 
esterase O 
activity O 
. O 
The O 
simulation O 
of O 
all O 
the O 
mutants O 
except O 
D70G O 
showed O 
a O 
much O 
larger O 
Cα O 
root O 
mean O 
square O 
deviation O 
from O 
the O 
wild O 
BChE O 
crystal O 
structure O 
, O 
showing O 
the O 
overall O 
conformational O 
disturbance O 
. O 
Further O 
analysis O 
revealed O 
that O 
secondary O 
structure O 
of O 
the O 
mutant O 
proteins O 
was O 
not O 
stable O 
. O 
The O 
orientation O 
of O 
the O 
catalytic O 
triad O 
is O 
also O 
distorted O 
in O 
all O 
the O 
mutants O 
. O 
The O 
distance O 
between O 
δ O 
nitrogen B-SYSTEMATIC 
of O 
His B-FORMULA 
438 O 
to O 
ε O 
oxygen B-SYSTEMATIC 
of O 
Glu B-FORMULA 
325 O 
and O 
ε O 
nitrogen B-SYSTEMATIC 
of O 
His B-FORMULA 
438 O 
to O 
γ O 
oxygen B-SYSTEMATIC 
of O 
Ser B-FORMULA 
198 O 
were O 
highly O 
altered O 
in O 
L307P O 
mutant O 
than O 
the O 
wild O 
and O 
other O 
three O 
variants O 
throughout O 
the O 
simulation O 
. O 
Such O 
disparity O 
of O 
distances O 
between O 
the O 
catalytic O 
residues O 
may O 
be O 
due O 
to O 
the O 
change O 
in O 
the O 
protein O 
conformation O 
attributing O 
to O 
their O 
differential O 
catalytic O 
activity O 
. O 
Our O 
studies O 
thus O 
prove O 
that O 
the O 
Indian O 
BChE O 
L307P O 
mutant O 
with O 
negligible O 
activity O 
is O 
possibly O 
due O 
to O 
its O 
structural O 
instability O 
when O 
compared O 
to O 
other O 
BChE O 
variants O 
. O 

quantitation O 
of O 
stevioside B-TRIVIAL 
and O 
rebaudioside B-TRIVIAL 
A I-TRIVIAL 
in O 
commercial O 
standards O 
by O 
quantitative O 
NMR O 
. O 

extract O 
prepared O 
from O 
the O 
leaves O 
of O 
Stevia O 
rebaudiana O 
BERTONI O 
( O 
Asteraceae O 
) O 
contains O 
sweet O 
steviol B-FAMILY 
glycosides I-FAMILY 
, O 
mainly O 
stevioside B-TRIVIAL 
and O 
rebaudioside B-TRIVIAL 
A I-TRIVIAL 
. O 
Highly O 
purified O 
stevia O 
extracts O 
have O 
become O 
popular O 
worldwide O 
as O 
a O 
natural O 
, O 
low O 
- O 
calorie O 
sweetener O 
. O 
They O 
contain O 
various O 
types O 
of O 
steviol B-FAMILY 
glycosides I-FAMILY 
, O 
and O 
their O 
main O 
components O 
are O 
stevioside B-TRIVIAL 
and O 
rebaudioside B-TRIVIAL 
A I-TRIVIAL 
. O 
The O 
content O 
of O 
each O 
steviol B-FAMILY 
glycoside I-FAMILY 
is O 
quantified O 
by O 
comparing O 
the O 
ratios O 
of O 
the O 
molecular O 
weights O 
and O 
the O 
chromatographic O 
peak O 
areas O 
of O 
the O 
samples O 
to O 
those O 
of O 
stevioside B-TRIVIAL 
or O 
rebaudioside B-TRIVIAL 
A I-TRIVIAL 
standards O 
of O 
the O 
Food O 
and O 
Agriculture O 
Organization O 
of O 
the O 
United O 
Nations O 
( O 
FAO O 
) O 
/ O 
World O 
Health O 
Organization O 
( O 
WHO O 
) O 
Joint O 
Expert O 
Committee O 
on O 
Food O 
Additives O 
( O 
JECFA O 
) O 
and O 
other O 
specifications O 
. O 
However O 
, O 
various O 
commercial O 
standard O 
reagents O 
of O 
stevioside B-TRIVIAL 
and O 
rebaudioside B-TRIVIAL 
A I-TRIVIAL 
are O 
available O 
. O 
Their O 
purities O 
are O 
different O 
and O 
their O 
exact O 
purities O 
are O 
not O 
indicated O 
. O 
Therefore O 
, O 
the O 
measured O 
values O 
of O 
stevioside B-TRIVIAL 
and O 
rebaudioside B-TRIVIAL 
A I-TRIVIAL 
contained O 
in O 
a O 
sample O 
vary O 
according O 
to O 
the O 
standard O 
used O 
for O 
the O 
quantification O 
. O 
In O 
this O 
study O 
, O 
we O 
utilized O 
an O 
accurate O 
method O 
, O 
quantitative O 
NMR O 
( O 
qNMR O 
) O 
, O 
for O 
determining O 
the O 
contents O 
of O 
stevioside B-TRIVIAL 
and O 
rebaudioside B-TRIVIAL 
A I-TRIVIAL 
in O 
standards O 
, O 
with O 
traceability O 
to O 
the O 
International O 
System O 
of O 
Units O 
( O 
SI O 
units O 
) O 
. O 
The O 
purities O 
of O 
several O 
commercial O 
standards O 
were O 
determined O 
to O 
confirm O 
their O 
actual O 
values O 
. O 

mitochondrial O 
respiratory O 
chain O 
complex O 
IV O 
( O 
cytochrome O 
c O 
oxidase O 
) O 
is O 
a O 
multi O 
- O 
subunit O 
enzyme O 
that O 
transfers O 
electrons O 
from O 
cytochrome O 
c O 
to O 
molecular O 
oxygen B-SYSTEMATIC 
, O 
yielding O 
water O 
. O 
Its O 
biogenesis O 
requires O 
concerted O 
expression O 
of O 
mitochondria- O 
and O 
nuclear O 
- O 
encoded O 
subunits O 
and O 
assembly O 
factors O 
. O 
In O 
this O 
report O 
, O 
we O 
describe O 
a O 
homozygous O 
missense O 
mutation O 
in O 
FAM36A O 
from O 
a O 
patient O 
who O 
displays O 
ataxia O 
and O 
muscle O 
hypotonia O 
. O 
The O 
FAM36A O 
gene O 
is O 
a O 
remote O 
, O 
putative O 
ortholog O 
of O 
the O 
fungal O 
complex O 
IV O 
assembly O 
factor O 
COX20 O 
. O 
Messenger O 
RNA O 
( O 
mRNA O 
) O 
and O 
protein O 
co O 
- O 
expression O 
analyses O 
support O 
the O 
involvement O 
of O 
FAM36A O 
in O 
complex O 
IV O 
function O 
in O 
mammals O 
. O 
The O 
c.154A O 
> O 
C O 
mutation O 
in O 
the O 
FAM36A O 
gene O 
, O 
a O 
mutation O 
that O 
is O 
absent O 
in O 
sequenced O 
exomes O 
, O 
leads O 
to O 
a O 
reduced O 
activity O 
and O 
lower O 
levels O 
of O 
complex O 
IV O 
and O 
its O 
protein O 
subunits O 
. O 
The O 
FAM36A O 
protein O 
is O 
nearly O 
absent O 
in O 
patient's O 
fibroblasts O 
. O 
Cells O 
affected O 
by O 
the O 
mutation O 
accumulate O 
subassemblies O 
of O 
complex O 
IV O 
that O 
contain O 
COX1 O 
but O 
are O 
almost O 
devoid O 
of O 
COX2 O 
protein O 
. O 
We O 
observe O 
co O 
- O 
purification O 
of O 
FAM36A O 
and O 
COX2 O 
proteins O 
, O 
supporting O 
that O 
the O 
FAM36A O 
defect O 
hampers O 
the O 
early O 
step O 
of O 
complex O 
IV O 
assembly O 
at O 
the O 
incorporation O 
of O 
the O 
COX2 O 
subunit O 
. O 
Lentiviral O 
complementation O 
of O 
patient's O 
fibroblasts O 
with O 
wild O 
- O 
type O 
FAM36A O 
increases O 
the O 
complex O 
IV O 
activity O 
as O 
well O 
as O 
the O 
amount O 
of O 
holocomplex O 
IV O 
and O 
of O 
individual O 
subunits O 
. O 
These O 
results O 
establish O 
the O 
function O 
of O 
the O 
human O 
gene O 
FAM36A O 
/ O 
COX20 O 
in O 
complex O 
IV O 
assembly O 
and O 
support O 
a O 
causal O 
role O 
of O 
the O 
gene O 
in O 
complex O 
IV O 
deficiency O 
. O 

compounds O 
as O 
TRPA1 O 
antagonists O 
( O 
WO O 
2012085662 O 
) O 
: O 
a O 
patent O 
evaluation O 
. O 

patent O 
claims O 
2-amino-4-arylthiazole B-FAMILY 
derivative O 
compounds O 
as O 
inhibitors O 
of O 
the O 
TRPA1 O 
( O 
transient O 
receptor O 
potential O 
ankyrin O 
, O 
member O 
1 O 
) O 
receptor O 
. O 
These O 
compounds O 
are O 
potent O 
antagonists O 
on O 
the O 
basis O 
of O 
the O 
results O 
of O 
in O 
vitro O 
assays O 
, O 
and O 
are O 
expected O 
to O 
be O 
useful O 
for O 
treating O 
conditions O 
and O 
disorders O 
associated O 
with O 
TRPA1 O 
function O 
such O 
as O 
pain O 
, O 
chronic O 
pain O 
, O 
neuropathic O 
pain O 
, O 
rheumatoid O 
arthritic O 
pain O 
, O 
osteoarthritic O 
pain O 
, O 
diabetic O 
neuropathy O 
and O 
inflammatory O 
disorders O 
. O 

dichloromethane B-SYSTEMATIC 
extract O 
of O 
the O 
aerial O 
parts O 
of O 
Salvia O 
chrysophylla O 
Stapf O 
( O 
Lamiaceae O 
) O 
, O 
which O 
is O 
an O 
endemic O 
species O 
to O 
south O 
- O 
western O 
Anatolia O 
, O 
was O 
studied O 
for O 
non-volatile O 
secondary O 
metabolites O 
for O 
the O 
first O 
time O 
in O 
this O 
study O 
. O 
Structures O 
of O 
the O 
isolated O 
compounds O 
were O 
elucidated O 
as O 
sclareol B-TRIVIAL 
, O 
β-sitosterol B-TRIVIAL 
, O 
salvigenin B-TRIVIAL 
, O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
and O 
ursolic B-TRIVIAL 
acid I-TRIVIAL 
. O 
The O 
lipid O 
peroxidation O 
inhibitory O 
activity O 
and O 
the O 
DPPH B-ABBREVIATION 
free O 
radical O 
scavenging O 
activity O 
of O 
the O 
pure O 
isolates O 
were O 
investigated O 
to O 
establish O 
their O 
antioxidant O 
potential O 
. O 
Their O 
anticholinesterase O 
activity O 
was O 
carried O 
out O 
by O 
the O 
Ellman O 
assay O 
against O 
both O 
enzymes O 
, O 
acetylcholinesterase O 
( O 
AChE O 
) O 
and O 
butyrylcholinesterase O 
, O 
and O 
diterpene O 
sclareol B-TRIVIAL 
exhibited O 
fairly O 
good O 
activity O 
against O 
both O 
the O 
enzymes O 
while O 
the O 
two O 
triterpenoids O 
oleanolic B-MULTIPLE 
and I-MULTIPLE 
ursolic I-MULTIPLE 
acids I-MULTIPLE 
exhibited O 
selective O 
activity O 
against O 
AChE O 
. O 

- O 
regulation O 
of O 
8-oxoguanine B-SYSTEMATIC 
DNA O 
glycosylase O 
1 O 
expression O 
in O 
the O 
airway O 
epithelium O 
ameliorates O 
allergic O 
lung O 
inflammation O 
. O 

airway O 
inflammation O 
is O 
characterized O 
by O 
increased O 
expression O 
of O 
pro O 
- O 
inflammatory O 
mediators O 
, O 
inflammatory O 
cell O 
infiltration O 
, O 
mucus O 
hypersecretion O 
, O 
and O 
airway O 
hyperresponsiveness O 
, O 
in O 
parallel O 
with O 
oxidative O 
DNA O 
base O 
and O 
strand O 
damage O 
, O 
whose O 
etiological O 
role O 
is O 
not O 
understood O 
. O 
Our O 
goal O 
was O 
to O 
establish O 
the O 
role O 
of O 
8-oxoguanine B-SYSTEMATIC 
( O 
8-oxoG B-SYSTEMATIC 
) O 
, O 
a O 
common O 
oxidatively O 
damaged O 
base O 
, O 
and O 
its O 
repair O 
by O 
8-oxoguanine B-SYSTEMATIC 
DNA O 
glycosylase O 
1 O 
( O 
Ogg1 O 
) O 
in O 
allergic O 
airway O 
inflammatory O 
processes O 
. O 
Airway O 
inflammation O 
was O 
induced O 
by O 
intranasally O 
administered O 
ragweed O 
( O 
Ambrosia O 
artemisiifolia O 
) O 
pollen O 
grain O 
extract O 
( O 
RWPE O 
) O 
in O 
sensitized O 
BALB O 
/ O 
c O 
mice O 
. O 
We O 
utilized O 
siRNA O 
technology O 
to O 
deplete O 
Ogg1 O 
from O 
airway O 
epithelium O 
; O 
8-oxoG B-SYSTEMATIC 
and O 
DNA O 
strand O 
break O 
levels O 
were O 
quantified O 
by O 
Comet O 
assays O 
. O 
Inflammatory O 
cell O 
infiltration O 
and O 
epithelial O 
methaplasia O 
were O 
determined O 
histologically O 
, O 
mucus O 
and O 
cytokines O 
levels O 
biochemically O 
and O 
enhanced O 
pause O 
was O 
used O 
as O 
the O 
main O 
index O 
of O 
airway O 
hyperresponsiveness O 
. O 
Decreased O 
Ogg1 O 
expression O 
and O 
thereby O 
8-oxoG B-SYSTEMATIC 
repair O 
in O 
the O 
airway O 
epithelium O 
conveyed O 
a O 
lower O 
inflammatory O 
response O 
after O 
RWPE O 
challenge O 
of O 
sensitized O 
mice O 
, O 
as O 
determined O 
by O 
expression O 
of O 
Th2 O 
cytokines O 
, O 
eosinophilia O 
, O 
epithelial O 
methaplasia O 
, O 
and O 
airway O 
hyperresponsiveness O 
. O 
In O 
contrast O 
, O 
8-oxoG B-SYSTEMATIC 
repair O 
in O 
Ogg1-proficient O 
airway O 
epithelium O 
was O 
coupled O 
to O 
an O 
increase O 
in O 
DNA O 
single O 
- O 
strand O 
break O 
( O 
SSB O 
) O 
levels O 
and O 
exacerbation O 
of O 
allergen O 
challenge O 
- O 
dependent O 
inflammation O 
. O 
Decreased O 
expression O 
of O 
the O 
Nei O 
- O 
like O 
glycosylases O 
Neil1 O 
and O 
Neil2 O 
that O 
preferentially O 
excise O 
ring O 
- O 
opened O 
purines O 
and O 
5-hydroxyuracil B-SYSTEMATIC 
, O 
respectively O 
, O 
did O 
not O 
alter O 
the O 
above O 
parameters O 
of O 
allergic O 
immune O 
responses O 
to O 
RWPE O 
. O 
These O 
results O 
show O 
that O 
DNA O 
SSBs O 
formed O 
during O 
Ogg1 O 
- O 
mediated O 
repair O 
of O 
8-oxoG B-SYSTEMATIC 
augment O 
antigen O 
- O 
driven O 
allergic O 
immune O 
responses O 
. O 
A O 
transient O 
modulation O 
of O 
OGG1 O 
expression O 
/ O 
activity O 
in O 
airway O 
epithelial O 
cells O 
could O 
have O 
clinical O 
benefits O 
. O 

fumigation O 
, O 
a O 
better O 
or O 
worse O 
choice O 
in O 
preservation O 
of O 
Traditional O 
Chinese O 
Medicine O 
? O 

fumigation O 
( O 
SF O 
) O 
in O 
Traditional O 
Chinese O 
Medicine O 
( O 
TCM O 
) O 
is O 
a O 
highly O 
efficient O 
and O 
important O 
traditional O 
preservation O 
method O 
in O 
China O 
. O 
This O 
method O 
has O 
generated O 
a O 
great O 
deal O 
of O 
concern O 
and O 
has O 
been O 
disputed O 
in O 
the O 
last O 
few O 
years O 
because O 
of O 
its O 
uncertain O 
safety O 
. O 
SF O 
can O 
alter O 
the O 
quality O 
of O 
TCMs O 
by O 
damaging O 
the O 
bioactive O 
compounds O 
, O 
changing O 
chemical O 
profiles O 
, O 
and O 
generating O 
detrimental O 
exogenous O 
materials O 
. O 
However O 
, O 
SF O 
is O 
still O 
widely O 
used O 
in O 
the O 
herbal O 
medicinal O 
industry O 
because O 
of O 
its O 
various O 
benefits O 
, O 
such O 
as O 
its O 
pesticidal O 
and O 
anti-bacterial O 
effects O 
, O 
easy O 
operation O 
, O 
and O 
low O 
- O 
cost O 
. O 
This O 
review O 
contains O 
the O 
current O 
situation O 
, O 
chemical O 
mechanism O 
and O 
reactions O 
during O 
SF O 
, O 
the O 
pharmacological O 
and O 
pharmacokinetic O 
research O 
, O 
and O 
the O 
influence O 
of O 
quality O 
caused O 
by O 
SF O 
. O 
In O 
addition O 
, O 
a O 
quantification O 
- O 
operation O 
sulfur B-SYSTEMATIC 
fumigation O 
device O 
( O 
QOSFD O 
) O 
, O 
which O 
can O 
maintain O 
the O 
quality O 
of O 
TCMs O 
by O 
controlling O 
the O 
SF O 
processing O 
parameters O 
, O 
has O 
been O 
designed O 
and O 
introduced O 
. O 
The O 
key O 
technologies O 
of O 
this O 
device O 
involve O 
controlling O 
the O 
O(2) B-FORMULA 
content O 
and O 
the O 
temperature O 
of O 
SO(2) B-FORMULA 
as O 
well O 
as O 
the O 
quantification O 
of O 
sulfur B-SYSTEMATIC 
in O 
SF O 
. O 
This O 
device O 
can O 
reduce O 
the O 
possibility O 
of O 
reaction O 
between O 
bioactive O 
compounds O 
and O 
sulfur B-SYSTEMATIC 
/ O 
sulfurous B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
as O 
well O 
as O 
control O 
the O 
limitation O 
of O 
SO(2) B-FORMULA 
residues O 
. O 
The O 
QOSFD O 
is O 
regarded O 
as O 
a O 
promising O 
preservation O 
technique O 
in O 
the O 
field O 
of O 
TCM O 
, O 
medicinal O 
materials O 
, O 
agriculture O 
, O 
and O 
fruit O 
industry O 
. O 

oleander O 
derived O 
cardiac O 
glycoside O 
oleandrin B-TRIVIAL 
is O 
a O 
novel O 
inhibitor O 
of O 
HIV O 
infectivity O 
. O 

evaluated O 
the O 
effectiveness O 
of O 
Anvirzel O 
™ O 
, O 
an O 
aqueous O 
extract O 
of O 
Nerium O 
oleander O 
on O 
HIV O 
infection O 
of O 
human O 
peripheral O 
blood O 
mononuclear O 
cells O 
. O 
Oleandrin B-TRIVIAL 
, O 
the O 
principle O 
cardiac O 
glycoside O 
( O 
CG O 
) O 
in O 
Anvirzel O 
™ O 
has O 
been O 
shown O 
to O 
exhibit O 
anti-cancer O 
properties O 
but O 
its O 
efficacy O 
against O 
HIV O 
is O 
unknown O 
. O 
Treatment O 
with O 
Anvirzel O 
™ O 
significantly O 
reduced O 
the O 
infectivity O 
of O 
virus O 
produced O 
from O 
infected O 
cells O 
without O 
any O 
change O 
in O 
the O 
total O 
amount O 
of O 
virus O 
produced O 
. O 
This O 
is O 
in O 
contrast O 
to O 
treatment O 
with O 
AZT B-ABBREVIATION 
, O 
a O 
potent O 
inhibitor O 
of O 
HIV O 
replication O 
that O 
has O 
been O 
shown O 
to O 
significantly O 
reduce O 
virus O 
production O 
. O 
Relative O 
to O 
untreated O 
cultures O 
, O 
virus O 
in O 
cultures O 
treated O 
with O 
oleandrin B-TRIVIAL 
had O 
significantly O 
reduced O 
expression O 
of O 
the O 
envelope O 
protein O 
gp120 O 
, O 
the O 
sole O 
determinant O 
of O 
virus O 
infectivity O 
, O 
suggesting O 
a O 
novel O 
mechanism O 
underlying O 
the O 
impaired O 
infectivity O 
. O 
These O 
results O 
support O 
the O 
potential O 
utility O 
of O 
the O 
Nerium O 
oleander O 
aqueous O 
extract O 
, O 
containing O 
the O 
CG O 
oleandrin B-TRIVIAL 
as O 
a O 
novel O 
candidate O 
anti-HIV O 
therapeutic O 
. O 

effect O 
of O 
cinnamon O 
polyphenols B-FAMILY 
against O 
STZ B-ABBREVIATION 
-diabetic O 
mice O 
fed O 
high O 
- O 
sugar O 
, O 
high O 
- O 
fat O 
diet O 
and O 
its O 
underlying O 
mechanism O 
. O 

study O 
was O 
designed O 
to O 
investigate O 
the O 
potential O 
effects O 
of O 
14days O 
' O 
intragastrically O 
given O 
of O 
cinnamon O 
polyphenols B-FAMILY 
( O 
CPS O 
) O 
in O 
treating O 
diabetic O 
mice O 
induced O 
by O 
intraperitoneal O 
injection O 
of O 
streptozotocin B-TRIVIAL 
(150mgkg(-1)) O 
and O 
fed O 
high- O 
sugar B-FAMILY 
, O 
high O 
- O 
fat O 
diet O 
. O 
The O 
diabetic O 
mice O 
model O 
was O 
successfully O 
established O 
through O 
determining O 
on O 
fasting O 
blood- O 
glucose B-TRIVIAL 
( O 
FBG O 
) O 
test O 
. O 
As O 
revealed O 
by O 
glucose B-TRIVIAL 
oxidase O 
( O 
GOD O 
) O 
and O 
radioimmunoassay O 
( O 
RIA O 
) O 
, O 
both O 
dimethyldiguanide B-SYSTEMATIC 
( O 
DC O 
, O 
0.6gkg(-1)d(-1) O 
) O 
and O 
CPS O 
( O 
0.3 O 
, O 
0.6 O 
, O 
1.2gkg(-1)d(-1) O 
) O 
treatments O 
significantly O 
resulted O 
in O 
down O 
- O 
regulation O 
of O 
blood O 
glucose B-TRIVIAL 
and O 
insulin O 
levels O 
in O 
serum O 
, O 
while O 
the O 
levels O 
of O 
oxidative O 
stress O 
markers O 
were O 
markedly O 
lowered O 
through O 
ELISA O 
assay O 
. O 
Meanwhile O 
, O 
the O 
pathological O 
damage O 
in O 
islet O 
with O 
pancreatic O 
beta O 
cells O 
was O 
ameliorated O 
by O 
treatment O 
of O 
CPS O 
at O 
different O 
doses O 
, O 
as O 
shown O 
in O 
HE O 
stain O 
. O 
At O 
the O 
same O 
time O 
, O 
the O 
treatments O 
also O 
caused O 
notable O 
reduction O 
of O 
iNOS O 
, O 
NF-κB O 
expressions O 
showing O 
in O 
Western O 
blot O 
analysis O 
. O 
These O 
findings O 
demonstrate O 
that O 
cinnamon O 
polyphenols B-FAMILY 
can O 
exert O 
the O 
hypoglycemic O 
and O 
hypolipidemic O 
effects O 
through O 
the O 
mechanisms O 
that O 
may O 
be O 
associated O 
with O 
repairing O 
pancreatic O 
beta O 
cells O 
in O 
diabetic O 
mice O 
and O 
improving O 
its O 
anti-oxidative O 
capacity O 
, O 
as O 
well O 
as O 
attenuating O 
cytotoxicity O 
via O 
inhibition O 
of O 
iNOS O 
, O 
NF-κB O 
activation O 
. O 

new O 
steroidal B-FAMILY 
glycosides I-FAMILY 
from O 
the O 
roots O 
of O 
Cynanchum O 
stauntonii O 
. O 

new O 
steroidal B-FAMILY 
glycosides I-FAMILY 
, O 
named O 
as O 
stauntosides B-MULTIPLE 
C-K I-MULTIPLE 
( O 
2 O 
, O 
5 O 
, O 
7-10 O 
, O 
13 O 
, O 
14 O 
, O 
and O 
16 O 
) O 
, O 
along O 
with O 
seven O 
known O 
compounds O 
( O 
1 O 
, O 
3 O 
, O 
4 O 
, O 
6 O 
, O 
11 O 
, O 
12 O 
, O 
and O 
15 O 
) O 
were O 
isolated O 
from O 
the O 
95% O 
ethanol B-SYSTEMATIC 
extract O 
of O 
the O 
roots O 
of O 
Cynanchum O 
stauntonii O 
. O 
The O 
structures O 
of O 
these O 
new O 
compounds O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
extensive O 
spectroscopic O 
analyses O 
, O 
mainly O 
1D O 
and O 
2D O 
NMR O 
, O 
and O 
HRESI-MS O 
, O 
and O 
qualitative O 
chemical O 
methods O 
. O 
Their O 
significance O 
in O 
terms O 
of O 
the O 
chemotaxonomy O 
of O 
C O 
. O 
stauntonii O 
is O 
discussed O 
. O 

in O 
OCTN1 O 
and O 
OCTN2 O 
transporters O 
genes O 
are O 
associated O 
with O 
prolonged O 
time O 
to O 
progression O 
in O 
unresectable O 
gastrointestinal O 
stromal O 
tumours O 
treated O 
with O 
imatinib B-TRIVIAL 
therapy O 
. O 

two O 
basic O 
mainstays O 
of O 
gastrointestinal O 
stromal O 
tumours O 
( O 
GIST O 
) O 
treatment O 
are O 
surgery O 
and O 
imatinib B-TRIVIAL 
, O 
a O 
selective O 
tyrosine B-TRIVIAL 
kinase O 
inhibitor O 
that O 
allows O 
achieving O 
a O 
stable O 
or O 
responding O 
disease O 
in O 
about O 
80% O 
of O 
patients O 
with O 
unresectable O 
/ O 
metastatic O 
GIST O 
. O 
Response O 
to O 
imatinib B-TRIVIAL 
mainly O 
depends O 
from O 
KIT O 
and O 
PDGFRα O 
mutational O 
status O 
. O 
Nevertheless O 
, O 
some O 
patients O 
with O 
a O 
potentially O 
responsive O 
genotype O 
do O 
not O 
respond O 
, O 
and O 
others O 
develop O 
a O 
pattern O 
of O 
resistance O 
to O 
imatinib B-TRIVIAL 
which O 
is O 
not O 
associated O 
with O 
secondary O 
mutations O 
. O 
This O 
emphasizes O 
the O 
presence O 
of O 
mechanisms O 
of O 
resistance O 
other O 
than O 
the O 
receptor O 
- O 
related O 
genotype O 
, O 
and O 
the O 
need O 
of O 
biological O 
predictors O 
to O 
select O 
the O 
optimal O 
therapeutic O 
strategy O 
, O 
particularly O 
now O 
that O 
other O 
potent O 
inhibitors O 
are O 
available O 
. O 
We O 
investigated O 
a O 
panel O 
of O 
31 O 
polymorphisms O 
in O 
11 O 
genes O 
, O 
potentially O 
associated O 
with O 
the O 
pharmacogenetics O 
of O 
imatinib B-TRIVIAL 
, O 
in O 
a O 
group O 
of O 
54 O 
unresectable O 
/ O 
metastatic O 
GISTs O 
treated O 
with O 
imatinib B-TRIVIAL 
400mg O 
daily O 
as O 
first O 
line O 
therapy O 
. O 
Included O 
in O 
this O 
analysis O 
were O 
polymorphisms O 
in O 
the O 
transporters O 
' O 
family O 
SLC22 O 
, O 
SLCO O 
, O 
ABC O 
, O 
and O 
in O 
the O 
metabolizing O 
genes O 
CYP-3A4 O 
and O 
-3A5 O 
. O 
Time O 
to O 
progression O 
was O 
significantly O 
improved O 
in O 
presence O 
of O 
the O 
C O 
allele O 
in O 
SLC22A4 O 
( O 
OCTN1 O 
rs1050152 O 
) O 
, O 
and O 
the O 
two O 
minor O 
alleles O 
( O 
G O 
) O 
in O 
SLC22A5 O 
( O 
OCTN2 O 
rs2631367 O 
and O 
rs2631372 O 
) O 
. O 
Importantly O 
, O 
multivariate O 
analysis O 
, O 
adjusting O 
for O 
age O 
, O 
gender O 
, O 
KIT O 
/ O 
PDGFRα O 
mutational O 
status O 
, O 
and O 
tumour O 
size O 
, O 
revealed O 
that O 
all O 
the O 
three O 
genotypes O 
maintained O 
independent O 
predictive O 
significance O 
. O 
In O 
conclusion O 
, O 
in O 
this O 
study O 
we O 
showed O 
that O 
SLC22A4 O 
and O 
SLC22A5 O 
genotypes O 
may O 
be O 
an O 
important O 
predictor O 
of O 
time O 
to O 
progression O 
in O 
GIST O 
patients O 
receiving O 
imatinib B-TRIVIAL 
therapy O 
. O 
Further O 
investigations O 
are O 
required O 
in O 
an O 
attempt O 
to O 
further O 
personalize O 
GIST O 
therapy O 
. O 

application O 
of O 
Fas O 
receptor O 
small O 
- O 
interfering O 
RNA O 
to O 
suppress O 
sulfur B-SYSTEMATIC 
mustard O 
- O 
induced O 
apoptosis O 
in O 
human O 
airway O 
epithelial O 
cells O 
: O 
implication O 
for O 
a O 
therapeutic O 
approach O 
. O 

mustard O 
( O 
SM O 
) O 
is O 
a O 
vesicant O 
chemical O 
warfare O 
and O 
terrorism O 
agent O 
. O 
Besides O 
skin O 
and O 
eye O 
injury O 
, O 
respiratory O 
damage O 
has O 
been O 
mainly O 
responsible O 
for O 
morbidity O 
and O 
mortality O 
after O 
SM O 
exposure O 
. O 
Previously O 
, O 
it O 
was O 
shown O 
that O 
suppressing O 
the O 
death O 
receptor O 
( O 
DR O 
) O 
response O 
by O 
the O 
dominant O 
- O 
negative O 
Fas-associated O 
death O 
domain O 
protein O 
prior O 
to O 
SM O 
exposure O 
blocked O 
apoptosis O 
and O 
microvesication O 
in O 
skin O 
. O 
Here O 
, O 
we O 
studied O 
whether O 
antagonizing O 
the O 
Fas O 
receptor O 
( O 
FasR O 
) O 
pathway O 
by O 
small O 
- O 
interfering O 
RNA O 
( O 
siRNA O 
) O 
applied O 
after O 
SM O 
exposure O 
would O 
prevent O 
apoptosis O 
and O 
, O 
thus O 
, O 
airway O 
injury O 
. O 
Normal O 
human O 
bronchial O 
/ O 
tracheal O 
epithelial O 
( O 
NHBE O 
) O 
cells O 
were O 
used O 
as O 
an O 
in O 
vitro O 
model O 
with O 
FasR O 
siRNA O 
, O 
FasR O 
agonistic O 
antibody O 
CH11 O 
, O 
and O 
FasR O 
antagonistic O 
antibody O 
ZB4 O 
as O 
investigative O 
tools O 
. O 
In O 
NHBE O 
cells O 
, O 
both O 
SM O 
( O 
300 O 
µM O 
) O 
and O 
CH11 O 
( O 
100 O 
ng O 
/ O 
ml O 
) O 
induced O 
caspase-3 O 
activation O 
, O 
which O 
was O 
inhibited O 
by O 
FasR O 
siRNA O 
and O 
ZB4 O 
, O 
indicating O 
that O 
SM-induced O 
apoptosis O 
was O 
via O 
the O 
Fas O 
response O 
. O 
FasR O 
siRNA O 
inhibited O 
SM-induced O 
caspase-3 O 
activation O 
when O 
added O 
to O 
NHBE O 
cultures O 
up O 
to O 
8 O 
hours O 
after O 
SM O 
. O 
Results O 
using O 
annexin O 
V/ O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
-stained O 
cells O 
showed O 
that O 
both O 
apoptosis O 
and O 
necrosis O 
were O 
involved O 
in O 
cell O 
death O 
due O 
to O 
SM O 
; O 
FasR O 
siRNA O 
decreased O 
both O 
apoptotic O 
and O 
necrotic O 
cell O 
populations O 
. O 
Bronchoalveolar O 
lavage O 
fluid O 
( O 
BALF O 
) O 
of O 
rats O 
exposed O 
to O 
SM O 
( O 
1 O 
mg O 
/ O 
kg O 
, O 
50 O 
minutes O 
) O 
revealed O 
a O 
significant O 
( O 
P O 
< O 
0.05 O 
) O 
increase O 
in O 
soluble O 
Fas O 
ligand O 
and O 
active O 
caspase-3 O 
in O 
BALF O 
cells O 
. O 
These O 
findings O 
suggest O 
an O 
intervention O 
of O 
Fas O 
- O 
mediated O 
apoptosis O 
as O 
a O 
postexposure O 
therapeutic O 
strategy O 
with O 
a O 
therapeutic O 
window O 
for O 
SM O 
inhalation O 
injury O 
and O 
possibly O 
other O 
respiratory O 
diseases O 
involving O 
the O 
Fas O 
response O 
. O 

is O 
an O 
evolutionarily O 
conserved O 
NAD(+) B-ABBREVIATION 
-dependent O 
deacetylase O 
which O 
has O 
been O 
shown O 
to O 
play O 
a O 
critical O 
role O 
in O 
glucose B-TRIVIAL 
and O 
fat O 
metabolism O 
. O 
In O 
this O 
study O 
, O 
we O 
have O 
perturbed O 
Drosophila O 
Sir2 O 
( O 
dSir2 O 
) O 
expression O 
, O 
bidirectionally O 
, O 
in O 
muscles O 
and O 
the O 
fat O 
body O 
. O 
We O 
report O 
that O 
dSir2 O 
plays O 
a O 
critical O 
role O 
in O 
insulin O 
signaling O 
, O 
glucose B-TRIVIAL 
homeostasis O 
, O 
and O 
mitochondrial O 
functions O 
. O 
Importantly O 
, O 
we O 
establish O 
the O 
nonautonomous O 
functions O 
of O 
fat O 
body O 
dSir2 O 
in O 
regulating O 
mitochondrial O 
physiology O 
and O 
insulin O 
signaling O 
in O 
muscles O 
. O 
We O 
have O 
identified O 
a O 
novel O 
interplay O 
between O 
dSir2 O 
and O 
dFOXO O 
at O 
an O 
organismal O 
level O 
, O 
which O 
involves O 
Drosophila O 
insulin O 
- O 
like O 
peptide O 
(dILP)-dependent O 
insulin O 
signaling O 
. O 
By O 
genetic O 
perturbations O 
and O 
metabolic O 
rescue O 
, O 
we O 
provide O 
evidence O 
to O 
illustrate O 
that O 
fat O 
body O 
dSir2 O 
mediates O 
its O 
effects O 
on O 
the O 
muscles O 
via O 
free O 
fatty B-FAMILY 
acids I-FAMILY 
( O 
FFA O 
) O 
and O 
dILPs O 
( O 
from O 
the O 
insulin O 
- O 
producing O 
cells O 
[ O 
IPCs O 
] O 
) O 
. O 
In O 
summary O 
, O 
we O 
show O 
that O 
fat O 
body O 
dSir2 O 
is O 
a O 
master O 
regulator O 
of O 
organismal O 
energy O 
homeostasis O 
and O 
is O 
required O 
for O 
maintaining O 
the O 
metabolic O 
regulatory O 
network O 
across O 
tissues O 
. O 

post O 
- O 
translational O 
modification O 
of O 
proteins O 
is O 
controlled O 
by O 
the O 
relative O 
activities O 
of O 
two O 
opposing O 
enzymes O 
. O 
For O 
example O 
, O 
the O 
extent O 
of O 
phosphorylation O 
of O 
tyrosine B-TRIVIAL 
residues O 
reflects O 
the O 
balance O 
of O 
a O 
kinase O 
and O 
a O 
phosphatase O 
enzyme O 
. O 
The O 
present O 
article O 
uses O 
as O 
a O 
model O 
system O 
a O 
self O 
- O 
assembled O 
monolayer O 
that O 
presents O 
a O 
peptide O 
that O 
can O 
be O 
phosphorylated O 
by O 
Abl O 
kinase O 
and O 
subsequently O 
dephosphorylated O 
by O 
Lambda O 
phosphatase O 
. O 
Treatment O 
of O 
monolayers O 
with O 
a O 
reaction O 
mixture O 
containing O 
both O 
enzymes O 
reveals O 
that O 
the O 
steady O 
- O 
state O 
level O 
of O 
peptide O 
phosphorylation O 
is O 
dependent O 
on O 
the O 
density O 
of O 
the O 
peptide O 
. O 
Using O 
identical O 
reaction O 
mixtures O 
, O 
surfaces O 
that O 
presented O 
the O 
substrate O 
at O 
high O 
density O 
led O 
to O 
a O 
phosphorylated O 
peptide O 
at O 
steady O 
- O 
state O 
, O 
whereas O 
surfaces O 
that O 
presented O 
the O 
substrate O 
at O 
low O 
density O 
led O 
to O 
unphosphorylated O 
peptide O 
at O 
steady O 
- O 
state O 
. O 
This O 
dependence O 
owes O 
to O 
an O 
autocatalytic O 
phosphorylation O 
reaction O 
that O 
operates O 
at O 
high O 
densities O 
of O 
substrate O 
. O 
This O 
work O 
provides O 
an O 
example O 
of O 
an O 
interfacial O 
reaction O 
that O 
has O 
properties O 
that O 
have O 
no O 
analogue O 
in O 
the O 
corresponding O 
solution O 
phase O 
reaction O 
. O 
It O 
also O 
provides O 
a O 
model O 
system O 
that O 
is O 
relevant O 
to O 
understanding O 
mechanisms O 
that O 
regulate O 
signaling O 
at O 
the O 
cellular O 
membrane O 
. O 

there O 
are O 
no O 
pharmacological O 
therapies O 
licensed O 
to O 
treat O 
sepsis O 
- O 
associated O 
acute O 
kidney O 
injury O 
( O 
AKI O 
) O 
. O 
Considering O 
the O 
high O 
incidence O 
and O 
mortality O 
of O 
sepsis O 
- O 
associated O 
AKI O 
, O 
there O 
is O 
an O 
urgent O 
medical O 
need O 
to O 
develop O 
effective O 
pharmacological O 
interventions O 
. O 
Two O 
phase O 
II O 
clinical O 
trials O 
recently O 
demonstrated O 
beneficial O 
effects O 
of O 
the O 
enzyme O 
alkaline O 
phosphatase O 
( O 
AP O 
) O 
. O 
In O 
critically O 
ill O 
patients O 
with O 
sepsis O 
- O 
associated O 
AKI O 
, O 
treatment O 
with O 
AP O 
reduced O 
the O 
urinary O 
excretion O 
of O 
tubular O 
injury O 
biomarkers O 
and O 
plasma O 
markers O 
of O 
inflammation O 
, O 
which O 
was O 
associated O 
with O 
improvement O 
of O 
renal O 
function O 
. O 
The O 
dephosphorylating O 
enzyme O 
, O 
AP O 
, O 
is O 
endogenously O 
present O 
in O 
the O 
renal O 
proximal O 
tubule O 
apical O 
membrane O 
but O 
becomes O 
depleted O 
during O 
ischemia O 
- O 
induced O 
AKI O 
, O 
thereby O 
possibly O 
contributing O 
to O 
further O 
renal O 
damage O 
. O 
The O 
exact O 
mechanism O 
of O 
action O 
of O 
AP O 
in O 
AKI O 
is O 
unknown O 
, O 
but O 
might O 
be O 
related O 
to O 
detoxification O 
of O 
circulating O 
lipopolysaccharide O 
and O 
other O 
proinflammatory O 
mediators O 
that O 
lose O 
their O 
proinflammatory O 
effects O 
after O 
dephosphorylation O 
. O 
Alternatively O 
, O 
tissue O 
damage O 
associated O 
with O 
systemic O 
inflammation O 
might O 
be O 
attenuated O 
by O 
an O 
AP O 
- O 
mediated O 
effect O 
on O 
adenosine B-TRIVIAL 
metabolism O 
. O 
Adenosine B-TRIVIAL 
is O 
a O 
signaling O 
molecule O 
that O 
has O 
been O 
shown O 
to O 
protect O 
the O 
body O 
from O 
inflammation O 
- O 
induced O 
tissue O 
injury O 
, O 
which O 
is O 
derived O 
through O 
dephosphorylation O 
of O 
ATP B-ABBREVIATION 
. O 
In O 
this O 
Perspectives O 
article O 
, O 
we O 
discuss O 
the O 
clinical O 
activity O 
of O 
AP O 
and O 
its O 
putative O 
molecular O 
modes O 
of O 
action O 
, O 
and O 
we O 
speculate O 
on O 
its O 
use O 
to O 
treat O 
and O 
possibly O 
prevent O 
sepsis O 
- O 
associated O 
AKI O 
. O 

structure O 
elucidation O 
of O 
heterocyclic O 
products O 
from O 
condensation O 
- O 
cyclisation O 
reactions O 
of O 
enaminones B-FAMILY 
by O 
2D O 
INADEQUATE O 
and O 
15N B-FORMULA 
NMR O 
. O 

reaction O 
of O 
enaminones B-FAMILY 
with O 
3-amino-2-cyanopent-2-enedinitrile B-SYSTEMATIC 
can O 
lead O 
to O 
an O 
array O 
of O 
12 O 
possible O 
products O 
, O 
depending O 
on O 
the O 
reaction O 
pathway O 
and O 
tautomerization O 
. O 
The O 
use O 
of O 
2D O 
INADEQUATE O 
and O 
(15)N B-FORMULA 
NMR O 
for O 
the O 
unambiguous O 
structure O 
elucidation O 
of O 
the O 
reaction O 
products O 
is O 
discussed O 
in O 
this O 
manuscript O 
. O 

kinase O 
6 O 
( O 
PAK6 O 
) O 
inhibits O 
prostate O 
cancer O 
growth O 
via O 
phosphorylation O 
of O 
androgen B-FAMILY 
receptor O 
and O 
tumorigenic O 
E3 O 
ligase O 
murine O 
double O 
minute-2 O 
( O 
Mdm2 O 
) O 
. O 

androgen B-FAMILY 
receptor O 
( O 
AR O 
) O 
signaling O 
pathway O 
plays O 
a O 
crucial O 
role O 
in O 
the O 
development O 
and O 
growth O 
of O 
prostate O 
malignancies O 
. O 
Regulation O 
of O 
AR O 
homeostasis O 
in O 
prostate O 
tumorigenesis O 
has O 
not O 
yet O 
been O 
fully O 
characterized O 
. O 
In O 
this O 
study O 
, O 
we O 
demonstrate O 
that O 
p21-activated O 
kinase O 
6 O 
( O 
PAK6 O 
) O 
inhibits O 
prostate O 
tumorigenesis O 
by O 
regulating O 
AR O 
homeostasis O 
. O 
First O 
, O 
we O 
demonstrated O 
that O 
in O 
normal O 
prostate O 
epithelium O 
, O 
AR O 
co O 
- O 
localizes O 
with O 
PAK6 O 
in O 
the O 
cytoplasm O 
and O 
translocates O 
into O 
the O 
nucleus O 
in O 
malignant O 
prostate O 
. O 
Furthermore O 
, O 
AR O 
phosphorylation O 
at O 
Ser B-FORMULA 
-578 O 
by O 
PAK6 O 
promotes O 
AR-E3 O 
ligase O 
murine O 
double O 
minute-2 O 
( O 
Mdm2 O 
) O 
association O 
, O 
causing O 
AR O 
degradation O 
upon O 
androgen B-FAMILY 
stimuli O 
. O 
We O 
also O 
showed O 
that O 
PAK6 O 
phosphorylates O 
Mdm2 O 
on O 
Thr B-FORMULA 
-158 O 
and O 
Ser B-FORMULA 
-186 O 
, O 
which O 
is O 
critical O 
for O 
AR O 
ubiquitin O 
- O 
mediated O 
degradation O 
. O 
Moreover O 
, O 
we O 
found O 
that O 
Thr B-FORMULA 
-158 O 
collaborates O 
with O 
Ser B-FORMULA 
-186 O 
for O 
AR-Mdm2 O 
association O 
and O 
AR O 
ubiquitin O 
- O 
mediated O 
degradation O 
as O 
it O 
facilitates O 
PAK6 O 
- O 
mediated O 
AR O 
homeostasis O 
. O 
PAK6 O 
knockdown O 
promotes O 
prostate O 
tumor O 
growth O 
in O 
vivo O 
. O 
Interestingly O 
, O 
we O 
found O 
a O 
strong O 
inverse O 
correlation O 
between O 
PAK6 O 
and O 
AR O 
expression O 
in O 
the O 
cytoplasm O 
of O 
prostate O 
cancer O 
cells O 
. O 
These O 
observations O 
indicate O 
that O 
PAK6 O 
may O 
be O 
important O 
for O 
the O 
maintenance O 
of O 
androgen B-FAMILY 
-induced O 
AR O 
signaling O 
homeostasis O 
and O 
in O 
prostate O 
malignancy O 
, O 
as O 
well O 
as O 
being O 
a O 
possible O 
new O 
therapeutic O 
target O 
for O 
AR-positive O 
and O 
hormone O 
- O 
sensitive O 
prostate O 
cancer O 
. O 

objective O 
of O 
this O 
study O 
was O 
to O 
establish O 
the O 
role O 
of O 
apoA-IV O 
, O 
ABCA1 O 
, O 
and O 
LCAT O 
in O 
the O 
biogenesis O 
of O 
apoA-IV O 
- O 
containing O 
HDL O 
( O 
HDL-A-IV O 
) O 
using O 
different O 
mouse O 
models O 
. O 
Adenovirus O 
- O 
mediated O 
gene O 
transfer O 
of O 
apoA-IV O 
in O 
apoA-I(- O 
/ O 
- O 
) O 
mice O 
did O 
not O 
change O 
plasma O 
lipid O 
levels O 
. O 
ApoA-IV O 
floated O 
in O 
the O 
HDL2 O 
/ O 
HDL3 O 
region O 
, O 
promoted O 
the O 
formation O 
of O 
spherical O 
HDL O 
particles O 
as O 
determined O 
by O 
electron O 
microscopy O 
, O 
and O 
generated O 
mostly O 
α- O 
and O 
a O 
few O 
pre-β O 
- O 
like O 
HDL O 
subpopulations O 
. O 
Gene O 
transfer O 
of O 
apoA-IV O 
in O 
apoA-I(- O 
/ O 
- O 
) O 
× O 
apoE(- O 
/ O 
- O 
) O 
mice O 
increased O 
plasma O 
cholesterol B-TRIVIAL 
and O 
triglyceride B-FAMILY 
levels O 
, O 
and O 
80% O 
of O 
the O 
protein O 
was O 
distributed O 
in O 
the O 
VLDL O 
/ O 
IDL O 
/ O 
LDL O 
region O 
. O 
This O 
treatment O 
likewise O 
generated O 
α- O 
and O 
pre-β O 
- O 
like O 
HDL O 
subpopulations O 
. O 
Spherical O 
and O 
α-migrating O 
HDL O 
particles O 
were O 
not O 
detectable O 
following O 
gene O 
transfer O 
of O 
apoA-IV O 
in O 
ABCA1(- O 
/ O 
- O 
) O 
or O 
LCAT(- O 
/ O 
- O 
) O 
mice O 
. O 
Coexpression O 
of O 
apoA-IV O 
and O 
LCAT O 
in O 
apoA-I(- O 
/ O 
- O 
) O 
mice O 
restored O 
the O 
formation O 
of O 
HDL-A-IV O 
. O 
Lipid O 
- O 
free O 
apoA-IV O 
and O 
reconstituted O 
HDL-A-IV O 
promoted O 
ABCA1 O 
and O 
scavenger O 
receptor O 
BI O 
( O 
SR-BI O 
) O 
- O 
mediated O 
cholesterol B-TRIVIAL 
efflux O 
, O 
respectively O 
, O 
as O 
efficiently O 
as O 
apoA-I O 
and O 
apoE O 
. O 
Our O 
findings O 
are O 
consistent O 
with O 
a O 
novel O 
function O 
of O 
apoA-IV O 
in O 
the O 
biogenesis O 
of O 
discrete O 
HDL-A-IV O 
particles O 
with O 
the O 
participation O 
of O 
ABCA1 O 
and O 
LCAT O 
, O 
and O 
may O 
explain O 
previously O 
reported O 
anti-inflammatory O 
and O 
atheroprotective O 
properties O 
of O 
apoA-IV O 
. O 

of O 
the O 
levonorgestrel B-TRIVIAL 
intrauterine O 
system O 
( O 
LNG B-ABBREVIATION 
-IUS O 
) O 
in O 
the O 
prevention O 
of O 
the O 
atypical O 
endometrial O 
hyperplasia O 
and O 
endometrial O 
cancer O 
: O 
retrospective O 
data O 
from O 
selected O 
obese O 
menopausal O 
symptomatic O 
women O 
. O 

aim O 
of O 
this O 
retrospective O 
study O 
was O 
to O 
evaluate O 
the O 
efficacy O 
of O 
levonorgestrel B-TRIVIAL 
intrauterine O 
system O 
- O 
releasing O 
( O 
LNG B-ABBREVIATION 
-IUS O 
) O 
insertion O 
in O 
preventing O 
atypical O 
endometrial O 
hyperplasia O 
( O 
AH O 
) O 
and O 
endometrial O 
cancer O 
( O 
EC O 
) O 
in O 
symptomatic O 
postmenopausal O 
overweight O 
/ O 
obese O 
women O 
. O 
A O 
total O 
of O 
34 O 
overweight O 
/ O 
obese O 
postmenopausal O 
women O 
, O 
presenting O 
abnormal O 
uterine O 
bleeding O 
( O 
AUB O 
) O 
and O 
endometrial O 
hyperplasia O 
( O 
EH O 
) O 
, O 
and O 
who O 
were O 
submitted O 
to O 
LNG B-ABBREVIATION 
-IUS O 
insertion O 
, O 
were O 
identified O 
from O 
registry O 
data O 
. O 
Endometrial O 
histology O 
at O 
LNG B-ABBREVIATION 
-IUS O 
insertion O 
showed O 
simple O 
EH O 
in O 
20 O 
cases O 
( O 
58.8% O 
) O 
, O 
complex O 
EH O 
in O 
14 O 
cases O 
( O 
41.2% O 
) O 
. O 
At O 
36 O 
months O 
, O 
91% O 
of O 
patients O 
showed O 
no O 
recurrence O 
of O 
AUB O 
and O 
a O 
significant O 
reduction O 
in O 
the O 
mean O 
endometrial O 
thickness O 
( O 
from O 
8.2 O 
± O 
2.2 O 
to O 
3.2 O 
± O 
1.5 O 
mm O 
, O 
p O 
< O 
0.05 O 
) O 
was O 
observed O 
. O 
Histologic O 
regression O 
of O 
EH O 
was O 
observed O 
in O 
27 O 
( O 
79.4% O 
) O 
and O 
33 O 
( O 
97.5% O 
) O 
cases O 
at O 
12 O 
and O 
36 O 
months O 
, O 
respectively O 
. O 
None O 
of O 
the O 
women O 
in O 
which O 
EH O 
persisted O 
, O 
reported O 
cellular O 
atypia O 
or O 
cancer O 
progression O 
at O 
12 O 
and O 
36 O 
months O 
of O 
follow O 
- O 
up O 
. O 
LNG B-ABBREVIATION 
-IUS O 
represents O 
an O 
effective O 
treatment O 
option O 
to O 
manage O 
postmenopausal O 
obese O 
women O 
affected O 
by O 
AUB O 
and O 
EH O 
. O 
The O 
device O 
seems O 
to O 
be O 
able O 
to O 
prevent O 
the O 
onset O 
of O 
AH O 
and O 
EC O 
in O 
women O 
at O 
high O 
risk O 
. O 
Further O 
prospective O 
controlled O 
studies O 
in O 
a O 
well O 
selected O 
group O 
of O 
women O 
are O 
needed O 
. O 

the O 
roles O 
of O 
different O 
monoamine B-FAMILY 
transmitters O 
and O 
impulse O 
control O 
using O 
the O 
5-choice O 
serial O 
reaction O 
time O 
task O 
. O 

studies O 
have O 
shown O 
that O 
drugs O 
which O 
block O 
the O 
reuptake O 
of O 
catecholamine B-TRIVIAL 
neurotransmitters O 
improve O 
impulse O 
control O 
in O 
diseases O 
such O 
as O 
attention O 
deficit O 
hyperactivity O 
disorder O 
( O 
ADHD O 
) O 
. O 
Serotonin B-TRIVIAL 
-specific O 
reuptake O 
inhibitors O 
( O 
SSRI O 
) O 
lack O 
efficacy O 
in O 
ADHD O 
and O 
have O 
been O 
linked O 
to O 
increased O 
suicide O 
risk O 
. O 
The O 
present O 
study O 
investigated O 
drugs O 
with O 
affinity O 
for O 
one O 
or O 
more O 
of O 
the O 
monoamine B-FAMILY 
reuptake O 
transporters O 
using O 
the O 
5-choice O 
serial O 
reaction O 
time O 
task O 
, O 
a O 
model O 
of O 
attention O 
and O 
impulsivity O 
in O 
rodents O 
. O 
We O 
also O 
tested O 
the O 
effects O 
of O 
the O 
alpha(2)-adreoceptor O 
antagonist O 
, O 
idazoxan B-TRIVIAL 
and O 
novel O 
antidepressant O 
, O 
agomelatine B-TRIVIAL 
, O 
which O 
both O 
increase O 
cortical O 
noradrenaline B-TRIVIAL 
concentrations O 
through O 
non-reuptake O 
mechanisms O 
. O 
Improvements O 
in O 
impulse O 
control O 
were O 
observed O 
with O 
venlafaxine B-TRIVIAL 
, O 
a O 
serotonin B-TRIVIAL 
and O 
noradrenaline B-TRIVIAL 
re O 
- O 
uptake O 
inhibitor O 
( O 
SNRI O 
) O 
but O 
not O 
bupropion B-TRIVIAL 
( O 
dopamine B-TRIVIAL 
and O 
noradrenaline B-TRIVIAL 
re O 
- O 
uptake O 
inhibitor O 
) O 
. O 
Sibutramine B-TRIVIAL 
( O 
SNRI O 
) O 
reduced O 
premature O 
responses O 
by O 
~50% O 
at O 
the O 
highest O 
dose O 
tested O 
but O 
this O 
was O 
not O 
significant O 
. O 
All O 
three O 
of O 
the O 
SSRIs O 
tested O 
reduced O 
premature O 
responding O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
, O 
although O 
also O 
slowed O 
response O 
and O 
collection O 
latencies O 
. O 
Neither O 
idazoxan B-TRIVIAL 
nor O 
agomelatine B-TRIVIAL 
significantly O 
reduced O 
premature O 
responding O 
, O 
suggesting O 
a O 
lack O 
of O 
efficacy O 
at O 
the O 
doses O 
tested O 
. O 
None O 
of O 
the O 
drugs O 
tested O 
improved O 
attention O 
in O 
this O 
task O 
but O 
sibutramine B-TRIVIAL 
( O 
SNRI O 
) O 
, O 
fluoxetine B-TRIVIAL 
( O 
SSRI O 
) O 
and O 
paroxetine B-TRIVIAL 
( O 
SSRI O 
) O 
all O 
increased O 
omissions O 
at O 
the O 
highest O 
dose O 
tested O 
. O 
These O 
data O 
suggest O 
that O 
the O 
SNRIs O 
and O 
SSRIs O 
reduce O 
premature O 
responding O 
but O 
tend O 
to O 
be O 
less O 
specific O 
than O 
noradrenaline B-TRIVIAL 
specific O 
reuptake O 
inhibitors O 
in O 
this O 
model O 
. O 
SSRIs O 
did O 
not O 
induce O 
any O 
specific O 
impairment O 
in O 
impulse O 
control O 
in O 
this O 
model O 
. O 

metallohormone O 
cadmium B-SYSTEMATIC 
modulates O 
AhR-associated O 
gene O 
expression O 
in O 
the O 
small O 
intestine O 
of O 
rats O 
similar O 
to O 
ethinyl-estradiol B-SYSTEMATIC 
. O 

( O 
Cd B-FORMULA 
) O 
affects O 
the O 
expression O 
of O 
estrogen B-FAMILY 
receptor O 
( O 
ER O 
) O 
and O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
(AhR)-associated O 
genes O 
in O 
rat O 
uterus O 
and O 
elicits O 
estrogen B-FAMILY 
-like O 
activity O 
in O 
vitro O 
. O 
The O 
small O 
intestine O 
is O 
highly O 
exposed O 
to O 
dietary O 
Cd B-FORMULA 
which O 
may O 
mimic O 
or O 
antagonize O 
estrogen B-FAMILY 
action O 
in O 
this O 
tissue O 
. O 
We O 
investigated O 
the O 
effects O 
of O 
Cd B-FORMULA 
and O 
17-alpha-ethinylestradiol B-SYSTEMATIC 
( O 
EE₂ B-ABBREVIATION 
) O 
on O 
AhR-associated O 
gene O 
expression O 
after O 
oral O 
exposure O 
of O 
ovariectomized O 
female O 
Wistar O 
rats O 
, O 
and O 
metallothionein O 
( O 
Mt1a O 
) O 
expression O 
as O 
a O 
typical O 
metal O 
- O 
response O 
marker O 
. O 
Mt1a O 
in O 
the O 
small O 
intestine O 
was O 
strongly O 
induced O 
by O 
co O 
- O 
treatment O 
with O 
CdCl₂ B-FORMULA 
at O 
2 O 
mg O 
/ O 
kg O 
b.wt O 
( O 
Cd B-FORMULA 
2 O 
) O 
and O 
0.1 O 
mg O 
/ O 
kg O 
b.wt O 
EE2 B-ABBREVIATION 
than O 
by O 
the O 
single O 
compound O 
( O 
3-day O 
gavage O 
) O 
. O 
The O 
Cd B-FORMULA 
2-induced O 
down O 
- O 
regulation O 
of O 
Cyp1a1 O 
, O 
Gsta2 O 
, O 
and O 
Nqo1 O 
mRNA O 
was O 
not O 
antagonized O 
by O 
pure O 
anti- O 
estrogen B-FAMILY 
( O 
2.5 O 
mg O 
/ O 
kg O 
b.wt O 
ZK191703 O 
s.c O 
. O 
, O 
ZK O 
) O 
. O 
Interestingly O 
, O 
the O 
EE₂ B-ABBREVIATION 
-induced O 
down O 
- O 
regulation O 
of O 
Cyp1a1 O 
, O 
Gsta2 O 
, O 
and O 
Nqo1 O 
mRNA O 
was O 
antagonized O 
by O 
Cd B-FORMULA 
2 O 
in O 
vivo O 
and O 
in O 
colon O 
cancer O 
cell O 
lines O 
( O 
HT-29 O 
and O 
CaCo-2 O 
, O 
treated O 
5 O 
days O 
with O 
Cd B-FORMULA 
1 O 
µM O 
and O 
/ O 
or O 
E₂ O 
0.01 O 
µM O 
) O 
with O 
low O 
or O 
no O 
ER-beta O 
expression O 
. O 
Dose O 
dependency O 
was O 
studied O 
after O 
Cd B-FORMULA 
exposure O 
with O 
drinking O 
water O 
( O 
5 O 
and O 
50 O 
ppm O 
CdCl₂ B-FORMULA 
equivalent O 
to O 
0.4 O 
and O 
4 O 
mg O 
/ O 
kg O 
b.wt O 
; O 
Cd B-FORMULA 
0.4 O 
, O 
Cd B-FORMULA 
4 O 
) O 
for O 
28 O 
days O 
and O 
EE₂ B-ABBREVIATION 
as O 
reference O 
. O 
Intestinal O 
Mt1a O 
expression O 
was O 
dose O 
dependently O 
induced O 
, O 
while O 
AhR O 
target O 
genes O 
were O 
down O 
- O 
regulated O 
by O 
Cd B-FORMULA 
0.4 O 
similar O 
to O 
EE₂ B-ABBREVIATION 
and O 
more O 
pronounced O 
than O 
by O 
Cd B-FORMULA 
4 O 
. O 
We O 
propose O 
that O 
Cd B-FORMULA 
modulates O 
intestinal O 
AhR-associated O 
gene O 
expression O 
similar O 
to O 
estrogens B-FAMILY 
, O 
but O 
( O 
contrary O 
to O 
its O 
effects O 
in O 
uterus O 
) O 
via O 
ER O 
- O 
independent O 
and O 
/ O 
or O 
ER-beta O 
- O 
mediated O 
mechanisms O 
. O 
Our O 
new O 
data O 
suggest O 
interference O 
of O 
Cd B-FORMULA 
with O 
estrogen B-FAMILY 
and O 
AhR O 
signaling O 
in O 
the O 
small O 
intestine O 
. O 

is O 
(68)Ga B-FORMULA 
labeling O 
of O 
macrocyclic O 
chelators O 
influenced O 
by O 
metal O 
ion O 
contaminants O 
in O 
(68)Ge B-FORMULA 
/ O 
(68)Ga B-FORMULA 
generator O 
eluates O 
? O 

assess O 
the O 
influence O 
of O 
Zn(2+) B-FORMULA 
, O 
Cu(2+) B-FORMULA 
, O 
Fe(3+) B-FORMULA 
, O 
Al(3+) B-FORMULA 
, O 
Ti B-FORMULA 
(IV) I-FORMULA 
, O 
and O 
Sn B-FORMULA 
(IV) I-FORMULA 
on O 
incorporation O 
of O 
( B-FORMULA 
68 I-FORMULA 
) I-FORMULA 
Ga(3+) I-FORMULA 
into O 
pendant O 
- O 
arm O 
macrocyclic O 
chelators O 
, O 
the O 
( B-FORMULA 
68 I-FORMULA 
) I-FORMULA 
Ga I-FORMULA 
labeling O 
of O 
1,4,7-triazacyclononane-1,4,7-triacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
NOTA B-ABBREVIATION 
) O 
, O 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DOTA B-ABBREVIATION 
) O 
, O 
1,4,7-triazacyclononane-1,4,7-tris[methyl(2-carboxyethyl)phosphinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
] I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
TRAP B-ABBREVIATION 
) O 
, O 
and O 
1,4,7-triazacyclononane-1-[methyl(2-carboxyethyl)phosphinic B-SYSTEMATIC 
acid]-4,7-bis[methyl(2-hydroxymethyl)phosphinic I-SYSTEMATIC 
acid I-SYSTEMATIC 
] I-SYSTEMATIC 
( O 
NOPO B-ABBREVIATION 
) O 
, O 
as O 
well O 
as O 
their O 
peptide O 
conjugates O 
, O 
was O 
investigated O 
in O 
the O 
presence O 
of O 
varying O 
concentrations O 
of O 
these O 
metal O 
ions O 
. O 
The O 
( B-FORMULA 
68 I-FORMULA 
) I-FORMULA 
Ga I-FORMULA 
labeling O 
yield O 
for O 
carboxylate B-SYSTEMATIC 
-type O 
chelators O 
NOTA B-ABBREVIATION 
and O 
DOTA B-ABBREVIATION 
is O 
decreased O 
at O 
lower O 
metal O 
ion O 
contaminant O 
concentrations O 
compared O 
with O 
phosphinate B-SYSTEMATIC 
-type O 
chelators O 
TRAP B-ABBREVIATION 
and O 
NOPO B-ABBREVIATION 
. O 
The O 
latter O 
are O 
able O 
to O 
rapidly O 
exchange O 
coordinated O 
Zn B-FORMULA 
(II) I-FORMULA 
with O 
( B-FORMULA 
68 I-FORMULA 
) I-FORMULA 
Ga(3+) I-FORMULA 
, O 
as O 
confirmed O 
by O 
mass O 
spectrometry O 
and O 
( B-FORMULA 
31 I-FORMULA 
) I-FORMULA 
P I-FORMULA 
NMR O 
spectroscopy O 
. O 
( B-FORMULA 
68 I-FORMULA 
) I-FORMULA 
Ga I-FORMULA 
labeling O 
of O 
Zn B-FORMULA 
(II) I-FORMULA 
complexes O 
of O 
TRAP B-ABBREVIATION 
and O 
NOPO B-ABBREVIATION 
proceeds O 
as O 
efficient O 
as O 
labeling O 
of O 
neat O 
NOTA B-ABBREVIATION 
; O 
this O 
applies O 
also O 
to O 
the O 
corresponding O 
peptide O 
conjugates O 
of O 
these O 
chelators O 
. O 
This O 
behavior O 
results O 
in O 
substantially O 
improved O 
selectivity O 
for O 
Ga(3+) B-FORMULA 
and O 
, O 
therefore O 
, O 
in O 
more O 
robust O 
and O 
reliable O 
( B-FORMULA 
68 I-FORMULA 
) I-FORMULA 
Ga I-FORMULA 
labeling O 
procedures O 
. O 
In O 
addition O 
, O 
none O 
of O 
the O 
investigated O 
chelators O 
binds O 
( B-FORMULA 
68 I-FORMULA 
) I-FORMULA 
Ge I-FORMULA 
, O 
rendering O 
post O 
- O 
labeling O 
purification O 
protocols O 
, O 
for O 
example O 
, O 
solid O 
- O 
phase O 
extraction O 
, O 
a O 
reliable O 
means O 
of O 
removal O 
of O 
( B-FORMULA 
68 I-FORMULA 
) I-FORMULA 
Ge I-FORMULA 
contamination O 
from O 
( B-FORMULA 
68 I-FORMULA 
) I-FORMULA 
Ga I-FORMULA 
radiopharmaceuticals O 
. O 

of O 
Progranulin O 
( O 
PGRN O 
) O 
, O 
a O 
gene O 
encoding O 
a O 
secreted O 
glycoprotein O 
, O 
is O 
a O 
major O 
cause O 
of O 
frontotemporal O 
lobar O 
degeneration O 
with O 
ubiquitin O 
( O 
FTLD-U O 
) O 
positive O 
inclusions O 
. O 
Single O 
nucleotide B-FAMILY 
polymorphisms O 
in O 
the O 
TMEM106B O 
gene O 
were O 
recently O 
discovered O 
as O 
a O 
risk O 
factor O 
for O 
FTLD-U O 
, O 
especially O 
in O 
patients O 
with O 
PGRN O 
mutations O 
. O 
TMEM106B O 
is O 
also O 
associated O 
with O 
cognitive O 
impairment O 
in O 
amyotrophic O 
lateral O 
sclerosis O 
patients O 
. O 
Despite O 
these O 
studies O 
, O 
little O 
is O 
known O 
about O 
TMEM106B O 
at O 
molecular O 
and O 
cellular O 
levels O 
and O 
how O 
TMEM106B O 
contributes O 
to O 
FTLD O 
. O 
Here O 
, O 
we O 
show O 
that O 
TMEM106B O 
is O 
localized O 
in O 
the O 
late O 
endosome O 
/ O 
lysosome O 
compartments O 
and O 
TMEM106B O 
levels O 
are O 
regulated O 
by O 
lysosomal O 
activities O 
. O 
Ectopic O 
expression O 
of O 
TMEM106B O 
induces O 
morphologic O 
changes O 
of O 
lysosome O 
compartments O 
and O 
delays O 
the O 
degradation O 
of O 
endocytic O 
cargoes O 
by O 
the O 
endolysosomal O 
pathway O 
. O 
Furthermore O 
, O 
overexpression O 
of O 
TMEM106B O 
correlates O 
with O 
elevated O 
levels O 
of O 
PGRN O 
, O 
possibly O 
by O 
attenuating O 
lysosomal O 
degradation O 
of O 
PGRN O 
. O 
These O 
results O 
shed O 
light O 
on O 
the O 
cellular O 
functions O 
of O 
TMEM106B O 
and O 
the O 
roles O 
of O 
TMEM106B O 
in O 
the O 
pathogenesis O 
of O 
FTLD-U O 
with O 
PGRN O 
mutations O 
. O 

- O 
dose O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
toxicity O 
cannot O 
be O 
prevented O 
by O 
the O 
co O 
- O 
administration O 
of O 
pharmacological O 
levels O 
of O 
epigallocatechin-3-gallate B-SYSTEMATIC 
which O 
in O 
turn O 
aggravates O 
the O 
toxicity O 
. O 

, O 
an O 
essential O 
trace O 
element O 
, O 
can O 
also O 
be O 
toxic O 
at O 
higher O 
levels O 
of O 
exposure O 
. O 
Several O 
lines O 
of O 
evidence O 
show O 
epigallocatechin-3-gallate B-SYSTEMATIC 
( O 
EGCG B-ABBREVIATION 
) O 
, O 
a O 
predominant O 
component O 
of O 
green O 
tea O 
catechins B-FAMILY 
with O 
numerous O 
health O 
benefits O 
, O 
can O 
ameliorate O 
the O 
toxicity O 
of O 
many O 
agents O 
. O 
A O 
proof O 
- O 
in O 
- O 
principle O 
experiment O 
was O 
conducted O 
to O 
determine O 
if O 
EGCG B-ABBREVIATION 
would O 
ameliorate O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
-induced O 
growth O 
suppression O 
. O 
Mice O 
were O 
intraperitioneally O 
injected O 
with O 
selenite B-TRIVIAL 
once O 
daily O 
for O 
five O 
days O 
at O 
a O 
dose O 
of O 
3 O 
mg O 
Se B-FORMULA 
/ O 
kg O 
, O 
which O 
fully O 
suppressed O 
animal O 
growth O 
but O 
did O 
not O 
cause O 
death O 
. O 
Surprisingly O 
the O 
co O 
- O 
administration O 
of O 
the O 
selenite B-TRIVIAL 
and O 
nontoxic O 
doses O 
of O 
EGCG B-ABBREVIATION 
( O 
10 O 
, O 
20 O 
and O 
40 O 
mg O 
/ O 
kg O 
, O 
intraperitioneally O 
) O 
resulted O 
in O 
the O 
mortality O 
of O 
treated O 
mice O 
in O 
a O 
dose O 
and O 
time O 
- O 
dependent O 
manner O 
( O 
33.3% O 
, O 
100% O 
and O 
100% O 
, O 
respectively O 
) O 
. O 
EGCG B-ABBREVIATION 
- O 
selenite B-TRIVIAL 
induced O 
lethality O 
did O 
not O 
result O 
from O 
enhanced O 
selenium B-SYSTEMATIC 
accumulation O 
but O 
appeared O 
to O 
involve O 
the O 
suppression O 
of O 
a O 
selenite B-TRIVIAL 
-induced O 
adaptive O 
response O 
as O 
evidenced O 
by O 
hepatic O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
activity O 
. O 
While O 
EGCG B-ABBREVIATION 
has O 
been O 
reported O 
to O 
ameliorate O 
the O 
toxicity O 
of O 
some O 
agents O 
, O 
the O 
induction O 
of O 
mortality O 
by O 
combined O 
treatment O 
with O 
pharmacological O 
doses O 
of O 
selenium B-SYSTEMATIC 
and O 
EGCG B-ABBREVIATION 
is O 
a O 
previously O 
unrecognized O 
synergism O 
that O 
must O 
be O 
considered O 
not O 
only O 
in O 
the O 
remediation O 
of O 
high O 
environmental O 
selenium B-SYSTEMATIC 
exposures O 
but O 
also O 
in O 
the O 
development O 
of O 
pharmaceuticals O 
and O 
nutriceuticals O 
. O 

Keli O 
( O 
constitutes O 
of O 
Root O 
of O 
Codonopsis O 
pilosula O 
, O 
Rhizoma O 
Atractylodis O 
Macrocephalae O 
, O 
Rhizoma O 
Curcumae O 
Aeruginosae O 
, O 
Rhizoma O 
Pinelliae O 
, O 
Actinidia O 
chinensis O 
Planch O 
, O 
and O 
Rhodiola O 
rosea O 
) O 
is O 
a O 
well O 
known O 
Chinese O 
herbal O 
formula O 
for O 
gastric O 
cancer O 
therapy O 
in O 
clinical O 
treatment O 
. O 
However O 
, O 
the O 
detailed O 
molecular O 
mechanisms O 
involved O 
are O 
still O 
not O 
fully O 
understood O 
. O 
In O 
this O 
study O 
, O 
we O 
found O 
that O 
Weikang O 
Keli O 
could O 
induce O 
patterns O 
of O 
autophagy O 
in O 
SGC-7901 O 
cells O 
, O 
including O 
intracellular O 
vacuole O 
formation O 
, O 
microtubule O 
- O 
associated O 
protein O 
1 O 
light O 
chain O 
3 O 
( O 
LC3 O 
) O 
conversion O 
. O 
Hoechst B-TRIVIAL 
33258 I-TRIVIAL 
staining O 
and O 
Western O 
blot O 
analysis O 
of O 
apoptosis O 
- O 
related O 
proteins O 
showed O 
that O 
WK O 
induced O 
SGC-7901 O 
cell O 
death O 
was O 
not O 
through O 
apoptosis O 
. O 
In O 
vivo O 
study O 
also O 
revealed O 
that O 
i.g O 
. O 
administration O 
of O 
Weikang O 
Keli O 
once O 
a O 
day O 
for O 
25 O 
days O 
could O 
significantly O 
reduce O 
tumor O 
volumes O 
by O 
about O 
50% O 
. O 
Collectively O 
, O 
the O 
current O 
data O 
indicated O 
that O 
Weikang O 
Keli O 
induced O 
gastric O 
cancer O 
cell O 
death O 
by O 
autophagy O 
effects O 
. O 

visceral O 
hyperalgesia O 
effect O 
of O 
Kangtai O 
capsule O 
and O 
its O 
potential O 
mechanisms O 
via O 
modulating O 
the O 
5-HT B-SYSTEMATIC 
and O 
NO B-FORMULA 
level O 
in O 
vivo O 
. O 

capsule O 
( O 
KT O 
) O 
is O 
one O 
type O 
of O 
traditional O 
Chinese O 
medicine O 
preparation O 
derived O 
from O 
the O 
proved O 
recipe O 
, O 
which O 
was O 
frequently O 
applied O 
as O 
an O 
effective O 
clinical O 
treatment O 
of O 
IBS O 
. O 
However O 
, O 
there O 
still O 
lack O 
the O 
reasonable O 
and O 
all O 
- O 
round O 
analytical O 
approach O 
and O 
the O 
scientific O 
studies O 
on O 
its O 
underlying O 
mechanisms O 
. O 
Therefore O 
, O 
our O 
study O 
aimed O 
to O 
develop O 
the O 
novel O 
method O 
for O 
evaluating O 
its O 
quality O 
as O 
well O 
as O 
to O 
interpret O 
the O 
potential O 
mechanisms O 
. O 
In O 
our O 
study O 
, O 
high O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
fingerprint O 
was O 
applied O 
to O 
provide O 
a O 
chemical O 
profile O 
of O 
KT O 
. O 
The O 
neonatal O 
maternal O 
separation O 
( O 
NMS O 
) O 
on O 
Sprague-Dawley O 
pups O 
was O 
employed O 
to O 
evaluate O 
the O 
therapeutic O 
effect O 
of O 
KT O 
by O 
virtue O 
of O 
various O 
parameters O 
including O 
visceral O 
hyperalgesia O 
, O 
serum O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
level O 
, O 
and O 
tissue O 
5-hydroxytryptamine B-SYSTEMATIC 
( O 
5-HT B-SYSTEMATIC 
) O 
level O 
. O 
Consequently O 
, O 
a O 
chromatographic O 
condition O 
, O 
which O 
was O 
carried O 
at O 
30°C O 
with O 
a O 
flow O 
rate O 
of O 
0.5 O 
ml O 
/ O 
min O 
on O 
AQUA O 
3μ O 
C18 O 
column O 
with O 
mobile O 
phase O 
of O 
acetonitrile B-SYSTEMATIC 
and O 
water- O 
phosphoric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
100 O 
: O 
0.1 O 
, O 
v O 
/ O 
v O 
) O 
, O 
was O 
established O 
to O 
give O 
a O 
common O 
fingerprint O 
chromatography O 
under O 
254 O 
nm O 
with O 
a O 
similarity O 
index O 
of O 
0.963 O 
within O 
ten O 
batches O 
of O 
KT O 
samples O 
. O 
On O 
the O 
NMS O 
model O 
, O 
KT O 
markedly O 
elevated O 
the O 
pain O 
threshold O 
of O 
NMS O 
rats O 
. O 
Furthermore O 
, O 
KT O 
at O 
three O 
doses O 
significantly O 
decreased O 
5-HT B-SYSTEMATIC 
content O 
from O 
distal O 
colon O 
of O 
visceral O 
hyperalgesia O 
rats O 
induced O 
by O 
NMS O 
, O 
while O 
the O 
significant O 
decrease O 
of O 
5-HT B-SYSTEMATIC 
content O 
in O 
serum O 
was O 
only O 
observed O 
in O 
the O 
group O 
with O 
KT O 
at O 
high O 
dose O 
. O 
However O 
, O 
compared O 
with O 
that O 
in O 
NMS O 
rats O 
without O 
KT O 
, O 
there O 
was O 
no O 
apparent O 
difference O 
of O 
5-HT B-SYSTEMATIC 
level O 
from O 
brain O 
issue O 
in O 
the O 
rats O 
with O 
various O 
doses O 
. O 
Besides O 
, O 
KT O 
could O 
substantially O 
elevate O 
the O 
concentration O 
of O 
NO B-FORMULA 
in O 
the O 
serum O 
. O 
The O 
results O 
showed O 
our O 
study O 
developed O 
the O 
simple O 
, O 
rapid O 
, O 
accurate O 
, O 
reproducible O 
qualitative O 
and O 
quantitative O 
analysis O 
by O 
HPLC O 
fingerprint O 
for O 
the O 
quality O 
control O 
for O 
KT O 
. O 
Data O 
from O 
the O 
pharmacological O 
investigation O 
suggested O 
that O 
the O 
curative O 
effect O 
of O 
KT O 
to O 
the O 
visceral O 
hypersensitivity O 
may O 
be O 
concerned O 
with O 
the O 
level O 
of O 
5-HT B-SYSTEMATIC 
and O 
NO B-FORMULA 
in O 
vivo O 
, O 
promising O 
its O 
potential O 
in O 
irritable O 
bowel O 
syndrome O 
treatment O 
. O 

report O 
of O 
the O 
use O 
of O 
a O 
saxitoxin B-TRIVIAL 
-protein O 
conjugate O 
to O 
develop O 
a O 
DNA O 
aptamer O 
to O 
a O 
small O 
molecule O 
toxin O 
. O 

( O 
STX B-ABBREVIATION 
) O 
is O 
a O 
low O 
molecular O 
weight O 
neurotoxin O 
mainly O 
produced O 
by O 
certain O 
marine O 
dinoflagellates O 
that O 
, O 
along O 
with O 
its O 
family O 
of O 
similarly O 
related O 
paralytic O 
shellfish O 
toxins O 
, O 
may O 
cause O 
the O 
potentially O 
fatal O 
intoxication O 
known O 
as O 
paralytic O 
shellfish O 
poisoning O 
. O 
Illness O 
and O 
fatality O 
rates O 
are O 
low O 
due O 
to O 
the O 
effective O 
monitoring O 
programs O 
that O 
determine O 
when O 
toxins O 
exceed O 
the O 
established O 
regulatory O 
action O 
level O 
and O 
effectuate O 
shellfish O 
harvesting O 
closures O 
accordingly O 
. O 
Such O 
monitoring O 
programs O 
rely O 
on O 
the O 
ability O 
to O 
rapidly O 
screen O 
large O 
volumes O 
of O 
samples O 
. O 
Many O 
of O 
the O 
screening O 
assays O 
currently O 
available O 
employ O 
antibodies O 
or O 
live O 
animals O 
. O 
This O 
research O 
focused O 
on O 
developing O 
an O 
analytical O 
recognition O 
element O 
that O 
would O 
eliminate O 
the O 
challenges O 
associated O 
with O 
the O 
limited O 
availability O 
of O 
antibodies O 
and O 
the O 
use O 
of O 
animals O 
. O 
Here O 
we O 
report O 
the O 
discovery O 
of O 
a O 
DNA O 
aptamer O 
that O 
targets O 
STX B-ABBREVIATION 
. O 
Concentration O 
- O 
dependent O 
and O 
selective O 
binding O 
of O 
the O 
aptamer O 
to O 
STX B-ABBREVIATION 
was O 
determined O 
using O 
a O 
surface O 
plasmon O 
resonance O 
sensor O 
. O 
Not O 
only O 
does O 
this O 
work O 
represent O 
the O 
first O 
reported O 
aptamer O 
to O 
STX B-ABBREVIATION 
, O 
but O 
also O 
the O 
first O 
aptamer O 
to O 
any O 
marine O 
biotoxin O 
. O 
A O 
novel O 
strategy O 
of O 
using O 
a O 
toxin O 
- O 
protein O 
conjugate O 
for O 
DNA O 
aptamer O 
selection O 
was O 
successfully O 
implemented O 
to O 
overcome O 
the O 
challenges O 
associated O 
with O 
aptamer O 
selection O 
to O 
small O 
molecules O 
. O 
Taking O 
advantage O 
of O 
such O 
an O 
approach O 
could O 
lead O 
to O 
increased O 
diversity O 
and O 
accessibility O 
of O 
aptamers O 
to O 
low O 
molecular O 
weight O 
toxins O 
, O 
which O 
could O 
then O 
be O 
incorporated O 
as O 
analytical O 
recognition O 
elements O 
in O 
diagnostic O 
assays O 
for O 
foodborne O 
toxin O 
detection O 
. O 
The O 
selected O 
STX B-ABBREVIATION 
aptamer O 
sequence O 
is O 
provided O 
here O 
, O 
making O 
it O 
available O 
to O 
any O 
investigator O 
for O 
use O 
in O 
assay O 
development O 
for O 
the O 
detection O 
of O 
STX B-ABBREVIATION 
. O 

for O 
the O 
treatment O 
of O 
retinal B-TRIVIAL 
and O 
optic O 
nerve O 
diseases O 
. O 

earliest O 
impact O 
of O 
nanomedicine O 
in O 
ophthalmology O 
is O 
likely O 
to O 
involve O 
the O 
areas O 
of O 
biopharmaceuticals O 
, O 
implantable O 
materials O 
( O 
e.g O 
. O 
tissue O 
regeneration O 
scaffolds O 
, O 
bioresorbable O 
materials O 
) O 
, O 
implantable O 
devices O 
( O 
e.g O 
. O 
glaucoma O 
drainage O 
valves O 
) O 
, O 
and O 
diagnostic O 
tools O 
( O 
e.g O 
. O 
intraocular O 
pressure O 
( O 
IOP O 
) O 
monitors O 
) O 
. O 
Nanotechnology O 
will O 
bring O 
about O 
the O 
development O 
of O 
regenerative O 
medicine O 
( O 
i.e O 
. O 
replacement O 
and O 
improvement O 
of O 
cells O 
, O 
tissues O 
, O 
and O 
organs O 
) O 
and O 
artificial O 
vision O 
. O 
In O 
this O 
chapter O 
, O 
we O 
review O 
ophthalmic O 
applications O 
of O 
nanotechnology O 
in O 
the O 
following O 
areas O 
: O 
drug O 
and O 
trophic O 
factor O 
therapy O 
for O 
glaucoma O 
, O 
retinal O 
degenerative O 
, O 
and O 
retinal O 
vascular O 
disease O 
; O 
gene O 
therapy O 
for O 
retinal B-TRIVIAL 
degenerative O 
disease O 
; O 
regenerative O 
medicine O 
, O 
including O 
optogenetics O 
and O 
optic O 
nerve O 
regeneration O 
; O 
and O 
diagnostics O 
( O 
minimally O 
invasive O 
IOP O 
monitoring O 
) O 
. O 
Nanotechnology O 
will O 
play O 
an O 
important O 
role O 
in O 
both O 
early O 
- O 
stage O 
and O 
late O 
- O 
stage O 
intervention O 
in O 
the O 
management O 
of O 
blinding O 
diseases O 
. O 

is O 
growing O 
interest O 
on O 
the O 
correlation O 
among O 
oxidative O 
stress O 
, O 
inflammation O 
, O 
apoptosis O 
and O 
primary O 
open O 
- O 
angle O 
glaucoma O 
initiation O 
and O 
progression O 
. O 
Reactive O 
oxygen B-SYSTEMATIC 
species O 
are O 
formed O 
in O 
the O 
eyes O 
following O 
a O 
wide O 
variety O 
of O 
stressors O 
, O 
and O 
are O 
largely O 
implicated O 
in O 
glaucoma O 
pathogenesis O 
. O 
Immune O 
- O 
inflammatory O 
response O 
mediators O 
have O 
recently O 
become O 
a O 
target O 
of O 
ophthalmologic O 
concern O 
, O 
including O 
glaucoma O 
. O 
Much O 
attention O 
has O 
been O 
derived O 
to O 
the O 
role O 
of O 
specific O 
pro O 
and O 
anti-apoptotic O 
molecules O 
in O 
glaucoma O 
. O 
This O 
article O 
reviews O 
the O 
early O 
evidence O 
suggesting O 
that O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
immune O 
inflammatory O 
response O 
mediators O 
, O 
and O 
apoptogenic O 
molecules O 
are O 
engaged O 
in O 
glaucoma O 
disease O 
. O 
Moreover O 
, O 
further O 
research O 
concerning O 
the O 
functions O 
, O 
effectors O 
and O 
signaling O 
pathways O 
of O 
the O 
above O 
molecules O 
and O 
their O 
interactions O 
, O 
may O 
lead O 
to O 
specifically O 
develop O 
targeted O 
screening O 
tools O 
based O 
on O 
presumptive O 
biomarkers O 
and O 
surrogate O 
endpoints O 
against O 
primary O 
open O 
- O 
angle O 
glaucoma O 
progression O 
and O 
blindness O 
. O 

in O 
androgen B-FAMILY 
sensitivity O 
contributes O 
to O 
population O 
differences O 
in O 
sexual O 
dimorphism O 
of O 
electrocommunication O 
behavior O 
. O 

- O 
electric O 
fish O 
( O 
Apteronotidae O 
) O 
produce O 
highly O 
diverse O 
electrocommunication O 
signals O 
. O 
Electric O 
organ O 
discharges O 
( O 
EODs O 
) O 
vary O 
across O 
species O 
, O 
sexes O 
, O 
and O 
in O 
the O 
magnitude O 
and O 
direction O 
of O 
their O 
sexual O 
dimorphism O 
. O 
Gonadal O 
steroid O 
hormones O 
can O 
modulate O 
EODs O 
, O 
and O 
differences O 
in O 
androgen B-FAMILY 
sensitivity O 
are O 
hypothesized O 
to O 
underlie O 
variation O 
in O 
the O 
degree O 
of O 
sexual O 
dimorphism O 
across O 
species O 
. O 
In O 
this O 
study O 
, O 
we O 
asked O 
whether O 
variation O 
in O 
androgen B-FAMILY 
sensitivity O 
explained O 
variation O 
in O 
sexual O 
dimorphism O 
of O 
EODs O 
within O 
species O 
, O 
at O 
the O 
population O 
level O 
. O 
We O 
examined O 
two O 
populations O 
of O 
black O 
ghost O 
knifefish O 
( O 
Apteronotus O 
albifrons O 
) O 
, O 
one O 
from O 
the O 
Orinoco O 
and O 
the O 
other O 
from O 
the O 
Amazon O 
River O 
Basin O 
. O 
EOD O 
frequency O 
( O 
EODf O 
) O 
and O 
chirp O 
rates O 
were O 
measured O 
to O 
characterize O 
diversity O 
in O 
sexual O 
dimorphism O 
across O 
populations O 
. O 
The O 
magnitude O 
of O 
sexual O 
dimorphism O 
in O 
EODf O 
differed O 
significantly O 
across O 
populations O 
, O 
and O 
was O 
more O 
pronounced O 
in O 
the O 
Orinoco O 
population O 
than O 
in O 
the O 
Amazon O 
population O 
. O 
Chirp O 
rates O 
were O 
sexually O 
monomorphic O 
in O 
both O 
populations O 
. O 
11-Ketotestosterone B-SYSTEMATIC 
( O 
11-kT B-SYSTEMATIC 
) O 
was O 
administered O 
over O 
a O 
two O 
- O 
week O 
period O 
to O 
assess O 
population O 
differences O 
in O 
sensitivity O 
to O 
androgens B-FAMILY 
. O 
11-kT B-SYSTEMATIC 
masculinized O 
EODf O 
significantly O 
more O 
in O 
the O 
population O 
with O 
the O 
greater O 
degree O 
of O 
sexual O 
dimorphism O 
. O 
11-kT B-SYSTEMATIC 
had O 
no O 
effect O 
on O 
the O 
sexually O 
monomorphic O 
chirping O 
rates O 
. O 
We O 
conclude O 
that O 
population O 
divergence O 
in O 
androgen B-FAMILY 
sensitivity O 
contributes O 
to O 
variation O 
in O 
sexual O 
dimorphism O 
of O 
EODf O 
in O 
A O 
. O 
albifrons O 
. O 

enzymes O 
in O 
Russell's O 
viper O 
( O 
Daboia O 
siamensis O 
) O 
venom O 
are O 
involved O 
in O 
the O 
venom O 
effects O 
and O 
renal O 
injury O 
. O 
The O 
effects O 
of O 
fractional O 
components O 
of O 
Russell's O 
viper O 
venom O 
, O 
phospholipase O 
A(2) O 
and O 
metalloprotease O 
fractions O 
, O 
were O 
examined O 
in O 
two O 
groups O 
of O 
four O 
experimental O 
dogs O 
each O 
. O 
Animals O 
received O 
an O 
intravenous O 
injection O 
of O 
140 O 
μg O 
/ O 
kg O 
of O 
each O 
venom O 
fraction O 
. O 
The O 
inflammatory O 
effects O 
and O 
renal O 
hemodynamic O 
changes O 
were O 
assessed O 
. O 
Plasma O 
concentrations O 
of O 
interleukin-6 O 
( O 
IL-6 O 
) O 
, O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
and O 
PGE2 B-ABBREVIATION 
were O 
elevated O 
by O 
both O 
phospholipase O 
A(2) O 
(PLA(2)) O 
and O 
metalloprotease O 
( O 
MP O 
) O 
fractions O 
. O 
The O 
plasma O 
level O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
was O 
increased O 
after O 
PLA(2) O 
fraction O 
injection O 
but O 
not O 
with O 
MP O 
fraction O 
injection O 
. O 
Leukocytosis O 
with O 
increase O 
in O 
lymphocytes O 
, O 
monocytes O 
and O 
granulocytes O 
was O 
observed O 
after O 
both O 
PLA(2) O 
and O 
MP O 
injections O 
. O 
Results O 
from O 
this O 
study O 
suggested O 
that O 
both O 
PLA(2) O 
and O 
MP O 
were O 
inflammatory O 
. O 
Increased O 
red O 
blood O 
cell O 
count O 
, O 
hematocrit O 
and O 
hemoglobin O 
concentration O 
were O 
observed O 
in O 
animals O 
injected O 
with O 
PLA(2) O 
fraction O 
, O 
but O 
not O 
with O 
MP O 
fraction O 
. O 
Hemodynamically O 
, O 
PLA(2) O 
fraction O 
induced O 
marked O 
decrease O 
in O 
mean O 
arterial O 
pressure O 
with O 
decreased O 
renal O 
vascular O 
resistance O 
initially O 
followed O 
later O 
by O 
increased O 
renal O 
vascular O 
resistance O 
. O 
MP O 
fraction O 
caused O 
less O 
decrease O 
of O 
mean O 
arterial O 
pressure O 
but O 
increased O 
renal O 
vascular O 
resistance O 
throughout O 
the O 
experiment O 
. O 
Both O 
enzymes O 
decreased O 
renal O 
blood O 
flow O 
, O 
glomerular O 
filtration O 
rate O 
and O 
urine O 
flow O 
. O 
The O 
findings O 
indicate O 
vasodilating O 
effect O 
of O 
PLA(2) O 
fraction O 
and O 
vasoconstricting O 
effect O 
and O 
decreased O 
cardiac O 
function O 
of O 
MP O 
fraction O 
. O 

( O 
HmTx O 
) O 
is O 
a O 
group O 
III O 
phospholipase O 
A(2) O 
produced O 
in O 
Heterometrus O 
laoticus O 
, O 
in O 
Thailand O 
. O 
In O 
this O 
study O 
, O 
HmTx O 
was O 
purified O 
from O 
venom O 
by O 
separation O 
chromatography O 
, O 
and O 
the O 
PLA(2) O 
activity O 
of O 
the O 
fractions O 
was O 
determined O 
by O 
lecithin O 
agar O 
assay O 
. O 
The O 
enzyme O 
is O 
an O 
acidic O 
protein O 
with O 
a O 
pI O 
of O 
5.6 O 
and O 
an O 
apparent O 
molecular O 
weight O 
of O 
14018.4 O 
Da O 
. O 
The O 
nucleotide B-FAMILY 
sequence O 
of O 
HmTx O 
contains O 
649 O 
bp O 
, O 
and O 
the O 
mature O 
protein O 
is O 
predicted O 
to O 
have O 
131 O 
amino B-FAMILY 
acid I-FAMILY 
residues-104 O 
of O 
which O 
make O 
up O 
the O 
large O 
subunit O 
, O 
and O 
27 O 
of O 
which O 
make O 
up O 
the O 
small O 
subunit O 
. O 
The O 
subunit O 
structure O 
of O 
HmTx O 
is O 
highly O 
similar O 
to O 
that O 
of O 
the O 
other O 
toxin O 
, O 
Pandinus O 
imperator O 
imperatoxin O 
I O 
(IpTx(i)) O 
and O 
to O 
Mesobuthus O 
tamulus O 
phospholipase O 
A(2) O 
(MtPLA(2)) O 
. O 
The O 
3D-structure O 
of O 
HmTx O 
consists O 
of O 
three O 
conserved O 
alpha-helices O 
: O 
h1 O 
( O 
Lys B-FORMULA 
24- O 
His B-FORMULA 
34 O 
) O 
, O 
h2 O 
( O 
Cys B-FORMULA 
59- O 
Asp B-FORMULA 
71 O 
) O 
, O 
and O 
h3 O 
( O 
Ala B-FORMULA 
80- O 
Phe B-FORMULA 
89 O 
) O 
. O 
The O 
beta-sheet O 
consisted O 
of O 
a O 
single O 
stranded O 
anti-parallel O 
beta-sheet O 
( O 
b1.1 O 
at O 
Glu B-FORMULA 
43- O 
Lys B-FORMULA 
45 O 
and O 
b1.2 O 
at O 
Lys B-FORMULA 
48- O 
Asn B-FORMULA 
50 O 
) O 
that O 
was O 
highly O 
similar O 
to O 
the O 
conserved O 
sequences O 
( O 
-CGXG- O 
, O 
-CCXXHDXC- O 
and O 
CXCEXXXXXC- O 
) O 
of O 
Apis O 
mellifera O 
( O 
bee O 
) O 
phospholipases O 
. O 

damage O 
tolerance O 
consisting O 
of O 
template O 
switching O 
and O 
translesion O 
synthesis O 
is O 
a O 
major O 
cellular O 
mechanism O 
in O 
response O 
to O 
unrepaired O 
DNA O 
lesions O 
during O 
replication O 
. O 
The O 
Rev1 O 
pathway O 
constitutes O 
the O 
major O 
mechanism O 
of O 
translesion O 
synthesis O 
and O 
base O 
damage O 
- O 
induced O 
mutagenesis O 
in O 
model O 
cell O 
systems O 
. O 
Rev1 O 
is O 
a O 
dCMP B-ABBREVIATION 
transferase O 
, O 
but O 
additionally O 
plays O 
non-catalytic O 
functions O 
in O 
translesion O 
synthesis O 
. O 
Using O 
the O 
yeast O 
model O 
system O 
, O 
we O 
attempted O 
to O 
gain O 
further O 
insights O 
into O 
the O 
non-catalytic O 
functions O 
of O 
Rev1 O 
. O 
Rev1 O 
stably O 
interacts O 
with O 
Rad5 O 
( O 
a O 
central O 
component O 
of O 
the O 
template O 
switching O 
pathway O 
) O 
via O 
the O 
C B-FORMULA 
-terminal O 
region O 
of O 
Rev1 O 
and O 
the O 
N B-FORMULA 
-terminal O 
region O 
of O 
Rad5 O 
. O 
Supporting O 
functional O 
significance O 
of O 
this O 
interaction O 
, O 
both O 
the O 
Rev1 O 
pathway O 
and O 
Rad5 O 
are O 
required O 
for O 
translesion O 
synthesis O 
and O 
mutagenesis O 
of O 
1,N(6)-ethenoadenine B-SYSTEMATIC 
. O 
Furthermore O 
, O 
disrupting O 
the O 
Rev1-Rad5 O 
interaction O 
by O 
mutating O 
Rev1 O 
did O 
not O 
affect O 
its O 
dCMP B-ABBREVIATION 
transferase O 
, O 
but O 
led O 
to O 
inactivation O 
of O 
the O 
Rev1 O 
non-catalytic O 
function O 
in O 
translesion O 
synthesis O 
of O 
UV-induced O 
DNA O 
damage O 
. O 
Deletion O 
analysis O 
revealed O 
that O 
the O 
C B-FORMULA 
-terminal O 
21- O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
of O 
Rev1 O 
is O 
uniquely O 
required O 
for O 
its O 
interaction O 
with O 
Rad5 O 
and O 
is O 
essential O 
for O 
its O 
non-catalytic O 
function O 
. O 
Deletion O 
analysis O 
additionally O 
implicated O 
a O 
C B-FORMULA 
-terminal O 
region O 
of O 
Rev1 O 
in O 
its O 
negative O 
regulation O 
. O 
These O 
results O 
show O 
that O 
a O 
non-catalytic O 
function O 
of O 
Rev1 O 
in O 
translesion O 
synthesis O 
and O 
mutagenesis O 
is O 
mediated O 
by O 
its O 
interaction O 
with O 
Rad5 O 
. O 

was O 
recently O 
suggested O 
that O 
the O 
non-neuronal O 
cholinergic O 
system O 
has O 
a O 
regulatory O 
role O 
in O 
pulmonary O 
inflammation O 
. O 
We O 
investigated O 
this O 
system's O 
involvement O 
in O 
the O 
control O 
of O 
cytokine O 
production O 
by O 
the O 
A549 O 
human O 
alveolar O 
epithelial O 
cell O 
line O 
. O 
CXCL8 O 
and O 
acetylcholine B-SYSTEMATIC 
( O 
ACh B-ABBREVIATION 
) O 
concentrations O 
were O 
measured O 
using O 
ELISA O 
and O 
LC-MS O 
/ O 
MS O 
, O 
respectively O 
. O 
The O 
mRNA O 
expression O 
of O 
muscarinic O 
receptor O 
( O 
MR O 
) O 
subtypes O 
was O 
determined O 
using O 
RT-PCR O 
. O 
In O 
A549 O 
cells O 
, O 
TNF-α O 
increased O 
the O 
release O 
of O 
CXCL8 O 
and O 
ACh B-ABBREVIATION 
and O 
the O 
expression O 
of O 
the O 
subtype O 
3 O 
MR O 
( O 
M3R O 
) O 
. O 
Furthermore O 
, O 
TNF-α-induced O 
CXCL8 O 
secretion O 
was O 
(i) O 
inhibited O 
by O 
the O 
MR O 
antagonist O 
tiotropium B-TRIVIAL 
and O 
the O 
M3R O 
antagonist O 
4-DAMP B-SYSTEMATIC 
and O 
(ii) O 
enhanced O 
by O 
the O 
M1 O 
/ O 
M3R O 
agonist O 
pilocarpine B-TRIVIAL 
and O 
the O 
cholinesterase O 
inhibitor O 
physostigmine B-TRIVIAL 
. O 
Taken O 
as O 
a O 
whole O 
, O 
these O 
results O 
suggest O 
that O 
ACh B-ABBREVIATION 
release O 
by O 
A549 O 
cells O 
enhances O 
TNF-α-induced O 
CXCL8 O 
secretion O 
through O 
activation O 
of O 
the O 
M3R O 
. O 
Western O 
blot O 
analysis O 
revealed O 
that O 
pilocarpine B-TRIVIAL 
and O 
physostigmine B-TRIVIAL 
enhanced O 
the O 
TNF-α-induced O 
phosphorylation O 
of O 
ERK1 O 
/ O 
2 O 
and O 
p38 O 
MAPK O 
and O 
the O 
degradation O 
of O 
IκBα O 
. O 
Inhibition O 
of O 
these O 
pathways O 
with O 
specific O 
inhibitors O 
abrogated O 
the O 
pilocarpine B-TRIVIAL 
-induced O 
CXCL8 O 
release O 
. O 
Our O 
results O 
suggest O 
that O 
the O 
TNF-α-induced O 
secretion O 
of O 
CXCL8 O 
in O 
A549 O 
cells O 
is O 
regulated O 
by O 
the O 
release O 
of O 
ACh B-ABBREVIATION 
, O 
the O 
latter's O 
binding O 
to O 
the O 
M3R O 
and O 
the O 
downstream O 
activation O 
of O 
NF-κB O 
and O 
the O 
ERK1 O 
/ O 
2 O 
and O 
p38 O 
MAPK O 
signaling O 
pathways O 
. O 
Our O 
findings O 
suggest O 
that O 
MR O 
antagonists O 
may O 
have O 
anti-inflammatory O 
effects O 
by O 
preventing O 
pro O 
- O 
inflammatory O 
events O 
driven O 
by O 
endogenous O 
, O 
non-neuronal O 
ACh B-ABBREVIATION 
. O 

of O 
vitellogenin O 
gene O 
induction O 
by O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
is O 
mediated O 
by O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
2 O 
( O 
AHR2 O 
) O 
in O 
zebrafish O 
( O 
Danio O 
rerio O 
) O 
. O 

are O 
hepatically O 
derived O 
yolk O 
- O 
protein O 
precursors O 
required O 
for O 
oogenesis O 
in O 
all O 
oviparous O 
teleosts O 
. O 
Altered O 
gene O 
- O 
regulation O 
of O 
vitellogenesis O 
by O 
environmental O 
contaminants O 
can O 
have O 
profound O 
effects O 
on O 
reproductive O 
success O 
, O 
and O 
ultimately O 
population O 
sustainability O 
. O 
To O 
better O 
understand O 
chemical O 
effects O 
on O 
vitellogenin O 
gene O 
regulation O 
, O 
we O 
tested O 
the O 
hypothesis O 
that O 
activation O 
of O 
the O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
2 O 
( O 
AHR2 O 
) O 
by O 
dioxin B-FAMILY 
inhibits O 
the O 
estrogen B-FAMILY 
receptor O 
pathway O 
regulation O 
of O 
3 O 
vitellogenin O 
genes O 
( O 
vtg1-3 O 
) O 
in O 
vivo O 
, O 
using O 
zebrafish O 
( O 
Danio O 
rerio O 
) O 
as O 
a O 
model O 
teleost O 
. O 
Using O 
an O 
embryo O 
- O 
larval O 
bioassay O 
, O 
embryos O 
were O 
either O 
treated O 
with O 
1000 O 
pptr O 
( O 
parts O 
- O 
per O 
- O 
trillion O 
, O 
pg O 
/ O 
mL O 
) O 
17α-ethynylestradiol B-SYSTEMATIC 
( O 
EE2 B-ABBREVIATION 
) O 
alone O 
from O 
6h O 
post O 
fertilization O 
( O 
hpf O 
) O 
to O 
4 O 
days O 
post O 
fertilization O 
( O 
dpf O 
) O 
, O 
or O 
pre O 
- O 
treated O 
with O 
dioxin O 
( O 
4-5 O 
hpf O 
) O 
prior O 
to O 
EE2 B-ABBREVIATION 
. O 
Pre O 
- O 
treatment O 
with O 
400 O 
pptr O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
2,3,7,8-TCDD B-SYSTEMATIC 
) O 
or O 
1,2,3,7,8-pentachlorodibenzo-p-dioxin B-SYSTEMATIC 
inhibited O 
the O 
EE2 B-ABBREVIATION 
induction O 
of O 
vtg1 O 
, O 
vtg2 O 
and O 
vtg3 O 
by O 
> O 
95% O 
( O 
p≤0.05 O 
) O 
. O 
In O 
comparison O 
, O 
a O 
splice O 
- O 
blocking O 
AHR2 O 
morpholino O 
used O 
to O 
down O 
- O 
regulate O 
ahr2 O 
expression O 
significantly O 
reduced O 
the O 
inhibition O 
of O 
vtg1 O 
, O 
vtg2 O 
and O 
vtg3 O 
by O 
400 O 
pptr O 
2,3,7,8-TCDD B-SYSTEMATIC 
( O 
20.7-27.4% O 
rescue O 
) O 
. O 
These O 
studies O 
demonstrate O 
that O 
2,3,7,8-TCDD B-SYSTEMATIC 
directly O 
inhibits O 
the O 
vitellogenin O 
pathway O 
in O 
vivo O 
through O 
activation O 
of O 
the O 
AHR2 O 
. O 
This O 
work O 
provides O 
evidence O 
for O 
AHR2 O 
dependent O 
cross O 
- O 
talk O 
inhibition O 
of O 
vitellogenin O 
genes O 
and O 
offers O 
insight O 
into O 
anti-estrogenic O 
reproductive O 
effects O 
observed O 
in O 
oviparous O 
species O 
exposed O 
to O 
AHR O 
agonist O 
contaminants O 
. O 

of O 
octylphenol B-SYSTEMATIC 
and O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
on O 
the O 
expression O 
of O 
calcium B-SYSTEMATIC 
transport O 
genes O 
in O 
the O 
mouse O 
duodenum O 
and O 
kidney O 
during O 
pregnancy O 
. O 

( O 
OP O 
) O 
is O 
the O 
degradative O 
product O 
of O 
alkylphenol B-FAMILY 
ethoxylates I-FAMILY 
that O 
are O 
widely O 
used O 
to O 
produce O 
rubber O 
, O 
pesticides O 
, O 
and O 
paints O 
. O 
Bisphenol B-TRIVIAL 
A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
is O 
an O 
organic O 
compound O 
with O 
two O 
functional O 
phenol B-SYSTEMATIC 
groups O 
, O 
and O 
used O 
for O 
manufacturing O 
polycarbonate B-FAMILY 
plastic O 
and O 
epoxy B-SYSTEMATIC 
resins O 
, O 
as O 
well O 
as O 
other O 
applications O 
. O 
OP O 
and O 
BPA B-ABBREVIATION 
are O 
known O 
as O 
endocrine O 
disruptors O 
( O 
EDs O 
) O 
with O 
estrogenic O 
activities O 
, O 
and O 
may O 
disturb O 
natural O 
calcium B-SYSTEMATIC 
( O 
Ca B-FORMULA 
) O 
metabolism O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
effects O 
of O 
OP O 
and O 
BPA B-ABBREVIATION 
on O 
Ca B-FORMULA 
levels O 
in O 
the O 
serum O 
and O 
expression O 
of O 
Ca B-FORMULA 
transport O 
genes O 
in O 
the O 
duodenum O 
, O 
and O 
kidney O 
were O 
investigated O 
in O 
pregnant O 
mice O 
. O 
Calbindin O 
refers O 
to O 
several O 
Ca B-FORMULA 
-binding O 
proteins O 
originally O 
described O 
as O 
vitamin B-FAMILY 
D I-FAMILY 
-dependent O 
Ca B-FORMULA 
-binding O 
factors O 
in O 
the O 
intestine O 
, O 
and O 
kidney O 
of O 
birds O 
and O 
mammals O 
. O 
Transient O 
receptor O 
potential O 
cation O 
channel O 
, O 
subfamily O 
V O 
, O 
member O 
6 O 
( O 
TRPV6 O 
) O 
and O 
transient O 
receptor O 
potential O 
cation O 
channel O 
, O 
subfamily O 
V O 
, O 
member O 
5 O 
( O 
TRPV5 O 
) O 
are O 
Ca B-FORMULA 
entry O 
channels O 
responsible O 
for O 
Ca B-FORMULA 
absorption O 
in O 
the O 
kidney O 
and O 
intestine O 
, O 
respectively O 
. O 
From O 
6.5 O 
to O 
16.5 O 
day O 
post O 
coitus O 
( O 
dpc O 
) O 
, O 
pregnant O 
mice O 
were O 
given O 
oral O 
doses O 
of O 
17α-ethynylestradiol B-SYSTEMATIC 
( O 
EE O 
, O 
0.2mg O 
/ O 
kg O 
/ O 
day O 
) O 
, O 
BPA B-ABBREVIATION 
( O 
5 O 
or O 
50mg O 
/ O 
kg O 
/ O 
day O 
) O 
, O 
or O 
OP O 
( O 
3 O 
, O 
12 O 
, O 
or O 
48 O 
mg O 
/ O 
kg O 
/ O 
day O 
) O 
dissolved O 
in O 
corn O 
oil O 
. O 
Samples O 
of O 
the O 
duodenum O 
, O 
kidney O 
, O 
and O 
blood O 
were O 
obtained O 
from O 
the O 
mice O 
on O 
day O 
17.5 O 
of O 
pregnancy O 
. O 
Serum O 
Ca B-FORMULA 
levels O 
were O 
decreased O 
in O 
the O 
groups O 
treated O 
with O 
OP O 
and O 
BPA B-ABBREVIATION 
. O 
The O 
expression O 
levels O 
of O 
Ca B-FORMULA 
transport O 
genes O 
, O 
TRPV5 O 
and O 
calbindin-D9k O 
( O 
CaBP-9k O 
) O 
, O 
in O 
the O 
kidney O 
were O 
decreased O 
after O 
treatment O 
with O 
OP O 
and O 
BPA B-ABBREVIATION 
. O 
Duodenal O 
expression O 
of O 
TRPV6 O 
was O 
also O 
reduced O 
by O 
BPA B-ABBREVIATION 
and O 
OP O 
administration O 
. O 
CaBP-9k O 
expression O 
was O 
differentially O 
regulated O 
by O 
BPA B-ABBREVIATION 
and O 
OP O 
. O 
Transcriptional O 
and O 
translational O 
levels O 
of O 
CaBP-9k O 
were O 
decreased O 
by O 
EE O 
and O 
BPA B-ABBREVIATION 
but O 
increased O 
by O 
a O 
high O 
dose O 
of O 
OP O 
. O 
Taken O 
together O 
, O 
our O 
findings O 
demonstrate O 
that O 
OP O 
and O 
BPA B-ABBREVIATION 
regulated O 
the O 
expression O 
of O 
genes O 
associated O 
with O 
Ca B-FORMULA 
transport O 
in O 
the O 
pregnant O 
mice O 
, O 
which O 
may O 
result O 
in O 
the O 
decreased O 
serum O 
Ca B-FORMULA 
levels O 
. O 

exact O 
mechanism O 
by O 
which O 
anesthetics O 
induce O 
cell O 
membrane O 
- O 
mediated O 
modifications O 
is O 
still O 
an O 
open O 
question O 
. O 
Although O 
the O 
fluidization O 
effect O 
of O 
the O 
anesthetic O 
molecules O 
on O 
the O 
cellular O 
membrane O 
is O 
widely O 
recognized O 
, O 
it O 
is O 
not O 
known O 
if O 
anesthetics O 
show O 
any O 
preference O 
for O 
specific O 
membrane O 
domains O 
, O 
namely O 
the O 
lipid O 
rafts O 
. O 
The O 
importance O 
of O 
these O 
membrane O 
micro O 
- O 
domains O 
derives O 
from O 
the O 
fact O 
that O 
they O 
have O 
been O 
associated O 
with O 
cell O 
signaling O 
pathways O 
, O 
as O 
well O 
as O 
with O 
specific O 
drug O 
interactions O 
. O 
The O 
objective O 
of O 
this O 
work O 
is O 
to O 
contribute O 
for O 
the O 
elucidation O 
of O 
this O 
question O 
through O 
the O 
comparison O 
of O 
the O 
anesthetic O 
interactions O 
with O 
membranes O 
of O 
various O 
lipid O 
compositions O 
. O 
Liposomes O 
prepared O 
with O 
an O 
equimolar O 
mixture O 
of O 
POPC B-ABBREVIATION 
, O 
sphingomyelin B-FAMILY 
and O 
cholesterol B-TRIVIAL 
, O 
were O 
chosen O 
as O 
models O 
for O 
lipid O 
rafts O 
. O 
The O 
interactions O 
of O 
these O 
liposomes O 
with O 
two O 
local O 
anesthetics O 
, O 
tetracaine B-TRIVIAL 
and O 
lidocaine B-TRIVIAL 
, O 
and O 
one O 
general O 
anesthetic O 
, O 
propofol B-TRIVIAL 
, O 
were O 
studied O 
. O 
The O 
effect O 
of O 
cholesterol B-TRIVIAL 
was O 
investigated O 
by O 
comparing O 
anesthetic O 
interactions O 
with O 
POPC B-ABBREVIATION 
/ O 
SM O 
liposomes O 
and O 
POPC B-ABBREVIATION 
/ O 
SM/ O 
CHOL B-ABBREVIATION 
liposomes O 
. O 
The O 
following O 
experimental O 
techniques O 
were O 
used O 
: O 
quartz B-TRIVIAL 
crystal O 
microbalance O 
with O 
dissipation O 
, O 
differential O 
scanning O 
calorimetry O 
and O 
phosphorus B-SYSTEMATIC 
nuclear O 
magnetic O 
resonance O 
. O 
Although O 
the O 
liposomes O 
investigated O 
by O 
the O 
different O 
techniques O 
are O 
not O 
in O 
the O 
same O 
conditions O 
, O 
it O 
is O 
possible O 
to O 
assemble O 
the O 
information O 
obtained O 
from O 
all O 
experimental O 
techniques O 
employed O 
to O 
reach O 
a O 
general O 
conclusion O 
. O 
Tetracaine B-TRIVIAL 
interacts O 
more O 
with O 
raftlike O 
domains O 
, O 
lidocaine B-TRIVIAL 
induces O 
stronger O 
modifications O 
on O 
POPC B-ABBREVIATION 
/ O 
SM O 
liposomes O 
and O 
the O 
results O 
for O 
propofol B-TRIVIAL 
are O 
not O 
fully O 
conclusive O 
but O 
it O 
seems O 
to O 
be O 
the O 
least O 
prone O 
to O 
lipid O 
interactions O 
. O 
The O 
results O 
were O 
compared O 
with O 
those O 
obtained O 
with O 
DMPC B-ABBREVIATION 
-containing O 
liposomes O 
, O 
reported O 
in O 
a O 
previous O 
work O 
. O 

transcription O 
and O 
biomarker O 
responses O 
in O 
the O 
clam O 
Ruditapes O 
philippinarum O 
after O 
exposure O 
to O 
ibuprofen B-TRIVIAL 
. O 

are O 
a O 
class O 
of O 
emerging O 
environmental O 
contaminants O 
that O 
continuously O 
enter O 
aquatic O 
environments O 
. O 
Presently O 
, O 
little O 
information O 
is O 
available O 
about O 
the O 
effects O 
of O 
these O 
substances O 
on O 
non-target O 
organisms O 
, O 
such O 
as O 
bivalves O 
. O 
We O 
investigated O 
the O 
effects O 
of O 
ibuprofen B-TRIVIAL 
( O 
IBU B-ABBREVIATION 
) O 
on O 
the O 
clam O 
Ruditapes O 
philippinarum O 
. O 
Clams O 
were O 
exposed O 
for O 
1 O 
, O 
3 O 
, O 
5 O 
and O 
7 O 
days O 
to O 
0 O 
, O 
100 O 
and O 
1000 O 
μgIBU O 
/ O 
L O 
, O 
and O 
established O 
biomarker O 
responses O 
( O 
haemolymph O 
lysozyme O 
, O 
gill O 
acetylcholinesterase O 
and O 
digestive O 
gland O 
superoxide B-TRIVIAL 
dismutase O 
activities O 
) O 
as O 
well O 
as O 
digestive O 
gland O 
transcriptome O 
were O 
evaluated O 
. O 
A O 
two O 
- O 
way O 
ANOVA O 
revealed O 
significant O 
effects O 
of O 
both O 
" O 
IBU B-ABBREVIATION 
concentration O 
" O 
and O 
" O 
exposure O 
duration O 
" O 
on O 
biomarker O 
responses O 
. O 
Overall O 
, O 
the O 
enzyme O 
activities O 
were O 
generally O 
lower O 
in O 
IBU B-ABBREVIATION 
-exposed O 
clams O 
than O 
in O 
controls O 
. O 
Although O 
limited O 
knowledge O 
of O 
the O 
mollusc O 
transcriptome O 
makes O 
it O 
difficult O 
to O 
interpret O 
the O 
effects O 
of O 
IBU B-ABBREVIATION 
on O 
clams O 
, O 
the O 
gene O 
transcription O 
analysis O 
using O 
DNA O 
microarrays O 
enabled O 
the O 
identification O 
of O 
the O 
putative O 
molecular O 
mode O 
of O 
action O 
of O 
the O 
IBU B-ABBREVIATION 
. O 
The O 
functional O 
analysis O 
of O 
differentially O 
transcribed O 
genes O 
suggests O 
that O 
IBU B-ABBREVIATION 
can O 
interfere O 
with O 
various O 
signalling O 
pathways O 
in O 
clams O 
, O 
such O 
as O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
metabolism O 
, O 
apoptosis O 
, O 
peroxisomal O 
proliferator O 
- O 
activated O 
receptors O 
, O 
and O 
nuclear O 
factor O 
- O 
kappa O 
B O 
. O 
In O 
addition O 
, O 
several O 
genes O 
involved O 
in O 
the O 
metabolism O 
of O 
xenobiotics O 
( O 
e.g O 
. O 
, O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
, O 
sulfotransferase O 
, O 
cytochrome O 
P450 O 
) O 
were O 
also O 
found O 
to O 
be O 
significantly O 
affected O 
by O 
IBU B-ABBREVIATION 
exposure O 
. O 
In O 
summary O 
, O 
the O 
integrated O 
approach O 
of O 
gene O 
transcription O 
analysis O 
and O 
biomarker O 
responses O 
facilitated O 
the O 
elucidation O 
of O 
the O 
putative O 
mechanisms O 
of O 
action O 
of O 
IBU B-ABBREVIATION 
in O 
non-target O 
species O 
. O 

-independent O 
formation O 
of O 
the O 
inactive O 
states O 
of O 
NiFe B-FORMULA 
hydrogenase O 
. O 

studied O 
the O 
mechanism O 
of O 
aerobic O 
inactivation O 
of O 
Desulfovibrio O 
fructosovorans O 
nickel B-SYSTEMATIC 
- I-SYSTEMATIC 
iron I-SYSTEMATIC 
( O 
NiFe B-FORMULA 
) O 
hydrogenase O 
by O 
quantitatively O 
examining O 
the O 
results O 
of O 
electrochemistry O 
, O 
EPR O 
and O 
FTIR O 
experiments O 
. O 
They O 
suggest O 
that O 
, O 
contrary O 
to O 
the O 
commonly O 
accepted O 
mechanism O 
, O 
the O 
attacking O 
O(2) B-FORMULA 
is O 
not O 
incorporated O 
as O 
an O 
active O 
site O 
ligand O 
but O 
, O 
rather O 
, O 
acts O 
as O 
an O 
electron O 
acceptor O 
. O 
Our O 
findings O 
offer O 
new O 
ways O 
toward O 
the O 
understanding O 
of O 
O(2) B-FORMULA 
inactivation O 
and O 
O(2) B-FORMULA 
tolerance O 
in O 
NiFe B-FORMULA 
hydrogenases O 
. O 

2-dimensional O 
hepatic O 
model O 
systems O 
often O 
fail O 
to O 
predict O 
chemically O 
induced O 
hepatotoxicity O 
due O 
to O 
the O 
loss O 
of O 
a O 
hepatocyte O 
- O 
specific O 
phenotype O 
in O 
culture O 
. O 
For O 
more O 
predictive O 
in O 
vitro O 
models O 
, O 
hepatocytes O 
have O 
to O 
be O 
maintained O 
in O 
a O 
3-dimensional O 
environment O 
that O 
allows O 
for O 
polarization O 
and O 
cell O 
- O 
cell O 
contacts O 
. O 
Preferably O 
, O 
the O 
model O 
will O 
reflect O 
an O 
in O 
vivo O 
- O 
like O 
multi O 
- O 
cell O 
type O 
environment O 
necessary O 
for O 
liver O 
- O 
like O 
responses O 
. O 
Here O 
, O 
we O 
report O 
the O 
characterization O 
of O 
a O 
multi O 
- O 
cell O 
type O 
microtissue O 
model O 
, O 
generated O 
from O 
primary O 
human O 
hepatocytes O 
and O 
liver O 
- O 
derived O 
non-parenchymal O 
cells O 
. O 
Liver O 
microtissues O 
were O 
stable O 
and O 
functional O 
for O 
5 O 
weeks O 
in O 
culture O 
enabling O 
, O 
for O 
example O 
, O 
long O 
- O 
term O 
toxicity O 
testing O 
of O 
acetaminophen B-TRIVIAL 
and O 
diclofenac B-TRIVIAL 
. O 
In O 
addition O 
, O 
Kupffer O 
cells O 
were O 
responsive O 
to O 
inflammatory O 
stimuli O 
such O 
as O 
LPS O 
demonstrating O 
the O 
possibility O 
to O 
detect O 
inflammation O 
- O 
mediated O 
toxicity O 
as O 
exemplified O 
by O 
the O 
drug O 
trovafloxacin B-TRIVIAL 
. O 
Herewith O 
, O 
we O 
present O 
a O 
novel O 
3D O 
liver O 
model O 
for O 
routine O 
testing O 
in O 
96-well O 
format O 
capable O 
of O 
reducing O 
the O 
risk O 
of O 
unwanted O 
toxic O 
effects O 
in O 
the O 
clinic O 
. O 

exposure O 
has O 
been O 
related O 
with O 
thyroid O 
disrupting O 
effects O 
in O 
different O 
vertebrate O 
species O 
. O 
However O 
, O 
very O 
little O 
is O 
known O 
about O 
the O 
effects O 
of O 
these O 
compounds O 
in O 
reptiles O 
. O 
In O 
the O 
Mediterranean O 
area O 
, O 
lacertid O 
lizards O 
are O 
the O 
most O 
abundant O 
vertebrate O 
group O 
in O 
agroecosystems O 
, O 
and O 
have O 
been O 
identified O 
as O 
potential O 
model O 
species O 
for O 
reptile O 
ecotoxicology O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
understand O 
if O 
the O 
herbicides O 
applied O 
in O 
corn O 
fields O 
have O 
thyroid O 
disruptive O 
effects O 
in O 
the O 
lizard O 
Podarcis O 
bocagei O 
. O 
Adult O 
male O 
lizards O 
were O 
captured O 
in O 
north O 
- O 
western O 
Portugal O 
in O 
corn O 
fields O 
treated O 
with O 
herbicides O 
( O 
exposed O 
sites O 
) O 
, O 
and O 
in O 
organic O 
agricultural O 
fields O 
( O 
reference O 
sites O 
) O 
. O 
Thyroid O 
and O 
male O 
gonad O 
morphology O 
and O 
functionality O 
, O 
and O 
testosterone B-TRIVIAL 
levels O 
were O 
investigated O 
through O 
histological O 
, O 
immunohistochemical O 
and O 
biochemical O 
techniques O 
. O 
Lizards O 
from O 
exposed O 
locations O 
displayed O 
thyroid O 
follicular O 
lumens O 
with O 
more O 
reabsorption O 
vacuoles O 
and O 
significantly O 
larger O 
follicular O 
area O 
than O 
those O 
from O 
reference O 
fields O 
. O 
Furthermore O 
, O 
testes O 
of O 
lizards O 
from O 
exposed O 
locations O 
had O 
significantly O 
larger O 
seminiferous O 
tubule O 
diameters O 
, O 
significantly O 
higher O 
number O 
of O 
spermatogenic O 
layers O 
and O 
displayed O 
an O 
up O 
- O 
regulation O 
of O 
thyroid O 
hormone O 
receptors O 
when O 
compared O 
with O 
lizards O 
from O 
reference O 
areas O 
. O 
These O 
findings O 
strongly O 
suggest O 
that O 
the O 
complex O 
mixture O 
of O 
herbicides O 
that O 
lizards O 
are O 
exposed O 
to O 
in O 
agricultural O 
areas O 
have O 
thyroid O 
disrupting O 
effects O 
which O 
ultimately O 
affect O 
the O 
male O 
reproductive O 
system O 
. O 
Alachlor B-TRIVIAL 
, O 
which O 
has O 
demonstrated O 
thyroid O 
effects O 
in O 
mammals O 
, O 
may O 
be O 
largely O 
responsible O 
for O 
the O 
observed O 
effects O 
. O 

of O 
pyrene B-SYSTEMATIC 
exposure O 
and O 
temperature O 
on O 
early O 
development O 
of O 
two O 
co O 
- O 
existing O 
Arctic O 
copepods O 
. O 

exploration O 
is O 
expected O 
to O 
increase O 
in O 
the O 
near O 
future O 
in O 
Western O 
Greenland O 
. O 
At O 
present O 
, O 
effects O 
of O 
exposure O 
to O 
oil O 
compounds O 
on O 
early O 
life O 
- O 
stages O 
of O 
the O 
ecologically O 
important O 
Calanus O 
spp O 
. O 
are O 
unknown O 
. O 
We O 
investigated O 
the O 
effects O 
of O 
the O 
oil O 
compound O 
pyrene B-SYSTEMATIC 
, O 
on O 
egg O 
hatching O 
and O 
naupliar O 
development O 
of O 
the O 
calanoid O 
copepods O 
Calanus O 
glacialis O 
and O 
C O 
. O 
finmarchicus O 
, O 
two O 
key O 
species O 
in O 
the O 
Disko O 
Bay O 
, O 
Western O 
Greenland O 
. O 
At O 
low O 
temperature O 
the O 
nauplii O 
of O 
C O 
. O 
glacialis O 
experienced O 
reduced O 
growth O 
when O 
exposed O 
to O 
pyrene B-SYSTEMATIC 
, O 
and O 
survival O 
in O 
both O 
species O 
decreased O 
. O 
Naupliar O 
mortality O 
increased O 
with O 
temperature O 
at O 
high O 
pyrene B-SYSTEMATIC 
concentration O 
in O 
C O 
. O 
finmarchicus O 
. O 
Both O 
Calanus O 
species O 
were O 
affected O 
by O 
pyrene B-SYSTEMATIC 
exposure O 
but O 
C O 
. O 
finmarchicus O 
was O 
more O 
sensitive O 
compared O 
to O 
C O 
. O 
glacialis O 
. O 
Lowered O 
growth O 
rate O 
and O 
increased O 
mortality O 
of O 
the O 
naupliar O 
stages O 
entail O 
reduced O 
recruitment O 
to O 
copepod O 
populations O 
. O 
Exposure O 
to O 
pyrene B-SYSTEMATIC 
from O 
an O 
oil O 
spill O 
may O 
reduce O 
the O 
standing O 
stock O 
of O 
Calanus O 
, O 
which O 
can O 
lead O 
to O 
less O 
energy O 
available O 
to O 
higher O 
trophic O 
levels O 
in O 
the O 
Arctic O 
marine O 
food O 
web O 
. O 

- O 
supported O 
aluminosilicate B-TRIVIAL 
ultrathin O 
films O 
as O 
a O 
versatile O 
tool O 
for O 
studying O 
the O 
surface O 
chemistry O 
of O 
zeolites B-FAMILY 
. O 

application O 
of O 
a O 
variety O 
of O 
" O 
surface O 
- O 
science O 
" O 
techniques O 
to O 
elucidate O 
surface O 
structures O 
and O 
mechanisms O 
of O 
chemical O 
reactions O 
at O 
zeolite B-TRIVIAL 
surfaces O 
has O 
long O 
been O 
considered O 
as O 
almost O 
impossible O 
because O 
of O 
the O 
poor O 
electrical O 
and O 
thermal O 
conductivity O 
of O 
those O 
materials O 
. O 
Here O 
, O 
we O 
show O 
that O 
the O 
growth O 
of O 
a O 
thin O 
aluminosilicate B-TRIVIAL 
film O 
on O 
a O 
metal O 
single O 
crystal O 
under O 
controlled O 
conditions O 
results O 
in O 
adequate O 
and O 
well O 
- O 
defined O 
model O 
systems O 
for O 
zeolite B-TRIVIAL 
surfaces O 
. O 
In O 
principle O 
, O 
silicate B-FAMILY 
films O 
that O 
contain O 
metals O 
other O 
than O 
Al B-FORMULA 
( O 
e.g O 
. O 
Ti B-FORMULA 
, O 
Fe B-FORMULA 
, O 
etc O 
) O 
may O 
be O 
prepared O 
in O 
a O 
similar O 
way O 
. O 
We O 
believe O 
that O 
this O 
approach O 
opens O 
up O 
a O 
new O 
playground O 
for O 
experimental O 
and O 
theoretical O 
modeling O 
of O 
zeolites B-FAMILY 
, O 
aimed O 
at O 
a O 
fundamental O 
understanding O 
of O 
structure O 
- O 
reactivity O 
relationships O 
in O 
such O 
materials O 
. O 

vitro O 
exposure O 
of O 
precision O 
- O 
cut O 
lung O 
slices O 
to O 
2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole B-SYSTEMATIC 
lysylamide I-SYSTEMATIC 
dihydrochloride I-SYSTEMATIC 
( O 
NSC B-IDENTIFIER 
710305 I-IDENTIFIER 
, O 
Phortress B-TRIVIAL 
) O 
increases O 
inflammatory O 
cytokine O 
content O 
and O 
tissue O 
damage O 
. O 

anticancer O 
drug O 
( O 
2-[4-amino-3-methylphenyl]-5-fluorobenzothiazole B-SYSTEMATIC 
lysylamide I-SYSTEMATIC 
dihydrochloride I-SYSTEMATIC 
) O 
( O 
NSC B-IDENTIFIER 
710305 I-IDENTIFIER 
, O 
Phortress B-TRIVIAL 
) O 
is O 
a O 
metabolically O 
activated O 
prodrug O 
that O 
causes O 
DNA O 
adduct O 
formation O 
and O 
subsequent O 
toxicity O 
. O 
Preclinically O 
, O 
it O 
was O 
found O 
that O 
hepatic O 
, O 
bone O 
marrow O 
, O 
and O 
pulmonary O 
toxicity O 
presented O 
challenges O 
to O 
developing O 
this O 
drug O 
. O 
An O 
ex O 
vivo O 
precision O 
- O 
cut O 
lung O 
slice O 
( O 
PCLS O 
) O 
model O 
was O 
used O 
to O 
search O 
for O 
concentration O 
dependent O 
effects O 
of O 
NSC B-IDENTIFIER 
710305 I-IDENTIFIER 
( O 
10 O 
, O 
25 O 
, O 
50 O 
, O 
and O 
100 O 
µM O 
) O 
on O 
cytokine O 
content O 
, O 
protein O 
content O 
, O 
and O 
immuno O 
/ O 
histological O 
endpoints O 
. O 
Preparation O 
and O 
culture O 
of O 
PCLS O 
caused O 
an O 
initial O 
spike O 
in O 
proinflammatory O 
cytokine O 
expression O 
and O 
therefore O 
treatment O 
with O 
NSC B-IDENTIFIER 
710305 I-IDENTIFIER 
was O 
delayed O 
until O 
48 O 
h O 
after O 
initiating O 
the O 
slice O 
cultures O 
to O 
avoid O 
confounding O 
the O 
response O 
to O 
slicing O 
with O 
any O 
drug O 
response O 
. O 
PCLSs O 
were O 
evaluated O 
after O 
24 O 
, O 
48 O 
, O 
and O 
72 O 
h O 
exposures O 
to O 
NSC B-IDENTIFIER 
710305 I-IDENTIFIER 
. O 
Reversibility O 
of O 
toxicity O 
due O 
to O 
the O 
72-h O 
treatment O 
was O 
evaluated O 
after O 
a O 
24-h O 
recovery O 
period O 
. O 
NSC B-IDENTIFIER 
710305 I-IDENTIFIER 
caused O 
a O 
concentration O 
- O 
dependent O 
cytokine O 
response O 
, O 
and O 
only O 
the O 
toxicity O 
caused O 
by O 
a O 
72-h O 
exposure O 
to O 
25 O 
µM O 
reversed O 
during O 
the O 
24-h O 
recovery O 
period O 
. O 
Immuno O 
/ O 
histological O 
examination O 
and O 
quantitation O 
of O 
tissue O 
protein O 
levels O 
indicated O 
that O 
tissue O 
destruction O 
, O 
ED-1 O 
( O 
activated O 
macrophage O 
) O 
staining O 
, O 
and O 
protein O 
levels O 
were O 
associated O 
with O 
the O 
levels O 
of O 
proinflammatory O 
cytokines O 
in O 
the O 
tissue O 
. O 
In O 
conclusion O 
, O 
the O 
concentration- O 
and O 
time O 
- O 
dependent O 
inflammatory O 
response O 
of O 
PCLS O 
to O 
NSC B-IDENTIFIER 
710305 I-IDENTIFIER 
preceded O 
relevant O 
tissue O 
damage O 
by O 
a O 
few O 
days O 
. O 
The O 
no O 
- O 
observable O 
adverse O 
effect O 
level O 
( O 
NOAEL O 
) O 
for O 
24 O 
, O 
48 O 
, O 
and O 
72 O 
h O 
exposures O 
was O 
established O 
as O 
10 O 
µM O 
NSC B-IDENTIFIER 
710305 I-IDENTIFIER 
. O 

feature O 
a O 
defined O 
number O 
of O 
terminal O 
groups O 
that O 
may O 
bind O 
RNA O 
or O 
be O 
functionalized O 
with O 
bioactive O 
molecules O 
. O 
These O 
competing O 
uses O 
of O 
terminal O 
groups O 
may O 
create O 
an O 
impasse O 
if O 
the O 
requisite O 
density O 
of O 
ligands O 
depletes O 
the O 
number O 
of O 
terminal O 
groups O 
for O 
binding O 
sufficient O 
RNA O 
, O 
or O 
vice O 
versa O 
. O 
A O 
novel O 
dendrimeric O 
platform O 
is O 
needed O 
that O 
maintains O 
high O 
ligand O 
density O 
while O 
retaining O 
sufficient O 
microRNA O 
- O 
binding O 
terminal O 
groups O 
. O 
Here O 
we O 
present O 
a O 
dendrimeric O 
" O 
bowtie O 
" O 
consisting O 
of O 
one O 
- O 
half O 
devoted O 
to O 
microRNA O 
binding O 
and O 
the O 
other O 
half O 
to O 
ligand O 
presentation O 
. O 
We O 
demonstrate O 
its O 
suitability O 
as O 
a O 
transfection O 
agent O 
by O 
delivering O 
miR-126 O 
to O 
human O 
vascular O 
endothial O 
cells O 
( O 
HUVECs O 
) O 
via O 
polyarginine B-FAMILY 
- O 
and O 
RGD O 
- O 
modified O 
bowties O 
and O 
evaluating O 
the O 
downstream O 
effects O 
on O 
proliferation O 
and O 
tube O 
formation O 
. O 
Our O 
findings O 
indicate O 
that O 
the O 
bowtie O 
elicits O 
desired O 
responses O 
and O 
may O 
possess O 
superior O 
delivery O 
properties O 
compared O 
to O 
nondecorated O 
dendrimeric O 
materials O 
. O 
The O 
bowtie O 
system O 
thereby O 
provides O 
a O 
new O 
design O 
model O 
for O 
developing O 
dendrimeric O 
delivery O 
vehicles O 
for O 
RNAi O 
therapeutics O 
. O 

modulates O 
intercellular O 
adhesion O 
through O 
inhibition O 
of O 
p-21 O 
activated O 
kinase-1 O 
. O 

( O 
5-ASA B-SYSTEMATIC 
) O 
is O 
widely O 
used O 
for O 
the O 
treatment O 
of O 
ulcerative O 
colitis O 
, O 
a O 
remitting O 
condition O 
characterized O 
by O 
chronic O 
inflammation O 
of O 
the O 
colon O 
. O 
Knowledge O 
about O 
the O 
molecular O 
and O 
cellular O 
targets O 
of O 
5-ASA B-SYSTEMATIC 
is O 
limited O 
and O 
a O 
clear O 
understanding O 
of O 
its O 
activity O 
in O 
intestinal O 
homeostasis O 
and O 
interference O 
with O 
neoplastic O 
progression O 
is O 
lacking O 
. O 
We O 
sought O 
to O 
identify O 
molecular O 
pathways O 
interfered O 
by O 
5-ASA B-SYSTEMATIC 
, O 
using O 
CRC O 
cell O 
lines O 
with O 
different O 
genetic O 
background O 
. O 
Microarray O 
was O 
performed O 
for O 
gene O 
expression O 
profile O 
of O 
5-ASA B-SYSTEMATIC 
-treated O 
and O 
untreated O 
cells O 
( O 
HCT116 O 
and O 
HT29 O 
) O 
. O 
Filtering O 
and O 
analysis O 
of O 
data O 
identified O 
three O 
oncogenic O 
pathways O 
interfered O 
by O 
5-ASA B-SYSTEMATIC 
: O 
MAPK O 
/ O 
ERK O 
pathway O 
, O 
cell O 
adhesion O 
and O 
β-catenin O 
/ O 
Wnt O 
signaling O 
. O 
PAK1 O 
emerged O 
as O 
a O 
consensus O 
target O 
of O 
5-ASA B-SYSTEMATIC 
, O 
orchestrating O 
these O 
pathways O 
. O 
We O 
further O 
investigated O 
the O 
effect O 
of O 
5-ASA B-SYSTEMATIC 
on O 
cell O 
adhesion O 
. O 
5-ASA B-SYSTEMATIC 
increased O 
cell O 
adhesion O 
which O 
was O 
measured O 
by O 
cell O 
adhesion O 
assay O 
and O 
transcellular O 
- O 
resistance O 
measurement O 
. O 
Moreover O 
, O 
5-ASA B-SYSTEMATIC 
treatment O 
restored O 
membranous O 
expression O 
of O 
adhesion O 
molecules O 
E-cadherin O 
and O 
β-catenin O 
. O 
Role O 
of O 
PAK1 O 
as O 
a O 
mediator O 
of O 
mesalamine O 
activity O 
was O 
validated O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Inhibition O 
of O 
PAK1 O 
by O 
RNA O 
interference O 
also O 
increased O 
cell O 
adhesion O 
. O 
PAK1 O 
expression O 
was O 
elevated O 
in O 
APC(min) O 
polyps O 
and O 
5-ASA B-SYSTEMATIC 
treatment O 
reduced O 
its O 
expression O 
. O 
Our O 
data O 
demonstrates O 
novel O 
pharmacological O 
mechanism O 
of O 
mesalamine B-TRIVIAL 
in O 
modulation O 
of O 
cell O 
adhesion O 
and O 
role O 
of O 
PAK1 O 
in O 
APC(min) O 
polyposis O 
. O 
We O 
propose O 
that O 
inhibition O 
of O 
PAK1 O 
expression O 
by O 
5-ASA B-SYSTEMATIC 
can O 
impede O 
with O 
neoplastic O 
progression O 
in O 
colorectal O 
carcinogenesis O 
. O 
The O 
mechanism O 
of O 
PAK1 O 
inhibition O 
and O 
induction O 
of O 
membranous O 
translocation O 
of O 
adhesion O 
proteins O 
by O 
5-ASA B-SYSTEMATIC 
might O 
be O 
independent O 
of O 
its O 
known O 
anti-inflammatory O 
action O 
. O 

inhibits O 
HMGB1-induced O 
inflammatory O 
responses O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

mobility O 
group O 
box O 
1 O 
( O 
HMGB1 O 
) O 
protein O 
acts O 
as O 
a O 
potent O 
proinflammatory O 
cytokine O 
and O 
is O 
involved O 
in O 
the O 
pathogenesis O 
of O 
several O 
vascular O 
diseases O 
, O 
such O 
as O 
, O 
systemic O 
vasculitis O 
and O 
sepsis O 
. O 
Emodin-6-O-β-D-glucoside B-SYSTEMATIC 
( O 
EG O 
) O 
is O 
a O 
new O 
active O 
compound O 
from O 
Reynoutria O 
japonica O 
, O 
and O 
its O 
biologic O 
activities O 
have O 
not O 
been O 
previously O 
investigated O 
. O 
In O 
this O 
study O 
, O 
we O 
first O 
investigated O 
the O 
antiinflammatory O 
activities O 
of O 
EG O 
on O 
HMGB1 O 
- O 
mediated O 
proinflammatory O 
responses O 
in O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
( O 
HUVECs O 
) O 
and O 
in O 
a O 
murine O 
cecal O 
ligation O 
and O 
puncture O 
(CLP)-model O 
of O 
sepsis O 
in O 
mice O 
. O 
EG O 
was O 
found O 
to O 
suppress O 
the O 
release O 
of O 
HMGB1 O 
, O 
the O 
production O 
of O 
tumor O 
necrosis O 
factor O 
(TNF)-α O 
, O 
and O 
the O 
activation O 
of O 
nuclear O 
factor-κB O 
( O 
NF-κB O 
) O 
by O 
HMGB1 O 
in O 
HUVECs O 
, O 
and O 
to O 
inhibit O 
HMGB1 O 
- O 
mediated O 
hyperpermeability O 
and O 
leukocyte O 
migration O 
in O 
mice O 
. O 
In O 
the O 
CLP O 
model O 
, O 
HMGB1 O 
was O 
highly O 
released O 
, O 
but O 
this O 
release O 
was O 
prevented O 
by O 
EG O 
. O 
Furthermore O 
, O 
EG O 
also O 
increased O 
the O 
survival O 
times O 
of O 
CLP O 
administered O 
mice O 
. O 
Collectively O 
, O 
this O 
study O 
shows O 
EG O 
can O 
protect O 
barrier O 
integrity O 
and O 
inhibit O 
HMGB1 O 
- O 
mediated O 
inflammatory O 
responses O 
, O 
which O 
suggests O 
a O 
potential O 
use O 
as O 
a O 
therapy O 
for O 
sepsis O 
or O 
septic O 
shock O 
. O 

mediates O 
hepatoprotection O 
against O 
CCl4 B-FORMULA 
-induced O 
hepatic O 
fibrosis O 
rats O 
through O 
attenuation O 
of O 
inflammation O 
response O 
and O 
amelioration O 
of O 
metabolic O 
function O 
. O 

study O 
was O 
designed O 
to O 
evaluate O 
the O 
potential O 
effects O 
of O 
puerarin B-TRIVIAL 
( O 
PR O 
) O 
, O 
an O 
effective O 
isoflavonoid B-FAMILY 
compound O 
purified O 
from O 
Pueraria O 
lobata O 
, O 
in O 
treating O 
hepatic O 
fibrosis O 
( O 
HF O 
) O 
rats O 
induced O 
by O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
( O 
CCl(4) B-FORMULA 
, O 
2 O 
mL O 
kg(-1) O 
d(-1) O 
) O 
. O 
Compared O 
to O 
model O 
control O 
, O 
PR O 
treatment O 
effectively O 
lowered O 
the O 
serum O 
levels O 
of O 
alanine B-TRIVIAL 
aminotransferase O 
( O 
ALT O 
) O 
, O 
aspartate B-TRIVIAL 
aminotransferase O 
( O 
AST O 
) O 
, O 
albumin O 
( O 
Alb O 
) O 
, O 
total O 
protein O 
( O 
TP O 
) O 
in O 
HF O 
rats O 
. O 
Masson O 
stained O 
analysis O 
showed O 
that O 
the O 
condition O 
of O 
HF O 
rats O 
was O 
mitigated O 
. O 
Meanwhile O 
, O 
the O 
tumor O 
necrosis O 
factor O 
alpha O 
( O 
TNF-α O 
) O 
, O 
nuclear O 
factor O 
- O 
kappa O 
B O 
( O 
NF-κB O 
) O 
expressions O 
were O 
significantly O 
down O 
- O 
regulated O 
at O 
protein O 
level O 
by O 
PR O 
intervention O 
. O 
Additionally O 
, O 
the O 
activity O 
of O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
was O 
elevated O 
, O 
while O 
the O 
content O 
of O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
was O 
lessened O 
in O 
liver O 
tissue O 
. O 
As O 
revealed O 
by O 
immunohistochemistry O 
assay O 
, O 
PR O 
therapy O 
resulted O 
in O 
reduced O 
production O 
of O 
transforming O 
growth O 
factor-βl O 
( O 
TGF-βl O 
) O 
. O 
Moreover O 
, O 
it O 
also O 
was O 
attributed O 
to O 
decreased O 
mRNA O 
level O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
using O 
RT-PCR O 
analysis O 
. O 
These O 
findings O 
demonstrate O 
that O 
puerarin B-TRIVIAL 
successfully O 
reverses O 
hepatotoxicity O 
in O 
CCl(4) B-FORMULA 
-induced O 
HF O 
rats O 
via O 
the O 
underlying O 
mechanisms O 
of O 
regulating O 
serum O 
enzymes O 
and O 
attenuating O 
TNF-α O 
/ O 
NF-κB O 
pathway O 
for O 
anti-inflammation O 
response O 
, O 
as O 
well O 
as O 
improving O 
metabolic O 
function O 
in O 
liver O 
tissue O 
. O 

effects O 
of O 
Gentiana O 
asclepiadea O 
L O 
. O 
extracts O 
against O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
induced O 
liver O 
injury O 
in O 
rats O 
. O 

study O 
is O 
an O 
attempt O 
to O 
evaluate O 
the O 
hepatoprotective O 
activity O 
of O 
Gentiana O 
asclepiadea O 
L O 
. O 
against O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
-induced O 
liver O 
injury O 
in O 
rats O 
. O 
Methanol B-SYSTEMATIC 
extracts O 
of O 
aerial O 
parts O 
( O 
GAA O 
) O 
and O 
roots O 
( O 
GAR O 
) O 
of O 
G O 
. O 
asclepiadea O 
at O 
doses O 
of O 
100 O 
, O 
200 O 
, O 
and O 
400mg/ O 
kg O 
b.w O 
. O 
were O 
orally O 
administered O 
to O 
Wistar O 
rats O 
once O 
daily O 
for O 
7 O 
days O 
before O 
they O 
were O 
treated O 
with O 
CCl(4) B-FORMULA 
. O 
The O 
hepatoprotective O 
activity O 
of O 
the O 
extracts O 
in O 
this O 
study O 
was O 
compared O 
with O 
the O 
reference O 
drug O 
silymarin O 
. O 
In O 
CCl(4) B-FORMULA 
treated O 
animals O 
, O 
GAA O 
and O 
GAR O 
significantly O 
decreased O 
levels O 
of O 
serum O 
transaminases O 
, O 
alkaline O 
phosphatase O 
and O 
total O 
bilirubin B-TRIVIAL 
, O 
and O 
increased O 
the O 
level O 
of O 
total O 
protein O 
. O 
Treatment O 
with O 
the O 
extracts O 
resulted O 
in O 
a O 
significant O 
increase O 
in O 
the O 
levels O 
of O 
catalase O 
, O 
superoxide B-TRIVIAL 
dismutase O 
and O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
, O 
accompanied O 
with O 
a O 
marked O 
reduction O 
in O 
the O 
levels O 
of O 
malondialdehyde B-TRIVIAL 
, O 
as O 
compared O 
to O 
CCl(4) B-FORMULA 
treated O 
group O 
. O 
The O 
histopathological O 
studies O 
confirmed O 
protective O 
effects O 
of O 
extracts O 
against O 
CCl(4) B-FORMULA 
-induced O 
liver O 
injuries O 
. O 
No O 
genotoxicity O 
was O 
observed O 
in O 
liver O 
cells O 
after O 
GAA O 
treatment O 
, O 
while O 
GAR O 
showed O 
only O 
slight O 
genotoxic O 
effects O 
by O 
comet O 
assay O 
. O 
Phytochemical O 
analysis O 
revealed O 
the O 
presence O 
of O 
sweroside B-TRIVIAL 
, O 
swertiamarin B-TRIVIAL 
and O 
gentiopicrin B-TRIVIAL 
in O 
high O 
concentrations O 
in O 
both O 
extracts O 
. O 
It O 
could O 
be O 
concluded O 
that O 
the O 
use O 
of O 
G O 
. O 
asclepiadea O 
extracts O 
in O 
the O 
treatment O 
of O 
chemical O 
- O 
induced O 
hepatotoxicity O 
. O 

disrupting O 
chemicals O 
( O 
EDCs O 
) O 
have O 
the O 
potential O 
to O 
interfere O 
with O 
the O 
hormonal O 
system O 
and O 
may O 
negatively O 
influence O 
human O 
health O 
. O 
Microarray O 
analysis O 
was O 
used O 
in O 
this O 
study O 
to O 
investigate O 
differential O 
gene O 
expression O 
in O 
human O 
peripheral O 
blood O 
cells O 
( O 
PBMCs O 
) O 
after O 
in O 
vitro O 
exposure O 
to O 
EDCs O 
. O 
PBMCs O 
, O 
isolated O 
from O 
blood O 
samples O 
of O 
four O 
male O 
and O 
four O 
female O 
healthy O 
individuals O 
, O 
were O 
exposed O 
in O 
vitro O 
for O 
18h O 
to O 
either O 
a O 
dioxin B-FAMILY 
-like O 
polychlorinated B-FAMILY 
biphenyl I-FAMILY 
( O 
PCB126 B-TRIVIAL 
, O 
1μM O 
) O 
, O 
a O 
non- O 
dioxin B-FAMILY 
-like O 
polychlorinated B-FAMILY 
biphenyl I-FAMILY 
( O 
PCB153 B-TRIVIAL 
, O 
10μM O 
) O 
, O 
a O 
brominated O 
flame O 
retardant O 
( O 
BDE47 B-IDENTIFIER 
, O 
10μM O 
) O 
, O 
a O 
perfluorinated B-FAMILY 
alkyl I-FAMILY 
acid I-FAMILY 
( O 
PFOA B-ABBREVIATION 
, O 
10μM O 
) O 
or O 
bisphenol B-TRIVIAL 
( O 
BPA B-ABBREVIATION 
, O 
10μM O 
) O 
. O 
ANOVA O 
analysis O 
revealed O 
a O 
significant O 
change O 
in O 
the O 
expression O 
of O 
862 O 
genes O 
as O 
a O 
result O 
of O 
EDC O 
exposure O 
. O 
The O 
gender O 
of O 
the O 
donors O 
did O 
not O 
affect O 
gene O 
expression O 
. O 
Hierarchical O 
cluster O 
analysis O 
created O 
three O 
groups O 
and O 
clustered O 
: O 
( O 
1 O 
) O 
PCB126 B-TRIVIAL 
-exposed O 
samples O 
, O 
( O 
2 O 
) O 
PCB153 B-TRIVIAL 
and O 
BDE47 B-IDENTIFIER 
, O 
( O 
3 O 
) O 
PFOA B-ABBREVIATION 
and O 
BPA B-ABBREVIATION 
. O 
The O 
number O 
of O 
differentially O 
expressed O 
genes O 
varied O 
per O 
compound O 
and O 
ranged O 
from O 
60 O 
to O 
192 O 
when O 
using O 
fold O 
change O 
and O 
multiplicity O 
corrected O 
p-value O 
as O 
filtering O 
criteria O 
. O 
Exposure O 
to O 
PCB126 B-TRIVIAL 
induced O 
the O 
AhR O 
signaling O 
pathway O 
. O 
BDE47 B-IDENTIFIER 
and O 
PCB153 B-TRIVIAL 
are O 
known O 
to O 
disrupt O 
thyroid O 
metabolism O 
and O 
exposure O 
influenced O 
the O 
expression O 
of O 
the O 
nuclear O 
receptors O 
PPARγ O 
and O 
ESR2 O 
, O 
respectively O 
. O 
BPA B-ABBREVIATION 
and O 
PFOA B-ABBREVIATION 
did O 
not O 
induce O 
significant O 
changes O 
in O 
the O 
expression O 
of O 
known O 
nuclear O 
receptors O 
. O 
Overall O 
, O 
each O 
compound O 
produced O 
a O 
unique O 
gene O 
expression O 
signature O 
affecting O 
pathways O 
and O 
GO O 
processes O 
linked O 
to O 
metabolism O 
and O 
inflammation O 
. O 
Twenty O 
- O 
nine O 
genes O 
were O 
significantly O 
altered O 
in O 
expression O 
under O 
all O 
experimental O 
conditions O 
. O 
Six O 
of O 
these O 
genes O 
( O 
HSD11B2 O 
, O 
MMP11 O 
, O 
ADIPOQ O 
, O 
CEL O 
, O 
DUSP9 O 
and O 
TUB O 
) O 
could O 
be O 
associated O 
with O 
obesity O 
and O 
metabolic O 
syndrome O 
. O 
In O 
conclusion O 
, O 
microarray O 
analysis O 
identified O 
that O 
PBMCs O 
altered O 
their O 
gene O 
expression O 
response O 
in O 
vitro O 
when O 
challenged O 
with O 
EDCs O 
. O 
Our O 
screening O 
approach O 
has O 
identified O 
a O 
number O 
of O 
gene O 
candidates O 
that O 
warrant O 
further O 
study O 
. O 

mechanism O 
of O 
carvacrol B-TRIVIAL 
-evoked O 
[ O 
Ca2+ B-FORMULA 
]i O 
rises O 
and O 
non- O 
Ca2+ B-FORMULA 
-triggered O 
cell O 
death O 
in O 
OC2 O 
human O 
oral O 
cancer O 
cells O 
. O 

is O 
one O 
of O 
the O 
main O 
substances O 
of O 
essential O 
oil O 
which O 
triggers O 
intracellular O 
Ca(2+) B-FORMULA 
mobilization O 
and O 
causes O 
cytotoxicity O 
in O 
diverse O 
cell O 
models O 
. O 
However O 
, O 
the O 
mechanism O 
of O 
carvacrol B-TRIVIAL 
-induced O 
Ca(2+) B-FORMULA 
movement O 
and O 
cytotoxicity O 
is O 
not O 
fully O 
understood O 
. O 
This O 
study O 
examined O 
the O 
effect O 
of O 
carvacrol B-TRIVIAL 
on O 
cytosolic O 
free O 
Ca(2+) B-FORMULA 
concentrations O 
( O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
) O 
, O 
cell O 
viability O 
and O 
apoptosis O 
in O 
OC2 O 
human O 
oral O 
cancer O 
cells O 
. O 
Carvacrol B-TRIVIAL 
induced O 
a O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
rise O 
and O 
the O 
signal O 
was O 
reduced O 
by O 
removal O 
of O 
extracellular O 
Ca(2+) B-FORMULA 
. O 
Carvacrol B-TRIVIAL 
-induced O 
Ca(2+) B-FORMULA 
entry O 
was O 
not O 
altered O 
by O 
store O 
- O 
operated O 
Ca(2+) B-FORMULA 
channel O 
inhibitors O 
and O 
protein O 
kinase O 
C O 
( O 
PKC O 
) O 
activator O 
, O 
but O 
was O 
inhibited O 
by O 
a O 
PKC O 
inhibitor O 
. O 
In O 
Ca(2+) B-FORMULA 
-free O 
medium O 
, O 
treatment O 
with O 
the O 
endoplasmic O 
reticulum O 
Ca(2+) B-FORMULA 
pump O 
inhibitor O 
thapsigargin B-TRIVIAL 
( O 
TG O 
) O 
or O 
2,5-di-tert-butylhydroquinone B-SYSTEMATIC 
( O 
BHQ B-ABBREVIATION 
) O 
inhibited O 
carvacrol B-TRIVIAL 
-induced O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
rise O 
. O 
Conversely O 
, O 
incubation O 
with O 
carvacrol B-TRIVIAL 
inhibited O 
TG O 
or O 
BHQ B-ABBREVIATION 
-induced O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
rise O 
. O 
Inhibition O 
of O 
phospholipase O 
C O 
( O 
PLC O 
) O 
with O 
U73122 B-IDENTIFIER 
abolished O 
carvacrol B-TRIVIAL 
-induced O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
rise O 
. O 
Carvacrol B-TRIVIAL 
decreased O 
cell O 
viability O 
, O 
which O 
was O 
not O 
reversed O 
when O 
cytosolic O 
Ca(2+) B-FORMULA 
was O 
chelated O 
with O 
BAPTA-AM B-ABBREVIATION 
( O 
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
- I-SYSTEMATIC 
acetoxymethyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
) O 
. O 
Carvacrol B-TRIVIAL 
-induced O 
apoptosis O 
and O 
activation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
and O 
caspase-3 O 
. O 
Together O 
, O 
carvacrol B-TRIVIAL 
induced O 
a O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
rise O 
by O 
inducing O 
PLC-dependent O 
Ca(2+) B-FORMULA 
release O 
from O 
the O 
endoplasmic O 
reticulum O 
and O 
Ca(2+) B-FORMULA 
entry O 
via O 
PKC-sensitive O 
, O 
non O 
store O 
- O 
operated O 
Ca(2+) B-FORMULA 
channels O 
. O 
Carvacrol B-TRIVIAL 
-induced O 
ROS- O 
and O 
caspase-3-associated O 
apoptosis O 
. O 

2,2',4,4'-tetrabromodiphenyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
hydroxylated O 
metabolites O 
5-OH-BDE-47 B-SYSTEMATIC 
and O 
6-OH-BDE-47 B-SYSTEMATIC 
stimulate O 
estradiol B-TRIVIAL 
secretion O 
in O 
the O 
ovary O 
by O 
activating O 
aromatase O 
expression O 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
assess O 
the O 
effect O 
of O 
two O 
hydroxylated B-TRIVIAL 
BDE-47 I-TRIVIAL 
metabolites O 
, O 
5-OH-BDE-47 B-SYSTEMATIC 
and O 
6-OH-BDE-47 B-SYSTEMATIC 
, O 
on O 
steroidogenesis O 
in O 
the O 
ovary O 
. O 
Both O 
metabolites O 
failed O 
to O 
affect O 
the O 
production O 
of O 
androstenedione B-TRIVIAL 
and O 
testosterone B-TRIVIAL 
but O 
increased O 
the O 
secretion O 
of O 
estradiol B-TRIVIAL 
at O 
all O 
concentrations O 
tested O 
. O 
The O 
increased O 
secretion O 
of O 
estradiol B-TRIVIAL 
was O 
due O 
to O 
the O 
stimulation O 
of O 
aromatase O 
gene O 
and O 
protein O 
expression O 
. O 
Direct O 
assessment O 
of O 
aromatase O 
activity O 
by O 
dibenzylfluorescein B-SYSTEMATIC 
assay O 
and O 
indirect O 
assessment O 
of O 
aromatase O 
activity O 
by O 
measurement O 
of O 
the O 
conversion O 
of O 
testosterone B-TRIVIAL 
to O 
estradiol B-TRIVIAL 
confirmed O 
that O 
5-OH-BDE-47 B-SYSTEMATIC 
and O 
6-OH-BDE-47 B-SYSTEMATIC 
stimulate O 
aromatase O 
activity O 
. O 
The O 
aromatase O 
inhibitor O 
CGS B-IDENTIFIER 
16949A I-IDENTIFIER 
abolished O 
this O 
stimulatory O 
activity O 
and O 
reduced O 
estradiol B-TRIVIAL 
levels O 
in O 
the O 
control O 
and O 
treatment O 
groups O 
. O 

effect O 
of O 
epigallocatechin B-TRIVIAL 
gallate I-TRIVIAL 
in O 
rats O 
is O 
mediated O 
via O 
decreased O 
expression O 
of O 
Mrp2 O 
. O 

gallate I-TRIVIAL 
( O 
EGCG B-ABBREVIATION 
) O 
has O 
been O 
shown O 
to O 
be O 
protective O 
in O 
various O 
experimental O 
models O 
of O 
liver O 
injury O 
, O 
although O 
opposite O 
effects O 
have O 
also O 
been O 
reported O 
. O 
Since O 
its O 
effect O 
on O 
biliary O 
physiology O 
has O 
not O 
been O 
thoroughly O 
investigated O 
, O 
the O 
present O 
study O 
evaluated O 
effect O 
of O 
EGCG B-ABBREVIATION 
on O 
bile O 
flow O 
and O 
bile B-FAMILY 
acid I-FAMILY 
homeostasis O 
in O 
rats O 
. O 
Compared O 
to O 
controls O 
, O 
EGCG B-ABBREVIATION 
treatment O 
decreased O 
bile O 
flow O 
by O 
23% O 
. O 
Hepatic O 
paracellular O 
permeability O 
and O 
biliary O 
bile B-FAMILY 
acid I-FAMILY 
excretion O 
were O 
not O 
altered O 
by O 
EGCG B-ABBREVIATION 
administration O 
, O 
but O 
biliary O 
glutathione B-TRIVIAL 
excretion O 
was O 
reduced O 
by O 
70% O 
. O 
Accordingly O 
, O 
the O 
main O 
glutathione B-TRIVIAL 
transporter O 
on O 
the O 
hepatocyte O 
canalicular O 
membrane O 
, O 
multidrug O 
resistance O 
- O 
associated O 
protein O 
2 O 
( O 
Mrp2 O 
) O 
, O 
was O 
significantly O 
decreased O 
at O 
the O 
protein O 
level O 
. O 
EGCG B-ABBREVIATION 
administration O 
also O 
doubled O 
plasma O 
bile B-FAMILY 
acid I-FAMILY 
levels O 
compared O 
to O 
controls O 
. O 
While O 
protein O 
levels O 
of O 
the O 
main O 
hepatic O 
bile B-FAMILY 
acid I-FAMILY 
transporters O 
were O 
unchanged O 
, O 
the O 
rate O 
- O 
limiting O 
enzyme O 
in O 
the O 
bile B-FAMILY 
acid I-FAMILY 
synthesis O 
, O 
Cyp7a1 O 
, O 
was O 
significantly O 
increased O 
by O 
EGCG B-ABBREVIATION 
. O 
Enhanced O 
bile B-FAMILY 
acid I-FAMILY 
synthesis O 
in O 
these O 
animals O 
was O 
also O 
confirmed O 
by O 
a O 
2-fold O 
increase O 
in O 
plasma O 
marker O 
7α-hydroxy-4-cholesten-3-one B-SYSTEMATIC 
. O 
In O 
contrast O 
, O 
EGCG B-ABBREVIATION 
markedly O 
downregulated O 
major O 
bile B-FAMILY 
acid I-FAMILY 
transporters O 
( O 
Asbt O 
and O 
Ostα O 
) O 
and O 
regulatory O 
molecules O 
( O 
Shp O 
and O 
Fgf15 O 
) O 
in O 
the O 
ileum O 
. O 
When O 
EGCG B-ABBREVIATION 
was O 
coadministered O 
with O 
ethinylestradiol B-SYSTEMATIC 
, O 
a O 
potent O 
cholestatic O 
agent O 
, O 
it O 
did O 
not O 
show O 
any O 
additional O 
effect O 
on O 
the O 
induced O 
cholestasis O 
. O 
This O 
study O 
shows O 
ability O 
of O 
EGCG B-ABBREVIATION 
to O 
raise O 
plasma O 
bile B-FAMILY 
acid I-FAMILY 
concentrations O 
, O 
mainly O 
through O 
Cyp7a1 O 
upregulation O 
, O 
and O 
to O 
decrease O 
bile O 
production O 
through O 
reduction O 
in O 
Mrp2 O 
- O 
mediated O 
bile B-FAMILY 
acid I-FAMILY 
-independent O 
bile O 
flow O 
. O 
In O 
conclusion O 
, O 
our O 
data O 
demonstrate O 
that O 
under O 
certain O 
conditions O 
EGCG B-ABBREVIATION 
may O 
induce O 
cholestasis O 
. O 

of O 
the O 
BcgI O 
restriction O 
- O 
modification O 
protein O 
for O 
the O 
transfer O 
of O 
one O 
methyl B-SYSTEMATIC 
group O 
to O 
DNA O 
. O 

Type O 
IIB O 
restriction O 
- O 
modification O 
protein O 
BcgI O 
contains O 
A O 
and O 
B O 
subunits O 
in O 
a O 
2 O 
: O 
1 O 
ratio O 
: O 
A O 
has O 
the O 
active O 
sites O 
for O 
both O 
endonuclease O 
and O 
methyltransferase O 
functions O 
while O 
B O 
recognizes O 
the O 
DNA O 
. O 
Like O 
almost O 
all O 
Type O 
IIB O 
systems O 
, O 
BcgI O 
needs O 
two O 
unmethylated O 
sites O 
for O 
nuclease O 
activity O 
; O 
it O 
cuts O 
both O 
sites O 
upstream O 
and O 
downstream O 
of O 
the O 
recognition O 
sequence O 
, O 
hydrolyzing O 
eight O 
phosphodiester B-SYSTEMATIC 
bonds O 
in O 
a O 
single O 
synaptic O 
complex O 
. O 
This O 
complex O 
may O 
incorporate O 
four O 
A(2)B O 
protomers O 
to O 
give O 
the O 
eight O 
catalytic O 
centres O 
( O 
one O 
per O 
A O 
subunit O 
) O 
needed O 
to O 
cut O 
all O 
eight O 
bonds O 
. O 
The O 
BcgI O 
recognition O 
sequence O 
contains O 
one O 
adenine B-TRIVIAL 
in O 
each O 
strand O 
that O 
can O 
be O 
N(6)-methylated O 
. O 
Although O 
most O 
DNA O 
methyltransferases O 
operate O 
at O 
both O 
unmethylated O 
and O 
hemi O 
- O 
methylated O 
sites O 
, O 
BcgI O 
methyltransferase O 
is O 
only O 
effective O 
at O 
hemi O 
- O 
methylated O 
sites O 
, O 
where O 
the O 
nuclease O 
component O 
is O 
inactive O 
. O 
Unlike O 
the O 
nuclease O 
, O 
the O 
methyltransferase O 
acts O 
at O 
solitary O 
sites O 
, O 
functioning O 
catalytically O 
rather O 
than O 
stoichiometrically O 
. O 
Though O 
it O 
transfers O 
one O 
methyl B-SYSTEMATIC 
group O 
at O 
a O 
time O 
, O 
presumably O 
through O 
a O 
single O 
A O 
subunit O 
, O 
BcgI O 
methyltransferase O 
can O 
be O 
activated O 
by O 
adding O 
extra O 
A O 
subunits O 
, O 
either O 
individually O 
or O 
as O 
part O 
of O 
A(2)B O 
protomers O 
, O 
which O 
indicates O 
that O 
it O 
requires O 
an O 
assembly O 
containing O 
at O 
least O 
two O 
A(2)B O 
units O 
. O 

is O 
a O 
major O 
factor O 
driving O 
the O 
composition O 
and O 
metabolism O 
of O 
the O 
colonic O 
microbiota O 
. O 
The O 
amount O 
, O 
type O 
and O 
balance O 
of O 
the O 
main O 
dietary O 
macronutrients O 
( O 
carbohydrates B-FAMILY 
, O 
proteins O 
and O 
fats O 
) O 
have O 
a O 
great O 
impact O 
on O 
the O 
large O 
intestinal O 
microbiota O 
. O 
The O 
human O 
colon O 
contains O 
a O 
dense O 
population O 
of O 
bacterial O 
cells O 
that O 
outnumber O 
host O 
cells O 
10-fold O 
. O 
Bacteroidetes O 
, O 
Firmicutes O 
and O 
Actinobacteria O 
are O 
the O 
three O 
major O 
phyla O 
that O 
inhabit O 
the O 
human O 
large O 
intestine O 
and O 
these O 
bacteria O 
possess O 
a O 
fascinating O 
array O 
of O 
enzymes O 
that O 
can O 
degrade O 
complex O 
dietary O 
substrates O 
. O 
Certain O 
colonic O 
bacteria O 
are O 
able O 
to O 
metabolise O 
a O 
remarkable O 
variety O 
of O 
substrates O 
whilst O 
other O 
species O 
carry O 
out O 
more O 
specialised O 
activities O 
, O 
including O 
primary O 
degradation O 
of O 
plant O 
cell O 
walls O 
. O 
Microbial O 
metabolism O 
of O 
dietary O 
carbohydrates B-FAMILY 
results O 
mainly O 
in O 
the O 
formation O 
of O 
short O 
chain O 
fatty B-FAMILY 
acids I-FAMILY 
and O 
gases O 
. O 
The O 
major O 
bacterial O 
fermentation O 
products O 
are O 
acetate B-SYSTEMATIC 
, O 
propionate B-SYSTEMATIC 
and O 
butyrate B-SYSTEMATIC 
; O 
and O 
the O 
production O 
of O 
these O 
tends O 
to O 
lower O 
the O 
colonic O 
pH O 
. O 
These O 
weak O 
acids O 
influence O 
the O 
microbial O 
composition O 
and O 
directly O 
affect O 
host O 
health O 
, O 
with O 
butyrate B-SYSTEMATIC 
the O 
preferred O 
energy O 
source O 
for O 
the O 
colonocytes O 
. O 
Certain O 
bacterial O 
species O 
in O 
the O 
colon O 
survive O 
by O 
cross O 
- O 
feeding O 
, O 
using O 
either O 
the O 
breakdown O 
products O 
of O 
complex O 
carbohydrate B-FAMILY 
degradation O 
or O 
fermentation O 
products O 
such O 
as O 
lactic B-TRIVIAL 
acid I-TRIVIAL 
for O 
growth O 
. O 
Microbial O 
protein O 
metabolism O 
results O 
in O 
additional O 
fermentation O 
products O 
, O 
some O 
of O 
which O 
are O 
potentially O 
harmful O 
to O 
host O 
health O 
. O 
The O 
current O 
' O 
omic O 
era O 
promises O 
rapid O 
progress O 
towards O 
understanding O 
how O 
diet O 
can O 
be O 
used O 
to O 
modulate O 
the O 
composition O 
and O 
metabolism O 
of O 
the O 
gut O 
microbiota O 
, O 
allowing O 
researchers O 
to O 
provide O 
informed O 
advice O 
, O 
that O 
should O 
improve O 
long O 
- O 
term O 
health O 
status O 
. O 

effect O 
of O 
(19Z)-halichondramide B-TRIVIAL 
, O 
a O 
novel O 
marine O 
macrolide O 
isolated O 
from O 
the O 
sponge O 
Chondrosia O 
corticata O 
, O 
is O 
associated O 
with O 
G2 O 
/ O 
M O 
cell O 
cycle O 
arrest O 
and O 
suppression O 
of O 
mTOR O 
signaling O 
in O 
human O 
lung O 
cancer O 
cells O 
. O 

oxazole B-SYSTEMATIC 
-containing O 
macrolides O 
isolated O 
from O 
the O 
marine O 
sponge O 
Chondrosia O 
corticata O 
were O 
evaluated O 
for O 
their O 
anti-proliferative O 
activity O 
in O 
a O 
panel O 
of O 
human O 
solid O 
cancer O 
cell O 
lines O 
. O 
(19Z)-Halichondramide B-TRIVIAL 
( O 
(19Z)-HCA B-ABBREVIATION 
) O 
, O 
a O 
novel O 
trisoxazole B-SYSTEMATIC 
-containing O 
macrolide O 
, O 
exhibited O 
the O 
highest O 
potency O 
among O 
the O 
macrolides O 
, O 
with O 
IC50 O 
values O 
in O 
the O 
submicro O 
- O 
molar O 
ranges O 
. O 
Prompted O 
by O 
the O 
high O 
potency O 
of O 
growth O 
inhibition O 
of O 
cancer O 
cells O 
, O 
we O 
investigated O 
the O 
mechanism O 
of O 
action O 
of O 
the O 
anti-proliferative O 
activity O 
of O 
(19Z)-HCA B-ABBREVIATION 
in O 
human O 
A549 O 
lung O 
cancer O 
cells O 
. O 
(19Z)-HCA B-ABBREVIATION 
induced O 
cell O 
cycle O 
arrest O 
in O 
the O 
G2 O 
/ O 
M O 
phase O 
, O 
and O 
this O 
event O 
was O 
highly O 
correlated O 
with O 
the O 
expression O 
of O 
checkpoint O 
proteins O 
, O 
including O 
the O 
up O 
- O 
regulation O 
of O 
p53 O 
and O 
GADD45α O 
and O 
the O 
down O 
- O 
regulation O 
of O 
cyclin O 
B1 O 
, O 
cyclin O 
A O 
, O 
CDC2 O 
, O 
and O 
CDC25C O 
. O 
In O 
addition O 
, O 
the O 
growth O 
inhibition O 
by O 
(19Z)-HCA B-ABBREVIATION 
was O 
associated O 
with O 
the O 
suppression O 
of O 
mTOR O 
and O 
its O 
downstream O 
effector O 
molecules O 
4EBP1 O 
and O 
p70S6K O 
. O 
The O 
modulation O 
of O 
mTOR O 
signaling O 
by O 
(19Z)-HCA B-ABBREVIATION 
was O 
found O 
to O 
be O 
mediated O 
by O 
the O 
regulation O 
of O 
upstream O 
proteins O 
, O 
including O 
the O 
down O 
- O 
regulation O 
of O 
Akt O 
and O 
p38 O 
MAPK O 
and O 
the O 
up O 
- O 
regulation O 
of O 
AMPK O 
. O 
These O 
data O 
suggest O 
the O 
potential O 
of O 
(19Z)-HCA B-ABBREVIATION 
to O 
serve O 
as O 
a O 
candidate O 
for O 
cancer O 
chemotherapeutic O 
agents O 
derived O 
from O 
marine O 
organisms O 
by O 
virtue O 
of O 
arresting O 
the O 
cell O 
cycle O 
in O 
the O 
G2 O 
/ O 
M O 
phase O 
and O 
the O 
modulation O 
of O 
mTOR O 
/ O 
AMPK O 
signaling O 
pathways O 
. O 

- O 
induced O 
oxidative O 
injury O 
to O 
red O 
blood O 
cells O 
results O 
in O 
Heinz O 
body O 
hemolytic O 
anemia O 
. O 
Here O 
, O 
we O 
evaluated O 
three O 
Heinz O 
body O 
staining O 
techniques O 
in O 
brown O 
pelican O 
( O 
Pelecanus O 
occidentalis O 
) O 
blood O 
. O 
Using O 
a O 
range O 
of O 
in O 
vitro O 
acetylphenylhydrazine B-SYSTEMATIC 
incubations O 
, O 
we O 
validated O 
a O 
field O 
- O 
adapted O 
technique O 
against O 
laboratory O 
wet O 
- O 
mounts O 
and O 
verified O 
the O 
stability O 
of O 
this O 
technique O 
for O 
one O 
month O 
following O 
preparation O 
. O 
Employing O 
this O 
technique O 
during O 
petrochemical O 
spill O 
responses O 
allows O 
for O 
delays O 
between O 
sample O 
collection O 
and O 
analysis O 
. O 

- O 
based O 
marine O 
ecological O 
risk O 
assessment O 
at O 
a O 
polychlorinated B-FAMILY 
biphenyl I-FAMILY 
-contaminated O 
site O 
in O 
Saglek O 
, O 
Labrador O 
, O 
Canada O 
. O 

the O 
presence O 
and O 
distribution O 
of O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
( O 
PCBs B-ABBREVIATION 
) O 
in O 
Arctic O 
marine O 
environments O 
has O 
been O 
well O 
documented O 
, O 
the O 
implications O 
for O 
the O 
health O 
of O 
biota O 
are O 
poorly O 
understood O 
. O 
In O 
the O 
present O 
study O 
, O 
multiple O 
lines O 
of O 
evidence O 
, O 
including O 
site O 
- O 
specific O 
effects O 
data O 
, O 
were O 
used O 
to O 
assess O 
PCB B-ABBREVIATION 
-related O 
risks O 
to O 
marine O 
biota O 
at O 
a O 
contaminated O 
military O 
site O 
in O 
Saglek O 
Bay O 
, O 
Labrador O 
, O 
Canada O 
, O 
from O 
1997 O 
to O 
1999 O 
. O 
Risks O 
were O 
evaluated O 
for O 
three O 
components O 
of O 
the O 
ecosystem O 
: O 
benthic O 
invertebrates O 
, O 
a O 
bottom O 
- O 
feeding O 
fish O 
( O 
shorthorn O 
sculpin O 
, O 
Myoxocephalus O 
scorpius O 
) O 
, O 
and O 
a O 
diving O 
seabird O 
( O 
black O 
guillemot O 
, O 
Cepphus O 
grylle O 
) O 
. O 
Average O 
sediment O 
PCB B-ABBREVIATION 
concentrations O 
exceeded O 
the O 
Canadian O 
interim O 
sediment O 
quality O 
guideline O 
level O 
by O 
41-fold O 
. O 
However O 
, O 
sediment O 
toxicity O 
testing O 
and O 
a O 
benthic O 
community O 
survey O 
showed O 
no O 
evidence O 
of O 
adverse O 
effects O 
. O 
In O 
contrast O 
, O 
shorthorn O 
sculpin O 
and O 
black O 
guillemot O 
PCB B-ABBREVIATION 
exposures O 
( O 
measured O 
as O 
sum O 
of O 
55 O 
congeners O 
) O 
were O 
elevated O 
enough O 
to O 
pose O 
risks O 
to O 
survival O 
or O 
reproduction O 
. O 
Based O 
on O 
the O 
collective O 
evidence O 
, O 
the O 
authors O 
estimated O 
that O 
risks O 
were O 
posed O 
by O 
sediment O 
PCB B-ABBREVIATION 
concentrations O 
greater O 
than O 
77 O 
ng O 
/ O 
g O 
dry O 
weight O 
for O 
black O 
guillemots O 
and O 
750 O 
ng O 
/ O 
g O 
dry O 
weight O 
for O 
shorthorn O 
sculpins O 
. O 
The O 
present O 
study O 
, O 
along O 
with O 
two O 
parallel O 
studies O 
, O 
provided O 
information O 
to O 
support O 
the O 
management O 
decisions O 
concerning O 
potential O 
remedial O 
action O 
on O 
the O 
contaminated O 
sediments O 
. O 
This O 
ecological O 
risk O 
assessment O 
describes O 
the O 
steps O 
and O 
rationale O 
taken O 
to O 
evaluate O 
the O 
risk O 
posed O 
by O 
an O 
area O 
of O 
PCB B-ABBREVIATION 
-contaminated O 
marine O 
sediments O 
in O 
an O 
otherwise O 
relatively O 
pristine O 
northern O 
coastal O 
environment O 
. O 

competent O 
human O 
skin O 
models O 
: O 
activation O 
and O 
genotoxicity O 
of O 
benzo[a]pyrene B-SYSTEMATIC 
. O 

polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbon I-FAMILY 
( O 
PAH B-ABBREVIATION 
) O 
benzo[a]pyrene B-SYSTEMATIC 
( O 
BP O 
) O 
is O 
metabolized O 
into O 
a O 
complex O 
pattern O 
of O 
BP O 
derivatives O 
, O 
among O 
which O 
the O 
ultimate O 
carcinogen O 
(+)-anti-BP-7,8-diol-9,10-epoxide B-SYSTEMATIC 
( O 
BPDE B-ABBREVIATION 
) O 
is O 
formed O 
to O 
certain O 
extents O 
. O 
Skin O 
is O 
frequently O 
in O 
contact O 
with O 
PAHs B-ABBREVIATION 
and O 
data O 
on O 
the O 
metabolic O 
capacity O 
of O 
skin O 
tissue O 
toward O 
these O 
compounds O 
are O 
inconclusive O 
. O 
We O 
compared O 
BP O 
metabolism O 
in O 
excised O 
human O 
skin O 
, O 
commercially O 
available O 
in O 
vitro O 
3D O 
skin O 
models O 
and O 
primary O 
2D O 
skin O 
cell O 
cultures O 
, O 
and O 
analyzed O 
the O 
metabolically O 
catalyzed O 
occurrence O 
of O 
seven O 
different O 
BP O 
follow O 
- O 
up O 
products O 
by O 
means O 
of O 
liquid O 
chromatography O 
coupled O 
to O 
tandem O 
mass O 
spectrometry O 
( O 
LC-MS O 
/ O 
MS O 
) O 
. O 
All O 
models O 
investigated O 
were O 
competent O 
to O 
metabolize O 
BP O 
, O 
and O 
the O 
metabolic O 
profiles O 
generated O 
by O 
ex O 
vivo O 
human O 
skin O 
and O 
skin O 
models O 
were O 
remarkably O 
similar O 
. O 
Furthermore O 
, O 
the O 
genotoxicity O 
of O 
BP O 
and O 
its O 
derivatives O 
was O 
monitored O 
in O 
these O 
models O 
via O 
comet O 
assays O 
. O 
In O 
a O 
full O 
- O 
thickness O 
skin O 
, O 
equivalent O 
BP O 
- O 
mediated O 
genotoxic O 
stress O 
was O 
generated O 
via O 
keratinocytes O 
. O 
Cultured O 
primary O 
keratinocytes O 
revealed O 
a O 
level O 
of O 
genotoxicity O 
comparable O 
with O 
that O 
of O 
direct O 
exposure O 
to O 
50-100 O 
nM O 
of O 
BPDE B-ABBREVIATION 
. O 
Our O 
data O 
demonstrate O 
that O 
the O 
metabolic O 
capacity O 
of O 
human O 
skin O 
ex O 
vivo O 
, O 
as O 
well O 
as O 
organotypic O 
human O 
3D O 
skin O 
models O 
toward O 
BP O 
, O 
is O 
sufficient O 
to O 
cause O 
significant O 
genotoxic O 
stress O 
and O 
thus O 
cutaneous O 
bioactivation O 
may O 
potentially O 
contribute O 
to O 
mutations O 
that O 
ultimately O 
lead O 
to O 
skin O 
cancer O 
. O 

to O 
variable O 
light O 
intensity O 
in O 
photoacclimated O 
algae O 
and O 
cyanobacteria O 
exposed O 
to O 
atrazine B-TRIVIAL 
. O 

is O 
frequently O 
detected O 
in O 
freshwater O 
ecosystems O 
exposed O 
to O 
agricultural O 
waste O 
waters O 
and O 
runoffs O 
worldwide O 
and O 
it O 
can O 
affect O 
non-target O 
organisms O 
( O 
mainly O 
photoautotrophic O 
) O 
and O 
modify O 
community O 
structure O 
. O 
Meanwhile O 
, O 
light O 
environment O 
is O 
known O 
to O 
vary O 
between O 
aquatic O 
ecosystems O 
, O 
but O 
also O 
before O 
and O 
during O 
the O 
exposure O 
to O 
atrazine B-TRIVIAL 
and O 
these O 
variations O 
may O 
modify O 
the O 
sensitivity O 
to O 
atrazine B-TRIVIAL 
of O 
photoautotroph O 
organisms O 
. O 
In O 
this O 
study O 
, O 
10 O 
species O 
of O 
phytoplankton O 
( O 
chlorophytes O 
, O 
baccilariophytes O 
and O 
cyanophytes O 
) O 
acclimated O 
to O 
low O 
or O 
high O 
light O 
intensities O 
were O 
exposed O 
to O 
atrazine B-TRIVIAL 
and O 
light O 
of O 
different O 
intensities O 
to O 
compare O 
their O 
combined O 
effect O 
. O 
Our O 
data O 
showed O 
that O 
chlorophytes O 
and O 
baccilariophytes O 
were O 
more O 
resistant O 
to O 
atrazine B-TRIVIAL 
compared O 
to O 
cyanophytes O 
for O 
all O 
light O 
conditions O 
. O 
Atrazine B-TRIVIAL 
was O 
found O 
to O 
inhibit O 
Φ'(M) O 
, O 
Ψ(0) O 
, O 
P(M) O 
and O 
non-photochemical O 
quenching O 
for O 
all O 
species O 
indicating O 
an O 
effect O 
on O 
electron O 
transport O 
, O 
primary O 
production O 
and O 
photoregulation O 
processes O 
. O 
These O 
data O 
also O 
indicate O 
a O 
higher O 
sensitivity O 
of O 
Ψ(0) O 
( O 
average O 
Ψ(0)-EC(50) O 
of O 
91 O 
± O 
11 O 
nM O 
or O 
19.6 O 
± O 
0.9 O 
μgL(-1) O 
) O 
compared O 
to O 
Φ'(M) O 
( O 
average O 
Φ'(M)-EC(50) O 
of O 
217 O 
± O 
19 O 
nM O 
or O 
46.8 O 
± O 
4.1 O 
μgL(-1) O 
) O 
and O 
suggest O 
that O 
photoregulation O 
processes O 
activated O 
in O 
presence O 
of O 
light O 
decrease O 
the O 
effect O 
of O 
atrazine B-TRIVIAL 
. O 
We O 
also O 
showed O 
that O 
increasing O 
light O 
intensity O 
decreased O 
Φ'(M)-EC(50) O 
in O 
both O 
low O 
( O 
except O 
baccilariophytes O 
) O 
and O 
high O 
light O 
acclimated O 
conditions O 
. O 
Despite O 
this O 
similarity O 
, O 
most O 
species O 
acclimated O 
to O 
high O 
light O 
were O 
found O 
to O 
have O 
higher O 
or O 
similar O 
Φ'(M)-EC(50) O 
compared O 
to O 
low O 
light O 
acclimated O 
cells O 
and O 
thus O 
, O 
were O 
less O 
sensitive O 
to O 
atrazine B-TRIVIAL 
in O 
low O 
light O 
and O 
high O 
light O 
environments O 
. O 
We O 
concluded O 
that O 
an O 
increase O 
in O 
the O 
plastoquinone B-TRIVIAL 
pool O 
induced O 
by O 
acclimation O 
to O 
high O 
light O 
decreased O 
the O 
sensitivity O 
to O 
atrazine B-TRIVIAL 
in O 
phytoplankton O 
and O 
we O 
hypothesized O 
that O 
the O 
effect O 
observed O 
was O 
the O 
result O 
of O 
a O 
dilution O 
of O 
atrazine B-TRIVIAL 
toxicity O 
through O 
increased O 
binding O 
site O 
availability O 
( O 
quinones B-FAMILY 
) O 
combined O 
with O 
increased O 
photoregulation O 
processes O 
capacity O 
. O 

duration O 
of O 
diabetes O 
and O 
disuse O 
of O 
sulfonylurea B-FAMILY 
have O 
any O 
association O 
with O 
insulin O 
cessation O 
of O 
the O 
patients O 
with O 
type O 
2 O 
diabetes O 
in O 
a O 
clinical O 
setting O 
in O 
Japan O 
( O 
JDDM O 
30 O 
) O 
. O 

therapy O 
is O 
often O 
required O 
to O 
achieve O 
good O 
glycemic O 
control O 
for O 
the O 
patients O 
with O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
, O 
while O 
protraction O 
of O 
glycemic O 
control O 
without O 
insulin O 
therapy O 
may O 
be O 
preferable O 
for O 
patients O 
. O 
To O 
determine O 
the O 
characteristics O 
of O 
and O 
therapeutic O 
regimen O 
in O 
outpatients O 
with O 
T2DM O 
who O 
were O 
able O 
to O 
stop O 
insulin O 
therapy O 
with O 
satisfactory O 
glycemic O 
control O 
in O 
a O 
real O 
clinical O 
practice O 
setting O 
in O 
Japan O 
by O 
a O 
case O 
- O 
control O 
study O 
. O 
The O 
present O 
study O 
was O 
performed O 
on O 
928 O 
patients O 
with O 
T2DM O 
who O 
started O 
insulin O 
therapy O 
in O 
2007 O 
. O 
Data O 
regarding O 
age O 
, O 
sex O 
, O 
body O 
mass O 
index O 
, O 
duration O 
of O 
diabetes O 
, O 
HbA1c O 
, O 
postprandial O 
plasma O 
glucose B-TRIVIAL 
, O 
plasma O 
fasting O 
C- O 
peptide O 
immunoreactivity O 
and O 
treatment O 
modality O 
were O 
compared O 
between O 
patients O 
who O 
were O 
able O 
to O 
stop O 
insulin O 
therapy O 
and O 
those O 
who O 
continued O 
with O 
insulin O 
. O 
Of O 
the O 
928 O 
patients O 
, O 
37 O 
had O 
stopped O 
insulin O 
therapy O 
within O 
1 O 
year O 
. O 
In O 
the O 
patients O 
who O 
stopped O 
insulin O 
therapy O 
, O 
the O 
duration O 
of O 
diabetes O 
was O 
significantly O 
shorter O 
and O 
the O 
daily O 
insulin O 
dosage O 
at O 
initiation O 
and O 
the O 
prevalence O 
of O 
sulfonylurea B-FAMILY 
pretreatment O 
significantly O 
lower O 
compared O 
with O 
patients O 
who O 
continued O 
on O 
insulin O 
. O 
In O 
conclusion O 
, O 
almost O 
4% O 
of O 
T2DM O 
patients O 
were O 
able O 
to O 
stop O 
insulin O 
therapy O 
with O 
satisfactory O 
glycemic O 
control O 
in O 
a O 
real O 
clinical O 
practice O 
setting O 
in O 
Japan O 
. O 
Shorter O 
duration O 
of O 
diabetes O 
and O 
disuse O 
of O 
sulfonylureas B-FAMILY 
prior O 
to O 
insulin O 
may O 
associate O 
with O 
stopping O 
insulin O 
therapy O 
as O 
a O 
near O 
- O 
normoglycemic O 
remission O 
in O 
outpatients O 
with O 
T2DM O 
in O 
Japan O 
. O 

, O 
synthesis O 
and O 
anticancer O 
activity O 
of O 
N(3),N(11)-bis(2-hydroxyethyl)-14-aryl-14H-dibenzo[a,j]xanthenes-3,11-dicarboxamide B-FAMILY 
. O 

series O 
of O 
novel O 
N(3),N(11)-bis(2-hydroxyethyl)-14-aryl-14H-dibenzo[a,j]xanthenes-3,11-dicarboxamide B-FAMILY 
, O 
three O 
N(3),N(11)-bis(2-hydroxyethyl)-14-aryl-14H-dibenzo[a,j]xanthene-3,11-dimethanamine B-FAMILY 
derivatives O 
and O 
their O 
intermediates O 
14-aryl-14H-dibenzo[a,j]xanthenes-3,11-dicarboxylic B-FAMILY 
acid I-FAMILY 
, O 
were O 
synthesized O 
, O 
and O 
the O 
structures O 
of O 
which O 
were O 
characterized O 
by O 
(1)H B-FORMULA 
-NMR O 
, O 
(13)C B-FORMULA 
-NMR O 
, O 
high O 
resolution O 
(HR)-MS O 
, O 
and O 
IR O 
spectra O 
. O 
The O 
antitumor O 
activities O 
of O 
these O 
molecules O 
were O 
evaluated O 
on O 
five O 
cancer O 
cell O 
lines O 
. O 
The O 
results O 
of O 
in O 
vitro O 
assay O 
against O 
human O 
hepatocellular O 
carcinoma O 
cell O 
lines O 
( O 
SK-HEP-1 O 
and O 
HepG2 O 
and O 
SMMC-7721 O 
cells O 
) O 
, O 
acute O 
promyelocytic O 
leukemia O 
NB4 O 
cells O 
and O 
uterine O 
cervix O 
cancer O 
HeLa O 
cells O 
, O 
show O 
several O 
compounds O 
to O 
be O 
endowed O 
with O 
cytotoxicity O 
in O 
micromolar O 
to O 
submicromolar O 
range O 
. O 
The O 
carboxamide B-SYSTEMATIC 
derivatives O 
6c O 
and O 
6e O 
exhibitted O 
good O 
inhibition O 
on O 
NB4 O 
cancer O 
cells O 
, O 
and O 
the O 
IC(50) O 
values O 
of O 
which O 
were O 
0.82 O 
µM O 
and O 
0.96 O 
µM O 
, O 
respectively O 
, O 
much O 
lower O 
than O 
5.01 O 
µM O 
of O 
the O 
positive O 
control O 
As(2)O(3) B-FORMULA 
. O 
Flow O 
cytometric O 
analysis O 
results O 
revealed O 
that O 
compounds O 
6e O 
and O 
6f O 
may O 
induce O 
tumor O 
cell O 
apoptosis O 
. O 

breast O 
cancer O 
resistance O 
protein O 
( O 
BCRP O 
/ O 
ABCG2 O 
) O 
is O 
a O 
member O 
of O 
the O 
ABC O 
transporter O 
superfamily O 
. O 
This O 
protein O 
has O 
a O 
number O 
of O 
physiological O 
functions O 
, O 
including O 
protection O 
of O 
the O 
human O 
body O 
from O 
xenobiotics O 
. O 
The O 
overexpression O 
of O 
BCRP O 
in O 
certain O 
tumor O 
cell O 
lines O 
causes O 
cross O 
- O 
resistance O 
against O 
various O 
drugs O 
used O 
in O 
chemotherapeutic O 
treatment O 
. O 
In O 
a O 
previous O 
work O 
we O 
showed O 
that O 
a O 
new O 
class O 
of O 
compounds O 
derived O 
from O 
XR9576 B-IDENTIFIER 
( O 
tariquidar B-TRIVIAL 
) O 
selectively O 
inhibits O 
BCRP O 
. O 
In O 
this O 
work O 
we O 
synthesized O 
more O 
members O 
of O 
this O 
class O 
, O 
with O 
modification O 
on O 
the O 
second O 
and O 
third O 
aromatic O 
rings O 
. O 
The O 
inhibitory O 
activities O 
against O 
BCRP O 
and O 
P-gp O 
were O 
assayed O 
using O 
a O 
Hoechst B-TRIVIAL 
33342 I-TRIVIAL 
assay O 
for O 
BCRP O 
and O 
a O 
calcein O 
AM O 
assay O 
for O 
P-gp O 
. O 
Finally O 
, O 
quantitative O 
structure O 
- O 
activity O 
relationships O 
for O 
both O 
aromatic O 
rings O 
were O 
established O 
. O 
The O 
results O 
obtained O 
show O 
the O 
importance O 
of O 
the O 
electron O 
density O 
on O 
the O 
third O 
aromatic O 
ring O 
, O 
influenced O 
by O 
substituents O 
, O 
pointing O 
to O 
interactions O 
with O 
aromatic O 
residues O 
of O 
the O 
protein O 
binding O 
site O 
. O 
In O 
the O 
second O 
aromatic O 
ring O 
the O 
activity O 
of O 
compounds O 
is O 
influenced O 
by O 
the O 
steric O 
volume O 
of O 
the O 
substituents O 
. O 

of O 
helical O 
content O 
by O 
insertion O 
of O 
a O 
disulfide B-SYSTEMATIC 
bond O 
leads O 
to O 
an O 
antimicrobial O 
peptide O 
with O 
decreased O 
hemolytic O 
activity O 
. O 

off O 
to O 
the O 
S-S B-FORMULA 
bond O 
: O 
Application O 
of O 
a O 
strategy O 
involving O 
the O 
introduction O 
of O 
intramolecular O 
disulfide B-SYSTEMATIC 
bonds O 
to O 
amphipathic O 
cationic O 
antimicrobial O 
peptides O 
( O 
CAPs O 
) O 
led O 
to O 
decreased O 
α-helicity O 
and O 
hydrophobicity O 
. O 
The O 
mutant O 
peptides O 
were O 
observed O 
to O 
have O 
significantly O 
increased O 
( O 
250-fold O 
) O 
minimum O 
hemolytic O 
concentrations O 
while O 
maintaining O 
MIC O 
values O 
against O 
E. O 
coli O 
, O 
affording O 
more O 
therapeutically O 
selective O 
CAPs O 
. O 

is O 
considerable O 
evidence O 
that O 
drug O 
disposition O 
is O 
altered O 
during O 
human O 
pregnancy O 
and O 
based O 
on O 
probe O 
drug O 
studies O 
, O 
CYP2D6 O 
activity O 
increases O 
during O 
human O 
pregnancy O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
whether O 
the O 
changes O 
of O 
CYP2D6 O 
activity O 
observed O 
during O 
human O 
pregnancy O 
could O 
be O 
replicated O 
in O 
the O 
mouse O 
, O 
and O 
explore O 
possible O 
mechanisms O 
of O 
increased O 
CYP2D6 O 
activity O 
during O 
pregnancy O 
. O 
Cyp2d11 O 
, O 
Cyp2d22 O 
, O 
Cyp2d26 O 
and O 
Cyp2d40 O 
mRNA O 
was O 
increased O 
( O 
P O 
< O 
0.05 O 
) O 
on O 
gestational O 
days O 
( O 
GD O 
) O 
15 O 
and O 
19 O 
compared O 
with O 
the O 
non-pregnant O 
controls O 
. O 
There O 
was O 
no O 
change O 
( O 
P O 
> O 
0.05 O 
) O 
in O 
Cyp2d9 O 
and O 
Cyp2d10 O 
mRNA O 
. O 
In O 
agreement O 
with O 
the O 
increased O 
Cyp2d O 
mRNA O 
, O 
Cyp2d O 
- O 
mediated O 
dextrorphan B-TRIVIAL 
formation O 
from O 
dextromethorphan B-TRIVIAL 
was O 
increased O 
2.7-fold O 
( O 
P O 
< O 
0.05 O 
) O 
on O 
GD19 O 
( O 
56.8±39.4 O 
pmol O 
/ O 
min O 
/ O 
mg O 
protein O 
) O 
when O 
compared O 
with O 
the O 
non-pregnant O 
controls O 
( O 
20.8±11.2 O 
pmol O 
/ O 
min O 
/ O 
mg O 
protein O 
) O 
. O 
An O 
increase O 
in O 
Cyp26a1 O 
mRNA O 
( O 
10-fold O 
) O 
and O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
receptor O 
(Rar)β O 
mRNA O 
( O 
2.8-fold O 
) O 
was O 
also O 
observed O 
during O 
pregnancy O 
. O 
The O 
increase O 
in O 
Cyp26a1 O 
and O 
Rarβ O 
mRNA O 
during O 
pregnancy O 
indicates O 
increased O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
signaling O 
in O 
the O 
liver O 
during O 
pregnancy O 
. O 
A O 
putative O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
response O 
element O 
was O 
identified O 
within O 
the O 
Cyp2d40 O 
promoter O 
and O 
the O 
mRNA O 
of O 
Cyp2d40 O 
correlated O 
( O 
P O 
< O 
0.05 O 
) O 
with O 
Cyp26a1 O 
and O 
Rarβ O 
. O 
These O 
results O 
show O 
that O 
Cyp2d O 
mRNA O 
is O 
increased O 
during O 
mouse O 
pregnancy O 
the O 
and O 
mouse O 
may O 
provide O 
a O 
suitable O 
model O 
to O 
investigate O 
the O 
mechanisms O 
underlying O 
the O 
increased O 
clearance O 
of O 
CYP2D6 O 
probes O 
observed O 
during O 
human O 
pregnancy O 
. O 
Our O 
findings O 
also O 
suggest O 
that O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
signaling O 
in O 
the O 
liver O 
is O 
increased O 
during O 
pregnancy O 
, O 
which O 
may O 
have O 
broader O 
implications O 
to O 
energy O 
homeostasis O 
in O 
the O 
liver O 
during O 
pregnancy O 
. O 

to O 
fatty B-FAMILY 
acid I-FAMILY 
-induced O 
β-cell O 
dysfunction O 
is O 
enhanced O 
in O 
prediabetic O 
diabetes O 
- O 
prone O 
biobreeding O 
rats O 
: O 
a O 
potential O 
link O 
between O 
β-cell O 
lipotoxicity O 
and O 
islet O 
inflammation O 
. O 

lipotoxicity O 
is O 
thought O 
to O 
play O 
an O 
important O 
role O 
in O 
the O 
development O 
of O 
type O 
2 O 
diabetes O 
. O 
However O 
, O 
no O 
study O 
has O 
examined O 
its O 
role O 
in O 
type O 
1 O 
diabetes O 
, O 
which O 
could O 
be O 
clinically O 
relevant O 
for O 
slow O 
- O 
onset O 
type O 
1 O 
diabetes O 
. O 
Reports O 
of O 
enhanced O 
cytokine O 
toxicity O 
in O 
fat O 
- O 
laden O 
islets O 
are O 
consistent O 
with O 
the O 
hypothesis O 
that O 
lipid O 
and O 
cytokine O 
toxicity O 
may O 
be O 
synergistic O 
. O 
Thus O 
, O 
β-cell O 
lipotoxicity O 
could O 
be O 
enhanced O 
in O 
models O 
of O 
autoimmune O 
diabetes O 
. O 
To O 
determine O 
this O 
, O 
we O 
examined O 
the O 
effects O 
of O 
prolonged O 
free O 
fatty B-FAMILY 
acids I-FAMILY 
elevation O 
on O 
β-cell O 
secretory O 
function O 
in O 
the O 
prediabetic O 
diabetes O 
- O 
prone O 
BioBreeding O 
( O 
dp-BB O 
) O 
rat O 
, O 
its O 
diabetes O 
- O 
resistant O 
BioBreeding O 
( O 
dr-BB O 
) O 
control O 
, O 
and O 
normal O 
Wistar-Furth O 
( O 
WF O 
) O 
rats O 
. O 
Rats O 
received O 
a O 
48-h O 
iv O 
infusion O 
of O 
saline O 
or O 
Intralipid O 
plus O 
heparin O 
( O 
IH O 
) O 
( O 
to O 
elevate O 
free O 
fatty B-FAMILY 
acid I-FAMILY 
levels O 
~2-fold O 
) O 
followed O 
by O 
hyperglycemic O 
clamp O 
or O 
islet O 
secretion O 
studies O 
ex O 
vivo O 
. O 
IH O 
significantly O 
decreased O 
β-cell O 
function O 
, O 
assessed O 
both O 
by O 
the O 
disposition O 
index O 
( O 
insulin O 
secretion O 
corrected O 
for O 
IH-induced O 
insulin O 
resistance O 
) O 
and O 
in O 
isolated O 
islets O 
, O 
in O 
dp-BB O 
, O 
but O 
not O 
in O 
dr-BB O 
or O 
WF O 
, O 
rats O 
, O 
and O 
the O 
effect O 
of O 
IH O 
was O 
inhibited O 
by O 
the O 
antioxidant O 
N-acetylcysteine B-SYSTEMATIC 
. O 
Furthermore O 
, O 
IH O 
significantly O 
increased O 
islet O 
cytokine O 
mRNA O 
and O 
plasma O 
cytokine O 
levels O 
( O 
monocyte O 
chemoattractant O 
protein-1 O 
and O 
IL-10 O 
) O 
in O 
dp-BB O 
, O 
but O 
not O 
in O 
dr-BB O 
or O 
WF O 
, O 
rats O 
. O 
All O 
dp-BB O 
rats O 
had O 
mononuclear O 
infiltration O 
of O 
islets O 
, O 
which O 
was O 
absent O 
in O 
dr-BB O 
and O 
WF O 
rats O 
. O 
In O 
conclusion O 
, O 
the O 
presence O 
of O 
insulitis O 
was O 
permissive O 
for O 
IH-induced O 
β-cell O 
dysfunction O 
in O 
the O 
BB O 
rat O 
, O 
which O 
suggests O 
a O 
link O 
between O 
β-cell O 
lipotoxicity O 
and O 
islet O 
inflammation O 
. O 

this O 
study O 
, O 
we O 
have O 
investigated O 
the O 
expression O 
and O 
function O 
of O 
the O 
transcription O 
factor O 
early O 
growth O 
response O 
factor O 
2 O 
( O 
Egr2 O 
) O 
/ O 
Krox20 O 
in O 
the O 
developing O 
anterior O 
pituitary O 
. O 
Egr2 O 
is O 
initially O 
expressed O 
in O 
all O 
differentiating O 
hormonal O 
cells O 
types O 
, O 
but O 
its O 
expression O 
is O 
mostly O 
restricted O 
to O 
the O 
somatotroph O 
lineage O 
after O 
birth O 
. O 
Egr2 O 
knockout O 
results O 
in O 
anterior O 
pituitary O 
hypoplasia O 
. O 
However O 
, O 
the O 
analysis O 
of O 
a O 
conditional O 
mutant O 
demonstrates O 
that O 
this O 
phenotype O 
does O 
not O 
originate O 
from O 
a O 
lack O 
of O 
Egr2 O 
expression O 
in O 
the O 
pituitary O 
. O 
Using O 
an O 
Egr2 O 
allele O 
driving O 
a O 
Cre O 
- O 
activable O 
toxin O 
gene O 
, O 
we O 
performed O 
a O 
genetic O 
ablation O 
of O 
Egr2-positive O 
cells O 
in O 
the O 
pituitary O 
. O 
During O 
the O 
postnatal O 
period O 
, O 
this O 
ablation O 
leads O 
to O 
specific O 
and O 
progressive O 
depletion O 
of O 
the O 
somatotroph O 
population O 
, O 
creating O 
a O 
novel O 
model O 
of O 
early O 
- O 
onset O 
isolated O 
GH O 
deficiency O 
( O 
GHD O 
) O 
. O 
Mutant O 
animals O 
were O 
subjected O 
to O 
a O 
complete O 
metabolic O 
analysis O 
, O 
revealing O 
atypical O 
and O 
expected O 
features O 
. O 
Consistent O 
with O 
an O 
adult O 
- O 
onset O 
isolated O 
GHD O 
model O 
, O 
mutant O 
animals O 
are O 
hypoglycemic O 
and O 
display O 
increased O 
insulin O 
sensitivity O 
and O 
glucose B-TRIVIAL 
clearance O 
. O 
This O 
latter O 
phenotype O 
is O 
in O 
contrast O 
to O 
the O 
glucose B-TRIVIAL 
intolerance O 
observed O 
in O 
another O 
early O 
- O 
onset O 
GHD O 
model O 
. O 
Surprisingly O 
, O 
increased O 
insulin O 
sensitivity O 
is O 
not O 
accompanied O 
by O 
a O 
modified O 
balance O 
between O 
fat O 
and O 
lean O 
tissues O 
, O 
but O 
by O 
reduced O 
metabolic O 
adaptability O 
between O 
glucose B-TRIVIAL 
and O 
lipid O 
oxidation O 
conditions O 
. O 
This O 
suggests O 
that O 
the O 
relationship O 
between O 
these O 
metabolic O 
features O 
and O 
insulin O 
sensitivity O 
should O 
be O 
reconsidered O 
. O 
In O 
conclusion O 
, O 
our O 
mutant O 
may O 
be O 
a O 
valuable O 
genetic O 
model O 
with O 
which O 
to O 
study O 
the O 
effects O 
of O 
long O 
- O 
term O 
GH O 
deficiency O 
, O 
in O 
conditions O 
of O 
normal O 
pancreatic O 
function O 
and O 
unaffected O 
balance O 
between O 
fat O 
and O 
glucose B-TRIVIAL 
metabolism O 
. O 

bulk O 
structure O 
of O 
biological O 
membranes O 
consists O 
of O 
a O 
bilayer O 
of O 
amphipathic O 
lipids O 
. O 
According O 
to O 
the O 
fluid O 
mosaic O 
model O 
proposed O 
by O 
Singer O 
and O 
Nicholson O 
, O 
the O 
glycerophospholipid B-FAMILY 
bilayer O 
is O 
a O 
two O 
- O 
dimensional O 
fluid O 
construct O 
that O 
allows O 
the O 
lateral O 
movement O 
of O 
membrane O 
components O 
. O 
Different O 
types O 
of O 
lateral O 
interactions O 
among O 
membrane O 
components O 
can O 
take O 
place O 
, O 
giving O 
rise O 
to O 
multiple O 
levels O 
of O 
lateral O 
order O 
that O 
lead O 
to O 
highly O 
organized O 
structures O 
. O 
Early O 
observations O 
suggested O 
that O 
some O 
of O 
the O 
lipid O 
components O 
of O 
biological O 
membranes O 
may O 
play O 
active O 
roles O 
in O 
the O 
creation O 
of O 
these O 
levels O 
of O 
order O 
. O 
In O 
the O 
late O 
1980s O 
, O 
a O 
diverse O 
series O 
of O 
experimental O 
findings O 
collectively O 
gave O 
rise O 
to O 
the O 
lipid O 
raft O 
hypothesis O 
. O 
Lipid O 
rafts O 
were O 
originally O 
defined O 
as O 
membrane O 
domains O 
, O 
i.e O 
. O 
, O 
ordered O 
structures O 
created O 
as O 
a O 
consequence O 
of O 
the O 
lateral O 
segregation O 
of O 
sphingolipids B-FAMILY 
and O 
differing O 
from O 
the O 
surrounding O 
membrane O 
in O 
their O 
molecular O 
composition O 
and O 
properties O 
. O 
This O 
definition O 
was O 
subsequently O 
modified O 
to O 
introduce O 
the O 
notion O 
that O 
lipid O 
rafts O 
correspond O 
to O 
membrane O 
areas O 
stabilized O 
by O 
the O 
presence O 
of O 
cholesterol B-TRIVIAL 
within O 
a O 
liquid O 
- O 
ordered O 
phase O 
. O 
During O 
the O 
past O 
two O 
decades O 
, O 
the O 
concept O 
of O 
lipid O 
rafts O 
has O 
become O 
extremely O 
popular O 
among O 
cell O 
biologists O 
, O 
and O 
these O 
structures O 
have O 
been O 
suggested O 
to O 
be O 
involved O 
in O 
a O 
great O 
variety O 
of O 
cellular O 
functions O 
and O 
biological O 
events O 
. O 
During O 
the O 
same O 
period O 
, O 
however O 
, O 
some O 
groups O 
presented O 
experimental O 
evidence O 
that O 
appeared O 
to O 
contradict O 
the O 
basic O 
tenets O 
that O 
underlie O 
the O 
lipid O 
raft O 
concept O 
. O 
The O 
concept O 
is O 
currently O 
being O 
re O 
- O 
defined O 
, O 
with O 
greater O 
consistency O 
regarding O 
the O 
true O 
nature O 
and O 
role O 
of O 
lipid O 
rafts O 
. O 
In O 
this O 
article O 
we O 
will O 
review O 
the O 
concepts O 
, O 
criticisms O 
, O 
and O 
the O 
novel O 
confirmatory O 
findings O 
relating O 
to O 
the O 
lipid O 
raft O 
hypothesis O 
. O 

protein O 
coupled O 
- O 
receptor O 
( O 
GPCR O 
) O 
kinases O 
( O 
GRKs O 
) O 
initiate O 
the O 
deactivation O 
of O 
GPCRs O 
by O 
phosphorylating O 
their O 
cytoplasmic O 
loops O 
and O 
C B-FORMULA 
-terminal O 
tails O 
. O 
They O 
are O 
regulated O 
not O 
only O 
by O 
allosteric O 
interactions O 
with O 
activated O 
GPCRs O 
, O 
but O 
also O 
by O 
the O 
membrane O 
environment O 
itself O 
. O 
Herein O 
we O 
describe O 
how O 
the O 
various O 
GRKs O 
are O 
recruited O 
to O 
lipid O 
bilayers O 
and O 
, O 
where O 
evident O 
, O 
how O 
specific O 
anionic O 
phospholipids O 
help O 
regulate O 
their O 
activity O 
. O 
Using O 
crystal O 
structures O 
representing O 
each O 
of O 
the O 
three O 
vertebrate O 
GRK O 
subfamilies O 
, O 
we O 
map O 
the O 
lipid O 
binding O 
sites O 
in O 
order O 
to O 
better O 
understand O 
how O 
these O 
enzymes O 
are O 
oriented O 
at O 
the O 
cell O 
surface O 
. O 
This O 
analysis O 
suggests O 
that O 
GRKs O 
bind O 
lipid O 
and O 
active O 
GPCRs O 
in O 
a O 
coordinated O 
manner O 
. O 

lipids O 
in O 
the O 
function O 
of O 
serotonin B-TRIVIAL 
and O 
adrenergic O 
receptors O 
. O 

- O 
protein O 
coupled O 
receptors O 
( O 
GPCRs O 
) O 
are O 
the O 
largest O 
class O 
of O 
molecules O 
involved O 
in O 
signal O 
transduction O 
across O 
membranes O 
, O 
and O 
represent O 
major O 
targets O 
in O 
the O 
development O 
of O 
novel O 
drug O 
candidates O 
in O 
all O 
clinical O 
areas O 
. O 
Since O 
GPCRs O 
are O 
integral O 
membrane O 
proteins O 
, O 
interaction O 
of O 
membrane O 
lipids O 
such O 
as O 
cholesterol B-TRIVIAL 
and O 
sphingolipids B-FAMILY 
with O 
GPCRs O 
constitutes O 
an O 
emerging O 
area O 
of O 
research O 
in O 
contemporary O 
biology O 
. O 
Cholesterol B-TRIVIAL 
and O 
sphingolipids B-FAMILY 
represent O 
important O 
lipid O 
components O 
of O 
eukaryotic O 
membranes O 
and O 
play O 
a O 
crucial O 
role O 
in O 
a O 
variety O 
of O 
cellular O 
functions O 
. O 
In O 
this O 
review O 
, O 
we O 
highlight O 
the O 
role O 
of O 
these O 
vital O 
lipids O 
in O 
the O 
function O 
of O 
two O 
representative O 
GPCRs O 
, O 
the O 
serotonin B-TRIVIAL 
( O 
1A O 
) O 
receptor O 
and O 
the O 
adrenergic O 
receptor O 
. O 
We O 
believe O 
that O 
development O 
in O 
deciphering O 
molecular O 
details O 
of O 
the O 
nature O 
of O 
GPCR-lipid O 
interaction O 
would O 
lead O 
to O 
better O 
insight O 
into O 
our O 
overall O 
understanding O 
of O 
GPCR O 
function O 
in O 
health O 
and O 
disease O 
. O 

number O 
of O 
integral O 
membrane O 
G O 
protein O 
- O 
coupled O 
receptors O 
( O 
GPCRs O 
) O 
share O 
common O 
structural O 
features O 
( O 
including O 
palmytoilated B-FAMILY 
aminoacid I-FAMILY 
residues O 
and O 
consensus O 
sequences O 
specific O 
for O 
interaction O 
with O 
cholesterol B-TRIVIAL 
) O 
that O 
allow O 
them O 
to O 
interact O 
with O 
lipid O 
rafts O 
, O 
membrane O 
cholesterol B-TRIVIAL 
-rich O 
microdomains O 
able O 
to O 
regulate O 
GPCR O 
signalling O 
and O 
functions O 
. O 
Among O 
GPCRs O 
, O 
type-1 O 
and O 
type-2 O 
cannabinoid O 
receptors O 
, O 
the O 
molecular O 
targets O 
of O 
endocannabinoids O 
( O 
eCBs O 
) O 
, O 
control O 
many O 
physiological O 
and O 
pathological O 
processes O 
through O 
the O 
activation O 
of O 
several O 
signal O 
transduction O 
pathways O 
. O 
Recently O 
, O 
the O 
orphan O 
GPR55 O 
receptor O 
has O 
been O 
proved O 
to O 
be O 
activated O 
by O 
many O 
eCBs O 
, O 
thus O 
leading O 
to O 
the O 
hypothesis O 
that O 
it O 
might O 
be O 
the O 
" O 
type-3 O 
" O 
cannabinoid O 
receptor O 
. O 
While O 
the O 
biological O 
activity O 
of O 
eCBs O 
and O 
the O 
influence O 
of O 
membrane O 
lipids O 
on O 
their O 
functions O 
are O 
rather O 
well O 
established O 
, O 
information O 
regarding O 
GPR55 O 
is O 
still O 
scarce O 
and O 
often O 
controversial O 
. O 
Based O 
on O 
this O 
background O 
, O 
here O 
we O 
shall O 
review O 
current O 
data O 
about O 
GPR55 O 
pharmacology O 
and O 
signalling O 
, O 
highlighting O 
its O 
involvement O 
in O 
several O 
pathophysiological O 
conditions O 
. O 
We O 
shall O 
also O 
outline O 
the O 
structural O 
features O 
that O 
allow O 
GPR55 O 
to O 
interact O 
with O 
cholesterol B-TRIVIAL 
and O 
to O 
associate O 
with O 
lipid O 
rafts O 
; O 
how O 
the O 
latter O 
lipid O 
microdomains O 
impact O 
the O 
biological O 
activity O 
of O 
GPR55 O 
is O 
also O 
addressed O 
, O 
as O 
well O 
as O 
their O 
potential O 
for O 
the O 
discovery O 
of O 
new O 
therapeutics O 
useful O 
for O 
the O 
treatment O 
of O 
those O 
human O 
diseases O 
that O 
might O 
be O 
associated O 
with O 
alterations O 
of O 
GPR55 O 
activity O 
. O 

-mediated O 
production O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
is O 
an O 
essential O 
step O 
in O 
the O 
mechanism O 
of O 
action O 
to O 
accelerate O 
human O 
keratinocyte O 
differentiation O 
. O 

is O 
commonly O 
observed O 
in O 
humans O 
exposed O 
to O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
; O 
yet O 
, O 
the O 
mechanism O 
of O 
toxicity O 
is O 
not O 
well O 
understood O 
. O 
Using O 
normal O 
human O 
epidermal O 
keratinocytes O 
, O 
we O 
investigated O 
the O 
mechanism O 
of O 
TCDD B-ABBREVIATION 
-mediated O 
enhancement O 
of O 
epidermal O 
differentiation O 
by O 
integrating O 
functional O 
genomic O 
, O 
metabolomic O 
, O 
and O 
biochemical O 
analyses O 
. O 
TCDD B-ABBREVIATION 
increased O 
the O 
expression O 
of O 
40% O 
of O 
the O 
genes O 
of O 
the O 
epidermal O 
differentiation O 
complex O 
found O 
on O 
chromosome O 
1q21 O 
and O 
75% O 
of O 
the O 
genes O 
required O 
for O 
de O 
novo O 
ceramide B-FAMILY 
biosynthesis O 
. O 
Lipid O 
analysis O 
demonstrated O 
that O 
eight O 
of O 
the O 
nine O 
classes O 
of O 
ceramides B-FAMILY 
were O 
increased O 
by O 
TCDD B-ABBREVIATION 
, O 
altering O 
the O 
ratio O 
of O 
ceramides B-FAMILY 
to O 
free O 
fatty B-FAMILY 
acids I-FAMILY 
. O 
TCDD B-ABBREVIATION 
decreased O 
the O 
expression O 
of O 
the O 
glucose B-TRIVIAL 
transporter O 
, O 
SLC2A1 O 
, O 
and O 
most O 
of O 
the O 
glycolytic O 
transcripts O 
, O 
followed O 
by O 
decreases O 
in O 
glycolytic O 
intermediates O 
, O 
including O 
pyruvate B-TRIVIAL 
. O 
NADH B-ABBREVIATION 
and O 
Krebs O 
cycle O 
intermediates O 
were O 
decreased O 
, O 
whereas O 
NAD(+) B-ABBREVIATION 
was O 
increased O 
. O 
Mitochondrial O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
reductase O 
activity O 
and O 
the O 
GSH B-ABBREVIATION 
/ O 
glutathione B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
ratio O 
were O 
decreased O 
by O 
TCDD B-ABBREVIATION 
, O 
ultimately O 
leading O 
to O 
mitochondrial O 
dysfunction O 
, O 
characterized O 
by O 
decreased O 
inner O 
mitochondrial O 
membrane O 
potential O 
and O 
ATP B-ABBREVIATION 
production O 
, O 
and O 
increased O 
production O 
of O 
the O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
. O 
Aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AHR O 
) O 
antagonists O 
blocked O 
the O 
response O 
of O 
many O 
transcripts O 
to O 
TCDD B-ABBREVIATION 
, O 
and O 
the O 
endpoints O 
of O 
decreased O 
ATP B-ABBREVIATION 
production O 
and O 
differentiation O 
, O 
suggesting O 
regulation O 
by O 
the O 
AHR O 
. O 
Cotreatment O 
of O 
cells O 
with O 
chemical O 
antioxidants O 
or O 
the O 
enzyme O 
catalase O 
blocked O 
the O 
TCDD B-ABBREVIATION 
-mediated O 
acceleration O 
of O 
keratinocyte O 
cornified O 
envelope O 
formation O 
, O 
an O 
endpoint O 
of O 
terminal O 
differentiation O 
. O 
Thus O 
, O 
TCDD B-ABBREVIATION 
-mediated O 
ROS O 
production O 
is O 
a O 
critical O 
step O 
in O 
the O 
mechanism O 
of O 
this O 
chemical O 
to O 
accelerate O 
keratinocyte O 
differentiation O 
. O 

impairs O 
the O 
inflammatory O 
response O 
to O 
influenza O 
infection O 
: O 
role O 
of O 
antigen O 
- O 
presenting O 
cells O 
and O 
the O 
cannabinoid O 
receptors O 
1 O 
and O 
2 O 
. O 

( O 
Δ(9)-THC B-SYSTEMATIC 
) O 
has O 
potent O 
immune O 
modulatory O 
properties O 
and O 
can O 
impair O 
pathogen O 
- O 
induced O 
immune O 
defenses O 
, O 
which O 
in O 
part O 
have O 
been O 
attributed O 
to O 
ligation O 
of O 
the O 
cannabinoid O 
receptors O 
1 O 
(CB(1)) O 
and O 
2 O 
(CB(2)) O 
. O 
Most O 
recently O 
, O 
dendritic O 
cells O 
( O 
DC O 
) O 
were O 
identified O 
for O 
their O 
potential O 
to O 
enhance O 
influenza O 
- O 
induced O 
immunopathology O 
in O 
mice O 
lacking O 
CB(1) O 
and O 
CB(2) O 
( O 
CB(1) O 
( O 
- O 
/ O 
-)CB(2 O 
) O 
( O 
- O 
/ O 
- O 
) O 
) O 
. O 
This O 
study O 
focused O 
on O 
the O 
modulation O 
of O 
the O 
inflammatory O 
immune O 
response O 
to O 
influenza O 
by O 
Δ(9)-THC B-SYSTEMATIC 
and O 
the O 
role O 
of O 
CB(1) O 
and O 
/ O 
or O 
CB(2) O 
as O 
receptor O 
targets O 
for O 
Δ(9)-THC B-SYSTEMATIC 
. O 
C57Bl O 
/ O 
6 O 
( O 
wild O 
type O 
) O 
and O 
CB(1) O 
( O 
- O 
/ O 
-)CB(2 O 
) O 
( O 
- O 
/ O 
- O 
) O 
mice O 
were O 
administered O 
Δ(9)-THC B-SYSTEMATIC 
( O 
75 O 
mg O 
/ O 
kg O 
) O 
surrounding O 
the O 
intranasal O 
instillation O 
of O 
A O 
/ O 
PR O 
/ O 
8 O 
/ O 
34 O 
influenza O 
virus O 
. O 
Three O 
days O 
post O 
infection O 
( O 
dpi O 
) O 
, O 
Δ(9)-THC B-SYSTEMATIC 
broadly O 
decreased O 
expression O 
levels O 
of O 
mRNA O 
induced O 
by O 
the O 
innate O 
immune O 
response O 
to O 
influenza O 
, O 
suppressed O 
the O 
percentage O 
of O 
interferon O 
- O 
gamma O 
(IFN-γ)-producing O 
CD4(+) O 
and O 
interleukin-17-producing O 
NK1.1(+) O 
cells O 
, O 
and O 
reduced O 
the O 
influx O 
of O 
antigen O 
- O 
presenting O 
cells O 
( O 
APC O 
) O 
, O 
including O 
inflammatory O 
myeloid O 
cells O 
and O 
monocytes O 
/ O 
macrophages O 
, O 
into O 
the O 
lung O 
in O 
a O 
CB(1)- O 
and O 
/ O 
or O 
CB(2)-dependent O 
manner O 
. O 
Δ(9)-THC B-SYSTEMATIC 
had O 
little O 
effect O 
on O 
the O 
expression O 
of O 
CD86 O 
, O 
major O 
histocompatibility O 
complex O 
I O 
( O 
MHC O 
I O 
) O 
, O 
and O 
MHC O 
II O 
by O 
APC O 
isolated O 
from O 
the O 
lung O 
. O 
In O 
vitro O 
studies O 
demonstrated O 
that O 
lipopolysaccharide O 
(LPS)-induced O 
maturation O 
was O 
suppressed O 
by O 
Δ(9)-THC B-SYSTEMATIC 
in O 
bone O 
marrow O 
- O 
derived O 
DC O 
( O 
bmDC O 
) O 
. O 
Furthermore O 
, O 
antigen O 
- O 
specific O 
IFN-γ O 
production O 
by O 
CD8(+) O 
T O 
cells O 
after O 
coculture O 
was O 
reduced O 
by O 
Δ(9)-THC B-SYSTEMATIC 
treatment O 
of O 
bmDC O 
in O 
a O 
CB(1)- O 
and O 
/ O 
or O 
CB(2)-dependent O 
manner O 
. O 
Collectively O 
, O 
these O 
studies O 
suggest O 
that O 
Δ(9)-THC B-SYSTEMATIC 
potently O 
suppresses O 
myeloid O 
cell O 
immune O 
function O 
, O 
in O 
a O 
manner O 
involving O 
CB(1) O 
and O 
/ O 
or O 
CB(2) O 
, O 
thereby O 
impairing O 
immune O 
responses O 
to O 
influenza O 
infection O 
. O 

bone O 
syndrome O 
( O 
HBS O 
) O 
refers O 
to O 
the O 
rapid O 
, O 
profound O 
, O 
and O 
prolonged O 
hypocalcaemia O 
associated O 
with O 
hypophosphataemia O 
and O 
hypomagnesaemia O 
, O 
and O 
is O 
exacerbated O 
by O 
suppressed O 
parathyroid O 
hormone O 
( O 
PTH O 
) O 
levels O 
, O 
which O 
follows O 
parathyroidectomy O 
in O 
patients O 
with O 
severe O 
primary O 
hyperparathyroidism O 
( O 
PHPT O 
) O 
and O 
preoperative O 
high O 
bone O 
turnover O 
. O 
It O 
is O 
a O 
relatively O 
uncommon O 
, O 
but O 
serious O 
adverse O 
effect O 
of O 
parathyroidectomy O 
. O 
We O 
conducted O 
a O 
literature O 
search O 
of O 
all O 
available O 
studies O 
reporting O 
a O 
' O 
hungry O 
bone O 
syndrome O 
' O 
in O 
patients O 
who O 
had O 
a O 
parathyroidectomy O 
for O 
PHPT O 
, O 
to O 
identify O 
patients O 
at O 
risk O 
and O 
address O 
the O 
pitfalls O 
in O 
their O 
management O 
. O 
The O 
severe O 
hypocalcaemia O 
is O 
believed O 
to O 
be O 
due O 
to O 
increased O 
influx O 
of O 
calcium B-SYSTEMATIC 
into O 
bone O 
, O 
due O 
to O 
the O 
sudden O 
removal O 
of O 
the O 
effect O 
of O 
high O 
circulating O 
levels O 
of O 
PTH O 
on O 
osteoclastic O 
resorption O 
, O 
leading O 
to O 
a O 
decrease O 
in O 
the O 
activation O 
frequency O 
of O 
new O 
remodelling O 
sites O 
and O 
to O 
a O 
decrease O 
in O 
remodelling O 
space O 
, O 
although O 
there O 
is O 
no O 
good O 
documentation O 
for O 
this O 
. O 
Various O 
risk O 
factors O 
have O 
been O 
suggested O 
for O 
the O 
development O 
of O 
HBS O 
, O 
including O 
older O 
age O 
, O 
weight O 
/ O 
volume O 
of O 
the O 
resected O 
parathyroid O 
glands O 
, O 
radiological O 
evidence O 
of O 
bone O 
disease O 
and O 
vitamin B-FAMILY 
D I-FAMILY 
deficiency O 
. O 
The O 
syndrome O 
is O 
reported O 
in O 
25-90% O 
of O 
patients O 
with O 
radiological O 
evidence O 
of O 
hyperparathyroid O 
bone O 
disease O 
vs O 
only O 
0-6% O 
of O 
patients O 
without O 
skeletal O 
involvement O 
. O 
There O 
is O 
insufficient O 
data O 
- O 
based O 
evidence O 
on O 
the O 
best O 
means O 
to O 
treat O 
, O 
minimise O 
or O 
prevent O 
this O 
severe O 
complication O 
of O 
parathyroidectomy O 
. O 
Treatment O 
is O 
aimed O 
at O 
replenishing O 
the O 
severe O 
calcium B-SYSTEMATIC 
deficit O 
by O 
using O 
high O 
doses O 
of O 
calcium B-SYSTEMATIC 
supplemented O 
by O 
high O 
doses O 
of O 
active O 
metabolites O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
. O 
Adequate O 
correction O 
of O 
magnesium B-SYSTEMATIC 
deficiency O 
and O 
normalisation O 
of O 
bone O 
turnover O 
are O 
required O 
for O 
resolution O 
of O 
the O 
hypocalcaemia O 
which O 
may O 
last O 
for O 
a O 
number O 
of O 
months O 
after O 
successful O 
surgery O 
. O 
Preoperative O 
treatment O 
with O 
bisphosphonates B-FAMILY 
has O 
been O 
suggested O 
to O 
reduce O 
post O 
- O 
operative O 
hypocalcaemia O 
, O 
but O 
there O 
are O 
to O 
date O 
no O 
prospective O 
studies O 
addressing O 
this O 
issue O 
. O 

of O 
solid O 
lipid O 
nanoparticles O 
( O 
SLNs O 
) O 
of O 
lopinavir B-TRIVIAL 
using O 
hot O 
self O 
nano O 
- O 
emulsification O 
( O 
SNE O 
) O 
technique O 
. O 

lipid O 
nanoparticles O 
( O 
SLNs O 
) O 
of O 
poor O 
orally O 
bioavailable O 
drug O 
lopinavir B-TRIVIAL 
were O 
prepared O 
using O 
hot O 
self O 
nano O 
- O 
emulsification O 
( O 
SNE O 
) O 
technique O 
. O 
Hot O 
isotropic O 
mixture O 
of O 
stearic B-TRIVIAL 
acid I-TRIVIAL 
, O 
poloxamer B-FAMILY 
and O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
was O 
spontaneously O 
self O 
nano O 
- O 
emulsify O 
in O 
hot O 
water O 
and O 
SLNs O 
were O 
formed O 
with O 
subsequent O 
rapid O 
cooling O 
. O 
Self O 
nano O 
- O 
emulsification O 
ability O 
of O 
stearic B-TRIVIAL 
acid I-TRIVIAL 
, O 
poloxamer B-FAMILY 
and O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
mixture O 
was O 
assessed O 
by O 
ternary O 
phase O 
diagram O 
study O 
. O 
Optimized O 
SLNs O 
were O 
having O 
particle O 
size O 
of O 
180.6 O 
± O 
2.32 O 
nm O 
( O 
PDI=0.133 O 
± O 
0.001 O 
) O 
, O 
91.5 O 
± O 
1.3% O 
entrapment O 
efficiency O 
and O 
zeta O 
potential O 
of O 
-13.4 O 
± O 
0.56 O 
mV O 
. O 
SLNs O 
were O 
evaluated O 
by O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
and O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
for O 
morphological O 
study O 
. O 
Further O 
, O 
Differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
and O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
of O 
SLNs O 
were O 
also O 
performed O 
for O 
checking O 
solid O 
state O 
characterization O 
. O 
Higher O 
oral O 
bioavailability O 
was O 
found O 
for O 
lopinavir B-TRIVIAL 
loaded O 
SLNs O 
in O 
comparison O 
to O 
bulk O 
lopinavir B-TRIVIAL 
due O 
to O 
higher O 
lymphatic O 
drug O 
transport O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Results O 
indicate O 
that O 
SLNs O 
of O 
higher O 
fatty B-FAMILY 
acids I-FAMILY 
can O 
be O 
successfully O 
prepared O 
by O 
hot O 
SNE O 
technique O 
. O 

drug O 
delivery O 
using O 
eyedrop O 
preparations O 
of O 
poly-L-lysine B-SYSTEMATIC 
-modified O 
liposomes O 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
develop O 
surface O 
- O 
modified O 
liposomes O 
that O 
enhance O 
the O 
efficiency O 
of O 
eye O 
drop O 
drug O 
delivery O 
to O 
the O 
retina O 
. O 
Various O 
molecular O 
weights O 
and O 
concentrations O 
of O 
the O 
water O 
- O 
soluble O 
cationic O 
polymer O 
poly-L-lysine B-SYSTEMATIC 
( O 
PLL B-ABBREVIATION 
) O 
were O 
used O 
to O 
modify O 
the O 
surface O 
of O 
submicronized O 
( O 
100 O 
nm O 
) O 
liposomes O 
. O 
Physicochemical O 
properties O 
of O 
surface O 
- O 
modified O 
liposomes O 
were O 
determined O 
in O 
vitro O 
, O 
and O 
the O 
efficiency O 
of O 
drug O 
delivery O 
to O 
the O 
retina O 
was O 
investigated O 
in O 
vivo O 
. O 
Using O 
coumarin-6 B-TRIVIAL 
as O 
a O 
model O 
drug O 
and O 
fluorescent O 
marker O 
, O 
we O 
show O 
that O 
liposome O 
surface O 
modification O 
by O 
PLL B-ABBREVIATION 
dramatically O 
increased O 
delivery O 
to O 
mouse O 
retina O 
segments O 
after O 
eye O 
drop O 
administration O 
. O 
However O 
, O 
when O 
PLL B-ABBREVIATION 
of O 
high O 
molecular O 
weight O 
( O 
> O 
30000 O 
) O 
was O 
used O 
at O 
higher O 
concentrations O 
( O 
> O 
0.05% O 
) O 
, O 
aggregation O 
of O 
surface O 
- O 
modified O 
liposomes O 
increased O 
particle O 
size O 
and O 
hampered O 
distribution O 
to O 
inner O 
ocular O 
tissues O 
. O 
As O 
a O 
result O 
, O 
the O 
efficiency O 
of O 
drug O 
delivery O 
of O 
these O 
aggregated O 
surface O 
- O 
modified O 
liposomes O 
was O 
the O 
same O 
as O 
unmodified O 
liposomes O 
. O 
The O 
optimal O 
molecular O 
weight O 
and O 
concentration O 
of O 
PLL B-ABBREVIATION 
in O 
drug O 
- O 
delivering O 
liposomes O 
were O 
15,000-30,000 O 
and O 
0.005% O 
, O 
respectively O 
. O 
Under O 
these O 
conditions O 
, O 
PLL B-ABBREVIATION 
-modified O 
liposomes O 
were O 
not O 
cytotoxic O 
in O 
corneal O 
or O 
conjunctival O 
cells O 
. O 
In O 
conclusion O 
, O 
surface O 
- O 
modified O 
liposomes O 
have O 
great O 
potential O 
as O 
effective O 
retinal O 
drug O 
delivery O 
carriers O 
in O 
eye O 
drop O 
formulations O 
. O 

acid I-FAMILY 
derivatives O 
as O 
transdermal O 
permeation O 
enhancers O 
. O 

permeation O 
enhancers O 
are O 
compounds O 
that O 
temporarily O 
decrease O 
skin O 
barrier O 
properties O 
to O 
promote O 
drug O 
flux O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
enhancers O 
with O 
amino B-FAMILY 
acids I-FAMILY 
( O 
proline B-TRIVIAL 
, O 
sarcosine B-TRIVIAL 
, O 
alanine B-TRIVIAL 
, O 
β-alanine B-TRIVIAL 
, O 
and O 
glycine B-TRIVIAL 
) O 
attached O 
to O 
hydrophobic O 
chain(s) O 
via O 
a O 
biodegradable O 
ester B-FAMILY 
link O 
. O 
The O 
double O 
- O 
chain O 
lipid O 
- O 
like O 
substances O 
displayed O 
no O 
enhancing O 
effect O 
, O 
whereas O 
single O 
- O 
chain O 
substances O 
significantly O 
increased O 
skin O 
permeability O 
. O 
The O 
proline B-TRIVIAL 
derivative O 
l-Pro B-FORMULA 
2 O 
reached O 
enhancement O 
ratios O 
of O 
up O 
to O 
40 O 
at O 
1% O 
concentration O 
, O 
which O 
is O 
higher O 
than O 
that O 
of O 
the O 
well O 
- O 
established O 
and O 
standard O 
enhancers O 
Azone B-TRIVIAL 
, O 
DDAIP B-ABBREVIATION 
, O 
DDAK B-ABBREVIATION 
, O 
and O 
Transkarbam B-TRIVIAL 
12 I-TRIVIAL 
. O 
No O 
stereoselectivity O 
was O 
observed O 
. O 
l-Pro B-FORMULA 
2 O 
acted O 
synergistically O 
with O 
propylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
. O 
Infrared O 
studies O 
revealed O 
that O 
l-Pro B-FORMULA 
2 O 
forms O 
a O 
separate O 
liquid O 
ordered O 
phase O 
in O 
the O 
stratum O 
corneum O 
lipids O 
and O 
has O 
no O 
significant O 
effect O 
on O 
proteins O 
. O 
l-Pro B-FORMULA 
2 O 
action O 
was O 
at O 
least O 
partially O 
reversible O 
as O 
measured O 
by O 
skin O 
electrical O 
impedance O 
. O 
Toxicity O 
in O 
keratinocyte O 
( O 
HaCaT O 
) O 
and O 
fibroblast O 
( O 
3T3 O 
) O 
cell O 
lines O 
showed O 
IC(50) O 
values O 
ranging O 
from O 
tens O 
to O 
hundreds O 
of O 
μM O 
, O 
which O 
is O 
comparable O 
with O 
standard O 
enhancers O 
. O 
Furthermore O 
, O 
l-Pro B-FORMULA 
2 O 
was O 
rapidly O 
decomposed O 
in O 
plasma O 
. O 
In O 
vivo O 
transdermal O 
absorption O 
studies O 
in O 
rats O 
confirmed O 
the O 
enhancing O 
activity O 
of O 
l-Pro B-FORMULA 
2 O 
and O 
suggested O 
its O 
negligible O 
skin O 
toxicity O 
and O 
minimal O 
effect O 
on O 
transepidermal O 
water O 
loss O 
. O 
These O 
properties O 
make O 
l-Pro B-FORMULA 
2 O 
a O 
promising O 
candidate O 
for O 
potential O 
clinical O 
use O 
. O 

onset O 
of O 
antineutrophil O 
cytoplasmic O 
antibody O 
- O 
associated O 
vasculitis O 
immediately O 
after O 
methimazole B-TRIVIAL 
was O 
switched O 
to O 
propylthiouracil B-SYSTEMATIC 
in O 
a O 
woman O 
with O 
Graves' O 
disease O 
who O 
wished O 
to O 
become O 
pregnant O 
. O 

( O 
PTU B-ABBREVIATION 
) O 
is O 
recommended O 
as O 
a O 
first O 
- O 
line O 
antithyroid O 
drug O 
( O 
ATD O 
) O 
during O 
first O 
trimester O 
organogenesis O 
in O 
pregnancy O 
because O 
recent O 
evidence O 
suggests O 
that O 
methimazole B-TRIVIAL 
( O 
MMI B-ABBREVIATION 
) O 
may O 
be O 
associated O 
with O 
congenital O 
anomalies O 
. O 
However O 
, O 
PTU B-ABBREVIATION 
more O 
commonly O 
causes O 
myeloperoxidase O 
(MPO)-antineutrophil O 
cytoplasmic O 
antibody O 
(ANCA)-associated O 
vasculitis O 
, O 
which O 
usually O 
occurs O 
during O 
prolonged O 
treatment O 
, O 
compared O 
with O 
MMI B-ABBREVIATION 
. O 
We O 
report O 
a O 
case O 
of O 
MPO-ANCA-associated O 
vasculitis O 
in O 
a O 
35-year- O 
old O 
woman O 
with O 
Graves'disease O 
. O 
Although O 
her O 
thyroid O 
function O 
could O 
be O 
maintained O 
euthyroid O 
by O 
MMI O 
, O 
her O 
ATD O 
was O 
switched O 
to O 
PTU B-ABBREVIATION 
because O 
she O 
wished O 
to O 
become O 
pregnant O 
. O 
The O 
patient O 
presented O 
with O 
flu O 
- O 
like O 
symptoms O 
8 O 
days O 
after O 
starting O 
PTU B-ABBREVIATION 
and O 
developed O 
hemoptysis O 
and O 
dyspnea O 
at O 
22 O 
days O 
. O 
Her O 
MPO-ANCA O 
titer O 
was O 
21 O 
ELISA O 
units O 
( O 
EUs O 
) O 
before O 
PTU B-ABBREVIATION 
treatment O 
but O 
increased O 
to O 
259 O 
EUs O 
at O 
22 O 
days O 
after O 
PTU B-ABBREVIATION 
treatment O 
. O 
Her O 
clinical O 
condition O 
improved O 
with O 
the O 
discontinuation O 
of O 
PTU B-ABBREVIATION 
and O 
with O 
immunosuppressive O 
therapy O 
. O 
This O 
case O 
indicated O 
that O 
MPO-ANCA O 
vasculitis O 
occurred O 
within O 
several O 
weeks O 
after O 
the O 
initiation O 
of O 
PTU B-ABBREVIATION 
and O 
that O 
this O 
side O 
effect O 
could O 
be O 
caused O 
by O 
the O 
change O 
from O 
MMI B-ABBREVIATION 
to O 
PTU B-ABBREVIATION 
. O 
Thus O 
, O 
our O 
clinical O 
observation O 
suggests O 
that O 
patients O 
treated O 
with O 
PTU B-ABBREVIATION 
should O 
be O 
carefully O 
monitored O 
for O 
MPO-ANCA O 
titers O 
and O 
variable O 
manifestations O 
of O 
MPO-ANCA-associated O 
vasculitis O 
regardless O 
of O 
the O 
period O 
of O 
administration O 
. O 

objective O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
ionic O 
interactions O 
between O 
alginate O 
and O 
a O 
monoclonal O 
antibody O 
( O 
mAb1 O 
) O 
and O 
to O 
utilize O 
those O 
interactions O 
for O 
the O 
sustained O 
release O 
of O 
mAb1 O 
. O 
The O 
existence O 
of O 
ionic O 
interactions O 
between O 
alginate O 
and O 
mAb1 O 
was O 
strongly O 
reflected O 
by O 
their O 
rheological O 
behavior O 
. O 
A O 
3-4 O 
times O 
increase O 
in O 
storage O 
modulus O 
( O 
G O 
' O 
) O 
was O 
observed O 
by O 
addition O 
of O 
30 O 
mg O 
/ O 
mL O 
mAb1 O 
to O 
a O 
20 O 
mg O 
/ O 
mL O 
alginate O 
solution O 
. O 
This O 
increase O 
was O 
strongly O 
dependent O 
on O 
pH O 
and O 
ionic O 
strength O 
. O 
In O 
vitro O 
release O 
studies O 
revealed O 
a O 
marked O 
pH-dependence O 
of O 
release O 
rates O 
and O 
the O 
reversibility O 
of O 
alginate-mAb1 O 
complexation O 
under O 
physiological O 
conditions O 
. O 
Two O 
alginate-mAb1 O 
sustained O 
release O 
formulations O 
were O 
developed O 
by O 
an O 
internal O 
gelation O 
technique O 
using O 
CaCO(3) B-FORMULA 
and O 
CaHPO(4) B-FORMULA 
as O 
calcium B-SYSTEMATIC 
sources O 
for O 
physical O 
cross O 
- O 
linking O 
. O 
The O 
CaCO(3) B-FORMULA 
formulation O 
provided O 
a O 
stable O 
pH-environment O 
, O 
optimally O 
suited O 
for O 
pH-sensitive O 
proteins O 
. O 
CaHPO(4) B-FORMULA 
led O 
to O 
a O 
lower O 
pH O 
and O 
stronger O 
alginate-mAb1 O 
interactions O 
. O 
The O 
CaHPO(4) B-FORMULA 
cross O 
- O 
linked O 
alginate O 
released O 
mAb1 O 
over O 
a O 
period O 
of O 
10- O 
15 O 
days O 
. O 
The O 
long O 
release O 
period O 
and O 
changes O 
in O 
viscoelastic O 
properties O 
of O 
alginate O 
, O 
when O 
being O 
mixed O 
with O 
mAb1 O 
, O 
indicate O 
the O 
incorporation O 
of O 
mAb1 O 
molecules O 
into O 
a O 
mixed O 
network O 
with O 
alginate O 
. O 
The O 
results O 
of O 
this O 
study O 
demonstrate O 
that O 
ionic O 
interactions O 
between O 
polyanions O 
and O 
mAb1 O 
are O 
present O 
and O 
that O 
they O 
can O 
be O 
exploited O 
for O 
sustained O 
release O 
delivery O 
of O 
mAb1 O 
. O 

- O 
derived O 
neurotropic O 
factor O 
( O 
BDNF O 
) O 
is O 
involved O 
in O 
the O 
development O 
of O 
the O 
brain O 
, O 
and O 
likely O 
influences O 
the O 
neuroplasticity O 
in O 
schizophrenia O 
. O 
BDNF O 
is O 
also O 
believed O 
to O 
interact O 
with O 
other O 
neurotransmitter O 
systems O 
implicated O 
in O 
schizophrenia O 
, O 
such O 
as O 
dopamine B-TRIVIAL 
, O 
glutamate B-TRIVIAL 
, O 
serotonin B-TRIVIAL 
and O 
GABA B-ABBREVIATION 
. O 
Therefore O 
, O 
BDNF O 
is O 
a O 
candidate O 
gene O 
for O 
schizophrenia O 
. O 
In O 
past O 
decades O 
, O 
the O 
blood O 
( O 
serum O 
or O 
plasma O 
) O 
BDNF O 
protein O 
levels O 
and O 
BDNF O 
gene O 
alleles O 
and O 
genotypes O 
to O 
the O 
clinical O 
features O 
of O 
schizophrenia O 
, O 
such O 
as O 
age O 
of O 
onset O 
, O 
clinical O 
subtypes O 
, O 
symptom O 
severity O 
, O 
and O 
drug O 
response O 
, O 
have O 
been O 
evaluated O 
among O 
different O 
populations O 
. O 
However O 
, O 
the O 
results O 
are O 
still O 
inconsistent O 
. O 
Further O 
, O 
different O 
drugs O 
have O 
been O 
reported O 
to O 
have O 
different O 
effects O 
on O 
BDNF O 
protein O 
levels O 
. O 
A O 
cross O 
- O 
sectional O 
survey O 
revealed O 
that O 
serum O 
BDNF O 
levels O 
in O 
chronic O 
schizophrenic O 
patients O 
treated O 
with O 
clozapine B-TRIVIAL 
exceeded O 
those O 
of O 
patients O 
treated O 
with O 
risperidone B-TRIVIAL 
or O 
with O 
typical O 
antipsychotics O 
. O 
In O 
recent O 
times O 
, O 
BDNF O 
epigenetic O 
studies O 
have O 
also O 
been O 
conducted O 
in O 
clinical O 
studies O 
of O 
schizophrenia O 
to O 
address O 
the O 
question O 
of O 
why O 
patients O 
with O 
the O 
same O 
gene O 
genotype O 
and O 
alleles O 
have O 
different O 
clinical O 
presentations O 
. O 
In O 
addition O 
, O 
the O 
effects O 
of O 
different O 
antipsychotic O 
drugs O 
on O 
gene O 
methylation O 
and O 
protein O 
acetylation O 
have O 
also O 
been O 
reported O 
. O 
In O 
conclusion O 
, O 
more O 
data O 
are O 
needed O 
regarding O 
BDNF O 
in O 
the O 
brain O 
and O 
in O 
peripheral O 
blood O 
, O 
including O 
protein O 
levels O 
, O 
single O 
nucleotide O 
polymorphisms O 
, O 
epigenetic O 
regulation O 
, O 
and O 
clinical O 
data O 
in O 
order O 
to O 
understand O 
the O 
role O 
of O 
BDNF O 
in O 
schizophrenia O 
. O 

effect O 
of O 
serotonin B-TRIVIAL 
( O 
1A O 
) O 
receptor O 
agonists O 
on O 
cognition O 
in O 
patients O 
with O 
schizophrenia O 
. O 

of O 
cognitive O 
function O 
are O 
considered O 
to O 
largely O 
affect O 
the O 
outcome O 
in O 
patients O 
with O 
schizophrenia O 
. O 
There O 
is O 
much O 
attention O 
to O 
the O 
role O 
of O 
psychotropic O 
compounds O 
acting O 
on O 
serotonin B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
) O 
receptors O 
in O 
ameliorating O 
cognitive O 
deficits O 
of O 
the O 
disease O 
. O 
Among O 
the O 
5-HT B-SYSTEMATIC 
receptor O 
subtypes O 
, O 
the O 
5-HT B-SYSTEMATIC 
( O 
1A O 
) O 
receptor O 
is O 
attracting O 
particular O 
interests O 
as O 
a O 
potential O 
target O 
for O 
enhancing O 
cognition O 
, O 
based O 
on O 
preclinical O 
and O 
clinical O 
evidence O 
. O 
The O 
neural O 
network O 
underlying O 
the O 
ability O 
of O 
5-HT B-SYSTEMATIC 
( O 
1A O 
) O 
agonists O 
to O 
treat O 
cognitive O 
impairments O 
of O 
schizophrenia O 
likely O 
includes O 
dopamine B-TRIVIAL 
, O 
glutamate B-TRIVIAL 
, O 
and O 
gamma-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
neurons O 
. O 
Recent O 
advances O 
of O 
electrophysiological O 
measures O 
, O 
such O 
as O 
event O 
- O 
related O 
potentials O 
, O 
have O 
provided O 
insights O 
into O 
facilitative O 
effects O 
on O 
cognition O 
of O 
some O 
atypical O 
antipsychotic O 
drugs O 
or O 
related O 
compounds O 
acting O 
directly O 
or O 
indirectly O 
on O 
5-HT B-SYSTEMATIC 
( O 
1A O 
) O 
receptors O 
. O 
These O 
considerations O 
are O 
expected O 
to O 
promote O 
the O 
development O 
of O 
novel O 
therapeutics O 
for O 
the O 
betterment O 
of O 
functional O 
outcome O 
in O 
people O 
suffering O 
from O 
schizophrenia O 
. O 

striatal O 
dopamine B-TRIVIAL 
transmission O 
in O 
schizophrenia O 
. O 

numerous O 
revisions O 
and O 
reformulations O 
, O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
hypothesis O 
of O 
schizophrenia O 
remains O 
a O 
pivotal O 
neurochemical O 
hypothesis O 
of O 
this O 
illness O 
. O 
The O 
aim O 
of O 
this O 
review O 
is O 
to O 
expose O 
and O 
discuss O 
findings O 
from O 
positron O 
emission O 
tomography O 
( O 
PET O 
) O 
or O 
single-photon- O 
emission O 
computed O 
tomography O 
( O 
SPECT O 
) O 
studies O 
investigating O 
DA O 
function O 
in O 
the O 
striatum O 
of O 
medicated O 
, O 
drug O 
- O 
naive O 
or O 
drug O 
- O 
free O 
patients O 
with O 
schizophrenia O 
and O 
in O 
individuals O 
at O 
risk O 
compared O 
with O 
healthy O 
volunteers O 
. O 
DA O 
function O 
was O 
studied O 
at O 
several O 
levels O 
: O 
i O 
) O 
at O 
a O 
presynaptic O 
level O 
where O 
neuroimaging O 
studies O 
investigating O 
DOPA B-ABBREVIATION 
uptake O 
capacity O 
clearly O 
show O 
an O 
increase O 
of O 
DA O 
synthesis O 
in O 
patients O 
with O 
schizophrenia O 
; O 
ii O 
) O 
at O 
a O 
synaptic O 
level O 
where O 
neuroimaging O 
studies O 
investigating O 
dopamine B-TRIVIAL 
transporter O 
availability O 
( O 
DAT O 
) O 
does O 
not O 
bring O 
any O 
evidence O 
of O 
dysfunction O 
; O 
iii O 
) O 
and O 
finally O 
, O 
neuroimaging O 
studies O 
investigating O 
DA O 
receptor O 
density O 
show O 
a O 
mild O 
increase O 
of O 
D2 O 
receptor O 
density O 
in O 
basic O 
condition O 
and O 
, O 
an O 
hyperreactivity O 
of O 
DA O 
system O 
in O 
dynamic O 
condition O 
. O 
These O 
results O 
are O 
discussed O 
regarding O 
laterality O 
, O 
sub O 
- O 
regions O 
of O 
striatum O 
and O 
implications O 
for O 
the O 
at O 
- O 
risk O 
population O 
. O 
Striatal O 
DA O 
abnormalities O 
are O 
now O 
clearly O 
demonstrated O 
in O 
patients O 
with O 
schizophrenia O 
and O 
at O 
risk O 
population O 
and O 
could O 
constitute O 
an O 
endophenotype O 
of O 
schizophrenia O 
. O 
Subtle O 
sub O 
- O 
clinical O 
striatal O 
DA O 
abnormalities O 
in O 
at O 
risk O 
population O 
could O 
be O 
a O 
biomarker O 
of O 
transition O 
from O 
a O 
vulnerability O 
state O 
to O 
the O 
expression O 
of O 
frank O 
psychosis O 
. O 

magnetic O 
resonance O 
spectroscopy O 
( O 
(1)H B-FORMULA 
MRS O 
) O 
enables O 
the O 
observation O 
of O 
brain O 
function O 
in O 
vivo O 
. O 
Several O 
brain O 
metabolites O 
can O 
be O 
measured O 
by O 
the O 
means O 
of O 
(1)H O 
MRS O 
: O 
N-acetylaspartate B-SYSTEMATIC 
( O 
NAA B-ABBREVIATION 
) O 
, O 
choline B-FAMILY 
containing O 
compounds O 
( O 
Cho O 
) O 
, O 
myo-inositol B-TRIVIAL 
( O 
mI O 
) O 
and O 
glutamate B-TRIVIAL 
( O 
Glu B-FORMULA 
) O 
, O 
glutamine B-TRIVIAL 
( O 
Gln B-FORMULA 
) O 
and O 
GABA B-ABBREVIATION 
( O 
together O 
as O 
Glx O 
complex O 
or O 
separately O 
) O 
. O 
(1)H B-FORMULA 
MRS O 
measures O 
have O 
been O 
found O 
to O 
be O 
abnormal O 
in O 
psychotic O 
disorders O 
such O 
as O 
schizophrenia O 
. O 
Here O 
we O 
specifically O 
review O 
the O 
influence O 
exerted O 
by O 
antipsychotic O 
drugs O 
on O 
brain O 
metabolism O 
, O 
as O 
detected O 
by O 
(1)H B-FORMULA 
MRS O 
. O 
We O 
systematically O 
reviewed O 
the O 
available O 
literature O 
and O 
uncovered O 
27 O 
studies O 
, O 
16 O 
before O 
- O 
after O 
treatment O 
and O 
11 O 
cross O 
- O 
sectional O 
. O 
Most O 
of O 
them O 
addressed O 
the O 
effects O 
of O 
antipsychotics O 
in O 
schizophrenia O 
and O 
mainly O 
focusing O 
on O 
NAA B-ABBREVIATION 
alterations O 
. O 
Follow O 
up O 
studies O 
indicated O 
antipsychotic O 
drugs O 
may O 
act O 
by O 
increasing O 
NAA B-ABBREVIATION 
levels O 
in O 
selected O 
brain O 
areas O 
( O 
the O 
frontal O 
lobe O 
and O 
thalamus O 
) O 
, O 
especially O 
during O 
the O 
short O 
- O 
time O 
observation O 
. O 
This O 
phenomenon O 
seems O 
to O 
vanish O 
after O 
longer O 
observation O 
. O 
Other O 
studies O 
indicated O 
that O 
glutamate B-TRIVIAL 
measures O 
are O 
decreasing O 
along O 
with O 
the O 
duration O 
of O 
the O 
disease O 
, O 
suggesting O 
both O 
a O 
neurodegenerative O 
process O 
present O 
in O 
schizophrenic O 
brain O 
as O 
well O 
as O 
an O 
influence O 
of O 
antipsychotics O 
. O 
The O 
above O 
results O 
were O 
reviewed O 
according O 
to O 
the O 
most O 
recent O 
theories O 
in O 
the O 
field O 
accounting O 
for O 
the O 
impact O 
of O 
antipsychotics O 
(1)H B-FORMULA 
MRS O 
measures O 
. O 

and O 
EEG O 
effects O 
of O 
chronic O 
rapamycin B-TRIVIAL 
treatment O 
in O 
a O 
mouse O 
model O 
of O 
Tuberous O 
Sclerosis O 
Complex O 
. O 

Sclerosis O 
Complex O 
( O 
TSC O 
) O 
is O 
a O 
multisystem O 
genetic O 
disorder O 
caused O 
by O 
mutation O 
in O 
either O 
Tsc1 O 
or O 
Tsc2 O 
genes O 
that O 
leads O 
to O 
the O 
hyper O 
activation O 
of O 
the O 
mTOR O 
pathway O 
, O 
a O 
key O 
signalling O 
pathway O 
for O 
synaptic O 
plasticity O 
. O 
TSC O 
is O 
characterized O 
by O 
benign O 
tumors O 
arising O 
in O 
different O 
organs O 
and O 
severe O 
neuropsychiatric O 
symptoms O 
, O 
such O 
as O 
epilepsy O 
, O 
intellectual O 
disability O 
, O 
autism O 
, O 
anxiety O 
and O 
depressive O 
behaviour O 
. O 
Rapamycin B-TRIVIAL 
is O 
a O 
potent O 
inhibitor O 
of O 
mTOR O 
and O 
its O 
efficacy O 
in O 
treating O 
epilepsy O 
and O 
neurological O 
symptoms O 
remains O 
elusive O 
. O 
In O 
a O 
mouse O 
model O 
in O 
which O 
Tsc1 O 
has O 
been O 
deleted O 
in O 
embryonic O 
telencephalic O 
neural O 
stem O 
cells O 
, O 
we O 
analyzed O 
anxiety- O 
and O 
depression O 
- O 
like O 
behaviour O 
by O 
elevated O 
- O 
plus O 
maze O 
( O 
EPM O 
) O 
, O 
open O 
- O 
field O 
test O 
( O 
OFT O 
) O 
, O 
forced O 
- O 
swim O 
test O 
( O 
FST O 
) O 
and O 
tail O 
- O 
suspension O 
test O 
( O 
TST O 
) O 
, O 
after O 
chronic O 
administration O 
of O 
rapamycin B-TRIVIAL 
. O 
In O 
addition O 
, O 
spectral O 
analysis O 
of O 
background O 
EEG O 
was O 
performed O 
. O 
Rapamycin B-TRIVIAL 
-treated O 
mutant O 
mice O 
displayed O 
a O 
reduction O 
in O 
anxiety- O 
and O 
depression O 
- O 
like O 
phenotype O 
, O 
as O 
shown O 
by O 
the O 
EPM O 
/ O 
OFT O 
and O 
FST O 
, O 
respectively O 
. O 
These O 
results O 
were O 
inline O 
with O 
EEG O 
power O 
spectra O 
outcomes O 
. O 
The O 
same O 
effects O 
of O 
rapamycin B-TRIVIAL 
were O 
observed O 
in O 
wild O 
- O 
type O 
mice O 
. O 
Notably O 
, O 
in O 
heterozygous O 
animals O 
we O 
did O 
not O 
observe O 
any O 
EEG O 
and O 
/ O 
or O 
behavioural O 
variation O 
after O 
rapamycin B-TRIVIAL 
treatment O 
. O 
Together O 
these O 
results O 
suggest O 
that O 
both O 
TSC1 O 
deletion O 
and O 
chronic O 
rapamycin B-TRIVIAL 
treatment O 
might O 
have O 
a O 
role O 
in O 
modulating O 
behaviour O 
and O 
brain O 
activity O 
, O 
and O 
point O 
out O 
to O 
the O 
potential O 
usefulness O 
of O 
background O 
EEG O 
analysis O 
in O 
tracking O 
brain O 
dysfunction O 
in O 
parallel O 
with O 
behavioural O 
testing O 
. O 

to O 
urbane O 
airborne O 
particulate O 
matter O 
( O 
PM O 
) O 
is O 
related O 
to O 
the O 
onset O 
and O 
exacerbation O 
of O 
cardiovascular O 
and O 
respiratory O 
diseases O 
. O 
The O 
fine O 
( O 
PM1 O 
) O 
, O 
and O 
quasi O 
- O 
ultrafine O 
( O 
PM0.4 O 
) O 
Milan O 
particles O 
collected O 
during O 
different O 
seasons O 
have O 
been O 
characterised O 
and O 
the O 
biological O 
effects O 
on O 
human O 
epithelial O 
lung O 
A549 O 
, O 
monocytes O 
THP-1 O 
cells O 
and O 
their O 
co O 
- O 
culture O 
, O 
evaluated O 
and O 
compared O 
with O 
the O 
results O 
obtained O 
on O 
the O 
PM10 O 
and O 
PM2.5 O 
fractions O 
. O 
Chemical O 
composition O 
and O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
analysis O 
of O 
PM0.4 O 
showed O 
that O 
this O 
fraction O 
was O 
very O 
similar O 
to O 
PM1 O 
for O 
biological O 
responses O 
and O 
dimension O 
. O 
All O 
the O 
winter O 
fractions O 
increased O 
within O 
1h O 
the O 
level O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
while O 
only O 
summer O 
PM2.5 O 
had O 
this O 
effect O 
on O 
A549 O 
cells O 
. O 
The O 
phosphorylation O 
of O 
H2AX O 
( O 
γH2AX O 
) O 
, O 
a O 
marker O 
of O 
double O 
strand O 
DNA O 
breaks O 
( O 
DSBs O 
) O 
, O 
was O 
increased O 
by O 
all O 
the O 
winter O 
fractions O 
on O 
A549 O 
and O 
THP-1 O 
cells O 
while O 
summer O 
PM O 
samples O 
did O 
not O 
induced O 
this O 
effect O 
. O 
PM0.4 O 
and O 
PM1 O 
biological O 
effects O 
are O 
partly O 
similar O 
and O 
related O 
to O 
the O 
season O 
of O 
sampling O 
, O 
with O 
effects O 
on O 
ROS O 
and O 
DNA O 
damage O 
induced O 
only O 
by O 
winter O 
PM O 
fractions O 
. O 
The O 
winter O 
PM O 
damaging O 
effect O 
on O 
DNA O 
correlates O 
with O 
the O 
presence O 
of O 
organic O 
compounds O 
. O 

of O 
molecular O 
weight O 
on O 
permeability O 
and O 
microstructure O 
of O 
mixed O 
ethyl-hydroxypropyl B-SYSTEMATIC 
-cellulose O 
films O 
. O 

of O 
ethyl B-SYSTEMATIC 
cellulose O 
( O 
EC O 
) O 
and O 
water O 
- O 
soluble O 
hydroxypropyl B-SYSTEMATIC 
cellulose O 
( O 
HPC O 
) O 
can O 
be O 
used O 
for O 
extended O 
release O 
coatings O 
in O 
oral O 
formulations O 
. O 
The O 
permeability O 
and O 
microstructure O 
of O 
free O 
EC O 
/ O 
HPC O 
films O 
with O 
30% O 
w O 
/ O 
w O 
HPC O 
were O 
studied O 
to O 
investigate O 
effects O 
of O 
EC O 
molecular O 
weight O 
. O 
Phase O 
separation O 
during O 
film O 
spraying O 
and O 
subsequent O 
HPC O 
leaching O 
after O 
immersion O 
in O 
aqueous O 
media O 
cause O 
pore O 
formation O 
in O 
such O 
films O 
. O 
It O 
was O 
found O 
that O 
sprayed O 
films O 
were O 
porous O 
throughout O 
the O 
bulk O 
of O 
the O 
films O 
after O 
water O 
immersion O 
. O 
The O 
molecular O 
weight O 
affected O 
HPC O 
leaching O 
, O 
pore O 
morphology O 
and O 
film O 
permeability O 
; O 
increasing O 
the O 
molecular O 
weight O 
resulted O 
in O 
decreasing O 
permeability O 
. O 
A O 
model O 
to O 
distinguish O 
the O 
major O 
factors O 
contributing O 
to O 
diffusion O 
retardation O 
in O 
porous O 
films O 
showed O 
that O 
the O 
trend O 
in O 
permeability O 
was O 
determined O 
predominantly O 
by O 
factors O 
associated O 
with O 
the O 
geometry O 
and O 
arrangement O 
of O 
pores O 
, O 
independent O 
of O 
the O 
diffusing O 
species O 
. O 
The O 
film O 
with O 
the O 
highest O 
molecular O 
weight O 
did O 
, O 
however O 
, O 
show O 
an O 
additional O 
contribution O 
from O 
pore O 
wall O 
/ O 
permeant O 
interactions O 
. O 
In O 
addition O 
, O 
rapid O 
drying O 
and O 
increasing O 
molecular O 
weight O 
resulted O 
in O 
smaller O 
pores O 
, O 
which O 
suggest O 
that O 
phase O 
separation O 
kinetics O 
affects O 
the O 
final O 
microstructure O 
of O 
EC O 
/ O 
HPC O 
films O 
. O 
Thus O 
, O 
the O 
molecular O 
weight O 
influences O 
the O 
microstructural O 
features O 
of O 
pores O 
, O 
which O 
are O 
crucial O 
for O 
mass O 
transport O 
in O 
EC O 
/ O 
HPC O 
films O 
. O 

subfamily O 
Phyllomedusinae O 
has O 
attracted O 
a O 
great O 
interest O 
of O 
many O 
researchers O 
mainly O 
due O 
to O 
the O 
high O 
diversity O 
of O 
these O 
frog O 
species O 
and O 
plethora O 
of O 
pharmacological O 
activities O 
frequently O 
observed O 
for O 
their O 
skin O 
secretions O 
. O 
Despite O 
of O 
this O 
fact O 
, O 
mainly O 
for O 
new O 
species O 
, O 
limited O 
information O 
is O 
available O 
regarding O 
the O 
molecular O 
composition O 
of O 
these O 
skin O 
secretions O 
and O 
the O 
cellular O 
components O 
involved O 
in O 
their O 
production O 
. O 
Phyllomedusa O 
nordestina O 
is O 
a O 
recently O 
described O 
Brazilian O 
frog O 
species O 
also O 
popularly O 
known O 
as O 
' O 
tree O 
- O 
frogs O 
' O 
. O 
Aiming O 
at O 
contributing O 
to O 
the O 
biological O 
knowledge O 
of O 
this O 
species O 
, O 
we O 
show O 
here O 
the O 
gene O 
expression O 
profile O 
of O 
this O 
frog O 
skin O 
secretion O 
using O 
a O 
global O 
ESTs O 
analysis O 
of O 
a O 
cDNA O 
library O 
. O 
The O 
marked O 
aspect O 
of O 
this O 
analysis O 
revealed O 
a O 
significant O 
higher O 
transcriptional O 
level O 
of O 
the O 
opioid O 
peptide O 
dermorphins O 
in O 
P O 
. O 
nordestina O 
skin O 
secretion O 
than O 
in O 
Phyllomedusa O 
hypochondrialis O 
, O 
which O 
is O 
its O 
closest O 
related O 
species O 
, O 
belonging O 
both O 
to O 
the O 
same O 
phylogenetic O 
group O 
. O 
Precursors O 
of O 
bioactive O 
peptides O 
as O 
dermaseptins O 
, O 
phylloseptins O 
, O 
tryptophyllins O 
, O 
and O 
bradykinin B-TRIVIAL 
-like O 
peptideswere O 
also O 
found O 
in O 
this O 
library O 
. O 
Transcripts O 
encoding O 
proteins O 
related O 
to O 
ordinary O 
cellular O 
functions O 
and O 
pathways O 
were O 
also O 
described O 
. O 
Some O 
of O 
them O 
are O 
chiefly O 
involved O 
in O 
the O 
production O 
of O 
the O 
skin O 
secretion O 
. O 
Taken O 
together O 
, O 
the O 
data O 
reported O 
here O 
constitute O 
a O 
contribution O 
to O 
the O 
characterization O 
of O 
the O 
molecular O 
diversity O 
of O 
gene O 
- O 
encoded O 
polypeptides O 
with O 
potential O 
possibility O 
of O 
pharmacological O 
exploitation O 
. O 
The O 
transcriptional O 
composition O 
of O 
the O 
skin O 
secretion O 
may O 
also O 
help O 
to O 
give O 
the O 
necessary O 
support O 
for O 
the O 
definition O 
of O 
P O 
. O 
nordestina O 
as O 
a O 
new O 
species O 
, O 
which O 
actually O 
relies O 
basically O 
on O 
frog O 
morphological O 
characteristics O 
and O 
geographical O 
distribution O 
. O 

dehydrogenases O 
: O 
from O 
eye O 
crystallins O 
to O 
metabolic O 
disease O 
and O 
cancer O 
stem O 
cells O 
. O 

aldehyde B-SYSTEMATIC 
dehydrogenase O 
( O 
ALDH O 
) O 
superfamily O 
is O 
composed O 
of O 
nicotinamide B-SYSTEMATIC 
adenine I-SYSTEMATIC 
dinucleotide I-SYSTEMATIC 
( I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
NAD(P)(+) B-ABBREVIATION 
)-dependent O 
enzymes O 
that O 
catalyze O 
the O 
oxidation O 
of O 
aldehydes B-FAMILY 
to O 
their O 
corresponding O 
carboxylic B-FAMILY 
acids I-FAMILY 
. O 
To O 
date O 
, O 
24 O 
ALDH O 
gene O 
families O 
have O 
been O 
identified O 
in O 
the O 
eukaryotic O 
genome O 
. O 
In O 
addition O 
to O 
aldehyde B-SYSTEMATIC 
metabolizing O 
capacity O 
, O 
ALDHs O 
have O 
additional O 
catalytic O 
( O 
e.g O 
. O 
esterase O 
and O 
reductase O 
) O 
and O 
non-catalytic O 
activities O 
. O 
The O 
latter O 
include O 
functioning O 
as O 
structural O 
elements O 
in O 
the O 
eye O 
( O 
crystallins O 
) O 
and O 
as O 
binding O 
molecules O 
to O 
endobiotics O 
and O 
xenobiotics O 
. O 
Mutations O 
in O 
human O 
ALDH O 
genes O 
and O 
subsequent O 
inborn O 
errors O 
in O 
aldehyde B-SYSTEMATIC 
metabolism O 
are O 
the O 
molecular O 
basis O 
of O 
several O 
diseases O 
. O 
Most O 
recently O 
ALDH O 
polymorphisms O 
have O 
been O 
associated O 
with O 
gout O 
and O 
osteoporosis O 
. O 
Aldehyde B-SYSTEMATIC 
dehydrogenase O 
enzymes O 
also O 
play O 
important O 
roles O 
in O 
embryogenesis O 
and O 
development O 
, O 
neurotransmission O 
, O 
oxidative O 
stress O 
and O 
cancer O 
. O 
This O 
article O 
serves O 
as O 
a O 
comprehensive O 
review O 
of O 
the O 
current O 
state O 
of O 
knowledge O 
regarding O 
the O 
ALDH O 
superfamily O 
and O 
the O 
contribution O 
of O 
ALDHs O 
to O 
various O 
physiological O 
and O 
pathophysiological O 
processes O 
. O 

and O 
molecular O 
mechanisms O 
of O 
N-acetyl B-SYSTEMATIC 
cysteine I-SYSTEMATIC 
and O 
silymarin O 
- O 
mediated O 
protection O 
against O 
maneb- O 
and O 
paraquat B-TRIVIAL 
-induced O 
hepatotoxicity O 
in O 
rats O 
. O 

stress O 
is O 
one O 
of O 
the O 
major O 
players O 
in O 
the O 
pathogenesis O 
of O 
maneb O 
( O 
MB O 
) O 
and O 
paraquat B-TRIVIAL 
(PQ)-induced O 
disorders O 
. O 
N-acetyl B-SYSTEMATIC 
cysteine I-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
, O 
a O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
precursor O 
and O 
silymarin O 
( O 
SIL O 
) O 
, O 
a O 
naturally O 
occurring O 
antioxidant O 
, O 
encounter O 
oxidative O 
stress O 
- O 
mediated O 
cellular O 
damage O 
. O 
The O 
present O 
study O 
was O 
aimed O 
to O 
investigate O 
the O 
effects O 
of O 
NAC B-ABBREVIATION 
and O 
SIL O 
against O 
MB O 
and O 
/ O 
or O 
PQ-induced O 
hepatotoxicity O 
in O 
rats O 
. O 
The O 
levels O 
of O 
hepatotoxicity O 
markers O 
- O 
alanine B-TRIVIAL 
aminotransaminase O 
( O 
ALT O 
) O 
, O 
aspartate B-TRIVIAL 
aminotransaminase O 
( O 
AST O 
) O 
and O 
total O 
bilirubin B-TRIVIAL 
, O 
histological O 
changes O 
, O 
oxidative O 
stress O 
indices O 
, O 
phase O 
I O 
and O 
phase O 
II O 
xenobiotic O 
metabolizing O 
enzymes O 
- O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
and O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
( O 
GST O 
) O 
and O 
pro O 
- O 
inflammatory O 
molecules O 
- O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
, O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
and O 
interleukin-1β O 
( O 
IL-1β O 
) O 
were O 
measured O 
in O 
animals O 
treated O 
with O 
MB O 
and O 
/ O 
or O 
PQ O 
in O 
the O 
presence O 
or O 
absence O 
of O 
NAC B-ABBREVIATION 
and O 
SIL O 
. O 
MB O 
and O 
/ O 
or O 
PQ O 
augmented O 
ALT O 
, O 
AST O 
, O 
total O 
bilirubin B-TRIVIAL 
, O 
lipid O 
peroxidation O 
and O 
nitrite B-SYSTEMATIC 
contents O 
and O 
catalytic O 
activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
however O 
, O 
the O 
GSH B-ABBREVIATION 
content O 
was O 
attenuated O 
. O 
NAC B-ABBREVIATION 
and O 
SIL O 
restored O 
the O 
above O 
- O 
mentioned O 
alterations O 
towards O 
basal O 
levels O 
but O 
the O 
restorations O 
were O 
more O 
pronounced O 
in O 
SIL O 
treated O 
groups O 
. O 
Similarly O 
, O 
MB O 
and O 
/ O 
or O 
PQ O 
- O 
mediated O 
histopathological O 
symptoms O 
and O 
changes O 
in O 
the O 
catalytic O 
activities O 
/ O 
expressions O 
of O 
CYP1A2 O 
, O 
CYP2E1 O 
, O 
iNOS O 
, O 
TNF-α O 
, O 
and O 
IL-1β O 
were O 
alleviated O 
by O 
NAC B-ABBREVIATION 
and O 
SIL O 
. O 
Conversely O 
, O 
MB O 
and O 
/ O 
or O 
PQ-induced O 
GSTA4-4 O 
expression O 
/ O 
activity O 
was O 
further O 
increased O 
by O 
NAC B-ABBREVIATION 
/ O 
SIL O 
and O 
glutathione B-TRIVIAL 
reductase O 
activity O 
was O 
also O 
increased O 
. O 
The O 
results O 
obtained O 
thus O 
suggest O 
that O 
NAC B-ABBREVIATION 
and O 
SIL O 
protect O 
MB O 
and O 
/ O 
or O 
PQ-induced O 
hepatotoxicity O 
by O 
reducing O 
oxidative O 
stress O 
, O 
inflammation O 
and O 
by O 
modulating O 
xenobitic O 
metabolizing O 
machinery O 
and O 
SIL O 
seems O 
to O 
be O 
more O 
effective O 
. O 

2u-globulin O 
mediated O 
hyaline O 
droplet O 
nephropathy O 
( O 
HDN O 
) O 
is O 
a O 
male O 
rat O 
specific O 
lesion O 
induced O 
when O 
a O 
compound O 
or O 
metabolite O 
binds O 
to O 
alpha O 
2u-globulin O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
investigate O 
if O 
the O 
newer O 
and O 
more O 
sensitive O 
renal O 
biomarkers O 
would O 
be O 
altered O 
with O 
HDN O 
as O 
well O 
as O 
be O 
able O 
to O 
distinguish O 
between O 
HDN O 
and O 
oxidative O 
stress O 
- O 
induced O 
kidney O 
injury O 
. O 
Rats O 
were O 
dosed O 
orally O 
for O 
7 O 
days O 
to O 
determine O 
( O 
1 O 
) O 
if O 
HDN O 
( O 
induced O 
by O 
2-propanol B-SYSTEMATIC 
or O 
D-limonene B-TRIVIAL 
) O 
altered O 
the O 
newer O 
renal O 
biomarkers O 
and O 
not O 
BUN O 
or O 
creatinine B-TRIVIAL 
, O 
( O 
2 O 
) O 
if O 
renal O 
biomarkers O 
could O 
distinguish O 
between O 
HDN O 
and O 
oxidative O 
stress O 
- O 
induced O 
kidney O 
injury O 
( O 
induced O 
by O 
potassium B-SYSTEMATIC 
bromate I-SYSTEMATIC 
) O 
, O 
( O 
3 O 
) O 
sensitivity O 
of O 
HDN-induced O 
renal O 
biomarker O 
changes O 
relative O 
to O 
D-limonene B-TRIVIAL 
dose O 
, O 
and O 
( O 
4 O 
) O 
reversibility O 
of O 
HDN O 
and O 
renal O 
biomarkers O 
, O 
using O 
vehicle O 
or O 
300 O 
mg O 
/ O 
kg O 
/ O 
day O 
D-limonene B-TRIVIAL 
with O 
7 O 
days O 
of O 
dosing O 
and O 
necropsies O 
scheduled O 
over O 
the O 
period O 
of O 
Days O 
8-85 O 
. O 
HDN-induced O 
renal O 
biomarker O 
changes O 
in O 
male O 
rats O 
were O 
potentially O 
compound O 
specific O 
: O 
( O 
1 O 
) O 
2-propanol B-SYSTEMATIC 
induced O 
mild O 
HDN O 
without O 
increased O 
renal O 
biomarkers O 
, O 
( O 
2 O 
) O 
potassium B-SYSTEMATIC 
bromate I-SYSTEMATIC 
induced O 
moderate O 
HDN O 
with O 
increased O 
clusterin O 
, O 
and O 
( O 
3 O 
) O 
D-limonene B-TRIVIAL 
induced O 
marked O 
HDN O 
with O 
increased O 
αGST O 
, O 
μGST O 
and O 
albumin O 
. O 
Administration O 
of O 
potassium B-SYSTEMATIC 
bromate I-SYSTEMATIC 
did O 
not O 
result O 
in O 
oxidative O 
stress O 
- O 
induced O 
kidney O 
injury O 
, O 
based O 
on O 
histopathology O 
and O 
renal O 
biomarkers O 
creatinine O 
and O 
BUN O 
. O 
The O 
compound O 
D-limonene B-TRIVIAL 
induced O 
a O 
dose O 
dependent O 
increase O 
in O 
HDN O 
severity O 
and O 
renal O 
biomarker O 
changes O 
without O 
altering O 
BUN O 
, O 
creatinine B-TRIVIAL 
or O 
NAG O 
: O 
( O 
1 O 
) O 
minimal O 
induction O 
of O 
HDN O 
and O 
no O 
altered O 
biomarkers O 
at O 
10 O 
mg O 
/ O 
kg O 
/ O 
day O 
, O 
( O 
2 O 
) O 
mild O 
induction O 
of O 
HDN O 
with O 
increased O 
αGST O 
and O 
μGST O 
at O 
50 O 
mg O 
/ O 
kg O 
/ O 
day O 
and O 
( O 
3 O 
) O 
marked O 
induction O 
of O 
HDN O 
with O 
increased O 
αGST O 
, O 
μGST O 
and O 
albumin O 
at O 
300 O 
mg O 
/ O 
kg O 
/ O 
day O 
. O 
HDN O 
induced O 
by O 
D-limonene B-TRIVIAL 
was O 
reversible O 
, O 
but O 
with O 
a O 
variable O 
renal O 
biomarker O 
pattern O 
over O 
time O 
: O 
Day O 
8 O 
there O 
was O 
increased O 
αGST O 
, O 
μGST O 
and O 
albumin O 
; O 
on O 
Day O 
15 O 
increased O 
clusterin O 
, O 
albumin O 
and O 
Kim-1 O 
. O 
In O 
summary O 
, O 
HDN O 
altered O 
the O 
newer O 
and O 
more O 
sensitive O 
renal O 
biomarkers O 
in O 
a O 
time O 
and O 
possibly O 
compound O 
dependent O 
manner O 
. O 

first O 
genetic O 
defect O 
in O 
human O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
(STAT)5b O 
was O 
identified O 
in O 
an O 
individual O 
with O 
profound O 
short O 
stature O 
and O 
GH O 
insensitivity O 
, O 
immune O 
dysfunction O 
, O 
and O 
severe O 
pulmonary O 
disease O 
, O 
and O 
was O 
caused O 
by O 
an O 
alanine B-TRIVIAL 
to O 
proline B-TRIVIAL 
substitution O 
( O 
A630P O 
) O 
within O 
the O 
Src O 
homology-2 O 
( O 
SH2 O 
) O 
domain O 
. O 
STAT5b(A630P) O 
was O 
found O 
to O 
be O 
an O 
inactive O 
transcription O 
factor O 
based O 
on O 
its O 
aberrant O 
folding O 
, O 
diminished O 
solubility O 
, O 
and O 
propensity O 
for O 
aggregation O 
triggered O 
by O 
its O 
misfolded O 
SH2 O 
domain O 
. O 
Here O 
we O 
have O 
characterized O 
the O 
second O 
human O 
STAT5b O 
amino B-FAMILY 
acid I-FAMILY 
substitution O 
mutation O 
in O 
an O 
individual O 
with O 
similar O 
pathophysiological O 
features O 
. O 
This O 
single O 
nucleotide B-FAMILY 
transition O 
, O 
predicted O 
to O 
change O 
phenyalanine B-TRIVIAL 
646 O 
to O 
serine B-TRIVIAL 
( O 
F646S O 
) O 
, O 
also O 
maps O 
to O 
the O 
SH2 O 
domain O 
. O 
Like O 
STAT5b(A630P) O 
, O 
STAT5b(F646S) O 
is O 
prone O 
to O 
aggregation O 
, O 
as O 
evidenced O 
by O 
its O 
detection O 
in O 
the O 
insoluble O 
fraction O 
of O 
cell O 
extracts O 
, O 
the O 
presence O 
of O 
dimers O 
and O 
higher O 
- O 
order O 
oligomers O 
in O 
the O 
soluble O 
fraction O 
, O 
and O 
formation O 
of O 
insoluble O 
cytoplasmic O 
inclusion O 
bodies O 
in O 
cells O 
. O 
Unlike O 
STAT5b(A630P) O 
, O 
which O 
showed O 
minimal O 
GH-induced O 
tyrosine B-TRIVIAL 
phosphorylation O 
and O 
no O 
transcriptional O 
activity O 
, O 
STAT5b(F646S) O 
became O 
tyrosine B-TRIVIAL 
phosphorylated O 
after O 
GH O 
treatment O 
and O 
could O 
function O 
as O 
a O 
GH-activated O 
transcription O 
factor O 
, O 
although O 
to O 
a O 
substantially O 
lesser O 
extent O 
than O 
STAT5b(WT) O 
. O 
Biochemical O 
characterization O 
demonstrated O 
that O 
the O 
isolated O 
SH2 O 
domain O 
containing O 
the O 
F646S O 
substitution O 
closely O 
resembled O 
the O 
wild O 
- O 
type O 
SH2 O 
domain O 
in O 
secondary O 
structure O 
, O 
but O 
exhibited O 
reduced O 
thermodynamic O 
stability O 
and O 
altered O 
tertiary O 
structure O 
that O 
were O 
intermediate O 
between O 
STAT5b(A630P) O 
and O 
STAT5b(WT) O 
. O 
Homology O 
- O 
based O 
structural O 
modeling O 
suggests O 
that O 
the O 
F646S O 
mutation O 
disrupts O 
key O 
hydrophobic O 
interactions O 
and O 
may O 
also O 
distort O 
the O 
phosphopeptide O 
- O 
binding O 
face O 
of O 
the O 
SH2 O 
domain O 
, O 
explaining O 
both O 
the O 
reduced O 
thermodynamic O 
stability O 
and O 
impaired O 
biological O 
activity O 
. O 

and O 
insulin O 
/ O 
IGF-I O 
synergistically O 
induce O 
the O 
proliferation O 
of O 
thyroid O 
cells O 
mainly O 
through O 
the O 
cAMP B-ABBREVIATION 
and O 
phosphatidylinositol B-TRIVIAL 
3-kinase O 
( O 
PI3K O 
) O 
pathways O 
. O 
However O 
, O 
the O 
events O 
involved O 
in O 
this O 
cooperative O 
induction O 
remain O 
unknown O 
, O 
and O 
molecules O 
that O 
are O 
potentially O 
controlled O 
by O 
both O 
TSH O 
and O 
IGF-I O 
are O 
interesting O 
candidates O 
as O 
integrators O 
of O 
both O 
stimuli O 
. O 
The O 
finding O 
that O 
the O 
PI3K O 
pathway O 
is O 
frequently O 
activated O 
in O 
thyroid O 
malignancies O 
has O 
attracted O 
attention O 
to O 
this O 
pathway O 
in O 
the O 
thyroid O 
field O 
. O 
One O 
of O 
the O 
targets O 
of O 
PI3K O 
is O 
Forkhead O 
box O 
O O 
(FoxO)-1 O 
, O 
a O 
widely O 
expressed O 
transcription O 
factor O 
involved O 
in O 
a O 
variety O 
of O 
cellular O 
processes O 
such O 
as O 
differentiation O 
, O 
proliferation O 
, O 
and O 
apoptosis O 
. O 
Here O 
we O 
show O 
that O 
FoxO1 O 
is O 
highly O 
expressed O 
in O 
differentiated O 
rat O 
thyroid O 
cells O 
and O 
human O 
thyroid O 
tissue O 
compared O 
with O 
human O 
thyroid O 
tumor O 
- O 
derived O 
cells O 
and O 
surgically O 
removed O 
thyroid O 
tumors O 
, O 
in O 
which O 
its O 
expression O 
is O 
reduced O 
. O 
In O 
differentiated O 
cells O 
, O 
TSH/ O 
cAMP B-ABBREVIATION 
treatment O 
decreases O 
FoxO1 O 
mRNA O 
and O 
protein O 
levels O 
through O 
proteasome O 
activation O 
, O 
whereas O 
both O 
TSH O 
and O 
IGF-I O 
control O 
FoxO1 O 
localization O 
by O 
promoting O 
a O 
rapid O 
exclusion O 
from O 
the O 
nucleus O 
in O 
an O 
Akt O 
- O 
dependent O 
manner O 
. O 
FoxO1 O 
can O 
control O 
p27(KIP1) O 
expression O 
in O 
differentiated O 
and O 
tumor O 
cells O 
of O 
the O 
thyroid O 
. O 
Furthermore O 
, O 
FoxO1 O 
reexpression O 
in O 
tumor O 
cells O 
promotes O 
a O 
decrease O 
in O 
their O 
proliferation O 
rate O 
, O 
whereas O 
FoxO1 O 
interference O 
in O 
differentiated O 
cells O 
increases O 
their O 
proliferation O 
. O 
These O 
data O 
point O 
to O 
an O 
important O 
role O 
of O 
FoxO1 O 
in O 
mediating O 
the O 
effects O 
of O 
TSH O 
and O 
IGF-I O 
on O 
thyroid O 
cell O 
proliferation O 
and O 
provide O 
a O 
link O 
between O 
loss O 
of O 
FoxO1 O 
expression O 
and O 
the O 
uncontrolled O 
proliferation O 
of O 
thyroid O 
tumor O 
cells O 
. O 

and O 
brain O 
glucose B-TRIVIAL 
sensing O 
: O 
critical O 
role O 
of O 
endozepines O 
. O 

glucose B-TRIVIAL 
sensing O 
is O 
involved O 
in O 
the O 
control O 
of O 
feeding O 
behavior O 
and O 
peripheral O 
glucose B-TRIVIAL 
homeostasis O 
, O 
and O 
glial O 
cells O 
are O 
suggested O 
to O 
play O 
an O 
important O 
role O 
in O 
this O 
process O 
. O 
Diazepam B-TRIVIAL 
-binding O 
inhibitor O 
( O 
DBI O 
) O 
and O 
its O 
processing O 
product O 
the O 
octadecaneuropeptide O 
( O 
ODN O 
) O 
, O 
collectively O 
named O 
endozepines O 
, O 
are O 
secreted O 
by O 
astroglia O 
, O 
and O 
ODN O 
is O 
a O 
potent O 
anorexigenic O 
factor O 
. O 
Therefore O 
, O 
we O 
investigated O 
the O 
involvement O 
of O 
endozepines O 
in O 
brain O 
glucose B-TRIVIAL 
sensing O 
. O 
First O 
, O 
we O 
showed O 
that O 
intracerebroventricular O 
administration O 
of O 
glucose B-TRIVIAL 
in O 
rats O 
increases O 
DBI O 
expression O 
in O 
hypothalamic O 
glial O 
- O 
like O 
tanycytes O 
. O 
We O 
then O 
demonstrated O 
that O 
glucose B-TRIVIAL 
stimulates O 
endozepine O 
secretion O 
from O 
hypothalamic O 
explants O 
. O 
Feeding O 
experiments O 
indicate O 
that O 
the O 
anorexigenic O 
effect O 
of O 
central O 
administration O 
of O 
glucose B-TRIVIAL 
was O 
blunted O 
by O 
coinjection O 
of O 
an O 
ODN O 
antagonist O 
. O 
Conversely O 
, O 
the O 
hyperphagic O 
response O 
elicited O 
by O 
central O 
glucoprivation O 
was O 
suppressed O 
by O 
an O 
ODN O 
agonist O 
. O 
The O 
anorexigenic O 
effects O 
of O 
centrally O 
injected O 
glucose B-TRIVIAL 
or O 
ODN O 
agonist O 
were O 
suppressed O 
by O 
blockade O 
of O 
the O 
melanocortin-3 O 
/ O 
4 O 
receptors O 
, O 
suggesting O 
that O 
glucose B-TRIVIAL 
sensing O 
involves O 
endozepinergic O 
control O 
of O 
the O 
melanocortin O 
pathway O 
. O 
Finally O 
, O 
we O 
found O 
that O 
brain O 
endozepines O 
modulate O 
blood O 
glucose B-TRIVIAL 
levels O 
, O 
suggesting O 
their O 
involvement O 
in O 
a O 
feedback O 
loop O 
controlling O 
whole O 
- O 
body O 
glucose B-TRIVIAL 
homeostasis O 
. O 
Collectively O 
, O 
these O 
data O 
indicate O 
that O 
endozepines O 
are O 
a O 
critical O 
relay O 
in O 
brain O 
glucose B-TRIVIAL 
sensing O 
and O 
potentially O 
new O 
targets O 
in O 
treatment O 
of O 
metabolic O 
disorders O 
. O 

M O 
- O 
type O 
kinesin O 
isoform O 
, O 
Kif9 O 
, O 
has O 
recently O 
been O 
implicated O 
in O 
maintaining O 
a O 
physical O 
connection O 
between O 
the O 
centrosome O 
and O 
nucleus O 
in O 
Dictyostelium O 
discoideum O 
. O 
However O 
, O 
the O 
mechanism O 
by O 
which O 
Kif9 O 
functions O 
to O 
link O 
these O 
two O 
organelles O 
remains O 
obscure O 
. O 
Here O 
we O 
demonstrate O 
that O 
the O 
Kif9 O 
protein O 
is O 
localized O 
to O 
the O 
nuclear O 
envelope O 
and O 
is O 
concentrated O 
in O 
the O 
region O 
underlying O 
the O 
centrosome O 
point O 
of O 
attachment O 
. O 
Nuclear O 
anchorage O 
appears O 
mediated O 
through O 
a O 
specialized O 
transmembrane O 
domain O 
located O 
in O 
the O 
carboxyl B-SYSTEMATIC 
terminus O 
. O 
Kif9 O 
interacts O 
with O 
microtubules O 
in O 
in O 
vitro O 
binding O 
assays O 
and O 
effects O 
an O 
endwise O 
depolymerization O 
of O 
the O 
polymer O 
. O 
These O 
results O 
suggest O 
a O 
model O 
whereby O 
Kif9 O 
is O 
anchored O 
to O 
the O 
nucleus O 
and O 
generates O 
a O 
pulling O 
force O 
that O 
reels O 
the O 
centrosome O 
up O 
against O 
the O 
nucleus O 
. O 
This O 
is O 
a O 
novel O 
activity O 
for O 
a O 
kinesin O 
motor O 
, O 
one O 
important O 
for O 
progression O 
of O 
cells O 
into O 
mitosis O 
and O 
to O 
ensure O 
centrosome O 
- O 
nuclear O 
parity O 
in O 
a O 
multinuclear O 
environment O 
. O 

- O 
term O 
fire O 
retardants O 
are O 
used O 
to O 
prevent O 
the O 
spread O 
of O 
wildland O 
fires O 
. O 
These O 
products O 
are O 
normally O 
applied O 
by O 
aircraft O 
and O 
are O 
intended O 
specifically O 
for O 
terrestrial O 
application O 
, O 
but O 
fire O 
retardants O 
have O 
entered O 
aquatic O 
habitats O 
by O 
misapplication O 
and O 
/ O 
or O 
accidental O 
spills O 
and O 
have O 
resulted O 
in O 
fish O 
mortalities O 
. O 
The O 
authors O 
examined O 
the O 
toxicity O 
of O 
two O 
fire O 
retardant O 
products O 
, O 
PHOS-CHEK B-MULTIPLE 
259F I-MULTIPLE 
and I-MULTIPLE 
LC-95A I-MULTIPLE 
, O 
to O 
salmon O 
undergoing O 
parr O 
- O 
smolt O 
transformation O 
. O 
Yearling O 
stream O 
- O 
type O 
chinook O 
salmon O 
at O 
the O 
smolt O 
stage O 
were O 
exposed O 
to O 
eight O 
concentrations O 
of O 
each O 
retardant O 
in O 
freshwater O 
and O 
a O 
no-PHOS-CHEK O 
control O 
for O 
96 O 
h O 
to O 
determine O 
acute O 
toxicity O 
. O 
Concentrations O 
of O 
the O 
products O 
that O 
caused O 
50% O 
mortality O 
were O 
140.5 O 
and O 
339.8 O 
mg O 
/ O 
L O 
for O 
259F B-TRIVIAL 
and O 
LC-95A B-TRIVIAL 
, O 
respectively O 
, O 
and O 
could O 
occur O 
during O 
accidental O 
drops O 
into O 
aquatic O 
habitats O 
. O 
Damage O 
to O 
gill O 
tissues O 
seen O 
in O 
histopathological O 
sections O 
was O 
attributed O 
to O 
fire O 
retardant O 
exposure O 
. O 
Un-ionized O 
ammonia O 
levels O 
, O 
from O 
259F B-TRIVIAL 
, O 
were O 
sufficient O 
to O 
cause O 
acute O 
mortality O 
; O 
but O 
additional O 
factors O 
, O 
indicated O 
by O 
increased O 
phagosome O 
prevalence O 
in O 
the O 
gills O 
, O 
might O 
have O 
contributed O 
to O 
mortality O 
during O 
LC-95A B-TRIVIAL 
exposure O 
. O 
Seawater O 
and O 
disease O 
challenges O 
were O 
performed O 
to O 
determine O 
sublethal O 
effects O 
of O 
product O 
exposures O 
on O 
fish O 
health O 
. O 
Although O 
PHOS-CHEK O 
exposure O 
did O 
not O 
adversely O 
affect O 
chinook O 
salmon's O 
susceptibility O 
to O 
Listonella O 
anguillarum O 
, O 
exposure O 
did O 
significantly O 
reduce O 
seawater O 
survival O 
. O 
Reduced O 
salmon O 
survival O 
resulting O 
from O 
prior O 
fire O 
retardant O 
exposure O 
during O 
their O 
transition O 
from O 
freshwater O 
rearing O 
environments O 
to O 
seawater O 
may O 
decrease O 
the O 
abundance O 
of O 
salmon O 
populations O 
. O 

relationships O 
derived O 
from O 
field O 
data O 
are O 
potentially O 
confounded O 
by O 
variables O 
that O 
are O 
correlated O 
with O 
both O 
the O 
cause O 
and O 
its O 
effect O 
. O 
The O 
present O 
study O 
presents O 
a O 
method O 
for O 
assessing O 
the O 
potential O 
for O 
confounding O 
and O 
applies O 
it O 
to O 
the O 
relationship O 
between O 
ionic O 
strength O 
and O 
impairment O 
of O 
benthic O 
invertebrate O 
assemblages O 
in O 
central O 
Appalachian O 
streams O 
. O 
The O 
method O 
weighs O 
all O 
available O 
evidence O 
for O 
and O 
against O 
confounding O 
by O 
each O 
potential O 
confounder O 
. O 
It O 
identifies O 
10 O 
types O 
of O 
evidence O 
for O 
confounding O 
, O 
presents O 
a O 
qualitative O 
scoring O 
system O 
, O 
and O 
provides O 
rules O 
for O 
applying O 
the O 
scores O 
. O 
Twelve O 
potential O 
confounders O 
were O 
evaluated O 
: O 
habitat O 
, O 
organic O 
enrichment O 
, O 
nutrients O 
, O 
deposited O 
sediments O 
, O 
pH O 
, O 
selenium B-SYSTEMATIC 
, O 
temperature O 
, O 
lack O 
of O 
headwaters O 
, O 
catchment O 
area O 
, O 
settling O 
ponds O 
, O 
dissolved O 
oxygen B-SYSTEMATIC 
, O 
and O 
metals O 
. O 
One O 
potential O 
confounder O 
, O 
low O 
pH O 
, O 
was O 
found O 
to O 
be O 
biologically O 
significant O 
and O 
eliminated O 
by O 
removing O 
sites O 
with O 
pH O 
< O 
6 O 
. O 
Other O 
potential O 
confounders O 
were O 
eliminated O 
based O 
on O 
the O 
weight O 
of O 
evidence O 
. O 
This O 
method O 
was O 
found O 
to O 
be O 
useful O 
and O 
defensible O 
. O 
It O 
could O 
be O 
applied O 
to O 
other O 
environmental O 
assessments O 
that O 
use O 
field O 
data O 
to O 
develop O 
causal O 
relationships O 
, O 
including O 
contaminated O 
site O 
remediation O 
or O 
management O 
of O 
natural O 
resources O 
. O 

eight O 
- O 
orders O 
of O 
magnitude O 
enhancement O 
in O 
current O 
across O 
Hg B-FORMULA 
/ O 
X- O 
styrene B-TRIVIAL 
- O 
Si B-FORMULA 
junctions O 
is O 
caused O 
by O 
merely O 
altering O 
a O 
substituent O 
, O 
X O 
. O 
Interface O 
states O 
are O 
passivated O 
and O 
, O 
depending O 
on O 
X O 
, O 
the O 
Si B-FORMULA 
Schottky O 
junction O 
encompasses O 
the O 
full O 
range O 
from O 
Ohmic O 
to O 
strongly O 
rectifying O 
. O 
This O 
powerful O 
electrostatic O 
molecular O 
effect O 
has O 
immediate O 
implications O 
for O 
interface O 
band O 
alignment O 
and O 
sensing O 
. O 

of O 
silver B-SYSTEMATIC 
doping O 
on O 
electron O 
transport O 
in O 
thin O 
films O 
of O 
PbSe B-FORMULA 
nanocrystals O 
. O 

- O 
effect O 
transistors O 
are O 
fabricated O 
from O 
thin O 
films O 
of O 
Ag-doped B-FORMULA 
PbSe I-FORMULA 
nanocrystals O 
to O 
analyze O 
the O 
influence O 
of O 
electronically O 
active O 
impurities O 
on O 
electrical O 
transport O 
in O 
this O 
important O 
material O 
for O 
nanocrystal O 
applications O 
. O 
Data O 
is O 
collected O 
as O 
a O 
function O 
of O 
nanocrystal O 
size O 
, O 
dopant O 
concentration O 
, O 
and O 
temperature O 
. O 
Changes O 
in O 
the O 
Fermi O 
level O 
and O 
transport O 
parameters O 
indicate O 
that O 
Ag B-FORMULA 
is O 
acting O 
as O 
a O 
p- O 
type O 
dopant O 
( O 
acceptor O 
) O 
. O 

horizons O 
for O 
diagnostics O 
and O 
therapeutic O 
applications O 
of O 
graphene B-TRIVIAL 
and O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
. O 

, O 
a O 
one O 
- O 
atom O 
- O 
thick O 
two O 
- O 
dimensional O 
( O 
2D O 
) O 
layer O 
of O 
sp(2) O 
-bonded O 
carbon B-SYSTEMATIC 
, O 
has O 
received O 
worldwide O 
attention O 
owing O 
to O 
its O 
extraordinary O 
physical O 
and O 
chemical O 
properties O 
. O 
Recently O 
, O 
great O 
efforts O 
have O 
been O 
devoted O 
to O 
explore O 
potential O 
applications O 
of O 
graphene B-TRIVIAL 
and O 
its O 
oxide O 
in O 
life O 
science O 
, O 
especially O 
in O 
disease O 
- O 
related O 
diagnostics O 
, O 
near-Infrared O 
( O 
NIR O 
) O 
phototherapy O 
and O 
imaging O 
. O 
Here O 
we O 
will O 
introduce O 
recent O 
advances O 
and O 
new O 
horizons O 
in O 
this O 
area O 
, O 
and O 
focus O 
on O 
the O 
rising O 
progress O 
on O 
NIR O 
photothermal O 
therapy O 
for O 
cancer O 
and O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
, O 
human O 
telomerase O 
detection O 
, O 
stem O 
cell O 
proliferation O 
and O 
differentiation O 
on O 
graphene B-TRIVIAL 
substrate O 
, O 
diagnosis O 
of O 
cancer O 
cell O 
and O 
related O 
biomarkers O 
, O 
drug/ O 
nucleotide B-FAMILY 
/ O 
peptide O 
delivery O 
and O 
cell O 
imaging O 
, O 
which O 
have O 
not O 
been O 
comprehensively O 
reviewed O 
. O 
We O 
hope O 
to O 
provide O 
an O 
outlook O 
to O 
the O 
applications O 
of O 
graphene B-TRIVIAL 
and O 
its O 
oxide O 
, O 
especially O 
on O 
the O 
new O 
horizons O 
in O 
this O 
field O 
, O 
and O 
inspire O 
broader O 
interests O 
across O 
various O 
disciplines O 
. O 

beyond O 
protein O 
- O 
ligand O 
interactions O 
: O 
By O 
combining O 
structure O 
- O 
affinity O 
relationships O 
, O 
protein O 
- O 
ligand O 
modeling O 
studies O 
, O 
and O 
quantum O 
mechanical O 
calculations O 
, O 
we O 
show O 
that O 
ligand O 
conformational O 
energies O 
and O 
basicity O 
play O 
critical O 
roles O 
in O 
ligand O 
binding O 
to O 
the O 
histamine B-TRIVIAL 
H4 O 
receptor O 
, O 
a O 
GPCR O 
that O 
plays O 
a O 
key O 
role O 
in O 
inflammation O 
. O 

play O 
a O 
role O 
in O 
functional O 
differentiation O 
of O 
pituitary O 
somatotrophs O 
and O 
lactotrophs O 
during O 
embryogenesis O 
. O 
Ras-dva O 
was O 
identified O 
as O 
a O 
gene O 
regulated O 
by O 
anterior O 
neural O 
fold O 
protein-1 O 
/ O 
homeobox O 
expressed O 
in O 
embryonic O 
stem O 
cells-1 O 
, O 
a O 
transcription O 
factor O 
known O 
to O 
be O 
critical O 
in O 
pituitary O 
development O 
, O 
and O 
has O 
an O 
expression O 
profile O 
in O 
the O 
chicken O 
embryonic O 
pituitary O 
gland O 
that O 
is O 
consistent O 
with O 
in O 
vivo O 
regulation O 
by O 
glucocorticoids O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
characterize O 
expression O 
and O 
regulation O 
of O 
ras-dva O 
mRNA O 
in O 
the O 
developing O 
chicken O 
anterior O 
pituitary O 
. O 
Pituitary O 
ras-dva O 
mRNA O 
levels O 
increased O 
during O 
embryogenesis O 
to O 
a O 
maximum O 
on O 
embryonic O 
day O 
( O 
e O 
) O 
18 O 
and O 
then O 
decreased O 
and O 
remained O 
low O 
or O 
undetectable O 
after O 
hatch O 
. O 
Ras-dva O 
expression O 
was O 
highly O 
enriched O 
in O 
the O 
pituitary O 
gland O 
on O 
e18 O 
relative O 
to O 
other O 
tissues O 
examined O 
. O 
Glucocorticoid O 
treatment O 
of O 
pituitary O 
cells O 
from O 
mid- O 
and O 
late O 
- O 
stage O 
embryos O 
rapidly O 
increased O 
ras-dva O 
mRNA O 
, O 
suggesting O 
it O 
may O 
be O 
a O 
direct O 
transcriptional O 
target O 
of O 
glucocorticoids O 
. O 
A O 
reporter O 
construct O 
driven O 
by O 
4 O 
kb O 
of O 
the O 
chicken O 
ras-dva O 
5'-flanking O 
region O 
, O 
containing O 
six O 
putative O 
pituitary O 
- O 
specific O 
transcription O 
factor-1 O 
( O 
Pit-1 O 
) O 
binding O 
sites O 
and O 
two O 
potential O 
glucocorticoid O 
receptor O 
( O 
GR O 
) O 
binding O 
sites O 
, O 
was O 
highly O 
activated O 
in O 
embryonic O 
pituitary O 
cells O 
and O 
up O 
- O 
regulated O 
by O 
corticosterone B-TRIVIAL 
. O 
Mutagenesis O 
of O 
the O 
most O 
proximal O 
Pit-1 O 
site O 
decreased O 
promoter O 
activity O 
in O 
chicken O 
e11 O 
pituitary O 
cells O 
, O 
indicating O 
regulation O 
of O 
ras-dva O 
by O 
Pit-1 O 
. O 
However O 
, O 
mutating O 
putative O 
GR O 
binding O 
sites O 
did O 
not O 
substantially O 
reduce O 
induction O 
of O 
ras-dva O 
promoter O 
activity O 
by O 
corticosterone B-TRIVIAL 
, O 
suggesting O 
additional O 
DNA O 
elements O 
within O 
the O 
5'-flanking O 
region O 
are O 
responsible O 
for O 
glucocorticoid O 
regulation O 
. O 
We O 
have O 
identified O 
ras-dva O 
as O 
a O 
glucocorticoid O 
- O 
regulated O 
gene O 
that O 
is O 
likely O 
expressed O 
in O 
cells O 
of O 
the O 
Pit-1 O 
lineage O 
within O 
the O 
developing O 
anterior O 
pituitary O 
gland O 
. O 

role O 
of O 
the O 
carbohydrate B-FAMILY 
response O 
element O 
- O 
binding O 
protein O 
in O 
male O 
fructose B-TRIVIAL 
-fed O 
rats O 
. O 

2030 O 
, O 
nearly O 
half O 
of O 
Americans O 
will O 
have O 
nonalcoholic O 
fatty O 
liver O 
disease O 
. O 
In O 
part O 
, O 
this O 
epidemic O 
is O 
fueled O 
by O 
the O 
increasing O 
consumption O 
of O 
caloric O 
sweeteners O 
coupled O 
with O 
an O 
innate O 
capacity O 
to O 
convert O 
sugar B-FAMILY 
into O 
fat O 
via O 
hepatic O 
de O 
novo O 
lipogenesis O 
. O 
In O 
addition O 
to O 
serving O 
as O 
substrates O 
, O 
monosaccharides B-FAMILY 
also O 
increase O 
the O 
expression O 
of O 
key O 
enzymes O 
involved O 
in O 
de O 
novo O 
lipogenesis O 
via O 
the O 
carbohydrate B-FAMILY 
response O 
element O 
- O 
binding O 
protein O 
( O 
ChREBP O 
) O 
. O 
To O 
determine O 
whether O 
ChREBP O 
is O 
a O 
potential O 
therapeutic O 
target O 
, O 
we O 
decreased O 
hepatic O 
expression O 
of O 
ChREBP O 
with O 
a O 
specific O 
antisense O 
oligonucleotide O 
( O 
ASO O 
) O 
in O 
male O 
Sprague-Dawley O 
rats O 
fed O 
either O 
a O 
high- O 
fructose B-TRIVIAL 
or O 
high O 
- O 
fat O 
diet O 
. O 
ChREBP O 
ASO O 
treatment O 
decreased O 
plasma O 
triglyceride B-FAMILY 
concentrations O 
compared O 
with O 
control O 
ASO O 
treatment O 
in O 
both O 
diet O 
groups O 
. O 
The O 
reduction O 
was O 
more O 
pronounced O 
in O 
the O 
fructose B-TRIVIAL 
-fed O 
group O 
and O 
attributed O 
to O 
decreased O 
hepatic O 
expression O 
of O 
ACC2 O 
, O 
FAS O 
, O 
SCD1 O 
, O 
and O 
MTTP O 
and O 
a O 
decrease O 
in O 
the O 
rate O 
of O 
hepatic O 
triglyceride B-FAMILY 
secretion O 
. O 
This O 
was O 
associated O 
with O 
an O 
increase O 
in O 
insulin O 
- O 
stimulated O 
peripheral O 
glucose B-TRIVIAL 
uptake O 
, O 
as O 
assessed O 
by O 
the O 
hyperinsulinemic O 
- O 
euglycemic O 
clamp O 
. O 
In O 
contrast O 
, O 
ChREBP O 
ASO O 
did O 
not O 
alter O 
hepatic O 
lipid O 
content O 
or O 
hepatic O 
insulin O 
sensitivity O 
. O 
Interestingly O 
, O 
fructose B-TRIVIAL 
-fed O 
rats O 
treated O 
with O 
ChREBP O 
ASO O 
had O 
increased O 
plasma O 
uric B-TRIVIAL 
acid I-TRIVIAL 
, O 
alanine B-TRIVIAL 
transaminase O 
, O 
and O 
aspartate B-TRIVIAL 
aminotransferase O 
concentrations O 
. O 
This O 
was O 
associated O 
with O 
decreased O 
expression O 
of O 
fructose B-TRIVIAL 
aldolase O 
and O 
fructokinase O 
, O 
reminiscent O 
of O 
inherited O 
disorders O 
of O 
fructose B-TRIVIAL 
metabolism O 
. O 
In O 
summary O 
, O 
these O 
studies O 
suggest O 
that O 
targeting O 
ChREBP O 
may O 
prevent O 
fructose B-TRIVIAL 
-induced O 
hypertriglyceridemia O 
but O 
without O 
the O 
improvements O 
in O 
hepatic O 
steatosis O 
and O 
hepatic O 
insulin O 
responsiveness O 
. O 

requirements O 
for O 
Moraxella O 
catarrhalis O 
growth O 
under O 
iron B-SYSTEMATIC 
-limiting O 
conditions O 
. O 

sequestration O 
by O 
the O 
human O 
host O 
is O 
a O 
first O 
line O 
defence O 
against O 
respiratory O 
pathogens O 
like O 
Moraxella O 
catarrhalis O 
, O 
which O 
consequently O 
experiences O 
a O 
period O 
of O 
iron B-SYSTEMATIC 
starvation O 
during O 
colonization O 
. O 
We O 
determined O 
the O 
genetic O 
requirements O 
for O 
M. O 
catarrhalis O 
BBH18 O 
growth O 
during O 
iron B-SYSTEMATIC 
starvation O 
using O 
the O 
high O 
- O 
throughput O 
genome O 
- O 
wide O 
screening O 
technology O 
genomic O 
array O 
footprinting O 
( O 
GAF O 
) O 
. O 
By O 
subjecting O 
a O 
large O 
random O 
transposon O 
mutant O 
library O 
to O 
growth O 
under O 
iron B-SYSTEMATIC 
-limiting O 
conditions O 
, O 
mutants O 
of O 
the O 
MCR_0996-rhlB-yggW O 
operon O 
, O 
rnd O 
, O 
and O 
MCR_0457 O 
were O 
negatively O 
selected O 
. O 
Growth O 
experiments O 
using O 
directed O 
mutants O 
confirmed O 
the O 
GAF O 
phenotypes O 
with O 
ΔyggW O 
( O 
putative O 
haem O 
- O 
shuttling O 
protein O 
) O 
and O 
ΔMCR_0457 O 
( O 
hypothetical O 
protein O 
) O 
most O 
severely O 
attenuated O 
during O 
iron B-SYSTEMATIC 
starvation O 
, O 
phenotypes O 
which O 
were O 
restored O 
upon O 
genetic O 
complementation O 
of O 
the O 
deleted O 
genes O 
. O 
Deletion O 
of O 
yggW O 
resulted O 
in O 
similar O 
attenuated O 
phenotypes O 
in O 
three O 
additional O 
strains O 
. O 
Transcriptional O 
profiles O 
of O 
ΔyggW O 
and O 
ΔMCR_0457 O 
were O 
highly O 
altered O 
with O 
393 O 
and O 
192 O 
differentially O 
expressed O 
genes O 
respectively O 
. O 
In O 
all O 
five O 
mutants O 
, O 
expression O 
of O 
nitrate B-SYSTEMATIC 
reductase O 
genes O 
was O 
increased O 
and O 
of O 
nitrite B-SYSTEMATIC 
reductase O 
decreased O 
, O 
suggesting O 
an O 
impaired O 
aerobic O 
respiration O 
. O 
Alteration O 
of O 
iron B-SYSTEMATIC 
metabolism O 
may O 
affect O 
nasopharyngeal O 
colonization O 
as O 
adherence O 
of O 
all O 
mutants O 
to O 
respiratory O 
tract O 
epithelial O 
cells O 
was O 
attenuated O 
. O 
In O 
conclusion O 
, O 
we O 
elucidated O 
the O 
genetic O 
requirements O 
for O 
M. O 
catarrhalis O 
growth O 
during O 
iron B-SYSTEMATIC 
starvation O 
and O 
characterized O 
the O 
roles O 
of O 
the O 
identified O 
genes O 
in O 
bacterial O 
growth O 
and O 
host O 
interaction O 
. O 

plasticity O 
in O 
the O 
hippocampus O 
shows O 
resistance O 
to O 
acute O 
ethanol B-SYSTEMATIC 
exposure O 
in O 
transgenic O 
mice O 
with O 
astrocyte O 
- O 
targeted O 
enhanced O 
CCL2 O 
expression O 
. O 

has O 
been O 
shown O 
that O 
ethanol O 
exposure O 
can O 
activate O 
astrocytes O 
and O 
microglia O 
resulting O 
in O 
the O 
production O 
of O 
neuroimmune O 
factors O 
, O 
including O 
the O 
chemokine O 
CCL2 O 
. O 
The O 
role O 
of O 
these O 
neuroimmune O 
factors O 
in O 
the O 
effects O 
of O 
ethanol B-SYSTEMATIC 
on O 
the O 
central O 
nervous O 
system O 
has O 
yet O 
to O 
be O 
elucidated O 
. O 
To O 
address O 
this O 
question O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
ethanol B-SYSTEMATIC 
on O 
synaptic O 
transmission O 
and O 
plasticity O 
in O 
the O 
hippocampus O 
from O 
mice O 
that O 
express O 
elevated O 
levels O 
of O 
CCL2 O 
in O 
the O 
brain O 
and O 
their O 
non-transgenic O 
littermate O 
controls O 
. O 
The O 
brains O 
of O 
the O 
transgenic O 
mice O 
simulate O 
one O 
aspect O 
of O 
the O 
alcoholic O 
brain O 
, O 
chronically O 
increased O 
levels O 
of O 
CCL2 O 
. O 
We O 
used O 
extracellular O 
field O 
potential O 
recordings O 
in O 
acutely O 
isolated O 
hippocampal O 
slices O 
to O 
identify O 
neuroadaptive O 
changes O 
produced O 
by O 
elevated O 
levels O 
of O 
CCL2 O 
and O 
how O 
these O 
neuroadaptive O 
changes O 
affect O 
the O 
actions O 
of O 
acute O 
ethanol B-SYSTEMATIC 
. O 
Results O 
showed O 
that O 
synaptic O 
transmission O 
and O 
the O 
effects O 
of O 
ethanol B-SYSTEMATIC 
on O 
synaptic O 
transmission O 
were O 
similar O 
in O 
the O 
CCL2-transgenic O 
and O 
non-transgenic O 
hippocampus O 
. O 
However O 
, O 
long O 
- O 
term O 
potentiation O 
( O 
LTP O 
) O 
, O 
a O 
cellular O 
mechanism O 
thought O 
to O 
underlie O 
learning O 
and O 
memory O 
, O 
in O 
the O 
CCL2-transgenic O 
hippocampus O 
was O 
resistant O 
to O 
the O 
ethanol B-SYSTEMATIC 
-induced O 
depression O 
of O 
LTP O 
observed O 
in O 
the O 
non-transgenic O 
hippocampus O 
. O 
Consistent O 
with O 
these O 
results O 
, O 
ethanol B-SYSTEMATIC 
pretreatment O 
significantly O 
impaired O 
cued O 
and O 
contextual O 
fear O 
conditioning O 
in O 
non-transgenic O 
mice O 
, O 
but O 
had O 
no O 
effect O 
in O 
CCL2-transgenic O 
mice O 
. O 
These O 
data O 
show O 
that O 
chronically O 
elevated O 
levels O 
of O 
CCL2 O 
in O 
the O 
hippocampus O 
produce O 
neuroadaptive O 
changes O 
that O 
block O 
the O 
depressing O 
effects O 
of O 
ethanol B-SYSTEMATIC 
on O 
hippocampal O 
synaptic O 
plasticity O 
and O 
support O 
the O 
hypothesis O 
that O 
CCL2 O 
may O 
provide O 
a O 
neuroprotective O 
effect O 
against O 
the O 
devastating O 
actions O 
of O 
ethanol B-SYSTEMATIC 
on O 
hippocampal O 
function O 
. O 

- O 
normal O 
stimulation O 
of O 
dopamine B-TRIVIAL 
D1 O 
receptors O 
in O 
the O 
prelimbic O 
cortex O 
blocks O 
behavioral O 
expression O 
of O 
both O 
aversive O 
and O 
rewarding O 
associative O 
memories O 
through O 
a O 
cyclic-AMP B-TRIVIAL 
-dependent O 
signaling O 
pathway O 
. O 

( O 
DA O 
) O 
receptor O 
transmission O 
through O 
either O 
D(1) O 
or O 
D(2) O 
- O 
like O 
subtypes O 
is O 
involved O 
critically O 
in O 
the O 
processing O 
of O 
emotional O 
information O 
within O 
the O 
medial O 
prefrontal O 
cortex O 
( O 
mPFC O 
) O 
. O 
However O 
the O 
functional O 
role O 
of O 
specific O 
DA O 
D(1) O 
- O 
like O 
receptor O 
transmission O 
in O 
the O 
expression O 
of O 
emotionally O 
salient O 
associative O 
memories O 
( O 
either O 
aversive O 
or O 
rewarding O 
) O 
is O 
not O 
currently O 
understood O 
. O 
Here O 
we O 
demonstrate O 
that O 
specific O 
activation O 
of O 
DA O 
D(1) O 
receptors O 
in O 
the O 
prelimbic O 
( O 
PLC O 
) O 
division O 
of O 
the O 
mPFC O 
causes O 
a O 
transient O 
block O 
in O 
the O 
behavioral O 
expression O 
of O 
both O 
aversive O 
and O 
rewarding O 
associative O 
memories O 
. O 
We O 
report O 
that O 
intra-PLC O 
microinfusions O 
of O 
a O 
selective O 
D(1) O 
receptor O 
agonist O 
block O 
the O 
spontaneous O 
expression O 
of O 
an O 
associative O 
olfactory O 
fear O 
memory O 
, O 
without O 
altering O 
the O 
stability O 
of O 
the O 
original O 
memory O 
trace O 
. O 
Furthermore O 
, O 
using O 
an O 
unbiased O 
place O 
conditioning O 
procedure O 
( O 
CPP O 
) O 
, O 
intra-PLC O 
D(1) O 
receptor O 
activation O 
blocks O 
the O 
spontaneous O 
expression O 
of O 
an O 
associative O 
morphine B-TRIVIAL 
( O 
5 O 
mg O 
/ O 
kg O 
; O 
i.p O 
. O 
) O 
reward O 
memory O 
, O 
while O 
leaving O 
morphine B-TRIVIAL 
-primed O 
memory O 
expression O 
intact O 
. O 
Interestingly O 
, O 
both O 
intra-PLC O 
D(1)-receptor O 
mediated O 
block O 
of O 
either O 
fear O 
- O 
related O 
or O 
reward O 
- O 
related O 
associative O 
memories O 
were O 
dependent O 
upon O 
downstream O 
cyclic-AMP B-TRIVIAL 
( O 
cAMP B-ABBREVIATION 
) O 
signaling O 
as O 
both O 
effects O 
were O 
rescued O 
by O 
co O 
- O 
administration O 
of O 
a O 
cAMP B-ABBREVIATION 
signaling O 
inhibitor O 
. O 
The O 
blockade O 
of O 
both O 
rewarding O 
and O 
aversive O 
associative O 
memories O 
is O 
mediated O 
through O 
a O 
D(1)-specific O 
signaling O 
pathway O 
, O 
as O 
neither O 
forms O 
of O 
spontaneous O 
memory O 
expression O 
were O 
blocked O 
by O 
intra-PLC O 
microinfusions O 
of O 
a O 
D(2) O 
- O 
like O 
receptor O 
agonist O 
. O 
Our O 
results O 
demonstrate O 
that O 
the O 
spontaneous O 
expression O 
of O 
either O 
rewarding O 
or O 
aversive O 
emotionally O 
salient O 
memories O 
shares O 
a O 
common O 
, O 
D(1)-receptor O 
mediated O 
substrate O 
within O 
the O 
mPFC O 
. O 

attenuates O 
impairments O 
in O 
memory O 
and O 
CREB O 
activation O 
produced O 
by O 
an O 
α4β2 O 
but O 
not O 
an O 
α7 O 
nicotinic O 
receptor O 
antagonist O 
. O 

improves O 
memory O 
for O 
a O 
variety O 
of O 
tasks O 
when O 
administered O 
to O 
rats O 
and O 
mice O 
near O 
the O 
time O 
of O 
training O 
. O 
Prior O 
work O 
indicates O 
glucose B-TRIVIAL 
may O 
enhance O 
memory O 
by O 
increasing O 
the O 
synthesis O 
and O 
release O 
of O 
the O 
neurotransmitter O 
acetylcholine B-SYSTEMATIC 
in O 
the O 
brain O 
. O 
To O 
investigate O 
if O 
specific O 
acetylcholine B-SYSTEMATIC 
receptor O 
subtypes O 
may O 
mediate O 
some O 
of O 
the O 
memory O 
- O 
enhancing O 
actions O 
of O 
glucose B-TRIVIAL 
, O 
we O 
examined O 
the O 
effects O 
of O 
subtype O 
- O 
specific O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
antagonists O 
on O 
memory O 
in O 
Fischer-344 O 
rats O 
and O 
also O 
examined O 
the O 
ability O 
of O 
glucose B-TRIVIAL 
to O 
reverse O 
drug O 
- O 
induced O 
impairments O 
. O 
Pre O 
- O 
training O 
peripheral O 
injections O 
of O 
methyllycaconitine B-TRIVIAL 
( O 
MLA B-ABBREVIATION 
) O 
or O 
dihydro-beta-erythroidine B-SYSTEMATIC 
( O 
DHβE B-ABBREVIATION 
) O 
, O 
which O 
are O 
specific O 
α7 O 
and O 
α4β2 O 
nicotinic O 
receptor O 
antagonists O 
, O 
respectively O 
, O 
dose O 
- O 
dependently O 
impaired O 
retention O 
latencies O 
in O 
an O 
inhibitory O 
avoidance O 
task O 
when O 
tested O 
7-days O 
but O 
not O 
1 O 
h O 
after O 
training O 
. O 
Immediate O 
post O 
- O 
training O 
glucose B-TRIVIAL 
injections O 
attenuated O 
the O 
impairments O 
, O 
but O 
were O 
more O 
effective O 
in O 
attenuating O 
the O 
DHβE B-ABBREVIATION 
-induced O 
impairments O 
. O 
Likewise O 
, O 
peripheral O 
or O 
direct O 
intrahippocampal O 
injections O 
of O 
MLA B-ABBREVIATION 
or O 
DHβE B-ABBREVIATION 
dose O 
- O 
dependently O 
impaired O 
spatial O 
working O 
memory O 
scores O 
on O 
a O 
spontaneous O 
alternation O 
task O 
. O 
Concurrent O 
administration O 
of O 
glucose B-TRIVIAL 
reversed O 
DHβE B-ABBREVIATION 
- O 
but O 
not O 
MLA B-ABBREVIATION 
-induced O 
impairments O 
. O 
CREB O 
phosphorylation O 
downstream O 
of O 
cholinergic O 
signaling O 
was O 
assessed O 
30 O 
min O 
after O 
spontaneous O 
alternation O 
testing O 
and O 
intrahippocampal O 
drug O 
infusions O 
. O 
Both O 
MLA B-ABBREVIATION 
and O 
DHβE B-ABBREVIATION 
impaired O 
hippocampal O 
CREB O 
phosphorylation O 
; O 
glucose B-TRIVIAL 
reversed O 
DHβE B-ABBREVIATION 
- O 
but O 
not O 
MLA B-ABBREVIATION 
-induced O 
deficits O 
. O 
The O 
effectiveness O 
of O 
glucose B-TRIVIAL 
in O 
reversing O 
DHβE B-ABBREVIATION 
- O 
but O 
not O 
MLA B-ABBREVIATION 
-induced O 
impairments O 
in O 
behavioral O 
performance O 
and O 
CREB O 
phosphorylation O 
suggests O 
that O 
activation O 
of O 
α7 O 
receptors O 
may O 
play O 
an O 
important O 
role O 
in O 
memory O 
enhancement O 
by O 
glucose B-TRIVIAL 
. O 

synthesis O 
of O 
derivatives O 
and O 
structure O 
- O 
activity O 
relationship O 
study O 
in O 
the O 
development O 
of O 
NA255 B-IDENTIFIER 
as O 
a O 
novel O 
host O 
- O 
targeting O 
anti-HCV O 
agent O 
. O 

C O 
virus O 
( O 
HCV O 
) O 
infection O 
represents O 
a O 
serious O 
health O 
- O 
care O 
problem O 
. O 
Previously O 
we O 
reported O 
the O 
identification O 
of O 
NA255 B-IDENTIFIER 
from O 
our O 
natural O 
products O 
library O 
using O 
a O 
HCV O 
sub O 
- O 
genomic O 
replicon O 
cell O 
culture O 
system O 
. O 
Herein O 
, O 
we O 
report O 
how O 
the O 
absolute O 
stereochemistry O 
of O 
NA255 B-IDENTIFIER 
was O 
determined O 
and O 
an O 
enantioselective O 
synthetic O 
method O 
for O 
NA255 B-IDENTIFIER 
derivatives O 
was O 
developed O 
. O 
The O 
structure O 
- O 
activity O 
relationship O 
of O 
the O 
NA255 B-IDENTIFIER 
derivatives O 
and O 
rat O 
pharmacokinetic O 
profiles O 
of O 
the O 
representative O 
compounds O 
are O 
disclosed O 
. O 

inhibits O 
LPS O 
plus O 
IFN-γ-induced O 
inflammatory O 
response O 
in O 
astrocytes O 
primary O 
cultures O 
. O 

large O 
body O 
of O 
evidence O 
suggests O 
that O 
the O 
inflammatory O 
reaction O 
plays O 
an O 
important O 
role O 
in O 
the O 
pathogenesis O 
of O 
neurodegenerative O 
diseases O 
. O 
Our O 
previous O 
studies O 
described O 
the O 
neuroprotective O 
effects O 
of O 
catalpol B-TRIVIAL 
in O 
lipopolysaccharide O 
(LPS)-induced O 
inflammatory O 
models O 
, O 
in O 
which O 
catalpol B-TRIVIAL 
was O 
shown O 
to O 
prevent O 
mesencephalic O 
neuron O 
death O 
and O 
ameliorate O 
cognitive O 
ability O 
animals O 
. O 
To O 
further O 
investigate O 
the O 
protective O 
effect O 
and O 
underlying O 
mechanism O 
of O 
catalpol B-TRIVIAL 
, O 
astrocytes O 
were O 
pretreated O 
with O 
low O 
( O 
0.1mM O 
) O 
and O 
high O 
dose O 
( O 
0.5mM O 
) O 
catalpol B-TRIVIAL 
for O 
1h O 
prior O 
to O 
LPS O 
plus O 
interferon-γ O 
stimulation O 
. O 
Biochemical O 
analyses O 
showed O 
that O 
NO B-FORMULA 
and O 
ROS O 
production O 
and O 
iNOS O 
activity O 
were O 
significantly O 
reduced O 
by O 
catalpol B-TRIVIAL 
. O 
Data O 
at O 
transcriptional O 
level O 
also O 
demonstrated O 
that O 
catalpol B-TRIVIAL 
potently O 
attenuated O 
gene O 
expressions O 
involved O 
in O 
inflammation O 
, O 
such O 
as O 
iNOS O 
, O 
COX-2 O 
and O 
TLR4 O 
. O 
In O 
addition O 
, O 
our O 
exploration O 
further O 
revealed O 
that O 
the O 
suppressive O 
action O 
of O 
catalpol B-TRIVIAL 
on O 
inflammation O 
was O 
mediated O 
via O 
inhibiting O 
nuclear O 
factor-κB O 
( O 
NF-κB O 
) O 
activation O 
. O 
Collectively O 
, O 
these O 
results O 
suggest O 
that O 
catalpol B-TRIVIAL 
can O 
exert O 
inhibitory O 
effects O 
on O 
the O 
inflammatory O 
reaction O 
in O 
astrocytes O 
and O 
that O 
inactivation O 
of O 
NF-κB O 
could O 
be O 
the O 
major O 
determinant O 
for O 
its O 
anti-inflammatory O 
mechanism O 
. O 
Therefore O 
, O 
catalpol B-TRIVIAL 
may O 
potentially O 
be O 
a O 
highly O 
effective O 
therapeutic O 
agent O 
in O 
treating O 
neurodegenerative O 
diseases O 
associated O 
with O 
inflammation O 
. O 

red O 
ginseng O 
ameliorates O 
acute O 
3-nitropropionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-induced O 
cochlear O 
damage O 
in O 
mice O 
. O 

acid I-SYSTEMATIC 
( O 
3-NP B-SYSTEMATIC 
) O 
, O 
a O 
mitochondrial O 
toxin O 
, O 
has O 
been O 
reported O 
to O 
induce O 
an O 
acute O 
cochlear O 
damage O 
. O 
Korean O 
red O 
ginseng O 
( O 
KRG O 
) O 
is O 
known O 
to O 
have O 
protective O 
effects O 
from O 
some O 
types O 
of O 
hearing O 
loss O 
. O 
This O 
study O 
aimed O 
to O 
observe O 
the O 
protective O 
effect O 
of O 
KRG O 
in O 
an O 
ototoxic O 
animal O 
model O 
using O 
3-NP B-SYSTEMATIC 
intratympanic O 
injection O 
. O 
BALB O 
/ O 
c O 
mice O 
were O 
classified O 
into O 
5 O 
groups O 
( O 
n=15 O 
) O 
and O 
dose O 
- O 
dependent O 
toxic O 
effects O 
after O 
intratympanic O 
injection O 
with O 
3-NP B-SYSTEMATIC 
( O 
300-5000 O 
mM O 
) O 
on O 
the O 
left O 
ear O 
were O 
investigated O 
to O 
determine O 
the O 
appropriate O 
toxicity O 
level O 
of O 
3-NP B-SYSTEMATIC 
. O 
For O 
observation O 
of O 
the O 
protective O 
effects O 
of O 
KRG O 
, O 
23 O 
mice O 
were O 
grouped O 
into O 
3-NP B-SYSTEMATIC 
( O 
500 O 
mM O 
, O 
n=12 O 
) O 
and O 
KRG+ O 
3-NP B-SYSTEMATIC 
groups O 
( O 
300 O 
mg O 
/ O 
kg O 
KRG O 
for O 
7 O 
days O 
before O 
500 O 
mM O 
3-NP B-SYSTEMATIC 
administration O 
, O 
n=11 O 
) O 
. O 
Auditory O 
brain O 
response O 
( O 
ABR O 
) O 
and O 
cochlear O 
morphological O 
evaluations O 
were O 
performed O 
before O 
and O 
after O 
drug O 
administration O 
. O 
The O 
ABR O 
thresholds O 
in O 
the O 
800-5000 O 
mM O 
groups O 
exceeded O 
the O 
maximum O 
recording O 
limit O 
at O 
16 O 
and O 
32 O 
kHz O 
1 O 
day O 
after O 
3-NP B-SYSTEMATIC 
administration O 
. O 
The O 
ABR O 
threshold O 
in O 
the O 
500 O 
mM O 
3-NP B-SYSTEMATIC 
+ O 
KRG O 
group O 
was O 
significantly O 
lower O 
than O 
that O 
in O 
the O 
500 O 
mM O 
3-NP B-SYSTEMATIC 
group O 
from O 
post O 
1 O 
week O 
to O 
1 O 
month O 
. O 
The O 
mean O 
type O 
II O 
fibrocyte O 
counts O 
significantly O 
differed O 
between O 
the O 
control O 
and O 
3-NP B-SYSTEMATIC 
groups O 
and O 
between O 
the O 
3-NP B-SYSTEMATIC 
and O 
3-NP B-SYSTEMATIC 
+ O 
KRG O 
groups O 
. O 
Spiral O 
ganglion O 
cell O 
degeneration O 
in O 
the O 
3-NP B-SYSTEMATIC 
group O 
was O 
more O 
severe O 
than O 
that O 
in O 
the O 
3-NP B-SYSTEMATIC 
+ O 
KRG O 
group O 
. O 
This O 
animal O 
model O 
exhibited O 
a O 
dose O 
- O 
dependent O 
hearing O 
loss O 
with O 
histological O 
changes O 
. O 
KRG O 
administration O 
ameliorated O 
the O 
deterioration O 
of O 
hearing O 
by O 
3-NP B-SYSTEMATIC 
. O 

and O 
developmental O 
toxicity O 
screening O 
test O 
of O 
3-cyanopyridine B-SYSTEMATIC 
in O 
rats O 
. O 

: O 
CD(SD)rats O 
were O 
given O 
3-cyanopyridine B-SYSTEMATIC 
by O 
gavage O 
at O 
0 O 
, O 
5 O 
, O 
30 O 
or O 
180 O 
mg O 
/ O 
kg O 
/ O 
day O 
. O 
Males O 
were O 
dosed O 
for O 
42 O 
days O 
beginning O 
14 O 
days O 
before O 
mating O 
, O 
and O 
females O 
for O 
40-53 O 
days O 
beginning O 
14 O 
days O 
before O 
mating O 
to O 
day O 
3 O 
of O 
lactation O 
, O 
including O 
throughout O 
the O 
mating O 
and O 
gestation O 
periods O 
. O 
General O 
toxicity O 
, O 
mainly O 
liver O 
damage O 
, O 
was O 
observed O 
in O 
males O 
at O 
≥ O 
30 O 
mg O 
/ O 
kg O 
/ O 
day O 
and O 
in O 
females O 
at O 
≥ O 
5 O 
mg O 
/ O 
kg O 
/ O 
day O 
. O 
Sertoli O 
cell O 
vacuolation O 
was O 
observed O 
at O 
180 O 
mg O 
/ O 
kg O 
/ O 
day O 
, O 
and O 
spermatocyte O 
damages O 
were O 
observed O 
at O 
≥ O 
30 O 
mg O 
/ O 
kg O 
/ O 
day O 
. O 
Effects O 
on O 
estrous O 
cycles O 
, O 
corpora O 
lutea O 
and O 
implantations O 
, O 
and O 
unsuccessfully O 
mated O 
females O 
, O 
despite O 
additional O 
mating O 
, O 
were O 
observed O 
at O 
180 O 
mg O 
/ O 
kg O 
/ O 
day O 
. O 
Delayed O 
initiation O 
of O 
delivery O 
, O 
dystocia O 
, O 
and O 
deaths O 
or O 
moribundities O 
of O 
pregnant O 
females O 
were O 
observed O 
at O 
180 O 
mg O 
/ O 
kg O 
/ O 
day O 
, O 
and O 
only O 
two O 
pregnant O 
rats O 
delivered O 
live O 
pups O 
at O 
that O 
dose O 
. O 
The O 
NOAEL O 
for O 
reproductive O 
/ O 
developmental O 
toxicity O 
was O 
concluded O 
to O 
be O 
30 O 
mg O 
/ O 
kg O 
/ O 
day O 
. O 

- O 
month O 
subchronic O 
intramuscular O 
toxicity O 
study O 
of O 
rotigotine B-TRIVIAL 
-loaded O 
microspheres O 
in O 
Cynomolgus O 
monkeys O 
. O 

dopaminergic O 
stimulation O 
( O 
CDS O 
) O 
is O 
an O 
important O 
drug O 
development O 
strategy O 
in O 
the O 
treatment O 
of O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
. O 
Rotigotine B-TRIVIAL 
is O 
a O 
non- O 
ergoline B-TRIVIAL 
D(3) O 
/ O 
D(2) O 
/ O 
D(1) O 
dopamine B-TRIVIAL 
receptor O 
agonist O 
for O 
treating O 
PD O 
. O 
As O 
a O 
new O 
treatment O 
option O 
for O 
CDS O 
, O 
rotigotine B-TRIVIAL 
-loaded O 
microspheres O 
( O 
RoMS O 
) O 
, O 
long O 
- O 
acting O 
sustained O 
- O 
release O 
microspheres O 
with O 
poly(lactide-co-glycolide) B-SYSTEMATIC 
as O 
drug O 
carrier O 
, O 
are O 
now O 
being O 
evaluated O 
in O 
clinical O 
trial O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
subchronic O 
toxicity O 
in O 
Cynomolgus O 
monkeys O 
has O 
been O 
characterized O 
via O 
intramuscular O 
administration O 
with O 
RoMS O 
at O 
0 O 
, O 
10 O 
, O 
40 O 
and O 
160 O 
mg O 
/ O 
kg O 
, O 
weekly O 
for O 
3 O 
months O 
with O 
a O 
1-month O 
recovery O 
period O 
. O 
The O 
NOAEL O 
was O 
10 O 
mg O 
/ O 
kg O 
/ O 
week O 
. O 
One O 
male O 
at O 
160 O 
mg O 
/ O 
kg O 
died O 
from O 
an O 
extensive O 
pulmonary O 
embolism O 
. O 
The O 
major O 
toxicological O 
effects O 
were O 
associated O 
with O 
dopamine B-TRIVIAL 
agonist O 
- O 
related O 
pharmacodynamic O 
properties O 
of O 
rotigotine B-TRIVIAL 
( O 
e.g O 
. O 
, O 
hyperactivity O 
and O 
stereotype O 
, O 
decreased O 
serum O 
prolactin O 
level O 
) O 
and O 
foreign O 
body O 
removal O 
reaction O 
induced O 
by O 
poly(lactide-co-glycolide) B-SYSTEMATIC 
and O 
carboxymethycellulose O 
sodium B-SYSTEMATIC 
( O 
e.g O 
. O 
, O 
increased O 
mononuclear O 
cells O 
and O 
neutrophils O 
, O 
thymus O 
atrophy O 
and O 
vacuolar O 
degeneration O 
of O 
adrenal O 
cortex O 
, O 
foreign O 
body O 
granuloma O 
with O 
foam O 
cells O 
accumulation O 
at O 
injection O 
sites O 
and O 
foam O 
cells O 
accumulation O 
in O 
spleen O 
and O 
multiple O 
lymph O 
sinuses O 
) O 
. O 
At O 
the O 
end O 
of O 
recovery O 
period O 
, O 
above O 
findings O 
recovered O 
to O 
a O 
normal O 
level O 
or O 
to O 
a O 
certain O 
degree O 
except O 
vacuolar O 
degeneration O 
of O 
adrenal O 
gland O 
. O 
RoMS O 
has O 
exhibited O 
high O 
safety O 
on O 
monkeys O 
. O 

human O 
populations O 
may O 
be O 
constantly O 
exposed O 
to O 
complex O 
pesticide O 
mixtures O 
through O 
their O 
diet O 
, O 
the O 
human O 
health O 
risk O 
of O 
pesticide O 
exposure O 
is O 
currently O 
assessed O 
on O 
the O 
basis O 
of O 
toxicity O 
data O 
on O 
individual O 
compounds O 
. O 
To O 
investigate O 
the O 
combined O 
toxic O 
effects O 
of O 
pesticide O 
cocktails O 
previously O 
identified O 
in O 
the O 
French O 
diet O 
, O 
we O 
first O 
studied O 
the O 
cytotoxicity O 
induced O 
by O 
seven O 
cocktails O 
composed O 
of O 
two O 
to O 
six O 
pesticides O 
on O 
human O 
hepatic O 
( O 
HepG2 O 
) O 
and O 
colon O 
( O 
Caco-2 O 
) O 
cell O 
lines O 
using O 
the O 
MTT B-ABBREVIATION 
and O 
neutral B-TRIVIAL 
red I-TRIVIAL 
uptake O 
assays O 
. O 
Secondly O 
, O 
we O 
challenged O 
to O 
assess O 
the O 
combined O 
effects O 
of O 
the O 
two O 
most O 
cytotoxic O 
cocktails O 
by O 
comparing O 
the O 
measured O 
effects O 
of O 
the O 
mixtures O 
with O 
the O 
predictions O 
based O 
on O 
additive O 
effects O 
on O 
two O 
concepts O 
- O 
independent O 
action O 
( O 
IA O 
) O 
and O 
concentration O 
addition O 
( O 
CA O 
) O 
. O 
For O 
the O 
cocktail O 
composed O 
of O 
dichlorodiphenyltrichloroethane B-SYSTEMATIC 
( O 
DDT B-ABBREVIATION 
) O 
and O 
dieldrin B-TRIVIAL 
, O 
the O 
cytotoxicity O 
of O 
the O 
equimolar O 
cocktail O 
proved O 
greater O 
than O 
the O 
additive O 
effect O 
estimated O 
by O 
the O 
two O 
concepts O 
. O 
Furthermore O 
, O 
apoptosis O 
induction O 
was O 
higher O 
in O 
equimolar O 
cocktail O 
than O 
predicted O 
by O 
summing O 
the O 
effects O 
of O 
DDT B-ABBREVIATION 
and O 
dieldrin B-TRIVIAL 
. O 
Thus O 
, O 
some O 
supra O 
- O 
additive O 
toxicity O 
was O 
found O 
in O 
the O 
DDT B-ABBREVIATION 
- O 
dieldrin B-TRIVIAL 
cocktail O 
. O 
Nevertheless O 
, O 
if O 
IA O 
and O 
CA O 
models O 
could O 
reveal O 
combined O 
effects O 
of O 
pesticide O 
cocktails O 
, O 
an O 
accurate O 
evaluation O 
remains O 
challenging O 
. O 

phages O 
are O 
genetically O 
enginnered O 
by O 
replacing O 
2 O 
N B-FORMULA 
-terminal O 
amino B-FAMILY 
acids I-FAMILY 
of O 
the O 
p8 O 
coat O 
protein O 
of O 
the O 
fd O 
phage O 
. O 
AGE O 
and O 
zeta O 
potential O 
measurements O 
show O 
that O 
SS O 
phages O 
carry O 
at O 
least O 
1 O 
/ O 
4 O 
less O 
net O 
negative O 
surface O 
charge O 
than O 
fd O 
phages O 
. O 
Morphology O 
and O 
thickness O 
of O 
phages O 
are O 
studied O 
at O 
different O 
counterion O 
concentrations O 
( O 
10(-3) O 
, O 
10(-2) O 
and O 
10(-1) O 
M O 
) O 
by O 
AFM O 
, O 
SEM O 
and O 
immunofluorescence O 
analyses O 
. O 
Bundles O 
induced O 
by O 
CoCl2 B-FORMULA 
and O 
CaCl2 B-FORMULA 
are O 
either O 
metallized O 
by O 
chemical O 
reduction O 
or O 
biomineralized O 
for O 
apatite O 
- O 
like O 
material O 
formation O 
. O 
EDX O 
spectroscopy O 
confirms O 
the O 
presence O 
of O 
Co B-FORMULA 
, O 
P B-FORMULA 
and O 
Ca B-FORMULA 
peaks O 
in O 
mineralized O 
samples O 
. O 
Such O 
bottom O 
- O 
up O 
manufactured O 
phage O 
scaffolds O 
might O 
be O 
applied O 
in O 
bioengineering O 
studies O 
. O 

dodecyl I-SYSTEMATIC 
benzene I-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
( O 
SDBS B-ABBREVIATION 
) O 
and O 
cetyl B-SYSTEMATIC 
trimethyl I-SYSTEMATIC 
ammonium I-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
CTAC B-ABBREVIATION 
) O 
are O 
two O 
kinds O 
of O 
surfactants O 
widely O 
applied O 
in O 
various O 
industries O 
. O 
The O 
tremendous O 
direct O 
discharge O 
of O 
these O 
surfactants O 
into O 
natural O 
waters O 
has O 
posed O 
a O 
significant O 
threat O 
to O 
ecosystems O 
. O 
Dunaliella O 
bardawil O 
was O 
employed O 
in O 
the O 
present O 
research O 
to O 
test O 
the O 
toxic O 
effects O 
of O 
SDBS B-ABBREVIATION 
, O 
CTAC B-ABBREVIATION 
, O 
and O 
their O 
mixture O 
on O 
cell O 
growth O 
, O 
cellular O 
morphology O 
, O 
β-carotene B-TRIVIAL 
accumulation O 
, O 
and O 
enzymatic O 
activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
and O 
catalase O 
( O 
CAT O 
) O 
. O 
The O 
results O 
showed O 
that O 
SDBS B-ABBREVIATION 
at O 
200 O 
, O 
550 O 
, O 
900 O 
, O 
1350 O 
, O 
1800 O 
, O 
and O 
2400 O 
mg O 
/ O 
L O 
and O 
CTAC B-ABBREVIATION 
at O 
0.4 O 
, O 
0.7 O 
, O 
1 O 
, O 
1.3 O 
, O 
2.8 O 
, O 
and O 
3.5 O 
mg O 
/ O 
L O 
inhibited O 
algal O 
growth O 
and O 
β-carotene B-TRIVIAL 
accumulation O 
, O 
both O 
of O 
which O 
declined O 
and O 
then O 
increased O 
. O 
In O 
particular O 
, O 
CTAC B-ABBREVIATION 
( O 
median O 
inhibitory O 
concentration O 
at O 
10 O 
days O 
[IC50](10 O 
d) O 
= O 
2.8 O 
± O 
1.49 O 
mg O 
/ O 
L O 
) O 
was O 
more O 
hazardous O 
than O 
SDBS B-ABBREVIATION 
( O 
IC50(10 O 
d) O 
= O 
2044 O 
± O 
637.3 O 
mg O 
/ O 
L O 
) O 
. O 
The O 
additive O 
index O 
( O 
AI O 
) O 
calculated O 
from O 
carotene O 
content O 
data O 
was O 
( O 
-4.1 O 
, O 
-1.67 O 
) O 
< O 
0 O 
, O 
indicating O 
an O 
antagonistic O 
effect O 
between O 
SDBS B-ABBREVIATION 
and O 
CTAC B-ABBREVIATION 
. O 
Algae O 
cultivated O 
at O 
level O 
6 O 
of O 
the O 
binary O 
system O 
showed O 
hormesis O 
due O 
to O 
the O 
mitigated O 
toxicity O 
; O 
SDBS B-ABBREVIATION 
at O 
2400 O 
mg O 
/ O 
L O 
, O 
CTAC O 
at O 
3.5 O 
mg O 
/ O 
L O 
, O 
and O 
combined O 
surfactants O 
at O 
level O 
6 O 
exerted O 
lethal O 
effects O 
on O 
D O 
. O 
bardawil O 
. O 
Both O 
SOD O 
and O 
CAT O 
activities O 
showed O 
similar O 
associations O 
with O 
varied O 
concentrations O 
of O 
surfactants O 
: O 
SOD O 
was O 
significantly O 
promoted O 
by O 
550 O 
to O 
1800 O 
mg O 
/ O 
L O 
SDBS B-ABBREVIATION 
, O 
0.7 O 
to O 
1.3 O 
mg O 
/ O 
L O 
CTAC B-ABBREVIATION 
, O 
and O 
mixtures O 
at O 
levels O 
2 O 
to O 
4 O 
; O 
CAT O 
was O 
clearly O 
promoted O 
by O 
900 O 
mg O 
/ O 
L O 
SDBS B-ABBREVIATION 
, O 
0.4 O 
to O 
1.3 O 
mg O 
/ O 
L O 
CTAC B-ABBREVIATION 
, O 
and O 
mixtures O 
at O 
levels O 
2 O 
to O 
4 O 
. O 

xanthones B-FAMILY 
as O 
orally O 
active O 
antitumor O 
agents O 
. O 

a O 
newly O 
developed O 
strategy O 
whose O 
key O 
step O 
is O 
the O 
regioselective O 
propargylation O 
of O 
hydroxyxanthone B-SYSTEMATIC 
substrates O 
, O 
99 O 
structurally O 
diverse O 
Garcinia O 
natural O 
- O 
product O 
- O 
like O 
xanthones B-FAMILY 
based O 
on O 
gambogic B-TRIVIAL 
acid I-TRIVIAL 
were O 
designed O 
and O 
synthesized O 
and O 
their O 
in O 
vitro O 
antitumor O 
activity O 
was O 
evaluated O 
. O 
A O 
set O 
of O 
40 O 
related O 
compounds O 
was O 
chosen O 
for O 
determination O 
of O 
their O 
physicochemical O 
properties O 
including O 
polar O 
surface O 
area O 
, O 
log O 
D₇.₄ O 
, O 
aqueous O 
solubility O 
, O 
and O 
permeability O 
at O 
pH O 
7.4 O 
. O 
In O 
the O 
light O 
of O 
the O 
in O 
vitro O 
antitumor O 
activity O 
and O 
the O 
physicochemical O 
properties O 
, O 
two O 
compounds O 
were O 
advanced O 
into O 
in O 
vivo O 
efficacy O 
experiments O 
. O 
The O 
antitumor O 
activity O 
of O 
compound O 
112 O 
, O 
administered O 
po O 
, O 
showed O 
more O 
potent O 
in O 
vivo O 
oral O 
antitumor O 
activity O 
than O 
gambogic B-TRIVIAL 
acid I-TRIVIAL 
. O 

, O 
metabolism O 
and O 
excretion O 
of O 
darexaban B-TRIVIAL 
( O 
YM150 B-IDENTIFIER 
) O 
, O 
a O 
new O 
direct O 
factor O 
Xa O 
inhibitor O 
in O 
humans O 
. O 

. O 
The O 
absorption O 
, O 
metabolism O 
and O 
excretion O 
of O 
darexaban B-TRIVIAL 
( O 
YM150 B-IDENTIFIER 
) O 
, O 
a O 
novel O 
oral O 
direct O 
factor O 
Xa O 
inhibitor O 
, O 
were O 
investigated O 
after O 
a O 
single O 
oral O 
administration O 
of O 
[(14)C]darexaban B-SYSTEMATIC 
maleate I-SYSTEMATIC 
at O 
a O 
dose O 
of O 
60 O 
mg O 
in O 
healthy O 
male O 
human O 
subjects O 
. O 
2 O 
. O 
[(14)C]Darexaban B-SYSTEMATIC 
was O 
rapidly O 
absorbed O 
, O 
with O 
both O 
blood O 
and O 
plasma O 
concentrations O 
peaking O 
at O 
approximately O 
0.75 O 
h O 
post O 
- O 
dose O 
. O 
Plasma O 
concentrations O 
of O 
darexaban B-TRIVIAL 
glucuronide I-TRIVIAL 
( O 
M1 O 
) O 
, O 
the O 
pharmacological O 
activity O 
of O 
which O 
is O 
equipotent O 
to O 
darexaban B-TRIVIAL 
in O 
vitro O 
, O 
also O 
peaked O 
at O 
approximately O 
0.75 O 
h O 
. O 
3 O 
. O 
Similar O 
amounts O 
of O 
dosed O 
radioactivity O 
were O 
excreted O 
via O 
faeces O 
( O 
51.9% O 
) O 
and O 
urine O 
( O 
46.4% O 
) O 
by O 
168 O 
h O 
post O 
- O 
dose O 
, O 
suggesting O 
that O 
at O 
least O 
approximately O 
half O 
of O 
the O 
administered O 
dose O 
is O 
absorbed O 
from O 
the O 
gastrointestinal O 
tract O 
. O 
4 O 
. O 
M1 O 
was O 
the O 
major O 
drug O 
- O 
related O 
component O 
in O 
plasma O 
and O 
urine O 
, O 
accounting O 
for O 
up O 
to O 
95.8% O 
of O 
radioactivity O 
in O 
plasma O 
. O 
The O 
N-oxides B-FAMILY 
of O 
M1 O 
, O 
a O 
mixture O 
of O 
two O 
diastereomers O 
designated O 
as O 
M2 O 
and O 
M3 O 
, O 
were O 
also O 
present O 
in O 
plasma O 
and O 
urine O 
, O 
accounting O 
for O 
up O 
to O 
13.2% O 
of O 
radioactivity O 
in O 
plasma O 
. O 
In O 
faeces O 
, O 
darexaban B-TRIVIAL 
was O 
the O 
major O 
drug O 
- O 
related O 
component O 
, O 
and O 
N-demethyl B-SYSTEMATIC 
darexaban I-SYSTEMATIC 
( O 
M5 O 
) O 
was O 
detected O 
as O 
a O 
minor O 
metabolite O 
. O 
5 O 
. O 
These O 
findings O 
suggested O 
that O 
, O 
following O 
oral O 
administration O 
of O 
darexaban B-TRIVIAL 
in O 
humans O 
, O 
M1 O 
is O 
quickly O 
formed O 
during O 
first O 
- O 
pass O 
metabolism O 
via O 
UDP B-ABBREVIATION 
-glucuronosyltransferases O 
, O 
exerting O 
its O 
pharmacological O 
activity O 
in O 
blood O 
before O 
being O 
excreted O 
into O 
urine O 
and O 
faeces O 
. O 

of O 
3-dimensional O 
cellular O 
constructs O 
via O 
microstereolithography O 
using O 
a O 
simple O 
, O 
three O 
- O 
component O 
, O 
poly(ethylene B-FAMILY 
glycol I-FAMILY 
) I-FAMILY 
acrylate I-FAMILY 
-based O 
system O 
. O 

novel O 
method O 
for O 
the O 
production O 
of O 
inhibitor- O 
and O 
solvent-free O 
resins O 
suitable O 
for O 
three O 
- O 
dimensional O 
( O 
3D O 
) O 
microstereolithography O 
is O 
reported O 
. O 
Using O 
an O 
exemplar O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
-based O 
resin O 
, O 
the O 
control O 
of O 
features O 
in O 
the O 
X O 
, O 
Y O 
, O 
and O 
Z O 
planes O 
is O 
demonstrated O 
such O 
that O 
complex O 
structures O 
can O 
be O 
manufactured O 
. O 
Human O 
mesenchymal O 
stem O 
cells O 
cultured O 
on O 
the O 
manufactured O 
scaffolds O 
remained O 
viable O 
during O 
the O 
7 O 
day O 
assessment O 
period O 
, O 
with O 
proliferation O 
rates O 
comparable O 
to O 
those O 
observed O 
on O 
tissue O 
culture O 
polystyrene B-SYSTEMATIC 
. O 
These O 
data O 
suggest O 
that O 
this O 
novel O 
, O 
yet O 
simple O 
, O 
method O 
is O 
suitable O 
for O 
the O 
production O 
of O 
3D O 
scaffolds O 
for O 
tissue O 
engineering O 
and O 
regenerative O 
medicine O 
applications O 
. O 

with O 
potent O 
antiprotozoal O 
activity O 
. O 

8,8-dialkyldihydroberberines B-FAMILY 
( O 
8,8-DDBs B-FAMILY 
) O 
were O 
found O 
to O 
possess O 
mid- O 
to O 
low O 
- O 
nanomolar O 
potency O 
against O 
Plasmodium O 
falciparum O 
blood O 
- O 
stage O 
parasites O 
, O 
Leishmania O 
donovani O 
intracellular O 
amastigotes O 
, O 
and O 
Trypanosoma O 
brucei O 
brucei O 
bloodstream O 
forms O 
. O 
For O 
example O 
, O 
8,8-diethyldihydroberberine B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
5b O 
) O 
exhibited O 
in O 
vitro O 
IC50 O 
values O 
of O 
77 O 
, O 
100 O 
, O 
and O 
5.3 O 
nM O 
against O 
these O 
three O 
parasites O 
, O 
respectively O 
. O 
In O 
turn O 
, O 
two O 
8,8-dialkylcanadines B-FAMILY 
, O 
obtained O 
by O 
reduction O 
of O 
the O 
corresponding O 
8,8-DDBs B-FAMILY 
, O 
were O 
much O 
less O 
potent O 
against O 
these O 
parasites O 
in O 
vitro O 
. O 
While O 
the O 
natural O 
product O 
berberine O 
is O 
a O 
weak O 
DNA O 
binder O 
, O 
the O 
8,8-DDBs B-FAMILY 
displayed O 
no O 
affinity O 
for O 
DNA O 
, O 
as O 
assessed O 
by O 
changes O 
in O 
the O 
melting O 
temperature O 
of O 
poly(dA·dT) B-FAMILY 
DNA O 
. O 
Selected O 
8,8-DDBs B-FAMILY 
showed O 
efficacy O 
in O 
mouse O 
models O 
of O 
visceral O 
leishmaniasis O 
and O 
African O 
trypanosomiasis O 
, O 
with O 
8,8-dimethyldihydroberberine B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
5a O 
) O 
reducing O 
liver O 
parasitemia O 
by O 
46% O 
in O 
L O 
. O 
donovani O 
- O 
infected O 
BALB O 
/ O 
c O 
mice O 
when O 
given O 
at O 
an O 
intraperitoneal O 
dose O 
of O 
10 O 
mg O 
/ O 
kg O 
/ O 
day O 
for O 
five O 
days O 
. O 
The O 
8,8-DDBs O 
may O 
thus O 
serve O 
as O 
leads O 
for O 
discovering O 
new O 
antimalarial O 
, O 
antileishmanial O 
, O 
and O 
antitrypanosomal O 
drug O 
candidates O 
. O 

is O 
anticonvulsant O 
by O 
potentiating O 
GABAergic O 
transmission O 
in O 
a O 
model O 
of O 
benzodiazepine B-FAMILY 
-refractory O 
status O 
epilepticus O 
. O 

( O 
BZDs B-FAMILY 
) O 
are O 
first O 
- O 
line O 
therapy O 
for O 
treatment O 
of O 
status O 
epilepticus O 
( O 
SE O 
) O 
. O 
However O 
, O 
BZD B-ABBREVIATION 
treatment O 
is O 
negatively O 
affected O 
by O 
seizure O 
duration O 
due O 
to O 
decreases O 
in O 
BZD B-ABBREVIATION 
-sensitive O 
GABA(A) O 
receptors O 
during O 
prolonged O 
SE O 
. O 
Stiripentol B-TRIVIAL 
( O 
STP B-ABBREVIATION 
) O 
is O 
an O 
anticonvulsant O 
that O 
is O 
used O 
as O 
add O 
- O 
on O 
treatment O 
for O 
Dravet O 
Syndrome O 
. O 
Recent O 
studies O 
have O 
shown O 
that O 
STP B-ABBREVIATION 
is O 
a O 
positive O 
allosteric O 
modulator O 
of O 
the O 
GABA(A) O 
receptor O 
. O 
The O 
subunit O 
selectivity O 
of O 
STP B-ABBREVIATION 
at O 
this O 
receptor O 
suggests O 
that O 
it O 
would O 
be O 
anticonvulsant O 
in O 
both O 
brief O 
as O 
well O 
as O 
prolonged O 
SE O 
. O 
We O 
tested O 
this O 
possibility O 
by O 
comparing O 
the O 
ability O 
of O 
STP B-ABBREVIATION 
and O 
diazepam B-TRIVIAL 
( O 
DZP B-ABBREVIATION 
) O 
, O 
a O 
commonly O 
used O 
BZD B-ABBREVIATION 
, O 
to O 
terminate O 
behavioral O 
convulsions O 
in O 
a O 
rodent O 
model O 
of O 
pharmacoresistant O 
SE O 
. O 
We O 
found O 
that O 
STP B-ABBREVIATION 
was O 
anticonvulsant O 
in O 
this O 
model O 
and O 
remained O 
effective O 
during O 
prolonged O 
SE O 
, O 
unlike O 
DZP B-ABBREVIATION 
which O 
exhibited O 
a O 
14 O 
fold O 
increase O 
in O 
its O 
ED(50) O 
. O 
Whole O 
cell O 
recording O 
from O 
hippocampal O 
slices O 
from O 
these O 
animals O 
revealed O 
that O 
STP B-ABBREVIATION 
potentiated O 
GABAergic O 
IPSCs O 
, O 
as O 
well O 
as O 
tonic O 
GABAergic O 
current O 
by O 
acting O 
at O 
a O 
site O 
on O 
the O 
GABA(A) O 
receptor O 
separate O 
from O 
the O 
BDZ B-ABBREVIATION 
binding O 
site O 
. O 
Potentiation O 
of O 
GABAergic O 
currents O 
by O 
STP B-ABBREVIATION 
remained O 
intact O 
during O 
prolonged O 
SE O 
, O 
while O 
potentiation O 
by O 
DZP B-ABBREVIATION 
was O 
lost O 
. O 
Both O 
IPSC O 
potentiation O 
and O 
anticonvulsant O 
activity O 
of O 
STP B-ABBREVIATION 
were O 
greater O 
in O 
younger O 
animals O 
than O 
in O 
adults O 
. O 
These O 
findings O 
suggest O 
that O 
at O 
doses O 
that O 
yield O 
therapeutically O 
relevant O 
concentrations O 
, O 
STP B-ABBREVIATION 
is O 
anticonvulsant O 
by O 
potentiating O 
GABAergic O 
inhibition O 
and O 
that O 
the O 
subunit O 
selectivity O 
profile O 
of O 
STP B-ABBREVIATION 
enables O 
it O 
to O 
remain O 
effective O 
despite O 
GABA(A) O 
receptor O 
subunit O 
changes O 
during O 
prolonged O 
SE O 
. O 

of O 
serotonin B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
) O 
function O 
by O 
a O 
VGLUT1 O 
dependent O 
glutamate B-TRIVIAL 
pathway O 
. O 

the O 
mechanisms O 
of O 
5-HT B-SYSTEMATIC 
neuron O 
control O 
might O 
provide O 
new O 
insights O 
into O 
depression O 
pathophysiology O 
. O 
In O 
addition O 
to O 
the O 
inhibitory O 
5-HT1A O 
autoreceptors O 
, O 
cortico O 
- O 
raphe O 
glutamatergic O 
descending O 
pathways O 
are O 
suggested O 
to O 
modulate O 
5-HT B-SYSTEMATIC 
activity O 
in O 
the O 
DRN O 
. O 
Here O 
we O 
studied O 
how O 
decreased O 
VGLUT1 O 
levels O 
in O 
the O 
brain O 
stem O 
affect O 
glutamate B-TRIVIAL 
regulation O 
of O 
5-HT B-SYSTEMATIC 
function O 
. O 
VGLUT1+ O 
/ O 
- O 
mice O 
( O 
C57BL O 
/ O 
6 O 
) O 
and O 
wild O 
type O 
( O 
WT O 
) O 
littermates O 
were O 
used O 
. O 
VGLUT1 O 
expression O 
in O 
the O 
DRN O 
, O 
5-HT B-SYSTEMATIC 
turnover O 
and O 
immuno O 
histochemical O 
analysis O 
of O 
neuronal O 
activity O 
in O 
different O 
areas O 
was O 
studied O 
. O 
Moreover O 
, O 
the O 
functionality O 
of O 
the O 
inhibitory O 
5-HT1A O 
autoreceptor O 
was O 
assessed O 
using O 
electrophysiological O 
, O 
biochemical O 
and O 
pharmacological O 
approaches O 
. O 
VGLUT1 O 
immunoreactivity O 
was O 
markedly O 
lower O 
in O 
the O 
DRN O 
of O 
the O 
VGLUT1+ O 
/ O 
- O 
mice O 
and O 
specifically O 
, O 
in O 
the O 
surroundings O 
of O 
GABA B-ABBREVIATION 
and O 
5-HT B-SYSTEMATIC 
cell O 
bodies O 
. O 
These O 
mice O 
showed O 
decreased O 
induced O 
neuronal O 
activity O 
in O 
5-HT B-SYSTEMATIC 
cells O 
bodies O 
and O 
in O 
different O 
forebrain O 
areas O 
, O 
as O 
well O 
as O 
decreased O 
hippocampal O 
cell O 
proliferation O 
and O 
5-HT B-SYSTEMATIC 
turnover O 
. O 
Further O 
, O 
5-HT1A O 
autoreceptor O 
desensitization O 
was O 
evidenced O 
by O 
electrophysiological O 
studies O 
, O 
GTP-γ-S B-ABBREVIATION 
coupling O 
to O 
5-HT1A O 
autoreceptor O 
and O 
a O 
lower O 
hypothermic O 
response O 
to O 
5-HT1A O 
activation O 
. O 
This O 
study O 
shows O 
first O 
time O 
that O 
VGLUT1 O 
dependent O 
glutamate B-TRIVIAL 
innervation O 
of O 
the O 
DRN O 
could O 
modulate O 
5-HT B-SYSTEMATIC 
function O 
. O 

and O 
pharmacokinetics O 
of O 
3-n-butylphthalide B-SYSTEMATIC 
( O 
NBP B-ABBREVIATION 
) O 
in O 
humans O 
: O 
the O 
role O 
of O 
cytochrome O 
P450s O 
and O 
alcohol B-FAMILY 
dehydrogenase O 
in O 
biotransformation O 
. O 

( O 
NBP B-ABBREVIATION 
) O 
is O 
a O 
cardiovascular O 
drug O 
currently O 
used O 
for O 
the O 
treatment O 
of O 
cerebral O 
ischemia O 
. O 
The O 
present O 
study O 
aims O 
to O 
investigate O 
the O 
metabolism O 
, O 
pharmacokinetics O 
, O 
and O 
excretion O 
of O 
NBP B-ABBREVIATION 
in O 
humans O 
and O 
identify O 
the O 
enzymes O 
responsible O 
for O 
the O 
formation O 
of O 
major O 
metabolites O 
. O 
NBP B-ABBREVIATION 
underwent O 
extensive O 
metabolism O 
after O 
an O 
oral O 
administration O 
of O 
200 O 
mg O 
NBP B-ABBREVIATION 
and O 
23 O 
metabolites O 
were O 
identified O 
in O 
human O 
plasma O 
and O 
urine O 
. O 
Principal O 
metabolic O 
pathways O 
included O 
hydroxylation O 
on O 
alkyl B-FAMILY 
side O 
chain O 
, O 
particularly O 
at O 
3- B-MULTIPLE 
, I-MULTIPLE 
ω-1- I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
ω-carbons I-MULTIPLE 
, O 
and O 
further O 
oxidation O 
and O 
conjugation O 
. O 
Approximately O 
81.6% O 
of O 
the O 
dose O 
was O 
recovered O 
in O 
urine O 
, O 
mainly O 
as O 
NBP-11-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
M5-2 O 
) O 
and O 
glucuronide O 
conjugates O 
of O 
M5-2 O 
and O 
mono-hydroxylated O 
products O 
. O 
10-Keto-NBP B-SYSTEMATIC 
( O 
M2 O 
) O 
, O 
3-hydroxy-NBP B-SYSTEMATIC 
( O 
M3-1 O 
) O 
, O 
10-hydroxy-NBP B-SYSTEMATIC 
( O 
M3-2 O 
) O 
, O 
and O 
M5-2 O 
were O 
the O 
major O 
circulating O 
metabolites O 
, O 
wherein O 
the O 
areas O 
under O 
the O 
curve O 
values O 
were O 
1.6- O 
, O 
2.9- O 
, O 
10.3- O 
, O 
and O 
4.1-fold O 
higher O 
than O 
that O 
of O 
NBP B-ABBREVIATION 
. O 
Reference O 
standards O 
of O 
these O 
four O 
metabolites O 
were O 
obtained O 
through O 
microbial O 
biotransformation O 
by O 
Cunninghamella O 
blakesleana O 
. O 
In O 
vitro O 
phenotyping O 
studies O 
demonstrated O 
that O 
multiple O 
cytochrome O 
P450 O 
( O 
P450 O 
) O 
isoforms O 
, O 
especially O 
CYP3A4 O 
, O 
20 O 
, O 
and O 
1A2 O 
, O 
were O 
involved O 
in O 
the O 
formation O 
of O 
M3-1 O 
, O 
M3-2 O 
, O 
and O 
11-hydroxy-NBP B-SYSTEMATIC 
. O 
Using O 
M3-2 O 
and O 
11-hydroxy-NBP B-SYSTEMATIC 
as O 
substrates O 
, O 
human O 
subcellular O 
fractions O 
experiments O 
revealed O 
that O 
P450 O 
, O 
alcohol B-FAMILY 
dehydrogenase O 
, O 
and O 
aldehyde B-SYSTEMATIC 
dehydrogenase O 
catalyzed O 
the O 
generation O 
of O 
M2 O 
and O 
M5-2 O 
. O 
Formation O 
of O 
M5-2 O 
was O 
much O 
faster O 
than O 
that O 
of O 
M2 O 
, O 
and O 
M5-2 O 
can O 
undergo O 
β-oxidation O 
to O 
yield O 
phthalide-3-acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
rat O 
liver O 
homogenate O 
. O 
Overall O 
, O 
our O 
study O 
demonstrated O 
that O 
NBP B-ABBREVIATION 
was O 
well O 
absorbed O 
and O 
extensively O 
metabolized O 
by O 
multiple O 
enzymes O 
to O 
various O 
metabolites O 
prior O 
to O 
urinary O 
excretion O 
. O 

, O 
metabolism O 
, O 
and O 
excretion O 
of O 
the O 
antidiabetic O 
agent O 
ertugliflozin B-TRIVIAL 
( O 
PF-04971729 B-IDENTIFIER 
) O 
in O 
healthy O 
male O 
subjects O 
. O 

disposition O 
of O 
ertugliflozin B-TRIVIAL 
( O 
PF-04971729 B-IDENTIFIER 
) O 
, O 
an O 
orally O 
active O 
selective O 
inhibitor O 
of O 
the O 
sodium B-SYSTEMATIC 
-dependent O 
glucose B-TRIVIAL 
cotransporter O 
2 O 
, O 
was O 
studied O 
after O 
a O 
single O 
25-mg O 
oral O 
dose O 
of O 
[(14)C]-ertugliflozin B-SYSTEMATIC 
to O 
healthy O 
human O 
subjects O 
. O 
Mass O 
balance O 
was O 
achieved O 
with O 
approximately O 
91% O 
of O 
the O 
administered O 
dose O 
recovered O 
in O 
urine O 
and O 
feces O 
. O 
The O 
total O 
administered O 
radioactivity O 
excreted O 
in O 
feces O 
and O 
urine O 
was O 
40.9% O 
and O 
50.2% O 
, O 
respectively O 
. O 
The O 
absorption O 
of O 
ertugliflozin B-TRIVIAL 
in O 
humans O 
was O 
rapid O 
with O 
a O 
T(max) O 
at O 
∼1.0 O 
hour O 
. O 
Of O 
the O 
total O 
radioactivity O 
excreted O 
in O 
feces O 
and O 
urine O 
, O 
unchanged O 
ertugliflozin B-TRIVIAL 
collectively O 
accounted O 
for O 
∼35.3% O 
of O 
the O 
dose O 
, O 
suggestive O 
of O 
moderate O 
metabolic O 
elimination O 
in O 
humans O 
. O 
The O 
principal O 
biotransformation O 
pathway O 
involved O 
glucuronidation O 
of O 
the O 
glycoside O 
hydroxyl B-SYSTEMATIC 
groups O 
to O 
yield O 
three O 
regioisomeric O 
metabolites O 
, O 
M4a O 
, O 
M4b O 
, O 
and O 
M4c O 
( O 
∼39.3% O 
of O 
the O 
dose O 
in O 
urine O 
) O 
, O 
of O 
which O 
M4c O 
was O 
the O 
major O 
regioisomer O 
( O 
∼31.7% O 
of O 
the O 
dose O 
) O 
. O 
The O 
structure O 
of O 
M4a O 
and O 
M4c O 
were O 
confirmed O 
to O 
be O 
ertugliflozin B-SYSTEMATIC 
-4-O-β- I-SYSTEMATIC 
and I-SYSTEMATIC 
-3-O-β-glucuronide I-SYSTEMATIC 
, O 
respectively O 
, O 
via O 
comparison O 
of O 
the O 
HPLC O 
retention O 
time O 
and O 
mass O 
spectra O 
with O 
authentic O 
standards O 
. O 
A O 
minor O 
metabolic O 
fate O 
involved O 
oxidation O 
by O 
cytochrome O 
P450 O 
to O 
yield O 
monohydroxylated O 
metabolites O 
M1 O 
and O 
M3 O 
and O 
des B-SYSTEMATIC 
- I-SYSTEMATIC 
ethyl I-SYSTEMATIC 
ertugliflozin I-SYSTEMATIC 
( O 
M2 O 
) O 
, O 
which O 
accounted O 
for O 
∼5.2% O 
of O 
the O 
dose O 
in O 
excreta O 
. O 
In O 
plasma O 
, O 
unchanged O 
ertugliflozin B-TRIVIAL 
and O 
the O 
corresponding O 
4-O-β- O 
( O 
M4a O 
) O 
and O 
3-O-β- O 
( O 
M4c O 
) O 
glucuronides O 
were O 
the O 
principal O 
components O 
, O 
which O 
accounted O 
for O 
49.9 O 
, O 
12.2 O 
, O 
and O 
24.1% O 
of O 
the O 
circulating O 
radioactivity O 
. O 
Overall O 
, O 
these O 
data O 
suggest O 
that O 
ertugliflozin O 
is O 
well O 
absorbed O 
in O 
humans O 
, O 
and O 
eliminated O 
largely O 
via O 
glucuronidation O 
. O 

role O 
of O 
cytochrome O 
P450-dependent O 
metabolism O 
in O 
the O 
regulation O 
of O 
mouse O 
hepatic O 
growth O 
hormone O 
signaling O 
components O 
and O 
target O 
genes O 
by O 
3-methylcholanthrene B-SYSTEMATIC 
. O 

( O 
MC O 
) O 
is O 
a O 
readily O 
metabolized O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AHR O 
) O 
agonist O 
. O 
MC O 
disrupts O 
expression O 
of O 
mouse O 
hepatic O 
growth O 
hormone O 
( O 
GH O 
) O 
signaling O 
components O 
and O 
suppresses O 
cytochrome O 
P450 O 
2D9 O 
( O 
Cyp2d9 O 
) O 
, O 
a O 
male O 
- O 
specific O 
gene O 
controlled O 
by O 
pulsatile O 
GH O 
via O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
5b O 
( O 
STAT5b O 
) O 
. O 
To O 
determine O 
if O 
these O 
effects O 
of O 
MC O 
depend O 
on O 
hepatic O 
microsomal O 
P450 O 
- O 
mediated O 
activity O 
, O 
we O 
examined O 
biologic O 
responses O 
to O 
MC O 
treatment O 
in O 
liver O 
Cpr O 
- O 
nan O 
( O 
LCN O 
) O 
mice O 
with O 
hepatocyte O 
- O 
specific O 
conditional O 
deletion O 
of O 
NADPH B-ABBREVIATION 
-cytochrome O 
P450 O 
oxidoreductase O 
( O 
POR O 
) O 
. O 
MC O 
caused O 
mild O 
induction O 
of O 
Por O 
and O 
a O 
hepatic O 
inflammatory O 
marker O 
in O 
wild O 
- O 
type O 
mice O 
, O 
whereas O 
MC O 
caused O 
strong O 
induction O 
of O 
AHR O 
target O 
genes O 
, O 
Cyp1a1 O 
, O 
Cyp1a2 O 
, O 
and O 
Cyp1b1 O 
in O 
wild O 
- O 
type O 
and O 
LCN O 
mice O 
. O 
Two O 
mouse O 
hepatic O 
STAT5b O 
target O 
genes O 
, O 
Cyp2d9 O 
and O 
major O 
urinary O 
protein O 
2 O 
( O 
Mup2 O 
) O 
, O 
were O 
suppressed O 
by O 
MC O 
in O 
wild O 
- O 
type O 
mice O 
, O 
and O 
the O 
CYP2D9 O 
mRNA O 
response O 
was O 
maintained O 
in O 
LCN O 
mice O 
. O 
In O 
wild O 
- O 
type O 
mice O 
only O 
, O 
MC O 
decreased O 
hepatic O 
GH O 
receptor O 
( O 
GHR O 
) O 
mRNA O 
but O 
increased O 
GHR O 
protein O 
levels O 
. O 
There O 
was O 
an O 
apparent O 
impairment O 
of O 
STAT5 O 
phosphorylation O 
by O 
MC O 
in O 
wild O 
- O 
type O 
and O 
LCN O 
mice O 
, O 
but O 
large O 
interanimal O 
variation O 
prevented O 
achievement O 
of O 
statistical O 
significance O 
. O 
In O 
vehicle O 
- O 
treated O 
mice O 
, O 
basal O 
levels O 
of O 
MUP2 O 
mRNA O 
, O 
GHR O 
mRNA O 
, O 
GHR O 
protein O 
, O 
and O 
the O 
activation O 
status O 
of O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
2 O 
and O 
Akt O 
were O 
influenced O 
by O 
hepatic O 
Por O 
genetic O 
status O 
. O 
These O 
results O 
indicate O 
that O 
the O 
effects O 
of O 
MC O 
on O 
hepatic O 
GH O 
signaling O 
components O 
and O 
target O 
genes O 
are O 
complex O 
, O 
involving O 
aspects O 
that O 
are O 
both O 
dependent O 
and O 
independent O 
of O 
hepatic O 
microsomal O 
P450 O 
- O 
mediated O 
activity O 
. O 

is O 
the O 
third O 
most O 
common O 
cause O 
of O 
death O 
in O 
the O 
industrialized O 
countries O 
and O 
adequate O 
primary O 
and O 
secondary O 
prevention O 
strategies O 
are O 
mandatory O 
. O 
In O 
addition O 
to O 
lifestyle O 
- O 
changes O 
and O 
correction O 
of O 
cardiovascular O 
risk O 
factors O 
, O 
the O 
mainstay O 
of O 
the O 
atherothrombotic O 
stroke O 
prevention O 
is O 
represented O 
by O 
antiplatelet O 
treatment O 
. O 
Although O 
aspirin B-TRIVIAL 
and O 
thienopyridines B-FAMILY 
have O 
proved O 
their O 
efficacy O 
in O 
the O 
prevention O 
of O 
arterial O 
thrombotic O 
events O 
, O 
limited O 
efficacy O 
, O 
increased O 
risk O 
of O 
bleeding O 
, O 
significant O 
inter O 
- O 
individual O 
variability O 
in O 
the O 
response O 
and O 
extended O 
duration O 
of O 
action O 
that O 
cannot O 
be O 
reversed O 
if O 
the O 
need O 
for O 
haemostasis O 
or O 
emergency O 
surgery O 
arises O 
represent O 
major O 
limitations O 
of O 
these O 
drugs O 
. O 
Moreover O 
, O 
despite O 
recommendations O 
and O 
guidelines O 
about O 
stroke O 
prevention O 
, O 
registries O 
data O 
clearly O 
suggest O 
an O 
underuse O 
of O 
antiplatelet O 
drugs O 
, O 
mainly O 
because O 
of O 
bleeding O 
episodes O 
fear O 
. O 
At O 
variance O 
with O 
newer O 
anticoagulant O 
drugs O 
, O 
which O 
showed O 
a O 
series O 
of O 
advantages O 
as O 
compared O 
with O 
the O 
traditional O 
warfarin B-TRIVIAL 
treatment O 
, O 
newer O 
antiplatelet O 
drugs O 
have O 
only O 
partially O 
overcome O 
these O 
limitations O 
. O 
Although O 
ad O 
hoc O 
studies O 
on O 
their O 
efficacy O 
in O 
the O 
stroke O 
prevention O 
are O 
currently O 
lacking O 
, O 
newer O 
antiplatelet O 
agents O 
( O 
mainly O 
ticagrelor B-TRIVIAL 
and O 
prasugrel B-TRIVIAL 
) O 
do O 
not O 
provide O 
a O 
significant O 
better O 
protection O 
over O 
and O 
above O 
aspirin B-TRIVIAL 
and O 
/ O 
or O 
clopidogrel B-TRIVIAL 
in O 
the O 
prevention O 
of O 
atherothrombotic O 
stroke O 
. O 
In O 
addition O 
, O 
a O 
significantly O 
increased O 
bleeding O 
risk O 
has O 
been O 
reported O 
in O 
subjects O 
receiving O 
these O 
new O 
thienopyridines B-FAMILY 
. O 
According O 
to O 
these O 
data O 
, O 
the O 
identification O 
of O 
further O 
molecular O 
targets O 
is O 
needed O 
, O 
in O 
order O 
to O 
design O 
future O 
antiplatelet O 
drugs O 
. O 
In O 
this O 
review O 
, O 
after O 
summarizing O 
major O 
literature O 
data O 
about O 
traditional O 
and O 
newer O 
antiplatelet O 
drugs O 
, O 
we O 
will O 
specifically O 
focus O 
on O 
novel O 
potential O 
target O 
candidates O 
for O 
antiplatelet O 
therapy O 
. O 

links O 
de O 
novo O 
fatty B-FAMILY 
acid I-FAMILY 
synthesis O 
to O 
sporulation O 
and O 
biofilm O 
development O 
in O 
Bacillus O 
subtilis O 
. O 

sporulation O 
in O 
Bacillus O 
subtilis O 
, O 
the O 
committed O 
- O 
cell O 
undergoes O 
substantial O 
membrane O 
rearrangements O 
to O 
generate O 
two O 
cells O 
of O 
different O 
sizes O 
and O 
fates O 
: O 
the O 
mother O 
cell O 
and O 
the O 
forespore O 
. O 
Here O 
, O 
we O 
demonstrate O 
that O 
the O 
master O 
transcription O 
factor O 
Spo0A O 
reactivates O 
lipid O 
synthesis O 
during O 
development O 
. O 
Maximal O 
Spo0A-dependent O 
lipid O 
synthesis O 
occurs O 
during O 
the O 
key O 
stages O 
of O 
asymmetric O 
division O 
and O 
forespore O 
engulfment O 
. O 
Spo0A O 
reactivates O 
the O 
accDA O 
operon O 
that O 
encodes O 
the O 
carboxylase O 
component O 
of O 
the O 
acetyl-CoA B-SYSTEMATIC 
carboxylase O 
enzyme O 
, O 
which O 
catalyses O 
the O 
first O 
and O 
rate O 
- O 
limiting O 
step O 
in O 
de O 
novo O 
lipid O 
biosynthesis O 
, O 
malonyl-CoA B-TRIVIAL 
formation O 
. O 
The O 
disruption O 
of O 
the O 
Spo0A O 
- O 
binding O 
box O 
in O 
the O 
promoter O 
region O 
of O 
accDA O 
impairs O 
its O 
transcriptional O 
reactivation O 
and O 
blocks O 
lipid O 
synthesis O 
. O 
The O 
Spo0A-insensitive O 
accDA(0A) O 
cells O 
were O 
proficient O 
in O 
planktonic O 
growth O 
but O 
defective O 
in O 
sporulation O 
( O 
σ(E) O 
activation O 
) O 
and O 
biofilm O 
development O 
( O 
cell O 
cluster O 
formation O 
and O 
water O 
repellency O 
) O 
. O 
Exogenous O 
fatty B-FAMILY 
acid I-FAMILY 
supplementation O 
to O 
accDA(0A) O 
cells O 
overcomes O 
their O 
inability O 
to O 
synthesize O 
lipids O 
during O 
development O 
and O 
restores O 
sporulation O 
and O 
biofilm O 
proficiencies O 
. O 
The O 
transient O 
exclusion O 
of O 
the O 
lipid O 
synthesis O 
regulon O 
from O 
the O 
forespore O 
and O 
the O 
known O 
compartmentalization O 
of O 
Spo0A O 
and O 
ACP O 
in O 
the O 
mother O 
cell O 
suggest O 
that O 
de O 
novo O 
lipid O 
synthesis O 
is O 
confined O 
to O 
the O 
mother O 
cell O 
. O 
The O 
significance O 
of O 
the O 
Spo0A-controlled O 
de O 
novo O 
lipid O 
synthesis O 
during O 
B. O 
subtilis O 
development O 
is O 
discussed O 
. O 

mycobacterial O 
binuclear O 
iron B-SYSTEMATIC 
monooxygenases O 
require O 
a O 
specific O 
chaperonin O 
- O 
like O 
protein O 
for O 
functional O 
expression O 
in O 
a O 
heterologous O 
host O 
. O 

mimABCD O 
gene O 
clusters O 
in O 
Mycobacterium O 
smegmatis O 
strain O 
mc(2) O 
155 O 
and O 
Mycobacterium O 
goodii O 
strain O 
12523 O 
encode O 
binuclear O 
iron B-SYSTEMATIC 
monooxygenases O 
that O 
oxidize O 
propane B-SYSTEMATIC 
and O 
phenol B-SYSTEMATIC 
. O 
In O 
this O 
study O 
, O 
we O 
attempted O 
to O 
express O 
each O 
mimABCD O 
gene O 
cluster O 
in O 
a O 
heterologous O 
host O 
. O 
The O 
actinomycetous O 
strain O 
Rhodococcus O 
opacus O 
B-4 O 
, O 
which O 
is O 
phylogenetically O 
close O 
to O 
Mycobacterium O 
, O 
was O 
selected O 
as O 
the O 
host O 
. O 
Each O 
mimABCD O 
gene O 
cluster O 
was O 
cloned O 
into O 
the O 
Rhodococcus-Escherichia O 
coli O 
shuttle O 
vector O 
, O 
pTip-QC2 O 
, O 
and O 
then O 
introduced O 
into O 
R O 
. O 
opacus O 
cells O 
. O 
Although O 
whole O 
- O 
cell O 
assays O 
were O 
performed O 
with O 
phenol B-SYSTEMATIC 
as O 
a O 
substrate O 
, O 
the O 
transformed O 
R O 
. O 
opacus O 
cells O 
did O 
not O 
oxidize O 
this O 
substrate O 
. O 
SDS B-ABBREVIATION 
/ O 
PAGE O 
analysis O 
revealed O 
that O 
the O 
oxygenase O 
large O 
subunit O 
MimA O 
was O 
expressed O 
in O 
the O 
insoluble O 
fraction O 
of O 
R O 
. O 
opacus O 
cells O 
. O 
We O 
found O 
that O 
a O 
gene O 
designated O 
mimG O 
, O 
which O 
lies O 
downstream O 
of O 
mimABCD O 
, O 
exhibits O 
similarity O 
in O 
the O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
of O 
its O 
product O 
with O 
the O 
products O 
of O 
genes O 
encoding O 
the O 
chaperonin O 
GroEL O 
. O 
When O 
the O 
mimG O 
gene O 
was O 
cloned O 
and O 
coexpressed O 
with O 
each O 
mimABCD O 
gene O 
cluster O 
in O 
R O 
. O 
opacus O 
strain O 
B-4 O 
, O 
this O 
host O 
successfully O 
acquired O 
oxidation O 
activity O 
towards O 
phenol B-SYSTEMATIC 
. O 
SDS B-ABBREVIATION 
/ O 
PAGE O 
and O 
western O 
blotting O 
analyses O 
demonstrated O 
that O 
MimA O 
was O 
clearly O 
soluble O 
when O 
in O 
the O 
presence O 
of O 
MimG O 
. O 
These O 
results O 
indicated O 
that O 
MimG O 
played O 
essential O 
roles O 
in O 
the O 
productive O 
folding O 
of O 
MimA O 
, O 
and O 
that O 
the O 
resulting O 
soluble O 
MimA O 
protein O 
led O 
to O 
the O 
active O 
expression O 
of O 
MimABCD O 
. O 

electrochemical O 
performance O 
based O 
on O 
ultrathin O 
porous O 
CuO B-FORMULA 
nanobelts O 
grown O 
on O 
Cu B-FORMULA 
substrate O 
as O 
integrated O 
electrode O 
. O 

facile O 
and O 
low O 
- O 
cost O 
approach O 
has O 
been O 
developed O 
to O 
fabricate O 
porous O 
CuO B-FORMULA 
nanobelts O 
directly O 
grown O 
on O 
a O 
Cu B-FORMULA 
substrate O 
. O 
The O 
as-prepared O 
CuO B-FORMULA 
samples O 
can O 
be O 
directly O 
used O 
as O 
integrated O 
electrodes O 
for O 
lithium B-SYSTEMATIC 
-ion O 
batteries O 
and O 
pseudo O 
- O 
supercapacitors O 
without O 
the O 
addition O 
of O 
other O 
ancillary O 
materials O 
such O 
as O 
carbon B-TRIVIAL 
black I-TRIVIAL 
or O 
a O 
binder O 
to O 
enhance O 
electrode O 
conductivity O 
and O 
cycling O 
stability O 
. O 
The O 
unique O 
nanostructural O 
features O 
endow O 
them O 
with O 
excellent O 
electrochemical O 
performance O 
as O 
demonstrated O 
by O 
high O 
capacities O 
of O 
640 O 
mA O 
h O 
g(-1) O 
after O 
100 O 
cycles O 
at O 
0.2 O 
C O 
rate O 
and O 
an O 
excellent O 
specific O 
capacitance O 
of O 
340 O 
F O 
g(-1) O 
, O 
which O 
corresponds O 
to O 
the O 
energy O 
density O 
of O 
45 O 
W O 
h O 
kg(-1) O 
. O 
The O 
cyclability O 
of O 
the O 
electrode O 
demonstrates O 
only O 
a O 
10-15% O 
loss O 
in O 
capacitance O 
over O 
5000 O 
cycles O 
. O 

Carlo O 
simulations O 
show O 
that O 
charge O 
- O 
regulation O 
alone O 
can O 
cause O 
highly O 
charged O 
zirconium B-FAMILY 
nanoparticles O 
to O 
adsorb O 
to O 
a O 
similarly O 
charged O 
or O 
neutral O 
silica B-TRIVIAL 
particle O 
and O 
thereby O 
stabilizing O 
the O 
latter O 
. O 
This O 
mechanism O 
, O 
referred O 
to O 
as O 
halo O 
stabilization O 
, O 
is O 
quite O 
general O 
and O 
applicable O 
in O 
a O 
range O 
of O 
systems O 
provided O 
that O 
pH O 
, O 
van O 
der O 
Waals O 
forces O 
, O 
and O 
dissociation O 
constants O 
of O 
the O 
charge O 
- O 
regulating O 
particles O 
are O 
properly O 
chosen O 
. O 
In O 
our O 
modeling O 
we O 
see O 
an O 
overall O 
attraction O 
at O 
low O 
volume O 
fractions O 
of O 
nanoparticles O 
, O 
while O 
at O 
higher O 
a O 
repulsive O 
barrier O 
is O 
created O 
, O 
stabilizing O 
the O 
microparticles O 
and O 
protecting O 
them O 
from O 
aggregation O 
. O 
The O 
charge O 
- O 
regulation O 
mechanism O 
also O 
turns O 
the O 
silica B-TRIVIAL 
surface O 
from O 
positively O 
charged O 
, O 
without O 
nanoparticles O 
, O 
to O 
negatively O 
charged O 
in O 
the O 
presence O 
of O 
nanoparticles O 
. O 

your O 
splice O 
: O 
FR901464 B-IDENTIFIER 
analogues O 
and O 
herboxidiene B-TRIVIAL 
inhibit O 
constitutive O 
splicing O 
, O 
most O 
likely O 
by O 
inhibiting O 
spliceosomal O 
subunit O 
SF3b O 
. O 
A O 
parallel O 
comparison O 
of O 
these O 
compounds O 
in O 
a O 
cell O 
- O 
based O 
assay O 
system O 
showed O 
meayamycin B-TRIVIAL 
B I-TRIVIAL 
as O 
the O 
most O 
potent O 
splicing O 
inhibitor O 
among O 
these O 
small O 
molecules O 
. O 

- O 
mobilizing O 
capability O 
of O 
fullerene B-TRIVIAL 
nanoparticles O 
( O 
nC60 B-FAMILY 
) O 
: O 
Effect O 
of O 
solvent O 
- O 
exchange O 
process O 
in O 
nC60 B-FAMILY 
formation O 
. O 

nanoparticles O 
( O 
nC(60) B-FAMILY 
) O 
in O 
aqueous O 
environments O 
can O 
significantly O 
enhance O 
the O 
transport O 
of O 
hydrophobic O 
organic O 
contaminants O 
by O 
serving O 
as O 
a O 
contaminant O 
carrier O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
authors O 
examine O 
the O 
effect O 
of O 
the O 
solvent O 
- O 
exchange O 
process O 
on O 
nC(60) B-FAMILY 
aggregate O 
formation O 
and O 
, O 
subsequently O 
, O 
on O 
nC(60) B-FAMILY 
' O 
s O 
contaminant O 
- O 
mobilizing O 
capability O 
. O 
A O 
series O 
of O 
nC(60) B-FAMILY 
samples O 
were O 
prepared O 
using O 
a O 
modified O 
toluene B-TRIVIAL 
-water O 
solvent O 
- O 
exchange O 
method O 
through O 
the O 
inclusion O 
of O 
a O 
secondary O 
organic O 
solvent O 
in O 
the O 
phase O 
transfer O 
of O 
molecular O 
C(60) B-TRIVIAL 
in O 
toluene B-TRIVIAL 
to O 
nC(60) B-FAMILY 
in O 
water O 
. O 
Two O 
groups O 
of O 
solvents O 
-- O 
a O 
water O 
- O 
miscible O 
group O 
and O 
a O 
non-water O 
- O 
miscible O 
group O 
- O 
of O 
varied O 
polarity O 
were O 
selected O 
as O 
secondary O 
solvents O 
. O 
The O 
involvement O 
of O 
a O 
secondary O 
solvent O 
in O 
the O 
phase O 
transfer O 
process O 
had O 
only O 
small O 
effects O 
on O 
the O 
particle O 
size O 
and O 
distribution O 
, O 
ζ O 
potential O 
, O 
and O 
mobility O 
of O 
the O 
nC(60) B-FAMILY 
products O 
but O 
significantly O 
influenced O 
the O 
capability O 
of O 
nC(60) B-FAMILY 
to O 
enhance O 
the O 
transport O 
of O 
2,2',5,5'-polychlorinated B-SYSTEMATIC 
biphenyl I-SYSTEMATIC 
( O 
PCB B-ABBREVIATION 
) O 
in O 
a O 
saturated O 
sandy O 
soil O 
column O 
, O 
regardless O 
of O 
whether O 
the O 
secondary O 
solvent O 
was O 
water O 
- O 
miscible O 
or O 
non-water O 
- O 
miscible O 
. O 
The O 
two O 
groups O 
of O 
secondary O 
solvents O 
appear O 
to O 
affect O 
the O 
aggregation O 
properties O 
of O 
nC(60) B-FAMILY 
in O 
water O 
via O 
different O 
mechanisms O 
. O 
In O 
general O 
, O 
nC(60) B-FAMILY 
products O 
made O 
with O 
a O 
secondary O 
water O 
- O 
miscible O 
solvent O 
have O 
stronger O 
capabilities O 
to O 
enhance O 
PCB B-ABBREVIATION 
transport O 
. O 
Taken O 
together O 
, O 
the O 
results O 
indicate O 
that O 
according O 
to O 
formation O 
conditions O 
and O 
solvent O 
constituents O 
, O 
nC(60) B-FAMILY 
will O 
vary O 
significantly O 
in O 
its O 
interactions O 
with O 
organic O 
contaminants O 
, O 
specifically O 
as O 
related O 
to O 
adsorption O 
or O 
desorption O 
as O 
well O 
as O 
transport O 
in O 
porous O 
media O 
. O 

nuclear O 
receptors O 
pregnane O 
X O 
receptor O 
, O 
constitutive O 
androstane B-TRIVIAL 
receptor O 
, O 
and O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
alpha O 
have O 
important O 
endogenous O 
functions O 
and O 
are O 
also O 
involved O 
in O 
the O 
induction O 
of O 
drug O 
- O 
metabolizing O 
enzymes O 
and O 
transporters O 
in O 
response O 
to O 
exogenous O 
xenobiotics O 
. O 
Though O 
not O 
belonging O 
to O 
the O 
same O 
protein O 
family O 
, O 
the O 
Per-Sim-ARNT O 
domain O 
receptor O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
functionally O 
overlaps O 
with O 
the O 
three O 
nuclear O 
receptors O 
in O 
many O 
aspects O 
and O 
is O 
therefore O 
included O 
in O 
this O 
review O 
. O 
Significant O 
species O 
differences O 
in O 
ligand O 
affinity O 
and O 
biological O 
responses O 
as O 
a O 
result O 
of O 
activation O 
of O 
these O 
receptors O 
have O 
been O 
described O 
. O 
Several O 
xenobiotic O 
receptor O 
humanized O 
mice O 
have O 
been O 
created O 
to O 
overcome O 
these O 
species O 
differences O 
and O 
to O 
provide O 
in O 
vivo O 
models O 
that O 
are O 
more O 
predictive O 
for O 
human O 
responses O 
. O 
This O 
review O 
provides O 
an O 
overview O 
of O 
the O 
different O 
xenobiotic O 
receptor O 
humanized O 
mouse O 
models O 
described O 
to O 
date O 
and O 
will O 
summarize O 
how O 
these O 
models O 
can O 
be O 
applied O 
in O 
basic O 
research O 
and O 
improve O 
drug O 
discovery O 
and O 
development O 
. O 
Some O 
of O 
the O 
key O 
applications O 
in O 
the O 
evaluation O 
of O 
drug O 
induction O 
, O 
drug O 
- O 
drug O 
interactions O 
, O 
nongenotoxic O 
carcinogenicity O 
, O 
other O 
toxicity O 
, O 
or O 
efficacy O 
studies O 
are O 
described O 
. O 
We O 
also O 
discuss O 
relevant O 
considerations O 
in O 
the O 
interpretation O 
of O 
such O 
data O 
and O 
potential O 
future O 
directions O 
for O 
the O 
use O 
of O 
xenobiotic O 
receptor O 
humanized O 
mice O 
. O 

relationship O 
between O 
carotid O 
intima O 
- O 
media O 
thickness O 
and O 
endogenous O 
androgens B-FAMILY 
in O 
young O 
women O 
with O 
polycystic O 
ovary O 
syndrome O 
in O 
Taiwan O 
. O 

ovary O 
syndrome O 
( O 
PCOS O 
) O 
is O 
a O 
common O 
and O 
complex O 
female O 
endocrinopathy O 
that O 
is O 
associated O 
with O 
multiple O 
vascular O 
risk O 
factors O 
. O 
Our O 
objective O 
was O 
to O 
investigate O 
the O 
relationship O 
between O 
carotid O 
intima O 
- O 
media O 
thickness O 
( O 
CIMT O 
) O 
and O 
endogenous O 
androgens B-FAMILY 
in O 
young O 
Taiwanese-Chinese O 
women O 
with O 
PCOS O 
. O 
We O 
measured O 
CIMT O 
with O 
B-mode O 
ultrasound O 
in O 
42 O 
young O 
PCOS O 
patients O 
and O 
43 O 
controls O 
. O 
Atherosclerosis O 
- O 
associated O 
profiles O 
and O 
endocrinological O 
parameters O 
were O 
also O 
measured O 
. O 
The O 
results O 
showed O 
that O 
although O 
Taiwanese-Chinese O 
PCOS O 
patients O 
tend O 
to O 
possess O 
more O 
risk O 
factors O 
for O 
atherosclerosis O 
than O 
controls O 
, O 
there O 
was O 
no O 
evidence O 
to O 
support O 
that O 
they O 
have O 
a O 
greater O 
CIMT O 
at O 
this O 
age O 
. O 
Furthermore O 
, O 
androstenedione B-TRIVIAL 
appears O 
to O 
be O 
inversely O 
associated O 
with O 
CIMT O 
. O 

effects O 
of O 
waterborne O 
copper B-SYSTEMATIC 
nanoparticles O 
and O 
copper B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
on O 
the O 
organs O 
of O 
rainbow O 
trout O 
( O 
Oncorhynchus O 
mykiss O 
) O 
. O 

is O 
unclear O 
whether O 
copper B-SYSTEMATIC 
nanoparticles O 
are O 
more O 
toxic O 
than O 
traditional O 
forms O 
of O 
dissolved O 
copper B-SYSTEMATIC 
. O 
This O 
study O 
aimed O 
to O 
describe O 
the O 
pathologies O 
in O 
gill O 
, O 
gut O 
, O 
liver O 
, O 
kidney O 
, O 
brain O 
and O 
muscle O 
of O 
juvenile O 
rainbow O 
trout O 
, O 
Oncorhynchus O 
mykiss O 
, O 
exposed O 
in O 
triplicate O 
to O 
either O 
a O 
control O 
( O 
no O 
added O 
Cu B-FORMULA 
) O 
, O 
20 O 
or O 
100 O 
μg O 
l(-1) O 
of O 
either O 
dissolved O 
Cu B-FORMULA 
( O 
as O 
CuSO(4) B-FORMULA 
) O 
or O 
Cu B-FORMULA 
-NPs O 
( O 
mean O 
primary O 
particle O 
size O 
of O 
87 O 
± O 
27 O 
nm O 
) O 
in O 
a O 
semi-static O 
waterborne O 
exposure O 
regime O 
. O 
Fish O 
were O 
sampled O 
at O 
days O 
0 O 
, O 
4 O 
, O 
and O 
10 O 
for O 
histology O 
. O 
All O 
treatments O 
caused O 
organ O 
injuries O 
, O 
and O 
the O 
kinds O 
of O 
pathologies O 
observed O 
with O 
Cu B-FORMULA 
-NPs O 
were O 
broadly O 
of O 
the O 
same O 
type O 
as O 
CuSO(4) B-FORMULA 
including O 
: O 
hyperplasia O 
, O 
aneurisms O 
, O 
and O 
necrosis O 
in O 
the O 
secondary O 
lamellae O 
of O 
the O 
gills O 
; O 
swelling O 
of O 
goblet O 
cells O 
, O 
necrosis O 
in O 
the O 
mucosa O 
layer O 
and O 
vacuole O 
formation O 
in O 
the O 
gut O 
; O 
hepatitis O 
- O 
like O 
injury O 
and O 
cells O 
with O 
pyknotic O 
nuclei O 
in O 
the O 
liver O 
; O 
damage O 
to O 
the O 
epithelium O 
of O 
some O 
renal O 
tubules O 
and O 
increased O 
Bowman's O 
space O 
in O 
the O 
kidney O 
. O 
In O 
the O 
brain O 
, O 
some O 
mild O 
changes O 
were O 
observed O 
in O 
the O 
nerve O 
cell O 
bodies O 
in O 
the O 
telencephalon O 
, O 
alteration O 
in O 
the O 
thickness O 
of O 
the O 
mesencephalon O 
layers O 
, O 
and O 
enlargement O 
of O 
blood O 
vessel O 
on O 
the O 
ventral O 
surface O 
of O 
the O 
cerebellum O 
. O 
Changes O 
in O 
the O 
proportional O 
area O 
of O 
muscle O 
fibres O 
were O 
observed O 
in O 
skeletal O 
muscle O 
. O 
Overall O 
the O 
data O 
showed O 
that O 
pathology O 
from O 
CuSO(4) B-FORMULA 
and O 
Cu B-FORMULA 
-NPs O 
were O 
of O 
similar O 
types O 
, O 
but O 
there O 
were O 
some O 
material O 
- O 
type O 
effects O 
in O 
the O 
severity O 
or O 
incidence O 
of O 
injuries O 
with O 
Cu B-FORMULA 
-NPs O 
causing O 
more O 
injury O 
in O 
the O 
intestine O 
, O 
liver O 
and O 
brain O 
than O 
the O 
equivalent O 
concentration O 
of O 
CuSO(4) B-FORMULA 
by O 
the O 
end O 
of O 
the O 
experiment O 
, O 
but O 
in O 
the O 
gill O 
and O 
muscle O 
CuSO(4) B-FORMULA 
caused O 
more O 
pathology O 
. O 

and O 
behavioral O 
characterization O 
of O 
the O 
novel O 
CRF(1) O 
antagonist O 
BMS-763534 B-IDENTIFIER 
. O 

is O 
a O 
potent O 
( O 
CRF(1) O 
IC(50) O 
= O 
0.4 O 
nM O 
) O 
and O 
selective O 
( O 
> O 
1000-fold O 
selectivity O 
vs O 
. O 
all O 
other O 
sites O 
tested O 
) O 
CRF(1) O 
receptor O 
antagonist O 
( O 
pA2 O 
= O 
9.47 O 
vs O 
. O 
CRF(1) O 
- O 
mediated O 
cAMP B-ABBREVIATION 
production O 
in O 
Y79 O 
cells O 
) O 
. O 
BMS-763534 B-IDENTIFIER 
accelerated O 
the O 
dissociation O 
of O 
(125)I B-FORMULA 
-o-CRF O 
from O 
rat O 
frontal O 
cortex O 
membrane O 
CRF(1) O 
receptors O 
consistent O 
with O 
a O 
negative O 
allosteric O 
modulation O 
of O 
CRF O 
binding O 
. O 
BMS-763534 B-IDENTIFIER 
produced O 
dose O 
- O 
dependent O 
increases O 
in O 
CRF(1) O 
receptor O 
occupancy O 
and O 
anxiolytic O 
efficacy O 
; O 
lowest O 
effective O 
anxiolytic O 
dose O 
= O 
0.56 O 
mg O 
/ O 
kg O 
, O 
PO O 
, O 
which O 
was O 
associated O 
with O 
71 O 
± O 
5% O 
CRF(1) O 
receptor O 
occupancy O 
of O 
frontoparietal O 
CRF(1) O 
receptors O 
. O 
Sedative O 
/ O 
ataxic O 
effects O 
of O 
BMS-763534 B-IDENTIFIER 
were O 
only O 
observed O 
at O 
high O 
dose O 
multiples O 
( O 
54-179× O 
) O 
relative O 
to O 
the O 
lowest O 
dose O 
required O 
for O 
anxiolytic O 
efficacy O 
. O 
At O 
doses O 
of O 
5- O 
to O 
18-fold O 
higher O 
than O 
the O 
lowest O 
efficacious O 
dose O 
in O 
the O 
anxiety O 
assay O 
, O 
BMS-763534 B-IDENTIFIER 
shared O 
subjective O 
effects O 
with O 
the O 
benzodiazepine O 
chlordiazepoxide B-TRIVIAL 
. O 
Interestingly O 
BMS-790318 B-IDENTIFIER 
, O 
the O 
O B-FORMULA 
-demethylated O 
metabolite O 
of O 
BMS-763534 B-IDENTIFIER 
, O 
showed O 
weak O 
affinity O 
for O 
the O 
TBOB B-ABBREVIATION 
site O 
of O 
the O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
receptor O 
( O 
67% O 
inhibition O 
at O 
10 O 
μM O 
) O 
and O 
augmented O 
GABA B-ABBREVIATION 
evoked O 
currents O 
( O 
EC(50) O 
= O 
1.6 O 
μM O 
) O 
. O 
Thus O 
, O 
the O 
unanticipated O 
signal O 
in O 
the O 
drug O 
discrimination O 
assay O 
may O 
have O 
resulted O 
from O 
an O 
interaction O 
of O 
the O 
metabolite O 
BMS-790318 B-IDENTIFIER 
with O 
the O 
TBOB B-ABBREVIATION 
site O 
on O 
the O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
channel O 
where O 
it O 
appears O 
to O 
behave O 
as O 
an O 
allosteric O 
potentiator O 
of O 
GABA B-ABBREVIATION 
evoked O 
currents O 
. O 

is O 
known O 
for O 
a O 
long O 
time O 
for O 
its O 
health O 
benefits O 
and O 
biological O 
activities O 
. O 
Here O 
, O 
the O 
red O 
variety O 
from O 
the O 
northeast O 
of O 
Brazil O 
was O 
chemically O 
analyzed O 
and O 
extracts O 
were O 
investigated O 
regarding O 
their O 
antioxidant O 
and O 
antitumor O 
activity O 
. O 
Hydroalcoholic O 
extracts O 
, O 
obtained O 
from O 
the O 
red O 
propolis O 
, O 
revealed O 
polyphenol B-FAMILY 
content O 
, O 
2,2-diphenyl-1-picrylhydrazyl B-SYSTEMATIC 
scavenging O 
potential O 
and O 
enzymatic O 
activities O 
for O 
catalase O 
- O 
like O 
and O 
superoxide B-TRIVIAL 
dismutase O 
- O 
like O 
. O 
Cytotoxic O 
activity O 
was O 
evaluated O 
for O 
human O 
laryngeal O 
epidermoid O 
carcinoma O 
cell O 
( O 
Hep-2 O 
) O 
, O 
human O 
cervical O 
adenocarcinoma O 
( O 
HeLa O 
) O 
and O 
human O 
normal O 
epithelial O 
embryonic O 
kidney O 
( O 
Hek-293 O 
) O 
. O 
Survival O 
analysis O 
for O 
non-tumor O 
cell O 
line O 
showed O 
greater O 
IC50 O 
compared O 
to O 
tumor O 
cell O 
lines O 
, O 
suggesting O 
an O 
increased O 
sensitivity O 
that O 
may O 
correlate O 
with O 
the O 
higher O 
proliferative O 
index O 
of O 
the O 
tumor O 
vs O 
. O 
normal O 
cells O 
. O 
Our O 
results O 
indicate O 
that O 
the O 
Brazilian O 
red O 
propolis O 
is O 
capable O 
of O 
inhibiting O 
cancer O 
cell O 
growth O 
and O 
constitutes O 
an O 
excellent O 
source O 
of O 
antioxidant O 
and O 
antitumor O 
natural O 
agent O 
. O 

properties O 
of O 
anthraquinones B-FAMILY 
and O 
their O 
relationship O 
with O 
the O 
regulation O 
of O 
P-glycoprotein O 
function O 
and O 
expression O 
. O 

is O 
a O 
growing O 
interest O 
in O 
natural O 
products O 
that O 
potentially O 
have O 
anti-inflammatory O 
properties O 
and O 
inhibit O 
P-glycoprotein O 
( O 
P-gp O 
) O 
function O 
. O 
In O 
this O 
report O 
, O 
we O 
assessed O 
the O 
effects O 
of O 
anthraquinone B-SYSTEMATIC 
derivatives O 
from O 
rhubarb O 
on O 
LPS-induced O 
RAW O 
264.7 O 
macrophages O 
to O 
determine O 
their O 
anti-inflammatory O 
potential O 
. O 
The O 
derivatives O 
were O 
also O 
tested O 
in O 
Caco-2 O 
cell O 
lines O 
to O 
evaluate O 
the O 
inhibition O 
of O 
the O 
drug O 
efflux O 
function O 
of O 
P-gp O 
. O 
The O 
transport O 
abilities O 
were O 
examined O 
and O 
the O 
cellular O 
accumulation O 
of O 
rhodamine-123 B-TRIVIAL 
( O 
R-123 B-ABBREVIATION 
) O 
was O 
also O 
measured O 
. O 
Electorphoretic O 
mobility O 
shift O 
assay O 
( O 
EMSA O 
) O 
was O 
performed O 
to O 
check O 
the O 
activator O 
protein-1 O 
( O 
AP-1 O 
) O 
DNA O 
binding O 
affinity O 
. O 
Five O 
anthraquinones B-FAMILY 
were O 
tested O 
to O 
determine O 
their O 
inhibitory O 
activities O 
on O 
NO B-FORMULA 
production O 
and O 
the O 
protein O 
and O 
mRNA O 
expression O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
and O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
. O 
Furthermore O 
, O 
the O 
level O 
of O 
prostaglandin B-TRIVIAL 
E(2) I-TRIVIAL 
( O 
PGE(2) B-ABBREVIATION 
) O 
was O 
determined O 
in O 
LPS-induced O 
RAW264.7 O 
macrophages O 
. O 
Emodin B-TRIVIAL 
was O 
found O 
to O 
be O 
the O 
most O 
potent O 
inhibitor O 
, O 
and O 
it O 
also O 
reduced O 
paw O 
swelling O 
in O 
the O 
mouse O 
model O 
of O 
carrageenan O 
- O 
induced O 
paw O 
edema O 
. O 
In O 
Caco-2 O 
cells O 
, O 
emodin O 
elevated O 
the O 
accumulation O 
of O 
R-123 B-ABBREVIATION 
and O 
decreased O 
the O 
efflux O 
ratio O 
of O 
R-123 B-ABBREVIATION 
, O 
which O 
indicates O 
the O 
inhibition O 
of O 
P-gp O 
function O 
. O 
The O 
inhibition O 
of O 
COX-2 O 
protein O 
by O 
emodin O 
paralleled O 
the O 
decrease O 
in O 
P-gp O 
expression O 
. O 
In O 
addition O 
, O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
expression O 
was O 
decreased O 
through O 
the O 
prevention O 
of O 
AP-1 O 
DNA O 
binding O 
, O 
which O 
leads O 
to O 
downregulation O 
in O 
the O 
expression O 
of O 
P-gp O 
. O 
Our O 
data O 
indicate O 
that O 
the O 
decrease O 
of O 
P-gp O 
expression O 
is O 
caused O 
by O 
the O 
decreased O 
expression O 
of O 
COX-2 O 
through O 
the O 
MAPK O 
/ O 
AP-1 O 
pathway O 
. O 
Based O 
on O 
our O 
results O 
, O 
we O 
suggest O 
that O 
anti-inflammatory O 
drugs O 
with O 
COX-2 O 
inhibitory O 
activity O 
might O 
be O 
used O 
to O 
modulate O 
P-gp O 
function O 
and O 
expression O 
. O 

sensitivity O 
of O 
CO B-FORMULA 
oxidation O 
on O 
Co3O4 B-FORMULA 
: O 
a O 
DFT O 
study O 
. O 

reaction O 
mechanism O 
of O 
CO B-FORMULA 
oxidation O 
on O 
the O 
Co(3)O(4) B-FORMULA 
( O 
110 O 
) O 
and O 
Co(3)O(4) B-FORMULA 
( O 
111 O 
) O 
surfaces O 
is O 
investigated O 
by O 
means O 
of O 
spin O 
- O 
polarized O 
density O 
functional O 
theory O 
( O 
DFT O 
) O 
within O 
the O 
GGA O 
+ O 
U O 
framework O 
. O 
Adsorption O 
situation O 
and O 
complete O 
reaction O 
cycles O 
for O 
CO B-FORMULA 
oxidation O 
are O 
clarified O 
. O 
The O 
results O 
indicate O 
that O 
1 O 
) O 
the O 
U O 
value O 
can O 
affect O 
the O 
calculated O 
energetic O 
result O 
significantly O 
, O 
not O 
only O 
the O 
absolute O 
adsorption O 
energy O 
but O 
also O 
the O 
trend O 
in O 
adsorption O 
energy O 
; O 
2 O 
) O 
CO B-FORMULA 
can O 
directly O 
react O 
with O 
surface O 
lattice O 
oxygen B-SYSTEMATIC 
atoms O 
( O 
O B-FORMULA 
(2f)/ O 
O B-FORMULA 
( O 
3f O 
) O 
) O 
to O 
form O 
CO(2) B-FORMULA 
via O 
the O 
Mars O 
- O 
van O 
Krevelen O 
reaction O 
mechanism O 
on O 
both O 
(110)-B O 
and O 
(111)-B O 
; O 
3 O 
) O 
pre O 
- O 
adsorbed O 
molecular O 
O(2) B-FORMULA 
can O 
enhance O 
CO B-FORMULA 
oxidation O 
through O 
the O 
channel O 
in O 
which O 
it O 
directly O 
reacts O 
with O 
molecular O 
CO B-FORMULA 
to O 
form O 
CO(2) B-FORMULA 
[ O 
O(2) B-FORMULA 
(a)+ O 
CO B-FORMULA 
(g)→ O 
CO(2) B-FORMULA 
(g)+ O 
O B-FORMULA 
( O 
a O 
) O 
] O 
on O 
(110)-A O 
/ O 
(111)-A O 
; O 
4 O 
) O 
CO B-FORMULA 
oxidation O 
is O 
a O 
structure O 
- O 
sensitive O 
reaction O 
, O 
and O 
the O 
activation O 
energy O 
of O 
CO B-FORMULA 
oxidation O 
follows O 
the O 
order O 
of O 
Co(3)O(4) B-FORMULA 
( O 
111)-A(0.78 O 
eV)> O 
Co(3)O(4) B-FORMULA 
(111)-B O 
( O 
0.68 O 
eV)> O 
Co(3)O(4) B-FORMULA 
(110)-A O 
( O 
0.51 O 
eV)> O 
Co(3)O(4) B-FORMULA 
(110)-B O 
( O 
0.41 O 
eV O 
) O 
, O 
that O 
is O 
, O 
the O 
( O 
110 O 
) O 
surface O 
shows O 
higher O 
reactivity O 
for O 
CO B-FORMULA 
oxidation O 
than O 
the O 
( O 
111 O 
) O 
surface O 
; O 
5 O 
) O 
in O 
addition O 
to O 
the O 
O B-FORMULA 
( O 
2f O 
) O 
, O 
it O 
was O 
also O 
found O 
that O 
Co(3+) B-FORMULA 
is O 
more O 
active O 
than O 
Co(2+) B-FORMULA 
, O 
so O 
both O 
O B-FORMULA 
( O 
2f O 
) O 
and O 
Co(3+) B-FORMULA 
control O 
the O 
catalytic O 
activity O 
of O 
CO B-FORMULA 
oxidation O 
on O 
Co(3)O(4) B-FORMULA 
, O 
as O 
opposed O 
to O 
a O 
previous O 
DFT O 
study O 
which O 
concluded O 
that O 
either O 
Co(3+) B-FORMULA 
or O 
O B-FORMULA 
( O 
2f O 
) O 
is O 
the O 
active O 
site O 
. O 

biloba O 
extract O 
attenuates O 
hippocampal O 
neuronal O 
loss O 
and O 
cognitive O 
dysfunction O 
resulting O 
from O 
trimethyltin B-SYSTEMATIC 
in O 
mice O 
. O 

present O 
study O 
was O 
an O 
attempt O 
to O 
investigate O 
the O 
neuromodulatory O 
potential O 
of O 
Ginkgo O 
biloba O 
extract O 
( O 
GBE O 
) O 
against O 
hippocamapal O 
structural O 
and O 
functional O 
damages O 
induced O 
by O 
trimethyltin B-SYSTEMATIC 
( O 
TMT B-ABBREVIATION 
) O 
a O 
potent O 
neurotoxicant O 
. O 
Male O 
Balb O 
/ O 
C O 
mice O 
were O 
administered O 
with O 
Ginkgo O 
biloba O 
extract O 
for O 
14 O 
days O 
at O 
a O 
dose O 
of O 
70 O 
mg O 
/ O 
kg O 
body O 
weight O 
interperitoneally O 
and O 
on O 
11-day O 
of O 
treatment O 
animals O 
were O 
exposed O 
to O 
Trimethyltin B-SYSTEMATIC 
( O 
2.5 O 
mg O 
/ O 
kg O 
b.w O 
) O 
single O 
intraperitoneal O 
injection O 
. O 
The O 
co O 
- O 
administered O 
of O 
TMT B-ABBREVIATION 
with O 
GBE O 
showed O 
marked O 
improvement O 
in O 
memory O 
and O 
aggressive O 
behavior O 
. O 
Which O 
were O 
in O 
turn O 
reflected O 
in O 
the O 
levels O 
of O 
serotonin B-TRIVIAL 
and O 
acetylcholine B-SYSTEMATIC 
esterase O 
. O 
The O 
conjunctive O 
treatment O 
also O 
showed O 
significant O 
decrease O 
in O 
oxidative O 
stress O 
as O 
assessed O 
by O 
MDA B-ABBREVIATION 
levels O 
and O 
the O 
antioxidant O 
enzymes O 
( O 
GSH B-ABBREVIATION 
, O 
GSSH B-ABBREVIATION 
, O 
GPX O 
, O 
total O 
glutathione B-TRIVIAL 
, O 
Catalase O 
and O 
Superoxide B-TRIVIAL 
dismutase O 
) O 
which O 
were O 
depressed O 
by O 
TMT B-ABBREVIATION 
treatment O 
was O 
significantly O 
improved O 
by O 
GBE O 
. O 
Correspondingly O 
, O 
induction O 
of O 
Bcl-2 O 
mitochondrial O 
apoptotic O 
pathway O 
by O 
trimethyltin B-SYSTEMATIC 
was O 
down O 
regulated O 
by O 
Ginkgo O 
biloba O 
treatment O 
. O 
The O 
structural O 
analysis O 
of O 
dentate O 
gyrus O 
revealed O 
improvement O 
in O 
degenerating O 
neurons O 
by O 
treatment O 
with O 
GBE O 
. O 
Therefore O 
, O 
it O 
is O 
suggested O 
that O 
prophylactic O 
treatment O 
of O 
Ginkgo O 
biloba O 
extract O 
protects O 
against O 
the O 
trimethyltin B-SYSTEMATIC 
induced O 
neurodegenration O 
by O 
multiple O 
mechanism O 
involved O 
in O 
its O 
antioxidant O 
effects O 
and O 
may O 
be O 
useful O 
in O 
developing O 
therapies O 
against O 
neurodegenration O 
. O 

control O 
by O 
ketogenic O 
diet O 
- O 
associated O 
medium O 
chain O 
fatty B-FAMILY 
acids I-FAMILY 
. O 

medium O 
chain O 
triglyceride B-FAMILY 
( O 
MCT O 
) O 
ketogenic O 
diet O 
is O 
used O 
extensively O 
for O 
treating O 
refractory O 
childhood O 
epilepsy O 
. O 
This O 
diet O 
increases O 
the O 
plasma O 
levels O 
of O 
medium O 
straight O 
chain O 
fatty B-FAMILY 
acids I-FAMILY 
. O 
A O 
role O 
for O 
these O 
and O 
related O 
fatty B-FAMILY 
acids I-FAMILY 
in O 
seizure O 
control O 
has O 
not O 
been O 
established O 
. O 
We O 
compared O 
the O 
potency O 
of O 
an O 
established O 
epilepsy O 
treatment O 
, O 
Valproate B-TRIVIAL 
( O 
VPA B-ABBREVIATION 
) O 
, O 
with O 
a O 
range O 
of O 
MCT O 
diet O 
- O 
associated O 
fatty B-FAMILY 
acids I-FAMILY 
( O 
and O 
related O 
branched O 
compounds O 
) O 
, O 
using O 
in O 
vitro O 
seizure O 
and O 
in O 
vivo O 
epilepsy O 
models O 
, O 
and O 
assessed O 
side O 
effect O 
potential O 
in O 
vitro O 
for O 
one O 
aspect O 
of O 
teratogenicity O 
, O 
for O 
liver O 
toxicology O 
and O 
in O 
vivo O 
for O 
sedation O 
, O 
and O 
for O 
a O 
neuroprotective O 
effect O 
. O 
We O 
identify O 
specific O 
medium O 
chain O 
fatty B-FAMILY 
acids I-FAMILY 
( O 
both O 
prescribed O 
in O 
the O 
MCT O 
diet O 
, O 
and O 
related O 
compounds O 
branched O 
on O 
the O 
fourth O 
carbon O 
) O 
that O 
provide O 
significantly O 
enhanced O 
in O 
vitro O 
seizure O 
control O 
compared O 
to O 
VPA B-ABBREVIATION 
. O 
The O 
activity O 
of O 
these O 
compounds O 
on O 
seizure O 
control O 
is O 
independent O 
of O 
histone O 
deacetylase O 
inhibitory O 
activity O 
( O 
associated O 
with O 
the O 
teratogenicity O 
of O 
VPA B-ABBREVIATION 
) O 
, O 
and O 
does O 
not O 
correlate O 
with O 
liver O 
cell O 
toxicity O 
. O 
In O 
vivo O 
, O 
these O 
compounds O 
were O 
more O 
potent O 
in O 
epilepsy O 
control O 
( O 
perforant O 
pathway O 
stimulation O 
induced O 
status O 
epilepticus O 
) O 
, O 
showed O 
less O 
sedation O 
and O 
enhanced O 
neuroprotection O 
compared O 
to O 
VPA B-ABBREVIATION 
. O 
Our O 
data O 
therefore O 
implicates O 
medium O 
chain O 
fatty B-FAMILY 
acids I-FAMILY 
in O 
the O 
mechanism O 
of O 
the O 
MCT O 
ketogenic O 
diet O 
, O 
and O 
highlights O 
a O 
related O 
new O 
family O 
of O 
compounds O 
that O 
are O 
more O 
potent O 
than O 
VPA B-ABBREVIATION 
in O 
seizure O 
control O 
with O 
a O 
reduced O 
potential O 
for O 
side O 
effects O 
. O 
This O 
article O 
is O 
part O 
of O 
the O 
Special O 
Issue O 
entitled O 
' O 
New O 
Targets O 
and O 
Approaches O 
to O 
the O 
Treatment O 
of O 
Epilepsy O 
' O 
. O 

, O 
an O 
α-secretase O 
activator O 
, O 
reduces O 
neuroinflammation O 
and O 
offers O 
persistent O 
neuroprotection O 
following O 
traumatic O 
brain O 
injury O 
in O 
mice O 
. O 

brain O 
injury O 
( O 
TBI O 
) O 
evokes O 
an O 
intense O 
neuroinflammatory O 
reaction O 
that O 
is O 
essentially O 
mediated O 
by O 
activated O 
microglia O 
and O 
that O 
has O 
been O 
reported O 
to O 
act O 
as O 
a O 
secondary O 
injury O 
mechanism O 
that O 
further O 
promotes O 
neuronal O 
death O 
. O 
It O 
involves O 
the O 
excessive O 
production O 
of O 
inflammatory O 
cytokines O 
and O 
the O 
diminution O 
of O 
neuroprotective O 
and O 
neurotrophic O 
factors O 
, O 
such O 
as O 
the O 
soluble O 
form O 
alpha O 
of O 
the O 
amyloid O 
precursor O 
protein O 
( O 
sAPPα O 
) O 
, O 
generated O 
by O 
the O 
activity O 
of O 
α-secretases O 
. O 
Hence O 
, O 
the O 
aim O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
effects O 
of O 
etazolate B-TRIVIAL 
, O 
an O 
α-secretase O 
activator O 
, O 
on O 
acute O 
and O 
belated O 
post-TBI O 
consequences O 
. O 
The O 
mouse O 
model O 
of O 
TBI O 
by O 
mechanical O 
percussion O 
was O 
used O 
and O 
injured O 
mice O 
received O 
either O 
the O 
vehicle O 
or O 
etazolate B-TRIVIAL 
at O 
the O 
dose O 
of O 
1 O 
, O 
3 O 
or O 
10 O 
mg O 
/ O 
kg O 
at O 
2 O 
h O 
post-TBI O 
. O 
Neurological O 
score O 
, O 
cerebral O 
œdema O 
, O 
IL-1β O 
and O 
sAPPα O 
levels O 
, O 
microglial O 
activation O 
and O 
lesion O 
size O 
were O 
evaluated O 
from O 
6 O 
to O 
24 O 
h O 
post-TBI O 
. O 
Spontaneous O 
locomotor O 
activity O 
was O 
evaluated O 
from O 
48 O 
h O 
to O 
12 O 
weeks O 
post-TBI O 
, O 
memory O 
function O 
at O 
5 O 
weeks O 
and O 
olfactory O 
bulb O 
lesions O 
at O 
13 O 
weeks O 
post-TBI O 
. O 
A O 
single O 
administration O 
of O 
etazolate B-TRIVIAL 
exerted O 
a O 
dose O 
- O 
dependent O 
anti-inflammatory O 
and O 
anti-œdematous O 
effect O 
accompanied O 
by O 
lasting O 
memory O 
improvement O 
, O 
reduction O 
of O 
locomotor O 
hyperactivity O 
and O 
olfactory O 
bulb O 
tissue O 
protection O 
, O 
with O 
a O 
therapeutic O 
window O 
of O 
at O 
least O 
2 O 
h O 
. O 
These O 
effects O 
were O 
associated O 
with O 
the O 
restoration O 
of O 
the O 
levels O 
of O 
the O 
sAPPα O 
protein O 
post-TBI O 
. O 
Taken O 
together O 
, O 
these O 
results O 
highlight O 
for O 
the O 
first O 
time O 
the O 
therapeutic O 
interest O 
of O 
an O 
α-secretase O 
activator O 
in O 
TBI O 
. O 

D I-FAMILY 
receptor O 
signaling O 
mechanisms O 
: O 
integrated O 
actions O 
of O 
a O 
well O 
- O 
defined O 
transcription O 
factor O 
. O 

main O 
physiological O 
actions O 
of O 
the O 
biologically O 
most O 
active O 
metabolite O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
, O 
1α,25-dihydroxyvitamin B-SYSTEMATIC 
D(3) I-SYSTEMATIC 
( O 
1α,25(OH)(2)D(3) B-SYSTEMATIC 
) O 
, O 
are O 
calcium B-SYSTEMATIC 
and O 
phosphorus B-SYSTEMATIC 
uptake O 
and O 
transport O 
and O 
thereby O 
controlling O 
bone O 
formation O 
. O 
Other O 
emergent O 
areas O 
of O 
1α,25(OH)(2)D(3) B-SYSTEMATIC 
action O 
are O 
in O 
the O 
control O 
of O 
immune O 
functions O 
, O 
cellular O 
growth O 
and O 
differentiation O 
. O 
All O 
genomic O 
actions O 
of O 
1α,25(OH)(2)D(3) B-SYSTEMATIC 
are O 
mediated O 
by O 
the O 
transcription O 
factor O 
vitamin B-FAMILY 
D I-FAMILY 
receptor O 
( O 
VDR O 
) O 
that O 
has O 
been O 
the O 
subject O 
of O 
intense O 
study O 
since O 
the O 
1980's O 
. O 
Thus O 
, O 
vitamin B-FAMILY 
D I-FAMILY 
signaling O 
primarily O 
implies O 
the O 
molecular O 
actions O 
of O 
the O 
VDR O 
. O 
In O 
this O 
review O 
, O 
we O 
present O 
different O 
perspectives O 
on O 
the O 
VDR O 
that O 
incorporate O 
its O 
role O 
as O 
transcription O 
factor O 
and O 
member O 
of O 
the O 
nuclear O 
receptor O 
superfamily O 
, O 
its O 
dynamic O 
changes O 
in O 
genome O 
- O 
wide O 
locations O 
and O 
DNA O 
binding O 
modes O 
, O 
its O 
interaction O 
with O 
chromatin O 
components O 
and O 
its O 
primary O 
protein O 
- O 
coding O 
and O 
non O 
- O 
protein O 
coding O 
target O 
genes O 
and O 
finally O 
how O 
these O 
aspects O 
are O 
united O 
in O 
regulatory O 
networks O 
. O 
By O 
comparing O 
the O 
actions O 
of O 
the O 
VDR O 
, O 
a O 
relatively O 
well O 
- O 
understood O 
and O 
characterized O 
protein O 
, O 
with O 
those O 
of O 
other O 
transcription O 
factors O 
, O 
we O 
aim O 
to O 
build O 
a O 
realistic O 
positioning O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
signaling O 
in O 
the O 
context O 
of O 
other O 
intracellular O 
signaling O 
systems O 
. O 

and O 
biological O 
characterization O 
of O 
two O 
serine B-TRIVIAL 
proteinases O 
from O 
Colombian O 
Crotalus O 
durissus O 
cumanensis O 
snake O 
venom O 
. O 

clotting O 
serine B-TRIVIAL 
proteinases O 
, O 
named O 
Cdc O 
SI O 
and O 
Cdc O 
SII O 
, O 
were O 
isolated O 
and O 
characterized O 
for O 
the O 
first O 
time O 
from O 
Colombian O 
Crotalus O 
durissus O 
cumanensis O 
snake O 
venom O 
. O 
The O 
enzymes O 
were O 
purified O 
using O 
two O 
chromatographic O 
steps O 
: O 
molecular O 
exclusion O 
on O 
Sephacryl O 
S-200 O 
and O 
RP-HPLC O 
on O 
C8 O 
Column O 
. O 
The O 
molecular O 
masses O 
of O 
the O 
proteins O 
, O 
determined O 
by O 
MALDI-TOF O 
mass O 
spectrometry O 
, O 
were O 
28561.4 O 
and O 
28799.2 O 
Da O 
for O 
Cdc O 
SI O 
and O 
Cdc O 
SII O 
, O 
respectively O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
enzymatic O 
, O 
coagulant O 
and O 
toxic O 
properties O 
of O 
the O 
two O 
enzymes O 
. O 
The O 
serine B-TRIVIAL 
proteinases O 
hydrolyzed O 
specific O 
chromogenic O 
substrate O 
( O 
BaPNA O 
) O 
and O 
exhibited O 
a O 
Michaelis-Menten O 
behavior O 
. O 
Cdc O 
SI O 
had O 
V(max) O 
of O 
0.038 O 
± O 
0.003 O 
nmol O 
/ O 
min O 
and O 
K(M) O 
of O 
0.034 O 
± O 
0.017 O 
mM O 
, O 
while O 
Cdc O 
SII O 
displayed O 
values O 
of O 
V(max) O 
of O 
0.267 O 
± O 
0.011 O 
nmol O 
/ O 
min O 
and O 
K(M) O 
of O 
0.145 O 
± O 
0.023 O 
mM O 
. O 
N B-FORMULA 
-terminal O 
sequences O 
were O 
VIGGDEXNIN O 
and O 
VIGGDICNINEHNFLVALYE O 
for O 
Cdc O 
SI O 
and O 
Cdc O 
SII O 
, O 
respectively O 
. O 
Molecular O 
masses O 
, O 
N B-FORMULA 
-terminal O 
sequences O 
, O 
inhibition O 
assays O 
, O 
and O 
enzymatic O 
profile O 
suggest O 
that O 
Cdc O 
SI O 
and O 
Cdc O 
SII O 
belong O 
to O 
the O 
family O 
of O 
snake O 
venom O 
thrombin O 
- O 
like O 
enzymes O 
. O 
These O 
serine B-TRIVIAL 
proteinases O 
differed O 
in O 
their O 
clotting O 
activity O 
on O 
human O 
plasma O 
, O 
showing O 
a O 
minimum O 
coagulant O 
dose O 
of O 
25 O 
μg O 
and O 
0.571 O 
μg O 
for O 
Cdc O 
SI O 
and O 
Cdc O 
SII O 
, O 
respectively O 
. O 
Enzymes O 
also O 
showed O 
coagulant O 
activity O 
on O 
bovine O 
fibrinogen O 
and O 
degraded O 
chain O 
α O 
of O 
this O 
protein O 
. O 
Toxins O 
lack O 
hemorrhagic O 
and O 
myotoxic O 
activities O 
, O 
but O 
are O 
capable O 
to O 
induce O 
defibrin(ogen)ation O 
, O 
moderate O 
edema O 
, O 
and O 
an O 
increase O 
in O 
vascular O 
permeability O 
. O 
These O 
serine B-TRIVIAL 
proteinases O 
may O 
contribute O 
indirectly O 
to O 
the O 
local O 
hemorrhage O 
induced O 
by O 
metalloproteinases O 
, O 
by O 
causing O 
blood O 
clotting O 
disturbances O 
, O 
and O 
might O 
also O 
contribute O 
to O 
cardiovascular O 
alterations O 
characteristic O 
of O 
patients O 
envenomed O 
by O 
C O 
. O 
d O 
. O 
cumanensis O 
in O 
Colombia O 
. O 

solubility O 
vs O 
. O 
pH O 
profiles O 
of O 
five O 
ionizable O 
drugs O 
of O 
different O 
nature O 
( O 
a O 
monoprotic O 
acid O 
, O 
a O 
monoprotic O 
base O 
, O 
a O 
diprotic O 
base O 
and O 
two O 
amphoteric O 
compounds O 
showing O 
a O 
zwitterionic O 
species O 
each O 
one O 
) O 
have O 
been O 
determined O 
through O 
two O 
different O 
methodologies O 
: O 
the O 
classical O 
shake O 
- O 
flask O 
( O 
S-F O 
) O 
and O 
the O 
potentiometric O 
Cheqsol O 
methods O 
using O 
in O 
both O 
instances O 
the O 
appropriate O 
Henderson-Hasselbalch O 
( O 
H-H O 
) O 
or O 
derived O 
relationships O 
. O 
The O 
results O 
obtained O 
independently O 
from O 
both O 
approaches O 
are O 
consistent O 
. O 
A O 
critical O 
revision O 
about O 
the O 
influence O 
of O 
the O 
electrolyte O 
used O 
as O 
buffering O 
agent O 
in O 
the O 
S-F O 
method O 
on O 
the O 
obtained O 
solubility O 
values O 
is O 
also O 
performed O 
. O 
Thus O 
, O 
some O 
deviations O 
of O 
the O 
experimental O 
points O 
with O 
respect O 
the O 
H-H O 
profiles O 
can O 
be O 
attributed O 
to O 
specific O 
interactions O 
between O 
the O 
buffering O 
electrolyte O 
and O 
the O 
drug O 
due O 
to O 
the O 
hydrotrophic O 
character O 
of O 
citric B-MULTIPLE 
and I-MULTIPLE 
lactic I-MULTIPLE 
acids I-MULTIPLE 
. O 
In O 
other O 
cases O 
, O 
the O 
observed O 
deviations O 
are O 
independent O 
of O 
the O 
buffers O 
used O 
since O 
they O 
are O 
caused O 
by O 
the O 
formation O 
of O 
new O 
species O 
such O 
as O 
drug O 
aggregates O 
( O 
cefadroxil B-TRIVIAL 
) O 
or O 
the O 
precipitation O 
of O 
a O 
salt O 
from O 
a O 
cationic O 
species O 
of O 
the O 
analyzed O 
compound O 
( O 
quetiapine B-TRIVIAL 
) O 
. O 

- O 
drug O 
interaction O 
of O 
Fucus O 
vesiculosus O 
extract O 
and O 
amiodarone B-TRIVIAL 
in O 
rats O 
: O 
a O 
potential O 
risk O 
for O 
reduced O 
bioavailability O 
of O 
amiodarone B-TRIVIAL 
in O 
clinical O 
practice O 
. O 

vesiculosus O 
is O 
a O 
seaweed O 
claimed O 
to O 
be O 
useful O 
for O 
obesity O 
management O 
. O 
Therefore O 
, O 
considering O 
the O 
relationship O 
between O 
obesity O 
and O 
cardiovascular O 
diseases O 
, O 
this O 
work O 
aimed O 
to O 
assess O 
the O 
potential O 
for O 
an O 
herb O 
- O 
drug O 
interaction O 
among O 
a O 
standardized O 
F O 
. O 
vesiculosus O 
extract O 
( O 
GMP O 
certificate O 
) O 
and O 
amiodarone B-TRIVIAL 
( O 
a O 
narrow O 
therapeutic O 
index O 
drug O 
) O 
in O 
rats O 
. O 
In O 
a O 
first O 
pharmacokinetic O 
study O 
, O 
rats O 
were O 
simultaneously O 
co O 
- O 
administered O 
with O 
a O 
single O 
- O 
dose O 
of O 
F O 
. O 
vesiculosus O 
( O 
575 O 
mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
and O 
amiodarone B-TRIVIAL 
( O 
50 O 
mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
; O 
in O 
a O 
second O 
study O 
, O 
rats O 
were O 
pre O 
- O 
treated O 
during O 
14 O 
days O 
with O 
F O 
. O 
vesiculosus O 
( O 
575 O 
mg O 
/ O 
kg O 
/ O 
day O 
, O 
p.o O 
. O 
) O 
and O 
received O 
amiodaron B-TRIVIAL 
e O 
( O 
50 O 
mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
on O 
the O 
15th O 
day O 
. O 
Rats O 
of O 
the O 
control O 
groups O 
received O 
the O 
corresponding O 
volume O 
of O 
vehicle O 
. O 
After O 
analysis O 
of O 
the O 
pharmacokinetic O 
data O 
it O 
deserves O 
to O 
be O 
highlighted O 
the O 
significant O 
decrease O 
in O 
the O 
peak O 
plasma O 
concentration O 
of O 
amiodaron B-TRIVIAL 
e O 
( O 
55.4% O 
) O 
as O 
well O 
as O 
the O 
reduction O 
of O 
systemic O 
exposure O 
to O 
the O 
parent O 
drug O 
( O 
~30% O 
) O 
following O 
the O 
simultaneous O 
co O 
- O 
administration O 
of O 
F O 
. O 
vesiculosus O 
extract O 
and O 
amiodaron B-TRIVIAL 
e O 
. O 
This O 
paper O 
reports O 
, O 
for O 
the O 
first O 
time O 
, O 
the O 
herb O 
- O 
drug O 
interaction O 
between O 
F O 
. O 
vesiculosus O 
and O 
amiodaron B-TRIVIAL 
e O 
, O 
which O 
determined O 
a O 
considerable O 
decrease O 
on O 
amiodaron B-TRIVIAL 
e O 
bioavailability O 
in O 
rats O 
. O 
Therefore O 
, O 
the O 
therapeutic O 
efficacy O 
of O 
amiodaron B-TRIVIAL 
e O 
may O 
be O 
compromised O 
by O 
the O 
concurrent O 
administration O 
of O 
herbal O 
slimming O 
medicines O 
/ O 
dietary O 
supplements O 
containing O 
F O 
. O 
vesiculosus O 
. O 

- O 
derived O 
diallyl B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
modulates O 
peroxisome O 
proliferator O 
activated O 
receptor O 
gamma O 
co O 
- O 
activator O 
1 O 
alpha O 
in O 
neuroblastoma O 
cells O 
. O 

peroxisome O 
proliferator O 
activated O 
receptor O 
gamma O 
co O 
- O 
activator O 
1 O 
alpha O 
( O 
PGC1α O 
) O 
is O 
an O 
inducible O 
transcriptional O 
co O 
- O 
activator O 
with O 
direct O 
function O 
in O 
the O 
induction O 
of O 
mitochondrial O 
biogenesis O 
. O 
In O 
the O 
present O 
report O 
we O 
show O 
that O 
, O 
in O 
SH-SY5Y O 
neuroblastoma O 
cells O 
, O 
garlic O 
- O 
derived O 
diallyl B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
( O 
DADS O 
) O 
is O 
able O 
to O 
increase O 
PGC1α O 
expression O 
in O 
a O 
ROS-dependent O 
manner O 
and O 
to O 
induce O 
mitochondrial O 
biogenesis O 
at O 
early O 
stage O 
of O 
treatment O 
that O 
precede O 
cell O 
cycle O 
arrest O 
and O 
apoptosis O 
outcome O 
. O 
In O 
particular O 
, O 
we O 
demonstrate O 
that O 
DADS O 
elicits O 
: O 
i O 
) O 
the O 
increase O 
of O 
PGC1α O 
within O 
nuclear O 
compartment O 
; O 
ii O 
) O 
the O 
decrease O 
of O 
PGC1α O 
non-active O 
acetylated O 
form O 
; O 
iii O 
) O 
the O 
induction O 
of O 
nuclear O 
- O 
encoded O 
mitochondrial O 
genes O 
such O 
as O 
TFAM O 
and O 
TFBM1 O 
. O 
We O 
also O 
show O 
an O 
accumulation O 
of O 
PGC1α O 
within O 
mitochondria O 
along O 
with O 
an O 
increased O 
association O 
with O 
the O 
regulatory O 
D-Loop O 
region O 
of O 
mtDNA O 
and O 
a O 
concomitant O 
augmented O 
expression O 
of O 
mitochondrial O 
RNA O 
. O 
Such O 
events O 
are O 
related O 
to O 
a O 
prompt O 
elevation O 
of O 
mitochondrial O 
mass O 
, O 
as O 
assessed O 
by O 
evaluating O 
the O 
content O 
of O 
mtDNA O 
. O 
We O 
show O 
that O 
the O 
induction O 
of O 
mitochondrial O 
biogenesis O 
is O 
directed O 
to O 
dampen O 
the O 
cytotoxic O 
effect O 
of O 
DADS O 
. O 
Indeed O 
, O 
PGC1α O 
overexpression O 
or O 
down O 
- O 
regulation O 
prevents O 
or O 
exacerbates O 
mtDNA O 
loss O 
and O 
apoptosis O 
. O 
Overall O 
the O 
data O 
highlight O 
an O 
anti-apoptotic O 
role O 
of O 
PGC1α O 
- O 
mediated O 
mitochondrial O 
biogenesis O 
in O 
neuroblatoma O 
cells O 
and O 
suggest O 
PGC1α O 
as O 
a O 
potential O 
target O 
for O 
enhancing O 
the O 
effectiveness O 
of O 
therapy O 
in O 
aggressive O 
neuroblastoma O 
with O 
high O 
drug O 
- O 
resistance O 
. O 

acid O 
( O 
HA O 
) O 
, O 
a O 
glycosaminoglycan O 
with O 
high O 
molecular O 
weight O 
, O 
has O 
been O 
reported O 
to O 
promote O 
cell O 
proliferation O 
and O 
serves O 
as O 
an O 
important O 
extracellular O 
matrix O 
component O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
in O 
vitro O 
investigate O 
whether O 
HA O 
is O 
able O 
to O 
reduce O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
(ROS)-induced O 
heart O 
ischemia O 
- O 
reperfusion O 
injury O 
and O 
activate O 
the O 
cardiomyocyte's O 
damage O 
surveillance O 
systems O 
. O 
Accordingly O 
, O 
rattus O 
cardiomyocyte O 
line O 
, O 
H9C2 O 
, O 
was O 
treated O 
with O 
H(2)O(2) B-FORMULA 
as O 
a O 
heart O 
ischemia O 
- O 
reperfusion O 
model O 
followed O 
by O 
incubation O 
with O 
low O 
molecular O 
weight O 
hyaluronan O 
( O 
LMW-HA O 
, O 
100 O 
kDa O 
) O 
or O 
high O 
molecular O 
weight O 
hyaluronan O 
( O 
HMW-HA O 
, O 
1000 O 
kDa O 
) O 
and O 
proteomic O 
analysis O 
was O 
performed O 
to O 
investigate O 
the O 
physiologic O 
protection O 
of O 
HA O 
in O 
H(2)O(2) B-FORMULA 
-induced O 
ischemia O 
- O 
reperfusion O 
in O 
cardiomyocyte O 
. O 
Our O 
data O 
demonstrated O 
that O 
HA O 
treatment O 
does O 
protect O 
cardiomyocyte O 
in O 
the O 
ROS-induced O 
ischemia O 
- O 
reperfusion O 
model O 
and O 
the O 
molecular O 
weight O 
of O 
HA O 
is O 
a O 
crucial O 
factor O 
. O 
HMW-HA O 
has O 
been O 
shown O 
to O 
significantly O 
facilitate O 
cell O 
migration O 
and O 
wound O 
healing O 
via O 
cytoskeletal O 
rearrangement O 
. O 
Additionally O 
, O 
2D-DIGE O 
combined O 
MALDI-TOF O 
/ O 
TOF O 
analysis O 
showed O 
that O 
HMW-HA O 
might O 
modulate O 
biosynthetic O 
pathways O 
, O 
cell O 
migration O 
, O 
cell O 
outgrowth O 
and O 
protein O 
folding O 
to O 
stimulate O 
wound O 
healing O 
as O 
well O 
as O 
prevent O 
these O 
ischemia O 
- O 
reperfusion O 
- O 
damaged O 
cardiomyocytes O 
from O 
cell O 
death O 
. O 
To O 
our O 
knowledge O 
, O 
we O 
report O 
for O 
the O 
first O 
time O 
the O 
cell O 
repair O 
mechanism O 
of O 
HMW-HA O 
against O 
ischemia O 
- O 
reperfusion O 
- O 
damage O 
in O 
cardiomyocytes O 
based O 
on O 
cell O 
biology O 
and O 
proteomic O 
analysis O 
. O 

chemotherapy O 
using O 
core O 
- O 
shell O 
nanoparticles O 
through O 
the O 
self O 
- O 
assembly O 
of O 
HPMA B-ABBREVIATION 
-based O 
copolymers O 
and O 
degradable O 
polyester B-FAMILY 
. O 

preparation O 
of O 
core O 
- O 
shell O 
polymeric O 
nanoparticles O 
simultaneously O 
loaded O 
with O 
docetaxel B-TRIVIAL 
( O 
DTXL B-ABBREVIATION 
) O 
and O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
is O 
reported O 
herein O 
. O 
The O 
self O 
- O 
assembly O 
of O 
the O 
aliphatic O 
biodegradable O 
copolyester O 
PBS B-ABBREVIATION 
/ O 
PBDL B-ABBREVIATION 
( O 
poly(butylene B-FAMILY 
succinate I-FAMILY 
- I-FAMILY 
co I-FAMILY 
- I-FAMILY 
butylene I-FAMILY 
dilinoleate I-FAMILY 
) I-FAMILY 
) O 
and O 
HPMA B-ABBREVIATION 
-based O 
copolymers O 
( O 
N-(2-hydroxypropyl)methacrylamide B-SYSTEMATIC 
-based O 
copolymers O 
) O 
hydrophobically O 
modified O 
by O 
the O 
incorporation O 
of O 
cholesterol B-TRIVIAL 
led O 
to O 
the O 
formation O 
of O 
narrow O 
- O 
size O 
- O 
distributed O 
( O 
PDI O 
< O 
0.1 O 
) O 
sub-200-nm O 
polymeric O 
nanoparticles O 
suitable O 
for O 
passive O 
tumor O 
- O 
targeting O 
drug O 
delivery O 
based O 
on O 
the O 
size O 
- O 
dependent O 
EPR O 
( O 
enhanced O 
permeability O 
and O 
retention O 
) O 
effect O 
. O 
The O 
PHPMA B-ABBREVIATION 
provided O 
to O 
the O 
self O 
- O 
assembled O 
nanoparticle O 
stability O 
against O 
aggregation O 
as O 
evaluated O 
in O 
vitro O 
. O 
The O 
highly O 
hydrophobic O 
drug O 
docetaxel B-TRIVIAL 
( O 
DTXL B-ABBREVIATION 
) O 
was O 
physically O 
entrapped O 
within O 
the O 
PBS B-ABBREVIATION 
/ O 
PBDL B-ABBREVIATION 
copolyester O 
core O 
and O 
the O 
hydrophilic O 
drug O 
doxorubicin B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
DOX·HCl B-FORMULA 
) O 
was O 
chemically O 
conjugated O 
to O 
the O 
reactive O 
PHPMA B-ABBREVIATION 
copolymer O 
shell O 
via O 
hydrazone B-FAMILY 
bonding O 
that O 
allowed O 
its O 
pH-sensitive O 
release O 
. O 
This O 
strategy O 
enabled O 
the O 
combination O 
chemotherapy O 
by O 
the O 
simultaneous O 
DOX B-ABBREVIATION 
and O 
DTXL B-ABBREVIATION 
drug O 
delivery O 
. O 
The O 
structure O 
of O 
the O 
nanoparticles O 
was O 
characterized O 
in O 
detail O 
using O 
static O 
( O 
SLS O 
) O 
, O 
dynamic O 
( O 
DLS O 
) O 
and O 
electrophoretic O 
( O 
ELS O 
) O 
light O 
scattering O 
besides O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
. O 
The O 
use O 
of O 
nanoparticles O 
simultaneously O 
loaded O 
with O 
DTXL B-ABBREVIATION 
and O 
DOX B-ABBREVIATION 
provided O 
a O 
more O 
efficient O 
suppression O 
of O 
tumor O 
- O 
cell O 
growth O 
in O 
mice O 
bearing O 
EL-4 O 
T O 
cell O 
lymphoma O 
when O 
compared O 
to O 
the O 
effect O 
of O 
nanoparticles O 
loaded O 
with O 
either O 
DTXL B-ABBREVIATION 
or O 
DOX B-ABBREVIATION 
separately O 
. O 
Additionally O 
, O 
the O 
obtained O 
self O 
- O 
assembled O 
nanoparticles O 
enable O 
further O 
development O 
of O 
targeting O 
strategies O 
based O 
on O 
the O 
use O 
of O 
multiple O 
ligands O 
attached O 
to O 
an O 
HPMA B-ABBREVIATION 
copolymer O 
on O 
the O 
particle O 
surface O 
for O 
simultaneous O 
passive O 
and O 
active O 
targeting O 
and O 
different O 
combination O 
therapies O 
. O 

excess O 
disturbs O 
metabolic O 
status O 
and O 
relative O 
gonad O 
mass O 
in O 
rats O 
on O 
high O 
fat O 
, O 
fructose B-TRIVIAL 
, O 
and O 
salt O 
diets O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
assess O 
the O 
metabolic O 
and O 
physiological O 
changes O 
in O 
rats O 
fed O 
a O 
diet O 
high O 
in O 
fat O 
, O 
fructose B-TRIVIAL 
, O 
and O 
salt O 
, O 
and O 
with O 
excess O 
iron B-SYSTEMATIC 
level O 
. O 
Mineral O 
status O 
was O 
also O 
estimated O 
. O 
Wistar O 
rats O 
were O 
assigned O 
to O 
groups O 
fed O 
either O 
a O 
standard O 
control O 
diet O 
( O 
C O 
) O 
or O 
a O 
diet O 
high O 
in O 
fat O 
, O 
fructose B-TRIVIAL 
, O 
and O 
salt O 
. O 
The O 
noncontrol O 
diets O 
contained O 
either O 
normal O 
( O 
M O 
) O 
or O 
high O 
level O 
( O 
MFe O 
) O 
of O 
iron B-SYSTEMATIC 
. O 
After O 
6 O 
weeks O 
, O 
the O 
length O 
and O 
weight O 
of O 
the O 
rats O 
were O 
measured O 
, O 
and O 
the O 
animals O 
were O 
euthanized O 
. O 
The O 
kidneys O 
and O 
gonads O 
were O 
collected O 
, O 
and O 
blood O 
samples O 
were O 
taken O 
. O 
Serum O 
levels O 
of O 
insulin O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
and O 
iron B-SYSTEMATIC 
were O 
measured O 
. O 
The O 
iron B-SYSTEMATIC 
, O 
zinc B-SYSTEMATIC 
, O 
copper B-SYSTEMATIC 
, O 
and O 
calcium B-SYSTEMATIC 
concentrations O 
of O 
tissues O 
were O 
determined O 
. O 
It O 
was O 
found O 
that O 
the O 
M O 
diet O 
led O 
to O 
a O 
significant O 
increase O 
in O 
the O 
relative O 
kidney O 
mass O 
of O 
the O 
rats O 
compared O 
with O 
the O 
control O 
group O 
. O 
Among O 
the O 
rats O 
fed O 
the O 
M O 
diet O 
, O 
markedly O 
higher O 
serum O 
level O 
of O 
iron B-SYSTEMATIC 
and O 
lower O 
levels O 
of O 
zinc B-SYSTEMATIC 
and O 
copper B-SYSTEMATIC 
were O 
observed O 
in O 
tissues O 
, O 
while O 
significantly O 
higher O 
calcium B-SYSTEMATIC 
levels O 
were O 
found O 
in O 
the O 
gonads O 
. O 
The O 
MFe O 
diet O 
resulted O 
in O 
decreased O 
obesity O 
index O 
, O 
insulin O 
level O 
, O 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
serum O 
concentration O 
in O 
the O 
rats O 
, O 
when O 
compared O 
with O 
both O 
the O 
M O 
and O 
C O 
diets O 
. O 
The O 
high O 
iron B-SYSTEMATIC 
level O 
in O 
the O 
modified O 
diet O 
increased O 
the O 
relative O 
mass O 
of O 
the O 
gonads O 
. O 
The O 
excess O 
iron B-SYSTEMATIC 
level O 
in O 
the O 
diet O 
disturbed O 
the O 
zinc B-SYSTEMATIC 
, O 
copper B-SYSTEMATIC 
, O 
and O 
calcium B-SYSTEMATIC 
status O 
of O 
tissues O 
. O 
The O 
decrease O 
in O 
insulin O 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
in O 
rats O 
fed O 
the O 
diet O 
high O 
in O 
iron B-SYSTEMATIC 
, O 
fat O 
, O 
fructose B-TRIVIAL 
, O 
and O 
salt O 
was O 
associated O 
with O 
disorders O 
of O 
zinc B-SYSTEMATIC 
, O 
copper B-SYSTEMATIC 
, O 
and O 
calcium B-SYSTEMATIC 
status O 
, O 
as O 
well O 
as O 
with O 
an O 
increase O 
in O 
the O 
relative O 
mass O 
of O 
the O 
gonads O 
. O 

note O 
to O 
: O 
The O 
effect O 
of O 
lead B-SYSTEMATIC 
acetate I-SYSTEMATIC 
toxicity O 
on O 
experimental O 
male O 
albino O 
rat O 
. O 

responses O 
to O 
nutrient O 
and O 
atrazine B-TRIVIAL 
mixtures O 
introduced O 
through O 
agricultural O 
runoff O 
. O 

runoff O 
often O 
contains O 
pollutants O 
with O 
antagonistic O 
impacts O 
. O 
The O 
individual O 
influence O 
of O 
nutrients O 
and O 
atrazine B-TRIVIAL 
on O 
periphyton O 
has O 
been O 
extensively O 
studied O 
, O 
but O 
their O 
impact O 
when O 
introduced O 
together O 
and O 
with O 
multiple O 
agricultural O 
pollutants O 
is O 
less O 
clear O 
. O 
We O 
simulated O 
a O 
field O 
- O 
scale O 
runoff O 
pulse O 
into O 
a O 
riverine O 
wetland O 
that O 
mimicked O 
pollutant O 
composition O 
typical O 
of O 
field O 
runoff O 
of O 
the O 
Mississippi O 
River O 
Alluvial O 
Plain O 
. O 
Periphyton O 
biomass O 
and O 
functional O 
responses O 
were O 
measured O 
for O 
2 O 
weeks O 
along O 
a O 
500 O 
m O 
section O 
. O 
Additionally O 
, O 
laboratory O 
chamber O 
assays O 
were O 
used O 
to O 
identify O 
potential O 
periphyton O 
changes O 
due O 
to O 
nutrients O 
, O 
atrazine B-TRIVIAL 
, O 
and O 
their O 
interactions O 
. O 
Generally O 
, O 
nutrients O 
stimulated O 
, O 
and O 
atrazine B-TRIVIAL 
reduced O 
chlorophyll B-TRIVIAL 
a I-TRIVIAL 
( O 
Chl B-ABBREVIATION 
a I-ABBREVIATION 
) O 
in O 
chambers O 
. O 
In O 
the O 
wetland O 
, O 
nutrient O 
and O 
atrazine B-TRIVIAL 
relationships O 
with O 
periphyton O 
were O 
weaker O 
, O 
and O 
when O 
found O 
, O 
were O 
often O 
opposite O 
of O 
trends O 
in O 
chambers O 
. O 
Total O 
nitrogen B-SYSTEMATIC 
( O 
TN O 
) O 
was O 
inversely O 
related O 
to O 
Chl B-ABBREVIATION 
a I-ABBREVIATION 
, O 
and O 
total O 
phosphorus B-SYSTEMATIC 
was O 
inversely O 
related O 
to O 
respiration O 
( O 
R O 
) O 
rates O 
. O 
Atrazine B-TRIVIAL 
( O 
10-20 O 
μg O 
L(-1) O 
in O 
the O 
wetland O 
) O 
had O 
a O 
positive O 
relationship O 
with O 
ash O 
- O 
free O 
dry O 
mass O 
( O 
AFDM O 
) O 
, O 
and O 
weakened O 
the O 
relationship O 
between O 
TN O 
and O 
AFDM O 
. O 
Wetland O 
periphyton O 
biomass O 
was O 
better O 
correlated O 
to O 
total O 
suspended O 
solids O 
than O 
nutrients O 
or O 
atrazine B-TRIVIAL 
. O 
Periphyton O 
function O 
was O 
resilient O 
as O 
periphyton O 
gross O 
primary O 
production O 
( O 
GPP O 
) O 
/ O 
R O 
ratios O 
were O 
not O 
strongly O 
impacted O 
by O 
runoff O 
. O 
However O 
, O 
whole O 
- O 
system O 
GPP O 
and O 
R O 
decreased O 
over O 
the O 
2-week O 
period O 
, O 
suggesting O 
that O 
although O 
periphyton O 
metabolism O 
recovered O 
quickly O 
, O 
whole O 
- O 
system O 
metabolism O 
took O 
longer O 
to O 
recover O 
. O 
The O 
individual O 
and O 
combined O 
impacts O 
of O 
nutrients O 
and O 
atrazine B-TRIVIAL 
in O 
complex O 
pollutant O 
mixtures O 
can O 
vary O 
substantially O 
from O 
their O 
influence O 
when O 
introduced O 
separately O 
, O 
and O 
non-linear O 
impacts O 
can O 
occur O 
with O 
distance O 
downstream O 
of O 
the O 
pollutant O 
introduction O 
point O 
. O 

neurotoxicity O 
( O 
DNT O 
) O 
and O 
many O 
forms O 
of O 
reproductive O 
toxicity O 
( O 
RT O 
) O 
often O 
manifest O 
themselves O 
in O 
functional O 
deficits O 
that O 
are O 
not O 
necessarily O 
based O 
on O 
cell O 
death O 
, O 
but O 
rather O 
on O 
minor O 
changes O 
relating O 
to O 
cell O 
differentiation O 
or O 
communication O 
. O 
The O 
fields O 
of O 
DNT O 
/ O 
RT O 
would O 
greatly O 
benefit O 
from O 
in O 
vitro O 
tests O 
that O 
allow O 
the O 
identification O 
of O 
toxicant O 
- O 
induced O 
changes O 
of O 
the O 
cellular O 
proteostasis O 
, O 
or O 
of O 
its O 
underlying O 
transcriptome O 
network O 
. O 
Therefore O 
, O 
the O 
' O 
human O 
embryonic O 
stem O 
cell O 
( O 
hESC O 
) O 
- O 
derived O 
novel O 
alternative O 
test O 
systems O 
( O 
ESNATS O 
) O 
' O 
European O 
commission O 
research O 
project O 
established O 
RT O 
tests O 
based O 
on O 
defined O 
differentiation O 
protocols O 
of O 
hESC O 
and O 
their O 
progeny O 
. O 
Valproic B-TRIVIAL 
acid I-TRIVIAL 
( O 
VPA B-ABBREVIATION 
) O 
and O 
methylmercury B-SYSTEMATIC 
( O 
MeHg B-FORMULA 
) O 
were O 
used O 
as O 
positive O 
control O 
compounds O 
to O 
address O 
the O 
following O 
fundamental O 
questions O 
: O 
( O 
1 O 
) O 
Does O 
transcriptome O 
analysis O 
allow O 
discrimination O 
of O 
the O 
two O 
compounds O 
? O 
( O 
2 O 
) O 
How O 
does O 
analysis O 
of O 
enriched O 
transcription O 
factor O 
binding O 
sites O 
( O 
TFBS O 
) O 
and O 
of O 
individual O 
probe O 
sets O 
( O 
PS O 
) O 
distinguish O 
between O 
test O 
systems O 
? O 
( O 
3 O 
) O 
Can O 
batch O 
effects O 
be O 
controlled O 
? O 
( O 
4 O 
) O 
How O 
many O 
DNA O 
microarrays O 
are O 
needed O 
? O 
( O 
5 O 
) O 
Is O 
the O 
highest O 
non-cytotoxic O 
concentration O 
optimal O 
and O 
relevant O 
for O 
the O 
study O 
of O 
transcriptome O 
changes O 
? O 
VPA O 
triggered O 
vast O 
transcriptional O 
changes O 
, O 
whereas O 
MeHg B-FORMULA 
altered O 
fewer O 
transcripts O 
. O 
To O 
attenuate O 
batch O 
effects O 
, O 
analysis O 
has O 
been O 
focused O 
on O 
the O 
500 O 
PS O 
with O 
highest O 
variability O 
. O 
The O 
test O 
systems O 
differed O 
significantly O 
in O 
their O 
responses O 
( O 
< O 
20 O 
% O 
overlap O 
) O 
. O 
Moreover O 
, O 
within O 
one O 
test O 
system O 
, O 
little O 
overlap O 
between O 
the O 
PS O 
changed O 
by O 
the O 
two O 
compounds O 
has O 
been O 
observed O 
. O 
However O 
, O 
using O 
TFBS O 
enrichment O 
, O 
a O 
relatively O 
large O 
' O 
common O 
response O 
' O 
to O 
VPA B-ABBREVIATION 
and O 
MeHg B-FORMULA 
could O 
be O 
distinguished O 
from O 
' O 
compound O 
- O 
specific O 
' O 
responses O 
. O 
In O 
conclusion O 
, O 
the O 
ESNATS O 
assay O 
battery O 
allows O 
classification O 
of O 
human O 
DNT O 
/ O 
RT O 
toxicants O 
on O 
the O 
basis O 
of O 
their O 
transcriptome O 
profiles O 
. O 

insufficiency O 
may O 
be O 
caused O 
by O 
the O 
destruction O 
or O 
altered O 
function O 
of O 
the O 
adrenal O 
gland O 
with O 
a O 
primary O 
deficit O 
in O 
cortisol B-TRIVIAL 
secretion O 
( O 
primary O 
adrenal O 
insufficiency O 
) O 
or O 
by O 
hypothalamic O 
- O 
pituitary O 
pathologies O 
determining O 
a O 
deficit O 
of O 
ACTH O 
( O 
secondary O 
adrenal O 
insufficiency O 
) O 
. O 
The O 
clinical O 
picture O 
is O 
determined O 
by O 
the O 
glucocorticoid O 
deficit O 
, O 
which O 
may O 
in O 
some O 
conditions O 
be O 
accompanied O 
by O 
a O 
deficit O 
of O 
mineralcorticoids O 
and O 
adrenal O 
androgens B-FAMILY 
. O 
The O 
substitutive O 
treatment O 
is O 
aimed O 
at O 
reducing O 
the O 
signs O 
and O 
symptoms O 
of O 
the O 
disease O 
as O 
well O 
as O 
at O 
preventing O 
the O 
development O 
of O 
an O 
addisonian O 
crisis O 
, O 
a O 
clinical O 
emergency O 
characterized O 
by O 
hypovolemic O 
shock O 
. O 
The O 
oral O 
substitutive O 
treatment O 
should O 
attempt O 
at O 
mimicking O 
the O 
normal O 
circadian O 
profile O 
of O 
cortisol B-TRIVIAL 
secretion O 
, O 
by O 
using O 
the O 
lower O 
possible O 
doses O 
able O 
to O 
guarantee O 
an O 
adequate O 
quality O 
of O 
life O 
to O 
patients O 
. O 
The O 
currently O 
available O 
hydrocortisone B-TRIVIAL 
or O 
cortisone B-SYSTEMATIC 
acetate I-SYSTEMATIC 
preparations O 
do O 
not O 
allow O 
an O 
accurate O 
reproduction O 
of O 
the O 
physiological O 
secretion O 
pattern O 
of O 
cortisol B-TRIVIAL 
. O 
A O 
novel O 
dual O 
- O 
release O 
formulation O 
of O 
hydrocortisone B-TRIVIAL 
, O 
recently O 
approved O 
by O 
EMEA O 
, O 
represents O 
an O 
advancement O 
in O 
the O 
optimization O 
of O 
the O 
clinical O 
management O 
of O 
patients O 
with O 
adrenal O 
insufficiency O 
. O 
Future O 
clinical O 
trials O 
of O 
immunomodulation O 
or O 
immunoprevention O 
will O 
test O 
the O 
possibility O 
to O 
delay O 
( O 
or O 
prevent O 
) O 
the O 
autoimmune O 
destruction O 
of O 
the O 
adrenal O 
gland O 
in O 
autoimmune O 
Addison's O 
disease O 
. O 

new O 
compound O 
named O 
amauroamoienin B-TRIVIAL 
( O 
1 O 
) O 
, O 
together O 
with O 
thirteen O 
known O 
compounds O 
( O 
2-14 O 
) O 
, O 
was O 
isolated O 
from O 
the O 
EtOAc B-FORMULA 
extract O 
of O 
Amauroderma O 
amoiensis O 
. O 
The O 
structures O 
of O 
these O 
compounds O 
were O 
elucidated O 
by O 
the O 
analysis O 
of O 
1D O 
and O 
2D O 
spectroscopic O 
data O 
and O 
the O 
MS O 
technique O 
. O 
The O 
bioassays O 
of O 
inhibitory O 
activities O 
of O 
these O 
isolates O 
against O 
acetylcholinesterase O 
were O 
evaluated O 
, O 
and O 
compounds O 
1 O 
, O 
3 O 
, O 
and O 
5 O 
exhibited O 
acetylcholinesterase O 
inhibitory O 
activities O 
. O 

- O 
dimensional O 
hierarchical O 
GeSe2 B-FORMULA 
nanostructures O 
for O 
high O 
performance O 
flexible O 
all O 
- O 
solid O 
- O 
state O 
supercapacitors O 
. O 

flexible O 
stacked O 
and O 
in O 
- O 
plane O 
all O 
- O 
solid O 
- O 
state O 
supercapacitors O 
are O 
fabricated O 
on O 
3D O 
hierarchical O 
GeSe2 B-FORMULA 
nanostructures O 
with O 
high O 
performance O 
, O 
and O 
, O 
when O 
configured O 
as O 
a O 
self O 
- O 
powered O 
photodetector O 
nanosystem O 
, O 
can O 
be O 
used O 
to O 
power O 
CdSe B-FORMULA 
nanowire O 
photodetectors O 
. O 

- O 
up O 
nutrient O 
and O 
top O 
- O 
down O 
fish O 
impacts O 
on O 
insect O 
- O 
mediated O 
mercury B-SYSTEMATIC 
flux O 
from O 
aquatic O 
ecosystems O 
. O 

mercury I-SYSTEMATIC 
( O 
MeHg B-FORMULA 
) O 
is O 
one O 
of O 
the O 
most O 
hazardous O 
contaminants O 
in O 
the O 
environment O 
, O 
adversely O 
affecting O 
the O 
health O 
of O 
wildlife O 
and O 
humans O 
. O 
Recent O 
studies O 
have O 
demonstrated O 
that O 
aquatic O 
insects O 
biotransport O 
MeHg B-FORMULA 
and O 
other O 
contaminants O 
to O 
terrestrial O 
consumers O 
, O 
but O 
the O 
factors O 
that O 
regulate O 
the O 
flux O 
of O 
MeHg B-FORMULA 
out O 
of O 
aquatic O 
ecosystems O 
via O 
emergent O 
insects O 
have O 
not O 
been O 
studied O 
. O 
The O 
authors O 
used O 
experimental O 
mesocosms O 
to O 
test O 
the O 
hypothesis O 
that O 
insect O 
emergence O 
and O 
the O 
associated O 
flux O 
of O 
MeHg B-FORMULA 
from O 
aquatic O 
to O 
terrestrial O 
ecosystems O 
is O 
affected O 
by O 
both O 
bottom O 
- O 
up O 
nutrient O 
effects O 
and O 
top O 
- O 
down O 
fish O 
consumer O 
effects O 
. O 
In O 
the O 
present O 
study O 
, O 
nutrient O 
addition O 
led O 
to O 
an O 
increase O 
in O 
MeHg B-FORMULA 
flux O 
primarily O 
by O 
enhancing O 
the O 
biomass O 
of O 
emerging O 
insects O 
whose O 
tissues O 
were O 
contaminated O 
with O 
MeHg B-FORMULA 
, O 
whereas O 
fish O 
decreased O 
MeHg B-FORMULA 
flux O 
primarily O 
by O 
reducing O 
the O 
biomass O 
of O 
emerging O 
insects O 
. O 
Furthermore O 
, O 
the O 
authors O 
found O 
that O 
these O 
factors O 
are O 
interdependent O 
such O 
that O 
the O 
effects O 
of O 
nutrients O 
are O 
more O 
pronounced O 
when O 
fish O 
are O 
absent O 
, O 
and O 
the O 
effects O 
of O 
fish O 
are O 
more O 
pronounced O 
when O 
nutrient O 
concentrations O 
are O 
high O 
. O 
The O 
present O 
study O 
is O 
the O 
first O 
to O 
demonstrate O 
that O 
the O 
flux O 
of O 
MeHg B-FORMULA 
from O 
aquatic O 
to O 
terrestrial O 
ecosystems O 
is O 
strongly O 
enhanced O 
by O 
bottom O 
- O 
up O 
nutrient O 
effects O 
and O 
diminished O 
by O 
top O 
- O 
down O 
consumer O 
effects O 
. O 

use O 
of O 
nanoparticles O 
( O 
NPs O 
) O 
in O 
biomedical O 
applications O 
creates O 
a O 
need O 
for O 
appropriate O 
model O 
systems O 
to O 
systematically O 
investigate O 
NP-membrane O 
interactions O 
under O 
well O 
- O 
defined O 
conditions O 
. O 
Black O 
lipid O 
membranes O 
( O 
BLMs O 
) O 
are O 
free O 
- O 
floating O 
membranes O 
with O 
defined O 
composition O 
that O 
are O 
ideally O 
suited O 
for O 
characterizing O 
NP-membrane O 
interactions O 
free O 
of O 
any O 
potential O 
perturbation O 
through O 
a O 
supporting O 
substrate O 
. O 
Herein O 
, O 
arrays O 
of O 
microfabricated O 
BLMs O 
are O 
integrated O 
into O 
a O 
chip O 
- O 
based O 
platform O 
that O 
is O 
compatible O 
with O 
high O 
- O 
speed O 
optical O 
NP O 
tracking O 
. O 
This O 
system O 
is O 
used O 
to O 
investigate O 
the O 
lateral O 
diffusion O 
of O 
40 O 
nm O 
gold O 
spheres O 
tethered O 
to O 
biotinylated O 
lipids O 
through O 
antibody O 
- O 
functionalized O 
ligands O 
( O 
single O 
- O 
stranded O 
DNA O 
or O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) O 
. O 
Although O 
the O 
NPs O 
show O 
an O 
almost O 
free O 
and O 
ergodic O 
diffusion O 
, O 
their O 
lateral O 
motion O 
is O 
subject O 
to O 
substantial O 
drag O 
at O 
the O 
membrane O 
surface O 
, O 
which O 
leads O 
to O 
systematically O 
smaller O 
diffusion O 
coefficients O 
than O 
those O 
obtained O 
for O 
lipids O 
in O 
the O 
membrane O 
through O 
fluorescence O 
recovery O 
after O 
photobleaching O 
. O 
The O 
lateral O 
mobility O 
of O 
the O 
NPs O 
is O 
influenced O 
by O 
the O 
chemical O 
composition O 
and O 
salt O 
concentration O 
at O 
the O 
NP-membrane O 
interface O 
, O 
but O 
is O 
independent O 
of O 
the O 
ligand O 
density O 
in O 
the O 
membrane O 
. O 
Together O 
with O 
the O 
observation O 
that O 
nanoprisms O 
, O 
which O 
have O 
a O 
larger O 
relative O 
contact O 
area O 
with O 
the O 
membrane O 
than O 
spherical O 
NPs O 
, O 
show O 
an O 
even O 
slower O 
diffusion O 
, O 
these O 
findings O 
indicate O 
that O 
the O 
lateral O 
mobility O 
of O 
NPs O 
tethered O 
in O 
close O 
vicinity O 
to O 
a O 
membrane O 
is O 
significantly O 
reduced O 
by O 
the O 
friction O 
at O 
the O 
NP-membrane O 
interface O 
. O 

new O 
class O 
of O 
room O 
- O 
temperature O 
multiferroic O 
thin O 
films O 
with O 
bismuth B-SYSTEMATIC 
-based O 
supercell O 
structure O 
. O 

of O 
two O 
partially O 
miscible O 
phases O 
of O 
BiFeO(3) B-FORMULA 
and O 
BiMnO(3) B-FORMULA 
gives O 
a O 
new O 
class O 
of O 
room O 
- O 
temperature O 
multiferroic O 
phase O 
, O 
Bi(3) B-FORMULA 
Fe(2) I-FORMULA 
Mn(2) I-FORMULA 
O(10+δ) I-FORMULA 
, O 
which O 
has O 
a O 
unique O 
supercell O 
( O 
SC O 
) O 
structure O 
. O 
The O 
SC O 
heterostructures O 
exhibit O 
simultaneously O 
room O 
- O 
temperature O 
ferrimagnetism O 
and O 
remanent O 
polarization O 
. O 
These O 
results O 
open O 
up O 
a O 
new O 
avenue O 
for O 
exploring O 
room O 
- O 
temperature O 
single O 
- O 
phase O 
multiferroic O 
thin O 
films O 
by O 
controlling O 
the O 
phase O 
mixing O 
of O 
two O 
perovskite B-TRIVIAL 
BiRO(3) B-FAMILY 
( O 
R O 
= O 
Cr B-FORMULA 
, O 
Mn B-FORMULA 
, O 
Fe B-FORMULA 
, O 
Co B-FORMULA 
, O 
Ni B-FORMULA 
) O 
materials O 
. O 

and O 
anti-angiogenic O 
activity O 
of O 
benzothiazole B-SYSTEMATIC 
, O 
benzimidazole B-SYSTEMATIC 
containing O 
phthalimide B-TRIVIAL 
derivatives O 
. O 

and O 
benzimidazole B-SYSTEMATIC 
containing O 
phthalimide B-TRIVIAL 
derivatives O 
( O 
NK037 B-IDENTIFIER 
, O 
NK041 B-IDENTIFIER 
, O 
NK042 B-IDENTIFIER 
, O 
NK0139A B-IDENTIFIER 
and O 
NK0148 B-IDENTIFIER 
) O 
have O 
been O 
synthesized O 
and O 
their O 
anti-angiogenic O 
activity O 
was O 
evaluated O 
using O 
ex O 
vivo O 
egg O 
yolk O 
angiogenesis O 
model O 
. O 
A O 
comparative O 
study O 
with O 
pure O 
thalidomide B-TRIVIAL 
( O 
NKTA O 
) O 
has O 
also O 
been O 
performed O 
to O 
describe O 
the O 
efficacy O 
of O 
these O 
derivatives O 
in O 
blocking O 
angiogenesis O 
. O 
NK037 B-IDENTIFIER 
, O 
NK041 B-IDENTIFIER 
and O 
NK042 B-IDENTIFIER 
were O 
equally O 
potent O 
in O 
blocking O 
egg O 
yolk O 
angiogenesis O 
and O 
the O 
anti-angiogenesis O 
effect O 
was O 
higher O 
than O 
NKTA B-TRIVIAL 
suggesting O 
the O 
efficacy O 
of O 
these O 
three O 
derivatives O 
in O 
blocking O 
angiogenesis O 
when O 
compare O 
to O 
control O 
. O 
Other O 
two O 
derivatives O 
NK0139A B-IDENTIFIER 
and O 
NK0148 B-IDENTIFIER 
showed O 
effect O 
less O 
than O 
NKTA B-TRIVIAL 
and O 
stronger O 
than O 
control O 
in O 
ex O 
vivo O 
angiogenesis O 
. O 

purpurea O 
is O 
an O 
aromatic O 
Apiaceae O 
plant O 
known O 
as O 
Alpine O 
lovage O 
. O 
Its O 
polar O 
extracts O 
consist O 
of O 
phenolic B-FAMILY 
acids I-FAMILY 
, O 
tannins B-FAMILY 
and O 
flavonoids B-FAMILY 
. O 
The O 
cytotoxic O 
effect O 
of O 
methanolic O 
and O 
aqueous O 
extracts O 
from O 
M O 
. O 
purpurea O 
was O 
studied O 
on O 
the O 
most O 
frequently O 
used O 
cell O 
lines O 
: O 
HeLa O 
and O 
BHK-21 O 
. O 
Taking O 
into O 
account O 
that O 
the O 
natural O 
products O 
are O 
often O 
used O 
with O 
other O 
medicines O 
there O 
is O 
a O 
risk O 
of O 
reciprocal O 
interaction O 
on O 
the O 
metabolic O 
level O 
. O 
Thus O 
, O 
the O 
influence O 
of O 
M O 
. O 
purpurea O 
extracts O 
was O 
investigated O 
on O 
the O 
activity O 
of O 
CYP2D6 O 
and O 
CYP3A4 O 
, O 
which O 
are O 
the O 
most O 
important O 
P450 O 
isoenzymes O 
from O 
the O 
pharmacological O 
and O 
toxicological O 
points O 
of O 
view O 
. O 
Additionally O 
, O 
because O 
M O 
. O 
purpurea O 
contains O 
phenolic B-FAMILY 
compounds O 
, O 
the O 
antioxidative O 
properties O 
of O 
this O 
plant O 
extracts O 
were O 
also O 
studied O 
and O 
compared O 
. O 

of O 
hypercholesterolemia O 
and O 
atherosclerosis O 
using O 
the O 
cholesterol B-TRIVIAL 
recognition O 
/ O 
interaction O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
of O 
the O 
translocator O 
protein O 
TSPO O 
. O 

translocator O 
protein O 
( O 
18-kDa O 
) O 
TSPO O 
is O 
an O 
ubiquitous O 
high O 
affinity O 
cholesterol B-TRIVIAL 
-binding O 
protein O 
reported O 
to O 
be O 
present O 
in O 
the O 
endothelial O 
and O 
smooth O 
muscle O 
cells O 
of O 
the O 
blood O 
vessels O 
; O 
its O 
expression O 
dramatically O 
increased O 
in O 
macrophages O 
found O 
in O 
atherosclerotic O 
plaques O 
. O 
A O 
domain O 
in O 
the O 
carboxy B-SYSTEMATIC 
-terminus O 
of O 
TSPO O 
was O 
identified O 
and O 
characterized O 
as O 
the O 
cholesterol B-TRIVIAL 
recognition O 
/ O 
interaction O 
amino B-FAMILY 
acid I-FAMILY 
consensus O 
( O 
CRAC O 
) O 
. O 
The O 
ability O 
of O 
the O 
CRAC O 
domain O 
to O 
bind O 
to O 
cholesterol B-TRIVIAL 
led O 
us O 
to O 
hypothesize O 
that O 
this O 
peptide O 
could O 
be O 
used O 
as O 
an O 
hypocholesterolemic O 
, O 
with O 
potential O 
anti-atherogenic O 
properties O 
, O 
agent O 
. O 
We O 
report O 
herein O 
the O 
therapeutic O 
benefit O 
that O 
resulted O 
for O 
the O 
administration O 
of O 
the O 
VLNYYVWR O 
human O 
CRAC O 
sequence O 
to O 
guinea O 
pigs O 
fed O 
with O 
a O 
high O 
cholesterol B-TRIVIAL 
diet O 
and O 
ApoE O 
knock O 
- O 
out O 
B6.129P2-Apoetm1Unc O 
/ O 
J O 
mice O 
. O 
CRAC O 
treatment O 
( O 
3 O 
and O 
30mg O 
/ O 
kg O 
once O 
daily O 
for O 
6 O 
weeks O 
) O 
resulted O 
in O 
reduced O 
circulating O 
cholesterol B-TRIVIAL 
levels O 
in O 
guinea O 
pigs O 
fed O 
with O 
2% O 
high O 
cholesterol B-TRIVIAL 
diet O 
and O 
ApoE O 
knock O 
- O 
out O 
B6.129P2-Apoetm1Unc O 
/ O 
J O 
mice O 
. O 
In O 
high O 
cholesterol B-TRIVIAL 
fed O 
guinea O 
pigs O 
, O 
CRAC O 
treatment O 
administered O 
once O 
daily O 
induced O 
an O 
increase O 
in O 
circulating O 
HDL O 
, O 
decreased O 
total O 
, O 
free O 
and O 
LDL O 
cholesterol B-TRIVIAL 
, O 
and O 
removed O 
atheroma O 
deposits O 
in O 
the O 
aorta O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
The O 
treatment O 
also O 
prevented O 
the O 
high O 
cholesterol B-TRIVIAL 
diet O 
- O 
induced O 
increase O 
in O 
serum O 
creatine B-TRIVIAL 
kinase O 
, O 
total O 
and O 
isoforms O 
, O 
markers O 
of O 
neurological O 
, O 
cardiac O 
and O 
muscular O 
damage O 
. O 
No O 
toxicity O 
was O 
observed O 
. O 
Taken O 
together O 
these O 
results O 
support O 
a O 
role O 
of O 
TSPO O 
in O 
lipid O 
homeostasis O 
and O 
atherosclerosis O 
and O 
indicate O 
that O 
CRAC O 
may O 
constitute O 
a O 
novel O 
and O 
safe O 
treatment O 
of O 
hypercholesterolemia O 
and O 
atherosclerosis O 
. O 

cytoskeletal O 
homeostasis O 
, O 
astrogliosis O 
and O 
apoptotic O 
cell O 
death O 
in O 
the O 
cerebellum O 
of O 
preweaning O 
rats O 
injected O 
with O 
diphenyl B-SYSTEMATIC 
ditelluride I-SYSTEMATIC 
. O 

the O 
present O 
report O 
15 O 
day O 
- O 
old O 
rats O 
were O 
injected O 
with O 
0.3μmol O 
of O 
diphenyl B-SYSTEMATIC 
ditelluride I-SYSTEMATIC 
(PhTe)(2) B-FORMULA 
/ O 
kg O 
body O 
weight O 
and O 
parameters O 
of O 
neurodegeneration O 
were O 
analyzed O 
in O 
slices O 
from O 
cerebellum O 
3 O 
and O 
6 O 
days O 
afterwards O 
. O 
The O 
earlier O 
responses O 
, O 
at O 
day O 
3 O 
after O 
injection O 
, O 
included O 
hyperphosphorylation O 
of O 
intermediate O 
filament O 
( O 
IF O 
) O 
proteins O 
from O 
astrocyte O 
( O 
glial O 
fibrillary O 
acidic O 
protein O 
- O 
GFAP O 
- O 
and O 
vimentin O 
) O 
and O 
neuron O 
( O 
low- O 
, O 
medium- O 
and O 
high O 
molecular O 
weight O 
neurofilament O 
subunits O 
: O 
NF-L O 
, O 
NF-M O 
and O 
NF-H O 
) O 
; O 
increased O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
( O 
Erk O 
and O 
p38MAPK O 
) O 
and O 
cAMP B-ABBREVIATION 
-dependent O 
protein O 
kinase O 
( O 
PKA O 
) O 
activities O 
. O 
Also O 
, O 
reactive O 
astrogliosis O 
takes O 
part O 
of O 
the O 
early O 
responses O 
to O 
the O 
insult O 
with O 
(PhTe)(2) B-FORMULA 
, O 
evidenced O 
by O 
upregulated O 
GFAP O 
in O 
Western O 
blot O 
, O 
PCR O 
and O 
immunofluorescence O 
analysis O 
. O 
Six O 
days O 
after O 
(PhTe)(2) B-FORMULA 
injection O 
we O 
found O 
persistent O 
astrogliosis O 
, O 
increased O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
( O 
PI O 
) O 
positive O 
cells O 
in O 
NeuN O 
positive O 
population O 
evidenced O 
by O 
flow O 
cytometry O 
and O 
reduced O 
immunofluorescence O 
for O 
NeuN O 
, O 
suggesting O 
that O 
the O 
in O 
vivo O 
exposure O 
to O 
(PhTe)(2) B-FORMULA 
progressed O 
to O 
neuronal O 
death O 
. O 
Moreover O 
, O 
activated O 
caspase O 
3 O 
suggested O 
apoptotic O 
neuronal O 
death O 
. O 
Neurodegeneration O 
was O 
related O 
with O 
decreased O 
[(3)H]glutamate B-SYSTEMATIC 
uptake O 
and O 
decreased O 
Akt O 
immunoreactivity O 
, O 
however O 
phospho-GSK-3-β O 
( O 
Ser B-FORMULA 
9 O 
) O 
was O 
not O 
altered O 
in O 
(PhTe)(2) B-FORMULA 
injected O 
rat O 
. O 
Therefore O 
, O 
the O 
present O 
results O 
show O 
that O 
the O 
earlier O 
cerebellar O 
responses O 
to O 
(PhTe)(2) B-FORMULA 
include O 
disruption O 
of O 
cytoskeletal O 
homeostasis O 
that O 
could O 
be O 
related O 
with O 
MAPK O 
and O 
PKA O 
activation O 
and O 
reactive O 
astrogliosis O 
. O 
Akt O 
inhibition O 
observed O 
at O 
this O 
time O 
could O 
also O 
play O 
a O 
role O 
in O 
the O 
neuronal O 
death O 
evidenced O 
afterwards O 
. O 
The O 
later O 
events O 
of O 
the O 
neurodegenerative O 
process O 
are O 
characterized O 
by O 
persistent O 
astrogliosis O 
and O 
activation O 
of O 
apoptotic O 
neuronal O 
death O 
through O 
caspase O 
3 O 
mediated O 
mechanisms O 
, O 
which O 
could O 
be O 
related O 
with O 
glutamate B-TRIVIAL 
excitotoxicity O 
. O 
The O 
progression O 
of O 
these O 
responses O 
are O 
therefore O 
likely O 
to O 
be O 
critical O 
for O 
the O 
outcome O 
of O 
the O 
neurodegeneration O 
provoked O 
by O 
(PhTe)(2) B-FORMULA 
in O 
rat O 
cerebellum O 
. O 

microsomal O 
enzyme O 
17β-hydroxysteroid B-SYSTEMATIC 
dehydrogenase O 
3 O 
faces O 
the O 
cytoplasm O 
and O 
uses O 
NADPH B-ABBREVIATION 
generated O 
by O 
glucose-6-phosphate B-SYSTEMATIC 
dehydrogenase O 
. O 

studies O 
proposed O 
a O 
functional O 
coupling O 
between O 
17β-hydroxysteroid B-SYSTEMATIC 
dehydrogenase O 
3 O 
(17β-HSD3)-dependent O 
testosterone O 
formation O 
and O 
11β-hydroxysteroid B-FAMILY 
dehydrogenase O 
1 O 
( O 
11β-HSD1 O 
) O 
- O 
mediated O 
interconversion O 
of O 
glucocorticoids O 
through O 
competition O 
for O 
the O 
luminal O 
pyridine B-FAMILY 
nucleotide I-FAMILY 
pool O 
. O 
To O 
test O 
this O 
hypothesis O 
, O 
we O 
used O 
human O 
embryonic O 
kidney-293 O 
cells O 
transfected O 
with O 
17β-HSD3 O 
and O 
/ O 
or O 
11β-HSD1 O 
, O 
in O 
the O 
absence O 
or O 
presence O 
of O 
hexose-6-phosphate B-SYSTEMATIC 
dehydrogenase O 
that O 
generates O 
reduced O 
nicotinamide B-SYSTEMATIC 
adenine I-SYSTEMATIC 
dinucleotide I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
( O 
NADPH B-ABBREVIATION 
) O 
in O 
the O 
endoplasmic O 
reticulum O 
and O 
determined O 
enzyme O 
activities O 
. O 
As O 
an O 
endogenous O 
cell O 
model O 
, O 
mouse O 
MA-10 O 
Leydig O 
cells O 
were O 
used O 
. O 
17β-HSD3-dependent O 
reduction O 
of O 
Δ4-androstene-3,17-dione B-SYSTEMATIC 
was O 
affected O 
by O 
neither O 
coexpression O 
with O 
11β-HSD1 O 
nor O 
overexpression O 
or O 
knockdown O 
of O 
hexose-6-phosphate B-SYSTEMATIC 
dehydrogenase O 
. O 
In O 
contrast O 
, O 
knockdown O 
of O 
glucose-6-phosphate B-SYSTEMATIC 
dehydrogenase O 
decreased O 
17β-HSD3 O 
activity O 
, O 
indicating O 
dependence O 
on O 
cytoplasmic O 
NADPH B-ABBREVIATION 
. O 
Upon O 
selective O 
permeabilization O 
of O 
the O 
plasma O 
membrane O 
by O 
digitonin B-TRIVIAL 
, O 
17β-HSD3 O 
but O 
not O 
11β-HSD1 O 
was O 
detected O 
by O 
antibodies O 
against O 
C B-FORMULA 
-terminal O 
epitope O 
tags O 
, O 
suggesting O 
a O 
cytoplasmic O 
orientation O 
of O 
17β-HSD3 O 
. O 
The O 
cytoplasmic O 
orientation O 
was O 
confirmed O 
using O 
proteinase O 
K O 
digestion O 
of O 
microsomal O 
preparations O 
and O 
by O 
analysis O 
of O 
glycosylation O 
of O 
wild O 
- O 
type O 
17β-HSD3 O 
and O 
chimera O 
in O 
which O 
the O 
N B-FORMULA 
-terminal O 
anchor O 
sequences O 
between O 
17β-HSD3 O 
and O 
11β-HSD1 O 
were O 
exchanged O 
. O 
In O 
conclusion O 
, O 
the O 
results O 
demonstrate O 
a O 
cytoplasmic O 
orientation O 
of O 
17β-HSD3 O 
and O 
dependence O 
on O 
glucose-6-phosphate B-SYSTEMATIC 
dehydrogenase O 
- O 
generated O 
NADPH B-ABBREVIATION 
, O 
explaining O 
the O 
lack O 
of O 
a O 
direct O 
functional O 
coupling O 
with O 
the O 
luminal O 
11β-HSD1- O 
mediated O 
glucocorticoid O 
metabolism O 
. O 

combined O 
nuclear O 
and O 
nucleolar O 
localization O 
motif O 
in O 
activation O 
- O 
induced O 
cytidine B-TRIVIAL 
deaminase O 
( O 
AID O 
) O 
controls O 
immunoglobulin O 
class O 
switching O 
. O 

- O 
induced O 
cytidine B-TRIVIAL 
deaminase O 
( O 
AID O 
) O 
is O 
a O 
DNA O 
mutator O 
enzyme O 
essential O 
for O 
adaptive O 
immunity O 
. O 
AID O 
initiates O 
somatic O 
hypermutation O 
and O 
class O 
switch O 
recombination O 
( O 
CSR O 
) O 
by O 
deaminating O 
cytosine B-TRIVIAL 
to O 
uracil B-TRIVIAL 
in O 
specific O 
immunoglobulin O 
( O 
Ig O 
) O 
gene O 
regions O 
. O 
However O 
, O 
other O 
loci O 
, O 
including O 
cancer O 
- O 
related O 
genes O 
, O 
are O 
also O 
targeted O 
. O 
Thus O 
, O 
tight O 
regulation O 
of O 
AID O 
is O 
crucial O 
to O 
balance O 
immunity O 
versus O 
disease O 
such O 
as O 
cancer O 
. O 
AID O 
is O 
regulated O 
by O 
several O 
mechanisms O 
including O 
nucleocytoplasmic O 
shuttling O 
. O 
Here O 
we O 
have O 
studied O 
nuclear O 
import O 
kinetics O 
and O 
subnuclear O 
trafficking O 
of O 
AID O 
in O 
live O 
cells O 
and O 
characterized O 
in O 
detail O 
its O 
nuclear O 
localization O 
signal O 
. O 
Importantly O 
, O 
we O 
find O 
that O 
the O 
nuclear O 
localization O 
signal O 
motif O 
also O 
directs O 
AID O 
to O 
nucleoli O 
where O 
it O 
colocalizes O 
with O 
its O 
interaction O 
partner O 
, O 
catenin-β O 
- O 
like O 
1 O 
( O 
CTNNBL1 O 
) O 
, O 
and O 
physically O 
associates O 
with O 
nucleolin O 
and O 
nucleophosmin O 
. O 
Moreover O 
, O 
we O 
demonstrate O 
that O 
release O 
of O 
AID O 
from O 
nucleoli O 
is O 
dependent O 
on O 
its O 
C B-FORMULA 
-terminal O 
motif O 
. O 
Finally O 
, O 
we O 
find O 
that O 
CSR O 
efficiency O 
correlates O 
strongly O 
with O 
the O 
arithmetic O 
product O 
of O 
AID O 
nuclear O 
import O 
rate O 
and O 
DNA O 
deamination O 
activity O 
. O 
Our O 
findings O 
suggest O 
that O 
directional O 
nucleolar O 
transit O 
is O 
important O 
for O 
the O 
physiological O 
function O 
of O 
AID O 
and O 
demonstrate O 
that O 
nuclear O 
/ O 
nucleolar O 
import O 
and O 
DNA O 
cytosine B-TRIVIAL 
deamination O 
together O 
define O 
the O 
biological O 
activity O 
of O 
AID O 
. O 
This O 
is O 
the O 
first O 
study O 
on O 
subnuclear O 
trafficking O 
of O 
AID O 
and O 
demonstrates O 
a O 
new O 
level O 
in O 
its O 
complex O 
regulation O 
. O 
In O 
addition O 
, O 
our O 
results O 
resolve O 
the O 
problem O 
related O 
to O 
dissociation O 
of O 
deamination O 
activity O 
and O 
CSR O 
activity O 
of O 
AID O 
mutants O 
. O 

pot O 
synthesis O 
and O 
biological O 
activity O 
evaluation O 
of O 
novel O 
Schiff B-FAMILY 
bases I-FAMILY 
derived O 
from O 
2-hydrazinyl-1,3,4-thiadiazole B-SYSTEMATIC 
. O 

the O 
structural O 
features O 
of O 
a O 
group O 
of O 
known O 
potent O 
inhibitors O 
of O 
human O 
platelet O 
aggregation O 
containing O 
hydrazone B-FAMILY 
structural O 
backbone O 
, O 
a O 
series O 
of O 
novel O 
hydrazone B-FAMILY 
derivatives O 
of O 
2-hydrazinyl-1,3,4-thiadiazole B-SYSTEMATIC 
were O 
synthesized O 
using O 
a O 
one O 
- O 
pot O 
process O 
and O 
tested O 
for O 
their O 
inhibitory O 
activity O 
against O 
platelet O 
aggregation O 
induced O 
by O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
and O 
ADP B-ABBREVIATION 
. O 
Among O 
the O 
derivatives O 
, O 
compounds O 
3l O 
, O 
3o O 
and O 
3p O 
exhibited O 
the O 
highest O 
antiplatelet O 
aggregation O 
activity O 
. O 
The O 
derivatives O 
were O 
also O 
screened O 
for O 
their O 
potential O 
antimycobacterial O 
activity O 
and O 
compounds O 
3g O 
, O 
3k O 
, O 
3p O 
and O 
3q O 
were O 
among O 
the O 
most O 
active O 
compounds O 
. O 

repellent O 
coatings O 
have O 
been O 
studied O 
and O 
keenly O 
sought O 
after O 
for O 
many O 
years O 
, O 
where O 
any O 
advances O 
in O 
the O 
durability O 
of O 
such O 
coatings O 
will O 
result O 
in O 
huge O 
energy O 
savings O 
across O 
many O 
fields O 
. O 
Progress O 
in O 
creating O 
anti-ice O 
and O 
anti-frost O 
surfaces O 
has O 
been O 
particularly O 
rapid O 
since O 
the O 
discovery O 
and O 
development O 
of O 
slippery O 
, O 
liquid O 
infused O 
porous O 
surfaces O 
( O 
SLIPS O 
) O 
. O 
Here O 
we O 
use O 
SLIPS O 
- O 
coated O 
differential O 
scanning O 
calorimeter O 
( O 
DSC O 
) O 
pans O 
to O 
investigate O 
the O 
effects O 
of O 
the O 
surface O 
modification O 
on O 
the O 
nucleation O 
of O 
supercooled O 
water O 
. O 
This O 
investigation O 
is O 
inherently O 
different O 
from O 
previous O 
studies O 
which O 
looked O 
at O 
the O 
adhesion O 
of O 
ice O 
to O 
SLIPS O 
surfaces O 
, O 
or O 
the O 
formation O 
of O 
ice O 
under O 
high O 
humidity O 
conditions O 
. O 
Given O 
the O 
stochastic O 
nature O 
of O 
nucleation O 
of O 
ice O 
from O 
supercooled O 
water O 
, O 
multiple O 
runs O 
on O 
the O 
same O 
sample O 
are O 
needed O 
to O 
determine O 
if O 
a O 
given O 
surface O 
coating O 
has O 
a O 
real O 
and O 
statistically O 
significant O 
effect O 
on O 
the O 
nucleation O 
temperature O 
. O 
We O 
have O 
cycled O 
supercooling O 
to O 
freezing O 
and O 
then O 
thawing O 
of O 
deionized O 
water O 
in O 
hydrophilic O 
( O 
untreated O 
aluminum B-SYSTEMATIC 
) O 
, O 
hydrophobic O 
, O 
superhydrophobic O 
, O 
and O 
SLIPS O 
- O 
treated O 
DSC O 
pans O 
multiple O 
times O 
to O 
determine O 
the O 
effects O 
of O 
surface O 
treatment O 
on O 
the O 
nucleation O 
and O 
subsequent O 
growth O 
of O 
ice O 
. O 
We O 
find O 
that O 
SLIPS O 
coatings O 
lower O 
the O 
nucleation O 
temperature O 
of O 
supercooled O 
water O 
in O 
contact O 
with O 
statistical O 
significance O 
and O 
show O 
no O 
deterioration O 
or O 
change O 
in O 
the O 
coating O 
performance O 
even O 
after O 
150 O 
freeze O 
- O 
thaw O 
cycles O 
. O 

- O 
linked O 
dystonia O 
parkinsonism O 
syndrome O 
( O 
XDP O 
, O 
lubag O 
) O 
: O 
disease O 
- O 
specific O 
sequence O 
change O 
DSC3 O 
in O 
TAF1 O 
/ O 
DYT3 O 
affects O 
genes O 
in O 
vesicular O 
transport O 
and O 
dopamine B-TRIVIAL 
metabolism O 
. O 

dystonia O 
parkinsonism O 
syndrome O 
( O 
XDP O 
, O 
' O 
lubag O 
' O 
) O 
is O 
associated O 
with O 
sequence O 
changes O 
within O 
the O 
TAF1 O 
/ O 
DYT3 O 
multiple O 
transcript O 
system O 
. O 
Although O 
most O 
sequence O 
changes O 
are O 
intronic O 
, O 
one O 
, O 
disease O 
- O 
specific O 
single- O 
nucleotide B-FAMILY 
change O 
3 O 
( O 
DSC3 O 
) O 
, O 
is O 
located O 
within O 
an O 
exon O 
( O 
d4 O 
) O 
. O 
Transcribed O 
exon O 
d4 O 
occurs O 
as O 
part O 
of O 
multiple O 
splice O 
variants O 
. O 
These O 
variants O 
include O 
exons O 
d3 O 
and O 
d4 O 
spliced O 
to O 
exons O 
of O 
TAF1 O 
, O 
and O 
an O 
independent O 
transcript O 
composed O 
of O 
exons O 
d2-d4 O 
. O 
Location O 
of O 
DSC3 O 
in O 
exon O 
d4 O 
and O 
utilization O 
of O 
this O 
exon O 
in O 
multiple O 
splice O 
variants O 
suggest O 
an O 
important O 
role O 
of O 
DSC3 O 
in O 
the O 
XDP O 
pathogenesis O 
. O 
To O 
test O 
this O 
hypothesis O 
, O 
we O 
transfected O 
neuroblastoma O 
cells O 
with O 
four O 
expression O 
constructs O 
, O 
including O 
exons O 
d2-d4 O 
[ O 
d2-d4 O 
/ O 
wild O 
- O 
type O 
( O 
wt O 
) O 
and O 
d2-d4 O 
/ O 
DSC3 O 
] O 
and O 
d3-d4 O 
( O 
d3-d4 O 
/ O 
wt O 
and O 
d3-d4 O 
/ O 
DSC3 O 
) O 
. O 
Expression O 
profiling O 
revealed O 
a O 
dramatic O 
effect O 
of O 
DSC3 O 
on O 
overall O 
gene O 
expression O 
. O 
Three O 
hundred O 
and O 
sixty O 
- O 
two O 
genes O 
differed O 
between O 
cells O 
containing O 
d2-d4 O 
/ O 
wt O 
and O 
d2-d4 O 
/ O 
DSC3 O 
. O 
Annotation O 
clustering O 
revealed O 
enrichment O 
of O 
genes O 
related O 
to O 
vesicular O 
transport O 
, O 
dopamine B-TRIVIAL 
metabolism O 
, O 
synapse O 
function O 
, O 
Ca(2+) B-FORMULA 
metabolism O 
and O 
oxidative O 
stress O 
. O 
Two O 
hundred O 
and O 
eleven O 
genes O 
were O 
differentially O 
expressed O 
in O 
d3-d4 O 
/ O 
wt O 
versus O 
d3-d4 O 
/ O 
DSC3 O 
. O 
Annotation O 
clustering O 
highlighted O 
genes O 
in O 
signal O 
transduction O 
and O 
cell O 
- O 
cell O 
interaction O 
. O 
The O 
data O 
show O 
an O 
important O 
role O 
of O 
physiologically O 
occurring O 
transcript O 
d2-d4 O 
in O 
normal O 
brain O 
function O 
. O 
Interference O 
with O 
this O 
role O 
by O 
DSC3 O 
is O 
a O 
likely O 
pathological O 
mechanism O 
in O 
XDP O 
. O 
Disturbance O 
of O 
dopamine O 
function O 
and O 
of O 
Ca(2+) B-FORMULA 
metabolism O 
can O 
explain O 
abnormal O 
movement O 
; O 
loss O 
of O 
protection O 
against O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
may O 
account O 
for O 
the O 
neurodegenerative O 
changes O 
in O 
XDP O 
. O 
Although O 
d3-d4 O 
also O 
affect O 
genes O 
potentially O 
related O 
to O 
neurodegenerative O 
processes O 
, O 
their O 
physiologic O 
role O 
as O 
splice O 
variants O 
of O 
TAF1 O 
awaits O 
further O 
exploration O 
. O 

approaches O 
to O 
modeling O 
protein O 
structures O 
have O 
made O 
significant O 
advances O 
over O 
the O 
past O 
decade O 
. O 
However O 
, O 
the O 
current O 
limitation O 
in O 
modeling O 
protein O 
structures O 
is O 
to O 
produce O 
protein O 
structures O 
consistently O 
below O 
the O 
limit O 
of O 
6 O 
Å O 
compared O 
to O 
their O 
native O 
structure O 
. O 
Therefore O 
, O 
improvement O 
of O 
protein O 
structures O 
consistently O 
below O 
the O 
6 O 
Å O 
limit O 
using O 
simulation O 
of O 
biophysical O 
forces O 
is O 
of O 
significant O 
interest O 
. O 
Current O 
protein O 
force O 
fields O 
such O 
as O 
those O 
implemented O 
in O 
CHARMM O 
, O 
AMBER O 
, O 
and O 
NAMD O 
have O 
been O 
deemed O 
complete O 
, O 
yet O 
their O 
use O 
in O 
ab O 
initio O 
approaches O 
to O 
protein O 
structure O 
determination O 
has O 
been O 
unsuccessful O 
. O 
Here O 
, O 
we O 
introduce O 
a O 
new O 
approach O 
in O 
evaluation O 
of O 
protein O 
structures O 
based O 
on O 
analysis O 
of O 
energy O 
profiles O 
produced O 
by O 
the O 
SCOPE O 
software O 
package O 
. O 
The O 
latest O 
version O 
of O 
SCOPE O 
produces O 
a O 
hydrogen B-SYSTEMATIC 
bond O 
profile O 
that O 
is O 
substantially O 
more O 
informative O 
than O 
a O 
single O 
hydrogen B-SYSTEMATIC 
bond O 
energy O 
value O 
. O 
We O 
demonstrate O 
how O 
analysis O 
of O 
SCOPE's O 
energy O 
profile O 
by O 
an O 
artificial O 
neural O 
network O 
shows O 
a O 
significant O 
improvement O 
compared O 
to O 
the O 
traditional O 
force O 
- O 
based O 
approaches O 
to O 
evaluation O 
of O 
structures O 
. O 
The O 
artificial O 
neural O 
network O 
based O 
analysis O 
of O 
SCOPE's O 
energy O 
profile O 
showed O 
identification O 
of O 
structures O 
to O 
within O 
the O 
range O 
of O 
1.5-3.0 O 
Å O 
of O 
the O 
native O 
structure O 
. O 
These O 
results O 
have O 
been O 
obtained O 
by O 
testing O 
structures O 
in O 
the O 
same O 
Homology O 
, O 
Topology O 
, O 
Architecture O 
, O 
or O 
Class O 
of O 
the O 
CATH O 
family O 
. O 

transition O 
moments O 
of O 
6-methyl B-SYSTEMATIC 
isoxanthopterin I-SYSTEMATIC 
-- O 
a O 
fluorescent O 
analogue O 
of O 
the O 
nucleic O 
acid O 
base O 
guanine B-TRIVIAL 
. O 

nucleic O 
acid O 
base O 
analogues O 
are O 
important O 
spectroscopic O 
tools O 
for O 
understanding O 
local O 
structure O 
and O 
dynamics O 
of O 
DNA O 
and O 
RNA O 
. O 
We O 
studied O 
the O 
orientations O 
and O 
magnitudes O 
of O 
the O 
electric O 
dipole O 
transition O 
moments O 
( O 
EDTMs O 
) O 
of O 
6-methyl B-SYSTEMATIC 
isoxanthopterin I-SYSTEMATIC 
( O 
6-MI B-SYSTEMATIC 
) O 
, O 
a O 
fluorescent O 
analogue O 
of O 
guanine B-TRIVIAL 
that O 
has O 
been O 
particularly O 
useful O 
in O 
biological O 
studies O 
. O 
Using O 
a O 
combination O 
of O 
absorption O 
spectroscopy O 
, O 
linear O 
dichroism O 
( O 
LD O 
) O 
and O 
quantum O 
chemical O 
calculations O 
, O 
we O 
identified O 
six O 
electronic O 
transitions O 
that O 
occur O 
within O 
the O 
25,000-50,000 O 
cm(-1) O 
spectral O 
range O 
. O 
Our O 
results O 
indicate O 
that O 
the O 
two O 
experimentally O 
observed O 
lowest O 
- O 
energy O 
transitions O 
, O 
which O 
occur O 
at O 
29687 O 
cm(-1) O 
( O 
337 O 
nm O 
) O 
and O 
34596 O 
cm(-1) O 
( O 
289 O 
nm O 
) O 
, O 
are O 
each O 
polarized O 
within O 
the O 
plane O 
of O 
the O 
6-MI B-SYSTEMATIC 
base O 
. O 
A O 
third O 
in O 
- O 
plane O 
polarized O 
transition O 
is O 
experimentally O 
observed O 
at O 
47547 O 
cm(-1) O 
( O 
210 O 
nm O 
) O 
. O 
The O 
theoretically O 
predicted O 
orientation O 
of O 
the O 
lowest O 
- O 
energy O 
transition O 
moment O 
agrees O 
well O 
with O 
experiment O 
. O 
Based O 
on O 
these O 
results O 
, O 
we O 
constructed O 
an O 
exciton O 
model O 
to O 
describe O 
the O 
absorption O 
spectra O 
of O 
a O 
6-MI B-SYSTEMATIC 
dinucleotide O 
- O 
substituted O 
double O 
- O 
stranded O 
DNA O 
construct O 
. O 
This O 
model O 
is O 
in O 
good O 
agreement O 
with O 
the O 
experimental O 
data O 
. O 
The O 
orientations O 
and O 
intensities O 
of O 
the O 
low O 
- O 
energy O 
electronic O 
transitions O 
of O 
6-MI B-SYSTEMATIC 
reported O 
here O 
should O 
be O 
useful O 
for O 
studying O 
local O 
conformations O 
of O 
DNA O 
and O 
RNA O 
in O 
biologically O 
important O 
complexes O 
. O 

of O 
romidepsin B-TRIVIAL 
for O 
clinical O 
activity O 
and O 
radioactive B-SYSTEMATIC 
iodine I-SYSTEMATIC 
reuptake O 
in O 
radioactive B-SYSTEMATIC 
iodine I-SYSTEMATIC 
-refractory O 
thyroid O 
carcinoma O 
. O 

: O 
Historically O 
, O 
systemic O 
therapy O 
for O 
radioactive B-SYSTEMATIC 
iodine I-SYSTEMATIC 
( O 
RAI B-ABBREVIATION 
)-refractory O 
thyroid O 
cancer O 
has O 
been O 
understudied O 
. O 
Available O 
drugs O 
have O 
modest O 
efficacy O 
. O 
Romidepsin B-TRIVIAL 
is O 
a O 
histone O 
deacetylase O 
inhibitor O 
with O 
potent O 
antitumor O 
effects O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
In O 
thyroid O 
cancer O 
cell O 
lines O 
, O 
romidepsin O 
increases O 
expression O 
of O 
both O 
thyroglobulin O 
and O 
the O 
sodium B-SYSTEMATIC 
iodide I-SYSTEMATIC 
symporter O 
messenger O 
RNAs O 
, O 
suggesting O 
the O 
possibility O 
of O 
improved O 
iodine B-SYSTEMATIC 
concentrating O 
ability O 
of O 
RAI B-ABBREVIATION 
-resistant O 
tumors O 
. O 
Methods O 
: O 
This O 
was O 
a O 
single O 
- O 
institution O 
Simon O 
2-stage O 
phase O 
II O 
clinical O 
study O 
. O 
Eligible O 
patients O 
had O 
progressive O 
, O 
RAI B-ABBREVIATION 
-refractory O 
, O 
recurrent O 
/ O 
metastatic O 
, O 
nonmedullary O 
, O 
nonanaplastic O 
thyroid O 
cancer O 
. O 
Response O 
Evaluation O 
Criteria O 
in O 
Solid O 
Tumors O 
( O 
RECIST O 
) O 
1 O 
measurable O 
disease O 
and O 
adequate O 
organ O 
/ O 
marrow O 
function O 
were O 
required O 
. O 
Romidepsin B-TRIVIAL 
13 O 
mg O 
/ O 
m(2) O 
was O 
administered O 
intravenously O 
on O 
days O 
1 O 
, O 
8 O 
, O 
and O 
15 O 
, O 
in O 
cycles O 
of O 
28 O 
days O 
. O 
The O 
primary O 
endpoint O 
was O 
the O 
response O 
rate O 
by O 
RECIST O 
; O 
change O 
in O 
RAI B-ABBREVIATION 
avidity O 
was O 
a O 
secondary O 
endpoint O 
. O 
The O 
study O 
closed O 
after O 
the O 
first O 
stage O 
due O 
to O 
the O 
lack O 
of O 
response O 
. O 
Results O 
: O 
Twenty O 
patients O 
were O 
enrolled O 
: O 
female O 
, O 
50% O 
; O 
median O 
age O 
, O 
64 O 
years O 
; O 
histology O 
, O 
8 O 
papillary O 
/ O 
1 O 
follicular O 
/ O 
11 O 
Hürthle O 
. O 
Grade O 
4-5 O 
adverse O 
events O 
( O 
AEs O 
) O 
possibly O 
related O 
to O 
the O 
drug O 
: O 
grade O 
5 O 
, O 
1 O 
sudden O 
death O 
; O 
grade O 
4 O 
, O 
1 O 
pulmonary O 
embolus O 
. O 
Twelve O 
of O 
20 O 
subjects O 
had O 
a O 
reported O 
adverse O 
event O 
. O 
No O 
RECIST O 
major O 
responses O 
have O 
been O 
seen O 
. O 
Response O 
per O 
protocol O 
: O 
stable O 
disease O 
, O 
13 O 
; O 
disease O 
progression O 
, O 
7 O 
. O 
Restoration O 
of O 
RAI B-ABBREVIATION 
avidity O 
was O 
documented O 
in O 
two O 
patients O 
. O 
Median O 
overall O 
survival O 
and O 
time O 
on O 
study O 
was O 
33.2 O 
( O 
1-71+ O 
) O 
and O 
1.7 O 
( O 
0.46-12 O 
) O 
months O 
, O 
respectively O 
. O 
Conclusions O 
: O 
We O 
observed O 
preliminary O 
signs O 
of O 
in O 
vivo O 
reversal O 
of O 
RAI B-ABBREVIATION 
resistance O 
after O 
treatment O 
with O 
romidepsin B-TRIVIAL 
. O 
However O 
, O 
no O 
major O 
responses O 
were O 
observed O 
and O 
accrual O 
was O 
poor O 
after O 
the O 
grade O 
5 O 
AE O 
. O 

P2X3 O 
receptor O 
activation O 
is O 
essential O 
to O 
the O 
hyperalgesia O 
induced O 
by O 
prostaglandins B-FAMILY 
and O 
sympathomimetic O 
amines B-FAMILY 
released O 
during O 
inflammation O 
. O 

have O 
demonstrated O 
that O 
the O 
activation O 
of O 
P2X3 O 
receptor O 
on O 
peripheral O 
afferent O 
neurons O 
is O 
critical O 
to O 
development O 
of O 
inflammatory O 
hyperalgesia O 
in O 
peripheral O 
tissue O 
, O 
although O 
pharmacological O 
administration O 
of O 
prostaglandin B-TRIVIAL 
E(2) I-TRIVIAL 
or O 
sympathomimetic O 
amines B-FAMILY 
is O 
enough O 
to O 
sensitize O 
primary O 
afferent O 
neurons O 
by O 
acting O 
directly O 
in O 
neuronal O 
receptors O 
. O 
Therefore O 
, O 
to O 
clarify O 
this O 
ambiguity O 
this O 
study O 
verifies O 
whether O 
P2X3 O 
receptor O 
activation O 
on O 
primary O 
afferent O 
neurons O 
enables O 
the O 
sensitization O 
induced O 
by O 
prostaglandin B-TRIVIAL 
E(2) I-TRIVIAL 
or O 
sympathomimetic O 
amine B-SYSTEMATIC 
. O 
Initially O 
, O 
this O 
study O 
confirmed O 
that O 
co O 
- O 
administration O 
of O 
A317491 B-IDENTIFIER 
( O 
60 O 
μg O 
/ O 
paw O 
) O 
, O 
a O 
selective O 
P2X3 O 
receptor O 
antagonist O 
, O 
or O 
pre O 
- O 
treatment O 
with O 
dexamethasone B-TRIVIAL 
( O 
1 O 
mg O 
/ O 
mL O 
/ O 
kg O 
) O 
prevents O 
the O 
mechanical O 
hyperalgesia O 
induced O 
by O 
carrageenan O 
( O 
300 O 
μg O 
/ O 
paw O 
) O 
in O 
the O 
rat's O 
hind O 
paw O 
. O 
Sub O 
- O 
threshold O 
doses O 
of O 
PGE(2) B-ABBREVIATION 
( O 
4 O 
ng O 
/ O 
paw O 
) O 
or O 
dopamine B-TRIVIAL 
( O 
0.4 O 
μg O 
/ O 
paw O 
) O 
, O 
that O 
do O 
not O 
induce O 
hyperalgesia O 
by O 
themselves O 
, O 
when O 
injected O 
just O 
following O 
αβmeATP B-ABBREVIATION 
or O 
carrageenan O 
in O 
rats O 
treated O 
with O 
dexamethasone B-TRIVIAL 
induced O 
hyperalgesia O 
, O 
which O 
is O 
prevented O 
by O 
A317491 B-IDENTIFIER 
or O 
treatment O 
with O 
periganglionar O 
( O 
DRG-L5 O 
) O 
injections O 
of O 
ODN-antisense O 
, O 
against O 
P2X3 O 
receptor O 
. O 
Furthermore O 
, O 
because O 
PKCɛ O 
translocation O 
induces O 
an O 
increase O 
of O 
neuronal O 
susceptibility O 
to O 
inflammatory O 
mediators O 
, O 
this O 
study O 
demonstrates O 
that O 
αβmeATP B-ABBREVIATION 
in O 
peripheral O 
tissue O 
increases O 
the O 
expression O 
of O 
PKCɛ O 
in O 
cell O 
membranes O 
of O 
DRG-L5 O 
, O 
and O 
in O 
contrast O 
, O 
the O 
administration O 
of O 
PKCɛ O 
translocation O 
inhibitor O 
( O 
1 O 
μg O 
/ O 
paw O 
) O 
in O 
peripheral O 
tissue O 
45 O 
min O 
before O 
αβmeATP B-ABBREVIATION 
, O 
prevented O 
the O 
hyperalgesia O 
induced O 
by O 
sub O 
- O 
threshold O 
dose O 
of O 
PGE(2) B-ABBREVIATION 
( O 
4 O 
ng O 
/ O 
paw O 
) O 
. O 
In O 
conclusion O 
, O 
this O 
study O 
suggests O 
that O 
neuronal O 
P2X3 O 
receptor O 
activation O 
and O 
the O 
consequent O 
PKCɛ O 
translocation O 
increase O 
the O 
susceptibility O 
of O 
nociceptor O 
to O 
inflammatory O 
mediators O 
allowing O 
the O 
development O 
of O 
inflammatory O 
hyperalgesia O 
. O 

is O 
considered O 
an O 
alternative O 
energy O 
because O 
it O 
is O 
produced O 
from O 
fats O 
and O 
vegetable O 
oils O 
by O 
means O 
of O 
transesterification O 
. O 
Furthermore O 
, O 
it O 
consists O 
of O 
fatty B-FAMILY 
acid I-FAMILY 
alkyl I-FAMILY 
esters I-FAMILY 
( O 
FAAS B-ABBREVIATION 
) O 
which O 
have O 
a O 
great O 
influence O 
on O 
biodiesel O 
fuel O 
properties O 
and O 
in O 
the O 
storage O 
lifetime O 
of O 
biodiesel O 
itself O 
. O 
The O 
biodiesel O 
storage O 
stability O 
is O 
directly O 
related O 
to O 
the O 
oxidative O 
stability O 
parameter O 
( O 
Induction O 
Time O 
- O 
IT O 
) O 
which O 
is O 
determined O 
by O 
means O 
of O 
the O 
Rancimat O 
® O 
method O 
. O 
This O 
method O 
uses O 
condutimetric O 
monitoring O 
and O 
induces O 
the O 
degradation O 
of O 
FAAS B-ABBREVIATION 
by O 
heating O 
the O 
sample O 
at O 
a O 
constant O 
temperature O 
. O 
The O 
European O 
Committee O 
for O 
Standardization O 
established O 
a O 
standard O 
( O 
EN O 
14214 O 
) O 
to O 
determine O 
the O 
oxidative O 
stability O 
of O 
biodiesel O 
, O 
which O 
requires O 
it O 
to O 
reach O 
a O 
minimum O 
induction O 
period O 
of O 
6h O 
as O 
tested O 
by O 
Rancimat O 
® O 
method O 
at O 
110°C O 
. O 
In O 
this O 
research O 
, O 
we O 
aimed O 
at O 
developing O 
a O 
fast O 
and O 
simple O 
alternative O 
method O 
to O 
determine O 
the O 
induction O 
time O 
( O 
IT O 
) O 
based O 
on O 
the O 
FAAS B-ABBREVIATION 
ultrasonic O 
- O 
accelerated O 
oxidation O 
. O 
The O 
sonodegradation O 
of O 
biodiesel O 
samples O 
was O 
induced O 
by O 
means O 
of O 
an O 
ultrasonic O 
homogenizer O 
fitted O 
with O 
an O 
immersible O 
horn O 
at O 
480Watts O 
of O 
power O 
and O 
20 O 
duty O 
cycles O 
. O 
The O 
UV-Vis O 
spectrometry O 
was O 
used O 
to O 
monitor O 
the O 
FAAS B-ABBREVIATION 
sonodegradation O 
by O 
measuring O 
the O 
absorbance O 
at O 
270nm O 
every O 
2 O 
. O 
Biodiesel O 
samples O 
from O 
different O 
feedstock O 
were O 
studied O 
in O 
this O 
work O 
. O 
In O 
all O 
cases O 
, O 
IT O 
was O 
established O 
as O 
the O 
inflection O 
point O 
of O 
the O 
absorbance O 
versus O 
time O 
curve O 
. O 
The O 
induction O 
time O 
values O 
of O 
all O 
biodiesel O 
samples O 
determined O 
using O 
the O 
proposed O 
method O 
was O 
in O 
accordance O 
with O 
those O 
measured O 
through O 
the O 
Rancimat O 
® O 
reference O 
method O 
by O 
showing O 
a O 
R(2)=0.998 O 
. O 

of O 
silanol B-SYSTEMATIC 
sites O 
for O 
the O 
most O 
common O 
mesoporous O 
ordered O 
silicas B-TRIVIAL 
and O 
organosilicas B-FAMILY 
: O 
total O 
versus O 
accessible O 
silanols B-FAMILY 
. O 

and O 
NMR O 
spectroscopy O 
were O 
used O 
to O 
determine O 
the O 
silanol B-SYSTEMATIC 
content O 
in O 
the O 
most O 
common O 
mesoporous O 
ordered O 
silicas B-TRIVIAL 
: O 
MCM-41 B-IDENTIFIER 
, O 
MCM-48 B-TRIVIAL 
, O 
SBA B-IDENTIFIER 
- I-IDENTIFIER 
15 I-IDENTIFIER 
and O 
SBA-16 B-TRIVIAL 
. O 
In O 
addition O 
, O 
a O 
spray O 
dried O 
MCM-41 B-IDENTIFIER 
and O 
an O 
ethene B-SYSTEMATIC 
bridged O 
PMO B-ABBREVIATION 
are O 
investigated O 
. O 
The O 
results O 
are O 
compared O 
with O 
a O 
commercial O 
chromatographic O 
silica B-TRIVIAL 
( O 
Nucleosil B-TRIVIAL 
) O 
. O 
The O 
complete O 
distribution O 
of O 
surface O 
and O 
bulk O 
silanols B-FAMILY 
, O 
and O 
of O 
isolated O 
, O 
geminal B-MULTIPLE 
and I-MULTIPLE 
vicinal I-MULTIPLE 
silanols I-MULTIPLE 
for O 
all O 
these O 
materials O 
is O 
presented O 
. O 
A O 
distinction O 
is O 
made O 
between O 
the O 
total O 
silanol B-SYSTEMATIC 
number O 
and O 
the O 
reachable O 
or O 
surface O 
silanol B-SYSTEMATIC 
content O 
. O 
The O 
latter O 
is O 
determined O 
by O 
controlled O 
reactions O 
with O 
simple O 
silanes B-FAMILY 
. O 
All O 
mesoporous O 
ordered O 
silicas B-TRIVIAL 
, O 
and O 
especially O 
the O 
thick O 
walled O 
SBA O 
- O 
type O 
materials O 
and O 
the O 
PMO B-ABBREVIATION 
contain O 
a O 
surprisingly O 
high O 
amount O 
of O 
total O 
silanol B-SYSTEMATIC 
sites O 
, O 
albeit O 
that O 
up O 
to O 
90% O 
of O 
these O 
silanols B-FAMILY 
are O 
buried O 
inside O 
the O 
walls O 
and O 
are O 
not O 
reachable O 
for O 
small O 
silanes B-FAMILY 
. I-FAMILY 

of O 
structural O 
defects O 
and O 
chemical O 
functionalisation O 
on O 
the O 
intrinsic O 
mechanical O 
properties O 
of O 
graphene B-TRIVIAL 
. O 

to O 
its O 
unique O 
mechanical O 
properties O 
, O 
graphene B-TRIVIAL 
can O 
be O 
applied O 
for O 
reinforcement O 
in O 
nanocomposites O 
. O 
We O 
analyse O 
the O 
Young's O 
modulus O 
of O 
graphene B-TRIVIAL 
at O 
the O 
semi-empirical O 
PM6 O 
level O 
of O 
theory O 
. O 
The O 
internal O 
forces O 
are O 
calculated O 
and O 
the O 
Young's O 
modulus O 
is O 
predicted O 
for O 
a O 
finite O 
graphene B-TRIVIAL 
sheet O 
when O 
external O 
strain O 
is O 
applied O 
on O 
the O 
system O 
. O 
These O 
results O 
are O 
in O 
a O 
good O 
agreement O 
with O 
theoretical O 
and O 
experimental O 
results O 
from O 
the O 
literature O 
giving O 
values O 
of O 
about O 
1 O 
TPa O 
for O 
the O 
Young's O 
modulus O 
. O 
Stress O 
- O 
strain O 
curves O 
are O 
computed O 
for O 
elongation O 
up O 
to O 
20% O 
. O 
In O 
addition O 
, O 
the O 
influence O 
of O 
the O 
presence O 
of O 
a O 
single O 
vacancy O 
, O 
as O 
well O 
as O 
for O 
oxygenation O 
of O 
a O 
vacancy O 
, O 
on O 
the O 
mechanical O 
properties O 
of O 
graphene B-TRIVIAL 
has O 
been O 
analysed O 
. O 
Our O 
results O 
indicate O 
that O 
when O 
applying O 
the O 
deformation O 
locally O 
onto O 
the O 
system O 
, O 
higher O 
local O 
stress O 
can O 
be O 
induced O 
, O 
as O 
confirmed O 
by O 
Finite O 
Element O 
Analysis O 
. O 
Also O 
, O 
the O 
presence O 
of O 
structural O 
defects O 
in O 
the O 
system O 
will O 
stiffen O 
the O 
system O 
upon O 
low O 
strain O 
, O 
but O 
reduces O 
the O 
elastic O 
limit O 
from O 
more O 
than O 
20% O 
strain O 
for O 
pristine B-TRIVIAL 
graphene I-TRIVIAL 
to O 
less O 
than O 
10% O 
strain O 
when O 
defects O 
are O 
present O 
. O 

incretin O 
hormones O 
glucagon O 
- O 
like O 
peptide-1 O 
and O 
glucose B-TRIVIAL 
-dependent O 
insulinotropic O 
peptide O 
are O 
secreted O 
by O 
enteroendocrine O 
cells O 
and O 
augment O 
glucose B-TRIVIAL 
-induced O 
insulin O 
secretion O 
in O 
response O 
to O 
food O 
ingestion O 
in O 
a O 
glucose B-TRIVIAL 
-dependent O 
manner O 
. O 
This O 
mechanism O 
forms O 
the O 
basis O 
for O 
incretin O 
- O 
based O 
therapies O 
in O 
type O 
2 O 
diabetes O 
. O 
However O 
, O 
the O 
insulinotropic O 
effect O 
of O 
incretins O 
is O 
diminished O 
in O 
type O 
2 O 
diabetic O 
patients O 
, O 
due O 
in O 
part O 
to O 
reduced O 
expression O 
of O 
incretin O 
receptors O 
as O 
a O 
consequence O 
of O 
glucotoxicity O 
. O 
In O 
this O 
issue O 
of O 
Diabetologia O 
, O 
Kang O 
et O 
al O 
( O 
DOI O 
: O 
10.1007 O 
/ O 
s00125-012-2776-x O 
) O 
provide O 
evidence O 
that O 
in O 
addition O 
to O 
glucotoxicity O 
, O 
lipotoxicity O 
also O 
affects O 
incretin O 
receptor O 
expression O 
and O 
signalling O 
in O 
insulin O 
- O 
secreting O 
cells O 
and O 
isolated O 
islets O 
. O 
In O 
animal O 
models O 
of O 
diabetes O 
, O 
the O 
authors O 
show O 
that O 
co O 
- O 
administration O 
of O 
a O 
lipid O 
- O 
lowering O 
drug O 
with O 
a O 
dipeptidyl O 
peptidase-4 O 
inhibitor O 
or O 
a O 
glucagon O 
- O 
like O 
peptide-1 O 
agonist O 
improved O 
glucose B-TRIVIAL 
tolerance O 
and O 
beta O 
cell O 
mass O 
. O 
These O 
novel O 
findings O 
provide O 
convincing O 
support O 
for O 
the O 
notion O 
that O 
restoring O 
normal O 
circulating O 
lipid O 
levels O 
in O 
type O 
2 O 
diabetes O 
might O 
help O 
improve O 
the O 
efficacy O 
of O 
incretin O 
- O 
based O 
therapies O 
. O 

of O 
the O 
antiproliferative O 
activity O 
of O 
some O 
naphthalene B-SYSTEMATIC 
diimide I-SYSTEMATIC 
G-quadruplex O 
ligands O 
. O 

are O 
higher O 
- O 
order O 
nucleic O 
acid O 
structures O 
that O 
can O 
form O 
in O 
G-rich O 
telomeres O 
and O 
promoter O 
regions O 
of O 
oncogenes O 
. O 
Telomeric O 
quadruplex O 
stabilization O 
by O 
small O 
molecules O 
can O 
lead O 
to O 
telomere O 
uncapping O 
, O 
followed O 
by O 
DNA O 
damage O 
response O 
and O 
senescence O 
, O 
as O 
well O 
as O 
chromosomal O 
fusions O 
leading O 
to O 
deregulation O 
of O 
mitosis O 
, O 
followed O 
by O 
apoptosis O 
and O 
downregulation O 
of O 
oncogene O 
expression O 
. O 
We O 
report O 
here O 
on O 
investigations O 
into O 
the O 
mechanism O 
of O 
action O 
of O 
tetra O 
- O 
substituted O 
naphthalene B-SYSTEMATIC 
diimide I-SYSTEMATIC 
ligands O 
on O 
the O 
basis O 
of O 
cell O 
biologic O 
data O 
together O 
with O 
a O 
National O 
Cancer O 
Institute O 
COMPARE O 
study O 
. O 
We O 
conclude O 
that O 
four O 
principal O 
mechanisms O 
of O 
action O 
are O 
implicated O 
for O 
these O 
compounds O 
: O 
1 O 
) O 
telomere O 
uncapping O 
with O 
subsequent O 
DNA O 
damage O 
response O 
and O 
senescence O 
; O 
2 O 
) O 
inhibition O 
of O 
transcription O 
/ O 
translation O 
of O 
oncogenes O 
; O 
3 O 
) O 
genomic O 
instability O 
through O 
telomeric O 
DNA O 
end O 
fusions O 
, O 
resulting O 
in O 
mitotic O 
catastrophe O 
and O 
apoptosis O 
; O 
and O 
4 O 
) O 
induction O 
of O 
chromosomal O 
instability O 
by O 
telomere O 
aggregate O 
formation O 
. O 

- O 
degrading O 
enzyme O 
( O 
IDE O 
) O 
is O 
a O 
highly O 
conserved O 
zinc B-SYSTEMATIC 
metallopeptidase O 
that O 
is O 
ubiquitously O 
distributed O 
in O 
human O 
tissues O 
, O 
and O 
particularly O 
abundant O 
in O 
the O 
brain O 
, O 
liver O 
, O 
and O 
muscles O 
. O 
IDE O 
activity O 
has O 
been O 
historically O 
associated O 
with O 
insulin O 
and O 
β-amyloid O 
catabolism O 
. O 
However O 
, O 
over O 
the O 
last O 
decade O 
, O 
several O 
experimental O 
findings O 
have O 
established O 
that O 
IDE O 
is O 
also O 
involved O 
in O 
a O 
wide O 
variety O 
of O 
physiopathological O 
processes O 
, O 
including O 
ubiquitin O 
clearance O 
and O 
Varicella O 
Zoster O 
Virus O 
infection O 
. O 
In O 
this O 
study O 
, O 
we O 
demonstrate O 
that O 
normal O 
and O 
malignant O 
cells O 
exposed O 
to O 
different O 
stresses O 
markedly O 
up O 
- O 
regulate O 
IDE O 
in O 
a O 
heat O 
shock O 
protein O 
( O 
HSP O 
) O 
- O 
like O 
fashion O 
. O 
Additionally O 
, O 
we O 
focused O 
our O 
attention O 
on O 
tumor O 
cells O 
and O 
report O 
that O 
(i) O 
IDE O 
is O 
overexpressed O 
in O 
vivo O 
in O 
tumors O 
of O 
the O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
; O 
(ii) O 
IDE-silencing O 
inhibits O 
neuroblastoma O 
( O 
SHSY5Y O 
) O 
cell O 
proliferation O 
and O 
triggers O 
cell O 
death O 
; O 
(iii) O 
IDE O 
inhibition O 
is O 
accompanied O 
by O 
a O 
decrease O 
of O 
the O 
poly O 
- O 
ubiquitinated O 
protein O 
content O 
and O 
co O 
- O 
immunoprecipitates O 
with O 
proteasome O 
and O 
ubiquitin O 
in O 
SHSY5Y O 
cells O 
. O 
In O 
this O 
work O 
, O 
we O 
propose O 
a O 
novel O 
role O 
for O 
IDE O 
as O 
a O 
heat O 
shock O 
protein O 
with O 
implications O 
in O 
cell O 
growth O 
regulation O 
and O 
cancer O 
progression O 
, O 
thus O 
opening O 
up O 
an O 
intriguing O 
hypothesis O 
of O 
IDE O 
as O 
an O 
anticancer O 
target O 
. O 

- O 
a O 
bioactive O 
xanthonoid B-TRIVIAL 
, O 
not O 
only O 
from O 
mango O 
and O 
not O 
just O 
antioxidant O 
. O 

is O 
a O 
plant O 
natural O 
polyphenol B-FAMILY 
of O 
C-glycosylxanthone B-FAMILY 
structure O 
and O 
various O 
pharmacological O 
activities O 
. O 
It O 
can O 
be O 
found O 
in O 
many O 
plant O 
species O 
, O 
among O 
which O 
the O 
mango O 
tree O 
( O 
Mangifera O 
indica O 
) O 
is O 
one O 
of O 
the O 
primary O 
sources O 
. O 
Mangiferin B-TRIVIAL 
is O 
also O 
present O 
in O 
some O 
medicinal O 
herbs O 
, O 
influencing O 
their O 
therapeutic O 
and O 
preventive O 
properties O 
, O 
and O 
in O 
honeybush O 
( O 
Cyclopia O 
sp O 
. O 
) O 
, O 
a O 
popular O 
South O 
African O 
herbal O 
tea O 
. O 
Mangiferin O 
dissolves O 
well O 
in O 
water O 
, O 
so O 
it O 
can O 
be O 
easily O 
extracted O 
into O 
infusions O 
and O 
decoctions O 
. O 
In O 
the O 
mangiferi B-TRIVIAL 
n O 
molecule O 
, O 
four O 
aromatic B-FAMILY 
hydroxy I-FAMILY 
l O 
groups O 
determine O 
its O 
strong O 
antiradical O 
and O 
antioxidant O 
properties O 
. O 
Mangiferin O 
is O 
also O 
an O 
efficient O 
iro B-SYSTEMATIC 
n O 
chelator O 
, O 
therefore O 
preventing O 
the O 
generation O 
of O 
hydroxy B-SYSTEMATIC 
l O 
radical O 
in O 
Fenton O 
- O 
type O 
reactions O 
. O 
Numerous O 
published O 
in O 
vitro O 
and O 
in O 
vivo O 
pharmacological O 
studies O 
, O 
demonstrated O 
many O 
other O 
activities O 
of O 
mangiferi B-TRIVIAL 
n O 
: O 
analgesic O 
, O 
antidiabetic O 
, O 
antisclerotic O 
, O 
atimicrobial O 
and O 
antiviral O 
, O 
cardio- O 
, O 
hepato- O 
, O 
and O 
neuroprotective O 
, O 
antiinflammatory O 
, O 
antiallergic O 
, O 
MAO O 
inhibiting O 
and O 
memory O 
improving O 
, O 
as O 
well O 
as O 
radioprotective O 
against O 
X-ray O 
, O 
gamma O 
, O 
and O 
UV O 
radiation O 
. O 
Several O 
studies O 
indicated O 
also O 
its O 
ability O 
to O 
inhibit O 
cancerogenesis O 
and O 
cancer O 
cells O 
growth O 
by O 
apoptosis O 
induction O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
It O 
is O 
also O 
used O 
in O 
cosmetics O 
, O 
due O 
to O 
antioxidant O 
and O 
UV O 
- O 
protecting O 
properties O 
. O 

compounds O 
as O 
antioxidants O 
: O 
carbonic O 
anhydrase O 
isoenzymes O 
inhibitors O 
. O 

compounds O 
can O 
scavenge O 
free O 
radicals O 
and O 
increase O 
shelf O 
life O 
by O 
retarding O 
the O 
process O 
of O 
lipid O 
peroxidation O 
, O 
which O 
is O 
one O 
of O 
the O 
major O 
reasons O 
for O 
deterioration O 
of O 
food O 
, O 
medicine O 
and O 
pharmaceutical O 
products O 
during O 
processing O 
and O 
storage O 
. O 
An O 
antioxidant O 
molecule O 
has O 
been O 
defined O 
as O 
any O 
substance O 
when O 
found O 
in O 
low O 
concentrations O 
compared O 
to O 
that O 
of O 
an O 
oxidizable O 
substrate O 
significantly O 
delays O 
or O 
inhibits O 
the O 
oxidation O 
. O 
The O 
major O 
antioxidant O 
compounds O 
are O 
especially O 
phenolics B-FAMILY 
and O 
flavonoids B-FAMILY 
, O 
which O 
are O 
responsible O 
for O 
their O 
health O 
benefits O 
. O 
Carbonic O 
anhydrase O 
( O 
EC O 
4.2.1.1 O 
. O 
, O 
CA O 
) O 
is O 
a O 
pH O 
regulatory O 
/ O 
metabolic O 
enzyme O 
in O 
all O 
life O 
kingdoms O 
, O 
being O 
found O 
in O 
organisms O 
all O 
over O 
the O 
phylogenetic O 
tree O 
. O 
It O 
catalyzes O 
the O 
hydration O 
of O 
carbon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
CO(2) B-FORMULA 
) O 
to O 
bicarbonate B-SYSTEMATIC 
( O 
HCO(3) B-FORMULA 
- I-FORMULA 
) O 
and O 
the O 
corresponding O 
dehydration O 
of O 
HCO(3) B-FORMULA 
- I-FORMULA 
in O 
acidic O 
medium O 
with O 
regeneration O 
of O 
CO(2) B-FORMULA 
. O 
Also O 
, O 
CA O 
isoforms O 
are O 
found O 
in O 
a O 
variety O 
of O 
tissues O 
where O 
they O 
participate O 
in O 
several O 
important O 
biological O 
processes O 
such O 
as O 
acid O 
- O 
base O 
balance O 
, O 
respiration O 
, O 
carbon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
and O 
ion O 
transport O 
, O 
bone O 
resorption O 
, O 
ureagenesis O 
, O 
gluconeogenesis O 
, O 
lipogenesis O 
and O 
electrolyte O 
secretion O 
. O 
On O 
the O 
other O 
hand O 
, O 
the O 
phenyl B-SYSTEMATIC 
moiety O 
of O 
phenol B-SYSTEMATIC 
was O 
found O 
to O 
lay O 
in O 
the O 
hydrophobic O 
part O 
of O 
the O 
CA O 
active O 
site O 
, O 
where O 
CO(2) B-FORMULA 
, O 
the O 
physiologic O 
substrate O 
of O 
the O 
CAs O 
, O 
binds O 
in O 
the O 
precatalytic O 
complex O 
, O 
explaining O 
thus O 
the O 
behavior O 
of O 
phenol B-SYSTEMATIC 
as O 
a O 
unique O 
CO(2) B-FORMULA 
competitive O 
inhibitor O 
. O 
This O 
review O 
consists O 
of O 
two O 
main O 
sections O 
. O 
The O 
first O 
section O 
is O 
devoted O 
to O 
main O 
phenolic B-FAMILY 
antioxidant O 
compounds O 
in O 
the O 
foodstuffs O 
and O 
beverages O 
. O 
The O 
second O 
general O 
section O 
is O 
about O 
some O 
definitions O 
of O 
CA O 
inhibitory O 
effects O 
of O 
the O 
main O 
phenolic B-FAMILY 
compounds O 
used O 
for O 
antioxidant O 
activity O 
. O 
The O 
phenolic B-FAMILY 
compounds O 
and O 
acids O 
had O 
marked O 
especially O 
CA O 
I O 
and O 
CA O 
II O 
inhibitory O 
effects O 
and O 
might O 
be O 
used O 
as O 
leads O 
for O 
generating O 
CA O 
isoenzyme O 
inhibitors O 
. O 
This O 
class O 
of O 
compounds O 
may O 
lead O 
to O 
isoform O 
- O 
selective O 
inhibitors O 
targeting O 
just O 
one O 
or O 
few O 
of O 
the O 
medicinally O 
relevant O 
CAs O 
. O 
In O 
addition O 
, O 
there O 
are O 
given O 
some O 
chemical O 
and O 
kinetic O 
basis O 
and O 
technical O 
details O 
related O 
to O 
phenolic B-FAMILY 
antioxidant O 
compounds O 
and O 
carbonic O 
anhydrase O 
isoenzymes O 
. O 

studies O 
of O 
antioxidant O 
quinoline B-SYSTEMATIC 
derivatives O 
. O 

derivatives O 
constitute O 
an O 
important O 
class O 
of O 
compounds O 
for O 
new O 
drug O 
development O 
. O 
As O 
a O 
large O 
number O 
of O 
experimental O 
and O 
theoretical O 
studies O 
have O 
shown O 
that O 
the O 
quinoline B-SYSTEMATIC 
ring O 
system O 
is O 
an O 
important O 
structural O 
unit O 
widely O 
existing O 
in O 
alkaloids O 
, O 
therapeutics O 
and O 
synthetic O 
analogues O 
with O 
exciting O 
biological O 
activities O 
. O 
The O 
present O 
review O 
provides O 
recent O 
antioxidant O 
activities O 
covering O 
in O 
vivo O 
and O 
in O 
vitro O 
studies O 
of O 
natural O 
and O 
synthetic O 
analogues O 
, O 
as O 
well O 
as O 
the O 
proposed O 
mechanisms O 
of O 
action O 
and O 
structure O 
- O 
activity O 
relationships O 
. O 

hydrogels O 
with O 
reverse O 
thermal O 
gelation O 
properties O 
from O 
(oligo)tyrosine B-FAMILY 
containing O 
block O 
copolymers O 
. O 

block O 
copolymers O 
comprising O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
and O 
an O 
oligo(tyrosine) B-FAMILY 
block O 
were O 
synthesized O 
in O 
different O 
compositions O 
by O 
N-carboxyanhydride B-SYSTEMATIC 
( O 
NCA B-ABBREVIATION 
) O 
polymerization O 
. O 
It O 
was O 
shown O 
that O 
PEG2000-Tyr(6) B-FORMULA 
undergoes O 
thermoresponsive O 
hydrogelation O 
at O 
a O 
low O 
concentration O 
range O 
of O 
0.25-3.0 O 
wt O 
% O 
within O 
a O 
temperature O 
range O 
of O 
25-50 O 
°C O 
. O 
Cryogenic O 
transmission O 
electron O 
microscopy O 
( O 
Cryo-TEM O 
) O 
revealed O 
a O 
continuous O 
network O 
of O 
fibers O 
throughout O 
the O 
hydrogel O 
sample O 
, O 
even O 
at O 
concentrations O 
as O 
low O 
as O 
0.25 O 
wt O 
% O 
. O 
Circular O 
dichroism O 
( O 
CD O 
) O 
results O 
suggest O 
that O 
better O 
packing O 
of O 
the O 
β-sheet O 
tyrosine B-TRIVIAL 
block O 
at O 
increasing O 
temperature O 
induces O 
the O 
reverse O 
thermogelation O 
. O 
A O 
preliminary O 
assessment O 
of O 
the O 
potential O 
of O 
the O 
hydrogel O 
for O 
in O 
vitro O 
application O 
confirmed O 
the O 
hydrogel O 
is O 
not O 
cytotoxic O 
, O 
is O 
biodegradable O 
, O 
and O 
produced O 
a O 
sustained O 
release O 
of O 
a O 
small O 
- O 
molecule O 
drug O 
. O 

: O 
a O 
novel O 
major O 
in O 
vitro O 
metabolite O 
of O 
benzophenone-3 B-TRIVIAL 
formed O 
by O 
rat O 
and O 
human O 
liver O 
microsomes O 
. O 

. O 
When O 
benzophenone-3 B-TRIVIAL 
( O 
2-hydroxy-4-methoxybenzophenone B-SYSTEMATIC 
; O 
BP-3 B-ABBREVIATION 
) O 
was O 
incubated O 
with O 
liver O 
microsomes O 
of O 
untreated O 
rats O 
in O 
the O 
presence O 
of O 
NADPH B-ABBREVIATION 
, O 
the O 
5-hydroxylated O 
metabolite O 
, O 
2,5-dihydroxy-4-methoxybenzophenone B-SYSTEMATIC 
( O 
5-OH-BP-3 B-SYSTEMATIC 
) O 
, O 
was O 
formed O 
as O 
a O 
major O 
novel O 
metabolite O 
of O 
BP-3 B-ABBREVIATION 
. O 
The O 
4-desmethylated O 
metabolite O 
, O 
2,4-dihydroxybenzophenone B-SYSTEMATIC 
( O 
2,4-diOH-BP B-SYSTEMATIC 
) O 
, O 
previously O 
reported O 
as O 
the O 
major O 
in O 
vivo O 
metabolite O 
of O 
BP-3 B-ABBREVIATION 
, O 
was O 
also O 
detected O 
. O 
However O 
, O 
the O 
amount O 
of O 
5-OH-BP-3 B-SYSTEMATIC 
formed O 
in O 
vitro O 
was O 
about O 
the O 
same O 
as O 
that O 
of O 
2,4-diOH-BP B-SYSTEMATIC 
. O 
2 O 
. O 
The O 
oxidase O 
activity O 
affording O 
5-OH-BP-3 B-SYSTEMATIC 
was O 
inhibited O 
by O 
SKF B-IDENTIFIER 
525-A I-IDENTIFIER 
and O 
ketoconazole B-TRIVIAL 
, O 
and O 
partly O 
by O 
quinidine B-TRIVIAL 
and O 
sulfaphenazole B-TRIVIAL 
. O 
The O 
oxidase O 
activity O 
affording O 
2,4-diOH-BP B-SYSTEMATIC 
was O 
inhibited O 
by O 
SKF B-IDENTIFIER 
525-A I-IDENTIFIER 
, O 
ketoconazole B-TRIVIAL 
and O 
α-naphthoflavone B-TRIVIAL 
, O 
and O 
partly O 
by O 
sulfaphenazole B-TRIVIAL 
. O 
3 O 
. O 
The O 
oxidase O 
activity O 
affording O 
5-OH-BP-3 B-SYSTEMATIC 
was O 
enhanced O 
in O 
liver O 
microsomes O 
of O 
dexamethasone B-TRIVIAL 
- O 
, O 
phenobarbital B-TRIVIAL 
- O 
and O 
3-methylcholanthrene B-SYSTEMATIC 
-treated O 
rats O 
. O 
The O 
activity O 
affording O 
2,4-diOH-BP B-SYSTEMATIC 
was O 
enhanced O 
in O 
liver O 
microsomes O 
of O 
3-methylcholanthrene B-SYSTEMATIC 
- O 
and O 
phenobarbital B-TRIVIAL 
-treated O 
rats O 
. O 
4 O 
. O 
When O 
examined O 
recombinant O 
rat O 
cytochrome O 
P450 O 
isoforms O 
catalyzing O 
the O 
metabolism O 
of O 
BP-3 B-ABBREVIATION 
, O 
5-hydroxylation O 
was O 
catalyzed O 
by O 
P450 O 
3A2 O 
, O 
1A1 O 
, O 
2B1 O 
, O 
2C6 O 
and O 
2D1 O 
, O 
while O 
4-desmethylation O 
was O 
catalyzed O 
by O 
P450 O 
2C6 O 
and O 
1A1 O 
. O 

inhibitory O 
polypeptide O 
( O 
GIP O 
) O 
is O 
an O 
incretin O 
released O 
from O 
enteroendocrine O 
K-cells O 
in O 
response O 
to O 
nutrient O 
ingestion O 
. O 
GIP O 
potentiates O 
glucose B-TRIVIAL 
-stimulated O 
insulin O 
secretion O 
and O 
induces O 
energy O 
accumulation O 
into O 
adipose O 
tissue O 
, O 
resulting O 
in O 
obesity O 
. O 
Plasma O 
GIP O 
levels O 
are O 
reported O 
to O 
be O 
increased O 
in O 
the O 
obese O 
state O 
. O 
However O 
, O 
the O 
molecular O 
mechanisms O 
of O 
GIP O 
secretion O 
and O 
high O 
fat O 
diet O 
(HFD)-induced O 
GIP O 
hypersecretion O 
remain O 
unclear O 
, O 
primarily O 
due O 
to O 
difficulties O 
in O 
separating O 
K-cells O 
from O 
other O 
intestinal O 
epithelial O 
cells O 
in O 
vivo O 
. O 
In O 
this O 
study O 
, O 
GIP-GFP O 
knock O 
- O 
in O 
mice O 
that O 
enable O 
us O 
to O 
visualize O 
K-cells O 
by O 
enhanced O 
GFP O 
were O 
established O 
. O 
Microarray O 
analysis O 
of O 
isolated O 
K-cells O 
from O 
these O 
mice O 
revealed O 
that O 
transcriptional O 
regulatory O 
factor O 
X6 O 
( O 
Rfx6 O 
) O 
is O 
expressed O 
exclusively O 
in O 
K-cells O 
. O 
In O 
vitro O 
experiments O 
using O 
the O 
mouse O 
intestinal O 
cell O 
line O 
STC-1 O 
showed O 
that O 
knockdown O 
of O 
Rfx6 O 
decreased O 
mRNA O 
expression O 
, O 
cellular O 
content O 
, O 
and O 
secretion O 
of O 
GIP O 
. O 
Rfx6 O 
bound O 
to O 
the O 
region O 
in O 
the O 
gip O 
promoter O 
that O 
regulates O 
gip O 
promoter O 
activity O 
, O 
and O 
overexpression O 
of O 
Rfx6 O 
increased O 
GIP O 
mRNA O 
expression O 
. O 
HFD O 
induced O 
obesity O 
and O 
GIP O 
hypersecretion O 
in O 
GIP-GFP O 
heterozygous O 
mice O 
in O 
vivo O 
. O 
Immunohistochemical O 
and O 
flow O 
cytometry O 
analysis O 
showed O 
no O 
significant O 
difference O 
in O 
K-cell O 
number O 
between O 
control O 
fat O 
diet O 
- O 
fed O 
( O 
CFD O 
) O 
and O 
HFD-fed O 
mice O 
. O 
However O 
, O 
GIP O 
content O 
in O 
the O 
upper O 
small O 
intestine O 
and O 
GIP O 
mRNA O 
expression O 
in O 
K-cells O 
were O 
significantly O 
increased O 
in O 
HFD-fed O 
mice O 
compared O 
with O 
those O 
in O 
CFD-fed O 
mice O 
. O 
Furthermore O 
, O 
expression O 
levels O 
of O 
Rfx6 O 
mRNA O 
were O 
increased O 
in O 
K-cells O 
of O 
HFD-fed O 
mice O 
. O 
These O 
results O 
suggest O 
that O 
Rfx6 O 
increases O 
GIP O 
expression O 
and O 
content O 
in O 
K-cells O 
and O 
is O 
involved O 
in O 
GIP O 
hypersecretion O 
in O 
HFD-induced O 
obesity O 
. O 

crystal O 
structure O 
of O 
the O 
protein- O 
disulfide B-SYSTEMATIC 
isomerase O 
family O 
member O 
ERp27 O 
provides O 
insights O 
into O 
its O 
substrate O 
binding O 
capabilities O 
. O 

one O 
- O 
third O 
of O 
all O 
cellular O 
proteins O 
pass O 
through O 
the O 
secretory O 
pathway O 
and O 
hence O 
undergo O 
oxidative O 
folding O 
in O 
the O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
. O 
Protein- O 
disulfide B-SYSTEMATIC 
isomerase O 
( O 
PDI O 
) O 
and O 
related O 
members O 
of O 
the O 
PDI O 
family O 
assist O 
in O 
the O 
folding O 
of O 
substrates O 
by O 
catalyzing O 
the O 
oxidation O 
of O 
two O 
cysteines B-FAMILY 
and O 
isomerization O 
of O 
disulfide B-SYSTEMATIC 
bonds O 
as O 
well O 
as O 
by O 
acting O 
as O 
chaperones O 
. O 
In O 
this O 
study O 
, O 
we O 
present O 
the O 
crystal O 
structure O 
of O 
ERp27 O 
, O 
a O 
redox O 
- O 
inactive O 
member O 
of O 
the O 
PDI O 
family O 
. O 
The O 
structure O 
reveals O 
its O 
substrate O 
- O 
binding O 
cleft O 
, O 
which O 
is O 
homologous O 
to O 
PDI O 
, O 
but O 
is O 
able O 
to O 
adapt O 
in O 
size O 
and O 
hydrophobicity O 
. O 
Isothermal O 
titration O 
calorimetry O 
experiments O 
demonstrate O 
that O 
ERp27 O 
is O 
able O 
to O 
distinguish O 
between O 
folded O 
and O 
unfolded O 
substrates O 
, O 
only O 
interacting O 
with O 
the O 
latter O 
. O 
ERp27 O 
is O 
up O 
- O 
regulated O 
during O 
ER O 
stress O 
, O 
thus O 
presumably O 
allowing O 
it O 
to O 
bind O 
accumulating O 
misfolded O 
substrates O 
and O 
present O 
them O 
to O 
ERp57 O 
for O 
catalysis O 
. O 

adhesion O 
during O 
inflammation O 
is O 
initiated O 
by O 
the O 
binding O 
of O 
sialofucosylated O 
carbohydrates B-FAMILY 
expressed O 
on O 
leukocytes O 
to O 
endothelial O 
E O 
/ O 
P-selectin O 
. O 
Although O 
the O 
glycosyltransferases O 
( O 
glycoTs O 
) O 
constructing O 
selectin O 
- O 
ligands O 
have O 
largely O 
been O 
identified O 
using O 
knock O 
- O 
out O 
mice O 
, O 
important O 
differences O 
may O 
exist O 
between O 
humans O 
and O 
mice O 
. O 
To O 
address O 
this O 
, O 
we O 
developed O 
a O 
systematic O 
lentivirus O 
- O 
based O 
shRNA O 
delivery O 
workflow O 
to O 
create O 
human O 
leukocytic O 
HL-60 O 
cell O 
lines O 
that O 
lack O 
up O 
to O 
three O 
glycoTs O 
. O 
Using O 
this O 
, O 
the O 
contributions O 
of O 
all O 
three O 
myeloid O 
α1,3-fucosyltransferases O 
( O 
FUT4 O 
, O 
FUT7 O 
, O 
and O 
FUT9 O 
) O 
to O 
selectin O 
- O 
ligand O 
biosynthesis O 
were O 
evaluated O 
. O 
The O 
cell O 
adhesion O 
properties O 
of O 
these O 
modified O 
cells O 
to O 
L- O 
, O 
E- O 
, O 
and O 
P-selectin O 
under O 
hydrodynamic O 
shear O 
were O 
compared O 
with O 
bone O 
marrow O 
- O 
derived O 
neutrophils O 
from O 
Fut4(- O 
/ O 
-)Fut7(- O 
/ O 
- O 
) O 
dual O 
knock O 
- O 
out O 
mice O 
. O 
Results O 
demonstrate O 
that O 
predominantly O 
FUT7 O 
, O 
and O 
to O 
a O 
lesser O 
extent O 
FUT4 O 
, O 
forms O 
the O 
selectin O 
- O 
ligand O 
at O 
the O 
N B-FORMULA 
terminus O 
of O 
leukocyte O 
P-selectin O 
glycoprotein O 
ligand-1 O 
( O 
PSGL-1 O 
) O 
in O 
humans O 
and O 
mice O 
. O 
Here O 
, O 
85% O 
reduction O 
in O 
leukocyte O 
interaction O 
was O 
observed O 
in O 
human O 
FUT4(-)7(-) O 
dual O 
knockdowns O 
on O 
P O 
/ O 
L-selectin O 
substrates O 
. O 
Unlike O 
Fut4(- O 
/ O 
-)Fut7(- O 
/ O 
- O 
) O 
mouse O 
neutrophils O 
, O 
however O 
, O 
human O 
knockdowns O 
lacking O 
FUT4 O 
and O 
FUT7 O 
only O 
exhibited O 
partial O 
reduction O 
in O 
rolling O 
interaction O 
on O 
E-selectin O 
. O 
In O 
this O 
case O 
, O 
the O 
third O 
α1,3-fucosyltransferase O 
FUT9 O 
played O 
an O 
important O 
role O 
because O 
leukocyte O 
adhesion O 
was O 
reduced O 
by O 
50-60% O 
in O 
FUT9-HL-60 O 
, O 
70-80% O 
in O 
dual O 
knockdown O 
FUT7(-)9(-) O 
cells O 
, O 
and O 
∼85% O 
in O 
FUT4(-)7(-)9(-) O 
triple O 
knockdowns O 
. O 
Gene O 
silencing O 
results O 
are O 
in O 
agreement O 
with O 
gain O 
- O 
of O 
- O 
function O 
experiments O 
where O 
all O 
three O 
fucosyltransferases O 
conferred O 
E-selectin- O 
mediated O 
rolling O 
in O 
HEK293T O 
cells O 
. O 
This O 
study O 
advances O 
new O 
tools O 
to O 
study O 
human O 
glycoT O 
function O 
. O 
It O 
suggests O 
a O 
species O 
- O 
specific O 
role O 
for O 
FUT9 O 
during O 
the O 
biosynthesis O 
of O 
human O 
E-selectin O 
ligands O 
. O 

asymmetric O 
synthesis O 
: O 
β-amino B-FAMILY 
alcohol I-FAMILY 
-catalyzed O 
direct O 
asymmetric O 
aldol B-FAMILY 
reactions O 
in O 
aqueous O 
micelles O 
. O 

ability O 
of O 
chiral B-FAMILY 
β-amino I-FAMILY 
alcohols I-FAMILY 
to O 
catalyze O 
the O 
direct O 
asymmetric O 
aldol B-FAMILY 
reaction O 
was O 
evaluated O 
for O 
the O 
first O 
time O 
in O 
aqueous O 
micellar O 
media O 
. O 
A O 
family O 
of O 
cheap O 
and O 
easily O 
accessible O 
β-amino B-FAMILY 
alcohols I-FAMILY 
, O 
obtained O 
in O 
one O 
step O 
from O 
naturally O 
occurring O 
amino B-FAMILY 
acids I-FAMILY 
, O 
was O 
shown O 
to O 
successfully O 
catalyze O 
the O 
asymmetric O 
aldol B-FAMILY 
reaction O 
between O 
a O 
series O 
of O 
ketones B-FAMILY 
and O 
aromatic B-FAMILY 
aldehydes I-FAMILY 
. O 
These O 
aldol B-FAMILY 
reactions O 
furnished O 
the O 
corresponding O 
β-hydroxy B-FAMILY 
ketones I-FAMILY 
with O 
up O 
to O 
93% O 
isolated O 
yield O 
and O 
89% O 
ee O 
. O 
(S)-2-phenylglycinol B-SYSTEMATIC 
and O 
Triton B-TRIVIAL 
X-100 I-TRIVIAL 
proved O 
to O 
be O 
the O 
best O 
organocatalyst O 
and O 
surfactant O 
, O 
respectively O 
. O 

, O 
physical O 
exercise O 
and O 
Orlistat B-TRIVIAL 
administration O 
increase O 
serum O 
Anti-Müllerian O 
Hormone O 
( O 
AMH O 
) O 
levels O 
in O 
women O 
with O 
polycystic O 
ovary O 
syndrome O 
( O 
PCOS O 
) O 
. O 

present O 
study O 
investigates O 
the O 
combined O 
effect O 
of O 
diet O 
, O 
physical O 
exercise O 
and O 
Orlistat B-TRIVIAL 
for O 
24 O 
weeks O 
, O 
on O 
serum O 
Anti-Müllerian O 
Hormone O 
( O 
AMH O 
) O 
levels O 
in O 
overweight O 
and O 
obese O 
women O 
with O 
polycystic O 
ovary O 
syndrome O 
( O 
PCOS O 
) O 
and O 
in O 
overweight O 
and O 
obese O 
controls O 
. O 
Sixty O 
- O 
one O 
( O 
61 O 
) O 
selected O 
women O 
with O 
PCOS O 
and O 
20 O 
overweight O 
and O 
obese O 
controls O 
followed O 
an O 
energy O 
- O 
restricted O 
diet O 
, O 
physical O 
exercise O 
plus O 
Orlistat B-TRIVIAL 
administration O 
( O 
120 O 
mg O 
, O 
3 O 
times O 
per O 
day O 
) O 
for O 
24 O 
weeks O 
. O 
At O 
baseline O 
, O 
week O 
12 O 
and O 
week O 
24 O 
, O 
serum O 
levels O 
of O 
AMH O 
, O 
FSH O 
, O 
LH O 
, O 
PRL O 
, O 
androgens B-FAMILY 
, O 
sex O 
hormone O 
- O 
binding O 
globulin O 
( O 
SHBG O 
) O 
, O 
glucose B-TRIVIAL 
, O 
and O 
insulin O 
were O 
measured O 
and O 
Free O 
Androgen B-FAMILY 
Index O 
( O 
FAI O 
) O 
and O 
Insulin O 
Resistance O 
( O 
IR O 
) O 
indices O 
were O 
calculated O 
. O 
In O 
PCOS O 
women O 
, O 
serum O 
AMH O 
levels O 
increased O 
after O 
12 O 
and O 
24 O 
weeks O 
of O 
treatment O 
. O 
After O 
12 O 
weeks O 
LH O 
and O 
SHBG O 
were O 
increased O 
, O 
while O 
Testosterone B-TRIVIAL 
decreased O 
. O 
After O 
12 O 
and O 
24 O 
weeks O 
, O 
FAI O 
was O 
decreased O 
and O 
all O 
indices O 
of O 
IR O 
were O 
significantly O 
improved O 
. O 
We O 
concluded O 
that O 
in O 
overweight O 
and O 
obese O 
women O 
with O 
PCOS O 
Orlistat B-TRIVIAL 
administration O 
, O 
combined O 
with O 
diet O 
and O 
physical O 
exercise O 
, O 
for O 
24 O 
weeks O 
, O 
resulted O 
in O 
significant O 
weight O 
loss O 
, O 
improvement O 
of O 
hyperandrogenism O 
and O 
insulin O 
sensitivity O 
, O 
and O 
increased O 
serum O 
AMH O 
levels O 
. O 

of O 
cartilage O 
defect O 
remains O 
a O 
challenge O 
, O 
as O 
the O 
current O 
treatments O 
are O 
ineffective O 
to O 
return O 
tissue O 
to O 
its O 
health O 
. O 
Thus O 
, O 
developing O 
therapies O 
for O 
treatment O 
of O 
cartilage O 
tissue O 
damage O 
caused O 
by O 
common O 
joint O 
diseases O 
including O 
osteoarthritis O 
, O 
rheumatoid O 
arthritis O 
, O 
and O 
accidents O 
is O 
crucial O 
. O 
Sulfated O 
glycosaminoglycan O 
molecules O 
are O 
vital O 
constituents O 
of O 
both O 
developing O 
and O 
mature O 
cartilage O 
extracellular O 
matrix O 
. O 
The O 
interplay O 
between O 
regulator O 
proteins O 
and O 
glycosaminoglycan O 
molecules O 
has O 
an O 
essential O 
role O 
in O 
coordinating O 
differentiation O 
, O 
expansion O 
, O 
and O 
patterning O 
during O 
cartilage O 
development O 
. O 
In O 
this O 
study O 
, O 
we O 
exploited O 
the O 
functional O 
role O 
of O 
an O 
extracellular O 
matrix O 
on O 
chondrogenic O 
differentiation O 
by O 
imitating O 
extracellular O 
matrix O 
both O 
chemically O 
by O 
imparting O 
functional O 
groups O 
of O 
native O 
glycosaminoglycans O 
and O 
structurally O 
through O 
peptide O 
nanofiber O 
network O 
. O 
For O 
this O 
purpose O 
, O 
sulfonate B-SYSTEMATIC 
, O 
carboxylate B-SYSTEMATIC 
, O 
and O 
hydroxyl B-SYSTEMATIC 
groups O 
were O 
incorporated O 
on O 
self O 
- O 
assembled O 
peptide O 
nanofibers O 
. O 
We O 
observed O 
that O 
when O 
ATDC5 O 
cells O 
were O 
cultured O 
on O 
functional O 
peptide O 
nanofibers O 
, O 
they O 
rapidly O 
aggregated O 
in O 
insulin O 
- O 
free O 
medium O 
and O 
formed O 
cartilage O 
- O 
like O 
nodules O 
and O 
deposited O 
sulfated O 
glycosaminoglycans O 
shown O 
by O 
Safranin-O B-TRIVIAL 
staining O 
. O 
Moreover O 
, O 
collagen O 
II O 
and O 
aggrecan O 
gene O 
expressions O 
revealed O 
by O 
qRT-PCR O 
were O 
significantly O 
enhanced O 
, O 
which O 
indicated O 
the O 
remarkable O 
bioactive O 
role O 
of O 
this O 
nanofiber O 
system O 
on O 
chondrogenic O 
differentiation O 
. O 
Overall O 
, O 
these O 
results O 
show O 
that O 
glycosaminoglycan O 
mimetic O 
peptide O 
nanofiber O 
system O 
provides O 
a O 
promising O 
platform O 
for O 
cartilage O 
regeneration O 
. O 

engineering O 
the O 
edge O 
termination O 
of O 
graphene B-TRIVIAL 
nanoribbons O 
. O 

edges O 
of O 
graphene B-TRIVIAL 
nanoribbons O 
( O 
GNRs O 
) O 
have O 
attracted O 
much O 
interest O 
due O 
to O 
their O 
potentially O 
strong O 
influence O 
on O 
GNR O 
electronic O 
and O 
magnetic O 
properties O 
. O 
Here O 
we O 
report O 
the O 
ability O 
to O 
engineer O 
the O 
microscopic O 
edge O 
termination O 
of O 
high O 
- O 
quality O 
GNRs O 
via O 
hydrogen B-SYSTEMATIC 
plasma O 
etching O 
. O 
Using O 
a O 
combination O 
of O 
high O 
- O 
resolution O 
scanning O 
tunneling O 
microscopy O 
and O 
first O 
- O 
principles O 
calculations O 
, O 
we O 
have O 
determined O 
the O 
exact O 
atomic O 
structure O 
of O 
plasma O 
- O 
etched O 
GNR O 
edges O 
and O 
established O 
the O 
chemical O 
nature O 
of O 
terminating O 
functional O 
groups O 
for O 
zigzag O 
, O 
armchair O 
, O 
and O 
chiral O 
edge O 
orientations O 
. O 
We O 
find O 
that O 
the O 
edges O 
of O 
hydrogen B-SYSTEMATIC 
-plasma O 
- O 
etched O 
GNRs O 
are O 
generally O 
flat O 
, O 
free O 
of O 
structural O 
reconstructions O 
, O 
and O 
terminated O 
by O 
hydrogen B-SYSTEMATIC 
atoms O 
with O 
no O 
rehybridization O 
of O 
the O 
outermost O 
carbon B-SYSTEMATIC 
edge O 
atoms O 
. O 
Both O 
zigzag O 
and O 
chiral O 
edges O 
show O 
the O 
presence O 
of O 
edge O 
states O 
. O 

feeding O 
is O 
a O 
critical O 
issue O 
in O 
the O 
over O 
- O 
consumption O 
of O 
calories O 
leading O 
to O 
human O 
obesity O 
. O 
To O 
investigate O 
the O 
mechanisms O 
involved O 
in O 
the O 
regulation O 
of O 
meal O 
feeding O 
in O 
rodents O 
, O 
we O 
studied O 
a O 
scheduled O 
feeding O 
regime O 
that O 
induces O 
substantial O 
food O 
intake O 
over O 
short O 
periods O 
of O 
time O 
. O 
Male O 
Sprague-Dawley O 
rats O 
and O 
C57BL6 O 
mice O 
were O 
fed O 
one O 
of O 
four O 
palatable O 
diets O 
[ O 
45% O 
fat O 
pellet O 
, O 
60% O 
fat O 
pellet O 
or O 
standard O 
pellet O 
supplemented O 
with O 
Ensure O 
( O 
EN O 
; O 
Abbott O 
Laboratories O 
, O 
Maidenhead O 
, O 
UK O 
) O 
or O 
12.5% O 
sucrose O 
( O 
SUC O 
) O 
] O 
either O 
ad O 
lib O 
. O 
or O 
with O 
daily O 
2-h O 
scheduled O 
access O 
and O 
standard O 
pellet O 
available O 
for O 
22 O 
h O 
. O 
Energy O 
balance O 
gene O 
expression O 
in O 
the O 
hypothalamic O 
arcuate O 
nucleus O 
( O 
ARC O 
) O 
and O 
nucleus O 
accumbens O 
( O 
NAcc O 
) O 
reward O 
gene O 
expression O 
were O 
assessed O 
by O 
in O 
situ O 
hybridisation O 
. O 
Rats O 
fed O 
ad O 
lib O 
. O 
on O 
45% O 
or O 
60% O 
fat O 
diet O 
were O 
heavier O 
and O 
fatter O 
than O 
controls O 
, O 
and O 
had O 
reduced O 
neuropeptide O 
Y O 
( O 
NPY O 
) O 
gene O 
expression O 
in O 
the O 
ARC O 
. O 
Mice O 
fed O 
ad O 
lib O 
. O 
on O 
any O 
of O 
the O 
palatable O 
diets O 
were O 
heavier O 
, O 
fatter O 
and O 
had O 
higher O 
blood O 
leptin O 
than O 
controls O 
, O 
and O 
had O 
reduced O 
NPY O 
and O 
increased O 
cocaine B-TRIVIAL 
- O 
and- O 
amphetamine B-TRIVIAL 
-regulated O 
transcript O 
mRNA O 
in O 
the O 
ARC O 
. O 
Schedule O 
- O 
fed O 
rats O 
and O 
mice O 
quickly O 
adapted O 
their O 
feeding O 
behaviour O 
to O 
2-h O 
access O 
on O 
palatable O 
food O 
. O 
Three O 
schedule O 
- O 
fed O 
groups O 
binged O 
: O 
the O 
percentage O 
of O 
daily O 
calories O 
consumed O 
in O 
2 O 
h O 
on O 
45% O 
fat O 
diet O 
, O 
60% O 
fat O 
diet O 
or O 
EN O 
, O 
respectively O 
, O 
was O 
55% O 
, O 
63% O 
and O 
49% O 
in O 
rats O 
, O 
and O 
86% O 
, O 
86% O 
and O 
45% O 
in O 
mice O 
. O 
However O 
, O 
changed O 
feeding O 
behaviour O 
was O 
not O 
reflected O 
in O 
an O 
induction O 
of O 
orexigenic O 
neuropeptide O 
or O 
suppression O 
of O 
anorexigenic O 
neuropeptide O 
gene O 
expression O 
in O 
the O 
ARC O 
, O 
in O 
the O 
2-h O 
period O 
prior O 
to O 
scheduled O 
feeding O 
. O 
The O 
mechanisms O 
underlying O 
large O 
meal O 
/ O 
binge O 
- O 
type O 
eating O 
may O 
be O 
regulated O 
by O 
nonhomeostatic O 
processes O 
involving O 
other O 
genes O 
in O 
the O 
hypothalamus O 
or O 
other O 
brain O 
areas O 
. O 
However O 
, O 
assessment O 
of O 
opioid O 
and O 
dopamine B-TRIVIAL 
receptor O 
gene O 
expression O 
in O 
the O 
NAcc O 
did O 
not O 
reveal O 
evidence O 
of O 
the O 
involvement O 
of O 
these O 
genes O 
in O 
driving O 
large O 
meals O 
, O 
at O 
least O 
at O 
the O 
investigated O 
time O 
point O 
. O 

allergen O 
Ara O 
h O 
6 O 
was O 
isolated O 
and O 
irradiated O 
at O 
1 O 
, O 
3 O 
, O 
5 O 
, O 
or O 
10 O 
kGy O 
, O 
and O 
a O 
whole O 
peanut O 
protein O 
extract O 
( O 
WPPE O 
) O 
was O 
also O 
treated O 
by O 
irradiation O 
. O 
Alteration O 
in O 
structure O 
of O 
Ara O 
h O 
6 O 
was O 
characterised O 
by O 
circular O 
dichroism O 
( O 
CD O 
) O 
spectroscopy O 
, O 
ultraviolet O 
( O 
UV O 
) O 
absorption O 
spectroscopy O 
, O 
fluorescence O 
spectroscopy O 
and O 
SDS B-ABBREVIATION 
-PAGE O 
, O 
and O 
antigenicity O 
was O 
evaluated O 
by O 
immunoblotting O 
and O 
indirect O 
ELISA O 
with O 
anti-Ara O 
h O 
6 O 
polyclonal O 
antibody O 
. O 
Irradiation O 
induced O 
significant O 
changes O 
in O 
the O 
secondary O 
and O 
tertiary O 
structures O 
of O 
Ara O 
h O 
6 O 
, O 
and O 
the O 
antigenicity O 
of O 
both O 
purified O 
Ara O 
h O 
6 O 
and O 
WPPE O 
were O 
reduced O 
upon O 
increasing O 
the O 
irradiation O 
doses O 
. O 
Moreover O 
, O 
a O 
good O 
correlation O 
between O 
the O 
loss O 
in O 
α-helix O 
and O 
IgG O 
binding O 
to O 
Ara O 
h O 
6 O 
was O 
observed O 
. O 
This O 
indicated O 
that O 
irradiation O 
might O 
be O 
an O 
efficient O 
approach O 
to O 
reduce O 
or O 
eliminate O 
peanut O 
allergenicity O 
. O 

of O 
total O 
polyphenols B-FAMILY 
in O 
wines O 
by O 
FIA O 
with O 
highly O 
stable O 
amperometric O 
detection O 
using O 
carbon B-SYSTEMATIC 
nanotube O 
- O 
modified O 
electrodes O 
. O 

use O 
of O 
glassy O 
carbon B-SYSTEMATIC 
electrodes O 
( O 
GCEs O 
) O 
modified O 
with O 
multi O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
( O 
CNT O 
) O 
films O 
for O 
the O 
continuous O 
monitoring O 
of O 
polyphenols B-FAMILY 
in O 
flow O 
systems O 
has O 
been O 
examined O 
. O 
The O 
performance O 
of O 
these O 
modified O 
electrodes O 
was O 
evaluated O 
and O 
compared O 
to O 
bare O 
GCE O 
by O 
cyclic O 
voltammetry O 
experiments O 
and O 
by O 
flow O 
injection O 
analysis O 
( O 
FIA O 
) O 
with O 
amperometric O 
detection O 
monitoring O 
the O 
response O 
of O 
gallic B-MULTIPLE 
, I-MULTIPLE 
caffeic I-MULTIPLE 
, I-MULTIPLE 
ferulic I-MULTIPLE 
and I-MULTIPLE 
p-coumaric I-MULTIPLE 
acids I-MULTIPLE 
in O 
0.05 O 
M O 
acetate B-SYSTEMATIC 
buffer O 
pH O 
4.5 O 
containing O 
100 O 
mM O 
NaCl B-FORMULA 
. O 
The O 
GCE O 
modified O 
with O 
CNT O 
dispersions O 
in O 
polyethyleneimine B-SYSTEMATIC 
( O 
PEI B-ABBREVIATION 
) O 
provided O 
lower O 
overpotentials O 
, O 
higher O 
sensitivity O 
and O 
much O 
higher O 
signal O 
stability O 
under O 
a O 
dynamic O 
regime O 
than O 
bare O 
GCEs O 
. O 
These O 
properties O 
allowed O 
the O 
estimation O 
of O 
the O 
total O 
polyphenol B-FAMILY 
content O 
in O 
red O 
and O 
white O 
wines O 
with O 
a O 
remarkable O 
long O 
- O 
term O 
stability O 
in O 
the O 
measurements O 
despite O 
the O 
presence O 
of O 
potential O 
fouling O 
substances O 
in O 
the O 
wine O 
matrix O 
. O 
In O 
addition O 
, O 
the O 
versatility O 
of O 
the O 
electrochemical O 
methodology O 
allowed O 
the O 
selective O 
estimation O 
of O 
the O 
easily O 
oxidisable O 
polyphenol B-FAMILY 
fraction O 
as O 
well O 
as O 
the O 
total O 
polyphenol B-FAMILY 
content O 
just O 
by O 
tuning O 
the O 
detection O 
potential O 
at O 
+ O 
0.3 O 
or O 
0.7 O 
V O 
, O 
respectively O 
. O 
The O 
significance O 
of O 
the O 
electrochemical O 
results O 
was O 
demonstrated O 
through O 
correlation O 
studies O 
with O 
the O 
results O 
obtained O 
with O 
conventional O 
spectrophotometric O 
assays O 
for O 
polyphenols B-FAMILY 
( O 
Folin-Ciocalteu O 
, O 
absorbance O 
at O 
280 O 
nm O 
index O 
and O 
colour O 
intensity O 
index O 
) O 
. O 

enzymatic O 
hydrolysis O 
of O 
β-lactoglobulin O 
and O 
the O 
fractionation O 
of O 
peptides O 
were O 
performed O 
in O 
one O 
step O 
in O 
an O 
electrodialysis O 
cell O 
with O 
ultrafiltration O 
membranes O 
stacked O 
. O 
After O 
240 O 
min O 
of O 
treatment O 
, O 
15 O 
anionic O 
and O 
4 O 
cationic O 
peptides O 
were O 
detected O 
in O 
the O 
anionic O 
and O 
cationic O 
peptide O 
recovery O 
compartments O 
. O 
Amongst O 
these O 
15 O 
anionic O 
peptides O 
, O 
2 O 
hypocholesterolemic O 
, O 
3 O 
antihypertensive O 
and O 
1 O 
antibacterial O 
peptides O 
were O 
recovered O 
and O 
concentrated O 
with O 
migration O 
rates O 
ranging O 
from O 
5.5% O 
and O 
81.7% O 
. O 
Amongst O 
the O 
4 O 
cationic O 
peptides O 
, O 
the O 
peptide O 
sequence O 
ALPMHIR O 
, O 
identified O 
as O 
lactokinin B-TRIVIAL 
and O 
known O 
to O 
exert O 
an O 
important O 
antihypertensive O 
effect O 
, O 
was O 
recovered O 
with O 
an O 
estimated O 
66% O 
migration O 
rate O 
. O 
To O 
our O 
knowledge O 
, O 
it O 
was O 
the O 
first O 
attempt O 
to O 
perform O 
hydrolysis O 
under O 
an O 
electric O 
field O 
and O 
to O 
simultaneously O 
separate O 
anionic O 
and O 
cationic O 
peptides O 
produced O 
. O 

heat O 
treatment O 
and O 
the O 
gelation O 
are O 
strong O 
determinants O 
of O 
the O 
kinetics O 
of O 
milk O 
proteins O 
digestion O 
and O 
of O 
the O 
peripheral O 
availability O 
of O 
amino B-FAMILY 
acids I-FAMILY 
. O 

study O 
aimed O 
to O 
determine O 
the O 
kinetics O 
of O 
milk O 
protein O 
digestion O 
and O 
amino B-FAMILY 
acid I-FAMILY 
absorption O 
after O 
ingestion O 
of O 
four O 
dairy O 
matrices O 
by O 
six O 
minipigs O 
: O 
unheated O 
or O 
heated O 
skim O 
milk O 
and O 
corresponding O 
rennet O 
gels O 
. O 
Digestive O 
contents O 
and O 
plasma O 
samples O 
were O 
collected O 
over O 
a O 
7 O 
h-period O 
after O 
meal O 
ingestion O 
. O 
Gelation O 
of O 
milk O 
slowed O 
down O 
the O 
outflow O 
of O 
the O 
meal O 
from O 
the O 
stomach O 
and O 
the O 
subsequent O 
absorption O 
of O 
amino B-FAMILY 
acids I-FAMILY 
, O 
and O 
decreased O 
their O 
bioavailability O 
in O 
peripheral O 
blood O 
. O 
The O 
gelled O 
rennet O 
matrices O 
also O 
led O 
to O 
low O 
levels O 
of O 
milk O 
proteins O 
at O 
the O 
duodenum O 
. O 
Caseins O 
and O 
β-lactoglobulin O 
, O 
respectively O 
, O 
were O 
sensitive O 
and O 
resistant O 
to O 
hydrolysis O 
in O 
the O 
stomach O 
with O 
the O 
unheated O 
matrices O 
, O 
but O 
showed O 
similar O 
digestion O 
with O 
the O 
heated O 
matrices O 
, O 
with O 
a O 
heat O 
- O 
induced O 
susceptibility O 
to O 
hydrolysis O 
for O 
β-lactoglobulin O 
. O 
These O 
results O 
suggest O 
a O 
significant O 
influence O 
of O 
the O 
meal O 
microstructure O 
( O 
resulting O 
from O 
heat O 
treatment O 
) O 
and O 
macrostructure O 
( O 
resulting O 
from O 
gelation O 
process O 
) O 
on O 
the O 
different O 
steps O 
of O 
milk O 
proteins O 
digestion O 
. O 

presence O 
of O 
D-fagomine B-TRIVIAL 
in O 
the O 
human O 
diet O 
from O 
buckwheat O 
- O 
based O 
foodstuffs O 
. O 

( O 
Fagopyrum O 
esculentum O 
Moench O 
) O 
groats O 
contain O 
the O 
iminosugar O 
D-fagomine B-TRIVIAL 
as O 
a O 
minor O 
component O 
that O 
might O 
contribute O 
to O 
the O 
alleged O 
health O 
benefits O 
of O 
this O 
pseudo O 
- O 
cereal O 
. O 
This O 
study O 
presents O 
analysis O 
of O 
D-fagomine B-TRIVIAL 
in O 
buckwheat O 
- O 
based O 
foodstuffs O 
by O 
liquid O 
chromatography O 
coupled O 
to O 
mass O 
spectrometry O 
and O 
an O 
estimation O 
of O 
its O 
presence O 
in O 
the O 
human O 
diet O 
based O 
on O 
a O 
published O 
population O 
- O 
based O 
cross O 
- O 
sectional O 
nutrition O 
survey O 
. O 
D-fagomine B-TRIVIAL 
is O 
present O 
in O 
common O 
buckwheat O 
- O 
based O 
foodstuffs O 
in O 
amounts O 
ranging O 
from O 
1 O 
to O 
25 O 
mg O 
/ O 
kg O 
or O 
mg O 
/ O 
L O 
, O 
it O 
is O 
stable O 
during O 
boiling O 
, O 
baking O 
, O 
frying O 
and O 
fermentation O 
, O 
and O 
it O 
is O 
biosynthesised O 
upon O 
sprouting O 
. O 
The O 
estimated O 
total O 
intake O 
of O 
D-fagomine B-TRIVIAL 
resulting O 
from O 
a O 
diet O 
that O 
includes O 
such O 
foodstuffs O 
would O 
be O 
between O 
3 O 
and O 
17 O 
mg O 
per O 
day O 
( O 
mean O 
for O 
both O 
genders O 
; O 
range O 
from O 
P5 O 
to O 
P95 O 
) O 
. O 
A O 
diet O 
rich O 
in O 
buckwheat O 
products O 
would O 
provide O 
a O 
daily O 
amount O 
of O 
D-fagomine B-TRIVIAL 
that O 
may O 
in O 
part O 
explain O 
the O 
beneficial O 
properties O 
traditionally O 
attributed O 
to O 
buckwheat O 
consumption O 
. O 

in O 
vivo O 
antioxidant O 
and O 
antifibrotic O 
properties O 
of O 
green O 
tea O 
( O 
Camellia O 
sinensis O 
, O 
Theaceae O 
) O 
were O 
investigated O 
with O 
a O 
study O 
of O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
( O 
CCl(4) B-FORMULA 
)-induced O 
oxidative O 
stress O 
and O 
hepatic O 
fibrosis O 
in O 
male O 
ICR O 
mice O 
. O 
Oral O 
administration O 
of O 
green O 
tea O 
extract O 
at O 
doses O 
of O 
125 O 
, O 
625 O 
and O 
1250 O 
mg O 
/ O 
kg O 
for O 
8 O 
weeks O 
significantly O 
reduced O 
( O 
p O 
< O 
0.05 O 
) O 
the O 
levels O 
of O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
-reactive O 
substances O 
( O 
TBARS O 
) O 
and O 
protein O 
carbonyls B-FAMILY 
in O 
the O 
liver O 
by O 
at O 
least O 
28% O 
compared O 
with O 
that O 
was O 
induced O 
by O 
CCl(4) B-FORMULA 
( O 
1 O 
mL O 
/ O 
kg O 
) O 
in O 
mice O 
. O 
Moreover O 
, O 
green O 
tea O 
extract O 
administration O 
significantly O 
increased O 
( O 
p O 
< O 
0.05 O 
) O 
the O 
activities O 
of O 
catalase O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GSH B-ABBREVIATION 
-Px O 
) O 
and O 
glutathione B-TRIVIAL 
reductase O 
( O 
GSH B-ABBREVIATION 
-Rd O 
) O 
in O 
the O 
liver O 
. O 
Our O 
study O 
found O 
that O 
oral O 
administration O 
of O 
green O 
tea O 
extract O 
prevented O 
CCl(4) B-FORMULA 
-induced O 
hepatic O 
fibrosis O 
, O 
as O 
evidenced O 
by O 
a O 
decreased O 
hydroxyproline B-SYSTEMATIC 
level O 
in O 
the O 
liver O 
and O 
a O 
reduced O 
incidence O 
of O 
hepatic O 
fibrosis O 
by O 
histological O 
observations O 
. O 
These O 
results O 
indicate O 
that O 
green O 
tea O 
exhibits O 
potent O 
protective O 
effects O 
against O 
CCl(4) B-FORMULA 
-induced O 
oxidative O 
stress O 
and O 
hepatic O 
fibrosis O 
in O 
mice O 
by O 
inhibiting O 
oxidative O 
damage O 
and O 
increasing O 
antioxidant O 
enzyme O 
activities O 
. O 

protein O 
has O 
been O 
suggested O 
to O 
be O 
potential O 
protective O 
agent O 
against O 
various O 
forms O 
of O 
stress O 
. O 
The O 
heat O 
shock O 
protein O 
HSP70 O 
confers O 
greater O 
cellular O 
tolerance O 
against O 
stressors O 
. O 
The O 
present O 
study O 
evaluated O 
the O 
effects O 
of O 
whey O 
protein O 
intake O 
on O 
HSP70 O 
expression O 
. O 
Forty O 
- O 
eight O 
male O 
Wistar O 
rats O 
were O 
divided O 
into O 
sedentary O 
and O 
exercised O 
groups O 
, O 
and O 
each O 
group O 
was O 
fed O 
as O 
a O 
protein O 
source O 
casein O 
( O 
CAS O 
) O 
, O 
whey O 
protein O 
( O 
WP O 
) O 
or O 
whey O 
protein O 
hydrolysate O 
( O 
WPH O 
) O 
for O 
3weeks O 
. O 
Exercise O 
on O 
a O 
treadmill O 
was O 
used O 
as O 
the O 
source O 
of O 
stress O 
in O 
the O 
animals O 
from O 
the O 
exercised O 
group O 
. O 
The O 
results O 
showed O 
a O 
larger O 
increase O 
in O 
HSP70 O 
expression O 
in O 
the O 
soleus O 
, O 
gastrocnemius O 
and O 
lung O 
of O 
the O 
WPH-fed O 
rats O 
than O 
WP O 
or O 
casein O 
- O 
fed O 
rats O 
. O 
HSP70 O 
expression O 
in O 
the O 
sedentary O 
rats O 
was O 
very O 
low O 
, O 
independent O 
of O 
the O 
diet O 
or O 
tissue O 
. O 
Protein O 
carbonyls B-FAMILY 
were O 
lower O 
in O 
the O 
group O 
that O 
consumed O 
WPH O 
. O 
These O 
data O 
suggest O 
that O 
the O 
consumption O 
of O 
WPH O 
enhances O 
HSP70 O 
expression O 
. O 

new O 
QSAR O 
model O 
, O 
for O 
angiotensin B-TRIVIAL 
I I-TRIVIAL 
-converting O 
enzyme O 
inhibitory O 
oligopeptides O 
. O 

new O 
quantitative O 
structure O 
activity O 
relationship O 
( O 
QSAR O 
) O 
model O 
is O 
established O 
for O 
oligopeptides O 
that O 
inhibit O 
angiotensin B-TRIVIAL 
I I-TRIVIAL 
-converting O 
enzyme O 
( O 
ACE O 
) O 
. O 
Information O 
concerning O 
the O 
C B-FORMULA 
-terminal O 
pentapeptide O 
is O 
considered O 
to O 
describe O 
the O 
peptide O 
structure O 
in O 
the O 
model O 
. O 
A O 
database O 
is O 
constructed O 
, O 
with O 
263 O 
ACE O 
inhibitory O 
peptides O 
and O 
38 O 
physicochemical O 
descriptors O 
, O 
abstracted O 
from O 
the O 
published O 
literature O 
. O 
The O 
model O 
is O 
generated O 
through O 
a O 
generalised O 
linear O 
model O 
, O 
with O 
a O 
gamma O 
distribution O 
that O 
yields O 
a O 
coefficient O 
of O 
determination O 
of O 
94.4% O 
. O 
The O 
whole O 
C B-FORMULA 
-terminal O 
pentapeptide O 
information O 
is O 
a O 
determinant O 
for O 
modelling O 
the O 
ACE O 
inhibition O 
activity O 
of O 
oligopeptides O 
. O 
Starting O 
from O 
the O 
C B-FORMULA 
-terminus O 
, O 
the O 
C-1 O 
position O 
is O 
the O 
most O 
relevant O 
position O 
in O 
the O 
model O 
; O 
this O 
is O 
followed O 
by O 
position O 
C-4 O 
. O 
In O 
C-1 O 
, O 
there O 
is O 
a O 
preference O 
for O 
aliphatic O 
and O 
tiny O 
residues O 
. O 
However O 
, O 
in O 
the O 
C-4 O 
position O 
, O 
the O 
model O 
indicates O 
a O 
clear O 
preference O 
for O 
bulky O 
hydrophobic O 
amino B-FAMILY 
acids I-FAMILY 
and O 
for O 
sulphur B-SYSTEMATIC 
-containing O 
amino B-FAMILY 
acids I-FAMILY 
. O 
Due O 
to O 
its O 
good O 
predictive O 
capability O 
, O 
this O 
model O 
could O 
be O 
used O 
as O 
a O 
tool O 
for O 
identifying O 
and O 
prioritizing O 
the O 
potential O 
ACE O 
inhibitory O 
peptides O 
present O 
in O 
a O 
complex O 
matrix O 
. O 

polyphenols B-FAMILY 
, O 
catechin B-TRIVIAL 
profiles O 
and O 
antioxidant O 
activity O 
of O 
tea O 
products O 
from O 
purple O 
leaf O 
coloured O 
tea O 
cultivars O 
. O 

( O 
aerated O 
) O 
and O 
green O 
( O 
unaerated O 
) O 
tea O 
products O 
, O 
processed O 
from O 
10 O 
green O 
and O 
18 O 
purple O 
leaf O 
coloured O 
cultivars O 
of O 
Kenyan O 
origin O 
, O 
and O 
two O 
tea O 
products O 
, O 
from O 
the O 
Japanese O 
cultivars O 
, O 
Yabukita O 
and O 
Yutakamidori O 
, O 
were O 
assayed O 
for O 
total O 
polyphenols B-FAMILY 
( O 
TP O 
) O 
content O 
, O 
individual O 
catechin B-TRIVIAL 
profiles O 
and O 
in O 
vitro O 
antioxidant O 
capacity O 
( O 
AA O 
) O 
. O 
In O 
addition O 
, O 
the O 
phenolic B-FAMILY 
content O 
of O 
the O 
tea O 
products O 
was O 
determined O 
using O 
the O 
Folin-Ciocalteu B-TRIVIAL 
phenol I-TRIVIAL 
reagent O 
. O 
Catechin B-TRIVIAL 
fractions O 
were O 
identified O 
using O 
reverse O 
phase O 
high O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
with O 
a O 
binary O 
gradient O 
elution O 
system O 
. O 
The O 
AA% O 
of O 
the O 
tea O 
products O 
was O 
determined O 
using O 
a O 
2,2'-diphenyl B-SYSTEMATIC 
picrylhydrazyl I-SYSTEMATIC 
( O 
DPPH B-ABBREVIATION 
) O 
radical O 
assay O 
method O 
. O 
The O 
results O 
showed O 
that O 
TPs O 
, O 
catechin B-TRIVIAL 
profiles O 
and O 
antioxidant O 
activities O 
were O 
significantly O 
( O 
p≤0.05 O 
) O 
higher O 
in O 
unaerated O 
than O 
in O 
aerated O 
teas O 
. O 
Tea O 
products O 
from O 
the O 
purple O 
leaf O 
coloured O 
tea O 
cultivars O 
had O 
levels O 
of O 
TPs O 
, O 
total O 
catechin B-TRIVIAL 
( O 
TC O 
) O 
and O 
antioxidant O 
activities O 
similar O 
to O 
those O 
from O 
the O 
green O 
leaf O 
coloured O 
cultivars O 
, O 
except O 
for O 
teas O 
from O 
the O 
Japanese O 
cultivars O 
that O 
were O 
very O 
low O 
in O 
the O 
assayed O 
parameters O 
. O 
Caffeine B-TRIVIAL 
content O 
was O 
significantly O 
( O 
p≤0.05 O 
) O 
lower O 
in O 
products O 
from O 
the O 
purple O 
leaf O 
coloured O 
cultivars O 
than O 
in O 
those O 
from O 
the O 
green O 
leaf O 
coloured O 
tea O 
cultivars O 
. O 
Antioxidant O 
activity O 
( O 
% O 
) O 
was O 
higher O 
in O 
tea O 
products O 
from O 
the O 
Kenyan O 
germplasm O 
than O 
in O 
those O 
from O 
the O 
Japanese O 
cultivars O 
. O 
Antioxidant O 
potency O 
of O 
tea O 
products O 
was O 
significantly O 
( O 
r=0.789(∗∗) O 
, O 
p≤0.01 O 
) O 
influenced O 
by O 
the O 
total O 
anthocyanin B-FAMILY 
content O 
of O 
the O 
purple O 
leaf O 
coloured O 
cultivars O 
. O 
Cyanidin-3-O-glucoside B-SYSTEMATIC 
was O 
the O 
anthocyanin B-FAMILY 
most O 
highly O 
correlated O 
with O 
AA% O 
( O 
r=0.843(∗∗) O 
, O 
p≤0.01 O 
in O 
unaerated O 
tea O 
) O 
. O 
Total O 
catechins B-FAMILY 
in O 
the O 
unaerated O 
products O 
from O 
the O 
green O 
leaf O 
coloured O 
tea O 
cultivars O 
were O 
also O 
significantly O 
correlated O 
with O 
antioxidant O 
capacity O 
( O 
r=0.818(∗∗) O 
, O 
p≤0.01 O 
) O 
. O 
Results O 
from O 
this O 
study O 
suggest O 
that O 
the O 
antioxidant O 
potency O 
of O 
teas O 
is O 
dependent O 
on O 
the O 
predominant O 
flavonoid B-FAMILY 
compound O 
, O 
the O 
type O 
of O 
tea O 
cultivar O 
and O 
the O 
processing O 
method O 
. O 

simple O 
multiresidue O 
analytical O 
method O 
is O 
developed O 
for O 
the O 
simultaneous O 
determination O 
of O 
carbendazim B-TRIVIAL 
( O 
CB O 
) O 
, O 
thiabendazole B-TRIVIAL 
( O 
TB O 
) O 
, O 
and O 
6-benzyl B-SYSTEMATIC 
aminopurine I-SYSTEMATIC 
( O 
6-BA B-SYSTEMATIC 
) O 
in O 
bean O 
sprouts O 
. O 
The O 
samples O 
were O 
extracted O 
with O 
acetonitrile B-SYSTEMATIC 
followed O 
by O 
partitioning O 
at O 
-80°C O 
for O 
5-10 O 
min O 
. O 
A O 
YMC O 
C(8) O 
column O 
was O 
used O 
to O 
separate O 
the O 
analytes O 
before O 
being O 
qualitatively O 
and O 
quantitatively O 
determined O 
by O 
liquid O 
chromatography O 
- O 
electrospray O 
ionization O 
tandem O 
mass O 
spectrometry O 
( O 
LC-ESI-MS O 
/ O 
MS O 
) O 
in O 
positive O 
ion O 
mode O 
using O 
multiple O 
reaction O 
monitoring O 
( O 
MRM O 
) O 
. O 
The O 
matrix O 
- O 
matched O 
calibration O 
curves O 
showed O 
good O 
linearity O 
in O 
the O 
range O 
0.01-1.0 O 
mg O 
/ O 
kg O 
with O 
correlation O 
coefficients O 
in O 
excess O 
of O 
0.998 O 
. O 
The O 
mean O 
recoveries O 
were O 
in O 
the O 
range O 
of O 
80.4-96.3% O 
at O 
0.1 O 
and O 
0.5 O 
spiked O 
levels O 
, O 
and O 
the O 
relative O 
standard O 
deviations O 
( O 
RSDs O 
) O 
were O 
in O 
the O 
range O 
of O 
0.5-7.6% O 
. O 
The O 
limits O 
of O 
quantifications O 
( O 
LOQ O 
) O 
were O 
in O 
the O 
range O 
of O 
0.005-0.01 O 
mg O 
/ O 
kg O 
. O 
The O 
method O 
was O 
successfully O 
applied O 
to O 
90 O 
samples O 
( O 
among O 
which O 
45 O 
were O 
organic O 
) O 
collected O 
from O 
a O 
commercial O 
bean O 
sprout O 
production O 
house O 
throughout O 
the O 
city O 
. O 
Except O 
for O 
6-BA B-SYSTEMATIC 
, O 
the O 
rest O 
of O 
the O 
analytes O 
had O 
values O 
lower O 
than O 
their O 
LOQs O 
. O 
In O 
sum O 
, O 
carbendazim B-TRIVIAL 
, O 
thiabendazole B-TRIVIAL 
, O 
and O 
6-BA B-SYSTEMATIC 
were O 
extracted O 
in O 
a O 
single O 
step O 
, O 
and O 
no O 
steps O 
for O 
clean O 
- O 
up O 
or O 
concentration O 
of O 
the O 
extracts O 
were O 
needed O 
. O 
The O 
current O 
method O 
can O 
be O 
used O 
for O 
sensitive O 
and O 
accurate O 
determination O 
and O 
confirmation O 
of O 
residues O 
in O 
bean O 
sprout O 
samples O 
. O 

Cyclocarya O 
paliurus O 
( O 
Batal O 
. O 
) O 
Iljinskaja O 
polysaccharide O 
( O 
CPP O 
) O 
was O 
isolated O 
and O 
purified O 
by O 
hot O 
water O 
extraction O 
, O 
ethanol B-SYSTEMATIC 
precipitation O 
, O 
deproteinisation O 
and O 
anion O 
- O 
exchange O 
chromatography O 
. O 
Its O 
physicochemical O 
properties O 
were O 
characterised O 
by O 
gel O 
permeation O 
chromatography O 
( O 
GPC O 
) O 
, O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
( O 
GC-MS O 
) O 
, O 
thermal O 
gravimetric O 
analysis O 
( O 
TGA O 
) O 
, O 
Fourier O 
transform O 
infrared O 
spectrometry O 
( O 
FTIR O 
) O 
, O 
UV-visible O 
spectrophotometry O 
, O 
dynamic O 
light O 
scattering O 
( O 
DLS O 
) O 
and O 
viscometry O 
analysis O 
. O 
The O 
anticancer O 
effect O 
of O 
CPP O 
in O 
human O 
gastric O 
cancer O 
HeLa O 
cells O 
was O 
also O 
evaluated O 
by O 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
MTT B-ABBREVIATION 
) O 
assay O 
. O 
The O 
results O 
showed O 
that O 
the O 
molecular O 
weight O 
of O 
CPP O 
was O 
900 O 
kDa O 
, O 
and O 
it O 
contained O 
64.8% O 
total O 
sugar O 
, O 
23.5% O 
uronic B-FAMILY 
acid I-FAMILY 
, O 
9.26% O 
protein O 
, O 
and O 
six O 
kinds O 
of O 
monosaccharides B-FAMILY 
, O 
including O 
glucose B-TRIVIAL 
, O 
rhamnose B-TRIVIAL 
, O 
arabinose B-TRIVIAL 
, O 
xylose B-TRIVIAL 
, O 
mannose B-TRIVIAL 
and O 
galactose B-TRIVIAL 
, O 
with O 
molar O 
percentages O 
of O 
32.7% O 
, O 
9.33% O 
, O 
30.6% O 
, O 
3.48% O 
, O 
10.4% O 
, O 
and O 
13.5% O 
, O 
respectively O 
. O 
Furthermore O 
, O 
the O 
results O 
showed O 
that O 
CPP O 
exhibited O 
a O 
strong O 
inhibition O 
effect O 
on O 
the O 
growth O 
of O 
human O 
gastric O 
cancer O 
HeLa O 
cells O 
. O 

term O 
compulsivity O 
on O 
the O 
5-choice O 
serial O 
reaction O 
time O 
task O 
after O 
acute O 
Chlorpyrifos B-TRIVIAL 
exposure O 
. O 

exposure O 
has O 
been O 
associated O 
with O 
neuropsychological O 
and O 
psychiatric O 
impairments O 
and O 
neurodegenerative O 
disorders O 
. O 
Pesticide O 
exposure O 
commonly O 
causes O 
a O 
deficit O 
in O 
inhibitory O 
control O 
behaviours O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
whether O 
acute O 
exposure O 
to O 
organophosphate B-FAMILY 
( O 
OP O 
) O 
chlorpyrifos B-TRIVIAL 
( O 
CPF B-ABBREVIATION 
) O 
is O 
related O 
to O 
long O 
- O 
term O 
lack O 
of O 
inhibitory O 
control O 
; O 
we O 
also O 
examined O 
the O 
possible O 
neurochemical O 
basis O 
of O 
this O 
association O 
. O 
Lister O 
Hooded O 
rats O 
were O 
exposed O 
to O 
an O 
acute O 
dose O 
of O 
CPF B-ABBREVIATION 
( O 
250 O 
mg O 
/ O 
kg O 
) O 
. O 
Seven O 
months O 
later O 
, O 
we O 
tested O 
inhibitory O 
control O 
with O 
the O 
5-choice O 
serial O 
reaction O 
time O 
task O 
( O 
5-CSRTT O 
) O 
. O 
We O 
manipulated O 
the O 
baseline O 
conditions O 
of O 
this O 
task O 
and O 
also O 
systemically O 
pre O 
- O 
administered O 
d-amphetamine B-TRIVIAL 
, O 
quinpirole B-TRIVIAL 
, O 
dizocilpine B-TRIVIAL 
( O 
MK-801 B-IDENTIFIER 
) O 
or O 
ketanserin B-TRIVIAL 
. O 
We O 
also O 
analysed O 
the O 
post O 
- O 
mortem O 
baseline O 
levels O 
of O 
monoamines B-FAMILY 
and O 
amino B-FAMILY 
acids I-FAMILY 
in O 
different O 
brain O 
regions O 
. O 
On O 
the O 
5-CSRT O 
task O 
, O 
CPF B-ABBREVIATION 
-exposed O 
rats O 
showed O 
elevated O 
perseverative O 
responses O 
that O 
persisted O 
across O 
manipulation O 
of O 
baseline O 
conditions O 
of O 
the O 
task O 
and O 
under O 
most O 
of O 
the O 
pharmacological O 
challenges O 
tested O 
. O 
Only O 
D-amphetamine B-TRIVIAL 
induced O 
a O 
dose O 
- O 
dependent O 
amelioration O 
of O 
the O 
increased O 
perseverative O 
responses O 
in O 
the O 
CPF B-ABBREVIATION 
group O 
. O 
The O 
CPF B-ABBREVIATION 
group O 
also O 
exhibited O 
increased O 
levels O 
of O 
dopamine B-TRIVIAL 
metabolism O 
in O 
the O 
hippocampus O 
and O 
decreased O 
levels O 
of O 
gamma-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
) O 
and O 
glutamate B-TRIVIAL 
in O 
the O 
striatum O 
compared O 
to O 
the O 
vehicle O 
group O 
. O 
These O 
findings O 
suggest O 
that O 
CPF B-ABBREVIATION 
induced O 
a O 
long O 
- O 
term O 
compulsivity O 
that O 
was O 
apparent O 
in O 
the O 
5-CSRT O 
task O 
and O 
associated O 
with O 
changes O 
in O 
monoaminergic O 
and O 
amino B-FAMILY 
acid I-FAMILY 
brain O 
systems O 
of O 
inhibitory O 
control O 
function O 
. O 
Exposure O 
to O 
high O 
doses O 
of O 
OP O 
should O 
be O 
taken O 
into O 
account O 
in O 
studies O 
of O 
environmental O 
causes O 
for O 
neurodegenerative O 
, O 
neuropsychological O 
and O 
neuropsychiatric O 
disorders O 
. O 

and O 
antiplasmodial O 
evaluation O 
of O 
novel O 
(4-aminobutyloxy)quinolines B-FAMILY 
. O 

variety O 
of O 
5- B-MULTIPLE 
, I-MULTIPLE 
6- I-MULTIPLE 
and I-MULTIPLE 
8-(4-aminobutyloxy)quinolines I-MULTIPLE 
as O 
novel O 
oxygen B-SYSTEMATIC 
analogues O 
of O 
known O 
4- B-MULTIPLE 
and I-MULTIPLE 
8-(4-aminobutylamino)quinoline I-MULTIPLE 
antimalarial O 
drugs O 
was O 
generated O 
from O 
hydroxyquinolines B-FAMILY 
through O 
a O 
three O 
- O 
step O 
approach O 
with O 
a O 
rhodium B-SYSTEMATIC 
-catalyzed O 
hydroformylation O 
as O 
the O 
key O 
step O 
. O 
Antiplasmodial O 
assays O 
of O 
these O 
new O 
quinolines B-FAMILY 
revealed O 
micromolar O 
potency O 
for O 
all O 
representatives O 
against O 
a O 
chloroquine B-TRIVIAL 
-sensitive O 
strain O 
of O 
Plasmodium O 
falciparum O 
, O 
and O 
three O 
compounds O 
showed O 
submicromolar O 
activity O 
against O 
a O 
chloroquine B-TRIVIAL 
-resistant O 
strain O 
of O 
P O 
. O 
falciparum O 
with O 
IC(50)-values O 
ranging O 
between O 
150 O 
and O 
680 O 
nM O 
. O 

experience O 
modifies O 
the O 
effects O 
of O 
estradiol B-TRIVIAL 
on O 
learning O 
and O 
memory O 
bias O 
in O 
female O 
rats O 
. O 

studies O 
have O 
shown O 
that O 
estrogen B-FAMILY 
affects O 
whether O 
a O 
hippocampus O 
- O 
mediated O 
place O 
( O 
allocentric O 
) O 
or O 
a O 
striatum O 
- O 
mediated O 
response O 
( O 
egocentric O 
) O 
memory O 
system O 
is O 
employed O 
by O 
female O 
rats O 
when O 
searching O 
for O 
a O 
food O 
reward O 
in O 
a O 
maze O 
. O 
Because O 
it O 
has O 
been O 
suggested O 
that O 
reproductive O 
experience O 
alters O 
some O 
of O 
the O 
responses O 
to O 
E O 
in O 
the O 
brain O 
, O 
two O 
experiments O 
were O 
carried O 
out O 
to O 
investigate O 
whether O 
reproductive O 
experience O 
would O 
also O 
alter O 
the O 
effect O 
of O 
E O 
on O 
place O 
and O 
response O 
learning O 
. O 
In O 
experiment O 
1 O 
, O 
152 O 
ovariectomized O 
nulliparous O 
( O 
n=77 O 
; O 
no O 
reproductive O 
experience O 
) O 
and O 
primiparous O 
( O 
n=74 O 
; O 
having O 
had O 
and O 
raised O 
one O 
litter O 
of O 
pups O 
) O 
Wistar O 
rats O 
were O 
trained O 
on O 
an O 
ambiguous O 
t-maze O 
task O 
and O 
tested O 
for O 
memory O 
system O 
bias O 
. O 
In O 
experiment O 
2 O 
, O 
35 O 
ovariectomized O 
nulliparous O 
( O 
n=16 O 
) O 
and O 
primiparous O 
( O 
n=19 O 
) O 
Wistar O 
rats O 
were O 
trained O 
on O 
place O 
and O 
response O 
plus O 
- O 
maze O 
tasks O 
. O 
All O 
rats O 
were O 
exposed O 
to O 
no O 
, O 
chronic O 
low O 
or O 
chronic O 
low O 
with O 
pulsatile O 
high O 
17β-estradiol B-SYSTEMATIC 
( O 
E2 O 
) O 
replacement O 
. O 
Congruent O 
with O 
previous O 
findings O 
, O 
low O 
E2 O 
nulliparous O 
rats O 
showed O 
predominant O 
use O 
of O 
response O 
memory O 
and O 
faster O 
response O 
learning O 
, O 
whereas O 
high O 
E2 O 
nulliparous O 
rats O 
showed O 
a O 
trend O 
towards O 
predominant O 
place O 
memory O 
use O 
. O 
Interestingly O 
, O 
the O 
facilitatory O 
effect O 
of O 
low O 
E2 O 
on O 
response O 
task O 
learning O 
and O 
memory O 
seen O 
in O 
nulliparous O 
rats O 
was O 
not O 
observed O 
in O 
low O 
E2 O 
primiparous O 
rats O 
in O 
either O 
experiment O 
. O 
In O 
conclusion O 
, O 
E2 O 
levels O 
do O 
dictate O 
the O 
rate O 
at O 
which O 
female O 
rats O 
learn O 
a O 
response O 
task O 
and O 
utilize O 
response O 
memory O 
, O 
but O 
only O 
in O 
those O 
with O 
no O 
reproductive O 
experience O 
. O 

- O 
dependent O 
regulation O 
of O 
phospho B-SYSTEMATIC 
-AKT O 
dynamics O 
by O 
the O 
ubiquitin O 
E3 O 
ligase O 
, O 
NEDD4-1 O 
, O 
in O 
the O 
insulin O 
- O 
like O 
growth O 
factor-1 O 
response O 
. O 

is O 
a O 
critical O 
effector O 
kinase O 
downstream O 
of O 
the O 
PI3K O 
pathway O 
that O 
regulates O 
a O 
plethora O 
of O 
cellular O 
processes O 
including O 
cell O 
growth O 
, O 
death O 
, O 
differentiation O 
, O 
and O 
migration O 
. O 
Mechanisms O 
underlying O 
activated O 
phospho B-SYSTEMATIC 
-AKT O 
( O 
pAKT O 
) O 
translocation O 
to O 
its O 
action O 
sites O 
remain O 
unclear O 
. O 
Here O 
we O 
show O 
that O 
NEDD4-1 O 
is O 
a O 
novel O 
E3 O 
ligase O 
that O 
specifically O 
regulates O 
ubiquitin O 
- O 
dependent O 
trafficking O 
of O 
pAKT O 
in O 
insulin O 
- O 
like O 
growth O 
factor O 
(IGF)-1 O 
signaling O 
. O 
NEDD4-1 O 
physically O 
interacts O 
with O 
AKT O 
and O 
promotes O 
HECT O 
domain O 
- O 
dependent O 
ubiquitination O 
of O 
exogenous O 
and O 
endogenous O 
AKT O 
. O 
NEDD4-1 O 
catalyzes O 
K63 O 
- O 
type O 
polyubiquitin O 
chain O 
formation O 
on O 
AKT O 
in O 
vitro O 
. O 
Plasma O 
membrane O 
binding O 
is O 
the O 
key O 
step O 
for O 
AKT O 
ubiquitination O 
by O 
NEDD4-1 O 
in O 
vivo O 
. O 
Ubiquitinated O 
pAKT O 
translocates O 
to O 
perinuclear O 
regions O 
, O 
where O 
it O 
is O 
released O 
into O 
the O 
cytoplasm O 
, O 
imported O 
into O 
the O 
nucleus O 
, O 
or O 
coupled O 
with O 
proteasomal O 
degradation O 
. O 
IGF-1 O 
signaling O 
specifically O 
stimulates O 
NEDD4-1 O 
- O 
mediated O 
ubiquitination O 
of O 
pAKT O 
, O 
without O 
altering O 
total O 
AKT O 
ubiquitination O 
. O 
A O 
cancer O 
- O 
derived O 
plasma O 
membrane O 
- O 
philic O 
mutant O 
AKT(E17K) O 
is O 
more O 
effectively O 
ubiquitinated O 
by O 
NEDD4-1 O 
and O 
more O 
efficiently O 
trafficked O 
into O 
the O 
nucleus O 
compared O 
with O 
wild O 
type O 
AKT O 
. O 
This O 
study O 
reveals O 
a O 
novel O 
mechanism O 
by O 
which O 
a O 
specific O 
E3 O 
ligase O 
is O 
required O 
for O 
ubiquitin O 
- O 
dependent O 
control O 
of O 
pAKT O 
dynamics O 
in O 
a O 
ligand O 
- O 
specific O 
manner O 
. O 

the O 
tumor O 
- O 
promoting O 
effects O 
of O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
, O 
coplanar O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
( O 
PCBs B-ABBREVIATION 
) O 
, O 
and O 
related O 
compounds O 
in O 
liver O 
tissue O 
are O 
primarily O 
attributed O 
to O 
the O 
activation O 
of O 
the O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AhR O 
) O 
, O 
the O 
underlying O 
molecular O 
mechanisms O 
are O 
still O 
unclear O 
. O 
Liver O 
progenitor O 
( O 
oval O 
) O 
cells O 
have O 
been O 
suggested O 
to O 
constitute O 
a O 
potential O 
target O 
for O 
hepatocarcinogenic O 
chemicals O 
. O 
To O 
better O 
understand O 
AhR-driven O 
pathways O 
, O 
we O 
analyzed O 
the O 
transcriptional O 
program O 
in O 
response O 
to O 
coplanar O 
PCB B-TRIVIAL 
126 I-TRIVIAL 
in O 
contact O 
- O 
inhibited O 
rat O 
liver O 
progenitor O 
WB-F344 O 
cells O 
using O 
high O 
- O 
density O 
microarrays O 
. O 
After O 
6-h O 
treatment O 
, O 
we O 
identified O 
145 O 
significantly O 
deregulated O 
genes O 
considered O 
to O 
be O 
direct O 
AhR-dependent O 
target O 
genes O 
. O 
The O 
number O 
of O 
differentially O 
regulated O 
genes O 
increased O 
to O 
658 O 
and O 
968 O 
genes O 
after O 
24 O 
and O 
72 O 
h O 
, O 
respectively O 
. O 
Gene O 
ontology O 
analysis O 
revealed O 
that O 
these O 
genes O 
were O 
primarily O 
involved O 
in O 
drug O 
and O 
lipid O 
metabolism O 
, O 
cell O 
cycle O 
and O 
growth O 
control O 
, O 
cancer O 
developmental O 
processes O 
, O 
cell O 
- O 
cell O 
communication O 
, O 
and O 
adhesion O 
. O 
Interestingly O 
, O 
the O 
Wnt O 
and O 
TGF-β O 
signaling O 
pathways O 
, O 
both O 
being O 
involved O 
in O 
developmental O 
and O 
tumorigenic O 
processes O 
, O 
belonged O 
to O 
the O 
most O 
affected O 
pathways O 
. O 
AhR- O 
and O 
ARNT-dependent O 
regulation O 
of O 
selected O 
target O 
genes O 
of O 
interest O 
was O 
then O 
confirmed O 
using O 
TCDD B-ABBREVIATION 
as O 
a O 
model O 
AhR O 
agonist O 
, O 
together O 
with O 
pharmacological O 
inhibition O 
of O 
the O 
AhR O 
and O 
by O 
RNA-interference O 
techniques O 
. O 
We O 
demonstrated O 
AhR-dependent O 
regulation O 
of O 
emerging O 
and O 
novel O 
AhR O 
target O 
genes O 
, O 
such O 
as O 
Fst O 
, O 
Areg O 
, O 
Hbegf O 
, O 
Ctgf O 
, O 
Btg2 O 
, O 
and O 
Foxq1 O 
. O 
Among O 
them O 
, O 
the O 
transcription O 
factor O 
Foxq1 O 
, O 
recently O 
suggested O 
to O 
contribute O 
to O 
tumor O 
promotion O 
and O 
/ O 
or O 
progression O 
, O 
was O 
found O 
to O 
be O 
regulated O 
at O 
both O 
mRNA O 
and O 
protein O 
levels O 
by O 
AhR O 
/ O 
ARNT O 
activation O 
. O 

properties O 
and O 
activity O 
of O 
water O 
- O 
soluble O 
polymer/ O 
c(60) B-TRIVIAL 
nanohybrids O 
for O 
photodynamic O 
therapy O 
. O 

- O 
soluble O 
star O 
- O 
like O 
poly(vinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
) I-SYSTEMATIC 
/ O 
C(60) B-TRIVIAL 
and O 
poly{[poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
acrylate]-co-(vinyl I-SYSTEMATIC 
acetate I-SYSTEMATIC 
) I-SYSTEMATIC 
} I-SYSTEMATIC 
/ O 
C(60) B-TRIVIAL 
nanohybrids O 
are O 
prepared O 
by O 
grafting O 
macroradicals O 
onto O 
C(60) B-TRIVIAL 
and O 
are O 
assessed O 
as O 
photosensitizers O 
for O 
photodynamic O 
therapy O 
. O 
The O 
photophysical O 
and O 
biological O 
properties O 
of O 
both O 
nanohybrids O 
highlight O 
key O 
characteristics O 
influencing O 
their O 
overall O 
efficiency O 
. O 
The O 
macromolecular O 
structure O 
( O 
linear O 
/ O 
graft O 
) O 
and O 
nature O 
( O 
presence O 
/ O 
absence O 
of O 
hydroxyl B-SYSTEMATIC 
groups O 
) O 
of O 
the O 
polymeric O 
arms O 
respectively O 
impact O 
the O 
photodynamic O 
activity O 
and O 
the O 
stealthiness O 
of O 
the O 
nanohybrids O 
. O 
The O 
advantages O 
of O 
both O 
nanohybrids O 
are O 
encountered O 
in O 
a O 
third O 
one O 
, O 
poly[(N-vinylpyrrolidone)-co-(vinyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
) I-SYSTEMATIC 
] I-SYSTEMATIC 
/ O 
C(60) B-TRIVIAL 
, O 
which O 
has O 
linear O 
grafts O 
without O 
hydroxyl B-SYSTEMATIC 
groups O 
, O 
and O 
shows O 
a O 
better O 
photodynamic O 
activity O 
. O 

of O 
transporters O 
associated O 
with O 
Etoposide B-TRIVIAL 
sensitivity O 
of O 
stomach O 
cancer O 
cell O 
lines O 
and O 
methotrexate B-TRIVIAL 
sensitivity O 
of O 
breast O 
cancer O 
cell O 
lines O 
by O 
quantitative O 
targeted O 
absolute O 
proteomics O 
. O 

transporter O 
proteins O 
may O 
influence O 
the O 
sensitivity O 
of O 
cancer O 
cells O 
to O 
anticancer O 
drugs O 
that O 
can O 
be O 
recognized O 
as O 
substrates O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
identify O 
proteins O 
that O 
play O 
a O 
key O 
role O 
in O 
the O 
drug O 
sensitivity O 
of O 
stomach O 
and O 
breast O 
cancer O 
cell O 
lines O 
by O 
measuring O 
the O 
absolute O 
protein O 
expression O 
levels O 
of O 
multiple O 
transporters O 
and O 
other O 
membrane O 
proteins O 
and O 
examining O 
their O 
correlation O 
to O 
drug O 
sensitivity O 
. O 
Absolute O 
protein O 
expression O 
levels O 
of O 
90 O 
membrane O 
proteins O 
were O 
examined O 
by O 
quantitative O 
targeted O 
absolute O 
proteomics O 
using O 
liquid O 
chromatography O 
- O 
linked O 
tandem O 
mass O 
spectrometry O 
. O 
Among O 
them O 
, O 
11 O 
and O 
14 O 
membrane O 
proteins O 
, O 
including O 
transporters O 
, O 
were O 
present O 
in O 
quantifiable O 
amounts O 
in O 
membrane O 
fraction O 
of O 
stomach O 
cancer O 
and O 
breast O 
cancer O 
cell O 
lines O 
, O 
respectively O 
. O 
In O 
stomach O 
cancer O 
cell O 
lines O 
, O 
the O 
protein O 
expression O 
level O 
of O 
multidrug O 
resistance O 
- O 
associated O 
protein O 
1 O 
( O 
MRP1 O 
) O 
was O 
inversely O 
correlated O 
with O 
etoposide B-TRIVIAL 
sensitivity O 
. O 
MK571 B-IDENTIFIER 
, O 
an O 
MRP O 
inhibitor O 
, O 
increased O 
both O 
the O 
cell O 
- O 
to O 
- O 
medium O 
ratio O 
of O 
etoposide O 
and O 
the O 
etoposide O 
sensitivity O 
of O 
MRP1-expressing O 
stomach O 
cancer O 
cell O 
lines O 
. O 
In O 
breast O 
cancer O 
cell O 
lines O 
, O 
the O 
protein O 
expression O 
level O 
of O 
reduced O 
folate O 
carrier O 
1 O 
( O 
RFC1 O 
) O 
was O 
directly O 
correlated O 
with O 
methotrexate B-TRIVIAL 
( O 
MTX B-ABBREVIATION 
) O 
sensitivity O 
. O 
Initial O 
uptake O 
rate O 
and O 
steady O 
- O 
state O 
cell O 
- O 
to O 
- O 
medium O 
ratio O 
of O 
[(3)H]MTX B-SYSTEMATIC 
were O 
correlated O 
with O 
both O 
RFC1 O 
expression O 
level O 
and O 
MTX B-ABBREVIATION 
sensitivity O 
. O 
These O 
results O 
suggest O 
that O 
MRP1 O 
modulates O 
the O 
etoposide B-TRIVIAL 
sensitivity O 
of O 
stomach O 
cancer O 
cell O 
lines O 
and O 
RFC1 O 
modulates O 
the O 
MTX B-ABBREVIATION 
sensitivity O 
of O 
breast O 
cancer O 
cell O 
lines O 
. O 
Our O 
results O 
indicate O 
that O 
absolute O 
quantification O 
of O 
multiple O 
membrane O 
proteins O 
could O 
be O 
a O 
useful O 
strategy O 
for O 
identification O 
of O 
candidate O 
proteins O 
involved O 
in O 
drug O 
sensitivity O 
. O 

studies O 
of O 
chronic O 
CB(1) O 
receptor O 
activation O 
may O 
provide O 
a O 
pharmacological O 
approach O 
to O 
understanding O 
efficacy O 
- O 
related O 
differences O 
among O 
CB(1) O 
ligands O 
as O 
well O 
as O 
mechanistic O 
commonalities O 
between O 
cannabinoid O 
and O 
noncannabinoid O 
drugs O 
. O 
In O 
the O 
present O 
studies O 
, O 
the O 
effects O 
of O 
CB(1) O 
agonists O 
[ O 
(6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol B-SYSTEMATIC 
( O 
AM411 B-IDENTIFIER 
) O 
, O 
9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol B-SYSTEMATIC 
( O 
AM4054 B-IDENTIFIER 
) O 
, O 
R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone B-SYSTEMATIC 
mesylate I-SYSTEMATIC 
( O 
WIN55,212.2 B-IDENTIFIER 
) O 
, O 
Δ(9)-tetrahydrocannabinol B-SYSTEMATIC 
( O 
Δ(9)-THC B-SYSTEMATIC 
) O 
, O 
(R)-(+)-arachidonyl-1'-hydroxy-2'-propylamide B-SYSTEMATIC 
( I-SYSTEMATIC 
methanandamide I-SYSTEMATIC 
) I-SYSTEMATIC 
] O 
, O 
CB(1) O 
antagonists O 
[ O 
5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide B-SYSTEMATIC 
( O 
SR141716A B-IDENTIFIER 
) O 
, O 
5-(4-alkylphenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide B-FAMILY 
( O 
AM4113 B-IDENTIFIER 
) O 
] O 
, O 
and O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
- O 
related O 
[ O 
methamphetamine B-TRIVIAL 
, O 
(±)-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine B-SYSTEMATIC 
hydrobromide I-SYSTEMATIC 
( O 
SKF82958 B-IDENTIFIER 
) O 
, O 
(R)-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
SCH23390 B-IDENTIFIER 
) O 
, O 
(6aR)-5,6,6a,7-tetrahydro-6-propyl-4H-dibenzo[de,g]quinoline-10,11-diol B-SYSTEMATIC 
( O 
R-(-)-NPA B-ABBREVIATION 
) O 
, O 
haloperidol B-TRIVIAL 
] O 
and O 
opioid O 
( O 
morphine B-TRIVIAL 
, O 
naltrexone B-TRIVIAL 
) O 
drugs O 
on O 
scheduled O 
- O 
controlled O 
responding O 
under O 
a O 
30-response O 
fixed O 
ratio O 
schedule O 
of O 
stimulus O 
- O 
shock O 
termination O 
in O 
squirrel O 
monkeys O 
were O 
compared O 
before O 
and O 
during O 
chronic O 
treatment O 
with O 
the O 
long O 
- O 
acting O 
CB(1) O 
agonist O 
AM411 B-IDENTIFIER 
( O 
1 O 
mg O 
/ O 
kg O 
per O 
day O 
, O 
i.m O 
. O 
) O 
. O 
Prechronic O 
treatment O 
with O 
all O 
drugs O 
except O 
naltrexone B-TRIVIAL 
( O 
1-10 O 
mg O 
/ O 
kg O 
) O 
produced O 
dose O 
- O 
related O 
decreases O 
in O 
responses O 
rates O 
. O 
Dose O 
- O 
response O 
re O 
- O 
determinations O 
during O 
chronic O 
treatment O 
revealed O 
the O 
following O 
: O 
1 O 
) O 
> O 
250-fold O 
( O 
AM411 B-IDENTIFIER 
, O 
methanandamide B-TRIVIAL 
) O 
and O 
> O 
45-fold O 
( O 
AM4054 B-IDENTIFIER 
, O 
WIN55,212.2 B-IDENTIFIER 
, O 
Δ(9)-THC B-SYSTEMATIC 
) O 
rightward O 
shifts O 
in O 
the O 
ED(50) O 
values O 
for O 
CB(1) O 
agonists O 
; O 
2 O 
) O 
> O 
100-fold O 
and O 
> O 
20-fold O 
leftward O 
shifts O 
in O 
the O 
ED(50) O 
values O 
for O 
SR141716A B-IDENTIFIER 
and O 
AM4113 B-IDENTIFIER 
, O 
respectively O 
; O 
and O 
3 O 
) O 
approximately O 
4.8-fold O 
and O 
10-fold O 
rightward O 
shifts O 
in O 
the O 
ED(50) O 
values O 
for O 
methamphetamine B-TRIVIAL 
and O 
the O 
DA O 
D(2) O 
agonist O 
R-(-)-NPA B-ABBREVIATION 
, O 
respectively O 
. O 
Dose O 
- O 
response O 
relationships O 
for O 
other O 
DA O 
- O 
related O 
and O 
opioid O 
drugs O 
were O 
unchanged O 
by O 
chronic O 
CB(1) O 
agonist O 
treatment O 
. O 
Differences O 
in O 
the O 
magnitude O 
of O 
tolerance O 
among O 
CB(1) O 
agonists O 
during O 
chronic O 
treatment O 
may O 
be O 
indicative O 
of O 
differences O 
in O 
their O 
pharmacological O 
efficacy O 
, O 
whereas O 
the O 
enhanced O 
sensitivity O 
to O 
behaviorally O 
disruptive O 
effects O 
of O 
CB(1) O 
antagonists O 
may O 
provide O 
evidence O 
for O 
CB(1) O 
- O 
related O 
behavioral O 
and O 
/ O 
or O 
physical O 
dependence O 
. O 
Finally O 
, O 
the O 
development O 
of O 
cross O 
- O 
tolerance O 
to O 
methamphetamine B-TRIVIAL 
and O 
R-(-)-NPA B-ABBREVIATION 
bolsters O 
previous O 
evidence O 
of O 
interplay O 
between O 
CB(1) O 
and O 
DA O 
D(2) O 
signaling O 
mechanisms O 
. O 

, O 
a O 
linear O 
polymer O 
of O 
α(1,4) O 
- O 
linked O 
glucosyl O 
units O 
and O 
a O 
major O 
constituent O 
of O 
starch O 
granules O 
, O 
can O 
also O 
be O 
enzymatically O 
synthesized O 
in O 
vitro O 
from O 
sucrose B-TRIVIAL 
by O 
bacterial O 
amylosucrases O 
. O 
Depending O 
on O 
the O 
initial O 
sucrose B-TRIVIAL 
concentration O 
and O 
the O 
enzyme O 
used O 
, O 
amylose O 
oligomers O 
( O 
or O 
polymers O 
) O 
are O 
formed O 
and O 
self O 
- O 
associate O 
during O 
synthesis O 
into O 
various O 
semicrystalline O 
morphologies O 
. O 
This O 
work O 
describes O 
for O 
the O 
first O 
time O 
a O 
synchrotron O 
SAXS O 
study O 
of O 
the O 
structure O 
in O 
solution O 
of O 
two O 
amylosucrases O 
, O 
namely O 
, O 
NpAS O 
and O 
the O 
thermostable O 
DgAS O 
, O 
under O 
conditions O 
of O 
polymer O 
synthesis O 
and O 
, O 
simultaneously O 
, O 
the O 
amylose O 
conformation O 
. O 
The O 
structure O 
in O 
solution O 
of O 
both O 
amylosucrases O 
during O 
the O 
reaction O 
was O 
shown O 
to O 
be O 
similar O 
to O 
the O 
known O 
crystallographic O 
structures O 
. O 
The O 
conformation O 
of O 
amylose O 
produced O 
at O 
an O 
early O 
stage O 
consists O 
of O 
a O 
mixture O 
of O 
wormlike O 
chains O 
and O 
double O 
helical O 
cylindrical O 
structures O 
. O 
In O 
the O 
case O 
of O 
NpAS O 
, O 
in O 
a O 
second O 
stage O 
, O 
individual O 
double O 
helices O 
pack O 
into O 
clusters O 
before O 
crystallizing O 
and O 
precipitating O 
. O 
Amylose O 
produced O 
by O 
DgAS O 
never O 
self O 
- O 
associates O 
in O 
such O 
clusters O 
due O 
to O 
the O 
higher O 
temperature O 
used O 
for O 
amylose O 
synthesis O 
. O 
All O 
the O 
dimensions O 
determined O 
for O 
wormlike O 
chains O 
and O 
cylindrical O 
conformations O 
at O 
different O 
times O 
of O 
NpAS O 
synthesis O 
are O 
in O 
very O 
good O 
agreement O 
with O 
structural O 
features O 
usually O 
observed O 
on O 
gels O 
of O 
amylose O 
extracted O 
from O 
starch O 
. O 
This O 
provides O 
new O 
insights O 
in O 
understanding O 
the O 
mechanisms O 
of O 
amylose O 
gelation O 
. O 

explore O 
the O 
transport O 
of O 
electrons O 
between O 
electrodes O 
that O 
encase O 
a O 
two O 
- O 
dimensional O 
array O 
of O 
metallic O 
quantum O 
dots O 
linked O 
by O 
molecular O 
bridges O 
( O 
such O 
as O 
α,ω O 
alkaline O 
dithiols B-FAMILY 
) O 
. O 
Because O 
the O 
molecules O 
can O 
move O 
at O 
finite O 
temperatures O 
, O 
the O 
entire O 
transport O 
structure O 
comprising O 
the O 
quantum O 
dots O 
and O 
the O 
molecules O 
is O 
in O 
dynamical O 
motion O 
while O 
the O 
charge O 
is O 
being O 
transported O 
. O 
There O 
are O 
then O 
several O 
physical O 
processes O 
( O 
physical O 
excursions O 
of O 
molecules O 
and O 
quantum O 
dots O 
, O 
electronic O 
migration O 
, O 
ordinary O 
vibrations O 
) O 
, O 
all O 
of O 
which O 
influence O 
electronic O 
transport O 
. O 
Each O 
can O 
occur O 
on O 
a O 
different O 
time O 
scale O 
. O 
It O 
is O 
therefore O 
not O 
appropriate O 
to O 
use O 
standard O 
approaches O 
to O 
this O 
sort O 
of O 
electron O 
transfer O 
problem O 
. O 
Instead O 
, O 
we O 
present O 
a O 
treatment O 
in O 
which O 
three O 
different O 
theoretical O 
approaches O 
- O 
kinetic O 
Monte O 
Carlo O 
, O 
classical O 
molecular O 
dynamics O 
, O 
and O 
quantum O 
transport O 
- O 
are O 
all O 
employed O 
. O 
In O 
certain O 
limits O 
, O 
some O 
of O 
the O 
dynamical O 
effects O 
are O 
unimportant O 
. O 
But O 
in O 
general O 
, O 
the O 
transport O 
seems O 
to O 
follow O 
a O 
sort O 
of O 
dynamic O 
bond O 
percolation O 
picture O 
, O 
an O 
approach O 
originally O 
introduced O 
as O 
formal O 
models O 
and O 
later O 
applied O 
to O 
polymer O 
electrolytes O 
. O 
Different O 
rate O 
- O 
determining O 
steps O 
occur O 
in O 
different O 
limits O 
. O 
This O 
approach O 
offers O 
a O 
powerful O 
scheme O 
for O 
dealing O 
with O 
multiple O 
time O 
scale O 
transport O 
problems O 
, O 
as O 
will O 
exist O 
in O 
many O 
situations O 
with O 
several O 
pathways O 
through O 
molecular O 
arrays O 
or O 
even O 
individual O 
molecules O 
that O 
are O 
dynamically O 
disordered O 
. O 

thermal O 
stability O 
, O 
physico O 
- O 
chemical O 
properties O 
and O 
effect O 
on O 
juice O 
clarification O 
of O 
hydrogel O 
formulations O 
of O 
ligninolytic O 
enzymes O 
from O 
Phanerochaete O 
chrysosporium O 
were O 
evaluated O 
. O 
The O 
results O 
showed O 
that O 
enzyme O 
entrapment O 
increase O 
significantly O 
( O 
P O 
< O 
0.05 O 
) O 
the O 
thermal O 
stability O 
of O 
enzymes O 
at O 
4 O 
and O 
75 O 
°C O 
. O 
At O 
75 O 
°C O 
, O 
maximum O 
activity O 
decreased O 
to O 
non O 
detectable O 
values O 
of O 
7.9% O 
for O 
free O 
laccase O 
, O 
manganese B-SYSTEMATIC 
peroxidase O 
( O 
MnP O 
) O 
, O 
lignin O 
peroxidase O 
( O 
LiP O 
) O 
, O 
respectively O 
; O 
to O 
94% O 
, O 
97% O 
, O 
93% O 
for O 
laccase O 
, O 
MnP O 
and O 
LiP O 
entrapped O 
into O 
Polyacrylamide B-FAMILY 
/ O 
pectin O 
, O 
94% O 
, O 
98% O 
, O 
88% O 
for O 
laccase O 
, O 
MnP O 
and O 
LiP O 
encapsulated O 
respectively O 
into O 
polyacrylamide B-SYSTEMATIC 
/ O 
gelatine O 
and O 
to O 
87% O 
, O 
91% O 
, O 
87% O 
for O 
laccase O 
, O 
MnP O 
and O 
LiP O 
entrapped O 
, O 
respectively O 
into O 
polyacrylamide B-SYSTEMATIC 
/ O 
carboxymethylcellulose O 
( O 
CMC O 
) O 
. O 
When O 
particle O 
size O 
and O 
viscosity O 
of O 
the O 
formulation O 
increased O 
, O 
enzyme O 
stability O 
increased O 
. O 
The O 
polyphenolic O 
reduction O 
and O 
clarity O 
amelioration O 
in O 
mixed O 
juice O 
of O 
berry O 
and O 
pomegranate O 
was O 
more O 
significant O 
( O 
p O 
> O 
0.05 O 
) O 
using O 
encapsulated O 
enzymes O 
treatment O 
than O 
free O 
enzymes O 
. O 
This O 
suggested O 
that O 
enzymatic O 
treatment O 
was O 
efficient O 
for O 
the O 
juice O 
clarification O 
. O 

of O 
high O 
- O 
pressure O 
treatment O 
on O 
biogenic O 
amines B-FAMILY 
formation O 
in O 
vacuum O 
- O 
packed O 
trout O 
flesh O 
( O 
Oncorhynchus O 
mykiss O 
) O 
. O 

effects O 
of O 
vacuum O 
packaging O 
followed O 
by O 
high O 
pressure O 
processing O 
on O 
the O 
shelf O 
- O 
life O 
of O 
fillets O 
of O 
rainbow O 
trout O 
( O 
Oncorhynchus O 
mykiss O 
) O 
were O 
examined O 
. O 
Samples O 
were O 
pressure O 
- O 
treated O 
at O 
300 O 
and O 
500 O 
MPa O 
and O 
were O 
stored O 
at O 
3.5 O 
and O 
12 O 
°C O 
for O 
up O 
to O 
28 O 
days O 
( O 
control O 
-- O 
0 O 
MPa O 
) O 
and O 
42 O 
or O 
70 O 
days O 
( O 
pressure O 
- O 
treated O 
; O 
12 O 
and O 
3.5 O 
°C O 
resp O 
. O 
) O 
. O 
The O 
content O 
of O 
eight O 
biogenic O 
amines B-FAMILY 
( O 
putrescine B-TRIVIAL 
, O 
cadaverine B-TRIVIAL 
, O 
spermidine B-TRIVIAL 
, O 
spermine B-TRIVIAL 
, O 
histamine B-TRIVIAL 
, O 
tyramine B-TRIVIAL 
, O 
tryptamine B-TRIVIAL 
and O 
phenylethylamine B-SYSTEMATIC 
) O 
were O 
determined O 
. O 
Putrescine B-TRIVIAL 
, O 
cadaverine B-TRIVIAL 
and O 
tyramine B-TRIVIAL 
showed O 
very O 
good O 
correspondence O 
with O 
the O 
level O 
of O 
applied O 
pressure O 
and O 
organoleptic O 
properties O 
. O 
Samples O 
of O 
very O 
good O 
quality O 
contained O 
less O 
than O 
10 O 
mg O 
/ O 
kg O 
of O 
each O 
of O 
these O 
amines B-FAMILY 
. O 
Polyamines B-FAMILY 
spermidine B-TRIVIAL 
and O 
spermine B-TRIVIAL 
did O 
not O 
show O 
statistically O 
significant O 
changes O 
with O 
the O 
level O 
of O 
applied O 
pressure O 
and O 
the O 
time O 
of O 
storage O 
. O 
Tryptamine B-TRIVIAL 
, O 
phenylethylamine B-SYSTEMATIC 
and O 
histamine B-TRIVIAL 
( O 
with O 
the O 
single O 
exception O 
of O 
a O 
sample O 
stored O 
for O 
70 O 
days O 
) O 
were O 
not O 
detected O 
in O 
pressure O 
- O 
treated O 
samples O 
kept O 
at O 
3.5 O 
°C O 
. O 

volatiles O 
are O 
recognised O 
as O 
a O 
potential O 
source O 
of O 
aroma O 
compounds O 
in O 
fruits O 
. O 
In O 
this O 
study O 
, O 
the O 
bound O 
volatiles O 
of O 
Actinidia O 
deliciosa O 
' O 
Hayward O 
' O 
and O 
A O 
. O 
chinensis O 
' O 
Hort16A O 
' O 
were O 
studied O 
at O 
three O 
different O 
ripening O 
stages O 
. O 
The O 
bound O 
volatile O 
content O 
tended O 
to O 
increase O 
as O 
the O 
fruit O 
ripened O 
from O 
under O 
- O 
ripe O 
to O 
ripe O 
, O 
and O 
then O 
decreased O 
in O 
over O 
- O 
ripe O 
fruit O 
. O 
Glycosides O 
of O 
(Z)-3-hexen-1-ol B-SYSTEMATIC 
and O 
hexanol B-SYSTEMATIC 
( O 
green O 
- O 
note O 
volatiles O 
) O 
were O 
present O 
in O 
considerable O 
amounts O 
. O 
β-Glucosidase O 
activity O 
in O 
' O 
Hayward O 
' O 
and O 
' O 
Hort16A O 
' O 
remained O 
fairly O 
constant O 
throughout O 
ripening O 
. O 
GC-olfactometry O 
analysis O 
of O 
the O 
hydrolysates O 
of O 
ripe O 
' O 
Hayward O 
' O 
and O 
' O 
Hort16A O 
' O 
revealed O 
the O 
presence O 
of O 
2-phenylethanol B-SYSTEMATIC 
, O 
β-damascenone B-TRIVIAL 
, O 
vanillin B-TRIVIAL 
and O 
2,5-dimethyl-4-hydroxy-3(2H)-furanone B-SYSTEMATIC 
( O 
DMHF B-ABBREVIATION 
) O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
DMHF B-ABBREVIATION 
in O 
' O 
Hayward O 
' O 
kiwifruit O 
. O 
For O 
both O 
' O 
Hayward O 
' O 
and O 
' O 
Hort16A O 
' O 
, O 
the O 
odour O 
- O 
active O 
compounds O 
found O 
in O 
the O 
bound O 
volatile O 
extracts O 
were O 
different O 
from O 
those O 
reported O 
as O 
contributors O 
to O 
the O 
aroma O 
of O 
the O 
ripe O 
fruit O 
, O 
suggesting O 
that O 
bound O 
volatiles O 
are O 
probably O 
not O 
significant O 
contributors O 
to O 
the O 
aroma O 
of O 
ripe O 
kiwifruit O 
. O 

composition O 
, O 
fatty B-FAMILY 
acid I-FAMILY 
profile O 
, O 
cholesterol B-TRIVIAL 
, O 
α-tocoferol B-TRIVIAL 
content O 
and O 
essential O 
( O 
K B-FORMULA 
, O 
Na B-FORMULA 
, O 
Cl B-FORMULA 
, O 
S B-FORMULA 
, O 
Mg B-FORMULA 
, O 
Ca B-FORMULA 
, O 
Zn B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Fe B-FORMULA 
, O 
Mn B-FORMULA 
, O 
and O 
Se B-FORMULA 
) O 
and O 
contaminant O 
element O 
( O 
Hg B-FORMULA 
/ O 
MeHg B-FORMULA 
, O 
Cd B-FORMULA 
, O 
Pb B-FORMULA 
, O 
and O 
As B-FORMULA 
) O 
levels O 
in O 
silver B-SYSTEMATIC 
scabbardfish O 
( O 
Lepidopus O 
caudatus O 
) O 
, O 
hake O 
( O 
Merluccius O 
merluccius O 
) O 
, O 
and O 
ray O 
( O 
Raja O 
spp O 
. O 
) O 
were O 
investigated O 
. O 
Results O 
showed O 
that O 
these O 
species O 
contain O 
high O 
protein O 
, O 
low O 
cholesterol B-TRIVIAL 
and O 
energy O 
levels O 
, O 
being O 
its O 
consumption O 
recommended O 
. O 
Polyunsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
PUFA B-ABBREVIATION 
) O 
were O 
the O 
dominant O 
group O 
of O 
the O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
being O 
80% O 
of O 
the O 
n-3 O 
family O 
. O 
Attending O 
to O 
the O 
dietary O 
reference O 
intakes O 
( O 
DRIs O 
) O 
, O 
these O 
fish O 
species O 
are O 
a O 
good O 
source O 
of O 
Se B-FORMULA 
and O 
the O 
other O 
minerals O 
can O 
give O 
a O 
relevant O 
contribution O 
to O 
the O 
DRIs O 
in O 
a O 
balanced O 
diet O 
. O 
More O 
than O 
one O 
weekly O 
meal O 
of O 
silver B-SYSTEMATIC 
scabbardfish O 
has O 
to O 
be O 
avoided O 
due O 
to O 
the O 
organic O 
mercury B-SYSTEMATIC 
concentration O 
. O 
More O 
accurate O 
dietary O 
recommendations O 
require O 
a O 
probabilistic O 
assessment O 
, O 
which O 
will O 
be O 
the O 
focus O 
of O 
this O 
study's O 
Part O 
B O 
. O 

paper O 
describes O 
the O 
use O 
of O 
QuEChERS O 
( O 
Quick O 
, O 
Easy O 
, O 
Cheap O 
, O 
Effective O 
, O 
Rugged O 
and O 
Safe O 
) O 
for O 
the O 
extraction O 
, O 
cleanup O 
and O 
detection O 
of O 
10 O 
paralytic O 
shellfish O 
toxins O 
( O 
PSP O 
) O 
in O 
sea O 
food O 
by O 
HILIC-MS O 
/ O 
MS O 
with O 
positive O 
ESI O 
. O 
Matrix O 
matched O 
calibration O 
standards O 
were O 
used O 
to O 
compensate O 
for O 
matrix O 
effects O 
. O 
The O 
toxins O 
were O 
extracted O 
with O 
acetonitrile B-SYSTEMATIC 
/ O 
water O 
( O 
90 O 
: O 
10 O 
, O 
v O 
/ O 
v O 
) O 
containing O 
0.1% O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
cleaned O 
by O 
HLB O 
and O 
GCB B-ABBREVIATION 
sorbents O 
. O 
Qualitative O 
and O 
quantitative O 
detection O 
for O 
the O 
analytes O 
were O 
carried O 
out O 
under O 
the O 
multiple O 
reaction O 
monitoring O 
( O 
MRM O 
) O 
in O 
positive O 
ionization O 
mode O 
after O 
chromatography O 
separation O 
on O 
a O 
TSK-gel O 
Amide B-SYSTEMATIC 
-80 O 
® O 
column O 
( O 
150 O 
mm×2.0 O 
mm×3 O 
μm O 
) O 
. O 
Studies O 
at O 
three O 
fortification O 
levels O 
for O 
the O 
toxins O 
in O 
the O 
range O 
of O 
8.1-225.5 O 
μg O 
/ O 
kg O 
gave O 
mean O 
recoveries O 
from O 
71.3% O 
to O 
104.6% O 
with O 
relative O 
standard O 
deviation O 
( O 
RSD O 
) O 
≤ O 
15.8% O 
. O 
The O 
limit O 
of O 
detection O 
( O 
LOD O 
) O 
was O 
below O 
the O 
recommended O 
regulatory O 
limit O 
of O 
170 O 
μg O 
STX B-ABBREVIATION 
( O 
equ O 
. O 
) O 
/ O 
kg O 
and O 
the O 
proposed O 
method O 
fully O 
meets O 
the O 
needs O 
of O 
daily O 
monitoring O 
. O 

of O 
HIV-1 O 
attachment O 
. O 
Part O 
10 O 
. O 
The O 
discovery O 
and O 
structure O 
- O 
activity O 
relationships O 
of O 
4-azaindole B-SYSTEMATIC 
cores O 
. O 

series O 
of O 
4-azaindole B-FAMILY 
oxoacetic I-FAMILY 
acid I-FAMILY 
piperazine I-FAMILY 
benzamides I-FAMILY 
was O 
synthesized O 
and O 
evaluated O 
in O 
an O 
effort O 
to O 
identify O 
an O 
oral O 
HIV-1 O 
attachment O 
inhibitor O 
with O 
the O 
potential O 
to O 
improve O 
upon O 
the O 
pre O 
- O 
clinical O 
profile O 
of O 
BMS-378806 B-IDENTIFIER 
( O 
7 O 
) O 
, O 
an O 
initial O 
clinical O 
compound O 
. O 
Modifications O 
at O 
the O 
7- O 
position O 
of O 
the O 
4-azaindole B-SYSTEMATIC 
core O 
modulated O 
potency O 
significantly O 
and O 
SAR O 
showed O 
that O 
certain O 
compounds O 
with O 
a O 
5-membered O 
ring O 
heteroaryl O 
group O 
at O 
that O 
position O 
were O 
the O 
most O 
potent O 
. O 
Four O 
of O 
the O 
compounds O 
with O 
the O 
best O 
profiles O 
were O 
evaluated O 
in O 
a O 
rat O 
pharmacokinetic O 
model O 
and O 
all O 
had O 
superior O 
oral O 
bioavailability O 
and O 
lower O 
clearance O 
when O 
compared O 
with O 
7 O 
. O 

( O 
KCA-1490 B-IDENTIFIER 
) O 
exhibits O 
moderate O 
dual O 
PDE3 O 
/ O 
4-inhibitory O 
activity O 
and O 
promises O 
as O 
a O 
combined O 
bronchodilatory O 
/ O 
anti-inflammatory O 
agent O 
. O 
N B-FORMULA 
-alkylation O 
of O 
the O 
pyridazinone B-SYSTEMATIC 
ring O 
markedly O 
enhances O 
potency O 
against O 
PDE4 O 
but O 
suppresses O 
PDE3 O 
inhibition O 
. O 
Addition O 
of O 
a O 
6-aryl-4,5-dihydropyridazin-3(2H)-one B-FAMILY 
extension O 
to O 
the O 
N B-FORMULA 
-alkyl O 
group O 
facilitates O 
both O 
enhancement O 
of O 
PDE4-inhibitory O 
activity O 
and O 
restoration O 
of O 
potent O 
PDE3 O 
inhibition O 
. O 
Both O 
dihydropyridazinone B-SYSTEMATIC 
rings O 
, O 
in O 
the O 
core O 
and O 
extension O 
, O 
can O 
be O 
replaced O 
by O 
achiral O 
4,4-dimethylpyrazolone B-SYSTEMATIC 
subunits O 
and O 
the O 
core O 
pyrazolopyridine B-SYSTEMATIC 
by O 
isosteric O 
bicyclic O 
heteroaromatics O 
. O 
In O 
combination O 
, O 
these O 
modifications O 
afford O 
potent O 
dual O 
PDE3 O 
/ O 
4 O 
inhibitors O 
that O 
suppress O 
histamine B-TRIVIAL 
-induced O 
bronchoconstriction O 
in O 
vivo O 
and O 
exhibit O 
promising O 
anti-inflammatory O 
activity O 
via O 
intratracheal O 
administration O 
. O 

from O 
the O 
dissection O 
of O 
the O 
activation O 
functions O 
( O 
AF-1 O 
and O 
AF-2 O 
) O 
of O 
the O 
estrogen B-FAMILY 
receptor O 
alpha O 
in O 
vivo O 
. O 

influence O 
most O 
of O 
the O 
physiological O 
processes O 
in O 
mammals O 
, O 
including O 
but O 
not O 
limited O 
to O 
reproduction O 
, O 
cognition O 
, O 
behavior O 
, O 
vascular O 
system O 
, O 
metabolism O 
and O 
bone O 
integrity O 
. O 
Given O 
this O 
widespread O 
role O 
for O 
estrogen B-FAMILY 
in O 
human O 
physiology O 
, O 
it O 
is O 
not O 
surprising O 
that O 
estrogen B-FAMILY 
influence O 
the O 
pathophysiology O 
of O 
numerous O 
diseases O 
, O 
including O 
cancer O 
( O 
of O 
the O 
reproductive O 
tract O 
as O 
breast O 
, O 
endometrial O 
but O 
also O 
colorectal O 
, O 
prostate,… O 
) O 
, O 
as O 
well O 
as O 
neurodegenerative O 
, O 
inflammatory O 
- O 
immune O 
, O 
cardiovascular O 
and O 
metabolic O 
diseases O 
, O 
and O 
osteoporosis O 
. O 
These O 
actions O 
are O 
mediated O 
by O 
the O 
activation O 
of O 
estrogen B-FAMILY 
receptors O 
( O 
ER O 
) O 
alpha O 
( O 
ERα O 
) O 
and O 
beta O 
( O 
ERβ O 
) O 
, O 
which O 
regulate O 
target O 
gene O 
transcription O 
( O 
genomic O 
action O 
) O 
through O 
two O 
independent O 
activation O 
functions O 
(AF)-1 O 
and O 
AF-2 O 
, O 
but O 
can O 
also O 
elicit O 
rapid O 
membrane O 
initiated O 
steroid B-FAMILY 
signals O 
( O 
MISS O 
) O 
. O 
Targeted O 
ER O 
gene O 
inactivation O 
has O 
shown O 
that O 
although O 
ERβ O 
plays O 
an O 
important O 
role O 
in O 
the O 
central O 
nervous O 
system O 
and O 
in O 
the O 
heart O 
, O 
ERα O 
appears O 
to O 
play O 
a O 
prominent O 
role O 
in O 
most O 
of O 
the O 
other O 
tissues O 
. O 
Pharmacological O 
activation O 
or O 
inhibition O 
of O 
ERα O 
and O 
/ O 
or O 
ERβ O 
provides O 
already O 
the O 
basis O 
for O 
many O 
therapeutic O 
interventions O 
, O 
from O 
hormone O 
replacement O 
at O 
menopause O 
to O 
prevention O 
of O 
the O 
recurrence O 
of O 
breast O 
cancer O 
. O 
However O 
, O 
the O 
use O 
of O 
these O 
estrogens B-FAMILY 
or O 
selective O 
estrogen B-FAMILY 
receptors O 
modulators O 
( O 
SERMs O 
) O 
have O 
also O 
induced O 
undesired O 
effects O 
. O 
Thus O 
, O 
an O 
important O 
challenge O 
consists O 
now O 
to O 
uncouple O 
the O 
beneficial O 
actions O 
from O 
other O 
deleterious O 
ones O 
. O 
The O 
in O 
vivo O 
molecular O 
" O 
dissection O 
" O 
of O 
ERα O 
represents O 
both O 
a O 
molecular O 
and O 
integrated O 
approach O 
that O 
already O 
allowed O 
to O 
delineate O 
in O 
mouse O 
the O 
role O 
of O 
the O 
main O 
" O 
subfunctions O 
" O 
of O 
the O 
receptor O 
and O 
that O 
could O 
pave O 
the O 
way O 
to O 
an O 
optimization O 
of O 
the O 
ER O 
modulation O 
. O 

of O 
quercetin B-TRIVIAL 
on O 
mRNA O 
expression O 
of O 
steroidogenesis O 
genes O 
in O 
primary O 
cultures O 
of O 
Leydig O 
cells O 
treated O 
with O 
atrazine B-TRIVIAL 
. O 

effect O 
of O 
the O 
phytoestrogen O 
, O 
quercetin B-TRIVIAL 
( O 
QT O 
) O 
on O 
the O 
reproductive O 
toxicity O 
of O 
atrazine B-TRIVIAL 
( O 
ATZ B-ABBREVIATION 
) O 
was O 
explored O 
in O 
interstitial O 
Leydig O 
cells O 
( O 
ILCs O 
) O 
. O 
We O 
measured O 
the O 
mRNA O 
expressions O 
of O 
steroidogenesis O 
genes O 
: O 
steroidogenic O 
acute O 
regulatory O 
protein O 
( O 
StAR O 
) O 
, O 
3β-hydroxysteroid B-FAMILY 
dehydrogenase O 
( O 
3β-HSD O 
) O 
, O 
cytochrome-P450 O 
( O 
CYP O 
) O 
11A1 O 
, O 
insulin O 
- O 
like O 
factor O 
3 O 
( O 
INSL-3 O 
) O 
, O 
CYP17A1 O 
, O 
inhibin-α O 
( O 
INH-α O 
) O 
, O 
androgen B-FAMILY 
receptor O 
( O 
AR O 
) O 
, O 
estrogen B-FAMILY 
receptor-α O 
( O 
ER-α O 
) O 
, O 
and O 
luteinising O 
hormone O 
receptor O 
( O 
LHR O 
) O 
in O 
isolated O 
ILCs O 
by O 
real-time-PCR O 
after O 
cultured O 
cells O 
were O 
treated O 
in O 
vitro O 
with O 
ATZ B-ABBREVIATION 
( O 
232 O 
μM O 
) O 
and O 
QT O 
( O 
50 O 
μM O 
) O 
. O 
The O 
mRNA O 
expression O 
of O 
tested O 
genes O 
increased O 
with O 
ATZ B-ABBREVIATION 
treatment O 
and O 
was O 
normalized O 
by O 
quercetin B-TRIVIAL 
except O 
AR O 
and O 
ER-α O 
expression O 
. O 
Treatment O 
of O 
cells O 
with O 
QT O 
alone O 
( O 
15-50 O 
μM O 
) O 
caused O 
a O 
dose O 
- O 
dependent O 
increase O 
in O 
AR O 
and O 
ER-α O 
mRNA O 
expression O 
. O 
We O 
also O 
found O 
that O 
QT O 
( O 
50 O 
μM O 
) O 
increased O 
the O 
expressions O 
of O 
AR O 
and O 
ER-α O 
in O 
the O 
presence O 
of O 
a O 
sub O 
- O 
threshold O 
level O 
of O 
cyclic-AMP B-TRIVIAL 
at O 
1h O 
culture O 
period O 
to O 
the O 
levels O 
seen O 
with O 
maximal O 
stimulation O 
of O 
cyclic-AMP B-TRIVIAL 
. O 
Furthermore O 
, O 
the O 
expressions O 
of O 
tested O 
genes O 
were O 
unaffected O 
by O 
cyclic-AMP B-TRIVIAL 
at O 
6h O 
when O 
the O 
stimulatory O 
effects O 
of O 
ATZ B-ABBREVIATION 
on O 
tested O 
genes O 
were O 
sustained O 
. O 
These O 
findings O 
suggest O 
that O 
ATZ B-ABBREVIATION 
may O 
stimulate O 
the O 
expression O 
of O 
tested O 
steroidogenesis O 
genes O 
in O 
ILCs O 
via O 
a O 
mechanism O 
independent O 
of O 
cyclic-AMP B-TRIVIAL 
which O 
was O 
partially O 
antagonize O 
by O 
QT O 
. O 

of O 
pubertal O 
exposure O 
to O 
thiazole B-SYSTEMATIC 
- O 
Zn B-FORMULA 
on O 
thyroid O 
function O 
and O 
development O 
in O 
female O 
rats O 
. O 

- O 
Zn B-FORMULA 
is O 
a O 
newly O 
Chinese O 
- O 
created O 
systemic O 
fungicide O 
, O 
and O 
belongs O 
to O 
the O 
sort O 
of O 
thiadiazole B-SYSTEMATIC 
compounds O 
, O 
some O 
of O 
which O 
have O 
been O 
found O 
to O 
be O 
thyroid O 
disrupters O 
. O 
To O 
determine O 
the O 
probable O 
adverse O 
effects O 
of O 
thiazole B-SYSTEMATIC 
- O 
Zn B-FORMULA 
on O 
thyroid O 
gland O 
and O 
development O 
function O 
, O 
the O 
rodent O 
20-day O 
Pubertal O 
Female O 
Assay O 
in O 
this O 
study O 
was O 
used O 
. O 
Postnatal O 
days O 
( O 
PND O 
) O 
22-old O 
Sprague-Dawley O 
rats O 
were O 
administered O 
with O 
thiazole B-SYSTEMATIC 
- O 
Zn B-FORMULA 
daily O 
by O 
oral O 
gavage O 
at O 
doses O 
0 O 
, O 
40 O 
, O 
100 O 
, O 
200 O 
mg O 
/ O 
kg O 
/ O 
day O 
for O 
20 O 
days O 
. O 
The O 
thyroid O 
endpoints O 
and O 
development O 
endpoints O 
were O 
assessed O 
. O 
The O 
results O 
indicated O 
that O 
serum O 
TT4 O 
and O 
TSH O 
levels O 
were O 
significantly O 
increased O 
at O 
all O 
concentrations O 
, O 
serum O 
TT3 O 
levels O 
were O 
significantly O 
reduced O 
only O 
at O 
40 O 
mg O 
/ O 
kg O 
thiazole B-SYSTEMATIC 
- O 
Zn B-FORMULA 
, O 
but O 
had O 
no O 
difference O 
from O 
controls O 
at O 
the O 
other O 
doses O 
. O 
Thyroid O 
histology O 
was O 
significantly O 
altered O 
at O 
all O 
doses O 
with O 
a O 
clear O 
dose O 
- O 
dependent O 
hypertrophy O 
and O 
hyperplasia O 
of O 
thyroid O 
cell O 
. O 
No O 
histological O 
changes O 
were O 
observed O 
in O 
any O 
of O 
the O 
other O 
observed O 
organs O 
. O 
In O 
addition O 
, O 
this O 
study O 
also O 
found O 
that O 
ovarian O 
weights O 
were O 
significantly O 
decreased O 
, O 
but O 
age O 
and O 
weight O 
at O 
vaginal O 
opening O 
( O 
VO O 
) O 
, O 
serum O 
E2 O 
levels O 
were O 
unaffected O 
in O 
all O 
treatment O 
groups O 
. O 
These O 
results O 
demonstrate O 
that O 
thiazole B-SYSTEMATIC 
- O 
Zn B-FORMULA 
is O 
likely O 
a O 
thyroid O 
disrupter O 
, O 
but O 
did O 
not O 
demonstrate O 
that O 
it O 
has O 
estrogenic O 
/ O 
anti-estrogenic O 
activity O 
. O 

10-minute O 
point O 
- O 
of O 
- O 
care O 
assay O 
for O 
detection O 
of O 
blood O 
protein O 
adducts O 
resulting O 
from O 
low O 
level O 
exposure O 
to O 
organophosphate B-FAMILY 
nerve O 
agents O 
. O 

OrganoTox O 
test O 
is O 
a O 
rapid O 
, O 
point O 
- O 
of O 
- O 
care O 
assay O 
capable O 
of O 
detecting O 
clinically O 
relevant O 
organophosphate B-FAMILY 
( O 
OP O 
) O 
poisoning O 
after O 
low O 
- O 
level O 
exposure O 
to O 
sarin B-TRIVIAL 
, O 
soman B-TRIVIAL 
, O 
tabun B-TRIVIAL 
, O 
or O 
VX O 
chemical O 
nerve O 
agents O 
. O 
The O 
test O 
utilizes O 
either O 
a O 
finger O 
stick O 
peripheral O 
blood O 
sample O 
or O 
plasma O 
specimen O 
. O 
While O 
high O 
- O 
level O 
nerve O 
agent O 
exposure O 
can O 
quickly O 
lead O 
to O 
death O 
, O 
low O 
- O 
level O 
exposure O 
produces O 
vague O 
, O 
nondescript O 
signs O 
and O 
symptoms O 
that O 
are O 
not O 
easily O 
clinically O 
differentiated O 
from O 
other O 
conditions O 
. O 
In O 
initial O 
testing O 
, O 
the O 
OrganoTox O 
test O 
was O 
used O 
to O 
detect O 
the O 
presence O 
of O 
blood O 
protein O 
- O 
nerve O 
agent O 
adducts O 
in O 
exposed O 
blood O 
samples O 
. O 
In O 
order O 
to O 
mimic O 
the O 
in O 
vivo O 
exposure O 
as O 
closely O 
as O 
possible O 
, O 
nerve O 
agents O 
stored O 
in O 
organic O 
solvents O 
were O 
spiked O 
in O 
minute O 
quantities O 
into O 
whole O 
blood O 
samples O 
. O 
For O 
performance O 
testing O 
, O 
40 O 
plasma O 
samples O 
were O 
spiked O 
with O 
sarin B-TRIVIAL 
, O 
soman B-TRIVIAL 
, O 
tabun B-TRIVIAL 
, O 
or O 
VX O 
and O 
10 O 
normal O 
plasma O 
samples O 
were O 
used O 
as O 
the O 
negative O 
control O 
. O 
The O 
40 O 
nerve O 
agent-spiked O 
plasma O 
samples O 
included O 
10 O 
replicates O 
of O 
each O 
agent O 
. O 
At O 
the O 
clinically O 
relevant O 
low O 
- O 
level O 
exposure O 
of O 
10ng O 
/ O 
ml O 
, O 
the O 
OrganoTox O 
test O 
demonstrated O 
100% O 
sensitivity O 
for O 
soman B-TRIVIAL 
, O 
tabun B-TRIVIAL 
, O 
and O 
VX O 
and O 
80% O 
sensitivity O 
for O 
sarin B-TRIVIAL 
. O 
The O 
OrganoTox O 
test O 
demonstrated O 
greater O 
than O 
97% O 
specificity O 
with O 
150 O 
blood O 
samples O 
obtained O 
from O 
healthy O 
adults O 
. O 
No O 
cross O 
- O 
reactivity O 
or O 
interference O 
from O 
pesticide O 
precursor O 
compounds O 
was O 
found O 
. O 
A O 
rapid O 
test O 
for O 
nerve O 
agent O 
exposure O 
will O 
help O 
identify O 
affected O 
patients O 
earlier O 
in O 
the O 
clinical O 
course O 
and O 
trigger O 
more O 
appropriate O 
medical O 
management O 
in O 
a O 
more O 
timely O 
manner O 
. O 

expression O 
of O 
genes O 
involved O 
in O 
progesterone B-TRIVIAL 
biosynthesis O 
, O 
metabolism O 
and O 
action O 
in O 
endometrial O 
cancer O 
. O 

cancer O 
( O 
EC O 
) O 
is O 
one O 
of O 
the O 
most O 
common O 
gynecological O 
malignancies O 
worldwide O 
. O 
It O 
is O 
associated O 
with O 
prolonged O 
exposure O 
to O 
estrogens O 
that O 
is O 
unopposed O 
by O 
the O 
protective O 
effects O 
of O 
progesterone B-TRIVIAL 
, O 
which O 
suggests O 
that O 
altered O 
progesterone B-TRIVIAL 
biosynthesis O 
, O 
metabolism O 
and O 
actions O 
might O 
be O 
implicated O 
in O 
the O 
development O 
of O 
EC O 
. O 
Our O 
aim O 
was O 
to O 
evaluate O 
these O 
processes O 
through O 
quantitative O 
real O 
- O 
time O 
PCR O 
expression O 
analysis O 
in O 
up O 
to O 
47 O 
pairs O 
of O 
EC O 
tissue O 
and O 
adjacent O 
control O 
endometrium O 
. O 
First O 
, O 
we O 
examined O 
the O 
expression O 
of O 
genes O 
encoding O 
proteins O 
associated O 
with O 
progesterone B-TRIVIAL 
biosynthesis O 
: O 
steroidogenic O 
acute O 
regulatory O 
protein O 
( O 
STAR O 
) O 
; O 
a O 
side O 
chain O 
cleavage O 
enzyme O 
( O 
CYP11A1 O 
) O 
; O 
and O 
3β-hydroxysteroid B-FAMILY 
dehydrogenase/ O 
ketosteroid B-FAMILY 
isomerase O 
( O 
HSD3B O 
) O 
. O 
There O 
were O 
1.9- O 
and O 
10.0-fold O 
decreased O 
expression O 
of O 
STAR O 
and O 
CYP11A1 O 
, O 
respectively O 
, O 
in O 
EC O 
versus O 
adjacent O 
control O 
endometrium O 
, O 
with O 
no O 
significant O 
differences O 
in O 
the O 
expression O 
of O 
HSD3B1 O 
and O 
HSD3B2 O 
. O 
Next O 
, O 
we O 
examined O 
expression O 
of O 
genes O 
encoding O 
five O 
progesterone B-TRIVIAL 
metabolizing O 
enzymes O 
: O 
the O 
3-keto B-MULTIPLE 
and I-MULTIPLE 
20-ketosteroid I-MULTIPLE 
reductases O 
( O 
AKR1C1-AKR1C3 O 
) O 
and O 
5α-reductases O 
( O 
SRD5A1 O 
and O 
SRD5A2 O 
) O 
; O 
and O 
the O 
opposing O 
20α-hydroxysteroid B-FAMILY 
dehydrogenase O 
( O 
HSD17B2 O 
) O 
. O 
These O 
genes O 
are O 
expressed O 
in O 
EC O 
and O 
adjacent O 
control O 
endometrium O 
. O 
No O 
statistically O 
significant O 
differences O 
were O 
seen O 
in O 
mRNA O 
levels O 
of O 
AKR1C1 O 
, O 
AKR1C2 O 
, O 
AKR1C3 O 
and O 
SRD5A1 O 
. O 
Expression O 
of O 
HSD17B2 O 
was O 
3.0-fold O 
increased O 
, O 
and O 
expression O 
of O 
SRD5A2 O 
was O 
3.7-fold O 
decreased O 
, O 
in O 
EC O 
versus O 
adjacent O 
control O 
endometrium O 
. O 
We O 
also O 
examined O 
mRNA O 
levels O 
of O 
progesterone B-TRIVIAL 
receptors O 
A O 
and O 
B O 
( O 
PGR O 
) O 
, O 
and O 
separately O 
the O 
expression O 
of O 
progesterone B-TRIVIAL 
receptor O 
B O 
( O 
PR-B O 
) O 
. O 
Here O 
we O 
saw O 
1.8- O 
and O 
2.0-fold O 
lower O 
mRNA O 
levels O 
of O 
PGR O 
and O 
PR-B O 
, O 
respectively O 
, O 
in O 
EC O 
versus O 
adjacent O 
control O 
endometrium O 
. O 
This O 
down O 
- O 
regulation O 
of O 
STAR O 
, O 
CYP11A1 O 
and O 
PGR O 
in O 
endometrial O 
cancer O 
may O 
lead O 
to O 
decreased O 
progesterone B-TRIVIAL 
biosynthesis O 
and O 
actions O 
although O 
the O 
effects O 
on O 
progesterone B-TRIVIAL 
levels O 
should O 
be O 
further O 
studied O 
. O 

and O 
evolution O 
of O 
medium O 
chain O 
alcohol B-FAMILY 
dehydrogenases O 
. O 

lines O 
of O 
alcohol B-FAMILY 
dehydrogenases O 
( O 
ADHs O 
) O 
have O 
separate O 
superfamily O 
origins O 
, O 
already O 
recognized O 
but O 
now O 
extended O 
and O 
re O 
- O 
evaluated O 
by O 
re O 
- O 
screening O 
of O 
the O 
latest O 
databank O 
update O 
. O 
The O 
short O 
- O 
chain O 
form O 
( O 
SDR O 
) O 
is O 
still O 
the O 
superfamily O 
with O 
most O 
abundant O 
occurrence O 
, O 
most O 
multiple O 
divergence O 
, O 
most O 
prokaryotic O 
emphasis O 
, O 
and O 
most O 
non-complicated O 
architecture O 
. O 
This O 
pattern O 
is O 
compatible O 
with O 
an O 
early O 
appearance O 
at O 
the O 
time O 
of O 
the O 
emergence O 
of O 
prokaryotic O 
cellular O 
life O 
. O 
The O 
medium O 
- O 
chain O 
form O 
( O 
MDR O 
) O 
is O 
also O 
old O 
but O 
second O 
in O 
terms O 
of O 
all O 
the O 
parameters O 
above O 
, O 
and O 
therefore O 
compatible O 
with O 
a O 
second O 
emergence O 
. O 
However O 
, O 
this O 
step O 
appears O 
seemingly O 
earlier O 
than O 
previously O 
considered O 
, O 
and O 
may O 
indicate O 
sub O 
- O 
stages O 
of O 
early O 
emergences O 
at O 
the O 
increased O 
resolution O 
available O 
from O 
the O 
now O 
greater O 
number O 
of O 
data O 
entries O 
. O 
The O 
Zn B-FORMULA 
-MDR O 
origin O 
constitutes O 
a O 
third O 
stage O 
, O 
possibly O 
compatible O 
with O 
the O 
transition O 
to O 
oxidative O 
conditions O 
on O 
earth O 
. O 
Within O 
all O 
these O 
three O 
lines O 
, O 
repeated O 
enzymogeneses O 
gave O 
the O 
present O 
divergence O 
. O 
MDR-ADH O 
origin(s) O 
, O 
at O 
a O 
fourth O 
stage O 
, O 
may O 
also O 
be O 
further O 
resolved O 
in O 
multiple O 
or O 
extended O 
modes O 
, O 
but O 
the O 
classical O 
liver O 
MDR-ADH O 
of O 
the O 
liver O 
type O 
can O 
still O 
be O 
traced O 
to O 
a O 
gene O 
duplication O 
~550 O 
MYA O 
( O 
million O 
years O 
ago O 
) O 
, O 
at O 
the O 
early O 
vertebrate O 
radiation O 
, O 
compatible O 
with O 
the O 
post O 
- O 
eon O 
- O 
shift O 
, O 
" O 
Cambrian O 
explosion O 
" O 
. O 
Classes O 
and O 
isozymes O 
correspond O 
to O 
subsequent O 
and O 
recent O 
duplicatory O 
events O 
, O 
respectively O 
. O 
They O 
illustrate O 
a O 
peculiar O 
pattern O 
with O 
functional O 
and O 
emerging O 
evolutionary O 
distinctions O 
between O 
parent O 
and O 
emerging O 
lines O 
, O 
suggesting O 
a O 
parallelism O 
between O 
duplicatory O 
and O 
mutational O 
events O 
, O 
now O 
also O 
visible O 
at O 
separate O 
sub O 
- O 
stages O 
. O 
Combined O 
, O 
all O 
forms O 
show O 
distinctive O 
patterns O 
at O 
different O 
levels O 
and O 
illustrate O 
correlations O 
with O 
global O 
events O 
. O 
They O 
further O 
show O 
that O 
simple O 
molecular O 
observations O 
on O 
patterns O 
, O 
multiplicities O 
and O 
occurrence O 
give O 
much O 
information O 
, O 
suggesting O 
common O 
divergence O 
rules O 
not O 
much O 
disturbed O 
by O 
horizontal O 
gene O 
transfers O 
after O 
the O 
initial O 
origins O 
. O 

new O 
acid O 
- O 
sensitive O 
drug O 
- O 
delivery O 
nanocarrier O 
has O 
been O 
developed O 
for O 
tumour O 
targeting O 
. O 
The O 
self O 
- O 
assembling O 
co O 
- O 
polymer O 
stearoyl-PEG-poly B-FAMILY 
- I-FAMILY 
sulfadimethoxine I-FAMILY 
methacrylate I-FAMILY 
( O 
stearoyl-PEG-polySDM B-ABBREVIATION 
) O 
was O 
prepared O 
to O 
obtain O 
micelles O 
with O 
responsive O 
behaviour O 
in O 
the O 
physiopathologic O 
pH O 
range O 
. O 
Stearoyl-PEG-polySDM B-ABBREVIATION 
was O 
synthesised O 
using O 
a O 
multi O 
- O 
step O 
procedure O 
that O 
includes O 
pH-sensitive O 
sulfadimethoxine B-TRIVIAL 
methacrylate I-TRIVIAL 
polymerisation O 
by O 
AGET-ATRP O 
at O 
the O 
amino B-FAMILY 
terminal O 
side O 
of O 
stearoyl-PEG-NH2 B-FORMULA 
. O 
Chemical O 
analysis O 
showed O 
that O 
the O 
stearoyl-PEG-polySDM B-ABBREVIATION 
co O 
- O 
polymer O 
contained O 
a O 
mean O 
of O 
seven O 
methacryloyl B-FAMILY 
sulfadimethoxines I-FAMILY 
per O 
molecule O 
. O 
Potentiometric O 
and O 
turbidimetric O 
analyses O 
showed O 
that O 
stearoyl-PEG-polySDM B-ABBREVIATION 
has O 
an O 
apparent O 
pKa O 
of O 
7.2 O 
and O 
a O 
cloud O 
point O 
at O 
pH O 
7 O 
. O 
In O 
water O 
at O 
pH O 
7.4 O 
, O 
the O 
co O 
- O 
polymer O 
assembled O 
spontaneously O 
into O 
13.2±3.1 O 
nm O 
micelles O 
with O 
a O 
critical O 
micelle O 
concentration O 
( O 
CMC O 
) O 
of O 
36 O 
μM O 
. O 
Cell O 
- O 
culture O 
studies O 
showed O 
that O 
the O 
material O 
was O 
more O 
biocompatible O 
with O 
respect O 
to O 
the O 
control O 
Brij-700 B-TRIVIAL 
® O 
. O 
The O 
paclitaxel O 
loading O 
capacity O 
of O 
the O 
micelles O 
was O 
3.25±0.25% O 
( O 
w O 
/ O 
w O 
, O 
% O 
) O 
. O 
The O 
colloidal O 
formulations O 
were O 
stable O 
at O 
pH O 
7.4 O 
for O 
several O 
hours O 
, O 
while O 
at O 
pH O 
6.5 O 
, O 
they O 
rapidly O 
rearranged O 
and O 
aggregated O 
. O 
Fluorescence O 
spectroscopic O 
and O 
cytofluorimetric O 
studies O 
showed O 
that O 
the O 
incubation O 
of O 
MCF-7 O 
tumour O 
cells O 
with O 
fluorescein B-TRIVIAL 
-labelled O 
stearoyl-PEG-polySDM B-ABBREVIATION 
at O 
pH O 
6.5 O 
resulted O 
in O 
massive O 
time O 
- O 
dependent O 
cell O 
association O 
, O 
while O 
the O 
incubation O 
at O 
pH O 
7.4 O 
showed O 
significantly O 
lower O 
cell O 
interaction O 
. O 
Confocal O 
microscopy O 
confirmed O 
that O 
at O 
pH O 
6.5 O 
, O 
the O 
micelles O 
are O 
taken O 
up O 
by O 
cells O 
and O 
that O 
the O 
fluorescein B-TRIVIAL 
-labelled O 
stearoyl-PEG-polySDM B-ABBREVIATION 
is O 
distributed O 
into O 
the O 
cytosol O 
. O 
At O 
pH O 
6.5 O 
, O 
paclitaxel B-TRIVIAL 
-loaded O 
stearoyl-PEG-polySDM B-ABBREVIATION 
micelles O 
had O 
a O 
higher O 
cytotoxic O 
effect O 
than O 
the O 
micelles O 
incubated O 
at O 
pH O 
7.4 O 
. O 
The O 
former O 
displayed O 
similar O 
cytotoxic O 
activity O 
to O 
free O 
paclitaxel B-TRIVIAL 
. O 

for O 
the O 
regulation O 
of O 
GnRH O 
and O 
GTH O 
expression O 
by O 
GnIH B-ABBREVIATION 
in O 
the O 
goldfish O 
, O 
Carassius O 
auratus O 
. O 

- I-TRIVIAL 
inhibitory I-TRIVIAL 
hormone I-TRIVIAL 
( O 
GnIH B-ABBREVIATION 
) O 
plays O 
an O 
important O 
role O 
in O 
regulating O 
of O 
reproduction O 
in O 
teleosts O 
. O 
To O 
clarify O 
the O 
mode O 
of O 
action O 
of O 
GnIH O 
on O 
the O 
synthesis O 
of O 
gonadotropin O 
releasing O 
hormone O 
( O 
GnRH O 
) O 
and O 
gonadotrophin O 
( O 
GtH O 
) O 
, O 
three O 
GnIHR O 
cDNAs O 
were O 
cloned O 
from O 
the O 
goldfish O 
brain O 
. O 
In O 
situ O 
hybridization O 
results O 
showed O 
that O 
GnIHRs O 
were O 
localized O 
to O 
the O 
hypothalamus O 
and O 
pituitary O 
. O 
In O 
the O 
hypothalamus O 
, O 
GnIHRs O 
were O 
found O 
in O 
the O 
NPP O 
, O 
NPO O 
and O 
NLT O 
, O 
whereas O 
sGnRH O 
neurons O 
were O 
reported O 
to O 
be O 
located O 
, O 
and O 
potentially O 
regulated O 
by O 
GnIH B-ABBREVIATION 
. O 
In O 
the O 
pituitary O 
, O 
only O 
two O 
GnIHRs O 
were O 
observed O 
and O 
they O 
were O 
localized O 
to O 
the O 
PI O 
instead O 
of O 
the O 
adenohypophysis O 
where O 
GtH-expressing O 
cells O 
are O 
localized O 
, O 
suggesting O 
indirect O 
regulation O 
of O 
GtH O 
by O 
GnIH B-ABBREVIATION 
. O 
In O 
vivo O 
, O 
intraperitoneal O 
( O 
i.p O 
. O 
) O 
injections O 
of O 
synthetic O 
goldfish O 
GnIH B-ABBREVIATION 
-II O 
peptide O 
and O 
GnIH B-ABBREVIATION 
-III O 
peptide O 
significantly O 
decreased O 
sGnRH O 
and O 
FSHβ O 
mRNA O 
levels O 
. O 
Only O 
GnIH B-ABBREVIATION 
-II O 
decreased O 
LHβ O 
mRNA O 
levels O 
significantly O 
. O 
In O 
vitro O 
, O 
both O 
GnIH B-ABBREVIATION 
-II O 
and O 
GnIH B-ABBREVIATION 
-III O 
showed O 
no O 
effect O 
on O 
GtH O 
synthesis O 
, O 
but O 
an O 
inhibition O 
of O 
GnRH-stimulated O 
LHβ O 
and O 
FSHβ O 
synthesis O 
was O 
observed O 
when O 
GnIH B-ABBREVIATION 
-III O 
was O 
applied O 
to O 
primary O 
pituitary O 
cells O 
in O 
culture O 
. O 
Thus O 
, O 
GnIH B-ABBREVIATION 
could O 
contribute O 
to O 
the O 
regulation O 
of O 
gonadotropin O 
in O 
the O 
brain O 
and O 
pituitary O 
in O 
teleosts O 
. O 

and O 
sex O 
- O 
induced O 
neural O 
activity O 
across O 
vasotocin B-TRIVIAL 
populations O 
in O 
the O 
brown O 
anole O 
. O 

within O 
the O 
social O 
behavior O 
neural O 
network O 
is O 
modulated O 
by O 
the O 
neuropeptide O 
arginine B-TRIVIAL 
vasotocin I-TRIVIAL 
( O 
AVT B-ABBREVIATION 
) O 
and O 
its O 
mammalian O 
homologue O 
arginine B-TRIVIAL 
vasopressin I-TRIVIAL 
( O 
AVP B-ABBREVIATION 
) O 
. O 
However O 
, O 
central O 
AVT B-ABBREVIATION 
/ O 
AVP B-ABBREVIATION 
release O 
causes O 
different O 
behavioral O 
effects O 
across O 
species O 
and O 
social O 
environments O 
. O 
These O 
differences O 
may O 
be O 
due O 
to O 
the O 
activation O 
of O 
different O 
neuronal O 
AVT B-ABBREVIATION 
/ O 
AVP B-ABBREVIATION 
populations O 
or O 
to O 
similar O 
activity O 
patterns O 
causing O 
different O 
behavioral O 
outputs O 
. O 
We O 
examined O 
neural O 
activity O 
( O 
assessed O 
as O 
Fos O 
induction O 
) O 
within O 
AVT B-ABBREVIATION 
neurons O 
in O 
male O 
brown O 
anole O 
lizards O 
( O 
Anolis O 
sagrei O 
) O 
participating O 
in O 
aggressive O 
or O 
sexual O 
encounters O 
. O 
Lizards O 
possess O 
simple O 
amniote O 
nervous O 
systems O 
, O 
and O 
their O 
examination O 
provides O 
a O 
comparative O 
framework O 
to O 
complement O 
avian O 
and O 
mammalian O 
studies O 
. O 
In O 
accordance O 
with O 
findings O 
in O 
other O 
species O 
, O 
AVT B-ABBREVIATION 
neurons O 
in O 
the O 
anole O 
paraventricular O 
nucleus O 
( O 
PVN O 
) O 
were O 
activated O 
during O 
aggressive O 
encounters O 
; O 
but O 
unlike O 
in O 
other O 
species O 
, O 
a O 
positive O 
correlation O 
was O 
found O 
between O 
aggression O 
levels O 
and O 
activation O 
. O 
Activation O 
of O 
AVT B-ABBREVIATION 
neurons O 
within O 
the O 
supraoptic O 
nucleus O 
( O 
SON O 
) O 
occurred O 
nonspecifically O 
with O 
participation O 
in O 
either O 
aggressive O 
or O 
sexual O 
encounters O 
. O 
Activation O 
of O 
AVT B-ABBREVIATION 
neurons O 
in O 
the O 
preoptic O 
area O 
( O 
POA O 
) O 
and O 
bed O 
nucleus O 
of O 
the O 
stria O 
terminalis O 
( O 
BNST O 
) O 
was O 
associated O 
with O 
engagement O 
in O 
sexual O 
behaviors O 
. O 
The O 
above O 
findings O 
are O 
congruent O 
with O 
neural O 
activation O 
patterns O 
observed O 
in O 
other O 
species O 
, O 
even O 
when O 
the O 
behavioral O 
outputs O 
( O 
i.e O 
. O 
, O 
aggression O 
level O 
) O 
differed O 
. O 
However O 
, O 
aggressive O 
encounters O 
also O 
increased O 
activation O 
of O 
AVT B-ABBREVIATION 
neurons O 
in O 
the O 
BNST O 
, O 
which O 
is O 
incongruous O 
with O 
findings O 
in O 
other O 
species O 
. O 
Thus O 
, O 
some O 
species O 
differences O 
involve O 
the O 
encoding O 
of O 
social O 
stimuli O 
as O 
different O 
neural O 
activation O 
patterns O 
within O 
the O 
AVT B-ABBREVIATION 
/ O 
AVP B-ABBREVIATION 
network O 
, O 
whereas O 
other O 
behavioral O 
differences O 
arise O 
downstream O 
of O 
this O 
system O 
. O 

is O 
recalcitrant O 
to O 
the O 
hydrolysis O 
by O 
alloforms O 
PON1 O 
Q192R O 
of O 
human O 
serum O 
. O 

( O 
ethyl B-SYSTEMATIC 
4-methylthio-m-tolyl I-SYSTEMATIC 
isopropylphosphoramidate I-SYSTEMATIC 
) O 
is O 
a O 
racemic O 
organophosphorus B-FAMILY 
nematicide O 
widely O 
used O 
in O 
agriculture O 
around O 
the O 
world O 
. O 
The O 
paraoxonase O 
1 O 
from O 
human O 
serum O 
( O 
PON1 O 
) O 
is O 
a O 
phosphotriesterase O 
( O 
PTE O 
) O 
that O 
hydrolyses O 
several O 
xenobiotics O 
including O 
drugs O 
and O 
organophosphorus B-FAMILY 
compounds O 
( O 
OPs O 
) O 
. O 
In O 
this O 
work O 
, O 
the O 
separation O 
of O 
the O 
enantiomers O 
of O 
fenamiphos B-TRIVIAL 
by O 
HPLC O 
using O 
the O 
column O 
CHIRALCEL O 
OJ O 
and O 
a O 
mobile O 
phase O 
of O 
hexane B-SYSTEMATIC 
/ O 
ethanol B-SYSTEMATIC 
( O 
99 O 
/ O 
1 O 
) O 
is O 
presented O 
. O 
A O 
liquid O 
- O 
liquid O 
extraction O 
method O 
was O 
implemented O 
for O 
the O 
characterization O 
of O 
commercial O 
nematicide O 
hydrolysis O 
by O 
PON1 O 
Q192R O 
alloforms O 
of O 
human O 
serum O 
from O 
children O 
and O 
adults O 
. O 
The O 
results O 
show O 
a O 
recovery O 
of O 
94% O 
for O 
each O 
isomer O 
from O 
the O 
biological O 
matrix O 
. O 
The O 
method O 
resulted O 
linear O 
response O 
in O 
a O 
range O 
concentration O 
between O 
50 O 
and O 
800μM O 
with O 
a O 
detection O 
and O 
quantification O 
limit O 
between O 
0.6 O 
and O 
2μM O 
for O 
the O 
(+)-fenamiphos B-TRIVIAL 
, O 
and O 
between O 
0.7 O 
and O 
2.3μM O 
for O 
the O 
(-)-fenamiphos B-TRIVIAL 
. O 
The O 
levels O 
of O 
the O 
Ca(2+) B-FORMULA 
-dependent O 
hydrolysis O 
( O 
residual O 
concentration O 
[ O 
μM O 
] O 
) O 
quantified O 
during O 
30min O 
of O 
reaction O 
were O 
only O 
just O 
4-14% O 
for O 
both O 
fenamiphos B-TRIVIAL 
enantiomers O 
with O 
the O 
three O 
alloforms O 
of O 
PON1 O 
Q192R O 
of O 
the O 
two O 
groups O 
of O 
serum O 
studied O 
. O 
These O 
results O 
demonstrate O 
that O 
human O 
serum O 
PON1 O 
is O 
could O 
be O 
involved O 
in O 
the O 
detoxification O 
of O 
a O 
limited O 
number O 
of O 
organophosphorus B-FAMILY 
insecticides O 
. O 

plasma O 
oxytocin B-TRIVIAL 
levels O 
in O 
female O 
patients O 
with O 
borderline O 
personality O 
disorder O 
. O 

neuropeptide O 
oxytocin B-TRIVIAL 
is O 
involved O 
in O 
social O 
cognition O 
and O 
interaction O 
across O 
species O 
and O 
plays O 
a O 
crucial O 
role O 
in O 
the O 
regulation O 
of O 
affiliative O 
behaviors O 
. O 
Oxytocin B-TRIVIAL 
levels O 
in O 
cerebrospinal O 
fluid O 
( O 
CSF O 
) O 
, O 
but O 
also O 
in O 
plasma O 
or O 
urine O 
, O 
have O 
been O 
shown O 
to O 
be O 
negatively O 
associated O 
with O 
childhood O 
traumata O 
, O 
aggressive O 
behavior O 
, O 
and O 
suicide O 
attempts O 
. O 
Recently O 
, O 
an O 
altered O 
activity O 
of O 
the O 
oxytocin B-TRIVIAL 
system O 
has O 
been O 
discussed O 
to O 
play O 
a O 
prominent O 
role O 
in O 
borderline O 
personality O 
disorder O 
( O 
BPD O 
) O 
, O 
which O 
is O 
thought O 
to O 
be O 
closely O 
related O 
to O 
traumatic O 
experiences O 
in O 
childhood O 
and O 
is O 
characterized O 
by O 
(para)suicidal O 
behaviors O 
as O 
well O 
as O 
aggressive O 
outbursts O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
compared O 
plasma O 
oxytocin B-TRIVIAL 
levels O 
of O 
women O 
with O 
and O 
without O 
BPD O 
in O 
the O 
follicular O 
phase O 
and O 
assessed O 
the O 
relationship O 
between O 
oxytocin B-TRIVIAL 
concentrations O 
and O 
childhood O 
traumata O 
. O 
Women O 
diagnosed O 
with O 
BPD O 
had O 
significantly O 
reduced O 
oxytocin B-TRIVIAL 
concentrations O 
, O 
even O 
after O 
controlling O 
for O 
estrogen B-FAMILY 
, O 
progesterone B-TRIVIAL 
, O 
and O 
contraceptive O 
intake O 
. O 
In O 
addition O 
, O 
plasma O 
oxytocin B-TRIVIAL 
correlated O 
negatively O 
with O 
experiences O 
of O 
childhood O 
traumata O 
, O 
in O 
particular O 
with O 
emotional O 
neglect O 
and O 
abuse O 
. O 
The O 
results O 
of O 
mediation O 
analyses O 
do O 
not O 
support O 
a O 
model O 
of O 
oxytocin B-TRIVIAL 
being O 
a O 
prominent O 
mediator O 
in O 
the O 
link O 
between O 
childhood O 
trauma O 
and O 
BPD O 
. O 
Thus O 
, O 
the O 
findings O 
indicate O 
dysregulations O 
in O 
the O 
oxytocin B-TRIVIAL 
system O 
of O 
patients O 
diagnosed O 
with O 
BPD O 
with O 
more O 
longitudinal O 
research O 
being O 
necessary O 
to O 
disentangle O 
the O 
relationship O 
between O 
childhood O 
adversities O 
, O 
oxytocin B-TRIVIAL 
system O 
, O 
and O 
psychopathology O 
. O 

evaluation O 
of O 
vitamins B-MULTIPLE 
B1 I-MULTIPLE 
, I-MULTIPLE 
B6 I-MULTIPLE 
and I-MULTIPLE 
B12 I-MULTIPLE 
in O 
vitro O 
and O 
in O 
vivo O 
, O 
with O 
the O 
Ames O 
test O 
. O 

aim O 
of O 
this O 
work O 
is O 
to O 
evaluate O 
vitamins B-FAMILY 
B I-FAMILY 
antimutagenic O 
effect O 
against O 
alkylatings O 
methyl-N-nitro-N-nitrosoguanidine B-SYSTEMATIC 
( O 
MNNG B-ABBREVIATION 
) O 
, O 
ethyl-N-nitro-N'- B-SYSTEMATIC 
nitrosoguanidine I-SYSTEMATIC 
( O 
ENNG B-ABBREVIATION 
) O 
, O 
frameshift O 
mutagens O 
2-aminoanthracene B-SYSTEMATIC 
( O 
2AA B-SYSTEMATIC 
) O 
and O 
2-acetyl-amino-fluorene B-SYSTEMATIC 
( O 
2AF B-SYSTEMATIC 
) O 
and O 
ROS-generating O 
antibiotics O 
norfloxacin B-TRIVIAL 
( O 
NOR B-ABBREVIATION 
) O 
and O 
nalidixic B-TRIVIAL 
acid I-TRIVIAL 
( O 
NLX B-ABBREVIATION 
) O 
, O 
using O 
the O 
in O 
vitro O 
Ames O 
test O 
. O 
In O 
vivo O 
antimutagenesis O 
studies O 
were O 
performed O 
against O 
urinary O 
mutagens O 
induced O 
by O 
NOR B-ABBREVIATION 
( O 
70 O 
mg O 
/ O 
kg O 
) O 
or O 
NLX B-ABBREVIATION 
( O 
100 O 
mg O 
/ O 
kg O 
) O 
in O 
CD1 O 
mice O 
. O 
Vitamin B-TRIVIAL 
B1 I-TRIVIAL 
was O 
antimutagenic O 
against O 
alkylatings O 
MNNG B-ABBREVIATION 
( O 
P O 
< O 
0.05 O 
) O 
or O 
ENNG B-ABBREVIATION 
( O 
P O 
< O 
0.001 O 
) O 
. O 
In O 
fact O 
as O 
per O 
the O 
results O 
observed O 
during O 
the O 
current O 
study O 
, O 
none O 
of O 
the O 
vitamins O 
reduced O 
mutagenesis O 
caused O 
by O 
frameshift O 
mutagens O 
. O 
All O 
of O 
them O 
reduced O 
mutagenesis O 
of O 
NOR B-ABBREVIATION 
or O 
NLX B-ABBREVIATION 
( O 
P O 
< O 
0.001 O 
) O 
. O 
In O 
vivo O 
studies O 
showed O 
that O 
vitamins B-MULTIPLE 
B1 I-MULTIPLE 
and I-MULTIPLE 
B6 I-MULTIPLE 
( O 
10 O 
or O 
100 O 
mg O 
/ O 
kg O 
) O 
reduced O 
urinary O 
mutagens O 
from O 
NOR B-ABBREVIATION 
( O 
P O 
< O 
0.001 O 
) O 
or O 
NLX B-ABBREVIATION 
( O 
P O 
< O 
0.02 O 
) O 
either O 
free O 
or O 
β-glucoronidase- O 
conjugates O 
. O 
None O 
of O 
the O 
studied O 
samples O 
were O 
toxic O 
for O 
the O 
employed O 
antimutagenic O 
system O 
. O 
Vitamin B-TRIVIAL 
B12 I-TRIVIAL 
( O 
4 O 
mg O 
/ O 
kg O 
) O 
reduced O 
urinary O 
mutagens O 
of O 
NOR B-ABBREVIATION 
or O 
NLX B-ABBREVIATION 
( O 
P O 
< O 
0.02 O 
) O 
. O 
Vitamins B-FAMILY 
B I-FAMILY 
inhibited O 
DNA O 
mutations O 
induced O 
by O 
ROS O 
generated O 
by O 
NLX B-ABBREVIATION 
or O 
NOR B-ABBREVIATION 
, O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Vitamin B-TRIVIAL 
B1 I-TRIVIAL 
is O 
antimutagenic O 
against O 
mutations O 
induced O 
by O 
the O 
alkylating O 
MNNG B-ABBREVIATION 
or O 
ENNG B-ABBREVIATION 
. O 
Based O 
on O 
the O 
observations O 
, O 
employment O 
of O 
vitamins B-FAMILY 
B I-FAMILY 
in O 
vivo O 
can O 
be O 
a O 
promising O 
alternative O 
to O 
reduce O 
genotoxic O 
risk O 
exposure O 
to O 
ROS O 
. O 

of O 
body O 
- O 
weight O 
loading O 
onto O 
the O 
articular O 
cartilage O 
on O 
the O 
occurrence O 
of O 
quinolone B-FAMILY 
-induced O 
chondrotoxicity O 
in O 
juvenile O 
rats O 
. O 

effect O 
of O 
body O 
- O 
weight O 
loading O 
onto O 
the O 
articular O 
cartilage O 
on O 
the O 
occurrence O 
of O 
chondrotoxicity O 
was O 
investigated O 
in O 
male O 
juvenile O 
Sprague-Dawley O 
rats O 
given O 
ofloxacin B-TRIVIAL 
( O 
OFLX B-ABBREVIATION 
) O 
orally O 
once O 
at O 
900 O 
mg O 
/ O 
kg O 
. O 
Just O 
after O 
dosing O 
of O 
OFLX B-ABBREVIATION 
, O 
hindlimb O 
unloading O 
was O 
performed O 
for O 
0 O 
, O 
2 O 
, O 
4 O 
, O 
or O 
8 O 
h O 
by O 
a O 
tail O 
- O 
suspension O 
method O 
. O 
Animals O 
were O 
sacrificed O 
at O 
8h O 
post O 
- O 
dose O 
, O 
and O 
then O 
the O 
distal O 
femoral O 
articular O 
cartilage O 
was O 
subjected O 
to O 
a O 
histological O 
examination O 
and O 
an O 
investigation O 
for O 
gene O 
expression O 
of O 
tumor O 
necrosis O 
factor O 
receptor O 
superfamily O 
, O 
member O 
12a O 
( O 
Tnfrsf12a O 
) O 
; O 
prostaglandin B-FAMILY 
-endoperoxide O 
synthase O 
2 O 
( O 
Ptgs2 O 
) O 
; O 
plasminogen O 
activator O 
, O 
urokinase O 
receptor O 
( O 
Plaur O 
) O 
; O 
and O 
matrix O 
metalloproteinase O 
3 O 
( O 
Mmp3 O 
) O 
by O 
qRT-PCR O 
analysis O 
. O 
As O 
a O 
result O 
, O 
cartilage O 
lesions O 
and O 
up O 
- O 
regulations O 
of O 
these O 
4 O 
genes O 
that O 
were O 
seen O 
in O 
rats O 
without O 
the O 
tail O 
suspension O 
were O 
not O 
observed O 
in O 
rats O 
with O 
the O 
8-h O 
tail O 
suspension O 
, O 
and O 
a O 
tendency O 
to O 
decrease O 
in O 
the O 
incidence O 
of O 
the O 
cartilage O 
lesions O 
and O 
the O 
gene O 
expression O 
was O 
noted O 
in O 
a O 
tail O 
- O 
suspension O 
time O 
dependent O 
manner O 
. O 
Our O 
results O 
clearly O 
indicate O 
that O 
body O 
- O 
weight O 
loading O 
onto O 
the O 
cartilage O 
is O 
necessary O 
to O 
induce O 
cartilage O 
lesions O 
and O 
gene O 
expression O 
of O 
Tnfrsf12a O 
, O 
Ptgs2 O 
, O 
Plaur O 
, O 
and O 
Mmp3 O 
in O 
juvenile O 
rats O 
treated O 
with O 
OFLX B-ABBREVIATION 
. O 

present O 
investigation O 
was O 
carried O 
out O 
to O 
evaluate O 
the O 
safety O 
of O 
hydro- O 
ethanol B-SYSTEMATIC 
extract O 
of O 
Bridelia O 
ferruginea O 
Benth O 
( O 
Euphorbiaceae O 
) O 
root O 
bark O 
. O 
For O 
acute O 
toxicity O 
study O 
, O 
a O 
single O 
dose O 
of O 
2000 O 
and O 
5000 O 
mg O 
/ O 
kg O 
of O 
the O 
B O 
. O 
ferruginea O 
root O 
bark O 
extract O 
was O 
given O 
orally O 
to O 
healthy O 
male O 
Wistar O 
rats O 
and O 
Balb O 
/ O 
c O 
mice O 
. O 
The O 
animals O 
were O 
observed O 
for O 
mortality O 
and O 
clinical O 
signs O 
for O 
3 O 
h O 
and O 
then O 
daily O 
for O 
14 O 
days O 
. O 
In O 
the O 
sub O 
- O 
chronic O 
toxicity O 
study O 
, O 
the O 
extract O 
was O 
administered O 
orally O 
at O 
doses O 
of O 
250 O 
, O 
500 O 
and O 
1000 O 
mg O 
/ O 
kg O 
/ O 
day O 
for O 
28 O 
days O 
to O 
male O 
Wistar O 
rats O 
. O 
Animals O 
were O 
sacrificed O 
to O 
examine O 
their O 
organs O 
, O 
and O 
urine O 
and O 
blood O 
serum O 
were O 
analyzed O 
. O 
In O 
the O 
acute O 
toxicity O 
study O 
, O 
B O 
. O 
ferruginea O 
root O 
bark O 
extract O 
caused O 
neither O 
significant O 
visible O 
signs O 
of O 
toxicity O 
, O 
nor O 
mortality O 
in O 
Wistar O 
rats O 
and O 
Balb O 
/ O 
c O 
mice O 
. O 
In O 
sub O 
- O 
chronic O 
toxicity O 
study O 
, O 
administration O 
of O 
the O 
B O 
. O 
ferruginea O 
root O 
bark O 
extract O 
at O 
250 O 
, O 
500 O 
, O 
and O 
1000 O 
mg O 
/ O 
kg O 
for O 
28 O 
consecutive O 
days O 
to O 
Wistar O 
rats O 
did O 
not O 
produce O 
mortality O 
. O 
No O 
significant O 
differences O 
were O 
found O 
in O 
relative O 
organ O 
weights O 
, O 
biochemical O 
studied O 
parameters O 
in O 
treated O 
groups O 
compared O 
to O 
control O 
group O 
. O 
No O 
obvious O 
histological O 
changes O 
were O 
observed O 
in O 
organs O 
of O 
B O 
. O 
ferruginea O 
extract O 
treated O 
animals O 
compared O 
to O 
controls O 
. O 

levels O 
of O 
ephrinB2 O 
over O 
- O 
expression O 
increases O 
the O 
osteogenic O 
differentiation O 
of O 
human O 
mesenchymal O 
stem O 
cells O 
and O 
promotes O 
enhanced O 
cell O 
mediated O 
mineralisation O 
in O 
a O 
polyethyleneimine B-SYSTEMATIC 
-ephrinB2 O 
gene O 
- O 
activated O 
matrix O 
. O 

therapy O 
can O 
be O 
combined O 
with O 
tissue O 
engineering O 
constructs O 
to O 
produce O 
gene O 
- O 
activated O 
matrices O 
( O 
GAMs O 
) O 
with O 
enhanced O 
capacity O 
for O 
repair O 
. O 
Polyethyleneimine B-FAMILY 
( O 
PEI B-ABBREVIATION 
) O 
, O 
a O 
non-viral O 
vector O 
, O 
has O 
previously O 
been O 
optimised O 
for O 
high O 
efficiency O 
gene O 
transfer O 
in O 
rat O 
mesenchymal O 
stem O 
cells O 
( O 
rMSCs O 
) O 
. O 
The O 
use O 
of O 
PEI B-ABBREVIATION 
to O 
transfect O 
human O 
MSCs O 
( O 
hMSCs O 
) O 
with O 
ephrinB2 O 
is O 
assessed O 
here O 
. O 
Recently O 
a O 
role O 
for O 
the O 
ephrinB2 O 
ligand O 
and O 
EphB4 O 
receptor O 
duo O 
has O 
been O 
proposed O 
in O 
bone O 
remodelling O 
. O 
Herein O 
, O 
over O 
- O 
expression O 
of O 
the O 
ephrinB2 O 
ligand O 
resulted O 
in O 
increased O 
osteogenic O 
differentiation O 
in O 
hMSCs O 
. O 
As O 
ephrinB2 O 
is O 
a O 
cell O 
surface O 
anchored O 
ligand O 
which O 
only O 
interacts O 
with O 
cells O 
expressing O 
the O 
cognate O 
EphB4 O 
receptor O 
through O 
direct O 
contact O 
, O 
we O 
have O 
shown O 
that O 
direct O 
cell O 
- O 
cell O 
contact O 
between O 
two O 
neighbouring O 
cells O 
is O 
responsible O 
for O 
enhanced O 
osteogenesis O 
. O 
In O 
an O 
effort O 
to O 
begin O 
to O 
elucidate O 
the O 
molecular O 
mechanisms O 
at O 
play O 
downstream O 
of O 
ephrinB2 O 
over O 
- O 
expression O 
, O 
RT-PCR O 
was O 
performed O 
on O 
the O 
GAMs O 
which O 
revealed O 
no O 
significant O 
changes O 
in O 
runx2 O 
or O 
BMP2 O 
expression O 
but O 
an O 
upregulation O 
of O 
osterix O 
( O 
Osx O 
) O 
and O 
Dlx5 O 
expression O 
prompting O 
the O 
belief O 
that O 
the O 
mode O 
of O 
osteogenesis O 
is O 
independent O 
of O 
the O 
BMP2 O 
pathway O 
. O 
This O 
select O 
interaction O 
, O 
coupled O 
with O 
the O 
transient O 
gene O 
expression O 
profile O 
of O 
PEI B-ABBREVIATION 
, O 
makes O 
the O 
PEI B-ABBREVIATION 
-ephrinB2 O 
GAM O 
an O 
ideal O 
candidate O 
matrix O 
for O 
a O 
bone O 
targeted O 
GAM O 
. O 

effect O 
of O 
salvianolic B-TRIVIAL 
acid I-TRIVIAL 
B I-TRIVIAL 
against O 
arsenic B-SYSTEMATIC 
trioxide I-SYSTEMATIC 
-induced O 
injury O 
in O 
cardiac O 
H9c2 O 
cells O 
via O 
the O 
PI3K O 
/ O 
Akt O 
signal O 
pathway O 
. O 

clinical O 
use O 
of O 
arsenic B-SYSTEMATIC 
trioxide I-SYSTEMATIC 
( O 
ATO B-ABBREVIATION 
) O 
, O 
a O 
potent O 
anti-neoplastic O 
agent O 
, O 
is O 
often O 
limited O 
because O 
of O 
its O 
severe O 
cardiotoxicity O 
. O 
Salviae O 
miltiorrhiza O 
is O 
widely O 
used O 
for O 
the O 
treatment O 
of O 
cardiovascular O 
diseases O 
. O 
One O 
of O 
the O 
most O 
abundant O 
ingredients O 
of O 
S O 
. O 
miltiorrhiza O 
is O 
salvianolic B-TRIVIAL 
acid I-TRIVIAL 
B I-TRIVIAL 
( O 
Sal B-ABBREVIATION 
B I-ABBREVIATION 
) O 
. O 
The O 
present O 
study O 
was O 
designed O 
to O 
evaluate O 
whether O 
Sal B-ABBREVIATION 
B I-ABBREVIATION 
protects O 
against O 
ATO B-ABBREVIATION 
-induced O 
cardiac O 
cell O 
injury O 
in O 
vitro O 
. O 
With O 
MTT B-ABBREVIATION 
cell O 
viability O 
assay O 
, O 
LDH O 
release O 
, O 
ROS O 
generation O 
, O 
caspase-3 O 
activity O 
assay O 
and O 
Hoechst B-TRIVIAL 
33342 I-TRIVIAL 
/ O 
PI O 
staining O 
, O 
we O 
found O 
that O 
Sal B-ABBREVIATION 
B I-ABBREVIATION 
pretreatment O 
provided O 
significantly O 
protection O 
against O 
ATO B-ABBREVIATION 
-induced O 
cell O 
death O 
. O 
The O 
effect O 
was O 
correlated O 
with O 
the O 
activation O 
of O 
the O 
PI3K O 
/ O 
Akt O 
signal O 
pathway O 
. O 
Conversely O 
, O 
blocking O 
Akt O 
activation O 
with O 
the O 
PI3K O 
inhibitor O 
LY294002 B-IDENTIFIER 
effectively O 
suppressed O 
the O 
protective O 
effect O 
of O 
Sal B-ABBREVIATION 
B I-ABBREVIATION 
against O 
ATO B-ABBREVIATION 
-induced O 
cell O 
apoptosis O 
. O 
In O 
addition O 
, O 
the O 
PI3K O 
inhibitor O 
partially O 
blocked O 
the O 
effects O 
of O 
Sal B-ABBREVIATION 
B I-ABBREVIATION 
on O 
the O 
upregulation O 
of O 
Bcl-2 O 
and O 
Bcl O 
- O 
xl O 
protein O 
expression O 
, O 
and O 
downregulation O 
of O 
Bax O 
protein O 
expression O 
. O 
Collectively O 
, O 
the O 
results O 
showed O 
that O 
Sal B-ABBREVIATION 
B I-ABBREVIATION 
decreased O 
the O 
apoptosis O 
and O 
necrosis O 
of O 
H9c2 O 
cardiomyocytes O 
caused O 
by O 
ATO B-ABBREVIATION 
treatment O 
, O 
and O 
PI3K O 
played O 
a O 
crucial O 
role O 
in O 
enhancing O 
cell O 
survival O 
during O 
this O 
process O 
. O 
These O 
observations O 
indicate O 
that O 
Sal B-ABBREVIATION 
B I-ABBREVIATION 
has O 
the O 
potential O 
to O 
exert O 
cardioprotective O 
effects O 
against O 
ATO B-ABBREVIATION 
toxicity O 
. O 

effects O 
of O 
short O 
- O 
term O 
( O 
1 O 
day O 
) O 
and O 
long O 
- O 
term O 
( O 
49 O 
days O 
) O 
of O 
lead O 
( O 
Pb B-FORMULA 
) O 
stress O 
on O 
growth O 
and O 
physiological O 
responses O 
in O 
the O 
leaves O 
and O 
roots O 
of O 
two O 
mangrove O 
plants O 
, O 
Kandelia O 
obovata O 
and O 
Acanthus O 
ilicifolius O 
, O 
were O 
compared O 
. O 
The O 
growth O 
of O 
both O 
species O 
was O 
affected O 
by O 
Pb B-FORMULA 
at O 
Day O 
49 O 
, O 
whereas O 
the O 
root O 
to O 
shoot O 
ratio O 
of O 
K O 
. O 
obovata O 
remained O 
unchanged O 
. O 
Compared O 
with O 
A O 
. O 
ilicifolius O 
, O 
less O 
Pb B-FORMULA 
accumulated O 
in O 
leaves O 
of O 
K O 
. O 
obovata O 
, O 
which O 
indicates O 
that O 
this O 
species O 
is O 
a O 
typical O 
Pb B-FORMULA 
-excluder O 
. O 
Significant O 
linear O 
relationships O 
were O 
observed O 
between O 
the O 
Pb B-FORMULA 
concentrations O 
in O 
the O 
roots O 
and O 
leaves O 
and O 
the O 
Pb B-FORMULA 
treatment O 
concentrations O 
in O 
the O 
sediments O 
in O 
A O 
. O 
ilicifolius O 
but O 
not O 
in O 
K O 
. O 
obovata O 
. O 
The O 
proline O 
concentration O 
increased O 
in O 
both O 
mangrove O 
species O 
at O 
Day O 
49 O 
, O 
especially O 
in O 
A O 
. O 
ilicifolius O 
, O 
but O 
no O 
changes O 
were O 
observed O 
at O 
Day O 
1 O 
. O 
The O 
tolerant O 
species O 
K O 
. O 
obovata O 
tended O 
to O 
acclimate O 
to O 
metal O 
stress O 
by O 
restricting O 
the O 
translocation O 
of O 
toxic O 
metals O 
and O 
by O 
increasing O 
and O 
/ O 
or O 
maintaining O 
high O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
activity O 
, O 
minimizing O 
lipid O 
peroxidation O 
, O 
and O 
exhibiting O 
prolonged O 
unaltered O 
growth O 
( O 
49 O 
days O 
) O 
under O 
Pb B-FORMULA 
treatment O 
. O 
The O 
non-tolerant O 
species O 
, O 
A O 
. O 
ilicifolius O 
, O 
did O 
not O 
acclimate O 
to O 
metal O 
stress O 
, O 
its O 
leaves O 
were O 
seriously O 
damaged O 
with O 
significant O 
increased O 
MDA B-ABBREVIATION 
content O 
, O 
and O 
its O 
SOD O 
activity O 
was O 
decreased O 
. O 
An O 
increase O 
of O 
endogenous O 
jasmonic B-TRIVIAL 
acid I-TRIVIAL 
concentration O 
was O 
observed O 
only O 
in O 
K O 
. O 
obovata O 
, O 
both O 
at O 
Day O 
1 O 
and O 
at O 
Day O 
49 O 
, O 
which O 
suggests O 
that O 
this O 
hormone O 
plays O 
an O 
important O 
role O 
in O 
metal O 
tolerance O 
under O 
short O 
- O 
term O 
and O 
long O 
- O 
term O 
metal O 
treatment O 
. O 

bound O 
trions O 
in O 
monolayer O 
MoS2 B-FORMULA 
. O 

- O 
dimensional O 
( O 
2D O 
) O 
atomic O 
crystals O 
, O 
such O 
as O 
graphene B-TRIVIAL 
and O 
transition B-FAMILY 
- I-FAMILY 
metal I-FAMILY 
dichalcogenides I-FAMILY 
, O 
have O 
emerged O 
as O 
a O 
new O 
class O 
of O 
materials O 
with O 
remarkable O 
physical O 
properties O 
. O 
In O 
contrast O 
to O 
graphene B-TRIVIAL 
, O 
monolayer O 
MoS(2) B-FORMULA 
is O 
a O 
non-centrosymmetric O 
material O 
with O 
a O 
direct O 
energy O 
gap O 
. O 
Strong O 
photoluminescence O 
, O 
a O 
current O 
on O 
/ O 
off O 
ratio O 
exceeding O 
10(8) O 
in O 
field O 
- O 
effect O 
transistors O 
, O 
and O 
efficient O 
valley O 
and O 
spin O 
control O 
by O 
optical O 
helicity O 
have O 
recently O 
been O 
demonstrated O 
in O 
this O 
material O 
. O 
Here O 
we O 
report O 
the O 
spectroscopic O 
identification O 
in O 
a O 
monolayer O 
MoS(2) B-FORMULA 
field O 
- O 
effect O 
transistor O 
of O 
tightly O 
bound O 
negative O 
trions O 
, O 
a O 
quasiparticle O 
composed O 
of O 
two O 
electrons O 
and O 
a O 
hole O 
. O 
These O 
quasiparticles O 
, O 
which O 
can O 
be O 
optically O 
created O 
with O 
valley O 
and O 
spin O 
polarized O 
holes O 
, O 
have O 
no O 
analogue O 
in O 
conventional O 
semiconductors O 
. O 
They O 
also O 
possess O 
a O 
large O 
binding O 
energy O 
( O 
~ O 
20 O 
meV O 
) O 
, O 
rendering O 
them O 
significant O 
even O 
at O 
room O 
temperature O 
. O 
Our O 
results O 
open O 
up O 
possibilities O 
both O 
for O 
fundamental O 
studies O 
of O 
many O 
- O 
body O 
interactions O 
and O 
for O 
optoelectronic O 
and O 
valleytronic O 
applications O 
in O 
2D O 
atomic O 
crystals O 
. O 

rechargeable O 
room O 
- O 
temperature O 
sodium B-SYSTEMATIC 
superoxide I-SYSTEMATIC 
( O 
NaO2 B-FORMULA 
) O 
battery O 
. O 

the O 
search O 
for O 
room O 
- O 
temperature O 
batteries O 
with O 
high O 
energy O 
densities O 
, O 
rechargeable O 
metal O 
- O 
air O 
( O 
more O 
precisely O 
metal- O 
oxygen B-SYSTEMATIC 
) O 
batteries O 
are O 
considered O 
as O 
particularly O 
attractive O 
owing O 
to O 
the O 
simplicity O 
of O 
the O 
underlying O 
cell O 
reaction O 
at O 
first O 
glance O 
. O 
Atmospheric O 
oxygen B-SYSTEMATIC 
is O 
used O 
to O 
form O 
oxides B-FAMILY 
during O 
discharging O 
, O 
which O 
- O 
ideally O 
- O 
decompose O 
reversibly O 
during O 
charging O 
. O 
Much O 
work O 
has O 
been O 
focused O 
on O 
aprotic O 
Li-O(2) B-FORMULA 
cells O 
( O 
mostly O 
with O 
carbonate B-FAMILY 
-based O 
electrolytes O 
and O 
Li(2)O(2) B-FORMULA 
as O 
a O 
potential O 
discharge O 
product O 
) O 
, O 
where O 
large O 
overpotentials O 
are O 
observed O 
and O 
a O 
complex O 
cell O 
chemistry O 
is O 
found O 
. O 
In O 
fact O 
, O 
recent O 
studies O 
evidence O 
that O 
Li-O(2) B-FORMULA 
cells O 
suffer O 
from O 
irreversible O 
electrolyte O 
decomposition O 
during O 
cycling O 
. O 
Here O 
we O 
report O 
on O 
a O 
Na-O(2) B-FORMULA 
cell O 
reversibly O 
discharging O 
/ O 
charging O 
at O 
very O 
low O 
overpotentials O 
( O 
< O 
200 O 
mV O 
) O 
and O 
current O 
densities O 
as O 
high O 
as O 
0.2 O 
mA O 
cm(-2) O 
using O 
a O 
pure O 
carbon B-SYSTEMATIC 
cathode O 
without O 
an O 
added O 
catalyst O 
. O 
Crystalline O 
sodium B-SYSTEMATIC 
superoxide I-SYSTEMATIC 
( O 
NaO(2) B-FORMULA 
) O 
forms O 
in O 
a O 
one O 
- O 
electron O 
transfer O 
step O 
as O 
a O 
solid O 
discharge O 
product O 
. O 
This O 
work O 
demonstrates O 
that O 
substitution O 
of O 
lithium B-SYSTEMATIC 
by O 
sodium B-SYSTEMATIC 
may O 
offer O 
an O 
unexpected O 
route O 
towards O 
rechargeable O 
metal O 
- O 
air O 
batteries O 
. O 

- O 
resolution O 
solid O 
- O 
state O 
13C B-FORMULA 
NMR O 
spectroscopy O 
of O 
the O 
paramagnetic O 
metal O 
- O 
organic O 
frameworks O 
, O 
STAM-1 O 
and O 
HKUST-1 O 
. O 

- O 
state O 
(13)C B-FORMULA 
magic O 
- O 
angle O 
spinning O 
( O 
MAS O 
) O 
NMR O 
spectroscopy O 
is O 
used O 
to O 
investigate O 
the O 
structure O 
of O 
the O 
Cu B-FORMULA 
(II) I-FORMULA 
-based O 
metal O 
- O 
organic O 
frameworks O 
( O 
MOFs O 
) O 
, O 
HKUST-1 O 
and O 
STAM-1 O 
, O 
and O 
the O 
structural O 
changes O 
occurring O 
within O 
these O 
MOFs O 
upon O 
activation O 
( O 
dehydration O 
) O 
. O 
NMR O 
spectroscopy O 
is O 
an O 
attractive O 
technique O 
for O 
the O 
investigation O 
of O 
these O 
materials O 
, O 
owing O 
to O 
its O 
high O 
sensitivity O 
to O 
local O 
structure O 
, O 
without O 
any O 
requirement O 
for O 
longer O 
- O 
range O 
order O 
. O 
However O 
, O 
interactions O 
between O 
nuclei O 
and O 
unpaired O 
electrons O 
in O 
paramagnetic O 
systems O 
( O 
e.g O 
. O 
, O 
Cu B-FORMULA 
(II) I-FORMULA 
-based O 
MOFs O 
) O 
pose O 
a O 
considerable O 
challenge O 
, O 
not O 
only O 
for O 
spectral O 
acquisition O 
, O 
but O 
also O 
in O 
the O 
assignment O 
and O 
interpretation O 
of O 
the O 
spectral O 
resonances O 
. O 
Here O 
, O 
we O 
exploit O 
the O 
rapid O 
T(1) O 
relaxation O 
of O 
these O 
materials O 
to O 
obtain O 
(13)C B-FORMULA 
NMR O 
spectra O 
using O 
a O 
spin O 
- O 
echo O 
pulse O 
sequence O 
at O 
natural O 
abundance O 
levels O 
, O 
and O 
employ O 
frequency O 
- O 
stepped O 
acquisition O 
to O 
ensure O 
uniform O 
excitation O 
of O 
resonances O 
over O 
a O 
wide O 
frequency O 
range O 
. O 
We O 
then O 
utilise O 
selective O 
(13)C B-FORMULA 
isotopic O 
labelling O 
of O 
the O 
organic O 
linker O 
molecules O 
to O 
enable O 
an O 
unambiguous O 
assignment O 
of O 
NMR O 
spectra O 
of O 
both O 
MOFs O 
for O 
the O 
first O 
time O 
. O 
We O 
show O 
that O 
the O 
monomethylated O 
linker O 
can O 
be O 
recovered O 
from O 
STAM-1 O 
intact O 
, O 
demonstrating O 
not O 
only O 
the O 
interesting O 
use O 
of O 
this O 
MOF O 
as O 
a O 
protecting O 
group O 
, O 
but O 
also O 
the O 
ability O 
( O 
for O 
both O 
STAM-1 O 
and O 
HKUST-1 O 
) O 
to O 
recover O 
isotopically O 
- O 
enriched O 
linkers O 
, O 
thereby O 
reducing O 
significantly O 
the O 
overall O 
cost O 
of O 
the O 
approach O 
. O 

, O 
synthesis O 
and O 
crystallographic O 
analysis O 
of O 
nitrile B-SYSTEMATIC 
-based O 
broad O 
- O 
spectrum O 
peptidomimetic O 
inhibitors O 
for O 
coronavirus O 
3C O 
- O 
like O 
proteases O 
. O 

infection O 
is O 
associated O 
with O 
up O 
to O 
5% O 
of O 
respiratory O 
tract O 
diseases O 
. O 
The O 
3C O 
- O 
like O 
protease O 
(3CL(pro)) O 
of O 
coronaviruses O 
is O 
required O 
for O 
proteolytic O 
processing O 
of O 
polyproteins O 
and O 
viral O 
replication O 
, O 
and O 
is O 
a O 
promising O 
target O 
for O 
the O 
development O 
of O 
drugs O 
against O 
coronaviral O 
infection O 
. O 
We O 
designed O 
and O 
synthesized O 
four O 
nitrile B-SYSTEMATIC 
-based O 
peptidomimetic O 
inhibitors O 
with O 
different O 
N B-FORMULA 
-terminal O 
protective O 
groups O 
and O 
different O 
peptide O 
length O 
, O 
and O 
examined O 
their O 
inhibitory O 
effect O 
on O 
the O 
in O 
- O 
vitro O 
enzymatic O 
activity O 
of O 
3CL(pro) O 
of O 
severe O 
- O 
acute O 
- O 
respiratory O 
- O 
syndrome O 
- O 
coronavirus O 
. O 
The O 
IC(50) O 
values O 
of O 
the O 
inhibitors O 
were O 
in O 
the O 
range O 
of O 
4.6-49 O 
μM O 
, O 
demonstrating O 
that O 
the O 
nitrile B-SYSTEMATIC 
warhead O 
can O 
effectively O 
inactivate O 
the O 
3CL(pro) O 
autocleavage O 
process O 
. O 
The O 
best O 
inhibitor O 
, O 
Cbz B-ABBREVIATION 
-AVLQ- O 
CN B-FORMULA 
with O 
an O 
N B-FORMULA 
-terminal O 
carbobenzyloxy B-SYSTEMATIC 
group O 
, O 
was O 
~10x O 
more O 
potent O 
than O 
the O 
other O 
inhibitors O 
tested O 
. O 
Crystal O 
structures O 
of O 
the O 
enzyme O 
- O 
inhibitor O 
complexes O 
showed O 
that O 
the O 
nitrile B-SYSTEMATIC 
warhead O 
inhibits O 
3CL(pro) O 
by O 
forming O 
a O 
covalent O 
bond O 
with O 
the O 
catalytic O 
Cys B-FORMULA 
145 O 
residue O 
, O 
while O 
the O 
AVLQ O 
peptide O 
forms O 
a O 
number O 
of O 
favourable O 
interactions O 
with O 
the O 
S1-S4 O 
substrate O 
- O 
binding O 
pockets O 
. O 
We O 
have O 
further O 
showed O 
that O 
the O 
peptidomimetic O 
inhibitor O 
, O 
Cbz B-ABBREVIATION 
-AVLQ- O 
CN B-FORMULA 
, O 
has O 
broad O 
- O 
spectrum O 
inhibition O 
against O 
3CL(pro) O 
from O 
human O 
coronavirus O 
strains O 
229E O 
, O 
NL63 O 
, O 
OC43 O 
, O 
HKU1 O 
, O 
and O 
infectious O 
bronchitis O 
virus O 
, O 
with O 
IC(50) O 
values O 
ranging O 
from O 
1.3 O 
to O 
3.7 O 
μM O 
, O 
but O 
no O 
detectable O 
inhibition O 
against O 
caspase-3 O 
. O 
In O 
summary O 
, O 
we O 
have O 
shown O 
that O 
the O 
nitrile B-SYSTEMATIC 
-based O 
peptidomimetic O 
inhibitors O 
are O 
effective O 
against O 
3CL(pro) O 
, O 
and O 
they O 
inhibit O 
3CL(pro) O 
from O 
a O 
broad O 
range O 
of O 
coronaviruses O 
. O 
Our O 
results O 
provide O 
further O 
insights O 
into O 
the O 
future O 
design O 
of O 
drugs O 
that O 
could O 
serve O 
as O 
a O 
first O 
line O 
defence O 
against O 
coronaviral O 
infection O 
. O 

and O 
antibacterial O 
and O 
antifungal O 
evaluation O 
of O 
some O 
chalcone B-FAMILY 
based O 
sulfones B-FAMILY 
and O 
bisulfones B-FAMILY 
. O 

series O 
of O 
chalcone B-FAMILY 
based O 
sulfone B-SYSTEMATIC 
and O 
bisulfone B-SYSTEMATIC 
derivatives O 
were O 
synthesized O 
using O 
chalcone B-FAMILY 
, O 
thiophenol B-SYSTEMATIC 
and O 
sodium B-SYSTEMATIC 
metal O 
at O 
room O 
temperature O 
, O 
followed O 
by O 
oxidation O 
of O 
chalcone B-FAMILY 
sulfides I-FAMILY 
with O 
m-CPBA B-ABBREVIATION 
at O 
0 O 
°C O 
in O 
a O 
novel O 
method O 
. O 
Both O 
sulfones B-FAMILY 
and O 
bisulfones B-FAMILY 
were O 
evaluated O 
for O 
their O 
antimicrobial O 
activities O 
against O 
Aspergillus O 
niger O 
and O 
Candida O 
albicans O 
( O 
yeast O 
) O 
, O 
Bacillus O 
subtilis O 
and O 
Staphylococcus O 
aureus O 
( O 
Gram O 
( O 
+ O 
) O 
bacteria O 
) O 
and O 
Pseudomonas O 
aeruginosa O 
and O 
Salmonella O 
typhimurium O 
( O 
Gram O 
( O 
- O 
) O 
bacteria O 
) O 
strains O 
. O 
Among O 
them O 
, O 
compounds O 
2c O 
, O 
3c O 
, O 
6c O 
, O 
7c O 
, O 
8c O 
and O 
9c O 
have O 
shown O 
high O 
antifungal O 
activity O 
against O 
C O 
. O 
albicans O 
compare O 
to O 
reference O 
drugs O 
viz O 
. O 
Amphotericin-B B-TRIVIAL 
and O 
Nystatin B-TRIVIAL 
. O 
Compound O 
1c O 
has O 
shown O 
slightly O 
better O 
antibacterial O 
activity O 
against O 
B O 
. O 
subtilis O 
and O 
compounds O 
5c O 
, O 
6c O 
and O 
7c O 
have O 
shown O 
excellent O 
antibacterial O 
activity O 
against O 
S O 
. O 
typhimurium O 
in O 
compare O 
to O 
reference O 
drugs O 
Ampicillin B-TRIVIAL 
and O 
Kanamycin B-TRIVIAL 
. O 

of O 
novel O 
chromenone B-TRIVIAL 
derivatives O 
as O 
interleukin-5 O 
inhibitors O 
. O 

series O 
of O 
(E)-5-alkoxy-3-(3-phenyl-3-oxoprop-1-enyl)-4H-chromen-4-ones B-FAMILY 
( O 
4 O 
) O 
and O 
(E)-5-alkoxy-3-(3-hydroxy-3-phenylprop-1-enyl)-4H-chromen-4-ones B-FAMILY 
( O 
5 O 
) O 
were O 
synthesized O 
and O 
evaluated O 
for O 
their O 
IL-5 O 
inhibitory O 
activity O 
. O 
Propenone B-SYSTEMATIC 
analogs O 
4 O 
possess O 
some O 
of O 
the O 
structurally O 
important O 
characteristics O 
of O 
isoflavone B-FAMILY 
2 O 
and O 
chalcone B-FAMILY 
3 O 
previously O 
known O 
as O 
potent O 
IL-5 O 
inhibitor O 
. O 
However O 
, O 
the O 
inhibitory O 
activity O 
of O 
4 O 
was O 
weak O 
and O 
therefore O 
this O 
structural O 
hybridization O 
appears O 
to O 
be O 
ineffective O 
for O 
the O 
design O 
of O 
IL-5 O 
inhibitor O 
. O 
Meanwhile O 
the O 
potent O 
activity O 
profile O 
of O 
compounds O 
5 O 
was O 
discovered O 
. O 
This O 
enhanced O 
activity O 
of O 
5 O 
compared O 
to O 
4 O 
could O 
be O 
due O 
to O 
the O 
effective O 
location O 
of O 
hydroxyl B-SYSTEMATIC 
group O 
of O 
allylic B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
moiety O 
of O 
5 O 
in O 
the O 
3D O 
structure O 
. O 
The O 
electron O 
withdrawing O 
substituents O 
at O 
position O 
4 O 
of O 
phenyl B-SYSTEMATIC 
ring O 
of O 
5 O 
enhances O 
the O 
activity O 
possibly O 
due O 
to O 
an O 
increase O 
in O 
the O 
strength O 
of O 
hydrogen B-SYSTEMATIC 
bonding O 
property O 
of O 
hydroxyl B-SYSTEMATIC 
group O 
of O 
allylic B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
moiety O 
. O 

, O 
antibacterial O 
activity O 
and O 
docking O 
of O 
14-membered B-FAMILY 
9-O-(3-arylalkyl) I-FAMILY 
oxime I-FAMILY 
11,12-cyclic I-FAMILY 
carbonate I-FAMILY 
ketolides I-FAMILY 
. O 

series O 
of O 
9-O-(3-aryl-2-propargyl)oxime B-FAMILY 
ketolides I-FAMILY 
8 O 
was O 
synthesized O 
and O 
evaluated O 
for O 
in O 
vitro O 
antibacterial O 
activity O 
. O 
Among O 
8 O 
, O 
8b-8d O 
, O 
and O 
8h-8l O 
displayed O 
dramatically O 
improved O 
potency O 
against O 
inducibly O 
MLS(B)-resistant O 
and O 
efflux O 
- O 
resistant O 
pathogens O 
as O 
compared O 
to O 
clarithromycin B-TRIVIAL 
and O 
azithromycin B-TRIVIAL 
. O 
Especially O 
, O 
8i O 
( O 
Ar= O 
4-isoquinolyl B-SYSTEMATIC 
) O 
possessed O 
an O 
MIC O 
of O 
0.064 O 
μg O 
/ O 
mL O 
against O 
constitutively O 
MLS(B)-resistant O 
Streptococcus O 
pneumoniae O 
, O 
and O 
MICs O 
of O 
0.032-0.064 O 
μg O 
/ O 
mL O 
against O 
methicillin B-TRIVIAL 
-resistant O 
Staphylococcus O 
aureus O 
and O 
methicillin B-TRIVIAL 
-resistant O 
Staphylococcus O 
hominis O 
. O 
The O 
analog O 
10 O 
with O 
a O 
propyl B-SYSTEMATIC 
linker O 
was O 
less O 
effective O 
than O 
both O 
the O 
corresponding O 
8 O 
and O 
9 O 
containing O 
propynyl B-SYSTEMATIC 
and O 
propenyl B-SYSTEMATIC 
linkers O 
. O 
A O 
docking O 
study O 
was O 
performed O 
to O 
gain O 
insight O 
into O 
the O 
binding O 
mode O 
of O 
series O 
8 O 
and O 
9 O 
and O 
to O 
rationalize O 
the O 
disparity O 
found O 
in O 
the O 
SAR O 
of O 
8 O 
and O 
9 O 
. O 

furoxanyl B-SYSTEMATIC 
N-acylhydrazone I-SYSTEMATIC 
derivatives O 
as O 
hits O 
for O 
the O 
development O 
of O 
neglected O 
diseases O 
drug O 
candidates O 
. O 

diseases O 
represent O 
a O 
major O 
health O 
problem O 
. O 
It O 
is O 
estimated O 
that O 
one O 
third O 
of O 
the O 
world O 
population O 
is O 
infected O 
with O 
tuberculosis O 
and O 
additionally O 
Leishmaniosis O 
and O 
Chagas O 
disease O 
affect O 
approximately O 
30 O 
million O 
people O 
. O 
N-Acylhydrazone B-SYSTEMATIC 
moiety O 
is O 
a O 
repeated O 
functional O 
group O 
present O 
in O 
several O 
prototypes O 
and O 
drug O 
candidates O 
for O 
these O 
neglected O 
diseases O 
. O 
On O 
the O 
other O 
hand O 
, O 
furoxan B-TRIVIAL 
system O 
has O 
been O 
studied O 
as O 
pharmacophore O 
for O 
Leishmaniosis O 
and O 
Chagas O 
diseases O 
. O 
Here O 
we O 
report O 
on O 
the O 
design O 
and O 
preparation O 
of O 
forty O 
hybrid O 
furoxanyl B-FAMILY 
N-acylhydrazones I-FAMILY 
and O 
on O 
their O 
activity O 
on O 
Mycobacterium O 
tuberculosis O 
, O 
H37Rv O 
and O 
MDR O 
strains O 
, O 
Trypanosoma O 
cruzi O 
, O 
and O 
Leishmania O 
amazonensis O 
. O 
Among O 
them O 
, O 
four O 
derivatives O 
displayed O 
excellent O 
to O 
good O 
selectivity O 
indexes O 
against O 
the O 
three O 
different O 
microorganisms O 
. O 
Hybrid O 
compound O 
N'-(4-phenyl-3-furoxanylmethylidene)isoniazide B-SYSTEMATIC 
9 O 
showed O 
the O 
best O 
antibacterial O 
profile O 
with O 
MIC O 
value O 
4.5 O 
lesser O 
than O 
the O 
value O 
for O 
the O 
reference O 
isoniazid B-TRIVIAL 
against O 
MDR O 
strain O 
. O 
Furoxanyl B-SYSTEMATIC 
N-acylhydrazone I-SYSTEMATIC 
(E)-2-methyl-N'-(4-phenyl-3-furoxanylmethylidene)-4H-imidazo[1,2-a]pyridine-3-carbohydrazide B-SYSTEMATIC 
15 O 
was O 
ten O 
- O 
fold O 
more O 
potent O 
against O 
T O 
. O 
cruzi O 
Amastigotes O 
than O 
the O 
standard O 
drug O 
nifurtimox O 
. O 
On O 
the O 
other O 
hand O 
, O 
derivatives O 
(E)-N'-(5-benzofuroxanylmethylidene)benzo[d][1,3]dioxole-5-carbohydrazide B-SYSTEMATIC 
25 O 
and O 
(E)-N'-(4-hydroxy-3-methoxyphenylmethylidene)-3-methylfuroxan-4-carbohydrazide B-SYSTEMATIC 
37 O 
emerged O 
as O 
leads O 
for O 
the O 
development O 
of O 
new O 
leishmanicidal O 
agents O 
. O 
The O 
adequate O 
stability O 
, O 
in O 
simulated O 
biological O 
system O 
and O 
plasma O 
, O 
and O 
the O 
lack O 
of O 
mutagenicity O 
of O 
these O 
derivatives O 
allow O 
us O 
to O 
propose O 
them O 
as O 
candidates O 
for O 
further O 
pre O 
- O 
clinical O 
studies O 
. O 

protein O 
amide O 
¹H(N) B-FORMULA 
chemical O 
shift O 
temperature O 
coefficient O 
reflects O 
thermal O 
expansion O 
of O 
the O 
N-H B-FORMULA 
··· O 
O=C B-FORMULA 
hydrogen B-SYSTEMATIC 
bond O 
. O 

protein O 
amide O 
(1)H(N) B-FORMULA 
chemical O 
shift O 
temperature O 
coefficient O 
can O 
be O 
determined O 
with O 
high O 
accuracy O 
by O 
recording O 
spectra O 
at O 
different O 
temperatures O 
, O 
but O 
the O 
physical O 
mechanism O 
responsible O 
for O 
this O 
temperature O 
dependence O 
is O 
not O 
well O 
understood O 
. O 
In O 
this O 
work O 
, O 
we O 
find O 
that O 
this O 
coefficient O 
strongly O 
correlates O 
with O 
the O 
temperature O 
coefficient O 
of O 
the O 
through- O 
hydrogen B-SYSTEMATIC 
-bond O 
coupling O 
, O 
(3h)J(NC') O 
, O 
based O 
on O 
NMR O 
measurements O 
of O 
protein O 
GB3 O 
. O 
Parallel O 
tempering O 
molecular O 
dynamics O 
simulation O 
suggests O 
that O 
the O 
hydrogen B-SYSTEMATIC 
bond O 
distance O 
variation O 
at O 
different O 
temperatures O 
/ O 
replicas O 
is O 
largely O 
responsible O 
for O 
the O 
(1)H(N) B-FORMULA 
chemical O 
shift O 
temperature O 
dependence O 
, O 
from O 
which O 
an O 
empirical O 
equation O 
is O 
proposed O 
to O 
predict O 
the O 
hydrogen B-SYSTEMATIC 
bond O 
thermal O 
expansion O 
coefficient O 
, O 
revealing O 
responses O 
of O 
individual O 
hydrogen B-SYSTEMATIC 
bonds O 
to O 
temperature O 
changes O 
. O 
Different O 
expansion O 
patterns O 
have O 
been O 
observed O 
for O 
various O 
networks O 
formed O 
by O 
β O 
strands O 
. O 

, O 
characterization O 
and O 
pharmacodynamics O 
of O 
vitamin-B(12) B-TRIVIAL 
-conjugated O 
glucagon O 
- O 
like O 
peptide-1 O 
. O 

the O 
way O 
: O 
Glucagon O 
- O 
like O 
peptide-1 O 
( O 
GLP-1 O 
) O 
receptor O 
agonists O 
are O 
proving O 
a O 
potent O 
weapon O 
in O 
the O 
treatment O 
of O 
type O 
II O 
diabetes O 
. O 
A O 
new O 
vitamin B-TRIVIAL 
B(12) I-TRIVIAL 
-GLP-1 O 
conjugate O 
is O 
investigated O 
and O 
shown O 
to O 
have O 
insulinotropic O 
properties O 
similar O 
to O 
the O 
unmodified O 
peptide O 
. O 
These O 
results O 
are O 
critical O 
to O 
the O 
exploitation O 
of O 
the O 
vitamin B-TRIVIAL 
B(12) I-TRIVIAL 
oral O 
uptake O 
pathway O 
for O 
peptide O 
delivery O 
. O 

inhibits O 
heart O 
regeneration O 
in O 
adult O 
zebrafish O 
. O 

adult O 
zebrafish O 
can O 
completely O 
regenerate O 
lost O 
myocardium O 
following O 
partial O 
amputation O 
of O 
the O 
ventricle O 
apex O 
. O 
We O 
report O 
that O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
significantly O 
impairs O 
this O 
regeneration O 
. O 
Adult O 
male O 
zebrafish O 
were O 
injected O 
with O 
vehicle O 
( O 
control O 
) O 
or O 
TCDD B-ABBREVIATION 
( O 
70ng O 
/ O 
g O 
, O 
ip O 
) O 
1 O 
day O 
prior O 
to O 
partial O 
amputation O 
of O 
the O 
ventricle O 
apex O 
. O 
Gross O 
observation O 
and O 
histological O 
analysis O 
of O 
the O 
amputated O 
heart O 
at O 
21 O 
days O 
postamputation O 
revealed O 
that O 
TCDD B-ABBREVIATION 
-exposed O 
fish O 
had O 
not O 
progressed O 
beyond O 
the O 
initial O 
clot O 
formation O 
stage O 
, O 
whereas O 
the O 
vehicle O 
control O 
fish O 
showed O 
substantial O 
recovery O 
and O 
almost O 
complete O 
resolution O 
of O 
the O 
formed O 
clot O 
. O 
In O 
contrast O 
, O 
hearts O 
that O 
were O 
not O 
surgically O 
wounded O 
showed O 
no O 
signs O 
of O 
TCDD B-ABBREVIATION 
toxicity O 
. O 
Striking O 
features O 
in O 
the O 
TCDD B-ABBREVIATION 
-exposed O 
hearts O 
were O 
the O 
absence O 
of O 
the O 
normal O 
sheath O 
of O 
new O 
tissue O 
enveloping O 
the O 
wound O 
and O 
the O 
absence O 
of O 
intense O 
cell O 
proliferation O 
at O 
the O 
site O 
of O 
the O 
wound O 
. O 
In O 
addition O 
, O 
the O 
patterns O 
of O 
collagen O 
deposition O 
at O 
the O 
wound O 
site O 
were O 
different O 
between O 
the O 
TCDD B-ABBREVIATION 
and O 
vehicle O 
groups O 
. O 
Because O 
the O 
receptor O 
for O 
TCDD B-ABBREVIATION 
is O 
the O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
ligand O 
- O 
activated O 
transcriptional O 
regulator O 
, O 
we O 
examined O 
the O 
effects O 
of O 
TCDD B-ABBREVIATION 
exposure O 
on O 
gene O 
expression O 
in O 
the O 
ventricle O 
using O 
DNA O 
microarrays O 
. O 
Samples O 
were O 
collected O 
just O 
prior O 
to O 
amputation O 
and O 
at O 
6h O 
and O 
7 O 
days O 
postamputation O 
. O 
TCDD B-ABBREVIATION 
-pretreated O 
hearts O 
had O 
dysregulated O 
expression O 
of O 
genes O 
involved O 
in O 
heart O 
function O 
, O 
tissue O 
regeneration O 
, O 
cell O 
growth O 
, O 
and O 
extracellular O 
matrix O 
. O 
Because O 
embryonic O 
, O 
but O 
not O 
adult O 
, O 
hearts O 
are O 
major O 
targets O 
for O 
TCDD B-ABBREVIATION 
-induced O 
cardiotoxicity O 
, O 
we O 
speculate O 
that O 
the O 
need O 
for O 
embryonic O 
- O 
like O 
cells O 
in O 
regeneration O 
is O 
connected O 
with O 
the O 
effects O 
of O 
TCDD B-ABBREVIATION 
in O 
inhibiting O 
the O 
response O 
to O 
wounding O 
. O 

calmodulin O 
regulator O 
protein O 
, O 
PEP-19 O 
, O 
sensitizes O 
ATP B-ABBREVIATION 
-induced O 
Ca2+ B-FORMULA 
release O 
. O 

is O 
a O 
small O 
, O 
intrinsically O 
disordered O 
protein O 
that O 
binds O 
to O 
the O 
C-domain O 
of O 
calmodulin O 
( O 
CaM O 
) O 
via O 
an O 
IQ O 
motif O 
and O 
tunes O 
its O 
Ca(2+) B-FORMULA 
binding O 
properties O 
via O 
an O 
acidic O 
sequence O 
. O 
We O 
show O 
here O 
that O 
the O 
acidic O 
sequence O 
of O 
PEP-19 O 
has O 
intrinsic O 
Ca(2+) B-FORMULA 
binding O 
activity O 
, O 
which O 
may O 
modulate O 
Ca(2+) B-FORMULA 
binding O 
to O 
CaM O 
by O 
stabilizing O 
an O 
initial O 
Ca(2+) B-FORMULA 
-CaM O 
complex O 
or O 
by O 
electrostatically O 
steering O 
Ca(2+) B-FORMULA 
to O 
and O 
from O 
CaM O 
. O 
Because O 
PEP-19 O 
is O 
expressed O 
in O 
cells O 
that O 
exhibit O 
highly O 
active O 
Ca(2+) B-FORMULA 
dynamics O 
, O 
we O 
tested O 
the O 
hypothesis O 
that O 
it O 
influences O 
ligand O 
- O 
dependent O 
Ca(2+) B-FORMULA 
release O 
. O 
We O 
show O 
that O 
PEP-19 O 
increases O 
the O 
sensitivity O 
of O 
HeLa O 
cells O 
to O 
ATP B-ABBREVIATION 
-induced O 
Ca(2+) B-FORMULA 
release O 
to O 
greatly O 
increase O 
the O 
percentage O 
of O 
cells O 
responding O 
to O 
sub O 
- O 
saturating O 
doses O 
of O 
ATP B-ABBREVIATION 
and O 
increases O 
the O 
frequency O 
of O 
Ca(2+) B-FORMULA 
oscillations O 
. O 
Mutations O 
in O 
the O 
acidic O 
sequence O 
of O 
PEP-19 O 
that O 
inhibit O 
or O 
prevent O 
it O 
from O 
modulating O 
Ca(2+) B-FORMULA 
binding O 
to O 
CaM O 
greatly O 
inhibit O 
its O 
effect O 
on O 
ATP B-ABBREVIATION 
-induced O 
Ca(2+) B-FORMULA 
release O 
. O 
Thus O 
, O 
this O 
cellular O 
effect O 
of O 
PEP-19 O 
does O 
not O 
depend O 
simply O 
on O 
binding O 
to O 
CaM O 
via O 
the O 
IQ O 
motif O 
but O 
requires O 
its O 
acidic O 
metal O 
binding O 
domain O 
. O 
Tuning O 
the O 
activities O 
of O 
Ca(2+) B-FORMULA 
mobilization O 
pathways O 
places O 
PEP-19 O 
at O 
the O 
top O 
of O 
CaM O 
signaling O 
cascades O 
, O 
with O 
great O 
potential O 
to O 
exert O 
broad O 
effects O 
on O 
downstream O 
CaM O 
targets O 
, O 
thus O 
expanding O 
the O 
biological O 
significance O 
of O 
this O 
small O 
regulator O 
of O 
CaM O 
signaling O 
. O 

of O 
single O 
or O 
repeated O 
silymarin O 
administration O 
on O 
pharmacokinetics O 
of O 
risperidone B-TRIVIAL 
and O 
its O 
major O 
metabolite O 
, O 
9-hydroxyrisperidone B-SYSTEMATIC 
in O 
rats O 
. O 

. O 
The O 
interactions O 
between O 
herbal O 
dietary O 
supplements O 
and O 
therapeutic O 
drugs O 
have O 
emerged O 
as O 
an O 
important O 
issue O 
and O 
P-glycoprotein O 
( O 
P-gp O 
) O 
has O 
been O 
reported O 
as O 
one O 
of O 
the O 
significant O 
factors O 
of O 
these O 
interactions O 
. O 
2 O 
. O 
The O 
objective O 
of O 
this O 
article O 
is O 
to O 
examine O 
the O 
effects O 
of O 
single O 
and O 
repeated O 
administrations O 
of O 
silymarin O 
on O 
pharmacokinetics O 
of O 
a O 
P-gp O 
substrate O 
, O 
risperidone B-TRIVIAL 
, O 
and O 
its O 
major O 
metabolite O 
, O 
9-hydroxyrisperidone B-SYSTEMATIC 
, O 
in O 
rats O 
. O 
3 O 
. O 
To O 
determine O 
the O 
plasma O 
levels O 
of O 
risperidone B-TRIVIAL 
and O 
9-hydroxyrisperidone B-SYSTEMATIC 
in O 
rats O 
, O 
a O 
HPLC O 
method O 
was O 
developed O 
using O 
a O 
liquid O 
- O 
liquid O 
acid O 
back O 
extraction O 
. O 
When O 
risperidone B-TRIVIAL 
( O 
6 O 
mg O 
/ O 
kg O 
) O 
was O 
co O 
- O 
administered O 
with O 
silymarin O 
( O 
40 O 
mg O 
/ O 
kg O 
) O 
to O 
rats O 
orally O 
, O 
the O 
C(max) O 
of O 
9-hydroxyrisperidone B-SYSTEMATIC 
was O 
significantly O 
increased O 
to1.3-fold O 
( O 
p O 
< O 
0.05 O 
) O 
, O 
while O 
the O 
other O 
pharmacokinetic O 
parameters O 
did O 
not O 
show O 
any O 
significant O 
differences O 
. O 
Expanding O 
the O 
experiment O 
where O 
rats O 
were O 
repeatedly O 
administered O 
with O 
silymarin O 
for O 
5 O 
days O 
prior O 
to O 
giving O 
risperidone B-TRIVIAL 
, O 
the O 
C(max) O 
of O 
risperidone B-TRIVIAL 
and O 
9-hydroxyrisperidone B-SYSTEMATIC 
were O 
significantly O 
increased O 
to O 
2.4-fold O 
( O 
p O 
< O 
0.001 O 
) O 
and O 
1.7-fold O 
( O 
p O 
< O 
0.001 O 
) O 
, O 
respectively O 
, O 
and O 
the O 
AUC(0-t) O 
, O 
as O 
well O 
to O 
1.7-fold O 
( O 
p O 
< O 
0.05 O 
) O 
and O 
2.1-fold O 
( O 
p O 
< O 
0.01 O 
) O 
, O 
respectively O 
. O 
4 O 
. O 
The O 
repeated O 
exposures O 
of O 
silymarin O 
, O 
compared O 
to O 
single O 
administration O 
of O 
silymarin O 
, O 
increased O 
oral O 
bioavailability O 
and O 
affected O 
the O 
pharmacokinetics O 
of O 
risperidone B-TRIVIAL 
and O 
9-hydroxyrisperidone B-SYSTEMATIC 
, O 
by O 
inhibiting O 
P-gp O 
. O 

. O 
Exposure O 
to O 
secondhand O 
smoke O 
( O 
SHS O 
) O 
can O 
occur O 
in O 
many O 
places O 
; O 
however O 
, O 
regulations O 
banning O 
smoking O 
may O 
reduce O 
the O 
sources O 
of O 
exposure O 
to O 
SHS O 
to O 
personal O 
areas O 
such O 
as O 
the O 
family O 
car O 
, O 
a O 
source O 
of O 
brief O 
but O 
potently O 
intense O 
exposure O 
. O 
2 O 
. O 
Fifteen O 
non-smoking O 
volunteers O 
were O 
exposed O 
to O 
sidestream O 
SHS O 
concentrations O 
of O 
5000 O 
µg O 
/ O 
m(3) O 
, O 
within O 
a O 
simulated O 
car O 
setting O 
. O 
The O 
Fraction O 
of O 
Exhaled O 
Nitric B-SYSTEMATIC 
Oxide I-SYSTEMATIC 
( O 
FeNO O 
) O 
was O 
calculated O 
, O 
dynamic O 
flow O 
volumes O 
were O 
assessed O 
through O 
spirometry O 
; O 
while O 
airway O 
impedance O 
( O 
Z O 
) O 
, O 
resistance O 
( O 
R O 
) O 
, O 
and O 
reactance O 
(X) O 
was O 
assessed O 
through O 
impulse O 
oscillometry O 
before O 
and O 
after O 
exposure O 
. O 
3 O 
. O 
Exposure O 
to O 
sidestream O 
SHS O 
within O 
this O 
experimental O 
condition O 
did O 
not O 
affect O 
dynamic O 
flow O 
volumes O 
, O 
however O 
FENO O 
decreased O 
from O 
15.34 O 
ppb O 
to O 
11.15 O 
ppb O 
, O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
Increases O 
in O 
airway O 
resistance O 
at O 
R5Hz O 
by O 
0.114 O 
kPa O 
/ O 
( O 
L O 
/ O 
s O 
) O 
( O 
p O 
= O 
0.002 O 
) O 
, O 
at O 
R10Hz O 
by O 
0.093[kPa O 
/ O 
( O 
L O 
/ O 
s O 
) O 
] O 
( O 
p O 
= O 
0.006 O 
) O 
and O 
at O 
R20Hz O 
by O 
0.093[kPa O 
/ O 
( O 
L O 
/ O 
s O 
) O 
] O 
( O 
p O 
= O 
0.008 O 
) O 
were O 
noted O 
. O 
Correspondingly O 
overall O 
peripheral O 
and O 
central O 
airway O 
resistance O 
was O 
also O 
found O 
to O 
increase O 
by O 
40% O 
( O 
by O 
0.083 O 
kPa O 
/ O 
( O 
L O 
/ O 
s O 
) O 
, O 
p O 
= O 
0.038 O 
) O 
and O 
25% O 
( O 
by O 
0.045 O 
kPa O 
/ O 
( O 
L O 
/ O 
s O 
) O 
, O 
p O 
= O 
0.047 O 
) O 
respectively O 
. O 
4 O 
. O 
Brief O 
but O 
elevated O 
exposure O 
to O 
sidestream O 
SHS O 
can O 
alter O 
airway O 
resistance O 
, O 
and O 
impedance O 
indicating O 
a O 
potential O 
additional O 
mechanistic O 
pathway O 
between O 
exposure O 
to O 
SHS O 
and O 
the O 
development O 
of O 
respiratory O 
disease O 
. O 
Further O 
research O 
is O 
needed O 
to O 
verify O 
these O 
pilot O 
results O 
. O 

new O 
perfluoropolyether B-FAMILY 
-based O 
hydrophobic O 
and O 
chemically O 
resistant O 
photoresist O 
structured O 
by O 
two O 
- O 
photon O 
polymerization O 
. O 

- O 
photon O 
polymerization O 
technology O 
has O 
been O 
used O 
to O 
fabricate O 
submicrometer O 
three O 
- O 
dimensional O 
( O 
3D O 
) O 
structures O 
using O 
a O 
new O 
polyfunctional O 
perfluoropolyether B-FAMILY 
-based O 
resist O 
, O 
which O 
is O 
a O 
polymer O 
intrinsically O 
hydrophobic O 
and O 
chemically O 
resistant O 
. O 
The O 
fluorinated O 
resist O 
was O 
designed O 
and O 
synthesized O 
in O 
this O 
work O 
and O 
successfully O 
employed O 
to O 
fabricate O 
woodpile O 
structures O 
in O 
various O 
experimental O 
conditions O 
. O 
This O 
is O 
the O 
first O 
demonstration O 
of O 
the O 
capability O 
to O 
fabricate O 
hydrophobic O 
and O 
chemically O 
resistant O 
3D O 
structures O 
with O 
submicrometer O 
resolution O 
and O 
arbitrary O 
geometry O 
. O 

of O 
the O 
lipid O 
environment O 
, O 
cholesterol B-TRIVIAL 
and O 
bile B-FAMILY 
acids I-FAMILY 
on O 
the O 
function O 
of O 
the O 
purified O 
and O 
reconstituted O 
human O 
ABCG2 O 
protein O 
. O 

human O 
ABCG2 O 
multidrug O 
transporter O 
actively O 
extrudes O 
a O 
wide O 
range O 
of O 
hydrophobic O 
drugs O 
and O 
xenobiotics O 
recognized O 
by O 
the O 
transporter O 
in O 
the O 
membrane O 
phase O 
. O 
In O 
order O 
to O 
examine O 
the O 
molecular O 
nature O 
of O 
the O 
transporter O 
and O 
its O 
effects O 
on O 
the O 
lipid O 
environment O 
, O 
we O 
have O 
established O 
an O 
efficient O 
protocol O 
for O 
the O 
purification O 
and O 
reconstitution O 
of O 
the O 
functional O 
protein O 
. O 
We O 
found O 
that O 
the O 
drug O 
- O 
stimulated O 
ATPase O 
and O 
the O 
transport O 
activity O 
of O 
ABCG2 O 
are O 
fully O 
preserved O 
by O 
applying O 
excess O 
lipids O 
and O 
mild O 
detergents O 
during O 
solubilization O 
, O 
whereas O 
a O 
detergent-induced O 
dissociation O 
of O 
the O 
ABCG2 O 
dimer O 
causes O 
an O 
irreversible O 
inactivation O 
. O 
By O 
using O 
the O 
purified O 
and O 
reconstituted O 
protein O 
we O 
demonstrate O 
that O 
cholesterol B-TRIVIAL 
is O 
an O 
essential O 
activator O 
, O 
whereas O 
bile B-FAMILY 
acids I-FAMILY 
are O 
important O 
modulators O 
of O 
ABCG2 O 
activity O 
. O 
Both O 
wild O 
- O 
type O 
ABCG2 O 
and O 
its O 
R482G O 
mutant O 
variant O 
require O 
cholesterol B-TRIVIAL 
for O 
full O 
activity O 
, O 
although O 
they O 
exhibit O 
different O 
cholesterol B-TRIVIAL 
sensitivities O 
. O 
Bile B-FAMILY 
acids I-FAMILY 
strongly O 
decrease O 
the O 
basal O 
ABCG2-ATPase O 
activity O 
both O 
in O 
the O 
wild O 
- O 
type O 
ABCG2 O 
and O 
in O 
the O 
mutant O 
variant O 
. O 
These O 
data O 
reinforce O 
the O 
results O 
for O 
the O 
modulatory O 
effects O 
of O 
cholesterol B-TRIVIAL 
and O 
bile B-FAMILY 
acids I-FAMILY 
of O 
ABCG2 O 
investigated O 
in O 
a O 
complex O 
cell O 
membrane O 
environment O 
. O 
Moreover O 
, O 
these O 
experiments O 
open O 
the O 
possibility O 
to O 
perform O 
functional O 
and O 
structural O 
studies O 
with O 
a O 
purified O 
, O 
reconstituted O 
and O 
highly O 
active O 
ABCG2 O 
multidrug O 
transporter O 
. O 

periodic O 
diameter O 
oscillations O 
in O 
InP B-FORMULA 
nanowires O 
: O 
the O 
role O 
of O 
interface O 
instabilities O 
. O 

have O 
observed O 
that O 
thin O 
InP B-FORMULA 
nanowires O 
generated O 
by O 
vapor O 
- O 
liquid O 
- O 
solid O 
growth O 
display O 
spontaneous O 
periodic O 
diameter O 
oscillations O 
when O 
large O 
group O 
III O 
supersaturations O 
are O 
used O 
. O 
Diameter O 
variations O 
are O 
associated O 
with O 
a O 
large O 
number O 
of O 
stacking O 
faults O 
and O 
crystallographic O 
phase O 
changes( O 
wurtzite B-TRIVIAL 
/ O 
zinc B-SYSTEMATIC 
- I-SYSTEMATIC 
blende I-SYSTEMATIC 
) O 
; O 
also O 
the O 
axial O 
distance O 
between O 
oscillations O 
depends O 
on O 
the O 
indium B-SYSTEMATIC 
precursor O 
flow O 
used O 
during O 
the O 
run O 
. O 
We O 
attribute O 
the O 
morphology O 
changes O 
to O 
a O 
substantial O 
deformation O 
of O 
the O 
triple O 
phase O 
line O 
( O 
vapor O 
- O 
liquid O 
- O 
solid O 
) O 
at O 
the O 
catalyst O 
nanoparticle O 
edge O 
originated O 
from O 
multistep O 
nucleation O 
during O 
growth O 
. O 
The O 
deformation O 
alters O 
the O 
mechanical O 
force O 
balance O 
acting O 
on O 
the O 
nanoparticle O 
during O 
growth O 
in O 
such O 
a O 
way O 
that O 
the O 
particle O 
displaces O 
from O 
the O 
nanowire O 
top O 
and O 
wets O 
the O 
nanowire O 
sidewall O 
. O 
Subsequently O 
, O 
as O 
catalytic O 
growth O 
occurs O 
at O 
the O 
sidewall O 
, O 
the O 
associated O 
increase O 
in O 
diameter O 
will O 
eventually O 
push O 
the O 
NP O 
back O 
to O 
its O 
original O 
wire O 
- O 
top O 
position O 
until O 
the O 
onset O 
of O 
a O 
new O 
instability O 
at O 
the O 
triple O 
phase O 
line O 
. O 

the O 
basis O 
of O 
a O 
vertically O 
aligned O 
ultralong O 
Pb(Zr(0.52)Ti(0.48))O(3) B-FORMULA 
( O 
PZT B-ABBREVIATION 
) O 
nanowire O 
array O 
fabricated O 
using O 
electrospinning O 
nanofibers O 
, O 
we O 
developed O 
a O 
new O 
type O 
of O 
integrated O 
nanogenerator O 
( O 
NG O 
) O 
with O 
ultrahigh O 
output O 
voltage O 
of O 
209 O 
V O 
and O 
current O 
density O 
of O 
23.5 O 
μA O 
/ O 
cm(2) O 
, O 
which O 
are O 
3.6 O 
times O 
and O 
2.9 O 
times O 
of O 
the O 
previous O 
record O 
values O 
, O 
respectively O 
. O 
The O 
output O 
electricity O 
can O 
be O 
directly O 
used O 
to O 
stimulate O 
the O 
frog's O 
sciatic O 
nerve O 
and O 
to O 
induce O 
a O 
contraction O 
of O 
a O 
frog's O 
gastrocnemius O 
. O 
The O 
NG O 
can O 
instantaneously O 
power O 
a O 
commercial O 
light O 
- O 
emitting O 
diode O 
( O 
LED O 
) O 
without O 
the O 
energy O 
storage O 
process O 
. O 

of O 
sarin B-TRIVIAL 
with O 
polyelectrolyte O 
membranes O 
: O 
a O 
molecular O 
dynamics O 
simulation O 
study O 
. O 

polyelectrolyte O 
membranes O 
( O 
PEMs O 
) O 
, O 
which O 
are O 
widely O 
used O 
as O 
permselective O 
diffusion O 
barriers O 
in O 
fuel O 
cell O 
technologies O 
and O 
electrochemical O 
processing O 
, O 
are O 
considered O 
as O 
protective O 
membranes O 
suitable O 
for O 
blocking O 
warfare O 
toxins O 
, O 
including O 
water O 
- O 
soluble O 
nerve O 
agents O 
such O 
as O 
sarin B-TRIVIAL 
. O 
In O 
this O 
article O 
, O 
we O 
examine O 
the O 
mechanisms O 
of O 
sorption O 
and O 
diffusion O 
of O 
sarin B-TRIVIAL 
in O 
hydrated O 
PEMs O 
by O 
means O 
of O 
atomistic O 
molecular O 
dynamics O 
simulations O 
. O 
Three O 
PEMs O 
are O 
considered O 
: O 
Nafion B-TRIVIAL 
, O 
sulfonated B-FAMILY 
polystyrene I-FAMILY 
( O 
sPS B-ABBREVIATION 
) O 
that O 
forms O 
the O 
hydrophilic O 
subphase O 
of O 
segregated O 
sPS B-ABBREVIATION 
- O 
polyolefin B-FAMILY 
block O 
copolymers O 
, O 
and O 
random O 
sPS B-ABBREVIATION 
- O 
polyethylene B-SYSTEMATIC 
copolymer O 
. O 
We O 
found O 
that O 
sarin B-TRIVIAL 
concentrates O 
at O 
the O 
interface O 
between O 
the O 
hydrophilic O 
and O 
hydrophobic O 
subphases O 
of O 
hydrated B-FAMILY 
Nafion I-FAMILY 
acting O 
as O 
a O 
surfactant O 
. O 
In O 
hydrated B-ABBREVIATION 
sPS I-ABBREVIATION 
, O 
where O 
the O 
scale O 
of O 
water O 
- O 
polymer O 
segregation O 
is O 
much O 
smaller O 
( O 
1-2 O 
nm O 
) O 
, O 
sarin B-TRIVIAL 
also O 
interacts O 
favorably O 
with O 
hydrophobic O 
and O 
hydrophilic O 
components O 
. O 
Water O 
diffusion O 
slows O 
as O 
the O 
sarin B-TRIVIAL 
content O 
increases O 
despite O 
the O 
overall O 
increase O 
in O 
solvent O 
content O 
, O 
which O 
suggests O 
that O 
sarin B-TRIVIAL 
and O 
water O 
have O 
somewhat O 
different O 
pathways O 
through O 
the O 
segregated O 
membrane O 
. O 
Upon O 
replacement O 
of O 
counterions O 
of O 
monovalent O 
potassium B-SYSTEMATIC 
with O 
those O 
of O 
divalent O 
calcium B-SYSTEMATIC 
, O 
sarin B-TRIVIAL 
diffusion O 
slows O 
but O 
remains O 
substantial O 
in O 
all O 
ionomers O 
considered O 
, O 
especially O 
at O 
high O 
sarin B-TRIVIAL 
concentrations O 
. O 
The O 
behavior O 
of O 
sarin B-TRIVIAL 
is O 
similar O 
to O 
that O 
of O 
its O 
common O 
simulant O 
, O 
dimethyl B-SYSTEMATIC 
methylphosphonate I-SYSTEMATIC 
. O 

Fe3O4 B-FORMULA 
@ O 
Ag B-FORMULA 
/ O 
SiO2 B-FORMULA 
/ O 
Au B-FORMULA 
core O 
- O 
shell O 
microspheres O 
as O 
a O 
novel O 
SERS-activity O 
label O 
via O 
long O 
- O 
range O 
plasmon O 
coupling O 
. O 

metallic O 
nanostructures O 
exhibit O 
a O 
phenomenon O 
known O 
as O 
surface O 
- O 
enhanced O 
Raman O 
scattering O 
( O 
SERS O 
) O 
in O 
which O 
the O 
Raman O 
scattering O 
cross O 
sections O 
are O 
dramatically O 
enhanced O 
for O 
the O 
molecules O 
adsorbed O 
thereon O 
. O 
Due O 
to O 
their O 
wide O 
accessible O 
potential O 
range O 
in O 
aqueous O 
solutions O 
and O 
the O 
high O 
biocompatibility O 
, O 
Au B-FORMULA 
supports O 
are O 
preferred O 
for O 
spectro O 
- O 
electrochemical O 
investigations O 
. O 
However O 
, O 
the O 
optical O 
range O 
in O 
SERS O 
spectroscopy O 
is O 
restricted O 
to O 
excitation O 
lines O 
above O 
600 O 
nm O 
, O 
which O 
is O 
shorter O 
than O 
the O 
Ag B-FORMULA 
supports O 
. O 
In O 
addition O 
, O 
these O 
SERS-activity O 
materials O 
are O 
not O 
easy O 
to O 
separate O 
and O 
reused O 
. O 
Herein O 
, O 
the O 
present O 
article O 
reports O 
the O 
novel O 
multifunctional O 
Fe(3)O(4) B-FORMULA 
@ O 
Ag B-FORMULA 
/ O 
SiO(2) B-FORMULA 
/ O 
Au B-FORMULA 
core O 
- O 
shell O 
microspheres O 
that O 
display O 
long O 
- O 
range O 
plasmon O 
transfer O 
of O 
Ag B-FORMULA 
to O 
Au B-FORMULA 
leading O 
to O 
enhanced O 
Raman O 
scattering O 
. O 
The O 
well O 
- O 
designed O 
microspheres O 
have O 
high O 
magnetization O 
and O 
uniform O 
sphere O 
size O 
. O 
As O 
a O 
result O 
, O 
Fe(3)O(4) B-FORMULA 
@ O 
Ag B-FORMULA 
/ O 
SiO(2) B-FORMULA 
/ O 
Au B-FORMULA 
microspheres O 
have O 
the O 
best O 
enhancement O 
effect O 
in O 
the O 
Raman O 
active O 
research O 
by O 
using O 
Rhodamine-b B-TRIVIAL 
( O 
RdB B-ABBREVIATION 
) O 
as O 
a O 
probe O 
molecule O 
. O 
The O 
enhancement O 
factor O 
is O 
estimated O 
to O 
be O 
2.2 O 
× O 
10(4) O 
for O 
RdB B-ABBREVIATION 
from O 
the O 
long O 
- O 
range O 
plasmon O 
transfer O 
of O 
Ag B-FORMULA 
to O 
Au B-FORMULA 
, O 
corresponding O 
to O 
an O 
attenuation O 
of O 
the O 
enhancement O 
by O 
a O 
factor O 
of O 
only O 
0.672 O 
× O 
10(4) O 
compared O 
to O 
RdB B-ABBREVIATION 
adsorbed O 
directly O 
on O 
the O 
Fe(3)O(4) B-FORMULA 
@ O 
Ag B-FORMULA 
microspheres O 
. O 
RdB B-ABBREVIATION 
can O 
be O 
detected O 
down O 
to O 
10(-9) O 
M O 
even O 
without O 
the O 
resonance O 
SERS O 
effect O 
. O 
The O 
unique O 
nanostructure O 
makes O 
the O 
microspheres O 
novel O 
stable O 
and O 
a O 
high O 
- O 
enhancement O 
effect O 
for O 
Raman O 
detection O 
. O 

: O 
There O 
is O 
a O 
continuing O 
need O 
for O 
an O 
immunosuppressive O 
therapy O 
that O 
offers O 
a O 
high O 
benefit O 
- O 
risk O 
profile O 
for O 
renal O 
transplant O 
recipients O 
, O 
supporting O 
long O 
- O 
term O 
patient O 
and O 
graft O 
survival O 
while O 
minimizing O 
cumulative O 
nephrotoxicity O 
and O 
other O 
side O 
effects O 
. O 
Belatacept O 
, O 
the O 
first O 
biological O 
agent O 
developed O 
for O 
primary O 
maintenance O 
immunosuppression O 
, O 
was O 
recently O 
approved O 
for O 
use O 
in O 
Europe O 
. O 
Belatacept O 
combined O 
with O 
corticosteroids B-FAMILY 
and O 
a O 
mycophenolic B-TRIVIAL 
acid I-TRIVIAL 
is O 
indicated O 
for O 
prophylaxis O 
of O 
graft O 
rejection O 
in O 
adults O 
receiving O 
renal O 
transplant O 
. O 
Its O 
use O 
is O 
contraindicated O 
in O 
Epstein-Barr O 
virus O 
seronegative O 
or O 
serostatus O 
unknown O 
patients O 
due O 
to O 
increased O 
risk O 
of O 
developing O 
posttransplant O 
lymphoproliferative O 
disorder O 
. O 
AREAS O 
COVERED O 
: O 
This O 
review O 
provides O 
practical O 
recommendations O 
for O 
the O 
use O 
of O 
belatacept O 
, O 
based O 
on O 
safety O 
and O 
efficacy O 
data O 
from O 
Phase O 
II O 
and O 
Phase O 
III O 
clinical O 
trials O 
in O 
de O 
novo O 
kidney O 
transplant O 
recipients O 
. O 
EXPERT O 
OPINION O 
: O 
Treatment O 
with O 
belatacept O 
is O 
associated O 
with O 
improved O 
long O 
- O 
term O 
graft O 
function O 
, O 
making O 
belatacept O 
an O 
important O 
option O 
for O 
prevention O 
of O 
kidney O 
allograft O 
rejection O 
. O 
Furthermore O 
, O 
efficacy O 
and O 
safety O 
data O 
over O 
several O 
years O 
of O 
therapy O 
suggest O 
that O 
belatacept O 
is O 
particularly O 
suitable O 
for O 
long O 
- O 
term O 
immunosuppression O 
, O 
and O 
the O 
selective O 
targeting O 
offered O 
by O 
belatacept O 
may O 
help O 
avoid O 
some O 
of O 
the O 
non-specific O 
chronic O 
safety O 
risks O 
associated O 
with O 
calcineurin O 
inhibitors O 
and O 
steroids O 
. O 
Future O 
studies O 
will O 
clarify O 
the O 
optimal O 
regimen O 
for O 
belatacept O 
usage O 
. O 

solvatochromic O 
fluorescent O 
naphthalimides B-FAMILY 
: O 
design O 
, O 
synthesis O 
, O 
photophysical O 
properties O 
and O 
fluorescence O 
switch O 
- O 
on O 
sensing O 
of O 
ct-DNA O 
. O 

report O 
the O 
design O 
, O 
synthesis O 
and O 
photophysical O 
properties O 
of O 
highly O 
solvatochromic O 
donor O 
/ O 
acceptor O 
substituted O 
naphthalimide B-FAMILY 
based O 
fluorophores O 
. O 
The O 
synthesized O 
naphthalimides B-FAMILY 
containing O 
propargyl B-SYSTEMATIC 
ends O 
showed O 
highly O 
solvatochromic O 
intramolecular O 
charge O 
transfer O 
( O 
ICT O 
) O 
feature O 
as O 
was O 
revealed O 
from O 
the O 
UV-visible O 
, O 
fluorescence O 
photophysical O 
properties O 
of O 
these O 
fluorophores O 
and O 
DFT O 
/ O 
TDDFT O 
calculation O 
. O 
Fluorescence O 
life O 
times O 
for O 
the O 
imide B-SYSTEMATIC 
fluorophores O 
were O 
also O 
measured O 
in O 
different O 
solvents O 
. O 
The O 
solid O 
state O 
photophysical O 
property O 
of O 
donor O 
substituted O 
naphthalimide B-FAMILY 
1 O 
showed O 
promising O 
for O 
future O 
application O 
in O 
material O 
sciences O 
. O 
Furthermore O 
, O 
both O 
the O 
donor O 
/ O 
acceptor O 
substituted O 
naphthalimide B-FAMILY 
fluorophores O 
1-2 O 
were O 
exploited O 
in O 
sensing O 
calf O 
- O 
thymus O 
DNA O 
via O 
switch O 
- O 
on O 
fluorescence O 
response O 
. O 
The O 
propargyl B-SYSTEMATIC 
linker O 
containing O 
naphthalimides B-FAMILY 
can O 
further O 
be O 
exploited O 
for O 
the O 
synthesis O 
of O 
labeled O 
biomolecular O 
building O 
blocks O 
. O 

, O 
synthesis O 
and O 
bioevalution O 
of O 
novel O 
benzamides B-FAMILY 
derivatives O 
as O 
HDAC O 
inhibitors O 
. O 

series O 
of O 
novel O 
benzamides B-FAMILY 
derivatives O 
was O 
designed O 
and O 
synthesized O 
as O 
HDAC O 
inhibitors O 
. O 
Exploration O 
of O 
the O 
structure O 
- O 
activity O 
relationships O 
resulted O 
in O 
compounds O 
that O 
are O 
potent O 
in O 
vitro O 
. O 
In O 
addition O 
, O 
the O 
best O 
compound O 
1a O 
exhibited O 
an O 
acceptable O 
pharmacokinetic O 
profile O 
with O 
bioavailability O 
in O 
rat O 
of O 
81% O 
and O 
could O 
be O 
considered O 
as O 
a O 
candidate O 
compound O 
for O 
further O 
development O 
. O 

systematic O 
study O 
of O 
the O 
degradation O 
of O 
dimethyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
using O 
a O 
high O 
- O 
frequency O 
ultrasonic O 
process O 
. O 

comprehensive O 
study O 
of O 
the O 
sonochemical O 
degradation O 
of O 
dimethyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DMP B-ABBREVIATION 
) O 
was O 
carried O 
out O 
using O 
high O 
- O 
frequency O 
ultrasonic O 
processes O 
. O 
The O 
effects O 
of O 
various O 
operating O 
parameters O 
were O 
investigated O 
, O 
including O 
ultrasonic O 
frequency O 
, O 
power O 
density O 
, O 
initial O 
DMP B-ABBREVIATION 
concentration O 
, O 
solution O 
pH O 
and O 
the O 
presence O 
of O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
. O 
In O 
general O 
, O 
a O 
frequency O 
of O 
400kHz O 
was O 
the O 
optimum O 
for O 
achieving O 
the O 
highest O 
DMP B-ABBREVIATION 
degradation O 
rate O 
. O 
The O 
degradation O 
rate O 
was O 
directly O 
proportional O 
to O 
the O 
power O 
density O 
and O 
inversely O 
related O 
to O 
the O 
initial O 
DMP B-ABBREVIATION 
concentration O 
. O 
It O 
was O 
interesting O 
to O 
find O 
that O 
faster O 
removal O 
rate O 
was O 
observed O 
under O 
weakly O 
acidic O 
condition O 
, O 
while O 
hydrolysis O 
effect O 
dominated O 
in O 
extreme O 
- O 
basic O 
condition O 
. O 
The O 
addition O 
of O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
can O 
increase O 
the O 
radical O 
generation O 
to O 
some O 
extent O 
. O 
Furthermore O 
, O 
both O 
hydroxylation O 
of O 
the O 
aromatic O 
ring O 
and O 
oxidation O 
of O 
the O 
aliphatic O 
chain O 
appear O 
to O 
be O 
the O 
major O 
mechanism O 
of O 
DMP B-ABBREVIATION 
degradation O 
by O 
sonolysis O 
based O 
on O 
LC O 
/ O 
ESI-MS O 
analysis O 
. O 
Among O 
the O 
principle O 
reaction O 
intermediates O 
identified O 
, O 
tri- O 
and O 
tetra O 
- O 
hydroxylated O 
derivatives O 
of O 
DMP B-ABBREVIATION 
, O 
as O 
well O 
as O 
hydroxylated B-FAMILY 
monomethyl I-FAMILY 
phthalates I-FAMILY 
and O 
hydroxylated B-TRIVIAL 
phthalic I-TRIVIAL 
acid I-TRIVIAL 
were O 
reported O 
for O 
the O 
first O 
time O 
in O 
this O 
study O 
. O 
Reaction O 
pathways O 
for O 
DMP O 
sonolysis O 
are O 
proposed O 
based O 
on O 
the O 
detected O 
intermediates O 
. O 

of O 
hydroxyl B-SYSTEMATIC 
radical O 
formation O 
in O 
aqueous O 
solutions O 
at O 
different O 
ultrasound O 
frequencies O 
and O 
powers O 
using O 
the O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
dosimeter O 
. O 

frequencies O 
of O 
20kHz O 
, O 
382kHz O 
, O 
584kHz O 
, O 
862kHz O 
( O 
and O 
998kHz O 
) O 
have O 
been O 
compared O 
with O 
regard O 
to O 
energy O 
output O 
and O 
hydroxyl B-SYSTEMATIC 
radical O 
formation O 
utilising O 
the O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
dosimeter O 
. O 
The O 
862kHz O 
frequency O 
inputs O 
6 O 
times O 
the O 
number O 
of O 
Watts O 
into O 
water O 
, O 
as O 
measured O 
by O 
calorimetry O 
, O 
with O 
the O 
other O 
frequencies O 
having O 
roughly O 
the O 
same O 
value O 
under O 
very O 
similar O 
conditions O 
. O 
A O 
plausible O 
explanation O 
involving O 
acoustic O 
fountain O 
formation O 
is O 
proposed O 
although O 
enhanced O 
coupling O 
between O 
this O 
frequency O 
and O 
water O 
cannot O 
be O 
discounted O 
. O 
Using O 
the O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
dosimeter O 
and O 
inputting O 
virtually O 
the O 
same O 
Wattages O 
it O 
is O 
established O 
that O 
862kHz O 
is O 
around O 
10% O 
more O 
efficient O 
at O 
generating O 
hydroxyl B-SYSTEMATIC 
radicals O 
than O 
the O 
382kHz O 
but O 
both O 
of O 
these O 
are O 
far O 
more O 
effective O 
than O 
the O 
other O 
frequencies O 
. O 
Also O 
, O 
it O 
is O 
found O 
that O 
as O 
temperature O 
increases O 
to O 
42°C O 
then O 
the O 
total O 
dihydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
Total O 
DHBA B-ABBREVIATION 
) O 
produced O 
is O 
virtually O 
identical O 
for O 
382kHz O 
and O 
862kHz O 
, O 
though O 
582kHz O 
is O 
substantially O 
lower O 
, O 
when O 
the O 
power O 
levels O 
are O 
set O 
at O 
approximately O 
9W O 
for O 
all O 
systems O 
. O 
An O 
equivalent O 
power O 
level O 
of O 
9W O 
could O 
not O 
be O 
obtained O 
for O 
the O 
998kHz O 
transducer O 
so O 
a O 
direct O 
comparison O 
could O 
not O 
be O 
made O 
in O 
this O 
instance O 
. O 
These O 
results O 
have O 
implications O 
for O 
the O 
optimum O 
frequencies O 
chosen O 
for O 
both O 
Advanced O 
Oxidation O 
Processes O 
( O 
AOPs O 
) O 
and O 
organic O 
synthesis O 
augmented O 
by O 
ultrasound O 
. O 

- O 
exchange O 
and O 
iontophoresis O 
- O 
controlled O 
delivery O 
of O 
apomorphine B-TRIVIAL 
. O 

objective O 
of O 
this O 
study O 
was O 
to O 
test O 
a O 
drug O 
delivery O 
system O 
that O 
combines O 
iontophoresis O 
and O 
cation O 
- O 
exchange O 
fibers O 
as O 
drug O 
matrices O 
for O 
the O 
controlled O 
transdermal O 
delivery O 
of O 
antiparkinsonian O 
drug O 
apomorphine B-TRIVIAL 
. O 
Positively O 
charged O 
apomorphine B-TRIVIAL 
was O 
bound O 
to O 
the O 
ion O 
- O 
exchange O 
groups O 
of O 
the O 
cation O 
- O 
exchange O 
fibers O 
until O 
it O 
was O 
released O 
by O 
mobile O 
counter O 
- O 
ions O 
in O 
the O 
external O 
solution O 
. O 
The O 
release O 
of O 
the O 
drug O 
was O 
controlled O 
by O 
modifying O 
either O 
the O 
fiber O 
type O 
or O 
the O 
ionic O 
composition O 
of O 
the O 
external O 
solution O 
. O 
Due O 
to O 
high O 
affinity O 
of O 
apomorphine B-TRIVIAL 
toward O 
the O 
ion O 
- O 
exchanger O 
, O 
a O 
clear O 
reduction O 
in O 
the O 
in O 
vitro O 
transdermal O 
fluxes O 
from O 
the O 
fibers O 
was O 
observed O 
compared O 
to O 
the O 
respective O 
fluxes O 
from O 
apomorphine B-TRIVIAL 
solutions O 
. O 
Changes O 
in O 
the O 
ionic O 
composition O 
of O 
the O 
donor O 
formulations O 
affected O 
both O 
the O 
release O 
and O 
iontophoretic O 
flux O 
of O 
the O 
drug O 
. O 
Upon O 
the O 
application O 
of O 
higher O 
co O 
- O 
ion O 
concentrations O 
or O 
co O 
- O 
ions O 
of O 
higher O 
valence O 
in O 
the O 
donor O 
formulation O 
, O 
the O 
release O 
from O 
the O 
fibers O 
was O 
enhanced O 
, O 
but O 
the O 
iontophoretic O 
steady O 
- O 
state O 
flux O 
was O 
decreased O 
. O 
Overall O 
, O 
the O 
present O 
study O 
has O 
demonstrated O 
a O 
promising O 
approach O 
using O 
ion O 
- O 
exchange O 
fibers O 
for O 
controlling O 
the O 
release O 
and O 
iontophoretic O 
transdermal O 
delivery O 
of O 
apomorphine B-TRIVIAL 
. O 

to O 
their O 
role O 
in O 
the O 
metabolism O 
of O 
monoamine O 
neurotransmitters O 
, O 
MAO-A O 
and O 
MAO-B O 
present O 
a O 
significant O 
pharmacological O 
interest O 
. O 
For O 
instance O 
the O 
inhibitors O 
of O 
human O 
MAO-B O 
are O 
considered O 
useful O 
tools O 
for O 
the O 
treatment O 
of O 
Parkinson O 
Disease O 
. O 
Therefore O 
, O 
the O 
rational O 
design O 
and O 
synthesis O 
of O 
new O 
MAOs O 
inhibitors O 
is O 
considered O 
of O 
great O 
importance O 
for O 
the O 
development O 
of O 
new O 
and O 
more O 
effective O 
treatments O 
of O 
Parkinson O 
Disease O 
. O 
In O 
this O 
work O 
, O 
Quantitative O 
Structure O 
Activity O 
Relationships O 
( O 
QSAR O 
) O 
has O 
been O 
developed O 
to O 
predict O 
the O 
human O 
MAO O 
inhibitory O 
activity O 
and O 
selectivity O 
. O 
The O 
first O 
step O 
was O 
the O 
selection O 
of O 
a O 
suitable O 
dataset O 
of O 
heterocyclic O 
compounds O 
that O 
include O 
chromones B-FAMILY 
, O 
coumarins B-FAMILY 
, O 
chalcones B-FAMILY 
, O 
thiazolylhydrazones B-FAMILY 
, O 
etc O 
. O 
These O 
compounds O 
were O 
previously O 
synthesized O 
in O 
one O 
of O 
our O 
laboratories O 
, O 
or O 
elsewhere O 
, O 
and O 
their O 
activities O 
measured O 
by O 
the O 
same O 
assays O 
and O 
for O 
the O 
same O 
laboratory O 
staff O 
. O 
Applying O 
linear O 
discriminant O 
analysis O 
to O 
data O 
derived O 
from O 
a O 
variety O 
of O 
molecular O 
representations O 
and O 
feature O 
selection O 
algorithms O 
, O 
reliable O 
QSAR O 
models O 
were O 
built O 
which O 
could O 
be O 
used O 
to O 
predict O 
for O 
test O 
compounds O 
the O 
inhibitory O 
activity O 
and O 
selectivity O 
toward O 
human O 
MAO O 
. O 
This O 
work O 
also O 
showed O 
how O 
several O 
QSAR O 
models O 
can O 
be O 
combined O 
to O 
make O 
better O 
predictions O 
. O 
The O 
final O 
models O 
exhibit O 
significant O 
statistics O 
, O 
interpretability O 
, O 
as O 
well O 
as O 
displaying O 
predictive O 
power O 
on O 
an O 
external O 
validation O 
set O 
made O 
up O 
of O 
chromone O 
derivatives O 
with O 
unknown O 
activity O 
( O 
that O 
are O 
being O 
reported O 
here O 
for O 
first O 
time O 
) O 
synthesized O 
by O 
our O 
group O 
, O 
and O 
coumarins B-FAMILY 
recently O 
reported O 
in O 
the O 
literature O 
. O 

saponins I-FAMILY 
from O 
Clethra O 
barbinervis O 
and O 
their O 
hyaluronidase O 
inhibitory O 
activities O 
. O 

extract O 
of O 
Clethra O 
barbinervis O 
with O 
an O 
inhibitory O 
effect O 
on O 
hyaluronidase O 
activity O 
was O 
fractionated O 
guided O 
by O 
the O 
results O 
of O 
an O 
assay O 
. O 
From O 
the O 
active O 
fractions O 
, O 
seven O 
new O 
triterpene B-FAMILY 
saponins I-FAMILY 
( O 
1-4 O 
, O 
6-8 O 
) O 
and O 
a O 
new O 
lignan B-FAMILY 
glycoside I-FAMILY 
( O 
14 O 
) O 
were O 
isolated O 
together O 
with O 
14 O 
known O 
compounds O 
( O 
5 O 
, O 
9-13 O 
, O 
15-22 O 
) O 
. O 
Some O 
of O 
the O 
saponins B-FAMILY 
( O 
2 O 
, O 
3 O 
, O 
9 O 
) O 
were O 
revealed O 
as O 
hyaluronidase O 
inhibitors O 
similar O 
to O 
epicatechin B-TRIVIAL 
( O 
17 O 
) O 
. O 

colorimetric O 
bacterial O 
detection O 
and O 
high O 
- O 
throughput O 
drug O 
screening O 
based O 
on O 
a O 
graphene B-TRIVIAL 
-enzyme O 
complex O 
. O 

simple O 
, O 
colorimetric O 
, O 
sensitive O 
, O 
cost O 
- O 
effective O 
and O 
high O 
- O 
throughput O 
system O 
based O 
on O 
a O 
positively O 
charged O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
-enzyme O 
complex O 
was O 
developed O 
for O 
bacterial O 
detection O 
and O 
drug O 
screening O 
. O 

II O 
makes O 
a O 
good O 
PET O 
: O 
Discovering O 
positron O 
emission O 
tomography O 
( O 
PET O 
) O 
probes O 
with O 
high O 
target O 
affinities O 
is O 
challenging O 
. O 
PET O 
probe O 
discovery O 
using O 
in O 
situ O 
click O 
chemistry O 
uses O 
( B-FORMULA 
19 I-FORMULA 
) I-FORMULA 
F I-FORMULA 
-bearing O 
fragments O 
as O 
( B-FORMULA 
18 I-FORMULA 
) I-FORMULA 
F I-FORMULA 
surrogates O 
. O 
This O 
ensures O 
that O 
the O 
lead O 
hits O 
and O 
PET O 
probes O 
have O 
equivalent O 
chemical O 
or O 
biological O 
characteristics O 
, O 
making O 
PET O 
probe O 
discovery O 
predictable O 
and O 
reliable O 
. O 

total O 
synthesis O 
of O 
(-)-bengamide B-TRIVIAL 
E I-TRIVIAL 
. O 

synthesis O 
of O 
the O 
polyhydroxy B-SYSTEMATIC 
caprolactam I-SYSTEMATIC 
amide I-SYSTEMATIC 
natural O 
product O 
, O 
bengamide B-TRIVIAL 
E I-TRIVIAL 
, O 
is O 
accomplished O 
starting O 
from O 
tartaric B-TRIVIAL 
acid I-TRIVIAL 
. O 
Key O 
reactions O 
in O 
the O 
synthesis O 
include O 
desymmetrization O 
of O 
the O 
bis(dimethylamide) B-SYSTEMATIC 
unit O 
of O 
tartaric B-TRIVIAL 
acid I-TRIVIAL 
, O 
Zn(BH(4))(2) B-FORMULA 
-mediated O 
anti-selective O 
reduction O 
, O 
and O 
a O 
Horner-Wadsworth-Emmons O 
olefination O 
. O 

of O 
multiple O 
protein O 
- O 
protein O 
interactions O 
using O 
microarray O 
technology O 
remains O 
challenging O 
, O 
and O 
site O 
- O 
specific O 
immobilization O 
of O 
functional O 
proteins O 
is O 
a O 
key O 
step O 
in O 
these O 
approaches O 
. O 
Here O 
we O 
establish O 
the O 
efficient O 
synthesis O 
of O 
protein-DNA O 
conjugates O 
for O 
several O 
members O 
of O 
a O 
small O 
family O 
of O 
GTPases O 
. O 
The O 
family O 
of O 
Rab O 
/ O 
Ypt O 
GTPases O 
is O 
intimately O 
involved O 
in O 
vesicular O 
trafficking O 
in O 
yeast O 
and O 
serves O 
as O 
a O 
model O 
for O 
the O 
much O 
larger O 
group O 
of O 
analogous O 
human O 
proteins O 
, O 
the O 
Rab O 
protein O 
family O 
, O 
with O 
more O 
than O 
60 O 
members O 
. O 
The O 
Ypt-DNA O 
hybrid O 
molecules O 
described O 
here O 
are O 
used O 
for O 
DNA-directed O 
immobilization O 
on O 
glass- O 
and O 
silica B-TRIVIAL 
-based O 
microarrays O 
. O 
Methods O 
for O 
the O 
detection O 
of O 
protein-DNA O 
conjugates O 
, O 
as O 
well O 
as O 
approaches O 
for O 
nucleotide B-FAMILY 
exchange O 
and O 
distinguishing O 
between O 
GDP B-ABBREVIATION 
- O 
and O 
GTP B-ABBREVIATION 
-bound O 
Ypts O 
on O 
microarrays O 
, O 
are O 
reported O 
. O 
The O 
high O 
specificity O 
of O 
different O 
Rab O 
/ O 
Ypt O 
- O 
effector O 
interactions O 
, O 
which O 
also O 
depends O 
on O 
the O 
bound O 
nucleotide B-FAMILY 
, O 
is O 
shown O 
by O 
fluorescence O 
readout O 
of O 
microarrays O 
. O 
Furthermore O 
, O 
initial O 
experiments O 
demonstrate O 
that O 
direct O 
readout O 
by O 
mass O 
spectrometry O 
can O 
be O 
achieved O 
with O 
commercially O 
available O 
instruments O 
. O 
These O 
developments O 
will O 
significantly O 
contribute O 
to O 
the O 
elucidation O 
of O 
complex O 
transport O 
networks O 
in O 
eukaryotic O 
cells O 
. O 

Marie O 
Tooth O 
disease O 
( O 
CMT O 
) O 
is O 
a O 
group O 
of O 
inherited O 
disorders O 
characterized O 
clinically O 
by O 
exclusively O 
or O 
predominantly O 
peripheral O 
nerve O 
dysfunction O 
. O 
CMT1X O 
, O 
the O 
most O 
common O 
form O 
of O 
X O 
- O 
linked O 
CMT O 
is O 
caused O 
by O 
mutations O 
in O 
connexin O 
32 O 
( O 
Cx32 O 
) O 
. O 
In O 
this O 
work O 
, O 
we O 
used O 
dual O 
whole O 
cell O 
patch O 
clamp O 
recording O 
to O 
examine O 
the O 
functional O 
effects O 
of O 
mutations O 
at O 
the O 
Arg B-FORMULA 
( O 
75 O 
) O 
position O 
. O 
This O 
residue O 
is O 
highly O 
conserved O 
among O 
members O 
of O 
the O 
connexin O 
family O 
, O 
and O 
disease O 
- O 
causing O 
mutations O 
have O 
been O 
identified O 
at O 
this O 
( O 
or O 
the O 
corresponding O 
) O 
position O 
in O 
Cx26 O 
, O 
Cx43 O 
, O 
and O 
Cx46 O 
. O 
Thus O 
, O 
a O 
better O 
understanding O 
of O 
the O 
effects O 
of O 
mutations O 
of O 
this O 
position O 
in O 
Cx32 O 
may O 
have O 
relevance O 
to O 
pathogenesis O 
of O 
a O 
number O 
of O 
different O 
human O 
diseases O 
. O 
All O 
three O 
mutants O 
associated O 
with O 
CMT1X O 
( O 
R75P O 
, O 
R75Q O 
, O 
and O 
R75W O 
) O 
showed O 
very O 
low O 
levels O 
of O 
coupling O 
similar O 
to O 
those O 
of O 
the O 
cells O 
transfected O 
with O 
vector O 
alone O 
. O 
Heterotypic O 
pairing O 
with O 
Cx32 O 
WT O 
showed O 
that O 
the O 
absence O 
of O 
coupling O 
for O 
these O 
mutants O 
in O 
the O 
homotypic O 
configuration O 
could O 
be O 
explained O 
by O 
shifts O 
in O 
their O 
hemichannel O 
G(j)-V(j) O 
relations O 
. O 
Examination O 
of O 
the O 
expression O 
levels O 
and O 
gating O 
characteristics O 
of O 
seven O 
additional O 
mutants O 
( O 
R75A O 
, O 
R75D O 
, O 
R75E O 
, O 
R75H O 
, O 
R75K O 
, O 
R75L O 
, O 
and O 
R75V O 
) O 
at O 
this O 
position O 
suggest O 
that O 
the O 
positive O 
charge O 
at O 
position O 
75 O 
in O 
Cx32 O 
is O 
required O 
for O 
normal O 
channel O 
function O 
but O 
not O 
for O 
gap O 
junction O 
assembly O 
. O 
Our O 
studies O 
also O 
suggest O 
that O 
disease O 
treatment O 
strategies O 
for O 
CMT1X O 
, O 
which O 
correct O 
trafficking O 
abnormalities O 
in O 
Cx32 O 
, O 
may O 
be O 
ineffective O 
for O 
the O 
group O 
of O 
mutations O 
also O 
conferring O 
changes O 
in O 
gating O 
properties O 
of O 
Cx32 O 
channels O 
. O 

- O 
molecule O 
modulation O 
of O 
protein O 
- O 
protein O 
interactions O 
( O 
PPIs O 
) O 
is O 
one O 
of O 
the O 
most O 
exciting O 
but O 
also O 
difficult O 
fields O 
in O 
chemical O 
biology O 
and O 
drug O 
development O 
. O 
As O 
one O 
of O 
the O 
most O 
important O 
" O 
hub O 
" O 
proteins O 
with O 
at O 
least O 
200-300 O 
interaction O 
partners O 
, O 
the O 
14-3-3 O 
proteins O 
are O 
an O 
especially O 
fruitful O 
case O 
for O 
PPI O 
intervention O 
. O 
Here O 
, O 
we O 
summarize O 
recent O 
success O 
stories O 
in O 
small O 
- O 
molecule O 
modulation O 
, O 
both O 
inhibition O 
and O 
stabilization O 
, O 
of O 
14-3-3 O 
PPIs O 
. O 
The O 
chemical O 
breath O 
of O 
modulators O 
includes O 
natural O 
products O 
such O 
as O 
fusicoccin B-TRIVIAL 
A I-TRIVIAL 
and O 
derivatives O 
but O 
also O 
compounds O 
identified O 
via O 
high O 
- O 
throughput O 
and O 
in O 
silico O 
screening O 
, O 
which O 
has O 
yielded O 
a O 
toolbox O 
of O 
useful O 
inhibitors O 
and O 
stabilizers O 
for O 
this O 
interesting O 
class O 
of O 
adapter O 
proteins O 
. O 
Protein O 
- O 
protein O 
interactions O 
( O 
PPIs O 
) O 
are O 
involved O 
in O 
almost O 
all O 
biological O 
processes O 
, O 
with O 
any O 
given O 
protein O 
typically O 
engaged O 
in O 
complexes O 
with O 
other O 
proteins O 
for O 
the O 
majority O 
of O 
its O 
lifetime O 
. O 
Hence O 
, O 
proteins O 
function O 
not O 
simply O 
as O 
single O 
, O 
isolated O 
entities O 
but O 
display O 
their O 
roles O 
by O 
interacting O 
with O 
other O 
cellular O 
components O 
. O 
These O 
different O 
interaction O 
patterns O 
are O 
presumably O 
as O 
important O 
as O 
the O 
intrinsic O 
biochemical O 
activity O 
status O 
of O 
the O 
protein O 
itself O 
. O 
The O 
biological O 
role O 
of O 
a O 
protein O 
is O 
therefore O 
decisively O 
dependent O 
on O 
the O 
underlying O 
PPI O 
network O 
that O 
furthermore O 
can O 
show O 
great O 
spatial O 
and O 
temporal O 
variations O 
. O 
A O 
thorough O 
appreciation O 
and O 
understanding O 
of O 
this O 
concept O 
and O 
its O 
regulation O 
mechanisms O 
could O 
help O 
to O 
develop O 
new O 
therapeutic O 
agents O 
and O 
concepts O 
. O 

- O 
assembly O 
process O 
of O 
soft O 
ferritin- O 
PNIPAAm B-ABBREVIATION 
conjugate O 
bionanoparticles O 
at O 
polar O 
- O 
apolar O 
interfaces O 
. O 

describe O 
an O 
in O 
- O 
depth O 
investigation O 
on O 
the O 
dynamics O 
and O 
assembly O 
behavior O 
at O 
polar O 
- O 
apolar O 
interfaces O 
of O 
ferritin- O 
PNIPAAm B-ABBREVIATION 
conjugates O 
( O 
poly-N-isopropylacrylamide B-SYSTEMATIC 
) O 
. O 
The O 
stabilization O 
of O 
oil O 
- O 
water O 
interfaces O 
by O 
the O 
modified O 
ferritin O 
was O 
investigated O 
by O 
dynamic O 
surface O 
tension O 
measurements O 
and O 
compared O 
to O 
the O 
individual O 
components O 
of O 
the O 
bionanoparticle O 
conjugate O 
, O 
namely O 
, O 
unmodified O 
ferritin O 
and O 
pure O 
PNIMAAm B-ABBREVIATION 
of O 
similar O 
molecular O 
weight O 
. O 
It O 
was O 
found O 
that O 
the O 
modified O 
ferritin O 
, O 
even O 
at O 
a O 
low O 
particle O 
concentration O 
, O 
rapidly O 
reduces O 
the O 
interfacial O 
tension O 
. O 
The O 
difference O 
in O 
interfacial O 
stabilization O 
was O 
also O 
shown O 
by O 
cryo O 
- O 
scanning O 
electron O 
microscopy O 
and O 
scanning O 
force O 
microscopy O 
, O 
which O 
displayed O 
very O 
different O 
morphologies O 
at O 
the O 
polar O 
- O 
apolar O 
interface O 
for O 
the O 
unmodified O 
ferritin O 
, O 
pure O 
PNIPAAm B-ABBREVIATION 
, O 
and O 
the O 
ferritin- O 
PNIPAAm B-ABBREVIATION 
conjugate O 
, O 
respectively O 
. O 
The O 
self O 
- O 
assembly O 
of O 
the O 
ferritin- O 
PNIPAAm B-ABBREVIATION 
was O 
further O 
analyzed O 
by O 
cryo O 
- O 
transmission O 
electron O 
microscopy O 
and O 
fluorescence O 
microscopy O 
, O 
for O 
which O 
a O 
fluorescently O 
labeled O 
polymer O 
was O 
used O 
. O 
Both O 
techniques O 
revealed O 
details O 
on O 
the O 
assembly O 
of O 
the O 
protein O 
- O 
polymer O 
conjugate O 
at O 
the O 
oil O 
- O 
water O 
interface O 
. O 

photoresponsive O 
micellar O 
solution O 
is O 
developed O 
as O 
a O 
promising O 
working O 
fluid O 
for O 
district O 
heating O 
/ O 
cooling O 
systems O 
( O 
DHCs O 
) O 
. O 
It O 
can O 
be O 
reversibly O 
switched O 
between O 
a O 
drag O 
reduction O 
( O 
DR O 
) O 
mode O 
and O 
an O 
efficient O 
heat O 
transfer O 
( O 
EHT O 
) O 
mode O 
by O 
light O 
irradiation O 
. O 
The O 
DR O 
mode O 
is O 
advantageous O 
during O 
fluid O 
transport O 
, O 
and O 
the O 
EHT O 
mode O 
is O 
favored O 
when O 
the O 
fluid O 
passes O 
through O 
heat O 
exchangers O 
. O 
This O 
smart O 
fluid O 
is O 
an O 
aqueous O 
solution O 
of O 
cationic O 
surfactant O 
oleyl B-SYSTEMATIC 
bis(2-hydroxyethyl)methyl I-SYSTEMATIC 
ammonium I-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
OHAC B-ABBREVIATION 
, O 
3.4 O 
mM O 
) O 
and O 
the O 
sodium B-SYSTEMATIC 
salt O 
of O 
4-phenylazo B-SYSTEMATIC 
benzoic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
ACA B-ABBREVIATION 
, O 
2 O 
mM O 
) O 
. O 
Initially O 
, O 
ACA B-ABBREVIATION 
is O 
in O 
a O 
trans O 
configuration O 
and O 
the O 
OHAC B-ABBREVIATION 
/ O 
ACA B-ABBREVIATION 
solution O 
is O 
viscoelastic O 
and O 
exhibits O 
DR O 
( O 
of O 
up O 
to O 
80% O 
relative O 
to O 
pure O 
water O 
) O 
. O 
At O 
the O 
same O 
time O 
, O 
this O 
solution O 
is O 
not O 
effective O 
for O 
heat O 
transfer O 
. O 
Upon O 
UV O 
irradiation O 
, O 
trans-ACA B-TRIVIAL 
is O 
converted O 
to O 
cis-ACA B-TRIVIAL 
, O 
and O 
in O 
turn O 
, O 
the O 
solution O 
is O 
converted O 
to O 
its O 
EHT O 
mode O 
( O 
i.e O 
. O 
, O 
it O 
loses O 
its O 
viscoelasticity O 
and O 
DR O 
) O 
but O 
it O 
now O 
has O 
a O 
heat O 
- O 
transfer O 
capability O 
comparable O 
to O 
that O 
of O 
water O 
. O 
Subsequent O 
irradiation O 
with O 
visible O 
light O 
reverts O 
the O 
fluid O 
to O 
its O 
viscoelastic O 
DR O 
mode O 
. O 
The O 
above O 
property O 
changes O 
are O 
connected O 
to O 
photoinduced O 
changes O 
in O 
the O 
nanostructure O 
of O 
the O 
fluid O 
. O 
In O 
the O 
DR O 
mode O 
, O 
the O 
OHAC B-ABBREVIATION 
/ O 
trans-ACA B-TRIVIAL 
molecules O 
assemble O 
into O 
long O 
threadlike O 
micelles O 
that O 
impart O 
viscoelasticity O 
and O 
DR O 
capability O 
to O 
the O 
fluid O 
. O 
Conversely O 
, O 
in O 
the O 
EHT O 
mode O 
the O 
mixture O 
of O 
OHAC B-ABBREVIATION 
and O 
cis-ACA B-TRIVIAL 
forms O 
much O 
shorter O 
cylindrical O 
micelles O 
that O 
contribute O 
to O 
negligible O 
viscoelasticity O 
and O 
effective O 
heat O 
transfer O 
. O 
These O 
nanostructural O 
changes O 
are O 
confirmed O 
by O 
cryo O 
- O 
transmission O 
electron O 
microscopy O 
( O 
cryo-TEM O 
) O 
, O 
and O 
the O 
photoisomerization O 
of O 
trans-ACA B-TRIVIAL 
and O 
cis-ACA B-TRIVIAL 
is O 
verified O 
by O 
(1)H B-FORMULA 
NMR O 
. O 

kinase O 
CK2 O 
( O 
Casein O 
Kinase O 
2 O 
) O 
is O 
an O 
essential O 
, O 
ubiquitous O 
and O 
highly O 
pleiotropic O 
protein O 
kinase O 
, O 
implicated O 
in O 
several O 
human O 
diseases O 
. O 
In O 
the O 
last O 
decade O 
, O 
several O 
inhibitors O 
of O 
CK2 O 
, O 
have O 
been O 
discovered O 
and O 
characterized O 
to O 
be O 
ATP B-ABBREVIATION 
-competitive O 
compounds O 
. O 
However O 
, O 
only O 
one O 
of O 
them O 
, O 
CX-4945 B-IDENTIFIER 
, O 
has O 
recently O 
completed O 
Phase O 
I O 
clinical O 
trial O 
as O 
potential O 
anticancer O 
drug O 
. O 
In O 
this O 
review O 
, O 
we O 
report O 
all O 
chemical O 
classes O 
of O 
CK2 O 
inhibitors O 
available O 
in O 
literature O 
, O 
focusing O 
our O 
attention O 
on O 
conventional O 
ATP B-ABBREVIATION 
-competitive O 
and O 
on O 
non O 
ATP B-ABBREVIATION 
-competitive O 
inhibitors O 
, O 
which O 
could O 
represent O 
a O 
new O 
frontier O 
in O 
CK2 O 
inhibition O 
and O 
, O 
consequently O 
, O 
a O 
promising O 
field O 
of O 
study O 
in O 
discovering O 
new O 
drug O 
candidates O 
. O 

of O 
plant O 
in O 
vitro O 
systems O 
for O 
the O 
mass O 
production O 
of O 
pharmaceutically O 
important O 
metabolites O 
: O 
paclitaxel B-TRIVIAL 
and O 
its O 
derivatives O 
. O 

( O 
paclitaxel B-TRIVIAL 
) O 
and O 
its O 
derivatives O 
are O 
microtubule O 
- O 
stabilizing O 
drugs O 
widely O 
used O 
in O 
the O 
treatment O 
of O 
several O 
types O 
of O 
cancer O 
, O 
including O 
mammary O 
, O 
prostate O 
, O 
ovarian O 
and O 
non-small O 
- O 
cell O 
lung O 
carcinoma O 
, O 
as O 
well O 
as O 
AIDS-associated O 
Kaposi's O 
sarcoma O 
and O 
other O 
types O 
of O 
tumor O 
. O 
Taxanes B-FAMILY 
stabilize O 
microtubules O 
by O 
enhancing O 
their O 
polymerization O 
and O 
inhibiting O 
depolymerization O 
. O 
Microtubule O 
dynamics O 
are O 
crucial O 
to O 
mitotic O 
spindle O 
formation O 
and O 
function O 
; O 
therefore O 
, O 
cells O 
exposed O 
to O 
taxanes B-FAMILY 
are O 
unable O 
to O 
undergo O 
chromosomal O 
separation O 
during O 
mitosis O 
, O 
become O 
arrested O 
in O 
the O 
G2 O 
/ O 
M O 
phases O 
of O 
the O 
cell O 
cycle O 
, O 
and O 
are O 
subsequently O 
targeted O 
for O 
apoptosis O 
. O 
Plant O 
cell O 
cultures O 
are O 
used O 
for O 
industrial O 
- O 
scale O 
biotechnological O 
production O 
of O 
important O 
bioactive O 
plant O 
secondary O 
metabolites O 
, O 
including O 
the O 
anticancer O 
agent O 
paclitaxel B-TRIVIAL 
. O 
In O 
the O 
last O 
two O 
decades O 
, O 
there O 
have O 
been O 
numerous O 
empirical O 
approaches O 
to O 
improve O 
the O 
biotechnological O 
production O 
of O 
taxanes B-FAMILY 
, O 
leading O 
to O 
the O 
conclusion O 
that O 
treatment O 
of O 
Taxus O 
sp O 
. O 
cells O 
with O 
methyl B-SYSTEMATIC 
jasmonate I-SYSTEMATIC 
or O 
other O 
elicitors O 
is O 
the O 
most O 
effective O 
strategy O 
. O 
However O 
, O 
little O 
insight O 
has O 
been O 
gained O 
into O 
how O 
the O 
elicitors O 
increase O 
taxane B-FAMILY 
biosynthesis O 
or O 
how O 
this O 
process O 
is O 
regulated O 
. O 
In O 
recent O 
years O 
, O 
with O 
the O 
help O 
of O 
" O 
omics O 
" O 
tools O 
, O 
a O 
rational O 
approach O 
has O 
provided O 
new O 
information O 
about O 
taxane B-FAMILY 
metabolism O 
and O 
its O 
control O 
. O 
Once O 
pathway O 
bottlenecks O 
have O 
been O 
identified O 
, O 
it O 
will O 
be O 
possible O 
to O 
engineer O 
Taxus O 
sp O 
. O 
cell O 
lines O 
with O 
overexpression O 
of O 
genes O 
that O 
control O 
the O 
flux O 
- O 
limiting O 
steps O 
, O 
thus O 
boosting O 
taxane B-FAMILY 
productivity O 
. O 
This O 
review O 
describes O 
the O 
chemical O 
and O 
biological O 
characterization O 
of O 
paclitaxel B-TRIVIAL 
and O 
its O 
derivatives O 
and O 
discusses O 
future O 
prospects O 
for O 
their O 
biotechnological O 
production O 
. O 

pentacyclic B-FAMILY 
triterpenoids I-FAMILY 
in O 
herbal O 
medicines O 
and O 
their O 
pharmacological O 
activities O 
in O 
diabetes O 
and O 
diabetic O 
complications O 
. O 

triterpenoids I-FAMILY 
including O 
the O 
oleanane B-TRIVIAL 
, O 
ursane B-TRIVIAL 
and O 
lupane B-TRIVIAL 
groups O 
are O 
widely O 
distributed O 
in O 
many O 
medicinal O 
plants O 
, O 
such O 
as O 
Glycyrrhiza O 
species O 
, O 
Gymnema O 
species O 
, O 
Centella O 
asiatica O 
, O 
Camellia O 
sinensis O 
, O 
Crataegus O 
species O 
and O 
Olea O 
europaea O 
, O 
which O 
are O 
commonly O 
used O 
in O 
traditional O 
medicine O 
for O 
the O 
treatment O 
of O 
diabetes O 
and O 
diabetic O 
complications O 
. O 
A O 
large O 
number O 
of O 
bioactive O 
pentacyclic B-FAMILY 
triterpenoids I-FAMILY 
, O 
such O 
as O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
, O 
glycyrrhizin B-TRIVIAL 
, O 
glycyrrhetinic B-TRIVIAL 
acid I-TRIVIAL 
, O 
ursolic B-TRIVIAL 
acid I-TRIVIAL 
, O 
betulin B-TRIVIAL 
, O 
betulinic B-TRIVIAL 
acid I-TRIVIAL 
and O 
lupeol B-TRIVIAL 
have O 
shown O 
multiple O 
biological O 
activities O 
with O 
apparent O 
effects O 
on O 
glucose B-TRIVIAL 
absorption O 
, O 
glucose B-TRIVIAL 
uptake O 
, O 
insulin O 
secretion O 
, O 
diabetic O 
vascular O 
dysfunction O 
, O 
retinopathy O 
and O 
nephropathy O 
. O 
The O 
versatility O 
of O 
the O 
pentacyclic B-FAMILY 
triterpenes I-FAMILY 
provides O 
a O 
promising O 
approach O 
for O 
diabetes O 
management O 
. O 

are O 
anuclear O 
blood O 
cells O 
originating O 
from O 
bone O 
megakaryocytes O 
. O 
Despite O 
being O 
anuclear O 
, O 
their O 
number O 
is O 
maintained O 
by O 
apoptosis O 
, O 
a O 
process O 
of O 
programmed O 
cell O 
death O 
. O 
The O 
rate O 
of O 
apoptotic O 
death O 
of O 
platelets O 
is O 
accelerated O 
by O 
oxidative O 
and O 
shear O 
stress O 
, O 
ex O 
vivo O 
storage O 
( O 
blood O 
banking O 
conditions O 
) O 
and O 
certain O 
pathophysiological O 
disorders O 
. O 
These O 
factors O 
initiate O 
apoptotic O 
events O 
through O 
the O 
mitochondria- O 
mediated O 
intrinsic O 
pathway O 
. O 
Besides O 
, O 
apoptotic O 
platelets O 
also O 
release O 
phosphatidylserine O 
- O 
positive O 
membrane O 
fractions O 
called O 
microparticles O 
, O 
which O 
cause O 
fibrin O 
deposition O 
and O 
thrombus O 
formation O 
, O 
and O 
are O 
involved O 
in O 
the O 
promulgation O 
of O 
a O 
host O 
of O 
disease O 
conditions O 
including O 
cardiovascular O 
diseases O 
. O 
In O 
this O 
context O 
, O 
several O 
phytochemicals O 
have O 
been O 
reported O 
to O 
be O 
cardioprotective O 
and O 
work O 
by O 
inhibiting O 
platelet O 
aggregation O 
or O 
by O 
dissolving O 
the O 
fibrin O 
clots O 
. O 
Besides O 
, O 
ample O 
reports O 
focus O 
on O 
the O 
positive O 
effects O 
of O 
phytochemicals O 
on O 
normal O 
physiology O 
of O 
platelets O 
, O 
but O 
do O 
not O 
focus O 
on O 
their O 
adverse O 
effects O 
on O 
platelets O 
. O 
Moreover O 
, O 
platelets O 
are O 
reported O 
to O 
be O 
extremely O 
sensitive O 
to O 
therapeutic O 
components O 
in O 
the O 
blood O 
. O 
For O 
example O 
, O 
resveratrol B-TRIVIAL 
and O 
thymoquinone B-TRIVIAL 
are O 
hitherto O 
known O 
compounds O 
to O 
possess O 
proapoptotic O 
effects O 
on O 
platelets O 
. O 
In O 
contrast O 
, O 
cinnamtannin B-TRIVIAL 
B1 I-TRIVIAL 
and O 
crocin B-TRIVIAL 
exhibit O 
antiapoptotic O 
effects O 
. O 
Thus O 
, O 
the O 
current O 
review O 
aims O 
to O 
elucidate O 
the O 
underlying O 
mechanisms O 
through O 
which O 
the O 
phytochemicals O 
mediate O 
their O 
effects O 
on O 
platelet O 
apoptosis O 
. O 
Moreover O 
, O 
the O 
need O 
for O 
scrutiny O 
of O 
therapeutic O 
compounds O 
for O 
their O 
effects O 
on O 
platelet O 
functions O 
before O 
including O 
them O 
in O 
treatment O 
regimen O 
is O 
also O 
being O 
emphasized O 
. O 

and O 
HIV-1 O 
inhibitory O 
activities O 
of O 
dicaffeoyl B-MULTIPLE 
and I-MULTIPLE 
digalloyl I-MULTIPLE 
esters I-MULTIPLE 
of O 
quinic B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
. O 

analogues O 
of O 
the O 
anti-HIV-1 O 
integrase O 
( O 
IN O 
) O 
inhibitors O 
dicaffeoylquinic B-FAMILY 
acids I-FAMILY 
( O 
DCQAs B-FAMILY 
) O 
were O 
prepared O 
. O 
Their O 
IC(50) O 
values O 
for O 
3'-end O 
processing O 
and O 
strand O 
transfer O 
against O 
recombinant O 
HIV-1IN O 
were O 
determined O 
in O 
vitro O 
, O 
and O 
their O 
cell O 
toxicities O 
and O 
EC(50) O 
against O 
HIV-1 O 
were O 
measured O 
in O 
cells O 
( O 
ex O 
vivo O 
) O 
. O 
Acetylated O 
or O 
benzylated O 
and O 
/ O 
or O 
with O 
cyclohexylidene B-SYSTEMATIC 
group O 
compounds O 
exhibited O 
no O 
inhibition O 
of O 
integration O 
in O 
biochemical O 
assays O 
or O 
viral O 
replication O 
in O 
HIV-infected O 
cells O 
, O 
with O 
the O 
exception O 
of O 
16 O 
and O 
36 O 
. O 
Removal O 
of O 
these O 
groups O 
, O 
however O 
, O 
correlated O 
with O 
potent O 
inhibition O 
. O 
Compounds O 
19 O 
, O 
31 O 
, O 
and O 
38 O 
, O 
all O 
digalloyls B-FAMILY 
, O 
exhibited O 
the O 
most O 
robust O 
inhibitory O 
performance O 
in O 
biochemical O 
assays O 
as O 
well O 
as O 
in O 
cell O 
culture O 
and O 
less O 
toxicity O 
than O 
other O 
molecules O 
in O 
the O 
current O 
study O 
. O 

is O 
defined O 
as O 
heritable O 
changes O 
in O 
gene O 
activity O 
and O 
expression O 
that O 
occur O 
without O 
alteration O 
in O 
DNA O 
sequence O 
. O 
The O 
gene O 
transcription O 
is O 
strictly O 
correlated O 
to O 
chromatin O 
structure O 
, O 
which O 
could O 
undergo O 
covalent O 
modifications O 
of O 
histones O 
involving O 
acetylation O 
, O 
methylation O 
, O 
phosphorylation O 
and O 
ubiquitination O 
. O 
Alterations O 
in O 
histones O 
are O 
implicated O 
in O 
many O 
diseases O 
, O 
including O 
cancer O 
, O 
by O 
leading O 
to O 
tumor O 
suppressor O 
silencing O 
or O 
pro O 
- O 
apoptotic O 
proteins O 
downregulation O 
. O 
Although O 
post O 
- O 
translational O 
addition O 
of O 
methyl B-SYSTEMATIC 
groups O 
to O 
the O 
histone O 
lysine B-TRIVIAL 
has O 
been O 
discovered O 
three O 
decades O 
ago O 
, O 
the O 
importance O 
of O 
this O 
epigenetic O 
modification O 
has O 
emerged O 
only O 
in O 
the O 
last O 
few O 
years O 
. O 
Thenceforward O 
histone O 
methyltransferase O 
inhibitors O 
have O 
been O 
developed O 
as O 
potential O 
therapeutic O 
cancer O 
agents O 
. O 
It O 
should O 
not O 
be O 
long O 
before O 
some O 
selective O 
inhibitors O 
make O 
their O 
way O 
into O 
clinical O 
trials O 
. O 
This O 
review O 
is O 
mainly O 
focused O 
on O 
the O 
evolution O 
in O 
the O 
development O 
of O 
new O 
epigenetic O 
modifier O 
molecules O 
modulating O 
histone O 
marks O 
. O 

of O 
dopamine B-TRIVIAL 
D2 O 
/ O 
D3 O 
receptor O 
ligands O 
on O 
food- O 
cocaine B-TRIVIAL 
choice O 
in O 
socially O 
housed O 
male O 
cynomolgus O 
monkeys O 
. O 

D2 O 
/ O 
D3 O 
receptor O 
partial O 
agonists O 
have O 
been O 
suggested O 
as O 
medications O 
for O 
cocaine B-TRIVIAL 
dependence O 
. O 
The O 
present O 
experiments O 
examined O 
the O 
effect O 
of O 
acute O 
and O 
repeated O 
administration O 
of O 
drugs O 
with O 
varying O 
intrinsic O 
efficacy O 
at O 
D2 O 
/ O 
D3 O 
receptors O 
on O 
the O 
relative O 
reinforcing O 
strength O 
of O 
cocaine B-TRIVIAL 
. O 
Use O 
of O 
socially O 
housed O 
cynomolgus O 
monkeys O 
permitted O 
the O 
assessment O 
of O 
whether O 
social O 
status O 
, O 
known O 
to O 
alter O 
D2 O 
/ O 
D3 O 
receptor O 
availability O 
, O 
influenced O 
the O 
behavioral O 
effects O 
of O 
D2 O 
/ O 
D3 O 
receptor O 
compounds O 
. O 
The O 
high O 
- O 
efficacy O 
agonist O 
R(-)-norpropylapomorphine B-TRIVIAL 
[ O 
(-)-NPA B-ABBREVIATION 
] O 
, O 
low O 
- O 
efficacy O 
agonist O 
aripiprazole B-TRIVIAL 
( O 
ARI B-ABBREVIATION 
) O 
, O 
and O 
antagonist O 
eticlopride B-TRIVIAL 
( O 
ETIC B-ABBREVIATION 
) O 
were O 
administered O 
acutely O 
to O 
monkeys O 
self O 
- O 
administering O 
cocaine B-TRIVIAL 
under O 
a O 
food- O 
cocaine B-TRIVIAL 
choice O 
procedure O 
in O 
which O 
a O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
dose O 
- O 
effect O 
curve O 
was O 
determined O 
daily O 
. O 
The O 
effects O 
of O 
5-day O 
treatment O 
with O 
ARI O 
and O 
(-)-NPA B-ABBREVIATION 
were O 
characterized O 
under O 
conditions O 
in O 
which O 
monkeys O 
did O 
( O 
ARI B-ABBREVIATION 
) O 
or O 
did O 
not O 
[ O 
ARI B-ABBREVIATION 
and O 
(-)-NPA B-ABBREVIATION 
] O 
self O 
- O 
administer O 
cocaine B-TRIVIAL 
during O 
treatment O 
. O 
When O 
administered O 
acutely O 
, O 
ARI B-ABBREVIATION 
and O 
ETIC B-ABBREVIATION 
increased O 
the O 
choice O 
of O 
low O 
cocaine B-TRIVIAL 
doses O 
, O 
and O 
only O 
(-)-NPA B-ABBREVIATION 
decreased O 
the O 
choice O 
of O 
higher O 
cocaine B-TRIVIAL 
doses O 
and O 
cocaine B-TRIVIAL 
intake O 
; O 
effects O 
were O 
similar O 
across O 
social O 
ranks O 
. O 
When O 
administered O 
repeatedly O 
while O 
self O 
administration O 
occurred O 
only O 
on O 
days O 
1 O 
and O 
5 O 
of O 
treatment O 
, O 
ARI B-ABBREVIATION 
, O 
but O 
not O 
(-)-NPA B-ABBREVIATION 
, O 
decreased O 
cocaine B-TRIVIAL 
choice O 
in O 
dominant O 
monkeys O 
, O 
whereas O 
(-)-NPA B-ABBREVIATION 
, O 
but O 
not O 
ARI B-ABBREVIATION 
, O 
did O 
so O 
in O 
subordinates O 
. O 
When O 
dominant O 
monkeys O 
self O 
- O 
administered O 
cocaine B-TRIVIAL 
on O 
all O 
five O 
days O 
of O 
ARI B-ABBREVIATION 
treatment O 
, O 
however O 
, O 
these O 
effects O 
were O 
not O 
observed O 
. O 
The O 
results O 
indicate O 
that O 
the O 
behavioral O 
effects O 
of O 
D2 O 
/ O 
D3 O 
receptor O 
agonists O 
can O 
differ O 
according O 
to O 
intrinsic O 
efficacy O 
and O 
subject O 
characteristics O 
. O 
Moreover O 
, O 
these O 
results O 
suggest O 
that O 
exposure O 
to O 
cocaine B-TRIVIAL 
during O 
treatment O 
can O 
counteract O 
treatment-induced O 
reductions O 
in O 
the O 
reinforcing O 
effects O 
of O 
cocaine B-TRIVIAL 
. O 

effect O 
of O 
70% O 
ethanolic O 
extract O 
of O 
Lindera O 
obtusiloba O 
Blume O 
on O 
tert-butyl B-SYSTEMATIC 
hydroperoxide I-SYSTEMATIC 
-induced O 
oxidative O 
hepatotoxicity O 
in O 
rats O 
. O 

obtusiloba O 
Blume O 
, O 
a O 
native O 
plant O 
of O 
East O 
Asia O 
, O 
has O 
traditionally O 
been O 
used O 
as O 
a O 
folk O 
medicine O 
for O 
liver O 
disease O 
. O 
We O 
studied O 
the O 
in O 
vitro O 
antioxidant O 
and O 
in O 
vivo O 
hepatoprotective O 
activities O 
of O 
a O 
70% O 
ethanolic O 
extract O 
of O 
L O 
. O 
obtusiloba O 
( O 
LOE O 
) O 
containing O 
62.9% O 
quercitrin B-TRIVIAL 
and O 
22.0% O 
afzelin B-TRIVIAL 
. O 
LOE O 
prevented O 
tert-butyl B-SYSTEMATIC 
hydroperoxide I-SYSTEMATIC 
( O 
t-BHP B-ABBREVIATION 
)-induced O 
oxidative O 
damage O 
in O 
HepG2 O 
cells O 
. O 
Along O 
with O 
its O 
high O 
antioxidant O 
potency O 
in O 
vitro O 
, O 
our O 
animal O 
study O 
confirmed O 
that O 
pretreatment O 
with O 
LOE O 
( O 
500 O 
or O 
2000 O 
mg O 
/ O 
kg O 
) O 
for O 
7 O 
days O 
prior O 
to O 
a O 
single O 
dose O 
of O 
t-BHP B-ABBREVIATION 
( O 
i.p O 
. O 
: O 
0.5 O 
mmol O 
/ O 
kg O 
) O 
significantly O 
lowered O 
the O 
serum O 
levels O 
of O 
alanin B-TRIVIAL 
e O 
and O 
aspartat B-TRIVIAL 
e O 
aminotransferases O 
. O 
In O 
addition O 
, O 
glutathion B-TRIVIAL 
e O 
levels O 
were O 
increased O 
in O 
the O 
liver O 
, O 
and O 
lipid O 
peroxidation O 
levels O 
were O 
decreased O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
The O 
histopathological O 
examinations O 
of O 
rat O 
livers O 
showed O 
that O 
LOE O 
significantly O 
reduced O 
the O 
incidence O 
of O 
liver O 
lesions O 
induced O 
by O 
t-BH B-ABBREVIATION 
P O 
. O 
Therefore O 
, O 
we O 
concluded O 
that O 
LOE O 
has O 
merit O 
as O 
a O 
potent O 
candidate O 
to O 
protect O 
the O 
liver O 
against O 
oxidative O 
damage O 
. O 

receptor O 
coactivator-1 O 
mediates O 
estrogenic O 
actions O 
to O 
prevent O 
body O 
weight O 
gain O 
in O 
female O 
mice O 
. O 

receptor-α O 
( O 
ERα O 
) O 
expressed O 
by O 
hypothalamic O 
proopiomelanocortin O 
and O 
steroidogenic O 
factor-1 O 
neurons O 
largely O 
mediates O 
the O 
antiobesity O 
effects O 
of O 
estrogens B-FAMILY 
in O 
females O 
. O 
However O 
, O 
the O 
critical O 
molecular O 
events O 
that O 
are O 
coupled O 
to O 
ERα O 
and O 
mediate O 
estrogenic O 
effects O 
on O 
energy O 
balance O 
remain O 
unknown O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
demonstrated O 
that O 
steroid B-FAMILY 
receptor O 
coactivator-1 O 
( O 
SRC1 O 
) O 
, O 
a O 
nuclear O 
receptor O 
coactivator O 
, O 
is O 
abundantly O 
expressed O 
by O 
both O 
proopiomelanocortin O 
and O 
steroidogenic O 
factor-1 O 
neurons O 
. O 
We O 
further O 
showed O 
that O 
central O 
administration O 
of O 
an O 
ERα O 
agonist O 
, O 
propyl B-SYSTEMATIC 
pyrazole I-SYSTEMATIC 
triol I-SYSTEMATIC 
, O 
acutely O 
increases O 
physical O 
interaction O 
between O 
SRC1 O 
and O 
ERα O 
in O 
the O 
hypothalamus O 
. O 
Finally O 
, O 
we O 
demonstrated O 
that O 
the O 
effects O 
of O 
estrogens B-FAMILY 
on O 
energy O 
homeostasis O 
are O 
significantly O 
blunted O 
in O 
female O 
mice O 
lacking O 
SRC1 O 
globally O 
. O 
Collectively O 
our O 
results O 
indicate O 
that O 
SRC1 O 
is O 
functionally O 
required O 
to O 
mediate O 
the O 
antiobesity O 
effects O 
of O 
estrogen B-FAMILY 
-ERα O 
signals O 
. O 

-ribosylation O 
of O 
guanosine B-TRIVIAL 
by O 
SCO5461 O 
protein O 
secreted O 
from O 
Streptomyces O 
coelicolor O 
. O 

Streptomyces O 
coelicolor O 
A3(2) O 
genome O 
encodes O 
a O 
possible O 
secretion O 
protein O 
, O 
SCO5461 O 
, O 
that O 
shares O 
a O 
30% O 
homology O 
with O 
the O 
activity O 
domains O 
of O 
two O 
toxic O 
ADP B-ABBREVIATION 
-ribosyltransferases O 
, O 
pierisins O 
and O 
mosquitocidal O 
toxin O 
. O 
We O 
found O 
ADP B-ABBREVIATION 
-ribosylating O 
activity O 
for O 
the O 
SCO5461 O 
protein O 
product O 
through O 
its O 
co O 
- O 
incubation O 
with O 
guanosine B-TRIVIAL 
and O 
NAD(+) B-ABBREVIATION 
, O 
which O 
resulted O 
in O 
the O 
formation O 
of O 
N(2)-(ADP-ribos-1-yl)-guanosine B-SYSTEMATIC 
( O 
(ar2)Guo B-ABBREVIATION 
) O 
, O 
with O 
a O 
K(m) O 
value O 
of O 
110 O 
μM O 
. O 
SCO5461 O 
was O 
further O 
found O 
to O 
ADP B-ABBREVIATION 
-ribosylate O 
deoxyguanosine B-SYSTEMATIC 
, O 
GMP B-ABBREVIATION 
, O 
dGMP B-ABBREVIATION 
, O 
GTP B-ABBREVIATION 
, O 
dGTP B-ABBREVIATION 
, O 
and O 
cyclic B-TRIVIAL 
GMP I-TRIVIAL 
with O 
k(cat) O 
values O 
of O 
150-370 O 
s(-1) O 
. O 
Oligo(dG) O 
, O 
oligo(G) O 
, O 
and O 
yeast O 
tRNA O 
were O 
also O 
ADP B-ABBREVIATION 
-ribosylated O 
by O 
this O 
protein O 
, O 
although O 
with O 
much O 
lower O 
k(cat) O 
values O 
of O 
0.2 O 
s(-1) O 
or O 
less O 
. O 
SCO5461 O 
showed O 
maximum O 
ADP B-ABBREVIATION 
-ribosylation O 
activity O 
towards O 
guanosine O 
at O 
30 O 
°C O 
, O 
and O 
maintained O 
20% O 
of O 
these O 
maximum O 
activity O 
levels O 
even O 
at O 
0 O 
°C O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
the O 
ADP B-ABBREVIATION 
-ribosylation O 
of O 
guanosine B-TRIVIAL 
and O 
guanine B-FAMILY 
mononucleotides I-FAMILY 
among O 
the O 
family O 
members O 
of O 
various O 
ADP B-ABBREVIATION 
-ribosylating O 
enzymes O 
. O 
We O 
additionally O 
observed O 
secretion O 
of O 
the O 
putative O 
gene O 
product O 
, O 
SCO5461 O 
, O 
in O 
liquid O 
cultures O 
of O 
S O 
. O 
coelicolor O 
. O 
We O 
thus O 
designated O 
the O 
SCO5461 O 
protein O 
product O 
as O 
S O 
. O 
coelicolor O 
ADP B-ABBREVIATION 
-ribosylating O 
protein O 
, O 
ScARP O 
. O 
Our O 
current O 
results O 
could O 
offer O 
new O 
insights O 
into O 
not O 
only O 
the O 
ADP B-ABBREVIATION 
-ribosylation O 
of O 
small O 
molecules O 
but O 
also O 
signal O 
transduction O 
events O 
via O 
enzymatic O 
nucleoside B-FAMILY 
modification O 
by O 
toxin O 
- O 
related O 
enzymes O 
. O 

K I-FAMILY 
antagonists O 
( O 
VKAs O 
) O 
were O 
, O 
until O 
recently O 
, O 
the O 
only O 
option O 
for O 
chronic O 
anticoagulation O 
in O 
patients O 
with O 
atrial O 
fibrillation O 
. O 
Three O 
new O 
oral O 
anticoagulants O 
have O 
been O 
tested O 
for O 
this O 
indication O 
in O 
recent O 
randomized O 
trials O 
: O 
dabigatran B-TRIVIAL 
, O 
rivaroxaban B-TRIVIAL 
, O 
and O 
apixaban B-TRIVIAL 
. O 
They O 
offer O 
the O 
promise O 
of O 
consistent O 
effect O 
without O 
the O 
need O 
for O 
monitoring O 
drug O 
levels O 
. O 
Overall O 
, O 
efficacy O 
and O 
safety O 
appear O 
to O 
be O 
noninferior O 
, O 
and O 
in O 
some O 
instances O 
superior O 
, O 
to O 
warfarin B-TRIVIAL 
. O 
However O 
, O 
the O 
new O 
drugs O 
have O 
their O 
downsides O 
, O 
and O 
switching O 
from O 
warfarin B-TRIVIAL 
is O 
not O 
recommended O 
for O 
all O 
patients O 
. O 
This O 
review O 
focuses O 
on O 
the O 
available O 
evidence O 
and O 
attempts O 
to O 
provide O 
guidance O 
to O 
clinicians O 
in O 
the O 
field O 
. O 

study O 
of O 
the O 
reaction O 
of O 
CH2XO B-FAMILY 
( O 
X O 
= O 
F B-FORMULA 
, O 
Cl B-FORMULA 
, O 
Br B-FORMULA 
) O 
radicals O 
with O 
the O 
NO B-FORMULA 
radical O 
. O 

this O 
paper O 
, O 
we O 
focus O 
on O 
the O 
multiple O 
- O 
channel O 
reactions O 
of O 
CH(2)XO B-FAMILY 
( O 
X O 
= O 
F B-FORMULA 
, O 
Cl B-FORMULA 
, O 
Br B-FORMULA 
) O 
radicals O 
with O 
the O 
NO B-FORMULA 
radical O 
by O 
means O 
of O 
direct O 
dynamic O 
methods O 
. O 
All O 
structures O 
of O 
the O 
stationary O 
points O 
were O 
obtained O 
at O 
the O 
MP2 O 
/ O 
6-311 O 
+ O 
G(d,p) O 
level O 
and O 
vibrational O 
frequency O 
analysis O 
was O 
also O 
performed O 
at O 
this O 
level O 
of O 
theory O 
. O 
The O 
minimum O 
energy O 
path O 
( O 
MEP O 
) O 
was O 
obtained O 
via O 
the O 
intrinsic O 
reaction O 
coordinate O 
( O 
IRC O 
) O 
theory O 
at O 
the O 
MP2 O 
/ O 
6-311 O 
+ O 
G(d,p) O 
level O 
, O 
and O 
higher O 
- O 
level O 
energetic O 
information O 
was O 
refined O 
by O 
the O 
MC-QCISD O 
method O 
. O 
The O 
rate O 
constants O 
for O 
the O 
three O 
hydrogen B-SYSTEMATIC 
abstraction O 
reaction O 
channels O 
over O 
the O 
temperature O 
range O 
200-1,500 O 
K O 
were O 
calculated O 
by O 
the O 
improved O 
canonical O 
variational O 
transition O 
state O 
theory O 
( O 
ICVT O 
) O 
with O 
a O 
correction O 
for O 
small O 
- O 
curvature O 
tunneling O 
( O 
SCT O 
) O 
. O 
The O 
rate O 
constants O 
calculated O 
in O 
this O 
manner O 
were O 
in O 
good O 
agreement O 
with O 
the O 
available O 
experimental O 
data O 
, O 
and O 
the O 
three O 
- O 
parameter O 
rate O 
- O 
temperature O 
formulae O 
for O 
the O 
temperature O 
range O 
200-1,500 O 
K O 
were O 
k(1a)(T) O 
= O 
0.32 O 
× O 
10(-18) O 
T(1.83) O 
exp(1748.54 O 
/ O 
T O 
) O 
, O 
k(2a)(T) O 
= O 
0.22 O 
× O 
10(-19) O 
T(2.19) O 
exp(1770.19 O 
/ O 
T O 
) O 
, O 
k(3a)(T) O 
= O 
0.88 O 
× O 
10(-20) O 
T(2.20) O 
exp(1513.82 O 
/ O 
T O 
) O 
( O 
in O 
units O 
of O 
cm(3) O 
molecule(-1) O 
s(-1) O 
) O 
. O 

hair O 
cells O 
( O 
OHCs O 
) O 
are O 
a O 
mammalian O 
innovation O 
for O 
mechanically O 
amplifying O 
sound O 
energy O 
to O 
overcome O 
the O 
viscous O 
damping O 
of O 
the O 
cochlear O 
partition O 
. O 
Although O 
the O 
voltage O 
- O 
dependent O 
OHC O 
membrane O 
motor O 
, O 
prestin O 
, O 
has O 
been O 
demonstrated O 
to O 
be O 
essential O 
for O 
mammalian O 
cochlear O 
amplification O 
, O 
the O 
molecular O 
mechanism O 
by O 
which O 
prestin O 
converts O 
electrical O 
energy O 
into O 
mechanical O 
displacement O 
/ O 
force O 
remains O 
elusive O 
. O 
Identifying O 
mutations O 
that O 
alter O 
the O 
motor O 
function O 
of O 
prestin O 
provides O 
vital O 
information O 
for O 
unraveling O 
the O 
energy O 
transduction O 
mechanism O 
of O 
prestin O 
. O 
We O 
show O 
that O 
the O 
V499G O 
/ O 
Y501H O 
mutation O 
does O 
not O 
deprive O 
prestin O 
of O 
its O 
voltage O 
- O 
induced O 
motor O 
activity O 
, O 
but O 
it O 
does O 
significantly O 
impair O 
the O 
fast O 
motor O 
kinetics O 
and O 
voltage O 
operating O 
range O 
. O 
Furthermore O 
, O 
mutagenesis O 
studies O 
suggest O 
that O 
Val B-ABBREVIATION 
-499 O 
is O 
the O 
primary O 
site O 
responsible O 
for O 
these O 
changes O 
. O 
We O 
also O 
show O 
that O 
V499G O 
/ O 
Y501H O 
prestin O 
forms O 
heteromers O 
with O 
wild O 
- O 
type O 
prestin O 
and O 
that O 
the O 
fast O 
motor O 
kinetics O 
of O 
wild O 
- O 
type O 
prestin O 
is O 
not O 
affected O 
by O 
heteromer O 
formation O 
with O 
V499G O 
/ O 
Y501H O 
prestin O 
. O 
These O 
results O 
suggest O 
that O 
prestin O 
subunits O 
are O 
individually O 
functional O 
within O 
a O 
given O 
multimer O 
. O 

of O 
phenanthrene B-SYSTEMATIC 
, O 
2-naphthol B-SYSTEMATIC 
, O 
and O 
1-naphthylamine B-SYSTEMATIC 
to O 
colloidal O 
oxidized O 
multiwalled O 
carbon B-SYSTEMATIC 
nanotubes O 
: O 
effects O 
of O 
humic O 
acid O 
and O 
surfactant O 
modification O 
. O 

nanotubes O 
( O 
CNTs O 
) O 
can O 
exist O 
in O 
the O 
form O 
of O 
colloidal O 
suspension O 
in O 
aquatic O 
environments O 
, O 
particularly O 
in O 
the O 
presence O 
of O 
natural O 
organic O 
matter O 
or O 
surfactants O 
, O 
and O 
may O 
significantly O 
affect O 
the O 
fate O 
and O 
transport O 
of O 
organic O 
contaminants O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
authors O 
examined O 
the O 
adsorption O 
of O 
phenanthrene B-SYSTEMATIC 
, O 
2-naphthol B-SYSTEMATIC 
, O 
and O 
1-naphthylamine B-SYSTEMATIC 
to O 
three O 
colloidal O 
CNTs O 
, O 
including O 
a O 
stable O 
suspension O 
of O 
oxidized O 
multiwalled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
O-MWNT O 
) O 
, O 
a O 
humic O 
acid O 
( O 
HA O 
) O 
- O 
modified O 
colloidal O 
O-MWNT O 
, O 
and O 
a O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
SDS B-ABBREVIATION 
) O 
- O 
modified O 
colloidal O 
O-MWNT O 
. O 
All O 
three O 
colloidal O 
O-MWNTs O 
exhibit O 
strong O 
adsorption O 
affinities O 
to O 
the O 
three O 
test O 
compounds O 
( O 
with O 
K(OC) O 
values O 
orders O 
of O 
magnitude O 
greater O 
than O 
those O 
of O 
natural O 
organic O 
matter O 
) O 
, O 
likely O 
resulting O 
from O 
strong O 
nonhydrophobic O 
interactions O 
such O 
as O 
π-π O 
electron O 
donor-acceptor O 
interactions O 
and O 
Lewis B-FAMILY 
acid I-FAMILY 
-base O 
interactions O 
. O 
When O 
thoroughly O 
mixed O 
, O 
HA O 
( O 
at O 
∼310 O 
mg O 
HA O 
/ O 
g O 
CNT O 
) O 
and O 
SDS B-ABBREVIATION 
( O 
at O 
∼750 O 
mg O 
SDS B-ABBREVIATION 
/g O 
CNT O 
) O 
significantly O 
affected O 
the O 
aggregation O 
properties O 
of O 
O-MWNT O 
, O 
causing O 
individually O 
dispersed O 
tubes O 
to O 
form O 
a O 
loosely O 
entangled O 
network O 
. O 
The O 
effects O 
of O 
HA O 
or O 
SDS B-ABBREVIATION 
modification O 
on O 
adsorption O 
are O 
twofold O 
. O 
Adsorption O 
of O 
HA/ O 
SDS B-ABBREVIATION 
significantly O 
reduces O 
surface O 
areas O 
of O 
O-MWNT O 
; O 
however O 
, O 
the O 
entangled O 
network O 
allows O 
adsorbate O 
molecules O 
to O 
interact O 
simultaneously O 
with O 
multiple O 
tubes O 
. O 
An O 
important O 
implication O 
is O 
that O 
humic O 
substances O 
and O 
surfactant O 
- O 
like O 
materials O 
not O 
only O 
facilitate O 
the O 
formation O 
of O 
colloidal O 
carbon B-SYSTEMATIC 
nanoparticles O 
but O 
also O 
affect O 
how O 
these O 
colloidal O 
carbon B-SYSTEMATIC 
nanoparticles O 
adsorb O 
organic O 
contaminants O 
. O 

studies O 
have O 
shown O 
inexplicable O 
declines O 
in O 
breeding O 
waterbirds O 
within O 
western O 
New O 
York O 
/ O 
New O 
Jersey O 
Harbor O 
between O 
1996 O 
and O 
2002 O 
and O 
elevated O 
polychlorinated B-FAMILY 
dibenzo-p-dioxins I-FAMILY 
and O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
( O 
PCBs B-ABBREVIATION 
) O 
in O 
double O 
- O 
crested O 
cormorant O 
( O 
Phalacrocorax O 
auritus O 
) O 
eggs O 
. O 
The O 
present O 
study O 
assessed O 
associations O 
between O 
immune O 
function O 
, O 
prefledgling O 
survival O 
, O 
and O 
selected O 
organochlorine B-FAMILY 
compounds O 
and O 
metals O 
in O 
herring O 
gulls O 
( O 
Larus O 
argentatus O 
) O 
and O 
black O 
- O 
crowned O 
night O 
herons O 
( O 
Nycticorax O 
nycticorax O 
) O 
in O 
lower O 
New O 
York O 
Harbor O 
during O 
2003 O 
. O 
In O 
pipping O 
gull O 
embryos O 
, O 
lymphoid O 
cells O 
were O 
counted O 
in O 
the O 
thymus O 
and O 
bursa O 
of O 
Fabricius O 
( O 
sites O 
of O 
T O 
and O 
B O 
lymphocyte O 
maturation O 
, O 
respectively O 
) O 
. O 
The O 
phytohemagglutinin O 
( O 
PHA O 
) O 
skin O 
response O 
assessed O 
T O 
cell O 
function O 
in O 
gull O 
and O 
heron O 
chicks O 
. O 
Lymphocyte O 
proliferation O 
was O 
measured O 
in O 
vitro O 
in O 
adult O 
and O 
prefledgling O 
gulls O 
. O 
Reference O 
data O 
came O 
from O 
the O 
Great O 
Lakes O 
and O 
Bay O 
of O 
Fundy O 
. O 
Survival O 
of O 
prefledgling O 
gulls O 
was O 
poor O 
, O 
with O 
only O 
0.68 O 
and O 
0.5 O 
chicks O 
per O 
nest O 
surviving O 
to O 
three O 
and O 
four O 
weeks O 
after O 
hatch O 
, O 
respectively O 
. O 
Developing O 
lymphoid O 
cells O 
were O 
reduced O 
51% O 
in O 
the O 
thymus O 
and O 
42% O 
in O 
the O 
bursa O 
of O 
gull O 
embryos O 
from O 
New O 
York O 
Harbor O 
. O 
In O 
vitro O 
lymphocyte O 
assays O 
demonstrated O 
reduced O 
spontaneous O 
proliferation O 
, O 
reduced O 
T O 
cell O 
mitogen O 
- O 
induced O 
proliferation O 
, O 
and O 
increased O 
B O 
cell O 
mitogen O 
- O 
induced O 
proliferation O 
in O 
gull O 
chicks O 
from O 
New O 
York O 
Harbor O 
. O 
The O 
PHA O 
skin O 
response O 
was O 
suppressed O 
70 O 
to O 
80% O 
in O 
gull O 
and O 
heron O 
chicks O 
. O 
Strong O 
negative O 
correlations O 
( O 
r O 
= O 
-0.95 O 
to O 
-0.98 O 
) O 
between O 
the O 
PHA O 
response O 
and O 
dioxins B-FAMILY 
and O 
PCBs B-ABBREVIATION 
in O 
gull O 
livers O 
was O 
strong O 
evidence O 
suggesting O 
that O 
these O 
chemicals O 
contribute O 
significantly O 
to O 
immunosuppression O 
in O 
New O 
York O 
Harbor O 
waterbirds O 
. O 

graphene I-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoribbon O 
networks O 
: O 
a O 
novel O 
approach O 
towards O 
scalable O 
fabrication O 
of O 
transparent O 
conductive O 
films O 
. O 

innovative O 
approach O 
is O 
developed O 
for O 
the O 
high O 
- O 
throughput O 
, O 
large O 
- O 
area O 
, O 
and O 
low O 
- O 
cost O 
fabrication O 
of O 
reduced B-SYSTEMATIC 
graphene I-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
RGO B-ABBREVIATION 
) O 
nanoribbon O 
networks O 
by O 
using O 
electrospun O 
polymer O 
- O 
based O 
nanowires O 
as O 
the O 
etching O 
mask O 
. O 
Combined O 
with O 
their O 
tunable O 
, O 
controllable O 
structures O 
and O 
transmittance O 
/ O 
conductivity O 
properties O 
, O 
the O 
as-fabricated O 
RGO B-ABBREVIATION 
nanoribbon O 
networks O 
exhibit O 
potential O 
as O 
transparent O 
conductive O 
film O 
electrodes O 
, O 
for O 
example O 
, O 
in O 
electrochromic O 
devices O 
. O 

exerts O 
antiapoptotic O 
effects O 
in O 
skeletal O 
myoblasts O 
via O 
mitochondrial O 
PTP O 
and O 
MnSOD O 
. O 

(E(2)) O 
protects O 
several O 
non-reproductive O 
tissues O 
from O 
apoptosis O 
, O 
including O 
skeletal O 
muscle O 
. O 
We O 
have O 
shown O 
that O 
E(2) O 
at O 
physiological O 
concentrations O 
prevented O 
apoptosis O 
induced O 
by O 
H(2)O(2) B-FORMULA 
in O 
C2C12 O 
skeletal O 
myoblasts O 
. O 
As O 
we O 
also O 
demonstrated O 
the O 
presence O 
of O 
estrogen B-FAMILY 
receptors O 
in O 
mitochondria O 
, O 
the O 
present O 
work O 
was O 
focused O 
on O 
the O 
effects O 
of O 
E(2) O 
on O 
this O 
organelle O 
. O 
Specifically O 
, O 
we O 
evaluated O 
the O 
actions O 
of O 
E(2) O 
on O 
the O 
mitochondrial O 
permeability O 
transition O 
pore O 
( O 
MPTP O 
) O 
by O 
the O 
calcein B-TRIVIAL 
- O 
acetoxymethylester B-SYSTEMATIC 
/ O 
cobalt B-SYSTEMATIC 
method O 
using O 
fluorescence O 
microscopy O 
and O 
flow O 
cytometry O 
. O 
Pretreatment O 
with O 
E(2) O 
prevented O 
MPTP O 
opening O 
induced O 
by O 
H(2)O(2) B-FORMULA 
, O 
which O 
preceded O 
loss O 
of O 
mitochondrial O 
membrane O 
potential O 
. O 
In O 
addition O 
, O 
it O 
was O 
observed O 
that O 
H(2)O(2) B-FORMULA 
induced O 
translocation O 
of O 
Bax O 
to O 
mitochondria O 
; O 
however O 
, O 
in O 
the O 
presence O 
of O 
the O 
steroid B-FAMILY 
this O 
effect O 
was O 
abrogated O 
suggesting O 
that O 
members O 
of O 
the O 
Bcl-2 O 
family O 
may O 
be O 
regulated O 
by O 
E(2) O 
to O 
exert O 
an O 
antiapoptotic O 
effect O 
. O 
Moreover O 
, O 
E(2) O 
increased O 
mitochondrial O 
manganese O 
superoxide B-TRIVIAL 
dismutase O 
protein O 
expression O 
and O 
activity O 
, O 
as O 
part O 
of O 
a O 
mechanism O 
activated O 
by O 
E(2) O 
that O 
improved O 
mitochondrial O 
performance O 
. O 
Our O 
results O 
suggest O 
a O 
role O 
of O 
E(2) O 
in O 
the O 
regulation O 
of O 
apoptosis O 
with O 
a O 
clear O 
action O 
at O 
the O 
mitochondrial O 
level O 
in O 
C2C12 O 
skeletal O 
myoblast O 
cells O 
. O 

of O 
functionalized O 
alkynyl B-FAMILY 
magnetic O 
microspheres O 
for O 
the O 
selective O 
enrichment O 
of O 
cell O 
glycoproteins O 
based O 
on O 
click O 
chemistry O 
. O 

alkynyl B-FAMILY 
polyvinyl I-FAMILY 
alcohol I-FAMILY 
magnetic O 
microspheres O 
( O 
PVA B-ABBREVIATION 
MMs O 
) O 
were O 
developed O 
for O 
the O 
specific O 
enrichment O 
of O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
-rich O 
glycoproteins O 
by O 
click O 
chemistry O 
. O 
The O 
capture O 
capability O 
for O 
proteins O 
was O 
evaluated O 
through O 
a O 
novel O 
dual O 
- O 
labeled O 
bovine O 
serum O 
albumin O 
( O 
BSA O 
) O 
that O 
utilizes O 
fluorescence O 
resonance O 
energy O 
transfer O 
( O 
FRET O 
) O 
. O 
The O 
PVA B-ABBREVIATION 
MM O 
parameters O 
, O 
including O 
the O 
size O 
and O 
coverage O 
of O 
functionalized O 
groups O 
, O 
were O 
optimized O 
by O 
response O 
surface O 
methodology O 
. O 
The O 
optimal O 
parameters O 
obtained O 
were O 
1.25-6.31 O 
μm O 
in O 
size O 
and O 
48.53-73.05% O 
in O 
coverage O 
. O 
Then O 
, O 
the O 
optimal O 
PVA B-ABBREVIATION 
MMs O 
were O 
synthesized O 
, O 
and O 
the O 
morphology O 
and O 
surface O 
chemical O 
properties O 
were O 
characterized O 
by O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
, O 
scanning O 
electron O 
microscopy O 
( O 
SEM O 
) O 
, O 
and O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
( O 
FT-IR O 
) O 
. O 
To O 
capture O 
glycoproteins O 
from O 
the O 
cell O 
surface O 
, O 
a O 
bioorthogonal O 
chemical O 
method O 
was O 
applied O 
to O 
metabolically O 
label O 
them O 
with O 
an O 
azide B-SYSTEMATIC 
group O 
. O 
The O 
functionalized O 
alkynyl B-FAMILY 
PVA I-FAMILY 
MMs O 
showed O 
a O 
high O 
specificity O 
and O 
strong O 
binding O 
capability O 
for O 
glycoproteins O 
through O 
a O 
[ O 
3 O 
+ O 
2 O 
] O 
cycloaddition O 
reaction O 
. O 
The O 
results O 
indicated O 
that O 
the O 
functionalized O 
alkynyl B-FAMILY 
PVA I-FAMILY 
MMs O 
could O 
be O 
applied O 
to O 
the O 
enrichment O 
of O 
cell O 
glycoproteins O 
, O 
and O 
the O 
merits O 
of O 
the O 
MMs O 
suggested O 
an O 
attractive O 
and O 
potential O 
way O 
to O 
facilitate O 
glycoprotein O 
research O 
. O 

is O 
a O 
lysosomal O 
cysteine B-TRIVIAL 
protease O 
whose O 
biological O 
function O 
remains O 
poorly O 
defined O 
. O 
Legumain O 
activity O 
is O 
up O 
- O 
regulated O 
in O 
most O 
human O 
cancers O 
and O 
inflammatory O 
diseases O 
most O 
likely O 
as O 
the O 
result O 
of O 
high O 
expression O 
in O 
populations O 
of O 
activated O 
macrophages O 
. O 
Within O 
the O 
tumor O 
microenvironment O 
, O 
legumain O 
activity O 
is O 
thought O 
to O 
promote O 
tumorigenesis O 
. O 
To O 
obtain O 
a O 
greater O 
understanding O 
of O 
the O 
role O 
of O 
legumain O 
activity O 
during O 
cancer O 
progression O 
and O 
inflammation O 
, O 
we O 
developed O 
an O 
activity O 
- O 
based O 
probe O 
that O 
becomes O 
fluorescent O 
only O 
upon O 
binding O 
active O 
legumain O 
. O 
This O 
probe O 
is O 
highly O 
selective O 
for O 
legumain O 
, O 
even O 
in O 
the O 
context O 
of O 
whole O 
cells O 
and O 
tissues O 
, O 
and O 
is O 
also O 
a O 
more O 
effective O 
label O 
of O 
legumain O 
than O 
previously O 
reported O 
probes O 
. O 
Here O 
we O 
present O 
the O 
synthesis O 
and O 
application O 
of O 
our O 
probe O 
to O 
the O 
analysis O 
of O 
legumain O 
activity O 
in O 
primary O 
macrophages O 
and O 
in O 
two O 
mouse O 
models O 
of O 
cancer O 
. O 
We O 
find O 
that O 
legumain O 
activity O 
is O 
highly O 
correlated O 
with O 
macrophage O 
activation O 
and O 
furthermore O 
that O 
it O 
is O 
an O 
ideal O 
marker O 
for O 
primary O 
tumor O 
inflammation O 
and O 
early O 
stage O 
metastatic O 
lesions O 
. O 

pumping O 
of O 
a O 
single O 
electron O 
spin O 
bound O 
to O 
a O 
fluorine B-SYSTEMATIC 
donor O 
in O 
a O 
ZnSe B-FORMULA 
nanostructure O 
. O 

we O 
demonstrate O 
optical O 
pumping O 
of O 
a O 
single O 
electron O 
within O 
a O 
semiconductor O 
nanostructure O 
comprised O 
of O 
a O 
single O 
fluorine B-SYSTEMATIC 
donor O 
located O 
within O 
a O 
ZnSe B-FORMULA 
/ O 
ZnMgSe B-FORMULA 
quantum O 
well O 
. O 
Experiments O 
were O 
performed O 
to O 
detect O 
optical O 
pumping O 
behavior O 
by O 
observing O 
single O 
photons O 
emitted O 
from O 
the O 
nanostructure O 
when O 
the O 
electron O 
changes O 
spin O 
state O 
. O 
These O 
results O 
demonstrate O 
initialization O 
and O 
read O 
- O 
out O 
of O 
the O 
electron O 
spin O 
qubit O 
and O 
open O 
the O 
door O 
for O 
coherent O 
optical O 
manipulation O 
of O 
a O 
spin O 
by O 
taking O 
advantage O 
of O 
an O 
unconventional O 
nanostructure O 
. O 

study O 
sought O 
to O 
investigate O 
the O 
inhibitory O 
effect O 
of O 
aqueous O 
extracts O 
of O 
two O 
varieties O 
( O 
red O 
and O 
white O 
) O 
of O 
Hibiscus O 
sabdariffa O 
( O 
Roselle O 
) O 
calyces O 
on O 
carbohydrate B-FAMILY 
hydrolyzing O 
enzymes O 
( O 
α-amylase O 
and O 
α-glucosidase O 
) O 
, O 
with O 
the O 
aim O 
of O 
providing O 
the O 
possible O 
mechanism O 
for O 
their O 
antidiabetes O 
properties O 
. O 
Aqueous O 
extracts O 
were O 
prepared O 
( O 
1 O 
: O 
100 O 
w O 
/ O 
v O 
) O 
and O 
the O 
supernatant O 
used O 
for O 
the O 
analysis O 
. O 
The O 
extracts O 
caused O 
inhibition O 
of O 
α-amylase O 
and O 
α-glucosidase O 
activities O 
in O 
vitro.The O 
IC(50) O 
revealed O 
that O 
the O 
red O 
variety O 
( O 
25.2 O 
μg O 
/ O 
mL O 
) O 
exhibited O 
higher O 
α-glucosidase O 
inhibitory O 
activity O 
than O 
the O 
white O 
variety O 
( O 
47.4 O 
μg O 
/ O 
mL O 
) O 
, O 
while O 
the O 
white O 
variety O 
( O 
90.5 O 
μg O 
/ O 
mL O 
) O 
exhibited O 
higher O 
α-amylase O 
inhibitory O 
activity O 
than O 
the O 
red O 
variety O 
( O 
187.9 O 
μg O 
/ O 
mL O 
) O 
. O 
However O 
, O 
the O 
α-glucosidase O 
inhibitory O 
activities O 
of O 
both O 
calyces O 
were O 
higher O 
than O 
that O 
of O 
their O 
α-amylase O 
. O 
In O 
addition O 
, O 
the O 
red O 
variety O 
possessed O 
higher O 
antioxidant O 
capacity O 
as O 
exemplified O 
by O 
the O 
(•)OH B-FORMULA 
scavenging O 
abilities O 
, O 
Fe(2+) B-FORMULA 
chelating O 
ability O 
, O 
and O 
inhibition O 
of O 
Fe(2+) B-FORMULA 
-induced O 
pancreatic O 
lipid O 
peroxidation O 
in O 
vitro O 
. O 
The O 
enzyme O 
inhibitory O 
activities O 
and O 
antioxidant O 
properties O 
of O 
the O 
roselle O 
extracts O 
agreed O 
with O 
their O 
phenolic B-FAMILY 
content O 
. O 
Hence O 
, O 
inhibition O 
of O 
α-amylase O 
and O 
α-glucosidase O 
, O 
coupled O 
with O 
strong O 
antioxidant O 
properties O 
could O 
be O 
the O 
possible O 
underlying O 
mechanism O 
for O 
the O 
antidiabetes O 
properties O 
of O 
H O 
. O 
sabdariffa O 
calyces O 
; O 
however O 
, O 
the O 
red O 
variety O 
appeared O 
to O 
be O 
more O 
potent O 
. O 

effect O 
of O 
aspalathin B-TRIVIAL 
from O 
rooibos O 
( O 
Aspalathus O 
linearis O 
) O 
on O 
acute O 
oxidative O 
stress O 
in O 
Caenorhabditis O 
elegans O 
. O 

leaves O 
and O 
fine O 
stems O 
( O 
Aspalathus O 
linearis O 
; O 
Fabaceae O 
) O 
are O 
increasingly O 
enjoyed O 
as O 
herbal O 
tea O 
, O 
largely O 
in O 
fermented O 
( O 
oxidised O 
) O 
red O 
- O 
brown O 
form O 
, O 
but O 
also O 
in O 
unfermented O 
( O 
unoxidised O 
) O 
green O 
form O 
. O 
Rooibos O 
is O 
rich O 
in O 
antioxidant O 
polyphenols B-FAMILY 
, O 
with O 
the O 
dihydrochalcone B-SYSTEMATIC 
, O 
aspalathin B-TRIVIAL 
, O 
as O 
a O 
major O 
active O 
ingredient O 
. O 
We O 
used O 
Caenorhabditis O 
elegans O 
as O 
model O 
organism O 
to O 
investigate O 
the O 
effect O 
of O 
rooibos O 
extracts O 
against O 
oxidative O 
stress O 
in O 
vivo O 
. O 
In O 
a O 
high O 
glucose B-TRIVIAL 
environment O 
, O 
C O 
. O 
elegans O 
treated O 
with O 
rooibos O 
extract O 
exhibited O 
an O 
extended O 
lifespan O 
. O 
Furthermore O 
, O 
green O 
rooibos O 
was O 
a O 
more O 
potent O 
antioxidant O 
than O 
red O 
rooibos O 
, O 
probably O 
due O 
to O 
its O 
substantially O 
higher O 
aspalathin B-TRIVIAL 
content O 
. O 
In O 
addition O 
, O 
rooibos O 
decreased O 
acute O 
oxidative O 
damage O 
caused O 
by O 
the O 
superoxide B-TRIVIAL 
anion O 
radical O 
generator O 
, O 
juglone B-TRIVIAL 
, O 
with O 
aspalathin B-TRIVIAL 
playing O 
a O 
major O 
role O 
in O 
improving O 
the O 
survival O 
rate O 
of O 
C O 
. O 
elegans O 
. O 
Quantitative O 
real O 
- O 
time O 
PCR O 
results O 
demonstrated O 
that O 
aspalathin B-TRIVIAL 
targets O 
stress O 
and O 
ageing O 
related O 
genes O 
, O 
reducing O 
the O 
endogenous O 
intracellular O 
level O 
of O 
ROS O 
. O 
These O 
findings O 
suggest O 
that O 
rooibos O 
increases O 
stress O 
resistance O 
and O 
promotes O 
longevity O 
under O 
stress O 
, O 
probably O 
mediated O 
via O 
a O 
regulation O 
of O 
the O 
DAF-16 O 
/ O 
FOXO O 
insulin O 
- O 
like O 
signalling O 
pathway O 
, O 
supporting O 
some O 
of O 
the O 
health O 
claims O 
put O 
forward O 
for O 
rooibos O 
tea O 
. O 

, O 
antimalarial O 
activity O 
and O 
cytotoxic O 
potential O 
of O 
new O 
monocarbonyl B-SYSTEMATIC 
analogues O 
of O 
curcumin B-TRIVIAL 
. O 

series O 
of O 
novel O 
monocarbonyl B-SYSTEMATIC 
analogues O 
of O 
curcumin B-TRIVIAL 
have O 
been O 
designed O 
, O 
synthesized O 
and O 
tested O 
for O 
their O 
activity O 
against O 
Molt4 O 
, O 
HeLa O 
, O 
PC3 O 
, O 
DU145 O 
and O 
KB O 
cancer O 
cell O 
lines O 
. O 
Six O 
of O 
the O 
analogues O 
showed O 
potent O 
cytotoxicity O 
towards O 
these O 
cell O 
lines O 
with O 
IC(50) O 
values O 
below O 
1 O 
μM O 
, O 
which O 
is O 
better O 
than O 
doxorubicin B-TRIVIAL 
, O 
a O 
US O 
FDA O 
approved O 
drug O 
. O 
Several O 
analogues O 
were O 
also O 
found O 
to O 
be O 
active O 
against O 
both O 
CQ-resistant O 
( O 
W2 O 
clone O 
) O 
and O 
CQ-sensitive O 
( O 
D6 O 
) O 
strains O 
of O 
Plasmodium O 
falciparum O 
in O 
an O 
in O 
- O 
vitro O 
antimalarial O 
screening O 
. O 
This O 
level O 
of O 
activity O 
warrants O 
further O 
investigation O 
of O 
the O 
compounds O 
for O 
development O 
as O 
anticancer O 
and O 
antimalarial O 
agents O 
. O 

effects O 
of O 
metachromins B-MULTIPLE 
L-Q I-MULTIPLE 
and O 
its O 
related O 
analogs O 
against O 
receptor O 
tyrosine B-TRIVIAL 
kinases O 
EGFR O 
and O 
HER2 O 
. O 

are O 
a O 
series O 
of O 
sesquiterpenoid B-FAMILY 
quinones I-FAMILY 
isolated O 
from O 
Okinawan O 
marine O 
sponges O 
. O 
Inhibitory O 
effects O 
of O 
metachromins B-MULTIPLE 
L-Q I-MULTIPLE 
( O 
1-6 O 
) O 
, O 
sesquiterpenoid B-FAMILY 
quinones I-FAMILY 
with O 
an O 
amino B-FAMILY 
acid I-FAMILY 
residue O 
, O 
and O 
their O 
related O 
analogs O 
( O 
7-18 O 
) O 
prepared O 
from O 
metachromins B-FAMILY 
A O 
( O 
19 O 
) O 
and O 
C O 
( O 
20 O 
) O 
against O 
receptor O 
tyrosine B-TRIVIAL 
kinases O 
EGFR O 
and O 
HER2 O 
were O 
investigated O 
. O 
Two O 
analogs O 
11 O 
and O 
12 O 
showed O 
relatively O 
stronger O 
inhibitory O 
activity O 
against O 
EGFR O 
, O 
while O 
metachromins B-MULTIPLE 
L-Q I-MULTIPLE 
( O 
1-6 O 
) O 
and O 
seven O 
analogs O 
( O 
8 O 
, O 
10 O 
, O 
11 O 
, O 
and O 
15-18 O 
) O 
showed O 
inhibitory O 
activities O 
against O 
HER2 O 
. O 

activities O 
of O 
Gegen O 
Qinlian O 
Decoction O 
in O 
high O 
- O 
fat O 
diet O 
combined O 
with O 
streptozotocin B-TRIVIAL 
-induced O 
diabetic O 
rats O 
and O 
in O 
3T3-L1 O 
adipocytes O 
. O 

Qinlian O 
Decoction O 
( O 
GGQLD O 
) O 
is O 
one O 
of O 
the O 
well O 
- O 
known O 
traditional O 
Chinese O 
medicines O 
. O 
Recently O 
, O 
it O 
was O 
reported O 
that O 
GGQLD O 
had O 
good O 
clinical O 
effects O 
on O 
type O 
2 O 
diabetes O 
mellitus O 
. O 
However O 
, O 
few O 
studies O 
have O 
confirmed O 
in O 
detail O 
the O 
anti-diabetic O 
activities O 
of O 
GGQLD O 
in O 
vivo O 
and O 
in O 
vitro O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
anti-diabetic O 
effects O 
of O 
GGQLD O 
in O 
high O 
- O 
fat O 
diet O 
combined O 
with O 
streptozotocin B-TRIVIAL 
-induced O 
diabetic O 
rats O 
and O 
in O 
3T3-L1 O 
adipocytes O 
. O 
The O 
present O 
results O 
suggested O 
GGQLD O 
( O 
4.95 O 
, O 
11.55 O 
and O 
18.15 O 
g O 
/ O 
kg O 
) O 
decreased O 
significantly O 
fasting O 
blood O 
glucose B-TRIVIAL 
, O 
glycosylated O 
serum O 
protein O 
, O 
and O 
glycosylated O 
hemoglobin O 
of O 
diabetic O 
rats O 
( O 
p O 
< O 
0.05 O 
) O 
, O 
and O 
GGQLD O 
( O 
4.95 O 
and O 
18.15 O 
g O 
/ O 
kg O 
) O 
decreased O 
significantly O 
fasting O 
serum O 
insulin O 
levels O 
of O 
diabetic O 
rats O 
( O 
p O 
< O 
0.05 O 
) O 
; O 
in O 
3T3-L1 O 
adipocytes O 
, O 
Gegen O 
Qinlian O 
Decoction O 
- O 
containing O 
serum O 
( O 
GGQLD-CS O 
) O 
( O 
4% O 
, O 
8% O 
and O 
16% O 
) O 
enhanced O 
glucose B-TRIVIAL 
consumption O 
, O 
triglyceride B-FAMILY 
( O 
TG O 
) O 
content O 
, O 
adiponectin O 
protein O 
concentration O 
and O 
the O 
mRNA O 
expression O 
of O 
adiponectin O 
. O 
Adiponectin O 
contributes O 
to O 
the O 
regulation O 
of O 
lipid O 
and O 
glucose B-TRIVIAL 
metabolism O 
, O 
and O 
can O 
play O 
a O 
critical O 
role O 
in O 
the O 
development O 
of O 
diabetes O 
mellitus O 
; O 
the O 
mechanisms O 
of O 
action O 
of O 
GGQLD O 
might O 
be O 
related O 
to O 
augmentation O 
of O 
adiponectin O 
protein O 
concentration O 
and O 
up O 
- O 
regulation O 
of O 
the O 
mRNA O 
expression O 
of O 
adiponectin O 
. O 
However O 
, O 
the O 
multi O 
- O 
target O 
mechanisms O 
of O 
action O 
of O 
GGQLD O 
need O 
to O 
be O 
clarified O 
further O 
. O 
The O 
present O 
study O 
further O 
validated O 
the O 
beneficial O 
effects O 
of O 
GGQLD O 
as O 
an O 
anti-diabetic O 
agent O 
. O 
These O 
findings O 
provide O 
a O 
new O 
insight O 
into O 
the O 
anti-diabetic O 
application O 
for O 
GGQLD O 
in O 
clinic O 
and O 
display O 
the O 
potential O 
of O 
GGQLD O 
as O 
a O 
new O 
drug O 
candidate O 
for O 
the O 
treatment O 
of O 
diabetes O 
mellitus O 
. O 

stimulates O 
the O 
expression O 
of O 
cathepsins O 
in O 
human O 
breast O 
cancer O 
cells O 
and O 
xenografted O 
breast O 
tumors O 
of O 
a O 
mouse O 
model O 
via O 
an O 
estrogen B-FAMILY 
receptor O 
- O 
mediated O 
signaling O 
pathway O 
. O 

disrupting O 
chemicals O 
( O 
EDCs O 
) O 
are O 
defined O 
as O 
environmental O 
compounds O 
that O 
modulate O 
steroid B-FAMILY 
hormone O 
receptor O 
- O 
dependent O 
responses O 
an O 
abnormal O 
manner O 
, O 
resulting O 
in O 
adverse O 
health O 
problems O 
for O 
humans O 
such O 
as O 
cancer O 
growth O 
and O 
metastasis O 
. O 
Cathepsins O 
are O 
proteases O 
that O 
have O 
been O 
implicated O 
in O 
cancer O 
progression O 
. O 
However O 
, O 
there O 
have O 
been O 
few O 
studies O 
about O 
the O 
association O 
between O 
cathepsins O 
and O 
estrogenic O 
chemicals O 
during O 
the O 
cancer O 
progression O 
. O 
In O 
this O 
study O 
, O 
we O 
examined O 
the O 
effect(s) O 
of O 
4-tert-octylphenol B-SYSTEMATIC 
( O 
OP O 
) O 
, O 
a O 
potent O 
EDC O 
, O 
on O 
the O 
expression O 
of O 
cathepsins O 
B O 
and O 
D O 
in O 
human O 
MCF-7 O 
breast O 
cancer O 
cells O 
and O 
a O 
xenograft O 
mouse O 
model O 
. O 
Treatment O 
with O 
OP O 
significantly O 
induced O 
the O 
proliferation O 
MCF-7 O 
cells O 
in O 
an O 
MTT B-ABBREVIATION 
assay O 
. O 
In O 
addition O 
, O 
the O 
expression O 
of O 
cathepsins O 
B O 
and O 
D O 
was O 
markedly O 
enhanced O 
in O 
MCF-7 O 
cells O 
at O 
both O 
the O 
transcriptional O 
and O 
the O 
translational O 
levels O 
following O 
treatment O 
with O 
E2 O 
or O 
OP O 
up O 
to O 
48h O 
. O 
These O 
results O 
demonstrated O 
the O 
ability O 
of O 
OP O 
to O 
disrupt O 
normal O 
transcriptional O 
regulation O 
of O 
cathepsins O 
B O 
and O 
D O 
in O 
human O 
breast O 
cancer O 
cells O 
. O 
However O 
, O 
the O 
effects O 
of O 
OP O 
on O 
cell O 
growth O 
or O 
overexpression O 
of O 
cathepsins O 
by O 
inhibiting O 
ER O 
- O 
mediated O 
signaling O 
were O 
abolished O 
by O 
an O 
ER O 
antagonist O 
and O 
siRNA O 
specific O 
for O 
ERα O 
. O 
In O 
conclusion O 
, O 
our O 
findings O 
suggest O 
that O 
OP O 
at O 
10(-6)M O 
, O 
like O 
E2 O 
, O 
may O 
accelerate O 
breast O 
cancer O 
cell O 
proliferation O 
and O 
the O 
expression O 
of O 
cathepsins O 
through O 
an O 
ER O 
- O 
mediated O 
signaling O 
pathway O 
. O 
In O 
addition O 
, O 
the O 
breast O 
cancer O 
cells O 
exposed O 
with O 
OP O 
to O 
a O 
xenograft O 
mouse O 
model O 
were O 
more O 
aggressive O 
according O 
to O 
our O 
histological O 
analysis O 
and O 
showed O 
markedly O 
increased O 
expression O 
of O 
cathepsin O 
B O 
. O 
These O 
effects O 
of O 
mouse O 
model O 
resulted O 
in O 
an O 
increased O 
potential O 
for O 
metastasis O 
in O 
breast O 
cancer O 
. O 
Taken O 
together O 
, O 
we O 
determined O 
that O 
OP O 
can O 
adversely O 
affect O 
human O 
health O 
by O 
promoting O 
cancer O 
proliferation O 
and O 
metastasis O 
through O 
the O 
amplification O 
of O 
cathepsins O 
B O 
and O 
D O 
via O 
the O 
ER O 
- O 
mediated O 
signaling O 
pathway O 
. O 

relation O 
between O 
lead O 
( O 
Pb B-FORMULA 
) O 
and O 
iron B-SYSTEMATIC 
( O 
Fe B-FORMULA 
) O 
becomes O 
increasingly O 
concerned O 
because O 
they O 
are O 
both O 
divalent O 
metals O 
that O 
are O 
absorbed O 
by O 
the O 
same O 
intestinal O 
mechanism O 
, O 
and O 
Pb B-FORMULA 
exposure O 
and O 
Fe B-FORMULA 
deficiency O 
in O 
the O 
developmental O 
brain O 
, O 
as O 
well O 
as O 
Fe B-FORMULA 
overload O 
in O 
the O 
aged O 
brain O 
, O 
can O 
cause O 
cognitive O 
deficits O 
. O 
However O 
, O 
the O 
interaction O 
between O 
Pb B-FORMULA 
exposure O 
and O 
Fe B-FORMULA 
status O 
in O 
the O 
brain O 
has O 
not O 
been O 
established O 
. O 
Therefore O 
, O 
in O 
the O 
current O 
study O 
, O 
we O 
examined O 
the O 
effects O 
of O 
maternal O 
ingestion O 
of O 
Pb B-FORMULA 
in O 
drinking O 
water O 
during O 
gestation O 
and O 
lactation O 
on O 
the O 
Fe B-FORMULA 
status O 
and O 
the O 
expression O 
of O 
divalent O 
metal O 
transporter O 
1 O 
( O 
DMT1 O 
) O 
and O 
ferroportin O 
1 O 
( O 
FP1 O 
) O 
in O 
the O 
brain O 
of O 
offspring O 
. O 
The O 
offspring O 
were O 
followed O 
through O 
old O 
age O 
, O 
with O 
measurements O 
taken O 
at O 
postnatal O 
week O 
3 O 
( O 
PNW3 O 
) O 
, O 
41 O 
( O 
PNW41 O 
) O 
and O 
70 O 
( O 
PNW70 O 
) O 
. O 
Pb B-FORMULA 
exposure O 
increases O 
the O 
Fe B-FORMULA 
content O 
in O 
the O 
old O 
- O 
aged O 
rats O 
' O 
brain O 
, O 
which O 
might O 
be O 
not O 
subjected O 
to O 
DMT1 O 
mediating O 
, O 
but O 
may O 
be O 
associated O 
with O 
the O 
decrease O 
expression O 
of O 
FP1 O 
. O 
Furthermore O 
, O 
the O 
effect O 
of O 
Pb B-FORMULA 
on O 
FP1 O 
expression O 
is O 
regulated O 
at O 
transcriptional O 
and O 
posttranscriptional O 
levels O 
. O 
The O 
perturbation O 
in O 
Fe B-FORMULA 
homeostasis O 
may O 
contribute O 
to O 
the O 
neurotoxicology O 
consequences O 
induced O 
by O 
Pb B-FORMULA 
exposure O 
, O 
and O 
FP1 O 
may O 
play O 
a O 
role O 
in O 
Pb B-FORMULA 
-induced O 
Fe B-FORMULA 
cumulation O 
in O 
the O 
brain O 
. O 

activity O 
of O 
(+)-sattabacin B-TRIVIAL 
against O 
varicella O 
zoster O 
. O 

first O 
report O 
of O 
the O 
antiviral O 
activity O 
of O 
(+)-sattabacin B-TRIVIAL 
against O 
varicella O 
- O 
zoster O 
virus O 
( O 
VZV O 
) O 
is O 
described O 
. O 
Our O 
results O 
show O 
that O 
(+)-sattabacin B-TRIVIAL 
potently O 
inhibits O 
the O 
growth O 
of O 
VZV O 
at O 
concentrations O 
in O 
the O 
range O 
of O 
other O 
drugs O 
commonly O 
prescribed O 
for O 
VZV O 
infection O 
. O 
Experiments O 
detailing O 
the O 
synthesis O 
of O 
(+)-sattabacin B-TRIVIAL 
, O 
quantification O 
of O 
cytotoxicity O 
and O 
gene O 
expression O 
data O 
in O 
human O 
fibroblast O 
cells O 
are O 
also O 
presented O 
. O 
Gene O 
expression O 
data O 
was O 
obtained O 
through O 
microarray O 
analysis O 
from O 
human O 
fibroblast O 
cells O 
exposed O 
to O 
sattabacin B-TRIVIAL 
in O 
order O 
to O 
identify O 
a O 
possible O 
mechanism O 
by O 
which O 
(+)-sattabacin B-TRIVIAL 
inhibits O 
VZV O 
replication O 
. O 

: O 
an O 
intriguing O 
molecule O 
exerting O 
dual O 
actions O 
in O 
the O 
Central O 
Nervous O 
System O 
. O 

pathway O 
is O 
gaining O 
attention O 
due O 
to O 
the O 
many O 
metabolic O 
processes O 
in O 
which O 
it O 
has O 
been O 
involved O 
. O 
The O 
tryptophan B-TRIVIAL 
conversion O 
into O 
several O 
other O 
metabolites O 
through O 
this O 
pathway O 
provides O 
neuronal O 
and O 
redox O 
modulators O 
useful O 
for O 
maintenance O 
of O 
major O 
functions O 
in O 
the O 
brain O 
. O 
However O 
, O 
when O 
physiopathological O 
conditions O 
prevail O 
- O 
i.e O 
. O 
oxidative O 
stress O 
, O 
excitotoxicity O 
, O 
and O 
inflammation O 
- O 
preferential O 
formation O 
and O 
accumulation O 
of O 
toxic O 
metabolites O 
could O 
trigger O 
factors O 
for O 
degeneration O 
in O 
neurological O 
disorders O 
. O 
3-Hydroxykynurenine B-SYSTEMATIC 
has O 
been O 
largely O 
described O 
as O 
one O 
of O 
these O 
toxic O 
metabolites O 
capable O 
of O 
inducing O 
oxidative O 
damage O 
and O 
cell O 
death O 
; O 
consequently O 
, O 
this O 
metabolite O 
has O 
been O 
hypothesized O 
to O 
play O 
a O 
pivotal O 
role O 
in O 
different O 
neurological O 
and O 
psychiatric O 
disorders O 
. O 
Supporting O 
evidence O 
has O 
shown O 
altered O 
3-hydroxykynurenine B-SYSTEMATIC 
levels O 
in O 
samples O 
of O 
patients O 
from O 
several O 
disorders O 
. O 
In O 
contrast O 
, O 
some O 
experimental O 
studies O 
have O 
provided O 
evidence O 
of O 
antioxidant O 
and O 
scavenging O 
properties O 
inherent O 
to O 
this O 
molecule O 
. O 
In O 
this O 
review O 
, O 
we O 
explored O 
most O 
of O 
literature O 
favoring O 
one O 
or O 
the O 
other O 
concept O 
, O 
in O 
order O 
to O 
provide O 
an O 
accurate O 
vision O 
on O 
the O 
real O 
participation O 
of O 
this O 
tryptophan B-TRIVIAL 
metabolite O 
in O 
both O 
experimental O 
paradigms O 
and O 
human O 
brain O 
pathologies O 
. O 
Through O 
this O 
collected O 
evidence O 
, O 
we O 
provide O 
an O 
integrative O 
hypothesis O 
on O 
how O 
3-hydroxykynurenine B-SYSTEMATIC 
is O 
exerting O 
its O 
dual O 
actions O 
in O 
the O 
Central O 
Nervous O 
System O 
and O 
what O 
will O 
be O 
the O 
course O 
of O 
investigations O 
in O 
this O 
field O 
for O 
the O 
next O 
years O 
. O 

enantiomers O 
with O 
human O 
formyl B-SYSTEMATIC 
-peptide O 
receptor O 
agonist O 
activity O 
: O 
molecular O 
modeling O 
of O 
chiral O 
recognition O 
by O 
FPR2 O 
. O 

formyl I-SYSTEMATIC 
peptide O 
receptors O 
( O 
FPRs O 
) O 
are O 
G O 
protein O 
- O 
coupled O 
receptors O 
( O 
GPCRs O 
) O 
that O 
play O 
critical O 
roles O 
in O 
inflammatory O 
reactions O 
, O 
and O 
FPR-specific O 
interactions O 
can O 
possibly O 
be O 
used O 
to O 
facilitate O 
the O 
resolution O 
of O 
pathological O 
inflammatory O 
reactions O 
. O 
Recent O 
studies O 
indicated O 
that O 
FPRs O 
have O 
stereo O 
- O 
selective O 
preference O 
for O 
chiral O 
ligands O 
. O 
Here O 
, O 
we O 
investigated O 
the O 
structure O 
- O 
activity O 
relationship O 
of O 
24 O 
chiral O 
ureidopropanamides B-FAMILY 
, O 
including O 
previously O 
reported O 
compounds O 
PD168368 B-IDENTIFIER 
/ O 
PD176252 B-IDENTIFIER 
and O 
their O 
close O 
analogs O 
, O 
and O 
used O 
molecular O 
modeling O 
to O 
define O 
chiral O 
recognition O 
by O 
FPR2 O 
. O 
Unlike O 
previously O 
reported O 
6-methyl-2,4- B-FAMILY 
disubstituted I-FAMILY 
pyridazin-3(2H)-ones I-FAMILY 
, O 
whose O 
R- O 
forms O 
preferentially O 
activated O 
FPR1 O 
/ O 
FPR2 O 
, O 
we O 
found O 
that O 
four O 
S-enantiomers O 
in O 
the O 
seven O 
ureidopropanamide B-SYSTEMATIC 
pairs O 
tested O 
preferentially O 
activated O 
intracellular O 
Ca(2+) B-FORMULA 
flux O 
in O 
FPR2-transfected O 
cells O 
, O 
while O 
the O 
R-counterpart O 
was O 
more O 
active O 
in O 
two O 
enantiomer O 
pairs O 
. O 
Thus O 
, O 
active O 
enantiomers O 
of O 
FPR2 O 
agonists O 
can O 
be O 
in O 
either O 
R- O 
or O 
S- O 
configurations O 
, O 
depending O 
on O 
the O 
molecular O 
scaffold O 
and O 
specific O 
substituents O 
at O 
the O 
chiral O 
center O 
. O 
Using O 
molecular O 
modeling O 
approaches O 
, O 
including O 
field O 
point O 
methodology O 
, O 
homology O 
modeling O 
, O 
and O 
docking O 
studies O 
, O 
we O 
propose O 
a O 
model O 
that O 
can O 
explain O 
stereoselective O 
activity O 
of O 
chiral O 
FPR2 O 
agonists O 
. O 
Importantly O 
, O 
our O 
docking O 
studies O 
of O 
FPR2 O 
chiral O 
agonists O 
correlated O 
well O 
with O 
the O 
FPR2 O 
pharmacophore O 
model O 
derived O 
previously O 
. O 
We O 
conclude O 
that O 
the O 
ability O 
of O 
FPR2 O 
to O 
discriminate O 
between O 
the O 
enantiomers O 
is O 
the O 
consequence O 
of O 
the O 
arrangement O 
of O 
the O 
three O 
asymmetric O 
hydrophobic O 
subpockets O 
at O 
the O 
main O 
orthosteric O 
FPR2 O 
binding O 
site O 
with O 
specific O 
orientation O 
of O 
charged O 
regions O 
in O 
the O 
subpockets O 
. O 

impact O 
of O 
phthalates B-FAMILY 
. O 

of O 
phthalic B-TRIVIAL 
acid I-TRIVIAL 
are O 
chemical O 
agents O 
used O 
to O 
improve O 
the O 
plasticity O 
of O 
industrial O 
polymers O 
. O 
Their O 
ubiquitous O 
use O 
in O 
multiple O 
commercial O 
products O 
results O 
in O 
extensive O 
exposure O 
to O 
humans O 
and O 
the O 
environment O 
. O 
This O 
study O 
investigated O 
cytotoxicity O 
, O 
endocrine O 
disruption O 
, O 
effects O 
mediated O 
via O 
AhR O 
, O 
lipid O 
peroxidation O 
and O 
effects O 
on O 
expression O 
of O 
enzymes O 
of O 
xenobiotic O 
metabolism O 
caused O 
by O 
di-(2-ethy B-SYSTEMATIC 
hexyl I-SYSTEMATIC 
) I-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DEHP B-ABBREVIATION 
) O 
, O 
diethyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DEP B-ABBREVIATION 
) O 
, O 
dibutyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DBP B-ABBREVIATION 
) O 
and O 
benzyl B-SYSTEMATIC 
butyl I-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
BBP B-ABBREVIATION 
) O 
in O 
developing O 
fish O 
embryos O 
. O 
Oxidative O 
stress O 
was O 
identified O 
as O 
the O 
critical O 
mechanism O 
of O 
toxicity O 
( O 
CMTA O 
) O 
in O 
the O 
case O 
of O 
DEHP B-ABBREVIATION 
and O 
DEP B-ABBREVIATION 
, O 
while O 
the O 
efficient O 
removal O 
of O 
DBP B-ABBREVIATION 
and O 
BBP B-ABBREVIATION 
by O 
phase O 
1 O 
enzymes O 
resulted O 
in O 
lesser O 
toxicity O 
. O 
DEHP B-ABBREVIATION 
and O 
DEP B-ABBREVIATION 
did O 
not O 
mimic O 
estradiol B-TRIVIAL 
(E(2)) O 
in O 
transactivation O 
studies O 
, O 
but O 
at O 
concentrations O 
of O 
10mg O 
/ O 
L O 
synthesis O 
of O 
sex O 
steroid B-FAMILY 
hormones O 
was O 
affected O 
. O 
Exposure O 
to O 
10mg O 
BBP O 
/ O 
L O 
resulted O 
in O 
weak O 
transactivation O 
of O 
the O 
estrogen B-FAMILY 
receptor O 
( O 
ER O 
) O 
. O 
All O 
phthalates B-FAMILY 
exhibited O 
weak O 
potency O 
as O 
agonists O 
of O 
the O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AhR O 
) O 
. O 
The O 
order O 
of O 
potency O 
of O 
the O 
4 O 
phthalates B-FAMILY 
studied O 
was O 
; O 
DEHP B-ABBREVIATION 
> O 
DEP B-ABBREVIATION 
> O 
BBP B-ABBREVIATION 
> O 
DBP B-ABBREVIATION 
. O 
The O 
study O 
highlights O 
the O 
need O 
for O 
simultaneous O 
assessment O 
of O 
: O 
( O 
1 O 
) O 
multiple O 
cellular O 
targets O 
affected O 
by O 
phthalates B-FAMILY 
and O 
( O 
2 O 
) O 
phthalate B-FAMILY 
mixtures O 
to O 
account O 
for O 
additive O 
effects O 
when O 
multiple O 
phthalates B-FAMILY 
modulate O 
the O 
same O 
pathway O 
. O 
Such O 
cumulative O 
assessment O 
of O 
multiple O 
biological O 
parameters O 
is O 
more O 
realistic O 
, O 
and O 
offers O 
the O 
possibility O 
of O 
more O 
accurately O 
identifying O 
the O 
CMTA O 
. O 

decreases O 
paraquat B-TRIVIAL 
accumulation O 
and O 
toxicity O 
in O 
Caco-2 O 
cells O 
. O 

( O 
P-gp O 
) O 
is O 
an O 
efflux O 
pump O 
belonging O 
to O 
the O 
ATP B-ABBREVIATION 
-binding O 
cassette O 
transporter O 
superfamily O 
expressed O 
in O 
several O 
organs O 
. O 
Considering O 
its O 
potential O 
protective O 
effects O 
, O 
the O 
induction O 
of O 
de O 
novo O 
synthesis O 
of O 
P-gp O 
could O 
be O 
used O 
therapeutically O 
in O 
the O 
treatment O 
of O 
intoxications O 
by O 
its O 
substrates O 
. O 
The O 
herbicide O 
paraquat B-TRIVIAL 
( O 
PQ O 
) O 
is O 
a O 
P-gp O 
substrate O 
responsible O 
for O 
thousands O 
of O 
fatal O 
intoxications O 
worldwide O 
that O 
still O 
lacks O 
an O 
effective O 
antidote O 
. O 
The O 
aim O 
of O 
the O 
present O 
work O 
was O 
to O 
evaluate O 
the O 
effectiveness O 
of O 
such O 
an O 
antidote O 
by O 
testing O 
whether O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
, O 
a O 
known O 
P-gp O 
inducer O 
, O 
could O 
efficiently O 
protect O 
Caco-2 O 
cells O 
against O 
PQ O 
cytotoxicity O 
, O 
6 O 
h O 
after O 
the O 
incubation O 
with O 
the O 
herbicide O 
, O 
reflecting O 
a O 
real O 
- O 
life O 
intoxication O 
scenario O 
. O 
Cytotoxicity O 
was O 
evaluated O 
by O 
the O 
MTT B-ABBREVIATION 
assay O 
and O 
PQ O 
intracellular O 
concentrations O 
were O 
measured O 
by O 
gas O 
chromatography O 
- O 
ion O 
trap O 
- O 
mass O 
spectrometry O 
( O 
GC-IT-MS O 
) O 
. O 
Also O 
, O 
the O 
DOX B-ABBREVIATION 
modulatory O 
effect O 
on O 
choline B-FAMILY 
uptake O 
transport O 
system O 
was O 
assessed O 
by O 
measuring O 
the O 
uptake O 
of O 
[³H]-choline B-FAMILY 
. O 
The O 
results O 
show O 
that O 
DOX B-ABBREVIATION 
exerts O 
protective O 
effects O 
against O 
PQ O 
cytotoxicity O 
, O 
preventing O 
the O 
intracellular O 
accumulation O 
of O 
the O 
herbicide O 
. O 
These O 
protective O 
effects O 
were O 
not O 
completely O 
prevented O 
by O 
the O 
incubation O 
with O 
the O 
UIC2 O 
antibody O 
, O 
a O 
specific O 
P-gp O 
inhibitor O 
, O 
suggesting O 
the O 
involvement O 
of O 
alternative O 
protection O 
mechanisms O 
. O 
In O 
fact O 
, O 
DOX B-ABBREVIATION 
also O 
efficiently O 
inhibited O 
the O 
choline B-FAMILY 
transport O 
system O 
that O 
influences O 
PQ O 
cellular O 
uptake O 
. O 
In O 
conclusion O 
, O 
in O 
this O 
cellular O 
model O 
, O 
DOX B-ABBREVIATION 
effectively O 
protects O 
against O 
PQ O 
toxicity O 
by O 
inducing O 
P-gp O 
and O 
through O 
the O 
interaction O 
with O 
the O 
choline B-FAMILY 
transporter O 
, O 
suggesting O 
that O 
compounds O 
presenting O 
this O 
double O 
feature O 
of O 
promoting O 
the O 
efflux O 
and O 
limiting O 
the O 
uptake O 
of O 
PQ O 
could O 
be O 
used O 
as O 
effective O 
antidotes O 
to O 
treat O 
intoxications O 
. O 

supergenerics O 
for O 
pulmonary O 
tuberculosis O 
treatment O 
: O 
preparation O 
, O 
in O 
vitro O 
, O 
and O 
in O 
vivo O 
characterization O 
. O 

pulmonary O 
route O 
is O 
one O 
of O 
the O 
main O 
strategies O 
investigated O 
to O 
improve O 
tuberculosis O 
therapy O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
develop O 
a O 
simple O 
and O 
scalable O 
method O 
to O 
produce O 
capreomycin B-TRIVIAL 
inhalable O 
powders O 
to O 
use O 
as O 
supergeneric O 
. O 
In O 
vitro O 
antimycobacterial O 
activity O 
and O 
in O 
vivo O 
acute O 
toxicity O 
were O 
assessed O 
using O 
agar O 
proportion O 
susceptibility O 
test O 
on O 
Mycobacterium O 
tuberculosis O 
and O 
chicken O 
chorioallantoic O 
membrane O 
assay O 
, O 
respectively O 
. O 
Capreomycin B-TRIVIAL 
and O 
three O 
different O 
hydrophobic O 
counterions O 
, O 
namely O 
oleate B-TRIVIAL 
, O 
linoleate B-TRIVIAL 
, O 
and O 
linolenate B-TRIVIAL 
, O 
were O 
combined O 
in O 
solution O 
to O 
obtain O 
hydrophobic O 
ion O 
- O 
pairs O 
that O 
were O 
successively O 
spray O 
- O 
dried O 
. O 
Ion O 
- O 
pairing O 
efficiency O 
was O 
influenced O 
by O 
the O 
spray O 
- O 
dryer O 
employed O 
to O 
produce O 
the O 
powder O 
. O 
In O 
the O 
case O 
of O 
capreomycin B-TRIVIAL 
oleate I-TRIVIAL 
, O 
both O 
instruments O 
, O 
mini O 
and O 
nano O 
spray O 
- O 
dryer O 
, O 
were O 
suitable O 
to O 
maintain O 
a O 
high O 
ion O 
- O 
paired O 
content O 
, O 
while O 
for O 
capreomycin B-MULTIPLE 
linoleate I-MULTIPLE 
and I-MULTIPLE 
linolenate I-MULTIPLE 
, O 
mini O 
spray O 
- O 
dryer O 
was O 
the O 
most O 
appropriate O 
instrument O 
. O 
The O 
three O 
formulations O 
showed O 
morphology O 
and O 
particle O 
sizes O 
potentially O 
suitable O 
for O 
inhalation O 
. O 
Capreomycin B-MULTIPLE 
oleate I-MULTIPLE 
and I-MULTIPLE 
linoleate I-MULTIPLE 
showed O 
the O 
same O 
efficacy O 
of O 
capreomycin B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
against O 
M O 
. O 
tuberculosis O 
, O 
while O 
capreomycin B-TRIVIAL 
linolenate I-TRIVIAL 
showed O 
a O 
reduced O 
efficacy O 
, O 
even O 
though O 
strain O 
growth O 
was O 
inhibited O 
at O 
10(-4) O 
mycobacterial O 
inoculum O 
. O 
In O 
vivo O 
acute O 
toxicity O 
studies O 
evidenced O 
the O 
lowest O 
toxic O 
potential O 
for O 
capreomycin B-TRIVIAL 
oleate I-TRIVIAL 
when O 
compared O 
to O 
the O 
single O 
components O 
or O 
the O 
other O 
two O 
salts O 
. O 
Overall O 
, O 
capreomycin B-TRIVIAL 
oleate I-TRIVIAL 
seems O 
to O 
possess O 
the O 
most O 
promising O 
characteristics O 
to O 
be O 
used O 
as O 
supergenerics O 
in O 
pulmonary O 
tuberculosis O 
treatment O 
. O 

aim O 
of O 
this O 
study O 
is O 
to O 
investigate O 
chemical O 
composition O 
of O 
acetone B-SYSTEMATIC 
extracts O 
of O 
the O 
lichens O 
Evernia O 
prunastri O 
and O 
Pseudoevernia O 
furfuraceae O 
and O 
in O 
vitro O 
antioxidant O 
, O 
antimicrobial O 
, O 
and O 
anticancer O 
activities O 
of O 
these O 
extracts O 
and O 
some O 
their O 
major O 
metabolites O 
. O 
HPLC-UV O 
method O 
was O 
used O 
for O 
identification O 
of O 
secondary O 
metabolites O 
. O 
Antioxidant O 
activity O 
was O 
evaluated O 
by O 
free O 
radical O 
scavenging O 
, O 
superoxide B-TRIVIAL 
anion O 
radical O 
scavenging O 
, O 
reducing O 
power O 
and O 
determination O 
of O 
total O 
phenolic B-FAMILY 
compounds O 
. O 
As O 
a O 
result O 
of O 
the O 
study O 
physodic O 
acid O 
had O 
largest O 
antioxidant O 
activities O 
. O 
Total O 
content O 
of O 
phenol B-SYSTEMATIC 
in O 
extracts O 
was O 
determined O 
as O 
pyrocatechol B-TRIVIAL 
equivalent O 
. O 
The O 
antimicrobial O 
activity O 
was O 
estimated O 
by O 
determination O 
of O 
the O 
minimal O 
inhibitory O 
concentration O 
by O 
the O 
broth O 
microdilution O 
method O 
. O 
The O 
most O 
active O 
was O 
also O 
physodic B-TRIVIAL 
acid I-TRIVIAL 
. O 
Anticancer O 
activity O 
was O 
tested O 
against O 
FemX O 
( O 
human O 
melanoma O 
) O 
and O 
LS174 O 
( O 
human O 
colon O 
carcinoma O 
) O 
cell O 
lines O 
using O 
MTT B-ABBREVIATION 
method O 
. O 

in O 
mixed O 
micelles O 
attenuates O 
the O 
cytotoxicity O 
of O 
bile B-FAMILY 
salts I-FAMILY 
in O 
Caco-2 O 
cells O 
. O 

study O 
was O 
designed O 
to O 
investigate O 
the O 
cytotoxicity O 
of O 
bile B-FAMILY 
salt I-FAMILY 
-lecithin O 
mixed O 
micelles O 
on O 
the O 
Caco-2 O 
cell O 
model O 
. O 
Cell O 
viability O 
and O 
proliferation O 
after O 
mixed O 
micelles O 
treatments O 
were O 
evaluated O 
with O 
the O 
MTT B-ABBREVIATION 
assay O 
, O 
and O 
the O 
integrity O 
of O 
Caco-2 O 
cell O 
monolayer O 
was O 
determined O 
by O 
quantitating O 
the O 
transepithelial O 
electrical O 
resistance O 
and O 
the O 
flux O 
of O 
tracer O 
, O 
FITC B-ABBREVIATION 
-dextran O 
4400 O 
. O 
The O 
apoptosis O 
induced O 
by O 
mixed O 
micelles O 
treatments O 
was O 
investigated O 
with O 
the O 
annexin O 
V O 
/ O 
PI O 
protocol O 
. O 
The O 
particle O 
size O 
of O 
mixed O 
micelles O 
was O 
all O 
smaller O 
than O 
100 O 
nm O 
. O 
The O 
mixed O 
micelles O 
with O 
lower O 
than O 
0.2mM O 
sodium B-SYSTEMATIC 
deoxycholate I-SYSTEMATIC 
( O 
SDC B-ABBREVIATION 
) O 
had O 
no O 
significant O 
effects O 
on O 
cell O 
viability O 
and O 
proliferation O 
. O 
When O 
the O 
level O 
of O 
SDC B-ABBREVIATION 
was O 
higher O 
than O 
0.4mM O 
and O 
the O 
lecithin/ O 
SDC B-ABBREVIATION 
ratio O 
was O 
lower O 
than O 
2 O 
: O 
1 O 
, O 
the O 
mixed O 
micelles O 
caused O 
significant O 
changes O 
in O 
cell O 
viability O 
and O 
proliferation O 
. O 
Furthermore O 
, O 
the O 
mixed O 
micelles O 
affected O 
tight O 
junctions O 
in O 
a O 
composition O 
- O 
dependent O 
manner O 
. O 
Specifically O 
, O 
the O 
tight O 
junctions O 
were O 
transiently O 
opened O 
rather O 
than O 
damaged O 
by O 
the O 
mixed O 
micelles O 
with O 
SDC B-ABBREVIATION 
of O 
between O 
0.2 O 
and O 
0.6mM O 
. O 
The O 
mixed O 
micelles O 
with O 
more O 
lecithin O 
also O 
induced O 
less O 
apoptosis O 
. O 
These O 
results O 
demonstrate O 
that O 
relatively O 
higher O 
concentrations O 
of O 
mixed O 
micelles O 
are O 
toxic O 
to O 
Caco-2 O 
cells O 
, O 
while O 
phospholipids O 
can O 
attenuate O 
the O 
toxicity O 
of O 
the O 
bile B-FAMILY 
salts I-FAMILY 
. O 

simple O 
molecular O 
modeling O 
method O 
for O 
the O 
characterization O 
of O 
polymeric O 
drug O 
carriers O 
is O 
presented O 
. O 
Six O 
biodegradable O 
polymers O 
have O 
been O 
investigated O 
as O 
drug O 
carriers O 
using O 
molecular O 
simulations O 
: O 
l-polylactide B-FAMILY 
, O 
d-polylactide B-FAMILY 
, O 
chitosan O 
, O 
polyglycolic B-FAMILY 
acid I-FAMILY 
, O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
and O 
cellulose O 
. O 
Cyclosporine B-TRIVIAL 
A I-TRIVIAL 
has O 
been O 
chosen O 
as O 
a O 
model O 
drug O 
substance O 
. O 
Classical O 
molecular O 
dynamics O 
and O 
docking O 
calculations O 
were O 
employed O 
to O 
model O 
and O 
predict O 
polymer O 
- O 
drug O 
interactions O 
. O 
These O 
interactions O 
have O 
been O 
analyzed O 
by O 
non O 
- O 
bond O 
interaction O 
energy O 
and O 
interaction O 
parameter O 
calculated O 
using O 
Flory-Huggins O 
theory O 
. O 
Flexibility O 
of O 
polymer O 
chains O 
has O 
been O 
characterized O 
by O 
the O 
change O 
of O 
gyration O 
radius O 
along O 
the O 
molecular O 
dynamics O 
trajectory O 
. O 
The O 
relationship O 
between O 
mixing O 
energy O 
, O 
chain O 
length O 
and O 
chain O 
flexibility O 
has O 
been O 
revealed O 
for O 
each O 
polymer O 
/ O 
drug O 
system O 
. O 

aim O 
of O 
this O 
prospective O 
study O 
was O 
to O 
report O 
the O 
outcomes O 
of O 
pain O 
and O 
vaginal O 
pressures O 
of O 
successive O 
botulinum O 
toxin O 
type O 
A O 
injections O 
for O 
women O 
with O 
objective O 
pelvic O 
floor O 
muscle O 
overactivity O 
and O 
a O 
two O 
- O 
year O 
history O 
of O 
pelvic O 
pain O 
. O 
Between O 
2005 O 
and O 
2008 O 
, O 
37 O 
women O 
underwent O 
injection O 
of O 
100 O 
IU O 
of O 
botulinum O 
toxin O 
type O 
A O 
into O 
the O 
puborectalis O 
and O 
pubococcygeous O 
muscles O 
with O 
dysmenorrhoea O 
, O 
dyspareunia O 
, O 
dyschesia O 
, O 
and O 
non-menstrual O 
pelvic O 
pain O 
assessed O 
using O 
a O 
visual O 
analogue O 
scale O 
( O 
VAS O 
) O 
, O 
and O 
vaginal O 
pressure O 
measured O 
by O 
vaginal O 
manometry O 
, O 
at O 
0 O 
, O 
4 O 
, O 
12 O 
and O 
26 O 
weeks O 
from O 
each O 
injection O 
. O 
26 O 
women O 
( O 
70% O 
) O 
had O 
one O 
injection O 
of O 
botulinum O 
toxin O 
type O 
A O 
and O 
11 O 
( O 
30% O 
) O 
had O 
2 O 
or O 
more O 
injections O 
. O 
The O 
second O 
injection O 
was O 
performed O 
at O 
the O 
earliest O 
at O 
26 O 
weeks O 
after O 
the O 
first O 
, O 
with O 
subsequent O 
injections O 
having O 
a O 
median O 
time O 
to O 
re O 
- O 
injection O 
of O 
33.4 O 
weeks O 
( O 
range O 
9.4-122.7 O 
weeks O 
) O 
. O 
Single O 
and O 
repeated O 
injections O 
both O 
demonstrated O 
a O 
statistically O 
significant O 
reduction O 
in O 
dyspareunia O 
by O 
VAS O 
scores O 
from O 
54 O 
to O 
30 O 
in O 
the O 
single O 
injection O 
group O 
and O 
from O 
51 O 
to O 
23 O 
in O 
the O 
multiple O 
injection O 
group O 
( O 
p O 
= O 
0.001 O 
) O 
, O 
non-menstrual O 
pelvic O 
pain O 
VAS O 
from O 
37 O 
to O 
25 O 
( O 
p O 
= O 
0.04 O 
) O 
, O 
as O 
well O 
as O 
vaginal O 
pressures O 
; O 
40 O 
versus O 
34 O 
cm O 
H(2)O B-FORMULA 
( O 
p O 
= O 
0.02 O 
) O 
. O 
No O 
statistically O 
significant O 
difference O 
in O 
dysmenorrhoea O 
or O 
dyschesia O 
was O 
observed O 
for O 
either O 
group O 
from O 
their O 
baseline O 
scores O 
. O 
Multiple O 
injections O 
of O 
botulinum O 
toxin O 
type O 
A O 
in O 
women O 
with O 
pelvic O 
floor O 
muscle O 
overactivity O 
provide O 
significant O 
relief O 
from O 
dyspareunia O 
and O 
non-menstrual O 
pelvic O 
pain O 
. O 
The O 
upper O 
limit O 
between O 
re O 
- O 
injection O 
is O 
not O 
yet O 
determined O 
, O 
nor O 
is O 
the O 
maximum O 
number O 
of O 
treatments O 
. O 
Clinical O 
outcomes O 
for O 
single O 
and O 
subsequent O 
injection O 
of O 
botulinum O 
toxin O 
type O 
A O 
for O 
recurrent O 
pelvic O 
pain O 
are O 
equivalent O 
. O 
Women O 
who O 
have O 
had O 
benefit O 
from O 
a O 
single O 
injection O 
of O 
botulinum O 
toxin O 
type O 
A O 
can O 
be O 
reassured O 
that O 
if O 
symptoms O 
reoccur O 
, O 
repeated O 
injections O 
can O 
be O 
expected O 
to O 
be O 
equally O 
efficacious O 
. O 

polyacetylene B-SYSTEMATIC 
-rich O 
extract O 
from O 
Gymnaster O 
koraiensis O 
strongly O 
inhibits O 
colitis O 
- O 
associated O 
colon O 
cancer O 
in O 
mice O 
. O 

koraiensis O 
( O 
GK O 
) O 
is O 
a O 
Korean O 
herb O 
used O 
in O 
folk O 
medicine O 
and O 
recently O 
found O 
to O 
positively O 
impact O 
liver O 
health O 
. O 
Because O 
GK O 
contains O 
polyacetylenes B-FAMILY 
and O 
because O 
other O 
polyacetylenes B-FAMILY 
have O 
been O 
found O 
to O 
exhibit O 
anti-inflammatory O 
and O 
anti-cancer O 
activities O 
, O 
we O 
hypothesized O 
that O 
the O 
polyacetylene B-SYSTEMATIC 
gymnasterkoreayne B-TRIVIAL 
B I-TRIVIAL 
( O 
GKB B-ABBREVIATION 
) O 
, O 
known O 
to O 
increase O 
hepatic O 
detoxification O 
enzymes O 
, O 
may O 
also O 
exert O 
anti-inflammatory O 
and O 
anti-cancer O 
activities O 
. O 
We O 
fed O 
male O 
C57BL O 
/ O 
6 O 
mice O 
purified O 
AIN93G O 
diets O 
containing O 
no O 
additions O 
, O 
GKB B-ABBREVIATION 
or O 
the O 
GKB B-ABBREVIATION 
-rich O 
fraction O 
of O 
an O 
ethanol B-SYSTEMATIC 
extract O 
( O 
GE O 
) O 
from O 
GK O 
to O 
determine O 
if O 
these O 
diets O 
would O 
slow O 
or O 
prevent O 
either O 
inflammation O 
or O 
inflammation O 
- O 
enhanced O 
colon O 
cancer O 
, O 
using O 
the O 
dextran O 
sulfate O 
sodium B-SYSTEMATIC 
/ O 
azoxymethane B-SYSTEMATIC 
mouse O 
model O 
. O 
The O 
GKB B-ABBREVIATION 
( O 
500 O 
μmol O 
/ O 
kg O 
diet O 
daily O 
) O 
showed O 
some O 
anti-inflammatory O 
activity O 
, O 
but O 
GE O 
, O 
containing O 
an O 
equal O 
dose O 
of O 
GKB B-ABBREVIATION 
, O 
protected O 
strongly O 
against O 
both O 
inflammation O 
and O 
colon O 
cancer O 
, O 
decreasing O 
adenocarcinomas O 
by O 
90% O 
. O 
These O 
data O 
support O 
further O 
research O 
into O 
GK O 
as O 
a O 
promising O 
potential O 
anti-cancer O 
agent O 
. O 

estrogenic O 
effects O 
of O 
benzylparaben B-SYSTEMATIC 
at O 
low O 
doses O 
based O 
on O 
uterotrophic O 
assay O 
in O 
immature O 
SD O 
rats O 
. O 

( O 
BzP B-ABBREVIATION 
) O 
, O 
a O 
type O 
of O 
parabens O 
being O 
used O 
as O 
a O 
preservative O 
agent O 
in O 
cosmetics O 
, O 
food O 
, O 
and O 
pharmaceutical O 
products O 
, O 
may O 
be O 
ingested O 
by O 
humans O 
. O 
In O 
this O 
study O 
, O 
we O 
performed O 
an O 
immature O 
uterotrophic O 
assay O 
using O 
Sprague O 
Dawley O 
( O 
SD O 
) O 
rats O 
by O 
intragastric O 
administration O 
to O 
determine O 
the O 
estrogenic O 
effects O 
of O 
BzP B-ABBREVIATION 
and O 
found O 
significant O 
increases O 
in O 
uterine O 
weight O 
with O 
doses O 
of O 
0.16 O 
mg O 
/ O 
kg O 
body O 
weight O 
and O 
higher O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
The O 
in O 
vivo O 
estrogenicity O 
of O 
BzP B-ABBREVIATION 
was O 
supported O 
by O 
in O 
vitro O 
results O 
from O 
the O 
human O 
estrogen B-FAMILY 
receptor O 
α O 
(hERα)-coactivator O 
recruiting O 
assay O 
and O 
in O 
silico O 
molecular O 
docking O 
analysis O 
performed O 
in O 
this O 
study O 
. O 
The O 
in O 
vitro O 
estrogenic O 
activity O 
of O 
BzP B-ABBREVIATION 
can O 
be O 
observed O 
at O 
concentrations O 
of O 
1.0×10(-8) O 
M O 
and O 
higher O 
. O 
Molecular O 
docking O 
analysis O 
showed O 
that O 
BzP B-ABBREVIATION 
fits O 
well O 
into O 
the O 
agonist O 
pocket O 
of O 
hERα O 
. O 
The O 
lowest O 
observed O 
effect O 
dose O 
( O 
LOED O 
) O 
( O 
0.16 O 
mg O 
/ O 
kg O 
/ O 
day O 
) O 
of O 
BzP B-ABBREVIATION 
is O 
much O 
lower O 
than O 
the O 
documented O 
LOEDs O 
of O 
other O 
parabens B-FAMILY 
. O 
Actual O 
risk O 
may O 
exist O 
for O 
people O 
who O 
consume O 
a O 
diet O 
high O 
in O 
BzP B-ABBREVIATION 
or O 
use O 
BzP B-ABBREVIATION 
-laden O 
cosmetics O 
. O 
In O 
addition O 
, O 
we O 
tested O 
the O 
sensitivity O 
of O 
Wistar O 
rats O 
to O 
17β-estradiol B-SYSTEMATIC 
by O 
immature O 
uterotrophic O 
assay O 
, O 
and O 
no O 
obvious O 
uterotrophic O 
response O 
was O 
observed O 
in O 
the O 
rats O 
given O 
doses O 
up O 
to O 
100 O 
μg O 
/ O 
kg O 
body O 
weight O 
. O 

signaling O 
pathways O 
regulate O 
mitochondrial O 
- O 
mediated O 
apoptosis O 
induced O 
by O 
isoorientin B-TRIVIAL 
in O 
human O 
hepatoblastoma O 
cancer O 
cells O 
. O 

( O 
ISO B-ABBREVIATION 
) O 
( O 
CAS O 
RN O 
: O 
4261-42-1 B-IDENTIFIER 
) O 
is O 
a O 
flavonoid B-FAMILY 
compound O 
that O 
can O 
be O 
extracted O 
from O 
several O 
plant O 
species O 
, O 
such O 
as O 
Phyllostachys O 
pubescens O 
, O 
Patrinia O 
, O 
and O 
Drosophyllum O 
lusitanicum O 
. O 
ISO B-ABBREVIATION 
is O 
able O 
to O 
induce O 
apoptosis O 
through O 
mitochondrial O 
dysfunction O 
and O 
inhibition O 
of O 
PI3K O 
/ O 
Akt O 
signaling O 
pathway O 
in O 
HepG2 O 
cells O 
, O 
however O 
, O 
the O 
effects O 
of O 
ISO B-ABBREVIATION 
on O 
MAPK O 
signaling O 
pathways O 
remain O 
unknown O 
. O 
The O 
present O 
study O 
investigated O 
the O 
effects O 
of O 
ISO B-ABBREVIATION 
on O 
this O 
pathway O 
, O 
and O 
the O 
roles O 
of O 
MAPK O 
kinases O 
on O 
mitochondrial O 
- O 
mediated O 
apoptosis O 
in O 
HepG2 O 
cells O 
. O 
The O 
results O 
showed O 
that O 
ISO B-ABBREVIATION 
induced O 
cell O 
death O 
in O 
a O 
dose- O 
and O 
time O 
- O 
dependent O 
manner O 
, O 
and O 
induction O 
apoptosis O 
is O 
main O 
cause O 
for O 
ISO B-ABBREVIATION 
-induced O 
cytotoxicity O 
in O 
HepG2 O 
cells O 
. O 
ISO B-ABBREVIATION 
significantly O 
inhibited O 
the O 
levels O 
of O 
ERK1 O 
/ O 
2 O 
kinase O 
and O 
increased O 
the O 
expression O 
of O 
JNK O 
and O 
p38 O 
kinases O 
. O 
Furthermore O 
, O 
U0126 B-IDENTIFIER 
( O 
an O 
ERK1 O 
/ O 
2 O 
inhibitor O 
) O 
significantly O 
enhanced O 
the O 
ISO B-ABBREVIATION 
-induced O 
the O 
Bax O 
/ O 
Bcl-2 O 
ratio O 
, O 
the O 
release O 
of O 
cytochrome O 
c O 
to O 
the O 
cytosol O 
fraction O 
, O 
and O 
the O 
levels O 
of O 
cleaved O 
caspase-3 O 
. O 
While O 
SP600125 B-IDENTIFIER 
( O 
a O 
JNK O 
inhibitor O 
) O 
and O 
SB203580 B-IDENTIFIER 
( O 
a O 
p38 O 
inhibitor O 
) O 
markedly O 
prevented O 
the O 
expression O 
of O 
these O 
proteins O 
induced O 
by O 
ISO B-ABBREVIATION 
. O 
Furthermore O 
, O 
the O 
ROS O 
inhibitor O 
( O 
NAC B-ABBREVIATION 
) O 
notably O 
promoted O 
the O 
inhibited O 
effect O 
of O 
ISO B-ABBREVIATION 
on O 
the O 
ERK1 O 
/ O 
2 O 
kinase O 
. O 
NAC B-ABBREVIATION 
also O 
suppressed O 
the O 
p-JNK O 
and O 
p-p38 O 
, O 
but O 
failed O 
to O 
reverse O 
the O 
effects O 
of O 
ISO B-ABBREVIATION 
. O 
These O 
results O 
demonstrated O 
for O 
the O 
first O 
time O 
that O 
ISO B-ABBREVIATION 
induces O 
apoptosis O 
in O 
HepG2 O 
cells O 
through O 
inactivating O 
ERK1 O 
/ O 
2 O 
kinase O 
and O 
activating O 
JNK O 
and O 
p38 O 
kinases O 
, O 
and O 
ROS O 
stimulated O 
by O 
ISO B-ABBREVIATION 
is O 
able O 
to O 
activate O 
the O 
MAPK O 
singaling O 
pathway O 
as O 
the O 
upstream O 
signaling O 
molecules O 
. O 
Initiating O 
event O 
of O 
the O 
mitochondrial O 
- O 
mediated O 
apoptosis O 
induced O 
by O 
ISO B-ABBREVIATION 
is O 
MAPK O 
signals O 
. O 

metabolism O 
of O 
sulfur B-FAMILY 
amino I-FAMILY 
acids I-FAMILY 
in O 
db O 
/ O 
db O 
mice O 
. O 

determine O 
the O 
effect O 
of O 
type-2 O 
diabetes O 
and O 
obesity O 
on O 
the O 
hepatic O 
metabolism O 
of O 
sulfur B-FAMILY 
amino I-FAMILY 
acids I-FAMILY 
, O 
hepatic O 
sulfur B-FAMILY 
amino I-FAMILY 
acid I-FAMILY 
metabolism O 
was O 
determined O 
in O 
db O 
/ O 
db O 
mice O 
. O 
Hepatic O 
methionine B-TRIVIAL 
was O 
markedly O 
decreased O 
in O 
db O 
/ O 
db O 
mice O 
, O 
although O 
the O 
hepatic O 
activity O 
of O 
betaine O 
homocysteine B-TRIVIAL 
methyltransferase O 
was O 
increased O 
. O 
The O 
decrease O 
in O 
hepatic O 
methionine B-TRIVIAL 
was O 
reflected O 
by O 
decreased O 
sulfur B-SYSTEMATIC 
-containing O 
methionine B-TRIVIAL 
metabolites O 
, O 
including O 
S-adenosylmethionine B-TRIVIAL 
, O 
homocysteine B-TRIVIAL 
, O 
cysteine B-TRIVIAL 
, O 
and O 
hypotaurine B-TRIVIAL 
in O 
liver O 
and O 
plasma O 
. O 
In O 
contrast O 
, O 
S-adenosylhomocysteine B-TRIVIAL 
, O 
putrescine B-TRIVIAL 
, O 
and O 
spermidine B-TRIVIAL 
were O 
increased O 
in O 
db O 
/ O 
db O 
mice O 
. O 
The O 
hepatic O 
level O 
and O 
activity O 
of O 
methionine B-TRIVIAL 
adenosyltransferase O 
I O 
/ O 
III O 
, O 
an O 
S-adenosylmethionine B-TRIVIAL 
synthesizing O 
enzyme O 
, O 
were O 
significantly O 
increased O 
. O 
These O 
results O 
suggest O 
that O 
increased O 
polyamine B-FAMILY 
synthesis O 
, O 
in O 
conjunction O 
with O 
decreased O 
hepatic O 
methionine B-TRIVIAL 
levels O 
, O 
is O 
partly O 
responsible O 
for O 
the O 
reduction O 
in O 
hepatic O 
S-adenosylmethionine B-TRIVIAL 
. O 
Decreased O 
homocysteine B-TRIVIAL 
in O 
liver O 
and O 
plasma O 
may O 
be O 
attributable O 
to O 
the O 
decrease O 
in O 
hepatic O 
methionine B-TRIVIAL 
and O 
upregulation O 
of O 
hepatic O 
betaine O 
homocysteine B-TRIVIAL 
methyltransferase O 
. O 
Glutathione B-TRIVIAL 
in O 
liver O 
and O 
plasma O 
did O 
not O 
change O 
despite O 
decreased O 
γ-glutamylcysteine B-SYSTEMATIC 
ligase O 
activity O 
. O 
The O 
decreased O 
hepatic O 
hypotaurine B-TRIVIAL 
may O 
be O 
attributable O 
to O 
the O 
downregulation O 
of O 
cysteine B-TRIVIAL 
dioxygenase O 
. O 
The O 
major O 
finding O 
of O 
this O 
study O 
is O 
that O 
db O 
/ O 
db O 
mice O 
exhibited O 
decreases O 
in O 
hepatic O 
methionine O 
and O 
its O 
sulfurcontaining O 
metabolites O 
. O 

and O 
profibrinolytic O 
activities O 
of O 
isorhamnetin-3-O-galactoside B-SYSTEMATIC 
and O 
hyperoside B-TRIVIAL 
. O 

potential O 
anticoagulant O 
activities O 
of O 
two O 
single O 
compounds O 
, O 
isorhamnetin-3-O-galactoside B-SYSTEMATIC 
( O 
IMG B-ABBREVIATION 
) O 
and O 
hyperoside B-TRIVIAL 
, O 
from O 
Oenanthe O 
javanica O 
, O 
were O 
tested O 
. O 
The O 
anticoagulant O 
activities O 
were O 
investigated O 
by O 
measuring O 
activated O 
partial O 
thromboplastin O 
time O 
( O 
aPTT O 
) O 
and O 
prothrombin O 
time O 
( O 
PT O 
) O 
, O 
and O 
the O 
ability O 
to O 
inhibit O 
production O 
of O 
thrombin O 
and O 
activated O 
factor O 
X O 
( O 
FXa O 
) O 
was O 
investigated O 
in O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
( O 
HUVECs O 
) O 
. O 
And O 
, O 
the O 
effects O 
of O 
the O 
compounds O 
on O 
expression O 
of O 
plasminogen O 
activator O 
inhibitor O 
type O 
1 O 
( O 
PAI-1 O 
) O 
and O 
tissue O 
- O 
type O 
plasminogen O 
activator O 
( O 
t-PA O 
) O 
were O 
tested O 
in O 
tumor O 
necrosis O 
factor-(TNF)-α O 
activated O 
HUVECs O 
. O 
Treatment O 
with O 
IMG B-ABBREVIATION 
and O 
hyperoside B-TRIVIAL 
resulted O 
in O 
significantly O 
prolonged O 
aPTT O 
and O 
PT O 
and O 
inhibition O 
of O 
the O 
activities O 
of O 
thrombin O 
and O 
FXa O 
, O 
and O 
IMG B-ABBREVIATION 
or O 
hyperoside B-TRIVIAL 
inhibited O 
production O 
of O 
thrombin O 
and O 
FXa O 
in O 
HUVECs O 
. O 
In O 
accordance O 
with O 
these O 
anticoagulant O 
activities O 
, O 
both O 
agents O 
elicited O 
anticoagulant O 
effects O 
in O 
mouse O 
. O 
In O 
addition O 
, O 
treatment O 
with O 
IMG B-ABBREVIATION 
and O 
hyperoside B-TRIVIAL 
resulted O 
in O 
inhibition O 
of O 
TNF-α-induced O 
production O 
of O 
PAI-1 O 
, O 
and O 
treatment O 
with O 
IMG B-ABBREVIATION 
resulted O 
in O 
significant O 
reduction O 
of O 
the O 
PAI-1 O 
to O 
t-PA O 
ratio O 
. O 
The O 
anticoagulant O 
and O 
profibrinolytic O 
effects O 
of O 
IMG B-ABBREVIATION 
were O 
greater O 
than O 
those O 
of O 
hyperoside B-TRIVIAL 
, O 
indicating O 
positive O 
regulation O 
of O 
its O 
anticoagulant O 
function O 
by O 
the O 
methoxy B-SYSTEMATIC 
group O 
of O 
IMG B-ABBREVIATION 
. O 
IMG B-ABBREVIATION 
and O 
hyperoside B-TRIVIAL 
possess O 
antithrombotic O 
activities O 
and O 
offer O 
bases O 
for O 
development O 
of O 
a O 
novel O 
anticoagulant O 
. O 

information O 
regulator O 
2 O 
( O 
Sir2 O 
) O 
enzymes O 
or O 
sirtuins O 
are O 
a O 
family O 
of O 
NAD(+) B-ABBREVIATION 
-dependent O 
protein O 
N(ε)-acetyl-lysine B-SYSTEMATIC 
( O 
AcK B-ABBREVIATION 
) O 
deacetylases O 
. O 
Sirtuins O 
are O 
also O 
evolutionarily O 
conserved O 
proteins O 
that O 
are O 
present O 
in O 
all O 
kingdoms O 
of O 
life O 
ranging O 
from O 
bacteria O 
to O 
humans O 
. O 
Interestingly O 
, O 
it O 
was O 
recently O 
found O 
that O 
the O 
sirtuins O 
found O 
in O 
various O 
human O 
parasites O 
( O 
especially O 
the O 
Plasmodium O 
, O 
Trypanosoma O 
, O 
and O 
Leishmania O 
species O 
) O 
were O 
pro O 
- O 
survival O 
for O 
the O 
parasites O 
under O 
various O 
conditions O 
. O 
Therefore O 
, O 
these O 
parasitic O 
sirtuins O 
have O 
emerged O 
as O 
novel O 
anti-parasitic O 
therapeutic O 
targets O 
. O 
This O 
article O 
reviews O 
the O 
currently O 
available O 
structural O 
, O 
biochemical O 
, O 
pharmacological O 
, O 
and O 
medicinal O 
chemistry O 
studies O 
on O 
these O 
enzymes O 
, O 
and O 
discusses O 
the O 
perspectives O 
of O 
selectively O 
targeting O 
the O 
parasitic O 
sirtuins O 
as O 
a O 
novel O 
therapeutic O 
strategy O 
for O 
the O 
human O 
parasitic O 
diseases O 
. O 

glucose B-TRIVIAL 
metabolism O 
in O 
late O 
pregnancy O 
: O 
normal O 
versus O 
high O 
- O 
fat O 
and O 
- O 
fructose B-TRIVIAL 
diet O 
. O 

hepatic O 
glucose B-TRIVIAL 
uptake O 
( O 
NHGU O 
) O 
is O 
an O 
important O 
contributor O 
to O 
postprandial O 
glycemic O 
control O 
. O 
We O 
hypothesized O 
that O 
NHGU O 
is O 
reduced O 
during O 
normal O 
pregnancy O 
and O 
in O 
a O 
pregnant O 
diet O 
- O 
induced O 
model O 
of O 
impaired O 
glucose B-TRIVIAL 
intolerance O 
/ O 
gestational O 
diabetes O 
mellitus O 
( O 
IGT O 
/ O 
GDM O 
) O 
. O 
Dogs O 
( O 
n O 
= O 
7 O 
per O 
group O 
) O 
that O 
were O 
nonpregnant O 
( O 
N O 
) O 
, O 
normal O 
pregnant O 
( O 
P O 
) O 
, O 
or O 
pregnant O 
with O 
IGT O 
/ O 
GDM O 
( O 
pregnant O 
dogs O 
fed O 
a O 
high O 
- O 
fat O 
and O 
- O 
fructose B-TRIVIAL 
diet O 
[ O 
P-HFF O 
] O 
) O 
underwent O 
a O 
hyperinsulinemic O 
- O 
hyperglycemic O 
clamp O 
with O 
intraportal O 
glucose B-TRIVIAL 
infusion O 
. O 
Clamp O 
period O 
insulin O 
, O 
glucagon O 
, O 
and O 
glucose B-TRIVIAL 
concentrations O 
and O 
hepatic O 
glucose B-TRIVIAL 
loads O 
did O 
not O 
differ O 
among O 
groups O 
. O 
The O 
N O 
dogs O 
reached O 
near O 
- O 
maximal O 
NHGU O 
rates O 
within O 
30 O 
min O 
; O 
mean O 
± O 
SEM O 
NHGU O 
was O 
105 O 
± O 
9 O 
µmol·100 O 
g O 
liver⁻¹·min⁻¹ O 
. O 
The O 
P O 
and O 
P-HFF O 
dogs O 
reached O 
maximal O 
NHGU O 
in O 
90-120 O 
min O 
; O 
their O 
NHGU O 
was O 
blunted O 
( O 
68 O 
± O 
9 O 
and O 
16 O 
± O 
17 O 
µmol·100 O 
g O 
liver⁻¹·min⁻¹ O 
, O 
respectively O 
) O 
. O 
Hepatic O 
glycogen O 
synthesis O 
was O 
reduced O 
20% O 
in O 
P O 
versus O 
N O 
and O 
40% O 
in O 
P-HFF O 
versus O 
P O 
dogs O 
. O 
This O 
was O 
associated O 
with O 
a O 
reduction O 
( O 
> O 
70% O 
) O 
in O 
glycogen O 
synthase O 
activity O 
in O 
P-HFF O 
versus O 
P O 
and O 
increased O 
glycogen O 
phosphorylase O 
( O 
GP O 
) O 
activity O 
in O 
both O 
P O 
( O 
1.7-fold O 
greater O 
than O 
N O 
) O 
and O 
P-HFF O 
( O 
1.8-fold O 
greater O 
than O 
P O 
) O 
dogs O 
. O 
Thus O 
, O 
NHGU O 
under O 
conditions O 
mimicking O 
the O 
postprandial O 
state O 
is O 
delayed O 
and O 
suppressed O 
in O 
normal O 
pregnancy O 
, O 
with O 
concomitant O 
reduction O 
in O 
glycogen O 
storage O 
. O 
NHGU O 
is O 
further O 
blunted O 
in O 
IGT O 
/ O 
GDM O 
. O 
This O 
likely O 
contributes O 
to O 
postprandial O 
hyperglycemia O 
during O 
pregnancy O 
, O 
with O 
potential O 
adverse O 
outcomes O 
for O 
the O 
fetus O 
and O 
mother O 
. O 

generation O 
in O 
organic O 
photovoltaics O 
( O 
OPVs O 
) O 
relies O 
on O 
the O 
dissociation O 
of O 
excitons O 
into O 
free O 
electrons O 
and O 
holes O 
at O 
donor O 
/ O 
acceptor O 
heterointerfaces O 
. O 
The O 
low O 
dielectric O 
constant O 
of O 
organic O 
semiconductors O 
leads O 
to O 
strong O 
Coulomb O 
interactions O 
between O 
electron O 
- O 
hole O 
pairs O 
that O 
should O 
in O 
principle O 
oppose O 
the O 
generation O 
of O 
free O 
charges O 
. O 
The O 
exact O 
mechanism O 
by O 
which O 
electrons O 
and O 
holes O 
overcome O 
this O 
Coulomb O 
trapping O 
is O 
still O 
unsolved O 
, O 
but O 
increasing O 
evidence O 
points O 
to O 
the O 
critical O 
role O 
of O 
hot O 
charge O 
- O 
transfer O 
( O 
CT O 
) O 
excitons O 
in O 
assisting O 
this O 
process O 
. O 
Here O 
we O 
provide O 
a O 
real O 
- O 
time O 
view O 
of O 
hot O 
CT O 
exciton O 
formation O 
and O 
relaxation O 
using O 
femtosecond O 
nonlinear O 
optical O 
spectroscopies O 
and O 
non-adiabatic O 
mixed O 
quantum O 
mechanics O 
/ O 
molecular O 
mechanics O 
simulations O 
in O 
the O 
phthalocyanine B-TRIVIAL 
- O 
fullerene B-TRIVIAL 
model O 
OPV O 
system O 
. O 
For O 
initial O 
excitation O 
on O 
phthalocyanine B-TRIVIAL 
, O 
hot O 
CT O 
excitons O 
are O 
formed O 
in O 
10(-13) O 
s O 
, O 
followed O 
by O 
relaxation O 
to O 
lower O 
energies O 
and O 
shorter O 
electron O 
- O 
hole O 
distances O 
on O 
a O 
10(-12) O 
s O 
timescale O 
. O 
This O 
hot O 
CT O 
exciton O 
cooling O 
process O 
and O 
collapse O 
of O 
charge O 
separation O 
sets O 
the O 
fundamental O 
time O 
limit O 
for O 
competitive O 
charge O 
separation O 
channels O 
that O 
lead O 
to O 
efficient O 
photocurrent O 
generation O 
. O 

cardiomyopathy O 
is O 
associated O 
with O 
suppression O 
of O 
cardiac O 
autophagy O 
, O 
and O 
activation O 
of O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
restores O 
cardiac O 
autophagy O 
and O 
prevents O 
cardiomyopathy O 
in O 
diabetic O 
mice O 
, O 
albeit O 
by O 
an O 
unknown O 
mechanism O 
. O 
We O 
hypothesized O 
that O 
AMPK-induced O 
autophagy O 
ameliorates O 
diabetic O 
cardiomyopathy O 
by O 
inhibiting O 
cardiomyocyte O 
apoptosis O 
and O 
examined O 
the O 
effects O 
of O 
AMPK O 
on O 
the O 
interaction O 
between O 
Beclin1 O 
and O 
Bcl-2 O 
, O 
a O 
switch O 
between O 
autophagy O 
and O 
apoptosis O 
, O 
in O 
diabetic O 
mice O 
and O 
high O 
glucose B-TRIVIAL 
-treated O 
H9c2 O 
cardiac O 
myoblast O 
cells O 
. O 
Exposure O 
of O 
H9c2 O 
cells O 
to O 
high O 
glucose B-TRIVIAL 
reduced O 
AMPK O 
activity O 
, O 
inhibited O 
Jun O 
NH2 B-FORMULA 
-terminal O 
kinase O 
1 O 
(JNK1)-B-cell O 
lymphoma O 
2 O 
( O 
Bcl-2 O 
) O 
signaling O 
, O 
and O 
promoted O 
Beclin1 O 
binding O 
to O 
Bcl-2 O 
. O 
Conversely O 
, O 
activation O 
of O 
AMPK O 
by O 
metformin O 
stimulated O 
JNK1-Bcl-2 O 
signaling O 
and O 
disrupted O 
the O 
Beclin1-Bcl-2 O 
complex O 
. O 
Activation O 
of O 
AMPK O 
, O 
which O 
normalized O 
cardiac O 
autophagy O 
, O 
attenuated O 
high O 
glucose B-TRIVIAL 
-induced O 
apoptosis O 
in O 
cultured O 
H9c2 O 
cells O 
. O 
This O 
effect O 
was O 
attenuated O 
by O 
inhibition O 
of O 
autophagy O 
. O 
Finally O 
, O 
chronic O 
administration O 
of O 
metformin B-TRIVIAL 
in O 
diabetic O 
mice O 
restored O 
cardiac O 
autophagy O 
by O 
activating O 
JNK1-Bcl-2 O 
pathways O 
and O 
dissociating O 
Beclin1 O 
and O 
Bcl-2 O 
. O 
The O 
induction O 
of O 
autophagy O 
protected O 
against O 
cardiac O 
apoptosis O 
and O 
improved O 
cardiac O 
structure O 
and O 
function O 
in O 
diabetic O 
mice O 
. O 
We O 
concluded O 
that O 
dissociation O 
of O 
Bcl-2 O 
from O 
Beclin1 O 
may O 
be O 
an O 
important O 
mechanism O 
for O 
preventing O 
diabetic O 
cardiomyopathy O 
via O 
AMPK O 
activation O 
that O 
restores O 
autophagy O 
and O 
protects O 
against O 
cardiac O 
apoptosis O 
. O 

activity O 
is O 
induced O 
by O 
approximately O 
2-fold O 
during O 
the O 
third O 
trimester O 
of O 
human O 
pregnancy O 
. O 
Placental O 
growth O 
hormone O 
( O 
PGH O 
) O 
, O 
estrogens B-FAMILY 
( O 
primarily O 
17β-estradiol B-SYSTEMATIC 
) O 
, O 
cortisol B-TRIVIAL 
, O 
and O 
progesterone B-TRIVIAL 
have O 
the O 
potential O 
to O 
modulate O 
CYP3A O 
activity O 
. O 
Therefore O 
, O 
we O 
determined O 
whether O 
the O 
elevated O 
plasma O 
concentrations O 
of O 
these O 
hormones O 
during O 
pregnancy O 
induce O 
hepatic O 
CYP3A O 
expression O 
. O 
We O 
incubated O 
sandwich O 
- O 
cultured O 
human O 
hepatocytes O 
( O 
SCHH O 
) O 
from O 
premenopausal O 
female O 
donors O 
( O 
n O 
= O 
2 O 
) O 
with O 
the O 
physiologic O 
( O 
unbound O 
, O 
1× O 
total O 
) O 
and O 
the O 
10× O 
total O 
third O 
trimester O 
hormone O 
plasma O 
concentrations O 
( O 
individually O 
and O 
in O 
combination O 
) O 
and O 
determined O 
their O 
effect O 
on O 
CYP3A O 
activity O 
and O 
the O 
transcripts O 
of O 
CYP3A4 O 
, O 
CYP3A5 O 
, O 
and O 
the O 
respective O 
hormone O 
receptors O 
( O 
growth O 
hormone O 
receptor O 
, O 
glucocorticoid O 
receptor O 
, O 
and O 
estrogen B-FAMILY 
receptor O 
alpha O 
) O 
. O 
Of O 
all O 
the O 
hormones O 
, O 
cortisol B-TRIVIAL 
was O 
the O 
most O 
potent O 
inducer O 
of O 
CYP3A O 
activity O 
and O 
CYP3A4 O 
, O 
CYP3A5 O 
mRNA O 
expression O 
. O 
The O 
combination O 
of O 
PGH O 
/ O 
growth O 
hormone O 
and O 
cortisol B-TRIVIAL 
induced O 
CYP3A O 
activity O 
and O 
expression O 
significantly O 
more O 
than O 
did O 
cortisol B-TRIVIAL 
alone O 
. O 
When O 
incubated O 
with O 
the O 
unbound O 
or O 
total O 
plasma O 
concentration O 
of O 
all O 
the O 
hormones O 
, O 
CYP3A O 
activity O 
in O 
SCHH O 
was O 
induced O 
to O 
an O 
extent O 
comparable O 
to O 
that O 
observed O 
in O 
vivo O 
during O 
the O 
third O 
trimester O 
. O 
These O 
hormones O 
had O 
only O 
a O 
modest O 
effect O 
on O 
the O 
mRNA O 
expression O 
of O 
the O 
hormone O 
receptors O 
. O 
The O 
pattern O 
of O 
induction O 
observed O 
in O 
SCHH O 
was O 
reproduced O 
in O 
HepaRG O 
cells O 
but O 
not O 
in O 
HuH7 O 
/ O 
HepG2 O 
cells O 
. O 
SCHH O 
or O 
HepaRG O 
cells O 
could O 
be O 
used O 
to O 
determine O 
the O 
mechanistic O 
basis O 
of O 
CYP3A O 
induction O 
during O 
pregnancy O 
and O 
to O 
predict O 
the O 
magnitude O 
of O 
induction O 
likely O 
to O 
be O 
observed O 
during O 
the O 
first O 
and O 
second O 
trimesters O 
, O 
when O 
phenotyping O 
studies O 
to O 
measure O 
in O 
vivo O 
CYP3A O 
activity O 
are O 
logistically O 
difficult O 
to O 
perform O 
. O 

phase O 
synthesis O 
of O 
copper B-SYSTEMATIC 
nanoparticles O 
: O 
a O 
link O 
between O 
heavy O 
metal O 
resistance O 
and O 
nanoparticle O 
synthesis O 
ability O 
in O 
bacterial O 
systems O 
. O 

demonstrate O 
aqueous O 
phase O 
biosynthesis O 
of O 
phase O 
- O 
pure O 
metallic O 
copper B-SYSTEMATIC 
nanoparticles O 
( O 
CuNPs O 
) O 
using O 
a O 
silver B-SYSTEMATIC 
resistant O 
bacterium O 
Morganella O 
morganii O 
. O 
This O 
is O 
particularly O 
important O 
considering O 
that O 
there O 
has O 
been O 
no O 
report O 
that O 
demonstrates O 
biosynthesis O 
and O 
stabilization O 
of O 
pure O 
copper O 
nanoparticles O 
in O 
the O 
aqueous O 
phase O 
. O 
Electrochemical O 
analysis O 
of O 
bacterial O 
cells O 
exposed O 
to O 
Cu(2+) B-FORMULA 
ions O 
provides O 
new O 
insights O 
into O 
the O 
mechanistic O 
aspect O 
of O 
Cu(2+) B-FORMULA 
ion O 
reduction O 
within O 
the O 
bacterial O 
cell O 
and O 
indicates O 
a O 
strong O 
link O 
between O 
the O 
silver B-SYSTEMATIC 
and O 
copper B-SYSTEMATIC 
resistance O 
machinery O 
of O 
bacteria O 
in O 
the O 
context O 
of O 
metal O 
ion O 
reduction O 
. O 
The O 
outcomes O 
of O 
this O 
study O 
take O 
us O 
a O 
step O 
closer O 
towards O 
designing O 
rational O 
strategies O 
for O 
biosynthesis O 
of O 
different O 
metal O 
nanoparticles O 
using O 
microorganisms O 
. O 

are O 
potent O 
agonists O 
at O 
the O 
bile B-FAMILY 
acid I-FAMILY 
receptor O 
GPBAR1 O 
( O 
TGR5 O 
) O 
. O 

with O 
potential O 
: O 
2-Phenoxy-nicotinamides B-FAMILY 
were O 
identified O 
as O 
potent O 
agonists O 
at O 
the O 
GPBAR1 O 
receptor O 
, O 
a O 
target O 
in O 
the O 
treatment O 
of O 
obesity O 
, O 
type O 
2 O 
diabetes O 
and O 
metabolic O 
syndrome O 
. O 
Extensive O 
structure O 
- O 
activity O 
relationship O 
studies O 
supported O 
by O 
homology O 
modeling O 
and O 
docking O 
resulted O 
in O 
the O 
identification O 
of O 
optimized O 
GPBAR1 O 
agonists O 
, O 
potent O 
against O 
both O 
human O 
and O 
mouse O 
receptors O 
, O 
endowed O 
with O 
favorable O 
physicochemical O 
properties O 
and O 
good O 
metabolic O 
stability O 
. O 

of O 
ganglioside B-TRIVIAL 
GM3 O 
synthase O 
gene O 
knockout O 
on O 
the O 
glycoprotein O 
N-glycan O 
profile O 
of O 
mouse O 
embryonic O 
fibroblast O 
. O 

structural O 
and O 
clinical O 
significance O 
of O 
cellular O 
glycoproteins O 
and O 
glycosphingolipids O 
( O 
GSLs O 
) O 
are O 
often O 
separately O 
discussed O 
. O 
Considering O 
the O 
biosynthetic O 
pathway O 
of O 
glycoconjugates O 
, O 
glycans O 
of O 
cell O 
- O 
surface O 
glycoproteins O 
and O 
GSLs O 
might O 
partially O 
share O 
functions O 
in O 
maintaining O 
cellular O 
homeostatis O 
. O 
The O 
purpose O 
of O 
this O 
study O 
is O 
to O 
establish O 
a O 
general O 
and O 
comprehensive O 
glycomics O 
protocol O 
for O 
cellular O 
GSLs O 
and O 
N-glycans O 
of O 
glycoproteins O 
. O 
To O 
test O 
the O 
feasibility O 
of O 
a O 
glycoblotting O 
- O 
based O 
protocol O 
, O 
whole O 
glycans O 
released O 
both O 
from O 
GSLs O 
and O 
glycoproteins O 
were O 
profiled O 
concurrently O 
by O 
using O 
GM3 O 
synthase O 
- O 
deficient O 
mouse O 
embryonic O 
fibroblast O 
GM3(- O 
/ O 
- O 
) O 
. O 
GM3(- O 
/ O 
- O 
) O 
cells O 
did O 
not O 
synthesize O 
GM3 O 
or O 
any O 
downstream O 
product O 
of O 
GM3 O 
synthase O 
. O 
Instead O 
, O 
expression O 
levels O 
of O 
o-series O 
gangliosides O 
involving O 
GM1-b O 
and O 
GD1-α O 
increased O 
dramatically O 
, O 
whereas O 
a- O 
/ O 
b-series O 
gangliosides B-FAMILY 
were O 
predominantly O 
detected O 
in O 
wild O 
- O 
type O 
( O 
WT O 
) O 
cells O 
. O 
We O 
also O 
discovered O 
that O 
glycoprotein O 
N-glycan O 
profiles O 
of O 
GM3(- O 
/ O 
- O 
) O 
cells O 
are O 
significantly O 
altered O 
as O 
compared O 
to O 
WT O 
cells O 
, O 
although O 
GM3 O 
synthase O 
is O 
responsible O 
only O 
for O 
GSLs O 
synthesis O 
and O 
is O 
not O 
associated O 
with O 
glycoprotein O 
N-glycan O 
biosynthesis O 
. O 
The O 
present O 
approach O 
allows O 
for O 
high O 
- O 
throughput O 
profiling O 
of O 
cellular O 
glycomes O 
enriched O 
by O 
different O 
classes O 
of O 
glycoconjugates O 
, O 
and O 
our O 
results O 
demonstrated O 
that O 
gene O 
knockout O 
of O 
the O 
enzymes O 
responsible O 
for O 
GSL O 
biosynthesis O 
significantly O 
influences O 
the O 
N-glycans O 
of O 
glycoproteins O 
. O 

: O 
A O 
review O 
of O 
their O 
reproductive O 
toxicity O 
, O 
biochemistry O 
, O 
and O 
environmental O 
fate O 
. O 

review O 
purposes O 
are O 
to O 
( O 
1 O 
) O 
evaluate O 
the O 
experimental O 
evidence O 
for O 
adverse O 
effects O 
on O 
reproduction O 
and O 
metabolism O 
and O 
( O 
2 O 
) O 
identify O 
the O 
current O 
knowledge O 
of O 
analytical O 
procedures O 
, O 
biochemistry O 
and O 
environmental O 
aspects O 
relating O 
to O 
organotins B-FAMILY 
. O 
Organotins B-FAMILY 
are O 
pollutants O 
that O 
are O 
used O 
as O 
biocides O 
in O 
antifouling O 
paints O 
. O 
They O 
produce O 
endocrine O 
- O 
disrupting O 
effects O 
in O 
mollusks O 
, O 
such O 
as O 
imposex O 
. O 
In O 
rodents O 
, O 
organotin B-FAMILY 
exposure O 
induces O 
developmental O 
and O 
reproductive O 
toxicity O 
as O 
well O 
as O 
alteration O 
of O 
metabolic O 
homeostasis O 
through O 
its O 
action O 
as O 
an O 
obesogen O 
. O 
The O 
adverse O 
effects O 
that O 
appear O 
in O 
rodents O 
have O 
raised O 
concerns O 
about O 
organotins B-FAMILY 
' O 
potential O 
health O 
risk O 
to O 
humans O 
in O 
relation O 
to O 
organotin B-FAMILY 
exposure O 
. O 
At O 
present O 
, O 
triorganotin B-FAMILY 
, O 
such O 
as O 
tributyltin B-SYSTEMATIC 
, O 
have O 
been O 
demonstrated O 
to O 
produce O 
imposex O 
, O 
and O 
mammalian O 
reproductive O 
and O 
metabolic O 
toxicity O 
. O 
For O 
most O 
mammals O 
, O 
triorganotin B-FAMILY 
exposure O 
predominantly O 
occurs O 
through O 
the O 
ingestion O 
, O 
and O 
this O 
compound O 
can O 
cross O 
the O 
placenta O 
. O 
With O 
these O 
risks O 
in O 
mind O 
, O 
it O 
is O 
important O 
to O 
improve O 
our O 
knowledge O 
of O 
organotins B-FAMILY 
' O 
effects O 
on O 
environmental O 
health O 
. O 

microRNAs O 
may O 
regulate O 
the O 
DNA O 
repair O 
enzyme O 
uracil B-TRIVIAL 
-DNA O 
glycosylase O 
. O 

nuclear O 
uracil B-TRIVIAL 
-DNA O 
glycosylase O 
UNG2 O 
is O 
essential O 
for O 
post O 
- O 
replicative O 
repair O 
of O 
uracil B-TRIVIAL 
in O 
DNA O 
, O 
and O 
UNG2 O 
protein O 
and O 
mRNA O 
levels O 
rapidly O 
decline O 
in O 
G2 O 
/ O 
M O 
phase O 
. O 
Previous O 
work O 
has O 
demonstrated O 
regulation O 
of O 
UNG2 O 
at O 
the O 
transcriptional O 
level O 
, O 
as O 
well O 
as O 
by O 
protein O 
phosphorylation O 
and O 
ubiquitylation O 
. O 
UNG2 O 
mRNA O 
, O 
encoded O 
by O 
the O 
UNG O 
gene O 
, O 
contains O 
a O 
long O 
3'untranslated O 
region O 
( O 
3'UTR O 
) O 
of O 
previously O 
unknown O 
function O 
. O 
Here O 
, O 
we O 
demonstrate O 
that O 
several O 
conserved O 
regions O 
in O 
the O 
3'UTR O 
are O 
potential O 
seed O 
sites O 
for O 
microRNAs O 
( O 
miRNAs O 
) O 
, O 
such O 
as O 
miR-16 O 
, O 
miR-34c O 
, O 
and O 
miR-199a O 
. O 
Our O 
results O 
show O 
that O 
these O 
miRNAs O 
down O 
- O 
regulate O 
UNG O 
activity O 
, O 
UNG O 
mRNA O 
, O 
and O 
UNG O 
protein O 
levels O 
. O 
Down O 
- O 
regulation O 
was O 
dependent O 
on O 
the O 
3'UTR O 
, O 
indicating O 
that O 
the O 
miRNAs O 
directly O 
target O 
the O 
conserved O 
seed O 
sites O 
in O 
the O 
3'UTR O 
. O 
These O 
results O 
add O 
miRNAs O 
as O 
a O 
new O 
modality O 
to O 
UNG's O 
increasing O 
list O 
of O 
complex O 
regulatory O 
mechanisms O 
. O 

modification O 
of O 
neurofilament-L O 
and O 
neuronal O 
cell O 
death O 
induced O 
by O 
the O 
catechol B-TRIVIAL 
neurotoxin O 
, O 
tetrahydropapaveroline B-SYSTEMATIC 
. O 

( O 
THP B-ABBREVIATION 
) O 
, O 
which O 
is O 
an O 
endogenous O 
neurotoxin O 
, O 
has O 
been O 
suspected O 
to O 
be O 
associated O 
with O 
dopaminergic O 
neurotoxicity O 
of O 
l-DOPA B-ABBREVIATION 
. O 
In O 
this O 
study O 
, O 
we O 
examined O 
oxidative O 
modification O 
of O 
neurofilament-L O 
( O 
NF-L O 
) O 
and O 
neuronal O 
cell O 
death O 
induced O 
by O 
THP B-ABBREVIATION 
. O 
When O 
disassembled O 
NF-L O 
was O 
incubated O 
with O 
THP B-ABBREVIATION 
, O 
protein O 
aggregation O 
was O 
increased O 
in O 
a O 
time- O 
and O 
THP B-ABBREVIATION 
dose O 
- O 
dependent O 
manner O 
. O 
The O 
formation O 
of O 
carbonyl B-FAMILY 
compounds O 
and O 
dityrosine B-TRIVIAL 
were O 
observed O 
in O 
the O 
THP B-ABBREVIATION 
-mediated O 
NF-L O 
aggregates O 
. O 
Radical O 
scavengers O 
reduced O 
THP B-ABBREVIATION 
-mediated O 
NF-L O 
modification O 
. O 
These O 
results O 
suggest O 
that O 
the O 
modification O 
of O 
NF-L O 
by O 
THP B-ABBREVIATION 
may O 
be O 
due O 
to O 
oxidative O 
damage O 
resulting O 
from O 
the O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
. O 
When O 
THP B-ABBREVIATION 
exposed O 
NF-L O 
was O 
subjected O 
to O 
amino B-FAMILY 
acid I-FAMILY 
analysis O 
, O 
glutamate B-TRIVIAL 
, O 
proline B-TRIVIAL 
and O 
lysine B-TRIVIAL 
residues O 
were O 
found O 
to O 
be O 
particularly O 
sensitive O 
. O 
We O 
also O 
investigated O 
the O 
effects O 
of O 
copper B-SYSTEMATIC 
ions O 
on O 
THP B-ABBREVIATION 
-mediated O 
NF-L O 
modification O 
. O 
At O 
a O 
low O 
concentration O 
of O 
THP B-ABBREVIATION 
, O 
copper B-SYSTEMATIC 
ions O 
enhanced O 
the O 
modification O 
of O 
NF-L O 
. O 
Treatment O 
of O 
C6 O 
astrocyte O 
cells O 
with O 
THP B-ABBREVIATION 
led O 
to O 
a O 
concentration O 
- O 
dependent O 
reduction O 
in O 
cell O 
viability O 
. O 
When O 
these O 
cells O 
were O 
treated O 
with O 
100μM O 
THP B-ABBREVIATION 
, O 
the O 
levels O 
of O 
ROS O 
increased O 
3.5-fold O 
compared O 
with O 
control O 
cells O 
. O 
Furthermore O 
, O 
treatment O 
of O 
cells O 
with O 
THP B-ABBREVIATION 
increased O 
NF-L O 
aggregate O 
formation O 
, O 
suggesting O 
the O 
involvement O 
of O 
NF-L O 
modification O 
in O 
THP B-ABBREVIATION 
-induced O 
cell O 
damage O 
. O 

and O 
antibacterial O 
evaluation O 
of O 
novel O 
11,4″- B-FAMILY 
disubstituted I-FAMILY 
azithromycin I-FAMILY 
analogs O 
with O 
greatly O 
improved O 
activity O 
against O 
erythromycin B-TRIVIAL 
-resistant O 
bacteria O 
. O 

series O 
of O 
novel O 
11,4″- B-FAMILY 
disubstituted I-FAMILY 
azithromycin I-FAMILY 
analogs O 
were O 
synthesized O 
and O 
evaluated O 
for O 
their O 
antibacterial O 
activity O 
. O 
All O 
the O 
11,4″- O 
disubstituted O 
analogs O 
exhibited O 
excellent O 
activity O 
( O 
0.03-0.12 O 
μg O 
/ O 
ml O 
) O 
against O 
erythromycin B-TRIVIAL 
-susceptible O 
Streptococcus O 
pneumoniae O 
, O 
and O 
significantly O 
improved O 
activity O 
against O 
three O 
phenotypes O 
of O 
erythromycin B-TRIVIAL 
-resistant O 
S. O 
pneumoniae O 
compared O 
with O 
erythromycin B-TRIVIAL 
A I-TRIVIAL 
, O 
clarithromycin B-TRIVIAL 
or O 
azithromycin B-TRIVIAL 
. O 
Among O 
them O 
, O 
compounds O 
26-28 O 
showed O 
the O 
most O 
potent O 
activity O 
( O 
0.25 O 
, O 
0.03 O 
and O 
2 O 
μg O 
/ O 
ml O 
) O 
against O 
S. O 
pneumoniae O 
expressing O 
the O 
erm O 
gene O 
, O 
the O 
mef O 
gene O 
and O 
the O 
erm O 
and O 
mef O 
genes O 
, O 
respectively O 
. O 
In O 
addition O 
, O 
compound O 
28 O 
was O 
the O 
most O 
effective O 
( O 
0.03 O 
and O 
0.12 O 
μg O 
/ O 
ml O 
) O 
against O 
erythromycin B-TRIVIAL 
-susceptible O 
S. O 
pneumoniae O 
and O 
Staphylococcus O 
aureus O 
as O 
well O 
. O 
It O 
is O 
noteworthy O 
that O 
the O 
most O 
active O 
compounds O 
described O 
above O 
possess O 
the O 
same O 
terminal O 
3,5-dinitrophenyl B-SYSTEMATIC 
groups O 
on O 
their O 
C-4″ O 
bisamide B-SYSTEMATIC 
side O 
chains O 
. O 

and O 
charged O 
phosphine B-MULTIPLE 
/ I-MULTIPLE 
scorpionate I-MULTIPLE 
copper I-MULTIPLE 
(I) I-MULTIPLE 
complexes I-MULTIPLE 
: O 
effects O 
of O 
ligand O 
assembly O 
on O 
their O 
antiproliferative O 
activity O 
. O 

- O 
exchange O 
reactions O 
of O 
copper B-SYSTEMATIC 
(I) I-SYSTEMATIC 
precursors O 
( O 
[Cu(CH(3)CN)(4)]BF(4) B-FORMULA 
, O 
CuCl B-FORMULA 
) O 
with O 
a O 
panel O 
of O 
bis(azolyl)borates B-FAMILY 
or O 
poly(pyrazolyl)methanes B-FAMILY 
and O 
a O 
tertiary B-SYSTEMATIC 
monodentate I-SYSTEMATIC 
phosphine I-SYSTEMATIC 
( O 
PTA B-ABBREVIATION 
= O 
1,3,5-triaza-7-phosphaadamantane B-SYSTEMATIC 
, O 
PCN B-ABBREVIATION 
= O 
tris(cyanoethyl)phosphine B-SYSTEMATIC 
) O 
produced O 
two O 
series O 
of O 
heteroleptic O 
, O 
either O 
' O 
2 O 
+ O 
1 O 
+ O 
1'- O 
or O 
' O 
3 O 
+ O 
1'- O 
type O 
complexes O 
, O 
which O 
have O 
been O 
characterized O 
by O 
elemental O 
analysis O 
, O 
FT-IR O 
, O 
ESI-MS O 
and O 
multinuclear O 
(31)P B-FORMULA 
and O 
(1)H B-FORMULA 
NMR O 
. O 
' O 
2 O 
+ O 
1 O 
+ O 
1'- O 
type O 
complexes O 
include O 
a O 
N B-FORMULA 
, O 
N B-FORMULA 
-bidentate O 
chelate O 
and O 
two O 
monodentate O 
phosphines B-FAMILY 
( O 
1-8 O 
) O 
and O 
' O 
3 O 
+ O 
1'- O 
type O 
complexes O 
comprise O 
a O 
N B-FORMULA 
, O 
N B-FORMULA 
, O 
O B-FORMULA 
- O 
or O 
N B-FORMULA 
, O 
N B-FORMULA 
, O 
N B-FORMULA 
-tridentate O 
chelate O 
and O 
one O 
monodentate O 
phosphine B-SYSTEMATIC 
( O 
9-12 O 
) O 
. O 
All O 
these O 
complexes O 
adopt O 
a O 
four O 
- O 
coordinate O 
, O 
tetrahedral O 
geometry O 
. O 
' O 
3 O 
+ O 
1 O 
' O 
complexes O 
show O 
better O 
red O 
- O 
ox O 
stability O 
and O 
a O 
greater O 
tendency O 
to O 
retain O 
the O 
native O 
' O 
3 O 
+ O 
1 O 
' O 
mixed O 
- O 
ligand O 
structure O 
. O 
Conversely O 
, O 
' O 
2 O 
+ O 
1 O 
+ O 
1 O 
' O 
complexes O 
exhibit O 
increased O 
propensity O 
to O 
dissociation O 
as O 
shown O 
by O 
ESI-MS O 
measurements O 
and O 
X-ray O 
structure O 
determination O 
at O 
low O 
temperature O 
( O 
150 O 
K O 
) O 
of O 
the O 
polymeric O 
complex O 
{[H(2)B(tz(NO2))(2)]Cu[PCN]}(n) B-FAMILY 
6b O 
. O 
In O 
this O 
complex O 
, O 
either O 
the O 
bis(triazolyl)borate B-SYSTEMATIC 
and O 
the O 
PCN B-ABBREVIATION 
ligands O 
act O 
as O 
bidentate O 
, O 
with O 
PCN B-ABBREVIATION 
being O 
also O 
the O 
μ(2)-bridiging O 
linker O 
between O 
adjacent O 
monomers O 
. O 
Compound O 
6b O 
is O 
the O 
first O 
reported O 
example O 
of O 
a O 
polymeric O 
PCN B-ABBREVIATION 
compound O 
with O 
a O 
tetra O 
- O 
coordinate O 
metal O 
centre O 
. O 
Cytotoxic O 
activity O 
of O 
all O 
compounds O 
has O 
been O 
evaluated O 
by O 
MTT B-ABBREVIATION 
test O 
against O 
a O 
panel O 
of O 
several O 
human O 
tumor O 
cell O 
lines O 
including O 
examples O 
of O 
breast O 
( O 
MCF-7 O 
) O 
, O 
colon O 
( O 
HCT O 
- O 
15 O 
and O 
LoVo O 
) O 
, O 
lung O 
( O 
A549 O 
) O 
, O 
cervix O 
( O 
A431 O 
) O 
and O 
ovarian O 
( O 
2008 O 
and O 
its O 
cisplatin B-TRIVIAL 
resistant O 
variant O 
, O 
C13* O 
) O 
carcinoma O 
, O 
melanoma O 
( O 
A375 O 
) O 
and O 
promyelocytic O 
leukemia O 
( O 
HL60 O 
) O 
. O 
Copper B-SYSTEMATIC 
complexes O 
generally O 
show O 
in O 
vitro O 
antitumour O 
activity O 
comparable O 
to O 
that O 
of O 
cisplatin B-TRIVIAL 
. O 
In O 
particular O 
, O 
neutral O 
' O 
3 O 
+ O 
1'- O 
type O 
complexes O 
9 O 
and O 
10 O 
, O 
show O 
IC(50) O 
values O 
appreciably O 
lower O 
than O 
those O 
exhibited O 
by O 
the O 
reference O 
metallodrug O 
. O 

Eisenia O 
andrei O 
to O 
assess O 
the O 
ecotoxicity O 
of O 
platinum B-SYSTEMATIC 
mine O 
tailings O 
disposal O 
facilities O 
. O 

Africa O 
is O 
an O 
important O 
platinum B-SYSTEMATIC 
mining O 
country O 
which O 
results O 
in O 
environmental O 
impacts O 
due O 
to O 
the O 
construction O 
of O 
tailing O 
disposal O 
facilities O 
( O 
TDFs O 
) O 
. O 
It O 
is O 
unclear O 
what O 
the O 
effects O 
of O 
ageing O 
are O 
on O 
the O 
ecotoxicity O 
of O 
TDFs O 
and O 
whether O 
it O 
increases O 
or O 
decreases O 
over O 
time O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
ecotoxicity O 
of O 
differently O 
aged O 
TDFs O 
by O 
investigating O 
earthworm O 
( O 
Eisenia O 
andrei O 
) O 
responses O 
viz O 
. O 
growth O 
, O 
reproduction O 
, O 
neutral O 
red O 
retention O 
times O 
( O 
NRRT O 
) O 
and O 
tissue O 
metal O 
concentrations O 
. O 
Further O 
, O 
to O 
evaluate O 
the O 
status O 
of O 
these O 
in O 
terms O 
of O 
a O 
geoaccumulation O 
index O 
(I(geo)) O 
, O 
pollution O 
index O 
and O 
integrated O 
pollution O 
index O 
. O 
Results O 
indicated O 
that O 
earthworms O 
showed O 
reduced O 
reproductive O 
success O 
( O 
hatchlings O 
per O 
cocoon O 
) O 
and O 
decreased O 
NRRT O 
in O 
all O 
the O 
sites O 
. O 
Juveniles O 
per O 
cocoon O 
between O 
all O 
of O 
the O 
different O 
treatment O 
groups O 
were O 
; O 
control O 
( O 
2.83 O 
± O 
0.54 O 
) O 
> O 
site O 
2 O 
( O 
20 O 
years O 
old O 
; O 
1.83 O 
± O 
0.27 O 
) O 
> O 
sites O 
1 O 
and O 
3 O 
( O 
40 O 
years O 
old O 
; O 
1.06 O 
± O 
0.15 O 
and O 
6 O 
years O 
old O 
; O 
0.88 O 
± O 
0.39 O 
) O 
. O 
This O 
might O 
be O 
ascribed O 
to O 
the O 
elevated O 
levels O 
of O 
Cr B-FORMULA 
( O 
±200 O 
to O 
1166 O 
μg O 
g(-1) O 
) O 
and O 
Ni B-FORMULA 
( O 
±100 O 
to O 
316 O 
μg O 
g(-1) O 
) O 
in O 
all O 
of O 
the O 
sites O 
. O 
Earthworms O 
did O 
not O 
bioaccumulate O 
metals O 
with O 
bioconcentration O 
factors O 
for O 
all O 
the O 
different O 
treatments O 
< O 
0.01 O 
. O 
Studies O 
like O 
these O 
could O 
be O 
useful O 
when O 
establishing O 
a O 
ranking O 
of O 
TDFs O 
in O 
the O 
future O 
to O 
provide O 
legislative O 
institutions O 
with O 
an O 
indication O 
of O 
the O 
environmental O 
liabilities O 
of O 
platinum B-SYSTEMATIC 
mines O 
. O 

folding O 
of O 
peptides O 
with O 
cystine B-TRIVIAL 
-knot O 
architectures O 
: O 
kinetic O 
studies O 
and O 
optimization O 
of O 
folding O 
conditions O 
. O 

peptides O 
often O 
contain O 
several O 
disulfide B-SYSTEMATIC 
bonds O 
that O 
provide O 
the O 
main O 
contribution O 
to O 
conformational O 
rigidity O 
and O 
structural O 
, O 
thermal O 
, O 
or O 
biological O 
stability O 
. O 
Among O 
them O 
, O 
cystine B-TRIVIAL 
-knot O 
peptides O 
- O 
commonly O 
named O 
" O 
knottins"-make O 
up O 
a O 
subclass O 
with O 
several O 
thousand O 
natural O 
members O 
. O 
Hence O 
, O 
they O 
are O 
considered O 
promising O 
frameworks O 
for O 
peptide O 
- O 
based O 
pharmaceuticals O 
. O 
Although O 
cystine B-TRIVIAL 
-knot O 
peptides O 
are O 
available O 
through O 
chemical O 
and O 
recombinant O 
synthetic O 
routes O 
, O 
oxidative O 
folding O 
to O 
afford O 
the O 
bioactive O 
isomers O 
still O 
remains O 
a O 
crucial O 
step O 
. O 
We O 
therefore O 
investigated O 
the O 
oxidative O 
folding O 
of O 
ten O 
protease O 
- O 
inhibiting O 
peptides O 
from O 
two O 
knottin O 
families O 
, O 
as O 
well O 
as O 
that O 
of O 
an O 
HIV O 
entry O 
inhibitor O 
and O 
of O 
aprotinin O 
, O 
under O 
two O 
conventional O 
sets O 
of O 
folding O 
conditions O 
and O 
by O 
a O 
newly O 
developed O 
procedure O 
. O 
Kinetic O 
studies O 
identified O 
folding O 
conditions O 
that O 
resulted O 
in O 
correctly O 
folded O 
miniproteins O 
with O 
high O 
rates O 
of O 
conversion O 
even O 
for O 
highly O 
hydrophobic O 
and O 
aggregation O 
- O 
prone O 
peptides O 
in O 
concentrated O 
solutions O 
. O 

Integrated O 
Stress O 
Response O 
( O 
ISR O 
) O 
is O 
a O 
signaling O 
program O 
that O 
enables O 
cellular O 
adaptation O 
to O 
stressful O 
conditions O 
like O 
hypoxia O 
and O 
nutrient O 
deprivation O 
in O 
the O 
tumor O 
microenvironment O 
. O 
An O 
important O 
effector O 
of O 
the O 
ISR O 
is O 
activating O 
transcription O 
factor O 
4 O 
( O 
ATF4 O 
) O 
, O 
a O 
transcription O 
factor O 
that O 
regulates O 
genes O 
involved O 
in O 
redox O 
homeostasis O 
and O 
amino B-FAMILY 
acid I-FAMILY 
metabolism O 
and O 
transport O 
. O 
Because O 
both O 
inhibition O 
and O 
overactivation O 
of O 
the O 
ISR O 
can O 
induce O 
tumor O 
cell O 
death O 
, O 
modulators O 
of O 
ATF4 O 
expression O 
could O 
prove O 
to O 
be O 
clinically O 
useful O 
. O 
In O 
this O 
study O 
, O 
chemical O 
libraries O 
were O 
screened O 
for O 
modulators O 
of O 
ATF4 O 
expression O 
. O 
We O 
identified O 
one O 
compound O 
, O 
E235 B-IDENTIFIER 
( B-SYSTEMATIC 
N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide I-SYSTEMATIC 
) I-SYSTEMATIC 
N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide B-SYSTEMATIC 
) O 
, O 
that O 
activated O 
the O 
ISR O 
and O 
dose O 
- O 
dependently O 
increased O 
levels O 
of O 
ATF4 O 
in O 
transformed O 
cells O 
. O 
A O 
dose O 
- O 
dependent O 
decrease O 
in O 
viability O 
was O 
observed O 
in O 
several O 
mouse O 
and O 
human O 
tumor O 
cell O 
lines O 
, O 
and O 
knockdown O 
of O 
ATF4 O 
significantly O 
increased O 
the O 
antiproliferative O 
effects O 
of O 
E235 B-IDENTIFIER 
. O 
Interestingly O 
, O 
low O 
μM O 
doses O 
of O 
E235 B-IDENTIFIER 
induced O 
senescence O 
in O 
many O 
cell O 
types O 
, O 
including O 
HT1080 O 
human O 
fibrosarcoma O 
and O 
B16F10 O 
mouse O 
melanoma O 
cells O 
. O 
E235 B-IDENTIFIER 
-mediated O 
induction O 
of O 
senescence O 
was O 
not O 
dependent O 
on O 
p21 O 
or O 
p53 O 
; O 
however O 
, O 
p21 O 
conferred O 
protection O 
against O 
the O 
growth O 
inhibitory O 
effects O 
of O 
E235 B-IDENTIFIER 
. O 
Treatment O 
with O 
E235 B-IDENTIFIER 
resulted O 
in O 
an O 
increase O 
in O 
cells O 
arrested O 
at O 
the O 
G2 O 
/ O 
M O 
phase O 
with O 
a O 
concurrent O 
decrease O 
in O 
S-phase O 
cells O 
. O 
E235 B-IDENTIFIER 
also O 
activated O 
DNA O 
damage O 
response O 
signaling O 
, O 
resulting O 
in O 
increased O 
levels O 
of O 
Ser B-FORMULA 
15-phosphorylated O 
p53 O 
, O 
γ-H2AX O 
, O 
and O 
phosphorylated O 
checkpoint O 
kinase O 
2 O 
( O 
Chk2 O 
) O 
, O 
although O 
E235 B-IDENTIFIER 
does O 
not O 
appear O 
to O 
cause O 
physical O 
DNA O 
damage O 
. O 
Induction O 
of O 
γ-H2AX O 
was O 
abrogated O 
in O 
ATF4 O 
knockdown O 
cells O 
. O 
Together O 
, O 
these O 
results O 
suggest O 
that O 
modulation O 
of O 
the O 
ISR O 
pathway O 
with O 
the O 
small O 
molecule O 
E235 B-IDENTIFIER 
could O 
be O 
a O 
promising O 
antitumor O 
strategy O 
. O 

how O 
noncatalytic O 
carbohydrate B-FAMILY 
binding O 
modules O 
can O 
display O 
specificity O 
for O 
xyloglucan O 
. O 

biomass O 
is O 
central O 
to O 
the O 
carbon B-SYSTEMATIC 
cycle O 
and O 
to O 
environmentally O 
sustainable O 
industries O 
exemplified O 
by O 
the O 
biofuel O 
sector O 
. O 
Plant O 
cell O 
wall O 
degrading O 
enzymes O 
generally O 
contain O 
noncatalytic O 
carbohydrate B-FAMILY 
binding O 
modules O 
( O 
CBMs O 
) O 
that O 
fulfil O 
a O 
targeting O 
function O 
, O 
which O 
enhances O 
catalysis O 
. O 
CBMs O 
that O 
bind O 
β-glucan O 
chains O 
often O 
display O 
broad O 
specificity O 
recognizing O 
β1,4-glucans O 
( O 
cellulose O 
) O 
, O 
β1,3-β1,4-mixed O 
linked O 
glucans O 
and O 
xyloglucan O 
, O 
a O 
β1,4-glucan O 
decorated O 
with O 
α1,6-xylose B-SYSTEMATIC 
residues O 
, O 
by O 
targeting O 
structures O 
common O 
to O 
the O 
three O 
polysaccharides O 
. O 
Thus O 
, O 
CBMs O 
that O 
recognize O 
xyloglucan O 
target O 
the O 
β1,4-glucan O 
backbone O 
and O 
only O 
accommodate O 
the O 
xylose O 
decorations O 
. O 
Here O 
we O 
show O 
that O 
two O 
closely O 
related O 
CBMs O 
, O 
CBM65A O 
and O 
CBM65B O 
, O 
derived O 
from O 
EcCel5A O 
, O 
a O 
Eubacterium O 
cellulosolvens O 
endoglucanase O 
, O 
bind O 
to O 
a O 
range O 
of O 
β-glucans O 
but O 
, O 
uniquely O 
, O 
display O 
significant O 
preference O 
for O 
xyloglucan O 
. O 
The O 
structures O 
of O 
the O 
two O 
CBMs O 
reveal O 
a O 
β-sandwich O 
fold O 
. O 
The O 
ligand O 
binding O 
site O 
comprises O 
the O 
β-sheet O 
that O 
forms O 
the O 
concave O 
surface O 
of O 
the O 
proteins O 
. O 
Binding O 
to O 
the O 
backbone O 
chains O 
of O 
β-glucans O 
is O 
mediated O 
primarily O 
by O 
five O 
aromatic O 
residues O 
that O 
also O 
make O 
hydrophobic O 
interactions O 
with O 
the O 
xylose B-TRIVIAL 
side O 
chains O 
of O 
xyloglucan O 
, O 
conferring O 
the O 
distinctive O 
specificity O 
of O 
the O 
CBMs O 
for O 
the O 
decorated O 
polysaccharide O 
. O 
Significantly O 
, O 
and O 
in O 
contrast O 
to O 
other O 
CBMs O 
that O 
recognize O 
β-glucans O 
, O 
CBM65A O 
utilizes O 
different O 
polar O 
residues O 
to O 
bind O 
cellulose O 
and O 
mixed O 
linked O 
glucans O 
. O 
Thus O 
, O 
Gln B-FORMULA 
( O 
106 O 
) O 
is O 
central O 
to O 
cellulose O 
recognition O 
, O 
but O 
is O 
not O 
required O 
for O 
binding O 
to O 
mixed O 
linked O 
glucans O 
. O 
This O 
report O 
reveals O 
the O 
mechanism O 
by O 
which O 
β-glucan- O 
specific O 
CBMs O 
can O 
distinguish O 
between O 
linear O 
and O 
mixed O 
linked O 
glucans O 
, O 
and O 
show O 
how O 
these O 
CBMs O 
can O 
exploit O 
an O 
extensive O 
hydrophobic O 
platform O 
to O 
target O 
the O 
side O 
chains O 
of O 
decorated O 
β-glucans O 
. O 

bovine O 
ATP B-ABBREVIATION 
-binding O 
cassette O 
transporter O 
ABCG2 O 
Tyr581Ser O 
single O 
- O 
nucleotide O 
polymorphism O 
increases O 
milk O 
secretion O 
of O 
the O 
fluoroquinolone O 
danofloxacin B-TRIVIAL 
. O 

bovine O 
adenosine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
-binding O 
cassette O 
transporter O 
G2 O 
( O 
ABCG2 O 
/ O 
breast O 
cancer O 
resistance O 
protein O 
) O 
polymorphism O 
Tyr581Ser O 
( O 
Y581S O 
) O 
has O 
recently O 
been O 
shown O 
to O 
increase O 
in O 
vitro O 
transepithelial O 
transport O 
of O 
antibiotics O 
. O 
Since O 
this O 
transporter O 
has O 
been O 
extensively O 
related O 
to O 
the O 
active O 
secretion O 
of O 
drugs O 
into O 
milk O 
, O 
the O 
potential O 
in O 
vivo O 
effect O 
of O 
this O 
polymorphism O 
on O 
secretion O 
of O 
xenobiotics O 
in O 
livestock O 
could O 
have O 
striking O 
consequences O 
for O 
milk O 
production O 
, O 
the O 
dairy O 
industry O 
, O 
and O 
public O 
health O 
. O 
Our O 
purpose O 
was O 
to O 
study O 
the O 
in O 
vivo O 
effect O 
of O 
this O 
polymorphism O 
on O 
the O 
secretion O 
of O 
danofloxacin B-TRIVIAL 
, O 
a O 
widely O 
used O 
veterinary O 
antibiotic O 
, O 
into O 
milk O 
. O 
Danofloxacin B-TRIVIAL 
( O 
1.25 O 
mg O 
/ O 
kg O 
) O 
was O 
administered O 
to O 
six O 
Y O 
/ O 
Y O 
581 O 
homozygous O 
and O 
six O 
Y O 
/ O 
S O 
581 O 
heterozygous O 
lactating O 
cows O 
, O 
and O 
plasma O 
and O 
milk O 
samples O 
were O 
collected O 
and O 
analyzed O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
. O 
No O 
differences O 
were O 
found O 
in O 
the O 
pharmacokinetic O 
parameters O 
of O 
danofloxacin B-TRIVIAL 
in O 
plasma O 
between O 
the O 
two O 
groups O 
of O 
animals O 
. O 
In O 
contrast O 
, O 
Y O 
/ O 
S O 
heterozygous O 
cows O 
showed O 
a O 
2-fold O 
increase O 
in O 
danofloxacin B-TRIVIAL 
levels O 
in O 
milk O 
. O 
In O 
addition O 
, O 
the O 
pharmacokinetic O 
elimination O 
parameters O 
, O 
mean O 
residence O 
time O 
and O 
elimination O 
half O 
- O 
life O 
, O 
were O 
significantly O 
lower O 
in O 
the O 
milk O 
of O 
the O 
animals O 
carrying O 
the O 
Y O 
/ O 
S O 
polymorphism O 
. O 
These O 
in O 
vivo O 
results O 
are O 
in O 
agreement O 
with O 
our O 
previously O 
published O 
in O 
vitro O 
data O 
, O 
which O 
showed O 
a O 
greater O 
capacity O 
of O 
the O 
S581 O 
variant O 
in O 
accumulation O 
assays O 
, O 
and O 
demonstrate O 
, O 
for O 
the O 
first O 
time O 
, O 
an O 
important O 
effect O 
of O 
the O 
Y581S O 
single O 
- O 
nucleotide O 
polymorphism O 
on O 
antibiotic O 
secretion O 
into O 
cow O 
milk O 
. O 
These O 
findings O 
could O 
be O 
extended O 
to O 
other O 
ABCG2 O 
substrates O 
, O 
and O 
may O 
be O 
relevant O 
for O 
the O 
treatment O 
of O 
mastitis O 
and O 
for O 
the O 
design O 
of O 
accurate O 
and O 
novel O 
strategies O 
to O 
handle O 
milk O 
residues O 
. O 

sub-100 O 
nm O 
nanoclusters O 
of O 
metal O 
nanoparticles O 
are O 
of O 
interest O 
in O 
many O 
fields O 
including O 
biomedical O 
imaging O 
, O 
sensors O 
, O 
and O 
catalysis O 
, O 
it O 
has O 
been O 
challenging O 
to O 
control O 
their O 
morphologies O 
and O 
chemical O 
properties O 
. O 
Herein O 
, O 
a O 
new O 
concept O 
is O 
presented O 
to O 
assemble O 
equilibrium O 
Au B-FORMULA 
nanoclusters O 
of O 
controlled O 
size O 
by O 
tuning O 
the O 
colloidal O 
interactions O 
with O 
a O 
polymeric O 
stabilizer O 
, O 
PLA B-ABBREVIATION 
(1k)-b- O 
PEG B-ABBREVIATION 
(10k)-b- O 
PLA B-ABBREVIATION 
( O 
1k O 
) O 
. O 
The O 
nanoclusters O 
form O 
upon O 
mixing O 
a O 
dispersion O 
of O 
~5 O 
nm O 
Au B-FORMULA 
nanospheres O 
with O 
a O 
polymer O 
solution O 
followed O 
by O 
partial O 
solvent O 
evaporation O 
. O 
A O 
weakly O 
adsorbed O 
polymer O 
quenches O 
the O 
equilibrium O 
nanocluster O 
size O 
and O 
provides O 
steric O 
stabilization O 
. O 
Nanocluster O 
size O 
is O 
tuned O 
from O 
~20 O 
to O 
~40 O 
nm O 
by O 
experimentally O 
varying O 
the O 
final O 
Au B-FORMULA 
nanoparticle O 
concentration O 
and O 
the O 
polymer/ O 
Au B-FORMULA 
ratio O 
, O 
along O 
with O 
the O 
charge O 
on O 
the O 
initial O 
Au B-FORMULA 
nanoparticle O 
surface O 
. O 
Upon O 
biodegradation O 
of O 
the O 
quencher O 
, O 
the O 
nanoclusters O 
reversibly O 
and O 
fully O 
dissociate O 
to O 
individual O 
~5 O 
nm O 
primary O 
particles O 
. O 
Equilibrium O 
cluster O 
size O 
is O 
predicted O 
semiquantitatively O 
with O 
a O 
free O 
energy O 
model O 
that O 
balances O 
short O 
- O 
ranged O 
depletion O 
and O 
van O 
der O 
Waals O 
attractions O 
with O 
longer O 
- O 
ranged O 
electrostatic O 
repulsion O 
, O 
as O 
a O 
function O 
of O 
the O 
Au B-FORMULA 
and O 
polymer O 
concentrations O 
. O 
The O 
close O 
spacings O 
of O 
the O 
Au B-FORMULA 
nanoparticles O 
in O 
the O 
clusters O 
produce O 
strong O 
NIR O 
extinction O 
over O 
a O 
broad O 
range O 
of O 
wavelengths O 
from O 
650 O 
to O 
900 O 
nm O 
, O 
which O 
is O 
of O 
practical O 
interest O 
in O 
biomedical O 
imaging O 
. O 

metabolisms O 
in O 
human O 
skin O 
commensal O 
Propionibacterium O 
acnes O 
bacteria O 
: O 
potential O 
application O 
to O 
monitor O 
human O 
radiation O 
risk O 
. O 

acnes O 
( O 
P O 
. O 
acnes O 
) O 
, O 
a O 
Gram O 
- O 
positive O 
anaerobic O 
bacterium O 
, O 
is O 
a O 
commensal O 
organism O 
in O 
human O 
skin O 
. O 
Like O 
human O 
cells O 
, O 
the O 
bacteria O 
produce O 
porphyrins B-FAMILY 
, O 
which O 
exhibit O 
fluorescence O 
properties O 
and O 
make O 
bacteria O 
visible O 
with O 
a O 
Wood's O 
lamp O 
. O 
In O 
this O 
review O 
, O 
we O 
compare O 
the O 
porphyrin B-FAMILY 
biosynthesis O 
in O 
humans O 
and O 
P O 
. O 
acnes O 
. O 
Also O 
, O 
since O 
P O 
. O 
acnes O 
living O 
on O 
the O 
surface O 
of O 
skin O 
receive O 
the O 
same O 
radiation O 
exposure O 
as O 
humans O 
, O 
we O 
envision O 
that O 
the O 
changes O 
in O 
porphyrin B-FAMILY 
profiles O 
( O 
the O 
absorption O 
spectra O 
and O 
/ O 
or O 
metabolism O 
) O 
of O 
P O 
. O 
acnes O 
by O 
radiation O 
may O 
mirror O 
the O 
response O 
of O 
human O 
cells O 
to O 
radiation O 
. O 
The O 
porphyrin B-FAMILY 
profiles O 
of O 
P O 
. O 
acnes O 
may O 
be O 
a O 
more O 
accurate O 
reflection O 
of O 
radiation O 
risk O 
to O 
the O 
patient O 
than O 
other O 
biodosimeters O 
/ O 
biomarkers O 
such O 
as O 
gene O 
up- O 
/ O 
down O 
- O 
regulation O 
, O 
which O 
may O 
be O 
non-specific O 
due O 
to O 
patient O 
related O 
factors O 
such O 
as O 
autoimmune O 
diseases O 
. O 
Lastly O 
, O 
we O 
discuss O 
the O 
challenges O 
and O 
possible O 
solutions O 
for O 
using O 
the O 
P O 
. O 
acnes O 
response O 
to O 
predict O 
the O 
radiation O 
risk O 
. O 

proton O 
conduction O 
is O 
of O 
utmost O 
importance O 
in O 
biology O 
, O 
materials O 
science O 
, O 
and O 
electrochemistry O 
; O 
yet O 
experimental O 
findings O 
of O 
ultrafast O 
proton O 
transport O 
at O 
densely O 
packed O 
arrays O 
of O 
anionic O 
surface O 
groups O 
have O 
remained O 
controversial O 
and O 
unexplained O 
. O 
We O 
present O 
an O 
ab O 
initio O 
molecular O 
dynamics O 
study O 
of O 
proton O 
dynamics O 
at O 
sulfonic B-SYSTEMATIC 
- I-SYSTEMATIC 
acid I-SYSTEMATIC 
terminated O 
surface O 
groups O 
. O 
Results O 
furnish O 
a O 
highly O 
efficient O 
collective O 
mechanism O 
of O 
hydronium B-SYSTEMATIC 
ion O 
translocations O 
at O 
a O 
critical O 
surface O 
group O 
separation O 
of O 
~6.5 O 
Å O 
. O 
Orientational O 
fluctuations O 
of O 
SG O 
trigger O 
hydrogen B-SYSTEMATIC 
bond O 
breaking O 
that O 
sets O 
off O 
the O 
hydronium B-SYSTEMATIC 
ion O 
motion O 
. O 
The O 
activation O 
free O 
energy O 
of O 
this O 
process O 
is O 
0.3 O 
eV O 
( O 
±0.1 O 
eV O 
) O 
. O 
The O 
soliton O 
- O 
like O 
nature O 
of O 
this O 
mechanism O 
is O 
owed O 
to O 
the O 
trigonal O 
symmetry O 
of O 
sulfonate B-SYSTEMATIC 
anions O 
and O 
exceptionally O 
strong O 
interfacial O 
hydrogen B-SYSTEMATIC 
bonding O 
. O 
These O 
insights O 
should O 
stimulate O 
surface O 
conductance O 
studies O 
at O 
SG O 
monolayers O 
with O 
sulfonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
groups O 
, O 
and O 
they O 
bolster O 
efforts O 
in O 
designing O 
proton O 
conducting O 
polymers O 
conducive O 
to O 
fuel O 
cell O 
operation O 
above O 
~100 O 
°C O 
. O 

of O 
polystyrene B-SYSTEMATIC 
/ O 
polysilsesquioxane B-FAMILY 
core O 
/ O 
shell O 
composite O 
particles O 
via O 
emulsion O 
polymerization O 
in O 
the O 
existence O 
of O 
poly(γ-methacryloxypropyl B-FAMILY 
trimethoxysilane I-FAMILY 
) I-FAMILY 
sol O 
. O 

, O 
we O 
synthesized O 
the O 
polystyrene B-SYSTEMATIC 
/ O 
polysilsesquioxane B-FAMILY 
( O 
PS/ O 
PSQ B-ABBREVIATION 
) O 
core O 
/ O 
shell O 
latex O 
particles O 
via O 
emulsion O 
polymerization O 
, O 
which O 
behave O 
as O 
an O 
amusing O 
morphology O 
. O 
First O 
, O 
the O 
nanosized O 
PSQ B-ABBREVIATION 
particles O 
were O 
prepared O 
by O 
the O 
hydrolysis O 
- O 
condensation O 
reaction O 
of O 
γ-methacryloxypropyl B-SYSTEMATIC 
trimethoxysilane I-SYSTEMATIC 
( O 
MPTS B-ABBREVIATION 
) O 
in O 
ethanol B-SYSTEMATIC 
medium O 
. O 
Subsequently O 
, O 
the O 
as-obtained O 
methacryloxypropylene B-SYSTEMATIC 
functionalized O 
PSQ B-ABBREVIATION 
( O 
PMPTS B-ABBREVIATION 
) O 
sol O 
was O 
directly O 
added O 
into O 
the O 
emulsion O 
system O 
of O 
styrene B-TRIVIAL 
( O 
St O 
) O 
monomer O 
, O 
and O 
PS/ O 
PSQ B-ABBREVIATION 
composite O 
particles O 
with O 
core O 
/ O 
shell O 
structure O 
were O 
obtained O 
through O 
emulsion O 
polymerization O 
. O 
We O 
found O 
that O 
the O 
structure O 
of O 
the O 
composite O 
particles O 
can O 
be O 
affected O 
by O 
the O 
synthesis O 
parameters O 
such O 
as O 
reaction O 
time O 
, O 
content O 
of O 
PMPTS B-ABBREVIATION 
added O 
in O 
the O 
reaction O 
, O 
amount O 
of O 
coemulsifier O 
, O 
and O 
the O 
pH O 
value O 
of O 
emulsion O 
system O 
, O 
which O 
were O 
systemically O 
explored O 
by O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
, O 
scanning O 
electron O 
microscope O 
( O 
SEM O 
) O 
, O 
Fourier O 
transform O 
infrared O 
( O 
FTIR O 
) O 
spectroscopy O 
, O 
dynamic O 
light O 
scattering O 
( O 
DLS O 
) O 
, O 
and O 
thermogravimetric O 
analysis O 
( O 
TGA O 
) O 
in O 
this O 
work O 
. O 
These O 
results O 
indicate O 
that O 
the O 
PMPTS B-ABBREVIATION 
particles O 
in O 
the O 
size O 
of O 
about O 
5 O 
nm O 
could O 
first O 
absorb O 
onto O 
the O 
surface O 
of O 
PS O 
latex O 
particles O 
so O 
as O 
to O 
assemble O 
in O 
a O 
strawberry O 
- O 
like O 
morphology O 
. O 
The O 
further O 
coalescence O 
among O 
the O 
PMPTS B-ABBREVIATION 
particles O 
would O 
result O 
in O 
a O 
continuous O 
PMPTS B-ABBREVIATION 
shell O 
around O 
the O 
PS O 
core O 
. O 
Moreover O 
, O 
the O 
hollow O 
PSQ B-ABBREVIATION 
capsules O 
were O 
prepared O 
after O 
extraction O 
of O 
the O 
PS O 
core O 
by O 
organic O 
solvent O 
, O 
further O 
confirming O 
the O 
core O 
/ O 
shell O 
structure O 
of O 
the O 
as-synthesized O 
PS/ O 
PMPTS B-ABBREVIATION 
particles O 
. O 
Meanwhile O 
, O 
we O 
also O 
explored O 
the O 
application O 
of O 
the O 
PS/ O 
PSQ B-ABBREVIATION 
core O 
/ O 
shell O 
particles O 
as O 
a O 
new O 
kind O 
of O 
Pickering O 
emulsifier O 
in O 
the O 
emulsion O 
polymerization O 
of O 
St O 
, O 
and O 
composite O 
particles O 
with O 
complex O 
patchy O 
morphologies O 
have O 
been O 
obtained O 
finally O 
under O 
different O 
ratios O 
of O 
styrene O 
monomer O 
to O 
PS/ O 
PMPTS B-ABBREVIATION 
colloidal O 
emulsifier O 
. O 

of O 
4-phenyl-2-phenylaminopyridine B-SYSTEMATIC 
based O 
TNIK O 
inhibitors O 
. O 

series O 
of O 
compounds O 
based O 
on O 
a O 
4-phenyl-2-phenylaminopyridine B-SYSTEMATIC 
scaffold O 
that O 
are O 
potent O 
and O 
selective O 
inhibitors O 
of O 
Traf2- O 
and O 
Nck O 
- O 
interacting O 
kinase O 
( O 
TNIK O 
) O 
activity O 
are O 
described O 
. O 
These O 
compounds O 
were O 
used O 
as O 
tools O 
to O 
test O 
the O 
importance O 
of O 
TNIK O 
kinase O 
activity O 
in O 
signaling O 
and O 
proliferation O 
in O 
Wnt O 
- O 
activated O 
colorectal O 
cancer O 
cells O 
. O 
The O 
results O 
indicate O 
that O 
pharmacological O 
inhibition O 
of O 
TNIK O 
kinase O 
activity O 
has O 
minimal O 
effects O 
on O 
either O 
Wnt O 
/ O 
TCF4 O 
/ O 
β-catenin- O 
driven O 
transcription O 
or O 
viability O 
. O 
The O 
findings O 
suggest O 
that O 
the O 
kinase O 
activity O 
of O 
TNIK O 
may O 
be O 
less O 
important O 
to O 
Wnt O 
signaling O 
than O 
other O 
aspects O 
of O 
TNIK O 
function O 
, O 
such O 
as O 
its O 
putative O 
role O 
in O 
stabilizing O 
the O 
TCF4 O 
/ O 
β-catenin O 
transcriptional O 
complex O 
. O 

at O 
the O 
recommended O 
human O 
doses O 
after O 
long O 
- O 
term O 
treatment O 
is O 
genotoxic O 
for O 
male O 
germ O 
cell O 
. O 

present O 
study O 
was O 
aimed O 
to O 
examine O 
if O 
multiple O 
oral O 
administration O 
of O 
citalopram B-TRIVIAL 
, O 
an O 
antidepressant O 
drug O 
, O 
has O 
any O 
genotoxic O 
potential O 
on O 
germ O 
cells O 
of O 
male O 
mice O 
. O 
Mice O 
were O 
treated O 
with O 
citalopram B-TRIVIAL 
for O 
4 O 
or O 
8 O 
weeks O 
at O 
the O 
doses O 
of O 
6 O 
, O 
12 O 
and O 
24 O 
mg O 
/ O 
kg O 
/ O 
day O 
and O 
were O 
sacrificed O 
24 O 
h O 
after O 
the O 
last O 
dose O 
. O 
Multiple O 
exposures O 
to O 
12 O 
and O 
24 O 
mg O 
/ O 
kg O 
/ O 
day O 
citalopram B-TRIVIAL 
significantly O 
increased O 
sperm O 
DNA O 
strand O 
breaks O 
( O 
14 O 
and O 
16 O 
, O 
respectively O 
, O 
compared O 
to O 
the O 
concurrent O 
control O 
of O 
6.8 O 
at O 
week O 
4 O 
and O 
15.2 O 
and O 
20.7 O 
, O 
respectively O 
, O 
compared O 
to O 
the O 
concurrent O 
control O 
of O 
7.2 O 
at O 
week O 
8 O 
) O 
and O 
aberrant O 
primary O 
spermatocytes O 
( O 
6.6% O 
and O 
7.6% O 
, O 
respectively O 
, O 
compared O 
to O 
the O 
control O 
of O 
2.8% O 
at O 
week O 
4 O 
and O 
7.4% O 
and O 
8.4% O 
, O 
respectively O 
, O 
compared O 
to O 
the O 
control O 
of O 
3.2% O 
at O 
week O 
8 O 
) O 
as O 
well O 
as O 
oxidative O 
DNA O 
damage O 
( O 
2.7 O 
and O 
3.1 O 
, O 
respectively O 
, O 
compared O 
to O 
the O 
control O 
of O 
1.6 O 
at O 
week O 
4 O 
and O 
3.3 O 
and O 
3.9 O 
, O 
respectively O 
, O 
compared O 
to O 
the O 
control O 
of O 
1.7 O 
at O 
week O 
8 O 
) O 
. O 
Overall O 
, O 
this O 
study O 
provides O 
that O 
citalopram B-TRIVIAL 
at O 
the O 
recommended O 
human O 
doses O 
after O 
long O 
- O 
term O 
treatment O 
is O 
genotoxic O 
for O 
mouse O 
germ O 
cells O 
. O 
Thus O 
, O 
male O 
patients O 
receiving O 
citalopram B-TRIVIAL 
may O 
stand O 
at O 
higher O 
risk O 
for O 
abnormal O 
reproductive O 
outcomes O 
, O 
particularly O 
in O 
the O 
reproductive O 
ages O 
. O 

luteinizing O 
hormone O 
/ O 
chorionic O 
gonadotropin O 
receptor O 
( O 
LHCGR O 
) O 
is O 
essential O 
for O 
normal O 
male O 
sex O 
differentiation O 
. O 
Recently O 
, O 
the O 
additional O 
primate O 
- O 
specific O 
exon O 
6A O 
of O 
the O 
LHCGR O 
was O 
discovered O 
and O 
it O 
was O 
shown O 
to O 
act O 
as O 
regulatory O 
element O 
at O 
the O 
transcriptional O 
level O 
. O 
Compound O 
heterozygous O 
mutations O 
in O 
exon O 
6A O 
( O 
c.580 O 
A O 
> O 
G O 
) O 
and O 
exon O 
11 O 
( O 
c.1244T O 
> O 
C O 
) O 
were O 
identified O 
in O 
the O 
LHCGR O 
of O 
a O 
male O 
46,XY O 
patient O 
with O 
genital O 
malformation O 
. O 
Analysis O 
revealed O 
that O 
mutation O 
c.580A O 
> O 
G O 
in O 
exon O 
6A O 
affects O 
the O 
splicing O 
pattern O 
resulting O 
in O 
an O 
increase O 
of O 
transcripts O 
containing O 
the O 
internal O 
variants O 
of O 
exon O 
6A O 
prone O 
to O 
nonsense O 
- O 
mediated O 
decay O 
. O 
In O 
contrast O 
, O 
mutation O 
c.1244T O 
> O 
C O 
results O 
in O 
an O 
amino B-FAMILY 
acid I-FAMILY 
substitution O 
( O 
Ile415Thr O 
) O 
, O 
which O 
abolishes O 
signal O 
transduction O 
due O 
to O 
structural O 
changes O 
. O 
When O 
inherited O 
in O 
a O 
compound O 
heterozygous O 
fashion O 
these O 
mutations O 
result O 
in O 
Leydig O 
cell O 
hypoplasia O 
( O 
LCH O 
) O 
type O 
II O 
. O 
Thus O 
this O 
study O 
provides O 
proof O 
that O 
mutations O 
causing O 
aberrant O 
transcription O 
can O 
impair O 
receptor O 
function O 
and O 
thereby O 
be O 
causative O 
of O 
LCH O 
. O 

amide B-FAMILY 
alkaloids I-FAMILY 
from O 
Piper O 
longum O 
. O 

- O 
guided O 
phytochemical O 
investigation O 
on O 
Piper O 
longum O 
resulted O 
in O 
the O 
isolation O 
of O 
two O 
new O 
compounds O 
. O 
By O 
analyses O 
of O 
the O 
MS O 
, O 
IR O 
, O 
UV O 
, O 
1D O 
and O 
2D O 
NMR O 
data O 
, O 
the O 
two O 
new O 
compounds O 
were O 
identified O 
as O 
3β B-SYSTEMATIC 
, I-SYSTEMATIC 
4α-dihydroxy-1-(3-phenylpropanoyl)-piperidine-2-one I-SYSTEMATIC 
( O 
1 O 
) O 
and O 
( B-SYSTEMATIC 
2E I-SYSTEMATIC 
, I-SYSTEMATIC 
4E I-SYSTEMATIC 
, I-SYSTEMATIC 
14Z)-6-hydroxyl-N-isobutyleicosa-2,4,14-trienamide I-SYSTEMATIC 
( O 
2 O 
) O 
. O 
In O 
vitro O 
anti-HBV O 
bioassay O 
demonstrated O 
compound O 
1 O 
possessed O 
remarkable O 
activity O 
suppressing O 
the O 
secretion O 
of O 
HBeAg O 
in O 
Hep O 
G2.2.15 O 
cell O 
line O 
, O 
with O 
an O 
IC(50) O 
value O 
of O 
0.21mM O 
and O 
SI O 
value O 
of O 
16.4 O 
. O 

isomeric O 
and O 
expanded O 
porphyrins B-FAMILY 
. O 

phenomenon O 
of O 
π-extension O 
has O 
been O 
widely O 
applied O 
to O 
, O 
and O 
exploited O 
within O 
, O 
the O 
field O 
porphyrin B-FAMILY 
chemistry O 
. O 
The O 
development O 
of O 
reliable O 
synthetic O 
routes O 
to O 
various O 
useful O 
starting O 
materials O 
has O 
facilitated O 
the O 
underlying O 
preparative O 
work O 
. O 
The O 
chemical O 
resemblance O 
between O 
porphyrins B-FAMILY 
and O 
expanded O 
and O 
isomeric O 
porphyrins B-FAMILY 
, O 
as O 
well O 
as O 
the O 
increasing O 
accessibility O 
of O 
the O 
requisite O 
starting O 
materials O 
is O 
giving O 
birth O 
to O 
the O 
hybrid O 
field O 
of O 
π-extended O 
expanded O 
and O 
isomeric O 
porphyrins B-FAMILY 
. O 
This O 
tutorial O 
review O 
is O 
intended O 
to O 
provide O 
an O 
overview O 
of O 
up O 
- O 
to O 
- O 
date O 
published O 
synthetic O 
efforts O 
and O 
to O 
summarize O 
the O 
effect O 
of O 
annulation O 
on O 
the O 
properties O 
of O 
expanded O 
and O 
isomeric O 
porphyrins B-FAMILY 
. O 

based O 
analysis O 
of O 
chlorothalonil B-TRIVIAL 
concentrations O 
following O 
application O 
to O 
managed O 
turf O 
. O 

concentrations O 
exceeding O 
acute O 
toxicity O 
levels O 
for O 
certain O 
organisms O 
have O 
been O 
measured O 
in O 
surface O 
water O 
discharge O 
events O 
from O 
managed O 
turf O 
watersheds O 
. O 
The O 
duration O 
of O 
exceedence O 
and O 
the O 
timing O 
of O 
these O 
events O 
related O 
to O 
precipitation O 
/ O 
runoff O 
and O 
time O 
since O 
application O 
, O 
however O 
, O 
have O 
not O 
been O 
explored O 
. O 
Chlorothalonil B-TRIVIAL 
concentrations O 
were O 
measured O 
from O 
discharge O 
waters O 
draining O 
a O 
managed O 
turf O 
watershed O 
in O 
Duluth O 
, O 
Minnesota O 
, O 
USA O 
, O 
between O 
2003 O 
and O 
2009 O 
. O 
The O 
median O 
chlorothalonil B-TRIVIAL 
concentration O 
was O 
0.58 O 
µg O 
/ O 
L O 
. O 
Approximately O 
2% O 
of O 
all O 
measured O 
concentrations O 
exceeded O 
the O 
7.6 O 
µg O 
/ O 
L O 
median O 
lethal O 
concentration O 
( O 
LC50 O 
) O 
acute O 
toxicity O 
level O 
for O 
rainbow O 
trout O 
. O 
One O 
- O 
twentieth O 
the O 
LC50 O 
concentration O 
, O 
equivalent O 
to O 
the O 
level O 
of O 
concern O 
( O 
0.38 O 
µg O 
/ O 
L O 
) O 
for O 
endangered O 
species O 
, O 
was O 
exceeded O 
31% O 
of O 
the O 
time O 
during O 
the O 
present O 
study O 
. O 
The O 
concentrations O 
that O 
exceeded O 
the O 
LC50 O 
threshold O 
were O 
associated O 
with O 
eight O 
rainfall O 
/ O 
runoff O 
events O 
. O 
Low O 
dose O 
exposures O 
are O 
a O 
more O 
important O 
biological O 
concern O 
than O 
acute O 
occurrences O 
. O 
Exceedence O 
concentrations O 
associated O 
with O 
acute O 
effects O 
were O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
correlated O 
to O 
time O 
since O 
application O 
and O 
were O 
measured O 
only O 
in O 
the O 
fall O 
following O 
extensive O 
application O 
. O 
A O 
conflict O 
exists O 
between O 
the O 
transportability O 
of O 
chlorothalonil B-TRIVIAL 
as O 
suggested O 
by O 
its O 
chemical O 
properties O 
and O 
the O 
data O 
collected O 
in O 
the O 
present O 
study O 
. O 
With O 
respect O 
to O 
course O 
- O 
wide O 
golf O 
course O 
application O 
, O 
avoiding O 
application O 
until O 
after O 
the O 
major O 
autumn O 
rainfall O 
period O 
but O 
before O 
the O 
first O 
snow O 
coverage O 
is O 
recommended O 
to O 
reduce O 
occurrence O 
of O 
chlorothalonil B-TRIVIAL 
concentrations O 
that O 
exceed O 
toxic O 
levels O 
associated O 
with O 
acute O 
and O 
chronic O 
levels O 
of O 
concern O 
. O 

and O 
synthesis O 
of O 
diazatricyclodecane B-SYSTEMATIC 
agonists O 
of O 
the O 
G O 
- O 
protein O 
- O 
coupled O 
receptor O 
119 O 
. O 

series O 
of O 
GPR119 O 
agonists O 
based O 
on O 
a O 
2,6-diazatricyclo[3.3.1.1∼3,7∼]decane B-SYSTEMATIC 
ring O 
system O 
is O 
described O 
. O 
Also O 
provided O 
is O 
a O 
detailed O 
account O 
of O 
the O 
development O 
of O 
a O 
multigram O 
scale O 
synthesis O 
of O 
the O 
diazatricyclic B-FAMILY 
ring O 
system O 
, O 
which O 
was O 
achieved O 
using O 
a O 
Hofmann-Löffler-Freytag O 
reaction O 
as O 
the O 
key O 
step O 
. O 
The O 
basis O 
for O 
the O 
use O 
of O 
this O 
complex O 
framework O 
lies O 
in O 
an O 
attempt O 
to O 
constrain O 
one O 
end O 
of O 
the O 
molecule O 
in O 
the O 
" O 
agonist O 
conformation O 
" O 
as O 
was O 
previously O 
described O 
for O 
3-oxa-7-aza-bicyclo[3.3.1]nonanes B-FAMILY 
. O 
Optimization O 
of O 
carbamate B-FAMILY 
analogues O 
of O 
the O 
diazatricylic B-FAMILY 
compounds O 
led O 
to O 
the O 
identification O 
of O 
32i O 
as O 
a O 
potent O 
agonist O 
of O 
the O 
GPR119 O 
receptor O 
with O 
low O 
unbound O 
human O 
liver O 
microsomal O 
clearance O 
. O 
The O 
use O 
of O 
an O 
agonist O 
response O 
weighted O 
ligand O 
lipophilic O 
efficiency O 
( O 
LLE O 
) O 
termed O 
AgLLE O 
is O 
discussed O 
along O 
with O 
the O 
issues O 
of O 
applying O 
efficiency O 
measures O 
to O 
agonist O 
programs O 
. O 
Ultimately O 
, O 
solubility O 
limited O 
absorption O 
and O 
poor O 
exposure O 
reduced O 
further O 
interest O 
in O 
these O 
molecules O 
. O 

of O 
monodisperse O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
NPs O 
and O 
their O 
properties O 
as O 
magnetically O 
recoverable O 
catalysts O 
. O 

we O 
report O 
the O 
functionalization O 
of O 
monodisperse O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
( O 
NPs O 
) O 
with O 
commercially O 
available O 
functional O 
acids O 
containing O 
multiple O 
double O 
bonds O 
such O 
as O 
linolenic B-MULTIPLE 
( I-MULTIPLE 
LLA I-MULTIPLE 
) I-MULTIPLE 
and I-MULTIPLE 
linoleic I-MULTIPLE 
( I-MULTIPLE 
LEA I-MULTIPLE 
) I-MULTIPLE 
acids I-MULTIPLE 
or O 
pyridine B-SYSTEMATIC 
moieties O 
such O 
as O 
6-methylpyridine-2-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
isonicotinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
3-hydroxypicolinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
and O 
6-(1-piperidinyl)pyridine-3-carboxlic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
PPCA B-ABBREVIATION 
) O 
. O 
Both O 
double O 
bonds O 
and O 
pyridine O 
groups O 
can O 
be O 
reacted O 
with O 
noble O 
metal O 
compounds O 
to O 
form O 
catalytically O 
active O 
species O 
in O 
the O 
exterior O 
of O 
magnetic O 
NPs O 
, O 
thus O 
making O 
them O 
promising O 
magnetically O 
recoverable O 
catalysts O 
. O 
We O 
determined O 
that O 
both O 
LLA B-ABBREVIATION 
and O 
LEA B-ABBREVIATION 
stabilize O 
magnetic O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
NPs O 
, O 
allowing O 
the O 
formation O 
of O 
π- O 
complexes O 
with O 
bis(acetonitrile)dichloropalladium B-SYSTEMATIC 
(II) I-SYSTEMATIC 
in O 
the O 
NP O 
shells O 
. O 
In O 
both O 
cases O 
, O 
this O 
leads O 
to O 
the O 
formation O 
of O 
NP O 
aggregates O 
because O 
of O 
interparticle O 
complexation O 
. O 
In O 
the O 
case O 
of O 
pyridine B-SYSTEMATIC 
-containing O 
ligands O 
, O 
only O 
PPCA B-ABBREVIATION 
with O 
two O 
N B-FORMULA 
-containing O 
rings O 
is O 
able O 
to O 
provide O 
NP O 
stabilization O 
and O 
functionalization O 
whereas O 
other O 
pyridine B-SYSTEMATIC 
-containing O 
acids O 
did O 
now O 
allow O 
sufficient O 
steric O 
stabilization O 
. O 
The O 
interaction O 
of O 
PPCA B-ABBREVIATION 
-based O 
particles O 
with O 
Pd B-SYSTEMATIC 
acetate I-SYSTEMATIC 
also O 
leads O 
to O 
aggregation O 
because O 
of O 
interparticle O 
interactions O 
, O 
but O 
the O 
aggregates O 
that O 
are O 
formed O 
are O 
much O 
smaller O 
. O 
Nevertheless O 
, O 
the O 
catalytic O 
properties O 
in O 
the O 
selective O 
hydrogenation O 
of O 
dimethylethynylcarbinol B-SYSTEMATIC 
( O 
DMEC B-ABBREVIATION 
) O 
to O 
dimethylvinylcarbinol B-SYSTEMATIC 
were O 
the O 
best O 
for O 
the O 
catalyst O 
based O 
on O 
LLA B-ABBREVIATION 
, O 
demonstrating O 
that O 
the O 
NP O 
aggregates O 
in O 
all O 
cases O 
are O 
penetrable O 
for O 
DMEC B-ABBREVIATION 
. O 
Easy O 
magnetic O 
separation O 
of O 
this O 
catalyst O 
from O 
the O 
reaction O 
solution O 
makes O 
it O 
promising O 
as O 
a O 
magnetically O 
recoverable O 
catalyst O 
. O 

recently O 
showed O 
that O 
the O 
developmentally O 
important O 
family O 
of O 
SOX O 
( O 
SRY O 
( O 
sex O 
determining O 
region O 
on O 
the O 
Y O 
chromosome O 
) O 
- O 
related O 
high O 
mobility O 
group O 
( O 
HMG O 
) O 
box O 
) O 
proteins O 
require O 
the O 
calcium B-SYSTEMATIC 
-binding O 
protein O 
calmodulin O 
( O 
CaM O 
) O 
for O 
optimal O 
nuclear O 
accumulation O 
, O 
with O 
clinical O 
mutations O 
in O 
SRY O 
that O 
specifically O 
impair O 
nuclear O 
accumulation O 
via O 
this O 
pathway O 
resulting O 
in O 
XY O 
sex O 
reversal O 
. O 
However O 
, O 
the O 
mechanism O 
by O 
which O 
CaM O 
facilitates O 
nuclear O 
accumulation O 
is O 
unknown O 
. O 
Here O 
, O 
we O 
show O 
, O 
for O 
the O 
first O 
time O 
, O 
that O 
the O 
70-kDa O 
heat O 
shock O 
cognate O 
protein O 
hsc70 O 
plays O 
a O 
key O 
role O 
in O 
CaM-dependent O 
nuclear O 
import O 
of O 
SRY O 
. O 
Using O 
a O 
reconstituted O 
nuclear O 
import O 
assay O 
, O 
we O 
show O 
that O 
antibodies O 
to O 
hsc70 O 
significantly O 
reduce O 
nuclear O 
accumulation O 
of O 
wild O 
type O 
SRY O 
and O 
mutant O 
derivatives O 
thereof O 
that O 
retain O 
CaM-dependent O 
nuclear O 
import O 
, O 
with O 
an O 
increased O 
rate O 
of O 
nuclear O 
accumulation O 
upon O 
addition O 
of O 
both O 
CaM O 
and O 
hsc70 O 
, O 
in O 
contrast O 
to O 
an O 
SRY O 
mutant O 
derivative O 
with O 
impaired O 
CaM O 
binding O 
. O 
siRNA O 
knockdown O 
of O 
hsc70 O 
in O 
intact O 
cells O 
showed O 
similar O 
results O 
, O 
indicating O 
clear O 
dependence O 
upon O 
hsc70 O 
for O 
CaM-dependent O 
nuclear O 
import O 
. O 
Analysis O 
using O 
the O 
technique O 
of O 
fluorescence O 
recovery O 
after O 
photobleaching O 
indicated O 
that O 
hsc70 O 
is O 
required O 
for O 
the O 
maximal O 
rate O 
of O 
SRY O 
nuclear O 
import O 
in O 
living O 
cells O 
but O 
has O 
no O 
impact O 
upon O 
SRY O 
nuclear O 
retention O 
/ O 
nuclear O 
dynamics O 
. O 
Finally O 
, O 
we O 
demonstrate O 
direct O 
binding O 
of O 
hsc70 O 
to O 
the O 
SRY·CaM O 
complex O 
, O 
with O 
immunoprecipitation O 
experiments O 
from O 
cell O 
extracts O 
showing O 
association O 
of O 
hsc70 O 
with O 
wild O 
type O 
SRY O 
, O 
but O 
not O 
with O 
a O 
mutant O 
derivative O 
with O 
impaired O 
CaM O 
binding O 
, O 
dependent O 
on O 
Ca(2+) B-FORMULA 
. O 
Our O 
novel O 
findings O 
strongly O 
implicate O 
hsc70 O 
in O 
CaM-dependent O 
nuclear O 
import O 
of O 
SRY O 
. O 

of O 
multilayer O 
structure O 
on O 
cyclic O 
performance O 
of O 
Si B-FORMULA 
/ O 
Fe B-FORMULA 
anode O 
electrode O 
in O 
lithium B-SYSTEMATIC 
-ion O 
secondary O 
batteries O 
. O 

buffer O 
- O 
strengthened O 
Si B-FORMULA 
/ O 
Fe B-FORMULA 
multilayer O 
film O 
, O 
consisting O 
of O 
amorphous O 
silicon B-SYSTEMATIC 
layers O 
and O 
polycrystalline O 
Fe B-FORMULA 
layers O 
, O 
is O 
investigated O 
as O 
the O 
anode O 
for O 
Li B-FORMULA 
-ion O 
batteries O 
. O 
This O 
film O 
can O 
achieve O 
a O 
stable O 
cycle O 
- O 
life O 
performance O 
with O 
a O 
high O 
capacity O 
. O 
Decreasing O 
the O 
thickness O 
of O 
the O 
Fe B-FORMULA 
layer O 
can O 
lead O 
to O 
a O 
higher O 
capacity O 
, O 
which O 
is O 
related O 
to O 
the O 
fast O 
transport O 
of O 
the O 
Li B-FORMULA 
ion O 
, O 
but O 
the O 
cyclic O 
performance O 
deteriorates O 
with O 
repeated O 
cycling O 
. O 
In O 
contrast O 
, O 
increasing O 
the O 
thickness O 
of O 
the O 
Fe B-FORMULA 
buffer O 
layers O 
and O 
the O 
number O 
of O 
deposit O 
stacks O 
improves O 
the O 
cycle O 
life O 
with O 
high O 
reversibility O 
. O 
Because O 
of O 
the O 
strain O 
in O 
the O 
Si B-FORMULA 
layers O 
suppressed O 
by O 
the O 
primary O 
multilayer O 
structure O 
, O 
the O 
long O 
- O 
term O 
strength O 
is O 
preserved O 
and O 
the O 
substantial O 
fracture O 
toughness O 
is O 
enhanced O 
by O 
the O 
increasing O 
numbers O 
of O 
effective O 
grain O 
boundaries O 
and O 
interfacial O 
layers O 
. O 
In O 
addition O 
, O 
we O 
demonstrate O 
that O 
the O 
Ti B-FORMULA 
underlayer O 
promotes O 
the O 
electrochemical O 
properties O 
in O 
the O 
Si B-FORMULA 
/ O 
Fe B-FORMULA 
multilayer O 
for O 
various O 
Fe B-FORMULA 
layer O 
thicknesses O 
because O 
of O 
the O 
enhanced O 
adhesion O 
of O 
the O 
interfacial O 
electrode O 
and O 
current O 
collector O 
. O 
The O 
mechanically O 
optimized O 
Si B-FORMULA 
/ O 
Fe B-FORMULA 
multilayer O 
films O 
can O 
have O 
superior O 
cycle O 
- O 
life O 
performances O 
and O 
higher O 
capacities O 
. O 
Notably O 
, O 
the O 
16-bilayer O 
deposited O 
electrode O 
exhibits O 
an O 
excellent O 
capacity O 
retention O 
of O 
~95% O 
with O 
~204 O 
mAh O 
g(-1) O 
over O 
300 O 
cycles O 
at O 
a O 
1 O 
C O 
rate O 
. O 

of O 
corticotropin O 
to O 
glucocorticoid O 
synthesis O 
in O 
adrenocortical O 
cells O 
is O 
provided O 
by O 
the O 
expression O 
of O 
the O 
ACTH O 
receptor O 
( O 
MC2R O 
) O 
. O 
Activation O 
of O 
the O 
MC2R O 
increases O 
stimulatory O 
G O 
- O 
protein O 
, O 
adenylyl O 
cyclase O 
, O 
and O 
protein O 
kinase O 
A O 
( O 
PKA O 
) O 
activities O 
. O 
Furthermore O 
, O 
PKA O 
phosphorylates O 
transcription O 
factors O 
that O 
have O 
a O 
stimulating O 
effect O 
on O 
glucocorticoid O 
synthesis O 
. O 
Sensitivity O 
of O 
adrenocortical O 
cells O 
to O 
renin O 
/ O 
angiotensin-2 O 
is O 
conferred O 
by O 
the O 
expression O 
of O 
the O 
inhibitory O 
G O 
- O 
protein O 
- O 
linked O 
angiotensin-2 O 
type O 
1 O 
receptor O 
( O 
AT1R O 
) O 
that O 
additionally O 
associates O 
to O 
the O 
phospholipase O 
C-activating O 
G O 
- O 
protein O 
q O 
. O 
The O 
AT1R O 
is O 
connected O 
to O 
the O 
adrenal O 
potassium B-SYSTEMATIC 
sensory O 
system O 
and O 
regulates O 
calcium B-SYSTEMATIC 
influx O 
as O 
well O 
as O 
phospholipase O 
C-β O 
( O 
PLC-β O 
) O 
and O 
thus O 
calmodulin O 
kinase O 
- O 
dependent O 
transcription O 
of O 
steroidogenic O 
enzymes O 
. O 
While O 
AT1R O 
signaling O 
suppresses O 
the O 
influence O 
of O 
corticotropin O 
on O 
the O 
generation O 
of O 
cyclic B-SYSTEMATIC 
adenosine I-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
, O 
the O 
expression O 
of O 
the O 
AT1R O 
and O 
its O 
associated O 
enzyme O 
activities O 
are O 
under O 
the O 
control O 
of O 
glucocorticoids O 
. O 
Thus O 
, O 
dominance O 
of O 
one O 
of O 
the O 
two O 
signaling O 
pathways O 
is O 
dependent O 
on O 
two O 
factors O 
: O 
the O 
extracellular O 
concentration O 
of O 
their O 
ligands O 
and O 
the O 
products O 
of O 
their O 
signaling O 
pathways O 
. O 
These O 
findings O 
are O 
in O 
favor O 
of O 
the O 
hypothesis O 
that O 
the O 
centripetal O 
blood O 
flow O 
through O 
the O 
adrenal O 
gland O 
builds O 
up O 
a O 
glucocorticoid O 
gradient O 
creating O 
a O 
morphogenetic O 
field O 
along O 
which O 
adrenal O 
cortical O 
cells O 
adopt O 
different O 
functional O 
states O 
, O 
leading O 
to O 
the O 
typical O 
zonation O 
of O 
the O 
adrenal O 
cortex O 
. O 

have O 
antifungal O 
activity O 
and O 
are O 
potent O 
inhibitors O 
of O 
Candida O 
albicans O 
acetohydroxyacid O 
synthase O 
. O 

sulfonylurea B-FAMILY 
herbicides O 
exert O 
their O 
activity O 
by O 
inhibiting O 
plant O 
acetohydroxyacid O 
synthase O 
( O 
AHAS O 
) O 
, O 
the O 
first O 
enzyme O 
in O 
the O 
branched O 
- O 
chain O 
amino B-FAMILY 
acid I-FAMILY 
biosynthesis O 
pathway O 
. O 
It O 
has O 
previously O 
been O 
shown O 
that O 
if O 
the O 
gene O 
for O 
AHAS O 
is O 
deleted O 
in O 
Candida O 
albicans O 
, O 
attenuation O 
of O 
virulence O 
is O 
achieved O 
, O 
suggesting O 
AHAS O 
as O 
an O 
antifungal O 
drug O 
target O 
. O 
Herein O 
, O 
we O 
have O 
cloned O 
, O 
expressed O 
, O 
and O 
purified O 
C O 
. O 
albicans O 
AHAS O 
and O 
shown O 
that O 
several O 
sulfonylureas B-FAMILY 
are O 
inhibitors O 
of O 
this O 
enzyme O 
and O 
possess O 
antifungal O 
activity O 
. O 
The O 
most O 
potent O 
of O 
these O 
compounds O 
is O 
ethyl B-SYSTEMATIC 
2-(N-((4-iodo-6-methoxypyrimidin-2-yl)carbamoyl)sulfamoyl)benzoate I-SYSTEMATIC 
( O 
10c O 
) O 
, O 
which O 
has O 
a O 
K O 
(i) O 
value O 
of O 
3.8 O 
nM O 
for O 
C O 
. O 
albicans O 
AHAS O 
and O 
an O 
MIC₉₀ O 
of O 
0.7 O 
μg O 
/ O 
mL O 
for O 
this O 
fungus O 
in O 
cell O 
- O 
based O 
assays O 
. O 
For O 
the O 
sulfonylureas B-FAMILY 
tested O 
there O 
was O 
a O 
strong O 
correlation O 
between O 
inhibitory O 
activity O 
toward O 
C O 
. O 
albicans O 
AHAS O 
and O 
fungicidal O 
activity O 
, O 
supporting O 
the O 
hypothesis O 
that O 
AHAS O 
is O 
the O 
target O 
for O 
their O 
inhibitory O 
activity O 
within O 
the O 
cell O 
. O 

-dependent O 
ligand O 
binding O 
and O 
G O 
- O 
protein O 
signaling O 
of O 
family O 
B O 
GPCR O 
parathyroid O 
hormone O 
1 O 
receptor O 
purified O 
in O 
nanodiscs O 
. O 

mediate O 
intracellular O 
signaling O 
upon O 
external O 
stimuli O 
, O 
making O 
them O 
ideal O 
drug O 
targets O 
. O 
However O 
, O 
little O 
is O 
known O 
about O 
their O 
activation O 
mechanisms O 
due O 
to O 
the O 
difficulty O 
in O 
purification O 
. O 
Here O 
, O 
we O 
introduce O 
a O 
method O 
to O 
purify O 
GPCRs O 
in O 
nanodiscs O 
, O 
which O 
incorporates O 
GPCRs O 
into O 
lipid O 
bilayers O 
immediately O 
after O 
membrane O 
solubilization O 
, O 
followed O 
by O 
single O 
- O 
step O 
purification O 
. O 
Using O 
this O 
approach O 
, O 
we O 
purified O 
a O 
family O 
B O 
GPCR O 
, O 
parathyroid O 
hormone O 
1 O 
receptor O 
( O 
PTH1R O 
) O 
, O 
which O 
regulates O 
calcium B-SYSTEMATIC 
and O 
phosphate B-SYSTEMATIC 
homeostasis O 
and O 
is O 
a O 
drug O 
target O 
for O 
osteoporosis O 
. O 
We O 
demonstrated O 
that O 
the O 
purified O 
PTH1R O 
in O 
nanodiscs O 
can O 
bind O 
to O 
PTH(1-34) O 
and O 
activate O 
G O 
protein O 
. O 
We O 
also O 
observed O 
that O 
Ca(2+) B-FORMULA 
is O 
a O 
weak O 
agonist O 
of O 
PTH1R O 
, O 
and O 
Ca(2+) B-FORMULA 
in O 
millimolar O 
concentration O 
can O 
switch O 
PTH(1-34) O 
from O 
an O 
inverse O 
agonist O 
to O 
an O 
agonist O 
. O 
Hence O 
, O 
our O 
results O 
show O 
that O 
nanodiscs O 
are O 
a O 
viable O 
vehicle O 
for O 
GPCR O 
purification O 
, O 
enabling O 
studies O 
of O 
GPCRs O 
under O 
precise O 
experimental O 
conditions O 
without O 
interference O 
from O 
other O 
cellular O 
or O 
membrane O 
components O 
. O 

showed O 
strong O 
inhibitory O 
effects O 
towards O 
multiple O 
UDP B-ABBREVIATION 
-glucuronosyltransferase O 
( O 
UGT O 
) O 
isoform O 
- O 
catalyzed O 
4-methylumbelliferone B-SYSTEMATIC 
( O 
4-MU B-SYSTEMATIC 
) O 
glucuronidation O 
. O 

, O 
a O 
herbal O 
ingredient O 
with O 
chalcone B-FAMILY 
structure O 
, O 
has O 
been O 
speculated O 
to O 
be O 
able O 
to O 
inhibit O 
one O 
of O 
the O 
most O 
drug O 
- O 
metabolizing O 
enzymes O 
( O 
DMEs O 
) O 
UDP B-ABBREVIATION 
-glucuronosyltransferase O 
( O 
UGT O 
) O 
. O 
Therefore O 
, O 
the O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
the O 
inhibition O 
of O 
isoliquiritigenin B-TRIVIAL 
towards O 
important O 
UGT O 
isoforms O 
in O 
the O 
liver O 
and O 
intestine O 
, O 
including O 
UGT1A1 O 
, O 
1A3 O 
, O 
1A6 O 
, O 
1A7 O 
, O 
1A8 O 
, O 
1A9 O 
and O 
1A10 O 
. O 
The O 
recombinant O 
UGT O 
- O 
catalyzed O 
4-methylumbelliferone B-SYSTEMATIC 
( O 
4-MU B-SYSTEMATIC 
) O 
glucuronidation O 
was O 
used O 
as O 
probe O 
reactions O 
. O 
The O 
results O 
showed O 
that O 
100μM O 
of O 
isoliquiritigenin B-TRIVIAL 
inhibited O 
the O 
activity O 
of O 
UGT1A1 O 
, O 
UGT1A3 O 
, O 
UGT1A6 O 
, O 
UGT1A7 O 
, O 
UGT1A8 O 
, O 
UGT1A9 O 
, O 
and O 
UGT1A10 O 
by O 
95.2% O 
, O 
76.1% O 
, O 
78.9% O 
, O 
87.2% O 
, O 
67.2% O 
, O 
94.8% O 
, O 
and O 
91.7% O 
, O 
respectively O 
. O 
The O 
data O 
fitting O 
using O 
Dixon O 
plot O 
and O 
Lineweaver-Burk O 
plot O 
showed O 
that O 
the O 
inhibition O 
of O 
UGT1A1 O 
, O 
UGT1A9 O 
and O 
UGT1A10 O 
by O 
isoliquiritigenin B-TRIVIAL 
was O 
all O 
best O 
fit O 
to O 
the O 
competitive O 
inhibition O 
, O 
and O 
the O 
second O 
plot O 
using O 
the O 
slopes O 
from O 
the O 
Lineweaver-Burk O 
plot O 
versus O 
isoliquiritigenin B-TRIVIAL 
concentrations O 
was O 
used O 
to O 
calculate O 
the O 
inhibition O 
kinetic O 
parameter O 
(K(i)) O 
to O 
be O 
0.7μM O 
, O 
0.3μM O 
, O 
and O 
18.3μM O 
for O 
UGT1A1 O 
, O 
UGT1A9 O 
, O 
and O 
UGT1A10 O 
, O 
respectively O 
. O 
All O 
these O 
results O 
indicated O 
the O 
risk O 
of O 
clinical O 
application O 
of O 
isoliquiritigenin B-TRIVIAL 
on O 
the O 
drug O 
- O 
drug O 
interaction O 
and O 
other O 
possible O 
diseases O 
induced O 
by O 
the O 
inhibition O 
of O 
isoliquiritigenin B-TRIVIAL 
towards O 
these O 
UGT O 
isoforms O 
. O 

and O 
structure O 
- O 
activity O 
relationship O 
of O 
piperidine B-SYSTEMATIC 
-derived O 
non- O 
urea B-TRIVIAL 
soluble O 
epoxide B-SYSTEMATIC 
hydrolase O 
inhibitors O 
. O 

series O 
of O 
potent O 
amide B-FAMILY 
non- O 
urea B-TRIVIAL 
inhibitors O 
of O 
soluble O 
epoxide B-SYSTEMATIC 
hydrolase O 
( O 
sEH O 
) O 
is O 
disclosed O 
. O 
The O 
inhibition O 
of O 
soluble O 
epoxide B-SYSTEMATIC 
hydrolase O 
leads O 
to O 
elevated O 
levels O 
of O 
epoxyeicosatrienoic B-FAMILY 
acids I-FAMILY 
( O 
EETs B-ABBREVIATION 
) O 
, O 
and O 
thus O 
inhibitors O 
of O 
sEH O 
represent O 
one O 
of O 
a O 
novel O 
approach O 
to O 
the O 
development O 
of O 
vasodilatory O 
and O 
anti-inflammatory O 
drugs O 
. O 
Structure O 
- O 
activities O 
studies O 
guided O 
optimization O 
of O 
a O 
lead O 
compound O 
, O 
identified O 
through O 
high O 
- O 
throughput O 
screening O 
, O 
gave O 
rise O 
to O 
sub O 
- O 
nanomolar O 
inhibitors O 
of O 
human O 
sEH O 
with O 
stability O 
in O 
human O 
liver O 
microsomal O 
assay O 
suitable O 
for O 
preclinical O 
development O 
. O 

properties O 
of O 
a O 
bacterial O 
acylating O 
acetaldehyde B-SYSTEMATIC 
dehydrogenase O 
: O 
evidence O 
for O 
several O 
active O 
oligomeric O 
states O 
and O 
coenzyme O 
A O 
activation O 
upon O 
binding O 
. O 

the O 
last O 
decade O 
, O 
two O 
unrelated O 
aldehyde B-SYSTEMATIC 
dehydrogenase O 
( O 
ALDH O 
) O 
superfamilies O 
, O 
i.e O 
. O 
the O 
phosphorylating O 
and O 
non-phosphorylating O 
superfamilies O 
, O 
were O 
known O 
to O 
catalyze O 
the O 
oxidation O 
of O 
aldehydes B-FAMILY 
to O 
activated O 
or O 
non-activated O 
acids O 
. O 
However O 
, O 
a O 
third O 
one O 
was O 
discovered O 
by O 
the O 
crystal O 
structure O 
of O 
a O 
bifunctional O 
enzyme O 
4-hydroxy-2-ketovalerate B-SYSTEMATIC 
aldolase O 
/ O 
acylating O 
acetaldehyde B-SYSTEMATIC 
dehydrogenase O 
( O 
DmpFG O 
) O 
from O 
Pseudomonas O 
sp O 
. O 
strain O 
CF600 O 
( O 
Manjasetty O 
et O 
al O 
. O 
, O 
Proc O 
. O 
Natl O 
. O 
Acad O 
. O 
Sci O 
. O 
USA O 
100 O 
( O 
2003 O 
) O 
6992-6997 O 
) O 
. O 
Indeed O 
, O 
DmpF O 
exhibits O 
a O 
non-phosphorylating O 
CoA B-ABBREVIATION 
-dependent O 
ALDH O 
activity O 
, O 
but O 
is O 
structurally O 
related O 
to O 
the O 
phosphorylating O 
superfamily O 
. O 
In O 
this O 
study O 
, O 
we O 
undertook O 
the O 
characterization O 
of O 
the O 
catalytic O 
and O 
structural O 
properties O 
of O 
MhpEF O 
from O 
Escherichia O 
coli O 
, O 
an O 
ortholog O 
of O 
DmpFG O 
in O 
which O 
MhpF O 
converts O 
acetaldehyde B-SYSTEMATIC 
, O 
produced O 
by O 
the O 
cleavage O 
of O 
4-hydroxy-2-ketovalerate B-SYSTEMATIC 
by O 
MhpE O 
, O 
into O 
acetyl-CoA B-SYSTEMATIC 
. O 
The O 
kinetic O 
data O 
obtained O 
under O 
steady O 
- O 
state O 
and O 
pre O 
- O 
steady O 
- O 
state O 
conditions O 
show O 
that O 
the O 
aldehyde B-SYSTEMATIC 
dehydrogenase O 
, O 
MhpF O 
, O 
is O 
active O 
as O 
a O 
monomer O 
, O 
a O 
unique O 
feature O 
relative O 
to O 
the O 
phosphorylating O 
and O 
non-phosphorylating O 
ALDH O 
superfamilies O 
. O 
Our O 
results O 
also O 
reveal O 
that O 
the O 
catalytic O 
properties O 
of O 
MhpF O 
are O 
not O 
dependent O 
on O 
its O 
oligomeric O 
state O 
, O 
supporting O 
the O 
hypothesis O 
of O 
a O 
structurally O 
and O 
catalytically O 
independent O 
entity O 
. O 
Moreover O 
, O 
the O 
transthioesterification O 
is O 
shown O 
to O 
be O 
rate O 
- O 
limiting O 
and O 
, O 
when O 
compared O 
with O 
a O 
chemical O 
model O 
, O 
its O 
catalytic O 
efficiency O 
is O 
increased O 
10(4)-fold O 
. O 
Therefore O 
, O 
CoA B-ABBREVIATION 
binding O 
to O 
MhpF O 
increases O 
its O 
reactivity O 
and O 
optimizes O 
its O 
positioning O 
relative O 
to O 
the O 
thioacylenzyme O 
intermediate O 
, O 
thus O 
enabling O 
the O 
formation O 
of O 
an O 
efficient O 
deacylation O 
complex O 
. O 

dependent O 
differences O 
in O 
the O 
regulation O 
of O 
hippocampal O 
steroid B-FAMILY 
hormones O 
and O 
receptor O 
genes O 
: O 
relations O 
to O 
motivation O 
and O 
cognition O 
in O 
male O 
rats O 
. O 

and O 
estrogenic O 
functions O 
are O 
age O 
- O 
dependently O 
involved O 
in O 
the O 
modulation O 
of O 
learning O 
, O 
memory O 
and O 
mood O 
in O 
female O 
humans O 
and O 
animals O 
. O 
However O 
, O 
the O 
investigation O 
of O 
estrogenic O 
effects O 
in O 
males O 
has O 
been O 
largely O 
neglected O 
. O 
Therefore O 
, O 
we O 
investigated O 
the O 
hippocampal O 
gene O 
expression O 
of O 
estrogen B-FAMILY 
receptors O 
α O 
and O 
β O 
( O 
ERα O 
, O 
β O 
) O 
in O 
8-week- O 
old O 
, O 
12-week- O 
old O 
and O 
24-week- O 
old O 
male O 
rats O 
. O 
To O 
control O 
for O 
possible O 
interactions O 
between O 
the O 
expression O 
of O 
the O 
estrogen B-FAMILY 
receptor O 
genes O 
and O 
other O 
learning O 
- O 
related O 
steroid B-FAMILY 
receptors O 
, O 
androgen B-FAMILY 
receptors O 
( O 
AR O 
) O 
, O 
corticosterone B-TRIVIAL 
-binding O 
glucocorticoid O 
receptors O 
( O 
GR O 
) O 
and O 
mineralocorticoid O 
receptors O 
( O 
MR O 
) O 
were O 
also O 
measured O 
. O 
Furthermore O 
, O 
the O 
concentrations O 
of O 
the O 
ligands O 
17β-estradiol B-SYSTEMATIC 
, O 
testosterone B-TRIVIAL 
and O 
corticosterone B-TRIVIAL 
were O 
measured O 
. O 
The O 
spatial O 
training O 
was O 
conducted O 
in O 
a O 
hole O 
- O 
board O 
. O 
The O 
8-week- O 
old O 
rats O 
exhibited O 
higher O 
levels O 
of O 
general O 
activity O 
and O 
exploration O 
during O 
the O 
training O 
and O 
performed O 
best O 
with O 
respect O 
to O 
spatial O 
learning O 
and O 
memory O 
, O 
whereas O 
no O 
difference O 
was O 
found O 
between O 
the O 
12-week- O 
old O 
and O 
24-week- O 
old O 
rats O 
. O 
The O 
trained O 
8-week- O 
old O 
rats O 
exhibited O 
increased O 
gene O 
expression O 
of O 
ERα O 
compared O 
with O 
the O 
untrained O 
rats O 
in O 
this O 
age O 
group O 
as O 
well O 
as O 
the O 
trained O 
12-week- O 
old O 
and O 
24-week- O 
old O 
rats O 
. O 
The O 
concentrations O 
of O 
estradiol B-TRIVIAL 
and O 
testosterone B-TRIVIAL 
, O 
however O 
, O 
were O 
generally O 
higher O 
in O 
the O 
24-week- O 
old O 
rats O 
than O 
in O 
the O 
8-week- O 
old O 
and O 
12-week- O 
old O 
rats O 
. O 
The O 
ERα O 
mRNA O 
concentrations O 
correlated O 
positively O 
with O 
behavior O 
that O 
indicate O 
general O 
learning O 
motivation O 
. O 
These O 
results O 
suggest O 
a O 
specific O 
role O 
of O 
ERα O 
in O 
the O 
age O 
- O 
related O 
differences O 
in O 
motivation O 
and O 
subsequent O 
success O 
in O 
the O 
task O 
. O 
Thus O 
, O 
estrogen B-FAMILY 
and O 
estrogenic O 
functions O 
may O 
play O 
a O 
more O 
prominent O 
role O 
in O 
young O 
male O 
behavior O 
and O 
development O 
than O 
has O 
been O 
previously O 
assumed O 
. O 

scrolling O 
of O 
SiGe B-FORMULA 
/ O 
Si B-FORMULA 
/ O 
Cr B-FORMULA 
nanoribbon O 
on O 
Si B-FORMULA 
( O 
111 O 
) O 
surfaces O 
controlled O 
by O 
two O 
- O 
fold O 
rotational O 
symmetry O 
underetching O 
. O 

controllable O 
fabrication O 
of O 
self O 
- O 
scrolling O 
SiGe B-FORMULA 
/ O 
Si B-FORMULA 
/ O 
Cr B-FORMULA 
helical O 
nanoribbons O 
on O 
Si B-FORMULA 
( O 
111 O 
) O 
substrates O 
is O 
investigated O 
. O 
The O 
initial O 
lateral O 
etching O 
profile O 
of O 
the O 
Si B-FORMULA 
( O 
111 O 
) O 
substrates O 
shows O 
a O 
2-fold O 
rotational O 
symmetry O 
using O 
4% O 
ammonia B-SYSTEMATIC 
solution O 
, O 
which O 
provides O 
guidance O 
for O 
initial O 
scrolling O 
of O 
one O 
- O 
end O 
- O 
fixed O 
nanoribbons O 
to O 
form O 
helical O 
structures O 
. O 
The O 
chirality O 
of O 
the O 
SiGe B-FORMULA 
/ O 
Si B-FORMULA 
/ O 
Cr B-FORMULA 
helices O 
with O 
isotropic O 
Young's O 
moduli O 
is O 
governed O 
by O 
the O 
anisotropic O 
underetching O 
in O 
the O 
initial O 
stage O 
, O 
which O 
can O 
be O 
precisely O 
judged O 
, O 
as O 
the O 
orientation O 
of O 
the O 
ribbon O 
is O 
predesigned O 
. O 
Furthermore O 
, O 
the O 
helicity O 
angle O 
and O 
radius O 
of O 
the O 
formed O 
helices O 
are O 
investigated O 
by O 
the O 
lateral O 
etching O 
behavior O 
and O 
Cosserat O 
curve O 
theory O 
of O 
the O 
Si B-FORMULA 
( O 
111 O 
) O 
substrates O 
, O 
respectively O 
, O 
which O 
are O 
consistent O 
with O 
the O 
experimental O 
data O 
. O 
The O 
present O 
work O 
provides O 
the O 
scrolling O 
rule O 
of O 
nanoribbons O 
with O 
an O 
isotropic O 
Young's O 
modulus O 
and O 
anisotropic O 
underetching O 
in O 
the O 
formation O 
of O 
micro- O 
/ O 
nanohelices O 
. O 

of O 
multidrug O 
resistance O 
in O 
cancer O 
cells O 
by O 
chelidonine B-TRIVIAL 
and O 
Chelidonium O 
majus O 
alkaloids O 
. O 

cells O 
often O 
develop O 
multidrug O 
resistance O 
( O 
MDR O 
) O 
which O 
is O 
a O 
multidimensional O 
problem O 
involving O 
several O 
mechanisms O 
and O 
targets O 
. O 
This O 
study O 
demonstrates O 
that O 
chelidonine B-TRIVIAL 
and O 
an O 
alkaloid O 
extract O 
from O 
Chelidonium O 
majus O 
, O 
which O 
contains O 
protoberberine B-MULTIPLE 
and I-MULTIPLE 
benzo[c]phenanthridine I-MULTIPLE 
alkaloids I-MULTIPLE 
, O 
has O 
the O 
ability O 
to O 
overcome O 
MDR O 
of O 
different O 
cancer O 
cell O 
lines O 
through O 
interaction O 
with O 
ABC-transporters O 
, O 
CYP3A4 O 
and O 
GST O 
, O 
by O 
induction O 
of O 
apoptosis O 
, O 
and O 
cytotoxic O 
effects O 
. O 
Chelidonine B-TRIVIAL 
and O 
the O 
alkaloid O 
extract O 
inhibited O 
P-gp O 
/ O 
MDR1 O 
activity O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
in O 
Caco-2 O 
and O 
CEM O 
/ O 
ADR5000 O 
and O 
reversed O 
their O 
doxorubicin B-TRIVIAL 
resistance O 
. O 
In O 
addition O 
, O 
chelidonine B-TRIVIAL 
and O 
the O 
alkaloid O 
extract O 
inhibited O 
the O 
activity O 
of O 
the O 
drug O 
modifying O 
enzymes O 
CYP3A4 O 
and O 
GST O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
The O 
alkaloids O 
induced O 
apoptosis O 
in O 
MDR O 
cells O 
which O 
was O 
accompanied O 
by O 
an O 
activation O 
of O 
caspase-3 O 
, O 
-8,-6 O 
/ O 
9 O 
, O 
and O 
phosphatidyl B-FAMILY 
serine I-FAMILY 
( O 
PS O 
) O 
exposure O 
. O 
cDNA O 
arrays O 
were O 
applied O 
to O 
identify O 
differentially O 
expressed O 
genes O 
after O 
treatment O 
with O 
chelidonine B-TRIVIAL 
and O 
the O 
alkaloid O 
extract O 
. O 
The O 
expression O 
analysis O 
identified O 
a O 
common O 
set O 
of O 
regulated O 
genes O 
related O 
to O 
apoptosis O 
, O 
cell O 
cycle O 
, O 
and O 
drug O 
metabolism O 
. O 
Treatment O 
of O 
Caco-2 O 
cells O 
with O 
50 O 
μg O 
/ O 
ml O 
alkaloid O 
extract O 
and O 
50 O 
μM O 
chelidonine B-TRIVIAL 
for O 
up O 
to O 
48 O 
h O 
resulted O 
in O 
a O 
significant O 
decrease O 
in O 
mRNA O 
levels O 
of O 
P-gp O 
/ O 
MDR1 O 
, O 
MRP1 O 
, O 
BCRP O 
, O 
CYP3A4 O 
, O 
GST O 
, O 
and O 
hPXR O 
and O 
in O 
a O 
significant O 
increase O 
in O 
caspase-3 O 
and O 
caspase-8 O 
mRNA O 
. O 
Thus O 
, O 
chelidonine B-TRIVIAL 
is O 
a O 
promising O 
model O 
compound O 
for O 
overcoming O 
MDR O 
and O 
for O 
enhancing O 
cytotoxicity O 
of O 
chemotherapeutics O 
, O 
especially O 
against O 
leukaemia O 
cells O 
. O 
Its O 
efficacy O 
needs O 
to O 
be O 
confirmed O 
in O 
animal O 
models O 
. O 

of O 
arsenic B-SYSTEMATIC 
resistant O 
bacteria O 
from O 
arsenic B-SYSTEMATIC 
rich O 
groundwater O 
of O 
West O 
Bengal O 
, O 
India O 
. O 

- O 
four O 
arsenic B-SYSTEMATIC 
( O 
As B-FORMULA 
) O 
resistant O 
bacteria O 
isolated O 
from O 
an O 
arsenic B-SYSTEMATIC 
rich O 
groundwater O 
sample O 
of O 
West O 
Bengal O 
were O 
characterized O 
to O 
investigate O 
their O 
potential O 
role O 
in O 
subsurface O 
arsenic B-SYSTEMATIC 
mobilization O 
. O 
Among O 
the O 
isolated O 
strains O 
predominance O 
of O 
genera O 
Agrobacterium O 
/ O 
Rhizobium O 
, O 
Ochrobactrum O 
and O 
Achromobacter O 
which O 
could O 
grow O 
chemolitrophically O 
and O 
utilize O 
arsenic B-SYSTEMATIC 
as O 
electron O 
donor O 
were O 
detected O 
. O 
Higher O 
tolerance O 
to O 
As(3+) B-FORMULA 
[ O 
maximum O 
tolerable O 
concentration O 
( O 
MTC O 
) O 
: O 
≥ O 
10 O 
mM O 
] O 
, O 
As B-FORMULA 
( O 
5+ O 
) O 
( O 
MTC O 
: O 
≥ O 
100 O 
mM O 
) O 
and O 
other O 
heavy O 
metals O 
like O 
Cu(2+) B-FORMULA 
, O 
Cr(2+) B-FORMULA 
, O 
Ni(2+) B-FORMULA 
etc O 
. O 
( O 
MTC O 
: O 
≥ O 
10 O 
mM O 
) O 
, O 
presence O 
of O 
arsenate B-SYSTEMATIC 
reductase O 
and O 
siderophore O 
was O 
frequently O 
observed O 
among O 
the O 
isolates O 
. O 
Ability O 
to O 
produce O 
arsenite B-SYSTEMATIC 
oxidase O 
and O 
phosphatase O 
enzyme O 
was O 
detected O 
in O 
50 O 
and O 
34 O 
% O 
of O 
the O 
isolates O 
, O 
respectively O 
. O 
Although O 
no O 
direct O 
correlation O 
among O 
taxonomic O 
identity O 
of O 
bacterial O 
strains O 
and O 
their O 
metabolic O 
abilities O 
as O 
mentioned O 
above O 
was O 
apparent O 
, O 
several O 
isolates O 
affiliated O 
to O 
genera O 
Ochrobactrum O 
, O 
Achromobacter O 
and O 
unclassified O 
Rhizobiaceae O 
members O 
were O 
found O 
to O 
be O 
highly O 
resistant O 
to O 
As(3+) B-FORMULA 
and O 
As(5+) B-FORMULA 
and O 
positive O 
for O 
all O 
the O 
test O 
properties O 
. O 
Arsenate B-SYSTEMATIC 
reductase O 
activity O 
was O 
found O 
to O 
be O 
conferred O 
by O 
arsC O 
gene O 
, O 
which O 
in O 
many O 
strains O 
was O 
coupled O 
with O 
arsenite B-SYSTEMATIC 
efflux O 
gene O 
arsB O 
as O 
well O 
. O 
Phylogenetic O 
incongruence O 
between O 
the O 
16S O 
rRNA O 
and O 
ars O 
genes O 
lineages O 
indicated O 
possible O 
incidence O 
of O 
horizontal O 
gene O 
transfer O 
for O 
ars O 
genes O 
. O 
Based O 
on O 
the O 
results O 
we O 
propose O 
that O 
under O 
the O 
prevailing O 
low O 
nutrient O 
condition O 
inhabitant O 
bacteria O 
capable O 
of O 
using O 
inorganic O 
electron O 
donors O 
play O 
a O 
synergistic O 
role O 
wherein O 
siderophores O 
and O 
phosphatase O 
activities O 
facilitate O 
the O 
release O 
of O 
sediment O 
bound O 
As(5+) B-FORMULA 
, O 
which O 
is O 
subsequently O 
reduced O 
by O 
arsenate B-SYSTEMATIC 
reductase O 
resulting O 
into O 
the O 
mobilization O 
of O 
As(3+) B-FORMULA 
in O 
groundwater O 
. O 

1 O 
and O 
phase O 
2 O 
drug O 
metabolism O 
and O 
bile B-FAMILY 
acid I-FAMILY 
production O 
of O 
HepaRG O 
cells O 
in O 
a O 
bioartificial O 
liver O 
in O 
absence O 
of O 
dimethyl B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
. O 

human O 
liver O 
cell O 
line O 
HepaRG O 
has O 
been O 
recognized O 
as O 
a O 
promising O 
source O 
for O 
in O 
vitro O 
testing O 
of O 
metabolism O 
and O 
toxicity O 
of O 
compounds O 
. O 
However O 
, O 
currently O 
the O 
hepatic O 
differentiation O 
of O 
these O 
cells O 
relies O 
on O 
exposure O 
to O 
dimethylsulfoxide B-SYSTEMATIC 
( O 
DMSO B-ABBREVIATION 
) O 
, O 
which O 
, O 
as O 
a O 
side O 
effect O 
, O 
has O 
a O 
cytotoxic O 
effect O 
and O 
represses O 
an O 
all O 
- O 
round O 
hepatic O 
functionality O 
. O 
The O 
AMC-bioartificial O 
liver O 
( O 
AMC-BAL O 
) O 
is O 
a O 
three O 
- O 
dimensional O 
bioreactor O 
that O 
has O 
previously O 
been O 
shown O 
to O 
upregulate O 
various O 
liver O 
functions O 
of O 
cultured O 
cells O 
. O 
We O 
therefore O 
cultured O 
HepaRG O 
cells O 
in O 
the O 
AMC-BAL O 
without O 
DMSO B-ABBREVIATION 
and O 
characterized O 
the O 
drug O 
metabolism O 
. O 
Within O 
14 O 
days O 
of O 
culture O 
, O 
the O 
HepaRG-AMC-BALs O 
contained O 
highly O 
polarized O 
viable O 
liver O 
- O 
like O 
tissue O 
with O 
heterogeneous O 
expression O 
of O 
CYP3A4 O 
. O 
We O 
found O 
a O 
substantial O 
metabolism O 
of O 
the O 
tested O 
substrates O 
, O 
ranging O 
from O 
26% O 
( O 
UDP B-ABBREVIATION 
-glucuronosyltransferase O 
1A1 O 
) O 
, O 
47% O 
( O 
CYP3A4 O 
) O 
, O 
to O 
240% O 
( O 
CYP2C9 O 
) O 
of O 
primary O 
human O 
hepatocytes O 
. O 
The O 
CYP3A4 O 
activity O 
could O 
be O 
induced O 
2-fold O 
by O 
rifampicin B-TRIVIAL 
, O 
whereas O 
CYP2C9 O 
activity O 
remained O 
equally O 
high O 
. O 
The O 
HepaRG-AMC-BAL O 
secreted O 
bile B-FAMILY 
acids I-FAMILY 
at O 
43% O 
the O 
rate O 
of O 
primary O 
human O 
hepatocytes O 
and O 
demonstrated O 
hydroxylation O 
, O 
conjugation O 
, O 
and O 
transport O 
of O 
bile B-FAMILY 
salts I-FAMILY 
. O 
Concluding O 
, O 
culturing O 
HepaRG O 
cells O 
in O 
the O 
AMC-BAL O 
yields O 
substantial O 
phase O 
1 O 
and O 
phase O 
2 O 
drug O 
metabolism O 
, O 
while O 
maintaining O 
high O 
viability O 
, O 
rendering O 
DMSO B-ABBREVIATION 
addition O 
superfluous O 
for O 
the O 
promotion O 
of O 
drug O 
metabolism O 
. O 
Therefore O 
, O 
AMC-BAL O 
culturing O 
makes O 
the O 
HepaRG O 
cells O 
more O 
suitable O 
for O 
testing O 
metabolism O 
and O 
toxicity O 
of O 
drugs O 
. O 

in O 
the O 
act O 
: O 
The O 
FRET-Capture O 
approach O 
exploits O 
a O 
bound O 
solvatochromic O 
fluorophore O 
, O 
4-N,N-dimethylamino-1,8-naphthalimide B-SYSTEMATIC 
, O 
as O 
a O 
FRET O 
donor O 
in O 
both O 
inter- O 
and O 
intramolecular O 
energy O 
transfer O 
. O 
A O 
unique O 
feature O 
of O 
this O 
method O 
is O 
the O 
additional O 
level O 
of O 
signal O 
selectivity O 
as O 
the O 
FRET O 
signal O 
is O 
only O 
turned O 
on O 
when O 
the O 
donor O 
is O 
specifically O 
bound O 
to O 
the O 
protein O 
of O 
interest O 
, O 
eliminating O 
high O 
background O 
and O 
false O 
positive O 
signals O 
. O 

: O 
a O 
new O 
fluorophore O 
displaying O 
both O 
remarkable O 
solvatochromism O 
and O 
crystalline O 
- O 
induced O 
emission O 
. O 

series O 
of O 
17,17-dialkyl-3,14-diaryltetrabenzofluorenes B-FAMILY 
were O 
efficiently O 
prepared O 
by O 
using O 
Suzuki-Miyaura O 
cross O 
- O 
coupling O 
reactions O 
of O 
the O 
corresponding O 
3,14-dibromo B-FAMILY 
derivatives O 
. O 
Studies O 
of O 
the O 
unique O 
fluorescence O 
properties O 
of O 
these O 
compounds O 
showed O 
that O 
they O 
display O 
intense O 
blue O 
to O 
yellow O 
fluorescence O 
with O 
high O 
quantum O 
yields O 
in O 
the O 
solution O 
state O 
and O 
blue O 
to O 
orange O 
fluorescence O 
with O 
moderate O 
quantum O 
yields O 
in O 
the O 
solid O 
state O 
. O 
In O 
addition O 
, O 
the O 
fluorescence O 
wavelength O 
of O 
the O 
bis(p-nitrophenyl) B-SYSTEMATIC 
derivative O 
is O 
remarkably O 
solvent-dependent O 
in O 
a O 
manner O 
that O 
correlates O 
with O 
the O 
solvent O 
polarity O 
parameter O 
E(T)(30) O 
. O 
The O 
results O 
of O 
density O 
function O 
theory O 
calculations O 
suggest O 
that O 
the O 
intramolecular O 
charge O 
- O 
transfer O 
character O 
of O 
the O 
HOMO-LUMO O 
transition O 
is O 
responsible O 
for O 
the O 
large O 
solvent O 
effect O 
. O 
Moreover O 
, O 
addition O 
of O 
water O 
to O 
a O 
tetrahydrofuran B-SYSTEMATIC 
( O 
THF B-ABBREVIATION 
) O 
solution O 
of O 
this O 
compound O 
leads O 
to O 
quenching O 
of O 
the O 
yellow O 
fluorescence O 
owing O 
to O 
an O 
increase O 
in O 
the O 
solvent O 
polarity O 
. O 
However O 
, O 
when O 
the O 
amount O 
of O 
water O 
fraction O 
exceeds O 
70% O 
, O 
a O 
new O 
fluorescence O 
band O 
appears O 
at O 
the O 
same O 
orange O 
- O 
red O 
emission O 
wavelength O 
as O 
that O 
of O 
the O 
solid O 
- O 
state O 
fluorescence O 
. O 
This O 
observation O 
suggests O 
the O 
occurrence O 
of O 
a O 
crystallization O 
- O 
induced O 
emission O 
( O 
CIE O 
) O 
phenomenon O 
in O 
highly O 
aqueous O 
THF B-ABBREVIATION 
. O 

Synthesis O 
of O 
Double-Wall O 
a- O 
FePO4 B-FORMULA 
Nanotubes O 
and O 
their O 
LIB O 
Cathode O 
Properties O 
. O 

- O 
wall O 
amorphous O 
FePO4 B-FORMULA 
nanotubes O 
are O 
prepared O 
by O 
an O 
oil O 
- O 
phase O 
chemical O 
route O 
. O 
The O 
inward O 
diffusion O 
of O 
vacancies O 
and O 
outward O 
diffusion O 
of O 
ions O 
through O 
passivation O 
layers O 
result O 
in O 
double O 
- O 
wall O 
nanotubes O 
with O 
thin O 
walls O 
. O 
Such O 
a O 
process O 
can O 
be O 
extended O 
to O 
prepare O 
hollow O 
polydedral O 
nanocrystals O 
and O 
hollow O 
ellipsoids O 
. O 
The O 
double O 
- O 
wall O 
FePO4 B-FORMULA 
nanotubes O 
show O 
interesting O 
cathode O 
performance O 
in O 
Li B-FORMULA 
ion O 
batteries O 
. O 

surface O 
attachment O 
is O 
essential O 
for O 
growing O 
embryonic O 
stem O 
( O 
ES O 
) O 
cells O 
in O 
an O 
undifferentiated O 
state O 
. O 
It O 
is O 
challenging O 
to O 
identify O 
the O 
optimal O 
surface O 
chemistry O 
of O 
the O 
substrata O 
for O 
ES O 
cell O 
attachment O 
and O 
maintenance O 
. O 
Using O 
a O 
rapid O 
, O 
high O 
- O 
throughput O 
polymerization O 
and O 
screening O 
platform O 
with O 
a O 
comprehensive O 
library O 
of O 
66 O 
monomer O 
- O 
grafted O 
membrane O 
surfaces O 
, O 
the O 
optimal O 
substrate O 
, O 
N-[3-(dimethylamino)propyl] B-SYSTEMATIC 
methacrylamide I-SYSTEMATIC 
( O 
DMAPMA B-ABBREVIATION 
) O 
has O 
been O 
identified O 
to O 
support O 
strong O 
attachment O 
, O 
high O 
expansion O 
capacity O 
, O 
and O 
long O 
- O 
term O 
self O 
- O 
renewal O 
of O 
ES O 
cells O 
( O 
up O 
to O 
7 O 
passages O 
) O 
. O 
This O 
monomer O 
- O 
based O 
, O 
chemically O 
defined O 
, O 
scalable O 
, O 
sustainable O 
, O 
relatively O 
inexpensive O 
, O 
covalently O 
grafted O 
, O 
and O 
controllable O 
polymeric O 
substrate O 
provides O 
a O 
new O 
opportunity O 
to O 
manipulate O 
surface O 
chemistry O 
for O 
pluripotent O 
stem O 
culture O 
. O 

multiscale O 
investigation O 
was O 
carried O 
out O 
to O 
study O 
the O 
dark O 
and O 
light O 
- O 
enhanced O 
bactericidal O 
mechanisms O 
of O 
poly(phenylene B-FAMILY 
ethynylene I-FAMILY 
) I-FAMILY 
( O 
PPE B-ABBREVIATION 
) O 
- O 
based O 
cationic O 
conjugated O 
polyelectrolytes O 
( O 
CPEs O 
) O 
and O 
oligo B-FAMILY 
- I-FAMILY 
phenylene I-FAMILY 
ethynylenes I-FAMILY 
( O 
OPEs B-FAMILY 
) O 
. O 
On O 
the O 
morphological O 
scale O 
, O 
Gram O 
- O 
negative O 
E O 
. O 
coli O 
cells O 
exposed O 
to O 
CPE O 
and O 
OPE B-ABBREVIATION 
compounds O 
in O 
the O 
dark O 
show O 
damage O 
to O 
the O 
cell O 
envelope O 
, O 
plasma O 
membrane O 
, O 
and O 
in O 
some O 
cases O 
the O 
cytoplasm O 
, O 
while O 
with O 
UV-irradiation O 
, O 
E O 
. O 
coli O 
sustained O 
catastrophic O 
damages O 
to O 
both O 
the O 
cell O 
envelope O 
and O 
cytoplasm O 
. O 
In O 
contrast O 
, O 
the O 
Gram O 
- O 
positive O 
S O 
. O 
epi O 
bacteria O 
appeared O 
intact O 
when O 
exposed O 
to O 
CPE O 
and O 
OPE B-ABBREVIATION 
compounds O 
in O 
the O 
dark O 
but O 
showed O 
damages O 
to O 
the O 
cell O 
envelope O 
with O 
UV-irradiation O 
. O 
To O 
better O 
understand O 
the O 
molecular O 
basis O 
of O 
CPE- O 
and O 
OPE B-ABBREVIATION 
-induced O 
morphological O 
changes O 
and O 
damages O 
to O 
bacteria O 
, O 
we O 
investigated O 
the O 
effect O 
of O 
these O 
compounds O 
on O 
model O 
bacterial O 
plasma O 
membrane O 
and O 
bacterial O 
proteins O 
and O 
plasmid O 
DNA O 
. O 
Measurements O 
of O 
dark O 
membrane O 
perturbation O 
activity O 
of O 
the O 
CPEs O 
and O 
OPEs B-FAMILY 
using O 
model O 
lipid O 
membranes O 
support O 
a O 
carpet O 
or O 
detergent O 
- O 
like O 
mechanism O 
by O 
which O 
the O 
antimicrobial O 
compounds O 
induce O 
membrane O 
collapse O 
and O 
phase O 
transitions O 
. O 
Under O 
UV-irradiation O 
, O 
E O 
. O 
coli O 
bacteria O 
exposed O 
to O 
CPEs O 
and O 
OPEs B-FAMILY 
showed O 
covalent O 
modifications O 
and O 
damages O 
to O 
both O 
cellular O 
protein O 
and O 
plasmid O 
DNA O 
, O 
likely O 
through O 
oxidative O 
pathways O 
mediated O 
by O 
singlet O 
oxygen B-SYSTEMATIC 
and O 
subsequent O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
sensitized O 
by O 
the O 
CPE O 
and O 
OPE B-ABBREVIATION 
compounds O 
. O 
Our O 
finding O 
thus O 
show O 
that O 
the O 
antimicrobial O 
polymers O 
and O 
oligomers O 
exert O 
toxicity O 
toward O 
Gram O 
- O 
negative O 
bacteria O 
by O 
disrupting O 
the O 
morphology O 
and O 
structures O 
of O 
cell O 
envelope O 
and O 
cytoplasm O 
, O 
including O 
cellular O 
components O 
such O 
as O 
proteins O 
and O 
DNA O 
, O 
while O 
exert O 
toxicity O 
toward O 
Gram O 
- O 
positive O 
bacteria O 
by O 
binding O 
to O 
and O 
disrupting O 
just O 
the O 
cell O 
wall O 
. O 

growth O 
mechanism O 
for O 
monolithic O 
integration O 
of O 
III-V O 
on O 
silicon B-SYSTEMATIC 
. O 

heterogeneous O 
integration O 
of O 
III-V O 
optoelectronic O 
devices O 
with O 
Si B-FORMULA 
electronic O 
circuits O 
is O 
highly O 
desirable O 
because O 
it O 
will O 
enable O 
many O 
otherwise O 
unattainable O 
capabilities O 
. O 
However O 
, O 
direct O 
growth O 
of O 
III-V O 
thin O 
film O 
on O 
silicon B-SYSTEMATIC 
substrates O 
has O 
been O 
very O 
challenging O 
because O 
of O 
large O 
mismatches O 
in O 
lattice O 
constants O 
and O 
thermal O 
coefficients O 
. O 
Furthermore O 
, O 
the O 
high O 
epitaxial O 
growth O 
temperature O 
is O 
detrimental O 
to O 
transistor O 
performance O 
. O 
Here O 
, O 
we O 
present O 
a O 
detailed O 
studies O 
on O 
a O 
novel O 
growth O 
mode O 
which O 
yields O 
a O 
catalyst O 
- O 
free O 
( O 
Al B-FORMULA 
, O 
In B-FORMULA 
) O 
GaAs B-FORMULA 
nanopillar O 
laser O 
on O 
a O 
silicon B-SYSTEMATIC 
substrate O 
by O 
metal O 
- O 
organic O 
chemical O 
vapor O 
deposition O 
at O 
the O 
low O 
temperature O 
of O 
400 O 
°C O 
. O 
We O 
study O 
the O 
growth O 
and O 
misfit O 
stress O 
relaxation O 
mechanism O 
by O 
cutting O 
through O 
the O 
center O 
of O 
the O 
InGaAs B-FORMULA 
/ O 
GaAs B-FORMULA 
nanopillars O 
using O 
focused O 
ion O 
beam O 
and O 
inspecting O 
with O 
high O 
- O 
resolution O 
transmission O 
electron O 
microscopy O 
. O 
The O 
bulk O 
material O 
of O 
the O 
nanopillar O 
is O 
in O 
pure O 
wurtzite B-TRIVIAL 
crystal O 
phase O 
, O 
despite O 
the O 
6% O 
lattice O 
mismatch O 
with O 
the O 
substrate O 
, O 
with O 
all O 
stacking O 
disorders O 
well O 
confined O 
in O 
the O 
bottom O 
- O 
most O 
transition O 
region O 
and O 
terminated O 
horizontally O 
. O 
Furthermore O 
, O 
InGaAs B-FORMULA 
was O 
found O 
to O 
be O 
in O 
direct O 
contact O 
with O 
silicon B-SYSTEMATIC 
, O 
in O 
agreement O 
with O 
the O 
observed O 
crystal O 
orientation O 
alignment O 
and O 
good O 
electrical O 
conduction O 
across O 
the O 
interface O 
. O 
This O 
is O 
in O 
sharp O 
contrast O 
to O 
many O 
III-V O 
nanowires O 
on O 
silicon B-SYSTEMATIC 
which O 
are O 
observed O 
to O 
stem O 
from O 
thin O 
SiN B-FAMILY 
(x) I-FAMILY 
, O 
SiO(2) B-FORMULA 
, O 
or O 
SiO(2) B-FORMULA 
/ O 
Si B-FORMULA 
openings O 
. O 
In O 
addition O 
, O 
GaAs B-FORMULA 
was O 
found O 
to O 
grow O 
perfectly O 
as O 
a O 
shell O 
layer O 
on O 
In(0.2)Ga(0.8)As B-FORMULA 
with O 
an O 
extraordinary O 
thickness O 
, O 
which O 
is O 
15 O 
times O 
greater O 
than O 
the O 
theoretical O 
thin O 
- O 
film O 
critical O 
thickness O 
for O 
a O 
1.5% O 
lattice O 
mismatch O 
. O 
This O 
is O 
attributed O 
to O 
the O 
core O 
- O 
shell O 
radial O 
geometry O 
allowing O 
the O 
outer O 
layers O 
to O 
expand O 
and O 
release O 
the O 
strain O 
due O 
to O 
lattice O 
mismatch O 
. O 
The O 
findings O 
in O 
this O 
study O 
redefine O 
the O 
rules O 
for O 
lattice O 
- O 
mismatched O 
growth O 
on O 
heterogeneous O 
substrates O 
and O 
device O 
structure O 
design O 
. O 

comparative O 
study O 
of O 
the O 
rotational O 
dynamics O 
of O 
PF6(-) B-FORMULA 
anions O 
in O 
the O 
crystals O 
and O 
liquid O 
states O 
of O 
1-butyl-3-methylimidazolium B-SYSTEMATIC 
hexafluorophosphate I-SYSTEMATIC 
: O 
results O 
from O 
31P B-FORMULA 
NMR O 
spectroscopy O 
. O 

rotational O 
dynamics O 
of O 
the O 
hexafluorophosphate B-SYSTEMATIC 
anion O 
( O 
PF(6)(-) B-FORMULA 
) O 
in O 
the O 
crystalline O 
and O 
liquid O 
states O 
of O 
the O 
archetypal O 
room O 
temperature O 
ionic O 
liquid O 
( O 
RTIL O 
) O 
1-butyl-3-methylimidazolium B-SYSTEMATIC 
hexafluorophosphate I-SYSTEMATIC 
( O 
[C(4)mim]PF(6) B-FORMULA 
) O 
are O 
investigated O 
using O 
(31)P B-FORMULA 
NMR O 
spectroscopy O 
line O 
shape O 
analyses O 
and O 
spin O 
- O 
lattice O 
relaxation O 
time O 
measurements O 
. O 
The O 
PF(6)(-) B-FORMULA 
anion O 
performs O 
isotropic O 
rotation O 
in O 
all O 
three O 
polymorphic O 
crystals O 
phases O 
α O 
, O 
β O 
, O 
and O 
γ O 
as O 
well O 
as O 
in O 
the O 
liquid O 
state O 
with O 
a O 
characteristic O 
time O 
scale O 
that O 
ranges O 
from O 
a O 
few O 
ps O 
to O 
a O 
few O 
hundred O 
ps O 
over O 
a O 
temperature O 
range O 
of O 
180-280 O 
K O 
. O 
The O 
rotational O 
correlation O 
time O 
τ(c) O 
for O 
PF(6)(-) B-FORMULA 
rotation O 
follows O 
the O 
sequence O 
γ-phase O 
< O 
α-phase O 
≈ O 
liquid O 
< O 
β-phase O 
. O 
On O 
the O 
other O 
hand O 
, O 
in O 
the O 
liquid O 
state O 
, O 
all O 
local O 
motions O 
in O 
the O 
cation O 
as O 
well O 
as O 
its O 
global O 
rotational O 
reorientation O 
are O 
characterized O 
by O 
time O 
scales O 
that O 
are O 
slower O 
compared O 
to O 
that O 
for O 
the O 
PF(6)(-) B-FORMULA 
anion O 
rotation O 
. O 
The O 
time O 
scale O 
τ(c) O 
and O 
the O 
activation O 
energy O 
of O 
PF(6)(-) B-FORMULA 
rotation O 
in O 
this O 
RTIL O 
are O 
found O 
to O 
be O 
comparable O 
with O 
those O 
observed O 
in O 
ordinary O 
alkali O 
and O 
ammonium B-FAMILY 
salts I-FAMILY 
despite O 
the O 
large O 
counterion O 
size O 
and O 
low O 
melting O 
point O 
of O 
the O 
former O 
. O 
The O 
high O 
sphericity O 
of O 
the O 
PF(6)(-) B-FORMULA 
ion O 
is O 
hypothesized O 
to O 
play O 
an O 
important O 
role O 
in O 
the O 
decoupling O 
of O 
its O 
rotational O 
dynamics O 
that O 
appear O 
to O 
be O 
practically O 
independent O 
of O 
the O 
averaged O 
cation O 
- O 
anion O 
interaction O 
. O 

developmental O 
toxicity O 
testing O 
, O 
in O 
vitro O 
screening O 
assays O 
are O 
highly O 
needed O 
to O 
increase O 
efficiency O 
and O 
to O 
reduce O 
animal O 
use O 
. O 
A O 
promising O 
in O 
vitro O 
assay O 
is O 
the O 
cardiac O 
embryonic O 
stem O 
cell O 
test O 
( O 
ESTc O 
) O 
, O 
in O 
which O 
the O 
effect O 
of O 
developmental O 
toxicants O 
on O 
cardiomyocyte O 
differentiation O 
is O 
assessed O 
. O 
Recently O 
, O 
we O 
developed O 
a O 
neural O 
differentiation O 
variant O 
of O 
the O 
stem O 
cell O 
test O 
( O 
neural O 
embryonic O 
stem O 
cell O 
test O 
[ O 
ESTn O 
] O 
) O 
. O 
In O 
both O 
of O 
these O 
models O 
, O 
we O 
have O 
previously O 
performed O 
a O 
series O 
of O 
transcriptomic O 
studies O 
to O 
characterize O 
gene O 
expression O 
changes O 
( O 
1 O 
) O 
across O 
time O 
during O 
normal O 
differentiation O 
and O 
( O 
2 O 
) O 
in O 
response O 
to O 
a O 
series O 
of O 
developmental O 
toxicants O 
in O 
the O 
ESTn O 
and O 
ESTc O 
. O 
Here O 
, O 
using O 
the O 
cumulative O 
of O 
these O 
studies O 
, O 
we O 
compared O 
gene O 
expression O 
profiles O 
of O 
ESTn O 
and O 
ESTc O 
over O 
time O 
as O 
well O 
as O 
model O 
- O 
specific O 
changes O 
induced O 
by O 
seven O 
compounds O 
, O 
comprising O 
six O 
known O 
in O 
vivo O 
developmental O 
toxicants O 
and O 
one O 
negative O 
control O 
. O 
Time O 
- O 
related O 
gene O 
expression O 
profiles O 
showed O 
similarities O 
between O 
the O 
two O 
EST O 
systems O 
. O 
However O 
, O 
specific O 
genes O 
could O 
be O 
identified O 
changing O 
over O 
time O 
differently O 
in O 
each O 
model O 
related O 
to O 
the O 
two O 
different O 
lineages O 
of O 
differentiation O 
. O 
Interestingly O 
, O 
compound O 
- O 
induced O 
gene O 
expression O 
changes O 
were O 
generally O 
model O 
specific O 
, O 
especially O 
for O 
methylmercury B-SYSTEMATIC 
and O 
flusilazole B-TRIVIAL 
, O 
which O 
were O 
predicted O 
better O 
in O 
ESTn O 
and O 
ESTc O 
, O 
respectively O 
. O 
Valproic B-TRIVIAL 
acid I-TRIVIAL 
-induced O 
gene O 
expression O 
changes O 
were O 
most O 
comparable O 
out O 
of O 
the O 
six O 
developmental O 
toxicants O 
between O 
the O 
ESTn O 
and O 
ESTc O 
. O 
Direct O 
transcriptomic O 
comparisons O 
between O 
the O 
ESTn O 
and O 
ESTc O 
indicate O 
that O 
combined O 
transcriptomic O 
analyses O 
support O 
and O 
complement O 
each O 
other O 
. O 
Therefore O 
, O 
a O 
combined O 
approach O 
incorporating O 
ESTc O 
and O 
ESTn O 
may O 
improve O 
developmental O 
toxicant O 
detection O 
over O 
individual O 
assays O 
. O 

carbon B-SYSTEMATIC 
nanotubes O 
( O 
CNTs O 
) O 
and O 
hydrophilic O 
nanofilaments O 
such O 
as O 
oxidized O 
CNTs O 
, O 
Pd B-FORMULA 
nanowires O 
( O 
NWs O 
) O 
, O 
and O 
MnO(2) B-FORMULA 
NWs O 
are O 
transformed O 
from O 
wires O 
to O 
rings O 
by O 
a O 
general O 
methodology O 
. O 
We O 
show O 
that O 
both O 
oil O 
- O 
in O 
- O 
water O 
and O 
water O 
- O 
in O 
- O 
oil O 
emulsions O 
, O 
so O 
long O 
as O 
their O 
droplet O 
size O 
is O 
sufficiently O 
small O 
, O 
can O 
exert O 
significant O 
force O 
to O 
the O 
entrapped O 
nanostructures O 
, O 
causing O 
their O 
deformation O 
. O 
This O 
effect O 
can O 
be O 
easily O 
achieved O 
by O 
simply O 
mixing O 
a O 
few O 
solutions O 
in O 
correct O 
ratios O 
. O 
Even O 
preformed O 
oil O 
droplets O 
can O 
take O 
in O 
CNTs O 
from O 
the O 
aqueous O 
solution O 
converting O 
them O 
into O 
rings O 
, O 
indicating O 
the O 
important O 
role O 
of O 
thermodynamics O 
: O 
The O 
question O 
here O 
is O 
not O 
if O 
the O 
droplets O 
can O 
exert O 
sufficient O 
force O 
to O 
bend O 
the O 
nanofilaments O 
, O 
because O 
their O 
random O 
vibration O 
may O 
be O 
already O 
doing O 
it O 
. O 
As O 
long O 
as O 
the O 
difference O 
in O 
solvation O 
energy O 
is O 
large O 
enough O 
for O 
a O 
nanofilament O 
, O 
it O 
would O 
" O 
want O 
" O 
to O 
move O 
away O 
from O 
the O 
bulk O 
solution O 
and O 
fit O 
inside O 
tiny O 
droplets O 
, O 
even O 
at O 
the O 
cost O 
of O 
induced O 
strain O 
energy O 
. O 
That O 
said O 
, O 
the O 
specific O 
interactions O 
between O 
a O 
droplet O 
and O 
a O 
filament O 
are O 
also O 
of O 
importance O 
. O 
For O 
example O 
, O 
when O 
an O 
oil O 
droplet O 
rapidly O 
shrinks O 
in O 
size O 
, O 
it O 
can O 
compress O 
the O 
entrapped O 
CNTs O 
in O 
multiple O 
stages O 
into O 
structures O 
with O 
higher O 
curvatures O 
( O 
thus O 
higher O 
strain O 
) O 
than O 
that O 
of O 
a O 
circular O 
ring O 
, O 
which O 
has O 
minimal O 
induced O 
strain O 
inside O 
a O 
spherical O 
droplet O 
. O 

of O 
raspberry O 
- O 
like O 
polymer O 
particles O 
by O 
a O 
heterocoagulation O 
technique O 
utilizing O 
hydrogen B-SYSTEMATIC 
bonding O 
interactions O 
between O 
steric O 
stabilizers O 
. O 

polystyrene B-SYSTEMATIC 
particles O 
stabilized O 
by O 
poly(acrylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PAA B-ABBREVIATION 
) O 
( O 
L- O 
PS(PAA) B-ABBREVIATION 
) O 
( O 
as O 
the O 
core O 
) O 
and O 
small O 
polystyrene B-SYSTEMATIC 
particles O 
stabilized O 
by O 
poly(vinyl B-FAMILY 
pyrrolidone I-FAMILY 
) I-FAMILY 
( O 
PVP B-ABBREVIATION 
) O 
( O 
S- O 
PS(PVP) B-ABBREVIATION 
) O 
( O 
as O 
the O 
corona O 
) O 
were O 
successfully O 
used O 
to O 
prepare O 
raspberry O 
- O 
like O 
particles O 
by O 
a O 
heterocoagulation O 
technique O 
utilizing O 
the O 
hydrogen B-SYSTEMATIC 
bonding O 
interaction O 
between O 
PAA B-ABBREVIATION 
and O 
PVP B-ABBREVIATION 
. O 
The O 
coverage O 
of O 
L- O 
PS(PAA) B-ABBREVIATION 
by O 
S- O 
PS(PVP) B-ABBREVIATION 
could O 
be O 
controlled O 
by O 
adding O 
PVP B-ABBREVIATION 
homopolymer O 
to O 
the O 
L- O 
PS(PAA) B-ABBREVIATION 
dispersion O 
and O 
by O 
changing O 
the O 
molecular O 
weight O 
of O 
the O 
stabilizers O 
. O 
Moreover O 
, O 
the O 
heterocoagulation O 
of O 
large O 
poly(methyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
particles O 
stabilized O 
by O 
PAA B-ABBREVIATION 
( O 
L- O 
PMMA(PAA) B-ABBREVIATION 
) O 
and O 
S- O 
PS(PVP) B-ABBREVIATION 
particles O 
was O 
also O 
accomplished O 
, O 
resulting O 
in O 
the O 
formation O 
of O 
L- O 
PMMA(PAA) B-ABBREVIATION 
-core O 
/ O 
S- O 
PS(PVP) B-ABBREVIATION 
-corona O 
raspberry O 
- O 
like O 
composite O 
particles O 
. O 
These O 
results O 
suggested O 
that O 
the O 
raspberry O 
- O 
like O 
particles O 
composed O 
of O 
various O 
polymer O 
particles O 
could O 
be O 
formed O 
by O 
the O 
heterocoagulation O 
technique O 
utilizing O 
the O 
hydrogen B-SYSTEMATIC 
bonding O 
interaction O 
. O 

of O 
B-doped B-TRIVIAL 
graphene I-TRIVIAL 
nanoplatelets O 
using O 
a O 
solution O 
process O 
and O 
their O 
supercapacitor O 
applications O 
. O 

modified O 
graphene B-TRIVIAL 
( O 
CMG O 
) O 
nanoplatelets O 
have O 
shown O 
great O 
promise O 
in O 
various O 
applications O 
due O 
to O 
their O 
electrical O 
properties O 
and O 
high O 
surface O 
area O 
. O 
Chemical O 
doping O 
is O 
one O 
of O 
the O 
most O 
effective O 
methods O 
to O 
tune O 
the O 
electronic O 
properties O 
of O 
graphene B-TRIVIAL 
materials O 
. O 
In O 
this O 
work O 
, O 
novel O 
B B-FORMULA 
-doped O 
nanoplatelets O 
( O 
borane B-SYSTEMATIC 
-reduced O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
B B-FORMULA 
-rG- O 
O B-FORMULA 
) O 
were O 
produced O 
on O 
a O 
large O 
scale O 
via O 
the O 
reduction O 
of O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
by O 
a O 
borane B-SYSTEMATIC 
- O 
tetrahydrofuran B-SYSTEMATIC 
adduct O 
under O 
reflux O 
, O 
and O 
their O 
use O 
for O 
supercapacitor O 
electrodes O 
was O 
studied O 
. O 
This O 
is O 
the O 
first O 
report O 
on O 
the O 
production O 
of O 
B-doped B-TRIVIAL 
graphene I-TRIVIAL 
nanoplatelets O 
from O 
a O 
solution O 
process O 
and O 
on O 
the O 
use O 
of O 
B-doped B-TRIVIAL 
graphene I-TRIVIAL 
materials O 
in O 
supercapacitors O 
. O 
The O 
B B-FORMULA 
-rG- O 
O B-FORMULA 
had O 
a O 
high O 
specific O 
surface O 
area O 
of O 
466 O 
m(2) O 
/ O 
g O 
and O 
showed O 
excellent O 
supercapacitor O 
performance O 
including O 
a O 
high O 
specific O 
capacitance O 
of O 
200 O 
F O 
/ O 
g O 
in O 
aqueous O 
electrolyte O 
as O 
well O 
as O 
superior O 
surface O 
area O 
- O 
normalized O 
capacitance O 
to O 
typical O 
carbon B-SYSTEMATIC 
-based O 
supercapacitor O 
materials O 
and O 
good O 
stability O 
after O 
4500 O 
cycles O 
. O 
Two- O 
and O 
three O 
- O 
electrode O 
cell O 
measurements O 
showed O 
that O 
energy O 
storage O 
in O 
the O 
B B-FORMULA 
-rG- O 
O B-FORMULA 
supercapacitors O 
was O 
contributed O 
by O 
ion O 
adsorption O 
on O 
the O 
surface O 
of O 
the O 
nanoplatelets O 
in O 
addition O 
to O 
electrochemical O 
redox O 
reactions O 
. O 

aggregation O 
behavior O 
of O 
a O 
carboxylate B-SYSTEMATIC 
gemini O 
surfactant O 
with O 
a O 
long O 
rigid O 
spacer O 
in O 
aqueous O 
solution O 
. O 

new O 
gemini O 
surfactant O 
with O 
a O 
long O 
and O 
rigid O 
spacer O 
, O 
O,O'-bis(sodium B-SYSTEMATIC 
2-dodecylcarboxylate)-p-dibenzenediol I-SYSTEMATIC 
( O 
referred O 
to O 
as O 
C(12)φ(2)C(12) B-FORMULA 
) O 
, O 
has O 
been O 
synthesized O 
. O 
Its O 
aggregation O 
in O 
aqueous O 
solution O 
has O 
been O 
studied O 
using O 
static O 
and O 
dynamic O 
light O 
scattering O 
measurements O 
. O 
The O 
homologue O 
O,O'-bis(sodium B-SYSTEMATIC 
2-dodecylcarboxylate)-p-benzenediol I-SYSTEMATIC 
( O 
C(12)φC(12) B-FORMULA 
) O 
whose O 
spacer O 
only O 
contains O 
a O 
single O 
phenyl B-SYSTEMATIC 
group O 
was O 
also O 
examined O 
for O 
comparison O 
. O 
Dynamic O 
light O 
scattering O 
( O 
DLS O 
) O 
revealed O 
the O 
unexpected O 
existence O 
of O 
large O 
aggregates O 
in O 
the O 
solution O 
of O 
C(12)φ(2)C(12) B-FORMULA 
. O 
However O 
, O 
C(12)φC(12) B-FORMULA 
showed O 
rather O 
normal O 
aggregation O 
behavior O 
. O 
Both O 
the O 
results O 
of O 
intrinsic O 
viscosity O 
and O 
light O 
scattering O 
demonstrated O 
a O 
loose O 
structure O 
for O 
the O 
large O 
aggregates O 
of O 
C(12)φ(2)C(12) B-FORMULA 
. O 
This O 
behavior O 
was O 
attributed O 
to O 
an O 
extending O 
configuration O 
of O 
C(12)φ(2)C(12) B-FORMULA 
with O 
the O 
two O 
alkyl B-FAMILY 
tails O 
stretching O 
toward O 
the O 
solution O 
due O 
to O 
the O 
rigidity O 
of O 
the O 
long O 
spacer O 
. O 
The O 
large O 
network O 
- O 
like O 
aggregate O 
formation O 
was O 
an O 
inevitable O 
outcome O 
of O 
spontaneously O 
reducing O 
the O 
energy O 
of O 
the O 
system O 
. O 
Freeze O 
- O 
fracture O 
transmission O 
electron O 
microscopy O 
( O 
FF-TEM O 
) O 
images O 
and O 
(1)H B-FORMULA 
NMR O 
measurements O 
supported O 
this O 
speculation O 
. O 
Due O 
to O 
the O 
columnar O 
- O 
like O 
molecular O 
geometry O 
, O 
the O 
large O 
network O 
- O 
like O 
aggregates O 
were O 
directly O 
transformed O 
into O 
rodlike O 
micelles O 
with O 
increasing O 
surfactant O 
concentration O 
. O 
Depending O 
on O 
further O 
micellar O 
growth O 
, O 
the O 
wormlike O 
micelles O 
were O 
finally O 
formed O 
as O 
confirmed O 
by O 
rheological O 
measurements O 
. O 

cationic O 
polymer O 
nanobrush O 
was O 
synthesized O 
, O 
attached O 
to O 
a O 
MALDI O 
target O 
, O 
and O 
used O 
for O 
the O 
fractionation O 
of O 
peptides O 
and O 
proteins O 
based O 
on O 
their O 
pI O 
, O 
prior O 
to O 
analysis O 
by O 
MALDI-MS O 
. O 
The O 
cationic O 
polymer O 
nanobrush O 
was O 
synthesized O 
on O 
a O 
gold O 
substrate O 
by O 
AIBN B-ABBREVIATION 
photoinitiated O 
polymerization O 
, O 
using O 
a O 
70 O 
: O 
30 O 
ratio O 
of O 
2-aminoethyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
AEMA B-ABBREVIATION 
) O 
: O 
N-isopropylacrylamide B-SYSTEMATIC 
( O 
NIPAAM B-ABBREVIATION 
) O 
. O 
This O 
brush O 
showed O 
selectivity O 
for O 
adsorption O 
of O 
acidic O 
peptides O 
and O 
proteins O 
and O 
allowed O 
fractionation O 
of O 
simple O 
two O 
- O 
component O 
mixtures O 
to O 
be O 
completed O 
in O 
less O 
than O 
10 O 
min O 
. O 
The O 
brush O 
- O 
adsorbed O 
biomolecules O 
were O 
recovered O 
by O 
treating O 
the O 
nanobrush O 
with O 
ammonium B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
, O 
which O 
effectively O 
collapsed O 
the O 
brush O 
, O 
thereby O 
releasing O 
the O 
trapped O 
compounds O 
for O 
MALDI O 
MS O 
analysis O 
. O 
These O 
results O 
demonstrate O 
that O 
nanobrush O 
can O 
serve O 
as O 
a O 
convenient O 
platform O 
for O 
rapid O 
fractionation O 
of O 
biomolecules O 
prior O 
to O 
analysis O 
by O 
MALDI-MS O 
. O 

measurement O 
of O 
Dirac O 
point O 
energy O 
at O 
the O 
graphene B-TRIVIAL 
/ O 
oxide B-SYSTEMATIC 
interface O 
. O 

report O 
the O 
direct O 
measurement O 
of O 
the O 
Dirac O 
point O 
, O 
the O 
Fermi O 
level O 
, O 
and O 
the O 
work O 
function O 
of O 
graphene B-TRIVIAL 
by O 
performing O 
internal O 
photoemission O 
measurements O 
on O 
a O 
graphene B-TRIVIAL 
/ O 
SiO(2) B-FORMULA 
/ O 
Si B-FORMULA 
structure O 
with O 
a O 
unique O 
optical O 
- O 
cavity O 
enhanced O 
test O 
structure O 
. O 
A O 
complete O 
electronic O 
band O 
alignment O 
at O 
the O 
graphene B-TRIVIAL 
/ O 
SiO(2) B-FORMULA 
/ O 
Si B-FORMULA 
interfaces O 
is O 
accurately O 
established O 
. O 
The O 
observation O 
of O 
enhanced O 
photoemission O 
from O 
a O 
one O 
- O 
atom O 
thick O 
graphene B-TRIVIAL 
layer O 
was O 
possible O 
by O 
taking O 
advantage O 
of O 
the O 
constructive O 
optical O 
interference O 
in O 
the O 
SiO(2) B-FORMULA 
cavity O 
. O 
The O 
photoemission O 
yield O 
was O 
found O 
to O 
follow O 
the O 
well O 
- O 
known O 
linear O 
density O 
- O 
of O 
- O 
states O 
dispersion O 
in O 
the O 
vicinity O 
of O 
the O 
Dirac O 
point O 
. O 
At O 
the O 
flat O 
band O 
condition O 
, O 
the O 
Fermi O 
level O 
was O 
extracted O 
and O 
found O 
to O 
reside O 
3.3 O 
eV O 
± O 
0.05 O 
eV O 
below O 
the O 
bottom O 
of O 
the O 
SiO(2) B-FORMULA 
conduction O 
band O 
. O 
When O 
combined O 
with O 
the O 
shift O 
of O 
the O 
Fermi O 
level O 
from O 
the O 
Dirac O 
point O 
, O 
we O 
are O 
able O 
to O 
ascertain O 
the O 
position O 
of O 
the O 
Dirac O 
point O 
at O 
3.6 O 
eV O 
± O 
0.05 O 
eV O 
with O 
respect O 
to O 
the O 
bottom O 
of O 
the O 
SiO(2) B-FORMULA 
conduction O 
band O 
edge O 
, O 
yielding O 
a O 
work O 
function O 
of O 
4.5 O 
eV O 
± O 
0.05 O 
eV O 
which O 
is O 
in O 
an O 
excellent O 
agreement O 
with O 
theory O 
. O 
The O 
accurate O 
determination O 
of O 
the O 
work O 
function O 
of O 
graphene B-TRIVIAL 
is O 
of O 
significant O 
importance O 
to O 
the O 
engineering O 
of O 
graphene B-TRIVIAL 
-based O 
devices O 
, O 
and O 
the O 
measurement O 
technique O 
we O 
have O 
advanced O 
in O 
this O 
Letter O 
will O 
have O 
significant O 
impact O 
on O 
numerous O 
applications O 
for O 
emerging O 
graphene B-TRIVIAL 
-like O 
2-dimensional O 
material O 
systems O 
. O 

dimeric O 
form O 
of O 
N-methoxycarbonyl-2-amino-1,8-naphthyridine B-SYSTEMATIC 
bound O 
to O 
the O 
A-A O 
mismatch O 
in O 
the O 
CAG O 
/ O 
CAG O 
base O 
triad O 
in O 
dsRNA O 
. O 

dimeric O 
form O 
of O 
N-methoxycarbonyl-2-amino-1,8-naphthyridine B-SYSTEMATIC 
( O 
MCND B-ABBREVIATION 
) O 
connected O 
at O 
the O 
C2 O 
position O 
with O 
a O 
three O 
- O 
atom O 
linker O 
was O 
examined O 
for O 
the O 
binding O 
to O 
mismatches O 
in O 
double O 
stranded O 
RNA O 
. O 
Despite O 
the O 
fully O 
complementary O 
hydrogen B-SYSTEMATIC 
bonding O 
groups O 
to O 
guanine B-TRIVIAL 
, O 
MCND B-ABBREVIATION 
did O 
not O 
bind O 
to O 
guanine B-TRIVIAL 
- O 
guanine B-TRIVIAL 
mismatch O 
but O 
did O 
to O 
adenine B-TRIVIAL 
- O 
adenine B-TRIVIAL 
mismatch O 
. O 
The O 
base O 
pairs O 
flanking O 
the O 
mismatch O 
had O 
weak O 
effect O 
on O 
the O 
binding O 
, O 
with O 
showing O 
the O 
strongest O 
binding O 
to O 
the O 
A-A O 
mismatch O 
in O 
the O 
CAG O 
/ O 
CAG O 
sequence O 
. O 
The O 
A-A O 
mismatch O 
in O 
the O 
GAC O 
/ O 
GAC O 
sequence O 
was O 
a O 
poor O 
substrate O 
for O 
the O 
MCND B-ABBREVIATION 
binding O 
. O 
A O 
monomeric O 
derivative O 
of O 
MCND B-ABBREVIATION 
and O 
another O 
derivative O 
lacking O 
a O 
methylcarbamate B-SYSTEMATIC 
group O 
showed O 
negligilble O 
binding O 
to O 
the O 
A-A O 
mismatch O 
and O 
the O 
sequence O 
selectivity O 
. O 
These O 
results O 
are O 
important O 
clues O 
for O 
the O 
better O 
molecular O 
design O 
of O 
RNA O 
binding O 
small O 
molecules O 
. O 

( O 
NTD B-ABBREVIATION 
) O 
integrase O 
inhibitors O 
: O 
N1 O 
protio O 
and O 
methyl B-SYSTEMATIC 
combination O 
substituent O 
effects O 
with O 
C3 O 
amide B-FAMILY 
groups O 
. O 

effects O 
of O 
a O 
series O 
of O 
N1 O 
protio O 
and O 
methyl B-SYSTEMATIC 
naphthyridinone I-SYSTEMATIC 
HIV-1 O 
integrase O 
strand O 
- O 
transfer O 
inhibitors O 
has O 
been O 
explored O 
. O 
The O 
effects O 
of O 
combinations O 
of O 
the O 
N1 O 
substituent O 
and O 
C3 O 
amide B-FAMILY 
groups O 
was O 
extensively O 
studied O 
to O 
compare O 
enzyme O 
inhibition O 
, O 
antiviral O 
activity O 
and O 
protein O 
binding O 
effects O 
on O 
potency O 
. O 
The O 
impact O 
of O 
substitution O 
on O 
ligand O 
efficiency O 
was O 
considered O 
and O 
several O 
compounds O 
were O 
advanced O 
into O 
in O 
vivo O 
pharmacokinetic O 
studies O 
ultimately O 
leading O 
to O 
the O 
clinical O 
candidate O 
GSK364735 B-IDENTIFIER 
. O 

of O 
Escherichia O 
coli O 
nucleotide B-FAMILY 
excision O 
repair O 
genes O 
after O 
cisplatin B-TRIVIAL 
-induced O 
damage O 
. O 

is O 
currently O 
used O 
in O 
tumor O 
chemotherapy O 
to O 
induce O 
the O 
death O 
of O 
malignant O 
cells O 
through O 
blockage O 
of O 
DNA O 
replication O 
. O 
It O 
is O 
a O 
commonly O 
used O 
chemotherapeutic O 
agent O 
binding O 
mono- O 
or O 
bifunctionally O 
to O 
guanines B-FAMILY 
in O 
DNA O 
. O 
Escherichia O 
coli O 
K12 O 
mutant O 
strains O 
deficient O 
in O 
nucleotide B-FAMILY 
excision O 
repair O 
( O 
NER O 
) O 
were O 
submitted O 
to O 
increasing O 
concentrations O 
of O 
cisplatin B-TRIVIAL 
, O 
and O 
the O 
results O 
revealed O 
that O 
uvrA O 
and O 
uvrB O 
mutants O 
are O 
sensitive O 
to O 
this O 
agent O 
, O 
while O 
uvrC O 
and O 
cho O 
mutants O 
remain O 
as O 
the O 
wild O 
type O 
strain O 
. O 
The O 
time O 
required O 
for O 
both O 
gene O 
expression O 
turn O 
- O 
off O 
and O 
return O 
to O 
normal O 
weight O 
DNA O 
in O 
wild O 
- O 
type O 
E O 
. O 
coli O 
was O 
not O 
accomplished O 
even O 
after O 
4 O 
h O 
post O 
- O 
treatment O 
with O 
cisplatin B-TRIVIAL 
, O 
while O 
the O 
same O 
process O 
takes O 
place O 
within O 
1.5 O 
h O 
after O 
ultraviolet O 
radiation O 
( O 
UV O 
) O 
. O 
Besides O 
, O 
a O 
heavily O 
damaging O 
action O 
of O 
cisplatin B-TRIVIAL 
can O 
be O 
seen O 
not O 
only O 
by O 
persistent O 
nicks O 
on O 
genomic O 
DNA O 
, O 
but O 
also O 
by O 
NER O 
gene O 
expression O 
exceeding O 
manifold O 
that O 
seen O 
after O 
equivalent O 
lethal O 
doses O 
of O 
UV O 
. O 
Moreover O 
, O 
cisplatin B-TRIVIAL 
caused O 
an O 
increase O 
in O 
uvrB O 
gene O 
expression O 
from O 
its O 
putative O 
upstream O 
promoter O 
P3 O 
in O 
an O 
SOS O 
- O 
independent O 
manner O 
. O 

thirteen O 
week O 
feeding O 
study O 
was O 
conducted O 
by O 
feeding O 
young O 
adult O 
male O 
and O 
female O 
Sprague O 
Dawley O 
[Crl:CD®(SD)] O 
rats O 
diets O 
containing O 
grain O 
from O 
genetically O 
modified O 
( O 
GM O 
) O 
DP-ØØ4114-3 O 
maize O 
that O 
was O 
either O 
untreated O 
( O 
4114 O 
) O 
or O 
treated O 
in O 
the O 
field O 
with O 
glufosinate B-SYSTEMATIC 
ammonium I-SYSTEMATIC 
( O 
4114GLU O 
) O 
. O 
Control O 
rats O 
were O 
fed O 
diets O 
containing O 
the O 
same O 
concentration O 
of O 
near O 
isogenic O 
, O 
non-GM O 
maize O 
grain O 
( O 
91 O 
) O 
or O 
one O 
of O 
three O 
types O 
of O 
commercially O 
available O 
non-GM O 
maize O 
grain O 
. O 
At O 
the O 
end O 
of O 
the O 
in O 
- O 
life O 
phase O 
, O 
renal O 
tubule O 
tumors O 
were O 
reported O 
in O 
two O 
male O 
rats O 
consuming O 
diets O 
containing O 
4114 O 
maize O 
grain O 
. O 
An O 
expert O 
panel O 
of O 
pathologists O 
was O 
convened O 
as O 
a O 
Pathology O 
Working O 
Group O 
( O 
PWG O 
) O 
to O 
review O 
coded O 
kidney O 
histology O 
sections O 
from O 
control O 
( O 
91 O 
) O 
and O 
treated O 
( O 
4114 O 
and O 
4114GLU O 
) O 
male O 
rats O 
. O 
The O 
objectives O 
were O 
for O 
the O 
panel O 
to O 
characterize O 
the O 
histopathologic O 
findings O 
and O 
to O 
interpret O 
their O 
relationship O 
to O 
consumption O 
of O 
the O 
indicated O 
diet O 
. O 
The O 
PWG O 
concluded O 
unanimously O 
that O 
the O 
kidney O 
tumors O 
were O 
characteristic O 
of O 
amphophilic O 
- O 
vacuolar O 
( O 
AV O 
) O 
tumors O 
and O 
AV O 
atypical O 
tubular O 
hyperplasia O 
which O 
represent O 
a O 
distinctive O 
phenotype O 
that O 
has O 
been O 
reported O 
to O 
occur O 
sporadically O 
in O 
young O 
Sprague O 
Dawley O 
Rats O 
. O 
The O 
PWG O 
determined O 
that O 
the O 
neoplasms O 
and O 
atypical O 
tubular O 
hyperplasias O 
were O 
multicentric O 
and O 
bilateral O 
which O 
typifies O 
tumors O 
of O 
familial O 
origin O 
. O 
Degenerative O 
/ O 
regenerative O 
or O 
cytotoxic O 
changes O 
consistent O 
with O 
nephrotoxicity O 
leading O 
to O 
tumor O 
induction O 
were O 
not O 
observed O 
in O 
these O 
rats O 
and O 
thus O 
supports O 
the O 
conclusion O 
that O 
tumors O 
were O 
unrelated O 
to O 
consumption O 
of O 
the O 
test O 
diet O 
. O 
It O 
was O 
the O 
unanimous O 
opinion O 
of O 
the O 
PWG O 
that O 
the O 
proliferative O 
renal O 
tubule O 
cell O 
lesions O 
were O 
spontaneous O 
and O 
not O 
related O 
to O 
consumption O 
of O 
diets O 
containing O 
4114 O 
maize O 
grain O 
. O 

Gd B-FORMULA 
-based O 
MRI O 
contrast O 
agents O 
are O 
optimal O 
for O 
encapsulation O 
into O 
phosphatidyldiglycerol B-TRIVIAL 
-based O 
thermosensitive O 
liposomes O 
. O 

liposomes O 
( O 
TSL O 
) O 
with O 
encapsulated O 
magnetic O 
resonance O 
imaging O 
( O 
MRI O 
) O 
longitudinal O 
relaxation O 
time O 
(T(1)) O 
contrast O 
agents O 
( O 
CAs O 
) O 
have O 
been O 
proposed O 
for O 
MRI O 
assisted O 
interventional O 
thermotherapy O 
in O 
solid O 
tumors O 
. O 
Here O 
the O 
feasibility O 
of O 
6 O 
clinically O 
approved O 
CAs O 
( O 
Gd-DTPA B-FORMULA 
, O 
Gd-BOPTA B-FORMULA 
, O 
Gd-DOTA B-FORMULA 
, O 
Gd-BT-DO3A B-FORMULA 
, O 
Gd-DTPA-BMA B-FORMULA 
, O 
and O 
Gd-HP-DO3A B-FORMULA 
) O 
for O 
formulation O 
into O 
TSL O 
was O 
investigated O 
. O 
CAs O 
were O 
passively O 
encapsulated O 
with O 
323 O 
mOs O 
kg(-1) O 
into O 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
/ O 
1,2-distearoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
/ O 
1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol B-SYSTEMATIC 
50 O 
/ O 
20 O 
/ O 
30 O 
( O 
mol O 
/ O 
mol O 
) O 
TSL O 
( O 
DPPG(2) B-ABBREVIATION 
-TSL O 
) O 
to O 
obtain O 
stable O 
formulations O 
. O 
T(1) O 
relaxivity O 
(r(1)) O 
and O 
diffusive O 
permeability O 
to O 
water O 
(P(d)) O 
across O 
the O 
membrane O 
were O 
determined O 
. O 
Shelf O 
life O 
at O 
4°C O 
was O 
investigated O 
by O 
determining O 
lysolipid O 
content O 
up O 
to O 
10 O 
weeks O 
after O 
preparation O 
. O 
All O 
preparations O 
were O 
monodispersed O 
with O 
comparable O 
small O 
vesicle O 
sizes O 
( O 
~135 O 
nm O 
) O 
. O 
Neither O 
zeta O 
potential O 
nor O 
phase O 
transition O 
temperature O 
(T(m)) O 
was O 
affected O 
by O 
the O 
CA O 
. O 
The O 
formulations O 
showed O 
an O 
increase O 
in O 
r(1) O 
in O 
the O 
temperature O 
range O 
between O 
38 O 
and O 
44°C O 
. O 
This O 
correlated O 
with O 
the O 
phase O 
transition O 
. O 
Change O 
in O 
r(1) O 
(Δr(1)=r(1)(45.3°C)-r(1)(37.6°C)) O 
and O 
r(1) O 
( O 
T O 
< O 
T(m) O 
) O 
depended O 
on O 
the O 
encapsulated O 
CA O 
concentration O 
. O 
P(d) O 
at O 
T≤37.6°C O 
was O 
lower O 
for O 
DPPG(2)-TSL O 
encapsulating O 
non-ionic O 
Gd-BT-DO3A O 
, O 
Gd-DTPA-BMA O 
, O 
and O 
Gd-HP-DO3A O 
. O 
All O 
CAs O 
except O 
Gd-DTPA-BMA O 
induced O 
phospholipid O 
hydrolysis O 
, O 
which O 
resulted O 
in O 
unwanted O 
CA O 
leakage O 
. O 
The O 
serum O 
proteins O 
HSA O 
and O 
IgG O 
both O 
contributed O 
to O 
the O 
increase O 
of O 
MRI O 
signal O 
at O 
30°C O 
by O 
increasing O 
P(d) O 
. O 
A O 
high O 
concentration O 
of O 
encapsulated O 
CA O 
is O 
a O 
prerequisite O 
to O 
achieve O 
a O 
sufficiently O 
high O 
Δr(1) O 
during O 
heat O 
triggered O 
CA O 
release O 
combined O 
with O 
a O 
low O 
r(1) O 
at O 
37°C O 
. O 
Hence O 
, O 
the O 
optimal O 
CA O 
is O 
characterized O 
by O 
a O 
non-ionic O 
structure O 
and O 
a O 
low O 
contribution O 
to O 
osmolality O 
. O 

inhibits O 
H2O2 B-FORMULA 
-induced O 
vascular O 
permeability O 
through O 
suppressing O 
the O 
phosphorylation O 
of O 
caveolin-1 O 
. O 

, O 
a O 
naturally O 
occurring O 
monoflavonoid B-FAMILY 
extracted O 
from O 
the O 
root O 
of O 
Scutellaria O 
baicalensis O 
Georgi O 
, O 
has O 
been O 
reported O 
for O 
its O 
anti-oxidant O 
activity O 
. O 
However O 
, O 
it O 
is O 
still O 
unclear O 
whether O 
wogonin B-TRIVIAL 
can O 
inhibit O 
oxidant O 
- O 
induced O 
vascular O 
permeability O 
. O 
In O 
this O 
study O 
, O 
we O 
evaluated O 
the O 
effects O 
of O 
wogonin B-TRIVIAL 
on O 
H2O2 B-FORMULA 
-induced O 
vascular O 
permeability O 
in O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
( O 
HUVECs O 
) O 
. O 
We O 
found O 
that O 
wogonin B-TRIVIAL 
can O 
suppress O 
the O 
H2O2 B-FORMULA 
-stimulated O 
actin O 
remodeling O 
and O 
albumin O 
uptake O 
of O 
HUVECs O 
, O 
as O 
well O 
as O 
transendothelial O 
cell O 
migration O 
of O 
the O 
human O 
breast O 
carcinoma O 
cell O 
MDA-MB-231 O 
. O 
The O 
mechanism O 
revealed O 
that O 
wogonin B-TRIVIAL 
inhibited O 
H2O2 B-FORMULA 
-induced O 
phosphorylation O 
of O 
caveolin-1 O 
( O 
cav-1 O 
) O 
associating O 
with O 
the O 
suppression O 
of O 
stabilization O 
of O 
VE-cadherin O 
and O 
β-catenin O 
. O 
Moreover O 
, O 
wogonin B-TRIVIAL 
repressed O 
anisomycin B-TRIVIAL 
-induced O 
phosphorylation O 
of O 
p38 O 
, O 
cav-1 O 
and O 
vascular O 
permeability O 
. O 
These O 
results O 
suggested O 
that O 
wogonin B-TRIVIAL 
could O 
inhibit O 
H2O2 B-FORMULA 
-induced O 
vascular O 
permeability O 
by O 
downregulating O 
the O 
phosphorylation O 
of O 
cav-1 O 
, O 
and O 
that O 
it O 
might O 
have O 
a O 
therapeutic O 
potential O 
for O 
the O 
diseases O 
associated O 
with O 
the O 
development O 
of O 
both O 
oxidant O 
and O 
vascular O 
permeability O 
. O 

this O 
study O 
, O 
we O 
evaluated O 
the O 
effect O 
of O 
the O 
Crotalus O 
durissus O 
terrificus O 
( O 
Cdt O 
) O 
venom O 
on O 
the O 
chronic O 
paw O 
edema O 
induced O 
by O 
the O 
injection O 
of O 
bacillus O 
Calmette-Guérin O 
( O 
BCG O 
) O 
into O 
the O 
footpad O 
of O 
mice O 
. O 
The O 
BCG O 
injection O 
evoked O 
chronic O 
edema O 
, O 
which O 
was O 
significantly O 
diminished O 
in O 
animals O 
treated O 
subcutaneously O 
( O 
s.c O 
. O 
) O 
with O 
Cdt O 
venom O 
1 O 
h O 
before O 
or O 
after O 
the O 
BCG O 
injection O 
. O 
This O 
inhibition O 
persisted O 
throughout O 
the O 
evaluation O 
period O 
( O 
15 O 
days O 
) O 
. O 
In O 
mice O 
injected O 
with O 
Cdt O 
venom O 
6 O 
or O 
11 O 
days O 
after O 
injection O 
of O 
BCG O 
, O 
we O 
observed O 
a O 
significant O 
reduction O 
in O 
edema O 
only O 
in O 
the O 
period O 
after O 
the O 
venom O 
injection O 
. O 
While O 
studying O 
possible O 
mechanisms O 
involved O 
in O 
this O 
inhibition O 
, O 
we O 
observed O 
that O 
pre O 
- O 
treatment O 
with O 
dexamethasone B-TRIVIAL 
, O 
zileuton B-TRIVIAL 
or O 
Boc2 B-FORMULA 
( O 
a O 
selective O 
antagonist O 
of O 
formyl B-SYSTEMATIC 
peptide O 
receptors O 
) O 
, O 
but O 
not O 
with O 
indomethacin B-TRIVIAL 
, O 
canceled O 
out O 
the O 
inhibitory O 
effect O 
of O 
Cdt O 
venom O 
on O 
the O 
edema O 
induced O 
by O 
BCG O 
. O 
These O 
results O 
strongly O 
suggest O 
that O 
this O 
rattlesnake O 
venom O 
can O 
stimulate O 
the O 
generation O 
of O 
mediators O 
from O 
the O 
lipoxygenase O 
pathway O 
, O 
which O 
can O 
down O 
- O 
regulate O 
this O 
chronic O 
inflammatory O 
edema O 
. O 
Using O 
fractionated O 
venom O 
, O 
the O 
results O 
indicated O 
that O 
crotoxin O 
was O 
the O 
only O 
component O 
of O 
Cdt O 
venom O 
responsible O 
for O 
this O 
inhibitory O 
effect O 
. O 
These O 
results O 
indicated O 
that O 
crotoxin O 
, O 
the O 
main O 
toxin O 
of O 
the O 
C O 
. O 
durissus O 
terrificus O 
venom O 
, O 
has O 
a O 
significant O 
inhibitory O 
effect O 
on O 
BCG-induced O 
chronic O 
edema O 
, O 
possibly O 
by O 
generating O 
anti-inflammatory O 
mediators O 
from O 
the O 
lipoxygenase O 
pathway O 
. O 

of O 
genotoxicity O 
in O 
leukocytes O 
and O 
testis O 
following O 
intra O 
- O 
vasal O 
contraception O 
with O 
RISUG O 
and O 
its O 
reversal O 
by O 
DMSO B-ABBREVIATION 
and O 
NaHCO3 B-FORMULA 
in O 
Wistar O 
albino O 
rats O 
. O 

of O 
genotoxicity O 
of O 
RISUG(®) O 
- O 
a O 
vas O 
based O 
contraceptive O 
, O 
was O 
carried O 
out O 
in O 
the O 
present O 
study O 
. O 
Animals O 
were O 
allotted O 
into O 
groups O 
of O 
sham O 
operated O 
control O 
, O 
vas O 
occlusion O 
with O 
RISUG O 
( O 
5-7μl O 
) O 
for O 
360 O 
days O 
and O 
reversal O 
by O 
DMSO B-ABBREVIATION 
( O 
250-500μl O 
) O 
and O 
5% O 
NaHCO3 B-FORMULA 
( O 
500μl O 
) O 
. O 
Blood O 
samples O 
and O 
testis O 
were O 
collected O 
at O 
360 O 
days O 
of O 
vas O 
occlusion O 
and O 
90 O 
days O 
of O 
vas O 
occlusion O 
reversal O 
for O 
comet O 
analysis O 
. O 
Hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
induced O 
samples O 
were O 
used O 
as O 
positive O 
control O 
. O 
Olive O 
moment O 
, O 
tail O 
length O 
and O 
percentage O 
DNA O 
in O 
tail O 
were O 
recorded O 
with O 
minimum O 
variation O 
in O 
all O 
groups O 
for O 
both O 
leukocytes O 
and O 
testis O 
. O 
When O 
compared O 
with O 
positive O 
control O 
the O 
variation O 
was O 
highly O 
significant O 
for O 
both O 
20μM O 
and O 
50μM O 
H2O2 B-FORMULA 
( O 
p O 
< O 
0.001 O 
) O 
. O 
It O 
is O 
concluded O 
that O 
vas O 
occlusion O 
with O 
RISUG O 
at O 
the O 
contraceptive O 
dose O 
regimen O 
is O 
not O 
associated O 
with O 
genotoxicity O 
in O 
leukocytes O 
or O 
the O 
testis O 
of O 
pre- O 
and O 
post O 
- O 
reversal O 
rats O 
. O 

of O 
developmental O 
lead O 
exposure O 
on O 
expression O 
of O 
DNA O 
methyltransferases O 
and O 
methyl B-SYSTEMATIC 
cytosine I-SYSTEMATIC 
-binding O 
proteins O 
in O 
hippocampus O 
. O 

exposure O 
to O 
lead O 
( O 
Pb B-FORMULA 
) O 
has O 
adverse O 
effects O 
on O 
cognitive O 
functioning O 
and O 
behavior O 
that O 
can O 
persist O 
into O 
adulthood O 
. O 
Exposures O 
that O 
occur O 
during O 
fetal O 
or O 
early O 
life O 
periods O 
may O 
produce O 
changes O 
in O 
brain O 
related O 
to O 
physiological O 
re O 
- O 
programming O 
from O 
an O 
epigenetic O 
influence O 
such O 
as O 
altered O 
DNA O 
methylation O 
status O 
. O 
Since O 
DNA O 
methylation O 
is O 
regulated O 
by O 
DNA O 
methyltransferases O 
and O 
methyl B-SYSTEMATIC 
cytosine I-SYSTEMATIC 
-binding O 
proteins O 
, O 
this O 
study O 
assessed O 
the O 
extent O 
to O 
which O 
developmental O 
Pb B-FORMULA 
exposure O 
might O 
affect O 
expression O 
of O 
these O 
proteins O 
in O 
the O 
hippocampus O 
. O 
Long O 
Evans O 
dams O 
were O 
fed O 
chow O 
with O 
or O 
without O 
added O 
Pb B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
0 O 
, O 
150 O 
, O 
375 O 
, O 
750 O 
ppm O 
) O 
prior O 
to O 
breeding O 
and O 
remained O 
on O 
the O 
same O 
diet O 
through O 
weaning O 
( O 
perinatal O 
exposure O 
group O 
) O 
. O 
Other O 
animals O 
were O 
exposed O 
to O 
the O 
same O 
doses O 
of O 
Pb B-FORMULA 
but O 
exposure O 
started O 
on O 
postnatal O 
day O 
1 O 
and O 
continued O 
through O 
weaning O 
( O 
early O 
postnatal O 
exposure O 
group O 
) O 
. O 
All O 
animals O 
were O 
euthanized O 
on O 
day O 
55 O 
and O 
hippocampi O 
were O 
removed O 
. O 
Western O 
blot O 
analyses O 
showed O 
significant O 
effects O 
of O 
Pb B-FORMULA 
exposure O 
on O 
DNMT1 O 
, O 
DNMT3a O 
, O 
and O 
MeCP2 O 
expression O 
, O 
with O 
effects O 
often O 
seen O 
at O 
the O 
lowest O 
level O 
of O 
exposure O 
and O 
modified O 
by O 
sex O 
and O 
developmental O 
window O 
of O 
Pb B-FORMULA 
exposure O 
. O 
These O 
data O 
suggest O 
potential O 
epigenetic O 
effects O 
of O 
developmental O 
Pb B-FORMULA 
exposure O 
on O 
DNA O 
methylation O 
mediated O 
at O 
least O 
in O 
part O 
through O 
dysregulation O 
of O 
methyltransferases O 
. O 

formulation O 
approaches O 
to O 
improve O 
solubility O 
and O 
drug O 
release O 
from O 
fixed O 
dose O 
combinations O 
: O 
Case O 
examples O 
pioglitazone B-TRIVIAL 
/ O 
glimepiride B-TRIVIAL 
and O 
ezetimibe B-TRIVIAL 
/ O 
simvastatin B-TRIVIAL 
. O 

aqueous O 
solubility O 
is O 
often O 
a O 
limiting O 
aspect O 
to O 
the O 
bioavailability O 
of O 
poorly O 
soluble O 
, O 
but O 
highly O 
permeable O 
drugs O 
( O 
class O 
II O 
compounds O 
according O 
to O 
the O 
Biopharmaceutics O 
Classification O 
System O 
- O 
BCS O 
) O 
administered O 
in O 
single O 
drug O 
products O 
or O 
as O 
fixed O 
dose O 
combinations O 
. O 
The O 
aim O 
of O 
the O 
present O 
series O 
of O 
experiments O 
was O 
to O 
improve O 
the O 
solubility O 
and O 
dissolution O 
of O 
two O 
fixed O 
dose O 
combination O 
formulations O 
( O 
FDC O 
) O 
, O 
each O 
consisting O 
of O 
two O 
BCS O 
class O 
II O 
drugs O 
. O 
The O 
first O 
FDC O 
contained O 
a O 
weak O 
acid O 
( O 
glimepiride B-TRIVIAL 
) O 
and O 
a O 
weak O 
base O 
( O 
pioglitazone B-TRIVIAL 
) O 
, O 
while O 
the O 
second O 
FDC O 
contained O 
two O 
compounds O 
( O 
simvastatin B-TRIVIAL 
and O 
ezetimibe B-TRIVIAL 
) O 
that O 
are O 
essentially O 
non-ionised O 
over O 
the O 
physiological O 
pH O 
range O 
. O 
The O 
formulation O 
approaches O 
used O 
were O 
as O 
follows O 
: O 
( O 
a O 
) O 
an O 
inclusion O 
complex O 
with O 
hydroxypropyl-β-cyclodextrin B-SYSTEMATIC 
( O 
HP-β-CD B-ABBREVIATION 
) O 
, O 
( O 
b O 
) O 
a O 
solid O 
dispersion O 
with O 
Soluplus B-TRIVIAL 
® O 
, O 
a O 
new O 
highly O 
water O 
soluble O 
polyvinyl B-SYSTEMATIC 
caprolactam I-SYSTEMATIC 
- O 
polyvinyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
- O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
graft O 
copolymer O 
and O 
( O 
c O 
) O 
a O 
ternary O 
inclusion O 
complex O 
with O 
both O 
HP-β-CD B-ABBREVIATION 
and O 
Soluplus B-TRIVIAL 
® O 
. O 
Solid O 
state O 
analysis O 
was O 
performed O 
for O 
the O 
pure O 
drugs O 
, O 
and O 
all O 
formulations O 
using O 
powder O 
X-ray O 
diffraction O 
( O 
PXRD O 
) O 
. O 
The O 
in O 
vitro O 
performance O 
of O 
the O 
different O 
formulation O 
approaches O 
, O 
as O 
gauged O 
by O 
solubility O 
and O 
dissolution O 
experiments O 
, O 
was O 
compared O 
with O 
that O 
of O 
the O 
marketed O 
products O 
containing O 
the O 
respective O 
fixed O 
dose O 
combinations O 
, O 
Tandemact B-TRIVIAL 
® O 
30mg O 
/ O 
4mg O 
tablets O 
and O 
Inegy B-TRIVIAL 
® O 
10mg O 
/ O 
40mg O 
tablets O 
. O 
The O 
FDCs O 
of O 
the O 
pure O 
drugs O 
and O 
the O 
marketed O 
products O 
showed O 
very O 
poor O 
( O 
and O 
especially O 
for O 
pioglitazone B-TRIVIAL 
, O 
strongly O 
pH-dependent O 
) O 
dissolution O 
. O 
By O 
contrast O 
, O 
all O 
binary O 
and O 
ternary O 
inclusion O 
complexes O 
showed O 
enhanced O 
release O 
for O 
both O 
drugs O 
in O 
the O 
FDC O 
. O 
The O 
ternary O 
inclusion O 
complex O 
generated O 
synergistic O 
improvement O 
in O 
solubility O 
and O 
dissolution O 
results O 
for O 
both O 
FDCs O 
. O 
For O 
example O 
, O 
in O 
pH O 
conditions O 
of O 
the O 
fasted O 
small O 
intestine O 
after O 
a O 
test O 
duration O 
of O 
240min O 
, O 
we O 
observed O 
100% O 
dissolution O 
of O 
both O 
drugs O 
from O 
the O 
ternary O 
pioglitazone B-TRIVIAL 
/ O 
glimepiride B-TRIVIAL 
( O 
30mg O 
/ O 
4mg O 
) O 
complex O 
formulation O 
, O 
whereas O 
from O 
the O 
marketed O 
formulation O 
less O 
than O 
5% O 
pioglitazone B-TRIVIAL 
, O 
and O 
only O 
25% O 
glimepiride B-TRIVIAL 
dissolved O 
. O 
Using O 
the O 
same O 
conditions O 
, O 
60% O 
ezetimibe B-TRIVIAL 
and O 
85% O 
simvastatin B-TRIVIAL 
dissolved O 
from O 
the O 
ternary O 
ezetimibe B-TRIVIAL 
/ O 
simvastatin B-TRIVIAL 
( O 
10mg O 
/ O 
40mg O 
) O 
complex O 
formulation O 
, O 
whereas O 
with O 
less O 
than O 
5% O 
ezetimibe B-TRIVIAL 
and O 
10% O 
simvastatin B-TRIVIAL 
dissolved O 
after O 
240min O 
, O 
the O 
marketed O 
FDC O 
formulation O 
showed O 
poor O 
dissolution O 
. O 
Based O 
on O 
the O 
results O 
of O 
the O 
present O 
study O 
, O 
the O 
bioavailability O 
of O 
both O 
drugs O 
in O 
the O 
fixed O 
dose O 
combination O 
is O 
likely O 
to O 
be O 
increased O 
after O 
oral O 
administration O 
of O 
the O 
new O 
formulations O 
, O 
especially O 
when O 
the O 
fixed O 
dose O 
combination O 
is O 
formulated O 
as O 
a O 
ternary O 
complex O 
consisting O 
of O 
HP-β-CD B-ABBREVIATION 
and O 
Soluplus B-TRIVIAL 
® O 
. O 

of O 
highly O 
porous O 
gastroretentive O 
metformin B-TRIVIAL 
tablets O 
using O 
a O 
sublimation O 
method O 
. O 

present O 
investigation O 
is O 
aimed O 
to O 
formulate O 
floating O 
gastroretentive O 
tablets O 
containing O 
metformin B-TRIVIAL 
using O 
a O 
sublimation O 
material O 
. O 
In O 
this O 
study O 
, O 
the O 
release O 
of O 
the O 
drug O 
from O 
a O 
matrix O 
tablet O 
was O 
highly O 
dependent O 
on O 
the O 
polymer O 
concentrations O 
. O 
In O 
all O 
formulations O 
, O 
initial O 
rapid O 
drug O 
release O 
was O 
observed O 
, O 
possibly O 
due O 
to O 
the O 
properties O 
of O 
the O 
drug O 
and O 
polymer O 
. O 
The O 
effect O 
of O 
the O 
amount O 
of O 
PEO B-ABBREVIATION 
on O 
swelling O 
and O 
eroding O 
of O 
the O 
tablets O 
was O 
determined O 
. O 
The O 
water O 
- O 
uptake O 
and O 
erosion O 
behavior O 
of O 
the O 
gastroretentive O 
( O 
GR O 
) O 
tablets O 
were O 
highly O 
dependent O 
on O 
the O 
amount O 
of O 
PEO B-ABBREVIATION 
. O 
The O 
water O 
- O 
uptake O 
increased O 
with O 
increasing O 
PEO B-ABBREVIATION 
concentration O 
in O 
the O 
tablet O 
matrix O 
. O 
The O 
weight O 
loss O 
from O 
tablets O 
decreased O 
with O 
increasing O 
amounts O 
of O 
PEO B-ABBREVIATION 
. O 
Camphor B-TRIVIAL 
was O 
used O 
as O 
the O 
sublimation O 
material O 
to O 
prepare O 
GR O 
tablets O 
that O 
are O 
low O 
- O 
density O 
and O 
easily O 
floatable O 
. O 
Camphor B-TRIVIAL 
was O 
changed O 
to O 
pores O 
in O 
the O 
tablet O 
during O 
the O 
sublimation O 
process O 
. O 
SEM O 
revealed O 
that O 
the O 
GR O 
tablets O 
have O 
a O 
highly O 
porous O 
morphology O 
. O 
Floating O 
properties O 
of O 
tablets O 
and O 
tablet O 
density O 
were O 
affected O 
by O 
the O 
sublimation O 
of O 
camphor B-TRIVIAL 
. O 
Prepared O 
floating O 
gastroretentive O 
tablets O 
floated O 
for O 
over O 
24 O 
h O 
and O 
had O 
no O 
floating O 
lag O 
time O 
. O 
However O 
, O 
as O 
the O 
amount O 
of O 
camphor B-TRIVIAL 
in O 
the O 
tablet O 
matrix O 
increased O 
, O 
the O 
crushing O 
strength O 
of O 
the O 
tablet O 
decreased O 
after O 
sublimation O 
. O 
Release O 
profiles O 
of O 
the O 
drug O 
from O 
the O 
GR O 
tablets O 
were O 
not O 
affected O 
by O 
tablet O 
density O 
or O 
porosity O 
. O 
In O 
pharmacokinetic O 
studies O 
, O 
the O 
mean O 
plasma O 
concentration O 
of O 
the O 
GR O 
tablets O 
after O 
oral O 
administration O 
was O 
greater O 
than O 
the O 
concentration O 
of O 
glucophase O 
XR O 
. O 
Also O 
, O 
the O 
mean O 
AUC(0-∞) O 
values O 
for O 
the O 
GR O 
tablets O 
were O 
significantly O 
greater O 
than O 
the O 
plasma O 
concentrations O 
of O 
glucophase O 
XR O 
. O 

ALDH2 O 
genes O 
encode O 
mitochondrial O 
enzymes O 
capable O 
of O 
metabolizing O 
acetaldehyde B-SYSTEMATIC 
and O 
other O 
biological O 
aldehydes B-FAMILY 
in O 
the O 
body O 
. O 
Mammalian O 
ALDH1B1 O 
, O 
another O 
mitochondrial O 
enzyme O 
sharing O 
72% O 
identity O 
with O 
ALDH2 O 
, O 
is O 
also O 
capable O 
of O 
metabolizing O 
acetaldehyde B-SYSTEMATIC 
but O 
has O 
a O 
tissue O 
distribution O 
and O 
pattern O 
of O 
activity O 
distinct O 
from O 
that O 
of O 
ALDH2 O 
. O 
Bioinformatic O 
analyses O 
of O 
several O 
vertebrate O 
genomes O 
were O 
undertaken O 
using O 
known O 
ALDH2 O 
and O 
ALDH1B1 O 
amino B-FAMILY 
acid I-FAMILY 
sequences O 
. O 
Phylogenetic O 
analysis O 
of O 
many O 
representative O 
vertebrate O 
species O 
( O 
including O 
fish O 
, O 
amphibians O 
, O 
birds O 
and O 
mammals O 
) O 
indicated O 
the O 
presence O 
of O 
ALDH1B1 O 
in O 
many O 
mammalian O 
species O 
and O 
in O 
frogs O 
( O 
Xenopus O 
tropicalis O 
) O 
; O 
no O 
evidence O 
was O 
found O 
for O 
ALDH1B1 O 
in O 
the O 
genomes O 
of O 
birds O 
, O 
reptiles O 
or O 
fish O 
. O 
Predicted O 
vertebrate O 
ALDH2 O 
and O 
ALDH1B1 O 
subunit O 
sequences O 
and O 
structures O 
were O 
highly O 
conserved O 
, O 
including O 
residues O 
previously O 
shown O 
to O 
be O 
involved O 
in O 
catalysis O 
and O 
coenzyme O 
binding O 
for O 
human O 
ALDH2 O 
. O 
Studies O 
of O 
ALDH1B1 O 
sequences O 
supported O 
the O 
hypothesis O 
that O 
the O 
ALDH1B1 O 
gene O 
originated O 
in O 
early O 
vertebrates O 
from O 
a O 
retrotransposition O 
of O 
the O 
vertebrate O 
ALDH2 O 
gene O 
. O 
Given O 
the O 
high O 
degree O 
of O 
similarity O 
between O 
ALDH2 O 
and O 
ALDH1B1 O 
, O 
it O 
is O 
surprising O 
that O 
individuals O 
with O 
an O 
inactivating O 
mutation O 
in O 
ALDH2 O 
( O 
ALDH2*2 O 
) O 
do O 
not O 
exhibit O 
a O 
compensatory O 
increase O 
in O 
ALDH1B1 O 
activity O 
. O 
We O 
hypothesized O 
that O 
the O 
similarity O 
between O 
the O 
two O 
ALDHs O 
would O 
allow O 
for O 
dominant O 
negative O 
heterotetramerization O 
between O 
the O 
inactive O 
ALDH2 O 
mutants O 
and O 
ALDH1B1 O 
. O 
Computational O 
- O 
based O 
molecular O 
modeling O 
studies O 
examining O 
predicted O 
protein O 
- O 
protein O 
interactions O 
indicated O 
that O 
heterotetramerization O 
between O 
ALDH2 O 
and O 
ALDH1B1 O 
subunits O 
was O 
highly O 
probable O 
and O 
may O 
partially O 
explain O 
a O 
lack O 
of O 
compensation O 
by O 
ALDH1B1 O 
in O 
ALDH2(∗)2 O 
individuals O 
. O 

similarity O 
evaluation O 
is O 
an O 
important O 
step O 
in O 
most O 
drug O 
development O 
strategies O 
, O 
since O 
molecular O 
similarity O 
is O 
usually O 
related O 
to O 
functional O 
similarity O 
. O 
Here O 
, O 
we O 
developed O 
a O 
method O 
based O 
on O 
the O 
Gaussian O 
description O 
of O 
molecular O 
shape O 
and O 
charge O 
distribution O 
for O 
molecular O 
similarity O 
identification O 
. O 
The O 
method O 
was O 
evaluated O 
using O 
the O 
Directory O 
of O 
Useful O 
Decoys O 
( O 
DUD O 
) O 
and O 
a O 
retrospective O 
test O 
. O 
Enrichment O 
factors O 
computed O 
for O 
DUD O 
targets O 
showed O 
that O 
the O 
proposed O 
method O 
performs O 
very O 
well O 
in O 
recognizing O 
molecules O 
with O 
similar O 
physicochemical O 
properties O 
and O 
dissimilar O 
topologies O 
, O 
reaching O 
an O 
average O 
AUC O 
of O 
0.63 O 
and O 
enrichment O 
factor O 
of O 
10 O 
at O 
0.5% O 
of O 
decoys O 
. O 
A O 
retrospective O 
test O 
also O 
showed O 
that O 
nine O 
mineralocorticoid O 
ligands O 
were O 
ranked O 
among O 
the O 
top O 
ten O 
molecules O 
in O 
a O 
search O 
of O 
a O 
database O 
of O 
approved O 
drugs O 
for O 
molecules O 
similar O 
to O 
aldosterone B-TRIVIAL 
. O 
Altogether O 
, O 
these O 
data O 
show O 
that O 
the O 
Gaussian O 
- O 
based O 
description O 
of O 
molecular O 
shape O 
and O 
charge O 
distribution O 
implemented O 
in O 
the O 
program O 
MolShaCS O 
is O 
an O 
efficient O 
method O 
for O 
molecular O 
similarity O 
identification O 
. O 
The O 
program O 
is O 
publicly O 
available O 
at O 
the O 
address O 
http O 
: O 
/ O 
/ O 
www.ifsc.usp.br O 
/ O 
biotechmol O 
. O 

of O 
direct O 
vibrational O 
excitation O 
in O 
gas-surface O 
collisions O 
of O 
CO B-FORMULA 
with O 
Au B-FORMULA 
( O 
111 O 
) O 
: O 
a O 
new O 
model O 
system O 
for O 
surface O 
dynamics O 
. O 

report O 
vibrational O 
excitation O 
of O 
CO B-FORMULA 
from O 
its O 
ground O 
( O 
v O 
= O 
0 O 
) O 
to O 
first O 
excited O 
( O 
v O 
= O 
1 O 
) O 
vibrational O 
state O 
in O 
collision O 
with O 
Au B-FORMULA 
( O 
111 O 
) O 
at O 
an O 
incidence O 
energy O 
of O 
translation O 
of O 
E O 
(I) O 
= O 
0.45 O 
eV O 
. O 
Unlike O 
past O 
work O 
, O 
we O 
can O 
exclude O 
an O 
excitation O 
mechanism O 
involving O 
temporary O 
adsorption O 
on O 
the O 
surface O 
followed O 
by O 
thermalization O 
and O 
desorption O 
. O 
The O 
angular O 
distributions O 
of O 
the O 
scattered O 
CO B-FORMULA 
molecules O 
are O 
narrow O 
, O 
consistent O 
with O 
direct O 
scattering O 
occurring O 
on O 
a O 
sub O 
- O 
ps O 
time O 
scale O 
. O 
The O 
absolute O 
excitation O 
probabilities O 
are O 
about O 
3% O 
of O 
those O 
expected O 
from O 
thermal O 
accommodation O 
. O 
The O 
surface O 
temperature O 
dependence O 
of O 
excitation O 
, O 
which O 
was O 
measured O 
between O 
373 O 
and O 
973 O 
K O 
, O 
is O 
Arrhenius O 
- O 
like O 
with O 
an O 
activation O 
energy O 
equal O 
to O 
the O 
energy O 
required O 
for O 
vibrational O 
excitation O 
. O 
Our O 
measurements O 
are O 
consistent O 
with O 
a O 
vibrational O 
excitation O 
mechanism O 
involving O 
coupling O 
of O 
thermally O 
excited O 
electron O 
- O 
hole O 
pairs O 
of O 
the O 
solid O 
to O 
CO B-FORMULA 
vibration O 
. O 

focused O 
- O 
ion O 
- O 
beam O 
sculpting O 
of O 
TiO2 B-FORMULA 
nanotubes O 
and O 
mechanism O 
understanding O 
. O 

TiO(2) B-FORMULA 
nanotubes O 
with O 
different O 
structures O 
, O 
doping O 
agents O 
, O 
and O 
decorations O 
have O 
been O 
studied O 
in O 
order O 
to O 
improve O 
energy O 
conversion O 
and O 
storage O 
efficiencies O 
such O 
as O 
in O 
dye O 
sensitized O 
solar O 
cells O 
, O 
solar O 
fuels O 
, O 
and O 
electrochemical O 
supercapacitors O 
. O 
However O 
, O 
the O 
top O 
surface O 
modification O 
of O 
TiO(2) B-FORMULA 
nanotubes O 
has O 
never O 
been O 
addressed O 
. O 
In O 
this O 
study O 
, O 
anodic O 
TiO(2) B-FORMULA 
nanotubes O 
have O 
been O 
selectively O 
closed O 
by O 
high O 
energy O 
focused O 
ion O 
beams O 
and O 
re O 
- O 
opened O 
by O 
low O 
energy O 
focused O 
ion O 
beams O 
. O 
Under O 
a O 
30 O 
kV O 
Ga(+) B-FORMULA 
beam O 
, O 
TiO(2) B-FORMULA 
nanotubes O 
are O 
closed O 
with O 
a O 
65 O 
nm O 
shield O 
layer O 
covering O 
the O 
top O 
entrance O 
when O 
the O 
ion O 
dose O 
is O 
larger O 
than O 
1.2 O 
× O 
10(17) O 
ions O 
per O 
cm(2) O 
; O 
under O 
a O 
5 O 
kV O 
Ga(+) B-FORMULA 
beam O 
, O 
the O 
shield O 
layer O 
is O 
removed O 
and O 
the O 
closed O 
tubes O 
are O 
re O 
- O 
opened O 
. O 
An O 
ion O 
- O 
induced O 
viscous O 
flow O 
model O 
has O 
been O 
proposed O 
to O 
explain O 
the O 
influence O 
of O 
Ga(+) B-FORMULA 
ion O 
beam O 
flux O 
, O 
substrate O 
temperature O 
, O 
initial O 
tube O 
diameter O 
, O 
ion O 
beam O 
dwell O 
time O 
, O 
and O 
the O 
incidence O 
angle O 
of O 
the O 
ion O 
beam O 
. O 

the O 
effects O 
of O 
chronic O 
exposure O 
to O 
pollutants O 
on O 
the O 
genome O 
and O 
transcriptome O 
of O 
diadromous O 
fish O 
populations O 
is O 
crucial O 
for O 
their O 
resilience O 
under O 
combined O 
anthropogenic O 
and O 
environmental O 
selective O 
pressures O 
. O 
The O 
catadromous O 
European O 
eel O 
( O 
Anguilla O 
anguilla O 
L O 
. O 
) O 
has O 
suffered O 
a O 
dramatic O 
decline O 
in O 
recruitment O 
for O 
three O 
decades O 
, O 
necessitating O 
a O 
thorough O 
assessment O 
of O 
the O 
transcriptional O 
effects O 
of O 
environmental O 
pollutants O 
on O 
resident O 
and O 
migrating O 
eels O 
in O 
natural O 
systems O 
. O 
We O 
investigated O 
the O 
relationship O 
between O 
muscular O 
bioaccumulation O 
levels O 
of O 
metals O 
( O 
Hg B-FORMULA 
, O 
Cd B-FORMULA 
, O 
Pb B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Zn B-FORMULA 
, O 
Ni B-FORMULA 
, O 
Cr B-FORMULA 
, O 
As B-FORMULA 
and O 
Se B-FORMULA 
) O 
, O 
PCBs B-ABBREVIATION 
and O 
organochlorine O 
pesticides O 
( O 
DDTs B-FAMILY 
) O 
, O 
the O 
health O 
status O 
( O 
condition O 
factor O 
and O 
lipid O 
reserves O 
) O 
and O 
the O 
associated O 
transcriptional O 
response O 
in O 
liver O 
and O 
gill O 
tissues O 
for O 
genes O 
involved O 
in O 
metal O 
detoxification O 
( O 
metallothionein O 
, O 
MT O 
) O 
and O 
oxidative O 
metabolism O 
( O 
cytochrome O 
P4501A O 
, O 
CYP1A O 
) O 
of O 
xenobiotic O 
compounds O 
. O 
In O 
total O 
84 O 
resident O 
eels O 
originating O 
from O 
three O 
Belgian O 
river O 
basins O 
( O 
Scheldt O 
, O 
Meuse O 
and O 
Yzer O 
) O 
were O 
analyzed O 
along O 
with O 
five O 
unpolluted O 
aquaculture O 
samples O 
as O 
control O 
group O 
. O 
There O 
was O 
a O 
large O 
spatial O 
variation O 
in O 
individual O 
contaminant O 
intensity O 
and O 
profile O 
, O 
while O 
tissue O 
pollution O 
levels O 
were O 
strongly O 
and O 
negatively O 
associated O 
with O 
condition O 
indices O 
, O 
suggesting O 
an O 
important O 
impact O 
of O 
pollution O 
on O 
the O 
health O 
of O 
sub O 
- O 
adult O 
resident O 
eels O 
. O 
Gene O 
transcription O 
patterns O 
revealed O 
a O 
complex O 
response O 
mechanism O 
to O 
a O 
cocktail O 
of O 
pollutants O 
, O 
with O 
a O 
high O 
variation O 
at O 
low O 
pollution O 
levels O 
, O 
but O 
strongly O 
down O 
- O 
regulated O 
hepatic O 
and O 
gill O 
gene O 
transcription O 
in O 
highly O 
polluted O 
eels O 
. O 
Resident O 
eels O 
clearly O 
experience O 
a O 
high O 
pollution O 
burden O 
and O 
seem O 
to O 
show O 
a O 
dysfunctional O 
gene O 
transcription O 
regulation O 
of O 
detoxification O 
genes O 
at O 
higher O 
pollutant O 
levels O 
, O 
correlated O 
with O 
low O 
energy O 
reserves O 
and O 
condition O 
. O 
To O 
fully O 
understand O 
the O 
evolutionary O 
implications O 
of O 
pollutants O 
on O 
eel O 
reproductive O 
fitness O 
, O 
analyses O 
of O 
mature O 
migrating O 
eels O 
and O 
the O 
characterization O 
of O 
their O 
transcriptome O 
- O 
wide O 
gene O 
transcription O 
response O 
would O 
be O 
appropriate O 
to O 
unveil O 
the O 
complex O 
responses O 
associated O 
with O 
multiple O 
interacting O 
stressors O 
and O 
the O 
long O 
- O 
term O 
consequences O 
at O 
the O 
entire O 
species O 
level O 
. O 
In O 
the O 
meanwhile O 
, O 
jointly O 
monitoring O 
environmental O 
and O 
tissue O 
pollution O 
levels O 
at O 
a O 
European O 
scale O 
should O 
be O 
initiated O 
, O 
while O 
preserving O 
high O 
quality O 
habitats O 
to O 
increase O 
the O 
recovery O 
chance O 
of O 
European O 
eel O 
in O 
the O 
future O 
. O 

comparative O 
VCD O 
study O 
of O 
methyl B-SYSTEMATIC 
mandelate I-SYSTEMATIC 
in O 
methanol B-SYSTEMATIC 
, O 
dimethyl B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
, O 
and O 
chloroform B-TRIVIAL 
: O 
explicit O 
and O 
implicit O 
solvation O 
models O 
. O 

absorption O 
( O 
VA O 
) O 
and O 
vibrational O 
circular O 
dichroism O 
( O 
VCD O 
) O 
spectra O 
of O 
methyl B-SYSTEMATIC 
mandelate I-SYSTEMATIC 
, O 
a O 
prototype O 
chiral O 
molecule O 
, O 
in O 
a O 
series O 
of O 
organic O 
solvents O 
, O 
namely O 
methanol B-SYSTEMATIC 
( O 
MeOH-d(4) B-FORMULA 
) O 
, O 
dimethyl B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
( O 
DMSO-d(6) B-ABBREVIATION 
) O 
, O 
and O 
chloroform B-TRIVIAL 
( O 
CDCl(3) B-FORMULA 
) O 
, O 
have O 
been O 
measured O 
in O 
the O 
finger O 
print O 
region O 
from O 
1800 O 
to O 
1150 O 
cm(-1) O 
. O 
Implicit O 
solvation O 
models O 
in O 
the O 
form O 
of O 
polarizable O 
continuum O 
model O 
and O 
explicit O 
solvation O 
models O 
have O 
been O 
employed O 
independently O 
and O 
simultaneously O 
. O 
The O 
goal O 
is O 
to O 
evaluate O 
their O 
efficiencies O 
in O 
dealing O 
with O 
solvent O 
effects O 
in O 
each O 
solution O 
and O 
to O 
establish O 
a O 
general O 
strategy O 
to O 
adequately O 
account O 
for O 
effects O 
of O 
solvents O 
. O 
Molecular O 
dynamics O 
( O 
MD O 
) O 
simulation O 
and O 
radial O 
distribution O 
function O 
analysis O 
have O 
been O 
performed O 
to O 
aid O 
the O 
construction O 
of O 
the O 
explicit O 
solvation O 
models O 
. O 
Initial O 
geometry O 
searches O 
have O 
been O 
carried O 
out O 
at O 
the O 
B3LYP O 
/ O 
6-31G(d) O 
level O 
for O 
the O 
methyl B-SYSTEMATIC 
mandelate I-SYSTEMATIC 
monomer O 
and O 
its O 
explicit O 
1 O 
: O 
1 O 
and O 
1 O 
: O 
2 O 
solute O 
- O 
solvent O 
hydrogen B-SYSTEMATIC 
-bonded O 
complexes O 
. O 
B3LYP O 
/ O 
cc-pVTZ O 
has O 
been O 
used O 
for O 
all O 
the O 
final O 
geometry O 
optimizations O 
, O 
the O 
vibrational O 
frequency O 
, O 
VA O 
and O 
VCD O 
intensity O 
, O 
and O 
optical O 
rotation O 
dispersion O 
( O 
ORD O 
) O 
calculations O 
. O 
The O 
results O 
show O 
that O 
inclusion O 
of O 
solvent O 
explicitly O 
and O 
implicitly O 
at O 
the O 
same O 
time O 
has O 
significant O 
impacts O 
on O 
the O 
appearance O 
of O 
the O 
VA O 
and O 
VCD O 
spectra O 
, O 
and O 
is O 
crucial O 
for O 
reliable O 
spectral O 
assignments O 
when O 
solvents O 
are O 
capable O 
of O 
hydrogen B-SYSTEMATIC 
-bonding O 
interactions O 
with O 
solutes O 
. O 
When O 
no O 
strong O 
solvent-solute O 
hydrogen B-SYSTEMATIC 
-bonding O 
interactions O 
in O 
the O 
case O 
of O 
chloroform B-TRIVIAL 
are O 
expected O 
, O 
the O 
gas O 
phase O 
monomer O 
model O 
is O 
adequate O 
for O 
spectral O 
interpretation O 
, O 
while O 
inclusion O 
of O 
implicit O 
solvation O 
improves O 
the O 
frequency O 
agreement O 
with O 
experiment O 
. O 
ORD O 
spectra O 
of O 
methyl B-SYSTEMATIC 
mandelate I-SYSTEMATIC 
in O 
the O 
aforementioned O 
solvents O 
at O 
different O 
concentrations O 
under O 
5 O 
excitation O 
wavelengths O 
have O 
also O 
been O 
measured O 
. O 
The O 
comparison O 
between O 
the O 
calculated O 
and O 
the O 
experimental O 
ORD O 
spectra O 
supports O 
the O 
conclusions O 
drawn O 
from O 
the O 
VA O 
and O 
VCD O 
investigations O 
. O 

of O 
Shiga O 
toxin O 
glycosphingolipid B-FAMILY 
receptors O 
with O 
membrane O 
microdomains O 
of O 
toxin O 
- O 
sensitive O 
lymphoid O 
and O 
myeloid O 
cells O 
. O 

( O 
GSLs O 
) O 
of O 
the O 
globo O 
- O 
series O 
constitute O 
specific O 
receptors O 
for O 
Shiga O 
toxins O 
( O 
Stxs O 
) O 
released O 
by O 
certain O 
types O 
of O 
pathogenic O 
Escherichia O 
coli O 
strains O 
. O 
Stx O 
- O 
loaded O 
leukocytes O 
may O 
act O 
as O 
transporter O 
cells O 
in O 
the O 
blood O 
and O 
transfer O 
the O 
toxin O 
to O 
endothelial O 
target O 
cells O 
. O 
Therefore O 
, O 
we O 
performed O 
a O 
thorough O 
investigation O 
on O 
the O 
expression O 
of O 
globo O 
- O 
series O 
GSLs O 
in O 
serum O 
- O 
free O 
cultivated O 
Raji O 
and O 
Jurkat O 
cells O 
, O 
representing O 
B- O 
and O 
T-lymphocyte O 
descendants O 
, O 
respectively O 
, O 
as O 
well O 
as O 
THP-1 O 
and O 
HL-60 O 
cells O 
of O 
the O 
monocyte O 
and O 
granulocyte O 
lineage O 
, O 
respectively O 
. O 
The O 
presence O 
of O 
Stx O 
- O 
receptors O 
in O 
GSL O 
preparations O 
of O 
Raji O 
and O 
THP-1 O 
cells O 
and O 
the O 
absence O 
in O 
Jurkat O 
and O 
HL-60 O 
cells O 
revealed O 
high O 
compliance O 
of O 
solid O 
- O 
phase O 
immunodetection O 
assays O 
with O 
the O 
expression O 
profiles O 
of O 
receptor O 
- O 
related O 
glycosyltransferases O 
, O 
performed O 
by O 
qRT-PCR O 
analysis O 
, O 
and O 
Stx2-caused O 
cellular O 
damage O 
. O 
Canonical O 
microdomain O 
association O 
of O 
Stx O 
GSL O 
receptors O 
, O 
sphingomyelin B-FAMILY 
, O 
and O 
cholesterol B-TRIVIAL 
in O 
membranes O 
of O 
Raji O 
and O 
THP-1 O 
cells O 
was O 
assessed O 
by O 
comparative O 
analysis O 
of O 
detergent-resistant O 
membrane O 
( O 
DRM O 
) O 
and O 
nonDRM O 
fractions O 
obtained O 
by O 
density O 
gradient O 
centrifugation O 
and O 
showed O 
high O 
correlation O 
based O 
on O 
nonparametric O 
statistical O 
analysis O 
. O 
Our O 
comprehensive O 
study O 
on O 
the O 
expression O 
of O 
Stx O 
- O 
receptors O 
and O 
their O 
subcellular O 
distribution O 
provides O 
the O 
basis O 
for O 
exploring O 
the O 
functional O 
role O 
of O 
lipid O 
raft O 
- O 
associated O 
Stx O 
- O 
receptors O 
in O 
cells O 
of O 
leukocyte O 
origin O 
. O 

flexible O 
nanoscale O 
ultrathin O 
body O 
silicon B-SYSTEMATIC 
integrated O 
circuits O 
on O 
plastic O 
. O 

recent O 
years O 
, O 
flexible O 
devices O 
based O 
on O 
nanoscale O 
materials O 
and O 
structures O 
have O 
begun O 
to O 
emerge O 
, O 
exploiting O 
semiconductor O 
nanowires O 
, O 
graphene B-TRIVIAL 
, O 
and O 
carbon B-SYSTEMATIC 
nanotubes O 
. O 
This O 
is O 
primarily O 
to O 
circumvent O 
the O 
existing O 
shortcomings O 
of O 
the O 
conventional O 
flexible O 
electronics O 
based O 
on O 
organic O 
and O 
amorphous O 
semiconductors O 
. O 
The O 
aim O 
of O 
this O 
new O 
class O 
of O 
flexible O 
nanoelectronics O 
is O 
to O 
attain O 
high O 
- O 
performance O 
devices O 
with O 
increased O 
packing O 
density O 
. O 
However O 
, O 
highly O 
integrated O 
flexible O 
circuits O 
with O 
nanoscale O 
transistors O 
have O 
not O 
yet O 
been O 
demonstrated O 
. O 
Here O 
, O 
we O 
show O 
nanoscale O 
flexible O 
circuits O 
on O 
60 O 
Å O 
thick O 
silicon B-SYSTEMATIC 
, O 
including O 
functional O 
ring O 
oscillators O 
and O 
memory O 
cells O 
. O 
The O 
100-stage O 
ring O 
oscillators O 
exhibit O 
the O 
stage O 
delay O 
of O 
~16 O 
ps O 
at O 
a O 
power O 
supply O 
voltage O 
of O 
0.9 O 
V O 
, O 
the O 
best O 
reported O 
for O 
any O 
flexible O 
circuits O 
to O 
date O 
. O 
The O 
mechanical O 
flexibility O 
is O 
achieved O 
by O 
employing O 
the O 
controlled O 
spalling O 
technology O 
, O 
enabling O 
the O 
large O 
- O 
area O 
transfer O 
of O 
the O 
ultrathin O 
body O 
silicon B-SYSTEMATIC 
devices O 
to O 
a O 
plastic O 
substrate O 
at O 
room O 
temperature O 
. O 
These O 
results O 
provide O 
a O 
simple O 
and O 
cost O 
- O 
effective O 
pathway O 
to O 
enable O 
ultralight O 
flexible O 
nanoelectronics O 
with O 
unprecedented O 
level O 
of O 
system O 
complexity O 
based O 
on O 
mainstream O 
silicon B-SYSTEMATIC 
technology O 
. O 

of O 
the O 
water O 
solubility O 
of O 
flavone B-FAMILY 
glycosides I-FAMILY 
by O 
disruption O 
of O 
molecular O 
planarity O 
of O 
the O 
aglycone O 
moiety O 
. O 

of O 
the O 
water O 
solubility O 
by O 
disruption O 
of O 
molecular O 
planarity O 
has O 
recently O 
been O 
reviewed O 
as O 
a O 
feasible O 
approach O 
in O 
small O 
- O 
molecule O 
drug O 
discovery O 
programs O 
. O 
We O 
applied O 
this O 
strategy O 
to O 
some O 
natural O 
flavone B-FAMILY 
glycosides I-FAMILY 
, O 
especially O 
diosmin B-TRIVIAL 
, O 
a O 
highly O 
insoluble O 
citroflavonoid B-FAMILY 
prescribed O 
as O 
an O 
oral O 
phlebotropic O 
drug O 
. O 
Disruption O 
of O 
planarity O 
at O 
the O 
aglycone O 
moiety O 
by O 
3-bromination O 
or O 
chlorination O 
afforded O 
3-bromo- B-MULTIPLE 
and I-MULTIPLE 
3-chlorodiosmin I-MULTIPLE 
, O 
displaying O 
a O 
dramatic O 
solubility O 
increase O 
compared O 
with O 
the O 
parent O 
compound O 
. O 

between O 
structure O 
and O 
relaxations O 
in O 
perfluorosulfonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
proton O 
conducting O 
membranes O 
. O 

study O 
focuses O 
on O 
changes O 
in O 
the O 
structure O 
of O 
ionomer O 
membranes O 
, O 
provided O 
by O 
the O 
3M O 
Fuel O 
Cells O 
Component O 
Group O 
, O 
as O 
a O 
function O 
of O 
the O 
equivalent O 
weight O 
( O 
EW O 
) O 
and O 
the O 
relationship O 
between O 
the O 
structure O 
and O 
the O 
properties O 
of O 
the O 
membrane O 
. O 
Wide-angle O 
X-ray O 
diffraction O 
results O 
showed O 
evidence O 
of O 
both O 
non-crystalline O 
and O 
crystalline O 
ordered O 
hydrophobic O 
regions O 
in O 
all O 
the O 
EW O 
membranes O 
except O 
the O 
700 O 
EW O 
membrane O 
. O 
The O 
spectral O 
changes O 
evident O 
in O 
the O 
vibrational O 
spectra O 
of O 
the O 
3M O 
membranes O 
can O 
be O 
associated O 
with O 
two O 
major O 
phenomena O 
: O 
( O 
1 O 
) O 
dissociation O 
of O 
the O 
proton O 
from O 
the O 
sulfonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
groups O 
even O 
in O 
the O 
presence O 
of O 
small O 
amounts O 
of O 
water O 
; O 
and O 
( O 
2 O 
) O 
changes O 
in O 
the O 
conformation O 
or O 
the O 
degree O 
of O 
crystallinity O 
of O 
the O 
poly(tetrafluoroethylene) B-FAMILY 
hydrophobic O 
domains O 
both O 
as O 
a O 
function O 
of O 
EW O 
and O 
membrane O 
water O 
content O 
. O 
All O 
the O 
membranes O 
, O 
regardless O 
of O 
EW O 
, O 
are O 
thermally O 
stable O 
up O 
to O 
360 O 
°C O 
. O 
The O 
wet O 
membranes O 
have O 
conductivities O 
between O 
7 O 
and O 
20 O 
mS O 
/ O 
cm O 
at O 
125 O 
°C O 
. O 
In O 
this O 
condition O 
, O 
the O 
conductivity O 
values O 
follow O 
VTF O 
behavior O 
, O 
which O 
suggests O 
that O 
the O 
proton O 
migration O 
occurs O 
via O 
proton O 
exchange O 
processes O 
between O 
delocalization O 
bodies O 
( O 
DBs O 
) O 
that O 
are O 
facilitated O 
by O 
the O 
dynamics O 
of O 
the O 
host O 
polymer O 
. O 
The O 
conductivity O 
along O 
the O 
interface O 
between O 
the O 
hydrophobic O 
and O 
hydrophilic O 
domains O 
makes O 
a O 
larger O 
contribution O 
in O 
the O 
smaller O 
EW O 
membranes O 
likely O 
due O 
to O 
the O 
existence O 
of O 
a O 
greater O 
number O 
of O 
interfaces O 
in O 
the O 
membrane O 
. O 
The O 
larger O 
crystalline O 
domains O 
present O 
in O 
the O 
higher O 
EW O 
membranes O 
provide O 
percolation O 
pathways O 
for O 
charge O 
migration O 
between O 
DBs O 
, O 
which O 
reduces O 
the O 
probability O 
of O 
charge O 
transfer O 
along O 
the O 
interface O 
. O 
Therefore O 
, O 
at O 
higher O 
EWs O 
although O 
there O 
is O 
charge O 
migration O 
along O 
the O 
interface O 
within O 
the O 
hydrophobic O 
- O 
hydrophilic O 
domains O 
, O 
the O 
exchange O 
of O 
protons O 
between O 
different O 
DBs O 
is O 
likely O 
the O 
rate O 
- O 
limiting O 
step O 
of O 
the O 
overall O 
conduction O 
process O 
. O 

, O 
for O 
the O 
first O 
time O 
, O 
we O 
show O 
that O 
with O 
addition O 
of O 
a O 
biological O 
buffer O 
, O 
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
HEPES B-ABBREVIATION 
) O 
, O 
into O 
aqueous O 
solutions O 
of O 
tetrahydrofuran B-SYSTEMATIC 
( O 
THF B-ABBREVIATION 
) O 
, O 
1,3-dioxolane B-SYSTEMATIC 
, I-SYSTEMATIC 
1,4-dioxane I-SYSTEMATIC 
, I-SYSTEMATIC 
1-propanol I-SYSTEMATIC 
, O 
2-propanol B-SYSTEMATIC 
, O 
tert-butanol B-SYSTEMATIC 
, O 
acetonitrile B-SYSTEMATIC 
, O 
or O 
acetone B-SYSTEMATIC 
, O 
the O 
organic O 
solvent O 
can O 
be O 
excluded O 
from O 
water O 
to O 
form O 
a O 
new O 
liquid O 
phase O 
. O 
The O 
phase O 
diagrams O 
have O 
been O 
determined O 
at O 
ambient O 
temperature O 
. O 
In O 
order O 
to O 
understand O 
why O 
and O 
how O 
a O 
zwitterion O 
solute O 
( O 
HEPES B-ABBREVIATION 
) O 
induced O 
phase O 
separation O 
of O 
the O 
investigated O 
systems O 
, O 
molecular O 
dynamics O 
( O 
MD O 
) O 
simulation O 
studies O 
are O 
performed O 
for O 
HEPES B-ABBREVIATION 
+ O 
water O 
+ O 
THF B-ABBREVIATION 
system O 
. O 
The O 
MD O 
simulations O 
were O 
conducted O 
for O 
the O 
aqueous O 
mixtures O 
with O 
12 O 
different O 
compositions O 
. O 
The O 
reliability O 
of O 
the O 
simulation O 
results O 
of O 
HEPES B-ABBREVIATION 
in O 
pure O 
water O 
and O 
beyond O 
the O 
phase O 
separation O 
mixtures O 
was O 
justified O 
by O 
comparing O 
the O 
densities O 
obtained O 
from O 
MD O 
with O 
the O 
experimental O 
values O 
. O 
The O 
simulation O 
results O 
of O 
HEPES B-ABBREVIATION 
in O 
pure O 
THF B-ABBREVIATION 
and O 
in O 
a O 
composition O 
inside O 
the O 
phase O 
separation O 
region O 
were O 
justified O 
qualitatively O 
. O 
Interestingly O 
, O 
all O 
HEPES B-ABBREVIATION 
molecules O 
entirely O 
aggregated O 
in O 
pure O 
THF B-ABBREVIATION 
. O 
This O 
reveals O 
that O 
HEPES B-ABBREVIATION 
is O 
insoluble O 
in O 
pure O 
THF B-ABBREVIATION 
, O 
which O 
is O 
consistent O 
with O 
the O 
experimental O 
results O 
. O 
Even O 
more O 
interestingly O 
, O 
the O 
MD O 
simulation O 
for O 
the O 
mixture O 
with O 
composition O 
inside O 
the O 
phase O 
separation O 
region O 
showed O 
the O 
formation O 
of O 
two O 
phases O 
. O 
The O 
THF B-ABBREVIATION 
molecules O 
are O 
squeezed O 
out O 
from O 
the O 
water O 
network O 
into O 
a O 
new O 
liquid O 
phase O 
. O 
The O 
hydrogen O 
bonds O 
( O 
HBs O 
) O 
, O 
HB O 
lifetime O 
, O 
HB O 
Gibbs O 
energy O 
( O 
ΔG O 
) O 
, O 
radial O 
distribution O 
functions O 
( O 
RDFs O 
) O 
, O 
coordination O 
numbers O 
( O 
CNs O 
) O 
, O 
electrostatic O 
interactions O 
, O 
and O 
the O 
van O 
der O 
Waals O 
interactions O 
between O 
the O 
different O 
species O 
have O 
been O 
analyzed O 
. O 
Further O 
, O 
MD O 
simulations O 
for O 
the O 
other O 
phase O 
separation O 
systems O 
by O 
choosing O 
a O 
composition O 
inside O 
the O 
two O 
liquids O 
region O 
for O 
each O 
system O 
were O 
also O 
simulated O 
. O 
Our O 
findings O 
will O 
therefore O 
pave O 
the O 
way O 
for O 
designing O 
new O 
benign O 
separation O 
auxiliary O 
agents O 
. O 

is O 
now O 
about O 
40 O 
years O 
since O 
Avram O 
Goldstein O 
proposed O 
the O 
use O 
of O 
the O 
stereoselectivity O 
of O 
opioid O 
receptors O 
to O 
identify O 
these O 
receptors O 
in O 
neural O 
membranes O 
. O 
In O 
2012 O 
, O 
the O 
crystal O 
structures O 
of O 
the O 
four O 
members O 
of O 
the O 
opioid O 
receptor O 
family O 
were O 
reported O 
, O 
providing O 
a O 
structural O 
basis O 
for O 
understanding O 
of O 
critical O 
features O 
affecting O 
the O 
actions O 
of O 
opiate O 
drugs O 
. O 
This O 
minireview O 
summarizes O 
these O 
recent O 
developments O 
in O 
our O 
understanding O 
of O 
opiate O 
receptors O 
. O 
Receptor O 
function O 
is O 
also O 
influenced O 
by O 
amino B-FAMILY 
acid I-FAMILY 
substitutions O 
in O 
the O 
protein O 
sequence O 
. O 
Among O 
opioid O 
receptor O 
genes O 
, O 
one O 
polymorphism O 
is O 
much O 
more O 
frequent O 
in O 
human O 
populations O 
than O 
the O 
many O 
others O 
that O 
have O 
been O 
found O 
, O 
but O 
the O 
functional O 
significance O 
of O 
this O 
single O 
nucleotide O 
polymorphism O 
( O 
SNP O 
) O 
has O 
been O 
unclear O 
. O 
Recent O 
studies O 
have O 
shed O 
new O 
light O 
on O 
how O 
this O 
SNP O 
might O 
influence O 
opioid O 
receptor O 
function O 
. O 
In O 
this O 
minireview O 
, O 
the O 
functional O 
significance O 
of O 
the O 
most O 
prevalent O 
genetic O 
polymorphism O 
among O 
the O 
opioid O 
receptor O 
genes O 
is O 
also O 
considered O 
. O 

limiting O 
distribution O 
of O 
the O 
threonine B-TRIVIAL 
-protein O 
kinase O 
B-RaF(V600E) O 
inhibitor O 
dabrafenib B-TRIVIAL 
to O 
the O 
brain O 
: O 
implications O 
for O 
the O 
treatment O 
of O 
melanoma O 
brain O 
metastases O 
. O 

metastases O 
are O 
a O 
common O 
cause O 
of O 
death O 
in O 
stage O 
IV O 
metastatic O 
melanoma O 
. O 
Dabrafenib O 
is O 
a O 
BRAF O 
( O 
gene O 
encoding O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
-protein O 
kinase O 
B-Raf O 
) O 
inhibitor O 
that O 
has O 
been O 
developed O 
to O 
selectively O 
target O 
the O 
valine B-TRIVIAL 
600 O 
to O 
glutamic B-TRIVIAL 
acid I-TRIVIAL 
substitution O 
(BRAF(V600E)) O 
, O 
which O 
is O 
commonly O 
found O 
in O 
metastatic O 
melanoma O 
. O 
Clinical O 
trials O 
with O 
dabrafenib B-TRIVIAL 
have O 
shown O 
encouraging O 
results O 
; O 
however O 
, O 
the O 
central O 
nervous O 
system O 
distribution O 
of O 
dabrafenib B-TRIVIAL 
remains O 
unknown O 
. O 
Thus O 
, O 
the O 
objective O 
of O 
the O 
current O 
study O 
was O 
to O 
evaluate O 
the O 
brain O 
distribution O 
of O 
dabrafenib B-TRIVIAL 
in O 
mice O 
, O 
and O 
to O 
see O 
whether O 
active O 
efflux O 
by O 
P-glycoprotein O 
( O 
P-gp O 
) O 
and O 
breast O 
cancer O 
resistance O 
protein O 
( O 
BCRP O 
) O 
restricts O 
its O 
delivery O 
across O 
the O 
blood O 
- O 
brain O 
barrier O 
( O 
BBB O 
) O 
. O 
In O 
vitro O 
accumulation O 
studies O 
conducted O 
in O 
Madin-Darby O 
canine O 
kidney O 
II O 
cells O 
indicate O 
that O 
dabrafenib B-TRIVIAL 
is O 
an O 
avid O 
substrate O 
for O 
both O 
P-gp O 
and O 
BCRP O 
. O 
Directional O 
flux O 
studies O 
revealed O 
greater O 
transport O 
in O 
the O 
basolateral O 
to O 
apical O 
direction O 
with O 
corrected O 
efflux O 
ratios O 
greater O 
than O 
2 O 
for O 
both O 
P-gp O 
and O 
Bcrp1 O 
transfected O 
cell O 
lines O 
. O 
In O 
vivo O 
, O 
the O 
ratio O 
of O 
area O 
under O 
the O 
concentration O 
- O 
time O 
curve O 
(AUC)(brain) O 
to O 
AUC(plasma) O 
(K(p)) O 
of O 
dabrafenib B-TRIVIAL 
after O 
an O 
i.v O 
. O 
dose O 
( O 
2.5 O 
mg O 
/ O 
kg O 
) O 
was O 
0.023 O 
, O 
which O 
increased O 
by O 
18-fold O 
in O 
Mdr1 O 
a O 
/ O 
b(- O 
/ O 
-)Bcrp1(- O 
/ O 
- O 
) O 
mice O 
to O 
0.42 O 
. O 
Dabrafenib B-TRIVIAL 
plasma O 
exposure O 
was O 
∼2-fold O 
greater O 
in O 
Mdr1 O 
a O 
/ O 
b(- O 
/ O 
-)Bcrp1(- O 
/ O 
- O 
) O 
mice O 
as O 
compared O 
with O 
wild O 
- O 
type O 
with O 
an O 
oral O 
dose O 
( O 
25 O 
mg O 
/ O 
kg O 
) O 
; O 
however O 
, O 
the O 
brain O 
distribution O 
was O 
increased O 
by O 
~10-fold O 
with O 
a O 
resulting O 
K(p) O 
of O 
0.25 O 
. O 
Further O 
, O 
compared O 
with O 
vemurafenib B-TRIVIAL 
, O 
another O 
BRAF(V600E) O 
inhibitor O 
, O 
dabrafenib B-TRIVIAL 
showed O 
greater O 
brain O 
penetration O 
with O 
a O 
similar O 
dose O 
. O 
In O 
conclusion O 
, O 
the O 
dabrafenib B-TRIVIAL 
brain O 
distribution O 
is O 
limited O 
in O 
an O 
intact O 
BBB O 
model O 
, O 
and O 
the O 
data O 
presented O 
herein O 
may O 
have O 
clinical O 
implications O 
in O 
the O 
prevention O 
and O 
treatment O 
of O 
melanoma O 
brain O 
metastases O 
. O 

inhibition O 
of O 
mitochondrial O 
carbonic O 
anhydrases O 
protects O 
mouse O 
cerebral O 
pericytes O 
from O 
high O 
glucose B-TRIVIAL 
-induced O 
oxidative O 
stress O 
and O 
apoptosis O 
. O 

- O 
associated O 
complications O 
in O 
the O 
microvasculature O 
of O 
the O 
brain O 
are O 
caused O 
by O 
oxidative O 
stress O 
, O 
generated O 
by O 
overproduction O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
from O 
hyperglycemia O 
- O 
induced O 
accelerated O 
oxidative O 
metabolism O 
of O 
glucose B-TRIVIAL 
. O 
Pericytes O 
, O 
essential O 
for O 
the O 
viability O 
of O 
the O 
microvasculature O 
, O 
are O 
especially O 
susceptible O 
to O 
oxidative O 
stress O 
. O 
Mitochondrial O 
carbonic O 
anhydrases O 
, O 
regulators O 
of O 
the O 
oxidative O 
metabolism O 
of O 
glucose B-TRIVIAL 
, O 
determine O 
the O 
rate O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
production O 
and O 
inhibition O 
of O 
mitochondrial O 
carbonic O 
anhydrases O 
rescues O 
glucose B-TRIVIAL 
-induced O 
pericyte O 
loss O 
in O 
the O 
diabetic O 
mouse O 
brain O 
. O 
We O 
hypothesized O 
that O 
high O 
glucose B-TRIVIAL 
induces O 
intracellular O 
oxidative O 
stress O 
and O 
pericyte O 
apoptosis O 
and O 
that O 
inhibition O 
of O 
mitochondrial O 
carbonic O 
anhydrases O 
protects O 
pericytes O 
from O 
oxidative O 
stress O 
- O 
induced O 
apoptosis O 
. O 
To O 
validate O 
our O 
hypothesis O 
, O 
conditionally O 
immortalized O 
cerebral O 
pericyte O 
( O 
IPC O 
) O 
cultures O 
were O 
established O 
from O 
Immortomice O 
to O 
investigate O 
the O 
effect O 
of O 
high O 
glucose B-TRIVIAL 
on O 
oxidative O 
stress O 
and O 
pericyte O 
apoptosis O 
. O 
The O 
IPCs O 
expressed O 
pericyte O 
markers O 
and O 
induced O 
high O 
transendothelial O 
electrical O 
resistance O 
and O 
low O 
permeability O 
in O 
brain O 
endothelial O 
cell O 
monolayers O 
comparable O 
with O 
pericytes O 
in O 
primary O 
cultures O 
. O 
The O 
IPCs O 
also O 
secreted O 
cytokines O 
constitutively O 
and O 
in O 
response O 
to O 
lipopolysaccharide O 
similar O 
to O 
pericytes O 
. O 
High O 
glucose B-TRIVIAL 
caused O 
oxidative O 
stress O 
and O 
apoptosis O 
of O 
these O 
cells O 
, O 
with O 
both O 
oxidative O 
stress O 
and O 
apoptosis O 
significantly O 
reduced O 
after O 
mitochondrial O 
carbonic O 
anhydrase O 
inhibition O 
. O 
These O 
results O 
provide O 
the O 
first O 
evidence O 
that O 
pharmacological O 
inhibition O 
of O 
mitochondrial O 
carbonic O 
anhydrases O 
attenuates O 
pericyte O 
apoptosis O 
caused O 
by O 
high O 
glucose B-TRIVIAL 
-induced O 
oxidative O 
stress O 
. O 
Carbonic O 
anhydrase O 
inhibitors O 
have O 
a O 
long O 
history O 
of O 
safe O 
clinical O 
use O 
and O 
can O 
be O 
immediately O 
evaluated O 
for O 
this O 
new O 
indication O 
in O 
translational O 
research O 
. O 
Thus O 
, O 
mitochondrial O 
carbonic O 
anhydrases O 
may O 
provide O 
a O 
new O 
therapeutic O 
target O 
for O 
oxidative O 
stress O 
- O 
related O 
illnesses O 
of O 
the O 
brain O 
. O 

follistatin O 
is O 
a O 
regulatory O 
glycoprotein O 
with O 
widespread O 
biologic O 
functions O 
, O 
including O 
antiinflammatory O 
activities O 
, O 
wound O 
- O 
healing O 
properties O 
, O 
and O 
muscle O 
- O 
stimulating O 
effects O 
. O 
The O 
role O 
of O 
follistatin O 
in O 
a O 
wide O 
range O 
of O 
biologic O 
activities O 
shows O 
promise O 
for O 
potential O 
clinical O 
application O 
, O 
which O 
has O 
prompted O 
considerable O 
interest O 
in O 
the O 
investigation O 
of O 
the O 
protein O 
as O 
a O 
potential O 
disease O 
- O 
modifying O 
agent O 
. O 
In O 
spite O 
of O 
this O 
potential O 
, O 
the O 
development O 
of O 
follistatin O 
as O 
a O 
broad O 
use O 
biotherapeutic O 
has O 
been O 
severely O 
hindered O 
by O 
a O 
poor O 
understanding O 
and O 
characterization O 
of O 
its O 
pharmacokinetic O 
/ O 
pharmacodynamic O 
( O 
PK O 
/ O 
PD O 
) O 
relationships O 
. O 
Therefore O 
, O 
to O 
better O 
define O 
these O 
relationships O 
, O 
we O 
performed O 
in O 
- O 
depth O 
analyses O 
of O 
the O 
PK O 
/ O 
PD O 
relationships O 
of O 
native O 
follistatin-315 O 
( O 
FST315 O 
) O 
. O 
Our O 
data O 
indicate O 
that O 
the O 
intrinsic O 
PK O 
/ O 
PD O 
properties O 
of O 
native O 
FST315 O 
are O 
poorly O 
suited O 
for O 
acting O 
as O 
a O 
parentally O 
administered O 
biotherapeutic O 
with O 
broad O 
systemic O 
effects O 
. O 
Here O 
, O 
we O 
leveraged O 
protein O 
engineering O 
to O 
modify O 
the O 
PK O 
characteristics O 
of O 
the O 
native O 
molecule O 
by O 
fusing O 
FST315 O 
to O 
a O 
murine O 
IgG(1) O 
Fc O 
and O 
removing O 
the O 
intrinsic O 
heparan O 
sulfate B-SYSTEMATIC 
-binding O 
activity O 
of O 
follistatin O 
. O 
The O 
engineered O 
variant O 
molecule O 
had O 
~100- O 
and O 
~1600-fold O 
improvements O 
in O 
terminal O 
half O 
- O 
life O 
and O 
exposure O 
, O 
respectively O 
. O 
In O 
contrast O 
to O 
the O 
native O 
FST315 O 
, O 
the O 
variant O 
showed O 
a O 
robust O 
, O 
dose O 
- O 
dependent O 
pharmacological O 
effect O 
when O 
administered O 
subcutaneously O 
on O 
a O 
weekly O 
basis O 
in O 
mouse O 
models O 
of O 
muscle O 
atrophy O 
and O 
degeneration O 
. O 
These O 
studies O 
highlight O 
the O 
underappreciated O 
and O 
critical O 
relationship O 
between O 
optimizing O 
multiple O 
physical O 
and O 
chemical O 
properties O 
of O 
follistatin O 
on O 
its O 
overall O 
PK O 
/ O 
PD O 
profile O 
. O 
Moreover O 
, O 
our O 
findings O 
provide O 
the O 
first O 
documented O 
strategy O 
toward O 
the O 
development O 
of O 
a O 
follistatin O 
therapeutic O 
with O 
potential O 
use O 
in O 
patients O 
affected O 
with O 
skeletal O 
muscle O 
diseases O 
. O 

interfering O 
RNAs O 
( O 
siRNAs O 
) O 
direct O 
Argonaute O 
proteins O 
, O 
the O 
core O 
components O 
of O 
the O 
RNA-induced O 
silencing O 
complex O 
( O 
RISC O 
) O 
, O 
to O 
cleave O 
complementary O 
target O 
RNAs O 
. O 
Here O 
, O 
we O 
describe O 
a O 
method O 
to O 
purify O 
active O 
RISC O 
containing O 
a O 
single O 
, O 
unique O 
small O 
RNA O 
guide O 
sequence O 
. O 
We O 
begin O 
by O 
capturing O 
RISC O 
using O 
a O 
complementary O 
2'-O-methyl B-SYSTEMATIC 
oligonucleotide O 
tethered O 
to O 
beads O 
. O 
Unlike O 
other O 
methods O 
that O 
capture O 
RISC O 
but O 
do O 
not O 
allow O 
its O 
recovery O 
, O 
our O 
strategy O 
purifies O 
active O 
, O 
soluble O 
RISC O 
in O 
good O 
yield O 
. O 
The O 
method O 
takes O 
advantage O 
of O 
the O 
finding O 
that O 
RISC O 
partially O 
paired O 
to O 
a O 
target O 
through O 
its O 
siRNA O 
guide O 
dissociates O 
more O 
than O 
300 O 
times O 
faster O 
than O 
a O 
fully O 
paired O 
siRNA O 
in O 
RISC O 
. O 
We O 
use O 
this O 
strategy O 
to O 
purify O 
fly O 
Ago1- O 
and O 
Ago2-RISC O 
, O 
as O 
well O 
as O 
mouse O 
AGO2-RISC O 
. O 
The O 
method O 
can O 
discriminate O 
among O 
RISCs O 
programmed O 
with O 
different O 
guide O 
strands O 
, O 
making O 
it O 
possible O 
to O 
deplete O 
and O 
recover O 
specific O 
RISC O 
populations O 
. O 
Endogenous O 
microRNA O 
: O 
Argonaute O 
complexes O 
can O 
also O 
be O 
purified O 
from O 
cell O 
lysates O 
. O 
Our O 
method O 
scales O 
readily O 
and O 
takes O 
less O 
than O 
a O 
day O 
to O 
complete O 
. O 

of O 
percutaneous O 
absorption O 
of O 
esculetin B-TRIVIAL 
: O 
effect O 
of O 
chemical O 
enhancers O 
. O 

transdermal O 
absorption O 
of O 
esculetin B-TRIVIAL 
( O 
6,7-dihydroxycoumarin B-SYSTEMATIC 
) O 
, O 
an O 
oxidative O 
damage O 
inhibitor O 
, O 
was O 
evaluated O 
by O 
means O 
of O 
in O 
vitro O 
permeation O 
studies O 
in O 
which O 
vertical O 
Franz O 
- O 
type O 
diffusion O 
cells O 
and O 
pig O 
ear O 
skin O 
were O 
employed O 
. O 
To O 
determine O 
the O 
absorption O 
of O 
esculetin B-TRIVIAL 
, O 
we O 
validated O 
a O 
simple O 
, O 
accurate O 
, O 
precise O 
, O 
and O 
rapid O 
HPLC-UV O 
method O 
. O 
Additionally O 
, O 
the O 
effects O 
of O 
several O 
percutaneous O 
enhancers O 
were O 
studied O 
. O 
Pretreatment O 
of O 
porcine O 
skin O 
was O 
performed O 
with O 
ethanol B-SYSTEMATIC 
( O 
control O 
vehicle O 
) O 
, O 
decenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
, O 
R-(+)-limonene B-TRIVIAL 
, O 
and O 
laurocapram B-TRIVIAL 
( O 
Azone B-TRIVIAL 
® O 
) O 
( O 
5% O 
in O 
ethanol B-SYSTEMATIC 
, O 
w O 
/ O 
w O 
, O 
respectively O 
) O 
. O 
Pretreatment O 
of O 
skin O 
with O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
or O 
laurocapram B-TRIVIAL 
led O 
to O 
statistically O 
significant O 
differences O 
in O 
the O 
transdermal O 
flux O 
of O 
esculetin B-TRIVIAL 
with O 
respect O 
to O 
controls O 
. O 
Of O 
the O 
two O 
enhancers O 
, O 
laurocapram B-TRIVIAL 
showed O 
the O 
greatest O 
capacity O 
to O 
enhance O 
the O 
flux O 
of O 
esculetin B-TRIVIAL 
across O 
pig O 
skin O 
. O 

and O 
exploration O 
of O 
novel O 
boronic B-SYSTEMATIC 
acid I-SYSTEMATIC 
inhibitors O 
reveals O 
important O 
interactions O 
with O 
a O 
clavulanic B-TRIVIAL 
acid I-TRIVIAL 
-resistant O 
sulfhydryl B-FAMILY 
-variable O 
( O 
SHV O 
) O 
β-lactamase O 
. O 

resistant O 
( O 
IR O 
) O 
class O 
A O 
β-lactamases O 
pose O 
a O 
significant O 
threat O 
to O 
many O 
current O 
antibiotic O 
combinations O 
. O 
The O 
K234R O 
substitution O 
in O 
the O 
SHV O 
β-lactamase O 
, O 
from O 
Klebsiella O 
pneumoniae O 
, O 
results O 
in O 
resistance O 
to O 
ampicillin B-TRIVIAL 
/ O 
clavulanate B-TRIVIAL 
. O 
After O 
site O 
- O 
saturation O 
mutagenesis O 
of O 
Lys B-FORMULA 
-234 O 
in O 
SHV O 
, O 
microbiological O 
and O 
biochemical O 
characterization O 
of O 
the O 
resulting O 
β-lactamases O 
revealed O 
that O 
only O 
- O 
Arg B-FORMULA 
conferred O 
resistance O 
to O 
ampicillin B-TRIVIAL 
/ O 
clavulanate B-TRIVIAL 
. O 
X-ray O 
crystallography O 
revealed O 
two O 
conformations O 
of O 
Arg B-FORMULA 
-234 O 
and O 
Ser B-FORMULA 
-130 O 
in O 
SHV O 
K234R O 
. O 
The O 
movement O 
of O 
Ser B-FORMULA 
-130 O 
is O 
the O 
principal O 
cause O 
of O 
the O 
observed O 
clavulanate B-TRIVIAL 
resistance O 
. O 
A O 
panel O 
of O 
boronic B-SYSTEMATIC 
acid I-SYSTEMATIC 
inhibitors O 
was O 
designed O 
and O 
tested O 
against O 
SHV-1 O 
and O 
SHV O 
K234R O 
. O 
A O 
chiral O 
ampicillin B-TRIVIAL 
analogue O 
was O 
discovered O 
to O 
have O 
a O 
2.4 O 
± O 
0.2 O 
nM O 
K O 
(i) O 
for O 
SHV O 
K234R O 
; O 
the O 
chiral O 
ampicillin B-TRIVIAL 
analogue O 
formed O 
a O 
more O 
complex O 
hydrogen B-SYSTEMATIC 
-bonding O 
network O 
in O 
SHV O 
K234R O 
vs O 
SHV-1 O 
. O 
Consideration O 
of O 
the O 
spatial O 
position O 
of O 
Ser B-FORMULA 
-130 O 
and O 
Lys B-FORMULA 
-234 O 
and O 
this O 
hydrogen B-SYSTEMATIC 
-bonding O 
network O 
will O 
be O 
important O 
in O 
the O 
design O 
of O 
novel O 
antibiotics O 
targeting O 
IR O 
β-lactamases O 
. O 

hierarchical O 
function O 
layers O 
on O 
self O 
- O 
assembled O 
viral O 
templates O 
as O 
3D O 
nano O 
- O 
array O 
electrodes O 
for O 
integrated O 
Li B-FORMULA 
-ion O 
microbatteries O 
. O 

work O 
enables O 
an O 
elegant O 
bottom O 
- O 
up O 
solution O 
to O 
engineer O 
3D O 
microbattery O 
arrays O 
as O 
integral O 
power O 
sources O 
for O 
microelectronics O 
. O 
Thus O 
, O 
multilayers O 
of O 
functional O 
materials O 
were O 
hierarchically O 
architectured O 
over O 
tobacco O 
mosaic O 
virus O 
( O 
TMV O 
) O 
templates O 
that O 
were O 
genetically O 
modified O 
to O 
self O 
- O 
assemble O 
in O 
a O 
vertical O 
manner O 
on O 
current-collectors O 
, O 
so O 
that O 
optimum O 
power O 
and O 
energy O 
densities O 
accompanied O 
with O 
excellent O 
cycle O 
- O 
life O 
could O 
be O 
achieved O 
on O 
a O 
minimum O 
footprint O 
. O 
The O 
resultant O 
microbattery O 
based O 
on O 
self O 
- O 
aligned O 
LiFePO(4) B-FORMULA 
nanoforests O 
of O 
shell O 
- O 
core O 
- O 
shell O 
structure O 
, O 
with O 
precise O 
arrangement O 
of O 
various O 
auxiliary O 
material O 
layers O 
including O 
a O 
central O 
nanometric O 
metal O 
core O 
as O 
direct O 
electronic O 
pathway O 
to O 
current O 
collector O 
, O 
delivers O 
excellent O 
energy O 
density O 
and O 
stable O 
cycling O 
stability O 
only O 
rivaled O 
by O 
the O 
best O 
Li B-FORMULA 
-ion O 
batteries O 
of O 
conventional O 
configurations O 
, O 
while O 
providing O 
rate O 
performance O 
per O 
foot O 
- O 
print O 
and O 
on O 
- O 
site O 
manufacturability O 
unavailable O 
from O 
the O 
latter O 
. O 
This O 
approach O 
could O 
open O 
a O 
new O 
avenue O 
for O 
microelectromechanical O 
systems O 
( O 
MEMS O 
) O 
applications O 
, O 
which O 
would O 
significantly O 
benefit O 
from O 
the O 
concept O 
that O 
electrochemically O 
active O 
components O 
be O 
directly O 
engineered O 
and O 
fabricated O 
as O 
an O 
integral O 
part O 
of O 
the O 
integrated O 
circuit O 
( O 
IC O 
) O 
. O 

integral O 
asymmetric O 
membrane O 
was O 
fabricated O 
in O 
a O 
fast O 
and O 
one O 
- O 
step O 
process O 
by O 
combining O 
the O 
self O 
- O 
assembly O 
of O 
an O 
amphiphilic O 
block O 
copolymer O 
( O 
PS-b-P4VP B-ABBREVIATION 
) O 
with O 
nonsolvent-induced O 
phase O 
separation O 
. O 
The O 
structure O 
was O 
found O 
to O 
be O 
composed O 
of O 
a O 
thin O 
layer O 
of O 
densely O 
packed O 
highly O 
ordered O 
cylindrical O 
channels O 
with O 
uniform O 
pore O 
sizes O 
perpendicular O 
to O 
the O 
surface O 
on O 
top O 
of O 
a O 
nonordered O 
sponge O 
- O 
like O 
layer O 
. O 
The O 
as-assembled O 
membrane O 
obtained O 
a O 
water O 
flux O 
of O 
more O 
than O 
3200 O 
L O 
m(-2) O 
h(-1) O 
bar(-1) O 
, O 
which O 
was O 
at O 
least O 
an O 
order O 
of O 
magnitude O 
higher O 
than O 
the O 
water O 
fluxes O 
of O 
commercially O 
available O 
membranes O 
with O 
comparable O 
pore O 
sizes O 
, O 
making O 
this O 
membrane O 
particularly O 
well O 
suited O 
to O 
size O 
- O 
selective O 
and O 
charge O 
- O 
based O 
separation O 
of O 
biomolecules O 
. O 
To O 
test O 
the O 
performance O 
of O 
the O 
membrane O 
, O 
we O 
conducted O 
diffusion O 
experiments O 
at O 
the O 
physiological O 
pH O 
of O 
7.4 O 
using O 
bovine O 
serum O 
albumin O 
( O 
BSA O 
) O 
and O 
globulin-γ O 
, O 
two O 
proteins O 
with O 
different O 
diameters O 
but O 
too O 
close O 
in O 
size O 
( O 
2-fold O 
difference O 
in O 
molecular O 
mass O 
) O 
to O 
be O 
efficiently O 
separated O 
via O 
conventional O 
dialysis O 
membrane O 
processes O 
. O 
The O 
diffusion O 
rate O 
differed O 
by O 
a O 
factor O 
of O 
87 O 
, O 
the O 
highest O 
value O 
reported O 
to O 
date O 
. O 
We O 
also O 
analyzed O 
charge O 
- O 
based O 
diffusive O 
transport O 
and O 
separation O 
of O 
two O 
proteins O 
of O 
similar O 
molecular O 
weight O 
( O 
BSA O 
and O 
bovine O 
hemoglobin O 
( O 
BHb O 
) O 
) O 
through O 
the O 
membrane O 
as O 
a O 
function O 
of O 
external O 
pH O 
. O 
The O 
membrane O 
achieved O 
a O 
selectivity O 
of O 
about O 
10 O 
at O 
pH O 
4.7 O 
, O 
the O 
isoelectric O 
point O 
( O 
pI O 
) O 
of O 
BSA O 
. O 
We O 
then O 
positively O 
charged O 
the O 
membrane O 
to O 
improve O 
the O 
separation O 
selectivity O 
. O 
With O 
the O 
modified O 
membrane O 
BSA O 
was O 
completely O 
blocked O 
when O 
the O 
pH O 
was O 
7 O 
, O 
the O 
pI O 
of O 
BHb O 
, O 
while O 
BHb O 
was O 
completely O 
blocked O 
at O 
pH O 
4.7 O 
. O 
Our O 
results O 
demonstrate O 
the O 
potential O 
of O 
our O 
asymmetric O 
membrane O 
to O 
efficiently O 
separate O 
biological O 
substances O 
/ O 
pharmaceuticals O 
in O 
bioscience O 
, O 
biotechnology O 
, O 
and O 
biomedicine O 
applications O 
. O 

in O 
the O 
cuprate O 
YBa(2)Cu(3)O(7) B-FORMULA 
( O 
YBCO B-ABBREVIATION 
) O 
persists O 
up O 
to O 
huge O 
magnetic O 
fields O 
( O 
B O 
) O 
up O 
to O 
several O 
tens O 
of O 
Teslas O 
, O 
and O 
sensitive O 
direct O 
current O 
( O 
dc O 
) O 
superconducting O 
quantum O 
interference O 
devices O 
( O 
SQUIDs O 
) O 
can O 
be O 
realized O 
in O 
epitaxially O 
grown O 
YBCO B-ABBREVIATION 
films O 
by O 
using O 
grain O 
boundary O 
Josephson O 
junctions O 
( O 
GBJs O 
) O 
. O 
Here O 
we O 
present O 
the O 
realization O 
of O 
high O 
- O 
quality O 
YBCO B-ABBREVIATION 
nanoSQUIDs O 
, O 
patterned O 
by O 
focused O 
ion O 
beam O 
milling O 
. O 
We O 
demonstrate O 
low O 
- O 
noise O 
performance O 
of O 
such O 
a O 
SQUID O 
up O 
to O 
B O 
= O 
1 O 
T O 
applied O 
parallel O 
to O 
the O 
plane O 
of O 
the O 
SQUID O 
loop O 
at O 
the O 
temperature O 
T O 
= O 
4.2 O 
K O 
. O 
The O 
GBJs O 
are O 
shunted O 
by O 
a O 
thin O 
Au B-FORMULA 
layer O 
to O 
provide O 
nonhysteretic O 
current O 
voltage O 
characteristics O 
, O 
and O 
the O 
SQUID O 
incorporates O 
a O 
90 O 
nm O 
wide O 
constriction O 
which O 
is O 
used O 
for O 
on O 
- O 
chip O 
modulation O 
of O 
the O 
magnetic O 
flux O 
through O 
the O 
SQUID O 
loop O 
. O 
The O 
white O 
flux O 
noise O 
of O 
the O 
device O 
increases O 
only O 
slightly O 
from O 
1.3 O 
μΦ(0) O 
/ O 
( O 
Hz)(1 O 
/ O 
2 O 
) O 
at O 
B O 
= O 
0 O 
to O 
2.3 O 
μΦ(0) O 
/ O 
( O 
Hz))(1 O 
/ O 
2 O 
) O 
at O 
1 O 
T O 
. O 
Assuming O 
that O 
a O 
point O 
- O 
like O 
magnetic O 
particle O 
with O 
magnetization O 
in O 
the O 
plane O 
of O 
the O 
SQUID O 
loop O 
is O 
placed O 
directly O 
on O 
top O 
of O 
the O 
constriction O 
and O 
taking O 
into O 
account O 
the O 
geometry O 
of O 
the O 
SQUID O 
, O 
we O 
calculate O 
a O 
spin O 
sensitivity O 
S(μ)(1 O 
/ O 
2 O 
) O 
= O 
62 O 
μ(B) O 
/ O 
( O 
Hz))(1 O 
/ O 
2 O 
) O 
at O 
B O 
= O 
0 O 
and O 
110 O 
μ(B) O 
/ O 
( O 
Hz))(1 O 
/ O 
2 O 
) O 
at O 
1 O 
T O 
. O 
The O 
demonstration O 
of O 
low O 
noise O 
of O 
such O 
a O 
SQUID O 
in O 
Tesla O 
fields O 
is O 
a O 
decisive O 
step O 
toward O 
utilizing O 
the O 
full O 
potential O 
of O 
ultrasensitive O 
nanoSQUIDs O 
for O 
direct O 
measurements O 
of O 
magnetic O 
hysteresis O 
curves O 
of O 
magnetic O 
nanoparticles O 
and O 
molecular O 
magnets O 
. O 

of O 
pharmacogenetics O 
in O 
busulfan B-TRIVIAL 
/ O 
cyclophosphamide B-TRIVIAL 
conditioning O 
therapy O 
prior O 
to O 
hematopoietic O 
stem O 
cell O 
transplantation O 
. O 

stem O 
cell O 
transplantation O 
( O 
HSCT O 
) O 
is O 
a O 
curative O 
treatment O 
for O 
several O 
malignant O 
and O 
nonmalignant O 
disorders O 
. O 
Busulfan B-TRIVIAL 
( O 
Bu O 
) O 
and O 
cyclophosphamide B-TRIVIAL 
( O 
Cy O 
) O 
are O 
the O 
most O 
commonly O 
used O 
alkylators O 
in O 
high O 
- O 
dose O 
pretransplant O 
conditioning O 
for O 
HSCT O 
; O 
a O 
treatment O 
that O 
is O 
correlated O 
with O 
drug O 
- O 
related O 
toxicity O 
and O 
relapse O 
. O 
Pharmacogenetic O 
investigations O 
have O 
shown O 
that O 
CYP450 O 
, O 
as O 
well O 
as O 
aldehyde B-SYSTEMATIC 
dehydrogenase O 
, O 
are O 
clearly O 
involved O 
with O 
Cy O 
metabolism O 
and O 
are O 
associated O 
with O 
altered O 
treatment O 
response O 
, O 
Cy O 
metabolism O 
and O 
the O 
unique O 
stem O 
- O 
cell O 
sparing O 
capacity O 
. O 
Moreover O 
, O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
isoenzymes O 
have O 
been O 
associated O 
with O 
cellular O 
outward O 
transport O 
of O 
various O 
alkylating O 
agents O 
, O 
including O 
Cy O 
metabolites O 
, O 
melphalan B-TRIVIAL 
, O 
Bu O 
and O 
chlorambucil B-TRIVIAL 
. O 
A O 
shift O 
from O 
genetic O 
- O 
based O 
studies O 
to O 
whole O 
- O 
genome O 
- O 
based O 
investigations O 
of O 
Cy- O 
and O 
Bu-associated O 
markers O 
may O 
contribute O 
to O 
personalizing O 
the O 
conditioning O 
therapy O 
and O 
enhancing O 
the O 
clinical O 
outcome O 
of O 
HSCT O 
. O 

effects O 
and O 
inhibition O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
in O 
macrophages O 
by O 
new O 
iron B-SYSTEMATIC 
-containing O 
carbon B-SYSTEMATIC 
monoxide I-SYSTEMATIC 
-releasing O 
molecules O 
( O 
CO-RMs O 
) O 
. O 

monoxide I-SYSTEMATIC 
-releasing O 
molecules O 
( O 
CO B-FORMULA 
-RMs O 
) O 
are O 
a O 
class O 
of O 
organometallo B-FAMILY 
carbonyl I-FAMILY 
complexes O 
capable O 
of O 
delivering O 
controlled O 
quantities O 
of O 
CO B-FORMULA 
gas O 
to O 
cells O 
and O 
tissues O 
thus O 
exerting O 
a O 
broad O 
spectrum O 
of O 
pharmacological O 
effects O 
. O 
Here O 
we O 
report O 
on O 
the O 
chemical O 
synthesis O 
, O 
CO B-FORMULA 
releasing O 
properties O 
, O 
cytotoxicity O 
profile O 
and O 
pharmacological O 
activities O 
of O 
four O 
novel O 
structurally O 
related O 
iron B-FAMILY 
- I-FAMILY 
allyl I-FAMILY 
carbonyls I-FAMILY 
. O 
The O 
major O 
difference O 
among O 
the O 
new O 
CO B-FORMULA 
-RMs O 
tested O 
was O 
that O 
three O 
compounds O 
( O 
CORM-307 B-IDENTIFIER 
, O 
CORM-308 B-IDENTIFIER 
and O 
CORM-314 B-IDENTIFIER 
) O 
were O 
soluble O 
in O 
dimethylsulfoxide B-SYSTEMATIC 
( O 
DMSO B-ABBREVIATION 
) O 
, O 
whereas O 
a O 
fourth O 
one O 
( O 
CORM-319 B-IDENTIFIER 
) O 
was O 
rendered O 
water O 
- O 
soluble O 
by O 
reacting O 
the O 
iron B-SYSTEMATIC 
- I-SYSTEMATIC 
carbonyl I-SYSTEMATIC 
with O 
hydrogen B-SYSTEMATIC 
tetrafluoroborate I-SYSTEMATIC 
. O 
We O 
found O 
that O 
despite O 
the O 
fact O 
all O 
compounds O 
liberated O 
CO B-FORMULA 
, O 
CO B-FORMULA 
-RMs O 
soluble O 
in O 
DMSO B-ABBREVIATION 
caused O 
a O 
more O 
pronounced O 
toxic O 
effect O 
both O 
in O 
vascular O 
and O 
inflammatory O 
cells O 
as O 
well O 
as O 
in O 
isolated O 
vessels O 
. O 
More O 
specifically O 
, O 
iron B-FAMILY 
carbonyls I-FAMILY 
soluble O 
in O 
DMSO B-ABBREVIATION 
released O 
CO B-FORMULA 
with O 
a O 
fast O 
kinetic O 
and O 
displayed O 
a O 
marked O 
cytotoxic O 
effect O 
in O 
smooth O 
muscle O 
cells O 
and O 
RAW O 
247.6 O 
macrophages O 
despite O 
exerting O 
a O 
rapid O 
and O 
pronounced O 
vasorelaxation O 
ex O 
vivo O 
. O 
In O 
contrast O 
, O 
CORM-319 B-IDENTIFIER 
that O 
is O 
soluble O 
in O 
water O 
and O 
liberated O 
CO B-FORMULA 
with O 
a O 
slower O 
rate O 
, O 
preserved O 
smooth O 
muscle O 
cell O 
viability O 
, O 
relaxed O 
aortic O 
tissue O 
and O 
exerted O 
a O 
significant O 
anti-inflammatory O 
effect O 
in O 
macrophages O 
challenged O 
with O 
endotoxin O 
. O 
These O 
data O 
suggest O 
that O 
iron B-FAMILY 
carbonyls I-FAMILY 
can O 
be O 
used O 
as O 
scaffolds O 
for O 
the O 
design O 
and O 
synthesis O 
of O 
pharmacologically O 
active O 
CO B-FORMULA 
-RMs O 
and O 
indicate O 
that O 
increasing O 
water O 
solubility O 
and O 
controlling O 
the O 
rate O 
of O 
CO B-FORMULA 
release O 
are O 
important O 
parameters O 
for O 
limiting O 
their O 
potential O 
toxic O 
effects O 
. O 

negative O 
and O 
positive O 
feedback O 
in O 
a O 
prenatal O 
androgen B-FAMILY 
-induced O 
mouse O 
model O 
of O 
polycystic O 
ovarian O 
syndrome O 
. O 

steroid B-FAMILY 
hormone O 
feedback O 
is O 
impaired O 
in O 
polycystic O 
ovarian O 
syndrome O 
( O 
PCOS O 
) O 
, O 
a O 
common O 
endocrine O 
disorder O 
characterized O 
by O 
hyperandrogenism O 
and O 
an O 
associated O 
increase O 
in O 
LH O 
pulse O 
frequency O 
. O 
Using O 
a O 
prenatal O 
androgen B-FAMILY 
( O 
PNA O 
) O 
- O 
treated O 
mouse O 
model O 
of O 
PCOS O 
, O 
we O 
aimed O 
to O 
investigate O 
negative O 
and O 
positive O 
feedback O 
effects O 
of O 
estrogens B-FAMILY 
on O 
the O 
hypothalamic O 
- O 
pituitary O 
axis O 
regulation O 
of O 
LH O 
. O 
PNA O 
- O 
treated O 
mice O 
exhibited O 
severely O 
disrupted O 
estrous O 
cycles O 
, O 
hyperandrogenism O 
, O 
significantly O 
reduced O 
fertility O 
, O 
and O 
altered O 
ovarian O 
morphology O 
. O 
To O 
assess O 
the O 
negative O 
feedback O 
effects O 
of O 
estrogens B-FAMILY 
, O 
LH O 
was O 
measured O 
before O 
and O 
after O 
ovariectomy O 
and O 
after O 
estradiol B-TRIVIAL 
( O 
E2 O 
) O 
administration O 
. O 
Compared O 
with O 
controls O 
, O 
PNA O 
- O 
treated O 
mice O 
exhibited O 
a O 
blunted O 
postcastration O 
rise O 
in O 
LH O 
( O 
P O 
< O 
0.001 O 
) O 
and O 
an O 
absence O 
of O 
LH O 
suppression O 
after O 
E2 O 
administration O 
. O 
To O 
assess O 
E2-positive O 
feedback O 
, O 
control O 
and O 
PNA O 
- O 
treated O 
GnRH-green O 
fluorescent O 
protein O 
transgenic O 
mice O 
were O 
subjected O 
to O 
a O 
standard O 
ovariectomy O 
with O 
E2-replacement O 
regimen O 
, O 
and O 
both O 
plasma O 
and O 
perfusion O 
- O 
fixed O 
brains O 
were O 
collected O 
at O 
the O 
time O 
of O 
the O 
expected O 
GnRH O 
/ O 
LH O 
surge O 
. O 
Immunocytochemistry O 
and O 
confocal O 
imaging O 
of O 
cFos O 
and O 
green O 
fluorescent O 
protein O 
were O 
used O 
to O 
assess O 
GnRH O 
neuron O 
activation O 
and O 
spine O 
density O 
. O 
In O 
the O 
surged O 
group O 
, O 
both O 
control O 
and O 
PNA O 
- O 
treated O 
mice O 
had O 
significantly O 
increased O 
LH O 
and O 
cFos O 
activation O 
in O 
GnRH O 
neurons O 
( O 
P O 
< O 
0.05 O 
) O 
compared O 
with O 
nonsurged O 
animals O 
. O 
Spine O 
density O 
was O 
quantified O 
in O 
cFos O 
- O 
positive O 
and O 
-negative O 
GnRH O 
neurons O 
to O 
examine O 
whether O 
there O 
was O 
an O 
increase O 
in O 
spine O 
density O 
in O 
cFos O 
- O 
expressing O 
GnRH O 
neurons O 
of O 
surged O 
mice O 
as O 
expected O 
. O 
A O 
significant O 
increase O 
in O 
spine O 
density O 
in O 
cFos O 
- O 
expressing O 
GnRH O 
neurons O 
was O 
evident O 
in O 
control O 
animals O 
; O 
however O 
, O 
no O 
significant O 
increase O 
was O 
observed O 
in O 
the O 
PNA O 
- O 
treated O 
mice O 
because O 
spine O 
density O 
was O 
elevated O 
across O 
all O 
GnRH O 
neurons O 
. O 
These O 
data O 
support O 
that O 
PNA O 
treatment O 
results O 
in O 
a O 
PCOS O 
- O 
like O 
phenotype O 
that O 
includes O 
impaired O 
E2-negative O 
feedback O 
. O 
Additionally O 
, O 
although O 
E2-positive O 
feedback O 
capability O 
is O 
retained O 
in O 
PNA O 
mice O 
, O 
elevated O 
GnRH O 
neuron O 
spine O 
density O 
may O 
reflect O 
altered O 
synaptic O 
regulation O 
. O 

effects O 
of O 
a O 
bazedoxifene B-TRIVIAL 
/ O 
conjugated O 
equine O 
estrogen B-FAMILY 
combination O 
on O 
human O 
breast O 
cancer O 
cells O 
in O 
vitro O 
. O 

cancer O 
incidence O 
is O 
increased O 
in O 
women O 
receiving O 
menopausal O 
hormone O 
therapy O 
with O 
estrogen B-FAMILY 
plus O 
progestin O 
but O 
not O 
with O 
estrogen B-FAMILY 
alone O 
. O 
The O 
use O 
of O 
a O 
tissue O 
- O 
selective O 
estrogen B-FAMILY 
complex O 
( O 
TSEC O 
) O 
has O 
been O 
proposed O 
as O 
a O 
novel O 
menopausal O 
hormone O 
therapy O 
strategy O 
to O 
eliminate O 
the O 
requirement O 
for O 
a O 
progestogen B-FAMILY 
. O 
Combination O 
of O 
bazedoxifene B-TRIVIAL 
( O 
BZA B-ABBREVIATION 
) O 
with O 
conjugated O 
estrogens B-FAMILY 
( O 
CEs O 
) O 
, O 
the O 
first O 
TSEC O 
, O 
has O 
shown O 
beneficial O 
effects O 
. O 
Whether O 
it O 
would O 
exert O 
antiestrogenic O 
effects O 
on O 
breast O 
cancer O 
is O 
not O 
clear O 
. O 
To O 
address O 
this O 
issue O 
, O 
we O 
compared O 
estradiol B-TRIVIAL 
(E(2)) O 
and O 
CE O 
alone O 
on O 
proliferation O 
and O 
apoptosis O 
in O 
MCF-7 O 
breast O 
cancer O 
cells O 
. O 
CE O 
stimulated O 
growth O 
of O 
MCF-7 O 
cells O 
at O 
a O 
peak O 
concentration O 
10-fold O 
higher O 
than O 
required O 
for O 
E(2) O 
. O 
Both O 
CE O 
and O 
E(2) O 
alone O 
increased O 
DNA O 
synthesis O 
and O 
reduced O 
apoptosis O 
with O 
activation O 
of O 
MAPK O 
, O 
Akt O 
, O 
and O 
p70S6K O 
and O 
up O 
- O 
regulation O 
of O 
antiapoptotic O 
factors O 
survivin O 
, O 
Bcl-2 O 
, O 
and O 
X O 
- O 
linked O 
inhibitor O 
of O 
apoptosis O 
protein O 
, O 
These O 
effects O 
could O 
be O 
completely O 
blocked O 
by O 
BZA B-ABBREVIATION 
. O 
Gene O 
expression O 
studies O 
demonstrated O 
that O 
CE O 
and O 
E(2) O 
were O 
equally O 
potent O 
on O 
expression O 
of O 
cMyc O 
, O 
pS2 O 
, O 
and O 
WNT1 O 
inducible O 
signaling O 
pathway O 
protein O 
2 O 
, O 
whereas O 
the O 
stimulatory O 
effects O 
of O 
CE O 
on O 
progesterone B-TRIVIAL 
receptor O 
and O 
amphiregulin O 
expression O 
were O 
weaker O 
than O 
E(2) O 
. O 
BZA B-ABBREVIATION 
effectively O 
blocked O 
each O 
of O 
these O 
effects O 
and O 
showed O 
no O 
estrogen B-FAMILY 
agonistic O 
effects O 
when O 
used O 
alone O 
. O 
Our O 
results O 
indicate O 
that O 
the O 
stimulatory O 
effects O 
of O 
E(2) O 
or O 
CE O 
on O 
breast O 
cancer O 
cells O 
could O 
be O 
completely O 
abrogated O 
by O 
BZA B-ABBREVIATION 
. O 
These O 
studies O 
imply O 
that O 
the O 
CE/ O 
BZA B-ABBREVIATION 
, O 
TSEC O 
, O 
exerts O 
antiestrogenic O 
effects O 
on O 
breast O 
cancer O 
cells O 
and O 
might O 
block O 
the O 
growth O 
of O 
occult O 
breast O 
neoplasms O 
in O 
postmenopausal O 
women O 
, O 
resulting O 
in O 
an O 
overall O 
reduction O 
in O 
tumor O 
incidence O 
. O 

and O 
characterization O 
of O 
self O 
- O 
bridged O 
silver B-SYSTEMATIC 
vanadium I-SYSTEMATIC 
oxide I-SYSTEMATIC 
/ O 
CNTs O 
composite O 
and O 
its O 
enhanced O 
lithium B-SYSTEMATIC 
storage O 
performance O 
. O 

improvement O 
of O 
the O 
electrochemical O 
properties O 
of O 
electrode O 
materials O 
with O 
large O 
capacity O 
and O 
good O 
capacity O 
retention O 
is O 
becoming O 
an O 
important O 
task O 
in O 
the O 
field O 
of O 
lithium B-SYSTEMATIC 
ion O 
batteries O 
( O 
LIBs O 
) O 
. O 
We O 
designed O 
a O 
function O 
- O 
oriented O 
hybrid O 
material O 
consisting O 
of O 
silver B-SYSTEMATIC 
vanadium I-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
β- O 
AgVO(3) B-FORMULA 
) O 
nanowires O 
modified O 
with O 
uniform O 
Ag B-FORMULA 
nanoparticles O 
and O 
multi O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
CNTs O 
) O 
as O 
a O 
high O 
- O 
performance O 
cathode O 
material O 
for O 
LIBs O 
. O 
The O 
Ag B-FORMULA 
nanoparticles O 
which O 
precipitated O 
automatically O 
in O 
the O 
synthetic O 
process O 
act O 
as O 
a O 
bridge O 
between O 
the O 
β- O 
AgVO(3) B-FORMULA 
nanowires O 
and O 
CNTs O 
, O 
creating O 
a O 
self O 
- O 
bridged O 
network O 
structure O 
. O 
The O 
Ag B-FORMULA 
particles O 
at O 
the O 
junction O 
of O 
the O 
nanowires O 
and O 
CNTs O 
facilitate O 
electron O 
transport O 
from O 
the O 
CNTs O 
to O 
the O 
nanowires O 
, O 
and O 
thereby O 
improve O 
the O 
electrical O 
conductivity O 
of O 
the O 
β- O 
AgVO(3) B-FORMULA 
nanowires O 
and O 
the O 
composite O 
. O 
Moreover O 
, O 
the O 
self O 
- O 
bridged O 
network O 
is O 
hierarchically O 
porous O 
with O 
a O 
high O 
surface O 
area O 
. O 
When O 
used O 
as O 
a O 
cathode O 
material O 
, O 
this O 
composite O 
electrode O 
reveals O 
high O 
discharge O 
capacities O 
, O 
excellent O 
rate O 
capability O 
, O 
and O 
good O 
cycling O 
stability O 
. O 
The O 
improved O 
performance O 
of O 
the O 
composite O 
arises O 
from O 
its O 
unique O 
nanosized O 
β- O 
AgVO(3) B-FORMULA 
nanowires O 
with O 
short O 
diffusion O 
pathway O 
for O 
lithium B-SYSTEMATIC 
ions O 
, O 
efficient O 
electron O 
collection O 
and O 
transfer O 
in O 
the O 
presence O 
of O 
Ag B-FORMULA 
nanoparticles O 
, O 
together O 
with O 
excellent O 
electrical O 
conductivity O 
of O 
CNTs O 
. O 

growth O 
factor O 
β O 
( O 
TGF-β O 
) O 
, O 
a O 
key O 
mediator O 
of O 
fibrotic O 
responses O 
, O 
is O 
increased O 
in O 
asthma O 
and O 
drives O 
airway O 
remodeling O 
by O 
inducing O 
expression O 
of O 
extracellular O 
matrix O 
( O 
ECM O 
) O 
proteins O 
. O 
We O 
investigated O 
the O 
molecular O 
mechanisms O 
underlying O 
TGF-β-induced O 
ECM O 
expression O 
by O 
airway O 
smooth O 
muscle O 
cells O 
and O 
demonstrate O 
a O 
novel O 
link O 
between O 
TGF-β O 
and O 
Wingless O 
/ O 
integrase O 
1 O 
( O 
WNT O 
) O 
signaling O 
in O 
ECM O 
deposition O 
. O 
Airway O 
smooth O 
muscle O 
expresses O 
abundant O 
WNT O 
ligands O 
, O 
with O 
the O 
noncanonical O 
WNT-5A O 
being O 
the O 
most O 
profoundly O 
expressed O 
. O 
Interestingly O 
, O 
WNT-5A O 
shows O 
∼2-fold O 
higher O 
abundance O 
in O 
airway O 
smooth O 
muscle O 
cells O 
isolated O 
from O 
individuals O 
with O 
asthma O 
than O 
individuals O 
without O 
asthma O 
. O 
WNT-5A O 
is O 
markedly O 
induced O 
in O 
response O 
to O 
TGF-β O 
( O 
4-16-fold O 
; O 
EC50 O 
0.3 O 
ng O 
/ O 
ml O 
) O 
and O 
is O 
required O 
for O 
collagen O 
and O 
fibronectin O 
expression O 
by O 
airway O 
smooth O 
muscle O 
. O 
WNT-5A O 
engages O 
noncanonical O 
WNT O 
signaling O 
pathways O 
, O 
as O 
inhibition O 
of O 
Ca(2+) B-FORMULA 
and O 
c-Jun O 
N B-FORMULA 
-terminal O 
kinase O 
( O 
JNK O 
) O 
signaling O 
attenuated O 
this O 
TGF-β O 
response O 
, O 
whereas O 
the O 
canonical O 
WNT O 
antagonist O 
Dickkopf O 
1 O 
( O 
DKK-1 O 
) O 
did O 
not O 
. O 
Accordingly O 
, O 
WNT-5A O 
induced O 
JNK O 
phosphorylation O 
and O 
nuclear O 
translocation O 
of O 
nuclear O 
factor O 
of O 
activated O 
T O 
cells O 
c1 O 
( O 
NFATc1 O 
) O 
. O 
Furthermore O 
, O 
silencing O 
of O 
the O 
WNT-5A O 
receptors O 
Frizzled O 
8 O 
( O 
FZD8 O 
) O 
and O 
RYK O 
attenuated O 
TGF-β-induced O 
ECM O 
expression O 
. O 
Collectively O 
, O 
these O 
findings O 
demonstrate O 
that O 
noncanonical O 
WNT-5A O 
signaling O 
is O 
activated O 
by O 
and O 
necessary O 
for O 
TGF-β-induced O 
ECM O 
production O 
by O 
airway O 
smooth O 
muscle O 
cells O 
, O 
which O 
could O 
have O 
significance O 
in O 
asthma O 
pathogenesis.-Kumawat O 
, O 
K O 
. O 
, O 
Menzen O 
, O 
M O 
. O 
H O 
. O 
. O 
, O 
Bos O 
, O 
I O 
. O 
S O 
. O 
T O 
. O 
, O 
Baarsma O 
, O 
H O 
. O 
A O 
. O 
, O 
Borger O 
, O 
P O 
. O 
, O 
Roth O 
, O 
M O 
. O 
, O 
Tamm O 
, O 
M O 
. O 
, O 
Halayko O 
, O 
A O 
. O 
J O 
. O 
, O 
Simoons O 
, O 
M O 
. O 
, O 
Prins O 
, O 
A O 
. O 
, O 
Postma O 
, O 
D O 
. O 
S O 
. O 
, O 
Schmidt O 
, O 
M O 
. O 
, O 
and O 
Gosens O 
, O 
R O 
. O 
Noncanonical O 
WNT-5A O 
signaling O 
regulates O 
TGF-β-induced O 
extracellular O 
matrix O 
production O 
by O 
airway O 
smooth O 
muscle O 
cells O 
. O 

photophysics O 
of O 
7-(N,N'-diethylamino)coumarin-3-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
water/ O 
AOT B-ABBREVIATION 
/ O 
isooctane B-SYSTEMATIC 
reverse O 
micelles O 
: O 
an O 
excitation O 
wavelength O 
dependent O 
study O 
. O 

this O 
manuscript O 
we O 
have O 
studied O 
the O 
photophysics O 
of O 
7-(N,N'-diethylamino)coumarin-3-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
7-DCCA B-SYSTEMATIC 
) O 
in O 
water/ O 
AOT B-ABBREVIATION 
/ O 
isooctane B-SYSTEMATIC 
reverse O 
micelles O 
. O 
For O 
this O 
purpose O 
we O 
have O 
used O 
steady O 
state O 
absorption O 
and O 
fluorescence O 
emission O 
spectroscopy O 
and O 
time O 
resolved O 
fluorescence O 
spectroscopy O 
. O 
We O 
have O 
studied O 
the O 
spectral O 
behaviour O 
of O 
7-DCCA B-SYSTEMATIC 
inside O 
the O 
water/ O 
AOT B-ABBREVIATION 
/ O 
isooctane B-SYSTEMATIC 
reverse O 
micelles O 
with O 
variation O 
of O 
excitation O 
wavelength O 
. O 
We O 
have O 
studied O 
the O 
dynamics O 
of O 
solvent O 
and O 
rotational O 
relaxation O 
by O 
using O 
two O 
different O 
excitation O 
wavelengths O 
( O 
λ(exi) O 
= O 
375 O 
nm O 
and O 
λ(exi) O 
= O 
405 O 
nm O 
) O 
. O 
We O 
have O 
observed O 
the O 
excitation O 
wavelength O 
dependent O 
dynamics O 
of O 
7-DCCA B-SYSTEMATIC 
in O 
the O 
reverse O 
micelles O 
. O 
The O 
fluorescence O 
quantum O 
yield O 
, O 
decay O 
time O 
, O 
solvent O 
relaxation O 
time O 
and O 
rotational O 
relaxation O 
time O 
of O 
7-DCCA B-SYSTEMATIC 
in O 
reverse O 
micelles O 
vary O 
with O 
the O 
excitation O 
wavelength O 
. O 
A O 
two O 
step O 
and O 
wobbling O 
- O 
in O 
- O 
cone O 
model O 
was O 
used O 
to O 
interpret O 
the O 
rotational O 
relaxation O 
dynamics O 
of O 
7-DCCA B-SYSTEMATIC 
in O 
reverse O 
micelles O 
. O 

and O 
stimulated O 
release O 
of O 
circulating O 
tumor O 
cells O 
on O 
polymer O 
- O 
grafted O 
silicon B-SYSTEMATIC 
nanostructures O 
. O 

platform O 
for O 
capture O 
and O 
release O 
of O 
circulating O 
tumor O 
cells O 
is O 
demonstrated O 
by O 
utilizing O 
polymer O 
grafted O 
silicon B-SYSTEMATIC 
nanowires O 
. O 
In O 
this O 
platform O 
, O 
integration O 
of O 
ligand O 
- O 
receptor O 
recognition O 
, O 
nanostructure O 
amplification O 
, O 
and O 
thermal O 
responsive O 
polymers O 
enables O 
a O 
highly O 
efficient O 
and O 
selective O 
capture O 
of O 
cancer O 
cells O 
. O 
Subsequently O 
, O 
these O 
captured O 
cells O 
are O 
released O 
upon O 
a O 
physical O 
stimulation O 
with O 
outstanding O 
cell O 
viability O 
. O 

of O 
disease O 
- O 
associated O 
N B-FORMULA 
-linked O 
glycoproteins O 
. O 

-linked O 
glycoproteins O 
play O 
important O 
roles O 
in O 
biological O 
processes O 
, O 
including O 
cell O 
- O 
to O 
- O 
cell O 
recognition O 
, O 
growth O 
, O 
differentiation O 
, O 
and O 
programmed O 
cell O 
death O 
. O 
Specific O 
N B-FORMULA 
-linked O 
glycoprotein O 
changes O 
are O 
associated O 
with O 
disease O 
progression O 
and O 
identification O 
of O 
these O 
N B-FORMULA 
-linked O 
glycoproteins O 
has O 
potential O 
for O 
use O 
in O 
disease O 
diagnosis O 
, O 
prognosis O 
, O 
and O 
prediction O 
of O 
treatments O 
. O 
In O 
this O 
review O 
, O 
we O 
summarize O 
common O 
strategies O 
for O 
N B-FORMULA 
-linked O 
glycoprotein O 
characterization O 
and O 
applications O 
of O 
these O 
strategies O 
to O 
identification O 
of O 
glycoprotein O 
changes O 
associated O 
with O 
disease O 
states O 
. O 
We O 
also O 
review O 
the O 
N B-FORMULA 
-linked O 
glycoproteins O 
altered O 
in O 
diseases O 
such O 
as O 
breast O 
cancer O 
, O 
lung O 
cancer O 
, O 
and O 
prostate O 
cancer O 
. O 
Although O 
assays O 
for O 
these O 
glycoproteins O 
have O 
potential O 
clinical O 
utility O 
, O 
research O 
is O 
needed O 
to O 
translate O 
these O 
glycoproteins O 
to O 
clinical O 
biomarkers O 
. O 

of O 
guanidinylation O 
on O 
the O 
properties O 
of O 
poly(2-aminoethylmethacrylate) B-FAMILY 
-based O 
antibacterial O 
materials O 
. O 

effect O 
of O 
converting O 
ammonium B-SYSTEMATIC 
into O 
guanidine B-TRIVIAL 
moieties O 
, O 
compared O 
to O 
other O 
factors O 
such O 
as O 
molecular O 
weight O 
or O 
hydrophobicity O 
, O 
on O 
the O 
antibacterial O 
activity O 
is O 
investigated O 
for O 
homo- O 
and O 
copolymers O 
of O 
2-aminoethylmethacrylate B-SYSTEMATIC 
in O 
solution O 
or O 
coatings O 
. O 
Polymers O 
are O 
obtained O 
by O 
free O 
radical O 
polymerization O 
, O 
polymer O 
- O 
analogous O 
guanidinylation O 
is O 
conducted O 
with O 
cyanamide B-SYSTEMATIC 
; O 
non-leaching O 
immobilization O 
is O 
achieved O 
by O 
LBL O 
assembly O 
of O 
homopolymers O 
or O 
crosslinking O 
of O 
functional O 
sidegroups O 
in O 
copolymers O 
. O 
Antibacterial O 
activity O 
to O 
Escherichia O 
coli O 
or O 
Bacillus O 
subtilis O 
is O 
determined O 
by O 
different O 
standard O 
methods O 
. O 
Guanidinylation O 
improves O 
antibacterial O 
activity O 
and O 
speed O 
as O 
well O 
as O 
cytotoxicity O 
of O 
hydrophilic O 
homo- O 
and O 
copolymers O 
in O 
solution O 
or O 
coatings O 
. O 

sclerosis O 
( O 
MS O 
) O 
is O 
a O 
nervous O 
system O 
disease O 
that O 
affects O 
the O 
fatty O 
myelin O 
sheaths O 
around O 
the O 
axons O 
of O 
the O 
brain O 
and O 
spinal O 
cord O 
, O 
leading O 
to O 
demyelination O 
and O 
a O 
broad O 
range O 
of O 
signs O 
and O 
symptoms O 
. O 
MS O 
can O 
be O 
difficult O 
to O 
diagnose O 
because O 
its O 
signs O 
and O 
symptoms O 
may O 
be O 
similar O 
to O 
other O 
medical O 
problems O 
. O 
To O 
find O 
out O 
which O 
metabolites O 
in O 
serum O 
are O 
effective O 
for O 
the O 
diagnosis O 
of O 
MS O 
, O 
we O 
utilized O 
metabolic O 
profiling O 
using O 
proton O 
nuclear O 
magnetic O 
resonance O 
spectroscopy O 
( O 
(1)H B-FORMULA 
-NMR O 
) O 
. O 
Random O 
forest O 
( O 
RF O 
) O 
was O 
used O 
to O 
classify O 
the O 
MS O 
patients O 
and O 
healthy O 
subjects O 
. O 
Atomic O 
absorption O 
spectroscopy O 
was O 
used O 
to O 
measure O 
the O 
serum O 
levels O 
of O 
selenium B-SYSTEMATIC 
. O 
The O 
results O 
showed O 
that O 
the O 
levels O 
of O 
selenium B-SYSTEMATIC 
were O 
lower O 
in O 
the O 
MS O 
group O 
, O 
when O 
compared O 
with O 
the O 
control O 
group O 
. O 
RF O 
was O 
used O 
to O 
identify O 
the O 
metabolites O 
that O 
caused O 
selenium B-SYSTEMATIC 
changes O 
in O 
people O 
with O 
MS O 
by O 
building O 
a O 
correlation O 
model O 
between O 
these O 
metabolites O 
and O 
serum O 
levels O 
of O 
selenium B-SYSTEMATIC 
. O 
For O 
the O 
external O 
test O 
set O 
, O 
the O 
obtained O 
classification O 
model O 
showed O 
a O 
93% O 
correct O 
classification O 
of O 
MS O 
and O 
healthy O 
subjects O 
. O 
The O 
regression O 
model O 
of O 
levels O 
of O 
selenium B-SYSTEMATIC 
and O 
metabolites O 
showed O 
the O 
correlation O 
(R(2)) O 
value O 
of O 
0.88 O 
for O 
the O 
external O 
test O 
set O 
. O 
The O 
results O 
indicate O 
the O 
suitability O 
of O 
NMR O 
as O 
a O 
screen O 
for O 
identifying O 
MS O 
patients O 
and O 
healthy O 
subjects O 
. O 
A O 
novel O 
model O 
with O 
good O 
prediction O 
outcomes O 
was O 
constructed O 
between O 
serum O 
levels O 
of O 
selenium B-SYSTEMATIC 
and O 
NMR O 
data O 
. O 

explore O 
the O 
effect O 
of O 
an O 
ultrathin O 
elastic O 
coating O 
to O 
optimize O 
the O 
mechanical O 
stability O 
of O 
an O 
underlying O 
polymer O 
film O 
for O 
nanoscale O 
applications O 
. O 
The O 
coating O 
consists O 
of O 
a O 
several O 
nanometer O 
thin O 
plasma O 
- O 
polymerized O 
norbornene B-TRIVIAL 
layer O 
. O 
Scanning O 
probes O 
are O 
used O 
to O 
characterize O 
the O 
system O 
in O 
terms O 
of O 
shear O 
- O 
force O 
- O 
induced O 
wear O 
and O 
thermally O 
assisted O 
indentation O 
. O 
The O 
layer O 
transforms O 
a O 
weakly O 
performing O 
polystyrene B-SYSTEMATIC 
film O 
into O 
a O 
highly O 
wear O 
- O 
resistive O 
system O 
, O 
ideal O 
for O 
high O 
- O 
density O 
and O 
low O 
- O 
power O 
data O 
storage O 
applications O 
. O 
The O 
result O 
can O 
be O 
understood O 
from O 
the O 
indentation O 
characteristics O 
with O 
a O 
hot O 
and O 
sharp O 
indenter O 
tip O 
. O 
The O 
latter O 
gives O 
rise O 
to O 
a O 
deformation O 
mode O 
in O 
the O 
fully O 
plastic O 
regime O 
, O 
enabling O 
a O 
simple O 
interpretation O 
of O 
the O 
results O 
. O 
The O 
softening O 
transition O 
and O 
the O 
yield O 
stress O 
of O 
the O 
system O 
on O 
a O 
microsecond O 
time O 
scale O 
and O 
a O 
nanometer O 
size O 
scale O 
were O 
obtained O 
. O 
We O 
show O 
that O 
the O 
plastic O 
deformation O 
is O 
governed O 
by O 
yielding O 
in O 
the O 
polystyrene B-SYSTEMATIC 
sublayer O 
, O 
which O 
renders O 
the O 
overall O 
system O 
soft O 
for O 
plastic O 
deformation O 
. O 
The O 
ultrathin O 
protection O 
layer O 
contributes O 
as O 
an O 
elastic O 
skin O 
, O 
which O 
shields O 
part O 
of O 
the O 
temperature O 
and O 
pressure O 
and O 
enables O 
the O 
high O 
wear O 
resistance O 
against O 
lateral O 
forces O 
. O 
Moreover O 
, O 
the O 
method O 
of O 
probing O 
polymers O 
at O 
microsecond O 
and O 
nanometer O 
size O 
scales O 
opens O 
up O 
new O 
opportunities O 
for O 
studying O 
polymer O 
physics O 
in O 
a O 
largely O 
unexplored O 
regime O 
. O 
Thus O 
, O 
we O 
find O 
softening O 
temperatures O 
of O 
more O 
than O 
100 O 
°C O 
above O 
the O 
polystyrene B-SYSTEMATIC 
glass O 
transition O 
, O 
which O 
implies O 
that O 
for O 
the O 
short O 
interaction O 
time O 
scales O 
the O 
glassy O 
state O 
of O 
the O 
polymer O 
is O 
preserved O 
up O 
to O 
this O 
temperature O 
. O 

activity O 
of O 
achiral O 
ligand O 
SCH3 B-FORMULA 
adsorbed O 
on O 
achiral O 
Ag55 B-FORMULA 
clusters O 
: O 
relationship O 
between O 
adsorption O 
site O 
and O 
circular O 
dichroism O 
. O 

electronic O 
circular O 
dichroism O 
( O 
CD O 
) O 
spectra O 
of O 
a O 
methyl-thiol B-SYSTEMATIC 
adsorbed O 
at O 
different O 
sites O 
on O 
an O 
icosahedral O 
silver B-SYSTEMATIC 
nanoparticle O 
is O 
studied O 
by O 
using O 
time O 
- O 
perturbed O 
density O 
functional O 
theory O 
. O 
Despite O 
that O 
separately O 
molecule O 
and O 
nanoparticle O 
are O 
achiral O 
and O 
consequently O 
optically O 
inactive O 
, O 
the O 
Ag(55)-SCH(3) B-FORMULA 
compound O 
emerges O 
with O 
a O 
new O 
symmetry O 
, O 
which O 
may O 
be O 
chiral O 
or O 
not O 
depending O 
on O 
the O 
adsorption O 
site O 
and O 
orientation O 
of O 
the O 
molecule O 
. O 
It O 
is O 
found O 
that O 
chirality O 
is O 
favored O 
when O 
the O 
thiol B-FAMILY 
is O 
adsorbed O 
between O 
two O 
atoms O 
of O 
different O 
coordination O 
number O 
. O 
Chiral O 
compounds O 
have O 
characteristic O 
CD O 
spectra O 
in O 
the O 
UV-visible O 
region O 
, O 
where O 
Ag(55) B-FORMULA 
shows O 
optical O 
absorption O 
but O 
SCH(3) B-FORMULA 
does O 
not O 
; O 
revealing O 
that O 
highly O 
degenerated O 
molecular O 
- O 
like O 
electronic O 
states O 
of O 
Ag(55) B-FORMULA 
are O 
modified O 
by O 
the O 
presence O 
of O 
the O 
molecule O 
inducing O 
optical O 
activity O 
. O 
It O 
is O 
concluded O 
that O 
CD O 
line O 
- O 
shapes O 
and O 
magnitude O 
strongly O 
depend O 
on O 
the O 
site O 
where O 
the O 
adsorption O 
takes O 
place O 
, O 
while O 
its O 
intensity O 
is O 
modulated O 
by O 
the O 
molecule O 
orientation O 
. O 

- O 
Assisted O 
Assembly O 
of O 
Fullerene B-TRIVIAL 
( O 
C(60) B-TRIVIAL 
) O 
Nanorods O 
and O 
Nanotubes O 
Formed O 
at O 
a O 
Liquid-Liquid O 
Interface O 
. O 

we O 
report O 
the O 
surfactant O 
- O 
triggered O 
assembly O 
of O 
fullerene B-TRIVIAL 
( O 
C(60) B-TRIVIAL 
) O 
into O 
3D O 
flowerlike O 
microcrystals O 
at O 
the O 
liquid O 
- O 
liquid O 
interface O 
. O 
C(60) B-TRIVIAL 
crystals O 
were O 
grown O 
using O 
a O 
liquid O 
- O 
liquid O 
interfacial O 
precipitation O 
( O 
LLIP O 
) O 
method O 
by O 
layering O 
surfactant O 
solution O 
in O 
butanol B-SYSTEMATIC 
with O 
a O 
saturated O 
solution O 
of O 
C(60) B-TRIVIAL 
in O 
benzene B-SYSTEMATIC 
. O 
In O 
the O 
LLIP O 
method O 
, O 
it O 
is O 
suggested O 
that O 
the O 
crystal O 
formation O 
mechanism O 
is O 
driven O 
by O 
supersaturation O 
related O 
to O 
the O 
low O 
C(60) B-TRIVIAL 
solubility O 
in O 
alcohol O 
. O 
We O 
found O 
that O 
the O 
dimensions O 
of O 
the O 
synthesized O 
C(60) B-TRIVIAL 
flowers O 
depend O 
on O 
the O 
concentration O 
and O 
surfactant O 
type O 
. O 
In O 
the O 
absence O 
of O 
surfactant O 
( O 
i.e O 
. O 
, O 
in O 
the O 
butanol B-SYSTEMATIC 
/ O 
benzene B-SYSTEMATIC 
system O 
) O 
, O 
1D O 
C(60) B-TRIVIAL 
nanowhiskers O 
( O 
nanorods O 
) O 
and O 
C(60) B-TRIVIAL 
nanotubes O 
( O 
diameter O 
400 O 
nm-2 O 
μm O 
and O 
length O 
5-20 O 
μm O 
) O 
are O 
obtained O 
. O 
However O 
, O 
when O 
surfactants O 
are O 
incorporated O 
into O 
the O 
system O 
flowerlike O 
microcrystals O 
consisting O 
of O 
C(60) B-TRIVIAL 
nanotubes O 
are O 
observed O 
. O 
For O 
instance O 
, O 
crystals O 
grown O 
at O 
the O 
interface O 
of O 
a O 
0.01% O 
diglycerol B-TRIVIAL 
monolaurate I-TRIVIAL 
( O 
C(12)G(2) B-FORMULA 
) O 
nonionic O 
surfactant O 
in O 
butanol B-SYSTEMATIC 
with O 
benzene B-SYSTEMATIC 
lead O 
to O 
the O 
formation O 
of O 
flower O 
- O 
shaped O 
microcrystals O 
of O 
average O 
sizes O 
in O 
the O 
range O 
of O 
10-35 O 
μm O 
. O 
To O 
the O 
best O 
of O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
example O 
of O 
the O 
surfactant O 
- O 
assisted O 
assembly O 
of O 
C(60) B-TRIVIAL 
crystals O 
. O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
and O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
measurements O 
have O 
shown O 
that O 
fullerene B-TRIVIAL 
flowers O 
have O 
a O 
hexagonal O 
structure O 
with O 
cell O 
dimensions O 
of O 
a O 
= O 
2.539 O 
nm O 
and O 
c O 
= O 
1.021 O 
nm O 
, O 
which O 
differ O 
from O 
that O 
of O 
pristine O 
C(60) B-TRIVIAL 
. O 
Mixtures O 
of O 
flower O 
- O 
shaped O 
C(60) B-TRIVIAL 
crystals O 
and O 
free O 
- O 
standing O 
C(60) B-TRIVIAL 
nanotubes O 
are O 
found O 
in O 
the O 
0.1% O 
C(12)G(2) B-FORMULA 
/ O 
butanol B-SYSTEMATIC 
system O 
. O 
However O 
, O 
clusters O 
or O 
giant O 
aggregates O 
of O 
nanowhiskers O 
lacking O 
any O 
specific O 
shape O 
are O 
observed O 
in O 
the O 
1% O 
C(12)G(2) B-FORMULA 
/ O 
butanol O 
system O 
although O 
these O 
crystals O 
exhibit O 
hexagonal O 
close O 
- O 
packed O 
structures O 
. O 
Flower O 
- O 
shaped O 
C(60) B-TRIVIAL 
microcrystals O 
are O 
also O 
observed O 
with O 
anionic O 
surfactants O 
cetyltrimethylammonium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
CTAB B-ABBREVIATION 
) O 
and O 
cetyltrimethylammonium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
CTAC B-ABBREVIATION 
) O 
. O 
C(60) B-TRIVIAL 
flowers O 
obtained O 
from O 
0.01% O 
CTAB B-ABBREVIATION 
and O 
0.01% O 
CTAC B-ABBREVIATION 
also O 
exhibit O 
hexagonal O 
structures O 
with O 
cell O 
dimensions O 
of O 
a O 
= O 
2.329 O 
nm O 
and O 
c O 
= O 
1.273 O 
nm O 
, O 
a O 
= O 
2.459 O 
nm O 
and O 
c O 
= O 
0.938 O 
nm O 
, O 
respectively O 
. O 
Our O 
C(60) B-TRIVIAL 
flowers O 
exhibit O 
intense O 
photoluminescence O 
( O 
PL O 
) O 
and O 
a O 
blue O 
- O 
shifted O 
PL O 
intensity O 
maximum O 
compared O 
to O 
the O 
same O 
parameters O 
for O 
pristine O 
C(60) B-TRIVIAL 
, O 
demonstrating O 
the O 
potential O 
to O 
control O 
the O 
optoelectronic O 
properties O 
of O 
fullerene B-TRIVIAL 
-based O 
nanostructures O 
. O 

of O 
drug O 
interactions O 
of O 
GSK1292263 B-IDENTIFIER 
( O 
a O 
GPR119 O 
agonist O 
) O 
with O 
statins O 
: O 
from O 
in O 
vitro O 
data O 
to O 
clinical O 
study O 
design O 
. O 

. O 
This O 
work O 
investigated O 
the O 
drug O 
interaction O 
potential O 
of O 
GSK1292263 B-IDENTIFIER 
, O 
a O 
novel O 
GPR119 O 
agonist O 
, O 
with O 
the O 
HMG-coA O 
reductase O 
inhibitors O 
simvastatin B-TRIVIAL 
and O 
rosuvastatin B-TRIVIAL 
. O 
2 O 
. O 
In O 
vitro O 
experiments O 
assessed O 
the O 
inhibition O 
of O 
transporters O 
and O 
CYP O 
enzymes O 
by O 
GSK1292263 B-IDENTIFIER 
, O 
and O 
a O 
clinical O 
drug O 
interaction O 
study O 
investigated O 
the O 
effect O 
of O 
GSK1292263 B-IDENTIFIER 
( O 
300 O 
mg O 
BID O 
) O 
on O 
the O 
pharmacokinetic O 
profile O 
of O 
simvastatin B-TRIVIAL 
( O 
40 O 
mg O 
single O 
dose O 
) O 
and O 
rosuvastatin B-TRIVIAL 
( O 
10 O 
mg O 
single O 
dose O 
) O 
. O 
3 O 
. O 
In O 
vitro O 
, O 
GSK1292263 B-IDENTIFIER 
demonstrated O 
little O 
/ O 
weak O 
inhibition O 
( O 
IC50 O 
values O 
> O 
30 O 
μM O 
) O 
towards O 
CYPs O 
( O 
CYP1A2 O 
, O 
2C9 O 
, O 
2C19 O 
, O 
2D6 O 
, O 
3A4 O 
) O 
, O 
Pgp O 
, O 
OATP1B3 O 
, O 
or O 
OCT2 O 
. O 
However O 
, O 
GSK1292263 B-IDENTIFIER 
inhibited O 
BCRP O 
and O 
OATP1B1 O 
, O 
which O 
are O 
transporters O 
involved O 
in O 
statin O 
disposition O 
. O 
4 O 
. O 
In O 
the O 
clinical O 
study O 
, O 
small O 
increases O 
in O 
the O 
AUC(0-inf) O 
of O 
simvastatin B-TRIVIAL 
[ O 
mean O 
ratio O 
( O 
90% O 
CI O 
) O 
of O 
1.34 O 
( O 
1.22 O 
, O 
1.48 O 
) O 
] O 
and O 
rosuvastatin B-TRIVIAL 
[ O 
mean O 
ratio O 
( O 
90% O 
CI O 
) O 
of O 
1.39 O 
( O 
1.3 O 
, O 
1.49 O 
) O 
] O 
were O 
observed O 
when O 
co O 
- O 
administered O 
with O 
GSK1292263 B-IDENTIFIER 
, O 
which O 
is O 
consistent O 
with O 
an O 
inhibitory O 
effect O 
on O 
intestinal O 
BCRP O 
and O 
CYP3A4 O 
. O 
In O 
contrast O 
, O 
GSK1292263 B-IDENTIFIER 
did O 
not O 
inhibit O 
OATP1B1 O 
based O 
on O 
the O 
lack O 
of O 
changes O 
in O 
simvastatin B-TRIVIAL 
acid O 
exposure O 
[ O 
mean O 
AUC(0-inf) O 
ratio O 
( O 
90% O 
CI O 
) O 
of O 
1.05 O 
( O 
0.91 O 
, O 
1.21 O 
) O 
] O 
. O 
5 O 
. O 
GSK1292263 B-IDENTIFIER 
has O 
a O 
weak O 
drug O 
interaction O 
with O 
simvastatin B-TRIVIAL 
and O 
rosuvastain B-TRIVIAL 
. O 
This O 
study O 
provides O 
a O 
mechanistic O 
understanding O 
of O 
the O 
in O 
vivo O 
inhibition O 
of O 
transporters O 
and O 
enzymes O 
by O 
GSK1292263 B-IDENTIFIER 
. O 

-catalyzed O 
enantioselective O 
allylic O 
vinylation O 
. O 

first O 
example O 
of O 
Ir B-FORMULA 
-catalyzed O 
asymmetric O 
substitution O 
reaction O 
with O 
vinyl B-FAMILY 
trifluoroborates I-FAMILY 
is O 
described O 
. O 
The O 
direct O 
reaction O 
between O 
branched O 
, O 
racemic O 
allylic B-FAMILY 
alcohols I-FAMILY 
and O 
potassium B-FAMILY 
alkenyltrifluoroborates I-FAMILY 
proceeded O 
with O 
high O 
site O 
selectivity O 
and O 
excellent O 
enantioselectivity O 
( O 
up O 
to O 
99% O 
) O 
mediated O 
by O 
an O 
Ir-(P,olefin) B-FAMILY 
complex O 
. O 
This O 
method O 
allows O 
rapid O 
access O 
to O 
various O 
1,4-dienes B-FAMILY 
or O 
trienes B-FAMILY 
including O 
the O 
biologically O 
active O 
natural O 
products O 
(-)-nyasol B-TRIVIAL 
and O 
(-)-hinokiresinol B-TRIVIAL 
. O 

toxicity O 
and O 
detoxification O 
in O 
ascomycetous O 
fungi O 
. O 

the O 
last O 
couple O 
of O 
decades O 
fungal O 
infections O 
have O 
become O 
a O 
significant O 
clinical O 
problem O 
. O 
A O 
major O 
interest O 
into O 
fungal O 
steroid B-FAMILY 
action O 
has O 
been O 
provoked O 
since O 
research O 
has O 
proven O 
that O 
steroid B-FAMILY 
hormones O 
are O 
toxic O 
to O 
fungi O 
and O 
affect O 
the O 
host O 
/ O 
fungus O 
relationship O 
. O 
Steroid B-FAMILY 
hormones O 
were O 
found O 
to O 
differ O 
in O 
their O 
antifungal O 
activity O 
in O 
ascomycetous O 
fungi O 
Hortaea O 
werneckii O 
, O 
Saccharomyces O 
cerevisiae O 
and O 
Aspergillus O 
oryzae O 
. O 
Dehydroepiandrosterone O 
was O 
shown O 
to O 
be O 
the O 
strongest O 
inhibitor O 
of O 
growth O 
in O 
all O 
three O 
varieties O 
of O 
fungi O 
followed O 
by O 
androstenedione B-TRIVIAL 
and O 
testosterone B-TRIVIAL 
. O 
For O 
their O 
protection O 
, O 
fungi O 
use O 
several O 
mechanisms O 
to O 
lower O 
the O 
toxic O 
effects O 
of O 
steroids B-FAMILY 
. O 
The O 
efficiency O 
of O 
biotransformation O 
in O 
detoxification O 
depended O 
on O 
the O 
microorganism O 
and O 
steroid B-FAMILY 
substrate O 
used O 
. O 
Biotransformation O 
was O 
a O 
relatively O 
slow O 
process O 
as O 
it O 
also O 
depended O 
on O 
the O 
growth O 
phase O 
of O 
the O 
fungus O 
. O 
In O 
addition O 
to O 
biotransformation O 
, O 
steroid B-FAMILY 
extrusion O 
out O 
of O 
the O 
cells O 
contributed O 
to O 
the O 
lowering O 
of O 
the O 
active O 
intracellular O 
steroid B-FAMILY 
concentration O 
. O 
Plasma O 
membrane O 
Pdr5 O 
transporter O 
was O 
found O 
to O 
be O 
the O 
most O 
effective O 
, O 
followed O 
by O 
Snq2 O 
transporter O 
and O 
vacuolar O 
transporters O 
Ybt1 O 
and O 
Ycf1 O 
. O 
Proteins O 
Aus1 O 
and O 
Dan1 O 
were O 
not O 
found O 
to O 
be O 
involved O 
in O 
steroid B-FAMILY 
import O 
. O 
The O 
research O 
of O 
possible O 
targets O 
of O 
steroid B-FAMILY 
hormone O 
action O 
in O 
fungi O 
suggests O 
that O 
steroid B-FAMILY 
hormones O 
inhibit O 
ergosterol B-TRIVIAL 
biosynthesis O 
in O 
S O 
. O 
cerevisiae O 
and O 
H O 
. O 
werneckii O 
. O 
Results O 
of O 
this O 
inhibition O 
caused O 
changes O 
in O 
the O 
sterol B-FAMILY 
content O 
of O 
the O 
cellular O 
membrane O 
. O 
The O 
presence O 
of O 
steroid B-FAMILY 
hormones O 
most O 
probably O 
causes O 
the O 
degradation O 
of O 
the O 
Tat2 O 
permease O 
and O 
impairment O 
of O 
tryptophan B-TRIVIAL 
import O 
. O 

, O 
a O 
potent O 
and O 
selective O 
negative O 
allosteric O 
modulator O 
of O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
7 O 
: O 
in O 
vitro O 
and O 
in O 
vivo O 
characterization O 
. O 

glutamate B-TRIVIAL 
receptor O 
7 O 
(mGlu(7)) O 
has O 
been O 
suggested O 
to O 
be O 
a O 
promising O 
novel O 
target O 
for O 
treatment O 
of O 
a O 
range O 
of O 
disorders O 
, O 
including O 
anxiety O 
, O 
post O 
- O 
traumatic O 
stress O 
disorder O 
, O 
depression O 
, O 
drug O 
abuse O 
, O 
and O 
schizophrenia O 
. O 
Here O 
we O 
characterized O 
a O 
potent O 
and O 
selective O 
mGlu(7) O 
negative O 
allosteric O 
modulator O 
( O 
NAM O 
) O 
(+)-6-(2,4-dimethylphenyl)-2-ethyl-6,7-dihydrobenzo[d]oxazol-4(5H)-one B-SYSTEMATIC 
( O 
ADX71743 B-IDENTIFIER 
) O 
. O 
In O 
vitro O 
, O 
Schild O 
plot O 
analysis O 
and O 
reversibility O 
tests O 
at O 
the O 
target O 
confirmed O 
the O 
NAM O 
properties O 
of O 
the O 
compound O 
and O 
attenuation O 
of O 
L-(+)-2-amino-4-phosphonobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
-induced O 
synaptic O 
depression O 
confirmed O 
activity O 
at O 
the O 
native O 
receptor O 
. O 
The O 
pharmacokinetic O 
analysis O 
of O 
ADX71743 B-IDENTIFIER 
in O 
mice O 
and O 
rats O 
revealed O 
that O 
it O 
is O 
bioavailable O 
after O 
s.c O 
. O 
administration O 
and O 
is O 
brain O 
penetrant O 
( O 
cerebrospinal O 
fluid O 
concentration O 
/ O 
total O 
plasma O 
concentration O 
ratio O 
at O 
C(max) O 
= O 
5.3% O 
) O 
. O 
In O 
vivo O 
, O 
ADX71743 B-IDENTIFIER 
( O 
50 O 
, O 
100 O 
, O 
150 O 
mg O 
/ O 
kg O 
, O 
s.c O 
. O 
) O 
caused O 
no O 
impairment O 
of O 
locomotor O 
activity O 
in O 
rats O 
and O 
mice O 
or O 
activity O 
on O 
rotarod O 
in O 
mice O 
. O 
ADX71743 B-IDENTIFIER 
had O 
an O 
anxiolytic O 
- O 
like O 
profile O 
in O 
the O 
marble O 
burying O 
and O 
elevated O 
plus O 
maze O 
tests O 
, O 
dose O 
- O 
dependently O 
reducing O 
the O 
number O 
of O 
buried O 
marbles O 
and O 
increasing O 
open O 
arm O 
exploration O 
, O 
respectively O 
. O 
Whereas O 
ADX71743 B-IDENTIFIER 
caused O 
a O 
small O 
reduction O 
in O 
amphetamine B-TRIVIAL 
-induced O 
hyperactivity O 
in O 
mice O 
, O 
it O 
was O 
inactive O 
in O 
the O 
mouse O 
2,5-dimethoxy-4-iodoamphetamine B-SYSTEMATIC 
-induced O 
head O 
twitch O 
and O 
the O 
rat O 
conditioned O 
avoidance O 
response O 
tests O 
. O 
In O 
addition O 
, O 
the O 
compound O 
was O 
inactive O 
in O 
the O 
mouse O 
forced O 
swim O 
test O 
. O 
These O 
data O 
suggest O 
that O 
ADX71743 B-IDENTIFIER 
is O 
a O 
suitable O 
compound O 
to O 
help O 
unravel O 
the O 
physiologic O 
role O 
of O 
mGlu(7) O 
and O 
to O 
better O 
understand O 
its O 
implication O 
in O 
central O 
nervous O 
system O 
diseases O 
. O 
Our O 
in O 
vivo O 
tests O 
using O 
ADX71743 B-IDENTIFIER 
, O 
reported O 
here O 
, O 
suggest O 
that O 
pharmacological O 
inhibition O 
of O 
mGlu(7) O 
is O 
a O 
valid O 
approach O 
for O 
developing O 
novel O 
pharmacotherapies O 
to O 
treat O 
anxiety O 
disorders O 
, O 
but O 
may O 
not O 
be O 
suitable O 
for O 
treatment O 
of O 
depression O 
or O 
psychosis O 
. O 

of O 
substituted O 
6-amino-4-(2,4-dimethoxyphenyl)-[1,2]dithiolo[4,3-b]pyrrol-5-ones B-FAMILY 
and O 
their O 
raising O 
leukocyte O 
count O 
activities O 
. O 

design O 
and O 
synthesis O 
of O 
a O 
series O 
of O 
substituted O 
6-amino-4-(2,4-dimethoxyphenyl)-[1,2]dithiolo[4,3-b]pyrrol-5-ones B-FAMILY 
are O 
described O 
. O 
All O 
the O 
synthesized O 
compounds O 
were O 
evaluated O 
for O 
raising O 
leukocyte O 
count O 
activities O 
in O 
normal O 
mice O 
. O 
Four O 
compounds O 
( O 
8a O 
, O 
b O 
, O 
d O 
, O 
h O 
) O 
exhibited O 
raising O 
leukocyte O 
count O 
activities O 
close O 
or O 
higher O 
than O 
positive O 
control O 
recombinant O 
human O 
granulocyte O 
colony O 
stimulating O 
factor O 
( O 
rhG-CSF O 
) O 
, O 
and O 
some O 
( O 
8e-g O 
, O 
k O 
, O 
p O 
, O 
r O 
) O 
had O 
a O 
moderate O 
effect O 
. O 
Among O 
them O 
, O 
the O 
most O 
potent O 
compound O 
8a O 
was O 
evaluated O 
for O 
its O 
antileukopenia O 
activity O 
in O 
cyclophosphamide B-TRIVIAL 
( O 
CTX O 
) O 
treated O 
mice O 
. O 
Interestingly O 
, O 
8a O 
exhibited O 
significant O 
antileukopenia O 
activity O 
as O 
compared O 
to O 
rhG-CSF O 
. O 
The O 
results O 
suggest O 
that O 
this O 
kind O 
of O 
compounds O 
might O 
be O 
utilized O 
for O 
the O 
development O 
of O 
new O 
candidate O 
for O 
treatment O 
of O 
leukocytopenia O 
. O 

of O 
steroidogenic O 
enzyme O 
expression O 
in O 
aldosterone B-TRIVIAL 
-producing O 
adenoma O 
: O 
a O 
comparison O 
with O 
various O 
human O 
adrenal O 
tumors O 
. O 

analyzed O 
the O 
expression O 
profiles O 
of O 
several O 
steroidogenic O 
enzymes O 
in O 
normal O 
adrenals O 
, O 
aldosterone B-TRIVIAL 
-producing O 
adenomas O 
( O 
APA O 
) O 
, O 
cortisol B-TRIVIAL 
-producing O 
adenomas O 
combined O 
with O 
Cushing's O 
syndrome O 
( O 
CPA O 
) O 
or O 
with O 
subclinical O 
Cushing's O 
syndrome O 
( O 
SCPA O 
) O 
, O 
and O 
nonfunctioning O 
adrenal O 
adenomas O 
( O 
NFA O 
) O 
to O 
clarify O 
the O 
nature O 
and O 
characteristics O 
of O 
steroidogenesis O 
in O 
APA O 
. O 
Clinical O 
data O 
were O 
collected O 
for O 
all O 
subjects O 
. O 
In O 
resected O 
adrenal O 
glands O 
( O 
normal O 
adrenals O 
, O 
APA O 
, O 
CPA O 
, O 
SCPA O 
, O 
and O 
NFA O 
) O 
, O 
the O 
mRNA O 
expression O 
levels O 
of O 
the O 
CYP17 O 
, O 
HSD3B2 O 
, O 
CYP11B1 O 
, O 
and O 
CYP11B2 O 
genes O 
were O 
studied O 
using O 
real O 
- O 
time O 
quantitative O 
PCR O 
and O 
immunohistochemistry O 
. O 
The O 
CYP11B2 O 
mRNA O 
level O 
in O 
APA O 
was O 
significantly O 
higher O 
than O 
that O 
in O 
other O 
groups O 
. O 
The O 
CYP17 O 
/ O 
HSD3B2 O 
ratio O 
for O 
mRNA O 
in O 
APA O 
was O 
significantly O 
lower O 
than O 
those O 
in O 
the O 
other O 
groups O 
. O 
Low O 
ratio O 
of O 
CYP17 O 
/ O 
HSD3B2 O 
with O 
high O 
expression O 
of O 
CYP11B2 O 
seems O 
to O 
explain O 
steroidogenic O 
characteristics O 
of O 
APA O 
. O 

theoretical O 
analysis O 
of O 
the O 
effect O 
of O 
the O 
hydrogenation O 
of O 
graphene B-TRIVIAL 
to O 
graphane B-TRIVIAL 
on O 
its O 
mechanical O 
properties O 
. O 

investigated O 
the O 
effect O 
of O 
the O 
hydrogenation O 
of O 
graphene B-TRIVIAL 
to O 
graphane B-TRIVIAL 
on O 
its O 
mechanical O 
properties O 
using O 
first O 
- O 
principles O 
calculations O 
based O 
on O 
density O 
- O 
functional O 
theory O 
. O 
The O 
hydrogenation O 
reduces O 
the O 
ultimate O 
strengths O 
in O 
all O 
three O 
tested O 
deformation O 
modes O 
-- O 
armchair O 
, O 
zigzag O 
, O 
and O 
biaxial O 
-- O 
and O 
the O 
in O 
- O 
plane O 
stiffness O 
by O 
1 O 
/ O 
3 O 
. O 
The O 
Poisson O 
ratio O 
was O 
reduced O 
from O 
0.178 O 
to O 
0.078 O 
, O 
a O 
56% O 
decrease O 
. O 
However O 
, O 
the O 
ultimate O 
strain O 
in O 
zigzag O 
deformation O 
was O 
increased O 
by O 
8.7% O 
. O 
The O 
shear O 
mode O 
elastic O 
constants O 
are O 
more O 
sensitive O 
than O 
longitudinal O 
ones O 
to O 
hydrogenation O 
. O 
The O 
fourth O 
and O 
fifth O 
order O 
longitudinal O 
mode O 
elastic O 
constants O 
are O 
inert O 
to O 
the O 
hydrogenation O 
, O 
in O 
contrast O 
to O 
a O 
large O 
decrease O 
of O 
those O 
in O 
second O 
and O 
third O 
order O 
. O 
The O 
hydrogenation O 
does O 
not O 
change O 
the O 
monotonic O 
decrement O 
of O 
the O 
Poisson O 
ratio O 
with O 
increasing O 
pressure O 
, O 
but O 
the O 
rate O 
is O 
tripled O 
. O 
Our O 
results O 
indicate O 
that O 
graphene B-TRIVIAL 
- O 
graphane B-TRIVIAL 
systems O 
could O 
be O 
used O 
for O 
hydrogen B-SYSTEMATIC 
storage O 
with O 
high O 
speed O 
of O 
charge O 
- O 
discharge O 
of O 
hydrogen B-SYSTEMATIC 
. O 

in O 
vacuo O 
and O 
in O 
solvents O 
: O 
a O 
quantum O 
chemical O 
study O 
of O 
a O 
prototypical O 
floppy O 
molecule O 
from O 
a O 
molecular O 
transport O 
perspective O 
. O 

report O 
results O 
of O 
quantum O 
chemical O 
calculations O 
for O 
the O 
neutral O 
and O 
anionic O 
species O 
of O 
(4,4')-bipyridine B-SYSTEMATIC 
( O 
44BPY B-SYSTEMATIC 
) O 
, O 
a O 
prototypical O 
molecule O 
with O 
a O 
floppy O 
degree O 
of O 
freedom O 
, O 
placed O 
in O 
vacuo O 
and O 
in O 
solvents O 
. O 
In O 
addition O 
to O 
equilibrium O 
geometries O 
and O 
vibrational O 
frequencies O 
and O 
spectra O 
, O 
we O 
present O 
adiabatic O 
energy O 
curves O 
for O 
the O 
vibrational O 
modes O 
with O 
significant O 
intramolecular O 
reorganization O 
upon O 
charge O 
transfer O 
. O 
Special O 
attention O 
is O 
paid O 
to O 
the O 
floppy O 
strongly O 
anharmonic O 
degree O 
of O 
freedom O 
of O 
44BPY B-SYSTEMATIC 
, O 
which O 
is O 
related O 
to O 
the O 
most O 
salient O 
structural O 
feature O 
, O 
namely O 
the O 
twist O 
angle O 
θ O 
between O 
the O 
two O 
pyridine B-SYSTEMATIC 
rings O 
. O 
The O 
relevance O 
of O 
the O 
present O 
results O 
for O 
molecular O 
transport O 
will O 
be O 
emphasized O 
. O 
We O 
show O 
that O 
the O 
solvent O 
acts O 
as O 
a O 
selective O 
gate O 
electrode O 
and O 
propose O 
a O 
scissor O 
operator O 
to O 
account O 
for O 
solvent O 
effects O 
on O 
molecular O 
transport O 
. O 
Our O 
result O 
on O 
the O 
conductance O 
G O 
vs O 
. O 
cos(2)θ O 
is O 
consistent O 
with O 
a O 
significant O 
transmission O 
in O 
perpendicular O 
conformation O 
indicated O 
by O 
previous O 
microscopic O 
analysis O 
. O 

3-sulfate I-SYSTEMATIC 
decreases O 
lipid O 
accumulation O 
in O 
diet O 
- O 
induced O 
nonalcoholic O 
fatty O 
liver O 
disease O 
mouse O 
model O 
. O 

regulatory O 
element O 
- O 
binding O 
protein-1c O 
( O 
SREBP-1c O 
) O 
increases O 
lipogenesis O 
at O 
the O 
transcriptional O 
level O 
, O 
and O 
its O 
expression O 
is O 
upregulated O 
by O 
liver O 
X O 
receptor O 
α O 
( O 
LXRα O 
) O 
. O 
The O 
LXRα O 
/ O 
SREBP-1c O 
signaling O 
may O 
play O 
a O 
crucial O 
role O 
in O 
the O 
pathogenesis O 
of O 
nonalcoholic O 
fatty O 
liver O 
disease O 
( O 
NAFLD O 
) O 
. O 
We O 
previously O 
reported O 
that O 
a O 
cholesterol B-TRIVIAL 
metabolite O 
, O 
5-cholesten-3β,25-diol B-SYSTEMATIC 
3-sulfate I-SYSTEMATIC 
( O 
25HC3S B-SYSTEMATIC 
) O 
, O 
inhibits O 
the O 
LXRα O 
signaling O 
and O 
reduces O 
lipogenesis O 
by O 
decreasing O 
SREBP-1c O 
expression O 
in O 
primary O 
hepatocytes O 
. O 
The O 
present O 
study O 
aims O 
to O 
investigate O 
the O 
effects O 
of O 
25HC3S B-SYSTEMATIC 
on O 
lipid O 
homeostasis O 
in O 
diet O 
- O 
induced O 
NAFLD O 
mouse O 
models O 
. O 
NAFLD O 
was O 
induced O 
by O 
feeding O 
a O 
high O 
- O 
fat O 
diet O 
( O 
HFD O 
) O 
in O 
C57BL O 
/ O 
6J O 
mice O 
. O 
The O 
effects O 
of O 
25HC3S B-SYSTEMATIC 
on O 
lipid O 
homeostasis O 
, O 
inflammatory O 
responses O 
, O 
and O 
insulin O 
sensitivity O 
were O 
evaluated O 
after O 
acute O 
treatments O 
or O 
long O 
- O 
term O 
treatments O 
. O 
Acute O 
treatments O 
with O 
25HC3S B-SYSTEMATIC 
decreased O 
serum O 
lipid O 
levels O 
, O 
and O 
long O 
- O 
term O 
treatments O 
decreased O 
hepatic O 
lipid O 
accumulation O 
in O 
the O 
NAFLD O 
mice O 
. O 
Gene O 
expression O 
analysis O 
showed O 
that O 
25HC3S B-SYSTEMATIC 
significantly O 
suppressed O 
the O 
SREBP-1c O 
signaling O 
pathway O 
that O 
was O 
associated O 
with O 
the O 
suppression O 
of O 
the O 
key O 
enzymes O 
involved O 
in O 
lipogenesis O 
: O 
fatty B-FAMILY 
acid I-FAMILY 
synthase O 
, O 
acetyl-CoA B-SYSTEMATIC 
carboxylase O 
1 O 
, O 
and O 
glycerol-3-phosphate B-SYSTEMATIC 
acyltransferase O 
. O 
In O 
addition O 
, O 
25HC3S B-SYSTEMATIC 
significantly O 
reduced O 
HFD-induced O 
hepatic O 
inflammation O 
as O 
evidenced O 
by O 
decreasing O 
tumor O 
necrosis O 
factor O 
and O 
interleukin O 
1 O 
α O 
/ O 
β O 
mRNA O 
levels O 
. O 
A O 
glucose B-TRIVIAL 
tolerance O 
test O 
and O 
insulin O 
tolerance O 
test O 
showed O 
that O 
25HC3S B-SYSTEMATIC 
administration O 
improved O 
HFD-induced O 
insulin O 
resistance O 
. O 
The O 
present O 
results O 
indicate O 
that O 
25HC3S B-SYSTEMATIC 
as O 
a O 
potent O 
endogenous O 
regulator O 
decreases O 
lipogenesis O 
, O 
and O 
oxysterol O 
sulfation O 
can O 
be O 
a O 
key O 
protective O 
regulatory O 
pathway O 
against O 
lipid O 
accumulation O 
and O 
lipid O 
- O 
induced O 
inflammation O 
in O 
vivo O 
. O 

tracer O 
diffusion O 
along O 
interfaces O 
of O 
strained O 
Y2O3 B-FORMULA 
/ O 
YSZ B-ABBREVIATION 
multilayers O 
. O 

boundaries O 
can O 
offer O 
fast O 
transport O 
paths O 
in O 
solid O 
electrolyte O 
materials O 
. O 
In O 
recent O 
studies O 
an O 
enhancement O 
of O 
the O 
ionic O 
conductivity O 
was O 
indeed O 
observed O 
in O 
micro- O 
/ O 
nanoscaled O 
Y(2)O(3) B-FORMULA 
-stabilised O 
ZrO(2) B-FORMULA 
( O 
YSZ B-ABBREVIATION 
) O 
composites O 
and O 
hetero O 
multilayers O 
of O 
thin O 
films O 
. O 
As O 
space O 
charge O 
regions O 
can O 
be O 
neglected O 
due O 
to O 
high O 
charger O 
carrier O 
concentrations O 
, O 
we O 
assume O 
that O 
strain O 
and O 
microstructural O 
changes O 
at O 
the O 
heterophase O 
boundaries O 
are O 
responsible O 
for O 
the O 
observed O 
conductivity O 
effects O 
. O 
In O 
order O 
to O 
obtain O 
independent O 
information O 
on O 
the O 
role O 
of O 
heterophase O 
boundaries O 
for O 
fast O 
transport O 
in O 
strained O 
solid O 
electrolytes O 
, O 
systematic O 
measurements O 
of O 
the O 
(18)O B-FORMULA 
-tracer O 
diffusion O 
coefficient O 
in O 
nanoscaled O 
YSZ B-ABBREVIATION 
/ O 
Y(2)O(3) B-FORMULA 
multilayers O 
were O 
performed O 
. O 
Multilayer O 
samples O 
were O 
prepared O 
by O 
Pulsed O 
Laser O 
Deposition O 
( O 
PLD O 
) O 
on O 
( O 
1 O 
) O 
Al(2)O(3) B-FORMULA 
substrates O 
and O 
characterised O 
by O 
X-Ray O 
Diffraction O 
( O 
XRD O 
) O 
, O 
Scanning O 
Electron O 
Microscopy O 
( O 
HRSEM O 
) O 
and O 
Time-of-Flight O 
Secondary O 
Ion O 
Mass O 
Spectrometry O 
( O 
ToF-SIMS O 
) O 
. O 
To O 
separate O 
interface O 
and O 
bulk O 
transport O 
from O 
the O 
total O 
oxygen B-SYSTEMATIC 
diffusivity O 
of O 
the O 
multilayer O 
system O 
, O 
the O 
( O 
average O 
) O 
thickness O 
of O 
the O 
YSZ B-ABBREVIATION 
-layers O 
in O 
the O 
multilayers O 
was O 
varied O 
from O 
45 O 
nm O 
to O 
12 O 
nm O 
. O 
Upon O 
decreasing O 
the O 
thickness O 
of O 
the O 
YSZ B-ABBREVIATION 
layers O 
, O 
respectively O 
increasing O 
the O 
density O 
of O 
parallel O 
interfaces O 
, O 
the O 
total O 
diffusion O 
coefficient O 
of O 
the O 
multilayer O 
system O 
is O 
increased O 
by O 
a O 
factor O 
of O 
2 O 
compared O 
to O 
bulk O 
YSZ B-ABBREVIATION 
. O 
The O 
experimental O 
results O 
agree O 
well O 
with O 
formerly O 
published O 
data O 
for O 
ionic O 
conductivity O 
measurements O 
. O 
They O 
also O 
support O 
a O 
negligible O 
contribution O 
of O 
partial O 
electronic O 
conductivity O 
in O 
the O 
multilayer O 
. O 

L-edge O 
X-ray O 
absorption O 
spectroscopy O 
of O 
oxy-picket O 
fence O 
porphyrin B-FAMILY 
: O 
experimental O 
insight O 
into O 
Fe B-FORMULA 
- O 
O2 B-FORMULA 
bonding O 
. O 

electronic O 
structure O 
of O 
the O 
Fe B-FORMULA 
- O 
O(2) B-FORMULA 
center O 
in O 
oxy-hemoglobin O 
and O 
oxy-myoglobin O 
is O 
a O 
long O 
- O 
standing O 
issue O 
in O 
the O 
field O 
of O 
bioinorganic O 
chemistry O 
. O 
Spectroscopic O 
studies O 
have O 
been O 
complicated O 
by O 
the O 
highly O 
delocalized O 
nature O 
of O 
the O 
porphyrin B-FAMILY 
, O 
and O 
calculations O 
require O 
interpretation O 
of O 
multideterminant O 
wave O 
functions O 
for O 
a O 
highly O 
covalent O 
metal O 
site O 
. O 
Here O 
, O 
iron B-SYSTEMATIC 
L-edge O 
X-ray O 
absorption O 
spectroscopy O 
, O 
interpreted O 
using O 
a O 
valence O 
bond O 
configuration O 
interaction O 
multiplet O 
model O 
, O 
is O 
applied O 
to O 
directly O 
probe O 
the O 
electronic O 
structure O 
of O 
the O 
iron B-SYSTEMATIC 
in O 
the O 
biomimetic O 
Fe B-FORMULA 
- O 
O(2) B-FORMULA 
heme B-FAMILY 
complex O 
[Fe(pfp)(1-MeIm)O(2)] B-FORMULA 
( O 
pfp B-ABBREVIATION 
( O 
" O 
picket B-FAMILY 
fence I-FAMILY 
porphyrin I-FAMILY 
" O 
) O 
= O 
meso-tetra(α,α,α,α-o-pivalamidophenyl)porphyrin B-SYSTEMATIC 
or O 
TpivPP B-ABBREVIATION 
) O 
. O 
This O 
method O 
allows O 
separate O 
estimates O 
of O 
σ- O 
donor O 
, O 
π- O 
donor O 
, O 
and O 
π-acceptor O 
interactions O 
through O 
ligand O 
- O 
to O 
- O 
metal O 
charge O 
transfer O 
and O 
metal O 
- O 
to O 
- O 
ligand O 
charge O 
transfer O 
mixing O 
pathways O 
. O 
The O 
L-edge O 
spectrum O 
of O 
[Fe(pfp)(1-MeIm)O(2)] B-FORMULA 
is O 
further O 
compared O 
to O 
those O 
of O 
[Fe(II)(pfp)(1-MeIm)(2)] B-FORMULA 
, O 
[Fe(II)(pfp)] B-FORMULA 
, O 
and O 
[Fe(III)(tpp)(ImH)(2)]Cl B-FORMULA 
( O 
tpp B-ABBREVIATION 
= O 
meso-tetraphenylporphyrin B-SYSTEMATIC 
) O 
which O 
have O 
Fe B-FORMULA 
(II) I-FORMULA 
S O 
= O 
0 O 
, O 
Fe B-FORMULA 
(II) I-FORMULA 
S O 
= O 
1 O 
, O 
and O 
Fe B-FORMULA 
(III) I-FORMULA 
S O 
= O 
1 O 
/ O 
2 O 
ground O 
states O 
, O 
respectively O 
. O 
These O 
serve O 
as O 
references O 
for O 
the O 
three O 
possible O 
contributions O 
to O 
the O 
ground O 
state O 
of O 
oxy-pfp B-SYSTEMATIC 
. O 
The O 
Fe B-FORMULA 
- O 
O(2) B-FORMULA 
pfp B-ABBREVIATION 
site O 
is O 
experimentally O 
determined O 
to O 
have O 
both O 
significant O 
σ-donation O 
and O 
a O 
strong O 
π-interaction O 
of O 
the O 
O(2) B-FORMULA 
with O 
the O 
iron B-SYSTEMATIC 
, O 
with O 
the O 
latter O 
having O 
implications O 
with O 
respect O 
to O 
the O 
spin O 
polarization O 
of O 
the O 
ground O 
state O 
. O 

the O 
Bonding O 
and O 
Electronic O 
Structure O 
of O 
Single O 
Atom O 
Dopants O 
in O 
Graphene B-TRIVIAL 
with O 
Electron O 
Energy O 
Loss O 
Spectroscopy O 
. O 

combination O 
of O 
scanning O 
transmission O 
electron O 
microscopy O 
, O 
electron O 
energy O 
loss O 
spectroscopy O 
, O 
and O 
ab O 
initio O 
calculations O 
reveal O 
striking O 
electronic O 
structure O 
differences O 
between O 
two O 
distinct O 
single O 
substitutional O 
Si B-FORMULA 
defect O 
geometries O 
in O 
graphene B-TRIVIAL 
. O 
Optimised O 
acquisition O 
conditions O 
allow O 
for O 
exceptional O 
signal O 
- O 
to O 
- O 
noise O 
levels O 
in O 
the O 
spectroscopic O 
data O 
. O 
The O 
near O 
- O 
edge O 
fine O 
structure O 
can O 
be O 
compared O 
with O 
great O 
accuracy O 
to O 
simulations O 
and O 
reveal O 
either O 
an O 
sp(3) O 
- O 
like O 
configuration O 
for O 
a O 
trivalent O 
Si B-FORMULA 
or O 
a O 
more O 
complicated O 
hybridized O 
structure O 
for O 
a O 
tetravalent O 
Si B-FORMULA 
impurity O 
. O 

the O 
pulsed O 
- O 
laser O 
- O 
induced O 
size O 
reduction O 
of O 
Au B-FORMULA 
and O 
Ag B-FORMULA 
nanoparticles O 
via O 
changes O 
in O 
the O 
external O 
pressure O 
, O 
laser O 
intensity O 
, O 
and O 
excitation O 
wavelength O 
. O 

laser O 
- O 
induced O 
size O 
reduction O 
of O 
aqueous O 
noble O 
metal O 
nanoparticles O 
has O 
been O 
the O 
subject O 
of O 
intensive O 
research O 
, O 
because O 
of O 
the O 
mechanistic O 
interest O 
in O 
the O 
light O 
- O 
nanoparticle O 
interactions O 
and O 
its O 
potential O 
application O 
to O 
size O 
control O 
. O 
The O 
photothermal O 
evaporation O 
hypothesis O 
has O 
gained O 
solid O 
support O 
. O 
However O 
, O 
the O 
polydispersity O 
of O 
the O 
final O 
products O 
is O 
considered O 
as O 
an O 
inherent O 
drawback O 
of O 
the O 
method O 
. O 
It O 
is O 
likely O 
that O 
the O 
polydispersity O 
arises O 
from O 
the O 
uncontrolled O 
heat O 
dissipation O 
caused O 
by O 
vapor O 
bubble O 
formation O 
in O 
the O 
ambient O 
atmosphere O 
. O 
To O 
overcome O 
this O 
problem O 
, O 
we O 
applied O 
high O 
pressures O 
of O 
30-100 O 
MPa O 
. O 
The O 
particle O 
size O 
was O 
regulated O 
by O 
adjusting O 
three O 
parameters O 
: O 
the O 
pressure O 
, O 
laser O 
intensity O 
, O 
and O 
excitation O 
wavelength O 
. O 
For O 
example O 
, O 
starting O 
from O 
a O 
colloidal O 
solution O 
of O 
100 O 
nm O 
diameter O 
gold O 
nanoparticles O 
, O 
highly O 
monodisperse O 
( O 
±3-5% O 
) O 
spheres O 
with O 
various O 
diameters O 
ranging O 
from O 
90 O 
to O 
30 O 
nm O 
were O 
fabricated O 
by O 
tuning O 
the O 
laser O 
intensity O 
at O 
100 O 
MPa O 
, O 
using O 
an O 
excitation O 
wavelength O 
of O 
532 O 
nm O 
. O 
Further O 
size O 
reduction O 
of O 
the O 
diameter O 
to O 
20 O 
nm O 
was O 
achieved O 
by O 
reducing O 
the O 
pressure O 
and O 
switching O 
the O 
excitation O 
wavelength O 
to O 
355 O 
nm O 
. O 
It O 
was O 
found O 
that O 
the O 
application O 
of O 
high O 
pressures O 
led O 
to O 
the O 
heat O 
loss O 
- O 
controlled O 
size O 
- O 
reduction O 
of O 
the O 
gold O 
nanoparticles O 
. O 
More O 
complicated O 
results O 
were O 
obtained O 
for O 
100 O 
nm O 
silver B-SYSTEMATIC 
nanoparticles O 
, O 
possibly O 
because O 
of O 
the O 
different O 
size O 
- O 
dependent O 
light O 
- O 
absorbing O 
nature O 
of O 
these O 
particles O 
. O 
Based O 
on O 
our O 
extensive O 
experimental O 
studies O 
, O 
a O 
detailed O 
picture O 
was O 
developed O 
for O 
the O 
nanosecond O 
laser O 
- O 
induced O 
fabrication O 
of O 
gold O 
and O 
silver B-SYSTEMATIC 
nanoparticles O 
, O 
leading O 
to O 
unprecedented O 
size O 
control O 
. O 

strategy O 
for O 
preparation O 
of O 
graphene B-TRIVIAL 
- O 
Pd B-FORMULA 
, O 
Pt B-FORMULA 
composite O 
, O 
and O 
its O 
enhanced O 
electrocatalytic O 
activity O 
for O 
alcohol B-FAMILY 
oxidation O 
. O 

advanced O 
electrodes O 
for O 
direct O 
alcohol B-FAMILY 
fuel O 
cells O 
, O 
graphene B-TRIVIAL 
- O 
Pd B-FORMULA 
and O 
graphene B-TRIVIAL 
- O 
Pt B-FORMULA 
composites O 
with O 
a O 
trace O 
of O 
SnO(2) B-FORMULA 
have O 
been O 
successfully O 
synthesized O 
by O 
a O 
modified O 
electroless O 
plating O 
technique O 
. O 
The O 
surface O 
of O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
is O 
first O 
sensitized O 
by O 
Sn(2+) B-FORMULA 
ions O 
, O 
and O 
subsequently O 
, O 
Pd B-FORMULA 
or O 
Pt B-FORMULA 
nanoparticles O 
are O 
deposited O 
on O 
the O 
surface O 
of O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
. O 
Finally O 
, O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
was O 
reduced O 
to O 
graphene B-TRIVIAL 
by O 
further O 
adding O 
NaBH(4) B-FORMULA 
. O 
Compared O 
to O 
other O 
carbon B-SYSTEMATIC 
-(e.g O 
. O 
, O 
Vulcan B-TRIVIAL 
XC-72R I-TRIVIAL 
) O 
supported O 
Pd B-FORMULA 
and O 
Pt B-FORMULA 
, O 
the O 
resultant O 
graphene B-TRIVIAL 
- O 
Pd B-FORMULA 
and O 
Pt B-FORMULA 
composites O 
exhibit O 
better O 
electrocatalytic O 
activity O 
and O 
long O 
- O 
term O 
stability O 
toward O 
alcohol B-FAMILY 
electrooxidation O 
. O 
Additionally O 
, O 
a O 
trace O 
amount O 
of O 
SnO(2) B-FORMULA 
formed O 
around O 
active O 
catalysts O 
may O 
also O 
be O 
beneficial O 
to O 
the O 
enhancement O 
of O 
electrochemical O 
activity O 
. O 

functionalization O 
of O 
polymer O 
surfaces O 
via O 
surface O 
- O 
initiated O 
atom O 
transfer O 
radical O 
polymerization O 
( O 
ATRP O 
) O 
is O 
of O 
crucial O 
importance O 
to O 
prepare O 
various O 
functional O 
materials O 
. O 
It O 
is O 
generally O 
complicated O 
to O 
conduct O 
ATRP O 
on O 
different O 
organic O 
material O 
surfaces O 
. O 
In O 
this O 
work O 
, O 
a O 
facile O 
photoinduced O 
one O 
- O 
step O 
method O 
was O 
first O 
developed O 
for O 
the O 
covalent O 
immobilization O 
of O 
ATRP O 
initiators O 
on O 
the O 
C-H B-FORMULA 
group O 
- O 
containing O 
substrates O 
such O 
as O 
biaxially O 
oriented O 
polypropylene B-SYSTEMATIC 
( O 
BOPP O 
) O 
. O 
The O 
C-H B-FORMULA 
bonds O 
of O 
precise O 
location O 
of O 
inert O 
polymer O 
surfaces O 
were O 
readily O 
transferred O 
to O 
bromoalkyl B-FAMILY 
initiator O 
, O 
followed O 
by O 
ATRP O 
of O 
2-(dimethylamino)ethyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
( O 
DMAEMA B-ABBREVIATION 
) O 
and O 
glycidyl B-TRIVIAL 
methacrylate I-TRIVIAL 
( O 
GMA B-ABBREVIATION 
) O 
, O 
respectively O 
, O 
to O 
produce O 
the O 
resultant O 
patterned O 
BOPP-g- O 
P(DMAEMA) B-ABBREVIATION 
and O 
BOPP-g- O 
P(GMA) B-ABBREVIATION 
films O 
. O 
The O 
epoxy B-SYSTEMATIC 
groups O 
of O 
the O 
P(GMA) B-ABBREVIATION 
microdomains O 
can O 
be O 
aminated O 
for O 
covalently O 
coupling O 
IgG O 
, O 
while O 
the O 
P(DMAEMA) B-ABBREVIATION 
microdomains O 
were O 
used O 
for O 
immobilizing O 
IgG O 
via O 
electronic O 
interactions O 
. O 
The O 
resultant O 
IgG-coupled O 
microdomains O 
could O 
interact O 
with O 
the O 
corresponding O 
target O 
proteins O 
, O 
anti-IgG O 
. O 

- O 
associated O 
phospholipase O 
A(2) O 
( O 
Lp-PLA(2) O 
or O 
PLA(2)G7 O 
) O 
binds O 
to O 
low O 
- O 
density O 
lipoprotein O 
( O 
LDL O 
) O 
particles O 
, O 
where O 
it O 
is O 
thought O 
to O 
hydrolyze O 
oxidatively O 
truncated O 
phospholipids O 
. O 
Lp-PLA(2) O 
has O 
also O 
been O 
implicated O 
as O 
a O 
pro O 
- O 
tumorigenic O 
enzyme O 
in O 
human O 
prostate O 
cancer O 
. O 
Several O 
inhibitors O 
of O 
Lp-PLA(2) O 
have O 
been O 
described O 
, O 
including O 
darapladib B-TRIVIAL 
, O 
which O 
is O 
currently O 
in O 
phase O 
3 O 
clinical O 
development O 
for O 
the O 
treatment O 
of O 
atherosclerosis O 
. O 
The O 
selectivity O 
that O 
darapladib B-TRIVIAL 
and O 
other O 
Lp-PLA(2) O 
inhibitors O 
display O 
across O 
the O 
larger O 
serine B-TRIVIAL 
hydrolase O 
family O 
has O 
not O 
, O 
however O 
, O 
been O 
reported O 
. O 
Here O 
, O 
we O 
describe O 
the O 
use O 
of O 
both O 
general O 
and O 
tailored O 
activity O 
- O 
based O 
probes O 
for O 
profiling O 
Lp-PLA(2) O 
and O 
inhibitors O 
of O 
this O 
enzyme O 
in O 
native O 
biological O 
systems O 
. O 
We O 
show O 
that O 
both O 
darapladib B-TRIVIAL 
and O 
a O 
novel O 
class O 
of O 
structurally O 
distinct O 
carbamate B-FAMILY 
inhibitors O 
inactivate O 
Lp-PLA(2) O 
in O 
mouse O 
tissues O 
and O 
human O 
cell O 
lines O 
with O 
high O 
selectivity O 
. O 
Our O 
findings O 
thus O 
identify O 
both O 
inhibitors O 
and O 
chemoproteomic O 
probes O 
that O 
are O 
suitable O 
for O 
investigating O 
Lp-PLA(2) O 
function O 
in O 
biological O 
systems O 
. O 

of O 
benzofuran B-SYSTEMATIC 
central O 
cores O 
for O 
the O 
inhibition O 
of O 
leukotriene B-TRIVIAL 
A(4) I-TRIVIAL 
hydrolase O 
. O 

( O 
LT's O 
) O 
are O 
known O 
to O 
play O 
a O 
physiological O 
role O 
in O 
inflammatory O 
immune O 
response O 
. O 
Leukotriene B-TRIVIAL 
A(4) I-TRIVIAL 
hydrolase O 
( O 
LTA(4)H O 
) O 
is O 
a O 
cystolic O 
enzyme O 
that O 
stereospecifically O 
catalyzes O 
the O 
transformation O 
of O 
LTA(4) B-ABBREVIATION 
to O 
LTB(4) B-ABBREVIATION 
. O 
LTB(4) B-ABBREVIATION 
is O 
a O 
known O 
pro O 
- O 
inflammatory O 
mediator O 
. O 
This O 
paper O 
describes O 
the O 
identification O 
and O 
synthesis O 
of O 
substituted O 
benzofurans B-FAMILY 
as O 
LTH(4)H O 
inhibitors O 
. O 
The O 
benzofuran B-SYSTEMATIC 
series O 
demonstrated O 
reduced O 
mouse O 
and O 
human O 
whole O 
blood O 
LTB(4) B-ABBREVIATION 
levels O 
in O 
vitro O 
and O 
led O 
to O 
the O 
identification O 
one O 
analog O 
for O 
advanced O 
profiling O 
. O 
Benzofuran B-SYSTEMATIC 
28 O 
showed O 
dose O 
responsive O 
target O 
engagement O 
and O 
provides O 
a O 
useful O 
tool O 
to O 
explore O 
a O 
LTA(4)H O 
inhibitor O 
for O 
the O 
treatment O 
of O 
inflammatory O 
diseases O 
, O 
such O 
as O 
asthma O 
and O 
inflammatory O 
bowel O 
disease O 
( O 
IBD O 
) O 
. O 

mismatch O 
repair O 
during O 
replication O 
is O 
a O 
conserved O 
process O 
essential O 
for O 
maintaining O 
genomic O 
stability O 
. O 
Mismatch O 
repair O 
is O 
also O 
implicated O 
in O 
cell O 
- O 
cycle O 
arrest O 
and O 
apoptosis O 
after O 
DNA O 
damage O 
. O 
Because O 
yeast O 
and O 
human O 
mismatch O 
repair O 
systems O 
are O 
well O 
conserved O 
, O 
we O 
have O 
employed O 
the O 
budding O 
yeast O 
Saccharomyces O 
cerevisiae O 
to O 
understand O 
the O 
regulation O 
and O 
function O 
of O 
the O 
mismatch O 
repair O 
gene O 
MSH2 O 
. O 
Using O 
a O 
luciferase O 
- O 
based O 
transcriptional O 
reporter O 
, O 
we O 
defined O 
a O 
218-bp O 
region O 
upstream O 
of O 
MSH2 O 
that O 
contains O 
cell O 
- O 
cycle O 
and O 
DNA O 
damage O 
responsive O 
elements O 
. O 
The O 
5 O 
' O 
end O 
of O 
the O 
MSH2 O 
transcript O 
was O 
mapped O 
by O 
primer O 
extension O 
and O 
was O 
found O 
to O 
encode O 
a O 
small O 
upstream O 
open O 
reading O 
frame O 
( O 
uORF O 
) O 
. O 
Mutagenesis O 
of O 
the O 
uORF O 
start O 
codon O 
or O 
of O 
the O 
uORF O 
stop O 
codon O 
, O 
which O 
creates O 
a O 
continuous O 
reading O 
frame O 
with O 
MSH2 O 
, O 
increased O 
Msh2 O 
steady O 
- O 
state O 
protein O 
levels O 
∼2-fold O 
. O 
Furthermore O 
, O 
we O 
found O 
that O 
the O 
cell O 
- O 
cycle O 
transcription O 
factors O 
Swi6 O 
, O 
Swi4 O 
, O 
and O 
Mbp1-along O 
with O 
SCB O 
/ O 
MCB O 
cell O 
- O 
cycle O 
binding O 
sites O 
upstream O 
of O 
MSH2-are O 
all O 
required O 
for O 
full O 
basal O 
expression O 
of O 
MSH2 O 
. O 
Mutagenesis O 
of O 
the O 
cell O 
- O 
cycle O 
boxes O 
resulted O 
in O 
a O 
minor O 
reduction O 
in O 
basal O 
Msh2 O 
levels O 
and O 
a O 
3-fold O 
defect O 
in O 
mismatch O 
repair O 
. O 
Disruption O 
of O 
the O 
cell O 
- O 
cycle O 
boxes O 
also O 
affected O 
growth O 
in O 
a O 
DNA O 
polymerase O 
- O 
defective O 
strain O 
background O 
where O 
mismatch O 
repair O 
is O 
essential O 
, O 
particularly O 
in O 
the O 
presence O 
of O 
the O 
DNA O 
damaging O 
agent O 
methyl B-SYSTEMATIC 
methane I-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
( O 
MMS B-ABBREVIATION 
) O 
. O 
Promoter O 
replacements O 
conferring O 
constitutive O 
expression O 
of O 
MSH2 O 
revealed O 
that O 
the O 
transcriptional O 
induction O 
in O 
response O 
to O 
MMS B-ABBREVIATION 
is O 
required O 
to O 
maintain O 
induced O 
levels O 
of O 
Msh2 O 
. O 
Turnover O 
experiments O 
confirmed O 
an O 
elevated O 
rate O 
of O 
degradation O 
in O 
the O 
presence O 
of O 
MMS B-ABBREVIATION 
. O 
Taken O 
together O 
, O 
the O 
data O 
show O 
that O 
the O 
DNA O 
damage O 
regulation O 
of O 
Msh2 O 
occurs O 
at O 
the O 
transcriptional O 
and O 
post O 
- O 
transcriptional O 
levels O 
. O 
The O 
transcriptional O 
and O 
translational O 
control O 
elements O 
identified O 
are O 
conserved O 
in O 
mammalian O 
cells O 
, O 
underscoring O 
the O 
use O 
of O 
yeast O 
as O 
a O 
model O 
system O 
to O 
examine O 
the O 
regulation O 
of O 
MSH2 O 
. O 

induces O 
in O 
vivo O 
regional O 
up O 
- O 
regulation O 
of O 
central O 
nicotinic O 
receptors O 
in O 
rats O 
and O 
potentiates O 
the O 
regulatory O 
effects O 
of O 
nicotine B-TRIVIAL 
on O 
these O 
receptors O 
. O 

( O 
NIC B-ABBREVIATION 
) O 
, O 
the O 
main O 
psychostimulant O 
compound O 
of O 
smoked O 
tobacco O 
, O 
exerts O 
its O 
effects O 
through O 
activation O 
of O 
central O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
nAChR O 
) O 
, O 
which O 
become O 
up O 
- O 
regulated O 
after O 
chronic O 
administration O 
. O 
Recent O 
work O 
has O 
demonstrated O 
that O 
the O 
recreational O 
drug O 
3,4-methylenedioxy-methamphetamine B-SYSTEMATIC 
( O 
MDMA B-ABBREVIATION 
) O 
has O 
affinity O 
for O 
nAChR O 
and O 
also O 
induces O 
up O 
- O 
regulation O 
of O 
nAChR O 
in O 
PC O 
12 O 
cells O 
. O 
Tobacco O 
and O 
MDMA B-ABBREVIATION 
are O 
often O 
consumed O 
together O 
. O 
In O 
the O 
present O 
work O 
we O 
studied O 
the O 
in O 
vivo O 
effect O 
of O 
a O 
classic O 
chronic O 
dosing O 
schedule O 
of O 
MDMA B-ABBREVIATION 
in O 
rats O 
, O 
alone O 
or O 
combined O 
with O 
a O 
chronic O 
schedule O 
of O 
NIC B-ABBREVIATION 
, O 
on O 
the O 
density O 
of O 
nAChR O 
and O 
on O 
serotonin B-TRIVIAL 
reuptake O 
transporters O 
. O 
MDMA B-ABBREVIATION 
induced O 
significant O 
decreases O 
in O 
[(3)H]paroxetine B-SYSTEMATIC 
binding O 
in O 
the O 
cortex O 
and O 
hippocampus O 
measured O 
24h O 
after O 
the O 
last O 
dose O 
and O 
these O 
decreases O 
were O 
not O 
modified O 
by O 
the O 
association O 
with O 
NIC B-ABBREVIATION 
. O 
In O 
the O 
prefrontal O 
cortex O 
, O 
NIC B-ABBREVIATION 
and O 
MDMA B-ABBREVIATION 
each O 
induced O 
significant O 
increases O 
in O 
[(3)H]epibatidine B-SYSTEMATIC 
binding O 
( O 
29.5 O 
and O 
34.6% O 
, O 
respectively O 
) O 
with O 
respect O 
to O 
saline O 
- O 
treated O 
rats O 
, O 
and O 
these O 
increases O 
were O 
significantly O 
potentiated O 
( O 
up O 
to O 
72.1% O 
) O 
when O 
the O 
two O 
drugs O 
were O 
associated O 
. O 
Also O 
in O 
this O 
area O 
, O 
[(3)H]methyllycaconitine B-SYSTEMATIC 
binding O 
was O 
increased O 
a O 
42.1% O 
with O 
NIC B-ABBREVIATION 
+ O 
MDMA B-ABBREVIATION 
but O 
not O 
when O 
they O 
were O 
given O 
alone O 
. O 
In O 
the O 
hippocampus O 
, O 
MDMA B-ABBREVIATION 
potentiated O 
the O 
α7 O 
regulatory O 
effects O 
of O 
NIC B-ABBREVIATION 
( O 
raising O 
a O 
25.5% O 
increase O 
to O 
52.5% O 
) O 
but O 
alone O 
was O 
devoid O 
of O 
effect O 
. O 
MDMA B-ABBREVIATION 
had O 
no O 
effect O 
on O 
heteromeric O 
nAChR O 
in O 
striatum O 
and O 
a O 
coronal O 
section O 
of O 
the O 
midbrain O 
containing O 
superior O 
colliculi O 
, O 
geniculate O 
nuclei O 
, O 
substantia O 
nigra O 
and O 
ventral O 
tegmental O 
area O 
. O 
Specific O 
immunoprecipitation O 
of O 
solubilised O 
receptors O 
suggests O 
that O 
the O 
up O 
- O 
regulated O 
heteromeric O 
nAChRs O 
contain O 
α4 O 
and O 
β2 O 
subunits O 
. O 
Western O 
blots O 
with O 
specific O 
α4 O 
and O 
α7 O 
antibodies O 
showed O 
no O 
significant O 
differences O 
between O 
the O 
groups O 
, O 
indicating O 
that O 
, O 
as O 
reported O 
for O 
nicotine B-TRIVIAL 
, O 
up O 
- O 
regulation O 
caused O 
by O 
MDMA B-ABBREVIATION 
is O 
due O 
to O 
post O 
- O 
translational O 
events O 
rather O 
than O 
increased O 
receptor O 
synthesis O 
. O 

, O 
expression O 
and O 
analysis O 
of O 
the O 
olfactory O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferases O 
in O 
coho O 
salmon O 
. O 

glutathione B-TRIVIAL 
S B-FORMULA 
-transferases O 
( O 
GSTs O 
) O 
provide O 
cellular O 
protection O 
by O 
detoxifying O 
xenobiotics O 
, O 
maintaining O 
redox O 
status O 
, O 
and O 
modulating O 
secondary O 
messengers O 
, O 
all O 
of O 
which O 
are O 
critical O 
to O 
maintaining O 
olfaction O 
in O 
salmonids O 
. O 
Here O 
, O 
we O 
characterized O 
the O 
major O 
coho O 
salmon O 
olfactory O 
GSTs O 
( O 
OlfGSTs O 
) O 
, O 
namely O 
omega O 
, O 
pi O 
, O 
and O 
rho O 
subclasses O 
. O 
OlfGST O 
omega O 
contained O 
an O 
open O 
reading O 
frame O 
of O 
720bp O 
and O 
encoded O 
a O 
protein O 
of O 
239 O 
amino B-FAMILY 
acids I-FAMILY 
. O 
OlfGST O 
pi O 
and O 
OlfGST O 
rho O 
contained O 
open O 
reading O 
frames O 
of O 
627 O 
and O 
681nt O 
, O 
respectively O 
, O 
and O 
encoded O 
proteins O 
of O 
208 O 
and O 
226 O 
amino B-FAMILY 
acids I-FAMILY 
. O 
Whole O 
- O 
protein O 
mass O 
spectrometry O 
yielded O 
molecular O 
weights O 
of O 
29950 O 
, O 
23354 O 
, O 
and O 
26,655Da O 
, O 
respectively O 
, O 
for O 
the O 
GST O 
omega O 
, O 
pi O 
, O 
and O 
rho O 
subunits O 
. O 
Homology O 
modeling O 
using O 
four O 
protein O 
- O 
structure O 
prediction O 
algorithms O 
suggest O 
that O 
the O 
active O 
sites O 
in O 
all O 
three O 
OlfGST O 
isoforms O 
resembled O 
counterparts O 
in O 
other O 
species O 
. O 
The O 
olfactory O 
GSTs O 
conjugated O 
prototypical O 
GST O 
substrates O 
, O 
but O 
only O 
OlfGST O 
rho O 
catalyzed O 
the O 
demethylation O 
of O 
the O 
pesticide O 
methyl B-TRIVIAL 
parathion I-TRIVIAL 
. O 
OlfGST O 
pi O 
and O 
rho O 
exhibited O 
thiol B-FAMILY 
oxidoreductase O 
activity O 
toward O 
2-hydroxyethyl B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
( O 
2-HEDS B-SYSTEMATIC 
) O 
and O 
conjugated O 
4-hydroxynonenal B-SYSTEMATIC 
( O 
HNE B-ABBREVIATION 
) O 
, O 
a O 
toxic O 
aldehyde B-SYSTEMATIC 
with O 
neurodegenerative O 
properties O 
. O 
The O 
kinetic O 
parameters O 
for O 
OlfGST O 
pi O 
conjugation O 
of O 
HNE B-ABBREVIATION 
were O 
K(M)=0.16 O 
± O 
0.06mM O 
and O 
V(max)=0.5 O 
± O 
0.1μmolmin⁻¹mg⁻¹ O 
, O 
whereas O 
OlfGST O 
rho O 
was O 
more O 
efficient O 
at O 
catalyzing O 
HNE B-ABBREVIATION 
conjugation O 
( O 
K(M)=0.022 O 
± O 
0.008 O 
mM O 
and O 
V(max)=0.47 O 
± O 
0.05μmolmin⁻¹mg⁻¹ O 
) O 
. O 
Our O 
findings O 
indicate O 
that O 
the O 
peripheral O 
olfactory O 
system O 
of O 
coho O 
expresses O 
GST O 
isoforms O 
that O 
detoxify O 
certain O 
electrophiles O 
and O 
pesticides O 
and O 
that O 
help O 
maintain O 
redox O 
status O 
and O 
signal O 
transduction O 
. O 

induced O 
apoptotic O 
changes O 
in O 
neural O 
stem O 
cells O 
: O 
amelioration O 
by O 
neurotrophin O 
support O 
. O 

( O 
SAL B-ABBREVIATION 
) O 
, O 
a O 
catechol B-FAMILY 
isoquinoline I-FAMILY 
has O 
invited O 
considerable O 
attention O 
due O 
to O 
its O 
structural O 
similarity O 
with O 
dopaminergic O 
neurotoxin O 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine B-SYSTEMATIC 
( O 
MPTP B-ABBREVIATION 
) O 
. O 
Its O 
high O 
endogenous O 
presence O 
in O 
Parkinsonian O 
brain O 
implicated O 
its O 
possible O 
association O 
with O 
the O 
disease O 
process O 
. O 
SAL B-ABBREVIATION 
is O 
also O 
present O 
in O 
alcohol O 
beverages O 
and O 
certain O 
food O 
materials O 
and O 
can O 
get O 
access O 
to O 
brain O 
especially O 
in O 
conditions O 
of O 
immature O 
or O 
impaired O 
BBB O 
. O 
Besides O 
this O 
, O 
the O 
effect O 
of O 
SAL B-ABBREVIATION 
on O 
neural O 
stem O 
cells O 
( O 
NSCs O 
) O 
which O 
are O 
potential O 
candidates O 
for O 
adult O 
neurogenesis O 
and O 
transplantation O 
mediated O 
rejuvenating O 
attempts O 
for O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
brain O 
has O 
not O 
been O 
known O 
so O 
far O 
. O 
NSCs O 
in O 
both O 
the O 
cases O 
have O 
to O 
overcome O 
suppressive O 
cues O 
of O 
diseased O 
brain O 
for O 
their O 
survival O 
and O 
function O 
. O 
In O 
this O 
study O 
we O 
explored O 
the O 
toxicity O 
of O 
SAL B-ABBREVIATION 
toward O 
NSCs O 
focusing O 
on O 
apoptosis O 
and O 
status O 
of O 
PI3K O 
survival O 
signaling O 
. O 
NSCs O 
cultured O 
from O 
embryonic O 
day O 
11 O 
rat O 
fetal O 
brain O 
including O 
those O 
differentiated O 
to O 
TH(+ve) O 
colonies O 
, O 
when O 
challenged O 
with O 
SAL B-ABBREVIATION 
( O 
1-100μM O 
) O 
, O 
elicited O 
a O 
concentration O 
and O 
time O 
dependent O 
cell O 
death O 
/ O 
loss O 
of O 
mitochondrial O 
viability O 
. O 
10μM O 
SAL B-ABBREVIATION 
on O 
which O 
significant O 
mitochondrial O 
impairment O 
initiated O 
was O 
further O 
used O 
to O 
study O 
mechanism O 
of O 
toxicity O 
. O 
Morphological O 
impairment O 
, O 
enhanced O 
TUNEL O 
positivity O 
, O 
cleaved O 
caspase-3 O 
and O 
decreased O 
Bcl-2 O 
: O 
Bax O 
suggested O 
apoptosis O 
. O 
Sal B-ABBREVIATION 
toxicity O 
coincided O 
with O 
reduced O 
pAkt O 
level O 
and O 
its O 
downstream O 
effectors O 
: O 
pCREB O 
, O 
pGSK-3β O 
, O 
Bcl-2 O 
and O 
neurotrophins O 
GDNF O 
, O 
BDNF O 
suggesting O 
repressed O 
PI3K O 
/ O 
Akt O 
signaling O 
. O 
Multiple O 
neurotrophic O 
factor O 
support O 
in O 
the O 
form O 
of O 
Olfactory O 
Ensheathing O 
Cell's O 
Conditioned O 
Media O 
( O 
OEC O 
CM O 
) O 
potentially O 
protected O 
NSCs O 
against O 
SAL B-ABBREVIATION 
through O 
activating O 
PI3K O 
/ O 
Akt O 
pathway O 
. O 
This O 
was O 
confirmed O 
on O 
adding O 
LY294002 B-IDENTIFIER 
the O 
PI3K O 
inhibitor O 
which O 
abolished O 
the O 
protection O 
. O 
We O 
inferred O 
that O 
SAL B-ABBREVIATION 
exerts O 
substantial O 
toxicity O 
toward O 
NSCs O 
. O 
These O 
findings O 
will O 
lead O 
to O 
better O 
understanding O 
of O 
endogenous O 
threats O 
that O 
might O 
affect O 
the O 
fate O 
of O 
transplanted O 
NSCs O 
and O 
their O 
probable O 
antidotes O 
. O 

in O 
vitro O 
test O 
systems O 
are O 
evaluated O 
for O 
assessment O 
of O 
the O 
toxicity O 
of O 
chemical O 
compounds O 
, O 
particular O 
efforts O 
are O 
made O 
to O 
mimic O 
the O 
in O 
vivo O 
reality O 
as O 
close O 
as O 
possible O 
. O 
Cellular O 
models O 
with O 
appropriate O 
metabolic O 
competence O 
, O 
i.e O 
. O 
with O 
the O 
potency O 
to O 
biotransform O 
chemical O 
compounds O 
, O 
are O 
considered O 
crucial O 
since O 
some O 
metabolites O 
have O 
a O 
different O 
toxicity O 
than O 
their O 
parent O 
compounds O 
. O 
In O 
this O 
study O 
a O 
cell O 
based O 
in O 
vitro O 
test O 
system O 
is O 
proposed O 
to O 
investigate O 
the O 
basal O 
cytotoxicity O 
of O 
several O 
reference O 
chemicals O 
. O 
Both O 
metabolic O 
competent O 
HepaRG O 
cells O 
and O 
cells O 
with O 
no O 
or O 
low O 
hepatic O 
enzyme O 
activity O 
( O 
undifferentiated O 
HepaRG O 
and O 
proliferating O 
HepG2 O 
) O 
were O 
used O 
. O 
The O 
classic O 
Neutral B-TRIVIAL 
Red I-TRIVIAL 
Uptake O 
( O 
NRU O 
) O 
assay O 
proved O 
to O 
be O 
robust O 
and O 
reliable O 
to O 
be O 
applied O 
as O 
viability O 
assay O 
. O 
The O 
test O 
was O 
performed O 
on O 
a O 
robotic O 
platform O 
, O 
which O 
enabled O 
fully O 
automated O 
and O 
simultaneous O 
screening O 
of O 
the O 
compounds O 
. O 
The O 
outcome O 
of O 
these O 
tests O 
grouped O 
the O 
tested O 
compounds O 
in O 
three O 
categories O 
following O 
their O 
detoxification O 
effect O 
( O 
benzo(a)pyrene B-SYSTEMATIC 
, O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
) O 
, O 
their O 
bio O 
- O 
activation O 
effect O 
( O 
aflatoxin B-TRIVIAL 
B1 I-TRIVIAL 
) O 
and O 
their O 
specific O 
effect O 
on O 
inhibition O 
of O 
cell O 
proliferation O 
( O 
cycloheximide B-TRIVIAL 
, O 
sodium B-SYSTEMATIC 
lauryl I-SYSTEMATIC 
sulphate I-SYSTEMATIC 
, O 
atropine B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
monohydrate I-SYSTEMATIC 
, O 
acetylsalicylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
. O 

results O 
from O 
a O 
subchronic O 
feeding O 
study O 
conducted O 
in O 
Sprague O 
– O 
Dawley O 
rats O 
fed O 
with O 
diets O 
containing O 
grain O 
from O 
4114 O 
( O 
OECD O 
unique O 
identifier O 
: O 
DP-ØØ4114-3 O 
) O 
maize O 
that O 
was O 
untreated O 
( O 
4114 O 
) O 
or O 
sprayed O 
in O 
field O 
with O 
glufosinate B-SYSTEMATIC 
ammonium I-SYSTEMATIC 
( O 
4114GLU O 
) O 
in O 
a O 
design O 
similar O 
to O 
previous O 
studies O 
are O 
reported O 
. O 
The O 
test O 
material O 
, O 
4114 O 
maize O 
, O 
is O 
a O 
hybrid O 
maize O 
produced O 
by O 
transformation O 
with O 
a O 
DNA O 
construct O 
encoding O 
4 O 
different O 
transgenic O 
proteins O 
for O 
resistance O 
to O 
lepidopteran O 
pests O 
, O 
coleopteran O 
pests O 
, O 
and O 
tolerance O 
to O 
the O 
herbicidal O 
active O 
ingredient O 
glufosinate B-SYSTEMATIC 
ammonium I-SYSTEMATIC 
. O 
There O 
were O 
a O 
total O 
of O 
144 O 
rats O 
divided O 
into O 
12 O 
groups O 
of O 
12 O 
rats O 
/ O 
sex O 
/ O 
group O 
. O 
All O 
experimental O 
diets O 
were O 
formulated O 
by O 
Purina O 
Mills O 
, O 
LLC O 
( O 
St O 
. O 
Louis O 
, O 
MO O 
) O 
in O 
accordance O 
with O 
the O 
standards O 
of O 
Purina O 
Mills O 
Labdiet O 
® O 
Certified O 
Rodent O 
LabDiet O 
® O 
5002 O 
. O 
The O 
incorporation O 
rate O 
of O 
maize O 
grain O 
in O 
all O 
diets O 
was O 
32% O 
( O 
wt O 
/ O 
wt O 
) O 
. O 
No O 
biologically O 
significant O 
, O 
treatment O 
related O 
differences O 
in O 
body O 
weight O 
, O 
food O 
consumption O 
, O 
clinical O 
pathology O 
parameters O 
( O 
hematology O 
, O 
blood O 
chemistry O 
, O 
urinalysis O 
, O 
or O 
organ O 
weight O 
) O 
were O 
observed O 
in O 
rats O 
consuming O 
the O 
diets O 
containing O 
4114 O 
maize O 
grain O 
compared O 
with O 
rats O 
fed O 
conventional O 
maize O 
diets O 
. O 
A O 
number O 
of O 
histologic O 
observations O 
were O 
noted O 
in O 
this O 
study O 
but O 
were O 
background O 
lesions O 
and O 
representative O 
of O 
what O 
would O 
be O 
expected O 
for O 
rats O 
of O 
this O 
age O 
and O 
strain O 
. O 
An O 
independent O 
panel O 
of O 
experts O 
determined O 
certain O 
observations O 
to O 
be O 
spontaneous O 
and O 
not O 
related O 
to O 
the O 
test O 
diet O 
. O 
Accordingly O 
, O 
these O 
results O 
support O 
the O 
conclusion O 
that O 
4114 O 
maize O 
grain O 
is O 
as O 
safe O 
and O 
nutritious O 
as O 
conventional O 
maize O 
grain O 
. O 

oil O 
oleuropein B-TRIVIAL 
has O 
anti-breast O 
cancer O 
properties O 
with O 
higher O 
efficiency O 
on O 
ER-negative O 
cells O 
. O 

cancer O 
constitutes O 
a O 
major O 
health O 
problem O 
for O 
women O 
worldwide O 
. O 
However O 
, O 
its O 
incidence O 
varies O 
between O 
populations O 
and O 
geographical O 
locations O 
. O 
These O 
variations O 
could O 
be O 
diet O 
- O 
related O 
, O 
since O 
there O 
are O 
several O 
carcinogenic O 
compounds O 
in O 
the O 
modern O 
diet O 
, O 
while O 
natural O 
products O 
contain O 
various O 
anti-cancer O 
elements O 
. O 
Several O 
lines O 
of O 
evidence O 
indicate O 
that O 
, O 
in O 
addition O 
to O 
their O 
clear O 
preventive O 
effect O 
, O 
these O 
compounds O 
could O 
also O 
be O 
used O 
as O 
therapeutic O 
agents O 
. O 
In O 
the O 
present O 
report O 
we O 
have O 
shown O 
that O 
oleuropein B-TRIVIAL 
, O 
a O 
pharmacologically O 
safe O 
natural O 
product O 
of O 
olive O 
leaf O 
, O 
has O 
potent O 
anti-breast O 
cancer O 
properties O 
. O 
Indeed O 
, O 
oleuropein B-TRIVIAL 
exhibits O 
specific O 
cytotoxicity O 
against O 
breast O 
cancer O 
cells O 
, O 
with O 
higher O 
effect O 
on O 
the O 
basal O 
- O 
like O 
MDA-MB-231 O 
cells O 
than O 
on O 
the O 
luminal O 
MCF-7 O 
cells O 
. O 
This O 
effect O 
is O 
mediated O 
through O 
the O 
induction O 
of O 
apoptosis O 
via O 
the O 
mitochondrial O 
pathway O 
. O 
Moreover O 
, O 
oleuropein B-TRIVIAL 
inhibits O 
cell O 
proliferation O 
by O 
delaying O 
the O 
cell O 
cycle O 
at O 
S O 
phase O 
and O 
up O 
- O 
regulated O 
the O 
cyclin O 
- O 
dependent O 
inhibitor O 
p21 O 
. O 
Furthermore O 
, O 
oleuropein B-TRIVIAL 
inhibited O 
the O 
anti-apoptosis O 
and O 
pro O 
- O 
proliferation O 
protein O 
NF-κB O 
and O 
its O 
main O 
oncogenic O 
target O 
cyclin O 
D1 O 
. O 
This O 
inhibition O 
could O 
explain O 
the O 
great O 
effect O 
of O 
oleuropein B-TRIVIAL 
on O 
cell O 
proliferation O 
and O 
cell O 
death O 
of O 
breast O 
cancer O 
cells O 
. O 
Therefore O 
, O 
oleuropein B-TRIVIAL 
warrants O 
further O 
investigations O 
to O 
prove O 
its O 
utility O 
in O 
preventing O 
/ O 
treating O 
breast O 
cancer O 
, O 
especially O 
the O 
less O 
- O 
responsive O 
basal O 
- O 
like O 
type O 
. O 

isolated O 
from O 
the O 
roots O 
of O 
Morinda O 
officinalis O 
ameliorates O 
proinflammatory O 
mediators O 
in O 
RAW O 
264.7 O 
macrophages O 
and O 
dextran O 
sulfate O 
sodium B-SYSTEMATIC 
(DSS)-induced O 
colitis O 
via O 
NF-κB O 
inactivation O 
. O 

previously O 
demonstrated O 
that O 
monotropein B-TRIVIAL 
isolated O 
from O 
the O 
roots O 
of O 
Morinda O 
officinalis O 
( O 
Rubiaceae O 
) O 
has O 
anti-inflammatory O 
effects O 
in O 
vivo O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
molecular O 
mechanisms O 
underlying O 
the O 
anti-inflammatory O 
effects O 
of O 
monotropein B-TRIVIAL 
in O 
lipopolysaccharide O 
(LPS)-induced O 
RAW O 
264.7 O 
macrophages O 
and O 
dextran O 
sulfate O 
sodium B-SYSTEMATIC 
(DSS)-induced O 
colitis O 
mouse O 
model O 
. O 
Monotropein B-TRIVIAL 
was O 
found O 
to O 
inhibit O 
the O 
expressions O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
, O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
, O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
, O 
and O 
interleukin-1β O 
( O 
IL-1β O 
) O 
mRNA O 
in O 
LPS-induced O 
RAW O 
264.7 O 
macrophages O 
. O 
Treatment O 
with O 
monotropein B-TRIVIAL 
decreased O 
the O 
DNA O 
binding O 
activity O 
of O 
nuclear O 
factor-κB O 
( O 
NF-κB O 
) O 
. O 
Consistent O 
with O 
these O 
findings O 
, O 
monotropein B-TRIVIAL 
also O 
suppressed O 
phosphorylation O 
and O 
degradation O 
of O 
inhibitory O 
κB-α O 
( O 
IκB-α O 
) O 
, O 
and O 
consequently O 
the O 
translocations O 
of O 
NF-κB O 
. O 
In O 
the O 
DSS-induced O 
colitis O 
model O 
, O 
monotropein B-TRIVIAL 
reduced O 
disease O 
activity O 
index O 
( O 
DAI O 
) O 
, O 
myeloperoxidase O 
( O 
MPO O 
) O 
activity O 
, O 
and O 
inflammation O 
- O 
related O 
protein O 
expressions O 
by O 
suppressing O 
NF-κB O 
activation O 
in O 
colon O 
mucosa O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
suggest O 
that O 
the O 
anti-inflammatory O 
effects O 
of O 
monotropein B-TRIVIAL 
are O 
mainly O 
related O 
to O 
the O 
inhibition O 
of O 
the O 
expressions O 
of O 
inflammatory O 
mediators O 
via O 
NF-κB O 
inactivation O 
, O 
and O 
support O 
its O 
possible O 
therapeutic O 
role O 
in O 
colitis O 
. O 

urinary O 
excretion O 
of O 
albumin O 
, O 
hemopexin O 
, O 
transferrin O 
and O 
VDBP O 
correlates O 
with O 
chronic O 
sensitization O 
to O 
gentamicin B-FAMILY 
nephrotoxicity O 
in O 
rats O 
. O 

nephrotoxicity O 
is O 
a O 
serious O 
health O 
and O 
economic O 
problem O 
worldwide O 
. O 
Rats O 
can O 
be O 
acutely O 
sensitized O 
to O 
acute O 
kidney O 
injury O 
( O 
AKI O 
) O 
by O 
subnephrotoxic O 
treatments O 
with O 
potentially O 
nephrotoxic O 
drugs O 
. O 
Acquired O 
sensitization O 
to O 
AKI O 
poses O 
a O 
silent O 
risk O 
impossible O 
to O 
diagnose O 
pre O 
- O 
emptively O 
with O 
the O 
technology O 
available O 
at O 
the O 
clinical O 
level O 
. O 
Herein O 
, O 
we O 
hypothesized O 
whether O 
a O 
chronic O 
, O 
subnephrotoxic O 
insult O 
to O 
the O 
kidneys O 
might O 
result O 
in O 
chronically O 
acquired O 
sensitization O 
to O 
AKI O 
, O 
and O 
whether O 
chronic O 
sensitization O 
might O 
be O 
detected O 
through O 
specific O 
urinary O 
markers O 
. O 
To O 
this O 
end O 
, O 
rats O 
were O 
treated O 
with O 
a O 
subtoxic O 
dosage O 
of O 
the O 
experimental O 
nephrotoxin O 
uranyl O 
nitrate B-SYSTEMATIC 
( O 
UN O 
) O 
in O 
the O 
drinking O 
water O 
for O 
21 O 
weeks O 
, O 
or O 
plain O 
water O 
( O 
as O 
control O 
) O 
, O 
and O 
then O 
with O 
low O 
- O 
dose O 
gentamicin B-FAMILY 
for O 
7 O 
days O 
. O 
Renal O 
function O 
and O 
renal O 
tissue O 
damage O 
were O 
evaluated O 
through O 
the O 
experiment O 
. O 
The O 
mild O 
renal O 
damage O 
caused O 
by O 
gentamicin B-FAMILY 
was O 
markedly O 
magnified O 
in O 
rats O 
having O 
received O 
UN O 
chronically O 
, O 
which O 
was O 
evident O 
both O 
at O 
the O 
functional O 
and O 
histological O 
level O 
. O 
Four O 
proteins O 
, O 
namely O 
albumin O 
, O 
hemopexin O 
, O 
transferrin O 
and O 
vitamin B-FAMILY 
D I-FAMILY 
binding O 
protein O 
were O 
increased O 
in O 
the O 
urine O 
in O 
temporal O 
association O 
with O 
the O 
appearance O 
of O 
chronic O 
predisposition O 
. O 
Although O 
further O 
studies O 
are O 
necessary O 
, O 
our O 
results O 
suggest O 
that O 
these O 
proteins O 
might O 
be O 
potentially O 
used O 
as O 
markers O 
of O 
hidden O 
, O 
chronic O 
predisposition O 
to O 
gentamicin B-FAMILY 
nephrotoxicity O 
, O 
in O 
order O 
to O 
appropriately O 
and O 
pre O 
- O 
emptively O 
stratify O 
and O 
handle O 
individuals O 
according O 
to O 
their O 
specific O 
risk O 
in O 
the O 
long O 
term O 
, O 
and O 
to O 
conveniently O 
optimize O 
their O 
life O 
conditions O 
or O 
additional O 
clinical O 
procedures O 
or O 
treatments O 
that O 
might O 
trigger O 
the O 
disease O 
. O 
This O 
might O 
reduce O 
AKI O 
incidence O 
and O 
severity O 
and O 
the O 
associated O 
costs O 
. O 

are O 
thought O 
to O 
play O 
an O 
important O 
role O 
in O 
several O 
aspects O 
of O 
bone O 
metabolism O 
including O 
the O 
recruitment O 
of O 
leukocytes O 
and O 
the O 
formation O 
of O 
osteoclasts O 
. O 
We O 
investigated O 
the O 
impact O 
of O 
diabetes O 
on O 
chemokine O 
expression O 
in O 
normal O 
and O 
diabetic O 
fracture O 
healing O 
. O 
Fracture O 
of O 
the O 
femur O 
was O 
performed O 
in O 
streptozotocin B-TRIVIAL 
-induced O 
diabetic O 
and O 
matched O 
normoglycemic O 
control O 
mice O 
. O 
Microarray O 
analysis O 
was O 
carried O 
out O 
and O 
chemokine O 
mRNA O 
levels O 
in O 
vivo O 
were O 
assessed O 
. O 
CCL4 O 
were O 
examined O 
in O 
fracture O 
calluses O 
by O 
immunohistochemistry O 
and O 
the O 
role O 
of O 
TNF O 
in O 
diabetes O 
- O 
enhanced O 
expression O 
was O 
investigated O 
by O 
treatment O 
of O 
animals O 
with O 
the O 
TNF-specific O 
inhibitor O 
, O 
pegsunercept O 
. O 
In O 
vitro O 
studies O 
were O 
conducted O 
with O 
ATDC5 O 
chondrocytes O 
. O 
Diabetes O 
significantly O 
upregulated O 
mRNA O 
levels O 
of O 
several O 
chemokines O 
in O 
vivo O 
including O 
CCL4 O 
, O 
CCL8 O 
, O 
CCL6 O 
, O 
CCL11 O 
, O 
CCL20 O 
, O 
CCL24 O 
, O 
CXCL2 O 
, O 
CXCL5 O 
and O 
chemokine O 
receptors O 
CCR5 O 
and O 
CXCR4 O 
. O 
Chondrocytes O 
were O 
identified O 
as O 
a O 
significant O 
source O 
of O 
CCL4 O 
and O 
its O 
expression O 
in O 
diabetic O 
fractures O 
was O 
dependent O 
on O 
TNF O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
TNF-α O 
significantly O 
increased O 
mRNA O 
levels O 
of O 
several O 
chemokines O 
in O 
vitro O 
which O 
were O 
knocked O 
down O 
with O 
FOXO1 O 
siRNA O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
CCL4 O 
expression O 
at O 
the O 
mRNA O 
and O 
proteins O 
levels O 
was O 
induced O 
by O 
FOXO1 O 
over O 
- O 
expression O 
and O 
reduced O 
by O 
FOXO1 O 
knockdown O 
. O 
The O 
current O 
studies O 
point O 
to O 
the O 
importance O 
of O 
TNF-α O 
as O 
a O 
mechanism O 
for O 
diabetes O 
enhanced O 
chemokine O 
expression O 
by O 
chondrocytes O 
, O 
which O 
may O 
contribute O 
to O 
the O 
accelerated O 
loss O 
of O 
cartilage O 
observed O 
in O 
diabetic O 
fracture O 
healing O 
. O 
Moreover O 
, O 
in O 
vitro O 
results O 
point O 
to O 
FOXO1 O 
as O 
a O 
potentially O 
important O 
transcription O 
factor O 
in O 
mediating O 
this O 
effect O 
. O 

, O 
crystal O 
structure O 
and O 
antidiabetic O 
activity O 
of O 
substituted O 
( B-SYSTEMATIC 
E)-3-(Benzo I-SYSTEMATIC 
[d]thiazol-2-ylamino I-SYSTEMATIC 
) I-SYSTEMATIC 
phenylprop-2-en-1-one I-SYSTEMATIC 
. O 

novel O 
series O 
of O 
substituted O 
( B-SYSTEMATIC 
E)-3-(Benzo I-SYSTEMATIC 
[d]thiazol-2-ylamino)phenylprop-2-en-1-one I-SYSTEMATIC 
were O 
synthesized O 
starting O 
from O 
2-aminobenzothiazole B-SYSTEMATIC 
and O 
1-aryl-3,3-bis- B-FAMILY 
(methylsulfanyl)-2-propen-1-ones I-FAMILY 
in O 
the O 
presence O 
of O 
a O 
catalytic O 
amount O 
of O 
sodium B-SYSTEMATIC 
hydride I-SYSTEMATIC 
in O 
THF B-ABBREVIATION 
. O 
The O 
synthesised O 
compounds O 
' O 
structures O 
were O 
confirmed O 
by O 
IR O 
, O 
Mass O 
spectrometry O 
, O 
(1)H B-FORMULA 
NMR O 
, O 
(13)C B-FORMULA 
NMR O 
and O 
HRMS O 
spectral O 
data O 
. O 
These O 
compounds O 
were O 
evaluated O 
for O 
their O 
antidiabetic O 
activity O 
, O 
and O 
most O 
of O 
the O 
derivatives O 
of O 
( B-SYSTEMATIC 
E)-3-(Benzo I-SYSTEMATIC 
[d]thiazol-2-ylamino)phenylprop-2-en-1-one I-SYSTEMATIC 
displayed O 
significant O 
antidiabetic O 
activity O 
. O 

the O 
past O 
10years O 
, O 
the O 
number O 
of O 
percutaneous O 
coronary O 
intervention O 
( O 
PCI O 
) O 
procedures O 
performed O 
in O 
the O 
United O 
States O 
has O 
increased O 
by O 
33% O 
; O 
however O 
, O 
restenosis O 
, O 
which O 
inhibits O 
complete O 
functional O 
recovery O 
of O 
the O 
vessel O 
wall O 
, O 
remains O 
a O 
complication O 
of O 
this O 
procedure O 
. O 
To O 
traverse O 
the O 
complications O 
associated O 
with O 
PCI O 
, O 
the O 
investigation O 
of O 
therapeutic O 
delivery O 
has O 
become O 
an O 
integral O 
topic O 
in O 
modern O 
research O 
. O 
One O 
such O 
therapeutic O 
, O 
a O 
mimic O 
of O 
the O 
proteoglycan O 
decorin O 
, O 
termed O 
DS-SILY O 
, O 
can O 
mask O 
exposed O 
collagen O 
and O 
thereby O 
effectively O 
decrease O 
platelet O 
activation O 
, O 
has O 
recently O 
been O 
developed O 
by O 
our O 
lab O 
. O 
Drawing O 
inspiration O 
from O 
coating O 
technologies O 
developed O 
by O 
the O 
pharmaceutical O 
industry O 
, O 
a O 
fast O 
- O 
dissolving O 
polymer O 
film O 
has O 
been O 
developed O 
to O 
deliver O 
active O 
therapeutic O 
agents O 
from O 
a O 
balloon O 
catheter O 
during O 
PCI O 
. O 
This O 
research O 
investigates O 
the O 
release O 
of O 
DS-SILY O 
from O 
fast O 
- O 
dissolving O 
polymer O 
films O 
composed O 
of O 
poly(vinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PVA B-ABBREVIATION 
) O 
and O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
. O 
Thin O 
, O 
uniform O 
polymer O 
films O 
were O 
produced O 
via O 
spin O 
coating O 
technique O 
. O 
The O 
dissolution O 
speed O 
of O 
the O 
polymer O 
films O 
was O 
found O 
to O 
be O 
dependent O 
on O 
the O 
concentration O 
of O 
polymer O 
solution O 
, O 
where O 
at O 
least O 
65% O 
of O 
the O 
films O 
were O 
shown O 
to O 
dissolve O 
into O 
nanometer O 
sized O 
polymer O 
fragments O 
within O 
2min O 
. O 
DS-SILY O 
, O 
up O 
to O 
6.26μg O 
/ O 
cm(2) O 
, O 
was O 
loaded O 
into O 
the O 
films O 
and O 
functional O 
release O 
of O 
the O 
mimic O 
was O 
demonstrated O 
by O 
its O 
successful O 
binding O 
to O 
collagen O 
upon O 
release O 
. O 
Furthermore O 
, O 
DS-SILY O 
released O 
from O 
films O 
resulted O 
in O 
increased O 
platelet O 
inhibition O 
. O 
These O 
results O 
indicate O 
that O 
use O 
of O 
fast O 
- O 
dissolving O 
polymer O 
films O 
allow O 
for O 
the O 
successful O 
release O 
of O 
biomolecules O 
and O 
further O 
investigation O 
of O 
their O 
use O 
for O 
localized O 
drug O 
delivery O 
during O 
PCI O 
procedures O 
is O 
warranted O 
. O 

and O 
evaluation O 
of O 
a O 
backbone O 
biodegradable O 
multiblock O 
HPMA B-ABBREVIATION 
copolymer O 
nanocarrier O 
for O 
the O 
systemic O 
delivery O 
of O 
paclitaxel B-TRIVIAL 
. O 

performance O 
and O 
safety O 
of O 
current O 
antineoplastic O 
agents O 
, O 
particularly O 
water O 
- O 
insoluble O 
drugs O 
, O 
are O 
still O 
far O 
from O 
satisfactory O 
. O 
For O 
example O 
, O 
the O 
currently O 
widely O 
used O 
Cremophor O 
EL O 
® O 
- O 
based O 
paclitaxel B-TRIVIAL 
( O 
PTX B-ABBREVIATION 
) O 
formulation O 
exhibits O 
pharmacokinetic O 
concerns O 
and O 
severe O 
side O 
effects O 
. O 
Thus O 
, O 
the O 
concept O 
of O 
a O 
biodegradable O 
polymeric O 
drug O 
- O 
delivery O 
system O 
, O 
which O 
can O 
significantly O 
improve O 
therapeutic O 
efficacy O 
and O 
reduce O 
side O 
effects O 
is O 
advocated O 
. O 
The O 
present O 
work O 
aims O 
to O 
develop O 
a O 
new O 
- O 
generation O 
of O 
long O 
- O 
circulating O 
, O 
biodegradable O 
carriers O 
for O 
effective O 
delivery O 
of O 
PTX B-ABBREVIATION 
. O 
First O 
, O 
a O 
multiblock O 
backbone O 
biodegradable O 
N-(2-hydroxypropyl)methacrylamide B-SYSTEMATIC 
( O 
HPMA B-ABBREVIATION 
) O 
copolymer- O 
PTX B-ABBREVIATION 
conjugate O 
( O 
mP- O 
PTX B-ABBREVIATION 
) O 
with O 
molecular O 
weight O 
( O 
Mw O 
) O 
of O 
335 O 
kDa O 
was O 
synthesized O 
by O 
RAFT O 
( O 
reversible O 
addition O 
- O 
fragmentation O 
chain O 
transfer O 
) O 
copolymerization O 
, O 
followed O 
by O 
chain O 
extension O 
. O 
In O 
vitro O 
studies O 
on O 
human O 
ovarian O 
carcinoma O 
A2780 O 
cells O 
were O 
carried O 
out O 
to O 
investigate O 
the O 
cytotoxicity O 
of O 
free O 
PTX B-ABBREVIATION 
, O 
HPMA B-ABBREVIATION 
copolymer- O 
PTX B-ABBREVIATION 
conjugate O 
with O 
Mw O 
of O 
48 O 
kDa O 
( O 
P- O 
PTX B-ABBREVIATION 
) O 
, O 
and O 
mP- O 
PTX B-ABBREVIATION 
. O 
The O 
experiments O 
demonstrated O 
that O 
mP- O 
PTX B-ABBREVIATION 
has O 
a O 
similar O 
cytotoxic O 
effect O 
against O 
A2780 O 
cells O 
as O 
free O 
PTX B-ABBREVIATION 
and O 
P- O 
PTX B-ABBREVIATION 
. O 
To O 
further O 
compare O 
the O 
behavior O 
of O 
this O 
new O 
biodegradable O 
conjugate O 
( O 
mP- O 
PTX B-ABBREVIATION 
) O 
with O 
free O 
PTX B-ABBREVIATION 
and O 
P- O 
PTX B-ABBREVIATION 
in O 
vivo O 
evaluation O 
was O 
performed O 
using O 
female O 
nu O 
/ O 
nu O 
mice O 
bearing O 
orthotopic O 
A2780 O 
ovarian O 
tumors O 
. O 
Pharmacokinetics O 
study O 
showed O 
that O 
high O 
Mw O 
mP- O 
PTX B-ABBREVIATION 
was O 
cleared O 
more O 
slowly O 
from O 
the O 
blood O 
than O 
commercial O 
PTX B-ABBREVIATION 
formulation O 
and O 
low O 
Mw O 
P- O 
PTX B-ABBREVIATION 
. O 
SPECT O 
/ O 
CT O 
imaging O 
and O 
biodistribution O 
studies O 
demonstrated O 
biodegradability O 
as O 
well O 
as O 
elimination O 
of O 
mP- O 
PTX B-ABBREVIATION 
from O 
the O 
body O 
. O 
The O 
tumors O 
in O 
the O 
mP- O 
PTX B-ABBREVIATION 
treated O 
group O 
grew O 
more O 
slowly O 
than O 
those O 
treated O 
with O 
saline O 
, O 
free O 
PTX B-ABBREVIATION 
, O 
and O 
P- O 
PTX B-ABBREVIATION 
( O 
single O 
dose O 
at O 
20 O 
mg O 
PTX B-ABBREVIATION 
/ O 
kg O 
equivalent O 
) O 
. O 
Moreover O 
, O 
mice O 
treated O 
with O 
mP- O 
PTX B-ABBREVIATION 
had O 
no O 
obvious O 
ascites O 
and O 
body O 
- O 
weight O 
loss O 
. O 
Histological O 
analysis O 
indicated O 
that O 
mP- O 
PTX B-ABBREVIATION 
had O 
no O 
toxicity O 
in O 
liver O 
and O 
spleen O 
, O 
but O 
induced O 
massive O 
cell O 
death O 
in O 
the O 
tumor O 
. O 
In O 
summary O 
, O 
this O 
biodegradable O 
drug O 
delivery O 
system O 
has O 
a O 
great O 
potential O 
to O 
improve O 
performance O 
and O 
safety O 
of O 
current O 
antineoplastic O 
agents O 
. O 

lactone I-FAMILY 
glycosides I-FAMILY 
from O 
stems O 
and O 
leaves O 
of O 
Paris O 
polyphylla O 
var O 
. O 
yunnanensis O 
. O 

phytochemical O 
investigation O 
on O 
the O 
stems O 
and O 
leaves O 
of O 
Paris O 
polyphylla O 
var O 
. O 
yunnanensis O 
has O 
led O 
to O 
the O 
isolation O 
of O 
three O 
C(22)-steroidal B-FAMILY 
lactone I-FAMILY 
glycosides I-FAMILY 
. O 
Two O 
of O 
these O 
are O 
new O 
compounds O 
, O 
designated O 
as O 
chonglouoside B-TRIVIAL 
SL-7 I-TRIVIAL 
( O 
1 O 
) O 
and O 
chonglouoside B-TRIVIAL 
SL-8 I-TRIVIAL 
( O 
2 O 
) O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
extensive O 
spectroscopic O 
analysis O 
, O 
as O 
well O 
as O 
comparison O 
with O 
the O 
reported O 
spectroscopic O 
data O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
C(22)-steroidal B-FAMILY 
lactone I-FAMILY 
glycosides I-FAMILY 
isolated O 
from O 
the O 
Paris O 
genus O 
. O 
Compounds O 
1 O 
and O 
3 O 
showed O 
moderate O 
antimicrobic O 
activity O 
against O 
Propionibacterium O 
acnes O 
with O 
MIC O 
values O 
of O 
31.3 O 
and O 
3.9μg O 
/ O 
mL O 
, O 
respectively O 
. O 

-induced O 
inhibition O 
of O 
the O 
activity O 
of O 
glutamate B-TRIVIAL 
transporter O 
type O 
3 O 
expressed O 
in O 
Xenopus O 
oocytes O 
. O 

has O 
been O 
known O 
to O 
trigger O 
seizures O 
, O 
however O 
, O 
the O 
precise O 
mechanism O 
about O 
the O 
proconvulsive O 
effect O 
of O 
caffeine B-TRIVIAL 
remains O 
unclear O 
. O 
Glutamate B-TRIVIAL 
transporters O 
play O 
an O 
important O 
role O 
to O 
maintain O 
the O 
homeostasis O 
of O 
glutamate B-TRIVIAL 
concentration O 
in O 
the O 
brain O 
tissue O 
. O 
Especially O 
, O 
dysfunction O 
of O 
excitatory O 
amino B-FAMILY 
acid I-FAMILY 
transporter O 
type O 
3 O 
( O 
EAAT3 O 
) O 
can O 
lead O 
to O 
seizures O 
. O 
We O 
investigated O 
the O 
effects O 
of O 
caffeine B-TRIVIAL 
on O 
the O 
activity O 
of O 
EAAT3 O 
and O 
the O 
involvement O 
of O 
protein O 
kinase O 
C O 
( O 
PKC O 
) O 
and O 
phosphatidylinositol O 
3-kinase O 
( O 
PI3K O 
) O 
. O 
Rat O 
EAAT3 O 
was O 
expressed O 
in O 
Xenopus O 
oocytes O 
by O 
injecting O 
EAAT3 O 
mRNA O 
. O 
l-Glutamate B-TRIVIAL 
(30μM)-induced O 
inward O 
currents O 
were O 
recorded O 
via O 
the O 
two O 
- O 
electrode O 
voltage O 
clamp O 
method O 
. O 
Caffeine B-TRIVIAL 
decreased O 
EAAT3 O 
activity O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Caffeine B-TRIVIAL 
( O 
30μM O 
for O 
3min O 
) O 
significantly O 
reduced O 
V(max) O 
, O 
but O 
did O 
not O 
alter O 
K(m) O 
value O 
of O 
EAAT3 O 
for O 
glutamate B-TRIVIAL 
. O 
When O 
preincubated O 
oocytes O 
with O 
phorbol-12-myristate-13-acetate B-SYSTEMATIC 
( O 
PMA B-ABBREVIATION 
, O 
a O 
PKC O 
activator O 
) O 
were O 
exposed O 
to O 
caffeine B-TRIVIAL 
, O 
PMA B-ABBREVIATION 
-induced O 
increase O 
in O 
EAAT3 O 
activity O 
was O 
abolished O 
. O 
Two O 
PKC O 
inhibitors O 
( O 
chelerythrine B-TRIVIAL 
and O 
staurosporine B-TRIVIAL 
) O 
significantly O 
reduced O 
basal O 
EAAT3 O 
activity O 
. O 
Whereas O 
, O 
there O 
were O 
no O 
significant O 
differences O 
among O 
the O 
PKC O 
inhibitors O 
, O 
caffeine B-TRIVIAL 
, O 
and O 
PKC O 
inhibitors+ O 
caffeine B-TRIVIAL 
groups O 
. O 
In O 
similarly O 
fashion O 
, O 
wortmannin B-TRIVIAL 
( O 
a O 
PI3K O 
inhibitor O 
) O 
significantly O 
decreased O 
EAAT3 O 
activity O 
, O 
however O 
no O 
statistical O 
differences O 
were O 
observed O 
among O 
the O 
wortmannin B-TRIVIAL 
, O 
caffeine B-TRIVIAL 
, O 
and O 
wortmannin B-TRIVIAL 
+ O 
caffeine B-TRIVIAL 
groups O 
. O 
Our O 
results O 
demonstrate O 
that O 
caffeine B-TRIVIAL 
attenuates O 
EAAT3 O 
activity O 
and O 
this O 
reducing O 
effect O 
of O 
caffeine B-TRIVIAL 
seems O 
to O 
be O 
mediated O 
by O 
PKC O 
and O 
PI3K O 
. O 

electroreduction O 
of O 
benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
: O 
voltammetric O 
observation O 
of O 
adsorbed O 
hydrogen B-SYSTEMATIC 
at O 
a O 
platinum B-SYSTEMATIC 
microelectrode O 
in O 
room O 
temperature O 
ionic O 
liquids O 
. O 

electrochemical O 
reduction O 
of O 
benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
the O 
presence O 
and O 
absence O 
of O 
hydrogen B-SYSTEMATIC 
( O 
H(2) B-FORMULA 
) O 
has O 
been O 
investigated O 
using O 
a O 
10 O 
μm O 
diameter O 
platinum B-SYSTEMATIC 
microelectrode O 
in O 
four O 
different O 
room O 
temperature O 
ionic O 
liquids O 
( O 
RTILs O 
) O 
, O 
namely O 
[C(4)mim][NTf(2)] B-ABBREVIATION 
, O 
[C(4)mpyrr][NTf(2)] B-ABBREVIATION 
, O 
[C(4)mim][OTf] B-ABBREVIATION 
and O 
[C(4)mim][BF(4)] B-FORMULA 
, O 
versus O 
Ag B-FORMULA 
/ O 
Ag(+) B-FORMULA 
. O 
In O 
all O 
cases O 
, O 
reductive O 
voltammetry O 
is O 
observed O 
, O 
and O 
is O 
suggested O 
to O 
occur O 
via O 
a O 
CE O 
mechanism O 
in O 
which O 
dissociation O 
of O 
benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
is O 
followed O 
by O 
electron O 
transfer O 
to O 
H(+) B-FORMULA 
ultimately O 
forming O 
adsorbed O 
hydrogen B-SYSTEMATIC 
. O 
Furthermore O 
, O 
the O 
adsorbed O 
H B-FORMULA 
atoms O 
, O 
formed O 
from O 
the O 
reduction O 
of O 
benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
could O 
be O 
used O 
to O 
achieve O 
the O 
rapid O 
hydrogenolysis O 
of O 
the O 
organic O 
compound O 
( O 
bis(benzyloxycarbonyl)-l-lysine B-SYSTEMATIC 
) O 
on O 
the O 
timescale O 
of O 
the O 
voltammetric O 
technique O 
under O 
moderate O 
conditions O 
( O 
25 O 
°C O 
) O 
. O 

the O 
structural O 
, O 
electronic O 
and O 
magnetic O 
properties O 
of O 
multicenter O 
Fe₂S₂ B-FORMULA 
⁰ O 
/ O 
⁻ O 
, O 
Fe₃S₄ B-FORMULA 
⁰ O 
/ O 
⁻ O 
and O 
Fe₄S₄ B-FORMULA 
⁰ O 
/ O 
⁻ O 
clusters O 
. O 

structural O 
, O 
electronic O 
and O 
magnetic O 
properties O 
of O 
neutral O 
and O 
anion O 
Fe2S2 B-FORMULA 
, O 
Fe3S4 B-FORMULA 
and O 
Fe4S4 B-FORMULA 
have O 
been O 
investigated O 
with O 
the O 
aid O 
of O 
previous O 
photoelectron O 
spectroscopy O 
and O 
density O 
functional O 
theory O 
calculations O 
. O 
Theoretical O 
electron O 
detachment O 
energies O 
( O 
both O 
vertical O 
and O 
adiabatic O 
) O 
of O 
anion O 
clusters O 
for O 
the O 
lowest O 
energy O 
structure O 
were O 
computed O 
and O 
compared O 
with O 
the O 
experimental O 
results O 
to O 
verify O 
the O 
ground O 
states O 
. O 
The O 
optimized O 
structures O 
show O 
that O 
the O 
ground O 
state O 
structures O 
of O 
Fe2S2 B-FORMULA 
( O 
0 O 
/ O 
- O 
) O 
, O 
Fe3S4 B-FORMULA 
( O 
0 O 
/ O 
- O 
) O 
and O 
Fe4S4 B-FORMULA 
( O 
0 O 
/ O 
- O 
) O 
favor O 
high O 
spin O 
state O 
and O 
are O 
similar O 
to O 
their O 
structures O 
in O 
proteins O 
. O 
The O 
electron O 
delocalization O 
pattern O 
for O 
all O 
the O 
clusters O 
and O 
the O 
nature O 
of O 
bonding O 
between O 
Fe B-FORMULA 
and O 
S B-FORMULA 
atoms O 
were O 
studied O 
by O 
analyzing O 
molecular O 
orbitals O 
. O 
Natural O 
population O 
analysis O 
demonstrates O 
that O 
Fe B-FORMULA 
atoms O 
act O 
as O 
an O 
electron O 
donor O 
in O 
all O 
clusters O 
, O 
and O 
the O 
electron O 
density O 
difference O 
map O 
clearly O 
shows O 
the O 
direction O 
of O 
the O 
electron O 
flow O 
over O 
the O 
whole O 
complex O 
. O 
Furthermore O 
, O 
the O 
investigated O 
magnetism O 
shows O 
that O 
the O 
Fe B-FORMULA 
atoms O 
carried O 
most O 
of O 
the O 
magnetic O 
moments O 
, O 
which O 
is O 
due O 
mainly O 
to O 
the O 
3d O 
state O 
, O 
while O 
only O 
very O 
small O 
magnetic O 
moments O 
are O 
found O 
on O 
S B-FORMULA 
atoms O 
. O 

of O 
expression O 
of O 
the O 
methylation O 
- O 
controlled O 
J O 
gene O 
, O 
MCJ O 
( O 
DNAJC15 O 
) O 
, O 
is O 
observed O 
in O 
cases O 
of O 
several O 
tumors O 
and O 
plays O 
a O 
crucial O 
role O 
in O 
the O 
chemoresistance O 
of O 
ovarian O 
cancer O 
cells O 
. O 
Aside O 
from O 
the O 
pathophysiological O 
effects O 
, O 
almost O 
nothing O 
is O 
known O 
about O 
the O 
cellular O 
function O 
of O 
MCJ O 
. O 
Here O 
, O 
we O 
provide O 
the O 
first O 
evidence O 
that O 
MCJ O 
acts O 
in O 
the O 
biogenesis O 
of O 
mitochondria O 
. O 
Our O 
results O 
demonstrate O 
that O 
MCJ O 
is O 
located O 
in O 
mitochondria O 
. O 
It O 
is O 
anchored O 
in O 
the O 
mitochondrial O 
inner O 
membrane O 
with O 
the O 
C B-FORMULA 
-terminal O 
J O 
domain O 
facing O 
the O 
matrix O 
space O 
. O 
We O 
show O 
that O 
MCJ O 
forms O 
a O 
stable O 
subcomplex O 
with O 
a O 
component O 
of O 
the O 
mitochondrial O 
import O 
motor O 
, O 
MAGMAS O 
, O 
a O 
protein O 
overexpressed O 
in O 
cells O 
treated O 
with O 
granulocyte O 
- O 
macrophage O 
colony O 
- O 
stimulating O 
factor O 
and O 
in O 
prostate O 
carcinomas O 
. O 
In O 
addition O 
, O 
MCJ O 
and O 
MAGMAS O 
interact O 
with O 
the O 
core O 
components O 
of O 
the O 
TIM23 O 
pre O 
- O 
protein O 
translocase O 
. O 
We O 
demonstrate O 
that O 
the O 
recombinant O 
soluble O 
MCJ O 
domain O 
stimulates O 
the O 
ATPase O 
activity O 
of O 
the O 
human O 
mtHsp70 O 
chaperone O 
, O 
mortalin O 
, O 
the O 
central O 
component O 
of O 
the O 
import O 
motor O 
of O 
the O 
TIM23 O 
translocase O 
. O 
This O 
stimulation O 
is O 
counteracted O 
by O 
MAGMAS O 
. O 
Moreover O 
, O 
pre O 
- O 
protein O 
import O 
into O 
mitochondria O 
is O 
impaired O 
in O 
the O 
absence O 
of O 
MCJ O 
. O 
Interestingly O 
, O 
MCJ O 
is O 
able O 
to O 
take O 
over O 
the O 
function O 
of O 
Tim14 O 
, O 
the O 
essential O 
J O 
co O 
- O 
chaperone O 
of O 
the O 
mitochondrial O 
protein O 
import O 
motor O 
in O 
yeast O 
. O 
In O 
summary O 
, O 
our O 
results O 
show O 
that O 
MCJ O 
functions O 
as O 
J O 
co O 
- O 
chaperone O 
of O 
the O 
human O 
TIM23 O 
pre O 
- O 
protein O 
translocase O 
, O 
suggesting O 
a O 
link O 
between O 
mitochondrial O 
pre O 
- O 
protein O 
import O 
and O 
tumorigenesis O 
. O 

yeast O 
eukaryotic O 
translation O 
initiation O 
factor O 
2B O 
translation O 
initiation O 
complex O 
interacts O 
with O 
the O 
fatty B-FAMILY 
acid I-FAMILY 
synthesis O 
enzyme O 
YBR159W O 
and O 
endoplasmic O 
reticulum O 
membranes O 
. O 

affinity O 
purifications O 
coupled O 
with O 
mass O 
spectrometry O 
and O 
yeast O 
two O 
- O 
hybrid O 
assays O 
, O 
we O 
show O 
the O 
Saccharomyces O 
cerevisiae O 
translation O 
initiation O 
factor O 
complex O 
eukaryotic O 
translation O 
initiation O 
factor O 
2B O 
( O 
eIF2B O 
) O 
and O 
the O 
very O 
- O 
long O 
- O 
chain O 
fatty B-FAMILY 
acid I-FAMILY 
( O 
VLCFA O 
) O 
synthesis O 
keto-reductase O 
enzyme O 
YBR159W O 
physically O 
interact O 
. O 
The O 
data O 
show O 
that O 
the O 
interaction O 
is O 
specifically O 
between O 
YBR159W O 
and O 
eIF2B O 
and O 
not O 
between O 
other O 
members O 
of O 
the O 
translation O 
initiation O 
or O 
VLCFA O 
pathways O 
. O 
A O 
ybr159wΔ O 
nan O 
strain O 
has O 
a O 
slow O 
- O 
growth O 
phenotype O 
and O 
a O 
reduced O 
translation O 
rate O 
but O 
a O 
normal O 
GCN4 O 
response O 
to O 
amino B-FAMILY 
acid I-FAMILY 
starvation O 
. O 
Although O 
YBR159W O 
localizes O 
to O 
the O 
endoplasmic O 
reticulum O 
membrane O 
, O 
subcellular O 
fractionation O 
experiments O 
show O 
that O 
a O 
fraction O 
of O 
eIF2B O 
cofractionates O 
with O 
lipid O 
membranes O 
in O 
a O 
YBR159W O 
- O 
independent O 
manner O 
. O 
We O 
show O 
that O 
a O 
ybr159wΔ O 
yeast O 
strain O 
and O 
other O 
strains O 
with O 
nan O 
mutations O 
in O 
the O 
VLCFA O 
pathway O 
cause O 
eIF2B O 
to O 
appear O 
as O 
numerous O 
foci O 
throughout O 
the O 
cytoplasm O 
. O 

response O 
of O 
soil O 
organism O 
communities O 
to O 
the O 
application O 
of O 
the O 
insecticide O 
lindane B-TRIVIAL 
in O 
terrestrial O 
model O 
ecosystems O 
. O 

EU O 
plant O 
protection O 
regulation O 
1107 O 
/ O 
2009 O 
/ O 
EC O 
defines O 
the O 
requirements O 
for O 
active O 
ingredients O 
to O 
be O 
approved O 
, O 
specifically O 
including O 
the O 
assessment O 
of O 
effects O 
on O 
biodiversity O 
and O 
ecosystems O 
. O 
According O 
to O 
that O 
, O 
semi-field O 
methods O 
are O 
expected O 
to O 
be O 
more O 
important O 
in O 
the O 
near O 
future O 
. O 
Therefore O 
, O 
a O 
higher O 
- O 
tier O 
experiment O 
suitable O 
to O 
assess O 
the O 
risk O 
for O 
soil O 
organisms O 
was O 
conducted O 
to O 
further O 
develop O 
the O 
TME O 
( O 
terrestrial O 
model O 
ecosystems O 
) O 
methodology O 
in O 
a O 
dose O 
- O 
response O 
design O 
with O 
the O 
persistent O 
insecticidal O 
model O 
compound O 
lindane B-TRIVIAL 
( O 
gamma-HCH B-TRIVIAL 
) O 
. O 
The O 
effects O 
of O 
lindane B-TRIVIAL 
on O 
soil O 
communities O 
such O 
as O 
collembolans O 
, O 
oribatid O 
mites O 
, O 
nematodes O 
, O 
soil O 
fungi O 
and O 
plant O 
biomass O 
were O 
determined O 
in O 
42 O 
TME O 
. O 
Intact O 
TME-soil O 
cores O 
( O 
diameter O 
300 O 
mm O 
, O 
height O 
400 O 
mm O 
) O 
from O 
undisturbed O 
grassland O 
were O 
stored O 
outdoor O 
under O 
natural O 
climatic O 
conditions O 
. O 
Lindane B-TRIVIAL 
was O 
applied O 
in O 
five O 
concentrations O 
between O 
0.032 O 
mg O 
active O 
ingredients O 
( O 
ai O 
) O 
/ O 
kg O 
dry O 
soil O 
and O 
3.2 O 
mg O 
ai O 
/ O 
kg O 
dry O 
weight O 
soil O 
, O 
six O 
- O 
fold O 
replicated O 
each O 
. O 
Twelve O 
TME O 
served O 
as O 
untreated O 
controls O 
. O 
Abundance O 
and O 
community O 
structures O 
of O 
oribatids O 
, O 
collembolans O 
, O 
enchytraeids O 
, O 
nematodes O 
and O 
fungi O 
were O 
recorded O 
. O 
Oribatid O 
mites O 
' O 
community O 
responded O 
3 O 
months O 
after O 
treatment O 
, O 
although O 
they O 
were O 
not O 
significantly O 
affected O 
by O 
the O 
overall O 
treatment O 
regimen O 
. O 
Collembolans O 
in O 
total O 
and O 
species O 
- O 
specific O 
abundance O 
as O 
well O 
as O 
the O 
community O 
endpoints O 
( O 
principal O 
response O 
curves O 
, O 
diversity O 
measures O 
) O 
were O 
adversely O 
affected O 
by O 
moderate O 
dosages O 
of O 
lindane O 
. O 
Effects O 
were O 
transient O 
between O 
3 O 
and O 
5 O 
months O 
after O 
treatment O 
with O 
a O 
recovery O 
within O 
1 O 
year O 
. O 
No O 
significant O 
effects O 
could O 
be O 
detected O 
for O 
enchytraeids O 
, O 
nematodes O 
and O 
fungi O 
. O 
The O 
study O 
design O 
and O 
the O 
obtained O 
results O 
allow O 
for O 
calculations O 
of O 
no O 
observed O 
effect O 
concentrations O 
below O 
the O 
highest O 
treatment O 
level O 
for O 
populations O 
and O 
for O 
soil O 
communities O 
as O 
defined O 
entities O 
, O 
as O 
well O 
as O 
effective O 
concentrations O 
. O 
The O 
paper O 
discusses O 
the O 
limits O 
of O 
effect O 
detection O 
in O 
the O 
light O 
of O 
achievable O 
coefficients O 
of O 
variation O 
and O 
by O 
means O 
of O 
minimum O 
detectable O 
differences O 
. O 
Outdoor O 
TME O 
are O 
useful O 
to O 
analyze O 
and O 
assess O 
functional O 
and O 
structural O 
endpoints O 
in O 
soil O 
organisms O 
' O 
communities O 
and O 
their O 
possible O 
recovery O 
after O 
pesticide O 
treatment O 
within O 
1 O 
year O 
. O 

of O 
peptide O 
transporter O 
1 O 
in O 
the O 
intestinal O 
permeability O 
of O 
valacyclovir B-TRIVIAL 
in O 
wild O 
- O 
type O 
and O 
PepT1 O 
knockout O 
mice O 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
quantitatively O 
determine O 
the O 
contribution O 
of O 
PepT1 O 
[ O 
peptide O 
transporter O 
1 O 
( O 
SLC15A1 O 
) O 
] O 
to O 
the O 
intestinal O 
permeability O 
of O 
valacyclovir B-TRIVIAL 
, O 
an O 
ester O 
prodrug O 
of O 
the O 
antiviral O 
drug O 
acyclovir B-TRIVIAL 
. O 
In O 
situ O 
single O 
- O 
pass O 
intestinal O 
perfusions O 
were O 
employed O 
( O 
pH O 
6.5 O 
× O 
90 O 
minutes O 
) O 
to O 
assess O 
the O 
effective O 
permeability O 
(P(eff)) O 
of O 
100 O 
μM O 
[(3)H]valacyclovir B-SYSTEMATIC 
in O 
wild O 
- O 
type O 
and O 
PepT1 O 
knockout O 
mice O 
. O 
Acyclovir B-TRIVIAL 
pharmacokinetics O 
was O 
also O 
evaluated O 
after O 
oral O 
administration O 
of O 
25 O 
nmol O 
/ O 
g O 
valacyclovir B-TRIVIAL 
. O 
In O 
wild O 
- O 
type O 
mice O 
, O 
jejunal O 
uptake O 
of O 
valacyclovir B-TRIVIAL 
was O 
best O 
described O 
by O 
both O 
saturable O 
( O 
K(m) O 
= O 
10.2 O 
mM O 
) O 
and O 
nonsaturable O 
components O 
where O 
the O 
saturable O 
pathway O 
accounted O 
for O 
82% O 
of O 
total O 
transport O 
. O 
Valacyclovir B-TRIVIAL 
P(eff) O 
was O 
2.4 O 
× O 
10(-4) O 
cm O 
/ O 
s O 
in O 
duodenum O 
, O 
1.7 O 
× O 
10(-4) O 
cm O 
/ O 
s O 
in O 
jejunum O 
, O 
2.1 O 
× O 
10(-4) O 
cm O 
/ O 
s O 
in O 
ileum O 
, O 
and O 
0.27 O 
× O 
10(-4) O 
cm O 
/ O 
s O 
in O 
colon O 
. O 
In O 
Pept1 O 
knockout O 
mice O 
, O 
P(eff) O 
values O 
were O 
about O 
10% O 
of O 
that O 
in O 
wild O 
- O 
type O 
animals O 
for O 
these O 
small O 
intestinal O 
segments O 
. O 
Valacyclovir B-TRIVIAL 
P(eff) O 
was O 
similar O 
in O 
the O 
colon O 
of O 
both O 
genotypes O 
. O 
There O 
were O 
no O 
differences O 
in O 
valacyclovir B-TRIVIAL 
P(eff) O 
between O 
any O 
of O 
the O 
intestinal O 
segments O 
of O 
PepT1 O 
knockout O 
mice O 
. O 
Valacyclovir B-TRIVIAL 
P(eff) O 
was O 
significantly O 
reduced O 
by O 
the O 
dipeptide O 
glycylsarcosine B-TRIVIAL 
and O 
the O 
aminocephalosporin B-SYSTEMATIC 
cefadroxil I-SYSTEMATIC 
, O 
but O 
not O 
by O 
the O 
amino B-FAMILY 
acids I-FAMILY 
l-valine B-TRIVIAL 
or O 
l-histidine B-TRIVIAL 
, O 
the O 
organic O 
acid O 
p-aminohippurate B-TRIVIAL 
, O 
or O 
the O 
organic O 
base O 
tetraethylammonium B-SYSTEMATIC 
( O 
all O 
at O 
25 O 
mM O 
) O 
. O 
PepT1 O 
ablation O 
resulted O 
in O 
3- O 
to O 
5-fold O 
reductions O 
in O 
the O 
in O 
vivo O 
rate O 
and O 
extent O 
of O 
valacyclovir B-TRIVIAL 
absorption O 
. O 
Our O 
findings O 
conclusively O 
demonstrate O 
, O 
using O 
in O 
situ O 
and O 
in O 
vivo O 
validations O 
in O 
genetically O 
modified O 
mice O 
, O 
that O 
PepT1 O 
has O 
a O 
major O 
influence O 
in O 
improving O 
the O 
oral O 
absorption O 
of O 
valacyclovir B-TRIVIAL 
. O 

frataxin O 
controls O 
sulfur B-SYSTEMATIC 
production O 
and O 
iron B-SYSTEMATIC 
entry O 
during O 
de O 
novo O 
Fe4S4 B-FORMULA 
cluster O 
assembly O 
. O 

- I-SYSTEMATIC 
sulfur I-SYSTEMATIC 
( O 
Fe-S B-FORMULA 
) O 
cluster O 
- O 
containing O 
proteins O 
are O 
essential O 
components O 
of O 
cells O 
. O 
In O 
eukaryotes O 
, O 
Fe-S B-FORMULA 
clusters O 
are O 
synthesized O 
by O 
the O 
mitochondrial O 
iron B-SYSTEMATIC 
- I-SYSTEMATIC 
sulfur I-SYSTEMATIC 
cluster O 
( O 
ISC O 
) O 
machinery O 
and O 
the O 
cytosolic O 
iron B-SYSTEMATIC 
- I-SYSTEMATIC 
sulfur I-SYSTEMATIC 
assembly O 
( O 
CIA O 
) O 
system O 
. O 
In O 
the O 
mammalian O 
ISC O 
machinery O 
, O 
preassembly O 
of O 
the O 
Fe-S B-FORMULA 
cluster O 
on O 
the O 
scaffold O 
protein O 
( O 
ISCU O 
) O 
involves O 
a O 
cysteine B-TRIVIAL 
desulfurase O 
complex O 
( O 
NFS1 O 
/ O 
ISD11 O 
) O 
and O 
frataxin O 
( O 
FXN O 
) O 
, O 
the O 
protein O 
deficient O 
in O 
Friedreich's O 
ataxia O 
. O 
Here O 
, O 
by O 
comparing O 
the O 
biochemical O 
and O 
spectroscopic O 
properties O 
of O 
quaternary O 
( O 
ISCU O 
/ O 
NFS1 O 
/ O 
ISD11 O 
/ O 
FXN O 
) O 
and O 
ternary O 
( O 
ISCU O 
/ O 
NFS1 O 
/ O 
ISD11 O 
) O 
complexes O 
, O 
we O 
show O 
that O 
FXN O 
stabilizes O 
the O 
quaternary O 
complex O 
and O 
controls O 
iron B-SYSTEMATIC 
entry O 
to O 
the O 
complex O 
through O 
activation O 
of O 
cysteine B-TRIVIAL 
desulfurization O 
. O 
Furthermore O 
, O 
we O 
show O 
for O 
the O 
first O 
time O 
that O 
in O 
the O 
presence O 
of O 
iron B-SYSTEMATIC 
and O 
L-cysteine B-TRIVIAL 
, O 
an O 
[ O 
Fe(4)S(4) B-FORMULA 
] O 
cluster O 
is O 
formed O 
within O 
the O 
quaternary O 
complex O 
that O 
can O 
be O 
transferred O 
to O 
mammalian O 
aconitase O 
( O 
mACO2 O 
) O 
to O 
generate O 
an O 
active O 
enzyme O 
. O 
In O 
the O 
absence O 
of O 
FXN O 
, O 
although O 
the O 
ternary O 
complex O 
can O 
assemble O 
an O 
Fe-S B-FORMULA 
cluster O 
, O 
the O 
cluster O 
is O 
inefficiently O 
transferred O 
to O 
ACO2 O 
. O 
Taken O 
together O 
, O 
these O 
data O 
help O 
to O 
unravel O 
further O 
the O 
Fe-S B-FORMULA 
cluster O 
assembly O 
process O 
and O 
the O 
molecular O 
basis O 
of O 
Friedreich's O 
ataxia O 
. O 

silicon B-SYSTEMATIC 
surfaces O 
decorated O 
by O 
square O 
arrays O 
of O 
pillars O 
with O 
adjustable O 
pitch O 
were O 
fabricated O 
. O 
The O 
wetting O 
behavior O 
, O 
especially O 
for O 
direction O 
- O 
dependent O 
water O 
contact O 
angles O 
on O 
textured O 
silicon B-SYSTEMATIC 
surfaces O 
after O 
silanization O 
, O 
was O 
investigated O 
by O 
incorporating O 
the O 
contact O 
line O 
fraction O 
into O 
a O 
modified O 
Wenzel O 
model O 
. O 
Also O 
, O 
the O 
effect O 
of O 
geometrical O 
parameters O 
on O 
the O 
anisotropic O 
wetting O 
behavior O 
of O 
water O 
was O 
examined O 
with O 
respect O 
to O 
water O 
droplet O 
impact O 
on O 
the O 
textured O 
surface O 
. O 
Moreover O 
, O 
the O 
maximum O 
spreading O 
factor O 
was O 
studied O 
theoretically O 
in O 
terms O 
of O 
energy O 
conservation O 
, O 
allowing O 
for O 
surface O 
topography O 
and O 
viscous O 
friction O 
of O 
the O 
liquid O 
flowing O 
among O 
the O 
arrays O 
of O 
the O 
posts O 
. O 
Theoretical O 
models O 
were O 
found O 
to O 
be O 
in O 
good O 
agreement O 
with O 
experimental O 
data O 
. O 

work O 
studies O 
the O 
effect O 
of O 
packing O 
cracked O 
seasoned O 
olives O 
with O 
NaCl B-FORMULA 
, O 
KCl B-FORMULA 
, O 
and O 
CaCl(2) B-FORMULA 
mixture O 
brines O 
on O 
their O 
mineral O 
nutrients O 
and O 
sensory O 
attributes O 
, O 
using O 
RSM O 
methodology O 
. O 
The O 
Na B-FORMULA 
, O 
K B-FORMULA 
, O 
Ca B-FORMULA 
, O 
and O 
residual O 
natural O 
Mn B-FORMULA 
contents O 
in O 
flesh O 
as O 
well O 
as O 
saltiness O 
, O 
bitterness O 
and O 
fibrousness O 
were O 
significantly O 
related O 
to O 
the O 
initial O 
concentrations O 
of O 
salts O 
in O 
the O 
packing O 
solution O 
. O 
This O 
new O 
process O 
led O 
to O 
table O 
olives O 
with O 
a O 
significantly O 
lower O 
sodium B-SYSTEMATIC 
content O 
( O 
about O 
31% O 
) O 
than O 
the O 
traditional O 
product O 
but O 
fortified O 
in O 
K B-FORMULA 
and O 
Ca B-FORMULA 
. O 
High O 
levels O 
of O 
Na B-FORMULA 
and O 
Ca B-FORMULA 
in O 
the O 
flesh O 
led O 
to O 
high O 
scores O 
of O 
acidity O 
and O 
saltiness O 
( O 
the O 
first O 
descriptor O 
) O 
and O 
bitterness O 
( O 
the O 
second O 
) O 
while O 
the O 
K B-FORMULA 
content O 
was O 
unrelated O 
to O 
any O 
sensory O 
descriptor O 
. O 
The O 
new O 
presentations O 
using O 
moderate O 
proportions O 
of O 
alternative O 
salts O 
will O 
therefore O 
have O 
improved O 
nutritional O 
value O 
and O 
healthier O 
characteristics O 
but O 
only O 
a O 
slightly O 
modified O 
sensory O 
profile O 
. O 

potentiometric O 
determination O 
of O 
starch O 
using O 
a O 
platinum B-SYSTEMATIC 
redox O 
sensor O 
. O 

, O 
we O 
describe O 
the O 
development O 
of O 
a O 
platinum B-SYSTEMATIC 
redox O 
sensor O 
for O 
the O 
direct O 
potentiometric O 
quantification O 
of O 
starch O 
in O 
solution O 
. O 
The O 
sensor O 
measures O 
the O 
decrease O 
in O 
free O 
triiodide B-SYSTEMATIC 
ion O 
after O 
it O 
complexes O 
with O 
starch O 
to O 
form O 
a O 
starch- O 
triiodide B-SYSTEMATIC 
complex O 
. O 
This O 
decrease O 
was O 
, O 
therefore O 
, O 
correlated O 
with O 
starch O 
concentration O 
, O 
and O 
the O 
composition O 
and O 
stability O 
of O 
the O 
potassium B-SYSTEMATIC 
triiodide I-SYSTEMATIC 
solution O 
were O 
optimised O 
. O 
The O 
starch- O 
triiodide B-SYSTEMATIC 
complex O 
was O 
characterized O 
potentiometrically O 
at O 
variable O 
starch O 
and O 
triiodide B-SYSTEMATIC 
concentrations O 
. O 
We O 
also O 
propose O 
a O 
response O 
mechanism O 
for O 
the O 
platinum B-SYSTEMATIC 
redox O 
sensor O 
towards O 
starch O 
and O 
an O 
appropriate O 
theoretical O 
model O 
. O 
The O 
optimised O 
method O 
exhibited O 
satisfactory O 
accuracy O 
and O 
precision O 
and O 
was O 
in O 
good O 
agreement O 
with O 
a O 
standard O 
spectrophotometric O 
method O 
. O 
The O 
sensor O 
was O 
tested O 
over O 
a O 
range O 
of O 
0.4-9 O 
mg O 
starch O 
, O 
with O 
recoveries O 
ranging O 
from O 
97.8% O 
to O 
103.4% O 
and O 
a O 
detection O 
limit O 
of O 
0.01 O 
mg O 
starch O 
. O 

application O 
of O 
attenuated O 
total O 
reflectance O 
mid O 
- O 
infrared O 
microspectroscopy O 
( O 
MIR-microspectroscopy O 
) O 
was O 
evaluated O 
as O 
a O 
rapid O 
method O 
for O 
detection O 
and O 
quantification O 
of O 
milk O 
adulteration O 
. O 
Milk O 
samples O 
were O 
purchased O 
from O 
local O 
grocery O 
stores O 
( O 
Columbus O 
, O 
OH O 
, O 
USA O 
) O 
and O 
spiked O 
at O 
different O 
concentrations O 
of O 
whey O 
, O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
, O 
synthetic O 
urine O 
, O 
urea B-TRIVIAL 
and O 
synthetic O 
milk O 
. O 
Samples O 
were O 
place O 
on O 
a O 
192-well O 
microarray O 
slide O 
, O 
air O 
- O 
dried O 
and O 
spectra O 
were O 
collected O 
by O 
using O 
MIR-microspectroscopy O 
. O 
Pattern O 
recognition O 
analysis O 
by O 
Soft O 
Independent O 
Modeling O 
of O 
Class O 
Analogy O 
( O 
SIMCA O 
) O 
showed O 
tight O 
and O 
well O 
- O 
separated O 
clusters O 
allowing O 
discrimination O 
of O 
control O 
samples O 
from O 
adulterated O 
milk O 
. O 
Partial O 
Least O 
Squares O 
Regression O 
( O 
PLSR O 
) O 
showed O 
standard O 
error O 
of O 
prediction O 
( O 
SEP O 
) O 
~2.33 O 
, O 
0.06 O 
, O 
0.41 O 
, O 
0.3 O 
and O 
0.014 O 
g O 
/ O 
L O 
for O 
estimation O 
of O 
levels O 
of O 
adulteration O 
with O 
whey O 
, O 
synthetic O 
milk O 
, O 
synthetic O 
urine O 
, O 
urea B-TRIVIAL 
and O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
, O 
respectively O 
. O 
Results O 
showed O 
that O 
MIR-microspectroscopy O 
can O 
provide O 
an O 
alternative O 
methodology O 
to O 
the O 
dairy O 
industry O 
for O 
screening O 
potential O 
fraudulent O 
practice O 
for O 
economic O 
adulteration O 
of O 
cow's O 
milk O 
. O 

apple O 
fibrous O 
residue O 
is O 
a O 
by O 
- O 
product O 
of O 
the O 
cashew O 
juice O 
industry O 
. O 
After O 
pressing O 
using O 
a O 
helical O 
type O 
continuous O 
press O 
followed O 
by O 
crossflow O 
microfiltration O 
, O 
an O 
aqueous O 
extract O 
was O 
obtained O 
from O 
these O 
cashew O 
apple O 
fibres O 
. O 
It O 
was O 
characterised O 
by O 
an O 
intense O 
yellow O 
colour O 
due O 
to O 
carotenoid O 
pigments O 
. O 
Carotenoids O 
were O 
identified O 
and O 
quantified O 
in O 
the O 
cashew O 
apple O 
before O 
extraction O 
, O 
in O 
its O 
aqueous O 
extract O 
and O 
in O 
the O 
concentrate O 
obtained O 
by O 
microfiltration O 
. O 
Cashew O 
apple O 
aqueous O 
extract O 
and O 
its O 
concentrate O 
presented O 
a O 
carotenoid O 
profile O 
with O 
11 O 
carotenoids O 
, O 
most O 
of O 
them O 
were O 
tentatively O 
identified O 
by O 
HPLC-DAD-MS O 
and O 
are O 
xanthophylls O 
present O 
under O 
an O 
esterified O 
form O 
. O 
Auroxanthin O 
and O 
β-cryptoxanthin B-TRIVIAL 
represented O 
around O 
50% O 
of O 
total O 
carotenoids O 
. O 
Concentration O 
of O 
the O 
extract O 
by O 
microfiltration O 
led O 
to O 
epoxy B-SYSTEMATIC 
- O 
furanoxy B-SYSTEMATIC 
rearrangement O 
of O 
violaxanthin B-TRIVIAL 
and O 
antheraxanthin B-TRIVIAL 
. O 
The O 
process O 
allowed O 
an O 
increase O 
of O 
10 O 
times O 
total O 
carotenoid O 
content O 
compared O 
with O 
initial O 
cashew O 
apple O 
. O 
Total O 
carotenoid O 
content O 
of O 
the O 
final O 
concentrated O 
extract O 
reached O 
54 O 
mg O 
/ O 
kg O 
. O 

effects O 
and O 
induction O 
of O 
apoptosis O 
of O 
flavonoids B-FAMILY 
on O 
the O 
prostate O 
cancer O 
cell O 
line O 
PC-3 O 
in O 
vitro O 
. O 

and O 
myricitrin B-TRIVIAL 
are O 
naturally O 
occurring O 
flavonoids B-FAMILY 
have O 
been O 
suggested O 
to O 
play O 
a O 
role O 
in O 
inhibition O 
of O 
proliferation O 
and O 
transformation O 
of O 
carcinogenic O 
cell O 
. O 
However O 
, O 
the O 
underlying O 
molecular O 
mechanisms O 
of O 
their O 
activity O 
have O 
not O 
yet O 
to O 
be O 
revealed O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
clarify O 
the O 
molecular O 
mechanisms O 
of O 
apoptosis O 
cell O 
on O 
the O 
prostate O 
cancer O 
induced O 
by O 
myricetin B-TRIVIAL 
, O 
myricitrin B-TRIVIAL 
, O 
quercetin B-TRIVIAL 
and O 
quercitrin B-TRIVIAL 
. O 
The O 
MTT B-ABBREVIATION 
assay O 
confirmed O 
that O 
myricetin B-TRIVIAL 
had O 
the O 
strongest O 
inhibitory O 
effect O 
on O 
human O 
prostate O 
cancer O 
cell O 
line O 
PC-3 O 
, O 
myricitrin B-TRIVIAL 
was O 
second O 
, O 
and O 
quercitrin B-TRIVIAL 
was O 
the O 
weakest O 
. O 
A O 
noticeable O 
synergistic O 
effect O 
was O 
observed O 
with O 
the O 
inhibition O 
of O 
cell O 
proliferation O 
when O 
myricetin B-TRIVIAL 
was O 
used O 
in O 
combination O 
with O 
myricitrin B-TRIVIAL 
. O 
In O 
the O 
concentration O 
range O 
of O 
37.5-300 O 
μmol O 
/ O 
L O 
, O 
the O 
inhibitory O 
effects O 
of O 
these O 
flavonoids B-FAMILY 
were O 
enhanced O 
with O 
increasing O 
dose O 
and O 
treatment O 
time O 
. O 
The O 
acridine B-TRIVIAL 
orange I-TRIVIAL 
analysis O 
and O 
annexin O 
V- O 
FITC B-ABBREVIATION 
/ O 
PI O 
double O 
- O 
staining O 
results O 
confirmed O 
that O 
myricetin B-TRIVIAL 
and O 
myricitrin B-TRIVIAL 
were O 
effective O 
in O 
inducing O 
PC-3 O 
cell O 
apoptosis O 
. O 
The O 
results O 
showed O 
that O 
myricetin B-TRIVIAL 
was O 
more O 
effective O 
than O 
myricitrin B-TRIVIAL 
in O 
inducing O 
cell O 
apoptosis O 
. O 
The O 
apoptosis O 
rate O 
increased O 
with O 
increasing O 
flavonoid B-FAMILY 
concentration O 
in O 
a O 
dose O 
dependent O 
manner O 
. O 
A O 
synergistic O 
effect O 
was O 
observed O 
on O 
the O 
apoptosis O 
rate O 
when O 
myricetin B-TRIVIAL 
was O 
used O 
in O 
combination O 
with O 
myricitrin B-TRIVIAL 
. O 

gas O 
chromatographic O 
method O 
for O 
the O 
determination O 
of O 
endocrine O 
disruptor O 
pesticides O 
( O 
Chlorpyrifos B-TRIVIAL 
, O 
Penconazole B-TRIVIAL 
, O 
Procymidone B-TRIVIAL 
, O 
Iprodione B-TRIVIAL 
, O 
Bromopropylate B-TRIVIAL 
and O 
Lambda-Cyhalothrin B-TRIVIAL 
) O 
in O 
wine O 
samples O 
is O 
described O 
. O 
A O 
general O 
DFG-S19 O 
method O 
for O 
residual O 
pesticide O 
determination O 
in O 
all O 
kind O 
of O 
food O 
stuff O 
was O 
investigated O 
to O 
simplify O 
and O 
adopt O 
for O 
wine O 
samples O 
in O 
this O 
work O 
. O 
Alternative O 
sample O 
preparation O 
routes O 
were O 
elucidated O 
and O 
compared O 
according O 
to O 
their O 
recovery O 
values O 
. O 
Four O 
different O 
separation O 
techniques O 
were O 
tested O 
and O 
the O 
method O 
employing O 
florosil B-TRIVIAL 
column O 
after O 
a O 
LLE O 
procedure O 
was O 
applied O 
for O 
wine O 
samples O 
with O 
satisfactory O 
recovery O 
ratios O 
( O 
72-97% O 
) O 
. O 
The O 
pesticides O 
were O 
extracted O 
from O 
the O 
sample O 
by O 
cyclohexane B-SYSTEMATIC 
- O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
mixture O 
( O 
1 O 
: O 
1 O 
v O 
/ O 
v O 
) O 
and O 
cleaned O 
up O 
by O 
florosil B-TRIVIAL 
column O 
. O 
The O 
regression O 
coefficients O 
were O 
at O 
least O 
0.99 O 
and O 
relative O 
standard O 
deviations O 
were O 
no O 
higher O 
than O 
16% O 
. O 
Detection O 
limits O 
were O 
in O 
the O 
range O 
of O 
0.6-2.9 O 
ng O 
/ O 
mL O 
and O 
the O 
relative O 
expanded O 
measurement O 
uncertainties O 
were O 
calculated O 
in O 
the O 
7-22% O 
range O 
. O 

mycelia O 
of O 
Antrodia O 
camphorata O 
, O 
Agaricus O 
blazei O 
, O 
Hericium O 
erinaceus O 
and O 
Phellinus O 
linteus O 
were O 
used O 
to O 
substitute O 
5% O 
of O 
wheat O 
flour O 
to O 
make O 
bread O 
. O 
Bread O 
quality O 
, O 
including O 
specific O 
volume O 
, O 
colour O 
property O 
, O 
equivalent O 
umami O 
concentration O 
( O 
EUC O 
) O 
, O 
texture O 
profile O 
analysis O 
, O 
sensory O 
evaluation O 
and O 
functional O 
components O 
, O 
was O 
analysed O 
. O 
Mycelium O 
- O 
supplemented O 
bread O 
was O 
smaller O 
in O 
loaf O 
volume O 
and O 
coloured O 
, O 
and O 
had O 
lower O 
lightness O 
and O 
white O 
index O 
values O 
. O 
White O 
bread O 
contained O 
the O 
lowest O 
amounts O 
of O 
free O 
umami O 
amino B-FAMILY 
acids I-FAMILY 
and O 
umami O 
5'- O 
nucleotides B-FAMILY 
and O 
showed O 
the O 
lowest O 
EUC O 
value O 
. O 
Incorporating O 
5% O 
mushroom O 
mycelia O 
into O 
the O 
bread O 
formula O 
did O 
not O 
adversely O 
affect O 
the O 
texture O 
profile O 
of O 
the O 
bread O 
. O 
However O 
, O 
incorporating O 
5% O 
mushroom O 
mycelia O 
into O 
the O 
bread O 
formula O 
did O 
lower O 
bread's O 
acceptability O 
. O 
After O 
baking O 
, O 
mycelium O 
- O 
supplemented O 
bread O 
still O 
contained O 
substantial O 
amounts O 
of O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
ergothioneine B-TRIVIAL 
( O 
0.23-0.86 O 
and O 
0.79-2.10 O 
mg O 
/ O 
g O 
dry O 
matter O 
, O 
respectively O 
) O 
. O 
Overall O 
, O 
mushroom O 
mycelium O 
could O 
be O 
incorporated O 
into O 
bread O 
to O 
provide O 
its O 
beneficial O 
health O 
effects O 
. O 

occurrence O 
of O 
deoxynivalenol B-TRIVIAL 
in O 
wheat O 
from O 
Paraná O 
State O 
, O 
Brazil O 
and O 
estimated O 
daily O 
intake O 
by O 
wheat O 
products O 
. O 

occurrence O 
of O 
deoxynivalenol B-TRIVIAL 
( O 
DON B-ABBREVIATION 
) O 
was O 
evaluated O 
in O 
113 O 
wheat O 
samples O 
from O 
the O 
northern O 
and O 
central O 
/ O 
southwestern O 
regions O 
of O 
Paraná O 
State O 
, O 
Brazil O 
during O 
the O 
2008 O 
and O 
2009 O 
growing O 
seasons O 
, O 
and O 
this O 
rate O 
of O 
occurrence O 
was O 
used O 
to O 
estimate O 
the O 
DON B-ABBREVIATION 
dietary O 
exposure O 
. O 
The O 
DON B-ABBREVIATION 
determination O 
was O 
carried O 
out O 
by O 
an O 
indirect O 
competitive O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
. O 
DON B-ABBREVIATION 
was O 
detected O 
in O 
66.4% O 
samples O 
at O 
levels O 
ranging O 
from O 
206.3 O 
to O 
4732.3 O 
μg O 
/ O 
kg O 
( O 
mean O 
1894.9 O 
μg O 
/ O 
kg O 
) O 
. O 
The O 
estimated O 
daily O 
intake O 
( O 
EDI O 
) O 
of O 
DON B-ABBREVIATION 
through O 
bread O 
and O 
pasta O 
was O 
evaluated O 
in O 
the O 
inhabitants O 
of O 
Londrina O 
City O 
in O 
northern O 
Paraná O 
State O 
, O 
Brazil O 
. O 
The O 
average O 
intake O 
of O 
these O 
inhabitants O 
was O 
0.79 O 
μg O 
/ O 
kg O 
body O 
weight O 
( O 
b.w O 
. O 
) O 
for O 
bread O 
and O 
0.35 O 
μg O 
/ O 
kg O 
b.w O 
. O 
for O 
pasta O 
. O 
The O 
total O 
EDI O 
was O 
1.13 O 
μg O 
/ O 
kg O 
, O 
which O 
is O 
above O 
the O 
Provisional O 
Tolerable O 
Daily O 
Maximum O 
Intake O 
( O 
PTDMI O 
) O 
of O 
1 O 
μg O 
/ O 
kg O 
b.w O 
. O 
To O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
report O 
on O 
natural O 
DON B-ABBREVIATION 
occurrence O 
in O 
wheat O 
and O 
DON B-ABBREVIATION 
dietary O 
exposure O 
estimation O 
from O 
Paraná O 
, O 
Brazil O 
. O 

effect O 
of O 
2,3-dehydrosilybin B-SYSTEMATIC 
on O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
-induced O 
liver O 
injury O 
in O 
rats O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
protective O 
effect O 
of O 
2,3-dehydrosilybin B-SYSTEMATIC 
( O 
DHS B-ABBREVIATION 
) O 
against O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
( O 
CCl(4) B-FORMULA 
)-induced O 
liver O 
injury O 
in O 
rats O 
. O 
Administration O 
of O 
DHS B-ABBREVIATION 
significantly O 
attenuated O 
the O 
levels O 
of O 
serum O 
aspartate B-TRIVIAL 
aminotransferase O 
, O 
alanine B-TRIVIAL 
aminotransferase O 
, O 
and O 
liver O 
lipid O 
peroxidation O 
in O 
CCl(4) B-FORMULA 
-treated O 
rats O 
. O 
Moreover O 
, O 
we O 
showed O 
that O 
DHS B-ABBREVIATION 
prevented O 
DNA O 
damage O 
and O 
decreased O 
the O 
protein O 
levels O 
of O 
γ-H2AX O 
, O 
which O 
is O 
a O 
specific O 
DNA O 
damage O 
marker O 
, O 
in O 
CCl(4) B-FORMULA 
-treated O 
rat O 
livers O 
. O 
DHS O 
also O 
markedly O 
increased O 
the O 
activity O 
of O 
antioxidant O 
enzymes O 
, O 
such O 
as O 
superoxide B-TRIVIAL 
dismutase O 
, O 
catalase O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
, O 
and O 
glutathione O 
reductase O 
in O 
CCl(4) B-FORMULA 
-treated O 
rat O 
livers O 
. O 
Furthermore O 
, O 
we O 
found O 
that O 
DHS B-ABBREVIATION 
significantly O 
inhibited O 
the O 
production O 
of O 
serum O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
as O 
well O 
as O 
the O 
levels O 
of O 
serum O 
IL-6 O 
, O 
IFN-γ O 
, O 
and O 
TNF-α O 
in O 
CCl(4) B-FORMULA 
-treated O 
rats O 
. O 
Additionally O 
, O 
DHS B-ABBREVIATION 
significantly O 
suppressed O 
iNOS O 
expression O 
on O 
the O 
protein O 
levels O 
in O 
CCl(4) B-FORMULA 
-treated O 
rat O 
livers O 
. O 
Collectively O 
, O 
the O 
present O 
study O 
suggests O 
that O 
DHS B-ABBREVIATION 
protects O 
the O 
liver O 
from O 
CCl(4) B-FORMULA 
-induced O 
hepatic O 
damage O 
via O 
antioxidant O 
and O 
anti-inflammatory O 
mechanisms O 
. O 

this O 
work O 
we O 
report O 
on O 
a O 
new O 
, O 
rapid O 
and O 
simple O 
voltammetric O 
method O 
to O 
determine O 
the O 
total O 
antioxidant O 
capacity O 
( O 
TAC O 
) O 
of O 
the O 
edible O 
oils O 
. O 
The O 
method O 
explores O 
the O 
ABTS B-ABBREVIATION 
radical O 
( O 
2,2'-azinobis(3-ethylbenzothiazoline-6-sulphonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
) O 
assay O 
as O 
a O 
redox O 
probe O 
and O 
it O 
relays O 
on O 
measuring O 
catalytic O 
voltammetric O 
currents O 
. O 
The O 
electrocatalysis O 
comprises O 
redox O 
regeneration O 
of O 
the O 
electrochemically O 
created O 
ABTS(+) B-ABBREVIATION 
radical O 
either O 
by O 
Trolox B-TRIVIAL 
( O 
6-hydroxy-2,5,7,8-tetramethychroman-2-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
or O 
by O 
antioxidants O 
present O 
in O 
studied O 
oils O 
. O 
The O 
detection O 
limit O 
of O 
the O 
method O 
is O 
determined O 
to O 
be O 
0.5 O 
mg O 
/ O 
L O 
of O 
Trolox B-TRIVIAL 
equivalent O 
, O 
being O 
a O 
slightly O 
lower O 
than O 
the O 
corresponding O 
UV-VIS O 
spectrophotometric O 
method O 
. O 
Applying O 
the O 
proposed O 
voltammetric O 
method O 
the O 
total O 
antioxidant O 
capacity O 
of O 
three O 
types O 
of O 
commercially O 
available O 
cold O 
- O 
pressed O 
edible O 
oils O 
are O 
determined O 
, O 
and O 
the O 
results O 
are O 
found O 
to O 
be O 
in O 
a O 
very O 
good O 
agreement O 
with O 
those O 
obtained O 
by O 
UV-VIS O 
spectrophotometry O 
. O 
The O 
reported O 
voltammetric O 
method O 
is O 
cheap O 
, O 
rapid O 
and O 
simple O 
, O 
and O 
it O 
can O 
be O 
used O 
as O 
a O 
sustainable O 
alternative O 
to O 
the O 
UV-VIS O 
methods O 
for O 
the O 
determination O 
of O 
total O 
antioxidant O 
capacitance O 
of O 
oils O 
and O 
other O 
liquid O 
lipophilic O 
nutrients O 
. O 
Potent O 
antioxidant O 
capacity O 
of O 
studied O 
oils O 
was O 
also O 
confirmed O 
by O 
electron O 
paramagnetic O 
resonance O 
spectroscopy O 
of O 
superoxide B-TRIVIAL 
anion O 
produced O 
by O 
macrophages O 
. O 

of O 
the O 
genistein B-TRIVIAL 
metabolite O 
on O 
leptin O 
secretion O 
in O 
murine O 
adipocytes O 
in O 
vitro O 
. O 

isoflavonoids B-FAMILY 
have O 
many O 
useful O 
properties O 
. O 
However O 
, O 
they O 
are O 
metabolized O 
in O 
vivo O 
, O 
including O 
in O 
humans O 
. O 
The O 
effect O 
of O 
the O 
metabolism O 
of O 
soy O 
isoflavonoids B-FAMILY 
on O 
their O 
properties O 
is O 
not O 
fully O 
understood O 
. O 
We O 
have O 
isolated O 
the O 
bacterial O 
strain O 
SY8519 O 
, O 
which O 
has O 
been O 
shown O 
to O 
metabolize O 
daidzein B-TRIVIAL 
to O 
O-desmethylangolensin B-TRIVIAL 
and O 
to O 
produce O 
2-(4-hydroxyphenyl)propionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
from O 
genistein B-TRIVIAL 
. O 
According O 
to O 
chiral O 
HPLC O 
analysis O 
, O 
the O 
2-(4-hydroxyphenyl)propionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
obtained O 
from O 
the O 
bacterium O 
was O 
optically O 
active O 
. O 
To O 
determine O 
the O 
absolute O 
stereochemistry O 
of O 
the O 
microbial O 
product O 
, O 
we O 
prepared O 
(S)-2-(4-hydroxyphenyl)propionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
from O 
(S)-2-phenylpropionic B-SYSTEMATIC 
and O 
concluded O 
that O 
the O 
microbial O 
product O 
had O 
an O 
R- O 
configuration O 
by O 
chiral O 
HPLC O 
analysis O 
. O 
We O 
also O 
applied O 
the O 
metabolite O 
to O 
mouse O 
adipocytes O 
and O 
found O 
that O 
2-HPPA B-SYSTEMATIC 
was O 
less O 
effective O 
at O 
reducing O 
leptin O 
secretion O 
than O 
the O 
parent O 
compound O 
genistein B-TRIVIAL 
. O 
Our O 
results O 
suggested O 
that O 
' O 
O-desmethylangolensin B-TRIVIAL 
-production O 
' O 
attenuates O 
the O 
effect O 
of O 
soy O 
isoflavonoids B-FAMILY 
by O 
reducing O 
not O 
only O 
the O 
activity O 
of O 
daidzein B-TRIVIAL 
but O 
also O 
that O 
of O 
genistein B-TRIVIAL 
. O 

detection O 
of O 
flavonoids B-FAMILY 
and O 
phenolic B-FAMILY 
acids I-FAMILY 
in O 
Herba O 
Lysimachiae O 
and O 
Herba O 
Desmodii O 
Styracifolii O 
using O 
liquid O 
chromatography O 
tandem O 
mass O 
spectrometry O 
. O 

sensitive O 
liquid O 
chromatography O 
and O 
tandem O 
mass O 
spectrometry O 
( O 
LC-MS O 
/ O 
MS O 
) O 
method O 
was O 
developed O 
and O 
validated O 
for O 
the O 
simultaneous O 
analysis O 
of O 
15 O 
flavonoids B-FAMILY 
and O 
3 O 
phenolic B-FAMILY 
acids I-FAMILY 
in O 
Herba O 
Lysimachiae O 
and O 
Herba O 
Desmodii O 
Styracifolii O 
. O 
Separation O 
was O 
performed O 
using O 
a O 
Diamonsil O 
C(18) O 
column O 
, O 
which O 
was O 
eluted O 
with O 
methanol B-SYSTEMATIC 
( O 
A O 
) O 
and O 
0.1‰ O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
B O 
) O 
. O 
The O 
gradient O 
condition O 
was O 
as O 
follows O 
: O 
0-34 O 
min O 
, O 
20-34% O 
A O 
; O 
34-38 O 
min O 
, O 
34-95% O 
A O 
; O 
maintained O 
95% O 
A O 
for O 
the O 
next O 
4 O 
min O 
. O 
Analytes O 
were O 
detected O 
using O 
a O 
hybrid O 
quadrupole O 
linear O 
ion O 
trap O 
mass O 
spectrometer O 
that O 
was O 
equipped O 
with O 
an O 
electrospray O 
ionisation O 
source O 
in O 
the O 
negative O 
ion O 
and O 
multiple O 
- O 
reaction O 
monitoring O 
modes O 
. O 
A O 
full O 
validation O 
of O 
the O 
method O 
was O 
performed O 
, O 
including O 
the O 
linearity O 
, O 
precision O 
, O 
and O 
accuracy O 
, O 
as O 
well O 
as O 
limits O 
of O 
detection O 
and O 
quantification O 
. O 
The O 
results O 
indicated O 
that O 
the O 
developed O 
method O 
was O 
simple O 
, O 
sensitive O 
and O 
reliable O 
. O 
Furthermore O 
, O 
the O 
method O 
was O 
successfully O 
applied O 
to O 
differentiate O 
16 O 
batches O 
of O 
Herba O 
Lysimachiae O 
and O 
21 O 
batches O 
of O 
Herba O 
Desmodii O 
Styracifolii O 
. O 

of O 
Vanilla O 
pompona O 
from O 
the O 
Peruvian O 
Amazon O 
as O 
a O 
potential O 
source O 
of O 
vanilla O 
essence O 
: O 
quantification O 
of O 
phenolics B-FAMILY 
by O 
HPLC-DAD O 
. O 

study O 
provides O 
the O 
first O 
chemical O 
investigation O 
of O 
wild O 
- O 
harvested O 
fruits O 
of O 
Vanilla O 
pompona O 
ssp O 
. O 
grandiflora O 
( O 
Lindl O 
. O 
) O 
Soto-Arenas O 
developed O 
in O 
their O 
natural O 
habitat O 
in O 
the O 
Peruvian O 
Amazon O 
. O 
Flowers O 
were O 
hand O 
- O 
pollinated O 
and O 
the O 
resulting O 
fruits O 
were O 
analysed O 
at O 
different O 
developmental O 
stages O 
using O 
an O 
HPLC-DAD O 
method O 
validated O 
for O 
the O 
quantification O 
of O 
glucovanillin B-TRIVIAL 
and O 
seven O 
other O 
compounds O 
. O 
The O 
method O 
showed O 
satisfactory O 
linearity O 
( O 
r(2) O 
> O 
0.9969 O 
) O 
, O 
precision O 
( O 
coefficient O 
of O 
variation O 
< O 
2% O 
) O 
, O 
recoveries O 
( O 
70-100% O 
) O 
, O 
limit O 
of O 
detection O 
( O 
0.008-0.212 O 
μg O 
/ O 
ml O 
) O 
, O 
and O 
limit O 
of O 
quantification O 
( O 
0.027-0.707 O 
μg O 
/ O 
ml O 
) O 
. O 
The O 
evaluation O 
of O 
crude O 
and O 
enzyme O 
- O 
hydrolyzed O 
Soxhlet O 
- O 
extracted O 
samples O 
confirmed O 
the O 
leading O 
role O 
of O 
glucosides O 
in O 
fruit O 
development O 
. O 
LC-ESI-MS O 
studies O 
corroborated O 
the O 
identities O 
of O 
four O 
glucosides O 
and O 
seven O 
aglycones O 
, O 
among O 
them O 
vanillin B-TRIVIAL 
( O 
5.7 O 
/ O 
100 O 
g O 
) O 
, O 
4-hydroxybenzyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
( O 
3.6 O 
/ O 
100 O 
g O 
) O 
, O 
and O 
anisyl B-TRIVIAL 
alcohol I-TRIVIAL 
( O 
7.1 O 
/ O 
100 O 
g O 
) O 
were O 
found O 
in O 
high O 
concentrations O 
. O 
The O 
attractive O 
flavor O 
/ O 
aroma O 
profile O 
exhibited O 
by O 
wild O 
V O 
. O 
pompona O 
fruits O 
supports O 
studies O 
focused O 
on O 
the O 
development O 
of O 
this O 
species O 
as O 
a O 
specialty O 
crop O 
. O 

mauritiana O 
( O 
masau O 
) O 
fruits O 
are O 
consumed O 
by O 
many O 
people O 
in O 
Zimbabwe O 
. O 
The O 
fruits O 
contribute O 
significantly O 
to O 
people's O 
diet O 
when O 
they O 
are O 
in O 
season O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
nutritional O 
content O 
of O 
the O 
fruits O 
and O 
, O 
hence O 
, O 
quantify O 
their O 
contribution O 
to O 
the O 
diet O 
. O 
Samples O 
of O 
masau O 
were O 
collected O 
in O 
two O 
seasons O 
( O 
August O 
2006 O 
and O 
August O 
2007 O 
) O 
. O 
Both O 
macronutrients O 
and O 
micronutrients O 
were O 
determined O 
using O 
standard O 
AOAC O 
methods O 
of O 
analysis O 
. O 
Dry O 
matter O 
content O 
ranged O 
from O 
21.1±0.2 O 
to O 
24.1±0.3 O 
g O 
100 O 
g(-1) O 
of O 
edible O 
portion O 
of O 
the O 
sweet O 
and O 
sour O 
fruits O 
, O 
and O 
84.8±0.2 O 
to O 
87.2±0.2 O 
g O 
100 O 
g(-1) O 
for O 
the O 
dried O 
fruit O 
. O 
Crude O 
protein O 
per O 
100g O 
edible O 
portion O 
of O 
dry O 
weight O 
ranged O 
between O 
7.9±0.0 O 
and O 
8.7±0.0 O 
g O 
, O 
crude O 
fat O 
from O 
0.8±0.0 O 
to O 
1.5±0.0 O 
g O 
, O 
crude O 
fibre O 
from O 
4.9±0.0 O 
to O 
7.3±0.0 O 
g O 
, O 
ash O 
between O 
3.0±0.0 O 
and O 
4.3±0.0 O 
g O 
and O 
carbohydrate B-FAMILY 
between O 
79.5±0.0 O 
and O 
83.2±0.0 O 
g O 
. O 
The O 
fruits O 
were O 
rich O 
in O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
( O 
15.0±0.0-43.8±0.02 O 
mg O 
100 O 
g(-1) O 
) O 
and O 
the O 
energy O 
values O 
ranged O 
between O 
1516.0±1.73 O 
and O 
1575.0±2.3 O 
kJ O 
100 O 
g(-1) O 
. O 
Furthermore O 
, O 
the O 
fruits O 
contained O 
( O 
mg O 
100 O 
g(-1) O 
of O 
dry O 
weight O 
) O 
potassium B-SYSTEMATIC 
from O 
1865.0±1.3 O 
to O 
2441.0±1.1 O 
, O 
calcium B-SYSTEMATIC 
from O 
160.0±0.3 O 
to O 
254.0±0.1 O 
, O 
sodium B-SYSTEMATIC 
between O 
185.0±0.1 O 
and O 
223.0±0.2 O 
, O 
magnesium B-SYSTEMATIC 
between O 
83.0±0.0 O 
and O 
150.0±0.13 O 
and O 
phosphorous B-SYSTEMATIC 
from O 
87.0±0.1 O 
to O 
148.0±0.5 O 
. O 
Manganese B-SYSTEMATIC 
and O 
copper B-SYSTEMATIC 
contents O 
ranged O 
between O 
0.7±0.03 O 
and O 
1.6±0.03 O 
, O 
while O 
iron B-SYSTEMATIC 
and O 
zinc B-SYSTEMATIC 
ranged O 
between O 
2.1±0.43 O 
and O 
4.3±0.1 O 
, O 
and O 
0.6±0.0-0.9±0.0 O 
mg O 
100 O 
g(-1) O 
of O 
dry O 
weight O 
, O 
respectively O 
. O 
The O 
masau O 
fruit O 
is O 
therefore O 
a O 
good O 
potential O 
source O 
of O 
carbohydrates B-FAMILY 
, O 
proteins O 
and O 
micronutrients O 
, O 
such O 
as O 
calcium B-SYSTEMATIC 
, O 
potassium B-SYSTEMATIC 
, O 
sodium B-SYSTEMATIC 
, O 
phosphorous B-SYSTEMATIC 
, O 
copper B-SYSTEMATIC 
, O 
iron B-SYSTEMATIC 
, O 
Vitamin B-TRIVIAL 
C I-TRIVIAL 
and O 
zinc B-SYSTEMATIC 
. O 

of O 
sample O 
preparation O 
method O 
for O 
isoliquiritigenin B-TRIVIAL 
, O 
liquiritin B-TRIVIAL 
, O 
and O 
glycyrrhizic B-TRIVIAL 
acid I-TRIVIAL 
analysis O 
in O 
licorice O 
by O 
ionic O 
liquids O 
- O 
ultrasound O 
based O 
extraction O 
and O 
high O 
- O 
performance O 
liquid O 
chromatography O 
detection O 
. O 

ionic O 
liquid O 
- O 
based O 
ultrasonic O 
- O 
assisted O 
extraction O 
( O 
ILUAE O 
) O 
method O 
had O 
been O 
used O 
for O 
the O 
effective O 
extraction O 
of O 
isoliquiritigenin B-TRIVIAL 
( O 
IQ O 
) O 
, O 
liquiritin B-TRIVIAL 
( O 
LQ O 
) O 
and O 
glycyrrhizic B-TRIVIAL 
acid I-TRIVIAL 
( O 
GA O 
) O 
from O 
licorice O 
. O 
The O 
ionic O 
liquids O 
with O 
different O 
cations O 
and O 
anions O 
were O 
investigated O 
in O 
this O 
work O 
and O 
0.5 O 
M O 
1-butyl-3-methylimidazolium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
solution O 
was O 
selected O 
as O 
solvent O 
. O 
In O 
addition O 
, O 
the O 
technical O 
parameters O 
including O 
soaking O 
time O 
, O 
solid O 
- O 
liquid O 
ratio O 
, O 
ultrasonic O 
power O 
and O 
time O 
were O 
optimized O 
. O 
Compared O 
with O 
the O 
conventional O 
solvent O 
extraction O 
, O 
the O 
proposed O 
approach O 
exhibited O 
higher O 
efficiency O 
, O 
which O 
indicated O 
the O 
ILUAE O 
was O 
an O 
efficient O 
, O 
rapid O 
and O 
simple O 
sample O 
preparation O 
technique O 
. O 
There O 
was O 
no O 
degradation O 
of O 
the O 
target O 
analytes O 
had O 
been O 
observed O 
at O 
the O 
optimum O 
conditions O 
which O 
was O 
evidenced O 
by O 
the O 
stability O 
studies O 
performed O 
with O 
standard O 
of O 
IQ O 
, O 
LQ O 
and O 
GA O 
. O 
The O 
proposed O 
method O 
also O 
showed O 
high O 
reproducibility O 
and O 
was O 
environmental O 
friendly O 
. O 

formation O 
of O 
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine B-SYSTEMATIC 
( O 
PhIP B-ABBREVIATION 
) O 
in O 
creatinine B-TRIVIAL 
/ O 
phenylalanine B-TRIVIAL 
and O 
creatinine B-TRIVIAL 
/ O 
phenylalanine B-TRIVIAL 
/ O 
4-oxo-2-nonenal B-SYSTEMATIC 
reaction O 
mixtures O 
. O 

comparative O 
formation O 
of O 
the O 
heterocyclic O 
aromatic O 
amine O 
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine B-SYSTEMATIC 
( O 
PhIP B-ABBREVIATION 
) O 
in O 
both O 
creatinine B-TRIVIAL 
/ O 
phenylalanine B-TRIVIAL 
( O 
CRN B-ABBREVIATION 
/ O 
Phe B-FORMULA 
) O 
and O 
creatinine B-TRIVIAL 
/ O 
phenylalanine B-TRIVIAL 
/ O 
4-oxo-2-nonenal B-SYSTEMATIC 
( O 
CRN B-ABBREVIATION 
/ O 
Phe B-FORMULA 
/ O 
ON O 
) O 
systems O 
was O 
studied O 
to O 
analyse O 
the O 
ability O 
of O 
lipid O 
- O 
derived O 
reactive O 
carbonyls B-FAMILY 
to O 
promote O 
PhIP B-ABBREVIATION 
formation O 
. O 
Although O 
PhIP B-ABBREVIATION 
was O 
produced O 
to O 
some O 
extent O 
in O 
the O 
CRN B-ABBREVIATION 
/ O 
Phe B-FORMULA 
system O 
, O 
the O 
presence O 
of O 
the O 
oxidized O 
lipid O 
increased O 
considerably O 
the O 
amount O 
of O 
PhIP B-ABBREVIATION 
produced O 
. O 
This O 
increase O 
seemed O 
to O 
be O 
a O 
consequence O 
of O 
the O 
decrease O 
in O 
the O 
E(a) O 
of O 
the O 
reaction O 
when O 
the O 
lipid O 
was O 
present O 
, O 
which O 
diminished O 
from O 
112.9 O 
to O 
80.9 O 
kJ O 
/ O 
mol O 
. O 
On O 
the O 
other O 
hand O 
, O 
the O 
addition O 
of O 
the O 
lipid O 
did O 
not O 
seem O 
to O 
produce O 
PhIP B-ABBREVIATION 
by O 
an O 
alternative O 
mechanism O 
because O 
PhIP B-ABBREVIATION 
was O 
formed O 
analogously O 
in O 
both O 
CRN B-ABBREVIATION 
/ O 
Phe B-FORMULA 
and O 
CRN B-ABBREVIATION 
/ O 
Phe B-FORMULA 
/ O 
ON O 
systems O 
as O 
a O 
function O 
of O 
pH O 
, O 
creatinine B-TRIVIAL 
concentration O 
, O 
phenylalanine B-TRIVIAL 
concentration O 
, O 
time O 
, O 
temperature O 
, O 
oxygen B-SYSTEMATIC 
concentration O 
in O 
the O 
reaction O 
atmosphere O 
, O 
and O 
the O 
addition O 
of O 
different O 
amounts O 
of O 
ammonia B-SYSTEMATIC 
. O 
All O 
these O 
results O 
suggest O 
that O 
the O 
ability O 
of O 
lipid O 
oxidation O 
products O 
to O 
produce O 
PhIP B-ABBREVIATION 
is O 
related O 
to O 
their O 
capacity O 
to O 
induce O 
the O 
Strecker O 
degradation O 
of O 
phenylalanine B-TRIVIAL 
to O 
phenylacetaldehyde B-SYSTEMATIC 
. O 
Therefore O 
, O 
any O 
other O 
reactive O 
carbonyl B-FAMILY 
compound O 
that O 
can O 
produce O 
the O 
Strecker O 
degradation O 
of O 
phenylalanine B-TRIVIAL 
should O 
also O 
be O 
considered O 
as O 
a O 
potential O 
inducer O 
of O 
PhIP B-ABBREVIATION 
formation O 
under O 
appropriate O 
conditions O 
. O 

avoid O 
the O 
traditional O 
and O 
time O 
consuming O 
hydrodistillation O 
, O 
the O 
analyses O 
of O 
volatile O 
components O 
in O 
aerial O 
parts O 
of O 
Echinophora O 
platyloba O 
DC O 
was O 
carried O 
out O 
by O 
a O 
simple O 
microwave O 
distillation O 
followed O 
by O 
headspace O 
single O 
drop O 
microextraction O 
( O 
MD-HS-SDME O 
) O 
coupled O 
to O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
( O 
GC-MS O 
) O 
. O 
The O 
headspace O 
volatile O 
compounds O 
were O 
collected O 
after O 
irradiation O 
using O 
a O 
single O 
drop O 
of O 
n-heptadecan B-SYSTEMATIC 
. O 
The O 
extraction O 
conditions O 
were O 
optimised O 
using O 
the O 
relative O 
peak O 
areas O 
as O 
index O 
. O 
The O 
chemical O 
composition O 
of O 
the O 
MD-HS-SDME O 
extracts O 
was O 
confirmed O 
according O 
to O 
their O 
retention O 
indexes O 
and O 
mass O 
spectra O 
. O 
Fifty O 
- O 
three O 
components O 
were O 
extracted O 
and O 
identified O 
by O 
using O 
the O 
MD-HS-SDME O 
method O 
. O 
E-β-ocimene B-TRIVIAL 
( O 
53.81% O 
) O 
, O 
R-D-decalactone O 
( O 
12.75% O 
) O 
, O 
α-pinene B-TRIVIAL 
( O 
6.43% O 
) O 
, O 
n-heptanol B-SYSTEMATIC 
( O 
6.27% O 
) O 
, O 
β-phellanderne B-TRIVIAL 
( O 
2.70% O 
) O 
and O 
linalool B-TRIVIAL 
( O 
1.89% O 
) O 
were O 
the O 
major O 
constituents O 
. O 

constituents O 
of O 
cuticular O 
membranes O 
( O 
CMs O 
) O 
isolated O 
from O 
three O 
tea O 
cultivars O 
( O 
Camellia O 
sinensis O 
( O 
L O 
. O 
) O 
O O 
. O 
Kuntze O 
cvs O 
. O 
Yabukita O 
, O 
Samidori O 
and O 
Gokou O 
) O 
were O 
compared O 
. O 
All O 
CMs O 
from O 
the O 
adaxial O 
side O 
of O 
the O 
leaves O 
showed O 
higher O 
accumulation O 
of O 
wax O 
, O 
cutin O 
and O 
polysaccharide O 
, O 
while O 
those O 
from O 
the O 
abaxial O 
side O 
were O 
abundant O 
in O 
cutan O 
, O 
showing O 
the O 
adaptation O 
of O 
the O 
adaxial O 
side O 
to O 
abiotic O 
stresses O 
, O 
such O 
as O 
wind O 
and O 
rain O 
, O 
in O 
contrast O 
to O 
the O 
abaxial O 
side O 
, O 
which O 
provides O 
defence O 
against O 
pathogens O 
. O 
Yabukita O 
, O 
a O 
major O 
tea O 
cultivar O 
in O 
Japan O 
, O 
developed O 
thick O 
CMs O 
while O 
Samidori O 
and O 
Gokou O 
, O 
shade-cultivated O 
tea O 
cultivars O 
, O 
had O 
lighter O 
CMs O 
, O 
reflecting O 
their O 
thin O 
and O 
soft O 
leaves O 
. O 
CMs O 
rapidly O 
accumulated O 
9,10-epoxy-18-hydroxyoctadecanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
at O 
a O 
very O 
early O 
stage O 
of O 
leaf O 
development O 
. O 
Additionally O 
, O 
shade O 
treatment O 
did O 
not O 
influence O 
cutin O 
biosynthesis O 
in O 
CMs O 
, O 
reflecting O 
high O 
adaptation O 
of O 
tea O 
leaves O 
under O 
low O 
light O 
levels O 
. O 

and O 
HPLC O 
of O 
caffeoyl B-FAMILY 
esters I-FAMILY 
in O 
wild O 
and O 
cultivated O 
Arctium O 
lappa O 
L O 
. O 

methods O 
including O 
ultra O 
- O 
performance O 
liquid O 
chromatography O 
( O 
UPLC O 
) O 
and O 
high O 
- O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
with O 
photodiode O 
array O 
( O 
PDA O 
) O 
detector O 
were O 
developed O 
for O 
the O 
analysis O 
of O 
caffeoylquinic B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
in O 
seeds O 
, O 
leaves O 
and O 
roots O 
of O 
Arctium O 
lappa O 
L O 
. O 
Separation O 
was O 
performed O 
on O 
C(18) O 
column O 
utilising O 
5% O 
( O 
v O 
/ O 
v O 
) O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
water O 
and O 
acetonitrile B-SYSTEMATIC 
at O 
330 O 
nm O 
. O 
Both O 
methodologies O 
were O 
validated O 
in O 
terms O 
of O 
linearity O 
, O 
precision O 
, O 
and O 
recovery O 
. O 
The O 
results O 
showed O 
that O 
the O 
major O 
advantages O 
of O 
UPLC O 
, O 
over O 
HPLC O 
were O 
the O 
fast O 
analysis O 
, O 
narrow O 
peaks O 
, O 
high O 
sensitivity O 
, O 
and O 
reduction O 
of O 
solvent O 
consumption O 
. O 
Subsequently O 
the O 
methods O 
were O 
applied O 
for O 
the O 
identification O 
and O 
quantification O 
of O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
( O 
5-CQA B-SYSTEMATIC 
) O 
and O 
1,5-dicaffeoylquinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
1,5-DCQA B-SYSTEMATIC 
) O 
as O 
main O 
compounds O 
in O 
samples O 
. O 
The O 
total O 
phenolic O 
content O 
of O 
samples O 
ranged O 
from O 
3.93 O 
to O 
14.13 O 
g O 
of O 
5-CQA B-SYSTEMATIC 
equivalent O 
/ O 
100g O 
dry O 
weight O 
( O 
DW O 
) O 
. O 
There O 
was O 
a O 
significant O 
variability O 
from O 
89 O 
to O 
571 O 
mg O 
/ O 
100g O 
for O 
5-CQA B-SYSTEMATIC 
and O 
48 O 
to O 
486 O 
mg O 
/ O 
100g O 
for O 
1,5-DCQA B-SYSTEMATIC 
in O 
dry O 
material O 
. O 

is O 
a O 
43-amino O 
acid O 
naturally O 
occurring O 
chemopreventive O 
peptide O 
with O 
demonstrated O 
anti-cancer O 
and O 
anti-inflammatory O 
properties O 
. O 
The O 
objectives O 
of O 
this O 
study O 
were O 
to O 
determine O 
the O 
effect O 
of O 
temperature O 
on O 
the O 
secondary O 
structure O 
of O 
lunasin O 
, O 
to O 
develop O 
a O 
method O 
of O 
isolating O 
lunasin O 
from O 
human O 
plasma O 
using O 
an O 
ion O 
- O 
exchange O 
microspin O 
column O 
and O 
to O 
quantify O 
the O 
amount O 
of O 
lunasin O 
using O 
an O 
optimized O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
. O 
Lunasin O 
was O 
purified O 
using O 
a O 
combination O 
of O 
ion O 
- O 
exchange O 
chromatography O 
, O 
ultrafiltration O 
and O 
gel O 
filtration O 
chromatography O 
. O 
Circular O 
dichroism O 
showed O 
that O 
increased O 
in O 
temperature O 
from O 
25 O 
to O 
100 O 
°C O 
resulted O 
in O 
changes O 
on O 
the O 
secondary O 
structure O 
of O 
lunasin O 
and O 
its O 
capability O 
to O 
interact O 
with O 
rabbit O 
polyclonal O 
antibody O 
. O 
Enzyme O 
linked O 
immunosorbent O 
assay O 
showed O 
that O 
lunasin O 
rabbit O 
polyclonal O 
antibody O 
has O 
a O 
titer O 
of O 
250 O 
and O 
a O 
specific O 
activity O 
of O 
0.05 O 
mL O 
/ O 
μg O 
. O 
A O 
linear O 
response O 
was O 
detected O 
between O 
16 O 
to O 
48 O 
ng O 
lunasin O 
per O 
mL O 
( O 
y=0.03x-0.38 O 
, O 
R(2)=0.96 O 
) O 
. O 
The O 
use O 
of O 
diethylaminoethyl B-SYSTEMATIC 
microspin O 
column O 
to O 
isolate O 
spiked O 
lunasin O 
in O 
human O 
plasma O 
showed O 
that O 
most O 
lunasin O 
( O 
37.8-46.5% O 
) O 
bound O 
to O 
the O 
column O 
eluted O 
with O 
Tris-HCl B-SYSTEMATIC 
buffer O 
, O 
pH O 
7.5 O 
with O 
a O 
yield O 
up O 
to O 
76.6% O 
. O 
In O 
conclusion O 
, O 
lunasin O 
can O 
be O 
isolated O 
from O 
human O 
plasma O 
by O 
a O 
simple O 
DEAE O 
microspin O 
column O 
technique O 
and O 
can O 
be O 
quantified O 
using O 
a O 
validated O 
and O 
optimized O 
immunoassay O 
procedure O 
. O 
This O 
method O 
can O 
be O 
used O 
directly O 
to O 
quantify O 
lunasin O 
from O 
plasma O 
in O 
different O 
human O 
and O 
animal O 
studies O 
aiming O 
to O 
determine O 
its O 
bioavailability O 
. O 

main O 
goal O 
of O 
present O 
study O 
was O 
the O 
development O 
, O 
optimization O 
and O 
application O 
of O 
different O 
extraction O 
protocols O 
, O 
especially O 
those O 
employing O 
green O 
technologies O 
, O 
in O 
order O 
to O 
obtain O 
from O 
Berberis O 
cretica O 
extracts O 
with O 
high O 
antioxidant O 
capacity O 
. O 
For O 
this O 
purpose O 
, O 
the O 
applied O 
methods O 
: O 
maceration O 
, O 
ASE O 
and O 
SFE O 
coupled O 
with O 
ASE O 
were O 
incorporated O 
. O 
The O 
antioxidant O 
assessment O 
was O 
carried O 
out O 
using O 
DPPH B-ABBREVIATION 
and O 
total O 
phenolic O 
content O 
( O 
Folin-Ciocalteu O 
) O 
assays O 
. O 
Major O 
constituents O 
were O 
elucidated O 
using O 
HPLC-DAD O 
and O 
UHPLC-HRMS O 
/ O 
MS O 
( O 
hybrid O 
IT-Orbital O 
trap O 
spectrometer O 
) O 
equipped O 
with O 
an O 
ESI O 
probe O 
. O 
The O 
chromatographic O 
and O 
spectral O 
data O 
revealed O 
the O 
presence O 
of O 
several O 
simple O 
phenolic B-FAMILY 
acids I-FAMILY 
, O 
derivatives O 
of O 
both O 
caffeic B-MULTIPLE 
and I-MULTIPLE 
benzoic I-MULTIPLE 
acids I-MULTIPLE 
, O 
and O 
flavonoids B-FAMILY 
in O 
the O 
produced O 
extracts O 
. O 
It O 
was O 
clearly O 
evidenced O 
that O 
the O 
extraction O 
method O 
and O 
solvents O 
used O 
affected O 
both O 
the O 
activity O 
and O 
the O 
chemical O 
content O 
of O 
the O 
results O 
, O 
significantly O 
. O 
The O 
most O 
beneficial O 
conditions O 
were O 
calculated O 
for O 
methanol B-SYSTEMATIC 
and O 
water O 
: O 
ethanol B-SYSTEMATIC 
( O 
50 O 
: O 
50 O 
) O 
extracts O 
derived O 
from O 
the O 
combination O 
of O 
SFE O 
and O 
ASE O 
methodologies O 
. O 
Obtained O 
results O 
classify O 
Cretan O 
barberry O 
as O 
a O 
strong O 
antioxidant O 
agent O 
. O 

, O 
antioxidant O 
activity O 
and O 
protein O 
- O 
precipitating O 
capacity O 
of O 
punicalin B-TRIVIAL 
from O 
pomegranate O 
husk O 
. O 

is O 
a O 
kind O 
of O 
ellagitannin O 
, O 
existing O 
in O 
pomegranate O 
husk O 
, O 
and O 
has O 
shown O 
remarkable O 
biological O 
activities O 
. O 
A O 
rapid O 
and O 
large O 
- O 
scale O 
separation O 
method O 
of O 
punicalin B-TRIVIAL 
from O 
pomegranate O 
husk O 
was O 
established O 
, O 
using O 
medium O 
pressure O 
liquid O 
chromatography O 
( O 
MPLC O 
) O 
. O 
The O 
optimal O 
mobile O 
phase O 
consisted O 
of O 
5% O 
methanol B-SYSTEMATIC 
and O 
0.1% O 
( O 
v O 
/ O 
v O 
) O 
TFA B-ABBREVIATION 
in O 
water O 
, O 
and O 
the O 
optimal O 
loading O 
amount O 
and O 
flow O 
rate O 
were O 
1 O 
g O 
and O 
80 O 
ml O 
/ O 
min O 
, O 
respectively O 
. O 
Under O 
this O 
condition O 
, O 
339 O 
mg O 
of O 
95.9% O 
punicalin B-TRIVIAL 
could O 
be O 
obtained O 
in O 
40 O 
min O 
. O 
59.7 O 
mg O 
of O 
78.0% O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
could O 
be O 
separated O 
simultaneously O 
. O 
This O 
method O 
was O 
practical O 
for O 
industrial O 
utilisation O 
of O 
pomegranate O 
husk O 
. O 
Afterwards O 
, O 
the O 
antioxidant O 
and O 
protein O 
- O 
precipitating O 
capacities O 
of O 
the O 
purified O 
punicalin B-TRIVIAL 
, O 
together O 
with O 
punicalagin B-TRIVIAL 
, O 
were O 
evaluated O 
. O 
Results O 
showed O 
that O 
punicalin B-TRIVIAL 
had O 
strong O 
antioxidant O 
activity O 
, O 
and O 
it O 
exhibited O 
a O 
low O 
affinity O 
for O 
protein O 
. O 
This O 
suggested O 
that O 
the O 
antioxidant O 
of O 
punicalin B-TRIVIAL 
would O 
not O 
be O 
greatly O 
masked O 
by O 
tannin B-FAMILY 
-protein O 
precipitation O 
in O 
application O 
, O 
and O 
hence O 
confirmed O 
punicalin B-TRIVIAL 
to O 
be O 
a O 
promising O 
antioxidant O 
. O 

of O 
vitamin B-FAMILY 
A I-FAMILY 
with O 
milk O 
α- O 
and O 
β-caseins O 
. O 

binding O 
sites O 
of O 
retinol B-TRIVIAL 
and O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
with O 
milk O 
α- O 
and O 
β-caseins O 
were O 
determined O 
, O 
using O 
constant O 
protein O 
concentration O 
and O 
various O 
retinoid O 
contents O 
. O 
FTIR O 
, O 
UV-visible O 
and O 
fluorescence O 
spectroscopic O 
methods O 
as O 
well O 
as O 
molecular O 
modelling O 
were O 
used O 
to O 
analyse O 
retinol B-TRIVIAL 
and O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
binding O 
sites O 
, O 
the O 
binding O 
constant O 
and O 
the O 
effect O 
of O 
retinoid B-FAMILY 
complexation O 
on O 
the O 
stability O 
and O 
conformation O 
of O 
caseins O 
. O 
Structural O 
analysis O 
showed O 
that O 
retinoids B-FAMILY 
bind O 
caseins O 
via O 
both O 
hydrophilic O 
and O 
hydrophobic O 
contacts O 
with O 
overall O 
binding O 
constants O 
of O 
K( O 
retinol B-TRIVIAL 
-)(α)(-caseins)=1.21 O 
(±0.4)×10(5) O 
M(-1) O 
and O 
K( O 
retinol B-TRIVIAL 
-)(β)(-caseins)=1.11 O 
(±0.5)×10(5) O 
M(-1) O 
and O 
K( O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
-)(α)(-caseins)=6.2 O 
(±0.6)×10(4) O 
M(-1) O 
and O 
K( O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
-)(β)(-caseins)=6.3 O 
(±0.6)×10(4) O 
M(-1) O 
. O 
The O 
number O 
of O 
bound O 
retinol B-TRIVIAL 
molecules O 
per O 
protein O 
( O 
n O 
) O 
was O 
1.5 O 
( O 
±0.1 O 
) O 
for O 
α-casein O 
and O 
1 O 
( O 
±0.1 O 
) O 
for O 
β-casein O 
, O 
while O 
1 O 
molecule O 
of O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
was O 
bound O 
in O 
the O 
α- O 
and O 
β-casein O 
complexes O 
. O 
Molecular O 
modelling O 
showed O 
different O 
binding O 
sites O 
for O 
retinol B-TRIVIAL 
and O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
on O 
α- O 
and O 
β-caseins O 
with O 
more O 
stable O 
complexes O 
formed O 
with O 
α-casein O 
. O 
Retinoid B-FAMILY 
-casein O 
complexation O 
induced O 
minor O 
alterations O 
of O 
protein O 
conformation O 
. O 
Caseins O 
might O 
act O 
as O 
carriers O 
for O 
transportation O 
of O 
retinoids B-FAMILY 
to O 
target O 
molecules O 
. O 

effect O 
of O 
genotype O 
( O 
G O 
) O 
, O 
growing O 
environment O 
( O 
E O 
) O 
, O 
and O 
their O 
interaction O 
( O 
G×E O 
) O 
on O 
the O 
antioxidant O 
properties O 
and O 
chemical O 
compositions O 
were O 
investigated O 
using O 
the O 
flour O 
samples O 
of O 
10 O 
wheat O 
varieties O 
grown O 
in O 
four O 
different O 
locations O 
in O 
Maryland O 
. O 
Lutein B-TRIVIAL 
content O 
of O 
wheat O 
flour O 
ranged O 
from O 
0.1 O 
to O 
0.69 O 
μg O 
/ O 
g O 
, O 
and O 
α-tocopherol B-TRIVIAL 
ranged O 
from O 
0.12 O 
to O 
0.83 O 
μg O 
/ O 
g O 
. O 
Total O 
carotenoids O 
were O 
primarily O 
affected O 
by O 
E O 
( O 
45.7% O 
) O 
, O 
while O 
G×E O 
interaction O 
had O 
a O 
larger O 
effect O 
on O 
the O 
level O 
of O 
total O 
tocopherols B-FAMILY 
( O 
71.6% O 
) O 
. O 
E O 
had O 
the O 
largest O 
effect O 
on O 
antioxidant O 
activity O 
against O 
oxygen B-SYSTEMATIC 
, O 
hydroxyl B-SYSTEMATIC 
, O 
and O 
ABTS(·+) B-ABBREVIATION 
radicals O 
. O 
G O 
had O 
the O 
least O 
influence O 
on O 
the O 
measured O 
phytochemicals O 
and O 
antioxidant O 
activity O 
assays O 
. O 
Total O 
carotenoids O 
had O 
a O 
significant O 
correlation O 
with O 
average O 
low O 
air O 
temperature O 
( O 
r=0.359 O 
, O 
p O 
< O 
0.01 O 
) O 
as O 
well O 
as O 
precipitation O 
level O 
( O 
r=0.214 O 
, O 
p O 
< O 
0.01 O 
) O 
. O 
ABTS(·+) B-ABBREVIATION 
radical O 
scavenging O 
capacity O 
had O 
a O 
positive O 
correlation O 
with O 
average O 
air O 
temperature O 
( O 
r=0.705 O 
, O 
p O 
< O 
0.01 O 
) O 
, O 
while O 
hydroxyl B-SYSTEMATIC 
radical O 
scavenging O 
capacity O 
had O 
a O 
negative O 
correlation O 
with O 
temperature O 
( O 
r=-0.269 O 
. O 
p O 
< O 
0.01 O 
) O 
. O 
These O 
results O 
show O 
that O 
environment O 
, O 
genotype O 
, O 
and O 
their O 
interaction O 
could O 
influence O 
the O 
levels O 
of O 
lipophilic O 
antioxidants O 
and O 
antioxidant O 
activities O 
of O 
wheat O 
flour O 
. O 

speciation O 
analysis O 
in O 
mono-varietal O 
wines O 
by O 
on O 
- O 
line O 
ionic O 
liquid O 
- O 
based O 
dispersive O 
liquid O 
- O 
liquid O 
microextraction O 
. O 

highly O 
efficient O 
separation O 
and O 
pre O 
- O 
concentration O 
method O 
for O 
arsenic B-SYSTEMATIC 
species O 
determination O 
, O 
based O 
on O 
ionic O 
liquid O 
( O 
IL O 
) O 
dispersive O 
microextraction O 
technique O 
implemented O 
in O 
a O 
flow O 
analysis O 
system O 
, O 
is O 
proposed O 
. O 
Highly O 
selective O 
separation O 
of O 
arsenite B-SYSTEMATIC 
species O 
[ O 
As B-FORMULA 
(III) I-FORMULA 
] O 
was O 
achieved O 
by O 
chelation O 
with O 
sodium B-SYSTEMATIC 
diethyldithiocarbamate I-SYSTEMATIC 
( O 
DDTC B-ABBREVIATION 
) O 
followed O 
by O 
dispersion O 
with O 
40 O 
mg O 
of O 
1-octyl-3-methylimidazolium B-SYSTEMATIC 
hexafluorophosphate I-SYSTEMATIC 
( O 
[C(8)mim][PF(6)] B-FORMULA 
) O 
IL O 
. O 
Analyte O 
extraction O 
, O 
retention O 
and O 
separation O 
of O 
IL O 
phase O 
were O 
achieved O 
with O 
a O 
packed O 
microcolumn O 
and O 
As B-FORMULA 
(III) I-FORMULA 
was O 
determined O 
in O 
eluent O 
solution O 
by O 
electrothermal O 
atomic O 
absorption O 
spectrometry O 
( O 
ETAAS O 
) O 
. O 
Concentration O 
of O 
As B-FORMULA 
(V) I-FORMULA 
was O 
deduced O 
by O 
the O 
difference O 
between O 
total O 
inorganic O 
arsenic B-SYSTEMATIC 
and O 
As B-FORMULA 
(III) I-FORMULA 
. O 
Thus O 
, O 
determination O 
of O 
total O 
arsenic B-SYSTEMATIC 
was O 
performed O 
by O 
previous O 
degradation O 
of O 
organo B-FAMILY 
- I-FAMILY 
arsenic I-FAMILY 
species O 
, O 
followed O 
by O 
a O 
reduction O 
. O 
Under O 
optimal O 
conditions O 
, O 
As B-FORMULA 
(III) I-FORMULA 
extraction O 
efficiency O 
was O 
100% O 
and O 
a O 
sensitivity O 
enhancement O 
factor O 
of O 
46 O 
was O 
obtained O 
with O 
only O 
4 O 
ml O 
of O 
sample O 
The O 
method O 
was O 
successfully O 
applied O 
for O 
arsenic B-SYSTEMATIC 
speciation O 
studies O 
in O 
mono-varietal O 
wines O 
. O 

of O 
anthocyanin B-FAMILY 
and O 
skullcap O 
flavone B-TRIVIAL 
complexes O 
-- O 
investigations O 
with O 
computer O 
simulation O 
and O 
experimental O 
methods O 
. O 

examined O 
the O 
stabilization O 
of O 
anthocyanins B-FAMILY 
with O 
flavones B-FAMILY 
from O 
the O 
practical O 
and O 
theoretical O 
perspective O 
. O 
The O 
influence O 
of O 
addition O 
of O 
skullcap O 
flavones B-FAMILY 
, O 
heating O 
to O 
50 O 
°C O 
, O 
and O 
12 O 
day O 
storage O 
time O 
( O 
in O 
the O 
presence O 
and O 
absence O 
of O 
light O 
) O 
on O 
the O 
stability O 
of O 
anthocyanins B-FAMILY 
in O 
honeysuckle O 
concentrates O 
was O 
investigated O 
experimentally O 
. O 
Theoretical O 
study O 
was O 
conducted O 
with O 
molecular O 
dynamics O 
methods O 
in O 
a O 
model O 
system O 
, O 
preceded O 
by O 
simulated O 
annealing O 
and O 
thermalization O 
. O 
By O 
the O 
methods O 
of O 
the O 
computer O 
simulation O 
of O 
the O 
copigmentation O 
process O 
we O 
determined O 
the O 
sites O 
responsible O 
for O 
the O 
stabilization O 
of O 
a O 
cyanidin B-TRIVIAL 
quinoidal I-TRIVIAL 
base I-TRIVIAL 
- O 
baicalin B-TRIVIAL 
complex O 
. O 
We O 
revealed O 
both O 
direct O 
and O 
water O 
- O 
mediated O 
hydrogen B-SYSTEMATIC 
bondings O 
that O 
keep O 
the O 
lamellar O 
stacking O 
structure O 
of O 
these O 
molecules O 
in O 
the O 
bounded O 
form O 
in O 
water O 
medium O 
. O 
The O 
stacking O 
occurs O 
also O 
due O 
to O 
hydrophobic O 
interactions O 
of O 
the O 
rings O 
of O 
both O 
molecules O 
. O 
The O 
experimental O 
part O 
of O 
the O 
study O 
confirmed O 
the O 
effectiveness O 
of O 
anthocyanins B-FAMILY 
stabilization O 
in O 
a O 
concentrate O 
of O 
honeysuckle O 
with O 
the O 
use O 
of O 
skullcap O 
flavones B-FAMILY 
. O 

fructooligosaccharide O 
induces O 
fungal O 
resistance O 
in O 
postharvest O 
Kyoho O 
grapes O 
by O 
activating O 
the O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
-dependent O 
pathway O 
and O 
inhibiting O 
browning O 
. O 

fructooligosaccharide O 
( O 
BFO O 
) O 
is O 
a O 
natural O 
elicitor O 
from O 
Arcitum O 
lappa O 
. O 
The O 
effects O 
of O 
BFO O 
in O 
controlling O 
postharvest O 
disease O 
in O 
grape O 
, O 
apple O 
, O 
banana O 
, O 
kiwi O 
, O 
citrus O 
, O 
strawberry O 
, O 
and O 
pear O 
were O 
investigated O 
. O 
The O 
disease O 
index O 
, O 
decay O 
percentage O 
, O 
and O 
area O 
under O 
the O 
disease O 
progress O 
curve O 
indicated O 
that O 
BFO O 
has O 
general O 
control O 
effects O 
on O 
postharvest O 
disease O 
of O 
fruits O 
. O 
Kyoho O 
grapes O 
were O 
studied O 
to O 
elucidate O 
the O 
mechanism O 
of O 
BFO O 
in O 
boosting O 
the O 
resistance O 
of O 
grapes O 
to O 
Botrytis O 
cinerea O 
infection O 
. O 
BFO O 
treatment O 
induced O 
upregulation O 
of O 
the O 
npr1 O 
, O 
pr1 O 
, O 
pal O 
, O 
and O 
sts O 
genes O 
, O 
and O 
inhibited O 
the O 
total O 
phenol B-SYSTEMATIC 
content O 
decrease O 
, O 
which O 
activated O 
chitinase O 
and O 
β-1,3-glucanase O 
. O 
These O 
results O 
indicated O 
that O 
the O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
-dependent O 
signalling O 
pathway O 
was O 
induced O 
. O 
The O 
delayed O 
colour O 
change O 
and O 
peroxidase O 
and O 
polyphenoloxidase O 
activity O 
suggested O 
that O 
BFO O 
delayed O 
grape O 
browning O 
. O 
The O 
reduced O 
respiration O 
rate O 
, O 
weight O 
loss O 
, O 
and O 
titratable O 
acidity O 
prolonged O 
the O 
shelf O 
life O 
of O 
postharvest O 
grapes O 
. O 
BFO O 
is O 
a O 
promising O 
elicitor O 
in O 
postharvest O 
disease O 
control O 
. O 

are O 
the O 
basés O 
diet O 
in O 
several O 
countries O 
. O 
They O 
hold O 
a O 
high O 
nutritional O 
value O 
, O 
but O 
other O 
properties O 
related O 
to O 
human O 
health O 
are O 
nowadays O 
being O 
studied O 
. O 
The O 
aim O 
of O 
this O 
work O 
was O 
to O 
study O 
the O 
influence O 
of O 
processes O 
( O 
boiling O 
or O 
germination O 
) O 
on O 
the O 
phenolic B-FAMILY 
composition O 
of O 
dark O 
beans O 
( O 
Phaseolus O 
vulgaris O 
L O 
. O 
c.v O 
. O 
Tolosana O 
) O 
and O 
their O 
effect O 
on O 
their O 
antioxidant O 
, O 
neuroprotective O 
and O 
anticancer O 
ability O 
. O 
Phenolic B-FAMILY 
composition O 
of O 
raw O 
and O 
processed O 
dark O 
beans O 
was O 
analysed O 
by O 
HPLC-PAD O 
and O 
HPLC-ESI O 
/ O 
MS O 
. O 
The O 
antioxidant O 
activity O 
was O 
evaluated O 
by O 
ORAC O 
. O 
Astrocytes O 
cultures O 
( O 
U-373 O 
) O 
have O 
been O 
used O 
to O 
test O 
their O 
neuroprotective O 
effect O 
. O 
Anticancer O 
activities O 
were O 
evaluated O 
on O 
three O 
different O 
cell O 
lines O 
( O 
renal O 
adenocarcinoma O 
( O 
TK-10 O 
) O 
, O 
breast O 
adenocarcinoma O 
( O 
MCF-7 O 
) O 
and O 
melanoma O 
( O 
UACC-62 O 
) O 
) O 
by O 
sulphorhodamine B-TRIVIAL 
B I-TRIVIAL 
method O 
. O 
Qualitative O 
and O 
quantitative O 
differences O 
in O 
phenolic B-FAMILY 
composition O 
have O 
been O 
observed O 
between O 
raw O 
and O 
processed O 
dark O 
beans O 
that O 
influence O 
the O 
antioxidant O 
activity O 
, O 
mainly O 
for O 
germinated O 
samples O 
which O 
show O 
a O 
decrease O 
of O 
antioxidant O 
capacity O 
. O 
Although O 
every O 
assayed O 
extracts O 
decreased O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
release O 
and O 
exhibited O 
cytotoxicity O 
activities O 
on O 
cancer O 
cell O 
lines O 
, O 
raw O 
beans O 
proved O 
to O 
be O 
the O 
most O 
active O 
in O 
neuroprotective O 
and O 
antitumoral O 
effects O 
; O 
this O 
sample O 
is O 
especially O 
rich O 
in O 
phenolic B-FAMILY 
compounds O 
, O 
mainly O 
anthocyanins B-FAMILY 
. O 
This O 
study O 
further O 
demonstrated O 
that O 
phenolic B-FAMILY 
composition O 
of O 
dark O 
beans O 
is O 
related O 
with O 
cooking O 
process O 
and O 
so O 
with O 
their O 
neuroprotective O 
and O 
anticancer O 
activity O 
; O 
cooking O 
of O 
dark O 
beans O 
improves O 
their O 
digestion O 
and O 
absorption O 
at O 
intestinal O 
level O 
, O 
while O 
maintaining O 
its O 
protective O 
ability O 
on O 
oxidative O 
process O 
at O 
cellular O 
level O 
. O 

, O 
fructose B-TRIVIAL 
and O 
sucrose B-TRIVIAL 
increase O 
the O 
solubility O 
of O 
protein- O 
tannin B-FAMILY 
complexes O 
and O 
at O 
high O 
concentration O 
, O 
glucose B-TRIVIAL 
and O 
sucrose B-TRIVIAL 
interfere O 
with O 
bisulphite B-SYSTEMATIC 
bleaching O 
of O 
wine O 
pigments O 
. O 

were O 
modified O 
with O 
increasing O 
sugar B-FAMILY 
concentrations O 
and O 
decreasing O 
tannin B-FAMILY 
concentrations O 
and O 
analysed O 
by O 
a O 
combination O 
of O 
protein O 
precipitation O 
and O 
bisulphite B-SYSTEMATIC 
bleaching O 
. O 
Increasing O 
sugar B-FAMILY 
concentration O 
decreased O 
the O 
precipitation O 
of O 
tannin B-FAMILY 
and O 
protein O 
- O 
precipitable O 
polymeric O 
pigments O 
( O 
PPP O 
) O 
. O 
The O 
use O 
of O 
a O 
hydrogen B-SYSTEMATIC 
bond O 
disruptor O 
( O 
urea B-TRIVIAL 
) O 
to O 
reduce O 
protein- O 
tannin B-FAMILY 
and O 
protein O 
- O 
pigment O 
complex O 
formation O 
showed O 
that O 
the O 
effect O 
of O 
sugar B-FAMILY 
concentration O 
occurred O 
by O 
increasing O 
the O 
solubility O 
of O 
the O 
tannin B-FAMILY 
-protein O 
complex O 
, O 
not O 
by O 
interfering O 
with O 
protein- O 
tannin B-FAMILY 
complex O 
formation O 
. O 
By O 
increasing O 
the O 
solubility O 
of O 
pigment O 
- O 
protein O 
complexes O 
, O 
non O 
- O 
protein O 
- O 
precipitable O 
polymeric O 
pigments O 
( O 
nPPP O 
) O 
appeared O 
to O 
increase O 
. O 
There O 
was O 
also O 
an O 
increase O 
in O 
total O 
polymeric O 
pigments O 
at O 
each O 
tannin B-FAMILY 
concentration O 
with O 
increasing O 
glucose B-TRIVIAL 
and O 
sucrose B-TRIVIAL 
concentration O 
, O 
indicating O 
that O 
sugar B-FAMILY 
concentration O 
might O 
also O 
affect O 
bisulphite B-SYSTEMATIC 
bleaching O 
of O 
wine O 
pigments O 
. O 
While O 
a O 
significant O 
effect O 
of O 
sugar B-FAMILY 
concentration O 
on O 
tannin B-FAMILY 
-protein O 
complex O 
solubility O 
was O 
observed O 
, O 
these O 
effects O 
were O 
greatest O 
at O 
sugar B-FAMILY 
concentrations O 
far O 
in O 
excess O 
of O 
normal O 
wine O 
making O 
conditions O 
. O 
Under O 
normal O 
wine O 
making O 
conditions O 
, O 
sugar B-FAMILY 
concentration O 
will O 
have O 
a O 
negligible O 
effect O 
on O 
protein O 
- O 
precipitable O 
tannin B-FAMILY 
, O 
PPP O 
and O 
nPPP O 
concentrations O 
. O 

is O 
a O 
new O 
processing O 
technology O 
in O 
the O 
dairy O 
industry O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
test O 
glycation O 
of O 
β-lactoglobulin O 
( O 
BLG O 
) O 
in O 
Maillard O 
reaction O 
( O 
MR O 
) O 
induced O 
by O 
high O 
- O 
intensity O 
ultrasound O 
in O 
aqueous O 
solution O 
under O 
neutral O 
conditions O 
at O 
10- O 
15 O 
°C O 
, O 
which O 
is O 
not O 
favourable O 
for O 
the O 
MR O 
. O 
BLG O 
was O 
sonicated O 
in O 
the O 
presence O 
of O 
glucose B-TRIVIAL 
, O 
galactose B-TRIVIAL 
, O 
lactose B-TRIVIAL 
, O 
fructose B-TRIVIAL 
, O 
ribose B-TRIVIAL 
and O 
arabinose B-TRIVIAL 
. O 
Formation O 
of O 
Maillard O 
reaction O 
products O 
( O 
MRPs O 
) O 
was O 
monitored O 
by O 
mass O 
spectrometry O 
, O 
spectrophotometry O 
and O 
fluorimetry O 
. O 
Ultrasound O 
treatment O 
resulted O 
in O 
formation O 
of O 
MRPs O 
with O 
all O 
tested O 
carbohydrates B-FAMILY 
. O 
Ribose B-TRIVIAL 
induced O 
the O 
highest O 
degree O 
of O 
modification O 
resulting O 
in O 
76% O 
of O 
BLG O 
modified O 
and O 
an O 
average O 
of O 
three O 
anhydroribose B-TRIVIAL 
units O 
attached O 
. O 
Circular O 
dichroism O 
spectra O 
analyses O 
indicated O 
only O 
minor O 
alterations O 
in O 
secondary O 
and O 
tertiary O 
structures O 
. O 
MRP O 
obtained O 
by O 
ultrasound O 
exhibited O 
1,1-diphenyl-2-picrylhydrazyl B-SYSTEMATIC 
( O 
DPPH B-ABBREVIATION 
) O 
scavenging O 
activity O 
and O 
possessed O 
increased O 
iron B-SYSTEMATIC 
-chelating O 
activity O 
and O 
reducing O 
power O 
. O 
High O 
- O 
intensity O 
ultrasound O 
efficiently O 
promotes O 
BLG-glycoconjugates O 
formation O 
by O 
MR O 
in O 
aqueous O 
solutions O 
under O 
non-denaturing O 
conditions O 
. O 

of O 
processing O 
on O 
the O 
volatile O 
profile O 
of O 
strawberry O 
spreads O 
made O 
with O 
isomaltulose B-TRIVIAL 
. O 

new O 
strawberry O 
spread O 
formulated O 
with O 
fructose B-TRIVIAL 
and O 
isomaltulose B-TRIVIAL 
( O 
replacing O 
sucrose B-TRIVIAL 
partially O 
or O 
totally O 
) O 
and O 
a O 
high O 
percentage O 
of O 
fruit O 
was O 
developed O 
in O 
line O 
with O 
the O 
new O 
trend O 
of O 
healthier O 
products O 
. O 
This O 
work O 
studies O 
the O 
influence O 
of O 
some O 
process O 
variables O 
( O 
percentage O 
of O 
sugar B-FAMILY 
, O 
pectin O 
and O 
citric B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
time O 
of O 
thermal O 
treatment O 
) O 
on O 
the O 
volatile O 
profile O 
of O 
these O 
spreads O 
with O 
different O 
formulations O 
. O 
The O 
ripeness O 
of O 
the O 
raw O 
strawberries O 
influences O 
the O 
concentrations O 
of O 
some O 
of O 
the O 
compounds O 
in O 
the O 
spreads O 
, O 
such O 
as O 
isobutyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
butyl B-SYSTEMATIC 
butyrate I-SYSTEMATIC 
, O 
3-hexen-1-yl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
or O 
propan-2-ol B-SYSTEMATIC 
. O 
The O 
process O 
conditions O 
have O 
an O 
important O 
effect O 
on O 
the O 
volatile O 
profiles O 
. O 
Most O 
of O 
the O 
esters B-FAMILY 
and O 
alcohols B-FAMILY 
decreased O 
whereas O 
13 O 
new O 
compounds O 
appear O 
, O 
mostly O 
furans B-FAMILY 
( O 
furfural B-TRIVIAL 
, O 
2-acetylfurane B-SYSTEMATIC 
, O 
5-methyl B-SYSTEMATIC 
furfural I-SYSTEMATIC 
, O 
mesifurane B-TRIVIAL 
) O 
and O 
aldehydes B-FAMILY 
( O 
octanal B-SYSTEMATIC 
, O 
nonanal B-SYSTEMATIC 
, O 
decanal B-SYSTEMATIC 
and O 
benzaldeyhde B-SYSTEMATIC 
) O 
. O 
In O 
general O 
, O 
the O 
spreads O 
formulated O 
with O 
sucrose B-TRIVIAL 
- O 
isomaltulose B-TRIVIAL 
that O 
contained O 
higher O 
levels O 
of O 
pectin O 
and O 
citric B-TRIVIAL 
acid I-TRIVIAL 
gave O 
better O 
results O 
in O 
the O 
preservation O 
of O 
the O 
original O 
aromatic O 
compounds O 
in O 
raw O 
strawberries O 
. O 

of O 
ABTS B-ABBREVIATION 
radical I-ABBREVIATION 
cation I-ABBREVIATION 
assay O 
specifically O 
for O 
determination O 
of O 
antioxidant O 
capacity O 
of O 
intracellular O 
extracts O 
of O 
microalgae O 
and O 
cyanobacteria O 
. O 

renewed O 
interest O 
in O 
antioxidants O 
has O 
arisen O 
in O 
recent O 
years O 
; O 
microalgae O 
and O 
cyanobacteria O 
are O 
potential O 
sources O 
thereof O 
for O 
use O 
as O 
food O 
/ O 
feed O 
ingredients O 
. O 
However O 
, O 
improved O 
methods O 
for O 
comprehensive O 
screening O 
of O 
antioxidant O 
capacity O 
specifically O 
in O 
intracellular O 
extracts O 
of O 
marine O 
microorganisms O 
are O 
required O 
- O 
encompassing O 
lipophilic O 
and O 
hydrophilic O 
compounds O 
simultaneously O 
. O 
The O 
original O 
ABTS B-ABBREVIATION 
method O 
was O 
thus O 
improved O 
, O 
and O 
in O 
particular O 
the O 
procedures O 
of O 
cell O 
disruption O 
and O 
storage O 
were O 
optimized O 
. O 
The O 
best O 
solvent O 
found O 
was O 
ethanol B-SYSTEMATIC 
/ O 
water O 
( O 
1 O 
: O 
1 O 
, O 
v O 
/ O 
v O 
) O 
. O 
The O 
reaction O 
to O 
form O 
ABTS(+) B-ABBREVIATION 
in O 
said O 
solvent O 
was O 
essentially O 
complete O 
by O 
eight O 
hours O 
, O 
and O 
this O 
radical O 
cation O 
was O 
stable O 
for O 
at O 
least O 
6 O 
days O 
; O 
at O 
room O 
temperature O 
, O 
the O 
ABTS(+) B-ABBREVIATION 
solution O 
remained O 
within O 
an O 
allowable O 
analytical O 
range O 
for O 
up O 
to O 
13 O 
h O 
. O 
Ultra O 
Turrax O 
was O 
the O 
best O 
cell O 
disruption O 
method O 
, O 
and O 
refrigeration O 
was O 
the O 
best O 
preservation O 
method O 
. O 
This O 
improved O 
methodology O 
was O 
validated O 
with O 
four O 
representative O 
strains O 
that O 
respond O 
poorly O 
to O 
cell O 
disruption O 
. O 

amines B-FAMILY 
formation O 
in O 
Streptococcus O 
thermophilus O 
isolated O 
from O 
home O 
- O 
made O 
natural O 
yogurt O 
. O 

different O 
biogenic O 
amines B-FAMILY 
formation O 
in O 
58 O 
isolates O 
of O 
Streptococcus O 
thermophilus O 
from O 
home O 
- O 
made O 
natural O 
yogurt O 
were O 
investigated O 
in O 
histidine B-TRIVIAL 
( O 
HDB O 
) O 
and O 
lysine B-TRIVIAL 
decarboxylase O 
broth O 
( O 
LDB O 
) O 
. O 
All O 
S O 
. O 
thermophilus O 
isolates O 
had O 
an O 
ability O 
to O 
produce O 
twelve O 
different O 
biogenic O 
amines B-FAMILY 
in O 
HDB O 
and O 
LDB O 
. O 
Most O 
of O 
the O 
S O 
. O 
thermophilus O 
isolates O 
formed O 
low O 
amounts O 
of O 
histamine B-TRIVIAL 
( O 
1-50 O 
mg O 
/ O 
L O 
) O 
from O 
histidine B-TRIVIAL 
. O 
Apart O 
from O 
one O 
isolate O 
, O 
S O 
. O 
thermophilus O 
produced O 
tyramine B-TRIVIAL 
at O 
low O 
( O 
47 O 
isolates O 
) O 
and O 
medium O 
( O 
10 O 
isolates O 
) O 
levels O 
. O 
The O 
amount O 
of O 
each O 
specific O 
biogenic O 
amine B-SYSTEMATIC 
produced O 
by O 
S O 
. O 
thermophilus O 
was O 
generally O 
lower O 
than O 
100 O 
mg O 
L(-1) O 
. O 
Also O 
, O 
the O 
presence O 
of O 
hdcA O 
gene O 
was O 
investigated O 
using O 
PCR O 
technique O 
and O 
relation O 
between O 
gene O 
and O 
histamine B-TRIVIAL 
production O 
was O 
conducted O 
in O 
S O 
. O 
thermophilus O 
isolates O 
. O 
This O 
study O 
showed O 
that O 
most O 
of O 
the O 
S O 
. O 
thermophilus O 
isolates O 
have O 
the O 
ability O 
to O 
form O 
biogenic O 
amines B-FAMILY 
, O 
especially O 
histamine B-TRIVIAL 
, O 
and O 
tyramine B-TRIVIAL 
, O 
which O 
is O 
an O 
important O 
consideration O 
when O 
selecting O 
strains O 
as O 
starter O 
cultures O 
. O 

heating O 
was O 
recently O 
used O 
to O 
develop O 
a O 
more O 
efficient O 
roasting O 
technology O 
than O 
traditional O 
hot O 
air O 
roasting O 
. O 
Therefore O 
, O 
in O 
this O 
study O 
, O 
we O 
evaluated O 
the O 
shelf O 
- O 
life O 
of O 
almonds O 
roasted O 
with O 
three O 
different O 
approaches O 
, O 
namely O 
infrared O 
( O 
IR O 
) O 
, O 
sequential O 
infrared O 
and O 
hot O 
air O 
( O 
SIRHA O 
) O 
and O 
regular O 
hot O 
air O 
( O 
HA O 
) O 
. O 
Nine O 
medium O 
roasted O 
almond O 
samples O 
produced O 
by O 
the O 
aforementioned O 
heating O 
methods O 
were O 
processed O 
at O 
three O 
different O 
temperatures O 
( O 
130 O 
, O 
140 O 
and O 
150 O 
°C O 
) O 
, O 
packed O 
in O 
paper O 
bags O 
and O 
then O 
stored O 
at O 
37 O 
°C O 
for O 
three O 
, O 
six O 
or O 
eight O 
months O 
. O 
Shelf O 
- O 
life O 
of O 
the O 
roasted O 
almonds O 
was O 
determined O 
by O 
measuring O 
the O 
changes O 
in O 
colour O 
, O 
peroxide B-SYSTEMATIC 
value O 
, O 
moisture O 
content O 
, O 
water O 
activity O 
, O 
volatile O 
components O 
and O 
sensory O 
quality O 
. O 
No O 
significant O 
difference O 
was O 
observed O 
in O 
moisture O 
content O 
and O 
water O 
activity O 
among O 
the O 
almond O 
samples O 
processed O 
with O 
different O 
roasting O 
methods O 
and O 
stored O 
under O 
the O 
same O 
conditions O 
. O 
GC O 
/ O 
MS O 
analysis O 
showed O 
that O 
aldehydes B-FAMILY 
, O 
alcohols B-FAMILY 
, O 
and O 
pyrazines B-FAMILY 
were O 
the O 
main O 
volatile O 
components O 
of O 
almonds O 
. O 
Aliphatic B-FAMILY 
aldehydes I-FAMILY 
such O 
as O 
hexanal B-SYSTEMATIC 
, O 
(E)-2-octenal B-SYSTEMATIC 
, O 
and O 
nonanal B-SYSTEMATIC 
were O 
produced O 
as O 
off O 
- O 
odours O 
during O 
storage O 
. O 
Although O 
the O 
overall O 
quality O 
of O 
roasted O 
almonds O 
produced O 
with O 
SIRHA O 
and O 
HA O 
heating O 
was O 
similar O 
during O 
the O 
first O 
three O 
months O 
of O 
storage O 
, O 
their O 
peroxide B-SYSTEMATIC 
value O 
and O 
concentration O 
of O 
aliphatic B-FAMILY 
aldehydes I-FAMILY 
differed O 
significantly O 
for O 
different O 
roasting O 
methods O 
and O 
increased O 
significantly O 
in O 
all O 
roasted O 
samples O 
during O 
storage O 
. O 
We O 
postulate O 
that O 
hexanal B-SYSTEMATIC 
and O 
nonanal B-SYSTEMATIC 
might O 
be O 
better O 
indicators O 
of O 
the O 
shelf O 
life O 
of O 
roasted O 
almonds O 
than O 
the O 
current O 
standard O 
, O 
peroxide B-SYSTEMATIC 
value O 
. O 

of O 
new O 
triazole B-FAMILY 
acetamides I-FAMILY 
with O 
inotropic O 
effects O 
. O 

series O 
of O 
new O 
triazole B-FAMILY 
acetamides I-FAMILY 
5a-w O 
were O 
synthesized O 
and O 
evaluated O 
for O 
their O 
positive O 
inotropic O 
activity O 
of O 
left O 
atrium O 
stroke O 
volume O 
on O 
isolated O 
rabbit O 
- O 
heart O 
preparations O 
. O 
The O 
majority O 
of O 
the O 
derivatives O 
presented O 
favorable O 
in O 
vitro O 
activity O 
compared O 
with O 
the O 
reference O 
drug O 
, O 
milrinone B-TRIVIAL 
. O 
Among O 
them O 
triazole B-SYSTEMATIC 
acetamide I-SYSTEMATIC 
5a O 
was O 
identified O 
as O 
the O 
most O 
potent O 
with O 
20.29 O 
± O 
0.18% O 
increased O 
stroke O 
volume O 
( O 
milrinone B-TRIVIAL 
: O 
2.46 O 
± O 
0.07% O 
) O 
at O 
a O 
concentration O 
of O 
3 O 
× O 
10(-5) O 
M O 
. O 
The O 
chronotropic O 
effects O 
of O 
the O 
compounds O 
having O 
inotropic O 
effects O 
were O 
also O 
evaluated O 
. O 

limonene B-TRIVIAL 
and O 
citral B-TRIVIAL 
based O 
2,5- B-FAMILY 
disubstituted-1,3,4-oxadiazoles I-FAMILY 
: O 
a O 
natural O 
product O 
coupled O 
approach O 
to O 
semicarbazones B-FAMILY 
for O 
antiepileptic O 
activity O 
. O 

novel O 
series O 
of O 
N(4)-(5-(2 B-FAMILY 
/ I-FAMILY 
3 I-FAMILY 
/ I-FAMILY 
4- I-FAMILY 
substituted-phenyl)-1,3,4-oxadiazol-2-yl)-N(1)-(2-methyl-5-(prop-1-en-2-yl)cyclohex-2-enylidene)semicarbazide I-FAMILY 
and O 
N(4)-(5-(2 B-FAMILY 
/ I-FAMILY 
3 I-FAMILY 
/ I-FAMILY 
4- I-FAMILY 
substituted-phenyl)-1,3,4-oxadiazol-2-yl)-N(1)-(3,7-dimethylocta-3,6-dienylidene)-semicarbazide I-FAMILY 
were O 
synthesized O 
to O 
meet O 
structural O 
prerequisite O 
indispensable O 
for O 
anticonvulsant O 
activity O 
. O 
The O 
anticonvulsant O 
activities O 
of O 
the O 
compounds O 
were O 
investigated O 
using O 
maximal O 
electroshock O 
seizure O 
( O 
MES O 
) O 
, O 
subcutaneous O 
pentylenetrtrazole B-TRIVIAL 
( O 
scPTZ O 
) O 
and O 
subcutaneous O 
strychnine B-TRIVIAL 
( O 
scSTY O 
) O 
models O 
. O 
The O 
rotorod O 
test O 
was O 
conducted O 
to O 
evaluate O 
neurotoxicity O 
. O 
Some O 
of O 
the O 
selected O 
active O 
compounds O 
were O 
subjected O 
to O 
GABA B-ABBREVIATION 
assay O 
to O 
confirm O 
their O 
mode O 
of O 
action O 
. O 
The O 
outcome O 
of O 
the O 
present O 
investigations O 
proved O 
that O 
the O 
four O 
binding O 
sites O 
pharmacophore O 
model O 
is O 
vital O 
for O 
anticonvulsant O 
activity O 
. O 
The O 
efforts O 
were O 
also O 
made O 
to O 
establish O 
structure O 
- O 
activity O 
relationships O 
among O 
test O 
compounds O 
. O 

optimization O 
of O 
isocytosine B-TRIVIAL 
-derived O 
xanthine B-TRIVIAL 
oxidase O 
inhibitors O 
. O 

report O 
our O 
attempts O 
at O 
improving O 
the O 
oral O 
efficacy O 
of O 
low O 
- O 
nanomolar O 
inhibitors O 
of O 
xanthine B-TRIVIAL 
oxidase O 
from O 
isocytosine B-TRIVIAL 
series O 
through O 
chemical O 
modifications O 
. O 
Our O 
lead O 
compound O 
had O 
earlier O 
shown O 
good O 
in O 
vivo O 
efficacy O 
when O 
administered O 
intraperitoneally O 
but O 
not O 
orally O 
. O 
Several O 
modifications O 
are O 
reported O 
here O 
which O 
achieved O 
more O 
than O 
twofold O 
improvement O 
in O 
exposure O 
. O 
A O 
compound O 
with O 
significant O 
improvement O 
in O 
oral O 
efficacy O 
was O 
also O 
obtained O 
. O 

and O 
preliminary O 
structure O 
- O 
activity O 
relationship O 
analysis O 
of O 
1,14-sperminediphenylacetamides B-FAMILY 
as O 
potent O 
and O 
selective O 
antimalarial O 
lead O 
compounds O 
. O 

of O 
synthesized O 
and O 
isolated O 
marine O 
natural O 
products O 
for O 
in O 
vitro O 
activity O 
against O 
four O 
parasitic O 
protozoa O 
has O 
identified O 
the O 
ascidian O 
metabolite O 
1,14-sperminedihomovanillamide B-SYSTEMATIC 
( O 
orthidine B-TRIVIAL 
F I-TRIVIAL 
, O 
1 O 
) O 
as O 
being O 
a O 
non-toxic O 
, O 
moderate O 
growth O 
inhibitor O 
of O 
Plasmodium O 
falciparum O 
( O 
IC(50) O 
0.89 O 
μM O 
) O 
. O 
Preliminary O 
structure O 
- O 
activity O 
relationship O 
investigation O 
identified O 
essentiality O 
of O 
the O 
spermine B-TRIVIAL 
polyamine B-FAMILY 
core O 
and O 
the O 
requirement O 
for O 
1,14-disubstitution O 
for O 
potent O 
activity O 
. O 
One O 
analogue O 
, O 
1,14-spermine-di-(2-hydroxyphenylacetamide) B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
exhibited O 
two O 
orders O 
of O 
magnitude O 
increased O 
anti-P O 
. O 
f O 
activity O 
( O 
IC(50) O 
8.6 O 
nM O 
) O 
with O 
no O 
detectable O 
in O 
vitro O 
toxicity O 
. O 
The O 
ease O 
of O 
synthesis O 
of O 
phenylacetamido B-FAMILY 
- I-FAMILY 
polyamines I-FAMILY 
, O 
coupled O 
with O 
potent O 
nM O 
levels O 
of O 
activity O 
towards O 
dual O 
drug O 
resistant O 
strains O 
of O 
P O 
. O 
falciparum O 
makes O 
this O 
compound O 
class O 
of O 
interest O 
in O 
the O 
development O 
of O 
new O 
antimalarial O 
therapeutics O 
. O 

optimization O 
of O 
a O 
dihydropyrrolopyrimidine B-SYSTEMATIC 
inhibitor O 
against O 
phosphoinositide O 
3-kinase O 
( O 
PI3K O 
) O 
to O 
improve O 
the O 
phenol B-SYSTEMATIC 
glucuronic I-SYSTEMATIC 
acid I-SYSTEMATIC 
conjugation O 
. O 

lead O 
compound O 
for O 
a O 
phosphoinositide O 
3-kinase O 
( O 
PI3K O 
) O 
inhibitor O 
( O 
1 O 
) O 
was O 
metabolically O 
unstable O 
because O 
of O 
rapid O 
glucuronidation O 
of O 
the O 
phenol B-SYSTEMATIC 
moiety O 
. O 
Based O 
on O 
structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
information O 
and O 
a O 
FlexSIS O 
docking O 
simulation O 
score O 
, O 
aminopyrimidine B-SYSTEMATIC 
was O 
identified O 
as O 
a O 
bioisostere O 
of O 
phenol B-SYSTEMATIC 
. O 
An O 
X-ray O 
structure O 
study O 
revealed O 
a O 
hydrogen B-SYSTEMATIC 
bonding O 
pattern O 
of O 
aminopyrimidine B-SYSTEMATIC 
derivatives O 
. O 
Finally O 
, O 
aminopyrimidine B-SYSTEMATIC 
derivatives O 
33 O 
showed O 
strong O 
tumor O 
growth O 
inhibition O 
against O 
a O 
KPL-4 O 
breast O 
cancer O 
xenograft O 
model O 
in O 
vivo O 
. O 

targeting O 
ligands O 
for O 
imaging O 
and O 
/ O 
or O 
therapy O 
of O 
cancer O 
are O 
limited O 
by O 
heterogeneity O 
of O 
receptor O 
expression O 
by O 
tumor O 
cells O 
, O 
both O 
inter O 
- O 
patient O 
and O 
intra O 
- O 
patient O 
. O 
It O 
is O 
often O 
more O 
important O 
for O 
imaging O 
agents O 
to O 
identify O 
local O 
and O 
distant O 
spread O 
of O 
disease O 
than O 
it O 
is O 
to O 
identify O 
a O 
specific O 
receptor O 
presence O 
. O 
Two O 
natural O 
hormone O 
peptide O 
receptors O 
, O 
GRPR O 
and O 
Y1 O 
, O 
are O 
specifically O 
interesting O 
because O 
expression O 
of O 
GRPR O 
, O 
Y1 O 
or O 
both O 
is O 
up O 
- O 
regulated O 
in O 
most O 
breast O 
cancers O 
. O 
We O 
describe O 
here O 
the O 
design O 
and O 
development O 
of O 
a O 
new O 
heterobivalent O 
peptide O 
ligand O 
, O 
truncated O 
bombesin B-TRIVIAL 
( O 
t-BBN O 
) O 
/ O 
BVD15-DO3A O 
, O 
for O 
dual O 
- O 
targeting O 
of O 
GRPR O 
and O 
Y1 O 
, O 
and O 
validation O 
of O 
its O 
dual O 
binding O 
capability O 
. O 
Such O 
a O 
probe O 
should O 
be O 
useful O 
in O 
imaging O 
cells O 
, O 
tissues O 
and O 
tumors O 
that O 
are O 
GRPR O 
and O 
/ O 
or O 
Y1 O 
positive O 
and O 
should O 
target O 
radioisotopes O 
, O 
for O 
example O 
, O 
(68)Ga O 
and O 
/ O 
or O 
(177)Lu O 
, O 
to O 
more O 
tumors O 
cells O 
than O 
single O 
GRPR O 
or O 
Y1 O 
targeted O 
probes O 
. O 
A O 
GRP O 
targeting O 
ligand O 
, O 
J-G-Abz4-QWAVGHLM-NH(2) O 
( O 
J-G-Abz4-t-BBN O 
) O 
, O 
and O 
an O 
Y1 O 
targeting O 
ligand O 
, O 
INP-K[ε-J-(α-DO3A-ε-DGa)-K]-YRLRY-NH(2)([ε-J-(α-DO3A-ε-DGa)-K]-BVD-15) O 
, O 
were O 
synthesized O 
and O 
coupled O 
to O 
produce O 
the O 
heterobivalent O 
ligand O 
, O 
t-BBN O 
/ O 
BVD15-DO3A O 
. O 
Competitive O 
displacement O 
binding O 
assays O 
using O 
t-BBN O 
/ O 
BVD15-DO3A O 
against O 
(125)I B-FORMULA 
- O 
Tyr B-FORMULA 
(4)-BBN O 
yielded O 
an O 
IC(50) O 
value O 
of O 
18 O 
± O 
0.7 O 
nM O 
for O 
GRPR O 
in O 
T-47D O 
cells O 
, O 
a O 
human O 
breast O 
cancer O 
cell O 
line O 
. O 
A O 
similar O 
assay O 
using O 
t-BBN O 
/ O 
BVD15-DO3A O 
against O 
porcine O 
(125)I B-FORMULA 
-NPY O 
showed O 
IC(50) O 
values O 
of O 
80 O 
± O 
11 O 
nM O 
for O 
Y1 O 
receptor O 
in O 
MCF7 O 
cells O 
, O 
another O 
human O 
breast O 
cancer O 
cell O 
line O 
. O 
In O 
conclusion O 
, O 
it O 
is O 
possible O 
to O 
construct O 
a O 
single O 
DO3A O 
chelate O 
containing O 
probe O 
that O 
can O 
target O 
both O 
GRPR O 
and O 
Y1 O 
on O 
human O 
tumor O 
cells O 
. O 

and O 
optimization O 
of O 
potent O 
broad O 
- O 
spectrum O 
arenavirus O 
inhibitors O 
derived O 
from O 
benzimidazole B-SYSTEMATIC 
. O 

chemically O 
diverse O 
library O 
of O 
about O 
400000 O 
small O 
molecules O 
was O 
screened O 
for O 
antiviral O 
activity O 
against O 
lentiviral O 
pseudotypes O 
with O 
the O 
Lassa O 
virus O 
envelope O 
glycoprotein O 
( O 
LASV O 
GP O 
) O 
gene O 
incorporated O 
. O 
High O 
- O 
throughput O 
screening O 
resulted O 
in O 
discovery O 
of O 
a O 
hit O 
compound O 
( O 
ST-37 B-IDENTIFIER 
) O 
possessing O 
a O 
benzimidazole B-SYSTEMATIC 
core O 
which O 
led O 
to O 
a O 
potent O 
compound O 
series O 
. O 
Herein O 
, O 
we O 
report O 
SAR O 
studies O 
which O 
involved O 
structural O 
modifications O 
to O 
the O 
phenyl B-SYSTEMATIC 
rings O 
and O 
methylamino B-SYSTEMATIC 
linker O 
portion O 
attached O 
to O 
the O 
benzimidazole B-SYSTEMATIC 
core O 
. O 
Many O 
analogs O 
in O 
this O 
study O 
possessed O 
single O 
digit O 
nanomolar O 
potency O 
against O 
LASV O 
pseudotypes O 
. O 
Compounds O 
in O 
this O 
benzimidazole B-SYSTEMATIC 
series O 
also O 
exhibited O 
nanomolar O 
antiviral O 
activity O 
against O 
pseudotypes O 
generated O 
from O 
other O 
arenavirus O 
envelopes O 
indicating O 
the O 
potential O 
for O 
development O 
of O 
a O 
broad O 
- O 
spectrum O 
inhibitor O 
. O 
Ultimately O 
, O 
lead O 
compound O 
ST-193 B-IDENTIFIER 
was O 
identified O 
and O 
later O 
found O 
to O 
be O 
efficacious O 
in O 
a O 
lethal O 
LASV O 
guinea O 
pig O 
model O 
showing O 
superior O 
protection O 
compared O 
to O 
ribavirin O 
treatment O 
. O 

and O 
snake O 
presynaptic O 
phospholipases O 
A2 O 
neurotoxins O 
target O 
the O 
presynaptic O 
membrane O 
of O 
axon O 
terminals O 
of O 
the O 
neuromuscular O 
junction O 
causing O 
paralysis O 
. O 
These O 
neurotoxins O 
display O 
different O 
biochemical O 
activities O 
, O 
but O 
similarly O 
alter O 
the O 
presynaptic O 
membrane O 
permeability O 
causing O 
Ca(2+) B-FORMULA 
overload O 
within O 
the O 
nerve O 
terminals O 
, O 
which O 
in O 
turn O 
induces O 
nerve O 
degeneration O 
. O 
Using O 
different O 
methods O 
, O 
here O 
we O 
show O 
that O 
the O 
calcium B-SYSTEMATIC 
-activated O 
proteases O 
calpains O 
are O 
involved O 
in O 
the O 
cytoskeletal O 
rearrangements O 
that O 
we O 
have O 
previously O 
documented O 
in O 
neurons O 
exposed O 
to O 
α-latrotoxin O 
or O 
to O 
snake O 
presynaptic O 
phospholipases O 
A2 O 
neurotoxins O 
. O 
These O 
results O 
indicate O 
that O 
calpains O 
, O 
activated O 
by O 
the O 
massive O 
calcium B-SYSTEMATIC 
influx O 
from O 
the O 
extracellular O 
medium O 
, O 
target O 
fundamental O 
components O 
of O 
neuronal O 
cytoskeleton O 
such O 
as O 
spectrin O 
and O 
neurofilaments O 
, O 
whose O 
cleavage O 
is O 
functional O 
to O 
the O 
ensuing O 
nerve O 
terminal O 
fragmentation O 
. O 

megalantha O 
is O 
a O 
rupicolous O 
shrub O 
with O 
succulent O 
roots O 
from O 
the O 
semiarid O 
region O 
of O 
Brazil O 
that O 
is O 
known O 
to O 
cause O 
fatal O 
poisoning O 
in O 
livestock O 
. O 
We O 
reported O 
spontaneous O 
cases O 
of O 
poisoning O 
by O 
M O 
. O 
megalantha O 
roots O 
in O 
bovine O 
, O 
caprine O 
, O 
ovine O 
, O 
and O 
equine O 
species O 
. O 
The O 
clinical O 
and O 
pathological O 
findings O 
of O 
experimental O 
administration O 
of O 
M O 
. O 
megalantha O 
to O 
sheep O 
, O 
goats O 
, O 
a O 
calf O 
and O 
a O 
pig O 
are O 
reported O 
. O 
Three O 
goats O 
, O 
two O 
sheep O 
and O 
a O 
calf O 
were O 
dosed O 
once O 
orally O 
with O 
freshly O 
chopped O 
roots O 
at O 
dose O 
of O 
25 O 
g O 
wet O 
plant O 
/ O 
kg O 
bw O 
; O 
another O 
sheep O 
and O 
a O 
pig O 
were O 
dosed O 
with O 
10 O 
g O 
wet O 
plant O 
/ O 
kg O 
bw O 
. O 
Poisoning O 
occurred O 
in O 
all O 
of O 
the O 
animals O 
except O 
the O 
three O 
goats O 
. O 
Clinical O 
signs O 
of O 
poisoning O 
included O 
tachycardia O 
, O 
opisthotonus O 
, O 
ruminal O 
bloat O 
, O 
dyspnea O 
, O 
nystagmus O 
, O 
mydriasis O 
, O 
ataxia O 
, O 
and O 
recumbence O 
with O 
paddling O 
movements O 
. O 
Pathological O 
evaluation O 
showed O 
segmental O 
laminar O 
neuronal O 
necrosis O 
and O 
spongiosis O 
in O 
the O 
telencephalic O 
cortex O 
and O 
degeneration O 
of O 
Purkinje O 
cells O 
. O 
The O 
picrate O 
paper O 
procedure O 
detected O 
no O 
cyanide B-SYSTEMATIC 
in O 
the O 
plant O 
roots O 
, O 
but O 
the O 
reaction O 
used O 
for O 
nitrate B-SYSTEMATIC 
detection O 
gave O 
a O 
strongly O 
positive O 
response O 
. O 
In O 
conclusion O 
, O 
M O 
. O 
megalantha O 
is O 
a O 
poisonous O 
plant O 
that O 
produces O 
acute O 
poisoning O 
characterized O 
mainly O 
by O 
nervous O 
disturbances O 
. O 
Livestock O 
producers O 
should O 
offer O 
alternative O 
food O 
during O 
the O 
dry O 
and O 
early O 
rainy O 
seasons O 
to O 
avoid O 
the O 
poisoning O 
by O 
this O 
plant O 
. O 

deprivation O 
partially O 
rescues O 
the O 
skeletal O 
mineralization O 
defects O 
of O 
Phex O 
- O 
deficient O 
Hyp O 
mice O 
. O 

- O 
linked O 
hypophosphatemic O 
rickets O 
( O 
XLH O 
) O 
is O 
a O 
genetic O 
disorder O 
caused O 
by O 
mutational O 
inactivation O 
of O 
the O 
PHEX O 
gene O 
, O 
encoding O 
a O 
transmembrane O 
endopeptidase O 
expressed O 
in O 
osteoblasts O 
. O 
Since O 
several O 
experiments O 
involving O 
Phex O 
- O 
deficient O 
Hyp O 
mice O 
have O 
demonstrated O 
that O 
an O 
increased O 
expression O 
of O 
Fgf23 O 
in O 
osteoblasts O 
is O 
causative O 
for O 
the O 
renal O 
phosphate B-SYSTEMATIC 
loss O 
characteristic O 
of O 
XLH O 
, O 
we O 
performed O 
genome O 
- O 
wide O 
expression O 
analysis O 
to O 
compare O 
differentiated O 
osteoblasts O 
from O 
wildtype O 
and O 
Hyp O 
mice O 
. O 
Here O 
we O 
did O 
not O 
only O 
observe O 
the O 
expected O 
increase O 
of O 
Fgf23 O 
expression O 
in O 
the O 
latter O 
ones O 
, O 
but O 
also O 
a O 
differential O 
expression O 
of O 
genes O 
that O 
are O 
either O 
induced O 
by O 
or O 
involved O 
in O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
signaling O 
, O 
which O 
led O 
us O 
to O 
analyze O 
whether O 
dietary O 
retinol B-TRIVIAL 
deprivation O 
would O 
influence O 
the O 
phenotype O 
of O 
Hyp O 
mice O 
. O 
Unexpectedly O 
, O 
feeding O 
a O 
retinol O 
- O 
free O 
diet O 
resulted O 
in O 
a O 
partial O 
rescue O 
of O 
the O 
growth O 
plate O 
and O 
bone O 
mineralization O 
defects O 
in O 
6 O 
weeks O 
old O 
Hyp O 
mice O 
. O 
When O 
we O 
fed O 
the O 
same O 
diet O 
for O 
24 O 
weeks O 
the O 
amount O 
of O 
non-mineralized O 
bone O 
matrix O 
( O 
osteoid O 
) O 
was O 
reduced O 
by O 
more O 
than O 
70% O 
, O 
although O 
phosphate B-SYSTEMATIC 
homeostasis O 
was O 
unaffected O 
. O 
In O 
contrast O 
, O 
a O 
dietary O 
normalization O 
of O 
serum O 
phosphate B-SYSTEMATIC 
levels O 
in O 
Hyp O 
mice O 
reduced O 
the O 
osteoid O 
amount O 
by O 
less O 
than O 
30% O 
, O 
thereby O 
demonstrating O 
a O 
previously O 
unknown O 
impact O 
of O 
retinol O 
on O 
the O 
cell O 
- O 
autonomous O 
mineralization O 
defect O 
of O 
Phex O 
- O 
deficient O 
osteoblasts O 
. O 

of O 
baicalein B-TRIVIAL 
on O 
apoptosis O 
, O 
cell O 
cycle O 
arrest O 
, O 
migration O 
and O 
invasion O 
of O 
osteosarcoma O 
cells O 
. O 

is O 
a O 
bioactive O 
flavonoid B-FAMILY 
that O 
is O 
widely O 
used O 
in O 
ancient O 
China O 
. O 
However O 
, O 
its O 
effects O 
on O 
the O 
most O 
common O 
primary O 
malignant O 
bone O 
tumor O 
, O 
osteosarcoma O 
, O 
remain O 
unknown O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
baicalein B-TRIVIAL 
in O 
osteosarcoma O 
cells O 
. O 
Our O 
results O 
indicate O 
baicalein B-TRIVIAL 
might O 
be O 
an O 
efficacious O 
anti-osteosarcoma O 
drug O 
. O 
We O 
found O 
that O 
baicalein B-TRIVIAL 
could O 
inhibit O 
cell O 
proliferation O 
in O 
a O 
time- O 
and O 
dose O 
- O 
dependent O 
manner O 
. O 
Additionally O 
, O 
we O 
demonstrated O 
that O 
baicalein B-TRIVIAL 
promotes O 
osteosarcoma O 
cell O 
apoptosis O 
, O 
and O 
our O 
mechanistic O 
studies O 
suggest O 
that O 
this O 
is O 
mediated O 
by O 
caspase O 
activation O 
, O 
especially O 
caspase-3 O 
. O 
We O 
also O 
showed O 
that O 
the O 
down O 
- O 
regulation O 
of O 
Bcl-2 O 
and O 
concurrent O 
increase O 
in O 
Bax O 
and O 
Bim O 
levels O 
contribute O 
to O 
the O 
apoptosis O 
induced O 
by O 
baicalein B-TRIVIAL 
. O 
In O 
addition O 
, O 
we O 
observed O 
that O 
baicalein B-TRIVIAL 
induces O 
G1 O 
cell O 
cycle O 
arrest O 
by O 
decreasing O 
cyclin O 
D1 O 
and O 
cyclin O 
- O 
dependent O 
kinase O 
4 O 
( O 
CDK4 O 
) O 
. O 
Furthermore O 
, O 
our O 
data O 
verifies O 
that O 
baicalein B-TRIVIAL 
can O 
reduce O 
osteosarcoma O 
cell O 
adhesion O 
, O 
migration O 
and O 
invasion O 
in O 
vitro O 
, O 
which O 
indicates O 
its O 
potential O 
to O 
inhibit O 
osteosarcoma O 
metastasis O 
. O 
The O 
decrease O 
in O 
expression O 
of O 
matrix O 
metalloproteinases O 
(MMP)-2 O 
and O 
MMP-9 O 
may O 
contribute O 
to O 
the O 
effects O 
of O 
baicalein B-TRIVIAL 
. O 
Taken O 
together O 
, O 
our O 
results O 
provide O 
evidence O 
that O 
baicalein B-TRIVIAL 
plays O 
important O 
roles O 
in O 
anti-osteosarcoma O 
therapy O 
, O 
and O 
thus O 
may O 
serve O 
as O 
a O 
novel O 
and O 
efficient O 
candidate O 
agent O 
for O 
osteosarcoma O 
treatment O 
. O 

and I-MULTIPLE 
diorganotin I-MULTIPLE 
(IV) I-MULTIPLE 
complexes O 
of O 
biologically O 
important O 
orotic B-TRIVIAL 
acid I-TRIVIAL 
: O 
synthesis O 
, O 
spectroscopic O 
studies O 
, O 
in O 
vitro O 
anti-cancer O 
, O 
DNA O 
fragmentation O 
, O 
enzyme O 
assays O 
and O 
in O 
vivo O 
anti-inflammatory O 
activities O 
. O 

- I-FAMILY 
and I-FAMILY 
diorganotin I-FAMILY 
(IV) I-FAMILY 
orotates I-FAMILY 
of O 
general O 
formula O 
, O 
R(n)Sn(H(2)Or)(m) B-FAMILY 
[ O 
n O 
= O 
3 O 
/ O 
2 O 
, O 
m O 
= O 
1 O 
/ O 
2 O 
, O 
R O 
= O 
Me B-FORMULA 
, O 
n-Bu B-FORMULA 
, O 
n-Oct B-FORMULA 
and O 
Ph B-FORMULA 
; O 
H(2)Or(-) B-FORMULA 
= O 
monoanion O 
of O 
orotic B-TRIVIAL 
acid I-TRIVIAL 
( O 
H(3)Or B-FORMULA 
) O 
] O 
( O 
n-Bu(2)Sn(HOr) B-FORMULA 
as O 
an O 
exception O 
) O 
have O 
been O 
synthesized O 
. O 
On O 
the O 
basis O 
of O 
various O 
spectroscopic O 
studies O 
it O 
is O 
revealed O 
that O 
R(3)Sn(H(2)Or) B-FAMILY 
and O 
R(2)Sn(H(2)Or)(2) B-FAMILY 
exhibit O 
distorted O 
trigonal O 
- O 
bipyramidal O 
and O 
distorted O 
octahedral O 
geometry O 
, O 
respectively O 
, O 
and O 
n-Bu(2)Sn(HOr) B-FORMULA 
shows O 
both O 
five O 
and O 
six O 
coordination O 
geometry O 
around O 
tin O 
. O 
In O 
vitro O 
anti-cancer O 
screening O 
against O 
MCF-7 O 
( O 
mammary O 
) O 
, O 
HEK-293 O 
( O 
kidney O 
) O 
, O 
PC-3 O 
( O 
prostate O 
) O 
, O 
HCT O 
- O 
15 O 
( O 
colon O 
) O 
and O 
HepG-2 O 
( O 
liver O 
) O 
cancer O 
cell O 
lines O 
suggest O 
that O 
the O 
n-Oct(2)Sn(H(2)Or)(2) B-FORMULA 
is O 
the O 
most O 
active O 
complex O 
among O 
all O 
of O 
the O 
studied O 
complexes O 
. O 
DNA O 
fragmentation O 
and O 
antioxidant O 
enzyme O 
assays O 
suggest O 
that O 
cytotoxic O 
effect O 
of O 
the O 
complexes O 
is O 
selectively O 
mediated O 
through O 
the O 
induction O 
of O 
apoptosis O 
. O 
They O 
also O 
exhibit O 
low O 
toxicity O 
and O 
good O 
anti-inflammatory O 
activity O 
( O 
in O 
vivo O 
) O 
. O 

of O 
bioactive O 
, O 
free O 
isothiocyanates B-FAMILY 
from O 
a O 
glucosinolate B-FAMILY 
-containing O 
phytotherapeutic O 
agent O 
: O 
a O 
pilot O 
study O 
with O 
in O 
vitro O 
models O 
and O 
human O 
intervention O 
. O 

( O 
ITCs B-FAMILY 
) O 
derived O 
from O 
plants O 
of O 
the O 
order O 
Brassicales O 
are O 
known O 
for O 
their O 
antibacterial O 
, O 
anti-inflammatory O 
or O 
anticarcinogenic O 
potential O 
. O 
Although O 
only O 
the O 
free O 
ITCs B-FAMILY 
exert O 
bioactivity O 
, O 
quantification O 
in O 
vivo O 
is O 
almost O 
exclusively O 
performed O 
on O 
total O 
ITC B-ABBREVIATION 
/ O 
metabolite O 
content O 
. O 
We O 
therefore O 
investigated O 
in O 
a O 
pilot O 
study O 
the O 
amount O 
of O 
free O 
ITC B-ABBREVIATION 
at O 
different O 
steps O 
critical O 
for O 
therapeutic O 
efficacy O 
. O 
A O 
sensitive O 
and O 
specific O 
GC-MS O 
/ O 
MS O 
method O 
for O 
the O 
simultaneous O 
quantification O 
of O 
individual O 
free O 
ITC B-ABBREVIATION 
after O 
solid O 
- O 
phase O 
extraction O 
( O 
SPE O 
) O 
was O 
developed O 
. O 
We O 
show O 
here O 
that O 
release O 
of O 
biologically O 
active O 
ITC B-ABBREVIATION 
from O 
plants O 
occurs O 
at O 
not O 
only O 
alkaline O 
but O 
also O 
acidic O 
pH O 
. O 
Furthermore O 
, O 
in O 
human O 
urine O 
conversion O 
of O 
the O 
ultimate O 
, O 
inactive O 
mercapturic B-TRIVIAL 
acid I-TRIVIAL 
conjugate O 
back O 
into O 
its O 
corresponding O 
bioactive O 
form O 
is O 
increased O 
at O 
alkaline O 
as O 
compared O 
to O 
neutral O 
pH O 
. O 
This O 
was O 
also O 
observed O 
in O 
the O 
urine O 
of O 
human O 
volunteers O 
, O 
where O 
- O 
in O 
correlation O 
with O 
the O 
pH O 
value O 
- O 
a O 
mean O 
of O 
0.16 O 
to O 
1.03 O 
μmol O 
ITC B-ABBREVIATION 
was O 
detected O 
after O 
oral O 
application O 
of O 
a O 
phytotherapeutic O 
agent O 
containing O 
30.4 O 
μmol O 
of O 
the O 
initial O 
pro O 
- O 
drugs O 
. O 
The O 
amounts O 
of O 
free O 
ITC B-ABBREVIATION 
being O 
necessary O 
for O 
bioactivity O 
in O 
vitro O 
were O 
found O 
to O 
be O 
indeed O 
achieved O 
in O 
vivo O 
. O 
These O 
data O 
might O 
be O 
helpful O 
to O 
better O 
understand O 
the O 
beneficial O 
effects O 
of O 
ITC B-ABBREVIATION 
observed O 
in O 
vivo O 
. O 

residual O 
disease O 
( O 
MRD O 
) O 
occurrence O 
with O 
some O 
chemotherapy O 
drugs O 
that O 
promote O 
tumor O 
cell O 
escape O 
is O 
also O 
a O 
key O 
factor O 
in O 
blood O 
malignancy O 
relapse O 
. O 
We O 
observed O 
that O 
cytarabine B-TRIVIAL 
promotes O 
multiple O 
myeloma O 
( O 
MM O 
) O 
cell O 
escape O 
and O 
that O 
the O 
number O 
of O 
cells O 
in O 
the O 
lower O 
chamber O 
increased O 
with O 
increasing O 
clinical O 
disease O 
stage O 
in O 
in O 
vitro O 
model O 
which O 
was O 
constructed O 
by O 
a O 
Boyden O 
chamber O 
, O 
matrigel O 
glue O 
and O 
serum O 
from O 
MM O 
patients O 
in O 
different O 
disease O 
stages O 
. O 
The O 
mechanism O 
of O 
cytarabine B-TRIVIAL 
that O 
promotes O 
MM O 
cell O 
escape O 
is O 
closely O 
associated O 
with O 
the O 
up O 
- O 
regulation O 
of O 
CXCR4 O 
. O 
SDF-1α O 
can O 
up O 
- O 
regulate O 
the O 
expression O 
of O 
MMP9 O 
and O 
RHoC O 
proteins O 
in O 
MM O 
cells O 
with O 
up O 
- O 
regulated O 
CXCR4 O 
, O 
and O 
further O 
promote O 
the O 
cell O 
escape O 
. O 
Fucoidan O 
, O 
a O 
sulfated O 
polysaccharide O 
in O 
the O 
cell O 
wall O 
matrix O 
of O 
brown O 
algae O 
, O 
has O 
attracted O 
much O 
attention O 
for O 
its O 
multiple O 
biological O 
activities O 
, O 
and O 
we O 
further O 
explored O 
the O 
effects O 
and O 
possible O 
underlying O 
mechanisms O 
of O 
fucoidan O 
on O 
MM O 
cell O 
escape O 
from O 
cytarabine B-TRIVIAL 
cytotoxicity O 
. O 
The O 
results O 
show O 
that O 
fucoidan O 
may O 
decrease O 
MM O 
cell O 
escape O 
from O 
cytarabine B-TRIVIAL 
cytotoxicity O 
, O 
and O 
that O 
fucoidan O 
can O 
down O 
- O 
regulate O 
CXCR4 O 
, O 
MMP9 O 
and O 
RHoC O 
expression O 
. O 
This O 
research O 
provides O 
new O 
direction O 
for O 
investigating O 
MRD O 
occurrence O 
and O 
prevention O 
. O 

and O 
structure O 
activity O 
relationships O 
of O 
phytosterol B-FAMILY 
from O 
Phyllanthus O 
emblica O 
. O 

sterols B-FAMILY 
( O 
1-14 O 
) O 
, O 
including O 
two O 
new O 
sterols B-FAMILY 
, O 
trihydroxysitosterol B-SYSTEMATIC 
( O 
2 O 
) O 
and O 
5α,6β,7α-7α-acetoxysitosterol B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
branches O 
and O 
leaves O 
of O 
Phyllanthus O 
emblica O 
L O 
. O 
The O 
isolated O 
compounds O 
and O 
a O 
structurally O 
related O 
sterol B-FAMILY 
15 O 
from O 
Aphanamixis O 
grandifolia O 
were O 
screened O 
for O 
cytotoxicity O 
in O 
two O 
tumor O 
cell O 
lines O 
( O 
HL-60 O 
and O 
SMMC-7721 O 
) O 
and O 
a O 
non-tumor O 
cell O 
line O 
( O 
HL-7702 O 
) O 
using O 
RSB O 
assay O 
. O 
Within O 
the O 
series O 
of O 
phytosterol B-FAMILY 
derivatives O 
tested O 
, O 
compound O 
15 O 
was O 
the O 
most O 
active O 
, O 
displaying O 
potent O 
cytotoxicity O 
against O 
HL-60 O 
with O 
IC(50) O 
of O 
5.10μmol O 
/ O 
L O 
, O 
and O 
most O 
of O 
the O 
active O 
compounds O 
showed O 
selective O 
cytotoxicity O 
against O 
tumor O 
and O 
non-tumor O 
cell O 
lines O 
, O 
especially O 
compound O 
10 O 
with O 
a O 
safety O 
index O 
of O 
4.42 O 
. O 

DNA O 
primase O 
DnaG O 
synthesizes O 
RNA O 
primers O 
required O 
for O 
chromosomal O 
DNA O 
replication O 
. O 
Biochemical O 
assays O 
measuring O 
primase O 
activity O 
have O 
been O 
limited O 
to O 
monitoring O 
formation O 
of O 
radioactively O 
labelled O 
primers O 
because O 
of O 
the O 
intrinsically O 
low O 
catalytic O 
efficiency O 
of O 
DnaG O 
. O 
Furthermore O 
, O 
DnaG O 
is O 
prone O 
to O 
aggregation O 
and O 
proteolytic O 
degradation O 
. O 
These O 
factors O 
have O 
impeded O 
discovery O 
of O 
DnaG O 
inhibitors O 
by O 
high O 
- O 
throughput O 
screening O 
( O 
HTS O 
) O 
. O 
In O 
this O 
study O 
, O 
we O 
expressed O 
and O 
purified O 
the O 
previously O 
uncharacterized O 
primase O 
DnaG O 
from O 
Mycobacterium O 
tuberculosis O 
( O 
Mtb O 
DnaG O 
) O 
. O 
By O 
coupling O 
the O 
activity O 
of O 
Mtb O 
DnaG O 
to O 
that O 
of O 
another O 
essential O 
enzyme O 
, O 
inorganic O 
pyrophosphatase O 
from O 
M O 
. O 
tuberculosis O 
( O 
Mtb O 
PPiase O 
) O 
, O 
we O 
developed O 
the O 
first O 
non-radioactive O 
primase O 
- O 
pyrophosphatase O 
assay O 
. O 
An O 
extensive O 
optimization O 
of O 
the O 
assay O 
enabled O 
its O 
efficient O 
use O 
in O 
HTS O 
( O 
Z O 
' O 
= O 
0.7 O 
in O 
the O 
384-well O 
format O 
) O 
. O 
HTS O 
of O 
2560 O 
small O 
molecules O 
to O 
search O 
for O 
inhibitory O 
compounds O 
yielded O 
several O 
hits O 
, O 
including O 
suramin B-TRIVIAL 
, O 
doxorubicin B-TRIVIAL 
and O 
ellagic B-TRIVIAL 
acid I-TRIVIAL 
. O 
We O 
demonstrate O 
that O 
these O 
three O 
compounds O 
inhibit O 
Mtb O 
DnaG O 
. O 
Both O 
suramin B-TRIVIAL 
and O 
doxorubicin B-TRIVIAL 
are O 
potent O 
( O 
low-µM O 
) O 
DNA- O 
and O 
nucleotide B-FAMILY 
triphosphate I-FAMILY 
-competitive O 
priming O 
inhibitors O 
that O 
interact O 
with O 
more O 
than O 
one O 
site O 
on O 
Mtb O 
DnaG O 
. O 
This O 
novel O 
assay O 
should O 
be O 
applicable O 
to O 
other O 
primases O 
and O 
inefficient O 
DNA O 
/ O 
RNA O 
polymerases O 
, O 
facilitating O 
their O 
characterization O 
and O 
inhibitor O 
discovery O 
. O 

of O 
hypoxia O 
- O 
inducible O 
factor O 
(HIF)-1α O 
inhibitors O 
: O 
effect O 
of O 
ortho-carborane B-TRIVIAL 
substituents O 
on O 
HIF O 
transcriptional O 
activity O 
under O 
hypoxia O 
. O 

series O 
of O 
substituted O 
ortho-carboranylphenoxyacetanilides B-FAMILY 
were O 
synthesized O 
and O 
evaluated O 
for O 
their O 
ability O 
to O 
inhibit O 
hypoxia O 
- O 
induced O 
HIF-1 O 
transcriptional O 
activity O 
using O 
a O 
cell O 
- O 
based O 
reporter O 
assay O 
in O 
HeLa O 
cells O 
expressing O 
the O 
HRE-dependent O 
firefly O 
luciferase O 
reporter O 
construct O 
( O 
HRE-Luc O 
) O 
and O 
constitutively O 
expressing O 
CMV-driven O 
Renilla O 
luciferase O 
reporter O 
, O 
and O 
their O 
ability O 
to O 
inhibit O 
cell O 
growth O 
(GI(50)) O 
using O 
the O 
MTT B-ABBREVIATION 
assay O 
. O 
Among O 
the O 
compounds O 
synthesized O 
, O 
1g O 
and O 
1l O 
showed O 
significant O 
inhibition O 
of O 
hypoxia O 
- O 
induced O 
HIF-1 O 
transcriptional O 
activity O 
( O 
IC(50) O 
: O 
1.9 O 
± O 
0.4 O 
and O 
1.4 O 
± O 
0.2 O 
μM O 
, O 
respectively O 
) O 
. O 
Both O 
compounds O 
suppressed O 
HIF-1α O 
accumulation O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 
The O 
porcine O 
heart O 
malate B-TRIVIAL 
dehydrogenase O 
( O 
MDH O 
) O 
refolding O 
assay O 
revealed O 
that O 
compound O 
1l O 
inhibited O 
human O 
Hsp60 O 
chaperone O 
activity O 
( O 
IC(50) O 
: O 
6.8 O 
± O 
0.25 O 
μM O 
) O 
and O 
this O 
inhibition O 
activity O 
was O 
higher O 
than O 
that O 
of O 
ETB B-ABBREVIATION 
( O 
IC(50) O 
: O 
10.9 O 
± O 
0.63 O 
μM O 
) O 
. O 

and O 
AMPA B-ABBREVIATION 
receptor O 
mediated O 
excitotoxicity O 
in O 
cerebral O 
cortex O 
of O 
streptozotocin B-TRIVIAL 
induced O 
diabetic O 
rat O 
: O 
ameliorating O 
effects O 
of O 
curcumin B-TRIVIAL 
. O 

activity O 
of O 
neurotransmitter O 
receptor O 
and O 
their O 
sensitivity O 
to O 
regulation O 
are O 
altered O 
in O 
DM O 
. O 
We O 
evaluated O 
the O 
neuroprotective O 
effect O 
of O 
curcumin B-TRIVIAL 
in O 
glutamate B-TRIVIAL 
mediated O 
excitotoxicity O 
in O 
cerebral O 
cortex O 
of O 
streptozotocin B-TRIVIAL 
induced O 
diabetic O 
rats O 
. O 
Gene O 
expression O 
studies O 
in O 
diabetic O 
rats O 
showed O 
a O 
down O 
regulation O 
of O 
glutamate B-TRIVIAL 
decarboxylase O 
mRNA O 
leading O 
to O 
accumulation O 
of O 
glutamate B-TRIVIAL 
. O 
Radioreceptor O 
binding O 
assays O 
showed O 
a O 
significant O 
increase O 
in O 
α-amino-3-hydroxy-5-methyl-4-isoxazole B-SYSTEMATIC 
propionate I-SYSTEMATIC 
and O 
N-methyl-D-aspartate B-SYSTEMATIC 
receptors O 
density O 
which O 
was O 
confirmed O 
by O 
immunohistochemical O 
studies O 
. O 
Decreased O 
glutathione B-TRIVIAL 
peroxidases O 
gene O 
expression O 
indicates O 
enhanced O 
oxidative O 
stress O 
in O 
diabetic O 
rats O 
. O 
This O 
leads O 
to O 
decreased O 
expression O 
of O 
glutamate B-TRIVIAL 
aspartate B-TRIVIAL 
transporter O 
, O 
which O 
in O 
turn O 
reduces O 
glutamate B-TRIVIAL 
transport O 
. O 
All O 
these O 
events O 
lead O 
to O 
excitotoxic O 
neuronal O 
death O 
in O 
the O 
cerebral O 
cortex O 
, O 
which O 
was O 
confirmed O 
by O 
the O 
increased O 
expression O 
of O 
caspase O 
3 O 
, O 
caspase O 
8 O 
and O 
BCL2-associated O 
X O 
protein O 
. O 
Curcumin B-TRIVIAL 
and O 
insulin O 
treatment O 
reversed O 
these O 
altered O 
parameters O 
to O 
near O 
control O 
. O 
We O 
establish O 
, O 
a O 
novel O 
therapeutic O 
role O 
of O 
curcumin B-TRIVIAL 
by O 
reducing O 
the O 
glutamate B-TRIVIAL 
mediated O 
excitotoxicity O 
in O 
cerebral O 
cortex O 
of O 
diabetes O 
through O 
modulating O 
the O 
altered O 
neurochemical O 
parameters O 
. O 

properties O 
of O 
Neu2000 B-IDENTIFIER 
on O 
mitochondrial O 
free O 
radicals O 
and O 
oxidative O 
damage O 
. O 

[ O 
2-hydroxy-5-(2,3,5,6-tetrafluoro-4 B-SYSTEMATIC 
trifluoromethylbenzylamino I-SYSTEMATIC 
) I-SYSTEMATIC 
benzoic I-SYSTEMATIC 
acid I-SYSTEMATIC 
] O 
is O 
a O 
dual O 
- O 
acting O 
neuroprotective O 
agent O 
that O 
functions O 
both O 
as O 
a O 
noncompetitive O 
N-methyl-d-aspartate B-SYSTEMATIC 
( O 
NMDA O 
) O 
receptor O 
antagonist O 
and O 
a O 
free O 
radical O 
scavenger O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
scavenging O 
activity O 
of O 
Neu2000 B-IDENTIFIER 
on O 
various O 
classes O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
and O 
reactive O 
nitrogen B-SYSTEMATIC 
species O 
( O 
ROS O 
/ O 
RNS O 
) O 
as O 
well O 
as O 
its O 
efficacy O 
for O 
reducing O 
free O 
radicals O 
and O 
oxidative O 
stress O 
/ O 
damage O 
induced O 
in O 
spinal O 
cord O 
mitochondrial O 
preparations O 
. O 
Neu2000 B-IDENTIFIER 
exerted O 
scavenging O 
activity O 
against O 
superoxide B-TRIVIAL 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
and O 
hydroxyl B-SYSTEMATIC 
radicals O 
, O 
and O 
efficiently O 
scavenged O 
peroxynitrite B-SYSTEMATIC 
. O 
In O 
the O 
mitochondrial O 
studies O 
, O 
Neu2000 B-IDENTIFIER 
markedly O 
inhibited O 
ROS O 
/ O 
RNS O 
and O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
levels O 
following O 
antimycin B-FAMILY 
treatment O 
. O 
In O 
addition O 
, O 
Neu2000 B-IDENTIFIER 
effectively O 
scavenged O 
hydroxyl B-SYSTEMATIC 
radicals O 
generated O 
by O 
iron(III)-ascorbate B-SYSTEMATIC 
, O 
reduced O 
protein O 
carbonyl B-FAMILY 
formation O 
mediated O 
by O 
hydroxyl B-SYSTEMATIC 
radicals O 
and O 
peroxynitrite B-SYSTEMATIC 
, O 
and O 
prevented O 
glutathione B-TRIVIAL 
oxidation O 
caused O 
by O 
tert-butyl B-SYSTEMATIC 
hydroperoxide I-SYSTEMATIC 
in O 
isolated O 
mitochondria O 
. O 
Interestingly O 
, O 
incubation O 
of O 
isolated O 
mitochondria O 
with O 
Neu2000 B-IDENTIFIER 
followed O 
by O 
centrifugation O 
and O 
removal O 
of O 
the O 
supernatant O 
also O 
resulted O 
in O 
a O 
concentration O 
- O 
dependent O 
decrease O 
in O 
lipid O 
peroxidation O 
. O 
This O 
observation O 
suggests O 
that O 
Neu2000 B-IDENTIFIER 
enters O 
mitochondria O 
to O 
target O 
free O 
radicals O 
or O 
indirectly O 
affects O 
mitochondrial O 
function O 
in O 
a O 
manner O 
that O 
promotes O 
antioxidant O 
activity O 
. O 
The O 
results O 
of O 
the O 
present O 
study O 
demonstrate O 
that O 
Neu2000 B-IDENTIFIER 
possesses O 
potent O 
in O 
vitro O 
antioxidant O 
activity O 
due O 
, O 
most O 
likely O 
, O 
to O 
its O 
active O 
phenoxy B-SYSTEMATIC 
group O 
. O 

: O 
a O 
comprehensive O 
software O 
for O 
analysing O 
whole O 
genome O 
bisulfite B-SYSTEMATIC 
sequencing O 
data O 
. O 

- O 
throughput O 
sequencing O 
is O 
increasingly O 
being O 
used O 
in O 
combination O 
with O 
bisulfite B-SYSTEMATIC 
( O 
BS O 
) O 
assays O 
to O 
study O 
DNA O 
methylation O 
at O 
nucleotide B-FAMILY 
resolution O 
. O 
Although O 
several O 
programmes O 
provide O 
genome O 
- O 
wide O 
alignment O 
of O 
BS O 
- O 
treated O 
reads O 
, O 
the O 
resulting O 
information O 
is O 
not O 
readily O 
interpretable O 
and O 
often O 
requires O 
further O 
bioinformatic O 
steps O 
for O 
meaningful O 
analysis O 
. O 
Current O 
post O 
- O 
alignment O 
BS-sequencing O 
programmes O 
are O 
generally O 
focused O 
on O 
the O 
gene O 
- O 
specific O 
level O 
, O 
a O 
restrictive O 
feature O 
when O 
analysis O 
in O 
the O 
non-coding O 
regions O 
, O 
such O 
as O 
enhancers O 
and O 
intergenic O 
microRNAs O 
, O 
is O 
required O 
. O 
Here O 
, O 
we O 
present O 
Genome O 
Bisulfite B-SYSTEMATIC 
Sequencing O 
Analyser O 
( O 
GBSA-http O 
: O 
/ O 
/ O 
ctrad-csi.nus.edu.sg O 
/ O 
gbsa O 
) O 
, O 
a O 
free O 
open O 
- O 
source O 
software O 
capable O 
of O 
analysing O 
whole O 
- O 
genome O 
bisulfite B-SYSTEMATIC 
sequencing O 
data O 
with O 
either O 
a O 
gene O 
- O 
centric O 
or O 
gene O 
- O 
independent O 
focus O 
. O 
Through O 
analysis O 
of O 
the O 
largest O 
published O 
data O 
sets O 
to O 
date O 
, O 
we O 
demonstrate O 
GBSA's O 
features O 
in O 
providing O 
sequencing O 
quality O 
assessment O 
, O 
methylation O 
scoring O 
, O 
functional O 
data O 
management O 
and O 
visualization O 
of O 
genomic O 
methylation O 
at O 
nucleotide O 
resolution O 
. O 
Additionally O 
, O 
we O 
show O 
that O 
GBSA's O 
output O 
can O 
be O 
easily O 
integrated O 
with O 
other O 
high O 
- O 
throughput O 
sequencing O 
data O 
, O 
such O 
as O 
RNA-Seq O 
or O 
ChIP-seq O 
, O 
to O 
elucidate O 
the O 
role O 
of O 
methylated O 
intergenic O 
regions O 
in O 
gene O 
regulation O 
. O 
In O 
essence O 
, O 
GBSA O 
allows O 
an O 
investigator O 
to O 
explore O 
not O 
only O 
known O 
loci O 
but O 
also O 
all O 
the O 
genomic O 
regions O 
, O 
for O 
which O 
methylation O 
studies O 
could O 
lead O 
to O 
the O 
discovery O 
of O 
new O 
regulatory O 
mechanisms O 
. O 

Permeability O 
Transition O 
Pore O 
Inhibitors O 
Prevent O 
Ethanol B-SYSTEMATIC 
-Induced O 
Neuronal O 
Death O 
in O 
Mice O 
. O 

induces O 
brain O 
injury O 
by O 
a O 
mechanism O 
that O 
remains O 
partly O 
unknown O 
. O 
Mitochondria O 
play O 
a O 
key O 
role O 
in O 
cell O 
death O 
processes O 
, O 
notably O 
through O 
the O 
opening O 
of O 
the O 
permeability O 
transition O 
pore O 
( O 
PTP O 
) O 
. O 
Here O 
, O 
we O 
tested O 
the O 
effect O 
of O 
ethanol B-SYSTEMATIC 
and O 
PTP O 
inhibitors O 
on O 
mitochondrial O 
physiology O 
and O 
cell O 
viability O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Direct O 
addition O 
of O 
ethanol B-SYSTEMATIC 
up O 
to O 
100 O 
mM O 
on O 
isolated O 
mouse O 
brain O 
mitochondria O 
slightly O 
decreased O 
oxygen B-SYSTEMATIC 
consumption O 
but O 
did O 
not O 
affect O 
PTP O 
regulation O 
. O 
In O 
comparison O 
, O 
when O 
isolated O 
from O 
ethanol B-SYSTEMATIC 
-treated O 
( O 
two O 
doses O 
of O 
2 O 
g O 
/ O 
kg O 
, O 
2 O 
h O 
apart O 
) O 
7-day- O 
old O 
mouse O 
pups O 
, O 
brain O 
mitochondria O 
displayed O 
a O 
transient O 
decrease O 
in O 
oxygen B-SYSTEMATIC 
consumption O 
but O 
no O 
change O 
in O 
PTP O 
regulation O 
or O 
H(2)O(2) B-FORMULA 
production O 
. O 
Conversely O 
, O 
exposure O 
of O 
primary O 
cultured O 
astrocytes O 
and O 
neurons O 
to O 
20 O 
mM O 
ethanol B-SYSTEMATIC 
for O 
3 O 
days O 
led O 
to O 
a O 
transient O 
PTP O 
opening O 
in O 
astrocytes O 
without O 
affecting O 
cell O 
viability O 
and O 
to O 
a O 
permanent O 
PTP O 
opening O 
in O 
10 O 
to O 
20% O 
neurons O 
with O 
the O 
same O 
percentage O 
of O 
cell O 
death O 
. O 
Ethanol B-SYSTEMATIC 
-treated O 
mouse O 
pups O 
displayed O 
a O 
widespread O 
caspase-3 O 
activation O 
in O 
neurons O 
but O 
not O 
in O 
astrocytes O 
and O 
dramatic O 
behavioral O 
alterations O 
. O 
Interestingly O 
, O 
two O 
different O 
PTP O 
inhibitors O 
( O 
namely O 
, O 
cyclosporin B-TRIVIAL 
A I-TRIVIAL 
and O 
nortriptyline B-TRIVIAL 
) O 
prevented O 
both O 
ethanol B-SYSTEMATIC 
-induced O 
neuronal O 
death O 
in O 
vivo O 
and O 
ethanol B-SYSTEMATIC 
-induced O 
behavioral O 
modifications O 
. O 
We O 
conclude O 
that O 
PTP O 
opening O 
is O 
involved O 
in O 
ethanol B-SYSTEMATIC 
-induced O 
neurotoxicity O 
in O 
the O 
mouse O 
. O 

selective O 
metabotropic O 
glutamate B-TRIVIAL 
2 O 
/ O 
3 O 
receptor O 
agonist O 
MGS0028 B-IDENTIFIER 
reverses O 
psychomotor O 
abnormalities O 
and O 
recognition O 
memory O 
deficits O 
in O 
mice O 
lacking O 
the O 
pituitary O 
adenylate O 
cyclase O 
- O 
activating O 
polypeptide O 
. O 

studies O 
suggest O 
that O 
metabotropic O 
glutamate B-TRIVIAL 
2 O 
/ O 
3 O 
receptors O 
are O 
involved O 
in O 
psychiatric O 
disorders O 
. O 
In O 
this O 
study O 
, O 
we O 
examined O 
the O 
effects O 
of O 
the O 
selective O 
metabotropic O 
glutamate B-TRIVIAL 
2 O 
/ O 
3 O 
( O 
mGlu2 O 
/ O 
3 O 
) O 
receptor O 
agonist O 
MGS0028 B-IDENTIFIER 
on O 
behavioral O 
abnormalities O 
in O 
mice O 
lacking O 
the O 
pituitary O 
adenylate O 
cyclase O 
- O 
activating O 
polypeptide O 
( O 
PACAP O 
) O 
, O 
an O 
experimental O 
model O 
of O 
psychiatric O 
disorders O 
such O 
as O 
schizophrenia O 
and O 
attention O 
- O 
deficit O 
/ O 
hyperactivity O 
disorder O 
. O 
We O 
found O 
that O 
PACAP-deficient O 
mice O 
showed O 
impairments O 
in O 
the O 
novel O 
object O 
recognition O 
test O 
and O 
these O 
impairments O 
were O 
improved O 
by O 
MGS0028 B-IDENTIFIER 
( O 
0.1 O 
mg O 
/ O 
kg O 
) O 
. O 
Similarly O 
, O 
MGS0028 B-IDENTIFIER 
improved O 
hyperactivity O 
and O 
jumping O 
behaviors O 
, O 
but O 
did O 
not O 
reverse O 
increased O 
immobility O 
times O 
in O 
the O 
forced O 
swim O 
test O 
in O 
PACAP-deficient O 
mice O 
. O 
These O 
results O 
suggest O 
that O 
MGS0028 B-IDENTIFIER 
may O 
be O 
a O 
potential O 
, O 
novel O 
treatment O 
for O 
psychiatric O 
disorders O 
. O 

Effects O 
of O 
Crambescins O 
and O 
Crambescidin B-TRIVIAL 
816 I-TRIVIAL 
in O 
Voltage-Gated O 
Sodium B-SYSTEMATIC 
, O 
Potassium B-SYSTEMATIC 
and O 
Calcium B-SYSTEMATIC 
Channels O 
in O 
Neurons O 
. O 

and O 
crambescidins B-FAMILY 
are O 
two O 
families O 
of O 
guanidine B-FAMILY 
alkaloids I-FAMILY 
from O 
the O 
marine O 
sponge O 
Crambe O 
crambe O 
. O 
Although O 
very O 
little O 
information O 
about O 
their O 
biological O 
effect O 
has O 
been O 
reported O 
, O 
it O 
is O 
known O 
that O 
crambescidin B-TRIVIAL 
816 I-TRIVIAL 
( O 
Cramb816 B-ABBREVIATION 
) O 
blocks O 
calcium B-SYSTEMATIC 
channels O 
in O 
a O 
neuroblastoma O 
X O 
glioma O 
cell O 
line O 
. O 
Taking O 
this O 
into O 
account O 
, O 
and O 
the O 
fact O 
that O 
ion O 
channels O 
are O 
frequent O 
targets O 
for O 
natural O 
toxins O 
, O 
we O 
examined O 
the O 
effect O 
of O 
Cramb816 B-ABBREVIATION 
and O 
three O 
compounds O 
from O 
the O 
crambescin B-FAMILY 
family O 
, O 
norcrambescin B-TRIVIAL 
A2 I-TRIVIAL 
( O 
NcrambA2 B-ABBREVIATION 
) O 
, O 
crambescin B-TRIVIAL 
A2 I-TRIVIAL 
( O 
CrambA2 B-ABBREVIATION 
) O 
, O 
and O 
crambescin B-TRIVIAL 
C1 I-TRIVIAL 
( O 
CrambC1 B-ABBREVIATION 
) O 
, O 
in O 
the O 
main O 
voltage O 
- O 
dependent O 
ion O 
channels O 
in O 
neurons O 
: O 
sodium B-SYSTEMATIC 
, O 
potassium B-SYSTEMATIC 
, O 
and O 
calcium B-SYSTEMATIC 
channels O 
. O 
Electrophysiological O 
recordings O 
of O 
voltage O 
gated O 
sodium B-SYSTEMATIC 
, O 
potassium B-SYSTEMATIC 
, O 
and O 
calcium B-SYSTEMATIC 
currents O 
, O 
in O 
the O 
presence O 
of O 
these O 
guanidine B-FAMILY 
alkaloids I-FAMILY 
, O 
were O 
performed O 
in O 
cortical O 
neurons O 
from O 
embryonic O 
mice O 
. O 
Different O 
effects O 
were O 
discovered O 
: O 
crambescins B-FAMILY 
inhibited O 
K(+) B-FORMULA 
currents O 
with O 
the O 
following O 
potency O 
: O 
NcrambA2 B-ABBREVIATION 
> O 
CrambC1 B-ABBREVIATION 
> O 
CrambA2 B-ABBREVIATION 
, O 
while O 
Cramb816 B-ABBREVIATION 
lacked O 
an O 
effect O 
. O 
Only O 
CrambC1 B-ABBREVIATION 
and O 
Cramb816 B-ABBREVIATION 
partially O 
blocked O 
Na(+) B-FORMULA 
total O 
current O 
. O 
However O 
, O 
Cramb816 B-ABBREVIATION 
partially O 
blocked O 
Ca(2+) B-FORMULA 
, O 
while O 
NcrambA2 B-ABBREVIATION 
did O 
not O 
. O 
Since O 
the O 
blocking O 
effect O 
of O 
Cramb816 B-ABBREVIATION 
on O 
calcium B-SYSTEMATIC 
currents O 
has O 
not O 
been O 
previously O 
reported O 
in O 
detail O 
, O 
we O 
further O 
pharmacologically O 
isolated O 
the O 
two O 
main O 
fractions O 
of O 
HVA O 
Ca(2+) B-FORMULA 
channels O 
in O 
neurons O 
and O 
investigated O 
the O 
Cramb816 B-ABBREVIATION 
effect O 
on O 
them O 
. O 
Here O 
, O 
we O 
revealed O 
that O 
Cav1 O 
or O 
L- O 
type O 
calcium B-SYSTEMATIC 
channels O 
are O 
the O 
main O 
target O 
for O 
Cramb816 B-ABBREVIATION 
. O 
These O 
two O 
families O 
of O 
guanidine B-FAMILY 
alkaloids I-FAMILY 
clearly O 
showed O 
a O 
structure O 
- O 
activity O 
relationship O 
with O 
the O 
crambescins B-FAMILY 
acting O 
on O 
voltage O 
- O 
gated O 
potassium B-SYSTEMATIC 
channels O 
, O 
while O 
Cramb816 B-ABBREVIATION 
blocks O 
the O 
voltage O 
- O 
gated O 
calcium B-SYSTEMATIC 
channel O 
Cav1 O 
with O 
higher O 
potency O 
than O 
nifedipine B-TRIVIAL 
. O 
The O 
novel O 
evidence O 
that O 
Cramb816 B-ABBREVIATION 
partially O 
blocked O 
Ca B-FORMULA 
(V) O 
and O 
Na B-FORMULA 
(V) O 
channels O 
in O 
neurons O 
suggests O 
that O 
this O 
compound O 
might O 
be O 
involved O 
in O 
decreasing O 
the O 
neurotransmitter O 
release O 
and O 
synaptic O 
transmission O 
in O 
the O 
central O 
nervous O 
system O 
. O 
The O 
findings O 
presented O 
here O 
provide O 
the O 
first O 
detailed O 
approach O 
on O 
the O 
different O 
effects O 
of O 
crambescin B-FAMILY 
and O 
crambescidin B-FAMILY 
compounds O 
in O 
voltage O 
- O 
gated O 
sodium B-SYSTEMATIC 
, O 
potassium B-SYSTEMATIC 
, O 
and O 
calcium B-SYSTEMATIC 
channels O 
in O 
neurons O 
and O 
thus O 
provide O 
a O 
basis O 
for O 
future O 
studies O 
. O 

synthesis O 
inhibition O 
and O 
oxidative O 
stress O 
induced O 
by O 
cylindrospermopsin B-TRIVIAL 
elicit O 
apoptosis O 
in O 
primary O 
rat O 
hepatocytes O 
. O 

increasing O 
presence O 
of O 
cyanotoxin O 
producers O 
in O 
several O 
regions O 
of O 
the O 
world O 
is O 
hazardous O 
for O 
humans O 
and O 
animals O 
. O 
Cylindrospermopsin B-TRIVIAL 
( O 
CYN B-ABBREVIATION 
) O 
is O 
nowadays O 
recognized O 
as O 
a O 
widely O 
distributed O 
freshwater O 
cyanobacterial O 
toxin O 
. O 
This O 
toxin O 
has O 
been O 
shown O 
to O 
induce O 
protein O 
synthesis O 
inhibition O 
as O 
well O 
as O 
inhibition O 
of O 
glutathione B-TRIVIAL 
synthesis O 
. O 
Given O 
that O 
the O 
liver O 
seems O 
to O 
be O 
the O 
main O 
target O 
of O 
cylindrospermopsin B-TRIVIAL 
, O 
in O 
this O 
work O 
we O 
used O 
cultures O 
of O 
primary O 
rat O 
hepatocytes O 
to O 
study O 
the O 
type O 
of O 
cell O 
death O 
induced O 
by O 
CYN B-ABBREVIATION 
nanomolar O 
concentrations O 
. O 
The O 
involvement O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
in O 
toxin O 
induced O 
cell O 
death O 
, O 
the O 
relationship O 
between O 
protein O 
synthesis O 
inhibition O 
and O 
toxicity O 
, O 
and O 
the O 
cell O 
endogenous O 
antioxidant O 
response O 
regulation O 
were O 
studied O 
. O 
We O 
show O 
that O 
cylindrospermopsin B-TRIVIAL 
induces O 
apoptosis O 
in O 
primary O 
rat O 
hepatocytes O 
. O 
At O 
the O 
concentrations O 
used O 
in O 
this O 
work O 
, O 
protein O 
synthesis O 
inhibition O 
and O 
oxidative O 
stress O 
were O 
involved O 
in O 
the O 
cytotoxic O 
effect O 
elicited O 
by O 
the O 
toxin O 
. O 
Finally O 
, O 
activation O 
of O 
the O 
cell O 
antioxidant O 
response O 
was O 
observed O 
at O 
the O 
transcriptional O 
and O 
translational O 
levels O 
. O 

binding O 
properties O 
of O 
a O 
self O 
- O 
assembled O 
coordination O 
cage O 
were O 
subtly O 
tuned O 
by O 
ancillary O 
groups O 
on O 
the O 
metal O 
corners O 
of O 
the O 
cage O 
. O 
Since O 
the O 
bulky O 
mesityl B-TRIVIAL 
groups O 
of O 
the O 
ligand O 
hang O 
over O 
the O 
cage O 
cavity O 
, O 
the O 
effective O 
cavity O 
volume O 
is O 
reduced O 
. O 
Due O 
to O 
the O 
tighter O 
guest O 
packing O 
inside O 
the O 
shrunken O 
cavity O 
, O 
smaller O 
guests O 
were O 
efficiently O 
bound O 
and O 
guest O 
motion O 
was O 
restricted O 
even O 
at O 
high O 
temperatures O 
. O 

and O 
insight O 
into O 
the O 
structure O 
- O 
activity O 
relationships O 
of O 
chalcones B-FAMILY 
as O 
antimalarial O 
agents O 
. O 

A I-TRIVIAL 
(I) O 
, O 
isolated O 
from O 
the O 
roots O 
of O 
Chinese O 
licorice O 
, O 
is O 
the O 
most O 
promising O 
antimalarial O 
compound O 
reported O 
so O 
far O 
. O 
In O 
continuation O 
of O 
our O 
drug O 
discovery O 
program O 
, O 
we O 
isolated O 
two O 
similar O 
chalcones B-FAMILY 
, O 
medicagenin B-TRIVIAL 
(II) O 
and O 
munchiwarin B-TRIVIAL 
(III) O 
, O 
from O 
Crotalaria O 
medicagenia O 
, O 
which O 
exhibited O 
antimalarial O 
activity O 
against O 
Plasmodium O 
falciparum O 
. O 
A O 
library O 
of O 
88 O 
chalcones B-FAMILY 
were O 
synthesized O 
and O 
evaluated O 
for O 
their O 
in O 
vitro O 
antimalarial O 
activity O 
. O 
Among O 
these O 
, O 
67 O 
, O 
68 O 
, O 
74 O 
, O 
77 O 
, O 
and O 
78 O 
exhibited O 
good O 
in O 
vitro O 
antimalarial O 
activity O 
against O 
P O 
. O 
falciparum O 
strains O 
3D7 O 
and O 
K1 O 
with O 
low O 
cytotoxicity O 
. O 
These O 
chalcones B-FAMILY 
also O 
showed O 
reduction O 
in O 
parasitemia O 
and O 
increased O 
survival O 
time O 
of O 
Swiss O 
mice O 
infected O 
with O 
Plasmodium O 
yoelii O 
( O 
strain O 
N-67 O 
) O 
. O 
Pharmacokinetic O 
studies O 
indicated O 
that O 
low O 
oral O 
bioavailability O 
due O 
to O 
poor O 
ADME O 
properties O 
. O 
Molecular O 
docking O 
studies O 
revealed O 
the O 
binding O 
orientation O 
of O 
these O 
inhibitors O 
in O 
active O 
sites O 
of O 
falcipain-2 O 
( O 
FP-2 O 
) O 
enzyme O 
. O 
Compounds O 
67 O 
, O 
68 O 
, O 
and O 
78 O 
showed O 
modest O 
inhibitory O 
activity O 
against O 
the O 
major O 
hemoglobin O 
degrading O 
cysteine O 
protease O 
FP-2 O 
. O 

molecule O 
probes O 
that O 
selectively O 
perturb O 
protein O 
- O 
protein O 
interactions O 
( O 
PPIs O 
) O 
are O 
pivotal O 
to O 
biomedical O 
science O 
, O 
but O 
their O 
discovery O 
is O 
challenging O 
. O 
We O 
hypothesized O 
that O 
conformational O 
resemblance O 
of O 
semirigid O 
scaffolds O 
expressing O 
amino B-FAMILY 
acid I-FAMILY 
side O 
- O 
chains O 
to O 
PPI-interface O 
regions O 
could O 
guide O 
this O 
process O 
. O 
Consequently O 
, O 
a O 
data O 
mining O 
algorithm O 
was O 
developed O 
to O 
sample O 
huge O 
numbers O 
of O 
PPIs O 
to O 
find O 
ones O 
that O 
match O 
preferred O 
conformers O 
of O 
a O 
selected O 
semirigid O 
scaffold O 
. O 
Conformations O 
of O 
one O 
such O 
chemotype O 
( O 
1aaa O 
; O 
all O 
methyl B-SYSTEMATIC 
side O 
- O 
chains O 
) O 
matched O 
several O 
biomedically O 
significant O 
PPIs O 
, O 
including O 
the O 
dimerization O 
interface O 
of O 
HIV-1 O 
protease O 
. O 
On O 
the O 
basis O 
of O 
these O 
observations O 
, O 
four O 
molecules O 
1 O 
with O 
side O 
- O 
chains O 
corresponding O 
to O 
the O 
matching O 
HIV-1 O 
dimerization O 
interface O 
regions O 
were O 
prepared O 
; O 
all O 
four O 
inhibited O 
HIV-1 O 
protease O 
via O 
perturbation O 
of O 
dimerization O 
. O 
These O 
data O 
indicate O 
this O 
approach O 
may O 
inspire O 
design O 
of O 
small O 
molecule O 
interface O 
probes O 
to O 
perturb O 
PPIs O 
. O 

full O 
circle O 
: O 
contributions O 
of O 
central O 
and O 
peripheral O 
oxytocin B-TRIVIAL 
actions O 
to O 
energy O 
balance O 
. O 

neuropeptide O 
oxytocin B-TRIVIAL 
has O 
emerged O 
as O 
an O 
important O 
anorexigen B-FAMILY 
in O 
the O 
regulation O 
of O 
energy O 
balance O 
. O 
Its O 
effects O 
on O 
food O 
intake O 
have O 
largely O 
been O 
attributed O 
to O 
limiting O 
meal O 
size O 
through O 
interactions O 
in O 
key O 
regulatory O 
brain O 
regions O 
such O 
as O 
the O 
hypothalamus O 
and O 
hindbrain O 
. O 
Pharmacologic O 
and O 
pair O 
- O 
feeding O 
studies O 
indicate O 
that O 
its O 
ability O 
to O 
reduce O 
body O 
mass O 
extends O 
beyond O 
that O 
of O 
food O 
intake O 
, O 
affecting O 
multiple O 
factors O 
that O 
determine O 
energy O 
balance O 
such O 
as O 
energy O 
expenditure O 
, O 
lipolysis O 
, O 
and O 
glucose B-TRIVIAL 
regulation O 
. O 
Systemic O 
administration O 
of O 
oxytocin B-TRIVIAL 
recapitulates O 
many O 
of O 
its O 
effects O 
when O 
administered O 
centrally O 
, O 
raising O 
the O 
questions O 
of O 
whether O 
and O 
to O 
what O 
extent O 
circulating O 
oxytocin B-TRIVIAL 
contributes O 
to O 
energy O 
regulation O 
. O 
Its O 
therapeutic O 
potential O 
to O 
treat O 
metabolic O 
conditions O 
remains O 
to O 
be O 
determined O 
, O 
but O 
data O 
from O 
diet O 
- O 
induced O 
and O 
genetically O 
obese O 
rodent O 
models O 
as O 
well O 
as O 
application O 
of O 
oxytocin B-TRIVIAL 
in O 
humans O 
in O 
other O 
areas O 
of O 
research O 
have O 
revealed O 
promising O 
results O 
thus O 
far O 
. O 

induces O 
atherosclerotic O 
plaque O 
vulnerability O 
in O 
apolipoprotein O 
E-knockout O 
mice O 
. O 

( O 
SFO B-ABBREVIATION 
) O 
is O 
the O 
major O 
electrophilic O 
metabolite O 
of O 
safrole B-TRIVIAL 
( O 
4-allyl-1 B-SYSTEMATIC 
, I-SYSTEMATIC 
2-methylenedioxybenzene I-SYSTEMATIC 
) O 
, O 
a O 
natural O 
plant O 
constituent O 
found O 
in O 
essential O 
oils O 
of O 
numerous O 
edible O 
herbs O 
and O 
spices O 
and O 
in O 
food O 
containing O 
these O 
herbs O 
, O 
such O 
as O 
pesto O 
sauce O 
, O 
cola O 
beverages O 
and O 
bologna O 
sausages O 
. O 
The O 
effects O 
of O 
SFO B-ABBREVIATION 
in O 
mammalian O 
systems O 
, O 
especially O 
the O 
cardiovascular O 
system O 
, O 
are O 
little O 
known O 
. O 
Disruption O 
of O 
vulnerable O 
atherosclerotic O 
plaques O 
in O 
atherosclerosis O 
, O 
a O 
chronic O 
inflammatory O 
disease O 
, O 
is O 
the O 
main O 
cause O 
of O 
cardiovascular O 
events O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
SFO B-ABBREVIATION 
-induced O 
atherosclerotic O 
plaque O 
vulnerability O 
( O 
possibility O 
of O 
rupture O 
) O 
in O 
apolipoprotein O 
E-knockout O 
( O 
apoE(- O 
/ O 
- O 
) O 
) O 
mice O 
. O 
Lipid O 
area O 
in O 
vessel O 
wall O 
reached O 
59.8% O 
in O 
high O 
dose O 
SFO B-ABBREVIATION 
( O 
SFO B-ABBREVIATION 
-HD O 
) O 
treated O 
group O 
, O 
which O 
is O 
only O 
31.2% O 
in O 
control O 
group O 
. O 
SFO B-ABBREVIATION 
treatment O 
changed O 
the O 
lesion O 
composition O 
to O 
an O 
unstable O 
phenotype O 
, O 
increased O 
the O 
number O 
of O 
apoptotic O 
cells O 
in O 
plaque O 
and O 
the O 
endothelium O 
in O 
plaques O 
was O 
damaged O 
after O 
SFO B-ABBREVIATION 
treatment O 
. O 
Furthermore O 
, O 
compared O 
with O 
control O 
groups O 
, O 
the O 
plaque O 
endothelium O 
level O 
of O 
p75(NTR) O 
was O 
3-fold O 
increased O 
and O 
the O 
liver O 
level O 
of O 
p75(NTR) O 
was O 
17.4-fold O 
increased O 
by O 
SFO B-ABBREVIATION 
-HD O 
. O 
Meanwhile O 
, O 
the O 
serum O 
level O 
of O 
KC O 
( O 
a O 
functional O 
homolog O 
of O 
IL-8 O 
and O 
the O 
main O 
proinflammatory O 
alpha O 
chemokine O 
in O 
mice O 
) O 
in O 
apoE(- O 
/ O 
- O 
) O 
mice O 
was O 
up O 
to O 
357pg O 
/ O 
ml O 
in O 
SFO B-ABBREVIATION 
-HD O 
treated O 
group O 
. O 
Thus O 
, O 
SFO B-ABBREVIATION 
contributes O 
to O 
the O 
instability O 
of O 
atherosclerotic O 
plaque O 
in O 
apoE(- O 
/ O 
- O 
) O 
mice O 
through O 
activating O 
p75(NTR) O 
and O 
IL-8 O 
and O 
cell O 
apoptosis O 
in O 
plaque O 
. O 

interactions O 
of O 
apamin O 
and O 
tetraethylammonium B-SYSTEMATIC 
are O 
differentially O 
affected O 
by O 
single O 
mutations O 
in O 
the O 
pore O 
mouth O 
of O 
small O 
conductance O 
calcium B-SYSTEMATIC 
-activated O 
potassium B-SYSTEMATIC 
( O 
SK O 
) O 
channels O 
. O 

residues O 
in O 
the O 
pore O 
region O 
of O 
SK2 O 
( O 
V366 O 
) O 
and O 
SK3 O 
( O 
V520 O 
) O 
were O 
replaced O 
by O 
either O 
an O 
alanine B-TRIVIAL 
or O 
a O 
phenylalanine B-TRIVIAL 
to O 
evaluate O 
the O 
impact O 
on O 
the O 
interactions O 
with O 
the O 
allosteric O 
blocker O 
apamin O 
. O 
Unlike O 
TEA B-ABBREVIATION 
which O 
showed O 
high O 
sensitivity O 
to O 
phenylalanine B-TRIVIAL 
mutated O 
channels O 
, O 
the O 
binding O 
affinity O 
of O 
apamin O 
to O 
the O 
phenylalanine B-TRIVIAL 
mutants O 
was O 
strongly O 
reduced O 
. O 
In O 
addition O 
, O 
currents O 
from O 
phenylalanine B-TRIVIAL 
mutants O 
were O 
largely O 
resistant O 
to O 
block O 
by O 
apamin O 
. O 
On O 
the O 
other O 
hand O 
, O 
when O 
the O 
valine B-TRIVIAL 
residue O 
was O 
replaced O 
by O 
an O 
alanine B-TRIVIAL 
residue O 
, O 
an O 
increase O 
of O 
the O 
binding O 
affinity O 
and O 
the O 
amount O 
of O 
block O 
by O 
apamin O 
was O 
observed O 
for O 
alanine B-TRIVIAL 
mutated O 
SK2 O 
channels O 
, O 
but O 
not O 
for O 
mutated O 
SK3 O 
channels O 
. O 
Interestingly O 
, O 
the O 
VA O 
mutation O 
reduced O 
the O 
sensitivity O 
to O 
TEA B-ABBREVIATION 
. O 
In O 
silico O 
data O 
confirmed O 
these O 
experimental O 
results O 
. O 
Therefore O 
, O 
such O 
mutations O 
in O 
the O 
pore O 
region O 
of O 
SK O 
channels O 
show O 
that O 
the O 
three O 
- O 
dimensional O 
structure O 
of O 
the O 
SK O 
tetramers O 
can O 
be O 
disorganized O 
in O 
the O 
outer O 
pore O 
region O 
leading O 
to O 
reduced O 
interaction O 
of O 
apamin O 
with O 
its O 
target O 
. O 

reverses O 
glomerular O 
hemodynamic O 
alterations O 
and O 
oxidant O 
stress O 
in O 
5 O 
/ O 
6 O 
nephrectomized O 
rats O 
. O 

administration O 
of O 
curcumin B-TRIVIAL 
before O 
and O 
throughout O 
the O 
study O 
attenuates O 
oxidant O 
stress O 
and O 
glomerular O 
hemodynamic O 
alterations O 
induced O 
by O 
5 O 
/ O 
6 O 
nephrectomy O 
( O 
5 O 
/ O 
6NX O 
) O 
. O 
The O 
purpose O 
of O 
this O 
work O 
was O 
to O 
study O 
if O 
curcumin B-TRIVIAL 
is O 
able O 
to O 
reverse O 
established O 
glomerular O 
hemodynamic O 
alterations O 
( O 
e.g O 
. O 
hyperfiltration O 
and O 
glomerular O 
hypertension O 
) O 
and O 
oxidant O 
stress O 
in O 
rats O 
with O 
5 O 
/ O 
6NX O 
. O 
Curcumin B-TRIVIAL 
( O 
120 O 
mg O 
/ O 
kg O 
) O 
was O 
given O 
to O 
rats O 
with O 
established O 
renal O 
injury O 
( O 
30 O 
days O 
after O 
surgery O 
) O 
and O 
continued O 
for O 
30 O 
days O 
( O 
days O 
31-60 O 
of O 
the O 
study O 
) O 
. O 
All O 
rats O 
were O 
studied O 
on O 
day O 
60 O 
after O 
surgery O 
. O 
Curcumin B-TRIVIAL 
was O 
able O 
( O 
a O 
) O 
to O 
reverse O 
5 O 
/ O 
6NX-induced O 
glomerular O 
hypertension O 
and O 
hyperfiltration O 
, O 
( O 
b O 
) O 
to O 
induce O 
cell O 
proliferation O 
and O 
nuclear O 
translocation O 
of O 
Nrf2 O 
and O 
( O 
c O 
) O 
to O 
reverse O 
5 O 
/ O 
6NX-induced O 
oxidant O 
stress O 
and O 
decrease O 
in O 
antioxidant O 
enzymes O 
. O 
These O 
beneficial O 
effects O 
of O 
curcumin B-TRIVIAL 
were O 
associated O 
with O 
the O 
ability O 
of O 
this O 
antioxidant O 
to O 
reverse O 
renal O 
structural O 
alterations O 
, O 
proteinuria O 
, O 
hypertension O 
, O 
interstitial O 
fibrosis O 
, O 
fibrotic O 
glomeruli O 
, O 
tubular O 
atrophy O 
and O 
mesangial O 
expansion O 
. O 
It O 
has O 
been O 
shown O 
for O 
the O 
first O 
time O 
that O 
curcumin B-TRIVIAL 
is O 
able O 
to O 
reverse O 
established O 
oxidants O 
stress O 
glomerular O 
hypertension O 
and O 
hyperfiltration O 
in O 
rats O 
with O 
5 O 
/ O 
6NX O 
. O 
These O 
novel O 
findings O 
may O 
play O 
a O 
key O 
role O 
in O 
the O 
attenuation O 
of O 
proteinuria O 
and O 
progression O 
of O 
renal O 
damage O 
in O 
rats O 
with O 
5 O 
/ O 
6NX O 
. O 
These O 
data O 
suggest O 
that O 
curcumin B-TRIVIAL 
may O 
be O 
useful O 
to O 
reverse O 
established O 
hemodynamic O 
alterations O 
and O 
renal O 
injury O 
in O 
patients O 
with O 
chronic O 
renal O 
failure O 
. O 

vitro O 
and O 
in O 
vivo O 
anti-inflammatory O 
effects O 
of O 
4-methoxy-5- B-SYSTEMATIC 
hydroxycanthin-6-one I-SYSTEMATIC 
, O 
a O 
natural O 
alkaloid O 
from O 
Picrasma O 
quassioides O 
. O 

the O 
present O 
study O 
, O 
we O 
evaluated O 
the O 
anti-inflammatory O 
effect O 
of O 
4-methoxy-5- B-SYSTEMATIC 
hydroxycanthin-6-one I-SYSTEMATIC 
( O 
CAN B-ABBREVIATION 
) O 
, O 
a O 
natural O 
alkaloid O 
isolated O 
from O 
Picrasma O 
quassioides O 
. O 
CAN B-ABBREVIATION 
significantly O 
inhibited O 
the O 
production O 
of O 
NO B-FORMULA 
and O 
the O 
release O 
of O 
TNF-α O 
induced O 
by O 
LPS O 
in O 
macrophage O 
RAW O 
264.7 O 
. O 
Western O 
blot O 
showed O 
that O 
CAN B-ABBREVIATION 
can O 
downregulate O 
the O 
expression O 
of O 
iNOS O 
protein O 
. O 
After O 
oral O 
administration O 
, O 
CAN B-ABBREVIATION 
( O 
3 O 
, O 
9 O 
, O 
and O 
27 O 
mg O 
/ O 
kg O 
) O 
reduced O 
the O 
development O 
of O 
carrageenan O 
- O 
induced O 
paw O 
edema O 
and O 
complete O 
Freund's O 
adjuvant O 
(CFA)-induced O 
chronic O 
arthritis O 
in O 
rats O 
. O 
The O 
observed O 
results O 
indicated O 
that O 
pre O 
- O 
treatment O 
with O 
CAN B-ABBREVIATION 
might O 
be O 
an O 
effective O 
therapeutic O 
intervention O 
against O 
inflammatory O 
diseases O 
including O 
chronic O 
arthritis O 
. O 

of O 
stabilised O 
ferrous B-SYSTEMATIC 
gluconate I-SYSTEMATIC 
with O 
glycine B-TRIVIAL 
in O 
fresh O 
cheese O 
matrix O 
: O 
a O 
novel O 
iron B-SYSTEMATIC 
compound O 
for O 
food O 
fortification O 
. O 

fortification O 
of O 
foods O 
continues O 
to O 
be O 
one O 
of O 
the O 
preferred O 
ways O 
of O 
improving O 
the O 
iron B-SYSTEMATIC 
status O 
of O 
the O 
population O 
. O 
Dairy O 
product O 
is O 
a O 
common O 
product O 
in O 
the O 
diet O 
; O 
therefore O 
, O 
it O 
is O 
a O 
plausible O 
vehicle O 
for O 
iron B-SYSTEMATIC 
fortification O 
. O 
This O 
study O 
aims O 
to O 
investigate O 
the O 
bioavailability O 
of O 
ferrous B-SYSTEMATIC 
gluconate I-SYSTEMATIC 
stabilised O 
with O 
glycine B-TRIVIAL 
( O 
FGSG O 
) O 
in O 
a O 
fresh O 
cheese O 
fortified O 
with O 
zinc B-SYSTEMATIC 
. O 
The O 
iron B-SYSTEMATIC 
bioavailability O 
of O 
fresh O 
cheese O 
fortified O 
with O 
either O 
FGSG O 
and O 
with O 
or O 
without O 
zinc B-SYSTEMATIC 
and O 
FGSG O 
in O 
aqueous O 
solution O 
and O 
a O 
water O 
solution O 
of O 
ferrous B-SYSTEMATIC 
ascorbate I-SYSTEMATIC 
( O 
reference O 
dose O 
) O 
was O 
studied O 
using O 
double O 
radio B-SYSTEMATIC 
iron I-SYSTEMATIC 
( O 
(55)Fe B-FORMULA 
and O 
(59)Fe B-FORMULA 
) O 
erythrocyte O 
incorporation O 
in O 
15 O 
male O 
subjects O 
. O 
All O 
subjects O 
presented O 
with O 
normal O 
values O 
for O 
iron B-SYSTEMATIC 
status O 
parameters O 
. O 
The O 
geometric O 
mean O 
of O 
iron B-SYSTEMATIC 
bioavailability O 
for O 
the O 
water O 
solution O 
of O 
FGSG O 
was O 
38.2 O 
% O 
, O 
adjusted O 
to O 
40 O 
% O 
from O 
reference O 
doses O 
( O 
N.S O 
. O 
) O 
. O 
Iron B-SYSTEMATIC 
bioavailability O 
in O 
fresh O 
cheese O 
fortified O 
with O 
Ca B-FORMULA 
and O 
Zn B-FORMULA 
was O 
15.4 O 
% O 
and O 
was O 
23.1 O 
% O 
without O 
Zn B-FORMULA 
, O 
adjusted O 
to O 
40 O 
% O 
from O 
reference O 
doses O 
( O 
N.S O 
. O 
) O 
. O 
The O 
results O 
of O 
the O 
present O 
study O 
show O 
that O 
the O 
novel O 
iron B-SYSTEMATIC 
compound O 
ferrous B-SYSTEMATIC 
gluconate I-SYSTEMATIC 
stabilised O 
with O 
glycine B-TRIVIAL 
in O 
a O 
fresh O 
cheese O 
matrix O 
is O 
a O 
good O 
source O 
of O 
iron B-SYSTEMATIC 
and O 
can O 
be O 
used O 
in O 
iron B-SYSTEMATIC 
fortification O 
programmes O 
. O 

of O 
cisplatin B-TRIVIAL 
with O 
adenine B-TRIVIAL 
and O 
guanine B-TRIVIAL 
: O 
a O 
combined O 
IRMPD O 
, O 
MS O 
/ O 
MS O 
, O 
and O 
theoretical O 
study O 
. O 

multiple O 
photon O 
dissociation O 
( O 
IRMPD O 
) O 
spectroscopy O 
of O 
cis-[Pt(NH(3))(2)(G)Cl](+) B-FORMULA 
and O 
cis-[Pt(NH(3))(2)(A)Cl](+) B-FORMULA 
ions O 
( O 
where O 
A O 
is O 
adenine B-TRIVIAL 
and O 
G O 
is O 
guanine B-TRIVIAL 
) O 
has O 
been O 
performed O 
in O 
two O 
spectral O 
regions O 
, O 
950-1900 O 
and O 
2900-3700 O 
cm(-1) O 
. O 
Quantum O 
chemical O 
calculations O 
at O 
the O 
B3LYP O 
/ O 
LACV3P O 
/ O 
6-311G** O 
level O 
yield O 
the O 
optimized O 
geometries O 
and O 
IR O 
spectra O 
for O 
the O 
conceivable O 
isomers O 
of O 
cis-[Pt(NH(3))(2)(G)Cl](+) B-FORMULA 
and O 
cis-[Pt(NH(3))(2)(A)Cl](+) B-FORMULA 
, O 
whereby O 
the O 
cisplatin B-TRIVIAL 
residue O 
is O 
attached O 
to O 
the O 
N7 O 
, O 
N3 O 
, O 
or O 
carbonyl B-SYSTEMATIC 
oxygen I-SYSTEMATIC 
atom O 
, O 
( O 
O6 B-FORMULA 
) O 
, O 
of O 
guanine B-TRIVIAL 
and O 
to O 
the O 
N7 O 
, O 
N3 O 
, O 
or O 
N1 O 
position O 
of O 
adenine B-TRIVIAL 
, O 
respectively O 
. O 
In O 
addition O 
to O 
the O 
conventional O 
binding O 
sites O 
of O 
native O 
adenine B-TRIVIAL 
, O 
complexes O 
with O 
N7-H O 
tautomers O 
have O 
also O 
been O 
considered O 
. O 
In O 
agreement O 
with O 
computational O 
results O 
, O 
the O 
IR O 
characterization O 
of O 
cis-[Pt(NH(3))(2)(G)Cl](+) B-FORMULA 
points O 
to O 
a O 
covalent O 
structure O 
where O 
Pt B-FORMULA 
is O 
bound O 
to O 
the O 
N7 O 
atom O 
of O 
guanine B-TRIVIAL 
. O 
The O 
characterized O 
conformer O 
has O 
a O 
hydrogen B-SYSTEMATIC 
-bonding O 
interaction O 
between O 
a O 
hydrogen B-SYSTEMATIC 
atom O 
of O 
one O 
NH(3) B-FORMULA 
ligand O 
and O 
the O 
carbonyl B-FAMILY 
group O 
of O 
guanine B-TRIVIAL 
. O 
The O 
experimental O 
C═O B-FORMULA 
stretching O 
feature O 
of O 
cis-[Pt(NH(3))(2)(G)Cl](+) B-FORMULA 
at O 
1718 O 
cm(-1) O 
, O 
remarkably O 
red O 
- O 
shifted O 
with O 
respect O 
to O 
an O 
unperturbed O 
C═O B-FORMULA 
stretching O 
mode O 
, O 
is O 
indicative O 
of O 
a O 
lengthened O 
CO B-FORMULA 
bond O 
in O 
guanine B-TRIVIAL 
, O 
a O 
signature O 
that O 
this O 
group O 
is O 
involved O 
in O 
hydrogen B-SYSTEMATIC 
bonding O 
. O 
The O 
IRMPD O 
spectra O 
of O 
cis-[Pt(NH(3))(2)(A)Cl](+) B-FORMULA 
are O 
consistent O 
with O 
the O 
presence O 
of O 
two O 
major O 
isomers O 
, O 
PtAN3 B-FORMULA 
and O 
PtAN1 B-FORMULA 
, O 
where O 
Pt B-FORMULA 
is O 
bound O 
to O 
the O 
N3 O 
and O 
N1 O 
positions O 
of O 
native O 
adenine B-TRIVIAL 
, O 
respectively O 
. O 

pombe O 
contains O 
two O 
paralogous O 
proteins O 
, O 
Mag1 O 
and O 
Mag2 O 
, O 
related O 
to O 
the O 
helix O 
- O 
hairpin O 
- O 
helix O 
( O 
HhH O 
) O 
superfamily O 
of O 
alkylpurine B-FAMILY 
DNA O 
glycosylases O 
from O 
yeast O 
and O 
bacteria O 
. O 
Phylogenetic O 
analysis O 
of O 
related O 
proteins O 
from O 
four O 
Schizosaccharomyces O 
and O 
other O 
fungal O 
species O 
shows O 
that O 
the O 
Mag1 O 
/ O 
Mag2 O 
duplication O 
is O 
unique O 
to O 
the O 
genus O 
Schizosaccharomyces O 
and O 
most O 
likely O 
occurred O 
in O 
its O 
ancestor O 
. O 
Mag1 O 
excises O 
N3- B-MULTIPLE 
and I-MULTIPLE 
N7-alkylguanines I-MULTIPLE 
and O 
1,N(6)-ethenoadenine B-SYSTEMATIC 
from O 
DNA O 
, O 
whereas O 
Mag2 O 
has O 
been O 
reported O 
to O 
have O 
no O 
detectible O 
alkylpurine B-FAMILY 
base O 
excision O 
activity O 
despite O 
high O 
sequence O 
and O 
active O 
site O 
similarity O 
to O 
Mag1 O 
. O 
To O 
understand O 
this O 
discrepancy O 
we O 
determined O 
the O 
crystal O 
structure O 
of O 
Mag2 O 
bound O 
to O 
abasic O 
DNA O 
and O 
compared O 
it O 
to O 
our O 
previously O 
determined O 
Mag1-DNA O 
structure O 
. O 
In O 
contrast O 
to O 
Mag1 O 
, O 
Mag2 O 
does O 
not O 
flip O 
the O 
abasic O 
moiety O 
into O 
the O 
active O 
site O 
or O 
stabilize O 
the O 
DNA O 
strand O 
5 O 
' O 
to O 
the O 
lesion O 
, O 
suggesting O 
that O 
it O 
is O 
incapable O 
of O 
forming O 
a O 
catalytically O 
competent O 
protein-DNA O 
complex O 
. O 
Subtle O 
differences O 
in O 
Mag1 O 
and O 
Mag2 O 
interactions O 
with O 
the O 
DNA O 
duplex O 
illustrate O 
how O 
Mag2 O 
can O 
stall O 
at O 
damage O 
sites O 
without O 
fully O 
engaging O 
the O 
lesion O 
. O 
We O 
tested O 
our O 
structural O 
predictions O 
by O 
mutational O 
analysis O 
of O 
base O 
excision O 
and O 
found O 
a O 
single O 
amino B-FAMILY 
acid I-FAMILY 
responsible O 
at O 
least O 
in O 
part O 
for O 
Mag2's O 
lack O 
of O 
activity O 
. O 
Substitution O 
of O 
Mag2 O 
Asp56 O 
, O 
which O 
caps O 
the O 
helix O 
at O 
the O 
base O 
of O 
the O 
DNA O 
intercalation O 
loop O 
, O 
with O 
the O 
corresponding O 
serine B-TRIVIAL 
residue O 
in O 
Mag1 O 
endows O 
Mag2 O 
with O 
ɛA O 
excision O 
activity O 
comparable O 
to O 
Mag1 O 
. O 
This O 
work O 
provides O 
novel O 
insight O 
into O 
the O 
chemical O 
and O 
physical O 
determinants O 
by O 
which O 
the O 
HhH O 
glycosylases O 
engage O 
DNA O 
in O 
a O 
catalytically O 
productive O 
manner O 
. O 

coupling O 
distance O 
between O 
presynaptic O 
Ca(2+) B-FORMULA 
influx O 
and O 
the O 
sensor O 
for O 
vesicular O 
transmitter O 
release O 
determines O 
speed O 
and O 
reliability O 
of O 
synaptic O 
transmission O 
. O 
Nanodomain O 
coupling O 
( O 
< O 
100 O 
nm O 
) O 
favors O 
fidelity O 
and O 
is O 
employed O 
by O 
synapses O 
specialized O 
for O 
escape O 
reflexes O 
and O 
by O 
inhibitory O 
synapses O 
involved O 
in O 
synchronizing O 
fast O 
network O 
oscillations O 
. O 
Cortical O 
glutamatergic O 
synapses O 
seem O 
to O 
forgo O 
the O 
benefits O 
of O 
tight O 
coupling O 
, O 
yet O 
quantitative O 
detail O 
is O 
lacking O 
. O 
The O 
reduced O 
transmission O 
fidelity O 
of O 
loose O 
coupling O 
, O 
however O 
, O 
raises O 
the O 
question O 
whether O 
it O 
is O 
indeed O 
a O 
general O 
characteristic O 
of O 
cortical O 
synapses O 
. O 
Here O 
we O 
analyzed O 
excitatory O 
parallel O 
fiber O 
to O 
Purkinje O 
cell O 
synapses O 
, O 
major O 
processing O 
sites O 
for O 
sensory O 
information O 
and O 
well O 
suited O 
for O 
analysis O 
because O 
they O 
typically O 
harbor O 
only O 
a O 
single O 
active O 
zone O 
. O 
We O 
quantified O 
the O 
coupling O 
distance O 
by O 
combining O 
multiprobability O 
fluctuation O 
analyses O 
, O 
presynaptic O 
Ca(2+) B-FORMULA 
imaging O 
, O 
and O 
reaction O 
- O 
diffusion O 
simulations O 
in O 
wild O 
- O 
type O 
and O 
calretinin O 
- O 
deficient O 
mice O 
. O 
We O 
found O 
a O 
coupling O 
distance O 
of O 
< O 
30 O 
nm O 
at O 
these O 
synapses O 
, O 
much O 
shorter O 
than O 
at O 
any O 
other O 
glutamatergic O 
cortical O 
synapse O 
investigated O 
to O 
date O 
. O 
Our O 
results O 
suggest O 
that O 
nanodomain O 
coupling O 
is O 
a O 
general O 
characteristic O 
of O 
conventional O 
cortical O 
synapses O 
involved O 
in O 
high O 
- O 
frequency O 
transmission O 
, O 
allowing O 
for O 
dense O 
gray O 
matter O 
packing O 
and O 
cost O 
- O 
effective O 
neurotransmission O 
. O 

pharmacokinetics O 
of O 
various O 
important O 
drugs O 
are O 
known O 
to O 
be O 
significantly O 
influenced O 
by O 
the O 
human O 
ABC O 
transporter O 
P-glycoprotein O 
( O 
P-gp O 
) O 
, O 
which O 
may O 
lead O 
to O 
clinically O 
relevant O 
drug O 
- O 
drug O 
interactions O 
. O 
In O 
contrast O 
to O 
therapeutic O 
drugs O 
, O 
emerging O 
drugs O 
of O 
abuse O 
( O 
DOA O 
) O 
are O 
sold O 
and O 
consumed O 
without O 
any O 
safety O 
pharmacology O 
testing O 
. O 
Only O 
some O 
studies O 
on O 
their O 
metabolism O 
were O 
published O 
, O 
but O 
none O 
about O 
their O 
affinity O 
to O 
the O 
transporter O 
systems O 
. O 
Therefore O 
, O 
47 O 
DOAs O 
from O 
various O 
classes O 
were O 
tested O 
for O 
their O 
P-gp O 
affinity O 
using O 
human O 
P-gp O 
( O 
hP-gp O 
) O 
to O 
predict O 
possible O 
drug O 
- O 
drug O 
interactions O 
. O 
DOAs O 
were O 
initially O 
screened O 
for O 
general O 
hP-gp O 
affinity O 
and O 
further O 
characterized O 
by O 
modeling O 
classic O 
Michaelis-Menten O 
kinetics O 
and O 
assessing O 
their O 
K(m) O 
and O 
V(max) O 
values O 
. O 
Among O 
the O 
tested O 
drugs O 
, O 
12 O 
showed O 
a O 
stimulation O 
of O 
ATPase O 
activity O 
. O 
The O 
most O 
intensive O 
stimulating O 
DOAs O 
were O 
further O 
investigated O 
and O 
compared O 
with O 
the O 
known O 
P-gp O 
model O 
substrates O 
sertraline B-TRIVIAL 
and O 
verapamil B-TRIVIAL 
. O 
ATPase O 
stimulation O 
kinetics O 
could O 
be O 
modeled O 
for O 
the O 
entactogen O 
3,4-methylenedioxy-α-ethylphenethylamine B-SYSTEMATIC 
( O 
3,4-BDB B-SYSTEMATIC 
) O 
, O 
the O 
hallucinogen O 
2,5-dimethoxy-4-iodoamphetamine B-SYSTEMATIC 
( O 
DOI B-ABBREVIATION 
) O 
, O 
the O 
abused O 
alkaloid O 
glaucine B-TRIVIAL 
, O 
the O 
opioid O 
- O 
like O 
drugs O 
N-iso-propyl-1,2-diphenylethylamine B-SYSTEMATIC 
( O 
NPDPA B-ABBREVIATION 
) O 
, O 
and O 
N-(1-phenylcyclohexyl)-3-ethoxypropanamine B-SYSTEMATIC 
( O 
PCEPA B-ABBREVIATION 
) O 
, O 
with O 
K(m) O 
and O 
V(max) O 
values O 
within O 
the O 
same O 
range O 
as O 
for O 
verapamil B-TRIVIAL 
or O 
sertraline B-TRIVIAL 
. O 
As O 
a O 
consequence O 
interactions O 
with O 
other O 
drugs O 
being O 
P-gp O 
substrates O 
might O 
be O 
considered O 
to O 
be O 
very O 
likely O 
and O 
further O 
studies O 
should O 
be O 
encouraged O 
. O 

-induced O 
apoptosis O 
and O 
mitochondrial O 
dysfunction O 
are O 
mediated O 
by O 
early O 
modulation O 
of O 
intracellular O 
signals O 
and O 
interaction O 
of O 
Nrf2 O 
and O 
NF-κB O 
factors O 
. O 

( O 
6-OHDA B-SYSTEMATIC 
) O 
is O 
a O 
neurotoxin O 
that O 
generates O 
an O 
experimental O 
model O 
of O 
Parkinson's O 
disease O 
in O 
rodents O 
and O 
is O 
commonly O 
employed O 
to O 
induce O 
a O 
lesion O 
in O 
dopaminergic O 
pathways O 
. O 
The O 
characterization O 
of O 
those O 
molecular O 
mechanisms O 
linked O 
to O 
6-OHDA B-SYSTEMATIC 
-induced O 
early O 
toxicity O 
is O 
needed O 
to O 
better O 
understand O 
the O 
cellular O 
events O 
further O 
leading O 
to O 
neurodegeneration O 
. O 
The O 
present O 
work O 
explored O 
how O 
6-OHDA B-SYSTEMATIC 
triggers O 
early O 
downstream O 
signaling O 
pathways O 
that O 
activate O 
neurotoxicity O 
in O 
the O 
rat O 
striatum O 
. O 
Mitochondrial O 
function O 
, O 
caspases O 
- O 
dependent O 
apoptosis O 
, O 
kinases O 
signaling O 
( O 
Akt O 
, O 
ERK O 
1 O 
/ O 
2 O 
, O 
SAP O 
/ O 
JNK O 
and O 
p38 O 
) O 
and O 
crosstalk O 
between O 
nuclear O 
factor O 
kappa O 
B O 
( O 
NF-κB O 
) O 
and O 
nuclear O 
factor-erythroid-2 O 
- O 
related O 
factor O 
2 O 
( O 
Nrf2 O 
) O 
were O 
evaluated O 
at O 
early O 
times O 
post O 
- O 
lesion O 
. O 
We O 
found O 
that O 
6-OHDA B-SYSTEMATIC 
initiates O 
cell O 
damage O 
via O 
mitochondrial O 
complex O 
I O 
inhibition O 
, O 
cytochrome O 
c O 
and O 
apoptosis O 
- O 
inducing O 
factor O 
( O 
AIF O 
) O 
release O 
, O 
as O 
well O 
as O 
activation O 
of O 
caspases O 
9 O 
and O 
3 O 
to O 
induce O 
apoptosis O 
, O 
kinase O 
signaling O 
modulation O 
and O 
NF-κB O 
- O 
mediated O 
inflammatory O 
responses O 
, O 
accompanied O 
by O 
inhibition O 
of O 
antioxidant O 
systems O 
regulated O 
by O 
the O 
Nrf2 O 
pathway O 
. O 
Our O 
results O 
suggest O 
that O 
kinases O 
SAP O 
/ O 
JNK O 
and O 
p38 O 
up O 
- O 
regulation O 
may O 
play O 
a O 
role O 
in O 
the O 
early O 
stages O 
of O 
6-OHDA B-SYSTEMATIC 
toxicity O 
to O 
trigger O 
intrinsic O 
pathways O 
for O 
apoptosis O 
and O 
enhanced O 
NF-κB O 
activation O 
. O 
In O 
turn O 
, O 
these O 
cellular O 
events O 
inhibit O 
the O 
activation O 
of O 
cytoprotective O 
mechanisms O 
, O 
thereby O 
leading O 
to O 
a O 
condition O 
of O 
general O 
damage O 
. O 

use O 
of O 
Reamer O 
Irrigator O 
Aspirator O 
( O 
RIA O 
) O 
autograft O 
harvest O 
in O 
the O 
treatment O 
of O 
critical O 
- O 
sized O 
iliac O 
wing O 
defects O 
in O 
sheep O 
: O 
investigation O 
of O 
dexamethasone B-TRIVIAL 
and O 
beta-tricalcium B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
augmentation O 
. O 

grafts O 
are O 
commonly O 
used O 
for O 
the O 
treatment O 
of O 
segmental O 
bone O 
defects O 
and O 
fracture O 
non O 
- O 
unions O 
. O 
Recently O 
, O 
osseous O 
particles O 
obtained O 
during O 
intermedullary O 
canal O 
reaming O 
( O 
using O 
a O 
Reamer-Irrigator-Aspirator O 
( O 
RIA O 
) O 
device O 
) O 
have O 
been O 
evaluated O 
as O 
graft O 
material O 
during O 
in O 
vitro O 
and O 
clinical O 
studies O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
and O 
quantify O 
new O 
bone O 
formation O 
after O 
implantation O 
of O 
bone O 
graft O 
material O 
obtained O 
after O 
reaming O 
of O 
the O 
tibia O 
in O 
a O 
bilateral O 
critical O 
- O 
sized O 
iliac O 
wing O 
defect O 
in O 
sheep O 
and O 
to O 
investigate O 
the O 
effect O 
of O 
the O 
augmentation O 
of O 
this O 
graft O 
. O 
A O 
reamer O 
bone O 
graft O 
alone O 
, O 
or O 
after O 
short O 
term O 
incubation O 
in O 
a O 
dexamethasone B-TRIVIAL 
enriched O 
solution O 
, O 
and O 
a O 
reamer O 
graft O 
collected O 
using O 
beta-tricalcium B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
( O 
β-TCP B-ABBREVIATION 
) O 
granules O 
in O 
the O 
filter O 
of O 
the O 
RIA O 
collection O 
device O 
were O 
compared O 
to O 
autologous O 
iliac O 
wing O 
graft O 
. O 
In O 
addition O 
, O 
reamer O 
graft O 
was O 
combined O 
with O 
the O 
cellular O 
fraction O 
collected O 
from O 
the O 
irrigation O 
fluid O 
with O 
and O 
without O 
short O 
- O 
term O 
incubation O 
in O 
a O 
dexamethasone B-TRIVIAL 
enriched O 
solution O 
. O 
It O 
was O 
hypothesized O 
that O 
the O 
amount O 
of O 
physical O 
bone O 
in O 
the O 
reamer O 
bone O 
graft O 
groups O 
would O 
be O 
higher O 
than O 
the O 
amount O 
in O 
the O 
autologous O 
iliac O 
wing O 
graft O 
group O 
and O 
that O 
augmentation O 
of O 
a O 
reamer O 
bone O 
graft O 
would O 
increase O 
bone O 
formation O 
. O 
Three O 
months O 
after O 
implantation O 
, O 
the O 
amount O 
of O 
new O 
bone O 
formation O 
( O 
as O 
percentage O 
of O 
the O 
total O 
defect O 
volume O 
) O 
in O 
the O 
defects O 
was O 
evaluated O 
ex O 
- O 
vivo O 
by O 
means O 
of O 
micro-CT O 
and O 
histomorphometry O 
. O 
The O 
mean O 
amount O 
of O 
bone O 
in O 
the O 
autologous O 
iliac O 
wing O 
graft O 
group O 
was O 
17.7% O 
and O 
16.8% O 
for O 
micro-CT O 
and O 
histomorphometry O 
, O 
respectively O 
. O 
The O 
mean O 
amount O 
of O 
bone O 
in O 
all O 
reamer O 
graft O 
groups O 
ranged O 
between O 
20.4-29.2% O 
( O 
micro-CT O 
) O 
and O 
17.0-25.4% O 
( O 
histomorphometry O 
) O 
. O 
Reamer O 
graft O 
collected O 
using O 
β-TCP B-ABBREVIATION 
granules O 
( O 
29.2±1.7% O 
) O 
in O 
the O 
filter O 
produced O 
a O 
significantly O 
higher O 
amount O 
of O 
bone O 
in O 
comparison O 
to O 
an O 
autologous O 
iliac O 
wing O 
graft O 
evaluated O 
by O 
micro-CT O 
. O 
RIA O 
bone O 
grafts O 
added O 
a O 
small O 
increase O 
in O 
bone O 
volume O 
to O 
the O 
3month O 
graft O 
volume O 
in O 
this O 
preclinical O 
sheep O 
model O 
. O 
The O 
current O 
model O 
does O 
not O 
support O 
the O 
use O 
of O 
short O 
- O 
term O 
high O 
concentration O 
dexamethasone B-TRIVIAL 
for O 
augmentation O 
of O 
a O 
graft O 
volume O 
. O 
If O 
avoidance O 
of O 
an O 
iliac O 
wing O 
graft O 
is O 
desirable O 
, O 
or O 
a O 
reaming O 
procedure O 
is O 
required O 
, O 
then O 
a O 
RIA O 
graft O 
or O 
RIA O 
graft O 
plus O 
β-TCP B-ABBREVIATION 
granules O 
are O 
as O 
good O 
as O 
the O 
current O 
gold O 
standard O 
for O 
this O 
model O 
. O 

hepatocytes O 
represent O 
a O 
well O 
- O 
established O 
in O 
vitro O 
system O 
. O 
However O 
, O 
the O 
applicability O 
of O 
hepatocytes O 
in O 
toxicogenomics O 
is O 
still O 
controversially O 
discussed O 
. O 
Recently O 
, O 
an O 
in O 
vivo O 
/ O 
in O 
vitro O 
discrepancy O 
has O 
been O 
described O 
, O 
whereby O 
the O 
non-genotoxic O 
rat O 
liver O 
carcinogen O 
methapyrilene B-TRIVIAL 
alters O 
the O 
expression O 
of O 
the O 
metabolizing O 
genes O 
SULT1A1 O 
and O 
ABAT O 
, O 
as O 
well O 
as O 
the O 
DNA O 
damage O 
response O 
gene O 
GADD34 O 
in O 
vitro O 
, O 
but O 
not O 
in O 
vivo O 
. O 
If O 
the O 
collagen O 
sandwich O 
cultures O 
of O 
hepatocytes O 
really O 
produce O 
false O 
- O 
positive O 
data O 
, O 
this O 
would O 
compromise O 
its O 
application O 
in O 
toxicogenomics O 
. O 
To O 
revisit O 
the O 
putative O 
in O 
vivo O 
/ O 
in O 
vitro O 
discrepancy O 
, O 
we O 
first O 
analyzed O 
and O 
modeled O 
methapyrilene B-TRIVIAL 
concentrations O 
in O 
the O 
portal O 
vein O 
of O 
rats O 
. O 
The O 
relatively O 
short O 
half O 
- O 
life O 
of O 
2.8 O 
h O 
implies O 
a O 
rapid O 
decrease O 
in O 
orally O 
administered O 
methapyrilene B-TRIVIAL 
in O 
vivo O 
below O 
concentrations O 
that O 
can O 
cause O 
gene O 
expression O 
alterations O 
. O 
This O 
corresponded O 
to O 
the O 
time O 
- O 
dependent O 
alteration O 
levels O 
of O 
GADD34 O 
, O 
ABAT O 
and O 
SULT1A1 O 
RNA O 
in O 
the O 
liver O 
: O 
RNA O 
levels O 
are O 
altered O 
1 O 
, O 
6 O 
and O 
12 O 
h O 
after O 
methapyrilene B-TRIVIAL 
administration O 
, O 
but O 
return O 
to O 
control O 
levels O 
after O 
24 O 
and O 
72 O 
h O 
. O 
In O 
contrast O 
, O 
methapyrilene B-TRIVIAL 
concentrations O 
in O 
the O 
culture O 
medium O 
supernatant O 
of O 
primary O 
rat O 
hepatocyte O 
cultures O 
decreased O 
slowly O 
. O 
This O 
explains O 
why O 
GADD34 O 
, O 
ABAT O 
and O 
SULT1A1 O 
were O 
still O 
deregulated O 
after O 
24 O 
h O 
exposure O 
in O 
vitro O 
, O 
but O 
not O 
in O 
vivo O 
. O 
It O 
should O 
also O 
be O 
considered O 
that O 
the O 
earliest O 
analyzed O 
time O 
point O 
in O 
the O 
previous O 
in O 
vivo O 
studies O 
was O 
24 O 
h O 
after O 
methapyrilene B-TRIVIAL 
administration O 
. O 
In O 
conclusion O 
, O 
previously O 
observed O 
in O 
vitro O 
/ O 
in O 
vivo O 
discrepancy O 
can O 
be O 
explained O 
by O 
different O 
pharmacokinetics O 
present O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
When O 
the O 
in O 
vivo O 
half O 
- O 
life O 
is O 
short O 
, O 
levels O 
of O 
some O 
initially O 
altered O 
genes O 
may O 
have O 
returned O 
to O 
control O 
levels O 
already O 
24 O 
h O 
after O 
administration O 
. O 

targets O 
for O 
the O 
antitumor O 
activity O 
of O 
gambogic B-TRIVIAL 
acid I-TRIVIAL 
in O 
hematologic O 
malignancies O 
. O 

acid I-TRIVIAL 
( O 
GA O 
) O 
is O 
the O 
main O 
active O 
ingredient O 
of O 
gamboge O 
, O 
a O 
brownish O 
to O 
orange O 
dry O 
resin O 
secreted O 
from O 
Garcinia O 
hanburyi O 
, O 
a O 
plant O 
that O 
is O 
widely O 
distributed O 
in O 
nature O 
. O 
Recent O 
in O 
vitro O 
and O 
in O 
vivo O 
studies O 
have O 
demonstrated O 
that O 
GA O 
exerts O 
potent O 
antitumor O 
effects O 
against O 
solid O 
tumors O 
of O 
various O 
derivations O 
, O 
and O 
its O 
antitumor O 
mechanisms O 
have O 
been O 
thoroughly O 
investigated O 
. O 
On O 
the O 
other O 
hand O 
, O 
normal O 
cells O 
remain O 
relatively O 
resistant O 
to O 
GA O 
, O 
indicating O 
a O 
therapeutic O 
window O 
. O 
GA O 
is O 
currently O 
in O 
clinical O 
trials O 
in O 
China O 
. O 
Over O 
the O 
last O 
decade O 
, O 
our O 
laboratory O 
demonstrates O 
that O 
GA O 
exhibits O 
potent O 
anticancer O 
activities O 
against O 
hematological O 
malignancies O 
. O 
This O 
review O 
focuses O 
on O 
the O 
new O 
mechanisms O 
through O 
which O 
GA O 
inhibits O 
proliferation O 
and O 
induces O 
apoptosis O 
in O 
malignant O 
hematological O 
cells O 
. O 
These O 
include O 
the O 
regulation O 
of O 
expression O 
and O 
intracellular O 
positioning O 
of O 
nucleoporin O 
and O 
nucleophosmin O 
; O 
downregulation O 
of O 
steroid B-FAMILY 
receptor O 
coactivator-3 O 
( O 
SRC-3 O 
) O 
and O 
its O 
downstream O 
proteins O 
; O 
upregulation O 
of O 
death O 
inducer O 
- O 
obliterator O 
( O 
DIO-1 O 
) O 
; O 
downregulation O 
of O 
HERG O 
potassium B-SYSTEMATIC 
channel O 
; O 
as O 
well O 
as O 
induction O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
accumulation O 
. O 

of O 
spirolactone B-SYSTEMATIC 
-type O 
diterpenoid B-FAMILY 
derivatives O 
from O 
kaurene B-TRIVIAL 
-type O 
oridonin B-TRIVIAL 
with O 
improved O 
antiproliferative O 
effects O 
and O 
their O 
apoptosis O 
- O 
inducing O 
activity O 
in O 
human O 
hepatoma O 
Bel-7402 O 
cells O 
. O 

series O 
of O 
novel O 
spirolactone B-SYSTEMATIC 
-type O 
diterpenoid B-FAMILY 
derivatives O 
of O 
oridonin B-TRIVIAL 
( O 
12a-j O 
) O 
were O 
designed O 
and O 
synthesized O 
. O 
All O 
the O 
target O 
compounds O 
showed O 
improved O 
anti-proliferative O 
activity O 
against O 
a O 
panel O 
of O 
human O 
cancer O 
cell O 
lines O 
and O 
the O 
most O 
effective O 
compound O 
12j O 
was O 
more O 
potent O 
than O 
positive O 
control O 
Taxol O 
in O 
K562 O 
and O 
Bel-7402 O 
cells O 
with O 
IC(50) O 
values O 
of O 
0.39 O 
μM O 
and O 
1.39 O 
μM O 
, O 
respectively O 
. O 
The O 
cellular O 
mechanisms O 
showed O 
that O 
compound O 
12j O 
induced O 
apoptosis O 
at O 
low O 
micromolar O 
concentrations O 
in O 
human O 
hepatoma O 
Bel-7402 O 
cells O 
. O 
These O 
results O 
demonstrate O 
that O 
the O 
spirolactone B-SYSTEMATIC 
-type O 
diterpenoid B-FAMILY 
derivatives O 
of O 
oridonin B-TRIVIAL 
have O 
optimized O 
growth O 
inhibitory O 
activity O 
against O 
cancer O 
cells O 
and O 
interesting O 
apoptosis O 
- O 
inducing O 
ability O 
. O 

zebra O 
finches O 
form O 
long O 
- O 
term O 
monogamous O 
pair O 
- O 
bonds O 
that O 
are O 
actively O 
maintained O 
year O 
- O 
round O 
, O 
even O 
when O 
not O 
in O 
breeding O 
condition O 
. O 
These O 
desert O 
finches O 
are O 
opportunistic O 
breeders O 
, O 
and O 
breeding O 
is O 
highly O 
influenced O 
by O 
unpredictable O 
rainfall O 
. O 
Their O 
high O 
levels O 
of O 
affiliation O 
and O 
complex O 
breeding O 
patterns O 
make O 
zebra O 
finches O 
an O 
excellent O 
model O 
in O 
which O 
to O 
study O 
the O 
endocrine O 
regulation O 
of O 
affiliation O 
. O 
Here O 
, O 
we O 
compared O 
zebra O 
finch O 
pairs O 
that O 
were O 
provided O 
with O 
water O 
ad O 
libitum O 
( O 
control O 
) O 
or O 
water O 
restricted O 
. O 
We O 
examined O 
( O 
1 O 
) O 
reproductive O 
physiology O 
, O 
( O 
2 O 
) O 
pair O 
- O 
maintenance O 
behaviors O 
in O 
several O 
contexts O 
, O 
and O 
( O 
3 O 
) O 
circulating O 
and O 
brain O 
steroid B-FAMILY 
levels O 
. O 
In O 
females O 
, O 
water O 
restriction O 
profoundly O 
reduced O 
largest O 
ovarian O 
follicle O 
size O 
, O 
ovary O 
size O 
, O 
oviduct O 
size O 
, O 
and O 
egg O 
laying O 
. O 
In O 
males O 
, O 
water O 
restriction O 
had O 
no O 
effect O 
on O 
testes O 
size O 
but O 
decreased O 
systemic O 
testosterone B-TRIVIAL 
levels O 
. O 
However O 
, O 
in O 
the O 
hypothalamus O 
, O 
local O 
testosterone B-TRIVIAL 
and O 
estradiol B-TRIVIAL 
levels O 
were O 
unaffected O 
by O 
water O 
restriction O 
in O 
both O 
sexes O 
. O 
Systemic O 
and O 
local O 
levels O 
of O 
the O 
androgen B-FAMILY 
precursor O 
dehydroepiandrosterone B-TRIVIAL 
( O 
DHEA B-ABBREVIATION 
) O 
were O 
also O 
unaffected O 
by O 
water O 
restriction O 
. O 
Lastly O 
, O 
in O 
three O 
different O 
behavioral O 
paradigms O 
, O 
we O 
examined O 
a O 
variety O 
of O 
pair O 
- O 
maintenance O 
behaviors O 
, O 
and O 
none O 
were O 
reduced O 
by O 
water O 
restriction O 
. O 
Taken O 
together O 
, O 
these O 
correlational O 
data O 
are O 
consistent O 
with O 
the O 
hypothesis O 
that O 
local O 
production O 
of O 
sex O 
steroids B-FAMILY 
in O 
the O 
brain O 
promotes O 
the O 
expression O 
of O 
pair O 
- O 
maintenance O 
behaviors O 
in O 
non-breeding O 
zebra O 
finches O 
. O 

toxicity O 
in O 
eukaryotes O 
: O 
cellular O 
and O 
molecular O 
mechanisms O 
in O 
plants O 
and O 
animals O 
. O 

are O 
sesquiterpenoid B-FAMILY 
mycotoxins I-FAMILY 
commonly O 
found O 
as O 
contaminants O 
in O 
cereal O 
grains O 
and O 
are O 
a O 
major O 
health O 
and O 
food O 
safety O 
concern O 
due O 
to O 
their O 
toxicity O 
to O 
humans O 
and O 
farm O 
animals O 
. O 
Trichothecenes B-FAMILY 
are O 
predominantly O 
produced O 
by O 
the O 
phytopathogenic O 
Fusarium O 
fungus O 
, O 
and O 
in O 
plants O 
they O 
act O 
as O 
a O 
virulence O 
factor O 
aiding O 
the O 
spread O 
of O 
the O 
fungus O 
during O 
disease O 
development O 
. O 
Known O 
for O 
their O 
inhibitory O 
effect O 
on O 
eukaryotic O 
protein O 
synthesis O 
, O 
trichothecenes B-FAMILY 
also O 
induce O 
oxidative O 
stress O 
, O 
DNA O 
damage O 
and O 
cell O 
cycle O 
arrest O 
and O 
affect O 
cell O 
membrane O 
integrity O 
and O 
function O 
in O 
eukaryotic O 
cells O 
. O 
In O 
animals O 
, O 
trichothecenes B-FAMILY 
can O 
be O 
either O 
immunostimulatory O 
or O 
immunosuppressive O 
and O 
induce O 
apoptosis O 
via O 
mitochondria O 
- O 
mediated O 
or O 
-independent O 
pathway O 
. O 
In O 
plants O 
, O 
trichothecenes B-FAMILY 
induce O 
programmed O 
cell O 
death O 
via O 
production O 
of O 
reactive O 
oxygen O 
species O 
. O 
Recent O 
advances O 
in O 
molecular O 
techniques O 
have O 
led O 
to O 
the O 
elucidation O 
of O 
signal O 
transduction O 
pathways O 
that O 
manifest O 
trichothecene B-FAMILY 
toxicity O 
in O 
eukaryotes O 
. O 
In O 
animals O 
, O 
trichothecenes B-FAMILY 
induce O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
signalling O 
cascades O 
via O 
ribotoxic O 
stress O 
response O 
and O 
/ O 
or O 
endoplasmic O 
reticulum O 
stress O 
response O 
. O 
The O 
upstream O 
signalling O 
events O 
that O 
lead O 
to O 
the O 
activation O 
trichothecene B-FAMILY 
-induced O 
ribotoxic O 
stress O 
response O 
are O 
discussed O 
. O 
In O 
plants O 
, O 
trichothecenes B-FAMILY 
exhibit O 
elicitor O 
- O 
like O 
activity O 
leading O 
to O 
the O 
inductions O 
MAPKs O 
and O 
genes O 
involved O 
in O 
oxidative O 
stress O 
, O 
cell O 
death O 
and O 
plant O 
defence O 
response O 
. O 
Trichothecenes B-FAMILY 
might O 
also O 
modulate O 
hormone O 
- O 
mediated O 
defence O 
signalling O 
and O 
abiotic O 
stress O 
signalling O 
in O 
plants O 
. O 

nanoparticles O 
disrupt O 
cellular O 
signaling O 
in O 
a O 
cholesterol B-TRIVIAL 
dependent O 
manner O 
. O 

this O 
study O 
, O 
we O 
investigate O 
the O 
interaction O 
of O 
charged O 
polystyrene B-SYSTEMATIC 
particles O 
with O 
respiratory O 
epithelial O 
cells O 
. O 
Experiments O 
were O 
designed O 
to O 
reveal O 
the O 
effect O 
of O 
cellular O 
interaction O 
with O 
particles O 
of O 
varying O 
size O 
and O 
charge O 
and O 
how O 
such O 
interactions O 
could O 
alter O 
cytokine O 
induced O 
cellular O 
processes O 
. O 
A549 O 
cells O 
, O 
containing O 
a O 
stably O 
transfected O 
Interleukin-8 O 
( O 
IL-8 O 
) O 
Luciferase O 
promoter O 
construct O 
, O 
were O 
cultured O 
in O 
the O 
presence O 
of O 
the O 
proinflammatory O 
cytokine O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
and O 
polystyrene B-SYSTEMATIC 
particles O 
for O 
4.5h O 
. O 
Several O 
endpoints O 
were O 
measured O 
: O 
IL-8 O 
gene O 
expression O 
, O 
IL-6 O 
protein O 
, O 
IL-8 O 
protein O 
, O 
and O 
NF-кB O 
translocation O 
. O 
At O 
4.5h O 
, O 
cellular O 
viability O 
was O 
maintained O 
for O 
the O 
particle O 
exposed O 
cells O 
. O 
Interestingly O 
, O 
we O 
found O 
that O 
only O 
the O 
cationic O 
nanoparticles O 
have O 
the O 
ability O 
to O 
disrupt O 
the O 
TNF-α O 
stimulated O 
cellular O 
signaling O 
by O 
reducing O 
the O 
IL-8 O 
promoter O 
activity O 
, O 
IL-6 O 
and O 
IL-8 O 
protein O 
. O 
Cationic O 
nanoparticles O 
reduce O 
these O 
processes O 
through O 
interfering O 
with O 
NF-κB O 
translocation O 
. O 
However O 
, O 
the O 
activity O 
of O 
the O 
cationic O 
nanoparticles O 
on O 
the O 
IL-8 O 
promoter O 
and O 
NF-κB O 
translocation O 
is O 
lost O 
when O 
cholesterol B-TRIVIAL 
is O 
depleted O 
from O 
A549 O 
cells O 
before O 
particle O 
exposure O 
, O 
which O 
suggests O 
that O 
cationic O 
nanoparticles O 
rely O 
on O 
membrane O 
cholesterol B-TRIVIAL 
integrity O 
to O 
disrupt O 
cellular O 
signaling O 
. O 

role O 
of O 
the O 
intestinal O 
microbiota O 
as O 
a O 
regulator O 
of O 
autoimmune O 
diabetes O 
in O 
animal O 
models O 
is O 
well O 
- O 
established O 
, O 
but O 
data O 
on O 
human O 
type O 
1 O 
diabetes O 
are O 
tentative O 
and O 
based O 
on O 
studies O 
including O 
only O 
a O 
few O 
study O 
subjects O 
. O 
To O 
exclude O 
secondary O 
effects O 
of O 
diabetes O 
and O 
HLA O 
risk O 
genotype O 
on O 
gut O 
microbiota O 
, O 
we O 
compared O 
the O 
intestinal O 
microbiota O 
composition O 
in O 
children O 
with O 
at O 
least O 
two O 
diabetes O 
- O 
associated O 
autoantibodies O 
( O 
n O 
= O 
18 O 
) O 
with O 
autoantibody O 
- O 
negative O 
children O 
matched O 
for O 
age O 
, O 
sex O 
, O 
early O 
feeding O 
history O 
, O 
and O 
HLA O 
risk O 
genotype O 
using O 
pyrosequencing O 
. O 
Principal O 
component O 
analysis O 
indicated O 
that O 
a O 
low O 
abundance O 
of O 
lactate B-FAMILY 
-producing O 
and O 
butyrate B-SYSTEMATIC 
-producing O 
species O 
was O 
associated O 
with O 
β-cell O 
autoimmunity O 
. O 
In O 
addition O 
, O 
a O 
dearth O 
of O 
the O 
two O 
most O 
dominant O 
Bifidobacterium O 
species O 
, O 
Bifidobacterium O 
adolescentis O 
and O 
Bifidobacterium O 
pseudocatenulatum O 
, O 
and O 
an O 
increased O 
abundance O 
of O 
the O 
Bacteroides O 
genus O 
were O 
observed O 
in O 
the O 
children O 
with O 
β-cell O 
autoimmunity O 
. O 
We O 
did O 
not O 
find O 
increased O 
fecal O 
calprotectin O 
or O 
IgA O 
as O 
marker O 
of O 
inflammation O 
in O 
children O 
with O 
β-cell O 
autoimmunity O 
. O 
Functional O 
studies O 
related O 
to O 
the O 
observed O 
alterations O 
in O 
the O 
gut O 
microbiome O 
are O 
warranted O 
because O 
the O 
low O 
abundance O 
of O 
bifidobacteria O 
and O 
butyrate B-SYSTEMATIC 
-producing O 
species O 
could O 
adversely O 
affect O 
the O 
intestinal O 
epithelial O 
barrier O 
function O 
and O 
inflammation O 
, O 
whereas O 
the O 
apparent O 
importance O 
of O 
the O 
Bacteroides O 
genus O 
in O 
development O 
of O 
type O 
1 O 
diabetes O 
is O 
insufficiently O 
understood O 
. O 

interactions O 
within O 
the O 
ventromedial O 
hypothalamus O 
influence O 
counterregulatory O 
hormone O 
release O 
and O 
local O 
glutamine B-TRIVIAL 
/ O 
glutamate B-TRIVIAL 
balance O 
during O 
hypoglycemia O 
. O 

of O 
β-cell O 
EphA5 O 
receptors O 
by O 
its O 
ligand O 
ephrinA5 O 
from O 
adjacent O 
β-cells O 
has O 
been O 
reported O 
to O 
decrease O 
insulin O 
secretion O 
during O 
hypoglycemia O 
. O 
Given O 
the O 
similarities O 
between O 
islet O 
and O 
ventromedial O 
hypothalamus O 
( O 
VMH O 
) O 
glucose B-TRIVIAL 
sensing O 
, O 
we O 
tested O 
the O 
hypothesis O 
that O 
the O 
EphA5 O 
/ O 
ephrinA5 O 
system O 
might O 
function O 
within O 
the O 
VMH O 
during O 
hypoglycemia O 
to O 
stimulate O 
counterregulatory O 
hormone O 
release O 
as O 
well O 
. O 
Counterregulatory O 
responses O 
and O 
glutamine B-TRIVIAL 
/ O 
glutamate B-TRIVIAL 
concentrations O 
in O 
the O 
VMH O 
were O 
assessed O 
during O 
a O 
hyperinsulinemic O 
- O 
hypoglycemic O 
glucose B-TRIVIAL 
clamp O 
study O 
in O 
chronically O 
catheterized O 
awake O 
male O 
Sprague-Dawley O 
rats O 
that O 
received O 
an O 
acute O 
VMH O 
microinjection O 
of O 
ephrinA5-Fc O 
, O 
chronic O 
VMH O 
knockdown O 
, O 
or O 
overexpression O 
of O 
ephrinA5 O 
using O 
an O 
adenoassociated O 
viral O 
construct O 
. O 
Local O 
stimulation O 
of O 
VMH O 
EphA5 O 
receptors O 
by O 
ephrinA5-Fc O 
or O 
ephrinA5 O 
overexpression O 
increased O 
, O 
whereas O 
knockdown O 
of O 
VMH O 
ephrinA5 O 
reduced O 
counterregulatory O 
responses O 
during O 
hypoglycemia O 
. O 
Overexpression O 
of O 
VMH O 
ephrinA5 O 
transiently O 
increased O 
local O 
glutamate B-TRIVIAL 
concentrations O 
, O 
whereas O 
ephrinA5 O 
knockdown O 
produced O 
profound O 
suppression O 
of O 
VMH O 
interstitial O 
fluid O 
glutamine B-TRIVIAL 
concentrations O 
in O 
the O 
basal O 
state O 
and O 
during O 
hypoglycemia O 
. O 
Changes O 
in O 
ephrinA5 O 
/ O 
EphA5 O 
interactions O 
within O 
the O 
VMH O 
, O 
a O 
key O 
brain O 
glucose B-TRIVIAL 
-sensing O 
region O 
, O 
act O 
in O 
concert O 
with O 
islets O 
to O 
restore O 
glucose B-TRIVIAL 
homeostasis O 
during O 
acute O 
hypoglycemia O 
, O 
and O 
its O 
effect O 
on O 
counterregulation O 
may O 
be O 
mediated O 
by O 
changes O 
in O 
glutamate B-TRIVIAL 
/ O 
glutamine B-TRIVIAL 
cycling O 
. O 

Stimuli O 
Release O 
ATP B-ABBREVIATION 
to O 
Increase O 
GLUT4 O 
Translocation O 
and O 
Glucose B-TRIVIAL 
Uptake O 
via O 
PI3Kγ-Akt-AS160 O 
in O 
Skeletal O 
Muscle O 
Cells O 
. O 

muscle O 
glucose B-TRIVIAL 
uptake O 
in O 
response O 
to O 
exercise O 
is O 
preserved O 
in O 
insulin O 
- O 
resistant O 
conditions O 
, O 
but O 
the O 
signals O 
involved O 
are O 
debated O 
. O 
ATP B-ABBREVIATION 
is O 
released O 
from O 
skeletal O 
muscle O 
by O 
contractile O 
activity O 
and O 
can O 
autocrinely O 
signal O 
through O 
purinergic O 
receptors O 
, O 
and O 
we O 
hypothesized O 
it O 
may O 
influence O 
glucose B-TRIVIAL 
uptake O 
. O 
Electrical O 
stimulation O 
, O 
ATP B-ABBREVIATION 
, O 
and O 
insulin O 
each O 
increased O 
fluorescent O 
2-NBD-Glucose B-SYSTEMATIC 
( O 
2-NBDG B-SYSTEMATIC 
) O 
uptake O 
in O 
primary O 
myotubes O 
, O 
but O 
only O 
electrical O 
stimulation O 
and O 
ATP B-ABBREVIATION 
-dependent O 
2-NBDG B-SYSTEMATIC 
uptake O 
were O 
inhibited O 
by O 
adenosine B-SYSTEMATIC 
- I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
phosphatase O 
and O 
by O 
purinergic O 
receptor O 
blockade O 
( O 
suramin B-TRIVIAL 
) O 
. O 
Electrical O 
stimulation O 
transiently O 
elevated O 
extracellular O 
ATP B-ABBREVIATION 
and O 
caused O 
Akt O 
phosphorylation O 
that O 
was O 
additive O 
to O 
insulin O 
and O 
inhibited O 
by O 
suramin B-TRIVIAL 
. O 
Exogenous O 
ATP B-ABBREVIATION 
transiently O 
activated O 
Akt O 
and O 
, O 
inhibiting O 
phosphatidylinositol O 
3-kinase O 
( O 
PI3K O 
) O 
or O 
Akt O 
as O 
well O 
as O 
dominant O 
- O 
negative O 
Akt O 
mutant O 
, O 
reduced O 
ATP B-ABBREVIATION 
-dependent O 
2-NBDG B-SYSTEMATIC 
uptake O 
and O 
Akt O 
phosphorylation O 
. O 
ATP B-ABBREVIATION 
-dependent O 
2-NBDG B-SYSTEMATIC 
uptake O 
was O 
also O 
inhibited O 
by O 
the O 
G O 
protein O 
βγ O 
subunit O 
- O 
interacting O 
peptide O 
βark O 
- O 
ct O 
and O 
by O 
the O 
phosphatidylinositol O 
3-kinase-γ O 
( O 
PI3Kγ O 
) O 
inhibitor O 
AS605240 B-IDENTIFIER 
. O 
ATP B-ABBREVIATION 
caused O 
translocation O 
of O 
GLUT4myc-eGFP O 
to O 
the O 
cell O 
surface O 
, O 
mechanistically O 
mediated O 
by O 
increased O 
exocytosis O 
involving O 
AS160 O 
/ O 
Rab8A O 
reduced O 
by O 
dominant O 
- O 
negative O 
Akt O 
or O 
PI3Kγ O 
kinase O 
- O 
dead O 
mutants O 
, O 
and O 
potentiated O 
by O 
myristoylated O 
PI3Kγ O 
. O 
ATP B-ABBREVIATION 
stimulated O 
2-NBDG B-SYSTEMATIC 
uptake O 
in O 
normal O 
and O 
insulin O 
- O 
resistant O 
adult O 
muscle O 
fibers O 
, O 
resembling O 
the O 
reported O 
effect O 
of O 
exercise O 
. O 
Hence O 
, O 
the O 
ATP B-ABBREVIATION 
-induced O 
pathway O 
may O 
be O 
tapped O 
to O 
bypass O 
insulin O 
resistance O 
. O 

in O 
the O 
insulin O 
( O 
INS O 
) O 
gene O 
may O 
cause O 
permanent O 
neonatal O 
diabetes O 
mellitus O 
( O 
PNDM O 
) O 
. O 
Ins2 O 
mutant O 
mouse O 
models O 
provided O 
important O 
insights O 
into O 
the O 
disease O 
mechanisms O 
of O 
PNDM O 
but O 
have O 
limitations O 
for O 
translational O 
research O 
. O 
To O 
establish O 
a O 
large O 
animal O 
model O 
of O 
PNDM O 
, O 
we O 
generated O 
INS(C94Y) O 
transgenic O 
pigs O 
. O 
A O 
line O 
expressing O 
high O 
levels O 
of O 
INS(C94Y) O 
mRNA O 
( O 
70-86% O 
of O 
wild O 
- O 
type O 
INS O 
transcripts O 
) O 
exhibited O 
elevated O 
blood O 
glucose B-TRIVIAL 
soon O 
after O 
birth O 
but O 
unaltered O 
β-cell O 
mass O 
at O 
the O 
age O 
of O 
8 O 
days O 
. O 
At O 
4.5 O 
months O 
, O 
INS(C94Y) O 
transgenic O 
pigs O 
exhibited O 
41% O 
reduced O 
body O 
weight O 
, O 
72% O 
decreased O 
β-cell O 
mass O 
( O 
-53% O 
relative O 
to O 
body O 
weight O 
) O 
, O 
and O 
60% O 
lower O 
fasting O 
insulin O 
levels O 
compared O 
with O 
littermate O 
controls O 
. O 
β-cells O 
of O 
INS(C94Y) O 
transgenic O 
pigs O 
showed O 
a O 
marked O 
reduction O 
of O 
insulin O 
secretory O 
granules O 
and O 
severe O 
dilation O 
of O 
the O 
endoplasmic O 
reticulum O 
. O 
Cataract O 
development O 
was O 
already O 
visible O 
in O 
8-day- O 
old O 
INS(C94Y) O 
transgenic O 
pigs O 
and O 
became O 
more O 
severe O 
with O 
increasing O 
age O 
. O 
Diabetes O 
- O 
associated O 
pathological O 
alterations O 
of O 
kidney O 
and O 
nervous O 
tissue O 
were O 
not O 
detected O 
during O 
the O 
observation O 
period O 
of O 
1 O 
year O 
. O 
The O 
stable O 
diabetic O 
phenotype O 
and O 
its O 
rescue O 
by O 
insulin O 
treatment O 
make O 
the O 
INS(C94Y) O 
transgenic O 
pig O 
an O 
attractive O 
model O 
for O 
insulin O 
supplementation O 
and O 
islet O 
transplantation O 
trials O 
, O 
and O 
for O 
studying O 
developmental O 
consequences O 
of O 
maternal O 
diabetes O 
mellitus O 
. O 

2 O 
diabetes O 
( O 
T2D O 
) O 
is O 
characterized O 
by O 
β-cell O 
dysfunction O 
and O 
the O 
subsequent O 
depletion O 
of O 
insulin O 
production O 
, O 
usually O 
in O 
a O 
context O 
of O 
increased O 
peripheral O 
insulin O 
resistance O 
. O 
T2D O 
patients O 
are O 
routinely O 
treated O 
with O 
oral O 
antidiabetic O 
agents O 
such O 
as O 
sulfonylureas B-FAMILY 
or O 
dipeptidyl O 
peptidase-4 O 
antagonists O 
, O 
which O 
promote O 
glucose B-TRIVIAL 
- O 
and O 
incretin O 
- O 
dependent O 
insulin O 
secretion O 
, O 
respectively O 
. O 
Interestingly O 
, O 
insulin O 
secretion O 
may O 
also O 
be O 
induced O 
by O 
neural O 
stimulation O 
. O 
Here O 
we O 
report O 
the O 
expression O 
of O 
Nogo-A O 
in O 
β-cells O 
. O 
Nogo-A O 
is O 
a O 
membrane O 
protein O 
that O 
inhibits O 
neurite O 
outgrowth O 
and O 
cell O 
migration O 
in O 
the O 
central O 
nervous O 
system O 
. O 
We O 
observed O 
that O 
Nogo-A-deficient O 
mice O 
display O 
improved O 
insulin O 
secretion O 
and O 
glucose B-TRIVIAL 
clearance O 
. O 
This O 
was O 
associated O 
with O 
a O 
stronger O 
parasympathetic O 
input O 
and O 
higher O 
sensitivity O 
of O 
β-cells O 
to O 
the O 
cholinergic O 
analog O 
carbachol B-TRIVIAL 
. O 
Insulin O 
secretion O 
was O 
also O 
improved O 
in O 
diabetic O 
db O 
/ O 
db O 
mice O 
treated O 
with O 
neutralizing O 
antibody O 
against O 
Nogo-A O 
. O 
Together O 
, O 
these O 
findings O 
suggest O 
that O 
promoting O 
the O 
vagal O 
stimulation O 
of O 
insulin O 
secretion O 
through O 
the O 
selective O 
inhibition O 
of O 
Nogo-A O 
could O 
be O 
a O 
novel O 
therapeutic O 
approach O 
in O 
T2D O 
. O 

vitro O 
cytotoxicity O 
and O 
genotoxicity O 
studies O 
of O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
TiO2 B-FORMULA 
) O 
nanoparticles O 
in O 
Chinese O 
hamster O 
lung O 
fibroblast O 
cells O 
. O 

are O 
increasing O 
safety O 
concerns O 
about O 
the O 
development O 
and O 
abundant O 
use O 
of O 
nanoparticles O 
. O 
The O 
unique O 
physical O 
and O 
chemical O 
characteristics O 
of O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
TiO2 B-FORMULA 
) O 
nanoparticles O 
result O 
in O 
different O 
chemical O 
and O 
biological O 
activities O 
compared O 
to O 
their O 
larger O 
micron O 
- O 
sized O 
counterparts O 
, O 
and O 
can O 
subsequently O 
play O 
an O 
important O 
role O 
in O 
influencing O 
toxicity O 
. O 
Therefore O 
, O 
our O 
objective O 
was O 
to O 
investigate O 
the O 
cytotoxicity O 
and O 
genotoxicity O 
of O 
commercially O 
available O 
TiO2 B-FORMULA 
nanoparticles O 
with O 
respect O 
to O 
their O 
selected O 
physicochemical O 
properties O 
, O 
as O 
well O 
as O 
the O 
role O 
of O 
surface O 
coating O 
of O 
these O 
nanoparticles O 
. O 
While O 
all O 
types O 
of O 
tested O 
TiO2 B-FORMULA 
samples O 
decrease O 
cell O 
viability O 
in O 
a O 
mass O 
- O 
based O 
concentration- O 
and O 
size O 
- O 
dependent O 
manner O 
, O 
the O 
polyacrylate B-FAMILY 
-coated O 
nano- O 
TiO2 B-FORMULA 
product O 
was O 
only O 
cytotoxic O 
at O 
higher O 
concentrations O 
. O 
A O 
similar O 
pattern O 
of O 
response O 
was O 
observed O 
for O 
induction O 
of O 
apoptosis O 
/ O 
necrosis O 
, O 
and O 
no O 
DNA O 
damage O 
was O 
detected O 
in O 
the O 
polyacrylate B-FAMILY 
-coated O 
nano- O 
TiO2 B-FORMULA 
model O 
. O 
Given O 
the O 
increasing O 
production O 
of O 
TiO2 B-FORMULA 
nanoparticles O 
, O 
toxicological O 
studies O 
should O 
take O 
into O 
account O 
the O 
physiochemical O 
properties O 
of O 
these O 
nanoparticles O 
that O 
may O 
help O 
researchers O 
to O 
develop O 
new O 
nanoparticles O 
with O 
minimum O 
toxicity O 
. O 

novel O 
stimuli O 
- O 
synchronized O 
alloy O 
- O 
treated O 
matrix O 
for O 
space O 
- O 
defined O 
gastrointestinal O 
delivery O 
of O 
mesalamine B-TRIVIAL 
in O 
the O 
Large O 
White O 
pig O 
model O 
. O 

study O 
focussed O 
on O 
designing O 
a O 
Stimuli-Synchronized O 
Matrix O 
( O 
SSM O 
) O 
for O 
space O 
- O 
defined O 
colonic O 
delivery O 
of O 
the O 
anti-inflammatory O 
drug O 
mesalamine B-TRIVIAL 
. O 
The O 
configured O 
matrix O 
provided O 
time O 
- O 
independent O 
delivery O 
and O 
stimuli O 
targeting O 
. O 
Formulations O 
were O 
optimized O 
according O 
to O 
a O 
Box-Behnken O 
experimental O 
design O 
that O 
constituted O 
mesalamine B-TRIVIAL 
-loaded O 
BaSO4 B-FORMULA 
-crosslinked O 
chitosan O 
dispersed O 
within O 
a O 
pectin O 
, O 
carboxymethylcellulose O 
and O 
xanthan O 
gum O 
complex O 
. O 
The O 
complex O 
was O 
compressed O 
into O 
matrices O 
and O 
subsequently O 
alloy O 
- O 
treated O 
with O 
pectin O 
and O 
ethylcellulose O 
. O 
In O 
vitro O 
drug O 
release O 
was O 
determined O 
in O 
the O 
presence O 
and O 
absence O 
of O 
colonic O 
enzymes O 
and O 
the O 
mean O 
dissolution O 
time O 
was O 
used O 
for O 
formulation O 
optimization O 
. O 
To O 
mechanistically O 
elucidate O 
the O 
synchronous O 
catalytic O 
action O 
of O 
the O 
enzymes O 
pectinase O 
and O 
glucosidase O 
on O 
the O 
matrix O 
, O 
computer O 
- O 
aided O 
3D O 
modelling O 
of O 
active O 
fractions O 
of O 
the O 
enzyme O 
- O 
substrate O 
complexes O 
was O 
generated O 
to O 
predict O 
the O 
orientation O 
of O 
residues O 
affecting O 
the O 
substrate O 
domain O 
. O 
Drug O 
release O 
profiles O 
revealed O 
distinct O 
colonic O 
enzyme O 
responsiveness O 
with O 
fractions O 
of O 
0.402 O 
and O 
0.152 O 
of O 
mesalamine B-TRIVIAL 
released O 
in O 
the O 
presence O 
and O 
absence O 
of O 
enzymes O 
, O 
respectively O 
after O 
24h O 
. O 
The O 
commercial O 
comparator O 
product O 
showed O 
irreproducible O 
release O 
profiles O 
over O 
the O 
same O 
period O 
( O 
SD=0.550 O 
) O 
compared O 
to O 
the O 
SSM O 
formulation O 
( O 
SD=0.037 O 
) O 
. O 
FTIR O 
spectra O 
of O 
alloy O 
- O 
treated O 
matrices O 
showed O 
no O 
peaks O 
from O 
1589 O 
to O 
1512cm(-1) O 
after O 
colonic O 
enzyme O 
exposure O 
. O 
With O 
increasing O 
enzyme O 
exposure O 
there O 
were O 
also O 
no O 
peaks O 
between O 
1646 O 
and O 
1132cm(-1) O 
. O 
This O 
indicated O 
polymeric O 
enzyme O 
cleavage O 
for O 
controlled O 
and O 
space O 
- O 
defined O 
release O 
of O 
mesalamine B-TRIVIAL 
. O 
Plasma O 
concentration O 
profiles O 
in O 
the O 
Large O 
White O 
pig O 
model O 
produced O 
a O 
Cmax O 
of O 
3.77±1.375μg O 
/ O 
mL O 
compared O 
to O 
10.604±2.846μg O 
/ O 
mL O 
for O 
the O 
comparator O 
formulation O 
. O 
The O 
SSM O 
formulation O 
proved O 
superior O 
over O 
the O 
comparator O 
product O 
by O 
providing O 
superiorly O 
controlled O 
enzyme O 
- O 
responsive O 
colonic O 
drug O 
delivery O 
. O 

stimulus O 
effects O 
of O 
the O 
GABAB O 
receptor O 
- O 
positive O 
modulator O 
rac-BHFF B-ABBREVIATION 
: O 
comparison O 
with O 
GABAB O 
receptor O 
agonists O 
and O 
drugs O 
of O 
abuse O 
. O 

( O 
B O 
) O 
receptor O 
- O 
positive O 
modulators O 
are O 
thought O 
to O 
have O 
advantages O 
as O 
potential O 
medications O 
for O 
anxiety O 
, O 
depression O 
, O 
and O 
drug O 
addiction O 
. O 
They O 
may O 
have O 
fewer O 
side O 
effects O 
than O 
GABA B-ABBREVIATION 
( O 
B O 
) O 
receptor O 
agonists O 
, O 
because O 
selective O 
enhancement O 
of O 
activated O 
receptors O 
could O 
have O 
effects O 
different O 
from O 
nonselective O 
activation O 
of O 
all O 
receptors O 
. O 
To O 
examine O 
this O 
, O 
pigeons O 
were O 
trained O 
to O 
discriminate O 
the O 
GABA B-ABBREVIATION 
( O 
B O 
) O 
receptor O 
- O 
positive O 
modulator O 
(R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one B-SYSTEMATIC 
( O 
rac-BHFF B-ABBREVIATION 
) O 
from O 
its O 
vehicle O 
. O 
The O 
discriminative O 
stimulus O 
effects O 
of O 
rac-BHFF B-ABBREVIATION 
were O 
not O 
mimicked O 
by O 
the O 
GABA B-ABBREVIATION 
( O 
B O 
) O 
receptor O 
agonists O 
baclofen B-TRIVIAL 
and O 
γ-hydroxybutyrate B-SYSTEMATIC 
( O 
GHB B-ABBREVIATION 
) O 
, O 
not O 
by O 
diazepam B-TRIVIAL 
, O 
and O 
not O 
by O 
alcohol B-FAMILY 
, O 
cocaine B-TRIVIAL 
, O 
and O 
nicotine B-TRIVIAL 
, O 
whose O 
self O 
- O 
administration O 
has O 
been O 
reported O 
to O 
be O 
attenuated O 
by O 
GABA B-ABBREVIATION 
( O 
B O 
) O 
receptor O 
- O 
positive O 
modulators O 
. O 
The O 
discriminative O 
stimulus O 
effects O 
of O 
rac-BHFF B-ABBREVIATION 
were O 
not O 
antagonized O 
by O 
the O 
GABA B-ABBREVIATION 
( O 
B O 
) O 
receptor O 
antagonist O 
3-aminopropyl B-SYSTEMATIC 
(diethoxymethyl)phosphinic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
CGP35348 B-IDENTIFIER 
) O 
but O 
were O 
attenuated O 
by O 
the O 
less O 
efficacious O 
GABA B-ABBREVIATION 
( O 
B O 
) O 
receptor O 
- O 
positive O 
modulator O 
2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol B-SYSTEMATIC 
( O 
CGP7930 B-IDENTIFIER 
) O 
, O 
suggesting O 
the O 
possibility O 
that O 
rac-BHFF B-ABBREVIATION 
produces O 
its O 
discriminative O 
stimulus O 
effects O 
by O 
directly O 
activating O 
GABA B-ABBREVIATION 
( O 
B2 O 
) O 
subunits O 
of O 
GABA B-ABBREVIATION 
( O 
B O 
) O 
receptors O 
. O 
At O 
a O 
dose O 
10-fold O 
lower O 
than O 
the O 
training O 
dose O 
, O 
rac-BHFF B-ABBREVIATION 
enhanced O 
the O 
discriminative O 
stimulus O 
effects O 
of O 
baclofen B-TRIVIAL 
, O 
but O 
not O 
of O 
GHB B-ABBREVIATION 
. O 
This O 
study O 
provides O 
evidence O 
that O 
the O 
effects O 
of O 
GABA B-ABBREVIATION 
( O 
B O 
) O 
receptor O 
- O 
positive O 
modulators O 
are O 
not O 
identical O 
to O 
those O 
of O 
GABA B-ABBREVIATION 
( O 
B O 
) O 
receptor O 
agonists O 
. O 
In O 
addition O 
, O 
the O 
results O 
suggest O 
that O 
positive O 
modulation O 
of O 
GABA B-ABBREVIATION 
( O 
B O 
) O 
receptors O 
does O 
not O 
produce O 
discriminative O 
stimulus O 
effects O 
similar O 
to O 
those O 
of O 
benzodiazepines B-FAMILY 
, O 
alcohol B-FAMILY 
, O 
cocaine B-TRIVIAL 
, O 
and O 
nicotine B-TRIVIAL 
. O 
Finally O 
, O 
the O 
finding O 
that O 
rac-BHFF B-ABBREVIATION 
enhanced O 
effects O 
of O 
baclofen B-TRIVIAL 
but O 
not O 
of O 
GHB B-ABBREVIATION 
is O 
consistent O 
with O 
converging O 
evidence O 
that O 
the O 
populations O 
of O 
GABA B-ABBREVIATION 
( O 
B O 
) O 
receptors O 
mediating O 
the O 
effects O 
of O 
baclofen B-TRIVIAL 
and O 
GHB B-ABBREVIATION 
are O 
not O 
identical O 
. O 

and O 
levofloxacin B-TRIVIAL 
delivery O 
of O 
mesoporous O 
materials O 
. O 

comparative O 
study O 
of O 
mesoporous O 
matrices O 
designed O 
for O 
both O 
drug O 
- O 
loading O 
methods O 
, O 
impregnation O 
( O 
IP O 
) O 
and O 
surfactant O 
- O 
assisted O 
drug O 
loading O 
( O 
also O 
denoted O 
as O 
one O 
- O 
pot O 
, O 
OP O 
) O 
, O 
has O 
been O 
carried O 
out O 
evaluating O 
their O 
physicochemical O 
characteristics O 
, O 
cell O 
response O 
, O 
drug O 
delivery O 
profiles O 
, O 
and O 
antibacterial O 
activity O 
. O 
Surfactant O 
- O 
free O 
( O 
calcined O 
) O 
and O 
surfactant O 
- O 
templated O 
( O 
non-calcined O 
) O 
mesoporous O 
silica B-TRIVIAL 
have O 
been O 
used O 
as O 
IP O 
and O 
OP O 
starting O 
matrices O 
, O 
respectively O 
. O 
Both O 
non-calcined O 
and O 
calcined O 
matrices O 
do O 
not O 
exert O 
any O 
cytotoxic O 
effect O 
on O 
osteoblasts O 
. O 
However O 
, O 
non-calcined O 
matrices O 
induce O 
on O 
fibroblasts O 
a O 
significant O 
proliferation O 
delay O 
with O 
morphological O 
alterations O 
and O 
dose O 
- O 
dependent O 
increases O 
in O 
fibroblast O 
size O 
, O 
internal O 
complexity O 
, O 
and O 
intracellular O 
calcium B-SYSTEMATIC 
content O 
but O 
without O 
cell O 
lysis O 
and O 
apoptosis O 
. O 
Residual O 
ethanol B-SYSTEMATIC 
and O 
the O 
surface O 
silanol B-SYSTEMATIC 
groups O 
in O 
these O 
non-calcined O 
matrices O 
are O 
involved O 
in O 
the O 
observed O 
fibroblast O 
changes O 
. O 
Finally O 
, O 
both O 
IP O 
and O 
OP O 
matrices O 
have O 
been O 
loaded O 
with O 
levofloxacin B-TRIVIAL 
to O 
compare O 
them O 
as O 
drug O 
delivery O 
systems O 
. O 
Both O 
IP O 
and O 
OP O 
matrices O 
exhibit O 
similar O 
in O 
vitro O 
levofloxacin B-TRIVIAL 
release O 
profiles O 
, O 
showing O 
an O 
initial O 
fast O 
delivery O 
followed O 
by O 
a O 
sustained O 
release O 
during O 
long O 
time O 
periods O 
. O 
These O 
profiles O 
and O 
the O 
antimicrobial O 
activity O 
results O 
suggest O 
the O 
use O 
of O 
these O 
IP O 
and O 
OP O 
matrices O 
as O 
local O 
drug O 
delivery O 
systems O 
in O 
the O 
osteomyelitis O 
and O 
other O 
bone O 
infection O 
treatments O 
. O 

transcription O 
factor O 
interferon O 
regulatory O 
factor O 
5 O 
( O 
IRF5 O 
) O 
exerts O 
crucial O 
functions O 
in O 
the O 
regulation O 
of O 
host O 
immunity O 
against O 
extracellular O 
pathogens O 
, O 
DNA O 
damage O 
- O 
induced O 
apoptosis O 
, O 
death O 
receptor O 
signaling O 
, O 
and O 
macrophage O 
polarization O 
. O 
Tight O 
regulation O 
of O 
IRF5 O 
is O 
thus O 
warranted O 
for O 
an O 
efficient O 
response O 
toward O 
extracellular O 
stressors O 
and O 
for O 
limiting O 
autoimmune O 
and O 
inflammatory O 
responses O 
. O 
Here O 
we O 
report O 
that O 
the O 
COP9 O 
signalosome O 
( O 
CSN O 
) O 
, O 
a O 
general O 
modulator O 
of O 
diverse O 
cellular O 
and O 
developmental O 
processes O 
, O 
associates O 
constitutively O 
with O 
IRF5 O 
and O 
promotes O 
its O 
protein O 
stability O 
. O 
The O 
constitutive O 
CSN O 
/ O 
IRF5 O 
interaction O 
was O 
identified O 
using O 
proteomics O 
and O 
confirmed O 
by O 
endogenous O 
immunoprecipitations O 
. O 
The O 
CSN O 
/ O 
IRF5 O 
interaction O 
occurred O 
on O 
the O 
carboxyl B-SYSTEMATIC 
and O 
amino B-FAMILY 
termini O 
of O 
IRF5 O 
; O 
a O 
single O 
internal O 
deletion O 
from O 
amino B-FAMILY 
acids I-FAMILY 
455 O 
to O 
466 O 
( O 
Δ455-466 O 
) O 
was O 
found O 
to O 
significantly O 
reduce O 
IRF5 O 
protein O 
stability O 
. O 
CSN O 
subunit O 
3 O 
( O 
CSN3 O 
) O 
was O 
identified O 
as O 
a O 
direct O 
interacting O 
partner O 
of O 
IRF5 O 
, O 
and O 
knockdown O 
of O 
this O 
subunit O 
with O 
small O 
interfering O 
RNAs O 
resulted O 
in O 
enhanced O 
degradation O 
. O 
Degradation O 
was O 
further O 
augmented O 
by O 
knockdown O 
of O 
CSN1 O 
and O 
CSN3 O 
together O 
. O 
The O 
ubiquitin O 
E1 O 
inhibitor O 
UBEI-41 O 
or O 
the O 
proteasome O 
inhibitor O 
MG132 O 
prevented O 
IRF5 O 
degradation O 
, O 
supporting O 
the O 
idea O 
that O 
its O 
stability O 
is O 
regulated O 
by O 
the O 
ubiquitin O 
- O 
proteasome O 
system O 
. O 
Importantly O 
, O 
activation O 
of O 
IRF5 O 
by O 
the O 
death O 
receptor O 
ligand O 
tumor O 
necrosis O 
factor O 
- O 
related O 
apoptosis O 
- O 
inducing O 
ligand O 
( O 
TRAIL O 
) O 
resulted O 
in O 
enhanced O 
degradation O 
via O 
loss O 
of O 
the O 
CSN O 
/ O 
IRF5 O 
interaction O 
. O 
This O 
study O 
defines O 
CSN O 
to O 
be O 
a O 
new O 
interacting O 
partner O 
of O 
IRF5 O 
that O 
controls O 
its O 
stability O 
. O 

overexpression O 
of O 
the O 
Notch1 O 
intracellular O 
domain O 
inhibits O 
osteoblast O 
differentiation O 
and O 
causes O 
osteopenia O 
, O 
and O 
inactivation O 
of O 
Notch1 O 
and O 
Notch2 O 
increases O 
bone O 
volume O 
transiently O 
and O 
induces O 
osteoblastic O 
differentiation O 
. O 
However O 
, O 
the O 
biology O 
of O 
Notch O 
is O 
cell O 
- O 
context O 
- O 
dependent O 
, O 
and O 
consequences O 
of O 
Notch O 
activation O 
in O 
cells O 
of O 
the O 
osteoblastic O 
lineage O 
at O 
various O 
stages O 
of O 
differentiation O 
and O 
in O 
osteocytes O 
have O 
not O 
been O 
defined O 
. O 
For O 
this O 
purpose O 
, O 
Rosa(Notch) O 
mice O 
, O 
where O 
a O 
loxP-flanked O 
STOP O 
cassette O 
placed O 
between O 
the O 
Rosa26 O 
promoter O 
and O 
the O 
NICD O 
coding O 
sequence O 
, O 
were O 
crossed O 
with O 
transgenics O 
expressing O 
the O 
Cre O 
recombinase O 
under O 
the O 
control O 
of O 
the O 
Osterix O 
( O 
Osx O 
) O 
, O 
Osteocalcin O 
( O 
Oc O 
) O 
, O 
Collagen O 
1a1 O 
( O 
Col2.3 O 
) O 
, O 
or O 
Dentin O 
matrix O 
protein1 O 
( O 
Dmp1 O 
) O 
promoters O 
. O 
At O 
1 O 
month O 
, O 
Osx-Cre;Rosa(Notch) O 
and O 
Oc-Cre;Rosa(Notch) O 
mice O 
exhibited O 
osteopenia O 
due O 
to O 
impaired O 
bone O 
formation O 
. O 
In O 
contrast O 
, O 
Col2.3-Cre;Rosa(Notch) O 
and O 
Dmp1-Cre;Rosa(Notch) O 
exhibited O 
increased O 
femoral O 
trabecular O 
bone O 
volume O 
due O 
to O 
a O 
decrease O 
in O 
osteoclast O 
number O 
and O 
eroded O 
surface O 
. O 
In O 
the O 
four O 
lines O 
studied O 
, O 
cortical O 
bone O 
was O 
either O 
not O 
present O 
, O 
was O 
porous O 
, O 
or O 
had O 
the O 
appearance O 
of O 
trabecular O 
bone O 
. O 
Oc-Cre;Rosa(Notch) O 
and O 
Col2.3-Cre;Rosa(Notch) O 
mice O 
exhibited O 
early O 
lethality O 
so O 
that O 
their O 
adult O 
phenotype O 
was O 
not O 
established O 
. O 
At O 
3 O 
months O 
, O 
Osx-Cre;Rosa(Notch) O 
and O 
Dmp1-Cre;Rosa(Notch) O 
mice O 
displayed O 
increased O 
bone O 
volume O 
, O 
and O 
increased O 
osteoblasts O 
although O 
calcein B-TRIVIAL 
-demeclocycline O 
labels O 
were O 
diffuse O 
and O 
fragmented O 
, O 
indicating O 
abnormal O 
bone O 
formation O 
. O 
In O 
conclusion O 
, O 
Notch O 
effects O 
in O 
the O 
skeleton O 
are O 
cell O 
- O 
context O 
- O 
dependent O 
. O 
When O 
expressed O 
in O 
immature O 
osteoblasts O 
, O 
Notch O 
arrests O 
their O 
differentiation O 
, O 
causing O 
osteopenia O 
, O 
and O 
when O 
expressed O 
in O 
osteocytes O 
, O 
it O 
causes O 
an O 
initial O 
suppression O 
of O 
bone O 
resorption O 
and O 
increased O 
bone O 
volume O 
, O 
a O 
phenotype O 
that O 
evolves O 
as O 
the O 
mice O 
mature O 
. O 

RNA O 
encoded O 
signals O 
that O 
are O 
involved O 
in O 
programmed O 
-1 O 
ribosomal O 
frameshifting O 
( O 
-1 O 
PRF O 
) O 
are O 
typically O 
two O 
- O 
stemmed O 
hairpin O 
(H)- O 
type O 
pseudoknots O 
( O 
pks O 
) O 
. O 
We O 
previously O 
described O 
an O 
unusual O 
three O 
- O 
stemmed O 
pseudoknot O 
from O 
the O 
severe O 
acute O 
respiratory O 
syndrome O 
( O 
SARS O 
) O 
coronavirus O 
( O 
CoV O 
) O 
that O 
stimulated O 
-1 O 
PRF O 
. O 
The O 
conserved O 
existence O 
of O 
a O 
third O 
stem O 
- O 
loop O 
suggested O 
an O 
important O 
hitherto O 
unknown O 
function O 
. O 
Here O 
we O 
present O 
new O 
information O 
describing O 
structure O 
and O 
function O 
of O 
the O 
third O 
stem O 
of O 
the O 
SARS O 
pseudoknot O 
. O 
We O 
uncovered O 
RNA O 
dimerization O 
through O 
a O 
palindromic O 
sequence O 
embedded O 
in O 
the O 
SARS-CoV O 
Stem O 
3 O 
. O 
Further O 
in O 
vitro O 
analysis O 
revealed O 
that O 
SARS-CoV O 
RNA O 
dimers O 
assemble O 
through O 
' O 
kissing O 
' O 
loop O 
- O 
loop O 
interactions O 
. O 
We O 
also O 
show O 
that O 
loop O 
- O 
loop O 
kissing O 
complex O 
formation O 
becomes O 
more O 
efficient O 
at O 
physiological O 
temperature O 
and O 
in O 
the O 
presence O 
of O 
magnesium B-SYSTEMATIC 
. O 
When O 
the O 
palindromic O 
sequence O 
was O 
mutated O 
, O 
in O 
vitro O 
RNA O 
dimerization O 
was O 
abolished O 
, O 
and O 
frameshifting O 
was O 
reduced O 
from O 
15 O 
to O 
5.7% O 
. O 
Furthermore O 
, O 
the O 
inability O 
to O 
dimerize O 
caused O 
by O 
the O 
silent O 
codon O 
change O 
in O 
Stem O 
3 O 
of O 
SARS-CoV O 
changed O 
the O 
viral O 
growth O 
kinetics O 
and O 
affected O 
the O 
levels O 
of O 
genomic O 
and O 
subgenomic O 
RNA O 
in O 
infected O 
cells O 
. O 
These O 
results O 
suggest O 
that O 
the O 
homodimeric O 
RNA O 
complex O 
formed O 
by O 
the O 
SARS O 
pseudoknot O 
occurs O 
in O 
the O 
cellular O 
environment O 
and O 
that O 
loop O 
- O 
loop O 
kissing O 
interactions O 
involving O 
Stem O 
3 O 
modulate O 
-1 O 
PRF O 
and O 
play O 
a O 
role O 
in O 
subgenomic O 
and O 
full O 
- O 
length O 
RNA O 
synthesis O 
. O 

of O 
recent O 
literature O 
related O 
to O 
the O 
biologically O 
active O 
4(3H)-quinazolinones B-FAMILY 
containing O 
fused O 
heterocycles O 
. O 

present O 
review O 
focuses O 
on O 
the O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
polycyclic B-FAMILY 
4(3H)-quinazolinones I-FAMILY 
containing O 
fused O 
aromatic O 
or O 
heteroaromatic O 
rings O 
. O 
The O 
first O 
part O 
of O 
the O 
review O 
is O 
related O 
to O 
compounds O 
with O 
ring O 
fused O 
to O 
the O 
pyrimidine B-SYSTEMATIC 
part O 
of O 
the O 
quinazoline B-SYSTEMATIC 
core O 
. O 
Most O 
of O 
the O 
quinazolinone B-FAMILY 
alkaloids I-FAMILY 
belong O 
to O 
this O 
class O 
of O 
molecules O 
. O 
The O 
second O 
part O 
presents O 
molecules O 
bearing O 
extra O 
ring(s) O 
fused O 
to O 
the O 
benzo B-SYSTEMATIC 
moiety O 
of O 
the O 
quinazolinone B-SYSTEMATIC 
skeleton O 
. O 
Their O 
structural O 
diversity O 
opens O 
new O 
fields O 
in O 
the O 
search O 
of O 
active O 
molecules O 
. O 

of O 
amino B-FAMILY 
groups O 
on O 
substrate O 
surfaces O 
by O 
simple O 
dip O 
- O 
coating O 
of O 
methacrylate B-TRIVIAL 
-based O 
polymers O 
and O 
its O 
application O 
to O 
DNA O 
immobilization O 
. O 

implementation O 
of O 
a O 
reactive O 
functional O 
group O 
onto O 
a O 
material O 
surface O 
is O 
of O 
great O 
importance O 
. O 
Reactive O 
functional O 
groups O 
( O 
e.g O 
. O 
, O 
an O 
amino B-FAMILY 
group O 
and O 
a O 
hydroxyl B-SYSTEMATIC 
group O 
) O 
are O 
usually O 
hydrophilic O 
, O 
which O 
makes O 
it O 
difficult O 
to O 
display O 
them O 
on O 
a O 
dry O 
polymer O 
surface O 
. O 
We O 
here O 
propose O 
a O 
novel O 
method O 
for O 
displaying O 
amino B-FAMILY 
groups O 
on O 
the O 
surfaces O 
of O 
polymeric O 
substrates O 
through O 
dip O 
- O 
coating O 
of O 
a O 
methacrylate B-TRIVIAL 
-based O 
copolymer O 
. O 
We O 
synthesized O 
copolymers O 
composed O 
of O 
methyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
and O 
2-aminoethyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
with O 
different O 
protecting O 
groups O 
or O 
ion O 
- O 
complexes O 
on O 
their O 
amino B-FAMILY 
groups O 
, O 
then O 
dip O 
- O 
coated O 
the O 
copolymers O 
onto O 
a O 
poly(methyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PMMA B-ABBREVIATION 
) O 
substrate O 
. O 
Evaluation O 
using O 
a O 
cleavable O 
fluorescent O 
compound O 
, O 
which O 
was O 
synthesized O 
in O 
the O 
present O 
study O 
to O 
quantify O 
a O 
small O 
amount O 
( O 
pmol O 
/ O 
cm(2) O 
) O 
of O 
amino B-FAMILY 
groups O 
on O 
a O 
solid O 
surface O 
, O 
revealed O 
that O 
the O 
protection O 
of O 
amino B-FAMILY 
groups O 
affected O 
their O 
surface O 
segregation O 
in O 
the O 
copolymer O 
coating O 
. O 
p-Toluenesulfonate B-SYSTEMATIC 
ion O 
- O 
complex O 
and O 
tert-butoxycarbonyl B-SYSTEMATIC 
( O 
Boc B-ABBREVIATION 
) O 
protection O 
of O 
amino B-FAMILY 
groups O 
were O 
found O 
to O 
effectively O 
display O 
amino B-FAMILY 
groups O 
on O 
the O 
surface O 
( O 
more O 
than O 
70 O 
pmol O 
/ O 
cm(2) O 
) O 
. O 
The O 
density O 
of O 
amino B-FAMILY 
groups O 
displayed O 
on O 
a O 
surface O 
can O 
be O 
easily O 
controlled O 
by O 
mixing O 
the O 
copolymer O 
and O 
PMMA B-ABBREVIATION 
before O 
dip O 
- O 
coating O 
. O 
Dip O 
- O 
coating O 
of O 
the O 
copolymer O 
with O 
Boc B-ABBREVIATION 
protection O 
on O 
various O 
polymeric O 
substrates O 
also O 
successfully O 
displayed O 
amino B-FAMILY 
groups O 
on O 
their O 
surfaces O 
. O 
Finally O 
, O 
we O 
demonstrated O 
that O 
the O 
amino B-FAMILY 
groups O 
displayed O 
can O 
be O 
utilized O 
for O 
the O 
immobilization O 
of O 
a O 
DNA O 
oligonucleotide O 
on O 
a O 
substrate O 
surface O 
. O 

of O 
the O 
reaction O 
of O 
crystal B-TRIVIAL 
violet I-TRIVIAL 
with O 
hydroxide B-SYSTEMATIC 
ion O 
in O 
the O 
critical O 
solution O 
of O 
2-butoxyethanol B-SYSTEMATIC 
+ O 
water O 
. O 

kinetics O 
of O 
alkaline O 
fading O 
of O 
crystal B-TRIVIAL 
violet I-TRIVIAL 
( O 
CV O 
) O 
has O 
been O 
studied O 
by O 
UV O 
spectrophotometry O 
and O 
microcalorimetry O 
in O 
the O 
critical O 
binary O 
solution O 
of O 
2-butoxyethanol B-SYSTEMATIC 
+ O 
water O 
at O 
the O 
initial O 
reaction O 
stage O 
and O 
various O 
temperatures O 
. O 
It O 
was O 
found O 
that O 
the O 
first O 
- O 
order O 
rate O 
constants O 
obtained O 
from O 
these O 
two O 
methods O 
are O 
well O 
accorded O 
with O 
each O 
other O 
, O 
and O 
the O 
temperature O 
dependence O 
of O 
the O 
rate O 
constant O 
obeyed O 
the O 
Arrhenius O 
equation O 
in O 
a O 
temperature O 
region O 
far O 
from O 
the O 
critical O 
point O 
. O 
The O 
critical O 
slowing O 
down O 
was O 
detected O 
by O 
both O 
methods O 
near O 
the O 
critical O 
point O 
. O 
A O 
simple O 
empirical O 
crossover O 
model O 
was O 
proposed O 
and O 
used O 
to O 
analyze O 
the O 
experimental O 
data O 
to O 
obtain O 
the O 
critical O 
exponents O 
, O 
which O 
were O 
0.158 O 
± O 
0.013 O 
and O 
0.133 O 
± O 
0.012 O 
from O 
UV O 
spectrophotometry O 
and O 
microcalorimetry O 
, O 
respectively O 
, O 
and O 
the O 
former O 
was O 
in O 
good O 
agreement O 
with O 
the O 
theoretical O 
prediction O 
of O 
0.151 O 
. O 
The O 
slight O 
lower O 
value O 
derived O 
from O 
microcalorimetry O 
was O 
attributed O 
to O 
the O 
stirring O 
in O 
the O 
microcalorimeter O 
, O 
which O 
weakened O 
the O 
critical O 
reduction O 
of O 
the O 
diffusion O 
coefficient O 
. O 

( O 
progesterone O 
receptor O 
membrane O 
component O 
2 O 
) O 
is O 
highly O 
homologous O 
if O 
compared O 
with O 
PGRMC1 O 
, O 
a O 
cytochrome O 
- O 
related O 
protein O 
, O 
which O 
is O 
induced O 
in O 
several O 
cancers O 
and O 
linked O 
to O 
cell O 
growth O 
in O 
these O 
cancers O 
. O 
Further O 
it O 
seems O 
to O 
be O 
involved O 
in O 
progesterone B-TRIVIAL 
signalling O 
and O 
cytochrome O 
P450 O 
binding O 
. O 
For O 
PGRMC2 O 
only O 
sparse O 
information O 
is O 
available O 
. O 
Recent O 
data O 
show O 
that O 
PGRMC1 O 
and O 
2 O 
share O 
several O 
similar O 
characteristics O 
, O 
but O 
there O 
are O 
also O 
important O 
differences O 
in O 
expression O 
and O 
function O 
of O 
the O 
both O 
proteins O 
. O 
Several O 
findings O 
point O 
to O 
the O 
fact O 
that O 
PGRMC2 O 
might O 
play O 
a O 
role O 
in O 
cancer O 
as O 
well O 
. O 
The O 
protein O 
influences O 
the O 
migration O 
rate O 
of O 
ovarian O 
cancer O 
cells O 
and O 
a O 
loss O 
of O 
PGRMC2 O 
might O 
result O 
in O 
higher O 
metastasis O 
rates O 
. O 
In O 
contrast O 
to O 
PGRMC1 O 
it O 
seems O 
more O 
likely O 
to O 
act O 
as O 
a O 
tumor O 
suppressor O 
than O 
a O 
promoter O 
. O 
Altered O 
PGRMC2 O 
expression O 
was O 
further O 
detected O 
in O 
the O 
context O 
of O 
term O 
and O 
preterm O 
labour O 
, O 
though O 
the O 
implications O 
of O 
this O 
finding O 
are O 
currently O 
unknown O 
and O 
need O 
further O 
examination O 
. O 
PGRMC2 O 
further O 
might O 
play O 
a O 
role O 
in O 
gynaecologic O 
diseases O 
like O 
preterm O 
labour O 
and O 
endometriosis O 
. O 
PGRMC2 O 
shares O 
the O 
cellular O 
localisation O 
and O 
the O 
ability O 
to O 
bind O 
cytochrome O 
enzymes O 
with O 
PGRMC1 O 
. O 
Further O 
the O 
protein O 
was O 
shown O 
to O 
influence O 
the O 
activity O 
of O 
CYP3A4 O 
. O 
In O 
conclusion O 
, O 
though O 
not O 
much O 
is O 
known O 
about O 
PGRMC2 O 
so O 
far O 
, O 
it O 
deserves O 
further O 
examination O 
as O 
data O 
point O 
to O 
a O 
role O 
of O 
PGRMC2 O 
as O 
tumor O 
suppressor O 
, O 
migration O 
inhibitor O 
and O 
regulator O 
of O 
cytochrome O 
P450 O 
proteins O 
. O 

- O 
mediated O 
P-glycoprotein O 
induction O 
by O 
small O 
molecule O 
tyrosine B-TRIVIAL 
kinase O 
inhibitors O 
. O 

rapid O 
development O 
of O 
drug O 
resistance O 
as O 
a O 
result O 
of O 
exposure O 
to O 
small O 
molecule O 
tyrosine B-TRIVIAL 
kinase O 
inhibitors O 
( O 
TKIs O 
) O 
is O 
an O 
important O 
drawback O 
to O 
the O 
successful O 
use O 
of O 
these O 
agents O 
in O 
the O 
clinic O 
. O 
Although O 
one O 
of O 
the O 
most O 
established O 
mechanisms O 
by O 
which O 
cells O 
acquire O 
drug O 
resistance O 
to O 
anticancer O 
drugs O 
is O 
the O 
up O 
regulation O 
of O 
drug O 
efflux O 
transporters O 
such O 
as O 
P-glycoprotein O 
( O 
PGP O 
) O 
, O 
it O 
is O 
currently O 
still O 
unknown O 
whether O 
TKIs O 
have O 
the O 
propensity O 
to O 
induce O 
PGP O 
. O 
The O 
effect O 
of O 
TKIs O 
on O 
the O 
protein O 
expression O 
and O 
activity O 
of O 
PGP O 
was O 
assessed O 
after O 
treatment O 
of O 
LS180 O 
cells O 
with O 
clinically O 
relevant O 
concentrations O 
of O 
the O 
TKIs O 
. O 
In O 
addition O 
, O 
the O 
involvement O 
of O 
the O 
nuclear O 
pregnane B-TRIVIAL 
X O 
receptor O 
( O 
PXR O 
) O 
, O 
a O 
known O 
regulator O 
of O 
PGP O 
expression O 
, O 
was O 
determined O 
. O 
At O 
least O 
five O 
out O 
of O 
the O 
nine O 
tested O 
TKIs O 
( O 
erlotinib B-TRIVIAL 
, O 
gefitinib B-TRIVIAL 
, O 
nilotinib B-TRIVIAL 
, O 
sorafenib B-TRIVIAL 
, O 
vandetanib B-TRIVIAL 
) O 
were O 
able O 
to O 
induce O 
the O 
expression O 
of O 
PGP O 
within O 
48 O 
h O 
in O 
LS180 O 
cells O 
. O 
Accordingly O 
, O 
these O 
TKIs O 
were O 
also O 
shown O 
to O 
affect O 
the O 
accumulation O 
of O 
a O 
P-glycoprotein O 
specific O 
probe O 
substrate O 
. O 
Furthermore O 
, O 
we O 
showed O 
that O 
the O 
pregnane B-TRIVIAL 
X O 
receptor O 
( O 
PXR O 
) O 
, O 
which O 
is O 
an O 
important O 
regulator O 
of O 
PGP O 
induction O 
, O 
is O 
involved O 
in O 
the O 
upregulation O 
of O 
PGP O 
protein O 
expression O 
following O 
exposure O 
to O 
these O 
TKIs O 
. O 
Our O 
data O 
show O 
that O 
PXR O 
- O 
mediated O 
upregulation O 
of O 
PGP O 
expression O 
by O 
TKIs O 
might O 
be O 
a O 
possible O 
mechanism O 
underlying O 
acquired O 
drug O 
resistance O 
in O 
cancer O 
cells O 
. O 

of O 
a O 
dry O 
, O 
stable O 
and O 
inhalable O 
acyl-homoserine B-FAMILY 
- I-FAMILY 
lactone I-FAMILY 
-acylase O 
powder O 
formulation O 
for O 
the O 
treatment O 
of O 
pulmonary O 
Pseudomonas O 
aeruginosa O 
infections O 
. O 

the O 
lungs O 
of O 
cystic O 
fibrosis O 
( O 
CF O 
) O 
patients O 
, O 
Pseudomonas O 
aeruginosa O 
commonly O 
causes O 
chronic O 
infections O 
. O 
It O 
has O 
been O 
shown O 
that O 
the O 
P O 
. O 
aeruginosa O 
quorum O 
sensing O 
( O 
QS O 
) O 
system O 
controls O 
the O 
expression O 
of O 
virulence O 
factors O 
during O 
invasion O 
and O 
infection O 
to O 
host O 
cells O 
. O 
PvdQ O 
is O 
an O 
acyl-homoserine B-FAMILY 
lactone I-FAMILY 
( O 
AHL B-ABBREVIATION 
) O 
acylase O 
able O 
to O 
degrade O 
the O 
signal O 
molecule O 
of O 
P O 
. O 
aeruginosa O 
QS O 
. O 
The O 
role O 
of O 
PvdQ O 
in O 
inhibiting O 
the O 
QS O 
and O 
its O 
successive O 
virulence O 
determinants O 
has O 
been O 
established O 
in O 
in O 
vitro O 
as O 
well O 
as O 
in O 
in O 
vivo O 
, O 
the O 
latter O 
in O 
a O 
Caenorabdhitis O 
elegans O 
model O 
. O 
For O 
the O 
treatment O 
of O 
pulmonary O 
P O 
. O 
aeruginosa O 
infections O 
, O 
we O 
propose O 
that O 
PvdQ O 
can O 
be O 
best O 
administered O 
directly O 
to O 
the O 
lungs O 
of O 
the O 
patients O 
as O 
a O 
dry O 
powder O 
because O 
this O 
is O 
expected O 
to O 
give O 
specific O 
advantages O 
in O 
delivery O 
as O 
compared O 
to O 
nebulizing O 
. O 
Therefore O 
in O 
this O 
study O 
we O 
investigated O 
the O 
production O 
of O 
a O 
PvdQ O 
powder O 
by O 
spray O 
- O 
freeze O 
drying O 
using O 
mannitol B-TRIVIAL 
, O 
trehalose B-TRIVIAL 
and O 
inulin O 
as O 
excipient O 
. O 
The O 
activity O 
of O 
PvdQ O 
in O 
the O 
powder O 
was O 
determined O 
immediately O 
after O 
production O 
and O 
after O 
subsequent O 
storage O 
during O 
4 O 
weeks O 
at O 
20°C O 
and O 
55°C O 
. O 
We O 
found O 
that O 
the O 
enzymatic O 
activity O 
of O 
PvdQ O 
is O 
fully O 
maintained O 
during O 
spray O 
- O 
freeze O 
drying O 
using O 
mannitol B-TRIVIAL 
, O 
trehalose B-TRIVIAL 
or O 
inulin O 
as O 
excipient O 
. O 
However O 
, O 
mannitol B-TRIVIAL 
was O 
not O 
able O 
to O 
stabilize O 
the O 
protein O 
during O 
storage O 
, O 
while O 
PvdQ O 
incorporated O 
in O 
trehalose B-TRIVIAL 
or O 
inulin O 
was O 
fully O 
stabilized O 
even O 
during O 
storage O 
at O 
55°C O 
for O 
at O 
least O 
4 O 
weeks O 
. O 
The O 
poor O 
stabilizing O 
capacities O 
of O 
mannitol B-TRIVIAL 
during O 
storage O 
could O 
be O 
related O 
to O 
its O 
crystalline O 
nature O 
while O 
the O 
excellent O 
stabilizing O 
capacities O 
of O 
trehalose B-TRIVIAL 
and O 
inulin O 
during O 
storage O 
could O 
be O 
related O 
to O 
their O 
amorphous O 
nature O 
. O 
The O 
trehalose B-TRIVIAL 
and O 
inulin O 
- O 
based O 
particles O 
consisted O 
of O 
porous O 
spheres O 
with O 
a O 
volume O 
average O 
aerodynamical O 
diameter O 
of O 
∼1.8 O 
μm O 
implying O 
that O 
they O 
are O 
suitable O 
for O 
pulmonary O 
delivery O 
. O 
This O 
is O 
the O 
first O 
study O 
in O 
which O 
an O 
AHL B-ABBREVIATION 
-degrading O 
enzyme O 
is O 
processed O 
into O 
spray O 
- O 
freeze O 
- O 
dried O 
powder O 
suitable O 
for O 
inhalation O 
. O 

-modified O 
elongation O 
factor O 
P O 
functions O 
in O 
translation O 
elongation O 
. O 

- O 
translational O 
modification O 
of O 
bacterial O 
elongation O 
factor O 
P O 
( O 
EF-P O 
) O 
with O 
(R)-β-lysine B-TRIVIAL 
at O 
a O 
conserved O 
lysine O 
residue O 
activates O 
the O 
protein O 
in O 
vivo O 
and O 
increases O 
puromycin O 
reactivity O 
of O 
the O 
ribosome O 
in O 
vitro O 
. O 
The O 
additional O 
hydroxylation O 
of O 
EF-P O 
at O 
the O 
same O 
lysine B-TRIVIAL 
residue O 
by O 
the O 
YfcM O 
protein O 
has O 
also O 
recently O 
been O 
described O 
. O 
The O 
roles O 
of O 
modified O 
and O 
unmodified O 
EF-P O 
during O 
different O 
steps O 
in O 
translation O 
, O 
and O 
how O 
this O 
correlates O 
to O 
its O 
physiological O 
role O 
in O 
the O 
cell O 
, O 
have O 
recently O 
been O 
linked O 
to O 
the O 
synthesis O 
of O 
polyproline B-FAMILY 
stretches O 
in O 
proteins O 
. O 
Polysome O 
analysis O 
indicated O 
that O 
EF-P O 
functions O 
in O 
translation O 
elongation O 
, O 
rather O 
than O 
initiation O 
as O 
proposed O 
previously O 
. O 
This O 
was O 
further O 
supported O 
by O 
the O 
inability O 
of O 
EF-P O 
to O 
enhance O 
the O 
rate O 
of O 
formation O 
of O 
fMet-Lys B-FORMULA 
or O 
fMet-Phe B-FORMULA 
, O 
indicating O 
that O 
the O 
role O 
of O 
EF-P O 
is O 
not O 
to O 
specifically O 
stimulate O 
formation O 
of O 
the O 
first O 
peptide O 
bond O 
. O 
Investigation O 
of O 
hydroxyl-(β)-lysyl B-SYSTEMATIC 
-EF-P O 
showed O 
30% O 
increased O 
puromycin B-TRIVIAL 
reactivity O 
but O 
no O 
differences O 
in O 
dipeptide O 
synthesis O 
rates O 
when O 
compared O 
with O 
the O 
β-lysylated O 
form O 
. O 
Unlike O 
disruption O 
of O 
the O 
other O 
genes O 
required O 
for O 
EF-P O 
modification O 
, O 
deletion O 
of O 
yfcM O 
had O 
no O 
phenotypic O 
consequences O 
in O 
Salmonella O 
. O 
Taken O 
together O 
, O 
our O 
findings O 
indicate O 
that O 
EF-P O 
functions O 
in O 
translation O 
elongation O 
, O 
a O 
role O 
critically O 
dependent O 
on O 
post O 
- O 
translational O 
β-lysylation O 
but O 
not O 
hydroxylation O 
. O 

of O 
toluene B-TRIVIAL 
exposure O 
in O 
rats O 
: O 
mercapturic B-FAMILY 
acids I-FAMILY 
versus O 
traditional O 
indicators O 
( O 
urinary O 
hippuric B-TRIVIAL 
acid I-TRIVIAL 
and O 
o-cresol B-TRIVIAL 
and O 
blood O 
toluene B-TRIVIAL 
) O 
. O 

1 O 
. O 
Toluene B-TRIVIAL 
( O 
TOL B-ABBREVIATION 
) O 
is O 
a O 
neurotoxic O 
, O 
ototoxic O 
and O 
reprotoxic O 
solvent O 
which O 
is O 
metabolized O 
via O 
the O 
glutathione B-TRIVIAL 
pathway O 
, O 
producing O 
benzylmercapturic B-MULTIPLE 
, I-MULTIPLE 
o- I-MULTIPLE 
, I-MULTIPLE 
m- I-MULTIPLE 
and I-MULTIPLE 
p-toluylmercapturic I-MULTIPLE 
acids I-MULTIPLE 
( O 
MAs B-MULTIPLE 
) O 
. O 
These O 
metabolites O 
could O 
be O 
useful O 
as O 
biomarkers O 
of O 
TOL B-ABBREVIATION 
exposure O 
. O 
2 O 
. O 
The O 
aims O 
of O 
this O 
study O 
were O 
( O 
1 O 
) O 
to O 
provide O 
data O 
on O 
MAs B-FAMILY 
excretion O 
in O 
rat O 
urine O 
following O 
TOL B-ABBREVIATION 
exposure O 
by O 
inhalation O 
, O 
( O 
2 O 
) O 
to O 
compare O 
them O 
to O 
data O 
from O 
traditional O 
TOL B-ABBREVIATION 
biomarkers O 
, O 
i.e O 
. O 
TOL B-ABBREVIATION 
in O 
blood O 
( O 
Tol B-ABBREVIATION 
-B O 
) O 
, O 
and O 
urinary O 
hippuric B-TRIVIAL 
acid I-TRIVIAL 
( O 
HA O 
) O 
and O 
o-cresol B-TRIVIAL 
( O 
oCre B-ABBREVIATION 
) O 
and O 
( O 
3 O 
) O 
to O 
establish O 
a O 
relationship O 
between O 
these O 
different O 
indicators O 
and O 
the O 
airborne O 
TOL B-ABBREVIATION 
concentration O 
( O 
Tol B-ABBREVIATION 
-A O 
) O 
. O 
3 O 
. O 
Sprague-Dawley O 
rats O 
were O 
exposed O 
to O 
a O 
range O 
of O 
TOL B-ABBREVIATION 
concentrations O 
. O 
Blood O 
and O 
urine O 
were O 
collected O 
and O 
analyzed O 
to O 
determine O 
biomarker O 
levels O 
. O 
4 O 
. O 
Levels O 
of O 
the O 
four O 
MAs B-FAMILY 
correlate O 
strongly O 
with O 
Tol B-ABBREVIATION 
-A O 
( O 
comparable O 
to O 
the O 
correlation O 
with O 
Tol B-ABBREVIATION 
-B O 
) O 
. O 
5 O 
. O 
MAs B-FAMILY 
are O 
thus O 
clearly O 
superior O 
to O 
oCre B-ABBREVIATION 
and O 
HA O 
as O 
potential O 
markers O 
of O 
exposure O 
to O 
TOL B-ABBREVIATION 
. O 

of O 
estrogen B-FAMILY 
receptor O 
- O 
positive O 
breast O 
cancer O 
. O 

receptor O 
( O 
ER O 
) O 
expression O 
is O 
the O 
main O 
indicator O 
of O 
potential O 
responses O 
to O 
endocrine O 
therapy O 
( O 
ET O 
) O 
, O 
and O 
approximately O 
70% O 
of O 
human O 
breast O 
cancers O 
( O 
BCs O 
) O 
are O 
hormone O 
- O 
dependent O 
and O 
ER-positive O 
. O 
The O 
introduction O 
of O 
adjuvant O 
systemic O 
therapy O 
led O 
to O 
a O 
significant O 
improvement O 
in O 
post O 
- O 
surgical O 
survival O 
and O 
a O 
reduction O 
in O 
disease O 
relapse O 
, O 
especially O 
in O 
women O 
with O 
early O 
BC O 
and O 
those O 
with O 
ER+ O 
tumors O 
, O 
who O 
may O 
receive O 
ET O 
alone O 
or O 
in O 
combination O 
with O 
cytotoxic O 
therapy O 
. O 
Adjuvant O 
ET O 
currently O 
consists O 
of O 
(i) O 
ovarian O 
suppression O 
, O 
(ii) O 
selective O 
estrogen B-FAMILY 
receptor O 
modulators O 
( O 
SERMs O 
) O 
and O 
down O 
- O 
regulators O 
, O 
and O 
(iii) O 
aromatase O 
inhibitors O 
( O 
AIs O 
) O 
. O 
In O 
patients O 
with O 
ER+ O 
tumors O 
pharmacologic O 
ovary O 
suppression O 
with O 
gonadotropin B-TRIVIAL 
- I-TRIVIAL 
releasing I-TRIVIAL 
hormone I-TRIVIAL 
agonists O 
in O 
combination O 
with O 
standard O 
adjuvant O 
therapy O 
is O 
generally O 
more O 
effective O 
than O 
adjuvant O 
chemotherapy O 
alone O 
. O 
Tamoxifen B-TRIVIAL 
is O 
the O 
best O 
established O 
SERM O 
, O 
has O 
favorable O 
effects O 
on O 
BC O 
control O 
and O 
bone O 
metabolism O 
, O 
but O 
also O 
has O 
adverse O 
effects O 
due O 
to O 
its O 
estrogenic O 
activity O 
in O 
other O 
tissues O 
. O 
For O 
these O 
reasons O 
, O 
other O 
SERMs O 
have O 
been O 
developed O 
. O 
Fulvestrant B-TRIVIAL 
is O 
an O 
ER O 
down O 
- O 
regulator O 
with O 
several O 
potential O 
advantages O 
over O 
SERMs O 
, O 
including O 
a O 
100-fold O 
increase O 
in O 
its O 
affinity O 
for O 
ER O 
compared O 
with O 
tamoxifen B-TRIVIAL 
and O 
no O 
estrogen B-FAMILY 
-like O 
activity O 
in O 
the O 
uterus O 
. O 
The O 
inhibition O 
of O 
the O 
aromatase O 
system O 
with O 
third O 
- O 
generation O 
AIs O 
is O 
associated O 
with O 
improved O 
survival O 
in O 
patients O 
with O 
advanced O 
BC O 
compared O 
with O 
SERMs O 
. O 
In O 
postmenopausal O 
patients O 
with O 
ER+ O 
BC O 
adjuvant O 
treatment O 
with O 
AIs O 
should O 
be O 
performed O 
, O 
either O 
as O 
sequential O 
treatment O 
after O 
tamoxifen B-TRIVIAL 
or O 
as O 
upfront O 
therapy O 
. O 
Studies O 
evaluating O 
the O 
role O 
of O 
AIs O 
as O 
first O 
- O 
line O 
therapy O 
are O 
ongoing O 
and O 
the O 
results O 
are O 
encouraging O 
. O 

- O 
negative O 
breast O 
cancer O 
( O 
TNBC O 
) O 
, O 
that O 
is O 
breast O 
cancer O 
which O 
stains O 
negatively O 
at O 
immunohistochemistry O 
for O 
estrogen B-FAMILY 
receptor O 
( O 
ER O 
) O 
, O 
progesterone B-TRIVIAL 
receptor O 
( O 
PR O 
) O 
and O 
human O 
epidermal O 
growth O 
factor O 
2 O 
( O 
HER2 O 
) O 
, O 
comprises O 
a O 
particularly O 
aggressive O 
subtype O 
of O 
breast O 
cancer O 
, O 
with O 
high O 
rate O 
of O 
early O 
local O 
and O 
distant O 
relapse O 
. O 
TNBC O 
have O 
demonstrated O 
sensitivity O 
to O 
cytotoxic O 
treatment O 
regimens O 
, O 
but O 
in O 
the O 
absence O 
of O 
HER2 O 
, O 
ER O 
and O 
PR O 
there O 
is O 
no O 
benefit O 
from O 
hormonal O 
therapy O 
or O 
trastuzumab O 
. O 
The O 
lack O 
of O 
known O 
specific O 
molecular O 
targets O 
has O 
promoted O 
abundant O 
research O 
in O 
order O 
to O 
find O 
possible O 
" O 
vulnerabilities O 
" O 
in O 
TNBC O 
and O 
the O 
evaluation O 
of O 
novel O 
biomarkers O 
overcoming O 
the O 
traditional O 
approach O 
based O 
on O 
hormonal O 
receptors O 
and O 
HER2-targeted O 
therapy O 
is O 
one O 
of O 
the O 
priorities O 
in O 
breast O 
cancer O 
research O 
. O 
Drugs O 
under O 
investigation O 
can O 
be O 
broadly O 
subdivided O 
into O 
four O 
groups O 
: O 
( O 
1 O 
) O 
Agents O 
that O 
create O 
DNA O 
damage O 
( O 
i.e O 
. O 
cisplatin B-TRIVIAL 
, O 
cyclophosphamide B-TRIVIAL 
) O 
; O 
( O 
2 O 
) O 
Agents O 
that O 
inhibit O 
poly B-SYSTEMATIC 
( I-SYSTEMATIC 
ADP-ribose I-SYSTEMATIC 
) I-SYSTEMATIC 
polymerase O 
( O 
PARP O 
) O 
; O 
( O 
3 O 
) O 
Tyrosin B-TRIVIAL 
-kinase O 
inhibitors O 
and O 
monoclonal O 
antibodies O 
; O 
( O 
4 O 
) O 
Agents O 
that O 
inhibit O 
downstream O 
signals O 
. O 
Several O 
preclinical O 
and O 
early O 
phase O 
clinical O 
trials O 
for O 
the O 
treatment O 
or O 
management O 
of O 
patients O 
with O 
triple O 
- O 
negative O 
breast O 
tumors O 
are O 
underway O 
. O 
Nonetheless O 
, O 
so O 
far O 
the O 
major O 
issue O 
to O 
deal O 
with O 
when O 
trying O 
to O 
provide O 
evidence O 
for O 
TNBC O 
is O 
the O 
small O 
numbers O 
of O 
the O 
sample O 
in O 
the O 
clinical O 
studies O 
and O 
the O 
retrospective O 
nature O 
of O 
most O 
of O 
them O 
. O 
Future O 
large O 
studies O 
could O 
help O 
in O 
defining O 
optimal O 
treatment O 
strategies O 
for O 
TNBC O 
, O 
both O 
in O 
the O 
advanced O 
setting O 
as O 
well O 
as O 
in O 
the O 
( O 
neo O 
) O 
adjuvant O 
setting O 
. O 

of O 
novel O 
androgen B-FAMILY 
receptor O 
antagonists O 
using O 
structure- O 
and O 
ligand O 
- O 
based O 
methods O 
. O 

receptor O 
( O 
AR O 
) O 
plays O 
a O 
critical O 
role O 
in O 
the O 
development O 
and O 
progression O 
of O 
prostate O 
cancer O 
( O 
PCa O 
) O 
. O 
The O 
AR O 
hormone O 
- O 
binding O 
site O 
( O 
HBS O 
) O 
is O 
intensively O 
studied O 
and O 
represents O 
the O 
target O 
area O 
for O 
current O 
antiandrogens O 
including O 
Bicalutamide B-TRIVIAL 
and O 
structurally O 
related O 
Enzalutamide B-TRIVIAL 
. O 
As O 
resistance O 
to O 
antiandrogens O 
invariably O 
emerges O 
in O 
advanced O 
prostate O 
cancer O 
, O 
there O 
exists O 
a O 
high O 
medical O 
need O 
for O 
the O 
identification O 
and O 
development O 
of O 
novel O 
AR O 
antagonists O 
of O 
different O 
chemotypes O 
. O 
Given O 
the O 
wealth O 
of O 
structural O 
information O 
on O 
the O 
AR O 
in O 
complex O 
with O 
a O 
variety O 
of O 
ligands O 
, O 
we O 
have O 
applied O 
an O 
integrated O 
structure- O 
and O 
ligand O 
- O 
based O 
virtual O 
screening O 
methodology O 
to O 
identify O 
novel O 
AR O 
antagonists O 
. O 
Virtual O 
hits O 
generated O 
by O 
a O 
consensus O 
voting O 
approach O 
were O 
experimentally O 
evaluated O 
and O 
resulted O 
in O 
the O 
discovery O 
of O 
a O 
number O 
of O 
structurally O 
diverse O 
submicromolar O 
antagonists O 
of O 
the O 
AR O 
. O 
In O 
particular O 
, O 
one O 
identified O 
compound O 
demonstrated O 
anti-AR O 
potency O 
in O 
vitro O 
that O 
is O 
comparable O 
to O 
the O 
clinically O 
used O 
Bicalutamide O 
. O 
These O 
results O 
set O 
a O 
ground O 
for O 
the O 
development O 
of O 
novel O 
classes O 
of O 
PCa O 
drugs O 
that O 
are O 
structurally O 
different O 
from O 
current O 
AR O 
antagonists O 
. O 

- O 
based O 
design O 
, O 
synthesis O 
and O 
evaluation O 
of O 
novel O 
anthra[1,2-d]imidazole-6,11-dione B-SYSTEMATIC 
derivatives O 
as O 
telomerase O 
inhibitors O 
and O 
potential O 
for O 
cancer O 
polypharmacology O 
. O 

series O 
of O 
anthra[1,2-d]imidazole-6,11-dione B-SYSTEMATIC 
derivatives O 
were O 
synthesized O 
and O 
evaluated O 
for O 
telomerase O 
inhibition O 
, O 
hTERT O 
expression O 
and O 
suppression O 
of O 
cancer O 
cell O 
growth O 
in O 
vitro O 
. O 
All O 
of O 
the O 
compounds O 
tested O 
, O 
except O 
for O 
compounds O 
4 O 
, O 
7 O 
, O 
16 O 
, O 
24 O 
, O 
27 O 
and O 
28 O 
were O 
selected O 
by O 
the O 
NCI O 
screening O 
system O 
. O 
Among O 
them O 
, O 
compounds O 
16 O 
, O 
39 O 
, O 
and O 
40 O 
repressed O 
hTERT O 
expression O 
without O 
greatly O 
affecting O 
cell O 
growth O 
, O 
suggesting O 
for O 
the O 
selectivity O 
toward O 
hTERT O 
expression O 
. O 
Taken O 
together O 
, O 
our O 
findings O 
indicated O 
that O 
the O 
analysis O 
of O 
cytotoxicity O 
and O 
telomerase O 
inhibition O 
might O 
provide O 
information O 
applicable O 
for O 
further O 
developing O 
potential O 
telomerase O 
and O 
polypharmacological O 
targeting O 
strategy O 
. O 

and O 
biological O 
activity O 
against O 
Trypanosoma O 
cruzi O 
of O 
substituted O 
1,4-naphthoquinones B-FAMILY 
. O 

discovery O 
and O 
development O 
of O 
essential O 
drugs O 
for O 
Chagas O 
disease O 
is O 
a O 
major O 
concern O 
worldwide O 
. O 
New O 
substituted O 
1,4-naphthoquinones B-FAMILY 
were O 
synthesized O 
and O 
tested O 
against O 
the O 
infective O 
bloodstream O 
form O 
of O 
Trypanosoma O 
cruzi O 
, O 
the O 
etiological O 
agent O 
of O 
Chagas O 
disease O 
. O 
These O 
products O 
exhibited O 
substantial O 
activity O 
against O 
T O 
. O 
cruzi O 
, O 
especially O 
2-((8E,11Z)-heptadeca-8,11-dienyl)-3-hydroxynaphthalene-1,4-dione B-SYSTEMATIC 
( O 
9 O 
) O 
with O 
IC(50) O 
of O 
7.8 O 
μM O 
. O 

and O 
Biological O 
Evaluation O 
of O 
[1,2,4]Triazolo[3,4-a]phthalazine B-SYSTEMATIC 
and O 
Tetrazolo[5,1-a]phthalazine B-SYSTEMATIC 
Derivatives O 
Bearing O 
Substituted O 
Benzylpiperazine B-SYSTEMATIC 
Moieties O 
as O 
Positive O 
Inotropic O 
Agents O 
. O 

series O 
of O 
[1,2,4]triazolo[3,4-a]phthalazine B-SYSTEMATIC 
and O 
tetrazolo[5,1-a]phthalazine B-SYSTEMATIC 
derivatives O 
bearing O 
substituted O 
benzylpiperazine B-SYSTEMATIC 
moieties O 
have O 
been O 
synthesized O 
and O 
evaluated O 
for O 
their O 
positive O 
inotropic O 
activity O 
by O 
measuring O 
left O 
atrium O 
stroke O 
volume O 
on O 
isolated O 
rabbit O 
heart O 
preparations O 
. O 
The O 
majority O 
of O 
the O 
derivatives O 
exhibited O 
better O 
in O 
vitro O 
activity O 
than O 
the O 
existing O 
drug O 
, O 
milrinone B-TRIVIAL 
, O 
and O 
6-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)tetrazolo[5,1-a]phthalazine B-SYSTEMATIC 
. O 
8 O 
m O 
in O 
particular O 
was O 
identified O 
as O 
the O 
most O 
potent O 
with O 
an O 
increased O 
stroke O 
volume O 
of O 
12.02 O 
± O 
0.20% O 
( O 
milrinone B-TRIVIAL 
: O 
2.46 O 
± O 
0.07% O 
) O 
at O 
a O 
concentration O 
of O 
3 O 
× O 
10(-5) O 
m O 
. O 
The O 
chronotropic O 
effects O 
of O 
the O 
compounds O 
that O 
exhibited O 
good O 
potency O 
were O 
also O 
evaluated O 
. O 

effects O 
of O 
the O 
herbicide O 
terbuthylazine B-TRIVIAL 
and O 
temperature O 
on O 
different O 
flagellates O 
from O 
the O 
Northern O 
Adriatic O 
Sea O 
. O 

triazinic O 
herbicide O 
terbuthylazine B-TRIVIAL 
( O 
TBA B-ABBREVIATION 
) O 
is O 
becoming O 
an O 
emergent O 
contaminant O 
in O 
Italian O 
rivers O 
and O 
in O 
coastal O 
and O 
groundwater O 
. O 
A O 
preliminary O 
analysis O 
of O 
the O 
sensitivity O 
of O 
marine O 
flagellates O 
to O 
TBA B-ABBREVIATION 
was O 
performed O 
by O 
monitoring O 
the O 
photosynthetic O 
efficiency O 
of O 
nine O 
species O 
( O 
belonging O 
to O 
the O 
Dinophyceae O 
or O 
Raphidophyceae O 
class O 
) O 
isolated O 
from O 
the O 
Adriatic O 
Sea O 
. O 
Different O 
sensitivity O 
levels O 
for O 
each O 
flagellate O 
were O 
observed O 
and O 
the O 
most O 
sensitive O 
microalgae O 
, O 
based O 
on O 
PSII O 
inhibition O 
, O 
were O 
: O 
Gonyaulax O 
spinifera O 
> O 
Fibrocapsa O 
japonica O 
> O 
Lingulodinium O 
polyedrum O 
while O 
the O 
most O 
resistant O 
were O 
two O 
species O 
belonging O 
to O 
the O 
Prorocentrum O 
genus O 
. O 
Then O 
the O 
response O 
of O 
two O 
microalgae O 
to O 
drivers O 
, O 
such O 
as O 
temperature O 
and O 
terbuthylazine B-TRIVIAL 
, O 
applied O 
in O 
combination O 
was O 
also O 
investigated O 
. O 
Two O 
potentially O 
toxic O 
flagellates O 
, O 
Prorocentrum O 
minimum O 
and O 
G O 
. O 
spinifera O 
, O 
were O 
exposed O 
, O 
under O 
different O 
temperature O 
conditions O 
( O 
15 O 
, O 
20 O 
and O 
25°C O 
) O 
, O 
to O 
TBA B-ABBREVIATION 
concentrations O 
that O 
did O 
not O 
completely O 
affect O 
PSII O 
. O 
For O 
both O 
flagellates O 
, O 
effects O 
of O 
TBA B-ABBREVIATION 
on O 
algal O 
growth O 
, O 
measured O 
through O 
cell O 
density O 
and O 
carbon B-SYSTEMATIC 
analysis O 
, O 
as O 
well O 
as O 
on O 
the O 
photosynthetic O 
activity O 
are O 
reported O 
. O 
All O 
parameters O 
analyzed O 
showed O 
a O 
negative O 
effect O 
of O 
TBA B-ABBREVIATION 
from O 
the O 
exponential O 
phase O 
. O 
TBA B-ABBREVIATION 
effect O 
on O 
algal O 
growth O 
was O 
significantly O 
enhanced O 
at O 
the O 
optimal O 
temperature O 
conditions O 
( O 
20 O 
and O 
25°C O 
) O 
, O 
while O 
no O 
difference O 
between O 
control O 
and O 
herbicide O 
treatments O 
were O 
detected O 
for O 
G O 
. O 
spinifera O 
grown O 
at O 
15°C O 
, O 
which O 
represented O 
a O 
stress O 
condition O 
for O 
this O 
species O 
. O 
The O 
maximum O 
inhibition O 
of O 
photosynthetic O 
efficiency O 
was O 
found O 
at O 
20°C O 
for O 
both O 
organisms O 
. O 
Both O 
flagellates O 
increased O 
cell O 
carbon B-SYSTEMATIC 
and O 
nitrogen B-SYSTEMATIC 
content O 
in O 
herbicide O 
treatments O 
compared O 
to O 
the O 
control O 
, O 
except O 
G O 
. O 
spinifera O 
grown O 
at O 
15°C O 
. O 
Chlorophyll-a B-TRIVIAL 
production O 
was O 
increased O 
only O 
in O 
G O 
. O 
spinifera O 
exposed O 
to O 
5 O 
μg O 
L(-1) O 
of O 
TBA B-ABBREVIATION 
and O 
the O 
effect O 
was O 
enhanced O 
with O 
the O 
increase O 
of O 
temperature O 
. O 
Herbicide-induced O 
variations O 
in O 
cellular O 
components O 
determined O 
changes O 
in O 
cellular O 
carbon B-SYSTEMATIC 
: O 
nitrogen B-SYSTEMATIC 
( O 
C B-FORMULA 
: O 
N B-FORMULA 
) O 
and O 
chlorophyll B-FAMILY 
: O 
carbon B-SYSTEMATIC 
( O 
Chl B-ABBREVIATION 
: O 
C B-FORMULA 
) O 
ratios O 
. O 
The O 
C B-FORMULA 
: O 
N B-FORMULA 
ratio O 
decreased O 
in O 
both O 
species O 
, O 
while O 
only O 
G O 
. O 
spinifera O 
showed O 
an O 
increase O 
in O 
the O 
Chl B-ABBREVIATION 
: O 
C B-FORMULA 
ratio O 
at O 
all O 
temperature O 
conditions O 
. O 
In O 
response O 
to O 
TBA B-ABBREVIATION 
exposure O 
G O 
. O 
spinifera O 
increased O 
extracellular O 
polysaccharides O 
release O 
at O 
20 O 
and O 
25°C O 
, O 
while O 
no O 
difference O 
was O 
reported O 
for O 
P O 
. O 
minimum O 
. O 
Changes O 
in O 
nutrient O 
uptake O 
rates O 
were O 
also O 
observed O 
for O 
P O 
. O 
minimum O 
. O 
Nitrate B-SYSTEMATIC 
and O 
phosphate B-SYSTEMATIC 
uptake O 
significantly O 
increased O 
in O 
the O 
presence O 
of O 
TBA B-ABBREVIATION 
and O 
this O 
response O 
was O 
enhanced O 
at O 
25°C O 
, O 
while O 
nitrate B-SYSTEMATIC 
uptake O 
increased O 
in O 
G O 
. O 
spinifera O 
only O 
when O 
grown O 
at O 
25°C O 
. O 
As O 
for O 
growth O 
rates O 
, O 
the O 
observed O 
changes O 
in O 
intracellular O 
component O 
contents O 
increased O 
at O 
optimal O 
temperature O 
conditions O 
. O 
In O 
this O 
work O 
it O 
is O 
shown O 
that O 
temperature O 
conditions O 
can O 
have O 
an O 
important O 
role O 
on O 
the O 
effect O 
of O 
terbuthylazine B-TRIVIAL 
on O 
algal O 
growth O 
and O 
on O 
the O 
physiological O 
responses O 
of O 
different O 
species O 
. O 
Furthermore O 
, O 
the O 
algal O 
resistance O 
and O 
recovery O 
can O 
be O 
dependent O 
on O 
nutrient O 
availability O 
. O 

of O 
action O 
of O 
human O 
pharmaceuticals O 
in O 
fish O 
: O 
the O 
effects O 
of O 
the O 
5-alpha-reductase O 
inhibitor O 
, O 
dutasteride B-TRIVIAL 
, O 
on O 
reproduction O 
as O 
a O 
case O 
study O 
. O 

recent O 
years O 
, O 
a O 
growing O 
number O 
of O 
human O 
pharmaceuticals O 
have O 
been O 
detected O 
in O 
the O 
aquatic O 
environment O 
, O 
generally O 
at O 
low O 
concentrations O 
( O 
sub O 
- O 
ng O 
/ O 
L-low O 
μg O 
/ O 
L O 
) O 
. O 
In O 
most O 
cases O 
, O 
these O 
compounds O 
are O 
characterised O 
by O 
highly O 
specific O 
modes O 
of O 
action O 
, O 
and O 
the O 
evolutionary O 
conservation O 
of O 
drug O 
targets O 
in O 
wildlife O 
species O 
suggests O 
the O 
possibility O 
that O 
pharmaceuticals O 
present O 
in O 
the O 
environment O 
may O 
cause O 
toxicological O 
effects O 
by O 
acting O 
through O 
the O 
same O 
targets O 
as O 
they O 
do O 
in O 
humans O 
. O 
Our O 
research O 
addressed O 
the O 
question O 
of O 
whether O 
or O 
not O 
dutasteride B-TRIVIAL 
, O 
a O 
pharmaceutical O 
used O 
to O 
treat O 
benign O 
prostatic O 
hyperplasia O 
, O 
may O 
cause O 
adverse O 
effects O 
in O 
a O 
teleost O 
fish O 
, O 
the O 
fathead O 
minnow O 
( O 
Pimephales O 
promelas O 
) O 
, O 
by O 
inhibiting O 
the O 
activity O 
of O 
both O 
isoforms O 
of O 
5α-reductase O 
( O 
5αR O 
) O 
, O 
the O 
enzyme O 
that O 
converts O 
testosterone B-TRIVIAL 
into O 
dihydrotestosterone B-SYSTEMATIC 
( O 
DHT B-ABBREVIATION 
) O 
. O 
Mammalian O 
pharmacological O 
and O 
toxicological O 
information O 
were O 
used O 
to O 
guide O 
the O 
experimental O 
design O 
and O 
the O 
selection O 
of O 
relevant O 
endpoints O 
, O 
according O 
to O 
the O 
so O 
- O 
called O 
" O 
read O 
- O 
across O 
approach O 
" O 
, O 
suggesting O 
that O 
dutasteride B-TRIVIAL 
may O 
affect O 
male O 
fertility O 
and O 
steroid B-FAMILY 
hormone I-FAMILY 
dynamics O 
. O 
Therefore O 
, O 
a O 
21-day O 
reproduction O 
study O 
was O 
conducted O 
to O 
determine O 
the O 
effects O 
of O 
dutasteride B-TRIVIAL 
( O 
10 O 
, O 
32 O 
and O 
100 O 
μg O 
/ O 
L O 
) O 
on O 
fish O 
reproduction O 
. O 
Exposure O 
to O 
dutasteride B-TRIVIAL 
significantly O 
reduced O 
fecundity O 
of O 
fish O 
and O 
affected O 
several O 
aspects O 
of O 
reproductive O 
endocrine O 
functions O 
in O 
both O 
males O 
and O 
females O 
. O 
However O 
, O 
none O 
of O 
the O 
observed O 
adverse O 
effects O 
occurred O 
at O 
concentrations O 
of O 
exposure O 
lower O 
than O 
32 O 
μg O 
/ O 
L O 
; O 
this O 
, O 
together O 
with O 
the O 
low O 
volume O 
of O 
drug O 
prescribed O 
every O 
year O 
( O 
10.34 O 
kg O 
in O 
the O 
UK O 
in O 
2011 O 
) O 
, O 
and O 
the O 
extremely O 
low O 
predicted O 
environmental O 
concentration O 
( O 
0.03 O 
ng O 
/ O 
L O 
) O 
, O 
suggest O 
that O 
, O 
at O 
present O 
, O 
the O 
potential O 
presence O 
of O 
dutasteride B-TRIVIAL 
in O 
the O 
environment O 
does O 
not O 
represent O 
a O 
threat O 
to O 
wild O 
fish O 
populations O 
. O 

of O 
zebra O 
mussels O 
( O 
Dreissena O 
polymorpha O 
) O 
as O 
biomonitors O 
of O 
mercury B-SYSTEMATIC 
contamination O 
in O 
aquatic O 
ecosystems O 
. O 

mussels O 
have O 
invaded O 
many O 
lakes O 
in O 
the O 
United O 
States O 
and O 
could O 
be O 
a O 
useful O 
tool O 
for O 
monitoring O 
responses O 
of O 
aquatic O 
biota O 
to O 
changes O 
in O 
mercury B-SYSTEMATIC 
loading O 
. O 
The O 
goal O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
zebra O 
mussels O 
for O 
use O 
as O 
a O 
biomonitor O 
of O 
mercury B-SYSTEMATIC 
contamination O 
by O 
comparing O 
zebra O 
mussel O 
mercury B-SYSTEMATIC 
concentrations O 
between O 
a O 
lake O 
with O 
only O 
indirect O 
atmospheric O 
mercury B-SYSTEMATIC 
contamination O 
( O 
Otisco O 
Lake O 
, O 
NY O 
, O 
USA O 
) O 
and O 
a O 
lake O 
that O 
was O 
directly O 
contaminated O 
by O 
mercury B-SYSTEMATIC 
discharges O 
( O 
Onondaga O 
Lake O 
, O 
NY O 
, O 
USA O 
) O 
. O 
Zebra O 
mussels O 
were O 
sampled O 
in O 
both O 
the O 
spring O 
and O 
fall O 
of O 
2004 O 
and O 
2005 O 
. O 
Total O 
mercury B-SYSTEMATIC 
( O 
THg O 
) O 
concentrations O 
in O 
zebra O 
mussels O 
were O 
approximately O 
seven O 
times O 
greater O 
in O 
Onondaga O 
Lake O 
than O 
in O 
Otisco O 
Lake O 
, O 
and O 
water O 
column O 
mercury B-SYSTEMATIC 
concentrations O 
differed O 
by O 
an O 
order O 
of O 
magnitude O 
between O 
the O 
two O 
lakes O 
. O 
Seasonal O 
differences O 
resulted O 
in O 
significantly O 
higher O 
zebra O 
mussel O 
THg O 
concentrations O 
during O 
the O 
fall O 
for O 
both O 
lakes O 
. O 
There O 
was O 
also O 
significant O 
variation O 
among O 
different O 
sampling O 
sites O 
in O 
Onondaga O 
Lake O 
. O 
Mussel O 
methylmercury B-SYSTEMATIC 
concentrations O 
averaged O 
53% O 
of O 
THg O 
concentrations O 
but O 
were O 
highly O 
variable O 
. O 
Strong O 
relationships O 
between O 
water O 
column O 
THg O 
and O 
zebra O 
mussel O 
THg O 
suggest O 
that O 
zebra O 
mussels O 
are O 
a O 
good O 
indicator O 
of O 
aquatic O 
mercury B-SYSTEMATIC 
concentrations O 
and O 
could O 
be O 
used O 
as O 
an O 
effective O 
biomonitor O 
of O 
mercury B-SYSTEMATIC 
contamination O 
in O 
aquatic O 
ecosystems O 
. O 

along O 
the O 
river O 
Saale O 
, O 
one O 
of O 
the O 
main O 
tributaries O 
of O 
the O 
river O 
Elbe O 
, O 
were O 
characterized O 
with O 
the O 
yeast O 
estrogen B-FAMILY 
screen O 
to O 
elucidate O 
possible O 
sources O 
of O 
endocrine O 
- O 
disrupting O 
compounds O 
that O 
might O 
contribute O 
to O 
the O 
downstream O 
contamination O 
of O 
the O 
river O 
Elbe O 
. O 
At O 
two O 
sampling O 
sites O 
, O 
elevated O 
levels O 
of O 
estrogenic O 
activity O 
up O 
to O 
55000 O 
ng O 
ethinylestradiol B-SYSTEMATIC 
equivalents O 
per O 
kilogram O 
sediment O 
dry O 
weight O 
were O 
detected O 
in O 
the O 
respective O 
sediment O 
extracts O 
. O 
Aliquots O 
of O 
the O 
sediment O 
extracts O 
were O 
analyzed O 
for O 
4-nonylphenols B-FAMILY 
and O 
natural O 
steroidal B-FAMILY 
estrogens I-FAMILY 
as O 
possible O 
candidates O 
with O 
an O 
estrogenic O 
potential O 
. O 
The O 
maximal O 
concentrations O 
of O 
4-iso-nonylphenol B-SYSTEMATIC 
and O 
estrone B-TRIVIAL 
were O 
115 O 
mg O 
/ O 
kg O 
dry O 
weight O 
and O 
20 O 
µg O 
/ O 
kg O 
dry O 
weight O 
at O 
the O 
sampling O 
site O 
Luppe O 
, O 
which O 
showed O 
in O 
accordance O 
the O 
highest O 
biological O 
activity O 
. O 
Under O 
consideration O 
of O 
compound O 
concentration O 
and O 
compound O 
specific O 
estrogenic O 
activity O 
the O 
4-iso-nonylphenols B-FAMILY 
contributed O 
most O 
to O 
the O 
observed O 
estrogenic O 
effect O 
. O 
A O 
strong O 
correlation O 
between O 
the O 
measured O 
estrogenic O 
activity O 
and O 
the O 
concentration O 
of O 
the O 
sediment-associated O 
4-iso-nonylphenol B-SYSTEMATIC 
underlines O 
the O 
relevance O 
of O 
this O 
compound O 
class O 
as O 
a O 
xenoestrogen O 
in O 
the O 
catchment O 
area O 
of O 
the O 
river O 
Saale O 
. O 

of O 
the O 
tricyclic O 
antidepressant O 
drugs O 
amitriptyline B-TRIVIAL 
and O 
nortriptyline B-TRIVIAL 
in O 
agriculture O 
soils O 
. O 

and O 
nortriptyline B-TRIVIAL 
are O 
widely O 
used O 
tricyclic O 
antidepressant O 
drugs O 
. O 
They O 
have O 
been O 
detected O 
in O 
wastewater O 
, O 
surface O 
runoff O 
, O 
and O 
effluents O 
from O 
sewage O 
treatment O 
plants O 
. O 
As O 
such O 
, O 
they O 
could O 
potentially O 
reach O 
agriculture O 
land O 
through O 
the O 
application O 
of O 
municipal O 
biosolids O 
or O 
reclaimed O 
water O 
. O 
In O 
the O 
absence O 
of O 
data O 
on O 
their O 
fate O 
in O 
the O 
environment O 
, O 
the O 
persistence O 
and O 
dissipation O 
pathways O 
of O 
radiolabeled O 
amitriptyline B-TRIVIAL 
were O 
determined O 
in O 
three O 
agriculture O 
soils O 
varying O 
widely O 
in O 
texture O 
and O 
chemical O 
properties O 
( O 
loam O 
soil O 
, O 
clay O 
loam O 
soil O 
, O 
and O 
sandy O 
loam O 
soil O 
) O 
. O 
Tritiated B-TRIVIAL 
amitriptyline I-TRIVIAL 
was O 
added O 
to O 
laboratory O 
microcosms O 
containing O 
soils O 
, O 
and O 
the O 
metabolism O 
of O 
the O 
extractable O 
( B-FORMULA 
3 I-FORMULA 
) I-FORMULA 
H I-FORMULA 
was O 
monitored O 
during O 
incubation O 
at O 
30°C O 
. O 
The O 
total O 
solvent O 
extractable O 
radioactivity O 
decreased O 
in O 
all O 
three O 
soils O 
with O 
times O 
to O 
dissipate O 
50% O 
of O 
material O 
( O 
DT50 O 
) O 
ranging O 
from O 
34.1 O 
± O 
3.2 O 
( O 
loam O 
soil O 
) O 
to O 
85.3 O 
± O 
3.2 O 
d O 
( O 
sandy O 
soil O 
) O 
. O 
Nortriptyline B-TRIVIAL 
( O 
N-desmethyl B-SYSTEMATIC 
amitriptyline I-SYSTEMATIC 
) O 
and O 
amitriptyline-N-oxide B-SYSTEMATIC 
were O 
identified O 
as O 
major O 
transformation O 
products O 
in O 
all O 
three O 
soils O 
by O 
high O 
performance O 
liquid O 
chromatography O 
with O 
photodiode O 
array O 
detector O 
and O 
time O 
- O 
of O 
- O 
flight O 
mass O 
spectrometry O 
( O 
HPLC-TOF-MS O 
/ O 
UV O 
) O 
. O 
The O 
addition O 
of O 
liquid O 
municipal O 
biosolids O 
to O 
the O 
loam O 
soil O 
had O 
no O 
effect O 
on O 
the O 
dissipation O 
of O 
amitriptyline B-TRIVIAL 
. O 
The O 
persistence O 
of O 
nortriptyline B-TRIVIAL 
was O 
evaluated O 
in O 
the O 
loam O 
soil O 
. O 
The O 
DT50 O 
of O 
nortriptyline B-TRIVIAL 
was O 
40.5 O 
± O 
3.2 O 
d O 
estimated O 
with O 
HPLC-TOF-MS O 
/ O 
UV O 
. O 
Approximately O 
10% O 
of O 
added O 
nortriptyline B-TRIVIAL 
was O 
converted O 
to O 
hydroxylated O 
products O 
after O 
50 O 
d O 
of O 
incubation O 
. O 
In O 
summary O 
, O 
amitriptyline B-TRIVIAL 
persisted O 
in O 
agricultural O 
soils O 
with O 
major O 
dissipation O 
mechanisms O 
, O 
including O 
forming O 
nonextractable O 
residues O 
and O 
producing O 
various O 
transformation O 
products O 
including O 
the O 
psychoactive O 
drug O 
nortriptyline B-TRIVIAL 
. O 

in O 
the O 
seafood O 
and O 
human O 
exposure O 
in O 
coastal O 
area O 
of O 
Guangdong O 
province O 
, O 
South O 
China O 
. O 

of O 
fish O 
and O 
aquatic O 
products O 
is O 
considered O 
to O 
be O 
the O 
main O 
pathway O 
of O 
human O 
exposure O 
to O 
methylmercury B-SYSTEMATIC 
( O 
MeHg B-FORMULA 
) O 
. O 
To O 
assess O 
human O 
health O 
risk O 
through O 
seafood O 
consumption O 
in O 
a O 
coastal O 
area O 
of O 
Guangdong O 
Province O 
, O 
South O 
China O 
, O 
a O 
total O 
of O 
518 O 
seafood O 
samples O 
( O 
including O 
fish O 
, O 
shrimp O 
, O 
crabs O 
, O 
and O 
mollusks O 
) O 
were O 
collected O 
from O 
11 O 
coastal O 
cities O 
for O 
total O 
mercury B-SYSTEMATIC 
( O 
THg O 
) O 
analysis O 
. O 
The O 
THg O 
concentrations O 
varied O 
significantly O 
among O 
different O 
seafood O 
groups O 
and O 
ranged O 
from O 
0.11 O 
to O 
317 O 
ng O 
/ O 
g O 
( O 
with O 
a O 
mean O 
of O 
37.2 O 
ng O 
/ O 
g O 
) O 
. O 
The O 
THg O 
concentrations O 
were O 
relatively O 
low O 
compared O 
with O 
fish O 
from O 
Europe O 
and O 
North O 
America O 
, O 
and O 
no O 
samples O 
exceeded O 
the O 
national O 
limit O 
recommended O 
by O 
the O 
Standardization O 
Administration O 
of O 
China O 
( O 
0.5 O 
ng O 
/ O 
g O 
wet O 
wt O 
) O 
. O 
The O 
ecological O 
functional O 
groups O 
and O 
cultured O 
styles O 
have O 
significant O 
effects O 
on O 
THg O 
concentrations O 
in O 
the O 
fish O 
tissue O 
. O 
The O 
median O 
of O 
probable O 
daily O 
intakes O 
( O 
PDIs O 
) O 
of O 
MeHg B-FORMULA 
via O 
seafood O 
consumption O 
ranged O 
from O 
42.6 O 
to O 
71.4 O 
ng O 
/ O 
g O 
for O 
different O 
age O 
groups O 
, O 
with O 
fish O 
contributing O 
the O 
major O 
portion O 
( O 
84% O 
) O 
. O 
The O 
results O 
indicated O 
potential O 
health O 
risks O 
associated O 
with O 
seafood O 
consumption O 
for O 
the O 
general O 
population O 
in O 
the O 
coastal O 
area O 
of O 
Guangdong O 
Province O 
, O 
South O 
China O 
. O 

carbon B-SYSTEMATIC 
nanotube O 
synapse O 
with O 
dynamic O 
logic O 
and O 
learning O 
. O 

carbon B-SYSTEMATIC 
nanotube O 
( O 
CNT O 
) O 
synapse O 
emulates O 
a O 
biological O 
synapse O 
with O 
its O 
dynamic O 
logic O 
, O 
learning O 
, O 
and O 
memory O 
functions O 
induced O 
by O 
the O 
interactions O 
between O 
CNTs O 
and O 
hydrogen B-SYSTEMATIC 
ions O 
in O 
an O 
electrochemical O 
cell O 
. O 
A O 
circuit O 
of O 
CNT O 
synapses O 
operates O 
with O 
extremely O 
low O 
- O 
energy O 
consumption O 
and O 
could O 
potentially O 
emulate O 
the O 
functions O 
of O 
the O 
neuronal O 
network O 
. O 

benzo[e]pyridoindolones B-FAMILY 
as O 
potent O 
inhibitors O 
of O 
aurora O 
kinases O 
. O 

kinases O 
play O 
an O 
essential O 
role O 
in O 
mitotic O 
progression O 
and O 
are O 
potentially O 
druggable O 
targets O 
in O 
cancer O 
therapy O 
. O 
We O 
identified O 
benzo[e]pyridoindoles B-FAMILY 
( O 
BePI B-ABBREVIATION 
) O 
as O 
powerful O 
aurora O 
kinase O 
inhibitors O 
. O 
Their O 
efficiency O 
was O 
demonstrated O 
both O 
in O 
enzymatic O 
inhibition O 
studies O 
and O 
in O 
cell O 
culture O 
assays O 
. O 
New O 
BePI B-ABBREVIATION 
molecules O 
were O 
synthesized O 
, O 
and O 
a O 
structure O 
- O 
activity O 
relationship O 
study O 
was O 
conducted O 
with O 
the O 
aim O 
of O 
improving O 
the O 
activity O 
and O 
solubility O 
of O 
the O 
lead O 
compound O 
. O 
Tetracyclic B-ABBREVIATION 
BePI I-ABBREVIATION 
derivatives O 
are O 
characterized O 
by O 
a O 
particular O 
curved O 
shape O 
, O 
and O 
the O 
presence O 
of O 
an O 
oxo B-SYSTEMATIC 
group O 
on O 
the O 
pyridine B-SYSTEMATIC 
ring O 
was O 
found O 
to O 
be O 
required O 
for O 
aurora O 
kinase O 
B O 
inhibition O 
. O 
New O 
hydrosoluble O 
benzo[e]pyridoindolones B-FAMILY 
were O 
subsequently O 
designed O 
, O 
and O 
their O 
efficacy O 
was O 
tested O 
by O 
a O 
combination O 
of O 
cell O 
- O 
cycle O 
analysis O 
and O 
time O 
- O 
lapse O 
experiments O 
in O 
live O 
cells O 
. O 
The O 
most O 
active O 
BePI B-ABBREVIATION 
derivative O 
, O 
13 O 
b O 
, O 
inhibited O 
the O 
cell O 
cycle O 
, O 
drove O 
cells O 
to O 
polyploidy O 
, O 
and O 
eventually O 
induced O 
apoptosis O 
. O 
It O 
exhibited O 
high O 
antiproliferative O 
activity O 
in O 
HeLa O 
cells O 
with O 
an O 
IC(50) O 
value O 
of O 
63 O 
nM O 
. O 
Relative O 
to O 
compounds O 
tested O 
in O 
clinical O 
trials O 
, O 
this O 
antiproliferative O 
potency O 
places O 
13 O 
b O 
among O 
the O 
top O 
10 O 
aurora O 
kinase O 
inhibitors O 
. O 
Our O 
results O 
justify O 
further O 
in O 
vivo O 
evaluation O 
in O 
preclinical O 
animal O 
models O 
of O 
cancer O 
. O 

synthesis O 
of O 
(20S)-10-(3-aminopropyloxy)-7-ethylcamptothecin B-SYSTEMATIC 
, O 
a O 
water O 
- O 
soluble O 
analogue O 
of O 
camptothecin B-TRIVIAL 
. O 

robust O 
, O 
practical O 
synthesis O 
of O 
(20S)-10-(3-aminopropyloxy)-7-ethylcamptothecin B-SYSTEMATIC 
( O 
T-2513 B-IDENTIFIER 
, O 
5 O 
) O 
, O 
which O 
is O 
a O 
water O 
- O 
soluble O 
analogue O 
of O 
camptothecin B-TRIVIAL 
, O 
has O 
been O 
developed O 
. O 
The O 
key O 
step O 
in O 
this O 
synthesis O 
is O 
a O 
highly O 
diastereoselective O 
ethylation O 
at O 
the O 
C20 O 
position O 
by O 
using O 
N-arylsulfonyl-(R)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic B-FAMILY 
acid I-FAMILY 
ester I-FAMILY 
as O 
a O 
chiral O 
auxiliary O 
, O 
which O 
affords O 
the O 
key O 
intermediate O 
ethyl-(S)-2-acyloxy-2-(6-cyano-5-oxo-1,2,3,5-tetrahydroindolizin-7-yl)butanoate B-FAMILY 
( O 
8k O 
) O 
in O 
93% O 
yield O 
and O 
87% O 
de O 
. O 
Optically O 
pure O 
compound O 
8k O 
was O 
obtained O 
by O 
a O 
single O 
recrystallization O 
from O 
acetone B-SYSTEMATIC 
and O 
its O 
further O 
elaboration O 
through O 
Friedlander O 
condensation O 
afforded O 
compound O 
5 O 
. O 
This O 
synthesis O 
does O 
not O 
require O 
any O 
chromatographic O 
purification O 
steps O 
and O 
can O 
provide O 
compound O 
5 O 
on O 
a O 
multi O 
- O 
gram O 
scale O 
in O 
6.3% O 
overall O 
yield O 
( O 
16 O 
steps O 
) O 
. O 

this O 
study O 
, O 
two O 
types O 
of O 
BolA O 
- O 
like O 
amphiphilic O 
peptides O 
with O 
dual O 
ligands O 
comprising O 
a O 
tumor O 
- O 
targeting O 
moiety O 
of O 
RGD O 
sequence O 
and O 
a O 
cell O 
- O 
penetrating O 
moiety O 
of O 
R8 O 
sequence O 
are O 
designed O 
and O 
synthesized O 
as O 
gene O 
vectors O 
. O 
The O 
BolA-structural O 
peptide O 
carriers O 
can O 
self O 
- O 
assemble O 
into O 
spherical O 
nanoparticles O 
with O 
a O 
hydrophilic O 
core O 
and O 
shell O 
, O 
which O 
are O 
similar O 
to O 
the O 
viral O 
capsid O 
and O 
can O 
bind O 
plasmid O 
DNA O 
in O 
an O 
aqueous O 
medium O 
to O 
form O 
viral O 
- O 
mimetic O 
complexes O 
. O 
It O 
is O 
found O 
that O 
the O 
BolA O 
- O 
like O 
dual O 
ligands O 
system O 
exhibits O 
significantly O 
enhanced O 
gene O 
expression O 
in O 
both O 
HeLa O 
and O 
293T O 
cell O 
lines O 
, O 
as O 
compared O 
with O 
poly(ethylenimine) B-FAMILY 
PEI B-ABBREVIATION 
. O 
These O 
BolA O 
- O 
like O 
amphiphilic O 
peptides O 
are O 
promising O 
in O 
clinical O 
trials O 
of O 
gene O 
therapy O 
. O 

cyclomyrsinol B-FAMILY 
diterpenes I-FAMILY 
from O 
Euphorbia O 
aellenii O 
with O 
their O 
immunomodulatory O 
effects O 
. O 

- O 
acetone B-SYSTEMATIC 
extract O 
of O 
the O 
aerial O 
parts O 
of O 
Euphorbia O 
aellenii O 
Rech O 
. O 
f O 
. O 
( O 
Euphorbiaceae O 
) O 
was O 
investigated O 
for O 
its O 
diterpenoidal B-FAMILY 
constituents O 
. O 
This O 
led O 
to O 
the O 
isolation O 
of O 
two O 
new O 
and O 
one O 
known O 
cyclomyrsinol B-TRIVIAL 
-type O 
diterpenes B-FAMILY 
1-3 O 
. O 
The O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
1D O 
and O 
2D O 
(1)H B-FORMULA 
and O 
(13)C B-FORMULA 
NMR O 
techniques O 
, O 
and O 
in O 
vitro O 
immunomodulatory O 
activity O 
was O 
evaluated O 
by O 
standard O 
proliferation O 
of O 
human O 
peripheral O 
blood O 
lymphocytes O 
. O 
Results O 
showed O 
that O 
all O 
the O 
three O 
compounds O 
were O 
found O 
to O 
inhibit O 
lymphocyte O 
proliferation O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
at O 
50 O 
μg O 
/ O 
ml O 
concentration O 
. O 
Among O 
them O 
, O 
compound O 
2 O 
showed O 
more O 
activity O 
against O 
phytohemagglutinin O 
- O 
activated O 
T-cell O 
proliferation O 
with O 
an O 
IC(50) O 
of O 
40.4 O 
± O 
9.35 O 
μg O 
/ O 
ml O 
. O 

biomimetic O 
membranes O 
( O 
SBMs O 
) O 
on O 
solid O 
substrates O 
have O 
been O 
commonly O 
prepared O 
from O 
vesicle O 
- O 
forming O 
double O 
- O 
tail O 
lipids O 
, O 
such O 
as O 
zwitterionic O 
phospholipids O 
, O 
using O 
the O 
method O 
of O 
vesicle O 
fusion O 
. O 
Here O 
we O 
report O 
on O 
the O 
preparation O 
of O 
SBMs O 
on O 
silica B-TRIVIAL 
surfaces O 
via O 
a O 
similar O 
process O 
of O 
" O 
micelle O 
fusion O 
" O 
from O 
a O 
cationic O 
single O 
- O 
tail O 
bolaamphiphile O 
GLH-20 O 
that O 
forms O 
spherical O 
and O 
elongated O 
thread O 
- O 
like O 
micelles O 
in O 
solution O 
. O 
We O 
demonstrate O 
that O 
, O 
in O 
contrast O 
to O 
zwitterionic O 
phospholipids O 
, O 
GLH-20 O 
self O 
- O 
assembles O 
into O 
a O 
stable O 
contiguous O 
SBM O 
at O 
both O 
low O 
and O 
high O 
ionic O 
strengths O 
. O 
The O 
cationic O 
charge O 
of O 
GLH-20 O 
promotes O 
the O 
formation O 
of O 
a O 
stable O 
SBM O 
through O 
enhanced O 
double O 
- O 
layer O 
interactions O 
with O 
the O 
negatively O 
charged O 
silica B-TRIVIAL 
surface O 
. O 
It O 
is O 
also O 
shown O 
that O 
spinach O 
aquaporin O 
PM-28 O 
was O 
successfully O 
incorporated O 
within O 
bolaamphiphile O 
SBM O 
in O 
a O 
manner O 
similar O 
to O 
SBMs O 
prepared O 
by O 
vesicle O 
/ O 
proteoliposome O 
fusion O 
; O 
thereby O 
the O 
inherent O 
curvature O 
of O 
the O 
micelle O 
surface O 
does O 
not O 
inhibit O 
protein O 
reconstitution O 
. O 
The O 
results O 
suggest O 
that O 
SBMs O 
based O 
on O 
charged O 
bolaamphiphiles O 
might O 
be O 
an O 
attractive O 
platform O 
for O 
applications O 
such O 
as O 
water O 
purification O 
and O 
biosensors O 
, O 
where O 
the O 
stability O 
and O 
low O 
defect O 
rate O 
of O 
SBMs O 
in O 
diverse O 
conditions O 
are O 
crucial O 
for O 
achieving O 
desired O 
performance O 
. O 

class O 
of O 
5-nitro-2-furancarboxylamides B-FAMILY 
with O 
potent O 
trypanocidal O 
activity O 
against O 
Trypanosoma O 
brucei O 
in O 
vitro O 
. O 

, O 
the O 
World O 
Health O 
Organization O 
approved O 
the O 
nifurtimox B-TRIVIAL 
- O 
eflornithine B-TRIVIAL 
combination O 
therapy O 
for O 
the O 
treatment O 
of O 
human O 
African O 
trypanosomiasis O 
, O 
renewing O 
interest O 
in O 
nitroheterocycle O 
therapies O 
for O 
this O 
and O 
associated O 
diseases O 
. O 
In O 
this O 
study O 
, O 
we O 
have O 
synthesized O 
a O 
series O 
of O 
novel O 
5-nitro-2-furancarboxylamides B-FAMILY 
that O 
show O 
potent O 
trypanocidal O 
activity O 
, O 
∼1000-fold O 
more O 
potent O 
than O 
nifurtimox B-TRIVIAL 
against O 
in O 
vitro O 
Trypanosoma O 
brucei O 
with O 
very O 
low O 
cytotoxicity O 
against O 
human O 
HeLa O 
cells O 
. O 
More O 
importantly O 
, O 
the O 
most O 
potent O 
analogue O 
showed O 
very O 
limited O 
cross O 
- O 
resistance O 
to O 
nifurtimox B-TRIVIAL 
-resistant O 
cells O 
and O 
vice O 
versa O 
. O 
This O 
implies O 
that O 
our O 
novel O 
, O 
relatively O 
easy O 
to O 
synthesize O 
and O 
therefore O 
cheap O 
, O 
5-nitro-2-furancarboxylamides B-FAMILY 
are O 
targeting O 
a O 
different O 
, O 
but O 
still O 
essential O 
, O 
biochemical O 
process O 
to O 
those O 
targeted O 
by O 
nifurtimox B-TRIVIAL 
or O 
its O 
metabolites O 
in O 
the O 
parasites O 
. O 
The O 
significant O 
increase O 
in O 
potency O 
( O 
smaller O 
dose O 
probably O 
required O 
) O 
has O 
the O 
potential O 
for O 
greatly O 
reducing O 
unwanted O 
side O 
effects O 
and O 
also O 
reducing O 
the O 
likelihood O 
of O 
drug O 
resistance O 
. O 
Collectively O 
, O 
these O 
findings O 
have O 
important O 
implications O 
for O 
the O 
future O 
therapeutic O 
treatment O 
of O 
African O 
sleeping O 
sickness O 
. O 

hormone I-FAMILY 
replacement O 
therapy O 
attenuates O 
the O 
decline O 
of O 
renal O 
function O 
in O 
chronic O 
kidney O 
disease O 
patients O 
with O 
subclinical O 
hypothyroidism O 
. O 

: O 
Subclinical O 
hypothyroidism O 
( O 
SH O 
) O 
is O 
not O 
a O 
rare O 
condition O 
in O 
females O 
, O 
the O 
elderly O 
, O 
or O 
patients O 
with O 
chronic O 
kidney O 
disease O 
( O 
CKD O 
) O 
. O 
Even O 
though O 
previous O 
studies O 
have O 
demonstrated O 
that O 
thyroid B-FAMILY 
hormone I-FAMILY 
replacement O 
therapy O 
( O 
THRT O 
) O 
improved O 
cardiac O 
function O 
and O 
dyslipidemia O 
in O 
patients O 
with O 
subclinical O 
hypothyroidism O 
, O 
it O 
remains O 
unclear O 
as O 
to O 
whether O 
THRT O 
can O 
improve O 
renal O 
function O 
in O 
CKD O 
patients O 
with O 
SH O 
. O 
This O 
study O 
investigated O 
the O 
impact O 
of O 
THRT O 
on O 
changes O 
in O 
estimated O 
glomerular O 
filtration O 
rates O 
( O 
eGFR O 
) O 
in O 
this O 
patient O 
population O 
. O 
Methods O 
: O 
A O 
total O 
of O 
113 O 
CKD O 
patients O 
with O 
SH O 
who O 
were O 
treated O 
with O 
L-thyroxine B-TRIVIAL 
and O 
had O 
eGFR O 
available O 
for O 
at O 
least O 
24 O 
months O 
before O 
and O 
after O 
THRT O 
were O 
enrolled O 
between O 
January O 
2005 O 
and O 
December O 
2011 O 
. O 
A O 
linear O 
mixed O 
model O 
was O 
used O 
to O 
compare O 
patients O 
' O 
clinical O 
and O 
biochemical O 
parameters O 
at O 
various O 
time O 
points O 
. O 
The O 
slope O 
of O 
the O 
decline O 
in O 
eGFR O 
over O 
time O 
, O 
both O 
before O 
and O 
after O 
THRT O 
, O 
was O 
also O 
calculated O 
and O 
compared O 
using O 
a O 
linear O 
mixed O 
model O 
. O 
Results O 
: O 
The O 
mean O 
age O 
of O 
the O 
study O 
participants O 
was O 
63.2 O 
± O 
12.7 O 
years O 
, O 
and O 
36 O 
patients O 
( O 
31.9% O 
) O 
were O 
male O 
. O 
The O 
mean O 
follow O 
- O 
up O 
duration O 
before O 
and O 
after O 
THRT O 
was O 
28.6 O 
± O 
4.5 O 
and O 
30.6 O 
± O 
6.4 O 
months O 
, O 
respectively O 
. O 
At O 
24-months O 
of O 
THRT O 
, O 
TSH O 
levels O 
were O 
significantly O 
reduced O 
[ O 
8.86 O 
( O 
0.49 O 
) O 
vs O 
. O 
1.41 O 
( O 
0.73 O 
) O 
IU O 
/ O 
mL O 
, O 
P O 
< O 
0.001 O 
] O 
, O 
but O 
there O 
were O 
no O 
significant O 
changes O 
in O 
T3 O 
and O 
fT4 O 
concentrations O 
. O 
Serum O 
albumin O 
, O 
calcium B-SYSTEMATIC 
, O 
phosphate B-SYSTEMATIC 
, O 
cholesterol B-TRIVIAL 
, O 
and O 
triglyceride B-FAMILY 
levels O 
were O 
also O 
comparable O 
after O 
THRT O 
. O 
The O 
rates O 
of O 
decline O 
in O 
eGFR O 
were O 
significantly O 
attenuated O 
by O 
THRT O 
[ O 
-4.31 O 
( O 
0.51 O 
) O 
vs O 
. O 
-1.08 O 
( O 
0.36 O 
) O 
mL O 
/ O 
min O 
/ O 
year O 
/ O 
1.73 O 
m2 O 
, O 
P O 
< O 
0.001 O 
] O 
even O 
after O 
adjustment O 
for O 
age O 
, O 
gender O 
, O 
diabetes O 
, O 
mean O 
arterial O 
pressure O 
, O 
serum O 
albumin O 
, O 
cholesterol B-TRIVIAL 
, O 
and O 
triglyceride B-FAMILY 
concentrations O 
( O 
P O 
< O 
0.001 O 
) O 
. O 
Conclusion O 
: O 
THRT O 
attenuated O 
the O 
rate O 
of O 
decline O 
in O 
renal O 
function O 
in O 
CKD O 
patients O 
with O 
SH O 
, O 
suggesting O 
that O 
THRT O 
may O 
delay O 
reaching O 
end O 
- O 
stage O 
renal O 
disease O 
in O 
these O 
patients O 
. O 

[ O 
4Fe-4S B-FORMULA 
] O 
clusters O 
containing O 
radical O 
SAM O 
enzyme O 
SkfB O 
catalyze O 
thioether B-SYSTEMATIC 
bond O 
formation O 
during O 
the O 
maturation O 
of O 
the O 
sporulation O 
killing O 
factor O 
. O 

sporulation O 
killing O 
factor O 
( O 
SKF O 
) O 
is O 
a O 
26-residue O 
ribosomally O 
assembled O 
and O 
posttranslationally O 
modified O 
sactipeptide O 
. O 
It O 
is O 
produced O 
by O 
Bacillus O 
subtilis O 
168 O 
and O 
plays O 
a O 
key O 
role O 
in O 
its O 
sporulation O 
. O 
Like O 
all O 
sactipeptides O 
, O 
SKF O 
contains O 
a O 
thioether B-SYSTEMATIC 
bond O 
, O 
which O 
links O 
the O 
cysteine B-TRIVIAL 
residue O 
Cys B-FORMULA 
4 O 
with O 
the O 
α-carbon B-SYSTEMATIC 
of O 
the O 
methionine B-TRIVIAL 
residue O 
Met B-FORMULA 
12 O 
. O 
In O 
this O 
study O 
we O 
demonstrate O 
that O 
this O 
bond O 
is O 
generated O 
by O 
the O 
two O 
[ O 
4Fe-4S B-FORMULA 
] O 
clusters O 
containing O 
radical O 
SAM B-ABBREVIATION 
enzyme O 
SkfB O 
, O 
which O 
is O 
encoded O 
in O 
the O 
skf O 
operon O 
. O 
By O 
mutational O 
analysis O 
of O 
both O 
cluster O 
- O 
binding O 
sites O 
, O 
we O 
were O 
able O 
to O 
postulate O 
a O 
mechanism O 
for O 
thioether O 
generation O 
which O 
is O 
in O 
agreement O 
with O 
that O 
of O 
AlbA O 
. O 
Furthermore O 
, O 
we O 
were O 
able O 
to O 
show O 
that O 
thioether B-SYSTEMATIC 
bond O 
formation O 
is O 
specific O 
toward O 
hydrophobic O 
amino B-FAMILY 
acids I-FAMILY 
at O 
the O 
acceptor O 
site O 
. O 
Additionally O 
we O 
demonstrate O 
that O 
generation O 
of O 
the O 
thioether B-SYSTEMATIC 
linkage O 
is O 
leader O 
- O 
peptide-dependent O 
, O 
suggesting O 
that O 
this O 
reaction O 
is O 
the O 
first O 
step O 
in O 
SKF O 
maturation O 
. O 

- O 
based O 
investigation O 
of O 
rat O 
aldehyde B-SYSTEMATIC 
oxidase O 
inhibition O 
by O 
flavonoids B-FAMILY 
. O 

1 O 
. O 
Flavonoids B-FAMILY 
are O 
a O 
group O 
of O 
polyphenolic B-FAMILY 
plant O 
metabolites O 
most O 
commonly O 
known O 
for O 
their O 
antioxidant O 
activities O 
. O 
They O 
also O 
show O 
inhibitory O 
activities O 
on O 
molybdo O 
- O 
flavoenzymes O 
family O 
of O 
enzymes O 
which O 
are O 
involved O 
in O 
biotransformation O 
of O 
some O 
exogenous O 
and O 
endogenous O 
chemicals O 
. O 
Most O 
notably O 
, O 
aldehyde B-SYSTEMATIC 
oxidase O 
( O 
AO O 
) O 
, O 
a O 
member O 
of O 
this O 
family O 
, O 
is O 
responsible O 
for O 
metabolism O 
of O 
some O 
therapeutic O 
agents O 
. O 
On O 
the O 
other O 
hand O 
, O 
there O 
are O 
some O 
therapeutics O 
which O 
inhibit O 
AO O 
. O 
As O 
flavonoids B-FAMILY 
are O 
ubiquitous O 
in O 
human O 
diet O 
and O 
have O 
potential O 
to O 
interact O 
with O 
AO O 
, O 
it O 
is O 
important O 
to O 
investigate O 
their O 
effects O 
at O 
the O 
molecular O 
details O 
. O 
2 O 
. O 
The O 
inhibitory O 
effects O 
of O 
15 O 
flavonoids B-FAMILY 
on O 
the O 
activity O 
of O 
rat O 
liver O 
AO O 
were O 
assessed O 
. O 
Quantitative O 
structure O 
- O 
activity O 
relationship O 
studies O 
were O 
performed O 
using O 
genetic O 
algorithm O 
coupled O 
partial O 
least O 
square O 
and O 
stepwise O 
multiple O 
linear O 
regression O 
methods O 
to O 
elucidate O 
the O 
important O 
structural O 
properties O 
responsible O 
for O 
the O 
observed O 
inhibitory O 
effects O 
. O 
To O 
further O 
understand O 
the O 
mode O 
of O 
interaction O 
between O 
these O 
flavonoids B-FAMILY 
and O 
AO O 
, O 
a O 
homology O 
model O 
of O 
the O 
enzyme O 
was O 
built O 
and O 
flavonoids B-FAMILY 
were O 
docked O 
into O 
its O 
active O 
site O 
. O 
The O 
most O 
important O 
amino B-FAMILY 
acids I-FAMILY 
involved O 
in O 
the O 
interactions O 
were O 
identified O 
. O 
3 O 
. O 
Quercetin B-TRIVIAL 
, O 
myricetin B-TRIVIAL 
and O 
genistein B-TRIVIAL 
were O 
the O 
most O 
potent O 
inhibitors O 
establishing O 
favorable O 
interactions O 
with O 
the O 
enzyme O 
. O 
However O 
, O 
the O 
glycosylated B-FAMILY 
flavonoids I-FAMILY 
showed O 
relatively O 
weaker O 
inhibition O 
which O 
may O 
be O 
attributed O 
to O 
their O 
hindered O 
binding O 
into O 
the O 
active O 
site O 
of O 
AO O 
by O 
bulky O 
sugar B-FAMILY 
groups O 
. O 

derivatives O 
from O 
the O 
Indonesian O 
sponge O 
Aaptos O 
suberitoides O 
. O 

new O 
aaptamine B-TRIVIAL 
derivatives O 
( O 
1-4 O 
) O 
along O 
with O 
aaptamine B-TRIVIAL 
( O 
5 O 
) O 
and O 
three O 
related O 
compounds O 
( O 
6-8 O 
) O 
were O 
isolated O 
from O 
the O 
ethanol B-SYSTEMATIC 
extract O 
of O 
the O 
sponge O 
Aaptos O 
suberitoides O 
collected O 
in O 
Indonesia O 
. O 
The O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
unambiguously O 
determined O 
by O 
one- O 
and O 
two O 
- O 
dimensional O 
NMR O 
and O 
by O 
HRESIMS O 
measurements O 
. O 
Compounds O 
3 O 
, O 
5 O 
, O 
and O 
6 O 
showed O 
cytotoxic O 
activity O 
against O 
the O 
murine O 
lymphoma O 
L5178Y O 
cell O 
line O 
, O 
with O 
IC(50) O 
values O 
ranging O 
from O 
0.9 O 
to O 
8.3 O 
μM O 
. O 

is O 
quercetin B-TRIVIAL 
a O 
better O 
antioxidant O 
than O 
taxifolin B-TRIVIAL 
? O 
Theoretical O 
study O 
of O 
mechanisms O 
involving O 
activated O 
forms O 
. O 

stronger O 
antioxidant O 
capacity O 
of O 
the O 
flavonoid O 
quercetin B-TRIVIAL 
( O 
Q O 
) O 
compared O 
with O 
taxifolin B-TRIVIAL 
( O 
dihydroquercetin B-SYSTEMATIC 
, O 
T O 
) O 
has O 
been O 
the O 
subject O 
of O 
previous O 
experimental O 
and O 
theoretical O 
studies O 
. O 
Theoretical O 
work O 
has O 
focused O 
on O 
the O 
analysis O 
of O 
hydrogen B-SYSTEMATIC 
bond O 
dissociation O 
energies O 
( O 
BDE O 
) O 
of O 
the O 
OH B-FORMULA 
phenolic B-FAMILY 
groups O 
, O 
but O 
consider O 
mechanisms O 
that O 
only O 
involve O 
the O 
transfer O 
of O 
one O 
hydrogen B-SYSTEMATIC 
atom O 
. O 
In O 
the O 
present O 
work O 
we O 
consider O 
other O 
mechanisms O 
involving O 
a O 
second O 
hydrogen B-SYSTEMATIC 
transfer O 
in O 
reactions O 
with O 
free O 
radicals O 
. O 
The O 
relative O 
stability O 
of O 
the O 
radicals O 
formed O 
after O 
the O 
first O 
hydrogen B-SYSTEMATIC 
transfer O 
reaction O 
is O 
considered O 
in O 
discussing O 
the O 
antioxidant O 
activity O 
of O 
Q O 
and O 
T O 
. O 
In O 
terms O 
of O 
global O 
and O 
local O 
theoretical O 
reactivity O 
descriptors O 
, O 
we O 
propose O 
that O 
the O 
radical O 
arising O 
from O 
Q O 
should O 
be O 
more O 
persistent O 
in O 
the O 
environment O 
and O 
with O 
the O 
capability O 
to O 
react O 
with O 
a O 
second O 
radical O 
by O 
hydrogen B-SYSTEMATIC 
transfer O 
, O 
proton O 
transfer O 
and O 
electron O 
transfer O 
mechanisms O 
. O 
These O 
mechanisms O 
could O 
be O 
responsible O 
of O 
the O 
stronger O 
antioxidant O 
capacity O 
of O 
Q O 
. O 

roots O 
of O 
Salvia O 
miltiorrhiza O 
( O 
" O 
Danshen O 
" O 
) O 
are O 
used O 
in O 
traditional O 
Chinese O 
medicine O 
for O 
the O 
treatment O 
of O 
numerous O 
ailments O 
including O 
cardiovascular O 
disease O 
, O 
hypertension O 
, O 
and O 
ischemic O 
stroke O 
. O 
Extracts O 
of O 
S O 
. O 
miltiorrhiza O 
roots O 
in O 
the O 
formulation O 
" O 
Compound O 
Danshen O 
Dripping O 
Pill O 
" O 
are O 
undergoing O 
clinical O 
trials O 
in O 
the O 
United O 
States O 
. O 
To O 
date O 
, O 
the O 
active O 
components O 
of O 
this O 
material O 
have O 
not O 
been O 
conclusively O 
identified O 
. O 
We O 
have O 
determined O 
that O 
S O 
. O 
miltiorrhiza O 
roots O 
contain O 
potent O 
human O 
carboxylesterase O 
( O 
CE O 
) O 
inhibitors O 
, O 
due O 
to O 
the O 
presence O 
of O 
tanshinones O 
. O 
K O 
(i) O 
values O 
in O 
the O 
nM O 
range O 
were O 
determined O 
for O 
inhibition O 
of O 
both O 
the O 
liver O 
and O 
intestinal O 
CEs O 
. O 
As O 
CEs O 
hydrolyze O 
clinically O 
used O 
drugs O 
, O 
the O 
ability O 
of O 
tanshinones O 
and O 
S O 
. O 
miltiorrhiza O 
root O 
extracts O 
to O 
modulate O 
the O 
metabolism O 
of O 
the O 
anticancer O 
prodrug O 
irinotecan B-TRIVIAL 
( O 
CPT-11 B-IDENTIFIER 
) O 
was O 
assessed O 
. O 
Our O 
results O 
indicate O 
that O 
marked O 
inhibition O 
of O 
human O 
CEs O 
occurs O 
following O 
incubation O 
with O 
both O 
pure O 
compounds O 
and O 
crude O 
material O 
and O 
that O 
drug O 
hydrolysis O 
is O 
significantly O 
reduced O 
. O 
Consequently O 
, O 
a O 
reduction O 
in O 
the O 
cytotoxicity O 
of O 
irinotecan O 
is O 
observed O 
following O 
dosing O 
with O 
either O 
purified O 
tanshinones O 
or O 
S O 
. O 
miltiorrhiza O 
root O 
extracts O 
. O 
It O 
is O 
concluded O 
that O 
remedies O 
containing O 
tanshinones O 
should O 
be O 
avoided O 
when O 
individuals O 
are O 
taking O 
esterified O 
agents O 
and O 
that O 
patients O 
should O 
be O 
warned O 
of O 
the O 
potential O 
drug O 
- O 
drug O 
interaction O 
that O 
may O 
occur O 
with O 
this O 
material O 
. O 

mesoporous O 
nanocomposites O 
with O 
magnetic O 
, O 
optical O 
, O 
and O 
sensing O 
features O 
: O 
synthesis O 
, O 
characterization O 
, O 
and O 
their O 
oxygen B-SYSTEMATIC 
-sensing O 
performance O 
. O 

this O 
paper O 
, O 
the O 
fabrication O 
, O 
characterization O 
, O 
and O 
application O 
in O 
oxygen B-SYSTEMATIC 
sensing O 
are O 
reported O 
for O 
a O 
novel O 
multifunctional O 
nanomaterial O 
of O 
[ O 
Ru(bpy)(2)phen B-FORMULA 
-MMS O 
] O 
( O 
bpy B-ABBREVIATION 
, O 
2,2'-bipyridyl B-SYSTEMATIC 
; O 
phen B-ABBREVIATION 
, O 
phenathrolin B-SYSTEMATIC 
) O 
which O 
was O 
simply O 
prepared O 
by O 
covalently O 
grafting O 
the O 
ruthenium B-FAMILY 
(II) I-FAMILY 
polypyridyl I-FAMILY 
compounds O 
into O 
the O 
channels O 
of O 
magnetic O 
mesoporous O 
silica B-TRIVIAL 
nanocomposites O 
( O 
MMS O 
) O 
. O 
Scanning O 
electron O 
microscopy O 
, O 
transmission O 
electron O 
microscopy O 
, O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
, O 
X-ray O 
diffraction O 
, O 
N(2) O 
adsorption O 
- O 
desorption O 
, O 
a O 
superconducting O 
quantum O 
interference O 
device O 
, O 
UV-vis O 
spectroscopy O 
, O 
and O 
photoluminescence O 
spectra O 
were O 
used O 
to O 
characterize O 
the O 
samples O 
. O 
The O 
well O 
- O 
designed O 
multifunctional O 
nanocomposites O 
show O 
superparamagnetic O 
behavior O 
and O 
ordered O 
mesoporous O 
characteristics O 
and O 
exhibit O 
a O 
strong O 
red O 
- O 
orange O 
metal O 
- O 
to O 
- O 
ligand O 
charge O 
transfer O 
emission O 
. O 
In O 
addition O 
, O 
the O 
obtained O 
nanocomposites O 
give O 
high O 
performance O 
in O 
oxygen B-SYSTEMATIC 
sensing O 
with O 
high O 
sensitivity O 
( O 
I(0) O 
/ O 
I(100) O 
= O 
5.2 O 
) O 
, O 
good O 
Stern-Volmer O 
characteristics O 
( O 
R(2) O 
= O 
0.9995 O 
) O 
, O 
and O 
short O 
response O 
/ O 
recovery O 
times O 
( O 
t↓ O 
= O 
6 O 
s O 
and O 
t↑ O 
= O 
12 O 
s O 
) O 
. O 
The O 
magnetic O 
, O 
mesoporous O 
, O 
luminescent O 
, O 
and O 
oxygen B-SYSTEMATIC 
-sensing O 
properties O 
of O 
this O 
multifunctional O 
nanostructure O 
make O 
it O 
hold O 
great O 
promise O 
as O 
a O 
novel O 
multifunctional O 
oxygen B-SYSTEMATIC 
-sensing O 
system O 
for O 
chemical O 
/ O 
biosensor O 
. O 

, O 
it O 
has O 
been O 
reported O 
that O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
produced O 
by O 
contact O 
allergens O 
can O 
affect O 
dendritic O 
cell O 
migration O 
and O 
contact O 
hypersensitivity O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
develop O 
a O 
new O 
in O 
vitro O 
assay O 
that O 
could O 
predict O 
the O 
skin O 
sensitizing O 
potential O 
of O 
chemicals O 
by O 
measuring O 
ROS O 
production O 
in O 
THP-1 O 
( O 
human O 
monocytic O 
leukemia O 
cell O 
line O 
) O 
cells O 
. O 
THP-1 O 
cells O 
were O 
pre O 
- O 
loaded O 
with O 
a O 
ROS O 
sensitive O 
fluorescent O 
dye O 
, O 
5-(and B-MULTIPLE 
6-)-chloromethyl-2 I-MULTIPLE 
' I-MULTIPLE 
, I-MULTIPLE 
7'-dichlorodihydrofluorescein I-MULTIPLE 
diacetate I-MULTIPLE 
, O 
acetyl B-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
CM-H2DCFDA B-ABBREVIATION 
) O 
, O 
for O 
15min O 
, O 
then O 
incubated O 
with O 
test O 
chemicals O 
for O 
30min O 
. O 
The O 
fluorescence O 
intensity O 
was O 
measured O 
by O 
flow O 
cytometry O 
. O 
For O 
the O 
skin O 
sensitizers O 
, O 
25 O 
out O 
of O 
30 O 
induced O 
over O 
a O 
2-fold O 
ROS O 
production O 
at O 
more O 
than O 
90% O 
of O 
cell O 
viability O 
. O 
In O 
contrast O 
, O 
increases O 
were O 
only O 
seen O 
in O 
4 O 
out O 
of O 
20 O 
non-sensitizers O 
. O 
The O 
overall O 
accuracy O 
for O 
the O 
local O 
lymph O 
node O 
assay O 
( O 
LLNA O 
) O 
was O 
82% O 
for O 
50 O 
chemicals O 
tested O 
. O 
A O 
correlation O 
was O 
found O 
between O 
the O 
estimated O 
concentration O 
showing O 
2-fold O 
ROS O 
production O 
in O 
the O 
ROS O 
assay O 
and O 
the O 
EC3 O 
values O 
( O 
estimated O 
concentration O 
required O 
to O 
induce O 
positive O 
response O 
) O 
of O 
the O 
LLNA O 
. O 
These O 
results O 
indicated O 
that O 
the O 
THP-1 O 
cell O 
- O 
based O 
ROS O 
assay O 
was O 
a O 
rapid O 
and O 
highly O 
sensitive O 
detection O 
system O 
able O 
to O 
predict O 
skin O 
sensitizing O 
potentials O 
and O 
potency O 
of O 
chemicals O 
. O 

of O 
T O 
- O 
type O 
calcium B-SYSTEMATIC 
channels O 
disrupts O 
Akt O 
signaling O 
and O 
promotes O 
apoptosis O 
in O 
glioblastoma O 
cells O 
. O 

multiforme O 
( O 
GBM O 
) O 
are O 
brain O 
tumors O 
that O 
are O 
exceptionally O 
resistant O 
to O 
both O 
radio- O 
and O 
chemotherapy O 
regimens O 
and O 
novel O 
approaches O 
to O 
treatment O 
are O 
needed O 
. O 
T O 
- O 
type O 
calcium B-SYSTEMATIC 
channels O 
are O 
one O 
type O 
of O 
low O 
voltage O 
- O 
gated O 
channel O 
( O 
LVCC O 
) O 
involved O 
in O 
embryonic O 
cell O 
proliferation O 
and O 
differentiation O 
; O 
however O 
they O 
are O 
often O 
over O 
- O 
expressed O 
in O 
tumors O 
, O 
including O 
GBM O 
. O 
In O 
this O 
study O 
, O 
we O 
found O 
that O 
inhibition O 
of O 
T O 
- O 
type O 
Ca(2+) B-FORMULA 
channels O 
in O 
GBM O 
cells O 
significantly O 
reduced O 
their O 
survival O 
and O 
resistance O 
to O 
therapy O 
. O 
Moreover O 
, O 
either O 
T O 
- O 
type O 
selective O 
antagonists O 
, O 
such O 
as O 
mibefradil O 
, O 
or O 
siRNA O 
- O 
mediated O 
knockdown O 
of O 
the O 
T O 
- O 
type O 
channel O 
alpha O 
subunits O 
not O 
only O 
reduced O 
cell O 
viability O 
and O 
clonogenic O 
potential O 
, O 
but O 
also O 
induced O 
apoptosis O 
. O 
In O 
response O 
to O 
channel O 
blockade O 
or O 
ablation O 
, O 
we O 
observed O 
reduced O 
phosphorylation O 
of O 
Akt O 
and O 
Rictor O 
, O 
suggesting O 
inhibition O 
of O 
the O 
mTORC2 O 
/ O 
Akt O 
pathway O 
. O 
This O 
was O 
followed O 
by O 
reduction O 
in O 
phosphorylation O 
of O 
anti-apoptotic O 
Bad O 
and O 
caspases O 
activation O 
. O 
The O 
apoptotic O 
response O 
was O 
specific O 
for O 
T O 
- O 
type O 
Ca(2+) B-FORMULA 
channels O 
, O 
as O 
inhibition O 
of O 
L- O 
type O 
Ca(2+) B-FORMULA 
channels O 
did O 
not O 
induce O 
similar O 
effects O 
. O 
Our O 
results O 
implicate O 
T O 
- O 
type O 
Ca(2+) B-FORMULA 
channels O 
as O 
distinct O 
entities O 
for O 
survival O 
signaling O 
in O 
GBM O 
cells O 
and O 
suggest O 
that O 
they O 
are O 
a O 
novel O 
molecular O 
target O 
for O 
tumor O 
therapy O 
. O 

anti-ischemic O 
efficacy O 
and O 
therapeutic O 
time O 
window O 
of O 
trans- B-MULTIPLE 
and I-MULTIPLE 
cis-hinokiresinols I-MULTIPLE 
: O 
Stereo O 
- O 
specific O 
antioxidant O 
and O 
anti-inflammatory O 
activities O 
. O 

cerebral O 
ischemia O 
, O 
neurons O 
are O 
injured O 
by O 
various O 
mechanisms O 
including O 
excitotoxicity O 
, O 
oxidative O 
stress O 
, O 
and O 
inflammatory O 
responses O 
. O 
Thus O 
, O 
pharmacological O 
manipulation O 
of O 
multiple O 
cytotoxic O 
pathways O 
has O 
been O 
pursued O 
for O 
the O 
treatment O 
of O 
ischemic O 
injury O 
. O 
Cis-hinokiresinol B-TRIVIAL 
, O 
a O 
naturally O 
occurring O 
phenylpropanoid B-SYSTEMATIC 
, O 
was O 
previously O 
reported O 
to O 
possess O 
anti-oxidant O 
, O 
anti-inflammatory O 
and O 
estrogen B-FAMILY 
-like O 
activities O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
anti-ischemic O 
effects O 
of O 
trans- B-MULTIPLE 
and I-MULTIPLE 
cis-hinokiresinols I-MULTIPLE 
using O 
in O 
vitro O 
as O 
well O 
as O 
in O 
vivo O 
experimental O 
models O 
. O 
The O 
ORAC O 
and O 
DPPH B-ABBREVIATION 
assays O 
showed O 
that O 
two O 
isomers O 
had O 
similar O 
free O 
radical O 
scavenging O 
activities O 
. O 
However O 
, O 
only O 
trans-hinokiresinol B-TRIVIAL 
significantly O 
decreased O 
neuronal O 
injury O 
in O 
cultured O 
cortical O 
neurons O 
exposed O 
to O 
oxygen B-SYSTEMATIC 
- O 
glucose B-TRIVIAL 
deprivation O 
( O 
75 O 
min O 
) O 
followed O 
by O 
re O 
- O 
oxygenation O 
( O 
9 O 
h O 
) O 
. O 
The O 
differential O 
neuroprotective O 
effect O 
could O 
be O 
due O 
to O 
the O 
stereo O 
- O 
specific O 
augmentation O 
of O 
Cu B-FORMULA 
/ O 
Zn B-FORMULA 
-SOD O 
activity O 
by O 
trans-hinokiresinol B-TRIVIAL 
, O 
when O 
compared O 
with O 
cis-hinokiresinol B-TRIVIAL 
. O 
Similarly O 
, O 
in O 
rats O 
subjected O 
to O 
transient O 
middle O 
cerebral O 
artery O 
occlusion O 
( O 
1.5 O 
h O 
) O 
followed O 
by O 
24-h O 
reperfusion O 
, O 
pre O 
- O 
ischemic O 
treatment O 
with O 
trans-hinokiresinol B-TRIVIAL 
, O 
but O 
not O 
with O 
cis- O 
isomer O 
, O 
reduced O 
cerebral O 
infarct O 
volume O 
. O 
Interestingly O 
, O 
however O 
, O 
post O 
- O 
ischemic O 
treatment O 
with O 
both O 
hinokiresinols B-FAMILY 
( O 
2 O 
and O 
7 O 
h O 
after O 
onset O 
of O 
ischemia O 
) O 
significantly O 
reduced O 
cerebral O 
infarct O 
. O 
When O 
administered O 
after O 
onset O 
of O 
ischemia O 
, O 
trans-hinokiresinol B-TRIVIAL 
, O 
but O 
not O 
its O 
cis- O 
isomer O 
reduced O 
nitrotyrosine B-SYSTEMATIC 
immunoreactivity O 
in O 
ischemic O 
regions O 
. O 
In O 
contrast O 
, O 
both O 
hinokiresinols B-FAMILY 
suppressed O 
neutrophil O 
infiltration O 
and O 
IL-1β O 
release O 
to O 
a O 
similar O 
extent O 
. O 
The O 
observed O 
differential O 
anti-oxidant O 
, O 
but O 
comparable O 
anti-inflammatory O 
, O 
activities O 
may O 
explain O 
the O 
stereo O 
- O 
specific O 
anti-ischemic O 
activities O 
and O 
different O 
therapeutic O 
time O 
windows O 
of O 
the O 
hinokiresinols B-FAMILY 
examined O 
. O 
More O 
detailed O 
delineation O 
of O 
the O 
anti-ischemic O 
mechanism(s) O 
of O 
hinokiresinols B-FAMILY 
may O 
provide O 
a O 
better O 
strategy O 
for O 
development O 
of O 
efficacious O 
regimens O 
for O 
cerebral O 
ischemic O 
stroke O 
. O 

yellow I-TRIVIAL 
FCF I-TRIVIAL 
, O 
a O 
permitted O 
food O 
dye O 
, O 
alters O 
functional O 
responses O 
of O 
splenocytes O 
at O 
non-cytotoxic O 
dose O 
. O 

yellow I-TRIVIAL 
FCF I-TRIVIAL 
( O 
SY O 
) O 
, O 
a O 
permitted O 
food O 
color O 
, O 
is O 
extensively O 
used O 
in O 
various O 
food O 
preparations O 
and O 
quite O 
often O 
exceeds O 
the O 
permissible O 
levels O 
( O 
100-200 O 
mg O 
/ O 
kg O 
) O 
. O 
Several O 
toxicity O 
studies O 
on O 
SY O 
are O 
reported O 
, O 
however O 
immunomodulatory O 
properties O 
have O 
not O 
been O 
explored O 
yet O 
. O 
To O 
investigate O 
the O 
immunotoxic O 
properties O 
of O 
SY O 
, O 
splenocytes O 
were O 
isolated O 
, O 
cultured O 
and O 
subjected O 
to O 
mitogen O 
stimulated O 
proliferation O 
assay O 
( O 
lipopolysaccharide O 
, O 
LPS O 
or O 
concanavalin O 
A O 
, O 
Con O 
A O 
) O 
, O 
mixed O 
lymphocyte O 
reaction O 
( O 
MLR O 
) O 
assay O 
, O 
immunophenotypic O 
analysis O 
of O 
cell O 
surface O 
receptor O 
expression O 
and O 
assay O 
for O 
cytokines O 
release O 
in O 
the O 
culture O 
supernatants O 
were O 
performed O 
in O 
the O 
presence O 
of O 
SY O 
. O 
Since O 
SY O 
did O 
not O 
exhibit O 
any O 
cytotoxicity O 
up O 
to O 
250 O 
μg O 
/ O 
ml O 
, O 
this O 
dose O 
was O 
used O 
for O 
further O 
studies O 
. O 
It O 
was O 
observed O 
that O 
SY O 
( O 
250 O 
μg O 
/ O 
ml O 
) O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
suppressed O 
the O 
mitogen O 
induced O 
proliferation O 
of O 
splenocytes O 
and O 
MLR O 
response O 
. O 
Further O 
, O 
immunophenotypic O 
analysis O 
revealed O 
that O 
SY O 
alters O 
the O 
relative O 
expression O 
of O 
CD3e O 
/ O 
CD4 O 
/ O 
CD8 O 
in O 
T O 
cells O 
and O 
CD19 O 
in O 
B-cells O 
. O 
Consistent O 
with O 
the O 
suppression O 
of O 
T-cell O 
and O 
B-cell O 
responses O 
and O 
altered O 
surface O 
receptor O 
expression O 
, O 
SY O 
also O 
lowered O 
the O 
expression O 
of O 
IL2 O 
, O 
IL4 O 
, O 
IL6 O 
, O 
IL-17 O 
, O 
IFN-γ O 
and O 
TNF-α O 
cytokines O 
. O 
These O 
results O 
suggest O 
that O 
non-cytotoxic O 
dose O 
of O 
SY O 
may O 
have O 
immunomodulatory O 
effects O 
. O 

trypsin O 
inhibitors O 
and O 
one O 
chymotrypsin O 
inhibitor O 
from O 
Chinese O 
Daboia O 
russellii O 
siamensis O 
venom O 
, O 
denoted O 
as O 
CBPTI-1 O 
, O 
CBPTI-2 O 
and O 
CBPTI-3 O 
were O 
purified O 
, O 
characterized O 
and O 
cloned O 
from O 
lyophilized O 
venom O 
- O 
derived O 
cDNA O 
libraries O 
. O 
The O 
N B-FORMULA 
-terminus O 
of O 
CBPTI-1 O 
was O 
modified O 
and O 
not O 
amenable O 
to O 
Edman O 
degradation O 
sequencing O 
, O 
however O 
an O 
internal O 
partial O 
sequence O 
was O 
found O 
to O 
be O 
SGRCRGHLRRIYYNPDSNKCE O 
. O 
The O 
N B-FORMULA 
-termini O 
of O 
CBPTI-2 O 
and O 
CBPTI-3 O 
were O 
unmodified O 
and O 
their O 
partial O 
sequences O 
were O 
established O 
as O 
HDRPTFCNLAPESGRCRAH O 
and O 
HDRPKFCYLPADPGECMAYIRSFYYDS O 
respectively O 
. O 
From O 
cloning O 
studies O 
CBPTI-1 O 
was O 
found O 
to O 
consist O 
of O 
66 O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
, O 
while O 
CBPTI-2 O 
and O 
CBPTI-3 O 
precursors O 
consist O 
of O 
60 O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
, O 
including O 
6 O 
cysteine B-TRIVIAL 
residues O 
. O 
Another O 
cDNA O 
sequence O 
( O 
CBPTI-4 O 
) O 
was O 
also O 
obtained O 
. O 
Alignment O 
of O 
cDNA O 
sequences O 
showed O 
that O 
CBPTI-3 O 
exhibited O 
similar O 
sequence O 
homology O 
to O 
CBPTI-4 O 
cDNA O 
except O 
for O 
an O 
8 O 
nucleotide B-FAMILY 
deletion O 
in O 
the O 
open O 
- O 
reading O 
frame O 
. O 
CBPTI-1 O 
and O 
CBPTI-2 O 
were O 
demonstrated O 
to O 
be O 
potent O 
trypsin O 
inhibitors O 
, O 
but O 
were O 
also O 
shown O 
to O 
be O 
effectively O 
potent O 
in O 
chymotrypsin O 
inhibition O 
. O 
The O 
K O 
(i) O 
values O 
of O 
CBPTI-1 O 
and O 
CBPTI-2 O 
for O 
trypsin O 
inhibition O 
were O 
4.07 O 
× O 
10(-7) O 
M O 
and O 
6.66 O 
× O 
10(-7) O 
M O 
, O 
respectively O 
, O 
and O 
they O 
were O 
non-competitive O 
in O 
their O 
activity O 
. O 
CBPTI-3 O 
showed O 
chymotrypsin O 
inhibition O 
activity O 
with O 
a O 
K O 
(i) O 
value O 
of O 
2.55 O 
× O 
10(-9) O 
M O 
, O 
but O 
did O 
not O 
show O 
trypsin O 
inhibitor O 
activity O 
. O 

phytochemical O 
studies O 
have O 
shown O 
that O 
the O 
plants O 
of O 
the O 
Albizia O 
genus O 
( O 
Fabaceae O 
) O 
contain O 
bioactive O 
saponins B-FAMILY 
, O 
lignans B-FAMILY 
, O 
spermine B-FAMILY 
alkaloids I-FAMILY 
, O 
flavonoids B-FAMILY 
, O 
glycosides B-FAMILY 
phenols I-FAMILY 
and O 
pyridoxine B-TRIVIAL 
derivatives O 
. O 
Their O 
extracts O 
sometimes O 
display O 
medical O 
properties O 
, O 
but O 
can O 
have O 
also O 
toxic O 
effects O 
. O 
The O 
purpose O 
of O 
our O 
study O 
was O 
to O 
determine O 
the O 
in O 
vivo O 
toxicity O 
of O 
Albizia O 
bernieri O 
seeds O 
in O 
the O 
experimental O 
model O 
of O 
the O 
medaka O 
fish O 
embryo O 
, O 
which O 
is O 
recommended O 
for O 
use O 
in O 
toxicity O 
studies O 
. O 
Our O 
results O 
show O 
clearly O 
that O 
incubating O 
the O 
embryos O 
or O 
larvae O 
of O 
the O 
medaka O 
fish O 
in O 
a O 
medium O 
containing O 
A O 
. O 
bernieri O 
extracts O 
caused O 
a O 
dose O 
- O 
dependent O 
reduction O 
in O 
embryo O 
or O 
larvae O 
survival O 
. O 
Embryos O 
exposed O 
to O 
an O 
extract O 
of O 
A O 
. O 
bernieri O 
displayed O 
cerebral O 
lesions O 
, O 
such O 
as O 
cell O 
lysis O 
and O 
the O 
emergence O 
of O 
lysosomes O 
in O 
the O 
glial O 
tissue O 
. O 
We O 
conclude O 
that O 
when O 
comparing O 
with O 
data O 
obtained O 
with O 
different O 
plant O 
extracts O 
tested O 
on O 
medaka O 
development O 
in O 
our O 
laboratory O 
, O 
A O 
. O 
bernieri O 
displays O 
an O 
unusually O 
high O 
toxicity O 
. O 
Focussing O 
on O 
the O 
cerebral O 
target O 
as O 
well O 
as O 
the O 
fish O 
behaviour O 
could O 
bring O 
more O 
specific O 
informations O 
. O 

stabilization O 
of O 
antiparallel O 
DNA O 
triplexes O 
by O 
strong O 
stacking O 
effects O 
of O 
consecutively O 
modified O 
nucleobases O 
containing O 
thiocarbonyl B-SYSTEMATIC 
groups O 
. O 

consecutive O 
arrangement O 
of O 
2'-deoxy-6-thioguanosines B-FAMILY 
( O 
s(6)Gs B-FAMILY 
) O 
and O 
4-thiothymidines B-FAMILY 
( O 
s(4)Ts B-FAMILY 
) O 
in O 
antiparallel O 
triplex O 
- O 
forming O 
oligonucleotides O 
( O 
TFOs O 
) O 
considerably O 
stabilized O 
the O 
resulting O 
antiparallel O 
triplexes O 
with O 
high O 
base O 
recognition O 
ability O 
by O 
the O 
strong O 
stacking O 
effects O 
of O 
thiocarbonyl B-SYSTEMATIC 
groups O 
. O 
This O 
result O 
was O 
remarkable O 
because O 
chemical O 
modifications O 
of O 
the O 
sugar B-FAMILY 
moieties O 
and O 
nucleobases O 
of O 
antiparallel O 
TFOs O 
generally O 
destabilize O 
triplex O 
structures O 
. O 
Moreover O 
, O 
in O 
comparison O 
with O 
unmodified O 
TFOs O 
, O 
it O 
was O 
found O 
that O 
TFOs O 
containing O 
s(6)Gs B-FAMILY 
and O 
s(4)Ts B-FAMILY 
could O 
selectively O 
bind O 
to O 
the O 
complementary O 
DNA O 
duplex O 
but O 
not O 
to O 
mismatched O 
DNA O 
duplexes O 
or O 
single O 
- O 
stranded O 
RNA O 
. O 

evidence O 
has O 
challenged O 
the O 
default O 
assumption O 
that O 
all O 
DNA-reactive O 
alkylating O 
agents O 
exhibit O 
a O 
linear O 
dose O 
- O 
response O 
. O 
Emerging O 
evidence O 
suggests O 
that O 
the O 
model O 
alkylating O 
agents O 
methyl B-SYSTEMATIC 
- O 
and O 
ethylmethanesulfonate B-SYSTEMATIC 
and O 
methylnitrosourea B-SYSTEMATIC 
( O 
MNU B-ABBREVIATION 
) O 
and O 
ethylnitrosourea B-SYSTEMATIC 
observe O 
a O 
nonlinear O 
dose O 
- O 
response O 
with O 
a O 
no O 
observed O 
genotoxic O 
effect O 
level O 
( O 
NOGEL O 
) O 
. O 
Follow O 
- O 
up O 
mechanistic O 
studies O 
are O 
essential O 
to O 
understand O 
the O 
mechanism O 
of O 
cellular O 
tolerance O 
and O 
biological O 
relevance O 
of O 
such O 
NOGELs O 
. O 
MNU B-ABBREVIATION 
is O 
one O 
of O 
the O 
most O 
mutagenic O 
simple O 
alkylators O 
. O 
Therefore O 
, O 
understanding O 
the O 
mechanism O 
of O 
mutation O 
induction O 
, O 
following O 
low O 
- O 
dose O 
MNU B-ABBREVIATION 
treatment O 
, O 
sets O 
precedence O 
for O 
weaker O 
mutagenic O 
alkylating O 
agents O 
. O 
Here O 
, O 
we O 
tested O 
MNU B-ABBREVIATION 
at O 
10-fold O 
lower O 
concentrations O 
than O 
a O 
previous O 
study O 
and O 
report O 
a O 
NOGEL O 
of O 
0.0075 O 
µg O 
/ O 
ml O 
( O 
72.8nM O 
) O 
in O 
human O 
lymphoblastoid O 
cells O 
, O 
quantified O 
through O 
the O 
hypoxanthine B-TRIVIAL 
( O 
guanine B-TRIVIAL 
) O 
phosphoribosyltransferase O 
assay O 
( O 
OECD O 
476 O 
) O 
. O 
Mechanistic O 
studies O 
reveal O 
that O 
the O 
NOGEL O 
is O 
dependent O 
upon O 
repair O 
of O 
O(6)-methylguanine B-SYSTEMATIC 
( O 
O(6)MeG B-FORMULA 
) O 
by O 
the O 
suicide O 
enzyme O 
O(6)MeG B-FORMULA 
-DNA O 
methyltransferase O 
( O 
MGMT O 
) O 
. O 
Inactivation O 
of O 
MGMT O 
sensitizes O 
cells O 
to O 
MNU B-ABBREVIATION 
-induced O 
mutagenesis O 
and O 
shifts O 
the O 
NOGEL O 
to O 
the O 
left O 
on O 
the O 
dose O 
axis O 
. O 

animal O 
model O 
of O 
marginal O 
iodine B-SYSTEMATIC 
deficiency O 
during O 
development O 
: O 
the O 
thyroid O 
axis O 
and O 
neurodevelopmental O 
outcome O 
. O 

hormones O 
( O 
THs O 
) O 
are O 
essential O 
for O 
brain O 
development O 
, O 
and O 
iodine B-SYSTEMATIC 
is O 
required O 
for O 
TH O 
synthesis O 
. O 
Environmental O 
chemicals O 
that O 
perturb O 
the O 
thyroid O 
axis O 
result O 
in O 
modest O 
reductions O 
in O 
TH O 
, O 
yet O 
there O 
is O 
a O 
paucity O 
of O 
data O 
on O 
the O 
extent O 
of O 
neurological O 
impairments O 
associated O 
with O 
low O 
- O 
level O 
TH O 
disruption O 
. O 
This O 
study O 
examined O 
the O 
dose O 
- O 
response O 
characteristics O 
of O 
marginal O 
iodine B-SYSTEMATIC 
deficiency O 
( O 
ID O 
) O 
on O 
parameters O 
of O 
thyroid O 
function O 
and O 
neurodevelopment O 
. O 
Diets O 
deficient O 
in O 
iodine B-SYSTEMATIC 
were O 
prepared O 
by O 
adding O 
975 O 
, O 
200 O 
, O 
125 O 
, O 
25 O 
, O 
or O 
0 O 
µg O 
/ O 
kg O 
potassium B-SYSTEMATIC 
iodate I-SYSTEMATIC 
to O 
the O 
base O 
casein O 
diet O 
to O 
produce O 
five O 
nominal O 
iodine B-SYSTEMATIC 
levels O 
ranging O 
from O 
ample O 
( O 
Diet O 
1 O 
: O 
1000 O 
μg O 
iodine B-SYSTEMATIC 
/ O 
kg O 
chow O 
, O 
D1 O 
) O 
to O 
deficient O 
( O 
Diet O 
5 O 
: O 
25 O 
µg O 
iodine B-SYSTEMATIC 
/ O 
kg O 
chow O 
, O 
D5 O 
) O 
. O 
Female O 
Long O 
Evans O 
rats O 
were O 
maintained O 
on O 
these O 
diets O 
beginning O 
7 O 
weeks O 
prior O 
to O 
breeding O 
until O 
the O 
end O 
of O 
lactation O 
. O 
Dams O 
were O 
sacrificed O 
on O 
gestational O 
days O 
16 O 
and O 
20 O 
, O 
or O 
when O 
pups O 
were O 
weaned O 
on O 
postnatal O 
day O 
( O 
PN O 
) O 
21 O 
. O 
Fetal O 
tissue O 
was O 
harvested O 
from O 
the O 
dams O 
, O 
and O 
pups O 
were O 
sacrificed O 
on O 
PN14 O 
and O 
PN21 O 
. O 
Blood O 
, O 
thyroid O 
gland O 
, O 
and O 
brain O 
were O 
collected O 
for O 
analysis O 
of O 
iodine B-SYSTEMATIC 
, O 
TH O 
, O 
and O 
TH O 
precursors O 
and O 
metabolites O 
. O 
Serum O 
and O 
thyroid O 
gland O 
iodine B-SYSTEMATIC 
and O 
TH O 
were O 
reduced O 
in O 
animals O 
receiving O 
two O 
diets O 
that O 
were O 
most O 
deficient O 
in O 
iodine B-SYSTEMATIC 
. O 
T4 O 
was O 
reduced O 
in O 
the O 
fetal O 
brain O 
but O 
was O 
not O 
altered O 
in O 
the O 
neonatal O 
brain O 
. O 
Neurobehavior O 
, O 
assessed O 
by O 
acoustic O 
startle O 
, O 
water O 
maze O 
learning O 
, O 
and O 
fear O 
conditioning O 
, O 
was O 
unchanged O 
in O 
adult O 
offspring O 
, O 
but O 
excitatory O 
synaptic O 
transmission O 
was O 
impaired O 
in O 
the O 
dentate O 
gyrus O 
in O 
animals O 
receiving O 
two O 
diets O 
that O 
were O 
most O 
deficient O 
in O 
iodine B-SYSTEMATIC 
. O 
A O 
15% O 
reduction O 
in O 
cortical O 
T4 O 
in O 
the O 
fetal O 
brain O 
was O 
sufficient O 
to O 
induce O 
permanent O 
reductions O 
in O 
synaptic O 
function O 
in O 
adults O 
. O 
These O 
findings O 
have O 
implications O 
for O 
regulation O 
of O 
TH-disrupting O 
chemicals O 
and O 
suggest O 
that O 
standard O 
behavioral O 
assays O 
do O 
not O 
readily O 
detect O 
neurotoxicity O 
induced O 
by O 
modest O 
developmental O 
TH O 
disruption O 
. O 

, O 
a O 
tyrosine B-TRIVIAL 
kinase O 
inhibitor O 
, O 
induces O 
cytochrome O 
P450 O 
1A1 O 
gene O 
in O 
human O 
breast O 
cancer O 
MCF7 O 
cells O 
through O 
ligand O 
- O 
independent O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
activation O 
. O 

( O 
SUN B-ABBREVIATION 
) O 
is O 
a O 
new O 
multi O 
- O 
targeted O 
oral O 
tyrosine B-TRIVIAL 
kinase O 
inhibitor O 
that O 
has O 
both O 
anti-angiogenic O 
and O 
anti-tumor O 
activities O 
. O 
However O 
, O 
information O 
reported O 
in O 
the O 
literature O 
on O 
the O 
effects O 
of O 
SUN B-ABBREVIATION 
on O 
the O 
constitutive O 
expression O 
of O 
cytochrome O 
P450 O 
1A1 O 
( O 
CYP1A1 O 
) O 
gene O 
in O 
cells O 
from O 
mammalian O 
species O 
remains O 
unclear O 
. O 
Therefore O 
, O 
the O 
main O 
objectives O 
of O 
the O 
current O 
work O 
were O 
to O 
investigate O 
the O 
potentiality O 
of O 
SUN B-ABBREVIATION 
to O 
induce O 
CYP1A1 O 
gene O 
expression O 
in O 
human O 
breast O 
cancer O 
MCF7 O 
cells O 
and O 
to O 
explore O 
the O 
molecular O 
mechanisms O 
involved O 
. O 
Our O 
results O 
showed O 
that O 
SUN B-ABBREVIATION 
induced O 
the O 
CYP1A1 O 
mRNA O 
, O 
protein O 
, O 
and O 
activity O 
levels O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
in O 
MCF7 O 
cells O 
. O 
The O 
increase O 
in O 
CYP1A1 O 
mRNA O 
by O 
SUN B-ABBREVIATION 
was O 
completely O 
blocked O 
by O 
the O 
transcriptional O 
inhibitor O 
, O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
; O 
implying O 
that O 
SUN B-ABBREVIATION 
increased O 
de O 
novo O 
RNA O 
synthesis O 
. O 
Furthermore O 
, O 
the O 
ability O 
of O 
SUN B-ABBREVIATION 
to O 
increase O 
luciferase O 
reporter O 
gene O 
expression O 
suggests O 
an O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
(AhR)-dependent O 
transcriptional O 
control O 
and O 
excludes O 
the O 
possibility O 
of O 
any O 
posttranscriptional O 
mechanisms O 
. O 
In O 
addition O 
, O 
blocking O 
of O 
AhR O 
activation O 
by O 
resveratrol O 
, O 
a O 
well O 
- O 
known O 
AhR O 
antagonist O 
, O 
prevented O 
the O 
SUN B-ABBREVIATION 
-induced O 
CYP1A1 O 
gene O 
expression O 
, O 
further O 
confirms O 
the O 
involvement O 
of O 
AhR O 
. O 
Interestingly O 
, O 
this O 
was O 
associated O 
with O 
the O 
inability O 
of O 
SUN B-ABBREVIATION 
to O 
directly O 
bind O 
to O 
and O 
induce O 
transformation O 
of O 
cytosolic O 
AhR O 
to O 
its O 
DNA O 
- O 
binding O 
form O 
in O 
vitro O 
, O 
suggesting O 
that O 
the O 
effect O 
of O 
SUN B-ABBREVIATION 
does O 
not O 
involve O 
direct O 
binding O 
to O 
AhR O 
. O 
The O 
current O 
manuscript O 
provides O 
the O 
first O 
evidence O 
for O 
the O 
ability O 
of O 
SUN B-ABBREVIATION 
to O 
induce O 
CYP1A1 O 
gene O 
expression O 
in O 
MCF7 O 
cells O 
through O 
AhR O 
ligand O 
- O 
independent O 
mechanisms O 
. O 

profile O 
of O 
artemisinin B-TRIVIAL 
derivatives O 
and O 
companion O 
drugs O 
used O 
in O 
artemisinin B-TRIVIAL 
-based O 
combination O 
therapies O 
for O 
the O 
treatment O 
of O 
Plasmodium O 
falciparum O 
malaria O 
in O 
children O 
. O 

is O 
one O 
of O 
the O 
most O 
common O 
parasitic O 
infections O 
worldwide O 
. O 
Plasmodium O 
falciparum O 
is O 
the O 
most O 
prevalent O 
strain O 
in O 
Africa O 
and O 
also O 
the O 
most O 
fatal O 
. O 
The O 
disease O 
especially O 
affects O 
children O 
, O 
with O 
those O 
under O 
age O 
5 O 
years O 
accounting O 
for O 
approximately O 
86 O 
% O 
of O 
malaria O 
deaths O 
in O 
2010 O 
. O 
The O 
objectives O 
of O 
this O 
review O 
are O 
to O 
summarize O 
and O 
evaluate O 
published O 
literature O 
reporting O 
the O 
pharmacokinetic O 
parameters O 
of O 
artemisinin B-TRIVIAL 
-based O 
combinations O 
used O 
to O 
treat O 
P O 
. O 
falciparum O 
in O 
paediatric O 
populations O 
and O 
to O 
identify O 
and O 
discuss O 
controversies O 
regarding O 
pharmacokinetics O 
of O 
these O 
agents O 
in O 
children O 
. O 
A O 
search O 
of O 
MEDLINE O 
( O 
1948-September O 
2012 O 
) O 
, O 
EMBASE O 
( O 
1980-September O 
2012 O 
) O 
, O 
International O 
Pharmaceutical O 
Abstracts O 
( O 
1970-September O 
2012 O 
) O 
, O 
Google O 
and O 
Google O 
Scholar O 
was O 
conducted O 
for O 
articles O 
describing O 
pharmacokinetics O 
of O 
antimalarials O 
in O 
children O 
. O 
Our O 
search O 
produced O 
30 O 
articles O 
, O 
of O 
which O 
23 O 
were O 
included O 
in O 
the O 
review O 
: O 
artemisinin B-TRIVIAL 
compounds O 
, O 
12 O 
articles O 
; O 
lumefantrine B-TRIVIAL 
, O 
four O 
articles O 
; O 
amodiaquine B-TRIVIAL 
, O 
five O 
articles O 
; O 
sulfadoxine B-TRIVIAL 
, O 
six O 
articles O 
; O 
pyrimethamine B-TRIVIAL 
, O 
one O 
article O 
; O 
mefloquine B-TRIVIAL 
, O 
three O 
articles O 
; O 
and O 
piperaquine B-TRIVIAL 
, O 
two O 
articles O 
. O 
Studies O 
were O 
summarized O 
based O 
on O 
comparison O 
groups O 
and O 
major O 
findings O 
. O 
Many O 
controversies O 
were O 
identified O 
, O 
including O 
pharmacokinetic O 
equivalence O 
of O 
novel O 
dosage O 
forms O 
, O 
altered O 
pharmacokinetic O 
parameters O 
in O 
children O 
versus O 
adults O 
, O 
effect O 
of O 
drug O 
interactions O 
, O 
and O 
association O 
of O 
pharmacokinetic O 
changes O 
with O 
clinical O 
outcomes O 
. O 
A O 
large O 
variation O 
in O 
pharmacokinetic O 
parameters O 
of O 
many O 
antimalarial O 
agents O 
was O 
shown O 
, O 
which O 
may O 
be O 
a O 
consequence O 
of O 
the O 
wide O 
range O 
of O 
ages O 
and O 
/ O 
or O 
bodyweights O 
of O 
each O 
paediatric O 
cohort O 
. O 
These O 
studies O 
may O 
mask O 
important O 
associations O 
with O 
age O 
and O 
bodyweight O 
and O 
produce O 
mean O 
data O 
that O 
do O 
not O 
adequately O 
represent O 
the O 
paediatric O 
population O 
as O 
a O 
whole O 
. O 
In O 
order O 
to O 
properly O 
assess O 
the O 
clinical O 
implications O 
of O 
such O 
pharmacokinetic O 
changes O 
and O 
recommend O 
safe O 
and O 
effective O 
dosage O 
regimens O 
, O 
there O 
is O 
an O 
urgent O 
need O 
for O 
dose O 
- O 
optimization O 
studies O 
for O 
all O 
recommended O 
first- O 
and O 
second O 
- O 
line O 
agents O 
, O 
along O 
with O 
the O 
different O 
drug O 
formulations O 
, O 
used O 
in O 
paediatric O 
populations O 
with O 
P O 
. O 
falciparum O 
. O 

and O 
stereospecificity O 
of O 
human O 
UDP B-ABBREVIATION 
-glucuronosyltransferases O 
in O 
the O 
glucuronidation O 
of O 
estriol B-TRIVIAL 
, O 
16-epiestriol B-SYSTEMATIC 
, O 
17-epiestriol B-SYSTEMATIC 
, O 
and O 
13-epiestradiol B-SYSTEMATIC 
. O 

glucuronidation O 
of O 
estriol B-TRIVIAL 
, O 
16-epiestriol B-SYSTEMATIC 
, O 
and O 
17-epiestriol B-SYSTEMATIC 
by O 
the O 
human O 
UDP B-ABBREVIATION 
-glucuronosyltransferases O 
( O 
UGTs O 
) O 
of O 
subfamilies O 
1A O 
, O 
2A O 
, O 
and O 
2B O 
was O 
examined O 
. O 
UGT1A10 O 
is O 
highly O 
active O 
in O 
the O 
conjugation O 
of O 
the O 
3-OH B-SYSTEMATIC 
in O 
all O 
these O 
estriols B-FAMILY 
, O 
whereas O 
UGT2B7 O 
is O 
the O 
most O 
active O 
UGT O 
toward O 
one O 
of O 
the O 
ring O 
D O 
hydroxyls O 
, O 
the O 
16-OH B-SYSTEMATIC 
in O 
estriol B-TRIVIAL 
and O 
16-epiestriol B-SYSTEMATIC 
, O 
but O 
the O 
17-OH B-SYSTEMATIC 
in O 
17-epiestriol B-SYSTEMATIC 
. O 
Kinetic O 
analyses O 
indicated O 
that O 
the O 
17-OH B-SYSTEMATIC 
configuration O 
plays O 
a O 
major O 
role O 
in O 
the O 
affinity O 
of O 
UGT2B7 O 
for O 
estrogens B-FAMILY 
. O 
The O 
glucuronidation O 
of O 
the O 
different O 
estriols B-FAMILY 
by O 
the O 
human O 
liver O 
and O 
intestine O 
microsomes O 
reflects O 
the O 
activity O 
of O 
UGT1A10 O 
and O 
UGT2B7 O 
in O 
combination O 
with O 
the O 
tissues O 
' O 
difference O 
in O 
UGT1A10 O 
expression O 
. O 
The O 
UGT1A10 O 
mutant O 
1A10-F93G O 
exhibited O 
much O 
higher O 
V(max) O 
values O 
than O 
UGT1A10 O 
in O 
estriol B-TRIVIAL 
and O 
17-epiestriol B-SYSTEMATIC 
glucuronidation O 
, O 
but O 
a O 
significantly O 
lower O 
value O 
in O 
16-epiestriol B-SYSTEMATIC 
glucuronidation O 
. O 
To O 
this O 
study O 
on O 
estriol B-TRIVIAL 
glucuronidation O 
we O 
have O 
added O 
experiments O 
with O 
13-epiestradiol B-SYSTEMATIC 
, O 
a O 
synthetic O 
estradiol B-TRIVIAL 
in O 
which O 
the O 
spatial O 
arrangement O 
of O 
the O 
methyl B-SYSTEMATIC 
on O 
C18 O 
and O 
the O 
hydroxyl B-SYSTEMATIC 
on O 
C17 O 
is O 
significantly O 
different O 
than O 
in O 
other O 
estrogens B-FAMILY 
. O 
In O 
comparison O 
with O 
estradiol B-TRIVIAL 
glucuronidation O 
, O 
the O 
C13 O 
configuration O 
change O 
decreases O 
the O 
turnover O 
of O 
UGTs O 
that O 
conjugate O 
the O 
3-OH B-SYSTEMATIC 
, O 
but O 
increases O 
it O 
in O 
UGTs O 
that O 
primarily O 
conjugate O 
the O 
17-OH B-SYSTEMATIC 
. O 
Unexpectedly O 
, O 
UGT2B17 O 
exhibited O 
similar O 
conjugation O 
rates O 
of O 
both O 
the O 
17-OH B-SYSTEMATIC 
and O 
3-OH B-SYSTEMATIC 
of O 
13-espiestradiol B-SYSTEMATIC 
. O 
The O 
combined O 
results O 
reveal O 
the O 
strong O 
preference O 
of O 
UGT1A10 O 
for O 
the O 
3-OH B-SYSTEMATIC 
of O 
physiologic O 
estrogens B-FAMILY 
and O 
the O 
equivalently O 
strong O 
preference O 
of O 
UGT2B7 O 
and O 
UGT2B17 O 
for O 
the O 
hydroxyls B-FAMILY 
on O 
ring O 
D O 
of O 
such O 
steroid B-FAMILY 
steroid B-FAMILY 
hormones I-FAMILY 
. O 

expression O 
of O 
cytochrome O 
P450 O 
1A O 
and O 
NAD(P)H B-ABBREVIATION 
: O 
quinone B-FAMILY 
oxidoreductase O 
determined O 
at O 
mRNA O 
, O 
protein O 
, O 
and O 
enzyme O 
activity O 
levels O 
in O 
rats O 
exposed O 
to O 
the O 
carcinogenic O 
azo B-SYSTEMATIC 
dye O 
1-phenylazo-2-naphthol B-SYSTEMATIC 
( O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
) O 
. O 

I I-TRIVIAL 
( O 
1-phenylazo-2-hydroxynaphthol B-SYSTEMATIC 
) O 
is O 
a O 
suspected O 
human O 
carcinogen O 
causing O 
tumors O 
in O 
the O 
livers O 
and O 
urinary O 
bladders O 
of O 
rats O 
, O 
mice O 
, O 
and O 
rabbits O 
. O 
Here O 
, O 
we O 
investigated O 
for O 
the O 
first O 
time O 
the O 
influence O 
of O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
exposure O 
on O 
the O 
expression O 
of O 
several O 
biotransformation O 
enzymes O 
in O 
the O 
livers O 
, O 
kidneys O 
, O 
and O 
lungs O 
of O 
rats O 
concomitantly O 
at O 
the O 
mRNA O 
and O 
protein O 
levels O 
and O 
assayed O 
their O 
enzymatic O 
activities O 
. O 
We O 
also O 
studied O 
its O 
effect O 
on O 
the O 
formation O 
of O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
-derived O 
DNA O 
adducts O 
in O 
vitro O 
. O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
increased O 
the O 
total O 
amounts O 
of O 
cytochrome O 
P450 O 
( O 
P450 O 
) O 
in O 
all O 
organs O 
tested O 
. O 
Western O 
blots O 
using O 
antibodies O 
raised O 
against O 
various O 
P450s O 
, O 
NADPH B-ABBREVIATION 
: O 
P450 O 
reductase O 
, O 
and O 
NAD(P)H B-ABBREVIATION 
: O 
quinone B-FAMILY 
oxidoreductase O 
1 O 
( O 
NQO1 O 
) O 
showed O 
that O 
the O 
expression O 
of O 
P450 O 
1A1 O 
and O 
NQO1 O 
was O 
induced O 
in O 
the O 
liver O 
, O 
kidney O 
, O 
and O 
lung O 
of O 
rats O 
treated O 
with O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
. O 
The O 
higher O 
protein O 
levels O 
correlated O 
with O 
increased O 
enzyme O 
activities O 
of O 
P450 O 
1A1 O 
/ O 
2 O 
and O 
NQO1 O 
. O 
Furthermore O 
, O 
9.9- O 
, O 
5.9- O 
, O 
and O 
2.8-fold O 
increases O 
in O 
the O 
formation O 
of O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
oxidative O 
metabolites O 
catalyzed O 
by O 
microsomes O 
isolated O 
from O 
the O 
liver O 
, O 
kidney O 
, O 
and O 
lung O 
, O 
respectively O 
, O 
of O 
rats O 
treated O 
with O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
were O 
found O 
. O 
The O 
relative O 
amounts O 
of O 
P450 O 
1A O 
and O 
NQO1 O 
mRNA O 
, O 
measured O 
by O 
real O 
- O 
time O 
polymerase O 
chain O 
reaction O 
( O 
RT-PCR O 
) O 
analysis O 
, O 
demonstrated O 
that O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
induced O 
the O 
expression O 
of O 
P450 O 
1A1 O 
and O 
NQO1 O 
mRNA O 
in O 
the O 
liver O 
, O 
kidney O 
, O 
and O 
lung O 
, O 
and O 
of O 
P450 O 
1A2 O 
mRNA O 
in O 
kidney O 
and O 
lung O 
. O 
Finally O 
, O 
microsomes O 
isolated O 
from O 
livers O 
, O 
kidneys O 
, O 
and O 
lungs O 
of O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
exposed O 
rats O 
more O 
effectively O 
catalyzed O 
the O 
formation O 
of O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
-DNA O 
adducts O 
than O 
microsomes O 
from O 
organs O 
of O 
control O 
rats O 
. O 
This O 
was O 
attributable O 
to O 
the O 
higher O 
P450 O 
1A1 O 
expression O 
. O 
Because O 
P450 O 
1A1 O 
is O 
playing O 
a O 
major O 
role O 
in O 
the O 
bioactivation O 
of O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
in O 
rat O 
and O 
human O 
systems O 
, O 
its O 
induction O 
by O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
may O 
have O 
a O 
profound O 
effect O 
on O 
cancer O 
risk O 
by O 
this O 
azo B-SYSTEMATIC 
dye O 
. O 
In O 
addition O 
, O 
the O 
induction O 
of O 
P450 O 
1A1 O 
/ O 
2 O 
and O 
NQO1 O 
enzymes O 
can O 
influence O 
individual O 
human O 
susceptibility O 
to O 
other O 
environmental O 
carcinogens O 
and O 
have O 
an O 
effect O 
on O 
cancer O 
risk O 
. O 

interacts O 
with O 
both O 
the O 
iron B-SYSTEMATIC 
center O 
and O 
the O 
porphyrin B-FAMILY 
ring O 
of O 
heme B-FAMILY 
: O 
mechanism O 
of O 
heme B-FAMILY 
' O 
s O 
action O 
on O 
Aβ O 
aggregation O 
and O 
disaggregation O 
. O 

β O 
peptide O 
( O 
Aβ O 
) O 
aggregation O 
is O 
a O 
pathological O 
hallmark O 
of O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
. O 
Modulation O 
of O 
the O 
self O 
- O 
assembly O 
processes O 
, O 
therefore O 
, O 
is O 
thought O 
to O 
be O 
an O 
attractive O 
strategy O 
for O 
the O 
prevention O 
and O 
treatment O 
of O 
AD O 
. O 
Interestingly O 
, O 
heme B-FAMILY 
has O 
been O 
found O 
to O 
inhibit O 
Aβ O 
aggregation O 
and O 
even O 
dismantle O 
Aβ O 
aggregates O 
. O 
However O 
, O 
the O 
mechanism O 
remains O 
unresolved O 
. O 
Recent O 
research O 
has O 
shown O 
that O 
heme B-FAMILY 
binds O 
preferentially O 
to O 
the O 
His B-FORMULA 
( O 
13 O 
) O 
residue O 
of O 
Aβ O 
with O 
the O 
iron B-SYSTEMATIC 
center O 
, O 
while O 
the O 
hydrophobic O 
domain O 
of O 
Aβ O 
is O 
also O 
able O 
to O 
bind O 
to O 
heme B-FAMILY 
. O 
Herein O 
, O 
absorption O 
spectrometric O 
, O 
Thioflavin B-TRIVIAL 
T I-TRIVIAL 
fluorescence O 
, O 
and O 
circular O 
dichroism O 
spectroscopic O 
and O 
transmission O 
electron O 
microscopic O 
measurements O 
revealed O 
that O 
the O 
iron B-SYSTEMATIC 
center O 
is O 
not O 
required O 
for O 
the O 
inhibition O 
of O 
Aβ O 
aggregation O 
but O 
do O 
influence O 
the O 
binding O 
affinity O 
of O 
heme B-FAMILY 
toward O 
Aβ O 
and O 
the O 
dismantlement O 
rate O 
and O 
degree O 
of O 
the O 
Aβ O 
aggregates O 
. O 
By O 
studying O 
the O 
interaction O 
of O 
different O 
truncated O 
or O 
mutated O 
Aβ O 
peptides O 
with O 
heme B-FAMILY 
or O 
protoporphyrin B-FAMILY 
, O 
we O 
further O 
found O 
that O 
the O 
porphyrin B-FAMILY 
ring O 
of O 
heme B-FAMILY 
is O 
implicated O 
to O 
interact O 
preferentially O 
with O 
the O 
Phe B-FORMULA 
( O 
19 O 
) O 
residue O 
, O 
facilitating O 
the O 
binding O 
of O 
heme B-FAMILY 
to O 
Aβ O 
and O 
disturbing O 
the O 
interstrand O 
aromatic O 
interaction O 
between O 
the O 
Phe B-FORMULA 
residues O 
, O 
which O 
is O 
crucial O 
for O 
Aβ O 
fibrillation O 
. O 
These O 
findings O 
open O 
new O 
avenues O 
in O 
the O 
understanding O 
of O 
the O 
interaction O 
between O 
the O 
heme B-FAMILY 
and O 
Aβ O 
and O 
the O 
pathways O 
for O 
modulation O 
of O 
Aβ O 
aggregation O 
and O 
disaggregation O 
, O 
which O 
would O 
be O 
helpful O 
in O 
designing O 
therapeutic O 
strategies O 
against O 
AD O 
. O 

mushroom O 
Agaricus O 
brasiliensis O 
( O 
sun O 
mushroom O 
) O 
, O 
native O 
from O 
the O 
southeast O 
of O 
Brazil O 
, O 
is O 
well O 
known O 
by O 
its O 
medicinal O 
properties O 
that O 
include O 
effects O 
on O 
diabetes O 
, O 
cholesterol B-TRIVIAL 
levels O 
, O 
and O 
osteoporosis O 
. O 
The O 
antimutagenic O 
effects O 
of O 
A O 
. O 
brasiliensis O 
has O 
been O 
investigated O 
recently O 
and O 
revealed O 
some O 
controversial O 
results O 
depending O 
on O 
the O 
temperature O 
by O 
which O 
the O 
A O 
. O 
brasiliensis O 
tea O 
is O 
obtained O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
evaluated O 
the O 
effect O 
of O 
the O 
A O 
. O 
brasiliensis O 
extract O 
prepared O 
in O 
two O 
different O 
temperatures O 
, O 
4°C O 
and O 
25°C O 
, O 
on O 
the O 
doxorubicin B-TRIVIAL 
-induced O 
DNA O 
strand O 
breaks O 
and O 
chromosomal O 
aberrations O 
( O 
CAs O 
) O 
in O 
human O 
lymphocytes O 
. O 
The O 
results O 
demonstrated O 
that O 
A O 
. O 
brasiliensis O 
was O 
able O 
to O 
reduce O 
the O 
DXR-induced O 
DNA O 
damage O 
in O 
both O 
temperatures O 
; O 
however O 
, O 
the O 
CA O 
test O 
was O 
more O 
sensitive O 
to O 
demonstrate O 
a O 
better O 
reduction O 
when O 
the O 
cells O 
were O 
treated O 
with O 
an O 
extract O 
obtained O 
at O 
25°C O 
. O 
A O 
. O 
brasiliensis O 
extract O 
obtained O 
in O 
different O 
temperatures O 
exhibited O 
antigenotoxic O 
and O 
anticlastogenic O 
effects O 
in O 
human O 
lymphocytes O 
. O 

new O 
strategy O 
for O 
intracellular O 
delivery O 
of O 
enzyme O 
using O 
mesoporous O 
silica B-TRIVIAL 
nanoparticles O 
: O 
superoxide B-TRIVIAL 
dismutase O 
. O 

developed O 
mesoporous O 
silica B-TRIVIAL 
nanoparticle O 
( O 
MSN O 
) O 
as O 
a O 
multifunctional O 
vehicle O 
for O 
enzyme O 
delivery O 
. O 
Enhanced O 
transmembrane O 
delivery O 
of O 
a O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
enzyme O 
embedded O 
in O 
MSN O 
was O 
demonstrated O 
. O 
Conjugation O 
of O 
the O 
cell O 
- O 
penetrating O 
peptide O 
derived O 
from O 
the O 
human O 
immunodeficiency O 
virus O 
1 O 
( O 
HIV O 
) O 
transactivator O 
protein O 
( O 
TAT O 
) O 
to O 
mesoporous O 
silica B-TRIVIAL 
nanoparticle O 
is O 
shown O 
to O 
be O 
an O 
effective O 
way O 
to O 
enhance O 
transmembrane O 
delivery O 
of O 
nanoparticles O 
for O 
intracellular O 
and O 
molecular O 
therapy O 
. O 
Cu B-FORMULA 
, O 
Zn B-FORMULA 
- O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
is O 
a O 
key O 
antioxidant O 
enzyme O 
that O 
detoxifies O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
ROS O 
, O 
thereby O 
protecting O 
cells O 
from O 
oxidative O 
damage O 
. O 
In O 
this O 
study O 
, O 
we O 
fused O 
a O 
human O 
Cu B-FORMULA 
, O 
Zn B-FORMULA 
-SOD O 
gene O 
with O 
TAT O 
in O 
a O 
bacterial O 
expression O 
vector O 
to O 
produce O 
a O 
genetic O 
in O 
- O 
frame O 
His O 
- O 
tagged O 
TAT-SOD O 
fusion O 
protein O 
. O 
The O 
His O 
- O 
tagged O 
TAT-SOD O 
fusion O 
protein O 
was O 
expressed O 
in O 
E O 
. O 
coli O 
using O 
IPTG O 
induction O 
and O 
purified O 
using O 
FMSN- O 
Ni B-FORMULA 
-NTA O 
. O 
The O 
purified O 
TAT-SOD O 
was O 
conjugated O 
to O 
FITC-MSN O 
forming O 
FMSN-TAT-SOD O 
. O 
The O 
effectiveness O 
of O 
FMSN-TAT-SOD O 
as O 
an O 
agent O 
against O 
ROS O 
was O 
investigated O 
, O 
which O 
included O 
the O 
level O 
of O 
ROS O 
and O 
apoptosis O 
after O 
free O 
radicals O 
induction O 
and O 
functional O 
recovery O 
after O 
ROS O 
damage O 
. O 
Confocal O 
microscopy O 
on O 
live O 
unfixed O 
cells O 
and O 
flow O 
cytometry O 
analysis O 
showed O 
characteristic O 
nonendosomal O 
distribution O 
of O 
FMSN-TAT-SOD O 
. O 
Results O 
suggested O 
that O 
FMSN-TAT-SOD O 
may O 
provide O 
a O 
strategy O 
for O 
the O 
therapeutic O 
delivery O 
of O 
antioxidant O 
enzymes O 
that O 
protect O 
cells O 
from O 
ROS O 
damage O 
. O 

1 O 
cannabinoid O 
receptor O 
( O 
CB1 O 
) O 
is O 
expressed O 
in O 
different O 
neuronal O 
populations O 
in O 
the O 
mammalian O 
brain O 
. O 
In O 
particular O 
, O 
CB1 O 
on O 
GABAergic O 
or O 
glutamatergic O 
neurons O 
exerts O 
different O 
functions O 
and O 
display O 
different O 
pharmacological O 
properties O 
in O 
vivo O 
. O 
This O 
suggests O 
the O 
existence O 
of O 
neuron O 
- O 
type O 
specific O 
signalling O 
pathways O 
activated O 
by O 
different O 
subpopulations O 
of O 
CB1 O 
. O 
In O 
this O 
study O 
, O 
we O 
analysed O 
CB1 O 
expression O 
, O 
binding O 
and O 
signalling O 
in O 
the O 
hippocampus O 
of O 
conditional O 
mutant O 
mice O 
, O 
bearing O 
CB1 O 
deletion O 
in O 
GABAergic O 
( O 
GABA-CB1-KO O 
mice O 
) O 
or O 
cortical O 
glutamatergic O 
neurons O 
( O 
Glu B-FORMULA 
-CB1-KO O 
mice O 
) O 
. O 
Compared O 
to O 
their O 
wild O 
- O 
type O 
littermates O 
, O 
Glu B-FORMULA 
-CB1-KO O 
displayed O 
a O 
small O 
decrease O 
of O 
CB1 O 
mRNA O 
amount O 
, O 
immunoreactivity O 
and O 
[³H]CP55,940 B-SYSTEMATIC 
binding O 
. O 
Conversely O 
, O 
GABA B-ABBREVIATION 
-CB1-KO O 
mice O 
showed O 
a O 
drastic O 
reduction O 
of O 
these O 
parameters O 
, O 
confirming O 
that O 
CB1 O 
is O 
present O 
at O 
much O 
higher O 
density O 
on O 
hippocampal O 
GABAergic O 
interneurons O 
than O 
glutamatergic O 
neurons O 
. O 
Surprisingly O 
, O 
however O 
, O 
saturation O 
analysis O 
of O 
HU210 B-IDENTIFIER 
-stimulated O 
[ B-SYSTEMATIC 
( I-SYSTEMATIC 
35 I-SYSTEMATIC 
) I-SYSTEMATIC 
S]GTPγS I-SYSTEMATIC 
binding O 
demonstrated O 
that O 
' O 
glutamatergic O 
' O 
CB1 O 
is O 
more O 
efficiently O 
coupled O 
to O 
G O 
protein O 
signalling O 
than O 
' O 
GABAergic O 
' O 
CB1 O 
. O 
Thus O 
, O 
the O 
minority O 
of O 
CB1 O 
on O 
glutamatergic O 
neurons O 
is O 
paradoxically O 
several O 
fold O 
more O 
strongly O 
coupled O 
to O 
G O 
protein O 
signalling O 
than O 
' O 
GABAergic O 
' O 
CB1 O 
. O 
This O 
selective O 
signalling O 
mechanism O 
raises O 
the O 
possibility O 
of O 
designing O 
novel O 
cannabinoid O 
ligands O 
that O 
differentially O 
activate O 
only O 
a O 
subset O 
of O 
physiological O 
effects O 
of O 
CB1 O 
stimulation O 
, O 
thereby O 
optimizing O 
therapeutic O 
action O 
. O 

III O 
phosphatidylinositol B-TRIVIAL 
3-kinase O 
and O 
its O 
catalytic O 
product O 
PtdIns3P B-SYSTEMATIC 
in O 
regulation O 
of O 
endocytic O 
membrane O 
traffic O 
. O 

and O 
subsequent O 
membrane O 
traffic O 
through O 
endosomes O 
are O 
cellular O 
processes O 
that O 
are O 
integral O 
to O 
eukaryotic O 
evolution O 
, O 
and O 
numerous O 
human O 
diseases O 
are O 
associated O 
with O 
their O 
dysfunction O 
. O 
Consequently O 
, O 
it O 
is O 
important O 
to O 
untangle O 
the O 
molecular O 
machineries O 
that O 
regulate O 
membrane O 
dynamics O 
and O 
protein O 
flow O 
in O 
the O 
endocytic O 
pathway O 
. O 
Central O 
in O 
this O 
context O 
is O 
class O 
III O 
phosphatidylinositol B-TRIVIAL 
3-kinase O 
, O 
an O 
evolutionarily O 
conserved O 
enzyme O 
complex O 
that O 
phosphorylates O 
phosphatidylinositol B-TRIVIAL 
into O 
phosphatidylinositol B-SYSTEMATIC 
3-phosphate I-SYSTEMATIC 
. O 
Phosphatidylinositol B-SYSTEMATIC 
3-phosphate I-SYSTEMATIC 
recruits O 
specific O 
effector O 
proteins O 
, O 
most O 
of O 
which O 
contain O 
FYVE O 
or O 
PX O 
domains O 
, O 
to O 
promote O 
endocytosis O 
, O 
endosome O 
fusion O 
, O 
endosome O 
motility O 
and O 
endosome O 
maturation O 
, O 
as O 
well O 
as O 
cargo O 
sorting O 
to O 
lysosomes O 
, O 
the O 
biosynthetic O 
pathway O 
or O 
the O 
plasma O 
membrane O 
. O 
Here O 
we O 
review O 
the O 
functions O 
of O 
key O 
phosphatidylinositol B-SYSTEMATIC 
3-phosphate I-SYSTEMATIC 
effectors O 
in O 
regulation O 
of O 
endocytic O 
membrane O 
dynamics O 
and O 
protein O 
sorting O 
. O 

, O 
synthesis O 
, O 
characterization O 
and O 
biological O 
evaluation O 
of O 
novel O 
pyrazole B-SYSTEMATIC 
integrated O 
benzophenones B-FAMILY 
. O 

series O 
of O 
novel O 
pyrazole B-SYSTEMATIC 
integrated O 
benzophenones B-FAMILY 
( O 
9a-j O 
) O 
have O 
been O 
designed O 
, O 
synthesized O 
from O 
1-methyl-5-(2,4,6-trimethoxy-phenyl)-1H-pyrazole B-SYSTEMATIC 
6 O 
. O 
The O 
structures O 
of O 
the O 
regioisomers O 
6 O 
and O 
7 O 
were O 
determined O 
by O 
2D O 
(1)H B-FORMULA 
- O 
(1)H B-FORMULA 
COSY O 
, O 
(1)H B-FORMULA 
- O 
(13)C B-FORMULA 
HSQC O 
and O 
(1)H B-FORMULA 
- O 
(13)C B-FORMULA 
HMBC O 
experiments O 
. O 
The O 
newly O 
synthesized O 
compounds O 
( O 
9a-j O 
) O 
were O 
evaluated O 
for O 
in O 
vivo O 
anti-inflammatory O 
activity O 
by O 
carrageenan O 
paw O 
edema O 
in O 
rats O 
and O 
in O 
vitro O 
COX-1 O 
/ O 
COX-2 O 
inhibition O 
and O 
antioxidant O 
potential O 
. O 
Among O 
the O 
synthesized O 
compounds O 
, O 
compounds O 
9b O 
, O 
9d O 
and O 
9f O 
, O 
were O 
found O 
to O 
be O 
active O 
anti-inflammatory O 
agents O 
in O 
addition O 
to O 
having O 
potent O 
antioxidant O 
activity O 
. O 

of O 
HIV-1 O 
replication O 
by O 
a O 
tricyclic B-TRIVIAL 
coumarin I-TRIVIAL 
GUT-70 B-TRIVIAL 
in O 
acutely O 
and O 
chronically O 
infected O 
cells O 
. O 

anti-HIV-1 O 
activity O 
of O 
GUT-70 B-TRIVIAL 
, O 
a O 
natural O 
product O 
derived O 
from O 
the O 
stem O 
bark O 
of O 
Chlophyllum O 
brasiliense O 
, O 
was O 
evaluated O 
. O 
GUT-70 B-TRIVIAL 
inhibited O 
HIV-1 O 
replication O 
in O 
both O 
acutely O 
and O 
chronically O 
infected O 
cells O 
through O 
suppression O 
of O 
NF-κB O 
. O 
Our O 
results O 
strengthen O 
the O 
idea O 
that O 
NF-κB O 
pathway O 
is O 
one O 
of O 
the O 
potential O 
targets O 
to O 
control O 
HIV-1 O 
replication O 
and O 
that O 
GUT-70 B-TRIVIAL 
could O 
serve O 
as O 
a O 
lead O 
compound O 
to O 
develop O 
novel O 
therapeutic O 
agents O 
against O 
HIV-1 O 
infection O 
. O 

characterization O 
of O 
the O 
drug O 
- O 
membrane O 
interactions O 
: O 
The O 
case O 
of O 
propranolol B-TRIVIAL 
and O 
acebutolol B-TRIVIAL 
. O 

interaction O 
of O 
propranolol B-TRIVIAL 
and O 
acebutolol B-TRIVIAL 
with O 
biological O 
membranes O 
was O 
assessed O 
in O 
the O 
present O 
work O 
by O 
using O 
a O 
range O 
of O 
biophysical O 
techniques O 
and O 
liposomes O 
, O 
as O 
membrane O 
mimetic O 
models O 
. O 
Liposomes O 
were O 
made O 
of O 
zwitterionic O 
phosphatidylcholines B-FAMILY 
and O 
experiments O 
were O 
performed O 
at O 
physiologic O 
pH O 
and O 
at O 
various O 
membrane O 
physical O 
states O 
( O 
gel O 
, O 
ripple O 
and O 
fluid O 
phases O 
) O 
. O 
Fluorescence O 
techniques O 
were O 
used O 
to O 
study O 
the O 
partition O 
coefficient O 
of O 
β-blockers O 
, O 
the O 
influence O 
of O 
drugs O 
on O 
membrane O 
fluidity O 
and O 
the O 
drugs O 
- O 
membrane O 
binding O 
. O 
Moreover O 
, O 
small O 
and O 
wide O 
angle O 
X-ray O 
scattering O 
techniques O 
were O 
used O 
to O 
evaluate O 
the O 
β-blockers O 
effect O 
on O 
long O 
range O 
bilayer O 
order O 
and O 
hydrocarbon B-FAMILY 
chain O 
packing O 
. O 
The O 
gathered O 
results O 
highlighted O 
the O 
importance O 
of O 
electrostatic O 
interactions O 
between O 
propranolol B-TRIVIAL 
and O 
acebutolol B-TRIVIAL 
with O 
membranes O 
. O 
Furthermore O 
, O 
both O 
β-blockers O 
exhibited O 
a O 
membrane O 
- O 
fluidizing O 
effect O 
and O 
the O 
capacity O 
to O 
disturb O 
the O 
membrane O 
organization O 
. O 
In O 
general O 
, O 
propranolol B-TRIVIAL 
unveiled O 
a O 
more O 
pronounced O 
effect O 
on O 
membrane O 
fluidity O 
and O 
structure O 
than O 
acebutolol B-TRIVIAL 
. O 
In O 
the O 
current O 
study O 
, O 
the O 
obtained O 
results O 
were O 
also O 
correlated O 
with O 
the O 
cardioprotective O 
properties O 
of O 
the O 
β-blockers O 
studied O 
. O 

and O 
carboxylesterase O 
inhibition O 
in O 
Planorbarius O 
corneus O 
exposed O 
to O 
binary O 
mixtures O 
of O 
azinphos B-TRIVIAL 
- I-TRIVIAL 
methyl I-TRIVIAL 
and O 
chlorpyrifos B-TRIVIAL 
. O 

pesticide O 
mixtures O 
are O 
commonly O 
encountered O 
in O 
fresh O 
water O 
systems O 
, O 
the O 
knowledge O 
of O 
their O 
effects O 
on O 
non-target O 
aquatic O 
species O 
is O 
scarce O 
. O 
The O 
present O 
investigation O 
was O 
undertaken O 
to O 
explore O 
the O 
in O 
vivo O 
inhibition O 
of O 
the O 
freshwater O 
gastropod O 
snail O 
Planorbarius O 
corneus O 
cholinesterase O 
( O 
ChE O 
) O 
and O 
carboxylesterases O 
( O 
CES O 
) O 
activities O 
by O 
the O 
organophosphorus B-FAMILY 
pesticides O 
azinphos B-TRIVIAL 
- I-TRIVIAL 
methyl I-TRIVIAL 
( O 
AZM B-ABBREVIATION 
) O 
and O 
chlorpyrifos B-TRIVIAL 
( O 
CPF B-ABBREVIATION 
) O 
. O 
To O 
this O 
end O 
, O 
snails O 
were O 
exposed O 
for O 
48 O 
h O 
to O 
different O 
concentrations O 
of O 
AZM B-ABBREVIATION 
and O 
CPF B-ABBREVIATION 
in O 
single O 
- O 
chemical O 
and O 
binary O 
- O 
mixture O 
studies O 
, O 
and O 
ChE O 
and O 
CES O 
activities O 
were O 
measured O 
in O 
the O 
whole O 
soft O 
body O 
tissues O 
and O 
hemolymph O 
. O 
ChE O 
activity O 
was O 
measured O 
with O 
acetylthiocholine B-SYSTEMATIC 
as O 
substrate O 
and O 
CES O 
activity O 
was O 
measured O 
with O 
four O 
substrates O 
: O 
p-nitrophenyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
p-nitrophenyl B-SYSTEMATIC 
butyrate I-SYSTEMATIC 
, O 
1- B-MULTIPLE 
and I-MULTIPLE 
2-naphthyl I-MULTIPLE 
acetate I-MULTIPLE 
. O 
Single O 
- O 
chemical O 
experiments O 
showed O 
that O 
CPF B-ABBREVIATION 
was O 
a O 
more O 
potent O 
inhibitor O 
of O 
ChE O 
activity O 
than O 
AZM B-ABBREVIATION 
( O 
350 O 
and O 
27 O 
times O 
for O 
the O 
whole O 
soft O 
tissue O 
and O 
hemolymph O 
, O 
respectively O 
) O 
. O 
CES O 
were O 
15 O 
times O 
more O 
sensitive O 
than O 
ChE O 
when O 
the O 
activities O 
were O 
measured O 
in O 
the O 
whole O 
soft O 
tissue O 
of O 
the O 
animals O 
exposed O 
to O 
AZM B-ABBREVIATION 
. O 
Based O 
on O 
a O 
default O 
assumption O 
of O 
concentration O 
addition O 
, O 
P O 
. O 
corneus O 
snails O 
were O 
exposed O 
to O 
mixtures O 
of O 
AZM B-ABBREVIATION 
+ O 
CPF B-ABBREVIATION 
designed O 
to O 
yield O 
predicted O 
soft O 
tissue O 
ChE O 
inhibitions O 
of O 
31% O 
( O 
mixture O 
1 O 
) O 
, O 
50% O 
( O 
mixture O 
2 O 
) O 
and O 
61% O 
( O 
mixture O 
3 O 
) O 
. O 
Results O 
showed O 
that O 
ChE O 
inhibition O 
produced O 
by O 
mixture O 
1 O 
followed O 
a O 
model O 
of O 
concentration O 
addition O 
. O 
In O 
contrast O 
, O 
the O 
other O 
mixtures O 
showed O 
synergism O 
, O 
both O 
in O 
whole O 
soft O 
tissue O 
and O 
hemolymph O 
. O 
In O 
addition O 
, O 
results O 
obtained O 
when O 
the O 
snails O 
were O 
exposed O 
sequentially O 
to O 
the O 
pesticides O 
showed O 
that O 
the O 
sequence O 
AZM B-ABBREVIATION 
/ O 
CPF B-ABBREVIATION 
produced O 
at O 
48 O 
h O 
a O 
higher O 
ChE O 
inhibition O 
than O 
the O 
sequence O 
CPF B-ABBREVIATION 
/ O 
CPF B-ABBREVIATION 
. O 
A O 
range O 
of O 
metabolic O 
pathways O 
and O 
responses O 
associated O 
with O 
bioactivation O 
or O 
detoxification O 
may O 
play O 
important O 
roles O 
in O 
organophosphorus B-FAMILY 
interactions O 
. O 
In O 
particular O 
, O 
the O 
data O 
presented O 
in O 
the O 
present O 
study O 
indicate O 
that O 
CES O 
enzymes O 
would O 
be O 
important O 
factors O 
in O 
determining O 
the O 
effects O 
of O 
the O 
mixtures O 
of O 
OPs B-FAMILY 
on O 
P O 
. O 
corneus O 
ChE O 
activity O 
. O 

vitro O 
study O 
of O 
intestinal O 
transport O 
of O 
fluoride B-SYSTEMATIC 
using O 
the O 
Caco-2 O 
cell O 
line O 
. O 

and O 
food O 
are O 
the O 
main O 
sources O 
of O 
fluoride B-SYSTEMATIC 
exposure O 
and O 
therefore O 
it O 
is O 
necessary O 
to O 
study O 
intestinal O 
absorption O 
in O 
order O 
to O 
make O 
a O 
correct O 
evaluation O 
of O 
the O 
risk O 
/ O 
benefit O 
associated O 
with O 
exposure O 
to O 
fluoride B-SYSTEMATIC 
. O 
The O 
present O 
study O 
characterizes O 
intestinal O 
transport O 
of O 
fluoride B-SYSTEMATIC 
, O 
using O 
the O 
Caco-2 O 
cell O 
line O 
as O 
a O 
model O 
of O 
the O 
intestinal O 
epithelium O 
, O 
and O 
evaluates O 
the O 
coefficients O 
of O 
apparent O 
permeability O 
and O 
intracellular O 
accumulation O 
in O 
various O 
conditions O 
( O 
pH O 
, O 
temperature O 
, O 
opening O 
of O 
cell O 
junctions O 
, O 
presence O 
of O 
anions O 
) O 
. O 
The O 
results O 
indicate O 
that O 
fluoride B-SYSTEMATIC 
is O 
an O 
element O 
with O 
moderate O 
absorption O 
( O 
< O 
70% O 
) O 
in O 
both O 
directions O 
( O 
absorptive O 
and O 
secretory O 
) O 
. O 
Both O 
in O 
absorption O 
( O 
apical O 
- O 
basolateral O 
) O 
and O 
in O 
secretion O 
( O 
basolateral O 
- O 
apical O 
) O 
there O 
is O 
transport O 
by O 
the O 
paracellular O 
pathway O 
, O 
which O 
may O 
be O 
considered O 
predominant O 
. O 
Absorption O 
and O 
secretion O 
of O 
fluoride B-SYSTEMATIC 
increase O 
at O 
acid O 
pH O 
levels O 
, O 
possibly O 
because O 
of O 
its O 
non-ionized O 
state O 
at O 
these O 
pHs O 
and O 
/ O 
or O 
because O 
of O 
participation O 
of O 
a O 
F(-) B-FORMULA 
/ O 
H(+) B-FORMULA 
cotransporter O 
or O 
a O 
F(-) B-FORMULA 
/ O 
OH(-) B-FORMULA 
antiporter O 
. O 
The O 
results O 
also O 
suggest O 
transcellular O 
participation O 
of O 
mechanisms O 
involved O 
in O 
transport O 
of O 
Cl(-) B-FORMULA 
and O 
of O 
an O 
active O 
transport O 
in O 
the O 
secretory O 
direction O 
. O 
The O 
present O 
study O 
extend O 
the O 
knowledge O 
on O 
the O 
cellular O 
transport O 
of O 
fluoride B-SYSTEMATIC 
and O 
provide O 
the O 
basis O 
for O 
future O 
studies O 
aimed O 
at O 
identifying O 
potential O 
transporters O 
involved O 
in O 
human O 
fluoride B-SYSTEMATIC 
absorption O 
. O 

receptor O 
subtype-3 O 
( O 
BRS-3 O 
) O 
, O 
a O 
novel O 
candidate O 
as O 
therapeutic O 
molecular O 
target O 
in O 
obesity O 
and O 
diabetes O 
. O 

KO-mice O 
developed O 
obesity O 
and O 
unbalanced O 
glucose B-TRIVIAL 
metabolism O 
, O 
suggesting O 
an O 
important O 
role O 
of O 
BRS-3 O 
receptor O 
in O 
glucose B-TRIVIAL 
homeostasis O 
. O 
We O 
explored O 
BRS-3 O 
expression O 
in O 
skeletal O 
muscle O 
from O 
normal O 
, O 
obese O 
or O 
type-2 O 
diabetic O 
( O 
T2D O 
) O 
patients O 
, O 
and O 
the O 
effect O 
of O 
[ O 
D-Phe B-FORMULA 
( O 
6 O 
) O 
, O 
β-Ala B-FORMULA 
( O 
11 O 
) O 
, O 
Phe B-FORMULA 
( O 
13 O 
) O 
, O 
Nle B-FORMULA 
( O 
14 O 
) O 
] O 
bombesin B-TRIVIAL 
(6-14)-BRS-3-agonist O 
- O 
peptide O 
( O 
BRS-3-AP O 
) O 
- O 
on O 
glucose B-TRIVIAL 
-related O 
effects O 
, O 
before O 
or O 
after O 
BRS-3 O 
gene O 
silencing O 
. O 
In O 
muscle O 
tissue O 
and O 
primary O 
cultured O 
myocytes O 
from O 
altered O 
metabolic O 
states O 
, O 
BRS-3 O 
gene O 
/ O 
protein O 
expressions O 
were O 
down O 
- O 
regulated O 
. O 
In O 
normal O 
, O 
obese O 
and O 
T2D O 
cells O 
: O 
A O 
) O 
BRS-3-AP O 
as O 
insulin O 
enhanced O 
BRS-3 O 
and O 
GLUT-4 O 
mRNA O 
/ O 
protein O 
levels O 
; O 
improving O 
glucotransporter O 
translocation O 
to O 
plasma O 
membrane O 
, O 
and O 
B O 
) O 
BRS-3-AP O 
caused O 
a O 
concentration O 
- O 
related O 
- O 
stimulation O 
of O 
glucose B-TRIVIAL 
transport O 
, O 
being O 
obese O 
and O 
T2D O 
myocytes O 
more O 
sensitive O 
to O 
the O 
ligand O 
than O 
normal O 
. O 
Wortmannin B-TRIVIAL 
and O 
PD98059 B-IDENTIFIER 
, O 
but O 
not O 
rapamycin B-TRIVIAL 
, O 
abolished O 
the O 
stimulatory O 
action O 
of O 
BRS-3-AP O 
on O 
glucose B-TRIVIAL 
transport O 
. O 
BRS-3 O 
plays O 
an O 
important O 
role O 
in O 
glucose B-TRIVIAL 
metabolism O 
, O 
and O 
could O 
be O 
use O 
as O 
a O 
molecular O 
target O 
, O 
and O 
/ O 
or O 
its O 
ligand O 
, O 
as O 
a O 
therapeutic O 
agent O 
for O 
obesity O 
and O 
diabetes O 
treatments O 
. O 

hydrocarbon I-FAMILY 
receptor O 
activation O 
attenuates O 
Per1 O 
gene O 
induction O 
and O 
influences O 
circadian O 
clock O 
resetting O 
. O 

- O 
stimulated O 
adjustment O 
of O 
the O 
circadian O 
clock O 
is O 
an O 
important O 
adaptive O 
physiological O 
response O 
that O 
allows O 
maintenance O 
of O 
behavioral O 
synchrony O 
with O 
solar O 
time O 
. O 
Our O 
previous O 
studies O 
indicate O 
that O 
the O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AhR O 
) O 
agonist O 
2,3,7,8- B-SYSTEMATIC 
tetrachlorodibenzo-p-dioxin I-SYSTEMATIC 
attenuates O 
light O 
- O 
induced O 
phase O 
resetting O 
in O 
early O 
night O 
. O 
However O 
, O 
the O 
mechanism O 
of O 
inhibition O 
remains O 
unclear O 
. O 
In O 
this O 
study O 
, O 
we O 
showed O 
that O 
another O 
potent O 
AhR O 
agonist- O 
β-naphthoflavone B-TRIVIAL 
( O 
BNF B-ABBREVIATION 
)-significantly O 
decreased O 
light O 
- O 
induced O 
phase O 
shifts O 
in O 
wild O 
- O 
type O 
( O 
WT O 
) O 
mice O 
, O 
whereas O 
AhR O 
knockout O 
mice O 
had O 
an O 
enhanced O 
response O 
to O 
light O 
that O 
was O 
unaffected O 
by O 
BNF B-ABBREVIATION 
. O 
Mechanistically O 
, O 
BNF B-ABBREVIATION 
blocked O 
light O 
induction O 
of O 
the O 
Per1 O 
transcript O 
in O 
suprachiasmatic O 
nucleus O 
and O 
liver O 
in O 
WT O 
mice O 
, O 
and O 
BNF B-ABBREVIATION 
blocked O 
forskolin B-TRIVIAL 
( O 
FSK B-ABBREVIATION 
)-induced O 
Per1 O 
transcripts O 
in O 
Hepa-1c1c7 O 
( O 
c7 O 
) O 
cells O 
. O 
An O 
E-box O 
decoy O 
did O 
not O 
affect O 
BNF B-ABBREVIATION 
inhibition O 
of O 
FSK B-ABBREVIATION 
-induced O 
Per1 O 
transcripts O 
in O 
c7 O 
cells O 
. O 
cAMP B-ABBREVIATION 
-response O 
element O 
(CRE)-dependent O 
induction O 
of O 
Per1 O 
promoter O 
activity O 
in O 
response O 
to O 
FSK B-ABBREVIATION 
in O 
combination O 
with O 
phorbol B-SYSTEMATIC 
12-tetradecanoate I-SYSTEMATIC 
13-acetate I-SYSTEMATIC 
was O 
suppressed O 
in O 
cells O 
that O 
expressed O 
high O 
levels O 
of O 
AhR O 
( O 
c7 O 
) O 
compared O 
with O 
cells O 
lacking O 
functional O 
AhR O 
activity O 
( O 
c12 O 
) O 
. O 
In O 
addition O 
, O 
the O 
inhibitory O 
effect O 
of O 
BNF B-ABBREVIATION 
on O 
FSK B-ABBREVIATION 
-induced O 
Per1 O 
was O 
dependent O 
on O 
phosphorylation O 
of O 
JNK O 
. O 
Together O 
, O 
these O 
results O 
suggest O 
that O 
AhR O 
activation O 
inhibits O 
light O 
- O 
induced O 
phase O 
resetting O 
through O 
the O 
activation O 
of O 
JNK O 
, O 
negative O 
regulation O 
of O 
CREs O 
in O 
the O 
Per1 O 
promoter O 
, O 
and O 
suppression O 
of O 
Per1 O 
. O 

, O 
preliminary O 
screening O 
of O 
new O 
types O 
of O 
steroid B-FAMILY 
conjugates O 
and O 
their O 
activities O 
on O 
steroid B-FAMILY 
receptors O 
. O 

were O 
synthesized O 
new O 
types O 
of O 
ribbon O 
type O 
steroidal O 
dimers O 
derived O 
from O 
three O 
types O 
of O 
steroidal O 
skeletons O 
( O 
cholic B-TRIVIAL 
acid I-TRIVIAL 
, O 
etienic B-TRIVIAL 
acid I-TRIVIAL 
, O 
estrone B-TRIVIAL 
) O 
using O 
Cu B-FORMULA 
(I) I-FORMULA 
catalyzed O 
1 O 
, O 
3-dipolar O 
cycloaddition O 
reaction O 
. O 
Steroid B-FAMILY 
parts O 
of O 
the O 
molecular O 
" O 
ribbons O 
" O 
are O 
linked O 
by O 
heterocyclic O 
moiety O 
, O 
namely O 
by O 
2,6-bis((1H-1,2,3-triazol-1-yl)-methyl)pyridine B-SYSTEMATIC 
. O 
Compounds O 
synthesized O 
possess O 
different O 
cytotoxic O 
and O 
hormone O 
receptor O 
modulating O 
activities O 
. O 

abuse O 
and O 
dependence O 
in O 
Germany O 
: O 
results O 
from O 
a O 
database O 
query O 
. O 

: O 
Pregabalin B-TRIVIAL 
( O 
PRG B-ABBREVIATION 
) O 
is O 
approved O 
for O 
the O 
treatment O 
of O 
neuropathic O 
pain O 
, O 
partial O 
seizures O 
and O 
generalised O 
anxiety O 
disorder O 
in O 
many O 
countries O 
and O 
currently O 
under O 
study O 
for O 
other O 
indications O 
. O 
Supported O 
by O 
case O 
reports O 
and O 
the O 
results O 
of O 
a O 
limited O 
number O 
of O 
studies O 
there O 
is O 
an O 
ongoing O 
debate O 
on O 
the O 
potential O 
of O 
PRG B-ABBREVIATION 
to O 
cause O 
addictive O 
behaviours O 
. O 
However O 
, O 
currently O 
available O 
evidence O 
on O 
this O 
issue O 
is O 
sparse O 
, O 
and O 
any O 
definitive O 
assessment O 
of O 
PRG B-ABBREVIATION 
' O 
s O 
potential O 
for O 
abuse O 
and O 
dependence O 
is O 
not O 
yet O 
in O 
sight O 
. O 
The O 
aim O 
of O 
our O 
study O 
was O 
to O 
identify O 
the O 
number O 
of O 
cases O 
of O 
PRG B-ABBREVIATION 
abuse O 
or O 
dependence O 
reported O 
to O 
the O 
database O 
of O 
a O 
German O 
medical O 
regulatory O 
body O 
and O 
to O 
obtain O 
insights O 
into O 
further O 
usage O 
- O 
specific O 
parameters O 
. O 
METHODS O 
: O 
We O 
conducted O 
a O 
query O 
of O 
the O 
entire O 
database O 
of O 
the O 
German O 
Federal O 
Institute O 
for O 
Drugs O 
and O 
Medical O 
Devices O 
( O 
BfArM O 
) O 
regarding O 
reports O 
of O 
PRG B-ABBREVIATION 
abuse O 
or O 
dependence O 
and O 
analysed O 
these O 
cases O 
on O 
the O 
basis O 
of O 
several O 
parameters O 
. O 
RESULTS O 
: O 
A O 
total O 
of O 
55 O 
reports O 
of O 
PRG B-ABBREVIATION 
abuse O 
or O 
dependence O 
were O 
identified O 
( O 
mean O 
age O 
36 O 
years O 
, O 
64 O 
% O 
of O 
reports O 
involved O 
males O 
) O 
. O 
The O 
first O 
reports O 
were O 
submitted O 
to O 
BfArM O 
in O 
2008 O 
, O 
and O 
the O 
reporting O 
frequency O 
has O 
increased O 
up O 
to O 
the O 
present O 
. O 
Mean O 
daily O 
PRG B-ABBREVIATION 
dosage O 
was O 
1424 O 
mg O 
. O 
Current O 
or O 
previous O 
polytoxicomania O 
was O 
present O 
in O 
40 O 
and O 
42 O 
% O 
of O 
cases O 
, O 
respectively O 
. O 
Psychiatric O 
diagnoses O 
other O 
than O 
substance O 
- O 
related O 
disorders O 
were O 
reported O 
in O 
13 O 
( O 
24 O 
% O 
) O 
cases O 
. O 
In O 
about O 
one O 
- O 
third O 
of O 
the O 
patients O 
withdrawal O 
syndromes O 
subsequent O 
to O 
discontinuation O 
of O 
PRG B-ABBREVIATION 
were O 
reported O 
. O 
CONCLUSIONS O 
: O 
Cases O 
of O 
PRG B-ABBREVIATION 
abuse O 
or O 
dependence O 
have O 
been O 
reported O 
to O 
the O 
BfArM O 
since O 
2008 O 
, O 
with O 
a O 
marked O 
increase O 
of O 
such O 
reports O 
in O 
subsequent O 
years O 
. O 
Male O 
sex O 
and O 
a O 
history O 
of O 
polytoxicomania O 
may O 
be O 
possible O 
risk O 
factors O 
for O 
the O 
development O 
of O 
addictive O 
behaviours O 
related O 
to O 
PRG B-ABBREVIATION 
. O 

decline O 
in O 
beta O 
cell O 
function O 
during O 
pregnancy O 
leads O 
to O 
the O 
development O 
of O 
glucose B-TRIVIAL 
intolerance O 
in O 
Japanese O 
women O 
. O 

aim O 
of O 
this O 
study O 
is O 
to O 
investigate O 
glucose B-TRIVIAL 
metabolism O 
longitudinally O 
during O 
pregnancy O 
to O 
explore O 
mechanisms O 
underlying O 
gestational O 
diabetes O 
mellitus O 
( O 
GDM O 
) O 
. O 
We O 
reviewed O 
a O 
total O 
of O 
62 O 
pregnant O 
Japanese O 
women O 
who O 
underwent O 
a O 
75g O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
( O 
OGTT O 
) O 
twice O 
during O 
pregnancy O 
( O 
median O 
: O 
early O 
, O 
13 O 
; O 
late O 
, O 
28 O 
weeks O 
' O 
gestation O 
) O 
because O 
of O 
positive O 
GDM O 
screening O 
. O 
All O 
showed O 
normal O 
OGTT O 
results O 
in O 
early O 
pregnancy O 
. O 
Based O 
on O 
late O 
OGTT O 
, O 
15 O 
had O 
GDM O 
( O 
late O 
- O 
onset O 
GDM O 
) O 
and O 
47 O 
normal O 
glucose B-TRIVIAL 
tolerance O 
( O 
NGT O 
) O 
. O 
In O 
early O 
pregnancy O 
, O 
there O 
were O 
no O 
significant O 
differences O 
in O 
insulin O 
sensitivity O 
( O 
insulin O 
sensitivity O 
index O 
derived O 
from O 
OGTT O 
[ O 
ISOGTT O 
] O 
and O 
homeostasis O 
model O 
assessment O 
for O 
insulin O 
resistance O 
[ O 
HOMA-IR O 
] O 
) O 
and O 
insulin O 
secretion O 
( O 
a O 
ratio O 
of O 
the O 
total O 
area O 
- O 
under O 
- O 
the O 
- O 
insulin O 
- O 
curve O 
to O 
the O 
total O 
area O 
- O 
under O 
- O 
the- O 
glucose B-TRIVIAL 
-curve O 
[ O 
AUCins O 
/ O 
glu O 
] O 
and O 
insulinogenic O 
index O 
[ O 
IGI O 
] O 
) O 
between O 
the O 
NGT O 
and O 
late O 
- O 
onset O 
GDM O 
groups O 
. O 
In O 
each O 
group O 
, O 
insulin O 
sensitivity O 
significantly O 
decreased O 
from O 
early O 
to O 
late O 
pregnancy O 
, O 
most O 
in O 
the O 
late O 
- O 
onset O 
GDM O 
group O 
( O 
each O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
insulin O 
secretion O 
showed O 
no O 
significant O 
changes O 
with O 
advancing O 
pregnancy O 
in O 
both O 
of O 
the O 
groups O 
, O 
although O 
late O 
- O 
onset O 
GDM O 
showed O 
significantly O 
lower O 
IGI O 
compared O 
with O 
NGT O 
in O 
late O 
OGTT O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
When O 
assessed O 
beta O 
cell O 
function O 
by O 
OGTT O 
- O 
derived O 
disposition O 
index O 
( O 
i.e O 
. O 
Insulin O 
Secretion-Sensitivity O 
Index-2 O 
and O 
IGI O 
/ O 
fasting O 
insulin O 
) O 
, O 
the O 
indices O 
significantly O 
decreased O 
from O 
early O 
to O 
late O 
pregnancy O 
in O 
the O 
both O 
groups O 
( O 
each O 
p O 
< O 
0.05 O 
) O 
. O 
Women O 
with O 
late O 
- O 
onset O 
GDM O 
showed O 
significantly O 
lower O 
indices O 
compared O 
with O 
NGT O 
( O 
each O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
failure O 
of O 
beta O 
cell O 
to O 
compensate O 
for O 
decreased O 
insulin O 
sensitivity O 
could O 
contribute O 
to O 
the O 
development O 
of O 
the O 
late O 
- O 
onset O 
GDM O 
. O 

expression O 
of O 
ligand O 
- O 
gated O 
ion O 
channels O 
( O 
LGICs O 
) O 
in O 
Xenopus O 
laevis O 
oocytes O 
combined O 
with O 
site O 
- O 
directed O 
mutagenesis O 
has O 
been O 
demonstrated O 
to O 
be O 
a O 
powerful O 
approach O 
to O 
study O 
structure O 
- O 
function O 
relationships O 
. O 
In O 
particular O 
, O 
introducing O 
unnatural O 
amino B-FAMILY 
acids I-FAMILY 
( O 
UAAs O 
) O 
has O 
enabled O 
modifications O 
that O 
are O 
not O 
found O 
in O 
natural O 
proteins O 
. O 
However O 
, O 
the O 
current O 
strategy O 
relies O 
on O 
the O 
technically O 
demanding O 
in O 
vitro O 
synthesis O 
of O 
aminoacylated O 
suppressor O 
tRNA O 
. O 
We O 
report O 
here O 
a O 
general O 
method O 
that O 
circumvents O 
this O 
limitation O 
by O 
utilizing O 
orthogonal O 
aminoacyl-tRNA O 
synthetase O 
( O 
aaRS O 
) O 
/ O 
suppressor O 
tRNA(CUA) O 
pairs O 
to O 
genetically O 
encode O 
UAAs O 
in O 
Xenopus O 
oocytes O 
. O 
We O 
show O 
that O 
UAAs O 
inserted O 
in O 
the O 
N B-FORMULA 
-terminal O 
domain O 
of O 
N-methyl-D-aspartate B-SYSTEMATIC 
receptors O 
( O 
NMDARs O 
) O 
serve O 
as O 
photo O 
- O 
crosslinkers O 
that O 
lock O 
the O 
receptor O 
in O 
a O 
discrete O 
conformational O 
state O 
in O 
response O 
to O 
UV O 
photo O 
treatment O 
. O 
Our O 
method O 
should O 
be O 
generally O 
applicable O 
to O 
studies O 
of O 
other O 
LGICs O 
in O 
Xenopus O 
oocytes O 
. O 

- O 
Mediated O 
Synthesis O 
of O 
Silver B-SYSTEMATIC 
Cubes O 
with O 
Unusual O 
Twinning O 
Structures O 
Using O 
Short O 
Wavelength O 
Excitation O 
. O 

plasmon O 
- O 
mediated O 
synthesis O 
of O 
silver B-SYSTEMATIC 
nanoparticles O 
is O 
a O 
versatile O 
synthetic O 
method O 
which O 
leverages O 
the O 
localized O 
surface O 
plasmon O 
resonance O 
( O 
LSPR O 
) O 
of O 
nanoscale O 
silver B-SYSTEMATIC 
to O 
generate O 
particles O 
with O 
non-spherical O 
shapes O 
and O 
control O 
over O 
dimensions O 
. O 
Herein O 
, O 
a O 
method O 
is O 
reported O 
for O 
controlling O 
the O 
twinning O 
structure O 
of O 
silver B-SYSTEMATIC 
nanoparticles O 
, O 
and O 
consequently O 
their O 
shape O 
, O 
via O 
the O 
plasmon O 
- O 
mediated O 
synthesis O 
, O 
solely O 
by O 
varying O 
the O 
excitation O 
wavelength O 
between O 
400 O 
, O 
450 O 
, O 
and O 
500 O 
nm O 
, O 
which O 
modulates O 
the O 
rate O 
of O 
Ag(+) B-FORMULA 
reduction O 
. O 
Shorter O 
, O 
higher O 
energy O 
excitation O 
wavelengths O 
lead O 
to O 
faster O 
rates O 
of O 
reaction O 
, O 
which O 
in O 
turn O 
yield O 
structures O 
containing O 
a O 
greater O 
number O 
of O 
twin O 
boundaries O 
. O 
With O 
this O 
method O 
, O 
silver B-SYSTEMATIC 
cubes O 
can O 
be O 
synthesized O 
using O 
450 O 
nm O 
excitation O 
, O 
which O 
represents O 
the O 
first O 
time O 
this O 
shape O 
has O 
been O 
realized O 
by O 
a O 
plasmon O 
- O 
mediated O 
synthetic O 
approach O 
. O 
In O 
addition O 
, O 
these O 
cubes O 
contain O 
an O 
unusual O 
twinning O 
structure O 
composed O 
of O 
two O 
intersecting O 
twin O 
boundaries O 
or O 
multiple O 
parallel O 
twin O 
boundaries O 
. O 
With O 
respect O 
to O 
their O 
twinning O 
structure O 
, O 
these O 
cubes O 
fall O 
between O 
planar O 
- O 
twinned O 
and O 
multiply O 
twinned O 
nanoparticles O 
, O 
which O 
are O 
synthesized O 
using O 
500 O 
and O 
400 O 
nm O 
excitation O 
, O 
respectively O 
. O 

on O 
gene O 
expression O 
in O 
rat O 
liver O 
after O 
administration O 
of O 
RXR O 
agonists O 
: O 
UAB30 B-IDENTIFIER 
, O 
4-methyl-UAB30 B-SYSTEMATIC 
, O 
and O 
Targretin B-TRIVIAL 
( O 
Bexarotene B-TRIVIAL 
) O 
. O 

of O 
three O 
retinoid B-FAMILY 
X O 
receptor O 
( O 
RXR O 
) O 
agonists O 
[ O 
Targretin B-TRIVIAL 
( O 
TRG B-ABBREVIATION 
) O 
, O 
UAB30 B-IDENTIFIER 
, O 
and O 
4-methyl-UAB30 B-SYSTEMATIC 
( O 
4-Me-UAB30 B-SYSTEMATIC 
) O 
] O 
showed O 
that O 
all O 
inhibited O 
mammary O 
cancer O 
in O 
rodents O 
and O 
two O 
( O 
TRG B-ABBREVIATION 
and O 
4-Me-UAB30 B-SYSTEMATIC 
) O 
strikingly O 
increased O 
serum O 
triglyceride B-FAMILY 
levels O 
. O 
Agents O 
were O 
administered O 
in O 
diets O 
to O 
female O 
Sprague-Dawley O 
rats O 
. O 
Liver O 
RNA O 
was O 
isolated O 
and O 
microarrayed O 
on O 
the O 
Affymetrix O 
GeneChip O 
Rat O 
Exon O 
1 O 
ST O 
array O 
. O 
Statistical O 
tests O 
identified O 
genes O 
that O 
exhibited O 
differential O 
expression O 
and O 
fell O 
into O 
groups O 
, O 
or O 
modules O 
, O 
with O 
differential O 
expression O 
among O 
agonists O 
. O 
Genes O 
in O 
specific O 
modules O 
were O 
changed O 
by O 
one O 
, O 
two O 
, O 
or O 
all O 
three O 
agonists O 
. O 
An O 
interactome O 
analysis O 
assessed O 
the O 
effects O 
on O 
genes O 
that O 
heterodimerize O 
with O 
known O 
nuclear O 
receptors O 
. O 
For O 
proliferator O 
- O 
activated O 
receptor O 
α O 
/ O 
RXR-activated O 
genes O 
, O 
the O 
strongest O 
response O 
was O 
TRG B-ABBREVIATION 
> O 
4-Me-UAB30 B-SYSTEMATIC 
> O 
UAB30 B-IDENTIFIER 
. O 
Many O 
liver O 
X O 
receptor O 
/ O 
RXR O 
- O 
related O 
genes O 
( O 
e.g O 
. O 
, O 
Scd-1 O 
and O 
Srebf1 O 
, O 
which O 
are O 
associated O 
with O 
increased O 
triglycerides B-FAMILY 
) O 
were O 
highly O 
expressed O 
in O 
TRG B-ABBREVIATION 
and O 
4-Me-UAB30 B-SYSTEMATIC 
- O 
but O 
not O 
UAB30 B-IDENTIFIER 
-treated O 
livers O 
. O 
Minimal O 
expression O 
changes O 
were O 
associated O 
with O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
receptor O 
or O 
vitamin B-FAMILY 
D I-FAMILY 
receptor O 
heterodimers O 
by O 
any O 
of O 
the O 
agonists O 
. O 
UAB30 B-IDENTIFIER 
unexpectedly O 
and O 
uniquely O 
activated O 
genes O 
associated O 
with O 
the O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
hydroxylase O 
( O 
Ah O 
) O 
receptor O 
( O 
Cyp1a1 O 
, O 
Cyp1a2 O 
, O 
Cyp1b1 O 
, O 
and O 
Nqo1 O 
) O 
. O 
Based O 
on O 
the O 
Ah O 
receptor O 
activation O 
, O 
UAB30 B-IDENTIFIER 
was O 
tested O 
for O 
its O 
ability O 
to O 
prevent O 
dimethylbenzanthracene B-SYSTEMATIC 
( O 
DMBA B-ABBREVIATION 
)-induced O 
mammary O 
cancers O 
, O 
presumably O 
by O 
inhibiting O 
DMBA B-ABBREVIATION 
activation O 
, O 
and O 
was O 
highly O 
effective O 
. O 
Gene O 
expression O 
changes O 
were O 
determined O 
by O 
reverse O 
transcriptase O 
- O 
polymerase O 
chain O 
reaction O 
in O 
rat O 
livers O 
treated O 
with O 
Targretin B-TRIVIAL 
for O 
2.3 O 
, O 
7 O 
, O 
and O 
21 O 
days O 
. O 
These O 
showed O 
similar O 
gene O 
expression O 
changes O 
at O 
all O 
three O 
time O 
points O 
, O 
arguing O 
some O 
steady O 
- O 
state O 
effect O 
. O 
Different O 
patterns O 
of O 
gene O 
expression O 
among O 
the O 
agonists O 
provided O 
insight O 
into O 
molecular O 
differences O 
and O 
allowed O 
one O 
to O 
predict O 
certain O 
physiologic O 
consequences O 
of O 
agonist O 
treatment O 
. O 

is O 
a O 
putative O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
kinase O 
and O 
was O 
shown O 
to O 
induce O 
extraembryonic O 
endoderm O 
differentiation O 
from O 
mouse O 
embryonic O 
stem O 
cells O 
. O 
However O 
, O 
little O 
is O 
known O 
about O 
its O 
physiological O 
function O 
in O 
vivo O 
. O 
Here O 
, O 
we O 
generate O 
Stk40 O 
knock O 
- O 
out O 
mice O 
and O 
demonstrate O 
that O 
loss O 
of O 
the O 
Stk40 O 
gene O 
causes O 
neonatal O 
lethality O 
at O 
birth O 
. O 
Further O 
examination O 
reveals O 
that O 
the O 
respiratory O 
distress O 
and O 
atelectasis O 
occur O 
in O 
the O 
homozygous O 
mutants O 
. O 
The O 
maturation O 
of O 
lung O 
and O 
alveolar O 
epithelium O 
is O 
delayed O 
in O 
the O 
mutant O 
, O 
as O 
indicated O 
by O 
narrowed O 
air O 
spaces O 
, O 
thickened O 
interstitial O 
septa O 
, O 
and O 
increased O 
glycogen O 
content O 
in O 
the O 
lungs O 
of O 
Stk40(- O 
/ O 
- O 
) O 
mice O 
. O 
The O 
reduction O 
in O 
levels O 
of O 
T1-α O 
, O 
SP-B O 
, O 
and O 
SP-C O 
indicates O 
delayed O 
maturation O 
of O 
both O 
type O 
I O 
and O 
type O 
II O 
respiratory O 
epithelial O 
cells O 
in O 
Stk40(- O 
/ O 
- O 
) O 
lungs O 
. O 
Moreover O 
, O 
Stk40 O 
is O 
found O 
to O 
be O 
most O 
highly O 
expressed O 
in O 
lungs O 
of O 
both O 
fetal O 
and O 
adult O 
mice O 
among O 
all O 
organs O 
tested O 
. O 
Mechanistically O 
, O 
a O 
genome O 
- O 
wide O 
RNA O 
microarray O 
analysis O 
reveals O 
significantly O 
altered O 
expression O 
of O 
multiple O 
genes O 
known O 
to O 
participate O 
in O 
lung O 
development O 
. O 
The O 
expression O 
of O 
some O 
genes O 
involved O 
in O 
lipid O 
metabolism O 
, O 
immune O 
response O 
, O 
and O 
glycogen O 
metabolism O 
is O 
also O 
disrupted O 
in O 
the O 
lung O 
of O 
Stk40(- O 
/ O 
- O 
) O 
mice O 
. O 
Protein O 
affinity O 
purification O 
identifies O 
RCN2 O 
, O 
an O 
activator O 
of O 
ERK O 
/ O 
MAPK O 
signaling O 
, O 
as O 
an O 
STK40-associated O 
protein O 
. O 
Consistently O 
, O 
Stk40 O 
deficiency O 
attenuates O 
the O 
ERK O 
/ O 
MAPK O 
activation O 
, O 
and O 
inhibition O 
of O 
ERK O 
/ O 
MAPK O 
activities O 
reduces O 
surfactant O 
protein O 
gene O 
expression O 
in O 
lung O 
epithelial O 
cells O 
. O 
Collectively O 
, O 
this O 
study O 
uncovers O 
an O 
important O 
role O 
of O 
STK40 O 
for O 
lung O 
maturation O 
and O 
neonatal O 
survival O 
. O 
STK40 O 
may O 
associate O 
with O 
RCN2 O 
to O 
activate O 
ERK O 
/ O 
MAPK O 
signaling O 
and O 
control O 
the O 
expression O 
of O 
multiple O 
key O 
regulators O 
of O 
lung O 
development O 
. O 

authors O 
evaluated O 
effects O 
of O 
feeding O 
ranch O 
mink O 
( O 
Mustela O 
vison O 
) O 
diets O 
containing O 
polychlorinated B-FAMILY 
biphenyl I-FAMILY 
( O 
PCB B-ABBREVIATION 
)-contaminated O 
fish O 
from O 
the O 
upper O 
Hudson O 
River O 
( O 
New O 
York O 
, O 
USA O 
) O 
on O 
adult O 
and O 
offspring O 
organ O 
mass O 
and O 
pathology O 
. O 
Diets O 
contained O 
2.5 O 
to O 
20% O 
Hudson O 
River O 
fish O 
, O 
providing O 
0.72 O 
to O 
6.1 O 
µg O 
Σ O 
PCBs B-ABBREVIATION 
/g O 
feed O 
( O 
4.8-38 O 
pg O 
toxic O 
equivalents O 
[ O 
TEQWHO O 
2005 O 
] O 
/ O 
g O 
feed O 
) O 
. O 
Absolute O 
thyroid O 
and O 
adrenal O 
gland O 
masses O 
were O 
increased O 
in O 
adult O 
females O 
and O 
31-week- O 
old O 
juveniles O 
, O 
respectively O 
, O 
and O 
absolute O 
liver O 
and O 
heart O 
masses O 
were O 
decreased O 
in O 
six O 
- O 
week O 
- O 
old O 
kits O 
exposed O 
to O 
dietary O 
PCBs B-ABBREVIATION 
. O 
Dietary O 
concentrations O 
of O 
0.72 O 
µg O 
Σ O 
PCBs B-ABBREVIATION 
/g O 
feed O 
( O 
4.8 O 
pg O 
TEQWHO O 
2005 O 
/g O 
feed O 
) O 
and O 
greater O 
induced O 
mandibular O 
and O 
maxillary O 
squamous O 
epithelial O 
proliferation O 
in O 
adult O 
animals O 
. O 
The O 
dietary O 
concentration O 
of O 
Σ O 
PCBs B-ABBREVIATION 
predicted O 
to O 
result O 
in O 
20% O 
incidence O 
of O 
the O 
jaw O 
lesion O 
( O 
EC20 O 
) O 
was O 
2.3 O 
µg O 
Σ O 
PCBs B-ABBREVIATION 
/g O 
feed O 
( O 
15 O 
pg O 
TEQWHO O 
2005 O 
/g O 
feed O 
) O 
, O 
and O 
the O 
hepatic O 
concentration O 
was O 
2.8 O 
µg O 
Σ O 
PCBs B-ABBREVIATION 
/g O 
liver O 
( O 
89 O 
pg O 
TEQWHO O 
2005 O 
/g O 
liver O 
) O 
. O 
The O 
EC20 O 
values O 
were O 
greater O 
than O 
the O 
dietary O 
and O 
hepatic O 
concentrations O 
predicted O 
to O 
result O 
in O 
a O 
20% O 
increase O 
in O 
kit O 
mortality O 
( O 
LC20 O 
) O 
at O 
six O 
weeks O 
of O 
age O 
( O 
0.34 O 
µg O 
Σ O 
PCBs B-ABBREVIATION 
/g O 
feed O 
or O 
2.6 O 
pg O 
TEQWHO O 
2005 O 
/g O 
feed O 
and O 
0.8 O 
µg O 
Σ O 
PCBs B-ABBREVIATION 
/g O 
liver O 
or O 
13 O 
pg O 
TEQWHO O 
2005 O 
/g O 
liver O 
) O 
. O 
However O 
, O 
the O 
EC20 O 
values O 
reflect O 
exposure O 
of O 
adults O 
to O 
PCBs B-ABBREVIATION 
for O 
approximately O 
six O 
months O 
, O 
and O 
the O 
LC20 O 
values O 
reflect O 
exposure O 
of O 
offspring O 
from O 
conception O 
onward O 
. O 

this O 
article O 
, O 
the O 
genotoxic O 
and O 
antigenotoxic O 
effects O 
of O 
methanol B-SYSTEMATIC 
extract O 
of O 
Evernia O 
prunastri O 
( O 
Huds O 
. O 
) O 
Willd O 
. O 
( O 
MEP O 
) O 
were O 
studied O 
using O 
WP2 O 
, O 
Ames O 
( O 
TA1535 O 
and O 
TA1537 O 
) O 
and O 
sister O 
chromatid O 
exchange O 
( O 
SCE O 
) O 
test O 
systems O 
. O 
The O 
results O 
obtained O 
from O 
bacterial O 
test O 
systems O 
demonstrated O 
that O 
MEP O 
has O 
strong O 
antimutagenic O 
potencies O 
on O 
TA1537 O 
and O 
WP2 O 
strains O 
. O 
The O 
highest O 
inhibition O 
rates O 
for O 
MEP O 
on O 
TA1537 O 
and O 
WP2 O 
strains O 
were O 
37.70% O 
and O 
69.70% O 
, O 
respectively O 
. O 
According O 
to O 
the O 
SCE O 
test O 
system O 
, O 
MEP O 
reduced O 
the O 
genotoxic O 
effects O 
of O 
aflatoxin B-FAMILY 
. O 
In O 
order O 
to O 
clarify O 
the O 
mechanism O 
underlying O 
the O 
antigenotoxic O 
effects O 
of O 
MEP O 
, O 
the O 
antioxidants O 
were O 
determined O 
. O 
Cotreatments O 
of O 
5 O 
, O 
10 O 
and O 
20 O 
µg O 
/ O 
mL O 
concentrations O 
of O 
MEP O 
with O 
aflatoxin B-TRIVIAL 
B(1) I-TRIVIAL 
decreased O 
the O 
frequencies O 
of O 
SCE O 
and O 
the O 
malondialdehyde B-TRIVIAL 
level O 
and O 
increased O 
amount O 
of O 
superoxide B-TRIVIAL 
dismutase O 
, O 
glutathione B-TRIVIAL 
and O 
glutathione B-TRIVIAL 
peroxidase O 
which O 
were O 
decreased O 
by O 
aflatoxin B-FAMILY 
. O 
The O 
data O 
obtained O 
from O 
this O 
work O 
have O 
clearly O 
shown O 
that O 
MEP O 
has O 
significant O 
antigenotoxic O 
effects O 
which O 
are O 
thought O 
to O 
be O 
partly O 
due O 
to O 
the O 
antioxidant O 
activities O 
and O 
antioxidant O 
inducing O 
capability O 
of O 
MEP O 
. O 
This O 
is O 
the O 
first O 
report O 
indicating O 
the O 
antigenotoxic O 
activities O 
of O 
MEP O 
against O 
several O 
mutagen O 
agents O 
such O 
as O 
N-methyl-N'-nitro-N-nitrosoguanidine B-SYSTEMATIC 
, O 
acridin B-TRIVIAL 
and O 
aflatoxin B-FAMILY 
. O 

of O 
trona B-TRIVIAL 
on O 
the O 
redox O 
status O 
of O 
cellular O 
system O 
of O 
male O 
rats O 
. O 

effects O 
of O 
trona B-TRIVIAL 
( O 
Kaun B-TRIVIAL 
) O 
, O 
a O 
food O 
additive O 
, O 
on O 
the O 
redox O 
status O 
of O 
the O 
liver O 
and O 
kidney O 
of O 
male O 
Wistar O 
rats O 
were O 
investigated O 
. O 
A O 
total O 
of O 
60 O 
male O 
rats O 
( O 
145 O 
± O 
2.52 O 
g O 
) O 
were O 
grouped O 
into O 
four O 
: O 
A O 
, O 
B O 
, O 
C O 
and O 
D O 
, O 
where O 
group O 
A O 
( O 
the O 
control O 
) O 
received O 
1 O 
mL O 
of O 
distilled O 
water O 
orally O 
while O 
those O 
in O 
groups O 
B O 
, O 
C O 
and O 
D O 
( O 
test O 
groups O 
) O 
received O 
orally O 
, O 
same O 
volume O 
of O 
trona B-TRIVIAL 
preparation O 
corresponding O 
to O 
100 O 
, O 
200 O 
and O 
400 O 
mg O 
/ O 
kg O 
body O 
weight O 
, O 
respectively O 
, O 
for O 
28 O 
days O 
. O 
Administration O 
of O 
trona B-TRIVIAL 
significantly O 
reduced O 
( O 
p O 
< O 
0.05 O 
) O 
alkaline O 
phosphatase O 
activity O 
in O 
the O 
liver O 
and O 
kidney O 
with O 
corresponding O 
increases O 
in O 
the O 
serum O 
enzyme O 
. O 
Acid O 
phosphatase O 
activity O 
increased O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
in O 
the O 
liver O 
and O 
kidney O 
with O 
no O 
significant O 
change O 
( O 
p O 
> O 
0.05 O 
) O 
in O 
the O 
activity O 
of O 
the O 
serum O 
enzyme O 
. O 
The O 
activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
, O 
catalase O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
, O 
glutathione B-TRIVIAL 
reductase O 
and O 
the O 
levels O 
of O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
, O 
vitamins B-MULTIPLE 
C I-MULTIPLE 
and I-MULTIPLE 
E I-MULTIPLE 
in O 
the O 
liver O 
and O 
kidney O 
of O 
the O 
animals O 
decreased O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
In O 
contrast O 
, O 
malondialdehyde B-TRIVIAL 
and O 
lipid O 
hydroperoxide B-FAMILY 
of O 
trona B-TRIVIAL 
-treated O 
animals O 
increased O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
in O 
liver O 
and O 
kidney O 
. O 
Overall O 
, O 
data O 
from O 
this O 
study O 
revealed O 
that O 
trona B-TRIVIAL 
exhibited O 
its O 
toxic O 
effect O 
by O 
suppressing O 
or O 
depleting O 
the O 
antioxidant O 
systems O 
and O 
increasing O 
the O 
risk O 
of O 
attack O 
by O 
oxidants O 
generated O 
either O 
from O 
its O 
metabolites O 
or O 
from O 
other O 
in O 
vivo O 
means O 
on O 
the O 
rat O 
cellular O 
system O 
. O 

vitro O 
assessment O 
of O 
drug O 
- O 
drug O 
interaction O 
potential O 
of O 
boceprevir B-TRIVIAL 
associated O 
with O 
drug O 
metabolizing O 
enzymes O 
and O 
transporters O 
. O 

inhibitory O 
effect O 
of O 
boceprevir B-TRIVIAL 
( O 
BOC B-ABBREVIATION 
) O 
, O 
an O 
inhibitor O 
of O 
hepatitis O 
C O 
virus O 
nonstructural O 
protein O 
3 O 
protease O 
was O 
evaluated O 
in O 
vitro O 
against O 
a O 
panel O 
of O 
drug O 
- O 
metabolizing O 
enzymes O 
and O 
transporters O 
. O 
BOC B-ABBREVIATION 
, O 
a O 
known O 
substrate O 
for O 
cytochrome O 
P450 O 
( O 
P450 O 
) O 
CYP3A O 
and O 
aldo O 
- O 
ketoreductases O 
, O 
was O 
a O 
reversible O 
time O 
- O 
dependent O 
inhibitor O 
( O 
k(inact) O 
= O 
0.12 O 
minute(-1) O 
, O 
K O 
(I) O 
= O 
6.1 O 
µM O 
) O 
of O 
CYP3A4 O 
/ O 
5 O 
but O 
not O 
an O 
inhibitor O 
of O 
other O 
major O 
P450s O 
, O 
nor O 
of O 
UDP B-ABBREVIATION 
-glucuronosyltransferases O 
1A1 O 
and O 
2B7 O 
. O 
BOC B-ABBREVIATION 
showed O 
weak O 
to O 
no O 
inhibition O 
of O 
breast O 
cancer O 
resistance O 
protein O 
( O 
BCRP O 
) O 
, O 
P-glycoprotein O 
( O 
Pgp O 
) O 
, O 
or O 
multidrug O 
resistance O 
protein O 
2 O 
. O 
It O 
was O 
a O 
moderate O 
inhibitor O 
of O 
organic O 
anion O 
transporting O 
polypeptide O 
( O 
OATP O 
) O 
1B1 O 
and O 
1B3 O 
, O 
with O 
an O 
IC(50) O 
of O 
18 O 
and O 
4.9 O 
µM O 
, O 
respectively O 
. O 
In O 
human O 
hepatocytes O 
, O 
BOC B-ABBREVIATION 
inhibited O 
CYP3A O 
- O 
mediated O 
metabolism O 
of O 
midazolam O 
, O 
OATP1B O 
- O 
mediated O 
hepatic O 
uptake O 
of O 
pitavastatin B-TRIVIAL 
, O 
and O 
both O 
the O 
uptake O 
and O 
metabolism O 
of O 
atorvastatin B-TRIVIAL 
. O 
The O 
inhibitory O 
potency O 
of O 
BOC B-ABBREVIATION 
was O 
lower O 
than O 
known O 
inhibitors O 
of O 
CYP3A O 
( O 
ketoconazole B-TRIVIAL 
) O 
, O 
OATP1B O 
( O 
rifampin B-TRIVIAL 
) O 
, O 
or O 
both O 
( O 
telaprevir B-TRIVIAL 
) O 
. O 
BOC B-ABBREVIATION 
was O 
a O 
substrate O 
for O 
Pgp O 
and O 
BCRP O 
but O 
not O 
for O 
OATP1B1 O 
, O 
OATP1B3 O 
, O 
OATP2B1 O 
, O 
organic O 
cation O 
transporter O 
, O 
or O 
sodium B-SYSTEMATIC 
/ O 
taurocholate B-TRIVIAL 
cotransporting O 
peptide O 
. O 
Overall O 
, O 
our O 
data O 
suggest O 
that O 
BOC B-ABBREVIATION 
has O 
the O 
potential O 
to O 
cause O 
pharmacokinetic O 
interactions O 
via O 
inhibition O 
of O 
CYP3A O 
and O 
CYP3A O 
/ O 
OATP1B O 
interplay O 
, O 
with O 
the O 
interaction O 
magnitude O 
lower O 
than O 
those O 
observed O 
with O 
known O 
potent O 
inhibitors O 
. O 
Conversely O 
, O 
pharmacokinetic O 
interactions O 
of O 
BOC B-ABBREVIATION 
, O 
either O 
as O 
a O 
perpetrator O 
or O 
victim O 
, O 
via O 
other O 
major O 
P450s O 
and O 
transporters O 
tested O 
are O 
less O 
likely O 
to O 
be O 
of O 
clinical O 
significance O 
. O 
The O 
results O 
from O 
clinical O 
drug O 
- O 
drug O 
interaction O 
studies O 
conducted O 
thus O 
far O 
are O 
generally O 
supportive O 
of O 
these O 
conclusions O 
. O 

modeling O 
of O 
oral O 
absorption O 
and O 
bioavailability O 
of O 
a O 
fluoroquinolone B-SYSTEMATIC 
after O 
its O 
precipitation O 
in O 
the O 
gastrointestinal O 
tract O 
. O 

1 O 
. O 
The O 
objective O 
was O 
to O 
characterize O 
the O 
in O 
vivo O 
absorption O 
and O 
bioavailability O 
( O 
BA O 
) O 
of O 
a O 
low O 
solubility O 
, O 
high O 
permeability O 
fluoroquinolone B-SYSTEMATIC 
( O 
CNV97101 B-IDENTIFIER 
) O 
that O 
precipitates O 
in O 
the O 
gastrointestinal O 
( O 
GI O 
) O 
tract O 
by O 
mathematical O 
modeling O 
approach O 
. O 
2 O 
. O 
In O 
situ O 
rat O 
intestinal O 
perfusion O 
studies O 
were O 
performed O 
to O 
characterize O 
the O 
absorption O 
mechanism O 
. O 
The O 
oral O 
fraction O 
absorbed O 
in O 
vivo O 
was O 
lower O 
than O 
the O 
predicted O 
based O 
on O 
the O 
in O 
situ O 
intestinal O 
permeability O 
. O 
Two O 
additional O 
routes O 
of O 
administration O 
, O 
intraduodenal O 
( O 
ID O 
) O 
and O 
intraperitoneal O 
( O 
IP O 
) O 
were O 
investigated O 
to O 
explore O 
if O 
precipitation O 
in O 
stomach O 
and O 
subsequent O 
partial O 
re O 
- O 
dissolution O 
were O 
the O 
causes O 
of O 
the O 
lower O 
in O 
vivo O 
BA O 
. O 
Ex O 
vivo O 
precipitation O 
studies O 
with O 
the O 
stomach O 
content O 
of O 
fasted O 
rats O 
were O 
also O 
carried O 
out O 
. O 
Fitting O 
procedures O 
were O 
performed O 
with O 
NONMEM O 
VII O 
1.2 O 
. O 
3 O 
. O 
The O 
in O 
situ O 
experiments O 
confirmed O 
simultaneous O 
passive O 
and O 
carrier O 
- O 
mediated O 
absorption O 
processes O 
. O 
The O 
ex O 
vivo O 
experiments O 
confirmed O 
precipitation O 
in O 
stomach O 
lowering O 
in O 
vivo O 
the O 
oral O 
fraction O 
absorbed O 
compared O 
with O 
the O 
IP O 
and O 
ID O 
administrations O 
. O 
Due O 
to O 
the O 
almost O 
complete O 
availability O 
of O 
CNV97101 B-IDENTIFIER 
following O 
IP O 
administration O 
, O 
a O 
first O 
hepatic O 
pass O 
could O 
be O 
excluded O 
. O 
The O 
ex O 
vivo O 
assay O 
results O 
and O 
the O 
pharmacokinetic O 
modeling O 
of O 
in O 
vivo O 
data O 
supported O 
the O 
hypothesis O 
of O 
precipitation O 
in O 
the O 
stomach O 
and O 
partial O 
re O 
- O 
dissolution O 
. O 
Nevertheless O 
, O 
other O 
factors O 
such O 
as O 
residence O 
time O 
in O 
the O 
GI O 
may O 
reduce O 
the O 
fraction O 
absorbed O 
even O 
for O 
low O 
oral O 
doses O 
for O 
which O 
re O 
- O 
dissolution O 
was O 
almost O 
complete O 
in O 
vivo O 
. O 

A-C I-MULTIPLE 
and O 
arundinones B-MULTIPLE 
A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
from O 
the O 
plant O 
endophytic O 
fungus O 
Microsphaeropsis O 
arundinis O 
. O 

new O 
ent-eudesmane B-FAMILY 
sesquiterpenoids I-FAMILY 
, O 
arundinols B-MULTIPLE 
A-C I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
one O 
isochroman-1-one B-SYSTEMATIC 
, O 
arundinone B-TRIVIAL 
A I-TRIVIAL 
( O 
4 O 
) O 
, O 
and O 
a O 
polyoxygenated B-FAMILY 
benzofuran-3(2H)-one I-FAMILY 
dimer O 
, O 
arundinone B-TRIVIAL 
B I-TRIVIAL 
( O 
5 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
extract O 
of O 
a O 
plant O 
endophytic O 
fungus O 
, O 
Microsphaeropsis O 
arundinis O 
. O 
Their O 
structures O 
were O 
elucidated O 
primarily O 
by O 
NMR O 
experiments O 
, O 
and O 
1 O 
was O 
confirmed O 
by O 
X-ray O 
crystallography O 
. O 
The O 
absolute O 
configuration O 
of O 
1 O 
was O 
assigned O 
by O 
X-ray O 
crystallography O 
using O 
Cu B-FORMULA 
Kα O 
radiation O 
, O 
whereas O 
those O 
of O 
the O 
C-11 O 
tertiary B-FAMILY 
alcohols I-FAMILY 
in O 
2 O 
and O 
3 O 
were O 
deduced O 
via O 
the O 
circular O 
dichroism O 
data O 
of O 
the O 
in O 
situ O 
formed O 
[Rh(2)(OCOCF(3))(4)] B-FORMULA 
Rh(2)(OCOCF(3))(4) B-FORMULA 
] O 
complexes O 
. O 
Arundinone B-TRIVIAL 
B I-TRIVIAL 
( O 
5 O 
) O 
represents O 
the O 
first O 
dimeric O 
benzofuran-3(2H)-one B-SYSTEMATIC 
, O 
showing O 
cytotoxicity O 
against O 
T24 O 
and O 
A549 O 
cells O 
. O 
The O 
co O 
- O 
isolated O 
known O 
compound O 
6 O 
showed O 
a O 
modest O 
inhibitory O 
effect O 
against O 
Staphylococcus O 
aureus O 
. O 

of O 
the O 
Yersinia O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
through O 
high O 
throughput O 
and O 
virtual O 
screening O 
approaches O 
. O 

bacterial O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
YopH O 
is O 
an O 
essential O 
virulence O 
determinant O 
in O 
Yersinia O 
pestis O 
and O 
a O 
potential O 
antibacterial O 
drug O 
target O 
. O 
Here O 
we O 
report O 
our O 
studies O 
of O 
screening O 
for O 
small O 
molecule O 
inhibitors O 
of O 
YopH O 
using O 
both O 
high O 
throughput O 
and O 
in O 
silico O 
approaches O 
. O 
The O 
identified O 
inhibitors O 
represent O 
a O 
diversity O 
of O 
chemotypes O 
and O 
novel O 
pTyr O 
mimetics O 
, O 
providing O 
a O 
starting O 
point O 
for O 
further O 
development O 
and O 
fragment O 
- O 
based O 
design O 
of O 
multi O 
- O 
site O 
binding O 
inhibitors O 
. O 
We O 
demonstrate O 
that O 
the O 
applications O 
of O 
high O 
throughput O 
and O 
virtual O 
screening O 
, O 
when O 
guided O 
by O 
structural O 
binding O 
mode O 
analysis O 
, O 
is O 
an O 
effective O 
approach O 
for O 
identifying O 
potent O 
and O 
selective O 
inhibitors O 
of O 
YopH O 
and O 
other O 
protein O 
phosphatases O 
for O 
rational O 
drug O 
design O 
. O 

covalently O 
modifies O 
cysteine B-TRIVIAL 
residues O 
of O 
human O 
carbonyl B-FAMILY 
reductase O 
1 O 
and O 
affects O 
its O 
activity O 
. O 

reductase O 
1 O 
( O 
CBR1 O 
or O 
SDR21C1 O 
) O 
is O 
a O 
ubiquitously O 
- O 
expressed O 
, O 
cytosolic O 
, O 
monomeric O 
, O 
and O 
NADPH B-ABBREVIATION 
-dependent O 
enzyme O 
. O 
CBR1 O 
participates O 
in O 
apoptosis O 
, O 
carcinogenesis O 
and O 
drug O 
resistance O 
, O 
and O 
has O 
a O 
protective O 
role O 
in O 
oxidative O 
stress O 
, O 
cancer O 
and O 
neurodegeneration O 
. O 
S-Nitrosoglutathione B-SYSTEMATIC 
( O 
GSNO B-ABBREVIATION 
) O 
represents O 
the O 
newest O 
addition O 
to O 
its O 
diverse O 
substrate O 
spectrum O 
, O 
which O 
includes O 
a O 
wide O 
range O 
of O 
xenobiotics O 
and O 
endogenous O 
substances O 
. O 
GSNO B-ABBREVIATION 
has O 
also O 
been O 
shown O 
to O 
covalently O 
modify O 
and O 
inhibit O 
CBR1 O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
quantify O 
and O 
characterize O 
the O 
resulting O 
modifications O 
. O 
Of O 
five O 
candidate O 
cysteines O 
for O 
modification O 
by O 
2 O 
mM O 
GSNO B-ABBREVIATION 
( O 
positions O 
26 O 
, O 
122 O 
, O 
150 O 
, O 
226 O 
, O 
227 O 
) O 
, O 
the O 
last O 
four O 
were O 
analyzed O 
using O 
MALDI-TOF O 
/ O 
TOF O 
mass O 
spectrometry O 
and O 
then O 
quantified O 
using O 
the O 
Selected O 
Reaction O 
Monitoring O 
Approach O 
on O 
hyphenated O 
HPLC O 
with O 
a O 
triple O 
quadrupole O 
mass O 
spectrometer O 
. O 
The O 
analysis O 
confirmed O 
GSNO B-ABBREVIATION 
concentration O 
- O 
dependent O 
S-glutathionylation B-SYSTEMATIC 
of O 
cysteines B-FAMILY 
at O 
positions O 
122 O 
, O 
150 O 
, O 
226 O 
, O 
227 O 
which O 
was O 
2-700 O 
times O 
higher O 
compared O 
to O 
wild O 
- O 
type O 
CBR1 O 
( O 
WT-CBR1 O 
) O 
. O 
Moreover O 
, O 
a O 
disulfide B-SYSTEMATIC 
bond O 
between O 
neighboring O 
Cys B-FORMULA 
-226 O 
and O 
Cys B-FORMULA 
-227 O 
was O 
detected O 
. O 
We O 
suggest O 
a O 
role O 
of O 
these O 
two O 
cysteines B-FAMILY 
as O 
a O 
redox O 
- O 
sensitive O 
cysteine O 
pair O 
. O 
The O 
catalytic O 
properties O 
of O 
wild O 
- O 
type O 
and O 
enzyme O 
modified O 
with O 
2 O 
mM O 
GSNO B-ABBREVIATION 
were O 
also O 
investigated O 
by O 
steady O 
state O 
kinetic O 
experiments O 
with O 
various O 
substrates O 
. O 
GSNO B-ABBREVIATION 
treatment O 
of O 
CBR1 O 
resulted O 
in O 
a O 
2-5-fold O 
decrease O 
in O 
kcat O 
with O 
menadione B-TRIVIAL 
, O 
4-benzoylpyridine B-SYSTEMATIC 
, O 
2,3-hexanedione B-SYSTEMATIC 
, O 
daunorubicin B-TRIVIAL 
and O 
1,4-naphthoquinone B-SYSTEMATIC 
. O 
In O 
contrast O 
, O 
the O 
same O 
treatment O 
increased O 
kcat O 
for O 
substrates O 
containing O 
a O 
1,2-diketo B-SYSTEMATIC 
group O 
in O 
a O 
ring O 
structure O 
( O 
1,2-naphthoquinone B-SYSTEMATIC 
, O 
9,10-phenanthrenequinone B-SYSTEMATIC 
, O 
isatin B-TRIVIAL 
) O 
. O 
Except O 
for O 
9,10-phenanthrenequinone B-SYSTEMATIC 
, O 
all O 
changes O 
in O 
kcat O 
were O 
at O 
least O 
in O 
part O 
compensated O 
for O 
by O 
a O 
similar O 
change O 
in O 
Km O 
, O 
overall O 
yielding O 
no O 
drastic O 
changes O 
in O 
catalytic O 
efficiency O 
. O 
The O 
findings O 
indicate O 
that O 
GSNO B-ABBREVIATION 
-induced O 
covalent O 
modification O 
of O 
cysteine B-TRIVIAL 
residues O 
affects O 
the O 
kinetic O 
mechanism O 
of O 
CBR1 O 
both O 
in O 
terms O 
of O 
substrate O 
binding O 
and O 
turnover O 
rate O 
, O 
probably O 
by O 
covalent O 
modification O 
of O 
Cys B-FORMULA 
-226 O 
and O 
/ O 
or O 
Cys B-FORMULA 
-227 O 
. O 

investigated O 
the O 
influence O 
of O 
maternal O 
airway O 
exposure O 
to O 
nanoparticulate O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
TiO2 B-FORMULA 
, O 
UV-Titan O 
) O 
and O 
carbon B-TRIVIAL 
black I-TRIVIAL 
( O 
CB O 
, O 
Printex90 B-TRIVIAL 
) O 
, O 
on O 
male O 
reproductive O 
function O 
in O 
the O 
two O 
following O 
generations O 
. O 
Time O 
- O 
mated O 
C57BL O 
/ O 
6J O 
mice O 
were O 
exposed O 
by O 
inhalation O 
to O 
UV-Titan O 
, O 
or O 
by O 
intratracheal O 
instillation O 
with O 
Printex90 B-TRIVIAL 
. O 
Body O 
and O 
testicle O 
weight O 
, O 
sperm O 
content O 
per O 
g O 
testicular O 
parenchyma O 
and O 
daily O 
sperm O 
production O 
( O 
DSP O 
) O 
were O 
assessed O 
. O 
The O 
protocol O 
for O 
assessment O 
of O 
DSP O 
was O 
optimized O 
for O 
application O 
in O 
mice O 
( O 
C57BL O 
/ O 
6J O 
) O 
and O 
the O 
influence O 
of O 
different O 
parameters O 
was O 
studied O 
. O 
Maternal O 
particulate O 
exposure O 
did O 
not O 
affect O 
DSP O 
statistically O 
significantly O 
in O 
the O 
F1 O 
generation O 
, O 
although O 
TiO2 B-FORMULA 
tended O 
to O 
reduce O 
sperm O 
counts O 
. O 
Overall O 
, O 
time O 
- O 
to O 
- O 
first O 
F2 O 
litter O 
increased O 
with O 
decreasing O 
sperm O 
production O 
. O 
There O 
was O 
no O 
effect O 
on O 
sperm O 
production O 
in O 
the O 
F2 O 
generation O 
originating O 
after O 
TiO2 B-FORMULA 
exposure O 
. O 
F2 O 
offspring O 
, O 
whose O 
fathers O 
were O 
prenatally O 
exposed O 
to O 
Printex90 B-TRIVIAL 
, O 
showed O 
lowered O 
sperm O 
production O 
. O 
Furthermore O 
, O 
we O 
report O 
statistically O 
significant O 
differences O 
in O 
sperm O 
production O 
between O 
mouse O 
strains O 
. O 

is O 
a O 
potent O 
allosteric O 
modulator O 
of O 
sigma-1 O 
receptor O 
. O 

( O 
3-methyl-6-chloro-7,8-hydroxy-1-[3-methylphenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine B-SYSTEMATIC 
) O 
, O 
an O 
atypical O 
dopamine B-TRIVIAL 
receptor-1 O 
( O 
D(1) O 
receptor O 
) O 
agonist O 
, O 
has O 
shown O 
many O 
D(1) O 
receptor O 
- O 
independent O 
effects O 
, O 
such O 
as O 
neuroprotection O 
, O 
blockade O 
of O 
Na(+) B-FORMULA 
channel O 
, O 
and O 
promotion O 
of O 
spontaneous O 
glutamate B-TRIVIAL 
release O 
, O 
which O 
resemble O 
the O 
effects O 
of O 
the O 
sigma-1 O 
receptor O 
activation O 
. O 
In O 
the O 
present O 
work O 
, O 
we O 
explored O 
the O 
potential O 
modulation O 
of O 
SKF83959 B-IDENTIFIER 
on O 
the O 
sigma-1 O 
receptor O 
. O 
The O 
results O 
indicated O 
that O 
SKF83959 B-IDENTIFIER 
dramatically O 
promoted O 
the O 
binding O 
of O 
(3)H(+)-pentazocine B-SYSTEMATIC 
( O 
a O 
selective O 
sigma-1 O 
receptor O 
agonist O 
) O 
to O 
the O 
sigma-1 O 
receptor O 
in O 
brain O 
and O 
liver O 
tissues O 
but O 
produced O 
no O 
effect O 
on O 
(3)H-progesterone B-SYSTEMATIC 
binding O 
( O 
a O 
sigma-1 O 
receptor O 
antagonist O 
) O 
. O 
The O 
saturation O 
assay O 
and O 
the O 
dissociation O 
kinetics O 
assay O 
confirmed O 
the O 
allosteric O 
effect O 
. O 
We O 
further O 
demonstrated O 
that O 
the O 
SKF83959 B-IDENTIFIER 
analogs O 
, O 
such O 
as O 
SCH22390 B-IDENTIFIER 
[ O 
(R)-(1)-7-chloro-8- B-SYSTEMATIC 
hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine I-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
] O 
and O 
SKF38393 B-IDENTIFIER 
[ O 
( B-SYSTEMATIC 
+ I-SYSTEMATIC 
/ I-SYSTEMATIC 
-)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol I-SYSTEMATIC 
hydrobromide I-SYSTEMATIC 
] O 
, O 
also O 
showed O 
the O 
similar O 
allosteric O 
effect O 
on O 
the O 
sigma-1 O 
receptor O 
in O 
the O 
liver O 
tissue O 
but O 
not O 
in O 
the O 
brain O 
tissue O 
. O 
Moreover O 
, O 
all O 
three O 
tested O 
chemicals O 
elicited O 
no O 
significant O 
effect O 
on O 
(3)H-1,3-di(2-tolyl)-guanidine B-SYSTEMATIC 
( O 
(3)H-DTG B-SYSTEMATIC 
) O 
binding O 
to O 
the O 
sigma-2 O 
receptor O 
. O 
The O 
present O 
data O 
uncovered O 
a O 
new O 
role O 
of O 
SKF83959 B-IDENTIFIER 
and O 
its O 
analogs O 
on O 
the O 
sigma-1 O 
receptor O 
, O 
which O 
, O 
in O 
turn O 
, O 
may O 
reveal O 
the O 
underlying O 
mechanism O 
for O 
the O 
D(1) O 
receptor O 
- O 
independent O 
effect O 
of O 
the O 
drug O 
. O 

nuclear O 
receptor O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
(PPAR)α O 
is O 
known O 
primarily O 
as O 
a O 
regulator O 
of O 
fatty B-FAMILY 
acid I-FAMILY 
metabolism O 
, O 
energy O 
balance O 
, O 
and O 
inflammation O 
, O 
but O 
evidence O 
suggests O 
a O 
wider O 
role O 
in O 
regulating O 
the O 
biotransformation O 
of O 
drugs O 
and O 
other O 
lipophilic O 
chemicals O 
. O 
We O 
investigated O 
whether O 
PPARα O 
directly O 
regulates O 
the O 
transcription O 
of O 
cytochrome O 
P450 O 
3A4 O 
, O 
the O 
major O 
human O 
drug O 
- O 
metabolizing O 
enzyme O 
. O 
Using O 
chromatin O 
immunoprecipitation O 
in O 
human O 
primary O 
hepatocytes O 
as O 
well O 
as O 
electrophoretic O 
mobility O 
shift O 
and O 
luciferase O 
reporter O 
- O 
gene O 
assays O 
, O 
we O 
identified O 
three O 
functional O 
PPARα O 
- O 
binding O 
regions O 
( O 
PBR-I O 
, O 
-II O 
, O 
and O 
-III O 
) O 
within O 
∼12 O 
kb O 
of O 
the O 
CYP3A4 O 
upstream O 
sequence O 
. O 
Furthermore O 
, O 
a O 
humanized O 
CYP3A4 O 
/ O 
3A7 O 
mouse O 
model O 
showed O 
in O 
vivo O 
induction O 
of O 
CYP3A4 O 
mRNA O 
and O 
protein O 
by O 
[ O 
4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
WY14,643 B-IDENTIFIER 
) O 
in O 
liver O 
but O 
not O 
in O 
intestine O 
, O 
whereas O 
hepatic O 
occupancy O 
of O 
PBRs O 
by O 
PPARα O 
was O 
ligand O 
independent O 
. O 
Using O 
lentiviral O 
gene O 
knock O 
- O 
down O 
and O 
treatment O 
with O 
WY14,643 B-IDENTIFIER 
in O 
primary O 
human O 
hepatocytes O 
, O 
PPARα O 
was O 
further O 
shown O 
to O 
affect O 
the O 
expression O 
of O 
a O 
distinct O 
set O 
of O 
CYPs O 
, O 
including O 
1A1 O 
, O 
1A2 O 
, O 
2B6 O 
, O 
2C8 O 
, O 
3A4 O 
, O 
and O 
7A1 O 
, O 
but O 
not O 
2C9 O 
, O 
2C19 O 
, O 
2D6 O 
, O 
or O 
20 O 
. O 
Interestingly O 
, O 
the O 
common O 
phospholipid O 
1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine B-SYSTEMATIC 
( O 
16 O 
: O 
0 O 
/ O 
18 O 
: O 
1-PC O 
) O 
, O 
previously O 
proposed O 
to O 
reflect O 
nutritional O 
status O 
and O 
shown O 
to O 
be O 
a O 
specific O 
endogenous O 
ligand O 
of O 
PPARα O 
, O 
induced O 
CYP3A4 O 
( O 
up O 
to O 
4-fold O 
) O 
and O 
other O 
biotransformation O 
genes O 
in O 
hepatocytes O 
with O 
similar O 
selectivity O 
and O 
potency O 
as O 
WY14,643 B-IDENTIFIER 
. O 
These O 
data O 
establish O 
PPARα O 
as O 
a O 
direct O 
transcriptional O 
regulator O 
of O 
hepatic O 
CYP3A4 O 
. O 
This O 
finding O 
warrants O 
investigation O 
of O 
both O 
known O 
and O 
newly O 
developed O 
PPARα-targeted O 
drugs O 
for O 
their O 
drug O 
- O 
drug O 
interaction O 
potential O 
. O 
Furthermore O 
, O 
our O 
data O 
suggest O 
that O 
nutritional O 
status O 
can O 
influence O 
drug O 
biotransformation O 
capacity O 
via O 
endogenous O 
phospholipid O 
signaling O 
. O 

triamcinolone I-FAMILY 
acetonide I-FAMILY 
triamcinolone B-TRIVIAL 
acetonide I-TRIVIAL 
nanoparticles O 
as O 
a O 
new O 
alternative O 
in O 
the O 
treatment O 
of O 
uveitis O 
: O 
In O 
vitro O 
and O 
in O 
vivo O 
studies O 
. O 

purpose O 
of O 
this O 
work O 
was O 
to O 
improve O 
the O 
efficacy O 
of O 
triamcinolone B-TRIVIAL 
acetonide I-TRIVIAL 
( O 
TA O 
) O 
in O 
the O 
treatment O 
of O 
endotoxin O 
- O 
induced O 
uveitis O 
( O 
EIU O 
) O 
using O 
a O 
polymeric O 
nanoparticulate O 
drug O 
delivery O 
system O 
. O 
Poly(d,l-lactide-co-glycolide) B-FAMILY 
( O 
PLGA B-ABBREVIATION 
) O 
nanoparticles O 
were O 
prepared O 
using O 
a O 
modified O 
emulsification O 
/ O 
solvent O 
diffusion O 
method O 
. O 
Processing O 
factors O 
affecting O 
loading O 
and O 
size O 
were O 
also O 
studied O 
. O 
After O 
physicochemical O 
studies O 
including O 
in O 
vitro O 
release O 
, O 
X-ray O 
powder O 
diffraction O 
, O 
differential O 
scanning O 
calorimetry O 
, O 
and O 
scanning O 
electron O 
microscopy O 
, O 
in O 
vivo O 
studies O 
were O 
conducted O 
using O 
nanoparticles O 
sized O 
195nm O 
with O 
3.16% O 
drug O 
loading O 
. O 
Inflammatory O 
factors O 
such O 
as O 
flare O 
, O 
cell O 
, O 
and O 
fibrin O 
were O 
studied O 
in O 
rabbit's O 
eye O 
over O 
96h O 
period O 
, O 
using O 
laser O 
flare O 
meter O 
and O 
slit O 
lamp O 
examination O 
. O 
Inflammatory O 
mediators O 
such O 
as O 
NO B-FORMULA 
, O 
PGE2 B-ABBREVIATION 
, O 
cell O 
, O 
and O 
protein O 
were O 
measured O 
quantitatively O 
36h O 
after O 
intravitreal O 
injection O 
of O 
endotoxin O 
in O 
aqueous O 
humor O 
, O 
and O 
the O 
therapeutic O 
effects O 
were O 
compared O 
in O 
different O 
groups O 
. O 
Results O 
indicated O 
statistically O 
significant O 
differences O 
between O 
the O 
effect O 
of O 
nanoparticles O 
in O 
the O 
treatment O 
of O 
EIU O 
compared O 
to O 
microparticles O 
of O 
TA O 
and O 
prednisolone B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
PA O 
) O 
. O 
There O 
were O 
no O 
significant O 
differences O 
between O 
the O 
effects O 
of O 
TA O 
injection O 
and O 
TA O 
nanoparticles O 
. O 
In O 
conclusion O 
, O 
sustain O 
release O 
biodegradable O 
TA O 
nanoparticles O 
are O 
potential O 
new O 
topical O 
treatment O 
options O 
which O 
can O 
provide O 
better O 
patient O 
compliance O 
. O 

of O 
A O 
and O 
B-site O 
cations O 
on O 
surface O 
exchange O 
coefficient O 
for O 
ABO3 O 
perovskite B-TRIVIAL 
materials O 
. O 

novel O 
approach O 
, O 
called O 
isothermal O 
isotope O 
exchange O 
( O 
IIE O 
) O 
, O 
was O 
applied O 
to O 
varying O 
A- O 
and O 
B-site O 
lanthanum B-FAMILY 
manganites I-FAMILY 
, O 
ferrites B-FAMILY 
, O 
and O 
cobaltites B-FAMILY 
in O 
the O 
perovskite B-TRIVIAL 
crystal O 
structure O 
in O 
order O 
to O 
extract O 
accurate O 
surface O 
exchange O 
coefficients O 
( O 
k* O 
) O 
. O 
Pure O 
electronic O 
conductors O 
revealed O 
temperature O 
dependent O 
isotope O 
exchange O 
, O 
while O 
for O 
mixed O 
ionic O 
and O 
electronic O 
conductors O 
( O 
MIEC O 
) O 
the O 
extent O 
of O 
exchange O 
was O 
independent O 
of O 
temperature O 
. O 
MIEC O 
materials O 
have O 
higher O 
k* O 
values O 
than O 
pure O 
electronic O 
conductors O 
in O 
the O 
temperature O 
range O 
from O 
500-850 O 
°C O 
, O 
demonstrating O 
the O 
importance O 
of O 
both O 
electronic O 
species O 
and O 
oxygen B-SYSTEMATIC 
vacancies O 
being O 
present O 
for O 
surface O 
exchange O 
. O 
Strontium B-FAMILY 
doped I-FAMILY 
perovskites I-FAMILY 
exhibited O 
opposite O 
temperature O 
dependencies O 
to O 
parent O 
materials O 
. O 
Some O 
perovskites B-FAMILY 
exhibited O 
an O 
apparent O 
negative O 
activation O 
energy O 
for O 
k* O 
, O 
the O 
behavior O 
of O 
which O 
is O 
explained O 
by O 
a O 
precursor O 
- O 
mediated O 
mechanism O 
for O 
dissociative O 
adsorption O 
. O 
The O 
results O 
have O 
significant O 
implications O 
for O 
the O 
improvement O 
of O 
the O 
oxygen B-SYSTEMATIC 
reduction O 
reaction O 
for O 
fuel O 
cells O 
, O 
metal O 
- O 
air O 
batteries O 
, O 
and O 
numerous O 
other O 
energy O 
technologies O 
. O 

to O 
achieve O 
maximum O 
nonlinear O 
optical O 
( O 
NLO O 
) O 
properties O 
from O 
the O 
molecular O 
to O 
the O 
macro O 
block O 
is O 
very O 
crucial O 
to O 
the O 
development O 
of O 
nonlinear O 
optical O 
materials O 
, O 
which O 
is O 
the O 
impetus O 
of O 
the O 
present O 
work O 
. O 
Buckybowls O 
present O 
large O 
first O 
hyperpolarizability O 
ascribed O 
to O 
noncentrosymmetric O 
charge O 
distribution O 
due O 
to O 
the O 
curved O 
shape O 
of O 
the O 
system O 
. O 
The O 
role O 
of O 
their O 
packing O 
pattern O 
in O 
maximizing O 
the O 
NLO O 
response O 
of O 
buckybowl O 
aggregates O 
is O 
investigated O 
. O 
In O 
( O 
corannulene B-TRIVIAL 
)(10 O 
) O 
and O 
( O 
sumanene B-TRIVIAL 
)(10 O 
) O 
aggregates O 
, O 
the O 
first O 
order O 
hyperpolarizabilities O 
(β(0)) O 
per O 
molecule O 
are O 
enhanced O 
5.59 O 
and O 
6.21 O 
times O 
with O 
respect O 
to O 
a O 
single O 
entity O 
respectively O 
. O 
For O 
a O 
larger O 
buckybowl O 
, O 
C(36)H(12) B-FORMULA 
, O 
the O 
β(0) O 
value O 
per O 
molecule O 
of O 
its O 
pentamer O 
reaches O 
191.4 O 
× O 
10(-30) O 
esu O 
which O 
is O 
much O 
higher O 
than O 
conventional O 
dipolar O 
or O 
octupolar O 
NLO O 
chromophores O 
ones O 
. O 
The O 
cohesive O 
coupling O 
among O 
electric O 
dipoles O 
in O 
packing O 
of O 
buckybowls O 
is O 
responsible O 
for O 
significant O 
enhancement O 
of O 
the O 
nonlinear O 
optical O 
response O 
of O 
the O 
aggregates O 
, O 
which O 
could O 
pave O 
the O 
way O 
for O 
designing O 
large O 
2nd O 
order O 
NLO O 
materials O 
with O 
a O 
good O 
balance O 
of O 
nonlinearity O 
, O 
transparency O 
, O 
and O 
stability O 
. O 

disrupting O 
effects O 
of O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
at O 
the O 
level O 
of O 
nuclear O 
receptor O 
activation O 
and O 
steroidogenesis O 
. O 

A I-TRIVIAL 
( O 
OTA B-ABBREVIATION 
) O 
is O 
a O 
mycotoxin O 
and O 
extrolite O 
of O 
fungi O 
which O 
has O 
been O 
reported O 
in O 
a O 
range O 
of O 
foods O 
. O 
This O 
study O 
uses O 
mammalian O 
reporter O 
gene O 
assays O 
( O 
RGAs O 
) O 
with O 
natural O 
steroid O 
receptors O 
and O 
the O 
H295R O 
steroidogenesis O 
assay O 
to O 
assess O 
the O 
endocrine O 
disrupting O 
activity O 
of O 
OTA B-ABBREVIATION 
. O 
At O 
the O 
receptor O 
level O 
, O 
OTA B-ABBREVIATION 
( O 
within O 
a O 
concentration O 
range O 
of O 
0.25-2500 O 
ng O 
/ O 
ml O 
) O 
did O 
not O 
induce O 
an O 
agonistic O 
response O 
in O 
an O 
oestrogen B-FAMILY 
, O 
androgen B-FAMILY 
, O 
progestagen B-FAMILY 
or O 
glucocorticoid O 
RGA O 
. O 
An O 
antagonistic O 
effect O 
was O 
observed O 
in O 
all O 
of O 
the O 
RGAs O 
at O 
the O 
highest O 
concentration O 
tested O 
( O 
2500 O 
ng O 
/ O 
ml O 
) O 
. O 
However O 
, O 
while O 
there O 
was O 
no O 
significant O 
cytotoxic O 
effect O 
observed O 
in O 
the O 
MTT B-ABBREVIATION 
( O 
thiazolyl B-SYSTEMATIC 
blue I-SYSTEMATIC 
tetrazolium I-SYSTEMATIC 
bromide I-SYSTEMATIC 
) O 
cell O 
viability O 
assay O 
at O 
this O 
concentration O 
, O 
there O 
was O 
a O 
corresponding O 
change O 
in O 
cell O 
morphology O 
which O 
may O 
be O 
related O 
to O 
the O 
resulting O 
antagonistic O 
effect O 
. O 
At O 
the O 
hormone O 
production O 
level O 
, O 
H295R O 
cells O 
were O 
used O 
as O 
a O 
steroidogenesis O 
model O 
and O 
exposed O 
to O 
OTA O 
( O 
within O 
a O 
concentration O 
range O 
of O 
0.1-1000 O 
ng O 
/ O 
ml O 
) O 
. O 
Treatment O 
of O 
the O 
cells O 
with O 
1000 O 
ng O 
/ O 
ml O 
OTA O 
increased O 
the O 
production O 
of O 
estradiol B-TRIVIAL 
( O 
117±14 O 
ng O 
/ O 
ml O 
) O 
over O 
3 O 
times O 
that O 
of O 
the O 
solvent O 
control O 
( O 
36±9 O 
pg O 
/ O 
ml O 
) O 
. O 
Western O 
blotting O 
confirmed O 
an O 
increase O 
in O 
aromatase O 
protein O 
. O 
Overall O 
the O 
results O 
indicate O 
that O 
OTA O 
does O 
not O 
appear O 
to O 
interact O 
with O 
steroid O 
receptors O 
but O 
has O 
the O 
potential O 
to O 
cause O 
endocrine O 
disruption O 
by O 
interfering O 
with O 
steroidogenesis O 
. O 
This O 
is O 
the O 
first O 
study O 
identifying O 
the O 
effect O 
OTA O 
may O 
have O 
on O 
production O 
of O 
the O 
steroid B-FAMILY 
hormone O 
estradiol B-TRIVIAL 
. O 

of O 
tolerance O 
to O 
morphine B-TRIVIAL 
-induced O 
respiratory O 
and O 
analgesic O 
effects O 
in O 
mice O 
. O 

is O 
responsible O 
for O 
severe O 
poisonings O 
in O 
chronically O 
treated O 
patients O 
. O 
We O 
hypothesize O 
that O 
toxicity O 
could O 
be O 
related O 
to O 
the O 
development O 
of O 
weaker O 
tolerance O 
for O 
morphine B-TRIVIAL 
-induced O 
deleterious O 
respiratory O 
effects O 
in O 
comparison O 
to O 
analgesic O 
effects O 
. O 
Our O 
objectives O 
were O 
to O 
compare O 
tolerance O 
to O 
both O 
effects O 
in O 
mice O 
and O 
investigate O 
possible O 
mechanisms O 
for O 
such O 
possible O 
differences O 
. O 
Tolerance O 
to O 
morphine B-TRIVIAL 
-induced O 
analgesia O 
and O 
respiratory O 
effects O 
was O 
assessed O 
using O 
hot O 
plate O 
response O 
latencies O 
and O 
plethysmography O 
, O 
respectively O 
. O 
Mechanisms O 
of O 
tolerance O 
were O 
investigated O 
using O 
binding O 
studies O 
to O 
mu-opioid O 
receptors O 
( O 
MOR O 
) O 
and O 
adenylate O 
cyclase O 
( O 
AC O 
) O 
activity O 
measurement O 
in O 
homogenates O 
of O 
cell O 
membranes O 
from O 
the O 
periaqueductal O 
gray O 
region O 
( O 
PAG O 
) O 
and O 
brainstem O 
. O 
Morphine B-TRIVIAL 
( O 
2.5 O 
mg O 
/ O 
kg O 
) O 
was O 
responsible O 
for O 
analgesia O 
with O 
significant O 
increase O 
in O 
inspiratory O 
time O 
. O 
Acute O 
tolerance O 
to O 
analgesia O 
( O 
p O 
< O 
0.01 O 
) O 
and O 
effects O 
on O 
respiratory O 
frequency O 
( O 
p O 
< O 
0.05 O 
) O 
was O 
observed O 
in O 
mice O 
pre O 
- O 
treated O 
with O 
100 O 
mg O 
/ O 
kg O 
morphine B-TRIVIAL 
in O 
comparison O 
to O 
saline O 
. O 
Following O 
repetitive O 
administration O 
( O 
2.5 O 
mg O 
/ O 
kg O 
/ O 
day O 
during O 
10 O 
days O 
) O 
, O 
we O 
observed O 
a O 
13-fold O 
increase O 
in O 
the O 
effective O 
dose-50% O 
( O 
ED₅₀ O 
) O 
of O 
morphine B-TRIVIAL 
-induced O 
analgesia O 
in O 
comparison O 
to O 
a O 
2- O 
or O 
4-fold O 
increase O 
in O 
the O 
ED₅₀ O 
of O 
its O 
related O 
increase O 
in O 
inspiratory O 
time O 
determined O 
in O 
air O 
and O 
4% O 
CO₂ B-FORMULA 
, O 
respectively O 
. O 
No O 
significant O 
alteration O 
in O 
MOR O 
expression O 
was O 
observed O 
in O 
either O 
PAG O 
or O 
brainstem O 
following O 
repeated O 
morphine B-TRIVIAL 
administration O 
. O 
However O 
, O 
in O 
PAG O 
, O 
in O 
contrast O 
to O 
brainstem O 
, O 
superactivation O 
of O 
AC O 
was O 
observed O 
in O 
morphine B-TRIVIAL 
-treated O 
mice O 
in O 
comparison O 
to O 
controls O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
In O 
conclusion O 
, O 
tolerance O 
to O 
morphine B-TRIVIAL 
-induced O 
respiratory O 
effects O 
is O 
much O 
more O 
limited O 
than O 
tolerance O 
to O 
its O 
analgesic O 
effects O 
in O 
repeatedly O 
morphine B-TRIVIAL 
-treated O 
mice O 
. O 
The O 
difference O 
in O 
morphine B-TRIVIAL 
-induced O 
AC O 
activation O 
between O 
the O 
brainstem O 
and O 
the O 
PAG O 
contributes O 
to O 
the O 
observed O 
difference O 
in O 
tolerance O 
between O 
both O 
morphine B-TRIVIAL 
effects O 
. O 

- O 
initiated O 
estradiol B-TRIVIAL 
signaling O 
in O 
immortalized O 
hypothalamic O 
N-38 O 
neurons O 
. O 

of O 
sexual O 
reproduction O 
by O 
estradiol B-TRIVIAL 
involves O 
the O 
activation O 
of O 
estrogen B-FAMILY 
receptors O 
( O 
ERs O 
) O 
in O 
the O 
hypothalamus O 
. O 
Of O 
the O 
two O 
classical O 
ERs O 
involved O 
in O 
reproduction O 
, O 
ERα O 
appears O 
to O 
be O 
the O 
critical O 
isoform O 
. O 
The O 
role O 
of O 
ERα O 
in O 
reproduction O 
has O 
been O 
found O 
to O 
involve O 
a O 
nuclear O 
ERα O 
that O 
induces O 
a O 
genomic O 
mechanism O 
of O 
action O 
. O 
More O 
recently O 
, O 
a O 
plasma O 
membrane O 
ERα O 
has O 
been O 
shown O 
to O 
trigger O 
signaling O 
pathways O 
involved O 
in O 
reproduction O 
. O 
Mechanisms O 
underlying O 
membrane O 
- O 
initiated O 
estradiol O 
signaling O 
are O 
emerging O 
, O 
including O 
evidence O 
that O 
activation O 
of O 
plasma O 
membrane O 
ERα O 
involves O 
receptor O 
trafficking O 
. O 
The O 
present O 
study O 
examined O 
the O 
insertion O 
of O 
ERα O 
into O 
the O 
plasma O 
membrane O 
of O 
N-38 O 
neurons O 
, O 
an O 
immortalized O 
murine O 
hypothalamic O 
cell O 
line O 
. O 
We O 
identified O 
, O 
using O 
western O 
blotting O 
and O 
PCR O 
that O 
N-38 O 
neurons O 
express O 
full O 
- O 
length O 
66kDa O 
ERα O 
and O 
a O 
52kDa O 
ERα O 
spliced O 
variant O 
missing O 
the O 
fourth O 
exon O 
- O 
ERαΔ4 O 
. O 
Using O 
surface O 
biotinylation O 
, O 
we O 
observed O 
that O 
treatment O 
of O 
N-38 O 
neurons O 
with O 
estradiol B-TRIVIAL 
or O 
with O 
a O 
membrane O 
impermeant O 
estradiol B-TRIVIAL 
elevated O 
plasma O 
membrane O 
ERα O 
protein O 
levels O 
, O 
indicating O 
that O 
membrane O 
signaling O 
increased O 
receptor O 
insertion O 
into O 
the O 
cell O 
membrane O 
. O 
Insertion O 
of O 
ERα O 
was O 
blocked O 
by O 
the O 
ER O 
antagonist O 
ICI B-IDENTIFIER 
182780 I-IDENTIFIER 
or O 
with O 
the O 
protein O 
kinase O 
C O 
( O 
PKC O 
) O 
pathway O 
inhibitor O 
bisindolylmaleimide B-TRIVIAL 
( O 
BIS B-FAMILY 
) O 
. O 
Downstream O 
membrane O 
- O 
initiated O 
signaling O 
was O 
confirmed O 
by O 
estradiol B-TRIVIAL 
activation O 
of O 
PKC O 
- O 
theta O 
( O 
PKCθ O 
) O 
and O 
the O 
release O 
of O 
intracellular O 
calcium O 
. O 
These O 
results O 
indicate O 
that O 
membrane O 
ERα O 
levels O 
in O 
N-38 O 
neurons O 
are O 
dynamically O 
autoregulated O 
by O 
estradiol B-TRIVIAL 
. O 

effect O 
of O 
remelting O 
on O 
the O 
physical O 
properties O 
of O 
borotellurite B-SYSTEMATIC 
glass O 
doped O 
with O 
manganese B-SYSTEMATIC 
. O 

systematic O 
set O 
of O 
borotellurite B-SYSTEMATIC 
glasses O 
doped O 
with O 
manganese B-SYSTEMATIC 
( B-FAMILY 
1-x I-FAMILY 
) I-FAMILY 
[(B(2)O(3))(0.3)(TeO(2))(0.7)]-xMnO I-FAMILY 
, O 
with O 
x O 
= O 
0.1 O 
, O 
0.2 O 
, O 
0.3 O 
and O 
0.4 O 
mol% O 
, O 
were O 
successfully O 
synthesized O 
by O 
using O 
a O 
conventional O 
melt O 
and O 
quench O 
- O 
casting O 
technique O 
. O 
In O 
this O 
study O 
, O 
the O 
remelting O 
effect O 
of O 
the O 
glass O 
samples O 
on O 
their O 
microstructure O 
was O 
investigated O 
through O 
density O 
measurement O 
and O 
FT-IR O 
spectra O 
and O 
evaluated O 
by O 
XRD O 
techniques O 
. O 
Initial O 
experimental O 
results O 
from O 
XRD O 
evaluation O 
show O 
that O 
there O 
are O 
two O 
distinct O 
phases O 
of O 
glassy O 
and O 
crystallite O 
microstructure O 
due O 
to O 
the O 
existence O 
of O 
peaks O 
in O 
the O 
sample O 
. O 
The O 
different O 
physical O 
behaviors O 
of O 
the O 
studied O 
glasses O 
were O 
closely O 
related O 
to O 
the O 
concentration O 
of O 
manganese B-SYSTEMATIC 
in O 
each O 
phase O 
. O 
FTIR O 
spectra O 
revealed O 
that O 
the O 
addition O 
of O 
manganese B-SYSTEMATIC 
oxide I-SYSTEMATIC 
contributes O 
the O 
transformation O 
of O 
TeO(4) B-FORMULA 
trigonal O 
bipyramids O 
with O 
bridging O 
oxygen B-SYSTEMATIC 
( O 
BO O 
) O 
to O 
TeO(3) B-FORMULA 
trigonal O 
pyramids O 
with O 
non-bridging O 
oxygen B-SYSTEMATIC 
( O 
NBO O 
) O 
. O 

of O 
Wine O 
Polyphenol B-FAMILY 
Resveratrol B-TRIVIAL 
on O 
the O 
Contractions O 
Elicited O 
Electrically O 
or O 
by O 
Norepinephrine B-TRIVIAL 
in O 
the O 
Rat O 
Portal O 
Vein O 
. O 

investigated O 
the O 
effects O 
of O 
resveratrol B-TRIVIAL 
on O 
rat O 
portal O 
vein O 
( O 
RPV O 
) O 
contractility O 
without O 
endothelium O 
. O 
Contractions O 
were O 
produced O 
by O 
electrical O 
field O 
stimulation O 
of O 
perivascular O 
nerves O 
( O 
EFS O 
) O 
, O 
norepinephrine B-TRIVIAL 
( O 
NE O 
) O 
, O 
adenosine B-SYSTEMATIC 
5'-triphosphate I-SYSTEMATIC 
( O 
ATP B-ABBREVIATION 
) O 
, O 
high O 
K(+) B-FORMULA 
solution O 
and O 
by O 
calcium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
CaCl(2) B-FORMULA 
) O 
in O 
Ca(2+) B-FORMULA 
-free O 
and O 
high O 
K(+) B-FORMULA 
, O 
Ca(2+) B-FORMULA 
-free O 
solution O 
. O 
The O 
EFS-evoked O 
contractions O 
were O 
more O 
sensitive O 
to O 
resveratrol B-TRIVIAL 
and O 
to O 
NS1619 B-IDENTIFIER 
-selective O 
openers O 
of O 
big O 
calcium B-SYSTEMATIC 
-sensitive O 
( O 
BK( O 
Ca B-FORMULA 
) O 
) O 
channels O 
, O 
than O 
NE-evoked O 
contractions O 
. O 
Effects O 
of O 
resveratrol B-TRIVIAL 
on O 
the O 
ATP B-ABBREVIATION 
-evoked O 
contractions O 
were O 
weak O 
. O 
Blockers O 
of O 
BK( O 
Ca B-FORMULA 
) O 
channels O 
partly O 
inhibited O 
the O 
effect O 
of O 
resveratrol B-TRIVIAL 
only O 
in O 
EFS-contracted O 
preparations O 
. O 
Western O 
blotting O 
showed O 
that O 
RPV O 
expressed O 
K B-FORMULA 
( O 
Ca B-FORMULA 
) O 
1.1 O 
protein O 
. O 
Inhibitors O 
of O 
ATP B-ABBREVIATION 
- O 
and O 
voltage O 
- O 
sensitive O 
K(+) B-FORMULA 
channels O 
did O 
not O 
modify O 
the O 
effects O 
of O 
resveratrol B-TRIVIAL 
. O 
None O 
of O 
the O 
antagonists O 
of O 
K(+) B-FORMULA 
channels O 
affected O 
the O 
resveratrol B-TRIVIAL 
inhibition O 
of O 
NE-evoked O 
contractions O 
and O 
effect O 
of O 
high O 
concentrations O 
of O 
resveratrol B-TRIVIAL 
on O 
the O 
EFS-evoked O 
contractions O 
. O 
Resveratrol B-TRIVIAL 
more O 
potently O 
inhibited O 
CaCl(2) B-FORMULA 
than O 
potassium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
contractions O 
of O 
RPV O 
. O 
Thus O 
, O 
BK( O 
Ca B-FORMULA 
) O 
channels O 
partly O 
mediate O 
the O 
inhibitory O 
effect O 
of O 
resveratrol B-TRIVIAL 
on O 
the O 
neurogenic O 
contractions O 
of O 
RPV O 
. O 
The O 
smooth O 
muscle O 
Ca(2+) B-FORMULA 
channels O 
and O 
/ O 
or O 
Ca(2+) B-FORMULA 
mobilizing O 
through O 
cells O 
might O 
be O 
involved O 
in O 
the O 
effects O 
of O 
resveratrol B-TRIVIAL 
on O 
the O 
contractility O 
of O 
RPV O 
. O 
Our O 
results O 
are O 
important O 
for O 
better O 
understanding O 
the O 
impact O 
of O 
resveratrol B-TRIVIAL 
on O 
the O 
portal O 
circulation O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

antinociceptive O 
effect O 
of O 
milnacipran B-TRIVIAL 
in O 
the O 
monosodium B-SYSTEMATIC 
iodoacetate I-SYSTEMATIC 
model O 
of O 
osteoarthritis O 
pain O 
and O 
its O 
relation O 
to O 
changes O 
in O 
descending O 
inhibition O 
. O 

( O 
OA O 
) O 
is O 
a O 
chronic O 
joint O 
disorder O 
whose O 
principal O 
symptom O 
is O 
chronic O 
pain O 
. O 
Current O 
analgesics O 
are O 
inadequate O 
and O 
the O 
mechanisms O 
contributing O 
to O 
this O 
pain O 
are O 
poorly O 
understood O 
but O 
likely O 
to O 
include O 
both O 
local O 
joint O 
changes O 
and O 
central O 
consequences O 
. O 
These O 
studies O 
used O 
monoamine B-FAMILY 
receptor O 
agents O 
combined O 
with O 
behavioral O 
studies O 
and O 
single O 
- O 
unit O 
dorsal O 
horn O 
recordings O 
to O 
examine O 
whether O 
descending O 
noradrenergic O 
and O 
serotonergic O 
inhibitions O 
are O 
altered O 
in O 
the O 
monosodium B-SYSTEMATIC 
iodoacetate I-SYSTEMATIC 
model O 
of O 
OA O 
pain O 
, O 
and O 
whether O 
increasing O 
these O 
inhibitions O 
with O 
the O 
serotonin B-TRIVIAL 
/ O 
noradrenaline B-TRIVIAL 
reuptake O 
inhibitor O 
milnacipran B-TRIVIAL 
can O 
attenuate O 
the O 
attendant O 
hypersensitivity O 
. O 
Early O 
and O 
late O 
in O 
the O 
course O 
of O 
this O 
model O 
, O 
milnacipran B-TRIVIAL 
( O 
s.c O 
. O 
) O 
reduced O 
behavioral O 
hypersensitivity O 
, O 
and O 
inhibited O 
evoked O 
responses O 
from O 
sensitized O 
dorsal O 
horn O 
neurons O 
. O 
In O 
naïve O 
animals O 
and O 
the O 
early O 
, O 
but O 
not O 
late O 
, O 
phase O 
of O 
the O 
model O 
, O 
spinal O 
administration O 
of O 
the O 
α(2)-adrenoceptor O 
antagonist O 
atipamezole B-TRIVIAL 
fully O 
reversed O 
this O 
neuronal O 
inhibition O 
, O 
whereas O 
atipamezole B-TRIVIAL 
administered O 
alone O 
revealed O 
that O 
endogenous O 
noradrenergic O 
inhibition O 
was O 
reduced O 
in O 
the O 
late O 
phase O 
. O 
Blocking O 
spinal O 
5-hydroxytryptamine B-SYSTEMATIC 
-7 O 
receptors O 
with O 
(2R)-1-[(3-hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-piperidinyl)ethyl]pyrrolidine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
suggested O 
that O 
the O 
effects O 
of O 
milnacipran B-TRIVIAL 
in O 
the O 
late O 
phase O 
were O 
partly O 
mediated O 
by O 
these O 
receptors O 
, O 
and O 
that O 
descending O 
serotonergic O 
inhibition O 
was O 
increased O 
in O 
this O 
phase O 
. O 
An O 
opioidergic O 
mechanism O 
behind O 
the O 
effects O 
of O 
milnacipran B-TRIVIAL 
was O 
indicated O 
by O 
a O 
partial O 
reversal O 
of O 
these O 
effects O 
with O 
naloxone B-TRIVIAL 
. O 
These O 
studies O 
demonstrate O 
antinociceptive O 
effects O 
for O 
milnacipran B-TRIVIAL 
in O 
a O 
model O 
of O 
OA O 
pain O 
, O 
whose O 
effects O 
come O 
via O 
descending O 
serotonergic O 
and O 
noradrenergic O 
, O 
as O 
well O 
as O 
opioidergic O 
, O 
pathways O 
. O 
Variations O 
in O 
the O 
activity O 
of O 
these O 
pathways O 
over O 
the O 
course O 
of O 
this O 
model O 
may O 
contribute O 
to O 
the O 
presence O 
of O 
behavioral O 
hypersensitivity O 
and O 
determine O 
through O 
which O 
endogenous O 
systems O 
milnacipran B-TRIVIAL 
exerts O 
its O 
effects O 
. O 

of O 
mercury B-SYSTEMATIC 
in O 
a O 
contaminated O 
stream O 
- O 
implications O 
for O 
the O 
timescale O 
of O 
recovery O 
. O 

contamination O 
in O 
East O 
Fork O 
Poplar O 
Creek O 
in O 
Tennessee O 
arises O 
from O 
dissolved O 
mercury B-SYSTEMATIC 
exiting O 
a O 
headwater O 
industrial O 
complex O 
and O 
residual O 
mercury B-SYSTEMATIC 
in O 
the O 
streambed O 
and O 
soil O 
throughout O 
the O 
watershed O 
downstream O 
. O 
The O 
headwater O 
inputs O 
generate O 
chronic O 
base O 
flow O 
concentrations O 
of O 
total O 
mercury B-SYSTEMATIC 
of O 
about O 
1000 O 
ng O 
/ O 
L O 
, O 
but O 
most O 
of O 
the O 
annual O 
export O 
of O 
mercury B-SYSTEMATIC 
from O 
the O 
system O 
appears O 
to O 
originate O 
farther O 
downstream O 
. O 
Effective O 
targeting O 
of O 
remedial O 
efforts O 
requires O 
determining O 
how O 
long O 
downstream O 
sources O 
might O 
continue O 
to O 
contaminate O 
the O 
system O 
following O 
elimination O 
of O 
the O 
headwater O 
mercury B-SYSTEMATIC 
inputs O 
. O 
The O 
authors O 
calculations O 
suggest O 
that O 
( O 
1 O 
) O 
contaminated O 
soils O 
and O 
sediments O 
account O 
for O 
> O 
80% O 
of O 
the O 
annual O 
mercury B-SYSTEMATIC 
export O 
from O 
the O 
entire O 
watershed O 
, O 
with O 
most O 
export O 
occurring O 
during O 
wet O 
weather O 
events O 
; O 
( O 
2 O 
) O 
bank O 
erosion O 
and O 
resuspension O 
of O 
streambed O 
particulates O 
are O 
the O 
major O 
mercury B-SYSTEMATIC 
sources O 
maintaining O 
high O 
annual O 
mercury B-SYSTEMATIC 
export O 
rates O 
; O 
and O 
( O 
3 O 
) O 
the O 
inventory O 
of O 
particle O 
- O 
associated O 
mercury B-SYSTEMATIC 
in O 
the O 
streambed O 
was O 
not O 
large O 
enough O 
to O 
sustain O 
the O 
estimated O 
export O 
rates O 
for O 
more O 
than O 
a O 
few O 
years O 
. O 
The O 
authors O 
findings O 
imply O 
that O 
to O 
prevent O 
waterborne O 
mercury B-SYSTEMATIC 
contamination O 
in O 
this O 
system O 
from O 
continuing O 
for O 
decades O 
, O 
remedial O 
actions O 
will O 
have O 
to O 
control O 
the O 
headwater O 
mercury B-SYSTEMATIC 
source O 
that O 
sustains O 
day O 
- O 
to O 
- O 
day O 
base O 
flow O 
mercury B-SYSTEMATIC 
concentrations O 
and O 
the O 
riparian O 
stream O 
- O 
bank O 
sources O 
that O 
generate O 
most O 
of O 
the O 
mercury B-SYSTEMATIC 
export O 
from O 
the O 
system O 
. O 

of O 
major O 
cations O 
( O 
Ca(2+) B-FORMULA 
, O 
Mg(2+) B-FORMULA 
, O 
Na(+) B-FORMULA 
, O 
K(+) B-FORMULA 
) O 
and O 
anions O 
( O 
SO B-FORMULA 
42- I-FORMULA 
, O 
Cl(-) B-FORMULA 
, O 
NO B-FORMULA 
3- I-FORMULA 
) O 
on O 
Ni B-FORMULA 
accumulation O 
and O 
toxicity O 
in O 
aquatic O 
plant O 
( O 
Lemna O 
minor O 
L O 
. O 
) O 
: O 
implications O 
For O 
Ni B-FORMULA 
risk O 
assessment O 
. O 

effect O 
of O 
major O 
cation O 
activity O 
( O 
Ca(2+) B-FORMULA 
, O 
Mg(2+) B-FORMULA 
, O 
Na(+) B-FORMULA 
, O 
K(+) B-FORMULA 
) O 
on O 
Ni B-FORMULA 
toxicity O 
, O 
with O 
dose O 
expressed O 
as O 
exposure O 
( O 
total O 
dissolved O 
Ni B-FORMULA 
concentration O 
NiTot O 
) O 
or O 
free O 
Ni B-FORMULA 
ion O 
activity O 
( O 
in O 
solution O 
Ni(2+) B-FORMULA 
) O 
, O 
or O 
as O 
tissue O 
residue O 
( O 
Ni B-FORMULA 
concentration O 
in O 
plant O 
tissue O 
NiTiss O 
) O 
to O 
the O 
aquatic O 
plant O 
Lemna O 
minor O 
L O 
. O 
was O 
examined O 
. O 
In O 
addition O 
, O 
Ni B-FORMULA 
accumulation O 
kinetics O 
was O 
explored O 
to O 
provide O 
mechanistic O 
insight O 
into O 
current O 
approaches O 
of O 
toxicity O 
modeling O 
, O 
such O 
as O 
the O 
tissue O 
residue O 
approach O 
and O 
the O 
biotic O 
ligand O 
model O 
( O 
BLM O 
) O 
, O 
and O 
the O 
implications O 
for O 
plant O 
Ni B-FORMULA 
risk O 
assessment O 
. O 
Major O 
cations O 
did O 
not O 
inhibit O 
Ni B-FORMULA 
accumulation O 
via O 
competitive O 
inhibition O 
as O 
expected O 
by O 
the O 
BLM O 
framework O 
. O 
For O 
example O 
, O 
Ca(2+) B-FORMULA 
and O 
Mg(2+) B-FORMULA 
( O 
sulfate B-SYSTEMATIC 
as O 
counter O 
- O 
anion O 
) O 
had O 
an O 
anticompetitive O 
effect O 
on O 
Ni B-FORMULA 
accumulation O 
, O 
suggesting O 
that O 
Ca B-FORMULA 
or O 
Mg B-FORMULA 
forms O 
a O 
ternary O 
complex O 
with O 
Ni B-FORMULA 
-biotic O 
ligand O 
. O 
The O 
counter O 
- O 
anion O 
of O 
the O 
added O 
Ca B-FORMULA 
( O 
sulfate B-SYSTEMATIC 
, O 
chloride B-SYSTEMATIC 
, O 
or O 
nitrate B-SYSTEMATIC 
) O 
affected O 
plant O 
response O 
( O 
percentage O 
of O 
root O 
growth O 
inhibition O 
) O 
to O 
Ni B-FORMULA 
. O 
Generally O 
, O 
sulfate B-SYSTEMATIC 
and O 
chloride B-SYSTEMATIC 
influenced O 
plant O 
response O 
while O 
nitrate B-SYSTEMATIC 
did O 
not O 
, O 
even O 
when O 
compared O 
within O 
the O 
same O 
range O 
of O 
Ca(2+) B-FORMULA 
, O 
which O 
suggests O 
that O 
the O 
anion O 
dominated O 
the O 
observed O 
plant O 
response O 
. O 
Overall O 
, O 
although O 
an O 
effect O 
of O 
major O 
cations O 
on O 
Ni B-FORMULA 
toxicity O 
to O 
L O 
. O 
minor O 
L O 
. O 
was O 
observed O 
at O 
a O 
physiological O 
level O 
, O 
Ni(2+) B-FORMULA 
or O 
NiTot O 
alone O 
modeled O 
plant O 
response O 
, O 
generally O 
within O 
a O 
span O 
of O 
twofold O 
, O 
over O 
a O 
wide O 
range O 
of O 
water O 
chemistry O 
. O 
Thus O 
, O 
consideration O 
of O 
major O 
cation O 
competition O 
for O 
improving O 
Ni B-FORMULA 
toxicity O 
predictions O 
in O 
risk O 
assessment O 
for O 
aquatic O 
plants O 
may O 
not O 
be O 
necessary O 
. O 

demyelinating O 
peripheral O 
neuropathy O 
Charcot-Marie-Tooth O 
type O 
4B O 
( O 
CMT4B O 
) O 
is O 
characterized O 
by O 
axonal O 
degeneration O 
and O 
myelin O 
outfoldings O 
. O 
CMT4B O 
results O 
from O 
mutations O 
in O 
either O 
myotubularin O 
- O 
related O 
protein O 
2 O 
( O 
MTMR2 O 
; O 
CMT4B1 O 
) O 
or O 
MTMR13 O 
( O 
CMT4B2 O 
) O 
, O 
phosphoinositide O 
( O 
PI O 
) O 
3-phosphatases O 
that O 
dephosphorylate O 
phosphatidylinositol B-SYSTEMATIC 
3-phosphate I-SYSTEMATIC 
( O 
PtdIns3P B-SYSTEMATIC 
) O 
and O 
PtdIns(3,5)P2 B-SYSTEMATIC 
, O 
lipids O 
which O 
regulate O 
endo-lysosomal O 
membrane O 
traffic O 
. O 
The O 
catalytically O 
active O 
MTMR2 O 
and O 
catalytically O 
inactive O 
MTMR13 O 
physically O 
associate O 
, O 
although O 
the O 
significance O 
of O 
this O 
association O 
is O 
not O 
well O 
understood O 
. O 
Here O 
we O 
show O 
that O 
Mtmr13 O 
loss O 
leads O 
to O 
axonal O 
degeneration O 
in O 
sciatic O 
nerves O 
of O 
older O 
mice O 
. O 
In O 
addition O 
, O 
CMT4B2 O 
- O 
like O 
myelin O 
outfoldings O 
are O 
present O 
in O 
Mtmr13(- O 
/ O 
- O 
) O 
nerves O 
at O 
postnatal O 
day O 
3 O 
. O 
Thus O 
, O 
Mtmr13(- O 
/ O 
- O 
) O 
mice O 
show O 
both O 
the O 
initial O 
dysmyelination O 
and O 
later O 
degenerative O 
pathology O 
of O 
CMT4B2 O 
. O 
Given O 
the O 
key O 
role O 
of O 
PI O 
3-kinase-Akt O 
signaling O 
in O 
myelination O 
, O 
we O 
investigated O 
the O 
state O 
of O 
the O 
pathway O 
in O 
nerves O 
of O 
CMT4B O 
models O 
. O 
We O 
found O 
that O 
Akt O 
activation O 
is O 
unaltered O 
in O 
Mtmr13(- O 
/ O 
- O 
) O 
and O 
Mtmr2(- O 
/ O 
- O 
) O 
mice O 
. O 
Mtmr2 O 
and O 
Mtmr13 O 
are O 
found O 
within O 
the O 
Schwann O 
cell O 
cytoplasm O 
, O 
where O 
the O 
proteins O 
are O 
partially O 
localized O 
to O 
punctate O 
compartments O 
, O 
suggesting O 
that O 
Mtmr2-Mtmr13 O 
may O 
dephosphorylate O 
their O 
substrates O 
on O 
specific O 
intracellular O 
compartments O 
. O 
Mtmr2-Mtmr13 O 
substrates O 
play O 
essential O 
roles O 
in O 
endo-lysosomal O 
membrane O 
traffic O 
. O 
However O 
, O 
endosomes O 
and O 
lysosomes O 
of O 
Mtmr13(- O 
/ O 
- O 
) O 
and O 
Mtmr2(- O 
/ O 
- O 
) O 
Schwann O 
cells O 
are O 
morphologically O 
indistinguishable O 
from O 
those O 
of O 
controls O 
, O 
indicating O 
that O 
loss O 
of O 
these O 
proteins O 
does O 
not O 
cause O 
wholesale O 
dysregulation O 
of O 
the O 
endo-lysosomal O 
system O 
. O 
Notably O 
, O 
Mtmr2 O 
and O 
Mtmr13 O 
depend O 
upon O 
each O 
other O 
to O 
achieve O 
wild O 
- O 
type O 
levels O 
of O 
protein O 
expression O 
. O 
Mtmr2 O 
stabilizes O 
Mtmr13 O 
on O 
membranes O 
, O 
indicating O 
that O 
the O 
Mtmr13 O 
pseudophosphatase O 
is O 
regulated O 
by O 
its O 
catalytically O 
active O 
binding O 
partner O 
. O 

Sideritis O 
italica O 
( O 
MILL O 
. O 
) O 
GREUTER O 
et O 
BURTER O 
( O 
Lamiaceae O 
) O 
occurs O 
mainly O 
in O 
Southern O 
Italy O 
and O 
Sicily O 
and O 
has O 
previously O 
only O 
been O 
studied O 
for O 
the O 
essential O 
oil O 
composition O 
. O 
In O 
this O 
paper O 
, O 
we O 
complete O 
the O 
phytochemical O 
study O 
of O 
a O 
sample O 
of O 
S O 
. O 
italica O 
, O 
previously O 
analysed O 
for O 
its O 
volatile O 
constituents O 
, O 
occurring O 
in O 
the O 
Appennino O 
Umbro-Marchigiano O 
( O 
Central O 
Italy O 
) O 
, O 
which O 
is O 
the O 
northern O 
border O 
of O 
the O 
areal O 
distribution O 
of O 
the O 
species O 
. O 
The O 
analysis O 
of O 
medium O 
polarity O 
constituents O 
led O 
to O 
the O 
isolation O 
of O 
several O 
glycosides O 
, O 
such O 
as O 
flavonoids B-FAMILY 
, O 
i.e O 
. O 
scutellarein B-TRIVIAL 
derivatives O 
; O 
phenylethanoids B-FAMILY 
, O 
i.e O 
. O 
verbascoside B-TRIVIAL 
; O 
and O 
iridoids B-FAMILY 
, O 
i.e O 
. O 
melittoside B-TRIVIAL 
and O 
5-allosyloxy-aucubin B-SYSTEMATIC 
, O 
besides O 
the O 
diterpene O 
siderol B-TRIVIAL 
. O 
The O 
data O 
reported O 
have O 
chemotaxonomic O 
relevance O 
, O 
since O 
they O 
are O 
in O 
contrast O 
with O 
the O 
hypothesis O 
that O 
in O 
Lamiaceae O 
the O 
species O 
producing O 
iridoids B-FAMILY 
do O 
not O 
usually O 
have O 
relevant O 
essential O 
oil O 
production O 
and O 
vice O 
versa O 
. O 

researchers O 
have O 
focused O 
on O 
the O 
preventive O 
and O 
curative O 
effects O 
of O 
garlic O 
( O 
Allium O 
sativum O 
) O 
, O 
particularly O 
on O 
cardiovascular O 
diseases O 
and O 
cancer O 
. O 
However O 
, O 
its O 
impacts O 
on O 
the O 
male O 
reproductive O 
system O 
have O 
not O 
been O 
clearly O 
defined O 
. O 
In O 
this O 
study O 
, O 
the O 
effect O 
of O 
chronic O 
consumption O 
of O 
two O 
garlic O 
fractions O 
was O 
tested O 
: O 
one O 
soluble O 
in O 
water O 
( O 
aqueous O 
solution O 
obtained O 
by O 
grinding O 
and O 
centrifugation O 
) O 
and O 
the O 
other O 
one O 
precipitated O 
by O 
ethanol B-SYSTEMATIC 
( O 
alcoholic O 
precipitate O 
obtained O 
by O 
precipitation O 
of O 
the O 
aqueous O 
solution O 
) O 
, O 
on O 
different O 
variables O 
of O 
male O 
rats O 
' O 
reproductive O 
functions O 
. O 
These O 
two O 
fractions O 
were O 
targeted O 
to O 
try O 
to O 
identify O 
the O 
nature O 
of O 
the O 
active O 
garlic O 
compounds O 
responsible O 
for O 
the O 
different O 
modifications O 
observed O 
on O 
testicular O 
parameters O 
. O 
The O 
observation O 
of O 
seminiferous O 
tubules O 
of O 
rats O 
treated O 
with O 
garlic O 
fractions O 
showed O 
an O 
increased O 
number O 
of O 
tubules O 
deprived O 
of O 
spermatozoa O 
. O 
In O 
addition O 
, O 
garlic O 
fractions O 
induced O 
apoptosis O 
of O 
testicular O 
germ O 
cells O 
( O 
TdT O 
- O 
mediated O 
dUTP B-ABBREVIATION 
-X O 
nick O 
- O 
end O 
labeling O 
[ O 
TUNEL O 
] O 
approach O 
) O 
and O 
a O 
decrease O 
of O 
serum O 
testosterone B-TRIVIAL 
levels O 
and O 
seminiferous O 
tubule O 
DNA O 
concentrations O 
. O 
In O 
summary O 
, O 
our O 
histological O 
and O 
molecular O 
results O 
suggest O 
that O 
one O 
or O 
several O 
substances O 
, O 
soluble O 
in O 
water O 
and O 
precipitated O 
by O 
alcohol B-FAMILY 
, O 
impaired O 
spermatogenesis O 
. O 

oils O 
of O 
Thymus O 
leucospermus O 
Hartvig O 
, O 
a O 
Greek O 
endemic O 
rich O 
in O 
phenolic B-FAMILY 
monoterpenes I-FAMILY 
. O 

leucospermus O 
Hartvig O 
is O 
a O 
Greek O 
endemic O 
species O 
of O 
Section O 
Teucrioides O 
Jalas O 
. O 
The O 
essential O 
oils O 
obtained O 
from O 
five O 
populations O 
growing O 
wild O 
in O 
the O 
National O 
Park O 
of O 
Northern O 
Pindhos O 
( O 
NW O 
Greece O 
) O 
were O 
studied O 
. O 
The O 
oil O 
content O 
ranged O 
between O 
1.1 O 
and O 
2 O 
mL O 
per O 
100 O 
g O 
of O 
dry O 
plant O 
weight O 
. O 
The O 
oils O 
were O 
particularly O 
rich O 
in O 
phenolic B-FAMILY 
monoterpenes I-FAMILY 
: O 
they O 
had O 
a O 
high O 
thymol B-TRIVIAL 
( O 
64.7-92.0% O 
) O 
or O 
carvacrol B-TRIVIAL 
( O 
93.4% O 
) O 
content O 
, O 
whereas O 
in O 
one O 
of O 
the O 
oils O 
considerable O 
amount O 
of O 
both O 
compounds O 
was O 
found O 
( O 
thymol B-TRIVIAL 
61.6% O 
and O 
carvacrol B-TRIVIAL 
26.4% O 
) O 
. O 
Our O 
results O 
show O 
that O 
T O 
. O 
leucospermus O 
is O 
a O 
high O 
- O 
quality O 
thyme O 
species O 
, O 
with O 
respect O 
to O 
both O 
oil O 
content O 
and O 
composition O 
. O 

morphology O 
and O 
mesophase O 
formation O 
by O 
naphthalene B-SYSTEMATIC 
-containing O 
poly(aryl B-FAMILY 
ether I-FAMILY 
) I-FAMILY 
dendron O 
- O 
based O 
low O 
- O 
molecular O 
- O 
weight O 
fluorescent O 
gels O 
. O 

poly(aryl B-FAMILY 
ether I-FAMILY 
) I-FAMILY 
dendron O 
- O 
based O 
low O 
- O 
molecular O 
- O 
weight O 
organogelaters O 
( O 
LMWG O 
) O 
containing O 
naphthalene B-SYSTEMATIC 
units O 
at O 
the O 
core O 
have O 
been O 
synthesized O 
, O 
and O 
the O 
self O 
- O 
assembly O 
of O 
the O 
system O 
has O 
been O 
examined O 
in O 
a O 
variety O 
of O 
solvents O 
and O 
solvent O 
mixtures O 
. O 
The O 
compounds O 
readily O 
form O 
gels O 
with O 
attractive O 
critical O 
gel O 
concentration O 
values O 
associated O 
with O 
gelation O 
- O 
induced O 
enhanced O 
emission O 
( O 
GIEE O 
) O 
. O 
In O 
addition O 
to O 
the O 
remarkable O 
properties O 
of O 
the O 
previously O 
reported O 
anthracene B-SYSTEMATIC 
and O 
pyrene B-SYSTEMATIC 
analogues O 
( O 
Rajamalli O 
, O 
P O 
. O 
; O 
Prasad O 
, O 
E O 
. O 
Org O 
. O 
Lett.2011 O 
, O 
13 O 
, O 
3714 O 
and O 
Rajamalli O 
, O 
P O 
. O 
; O 
Prasad O 
, O 
E O 
. O 
Soft O 
Matter2012 O 
, O 
8 O 
, O 
8896 O 
) O 
, O 
the O 
self O 
- O 
assembled O 
systems O 
exhibit O 
distinctly O 
different O 
structure O 
- O 
property O 
relationships O 
. O 
Unlike O 
the O 
reported O 
ones O 
, O 
the O 
present O 
system O 
forms O 
sheetlike O 
morphology O 
in O 
nonpolar O 
solvent O 
mixtures O 
, O 
giant O 
vesicles O 
in O 
polar O 
solvent O 
mixtures O 
, O 
and O 
lamellar O 
or O 
hexagonal O 
columnar O 
phases O 
in O 
single O 
solvents O 
. O 
The O 
unique O 
properties O 
of O 
the O 
self O 
- O 
assembled O 
systems O 
, O 
which O 
were O 
analyzed O 
through O 
electron O 
microscopic O 
( O 
SEM O 
, O 
TEM O 
, O 
AFM O 
) O 
and O 
spectroscopic O 
techniques O 
( O 
POM O 
, O 
fluorescence O 
) O 
, O 
are O 
attributed O 
to O 
the O 
replacement O 
of O 
anthracene B-SYSTEMATIC 
/ O 
pyrene B-SYSTEMATIC 
units O 
by O 
naphthalene B-SYSTEMATIC 
units O 
. O 
The O 
present O 
work O 
unravels O 
the O 
subtle O 
role O 
of O 
minute O 
structural O 
change O 
in O 
altering O 
the O 
properties O 
of O 
LMWGs O 
based O 
on O 
poly(aryl B-FAMILY 
ether I-FAMILY 
) I-FAMILY 
dendrons O 
. O 

of O 
solid O 
state O 
amorphization O 
of O 
glucose B-TRIVIAL 
upon O 
milling O 
. O 

α-glucose B-TRIVIAL 
is O 
known O 
to O 
amorphize O 
upon O 
milling O 
at O 
-15 O 
°C O 
while O 
it O 
remains O 
structurally O 
invariant O 
upon O 
milling O 
at O 
room O 
temperature O 
. O 
We O 
have O 
taken O 
advantage O 
of O 
this O 
behavior O 
to O 
compare O 
the O 
microstructural O 
evolutions O 
of O 
the O 
material O 
in O 
both O 
conditions O 
in O 
order O 
to O 
identify O 
the O 
essential O 
microstructural O 
features O 
which O 
drive O 
the O 
amorphization O 
process O 
upon O 
milling O 
. O 
The O 
investigations O 
have O 
been O 
performed O 
by O 
differential O 
scanning O 
calorimetry O 
and O 
by O 
powder O 
X-ray O 
diffraction O 
. O 
The O 
results O 
indicate O 
that O 
two O 
different O 
amorphization O 
mechanisms O 
occur O 
upon O 
milling O 
: O 
an O 
amorphization O 
at O 
the O 
surface O 
of O 
crystallites O 
due O 
to O 
the O 
mechanical O 
shocks O 
and O 
a O 
spontaneous O 
amorphization O 
of O 
the O 
crystallites O 
as O 
they O 
reach O 
a O 
critical O 
size O 
, O 
which O 
is O 
close O 
to O 
200 O 
Å O 
in O 
the O 
particular O 
case O 
of O 
α-glucose B-TRIVIAL 
. O 

as O 
in O 
situ O 
light O 
source O 
in O 
meso-tetraphenylporphyrin B-SYSTEMATIC 
-mediated O 
photodynamic O 
therapy O 
. O 

light O 
sources O 
used O 
in O 
current O 
photodynamic O 
therapy O 
are O 
mainly O 
lasers O 
or O 
light O 
emitting O 
diodes O 
, O 
which O 
are O 
not O 
suitable O 
to O 
treat O 
large O 
- O 
volume O 
tumors O 
and O 
those O 
located O 
in O 
the O 
inner O 
body O 
. O 
To O 
overcome O 
the O 
limitation O 
, O 
we O 
propose O 
an O 
in O 
situ O 
light O 
source O 
to O 
activate O 
the O 
photosensitizer O 
and O 
kill O 
the O 
cancer O 
cells O 
directly O 
. O 
In O 
the O 
present O 
work O 
, O 
we O 
use O 
luminol B-TRIVIAL 
as O 
light O 
source O 
and O 
meso-tetraphenylporphyrin B-SYSTEMATIC 
as O 
the O 
photosensitizer O 
. O 
According O 
to O 
the O 
results O 
, O 
cells O 
incubated O 
with O 
meso-tetraphenylporphyrin B-SYSTEMATIC 
, O 
subsequently O 
triggered O 
by O 
luminol B-TRIVIAL 
, O 
decreased O 
significantly O 
in O 
assays O 
including O 
cell O 
viability O 
and O 
cytotoxicity O 
, O 
while O 
the O 
other O 
groups O 
showed O 
only O 
minor O 
differences O 
. O 
The O 
flow O 
cytometric O 
and O 
fluorescent O 
microscopy O 
analysis O 
showed O 
similar O 
results O 
as O 
well O 
. O 
In O 
the O 
analysis O 
of O 
cell O 
death O 
pathway O 
, O 
cell O 
shrinkage O 
was O 
noticed O 
after O 
photodynamic O 
therapy O 
treatment O 
, O 
which O 
might O 
refer O 
to O 
apoptosis O 
. O 
Briefly O 
, O 
we O 
suggest O 
that O 
luminol B-TRIVIAL 
is O 
a O 
promising O 
light O 
source O 
in O 
meso-tetraphenylporphyrin B-SYSTEMATIC 
-mediated O 
photodynamic O 
therapy O 
for O 
its O 
greater O 
penetration O 
depth O 
and O 
well O 
matched O 
emission O 
wavelength O 
. O 

development O 
of O 
molecular O 
analyses O 
for O 
thyroid O 
pathologies O 
is O 
on O 
going O 
. O 
These O 
analyses O 
provide O 
new O 
diagnostic O 
tools O 
with O 
the O 
aim O 
of O 
accurately O 
distinguishing O 
malignant O 
and O 
benign O 
thyroid O 
tumors O 
. O 
They O 
are O 
particularly O 
useful O 
as O 
most O 
of O 
them O 
can O 
be O 
done O 
preoperatively O 
on O 
thyroid O 
fine O 
- O 
needle O 
aspiration O 
biopsy O 
samples O 
. O 
Furthermore O 
, O 
molecular O 
biomarkers O 
may O 
play O 
a O 
promising O 
role O 
since O 
they O 
are O 
able O 
to O 
predict O 
the O 
prognosis O 
of O 
patients O 
with O 
thyroid O 
tumors O 
. O 
Moreover O 
, O 
identification O 
of O 
molecular O 
markers O 
as O 
well O 
as O 
a O 
better O 
understanding O 
of O 
thyroid O 
carcinogenesis O 
will O 
help O 
develop O 
innovative O 
targeted O 
therapies O 
, O 
particularly O 
in O 
patients O 
with O 
metastatic O 
iodo B-SYSTEMATIC 
-resistant O 
thyroid O 
carcinoma O 
. O 
To O 
date O 
, O 
four O 
types O 
of O 
somatic O 
genetic O 
alterations O 
are O 
known O 
to O 
hold O 
potential O 
interest O 
for O 
the O 
diagnosis O 
and O 
/ O 
or O 
prognosis O 
of O 
follicular O 
cell O 
- O 
derived O 
thyroid O 
carcinomas O 
: O 
BRAF O 
and O 
RAS O 
mutations O 
, O 
and O 
RET O 
/ O 
PTC O 
and O 
PAX8 O 
/ O 
PPARγ O 
rearrangements O 
. O 
Other O 
recent O 
molecular O 
biomarkers O 
have O 
been O 
investigated O 
in O 
thyroid O 
oncology O 
, O 
in O 
particular O 
different O 
microRNA O 
signatures O 
. O 
This O 
review O 
describes O 
the O 
different O 
aspects O 
of O 
ancillary O 
methods O 
, O 
including O 
those O 
bassed O 
on O 
molecular O 
biology O 
, O 
that O 
are O 
of O 
current O 
interest O 
for O 
the O 
diagnosis O 
, O 
prognosis O 
and O 
treatment O 
of O 
follicular O 
cell O 
- O 
derived O 
thyroid O 
carcinomas O 
. O 

nanoparticles O 
in O 
cancer O 
: O 
therapeutic O 
efficacy O 
and O 
toxicity O 
. O 

recent O 
years O 
, O 
there O 
has O 
been O 
escalating O 
interest O 
in O 
the O 
biomedical O 
applications O 
of O 
nanoparticles O 
( O 
NPs O 
) O 
. O 
In O 
particular O 
, O 
silver B-SYSTEMATIC 
nanoparticles O 
( O 
AgNPs O 
) O 
are O 
increasingly O 
being O 
investigated O 
as O 
tools O 
for O 
novel O 
cancer O 
therapeutics O 
, O 
capitalizing O 
on O 
their O 
unique O 
properties O 
to O 
enhance O 
potential O 
therapeutic O 
efficacy O 
. O 
However O 
, O 
questions O 
as O 
to O 
are O 
we O 
able O 
to O 
contain O 
or O 
control O 
the O 
toxicity O 
effects O 
of O 
AgNPs O 
, O 
and O 
how O 
much O 
do O 
we O 
know O 
about O 
the O 
toxicological O 
profile O 
of O 
AgNPs O 
which O 
are O 
commonly O 
used O 
in O 
emerging O 
nanotechnology O 
- O 
based O 
applications O 
, O 
still O 
remain O 
. O 
Hence O 
, O 
serious O 
considerations O 
have O 
to O 
be O 
given O 
to O 
the O 
hazards O 
and O 
risks O 
of O 
toxicity O 
associated O 
with O 
the O 
use O 
of O 
AgNPs O 
. O 
This O 
review O 
focuses O 
on O 
the O 
current O 
applications O 
of O 
AgNPs O 
, O 
their O 
known O 
effects O 
and O 
toxicity O 
, O 
as O 
well O 
as O 
the O 
potential O 
of O 
harnessing O 
them O 
for O 
use O 
in O 
cancer O 
therapy O 
. O 

P2 O 
tris B-SYSTEMATIC 
- I-SYSTEMATIC 
tetrahydrofuran I-SYSTEMATIC 
group O 
in O 
antiviral O 
compound O 
1 O 
( O 
GRL-0519 B-IDENTIFIER 
) O 
fills O 
the O 
S2 O 
binding O 
pocket O 
of O 
selected O 
mutants O 
of O 
HIV-1 O 
protease O 
. O 

( O 
1 O 
) O 
is O 
a O 
potent O 
antiviral O 
inhibitor O 
of O 
HIV-1 O 
protease O 
( O 
PR O 
) O 
possessing O 
tris B-SYSTEMATIC 
- I-SYSTEMATIC 
tetrahydrofuran I-SYSTEMATIC 
( O 
tris-THF B-SYSTEMATIC 
) O 
at O 
P2 O 
. O 
The O 
high O 
resolution O 
X-ray O 
crystal O 
structures O 
of O 
inhibitor O 
1 O 
in O 
complexes O 
with O 
single O 
substitution O 
mutants O 
PR(R8Q) O 
, O 
PR(D30N) O 
, O 
PR(I50V) O 
, O 
PR(I54M) O 
, O 
and O 
PR(V82A) O 
were O 
analyzed O 
in O 
relation O 
to O 
kinetic O 
data O 
. O 
The O 
smaller O 
valine O 
side O 
chain O 
in O 
PR(I50V) O 
eliminated O 
hydrophobic O 
interactions O 
with O 
inhibitor O 
and O 
the O 
other O 
subunit O 
consistent O 
with O 
60-fold O 
worse O 
inhibition O 
. O 
Asn30 O 
in O 
PR(D30N) O 
showed O 
altered O 
interactions O 
with O 
neighboring O 
residues O 
and O 
18-fold O 
worse O 
inhibition O 
. O 
Mutations O 
V82A O 
and O 
I54M O 
showed O 
compensating O 
structural O 
changes O 
consistent O 
with O 
6-7-fold O 
lower O 
inhibition O 
. O 
Gln8 O 
in O 
PR(R8Q) O 
replaced O 
the O 
ionic O 
interactions O 
of O 
wild O 
type O 
Arg8 O 
with O 
hydrogen B-SYSTEMATIC 
bond O 
interactions O 
without O 
changing O 
the O 
inhibition O 
significantly O 
. O 
The O 
carbonyl B-FAMILY 
oxygen B-SYSTEMATIC 
of O 
Gly48 O 
showed O 
two O 
alternative O 
conformations O 
in O 
all O 
structures O 
likely O 
due O 
to O 
the O 
snug O 
fit O 
of O 
the O 
large O 
tris-THF B-SYSTEMATIC 
group O 
in O 
the O 
S2 O 
subsite O 
in O 
agreement O 
with O 
high O 
antiviral O 
efficacy O 
of O 
1 O 
on O 
resistant O 
virus O 
. O 

novel O 
method O 
for O 
the O 
manufacture O 
of O 
protein O 
/ O 
peptide O 
- O 
containing O 
submicron O 
particles O 
was O 
developed O 
in O 
an O 
attempt O 
to O 
provide O 
particles O 
with O 
increased O 
activity O 
while O 
using O 
high O 
energy O 
input O 
technologies O 
. O 
The O 
method O 
consists O 
of O 
antisolvent O 
co O 
- O 
precipitation O 
from O 
an O 
aqueous O 
solution O 
containing O 
both O 
an O 
amino B-FAMILY 
acid I-FAMILY 
core O 
material O 
( O 
e.g O 
. O 
D,L-valine B-TRIVIAL 
) O 
, O 
and O 
either O 
bovine O 
serum O 
albumin O 
( O 
BSA O 
) O 
or O 
lysozyme O 
( O 
Lys O 
) O 
as O 
model O 
proteins O 
. O 
The O 
aqueous O 
solution O 
was O 
added O 
to O 
the O 
organic O 
phase O 
by O 
means O 
of O 
a O 
nebulizer O 
to O 
increase O 
the O 
total O 
surface O 
area O 
of O 
interaction O 
for O 
the O 
precipitation O 
process O 
. O 
Sonication O 
proved O 
to O 
be O 
an O 
effective O 
method O 
to O 
produce O 
small O 
particle O 
sizes O 
while O 
maintaining O 
high O 
activity O 
of O 
Lys O 
. O 
The O 
use O 
of O 
a O 
polysorbate B-FAMILY 
or O 
sorbitan B-TRIVIAL 
ester I-TRIVIAL 
derivatives O 
as O 
stabilizers O 
proved O 
to O 
be O 
necessary O 
to O 
yield O 
submicron O 
particles O 
. O 
Particles O 
with O 
very O 
high O 
yields O 
( O 
approximately O 
100% O 
) O 
and O 
very O 
high O 
activity O 
after O 
manufacture O 
( O 
approximately O 
100% O 
) O 
could O 
be O 
obtained O 
. O 
A O 
particle O 
size O 
of O 
439 O 
nm O 
, O 
with O 
a O 
yield O 
of O 
48.8% O 
and O 
with O 
final O 
remaining O 
activity O 
of98.7% O 
was O 
obtained O 
. O 
By O 
studying O 
various O 
factors O 
using O 
a O 
design O 
of O 
experiments O 
strategy O 
( O 
DoE O 
) O 
we O 
were O 
able O 
to O 
establish O 
the O 
critical O 
controlling O 
factors O 
for O 
this O 
new O 
method O 
of O 
manufacture O 
. O 

, O 
characterization O 
and O 
targeting O 
potential O 
of O 
zidovudine B-TRIVIAL 
loaded O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
conjugated- O 
mannosylated B-FAMILY 
poly(propyleneimine) I-FAMILY 
dendrimers O 
. O 

present O 
investigation O 
was O 
aimed O 
at O 
exploring O 
dual O 
targeting O 
of O 
anti-HIV O 
drug O 
, O 
zidovudine B-TRIVIAL 
( O 
ZDV B-ABBREVIATION 
) O 
via O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
conjugated- O 
mannosylated B-FAMILY 
poly(propyleneimine) I-FAMILY 
( O 
PPI B-ABBREVIATION 
) O 
dendritic O 
nano O 
- O 
constructs O 
. O 
Fourth O 
generation O 
PPI B-ABBREVIATION 
dendrimers O 
, O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
conjugated O 
PPI B-ABBREVIATION 
dendrimers O 
( O 
SPPI O 
) O 
, O 
mannose B-TRIVIAL 
conjugated O 
PPI B-ABBREVIATION 
dendrimers O 
( O 
MPPI O 
) O 
and O 
dual O 
ligand O 
system O 
i.e O 
. O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
conjugated- O 
mannosylated B-ABBREVIATION 
PPI I-ABBREVIATION 
PPI B-ABBREVIATION 
dendrimers O 
( O 
SMPPI O 
) O 
were O 
synthesized O 
and O 
characterized O 
by O 
FT-IR O 
and O 
(1)H B-FORMULA 
NMR O 
spectroscopies O 
and O 
were O 
further O 
confirmed O 
by O 
size O 
exclusion O 
chromatography O 
and O 
differential O 
scanning O 
calorimetry O 
. O 
Various O 
parameters O 
like O 
drug O 
loading O 
, O 
pH O 
dependent O 
in O 
vitro O 
release O 
, O 
hemolytic O 
toxicity O 
, O 
macrophage O 
uptake O 
and O 
cytotoxicity O 
concerning O 
PPI B-ABBREVIATION 
, O 
SPPI O 
, O 
MPPI O 
and O 
SMPPI O 
dendrimers O 
were O 
evaluated O 
. O 
ZDV B-ABBREVIATION 
loaded O 
SMPPI O 
, O 
SPPI O 
and O 
MPPI O 
have O 
shown O 
reduced O 
hemolytic O 
toxicity O 
, O 
cytotoxicity O 
and O 
in O 
vitro O 
drug O 
release O 
at O 
pH O 
7.4 O 
. O 
Extremely O 
significant O 
( O 
P O 
< O 
0.001 O 
) O 
increase O 
in O 
cellular O 
uptake O 
of O 
ZDV B-ABBREVIATION 
by O 
macrophage O 
cells O 
was O 
observed O 
in O 
case O 
of O 
SMPPI O 
as O 
compared O 
to O 
PPI B-ABBREVIATION 
and O 
free O 
drug O 
. O 
The O 
in O 
vivo O 
blood O 
level O 
and O 
tissue O 
distribution O 
studies O 
in O 
albino O 
rats O 
also O 
demonstrated O 
potential O 
of O 
dual O 
targeted O 
system O 
towards O 
sialoadhesin O 
and O 
carbohydrate B-FAMILY 
receptors O 
. O 
The O 
drug O 
concentration O 
in O 
lymph O 
nodes O 
was O 
increased O 
to O 
about O 
28 O 
times O 
in O 
case O 
of O 
SMPPI O 
( O 
1335 O 
± O 
17.6 O 
ng O 
/ O 
g O 
) O 
as O 
compared O 
to O 
free O 
drug O 
( O 
48 O 
± O 
5.8 O 
ng O 
/ O 
g O 
) O 
at O 
6th O 
hr O 
. O 
The O 
results O 
suggested O 
that O 
such O 
dual O 
ligand O 
dendritic O 
system O 
( O 
SMPPI O 
) O 
hold O 
potential O 
to O 
enhance O 
biocompatibility O 
and O 
site O 
specific O 
delivery O 
of O 
antiretroviral O 
drug O 
, O 
ZDV B-ABBREVIATION 
. O 

permeability O 
study O 
: O 
a O 
comparison O 
between O 
PAMPA O 
, O 
ex O 
vivo O 
and O 
in O 
situ O 
Single-Pass O 
Intestinal O 
Perfusion O 
( O 
SPIP O 
) O 
in O 
rat O 
jejunum O 
. O 

order O 
to O 
reach O 
the O 
bloodstream O 
and O 
thus O 
the O 
target O 
receptor O 
, O 
an O 
orally O 
- O 
administered O 
drug O 
must O 
first O 
cross O 
the O 
intestinal O 
barrier O 
, O 
which O 
can O 
occur O 
via O 
a O 
paracellular O 
, O 
passive O 
transcellular O 
, O 
or O 
carrier O 
- O 
mediated O 
uptake O 
and O 
/ O 
or O 
efflux O 
process O 
( O 
active O 
or O 
concentration O 
gradient-driven O 
) O 
. O 
Our O 
work O 
aimed O 
to O 
explore O 
the O 
transport O 
mechanism O 
of O 
the O 
antiretroviral O 
lamivudine B-TRIVIAL 
( O 
deoxycytidine B-TRIVIAL 
nucleoside I-TRIVIAL 
analogue O 
) O 
, O 
using O 
a O 
three O 
- O 
part O 
strategy O 
: O 
in O 
vitro O 
, O 
an O 
ex O 
vivo O 
and O 
an O 
in O 
situ O 
method O 
, O 
represented O 
by O 
PAMPA O 
, O 
rat O 
jejunum O 
patches O 
and O 
rat O 
Single O 
Pass O 
Intestinal O 
Perfusion O 
( O 
SPIP O 
) O 
, O 
respectively O 
. O 
The O 
determined O 
permeability O 
coefficients O 
were O 
compared O 
with O 
those O 
from O 
a O 
published O 
Caco-2 O 
and O 
MDCK O 
study O 
. O 
Computational O 
prediction O 
of O 
human O 
jejunal O 
permeability O 
was O 
explored O 
, O 
using O 
various O 
non-human O 
permeability O 
coefficients O 
as O 
descriptors O 
. O 
The O 
ex O 
vivo O 
technique O 
was O 
performed O 
in O 
Franz O 
- O 
type O 
diffusion O 
cells O 
, O 
mounted O 
with O 
male O 
Wistar O 
rat O 
jejunum O 
segment O 
patches O 
. O 
PAMPA O 
was O 
performed O 
with O 
an O 
acceptor O 
solution O 
simulating O 
the O 
binding O 
of O 
serum O 
proteins O 
, O 
an O 
artificial O 
membrane O 
impregnated O 
with O 
egg O 
lecithin/ O 
cholesterol B-TRIVIAL 
and O 
a O 
gradient O 
of O 
pH O 
between O 
donor O 
and O 
acceptor O 
solutions O 
. O 
The O 
SPIP O 
was O 
conducted O 
by O 
proximal O 
jejunum O 
cannulation O 
and O 
drug O 
perfusion O 
in O 
a O 
constant O 
flow O 
rate O 
of O 
0.2 O 
mL O 
/ O 
min O 
. O 
The O 
outcomes O 
of O 
our O 
studies O 
showed O 
the O 
following O 
predicted O 
pattern O 
for O 
lamivudine B-TRIVIAL 
effective O 
jejunal O 
permeability O 
: O 
P(eff)(exvivoA O 
> O 
B O 
) O 
> O 
P(eff)(SPIP) O 
> O 
P(eff)(exvivo O 
B O 
> O 
A O 
) O 
> O 
P(eff)(Caco-2)≈P(eff)(MDCK)≈P(eff)(PAMPA O 
) O 
, O 
strongly O 
suggesting O 
that O 
this O 
compound O 
has O 
carrier O 
- O 
mediated O 
uptake O 
as O 
its O 
dominant O 
transport O 
mechanism O 
. O 
Notwithstanding O 
, O 
Caco-2 O 
cells O 
may O 
indicate O 
an O 
under O 
- O 
expression O 
of O 
uptake O 
transporters O 
and O 
possibly O 
an O 
over O 
- O 
expression O 
efflux O 
transporters O 
, O 
compared O 
to O 
that O 
found O 
in O 
the O 
rat O 
jejunum O 
. O 

core O 
- O 
shell O 
nanoassemblies O 
for O 
the O 
delivery O 
of O 
docetaxel B-TRIVIAL 
and O 
Zn B-FORMULA 
(II) I-FORMULA 
- O 
phthalocyanine B-TRIVIAL 
inspired O 
by O 
combination O 
therapy O 
for O 
cancer O 
. O 

therapies O 
for O 
cancer O 
aim O 
to O 
exploit O 
either O 
additive O 
or O 
synergistic O 
effects O 
arising O 
from O 
the O 
action O 
of O 
two O 
species O 
with O 
the O 
final O 
goal O 
to O 
maximize O 
the O 
therapeutic O 
efficacy O 
. O 
In O 
this O 
work O 
, O 
we O 
develop O 
multifunctional O 
nanoparticles O 
( O 
NPs O 
) O 
for O 
co O 
- O 
delivery O 
of O 
the O 
conventional O 
anticancer O 
drug O 
docetaxel B-TRIVIAL 
( O 
DTX B-ABBREVIATION 
) O 
and O 
the O 
second O 
generation O 
photosensitizer O 
zinc B-SYSTEMATIC 
- O 
phthalocyanine B-TRIVIAL 
( O 
ZnPc B-FORMULA 
) O 
as O 
potential O 
dual O 
carrier O 
system O 
for O 
the O 
combination O 
of O 
chemotherapy O 
and O 
photodynamic O 
therapy O 
( O 
PDT O 
) O 
. O 
Biodegradable O 
and O 
amphiphilic O 
block O 
copolymers O 
based O 
on O 
poly(ε-caprolactone) B-FAMILY 
( O 
PCL B-ABBREVIATION 
= O 
B O 
) O 
and O 
poly(ethylene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEO B-ABBREVIATION 
= O 
A O 
) O 
, O 
with O 
AB O 
and O 
ABA O 
architectures O 
, O 
were O 
assembled O 
in O 
" O 
core O 
- O 
shell O 
" O 
NPs O 
and O 
loaded O 
with O 
both O 
DTX B-ABBREVIATION 
and O 
ZnPc B-FORMULA 
employing O 
the O 
melting O 
/ O 
sonication O 
method O 
. O 
Hydrodynamic O 
diameters O 
within O 
the O 
range O 
60-100nm O 
and O 
low O 
polydispersity O 
indexes O 
were O 
obtained O 
. O 
Zeta O 
potential O 
was O 
negative O 
for O 
all O 
the O 
formulations O 
and O 
unaffected O 
by O 
drug O 
encapsulation O 
. O 
Concerning O 
drug O 
loading O 
ability O 
of O 
NPs O 
, O 
the O 
entrapment O 
efficiency O 
was O 
related O 
to O 
initial O 
ZnPc B-FORMULA 
/ O 
DTX B-ABBREVIATION 
ratio O 
. O 
Steady O 
- O 
stationary O 
and O 
time O 
- O 
resolved O 
emission O 
fluorescence O 
measurements O 
pointed O 
out O 
the O 
embedding O 
of O 
monomeric O 
ZnPc B-FORMULA 
in O 
the O 
NPs O 
, O 
excluding O 
the O 
presence O 
of O 
ZnPc B-FORMULA 
self O 
- O 
supramolecular O 
oligomers O 
. O 
The O 
release O 
of O 
DTX B-ABBREVIATION 
was O 
biphasic O 
whereas O 
ZnPc B-FORMULA 
remained O 
mainly O 
associated O 
with O 
NPs O 
. O 
Singlet O 
oxygen B-SYSTEMATIC 
generation O 
was O 
observed O 
when O 
ZnPc B-FORMULA 
-loaded O 
NPs O 
were O 
irradiated O 
at O 
610nm O 
within O 
a O 
45min O 
time O 
range O 
, O 
despite O 
that O 
ZnPc B-FORMULA 
was O 
not O 
released O 
in O 
the O 
medium O 
. O 
Stability O 
of O 
NPs O 
in O 
the O 
presence O 
of O 
serum O 
proteins O 
and O 
plasma O 
was O 
excellent O 
and O 
no O 
toxicity O 
toward O 
red O 
blood O 
cells O 
was O 
found O 
. O 
NPs O 
cytotoxicity O 
was O 
evaluated O 
in O 
HeLa O 
cells O 
irradiated O 
for O 
30min O 
with O 
a O 
halogen O 
lamp O 
. O 
After O 
72h O 
, O 
viability O 
of O 
cells O 
treated O 
with O 
ZnPc B-FORMULA 
/ O 
DTX B-ABBREVIATION 
-loaded O 
NPs O 
strongly O 
decreased O 
as O 
compared O 
to O 
NPs O 
loaded O 
only O 
with O 
DTX B-ABBREVIATION 
, O 
thus O 
showing O 
a O 
combined O 
effect O 
of O 
both O 
DTX B-ABBREVIATION 
and O 
ZnPc B-FORMULA 
. O 
Superior O 
antitumor O 
activity O 
of O 
ZnPc B-FORMULA 
/ O 
DTX B-ABBREVIATION 
-loaded O 
NPs O 
as O 
compared O 
to O 
DTX B-ABBREVIATION 
-loaded O 
NPs O 
was O 
confirmed O 
in O 
an O 
animal O 
model O 
of O 
orthotopic O 
amelanotic O 
melanoma O 
, O 
thus O 
pointing O 
to O 
the O 
application O 
of O 
PEO B-ABBREVIATION 
- O 
PCL B-ABBREVIATION 
NPs O 
in O 
the O 
combined O 
chemo O 
- O 
photodynamic O 
therapy O 
of O 
cancer O 
. O 

combined O 
with O 
liposomes O 
and O 
with O 
decreased O 
numbers O 
of O 
primary B-FAMILY 
amine I-FAMILY 
residues O 
strongly O 
enhanced O 
therapeutic O 
antiviral O 
efficiency O 
against O 
herpes O 
simplex O 
virus O 
type O 
2 O 
in O 
a O 
mouse O 
model O 
. O 

development O 
of O 
antiviral O 
agents O 
that O 
have O 
novel O 
mechanisms O 
of O 
action O 
is O 
urgently O 
required O 
in O 
the O 
topical O 
therapy O 
of O 
herpes O 
simplex O 
virus O 
type O 
2 O 
( O 
HSV-2 O 
) O 
infections O 
. O 
We O 
reported O 
previously O 
that O 
topical O 
application O 
of O 
branched O 
3610-Da O 
polyethylenimine B-SYSTEMATIC 
( O 
PEI B-ABBREVIATION 
) O 
exhibited O 
preventative O 
antiviral O 
activity O 
. O 
In O 
this O 
study O 
, O 
to O 
develop O 
therapeutic O 
anti-HSV-2 O 
agents O 
, O 
the O 
most O 
potent O 
PEI B-ABBREVIATION 
combined O 
with O 
~200 O 
nm O 
- O 
sized O 
liposomes O 
with O 
or O 
without O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
( O 
liposomes/ O 
PEI B-ABBREVIATION 
) O 
was O 
selected O 
in O 
vitro O 
and O 
further O 
evaluated O 
using O 
in O 
vivo O 
studies O 
. O 
The O 
mechanism O 
of O 
action O 
in O 
vivo O 
was O 
elucidated O 
using O 
PEIs B-ABBREVIATION 
with O 
decreased O 
numbers O 
of O 
primary B-FAMILY 
amine I-FAMILY 
residues O 
, O 
resulting O 
from O 
ethylene B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
treatment O 
, O 
and O 
polyallylamine B-FAMILY 
, O 
a O 
linear O 
polyamine B-FAMILY 
consisting O 
of O 
primary B-FAMILY 
amines I-FAMILY 
. O 
Cytotoxicity O 
and O 
antiviral O 
activity O 
in O 
vitro O 
, O 
and O 
the O 
appearance O 
of O 
acute O 
herpetic O 
disease O 
and O 
virus O 
yields O 
in O 
mice O 
intravaginally O 
administered O 
with O 
liposomes/ O 
PEI B-ABBREVIATION 
were O 
evaluated O 
in O 
cell O 
culture O 
assays O 
and O 
a O 
mouse O 
genital O 
herpes O 
model O 
, O 
respectively O 
. O 
In O 
addition O 
, O 
the O 
cellular O 
association O 
of O 
liposome/ O 
PEI B-ABBREVIATION 
was O 
examined O 
by O 
flow O 
cytometry O 
and O 
confocal O 
microscopy O 
. O 
PEI B-ABBREVIATION 
showed O 
higher O 
antiviral O 
activity O 
postinfection O 
than O 
preinfection O 
in O 
vivo O 
. O 
Liposome/ O 
PEI B-ABBREVIATION 
and O 
PEI B-ABBREVIATION 
with O 
decreased O 
numbers O 
of O 
primary B-FAMILY 
amine I-FAMILY 
residues O 
at O 
a O 
dose O 
of O 
0.2 O 
mg O 
PEI B-ABBREVIATION 
/ O 
mouse O 
exhibited O 
more O 
potent O 
therapeutic O 
antiviral O 
activity O 
than O 
acyclovir B-TRIVIAL 
and O 
PEI B-ABBREVIATION 
alone O 
without O 
acute O 
lesion O 
appearance O 
or O 
toxicity O 
pre- O 
or O 
postinfection O 
, O 
but O 
polyallylamine B-FAMILY 
was O 
moderately O 
effective O 
only O 
preinfection O 
. O 
Liposome O 
concentrations O 
were O 
important O 
for O 
the O 
effectiveness O 
of O 
liposome/ O 
PEI B-ABBREVIATION 
. O 
This O 
finding O 
suggests O 
that O 
PEI B-ABBREVIATION 
combined O 
with O 
liposomes O 
and O 
with O 
slightly O 
decreased O 
numbers O 
of O 
primary B-FAMILY 
amines I-FAMILY 
may O 
be O 
an O 
effective O 
vaginally O 
administrated O 
antiviral O 
drug O 
, O 
and O 
secondary B-MULTIPLE 
and I-MULTIPLE 
tertiary I-MULTIPLE 
amine I-MULTIPLE 
residues O 
of O 
PEI B-ABBREVIATION 
may O 
contribute O 
to O 
the O 
inhibitory O 
efficiency O 
against O 
viral O 
infection O 
. O 

situ O 
forming O 
nimodipine B-TRIVIAL 
depot O 
system O 
based O 
on O 
microparticles O 
for O 
the O 
treatment O 
of O 
posthemorrhagic O 
cerebral O 
vasospasm O 
. O 

present O 
study O 
was O 
conducted O 
to O 
examine O 
the O 
feasibility O 
of O 
nimodipine B-TRIVIAL 
-loaded O 
PLGA B-ABBREVIATION 
microparticles O 
suspended O 
in O 
Tisseel O 
™ O 
fibrin O 
sealant O 
as O 
an O 
in O 
situ O 
forming O 
depot O 
system O 
. O 
This O 
device O 
locally O 
placed O 
can O 
be O 
used O 
for O 
the O 
treatment O 
of O 
vasospasm O 
after O 
a O 
subarachnoid O 
hemorrhage O 
. O 
Microparticles O 
were O 
prepared O 
via O 
spray O 
- O 
drying O 
by O 
using O 
the O 
vibration O 
mesh O 
spray O 
technology O 
of O 
Nano O 
Spray O 
Dryer O 
B-90 O 
. O 
Spherically O 
shaped O 
microparticles O 
with O 
different O 
loadings O 
and O 
high O 
encapsulation O 
efficiencies O 
of O 
93.3-97.8% O 
were O 
obtained O 
. O 
Depending O 
on O 
nimodipine B-TRIVIAL 
loading O 
( O 
10-40% O 
) O 
, O 
the O 
particle O 
diameter O 
ranged O 
from O 
1.9±1.2μm O 
to O 
2.4±1.3μm O 
. O 
Thermal O 
analyses O 
using O 
DSC O 
revealed O 
that O 
nimodipine B-TRIVIAL 
is O 
dissolved O 
in O 
the O 
PLGA O 
matrix O 
. O 
Also O 
, O 
fluorescent O 
dye O 
loaded O 
microparticles O 
were O 
encapsulated O 
in O 
Tisseel O 
™ O 
to O 
examine O 
the O 
homogeneity O 
of O 
particles O 
. O 
3D-pictures O 
of O 
the O 
in O 
situ O 
forming O 
devices O 
displayed O 
uniform O 
particle O 
homogeneity O 
in O 
the O 
sealant O 
matrix O 
. O 
Drug O 
release O 
was O 
examined O 
by O 
fluorescence O 
spectrophotometry O 
which O 
demonstrated O 
a O 
drug O 
release O 
proportional O 
to O 
the O 
square O 
root O 
of O 
time O 
. O 
A O 
prolonged O 
drug O 
release O 
of O 
19.5h O 
was O 
demonstrated O 
under O 
in O 
vitro O 
conditions O 
. O 
Overall O 
, O 
the O 
nimodipine B-TRIVIAL 
in O 
situ O 
forming O 
device O 
could O 
be O 
a O 
promising O 
candidate O 
for O 
the O 
local O 
treatment O 
of O 
vasospasm O 
after O 
a O 
subarachnoid O 
hemorrhage O 
. O 

of O 
HO-1 O 
through O 
p38 O 
MAPK O 
/ O 
Nrf2 O 
signaling O 
pathway O 
by O 
ethanol B-SYSTEMATIC 
extract O 
of O 
Inula O 
helenium O 
L O 
. O 
reduces O 
inflammation O 
in O 
LPS-activated O 
RAW O 
264.7 O 
cells O 
and O 
CLP-induced O 
septic O 
mice O 
. O 

mobility O 
group O 
box O 
1 O 
( O 
HMGB1 O 
) O 
plays O 
a O 
crucial O 
mediator O 
in O 
the O 
pathogenesis O 
of O 
many O 
inflammatory O 
diseases O 
. O 
We O 
recently O 
proposed O 
that O 
heme B-FAMILY 
oxygenase-1 O 
( O 
HO-1 O 
) O 
negatively O 
regulates O 
HMGB1 O 
in O 
inflammatory O 
conditions O 
. O 
We O 
investigated O 
whether O 
ethanol B-SYSTEMATIC 
extract O 
of O 
Inula O 
helenium O 
L O 
. O 
( O 
EIH O 
) O 
activates O 
p38 O 
MAPK O 
/ O 
Nrf2 O 
/ O 
HO-1 O 
pathways O 
in O 
RAW264.7 O 
cells O 
and O 
reduces O 
inflammation O 
in O 
CLP-induced O 
septic O 
mice O 
. O 
EIH O 
induced O 
expression O 
of O 
HO-1 O 
protein O 
in O 
a O 
time- O 
and O 
concentration O 
- O 
dependent O 
manner O 
. O 
EIH O 
significantly O 
diminished O 
HO-1 O 
expression O 
in O 
siNrf2 O 
RNA-transfected O 
cells O 
. O 
As O 
expected O 
, O 
the O 
inhibited O 
expression O 
of O 
iNOS O 
/ O 
NO O 
, O 
COX-2 O 
/ O 
PGE2 O 
, O 
HMGB1 O 
release O 
by O 
EIH O 
in O 
LPS-activated O 
RAW264.7 O 
cells O 
was O 
significantly O 
reversed O 
by O 
siHO-1RNA O 
transfection O 
. O 
Furthermore O 
, O 
EIH O 
not O 
only O 
inhibited O 
NF-κB O 
luciferase O 
activity O 
, O 
phosphorylation O 
of O 
IκBα O 
in O 
LPS-activated O 
cells O 
but O 
also O 
significantly O 
suppressed O 
expression O 
of O 
adhesion O 
molecules O 
( O 
ICAM-1 O 
and O 
VCAM-1 O 
) O 
in O 
TNF-α O 
activated O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
. O 
The O 
induction O 
of O 
HO-1 O 
by O 
EIH O 
was O 
inhibited O 
by O 
SB203580 B-IDENTIFIER 
but O 
not O 
by O 
SP600125 B-IDENTIFIER 
, O 
PD98059 B-IDENTIFIER 
, O 
nor O 
LY294002 B-IDENTIFIER 
. O 
Most O 
importantly O 
, O 
administration O 
of O 
EIH O 
significantly O 
reduced O 
not O 
only O 
increase O 
in O 
blood O 
HMGB1 O 
, O 
ALT O 
, O 
AST O 
, O 
BUN O 
, O 
creatinine B-TRIVIAL 
levels O 
but O 
also O 
decrease O 
macrophage O 
infiltrate O 
in O 
the O 
liver O 
of O 
septic O 
mice O 
, O 
which O 
were O 
reversed O 
by O 
ZnPPIX O 
, O 
a O 
HO-1 O 
inhibitor O 
. O 
We O 
concluded O 
that O 
EIH O 
has O 
anti-inflammatory O 
effect O 
via O 
the O 
induction O 
of O 
p38 O 
MAPK-dependent O 
HO-1 O 
signaling O 
pathway O 
. O 

of O 
insulin O 
- O 
like O 
growth O 
factor O 
acid O 
- O 
labile O 
subunit O 
as O 
a O 
potential O 
biomarker O 
of O 
effect O 
for O 
deoxynivalenol B-TRIVIAL 
-induced O 
proinflammatory O 
cytokine O 
expression O 
. O 

of O 
the O 
trichothecene O 
deoxynivalenol B-TRIVIAL 
( O 
DON B-ABBREVIATION 
) O 
suppresses O 
growth O 
in O 
experimental O 
animals O 
- O 
an O 
adverse O 
effect O 
that O 
was O 
used O 
to O 
establish O 
the O 
tolerable O 
daily O 
intake O 
for O 
this O 
toxin O 
. O 
DON B-ABBREVIATION 
ingestion O 
has O 
been O 
recently O 
found O 
to O 
suppress O 
plasma O 
insulin O 
- O 
like O 
growth O 
factor O 
acid O 
- O 
labile O 
subunit O 
( O 
IGFALS O 
) O 
, O 
a O 
protein O 
essential O 
for O 
growth O 
. O 
Studies O 
were O 
conducted O 
to O 
explore O 
the O 
feasibility O 
of O 
using O 
plasma O 
IGFALS O 
as O 
a O 
biomarker O 
of O 
effect O 
for O 
DON B-ABBREVIATION 
. O 
In O 
the O 
first O 
study O 
, O 
weanling O 
mice O 
were O 
fed O 
0 O 
, O 
1 O 
, O 
2.5 O 
, O 
5 O 
and O 
10 O 
ppm O 
DON B-ABBREVIATION 
and O 
weight O 
and O 
plasma O 
IGFALS O 
determined O 
at O 
intervals O 
over O 
9 O 
wk O 
. O 
Reduced O 
body O 
weight O 
gains O 
were O 
detectable O 
beginning O 
at O 
wk O 
5 O 
in O 
the O 
10 O 
ppm O 
dose O 
and O 
wk O 
7 O 
at O 
the O 
5 O 
ppm O 
dose O 
. O 
Plasma O 
IGFALS O 
was O 
significantly O 
depressed O 
at O 
wk O 
5 O 
in O 
the O 
5 O 
and O 
10 O 
ppm O 
groups O 
at O 
wk O 
9 O 
in O 
the O 
10 O 
ppm O 
group O 
. O 
Depressed O 
IGFALS O 
significantly O 
correlated O 
with O 
reduced O 
body O 
weight O 
at O 
wk O 
5 O 
and O 
9 O 
. O 
Benchmark O 
dose O 
modeling O 
revealed O 
the O 
BMDL O 
and O 
BMD O 
for O 
plasma O 
IGFALS O 
reduction O 
were O 
1.1 O 
and O 
3 O 
ppm O 
DON B-ABBREVIATION 
and O 
for O 
weight O 
reduction O 
were O 
2.1 O 
and O 
4.5 O 
ppm O 
DON B-ABBREVIATION 
. O 
In O 
the O 
second O 
study O 
, O 
it O 
was O 
demonstrated O 
that O 
mice O 
fed O 
15 O 
ppm O 
DON B-ABBREVIATION 
diet O 
had O 
significantly O 
less O 
plasma O 
IGFALS O 
than O 
mice O 
fed O 
identical O 
amounts O 
of O 
control O 
diet O 
. O 
Thus O 
DON B-ABBREVIATION 
' O 
s O 
influence O 
on O 
IGFALS O 
likely O 
reflects O 
the O 
combined O 
effects O 
of O 
reduced O 
food O 
intake O 
as O 
well O 
as O 
its O 
physiological O 
action O 
involving O 
suppressors O 
of O 
cytokine O 
signaling O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
suggest O 
that O 
plasma O 
IGFALS O 
might O 
be O 
a O 
useful O 
biomarker O 
for O 
DON B-ABBREVIATION 
' O 
s O 
adverse O 
effects O 
on O 
growth O 
. O 

administered O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
prevents O 
aeroallergen O 
- O 
induced O 
airway O 
sensitization O 
in O 
mice O 
through O 
immunomodulatory O 
mechanisms O 
. O 

E2 I-TRIVIAL 
attenuates O 
airway O 
pathology O 
in O 
asthmatic O 
patients O 
and O 
exerts O 
a O 
protective O 
effect O 
in O 
antigen O 
- O 
sensitized O 
mice O 
when O 
administered O 
systemically O 
. O 
We O 
aimed O 
to O 
establish O 
the O 
consequences O 
of O 
intranasal O 
PGE2 B-ABBREVIATION 
administration O 
on O 
airway O 
reactivity O 
to O 
aeroallergens O 
in O 
mice O 
and O 
reveal O 
the O 
underlying O 
immunoinflammatory O 
mechanisms O 
. O 
PGE2 B-ABBREVIATION 
was O 
administered O 
either O 
daily O 
during O 
a O 
10-day O 
exposure O 
to O 
house O 
dust O 
mite O 
( O 
HDM O 
) O 
extracts O 
or O 
for O 
limited O 
intervals O 
. O 
Airway O 
hyperreactivity O 
was O 
measured O 
by O 
whole O 
- O 
body O 
and O 
invasive O 
plethysmography O 
. O 
The O 
phenotypes O 
of O 
lung O 
immune O 
cells O 
and O 
cytokine O 
production O 
were O 
analysed O 
by O 
flow O 
cytometry O 
and O 
ELISA O 
, O 
respectively O 
. O 
Airway O 
hyperreactivity O 
was O 
sustainably O 
reduced O 
only O 
when O 
PGE2 B-ABBREVIATION 
administration O 
was O 
restricted O 
to O 
the O 
initial O 
5 O 
days O 
of O 
exposure O 
to O 
HDM O 
. O 
Lung O 
inflammation O 
, O 
IL-4 O 
production O 
, O 
and O 
airway O 
mast O 
cell O 
activity O 
were O 
also O 
prevented O 
under O 
this O 
early O 
short O 
- O 
term O 
treatment O 
with O 
PGE2 B-ABBREVIATION 
. O 
Interestingly O 
, O 
a O 
Th2 O 
response O 
was O 
already O 
committed O 
on O 
day O 
5 O 
of O 
exposure O 
to O 
HDM O 
. O 
This O 
was O 
paralleled O 
by O 
GM-CSF O 
and O 
osteopontin O 
upregulation O 
and O 
a O 
decreased O 
number O 
of O 
plasmacytoid O 
dendritic O 
and O 
T O 
regulatory O 
cells O 
, O 
as O 
well O 
as O 
a O 
trend O 
towards O 
reduced O 
IL-10 O 
expression O 
. O 
Local O 
PGE2 B-ABBREVIATION 
administration O 
prevented O 
the O 
increase O 
of O 
airway O 
IL-13 O 
and O 
osteopontin O 
and O 
kept O 
lung O 
plasmacytoid O 
dendritic O 
cell O 
counts O 
close O 
to O 
baseline O 
. O 
GM-CSF O 
and O 
Tregs O 
were O 
unaffected O 
by O 
the O 
treatment O 
. O 
These O 
findings O 
suggest O 
that O 
the O 
protection O 
provided O 
by O 
PGE2 B-ABBREVIATION 
is O 
a O 
result O 
of O 
the O 
modulation O 
of O 
early O 
lung O 
immunomodulatory O 
mechanisms O 
, O 
and O 
possibly O 
a O 
shift O 
in O 
the O 
balance O 
of O 
dendritic O 
cells O 
towards O 
a O 
tolerogenic O 
profile O 
. O 

of O 
benzyloxazoles B-FAMILY 
as O 
non- O 
nucleoside B-FAMILY 
inhibitors O 
of O 
HIV-1 O 
reverse O 
transcriptase O 
to O 
enhance O 
Y181C O 
potency O 
. O 

of O 
non- O 
nucleoside B-FAMILY 
inhibitors O 
of O 
HIV-1 O 
reverse O 
transcriptase O 
with O 
improved O 
activity O 
towards O 
Tyr181Cys O 
containing O 
variants O 
was O 
pursued O 
with O 
the O 
assistance O 
of O 
free O 
energy O 
perturbation O 
( O 
FEP O 
) O 
calculations O 
. O 
Optimization O 
of O 
the O 
4-R O 
substituent O 
in O 
1 O 
led O 
to O 
ethyl B-SYSTEMATIC 
and O 
isopropyl B-SYSTEMATIC 
analogs O 
1e O 
and O 
1f O 
with O 
1-7 O 
nM O 
potency O 
towards O 
both O 
the O 
wild O 
- O 
type O 
virus O 
and O 
a O 
Tyr181C O 
variant O 
. O 

N B-FORMULA 
-demethylation O 
by O 
the O 
common O 
CYP2B6 O 
allelic O 
variant O 
CYP2B6.6 O 
. O 

long O 
- O 
acting O 
opioid O 
methadone B-TRIVIAL 
displays O 
considerable O 
unexplained O 
interindividual O 
pharmacokinetic O 
variability O 
. O 
Methadone B-TRIVIAL 
metabolism O 
clinically O 
occurs O 
primarily O 
by O 
N B-FORMULA 
-demethylation O 
to O 
2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine B-SYSTEMATIC 
( O 
EDDP B-ABBREVIATION 
) O 
, O 
catalyzed O 
predominantly O 
by O 
CYP2B6 O 
. O 
Retrospective O 
studies O 
suggest O 
that O 
the O 
common O 
allele O 
variant O 
CYP2B6*6 O 
may O 
influence O 
methadone B-TRIVIAL 
plasma O 
concentrations O 
. O 
The O 
catalytic O 
activity O 
of O 
CYP2B6.6 O 
, O 
encoded O 
by O 
CYP2B6*6 O 
, O 
is O 
highly O 
substrate O 
- O 
dependent O 
. O 
This O 
investigation O 
compared O 
methadone B-TRIVIAL 
N B-FORMULA 
-demethylation O 
by O 
CYP2B6.6 O 
with O 
that O 
by O 
wild O 
- O 
type O 
CYP2B6.1 O 
. O 
Methadone B-TRIVIAL 
enantiomer O 
and O 
racemate O 
N B-FORMULA 
-demethylation O 
by O 
recombinant O 
- O 
expressed O 
CYP2B6.6 O 
and O 
CYP2B6.1 O 
was O 
determined O 
. O 
At O 
substrate O 
concentrations O 
( O 
0.25-2 O 
µM O 
) O 
approximating O 
plasma O 
concentrations O 
occurring O 
clinically O 
, O 
rates O 
of O 
methadone B-TRIVIAL 
enantiomer O 
N B-FORMULA 
-demethylation O 
by O 
CYP2B6.6 O 
, O 
incubated O 
individually O 
or O 
as O 
the O 
racemate O 
, O 
were O 
one O 
- O 
third O 
to O 
one O 
- O 
fourth O 
those O 
by O 
CYP2B6.1 O 
. O 
For O 
methadone B-TRIVIAL 
individual O 
enantiomers O 
and O 
metabolism O 
by O 
CYP2B6.6 O 
compared O 
with O 
CYP2B6.1 O 
, O 
Vmax O 
was O 
diminished O 
, O 
Ks O 
was O 
greater O 
and O 
the O 
in O 
vitro O 
intrinsic O 
clearance O 
was O 
diminished O 
5- O 
to O 
6-fold O 
. O 
The O 
intrinsic O 
clearance O 
for O 
R- B-MULTIPLE 
and I-MULTIPLE 
S-EDDP I-MULTIPLE 
formation O 
from O 
racemic B-TRIVIAL 
methadone I-TRIVIAL 
was O 
diminished O 
approximately O 
6-fold O 
and O 
3-fold O 
for O 
R- B-MULTIPLE 
and I-MULTIPLE 
S-methadone I-MULTIPLE 
, O 
respectively O 
. O 
Both O 
CYP2B6.6 O 
and O 
CYP2B6.1 O 
showed O 
similar O 
stereoselectivity O 
( O 
S B-MULTIPLE 
> I-MULTIPLE 
R-methadone I-MULTIPLE 
) O 
. O 
Human O 
liver O 
microsomes O 
with O 
diminished O 
CYP2B6 O 
content O 
due O 
to O 
a O 
CYP2B6*6 O 
allele O 
had O 
lower O 
rates O 
of O 
methadone B-TRIVIAL 
N B-FORMULA 
-demethylation O 
. O 
Results O 
show O 
that O 
methadone B-TRIVIAL 
N B-FORMULA 
-demethylation O 
catalyzed O 
by O 
CYP2B6.6 O 
, O 
the O 
CYP2B6 O 
variant O 
encoded O 
by O 
the O 
CYP2B6*6 O 
polymorphism O 
, O 
is O 
catalytically O 
deficient O 
compared O 
with O 
wild O 
- O 
type O 
CYP2B6.1 O 
. O 
Diminished O 
methadone B-TRIVIAL 
N B-FORMULA 
-demethylation O 
by O 
CYP2B6.6 O 
may O 
provide O 
a O 
mechanistic O 
explanation O 
for O 
clinical O 
observations O 
of O 
altered O 
methadone B-TRIVIAL 
disposition O 
in O 
individuals O 
carrying O 
the O 
CYP2B6*6 O 
polymorphism O 
. O 

nuclear O 
receptors O 
constitutive O 
androstane B-TRIVIAL 
receptor O 
( O 
CAR O 
) O 
, O 
pregnane B-TRIVIAL 
X O 
receptor O 
( O 
PXR O 
) O 
and O 
vitamin B-FAMILY 
D I-FAMILY 
receptor O 
( O 
VDR O 
) O 
control O 
a O 
large O 
array O 
of O 
genes O 
that O 
code O 
for O 
important O 
proteins O 
in O 
humans O 
including O 
metabolic O 
enzymes O 
and O 
transporters O 
. O 
3D O 
structures O 
for O 
the O 
ligand O 
- O 
binding O 
domain O 
( O 
LBD O 
) O 
of O 
these O 
receptors O 
are O 
abundantly O 
available O 
, O 
providing O 
valuable O 
insights O 
into O 
the O 
ligand O 
- O 
binding O 
specificity O 
as O 
well O 
as O 
the O 
activation O 
mechanisms O 
. O 
The O 
ligand O 
- O 
binding O 
site O 
of O 
PXR O 
is O 
large O 
and O 
flexible O 
, O 
whereas O 
those O 
of O 
CAR O 
and O 
VDR O 
are O 
compact O 
and O 
rigid O 
, O 
respectively O 
. O 
In O 
general O 
, O 
the O 
ligand O 
profiles O 
of O 
the O 
receptors O 
are O 
in O 
agreement O 
with O 
the O 
LBD O 
structures O 
. O 
The O 
crystal O 
structures O 
have O 
greatly O 
helped O 
us O 
to O 
understand O 
the O 
promiscuity O 
and O 
/ O 
or O 
specificity O 
of O 
CAR O 
, O 
PXR O 
and O 
VDR O 
. O 

oral O 
toxicity O 
of O 
combinations O 
of O 
selected O 
synthetic O 
pyrethroids B-FAMILY 
, O 
piperonyl B-SYSTEMATIC 
butoxide I-SYSTEMATIC 
, O 
and O 
tetramethrin B-TRIVIAL 
in O 
rats O 
. O 

this O 
study O 
, O 
70 O 
Wistar O 
rats O 
were O 
randomly O 
divided O 
into O 
seven O 
equal O 
groups O 
( O 
six O 
experimental O 
and O 
one O 
control O 
) O 
, O 
which O 
consisted O 
of O 
animals O 
belonging O 
to O 
both O 
sexes O 
. O 
Different O 
combinations O 
of O 
insecticides O 
were O 
administered O 
daily O 
to O 
the O 
experimental O 
groups O 
( O 
group O 
1 O 
: O 
cypermethrin B-TRIVIAL 
+ O 
piperonyl B-SYSTEMATIC 
butoxide I-SYSTEMATIC 
( O 
PBO B-ABBREVIATION 
) O 
; O 
group O 
2 O 
: O 
alphacypermethrin B-TRIVIAL 
+ O 
PBO B-ABBREVIATION 
; O 
group O 
3 O 
: O 
deltamethrin B-TRIVIAL 
+ O 
PBO B-ABBREVIATION 
; O 
group O 
4 O 
: O 
cypermethrin B-TRIVIAL 
+ O 
PBO B-ABBREVIATION 
+ O 
tetramethrin B-TRIVIAL 
; O 
group O 
5 O 
: O 
alphacypermethrin B-TRIVIAL 
+ O 
PBO B-ABBREVIATION 
+ O 
tetramethrin B-TRIVIAL 
; O 
and O 
group O 
6 O 
: O 
deltamethrin B-TRIVIAL 
+ O 
PBO B-ABBREVIATION 
+ O 
tetramethrin O 
) O 
for O 
28 O 
days O 
. O 
During O 
the O 
study O 
period O 
, O 
mortality O 
and O 
serious O 
clinical O 
findings O 
were O 
not O 
observed O 
in O 
any O 
animal O 
. O 
However O 
, O 
feed O 
consumptions O 
decreased O 
in O 
groups O 
1 O 
and O 
3 O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Red O 
blood O 
cells O 
, O 
white O 
blood O 
cells O 
, O 
and O 
hemoglobin O 
levels O 
, O 
especially O 
in O 
cypermethrin B-TRIVIAL 
and O 
alphacypermethrin B-TRIVIAL 
groups O 
( O 
groups O 
1 O 
, O 
2 O 
, O 
and O 
4 O 
) O 
, O 
were O 
found O 
to O 
be O 
higher O 
than O 
the O 
control O 
group O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Furthermore O 
, O 
biochemical O 
changes O 
related O 
to O 
liver O 
, O 
kidney O 
functions O 
, O 
and O 
protein O 
metabolism O 
occurred O 
in O 
males O 
of O 
almost O 
all O 
the O 
groups O 
. O 
Relative O 
liver O 
and O 
kidney O 
weights O 
of O 
the O 
male O 
animals O 
increased O 
in O 
the O 
cypermethrin B-TRIVIAL 
and O 
alphacypermethrin B-TRIVIAL 
groups O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
most O 
common O 
finding O 
observed O 
during O 
the O 
histopathological O 
examination O 
of O 
all O 
the O 
experimental O 
groups O 
was O 
centrilobular O 
degeneration O 
in O 
the O 
liver O 
. O 
It O 
was O 
concluded O 
that O 
although O 
clinical O 
symptoms O 
were O 
not O 
observed O 
, O 
synthetic O 
pyrethroid B-FAMILY 
, O 
synergist O 
, O 
and O 
knockdown O 
agent O 
combinations O 
might O 
cause O 
serious O 
abnormalities O 
when O 
administered O 
in O 
certain O 
doses O 
in O 
mammalians O 
. O 

Serum-Tolerant O 
Hydroxyl B-SYSTEMATIC 
-Modified O 
Polyethylenimine B-FAMILY 
as O 
Versatile O 
Carriers O 
of O 
pDNA O 
/ O 
siRNA O 
. O 

polyethylenimine B-SYSTEMATIC 
( O 
PEI B-ABBREVIATION 
) O 
derivatives O 
( O 
PTn O 
) O 
are O 
prepared O 
by O 
treating O 
PEI25k O 
with O 
Tris(hydroxymethyl) B-SYSTEMATIC 
acrylamidomethane I-SYSTEMATIC 
via O 
the O 
Michael O 
addition O 
. O 
These O 
PTns O 
can O 
effectively O 
condense O 
nucleic O 
acids O 
into O 
nanosized O 
particles O 
with O 
positive O 
surface O 
charges O 
. O 
The O 
PTns O 
show O 
lower O 
cytotoxicity O 
and O 
better O 
serum O 
- O 
resistant O 
capacity O 
than O 
PEI25k O 
. O 
Specially O 
, O 
the O 
transfection O 
efficiency O 
of O 
PT26 O 
/ O 
DNA O 
is O 
29-fold O 
higher O 
than O 
that O 
of O 
PEI25k O 
in O 
HeLa O 
cells O 
in O 
serum O 
- O 
containing O 
medium O 
. O 
The O 
PTn O 
/ O 
siRNA O 
complexes O 
show O 
superior O 
knockdown O 
effect O 
in O 
CT26 O 
cells O 
in O 
serum O 
- O 
containing O 
medium O 
. O 
In O 
addition O 
, O 
flow O 
cytometry O 
analysis O 
shows O 
that O 
the O 
PTns O 
can O 
efficiently O 
mediate O 
the O 
entry O 
of O 
nucleic O 
acids O 
into O 
the O 
cell O 
. O 
Thus O 
, O 
PTns O 
are O 
potentially O 
applicable O 
as O 
non-viral O 
carriers O 
of O 
nucleic O 
acids O 
and O 
warrant O 
further O 
development O 
for O 
use O 
in O 
gene O 
therapy O 
. O 

evaluate O 
the O 
associations O 
between O 
adiponectin O 
levels O 
and O 
1 O 
) O 
the O 
risk O 
of O 
developing O 
gestational O 
diabetes O 
mellitus O 
( O 
GDM O 
) O 
, O 
and O 
2 O 
) O 
insulin O 
resistance O 
/ O 
sensitivity O 
, O 
β-cell O 
function O 
, O 
and O 
compensation O 
indices O 
in O 
a O 
prospective O 
cohort O 
representative O 
of O 
the O 
general O 
population O 
of O 
pregnant O 
women.RESEARCH O 
DESIGN O 
AND O 
METHODSWe O 
performed O 
anthropometric O 
measurements O 
and O 
collected O 
blood O 
samples O 
at O 
1st O 
( O 
6-13 O 
weeks O 
) O 
and O 
2nd O 
( O 
24-28 O 
weeks O 
) O 
trimesters O 
. O 
Diagnosis O 
of O 
GDM O 
was O 
made O 
at O 
2nd O 
trimester O 
, O 
based O 
on O 
a O 
75-g O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
( O 
International O 
Association O 
of O 
Diabetes O 
and O 
Pregnancy O 
Study O 
Group O 
criteria O 
) O 
. O 
Insulin O 
was O 
measured O 
( O 
ELISA O 
; O 
Luminex O 
) O 
to O 
estimate O 
homeostasis O 
model O 
assessment O 
of O 
insulin O 
resistance O 
( O 
HOMA-IR O 
) O 
, O 
β-cell O 
function O 
( O 
HOMA-B O 
) O 
, O 
insulin O 
sensitivity O 
( O 
Matsuda O 
index O 
) O 
, O 
insulin O 
secretion O 
( O 
AUC(insulin/ O 
glucose B-TRIVIAL 
) O 
) O 
, O 
and O 
β-cell O 
compensation O 
( O 
insulin O 
secretion O 
sensitivity O 
index-2 O 
) O 
. O 
Adiponectin O 
was O 
measured O 
by O 
radioimmunoassay.RESULTSAmong O 
the O 
445 O 
participants O 
included O 
in O 
this O 
study O 
, O 
38 O 
women O 
developed O 
GDM O 
. O 
Women O 
who O 
developed O 
GDM O 
had O 
lower O 
1st O 
- O 
trimester O 
adiponectin O 
levels O 
( O 
9.67 O 
± O 
3.84 O 
vs O 
. O 
11.92 O 
± O 
4.59 O 
µg O 
/ O 
mL O 
in O 
women O 
with O 
normal O 
glucose B-TRIVIAL 
tolerance O 
) O 
. O 
Lower O 
adiponectin O 
levels O 
were O 
associated O 
with O 
higher O 
risk O 
of O 
developing O 
GDM O 
( O 
OR O 
, O 
1.12 O 
per O 
1 O 
µg O 
/ O 
mL O 
decrease O 
of O 
adiponectin O 
levels O 
; O 
P O 
= O 
0.02 O 
, O 
adjusted O 
for O 
BMI O 
and O 
HbA(1c) O 
at O 
1st O 
trimester O 
) O 
. O 
Adiponectin O 
levels O 
at O 
1st O 
and O 
2nd O 
trimesters O 
were O 
associated O 
with O 
HOMA-IR O 
( O 
both O 
: O 
r O 
= O 
-0.22 O 
, O 
P O 
< O 
0.0001 O 
) O 
and O 
Matsuda O 
index O 
( O 
r O 
= O 
0.28 O 
, O 
P O 
< O 
0.0001 O 
, O 
and O 
r O 
= O 
0.29 O 
, O 
P O 
< O 
0.0001 O 
) O 
. O 
After O 
adjustment O 
for O 
confounding O 
factors O 
, O 
we O 
found O 
no O 
significant O 
association O 
with O 
HOMA-B O 
and O 
AUC(insulin/ O 
glucose B-TRIVIAL 
).CONCLUSIONSPregnant O 
women O 
with O 
lower O 
adiponectin O 
levels O 
at O 
1st O 
trimester O 
have O 
higher O 
levels O 
of O 
insulin O 
resistance O 
and O 
are O 
more O 
likely O 
to O 
develop O 
GDM O 
independently O 
of O 
adiposity O 
or O 
glycemic O 
measurements O 
. O 

interactions O 
between O 
nanosized O 
particles O 
and O 
living O 
systems O 
are O 
commonly O 
mediated O 
by O 
what O 
adsorbs O 
to O 
the O 
nanoparticle O 
in O 
the O 
biological O 
environment O 
, O 
its O 
biomolecular O 
corona O 
, O 
rather O 
than O 
the O 
pristine O 
surface O 
. O 
Here O 
, O 
we O 
characterize O 
the O 
adhesion O 
toward O 
the O 
cell O 
membrane O 
of O 
nanoparticles O 
of O 
different O 
material O 
and O 
size O 
and O 
study O 
how O 
this O 
is O 
modulated O 
by O 
the O 
presence O 
or O 
absence O 
of O 
a O 
corona O 
on O 
the O 
nanoparticle O 
surface O 
. O 
The O 
results O 
are O 
corroborated O 
with O 
adsorption O 
to O 
simple O 
model O 
supported O 
lipid O 
bilayers O 
using O 
a O 
quartz B-TRIVIAL 
crystal O 
microbalance O 
. O 
We O 
conclude O 
that O 
the O 
adsorption O 
of O 
proteins O 
on O 
the O 
nanoparticle O 
surface O 
strongly O 
reduces O 
nanoparticle O 
adhesion O 
in O 
comparison O 
to O 
what O 
is O 
observed O 
for O 
the O 
bare O 
material O 
. O 
Nanoparticle O 
uptake O 
is O 
described O 
as O 
a O 
two O 
- O 
step O 
process O 
, O 
where O 
the O 
nanoparticles O 
initially O 
adhere O 
to O 
the O 
cell O 
membrane O 
and O 
subsequently O 
are O 
internalized O 
by O 
the O 
cells O 
via O 
energy O 
- O 
dependent O 
pathways O 
. O 
The O 
lowered O 
adhesion O 
in O 
the O 
presence O 
of O 
proteins O 
thereby O 
causes O 
a O 
concomitant O 
decrease O 
in O 
nanoparticle O 
uptake O 
efficiency O 
. O 
The O 
presence O 
of O 
a O 
biomolecular O 
corona O 
may O 
confer O 
specific O 
interactions O 
between O 
the O 
nanoparticle O 
- O 
corona O 
complex O 
and O 
the O 
cell O 
surface O 
including O 
triggering O 
of O 
regulated O 
cell O 
uptake O 
. O 
An O 
important O 
effect O 
of O 
the O 
corona O 
is O 
, O 
however O 
, O 
a O 
reduction O 
in O 
the O 
purely O 
unspecific O 
interactions O 
between O 
the O 
bare O 
material O 
and O 
the O 
cell O 
membrane O 
, O 
which O 
in O 
itself O 
disregarding O 
specific O 
interactions O 
, O 
causes O 
a O 
decrease O 
in O 
cellular O 
uptake O 
. O 
We O 
suggest O 
that O 
future O 
nanoparticle O 
- O 
cell O 
studies O 
include O 
, O 
together O 
with O 
characterization O 
of O 
size O 
, O 
charge O 
, O 
and O 
dispersion O 
stability O 
, O 
an O 
evaluation O 
of O 
the O 
adhesion O 
properties O 
of O 
the O 
material O 
to O 
relevant O 
membranes O 
. O 

derivatives O 
of O 
guanidine B-TRIVIAL 
diaromatic O 
minor O 
groove O 
binders O 
with O 
antiprotozoal O 
activity O 
. O 

the O 
strong O 
DNA O 
minor O 
groove O 
binding O 
observed O 
for O 
our O 
previous O 
series O 
of O 
diaromatic O 
symmetric O 
and O 
asymmetric O 
guanidinium B-SYSTEMATIC 
and O 
2-aminoimidazolinium B-SYSTEMATIC 
derivatives O 
, O 
we O 
report O 
now O 
the O 
synthesis O 
of O 
new O 
aminoalkyl B-FAMILY 
derivatives O 
of O 
diaromatic O 
guanidines O 
with O 
potential O 
as O 
DNA O 
minor O 
groove O 
binders O 
and O 
antiprotozoal O 
activity O 
. O 
The O 
preparation O 
of O 
these O 
aminoalkyl B-FAMILY 
derivatives O 
( O 
12a-e O 
, O 
13a-e O 
, O 
14a-c,e O 
, O 
15a-e O 
, O 
16a-e O 
) O 
is O 
presented O 
as O 
well O 
as O 
their O 
affinity O 
for O 
DNA O 
which O 
was O 
evaluated O 
by O 
means O 
of O 
DNA O 
thermal O 
denaturation O 
experiments O 
. O 
Finally O 
, O 
the O 
antiprotozoal O 
activity O 
of O 
most O 
of O 
these O 
aminoalkyl B-FAMILY 
minor O 
groove O 
binders O 
was O 
evaluated O 
in O 
vitro O 
against O 
Trypanosoma O 
brucei O 
rhodesiense O 
( O 
8 O 
compounds O 
) O 
and O 
Plasmodium O 
falciparum O 
( O 
18 O 
compounds O 
) O 
. O 
The O 
O B-FORMULA 
-linked O 
derivatives O 
13c O 
and O 
14c O 
showed O 
100 O 
nM O 
activities O 
against O 
P O 
. O 
falciparum O 
, O 
whereas O 
for O 
T O 
. O 
b O 
. O 
rhodesiense O 
all O 
compounds O 
tested O 
showed O 
micromolar O 
activity O 
. O 
Some O 
of O 
the O 
derivatives O 
prepared O 
seem O 
to O 
exert O 
the O 
antimalarial O 
activity O 
by O 
binding O 
to O 
the O 
DNA O 
minor O 
groove O 
whereas O 
other O 
sets O 
of O 
compounds O 
could O 
exert O 
this O 
antimalarial O 
activity O 
by O 
inhibiting O 
the O 
parasite O 
dihydrofolate B-SYSTEMATIC 
reductase O 
, O 
for O 
example O 
. O 

linker O 
- O 
induced O 
dense O 
PEG B-ABBREVIATION 
conformation O 
improves O 
the O 
efficacy O 
of O 
C B-FORMULA 
-terminally O 
monoPEGylated O 
staphylokinase O 
. O 

can O 
improve O 
the O 
protein O 
efficacy O 
by O 
prolonging O 
serum O 
half O 
- O 
life O 
and O 
reducing O 
proteolytic O 
sensitivity O 
and O 
immunogenicity O 
. O 
However O 
, O 
PEGylation O 
may O 
decrease O 
the O 
bioactivity O 
of O 
a O 
protein O 
by O 
interfering O 
with O 
binding O 
of O 
its O 
substrate O 
or O 
receptors O 
. O 
Here O 
, O 
staphylokinase O 
( O 
SAK O 
) O 
, O 
a O 
thrombolysis O 
agent O 
for O 
therapy O 
of O 
myocardial O 
infarction O 
, O 
was O 
mono-PEGylated O 
at O 
the O 
C B-FORMULA 
-terminus O 
of O 
SAK O 
far O 
from O 
its O 
bioactive O 
domain O 
. O 
Phenyl B-SYSTEMATIC 
, O 
propyl B-SYSTEMATIC 
, O 
and O 
amyl B-SYSTEMATIC 
moieties O 
were O 
used O 
as O 
linkers O 
between O 
SAK O 
and O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
, O 
respectively O 
. O 
Flexible O 
propyl B-SYSTEMATIC 
and O 
amyl B-SYSTEMATIC 
linkers O 
lead O 
to O 
loose O 
conformation O 
. O 
In O 
contrast O 
, O 
rigid O 
and O 
hydrophobic O 
phenyl B-SYSTEMATIC 
linker O 
induces O 
dense O 
PEG B-ABBREVIATION 
conformation O 
that O 
can O 
extensively O 
shield O 
most O 
domains O 
adjacent O 
to O 
C B-FORMULA 
-terminus O 
( O 
e.g O 
. O 
, O 
the O 
antigen O 
epitopes O 
and O 
proteolytic O 
sites O 
) O 
of O 
SAK O 
and O 
inefficiently O 
shield O 
its O 
bioactive O 
domain O 
. O 
As O 
compared O 
with O 
loose O 
PEG B-ABBREVIATION 
conformation O 
, O 
dense O 
PEG B-ABBREVIATION 
conformation O 
is O 
more O 
efficient O 
to O 
maintain O 
the O 
bioactivity O 
, O 
increase O 
the O 
plasma O 
half O 
- O 
life O 
, O 
and O 
decrease O 
the O 
proteolytic O 
sensitivity O 
and O 
immunogenicity O 
of O 
the O 
PEGylated O 
SAK O 
. O 

probing O 
of O 
the O 
electronic O 
interaction O 
between O 
graphene B-TRIVIAL 
and O 
hexagonal O 
boron B-SYSTEMATIC 
nitride I-SYSTEMATIC 
. O 

weak O 
van O 
der O 
Waals O 
( O 
vdW O 
) O 
adhesion O 
between O 
two O 
- O 
dimensional O 
solids O 
may O 
perturb O 
their O 
various O 
materials O 
properties O 
owing O 
to O 
their O 
low O 
dimensionality O 
. O 
Although O 
the O 
electronic O 
structure O 
of O 
graphene B-TRIVIAL 
has O 
been O 
predicted O 
to O 
be O 
modified O 
by O 
the O 
vdW O 
interaction O 
with O 
other O 
materials O 
, O 
its O 
optical O 
characterization O 
has O 
not O 
been O 
successful O 
. O 
In O 
this O 
report O 
, O 
we O 
demonstrate O 
that O 
Raman O 
spectroscopy O 
can O 
be O 
utilized O 
to O 
detect O 
a O 
few O 
percent O 
decrease O 
in O 
the O 
Fermi O 
velocity O 
(v(F)) O 
of O 
graphene B-TRIVIAL 
caused O 
by O 
the O 
vdW O 
interaction O 
with O 
underlying O 
hexagonal O 
boron B-SYSTEMATIC 
nitride I-SYSTEMATIC 
( O 
hBN O 
) O 
. O 
Our O 
study O 
also O 
establishes O 
Raman O 
spectroscopic O 
analysis O 
which O 
enables O 
separation O 
of O 
the O 
effects O 
by O 
the O 
vdW O 
interaction O 
from O 
those O 
by O 
mechanical O 
strain O 
or O 
extra O 
charge O 
carriers O 
. O 
The O 
analysis O 
reveals O 
that O 
spectral O 
features O 
of O 
graphene B-TRIVIAL 
on O 
hBN O 
are O 
mainly O 
affected O 
by O 
change O 
in O 
v(F) O 
and O 
mechanical O 
strain O 
but O 
not O 
by O 
charge O 
doping O 
, O 
unlike O 
graphene B-TRIVIAL 
supported O 
on O 
SiO₂ B-FORMULA 
substrates O 
. O 
Graphene B-TRIVIAL 
on O 
hBN O 
was O 
also O 
found O 
to O 
be O 
less O 
susceptible O 
to O 
thermally O 
induced O 
hole O 
doping O 
. O 

flavaglines B-FAMILY 
and O 
other O 
constituents O 
isolated O 
from O 
Aglaia O 
perviridis O 
. O 

new O 
compounds O 
, O 
including O 
two O 
cyclopenta[b]benzopyran B-SYSTEMATIC 
derivatives O 
( O 
1 O 
, O 
2 O 
) O 
, O 
two O 
cyclopenta[b]benzofuran B-SYSTEMATIC 
derivatives O 
( O 
3 O 
, O 
4 O 
) O 
, O 
three O 
cycloartane B-FAMILY 
triterpenoids I-FAMILY 
( O 
5-7 O 
) O 
, O 
and O 
an O 
apocarotenoid O 
( O 
8 O 
) O 
, O 
together O 
with O 
16 O 
known O 
compounds O 
, O 
were O 
isolated O 
from O 
the O 
chloroform B-TRIVIAL 
-soluble O 
partitions O 
of O 
separate O 
methanol B-SYSTEMATIC 
extracts O 
of O 
a O 
combination O 
of O 
the O 
fruits O 
, O 
leaves O 
, O 
and O 
twigs O 
and O 
of O 
the O 
roots O 
of O 
Aglaia O 
perviridis O 
collected O 
in O 
Vietnam O 
. O 
Isolation O 
work O 
was O 
monitored O 
using O 
human O 
colon O 
cancer O 
cells O 
( O 
HT-29 O 
) O 
and O 
facilitated O 
with O 
an O 
LC O 
/ O 
MS O 
dereplication O 
procedure O 
. O 
The O 
structures O 
of O 
the O 
new O 
compounds O 
( O 
1-8 O 
) O 
were O 
determined O 
on O 
the O 
basis O 
of O 
spectroscopic O 
data O 
interpretation O 
. O 
The O 
Mosher O 
ester O 
method O 
was O 
employed O 
to O 
determine O 
the O 
absolute O 
configurations O 
of O 
5-7 O 
, O 
and O 
the O 
absolute O 
configuration O 
of O 
the O 
9,10- O 
diol B-SYSTEMATIC 
unit O 
of O 
compound O 
8 O 
was O 
established O 
by O 
a O 
dimolybdenum B-SYSTEMATIC 
tetraacetate I-SYSTEMATIC 
[ O 
Mo2(AcO)4 B-FORMULA 
] O 
induced O 
circular O 
dichroism O 
procedure O 
. O 
Seven O 
known O 
rocaglate B-TRIVIAL 
derivatives O 
( O 
9- O 
15 O 
) O 
exhibited O 
significant O 
cytotoxicity O 
against O 
the O 
HT-29 O 
cell O 
line O 
, O 
with O 
rocaglaol B-TRIVIAL 
( O 
9 O 
) O 
being O 
the O 
most O 
potent O 
( O 
ED50 O 
0.0007 O 
μM O 
) O 
. O 
The O 
new O 
compounds O 
2-4 O 
were O 
also O 
active O 
against O 
this O 
cell O 
line O 
, O 
with O 
ED50 O 
values O 
ranging O 
from O 
0.46 O 
to O 
4.7 O 
μM O 
. O 
The O 
cytotoxic O 
compounds O 
were O 
evaluated O 
against O 
a O 
normal O 
colon O 
cell O 
line O 
, O 
CCD-112CoN O 
. O 
In O 
addition O 
, O 
the O 
new O 
compound O 
perviridicin B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
, O 
three O 
known O 
rocaglate B-TRIVIAL 
derivatives O 
( O 
9 O 
, O 
11 O 
, O 
12 O 
) O 
, O 
and O 
a O 
known O 
sesquiterpene B-FAMILY 
, O 
2-oxaisodauc-5-en-12-al B-SYSTEMATIC 
( O 
17 O 
) O 
, O 
showed O 
significant O 
NF-κB O 
( O 
p65 O 
) O 
inhibitory O 
activity O 
in O 
an O 
ELISA O 
assay O 
. O 

powerful O 
aluminum B-SYSTEMATIC 
catalyst O 
for O 
the O 
synthesis O 
of O 
highly O 
functional O 
organic B-FAMILY 
carbonates I-FAMILY 
. O 

aluminum B-SYSTEMATIC 
complex O 
based O 
on O 
an O 
amino B-SYSTEMATIC 
triphenolate I-SYSTEMATIC 
ligand O 
scaffold O 
shows O 
unprecedented O 
high O 
activity O 
( O 
initial O 
TOFs O 
up O 
to O 
36000 O 
h(-1) O 
) O 
, O 
broad O 
substrate O 
scope O 
, O 
and O 
functional O 
group O 
tolerance O 
in O 
the O 
formation O 
of O 
highly O 
functional O 
organic B-FAMILY 
carbonates I-FAMILY 
prepared O 
from O 
epoxides B-FAMILY 
and O 
CO(2) B-FORMULA 
. O 
The O 
developed O 
catalytic O 
protocol O 
is O 
further O 
characterized O 
by O 
low O 
catalyst O 
loadings O 
and O 
relative O 
mild O 
reaction O 
conditions O 
using O 
a O 
cheap O 
, O 
abundant O 
, O 
and O 
nontoxic O 
metal O 
. O 

smoke O 
, O 
a O 
collection O 
of O 
many O 
toxic O 
chemicals O 
, O 
contributes O 
to O 
the O 
pathogenesis O 
of O 
smoking O 
- O 
related O 
diseases O 
such O 
as O 
chronic O 
obstructive O 
pulmonary O 
disease O 
and O 
cancer O 
. O 
Much O 
work O 
has O 
been O 
done O 
on O 
the O 
chemical O 
analysis O 
of O 
ingredients O 
in O 
cigarette O 
smoke O 
, O 
but O 
there O 
are O 
few O 
reports O 
on O 
the O 
active O 
ingredients O 
that O 
can O 
modify O 
biomolecules O 
. O 
We O 
used O 
a O 
sensitive O 
liquid O 
chromatography O 
- O 
mass O 
spectrometry O 
( O 
LC O 
/ O 
MS O 
) O 
and O 
LC O 
/ O 
MS O 
/ O 
MS O 
method O 
to O 
show O 
that O 
L-tyrosine B-TRIVIAL 
( O 
Tyr B-FORMULA 
) O 
, O 
an O 
amino B-FAMILY 
acid I-FAMILY 
with O 
a O 
highly O 
reactive O 
hydroxyl B-SYSTEMATIC 
group O 
, O 
readily O 
reacts O 
with O 
cigarette O 
smoke O 
extract O 
( O 
CSE O 
) O 
at O 
body O 
temperature O 
( O 
37°C O 
) O 
to O 
form O 
various O 
Tyr B-FORMULA 
derivatives O 
. O 
Among O 
these O 
derivatives O 
were O 
N-(3-oxobutyl)-Tyr B-SYSTEMATIC 
and O 
two O 
acetylated O 
compounds O 
, O 
N-acetyl-Tyr B-SYSTEMATIC 
and O 
O-acetyl-Tyr B-SYSTEMATIC 
, O 
which O 
were O 
synthesized O 
by O 
reaction O 
of O 
Tyr B-FORMULA 
with O 
methyl B-SYSTEMATIC 
vinyl I-SYSTEMATIC 
ketone I-SYSTEMATIC 
and O 
acetic B-SYSTEMATIC 
anhydride I-SYSTEMATIC 
, O 
respectively O 
, O 
at O 
37°C O 
. O 
The O 
presence O 
of O 
methyl B-SYSTEMATIC 
vinyl I-SYSTEMATIC 
ketone I-SYSTEMATIC 
and O 
acetic B-SYSTEMATIC 
anhydride I-SYSTEMATIC 
in O 
CSE O 
was O 
confirmed O 
by O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
( O 
GC O 
/ O 
MS O 
) O 
. O 
These O 
results O 
indicate O 
that O 
Tyr B-FORMULA 
can O 
easily O 
react O 
with O 
active O 
ingredients O 
in O 
CSE O 
. O 
The O 
present O 
analytical O 
methods O 
should O 
aid O 
the O 
search O 
for O 
active O 
ingredients O 
in O 
cigarette O 
smoke O 
. O 

A-E I-MULTIPLE 
: O 
five O 
new O 
dibenzocyclooctadiene B-FAMILY 
lignans I-FAMILY 
from O 
Schisandra O 
sphenanthera O 
. O 

new O 
dibenzocyclooctadiene B-FAMILY 
lignans I-FAMILY 
, O 
schisphenlignans B-MULTIPLE 
A-E I-MULTIPLE 
( O 
1-5 O 
) O 
, O 
together O 
with O 
eight O 
known O 
ones O 
, O 
were O 
isolated O 
from O 
the O 
stems O 
of O 
Schisandra O 
sphenanthera O 
. O 
The O 
structures O 
of O 
1-5 O 
were O 
elucidated O 
based O 
on O 
the O 
analysis O 
of O 
their O 
NMR O 
, O 
MS O 
and O 
circular O 
dichroism O 
( O 
CD O 
) O 
spectra O 
. O 
Some O 
isolates O 
were O 
tested O 
for O 
their O 
acute O 
activities O 
on O 
insulin O 
sensitivity O 
in O 
3T3-L1 O 
differentiated O 
adipocytes O 
, O 
but O 
none O 
of O 
them O 
showed O 
significant O 
bioactivity O 
with O 
10 O 
µM O 
administration O 
of O 
the O 
tested O 
compounds O 
. O 

spin O 
Hamiltonian O 
parameters O 
of O 
encapsulated O 
spin O 
- O 
labels O 
: O 
impact O 
of O 
the O 
hydrogen B-SYSTEMATIC 
bonding O 
topology O 
. O 

of O 
spin O 
- O 
labels O 
into O 
" O 
host O 
" O 
compounds O 
, O 
like O 
cucurbit[n]urils O 
or O 
cyclodextrins O 
, O 
in O 
solutions O 
has O 
profound O 
effects O 
on O 
the O 
EPR O 
spin O 
Hamiltonian O 
parameters O 
of O 
the O 
spin O 
- O 
labels O 
. O 
In O 
this O 
work O 
we O 
study O 
the O 
microscopic O 
origin O 
of O 
the O 
EPR O 
spin O 
Hamiltonian O 
parameters O 
of O 
spin O 
- O 
labels O 
enclosed O 
in O 
hydrophobic O 
cavities O 
. O 
We O 
focus O 
on O 
the O 
dependence O 
of O 
the O 
EPR O 
properties O 
of O 
encapsulated O 
spin O 
- O 
labels O 
on O 
the O 
hydrogen B-SYSTEMATIC 
bonding O 
topologies O 
that O 
occur O 
upon O 
encapsulation O 
, O 
and O 
quantize O 
various O 
contributions O 
to O 
these O 
parameters O 
according O 
to O 
specific O 
hydrogen B-SYSTEMATIC 
bonding O 
patterns O 
. O 
The O 
obtained O 
results O 
provide O 
refined O 
insight O 
into O 
the O 
role O 
of O 
the O 
hydrogen B-SYSTEMATIC 
bonding O 
induced O 
encapsulation O 
shifts O 
of O 
EPR O 
spin O 
Hamiltonian O 
parameters O 
in O 
solvated O 
" O 
spin-label@host O 
compound O 
" O 
complexes O 
. O 

johnsonii O 
inhibits O 
indoleamine B-SYSTEMATIC 
2,3-dioxygenase O 
and O 
alters O 
tryptophan B-TRIVIAL 
metabolite O 
levels O 
in O 
BioBreeding O 
rats O 
. O 

our O 
previous O 
work O 
, O 
we O 
found O 
that O 
feeding O 
Lactobacillus O 
johnsonii O 
to O 
BioBreeding O 
diabetes O 
- O 
prone O 
( O 
BBDP O 
) O 
rats O 
decreased O 
the O 
incidence O 
of O 
diabetes O 
development O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
host O 
pathways O 
affected O 
by O 
L O 
. O 
johnsonii O 
, O 
with O 
specific O 
focus O 
on O 
the O 
rate O 
- O 
limiting O 
enzyme O 
of O 
tryptophan B-TRIVIAL 
catabolism O 
, O 
indoleamine B-SYSTEMATIC 
2,3-dioxygenase O 
( O 
IDO O 
) O 
. O 
Suspensions O 
of O 
L O 
. O 
johnsonii O 
or O 
an O 
equal O 
volume O 
of O 
vehicle O 
were O 
orally O 
administered O 
to O 
BBDP O 
rats O 
. O 
Tissue O 
IDO O 
was O 
investigated O 
using O 
quantitative O 
RT-PCR O 
and O 
Western O 
blot O 
, O 
whereas O 
tryptophan B-TRIVIAL 
, O 
kynurenine B-TRIVIAL 
, O 
and O 
5-hydroxytryptamine B-SYSTEMATIC 
( O 
5-HT B-SYSTEMATIC 
) O 
concentrations O 
were O 
quantified O 
by O 
HPLC O 
and O 
ELISA O 
. O 
IDO O 
activity O 
was O 
also O 
investigated O 
using O 
L O 
. O 
johnsonii O 
culture O 
cell O 
- O 
free O 
supernatant O 
( O 
CFS O 
) O 
with O 
affinity O 
- O 
purified O 
IDO O 
and O 
HT-29 O 
intestinal O 
epithelial O 
cells O 
. O 
L O 
. O 
johnsonii O 
feeding O 
resulted O 
in O 
a O 
17% O 
reduction O 
in O 
serum O 
kynurenine B-TRIVIAL 
compared O 
with O 
that O 
in O 
vehicle O 
- O 
fed O 
controls O 
, O 
correlating O 
with O 
a O 
1.4-fold O 
elevation O 
in O 
5-HT B-SYSTEMATIC 
levels O 
. O 
H2O2 B-FORMULA 
produced O 
by O 
L O 
. O 
johnsonii O 
abolished O 
IDO O 
activity O 
in O 
vitro O 
, O 
and O 
L O 
. O 
johnsonii O 
feeding O 
resulted O 
in O 
a O 
3.9-fold O 
increase O 
in O 
ileum O 
lumen O 
H2O2 B-FORMULA 
. O 
L O 
. O 
johnsonii O 
CFS O 
significantly O 
reduced O 
IDO O 
activity O 
in O 
HT-29 O 
intestinal O 
epithelial O 
cells O 
( O 
47% O 
reduction O 
) O 
compared O 
with O 
that O 
in O 
vehicle O 
- O 
treated O 
controls O 
, O 
an O 
effect O 
abolished O 
by O 
catalase O 
treatment O 
. O 
These O 
data O 
support O 
the O 
role O 
of O 
H2O2 B-FORMULA 
in O 
commensal O 
bacteria O 
- O 
host O 
interactions O 
and O 
highlight O 
the O 
influence O 
of O 
commensal O 
bacteria O 
- O 
derived O 
H2O2 B-FORMULA 
on O 
host O 
physiology.-Valladares O 
, O 
R O 
. O 
, O 
Bojilova O 
, O 
L O 
. O 
, O 
Potts O 
, O 
A O 
. O 
H O 
. O 
, O 
Cameron O 
, O 
E O 
. O 
, O 
Gardner O 
, O 
C O 
. O 
, O 
Lorca O 
, O 
G O 
. O 
, O 
Gonzalez O 
, O 
C O 
. O 
F O 
. O 
Lactobacillus O 
johnsonii O 
inhibits O 
indoleamine B-SYSTEMATIC 
2,3-dioxygenase O 
and O 
alters O 
tryptophan B-TRIVIAL 
metabolite O 
levels O 
in O 
BioBreeding O 
rats O 
. O 

of O 
Pt B-FORMULA 
nanoparticles O 
induced O 
by O 
surface- O 
oxide B-SYSTEMATIC 
formation O 
. O 

density O 
functional O 
theory O 
( O 
DFT O 
) O 
and O 
thermodynamic O 
considerations O 
we O 
studied O 
the O 
equilibrium O 
shape O 
of O 
Pt B-FORMULA 
nanoparticles O 
( O 
NPs O 
) O 
under O 
electrochemical O 
conditions O 
. O 
We O 
found O 
that O 
at O 
very O 
high O 
oxygen B-SYSTEMATIC 
coverage O 
, O 
obtained O 
at O 
high O 
electrode O 
potentials O 
, O 
the O 
experimentally O 
- O 
observed O 
tetrahexahedral O 
( O 
THH O 
) O 
NPs O 
consist O 
of O 
high O 
- O 
index O 
( O 
520 O 
) O 
faces O 
. O 
Since O 
high O 
- O 
index O 
surfaces O 
often O 
show O 
higher O 
(electro-)chemical O 
activity O 
in O 
comparison O 
to O 
their O 
close O 
- O 
packed O 
counterparts O 
, O 
the O 
THH O 
NPs O 
can O 
be O 
promising O 
candidates O 
for O 
various O 
(electro-)catalytic O 
applications O 
. O 

catalytic O 
selectivity O 
of O 
supported O 
metal O 
nanoparticles O 
with O 
capping O 
ligands O 
is O 
demonstrated O 
using O 
an O 
Au B-FORMULA 
/ O 
SiO(2) B-FORMULA 
catalyst O 
in O 
liquid O 
phase O 
aerobic O 
oxidation O 
of O 
benzyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
. O 
Chemisorption O 
of O 
an O 
appropriate O 
amount O 
of O 
polyvinylpyrrolidone B-SYSTEMATIC 
on O 
the O 
Au B-FORMULA 
/ O 
SiO(2) B-FORMULA 
catalyst O 
greatly O 
enhances O 
the O 
benzaldehyde B-SYSTEMATIC 
selectivity O 
from O 
43% O 
to O 
~100% O 
and O 
its O 
yield O 
from O 
4.9% O 
to O 
7.2% O 
. O 

E- O 
and O 
H-field O 
control O 
of O 
microwave O 
performance O 
with O 
enhanced O 
ferromagnetic O 
resonance O 
( O 
FMR O 
) O 
tunability O 
has O 
been O 
demonstrated O 
in O 
microwave O 
composites O 
FeGaB B-FORMULA 
/ O 
PZN-PT B-ABBREVIATION 
( O 
11 O 
) O 
. O 
A O 
voltage O 
- O 
impulse O 
- O 
induced O 
non-volatile O 
magnetization O 
switching O 
was O 
also O 
realized O 
in O 
this O 
work O 
, O 
resulting O 
from O 
the O 
hysteretic O 
type O 
of O 
phase O 
transition O 
in O 
PZN-PT B-ABBREVIATION 
( O 
11 O 
) O 
at O 
high O 
electric O 
fields O 
. O 
The O 
results O 
provide O 
a O 
framework O 
for O 
developing O 
lightweight O 
, O 
energy O 
efficient O 
, O 
voltage O 
- O 
tunable O 
RF O 
/ O 
microwave O 
devices O 
. O 

bonding O 
: O 
an O 
interim O 
discussion O 
. O 

bonding O 
is O 
a O 
noncovalent O 
interaction O 
that O 
is O 
receiving O 
rapidly O 
increasing O 
attention O 
because O 
of O 
its O 
significance O 
in O 
biological O 
systems O 
and O 
its O 
importance O 
in O 
the O 
design O 
of O 
new O 
materials O 
in O 
a O 
variety O 
of O 
areas O 
, O 
for O 
example O 
, O 
electronics O 
, O 
nonlinear O 
optical O 
activity O 
, O 
and O 
pharmaceuticals O 
. O 
The O 
interactions O 
can O 
be O 
understood O 
in O 
terms O 
of O 
electrostatics O 
/ O 
polarization O 
and O 
dispersion O 
; O 
they O 
involve O 
a O 
region O 
of O 
positive O 
electrostatic O 
potential O 
on O 
a O 
covalently O 
bonded O 
halogen B-FAMILY 
and O 
a O 
negative O 
site O 
, O 
such O 
as O 
the O 
lone O 
pair O 
of O 
a O 
Lewis O 
base O 
. O 
The O 
positive O 
potential O 
, O 
labeled O 
a O 
σ O 
hole O 
, O 
is O 
on O 
the O 
extension O 
of O 
the O 
covalent O 
bond O 
to O 
the O 
halogen B-FAMILY 
, O 
which O 
accounts O 
for O 
the O 
characteristic O 
near O 
- O 
linearity O 
of O 
halogen B-FAMILY 
bonding O 
. O 
In O 
many O 
instances O 
, O 
the O 
lateral O 
sides O 
of O 
the O 
halogen B-FAMILY 
have O 
negative O 
electrostatic O 
potentials O 
, O 
allowing O 
it O 
to O 
also O 
interact O 
favorably O 
with O 
positive O 
sites O 
. O 
In O 
this O 
discussion O 
, O 
after O 
looking O 
at O 
some O 
of O 
the O 
experimental O 
observations O 
of O 
halogen B-FAMILY 
bonding O 
, O 
we O 
address O 
the O 
origins O 
of O 
σ O 
holes O 
, O 
the O 
factors O 
that O 
govern O 
the O 
magnitudes O 
of O 
their O 
electrostatic O 
potentials O 
, O 
and O 
the O 
properties O 
of O 
the O 
resulting O 
complexes O 
with O 
negative O 
sites O 
. O 
The O 
relationship O 
of O 
halogen B-FAMILY 
and O 
hydrogen B-SYSTEMATIC 
bonding O 
is O 
examined O 
. O 
We O 
also O 
point O 
out O 
that O 
σ-hole O 
interactions O 
are O 
not O 
limited O 
to O 
halogens B-FAMILY 
, O 
but O 
can O 
also O 
involve O 
covalently O 
bonded O 
atoms O 
of O 
Groups O 
IV-VI O 
. O 
Examples O 
of O 
applications O 
in O 
biological O 
/ O 
medicinal O 
chemistry O 
and O 
in O 
crystal O 
engineering O 
are O 
mentioned O 
, O 
taking O 
note O 
that O 
halogen B-FAMILY 
bonding O 
can O 
be O 
" O 
tuned O 
" O 
to O 
fit O 
various O 
requirements O 
, O 
that O 
is O 
, O 
strength O 
of O 
interaction O 
, O 
steric O 
factors O 
, O 
and O 
so O 
forth O 
. O 

( O 
RV O 
) O 
infection O 
is O 
the O 
main O 
cause O 
of O 
acute O 
dehydrating O 
diarrhea O 
in O 
infants O 
and O 
young O 
children O 
below O 
5 O 
years O 
old O 
worldwide O 
. O 
RV O 
infection O 
causes O 
a O 
global O 
shutoff O 
of O 
host O 
proteins O 
as O 
many O 
other O 
viruses O 
do O 
. O 
However O 
, O 
previous O 
studies O 
revealed O 
that O 
RV O 
could O 
selectively O 
upregulated O 
the O 
expression O 
of O 
some O 
host O 
proteins O 
that O 
then O 
played O 
important O 
roles O 
in O 
RV O 
infection O 
. O 
To O 
globally O 
explor O 
such O 
host O 
proteins O 
that O 
were O 
upregulated O 
in O 
early O 
human O 
rotavirus O 
( O 
HRV O 
) O 
infection O 
, O 
proteomic O 
methods O 
were O 
used O 
and O 
a O 
total O 
of O 
ten O 
upregulated O 
host O 
proteins O 
were O 
unambiguously O 
identified O 
. O 
Cyclophilin O 
A O 
( O 
CYPA O 
) O 
, O 
a O 
peptidyl- O 
prolyl B-TRIVIAL 
cis-trans O 
isomerase O 
, O 
was O 
among O 
these O 
upregulated O 
host O 
proteins O 
. O 
Following O 
infection O 
, O 
CYPA O 
was O 
recruited O 
to O 
the O 
viroplasm O 
and O 
interacted O 
with O 
HRV O 
structural O 
protein O 
VP2 O 
; O 
CYPA O 
reduced O 
host O 
susceptibility O 
to O 
HRV O 
infection O 
and O 
inhibited O 
replication O 
of O 
HRV O 
by O 
repressing O 
the O 
expression O 
of O 
viral O 
proteins O 
. O 
Furthermore O 
, O 
we O 
found O 
that O 
the O 
increased O 
expression O 
of O 
CYPA O 
in O 
enterocytes O 
of O 
small O 
intestine O 
correlated O 
to O 
the O 
period O 
when O 
BALB O 
/ O 
c O 
mice O 
became O 
resistant O 
to O 
RV O 
diarrhea O 
. O 
Together O 
, O 
we O 
identified O 
CYPA O 
as O 
a O 
novel O 
host O 
restriction O 
factor O 
that O 
confered O 
protection O 
against O 
RV O 
infection O 
and O 
might O 
contribute O 
to O 
host O 
susceptibility O 
to O 
RV O 
diarrhea O 
. O 

describe O 
a O 
new O 
class O 
of O 
fluorescent O 
reporter O 
and O 
its O 
employment O 
to O 
visualize O 
the O 
biotin B-TRIVIAL 
/ O 
avidin O 
binding O 
interaction O 
. O 
Derivatives O 
of O 
the O 
azamacrocycle O 
cyclam B-TRIVIAL 
that O 
contain O 
a O 
pendant O 
naphthalimide B-FAMILY 
dye O 
are O 
inherently O 
fluorescent O 
when O 
zinc B-SYSTEMATIC 
(II) I-SYSTEMATIC 
is O 
coordinated O 
. O 
Introducing O 
a O 
second O 
pendant O 
group-- O 
biotin B-TRIVIAL 
-- O 
affords O 
an O 
unsymmetrical O 
bis-triazole B-SYSTEMATIC 
-scorpionand O 
ligand O 
that O 
interacts O 
specifically O 
with O 
avidin O 
. O 
This O 
ligand O 
has O 
been O 
assembled O 
by O 
using O 
a O 
one O 
- O 
pot O 
" O 
double O 
- O 
click O 
" O 
strategy O 
and O 
complexed O 
with O 
copper B-SYSTEMATIC 
(II) I-SYSTEMATIC 
and O 
zinc B-SYSTEMATIC 
(II) I-SYSTEMATIC 
. O 
The O 
zinc B-SYSTEMATIC 
(II) I-SYSTEMATIC 
complex O 
is O 
fluorescent O 
, O 
and O 
its O 
fluorescence O 
output O 
changes O 
in O 
the O 
presence O 
of O 
avidin O 
. O 
Upon O 
avidin O 
binding O 
, O 
the O 
fluorescence O 
output O 
is O 
diminished O 
by O 
interaction O 
with O 
the O 
protein O 
, O 
at O 
[ O 
complex O 
] O 
/ O 
[ O 
avidin O 
] O 
ratios O 
of O 
up O 
to O 
4 O 
: O 
1 O 
. O 
The O 
observed O 
change O 
might O 
arise O 
from O 
a O 
specific O 
quenching O 
effect O 
in O 
the O 
biotin B-TRIVIAL 
binding O 
pocket O 
or O 
from O 
a O 
binding O 
- O 
induced O 
change O 
in O 
the O 
coordination O 
geometry O 
of O 
the O 
complex O 
. O 

catalysis O 
of O 
asymmetric O 
Michael O 
- O 
type O 
additions O 
of O 
linear O 
aldehydes B-FAMILY 
to O 
β-nitrostyrene B-SYSTEMATIC 
by O 
the O 
proline B-TRIVIAL 
-based O 
enzyme O 
4-oxalocrotonate B-SYSTEMATIC 
tautomerase O 
. O 

catalytic O 
promiscuity O 
: O 
The O 
proline B-TRIVIAL 
-based O 
enzyme O 
4-oxalocrotonate B-SYSTEMATIC 
tautomerase O 
( O 
4-OT B-SYSTEMATIC 
) O 
promiscuously O 
catalyzes O 
asymmetric O 
Michael O 
- O 
type O 
additions O 
of O 
linear O 
aldehydes B-FAMILY 
-- O 
ranging O 
from O 
acetaldehyde B-SYSTEMATIC 
to O 
octanal B-SYSTEMATIC 
-- O 
to O 
trans-β-nitrostyrene B-SYSTEMATIC 
in O 
aqueous O 
solvent O 
. O 
The O 
presence O 
of O 
1.4 O 
mol% O 
of O 
4-OT B-SYSTEMATIC 
effected O 
formation O 
of O 
the O 
anticipated O 
γ-nitroaldehydes B-FAMILY 
in O 
fair O 
to O 
good O 
yields O 
with O 
dr O 
values O 
of O 
up O 
to O 
93 O 
: O 
7 O 
and O 
ee O 
values O 
of O 
up O 
to O 
81 O 
% O 
. O 

application O 
of O 
an O 
ionic O 
liquid O 
carrying O 
the O 
fluoride B-SYSTEMATIC 
counter O 
- O 
ion O 
in O 
biomacromolecular O 
chemistry O 
: O 
microwave O 
- O 
assisted O 
acylation O 
of O 
cellulose O 
in O 
the O 
presence O 
of O 
1-allyl-3-methylimidazolium B-SYSTEMATIC 
fluoride I-SYSTEMATIC 
/ O 
DMSO B-ABBREVIATION 
mixtures O 
. O 

use O 
of O 
ionic O 
liquids O 
with O 
fluoride B-SYSTEMATIC 
anion O 
( O 
IL-F O 
) O 
is O 
challenging O 
because O 
of O 
side O 
reactions O 
. O 
Neat O 
1-allyl-3-methylimidazolium B-SYSTEMATIC 
fluoride I-SYSTEMATIC 
( O 
AlMeImF B-FORMULA 
) O 
is O 
used O 
as O 
a O 
solvent O 
in O 
microwave O 
- O 
assisted O 
acylation O 
of O 
cellulose O 
. O 
The O 
results O 
are O 
disappointing O 
due O 
to O 
side O 
reactions O 
in O 
the O 
IL O 
proper O 
, O 
and O 
F(-) B-FORMULA 
-mediated O 
hydrolysis O 
of O 
the O 
produced O 
ester B-FAMILY 
. O 
A O 
dramatic O 
improvement O 
is O 
observed O 
, O 
when O 
AlMeImF B-FORMULA 
/ O 
DMSO B-ABBREVIATION 
mixture O 
is O 
employed O 
. O 
The O 
results O 
are O 
comparable O 
to O 
those O 
obtained O 
when O 
pure O 
1-allyl-3-methylimidazolium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
is O 
employed O 
. O 
FTIR O 
spectroscopy O 
shows O 
that O 
dissolving O 
a O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
anhydride I-SYSTEMATIC 
in O 
IL-F O 
leads O 
to O 
the O 
formation O 
of O 
acyl B-FAMILY 
fluoride I-FAMILY 
. O 
Thus O 
ILs O 
are O 
far O 
from O 
being O 
" O 
spectator O 
" O 
solvents O 
. O 
The O 
new O 
approach O 
( O 
use O 
of O 
IL-F/ O 
DMSO B-ABBREVIATION 
) O 
is O 
attractive O 
because O 
of O 
its O 
efficiency O 
, O 
low O 
cost O 
, O 
and O 
applicability O 
to O 
the O 
derivatization O 
of O 
any O 
polymer O 
. O 

and O 
myocardial O 
activity O 
of O 
thaliporphine B-TRIVIAL 
N B-FORMULA 
-homologues O 
. O 

N B-FORMULA 
-homologues O 
and O 
optical O 
isomers O 
of O 
thaliporphine B-TRIVIAL 
( O 
5a O 
) O 
, O 
a O 
potent O 
antiarrhythmic O 
agent O 
, O 
were O 
prepared O 
starting O 
from O 
laurolitsine B-TRIVIAL 
( O 
1 O 
) O 
, O 
an O 
abundant O 
aporphine B-FAMILY 
present O 
in O 
Phoebe O 
formosana O 
. O 
Treating O 
N-propylnorglaucine B-SYSTEMATIC 
with O 
90% O 
H2SO4 B-FORMULA 
yielded O 
one O 
additional O 
product O 
, O 
an O 
11-sulfonyl-1,11-anhydroaporphine B-SYSTEMATIC 
. O 
Reaction O 
of O 
N- B-SYSTEMATIC 
formylnorglaucine I-SYSTEMATIC 
( O 
3a O 
) O 
with O 
90% O 
H2SO4 B-FORMULA 
, O 
however O 
, O 
yielded O 
the O 
9-sulfonyl-seco B-SYSTEMATIC 
product O 
as O 
a O 
major O 
product O 
. O 
Treatment O 
of O 
3a O 
with O 
98% O 
H2SO4 B-FORMULA 
yielded O 
pancordine O 
( O 
10 O 
) O 
, O 
which O 
, O 
upon O 
catalytic O 
hydrogenation O 
, O 
yielded O 
(±)-wilsonirine B-TRIVIAL 
. O 
(1)H B-FORMULA 
NMR O 
spectroscopic O 
analysis O 
was O 
applied O 
successfully O 
to O 
monitor O 
the O 
optical O 
purity O 
of O 
the O 
crystalline O 
salt O 
while O 
undertaking O 
optical O 
resolution O 
. O 
Thaliporphine B-TRIVIAL 
( O 
5a O 
) O 
was O 
demonstrated O 
to O 
possess O 
better O 
positive O 
inotropic O 
and O 
less O 
negative O 
chronotropic O 
effects O 
than O 
the O 
left O 
- O 
hand O 
optical O 
isomer O 
and O 
showed O 
the O 
best O 
activity O 
on O 
rat O 
cardiac O 
tissue O 
among O 
the O 
N B-FORMULA 
-homologues O 
prepared O 
. O 

transformations O 
of O 
Bioglass B-TRIVIAL 
45S5 I-TRIVIAL 
during O 
scaffold O 
synthesis O 
for O 
bone O 
tissue O 
engineering O 
. O 

physiological O 
fluid O 
, O 
a O 
layer O 
of O 
hydroxycarbonate B-SYSTEMATIC 
apatite I-SYSTEMATIC 
, O 
similar O 
to O 
bone O 
mineral O 
, O 
develops O 
on O 
the O 
surface O 
of O 
Bioglass B-TRIVIAL 
45S5 I-TRIVIAL 
. O 
Collagen O 
from O 
the O 
surrounding O 
tissue O 
is O 
adsorbed O 
on O 
this O 
layer O 
that O 
attracts O 
osteoblasts O 
, O 
and O 
favors O 
bone O 
regrowth O 
. O 
Bioglass O 
is O 
therefore O 
an O 
osteoinductive O 
material O 
. O 
Still O 
, O 
due O 
to O 
its O 
brittleness O 
, O 
the O 
glass O 
alone O 
cannot O 
be O 
used O 
to O 
heal O 
large O 
bone O 
defects O 
. O 
To O 
overcome O 
this O 
issue O 
, O 
Bioglass O 
is O 
used O 
to O 
form O 
a O 
composite O 
scaffold O 
with O 
poly(D,L-lactide) B-SYSTEMATIC 
( O 
PDLLA B-ABBREVIATION 
) O 
, O 
a O 
biodegradable O 
polymer O 
. O 
The O 
goal O 
of O 
this O 
work O 
is O 
to O 
understand O 
Bioglass O 
reactivity O 
throughout O 
scaffold O 
fabrication O 
via O 
a O 
low O 
- O 
temperature O 
route O 
, O 
the O 
solvent O 
casting O 
and O 
particulate O 
leaching O 
technique O 
. O 
Changes O 
in O 
Bioglass O 
( O 
especially O 
its O 
surface O 
) O 
are O 
susceptible O 
to O 
occur O 
both O 
while O 
in O 
contact O 
with O 
the O 
processing O 
fluids O 
and O 
potentially O 
through O 
a O 
reaction O 
with O 
the O 
surrounding O 
polymeric O 
matrix O 
. O 
Here O 
we O 
analyzed O 
the O 
surface O 
changes O 
of O 
three O 
different O 
Bioglass O 
samples O 
: O 
(i) O 
as-received O 
, O 
(ii) O 
treated O 
in O 
solutions O 
that O 
parallel O 
those O 
used O 
in O 
scaffold O 
fabrication O 
, O 
and O 
(iii) O 
extracted O 
from O 
the O 
scaffolds O 
. O 
We O 
showed O 
that O 
extracted O 
, O 
just O 
like O 
treated O 
, O 
Bioglass O 
deviates O 
from O 
the O 
as-received O 
, O 
but O 
to O 
a O 
larger O 
extent O 
. O 
X-ray O 
photoelectron O 
and O 
infrared O 
spectroscopy O 
support O 
the O 
theory O 
that O 
Bioglass O 
surface O 
was O 
modified O 
not O 
just O 
through O 
contact O 
with O 
the O 
solutions O 
in O 
scaffold O 
fabrication O 
, O 
but O 
upon O 
an O 
interaction O 
with O 
the O 
polymeric O 
matrix O 
. O 
The O 
polymer O 
network O 
slows O 
down O 
the O 
Na(+) B-FORMULA 
/ O 
H(+) B-FORMULA 
exchange O 
between O 
Bioglass O 
and O 
water O 
used O 
to O 
leach O 
salt O 
particles O 
to O 
create O 
pores O 
within O 
the O 
scaffold O 
. O 
Changes O 
in O 
surface O 
properties O 
affect O 
the O 
bioactivity O 
of O 
Bioglass O 
and O 
thus O 
of O 
the O 
composite O 
scaffolds O 
, O 
and O 
are O 
therefore O 
critical O 
to O 
identify O 
. O 

demonstrate O 
an O 
excitation O 
transfer O 
along O 
a O 
fluorescently O 
labeled O 
dsDNA O 
nanowire O 
over O 
a O 
length O 
of O 
several O 
micrometers O 
. O 
Launching O 
of O 
the O 
excitation O 
is O 
done O 
by O 
exciting O 
a O 
localized O 
surface O 
plasmon O 
mode O 
of O 
a O 
40 O 
nm O 
silver B-SYSTEMATIC 
nanoparticle O 
by O 
800 O 
nm O 
femtosecond O 
laser O 
pulses O 
via O 
two O 
- O 
photon O 
absorption O 
. O 
The O 
plasmonic O 
mode O 
is O 
subsequently O 
coupled O 
or O 
transformed O 
to O 
excitation O 
in O 
the O 
nanowire O 
in O 
contact O 
with O 
the O 
particle O 
and O 
propagated O 
along O 
it O 
, O 
inducing O 
bleaching O 
of O 
the O 
dyes O 
on O 
its O 
way O 
. O 
In O 
situ O 
as O 
well O 
as O 
ex O 
situ O 
fluorescence O 
microscopy O 
is O 
utilized O 
to O 
observe O 
the O 
phenomenon O 
. O 
In O 
addition O 
, O 
transfer O 
of O 
the O 
excitation O 
along O 
the O 
nanowire O 
to O 
another O 
nanoparticle O 
over O 
a O 
separation O 
of O 
5.7 O 
μm O 
was O 
clearly O 
observed O 
. O 
The O 
nature O 
of O 
the O 
excitation O 
coupling O 
and O 
transfer O 
could O 
not O 
be O 
fully O 
resolved O 
here O 
, O 
but O 
injection O 
of O 
an O 
electron O 
into O 
the O 
DNA O 
from O 
the O 
excited O 
nanoparticle O 
and O 
subsequent O 
coupled O 
transfer O 
of O 
charge O 
( O 
Dexter O 
) O 
and O 
delocalized O 
exciton O 
( O 
Frenkel O 
) O 
is O 
the O 
most O 
probable O 
mechanism O 
. O 
However O 
, O 
a O 
direct O 
plasmonic O 
or O 
optical O 
coupling O 
and O 
energy O 
transfer O 
along O 
the O 
nanowire O 
cannot O 
be O 
totally O 
ruled O 
out O 
either O 
. O 
By O 
further O 
studies O 
the O 
observed O 
phenomenon O 
could O 
be O 
utilized O 
in O 
novel O 
molecular O 
systems O 
, O 
providing O 
a O 
long O 
- O 
needed O 
communication O 
method O 
between O 
molecular O 
devices O 
. O 

, O 
metabolism O 
, O 
and O 
excretion O 
of O 
the O 
glycogen O 
synthase O 
kinase-3 O 
inhibitor O 
LY2090314 B-IDENTIFIER 
in O 
rats O 
, O 
dogs O 
, O 
and O 
humans O 
: O 
a O 
case O 
study O 
in O 
rapid O 
clearance O 
by O 
extensive O 
metabolism O 
with O 
low O 
circulating O 
metabolite O 
exposure O 
. O 

( O 
3-[9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indol-7-yl]-4-imidazo[1,2-a]pyridin-3-yl-1H-pyrrole-2,5-dione B-SYSTEMATIC 
) O 
is O 
an O 
intravenous O 
glycogen O 
synthase O 
kinase-3 O 
inhibitor O 
in O 
oncology O 
trials O 
. O 
Drug O 
disposition O 
was O 
characterized O 
after O 
intravenous O 
infusion O 
of O 
[(14)C]LY2090314 B-SYSTEMATIC 
to O 
rats O 
and O 
dogs O 
, O 
and O 
was O 
related O 
to O 
available O 
clinical O 
data O 
. O 
LY2090314 B-IDENTIFIER 
exhibited O 
high O 
clearance O 
( O 
approximating O 
hepatic O 
blood O 
flow O 
) O 
and O 
a O 
moderate O 
volume O 
of O 
distribution O 
( O 
∼1-2 O 
l O 
/ O 
kg O 
) O 
resulting O 
in O 
rapid O 
elimination O 
( O 
half O 
- O 
life O 
∼0.4 O 
, O 
0.7 O 
, O 
and O 
1.8-3.4 O 
hours O 
in O 
rats O 
, O 
dogs O 
, O 
and O 
humans O 
, O 
respectively O 
) O 
. O 
Scaled O 
clearance O 
from O 
liver O 
microsomes O 
accurately O 
predicted O 
perfusion O 
- O 
limited O 
clearance O 
across O 
species O 
. O 
LY2090314 B-IDENTIFIER 
was O 
cleared O 
by O 
extensive O 
metabolism O 
, O 
and O 
the O 
numerous O 
metabolites O 
were O 
rapidly O 
excreted O 
into O 
feces O 
via O 
bile O 
( O 
69-97% O 
of O 
dose O 
; O 
62-93% O 
within O 
0-24 O 
hours O 
) O 
; O 
urinary O 
recovery O 
of O 
drug O 
- O 
related O 
material O 
was O 
low O 
( O 
≤ O 
3% O 
of O 
dose O 
) O 
. O 
Despite O 
extensive O 
metabolism O 
, O 
in O 
rats O 
and O 
humans O 
the O 
parent O 
compound O 
was O 
the O 
sole O 
identifiable O 
drug O 
- O 
related O 
moiety O 
in O 
plasma O 
. O 
Even O 
in O 
Mdr1a- O 
, O 
Bcrp- O 
, O 
and O 
Mrp2-knockout O 
rats O 
, O 
LY2090314 B-IDENTIFIER 
metabolites O 
did O 
not O 
appear O 
in O 
circulation O 
, O 
and O 
their O 
urinary O 
excretion O 
was O 
not O 
enhanced O 
, O 
because O 
the O 
hypothesized O 
impaired O 
biliary O 
excretion O 
of O 
metabolites O 
in O 
the O 
absence O 
of O 
these O 
canalicular O 
transporters O 
was O 
not O 
observed O 
. O 
Canine O 
metabolite O 
disposition O 
was O 
generally O 
similar O 
, O 
with O 
the O 
notable O 
exception O 
of O 
dog O 
- O 
unique O 
LY2090314 B-IDENTIFIER 
glucuronide I-IDENTIFIER 
. O 
This O 
conjugate O 
was O 
formed O 
in O 
the O 
dog O 
liver O 
and O 
was O 
preferentially O 
excreted O 
into O 
the O 
blood O 
, O 
where O 
it O 
accounted O 
for O 
the O 
majority O 
of O 
circulating O 
radioactivity O 
at O 
later O 
times O 
, O 
and O 
was O 
predominantly O 
recovered O 
in O 
urine O 
( O 
16% O 
of O 
dose O 
) O 
. O 
In O 
conclusion O 
, O 
LY2090314 B-IDENTIFIER 
was O 
rapidly O 
cleared O 
by O 
extensive O 
metabolism O 
with O 
negligible O 
circulating O 
metabolite O 
exposures O 
due O 
to O 
biliary O 
excretion O 
of O 
metabolites O 
into O 
feces O 
with O 
no O 
apparent O 
intestinal O 
reabsorption O 
. O 

new O 
phenolic B-FAMILY 
compounds O 
from O 
the O 
roots O 
of O 
Glycyrrhiza O 
yunnanensis O 
. O 

new O 
phenolic B-FAMILY 
compounds O 
( O 
1-3 O 
) O 
, O 
together O 
with O 
16 O 
known O 
compounds O 
( O 
4-19 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
roots O 
of O 
Glycyrrhiza O 
yunnanensis O 
Cheng O 
f O 
. O 
et O 
L O 
. O 
K O 
. O 
Dai O 
. O 
On O 
the O 
basis O 
of O 
1D O 
and O 
2D O 
NMR O 
, O 
HR-ESI-MS O 
, O 
and O 
circular O 
dichroism O 
( O 
CD O 
) O 
spectroscopic O 
analysis O 
, O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
elucidated O 
as O 
2-(2'-methoxy-4'-hydroxy)-aryl-3-methy-6-hydroxy-benzofuran B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
(2S)-6,7-(2,2-dimethyldihydropyrano)-8-prenyl-4'-hydroxyflavanone B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
and O 
6-prenyl-7,3',4'-trihydroxyflavone B-SYSTEMATIC 
( O 
3 O 
) O 
. O 
Compounds O 
1 O 
, O 
3 O 
, O 
5 O 
, O 
12 O 
, O 
14 O 
, O 
15 O 
and O 
16 O 
showed O 
antioxidant O 
activity O 
by O 
an O 
ABTS B-ABBREVIATION 
-based O 
assay O 
. O 

factor O 
NF-E2 O 
- O 
related O 
factor O 
2 O 
( O 
NRF2 O 
) O 
plays O 
a O 
crucial O 
role O 
in O 
the O 
cellular O 
defense O 
against O 
oxidative O 
/ O 
electrophilic O 
stress O 
by O 
up O 
- O 
regulating O 
multiple O 
antioxidant O 
genes O 
. O 
Numerous O 
studies O 
with O 
genetically O 
modified O 
animals O 
have O 
demonstrated O 
that O 
Nrf2 O 
is O 
a O 
sensitivity O 
determining O 
factor O 
upon O 
the O 
exposure O 
to O 
environmental O 
chemicals O 
including O 
carcinogens O 
. O 
Moreover O 
, O 
recent O 
studies O 
have O 
demonstrated O 
that O 
polymorphism O 
in O 
the O 
human O 
NRF2 O 
promoter O 
is O 
associated O 
with O 
higher O 
risks O 
for O 
developing O 
acute O 
lung O 
injury O 
, O 
gastric O 
mucosal O 
inflammation O 
, O 
and O 
nephritis O 
. O 
Therefore O 
, O 
the O 
identification O 
of O 
reliable O 
and O 
effective O 
human O 
target O 
genes O 
of O 
NRF2 O 
may O 
allow O 
the O 
monitoring O 
of O 
NRF2 O 
activity O 
and O 
to O 
predict O 
individual O 
sensitivity O 
to O 
environmental O 
stress O 
- O 
induced O 
damage O 
. O 
For O 
this O 
purpose O 
, O 
we O 
investigated O 
genes O 
that O 
are O 
tightly O 
controlled O 
by O 
NRF2 O 
to O 
establish O 
markers O 
for O 
NRF2 O 
activity O 
in O 
human O 
cells O 
. O 
Firstly O 
, O 
in O 
the O 
normal O 
human O 
renal O 
epithelial O 
HK-2 O 
cells O 
, O 
the O 
measurement O 
of O 
the O 
expression O 
of O 
30 O 
previously O 
reported O 
NRF2 O 
target O 
genes O 
in O 
response O 
to O 
NRF2 O 
inducers O 
( O 
sulforaphane B-TRIVIAL 
, O 
tert-butylhydroquinone B-SYSTEMATIC 
, O 
cinnamic B-TRIVIAL 
aldehyde I-TRIVIAL 
, O 
and O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
) O 
showed O 
that O 
the O 
aldo O 
- O 
keto O 
reductase O 
( O 
AKR O 
) O 
1C1 O 
is O 
highly O 
inducible O 
by O 
all O 
treatments O 
. O 
Accordantly O 
, O 
the O 
basal O 
and O 
inducible O 
expressions O 
of O 
AKRs O 
were O 
significantly O 
attenuated O 
in O 
NRF2-silenced O 
HK-2 O 
cells O 
. O 
Whereas O 
, O 
cells O 
with O 
stable O 
KEAP1 O 
knockdown O 
, O 
which O 
causes O 
a O 
modest O 
NRF2 O 
activation O 
, O 
demonstrated O 
substantially O 
increased O 
levels O 
of O 
AKR1A1 O 
, O 
1B1 O 
, O 
1B10 O 
, O 
1C1 O 
, O 
1C2 O 
, O 
and O 
1C3 O 
. O 
Secondly O 
, O 
the O 
linkage O 
between O 
NRF2 O 
and O 
the O 
AKRs O 
was O 
confirmed O 
in O 
human O 
monocytic O 
leukemia O 
cell O 
line O 
U937 O 
, O 
which O 
can O 
be O 
a O 
model O 
of O 
peripherally O 
available O 
blood O 
cells O 
. O 
The O 
treatment O 
of O 
U937 O 
cells O 
with O 
NRF2 O 
inducers O 
including O 
sulforaphane B-TRIVIAL 
effectively O 
elevated O 
the O 
expression O 
of O 
AKR1B1 O 
, O 
1B10 O 
, O 
1C1 O 
, O 
1C2 O 
, O 
and O 
1C3 O 
. O 
Whereas O 
, O 
the O 
levels O 
of O 
both O 
the O 
basal O 
and O 
sulforaphane B-TRIVIAL 
-inducible O 
expression O 
of O 
AKR1C1 O 
were O 
significantly O 
reduced O 
in O 
NRF2-silenced O 
stable O 
U937 O 
cells O 
compared O 
to O 
the O 
control O 
cells O 
. O 
Similarly O 
, O 
the O 
inducible O 
expression O 
of O 
AKR1C1 O 
was O 
observed O 
in O 
another O 
human O 
monocytic O 
leukemia O 
cell O 
line O 
THP-1 O 
as O 
well O 
as O 
in O 
human O 
primary O 
blood O 
CD14(+) O 
monocytes O 
. O 
In O 
conclusion O 
, O 
together O 
with O 
the O 
high O 
inducibility O 
and O 
NRF2 O 
dependency O 
shown O 
in O 
renal O 
epithelial O 
cells O 
as O 
well O 
as O 
in O 
peripherally O 
available O 
blood O 
cells O 
, O 
current O 
findings O 
suggest O 
that O 
AKRs O 
can O 
be O 
utilized O 
as O 
a O 
marker O 
of O 
NRF2 O 
activity O 
in O 
human O 
cells O 
. O 

dysfunction O 
contributes O 
to O 
the O 
cytotoxicity O 
of O 
some O 
3,5-bis(benzylidene)-4-piperidone B-SYSTEMATIC 
derivatives O 
in O 
colon O 
HCT-116 O 
cells O 
. O 

objectives O 
of O 
this O 
study O 
are O 
to O 
investigate O 
the O 
possible O 
ways O 
by O 
which O 
the O 
curcumin O 
analogs O 
2a O 
and O 
2b O 
exert O 
their O 
antiproliferative O 
properties O 
. O 
The O 
analogs O 
2a O 
and O 
2b O 
have O 
submicromolar O 
IC(50) O 
values O 
towards O 
human O 
HCT-116 O 
colon O 
cancer O 
cells O 
but O 
are O 
far O 
less O 
toxic O 
to O 
human O 
non-malignant O 
CRL-1790 O 
colon O 
cells O 
. O 
Both O 
compounds O 
affected O 
a O 
number O 
of O 
mitochondrial O 
functions O 
in O 
HCT-116 O 
cells O 
namely O 
increasing O 
the O 
intracellular O 
concentrations O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
inhibiting O 
oxygen B-SYSTEMATIC 
consumption O 
and O 
decreasing O 
the O 
mitochondrial O 
membrane O 
potential O 
. O 
These O 
molecules O 
also O 
produced O 
swelling O 
of O 
isolated O 
rat O 
liver O 
mitochondria O 
, O 
supporting O 
a O 
mitochondrial O 
mechanism O 
of O 
cytotoxicity O 
. O 
Both O 
compounds O 
reacted O 
with O 
glutathione B-TRIVIAL 
in O 
the O 
presence O 
of O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
π O 
and O 
hence O 
they O 
may O 
be O 
classified O 
as O 
thiol B-FAMILY 
alkylators O 
. O 

of O 
apigenin B-TRIVIAL 
nanocrystals O 
using O 
supercritical O 
antisolvent O 
process O 
for O 
dissolution O 
and O 
bioavailability O 
enhancement O 
. O 

aim O 
of O 
the O 
study O 
was O 
to O 
investigate O 
the O 
potential O 
of O 
nanocrystals O 
to O 
enhance O 
the O 
oral O 
bioavailability O 
of O 
apigenin B-TRIVIAL 
( O 
AP O 
) O 
, O 
a O 
bioactive O 
flavonoid B-FAMILY 
with O 
various O 
pharmacological O 
activities O 
but O 
poor O 
aqueous O 
solubility O 
. O 
In O 
the O 
present O 
investigation O 
, O 
the O 
AP O 
nanocrystals O 
were O 
prepared O 
by O 
the O 
supercritical O 
antisolvent O 
process O 
. O 
In O 
vitro O 
characterization O 
was O 
performed O 
by O 
scanning O 
electron O 
microscopy O 
, O 
FT-IR O 
, O 
differential O 
scanning O 
calorimetry O 
, O 
X-ray O 
powder O 
diffractometry O 
. O 
In O 
vitro O 
dissolution O 
of O 
prepared O 
nanocrystals O 
was O 
studied O 
and O 
compared O 
with O 
untreated O 
coarse O 
powder O 
. O 
In O 
addition O 
, O 
the O 
pharmacokinetic O 
study O 
of O 
AP O 
nanocrystals O 
, O 
in O 
comparison O 
to O 
coarse O 
powder O 
, O 
was O 
also O 
performed O 
in O 
rats O 
after O 
a O 
single O 
oral O 
dose O 
. O 
The O 
prepared O 
AP O 
nanocrystals O 
, O 
without O 
change O 
in O 
crystalline O 
structure O 
, O 
appeared O 
in O 
spherical O 
shape O 
with O 
particle O 
size O 
of O 
about O 
400-800 O 
nm O 
. O 
The O 
reduction O 
of O 
particle O 
size O 
resulted O 
in O 
a O 
more O 
rapid O 
dissolution O 
of O 
AP O 
from O 
nanocrystals O 
than O 
from O 
coarse O 
powder O 
. O 
In O 
comparison O 
to O 
coarse O 
powder O 
, O 
AP O 
nanocrystals O 
exhibited O 
a O 
significantly O 
decreased O 
t(max) O 
, O 
a O 
3.6-fold O 
higher O 
peak O 
plasma O 
concentration O 
(C(max)) O 
and O 
3.4-fold O 
higher O 
area O 
under O 
the O 
curve O 
( O 
AUC O 
) O 
. O 

of O 
tris(1,3-dichloro-2-propyl) B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
and O 
triphenyl B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
on O 
receptor O 
- O 
associated O 
mRNA O 
expression O 
in O 
zebrafish O 
embryos O 
/ O 
larvae O 
. O 

phosphate I-SYSTEMATIC 
( O 
TDCPP B-ABBREVIATION 
) O 
and O 
triphenyl B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
( O 
TPP B-ABBREVIATION 
) O 
are O 
frequently O 
detected O 
in O 
biota O 
, O 
including O 
fish O 
. O 
However O 
, O 
knowledge O 
of O 
the O 
toxicological O 
and O 
molecular O 
effects O 
of O 
these O 
currently O 
used O 
flame O 
retardants O 
is O 
limited O 
. O 
In O 
the O 
present O 
study O 
, O 
an O 
in O 
vivo O 
screening O 
approach O 
was O 
developed O 
to O 
evaluate O 
effects O 
of O 
TDCPP B-ABBREVIATION 
and O 
TPP B-ABBREVIATION 
on O 
developmental O 
endpoints O 
and O 
receptor O 
- O 
associated O 
expression O 
of O 
mRNA O 
in O 
zebrafish O 
embryos O 
/ O 
larvae O 
. O 
Exposure O 
to O 
TDCPP B-ABBREVIATION 
or O 
TPP B-ABBREVIATION 
resulted O 
in O 
significantly O 
smaller O 
rates O 
of O 
hatching O 
and O 
survival O 
, O 
in O 
dose- O 
and O 
time O 
- O 
dependent O 
manners O 
. O 
The O 
median O 
lethal O 
concentration O 
(LC(50)) O 
was O 
7 O 
mg O 
/ O 
L O 
for O 
TDCPP B-ABBREVIATION 
and O 
29.6 O 
mg O 
/ O 
L O 
for O 
TPP B-ABBREVIATION 
at O 
120 O 
hour O 
post O 
- O 
fertilization O 
( O 
hpf O 
) O 
. O 
Real O 
- O 
time O 
PCR O 
revealed O 
alterations O 
in O 
expression O 
of O 
mRNAs O 
involved O 
in O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptors O 
(AhRs)- O 
, O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
alpha O 
(PPARα)- O 
, O 
estrogenic O 
receptors O 
(ERs)- O 
, O 
thyroid B-FAMILY 
hormone I-FAMILY 
receptor O 
alpha O 
(TRα)- O 
, O 
glucocorticoid O 
receptor O 
(GR)- O 
, O 
and O 
mineralocorticoid O 
receptor O 
(MR)-centered O 
gene O 
networks O 
. O 
Exposure O 
to O 
positive O 
control O 
chemicals O 
significantly O 
altered O 
abundances O 
of O 
mRNA O 
in O 
corresponding O 
receptor O 
- O 
centered O 
gene O 
networks O 
, O 
a O 
result O 
that O 
suggests O 
that O 
it O 
is O 
feasible O 
to O 
use O 
zebrafish O 
embryos O 
/ O 
larvae O 
to O 
evaluate O 
effects O 
of O 
chemicals O 
on O 
mRNA O 
expression O 
in O 
these O 
gene O 
networks O 
. O 
Exposure O 
to O 
TDCPP B-ABBREVIATION 
altered O 
transcriptional O 
profiles O 
in O 
all O 
six O 
receptor O 
- O 
centered O 
gene O 
networks O 
, O 
thus O 
exerting O 
multiple O 
toxic O 
effects O 
. O 
TPP B-ABBREVIATION 
was O 
easily O 
metabolized O 
and O 
its O 
potency O 
to O 
change O 
expression O 
of O 
mRNA O 
involved O 
in O 
receptor O 
- O 
centered O 
gene O 
networks O 
was O 
weaker O 
than O 
that O 
of O 
TDCPP B-ABBREVIATION 
. O 
The O 
PPARα- O 
and O 
TRα-centered O 
gene O 
networks O 
might O 
be O 
the O 
primary O 
pathways O 
affected O 
by O 
TPP B-ABBREVIATION 
. O 
Taken O 
together O 
, O 
these O 
results O 
demonstrated O 
that O 
TDCPP B-ABBREVIATION 
and O 
TPP B-ABBREVIATION 
could O 
alter O 
mRNA O 
expression O 
of O 
genes O 
involved O 
in O 
the O 
six O 
receptor O 
- O 
centered O 
gene O 
networks O 
in O 
zebrafish O 
embryos O 
/ O 
larvae O 
, O 
and O 
TDCPP B-ABBREVIATION 
seemed O 
to O 
have O 
higher O 
potency O 
in O 
changing O 
the O 
mRNA O 
expression O 
of O 
these O 
genes O 
. O 

composition O 
of O 
Chlorella O 
vulgaris O 
( O 
Trebouxiophyceae O 
) O 
as O 
a O 
function O 
of O 
different O 
cadmium B-SYSTEMATIC 
and O 
phosphate B-SYSTEMATIC 
concentrations O 
. O 

acids I-FAMILY 
are O 
the O 
fundamental O 
structural O 
components O 
of O 
membrane O 
lipids O 
, O 
and O 
the O 
degree O 
of O 
saturation O 
of O 
the O 
long O 
hydrocarbon B-FAMILY 
chains O 
in O 
microalgae O 
contributes O 
to O 
regulation O 
of O 
growth O 
, O 
biomass O 
production O 
and O 
reproduction O 
of O 
aquatic O 
consumers O 
. O 
This O 
research O 
aimed O 
at O 
evaluating O 
the O 
effects O 
of O 
cadmium B-SYSTEMATIC 
( O 
2×10(-8) O 
; O 
10(-7) O 
mol O 
L(-1) O 
Cd B-FORMULA 
) O 
on O 
lipid O 
class O 
and O 
fatty B-FAMILY 
acid I-FAMILY 
composition O 
of O 
the O 
microalga O 
Chlorella O 
vulgaris O 
under O 
varying O 
phosphate B-SYSTEMATIC 
( O 
PO(4)(3-) B-FORMULA 
) O 
concentrations O 
( O 
6.0×10(-7) O 
to O 
2.3×10(-4) O 
mol O 
L(-1) O 
) O 
. O 
Under O 
PO(4)(3-) B-FORMULA 
limitation O 
and O 
Cd B-FORMULA 
stress O 
, O 
the O 
storage O 
lipid O 
class O 
triacylglycerol B-FAMILY 
( O 
TAG B-ABBREVIATION 
) O 
was O 
the O 
most O 
accumulated O 
among O 
the O 
lipid O 
classes O 
. O 
Fatty B-FAMILY 
acid I-FAMILY 
composition O 
revealed O 
that O 
the O 
degree O 
of O 
saturation O 
increased O 
with O 
increasing O 
Cd B-FORMULA 
stress O 
and O 
PO(4)(3-) B-FORMULA 
limitation O 
. O 
Decreasing O 
PO(4)(3-) B-FORMULA 
and O 
increasing O 
Cd B-FORMULA 
concentrations O 
resulted O 
in O 
higher O 
saturated B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
( O 
SAFA B-ABBREVIATION 
) O 
and O 
monounsaturated B-ABBREVIATION 
FA I-ABBREVIATION 
( O 
MUFA B-ABBREVIATION 
) O 
concentrations O 
. O 
Total O 
polyunsaturated B-ABBREVIATION 
FA I-ABBREVIATION 
( O 
PUFA B-ABBREVIATION 
) O 
and O 
ω3 B-ABBREVIATION 
PUFA I-ABBREVIATION 
, O 
and O 
PUFA B-ABBREVIATION 
: O 
SAFA B-ABBREVIATION 
ratios O 
were O 
higher O 
in O 
the O 
control O 
( O 
2.3×10(-4) O 
mol O 
L(-1) O 
PO(4)(3-) B-FORMULA 
) O 
cells O 
than O 
in O 
either O 
PO(4)(3-) B-FORMULA 
limitation O 
or O 
Cd B-FORMULA 
stress O 
, O 
or O 
in O 
the O 
combination O 
of O 
both O 
stresses O 
. O 
Contrasting O 
with O 
all O 
the O 
other O 
PUFAs B-ABBREVIATION 
, O 
18 O 
: O 
2n O 
- O 
6 O 
increased O 
as O 
PO(4)(3-) B-FORMULA 
limitation O 
increased O 
. O 
A O 
significant O 
positive O 
relationship O 
of O 
PUFAs B-ABBREVIATION 
, O 
acetone B-SYSTEMATIC 
mobile O 
polar O 
lipids O 
( O 
AMPL O 
) O 
and O 
phospholipids O 
( O 
PL O 
) O 
with O 
phosphate B-SYSTEMATIC 
concentration O 
in O 
the O 
culture O 
media O 
was O 
obtained O 
, O 
while O 
TAG B-ABBREVIATION 
concentrations O 
had O 
a O 
positive O 
association O 
with O 
total O 
MUFA B-ABBREVIATION 
and O 
SAFA B-ABBREVIATION 
. O 
Total O 
SAFA B-ABBREVIATION 
, O 
14 O 
: O 
0 O 
, O 
18 O 
: O 
1n O 
- O 
9 O 
and O 
18 O 
: O 
2n O 
- O 
6 O 
were O 
positively O 
correlated O 
with O 
Cd B-FORMULA 
and O 
negatively O 
with O 
PO(4)(3-) B-FORMULA 
concentrations O 
. O 
The O 
microalga O 
responded O 
to O 
combined O 
PO(4)(3-) B-FORMULA 
limitation O 
and O 
Cd B-FORMULA 
exposure O 
by O 
increasing O 
its O 
total O 
lipid O 
production O 
and O 
significantly O 
altering O 
its O 
lipid O 
composition O 
. O 
The O 
FA O 
18 O 
: O 
2n O 
- O 
6 O 
may O 
be O 
considered O 
a O 
stress O 
biomarker O 
for O 
PO(4)(3-) B-FORMULA 
limitation O 
and O 
Cd B-FORMULA 
stress O 
in O 
C O 
. O 
vulgaris O 
. O 

complex O 
I O 
couples O 
electron O 
transfer O 
between O 
matrix O 
NADH B-ABBREVIATION 
and O 
inner O 
- O 
membrane O 
ubiquinone B-FAMILY 
to O 
the O 
pumping O 
of O 
protons O 
against O 
a O 
proton O 
motive O 
force O 
. O 
The O 
accepted O 
proton O 
pumping O 
stoichiometry O 
was O 
4 O 
protons O 
per O 
2 O 
electrons O 
transferred O 
( O 
4 O 
H(+) B-FORMULA 
/ O 
2e(-) O 
) O 
but O 
it O 
has O 
been O 
suggested O 
that O 
stoichiometry O 
may O 
be O 
3 O 
H(+) B-FORMULA 
/ O 
2e(-) O 
based O 
on O 
the O 
identification O 
of O 
only O 
3 O 
proton O 
pumping O 
units O 
in O 
the O 
crystal O 
structure O 
and O 
a O 
revision O 
of O 
the O 
previous O 
experimental O 
data O 
. O 
Measurement O 
of O 
proton O 
pumping O 
stoichiometry O 
is O 
challenging O 
because O 
, O 
even O 
in O 
isolated O 
mitochondria O 
, O 
it O 
is O 
difficult O 
to O 
measure O 
the O 
proton O 
motive O 
force O 
while O 
simultaneously O 
measuring O 
the O 
redox O 
potentials O 
of O 
the O 
NADH B-ABBREVIATION 
/ O 
NAD(+) B-ABBREVIATION 
and O 
ubiquinol B-TRIVIAL 
/ O 
ubiquinone B-FAMILY 
pools O 
. O 
Here O 
we O 
employ O 
a O 
new O 
method O 
to O 
quantify O 
the O 
proton O 
motive O 
force O 
in O 
living O 
cells O 
from O 
the O 
redox O 
poise O 
of O 
the O 
bc(1) O 
complex O 
measured O 
using O 
multiwavelength O 
cell O 
spectroscopy O 
and O 
show O 
that O 
the O 
correct O 
stoichiometry O 
for O 
complex O 
I O 
is O 
4 O 
H(+) B-FORMULA 
/ O 
2e(-) O 
in O 
mouse O 
and O 
human O 
cells O 
at O 
high O 
and O 
physiological O 
proton O 
motive O 
force O 
. O 

hepatoprotection O 
of O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
and O 
rosmarinic B-TRIVIAL 
acid I-TRIVIAL 
, O 
major O 
compounds O 
of O 
Perilla O 
frutescens O 
, O 
against O 
t-BHP B-ABBREVIATION 
-induced O 
oxidative O 
liver O 
damage O 
. O 

frutescens O 
leaves O 
are O 
often O 
used O 
in O 
East O 
Asian O 
gourmet O 
food O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
hepatoprotective O 
effects O 
of O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
( O 
CA O 
) O 
, O 
rosmarinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
RA O 
) O 
, O 
and O 
their O 
combination O 
. O 
P O 
. O 
frutescens O 
contains O 
1.32μg O 
CA O 
/ O 
mg O 
dry O 
material O 
( O 
DM O 
) O 
and O 
26.84μg O 
RA O 
/ O 
mg O 
DM O 
analyzed O 
by O 
HPLC-DAD O 
and O 
HPLC-MS O 
. O 
CA O 
remarkably O 
reduced O 
the O 
oxidative O 
damage O 
than O 
rosmarinic B-TRIVIAL 
acid I-TRIVIAL 
in O 
an O 
in O 
vitro O 
study O 
. O 
Oral O 
intubation O 
with O 
CA O 
or O 
RA O 
alone O 
for O 
five O 
days O 
was O 
conducted O 
prior O 
to O 
treatment O 
with O 
a O 
single O 
dose O 
of O 
tert-butyl B-SYSTEMATIC 
hydroperoxide I-SYSTEMATIC 
( O 
0.5mmol O 
/ O 
kg O 
b.w O 
. O 
, O 
i.p O 
. O 
) O 
, O 
which O 
led O 
to O 
a O 
significant O 
reduction O 
of O 
indicators O 
of O 
hepatic O 
toxicity O 
, O 
such O 
as O 
aspartat B-TRIVIAL 
e O 
aminotransferase O 
, O 
alanin B-TRIVIAL 
e O 
aminotransferase O 
, O 
oxidized B-TRIVIAL 
glutathion I-TRIVIAL 
e O 
, O 
lipid O 
peroxidation O 
and O 
enzyme O 
activities O 
related O 
to O 
antioxidant O 
such O 
as O 
catalase O 
, O 
glutathion B-TRIVIAL 
e O 
peroxidase O 
and O 
superoxid B-TRIVIAL 
e O 
dismutase O 
. O 
Interestingly O 
, O 
compared O 
to O 
treatment O 
with O 
CA O 
or O 
RA O 
alone O 
, O 
a O 
combination O 
of O 
both O 
compounds O 
more O 
increased O 
the O 
endogenous O 
antioxidant O 
enzymes O 
and O 
glutathion B-TRIVIAL 
e O 
( O 
GSH O 
) O 
and O 
decreased O 
lipid O 
peroxidation O 
in O 
livers O 
. O 
These O 
results O 
suggest O 
that O 
CA O 
from O 
perilla O 
leaves O 
plays O 
a O 
role O 
in O 
the O 
increased O 
hepatic O 
GS B-ABBREVIATION 
H O 
concentration O 
, O 
and O 
shows O 
an O 
additive O 
hepatic O 
protection O 
with O 
RA O 
against O 
oxidative O 
hepatic O 
damage O 
. O 

of O 
silicon B-SYSTEMATIC 
on O 
osteoblast O 
activity O 
and O 
bone O 
mineralization O 
of O 
MC3T3-E1 O 
cells O 
. O 

studies O 
have O 
reported O 
that O 
dietary O 
silicon B-SYSTEMATIC 
( O 
Si B-FORMULA 
) O 
intake O 
is O 
positively O 
associated O 
with O 
bone O 
health O 
including O 
bone O 
mineral O 
density O 
. O 
Although O 
the O 
amount O 
of O 
Si B-FORMULA 
intake O 
is O 
high O 
among O 
trace O 
elements O 
in O 
humans O 
, O 
how O 
dietary O 
Si B-FORMULA 
affects O 
bone O 
formation O 
at O 
the O 
cellular O 
level O 
is O 
not O 
well O 
addressed O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
role O 
of O 
Si B-FORMULA 
in O 
osteoblast O 
activity O 
and O 
bone O 
mineralization O 
. O 
MC3T3-E1 O 
was O 
cultured O 
as O 
mature O 
osteoblasts O 
and O 
treated O 
with O 
sodium B-SYSTEMATIC 
metasilicate I-SYSTEMATIC 
( O 
0 O 
, O 
1 O 
, O 
5 O 
, O 
10 O 
, O 
25 O 
, O 
50 O 
, O 
and O 
100 O 
μM O 
) O 
as O 
a O 
source O 
of O 
Si B-FORMULA 
. O 
After O 
7 O 
days O 
of O 
treatment O 
, O 
5 O 
and O 
10 O 
μM O 
of O 
sodium B-SYSTEMATIC 
metasilicate I-SYSTEMATIC 
significantly O 
increased O 
intracellular O 
alkaline O 
phosphatase O 
activity O 
( O 
p O 
< O 
0.05 O 
) O 
when O 
compared O 
to O 
the O 
control O 
. O 
Additionally O 
, O 
all O 
doses O 
of O 
sodium B-SYSTEMATIC 
metasilicate I-SYSTEMATIC 
( O 
1 O 
, O 
5 O 
, O 
10 O 
, O 
25 O 
, O 
50 O 
, O 
and O 
100 O 
μM O 
) O 
increased O 
mineralized O 
nodule O 
formation O 
at O 
14 O 
days O 
of O 
differentiation O 
as O 
evidenced O 
by O 
increased O 
Alizarin B-TRIVIAL 
Red I-TRIVIAL 
S I-TRIVIAL 
staining O 
. O 
In O 
the O 
analysis O 
of O 
gene O 
expression O 
, O 
50 O 
μM O 
of O 
sodium B-SYSTEMATIC 
metasilicate I-SYSTEMATIC 
upregulated O 
type O 
I O 
collagen O 
( O 
COL-I O 
) O 
compared O 
to O 
the O 
control O 
group O 
. O 
However O 
, O 
the O 
increase O 
of O 
COL-I O 
gene O 
expression O 
as O 
a O 
result O 
of O 
treatment O 
with O 
1 O 
, O 
10 O 
, O 
25 O 
, O 
and O 
100 O 
μM O 
of O 
sodium B-SYSTEMATIC 
metasilicate I-SYSTEMATIC 
did O 
not O 
reach O 
statistical O 
significance O 
. O 
mRNA O 
expression O 
of O 
insulin O 
- O 
like O 
growth O 
factor-I O 
and O 
receptor O 
activator O 
of O 
NF-κB O 
ligand O 
was O 
not O 
significantly O 
changed O 
at O 
any O 
dose O 
of O 
sodium B-SYSTEMATIC 
metasilicate I-SYSTEMATIC 
( O 
0 O 
, O 
1 O 
, O 
5 O 
, O 
10 O 
, O 
25 O 
, O 
50 O 
, O 
and O 
100 O 
μM O 
) O 
. O 
In O 
light O 
of O 
the O 
results O 
, O 
we O 
conclude O 
that O 
Si B-FORMULA 
has O 
a O 
positive O 
effect O 
on O 
bone O 
metabolism O 
by O 
enhancing O 
osteoblast O 
mineralization O 
activity O 
. O 

: O 
a O 
new O 
treatment O 
option O 
for O 
myelofibrosis O 
. O 

is O 
a O 
myeloproliferative O 
neoplasm O 
characterized O 
by O 
bone O 
marrow O 
fibrosis O 
and O 
extramedullary O 
hematopoiesis O 
. O 
Evolution O 
of O 
myelofibrosis O 
can O 
lead O 
to O 
life O 
- O 
threatening O 
complications O 
, O 
including O 
transformation O 
to O 
leukemia O 
, O 
thrombotic O 
events O 
, O 
and O 
hemorrhagic O 
episodes O 
. O 
The O 
only O 
curative O 
therapy O 
for O 
myelofibrosis O 
is O 
allogeneic O 
hematopoietic O 
stem O 
cell O 
transplantation O 
. O 
Because O 
this O 
disease O 
manifests O 
primarily O 
in O 
the O 
older O 
population O 
, O 
many O 
patients O 
diagnosed O 
with O 
myelofibrosis O 
are O 
not O 
considered O 
medically O 
fit O 
for O 
such O 
aggressive O 
therapy O 
. O 
Other O 
available O 
medical O 
therapies O 
do O 
not O 
halt O 
disease O 
progression O 
; O 
instead O 
, O 
current O 
treatment O 
strategies O 
have O 
focused O 
on O 
targeting O 
specific O 
symptomology O 
, O 
although O 
with O 
limited O 
efficacy O 
. O 
The O 
lack O 
of O 
effective O 
treatment O 
options O 
for O 
patients O 
with O 
myelofibrosis O 
has O 
rendered O 
this O 
orphan O 
disease O 
state O 
an O 
unmet O 
medical O 
need O 
, O 
and O 
novel O 
approaches O 
to O 
improve O 
outcomes O 
are O 
necessary O 
. O 
Emerging O 
research O 
has O 
identified O 
numerous O 
molecular O 
mutations O 
in O 
patients O 
with O 
myelofibrosis O 
, O 
making O 
this O 
disease O 
a O 
potential O 
candidate O 
for O 
molecularly O 
targeted O 
therapy O 
. O 
The O 
most O 
prevalent O 
mutation O 
identified O 
is O 
a O 
gain O 
- O 
of O 
- O 
function O 
mutation O 
in O 
the O 
Janus O 
kinase O 
( O 
JAK O 
) O 
family O 
, O 
JAK2 O 
V617F O 
, O 
which O 
has O 
been O 
identified O 
in O 
more O 
than O 
half O 
of O 
patients O 
with O 
myelofibrosis O 
. O 
This O 
mutation O 
results O 
in O 
a O 
constitutively O 
active O 
JAK-signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
pathway O 
resulting O 
in O 
dysregulated O 
cellular O 
proliferation O 
and O 
hematopoiesis O 
. O 
Ruxolitinib B-TRIVIAL 
is O 
a O 
small O 
- O 
molecule O 
inhibitor O 
of O 
JAK1 O 
and O 
JAK2 O 
and O 
recently O 
became O 
the O 
first O 
drug O 
approved O 
by O 
the O 
United O 
States O 
Food O 
and O 
Drug O 
Administration O 
for O 
the O 
treatment O 
of O 
symptomatic O 
intermediate- O 
or O 
high O 
- O 
risk O 
myelofibrosis O 
. O 
In O 
clinical O 
trials O 
, O 
ruxolitinib B-TRIVIAL 
demonstrated O 
promising O 
efficacy O 
in O 
reducing O 
splenomegaly O 
and O 
myelofibrosis O 
- O 
related O 
symptoms O 
. O 
However O 
, O 
ruxolitinib B-TRIVIAL 
did O 
not O 
demonstrate O 
disease O 
- O 
modifying O 
potential O 
and O 
is O 
not O 
considered O 
a O 
curative O 
therapeutic O 
option O 
. O 
Adverse O 
events O 
associated O 
with O 
ruxolitinib B-TRIVIAL 
are O 
primarily O 
hematologic O 
, O 
with O 
thrombocytopenia O 
and O 
anemia O 
being O 
the O 
most O 
common O 
toxicologic O 
events O 
identified O 
. O 
Future O 
research O 
will O 
shed O 
light O 
on O 
whether O 
ruxolitinib B-TRIVIAL 
in O 
combination O 
with O 
other O 
treatments O 
will O 
further O 
enhance O 
outcomes O 
in O 
myelofibrosis O 
. O 

optical O 
properties O 
of O 
Si B-FORMULA 
quantum O 
dots O 
by O 
π-conjugated O 
capping O 
molecules O 
. O 

absorption O 
and O 
photoluminescence O 
( O 
PL O 
) O 
properties O 
of O 
silicon B-SYSTEMATIC 
quantum O 
dots O 
( O 
QDs O 
) O 
are O 
greatly O 
influenced O 
by O 
their O 
size O 
and O 
surface O 
chemistry O 
. O 
Herein O 
, O 
we O 
examined O 
the O 
optical O 
properties O 
of O 
three O 
Si B-FORMULA 
QDs O 
with O 
increasing O 
σ-π O 
conjugation O 
length O 
: O 
octyl B-SYSTEMATIC 
- O 
, O 
(trimethylsilyl)vinyl B-SYSTEMATIC 
- O 
, O 
and O 
2-phenylvinyl B-SYSTEMATIC 
-capped O 
Si B-FORMULA 
QDs O 
. O 
The O 
PL O 
photon O 
energy O 
obtained O 
from O 
as-prepared O 
samples O 
decreased O 
by O 
0.1-0.3 O 
eV O 
, O 
while O 
the O 
PL O 
excitation O 
( O 
PLE O 
) O 
extended O 
from O 
360 O 
nm O 
( O 
octyl B-SYSTEMATIC 
-capped O 
Si B-FORMULA 
QDs O 
) O 
to O 
400 O 
nm O 
( O 
2-phenylvinyl B-SYSTEMATIC 
-capped O 
Si B-FORMULA 
QDs O 
) O 
. O 
A O 
vibrational O 
PL O 
feature O 
was O 
observed O 
in O 
all O 
samples O 
with O 
an O 
energy O 
separation O 
of O 
about O 
0.192±0.013 O 
eV O 
, O 
which O 
was O 
explained O 
based O 
on O 
electron O 
- O 
phonon O 
coupling O 
. O 
After O 
soft O 
oxidization O 
through O 
drying O 
, O 
all O 
samples O 
showed O 
blue O 
PL O 
with O 
maxima O 
at O 
approximately O 
410 O 
nm O 
. O 
A O 
similar O 
high O 
- O 
energy O 
peak O 
was O 
observed O 
with O 
the O 
bare O 
Si B-FORMULA 
QD O 
sample O 
. O 
The O 
changes O 
in O 
the O 
optical O 
properties O 
of O 
Si B-FORMULA 
QDs O 
were O 
mainly O 
explained O 
by O 
the O 
formation O 
of O 
additional O 
states O 
arising O 
from O 
the O 
strong O 
σ-π O 
conjugation O 
and O 
QD O 
oxidation O 
. O 

- O 
selective O 
O6-alkylguanine B-FAMILY 
-DNA O 
alkyltransferase O 
inhibitors O 
: O 
design O 
, O 
synthesis O 
, O 
and O 
evaluation O 
of O 
6-(benzyloxy)-2-(aryldiazenyl)-9H-purines B-FAMILY 
as O 
prodrugs O 
of O 
O6-benzylguanine B-SYSTEMATIC 
. O 

-DNA O 
alkyltransferase O 
( O 
AGT O 
) O 
is O 
a O 
DNA O 
repair O 
protein O 
which O 
removes O 
alkyl O 
groups O 
from O 
the O 
O-6 O 
position O 
of O 
guanine B-TRIVIAL 
, O 
thereby O 
providing O 
strong O 
resistance O 
to O 
anticancer O 
agents O 
which O 
alkylate O 
this O 
position O 
. O 
The O 
clinical O 
usefulness O 
of O 
these O 
anticancer O 
agents O 
would O 
be O 
substantially O 
augmented O 
if O 
AGT O 
could O 
be O 
selectively O 
inhibited O 
in O 
tumor O 
tissue O 
, O 
without O 
a O 
corresponding O 
depletion O 
in O 
normal O 
tissue O 
. O 
We O 
report O 
the O 
synthesis O 
of O 
a O 
new O 
AGT O 
inhibitor O 
( O 
5c O 
) O 
which O 
selectively O 
depletes O 
AGT O 
in O 
hypoxic O 
tumor O 
cells O 
. O 

investigate O 
the O 
effects O 
of O 
variation O 
in O 
chemical O 
conditions O 
( O 
solvent O 
composition O 
, O 
water O 
content O 
, O 
polymer O 
concentration O 
, O 
and O 
added O 
salt O 
) O 
on O 
the O 
morphologies O 
formed O 
by O 
PS-b-PAA B-ABBREVIATION 
in O 
DMF B-ABBREVIATION 
/ O 
dioxane B-SYSTEMATIC 
/ O 
water O 
mixtures O 
in O 
a O 
two O 
- O 
phase O 
gas-liquid O 
segmented O 
microfluidic O 
reactor O 
. O 
The O 
differences O 
in O 
morphologies O 
between O 
off O 
- O 
chip O 
and O 
on O 
- O 
chip O 
self O 
- O 
assembly O 
and O 
on O 
- O 
chip O 
morphological O 
trends O 
for O 
different O 
chemical O 
conditions O 
are O 
explained O 
by O 
the O 
interplay O 
of O 
top O 
- O 
down O 
shear O 
effects O 
( O 
coalescence O 
and O 
breakup O 
) O 
and O 
bottom O 
- O 
up O 
chemical O 
forces O 
. O 
Using O 
off O 
- O 
chip O 
morphology O 
results O 
, O 
we O 
construct O 
a O 
water O 
content-solvent O 
composition O 
phase O 
diagram O 
showing O 
disordered O 
, O 
sphere O 
, O 
cylinder O 
, O 
and O 
vesicle O 
regions O 
. O 
On-chip O 
morphologies O 
are O 
found O 
to O 
deviate O 
from O 
off O 
- O 
chip O 
morphologies O 
by O 
three O 
identified O 
shear O 
- O 
induced O 
paths O 
: O 
1 O 
) O 
sphere O 
- O 
to O 
- O 
cylinder O 
, O 
and O 
2 O 
) O 
sphere O 
- O 
to O 
- O 
vesicle O 
transitions O 
, O 
both O 
via O 
shear O 
- O 
induced O 
coalescence O 
when O 
initial O 
micelle O 
sizes O 
are O 
small O 
, O 
and O 
3 O 
) O 
cylinder O 
- O 
to O 
- O 
sphere O 
transitions O 
via O 
shear O 
- O 
induced O 
breakup O 
when O 
initial O 
micelle O 
sizes O 
are O 
large O 
( O 
high O 
capillary O 
number O 
conditions O 
) O 
. O 
These O 
pathways O 
contribute O 
to O 
the O 
generation O 
of O 
large O 
extended O 
bilayer O 
aggregates O 
uniquely O 
on O 
- O 
chip O 
, O 
at O 
either O 
increased O 
polymer O 
or O 
salt O 
concentrations O 
. O 
Collectively O 
these O 
results O 
demonstrate O 
the O 
broad O 
utility O 
of O 
top O 
- O 
down O 
directed O 
molecular O 
self O 
- O 
assembly O 
in O 
conjunction O 
with O 
chemical O 
forces O 
to O 
control O 
morphology O 
and O 
size O 
of O 
polymer O 
colloids O 
at O 
the O 
nanoscale O 
. O 

this O 
study O 
, O 
we O 
report O 
thermosensitive O 
hydrogels O 
based O 
on O 
poly(ethylene B-FAMILY 
glycol)-block-poly(γ-propargyl-l-glutamate I-FAMILY 
) I-FAMILY 
( O 
PEG-PPLG B-ABBREVIATION 
) O 
. O 
(13)C B-FORMULA 
NMR O 
spectra O 
, O 
DLS O 
, O 
and O 
circular O 
dichroism O 
spectra O 
were O 
employed O 
to O 
study O 
the O 
mechanism O 
of O 
the O 
sol O 
- O 
gel O 
phase O 
transition O 
. O 
Mouse O 
fibroblast O 
L929 O 
cells O 
were O 
encapsulated O 
and O 
cultured O 
within O 
the O 
hydrogel O 
matrices O 
, O 
and O 
the O 
encapsulated O 
cells O 
were O 
shown O 
to O 
be O 
highly O 
viable O 
in O 
the O 
gel O 
matrices O 
, O 
suggesting O 
that O 
the O 
hydrogels O 
have O 
excellent O 
cytocompatibilities O 
. O 
The O 
mass O 
loss O 
of O 
the O 
hydrogels O 
in O 
vitro O 
was O 
accelerated O 
by O 
the O 
presence O 
of O 
proteinase O 
K O 
compared O 
to O 
the O 
control O 
group O 
. O 
In O 
vivo O 
biocompatibility O 
studies O 
revealed O 
that O 
the O 
in O 
situ O 
formed O 
gels O 
in O 
the O 
subcutaneous O 
layer O 
last O 
for O 
∼21 O 
days O 
, O 
and O 
H&E O 
staining O 
study O 
suggested O 
acceptable O 
biocompatibility O 
of O 
our O 
materials O 
in O 
vivo O 
. O 
The O 
presence O 
of O 
alkynyl B-FAMILY 
side O 
groups O 
in O 
the O 
PEG-PPLG B-ABBREVIATION 
copolymers O 
allowed O 
convenient O 
further O 
functionalization O 
with O 
azide B-SYSTEMATIC 
-modified O 
bioactive O 
molecules O 
, O 
such O 
as O 
biotin B-TRIVIAL 
and O 
galactose B-TRIVIAL 
. O 
The O 
biofunctionalized O 
PEG B-ABBREVIATION 
-polypeptide O 
block O 
copolymers O 
showed O 
sol O 
- O 
gel O 
phase O 
transitions O 
similar O 
to O 
the O 
parent O 
copolymers O 
. O 
Interestingly O 
, O 
the O 
incorporation O 
of O 
galactose B-TRIVIAL 
groups O 
into O 
the O 
hydrogels O 
was O 
found O 
to O 
improve O 
cell O 
adhesion O 
, O 
likely O 
due O 
to O 
the O 
adsorption O 
of O 
fibronectin O 
( O 
FN O 
) O 
in O 
cell O 
- O 
extracellular O 
matrix O 
( O 
ECM O 
) O 
. O 
Because O 
bioactive O 
materials O 
have O 
shown O 
unique O 
advantages O 
in O 
biomedical O 
applications O 
, O 
especially O 
tissue O 
engineering O 
and O 
regenerative O 
medicine O 
applications O 
, O 
we O 
believe O 
our O 
novel O 
functionalizable O 
thermosensitive O 
hydrogels O 
have O 
potential O 
to O 
serve O 
as O 
a O 
versatile O 
platform O 
for O 
the O 
development O 
of O 
new O 
biofunctional O 
materials O 
, O 
for O 
example O 
, O 
bioadhesive O 
and O 
bioresponsive O 
hydrogels O 
. O 

and O 
tribological O 
behaviors O 
of O 
the O 
bioinspired O 
polydopamine B-TRIVIAL 
thin O 
films O 
under O 
dry O 
and O 
wet O 
conditions O 
. O 

is O 
a O 
" O 
sticky O 
" O 
biomolecule O 
containing O 
the O 
typical O 
functional O 
groups O 
of O 
mussel O 
adhesive O 
proteins O 
. O 
It O 
can O 
self O 
- O 
polymerize O 
into O 
a O 
nanoscale O 
thin O 
film O 
on O 
various O 
surfaces O 
. O 
We O 
investigated O 
the O 
surface O 
, O 
adhesion O 
, O 
friction O 
, O 
and O 
cracking O 
properties O 
of O 
polydopamine B-TRIVIAL 
( O 
PDA B-ABBREVIATION 
) O 
thin O 
films O 
for O 
their O 
effective O 
transfer O 
to O 
functional O 
devices O 
and O 
biocompatible O 
coatings O 
. O 
A O 
series O 
of O 
surface O 
characterizations O 
and O 
mechanical O 
tests O 
were O 
performed O 
to O 
reveal O 
the O 
static O 
and O 
dynamic O 
properties O 
of O 
PDA B-ABBREVIATION 
films O 
coated O 
on O 
glass O 
, O 
polydimethylsiloxane B-SYSTEMATIC 
( O 
PDMS B-ABBREVIATION 
) O 
, O 
and O 
epoxy B-SYSTEMATIC 
. O 
We O 
found O 
that O 
PDA B-ABBREVIATION 
films O 
are O 
highly O 
hydrated O 
under O 
wet O 
conditions O 
because O 
of O 
their O 
porous O 
membrane O 
- O 
like O 
nanostructures O 
and O 
hydrophilic O 
functional O 
groups O 
. O 
Upon O 
dehydration O 
, O 
the O 
films O 
form O 
cracks O 
when O 
they O 
are O 
coated O 
on O 
soft O 
substrates O 
due O 
to O 
internal O 
stresses O 
and O 
the O 
large O 
mismatch O 
in O 
elastic O 
modulus O 
. O 
The O 
adhesive O 
pull O 
- O 
off O 
force O 
or O 
the O 
effective O 
work O 
of O 
adhesion O 
increased O 
with O 
the O 
contact O 
time O 
, O 
suggesting O 
dynamic O 
interactions O 
at O 
the O 
interface O 
. O 
A O 
significant O 
decrease O 
in O 
friction O 
forces O 
in O 
water O 
was O 
observed O 
on O 
all O 
three O 
material O 
surfaces O 
coated O 
with O 
PDA B-ABBREVIATION 
; O 
thus O 
, O 
the O 
film O 
might O 
serve O 
as O 
a O 
water O 
- O 
based O 
lubrication O 
coating O 
. O 
We O 
attributed O 
the O 
different O 
behavior O 
of O 
PDA B-ABBREVIATION 
films O 
in O 
air O 
and O 
in O 
water O 
to O 
its O 
hydration O 
effects O 
. O 
These O 
research O 
findings O 
provide O 
insight O 
into O 
the O 
stability O 
, O 
mechanical O 
, O 
and O 
adhesive O 
properties O 
of O 
the O 
PDA B-ABBREVIATION 
films O 
, O 
which O 
are O 
critical O 
for O 
their O 
applications O 
. O 

and O 
controlling O 
water O 
- O 
based O 
aqueous O 
solutions O 
with O 
the O 
use O 
of O 
virtual O 
walls O 
is O 
relatively O 
simple O 
compared O 
to O 
that O 
of O 
nonaqueous O 
low O 
- O 
surface O 
- O 
tension O 
liquids O 
, O 
which O 
pose O 
greater O 
challenges O 
to O 
microfluidic O 
devices O 
. O 
This O 
letter O 
reports O 
a O 
novel O 
technique O 
to O 
form O 
a O 
virtual O 
wall O 
for O 
various O 
low O 
- O 
surface O 
- O 
tension O 
liquids O 
. O 
A O 
microfluidic O 
channel O 
with O 
virtual O 
walls O 
has O 
been O 
made O 
to O 
guide O 
low O 
- O 
surface O 
- O 
tension O 
liquids O 
by O 
using O 
a O 
specially O 
designed O 
oil O 
- O 
repellent O 
surface O 
. O 
Unlike O 
generic O 
superoleophobic O 
surfaces O 
, O 
our O 
oil O 
- O 
repellent O 
surface O 
exhibited O 
strong O 
repellency O 
to O 
the O 
lateral O 
flow O 
of O 
low O 
- O 
surface O 
- O 
tension O 
liquids O 
such O 
as O 
hexadecane B-SYSTEMATIC 
and O 
dodecane B-SYSTEMATIC 
. O 
A O 
plasma O 
- O 
assisted O 
surface O 
micromachining O 
process O 
has O 
been O 
utilized O 
to O 
form O 
the O 
oil O 
- O 
repellent O 
surface O 
. O 
The O 
use O 
of O 
combined O 
features O 
of O 
re O 
- O 
entrant O 
geometries O 
on O 
the O 
surface O 
played O 
an O 
important O 
role O 
in O 
promoting O 
its O 
repellence O 
to O 
the O 
lateral O 
flow O 
of O 
low O 
- O 
surface O 
- O 
tension O 
liquids O 
. O 
We O 
have O 
successfully O 
demonstrated O 
how O 
low O 
- O 
surface O 
- O 
tension O 
liquids O 
can O 
be O 
well O 
confined O 
by O 
the O 
virtual O 
walls O 
. O 

of O 
Coumarin B-TRIVIAL 
and O 
Neoflavone B-TRIVIAL 
Derivatives O 
as O 
HCV O 
NS5B O 
Polymerase O 
Inhibitors O 
. O 

and O 
coumestans B-FAMILY 
represent O 
an O 
important O 
family O 
of O 
compounds O 
with O 
diverse O 
pharmacological O 
properties O 
. O 
We O 
recently O 
identified O 
coumestans B-FAMILY 
as O 
novel O 
inhibitors O 
of O 
hepatitis O 
C O 
virus O 
NS5B O 
polymerase O 
and O 
predicted O 
their O 
binding O 
in O 
thumb O 
pocket-1 O 
( O 
TP-1 O 
) O 
of O 
NS5B O 
. O 
As O 
the O 
coumarins B-FAMILY 
are O 
structurally O 
related O 
to O 
coumestans B-FAMILY 
by O 
virtue O 
of O 
their O 
common O 
A- O 
and O 
B-rings O 
, O 
we O 
postulated O 
them O 
to O 
also O 
exhibit O 
similar O 
binding O 
interaction O 
with O 
NS5B O 
and O 
inhibit O 
its O 
polymerase O 
function O 
. O 
We O 
therefore O 
investigated O 
24 O 
coumarin B-TRIVIAL 
and O 
neoflavone B-TRIVIAL 
derivatives O 
as O 
candidate O 
NS5B O 
inhibitors O 
and O 
identified O 
14 O 
compounds O 
inhibiting O 
NS5B O 
polymerase O 
activity O 
with O 
IC50 O 
values O 
between O 
17 O 
and O 
63 O 
μm O 
. O 
Of O 
these O 
, O 
the O 
newly O 
synthesized O 
6,8-diallyl-5,7-dihydroxycoumarin B-SYSTEMATIC 
( O 
8a O 
) O 
was O 
produced O 
in O 
three O 
steps O 
in O 
high O 
chemical O 
yield O 
from O 
floroglucinol B-TRIVIAL 
and O 
found O 
to O 
be O 
the O 
most O 
potent O 
of O 
this O 
series O 
, O 
exhibiting O 
activity O 
similar O 
to O 
the O 
reference O 
coumestan B-TRIVIAL 
LQB-34 B-IDENTIFIER 
. O 
The O 
binding O 
site O 
of O 
8a O 
was O 
mapped O 
to O 
TP-1 O 
of O 
NS5B O 
by O 
counter O 
screening O 
against O 
P495L O 
NS5B O 
mutant O 
, O 
employed O 
as O 
a O 
screen O 
for O 
TP-1 O 
site O 
binders O 
. O 
NS5B-TP-1-8a O 
interaction O 
map O 
provided O 
insight O 
into O 
8a O 
binding O 
and O 
offered O 
clues O 
for O 
future O 
SAR O 
optimization O 
. O 

, O 
a O 
metabolite O 
associated O 
with O 
atherosclerosis O 
, O 
exhibits O 
complex O 
genetic O 
and O 
dietary O 
regulation O 
. O 

trimethylamine-N-oxide B-SYSTEMATIC 
( O 
TMAO B-ABBREVIATION 
) O 
levels O 
are O 
strongly O 
associated O 
with O 
atherosclerosis O 
. O 
We O 
now O 
examine O 
genetic O 
, O 
dietary O 
, O 
and O 
hormonal O 
factors O 
regulating O 
TMAO B-ABBREVIATION 
levels O 
. O 
We O 
demonstrate O 
that O 
two O 
flavin B-FAMILY 
mono-oxygenase O 
family O 
members O 
, O 
FMO1 O 
and O 
FMO3 O 
, O 
oxidize O 
trimethylamine B-SYSTEMATIC 
( O 
TMA B-ABBREVIATION 
) O 
, O 
derived O 
from O 
gut O 
flora O 
metabolism O 
of O 
choline B-FAMILY 
, O 
to O 
TMAO B-ABBREVIATION 
. O 
Further O 
, O 
we O 
show O 
that O 
FMO3 O 
exhibits O 
10-fold O 
higher O 
specific O 
activity O 
than O 
FMO1 O 
. O 
FMO3 O 
overexpression O 
in O 
mice O 
significantly O 
increases O 
plasma O 
TMAO B-ABBREVIATION 
levels O 
while O 
silencing O 
FMO3 O 
decreases O 
TMAO B-ABBREVIATION 
levels O 
. O 
In O 
both O 
humans O 
and O 
mice O 
, O 
hepatic O 
FMO3 O 
expression O 
is O 
reduced O 
in O 
males O 
compared O 
to O 
females O 
. O 
In O 
mice O 
, O 
this O 
reduction O 
in O 
FMO3 O 
expression O 
is O 
due O 
primarily O 
to O 
downregulation O 
by O 
androgens B-FAMILY 
. O 
FMO3 O 
expression O 
is O 
induced O 
by O 
dietary O 
bile B-FAMILY 
acids I-FAMILY 
by O 
a O 
mechanism O 
that O 
involves O 
the O 
farnesoid O 
X O 
receptor O 
( O 
FXR O 
) O 
, O 
a O 
bile B-FAMILY 
acid I-FAMILY 
-activated O 
nuclear O 
receptor O 
. O 
Analysis O 
of O 
natural O 
genetic O 
variation O 
among O 
inbred O 
strains O 
of O 
mice O 
indicates O 
that O 
FMO3 O 
and O 
TMAO B-ABBREVIATION 
are O 
significantly O 
correlated O 
, O 
and O 
TMAO B-ABBREVIATION 
levels O 
explain O 
11% O 
of O 
the O 
variation O 
in O 
atherosclerosis O 
. O 

of O 
N-acyl B-FAMILY 
4-(5-pyrimidine-2,4-dionyl)phenylalanine I-FAMILY 
derivatives O 
and O 
their O 
orally O 
active O 
prodrug O 
esters B-FAMILY 
as O 
dual O 
- O 
acting O 
alpha4-beta1 O 
and O 
alpha4-beta7 O 
receptor O 
antagonists O 
. O 

4-(5-pyrimidine-2,4-dionyl)phenylalanine I-FAMILY 
derivatives O 
of O 
type O 
4 O 
were O 
designed O 
to O 
replace O 
the O 
2,6-dichlorobenzoylamine B-SYSTEMATIC 
portion O 
of O 
compound O 
1 O 
in O 
order O 
to O 
identify O 
novel O 
compounds O 
with O 
improved O 
potency O 
against O 
α4-integrins O 
. O 
Several O 
derivatives O 
were O 
identified O 
as O 
very O 
potent O 
dual O 
- O 
acting O 
α4-integrin O 
, O 
α4β1 O 
and O 
α4β7 O 
antagonists O 
. O 
Investigation O 
of O 
a O 
limited O 
number O 
of O 
prodrug O 
esters O 
led O 
to O 
the O 
discovery O 
of O 
the O 
ethyl B-SYSTEMATIC 
ester I-SYSTEMATIC 
prodrug O 
42 O 
, O 
which O 
demonstrated O 
good O 
intestinal O 
fluid O 
stability O 
and O 
good O 
permeability O 
. O 
Despite O 
low O 
solubility O 
, O 
42 O 
gave O 
acceptable O 
blood O 
levels O 
of O 
30 O 
when O 
dosed O 
orally O 
in O 
non-human O 
primates O 
. O 
Additionally O 
, O 
42 O 
had O 
an O 
overall O 
excellent O 
profile O 
and O 
was O 
selected O 
for O 
clinical O 
trials O 
. O 
Investigation O 
of O 
N-acyl B-FAMILY 
4-(5-pyrimidine-2,4-dionyl)phenylalanine I-FAMILY 
derivatives O 
led O 
to O 
the O 
discovery O 
of O 
several O 
very O 
potent O 
dual O 
- O 
acting O 
α4-integrin O 
antagonists O 
. O 
Ethyl B-SYSTEMATIC 
ester I-SYSTEMATIC 
prodrug O 
42 O 
advanced O 
to O 
human O 
clinical O 
trials O 
based O 
on O 
the O 
excellent O 
intestinal O 
fluid O 
stability O 
, O 
good O 
permeability O 
and O 
superior O 
efficacy O 
in O 
non-human O 
primates O 
. O 

F-H I-MULTIPLE 
: O 
three O 
new O 
mixed O 
terpenoids B-FAMILY 
produced O 
by O 
an O 
endolichenic O 
fungus O 
Ulocladium O 
sp O 
. O 
using O 
OSMAC O 
method O 
. O 

new O 
mixed O 
terpenoids B-FAMILY 
, O 
tricycloalternarenes B-FAMILY 
( O 
TCAs B-FAMILY 
) O 
F-H O 
( O 
1-3 O 
) O 
, O 
together O 
with O 
ten O 
known O 
tricycloalternarenes B-FAMILY 
( O 
4-13 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
Czapek's O 
culture O 
of O 
an O 
endophytic O 
fungus O 
Ulocladium O 
sp O 
. O 
Their O 
structures O 
were O 
identified O 
by O 
extensive O 
spectroscopic O 
experiments O 
( O 
NMR O 
and O 
MS O 
) O 
and O 
comparison O 
with O 
literature O 
data O 
. O 
TCA B-ABBREVIATION 
1b O 
( O 
5 O 
) O 
showed O 
weak O 
activity O 
against O 
the O 
Bacille O 
Calmette-Guerin O 
strain O 
with O 
the O 
MIC O 
of O 
125μg O 
/ O 
mL O 
. O 
TCA B-ABBREVIATION 
9b O 
( O 
10 O 
) O 
exhibited O 
strong O 
cytotoxic O 
activity O 
against O 
Hela O 
cell O 
line O 
with O 
IC50 O 
of O 
8.58μM O 
. O 

A-D I-MULTIPLE 
, O 
cycloartane B-FAMILY 
triterpenoids I-FAMILY 
with O 
antibacterial O 
activities O 
from O 
Aphanamixis O 
grandifolia O 
. O 

new O 
cycloartane B-FAMILY 
triterpenoids I-FAMILY 
, O 
aphagrandinoids B-MULTIPLE 
A-C I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
and O 
a O 
new O 
natural O 
product O 
, O 
aphagrandinoid B-TRIVIAL 
D I-TRIVIAL 
( O 
4 O 
) O 
, O 
together O 
with O 
a O 
known O 
compound O 
, O 
were O 
isolated O 
from O 
the O 
leaves O 
and O 
twigs O 
of O 
Aphanamixis O 
grandifolia O 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
extensive O 
NMR O 
and O 
MS O 
techniques O 
. O 
Aphagrandinoid B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
, O 
a O 
29-nor-cycloart B-SYSTEMATIC 
triterpenoid I-SYSTEMATIC 
, O 
features O 
with O 
a O 
sprio O 
ring O 
system O 
at O 
the O 
side O 
chain O 
, O 
while O 
aphagrandinoid B-TRIVIAL 
C I-TRIVIAL 
( O 
3 O 
) O 
is O 
a O 
pentnortriterpenoid B-FAMILY 
. O 
Antibacterial O 
activities O 
of O 
these O 
five O 
compounds O 
were O 
also O 
evaluated O 
. O 
Compounds O 
1 O 
and O 
5 O 
showed O 
weak O 
antibacterial O 
activities O 
( O 
MIC O 
values O 
: O 
1.57-3.13μg O 
/ O 
mL O 
) O 
against O 
Staphylococcus O 
aureus O 
, O 
MRSA O 
92(#) O 
, O 
and O 
MRSA O 
98(#) O 
. O 

are O 
the O 
physiological O 
estrogens B-FAMILY 
? O 

( O 
E2 O 
) O 
is O 
the O 
principal O 
physiological O 
estrogen O 
in O 
mammals O 
. O 
E2 O 
and O 
its O 
active O 
metabolites O 
, O 
estrone B-TRIVIAL 
and O 
estriol B-TRIVIAL 
have O 
a O 
characteristic O 
phenolic O 
A O 
ring O 
, O 
unlike O 
progesterone B-TRIVIAL 
, O 
testosterone B-TRIVIAL 
, O 
cortisol B-TRIVIAL 
and O 
aldosterone B-TRIVIAL 
, O 
which O 
have O 
an O 
A O 
ring O 
containing O 
a O 
C3- O 
ketone B-SYSTEMATIC 
, O 
a O 
Δ(4) O 
bond O 
and O 
a O 
C19 O 
methyl B-SYSTEMATIC 
group O 
. O 
Crystal O 
structures O 
of O 
E2 O 
in O 
the O 
estrogen B-FAMILY 
receptor O 
( O 
ER O 
) O 
confirm O 
the O 
importance O 
of O 
the O 
A O 
ring O 
in O 
stabilizing O 
E2 O 
in O 
the O 
ER O 
. O 
However O 
, O 
other O 
steroids B-FAMILY 
, O 
including O 
Δ(5)-androstenediol B-SYSTEMATIC 
, O 
5α-androstanediol B-SYSTEMATIC 
and O 
27-hydroxycholesterol B-SYSTEMATIC 
, O 
which O 
have O 
a O 
saturated O 
A O 
ring O 
containing O 
a O 
3β-hydroxyl B-SYSTEMATIC 
and O 
a O 
C19 O 
methyl B-SYSTEMATIC 
group O 
, O 
also O 
mediate O 
physiological O 
responses O 
through O 
binding O 
to O 
estrogen B-FAMILY 
receptor-α O 
( O 
ERα O 
) O 
and O 
ERβ O 
. O 
Moreover O 
, O 
selective O 
estrogen B-FAMILY 
response O 
modulators O 
( O 
SERMs O 
) O 
with O 
diverse O 
structures O 
also O 
regulate O 
transcription O 
of O 
ERα O 
and O 
ERβ O 
. O 
Our O 
understanding O 
of O 
the O 
physiological O 
responses O 
mediated O 
by O 
these O 
" O 
alternative O 
" O 
estrogens B-FAMILY 
is O 
in O 
its O 
infancy O 
. O 
Further O 
studies O 
of O 
the O 
role O 
of O 
these O 
steroids B-FAMILY 
and O 
SERMs O 
in O 
regulating O 
responses O 
mediated O 
by O 
ERα O 
and O 
ERβ O 
a O 
variety O 
of O 
tissues O 
, O 
during O 
different O 
stages O 
of O 
development O 
, O 
are O 
likely O 
to O 
uncover O 
additional O 
estrogenic O 
activities O 
. O 

of O 
male O 
sexual O 
behavior O 
in O 
mice O 
( O 
Mus O 
musculus O 
) O 
within O 
a O 
discrete O 
range O 
of O 
perinatal O 
bisphenol-A B-TRIVIAL 
doses O 
in O 
the O 
context O 
of O 
a O 
high- O 
or O 
low O 
- O 
phytoestrogen O 
diet O 
. O 

of O 
masculine O 
and O 
feminine O 
behavior O 
in O 
mammals O 
depends O 
on O 
perinatal O 
sex O 
steroids B-FAMILY 
. O 
As O 
bisphenol-A B-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
can O 
be O 
estrogenic O 
and O 
anti-androgenic O 
, O 
we O 
examined O 
impacts O 
of O 
perinatal O 
exposure O 
upon O 
adult O 
sexual O 
behavior O 
and O 
morphology O 
of O 
male O 
mice O 
. O 
In O 
Experiment O 
1 O 
, O 
dams O 
were O 
fed O 
either O 
a O 
high- O 
or O 
low O 
- O 
phytoestrogen O 
diet O 
and O 
received O 
daily O 
oral O 
doses O 
of O 
0 O 
, O 
0.175 O 
, O 
1.75 O 
, O 
or O 
17.5μg O 
BPA B-ABBREVIATION 
from O 
gestation O 
day O 
10 O 
through O 
post O 
- O 
partum O 
day O 
9 O 
. O 
Male O 
offspring O 
from O 
the O 
high O 
- O 
phytoestrogen O 
plus O 
17.5μg O 
BPA B-ABBREVIATION 
condition O 
showed O 
reduced O 
mass O 
of O 
vesicular O 
- O 
coagulating O 
but O 
not O 
other O 
male O 
glands O 
, O 
and O 
showed O 
increased O 
latency O 
to O 
insemination O 
when O 
paired O 
with O 
females O 
. O 
In O 
Experiment O 
2 O 
, O 
these O 
procedures O 
were O 
replicated O 
but O 
with O 
all O 
animals O 
fed O 
the O 
high O 
- O 
phytoestrogen O 
diet O 
and O 
perinatal O 
BPA B-ABBREVIATION 
doses O 
of O 
0 O 
, O 
17.5 O 
, O 
175 O 
, O 
or O 
1750μg O 
/ O 
day O 
. O 
Adult O 
masses O 
of O 
testes O 
and O 
male O 
- O 
accessory O 
glands O 
and O 
levels O 
of O 
urinary O 
steroids B-FAMILY 
were O 
not O 
significantly O 
affected O 
. O 
When O 
males O 
each O 
encountered O 
a O 
sexually O 
receptive O 
female O 
, O 
there O 
were O 
fewer O 
intromissions O 
among O 
those O 
given O 
17.5 O 
or O 
175μg O 
and O 
fewer O 
ejaculations O 
among O 
those O 
given O 
17.5μg O 
, O 
but O 
the O 
1750μg O 
dose O 
had O 
no O 
effect O 
. O 
Perinatal O 
BPA B-ABBREVIATION 
dosages O 
thus O 
influenced O 
male O 
sexual O 
behavior O 
non-monotonically O 
, O 
with O 
impairment O 
evident O 
in O 
a O 
discrete O 
dose O 
range O 
among O 
males O 
on O 
a O 
high O 
- O 
phytoestrogen O 
diet O 
. O 

brain O 
injury O 
( O 
TBI O 
) O 
induces O 
primary O 
and O 
secondary O 
damage O 
in O 
both O 
the O 
endothelium O 
and O 
the O 
brain O 
parenchyma O 
. O 
While O 
neurons O 
die O 
quickly O 
by O 
necrosis O 
, O 
a O 
vicious O 
cycle O 
of O 
secondary O 
injury O 
in O 
endothelial O 
cells O 
exacerbates O 
the O 
initial O 
injury O 
. O 
Thyroid O 
hormones O 
are O 
reported O 
to O 
be O 
decreased O 
in O 
patients O 
with O 
brain O 
injury O 
. O 
Controlled O 
cortical O 
impact O 
injury O 
( O 
CCI O 
) O 
is O 
a O 
widely O 
used O 
, O 
clinically O 
relevant O 
model O 
of O 
TBI O 
. O 
Here O 
, O 
using O 
CCI O 
in O 
adult O 
male O 
mice O 
, O 
we O 
set O 
to O 
determine O 
whether O 
3,5,3'-triiodothyronine B-SYSTEMATIC 
( O 
T3 O 
) O 
attenuates O 
posttraumatic O 
neurodegeneration O 
and O 
neuroinflammation O 
in O 
an O 
experimental O 
model O 
of O 
TBI O 
. O 
Treatment O 
with O 
T3 O 
( O 
1.2μg O 
/ O 
100g O 
body O 
weight O 
, O 
i.p O 
. O 
) O 
1h O 
after O 
TBI O 
resulted O 
in O 
a O 
significant O 
improvement O 
in O 
motor O 
and O 
cognitive O 
recovery O 
after O 
CCI O 
, O 
as O 
well O 
as O 
in O 
marked O 
reduction O 
of O 
lesion O 
volumes O 
. O 
Mouse O 
model O 
for O 
brain O 
injury O 
showed O 
reactive O 
astrocytes O 
with O 
increased O 
glial O 
fibrillary O 
acidic O 
protein O 
, O 
and O 
formation O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
. O 
Western O 
blot O 
analysis O 
revealed O 
the O 
ability O 
of O 
T3 O 
to O 
reduce O 
brain O 
trauma O 
through O 
modulation O 
of O 
cytoplasmic O 
- O 
nuclear O 
shuttling O 
of O 
nuclear O 
factor-κB O 
( O 
NF-κB O 
) O 
. O 
Twenty O 
- O 
four O 
hours O 
after O 
brain O 
trauma O 
, O 
T3 O 
- O 
treated O 
mice O 
also O 
showed O 
significantly O 
lower O 
number O 
of O 
TUNEL(+) O 
apoptotic O 
neurons O 
and O 
curtailed O 
induction O 
of O 
Bax O 
, O 
compared O 
to O 
vehicle O 
control O 
. O 
In O 
addition O 
, O 
T3 O 
significantly O 
enhanced O 
the O 
post-TBI O 
expression O 
of O 
the O 
neuroprotective O 
neurotrophins O 
( O 
BDNF O 
and O 
GDNF O 
) O 
compared O 
to O 
vehicle O 
. O 
Our O 
data O 
provide O 
an O 
additional O 
mechanism O 
for O 
the O 
anti-inflammatory O 
effects O 
of O 
thyroid O 
hormone O 
with O 
critical O 
implications O 
in O 
immunopathology O 
at O 
the O 
cross O 
- O 
roads O 
of O 
the O 
immune O 
- O 
endocrine O 
circuits O 
. O 

lung O 
injury O 
( O 
ALI O 
) O 
has O 
many O 
possible O 
etiopathologies O 
and O 
is O 
characterized O 
by O 
acute O 
diffuse O 
lung O 
damage O 
with O 
poor O 
prognosis O 
. O 
Lipopolysaccharide O 
( O 
LPS O 
) O 
is O 
widely O 
used O 
as O 
septic O 
model O 
of O 
ALI O 
in O 
pharmacological O 
research O 
. O 
This O 
study O 
compares O 
intratracheal O 
bolus O 
instillation O 
( O 
IT O 
) O 
with O 
dose O 
- O 
adjusted O 
aerosol O 
inhalation O 
( O 
IH O 
) O 
of O 
LPS O 
in O 
Wistar O 
rats O 
using O 
both O 
non-invasive O 
and O 
terminal O 
endpoints O 
. O 
The O 
former O 
comprised O 
exhaled O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NOE O 
) O 
and O 
' O 
enhanced O 
pause O 
' O 
( O 
Penh O 
) O 
both O 
measured O 
in O 
spontaneous O 
breathing O 
conscious O 
rats O 
. O 
Terminal O 
endpoints O 
included O 
lung O 
weights O 
, O 
LDH O 
, O 
protein O 
, O 
total O 
cell O 
counts O 
, O 
and O 
cytodifferentiation O 
in O 
bronchoalveolar O 
lavage O 
( O 
BAL O 
) O 
. O 
Measurements O 
were O 
made O 
1 O 
, O 
3 O 
, O 
7 O 
, O 
and O 
14 O 
days O 
after O 
IT O 
instillation O 
( O 
5 O 
mg O 
LPS O 
/ O 
kg O 
body O 
weight O 
) O 
or O 
6-hour O 
directed O 
- O 
flow O 
nose O 
- O 
only O 
inhalation O 
exposure O 
to O 
respirable O 
LPS-aerosol O 
at O 
100 O 
mg O 
/ O 
m(3) O 
( O 
thoracic O 
dose O 
: O 
2.6 O 
mgLPS O 
/ O 
kg O 
body O 
weight O 
) O 
. O 
Controls O 
received O 
saline O 
( O 
IT O 
) O 
or O 
air O 
only O 
( O 
IH O 
) O 
. O 
LDH O 
and O 
protein O 
were O 
significantly O 
different O 
from O 
the O 
control O 
in O 
the O 
LPS-IH O 
group O 
( O 
days O 
1 O 
and O 
3 O 
) O 
with O 
a O 
somewhat O 
inconclusive O 
outcome O 
in O 
the O 
LPS-IT O 
group O 
due O 
to O 
the O 
effects O 
occurring O 
in O 
the O 
control O 
. O 
Total O 
cell O 
counts O 
were O 
equally O 
elevated O 
with O 
similar O 
time O 
- O 
course O 
changes O 
in O 
the O 
LPS-IT O 
and O 
-IH O 
groups O 
. O 
Polymorphonuclear O 
neutrophils O 
( O 
PMNs O 
) O 
were O 
indistinguishable O 
amongst O 
LPS-dosed O 
rats O 
. O 
Again O 
, O 
IT-dosed O 
control O 
rats O 
displayed O 
markedly O 
higher O 
background O 
levels O 
than O 
those O 
dosed O 
by O 
inhalation O 
. O 
Similarly O 
NOE O 
was O 
significantly O 
elevated O 
on O 
post-LPS O 
day O 
1 O 
as O 
was O 
Penh O 
. O 
In O 
summary O 
, O 
the O 
LPS-aerosol O 
dose O 
delivered O 
by O 
nose O 
- O 
only O 
exposure O 
over O 
6 O 
h O 
was O 
equally O 
potent O 
as O 
the O 
2-times O 
higher O 
LPS-IT O 
bolus O 
dose O 
on O 
post-LPS O 
day O 
1 O 
with O 
somewhat O 
faster O 
recovery O 
thereafter O 
. O 
The O 
climax O 
and O 
discriminatory O 
power O 
of O 
the O 
non-invasive O 
endpoints O 
matched O 
those O 
determined O 
terminally O 
. O 
This O 
supports O 
the O 
conclusion O 
that O 
the O 
pharmacological O 
efficacy O 
and O 
side O 
effects O 
of O 
inhalation O 
pharmaceuticals O 
designed O 
to O 
mitigate O 
ALI O 
can O 
better O 
be O 
identified O 
by O 
LPS-aerosol O 
than O 
by O 
LPS-IT O 
. O 
Non-invasive O 
time O 
- O 
course O 
measurements O 
may O 
deliver O 
apt O 
information O 
both O 
on O 
the O 
efficacious O 
dose O 
as O 
well O 
as O 
the O 
dosing O 
intervals O 
required O 
to O 
maintain O 
the O 
targeted O 
efficacy O 
using O 
a O 
minimum O 
of O 
experimental O 
animals O 
. O 
The O 
outcome O 
of O 
this O 
comparative O 
study O 
supports O 
the O 
conclusion O 
that O 
the O 
inhalation O 
route O 
produces O 
a O 
more O 
uniform O 
type O 
of O 
injury O 
at O 
lower O 
, O 
more O 
meaningful O 
dosages O 
. O 
When O 
designing O 
studies O 
for O 
screening O 
of O 
effective O 
drugs O 
this O 
mode O 
of O 
delivery O 
appears O 
to O 
better O 
approximate O 
the O 
human O 
condition O 
with O 
less O 
dosimetric O 
uncertainty O 
, O 
less O 
experimental O 
variability O 
and O 
better O 
characterization O 
of O 
what O 
was O 
actually O 
delivered O 
to O 
the O 
entire O 
respiratory O 
tract O 
. O 

up O 
- O 
regulation O 
of O 
the O 
GADD45γ O 
tumor O 
suppressor O 
gene O 
in O 
MDA-MB-231 O 
breast O 
cancer O 
cells O 
: O 
role O 
of O 
topoisomerase O 
IIα O 
inhibition O 
and O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
. O 

, O 
we O 
reported O 
that O 
(-)-xanthatin B-TRIVIAL 
, O 
a O 
naturally O 
occurring O 
xanthanolide B-FAMILY 
present O 
in O 
the O 
Cocklebur O 
plant O 
, O 
exhibits O 
potent O 
anti-proliferative O 
effects O 
on O 
human O 
breast O 
cancer O 
cells O 
, O 
accompanied O 
by O 
an O 
induction O 
of O 
the O 
growth O 
arrest O 
and O 
DNA O 
damage O 
- O 
inducible O 
gene O 
45γ O 
( O 
GADD45γ O 
) O 
, O 
recognized O 
recently O 
as O 
a O 
novel O 
tumor O 
suppressor O 
gene O 
. O 
However O 
, O 
the O 
mechanisms O 
mediating O 
this O 
activation O 
were O 
unknown O 
. O 
Topoisomerase O 
IIα O 
( O 
Topo O 
IIα O 
) O 
inhibition O 
has O 
been O 
reported O 
to O 
produce O 
a O 
cell O 
death O 
response O 
accompanied O 
by O 
an O 
atypical O 
DNA O 
laddering O 
fragmentation O 
profile O 
, O 
similar O 
to O 
that O 
noted O 
previously O 
for O 
(-)-xanthatin B-TRIVIAL 
. O 
Therefore O 
we O 
hypothesized O 
that O 
(-)-xanthatin B-TRIVIAL 
' O 
s O 
GADD45γ O 
activation O 
was O 
mediated O 
through O 
the O 
Topo O 
IIα O 
pathway O 
. O 
Here O 
, O 
we O 
identify O 
that O 
(-)-xanthatin B-TRIVIAL 
does O 
function O 
as O 
a O 
catalytic O 
inhibitor O 
of O 
Topo O 
IIα O 
, O 
promoting O 
DNA O 
damage O 
. O 
In O 
addition O 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
were O 
elevated O 
in O 
cells O 
treated O 
with O 
this O 
agent O 
. O 
Mechanistically O 
, O 
it O 
was O 
determined O 
that O 
the O 
induced O 
levels O 
of O 
GADD45γ O 
mRNA O 
resulting O 
from O 
(-)-xanthatin B-TRIVIAL 
exposures O 
were O 
stabilized O 
by O 
coordinately O 
produced O 
ROS O 
, O 
and O 
that O 
the O 
consequent O 
induction O 
of O 
GADD45γ O 
mRNA O 
, O 
GADD45γ O 
protein O 
and O 
ROS O 
generation O 
were O 
abrogated O 
by O 
co O 
- O 
treatment O 
with O 
N-acetyl-l-cysteine B-SYSTEMATIC 
. O 
Taken O 
together O 
, O 
the O 
data O 
support O 
the O 
concept O 
that O 
Topo O 
IIα O 
inhibition O 
by O 
(-)-xanthatin B-TRIVIAL 
is O 
a O 
trigger O 
that O 
stimulates O 
expression O 
of O 
DNA O 
damage O 
- O 
inducible O 
GADD45γ O 
mRNA O 
and O 
that O 
concomitantly O 
produced O 
ROS O 
act O 
downstream O 
to O 
further O 
enhance O 
the O 
GADD45γ O 
mRNA O 
/ O 
GADD45γ O 
protein O 
induction O 
process O 
, O 
resulting O 
in O 
breast O 
cancer O 
cell O 
death O 
. O 

tuberosum O 
L O 
. O 
var O 
. O 
Vitelotte O 
is O 
a O 
potato O 
variety O 
widely O 
used O 
for O 
human O 
consumption O 
. O 
The O 
pigments O 
responsible O 
for O 
its O 
attractive O 
color O 
belong O 
to O 
the O 
class O 
of O 
anthocyanins B-FAMILY 
. O 
The O 
objectives O 
of O 
this O 
study O 
were O 
to O 
characterize O 
and O 
measure O 
the O 
concentration O 
of O 
anthocyanins B-FAMILY 
in O 
pigmented O 
potatoes O 
and O 
to O 
evaluate O 
their O 
antioxidant O 
and O 
antimicrobial O 
activities O 
and O 
their O 
anti-proliferative O 
effects O 
in O 
solid O 
and O 
hematological O 
cancer O 
cell O 
lines O 
. O 
Anthocyanins B-FAMILY 
exert O 
anti-bacterial O 
activity O 
against O 
different O 
bacterial O 
strains O 
and O 
a O 
slight O 
activity O 
against O 
three O 
fungal O 
strains O 
. O 
The O 
Gram O 
- O 
positive O 
bacterium O 
Staphylococcus O 
aureus O 
and O 
the O 
fungus O 
Rhyzoctonia O 
solani O 
were O 
the O 
most O 
affected O 
microorganisms O 
. O 
Antioxidant O 
activities O 
were O 
evaluated O 
by O 
DPPH B-ABBREVIATION 
and O 
FRAP O 
methods O 
; O 
the O 
extract O 
showed O 
a O 
higher O 
reducing O 
capability O 
than O 
anti-radical O 
activity O 
. O 
Moreover O 
, O 
we O 
found O 
that O 
in O 
different O 
cancer O 
cell O 
models O 
the O 
anthocyanins B-FAMILY 
cause O 
inhibition O 
of O 
proliferation O 
and O 
apoptosis O 
in O 
a O 
dose O 
dependent O 
manner O 
. O 
These O 
biological O 
activities O 
are O 
likely O 
due O 
to O 
the O 
high O 
content O 
of O 
malvidin B-SYSTEMATIC 
3-O-p-coumaroyl-rutinoside-5-O-glucoside I-SYSTEMATIC 
and O 
petunidin B-SYSTEMATIC 
3-O-p-coumaroyl-rutinoside-5-O-glucoside I-SYSTEMATIC 
. O 

synthesis O 
and O 
anti-protozoal O 
activity O 
of O 
the O 
8,4'-oxyneolignans B-FAMILY 
virolin B-TRIVIAL 
, O 
surinamensin B-TRIVIAL 
and O 
analogues O 
. O 

asymmetric O 
synthesis O 
of O 
8,4'-oxyneolignans B-FAMILY 
(-)-virolin B-TRIVIAL 
, O 
(-)-surinamensin B-TRIVIAL 
and O 
a O 
number O 
of O 
analogues O 
has O 
been O 
achieved O 
. O 
A O 
divergent O 
synthesis O 
was O 
used O 
, O 
with O 
all O 
compounds O 
being O 
elaborated O 
from O 
a O 
single O 
chiral O 
aldehyde B-SYSTEMATIC 
derived O 
from O 
ethyl B-SYSTEMATIC 
lactate I-SYSTEMATIC 
. O 
In O 
the O 
15 O 
compounds O 
that O 
were O 
tested O 
, O 
the O 
level O 
of O 
substitution O 
on O 
the O 
A-ring O 
was O 
found O 
to O 
directly O 
influence O 
the O 
activity O 
against O 
Leishmania O 
donovani O 
whilst O 
the O 
activity O 
against O 
Plasmodium O 
falciparum O 
was O 
influenced O 
by O 
numerous O 
substitution O 
and O 
stereochemical O 
factors O 
. O 

- O 
loaded O 
microspheres O 
composed O 
of O 
chitosan O 
3% O 
( O 
w O 
/ O 
v O 
) O 
, O 
and O 
loading O 
120 O 
IU O 
insulin O 
were O 
produced O 
by O 
emulsion O 
cross O 
- O 
linking O 
method O 
. O 
Cross O 
- O 
linking O 
time O 
was O 
5 O 
h O 
and O 
glutaraldehyde B-TRIVIAL 
3.5% O 
( O 
v O 
/ O 
v O 
) O 
was O 
used O 
as O 
cross O 
- O 
linker O 
. O 
Swelling O 
ratio O 
studies O 
were O 
evaluated O 
to O 
predict O 
release O 
of O 
insulin O 
from O 
chitosan O 
microspheres O 
. O 
Bacitracin B-TRIVIAL 
and O 
sodium B-SYSTEMATIC 
taurocholate I-SYSTEMATIC 
were O 
incorporated O 
in O 
the O 
formulations O 
as O 
proteolytic O 
enzyme O 
inhibitor O 
and O 
absorption O 
enhancer O 
, O 
respectively O 
. O 
In O 
vitro O 
insulin O 
release O 
studies O 
were O 
performed O 
in O 
phosphate B-SYSTEMATIC 
buffer O 
pH O 
7.4 O 
and O 
also O 
in O 
HCl B-FORMULA 
pH O 
2 O 
with O 
and O 
without O 
trypsin O 
. O 
Activity O 
of O 
bacitracin B-TRIVIAL 
was O 
also O 
evaluated O 
. O 
In O 
vitro O 
release O 
showed O 
a O 
controlled O 
profile O 
up O 
to O 
12 O 
h O 
and O 
the O 
formulation O 
containing O 
0.15% O 
( O 
w O 
/ O 
v O 
) O 
of O 
bacitracin B-TRIVIAL 
revealed O 
a O 
maximum O 
biological O 
activity O 
of O 
about O 
49.1 O 
± O 
4.1% O 
. O 
Mathematical O 
modeling O 
using O 
Higuchi O 
and O 
Korsmeyer-Peppas O 
suggested O 
a O 
non-Fickian O 
diffusion O 
as O 
the O 
mechanism O 
of O 
insulin O 
release O 
. O 
Insulin O 
- O 
loaded O 
chitosan O 
microspheres O 
for O 
oral O 
delivery O 
showed O 
to O 
be O 
an O 
innovative O 
and O 
reliable O 
delivery O 
system O 
to O 
overcome O 
conventional O 
insulin O 
therapy O 
. O 

of O 
2-amino-1-methyl-6-phenylimidazo B-SYSTEMATIC 
[ I-SYSTEMATIC 
4 I-SYSTEMATIC 
, I-SYSTEMATIC 
5-b I-SYSTEMATIC 
] I-SYSTEMATIC 
pyridine I-SYSTEMATIC 
( O 
PhIP B-ABBREVIATION 
) O 
on O 
histopathology O 
, O 
oxidative O 
stress O 
, O 
and O 
expression O 
of O 
c-fos O 
, O 
c-jun O 
and O 
p16 O 
in O 
rat O 
stomachs O 
. O 

[ I-SYSTEMATIC 
4 I-SYSTEMATIC 
, I-SYSTEMATIC 
5-b I-SYSTEMATIC 
] I-SYSTEMATIC 
pyridine I-SYSTEMATIC 
( O 
PhIP B-ABBREVIATION 
) O 
is O 
one O 
of O 
the O 
most O 
abundant O 
heterocyclic B-FAMILY 
amines I-FAMILY 
( O 
HCAs B-ABBREVIATION 
) O 
generated O 
from O 
overcooking O 
meat O 
at O 
high O 
temperatures O 
. O 
To O 
understand O 
the O 
possible O 
mechanism O 
of O 
PhIP B-ABBREVIATION 
-associated O 
stomach O 
cancer O 
, O 
the O 
effects O 
of O 
PhIP B-ABBREVIATION 
on O 
morphology O 
, O 
oxidative O 
stress O 
, O 
gene O 
expression O 
of O 
c-fos O 
, O 
c-jun O 
and O 
p16 O 
in O 
rat O 
stomachs O 
were O 
investigated O 
. O 
The O 
results O 
showed O 
that O 
( O 
1 O 
) O 
15mg O 
/ O 
kg O 
body O 
weight O 
PhIP B-ABBREVIATION 
induced O 
obvious O 
histopathological O 
changes O 
in O 
gastric O 
mucosa O 
; O 
( O 
2 O 
) O 
PhIP B-ABBREVIATION 
( O 
10 O 
and O 
/ O 
or O 
15mg O 
/ O 
kg O 
) O 
significantly O 
decreased O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
and O 
glutathioneperoxidase O 
( O 
GPx O 
) O 
activities O 
, O 
while O 
increased O 
catalase O 
( O 
CAT O 
) O 
activity O 
compared O 
with O 
the O 
control O 
. O 
With O 
the O 
elevated O 
doses O 
of O 
PhIP B-ABBREVIATION 
, O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
contents O 
, O 
protein O 
carbonyl B-FAMILY 
( O 
PCO O 
) O 
contents O 
and O 
DNA O 
- O 
protein O 
crosslinks O 
( O 
DPC O 
) O 
coefficients O 
were O 
significantly O 
raised O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
; O 
( O 
3 O 
) O 
PhIP B-ABBREVIATION 
at O 
the O 
doses O 
of O 
10mg O 
/ O 
kg O 
and O 
/ O 
or O 
15mg O 
/ O 
kg O 
significantly O 
inhibited O 
p16 O 
mRNA O 
and O 
protein O 
expression O 
, O 
whereas O 
enhanced O 
c-fos O 
and O 
c-jun O 
expression O 
relative O 
to O 
control O 
. O 
The O 
data O 
indicated O 
that O 
PhIP B-ABBREVIATION 
could O 
cause O 
stomach O 
injury O 
, O 
oxidative O 
stress O 
in O 
rat O 
stomachs O 
as O 
well O 
as O 
the O 
activation O 
of O 
c-fos O 
and O 
c-jun O 
and O 
inactivation O 
of O 
p16 O 
, O 
which O 
may O 
play O 
a O 
role O 
in O 
the O 
pathogenesis O 
of O 
PhIP B-ABBREVIATION 
-associated O 
stomach O 
cancer O 
. O 

effect O 
on O 
T O 
and O 
B-cell O 
proliferation O 
of O 
non-cytotoxic O 
α-santonin B-TRIVIAL 
derived O 
1,2,3-triazoles B-FAMILY 
: O 
a O 
report O 
. O 

derived O 
new O 
series O 
of O 
1,2,3-triazoles B-FAMILY 
synthesized O 
through O 
Azide-Alkyne B-FAMILY 
Huisgen O 
1,3-dipolar O 
cycloaddition O 
reaction O 
between O 
substituted O 
aryl B-FAMILY 
azide I-FAMILY 
and O 
a O 
propargylated B-TRIVIAL 
α-desmotrosantonin I-TRIVIAL 
were O 
bio O 
- O 
evaluated O 
for O 
their O 
diminutive O 
effect O 
on O 
ConA O 
induced O 
T-cell O 
and O 
LPS O 
induced O 
B-cell O 
proliferation O 
. O 
Interestingly O 
, O 
most O 
of O 
the O 
synthesized O 
compounds O 
showed O 
better O 
immunosuppressant O 
activity O 
than O 
α-santonin B-TRIVIAL 
. O 
Triazole B-FAMILY 
derivatives O 
9 O 
, O 
10 O 
, O 
17 O 
, O 
18 O 
, O 
29 O 
, O 
and O 
30 O 
displayed O 
significant O 
diminutive O 
effect O 
on O 
cell O 
proliferation O 
. O 
Compounds O 
12 O 
and O 
13 O 
were O 
found O 
selective O 
against O 
ConA O 
T-cell O 
proliferation O 
exhibiting O 
> O 
90% O 
inhibition O 
at O 
1 O 
× O 
10(-6) O 
M O 
concentration O 
. O 
The O 
present O 
study O 
resulted O 
in O 
identification O 
of O 
several O 
triazole B-FAMILY 
derivatives O 
as O 
effective O 
immunosuppressive O 
agents O 
. O 

exposure O 
influences O 
predatory O 
behavior O 
, O 
neurotransmitter O 
content O 
and O 
receptor O 
expression O 
in O 
Sebastiscus O 
marmoratus O 
. O 

( O 
TBT B-ABBREVIATION 
) O 
is O 
a O 
ubiquitous O 
marine O 
contaminant O 
due O 
to O 
its O 
extensive O 
use O 
as O 
a O 
biocide O 
, O 
fungicide O 
and O 
antifouling O 
agent O 
. O 
However O 
, O 
the O 
neurotoxic O 
effect O 
of O 
TBT B-ABBREVIATION 
has O 
not O 
been O 
extensively O 
studied O 
, O 
especially O 
in O 
marine O 
fish O 
. O 
This O 
study O 
was O 
conducted O 
to O 
investigate O 
the O 
effects O 
of O 
TBT B-ABBREVIATION 
( O 
10 O 
, O 
100 O 
and O 
1000 O 
ng O 
/ O 
L O 
) O 
on O 
the O 
predatory O 
behavior O 
of O 
Sebastiscus O 
marmoratus O 
and O 
to O 
look O 
into O 
the O 
mechanism O 
involved O 
. O 
The O 
results O 
showed O 
that O 
TBT B-ABBREVIATION 
exposure O 
depressed O 
predatory O 
activity O 
after O 
50 O 
days O 
exposure O 
. O 
Dopamine B-TRIVIAL 
levels O 
in O 
the O 
fish O 
brains O 
increased O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
, O 
while O 
5-hydroxytryptamine B-SYSTEMATIC 
and O 
norepinephrine B-TRIVIAL 
levels O 
decreased O 
significantly O 
in O 
the O 
TBT B-ABBREVIATION 
exposure O 
group O 
compared O 
to O 
the O 
control O 
. O 
The O 
mRNA O 
levels O 
of O 
dopamine B-TRIVIAL 
receptors O 
, O 
which O 
have O 
functions O 
such O 
as O 
cognition O 
, O 
motor O 
activity O 
, O 
motivation O 
and O 
reward O 
, O 
mood O 
, O 
attention O 
and O 
learning O 
, O 
were O 
significantly O 
down O 
- O 
regulated O 
by O 
TBT B-ABBREVIATION 
exposure O 
. O 
Although O 
the O 
levels O 
of O 
amino B-FAMILY 
acid I-FAMILY 
neurotransmitters O 
, O 
including O 
glutamate B-TRIVIAL 
, O 
did O 
not O 
show O 
marked O 
alteration O 
, O 
the O 
expression O 
of O 
the O 
glutamatergic O 
signaling O 
pathway O 
such O 
as O 
N-methyl-D-aspartate B-SYSTEMATIC 
receptors O 
, O 
a-amino-3-hydroxy-5-methylisoxazole-4-propionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
receptor O 
, O 
calmodulin O 
, O 
Ca(2+) B-FORMULA 
/ O 
calmodulin O 
- O 
dependent O 
protein O 
kinases-II O 
and O 
cyclic B-SYSTEMATIC 
adenosine I-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
responsive O 
element O 
binding O 
protein O 
, O 
was O 
significantly O 
reduced O 
by O 
TBT B-ABBREVIATION 
exposure O 
, O 
which O 
indicated O 
that O 
central O 
nerve O 
activities O 
were O 
in O 
a O 
state O 
of O 
depression O 
, O 
thus O 
affecting O 
the O 
predatory O 
activities O 
of O 
the O 
fish O 
. O 

field O 
stimulation O 
(EFS)-induced O 
relaxations O 
turn O 
into O 
contractions O 
upon O 
removal O 
of O 
extracellular O 
calcium B-SYSTEMATIC 
in O 
rat O 
mesenteric O 
artery O 
. O 

the O 
present O 
study O 
, O 
we O 
aimed O 
to O 
examine O 
the O 
effect O 
of O 
blockade O 
of O 
L- O 
type O 
Ca(2+) B-FORMULA 
channels O 
( O 
LTCC O 
) O 
and O 
in O 
addition O 
the O 
removal O 
of O 
extracellular O 
Ca(2+) B-FORMULA 
, O 
on O 
EFS-induced O 
relaxations O 
in O 
rings O 
of O 
rat O 
mesenteric O 
artery O 
. O 
EFS O 
applied O 
to O 
the O 
tissues O 
precontracted O 
with O 
phenylephrine B-TRIVIAL 
caused O 
relaxations O 
which O 
were O 
markedly O 
inhibited O 
by O 
nifedipine B-TRIVIAL 
( O 
10(-7)M O 
) O 
and O 
tetraethylammonium B-SYSTEMATIC 
( O 
TEA B-ABBREVIATION 
) O 
( O 
1mM O 
) O 
. O 
Addition O 
of O 
LTCC O 
opener O 
BAY B-IDENTIFIER 
K I-IDENTIFIER 
8644 I-IDENTIFIER 
( O 
10(-7)M O 
) O 
failed O 
to O 
enhance O 
the O 
relaxations O 
. O 
Upon O 
removal O 
of O 
Ca(2+) B-FORMULA 
, O 
EFS O 
with O 
the O 
same O 
stimulation O 
parameters O 
produced O 
frequency O 
- O 
dependent O 
transient O 
contractions O 
. O 
Tetrodotoxin B-TRIVIAL 
( O 
10(-6)M O 
) O 
, O 
capsaicin B-TRIVIAL 
( O 
10(-5)M O 
) O 
and O 
removal O 
of O 
endothelium O 
did O 
not O 
alter O 
these O 
contractions O 
suggesting O 
that O 
they O 
were O 
not O 
neural O 
in O 
origin O 
and O 
endothelium O 
- O 
derived O 
contracting O 
factors O 
were O 
unlikely O 
to O 
be O 
involved O 
. O 
However O 
, O 
they O 
were O 
increased O 
by O 
nearly O 
40% O 
in O 
response O 
to O 
BAY B-IDENTIFIER 
K I-IDENTIFIER 
8644 I-IDENTIFIER 
( O 
10(-7)M O 
) O 
and O 
were O 
inhibited O 
by O 
nifedipine B-TRIVIAL 
( O 
10(-7)M O 
) O 
, O 
indicating O 
that O 
activation O 
of O 
the O 
LTCCs O 
was O 
essential O 
. O 
Inositol B-TRIVIAL 
triphosphate I-TRIVIAL 
( O 
InsP3 O 
) O 
receptor O 
antagonist O 
2-APB B-SYSTEMATIC 
( O 
10(-4)M O 
) O 
significantly O 
reduced O 
, O 
and O 
high O 
concentration O 
of O 
caffeine B-TRIVIAL 
( O 
20mM O 
) O 
almost O 
totally O 
suppressed O 
the O 
contractions O 
. O 
These O 
results O 
suggest O 
that O 
in O 
the O 
absence O 
of O 
extracellular O 
Ca(2+) B-FORMULA 
EFS O 
through O 
membrane O 
depolarization O 
, O 
evokes O 
the O 
opening O 
of O 
the O 
LTCCs O 
which O 
subsequently O 
leads O 
to O 
the O 
release O 
of O 
Ca(2+) B-FORMULA 
from O 
internal O 
stores O 
via O 
InsP3 O 
receptors O 
, O 
a O 
phenomenon O 
known O 
as O 
Ca(2+) B-FORMULA 
channel O 
- O 
induced O 
Ca(2+) B-FORMULA 
release O 
( O 
CCICR O 
) O 
, O 
to O 
trigger O 
vasoconstriction O 
. O 
That O 
activation O 
of O 
LTCCs O 
causes O 
arterial O 
relaxation O 
or O 
contraction O 
depending O 
on O 
the O 
Ca(2+) B-FORMULA 
status O 
apparently O 
exemplifies O 
how O 
the O 
same O 
messenger O 
fulfils O 
opposing O 
physiological O 
functions O 
in O 
a O 
given O 
cell O 
. O 

exposure O 
to O 
pentachlorophenol B-SYSTEMATIC 
causing O 
lymphoma O 
and O 
hematopoietic O 
malignancy O 
for O 
two O 
generations O 
. O 

: O 
Pentachlorophenol B-SYSTEMATIC 
( O 
PCP B-ABBREVIATION 
) O 
is O 
characterized O 
as O 
likely O 
carcinogen O 
of O 
lymphoma O 
and O 
hematopoietic O 
neoplasm O 
. O 
But O 
the O 
carcinogenicity O 
to O 
human O 
was O 
uncertain O 
based O 
on O 
population O 
studies O 
. O 
A O 
systematic O 
review O 
was O 
conducted O 
to O 
explore O 
two O 
kinds O 
of O 
associations O 
, O 
one O 
was O 
between O 
the O 
workers O 
exposed O 
to O 
PCP B-ABBREVIATION 
with O 
lymphoma O 
and O 
hematopoietic O 
neoplasm O 
, O 
the O 
other O 
was O 
between O 
childhood O 
lymphoma O 
and O 
leukemia O 
with O 
their O 
parents O 
exposed O 
to O 
PCP B-ABBREVIATION 
. O 
METHODS O 
: O 
Systematic O 
search O 
for O 
epidemiologic O 
studies O 
was O 
carried O 
out O 
and O 
the O 
data O 
were O 
collected O 
from O 
MEDLINE O 
database O 
and O 
from O 
the O 
reference O 
lists O 
of O 
relevant O 
studies O 
. O 
Data O 
were O 
extracted O 
from O 
20 O 
included O 
studies O 
published O 
between O 
1986 O 
and O 
2012 O 
. O 
RESULTS O 
: O 
The O 
meta-analysis O 
suggested O 
a O 
significant O 
association O 
between O 
lymphoma O 
and O 
workers O 
' O 
occupational O 
exposing O 
to O 
PCP B-ABBREVIATION 
, O 
for O 
the O 
pooled O 
odds O 
ratio O 
= O 
2.57 O 
( O 
95% O 
confidence O 
interval O 
( O 
CI O 
) O 
= O 
1.52-4.35 O 
) O 
. O 
The O 
subgroup O 
analysis O 
indicated O 
significant O 
association O 
for O 
non-Hodgkin's O 
lymphoma O 
, O 
but O 
not O 
for O 
Hodgkin's O 
disease O 
. O 
The O 
cohort O 
studies O 
also O 
showed O 
comparatively O 
higher O 
relative O 
risk O 
( O 
RR O 
) O 
and O 
standardized O 
mortality O 
ratio O 
( O 
SMR O 
) O 
. O 
Two O 
of O 
the O 
cohort O 
studies O 
found O 
increased O 
RR O 
as O 
the O 
cumulative O 
exposure O 
time O 
added O 
. O 
Another O 
cohort O 
study O 
discovered O 
that O 
the O 
white O 
males O 
had O 
significantly O 
elevated O 
non-Hodgkin's O 
lymphoma O 
mortality O 
( O 
SMR O 
= O 
1.98 O 
, O 
95% O 
CI O 
= O 
1.15-3.17 O 
) O 
, O 
and O 
males O 
of O 
other O 
races O 
had O 
increased O 
leukemia O 
mortality O 
( O 
SMR O 
= O 
4.57 O 
, O 
95% O 
CI O 
= O 
1.25-11.7 O 
) O 
. O 
For O 
the O 
relationship O 
of O 
childhood O 
leukemia O 
and O 
parental O 
exposure O 
to O 
PCP B-ABBREVIATION 
, O 
three O 
published O 
studies O 
suggested O 
an O 
increased O 
risk O 
of O 
childhood O 
leukemia O 
because O 
of O 
their O 
parental O 
exposure O 
to O 
PCP B-ABBREVIATION 
at O 
the O 
preconception O 
period O 
. O 
CONCLUSION O 
: O 
Our O 
review O 
provided O 
the O 
evidence O 
that O 
occupational O 
exposure O 
of O 
workers O 
to O 
PCP B-ABBREVIATION 
might O 
increase O 
the O 
risk O 
of O 
lymphoma O 
and O 
hematopoietic O 
neoplasm O 
in O 
themselves O 
and O 
in O 
their O 
children O 
. O 

nanoparticles O 
- O 
induced O 
cytotoxicity O 
, O 
oxidative O 
stress O 
and O 
apoptosis O 
in O 
cultured O 
A431 O 
and O 
A549 O 
cells O 
. O 

medicine O 
, O 
the O 
use O 
of O 
silica B-TRIVIAL 
nanoparticles O 
( O 
SiO(2) B-FORMULA 
NPs O 
) O 
offers O 
new O 
perspectives O 
in O 
biosensor O 
, O 
drug O 
delivery O 
and O 
cancer O 
therapy O 
. O 
However O 
, O 
questions O 
about O 
potential O 
toxic O 
and O 
deleterious O 
effects O 
of O 
SiO(2) B-FORMULA 
NPs O 
have O 
also O 
been O 
raised O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
induction O 
of O 
cytotoxicity O 
, O 
oxidative O 
stress O 
and O 
apoptosis O 
by O 
SiO(2) B-FORMULA 
NPs O 
( O 
size O 
15 O 
nm O 
) O 
in O 
human O 
skin O 
epithelial O 
( O 
A431 O 
) O 
and O 
human O 
lung O 
epithelial O 
( O 
A549 O 
) O 
cells O 
. O 
SiO(2) B-FORMULA 
NPs O 
( O 
concentration O 
range O 
25-200 O 
µg O 
/ O 
ml O 
) O 
induced O 
dose O 
- O 
dependent O 
cytotoxicity O 
in O 
both O 
types O 
of O 
cells O 
, O 
which O 
was O 
demonstrated O 
by O 
cell O 
viability O 
( O 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide B-SYSTEMATIC 
) O 
and O 
lactate B-FAMILY 
dehydrogenase O 
leakage O 
assays O 
. O 
SiO(2) B-FORMULA 
NPs O 
were O 
also O 
found O 
to O 
induce O 
oxidative O 
stress O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
, O 
indicated O 
by O 
depletion O 
of O 
glutathione B-TRIVIAL 
and O 
induction O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
generation O 
and O 
lipid O 
peroxidation O 
. O 
Quantitative O 
real O 
- O 
time O 
polymerase O 
chain O 
reaction O 
analysis O 
showed O 
that O 
following O 
the O 
exposure O 
of O 
cells O 
to O 
SiO(2) B-FORMULA 
NPs O 
, O 
the O 
messenger O 
RNA O 
level O 
of O 
apoptotic O 
genes O 
( O 
caspase-3 O 
and O 
caspase-9 O 
) O 
were O 
upregulated O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Moreover O 
, O 
activities O 
of O 
caspase-3 O 
and O 
caspase-9 O 
enzymes O 
were O 
also O 
significantly O 
higher O 
in O 
both O 
kinds O 
of O 
cells O 
exposed O 
to O 
SiO(2) B-FORMULA 
NPs O 
. O 
This O 
study O 
suggested O 
that O 
SiO(2) B-FORMULA 
NPs O 
induce O 
cytotoxicity O 
and O 
apoptosis O 
in O 
A431 O 
and O 
A549 O 
cells O 
, O 
which O 
is O 
likely O 
to O 
be O 
mediated O 
through O 
ROS O 
generation O 
and O 
oxidative O 
stress O 
. O 

II O 
of O 
the O 
mitochondrial O 
respiratory O 
chain O 
is O 
the O 
key O 
mediator O 
of O 
divalent B-SYSTEMATIC 
manganese I-SYSTEMATIC 
-induced O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
production O 
in O 
microglia O 
. O 

to O 
excessive O 
levels O 
of O 
manganese B-SYSTEMATIC 
( O 
Mn B-FORMULA 
) O 
is O 
associated O 
with O 
the O 
development O 
of O 
movement O 
disorders O 
, O 
with O 
symptoms O 
overlapping O 
with O 
Parkinson's O 
disease O 
. O 
Oxidative O 
damage O 
has O 
been O 
implicated O 
as O 
a O 
key O 
contributor O 
to O 
Mn B-FORMULA 
-induced O 
neurotoxicity O 
. O 
We O 
have O 
recently O 
reported O 
that O 
divalent B-FORMULA 
Mn I-FORMULA 
( O 
Mn(2+) B-FORMULA 
) O 
stimulates O 
brain O 
microglia O 
to O 
produce O 
and O 
release O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
H2O2 B-FORMULA 
) O 
, O 
and O 
microglial O 
- O 
free O 
radical O 
generation O 
facilitates O 
Mn(2+) B-FORMULA 
-induced O 
dopaminergic O 
neurotoxicity O 
. O 
The O 
goal O 
of O 
this O 
study O 
was O 
to O 
elucidate O 
the O 
underlying O 
mechanism O 
of O 
the O 
Mn(2+) B-FORMULA 
-induced O 
H2O2 B-FORMULA 
production O 
in O 
microglia O 
. O 
Exposure O 
to O 
low O 
micromolar O 
concentrations O 
of O 
Mn(2+) B-FORMULA 
, O 
but O 
not O 
divalent B-MULTIPLE 
copper I-MULTIPLE 
, I-MULTIPLE 
cadmium I-MULTIPLE 
, I-MULTIPLE 
nickel I-MULTIPLE 
, I-MULTIPLE 
cobalt I-MULTIPLE 
, I-MULTIPLE 
zinc I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
iron I-MULTIPLE 
, O 
induced O 
a O 
significant O 
production O 
of O 
H2O2 B-FORMULA 
from O 
rat O 
microglial O 
but O 
not O 
astroglial O 
cells O 
. O 
Subcellular O 
fractionation O 
studies O 
revealed O 
that O 
Mn(2+) B-FORMULA 
was O 
capable O 
of O 
inducing O 
significant O 
H2O2 B-FORMULA 
production O 
in O 
the O 
mitochondrial O 
but O 
not O 
the O 
cytosolic O 
or O 
nuclear O 
fraction O 
prepared O 
from O 
microglia O 
. O 
Analysis O 
of O 
the O 
relative O 
contribution O 
of O 
mitochondrial O 
respiratory O 
chain O 
complexes O 
indicated O 
that O 
Mn(2+) B-FORMULA 
-induced O 
mitochondrial O 
H2O2 B-FORMULA 
production O 
required O 
the O 
presence O 
of O 
complex O 
II O 
substrate O 
succinate B-TRIVIAL 
. O 
In O 
contrast O 
, O 
complex O 
I O 
substrates O 
malate B-TRIVIAL 
and O 
glutamate B-TRIVIAL 
failed O 
to O 
support O 
H2O2 B-FORMULA 
production O 
in O 
the O 
presence O 
of O 
Mn(2+) B-FORMULA 
. O 
Furthermore O 
, O 
the O 
succinate B-TRIVIAL 
-supported O 
Mn(2+) B-FORMULA 
-induced O 
mitochondrial O 
H2O2 B-FORMULA 
production O 
was O 
abolished O 
by O 
pharmacological O 
inhibition O 
of O 
complex O 
II O 
but O 
not O 
that O 
of O 
complexes O 
I O 
and O 
III O 
, O 
suggesting O 
that O 
mitochondrial O 
complex O 
II O 
is O 
a O 
key O 
mediator O 
in O 
Mn(2+) B-FORMULA 
-induced O 
H2O2 B-FORMULA 
production O 
. O 
These O 
findings O 
advance O 
our O 
knowledge O 
on O 
the O 
mechanisms O 
by O 
which O 
Mn B-FORMULA 
induces O 
oxidative O 
stress O 
and O 
the O 
potential O 
contribution O 
to O 
Mn O 
neurotoxicity O 
. O 

damage O 
to O 
cardiomyocytes O 
or O 
loss O 
of O 
viability O 
( O 
structural O 
cardiotoxicity O 
) O 
is O 
a O 
common O 
cause O 
of O 
attrition O 
in O 
preclinical O 
and O 
clinical O 
drug O 
development O 
. O 
Currently O 
, O 
no O 
predictive O 
in O 
vitro O 
approaches O 
are O 
available O 
to O 
detect O 
this O 
liability O 
early O 
in O 
drug O 
discovery O 
, O 
and O 
knowledge O 
of O 
the O 
mechanisms O 
involved O 
is O 
limited O 
. O 
Human O 
embryonic O 
stem O 
cell O 
- O 
derived O 
cardiomyocytes O 
( O 
hESC-CMs O 
) O 
and O 
the O 
rat O 
myoblastic O 
H9c2 O 
cell O 
lines O 
were O 
used O 
to O 
phenotypically O 
profile O 
a O 
panel O 
of O 
structural O 
cardiotoxins O 
by O 
live O 
- O 
cell O 
fluorescent O 
imaging O 
of O 
mitochondrial O 
membrane O 
potential O 
, O 
endoplasmic O 
reticulum O 
integrity O 
, O 
Ca(2+) B-FORMULA 
mobilization O 
, O 
and O 
membrane O 
permeability O 
combined O 
with O 
an O 
assessment O 
of O 
cell O 
viability O 
( O 
ATP B-ABBREVIATION 
depletion O 
) O 
. O 
Assay O 
results O 
were O 
normalized O 
to O 
known O 
therapeutically O 
relevant O 
concentrations O 
. O 
By O 
comparing O 
the O 
outcome O 
of O 
each O 
assay O 
to O 
the O 
known O 
in O 
vivo O 
effects O 
, O 
hESC-CMs O 
offered O 
an O 
improved O 
model O 
over O 
H9c2 O 
cells O 
for O 
the O 
detection O 
of O 
structural O 
cardiotoxicity O 
at O 
therapeutically O 
relevant O 
concentrations O 
. O 
Inhibition O 
of O 
the O 
spontaneously O 
beating O 
phenotype O 
, O 
a O 
feature O 
of O 
stem O 
cell O 
- O 
derived O 
cardiomyocytes O 
, O 
revealed O 
some O 
degree O 
of O 
cardioprotection O 
following O 
10 O 
out O 
of O 
13 O 
structural O 
cardiotoxins O 
, O 
illustrating O 
the O 
intricate O 
relationship O 
between O 
the O 
function O 
and O 
structure O 
of O 
cardiomyocytes O 
. O 
Classification O 
of O 
structural O 
cardiotoxins O 
into O 
mechanistic O 
themes O 
revealed O 
mitochondria O 
and O 
calcium B-SYSTEMATIC 
mobilization O 
to O 
be O 
major O 
distal O 
targets O 
, O 
with O 
only O 
4 O 
out O 
of O 
15 O 
compounds O 
affecting O 
contractile O 
function O 
in O 
freshly O 
isolated O 
canine O 
cardiomyocytes O 
at O 
therapeutically O 
relevant O 
concentrations O 
. O 
Our O 
data O 
demonstrate O 
the O 
utility O 
of O 
hESC-CMs O 
during O 
drug O 
development O 
to O 
support O 
structural O 
cardiotoxicity O 
hazard O 
identification O 
and O 
to O 
gain O 
insight O 
into O 
the O 
intricate O 
mechanisms O 
implicated O 
in O 
structural O 
cardiotoxicity O 
. O 

cytochrome O 
P450 O 
superfamily O 
encompasses O 
a O 
diverse O 
group O 
of O 
enzymes O 
that O 
catalyze O 
the O 
oxidation O 
of O 
various O 
substrates O 
. O 
The O 
mouse O 
CYP2J O 
subfamily O 
includes O 
members O 
that O 
have O 
wide O 
tissue O 
distribution O 
and O 
are O 
active O 
in O 
the O 
metabolism O 
of O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
( O 
AA O 
) O 
, O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
( O 
LA O 
) O 
, O 
and O 
other O 
lipids O 
and O 
xenobiotics O 
. O 
The O 
mouse O 
Cyp2j O 
locus O 
contains O 
seven O 
genes O 
and O 
three O 
pseudogenes O 
located O 
in O 
a O 
contiguous O 
0.62 O 
megabase O 
cluster O 
on O 
chromosome O 
4 O 
. O 
We O 
describe O 
four O 
new O 
mouse O 
CYP2J O 
isoforms O 
( O 
designated O 
CYP2J8 O 
, O 
CYP2J11 O 
, O 
CYP2J12 O 
, O 
and O 
CYP2J13 O 
) O 
. O 
The O 
four O 
cDNAs O 
contain O 
open O 
reading O 
frames O 
that O 
encode O 
polypeptides O 
with O 
62-84% O 
identity O 
with O 
the O 
three O 
previously O 
identified O 
mouse O 
CYP2Js O 
. O 
All O 
four O 
new O 
CYP2J O 
proteins O 
were O 
expressed O 
in O 
Sf21 O 
insect O 
cells O 
. O 
Each O 
recombinant O 
protein O 
metabolized O 
AA O 
and O 
LA O 
to O 
epoxides B-FAMILY 
and O 
hydroxy B-SYSTEMATIC 
derivatives O 
. O 
Specific O 
antibodies O 
, O 
mRNA O 
probes O 
, O 
and O 
polymerase O 
chain O 
reaction O 
primer O 
sets O 
were O 
developed O 
for O 
each O 
mouse O 
CYP2J O 
to O 
examine O 
their O 
tissue O 
distribution O 
. O 
CYP2J8 O 
transcripts O 
were O 
found O 
in O 
the O 
kidney O 
, O 
liver O 
, O 
and O 
brain O 
, O 
and O 
protein O 
expression O 
was O 
confirmed O 
in O 
the O 
kidney O 
and O 
brain O 
( O 
neuropil O 
) O 
. O 
CYP2J11 O 
transcripts O 
were O 
most O 
abundant O 
in O 
the O 
kidney O 
and O 
heart O 
, O 
with O 
protein O 
detected O 
primarily O 
in O 
the O 
kidney O 
( O 
proximal O 
convoluted O 
tubules O 
) O 
, O 
liver O 
, O 
and O 
heart O 
( O 
cardiomyocytes O 
) O 
. O 
CYP2J12 O 
transcripts O 
were O 
prominently O 
present O 
in O 
the O 
brain O 
, O 
and O 
CYP2J13 O 
transcripts O 
were O 
detected O 
in O 
multiple O 
tissues O 
, O 
with O 
the O 
highest O 
expression O 
in O 
the O 
kidney O 
. O 
CYP2J12 O 
and O 
CYP2J13 O 
protein O 
expression O 
could O 
not O 
be O 
determined O 
because O 
the O 
antibodies O 
developed O 
were O 
not O 
immunospecific O 
. O 
We O 
conclude O 
that O 
the O 
four O 
new O 
CYP2J O 
isoforms O 
might O 
be O 
involved O 
in O 
the O 
metabolism O 
of O 
AA O 
and O 
LA O 
to O 
bioactive O 
lipids O 
in O 
mouse O 
hepatic O 
and O 
extrahepatic O 
tissues O 
. O 

thermal O 
gels O 
have O 
numerous O 
biomedical O 
implications O 
, O 
as O 
they O 
undergo O 
physical O 
gelation O 
upon O 
temperature O 
increases O 
and O 
can O 
incorporate O 
biomolecules O 
to O 
promote O 
tissue O 
repair O 
. O 
Such O 
a O 
material O 
is O 
developed O 
for O 
the O 
sustained O 
release O 
of O 
bevacizumab O 
( O 
Avastin O 
) O 
, O 
a O 
drug O 
used O 
to O 
treat O 
age O 
- O 
related O 
macular O 
degeneration O 
. O 
The O 
polymer O 
, O 
poly(ethylene B-FAMILY 
glycol)-poly(serinol I-FAMILY 
hexamethylene I-FAMILY 
urethane I-FAMILY 
) I-FAMILY 
( O 
ESHU B-ABBREVIATION 
) O 
, O 
forms O 
a O 
physical O 
gel O 
when O 
heated O 
to O 
37 O 
°C O 
and O 
shows O 
good O 
cytocompatibility O 
with O 
ocular O 
cells O 
. O 
ESHU B-ABBREVIATION 
is O 
capable O 
of O 
sustaining O 
bevacizumab O 
release O 
over O 
17 O 
weeks O 
in O 
vitro O 
, O 
and O 
the O 
release O 
kinetics O 
can O 
be O 
altered O 
by O 
changing O 
the O 
drug O 
dose O 
and O 
the O 
ESHU B-ABBREVIATION 
concentration O 
. O 
These O 
results O 
suggest O 
that O 
ESHU B-ABBREVIATION 
is O 
biologically O 
safe O 
, O 
and O 
suitable O 
for O 
ocular O 
drug O 
delivery O 
. O 

and O 
originality O 
in O 
the O 
strategies O 
developed O 
by O 
bacteria O 
to O 
get O 
access O 
to O 
iron B-SYSTEMATIC 
. O 

c-abl O 
proto O 
- O 
oncogene O 
encodes O 
a O 
unique O 
protein- O 
tyrosine B-TRIVIAL 
kinase O 
( O 
Abl O 
) O 
distinct O 
from O 
c-Src O 
, O 
c-Fes O 
, O 
and O 
other O 
cytoplasmic O 
tyrosine B-TRIVIAL 
kinases O 
. O 
In O 
normal O 
cells O 
, O 
Abl O 
plays O 
prominent O 
roles O 
in O 
cellular O 
responses O 
to O 
genotoxic O 
stress O 
as O 
well O 
as O 
in O 
the O 
regulation O 
of O 
the O 
actin O 
cytoskeleton O 
. O 
Abl O 
is O 
also O 
well O 
known O 
in O 
the O 
context O 
of O 
Bcr-Abl O 
, O 
the O 
oncogenic O 
fusion O 
protein O 
characteristic O 
of O 
chronic O 
myelogenous O 
leukemia O 
. O 
Selective O 
inhibitors O 
of O 
Bcr-Abl O 
, O 
of O 
which O 
imatinib B-TRIVIAL 
is O 
the O 
prototype O 
, O 
have O 
had O 
a O 
tremendous O 
impact O 
on O 
clinical O 
outcomes O 
in O 
chronic O 
myelogenous O 
leukemia O 
and O 
revolutionized O 
the O 
field O 
of O 
targeted O 
cancer O 
therapy O 
. O 
In O 
this O 
minireview O 
, O 
we O 
focus O 
on O 
the O 
structural O 
organization O 
and O 
dynamics O 
of O 
Abl O 
kinases O 
and O 
how O 
these O 
features O 
influence O 
inhibitor O 
sensitivity O 
. O 

this O 
study O 
, O 
supercritical O 
fluid O 
extraction O 
( O 
SFE O 
) O 
with O 
CO(2) B-FORMULA 
and O 
hydrodistillation O 
( O 
HD O 
) O 
were O 
compared O 
as O 
methods O 
to O 
isolate O 
the O 
essential O 
oil O 
from O 
Cupressus O 
sempervirens O 
. O 
The O 
odour O 
of O 
the O 
oil O 
obtained O 
by O 
SFE O 
at O 
90 O 
bar O 
and O 
40°C O 
was O 
very O 
close O 
to O 
the O 
odour O 
of O 
the O 
leaves O 
of O 
C O 
. O 
sempervirens O 
before O 
the O 
extraction O 
. O 
Compounds O 
extracted O 
by O 
both O 
SFE O 
and O 
HD O 
were O 
identified O 
by O 
GC-FID O 
and O 
GC-MS O 
. O 
Moreover O 
, O 
the O 
difference O 
in O 
the O 
chemical O 
composition O 
obtained O 
by O 
SFE O 
and O 
HD O 
was O 
quite O 
noticeable O 
qualitatively O 
and O 
quantitatively O 
. O 
Phenolic O 
composition O 
and O 
antioxidant O 
activity O 
were O 
also O 
determined O 
. O 
Compared O 
to O 
HD O 
, O 
the O 
SFE O 
method O 
presents O 
some O 
advantages O 
: O 
the O 
extraction O 
was O 
completed O 
after O 
1 O 
h O 
in O 
SFE O 
, O 
although O 
4 O 
h O 
is O 
necessary O 
for O 
HD O 
, O 
and O 
the O 
yield O 
was O 
improved O 
by O 
34% O 
. O 
Finally O 
, O 
it O 
has O 
also O 
been O 
shown O 
that O 
SFE O 
is O 
very O 
selective O 
towards O 
some O 
specific O 
components O 
such O 
as O 
manoyl B-TRIVIAL 
oxide I-TRIVIAL 
, O 
trans-totarol B-TRIVIAL 
and O 
α-acoradiene B-TRIVIAL 
. O 

adenosine B-TRIVIAL 
signaling O 
to O 
treatment O 
of O 
diabetic O 
nephropathy O 
. O 

nephropathy O 
( O 
DN O 
) O 
continues O 
being O 
the O 
primary O 
cause O 
of O 
chronic O 
hemodialysis O 
and O 
terminal O 
renal O 
disease O 
worldwide O 
. O 
At O 
tissue O 
levels O 
the O 
DN O 
occurs O 
with O 
glomerulopathy O 
affecting O 
the O 
integrity O 
of O 
the O 
filtration O 
barrier O 
and O 
with O 
an O 
extensive O 
glomerular O 
and O 
tubule O 
- O 
interstitial O 
fibrosis O 
. O 
Current O 
available O 
therapeutic O 
approaches O 
have O 
only O 
demonstrated O 
a O 
modest O 
effect O 
on O 
progression O 
of O 
kidney O 
injury O 
. O 
Therefore O 
, O 
more O 
research O 
concerning O 
the O 
pathomechanisms O 
and O 
possible O 
interventions O 
are O 
needed O 
. O 
Interestingly O 
, O 
in O 
the O 
last O 
years O 
it O 
has O 
been O 
documented O 
that O 
DN O 
progresses O 
with O 
growing O 
levels O 
of O 
the O 
nucleoside O 
adenosine B-TRIVIAL 
. O 
This O 
finding O 
increased O 
the O 
interest O 
in O 
the O 
events O 
controlling O 
the O 
extracellular O 
levels O 
of O 
the O 
nucleoside B-FAMILY 
. O 
While O 
the O 
metabolism O 
of O 
extracellular O 
ATP B-ABBREVIATION 
and O 
cyclic B-TRIVIAL 
AMP I-TRIVIAL 
are O 
well O 
recognized O 
sources O 
, O 
evidences O 
regarding O 
the O 
role O 
of O 
the O 
equilibrative O 
nucleoside B-FAMILY 
transporters O 
in O 
controlling O 
adenosine B-TRIVIAL 
availability O 
and O 
promoting O 
diabetic O 
glomerulopathy O 
have O 
recently O 
acquired O 
a O 
pivotal O 
role O 
. O 
The O 
physiological O 
effects O 
of O 
nucleoside B-FAMILY 
are O 
mediated O 
by O 
the O 
P1 O 
family O 
of O 
adenosine B-TRIVIAL 
receptors O 
. O 
It O 
has O 
been O 
shown O 
in O 
vivo O 
that O 
the O 
use O 
of O 
an O 
antagonist O 
of O 
the O 
A2B O 
receptor O 
subtype O 
can O 
block O 
the O 
most O 
remarkable O 
early O 
alterations O 
seen O 
in O 
diabetic O 
glomerulopathy O 
. O 
Furthermore O 
, O 
using O 
models O 
of O 
chronic O 
kidney O 
injury O 
it O 
was O 
demonstrated O 
that O 
fibrosis O 
can O 
also O 
be O 
blocked O 
using O 
treatment O 
with O 
the O 
antagonist O 
of O 
A2B O 
receptor O 
subtype O 
. O 
This O 
review O 
highlights O 
these O 
findings O 
that O 
correlate O 
the O 
activity O 
of O 
a O 
low O 
affinity O 
adenosine B-TRIVIAL 
receptor O 
with O 
an O 
increase O 
in O 
the O 
ligand O 
availability O 
in O 
the O 
pathological O 
state O 
. O 
In O 
addition O 
, O 
we O 
discuss O 
the O 
possible O 
therapeutic O 
interventions O 
of O 
adenosine B-TRIVIAL 
signaling O 
with O 
regards O 
to O 
DN O 
treatment O 
. O 

veins O 
( O 
VVs O 
) O 
are O 
a O 
common O 
venous O 
disease O 
of O 
the O 
lower O 
extremity O 
characterized O 
by O 
incompetent O 
valves O 
, O 
venous O 
reflux O 
, O 
and O 
dilated O 
and O 
tortuous O 
veins O 
. O 
If O 
untreated O 
, O 
VVs O 
could O 
lead O 
to O 
venous O 
thrombosis O 
, O 
thrombophlebitis O 
and O 
chronic O 
venous O 
leg O 
ulcers O 
. O 
Various O 
genetic O 
, O 
hormonal O 
and O 
environmental O 
factors O 
may O 
lead O 
to O 
structural O 
changes O 
in O 
the O 
vein O 
valves O 
and O 
make O 
them O 
incompetent O 
, O 
leading O 
to O 
venous O 
reflux O 
, O 
increased O 
venous O 
pressure O 
and O 
vein O 
wall O 
dilation O 
. O 
Prolonged O 
increases O 
in O 
venous O 
pressure O 
and O 
vein O 
wall O 
tension O 
are O 
thought O 
to O 
increase O 
the O 
expression O 
/ O 
activity O 
of O 
matrix O 
metalloproteinases O 
( O 
MMPs O 
) O 
. O 
Members O 
of O 
the O 
MMPs O 
family O 
include O 
collagenases O 
, O 
gelatinases O 
, O 
stromelysins O 
, O 
matrilysins O 
, O 
membrane- O 
type O 
MMPs O 
and O 
others O 
. O 
MMPs O 
are O 
known O 
to O 
degrade O 
various O 
components O 
of O 
the O 
extracellular O 
matrix O 
( O 
ECM O 
) O 
. O 
MMPs O 
may O 
also O 
affect O 
the O 
endothelium O 
and O 
vascular O 
smooth O 
muscle O 
, O 
causing O 
changes O 
in O 
the O 
vein O 
relaxation O 
and O 
contraction O 
mechanisms O 
. O 
Endothelial O 
cell O 
injury O 
also O 
triggers O 
leukocyte O 
infiltration O 
, O 
activation O 
and O 
inflammation O 
, O 
which O 
lead O 
to O 
further O 
vein O 
wall O 
damage O 
. O 
The O 
vein O 
wall O 
dilation O 
and O 
valve O 
dysfunction O 
, O 
and O 
the O 
MMP O 
activation O 
and O 
superimposed O 
inflammation O 
and O 
fibrosis O 
would O 
lead O 
to O 
progressive O 
venous O 
dilation O 
and O 
VVs O 
formation O 
. O 
Surgical O 
ablation O 
is O 
an O 
effective O 
treatment O 
for O 
VVs O 
, O 
but O 
may O 
be O 
associated O 
with O 
high O 
recurrence O 
rate O 
, O 
and O 
other O 
less O 
invasive O 
approaches O 
that O 
target O 
the O 
cause O 
of O 
the O 
disease O 
are O 
needed O 
. O 
MMP O 
inhibitors O 
including O 
endogenous O 
tissue O 
inhibitors O 
( O 
TIMPs O 
) O 
and O 
pharmacological O 
inhibitors O 
such O 
as O 
zinc B-SYSTEMATIC 
chelators O 
, O 
doxycycline B-TRIVIAL 
, O 
batimastat B-TRIVIAL 
and O 
marimastat B-TRIVIAL 
, O 
have O 
been O 
used O 
as O 
diagnostic O 
and O 
therapeutic O 
tools O 
in O 
cancer O 
, O 
autoimmune O 
and O 
cardiovascular O 
disease O 
. O 
However O 
, O 
MMP O 
inhibitors O 
may O 
have O 
side O 
effects O 
especially O 
on O 
the O 
musculoskeletal O 
system O 
. O 
With O 
the O 
advent O 
of O 
new O 
genetic O 
and O 
pharmacological O 
tools O 
, O 
specific O 
MMP O 
inhibitors O 
with O 
fewer O 
undesirable O 
effects O 
could O 
be O 
useful O 
to O 
retard O 
the O 
progression O 
and O 
prevent O 
the O 
recurrence O 
of O 
VVs O 
. O 

A-F I-MULTIPLE 
, O 
glycosylated B-FAMILY 
phenazines I-FAMILY 
from O 
Streptomyces O 
sp O 
. O 
strain O 
DL-93 O 
. O 

a O 
survey O 
of O 
actinobacteria O 
known O 
to O 
suppress O 
the O 
growth O 
of O 
Streptomyces O 
scabies O 
( O 
the O 
causative O 
agent O 
of O 
potato O 
scab O 
disease O 
) O 
in O 
vivo O 
, O 
six O 
new O 
rhamnosylated O 
alkaloids O 
, O 
the O 
solphenazines B-MULTIPLE 
A-F I-MULTIPLE 
( O 
1-6 O 
) O 
, O 
were O 
isolated O 
from O 
a O 
biological O 
control O 
strain O 
of O 
Streptomyces O 
( O 
DL-93 O 
) O 
. O 
The O 
known O 
rhamnosyl B-TRIVIAL 
analogue O 
of O 
paraben B-FAMILY 
( O 
9 O 
) O 
was O 
also O 
isolated O 
along O 
with O 
a O 
new O 
rhamnosylated O 
derivative O 
of O 
N-methyl-p-aminobenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
10 O 
) O 
. O 
None O 
of O 
the O 
compounds O 
exhibited O 
any O 
antibacterial O 
or O 
antifungal O 
activity O 
against O 
a O 
standard O 
panel O 
of O 
microorganisms O 
, O 
but O 
compounds O 
1 O 
, O 
2 O 
, O 
and O 
6 O 
displayed O 
some O 
cytotoxicity O 
against O 
HCT-116 O 
cancer O 
cells O 
. O 
Additional O 
in O 
vitro O 
testing O 
provided O 
data O 
suggesting O 
that O 
the O 
cytotoxic O 
activity O 
is O 
not O 
due O 
to O 
DNA O 
intercalation O 
or O 
topoisomerase O 
inhibition O 
. O 

and O 
biological O 
evaluation O 
as O 
microtubule O 
- O 
active O 
agents O 
of O 
several O 
tetrahydrofuran B-SYSTEMATIC 
and O 
spiroacetal B-FAMILY 
derivatives O 
. O 

stereoselective O 
preparation O 
of O 
several O 
molecules O 
containing O 
structural O 
fragments O 
of O 
the O 
tetrahydrofuran B-SYSTEMATIC 
and O 
spiroacetal B-FAMILY 
type O 
is O 
described O 
. O 
Their O 
degree O 
of O 
cytotoxicity O 
and O 
their O 
interactions O 
with O 
tubulin O 
have O 
been O 
investigated O 
. O 
It O 
has O 
been O 
confirmed O 
that O 
the O 
tetrahydrofuran B-SYSTEMATIC 
derivatives O 
are O 
cytotoxic O 
but O 
, O 
in O 
contrast O 
to O 
previous O 
reports O 
, O 
it O 
has O 
been O 
found O 
that O 
the O 
cytoxicity O 
is O 
not O 
due O 
to O 
interactions O 
with O 
the O 
microtubule O 
network O 
. O 
Furthermore O 
, O 
and O 
also O 
in O 
contrast O 
to O 
a O 
previous O 
report O 
on O 
closely O 
related O 
compounds O 
, O 
the O 
spiroacetal B-FAMILY 
derivatives O 
do O 
show O 
interactions O 
with O 
tubulin O 
, O 
even O 
though O 
the O 
precise O 
mechanism O 
and O 
the O 
binding O 
site O 
still O 
remain O 
to O 
be O 
established O 
. O 

oxygen B-SYSTEMATIC 
therapy O 
. O 

( O 
O(2) B-FORMULA 
) O 
is O 
a O 
vital O 
element O 
. O 
Shortage O 
of O 
O(2) B-FORMULA 
results O 
in O 
deranged O 
metabolism O 
and O 
important O 
changes O 
in O 
vascular O 
tone O 
with O 
opposite O 
effects O 
on O 
the O 
systemic O 
and O 
pulmonary O 
circulation O 
. O 
During O 
hypoxemia O 
, O 
oxidative O 
stress O 
exposes O 
the O 
organism O 
to O 
a O 
sort O 
of O 
accelerated O 
senescence O 
as O 
well O 
as O 
to O 
several O 
acute O 
untoward O 
effects O 
. O 
Thus O 
, O 
hypoxemia O 
should O 
be O 
promptly O 
recognized O 
and O 
treated O 
, O 
hopefully O 
by O 
measures O 
tailored O 
to O 
the O 
pathophysiological O 
mechanisms O 
underlying O 
hypoxemia O 
. O 
However O 
, O 
O(2) B-FORMULA 
therapy O 
remains O 
the O 
most O 
common O 
therapy O 
of O 
hypoxemia O 
, O 
but O 
it O 
must O 
be O 
carefully O 
tailored O 
to O 
relieve O 
hypoxemia O 
without O 
provoking O 
hyperoxia O 
or O 
hypercarbia O 
. O 
Then O 
, O 
the O 
individual O 
response O 
to O 
O(2) B-FORMULA 
as O 
well O 
as O 
changing O 
needs O 
of O 
O(2) B-FORMULA 
during O 
sleep O 
or O 
exercise O 
must O 
be O 
evaluated O 
to O 
provide O 
the O 
best O 
O(2) B-FORMULA 
therapy O 
. O 
Hyperoxia O 
, O 
the O 
effect O 
of O 
overcorrection O 
of O 
hypoxia O 
, O 
can O 
dramatically O 
impact O 
the O 
health O 
status O 
and O 
threaten O 
the O 
survival O 
of O 
the O 
newborn O 
and O 
, O 
through O 
different O 
mechanisms O 
and O 
effects O 
, O 
the O 
adult O 
. O 
A O 
thorough O 
knowledge O 
of O 
the O 
pathophysiological O 
bases O 
of O 
hypoxemia O 
and O 
O(2) B-FORMULA 
storage O 
and O 
delivery O 
devices O 
is O 
then O 
mandatory O 
to O 
administer O 
O(2) B-FORMULA 
therapy O 
guaranteeing O 
for O 
optimal O 
correction O 
of O 
hypoxemia O 
and O 
minimizing O 
the O 
risk O 
of O 
hyperoxia O 
. O 
Consistent O 
with O 
this O 
aim O 
also O 
is O 
a O 
careful O 
scrutiny O 
of O 
instruments O 
and O 
procedures O 
for O 
monitoring O 
the O 
individual O 
response O 
to O 
O(2) B-FORMULA 
over O 
time O 
. O 
Thus O 
, O 
at O 
variance O 
from O 
classical O 
pharmacological O 
therapy O 
, O 
performing O 
O(2) B-FORMULA 
therapy O 
requires O 
a O 
vast O 
array O 
of O 
clinical O 
and O 
technical O 
competences O 
. O 
The O 
optimal O 
integration O 
of O 
these O 
competences O 
is O 
needed O 
to O 
optimize O 
O(2) B-FORMULA 
therapy O 
on O 
individual O 
bases O 
. O 

Developments O 
of O 
p38α O 
MAP O 
Kinase O 
Inhibitors O 
as O 
Antiinflammatory O 
Agents O 
Based O 
on O 
the O 
Imidazole B-SYSTEMATIC 
Scaffolds O 
. O 

arthritis O 
( O 
RA O 
) O 
and O 
other O 
chronic O 
inflammatory O 
diseases O 
are O 
always O 
the O 
major O 
therapeutic O 
challenges O 
. O 
Recent O 
research O 
efforts O 
provided O 
new O 
insights O 
into O 
the O 
molecular O 
basis O 
of O 
these O 
diseases O 
and O 
new O 
opportunities O 
for O 
developing O 
improved O 
anti-inflammatory O 
drugs O 
. O 
The O 
p38 O 
mitogen O 
- O 
activated O 
protein O 
( O 
MAP O 
) O 
kinase O 
plays O 
a O 
central O 
role O 
in O 
the O 
regulation O 
of O 
the O 
biosynthesis O 
and O 
release O 
of O 
several O 
proinflammatory O 
cytokines O 
including O 
tumor O 
necrosis O 
factor O 
alpha O 
( O 
TNF-α O 
) O 
and O 
interleukin-1 O 
beta O 
( O 
IL-1β O 
) O 
. O 
Hence O 
, O 
inhibition O 
of O 
the O 
p38 O 
MAP O 
kinase O 
is O 
regarded O 
as O 
a O 
promising O 
therapeutic O 
strategy O 
for O 
controlling O 
inflammatory O 
diseases O 
. O 
A O 
diverse O 
range O 
of O 
p38α O 
MAP O 
kinase O 
inhibitors O 
have O 
been O 
developed O 
as O 
potential O 
anti-inflammatory O 
agents O 
, O 
and O 
some O 
of O 
them O 
have O 
entered O 
the O 
phase O 
II O 
clinical O 
trials O 
. O 
The O 
imidazole B-SYSTEMATIC 
derivatives O 
are O 
known O 
as O 
competitive O 
inhibitors O 
at O 
the O 
ATP B-ABBREVIATION 
binding O 
site O 
of O 
the O 
p38α O 
MAP O 
kinase O 
. O 
Modifications O 
on O 
the O 
imidazole B-SYSTEMATIC 
scaffold O 
have O 
led O 
to O 
a O 
large O 
amount O 
of O 
potent O 
p38α O 
MAP O 
kinase O 
inhibitors O 
. O 
This O 
review O 
will O 
summarize O 
the O 
developments O 
of O 
small O 
molecule O 
p38α O 
MAP O 
kinase O 
inhibitors O 
based O 
on O 
the O 
imidazole B-SYSTEMATIC 
core O 
scaffolds O 
in O 
recent O 
10 O 
years O 
. O 
Variations O 
at O 
the O 
N1 O 
, O 
C2 O 
, O 
C4 O 
and O 
C5 O 
positions O 
of O 
imidazole B-SYSTEMATIC 
were O 
introduced O 
, O 
and O 
the O 
structure O 
- O 
activity O 
relationships O 
of O 
these O 
imidazole B-SYSTEMATIC 
inhibitors O 
were O 
also O 
discussed O 
. O 

happens O 
to O 
the O 
thiolates B-FAMILY 
created O 
by O 
reductively O 
desorbing O 
SAMs O 
? O 
An O 
in O 
situ O 
study O 
using O 
fluorescence O 
microscopy O 
and O 
electrochemistry O 
. O 

situ O 
examination O 
of O 
the O 
reductive O 
desorption O 
process O 
for O 
Au B-FORMULA 
microelectrodes O 
modified O 
with O 
a O 
thiol B-FAMILY 
self O 
- O 
assembled O 
monolayer O 
( O 
SAM O 
) O 
using O 
fluorescence O 
microscopy O 
enabled O 
the O 
study O 
of O 
the O 
fate O 
of O 
the O 
desorbed O 
thiolate B-SYSTEMATIC 
species O 
. O 
The O 
Bodipy O 
labeled O 
alkyl- O 
thiol B-FAMILY 
SAM O 
, O 
when O 
adsorbed O 
, O 
is O 
not O 
fluorescent O 
due O 
to O 
quenching O 
by O 
the O 
Au B-FORMULA 
surface O 
. O 
Once O 
reductively O 
desorbed O 
, O 
the O 
thiolate B-SYSTEMATIC 
molecules O 
fluoresce O 
and O 
their O 
direction O 
and O 
speed O 
are O 
monitored O 
. O 
At O 
moderately O 
negative O 
reduction O 
potentials O 
, O 
the O 
thiolate B-SYSTEMATIC 
species O 
hemispherically O 
diffuse O 
away O 
from O 
the O 
microelectrode O 
. O 
Also O 
observed O 
is O 
the O 
influence O 
of O 
a O 
closely O 
positioned O 
counter O 
electrode O 
on O 
the O 
direction O 
of O 
the O 
desorbed O 
thiolate B-SYSTEMATIC 
movement O 
. O 
As O 
the O 
potential O 
becomes O 
more O 
negative O 
, O 
the O 
molecules O 
move O 
in O 
an O 
upward O 
direction O 
, O 
with O 
a O 
speed O 
that O 
depends O 
on O 
the O 
amount O 
of O 
dissolved O 
H(2) B-FORMULA 
produced O 
by O 
water O 
reduction O 
. O 
Shown O 
is O 
that O 
this O 
motion O 
is O 
controlled O 
, O 
in O 
large O 
part O 
, O 
by O 
the O 
change O 
in O 
the O 
electrolyte O 
density O 
near O 
the O 
electrode O 
due O 
to O 
dissolved O 
H(2) B-FORMULA 
. O 
These O 
results O 
should O 
help O 
in O 
explaining O 
the O 
extent O 
of O 
readsorption O 
at O 
oxidative O 
potentials O 
observed O 
in O 
cyclic O 
voltammetry O 
( O 
CV O 
) O 
reductive O 
desorption O 
measurements O 
, O 
as O 
well O 
as O 
improving O 
the O 
general O 
understanding O 
of O 
the O 
SAM O 
removal O 
process O 
by O 
reductive O 
desorption O 
. O 
The O 
electrogenerated O 
H(2) B-FORMULA 
was O 
also O 
shown O 
to O 
be O 
able O 
to O 
reductively O 
remove O 
the O 
thiol O 
SAM O 
from O 
the O 
Pt B-FORMULA 
/ O 
Ir B-FORMULA 
particles O 
that O 
decorate O 
the O 
microelectrode O 
glass O 
sheath O 
. O 

optimization O 
of O 
a O 
pyridine B-SYSTEMATIC 
- I-SYSTEMATIC 
carboxamide I-SYSTEMATIC 
series O 
as O 
DGAT-1 O 
inhibitors O 
. O 

structure O 
- O 
activity O 
relationship O 
studies O 
of O 
a O 
novel O 
series O 
of O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
derivatives O 
of O 
pyridine B-FAMILY 
- I-FAMILY 
carboxamides I-FAMILY 
as O 
DGAT-1 O 
inhibitors O 
is O 
described O 
. O 
The O 
optimization O 
of O 
the O 
initial O 
lead O 
compound O 
6 O 
based O 
on O 
in O 
vitro O 
and O 
in O 
vivo O 
activity O 
led O 
to O 
the O 
discovery O 
of O 
key O 
compounds O 
10j O 
and O 
17h O 
. O 

of O 
high O 
- O 
energy O 
X-ray O 
diffraction O 
experiments O 
coupled O 
to O 
atomic O 
pair O 
distribution O 
function O 
analysis O 
of O 
disordered O 
low-Z O 
materials O 
are O 
presented O 
. O 
Several O 
scientifically O 
and O 
technologically O 
important O 
classes O 
of O 
disordered O 
low-Z O 
materials O 
such O 
as O 
small O 
and O 
large O 
organic O 
molecules O 
, O 
graphitic B-TRIVIAL 
powders O 
, O 
polymers O 
and O 
liquids O 
are O 
intentionally O 
explored O 
to O 
certify O 
the O 
technique's O 
performance O 
. O 
Results O 
clearly O 
show O 
that O 
disordered O 
low-Z O 
materials O 
can O 
be O 
well O 
characterized O 
in O 
terms O 
of O 
material's O 
phase O 
identity O 
, O 
relative O 
abundance O 
in O 
mixtures O 
and O 
atomic O 
- O 
scale O 
structure O 
. O 
The O 
demonstrated O 
efficiency O 
of O 
the O 
technique O 
provides O 
the O 
scientific O 
community O 
with O 
much O 
needed O 
confidence O 
to O 
apply O 
it O 
more O 
often O 
than O 
now O 
. O 

is O 
frequently O 
highly O 
expressed O 
in O 
premalignant O 
breast O 
cancers O 
, O 
including O 
ductal O 
carcinoma O 
in O 
situ O 
( O 
DCIS O 
) O 
; O 
however O 
, O 
little O 
is O 
known O 
about O 
the O 
signals O 
or O 
pathways O 
it O 
contributes O 
to O 
progression O 
into O 
the O 
invasive O 
/ O 
malignant O 
state O 
. O 
Radiotherapy O 
is O 
often O 
used O 
to O 
treat O 
early O 
premalignant O 
lesions O 
regardless O 
of O 
ErbB2 O 
status O 
. O 
Here O 
, O 
we O 
show O 
that O 
clinically O 
relevant O 
doses O 
of O 
ionizing O 
radiation O 
(IR)-induce O 
cellular O 
invasion O 
of O 
ErbB2-expressing O 
breast O 
cancer O 
cells O 
, O 
as O 
well O 
as O 
MCF10A O 
cells O 
overexpressing O 
ErbB2 O 
. O 
ErbB2-negative O 
breast O 
cancer O 
cells O 
, O 
such O 
as O 
MCF7 O 
and O 
T47D O 
, O 
do O 
not O 
invade O 
following O 
treatment O 
with O 
IR O 
nor O 
do O 
MCF10A O 
cells O 
overexpressing O 
epidermal O 
growth O 
factor O 
receptor O 
. O 
ErbB2 O 
becomes O 
phosphorylated O 
at O 
tyrosine B-TRIVIAL 
877 O 
in O 
a O 
dose- O 
and O 
time- O 
dependent O 
manner O 
following O 
exposure O 
to O 
X-rays O 
, O 
and O 
activates O 
downstream O 
signaling O 
cascades O 
including O 
PI3K O 
/ O 
Akt O 
. O 
Inhibition O 
of O 
these O 
pathways O 
, O 
as O 
well O 
as O 
inhibition O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
with O 
antioxidants O 
, O 
prevents O 
IR-induced O 
invasion O 
. O 
Activation O 
of O 
ErbB2-dependent O 
signaling O 
results O 
in O 
upregulation O 
of O 
the O 
forkhead O 
family O 
transcription O 
factor O 
, O 
FoxM1 O 
, O 
and O 
its O 
transcriptional O 
targets O 
, O 
including O 
matrix O 
metalloproteinase O 
2 O 
( O 
MMP2 O 
) O 
. O 
Inhibition O 
of O 
FoxM1 O 
by O 
RNA O 
interference O 
prevented O 
induction O 
of O 
invasion O 
by O 
IR O 
, O 
and O 
overexpression O 
of O 
FoxM1 O 
in O 
MCF10A O 
cells O 
was O 
sufficient O 
to O 
promote O 
IR-induced O 
invasion O 
. O 
Moreover O 
, O 
we O 
found O 
that O 
14-3-3ζ O 
is O 
also O 
upregulated O 
by O 
IR O 
in O 
cancer O 
cells O 
in O 
a O 
ROS-dependent O 
manner O 
, O 
is O 
required O 
for O 
IR-induced O 
invasion O 
in O 
ErbB2-positive O 
breast O 
cancer O 
cells O 
and O 
together O 
with O 
FoxM1 O 
is O 
sufficient O 
for O 
invasion O 
in O 
ErbB2-negative O 
breast O 
cancer O 
cells O 
. O 
Thus O 
, O 
our O 
data O 
show O 
that O 
IR O 
- O 
mediated O 
activation O 
of O 
ErbB2 O 
and O 
induction O 
of O 
14-3-3ζ O 
collaborate O 
to O 
regulate O 
FoxM1 O 
and O 
promote O 
invasion O 
of O 
breast O 
cancer O 
cells O 
and O 
furthermore O 
, O 
may O 
serve O 
as O 
therapeutic O 
targets O 
to O 
enhance O 
radiosensitivity O 
of O 
breast O 
cancers.Oncogene O 
advance O 
online O 
publication O 
, O 
14 O 
January O 
2013 O 
; O 
doi O 
: O 
10.1038 O 
/ O 
onc.2012.629 O 
. O 

of O 
celiac O 
superior O 
mesenteric O 
ganglionectomy O 
on O 
glucose B-TRIVIAL 
homeostasis O 
and O 
hormonal O 
changes O 
during O 
oral O 
glucose B-TRIVIAL 
tolerance O 
testing O 
in O 
rats O 
. O 

liver O 
plays O 
an O 
important O 
role O 
in O 
maintaining O 
glucose B-TRIVIAL 
homeostasis O 
in O 
the O 
body O 
. O 
In O 
the O 
prandial O 
state O 
, O 
some O 
of O 
the O 
glucose B-TRIVIAL 
which O 
is O 
absorbed O 
by O 
the O 
gastrointestinal O 
tract O 
is O 
converted O 
into O 
glycogen O 
and O 
stored O 
in O 
the O 
liver O 
. O 
In O 
contrast O 
, O 
the O 
liver O 
produces O 
glucose B-TRIVIAL 
by O 
glycogenolysis O 
and O 
gluconeogenesis O 
while O 
fasting O 
. O 
Thus O 
, O 
the O 
liver O 
contributes O 
to O 
maintaining O 
blood O 
glucose B-TRIVIAL 
level O 
within O 
normoglycemic O 
range O 
. O 
Glycogenesis O 
and O 
glycogenolysis O 
are O 
regulated O 
by O 
various O 
mechanisms O 
including O 
hormones O 
, O 
the O 
sympathetic O 
and O 
parasympathetic O 
nervous O 
systems O 
and O 
the O 
hepatic O 
glucose B-TRIVIAL 
content O 
. O 
In O 
this O 
study O 
, O 
we O 
examined O 
a O 
rat O 
model O 
in O 
which O 
the O 
celiac O 
superior O 
mesenteric O 
ganglion O 
( O 
CSMG O 
) O 
was O 
resected O 
. O 
We O 
attempted O 
to O 
elucidate O 
how O 
the O 
celiac O 
sympathetic O 
nervous O 
system O 
is O 
involved O 
in O 
regulating O 
glucose B-TRIVIAL 
homeostasis O 
by O 
assessing O 
the O 
effects O 
of O 
CSMG O 
resection O 
on O 
glucose B-TRIVIAL 
excursion O 
during O 
an O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
, O 
and O 
by O 
examining O 
hepatic O 
glycogen O 
content O 
and O 
hepatic O 
glycogen O 
phosphorylase O 
( O 
GP O 
) O 
activity O 
. O 
On O 
the O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
, O 
CSMG-resected O 
rats O 
demonstrated O 
improved O 
glucose B-TRIVIAL 
tolerance O 
and O 
significantly O 
increased O 
GP O 
activity O 
compared O 
with O 
sham O 
- O 
operated O 
rats O 
, O 
whereas O 
there O 
were O 
no O 
significant O 
differences O 
in O 
insulin O 
, O 
glucagon O 
or O 
catecholamine B-TRIVIAL 
levels O 
between O 
the O 
2 O 
groups O 
. O 
These O 
results O 
suggest O 
that O 
the O 
celiac O 
sympathetic O 
nervous O 
system O 
is O 
involved O 
in O 
regulating O 
the O 
rate O 
of O 
glycogen O 
consumption O 
through O 
GP O 
activity O 
. O 
In O 
conclusion O 
, O 
the O 
examined O 
rat O 
model O 
showed O 
that O 
the O 
celiac O 
sympathetic O 
nervous O 
system O 
regulates O 
hepatic O 
glucose B-TRIVIAL 
metabolism O 
in O 
conjunction O 
with O 
vagal O 
nerve O 
innervations O 
and O 
is O 
a O 
critical O 
component O 
in O 
the O 
maintenance O 
of O 
blood O 
glucose B-TRIVIAL 
homeostasis O 
. O 

protects O 
human O 
dental O 
pulp O 
cells O 
from O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
-induced O 
oxidative O 
toxicity O 
via O 
Nrf2 O 
pathway O 
- O 
dependent O 
heme O 
oxygenase-1 O 
expressions O 
. O 

verniciflua O 
Stokes O 
is O 
a O 
plant O 
that O 
is O 
native O 
to O 
East O 
Asian O 
countries O 
, O 
such O 
as O 
Korea O 
, O 
China O 
, O 
and O 
Japan O 
. O 
Butein B-TRIVIAL 
, O 
a O 
plant O 
polyphenol B-FAMILY 
, O 
is O 
one O 
of O 
the O 
major O 
active O 
components O 
of O 
R O 
. O 
verniciflua O 
. O 
Reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
produced O 
via O 
dental O 
adhesive O 
bleaching O 
agents O 
and O 
pulpal O 
disease O 
, O 
can O 
cause O 
oxidative O 
stress O 
. O 
Here O 
, O 
we O 
found O 
that O 
butein B-TRIVIAL 
possesses O 
cytoprotective O 
effects O 
on O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
H2O2 B-FORMULA 
)-induced O 
dental O 
cell O 
death O 
. O 
H2O2 B-FORMULA 
is O 
a O 
representative O 
ROS O 
and O 
causes O 
cell O 
death O 
through O 
necrosis O 
in O 
human O 
dental O 
pulp O 
( O 
HDP O 
) O 
cells O 
. O 
H2O2 B-FORMULA 
-induced O 
cytotoxicity O 
and O 
production O 
of O 
ROS O 
were O 
blocked O 
in O 
the O 
presence O 
of O 
butein B-TRIVIAL 
, O 
and O 
these O 
effects O 
were O 
dose O 
dependent O 
. O 
Butein B-TRIVIAL 
also O 
increased O 
heme B-FAMILY 
oxygenase-1 O 
( O 
HO-1 O 
) O 
protein O 
expression O 
and O 
HO O 
activity O 
. O 
In O 
addition O 
, O 
butein B-TRIVIAL 
-dependent O 
HO-1 O 
expression O 
was O 
required O 
for O 
the O 
inhibition O 
of O 
H2O2 B-FORMULA 
-induced O 
cell O 
death O 
and O 
ROS O 
generation O 
. O 
Furthermore O 
, O 
butein B-TRIVIAL 
treatment O 
caused O 
nuclear O 
accumulation O 
of O 
nuclear O 
factor-E2 O 
- O 
related O 
factor O 
2 O 
( O 
Nrf2 O 
) O 
and O 
increased O 
the O 
promoter O 
activity O 
of O 
antioxidant O 
response O 
elements O 
( O 
AREs O 
) O 
. O 
Treatment O 
of O 
HDP O 
cells O 
with O 
a O 
c-Jun O 
NH2 B-FORMULA 
-terminal O 
kinase O 
( O 
JNK O 
) O 
inhibitor O 
also O 
reduced O 
butein B-TRIVIAL 
-induced O 
HO-1 O 
expression O 
, O 
and O 
butein B-TRIVIAL 
treatment O 
led O 
to O 
increased O 
JNK O 
phosphorylation O 
. O 
These O 
results O 
indicate O 
that O 
butein B-TRIVIAL 
may O 
be O 
used O 
to O 
prevent O 
functional O 
dental O 
cell O 
death O 
and O 
thus O 
may O 
be O 
useful O 
as O 
a O 
pulpal O 
disease O 
agent O 
. O 

and O 
nitrosative O 
stress O 
and O 
apoptosis O 
in O 
oral O 
mucosa O 
cells O 
after O 
ex O 
vivo O 
exposure O 
to O 
lead O 
and O 
benzo[a]pyrene B-SYSTEMATIC 
. O 

of O 
human O 
oral O 
mucosa O 
to O 
lead O 
( O 
Pb B-FORMULA 
) O 
and O 
benzo[a]pyrene B-SYSTEMATIC 
( O 
BaP B-ABBREVIATION 
) O 
by O 
inhalation O 
and O 
ingestion O 
can O 
lead O 
to O 
pathological O 
conditions O 
via O 
apoptosis O 
and O 
oxidative O 
and O 
nitrosative O 
stress O 
. O 
However O 
, O 
few O 
studies O 
have O 
investigated O 
the O 
effects O 
of O 
Pb B-FORMULA 
and O 
BaP B-ABBREVIATION 
on O 
oral O 
mucosa O 
cells O 
. O 
Furthermore O 
, O 
previous O 
studies O 
focused O 
on O 
chronic O 
Pb B-FORMULA 
and O 
BaP B-ABBREVIATION 
exposure O 
. O 
Therefore O 
, O 
we O 
evaluated O 
important O 
markers O 
of O 
apoptosis O 
and O 
oxidative O 
and O 
nitrosative O 
stress O 
in O 
oral O 
mucosa O 
cells O 
by O 
incubating O 
the O 
cells O 
with O 
Pb B-FORMULA 
and O 
BaP B-ABBREVIATION 
for O 
5-360 O 
min O 
. O 
Ex O 
vivo O 
samples O 
of O 
human O 
oral O 
mucosa O 
were O 
exposed O 
to O 
Pb B-FORMULA 
or O 
BaP B-ABBREVIATION 
, O 
and O 
immunohistochemical O 
staining O 
was O 
performed O 
to O 
evaluate O 
active O 
caspase-3 O 
, O 
8-epi-prostaglandin B-SYSTEMATIC 
F2 I-SYSTEMATIC 
alpha I-SYSTEMATIC 
( O 
8-epi-PGF2a B-SYSTEMATIC 
) O 
, O 
and O 
3-nitrotyrosine B-SYSTEMATIC 
( O 
3-NT B-SYSTEMATIC 
) O 
. O 
Pb B-FORMULA 
and O 
BaP B-ABBREVIATION 
treatments O 
significantly O 
increased O 
active O 
caspase-3 O 
levels O 
in O 
a O 
time O 
- O 
dependent O 
manner O 
. O 
Furthermore O 
, O 
the O 
treatments O 
induced O 
an O 
early O 
increase O 
in O 
3-NT B-SYSTEMATIC 
level O 
, O 
which O 
ceased O 
with O 
longer O 
incubation O 
times O 
. O 
8-Epi-PGF2a B-SYSTEMATIC 
level O 
increased O 
only O 
after O 
prolonged O 
incubation O 
with O 
Pb B-FORMULA 
, O 
and O 
this O 
elevation O 
was O 
irrespective O 
of O 
BaP B-ABBREVIATION 
incubation O 
duration O 
. O 
Smokers' O 
samples O 
had O 
significantly O 
lower O 
levels O 
of O 
markers O 
of O 
oxidative O 
and O 
nitrosative O 
stress O 
than O 
did O 
nonsmokers O 
' O 
samples O 
. O 
Thus O 
, O 
single O 
, O 
short O 
- O 
term O 
exposure O 
to O 
Pb B-FORMULA 
or O 
BaP B-ABBREVIATION 
increases O 
the O 
levels O 
of O 
apoptosis O 
markers O 
and O 
markers O 
of O 
oxidative O 
and O 
nitrosative O 
stress O 
. O 

of O 
enzymatically O 
modified O 
isoquercitrin B-TRIVIAL 
on O 
preneoplastic O 
liver O 
cell O 
lesions O 
induced O 
by O 
thioacetamide B-SYSTEMATIC 
promotion O 
in O 
a O 
two O 
- O 
stage O 
hepatocarcinogenesis O 
model O 
using O 
rats O 
. O 

investigate O 
the O 
protective O 
effect O 
of O 
enzymatically O 
modified O 
isoquercitrin B-TRIVIAL 
( O 
EMIQ O 
) O 
on O 
the O 
hepatocarcinogenic O 
process O 
, O 
we O 
used O 
a O 
two O 
- O 
stage O 
hepatocarcinogenesis O 
model O 
in O 
N-diethylnitrosamine B-SYSTEMATIC 
-initiated O 
and O 
thioacetamide B-SYSTEMATIC 
( O 
TAA B-ABBREVIATION 
) O 
- O 
promoted O 
rats O 
. O 
We O 
examined O 
the O 
modifying O 
effect O 
of O 
co O 
- O 
administration O 
with O 
EMIQ O 
on O 
the O 
liver O 
tissue O 
environment O 
including O 
hepatic O 
macrophages O 
and O 
lymphocytes O 
and O 
on O 
the O 
induction O 
mechanism O 
of O 
preneoplastic O 
cell O 
apoptosis O 
during O 
early O 
stages O 
of O 
hepatocellular O 
tumor O 
promotion O 
. O 
TAA B-ABBREVIATION 
increased O 
the O 
number O 
and O 
area O 
of O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
placental O 
form O 
(GST-P)(+) O 
liver O 
cell O 
foci O 
and O 
the O 
numbers O 
of O 
proliferating O 
and O 
apoptotic O 
cells O 
in O 
randomly O 
selected O 
areas O 
in O 
liver O 
sections O 
. O 
Co-administration O 
with O 
EMIQ O 
suppressed O 
these O 
effects O 
. O 
TAA B-ABBREVIATION 
also O 
increased O 
the O 
numbers O 
of O 
ED2(+) O 
, O 
cyclooxygenase-2(+) O 
, O 
and O 
heme B-FAMILY 
oxygenase-1(+) O 
liver O 
cells O 
, O 
as O 
well O 
as O 
the O 
number O 
of O 
CD3(+) O 
lymphocytes O 
. O 
These O 
effects O 
were O 
also O 
suppressed O 
by O 
EMIQ O 
. O 
EMIQ O 
increased O 
liver O 
levels O 
of O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
-reactive O 
substance O 
and O 
8-hydroxydeoxyguanosine B-SYSTEMATIC 
, O 
and O 
TUNEL(+) O 
apoptotic O 
cells O 
, O 
death O 
receptor O 
5 O 
(DR5)(+) O 
cells O 
and O 
4-hydroxy-2-nonenal B-SYSTEMATIC 
( O 
+ O 
) O 
cells O 
within O 
GST-P(+) O 
foci O 
. O 
Outside O 
the O 
GST-P(+) O 
foci O 
, O 
EMIQ O 
decreased O 
the O 
numbers O 
of O 
apoptotic O 
cells O 
and O 
DR5(+) O 
cells O 
. O 
These O 
results O 
suggest O 
that O 
TAA B-ABBREVIATION 
-induced O 
tumor O 
promotion O 
involves O 
activation O 
of O 
hepatic O 
macrophages O 
producing O 
proinflammatory O 
factors O 
. O 
EMIQ O 
may O 
suppress O 
the O 
TAA B-ABBREVIATION 
-induced O 
tumor O 
- O 
promoting O 
activity O 
by O 
an O 
anti-inflammatory O 
mechanism O 
mediated O 
by O 
suppressing O 
the O 
activation O 
of O 
these O 
macrophages O 
. O 
Furthermore O 
, O 
EMIQ O 
may O 
suppress O 
tumor O 
- O 
promoting O 
activity O 
differentially O 
between O 
the O 
inside O 
and O 
outside O 
of O 
GST-P(+) O 
foci O 
. O 
Within O 
GST-P(+) O 
foci O 
, O 
EMIQ O 
facilitates O 
the O 
apoptosis O 
of O 
preneoplastic O 
cells O 
through O 
the O 
upregulation O 
of O 
DR5 O 
. O 
Outside O 
the O 
GST-P(+) O 
foci O 
, O 
EMIQ O 
suppresses O 
apoptosis O 
and O 
the O 
subsequent O 
regeneration O 
of O 
non-transformed O 
liver O 
cells O 
. O 

and O 
intravenous O 
toxicokinetic O 
parameters O 
for O 
Pacific O 
ciguatoxin B-TRIVIAL 
P- O 
CTX-1 B-ABBREVIATION 
in O 
rats O 
. O 

are O 
sodium B-SYSTEMATIC 
channel O 
activator O 
toxins O 
responsible O 
for O 
ciguatera O 
fish O 
poisoning O 
. O 
In O 
this O 
study O 
, O 
we O 
determined O 
the O 
toxicokinetic O 
parameters O 
of O 
the O 
Pacific O 
ciguatoxin B-TRIVIAL 
P- O 
CTX-1 B-ABBREVIATION 
in O 
rats O 
after O 
an O 
intravenous O 
(iv) O 
dose O 
of O 
0.13 O 
ng O 
P- O 
CTX-1 B-ABBREVIATION 
per O 
g O 
of O 
body O 
weight O 
. O 
The O 
ciguatoxin B-TRIVIAL 
activity O 
was O 
assessed O 
over O 
time O 
in O 
blood O 
using O 
the O 
sensitive O 
functional O 
Neuro2a O 
assay O 
. O 
The O 
data O 
were O 
analyzed O 
with O 
a O 
two O 
- O 
compartmental O 
model O 
. O 
After O 
exposure O 
, O 
the O 
ciguatoxin B-TRIVIAL 
activity O 
exhibited O 
a O 
rapid O 
( O 
alpha O 
half O 
- O 
life O 
of O 
6 O 
min O 
) O 
and O 
extensive O 
distribution O 
into O 
tissues O 
( O 
apparent O 
steady O 
state O 
volume O 
of O 
distribution O 
of O 
7.8 O 
L O 
) O 
. O 
Ciguatoxin B-TRIVIAL 
elimination O 
from O 
blood O 
was O 
slower O 
with O 
a O 
beta O 
half O 
- O 
life O 
estimated O 
at O 
35.5 O 
h O 
. O 
The O 
toxicokinetic O 
parameters O 
determined O 
from O 
this O 
study O 
were O 
compared O 
to O 
data O 
previously O 
obtained O 
after O 
oral O 
and O 
intraperitoneal O 
exposure O 
of O 
rats O 
to O 
0.26 O 
ng O 
P- O 
CTX-1 B-ABBREVIATION 
per O 
g O 
of O 
body O 
weight O 
. O 
Maximal O 
bioavailability O 
was O 
determined O 
by O 
the O 
area O 
under O 
the O 
concentration O 
curve O 
, O 
and O 
was O 
used O 
to O 
calculate O 
the O 
absolute O 
P- O 
CTX-1 B-ABBREVIATION 
bioavailabilities O 
for O 
oral O 
and O 
intraperitoneal O 
routes O 
of O 
exposures O 
of O 
39% O 
and O 
75% O 
, O 
respectively O 
. O 

characteristics O 
of O 
human O 
red O 
blood O 
cell O 
membrane O 
change O 
due O 
to O 
C60 B-TRIVIAL 
nanoparticle O 
infiltration O 
. O 

mechanical O 
characteristics O 
of O 
human O 
red O 
blood O 
cell O 
( O 
RBC O 
) O 
membrane O 
change O 
due O 
to O 
C(60) B-TRIVIAL 
nanoparticle O 
( O 
NP O 
) O 
infiltration O 
have O 
been O 
investigated O 
in O 
the O 
present O 
work O 
. O 
Using O 
experimental O 
approaches O 
, O 
including O 
optical O 
tweezer O 
( O 
OT O 
) O 
stretching O 
and O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
indentation O 
, O 
we O 
found O 
that O 
RBCs O 
in O 
the O 
presence O 
of O 
C(60) B-TRIVIAL 
NPs O 
are O 
softer O 
than O 
normal O 
RBCs O 
. O 
The O 
strain O 
- O 
stress O 
relations O 
of O 
both O 
normal O 
and O 
C(60) B-TRIVIAL 
infiltrated O 
RBC O 
membranes O 
are O 
extracted O 
from O 
the O 
data O 
of O 
AFM O 
indentation O 
, O 
from O 
which O 
we O 
proved O 
that O 
C(60) B-TRIVIAL 
NP O 
infiltration O 
can O 
affect O 
the O 
mechanical O 
properties O 
of O 
RBC O 
membrane O 
and O 
tend O 
to O 
weaken O 
the O 
tensile O 
resistance O 
of O 
lipids O 
bilayers O 
. O 
In O 
order O 
to O 
explain O 
this O 
experimental O 
phenomenon O 
, O 
a O 
mechanical O 
model O 
has O 
been O 
developed O 
. O 
Based O 
on O 
this O 
model O 
, O 
the O 
strain O 
- O 
stress O 
relations O 
of O 
both O 
normal O 
and O 
C(60) B-TRIVIAL 
infiltrated O 
lipid O 
bilayers O 
are O 
calculated O 
with O 
consideration O 
of O 
intermolecular O 
interactions O 
. O 
The O 
theoretical O 
results O 
are O 
in O 
great O 
agreement O 
with O 
the O 
experimental O 
results O 
. O 
The O 
influence O 
of O 
C(60) B-TRIVIAL 
NP O 
concentration O 
on O 
the O 
mechanical O 
properties O 
of O 
RBC O 
membrane O 
is O 
successfully O 
predicted O 
. O 
Higher O 
concentrations O 
of O 
C(60) B-TRIVIAL 
NPs O 
in O 
the O 
lipid O 
bilayers O 
will O 
lead O 
to O 
increased O 
damage O 
to O 
the O 
cell O 
membrane O 
, O 
implying O 
that O 
the O 
dosage O 
of O 
C(60) B-TRIVIAL 
NPs O 
should O 
be O 
controlled O 
in O 
medical O 
applications O 
. O 

engineered O 
specific O 
microfluidic O 
devices O 
based O 
on O 
the O 
pervaporation O 
of O 
water O 
through O 
a O 
PDMS B-ABBREVIATION 
membrane O 
, O 
to O 
formulate O 
continuous O 
and O 
steady O 
concentration O 
gradients O 
of O 
a O 
binary O 
aqueous O 
molecular O 
mixture O 
at O 
the O 
nanolitre O 
scale O 
. O 
In O 
the O 
case O 
of O 
a O 
model O 
complex O 
fluid O 
( O 
a O 
triblock O 
copolymer O 
solution O 
) O 
, O 
we O 
demonstrate O 
that O 
such O 
a O 
steady O 
gradient O 
crosses O 
the O 
phase O 
diagram O 
from O 
pure O 
water O 
up O 
to O 
a O 
succession O 
of O 
highly O 
viscous O 
mesophases O 
. O 
We O 
then O 
performed O 
in O 
situ O 
spatially O 
resolved O 
measurements O 
( O 
confocal O 
spectroscopy O 
and O 
small O 
- O 
angle O 
X-ray O 
scattering O 
) O 
to O 
quantitatively O 
measure O 
the O 
concentration O 
profile O 
and O 
to O 
determine O 
the O 
microstructure O 
of O 
the O 
different O 
textures O 
. O 
Within O 
a O 
single O 
microfluidic O 
channel O 
, O 
we O 
thus O 
screen O 
quantitatively O 
and O 
continuously O 
the O 
phase O 
diagram O 
of O 
a O 
complex O 
fluid O 
. O 
Beside O 
, O 
as O 
such O 
a O 
gradient O 
corresponds O 
to O 
an O 
out O 
- O 
of O 
- O 
equilibrium O 
regime O 
, O 
we O 
also O 
extract O 
from O 
the O 
concentration O 
measurement O 
a O 
precise O 
estimate O 
of O 
the O 
collective O 
diffusion O 
coefficient O 
of O 
the O 
mixture O 
as O 
a O 
function O 
of O 
the O 
concentration O 
. O 
In O 
the O 
present O 
case O 
of O 
the O 
triblock O 
copolymer O 
, O 
this O 
transport O 
coefficient O 
features O 
discontinuities O 
at O 
some O 
phase O 
boundaries O 
, O 
which O 
have O 
never O 
been O 
observed O 
before O 
. O 

N B-FORMULA 
-terminal O 
nuclear O 
export O 
signal O 
regulates O 
trafficking O 
and O 
aggregation O 
of O 
Huntingtin O 
( O 
Htt O 
) O 
protein O 
exon O 
1 O 
. O 

disease O 
is O 
a O 
dominantly O 
inherited O 
neurodegenerative O 
condition O 
caused O 
by O 
polyglutamine B-FAMILY 
expansion O 
in O 
the O 
N B-FORMULA 
terminus O 
of O 
the O 
huntingtin O 
protein O 
( O 
Htt O 
) O 
. O 
The O 
first O 
17 O 
amino B-FAMILY 
acids I-FAMILY 
( O 
N17 O 
) O 
of O 
Htt O 
play O 
a O 
key O 
role O 
in O 
regulating O 
its O 
toxicity O 
and O 
aggregation O 
. O 
Both O 
nuclear O 
export O 
and O 
cytoplasm O 
retention O 
functions O 
have O 
been O 
ascribed O 
to O 
N17 O 
. O 
We O 
have O 
determined O 
that O 
N17 O 
acts O 
as O 
a O 
nuclear O 
export O 
sequence O 
( O 
NES O 
) O 
within O 
Htt O 
exon O 
and O 
when O 
fused O 
to O 
yellow O 
fluorescent O 
protein O 
. O 
We O 
have O 
defined O 
amino B-FAMILY 
acids I-FAMILY 
within O 
N17 O 
that O 
constitute O 
the O 
nuclear O 
export O 
sequence O 
( O 
NES O 
) O 
. O 
Mutation O 
of O 
any O 
of O 
the O 
conserved O 
residues O 
increases O 
nuclear O 
accumulation O 
of O 
Htt O 
exon O 
1 O 
. O 
Nuclear O 
export O 
of O 
Htt O 
is O 
sensitive O 
to O 
leptomycin B-TRIVIAL 
B I-TRIVIAL 
and O 
is O 
reduced O 
by O 
knockdown O 
of O 
exportin O 
1 O 
. O 
In O 
HEK293 O 
cells O 
, O 
NES O 
mutations O 
decrease O 
overall O 
Htt O 
aggregation O 
but O 
increase O 
the O 
fraction O 
of O 
cells O 
with O 
nuclear O 
inclusions O 
. O 
In O 
primary O 
cultured O 
neurons O 
, O 
NES O 
mutations O 
increase O 
nuclear O 
accumulation O 
and O 
increase O 
overall O 
aggregation O 
. O 
This O 
work O 
defines O 
a O 
bona O 
fide O 
nuclear O 
export O 
sequence O 
within O 
N17 O 
and O 
links O 
it O 
to O 
effects O 
on O 
protein O 
aggregation O 
. O 
This O 
may O 
help O 
explain O 
the O 
important O 
role O 
of O 
N17 O 
in O 
controlling O 
Htt O 
toxicity O 
. O 

- O 
controlled O 
metal O 
nanocrystals O 
are O 
a O 
new O 
generation O 
of O 
nanoscale O 
catalysts O 
. O 
Depending O 
on O 
their O 
shapes O 
, O 
these O 
nanocrystals O 
exhibit O 
various O 
surface O 
facets O 
, O 
and O 
the O 
assignments O 
of O 
their O 
surface O 
facets O 
have O 
routinely O 
been O 
used O 
to O 
rationalize O 
or O 
predict O 
their O 
catalytic O 
activity O 
in O 
a O 
variety O 
of O 
chemical O 
transformations O 
. O 
Recently O 
we O 
discovered O 
that O 
for O 
1-dimensional O 
( O 
1D O 
) O 
nanocrystals O 
( O 
Au B-FORMULA 
nanorods O 
) O 
, O 
the O 
catalytic O 
activity O 
is O 
not O 
constant O 
along O 
the O 
same O 
side O 
facets O 
of O 
single O 
nanorods O 
but O 
rather O 
differs O 
significantly O 
and O 
further O 
shows O 
a O 
gradient O 
along O 
its O 
length O 
, O 
which O 
we O 
attributed O 
to O 
an O 
underlying O 
gradient O 
of O 
surface O 
defect O 
density O 
resulting O 
from O 
their O 
linear O 
decay O 
in O 
growth O 
rate O 
during O 
synthesis O 
( O 
Nat O 
. O 
Nanotechnol.2012 O 
, O 
7 O 
, O 
237-241 O 
) O 
. O 
Here O 
we O 
report O 
that O 
this O 
behavior O 
also O 
extends O 
to O 
2D O 
nanocrystals O 
, O 
even O 
for O 
a O 
different O 
catalytic O 
reaction O 
. O 
By O 
using O 
super O 
- O 
resolution O 
fluorescence O 
microscopy O 
to O 
map O 
out O 
the O 
locations O 
of O 
catalytic O 
events O 
within O 
individual O 
triangular O 
and O 
hexagonal O 
Au B-FORMULA 
nanoplates O 
in O 
correlation O 
with O 
scanning O 
electron O 
microscopy O 
, O 
we O 
find O 
that O 
the O 
catalytic O 
activity O 
within O 
the O 
flat O 
{ O 
111 O 
} O 
surface O 
facet O 
of O 
a O 
Au B-FORMULA 
nanoplate O 
exhibits O 
a O 
2D O 
radial O 
gradient O 
from O 
the O 
center O 
toward O 
the O 
edges O 
. O 
We O 
propose O 
that O 
this O 
activity O 
gradient O 
results O 
from O 
a O 
growth O 
- O 
dependent O 
surface O 
defect O 
distribution O 
. O 
We O 
also O 
quantify O 
the O 
site O 
- O 
specific O 
activity O 
at O 
different O 
regions O 
within O 
a O 
nanoplate O 
: O 
The O 
corner O 
regions O 
have O 
the O 
highest O 
activity O 
, O 
followed O 
by O 
the O 
edge O 
regions O 
and O 
then O 
the O 
flat O 
surface O 
facets O 
. O 
These O 
discoveries O 
highlight O 
the O 
spatial O 
complexity O 
of O 
catalytic O 
activity O 
at O 
the O 
nanoscale O 
as O 
well O 
as O 
the O 
interplay O 
amid O 
nanocrystal O 
growth O 
, O 
morphology O 
, O 
and O 
surface O 
defects O 
in O 
determining O 
nanocatalyst O 
properties O 
. O 

factor O 
σ(54) O 
has O 
a O 
distinct O 
modus O 
operandi O 
for O 
mediating O 
the O 
activation O 
of O 
bacterial O 
RNA O 
polymerase O 
( O 
RNAP O 
) O 
at O 
promoter O 
recognition O 
motifs O 
12 O 
and O 
24 O 
bp O 
upstream O 
from O 
transcription O 
start O 
sites O 
. O 
σ(54) O 
was O 
thought O 
to O 
act O 
as O 
monomer O 
in O 
all O 
transcription O 
steps O 
. O 
However O 
, O 
we O 
provide O 
evidence O 
that O 
σ(54) O 
of O 
Pseudomonas O 
putida O 
interacts O 
stably O 
with O 
itself O 
. O 
The O 
interface O 
between O 
monomers O 
involves O 
contacts O 
in O 
σ(54) O 
regions O 
I O 
and O 
III O 
, O 
sequences O 
that O 
play O 
key O 
roles O 
in O 
the O 
transcription O 
activation O 
of O 
σ(54)-RNAP O 
holoenzyme O 
. O 
These O 
roles O 
include O 
interactions O 
with O 
activator O 
proteins O 
and O 
the O 
-12 O 
and O 
-24 O 
motifs O 
. O 
In O 
particular O 
, O 
we O 
detected O 
inter O 
- O 
monomer O 
contacts O 
between O 
region O 
I O 
, O 
and O 
between O 
region O 
I O 
and O 
the O 
C B-FORMULA 
-terminal O 
portion O 
of O 
region O 
III O 
. O 
Our O 
results O 
suggest O 
a O 
new O 
auto O 
- O 
antagonistic O 
regulatory O 
state O 
of O 
σ(54) O 
. O 

of O 
regioselectivity O 
and O 
chemoselectivity O 
in O 
fosfomycin B-TRIVIAL 
resistance O 
protein O 
FosA O 
from O 
QM O 
/ O 
MM O 
calculations O 
. O 

is O 
a O 
manganese B-SYSTEMATIC 
-dependent O 
enzyme O 
that O 
utilizes O 
a O 
Mn(2+) B-FORMULA 
ion O 
to O 
catalyze O 
the O 
inactivation O 
of O 
the O 
fosfomycin B-TRIVIAL 
antibiotic O 
by O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
addition O 
. O 
We O 
report O 
a O 
theoretical O 
study O 
on O 
the O 
catalytic O 
mechanism O 
and O 
the O 
factors O 
governing O 
the O 
regioselectivity O 
and O 
chemoselectivity O 
of O 
FosA O 
. O 
Density O 
functional O 
theory O 
( O 
DFT O 
) O 
calculations O 
on O 
the O 
uncatalyzed O 
reaction O 
give O 
high O 
barriers O 
and O 
almost O 
no O 
regioselectivity O 
even O 
when O 
adding O 
two O 
water O 
molecules O 
to O 
assist O 
the O 
proton O 
transfer O 
. O 
According O 
to O 
quantum O 
mechanics O 
/ O 
molecular O 
mechanics O 
( O 
QM O 
/ O 
MM O 
) O 
calculations O 
on O 
the O 
full O 
solvated O 
protein O 
, O 
the O 
enzyme O 
- O 
catalyzed O 
glutathione B-TRIVIAL 
addition O 
reaction O 
involves O 
two O 
major O 
chemical O 
steps O 
that O 
both O 
proceed O 
in O 
the O 
sextet O 
state O 
: O 
proton O 
transfer O 
from O 
the O 
GSH B-SYSTEMATIC 
thiol I-SYSTEMATIC 
group O 
to O 
the O 
Tyr B-FORMULA 
39 O 
anion O 
and O 
nucleophilic O 
attack O 
by O 
the O 
GSH B-SYSTEMATIC 
thiolate I-SYSTEMATIC 
leading O 
to O 
epoxide B-SYSTEMATIC 
ring O 
- O 
opening O 
. O 
The O 
second O 
step O 
is O 
rate O 
- O 
limiting O 
and O 
is O 
facilitated O 
by O 
the O 
presence O 
of O 
the O 
high O 
- O 
spin O 
Mn(2+) B-FORMULA 
ion O 
that O 
functions O 
as O 
a O 
Lewis B-FAMILY 
acid I-FAMILY 
and O 
stabilizes O 
the O 
leaving O 
oxyanion O 
through O 
direct O 
coordination O 
. O 
The O 
barrier O 
for O 
C1 O 
attack O 
is O 
computed O 
to O 
be O 
8.9 O 
kcal O 
/ O 
mol O 
lower O 
than O 
that O 
for O 
C2 O 
attack O 
, O 
in O 
agreement O 
with O 
the O 
experimentally O 
observed O 
regioselectivity O 
of O 
the O 
enzyme O 
. O 
Further O 
QM O 
/ O 
MM O 
calculations O 
on O 
the O 
alternative O 
water O 
attack O 
predict O 
a O 
concerted O 
mechanism O 
for O 
this O 
reaction O 
, O 
where O 
the O 
deprotonation O 
of O 
water O 
, O 
nucleophilic O 
attack O 
, O 
and O 
epoxide B-SYSTEMATIC 
ring O 
- O 
opening O 
take O 
place O 
via O 
the O 
same O 
transition O 
state O 
. O 
The O 
calculated O 
barrier O 
is O 
8.3 O 
kcal O 
/ O 
mol O 
higher O 
than O 
that O 
for O 
GSH B-ABBREVIATION 
attack O 
, O 
in O 
line O 
with O 
the O 
observed O 
chemoselectivity O 
of O 
the O 
enzyme O 
, O 
which O 
manages O 
to O 
catalyze O 
the O 
addition O 
of O 
GSH B-ABBREVIATION 
in O 
the O 
presence O 
of O 
water O 
molecules O 
around O 
its O 
active O 
site O 
. O 
The O 
catalytic O 
efficiency O 
, O 
regioselectivity O 
, O 
and O 
chemoselectivity O 
of O 
FosA O 
are O 
rationalized O 
in O 
terms O 
of O 
the O 
influence O 
of O 
the O 
active O 
- O 
site O 
protein O 
environment O 
and O 
the O 
different O 
stabilization O 
of O 
the O 
distorted O 
substrates O 
in O 
the O 
relevant O 
transition O 
states O 
. O 

is O 
the O 
contact O 
angle O 
of O 
water O 
on O 
graphene B-TRIVIAL 
? O 

experimental O 
and O 
theoretical O 
studies O 
have O 
addressed O 
the O 
question O 
of O 
the O 
wetting O 
properties O 
of O 
graphene B-TRIVIAL 
, O 
the O 
actual O 
value O 
of O 
the O 
contact O 
angle O 
of O 
water O 
on O 
an O 
isolated O 
graphene B-TRIVIAL 
monolayer O 
remains O 
unknown O 
. O 
While O 
recent O 
experimental O 
literature O 
indicates O 
that O 
the O 
contact O 
angle O 
of O 
water O 
on O 
graphite B-TRIVIAL 
is O 
in O 
the O 
range O 
90-95° O 
, O 
it O 
has O 
been O 
suggested O 
that O 
the O 
contact O 
angle O 
on O 
graphene B-TRIVIAL 
may O 
either O 
be O 
as O 
high O 
as O 
127° O 
or O 
moderately O 
enhanced O 
in O 
comparison O 
with O 
graphite B-TRIVIAL 
. O 
With O 
the O 
support O 
of O 
classical O 
molecular O 
dynamics O 
simulations O 
using O 
empirical O 
force O 
- O 
fields O 
, O 
we O 
develop O 
an O 
argumentation O 
to O 
show O 
that O 
the O 
value O 
of O 
127° O 
is O 
an O 
unrealistic O 
estimate O 
and O 
that O 
a O 
value O 
of O 
the O 
order O 
of O 
95-100° O 
should O 
be O 
expected O 
. O 
Our O 
study O 
establishes O 
a O 
connection O 
between O 
the O 
variation O 
of O 
the O 
work O 
of O 
adhesion O 
of O 
water O 
on O 
graphene B-TRIVIAL 
-based O 
surfaces O 
and O 
the O 
interaction O 
potential O 
between O 
individual O 
water O 
molecules O 
and O 
these O 
surfaces O 
. O 
We O 
show O 
that O 
a O 
variation O 
of O 
the O 
contact O 
angle O 
from O 
90° O 
on O 
graphite B-TRIVIAL 
to O 
127° O 
on O 
graphene B-TRIVIAL 
would O 
imply O 
that O 
both O 
of O 
the O 
first O 
two O 
carbon B-SYSTEMATIC 
layers O 
of O 
graphite B-TRIVIAL 
contribute O 
approximately O 
the O 
same O 
interaction O 
energy O 
with O 
water O 
. O 
Such O 
a O 
situation O 
is O 
incompatible O 
with O 
the O 
short O 
- O 
range O 
nature O 
of O 
the O 
interaction O 
between O 
water O 
and O 
this O 
substrate O 
. O 
We O 
also O 
show O 
that O 
the O 
interaction O 
potential O 
energy O 
between O 
water O 
and O 
the O 
graphene B-TRIVIAL 
-based O 
substrates O 
is O 
the O 
main O 
contribution O 
to O 
the O 
work O 
of O 
adhesion O 
of O 
water O 
with O 
a O 
relative O 
magnitude O 
that O 
is O 
independent O 
of O 
the O 
number O 
of O 
graphene B-TRIVIAL 
layers O 
. O 
We O 
introduce O 
the O 
idea O 
that O 
the O 
remaining O 
contribution O 
is O 
entropic O 
in O 
nature O 
and O 
is O 
connected O 
to O 
the O 
fluctuations O 
in O 
the O 
water O 
- O 
substrate O 
interaction O 
energy O 
. O 

gene O 
targeting O 
has O 
been O 
extensively O 
used O 
for O 
in O 
vivo O 
analysis O 
of O 
gene O 
function O 
in O 
adipocyte O 
cell O 
biology O 
but O 
often O 
with O 
debate O 
over O 
the O 
tissue O 
specificity O 
and O 
the O 
efficacy O 
of O 
inactivation O 
. O 
To O 
directly O 
compare O 
the O 
specificity O 
and O 
efficacy O 
of O 
different O 
Cre O 
lines O 
in O 
mediating O 
adipocyte O 
specific O 
recombination O 
, O 
transgenic O 
Cre O 
lines O 
driven O 
by O 
the O 
adipocyte O 
protein O 
2 O 
( O 
aP2 O 
) O 
and O 
adiponectin O 
( O 
Adipoq O 
) O 
gene O 
promoters O 
, O 
as O 
well O 
as O 
a O 
tamoxifen B-TRIVIAL 
-inducible O 
Cre O 
driven O 
by O 
the O 
aP2 O 
gene O 
promoter O 
( O 
iaP2 O 
) O 
, O 
were O 
bred O 
to O 
the O 
Rosa26R O 
( O 
R26R O 
) O 
reporter O 
. O 
All O 
three O 
Cre O 
lines O 
demonstrated O 
recombination O 
in O 
the O 
brown O 
and O 
white O 
fat O 
pads O 
. O 
Using O 
different O 
floxed O 
loci O 
, O 
the O 
individual O 
Cre O 
lines O 
displayed O 
a O 
range O 
of O 
efficacy O 
to O 
Cre O 
- O 
mediated O 
recombination O 
that O 
ranged O 
from O 
no O 
observable O 
recombination O 
to O 
complete O 
recombination O 
within O 
the O 
fat O 
. O 
The O 
Adipoq-Cre O 
exhibited O 
no O 
observable O 
recombination O 
in O 
any O 
other O 
tissues O 
examined O 
, O 
whereas O 
both O 
aP2-Cre O 
lines O 
resulted O 
in O 
recombination O 
in O 
endothelial O 
cells O 
of O 
the O 
heart O 
and O 
nonendothelial O 
, O 
nonmyocyte O 
cells O 
in O 
the O 
skeletal O 
muscle O 
. O 
In O 
addition O 
, O 
the O 
aP2-Cre O 
line O 
can O 
lead O 
to O 
germline O 
recombination O 
of O 
floxed O 
alleles O 
in O 
~2% O 
of O 
spermatozoa O 
. O 
Thus O 
, O 
different O 
" O 
adipocyte O 
- O 
specific O 
" O 
Cre O 
lines O 
display O 
different O 
degrees O 
of O 
efficiency O 
and O 
specificity O 
, O 
illustrating O 
important O 
differences O 
that O 
must O 
be O 
taken O 
into O 
account O 
in O 
their O 
use O 
for O 
studying O 
adipose O 
biology O 
. O 

and O 
related O 
µ-opioid O 
receptor O 
( O 
MOR O 
) O 
agonists O 
remain O 
among O 
the O 
most O 
effective O 
drugs O 
known O 
for O 
acute O 
relief O 
of O 
severe O 
pain O 
. O 
A O 
major O 
problem O 
in O 
treating O 
painful O 
conditions O 
is O 
that O 
tolerance O 
limits O 
the O 
long O 
- O 
term O 
utility O 
of O 
opioid O 
agonists O 
. O 
Considerable O 
effort O 
has O 
been O 
expended O 
on O 
developing O 
an O 
understanding O 
of O 
the O 
molecular O 
and O 
cellular O 
processes O 
that O 
underlie O 
acute O 
MOR O 
signaling O 
, O 
short O 
- O 
term O 
receptor O 
regulation O 
, O 
and O 
the O 
progression O 
of O 
events O 
that O 
lead O 
to O 
tolerance O 
for O 
different O 
MOR O 
agonists O 
. O 
Although O 
great O 
progress O 
has O 
been O 
made O 
in O 
the O 
past O 
decade O 
, O 
many O 
points O 
of O 
contention O 
and O 
controversy O 
cloud O 
the O 
realization O 
of O 
this O 
progress O 
. O 
This O 
review O 
attempts O 
to O 
clarify O 
some O 
confusion O 
by O 
clearly O 
defining O 
terms O 
, O 
such O 
as O 
desensitization O 
and O 
tolerance O 
, O 
and O 
addressing O 
optimal O 
pharmacological O 
analyses O 
for O 
discerning O 
relative O 
importance O 
of O 
these O 
cellular O 
mechanisms O 
. O 
Cellular O 
and O 
molecular O 
mechanisms O 
regulating O 
MOR O 
function O 
by O 
phosphorylation O 
relative O 
to O 
receptor O 
desensitization O 
and O 
endocytosis O 
are O 
comprehensively O 
reviewed O 
, O 
with O 
an O 
emphasis O 
on O 
agonist O 
- O 
biased O 
regulation O 
and O 
areas O 
where O 
knowledge O 
is O 
lacking O 
or O 
controversial O 
. O 
The O 
implications O 
of O 
these O 
mechanisms O 
for O 
understanding O 
the O 
substantial O 
contribution O 
of O 
MOR O 
signaling O 
to O 
opioid O 
tolerance O 
are O 
then O 
considered O 
in O 
detail O 
. O 
While O 
some O 
functional O 
MOR O 
regulatory O 
mechanisms O 
contributing O 
to O 
tolerance O 
are O 
clearly O 
understood O 
, O 
there O 
are O 
large O 
gaps O 
in O 
understanding O 
the O 
molecular O 
processes O 
responsible O 
for O 
loss O 
of O 
MOR O 
function O 
after O 
chronic O 
exposure O 
to O 
opioids O 
. O 
Further O 
elucidation O 
of O 
the O 
cellular O 
mechanisms O 
that O 
are O 
regulated O 
by O 
opioids O 
will O 
be O 
necessary O 
for O 
the O 
successful O 
development O 
of O 
MOR O 
- O 
based O 
approaches O 
to O 
new O 
pain O 
therapeutics O 
that O 
limit O 
the O 
development O 
of O 
tolerance O 
. O 

of O 
a O 
Self-Administered O 
Oral O 
Glucose B-TRIVIAL 
Tolerance O 
Test O 
. O 

assess O 
the O 
feasibility O 
of O 
using O 
a O 
disposable O 
, O 
self O 
- O 
administered O 
, O 
capillary O 
blood O 
sampling O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
( O 
OGTT O 
) O 
device O 
in O 
a O 
community O 
setting.RESEARCH O 
DESIGN O 
AND O 
METHODSEighteen O 
healthy O 
and O 
12 O 
type O 
2 O 
diabetic O 
volunteers O 
underwent O 
six O 
75-g O 
OGTTs O 
using O 
a O 
prototype O 
device O 
in O 
the O 
following O 
three O 
settings O 
: O 
unaided O 
at O 
home O 
( O 
twice O 
) O 
; O 
unaided O 
but O 
observed O 
in O 
clinic O 
( O 
twice O 
) O 
; O 
and O 
performed O 
by O 
a O 
nurse O 
with O 
simultaneous O 
laboratory O 
glucose B-TRIVIAL 
assays O 
of O 
0- O 
and O 
120-min O 
venous O 
plasma O 
samples O 
( O 
twice O 
) O 
. O 
The O 
device O 
displayed O 
no O 
results O 
. O 
A O 
detachable O 
data O 
recorder O 
returned O 
to O 
the O 
clinic O 
provided O 
plasma O 
- O 
equivalent O 
0- O 
and O 
120-min O 
glucose B-TRIVIAL 
values O 
and O 
key O 
parameters O 
, O 
including O 
test O 
date O 
, O 
start O 
and O 
end O 
times O 
, O 
and O 
time O 
taken O 
to O 
consume O 
the O 
glucose B-TRIVIAL 
drink.RESULTSThe O 
device O 
was O 
universally O 
popular O 
with O 
participants O 
, O 
was O 
perceived O 
as O 
easy O 
to O 
use O 
, O 
and O 
the O 
ability O 
to O 
test O 
at O 
home O 
was O 
well O 
- O 
liked O 
. O 
Device O 
failures O 
meant O 
that O 
0- O 
and O 
120-min O 
glucose B-TRIVIAL 
values O 
were O 
obtained O 
for O 
only O 
141 O 
( O 
78% O 
) O 
of O 
the O 
180 O 
OGTTs O 
performed O 
, O 
independent O 
of O 
setting O 
. O 
Device O 
glucose B-TRIVIAL 
measurements O 
showed O 
a O 
mean O 
bias O 
compared O 
with O 
laboratory O 
- O 
measured O 
values O 
of O 
+ O 
0.9 O 
at O 
5 O 
mmol O 
/ O 
L O 
increasing O 
to O 
+ O 
4.4 O 
at O 
15 O 
mmol O 
/ O 
L O 
. O 
Paired O 
device O 
glucose B-TRIVIAL 
values O 
were O 
equally O 
reproducible O 
across O 
settings O 
, O 
with O 
repeat O 
testing O 
showing O 
no O 
training O 
effect O 
regardless O 
of O 
setting O 
order.CONCLUSIONSSelf O 
- O 
administered O 
OGTTs O 
can O 
be O 
performed O 
successfully O 
by O 
untrained O 
individuals O 
in O 
a O 
community O 
setting O 
. O 
With O 
improved O 
device O 
reliability O 
and O 
appropriate O 
calibration O 
, O 
this O 
novel O 
technology O 
could O 
be O 
used O 
in O 
routine O 
practice O 
to O 
screen O 
people O 
who O 
might O 
need O 
a O 
formal O 
OGTT O 
to O 
confirm O 
the O 
presence O 
of O 
impaired O 
glucose B-TRIVIAL 
tolerance O 
or O 
diabetes O 
. O 

and O 
evaluation O 
of O 
antibacterial O 
activity O 
of O 
7-alkyloxy-4,5-dihydro-imidazo[1,2-a]quinoline B-FAMILY 
derivatives O 
. O 

this O 
study O 
, O 
a O 
series O 
of O 
7-alkyloxy-4,5-dihydro-imidazo[1,2-a]quinoline B-FAMILY 
derivatives O 
was O 
synthesized O 
and O 
tested O 
for O 
their O 
antibacterial O 
activity O 
against O 
various O 
bacterial O 
strains O 
. O 
Most O 
of O 
the O 
compounds O 
exhibited O 
potential O 
antibacterial O 
activity O 
against O 
gram O 
- O 
negative O 
and O 
gram O 
- O 
positive O 
bacteria O 
. O 
Compound O 
7p O 
( O 
7-heptyloxy-4,5-dihydro-imidazo[1,2-a]quinoline B-SYSTEMATIC 
) O 
was O 
found O 
to O 
be O 
the O 
most O 
potent O 
inhibitor O 
. O 
The O 
minimum O 
inhibitory O 
concentration O 
( O 
MIC O 
) O 
of O 
compound O 
7p O 
against O 
Escherichia O 
coli O 
was O 
0.5 O 
μg O 
/ O 
mL O 
, O 
better O 
than O 
that O 
of O 
reference O 
agent O 
ciprofloxacin B-TRIVIAL 
and O 
amoxicillin B-TRIVIAL 
. O 
Furthermore O 
, O 
compound O 
7p O 
exhibited O 
a O 
modest O 
activity O 
against O 
several O 
gram O 
- O 
negative O 
bacterial O 
strains O 
at O 
a O 
dose O 
range O 
of O 
2-64 O 
μg O 
/ O 
mL O 
. O 

is O 
a O 
common O 
disease O 
characterized O 
by O 
an O 
increased O 
susceptibility O 
to O 
fracture O 
. O 
It O 
is O 
a O 
complex O 
disorder O 
resulting O 
from O 
the O 
interaction O 
of O 
several O 
polymorphisms O 
in O 
different O 
genes O 
and O 
environmental O 
factors O 
. O 
Since O 
we O 
recently O 
reported O 
a O 
role O 
for O 
low O 
density O 
lipoprotein O 
- O 
related O 
protein O 
(LRP)-4 O 
in O 
monogenic O 
disorders O 
with O 
bone O 
overgrowth O 
, O 
we O 
now O 
wanted O 
to O 
evaluate O 
whether O 
genetic O 
variation O 
in O 
the O 
LRP4 O 
gene O 
has O 
an O 
effect O 
on O 
the O 
susceptibility O 
to O 
osteoporosis O 
in O 
a O 
population O 
based O 
cohort O 
from O 
the O 
Odense O 
Androgen B-FAMILY 
Study O 
. O 
We O 
chose O 
to O 
genotype O 
four O 
common O 
( O 
minor O 
allele O 
frequency O 
(MAF)≥0.05 O 
) O 
and O 
non-synonymous O 
coding O 
polymorphisms O 
located O 
in O 
the O 
extracellular O 
region O 
of O 
the O 
LRP4 O 
protein O 
: O 
rs3816614 O 
( O 
A O 
/ O 
g O 
) O 
, O 
rs2306029 O 
( O 
G O 
/ O 
a O 
) O 
, O 
rs2306033 O 
( O 
C O 
/ O 
t O 
) O 
and O 
rs6485702 O 
( O 
G O 
/ O 
a O 
) O 
( O 
large O 
and O 
small O 
characters O 
indicate O 
major O 
and O 
minor O 
alleles O 
, O 
respectively O 
) O 
. O 
Bone O 
mineral O 
density O 
( O 
BMD O 
) O 
measurements O 
of O 
the O 
hip O 
, O 
the O 
spine O 
and O 
whole O 
body O 
as O 
well O 
as O 
different O 
hip O 
geometry O 
parameters O 
were O 
available O 
for O 
a O 
total O 
of O 
1404 O 
Danish O 
men O 
from O 
two O 
age O 
groups O 
( O 
[ O 
20-29 O 
years O 
] O 
: O 
n=804 O 
; O 
[ O 
60-74 O 
years O 
] O 
: O 
n=600 O 
) O 
. O 
Using O 
linear O 
regression O 
analysis O 
adjusted O 
for O 
age O 
, O 
height O 
and O 
weight O 
, O 
we O 
found O 
significant O 
associations O 
between O 
both O 
rs2306029 O 
and O 
rs6485702 O 
and O 
BMD O 
at O 
all O 
sites O 
except O 
the O 
lumbar O 
spine O 
. O 
The O 
most O 
significant O 
association O 
was O 
found O 
with O 
whole O 
body O 
BMD O 
(p=4.7×10(-5)) O 
. O 
In O 
addition O 
, O 
we O 
found O 
these O 
two O 
polymorphisms O 
to O 
be O 
associated O 
with O 
different O 
geometry O 
parameters O 
especially O 
of O 
the O 
femoral O 
shaft O 
. O 
Analysis O 
of O 
the O 
two O 
associated O 
SNPs O 
in O 
the O 
separate O 
age O 
groups O 
demonstrated O 
that O 
most O 
associations O 
are O 
only O 
present O 
in O 
the O 
youngest O 
group O 
of O 
Danish O 
men O 
. O 
In O 
the O 
group O 
of O 
elderly O 
men O 
, O 
one O 
Bonferroni O 
corrected O 
association O 
between O 
whole O 
body O 
BMD O 
and O 
rs6485702 O 
was O 
found O 
to O 
be O 
significant O 
. O 
Subsequently O 
, O 
all O 
polymorphisms O 
were O 
included O 
in O 
haplotype O 
analyses O 
using O 
the O 
PLINK O 
software O 
( O 
v1.07 O 
) O 
. O 
After O 
adjusting O 
for O 
age O 
, O 
height O 
and O 
weight O 
, O 
two O 
out O 
of O 
five O 
common O 
haplotypes O 
( O 
MAF≥0.01 O 
) O 
were O 
found O 
to O 
be O 
of O 
particular O 
interest O 
in O 
the O 
regulation O 
of O 
hip O 
and O 
whole O 
body O 
BMD O 
( O 
AGCG O 
, O 
AACA O 
) O 
. O 
Additional O 
analysis O 
suggested O 
that O 
these O 
latter O 
associations O 
are O 
driven O 
by O 
the O 
association O 
of O 
rs6485702 O 
. O 
We O 
suggest O 
, O 
based O 
on O 
these O 
results O 
and O 
the O 
localisation O 
of O 
the O 
variant O 
in O 
the O 
third O 
β-propeller O 
domain O 
of O 
LRP4 O 
, O 
that O 
the O 
variant O 
has O 
possibly O 
a O 
functional O 
effect O 
. O 
Hereby O 
, O 
we O 
conclude O 
that O 
common O 
variation O 
in O 
the O 
LRP4 O 
gene O 
determines O 
hip O 
and O 
whole O 
body O 
BMD O 
and O 
thus O 
confirm O 
previous O 
results O 
from O 
different O 
GWAs O 
. O 
In O 
addition O 
, O 
our O 
data O 
proves O 
an O 
additional O 
role O 
for O 
LRP4 O 
in O 
regulating O 
hip O 
structure O 
. O 
Finally O 
, O 
interaction O 
analysis O 
for O 
LRP4 O 
with O 
SOST O 
and O 
LRP5 O 
showed O 
interaction O 
with O 
LRP5 O 
for O 
femoral O 
shaft O 
geometry O 
. O 

potential O 
of O 
N,α-L-rhamnopyranosyl B-SYSTEMATIC 
vincosamide I-SYSTEMATIC 
, O 
an O 
indole B-FAMILY 
alkaloid I-FAMILY 
, O 
isolated O 
from O 
the O 
leaves O 
of O 
Moringa O 
oleifera O 
in O 
isoproterenol B-TRIVIAL 
induced O 
cardiotoxic O 
rats O 
: O 
in O 
vivo O 
and O 
in O 
vitro O 
studies O 
. O 

unknown O 
protective O 
effect O 
of O 
N,α-L-rhamnopyranosyl B-SYSTEMATIC 
vincosamide I-SYSTEMATIC 
( O 
VR O 
) O 
, O 
isolated O 
from O 
Moringa O 
oleifera O 
leaves O 
in O 
isoproterenol B-TRIVIAL 
( O 
ISO B-ABBREVIATION 
)-induced O 
cardiac O 
toxicity O 
was O 
evaluated O 
in O 
rats O 
. O 
Oral O 
administration O 
of O 
VR O 
at O 
40 O 
mg O 
/ O 
kg O 
for O 
7 O 
days O 
markedly O 
reduced O 
the O 
ISO B-ABBREVIATION 
-induced O 
increase O 
in O 
the O 
levels O 
of O 
serum O 
cardiac O 
markers O 
such O 
as O 
troponin-T O 
, O 
creatine B-TRIVIAL 
kinase-MB O 
, O 
lactate B-FAMILY 
dehydrogenase O 
and O 
glutamate B-TRIVIAL 
pyruvate B-TRIVIAL 
transaminase O 
as O 
well O 
as O 
cardiac O 
lipid O 
peroxidation O 
with O 
a O 
parallel O 
increase O 
in O 
the O 
cellular O 
antioxidants O 
suggesting O 
its O 
cardio O 
- O 
protective O 
and O 
free O 
radical O 
scavenging O 
potential O 
, O 
which O 
was O 
latter O 
confirmed O 
by O 
in O 
vitro O 
study O 
. O 
Rats O 
treated O 
with O 
test O 
compound O 
also O 
improved O 
the O 
ISO B-ABBREVIATION 
-induced O 
abnormal O 
changes O 
in O 
ECG O 
as O 
well O 
as O 
in O 
cardiac O 
histology O 
. O 
A O 
reduction O 
in O 
myocardial O 
necrosis O 
was O 
further O 
evidenced O 
by O 
the O 
tri B-SYSTEMATIC 
- I-SYSTEMATIC 
phenyl I-SYSTEMATIC 
tetrazolium I-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
TTC B-ABBREVIATION 
) O 
stain O 
in O 
isolated O 
test O 
drug O 
pretreated O 
rats O 
. O 
These O 
findings O 
suggest O 
the O 
cardio O 
- O 
protective O 
potential O 
of O 
the O 
isolated O 
alkaloid O 
and O 
possibly O 
the O 
beneficial O 
action O 
is O 
mediated O 
through O 
its O 
free O 
radical O 
scavenging O 
property O 
. O 

derivatives O 
as O 
topoisomerase O 
II-inhibiting O 
anticancer O 
agents O 
. O 

on O 
known O 
heterocyclic O 
topoisomerase O 
II O 
inhibitors O 
and O 
anticancer O 
agents O 
, O 
various O 
indenoindolone B-SYSTEMATIC 
derivatives O 
were O 
predicted O 
as O 
potential O 
topoisomerase O 
II-inhibiting O 
anticancer O 
agents O 
. O 
They O 
are O 
hydrazones B-FAMILY 
, O 
(thio)semicarbazones B-FAMILY 
, O 
and O 
oximes B-FAMILY 
of I-FAMILY 
indenoindolones I-FAMILY 
, O 
and O 
indenoindolols B-FAMILY 
. O 
These O 
derivatives O 
with O 
suitable O 
substitutions O 
exhibited O 
potent O 
specific O 
inhibition O 
of O 
human O 
DNA O 
TopoIIα O 
while O 
not O 
showing O 
inhibition O 
of O 
topoisomerase O 
I O 
and O 
DNA O 
intercalation O 
, O 
despite O 
the O 
fact O 
that O 
parent O 
indenoindolones B-FAMILY 
are O 
known O 
poor O 
/ O 
moderate O 
inhibitors O 
of O 
topoisomerase O 
II O 
. O 
The O 
potent O 
topoisomerase O 
II O 
inhibitor O 
indenoindolone B-SYSTEMATIC 
derivatives O 
exhibited O 
good O 
anticancer O 
activities O 
compared O 
to O 
etoposide B-TRIVIAL 
and O 
5-fluorouracil B-SYSTEMATIC 
, O 
and O 
relatively O 
low O 
toxicity O 
to O 
normal O 
cells O 
. O 
These O 
derivatizations O 
of O 
indenoindolones B-FAMILY 
were O 
found O 
to O 
result O 
in O 
enhancement O 
of O 
anticancer O 
activities O 
. O 

α7 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
nAChR O 
) O 
is O 
highly O 
expressed O 
in O 
different O 
regions O 
of O 
the O 
brain O 
and O 
is O 
associated O 
with O 
cognitive O 
function O 
as O 
well O 
as O 
anxiety O 
. O 
Agonists O 
and O 
positive O 
allosteric O 
modulators O 
( O 
PAMs O 
) O 
of O 
the O 
α7 O 
subtype O 
of O 
nAChRs O 
have O 
been O 
shown O 
to O 
improve O 
cognition O 
. O 
Previously O 
nicotine B-TRIVIAL 
, O 
which O 
activates O 
both O 
α7 O 
and O 
non-α7 O 
subtypes O 
of O 
nAChRs O 
, O 
has O 
been O 
shown O 
to O 
have O 
an O 
anxiogenic O 
effect O 
in O 
behavioral O 
tests O 
. O 
In O 
this O 
study O 
, O 
we O 
compared O 
the O 
effects O 
of O 
the O 
α7-selective O 
agonist O 
( O 
PNU-282987 B-IDENTIFIER 
) O 
and O 
PAM O 
( O 
PNU-120596 B-IDENTIFIER 
) O 
in O 
a O 
variety O 
of O 
behavioral O 
tests O 
in O 
Sprague O 
Dawley O 
rats O 
to O 
look O 
at O 
their O 
effects O 
on O 
learning O 
and O 
memory O 
as O 
well O 
as O 
anxiety O 
. O 
We O 
found O 
that O 
neither O 
PNU-282987 B-IDENTIFIER 
nor O 
PNU-120596 B-IDENTIFIER 
improved O 
spatial O 
- O 
learning O 
or O 
episodic O 
memory O 
by O 
themselves O 
. O 
However O 
when O 
cognitive O 
impairment O 
was O 
induced O 
in O 
the O 
rats O 
with O 
scopolamine B-TRIVIAL 
( O 
1 O 
mg O 
/ O 
kg O 
) O 
, O 
both O 
PNU-120596 B-IDENTIFIER 
and O 
PNU-282987 B-IDENTIFIER 
were O 
able O 
to O 
reverse O 
this O 
memory O 
impairment O 
and O 
restore O 
it O 
back O 
to O 
normal O 
levels O 
. O 
While O 
PNU-120596 B-IDENTIFIER 
reversed O 
the O 
scopolamine O 
- O 
induced O 
cognitive O 
impairment O 
, O 
it O 
did O 
not O 
have O 
any O 
adverse O 
effect O 
on O 
anxiety O 
. O 
PNU-282987 B-IDENTIFIER 
on O 
the O 
other O 
hand O 
displayed O 
an O 
increase O 
in O 
anxiety O 
- O 
like O 
behavior O 
at O 
a O 
higher O 
dose O 
( O 
10 O 
mg O 
/ O 
kg O 
) O 
that O 
was O 
significantly O 
reduced O 
by O 
the O 
serotonin O 
5-HT1a O 
receptor O 
antagonist O 
WAY-100135 B-IDENTIFIER 
. O 
However O 
the O 
α7 O 
receptor O 
antagonist O 
methyllycaconitine B-TRIVIAL 
was O 
unable O 
to O 
reverse O 
these O 
anxiety O 
- O 
like O 
effects O 
seen O 
with O 
PNU-282987 B-IDENTIFIER 
. O 
These O 
results O 
suggest O 
that O 
α7 O 
nAChR O 
PAMs O 
are O 
pharmacologically O 
advantageous O 
over O 
agonists O 
, O 
and O 
should O 
be O 
considered O 
for O 
further O 
development O 
as O 
therapeutic O 
drugs O 
targeting O 
the O 
α7 O 
receptors O 
. O 

has O 
been O 
much O 
recent O 
interest O 
in O 
lysophosphatidic B-TRIVIAL 
acid I-TRIVIAL 
( O 
LPA B-ABBREVIATION 
) O 
signaling O 
through O 
one O 
of O 
its O 
receptors O 
, O 
LPA1 O 
, O 
in O 
fibrotic O 
diseases O 
, O 
but O 
the O 
mechanisms O 
by O 
which O 
LPA B-ABBREVIATION 
-LPA1 O 
signaling O 
promotes O 
pathological O 
fibrosis O 
remain O 
to O 
be O 
fully O 
elucidated O 
. O 
Using O 
a O 
mouse O 
peritoneal O 
fibrosis O 
model O 
, O 
we O 
demonstrate O 
central O 
roles O 
for O 
LPA B-ABBREVIATION 
and O 
LPA1 O 
in O 
fibroblast O 
proliferation O 
. O 
Genetic O 
deletion O 
or O 
pharmacological O 
antagonism O 
of O 
LPA1 O 
protected O 
mice O 
from O 
peritoneal O 
fibrosis O 
, O 
blunting O 
the O 
increases O 
in O 
peritoneal O 
collagen O 
by O 
65.4 O 
and O 
52.9% O 
, O 
respectively O 
, O 
compared O 
to O 
control O 
animals O 
and O 
demonstrated O 
that O 
peritoneal O 
fibroblast O 
proliferation O 
was O 
highly O 
LPA1 O 
dependent O 
. O 
Activation O 
of O 
LPA1 O 
on O 
mesothelial O 
cells O 
induced O 
these O 
cells O 
to O 
express O 
connective O 
tissue O 
growth O 
factor O 
( O 
CTGF O 
) O 
, O 
driving O 
fibroblast O 
proliferation O 
in O 
a O 
paracrine O 
fashion O 
. O 
Activation O 
of O 
mesothelial O 
cell O 
LPA1 O 
induced O 
CTGF O 
expression O 
by O 
inducing O 
cytoskeleton O 
reorganization O 
in O 
these O 
cells O 
, O 
causing O 
nuclear O 
translocation O 
of O 
myocardin O 
- O 
related O 
transcription O 
factor O 
(MRTF)-A O 
and O 
MRTF-B O 
. O 
Pharmacological O 
inhibition O 
of O 
MRTF-induced O 
transcription O 
also O 
diminished O 
CTGF O 
expression O 
and O 
fibrosis O 
in O 
the O 
peritoneal O 
fibrosis O 
model O 
, O 
mitigating O 
the O 
increase O 
in O 
peritoneal O 
collagen O 
content O 
by O 
57.9% O 
compared O 
to O 
controls O 
. O 
LPA1-induced O 
cytoskeleton O 
reorganization O 
therefore O 
makes O 
a O 
previously O 
unrecognized O 
but O 
critically O 
important O 
contribution O 
to O 
the O 
profibrotic O 
activities O 
of O 
LPA B-ABBREVIATION 
by O 
driving O 
MRTF-dependent O 
CTGF O 
expression O 
, O 
which O 
, O 
in O 
turn O 
, O 
drives O 
fibroblast O 
proliferation.-Sakai O 
, O 
N O 
. O 
, O 
Chun O 
, O 
J O 
. O 
, O 
Duffield O 
, O 
J O 
. O 
S O 
. O 
, O 
Wada O 
, O 
T O 
. O 
, O 
Luster O 
, O 
A O 
. O 
D O 
. O 
, O 
Tager O 
, O 
A O 
. O 
M O 
. O 
LPA1-induced O 
cytoskeleton O 
reorganization O 
drives O 
fibrosis O 
through O 
CTGF-dependent O 
fibroblast O 
proliferation O 
. O 

resistance O 
is O 
a O 
very O 
common O 
associate O 
of O 
polycystic O 
ovary O 
syndrome O 
( O 
PCOS O 
) O 
. O 
Pathophysiology O 
in O 
relation O 
with O 
the O 
essential O 
elements O 
including O 
copper B-SYSTEMATIC 
, O 
magnesium B-SYSTEMATIC 
, O 
zinc B-SYSTEMATIC 
, O 
manganese B-SYSTEMATIC 
, O 
chromium B-SYSTEMATIC 
, O 
and O 
calcium B-SYSTEMATIC 
has O 
been O 
reported O 
in O 
women O 
with O 
insulin O 
resistance O 
. O 
This O 
prospective O 
study O 
was O 
designed O 
to O 
explore O 
whether O 
the O 
women O 
with O 
PCOS O 
do O 
exhibit O 
altered O 
serum O 
element O 
levels O 
in O 
association O 
with O 
/ O 
without O 
insulin O 
resistance O 
. O 
One O 
hundred O 
and O 
thirty O 
- O 
two O 
women O 
with O 
PCOS O 
and O 
forty O 
- O 
six O 
control O 
women O 
were O 
studied O 
. O 
Women O 
with O 
PCOS O 
were O 
further O 
divided O 
based O 
on O 
the O 
presence O 
of O 
insulin O 
resistance O 
( O 
insulin O 
resistant O 
: O 
n O 
= O 
50 O 
; O 
non-insulin O 
resistant O 
: O 
n O 
= O 
82 O 
) O 
. O 
In O 
all O 
women O 
, O 
basal O 
levels O 
of O 
gonadotropins O 
, O 
prolactin O 
, O 
testosterone B-TRIVIAL 
, O 
insulin O 
, O 
glucose B-TRIVIAL 
, O 
and O 
the O 
six O 
different O 
elements O 
were O 
measured O 
. O 
Serum O 
levels O 
of O 
testosterone B-TRIVIAL 
( O 
p O 
< O 
0.001 O 
) O 
, O 
luteinizing O 
hormone O 
( O 
p O 
< O 
0.05 O 
) O 
, O 
and O 
fasting O 
insulin O 
( O 
p O 
< O 
0.004 O 
) O 
were O 
significantly O 
higher O 
in O 
the O 
PCOS O 
population O 
compared O 
to O 
controls O 
as O 
well O 
as O 
PCOS O 
women O 
without O 
insulin O 
resistance O 
. O 
Women O 
with O 
PCOS O 
exhibited O 
a O 
significantly O 
high O 
calcium B-SYSTEMATIC 
( O 
p O 
< O 
0.04 O 
) O 
and O 
lower O 
manganese B-SYSTEMATIC 
levels O 
( O 
p O 
< O 
0.002 O 
) O 
when O 
compared O 
to O 
controls O 
. O 
However O 
, O 
the O 
PCOS O 
women O 
with O 
insulin O 
resistance O 
exhibited O 
significantly O 
lower O 
serum O 
levels O 
of O 
magnesium B-SYSTEMATIC 
and O 
chromium B-SYSTEMATIC 
( O 
p O 
< O 
0.04 O 
) O 
, O 
in O 
addition O 
to O 
higher O 
levels O 
of O 
zinc B-SYSTEMATIC 
and O 
copper B-SYSTEMATIC 
( O 
p O 
< O 
0.04 O 
) O 
. O 
The O 
differences O 
in O 
calcium B-SYSTEMATIC 
( O 
p O 
< O 
0.03 O 
) O 
and O 
manganese B-SYSTEMATIC 
levels O 
( O 
p O 
< O 
0.0001 O 
) O 
became O 
aggravated O 
with O 
the O 
presence O 
of O 
insulin O 
resistance O 
when O 
compared O 
to O 
control O 
as O 
well O 
as O 
PCOS O 
women O 
without O 
insulin O 
resistance O 
. O 
In O 
PCOS-associated O 
insulin O 
resistance O 
, O 
circulating O 
serum O 
magnesium B-SYSTEMATIC 
( O 
r O 
= O 
-0.31 O 
; O 
p O 
< O 
0.03 O 
) O 
and O 
chromium B-SYSTEMATIC 
( O 
r O 
= O 
-0.38 O 
; O 
p O 
< O 
0.006 O 
) O 
status O 
significantly O 
correlated O 
with O 
fasting O 
insulin O 
levels O 
. O 
We O 
conclude O 
that O 
imbalanced O 
element O 
status O 
may O 
be O 
a O 
key O 
foundation O 
for O 
insulin O 
resistance O 
in O 
PCOS O 
. O 
The O 
findings O 
in O 
this O 
study O 
should O 
be O 
investigated O 
with O 
further O 
trials O 
in O 
order O 
to O 
obtain O 
new O 
insights O 
into O 
PCOS O 
. O 

structured O 
: O 
As O 
a O 
new O 
triose B-FAMILY 
phosphate I-FAMILY 
isomerase O 
( O 
TIM O 
) O 
barrel O 
- O 
fold O 
prenyl O 
transferase O 
, O 
PcrB O 
catalyzes O 
the O 
production O 
of O 
heptaprenylglyceryl B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
from O 
heptaprenyl B-SYSTEMATIC 
diphosphate I-SYSTEMATIC 
and O 
glycerol-1-phosphate B-SYSTEMATIC 
. O 
Crystal O 
structures O 
of O 
PcrB O 
from O 
Bacillus O 
subtilis O 
and O 
Staphylococcus O 
aureus O 
in O 
complex O 
with O 
ligands O 
were O 
solved O 
, O 
and O 
together O 
with O 
site O 
- O 
directed O 
mutagenesis O 
and O 
bioinformatics O 
analyses O 
, O 
clearly O 
reveal O 
the O 
catalytic O 
mechanism O 
of O 
the O 
enzyme O 
. O 

tolerance O 
and O 
cross O 
- O 
tolerance O 
in O 
nontarget O 
organisms O 
is O 
often O 
overlooked O 
despite O 
its O 
potential O 
to O 
buffer O 
natural O 
systems O 
from O 
anthropogenic O 
influence O 
. O 
We O 
exposed O 
wood O 
frog O 
tadpoles O 
from O 
15 O 
populations O 
to O 
three O 
acetylcholine B-SYSTEMATIC 
esterase O 
- O 
inhibiting O 
insecticides O 
and O 
found O 
widespread O 
variation O 
in O 
insecticide O 
tolerance O 
and O 
evidence O 
for O 
cross O 
- O 
tolerance O 
to O 
these O 
insecticides O 
. O 
Our O 
results O 
demonstrate O 
that O 
amphibian O 
populations O 
with O 
tolerance O 
to O 
one O 
pesticide O 
may O 
be O 
tolerant O 
to O 
many O 
other O 
pesticides O 
. O 

between O 
perfluoroalkyl B-FAMILY 
compounds O 
and O 
immune O 
and O 
clinical O 
chemistry O 
parameters O 
in O 
highly O 
exposed O 
bottlenose O 
dolphins O 
( O 
Tursiops O 
truncatus O 
) O 
. O 

compounds O 
( O 
PFCs O 
) O 
are O 
ubiquitous O 
, O 
persistent O 
chemical O 
contaminants O 
found O 
in O 
the O 
environment O 
, O 
wildlife O 
, O 
and O 
humans O 
. O 
Despite O 
the O 
widespread O 
occurrence O 
of O 
PFCs O 
, O 
little O 
is O 
known O 
about O 
the O 
impact O 
these O 
contaminants O 
have O 
on O 
the O 
health O 
of O 
wildlife O 
populations O 
. O 
The O 
authors O 
investigated O 
the O 
relationship O 
between O 
PFCs O 
( O 
including O 
∑ O 
perfluorocarboxylates B-FAMILY 
, O 
∑ O 
perfluoroalkyl B-FAMILY 
sulfonates I-FAMILY 
, O 
perfluorooctane B-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
, O 
perfluorooctanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
and O 
perfluorodecanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
and O 
the O 
clinocopathologic O 
and O 
immune O 
parameters O 
in O 
a O 
highly O 
exposed O 
population O 
( O 
n O 
= O 
79 O 
) O 
of O 
Atlantic O 
bottlenose O 
dolphins O 
( O 
mean O 
∑PFCs O 
= O 
1970 O 
ng O 
/ O 
ml O 
; O 
range O 
574-8670 O 
ng O 
/ O 
ml O 
) O 
sampled O 
from O 
2003 O 
to O 
2005 O 
near O 
Charleston O 
, O 
South O 
Carolina O 
, O 
USA O 
. O 
Age O 
- O 
adjusted O 
linear O 
regression O 
models O 
showed O 
statistically O 
significant O 
positive O 
associations O 
between O 
exposure O 
to O 
one O 
or O 
more O 
of O 
the O 
PFC O 
totals O 
and O 
/ O 
or O 
individual O 
analytes O 
and O 
the O 
following O 
immunological O 
parameters O 
: O 
absolute O 
numbers O 
of O 
CD2+ O 
T O 
cells O 
, O 
CD4+ O 
helper O 
T O 
cells O 
, O 
CD19+ O 
immature O 
B O 
cells O 
, O 
CD21+ O 
mature O 
B O 
cells O 
, O 
CD2 O 
/ O 
CD21 O 
ratio O 
, O 
MHCII+ O 
cells O 
, O 
B O 
cell O 
proliferation O 
, O 
serum O 
IgG1 O 
, O 
granulocytic O 
, O 
and O 
monocytic O 
phagocytosis O 
. O 
Several O 
PFC O 
analyte O 
groups O 
were O 
also O 
positively O 
associated O 
with O 
serum O 
alanine B-TRIVIAL 
aminotransferase O 
, O 
gamma-glutamyltransferase O 
, O 
creatinine B-TRIVIAL 
, O 
phosphorus B-SYSTEMATIC 
, O 
amylase O 
, O 
and O 
anion O 
gap O 
and O 
negatively O 
associated O 
with O 
cholesterol B-TRIVIAL 
levels O 
, O 
creatinine B-TRIVIAL 
phosphokinase O 
, O 
eosinophils O 
, O 
and O 
monocytes O 
. O 
Based O 
on O 
these O 
relationships O 
, O 
the O 
authors O 
suggest O 
that O 
the O 
PFC O 
concentrations O 
found O 
in O 
Charleston O 
dolphins O 
may O 
have O 
effects O 
on O 
immune O 
, O 
hematopoietic O 
, O 
kidney O 
, O 
and O 
liver O 
function O 
. O 
The O 
results O 
contribute O 
to O 
the O 
emerging O 
data O 
on O 
PFC O 
health O 
effects O 
in O 
this O 
first O 
study O 
to O 
describe O 
associations O 
between O 
PFCs O 
and O 
health O 
parameters O 
in O 
dolphins O 
. O 

conducting O 
toxicity O 
tests O 
with O 
nano O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
, O 
the O 
authors O 
found O 
that O 
test O 
suspensions O 
were O 
being O 
contaminated O 
with O 
aluminum B-SYSTEMATIC 
and O 
titanium B-SYSTEMATIC 
from O 
tip O 
erosion O 
during O 
direct O 
sonication O 
. O 
The O 
contaminating O 
alloy O 
particles O 
had O 
a O 
measurable O 
size O 
distribution O 
and O 
zeta O 
potential O 
using O 
dynamic O 
light O 
scattering O 
, O 
which O 
changed O 
the O 
measured O 
characteristics O 
of O 
the O 
suspensions O 
. O 
Caution O 
should O 
be O 
used O 
when O 
employing O 
direct O 
sonication O 
for O 
preparing O 
test O 
suspensions O 
due O 
to O 
potential O 
interferences O 
of O 
these O 
particles O 
in O 
toxicological O 
assessments O 
. O 

as O 
nonclassical O 
bioisosteres O 
of O 
α-amino B-FAMILY 
acids I-FAMILY 
. O 

of O 
α-amino B-FAMILY 
acids I-FAMILY 
is O 
often O 
accomplished O 
by O 
replacing O 
the O 
α-carboxylate B-SYSTEMATIC 
with O 
one O 
of O 
the O 
many O 
known O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
bioisosteres O 
. O 
However O 
, O 
bioisosterism O 
of O 
the O 
whole O 
α-amino B-FAMILY 
acid I-FAMILY 
moiety O 
is O 
accomplished O 
with O 
heterocyclic O 
bioisosteres O 
that O 
often O 
display O 
an O 
acidic O 
function O 
. O 
In O 
this O 
Minireview O 
, O 
we O 
summarized O 
the O 
reported O 
heterocycles O 
as O 
nonclassical O 
bioisosteres O 
of O 
α-amino B-FAMILY 
acids I-FAMILY 
, O 
which O 
include O 
quinoxaline-2,4(1H)-dione B-SYSTEMATIC 
, O 
quinoxaline-2,3(1H)-dione B-SYSTEMATIC 
and O 
quinolin-2(1H)-one B-SYSTEMATIC 
, O 
azagrevellin B-TRIVIAL 
and O 
azepine B-SYSTEMATIC 
-derived O 
structures O 
. O 
The O 
binding O 
mode O 
of O 
the O 
crystalized O 
bioisosteres O 
were O 
compared O 
with O 
those O 
of O 
the O 
crystalized O 
α-amino B-FAMILY 
acids I-FAMILY 
that O 
bind O 
in O 
the O 
same O 
domain O 
, O 
and O 
where O 
no O 
data O 
on O 
the O 
crystal O 
structure O 
were O 
available O 
, O 
the O 
displacement O 
studies O 
of O 
known O 
orthosteric O 
ligands O 
were O 
used O 
. O 
The O 
reported O 
bioisosteres O 
share O 
the O 
following O 
essential O 
structural O 
features O 
for O 
mimicking O 
α-amino B-FAMILY 
acids I-FAMILY 
: O 
an O 
aromatic O 
ring O 
system O 
joined O 
to O 
a O 
lactam O 
ring O 
system O 
with O 
an O 
acidic O 
feature O 
next O 
to O 
the O 
lactam B-SYSTEMATIC 
carbonyl I-SYSTEMATIC 
, O 
where O 
this O 
acidic O 
feature O 
together O 
with O 
the O 
lactam B-SYSTEMATIC 
carbonyl I-SYSTEMATIC 
can O 
mimic O 
the O 
α-carboxylate O 
, O 
and O 
the O 
lactam O 
nitrogen O 
together O 
with O 
the O 
aromatic O 
ring O 
system O 
can O 
mimic O 
the O 
α-ammonium B-SYSTEMATIC 
. O 
The O 
majority O 
of O 
these O 
heterocycles O 
can O 
be O 
prepared O 
from O 
three O 
common O 
corresponding O 
starting O 
materials O 
: O 
the O 
corresponding O 
anilines B-FAMILY 
, O 
isatins B-FAMILY 
or O 
anthranilic B-FAMILY 
esters I-FAMILY 
. O 
The O 
data O 
collected O 
here O 
show O 
the O 
potential O 
of O 
this O 
class O 
of O 
bioisosteres O 
in O 
the O 
design O 
of O 
glutamate B-TRIVIAL 
receptor O 
ligands O 
and O 
beyond O 
. O 

of O 
antiresorptive O 
therapies O 
on O 
glucose B-TRIVIAL 
metabolism O 
: O 
Results O 
from O 
the O 
FIT O 
, O 
HORIZON-PFT O 
and O 
FREEDOM O 
trials O 
. O 

rodent O 
models O 
undercarboxylated O 
osteocalcin O 
( O 
ucOC O 
) O 
acts O 
as O 
a O 
hormone O 
promoting O 
insulin O 
sensitivity O 
and O 
secretion O 
. O 
If O 
ucOC O 
plays O 
a O 
similar O 
role O 
in O 
humans O 
, O 
then O 
antiresorptive O 
therapies O 
, O 
which O 
reduce O 
ucOC O 
levels O 
, O 
may O 
increase O 
the O 
risk O 
of O 
insulin O 
resistance O 
and O 
diabetes O 
. O 
We O 
tested O 
whether O 
antiresorptive O 
therapies O 
result O 
in O 
higher O 
fasting O 
glucose B-TRIVIAL 
, O 
increased O 
weight O 
, O 
or O 
greater O 
diabetes O 
incidence O 
in O 
post O 
- O 
hoc O 
analyses O 
of O 
three O 
randomized O 
, O 
placebo O 
- O 
controlled O 
trials O 
in O 
postmenopausal O 
women O 
: O 
Fracture O 
Intervention O 
Trial O 
( O 
FIT O 
) O 
( O 
N=6151 O 
) O 
of O 
alendronate B-TRIVIAL 
( O 
4 O 
years O 
) O 
, O 
Health O 
Outcomes O 
and O 
Reduced O 
Incidence O 
with O 
Zoledronic B-TRIVIAL 
Acid I-TRIVIAL 
Once O 
Yearly O 
Pivotal O 
Fracture O 
Trial O 
( O 
HORIZON-PFT O 
) O 
( O 
N=7113 O 
) O 
of O 
zoledronic B-TRIVIAL 
acid I-TRIVIAL 
( O 
3 O 
years O 
) O 
, O 
and O 
Fracture O 
REduction O 
Evaluation O 
of O 
Denosumab O 
in O 
Osteoporosis O 
Every O 
6 O 
Months O 
( O 
FREEDOM O 
) O 
trial O 
( O 
N=7076 O 
) O 
of O 
denosumab O 
( O 
3 O 
years O 
) O 
. O 
Fasting O 
glucose B-TRIVIAL 
was O 
measured O 
annually O 
in O 
FIT O 
and O 
HORIZON O 
in O 
a O 
subset O 
of O 
women O 
, O 
and O 
every O 
6 O 
months O 
in O 
FREEDOM O 
on O 
all O 
participants O 
. O 
Weight O 
was O 
measured O 
annually O 
in O 
all O 
trials O 
. O 
Incident O 
diabetes O 
was O 
identified O 
from O 
adverse O 
event O 
reports O 
, O 
initiation O 
of O 
diabetes O 
medication O 
, O 
or O 
elevated O 
fasting O 
glucose B-TRIVIAL 
. O 
Differences O 
in O 
fasting O 
glucose B-TRIVIAL 
changes O 
from O 
randomization O 
to O 
trial O 
conclusion O 
between O 
treatment O 
and O 
placebo O 
groups O 
were O 
not O 
statistically O 
significant O 
: O 
-0.47 O 
mg O 
/ O 
dL O 
in O 
FIT O 
, O 
0.2 O 
mg O 
/ O 
dL O 
in O 
HORIZON-PFT O 
and O 
0.09 O 
mg O 
/ O 
dL O 
in O 
FREEDOM O 
, O 
all O 
p O 
> O 
0.6 O 
. O 
Weight O 
change O 
differed O 
between O 
treatment O 
and O 
placebo O 
groups O 
in O 
FIT O 
( O 
0.32 O 
kg O 
, O 
p=0.003 O 
) O 
and O 
FREEDOM O 
( O 
0.31 O 
kg O 
, O 
p=0.023 O 
) O 
, O 
but O 
not O 
in O 
HORIZON-PFT O 
( O 
0.15 O 
kg O 
, O 
p=0.132 O 
) O 
. O 
In O 
the O 
three O 
trials O 
combined O 
, O 
diabetes O 
occurred O 
in O 
203 O 
and O 
225 O 
women O 
assigned O 
to O 
treatment O 
or O 
placebo O 
, O 
respectively O 
. O 
Diabetes O 
incidence O 
was O 
not O 
increased O 
in O 
any O 
of O 
the O 
treatment O 
groups O 
or O 
in O 
the O 
pooled O 
estimate O 
( O 
Pooled O 
RR O 
= O 
0.9 O 
; O 
95% O 
CI O 
0.74 O 
, O 
1.1 O 
) O 
. O 
Antiresorptive O 
therapy O 
does O 
not O 
have O 
a O 
clinically O 
important O 
effect O 
on O 
fasting O 
glucose B-TRIVIAL 
, O 
weight O 
or O 
diabetes O 
risk O 
in O 
postmenopausal O 
women O 
. O 
Contrary O 
to O 
predictions O 
from O 
mouse O 
models O 
, O 
reduced O 
bone O 
turnover O 
does O 
not O 
appear O 
to O 
play O 
a O 
significant O 
role O 
in O 
glucose B-TRIVIAL 
metabolism O 
in O 
humans O 
. O 
© O 
2013 O 
American O 
Society O 
for O 
Bone O 
and O 
Mineral O 
Research O 
. O 

- O 
walled O 
carbon B-SYSTEMATIC 
nanotube/ O 
polyaniline B-SYSTEMATIC 
/ O 
n- O 
silicon B-SYSTEMATIC 
solar O 
cells O 
: O 
fabrication O 
, O 
characterization O 
, O 
and O 
performance O 
measurements O 
. O 

nanotube- O 
silicon B-SYSTEMATIC 
solar O 
cells O 
are O 
a O 
recently O 
investigated O 
photovoltaic O 
architecture O 
with O 
demonstrated O 
high O 
efficiencies O 
. O 
Silicon B-SYSTEMATIC 
solar O 
- O 
cell O 
devices O 
fabricated O 
with O 
a O 
thin O 
film O 
of O 
conductive O 
polymer O 
( O 
polyaniline B-SYSTEMATIC 
) O 
have O 
been O 
reported O 
, O 
but O 
these O 
devices O 
can O 
suffer O 
from O 
poor O 
performance O 
due O 
to O 
the O 
limited O 
lateral O 
current-carrying O 
capacity O 
of O 
thin O 
polymer O 
films O 
. O 
Herein O 
, O 
hybrid O 
solar O 
- O 
cell O 
devices O 
of O 
a O 
thin O 
film O 
of O 
polyaniline B-SYSTEMATIC 
deposited O 
on O 
silicon B-SYSTEMATIC 
and O 
covered O 
by O 
a O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
film O 
are O 
fabricated O 
and O 
characterized O 
. O 
These O 
hybrid O 
devices O 
combine O 
the O 
conformal O 
coverage O 
given O 
by O 
the O 
polymer O 
and O 
the O 
excellent O 
electrical O 
properties O 
of O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
films O 
and O 
significantly O 
outperform O 
either O 
of O 
their O 
component O 
counterparts O 
. O 
Treatment O 
of O 
the O 
silicon B-SYSTEMATIC 
base O 
and O 
carbon B-SYSTEMATIC 
nanotubes O 
with O 
hydrofluoric B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
a O 
strong O 
oxidizer O 
( O 
thionyl B-SYSTEMATIC 
chloride I-SYSTEMATIC 
) O 
leads O 
to O 
a O 
significant O 
improvement O 
in O 
performance O 
. O 

regulation O 
of O 
Runx2 O 
by O 
FGF2 O 
and O 
connexin43 O 
requires O 
the O 
inositol B-FAMILY 
polyphosphate I-FAMILY 
/ O 
protein O 
kinase O 
Cδ O 
cascade O 
. O 

( O 
Cx43 O 
) O 
plays O 
a O 
critical O 
role O 
in O 
osteoblast O 
function O 
and O 
bone O 
mass O 
accrual O 
, O 
yet O 
the O 
identity O 
of O 
the O 
second O 
messengers O 
communicated O 
by O 
Cx43 O 
gap O 
junctions O 
, O 
the O 
targets O 
of O 
these O 
second O 
messengers O 
and O 
how O 
they O 
regulate O 
osteoblast O 
function O 
remain O 
largely O 
unknown O 
. O 
We O 
have O 
shown O 
that O 
alterations O 
of O 
Cx43 O 
expression O 
in O 
osteoblasts O 
can O 
impact O 
the O 
responsiveness O 
to O 
fibroblast O 
growth O 
factor-2 O 
( O 
FGF2 O 
) O 
, O 
by O 
modulating O 
the O 
transcriptional O 
activity O 
of O 
Runx2 O 
. O 
In O 
this O 
study O 
, O 
we O 
examined O 
the O 
contribution O 
of O 
the O 
phospholipase O 
Cγ1/ O 
inositol B-FAMILY 
polyphosphate I-FAMILY 
/ O 
PKCδ O 
cascade O 
to O 
the O 
Cx43-dependent O 
transcriptional O 
response O 
of O 
MC3T3 O 
osteoblasts O 
to O 
FGF2 O 
. O 
Knockdown O 
of O 
expression O 
and O 
/ O 
or O 
inhibition O 
of O 
function O 
of O 
phospholipase O 
Cγ1 O 
, O 
inositol B-FAMILY 
polyphosphate I-FAMILY 
multikinase O 
, O 
which O 
generates O 
InsP(4) O 
and O 
InsP(5) O 
, O 
and O 
inositol B-SYSTEMATIC 
hexakisphosphate I-SYSTEMATIC 
kinase O 
1 O 
/ O 
2 O 
, O 
which O 
generates O 
inositol B-FAMILY 
pyrophosphates I-FAMILY 
, O 
prevented O 
the O 
ability O 
of O 
Cx43 O 
to O 
potentiate O 
FGF2-induced O 
signaling O 
through O 
Runx2 O 
. O 
Conversely O 
, O 
overexpression O 
of O 
phospholipase O 
Cγ1 O 
and O 
inositol B-SYSTEMATIC 
hexakisphosphate I-SYSTEMATIC 
kinase O 
1 O 
/ O 
2 O 
enhanced O 
FGF2 O 
activation O 
of O 
Runx2 O 
and O 
the O 
effect O 
of O 
Cx43 O 
overexpression O 
on O 
this O 
response O 
. O 
Disruption O 
of O 
these O 
pathways O 
blocked O 
the O 
nuclear O 
accumulation O 
of O 
PKCδ O 
and O 
the O 
FGF2-dependent O 
interaction O 
of O 
PKCδ O 
and O 
Runx2 O 
, O 
reducing O 
Runx2 O 
transcriptional O 
activity O 
. O 
These O 
data O 
reveal O 
that O 
FGF2-signaling O 
involves O 
the O 
inositol B-FAMILY 
polyphosphate I-FAMILY 
cascade O 
, O 
including O 
IP6K O 
, O 
and O 
demonstrate O 
that O 
IP6K O 
regulates O 
Runx2 O 
and O 
osteoblast O 
gene O 
expression O 
. O 
Additionally O 
, O 
these O 
data O 
implicate O 
the O 
water O 
- O 
soluble O 
inositol B-FAMILY 
polyphosphates I-FAMILY 
as O 
mediators O 
of O 
the O 
Cx43-dependent O 
amplification O 
of O 
the O 
osteoblast O 
response O 
to O 
FGF2 O 
, O 
and O 
suggest O 
that O 
these O 
low O 
molecular O 
weight O 
second O 
messengers O 
may O 
be O 
biologically O 
relevant O 
mediators O 
of O 
osteoblast O 
function O 
that O 
are O 
communicated O 
by O 
Cx43-gap O 
junctions O 
. O 
© O 
2013 O 
American O 
Society O 
for O 
Bone O 
and O 
Mineral O 
Research O 
. O 

of O 
plasma O 
cholesterol B-TRIVIAL 
levels O 
is O 
a O 
major O 
therapeutic O 
strategy O 
for O 
management O 
of O 
coronary O 
artery O 
disease O 
( O 
CAD O 
) O 
. O 
Although O 
reducing O 
LDL O 
cholesterol B-TRIVIAL 
( O 
LDL-c O 
) O 
levels O 
decreases O 
morbidity O 
and O 
mortality O 
, O 
this O 
therapeutic O 
intervention O 
only O 
translates O 
into O 
a O 
25-40% O 
reduction O 
in O 
cardiovascular O 
events O 
. O 
Epidemiological O 
studies O 
have O 
shown O 
that O 
a O 
high O 
LDL-c O 
level O 
is O 
not O 
the O 
only O 
risk O 
factor O 
for O 
CAD O 
; O 
low O 
HDL O 
cholesterol B-TRIVIAL 
( O 
HDL-c O 
) O 
is O 
an O 
independent O 
risk O 
factor O 
for O 
CAD O 
. O 
Apolipoprotein O 
A-I O 
( O 
ApoA-I O 
) O 
is O 
the O 
major O 
protein O 
component O 
of O 
HDL-c O 
that O 
mediates O 
reverse O 
cholesterol B-TRIVIAL 
transport O 
from O 
tissues O 
to O 
the O 
liver O 
for O 
excretion O 
. O 
Therefore O 
, O 
increasing O 
ApoA-I O 
levels O 
is O 
an O 
attractive O 
strategy O 
for O 
HDL-c O 
elevation O 
. O 
Using O 
genome O 
- O 
wide O 
siRNA O 
screening O 
, O 
targets O 
that O 
regulate O 
hepatocyte O 
ApoA-I O 
secretion O 
were O 
identified O 
through O 
transfection O 
of O 
21789 O 
siRNAs O 
into O 
hepatocytes O 
whereby O 
cell O 
supernatants O 
were O 
assayed O 
for O 
ApoA-I O 
. O 
Approximately O 
800 O 
genes O 
were O 
identified O 
and O 
triaged O 
using O 
a O 
convergence O 
of O 
information O 
, O 
including O 
genetic O 
associations O 
with O 
HDL-c O 
levels O 
, O 
tissue O 
- O 
specific O 
gene O 
expression O 
, O 
druggability O 
assessments O 
, O 
and O 
pathway O 
analysis O 
. O 
Fifty O 
- O 
nine O 
genes O 
were O 
selected O 
for O 
reconfirmation O 
; O 
40 O 
genes O 
were O 
confirmed O 
. O 
Here O 
we O 
describe O 
the O 
siRNA O 
screening O 
strategy O 
, O 
assay O 
implementation O 
and O 
validation O 
, O 
data O 
triaging O 
, O 
and O 
example O 
genes O 
of O 
interest O 
. O 
The O 
genes O 
of O 
interest O 
include O 
known O 
and O 
novel O 
genes O 
encoding O 
secreted O 
enzymes O 
, O 
proteases O 
, O 
G O 
- O 
protein O 
- O 
coupled O 
receptors O 
, O 
metabolic O 
enzymes O 
, O 
ion O 
transporters O 
, O 
and O 
proteins O 
of O 
unknown O 
function O 
. O 
Repression O 
of O 
farnesyltransferase O 
( O 
FNTA O 
) O 
by O 
siRNA O 
and O 
the O 
enzyme O 
inhibitor O 
manumycin B-TRIVIAL 
A I-TRIVIAL 
caused O 
elevation O 
of O 
ApoA-I O 
secretion O 
from O 
hepatocytes O 
and O 
from O 
transgenic O 
mice O 
expressing O 
hApoA-I O 
and O 
cholesterol B-FAMILY 
ester I-FAMILY 
transfer O 
protein O 
transgenes O 
. O 
In O 
total O 
, O 
this O 
work O 
underscores O 
the O 
power O 
of O 
functional O 
genetic O 
assessment O 
to O 
identify O 
new O 
therapeutic O 
targets O 
. O 

of O 
Non- O 
ATP B-ABBREVIATION 
Competitive O 
CDK O 
/ O 
Cyclin O 
Groove O 
Inhibitors O 
through O 
REPLACE O 
- O 
Mediated O 
Fragment O 
Assembly O 
. O 

major O 
challenge O 
in O 
drug O 
discovery O 
is O 
to O 
develop O 
and O 
improve O 
methods O 
for O 
targeting O 
protein O 
- O 
protein O 
interactions O 
. O 
Further O 
exemplification O 
of O 
the O 
REPLACE O 
( O 
REplacement O 
with O 
Partial O 
Ligand O 
Alternatives O 
through O 
Computational O 
Enrichment O 
) O 
strategy O 
for O 
generating O 
inhibitors O 
of O 
protein O 
- O 
protein O 
interactions O 
demonstrated O 
that O 
it O 
can O 
be O 
used O 
to O 
optimize O 
fragment O 
alternatives O 
of O 
key O 
determinants O 
, O 
to O 
combine O 
these O 
in O 
an O 
effective O 
way O 
, O 
and O 
this O 
was O 
achieved O 
for O 
compounds O 
targeting O 
the O 
cyclin O 
- O 
dependent O 
kinase O 
2 O 
( O 
CDK2 O 
) O 
substrate O 
recruitment O 
site O 
on O 
the O 
cyclin O 
regulatory O 
subunit O 
. O 
Phenylheterocyclic O 
isosteres O 
replacing O 
a O 
critical O 
charge O 
- O 
charge O 
interaction O 
provided O 
new O 
structural O 
insights O 
for O 
binding O 
to O 
the O 
cyclin O 
groove O 
. O 
In O 
particular O 
, O 
these O 
results O 
shed O 
light O 
onto O 
the O 
key O 
contributions O 
of O 
a O 
H B-FORMULA 
-bond O 
observed O 
in O 
crystal O 
structures O 
of O 
N B-FORMULA 
-terminally O 
capped O 
peptides O 
. O 
Furthermore O 
, O 
the O 
structure O 
- O 
activity O 
relationship O 
of O 
a O 
bis(aryl) B-FAMILY 
ether I-FAMILY 
C B-FORMULA 
-terminal O 
capping O 
group O 
mimicking O 
dipeptide B-FAMILY 
interactions O 
was O 
probed O 
through O 
ring O 
substitutions O 
, O 
allowing O 
increased O 
complementarity O 
with O 
the O 
primary O 
hydrophobic O 
pocket O 
. O 
This O 
study O 
further O 
validates O 
REPLACE O 
as O 
an O 
effective O 
strategy O 
for O 
converting O 
peptidic O 
compounds O 
to O 
more O 
pharmaceutically O 
relevant O 
compounds O 
. O 

new O 
koumine B-TRIVIAL 
metabolites O 
in O 
rat O 
liver O 
microsomes O 
. O 

new O 
metabolites O 
M-1 O 
[ O 
1,2,18,19-tetradehydro-4-demethyl-3,17-epoxy-7,20(2H,19H)-cyclovobasan B-SYSTEMATIC 
] O 
, O 
M-2 O 
[ O 
1,2,4,21,18,19-hexadehydro-4-demethyl-3,17-epoxy-7,20(2H,19H)-cyclovobasan B-SYSTEMATIC 
] O 
, O 
M-3 O 
[ O 
1,2,18,19-tetradehydro-4-demethyl-4- B-SYSTEMATIC 
formaldehyde-3,17-epoxy-7,20(2H,19H)-cyclovobasan I-SYSTEMATIC 
] O 
, O 
and O 
M-4 O 
[ O 
1,2,4,21,18,19-hexadehydro-4-demethyl-4-oxy-3,17-epoxy-7,20(2H,19H)-cyclovobasan B-SYSTEMATIC 
] O 
were O 
isolated O 
from O 
the O 
chloroform B-TRIVIAL 
extract O 
of O 
koumine B-TRIVIAL 
incubated O 
with O 
phenobarbital B-TRIVIAL 
-treated O 
rat O 
liver O 
microsomes O 
. O 
The O 
structures O 
of O 
M-1 O 
, O 
M-2 O 
, O 
M-3 O 
, O 
and O 
M-4 O 
were O 
elucidated O 
by O 
spectroscopic O 
methods O 
including O 
ESI-TOF-MS O 
, O 
1D O 
, O 
and O 
2D O 
NMR O 
experiments O 
. O 
The O 
metabolic O 
pathway O 
of O 
koumine B-TRIVIAL 
was O 
proposed O 
. O 
The O 
cytotoxic O 
activities O 
between O 
koumine B-TRIVIAL 
and O 
its O 
metabolites O 
were O 
also O 
compared O 
in O 
the O 
A549 O 
cell O 
line O 
. O 

of O 
GeSbTe B-FORMULA 
superlattice O 
nanowires O 
. O 

- O 
down O 
of O 
phase O 
change O 
materials O 
to O 
a O 
nanowire O 
( O 
NW O 
) O 
geometry O 
is O 
critical O 
to O 
a O 
fast O 
switching O 
speed O 
of O 
nonvolatile O 
memory O 
devices O 
. O 
Herein O 
, O 
we O 
report O 
novel O 
composition O 
- O 
phase O 
- O 
tuned O 
GeSbTe B-FORMULA 
NWs O 
, O 
synthesized O 
by O 
a O 
chemical O 
vapor O 
transport O 
method O 
, O 
which O 
guarantees O 
promising O 
applications O 
in O 
the O 
field O 
of O 
nanoscale O 
electric O 
devices O 
. O 
As O 
the O 
Sb B-FORMULA 
content O 
increased O 
, O 
they O 
showed O 
a O 
distinctive O 
rhombohedral O 
- O 
cubic O 
- O 
rhombohedral O 
phase O 
evolution O 
. O 
Remarkable O 
superlattice O 
structures O 
were O 
identified O 
for O 
the O 
Ge(8)Sb(2)Te(11) B-FORMULA 
, O 
Ge(3)Sb(2)Te(6) B-FORMULA 
, O 
Ge(3)Sb(8)Te(6) B-FORMULA 
, O 
and O 
Ge(2)Sb(7)Te(4) B-FORMULA 
NWs O 
. O 
The O 
coexisting O 
cubic O 
- O 
rhombohedral O 
phase O 
Ge(3)Sb(2)Te(6) B-FORMULA 
NWs O 
exhibited O 
an O 
exclusively O 
uniform O 
superlattice O 
structure O 
consisting O 
of O 
2.2 O 
nm O 
period O 
slabs O 
. O 
The O 
rhombohedral O 
phase O 
Ge(3)Sb(8)Te(6) B-FORMULA 
and O 
Ge(2)Sb(7)Te(4) B-FORMULA 
NWs O 
adopted O 
an O 
innovative O 
structure O 
; O 
3Sb(2) B-FORMULA 
layers O 
intercalated O 
the O 
Ge(3)Sb(2)Te(6) B-FORMULA 
and O 
Ge(2)Sb(1)Te(4) B-FORMULA 
domains O 
, O 
respectively O 
, O 
producing O 
3.4 O 
and O 
2.7 O 
nm O 
period O 
slabs O 
. O 
The O 
current-voltage O 
measurement O 
of O 
the O 
individual O 
NW O 
revealed O 
that O 
the O 
vacancy O 
layers O 
of O 
Ge(8)Sb(2)Te(11) B-FORMULA 
and O 
Ge(3)Sb(2)Te(6) B-FORMULA 
decreased O 
the O 
electrical O 
conductivity O 
. O 

new O 
flavonoid B-FAMILY 
with O 
6-phenyl B-SYSTEMATIC 
substituent O 
from O 
Selaginella O 
uncinata O 
. O 

new O 
flavonoid B-FAMILY 
, O 
6-(5-acetyl-2-methoxyphenyl)-apigenin B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
together O 
with O 
nine O 
known O 
compounds O 
( O 
2-10 O 
) O 
, O 
was O 
isolated O 
from O 
Selaginella O 
uncinata O 
( O 
Desv O 
. O 
) O 
Spring O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
the O 
spectroscopic O 
data O 
of O 
compound O 
3 O 
. O 
Compound O 
2 O 
was O 
first O 
reported O 
from O 
this O 
species O 
. O 
The O 
structure O 
of O 
the O 
new O 
compound O 
was O 
elucidated O 
on O 
the O 
basis O 
of O 
spectroscopic O 
evidence O 
, O 
including O 
1D O 
and O 
2D O 
NMR O 
as O 
well O 
as O 
HR-EI-MS O 
analysis O 
. O 

assembly O 
and O 
release O 
of O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
based O 
on O 
the O 
layer O 
- O 
by O 
- O 
layer O 
method O 
. O 

- I-TRIVIAL 
trans I-TRIVIAL 
retinoic I-TRIVIAL 
acid I-TRIVIAL 
( O 
RA O 
) O 
has O 
been O 
proved O 
to O 
play O 
important O 
roles O 
in O 
regulating O 
cell O 
growth O 
in O 
various O 
types O 
of O 
cells O 
. O 
Yet O 
most O 
experiments O 
were O 
performed O 
by O 
adding O 
RA O 
in O 
solution O 
previously O 
. O 
In O 
this O 
Article O 
, O 
we O 
focus O 
on O 
the O 
incorporation O 
of O 
RA O 
, O 
as O 
a O 
negatively O 
charged O 
moiety O 
, O 
into O 
layered O 
polyelectrolyte O 
films O 
on O 
surfaces O 
by O 
means O 
of O 
layer O 
- O 
by O 
- O 
layer O 
( O 
LbL O 
) O 
deposition O 
, O 
followed O 
by O 
adding O 
of O 
capping O 
layers O 
to O 
regulate O 
the O 
release O 
of O 
RA O 
from O 
the O 
films O 
. O 
The O 
incorporated O 
RA O 
was O 
designed O 
to O 
release O 
over O 
5 O 
days O 
in O 
buffer O 
solution O 
. O 
The O 
assembly O 
and O 
release O 
of O 
RA O 
were O 
verified O 
by O 
UV O 
and O 
QCM O 
results O 
. O 
The O 
controlled O 
release O 
of O 
RA O 
from O 
multilayer O 
films O 
can O 
serve O 
as O 
a O 
model O 
system O 
to O 
study O 
the O 
influence O 
of O 
small O 
molecules O 
on O 
cell O 
growth O 
. O 

separation O 
induced O 
by O 
Au B-FORMULA 
catalysts O 
in O 
ternary O 
InGaAs B-FORMULA 
nanowires O 
. O 

report O 
a O 
novel O 
phase O 
separation O 
phenomenon O 
observed O 
in O 
the O 
growth O 
of O 
ternary O 
In(x)Ga(1-x)As B-FAMILY 
nanowires O 
by O 
metalorganic O 
chemical O 
vapor O 
deposition O 
. O 
A O 
spontaneous O 
formation O 
of O 
core O 
- O 
shell O 
nanowires O 
is O 
investigated O 
by O 
cross O 
- O 
sectional O 
transmission O 
electron O 
microscopy O 
, O 
revealing O 
the O 
compositional O 
complexity O 
within O 
the O 
ternary O 
nanowires O 
. O 
It O 
has O 
been O 
found O 
that O 
for O 
In(x)Ga(1-x)As B-FAMILY 
nanowires O 
high O 
precursor O 
flow O 
rates O 
generate O 
ternary O 
In(x)Ga(1-x)As B-FAMILY 
cores O 
with O 
In-rich O 
shells O 
, O 
while O 
low O 
precursor O 
flow O 
rates O 
produce O 
binary O 
GaAs B-FORMULA 
cores O 
with O 
ternary O 
In(x)Ga(1-x)As B-FAMILY 
shells O 
. O 
First O 
- O 
principle O 
calculations O 
combined O 
with O 
thermodynamic O 
considerations O 
suggest O 
that O 
this O 
phenomenon O 
is O 
due O 
to O 
competitive O 
alloying O 
of O 
different O 
group-III O 
elements O 
with O 
Au B-FORMULA 
catalysts O 
, O 
and O 
variations O 
in O 
elemental O 
concentrations O 
of O 
group-III O 
materials O 
in O 
the O 
catalyst O 
under O 
different O 
precursor O 
flow O 
rates O 
. O 
This O 
study O 
shows O 
that O 
precursor O 
flow O 
rates O 
are O 
critical O 
factors O 
for O 
manipulating O 
Au B-FORMULA 
catalysts O 
to O 
produce O 
nanowires O 
of O 
desired O 
composition O 
. O 

and O 
antibacterial O 
evaluation O 
of O 
typharin B-TRIVIAL 
analog O 
: O 
6,8-dihydroxy-7-methyl-3-styryl-3,4-dihydroisocoumarin B-SYSTEMATIC 
. O 

of O 
the O 
6-hydroxy-7-methyl B-SYSTEMATIC 
analog O 
of O 
typharin B-TRIVIAL 
( O 
8-dihydroxy-3-styryl-3,4-dihydroisocoumarin B-SYSTEMATIC 
) O 
isolated O 
from O 
the O 
rhizomes O 
of O 
Typha O 
capensis O 
has O 
been O 
described O 
. O 
Direct O 
condensation O 
of O 
3,5-dimethoxy-4-methylhomophthalic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
1 O 
) O 
with O 
cinnamoyl B-SYSTEMATIC 
chloride I-SYSTEMATIC 
at O 
elevated O 
temperature O 
under O 
inert O 
conditions O 
afforded O 
6,8-dihydroxy-7-methyl-3-styrylisocoumarin B-SYSTEMATIC 
( O 
2 O 
) O 
. O 
Hydrolysis O 
of O 
isocoumarin B-TRIVIAL 
to O 
keto B-FAMILY 
acid I-FAMILY 
( O 
3 O 
) O 
followed O 
by O 
reduction O 
and O 
cyclodehydration O 
of O 
hydroxy B-FAMILY 
acid I-FAMILY 
analog O 
( O 
4 O 
) O 
afforded O 
( B-SYSTEMATIC 
± I-SYSTEMATIC 
)-6,8-dimethoxy-3-(4-methoxyphenyl)-3,4-dihydroisocoumarin I-SYSTEMATIC 
( O 
5 O 
) O 
. O 
Demethylation O 
of O 
the O 
latter O 
using O 
anhydrous O 
aluminum B-SYSTEMATIC 
chloride I-SYSTEMATIC 
/ O 
ethane B-SYSTEMATIC 
thiol I-SYSTEMATIC 
furnished O 
the O 
title O 
isocoumarin B-TRIVIAL 
( O 
6 O 
) O 
. O 
Compounds O 
( O 
1-6 O 
) O 
were O 
screened O 
for O 
in O 
vitro O 
antibacterial O 
activity O 
against O 
a O 
representative O 
panel O 
of O 
Gram O 
- O 
positive O 
and O 
Gram O 
- O 
negative O 
bacteria O 
using O 
levofloxacin B-TRIVIAL 
as O 
the O 
reference O 
drug O 
. O 

factorial O 
design O 
for O 
the O 
optimization O 
of O 
methylprednisolone B-SYSTEMATIC 
encapsulation O 
in O 
biodegradable O 
nanoparticles O 
. O 

to O 
their O 
crystalline O 
nature O 
, O 
the O 
encapsulation O 
of O 
hydrophobic O 
corticosteroids B-FAMILY 
within O 
polymeric O 
nanoparticles O 
by O 
o O 
/ O 
w O 
solvent O 
evaporation O 
method O 
is O 
often O 
difficult O 
to O 
achieve O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
effect O 
of O 
both O 
process O 
and O 
formulation O 
parameters O 
on O 
the O 
encapsulation O 
of O 
a O 
model O 
corticosteroid B-TRIVIAL 
: O 
methylprednisolone B-SYSTEMATIC 
( O 
MP O 
) O 
. O 
For O 
this O 
purpose O 
, O 
a O 
3(2)factorial O 
design O 
was O 
performed O 
evaluating O 
the O 
effects O 
of O 
the O 
concentration O 
of O 
emulsifiers O 
and O 
sonication O 
time O 
on O 
the O 
manufactured O 
nanoparticles O 
, O 
followed O 
by O 
a O 
multiresponse O 
optimization O 
. O 
The O 
study O 
also O 
included O 
the O 
evaluation O 
of O 
other O 
parameters O 
such O 
as O 
the O 
type O 
of O 
organic O 
solvent O 
used O 
, O 
polymer O 
characteristics O 
and O 
the O 
initial O 
mass O 
of O 
drug O 
. O 
The O 
optimal O 
nanoparticle O 
formulation O 
using O 
0.25% O 
( O 
w O 
/ O 
v O 
) O 
of O 
emulsifying O 
agent O 
( O 
Polyvinyl-alcohol B-FAMILY 
, O 
PVA B-ABBREVIATION 
) O 
and O 
5 O 
min O 
of O 
sonication O 
was O 
then O 
characterized O 
. O 
The O 
highest O 
encapsulation O 
was O 
obtained O 
with O 
an O 
organic O 
phase O 
consisting O 
of O 
acetone B-SYSTEMATIC 
: O 
dichloromethane B-SYSTEMATIC 
( O 
1 O 
: O 
1 O 
) O 
, O 
polyD,L-lactide-co B-FAMILY 
- I-FAMILY 
glycolide I-FAMILY 
( O 
PLGA B-ABBREVIATION 
) O 
50 O 
: O 
50 O 
as O 
polymer O 
and O 
an O 
initial O 
mass O 
of O 
6.6 O 
mg O 
of O 
methylprednisolone B-SYSTEMATIC 
. O 
Nanoparticles O 
size O 
and O 
ζ O 
potential O 
of O 
optimized O 
formulation O 
were O 
respectively O 
around O 
230 O 
nm O 
and O 
-14 O 
mV O 
. O 
Differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
and O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
demonstrated O 
that O 
the O 
drug O 
was O 
molecularly O 
dispersed O 
within O 
the O 
nanoparticles O 
. O 
Release O 
study O 
showed O 
that O 
MP-loaded O 
nanoparticles O 
sustained O 
drug O 
release O 
for O 
up O 
to O 
120 O 
h O 
. O 
This O 
study O 
reflects O 
the O 
importance O 
of O 
factorial O 
design O 
to O 
optimize O 
the O 
manufacture O 
of O 
nanoparticles O 
encapsulating O 
hydrophobic O 
drugs O 
. O 

, O 
a O 
novel O 
sesquiterpene B-FAMILY 
pyridine B-FAMILY 
alkaloid I-FAMILY 
from O 
a O 
Guangxi O 
sponge O 
Fasciospongia O 
sp O 
. O 

( O 
1 O 
) O 
, O 
a O 
novel O 
sesquiterpene B-FAMILY 
pyridine B-FAMILY 
alkaloid I-FAMILY 
with O 
a O 
previously O 
unreported O 
skeleton O 
featuring O 
a O 
monocyclicfarnesane B-TRIVIAL 
moiety O 
attached O 
to O 
a O 
3-methylenepyridine B-SYSTEMATIC 
residue O 
, O 
was O 
isolated O 
from O 
the O 
sponge O 
Fasciospongia O 
sp O 
. O 
from O 
Weizhou O 
Island O 
, O 
Guangxi O 
Autonomous O 
Region O 
. O 
The O 
structure O 
and O 
the O 
relative O 
stereochemistry O 
of O 
1 O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
extensive O 
analysis O 
of O 
its O 
1D O 
and O 
2D O 
NMR O 
spectroscopic O 
techniques O 
. O 

and O 
Torsional O 
Combination O 
Bands O 
of O 
Two O 
Isomers O 
of O 
the O 
OCS B-FORMULA 
- O 
CO(2) B-FORMULA 
Complex O 
in O 
the O 
CO(2) B-FORMULA 
ν(3) O 
Region O 
. O 

of O 
two O 
isomers O 
of O 
the O 
weakly O 
bound O 
complex O 
OCS B-FORMULA 
- O 
CO(2) B-FORMULA 
are O 
observed O 
in O 
the O 
region O 
of O 
the O 
CO(2) B-FORMULA 
ν(3) O 
fundamental O 
vibration O 
( O 
∼2349 O 
cm(-1) O 
) O 
, O 
using O 
an O 
infrared O 
tunable O 
diode O 
laser O 
to O 
probe O 
a O 
pulsed O 
supersonic O 
slit O 
- O 
jet O 
expansion O 
. O 
Two O 
bands O 
are O 
measured O 
and O 
analyzed O 
for O 
each O 
isomer O 
, O 
the O 
fundamental O 
asymmetric O 
stretch O 
of O 
the O 
CO(2) B-FORMULA 
component O 
and O 
a O 
combination O 
band O 
involving O 
this O 
fundamental O 
plus O 
the O 
intermolecular O 
out O 
- O 
of O 
- O 
plane O 
torsional O 
mode O 
. O 
For O 
one O 
isomer O 
, O 
the O 
corresponding O 
torsional O 
combination O 
band O 
is O 
also O 
detected O 
in O 
the O 
OCS B-FORMULA 
ν(1) O 
stretching O 
region O 
( O 
∼2060 O 
cm(-1) O 
) O 
. O 
The O 
resulting O 
torsional O 
frequencies O 
are O 
found O 
to O 
be O 
18.8 O 
and O 
15.9 O 
cm(-1) O 
for O 
isomers O 
a O 
and O 
b O 
of O 
OCS B-FORMULA 
- O 
CO(2) B-FORMULA 
, O 
respectively O 
. O 
This O 
may O 
be O 
the O 
first O 
time O 
that O 
such O 
a O 
combination O 
band O 
is O 
observed O 
for O 
a O 
higher O 
- O 
energy O 
isomer O 
of O 
a O 
weakly O 
bound O 
complex O 
. O 

resolution O 
of O 
aglinin B-TRIVIAL 
A I-TRIVIAL 
epimers O 
and O 
their O 
NMR O 
assignments O 
. O 

A I-TRIVIAL 
( O 
1 O 
) O 
is O 
a O 
mixture O 
of O 
C(24)-epimeric O 
20S,24-epoxy-24,25-dihydroxy-3,4-secodammar-4(28)-en-3-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
present O 
in O 
plants O 
of O 
the O 
family O 
Meliaceae O 
. O 
The O 
two O 
epimers O 
of O 
1 O 
were O 
resolved O 
through O 
an O 
acetonide B-SYSTEMATIC 
reaction O 
, O 
and O 
the O 
absolute O 
configurations O 
of O 
two O 
derivatives O 
were O 
deduced O 
by O 
the O 
analysis O 
of O 
their O 
(13)C B-FORMULA 
NMR O 
differences O 
induced O 
by O 
γ-gauche O 
or O 
steric O 
effect O 
. O 
Based O 
on O 
it O 
, O 
the O 
(13)C B-FORMULA 
NMR O 
assignment O 
of O 
24R-1 O 
and O 
24S-1 O 
was O 
also O 
established O 
. O 

inhibitors O 
of O 
inosine-5'-monophosphate B-SYSTEMATIC 
dehydrogenase O 
from O 
Cryptosporidium O 
parvum O 
. O 

parvum O 
( O 
Cp O 
) O 
is O 
a O 
potential O 
biowarfare O 
agent O 
and O 
major O 
cause O 
of O 
diarrhea O 
and O 
malnutrition O 
. O 
This O 
protozoan O 
parasite O 
relies O 
on O 
inosine B-SYSTEMATIC 
5'-monophosphate I-SYSTEMATIC 
dehydrogenase O 
( O 
IMPDH O 
) O 
for O 
the O 
production O 
of O 
guanine B-FAMILY 
nucleotides I-FAMILY 
. O 
A O 
CpIMPDH-selective O 
N-aryl-3,4-dihydro-3-methyl-4-oxo-1-phthalazineacetamide B-FAMILY 
inhibitor O 
was O 
previously O 
identified O 
in O 
a O 
high O 
throughput O 
screening O 
campaign O 
. O 
Herein O 
we O 
report O 
a O 
structure O 
- O 
activity O 
relationship O 
study O 
for O 
the O 
phthalazinone B-TRIVIAL 
-based O 
series O 
that O 
resulted O 
in O 
the O 
discovery O 
of O 
benzofuranamide B-FAMILY 
analogs O 
that O 
exhibit O 
low O 
nanomolar O 
inhibition O 
of O 
CpIMPDH O 
. O 
In O 
addition O 
, O 
the O 
antiparasitic O 
activity O 
of O 
select O 
analogs O 
in O 
a O 
Toxoplasma O 
gondii O 
model O 
of O 
C O 
. O 
parvum O 
infection O 
is O 
also O 
presented O 
. O 

composition O 
of O 
carbohydrates B-FAMILY 
contributes O 
to O 
the O 
development O 
of O 
experimental O 
type O 
2 O 
diabetes O 
. O 

has O 
emerged O 
supporting O 
a O 
link O 
between O 
high O 
glycaemic O 
index O 
( O 
GI O 
) O 
diets O 
and O 
type O 
2 O 
diabetes O 
( O 
T2D O 
) O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
if O 
dietary O 
GI O 
influences O 
the O 
development O 
of O 
hyperglycaemia O 
in O 
C57BL O 
/ O 
6 O 
mice O 
to O 
more O 
closely O 
reflect O 
T2D O 
. O 
Male O 
C57BL O 
/ O 
6 O 
mice O 
( O 
n=30 O 
) O 
were O 
randomly O 
divided O 
into O 
3 O 
dietary O 
groups O 
consisting O 
of O 
either O 
standard O 
rodent O 
chow O 
( O 
4.8 O 
% O 
fat O 
, O 
20 O 
% O 
protein O 
) O 
, O 
or O 
a O 
high O 
fat O 
( O 
HF O 
) O 
diet O 
( O 
21-23 O 
% O 
fat O 
, O 
19 O 
% O 
protein O 
) O 
with O 
low O 
GI O 
( O 
15.4 O 
% O 
starch O 
; O 
HF-LG O 
) O 
or O 
high O 
GI O 
( O 
50.5 O 
% O 
dextrose B-TRIVIAL 
; O 
HF-HG O 
) O 
ad O 
libitum O 
for O 
10 O 
weeks O 
. O 
Body O 
weight O 
, O 
blood O 
glucose B-TRIVIAL 
, O 
glucose B-TRIVIAL 
tolerance O 
, O 
and O 
circulating O 
cholesterol B-TRIVIAL 
and O 
triglyceride B-FAMILY 
levels O 
were O 
measured O 
for O 
the O 
duration O 
of O 
the O 
study O 
. O 
We O 
found O 
that O 
increasing O 
the O 
GI O 
of O 
a O 
moderately O 
HF O 
diet O 
induces O 
severe O 
hyperglycaemia O 
and O 
insulin O 
resistance O 
in O 
C57BL O 
/ O 
6 O 
mice O 
, O 
reflective O 
of O 
criteria O 
for O 
diagnosis O 
of O 
T2D O 
, O 
whilst O 
littermates O 
consuming O 
an O 
equivalent O 
low O 
GI O 
diet O 
maintain O 
glucose B-TRIVIAL 
homeostasis O 
. O 
This O 
study O 
demonstrates O 
the O 
significant O 
contribution O 
of O 
both O 
dietary O 
carbohydrate B-FAMILY 
and O 
fat O 
composition O 
in O 
the O 
aetiopathogenesis O 
of O 
T2D O 
. O 

high O 
harm O 
score O 
of O 
alcohol B-FAMILY 
. O 
Time O 
for O 
drug O 
policy O 
to O 
be O 
revisited O 
? O 

aim O 
of O 
this O 
paper O 
is O 
to O 
create O 
awareness O 
of O 
the O 
negative O 
health O 
impact O 
and O 
economic O 
burden O 
and O 
benefits O 
associated O 
to O 
alcohol B-FAMILY 
consumption O 
. O 
Worldwide O 
about O 
two O 
billion O 
people O 
consume O 
alcohol B-FAMILY 
. O 
Low O 
intake O 
of O 
alcohol B-FAMILY 
has O 
a O 
minor O 
protective O 
cardiovascular O 
effect O 
. O 
On O 
the O 
other O 
hand O 
, O 
even O 
moderate O 
alcohol B-FAMILY 
consumption O 
appears O 
to O 
be O 
weakly O 
, O 
but O 
significantly O 
, O 
associated O 
to O 
a O 
limited O 
number O 
of O 
chronic O 
diseases O 
. O 
Alcohol B-SYSTEMATIC 
causes O 
a O 
considerable O 
economic O 
burden O 
to O 
society O 
due O 
to O 
the O 
high O 
absolute O 
number O 
of O 
alcohol B-FAMILY 
consumers O 
. O 
As O 
such O 
, O 
alcohol B-FAMILY 
abuse O 
is O 
more O 
harmful O 
for O 
public O 
health O 
and O 
society O 
than O 
illicit O 
drug O 
use O 
. O 
Some O 
3.7% O 
of O 
alcohol B-FAMILY 
consumers O 
( O 
worldwide O 
76 O 
million O 
people O 
) O 
have O 
an O 
alcohol B-FAMILY 
use O 
disorder O 
leading O 
to O 
60-70% O 
of O 
the O 
societal O 
costs O 
related O 
to O 
alcohol B-FAMILY 
. O 
Therefore O 
, O 
policy O 
measures O 
should O 
, O 
in O 
addition O 
to O 
regulatory O 
measures O 
to O 
reduce O 
alcohol B-FAMILY 
use O 
, O 
aim O 
at O 
closing O 
the O 
treatment O 
gap O 
and O 
improving O 
treatment O 
effectiveness O 
of O 
people O 
with O 
an O 
alcohol B-FAMILY 
use O 
disorder O 
. O 
The O 
key O 
message O 
is O 
that O 
policy O 
- O 
makers O 
unjustifiably O 
focus O 
on O 
the O 
harm O 
of O 
illicit O 
drugs O 
, O 
whereas O 
they O 
underestimate O 
the O 
harm O 
of O 
alcohol B-FAMILY 
use O 
. O 
Policy O 
makers O 
should O 
therefore O 
consider O 
alcohol B-FAMILY 
to O 
be O 
at O 
least O 
as O 
harmful O 
as O 
illicit O 
drugs O 
and O 
invest O 
more O 
in O 
prevention O 
and O 
harm O 
reduction O 
strategies O 
for O 
alcohol B-FAMILY 
abuse O 
and O 
dependence O 
. O 

aripiprazole B-TRIVIAL 
therapy O 
with O 
escitalopram B-TRIVIAL 
in O 
patients O 
with O 
co O 
- O 
morbid O 
major O 
depressive O 
disorder O 
and O 
alcohol B-FAMILY 
dependence O 
: O 
clinical O 
and O 
neuroimaging O 
evidence O 
. O 

effective O 
treatment O 
of O 
depression O 
has O 
been O 
reported O 
to O 
reduce O 
the O 
severity O 
of O 
alcohol B-FAMILY 
use O 
, O 
potentially O 
reflecting O 
improvements O 
in O 
common O 
brain O 
reward O 
circuits O 
. O 
We O 
hypothesized O 
that O 
augmentation O 
therapy O 
of O 
escitalopram B-TRIVIAL 
with O 
aripiprazole B-TRIVIAL 
would O 
improve O 
depressive O 
symptoms O 
as O 
well O 
as O 
reduce O 
craving O 
for O 
alcohol B-FAMILY 
and O 
cue O 
- O 
induced O 
brain O 
activity O 
in O 
patients O 
with O 
co O 
- O 
morbid O 
alcohol B-FAMILY 
dependence O 
and O 
major O 
depressive O 
disorder O 
, O 
compared O 
with O 
treatment O 
with O 
escitalopram B-TRIVIAL 
alone O 
. O 
Thirty O 
- O 
five O 
subjects O 
with O 
major O 
depressive O 
disorder O 
and O 
alcohol B-FAMILY 
dependence O 
were O 
recruited O 
and O 
randomly O 
assigned O 
into O 
17 O 
aripiprazole B-TRIVIAL 
+ O 
escitalopram B-TRIVIAL 
and O 
18 O 
escitalopram B-TRIVIAL 
only O 
groups O 
. O 
At O 
baseline O 
and O 
following O 
six O 
weeks O 
of O 
treatment O 
, O 
symptoms O 
of O 
depression O 
, O 
craving O 
for O 
alcohol B-FAMILY 
and O 
brain O 
activity O 
were O 
evaluated O 
. O 
During O 
the O 
six O 
week O 
treatment O 
period O 
, O 
Beck O 
Depression O 
Inventory O 
and O 
clinical O 
global O 
index O 
- O 
severity O 
( O 
CGI-S O 
) O 
scores O 
decreased O 
in O 
both O 
the O 
aripiprazole B-TRIVIAL 
+ O 
escitalopram B-TRIVIAL 
and O 
escitalopram B-TRIVIAL 
only O 
groups O 
. O 
In O 
addition O 
, O 
following O 
the O 
treatment O 
period O 
, O 
the O 
Korean O 
alcohol B-FAMILY 
urge O 
questionnaire O 
scores O 
in O 
the O 
aripiprazole B-TRIVIAL 
+ O 
escitalopram B-TRIVIAL 
group O 
were O 
reduced O 
from O 
23.3±8.4 O 
to O 
14.3±4.9 O 
, O 
compared O 
with O 
those O 
of O 
the O 
escitalopram B-TRIVIAL 
group O 
of O 
from O 
21.6±8.4 O 
to O 
19.3±7.1 O 
( O 
F=13.1 O 
, O 
p O 
< O 
0.01 O 
) O 
. O 
The O 
activity O 
within O 
the O 
anterior O 
cingulate O 
was O 
increased O 
in O 
response O 
to O 
the O 
presentation O 
of O 
alcohol B-FAMILY 
drinking O 
scenes O 
following O 
treatment O 
in O 
the O 
aripiprazole B-TRIVIAL 
+ O 
escitalopram B-TRIVIAL 
group O 
. O 
The O 
change O 
of O 
brain O 
activity O 
within O 
the O 
left O 
anterior O 
cingulate O 
gyrus O 
in O 
all O 
patients O 
with O 
co O 
- O 
morbid O 
alcohol B-FAMILY 
dependence O 
and O 
major O 
depressive O 
disorder O 
was O 
negatively O 
correlated O 
with O 
the O 
change O 
in O 
craving O 
for O 
alcohol B-FAMILY 
. O 
These O 
findings O 
suggest O 
that O 
the O 
effects O 
of O 
aripiprazole B-TRIVIAL 
on O 
anterior O 
cingulate O 
cortex O 
might O 
mediate O 
the O 
successful O 
treatment O 
of O 
alcohol B-FAMILY 
dependence O 
in O 
patients O 
with O 
major O 
depressive O 
disorder O 
. O 

concentration-QT O 
relationship O 
in O 
healthy O 
volunteers O 
: O 
meta-analysis O 
of O 
data O 
from O 
six O 
clinical O 
trials O 
. O 

: O 
The O 
objective O 
of O 
this O 
work O 
was O 
to O 
describe O 
the O 
losmapimod B-TRIVIAL 
concentration-QT O 
relationship O 
using O 
meta-analysis O 
of O 
data O 
from O 
clinical O 
trials O 
with O 
healthy O 
volunteers O 
and O 
to O 
evaluate O 
the O 
covariates O 
that O 
have O 
significant O 
impact O 
on O 
the O 
QT O 
prolongation O 
. O 
METHODS O 
: O 
Losmapimod B-TRIVIAL 
plasma O 
concentration O 
and O 
QT O 
interval O 
data O 
were O 
collected O 
from O 
six O 
early O 
clinical O 
studies O 
with O 
healthy O 
volunteers O 
. O 
The O 
electrocardiograms O 
( O 
ECGs O 
) O 
were O 
collected O 
at O 
baseline O 
and O 
at O 
a O 
number O 
of O 
post O 
- O 
dose O 
time O 
points O 
( O 
losmapimod B-TRIVIAL 
or O 
placebo O 
) O 
. O 
The O 
population O 
pharmacokinetic O 
/ O 
pharmacodynamic O 
( O 
PK O 
/ O 
PD O 
) O 
modelling O 
approach O 
was O 
applied O 
to O 
investigate O 
the O 
relationship O 
between O 
losmapimod B-TRIVIAL 
concentration O 
and O 
QT O 
prolongation O 
. O 
RESULTS O 
: O 
The O 
dataset O 
for O 
analysis O 
comprised O 
190 O 
healthy O 
adults O 
who O 
took O 
at O 
least O 
one O 
dose O 
of O 
losmapimod B-TRIVIAL 
or O 
placebo O 
. O 
Of O 
the O 
2494 O 
QT O 
observations O 
collected O 
, O 
1532 O 
observations O 
had O 
matched O 
QT O 
and O 
losmapimod B-TRIVIAL 
plasma O 
concentration O 
data O 
. O 
Population O 
PK O 
/ O 
PD O 
analyses O 
indicated O 
that O 
the O 
model O 
with O 
the O 
individual O 
heart O 
rate O 
correction O 
factor O 
( O 
α O 
) O 
fitted O 
the O 
data O 
better O 
than O 
those O 
using O 
fixed O 
α O 
( O 
0.33 O 
for O 
Fridericia's O 
correction O 
or O 
0.5 O 
for O 
Bazett's O 
correction O 
) O 
and O 
that O 
there O 
was O 
no O 
relationship O 
between O 
losmapimod B-TRIVIAL 
concentration O 
and O 
QT O 
interval O 
. O 
Female O 
volunteers O 
had O 
about O 
a O 
3 O 
% O 
higher O 
QT O 
interval O 
at O 
baseline O 
than O 
the O 
male O 
volunteers O 
. O 
No O 
other O 
covariates O 
had O 
a O 
significant O 
effect O 
on O 
the O 
QT O 
interval O 
. O 
CONCLUSIONS O 
: O 
It O 
is O 
appropriate O 
to O 
apply O 
population O 
PK O 
/ O 
PD O 
analysis O 
to O 
investigate O 
the O 
effect O 
of O 
drug O 
concentration O 
on O 
QT O 
prolongation O 
. O 
Our O 
meta-analysis O 
of O 
healthy O 
volunteer O 
data O 
indicated O 
no O 
relationship O 
between O 
systemic O 
losmapimod B-TRIVIAL 
concentration O 
and O 
QT O 
interval O 
in O 
healthy O 
volunteers O 
. O 

of O 
AMP B-ABBREVIATION 
-activated O 
Protein O 
Kinase O 
and O 
Phosphorylation O 
of O 
Glycogen O 
Synthase O 
Kinase3 O 
β O 
Mediate O 
Ursolic B-TRIVIAL 
Acid I-TRIVIAL 
Induced O 
Apoptosis O 
in O 
HepG2 O 
Liver O 
Cancer O 
Cells O 
. O 

the O 
antitumour O 
effect O 
of O 
ursolic B-TRIVIAL 
acid I-TRIVIAL 
observed O 
in O 
several O 
cancers O 
, O 
the O 
underlying O 
mechanism O 
remains O 
unclear O 
. O 
Thus O 
, O 
in O 
the O 
present O 
study O 
, O 
the O 
roles O 
of O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
and O 
glycogen O 
synthase O 
kinase O 
3 O 
beta O 
( O 
GSK3β O 
) O 
were O 
examined O 
in O 
ursolic O 
acid O 
induced O 
apoptosis O 
in O 
HepG2 O 
hepatocellular O 
carcinoma O 
cells O 
. O 
Ursolic B-TRIVIAL 
acid I-TRIVIAL 
significantly O 
exerted O 
cytotoxicity O 
, O 
increased O 
the O 
sub-G1 O 
population O 
and O 
the O 
number O 
of O 
ethidium B-TRIVIAL 
homodimer O 
and O 
terminal O 
deoxynucleotidyl O 
transferase(TdT) O 
mediated O 
dUTP B-ABBREVIATION 
nick O 
end O 
labeling O 
positive O 
cells O 
in O 
HepG2 O 
cells O 
. O 
Also O 
, O 
ursolic O 
acid O 
enhanced O 
the O 
cleavages O 
of O 
poly-ADP-ribose B-FAMILY 
polymerase O 
( O 
PARP O 
) O 
and O 
caspase3 O 
, O 
attenuated O 
the O 
expression O 
of O 
astrocyte O 
elevated O 
gene O 
( O 
AEG1 O 
) O 
and O 
survivin O 
in O 
HepG2 O 
cells O 
. O 
Interestingly O 
, O 
ursolic B-TRIVIAL 
acid I-TRIVIAL 
increased O 
the O 
phosphorylation O 
of O 
AMPK O 
and O 
coenzyme O 
A O 
carboxylase O 
and O 
also O 
enhanced O 
phosphorylation O 
of O 
GSK3β O 
at O 
inactive O 
form O 
serine B-TRIVIAL 
9 O 
, O 
whereas O 
ursolic B-TRIVIAL 
acid I-TRIVIAL 
attenuated O 
the O 
phosphorylation O 
of O 
AKT O 
and O 
mTOR O 
in O 
HepG2 O 
cells O 
. O 
Conversely O 
, O 
AMPK O 
inhibitor O 
compound B-TRIVIAL 
C I-TRIVIAL 
or O 
GSK3β O 
inhibitor O 
SB216763 B-IDENTIFIER 
blocked O 
the O 
cleavages O 
of O 
PARP O 
and O 
caspase O 
3 O 
induced O 
by O 
ursolic B-TRIVIAL 
acid I-TRIVIAL 
in O 
HepG2 O 
cells O 
. O 
Furthermore O 
, O 
proteosomal O 
inhibitor O 
MG132 B-IDENTIFIER 
suppressed O 
AMPK O 
activation O 
, O 
GSK3β O 
phosphorylation O 
, O 
cleaved O 
PARP O 
and O 
deceased O 
AEG-1 O 
induced O 
by O 
ursolic B-TRIVIAL 
acid I-TRIVIAL 
in O 
HepG2 O 
cells O 
. O 
Overall O 
, O 
our O 
findings O 
suggest O 
that O 
ursolic B-TRIVIAL 
acid I-TRIVIAL 
induced O 
apoptosis O 
in O 
HepG2 O 
cells O 
via O 
AMPK O 
activation O 
and O 
GSK3β O 
phosphorylation O 
as O 
a O 
potent O 
chemopreventive O 
agent O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

, O 
synthesis O 
, O 
in O 
vitro O 
MAO-B O 
inhibitory O 
evaluation O 
, O 
and O 
computational O 
studies O 
of O 
some O 
6-nitrobenzothiazole B-SYSTEMATIC 
-derived O 
semicarbazones B-FAMILY 
. O 

oxidase O 
B O 
( O 
MAO-B O 
) O 
is O 
an O 
important O 
drug O 
target O 
for O 
the O 
treatment O 
of O 
neurological O 
disorders O 
. O 
A O 
series O 
of O 
6-nitrobenzothiazole B-SYSTEMATIC 
-derived O 
semicarbazones B-FAMILY 
were O 
designed O 
, O 
synthesized O 
, O 
and O 
evaluated O 
as O 
inhibitors O 
of O 
the O 
rat O 
brain O 
MAO-B O 
isoenzyme O 
. O 
Most O 
of O 
the O 
compounds O 
were O 
found O 
to O 
be O 
potent O 
inhibitors O 
of O 
MAO-B O 
, O 
with O 
IC(50) O 
values O 
in O 
the O 
nanomolar O 
to O 
micromolar O 
range O 
. O 
Molecular O 
docking O 
studies O 
were O 
performed O 
with O 
AutoDock O 
4.2 O 
to O 
deduce O 
the O 
affinity O 
and O 
binding O 
mode O 
of O 
these O 
inhibitors O 
toward O 
the O 
MAO-B O 
active O 
site O 
. O 
The O 
free O 
energies O 
of O 
binding O 
( O 
ΔG O 
) O 
and O 
inhibition O 
constants O 
(K(i)) O 
of O 
the O 
docked O 
compounds O 
were O 
calculated O 
by O 
the O 
Lamarckian O 
genetic O 
algorithm O 
( O 
LGA O 
) O 
of O 
AutoDock O 
4.2 O 
. O 
Good O 
correlations O 
between O 
the O 
calculated O 
and O 
experimental O 
results O 
were O 
obtained O 
. O 
1-[(4-Chlorophenyl)(phenyl)methylene]-4-(6-nitrobenzothiazol-2-yl)semicarbazide B-SYSTEMATIC 
emerged O 
as O 
the O 
lead O 
MAO-B O 
inhibitor O 
, O 
with O 
top O 
ranking O 
in O 
both O 
the O 
experimental O 
MAO-B O 
assay O 
( O 
IC(50) O 
: O 
0.004±0.001 O 
μM O 
) O 
and O 
in O 
computational O 
docking O 
studies O 
( O 
K O 
(i) O 
: O 
1.08 O 
μM O 
) O 
. O 
Binding O 
mode O 
analysis O 
of O 
potent O 
inhibitors O 
suggests O 
that O 
these O 
compounds O 
are O 
well O 
accommodated O 
by O 
the O 
MAO-B O 
active O 
site O 
through O 
stable O 
hydrophobic O 
and O 
hydrogen B-SYSTEMATIC 
bonding O 
interactions O 
. O 
Interestingly O 
, O 
the O 
6-nitrobenzothiazole B-SYSTEMATIC 
moiety O 
is O 
stabilized O 
in O 
the O 
substrate O 
cavity O 
with O 
the O 
aryl O 
or O 
diaryl O 
residues O 
extending O 
up O 
into O 
the O 
entrance O 
cavity O 
of O 
the O 
active O 
site O 
. O 
According O 
to O 
our O 
results O 
, O 
docking O 
experiments O 
could O 
be O 
an O 
interesting O 
approach O 
for O 
predicting O 
the O 
activity O 
and O 
binding O 
interactions O 
of O 
this O 
class O 
of O 
semicarbazones B-FAMILY 
against O 
MAO-B O 
. O 
Thus O 
, O 
a O 
binding O 
site O 
model O 
consisting O 
of O 
three O 
essential O 
pharmacophoric O 
features O 
is O 
proposed O 
, O 
and O 
this O 
can O 
be O 
used O 
for O 
the O 
design O 
of O 
future O 
MAO-B O 
inhibitors O 
. O 

biogenesis O 
GTPase O 
A O 
protein O 
( O 
RbgA O 
) O 
is O 
an O 
essential O 
GTPase O 
required O 
for O 
the O 
biogenesis O 
of O 
the O 
50S O 
subunit O 
in O 
Bacillus O 
subtilis O 
. O 
Homologs O 
of O 
RbgA O 
are O 
widely O 
distributed O 
in O 
bacteria O 
and O 
eukaryotes O 
and O 
are O 
implicated O 
in O 
ribosome O 
assembly O 
in O 
the O 
mitochondria O 
, O 
chloroplast O 
and O 
cytoplasm O 
. O 
Cells O 
depleted O 
of O 
RbgA O 
accumulate O 
an O 
immature O 
large O 
subunit O 
that O 
is O 
missing O 
key O 
ribosomal O 
proteins O 
. O 
RbgA O 
, O 
unlike O 
many O 
members O 
of O 
the O 
Ras O 
superfamily O 
of O 
GTPases O 
, O 
lacks O 
a O 
defined O 
catalytic O 
residue O 
for O 
carrying O 
out O 
guanosine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
( O 
GTP B-ABBREVIATION 
) O 
hydrolysis O 
. O 
To O 
probe O 
RbgA O 
function O 
in O 
ribosome O 
assembly O 
, O 
we O 
used O 
a O 
combined O 
bioinformatics O 
, O 
genetic O 
and O 
biochemical O 
approach O 
. O 
We O 
identified O 
a O 
RNA O 
- O 
binding O 
domain O 
within O 
the O 
C B-FORMULA 
-terminus O 
of O 
RbgA O 
that O 
is O 
structurally O 
similar O 
to O 
AmiR-NasR O 
Transcription O 
Anti-termination O 
Regulator O 
( O 
ANTAR O 
) O 
domains O 
, O 
which O 
are O 
known O 
to O 
bind O 
structured O 
RNA O 
. O 
Mutation O 
of O 
key O 
residues O 
in O 
the O 
ANTAR O 
domain O 
altered O 
RbgA O 
association O 
with O 
the O 
ribosome O 
. O 
We O 
identified O 
a O 
putative O 
catalytic O 
residue O 
within O 
a O 
highly O 
conserved O 
region O 
of O 
RbgA O 
, O 
His9 O 
, O 
which O 
is O 
contained O 
within O 
a O 
similar O 
PGH O 
motif O 
found O 
in O 
elongation O 
factor O 
Tu O 
( O 
EF-Tu O 
) O 
that O 
is O 
required O 
for O 
GTP B-ABBREVIATION 
hydrolysis O 
on O 
interaction O 
with O 
the O 
ribosome O 
. O 
Finally O 
, O 
our O 
results O 
support O 
a O 
model O 
in O 
which O 
the O 
GTPase O 
activity O 
of O 
RbgA O 
directly O 
participates O 
in O 
the O 
maturation O 
of O 
the O 
large O 
subunit O 
rather O 
than O 
solely O 
promoting O 
dissociation O 
of O 
RbgA O 
from O 
the O 
50S O 
subunit O 
. O 

functionalized O 
double O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
combine O 
high O 
sensitivity O 
and O 
selectivity O 
in O 
the O 
electrical O 
detection O 
of O 
small O 
molecules O 
. O 

- O 
thick O 
materials O 
such O 
as O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWCNTs O 
) O 
and O 
graphene B-TRIVIAL 
exhibit O 
ultrahigh O 
sensitivity O 
to O 
chemical O 
perturbation O 
partly O 
because O 
all O 
of O 
the O 
constituent O 
atoms O 
are O 
surface O 
atoms O 
. O 
However O 
, O 
low O 
selectivity O 
due O 
to O 
nonspecific O 
binding O 
on O 
the O 
graphitic O 
surface O 
is O 
a O 
challenging O 
issue O 
to O 
many O 
applications O 
including O 
chemical O 
sensing O 
. O 
Here O 
, O 
we O 
demonstrated O 
simultaneous O 
attainment O 
of O 
high O 
sensitivity O 
and O 
selectivity O 
in O 
thin O 
- O 
film O 
field O 
effect O 
transistors O 
( O 
TFTs O 
) O 
based O 
on O 
outer O 
- O 
wall O 
selectively O 
functionalized O 
double O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
DWCNTs O 
) O 
. O 
With O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
functionalized O 
DWCNT O 
TFTs O 
, O 
we O 
obtained O 
excellent O 
gate O 
modulation O 
( O 
on O 
/ O 
off O 
ratio O 
as O 
high O 
as O 
4000 O 
) O 
with O 
relatively O 
high O 
ON O 
currents O 
at O 
a O 
CNT O 
areal O 
density O 
as O 
low O 
as O 
35 O 
ng O 
/ O 
cm(2) O 
. O 
The O 
devices O 
displayed O 
an O 
NH(3) B-FORMULA 
sensitivity O 
of O 
60 O 
nM O 
( O 
or O 
~1 O 
ppb O 
) O 
, O 
which O 
is O 
comparable O 
to O 
small O 
molecule O 
aqueous O 
solution O 
detection O 
using O 
state O 
- O 
of O 
- O 
the O 
- O 
art O 
SWCNT O 
TFT O 
sensors O 
while O 
concomitantly O 
achieving O 
6000 O 
times O 
higher O 
chemical O 
selectivity O 
toward O 
a O 
variety O 
of O 
amine B-SYSTEMATIC 
-containing O 
analyte O 
molecules O 
over O 
that O 
of O 
other O 
small O 
molecules O 
. O 
These O 
results O 
highlight O 
the O 
potential O 
of O 
using O 
covalently O 
functionalized O 
double O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
for O 
simultaneous O 
ultrahigh O 
selective O 
and O 
sensitive O 
detection O 
of O 
chemicals O 
and O 
illustrate O 
some O 
of O 
the O 
structural O 
advantages O 
of O 
this O 
double O 
- O 
wall O 
materials O 
strategy O 
to O 
nanoelectronics O 
. O 

Objective O 
: O 
To O 
design O 
and O 
evaluate O 
a O 
novel O 
pressure O 
sensitive O 
adhesive O 
( O 
PSA O 
) O 
patch O 
containing O 
traditional O 
Chinese O 
medicine O 
( O 
TCM O 
) O 
using O 
styrene B-TRIVIAL 
- I-TRIVIAL 
isoprene I-TRIVIAL 
- I-TRIVIAL 
styrene I-TRIVIAL 
( O 
SIS B-ABBREVIATION 
) O 
copolymer O 
. O 
Method O 
: O 
A O 
mixture O 
D-optimal O 
design O 
with O 
ternary O 
response O 
surface O 
diagram O 
was O 
employed O 
in O 
the O 
optimization O 
process O 
. O 
The O 
proportions O 
of O 
SIS B-ABBREVIATION 
copolymer O 
, O 
tackifying O 
resin O 
and O 
plasticizer O 
were O 
selected O 
as O 
the O 
independent O 
variables O 
while O 
tack O 
force O 
, O 
peel O 
strength O 
of O 
the O 
patch O 
and O 
skin O 
penetrability O 
of O 
methyl B-SYSTEMATIC 
salicylate I-SYSTEMATIC 
were O 
selected O 
as O 
the O 
dependent O 
variables O 
. O 
The O 
optimized O 
patch O 
was O 
then O 
evaluated O 
including O 
in O 
vivo O 
absorption O 
, O 
pharmacological O 
activities O 
and O 
skin O 
irritation O 
, O 
by O 
comparing O 
with O 
a O 
commercial O 
patch O 
based O 
on O 
natural O 
rubber O 
. O 
Results O 
: O 
The O 
optimized O 
patch O 
, O 
which O 
comprised O 
30.0% O 
SIS B-ABBREVIATION 
copolymer O 
, O 
26.6% O 
tackifying O 
resin O 
and O 
43.4% O 
plasticizer O 
, O 
was O 
superior O 
to O 
commercial O 
patch O 
in O 
skin O 
permeation O 
, O 
pharmacological O 
activities O 
and O 
skin O 
biocompatibility O 
. O 
Conclusion O 
: O 
SIS B-ABBREVIATION 
copolymer O 
was O 
a O 
suitable O 
substitute O 
to O 
natural O 
rubber O 
in O 
producing O 
patches O 
containing O 
TCM O 
formula O 
. O 

- O 
contrast O 
electrooptic O 
modulation O 
of O 
a O 
photonic O 
crystal O 
nanocavity O 
by O 
electrical O 
gating O 
of O 
graphene B-TRIVIAL 
. O 

demonstrate O 
high O 
- O 
contrast O 
electro O 
- O 
optic O 
modulation O 
of O 
a O 
photonic O 
crystal O 
nanocavity O 
integrated O 
with O 
an O 
electrically O 
gated O 
monolayer O 
graphene B-TRIVIAL 
. O 
A O 
silicon O 
air O 
- O 
slot O 
nanocavity O 
provides O 
strong O 
overlap O 
between O 
the O 
resonant O 
optical O 
field O 
and O 
graphene B-TRIVIAL 
. O 
Tuning O 
the O 
Fermi O 
energy O 
of O 
the O 
graphene B-TRIVIAL 
layer O 
to O 
0.85 O 
eV O 
enables O 
strong O 
control O 
of O 
its O 
optical O 
conductivity O 
at O 
telecom O 
wavelengths O 
, O 
which O 
allows O 
modulation O 
of O 
cavity O 
reflection O 
in O 
excess O 
of O 
10 O 
dB O 
for O 
a O 
swing O 
voltage O 
of O 
only O 
1.5 O 
V O 
. O 
The O 
cavity O 
resonance O 
at O 
1570 O 
nm O 
is O 
found O 
to O 
undergo O 
a O 
shift O 
in O 
wavelength O 
of O 
nearly O 
2 O 
nm O 
, O 
together O 
with O 
a O 
3-fold O 
increase O 
in O 
quality O 
factor O 
. O 
These O 
observations O 
enable O 
a O 
cavity O 
- O 
enhanced O 
determination O 
of O 
graphene B-TRIVIAL 
' O 
s O 
complex O 
optical O 
sheet O 
conductivity O 
at O 
different O 
doping O 
levels O 
. O 
Our O 
simple O 
device O 
demonstrates O 
the O 
feasibility O 
of O 
high O 
- O 
contrast O 
, O 
low O 
- O 
power O 
, O 
and O 
frequency O 
- O 
selective O 
electro O 
- O 
optic O 
modulators O 
in O 
graphene B-TRIVIAL 
-integrated O 
silicon B-SYSTEMATIC 
photonic O 
integrated O 
circuits O 
. O 

- O 
dependent O 
metabolism O 
of O 
a O 
novel O 
selective O 
α7 O 
neuronal O 
acetylcholine B-SYSTEMATIC 
receptor O 
agonist O 
ABT-107 O 
. O 

1 O 
. O 
Metabolism O 
of O 
ABT-107 B-IDENTIFIER 
was O 
investigated O 
in O 
in O 
vitro O 
hepatic O 
systems O 
, O 
in O 
rat O 
and O 
monkey O 
receiving O 
[(14)C]ABT-107 B-SYSTEMATIC 
, O 
and O 
in O 
vivo O 
plasma O 
in O 
rat O 
, O 
dog O 
, O 
monkey O 
and O 
human O 
. O 
2 O 
. O 
In O 
in O 
vitro O 
hepatic O 
systems O 
, O 
ABT-107 B-IDENTIFIER 
was O 
primarily O 
cleared O 
via O 
oxidative O 
metabolism O 
, O 
and O 
proceeded O 
via O 
two O 
parallel O 
pathways O 
. O 
Pathway O 
1 O 
, O 
ABT-107 B-IDENTIFIER 
was O 
oxidized O 
at O 
the O 
nitrogen B-SYSTEMATIC 
of O 
quinuclidine B-TRIVIAL 
moiety O 
to O 
form O 
M1 O 
. O 
Pathway O 
2 O 
, O 
oxidation O 
occurred O 
at O 
indole B-SYSTEMATIC 
-containing O 
moiety O 
to O 
form O 
M2 O 
. O 
Metabolism O 
via O 
N B-FORMULA 
-oxidation O 
was O 
predominant O 
in O 
dog O 
and O 
rat O 
, O 
while O 
in O 
monkey O 
and O 
human O 
, O 
metabolism O 
proceeded O 
primarily O 
via O 
oxidation O 
of O 
indole B-SYSTEMATIC 
-containing O 
moiety O 
. O 
3 O 
. O 
ABT-107 B-IDENTIFIER 
was O 
extensively O 
metabolized O 
in O 
vivo O 
in O 
rat O 
and O 
monkey O 
. O 
M1 O 
was O 
primarily O 
found O 
in O 
rat O 
urine O 
and O 
bile O 
; O 
whereas O 
, O 
M2 O 
was O 
the O 
major O 
metabolite O 
in O 
monkey O 
urine O 
and O 
feces O 
. O 
M1 O 
was O 
the O 
predominant O 
circulating O 
metabolite O 
in O 
dog O 
and O 
rat O 
. O 
M2 O 
was O 
the O 
primary O 
circulating O 
metabolite O 
in O 
monkey O 
and O 
human O 
. O 
4 O 
. O 
Enzymatic O 
studies O 
suggested O 
M1 O 
formation O 
was O 
primarily O 
mediated O 
by O 
renal O 
FMO1 O 
. O 
CYP3A4 O 
, O 
1A2 O 
, O 
2J2 O 
and O 
2D6 O 
were O 
primary O 
enzymes O 
catalyzing O 
M2 O 
formation O 
. O 
5 O 
. O 
Biotransformation O 
of O 
ABT-107 B-IDENTIFIER 
in O 
human O 
and O 
monkey O 
is O 
markedly O 
different O 
from O 
that O 
in O 
dog O 
and O 
rat O 
, O 
suggesting O 
that O 
monkey O 
is O 
an O 
appropriate O 
model O 
for O 
predicting O 
human O 
biotransformation O 
and O 
toxicology O 
of O 
ABT-107 B-IDENTIFIER 
. O 

transformation O 
of O 
tetrathienoanthracene B-SYSTEMATIC 
into O 
pentacene B-SYSTEMATIC 
on O 
Ni(111) B-FORMULA 
. O 

imaging O 
and O 
characterization O 
of O 
single O 
- O 
molecule O 
reaction O 
events O 
is O 
essential O 
to O 
both O 
extending O 
our O 
basic O 
understanding O 
of O 
chemistry O 
and O 
applying O 
this O 
understanding O 
to O 
challenges O 
at O 
the O 
frontiers O 
of O 
technology O 
, O 
for O 
example O 
, O 
in O 
nanoelectronics O 
. O 
Specifically O 
, O 
understanding O 
the O 
behavior O 
of O 
individual O 
molecules O 
can O 
elucidate O 
processes O 
critical O 
to O 
the O 
controlled O 
synthesis O 
of O 
materials O 
for O 
applications O 
in O 
multiple O 
nanoscale O 
technologies O 
. O 
Here O 
, O 
we O 
report O 
the O 
synthesis O 
of O 
an O 
important O 
semiconducting O 
organic O 
molecule O 
through O 
an O 
unprecedented O 
reaction O 
observed O 
with O 
submolecular O 
resolution O 
by O 
scanning O 
tunneling O 
microscopy O 
( O 
STM O 
) O 
under O 
ultrahigh O 
vacuum O 
( O 
UHV O 
) O 
conditions O 
. O 
Our O 
images O 
reveal O 
a O 
sulfur B-SYSTEMATIC 
abstraction O 
and O 
cyclization O 
reaction O 
that O 
converts O 
tetrathienoanthracene B-SYSTEMATIC 
precursors O 
into O 
pentacene B-SYSTEMATIC 
on O 
the O 
Ni(111) B-FORMULA 
surface O 
. O 
The O 
identity O 
of O 
the O 
final O 
reaction O 
product O 
was O 
confirmed O 
by O 
time O 
- O 
of O 
- O 
flight O 
secondary O 
ion O 
mass O 
spectrometry O 
( O 
TOF-SIMS O 
) O 
. O 
This O 
reaction O 
has O 
no O 
known O 
literature O 
analogue O 
, O 
and O 
highlights O 
the O 
power O 
of O 
local O 
- O 
probe O 
techniques O 
for O 
exploring O 
new O 
chemical O 
pathways O 
. O 

study O 
is O 
designed O 
to O 
evaluate O 
the O 
relationship O 
between O 
endometrial O 
thickness O 
and O 
clinical O 
/ O 
biochemical O 
parameters O 
in O 
women O 
with O 
chronic O 
anovulation O 
. O 
One O 
hundred O 
and O 
twenty O 
women O 
with O 
ovulatory O 
dysfunction O 
were O 
prospective O 
included O 
, O 
endometrial O 
thickness O 
and O 
endocrine O 
and O 
metabolic O 
parameters O 
were O 
measured O 
. O 
The O 
interval O 
between O 
the O 
examination O 
day O 
and O 
the O 
day O 
of O 
the O 
most O 
recent O 
menstrual O 
bleeding O 
( O 
the O 
anovulatory O 
interval O 
) O 
for O 
the O 
studied O 
subject O 
was O 
an O 
average O 
of O 
145 O 
± O 
186 O 
days O 
. O 
The O 
endometrial O 
thickness O 
averaged O 
7.1 O 
± O 
3.2 O 
mm O 
. O 
Correlation O 
analyses O 
revealed O 
that O 
the O 
endometrial O 
thickness O 
was O 
positively O 
correlated O 
with O 
body O 
mass O 
index O 
but O 
was O 
not O 
correlated O 
with O 
age O 
, O 
serum O 
androgens B-FAMILY 
, O 
or O 
estradiol B-TRIVIAL 
( O 
E2 O 
) O 
levels O 
. O 
We O 
further O 
classified O 
the O 
subjects O 
into O 
two O 
groups O 
based O 
on O 
endometrial O 
thickness O 
: O 
Group O 
A O 
, O 
endometrial O 
thickness O 
< O 
7 O 
mm O 
and O 
Group O 
B O 
, O 
endometrial O 
thickness O 
≥ O 
7 O 
mm O 
. O 
The O 
anovulatory O 
interval O 
, O 
follicle O 
- O 
stimulating O 
hormone O 
, O 
luteinizing O 
hormone O 
, O 
E2 O 
and O 
androgen B-FAMILY 
levels O 
were O 
not O 
significantly O 
different O 
between O 
Groups O 
A O 
and O 
B O 
. O 
Group O 
B O 
had O 
higher O 
body O 
weight O 
and O 
more O 
risk O 
for O 
metabolic O 
syndrome O 
. O 
We O 
concluded O 
that O 
endometrial O 
thickness O 
in O 
women O 
with O 
ovulatory O 
dysfunction O 
is O 
positively O 
correlated O 
with O 
body O 
weight O 
status O 
but O 
is O 
not O 
correlated O 
with O 
serum O 
androgens B-FAMILY 
or O 
E2 O 
levels O 
. O 

macrocyclic O 
peptide O 
natural O 
product O 
CJ-15,208 B-IDENTIFIER 
is O 
orally O 
active O 
and O 
prevents O 
reinstatement O 
of O 
extinguished O 
cocaine B-TRIVIAL 
-seeking O 
behavior O 
. O 

macrocyclic B-FAMILY 
tetrapeptide I-FAMILY 
natural O 
product O 
CJ-15,208 B-IDENTIFIER 
( O 
cyclo[Phe-d-Pro-Phe-Trp] B-TRIVIAL 
) O 
exhibited O 
both O 
dose O 
- O 
dependent O 
antinociception O 
and O 
kappa O 
opioid O 
receptor O 
( O 
KOR O 
) O 
antagonist O 
activity O 
after O 
oral O 
administration O 
. O 
CJ-15,208 B-IDENTIFIER 
antagonized O 
a O 
centrally O 
administered O 
KOR O 
selective O 
agonist O 
, O 
providing O 
strong O 
evidence O 
it O 
crosses O 
the O 
blood O 
- O 
brain O 
barrier O 
to O 
reach O 
KOR O 
in O 
the O 
CNS O 
. O 
Orally O 
administered O 
CJ-15,208 B-IDENTIFIER 
also O 
prevented O 
both O 
cocaine B-TRIVIAL 
- O 
and O 
stress O 
- O 
induced O 
reinstatement O 
of O 
extinguished O 
cocaine B-TRIVIAL 
-seeking O 
behavior O 
in O 
the O 
conditioned O 
place O 
preference O 
assay O 
in O 
a O 
time- O 
and O 
dose O 
- O 
dependent O 
manner O 
. O 
Thus O 
, O 
CJ-15,208 B-IDENTIFIER 
is O 
a O 
promising O 
lead O 
compound O 
with O 
a O 
unique O 
activity O 
profile O 
for O 
potential O 
development O 
, O 
particularly O 
as O 
a O 
therapeutic O 
to O 
prevent O 
relapse O 
to O 
drug O 
- O 
seeking O 
behavior O 
in O 
abstinent O 
subjects O 
. O 

- O 
activatable O 
fibrinolysis O 
inhibitor O 
( O 
TAFI O 
) O 
is O 
a O 
procarboxypeptidase O 
, O 
which O 
is O 
synthesised O 
in O 
liver O 
and O 
activated O 
by O 
thrombin O 
and O 
the O 
thrombin O 
- O 
thrombomodulin O 
complex O 
. O 
TAFI O 
suppresses O 
fibrinolysis O 
by O 
removing O 
carboxy B-SYSTEMATIC 
-terminal O 
lysine B-TRIVIAL 
residues O 
from O 
partially O 
degraded O 
fibrin O 
. O 
In O 
this O 
study O 
we O 
aimed O 
to O 
assess O 
the O 
circulating O 
levels O 
of O 
TAFI O 
antigen O 
, O 
' O 
a O 
fibrinolytic O 
parameter O 
' O 
in O 
women O 
with O 
gestational O 
diabetes O 
( O 
GDM O 
) O 
. O 
Thirty O 
- O 
four O 
pregnant O 
women O 
with O 
GDM O 
and O 
50 O 
pregnant O 
women O 
with O 
normal O 
glucose O 
tolerance O 
were O 
included O 
in O 
the O 
study O 
. O 
Plasma O 
TAFI O 
antigen O 
levels O 
were O 
significantly O 
higher O 
in O 
pregnant O 
women O 
with O 
GDM O 
when O 
compared O 
with O 
controls O 
. O 
Increased O 
TAFI O 
levels O 
may O 
contribute O 
to O 
the O 
decreased O 
fibrinolytic O 
potency O 
, O 
causing O 
a O 
thrombophilic O 
state O 
. O 
GDM O 
is O 
regarded O 
as O 
a O 
specific O 
form O 
of O 
diabetes O 
, O 
and O 
it O 
could O 
in O 
addition O 
be O 
a O 
predictor O 
of O 
type O 
2 O 
diabetes O 
mellitus O 
in O 
the O 
future O 
and O 
the O 
risk O 
of O 
complications O 
due O 
to O 
hypercoagulability O 
increases O 
in O 
this O 
disease O 
. O 
Increased O 
TAFI O 
levels O 
may O 
also O 
have O 
a O 
role O 
in O 
increased O 
risk O 
of O 
hypercoagulability O 
. O 

accelerates O 
cutaneous O 
wound O 
healing O 
in O 
diabetic O 
rats O 
. O 

study O 
reports O 
the O 
effect O 
of O 
embelin B-TRIVIAL 
( O 
1 O 
) O 
on O 
cutaneous O 
wound O 
in O 
streptozotocin B-TRIVIAL 
( O 
STZ B-ABBREVIATION 
)-induced O 
diabetic O 
rats O 
. O 
The O 
effect O 
was O 
studied O 
using O 
excision O 
, O 
incision O 
, O 
and O 
dead O 
space O 
models O 
. O 
In O 
diabetic O 
rats O 
, O 
topical O 
application O 
of O 
embelin B-TRIVIAL 
5% O 
( O 
w O 
/ O 
w O 
) O 
ointment O 
showed O 
a O 
significant O 
increase O 
in O 
wound O 
contraction O 
and O 
better O 
epithelialization O 
, O 
thereby O 
facilitating O 
the O 
healing O 
. O 
Embelin B-TRIVIAL 
was O 
also O 
active O 
by O 
the O 
oral O 
route O 
( O 
25 O 
and O 
50 O 
mg O 
/ O 
kg O 
) O 
in O 
the O 
incision O 
and O 
dead O 
space O 
wound O 
models O 
. O 
In O 
incision O 
wound O 
model O 
, O 
wound O 
granulation O 
tissues O 
were O 
removed O 
on O 
8th O 
post O 
- O 
wounding O 
day O 
, O 
and O 
the O 
hydroxyproline B-SYSTEMATIC 
, O 
hexosamine B-FAMILY 
, O 
total O 
protein O 
, O 
and O 
DNA O 
contents O 
were O 
determined O 
. O 
In O 
STZ B-ABBREVIATION 
diabetic O 
rats O 
, O 
topical O 
and O 
oral O 
applications O 
of O 
embelin B-TRIVIAL 
showed O 
an O 
increase O 
in O 
hydroxyproline B-SYSTEMATIC 
, O 
hexosamine B-FAMILY 
, O 
total O 
protein O 
, O 
and O 
DNA O 
contents O 
. O 
It O 
also O 
showed O 
a O 
significant O 
increase O 
in O 
wound O 
breaking O 
strength O 
. O 
Embelin B-TRIVIAL 
significantly O 
increased O 
granuloma O 
tissue O 
weight O 
and O 
breaking O 
strength O 
in O 
dead O 
space O 
model O 
. O 
These O 
results O 
indicated O 
that O 
embelin B-TRIVIAL 
accelerated O 
wound O 
healing O 
in O 
diabetic O 
rat O 
. O 

-type O 
diterpenes B-FAMILY 
from O 
Euphorbia O 
sikkimensis O 
. O 

new O 
jatropholane B-TRIVIAL 
-type O 
diterpenes B-FAMILY 
( O 
1-4 O 
) O 
, O 
named O 
sikkimenoids B-MULTIPLE 
A-D I-MULTIPLE 
, O 
were O 
isolated O 
from O 
the O 
aerial O 
parts O 
of O 
Euphorbia O 
sikkimensis O 
. O 
The O 
structural O 
elucidations O 
of O 
1-4 O 
were O 
accomplished O 
by O 
extensive O 
NMR O 
analyses O 
, O 
and O 
their O 
absolute O 
configurations O 
were O 
established O 
by O 
ECD O 
calculations O 
. O 
Compound O 
2 O 
exhibited O 
weak O 
antiangiogenic O 
activity O 
with O 
an O 
IC(50) O 
value O 
of O 
43 O 
μM O 
when O 
evaluated O 
using O 
a O 
zebrafish O 
model O 
. O 

( O 
NPM1 O 
) O 
is O 
an O 
abundant O 
nucleolar O 
protein O 
implicated O 
in O 
ribosome O 
maturation O 
and O 
export O 
, O 
centrosome O 
duplication O 
and O 
response O 
to O 
stress O 
stimuli O 
. O 
NPM1 O 
is O 
the O 
most O 
frequently O 
mutated O 
gene O 
in O 
acute O 
myeloid O 
leukemia O 
. O 
Mutations O 
at O 
the O 
C B-FORMULA 
-terminal O 
domain O 
led O 
to O 
variant O 
proteins O 
that O 
aberrantly O 
and O 
stably O 
translocate O 
to O 
the O 
cytoplasm O 
. O 
We O 
have O 
previously O 
shown O 
that O 
NPM1 O 
C B-FORMULA 
-terminal O 
domain O 
binds O 
with O 
high O 
affinity O 
G-quadruplex O 
DNA O 
. O 
Here O 
, O 
we O 
investigate O 
the O 
structural O 
determinants O 
of O 
NPM1 O 
nucleolar O 
localization O 
. O 
We O 
show O 
that O 
NPM1 O 
interacts O 
with O 
several O 
G-quadruplex O 
regions O 
found O 
in O 
ribosomal O 
DNA O 
, O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Furthermore O 
, O 
the O 
most O 
common O 
leukemic O 
NPM1 O 
variant O 
completely O 
loses O 
this O 
activity O 
. O 
This O 
is O 
the O 
consequence O 
of O 
G-quadruplex O 
- O 
binding O 
domain O 
destabilization O 
, O 
as O 
mutations O 
aimed O 
at O 
refolding O 
the O 
leukemic O 
variant O 
also O 
result O 
in O 
rescuing O 
the O 
G-quadruplex O 
- O 
binding O 
activity O 
and O 
nucleolar O 
localization O 
. O 
Finally O 
, O 
we O 
show O 
that O 
treatment O 
of O 
cells O 
with O 
a O 
G-quadruplex O 
selective O 
ligand O 
results O 
in O 
wild O 
- O 
type O 
NPM1 O 
dislocation O 
from O 
nucleoli O 
into O 
nucleoplasm O 
. O 
In O 
conclusion O 
, O 
this O 
work O 
establishes O 
a O 
direct O 
correlation O 
between O 
NPM1 O 
G-quadruplex O 
binding O 
at O 
rDNA O 
and O 
its O 
nucleolar O 
localization O 
, O 
which O 
is O 
impaired O 
in O 
the O 
acute O 
myeloid O 
leukemia O 
- O 
associated O 
protein O 
variants O 
. O 

is O 
increasing O 
evidence O 
that O 
pregnancy O 
alters O 
the O 
function O 
of O 
drug O 
- O 
metabolizing O 
enzymes O 
and O 
drug O 
transporters O 
in O 
a O 
gestational O 
- O 
stage O 
and O 
tissue O 
- O 
specific O 
manner O 
. O 
In O 
vivo O 
probe O 
studies O 
have O 
shown O 
that O 
the O 
activity O 
of O 
several O 
hepatic O 
cytochrome O 
P450 O 
enzymes O 
, O 
such O 
as O 
CYP2D6 O 
and O 
CYP3A4 O 
, O 
is O 
increased O 
during O 
pregnancy O 
, O 
whereas O 
the O 
activity O 
of O 
others O 
, O 
such O 
as O 
CYP1A2 O 
, O 
is O 
decreased O 
. O 
The O 
activity O 
of O 
some O 
renal O 
transporters O 
, O 
including O 
organic O 
cation O 
transporter O 
and O 
P-glycoprotein O 
, O 
also O 
appears O 
to O 
be O 
increased O 
during O 
pregnancy O 
. O 
Although O 
much O 
has O 
been O 
learned O 
, O 
significant O 
gaps O 
still O 
exist O 
in O 
our O 
understanding O 
of O 
the O 
spectrum O 
of O 
drug O 
metabolism O 
and O 
transport O 
genes O 
affected O 
, O 
gestational O 
age O 
- O 
dependent O 
changes O 
in O 
the O 
activity O 
of O 
encoded O 
drug O 
metabolizing O 
and O 
transporting O 
processes O 
, O 
and O 
the O 
mechanisms O 
of O 
pregnancy O 
- O 
induced O 
alterations O 
. O 
In O 
this O 
issue O 
of O 
Drug O 
Metabolism O 
and O 
Disposition O 
, O 
a O 
series O 
of O 
articles O 
is O 
presented O 
that O 
address O 
the O 
predictability O 
, O 
mechanisms O 
, O 
and O 
magnitude O 
of O 
changes O 
in O 
drug O 
metabolism O 
and O 
transport O 
processes O 
during O 
pregnancy O 
. O 
The O 
articles O 
highlight O 
state O 
- O 
of O 
- O 
the O 
- O 
art O 
approaches O 
to O 
studying O 
mechanisms O 
of O 
changes O 
in O 
drug O 
disposition O 
during O 
pregnancy O 
, O 
and O 
illustrate O 
the O 
use O 
and O 
integration O 
of O 
data O 
from O 
in O 
vitro O 
models O 
, O 
animal O 
studies O 
, O 
and O 
human O 
clinical O 
studies O 
. O 
The O 
findings O 
presented O 
show O 
the O 
complex O 
inter O 
- O 
relationships O 
between O 
multiple O 
regulators O 
of O 
drug O 
metabolism O 
and O 
transport O 
genes O 
, O 
such O 
as O 
estrogens B-FAMILY 
, O 
progesterone B-TRIVIAL 
, O 
and O 
growth O 
hormone O 
, O 
and O 
their O 
effects O 
on O 
enzyme O 
and O 
transporter O 
expression O 
in O 
different O 
tissues O 
. O 
The O 
studies O 
provide O 
the O 
impetus O 
for O 
a O 
mechanism- O 
and O 
evidence O 
- O 
based O 
approach O 
to O 
optimally O 
managing O 
drug O 
therapies O 
during O 
pregnancy O 
and O 
improving O 
treatment O 
outcomes O 
. O 

Mithramycin B-TRIVIAL 
SA I-TRIVIAL 
Derivatives O 
with O 
Improved O 
AntiCancer O 
Activity O 
. O 

( O 
MTM B-ABBREVIATION 
) O 
is O 
a O 
potent O 
anti-cancer O 
agent O 
that O 
has O 
recently O 
garnered O 
renewed O 
attention O 
. O 
This O 
manuscript O 
describes O 
the O 
design O 
and O 
development O 
of O 
mithramycin B-TRIVIAL 
derivatives O 
through O 
a O 
combinational O 
approach O 
of O 
biosynthetic O 
analogue O 
generation O 
followed O 
by O 
synthetic O 
manipulation O 
for O 
further O 
derivatization O 
. O 
Mithramycin B-TRIVIAL 
SA I-TRIVIAL 
is O 
a O 
previously O 
discovered O 
analogue O 
produced O 
by O 
the O 
M7W1 O 
mutant O 
strain O 
alongside O 
the O 
improved O 
mithramycin B-TRIVIAL 
analogues O 
mithramycin B-TRIVIAL 
SK I-TRIVIAL 
and O 
mithramycin B-TRIVIAL 
SDK I-TRIVIAL 
. O 
Mithramycin B-TRIVIAL 
SA I-TRIVIAL 
shows O 
decreased O 
anti-cancer O 
activity O 
compared O 
to O 
mithramycin B-TRIVIAL 
and O 
has O 
a O 
shorter O 
, O 
two O 
carbon B-SYSTEMATIC 
aglycon O 
side O 
chain O 
that O 
is O 
terminated O 
in O 
a O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
The O 
aglycon O 
side O 
chain O 
is O 
responsible O 
for O 
an O 
interaction O 
with O 
the O 
DNA- O 
phosphate B-SYSTEMATIC 
backbone O 
as O 
mithramycin B-TRIVIAL 
interacts O 
with O 
its O 
target O 
DNA O 
. O 
It O 
was O 
therefore O 
decided O 
to O 
further O 
functionalize O 
this O 
side O 
chain O 
through O 
reactions O 
with O 
the O 
terminal O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
an O 
effort O 
to O 
enhance O 
the O 
interaction O 
with O 
the O 
DNA O 
phosphate B-SYSTEMATIC 
backbone O 
and O 
improve O 
the O 
anti-cancer O 
activity O 
. O 
This O 
side O 
chain O 
was O 
modified O 
with O 
a O 
variety O 
of O 
molecules O 
increasing O 
the O 
anti-cancer O 
activity O 
to O 
a O 
comparable O 
level O 
to O 
mithramycin B-TRIVIAL 
SK I-TRIVIAL 
. O 
This O 
work O 
shows O 
the O 
ability O 
to O 
transform O 
the O 
previously O 
useless O 
mithramycin B-TRIVIAL 
SA I-TRIVIAL 
into O 
a O 
valuable O 
molecule O 
and O 
opens O 
the O 
door O 
to O 
further O 
functionalization O 
and O 
semi-synthetic O 
modification O 
for O 
the O 
development O 
of O 
molecules O 
with O 
increased O 
specificity O 
and O 
/ O 
or O 
drug O 
formulation O 
. O 

in O 
the O 
central O 
amygdaloid O 
nucleus O 
modulates O 
the O 
neuroendocrine O 
responses O 
induced O 
by O 
hypertonic O 
volume O 
expansion O 
in O 
the O 
rat O 
. O 

present O 
study O 
investigated O 
the O 
involvement O 
of O 
the O 
oxytocinergic O 
neurones O 
that O 
project O 
into O 
the O 
central O 
amygdala O 
( O 
CeA O 
) O 
in O 
the O 
control O 
of O 
electrolyte O 
excretion O 
and O 
hormone O 
secretion O 
in O 
unanaesthetised O 
rats O 
subjected O 
to O 
acute O 
hypertonic O 
blood O 
volume O 
expansion O 
( O 
BVE O 
; O 
0.3 O 
M O 
NaCl B-FORMULA 
, O 
2 O 
ml O 
/ O 
100 O 
g O 
of O 
body O 
weight O 
over O 
1 O 
min O 
) O 
. O 
Oxytocin B-TRIVIAL 
and O 
vasopressin O 
mRNA O 
expression O 
in O 
the O 
paraventricular O 
( O 
Pa O 
) O 
and O 
supraoptic O 
nucleus O 
( O 
SON O 
) O 
of O 
the O 
hypothalamus O 
were O 
also O 
determined O 
using O 
the O 
real O 
time O 
- O 
polymerase O 
chain O 
reaction O 
and O 
in O 
situ O 
hybridisation O 
. O 
Male O 
Wistar O 
rats O 
with O 
unilaterally O 
implanted O 
stainless O 
steel O 
cannulas O 
in O 
the O 
CeA O 
were O 
used O 
. O 
Oxytocin B-TRIVIAL 
( O 
1 O 
μg O 
/ O 
0.2 O 
μl O 
) O 
, O 
vasotocin B-TRIVIAL 
, O 
an O 
oxytocin B-TRIVIAL 
antagonist O 
( O 
1 O 
μg O 
/ O 
0.2 O 
μl O 
) O 
or O 
vehicle O 
was O 
injected O 
into O 
the O 
CeA O 
20 O 
min O 
before O 
the O 
BVE O 
. O 
In O 
rats O 
treated O 
with O 
vehicle O 
in O 
the O 
CeA O 
, O 
hypertonic O 
BVE O 
increased O 
urinary O 
volume O 
, O 
sodium O 
excretion O 
, O 
plasma O 
oxytocin B-TRIVIAL 
( O 
OT O 
) O 
, O 
vasopressin O 
( O 
AVP O 
) O 
and O 
atrial O 
natriuretic O 
peptide O 
( O 
ANP O 
) O 
levels O 
and O 
also O 
increased O 
the O 
expression O 
of O 
OT O 
and O 
AVP O 
mRNA O 
in O 
the O 
Pa O 
and O 
SON O 
. O 
In O 
rats O 
pre O 
- O 
treated O 
with O 
OT O 
in O 
the O 
CeA O 
, O 
previously O 
to O 
the O 
hypertonic O 
BVE O 
, O 
there O 
were O 
further O 
significant O 
increases O 
in O 
plasma O 
AVP O 
, O 
OT O 
and O 
ANP O 
levels O 
, O 
urinary O 
sodium B-SYSTEMATIC 
and O 
urine O 
output O 
, O 
as O 
well O 
as O 
in O 
gene O 
expression O 
( O 
AVP O 
and O 
OT O 
mRNA O 
) O 
in O 
the O 
Pa O 
and O 
SON O 
compared O 
to O 
BVE O 
alone O 
. O 
Vasotocin B-TRIVIAL 
reduced O 
sodium B-SYSTEMATIC 
, O 
urine O 
output O 
and O 
ANP O 
levels O 
, O 
although O 
no O 
changes O 
were O 
observed O 
in O 
plasma O 
AVP O 
and O 
OT O 
levels O 
or O 
in O 
the O 
expression O 
of O 
the O 
AVP O 
and O 
OT O 
genes O 
in O 
both O 
hypothalamic O 
nuclei O 
. O 
The O 
results O 
of O 
the O 
present O 
study O 
suggest O 
that O 
oxytocin O 
in O 
the O 
CeA O 
exerts O 
a O 
facilitatory O 
role O 
in O 
the O 
maintenance O 
of O 
hydroelectrolyte O 
balance O 
in O 
response O 
to O 
changes O 
in O 
extracellular O 
volume O 
and O 
osmolality O 
. O 

deficiency O 
induces O 
markedly O 
decreased O 
serum O 
triglycerides B-FAMILY 
, O 
increased O 
small O 
dense O 
LDL O 
, O 
and O 
hepatic O 
steatosis O 
mediated O 
by O 
dysregulation O 
of O 
lipid O 
assembly O 
and O 
secretion O 
in O 
mice O 
fed O 
a O 
high O 
- O 
fat O 
diet O 
. O 

: O 
Although O 
low O 
serum O 
testosterone B-TRIVIAL 
( O 
T O 
) O 
is O 
associated O 
with O 
metabolic O 
disorders O 
, O 
the O 
mechanism O 
of O 
this O 
association O 
is O 
unclear O 
. O 
The O 
objective O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
the O 
combined O 
effects O 
of O 
T O 
deficiency O 
and O 
a O 
high O 
- O 
fat O 
diet O 
( O 
HFD O 
) O 
on O 
hepatic O 
lipid O 
homeostasis O 
in O 
mice O 
. O 
MATERIALS O 
/ O 
METHODS O 
: O 
Orchiectomized O 
( O 
ORX O 
) O 
mice O 
and O 
sham O 
- O 
operated O 
( O 
SHAM O 
) O 
mice O 
were O 
randomly O 
divided O 
into O 
five O 
groups O 
: O 
SHAM O 
mice O 
fed O 
a O 
standard O 
diet O 
( O 
SD O 
) O 
, O 
SHAM O 
mice O 
fed O 
HFD O 
, O 
ORX O 
mice O 
fed O 
SD O 
, O 
ORX O 
mice O 
fed O 
HFD O 
, O 
and O 
ORX O 
mice O 
fed O 
HFD O 
with O 
T O 
supplementation O 
. O 
After O 
4weeks O 
of O 
treatment O 
, O 
we O 
investigated O 
the O 
synthesis O 
and O 
secretion O 
of O 
lipids O 
in O 
the O 
liver O 
and O 
detailed O 
serum O 
lipoprotein O 
profiles O 
in O 
each O 
group O 
. O 
RESULTS O 
: O 
ORX O 
mice O 
fed O 
HFD O 
showed O 
increased O 
hepatic O 
steatosis O 
, O 
markedly O 
decreased O 
serum O 
triglyceride B-FAMILY 
( O 
TG O 
) O 
and O 
TG-VLDL O 
content O 
, O 
and O 
increased O 
serum O 
very O 
small-LDL O 
content O 
. O 
Gene O 
expression O 
analysis O 
revealed O 
that O 
ORX O 
mice O 
fed O 
HFD O 
showed O 
significantly O 
decreased O 
expression O 
of O 
microsomal O 
triglyceride B-FAMILY 
transfer O 
protein O 
, O 
lipin-1 O 
, O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
(PPAR)-α O 
and O 
PPAR-γ O 
coactivator O 
1-α O 
, O 
and O 
significantly O 
increased O 
sterol B-FAMILY 
regulatory O 
element O 
- O 
binding O 
protein-1 O 
, O 
diacylglycerol B-FAMILY 
acyltransferase-2 O 
and O 
fatty B-FAMILY 
acid I-FAMILY 
synthase O 
. O 
Reduction O 
of O 
hepatic O 
AMPK O 
phosphorylation O 
was O 
observed O 
in O 
ORX O 
mice O 
fed O 
HFD O 
. O 
These O 
perturbations O 
in O 
ORX O 
mice O 
fed O 
HFD O 
were O 
normalized O 
to O 
the O 
levels O 
of O 
SHAM O 
mice O 
fed O 
HFD O 
by O 
T O 
supplementation O 
. O 
CONCLUSION O 
: O 
T O 
deficiency O 
is O 
associated O 
with O 
failure O 
of O 
lipid O 
homeostasis O 
mediated O 
by O 
altered O 
expression O 
of O 
genes O 
involved O 
in O 
hepatic O 
assembly O 
and O 
secretion O 
of O 
lipids O 
. O 

and O 
antiplatelet O 
drugs O 
are O 
used O 
and O 
studied O 
in O 
numerous O 
trials O 
for O 
primary O 
and O 
secondary O 
prevention O 
of O 
atherothrombosis O 
since O 
decades O 
. O 
The O 
annual O 
rate O 
for O 
cardiovascular O 
morbidity O 
and O 
mortality O 
is O 
high O 
in O 
patients O 
following O 
an O 
acute O 
coronary O 
syndrome O 
and O 
in O 
patients O 
with O 
peripheral O 
arterial O 
disease O 
( O 
PAD O 
) O 
due O 
to O 
concomitant O 
cardiac O 
and O 
cerebrovascular O 
diseases O 
. O 
Plaque O 
rupture O 
and O 
subsequent O 
thrombosis O 
involves O 
activation O 
of O 
both O 
platelets O 
and O 
coagulation O 
factors O 
. O 
Therefore O 
the O 
combination O 
of O 
aspirin B-TRIVIAL 
and O 
warfarin B-TRIVIAL 
to O 
improve O 
prevention O 
of O 
atherothrombosis O 
compared O 
to O 
antiplatelet O 
therapy O 
alone O 
was O 
studied O 
but O 
could O 
not O 
be O 
established O 
due O 
to O 
significantly O 
increased O 
risk O 
of O 
major O 
bleeding O 
compared O 
to O 
a O 
nonsignificant O 
reduction O 
in O 
ischemic O 
events O 
. O 
During O 
the O 
past O 
two O 
decades O 
, O 
clinical O 
trials O 
focused O 
on O 
combined O 
antiplatelet O 
therapies O 
for O 
the O 
prevention O 
of O 
secondary O 
events O 
following O 
acute O 
coronary O 
syndromes O 
and O 
very O 
recently O 
on O 
the O 
new O 
oral O 
anticoagulants O 
in O 
combination O 
with O 
antiplatelet O 
therapy O 
. O 
This O 
review O 
discusses O 
the O 
role O 
of O 
the O 
new O 
oral O 
anticoagulants O 
such O 
as O 
Factor O 
IIa O 
( O 
thrombin O 
) O 
and O 
Factor O 
Xa O 
inhibitors O 
in O 
atherothrombosis O 
, O 
their O 
pharmacological O 
properties O 
and O 
recently O 
published O 
clinical O 
data O 
in O 
secondary O 
prevention O 
of O 
atherothrombotic O 
events O 
and O 
potential O 
implications O 
for O 
patients O 
with O 
PAD O 
. O 

perception O 
of O 
aldosterone B-TRIVIAL 
action O 
to O 
be O 
restricted O 
to O 
regulation O 
of O 
fluid O 
balance O 
via O 
sodium B-SYSTEMATIC 
reabsorption O 
and O 
potassium B-SYSTEMATIC 
excretion O 
is O 
incomplete O 
; O 
plenty O 
of O 
experimental O 
and O 
clinical O 
studies O 
have O 
shown O 
that O 
aldosterone B-TRIVIAL 
plays O 
a O 
pivotal O 
role O 
in O 
a O 
variety O 
of O 
( O 
patho- O 
) O 
physiologic O 
conditions O 
within O 
the O 
cardiovascular O 
continuum O 
. O 
Deleterious O 
effects O 
include O 
cardiovascular O 
inflammation O 
, O 
endothelial O 
dysfunction O 
, O 
structural O 
and O 
electrical O 
remodelling O 
. O 
Mineralocorticoid O 
receptor O 
antagonists O 
( O 
MRAs O 
) O 
, O 
such O 
as O 
spironolactone B-TRIVIAL 
and O 
eplerenone B-TRIVIAL 
, O 
prevent O 
some O 
of O 
these O 
maladaptive O 
effects O 
on O 
the O 
cardiovascular O 
system O 
and O 
have O 
proven O 
to O 
be O 
a O 
highly O 
efficacious O 
pharmacological O 
therapy O 
. O 
In O 
this O 
article O 
we O 
review O 
the O 
current O 
clinical O 
impact O 
of O 
MRAs O 
in O 
the O 
treatment O 
of O 
coronary O 
artery O 
disease O 
( O 
CAD O 
) O 
and O 
its O 
related O 
complications O 
, O 
for O 
example O 
, O 
acute O 
myocardial O 
infarction O 
( O 
MI O 
) O 
and O 
chronic O 
heart O 
failure O 
. O 

series O 
of O 
tetrahydroisoquinolines B-FAMILY 
were O 
designed O 
, O 
synthesized O 
and O 
evaluated O 
as O 
the O 
first O 
non-natural O 
product O 
type O 
of O 
compounds O 
with O 
dual O 
D(1) O 
receptor O 
( O 
D(1)R O 
) O 
agonism O 
and O 
D(2) O 
receptor O 
( O 
D(2)R O 
) O 
antagonism O 
properties O 
for O 
treatment O 
of O 
schizophrenia O 
. O 
The O 
initial O 
SAR O 
of O 
the O 
series O 
was O 
explored O 
. O 
The O 
lead O 
in O 
the O 
series O 
, O 
3g O 
, O 
exhibited O 
high O 
affinity O 
and O 
good O 
potency O 
. O 
Compound O 
3g O 
displayed O 
95% O 
of O 
D(1)R O 
occupancy O 
( O 
10 O 
mg O 
/ O 
kg O 
, O 
sc O 
) O 
and O 
75% O 
of O 
D(2)R O 
occupancy O 
( O 
10 O 
mg O 
/ O 
kg O 
, O 
sc O 
) O 
in O 
the O 
striatum O 
of O 
male O 
CD-1 O 
mice O 
. O 
The O 
series O 
exhibited O 
unique O 
pharmacology O 
and O 
merit O 
as O 
tool O 
compounds O 
for O 
target O 
validation O 
and O 
future O 
optimizations O 
. O 

appropriate O 
execution O 
of O 
DNA O 
double O 
- O 
strand O 
break O 
( O 
DSB O 
) O 
repair O 
is O 
critical O 
for O 
genome O 
stability O 
and O 
tumor O 
avoidance O 
. O 
53BP1 O 
and O 
BRCA1 O 
directly O 
influence O 
DSB O 
repair O 
pathway O 
choice O 
by O 
regulating O 
5 O 
' O 
end O 
resection O 
, O 
but O 
how O 
this O 
is O 
achieved O 
remains O 
uncertain O 
. O 
Here O 
we O 
report O 
that O 
Rif1(- O 
/ O 
- O 
) O 
mice O 
are O 
severely O 
compromised O 
for O 
53BP1-dependent O 
class O 
switch O 
recombination O 
( O 
CSR O 
) O 
and O 
fusion O 
of O 
dysfunctional O 
telomeres O 
. O 
The O 
inappropriate O 
accumulation O 
of O 
RIF1 O 
at O 
DSBs O 
in O 
S O 
phase O 
is O 
antagonized O 
by O 
BRCA1 O 
, O 
and O 
deletion O 
of O 
Rif1 O 
suppresses O 
toxic O 
nonhomologous O 
end O 
joining O 
( O 
NHEJ O 
) O 
induced O 
by O 
PARP O 
inhibition O 
in O 
Brca1-deficient O 
cells O 
. O 
Mechanistically O 
, O 
RIF1 O 
is O 
recruited O 
to O 
DSBs O 
via O 
the O 
N B-FORMULA 
-terminal O 
phospho B-SYSTEMATIC 
-SQ O 
/ O 
TQ O 
domain O 
of O 
53BP1 O 
, O 
and O 
DSBs O 
generated O 
by O 
ionizing O 
radiation O 
or O 
during O 
CSR O 
are O 
hyperresected O 
in O 
the O 
absence O 
of O 
RIF1 O 
. O 
Thus O 
, O 
RIF1 O 
and O 
53BP1 O 
cooperate O 
to O 
block O 
DSB O 
resection O 
to O 
promote O 
NHEJ O 
in O 
G1 O 
, O 
which O 
is O 
antagonized O 
by O 
BRCA1 O 
in O 
S O 
phase O 
to O 
ensure O 
a O 
switch O 
of O 
DSB O 
repair O 
mode O 
to O 
homologous O 
recombination O 
. O 

electron O 
transport O 
is O 
inhibited O 
by O 
disappearance O 
of O 
metallothionein O 
in O 
human O 
bronchial O 
epithelial O 
cells O 
following O 
exposure O 
to O 
silver B-SYSTEMATIC 
nitrate I-SYSTEMATIC 
. O 

( O 
Ag B-FORMULA 
) O 
possesses O 
antibacterial O 
activity O 
and O 
has O 
been O 
used O 
in O 
wound O 
dressings O 
and O 
deodorant O 
powders O 
worldwide O 
. O 
However O 
, O 
the O 
metabolic O 
behavior O 
and O 
biological O 
roles O 
of O 
Ag B-FORMULA 
in O 
mammals O 
have O 
not O 
been O 
well O 
characterized O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
exposed O 
human O 
bronchial O 
epithelial O 
cells O 
( O 
BEAS-2B O 
) O 
to O 
AgNO3 B-FORMULA 
and O 
investigated O 
uptake O 
and O 
intracellular O 
distribution O 
of O 
Ag B-FORMULA 
, O 
expression O 
of O 
metallothionein O 
( O 
MT O 
) O 
, O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
and O 
changes O 
in O 
mitochondrial O 
respiration O 
. O 
The O 
culture O 
medium O 
concentration O 
of O 
Ag B-FORMULA 
decreased O 
with O 
time O 
and O 
stabilized O 
at O 
12h O 
. O 
The O 
concentration O 
of O 
both O 
Ag B-FORMULA 
and O 
MT O 
in O 
the O 
soluble O 
cellular O 
fraction O 
increased O 
up O 
to O 
3h O 
and O 
then O 
decreased O 
, O 
indicating O 
that O 
cytosolic O 
Ag B-FORMULA 
relocated O 
to O 
the O 
insoluble O 
fraction O 
of O 
the O 
cells O 
. O 
The O 
levels O 
of O 
mRNAs O 
for O 
the O 
major O 
human O 
MT O 
isoforms O 
MT-I O 
and O 
MT-II O 
paralleled O 
with O 
the O 
protein O 
levels O 
of O 
Ag B-FORMULA 
-MT O 
. O 
The O 
intensity O 
of O 
fluorescence O 
derived O 
from O 
ROS O 
was O 
elevated O 
in O 
the O 
mitochondrial O 
region O 
at O 
24h O 
. O 
Ag B-FORMULA 
decreased O 
mitochondrial O 
oxygen B-SYSTEMATIC 
consumption O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
and O 
the O 
activity O 
of O 
mitochondrial O 
complex O 
I-IV O 
enzymes O 
was O 
significantly O 
inhibited O 
following O 
exposure O 
to O 
Ag B-FORMULA 
. O 
In O 
a O 
separate O 
experiment O 
, O 
we O 
found O 
that O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
H2O2 B-FORMULA 
) O 
at O 
concentrations O 
as O 
low O 
as O 
0.001% O 
( O 
equivalent O 
to O 
the O 
concentration O 
of O 
H2O2 B-FORMULA 
in O 
Ag B-FORMULA 
-exposed O 
cells O 
) O 
removed O 
Ag B-FORMULA 
from O 
MT O 
. O 
These O 
results O 
suggest O 
MT O 
was O 
decomposed O 
by O 
cytosolic O 
H2O2 B-FORMULA 
, O 
and O 
then O 
Ag B-FORMULA 
released O 
from O 
MT O 
relocated O 
to O 
insoluble O 
cellular O 
fractions O 
and O 
inhibited O 
electron O 
chain O 
transfer O 
of O 
mitochondrial O 
complexes O 
, O 
which O 
eventually O 
led O 
to O 
cell O 
damage O 
. O 

oxide I-SYSTEMATIC 
generated O 
by O 
the O 
compound O 
RuBPY B-FORMULA 
promotes O 
the O 
vascular O 
smooth O 
cell O 
membrane O 
hyperpolarization O 
. O 

cis-[Ru(bpy)(2)(py)NO(2)](PF(6)) B-FORMULA 
specie O 
( O 
RuBPY B-FORMULA 
) O 
has O 
been O 
used O 
as O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
delivery O 
agent O 
. O 
It O 
is O 
an O 
NO B-FORMULA 
reservoir O 
and O 
it O 
is O 
thermodynamically O 
stable O 
in O 
aqueous O 
solution O 
. O 
This O 
study O 
aimed O 
to O 
evaluate O 
the O 
NO B-FORMULA 
specie O 
generated O 
by O 
RuBPY B-FORMULA 
as O 
compared O 
to O 
NO B-FORMULA 
released O 
from O 
sodium B-SYSTEMATIC 
nitroprusside I-SYSTEMATIC 
( O 
SNP B-ABBREVIATION 
) O 
and O 
to O 
study O 
the O 
cellular O 
mechanisms O 
specially O 
focusing O 
the O 
activation O 
of O 
soluble O 
guanylyl B-TRIVIAL 
-cyclase O 
( O 
sGC O 
) O 
, O 
K(+) B-FORMULA 
channels O 
and O 
the O 
cell O 
membrane O 
hyperpolarization O 
, O 
which O 
are O 
the O 
main O 
targets O 
for O 
NO B-FORMULA 
-inducing O 
vascular O 
relaxation O 
. O 
NO B-FORMULA 
generated O 
by O 
RuBPY B-FORMULA 
and O 
the O 
vascular O 
smooth O 
muscle O 
cell O 
( O 
VSMC O 
) O 
membrane O 
potential O 
were O 
measured O 
by O 
confocal O 
microscopy O 
. O 
The O 
cellular O 
mechanisms O 
of O 
aorta O 
relaxation O 
were O 
investigated O 
using O 
K(+) B-FORMULA 
channel O 
blockers O 
and O 
sGC O 
inhibitor O 
. O 
NO B-FORMULA 
released O 
from O 
RuBPY B-FORMULA 
was O 
higher O 
than O 
NO B-FORMULA 
released O 
from O 
SNP B-ABBREVIATION 
. O 
RuBPY B-FORMULA 
released O 
only O 
radicalar B-FORMULA 
NO I-FORMULA 
( O 
0 O 
) O 
and O 
SNP B-ABBREVIATION 
released O 
both O 
NO(-) B-FORMULA 
and O 
NO B-FORMULA 
( O 
0 O 
) O 
. O 
The O 
concentration O 
- O 
effect O 
curves O 
for O 
RuBPY B-FORMULA 
-induced O 
relaxation O 
was O 
shifted O 
to O 
the O 
right O 
by O 
inhibition O 
of O 
sGC O 
with O 
ODQ B-ABBREVIATION 
and O 
by O 
the O 
non-selective O 
blockade O 
of O 
K(+) B-FORMULA 
channels O 
with O 
TEA B-ABBREVIATION 
. O 
The O 
simultaneous O 
combination O 
of O 
ODQ B-ABBREVIATION 
and O 
TEA B-ABBREVIATION 
abolished O 
the O 
vasorelaxation O 
induced O 
by O 
RuBPY B-FORMULA 
. O 
The O 
membrane O 
potential O 
measured O 
by O 
the O 
sensitive O 
dye O 
4-Di-ANNEPS B-SYSTEMATIC 
demonstrated O 
that O 
RuBPY B-FORMULA 
induces O 
cell O 
membrane O 
hyperpolarization O 
. O 
Taken O 
together O 
, O 
our O 
results O 
indicate O 
that O 
the O 
large O 
amount O 
of O 
NO B-FORMULA 
( O 
0 O 
) O 
specie O 
generated O 
by O 
RuBPY B-FORMULA 
induces O 
vasorelaxation O 
due O 
to O 
activation O 
of O 
sGC O 
, O 
K(+) B-FORMULA 
channels O 
sensitive O 
to O 
TEA B-ABBREVIATION 
, O 
and O 
cell O 
membrane O 
hyperpolarization O 
. O 
These O 
results O 
indicate O 
that O 
NO B-FORMULA 
( O 
0 O 
) O 
generated O 
from O 
RuBPY B-FORMULA 
can O 
also O 
directly O 
activate O 
the O 
K(+) B-FORMULA 
channels O 
in O 
an O 
independent O 
way O 
of O 
sGC O 
. O 

inhibition O 
of O 
HIF-2α O 
on O 
the O 
ATM O 
/ O 
Chk-2 O 
pathway O 
is O 
involved O 
in O 
the O 
promotion O 
effect O 
of O 
arsenite B-SYSTEMATIC 
on O 
benzo(a)pyrene B-SYSTEMATIC 
-induced O 
cell O 
transformation O 
. O 

arsenite B-SYSTEMATIC 
and O 
benzo(a)pyrene B-SYSTEMATIC 
( O 
BaP B-ABBREVIATION 
) O 
are O 
known O 
human O 
carcinogens O 
. O 
Studies O 
on O 
the O 
mode-of O 
- O 
action O 
of O 
arsenite B-SYSTEMATIC 
indicate O 
that O 
it O 
can O 
also O 
act O 
as O 
co O 
- O 
carcinogen O 
or O 
as O 
a O 
cancer O 
promoter O 
, O 
and O 
that O 
it O 
can O 
facilitate O 
progression O 
of O 
cancers O 
. O 
Some O 
studies O 
on O 
development O 
of O 
lung O 
cancers O 
have O 
suggested O 
a O 
synergism O 
between O 
arsenite B-SYSTEMATIC 
exposure O 
and O 
cigarette O 
smoking O 
. O 
The O 
mechanism O 
of O 
action O 
for O 
such O 
an O 
effect O 
, O 
however O 
, O 
remains O 
obscure O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
HIF-2α O 
on O 
arsenite B-SYSTEMATIC 
- O 
and O 
BaP B-ABBREVIATION 
-induced O 
cell O 
malignant O 
transformation O 
as O 
well O 
as O 
on O 
signal O 
transduction O 
pathways O 
in O 
human O 
bronchial O 
epithelial O 
( O 
HBE O 
) O 
cells O 
. O 
The O 
results O 
show O 
that O 
arsenite B-SYSTEMATIC 
accelerates O 
the O 
neoplastic O 
transformation O 
and O 
migration O 
of O 
cells O 
and O 
enhances O 
chromosomal O 
aberrations O 
induced O 
by O 
BaP B-ABBREVIATION 
. O 
HIF-2α O 
is O 
involved O 
in O 
blocking O 
the O 
effects O 
of O 
arsenite B-SYSTEMATIC 
in O 
activating O 
the O 
ATM O 
/ O 
Chk-2 O 
pathway O 
and O 
in O 
repair O 
of O 
DNA O 
damage O 
induced O 
by O 
BaP B-ABBREVIATION 
. O 
Moreover O 
, O 
blocking O 
of O 
HIF-2α O 
prevents O 
the O 
effects O 
of O 
arsenite B-SYSTEMATIC 
on O 
the O 
neoplastic O 
transformation O 
, O 
cell O 
migration O 
, O 
and O 
chromosomal O 
aberrations O 
caused O 
by O 
BaP B-ABBREVIATION 
. O 
These O 
results O 
indicate O 
that O 
the O 
repressive O 
effect O 
of O 
HIF-2α O 
on O 
the O 
ATM O 
/ O 
Chk-2 O 
pathway O 
leads O 
to O 
genomic O 
instability O 
, O 
which O 
is O 
involved O 
in O 
arsenite B-SYSTEMATIC 
-accelerated O 
, O 
BaP B-ABBREVIATION 
-induced O 
malignant O 
transformation O 
of O 
HBE O 
cells O 
. O 

and O 
dihydrotanshinone B-TRIVIAL 
I I-TRIVIAL 
exhibit O 
strong O 
inhibition O 
towards O 
human O 
liver O 
microsome O 
( O 
HLM O 
) O 
- O 
catalyzed O 
propofol B-TRIVIAL 
glucuronidation O 
. O 

is O 
one O 
of O 
the O 
most O 
famous O 
herbs O 
in O 
the O 
world O 
, O 
and O 
more O 
and O 
more O 
danshen O 
- O 
prescribed O 
drugs O 
interactions O 
have O 
been O 
reported O 
in O 
recent O 
years O 
. O 
Evaluation O 
of O 
inhibition O 
potential O 
of O 
danshen's O 
major O 
ingredients O 
towards O 
UDP B-ABBREVIATION 
-glucuronosyltransferases O 
( O 
UGTs O 
) O 
will O 
be O 
helpful O 
for O 
understanding O 
detailed O 
mechanisms O 
for O 
danshen O 
- O 
drugs O 
interaction O 
. O 
Therefore O 
, O 
the O 
aim O 
of O 
the O 
present O 
study O 
is O 
to O 
investigate O 
the O 
inhibitory O 
situation O 
of O 
cryptotanshinone B-TRIVIAL 
and O 
dihydrotanshinone B-TRIVIAL 
I I-TRIVIAL 
towards O 
UGT O 
enzyme O 
- O 
catalyzed O 
propofol B-TRIVIAL 
glucuronidation O 
. O 
In O 
vitro O 
the O 
human O 
liver O 
microsome O 
( O 
HLM O 
) O 
incubation O 
system O 
was O 
used O 
, O 
and O 
the O 
results O 
showed O 
that O 
cryptotanshinone B-TRIVIAL 
and O 
dihydrotanshinone B-TRIVIAL 
I I-TRIVIAL 
exhibited O 
dose O 
- O 
dependent O 
inhibition O 
towards O 
HLM O 
- O 
catalyzed O 
propofol B-TRIVIAL 
glucuronidation O 
. O 
Dixon O 
plot O 
and O 
Lineweaver-Burk O 
plot O 
showed O 
that O 
the O 
inhibition O 
type O 
was O 
best O 
fit O 
to O 
competitive O 
inhibition O 
type O 
for O 
both O 
cryptotanshinone B-TRIVIAL 
and O 
dihydrotanshinone B-TRIVIAL 
I I-TRIVIAL 
. O 
The O 
second O 
plot O 
using O 
the O 
slopes O 
from O 
the O 
Lineweaver-Burk O 
plot O 
versus O 
the O 
concentrations O 
of O 
cryptotanshinone B-TRIVIAL 
or O 
dihydrotanshinone B-TRIVIAL 
I I-TRIVIAL 
was O 
employed O 
to O 
calculate O 
the O 
inhibition O 
parameters O 
( O 
Ki O 
) O 
to O 
be O 
0.4 O 
and O 
1.7μM O 
, O 
respectively O 
. O 
Using O 
the O 
reported O 
maximum O 
plasma O 
concentration O 
( O 
Cmax O 
) O 
, O 
the O 
altered O 
in O 
vivo O 
exposure O 
of O 
propofol B-TRIVIAL 
increased O 
by O 
10% O 
and O 
8.2% O 
for O 
the O 
co O 
- O 
administration O 
of O 
dihydrotanshinone B-TRIVIAL 
I I-TRIVIAL 
and O 
cryptotanshinone B-TRIVIAL 
, O 
respectively O 
. O 
All O 
these O 
results O 
indicated O 
the O 
possible O 
danshen- O 
propofol B-TRIVIAL 
interaction O 
due O 
to O 
the O 
inhibition O 
of O 
dihydrotanshinone B-TRIVIAL 
I I-TRIVIAL 
and O 
cryptotanshinone B-TRIVIAL 
towards O 
the O 
glucuronidation O 
reaction O 
of O 
propofol B-TRIVIAL 
. O 

of O 
dipeptide B-FAMILY 
structures O 
containing O 
pyrrolysine B-TRIVIAL 
as O 
N B-FORMULA 
-terminal O 
residues O 
: O 
a O 
DFT O 
study O 
in O 
gas O 
and O 
aqueous O 
phase O 
. O 

set O 
of O 
six O 
dipeptides B-FAMILY 
containing O 
pyrrolysine B-TRIVIAL 
invariably O 
at O 
their O 
N B-FORMULA 
-terminal O 
positions O 
is O 
studied O 
in O 
gas O 
and O 
aqueous O 
phase O 
using O 
a O 
polarizable O 
continuum O 
model O 
( O 
PCM O 
) O 
. O 
The O 
molecular O 
geometries O 
of O 
the O 
dipeptides B-FAMILY 
are O 
fully O 
optimized O 
at O 
B3LYP O 
/ O 
6-31 O 
+ O 
+ O 
G(d,p) O 
level O 
of O 
theory O 
and O 
a O 
second O 
derivative O 
( O 
frequency O 
) O 
analysis O 
confirms O 
that O 
all O 
the O 
optimized O 
geometries O 
are O 
true O 
minima O 
. O 
The O 
effects O 
of O 
solvation O 
and O 
identity O 
of O 
the O 
varying O 
C B-FORMULA 
-terminal O 
residue O 
on O 
the O 
energetics O 
, O 
structural O 
features O 
of O 
the O 
peptide O 
planes O 
, O 
values O 
of O 
the O 
ψ O 
and O 
ϕ O 
dihedrals O 
, O 
geometry O 
around O 
the O 
α-carbon B-SYSTEMATIC 
atoms O 
and O 
theoretically O 
predicted O 
vibrational O 
spectra O 
of O 
the O 
dipeptides B-FAMILY 
are O 
thoroughly O 
analyzed O 
. O 
Solvation O 
effects O 
are O 
found O 
to O 
modify O 
the O 
gas O 
phase O 
conformation O 
of O 
the O 
dipeptides B-FAMILY 
around O 
ψ O 
dihedrals O 
while O 
the O 
identity O 
of O 
the O 
varying O 
C B-FORMULA 
-terminal O 
residue O 
affect O 
the O 
values O 
of O 
ϕ O 
, O 
planarity O 
of O 
the O 
peptide O 
planes O 
and O 
geometry O 
around O 
the O 
α-carbon B-SYSTEMATIC 
atoms O 
. O 
The O 
presence O 
or O 
absence O 
of O 
three O 
types O 
of O 
intramolecular O 
H B-FORMULA 
-bonds O 
, O 
namely O 
O B-FORMULA 
. O 
. O 
. O 
H-N B-FORMULA 
, O 
N B-FORMULA 
. O 
. O 
. O 
H-N B-FORMULA 
and O 
O B-FORMULA 
. O 
. O 
. O 
H-C B-FORMULA 
that O 
leave O 
noticeable O 
signatures O 
in O 
the O 
IR O 
spectra O 
, O 
play O 
crucial O 
roles O 
in O 
influencing O 
the O 
geometry O 
of O 
the O 
peptide O 
planes O 
and O 
in O 
determining O 
the O 
energetics O 
of O 
the O 
dipeptides B-FAMILY 
. O 

synthesis O 
of O 
CdTe B-FORMULA 
/ O 
SWNT O 
hybrid O 
nanostructures O 
and O 
their O 
tunable O 
electrical O 
and O 
optoelectrical O 
properties O 
. O 

facile O 
electrodeposition O 
technique O 
was O 
utilized O 
to O 
deposit O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWNTs O 
) O 
with O 
cadmium B-SYSTEMATIC 
telluride I-SYSTEMATIC 
( O 
CdTe B-FORMULA 
) O 
with O 
well O 
- O 
controlled O 
size O 
, O 
density O 
, O 
surface O 
morphology O 
, O 
and O 
composition O 
. O 
By O 
controlling O 
the O 
applied O 
charge O 
, O 
the O 
morphology O 
of O 
these O 
hybrid O 
nanostructures O 
was O 
altered O 
from O 
CdTe B-FORMULA 
nanoparticles O 
on O 
SWNTs O 
to O 
SWNT/ O 
CdTe B-FORMULA 
core O 
/ O 
shell O 
nanostructures O 
and O 
the O 
composition O 
of O 
the O 
CdTe B-FORMULA 
nanoparticles O 
was O 
altered O 
from O 
Te B-FORMULA 
-rich O 
( O 
29 O 
at% O 
Cd B-FORMULA 
) O 
to O 
Cd B-FORMULA 
-rich O 
( O 
79 O 
at% O 
Cd B-FORMULA 
) O 
CdTe B-FORMULA 
by O 
adjusting O 
the O 
deposition O 
potential O 
. O 
The O 
electrical O 
and O 
optoelectrical O 
properties O 
of O 
these O 
hybrid O 
nanostructures O 
showed O 
that O 
photo O 
- O 
induced O 
current O 
can O 
be O 
tuned O 
by O 
tailoring O 
the O 
conductivity O 
type O 
( O 
n O 
- O 
type O 
or O 
p- O 
type O 
) O 
, O 
morphology O 
, O 
and O 
size O 
of O 
the O 
CdTe B-FORMULA 
nanostructures O 
, O 
with O 
a O 
maximum O 
photosensitivity O 
( O 
ΔI O 
/ O 
I(0) O 
) O 
of O 
about O 
30% O 
for O 
SWNT/ O 
Cd B-FORMULA 
-rich O 
CdTe B-FORMULA 
( O 
n O 
- O 
type O 
) O 
core O 
/ O 
shell O 
nanostructures O 
. O 
This O 
work O 
demonstrates O 
a O 
novel O 
approach O 
for O 
synthesizing O 
metal O 
chalcogenide O 
/ O 
SWNT O 
hybrid O 
nanostructures O 
for O 
various O 
electrical O 
and O 
optoelectrical O 
applications O 
. O 

- O 
inhibiting O 
proteins O 
( O 
PGIPs O 
) O 
are O 
plant O 
cell O 
wall O 
glycoproteins O 
that O 
can O 
inhibit O 
fungal O 
endopolygalacturonases O 
( O 
PGs O 
) O 
. O 
The O 
PGIPs O 
directly O 
reduce O 
the O 
aggressive O 
potential O 
of O 
PGs O 
. O 
Here O 
, O 
we O 
isolated O 
and O 
functionally O 
characterized O 
three O 
members O 
of O 
the O 
pepper O 
( O 
Capsicum O 
annuum O 
) O 
PGIP O 
gene O 
family O 
. O 
Each O 
was O 
up O 
- O 
regulated O 
at O 
a O 
different O 
time O 
following O 
stimulation O 
of O 
the O 
pepper O 
leaves O 
by O 
Phytophthora O 
capcisi O 
and O 
abiotic O 
stresses O 
including O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
, O 
methyl B-SYSTEMATIC 
jasmonate I-SYSTEMATIC 
, O 
abscisic B-TRIVIAL 
acid I-TRIVIAL 
, O 
wounding O 
and O 
cold O 
treatment O 
. O 
Purified O 
recombinant O 
proteins O 
individually O 
inhibited O 
activity O 
of O 
PGs O 
produced O 
by O 
Alternaria O 
alternata O 
and O 
Colletotrichum O 
nicotianae O 
, O 
respectively O 
, O 
and O 
virus O 
- O 
induced O 
gene O 
silencing O 
in O 
pepper O 
conferred O 
enhanced O 
susceptibility O 
to O 
P O 
. O 
capsici O 
. O 
Because O 
three O 
PGIP O 
genes O 
acted O 
similarily O 
in O 
conferring O 
resistance O 
to O 
infection O 
by O 
P O 
. O 
capsici O 
, O 
and O 
because O 
individually O 
purified O 
proteins O 
showed O 
consistent O 
inhibition O 
against O 
PG O 
activity O 
of O 
both O 
pathogens O 
, O 
CaPGIP1 O 
was O 
selected O 
for O 
manipulating O 
transgenic O 
tobacco O 
. O 
The O 
crude O 
proteins O 
from O 
transgenic O 
tobacco O 
exhibited O 
distinct O 
enhanced O 
resistance O 
to O 
PG O 
activity O 
of O 
both O 
fungi O 
. O 
Moreover O 
, O 
the O 
transgenic O 
tobacco O 
showed O 
effective O 
resistance O 
to O 
infection O 
and O 
a O 
significant O 
reduction O 
in O 
the O 
number O 
of O 
infection O 
sites O 
, O 
number O 
of O 
lesions O 
and O 
average O 
size O 
of O 
lesions O 
in O 
the O 
leaves O 
. O 
All O 
results O 
suggest O 
that O 
CaPGIPs O 
may O 
be O 
involved O 
in O 
plant O 
defense O 
response O 
and O 
play O 
an O 
important O 
role O 
in O 
a O 
plant's O 
resistance O 
to O 
disease O 
. O 

overload O 
inhibits O 
osteoblast O 
biological O 
activity O 
through O 
oxidative O 
stress O 
. O 

overload O 
has O 
recently O 
been O 
connected O 
with O 
bone O 
mineral O 
density O 
in O 
osteoporosis O 
. O 
However O 
, O 
to O 
date O 
, O 
the O 
effect O 
of O 
iron B-SYSTEMATIC 
overload O 
on O 
osteoblasts O 
remains O 
poorly O 
understood O 
. O 
The O 
purpose O 
of O 
this O 
study O 
is O 
to O 
examine O 
osteoblast O 
biological O 
activity O 
under O 
iron B-SYSTEMATIC 
overload O 
. O 
The O 
osteoblast O 
cells O 
( O 
hFOB1.19 O 
) O 
were O 
cultured O 
in O 
a O 
medium O 
supplemented O 
with O 
different O 
concentrations O 
( O 
50 O 
, O 
100 O 
, O 
and O 
200 O 
μM O 
) O 
of O 
ferric B-SYSTEMATIC 
ammonium I-SYSTEMATIC 
citrate I-SYSTEMATIC 
as O 
a O 
donor O 
of O 
ferric B-SYSTEMATIC 
ion O 
. O 
Intracellular O 
iron B-SYSTEMATIC 
was O 
measured O 
with O 
a O 
confocal O 
laser O 
scanning O 
microscope O 
. O 
Reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
were O 
detected O 
by O 
2,7-dichlorofluorescin B-SYSTEMATIC 
diacetate I-SYSTEMATIC 
fluorophotometry O 
. O 
Osteoblast O 
biological O 
activities O 
were O 
evaluated O 
by O 
measuring O 
the O 
activity O 
of O 
alkaline O 
phosphatase O 
( O 
ALP O 
) O 
and O 
mineralization O 
function O 
. O 
Results O 
indicated O 
that O 
iron B-SYSTEMATIC 
overload O 
could O 
consequently O 
increase O 
intracellular O 
iron B-SYSTEMATIC 
concentration O 
and O 
intracellular O 
ROS O 
levels O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 
Additionally O 
, O 
ALP O 
activity O 
was O 
suppressed O 
, O 
and O 
a O 
decline O 
in O 
the O 
number O 
of O 
mineralized O 
nodules O 
was O 
observed O 
in O 
in O 
vitro O 
cultured O 
osteoblast O 
cells O 
. O 
According O 
to O 
these O 
results O 
, O 
it O 
seems O 
that O 
iron B-SYSTEMATIC 
overload O 
probably O 
inhibits O 
osteoblast O 
function O 
through O 
higher O 
oxidative O 
stress O 
following O 
increased O 
intracellular O 
iron B-SYSTEMATIC 
concentrations O 
. O 

effects O 
of O 
Ginkgo O 
biloba O 
extract O 
in O 
estrogen B-FAMILY 
-negative O 
human O 
breast O 
cancer O 
cells O 
. O 

level O 
of O 
estrogen B-FAMILY 
is O 
considered O 
as O 
a O 
main O 
cause O 
of O 
breast O 
cancer O 
, O 
therefore O 
, O 
many O 
studies O 
have O 
focused O 
on O 
estrogen B-FAMILY 
receptor O 
(ER)-positive O 
breast O 
cancer O 
, O 
even O 
though O 
ER-negative O 
cancer O 
has O 
a O 
poor O 
prognosis O 
than O 
ER-positive O 
breast O 
cancer O 
. O 
We O 
evaluated O 
the O 
anti-cancer O 
effects O 
of O 
Ginkgo O 
biloba O 
extract O 
( O 
GBE O 
) O 
in O 
estrogen B-FAMILY 
-independent O 
breast O 
cancer O 
. O 
GBE O 
has O 
been O 
traditionally O 
used O 
as O 
a O 
platelet O 
activating O 
factor O 
, O 
a O 
circulatory O 
stimulant O 
, O 
a O 
tonic O 
, O 
and O 
anti-asthmatic O 
drug O 
, O 
and O 
anti-cancer O 
agent O 
. O 
However O 
, O 
anti-cancer O 
effects O 
of O 
GBE O 
on O 
ER-negative O 
breast O 
cancer O 
have O 
not O 
been O 
proved O 
yet O 
. O 
In O 
this O 
study O 
, O 
we O 
tested O 
chemotherapeutic O 
potential O 
of O 
GBE O 
in O 
the O 
MDA-MB-231 O 
( O 
ER-negative O 
) O 
human O 
breast O 
cancer O 
cell O 
line O 
. O 
Our O 
results O 
showed O 
that O 
cytotoxicity O 
effects O 
of O 
GBE O 
in O 
MDA-MB-231 O 
lead O 
to O 
DNA O 
fragmentation O 
at O 
high O 
concentrations O 
( O 
500 O 
and O 
1000 O 
μg O 
/ O 
ml O 
) O 
. O 
Caspase-3 O 
was O 
significantly O 
activated O 
and O 
mRNA O 
levels O 
of O 
apoptosis O 
- O 
related O 
genes O 
( O 
Bcl-2 O 
and O 
Bax O 
) O 
were O 
altered O 
. O 
These O 
results O 
indicate O 
that O 
GBE O 
induces O 
apoptosis O 
in O 
MDA-MB-231 O 
cells O 
. O 
It O 
is O 
presumed O 
that O 
GBE O 
has O 
chemopreventive O 
effects O 
in O 
ER O 
- O 
independent O 
breast O 
cancer O 
through O 
anti-proliferation O 
and O 
apoptosis O 
- O 
inducing O 
activities O 
. O 

- O 
temperature O 
ferromagnetism O 
in O 
ZnO B-FORMULA 
-encapsulated O 
1.9 O 
nm O 
FePt3 B-FORMULA 
nanoparticle O 
- O 
composite O 
thin O 
films O 
with O 
giant O 
interfacial O 
anisotropy O 
. O 

synthesized O 
1.9-nm O 
FePt3 B-FORMULA 
nanoparticles O 
are O 
superparamagnetic O 
at O 
room O 
temperature O 
. O 
Coating O 
those O 
nanoparticles O 
with O 
ZnO B-FORMULA 
renders O 
them O 
permanently O 
ferromagnetic O 
with O 
coercivity O 
field O 
of O 
650 O 
Oe O 
at O 
room O 
temperature O 
. O 
First O 
- O 
principles O 
calculations O 
indicate O 
that O 
giant O 
interfacial O 
anisotropy O 
, O 
induced O 
by O 
the O 
strong O 
spin O 
- O 
orbit O 
interaction O 
of O 
enhanced O 
orbit O 
momentum O 
of O 
Fe B-FORMULA 
, O 
overcomes O 
the O 
superparamagnetic O 
limit O 
, O 
leading O 
to O 
exceptional O 
room O 
- O 
temperature O 
permanent O 
ferromagnetism O 
. O 
The O 
findings O 
are O 
important O 
for O 
the O 
understanding O 
of O 
the O 
origin O 
of O 
permanent O 
ferromagnetism O 
at O 
ultrasmall O 
size O 
and O 
critical O 
for O 
ultrahigh O 
density O 
recording O 
and O 
information O 
processing O 
. O 

, O 
reversible O 
, O 
and O 
general O 
photomechanical O 
motion O 
in O 
single O 
crystals O 
of O 
various O 
azo B-SYSTEMATIC 
compounds O 
using O 
visible O 
light O 
. O 

of O 
enantiomeric O 
degradation O 
of O 
the O 
triazole B-FAMILY 
fungicide O 
hexaconazole B-TRIVIAL 
in O 
tomato O 
, O 
cucumber O 
, O 
and O 
field O 
soil O 
by O 
chiral O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
. O 

pesticide O 
enantiomers O 
often O 
show O 
different O 
bioactivity O 
and O 
toxicity O 
; O 
however O 
, O 
this O 
property O 
is O 
usually O 
ignored O 
when O 
evaluating O 
their O 
environmental O 
and O 
public O 
health O 
risks O 
. O 
Hexaconazole B-TRIVIAL 
is O 
a O 
chiral O 
fungicide O 
used O 
on O 
a O 
variety O 
of O 
crops O 
for O 
the O 
control O 
of O 
many O 
fungal O 
diseases O 
. O 
This O 
use O 
provides O 
opportunities O 
for O 
the O 
pollution O 
of O 
food O 
and O 
soil O 
. O 
In O 
this O 
study O 
, O 
a O 
sensitive O 
and O 
convenient O 
chiral O 
liquid O 
chromatography O 
coupled O 
with O 
tandem O 
mass O 
spectrometry O 
( O 
LC-MS O 
/ O 
MS O 
) O 
method O 
was O 
developed O 
and O 
validated O 
for O 
measuring O 
hexaconazole B-TRIVIAL 
enantiomers O 
in O 
tomato O 
, O 
cucumber O 
, O 
and O 
soil O 
. O 
Separation O 
was O 
by O 
a O 
reversed O 
- O 
phase O 
Chiralcel O 
OD-RH O 
column O 
, O 
under O 
isocratic O 
conditions O 
using O 
a O 
mixture O 
of O 
acetonitrile B-SYSTEMATIC 
-2 O 
mM O 
ammonium B-SYSTEMATIC 
acetate I-SYSTEMATIC 
in O 
water O 
( O 
60 O 
/ O 
40 O 
, O 
v O 
/ O 
v O 
) O 
as O 
the O 
mobile O 
phase O 
at O 
a O 
flow O 
rate O 
of O 
0.4 O 
mL O 
/ O 
min O 
. O 
Parameters O 
including O 
the O 
matrix O 
effect O 
, O 
linearity O 
, O 
precision O 
, O 
accuracy O 
and O 
stability O 
were O 
undertaken O 
. O 
Then O 
the O 
proposed O 
method O 
was O 
successfully O 
applied O 
to O 
investigate O 
the O 
possible O 
enantioselective O 
degradation O 
of O 
rac B-TRIVIAL 
- I-TRIVIAL 
hexaconazole I-TRIVIAL 
in O 
plants O 
( O 
tomato O 
and O 
cucumber O 
) O 
and O 
soil O 
under O 
field O 
conditions O 
. O 
The O 
degradation O 
of O 
the O 
two O 
enantiomers O 
of O 
hexaconazole B-TRIVIAL 
proved O 
to O 
be O 
enantioselective O 
and O 
dependent O 
on O 
the O 
media O 
: O 
The O 
(+)-enantiomer O 
showed O 
a O 
faster O 
degradation O 
in O 
plants O 
, O 
while O 
the O 
(-)-enantiomer O 
dissipated O 
faster O 
than O 
the O 
(+)- O 
form O 
in O 
field O 
soil O 
, O 
resulting O 
in O 
relative O 
enrichment O 
of O 
the O 
opposite O 
enantiomer O 
. O 
The O 
results O 
of O 
this O 
work O 
demonstrate O 
that O 
both O 
the O 
environmental O 
media O 
and O 
environmental O 
conditions O 
influenced O 
the O 
direction O 
and O 
rate O 
of O 
enantioselective O 
degradation O 
of O 
hexaconazole B-TRIVIAL 
. O 

transfer O 
dissociation O 
( O 
ETD O 
) O 
: O 
the O 
mass O 
spectrometric O 
breakthrough O 
essential O 
for O 
O-GlcNAc B-FORMULA 
protein O 
site O 
assignments-a O 
study O 
of O 
the O 
O B-FORMULA 
-GlcNAcylated O 
protein O 
host O 
cell O 
factor O 
C1 O 
. O 

development O 
of O 
electron O 
- O 
based O 
, O 
unimolecular O 
dissociation O 
MS O 
, O 
i.e O 
. O 
electron O 
capture O 
and O 
electron O 
transfer O 
dissociation O 
( O 
ECD O 
and O 
ETD O 
, O 
respectively O 
) O 
, O 
has O 
greatly O 
increased O 
the O 
speed O 
and O 
reliability O 
of O 
labile O 
PTM O 
site O 
assignment O 
. O 
The O 
field O 
of O 
intracellular O 
O-GlcNAc B-FORMULA 
( O 
O B-FORMULA 
-linked O 
N-acetylglucosamine B-SYSTEMATIC 
) O 
signaling O 
has O 
especially O 
advanced O 
with O 
the O 
advent O 
of O 
ETD O 
MS O 
. O 
Only O 
within O 
the O 
last O 
five O 
years O 
have O 
proteomic O 
- O 
scale O 
experiments O 
utilizing O 
ETD O 
allowed O 
the O 
assignment O 
of O 
hundreds O 
of O 
O-GlcNAc B-FORMULA 
sites O 
within O 
cells O 
and O 
subcellular O 
structures O 
. O 
Our O 
ability O 
to O 
identify O 
and O 
unambiguously O 
assign O 
the O 
site O 
of O 
O-GlcNAc B-FORMULA 
modifications O 
using O 
ETD O 
is O 
rapidly O 
increasing O 
our O 
understanding O 
of O 
this O 
regulatory O 
glycosylation O 
and O 
its O 
potential O 
interaction O 
with O 
other O 
PTMs O 
. O 
Here O 
, O 
we O 
discuss O 
the O 
advantages O 
of O 
using O 
ETD O 
, O 
complimented O 
with O 
collisional O 
- O 
activation O 
MS O 
, O 
in O 
a O 
study O 
of O 
the O 
extensively O 
O B-FORMULA 
-GlcNAcylated O 
protein O 
Host O 
Cell O 
Factor O 
C1 O 
( O 
HCF-1 O 
) O 
. O 
HCF-1 O 
is O 
a O 
transcriptional O 
coregulator O 
that O 
forms O 
a O 
stable O 
complex O 
with O 
O-GlcNAc B-FORMULA 
transferase O 
and O 
controls O 
cell O 
cycle O 
progression O 
. O 
ETD O 
, O 
along O 
with O 
higher O 
energy O 
collisional O 
dissociation O 
( O 
HCD O 
) O 
MS O 
, O 
was O 
employed O 
to O 
assign O 
the O 
PTMs O 
of O 
the O 
HCF-1 O 
protein O 
isolated O 
from O 
HEK293T O 
cells O 
. O 
These O 
include O 
19 O 
sites O 
of O 
O B-FORMULA 
-GlcNAcylation O 
, O 
two O 
sites O 
of O 
phosphorylation O 
, O 
and O 
two O 
sites O 
bearing O 
dimethylarginine B-SYSTEMATIC 
, O 
and O 
showcase O 
the O 
residue O 
- O 
specific O 
, O 
PTM O 
complexity O 
of O 
this O 
regulator O 
of O 
cell O 
proliferation O 
. O 

is O 
a O 
CO(2) B-FORMULA 
-selective O 
steam O 
reforming O 
catalyst O 
. O 

was O 
tested O 
as O 
possible O 
methanol B-SYSTEMATIC 
and O 
- O 
since O 
formaldehyde B-SYSTEMATIC 
is O 
one O 
of O 
the O 
key O 
intermediates O 
in O 
methanol B-SYSTEMATIC 
conversion O 
reactions O 
- O 
also O 
as O 
formaldehyde B-SYSTEMATIC 
steam O 
reforming O 
catalyst O 
. O 
Catalytic O 
experiments O 
in O 
a O 
batch O 
as O 
well O 
as O 
a O 
flow O 
reactor O 
resulted O 
in O 
highly O 
selective O 
steam O 
reforming O 
, O 
though O 
at O 
low O 
specific O 
activities O 
, O 
of O 
formaldehyde B-SYSTEMATIC 
and O 
methanol B-SYSTEMATIC 
over O 
ZnO B-FORMULA 
toward O 
CO(2) B-FORMULA 
( O 
selectivity O 
of O 
95-99.6% O 
) O 
. O 
Comparison O 
of O 
the O 
behavior O 
of O 
ZnPd B-FORMULA 
near O 
- O 
surface O 
intermetallic O 
phases O 
, O 
unsupported O 
intermetallic O 
ZnPd B-FORMULA 
and O 
supported O 
ZnPd B-FORMULA 
/ O 
ZnO B-FORMULA 
catalysts O 
reveals O 
that O 
formaldehyde B-SYSTEMATIC 
is O 
formed O 
from O 
methanol B-SYSTEMATIC 
in O 
parallel O 
with O 
CO(2) B-FORMULA 
on O 
the O 
former O 
, O 
while O 
on O 
unsupported O 
intermetallic O 
ZnPd B-FORMULA 
and O 
ZnO B-FORMULA 
-supported O 
ZnPd B-FORMULA 
, O 
it O 
is O 
efficiently O 
reacted O 
toward O 
CO(2) B-FORMULA 
, O 
thus O 
, O 
a O 
beneficial O 
role O 
of O 
ZnO B-FORMULA 
in O 
oxidizing O 
formaldehyde B-SYSTEMATIC 
-derived O 
intermediates O 
toward O 
CO(2) B-FORMULA 
is O 
evident O 
. O 

new O 
aliphatic O 
enone O 
, O 
(17Z,20Z)-hexacosa-17,20-dien-9-one B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
and O 
one O 
new O 
bisindole B-FAMILY 
alkaloid I-FAMILY 
, O 
gangenoid B-TRIVIAL 
( O 
6 O 
) O 
, O 
together O 
with O 
seven O 
known O 
compounds O 
were O 
isolated O 
from O 
the O 
roots O 
and O 
aerial O 
parts O 
of O 
Desmodium O 
gangeticum O 
( O 
family O 
: O 
Leguminosae O 
) O 
. O 
All O 
the O 
compounds O 
except O 
2 O 
and O 
7 O 
were O 
isolated O 
from O 
this O 
plant O 
for O 
the O 
first O 
time O 
, O 
which O 
may O 
be O 
of O 
chemotaxonomic O 
importance O 
. O 
Structures O 
of O 
compounds O 
3 O 
and O 
6 O 
were O 
determined O 
on O 
the O 
basis O 
of O 
their O 
detailed O 
spectroscopic O 
analyses O 
( O 
NMR O 
, O 
IR O 
and O 
mass O 
) O 
. O 
In O 
addition O 
, O 
compounds O 
3 O 
and O 
6 O 
were O 
investigated O 
for O 
their O 
effects O 
on O 
lipopolysaccharide-stimulated O 
macrophages O 
for O 
the O 
production O 
of O 
pro O 
- O 
inflammatory O 
cytokines O 
such O 
as O 
tumour O 
necrosis O 
factor-α O 
and O 
interleukin-6 O 
. O 

mapping O 
of O 
lithium B-SYSTEMATIC 
-ion O 
diffusion O 
in O 
a O 
cathode O 
within O 
an O 
all O 
- O 
solid O 
- O 
state O 
lithium B-SYSTEMATIC 
-ion O 
battery O 
by O 
advanced O 
scanning O 
probe O 
microscopy O 
techniques O 
. O 

- O 
resolution O 
real O 
- O 
space O 
mapping O 
of O 
Li B-FORMULA 
-ion O 
diffusion O 
in O 
the O 
LiNi(1 B-FORMULA 
/ I-FORMULA 
3)Co(1 I-FORMULA 
/ I-FORMULA 
3)Mn(1 I-FORMULA 
/ I-FORMULA 
3)O₂ I-FORMULA 
cathode O 
within O 
an O 
all O 
- O 
solid O 
- O 
state O 
thin O 
film O 
Li B-FORMULA 
-ion O 
battery O 
has O 
been O 
conducted O 
using O 
advanced O 
scanning O 
probe O 
microscopy O 
techniques O 
, O 
namely O 
, O 
band O 
excitation O 
electrochemical O 
strain O 
microscopy O 
( O 
BE-ESM O 
) O 
and O 
conductive O 
atomic O 
force O 
microscopy O 
. O 
In O 
addition O 
, O 
local O 
variations O 
of O 
the O 
electrochemical O 
response O 
in O 
the O 
LiNi(1 B-FORMULA 
/ I-FORMULA 
3)Co(1 I-FORMULA 
/ I-FORMULA 
3)Mn(1 I-FORMULA 
/ I-FORMULA 
3)O₂ I-FORMULA 
thin O 
film O 
cathode O 
at O 
different O 
cycling O 
stages O 
have O 
been O 
investigated O 
. O 
This O 
work O 
demonstrates O 
the O 
unique O 
feature O 
and O 
applications O 
of O 
the O 
BE-ESM O 
technique O 
on O 
battery O 
research O 
. O 
The O 
results O 
allow O 
us O 
to O 
establish O 
a O 
direct O 
relationship O 
of O 
the O 
changes O 
in O 
ionic O 
mobility O 
as O 
well O 
as O 
the O 
electrochemical O 
activity O 
at O 
the O 
nanoscale O 
with O 
the O 
numbers O 
of O 
charge O 
/ O 
discharge O 
cycles O 
. O 
Furthermore O 
, O 
various O 
factors O 
influencing O 
the O 
BE-ESM O 
measurements O 
, O 
including O 
sample O 
mechanical O 
properties O 
( O 
e.g O 
. O 
, O 
elastic O 
and O 
dissipative O 
properties O 
) O 
as O 
well O 
as O 
surface O 
electrical O 
properties O 
, O 
have O 
also O 
been O 
studied O 
to O 
investigate O 
the O 
coupling O 
effects O 
on O 
the O 
electrochemical O 
strain O 
. O 
The O 
study O 
on O 
the O 
relationships O 
between O 
the O 
Li B-FORMULA 
-ion O 
redistribution O 
and O 
microstructure O 
of O 
the O 
electrode O 
materials O 
within O 
thin O 
film O 
Li B-FORMULA 
-ion O 
battery O 
will O 
provide O 
further O 
understanding O 
of O 
the O 
electrochemical O 
degradation O 
mechanisms O 
of O 
Li B-FORMULA 
-ion O 
rechargeable O 
batteries O 
at O 
the O 
nanoscale O 
. O 

inhibit O 
extracellular O 
matrix O 
mineralization O 
in O 
MC3T3-E1 O 
osteoblast O 
cultures O 
. O 

on O 
various O 
compounds O 
of O 
inorganic O 
phosphate B-SYSTEMATIC 
, O 
as O 
well O 
as O 
on O 
organic O 
phosphate B-SYSTEMATIC 
added O 
by O 
post O 
- O 
translational O 
phosphorylation O 
of O 
proteins O 
, O 
all O 
demonstrate O 
a O 
central O 
role O 
for O 
phosphate B-SYSTEMATIC 
in O 
biomineralization O 
processes O 
. O 
Inorganic O 
polyphosphates B-FAMILY 
are O 
chains O 
of O 
orthophosphates B-FAMILY 
linked O 
by O 
phosphoanhydride B-SYSTEMATIC 
bonds O 
that O 
can O 
be O 
up O 
to O 
hundreds O 
of O 
orthophosphates B-FAMILY 
in O 
length O 
. O 
The O 
role O 
of O 
polyphosphates B-FAMILY 
in O 
mammalian O 
systems O 
, O 
where O 
they O 
are O 
ubiquitous O 
in O 
cells O 
, O 
tissues O 
and O 
bodily O 
fluids O 
, O 
and O 
are O 
at O 
particularly O 
high O 
levels O 
in O 
osteoblasts O 
, O 
is O 
not O 
well O 
understood O 
. O 
In O 
cell O 
- O 
free O 
systems O 
, O 
polyphosphates B-FAMILY 
inhibit O 
hydroxyapatite O 
nucleation O 
, O 
crystal O 
formation O 
and O 
growth O 
, O 
and O 
solubility O 
. O 
In O 
animal O 
studies O 
, O 
polyphosphate O 
injections O 
inhibit O 
induced O 
ectopic O 
calcification O 
. O 
While O 
recent O 
work O 
has O 
proposed O 
an O 
integrated O 
view O 
of O 
polyphosphate O 
function O 
in O 
bone O 
, O 
little O 
experimental O 
data O 
for O 
bone O 
are O 
available O 
. O 
Here O 
we O 
demonstrate O 
in O 
osteoblast O 
cultures O 
producing O 
an O 
abundant O 
collagenous O 
matrix O 
that O 
normally O 
show O 
robust O 
mineralization O 
, O 
that O 
two O 
polyphosphates B-FAMILY 
( O 
PolyP5 B-ABBREVIATION 
and O 
PolyP65 B-ABBREVIATION 
, O 
polyphosphates B-FAMILY 
of O 
5 O 
and O 
65 O 
phosphate B-SYSTEMATIC 
residues O 
in O 
length O 
) O 
are O 
potent O 
mineralization O 
inhibitors O 
. O 
Twelve O 
- O 
day O 
MC3T3-E1 O 
osteoblast O 
cultures O 
with O 
added O 
ascorbic O 
acid O 
( O 
for O 
collagen O 
matrix O 
assembly O 
) O 
and O 
β-glycerophosphate B-SYSTEMATIC 
( O 
a O 
source O 
of O 
phosphate B-SYSTEMATIC 
for O 
mineralization O 
) O 
were O 
treated O 
with O 
either O 
PolyP5 B-ABBREVIATION 
or O 
PolyP65 B-ABBREVIATION 
. O 
Von O 
Kossa O 
staining O 
and O 
calcium O 
quantification O 
revealed O 
that O 
mineralization O 
was O 
inhibited O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
by O 
both O 
polyphosphates B-FAMILY 
, O 
with O 
complete O 
mineralization O 
inhibition O 
at O 
10μM O 
. O 
Cell O 
proliferation O 
and O 
collagen O 
assembly O 
were O 
unaffected O 
by O 
polyphosphate O 
treatment O 
, O 
indicating O 
that O 
polyphosphate O 
inhibition O 
of O 
mineralization O 
results O 
not O 
from O 
cell O 
and O 
matrix O 
effects O 
but O 
from O 
direct O 
inhibition O 
of O 
mineralization O 
. O 
This O 
was O 
confirmed O 
by O 
showing O 
that O 
PolyP5 B-ABBREVIATION 
and O 
PolyP65 B-ABBREVIATION 
bound O 
to O 
synthetic O 
hydroxyapatite B-TRIVIAL 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 
Tissue O 
- O 
nonspecific O 
alkaline O 
phosphatase O 
( O 
TNAP O 
, O 
ALPL O 
) O 
efficiently O 
hydrolyzed O 
the O 
two O 
PolyPs B-FAMILY 
as O 
measured O 
by O 
Pi O 
release O 
. O 
Importantly O 
, O 
at O 
the O 
concentrations O 
of O 
polyphosphates B-FAMILY 
used O 
in O 
this O 
study O 
which O 
inhibited O 
bone O 
cell O 
culture O 
mineralization O 
, O 
the O 
polyphosphates B-FAMILY 
competitively O 
saturated O 
TNAP O 
, O 
thus O 
potentially O 
interfering O 
with O 
its O 
ability O 
to O 
hydrolyze O 
mineralization O 
- O 
inhibiting O 
pyrophosphate B-SYSTEMATIC 
( O 
PPi B-ABBREVIATION 
) O 
and O 
mineralizing O 
- O 
promoting O 
β-glycerophosphate B-SYSTEMATIC 
( O 
in O 
cell O 
culture O 
) O 
. O 
In O 
the O 
biological O 
setting O 
, O 
polyphosphates B-FAMILY 
may O 
regulate O 
mineralization O 
by O 
shielding O 
the O 
essential O 
inhibitory O 
substrate O 
pyrophosphate B-SYSTEMATIC 
from O 
TNAP O 
degradation O 
, O 
and O 
in O 
the O 
same O 
process O 
, O 
delay O 
the O 
release O 
of O 
phosphate B-SYSTEMATIC 
from O 
this O 
source O 
. O 
In O 
conclusion O 
, O 
the O 
inhibition O 
of O 
mineralization O 
by O 
polyphosphates B-FAMILY 
is O 
shown O 
to O 
occur O 
via O 
direct O 
binding O 
to O 
apatitic O 
mineral O 
and O 
by O 
mixed O 
inhibition O 
of O 
TNAP O 
. O 

differences O 
in O 
the O 
antidepressant O 
- O 
like O 
effects O 
of O 
ketamine B-TRIVIAL 
. O 

medications O 
for O 
major O 
depression O 
suffer O 
from O 
numerous O 
limitations O 
. O 
Once O 
the O 
right O 
drug O 
for O 
treatment O 
has O 
been O 
determined O 
, O 
it O 
still O 
takes O 
several O 
weeks O 
for O 
it O 
to O 
take O 
effect O 
and O 
improve O 
mood O 
. O 
This O 
time O 
lag O 
is O 
a O 
serious O 
concern O 
for O 
the O 
healthcare O 
community O 
when O 
dealing O 
with O 
patients O 
with O 
suicidal O 
thoughts O 
. O 
However O 
, O 
recent O 
clinical O 
studies O 
have O 
shown O 
that O 
a O 
single O 
low O 
- O 
dose O 
injection O 
of O 
ketamine B-TRIVIAL 
, O 
an O 
N-methyl B-SYSTEMATIC 
d-aspartate I-SYSTEMATIC 
receptor O 
( O 
NMDAR O 
) O 
antagonist O 
, O 
has O 
rapid O 
antidepressant O 
effects O 
that O 
are O 
observed O 
within O 
hours O 
and O 
are O 
long O 
lasting O 
. O 
Although O 
major O 
depression O 
affects O 
twice O 
as O 
many O 
women O 
as O 
men O 
, O 
all O 
studies O 
examining O 
the O 
rapid O 
antidepressant O 
effects O 
of O 
ketamine B-TRIVIAL 
have O 
focused O 
on O 
male O 
subjects O 
. O 
Thus O 
, O 
we O 
have O 
investigated O 
the O 
behavioral O 
and O 
molecular O 
effects O 
of O 
ketamine B-TRIVIAL 
in O 
both O 
male O 
and O 
female O 
rats O 
and O 
demonstrated O 
greater O 
sensitivity O 
in O 
female O 
rats O 
at O 
a O 
low O 
dose O 
of O 
ketamine B-TRIVIAL 
, O 
a O 
dose O 
does O 
not O 
have O 
antidepressant O 
- O 
like O 
effects O 
in O 
male O 
rats O 
. O 
The O 
antidepressant O 
- O 
like O 
effects O 
of O 
this O 
low O 
dose O 
of O 
ketamine B-TRIVIAL 
were O 
completely O 
abolished O 
when O 
female O 
rats O 
were O 
ovariectomized O 
( O 
OVX O 
) O 
, O 
and O 
restored O 
when O 
physiological O 
levels O 
of O 
estrogen B-FAMILY 
and O 
progesterone B-TRIVIAL 
were O 
supplemented O 
, O 
suggesting O 
a O 
critical O 
role O 
for O 
gonadal O 
hormones O 
in O 
enhancing O 
the O 
antidepressant O 
- O 
like O 
effects O 
of O 
ketamine B-TRIVIAL 
in O 
female O 
rats O 
. O 
In O 
preclinical O 
studies O 
, O 
the O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
( O 
mTOR O 
) O 
in O 
the O 
medial O 
prefrontal O 
cortex O 
and O 
the O 
eukaryotic O 
elongation O 
factor O 
( O 
eEF2 O 
) O 
in O 
the O 
hippocampus O 
have O 
been O 
proposed O 
as O 
critical O 
mediators O 
of O 
ketamine B-TRIVIAL 
' O 
s O 
rapid O 
antidepressant O 
actions O 
. O 
In O 
our O 
hands O 
, O 
the O 
increased O 
sensitivity O 
of O 
female O 
rats O 
to O 
a O 
low O 
dose O 
of O 
ketamine B-TRIVIAL 
was O 
not O 
mediated O 
through O 
phosphorylation O 
of O 
mTOR O 
or O 
eEF2 O 
. O 

contribution O 
of O 
mesoaccumbens O 
and O 
mesohabenular O 
dopamine B-TRIVIAL 
to O 
intracranial O 
self O 
- O 
stimulation O 
. O 

contribution O 
of O 
mesoaccumbens O 
dopamine B-TRIVIAL 
transmission O 
to O 
intracranial O 
self O 
- O 
stimulation O 
is O 
well O 
- O 
established O 
. O 
However O 
, O 
although O 
the O 
nucleus O 
accumbens O 
comprises O 
two O 
main O 
subregions O 
, O 
the O 
shell O 
and O 
the O 
core O 
, O 
little O 
is O 
known O 
of O 
the O 
contribution O 
of O 
each O 
to O 
this O 
behaviour O 
. O 
Our O 
first O 
aim O 
was O 
to O 
study O 
the O 
effects O 
of O 
d-amphetamine B-TRIVIAL 
infusions O 
into O 
the O 
shell O 
and O 
core O 
in O 
order O 
to O 
understand O 
their O 
relative O 
importance O 
to O 
reward O 
and O 
operant O 
responding O 
. O 
Our O 
second O 
aim O 
was O 
to O 
examine O 
the O 
contribution O 
of O 
a O 
lesser O 
studied O 
group O 
of O 
dopamine B-TRIVIAL 
neurons O 
, O 
those O 
within O 
the O 
mesohabenular O 
pathway O 
, O 
to O 
intracranial O 
self O 
- O 
stimulation O 
. O 
Male O 
Sprague-Dawley O 
rats O 
were O 
implanted O 
with O 
bilateral O 
cannulae O 
in O 
the O 
nucleus O 
accumbens O 
shell O 
, O 
core O 
or O 
in O 
the O 
lateral O 
habenula O 
and O 
a O 
monopolar O 
stimulation O 
electrode O 
in O 
the O 
posterior O 
mesencephalon O 
, O 
a O 
brain O 
site O 
that O 
is O 
sensitive O 
to O 
changes O 
in O 
dopamine B-TRIVIAL 
transmission O 
. O 
Using O 
curve O 
- O 
shift O 
scaling O 
, O 
we O 
measured O 
the O 
reward- O 
and O 
performance O 
- O 
enhancing O 
effects O 
of O 
intra O 
- O 
accumbens O 
( O 
1-20 O 
μg O 
) O 
and O 
intra O 
- O 
habenular O 
( O 
10-40 O 
μg O 
) O 
infusions O 
of O 
d-amphetamine B-TRIVIAL 
or O 
vehicle O 
. O 
Within O 
the O 
nucleus O 
accumbens O 
, O 
the O 
use O 
of O 
multiple O 
doses O 
and O 
long O 
test O 
sessions O 
allowed O 
us O 
to O 
observe O 
an O 
interaction O 
between O 
drug O 
effect O 
and O 
infusion O 
site O 
. O 
We O 
show O 
, O 
for O 
the O 
first O 
time O 
, O 
differences O 
in O 
the O 
minimal O 
doses O 
necessary O 
to O 
enhance O 
rewarding O 
effectiveness O 
and O 
operant O 
responding O 
, O 
in O 
the O 
magnitude O 
of O 
these O 
enhancements O 
as O 
well O 
as O 
in O 
their O 
duration O 
. O 
Conversely O 
, O 
regardless O 
of O 
dose O 
, O 
intra O 
- O 
habenular O 
d-amphetamine B-TRIVIAL 
did O 
not O 
alter O 
rewarding O 
effectiveness O 
or O 
operant O 
rate O 
, O 
highlighting O 
the O 
differential O 
contribution O 
of O 
mesoaccumbens O 
and O 
mesohabenular O 
dopamine B-TRIVIAL 
pathways O 
to O 
intracranial O 
self O 
- O 
stimulation O 
. O 

survive O 
the O 
arsenic B-SYSTEMATIC 
trioxide I-SYSTEMATIC 
treatment O 
by O 
activation O 
of O 
ATM O 
- O 
mediated O 
pathway O 
. O 

trioxide I-SYSTEMATIC 
( O 
ATO B-ABBREVIATION 
) O 
is O 
widely O 
used O 
in O 
tumor O 
treatment O 
, O 
but O 
excessive O 
arsenic B-SYSTEMATIC 
exposure O 
can O 
have O 
adverse O 
effects O 
. O 
We O 
recently O 
found O 
that O 
, O 
in O 
primary O 
osteoblasts O 
, O 
ATO B-ABBREVIATION 
produces O 
oxidative O 
stress O 
and O 
causes O 
DNA O 
tailing O 
, O 
but O 
does O 
not O 
induce O 
apoptosis O 
. O 
We O 
further O 
examined O 
the O 
signaling O 
pathway O 
by O 
which O 
osteoblasts O 
survive O 
ATO B-ABBREVIATION 
treatment O 
, O 
and O 
found O 
that O 
they O 
were O 
arrested O 
at O 
G2 O 
/ O 
M O 
phase O 
of O 
the O 
cell O 
cycle O 
at O 
30h O 
and O 
overrode O 
the O 
G2 O 
/ O 
M O 
boundary O 
at O 
48h O 
. O 
After O 
treatment O 
for O 
30h O 
, O 
there O 
was O 
increased O 
Cdc2 O 
phosphorylation O 
and O 
expression O 
of O 
Wee1 O 
, O 
a O 
Cdc2 O 
kinase O 
, O 
and O 
expression O 
of O 
the O 
cell O 
cycle O 
inhibitor O 
, O 
p21(waf1 O 
/ O 
cip1 O 
) O 
, O 
which O 
interacts O 
with O 
Cdc2 O 
. O 
Furthermore O 
, O 
levels O 
of O 
the O 
phosphatase O 
Cdc25C O 
, O 
which O 
activates O 
Cdc2 O 
, O 
were O 
decreased O 
, O 
while O 
the O 
ratio O 
of O 
its O 
phosphorylated O 
/ O 
inactivated O 
form O 
to O 
the O 
total O 
amount O 
was O 
increased O 
. O 
Moreover O 
, O 
phosphorylation O 
/ O 
activation O 
of O 
the O 
checkpoint O 
kinases O 
Chk1 O 
, O 
Chk2 O 
and O 
p53 O 
levels O 
were O 
increased O 
, O 
as O 
were O 
levels O 
of O 
activated O 
ATM O 
and O 
γ-H2AX O 
. O 
The O 
cell O 
viability O 
was O 
decreased O 
as O 
an O 
ATM O 
inhibitor O 
was O 
added O 
. O 
Additionally O 
, O 
these O 
effects O 
of O 
ATO B-ABBREVIATION 
on O 
γ-H2AX O 
, O 
Chk1 O 
, O 
Chk2 O 
, O 
p53 O 
, O 
and O 
p21(waf1 O 
/ O 
cip1 O 
) O 
were O 
reduced O 
by O 
an O 
ATM O 
inhibitor O 
. O 
These O 
findings O 
suggest O 
that O 
G2 O 
/ O 
M O 
phase O 
arrest O 
of O 
osteoblasts O 
is O 
mediated O 
by O 
Chk1 O 
/ O 
Chk2 O 
activation O 
via O 
an O 
ATM-dependent O 
pathway O 
by O 
which O 
osteoblasts O 
survive O 
. O 

effects O 
of O 
3-hydroxychromone B-SYSTEMATIC 
derivative O 
, O 
a O 
novel O 
small O 
- O 
molecule O 
inhibitor O 
of O 
glycogen O 
synthase O 
kinase-3 O 
. O 

synthase O 
kinase O 
3 O 
( O 
GSK-3 O 
) O 
plays O 
a O 
central O 
role O 
in O 
cellular O 
energy O 
metabolism O 
, O 
and O 
dysregulation O 
of O 
GSK-3 O 
activity O 
is O 
implicated O 
in O 
a O 
variety O 
of O 
metabolic O 
disorders O 
, O 
including O 
obesity O 
, O 
type O 
2 O 
diabetes O 
, O 
and O 
cancer O 
. O 
Hence O 
, O 
GSK-3 O 
has O 
emerged O 
as O 
an O 
attractive O 
target O 
molecule O 
for O 
the O 
treatment O 
of O 
metabolic O 
disorders O 
. O 
Therefore O 
, O 
this O 
research O 
focused O 
on O 
identification O 
and O 
characterization O 
of O 
a O 
novel O 
small O 
- O 
molecule O 
GSK-3 O 
inhibitor O 
. O 
Compound O 
1a O 
, O 
a O 
structure O 
based O 
on O 
3-hydroxychromone B-SYSTEMATIC 
bearing O 
isothiazolidine-1,1-dione B-SYSTEMATIC 
, O 
was O 
identified O 
from O 
chemical O 
library O 
as O 
a O 
highly O 
potent O 
GSK-3 O 
inhibitor O 
. O 
An O 
in O 
vitro O 
kinase O 
assay O 
utilizing O 
a O 
panel O 
of O 
kinases O 
demonstrated O 
that O 
compound O 
1a O 
strongly O 
inhibits O 
GSK-3β O 
. O 
The O 
potential O 
effects O 
of O 
compound O 
1a O 
on O 
the O 
inactivation O 
of O 
GSK-3 O 
were O 
confirmed O 
in O 
human O 
liver O 
HepG2 O 
and O 
human O 
embryonic O 
kidney O 
HEK293 O 
cells O 
. O 
Stabilization O 
of O 
glycogen O 
synthase O 
and O 
β-catenin O 
, O 
which O 
are O 
direct O 
targets O 
of O 
GSK-3 O 
, O 
by O 
compound O 
1a O 
was O 
assessed O 
in O 
comparison O 
with O 
two O 
other O 
GSK-3 O 
inhibitors O 
: O 
LiCl B-FORMULA 
and O 
SB-415286 B-IDENTIFIER 
. O 
In O 
mouse O 
3T3-L1 O 
preadipocytes O 
, O 
compound O 
1a O 
markedly O 
blocked O 
adipocyte O 
differentiation O 
. O 
Consistently O 
, O 
intraperitoneal O 
administration O 
of O 
compound O 
1a O 
to O 
diet O 
- O 
induced O 
obese O 
mice O 
significantly O 
ameliorated O 
their O 
key O 
symptoms O 
such O 
as O 
body O 
weight O 
gain O 
, O 
increased O 
adiposity O 
, O 
dyslipidemia O 
, O 
and O 
hepatic O 
steatosis O 
due O 
to O 
the O 
marked O 
reduction O 
of O 
whole O 
- O 
body O 
lipid O 
level O 
. O 
In O 
vitro O 
and O 
in O 
vivo O 
effects O 
were O 
accompanied O 
by O 
upregulation O 
of O 
β-catenin O 
stability O 
and O 
downregulation O 
of O 
the O 
expression O 
of O 
several O 
critical O 
genes O 
related O 
to O 
lipid O 
metabolism O 
. O 
From O 
these O 
results O 
, O 
it O 
can O 
be O 
concluded O 
that O 
compound O 
1a O 
, O 
a O 
novel O 
small O 
- O 
molecule O 
inhibitor O 
of O 
GSK-3 O 
, O 
has O 
potential O 
as O 
a O 
new O 
class O 
of O 
therapeutic O 
agent O 
for O 
obesity O 
treatment O 
. O 

-biomolecule O 
conjugates O 
: O 
a O 
new O 
approach O 
to O 
create O 
hybrid O 
drugs O 
for O 
cancer O 
therapeutics O 
. O 

polyoxometalate B-FAMILY 
( O 
POM B-ABBREVIATION 
) O 
clusters O 
have O 
demonstrated O 
attractive O 
anticancer O 
properties O 
. O 
Unfortunately O 
, O 
their O 
cytotoxicity O 
upon O 
normal O 
cell O 
is O 
one O 
of O 
fateful O 
side O 
effects O 
obstructing O 
their O 
further O 
clinic O 
application O 
as O 
inorganic O 
drugs O 
. O 
In O 
this O 
communication O 
, O 
we O 
report O 
a O 
new O 
approach O 
to O 
create O 
hybrid O 
drugs O 
potentially O 
for O 
cancer O 
therapeutics O 
. O 
At O 
first O 
, O 
the O 
POM B-ABBREVIATION 
cluster O 
bioconjugates O 
were O 
created O 
by O 
attaching O 
the O 
bioactive O 
ligands O 
on O 
an O 
amine B-SYSTEMATIC 
grafted O 
POM O 
via O 
simple O 
amidation O 
reaction O 
. O 
The O 
cytotoxicity O 
study O 
with O 
breast O 
cancer O 
cells O 
( O 
MCF-7 O 
and O 
MDA-MB-231 O 
) O 
and O 
non-cancerous O 
breast O 
epithelial O 
cell O 
( O 
MCF-10A O 
) O 
showed O 
that O 
rationally O 
selected O 
ligands O 
with O 
cancer O 
- O 
cell O 
targeting O 
ability O 
on O 
POM B-ABBREVIATION 
-biomolecule O 
conjugates O 
can O 
impart O 
enhanced O 
anti-tumor O 
activity O 
and O 
selectivity O 
, O 
thus O 
representing O 
a O 
new O 
concept O 
to O 
develop O 
novel O 
POM B-ABBREVIATION 
-biomolecule O 
hybrid O 
drugs O 
with O 
the O 
potential O 
synergistic O 
effect O 
: O 
increased O 
bioactivity O 
and O 
lower O 
side O 
effect O 
. O 

naphthoquinone B-FAMILY 
derivatives O 
: O 
synthesis O 
and O 
activity O 
against O 
human O 
African O 
trypanosomiasis O 
. O 

series O 
of O 
naphthoquinone B-FAMILY 
derivatives O 
has O 
been O 
synthesized O 
and O 
tested O 
for O 
its O 
biological O 
activity O 
against O 
human O 
African O 
trypanosomiasis O 
. O 
The O 
use O 
of O 
reverse O 
micellar O 
medium O 
not O 
only O 
enhanced O 
the O 
conversion O 
rate O 
, O 
but O 
also O 
showed O 
selectivity O 
towards O 
mono-coupled O 
product O 
in O 
aryl B-FAMILY 
chloride I-FAMILY 
- O 
aniline B-SYSTEMATIC 
coupling O 
reactions O 
. O 
Two O 
derivatives O 
of O 
naphthoquinone B-FAMILY 
( O 
9b O 
and O 
9c O 
) O 
exhibited O 
potent O 
activity O 
against O 
Trypanosoma O 
brucei O 
in O 
vitro O 
with O 
low O 
cytotoxicity O 
. O 

compounds O 
as O 
novel O 
potential O 
affordable O 
antitubercular O 
agents O 
. O 

molecules O 
with O 
oxathiazol-2-one B-SYSTEMATIC 
moiety O 
were O 
recently O 
reported O 
as O 
potent O 
inhibitors O 
of O 
Mycobacterium O 
bovis O 
var O 
. O 
bacilli O 
Calmette-Guérin O 
( O 
BCG O 
) O 
, O 
among O 
which O 
HT1171 B-IDENTIFIER 
was O 
the O 
most O 
potent O 
and O 
selective O 
proteasome O 
inhibitor O 
. O 
Herein O 
we O 
synthesized O 
a O 
series O 
of O 
novel O 
compounds O 
by O 
bioisosteric O 
replacement O 
of O 
the O 
oxathiazol-2-one B-SYSTEMATIC 
ring O 
with O 
3H-1,2,4-dithiazol-3-one B-SYSTEMATIC 
, O 
and O 
also O 
fifteen O 
1,3,4-oxathiazol-2-one B-SYSTEMATIC 
molecules O 
in O 
order O 
for O 
potency O 
comparison O 
and O 
structure O 
- O 
activity O 
relationship O 
elucidation O 
since O 
their O 
antibacterial O 
effects O 
on O 
the O 
virulent O 
strains O 
were O 
not O 
evaluated O 
before O 
. O 
All O 
the O 
compounds O 
were O 
assessed O 
for O 
antitubercular O 
activities O 
on O 
the O 
virulent O 
H37Rv O 
strain O 
by O 
a O 
serial O 
dilution O 
method O 
. O 
Among O 
the O 
tested O 
compounds O 
, O 
3H-1,2,4-dithiazol-3-one B-SYSTEMATIC 
compound O 
4n O 
was O 
found O 
to O 
be O 
the O 
most O 
active O 
with O 
a O 
lowest O 
MIC(90) O 
value O 
of O 
1 O 
μg O 
/ O 
mL O 
. O 
Furthermore O 
, O 
the O 
cytotoxicities O 
of O 
all O 
the O 
compounds O 
against O 
normal O 
human O 
liver O 
cell O 
line O 
L02 O 
were O 
determined O 
by O 
an O 
MTT B-ABBREVIATION 
method O 
. O 
Compound O 
4n O 
displayed O 
a O 
lower O 
inhibitory O 
ratio O 
than O 
HT1171 B-IDENTIFIER 
at O 
the O 
concentration O 
of O 
100 O 
μM O 
, O 
indicating O 
its O 
better O 
safety O 
profile O 
. O 

assessment O 
on O 
trophoblast O 
cells O 
for O 
some O 
environment O 
polluting O 
chemicals O 
and O 
17β-estradiol B-SYSTEMATIC 
. O 

identification O 
of O 
reproductive O 
toxicants O 
is O 
a O 
major O 
scientific O 
challenge O 
for O 
human O 
health O 
. O 
We O 
investigated O 
the O 
effects O 
of O 
a O 
selected O 
group O 
of O 
environmental O 
polluting O 
chemicals O 
mostly O 
provided O 
with O 
estrogenic O 
activity O 
on O 
the O 
human O 
trophoblast O 
cell O 
lines O 
BeWo O 
and O 
HTR-8 O 
/ O 
SVneo O 
. O 
Cells O 
were O 
exposed O 
for O 
24h O 
to O 
various O 
concentrations O 
( O 
from O 
0.1 O 
pM O 
to O 
1 O 
mM O 
) O 
of O 
atrazine B-TRIVIAL 
( O 
ATR B-ABBREVIATION 
) O 
, O 
diethylstilbestrol B-SYSTEMATIC 
( O 
DES B-ABBREVIATION 
) O 
, O 
para-nonylphenol B-SYSTEMATIC 
( O 
p-NP B-ABBREVIATION 
) O 
, O 
resveratrol B-TRIVIAL 
( O 
RES B-ABBREVIATION 
) O 
and O 
17 B-SYSTEMATIC 
β-estradiol I-SYSTEMATIC 
( O 
E2 O 
) O 
and O 
assayed O 
for O 
cell O 
viability O 
and O 
human O 
beta-Chorionic O 
Gonadotropin O 
( O 
β-hCG O 
) O 
secretion O 
. O 
Decrease O 
of O 
cell O 
viability O 
as O 
respect O 
to O 
control O 
, O 
vehicle O 
- O 
treated O 
, O 
cultures O 
was O 
obtained O 
for O 
all O 
chemicals O 
in O 
the O 
concentration O 
range O 
of O 
1 O 
μM-1 O 
mM O 
in O 
both O 
cell O 
types O 
. O 
A O 
parallel O 
decrease O 
of O 
β-hCG O 
secretion O 
was O 
observed O 
in O 
BeWo O 
cells O 
, O 
at O 
1 O 
μM-1 O 
mM O 
concentrations O 
, O 
with O 
the O 
only O 
exception O 
of O 
ATR B-ABBREVIATION 
which O 
caused O 
an O 
increase O 
at O 
concentrations O 
up O 
to O 
1mM O 
. O 
β-hCG O 
release O 
was O 
also O 
unexpectedly O 
inhibited O 
by O 
ATR B-ABBREVIATION 
, O 
DES B-ABBREVIATION 
, O 
p-NP B-ABBREVIATION 
and O 
RES B-ABBREVIATION 
at O 
non-toxic O 
( O 
pM-nM O 
) O 
concentrations O 
. O 
These O 
findings O 
raise O 
concern O 
about O 
the O 
negative O 
, O 
potential O 
effects O 
of O 
various O 
environmental O 
polluting O 
chemicals O 
on O 
pregnancy O 
success O 
and O 
fetal O 
health O 
. O 

and O 
EPR O 
spectra O 
of O 
the O 
species O 
involved O 
in O 
[W10O32]4- B-FORMULA 
photocatalysis O 
. O 
A O 
relativistic O 
DFT O 
investigation O 
. O 

decatungstate O 
anion O 
[W(10)O(32)](4-) B-FORMULA 
is O 
widely O 
used O 
as O 
a O 
photocatalyst O 
in O 
different O 
transformations O 
, O 
during O 
which O 
it O 
undergoes O 
one O 
- O 
electron O 
reduction O 
to O 
[W(10)O(32)](5-) B-FORMULA 
, O 
possibly O 
protonated O 
; O 
the O 
bi O 
- O 
reduced O 
species O 
[W(10)O(32)](6-) B-FORMULA 
is O 
obtained O 
by O 
ensuing O 
disproportionation O 
. O 
Relativistic O 
DFT O 
calculations O 
were O 
used O 
to O 
predict O 
the O 
UV-VIS O 
spectra O 
and O 
EPR O 
parameters O 
of O 
all O 
such O 
species O 
. O 

bortezomib B-TRIVIAL 
: O 
in O 
multiple O 
myeloma O 
. O 

subcutaneous O 
formulation O 
of O 
bortezomib B-TRIVIAL 
is O 
now O 
indicated O 
in O 
the O 
EU O 
and O 
the O 
US O 
for O 
the O 
treatment O 
of O 
patients O 
with O 
multiple O 
myeloma O 
. O 
This O 
article O 
reviews O 
pharmacological O 
, O 
therapeutic O 
efficacy O 
and O 
tolerability O 
data O 
relevant O 
to O 
the O 
utilization O 
of O 
subcutaneous O 
bortezomib B-TRIVIAL 
( O 
Velcade B-TRIVIAL 
( O 
® O 
) O 
) O 
in O 
the O 
treatment O 
of O 
patients O 
with O 
multiple O 
myeloma O 
. O 
In O 
a O 
randomized O 
, O 
nonblind O 
, O 
phase O 
III O 
study O 
, O 
subcutaneous O 
bortezomib B-TRIVIAL 
was O 
noninferior O 
to O 
intravenous O 
bortezomib B-TRIVIAL 
in O 
the O 
treatment O 
of O 
adults O 
with O 
relapsed O 
multiple O 
myeloma O 
, O 
as O 
determined O 
by O 
the O 
overall O 
response O 
rate O 
after O 
four O 
cycles O 
of O 
therapy O 
( O 
primary O 
endpoint O 
) O 
. O 
No O 
significant O 
differences O 
between O 
the O 
subcutaneous O 
and O 
intravenous O 
bortezomib B-TRIVIAL 
formulations O 
were O 
observed O 
in O 
the O 
median O 
time O 
to O 
first O 
response O 
, O 
median O 
progression O 
- O 
free O 
survival O 
, O 
median O 
time O 
to O 
progression O 
and O 
1-year O 
overall O 
survival O 
. O 
Compared O 
with O 
intravenous O 
bortezomib B-TRIVIAL 
, O 
subcutaneous O 
bortezomib B-TRIVIAL 
confers O 
a O 
significant O 
advantage O 
with O 
respect O 
to O 
the O 
incidence O 
of O 
peripheral O 
neuropathy O 
( O 
all O 
grades O 
, O 
grade O 
≥ O 
2 O 
and O 
grade O 
≥ O 
3 O 
) O 
. O 
As O 
a O 
consequence O 
, O 
it O 
provides O 
a O 
new O 
treatment O 
option O 
for O 
patients O 
with O 
multiple O 
myeloma O 
, O 
particularly O 
those O 
with O 
pre O 
- O 
existing O 
neuropathy O 
or O 
at O 
a O 
high O 
risk O 
of O 
developing O 
peripheral O 
neuropathy O 
. O 

demonstrate O 
localized O 
electrodeposition O 
of O 
anisotropic O 
metal O 
nanoobjects O 
, O 
namely O 
Au B-FORMULA 
nanorods O 
( O 
GNR O 
) O 
, O 
on O 
indium B-SYSTEMATIC 
tin I-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
ITO B-ABBREVIATION 
) O 
using O 
scanning O 
electrochemical O 
microscopy O 
( O 
SECM O 
) O 
. O 
A O 
gold O 
microelectrode O 
was O 
the O 
source O 
of O 
the O 
gold O 
ions O 
whereby O 
double O 
pulse O 
chronoamperometry O 
was O 
employed O 
to O 
generate O 
initially O 
Au B-FORMULA 
seeds O 
which O 
were O 
further O 
grown O 
under O 
controlled O 
conditions O 
. O 
The O 
distance O 
between O 
the O 
microelectrode O 
and O 
the O 
ITO B-ABBREVIATION 
surface O 
as O 
well O 
as O 
the O 
different O 
experimental O 
parameters O 
( O 
electrodeposition O 
regime O 
, O 
solution O 
composition O 
and O 
temperature O 
) O 
were O 
optimized O 
to O 
produce O 
faceted O 
gold O 
seeds O 
with O 
the O 
required O 
characteristics O 
( O 
size O 
and O 
distribution O 
) O 
. O 
Colloidal O 
chemical O 
synthesis O 
was O 
successfully O 
exploited O 
for O 
better O 
understanding O 
the O 
role O 
of O 
the O 
surfactant O 
and O 
different O 
additives O 
in O 
breaking O 
the O 
crystallographic O 
symmetry O 
and O 
anisotropic O 
growth O 
of O 
GNR O 
. O 
Experiments O 
performed O 
in O 
a O 
conventional O 
three O 
- O 
electrode O 
cell O 
revealed O 
the O 
most O 
appropriate O 
electrochemical O 
conditions O 
allowing O 
high O 
yield O 
synthesis O 
of O 
nanorods O 
with O 
well O 
- O 
defined O 
shape O 
as O 
well O 
as O 
nanocubes O 
and O 
bipyramids O 
. O 

of O 
long O 
- O 
circulating O 
, O 
backbone O 
degradable O 
HPMA B-ABBREVIATION 
copolymer- O 
doxorubicin B-TRIVIAL 
conjugates O 
and O 
evaluation O 
of O 
molecular O 
- O 
weight O 
- O 
dependent O 
antitumor O 
efficacy O 
. O 

degradable O 
, O 
linear O 
, O 
multiblock O 
N-(2-hydroxypropyl)methacrylamide B-SYSTEMATIC 
( O 
HPMA B-ABBREVIATION 
) O 
copolymer- O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
conjugates O 
are O 
synthesized O 
by O 
reversible O 
addition O 
- O 
fragmentation O 
chain O 
transfer O 
( O 
RAFT O 
) O 
polymerization O 
followed O 
by O 
chain O 
extension O 
via O 
thiol B-FAMILY 
-ene O 
click O 
reaction O 
. O 
The O 
examination O 
of O 
molecular O 
- O 
weight O 
- O 
dependent O 
antitumor O 
activity O 
toward O 
human O 
ovarian O 
A2780 O 
/ O 
AD O 
carcinoma O 
in O 
nude O 
mice O 
reveals O 
enhanced O 
activity O 
of O 
multiblock O 
, O 
second O 
- O 
generation O 
, O 
higher O 
molecular O 
weight O 
conjugates O 
when O 
compared O 
with O 
traditional O 
HPMA B-ABBREVIATION 
copolymer- O 
DOX B-ABBREVIATION 
conjugates O 
. O 
The O 
examination O 
of O 
body O 
weight O 
changes O 
during O 
treatment O 
indicates O 
the O 
absence O 
of O 
non-specific O 
adverse O 
effects O 
. O 

prediction O 
of O 
binary O 
pernitride B-SYSTEMATIC 
MN2 B-FAMILY 
compounds O 
( O 
M= O 
Ca B-FORMULA 
, O 
Sr B-FORMULA 
, O 
Ba B-FORMULA 
, O 
La B-FORMULA 
, O 
and O 
Ti B-FORMULA 
) O 
. O 

- I-FAMILY 
pernitride I-FAMILY 
compounds O 
belong O 
to O 
a O 
class O 
of O 
chemical O 
systems O 
in O 
which O 
both O 
the O 
complex O 
ions O 
and O 
the O 
non O 
- O 
bonding O 
electrons O 
may O 
play O 
roles O 
in O 
the O 
formation O 
of O 
their O 
modified O 
crystalline O 
structures O 
. O 
To O 
investigate O 
this O 
issue O 
, O 
the O 
energy O 
landscapes O 
of O 
pernitrides B-FAMILY 
of O 
metals O 
with O 
different O 
maximum O 
valence O 
( O 
M= O 
Ca B-FORMULA 
, O 
Sr B-FORMULA 
, O 
Ba B-FORMULA 
, O 
La B-FORMULA 
, O 
and O 
Ti B-FORMULA 
) O 
were O 
globally O 
explored O 
on O 
the O 
ab O 
initio O 
level O 
at O 
standard O 
and O 
high O 
pressures O 
, O 
thereby O 
yielding O 
possible O 
(meta)stable O 
modifications O 
in O 
these O 
systems O 
together O 
with O 
information O 
on O 
how O 
the O 
landscape O 
changed O 
as O 
function O 
of O 
the O 
valence O 
of O 
the O 
metal O 
cation O 
. O 
For O 
all O 
of O 
the O 
systems O 
in O 
which O 
no O 
compounds O 
had O 
been O 
synthesized O 
so O 
far O 
, O 
we O 
predicted O 
the O 
existence O 
of O 
kinetically O 
stable O 
modifications O 
that O 
should O 
, O 
in O 
principle O 
, O 
be O 
experimentally O 
accessible O 
. O 
In O 
particular O 
, O 
TiN2 B-FORMULA 
should O 
crystallize O 
in O 
a O 
new O 
structure O 
type O 
, O 
TiN2 B-FORMULA 
-I O 
. O 

pathways O 
of O 
the O 
potent O 
organophosphate B-FAMILY 
CBDP B-ABBREVIATION 
with O 
cholinesterases O 
revealed O 
by O 
X-ray O 
crystallographic O 
snapshots O 
and O 
mass O 
spectrometry O 
. O 

( O 
TOCP B-ABBREVIATION 
) O 
is O 
a O 
common O 
additive O 
in O 
jet O 
engine O 
lubricants O 
and O 
hydraulic O 
fluids O 
suspected O 
to O 
have O 
a O 
role O 
in O 
aerotoxic O 
syndrome O 
in O 
humans O 
. O 
TOCP B-ABBREVIATION 
is O 
metabolized O 
to O 
cresyl B-SYSTEMATIC 
saligenin I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
( O 
CBDP B-ABBREVIATION 
) O 
, O 
a O 
potent O 
irreversible O 
inhibitor O 
of O 
butyrylcholinesterase O 
( O 
BChE O 
) O 
, O 
a O 
natural O 
bioscavenger O 
present O 
in O 
the O 
bloodstream O 
, O 
and O 
acetylcholinesterase O 
( O 
AChE O 
) O 
, O 
the O 
off O 
- O 
switch O 
at O 
cholinergic O 
synapses O 
. O 
Mechanistic O 
details O 
of O 
cholinesterase O 
( O 
ChE O 
) O 
inhibition O 
have O 
, O 
however O 
, O 
remained O 
elusive O 
. O 
Also O 
, O 
the O 
inhibition O 
of O 
AChE O 
by O 
CBDP B-ABBREVIATION 
is O 
unexpected O 
, O 
from O 
a O 
structural O 
standpoint O 
, O 
i.e O 
. O 
, O 
considering O 
the O 
narrowness O 
of O 
AChE O 
active O 
site O 
and O 
the O 
bulkiness O 
of O 
CBDP B-ABBREVIATION 
. O 
In O 
the O 
following O 
, O 
we O 
report O 
on O 
kinetic O 
X-ray O 
crystallography O 
experiments O 
that O 
provided O 
2.7-3.3 O 
Å O 
snapshots O 
of O 
the O 
reaction O 
of O 
CBDP B-ABBREVIATION 
with O 
mouse O 
AChE O 
and O 
human O 
BChE O 
. O 
The O 
series O 
of O 
crystallographic O 
snapshots O 
reveals O 
that O 
AChE O 
and O 
BChE O 
react O 
with O 
the O 
opposite O 
enantiomers O 
and O 
that O 
an O 
induced O 
- O 
fit O 
rearrangement O 
of O 
Phe B-FORMULA 
297 O 
enlarges O 
the O 
active O 
site O 
of O 
AChE O 
upon O 
CBDP B-ABBREVIATION 
binding O 
. O 
Mass O 
spectrometry O 
analysis O 
of O 
aging O 
in O 
either O 
H(2)(16)O B-FORMULA 
or O 
H(2)(18)O B-FORMULA 
furthermore O 
allowed O 
us O 
to O 
identify O 
the O 
inhibition O 
steps O 
, O 
in O 
which O 
water O 
molecules O 
are O 
involved O 
, O 
thus O 
providing O 
insights O 
into O 
the O 
mechanistic O 
details O 
of O 
inhibition O 
. O 
X-ray O 
crystallography O 
and O 
mass O 
spectrometry O 
show O 
the O 
formation O 
of O 
an O 
aged O 
end O 
product O 
formed O 
in O 
both O 
AChE O 
and O 
BChE O 
that O 
cannot O 
be O 
reactivated O 
by O 
current O 
oxime B-SYSTEMATIC 
-based O 
therapeutics O 
. O 
Our O 
study O 
thus O 
shows O 
that O 
only O 
prophylactic O 
and O 
symptomatic O 
treatments O 
are O 
viable O 
to O 
counter O 
the O 
inhibition O 
of O 
AChE O 
and O 
BChE O 
by O 
CBDP B-ABBREVIATION 
. O 

of O 
the O 
40 O 
and O 
42 O 
residue O 
amyloid-β O 
peptides O 
( O 
Aβ40 O 
and O 
Aβ42 O 
) O 
have O 
been O 
implicated O 
in O 
the O 
neuronal O 
damage O 
and O 
impaired O 
cognitive O 
function O 
associated O 
with O 
Alzheimer's O 
disease O 
. O 
However O 
, O 
little O 
is O 
known O 
about O 
the O 
specific O 
mechanisms O 
by O 
which O 
these O 
misfolded O 
species O 
induce O 
such O 
detrimental O 
effects O 
on O 
cells O 
. O 
In O 
this O 
work O 
, O 
we O 
use O 
single O 
- O 
molecule O 
imaging O 
techniques O 
to O 
examine O 
the O 
initial O 
interactions O 
between O 
Aβ O 
monomers O 
and O 
oligomers O 
and O 
the O 
membranes O 
of O 
live O 
cells O 
. O 
This O 
highly O 
sensitive O 
method O 
enables O 
the O 
visualization O 
of O 
individual O 
Aβ O 
species O 
on O 
the O 
cell O 
surface O 
and O 
characterization O 
of O 
their O 
oligomerization O 
state O 
, O 
all O 
at O 
biologically O 
relevant O 
, O 
nanomolar O 
concentrations O 
. O 
The O 
results O 
indicate O 
that O 
oligomers O 
preferentially O 
interact O 
with O 
cell O 
membranes O 
, O 
relative O 
to O 
monomers O 
and O 
that O 
the O 
oligomers O 
become O 
immobilized O 
on O 
the O 
cell O 
surface O 
. O 
Additionally O 
, O 
we O 
observe O 
that O 
the O 
interaction O 
of O 
Aβ O 
species O 
with O 
the O 
cell O 
membrane O 
is O 
inhibited O 
by O 
the O 
presence O 
of O 
ATP B-ABBREVIATION 
-independent O 
molecular O 
chaperones O 
. O 
This O 
study O 
demonstrates O 
the O 
power O 
of O 
this O 
methodology O 
for O 
characterizing O 
the O 
interactions O 
between O 
protein O 
aggregates O 
and O 
the O 
membranes O 
of O 
live O 
neuronal O 
cells O 
at O 
physiologically O 
relevant O 
concentrations O 
and O 
opens O 
the O 
door O 
to O 
quantitative O 
studies O 
of O 
the O 
cellular O 
responses O 
to O 
potentially O 
pathogenic O 
oligomers O 
. O 

hormone I-FAMILY 
levels O 
within O 
reference O 
range O 
are O 
associated O 
with O 
heart O 
rate O 
, O 
cardiac O 
structure O 
and O 
function O 
in O 
middle O 
- O 
aged O 
men O 
and O 
women O 
. O 

Triiodothyronine B-SYSTEMATIC 
( O 
T3 O 
) O 
has O 
many O 
effects O 
on O 
the O 
heart O 
and O 
marked O 
changes O 
in O 
cardiac O 
function O 
and O 
structure O 
occur O 
in O 
patients O 
with O 
( O 
subclinical O 
) O 
thyroid O 
disease O 
. O 
We O 
investigated O 
whether O 
between O 
- O 
subject O 
variation O 
in O 
thyroid B-FAMILY 
hormone I-FAMILY 
levels O 
within O 
the O 
euthyroid O 
range O 
is O 
also O 
associated O 
with O 
heart O 
rate O 
and O 
echocardiographic O 
heart O 
function O 
and O 
structure O 
. O 
Methods O 
Subjects O 
were O 
selected O 
from O 
the O 
Asklepios O 
study O 
( O 
n=2524 O 
) O 
, O 
a O 
population O 
- O 
representative O 
random O 
sample O 
between O 
35 O 
and O 
55 O 
yrs O 
, O 
free O 
from O 
overt O 
cardiovascular O 
disease O 
at O 
baseline O 
. O 
Analyses O 
were O 
restricted O 
to O 
2078 O 
subjects O 
( O 
1013 O 
women O 
and O 
1065 O 
men O 
) O 
, O 
not O 
using O 
antihypertensive O 
or O 
thyroid O 
medication O 
nor O 
having O 
anti-TPO O 
levels O 
above O 
clinical O 
cut O 
- O 
off O 
or O 
TSH O 
levels O 
outside O 
the O 
reference O 
range O 
. O 
All O 
subjects O 
were O 
phenotyped O 
in O 
- O 
depth O 
and O 
underwent O 
comprehensive O 
echocardiography O 
, O 
including O 
diastolic O 
evaluation O 
. O 
Thyroid O 
function O 
parameters O 
were O 
determined O 
by O 
automated O 
electrochemiluminescence O 
. O 
Results O 
Heart O 
rate O 
was O 
robustly O 
positively O 
associated O 
with O 
( O 
quartiles O 
of O 
) O 
(F)T3 O 
, O 
both O 
in O 
subjects O 
with O 
TSH O 
levels O 
within O 
reference O 
( O 
0.27-4.2 O 
µU O 
/ O 
l O 
) O 
as O 
in O 
narrow O 
TSH-range O 
( O 
0.5-2.5 O 
µU O 
/ O 
l O 
) O 
( O 
p≤0.0001 O 
) O 
. O 
(F)T3 O 
was O 
negatively O 
associated O 
with O 
LV O 
( O 
left O 
ventricular O 
) O 
end O 
- O 
diastolic O 
volume O 
but O 
positively O 
with O 
relative O 
wall O 
thickness O 
. O 
TT3 O 
was O 
associated O 
with O 
enhanced O 
ventricular O 
contraction O 
( O 
as O 
assessed O 
by O 
tissue O 
Doppler O 
imaging O 
) O 
. O 
FT4 O 
, O 
FT3 O 
and O 
TT3 O 
were O 
positively O 
associated O 
with O 
late O 
ventricular O 
filling O 
, O 
and O 
TT3 O 
was O 
associated O 
with O 
early O 
ventricular O 
filling O 
. O 
Conclusion O 
We O 
have O 
demonstrated O 
a O 
strong O 
positive O 
association O 
between O 
thyroid B-FAMILY 
hormone I-FAMILY 
levels O 
within O 
the O 
euthyroid O 
range O 
and O 
heart O 
rate O 
, O 
and O 
more O 
subtle O 
effects O 
on O 
cardiac O 
function O 
and O 
structure O 
. O 
More O 
specifically O 
, O 
we O 
suggest O 
smaller O 
LV O 
cavity O 
size O 
( O 
with O 
increased O 
relative O 
wall O 
thickness O 
) O 
, O 
an O 
enhanced O 
atrial O 
and O 
ventricular O 
contraction O 
and O 
LV O 
relaxation O 
with O 
higher O 
circulating O 
thyroid B-FAMILY 
hormones I-FAMILY 
. O 
These O 
results O 
illustrate O 
that O 
variation O 
of O 
thyroid B-FAMILY 
hormone I-FAMILY 
levels O 
even O 
within O 
the O 
reference O 
range O 
exerts O 
effects O 
on O 
the O 
heart O 
. O 

imposed O 
limits O 
of O 
mono- O 
and O 
bilayer O 
graphene B-TRIVIAL 
electronic O 
modification O 
using O 
covalent O 
chemistry O 
. O 

central O 
question O 
in O 
graphene B-TRIVIAL 
chemistry O 
is O 
to O 
what O 
extent O 
chemical O 
modification O 
can O 
control O 
an O 
electronically O 
accessible O 
band O 
gap O 
in O 
monolayer O 
and O 
bilayer O 
graphene B-TRIVIAL 
( O 
MLG O 
and O 
BLG O 
) O 
. O 
Density O 
functional O 
theory O 
predicts O 
gaps O 
in O 
covalently O 
functionalized O 
graphene B-TRIVIAL 
as O 
high O 
as O 
2 O 
eV O 
, O 
while O 
this O 
approach O 
neglects O 
the O 
fact O 
that O 
lattice O 
symmetry O 
breaking O 
occurs O 
over O 
only O 
a O 
prescribed O 
radius O 
of O 
nanometer O 
dimension O 
, O 
which O 
we O 
label O 
the O 
S-region O 
. O 
Therefore O 
, O 
high O 
chemical O 
conversion O 
is O 
central O 
to O 
observing O 
this O 
band O 
gap O 
in O 
transport O 
. O 
We O 
use O 
an O 
electrochemical O 
approach O 
involving O 
phenyl-diazonium B-FAMILY 
salts I-FAMILY 
to O 
systematically O 
probe O 
electronic O 
modification O 
in O 
MLG O 
and O 
BLG O 
with O 
increasing O 
functionalization O 
for O 
the O 
first O 
time O 
, O 
obtaining O 
the O 
highest O 
conversion O 
values O 
to O 
date O 
. O 
We O 
find O 
that O 
both O 
MLG O 
and O 
BLG O 
retain O 
their O 
relatively O 
high O 
conductivity O 
after O 
functionalization O 
even O 
at O 
high O 
conversion O 
, O 
as O 
mobility O 
losses O 
are O 
offset O 
by O 
increases O 
in O 
carrier O 
concentration O 
. O 
For O 
MLG O 
, O 
we O 
find O 
that O 
band O 
gap O 
opening O 
as O 
measured O 
during O 
transport O 
is O 
linearly O 
increased O 
with O 
respect O 
to O 
the O 
I(D) O 
/ O 
I(G) O 
ratio O 
but O 
remains O 
below O 
0.1 O 
meV O 
in O 
magnitude O 
for O 
SiO(2) B-FORMULA 
supported O 
graphene B-TRIVIAL 
. O 
The O 
largest O 
transport O 
band O 
gap O 
obtained O 
in O 
a O 
suspended O 
, O 
highly O 
functionalized O 
( O 
I(D) O 
/ O 
I(G) O 
= O 
4.5 O 
) O 
graphene B-TRIVIAL 
is O 
about O 
1 O 
meV O 
, O 
lower O 
than O 
our O 
theoretical O 
predictions O 
considering O 
the O 
quantum O 
interference O 
effect O 
between O 
two O 
neighboring O 
S-regions O 
and O 
attributed O 
to O 
its O 
population O 
with O 
midgap O 
states O 
. O 
On O 
the O 
other O 
hand O 
, O 
heavily O 
functionalized O 
BLG O 
( O 
I(D) O 
/ O 
I(G) O 
= O 
1.8 O 
) O 
still O 
retains O 
its O 
signature O 
dual O 
- O 
gated O 
band O 
gap O 
opening O 
due O 
to O 
electric O 
- O 
field O 
symmetry O 
breaking O 
. O 
We O 
find O 
a O 
notable O 
asymmetric O 
deflection O 
of O 
the O 
charge O 
neutrality O 
point O 
( O 
CNP O 
) O 
under O 
positive O 
bias O 
which O 
increases O 
the O 
apparent O 
on O 
/ O 
off O 
current O 
ratio O 
by O 
50% O 
, O 
suggesting O 
that O 
synergy O 
between O 
symmetry O 
breaking O 
, O 
disorder O 
, O 
and O 
quantum O 
interference O 
may O 
allow O 
the O 
observation O 
of O 
new O 
transistor O 
phenomena O 
. O 
These O 
important O 
observations O 
set O 
definitive O 
limits O 
on O 
the O 
extent O 
to O 
which O 
chemical O 
modification O 
can O 
control O 
graphene B-TRIVIAL 
electronically O 
. O 

as O 
potential O 
anticancer O 
agents O 
with O 
anti-inflammatory O 
properties O 
. O 

series O 
of O 
novel O 
5-((1-aroyl-1H-indol-3-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-diones B-FAMILY 
( O 
3a-z O 
) O 
have O 
been O 
evaluated O 
for O 
in O 
vitro O 
cytotoxicity O 
against O 
a O 
panel O 
of O 
60 O 
human O 
tumor O 
cell O 
lines O 
. O 
Compound O 
3k O 
exhibited O 
the O 
most O 
potent O 
growth O 
inhibition O 
against O 
melanoma O 
MDA-MB-435 O 
cells O 
( O 
GI(50)=850 O 
nM O 
) O 
, O 
against O 
leukemia O 
SR O 
cancer O 
cells O 
( O 
GI(50)=1.45 O 
μM O 
) O 
, O 
and O 
OVCAR-3 O 
( O 
GI(50)=1.26 O 
μM O 
) O 
ovarian O 
cancer O 
cell O 
lines O 
. O 
The O 
structurally O 
related O 
compound O 
3s O 
had O 
a O 
GI(50) O 
value O 
of O 
1.77 O 
μM O 
against O 
MDA-MB-435 O 
cells O 
. O 
The O 
N B-FORMULA 
- O 
naphthoyl B-SYSTEMATIC 
analogue O 
3t O 
had O 
GI(50) O 
values O 
of O 
1.3 O 
and O 
1.91 O 
μM O 
against O 
HOP-92 O 
non-small O 
cell O 
lung O 
cancer O 
and O 
MDA-MB-435 O 
melanoma O 
cell O 
lines O 
, O 
respectively O 
. O 
The O 
related O 
analogue O 
3w O 
had O 
GI(50) O 
values O 
of O 
1.09 O 
μM O 
against O 
HOP-92 O 
non-small O 
cell O 
lung O 
cancer O 
cell O 
lines O 
. O 
Interestingly O 
, O 
docking O 
of O 
the O 
two O 
active O 
molecules O 
3k O 
and O 
3w O 
into O 
the O 
active O 
site O 
of O 
COX-2 O 
indicates O 
that O 
these O 
compounds O 
are O 
COX-2 O 
ligands O 
with O 
strong O 
hydrophobic O 
and O 
hydrogen B-SYSTEMATIC 
bonding O 
interactions O 
. O 
Thus O 
, O 
compounds O 
3k O 
, O 
3t O 
, O 
3s O 
, O 
and O 
3w O 
constitute O 
a O 
new O 
class O 
of O 
anticancer O 
/ O 
anti-inflammatory O 
agents O 
that O 
may O 
have O 
unique O 
potential O 
for O 
cancer O 
therapy O 
. O 

of O 
cooking O 
and O 
handling O 
conditions O 
on O 
furanic B-FAMILY 
compounds O 
in O 
breaded O 
fish O 
products O 
. O 

study O 
evaluates O 
the O 
influence O 
of O 
cooking O 
and O 
handling O 
conditions O 
on O 
the O 
quantity O 
of O 
furanic B-FAMILY 
compounds O 
( O 
furan B-SYSTEMATIC 
, O 
2-furfural B-SYSTEMATIC 
, O 
furfuryl B-TRIVIAL 
alcohol I-TRIVIAL 
, O 
2-pentylfuran B-SYSTEMATIC 
, O 
5-hydroxymethylfurfural B-SYSTEMATIC 
) O 
in O 
breaded O 
fish O 
products O 
. O 
Oven O 
- O 
baking O 
and O 
reheating O 
in O 
the O 
microwave O 
lead O 
to O 
low O 
furanic B-FAMILY 
compounds O 
formation O 
in O 
comparison O 
with O 
deep O 
- O 
frying O 
. O 
The O 
use O 
of O 
olive O 
oil O 
for O 
deep O 
- O 
frying O 
promoted O 
higher O 
levels O 
of O 
furanic B-FAMILY 
compounds O 
than O 
sunflower O 
oil O 
. O 
The O 
amounts O 
of O 
these O 
compounds O 
diminished O 
as O 
the O 
temperature O 
and O 
time O 
of O 
deep O 
- O 
frying O 
decreased O 
as O 
well O 
as O 
after O 
a O 
delay O 
after O 
deep O 
- O 
frying O 
. O 
Thus O 
, O 
the O 
generation O 
of O 
furanic B-FAMILY 
compounds O 
can O 
be O 
minimized O 
by O 
adjusting O 
the O 
cooking O 
method O 
and O 
conditions O 
, O 
such O 
as O 
using O 
an O 
electric O 
oven O 
, O 
deep O 
- O 
frying O 
in O 
sunflower O 
oil O 
at O 
160°C O 
during O 
4min O 
, O 
or O 
waiting O 
10min O 
after O 
cooking O 
. O 
However O 
, O 
these O 
conditions O 
that O 
reduce O 
furanic B-FAMILY 
compounds O 
levels O 
also O 
reduce O 
the O 
content O 
of O 
volatile O 
compounds O 
related O 
to O 
the O 
aroma O 
and O 
flavour O 
of O 
fried O 
foods O 
. O 
In O 
this O 
sense O 
, O 
new O 
efforts O 
should O 
be O 
done O 
to O 
reduce O 
the O 
formation O 
of O 
furanic B-FAMILY 
compounds O 
without O 
being O 
detrimental O 
to O 
the O 
volatile O 
profile O 
. O 

endocrine O 
disrupting O 
chemical O 
tolylfluanid B-TRIVIAL 
alters O 
adipocyte O 
metabolism O 
via O 
glucocorticoid O 
receptor O 
activation O 
. O 

signaling O 
plays O 
a O 
critical O 
role O 
in O 
regulating O 
energy O 
metabolism O 
. O 
Emerging O 
data O 
implicate O 
environmental O 
endocrine O 
- O 
disrupting O 
chemicals O 
as O 
contributors O 
to O 
the O 
obesity O 
and O 
diabetes O 
epidemics O 
. O 
Previous O 
studies O 
have O 
shown O 
that O 
the O 
phenylsulfamide B-SYSTEMATIC 
fungicide O 
tolylfluanid B-TRIVIAL 
( O 
TF O 
) O 
augments O 
glucocorticoid O 
receptor O 
(GR)-dependent O 
luciferase O 
expression O 
in O 
3T3-L1 O 
preadipocytes O 
while O 
modulating O 
insulin O 
action O 
in O 
primary O 
murine O 
and O 
human O 
adipocytes O 
. O 
Studies O 
were O 
performed O 
to O 
interrogate O 
glucocorticoid O 
signaling O 
in O 
primary O 
adipocytes O 
exposed O 
to O 
TF O 
. O 
TF O 
mimicked O 
the O 
gene O 
transcription O 
profile O 
of O 
the O 
murine O 
glucocorticoid O 
corticosterone B-TRIVIAL 
( O 
Cort B-ABBREVIATION 
) O 
. O 
Cellular O 
fractionation O 
assays O 
demonstrated O 
that O 
TF O 
treatment O 
promoted O 
the O 
activating O 
serine B-TRIVIAL 
phosphorylation O 
of O 
GR O 
, O 
augmenting O 
its O 
cytoplasmic O 
- O 
to O 
- O 
nuclear O 
translocation O 
as O 
well O 
as O 
its O 
enrichment O 
at O 
glucocorticoid O 
response O 
elements O 
on O 
the O 
glucocorticoid O 
- O 
induced O 
leucine B-TRIVIAL 
zipper O 
gene O 
promoter O 
. O 
After O 
acute O 
treatment O 
, O 
Cort B-ABBREVIATION 
or O 
TF O 
promoted O 
insulin O 
receptor O 
substrate-1 O 
( O 
IRS-1 O 
) O 
gene O 
and O 
protein O 
expression O 
. O 
Either O 
treatment O 
also O 
enriched O 
GR O 
binding O 
at O 
an O 
identified O 
glucocorticoid O 
response O 
element O 
in O 
the O 
IRS-1 O 
gene O 
. O 
TF O 
or O 
Cort B-ABBREVIATION 
each O 
increased O 
insulin O 
- O 
stimulated O 
lipogenesis O 
, O 
an O 
effect O 
resulting O 
from O 
increased O 
lipogenic O 
gene O 
expression O 
and O 
enhanced O 
insulin O 
- O 
stimulated O 
dephosphorylation O 
of O 
acetyl-coenzyme B-SYSTEMATIC 
A I-SYSTEMATIC 
carboxylase O 
. O 
The O 
augmentation O 
of O 
insulin O 
- O 
stimulated O 
lipogenesis O 
was O 
mediated O 
through O 
a O 
specific O 
enhancement O 
of O 
Akt O 
phosphorylation O 
at O 
T308 O 
. O 
These O 
findings O 
support O 
modulation O 
of O 
IRS-1 O 
levels O 
as O 
a O 
mechanism O 
for O 
glucocorticoid O 
- O 
mediated O 
changes O 
in O 
insulin O 
action O 
in O 
primary O 
adipocytes O 
. O 
Albeit O 
with O 
less O 
affinity O 
than O 
Cort B-ABBREVIATION 
, O 
in O 
silico O 
analysis O 
suggests O 
that O 
TF O 
can O 
interact O 
with O 
the O 
ligand O 
binding O 
pocket O 
of O 
GR O 
. O 
Collectively O 
, O 
these O 
studies O 
identify O 
TF O 
as O 
a O 
structurally O 
unique O 
environmental O 
glucocorticoid O 
. O 
Glucocorticoid O 
signaling O 
may O 
thus O 
represent O 
a O 
novel O 
pathway O 
by O 
which O 
environmental O 
toxicants O 
promote O 
the O 
development O 
of O 
metabolic O 
diseases O 
. O 

compounds O 
induce O 
cell O 
death O 
and O 
formation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
in O 
cultured O 
cerebellar O 
granule O 
cells O 
. O 

present O 
communication O 
investigates O 
the O 
effects O 
of O 
different O 
perfluoroalkylated O 
compounds O 
( O 
PFCs O 
) O 
on O 
formation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
and O 
cell O 
death O 
in O 
cultured O 
cerebellar O 
granule O 
cells O 
. O 
This O 
allows O 
direct O 
comparison O 
with O 
similar O 
effects O 
found O 
for O 
other O 
environmental O 
contaminants O 
like O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
and O 
brominated O 
flame O 
- O 
retardants O 
. O 
The O 
increase O 
in O 
ROS O 
formation O 
and O 
cell O 
death O 
was O 
assayed O 
using O 
the O 
fluorescent O 
probe O 
2,7-dichlorofluorescin B-SYSTEMATIC 
diacetate I-SYSTEMATIC 
( O 
DCFH-DA B-ABBREVIATION 
) O 
and O 
the O 
trypan B-TRIVIAL 
blue I-TRIVIAL 
exclusion O 
assay O 
. O 
The O 
effects O 
of O 
the O 
PFCs O 
were O 
structure O 
dependent O 
. O 
Cell O 
death O 
was O 
induced O 
at O 
relatively O 
low O 
concentrations O 
by O 
perfluorooctyl B-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
( O 
PFOS B-ABBREVIATION 
) O 
, O 
perfluorooctane B-SYSTEMATIC 
sulfonylamide I-SYSTEMATIC 
( O 
PFOSA B-ABBREVIATION 
) O 
and O 
the O 
fluorotelomer B-FAMILY 
alcohol I-FAMILY 
1H B-SYSTEMATIC 
, I-SYSTEMATIC 
1H I-SYSTEMATIC 
, I-SYSTEMATIC 
2H I-SYSTEMATIC 
, I-SYSTEMATIC 
2H-perfluorodecanol I-SYSTEMATIC 
( O 
FTOH B-ABBREVIATION 
8 I-ABBREVIATION 
: I-ABBREVIATION 
2 I-ABBREVIATION 
) O 
with O 
EC(50)-values O 
of O 
62 O 
± O 
7.6 O 
, O 
13 O 
± O 
1.8 O 
and O 
15 O 
± O 
4.2 O 
μM O 
( O 
mean O 
± O 
SD O 
) O 
respectively O 
. O 
PFOS B-ABBREVIATION 
, O 
perfluorooctanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
PFOA B-ABBREVIATION 
) O 
and O 
PFOSA B-ABBREVIATION 
induced O 
a O 
concentration O 
dependent O 
increase O 
in O 
ROS O 
formation O 
with O 
EC(50)-values O 
of O 
27 O 
± O 
9 O 
, O 
25 O 
± O 
11 O 
and O 
57 O 
± O 
19μM O 
respectively O 
. O 
Reduced O 
cell O 
viability O 
and O 
ROS O 
formation O 
were O 
observed O 
at O 
concentration O 
level O 
close O 
to O 
what O 
is O 
found O 
in O 
serum O 
of O 
occupationally O 
exposed O 
workers O 
. O 
The O 
effect O 
of O 
PFCs O 
on O 
ROS O 
formation O 
and O 
cell O 
viability O 
was O 
compared O 
with O 
other O 
halogenated O 
compounds O 
and O 
future O 
investigations O 
should O 
emphasize O 
effects O 
of O 
mixtures O 
and O 
how O 
physical O 
chemical O 
properties O 
of O 
the O 
compounds O 
influence O 
their O 
toxicity O 
. O 

study O 
of O 
complex O 
heterodimeric O 
peptide O 
ligands O 
has O 
been O 
hampered O 
by O 
a O 
paucity O 
of O 
pharmacological O 
tools O 
. O 
To O 
facilitate O 
such O 
investigations O 
, O 
we O 
have O 
explored O 
the O 
utility O 
of O 
membrane O 
tethered O 
ligands O 
( O 
MTLs O 
) O 
. O 
Feasibility O 
of O 
this O 
recombinant O 
approach O 
was O 
explored O 
with O 
a O 
focus O 
on O 
Drosophila O 
bursicon O 
, O 
a O 
heterodimeric O 
cystine B-TRIVIAL 
-knot O 
protein O 
that O 
activates O 
the O 
G O 
protein O 
- O 
coupled O 
receptor O 
rickets O 
( O 
rk O 
) O 
. O 
Rk O 
/ O 
bursicon O 
signaling O 
is O 
an O 
evolutionarily O 
conserved O 
pathway O 
in O 
insects O 
required O 
for O 
wing O 
expansion O 
, O 
cuticle O 
hardening O 
, O 
and O 
melanization O 
during O 
development O 
. O 
We O 
initially O 
engineered O 
two O 
distinct O 
MTL O 
constructs O 
, O 
each O 
composed O 
of O 
a O 
type O 
II O 
transmembrane O 
domain O 
, O 
a O 
peptide O 
linker O 
, O 
and O 
a O 
C B-FORMULA 
terminal O 
extracellular O 
ligand O 
that O 
corresponded O 
to O 
either O 
the O 
α O 
or O 
β O 
bursicon O 
subunit O 
. O 
Coexpression O 
of O 
the O 
two O 
complementary O 
bursicon O 
MTLs O 
triggered O 
rk O 
- O 
mediated O 
signaling O 
in O 
vitro O 
. O 
We O 
were O 
then O 
able O 
to O 
generate O 
functionally O 
active O 
bursicon O 
MTLs O 
in O 
which O 
the O 
two O 
subunits O 
were O 
fused O 
into O 
a O 
single O 
heterodimeric O 
peptide O 
, O 
oriented O 
as O 
either O 
α-β O 
or O 
β-α O 
. O 
Carboxy B-SYSTEMATIC 
-terminal O 
deletion O 
of O 
32 O 
amino B-FAMILY 
acids I-FAMILY 
in O 
the O 
β-α O 
MTL O 
construct O 
resulted O 
in O 
loss O 
of O 
agonist O 
activity O 
. O 
Coexpression O 
of O 
this O 
construct O 
with O 
rk O 
inhibited O 
receptor O 
- O 
mediated O 
signaling O 
by O 
soluble O 
bursicon O 
. O 
We O 
have O 
thus O 
generated O 
membrane O 
- O 
anchored O 
bursicon O 
constructs O 
that O 
can O 
activate O 
or O 
inhibit O 
rk O 
signaling O 
. O 
These O 
probes O 
can O 
be O 
used O 
in O 
future O 
studies O 
to O 
explore O 
the O 
tissue O 
and O 
/ O 
or O 
developmental O 
stage O 
- O 
dependent O 
effects O 
of O 
bursicon O 
in O 
the O 
genetically O 
tractable O 
Drosophila O 
model O 
organism O 
. O 
In O 
addition O 
, O 
our O 
success O 
in O 
generating O 
functionally O 
diverse O 
bursicon O 
MTLs O 
offers O 
promise O 
that O 
such O 
technology O 
can O 
be O 
broadly O 
applied O 
to O 
other O 
complex O 
ligands O 
, O 
including O 
the O 
family O 
of O 
mammalian O 
cystine O 
- O 
knot O 
proteins O 
. O 

ultraviolet O 
( O 
UV O 
) O 
B O 
exposure O 
causes O 
photokeratitis O 
and O 
induces O 
apoptosis O 
in O 
corneal O 
cells O 
. O 
Geranylgeranylacetone B-TRIVIAL 
( O 
GGA B-ABBREVIATION 
) O 
is O 
an O 
acyclic B-FAMILY 
polyisoprenoid I-FAMILY 
that O 
induces O 
expression O 
of O 
heat O 
shock O 
protein O 
(HSP)70 O 
, O 
a O 
soluble O 
intracellular O 
chaperone O 
protein O 
expressed O 
in O 
various O 
tissues O 
, O 
protecting O 
cells O 
against O 
stress O 
conditions O 
. O 
We O 
examined O 
whether O 
induction O 
of O 
HSP70 O 
has O 
therapeutic O 
effects O 
on O 
UV-photokeratitis O 
in O 
mice O 
. O 
C57 O 
BL O 
/ O 
6 O 
mice O 
were O 
divided O 
into O 
four O 
groups O 
, O 
GGA B-ABBREVIATION 
-treated O 
( O 
500 O 
mg O 
/ O 
kg O 
/ O 
mouse O 
) O 
and O 
UVB-exposed O 
( O 
400 O 
mJ O 
/ O 
cm2 O 
) O 
, O 
GGA B-ABBREVIATION 
-untreated O 
UVB-exposed O 
( O 
400 O 
mJ O 
/ O 
cm2 O 
) O 
, O 
GGA B-ABBREVIATION 
-treated O 
( O 
500 O 
mg O 
/ O 
kg O 
/ O 
mouse O 
) O 
but O 
not O 
exposed O 
and O 
naive O 
controls O 
. O 
Eyeballs O 
were O 
collected O 
24 O 
h O 
after O 
irradiation O 
, O 
and O 
corneas O 
were O 
stained O 
with O 
hematoxylin B-TRIVIAL 
and O 
eosin B-FAMILY 
( O 
H&amp;E O 
) O 
and O 
terminal O 
deoxynucleotidyl O 
transferase O 
dUTP B-ABBREVIATION 
nick O 
end O 
labeling O 
( O 
TUNEL O 
) O 
. O 
HSP70 O 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
production O 
, O 
nuclear O 
factor O 
kappa-light O 
- O 
chain O 
- O 
enhancer O 
of O 
activated O 
B O 
cells O 
( O 
NF-κB O 
) O 
and O 
protein O 
kinase O 
B O 
( O 
Akt O 
) O 
expression O 
were O 
also O 
evaluated O 
. O 
Irradiated O 
corneal O 
epithelium O 
was O 
significantly O 
thicker O 
in O 
the O 
eyes O 
of O 
mice O 
treated O 
with O 
GGA B-ABBREVIATION 
compared O 
with O 
those O 
given O 
the O 
vehicle O 
alone O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
Significantly O 
fewer O 
TUNEL-positive O 
cells O 
were O 
observed O 
in O 
the O 
eyes O 
of O 
GGA B-ABBREVIATION 
-treated O 
mice O 
than O 
controls O 
after O 
irradiation O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
Corneal O 
HSP70 O 
levels O 
were O 
significantly O 
elevated O 
in O 
corneas O 
of O 
mice O 
treated O 
with O 
GGA B-ABBREVIATION 
( O 
p O 
< O 
0.05 O 
) O 
. O 
ROS O 
signal O 
was O 
not O 
affected O 
by O 
GGA B-ABBREVIATION 
. O 
NF-κB O 
activation O 
was O 
reduced O 
but O 
phospho-( O 
Ser B-FORMULA 
/ O 
Ther B-FORMULA 
) O 
Akt O 
substrate O 
expression O 
was O 
increased O 
in O 
corneas O 
after O 
irradiation O 
when O 
treated O 
with O 
GGA B-ABBREVIATION 
. O 
GGA B-ABBREVIATION 
-treatment O 
induced O 
HSP70 O 
expression O 
and O 
ameliorated O 
UV-induced O 
corneal O 
damage O 
through O 
the O 
reduced O 
NF-κB O 
activation O 
and O 
possibly O 
increased O 
Akt O 
phosphorilation O 
. O 

crystallography O 
of O 
α-poly(L-lactide) B-FAMILY 
. O 

complementary O 
approach O 
that O 
combines O 
NMR O 
measurements O 
, O 
analysis O 
of O 
X-ray O 
and O 
neutron O 
powder O 
diffraction O 
data O 
and O 
advanced O 
quantum O 
mechanical O 
calculations O 
was O 
employed O 
to O 
study O 
the O 
α-polymorph O 
of O 
L-polylactide B-FAMILY 
. O 
Such O 
a O 
strategy O 
, O 
which O 
is O 
known O 
as O 
NMR O 
crystallography O 
, O 
to O 
the O 
best O 
of O 
our O 
knowledge O 
, O 
is O 
used O 
here O 
for O 
the O 
first O 
time O 
for O 
the O 
fine O 
refinement O 
of O 
the O 
crystal O 
structure O 
of O 
a O 
synthetic O 
polymer O 
. O 
The O 
GIPAW O 
method O 
was O 
used O 
to O 
compute O 
the O 
NMR O 
shielding O 
parameters O 
for O 
the O 
different O 
models O 
, O 
which O 
included O 
the O 
α-PLLA B-ABBREVIATION 
structure O 
obtained O 
by O 
2-dimensional O 
wide-angle O 
X-ray O 
diffraction O 
( O 
WAXD O 
) O 
at O 
-150 O 
°C O 
( O 
model O 
M1 O 
) O 
and O 
at O 
25 O 
°C O 
( O 
model O 
M2 O 
) O 
, O 
neutron O 
diffraction O 
( O 
WAND O 
) O 
measurements O 
( O 
model O 
M3 O 
) O 
and O 
the O 
fully O 
optimized O 
geometry O 
of O 
the O 
PLLA O 
chains O 
in O 
the O 
unit O 
cell O 
with O 
defined O 
size O 
( O 
model O 
M4 O 
) O 
. O 
The O 
influence O 
of O 
changes O 
in O 
the O 
chain O 
conformation O 
on O 
the O 
(13)C B-FORMULA 
σ O 
(ii) O 
NMR O 
shielding O 
parameters O 
is O 
shown O 
. O 
The O 
correlation O 
between O 
the O 
σ O 
(ii) O 
and O 
δ O 
(ii) O 
values O 
for O 
the O 
M1-M4 O 
models O 
revealed O 
that O 
the O 
M4 O 
model O 
provided O 
the O 
best O 
fit O 
. O 
Moreover O 
, O 
a O 
comparison O 
of O 
the O 
experimental O 
(13)C B-FORMULA 
NMR O 
spectra O 
with O 
the O 
spectra O 
calculated O 
using O 
the O 
M1-M4 O 
models O 
strongly O 
supports O 
the O 
data O 
for O 
the O 
M4 O 
model O 
. O 
The O 
GIPAW O 
method O 
, O 
via O 
verification O 
using O 
NMR O 
measurements O 
, O 
was O 
shown O 
to O 
be O 
capable O 
of O 
the O 
fine O 
refinement O 
of O 
the O 
crystal O 
structures O 
of O 
polymers O 
when O 
coarse O 
X-ray O 
diffraction O 
data O 
for O 
powdered O 
samples O 
are O 
available O 
. O 

imaging O 
of O 
small O 
aluminum B-SYSTEMATIC 
clusters O 
: O 
quantifying O 
s-p O 
hybridization O 
. O 

imaging O 
experiments O 
and O 
detailed O 
calculations O 
are O 
conducted O 
on O 
Al(n)(-) B-FAMILY 
clusters O 
( O 
n O 
= O 
3-6 O 
) O 
and O 
a O 
calibration O 
method O 
is O 
developed O 
for O 
connecting O 
experimental O 
observations O 
of O 
photoelectron O 
angular O 
distributions O 
to O 
theoretical O 
predictions O 
. O 
It O 
is O 
shown O 
that O 
this O 
method O 
can O 
be O 
used O 
to O 
quantify O 
the O 
degree O 
to O 
which O 
the O 
molecular O 
orbitals O 
are O 
built O 
from O 
s- O 
or O 
p- O 
like O 
atomic O 
orbitals O 
. O 
The O 
highest O 
occupied O 
molecular O 
orbitals O 
of O 
these O 
small O 
aluminum B-SYSTEMATIC 
clusters O 
are O 
found O 
to O 
contain O 
varying O 
degrees O 
of O 
s-p O 
mixing O 
, O 
with O 
Al(3)(-) B-FORMULA 
containing O 
the O 
" O 
most O 
hybridized O 
" O 
orbital O 
and O 
Al(4)(-) B-FORMULA 
containing O 
the O 
" O 
least O 
hybridized O 
" O 
orbital O 
. O 
It O 
is O 
shown O 
experimentally O 
that O 
s-p O 
hybridization O 
is O 
already O 
present O 
for O 
the O 
trimer O 
species O 
and O 
, O 
similar O 
to O 
other O 
properties O 
of O 
small O 
metal O 
clusters O 
, O 
oscillates O 
with O 
cluster O 
size O 
. O 

" O 
clickable O 
" O 
MTX B-ABBREVIATION 
reagent O 
as O 
a O 
practical O 
tool O 
for O 
profiling O 
small O 
- O 
molecule O 
- O 
intracellular O 
target O 
interactions O 
via O 
MASPIT O 
. O 

present O 
a O 
scalable O 
synthesis O 
of O 
a O 
versatile O 
MTX B-ABBREVIATION 
reagent O 
with O 
an O 
azide B-SYSTEMATIC 
ligation O 
handle O 
that O 
allows O 
rapid O 
γ-selective O 
conjugation O 
to O 
yield O 
MTX B-ABBREVIATION 
fusion O 
compounds O 
( O 
MFCs O 
) O 
appropriate O 
for O 
MASPIT O 
, O 
a O 
three O 
- O 
hybrid O 
system O 
that O 
enables O 
the O 
identification O 
of O 
mammalian O 
cytosolic O 
proteins O 
that O 
interact O 
with O 
a O 
small O 
molecule O 
of O 
interest O 
. O 
We O 
selected O 
three O 
structurally O 
diverse O 
pharmacologically O 
active O 
compounds O 
( O 
tamoxifen B-TRIVIAL 
, O 
reversine B-TRIVIAL 
, O 
and O 
FK506 B-IDENTIFIER 
) O 
as O 
model O 
baits O 
. O 
After O 
acetylene B-SYSTEMATIC 
functionalization O 
of O 
these O 
baits O 
, O 
MFCs O 
were O 
synthesized O 
via O 
a O 
CuAAC O 
reaction O 
, O 
demonstrating O 
the O 
general O 
applicability O 
of O 
the O 
MTX B-ABBREVIATION 
reagent O 
. O 
In O 
analytical O 
mode O 
, O 
MASPIT O 
was O 
able O 
to O 
give O 
concentration O 
- O 
dependent O 
reporter O 
signals O 
for O 
the O 
established O 
target O 
proteins O 
. O 
Furthermore O 
, O 
we O 
demonstrate O 
that O 
the O 
sensitivity O 
obtained O 
with O 
the O 
new O 
MTX B-ABBREVIATION 
reagent O 
was O 
significantly O 
stronger O 
than O 
that O 
of O 
a O 
previously O 
used O 
non-regiomeric O 
conjugate O 
mixture O 
. O 
Finally O 
, O 
the O 
FK506 B-IDENTIFIER 
MFC O 
was O 
explored O 
in O 
a O 
cellular O 
array O 
screen O 
for O 
targets O 
of O 
FK506 B-IDENTIFIER 
. O 
Out O 
of O 
a O 
pilot O 
collection O 
of O 
nearly O 
2000 O 
full O 
- O 
length O 
human O 
ORF O 
preys O 
, O 
FKBP12 O 
, O 
the O 
established O 
target O 
of O 
FK506 B-IDENTIFIER 
, O 
emerged O 
as O 
the O 
prey O 
protein O 
that O 
gave O 
the O 
highest O 
increase O 
in O 
luciferase O 
activity O 
. O 
This O 
indicates O 
that O 
our O 
newly O 
developed O 
synthetic O 
strategy O 
for O 
the O 
straightforward O 
generation O 
of O 
MFCs O 
is O 
a O 
promising O 
asset O 
to O 
uncover O 
new O 
intracellular O 
targets O 
using O 
MASPIT O 
cellular O 
array O 
screening O 
. O 

role O 
of O 
silver B-SYSTEMATIC 
and O 
vanadium B-SYSTEMATIC 
release O 
in O 
the O 
toxicity O 
of O 
silver B-SYSTEMATIC 
vanadate I-SYSTEMATIC 
nanowires O 
toward O 
Daphnia O 
similis O 
. O 

are O 
used O 
in O 
a O 
wide O 
spectrum O 
of O 
applications O 
, O 
including O 
nanowires O 
that O 
are O 
objects O 
with O 
at O 
least O 
one O 
of O 
its O 
dimensions O 
in O 
the O 
range O 
of O 
1 O 
to O 
100 O 
nm O 
. O 
Recently O 
, O 
a O 
new O 
type O 
of O 
silver B-SYSTEMATIC 
vanadate I-SYSTEMATIC 
nanowire O 
decorated O 
with O 
silver B-SYSTEMATIC 
nanoparticles O 
( O 
SVSN-LQES1 O 
) O 
with O 
promising O 
antimicrobial O 
activity O 
against O 
different O 
pathogenic O 
bacteria O 
was O 
described O 
. O 
The O 
objective O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
the O 
role O 
of O 
silver B-SYSTEMATIC 
and O 
vanadium B-SYSTEMATIC 
release O 
in O 
the O 
acute O 
toxicity O 
of O 
this O 
material O 
using O 
Daphnia O 
similis O 
. O 
To O 
verify O 
the O 
effect O 
of O 
the O 
presence O 
of O 
the O 
nanowires O 
in O 
the O 
test O 
solution O 
, O 
tests O 
were O 
performed O 
before O 
and O 
after O 
filtration O 
. O 
Total O 
silver B-SYSTEMATIC 
release O 
to O 
the O 
testing O 
media O 
was O 
determined O 
using O 
the O 
method O 
of O 
inductively O 
coupled O 
plasma O 
atomic O 
emission O 
spectroscopy O 
( O 
ICP-AES O 
) O 
. O 
Silver B-SYSTEMATIC 
vanadate I-SYSTEMATIC 
nanowires O 
decorated O 
with O 
silver B-SYSTEMATIC 
nanoparticles O 
( O 
SVSN-LQES1 O 
) O 
are O 
acutely O 
toxic O 
to O 
D O 
. O 
similis O 
. O 
The O 
release O 
of O 
silver B-SYSTEMATIC 
from O 
the O 
nanomaterial O 
trapped O 
in O 
the O 
gut O 
along O 
with O 
the O 
silver B-SYSTEMATIC 
released O 
to O 
the O 
test O 
media O 
seems O 
to O 
be O 
responsible O 
for O 
the O 
observed O 
toxicity O 
. O 
Although O 
toxic O 
to O 
Daphnia O 
, O 
vanadium B-SYSTEMATIC 
does O 
not O 
contribute O 
to O 
the O 
toxicity O 
of O 
SVSN-LQES1 O 
. O 
The O 
observed O 
increase O 
in O 
lipid O 
droplets O 
appears O 
to O 
be O 
related O 
to O 
the O 
exposure O 
of O 
the O 
organisms O 
to O 
the O 
nanomaterials O 
, O 
but O 
the O 
significance O 
of O 
this O 
response O 
needs O 
further O 
investigation O 
. O 

stressors O 
promote O 
metabolic O 
disturbances O 
, O 
including O 
obesity O 
and O 
metabolic O 
syndrome O 
. O 
Ghrelin O 
, O 
a O 
peptide O 
that O 
promotes O 
appetite O 
and O 
the O 
accumulation O 
of O 
adipose O 
tissue O 
, O 
is O 
also O 
secreted O 
in O 
response O 
to O 
stressors O 
to O 
protect O 
the O 
brain O 
and O 
peripheral O 
tissues O 
from O 
the O 
effects O 
of O 
these O 
stressors O 
. O 
Here O 
we O 
demonstrate O 
that O 
elevated O 
ghrelin O 
levels O 
produced O 
by O 
chronic O 
exposure O 
to O 
social O 
stress O 
are O 
associated O 
with O 
increased O 
caloric O 
intake O 
and O 
body O 
weight O 
gain O 
in O 
male O 
C57BL O 
mice O 
. O 
In O 
contrast O 
, O 
stressed O 
mice O 
lacking O 
ghrelin O 
receptors O 
( O 
GHSR O 
KO O 
mice O 
) O 
or O 
C57BL O 
mice O 
receiving O 
chronic O 
intracerebroventricular O 
delivery O 
of O 
the O 
ghrelin O 
receptor O 
antagonist O 
[ O 
d- O 
Lys B-FORMULA 
(3)]-GHRP-6 O 
show O 
attenuated O 
weight O 
gain O 
and O 
feeding O 
responses O 
under O 
the O 
same O 
social O 
stress O 
paradigm O 
. O 
Interestingly O 
, O 
stressed O 
GHSR O 
KO O 
mice O 
showed O 
depleted O 
sc O 
and O 
intrascapular O 
brown O 
fat O 
depots O 
, O 
whereas O 
stressed O 
young O 
wild O 
- O 
type O 
mice O 
did O 
not O 
. O 
In O 
old O 
wild O 
- O 
type O 
mice O 
, O 
chronic O 
social O 
defeat O 
increased O 
visceral O 
and O 
intrascapular O 
brown O 
fat O 
depots O 
in O 
association O 
with O 
increases O 
in O 
obesity O 
markers O 
like O 
hyperleptinemia O 
and O 
hyperinsulinemia O 
along O 
with O 
increased O 
hypothalamic O 
expression O 
of O 
neuropeptide O 
Y O 
and O 
Agouti O 
related O 
peptide O 
. O 
Importantly O 
, O 
the O 
elevated O 
expression O 
of O 
these O 
peptides O 
persisted O 
least O 
for O 
2 O 
weeks O 
after O 
cessation O 
of O 
the O 
stressor O 
regimen O 
. O 
In O 
contrast O 
, O 
old O 
GHSR O 
KO O 
mice O 
did O 
not O 
show O 
these O 
alterations O 
after O 
chronic O 
social O 
defeat O 
. O 
These O 
results O 
suggest O 
that O 
ghrelin O 
plays O 
an O 
important O 
role O 
in O 
the O 
metabolic O 
adaptations O 
necessary O 
to O 
meet O 
the O 
energetic O 
demands O 
posed O 
by O 
stressors O 
, O 
but O 
chronic O 
exposure O 
to O 
stress O 
- O 
induced O 
ghrelin O 
elevations O 
ultimately O 
could O 
lead O 
to O 
long O 
lasting O 
metabolic O 
dysfunctions O 
. O 

composition O 
of O 
55 O 
samples O 
of O 
essential O 
oil O 
isolated O 
from O 
the O 
aerial O 
parts O 
of O 
wild O 
growing O 
Myrtus O 
communis O 
L O 
. O 
harvested O 
in O 
16 O 
locations O 
from O 
East O 
to O 
West O 
Algeria O 
were O 
investigated O 
by O 
GC O 
( O 
determination O 
of O 
retention O 
indices O 
) O 
and O 
( B-FORMULA 
13 I-FORMULA 
) I-FORMULA 
C I-FORMULA 
-NMR O 
analyses O 
. O 
The O 
essential O 
oils O 
consisted O 
mainly O 
of O 
monoterpenes B-FAMILY 
, O 
α-pinene B-TRIVIAL 
( O 
27.4-59.2% O 
) O 
and O 
1,8-cineole B-SYSTEMATIC 
( O 
6.1-34.3% O 
) O 
being O 
the O 
major O 
components O 
. O 
They O 
were O 
also O 
characterized O 
by O 
the O 
absence O 
of O 
myrtenyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
. O 
The O 
compositions O 
of O 
the O 
55 O 
oils O 
were O 
submitted O 
to O 
k-means O 
partitioning O 
and O 
principal O 
component O 
analysis O 
, O 
which O 
allowed O 
the O 
distinction O 
of O 
two O 
groups O 
within O 
the O 
oil O 
samples O 
, O 
which O 
could O 
be O 
subdivided O 
into O 
two O 
subgroups O 
each O 
. O 
Groups O 
I O 
( O 
78% O 
of O 
the O 
samples O 
) O 
and O 
II O 
were O 
differentiated O 
on O 
the O 
basis O 
of O 
the O 
contents O 
of O 
α-pinene B-TRIVIAL 
, O 
linalool B-TRIVIAL 
, O 
and O 
linalyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
. O 
Subgroups O 
IA O 
and O 
IB O 
could O 
be O 
distinguished O 
by O 
their O 
contents O 
of O 
α-pinene B-TRIVIAL 
and O 
1,8-cineole B-SYSTEMATIC 
. O 
Subgroups O 
IIA O 
and O 
IIB O 
differed O 
substantially O 
in O 
their O 
contents O 
of O 
1,8-cineole B-SYSTEMATIC 
and O 
limonene B-TRIVIAL 
. O 
All O 
the O 
samples O 
contained O 
3,3,5,5,8,8-hexamethyl-7-oxabicyclo[4.3.0]non-1(6)-ene-2,4-dione B-SYSTEMATIC 
( O 
up O 
to O 
4.9% O 
) O 
. O 

of O 
dietary O 
methylmercury B-SYSTEMATIC 
and O 
effects O 
on O 
growth O 
and O 
survival O 
in O 
two O 
estuarine O 
forage O 
fish O 
: O 
Cyprinodon O 
variegatus O 
and O 
Menidia O 
beryllina O 
. O 

methylmercury B-SYSTEMATIC 
( O 
MeHg B-FORMULA 
) O 
uptake O 
by O 
fish O 
in O 
relation O 
to O 
life O 
stage O 
, O 
species O 
, O 
and O 
level O 
of O 
exposure O 
is O 
poorly O 
understood O 
in O 
lower O 
trophic O 
levels O 
, O 
particularly O 
in O 
estuarine O 
species O 
. O 
The O 
authors O 
compared O 
accumulation O 
of O 
dietary O 
MeHg B-FORMULA 
as O 
well O 
as O 
sensitivity O 
( O 
survival O 
and O 
growth O 
) O 
to O 
dietary O 
MeHg B-FORMULA 
exposure O 
in O 
two O 
species O 
of O 
estuarine O 
forage O 
fish O 
, O 
Cyprinodon O 
variegatus O 
and O 
Menidia O 
beryllina O 
. O 
Fish O 
were O 
fed O 
one O 
of O 
five O 
dietary O 
MeHg B-FORMULA 
concentrations O 
( O 
ranging O 
from O 
0.04 O 
to O 
14 O 
µg O 
/ O 
g O 
dry O 
wt O 
) O 
over O 
a O 
period O 
of O 
70 O 
d O 
. O 
Growth O 
rate O 
and O 
the O 
level O 
of O 
dietary O 
exposure O 
influenced O 
MeHg B-FORMULA 
tissue O 
concentrations O 
in O 
both O 
species O 
. O 
Mercury B-SYSTEMATIC 
in O 
the O 
diet O 
exhibited O 
a O 
strong O 
linear O 
relationship O 
with O 
fish O 
Hg B-FORMULA 
tissue O 
concentrations O 
. O 
Additionally O 
, O 
the O 
authors O 
found O 
that O 
M O 
. O 
beryllina O 
was O 
more O 
sensitive O 
to O 
dietary O 
MeHg B-FORMULA 
exposure O 
than O 
C O 
. O 
variegatus O 
. O 
Both O 
species O 
showed O 
some O 
decreases O 
in O 
growth O 
related O 
to O 
MeHg B-FORMULA 
exposure O 
, O 
although O 
these O 
patterns O 
were O 
not O 
consistent O 
among O 
treatments O 
. O 
Overall O 
, O 
C O 
. O 
variegatus O 
and O 
M O 
. O 
beryllina O 
were O 
found O 
to O 
have O 
a O 
high O 
tolerance O 
for O 
dietary O 
MeHg B-FORMULA 
exposure O 
. O 
If O 
fish O 
occupying O 
low O 
trophic O 
levels O 
are O 
capable O 
of O 
surviving O 
with O 
high O 
Hg B-FORMULA 
body O 
burdens O 
, O 
this O 
tolerance O 
has O 
important O 
implications O 
for O 
Hg B-FORMULA 
exposure O 
of O 
organisms O 
occupying O 
higher O 
trophic O 
levels O 
. O 

VII-activating O 
protease O 
( O 
FSAP O 
) O 
is O 
a O 
circulating O 
protease O 
involved O 
in O 
the O 
pathogenesis O 
of O 
atherosclerosis O 
, O 
calcification O 
, O 
and O 
fibrotic O 
processes O 
. O 
To O 
understand O 
how O 
FSAP O 
controls O 
the O 
balance O 
of O 
local O 
growth O 
factors O 
, O 
we O 
have O 
investigated O 
its O 
effect O 
on O 
the O 
regulation O 
of O 
bone O 
morphogenetic O 
proteins O 
( O 
BMPs O 
) O 
. O 
BMP-2 O 
is O 
produced O 
as O 
a O 
large O 
pro O 
- O 
form O 
and O 
secreted O 
as O 
a O 
mature O 
heparin O 
- O 
binding O 
growth O 
factor O 
after O 
intracellular O 
processing O 
by O 
pro O 
- O 
protein O 
convertases O 
( O 
PCs O 
) O 
. O 
In O 
this O 
study O 
, O 
we O 
discovered O 
that O 
FSAP O 
enhances O 
the O 
biological O 
activity O 
of O 
mature O 
BMP-2 O 
as O 
well O 
as O 
its O 
pro O 
- O 
form O 
, O 
as O 
shown O 
by O 
osteogenic O 
differentiation O 
of O 
C2C12 O 
myoblasts O 
. O 
These O 
findings O 
were O 
complemented O 
by O 
knockdown O 
of O 
FSAP O 
in O 
hepatocytes O 
, O 
which O 
revealed O 
BMP-2 O 
processing O 
by O 
endogenous O 
FSAP O 
. O 
N B-FORMULA 
-terminal O 
sequencing O 
indicated O 
that O 
pro-BMP-2 O 
was O 
cleaved O 
by O 
FSAP O 
at O 
the O 
canonical O 
PC O 
cleavage O 
site O 
, O 
giving O 
rise O 
to O 
mature O 
BMP-2 O 
( O 
Arg B-FORMULA 
(282)↓ O 
Gln B-FORMULA 
( O 
283 O 
) O 
) O 
, O 
as O 
well O 
as O 
in O 
the O 
N B-FORMULA 
-terminal O 
heparin O 
binding O 
region O 
of O 
mature O 
BMP-2 O 
, O 
generating O 
a O 
truncated O 
mature O 
BMP-2 O 
peptide O 
( O 
Arg B-FORMULA 
(289)↓ O 
Lys B-FORMULA 
( O 
290 O 
) O 
) O 
. O 
Similarly O 
, O 
mature O 
BMP-2 O 
was O 
also O 
cleaved O 
to O 
a O 
truncated O 
peptide O 
within O 
its O 
N B-FORMULA 
-terminal O 
region O 
( O 
Arg B-FORMULA 
(289)↓ O 
Lys B-FORMULA 
( O 
290 O 
) O 
) O 
. O 
Plasmin O 
exhibited O 
a O 
similar O 
activity O 
, O 
but O 
it O 
was O 
weaker O 
compared O 
with O 
FSAP O 
. O 
Thrombin O 
, O 
Factor O 
VIIa O 
, O 
Factor O 
Xa O 
, O 
and O 
activated O 
protein O 
C O 
were O 
not O 
effective O 
. O 
These O 
results O 
were O 
further O 
supported O 
by O 
the O 
observation O 
that O 
the O 
mutation O 
of O 
the O 
heparin O 
binding O 
region O 
of O 
BMP-2 O 
inhibited O 
the O 
processing O 
by O 
FSAP O 
but O 
not O 
by O 
PC O 
. O 
Thus O 
, O 
the O 
proteolysis O 
and O 
activation O 
of O 
pro-BMP-2 O 
and O 
mature O 
BMP-2 O 
by O 
FSAP O 
can O 
regulate O 
cell O 
differentiation O 
and O 
calcification O 
in O 
vasculature O 
and O 
may O 
explain O 
why O 
polymorphisms O 
in O 
the O 
gene O 
encoding O 
for O 
FSAP O 
are O 
related O 
to O 
vascular O 
diseases O 
. O 

of O 
doping O 
on O 
the O 
magnetostructural O 
ordered O 
phase O 
of O 
iron B-FAMILY 
arsenides I-FAMILY 
: O 
a O 
comparative O 
study O 
of O 
the O 
resistivity O 
anisotropy O 
in O 
doped O 
BaFe2As2 B-FORMULA 
with O 
doping O 
into O 
three O 
different O 
sites O 
. O 

unravel O 
the O 
role O 
of O 
doping O 
in O 
iron B-SYSTEMATIC 
-based O 
superconductors O 
, O 
we O 
investigated O 
the O 
in O 
- O 
plane O 
resistivity O 
of O 
BaFe(2)As(2) B-FORMULA 
doped O 
at O 
one O 
of O 
the O 
three O 
different O 
lattice O 
sites O 
, O 
Ba(Fe(1-x)Co(x))(2)As(2) B-FAMILY 
, O 
BaFe(2)(As(1-x)P(x))(2) B-FAMILY 
, O 
and O 
Ba(1-x)K(x)Fe(2)As(2) B-FAMILY 
, O 
focusing O 
on O 
the O 
doping O 
effect O 
in O 
the O 
low O 
- O 
temperature O 
antiferromagnetic O 
/ O 
orthorhombic O 
( O 
AFO O 
) O 
phase O 
. O 
A O 
major O 
role O 
of O 
doping O 
in O 
the O 
high O 
- O 
temperature O 
paramagnetic O 
/ O 
tetragonal O 
( O 
PT O 
) O 
phase O 
is O 
known O 
to O 
change O 
the O 
Fermi O 
surface O 
by O 
supplying O 
charge O 
carriers O 
or O 
exerting O 
chemical O 
pressure O 
. O 
In O 
the O 
AFO O 
phase O 
, O 
we O 
found O 
a O 
clear O 
correlation O 
between O 
the O 
magnitude O 
of O 
the O 
residual O 
resistivity O 
and O 
the O 
resistivity O 
anisotropy O 
. O 
This O 
indicates O 
that O 
the O 
resistivity O 
anisotropy O 
originates O 
from O 
anisotropic O 
impurity O 
scattering O 
due O 
to O 
dopant O 
atoms O 
. O 
The O 
magnitude O 
of O 
the O 
residual O 
resistivity O 
was O 
also O 
found O 
to O 
be O 
a O 
parameter O 
controlling O 
the O 
suppression O 
rate O 
of O 
the O 
AFO O 
ordering O 
temperature O 
. O 
Therefore O 
, O 
the O 
dominant O 
role O 
of O 
doping O 
in O 
the O 
AFO O 
phase O 
is O 
to O 
introduce O 
disorder O 
to O 
the O 
system O 
, O 
distinct O 
from O 
that O 
in O 
the O 
PT O 
phase O 
. O 

Context O 
: O 
The O 
SeDeM O 
expert O 
system O 
is O 
based O 
on O 
the O 
experimental O 
study O 
and O 
quantitative O 
determination O 
of O 
the O 
characterization O 
parameters O 
of O 
powdered O 
substances O 
, O 
the O 
aim O 
being O 
to O 
determine O 
whether O 
a O 
substance O 
is O 
suitable O 
for O 
producing O 
tablets O 
by O 
means O 
of O 
direct O 
compression O 
( O 
DC O 
) O 
technology O 
, O 
thereby O 
reducing O 
the O 
lead O 
time O 
for O 
pre O 
- O 
formulation O 
studies O 
. O 
Additionally O 
, O 
this O 
expert O 
system O 
also O 
provides O 
formulations O 
with O 
a O 
minimum O 
number O 
of O 
excipients O 
. O 
Objective O 
: O 
We O 
used O 
this O 
system O 
to O 
analyze O 
suitable O 
formulas O 
for O 
the O 
production O 
of O 
orodispersible O 
ibuprofen B-TRIVIAL 
tablets O 
. O 
Method O 
: O 
Twenty O 
- O 
one O 
disintegrants O 
and O 
ibuprophen B-TRIVIAL 
were O 
characterized O 
using O 
SeDeM O 
methodology O 
. O 
Results O 
: O 
The O 
results O 
indicated O 
that O 
production O 
of O 
ibuprofen B-TRIVIAL 
tablets O 
by O 
DC O 
would O 
require O 
improvements O 
in O 
the O 
dimension O 
and O 
compressibility O 
factors O 
of O 
the O 
active O 
pharmaceutical O 
ingredient O 
. O 
The O 
expert O 
system O 
analysis O 
provided O 
the O 
specific O 
percentage O 
of O 
disintegrant O 
needed O 
to O 
blend O 
with O 
ibuprofen B-TRIVIAL 
and O 
a O 
standardized O 
formula O 
of O 
lubricants O 
in O 
order O 
to O 
obtain O 
a O 
powder O 
mix O 
that O 
would O 
successfully O 
produce O 
tablets O 
by O 
DC O 
. O 
The O 
eight O 
formulas O 
proposed O 
by O 
SeDeM O 
were O 
produced O 
and O 
tested O 
in O 
the O 
laboratory O 
. O 
Conclusion O 
: O 
All O 
eight O 
formulas O 
successfully O 
produced O 
tablets O 
by O 
DC O 
, O 
but O 
only O 
four O 
of O 
them O 
could O 
be O 
considered O 
suitable O 
for O 
use O 
as O 
an O 
orodispersible O 
tablet O 
and O 
accomplishes O 
all O 
the O 
pharmaceutical O 
quality O 
parameters O 
. O 
So O 
, O 
in O 
fact O 
, O 
the O 
use O 
of O 
the O 
SeDeM O 
system O 
reduced O 
the O 
time O 
of O 
medicine's O 
development O 
and O 
therefore O 
the O 
cost O 
of O 
the O 
activity O 
. O 

two O 
- O 
electron O 
reduction O 
of O 
dioxygen B-SYSTEMATIC 
to O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
with O 
one O 
- O 
electron O 
reductants O 
with O 
a O 
small O 
overpotential O 
catalyzed O 
by O 
a O 
cobalt B-SYSTEMATIC 
chlorin I-SYSTEMATIC 
complex O 
. O 

cobalt B-SYSTEMATIC 
chlorin I-SYSTEMATIC 
complex O 
( O 
Co(II)(Ch) B-FORMULA 
) O 
efficiently O 
and O 
selectively O 
catalyzed O 
two O 
- O 
electron O 
reduction O 
of O 
dioxygen B-SYSTEMATIC 
( O 
O(2) B-FORMULA 
) O 
by O 
one O 
- O 
electron O 
reductants O 
( O 
ferrocene B-TRIVIAL 
derivatives O 
) O 
to O 
produce O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
H(2)O(2) B-FORMULA 
) O 
in O 
the O 
presence O 
of O 
perchloric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
HClO(4) B-FORMULA 
) O 
in O 
benzonitrile B-SYSTEMATIC 
( O 
PhCN B-FORMULA 
) O 
at O 
298 O 
K O 
. O 
The O 
catalytic O 
reactivity O 
of O 
Co(II)(Ch) B-FORMULA 
was O 
much O 
higher O 
than O 
that O 
of O 
a O 
cobalt B-SYSTEMATIC 
porphyrin I-SYSTEMATIC 
complex O 
( O 
Co(II)(OEP) B-FORMULA 
, O 
OEP(2-) B-ABBREVIATION 
= O 
octaethylporphyrin B-SYSTEMATIC 
dianion O 
) O 
, O 
which O 
is O 
a O 
typical O 
porphyrinoid O 
complex O 
. O 
The O 
two O 
- O 
electron O 
reduction O 
of O 
O(2) B-FORMULA 
by O 
1,1'-dibromoferrocene B-SYSTEMATIC 
( O 
Br(2)Fc B-FORMULA 
) O 
was O 
catalyzed O 
by O 
Co(II)(Ch) B-FORMULA 
, O 
whereas O 
virtually O 
no O 
reduction O 
of O 
O(2) B-FORMULA 
occurred O 
with O 
Co(II)(OEP) B-FORMULA 
. O 
In O 
addition O 
, O 
Co(II)(Ch) B-FORMULA 
is O 
more O 
stable O 
than O 
Co(II)(OEP) B-FORMULA 
, O 
where O 
the O 
catalytic O 
turnover O 
number O 
( O 
TON O 
) O 
of O 
the O 
two O 
- O 
electron O 
reduction O 
of O 
O(2) B-FORMULA 
catalyzed O 
by O 
Co(II)(Ch) B-FORMULA 
exceeded O 
30000 O 
. O 
The O 
detailed O 
kinetic O 
studies O 
have O 
revealed O 
that O 
the O 
rate O 
- O 
determining O 
step O 
in O 
the O 
catalytic O 
cycle O 
is O 
the O 
proton O 
- O 
coupled O 
electron O 
transfer O 
reduction O 
of O 
O(2) B-FORMULA 
with O 
the O 
protonated O 
Co(II)(Ch) B-FORMULA 
( O 
[Co(II)(ChH)](+) B-FORMULA 
) O 
that O 
is O 
produced O 
by O 
facile O 
electron O 
- O 
transfer O 
reduction O 
of O 
[Co(III)(ChH)](2+) B-FORMULA 
by O 
ferrocene B-TRIVIAL 
derivative O 
in O 
the O 
presence O 
of O 
HClO(4) B-FORMULA 
. O 
The O 
one O 
- O 
electron O 
- O 
reduction O 
potential O 
of O 
[Co(III)(Ch)](+) B-FORMULA 
was O 
positively O 
shifted O 
from O 
0.37 O 
V O 
( O 
vs O 
SCE O 
) O 
to O 
0.48 O 
V O 
by O 
the O 
addition O 
of O 
HClO(4) B-FORMULA 
due O 
to O 
the O 
protonation O 
of O 
[Co(III)(Ch)](+) B-FORMULA 
. O 
Such O 
a O 
positive O 
shift O 
of O 
[Co(III)(Ch)](+) B-FORMULA 
by O 
protonation O 
resulted O 
in O 
enhancement O 
of O 
the O 
catalytic O 
reactivity O 
of O 
[Co(III)(ChH)](2+) B-FORMULA 
for O 
the O 
two O 
- O 
electron O 
reduction O 
of O 
O(2) B-FORMULA 
with O 
a O 
lower O 
overpotential O 
as O 
compared O 
with O 
that O 
of O 
[Co(III)(OEP)](+) B-FORMULA 
. O 

diffusion O 
coefficients O 
for O 
mixtures O 
of O 
ionic O 
liquids O 
[EMIM][N(CN)2] B-FORMULA 
, O 
[EMIM][NTf2] B-FORMULA 
, O 
and O 
[HMIM][NTf2] B-FORMULA 
with O 
acetone B-SYSTEMATIC 
and O 
ethanol B-SYSTEMATIC 
by O 
dynamic O 
light O 
scattering O 
( O 
DLS O 
) O 
. O 

diffusivities O 
for O 
binary O 
mixtures O 
of O 
the O 
ionic O 
liquids O 
( O 
ILs O 
) O 
[EMIM][N(CN)2] B-FORMULA 
( O 
1-ethyl-3-methylimidazolium B-SYSTEMATIC 
dicyanimide I-SYSTEMATIC 
) O 
, O 
[EMIM][NTf2] B-FORMULA 
( O 
1-ethyl-3-methylimidazolium B-SYSTEMATIC 
bis(trifluoromethylsulfonyl)imide I-SYSTEMATIC 
) O 
, O 
and O 
[HMIM][NTf2] B-FORMULA 
( O 
1-hexyl-3-methylimidazolium B-SYSTEMATIC 
bis(trifluoromethylsulfonyl)imide I-SYSTEMATIC 
) O 
with O 
acetone B-SYSTEMATIC 
and O 
ethanol B-SYSTEMATIC 
were O 
studied O 
in O 
dependence O 
on O 
composition O 
in O 
the O 
temperature O 
range O 
from O 
283.15 O 
to O 
323.15 O 
K O 
, O 
applying O 
dynamic O 
light O 
scattering O 
( O 
DLS O 
) O 
. O 
The O 
influence O 
of O 
experimental O 
parameters O 
on O 
the O 
achievable O 
uncertainties O 
was O 
analyzed O 
to O 
ensure O 
the O 
acquisition O 
of O 
accurate O 
data O 
in O 
adequate O 
measurement O 
times O 
. O 
For O 
all O 
probed O 
systems O 
, O 
increasing O 
binary O 
diffusion O 
coefficients O 
were O 
found O 
for O 
increasing O 
temperatures O 
. O 
The O 
systematic O 
variation O 
of O 
anion O 
and O 
cation O 
of O 
the O 
investigated O 
ILs O 
as O 
well O 
as O 
a O 
comparison O 
with O 
the O 
literature O 
data O 
demonstrates O 
the O 
considerable O 
influence O 
of O 
different O 
ions O 
on O 
the O 
resulting O 
binary O 
diffusion O 
coefficients O 
. O 
Mutual O 
diffusivities O 
were O 
found O 
to O 
be O 
lower O 
for O 
the O 
mixtures O 
with O 
ethanol B-SYSTEMATIC 
than O 
for O 
those O 
with O 
acetone B-SYSTEMATIC 
, O 
which O 
could O 
be O 
related O 
to O 
the O 
formation O 
of O 
hydrogen B-SYSTEMATIC 
bonds O 
between O 
ethanol B-SYSTEMATIC 
and O 
the O 
ions O 
. O 
Most O 
of O 
the O 
investigated O 
IL O 
solvent O 
mixtures O 
show O 
increasing O 
binary O 
diffusion O 
coefficients O 
with O 
increasing O 
solvent O 
concentration O 
. O 
For O 
the O 
mixtures O 
of O 
[EMIM][NTf2] B-FORMULA 
with O 
ethanol B-SYSTEMATIC 
, O 
however O 
, O 
a O 
minimum O 
of O 
the O 
mutual O 
diffusivities O 
was O 
found O 
in O 
the O 
ethanol B-SYSTEMATIC 
mole O 
fraction O 
range O 
from O 
0.7 O 
to O 
0.8 O 
, O 
which O 
may O 
hint O 
at O 
the O 
vicinity O 
of O 
a O 
critical O 
demixing O 
point O 
. O 
The O 
viscosity O 
of O 
the O 
pure O 
ILs O 
turned O 
out O 
to O 
be O 
no O 
reliable O 
indicator O 
for O 
the O 
mutual O 
diffusivity O 
in O 
mixtures O 
with O 
the O 
same O 
solvent O 
. O 

name O 
" O 
cosmeceuticals O 
" O 
is O 
derived O 
from O 
" O 
cosmetics O 
and O 
pharmaceuticals O 
" O 
, O 
indicating O 
that O 
a O 
specific O 
product O 
contains O 
active O 
ingredients O 
. O 
Marine O 
algae O 
have O 
gained O 
much O 
importance O 
in O 
cosmeceutical O 
product O 
development O 
due O 
to O 
their O 
rich O 
bioactive O 
compounds O 
. O 
In O 
the O 
present O 
review O 
, O 
marine O 
algal O 
compounds O 
( O 
phlorotannins B-FAMILY 
, O 
sulfated O 
polysaccharides O 
and O 
tyrosinase O 
inhibitors O 
) O 
have O 
been O 
discussed O 
toward O 
cosmeceutical O 
application O 
. O 
In O 
addition O 
, O 
atopic O 
dermatitis O 
and O 
the O 
possible O 
role O 
of O 
matrix O 
metalloproteinase O 
( O 
MMP O 
) O 
in O 
skin O 
- O 
related O 
diseases O 
have O 
been O 
explored O 
extensively O 
for O 
cosmeceutical O 
products O 
. O 
The O 
proper O 
development O 
of O 
marine O 
algae O 
compounds O 
will O 
be O 
helpful O 
in O 
cosmeceutical O 
product O 
development O 
and O 
in O 
the O 
development O 
of O 
the O 
cosmeceutical O 
industry O 
. O 

divergent O 
approach O 
to O 
the O 
synthesis O 
of O 
the O 
yohimbinoid B-FAMILY 
alkaloids I-FAMILY 
venenatine B-TRIVIAL 
and O 
alstovenine B-TRIVIAL 
. O 

yohimbinoid B-FAMILY 
alkaloids I-FAMILY 
continue O 
to O 
receive O 
considerable O 
attention O 
from O 
the O 
synthetic O 
community O 
because O 
of O 
their O 
interesting O 
chemical O 
structures O 
and O 
varied O 
biological O 
activity O 
. O 
Although O 
there O 
are O 
several O 
elegant O 
syntheses O 
of O 
certain O 
members O 
of O 
this O 
group O 
of O 
alkaloids O 
, O 
a O 
truly O 
unified O 
approach O 
has O 
yet O 
to O 
be O 
developed O 
. O 
In O 
short O 
, O 
general O 
approaches O 
to O 
this O 
compound O 
class O 
are O 
hampered O 
by O 
a O 
lack O 
of O 
complete O 
control O 
in O 
setting O 
the O 
C(3) O 
stereocentre O 
at O 
a O 
late O 
stage O 
. O 
Herein O 
, O 
we O 
report O 
that O 
a O 
functionalized O 
hydrindanone B-TRIVIAL 
enables O 
a O 
divergent O 
strategy O 
that O 
builds O 
on O 
existing O 
precedent O 
to O 
address O 
this O 
long O 
- O 
standing O 
challenge O 
. O 
Utilizing O 
an O 
aminonitrile B-SYSTEMATIC 
intermediate O 
, O 
the O 
stereochemistry O 
at O 
C(3) O 
of O 
the O 
yohimbinoid O 
skeleton O 
can O 
be O 
controlled O 
effectively O 
in O 
a O 
Pictet-Spengler O 
reaction O 
. O 
We O 
applied O 
this O 
approach O 
to O 
the O 
first O 
total O 
syntheses O 
of O 
the O 
C(3) O 
epimeric O 
natural O 
products O 
venenatine B-TRIVIAL 
and O 
alstovenine B-TRIVIAL 
. O 

anion O 
transporter O 
3 O 
interacts O 
selectively O 
with O 
lipophilic O 
β-lactam B-TRIVIAL 
antibiotics O 
. O 

are O 
major O 
determinants O 
of O 
the O 
disposition O 
of O 
xenobiotics O 
and O 
endogenous O 
chemicals O 
in O 
the O 
body O 
. O 
Organic O 
anion O 
transporter O 
3 O 
( O 
Oat3 O 
) O 
functions O 
in O 
the O 
kidney O 
and O 
brain O 
to O 
remove O 
metabolic O 
waste O 
, O 
toxins O 
, O 
and O 
drugs O 
, O 
and O 
thus O 
transports O 
diverse O 
chemicals O 
. O 
Some O 
β-lactam B-TRIVIAL 
antibiotics O 
interact O 
with O 
Oat3 O 
, O 
and O 
penicillin B-TRIVIAL 
G I-TRIVIAL 
exhibits O 
a O 
strong O 
dependence O 
on O 
Oat3 O 
for O 
renal O 
elimination O 
. O 
However O 
, O 
over O 
80 O 
β-lactams B-FAMILY 
exist O 
, O 
and O 
many O 
have O 
not O 
been O 
assessed O 
for O 
an O 
interaction O 
with O 
Oat3 O 
. O 
Moreover O 
, O 
β-lactams B-FAMILY 
continue O 
to O 
receive O 
U.S O 
. O 
Food O 
and O 
Drug O 
Administration O 
approval O 
. O 
This O 
study O 
identified O 
new O 
β-lactam B-TRIVIAL 
-Oat3 O 
interactions O 
, O 
provided O 
a O 
head O 
- O 
to O 
- O 
head O 
comparison O 
with O 
Oat1 O 
, O 
and O 
characterized O 
the O 
physicochemical O 
determinants O 
of O 
affinity O 
for O 
Oat3 O 
. O 
Cells O 
expressing O 
mouse O 
Oat3 O 
( O 
mOat3 O 
) O 
and O 
Oat1 O 
( O 
mOat1 O 
) O 
, O 
and O 
human O 
OAT3 O 
( O 
hOAT3 O 
) O 
were O 
used O 
to O 
test O 
inhibitors O 
, O 
and O 
high O 
- O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
was O 
used O 
to O 
measure O 
transport O 
. O 
Of O 
26 O 
β-lactams B-FAMILY 
tested O 
, O 
12 O 
were O 
clear O 
inhibitors O 
of O 
Oat3 O 
, O 
and O 
14 O 
exhibited O 
poor O 
interactions O 
. O 
Inhibitors O 
exhibited O 
a O 
nearly O 
identical O 
rank O 
- O 
order O 
of O 
potency O 
against O 
mOat3 O 
and O 
hOAT3 O 
. O 
Oat1 O 
demonstrated O 
a O 
poor O 
interaction O 
with O 
most O 
β-lactams B-FAMILY 
. O 
The O 
majority O 
of O 
Oat3 O 
inhibitors O 
were O 
substrates O 
, O 
and O 
there O 
were O 
clear O 
physicochemical O 
differences O 
between O 
inhibitors O 
and O 
noninhibitors O 
. O 
That O 
is O 
, O 
inhibitors O 
had O 
nearly O 
40% O 
fewer O 
hydrogen B-SYSTEMATIC 
bond O 
donors O 
( O 
P O 
< O 
0.001 O 
) O 
, O 
a O 
lower O 
total O 
polar O 
surface O 
area O 
( O 
P O 
< O 
0.05 O 
) O 
, O 
and O 
greater O 
lipophilicity O 
( O 
LogP O 
of O 
inhibitors O 
, O 
+ O 
1.41 O 
; O 
noninhibitors O 
, O 
-1.54 O 
; O 
P O 
< O 
0.001 O 
) O 
. O 
Pharmacophore O 
mapping O 
revealed O 
a O 
prohibitive O 
hydrogen B-SYSTEMATIC 
bond O 
donor O 
group O 
in O 
noninhibitors O 
adjacent O 
to O 
a O 
hydrophobic O 
moiety O 
that O 
was O 
important O 
for O 
binding O 
to O 
Oat3 O 
. O 
These O 
findings O 
indicate O 
that O 
Oat3 O 
recognizes O 
lipophilic O 
β-lactams B-FAMILY 
more O 
readily O 
. O 
Moreover O 
, O 
this O 
study O 
has O 
potential O 
implications O 
for O 
designing O 
β-lactams B-FAMILY 
to O 
avoid O 
renal O 
accumulation O 
or O 
brain O 
efflux O 
via O 
Oat3 O 
. O 

design O 
and O 
experimental O 
implementation O 
of O 
Ag B-FORMULA 
/ O 
Au B-FORMULA 
electrodes O 
for O 
the O 
electrochemical O 
reduction O 
of O 
nitrate B-SYSTEMATIC 
. O 

current O 
imbalance O 
in O 
the O 
biogeochemical O 
cycle O 
of O 
nitrogen B-SYSTEMATIC 
is O 
as O 
serious O 
as O 
that O 
of O 
carbon B-SYSTEMATIC 
. O 
One O 
way O 
to O 
mitigate O 
this O 
problem O 
is O 
through O 
the O 
electrochemical O 
reduction O 
of O 
nitrates B-FAMILY 
under O 
mild O 
conditions O 
, O 
which O 
is O 
an O 
appealing O 
though O 
not O 
fully O 
understood O 
process O 
. O 
Therefore O 
, O 
deeper O 
insight O 
into O 
the O 
electrocatalytic O 
reaction O 
mechanism O 
is O 
needed O 
to O 
optimize O 
this O 
process O 
. O 
Here O 
we O 
thoroughly O 
analyse O 
the O 
adsorption O 
energy O 
of O 
nitrate B-SYSTEMATIC 
with O 
DFT O 
calculations O 
on O 
various O 
surface O 
facets O 
of O 
pure O 
Au B-FORMULA 
, O 
Ag B-FORMULA 
, O 
and O 
their O 
near O 
- O 
surface O 
and O 
surface O 
alloys O 
, O 
as O 
the O 
adsorption O 
and O 
subsequent O 
reduction O 
of O 
nitrate B-SYSTEMATIC 
are O 
thought O 
to O 
be O 
rate O 
limiting O 
in O 
the O 
electrocatalytic O 
reaction O 
. O 
The O 
observed O 
systematic O 
trends O 
allow O 
prediction O 
of O 
the O 
surface O 
with O 
highest O 
electrocatalytic O 
activity O 
for O 
the O 
reduction O 
of O 
nitrate B-SYSTEMATIC 
. O 
This O 
prediction O 
was O 
verified O 
experimentally O 
by O 
depositing O 
sub O 
- O 
monolayer O 
amounts O 
of O 
Ag B-FORMULA 
on O 
polycrystalline O 
Au B-FORMULA 
electrodes O 
. O 
We O 
observe O 
a O 
well O 
- O 
defined O 
volcano O 
curve O 
which O 
correlates O 
the O 
amount O 
of O 
Ag B-FORMULA 
deposited O 
on O 
the O 
surface O 
with O 
the O 
current O 
density O 
at O 
a O 
fixed O 
potential O 
, O 
with O 
the O 
peak O 
activity O 
around O 
2 O 
/ O 
3 O 
ML O 
Ag B-FORMULA 
surface O 
coverage O 
. O 
The O 
electrocatalytic O 
activity O 
and O 
stability O 
of O 
the O 
bimetallic O 
Ag B-FORMULA 
- O 
Au B-FORMULA 
systems O 
, O 
found O 
through O 
the O 
interplay O 
of O 
theoretical O 
modelling O 
and O 
empirical O 
observations O 
, O 
serve O 
as O 
a O 
clear O 
example O 
for O 
the O 
rational O 
design O 
of O 
novel O 
catalytic O 
materials O 
and O 
confirm O 
the O 
key O 
role O 
that O 
the O 
adsorption O 
of O 
nitrate B-SYSTEMATIC 
plays O 
in O 
the O 
overall O 
nitrate B-SYSTEMATIC 
reduction O 
rate O 
. O 

accumulation O 
and O 
species O 
- O 
specific O 
metabolism O 
of O 
technical O 
pentabrominated B-SYSTEMATIC 
diphenyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
DE-71 B-TRIVIAL 
) O 
in O 
two O 
predator O 
fish O 
. O 

tissue O 
- O 
specific O 
accumulation O 
and O 
species O 
- O 
specific O 
metabolism O 
of O 
polybrominated B-FAMILY 
diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
in O 
two O 
predator O 
fish O 
species O 
( O 
redtail O 
catfish O 
and O 
oscar O 
fish O 
) O 
feeding O 
on O 
the O 
same O 
prey O 
( O 
tiger O 
barb O 
) O 
that O 
was O 
exposed O 
to O 
technical O 
pentabrominated B-SYSTEMATIC 
diphenyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
DE-71 B-TRIVIAL 
) O 
in O 
the O 
laboratory O 
were O 
investigated O 
. O 
The O 
trends O 
in O 
the O 
wet O 
- O 
weight O 
tissue O 
concentration O 
of O 
PBDEs B-ABBREVIATION 
in O 
two O 
predatory O 
fish O 
species O 
suggested O 
that O 
the O 
tissue O 
distribution O 
of O 
PBDEs B-ABBREVIATION 
occurs O 
through O 
a O 
series O 
of O 
events O 
involving O 
passive O 
diffusion O 
to O 
the O 
lipid O 
compartment O 
. O 
A O 
comparison O 
of O 
the O 
fugacities O 
of O 
PBDEs B-ABBREVIATION 
in O 
various O 
tissues O 
and O 
in O 
the O 
serum O 
revealed O 
that O 
the O 
liver O 
, O 
gill O 
, O 
and O 
perivisceral O 
adipose O 
tissue O 
readily O 
achieved O 
equilibrium O 
with O 
the O 
serum O 
, O 
but O 
the O 
muscle O 
, O 
kidney O 
, O 
and O 
intestine O 
exhibited O 
the O 
potential O 
to O 
accumulate O 
PBDEs B-ABBREVIATION 
. O 
The O 
lower O 
fugacities O 
of O 
PBDEs B-ABBREVIATION 
in O 
the O 
intestine O 
may O 
have O 
significance O 
in O 
the O 
transportation O 
of O 
PBDEs B-ABBREVIATION 
from O 
prey O 
to O 
predatory O 
fish O 
. O 
No O 
tissue O 
- O 
specific O 
differences O 
in O 
PBDE B-ABBREVIATION 
congener O 
profiles O 
were O 
found O 
, O 
while O 
interspecies O 
differences O 
in O 
PBDE B-ABBREVIATION 
profiles O 
were O 
evident O 
. O 
The O 
difference O 
in O 
profiles O 
between O 
two O 
species O 
could O 
be O 
attributed O 
to O 
species O 
- O 
specific O 
debromination O 
of O 
PBDE B-ABBREVIATION 
. O 
No O 
metabolic O 
debromination O 
of O 
PBDE B-ABBREVIATION 
was O 
observed O 
in O 
redtail O 
catfish O 
, O 
but O 
extensive O 
debromination O 
of O 
PBDEs B-ABBREVIATION 
occurred O 
in O 
oscar O 
fish O 
. O 
Several O 
hydroxylated B-FAMILY 
PBDEs I-FAMILY 
( O 
OH-PBDEs B-FAMILY 
) O 
were O 
detected O 
in O 
serum O 
samples O 
from O 
the O 
two O 
fish O 
species O 
, O 
but O 
no O 
methoxylated O 
PBDEs B-ABBREVIATION 
were O 
found O 
. O 
The O 
similarities O 
in O 
the O 
OH-PBDE B-FORMULA 
congener O 
profile O 
and O 
the O 
ratio O 
of O 
OH-PBDEs B-FAMILY 
to O 
total O 
PBDEs B-ABBREVIATION 
between O 
the O 
two O 
fish O 
species O 
indicated O 
that O 
the O 
hydroxylation O 
of O 
PBDEs B-ABBREVIATION 
might O 
not O 
be O 
species O 
- O 
specific O 
. O 

ability O 
to O 
identify O 
inhibitors O 
of O 
protein O 
- O 
protein O 
interactions O 
represents O 
a O 
major O 
challenge O 
in O 
modern O 
drug O 
discovery O 
and O 
in O 
the O 
development O 
of O 
tools O 
for O 
chemical O 
biology O 
. O 
In O 
recent O 
years O 
, O 
fragment O 
- O 
based O 
approaches O 
have O 
emerged O 
as O 
a O 
new O 
methodology O 
in O 
drug O 
discovery O 
; O 
however O 
, O 
few O 
examples O 
of O 
small O 
molecules O 
that O 
are O 
active O 
against O 
chemotherapeutic O 
targets O 
have O 
been O 
published O 
. O 
Herein O 
, O 
we O 
describe O 
the O 
fragment O 
- O 
based O 
approach O 
of O 
targeting O 
the O 
interaction O 
between O 
the O 
tumour O 
suppressor O 
BRCA2 O 
and O 
the O 
recombination O 
enzyme O 
RAD51 O 
; O 
it O 
makes O 
use O 
of O 
a O 
screening O 
pipeline O 
of O 
biophysical O 
techniques O 
that O 
we O 
expect O 
to O 
be O 
more O 
generally O 
applicable O 
to O 
similar O 
targets O 
. O 
Disruption O 
of O 
this O 
interaction O 
in O 
vivo O 
is O 
hypothesised O 
to O 
give O 
rise O 
to O 
cellular O 
hypersensitivity O 
to O 
radiation O 
and O 
genotoxic O 
drugs O 
. O 
We O 
have O 
used O 
protein O 
engineering O 
to O 
create O 
a O 
monomeric O 
form O 
of O 
RAD51 O 
by O 
humanising O 
a O 
thermostable O 
archaeal O 
orthologue O 
, O 
RadA O 
, O 
and O 
used O 
this O 
protein O 
for O 
fragment O 
screening O 
. O 
The O 
initial O 
fragment O 
hits O 
were O 
thoroughly O 
validated O 
biophysically O 
by O 
isothermal O 
titration O 
calorimetry O 
( O 
ITC O 
) O 
and O 
NMR O 
techniques O 
and O 
observed O 
by O 
X-ray O 
crystallography O 
to O 
bind O 
in O 
a O 
shallow O 
surface O 
pocket O 
that O 
is O 
occupied O 
in O 
the O 
native O 
complex O 
by O 
the O 
side O 
chain O 
of O 
a O 
phenylalanine B-TRIVIAL 
from O 
the O 
conserved O 
FxxA O 
interaction O 
motif O 
found O 
in O 
BRCA2 O 
. O 
This O 
represents O 
the O 
first O 
report O 
of O 
fragments O 
or O 
any O 
small O 
molecule O 
binding O 
at O 
this O 
protein O 
- O 
protein O 
interaction O 
site O 
. O 

( O 
Pb B-FORMULA 
) O 
is O 
a O 
highly O 
toxic O 
metal O 
that O 
can O 
induce O 
oxidative O 
stress O 
and O 
affect O 
the O 
immune O 
system O 
by O 
modifying O 
the O 
expression O 
of O 
immunomodulator O 
- O 
related O 
genes O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
the O 
association O 
between O 
Pb B-FORMULA 
exposure O 
and O 
the O 
transcriptional O 
profiles O 
of O 
some O 
cytokines O 
, O 
as O 
well O 
as O 
the O 
relationship O 
between O 
Pb B-FORMULA 
exposure O 
and O 
changes O 
in O 
oxidative O 
stress O 
biomarkers O 
observed O 
in O 
the O 
spleen O 
of O 
wild O 
ungulates O 
exposed O 
to O 
mining O 
pollution O 
. O 
Red O 
deer O 
and O 
wild O 
boar O 
from O 
the O 
mining O 
area O 
studied O 
had O 
higher O 
spleen O 
, O 
liver O 
, O 
and O 
bone O 
Pb B-FORMULA 
levels O 
than O 
controls O 
, O 
indicating O 
a O 
chronic O 
exposure O 
to O 
Pb B-FORMULA 
pollution O 
. O 
Such O 
exposure O 
caused O 
a O 
depletion O 
of O 
spleen O 
glutathione B-TRIVIAL 
levels O 
in O 
both O 
species O 
and O 
disrupted O 
the O 
activity O 
of O 
antioxidant O 
enzymes O 
, O 
suggesting O 
the O 
generation O 
of O 
oxidative O 
stress O 
conditions O 
. O 
Deer O 
from O 
the O 
mining O 
area O 
also O 
showed O 
an O 
induced O 
T-helper O 
( O 
Th O 
)-dependent O 
immune O 
response O 
toward O 
the O 
Th O 
2 O 
pathway O 
, O 
whereas O 
boar O 
from O 
the O 
mining O 
area O 
showed O 
a O 
cytokine O 
profile O 
suggesting O 
an O 
inclination O 
of O 
the O 
immune O 
response O 
toward O 
the O 
Th O 
1 O 
pathway O 
. O 
These O 
results O 
indicate O 
that O 
environmental O 
exposure O 
to O 
Pb B-FORMULA 
may O 
alter O 
immune O 
responses O 
in O 
wild O 
ungulates O 
exposed O 
to O 
mining O 
pollution O 
. O 
However O 
, O 
evidence O 
of O 
direct O 
relationships O 
between O 
Pb B-FORMULA 
-mediated O 
oxidative O 
stress O 
and O 
the O 
changes O 
detected O 
in O 
immune O 
responses O 
were O 
not O 
found O 
. O 
Further O 
research O 
is O 
needed O 
to O 
evaluate O 
the O 
immunotoxic O 
potential O 
of O 
Pb B-FORMULA 
pollution O 
, O 
also O 
considering O 
the O 
prevalence O 
of O 
chronic O 
infectious O 
diseases O 
in O 
wildlife O 
in O 
environments O 
affected O 
by O 
mining O 
activities O 
. O 

hydrogenation O 
and O 
deoxygenation O 
of O 
glucose B-TRIVIAL 
on O 
solid O 
metal O 
electrodes O 
. O 

Full O 
Paper O 
addresses O 
the O 
electrocatalytic O 
hydrogenation O 
of O 
glucose B-TRIVIAL 
to O 
sorbitol B-TRIVIAL 
or O 
2-deoxysorbitol B-SYSTEMATIC 
on O 
solid O 
metal O 
electrodes O 
in O 
neutral O 
media O 
. O 
Combining O 
voltammetry O 
and O 
online O 
product O 
analysis O 
with O 
high O 
- O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
, O 
provides O 
both O 
qualitative O 
and O 
quantitative O 
information O 
regarding O 
the O 
reaction O 
products O 
as O 
a O 
function O 
of O 
potential O 
. O 
Three O 
groups O 
of O 
catalysts O 
clearly O 
show O 
affinities O 
toward O 
: O 
(1) O 
hydrogen B-SYSTEMATIC 
formation O 
[ O 
on O 
early O 
transition B-FAMILY 
metals I-FAMILY 
( O 
Ti B-FORMULA 
, O 
V B-FORMULA 
, O 
Cr B-FORMULA 
, O 
Mn B-FORMULA 
, O 
Zr B-FORMULA 
, O 
Nb B-FORMULA 
, O 
Mo B-FORMULA 
, O 
Hf B-FORMULA 
, O 
Ta B-FORMULA 
, O 
We B-FORMULA 
, O 
and O 
Re B-FORMULA 
) O 
and O 
platinum B-SYSTEMATIC 
group O 
metals O 
( O 
Ru B-FORMULA 
, O 
Rh B-FORMULA 
, O 
Ir B-FORMULA 
, O 
and O 
Pt B-FORMULA 
) O 
] O 
, O 
(2) O 
sorbitol B-TRIVIAL 
formation O 
[ O 
on O 
late O 
transition B-FAMILY 
metals I-FAMILY 
( O 
Fe B-FORMULA 
, O 
Co B-FORMULA 
, O 
Ni B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Pd B-FORMULA 
, O 
Au B-FORMULA 
, O 
and O 
Ag B-FORMULA 
) O 
and O 
Al B-FORMULA 
( O 
sp O 
metal O 
) O 
] O 
, O 
and O 
(3) O 
sorbitol B-TRIVIAL 
and O 
2-deoxysorbitol B-SYSTEMATIC 
formation O 
[ O 
on O 
post- O 
transition B-FAMILY 
metals I-FAMILY 
( O 
In B-FORMULA 
, O 
Sn B-FORMULA 
, O 
Sb B-FORMULA 
, O 
Pb B-FORMULA 
, O 
and O 
Bi B-FORMULA 
) O 
, O 
as O 
well O 
as O 
Zn B-FORMULA 
and O 
Cd B-FORMULA 
( O 
d O 
metals O 
) O 
] O 
. O 
Ni B-FORMULA 
shows O 
the O 
lowest O 
overpotential O 
for O 
the O 
onset O 
of O 
sorbitol B-TRIVIAL 
formation O 
( O 
-0.25 O 
V O 
) O 
whereas O 
Pb B-FORMULA 
generates O 
sorbitol B-TRIVIAL 
with O 
the O 
highest O 
yield O 
( O 
< O 
0.7 O 
mM O 
cm(-2) O 
) O 
. O 
Different O 
from O 
a O 
smooth O 
Pt B-FORMULA 
electrode O 
, O 
a O 
large O 
- O 
surface O 
- O 
area O 
Pt B-FORMULA 
/ O 
C B-FORMULA 
electrode O 
hydrogenates O 
glucose B-TRIVIAL 
to O 
sorbitol B-TRIVIAL 
from O 
-0.21 O 
V O 
with O 
relatively O 
low O 
current O 
. O 
This O 
emphasizes O 
the O 
importance O 
of O 
the O 
active O 
sites O 
and O 
the O 
surface O 
area O 
of O 
the O 
catalyst O 
. O 
The O 
mechanism O 
to O 
form O 
2-deoxysorbitol B-SYSTEMATIC 
from O 
glucose B-TRIVIAL 
and O 
/ O 
or O 
fructose B-TRIVIAL 
is O 
discussed O 
according O 
to O 
the O 
observed O 
reaction O 
products O 
. O 
The O 
yield O 
and O 
selectivity O 
of O 
hydrogenated O 
products O 
are O 
highly O 
sensitive O 
to O 
the O 
chemical O 
nature O 
and O 
state O 
of O 
the O 
catalyst O 
surface O 
. O 

oxidases O 
transport O 
electrons O 
from O 
cytosolic O 
NADPH B-ABBREVIATION 
through O 
biological O 
membranes O 
to O 
generate O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
. O 
NADPH B-ABBREVIATION 
oxidase O 
4 O 
, O 
broadly O 
expressed O 
in O 
humans O 
, O 
is O 
an O 
interesting O 
pharmacological O 
target O 
, O 
since O 
its O 
activity O 
is O 
deregulated O 
in O 
several O 
diseases O 
, O 
including O 
pulmonary O 
fibrosis O 
, O 
diabetic O 
nephropathy O 
, O 
and O 
cardiac O 
hypertrophy O 
. O 
Whereas O 
several O 
candidate O 
NADPH B-ABBREVIATION 
oxidase O 
4 O 
inhibitors O 
were O 
recently O 
described O 
, O 
most O 
of O 
these O 
compounds O 
are O 
either O 
unspecific O 
or O 
toxic O 
. O 
Here O 
we O 
set O 
out O 
to O 
identify O 
new O 
NADPH B-ABBREVIATION 
oxidase O 
4 O 
inhibitors O 
from O 
edible O 
plants O 
, O 
in O 
an O 
attempt O 
to O 
decrease O 
the O 
number O 
of O 
hits O 
with O 
toxic O 
side O 
effects O 
. O 
We O 
screened O 
a O 
compound O 
library O 
prepared O 
from O 
edible O 
plants O 
for O 
new O 
bioactives O 
with O 
the O 
ability O 
to O 
inhibit O 
the O 
activity O 
of O 
NADPH B-ABBREVIATION 
oxidase O 
4 O 
. O 
Using O 
both O 
cell O 
- O 
based O 
and O 
cell O 
- O 
free O 
assays O 
, O 
we O 
identified O 
several O 
compounds O 
with O 
significant O 
inhibitory O 
activity O 
towards O 
NADPH B-ABBREVIATION 
oxidase O 
4 O 
. O 
For O 
selected O 
compounds O 
, O 
the O 
activity O 
profile O 
towards O 
NADPH B-ABBREVIATION 
oxidase O 
2 O 
and O 
NADPH B-ABBREVIATION 
oxidase O 
5 O 
was O 
established O 
, O 
and O 
controls O 
were O 
carried O 
out O 
to O 
exclude O 
general O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
scavengers O 
. O 
A O 
number O 
of O 
promising O 
NADPH B-ABBREVIATION 
oxidase O 
4 O 
inhibitors O 
from O 
edible O 
plants O 
was O 
identified O 
and O 
characterised O 
. O 
Several O 
new O 
chemical O 
entities O 
are O 
disclosed O 
which O 
act O 
as O 
NADPH B-ABBREVIATION 
oxidase O 
4 O 
inhibitors O 
, O 
and O 
the O 
efficacies O 
of O 
our O 
best O 
hits O 
, O 
in O 
particular O 
several O 
diarylheptanoids B-FAMILY 
and O 
lignans B-FAMILY 
, O 
are O 
comparable O 
to O 
the O 
best O 
available O 
pharmacological O 
NADPH B-ABBREVIATION 
oxidase O 
4 O 
inhibitors O 
. O 
These O 
findings O 
will O 
provide O 
valuable O 
tools O 
to O 
study O 
mechanisms O 
of O 
NADPH B-ABBREVIATION 
oxidase O 
inhibition O 
. O 

synthesis O 
of O 
amino B-FAMILY 
acid I-FAMILY 
-based O 
pH-responsive O 
chiral O 
polymers O 
and O 
self O 
- O 
assembly O 
of O 
their O 
block O 
copolymers O 
. O 

/ O 
isoleucine B-TRIVIAL 
side O 
chain O 
polymers O 
are O 
of O 
interest O 
due O 
to O 
their O 
hydrophobicity O 
and O 
reported O 
role O 
in O 
the O 
formation O 
of O 
α-helical O 
structures O 
. O 
The O 
synthesis O 
and O 
reversible O 
addition O 
- O 
fragmentation O 
chain O 
transfer O 
( O 
RAFT O 
) O 
polymerization O 
of O 
amino B-FAMILY 
acid I-FAMILY 
-based O 
chiral O 
monomers O 
, O 
namely O 
Boc-L-leucine B-SYSTEMATIC 
methacryloyloxyethyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
Boc-L-Leu-HEMA B-FORMULA 
, O 
1a O 
) O 
, O 
Boc-L-leucine B-SYSTEMATIC 
acryloyloxyethyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
Boc-L-Leu-HEA B-FORMULA 
, O 
1b O 
) O 
, O 
Boc-L-isoleucine B-SYSTEMATIC 
methacryloyloxyethyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
Boc-L-Ile-HEMA B-FORMULA 
, O 
1c O 
) O 
, O 
and O 
Boc-L-isoleucine B-SYSTEMATIC 
acryloyloxyethyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
Boc-L-Ile-HEA B-FORMULA 
, O 
1d O 
) O 
, O 
are O 
reported O 
. O 
The O 
controlled O 
nature O 
of O 
the O 
polymerization O 
of O 
the O 
said O 
chiral O 
monomers O 
in O 
N B-SYSTEMATIC 
, I-SYSTEMATIC 
N-dimethylformamide I-SYSTEMATIC 
( O 
DMF B-ABBREVIATION 
) O 
at O 
70 O 
°C O 
is O 
evident O 
from O 
the O 
formation O 
of O 
narrow O 
polydisperse O 
polymers O 
, O 
the O 
molecular O 
weight O 
controlled O 
by O 
the O 
monomer O 
/ O 
chain O 
transfer O 
agent O 
( O 
CTA O 
) O 
molar O 
ratio O 
and O 
the O 
linear O 
relationship O 
between O 
molecular O 
weight O 
and O 
monomer O 
conversion O 
. O 
The O 
resulting O 
well O 
- O 
defined O 
polymers O 
were O 
used O 
as O 
macro-CTAs O 
to O 
prepare O 
corresponding O 
diblock O 
copolymers O 
by O 
RAFT O 
polymerization O 
of O 
methyl B-SYSTEMATIC 
(meth)acrylate I-SYSTEMATIC 
monomers O 
. O 
Deprotection O 
of O 
Boc B-ABBREVIATION 
groups O 
in O 
the O 
homopolymers O 
and O 
block O 
copolymers O 
under O 
acidic O 
conditions O 
produced O 
cationic O 
, O 
pH-responsive O 
polymers O 
with O 
primary B-FAMILY 
amine I-FAMILY 
moieties O 
at O 
the O 
side O 
chains O 
. O 
The O 
optical O 
activity O 
of O 
the O 
homopolymers O 
and O 
block O 
copolymers O 
were O 
studied O 
using O 
circular O 
dichroism O 
( O 
CD O 
) O 
spectroscopy O 
and O 
specific O 
rotation O 
measurements O 
. O 
The O 
self O 
- O 
assembling O 
nature O 
of O 
the O 
block O 
copolymers O 
to O 
produce O 
highly O 
ordered O 
structures O 
was O 
illustrated O 
through O 
dynamic O 
light O 
scattering O 
( O 
DLS O 
) O 
and O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
studies O 
. O 
The O 
side O 
chain O 
amine B-SYSTEMATIC 
functionality O 
instills O 
pH-responsive O 
behavior O 
, O 
which O 
makes O 
these O 
cationic O 
polymers O 
attractive O 
candidates O 
for O 
drug O 
delivery O 
applications O 
, O 
as O 
well O 
as O 
for O 
conjugation O 
of O 
biomolecules O 
. O 

have O 
investigated O 
the O 
role O 
of O 
linker O 
molecules O 
in O 
quantum O 
- O 
dot O 
- O 
sensitized O 
solar O 
cells O 
( O 
QDSSCs O 
) O 
using O 
density O 
- O 
functional O 
theory O 
( O 
DFT O 
) O 
and O 
experiments O 
. O 
Linkers O 
not O 
only O 
govern O 
the O 
number O 
of O 
attached O 
QDs O 
but O 
also O 
influence O 
charge O 
separation O 
, O 
recombination O 
, O 
and O 
transport O 
. O 
Understanding O 
their O 
behavior O 
is O 
therefore O 
not O 
straightforward O 
. O 
DFT O 
calculations O 
show O 
that O 
mercaptopropionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
MPA B-ABBREVIATION 
) O 
and O 
cysteine B-TRIVIAL 
( O 
Cys B-FORMULA 
) O 
exhibit O 
characteristic O 
binding O 
configurations O 
on O 
TiO(2) B-FORMULA 
surfaces O 
. O 
This O 
information O 
is O 
used O 
to O 
optimize O 
the O 
cell O 
assembly O 
process O 
, O 
yielding O 
Cys B-FORMULA 
-based O 
cells O 
that O 
significantly O 
outperform O 
MPA B-ABBREVIATION 
cells O 
, O 
and O 
reach O 
power O 
conversion O 
efficiencies O 
( O 
PCE O 
) O 
as O 
high O 
as O 
2.7% O 
under O 
AM O 
1.5 O 
illumination O 
. O 
Importantly O 
, O 
the O 
structural O 
information O 
from O 
theory O 
also O 
helps O 
understand O 
the O 
cause O 
for O 
this O 
improved O 
performance O 
. O 

uplift O 
played O 
a O 
key O 
role O 
in O 
Neotropical O 
bird O 
diversification O 
, O 
yet O 
past O 
dispersal O 
and O 
genetic O 
adaptation O 
to O 
high O 
- O 
altitude O 
environments O 
remain O 
little O 
understood O 
. O 
Here O 
we O 
use O 
multilocus O 
population O 
genetics O 
to O 
study O 
population O 
history O 
and O 
historical O 
demographic O 
processes O 
in O 
the O 
ruddy O 
duck O 
( O 
Oxyura O 
jamaicensis O 
) O 
, O 
a O 
stiff O 
- O 
tailed O 
diving O 
duck O 
comprising O 
three O 
subspecies O 
distributed O 
from O 
Canada O 
to O 
Tierra O 
del O 
Fuego O 
and O 
inhabiting O 
wetlands O 
from O 
sea O 
level O 
to O 
4500 O 
m O 
in O 
the O 
Andes O 
. O 
We O 
sequenced O 
the O 
mitochondrial O 
DNA O 
, O 
four O 
autosomal O 
introns O 
and O 
three O 
haemoglobin O 
genes O 
( O 
α(A) O 
, O 
α(D) O 
, O 
β(A) O 
) O 
and O 
used O 
isolation O 
- O 
with O 
- O 
migration O 
( O 
IM O 
) O 
models O 
to O 
study O 
gene O 
flow O 
between O 
North O 
America O 
and O 
South O 
America O 
, O 
and O 
between O 
the O 
tropical O 
and O 
southern O 
Andes O 
. O 
Our O 
analyses O 
indicated O 
that O 
ruddy O 
ducks O 
dispersed O 
first O 
from O 
North O 
America O 
to O 
the O 
tropical O 
Andes O 
, O 
then O 
from O 
the O 
tropical O 
Andes O 
to O 
the O 
southern O 
Andes O 
. O 
While O 
no O 
nonsynonymous O 
substitutions O 
were O 
found O 
in O 
either O 
α O 
globin O 
gene O 
, O 
three O 
amino B-FAMILY 
acid I-FAMILY 
substitutions O 
were O 
observed O 
in O 
the O 
β(A) O 
globin O 
. O 
Based O 
on O 
phylogenetic O 
reconstruction O 
and O 
power O 
analysis O 
, O 
the O 
first O 
β(A) O 
substitution O 
, O 
found O 
in O 
all O 
Andean O 
individuals O 
, O 
was O 
acquired O 
when O 
ruddy O 
ducks O 
dispersed O 
from O 
low O 
altitude O 
in O 
North O 
America O 
to O 
high O 
altitude O 
in O 
the O 
tropical O 
Andes O 
, O 
whereas O 
the O 
two O 
additional O 
substitutions O 
occurred O 
more O 
recently O 
, O 
when O 
ruddy O 
ducks O 
dispersed O 
from O 
high O 
altitude O 
in O 
the O 
tropical O 
Andes O 
to O 
low O 
altitude O 
in O 
the O 
southern O 
Andes O 
. O 
This O 
stepwise O 
colonization O 
pattern O 
accompanied O 
by O 
polarized O 
β(A) O 
globin O 
amino B-FAMILY 
acid I-FAMILY 
replacements O 
suggest O 
that O 
ruddy O 
ducks O 
first O 
acclimatized O 
or O 
adapted O 
to O 
the O 
Andean O 
highlands O 
and O 
then O 
again O 
to O 
the O 
lowlands O 
. O 
In O 
addition O 
, O 
ruddy O 
ducks O 
colonized O 
the O 
Andean O 
highlands O 
via O 
a O 
less O 
common O 
route O 
as O 
compared O 
to O 
other O 
waterbird O 
species O 
that O 
colonized O 
the O 
Andes O 
northwards O 
from O 
the O 
southern O 
cone O 
of O 
South O 
America O 
. O 

and O 
pharmacokinetics O 
of O 
inositol B-TRIVIAL 
hexanicotinate I-TRIVIAL 
in O 
rats O 
. O 

1 O 
. O 
Inositol B-TRIVIAL 
hexanicotinate I-TRIVIAL 
( O 
IHN B-ABBREVIATION 
) O 
is O 
an O 
ester O 
of O 
the O 
anti-hyperlipidemic O 
drug O 
nicotinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
nan O 
) O 
. O 
This O 
study O 
assessed O 
the O 
hydrolysis O 
rate O 
of O 
IHN O 
in O 
human O 
and O 
rat O 
plasma O 
, O 
and O 
pharmacokinetics O 
of O 
the O 
drug O 
using O 
a O 
rat O 
animal O 
model O 
. O 
2 O 
. O 
IHN B-ABBREVIATION 
( O 
10 O 
or O 
50 O 
µg O 
/ O 
mL O 
) O 
was O 
incubated O 
in O 
plasma O 
at O 
37 O 
°C O 
for O 
72 O 
h O 
. O 
Kinetic O 
parameters O 
were O 
determined O 
based O 
on O 
the O 
disappearance O 
of O 
IHN B-ABBREVIATION 
and O 
the O 
appearance O 
of O 
nan O 
. O 
The O 
mean O 
IHN B-ABBREVIATION 
disappearance O 
and O 
nan O 
appearance O 
half O 
- O 
lives O 
were O 
1.07 O 
and O 
3.93 O 
h O 
in O 
human O 
plasma O 
, O 
and O 
0.152 O 
and O 
2.68 O 
h O 
in O 
rat O 
plasma O 
. O 
Increasing O 
the O 
initial O 
plasma O 
concentration O 
to O 
50 O 
µg O 
/ O 
mL O 
increased O 
the O 
nan O 
appearance O 
half O 
- O 
life O 
in O 
human O 
and O 
rat O 
plasma O 
to O 
4.66 O 
and O 
6.47 O 
h O 
, O 
respectively O 
. O 
3 O 
. O 
After O 
single O 
50 O 
or O 
100 O 
mg O 
/ O 
kg O 
intravenous O 
dose O 
of O 
IHN B-ABBREVIATION 
to O 
Sprague-Dawley O 
rats O 
, O 
the O 
drug O 
showed O 
statistically O 
significant O 
dose O 
- O 
dependent O 
alterations O 
in O 
systemic O 
clearance O 
, O 
suggesting O 
a O 
non-linear O 
saturable O 
elimination O 
of O 
IHN B-ABBREVIATION 
. O 
Dose O 
- O 
normalized O 
mean O 
plasma O 
levels O 
of O 
nan O 
increased O 
by O 
30% O 
with O 
increasing O 
IHN B-ABBREVIATION 
dose O 
( O 
p O 
< O 
0.02 O 
) O 
. O 
The O 
mean O 
metabolic O 
ratio O 
( O 
i.e O 
. O 
NA/ O 
IHN B-ABBREVIATION 
AUC O 
ratio O 
) O 
significantly O 
increased O 
with O 
increasing O 
IHN B-ABBREVIATION 
dose O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
4 O 
. O 
The O 
results O 
provide O 
first O 
indication O 
of O 
saturable O 
elimination O 
and O 
rapid O 
disappearance O 
of O 
IHN B-ABBREVIATION 
, O 
while O 
niacin B-TRIVIAL 
was O 
slowly O 
formed O 
. O 

erythrocyte O 
membrane O 
, O 
a O 
metabolically O 
regulated O 
active O 
structure O 
that O 
comprises O 
lipid O 
molecules O 
, O 
junctional O 
complexes O 
, O 
and O 
the O 
spectrin O 
network O 
, O 
enables O 
the O 
cell O 
to O 
undergo O 
large O 
passive O 
deformations O 
when O 
passing O 
through O 
the O 
microvascular O 
system O 
. O 
Here O 
we O 
use O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
imaging O 
and O 
quantitative O 
mechanical O 
mapping O 
at O 
nanometer O 
resolution O 
to O 
correlate O 
structure O 
and O 
mechanics O 
of O 
key O 
components O 
of O 
the O 
erythrocyte O 
membrane O 
, O 
crucial O 
for O 
cell O 
integrity O 
and O 
function O 
. O 
Our O 
data O 
reveal O 
structural O 
and O 
mechanical O 
heterogeneity O 
modulated O 
by O 
the O 
metabolic O 
state O 
at O 
unprecedented O 
nanometer O 
resolution O 
. O 
ATP B-ABBREVIATION 
-depletion O 
, O 
reducing O 
skeletal O 
junction O 
phosphorylation O 
in O 
RBC O 
cells O 
, O 
leads O 
to O 
membrane O 
stiffening O 
. O 
Analysis O 
of O 
ghosts O 
and O 
shear O 
- O 
force O 
opened O 
erythrocytes O 
show O 
that O 
, O 
in O 
the O 
absence O 
of O 
cytosolic O 
kinases O 
, O 
spectrin O 
phosphorylation O 
results O 
in O 
membrane O 
stiffening O 
at O 
the O 
extracellular O 
face O 
and O 
a O 
reduced O 
junction O 
remodeling O 
in O 
response O 
to O 
loading O 
forces O 
. O 
Topography O 
and O 
mechanical O 
mapping O 
of O 
single O 
components O 
at O 
the O 
cytoplasmic O 
face O 
reveal O 
that O 
, O 
surprisingly O 
, O 
spectrin O 
phosphorylation O 
by O 
ATP B-ABBREVIATION 
softens O 
individual O 
filaments O 
. O 
Our O 
findings O 
suggest O 
that O 
, O 
besides O 
the O 
mechanical O 
signature O 
of O 
each O 
component O 
, O 
the O 
RBC O 
membrane O 
mechanics O 
is O 
regulated O 
by O 
the O 
metabolic O 
state O 
and O 
the O 
assembly O 
of O 
its O 
structural O 
elements O 
. O 

Several O 
studies O 
report O 
that O 
endocrine O 
disrupting O 
chemicals O 
( O 
EDC O 
) O 
able O 
to O 
interfere O 
with O 
endocrine O 
homeostasis O 
may O 
affect O 
women's O 
reproductive O 
health O 
. O 
We O 
analyzed O 
EDC O 
serum O 
levels O 
and O 
nuclear O 
receptors O 
( O 
NRs O 
) O 
expression O 
in O 
order O 
to O 
have O 
an O 
indication O 
of O 
the O 
internal O 
dose O 
of O 
biologically O 
active O 
compounds O 
and O 
a O 
measurement O 
of O 
indicators O 
of O 
their O 
effects O 
, O 
as O 
a O 
result O 
of O 
the O 
repeated O 
uptake O 
from O 
environmental O 
source O 
. O 
The O 
percentage O 
of O 
patients O 
with O 
detectable O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
concentrations O 
was O 
significantly O 
higher O 
in O 
the O 
infertile O 
patients O 
compared O 
with O 
fertile O 
subjects O 
. O 
No O 
significant O 
difference O 
was O 
found O 
between O 
the O 
groups O 
with O 
regard O 
to O 
perfluorooctane B-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
( O 
PFOS B-ABBREVIATION 
) O 
, O 
perfluorooctanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
PFOA B-ABBREVIATION 
) O 
, O 
mono-ethylhexyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
MEHP B-ABBREVIATION 
) O 
and O 
di-(2-ethylhexyl) B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DEHP B-ABBREVIATION 
) O 
concentrations O 
. O 
Among O 
infertile O 
women O 
, O 
the O 
mean O 
expression O 
of O 
estrogen B-FAMILY 
receptor O 
alpha O 
( O 
ERα O 
) O 
and O 
beta O 
( O 
Erβ O 
) O 
, O 
androgen B-FAMILY 
receptor O 
( O 
AR O 
) O 
and O 
pregnane B-TRIVIAL 
X O 
receptor O 
( O 
PXR O 
) O 
was O 
significantly O 
higher O 
than O 
fertile O 
patients O 
. O 
The O 
mean O 
expression O 
of O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AhR O 
) O 
and O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
gamma O 
( O 
PPARγ O 
) O 
did O 
not O 
show O 
significant O 
differences O 
between O 
two O 
groups O 
. O 
Patients O 
with O 
endometriosis O 
had O 
higher O 
levels O 
of O 
PPARγ O 
than O 
all O 
women O 
with O 
other O 
causes O 
of O 
infertility O 
. O 
This O 
study O 
led O 
further O 
support O 
to O 
EDC O 
exposure O 
as O 
a O 
risk O 
factor O 
for O 
women's O 
fertility O 
. O 

mycotoxins O 
are O 
secondary O 
metabolites O 
produced O 
by O 
Fusarium O 
spp O 
. O 
in O 
cereals O 
. O 
Among O 
them O 
, O 
deoxynivalenol B-TRIVIAL 
( O 
DON B-ABBREVIATION 
) O 
and O 
zearalenone B-TRIVIAL 
( O 
ZEN B-ABBREVIATION 
) O 
are O 
widespread O 
worldwide O 
contaminants O 
of O 
cereal O 
commodities O 
and O 
are O 
ranked O 
as O 
the O 
most O 
important O 
chronic O 
dietary O 
risk O 
factors O 
. O 
Their O 
conjugates O 
, O 
known O 
as O 
masked O 
mycotoxins O 
, O 
have O 
been O 
described O 
but O 
are O 
still O 
not O 
accounted O 
for O 
in O 
risk O 
assessment O 
studies O 
. O 
This O 
study O 
demonstrates O 
for O 
the O 
first O 
time O 
that O 
DON B-ABBREVIATION 
and O 
ZEN B-ABBREVIATION 
are O 
effectively O 
deconjugated O 
by O 
the O 
human O 
colonic O 
microbiota O 
, O 
releasing O 
their O 
toxic O 
aglycones O 
and O 
generating O 
yet O 
unidentified O 
catabolites O 
. O 
For O 
this O 
reason O 
, O 
masked O 
mycotoxins O 
should O 
be O 
considered O 
when O 
evaluating O 
population O 
exposure O 
. O 

diterpenoids B-FAMILY 
from O 
Croton O 
tonkinensis O 
. O 

investigation O 
of O 
the O 
methanolic O 
extract O 
of O 
Croton O 
tonkinensis O 
afforded O 
two O 
known O 
kauranes B-FAMILY 
( O 
1 O 
, O 
2 O 
) O 
, O 
eight O 
new O 
ent-kauranes B-FAMILY 
( O 
3-10 O 
) O 
, O 
and O 
16 O 
known O 
ent-kaurane B-TRIVIAL 
-type O 
diterpenoids B-FAMILY 
( O 
12-27 O 
) O 
. O 
In O 
addition O 
, O 
30 O 
known O 
compounds O 
were O 
identified O 
by O 
comparison O 
of O 
their O 
physical O 
and O 
spectroscopic O 
data O 
with O 
reported O 
data O 
. O 
Among O 
the O 
isolated O 
compounds O 
, O 
ent-18-acetoxykaur-16-en-15-one B-SYSTEMATIC 
( O 
20 O 
) O 
displayed O 
the O 
most O 
significant O 
inhibition O 
of O 
superoxide B-TRIVIAL 
anion O 
generation O 
and O 
elastase O 
release O 
. O 

promotes O 
the O 
degradation O 
of O 
polyglutamine B-FAMILY 
-expanded O 
ataxin-3 O 
or O 
ataxin-7 O 
independently O 
of O 
its O 
ROCK-inhibiting O 
effect O 
and O 
ameliorates O 
mutant O 
ataxin-3-induced O 
neurodegeneration O 
in O 
the O 
SCA3 O 
transgenic O 
mouse O 
. O 

ataxia O 
type O 
3 O 
( O 
SCA3 O 
) O 
caused O 
by O 
polyglutamine B-FAMILY 
-expanded O 
ataxin-3 O 
is O 
the O 
most O 
prevalent O 
subtype O 
of O 
spinocerebellar O 
ataxias O 
. O 
A O 
compound O 
, O 
which O 
decreases O 
protein O 
level O 
of O 
mutant O 
ataxin-3 O 
in O 
SCA3 O 
affected O 
CNS O 
regions O 
, O 
should O 
be O 
a O 
promising O 
therapeutic O 
agent O 
for O 
SCA3 O 
. O 
SCA3 O 
and O 
Huntington's O 
disease O 
( O 
HD O 
) O 
belong O 
to O 
a O 
family O 
of O 
polyglutamine B-FAMILY 
neurodegenerative O 
diseases O 
. O 
Rho-kinase O 
( O 
ROCK O 
) O 
inhibitor O 
Y27632 B-IDENTIFIER 
reduced O 
brain O 
level O 
of O 
polyglutamine B-FAMILY 
-expanded O 
huntingtin O 
in O 
HD O 
transgenic O 
mouse O 
. O 
Therefore O 
, O 
we O 
tested O 
the O 
possibility O 
that O 
ROCK O 
inhibitors O 
, O 
Y27632 B-IDENTIFIER 
, O 
H1152 B-IDENTIFIER 
and O 
GSK429286 B-IDENTIFIER 
, O 
downregulate O 
protein O 
expression O 
of O 
polyglutamine B-FAMILY 
-expanded O 
ataxin-3-Q79 O 
. O 
Y27632 B-IDENTIFIER 
or O 
H1152 B-IDENTIFIER 
reduced O 
protein O 
level O 
of O 
HA-tagged O 
ataxin-3-Q79 O 
( O 
ATX-3-Q79HA O 
) O 
expressed O 
in O 
HEK O 
293 O 
cells O 
. O 
Compared O 
to O 
Y27632 B-IDENTIFIER 
, O 
H1152 B-IDENTIFIER 
decreased O 
ATX-3-Q79HA O 
protein O 
level O 
with O 
a O 
significantly O 
more O 
potency O 
and O 
efficacy O 
. O 
H1152 B-IDENTIFIER 
also O 
reduced O 
protein O 
level O 
of O 
HA-tagged O 
polyglutamine B-FAMILY 
-expanded O 
ataxin-7-Q52 O 
( O 
ATX-7-Q52HA O 
) O 
, O 
which O 
causes O 
spinocerebellar O 
ataxia O 
type O 
7 O 
( O 
SCA7 O 
) O 
. O 
H1152 B-IDENTIFIER 
decreased O 
ATX-3-Q79HA O 
or O 
ATX-7-Q52HA O 
protein O 
level O 
in O 
vitro O 
by O 
augmenting O 
proteasome O 
activity O 
and O 
promoting O 
ATX-3-Q79HA O 
or O 
ATX-7-Q52HA O 
degradation O 
. O 
GSK429286 B-IDENTIFIER 
, O 
which O 
is O 
structurally O 
different O 
from O 
H1152 B-IDENTIFIER 
but O 
equally O 
inhibits O 
ROCK O 
, O 
failed O 
to O 
affect O 
protein O 
level O 
of O 
ATX-3-Q79HA O 
or O 
ATX-7-Q52HA O 
. O 
Furthermore O 
, O 
shRNA O 
- O 
mediated O 
suppression O 
of O 
ROCK1 O 
or O 
ROCK2 O 
expression O 
in O 
293 O 
cells O 
did O 
not O 
affect O 
protein O 
level O 
of O 
ATX-3-Q79HA O 
or O 
ATX-7-Q52HA O 
and O 
H1152 B-IDENTIFIER 
reduction O 
of O 
ATX-3-Q79HA O 
. O 
Daily O 
intraperitoneal O 
administration O 
of O 
H1152 B-IDENTIFIER 
significantly O 
decreased O 
protein O 
level O 
of O 
ATX-3-Q79HA O 
in O 
the O 
cerebellum O 
, O 
pontine O 
nuclei O 
and O 
spinal O 
cord O 
of O 
SCA3 O 
transgenic O 
mice O 
. O 
H1152 B-IDENTIFIER 
also O 
ameliorated O 
pontine O 
neuronal O 
death O 
and O 
neurological O 
phenotype O 
of O 
SCA3 O 
transgenic O 
mice O 
. O 
Our O 
results O 
suggest O 
that O 
H1152 B-IDENTIFIER 
might O 
be O 
an O 
effective O 
therapeutic O 
agent O 
for O 
SCA3 O 
or O 
SCA7 O 
. O 

ameliorate O 
insulin O 
resistance O 
and O 
up O 
- O 
regulates O 
cellular O 
antioxidants O 
during O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
induced O 
hepatic O 
steatosis O 
in O 
HepG2 O 
cells O 
. O 

lipid O 
accumulation O 
and O 
oxidative O 
stress O 
contribute O 
to O 
non-alcoholic O 
fatty O 
liver O 
disease O 
( O 
NAFLD O 
) O 
. O 
Thus O 
, O 
we O 
hypothesized O 
that O 
the O 
hypolipidemic O 
and O 
antioxidant O 
activity O 
of O 
quercetin B-TRIVIAL 
would O 
attenuate O 
events O 
leading O 
to O 
NAFLD O 
. O 
Addition O 
of O 
2.0mM O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
( O 
OA O 
) O 
into O 
the O 
culture O 
media O 
induced O 
fatty O 
liver O 
condition O 
in O 
HepG2 O 
cells O 
by O 
24h O 
. O 
It O 
was O 
marked O 
by O 
significant O 
accumulation O 
of O 
lipid O 
droplets O 
as O 
determined O 
by O 
Oil-Red-O B-TRIVIAL 
( O 
ORO B-ABBREVIATION 
) O 
based O 
colorimetric O 
assay O 
, O 
increased O 
triacylglycerol B-FAMILY 
( O 
TAG B-ABBREVIATION 
) O 
and O 
increased O 
lipid O 
peroxidation O 
. O 
The O 
inflammatory O 
cytokines O 
TNF-α O 
and O 
IL-8 O 
levels O 
were O 
significantly O 
increased O 
with O 
decreased O 
antioxidant O 
molecules O 
. O 
OA O 
induced O 
insulin O 
resistance O 
which O 
was O 
evident O 
by O 
inhibition O 
of O 
glucose B-TRIVIAL 
uptake O 
and O 
cell O 
proliferation O 
. O 
Quercetin B-TRIVIAL 
( O 
10 O 
μM O 
) O 
increased O 
cell O 
proliferation O 
by O 
3.05 O 
folds O 
with O 
decreased O 
TAG B-ABBREVIATION 
content O 
( O 
45% O 
) O 
and O 
was O 
effective O 
in O 
increasing O 
insulin O 
mediated O 
glucose B-TRIVIAL 
uptake O 
by O 
2.65 O 
folds O 
. O 
The O 
intracellular O 
glutathione B-TRIVIAL 
content O 
was O 
increased O 
by O 
2 O 
folds O 
without O 
substantial O 
increase O 
in O 
GSSG B-ABBREVIATION 
content O 
. O 
Quercetin B-TRIVIAL 
( O 
10 O 
μM O 
) O 
decreased O 
TNF-α O 
and O 
IL-8 O 
by O 
59.74% O 
and O 
41.11% O 
respectively O 
and O 
inhibited O 
generation O 
of O 
lipid O 
peroxides B-FAMILY 
by O 
50.5% O 
. O 
In O 
addition O 
, O 
RT-PCR O 
results O 
confirmed O 
quercetin B-TRIVIAL 
( O 
10 O 
μM O 
) O 
inhibited O 
TNF-alpha O 
gene O 
expression O 
. O 
Further O 
, O 
superoxide B-TRIVIAL 
dismutase O 
, O 
catalase O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
activities O 
were O 
increased O 
by O 
1.68 O 
, O 
2.19 O 
and O 
1.71 O 
folds O 
respectively O 
. O 
Albumin O 
and O 
urea B-TRIVIAL 
content O 
was O 
increased O 
while O 
the O 
alanine B-TRIVIAL 
aminotransferase O 
( O 
ALAT O 
) O 
activity O 
was O 
significantly O 
decreased O 
by O 
quercetin B-TRIVIAL 
. O 
Hence O 
, O 
quercetin B-TRIVIAL 
effectively O 
reversed O 
NAFLD O 
symptoms O 
by O 
decreased O 
triacyl B-FAMILY 
glycerol I-FAMILY 
accumulation O 
, O 
insulin O 
resistance O 
, O 
inflammatory O 
cytokine O 
secretion O 
and O 
increased O 
cellular O 
antioxidants O 
in O 
OA O 
induced O 
hepatic O 
steatosis O 
in O 
HepG2 O 
cells O 
. O 

male O 
mammary O 
gland O 
: O 
a O 
target O 
for O 
the O 
xenoestrogen O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
. O 

of O 
some O 
strains O 
of O 
mice O 
retain O 
their O 
mammary O 
epithelium O 
even O 
in O 
the O 
absence O 
of O 
nipples O 
. O 
Here O 
, O 
we O 
have O 
characterized O 
the O 
mammary O 
gland O 
in O 
male O 
CD-1 O 
mice O 
both O 
in O 
whole O 
mounts O 
and O 
histological O 
sections O 
. O 
We O 
also O 
examined O 
the O 
effects O 
of O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
, O 
an O 
estrogen B-FAMILY 
mimic O 
that O 
alters O 
development O 
of O 
the O 
female O 
mouse O 
mammary O 
gland O 
. O 
BPA B-ABBREVIATION 
was O 
administered O 
at O 
a O 
range O 
of O 
environmentally O 
relevant O 
doses O 
( O 
0.25-250μg O 
/ O 
kg O 
/ O 
day O 
) O 
to O 
pregnant O 
and O 
lactating O 
mice O 
and O 
then O 
the O 
mammary O 
glands O 
of O 
male O 
offspring O 
were O 
examined O 
at O 
several O 
periods O 
in O 
adulthood O 
. O 
We O 
observed O 
age- O 
and O 
dose O 
- O 
specific O 
effects O 
on O 
mammary O 
gland O 
morphology O 
, O 
indicating O 
that O 
perinatal O 
BPA B-ABBREVIATION 
exposures O 
alter O 
the O 
male O 
mammary O 
gland O 
in O 
adulthood O 
. O 
These O 
results O 
may O 
provide O 
insight O 
into O 
gynecomastia O 
, O 
the O 
most O 
common O 
male O 
breast O 
disease O 
in O 
humans O 
, O 
where O 
proliferation O 
of O 
the O 
mammary O 
epithelium O 
leads O 
to O 
breast O 
enlargement O 
. O 

in O 
vivo O 
proof O 
of O 
concept O 
of O 
a O 
novel O 
double O 
- O 
coating O 
system O 
, O 
based O 
on O 
enteric O 
polymers O 
, O 
which O 
accelerated O 
drug O 
release O 
in O 
the O 
ileo O 
- O 
colonic O 
region O 
, O 
was O 
investigated O 
in O 
humans O 
. O 
Prednisolone B-TRIVIAL 
tablets O 
were O 
coated O 
with O 
a O 
double O 
- O 
coating O 
formulation O 
by O 
applying O 
an O 
inner O 
layer O 
composed O 
of O 
EUDRAGIT B-FAMILY 
® O 
S O 
neutralised O 
to O 
pH O 
8 O 
and O 
a O 
buffer O 
salt O 
( O 
10% O 
KH(2)PO(4) B-FORMULA 
) O 
, O 
which O 
was O 
overcoated O 
with O 
layer O 
of O 
standard O 
EUDRAGIT B-FAMILY 
® O 
S O 
organic O 
solution O 
. O 
For O 
comparison O 
, O 
a O 
single O 
coating O 
system O 
was O 
produced O 
by O 
applying O 
the O 
same O 
amount O 
of O 
EUDRAGIT B-FAMILY 
® O 
S O 
organic O 
solution O 
on O 
the O 
tablet O 
cores O 
. O 
Dissolution O 
tests O 
on O 
the O 
tablets O 
were O 
carried O 
out O 
using O 
USP O 
II O 
apparatus O 
in O 
0.1N O 
HCl B-FORMULA 
for O 
2h O 
and O 
subsequently O 
in O 
pH O 
7.4 O 
Krebs O 
bicarbonate O 
buffer O 
. O 
For O 
comparison O 
, O 
tablets O 
were O 
also O 
tested O 
under O 
the O 
USP O 
method O 
established O 
for O 
modified O 
release O 
mesalamine B-TRIVIAL 
formulations O 
. O 
Ten O 
fasted O 
volunteers O 
received O 
the O 
double O 
- O 
coated O 
and O 
single O 
- O 
coated O 
tablets O 
in O 
a O 
two O 
- O 
way O 
crossover O 
study O 
. O 
The O 
formulations O 
were O 
radiolabelled O 
and O 
followed O 
by O 
gamma O 
scintigraphy O 
; O 
the O 
disintegration O 
times O 
and O 
positions O 
were O 
recorded O 
. O 
There O 
was O 
no O 
drug O 
release O 
from O 
the O 
single O 
- O 
coated O 
or O 
double O 
- O 
coated O 
tablets O 
in O 
0.1N O 
HCl B-FORMULA 
for O 
2h O 
. O 
The O 
single O 
- O 
coated O 
tablets O 
showed O 
slow O 
release O 
in O 
subsequent O 
Krebs O 
bicarbonate O 
buffer O 
with O 
a O 
lag O 
time O 
of O 
120min O 
, O 
while O 
in O 
contrast O 
drug O 
release O 
from O 
the O 
double O 
- O 
coated O 
tablets O 
was O 
initiated O 
at O 
60min O 
. O 
In O 
contrast O 
, O 
using O 
the O 
USP O 
dissolution O 
method O 
, O 
normally O 
employed O 
for O 
modified O 
release O 
mesalamine B-TRIVIAL 
products O 
, O 
no O 
discrimination O 
was O 
attained O 
. O 
The O 
in O 
vivo O 
disintegration O 
of O 
the O 
single O 
- O 
coated O 
EUDRAGIT B-FAMILY 
® O 
S O 
tablets O 
in O 
the O 
large O 
intestine O 
was O 
erratic O 
. O 
Furthermore O 
, O 
in O 
2 O 
volunteers O 
, O 
the O 
single O 
- O 
coated O 
tablet O 
was O 
voided O 
intact O 
. O 
Double O 
- O 
coated O 
tablets O 
disintegrated O 
in O 
a O 
more O 
consistent O 
way O 
, O 
mainly O 
in O 
the O 
ileo O 
- O 
caecal O 
junction O 
or O 
terminal O 
ileum O 
. O 
The O 
accelerated O 
in O 
vivo O 
disintegration O 
of O 
the O 
double O 
- O 
coating O 
EUDRAGIT B-FAMILY 
® O 
S O 
system O 
can O 
overcome O 
the O 
limitations O 
of O 
conventional O 
enteric O 
coatings O 
targeting O 
the O 
colon O 
and O 
avoid O 
the O 
pass O 
- O 
through O 
of O 
intact O 
tablets O 
. O 
Moreover O 
, O 
Krebs O 
bicarbonate B-SYSTEMATIC 
buffer O 
has O 
the O 
ability O 
to O 
discriminate O 
between O 
formulations O 
designed O 
to O 
target O 
the O 
ileo O 
- O 
colonic O 
region O 
. O 

( O 
PEs O 
) O 
are O 
naturally O 
occurring O 
plant O 
components O 
, O 
with O 
the O 
ability O 
to O 
induce O 
biological O 
responses O 
in O 
vertebrates O 
by O 
mimicking O 
or O 
modulating O 
the O 
action O 
of O 
endogenous O 
hormones O 
. O 
Single O 
isoflavones B-FAMILY 
have O 
been O 
shown O 
to O 
affect O 
adipocyte O 
differentiation O 
, O 
but O 
knowledge O 
on O 
the O 
effect O 
of O 
dietary O 
relevant O 
mixtures O 
of O 
PEs O 
, O 
including O 
for O 
instance O 
lignans O 
, O 
is O 
lacking O 
. O 
In O 
the O 
current O 
study O 
dietary O 
relevant O 
mixtures O 
of O 
isoflavones B-FAMILY 
and O 
their O 
metabolites O 
, O 
lignans B-FAMILY 
and O 
their O 
metabolites O 
, O 
coumestrol B-TRIVIAL 
, O 
and O 
a O 
mixture O 
containing O 
all O 
of O 
them O 
, O 
were O 
examined O 
for O 
effects O 
on O 
adipogenesis O 
in O 
3T3-L1 O 
adipocytes O 
, O 
as O 
well O 
as O 
tested O 
for O 
their O 
PPARγ O 
activating O 
abilities O 
. O 
The O 
results O 
showed O 
that O 
mixtures O 
of O 
isoflavonoid B-FAMILY 
parent O 
compounds O 
and O 
metabolites O 
, O 
respectively O 
, O 
a O 
mixture O 
of O 
lignan B-FAMILY 
metabolites O 
, O 
as O 
well O 
as O 
coumestrol B-TRIVIAL 
concentration O 
- O 
dependently O 
inhibited O 
adipocyte O 
differentiation O 
. O 
Furthermore O 
, O 
a O 
mixture O 
of O 
isoflavonoid B-FAMILY 
parent O 
compounds O 
, O 
and O 
a O 
mixture O 
of O 
isoflavonoid B-FAMILY 
metabolites O 
were O 
found O 
to O 
have O 
PPARγ O 
activating O 
abilities O 
. O 
These O 
results O 
suggest O 
that O 
PEs O 
can O 
affect O 
pathways O 
known O 
to O 
play O 
a O 
role O 
in O 
obesity O 
development O 
, O 
and O 
indicate O 
that O 
the O 
inhibitory O 
effect O 
on O 
adipocyte O 
differentiation O 
does O 
not O 
appear O 
to O 
be O 
strictly O 
associated O 
with O 
PPARγ O 
activation O 
/ O 
inhibition O 
. O 
The O 
current O 
study O 
support O 
the O 
hypothesis O 
that O 
compounds O 
with O 
endocrine O 
activity O 
can O 
affect O 
pathways O 
playing O 
a O 
role O 
in O 
the O 
development O 
obesity O 
and O 
obesity O 
related O 
diseases O 
. O 

novel O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
5 O 
positive O 
allosteric O 
modulator O 
acts O 
at O 
a O 
unique O 
site O 
and O 
confers O 
stimulus O 
bias O 
to O 
mGlu5 O 
signaling O 
. O 

glutamate B-TRIVIAL 
receptor O 
5 O 
( O 
mGlu5 O 
) O 
is O 
a O 
target O 
for O 
the O 
treatment O 
of O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
disorders O 
, O 
such O 
as O 
schizophrenia O 
and O 
Alzheimer's O 
disease O 
. O 
Furthermore O 
, O 
mGlu5 O 
has O 
been O 
shown O 
to O 
play O 
an O 
important O 
role O 
in O 
hippocampal O 
synaptic O 
plasticity O 
, O 
specifically O 
in O 
long O 
- O 
term O 
depression O 
( O 
LTD O 
) O 
and O 
long O 
- O 
term O 
potentiation O 
( O 
LTP O 
) O 
, O 
which O 
is O 
thought O 
to O 
be O 
involved O 
in O 
cognition O 
. O 
Multiple O 
mGlu5-positive O 
allosteric O 
modulators O 
( O 
PAMs O 
) O 
have O 
been O 
developed O 
from O 
a O 
variety O 
of O 
different O 
scaffolds O 
. O 
Previous O 
work O 
has O 
extensively O 
characterized O 
a O 
common O 
allosteric O 
site O 
on O 
mGlu5 O 
, O 
termed O 
the O 
MPEP B-ABBREVIATION 
( O 
2-Methyl-6-(phenylethynyl)pyridine B-SYSTEMATIC 
) O 
binding O 
site O 
. O 
However O 
, O 
one O 
mGlu5 O 
PAM O 
, O 
CPPHA B-ABBREVIATION 
( O 
N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide B-SYSTEMATIC 
) O 
, O 
interacts O 
with O 
a O 
separate O 
allosteric O 
site O 
on O 
mGlu5 O 
. O 
Using O 
cell O 
- O 
based O 
assays O 
and O 
brain O 
slice O 
preparations O 
, O 
we O 
characterized O 
the O 
interaction O 
of O 
a O 
potent O 
and O 
efficacious O 
mGlu5 O 
PAM O 
from O 
the O 
CPPHA B-ABBREVIATION 
series O 
termed O 
NCFP B-ABBREVIATION 
( O 
N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide B-SYSTEMATIC 
) O 
. O 
NCFP B-ABBREVIATION 
binds O 
to O 
the O 
CPPHA B-ABBREVIATION 
site O 
on O 
mGlu5 O 
and O 
potentiates O 
mGlu5 O 
- O 
mediated O 
responses O 
in O 
both O 
recombinant O 
and O 
native O 
systems O 
. O 
However O 
, O 
NCFP B-ABBREVIATION 
provides O 
greater O 
mGlu5 O 
subtype O 
selectivity O 
than O 
does O 
CPPHA B-ABBREVIATION 
, O 
making O 
it O 
more O 
suitable O 
for O 
studies O 
of O 
effects O 
on O 
mGlu5 O 
in O 
CNS O 
preparations O 
. O 
Of O 
interest O 
, O 
NCFP B-ABBREVIATION 
does O 
not O 
potentiate O 
responses O 
involved O 
in O 
hippocampal O 
synaptic O 
plasticity O 
( O 
LTD O 
/ O 
LTP O 
) O 
, O 
setting O 
it O 
apart O 
from O 
other O 
previously O 
characterized O 
MPEP B-ABBREVIATION 
site O 
PAMs O 
. O 
This O 
suggests O 
that O 
although O 
mGlu5 O 
PAMs O 
may O 
have O 
similar O 
responses O 
in O 
some O 
systems O 
, O 
they O 
can O 
induce O 
differential O 
effects O 
on O 
mGlu5 O 
- O 
mediated O 
physiologic O 
responses O 
in O 
the O 
CNS O 
. O 
Such O 
stimulus O 
bias O 
by O 
mGlu5 O 
PAMs O 
may O 
complicate O 
drug O 
discovery O 
efforts O 
but O 
would O 
also O 
allow O 
for O 
specifically O 
tailored O 
therapies O 
, O 
if O 
pharmacological O 
biases O 
can O 
be O 
attributed O 
to O 
different O 
therapeutic O 
outcomes O 
. O 

stereoisomer O 
(+)-naloxone B-TRIVIAL 
potentiates O 
G O 
- O 
protein O 
coupling O 
and O 
feeding O 
associated O 
with O 
stimulation O 
of O 
mu O 
opioid O 
receptors O 
in O 
the O 
parabrachial O 
nucleus O 
. O 

, O 
opioids O 
produce O 
their O 
effects O 
by O 
activating O 
Gi O 
- O 
proteins O 
that O 
inhibit O 
adenylate O 
cyclase O 
activity O 
. O 
Previous O 
studies O 
proposed O 
that O 
mu-opioid O 
receptors O 
can O 
also O 
stimulate O 
adenylate B-TRIVIAL 
cyclase O 
due O 
to O 
an O 
initial O 
transient O 
coupling O 
to O 
Gs O 
- O 
proteins O 
. O 
Treatment O 
with O 
ultra O 
- O 
low O 
doses O 
of O 
the O 
nonselective O 
opioid O 
antagonist O 
(-)-naloxone B-TRIVIAL 
or O 
its O 
inactive O 
enantiomer O 
(+)-naloxone B-TRIVIAL 
blocks O 
this O 
excitatory O 
effect O 
and O 
enhances O 
Gi-coupling O 
. O 
Previously O 
we O 
reported O 
that O 
infusion O 
of O 
the O 
mu-opioid O 
receptor O 
agonist O 
[ B-SYSTEMATIC 
D-Ala2 I-SYSTEMATIC 
, I-SYSTEMATIC 
N-Me-Phe4 I-SYSTEMATIC 
, I-SYSTEMATIC 
Glycinol5]-Enkephalin I-SYSTEMATIC 
( O 
DAMGO B-ABBREVIATION 
) O 
into O 
the O 
mu-opioid O 
receptor O 
expressing O 
lateral O 
parabrachial O 
nucleus O 
increases O 
feeding O 
. O 
Pretreatment O 
with O 
(-)-naloxone B-TRIVIAL 
blocks O 
this O 
effect O 
. O 
We O 
used O 
this O 
parabrachial O 
circuit O 
as O 
a O 
model O 
to O 
assess O 
cellular O 
actions O 
of O 
ultra O 
- O 
low O 
doses O 
of O 
(-)-naloxone B-TRIVIAL 
and O 
(+)-naloxone B-TRIVIAL 
in O 
modifying O 
the O 
effects O 
of O 
DAMGO B-ABBREVIATION 
. O 
Our O 
results O 
showed O 
that O 
an O 
ultra O 
- O 
low O 
concentration O 
of O 
(-)-naloxone B-TRIVIAL 
( O 
0.001 O 
nM O 
) O 
and O 
several O 
concentrations O 
of O 
(+)-naloxone B-TRIVIAL 
( O 
0.01-10 O 
nM O 
) O 
enhanced O 
DAMGO B-ABBREVIATION 
-stimulated O 
guanosine-5'-0-(γ-thio)-triphosphate B-SYSTEMATIC 
incorporation O 
in O 
parabrachial O 
sections O 
in O 
vitro O 
. O 
Further O 
, O 
we O 
analyzed O 
the O 
relevance O 
of O 
these O 
effects O 
in O 
vivo O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
show O 
that O 
(+)-naloxone B-TRIVIAL 
can O 
potentiate O 
DAMGO B-ABBREVIATION 
-induced O 
feeding O 
at O 
doses O 
at O 
which O 
(-)-naloxone B-TRIVIAL 
was O 
an O 
antagonist O 
. O 
These O 
results O 
implicated O 
(+)-naloxone B-TRIVIAL 
as O 
a O 
novel O 
tool O 
for O 
studying O 
mu-opioid O 
receptor O 
functions O 
and O 
suggest O 
that O 
(+)-naloxone B-TRIVIAL 
may O 
have O 
therapeutic O 
value O 
to O 
enhance O 
clinical O 
actions O 
of O 
opiate O 
drugs O 
. O 

nonsense O 
mutation O 
in O 
cereblon O 
( O 
CRBN O 
) O 
causes O 
a O 
mild O 
type O 
of O 
mental O 
retardation O 
in O 
humans O 
. O 
An O 
earlier O 
study O 
showed O 
that O 
CRBN O 
negatively O 
regulates O 
the O 
functional O 
activity O 
of O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
in O 
vitro O 
by O 
binding O 
directly O 
to O 
the O 
α1 O 
subunit O 
of O 
the O 
AMPK O 
complex O 
. O 
However O 
, O 
the O 
in O 
vivo O 
role O 
of O 
CRBN O 
was O 
not O 
studied O 
. O 
To O 
elucidate O 
the O 
physiological O 
functions O 
of O 
Crbn O 
, O 
a O 
mouse O 
strain O 
was O 
generated O 
in O 
which O 
the O 
Crbn O 
gene O 
was O 
deleted O 
throughout O 
the O 
whole O 
body O 
. O 
In O 
Crbn O 
- O 
deficient O 
mice O 
fed O 
a O 
normal O 
diet O 
, O 
AMPK O 
in O 
the O 
liver O 
showed O 
hyper O 
- O 
phosphorylation O 
, O 
which O 
indicated O 
the O 
constitutive O 
activation O 
of O 
AMPK O 
. O 
Since O 
Crbn O 
- O 
deficient O 
mice O 
showed O 
significantly O 
less O 
weight O 
gain O 
when O 
fed O 
a O 
high O 
fat O 
diet O 
and O 
their O 
insulin O 
sensitivity O 
was O 
considerably O 
improved O 
, O 
the O 
functions O 
of O 
Crbn O 
in O 
the O 
liver O 
were O 
primarily O 
investigated O 
. O 
These O 
results O 
provide O 
the O 
first O 
in O 
vivo O 
evidence O 
that O 
Crbn O 
is O 
a O 
negative O 
modulator O 
of O 
AMPK O 
, O 
which O 
suggests O 
that O 
Crbn O 
may O 
be O 
a O 
potential O 
target O 
for O 
metabolic O 
disorders O 
of O 
the O 
liver O 
. O 

existence O 
of O 
adult O 
β-cell O 
progenitors O 
remains O 
the O 
most O 
controversial O 
developmental O 
biology O 
topic O 
in O 
diabetes O 
research O 
. O 
It O 
has O 
been O 
reported O 
that O 
β-cell O 
progenitors O 
can O 
be O 
activated O 
by O 
ductal O 
ligation O 
- O 
induced O 
injury O 
of O 
adult O 
mouse O 
pancreas O 
and O 
apparently O 
act O 
in O 
a O 
cell O 
- O 
autonomous O 
manner O 
to O 
double O 
the O 
functional O 
β-cell O 
mass O 
within O 
a O 
week O 
by O 
differentiation O 
and O 
proliferation O 
. O 
Here O 
, O 
we O 
demonstrate O 
that O 
pancreatic O 
duct O 
ligation O 
( O 
PDL O 
) O 
does O 
not O 
activate O 
progenitors O 
to O 
contribute O 
to O 
β-cell O 
mass O 
expansion O 
. O 
Rather O 
, O 
PDL O 
stimulates O 
massive O 
pancreatic O 
injury O 
, O 
which O 
alters O 
pancreatic O 
composition O 
and O 
thus O 
complicates O 
accurate O 
measurement O 
of O 
β-cell O 
content O 
via O 
traditional O 
morphometry O 
methodologies O 
that O 
superficially O 
sample O 
the O 
pancreas O 
. O 
To O 
overcome O 
this O 
potential O 
bias O 
, O 
we O 
quantified O 
β-cells O 
from O 
the O 
entire O 
pancreas O 
and O 
observed O 
that O 
β-cell O 
mass O 
and O 
insulin O 
content O 
are O 
totally O 
unchanged O 
by O 
PDL-induced O 
injury O 
. O 
Lineage O 
- O 
tracing O 
studies O 
using O 
sequential O 
administration O 
of O 
thymidine B-TRIVIAL 
analogs O 
, O 
rat O 
insulin O 
2 O 
promoter O 
- O 
driven O 
cre O 
- O 
lox O 
, O 
and O 
low O 
- O 
frequency O 
ubiquitous O 
cre O 
- O 
lox O 
reveal O 
that O 
PDL O 
does O 
not O 
convert O 
progenitors O 
to O 
the O 
β-cell O 
lineage O 
. O 
Thus O 
, O 
we O 
conclude O 
that O 
β-cells O 
are O 
not O 
generated O 
in O 
injured O 
adult O 
mouse O 
pancreas O 
. O 

- O 
induced O 
diabetes O 
is O 
associated O 
with O 
low O 
- O 
grade O 
inflammation O 
in O 
adipose O 
tissue O 
and O 
macrophage O 
infiltration O 
of O 
islets O 
. O 
We O 
show O 
that O 
ablation O 
of O 
Galectin-3 O 
, O 
a O 
galactoside O 
- O 
binding O 
lectin O 
, O 
accelerates O 
high O 
- O 
fat O 
diet O 
- O 
induced O 
obesity O 
and O 
diabetes O 
. O 
Obese O 
LGALS3(- O 
/ O 
- O 
) O 
mice O 
have O 
increased O 
body O 
weight O 
, O 
amount O 
of O 
total O 
visceral O 
adipose O 
tissue O 
, O 
fasting O 
blood O 
glucose B-TRIVIAL 
and O 
insulin O 
levels O 
, O 
HOMA-IR O 
and O 
markers O 
of O 
systemic O 
inflammation O 
compared O 
to O 
diet O 
- O 
matched O 
WT O 
animals O 
. O 
Obese O 
LGALS3(- O 
/ O 
- O 
) O 
visceral O 
adipose O 
tissue O 
exhibited O 
increased O 
incidence O 
of O 
Type-1 O 
T O 
and O 
NKT O 
lymphocytes O 
and O 
pro O 
- O 
inflammatory O 
CD11c O 
+ O 
CD11b O 
macrophages O 
and O 
decreased O 
CD4 O 
+ O 
CD25 O 
+ O 
FoxP3+ O 
Tregs O 
and O 
M2 O 
macrophages O 
. O 
Pronounced O 
mononuclear O 
cell O 
infiltrate O 
, O 
increased O 
expression O 
of O 
NLRP3 O 
inflammasome O 
and O 
IL-1β O 
in O 
macrophages O 
and O 
increased O 
accumulation O 
of O 
advanced O 
glycation O 
endproducts O 
( O 
AGE O 
) O 
and O 
receptor O 
for O 
AGE O 
( O 
RAGE O 
) O 
expression O 
were O 
present O 
in O 
pancreatic O 
islets O 
of O 
obese O 
LGALS3(- O 
/ O 
- O 
) O 
animals O 
accompanied O 
with O 
elevated O 
phosphorilated O 
NFκB O 
p65 O 
and O 
mature O 
Caspase-1 O 
protein O 
expression O 
in O 
pancreatic O 
and O 
visceral O 
adipose O 
tissue O 
. O 
In O 
vitro O 
stimulation O 
of O 
LGALS3(- O 
/ O 
- O 
) O 
peritoneal O 
macrophages O 
with O 
lypopolysaccharide O 
( O 
LPS O 
) O 
and O 
saturated O 
fatty O 
acid O 
palmitate B-TRIVIAL 
caused O 
increased O 
Caspase-1 O 
dependent O 
IL-1β O 
production O 
and O 
increased O 
phosphorilation O 
of O 
NFκB O 
p65 O 
compared O 
to O 
WT O 
cells O 
. O 
Transfection O 
of O 
LGALS3(- O 
/ O 
- O 
) O 
macrophages O 
with O 
NLRP3 O 
siRNA O 
attenuated O 
IL-1β O 
production O 
in O 
response O 
to O 
palmitate B-TRIVIAL 
and O 
LPS O 
plus O 
palmitate B-TRIVIAL 
. O 
Obtained O 
results O 
suggest O 
important O 
protective O 
roles O 
for O 
Gal-3 O 
in O 
obesity O 
- O 
induced O 
inflammation O 
and O 
diabetes O 
. O 

receptor O 
( O 
GHR O 
) O 
gene O 
- O 
disrupted O 
mice O 
( O 
GHR- O 
/ O 
- O 
) O 
have O 
provided O 
countless O 
discoveries O 
as O 
to O 
the O 
numerous O 
actions O 
of O 
GH O 
. O 
Many O 
of O 
these O 
discoveries O 
highlight O 
the O 
importance O 
of O 
GH O 
in O 
adipose O 
tissue O 
. O 
For O 
example O 
GHR- O 
/ O 
- O 
mice O 
are O 
insulin O 
sensitive O 
yet O 
obese O 
with O 
preferential O 
enlargement O 
of O 
the O 
sc O 
adipose O 
depot O 
. O 
GHR- O 
/ O 
- O 
mice O 
also O 
have O 
elevated O 
levels O 
of O 
leptin O 
, O 
resistin O 
, O 
and O 
adiponectin O 
, O 
compared O 
with O 
controls O 
leading O 
some O 
to O 
suggest O 
that O 
GH O 
may O 
negatively O 
regulate O 
certain O 
adipokines O 
. O 
To O 
help O 
clarify O 
the O 
role O 
that O 
GH O 
exerts O 
specifically O 
on O 
adipose O 
tissue O 
in O 
vivo O 
, O 
we O 
selectively O 
disrupted O 
GHR O 
in O 
adipose O 
tissue O 
to O 
produce O 
Fat O 
GHR O 
Knockout O 
( O 
FaGHRKO O 
) O 
mice O 
. O 
Surprisingly O 
, O 
FaGHRKOs O 
shared O 
only O 
a O 
few O 
characteristics O 
with O 
global O 
GHR- O 
/ O 
- O 
mice O 
. O 
Like O 
the O 
GHR- O 
/ O 
- O 
mice O 
, O 
FaGHRKO O 
mice O 
are O 
obese O 
with O 
increased O 
total O 
body O 
fat O 
and O 
increased O 
adipocyte O 
size O 
. O 
However O 
, O 
FaGHRKO O 
mice O 
have O 
increases O 
in O 
all O 
adipose O 
depots O 
with O 
no O 
improvements O 
in O 
measures O 
of O 
glucose B-TRIVIAL 
homeostasis O 
. O 
Furthermore O 
, O 
resistin O 
and O 
adiponectin O 
levels O 
in O 
FaGHRKO O 
mice O 
are O 
similar O 
to O 
controls O 
( O 
or O 
slightly O 
decreased O 
) O 
unlike O 
the O 
increased O 
levels O 
found O 
in O 
GHR- O 
/ O 
- O 
mice O 
, O 
suggesting O 
that O 
GH O 
does O 
not O 
regulate O 
these O 
adipokines O 
directly O 
in O 
adipose O 
tissue O 
in O 
vivo O 
. O 
Other O 
features O 
of O 
FaGHRKO O 
mice O 
include O 
decreased O 
levels O 
of O 
adipsin O 
, O 
a O 
near O 
- O 
normal O 
GH O 
/ O 
IGF-1 O 
axis O 
, O 
and O 
minimal O 
changes O 
to O 
a O 
large O 
assortment O 
of O 
circulating O 
factors O 
that O 
were O 
measured O 
such O 
as O 
IGF O 
- O 
binding O 
proteins O 
. O 
In O 
conclusion O 
, O 
specific O 
removal O 
of O 
GHR O 
in O 
adipose O 
tissue O 
is O 
sufficient O 
to O 
increase O 
adipose O 
tissue O 
and O 
decrease O 
circulating O 
adipsin O 
. O 
However O 
, O 
removal O 
of O 
GHR O 
in O 
adipose O 
tissue O 
alone O 
is O 
not O 
sufficient O 
to O 
increase O 
levels O 
of O 
resistin O 
or O 
adiponectin O 
and O 
does O 
not O 
alter O 
glucose B-TRIVIAL 
metabolism O 
. O 

- O 
thirds O 
of O 
adults O 
in O 
the O 
U.S O 
. O 
are O 
overweight O 
or O 
obese O 
, O 
and O 
another O 
26 O 
million O 
have O 
type O 
2 O 
diabetes O 
( O 
T2D O 
) O 
. O 
Patients O 
with O 
diabetes O 
and O 
/ O 
or O 
the O 
metabolic O 
syndrome O 
have O 
a O 
significantly O 
increased O 
risk O 
of O 
heart O 
attack O 
and O 
stroke O 
compared O 
with O 
people O 
with O 
normal O 
insulin O 
sensitivity O 
. O 
Decreased O 
insulin O 
sensitivity O 
in O 
cardiovascular O 
tissues O 
as O 
well O 
as O 
in O 
traditional O 
targets O 
of O 
insulin O 
metabolic O 
signaling O 
, O 
such O 
as O 
skeletal O 
muscle O 
, O 
is O 
an O 
underlying O 
abnormality O 
in O 
obesity O 
, O 
hypertension O 
, O 
and O 
T2D O 
. O 
In O 
the O 
vasculature O 
, O 
insulin O 
signaling O 
plays O 
a O 
critical O 
role O 
in O 
normal O 
vascular O 
function O 
via O 
endothelial O 
cell O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
and O 
modulation O 
of O 
Ca(2+) B-FORMULA 
handling O 
and O 
sensitivity O 
in O 
vascular O 
smooth O 
muscle O 
cells O 
. O 
Available O 
evidence O 
suggests O 
that O 
impaired O 
vascular O 
insulin O 
sensitivity O 
may O 
be O 
an O 
early O 
, O 
perhaps O 
principal O 
, O 
defect O 
of O 
vascular O 
function O 
and O 
contributor O 
to O 
the O 
pathogenesis O 
of O 
vascular O 
disease O 
in O 
persons O 
with O 
obesity O 
, O 
hypertension O 
, O 
and O 
T2D O 
. O 
In O 
the O 
overweight O 
and O 
obese O 
individual O 
, O 
as O 
well O 
as O 
in O 
persons O 
with O 
hypertension O 
, O 
systemic O 
and O 
vascular O 
insulin O 
resistance O 
often O 
occur O 
in O 
concert O 
with O 
elevations O 
in O 
plasma O 
aldosterone B-TRIVIAL 
. O 
Indeed O 
, O 
basic O 
and O 
clinical O 
studies O 
have O 
demonstrated O 
that O 
elevated O 
plasma O 
aldosterone B-TRIVIAL 
levels O 
predict O 
the O 
development O 
of O 
insulin O 
resistance O 
and O 
that O 
aldosterone B-TRIVIAL 
directly O 
interferes O 
with O 
insulin O 
signaling O 
in O 
vascular O 
tissues O 
. O 
Furthermore O 
, O 
elevated O 
plasma O 
aldosterone B-TRIVIAL 
levels O 
are O 
associated O 
with O 
increased O 
heart O 
attack O 
and O 
stroke O 
risk O 
. O 
Conversely O 
, O 
renin-angiotensin- O 
aldosterone B-TRIVIAL 
system O 
and O 
mineralocorticoid O 
receptor O 
( O 
MR O 
) O 
antagonism O 
reduces O 
cardiovascular O 
risk O 
in O 
these O 
patient O 
populations O 
. O 
Recent O 
and O 
accumulating O 
evidence O 
in O 
this O 
area O 
has O 
implicated O 
excessive O 
Ser B-FORMULA 
phosphorylation O 
and O 
proteosomal O 
degradation O 
of O 
the O 
docking O 
protein O 
, O 
insulin O 
receptor O 
substrate O 
, O 
and O 
enhanced O 
signaling O 
through O 
hybrid O 
insulin O 
/ O 
IGF-1 O 
receptor O 
as O 
important O 
mechanisms O 
underlying O 
aldosterone B-TRIVIAL 
-mediated O 
interruption O 
of O 
downstream O 
vascular O 
insulin O 
signaling O 
. O 
Prevention O 
or O 
restoration O 
of O 
these O 
changes O 
via O 
blockade O 
of O 
aldosterone B-TRIVIAL 
action O 
in O 
the O 
vascular O 
wall O 
with O 
MR O 
antagonists O 
( O 
i.e O 
. O 
, O 
spironolactone B-TRIVIAL 
, O 
eplerenone B-TRIVIAL 
) O 
may O 
therefore O 
account O 
for O 
the O 
clinical O 
benefit O 
of O 
these O 
compounds O 
in O 
obese O 
and O 
diabetic O 
patients O 
with O 
cardiovascular O 
disease O 
. O 
This O 
review O 
will O 
highlight O 
recent O 
evidence O 
supporting O 
the O 
hypothesis O 
that O 
aldosterone B-TRIVIAL 
and O 
MR O 
signaling O 
represent O 
an O 
ideal O 
candidate O 
pathway O 
linking O 
early O 
promoters O 
of O 
diabetes O 
, O 
especially O 
overnutrition O 
and O 
obesity O 
, O 
to O 
vascular O 
insulin O 
resistance O 
, O 
dysfunction O 
, O 
and O 
disease O 
. O 

properties O 
of O 
graphdiyne B-TRIVIAL 
and O 
graphene B-TRIVIAL 
modified O 
TiO₂ B-FORMULA 
: O 
from O 
theory O 
to O 
experiment O 
. O 

chemical O 
structure O 
and O 
electronic O 
properties O 
of O 
two O 
- O 
dimensional O 
( O 
2D O 
) O 
carbon B-SYSTEMATIC 
-supported O 
TiO₂ B-FORMULA 
, O 
TiO₂ B-FORMULA 
TiO₂-graphdiyne B-FORMULA 
graphdiyne B-TRIVIAL 
, O 
and O 
TiO₂ B-FORMULA 
TiO₂-graphene B-FORMULA 
graphene B-TRIVIAL 
composites O 
have O 
been O 
studied O 
by O 
first O 
- O 
principles O 
density O 
functional O 
theory O 
. O 
Calculation O 
results O 
show O 
that O 
TiO₂ B-FORMULA 
(001)- O 
graphdiyne B-TRIVIAL 
composites O 
possess O 
superior O 
charge O 
separation O 
and O 
oxidation O 
properties O 
, O 
having O 
the O 
longest O 
lifetimes O 
of O 
photoexcited O 
carriers O 
among O 
all O 
of O 
the O 
2D O 
composites O 
containing O 
TiO₂ B-FORMULA 
of O 
different O 
facets O 
. O 
Our O 
experimental O 
results O 
further O 
proved O 
that O 
TiO₂ B-FORMULA 
(001)- O 
graphdiyne B-TRIVIAL 
composites O 
could O 
be O 
a O 
promising O 
photocatalyst O 
. O 
For O 
photocatalytic O 
degradation O 
of O 
methylene B-TRIVIAL 
blue I-TRIVIAL 
, O 
the O 
rate O 
constant O 
of O 
the O 
TiO₂ B-FORMULA 
(001)- O 
graphdiyne B-TRIVIAL 
composite O 
is O 
1.63 O 
± O 
0.15 O 
times O 
that O 
of O 
the O 
pure O 
TiO₂ B-FORMULA 
( O 
1 O 
) O 
and O 
1.27 O 
± O 
0.12 O 
times O 
that O 
of O 
the O 
TiO₂ B-FORMULA 
(001)- O 
graphene B-TRIVIAL 
composite O 
. O 

vivo O 
microdialysis O 
for O 
the O 
evaluation O 
of O 
transfersomes O 
as O 
a O 
novel O 
transdermal O 
delivery O 
vehicle O 
for O 
cinnamic B-TRIVIAL 
acid I-TRIVIAL 
. O 

In O 
this O 
study O 
, O 
cinnamic B-TRIVIAL 
acid I-TRIVIAL 
-loaded O 
transfersomes O 
were O 
prepared O 
and O 
dermal O 
microdialysis O 
sampling O 
was O 
used O 
in O 
Sprague-Dawley O 
rats O 
to O 
compare O 
the O 
amount O 
of O 
drug O 
released O 
into O 
the O 
skin O 
using O 
transfersomes O 
as O 
transdermal O 
carriers O 
with O 
that O 
released O 
on O 
using O 
conventional O 
liposomes O 
. O 
The O 
formulation O 
of O 
cinnamic B-TRIVIAL 
acid I-TRIVIAL 
-loaded O 
transfersomes O 
was O 
optimized O 
by O 
a O 
uniform O 
design O 
through O 
in O 
vitro O 
transdermal O 
permeation O 
studies O 
. O 
Hydration O 
time O 
was O 
confirmed O 
as O 
a O 
significant O 
factor O 
influencing O 
the O 
entrapment O 
efficiency O 
of O 
transfersomes O 
, O 
further O 
affecting O 
their O 
transdermal O 
flux O 
in O 
vitro O 
. O 
The O 
fluxes O 
of O 
cinnamic B-TRIVIAL 
acid I-TRIVIAL 
from O 
transfersomes O 
were O 
all O 
higher O 
than O 
those O 
from O 
conventional O 
liposomes O 
, O 
and O 
the O 
flux O 
from O 
the O 
optimal O 
transfersome O 
formulation O 
was O 
3.01-fold O 
higher O 
than O 
that O 
from O 
the O 
conventional O 
liposomes O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
An O 
in O 
vivo O 
microdialysis O 
sampling O 
method O 
revealed O 
that O 
the O 
dermal O 
drug O 
concentrations O 
from O 
transfersomes O 
applied O 
on O 
various O 
skin O 
regions O 
were O 
much O 
lower O 
than O 
those O 
required O 
with O 
conventional O 
liposomes O 
. O 
After O 
the O 
administration O 
of O 
drug O 
- O 
containing O 
transfersomes O 
and O 
liposomes O 
on O 
abdominal O 
skin O 
regions O 
of O 
rats O 
for O 
a O 
period O 
of O 
10 O 
h O 
, O 
the O 
C(max) O 
of O 
cinnamic B-TRIVIAL 
acid I-TRIVIAL 
from O 
the O 
compared O 
liposomes O 
was O 
3.21 O 
± O 
0.25 O 
μg O 
/ O 
mL O 
and O 
that O 
from O 
the O 
transfersomes O 
was O 
merely O 
0.59 O 
± O 
0.02 O 
μg O 
/ O 
mL O 
. O 
The O 
results O 
suggest O 
that O 
transfersomes O 
can O 
be O 
used O 
as O 
carriers O 
to O 
enhance O 
the O 
transdermal O 
delivery O 
of O 
cinnamic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
that O 
these O 
vehicles O 
may O 
penetrate O 
the O 
skin O 
in O 
the O 
complete O 
form O 
, O 
given O 
their O 
significant O 
deformability O 
. O 

of O 
amoxicillin B-TRIVIAL 
and O 
cefuroxime B-TRIVIAL 
: O 
rapid O 
therapeutic O 
concentrations O 
in O 
skin O 
. O 

Context O 
: O 
Amoxicillin B-TRIVIAL 
( O 
AMX B-ABBREVIATION 
) O 
and O 
cefuroxime B-TRIVIAL 
( O 
CFX B-ABBREVIATION 
) O 
are O 
antibiotics O 
used O 
often O 
to O 
treat O 
skin O 
bacterial O 
infections O 
. O 
Typically O 
, O 
high O 
oral O 
doses O 
are O 
required O 
to O 
achieve O 
minimum O 
inhibitory O 
concentration O 
( O 
MIC O 
) O 
at O 
the O 
site O 
of O 
infection O 
that O 
may O 
affect O 
only O 
a O 
very O 
small O 
area O 
of O 
skin O 
. O 
Objectives O 
: O 
To O 
lower O 
side O 
effects O 
and O 
increase O 
therapeutic O 
effectiveness O 
, O 
the O 
percutaneous O 
absorption O 
and O 
retention O 
of O 
AMX B-ABBREVIATION 
and O 
CFX B-ABBREVIATION 
administered O 
by O 
iontophoresis O 
was O 
investigated O 
in O 
a O 
rabbit O 
model O 
by O 
measuring O 
dermis O 
concentrations O 
via O 
microdialysis O 
. O 
Methods O 
: O 
Iontophoresis O 
was O 
performed O 
using O 
a O 
stainless O 
steel O 
electrode O 
and O 
a O 
non-woven O 
polypropylene B-SYSTEMATIC 
pad O 
. O 
The O 
cartridge O 
pad O 
was O 
soaked O 
with O 
a O 
solution O 
of O 
AMX B-ABBREVIATION 
in O 
glycerin O 
or O 
of O 
CFX B-ABBREVIATION 
in O 
glycerin O 
/ O 
water O 
( O 
60 O 
: O 
40 O 
) O 
. O 
Constant O 
current O 
density O 
of O 
0 O 
, O 
100 O 
, O 
200 O 
or O 
300 O 
µA O 
/ O 
cm(2) O 
was O 
applied O 
for O 
60 O 
min O 
. O 
Results O 
: O 
For O 
AMX B-ABBREVIATION 
, O 
therapeutically O 
effective O 
skin O 
concentrations O 
were O 
detected O 
immediately O 
after O 
the O 
application O 
of O 
electrical O 
current O 
for O 
any O 
of O 
the O 
current O 
density O 
tested O 
and O 
remained O 
above O 
it O 
for O 
at O 
least O 
2 O 
h O 
from O 
the O 
end O 
of O 
iontophoresis O 
. O 
For O 
CFX B-ABBREVIATION 
, O 
skin O 
concentrations O 
rose O 
above O 
MIC O 
only O 
at O 
the O 
higher O 
current O 
densities O 
and O 
fell O 
below O 
the O 
MIC O 
by O 
the O 
end O 
of O 
the O 
experiment O 
. O 
Conclusion O 
: O 
Iontophoresis O 
is O 
a O 
promising O 
method O 
to O 
obtain O 
a O 
fast O 
and O 
sustained O 
concentration O 
of O 
AMX B-ABBREVIATION 
and O 
CFX B-ABBREVIATION 
in O 
skin O 
. O 

discovered O 
new O 
structural O 
diversity O 
to O 
a O 
prevalent O 
, O 
yet O 
medicinally O 
underappreciated O 
, O 
cyanobacterial O 
protease O 
inhibitor O 
scaffold O 
and O 
undertook O 
comprehensive O 
protease O 
profiling O 
to O 
reveal O 
potent O 
and O 
selective O 
elastase O 
inhibition O 
. O 
Structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
studies O 
and O 
X-ray O 
cocrystal O 
structure O 
analysis O 
allowed O 
a O 
detailed O 
assessment O 
of O 
critical O 
and O 
tunable O 
structural O 
elements O 
. O 
To O 
realize O 
the O 
therapeutic O 
potential O 
of O 
these O 
cyclodepsipeptides O 
, O 
we O 
probed O 
the O 
cellular O 
effects O 
of O 
a O 
novel O 
and O 
representative O 
family O 
member O 
, O 
symplostatin B-TRIVIAL 
5 I-TRIVIAL 
( O 
1 O 
) O 
, O 
which O 
attenuated O 
the O 
downstream O 
cellular O 
effects O 
of O 
elastase O 
in O 
an O 
epithelial O 
lung O 
airway O 
model O 
system O 
, O 
alleviating O 
clinical O 
hallmarks O 
of O 
chronic O 
pulmonary O 
diseases O 
such O 
as O 
cell O 
death O 
, O 
cell O 
detachment O 
, O 
and O 
inflammation O 
. O 
This O 
compound O 
attenuated O 
the O 
effects O 
of O 
elastase O 
on O 
receptor O 
activation O 
, O 
proteolytic O 
processing O 
of O 
the O 
adhesion O 
protein O 
ICAM-1 O 
, O 
NF-κB O 
activation O 
, O 
and O 
transcriptomic O 
changes O 
, O 
including O 
the O 
expression O 
of O 
pro O 
- O 
inflammatory O 
cytokines O 
IL1A O 
, O 
IL1B O 
, O 
and O 
IL8 O 
. O 
Compound O 
1 O 
exhibited O 
activity O 
comparable O 
to O 
the O 
clinically O 
approved O 
elastase O 
inhibitor O 
sivelestat B-TRIVIAL 
in O 
short O 
- O 
term O 
assays O 
and O 
demonstrated O 
superior O 
sustained O 
activity O 
in O 
longer O 
- O 
term O 
assays O 
. O 

, O 
active O 
compounds O 
were O 
discovered O 
from O 
natural O 
product O 
extracts O 
by O 
bioassay O 
- O 
guided O 
fractionation O 
, O 
which O 
was O 
with O 
high O 
cost O 
and O 
low O 
efficiency O 
. O 
A O 
well O 
- O 
trained O 
support O 
vector O 
regression O 
model O 
based O 
on O 
mean O 
impact O 
value O 
was O 
used O 
to O 
identify O 
lead O 
active O 
compounds O 
on O 
inhibiting O 
the O 
proliferation O 
of O 
the O 
HeLa O 
cells O 
in O 
curcuminoids B-FAMILY 
from O 
Curcuma O 
longa O 
L O 
. O 
Eight O 
constituents O 
possessing O 
the O 
high O 
absolute O 
mean O 
impact O 
value O 
were O 
identified O 
to O 
have O 
significant O 
cytotoxicity O 
, O 
and O 
the O 
cytotoxic O 
effect O 
of O 
these O 
constituents O 
was O 
partly O 
confirmed O 
by O 
subsequent O 
MTT B-ABBREVIATION 
( O 
3-(4 B-SYSTEMATIC 
, I-SYSTEMATIC 
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium I-SYSTEMATIC 
bromide I-SYSTEMATIC 
) O 
assays O 
and O 
previous O 
reports O 
. O 
In O 
the O 
dosage O 
range O 
of O 
0.2-211.2 O 
, O 
0.1-140.2 O 
, O 
0.2-149.9 O 
μm O 
, O 
50% O 
inhibiting O 
concentrations O 
( O 
IC50 O 
) O 
of O 
curcumin B-TRIVIAL 
, O 
demethoxycurcumin B-SYSTEMATIC 
, O 
and O 
bisdemethoxycurcumin B-SYSTEMATIC 
were O 
26.99 O 
± O 
1.11 O 
, O 
19.9 O 
± O 
1.22 O 
, O 
and O 
35.51 O 
± O 
7.29 O 
μm O 
, O 
respectively O 
. O 
It O 
was O 
demonstrated O 
that O 
our O 
method O 
could O 
successfully O 
identify O 
lead O 
active O 
compounds O 
in O 
curcuminoids B-FAMILY 
from O 
Curcuma O 
longa O 
L O 
. O 
prior O 
to O 
bioassay O 
- O 
guided O 
separation O 
. O 
The O 
use O 
of O 
a O 
support O 
vector O 
regression O 
model O 
combined O 
with O 
mean O 
impact O 
value O 
analysis O 
could O 
provide O 
an O 
efficient O 
and O 
economical O 
approach O 
for O 
drug O 
discovery O 
from O 
natural O 
products O 
. O 

of O 
DNA O 
by O 
proton O 
- O 
coupled O 
electron O 
transfer O 
to O 
a O 
photoexcited O 
, O 
hydrated B-SYSTEMATIC 
Ru I-SYSTEMATIC 
(II) I-SYSTEMATIC 
1,10-phenanthroline-5,6-dione I-SYSTEMATIC 
complex O 
. O 

light O 
irradiation O 
of O 
a O 
ruthenium B-SYSTEMATIC 
(II) I-SYSTEMATIC 
quinone B-FAMILY 
-containing O 
complex O 
, O 
[(phen)(2)Ru(phendione)](2+) B-FORMULA 
(1(2+)) O 
, O 
where O 
phendione B-ABBREVIATION 
= O 
1,10-phenanthroline-5,6-dione B-SYSTEMATIC 
, O 
leads O 
to O 
DNA O 
cleavage O 
in O 
an O 
oxygen B-SYSTEMATIC 
independent O 
manner O 
. O 
A O 
combination O 
of O 
NMR O 
analyses O 
, O 
transient O 
absorption O 
spectroscopy O 
, O 
and O 
fluorescence O 
measurements O 
in O 
water O 
and O 
acetonitrile B-SYSTEMATIC 
reveal O 
that O 
complex O 
1(2+) O 
must O 
be O 
hydrated O 
at O 
the O 
quinone B-FAMILY 
functionality O 
, O 
giving O 
[(phen)(2)Ru(phenH(2)O)](2+) B-FORMULA 
( O 
1 O 
H(2)O(2+) B-FORMULA 
, O 
where O 
phenH(2)O B-FORMULA 
= O 
1,10-phenanthroline-6-one-5-diol B-SYSTEMATIC 
) O 
, O 
in O 
order O 
to O 
access O 
a O 
long O 
- O 
lived O 
( O 
3)MLCT( O 
hydrate B-SYSTEMATIC 
) O 
state O 
( O 
τ O 
∼ O 
360 O 
ns O 
in O 
H(2)O B-FORMULA 
) O 
which O 
is O 
responsible O 
for O 
DNA O 
cleavage O 
. O 
In O 
effect O 
, O 
hydration O 
at O 
one O 
of O 
the O 
carbonyl B-FAMILY 
functions O 
effectively O 
eliminates O 
the O 
low O 
- O 
energy O 
(3)MLCT(SQ) O 
state O 
( O 
Ru B-FORMULA 
(III) I-FORMULA 
phen I-FORMULA 
- I-FORMULA 
semiquinone I-FORMULA 
radical O 
anion O 
) O 
as O 
the O 
predominant O 
nonradiative O 
decay O 
pathway O 
. O 
This O 
(3)MLCT(SQ) O 
state O 
is O 
very O 
short O 
- O 
lived O 
( O 
< O 
1 O 
ns O 
) O 
as O 
expected O 
from O 
the O 
energy O 
gap O 
law O 
for O 
nonradiative O 
decay O 
, O 
( O 
1 O 
) O 
and O 
too O 
short O 
- O 
lived O 
to O 
be O 
the O 
photoactive O 
species O 
. O 
The O 
resulting O 
excited O 
state O 
in O 
1 O 
H(2)O(2+) B-FORMULA 
* O 
has O 
photophysical O 
properties O 
similar O 
to O 
the O 
(3)MLCT O 
state O 
in O 
[Ru(phen)(3)](2+) B-FORMULA 
* O 
with O 
the O 
added O 
functionality O 
of O 
basic O 
sites O 
at O 
the O 
ligand O 
periphery O 
. O 
Whereas O 
[Ru(phen)(3)](2+) B-FORMULA 
* O 
does O 
not O 
show O 
direct O 
DNA O 
cleavage O 
, O 
the O 
deprotonated O 
form O 
of O 
1 O 
H(2)O(2+) B-FORMULA 
* O 
does O 
via O 
a O 
proton O 
- O 
coupled O 
electron O 
transfer O 
( O 
PCET O 
) O 
mechanism O 
where O 
the O 
peripheral O 
basic O 
oxygen B-SYSTEMATIC 
sites O 
act O 
as O 
the O 
proton O 
acceptor O 
. O 
Analysis O 
of O 
the O 
small O 
molecule O 
byproducts O 
of O 
DNA O 
scission O 
supports O 
the O 
conclusion O 
that O 
cleavage O 
occurs O 
via O 
H B-FORMULA 
-atom O 
abstraction O 
from O 
the O 
sugar B-FAMILY 
moieties O 
, O 
consistent O 
with O 
a O 
PCET O 
mechanism O 
. O 
Complex O 
1(2+) O 
is O 
a O 
rare O 
example O 
of O 
a O 
ruthenium B-SYSTEMATIC 
complex O 
which O 
' O 
turns O 
on O 
' O 
both O 
reactivity O 
and O 
luminescence O 
upon O 
switching O 
to O 
a O 
hydrated O 
state O 
. O 

protein O 
sorption O 
in O 
poly(acrylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
-containing O 
films O 
through O 
incorporation O 
of O 
comb O 
- O 
like O 
polymers O 
and O 
film O 
adsorption O 
at O 
low O 
pH O 
and O 
high O 
ionic O 
strength O 
. O 

principle O 
, O 
incorporation O 
of O 
comb O 
- O 
like O 
block O 
copolymers O 
in O 
multilayer O 
polyelectrolyte O 
films O 
can O 
both O 
increase O 
film O 
thickness O 
relative O 
to O 
coatings O 
containing O 
linear O 
polymers O 
and O 
provide O 
more O 
swollen O 
films O 
for O 
increased O 
sorption O 
of O 
proteins O 
. O 
In O 
the O 
absence O 
of O 
added O 
salt O 
, O 
alternating O 
adsorption O 
of O 
5 O 
bilayers O 
of O 
protonated O 
poly(allylamine) B-FAMILY 
( O 
PAH B-ABBREVIATION 
) O 
and O 
comb O 
- O 
like O 
poly(2-hydroxyethyl B-FAMILY 
methacrylate)-graft-poly(acrylic I-FAMILY 
acid I-FAMILY 
) I-FAMILY 
( O 
PHEMA-g-PAA B-ABBREVIATION 
) O 
leads O 
to O 
∼2-fold O 
thicker O 
coatings O 
than O 
adsorption O 
of O 
PAH B-ABBREVIATION 
and O 
linear O 
PAA B-ABBREVIATION 
, O 
and O 
the O 
difference O 
in O 
the O 
thicknesses O 
of O 
the O 
two O 
coatings O 
increases O 
with O 
the O 
number O 
of O 
bilayers O 
. O 
Moreover O 
, O 
the O 
( O 
PAH B-ABBREVIATION 
/ O 
PHEMA-g-PAA B-ABBREVIATION 
)n O 
films O 
sorb O 
2- O 
to O 
4-fold O 
more O 
protein O 
than O 
corresponding O 
films O 
prepared O 
with O 
linear O 
PAA B-ABBREVIATION 
, O 
and O 
coatings O 
deposited O 
at O 
pH O 
3 O 
sorb O 
more O 
protein O 
than O 
coatings O 
adsorbed O 
at O 
pH O 
5 O 
, O 
7 O 
, O 
or O 
9 O 
. O 
In O 
fact O 
changes O 
in O 
deposition O 
pH O 
and O 
addition O 
of O 
0.5 O 
M O 
NaCl B-FORMULA 
to O 
polyelectrolyte O 
adsorption O 
solutions O 
alter O 
protein O 
sorption O 
more O 
dramatically O 
than O 
variations O 
in O 
the O 
constituent O 
polymer O 
architecture O 
. O 
When O 
deposited O 
from O 
0.5 O 
M O 
NaCl B-FORMULA 
at O 
pH O 
3 O 
, O 
both O 
( O 
PAH B-ABBREVIATION 
/ O 
PHEMA-g-PAA B-ABBREVIATION 
)5 O 
and O 
( O 
PAH B-ABBREVIATION 
/ O 
PAA B-ABBREVIATION 
)5 O 
films O 
increase O 
in O 
thickness O 
more O 
than O 
400% O 
upon O 
adsorption O 
of O 
lysozyme O 
. O 
These O 
films O 
contain O 
a O 
high O 
concentration O 
of O 
free O 
- O 
COOH B-FORMULA 
groups O 
, O 
and O 
subsequent O 
deprotonation O 
of O 
these O 
groups O 
at O 
neutral O 
pH O 
likely O 
contributes O 
to O 
increased O 
protein O 
binding O 
. O 
Lysozyme O 
sorption O 
stabilizes O 
these O 
films O 
, O 
as O 
without O 
lysozyme O 
films O 
deposited O 
at O 
pH O 
3 O 
from O 
0.5 O 
M O 
NaCl B-FORMULA 
desorb O 
at O 
neutral O 
pH O 
. O 
Films O 
deposited O 
at O 
pH O 
9 O 
from O 
0.5 O 
M O 
NaCl B-FORMULA 
are O 
more O 
stable O 
and O 
also O 
bind O 
large O 
amounts O 
of O 
lysozyme O 
. O 
The O 
high O 
binding O 
capacities O 
of O 
these O 
films O 
make O 
them O 
attractive O 
for O 
potential O 
applications O 
in O 
protein O 
isolation O 
or O 
immobilization O 
of O 
enzymes O 
. O 

date O 
, O 
a O 
number O 
of O 
biomolecule O 
- O 
mediated O 
nanoparticle O 
self O 
- O 
assembly O 
systems O 
have O 
been O 
developed O 
that O 
are O 
amenable O 
to O 
controllable O 
disassembly O 
under O 
relatively O 
gentle O 
conditions O 
. O 
However O 
, O 
for O 
some O 
applications O 
such O 
as O 
design O 
of O 
self O 
- O 
assembled O 
multifunctional O 
theragnostic O 
agents O 
, O 
high O 
stability O 
of O 
the O 
assembled O 
structures O 
can O 
be O 
of O 
primary O 
importance O 
. O 
Here O 
, O 
we O 
report O 
extraordinarily O 
high O 
durability O 
of O 
protein O 
- O 
assisted O 
nanoparticle O 
self O 
- O 
assembly O 
systems O 
yielding O 
bifunctional O 
colloidal O 
superstructures O 
resistant O 
to O 
extreme O 
denaturing O 
conditions O 
intolerable O 
for O 
most O 
proteins O 
( O 
e.g O 
. O 
, O 
high O 
concentrations O 
of O 
chaotropic O 
agents O 
, O 
high O 
temperature O 
) O 
. O 
Among O 
the O 
tested O 
systems O 
( O 
barnase O 
- O 
barstar O 
( O 
BBS O 
) O 
, O 
streptavidin B-TRIVIAL 
- O 
biotin B-TRIVIAL 
, O 
antibody O 
- O 
antigen O 
, O 
and O 
protein O 
A-immunoglobulin O 
) O 
, O 
the O 
BBS O 
is O 
notable O 
due O 
to O 
the O 
combination O 
of O 
its O 
high O 
resistance O 
to O 
severe O 
chemical O 
perturbation O 
and O 
unique O 
advantages O 
offered O 
by O 
genetic O 
engineering O 
of O 
this O 
entirely O 
protein O 
- O 
based O 
system O 
. O 
Comparison O 
of O 
the O 
self O 
- O 
assembly O 
systems O 
shows O 
that O 
whereas O 
in O 
all O 
cases O 
the O 
preassembled O 
structures O 
proved O 
essentially O 
resistant O 
to O 
extreme O 
conditions O 
, O 
the O 
ability O 
of O 
the O 
complementary O 
biomolecular O 
pairs O 
to O 
mediate O 
assembly O 
of O 
the O 
initial O 
biomolecule O 
- O 
particle O 
conjugates O 
differs O 
substantially O 
in O 
these O 
conditions O 
. O 

constituents O 
of O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
fraction O 
from O 
Dianthus O 
superbus O 
. O 

ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
fraction O 
( O 
EE-DS O 
) O 
from O 
Dianthus O 
superbus O 
was O 
found O 
to O 
possess O 
the O 
cytotoxic O 
activity O 
against O 
cancer O 
cells O 
in O 
previous O 
study O 
. O 
To O 
investigate O 
cytotoxic O 
constituents O 
, O 
the O 
bioassay O 
- O 
guided O 
isolation O 
of O 
compounds O 
from O 
EE-DS O 
was O 
performed O 
. O 
Two O 
dianthramides B-FAMILY 
( O 
1 O 
and O 
2 O 
) O 
, O 
three O 
flavonoids B-FAMILY 
( O 
3-5 O 
) O 
, O 
two O 
coumarins B-FAMILY 
( O 
6 O 
and O 
7 O 
) O 
and O 
three O 
other O 
compounds O 
( O 
8-10 O 
) O 
were O 
obtained O 
. O 
Structures O 
of O 
isolated O 
compounds O 
were O 
identified O 
by O 
spectroscopic O 
analysis O 
. O 
Cytotoxicity O 
of O 
the O 
compounds O 
against O 
HepG2 O 
cells O 
was O 
evaluated O 
. O 
Compound O 
1 O 
showed O 
the O 
strongest O 
cytotoxicity O 
, O 
compounds O 
10 O 
, O 
4 O 
, O 
3 O 
and O 
5 O 
had O 
moderate O 
cytotoxicity O 
. O 

and O 
characterization O 
of O 
diblock O 
copolymer O 
of O 
p(3-Hydroxypropionate)-block-p(4-hydroxybutyrate) B-FAMILY 
from O 
recombinant O 
Escherichia O 
coli O 
. O 

( O 
P4HB B-SYSTEMATIC 
) O 
is O 
a O 
highly O 
elastic O 
polymer O 
, O 
whereas O 
poly(3-hydroxypropionate) B-FAMILY 
( O 
P3HP B-SYSTEMATIC 
) O 
is O 
a O 
polymer O 
with O 
enormous O 
tensile O 
strength O 
. O 
This O 
study O 
aimed O 
to O 
biosynthesize O 
a O 
block O 
copolymer O 
consisting O 
of O 
soft O 
P4HB B-SYSTEMATIC 
block O 
with O 
a O 
strong O 
P3HP B-SYSTEMATIC 
block O 
to O 
gain O 
unique O 
and O 
excellent O 
material O 
properties O 
. O 
A O 
recombinant O 
Escherichia O 
coli O 
strain O 
that O 
produces O 
homopolymers O 
of O 
P3HP B-SYSTEMATIC 
and O 
P4HB B-SYSTEMATIC 
was O 
employed O 
for O 
the O 
block O 
copolymer O 
synthesis O 
. O 
When O 
the O 
strain O 
was O 
grown O 
in O 
the O 
presence O 
of O 
1,4-butanediol B-SYSTEMATIC 
( O 
BDO B-ABBREVIATION 
) O 
as O 
a O 
4HB B-SYSTEMATIC 
precursor O 
, O 
P4HB B-SYSTEMATIC 
block O 
was O 
formed O 
. O 
Sequential O 
supplementation O 
of O 
1,3-propanediol B-SYSTEMATIC 
( O 
PDO B-ABBREVIATION 
) O 
as O 
a O 
3HP B-SYSTEMATIC 
precursor O 
allowed O 
the O 
strain O 
to O 
produce O 
P3HP B-SYSTEMATIC 
block O 
. O 
Thermal O 
, O 
NMR O 
, O 
fractionation O 
, O 
and O 
mechanical O 
characterizations O 
confirmed O 
the O 
resulting O 
polymer O 
as O 
a O 
block O 
copolymer O 
of O 
P3HP-b-P4HB B-SYSTEMATIC 
. O 
Two O 
block O 
copolymers O 
were O 
formed O 
from O 
this O 
study O 
, O 
including O 
the O 
P3HP B-SYSTEMATIC 
-b-29% O 
P4HB B-SYSTEMATIC 
and O 
P3HP B-SYSTEMATIC 
-b-37% O 
P4HB B-SYSTEMATIC 
, O 
they O 
showed O 
superior O 
properties O 
over O 
random O 
copolymers O 
P(3HP-co-4HB) B-SYSTEMATIC 
. O 
The O 
block O 
copolymers O 
had O 
two O 
glass O 
transition O 
temperatures O 
( O 
Tg O 
) O 
and O 
two O 
melting O 
temperatures O 
( O 
Tm O 
) O 
. O 
In O 
comparison O 
to O 
the O 
homopolymers O 
P3HP B-SYSTEMATIC 
and O 
P4HB B-SYSTEMATIC 
, O 
incorporation O 
of O 
block O 
microstructure O 
resulted O 
in O 
the O 
lowering O 
of O 
Tm O 
, O 
block O 
copolymers O 
were O 
revealed O 
with O 
higher O 
Young's O 
modulus O 
, O 
yield O 
strengths O 
, O 
and O 
tension O 
strengths O 
much O 
better O 
than O 
the O 
previously O 
reported O 
random O 
copolymers O 
of O 
similar O 
compositions O 
. O 
Block O 
copolymerization O 
of O 
P3HP B-SYSTEMATIC 
and O 
P4HB B-SYSTEMATIC 
adds O 
a O 
new O 
vision O 
on O 
PHA B-ABBREVIATION 
polymerization O 
by O 
generation O 
of O 
new O 
polymers O 
with O 
superior O 
properties O 
. O 

effects O 
of O 
inhaled O 
lavender O 
oil O 
on O 
scopolamine B-TRIVIAL 
-induced O 
dementia O 
via O 
anti-oxidative O 
activities O 
in O 
rats O 
. O 

is O 
used O 
in O 
traditional O 
medicines O 
in O 
Asia O 
, O 
Europe O 
, O 
ancient O 
Greece O 
and O 
Rome O 
, O 
and O 
was O 
mentioned O 
in O 
the O 
Bible O 
and O 
in O 
ancient O 
Jewish O 
texts O 
. O 
Also O 
, O 
lavender O 
is O 
reported O 
to O 
be O 
an O 
effective O 
medical O 
plant O 
in O 
treating O 
inflammation O 
, O 
depression O 
, O 
stress O 
and O 
headache O 
. O 
The O 
present O 
study O 
was O 
undertaken O 
in O 
order O 
to O 
investigate O 
the O 
antioxidant O 
and O 
antiapoptotic O 
activities O 
of O 
the O 
lavender O 
essential O 
oils O 
from O 
Lavandula O 
angustifolia O 
ssp O 
. O 
angustifolia O 
Mill O 
. O 
and O 
Lavandula O 
hybrida O 
Rev O 
. O 
using O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPX O 
) O 
and O 
catalase O 
( O 
CAT O 
) O 
specific O 
activities O 
, O 
total O 
content O 
of O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
, O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
level O 
( O 
lipid O 
peroxidation O 
) O 
and O 
DNA O 
fragmentation O 
assays O 
in O 
male O 
Wistar O 
rats O 
subjected O 
to O 
scopolamine B-TRIVIAL 
-induced O 
dementia O 
rat O 
model O 
. O 
In O 
scopolamine B-TRIVIAL 
-treated O 
rats O 
, O 
lavender O 
essential O 
oils O 
showed O 
potent O 
antioxidant O 
and O 
antiapoptotic O 
activities O 
. O 
Subacute O 
exposures O 
( O 
daily O 
, O 
for O 
7 O 
continuous O 
days O 
) O 
to O 
lavender O 
oils O 
significantly O 
increased O 
antioxidant O 
enzyme O 
activities O 
( O 
SOD O 
, O 
GPX O 
and O 
CAT O 
) O 
, O 
total O 
content O 
of O 
reduced O 
GSH B-ABBREVIATION 
and O 
reduced O 
lipid O 
peroxidation O 
( O 
MDA B-ABBREVIATION 
level O 
) O 
in O 
rat O 
temporal O 
lobe O 
homogenates O 
, O 
suggesting O 
antioxidant O 
potential O 
. O 
Also O 
, O 
DNA O 
cleavage O 
patterns O 
were O 
absent O 
in O 
the O 
lavender O 
groups O 
, O 
suggesting O 
antiapoptotic O 
activity O 
. O 
Taken O 
together O 
, O 
our O 
results O 
suggest O 
that O 
antioxidant O 
and O 
antiapoptotic O 
activities O 
of O 
the O 
lavender O 
essential O 
oils O 
are O 
the O 
major O 
mechanisms O 
for O 
their O 
potent O 
neuroprotective O 
effects O 
against O 
scopolamine B-TRIVIAL 
-induced O 
oxidative O 
stress O 
in O 
the O 
rat O 
brain O 
. O 

effects O 
of O 
oral O 
crocin B-TRIVIAL 
against O 
intracerebroventricular O 
streptozotocin B-TRIVIAL 
-induced O 
spatial O 
memory O 
deficit O 
and O 
oxidative O 
stress O 
in O 
rats O 
. O 

( O 
ICV O 
) O 
streptozotocin B-TRIVIAL 
( O 
STZ B-ABBREVIATION 
) O 
has O 
been O 
shown O 
to O 
cause O 
cognitive O 
impairment O 
, O 
associated O 
with O 
free O 
radical O 
generation O 
. O 
In O 
this O 
study O 
, O 
we O 
evaluated O 
the O 
effects O 
of O 
crocin B-TRIVIAL 
on O 
cognitive O 
performance O 
in O 
ICV O 
STZ B-ABBREVIATION 
-lesioned O 
rats O 
( O 
3mg O 
/ O 
kg O 
bilaterally O 
, O 
on O 
day O 
1 O 
and O 
3 O 
) O 
. O 
Crocin B-TRIVIAL 
( O 
100mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
was O 
administered O 
for O 
21 O 
consecutive O 
days O 
, O 
starting O 
1h O 
prior O 
to O 
the O 
first O 
dose O 
of O 
STZ B-ABBREVIATION 
. O 
Cognitive O 
performance O 
was O 
assessed O 
using O 
Morris O 
water O 
maze O 
task O 
while O 
the O 
parameters O 
of O 
oxidative O 
stress O 
assessed O 
, O 
were O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
and O 
total O 
thiol B-FAMILY 
levels O 
besides O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
activity O 
. O 
STZ B-ABBREVIATION 
-lesioned O 
rats O 
showed O 
a O 
severe O 
deficit O 
in O 
memory O 
associated O 
with O 
elevated O 
MDA B-ABBREVIATION 
levels O 
, O 
reduced O 
GPx O 
activity O 
and O 
total O 
thiol O 
content O 
. O 
Crocin B-TRIVIAL 
treatment O 
improved O 
cognitive O 
performance O 
and O 
resulted O 
in O 
a O 
significant O 
reduction O 
in O 
MDA B-ABBREVIATION 
levels O 
and O 
elevation O 
in O 
total O 
thiol B-FAMILY 
content O 
and O 
GPx O 
activity O 
. O 
This O 
study O 
demonstrates O 
that O 
crocin B-TRIVIAL 
may O 
have O 
beneficial O 
effects O 
in O 
the O 
treatment O 
of O 
neurodegenerative O 
disorders O 
such O 
as O 
Alzheimer's O 
disease O 
. O 

imidazo[1,2-a]pyridines B-FAMILY 
carrying O 
active O 
pharmacophores O 
: O 
synthesis O 
and O 
anticonvulsant O 
studies O 
. O 

new O 
series O 
of O 
imidazo[1,2-a]pyridines B-FAMILY 
carrying O 
biologically O 
active O 
pyrazoline B-SYSTEMATIC 
( O 
4a-e O 
) O 
, O 
cyanopyridone B-SYSTEMATIC 
( O 
5a O 
, O 
b O 
) O 
, O 
cyanopyridine B-SYSTEMATIC 
( O 
6a-f O 
) O 
, O 
2-aminopyrimidine B-SYSTEMATIC 
( O 
7a-f O 
) O 
and O 
pyrimidine-2-thione B-SYSTEMATIC 
( O 
8a-d O 
) O 
systems O 
were O 
designed O 
and O 
synthesized O 
as O 
prominent O 
anticonvulsant O 
agents O 
. O 
The O 
target O 
compounds O 
were O 
screened O 
for O 
their O 
in O 
vivo O 
anticonvulsant O 
activity O 
following O 
maximal O 
electroshock O 
( O 
MES O 
) O 
and O 
subcutaneous O 
pentylene B-TRIVIAL 
tetrazole I-TRIVIAL 
( O 
scPTZ O 
) O 
methods O 
at O 
a O 
small O 
test O 
dose O 
of O 
10 O 
mg O 
/ O 
kg O 
. O 
Further O 
, O 
Rotarod O 
toxicity O 
method O 
was O 
used O 
to O 
study O 
the O 
toxicity O 
profile O 
of O 
selected O 
compounds O 
. O 
Compounds O 
4b O 
, O 
5a O 
, O 
5b O 
, O 
6a O 
, O 
7e O 
and O 
8d O 
possessing O 
4-fluorophenyl B-SYSTEMATIC 
substituent O 
at O 
2nd O 
position O 
of O 
imidazo[1,2-a]pyridine B-SYSTEMATIC 
ring O 
displayed O 
potent O 
anticonvulsant O 
activity O 
without O 
displaying O 
any O 
toxicity O 
. O 
Enhanced O 
activity O 
profile O 
was O 
observed O 
for O 
new O 
compounds O 
in O 
PTZ B-ABBREVIATION 
method O 
over O 
MES O 
method O 
. O 

capacity O 
and O 
allergenicity O 
of O 
enzymatically O 
cross O 
- O 
linked O 
sodium B-SYSTEMATIC 
caseinate O 
in O 
comparison O 
to O 
sodium B-SYSTEMATIC 
caseinate O 
in O 
a O 
mouse O 
model O 
for O 
cow's O 
milk O 
allergy O 
. O 

transglutaminase O 
cross O 
- O 
linked O 
caseinate O 
was O 
designed O 
for O 
use O 
in O 
dairy O 
products O 
to O 
increase O 
the O 
viscosity O 
of O 
food O 
matrices O 
. O 
The O 
difference O 
in O 
structure O 
of O 
cross O 
- O 
linked O 
caseinate O 
might O 
have O 
implications O 
for O 
the O 
risk O 
of O 
developing O 
cow's O 
milk O 
allergy O 
. O 
The O 
sensitizing O 
capacity O 
and O 
the O 
allergenicity O 
( O 
the O 
potency O 
to O 
induce O 
an O 
allergic O 
effector O 
response O 
) O 
of O 
cross O 
- O 
linked O 
sodium B-SYSTEMATIC 
caseinate O 
was O 
investigated O 
using O 
a O 
mouse O 
model O 
for O 
cow's O 
milk O 
allergy O 
. O 
Mice O 
were O 
orally O 
sensitized O 
with O 
cross O 
- O 
linked O 
caseinate O 
or O 
caseinate O 
using O 
cholera O 
toxin O 
as O 
adjuvant O 
. O 
Anaphylactic O 
shock O 
reactions O 
, O 
change O 
in O 
body O 
temperature O 
, O 
acute O 
allergic O 
skin O 
response O 
, O 
caseinate- O 
, O 
cross O 
- O 
linked O 
caseinate-IgE O 
and O 
mMCP-1 O 
concentrations O 
were O 
determined O 
after O 
challenge O 
with O 
cross O 
- O 
linked O 
caseinate O 
or O 
caseinate O 
. O 
Sensitization O 
with O 
cross O 
- O 
linked O 
caseinate O 
did O 
not O 
result O 
in O 
anaphylactic O 
shock O 
symptoms O 
, O 
drop O 
in O 
body O 
temperature O 
or O 
release O 
of O 
serum O 
mMCP-1 O 
. O 
A O 
tendency O 
toward O 
decreased O 
casein O 
- O 
specific O 
IgE O 
levels O 
was O 
observed O 
. O 
The O 
allergenicity O 
did O 
not O 
differ O 
between O 
both O 
products O 
. O 
These O 
results O 
indicate O 
that O 
in O 
already O 
caseinate O 
- O 
sensitized O 
mice O 
, O 
cross O 
- O 
linked O 
caseinate O 
did O 
not O 
provoke O 
more O 
pronounced O 
allergenic O 
reactions O 
compared O 
to O 
sodium B-SYSTEMATIC 
caseinate O 
. O 
On O 
top O 
of O 
that O 
, O 
reduced O 
sensitization O 
to O 
cross O 
- O 
linked O 
caseinate O 
was O 
observed O 
. O 
Cross O 
- O 
linked O 
caseinate O 
might O 
therefore O 
be O 
an O 
interesting O 
new O 
dietary O 
concept O 
for O 
humans O 
at O 
risk O 
for O 
food O 
allergy O 
although O 
more O 
mechanistic O 
studies O 
and O 
clinical O 
trials O 
are O 
needed O 
for O 
validation O 
. O 

oxide)-poly(ethylene I-FAMILY 
oxide I-FAMILY 
) I-FAMILY 
block O 
copolymers O 
: O 
From O 
" O 
classical O 
" O 
chemotherapeutic O 
nanocarriers O 
to O 
active O 
cell O 
- O 
response O 
inducers O 
. O 

poly(styrene B-FAMILY 
oxide)-poly(ethylene I-FAMILY 
oxide I-FAMILY 
) I-FAMILY 
( O 
PSO-PEO B-ABBREVIATION 
) O 
triblock O 
copolymers O 
with O 
different O 
chain O 
lengths O 
were O 
analyzed O 
as O 
potential O 
chemotherapeutic O 
nanocarriers O 
, O 
and O 
their O 
ability O 
to O 
inhibit O 
the O 
P-glycoprotein O 
( O 
P-gp O 
) O 
efflux O 
pump O 
in O 
a O 
multidrug O 
resistant O 
( O 
MDR O 
) O 
cell O 
line O 
were O 
measured O 
in O 
order O 
to O 
establish O 
possible O 
cell O 
- O 
responses O 
induced O 
by O 
the O 
presence O 
of O 
the O 
copolymer O 
molecules O 
. O 
Thus O 
, O 
EO33SO14EO33 O 
and O 
EO38SO10EO38 O 
polymeric O 
micelles O 
were O 
tested O 
regarding O 
doxorubicin B-TRIVIAL 
( O 
DOXO B-ABBREVIATION 
) O 
entrapment O 
efficiency O 
( O 
solubilization O 
test O 
) O 
, O 
physical O 
stability O 
( O 
DLS O 
) O 
, O 
cytocompatibility O 
( O 
fibroblasts O 
) O 
, O 
release O 
profiles O 
at O 
various O 
pHs O 
( O 
in O 
vitro O 
tests O 
) O 
, O 
as O 
well O 
as O 
P-gp O 
inhibition O 
and O 
evasion O 
and O 
cytotoxicity O 
of O 
the O 
DOXO B-ABBREVIATION 
-loaded O 
micelles O 
in O 
an O 
ovarian O 
MDR O 
NCI-ADR O 
/ O 
RES O 
cell O 
line O 
and O 
in O 
DOXO B-ABBREVIATION 
-sensitive O 
MCF-7 O 
cells O 
. O 
EO33SO14EO33 O 
and O 
EO38SO10EO38 O 
formed O 
spherical O 
micelles O 
( O 
~13nm O 
) O 
at O 
lower O 
concentration O 
than O 
other O 
copolymers O 
under O 
clinical O 
evaluation O 
( O 
e.g O 
. O 
Pluronic B-FAMILY 
® O 
) O 
, O 
exhibited O 
0.2% O 
to O 
1.8% O 
loading O 
capacity O 
, O 
enhancing O 
more O 
than O 
60 O 
times O 
drug O 
apparent O 
solubility O 
, O 
and O 
retained O 
the O 
cargo O 
for O 
long O 
time O 
. O 
The O 
copolymer O 
unimers O 
inhibited O 
P-gp O 
ATPase O 
activity O 
in O 
a O 
similar O 
way O 
as O 
Pluronic B-TRIVIAL 
P85 I-TRIVIAL 
, O 
favoring O 
DOXO B-ABBREVIATION 
accumulation O 
in O 
the O 
resistant O 
cell O 
line O 
, O 
but O 
not O 
in O 
the O 
sensitive O 
cell O 
line O 
. O 
DOXO B-ABBREVIATION 
loaded O 
in O 
the O 
micelles O 
accumulated O 
more O 
slowly O 
inside O 
the O 
cells O 
, O 
but O 
caused O 
greater O 
cytotoxicity O 
than O 
free O 
drug O 
solutions O 
in O 
the O 
NCI-ADR-RES O 
cell O 
line O 
, O 
which O 
overexpressed O 
P-gp O 
. O 
Hence O 
, O 
PSO-PEO B-ABBREVIATION 
block O 
copolymers O 
offer O 
interesting O 
features O 
as O 
new O 
biological O 
response O 
modifiers O 
to O 
be O 
used O 
in O 
the O 
design O 
of O 
efficient O 
nanocarriers O 
for O 
cancer O 
chemotherapy O 
. O 

of O 
Nod1 O 
and O 
Nod2 O 
receptor O 
ligands O 
into O 
poly(lactic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
nanoparticles O 
potentiates O 
their O 
immune O 
properties O 
. O 

successful O 
vaccines O 
are O 
able O 
to O 
induce O 
persistent O 
antibody O 
responses O 
that O 
can O 
last O 
a O 
lifetime O 
. O 
Emerging O 
evidences O 
indicate O 
that O 
activation O 
of O 
immune O 
cells O 
through O 
pattern O 
recognition O 
receptors O 
( O 
PRRs O 
) O 
such O 
as O 
Toll O 
- O 
like O 
receptors O 
( O 
TLRs O 
) O 
or O 
Nod O 
- O 
like O 
receptors O 
( O 
NLRs O 
) O 
may O 
be O 
critical O 
mechanisms O 
. O 
Among O 
PRRs O 
, O 
the O 
use O 
of O 
TLR O 
ligands O 
as O 
adjuvants O 
is O 
already O 
largely O 
described O 
whereas O 
the O 
use O 
of O 
NLRs O 
ligands O 
remains O 
largely O 
unexplored O 
. O 
As O 
activation O 
of O 
intracytoplasmic O 
NLRs O 
is O 
able O 
to O 
induce O 
proinflammatory O 
molecules O 
, O 
the O 
added O 
value O 
of O 
encapsulation O 
of O 
Nod1 O 
and O 
Nod2 O 
receptor O 
ligands O 
into O 
Poly(Lactic B-FAMILY 
Acid I-FAMILY 
) I-FAMILY 
( O 
PLA B-ABBREVIATION 
) O 
biodegradable O 
nanocarriers O 
to O 
modulate O 
their O 
immune O 
properties O 
on O 
human O 
dendritic O 
cells O 
( O 
DCs O 
) O 
maturation O 
has O 
been O 
evaluated O 
. O 
Their O 
ability O 
to O 
induce O 
systemic O 
immune O 
responses O 
in O 
mice O 
was O 
also O 
measured O 
and O 
compared O 
to O 
free O 
ligands O 
and O 
the O 
Alum O 
adjuvant O 
. O 
Nod O 
ligands O 
encapsulated O 
into O 
PLA B-ABBREVIATION 
NPs O 
were O 
efficiently O 
taken O 
up O 
by O 
DCs O 
and O 
subsequently O 
induced O 
a O 
strong O 
up O 
- O 
regulation O 
of O 
maturation O 
markers O 
and O 
the O 
enhancement O 
of O 
proinflammatory O 
cytokine O 
secretion O 
by O 
DCs O 
. O 
Furthermore O 
, O 
co O 
- O 
injection O 
of O 
encapsulated O 
Nod O 
- O 
ligands O 
with O 
PLA B-ABBREVIATION 
particles O 
carrying O 
Gag O 
p24 O 
HIV-1 O 
antigen O 
allowed O 
a O 
100 O 
fold O 
increase O 
in O 
antibody O 
responses O 
in O 
comparison O 
to O 
Alum O 
. O 
These O 
results O 
suggest O 
that O 
encapsulation O 
of O 
Nod O 
ligands O 
into O 
PLA B-ABBREVIATION 
-NPs O 
could O 
be O 
an O 
effective O 
way O 
to O 
improve O 
vaccine O 
efficiency O 
. O 

plays O 
a O 
critical O 
role O 
in O 
the O 
treatment O 
of O 
non-small O 
cell O 
lung O 
cancer O 
( O 
NSCLC O 
) O 
. O 
However O 
, O 
radioresistance O 
is O 
a O 
major O 
barrier O 
against O 
increasing O 
the O 
efficiency O 
of O 
radiotherapy O 
for O 
NSCLC O 
. O 
To O 
understand O 
the O 
mechanisms O 
underlying O 
NSCLC O 
radioresistance O 
, O 
we O 
previously O 
focused O 
on O 
the O 
potential O 
involvement O 
of O 
PIM1 O 
, O 
PRAS40 O 
, O 
FOXO3a O 
, O 
14-3-3 O 
, O 
and O 
protein O 
phosphatases O 
. O 
Among O 
these O 
proteins O 
, O 
PIM1 O 
functioned O 
as O 
an O 
oncogene O 
and O 
was O 
found O 
to O 
act O 
as O 
a O 
crucial O 
mediator O 
in O 
radioresistant O 
NSCLC O 
cells O 
. O 
Therefore O 
, O 
we O 
investigated O 
the O 
use O 
of O 
PIM1-specific O 
inhibitors O 
as O 
novel O 
therapeutic O 
drugs O 
to O 
regulate O 
radiosensitivity O 
in O 
NSCLC O 
. O 
After O 
structure O 
- O 
based O 
drug O 
selection O 
, O 
SGI-1776 B-IDENTIFIER 
, O 
ETP-45299 B-IDENTIFIER 
, O 
and O 
tryptanthrin B-TRIVIAL 
were O 
selected O 
as O 
candidates O 
of O 
PIM1 O 
inhibitors O 
that O 
act O 
as O 
radiosensitizers O 
. O 
With O 
irradiation O 
, O 
these O 
drugs O 
inhibited O 
only O 
PIM1 O 
kinase O 
activity O 
without O 
affecting O 
PIM1 O 
mRNA O 
/ O 
protein O 
levels O 
or O 
cellular O 
localization O 
. O 
When O 
PIM1 O 
kinase O 
activity O 
was O 
suppressed O 
by O 
these O 
inhibitors O 
, O 
PRAS40 O 
was O 
not O 
phosphorylated O 
. O 
Consequently O 
, O 
unphosphorylated O 
PRAS40 O 
did O 
not O 
form O 
trimeric O 
complexes O 
with O 
14-3-3 O 
and O 
FOXO3a O 
, O 
leading O 
to O 
increased O 
nuclear O 
localization O 
of O 
FOXO3a O 
. O 
Nuclear O 
FOXO3a O 
promoted O 
the O 
expression O 
of O 
pro O 
- O 
apoptotic O 
proteins O 
such O 
as O 
Bim O 
and O 
FasL O 
, O 
resulting O 
in O 
a O 
radiosensitizing O 
effect O 
on O 
radioresistant O 
NSCLC O 
cells O 
. O 
Moreover O 
, O 
an O 
in O 
vivo O 
xenograft O 
mouse O 
model O 
confirmed O 
this O 
radiosensitizing O 
effect O 
induced O 
by O 
PIM1 O 
inhibitors O 
. O 
In O 
these O 
model O 
systems O 
, O 
tumor O 
volume O 
was O 
significantly O 
reduced O 
by O 
a O 
combinational O 
treatment O 
with O 
irradiation O 
and O 
PIM1 O 
inhibitors O 
compared O 
to O 
irradiation O 
alone O 
. O 
Taken O 
together O 
, O 
our O 
findings O 
provided O 
evidence O 
that O 
PIM1-specific O 
inhibitors O 
, O 
SGI-1776 B-IDENTIFIER 
, O 
ETP-45299 B-IDENTIFIER 
, O 
and O 
tryptanthrin B-TRIVIAL 
, O 
can O 
act O 
as O 
novel O 
radiosensitizers O 
to O 
enhance O 
the O 
efficacy O 
of O 
radiotherapy O 
by O 
inhibiting O 
irradiation O 
- O 
induced O 
signaling O 
pathway O 
associated O 
with O 
radioresistance O 
. O 

regulation O 
of O 
drug O 
transporter O 
expression O 
by O 
all B-TRIVIAL 
- I-TRIVIAL 
trans I-TRIVIAL 
retinoic I-TRIVIAL 
acid I-TRIVIAL 
in O 
hepatoma O 
HepaRG O 
cells O 
and O 
human O 
hepatocytes O 
. O 

- I-TRIVIAL 
trans I-TRIVIAL 
retinoic I-TRIVIAL 
acid I-TRIVIAL 
( O 
atRA B-ABBREVIATION 
) O 
is O 
the O 
active O 
form O 
of O 
vitamin B-FAMILY 
A I-FAMILY 
, O 
known O 
to O 
activate O 
retinoid O 
receptors O 
, O 
especially O 
the O 
heterodimer O 
retinoid O 
X O 
receptor O 
( O 
RXR O 
) O 
: O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
receptor O 
( O 
RAR O 
) O 
that O 
otherwise O 
may O 
play O 
a O 
role O 
in O 
regulation O 
of O 
some O 
drug O 
transporters O 
. O 
The O 
present O 
study O 
was O 
designed O 
to O 
characterize O 
the O 
nature O 
of O 
human O 
hepatic O 
transporters O 
that O 
may O 
be O 
targeted O 
by O 
atRA B-ABBREVIATION 
and O 
the O 
heterodimer O 
RXR O 
: O 
RAR O 
. O 
Exposure O 
of O 
human O 
hepatoma O 
HepaRG O 
cells O 
and O 
primary O 
human O 
hepatocytes O 
to O 
5 O 
μM O 
atRA B-ABBREVIATION 
down O 
- O 
regulated O 
mRNA O 
levels O 
of O 
various O 
sinusoidal O 
solute O 
carrier O 
( O 
SLC O 
) O 
influx O 
transporters O 
, O 
including O 
organic O 
anion O 
transporting O 
polypeptide O 
( O 
OATP O 
) O 
2B1 O 
, O 
OATP1B1 O 
, O 
organic O 
cation O 
transporter O 
( O 
OCT O 
) O 
1 O 
and O 
organic O 
anion O 
transporter O 
( O 
OAT O 
) O 
2 O 
, O 
and O 
induced O 
those O 
of O 
the O 
canalicular O 
breast O 
cancer O 
resistance O 
protein O 
( O 
BCRP O 
) O 
. O 
The O 
retinoid O 
concomitantly O 
reduced O 
protein O 
expression O 
of O 
OATP2B1 O 
and O 
OATP1B1 O 
and O 
activity O 
of O 
OATPs O 
and O 
OCT1 O 
and O 
induced O 
BCRP O 
protein O 
expression O 
in O 
HepaRG O 
cells O 
. O 
Some O 
transporters O 
such O 
as O 
OATP1B3 O 
and O 
the O 
bile O 
salt O 
export O 
pump O 
( O 
BSEP O 
) O 
were O 
however O 
down O 
- O 
regulated O 
by O 
atRA B-ABBREVIATION 
in O 
primary O 
human O 
hepatocytes O 
, O 
but O 
induced O 
in O 
HepaRG O 
cells O 
, O 
thus O 
pointing O 
out O 
discrepancies O 
between O 
these O 
two O 
liver O 
cell O 
models O 
in O 
terms O 
of O 
detoxifying O 
protein O 
regulation O 
. O 
atRA B-ABBREVIATION 
-mediated O 
repressions O 
of O 
OATP2B1 O 
, O 
OATP1B1 O 
, O 
OAT2 O 
and O 
OCT1 O 
mRNA O 
expression O 
were O 
finally O 
shown O 
to O 
be O 
counteracted O 
by O 
knocking O 
- O 
down O 
expression O 
of O 
RARα O 
and O 
RXRα O 
through O 
siRNA O 
transfection O 
in O 
HepaRG O 
cells O 
. O 
atRA B-ABBREVIATION 
thus O 
differentially O 
regulated O 
human O 
hepatic O 
drug O 
transporters O 
, O 
mainly O 
in O 
a O 
RXR O 
: O 
RAR-dependent O 
manner O 
, O 
therefore O 
establishing O 
retinoids O 
and O 
retinoid O 
receptors O 
as O 
modulators O 
of O 
liver O 
drug O 
transporter O 
expression O 
. O 

Penta-O-galloyl-β-d-glucose I-SYSTEMATIC 
, O 
a O 
bioactivity O 
guided O 
isolated O 
compound O 
from O 
Mangifera O 
indica O 
inhibits O 
11β-HSD-1 O 
and O 
ameliorates O 
high O 
fat O 
diet O 
- O 
induced O 
diabetes O 
in O 
C57BL O 
/ O 
6 O 
mice O 
. O 

leaf O 
extract O 
of O 
Mangifera O 
indica O 
( O 
MEMI O 
) O 
was O 
subjected O 
to O 
bioactivity O 
guided O 
fractionation O 
in O 
order O 
to O 
identify O 
the O 
active O 
antidiabetic O 
constituent O 
. O 
32 O 
fractions O 
were O 
evaluated O 
for O 
possible O 
11β-HSD-1 O 
inhibition O 
activity O 
under O 
in O 
vitro O 
conditions O 
. O 
The O 
EA-7 O 
/ O 
8-9 O 
/ O 
10-4 O 
fraction O 
was O 
evolved O 
as O 
a O 
most O 
potent O 
fraction O 
among O 
all O 
the O 
fractions O 
and O 
it O 
was O 
identified O 
as O 
well O 
known O 
gallotannin B-FAMILY 
compound O 
1,2,3,4,6 B-SYSTEMATIC 
penta-O-galloyl-β-d-glucose I-SYSTEMATIC 
( O 
PGG B-ABBREVIATION 
) O 
by O 
spectral O 
analysis O 
. O 
Based O 
on O 
these O 
results O 
the O 
PGG B-ABBREVIATION 
was O 
further O 
evaluated O 
in O 
ex O 
vivo O 
11β-HSD-1 O 
inhibition O 
assay O 
and O 
high O 
fat O 
diet O 
(HFD)-induced O 
diabetes O 
in O 
male O 
C57BL O 
/ O 
6 O 
mice O 
. O 
Single O 
dose O 
( O 
10 O 
, O 
25 O 
, O 
50 O 
and O 
100mg O 
/ O 
kg O 
) O 
of O 
PGG B-ABBREVIATION 
and O 
carbenoxolone B-TRIVIAL 
( O 
CBX B-ABBREVIATION 
) O 
have O 
dose O 
dependently O 
inhibited O 
the O 
11β-HSD-1 O 
activity O 
in O 
liver O 
and O 
adipose O 
tissue O 
. O 
Furthermore O 
, O 
HFD O 
appraisal O 
to O 
male O 
C57BL O 
/ O 
6 O 
mice O 
caused O 
severe O 
hyperglycemia O 
, O 
hypertriglyceridemia O 
, O 
elevated O 
levels O 
of O 
plasma O 
corticosterone B-TRIVIAL 
and O 
insulin O 
, O 
increased O 
liver O 
and O 
white O 
adipose O 
mass O 
with O 
increase O 
in O 
body O 
weight O 
was O 
observed O 
compare O 
to O 
normal O 
control O 
. O 
Also O 
, O 
oral O 
glucose B-TRIVIAL 
tolerance O 
was O 
significantly O 
impaired O 
compare O 
to O 
normal O 
control O 
. O 
Interestingly O 
, O 
post O 
- O 
treatment O 
with O 
PGG B-ABBREVIATION 
for O 
21 O 
days O 
had O 
alleviated O 
the O 
HFD-induced O 
biochemical O 
alterations O 
and O 
improved O 
oral O 
glucose B-TRIVIAL 
tolerance O 
compare O 
to O 
HFD-control O 
. O 
In O 
conclusion O 
, O 
the O 
PGG B-ABBREVIATION 
isolated O 
from O 
MEMI O 
inhibits O 
11β-HSD-1 O 
activity O 
and O 
ameliorates O 
HFD-induced O 
diabetes O 
in O 
male O 
C57BL O 
/ O 
6 O 
mice O 
. O 

diterpenoids I-FAMILY 
and O 
lignans B-FAMILY 
from O 
Calocedrus O 
macrolepis O 
. O 

new O 
labdane B-FAMILY 
diterpenoids I-FAMILY 
, O 
calomacrins B-MULTIPLE 
A-C I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
and O 
a O 
new O 
diaryl B-FAMILY 
butyrolactone I-FAMILY 
-type O 
lignan B-FAMILY 
, O 
calomacrol B-TRIVIAL 
A I-TRIVIAL 
( O 
8 O 
) O 
, O 
as O 
well O 
as O 
four O 
known O 
labdane B-FAMILY 
diterpenoids I-FAMILY 
and O 
six O 
known O 
lignans B-FAMILY 
, O 
were O 
isolated O 
from O 
the O 
twigs O 
and O 
leaves O 
of O 
Calocedrus O 
macrolepis O 
. O 
Structures O 
of O 
the O 
new O 
compounds O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
their O 
spectroscopic O 
methods O 
, O 
including O 
1D O 
and O 
2D O 
NMR O 
techniques O 
. O 
Compounds O 
3-14 O 
were O 
evaluated O 
for O 
cytotoxicity O 
against O 
HL-60 O 
, O 
SMMC-7721 O 
, O 
A-549 O 
, O 
MCF-7 O 
, O 
and O 
SW480 O 
cell O 
lines O 
. O 

magnifies O 
therapeutic O 
impact O 
of O 
ceramide B-FAMILY 
in O 
human O 
colorectal O 
cancer O 
cells O 
independent O 
of O 
p53 O 
. O 

prognosis O 
in O 
patients O 
with O 
later O 
stage O 
colorectal O 
cancer O 
( O 
CRC O 
) O 
necessitates O 
the O 
search O 
for O 
new O 
treatment O 
strategies O 
. O 
Ceramide B-FAMILY 
, O 
because O 
of O 
its O 
role O 
in O 
orchestrating O 
death O 
cascades O 
in O 
cancer O 
cells O 
, O 
is O 
a O 
versatile O 
alternative O 
. O 
Ceramide B-FAMILY 
can O 
be O 
generated O 
by O 
exposure O 
to O 
chemotherapy O 
or O 
ionizing O 
radiation O 
, O 
or O 
it O 
can O 
be O 
administered O 
in O 
the O 
form O 
of O 
short O 
- O 
chain O 
analogs O 
( O 
C6-ceramide B-TRIVIAL 
) O 
. O 
Because O 
intracellular O 
P-glycoprotein O 
( O 
P-gp O 
) O 
plays O 
a O 
role O 
in O 
catalyzing O 
the O 
conversion O 
of O 
ceramide B-FAMILY 
to O 
higher O 
sphingolipids B-FAMILY 
, O 
we O 
hypothesized O 
that O 
administration O 
of O 
P-gp O 
antagonists O 
with O 
C6-ceramide B-TRIVIAL 
would O 
magnify O 
cell O 
death O 
cascades O 
. O 
Human O 
CRC O 
cell O 
lines O 
were O 
employed O 
, O 
HCT O 
- O 
15 O 
, O 
HT-29 O 
, O 
and O 
LoVo O 
. O 
The O 
addition O 
of O 
either O 
tamoxifen B-TRIVIAL 
, O 
VX-710 B-IDENTIFIER 
, O 
verapamil B-TRIVIAL 
, O 
or O 
cyclosporin B-TRIVIAL 
A I-TRIVIAL 
, O 
antagonists O 
of O 
P-gp O 
, O 
enhanced O 
C6-ceramide B-TRIVIAL 
cytotoxicity O 
in O 
all O 
cell O 
lines O 
. O 
In O 
depth O 
studies O 
with O 
C6-ceramide B-TRIVIAL 
and O 
tamoxifen B-TRIVIAL 
in O 
LoVo O 
cells O 
showed O 
the O 
regimen O 
induced O 
PARP O 
cleavage O 
, O 
caspase O 
- O 
dependent O 
apoptosis O 
, O 
mitochondrial O 
membrane O 
permeabilization O 
( O 
MMP O 
) O 
, O 
and O 
cell O 
cycle O 
arrest O 
at O 
G1 O 
and O 
G2 O 
. O 
At O 
the O 
molecular O 
level O 
, O 
the O 
regimen O 
, O 
but O 
not O 
single O 
agents O 
, O 
induced O 
time O 
- O 
dependent O 
upregulation O 
of O 
tumor O 
suppressor O 
protein O 
p53 O 
; O 
however O 
, O 
introduction O 
of O 
a O 
p53 O 
inhibitor O 
staved O 
neither O 
MMP O 
nor O 
apoptosis O 
. O 
Nanoliposomal O 
formulations O 
of O 
C6-ceramide B-TRIVIAL 
and O 
tamoxifen B-TRIVIAL 
were O 
also O 
effective O 
, O 
yielding O 
synergistic O 
cell O 
kill O 
. O 
We O 
conclude O 
that O 
tamoxifen B-TRIVIAL 
is O 
a O 
favorable O 
adjuvant O 
for O 
enhancing O 
C6-ceramide B-TRIVIAL 
cytotoxicity O 
in O 
CRC O 
, O 
and O 
demonstrates O 
uniquely O 
integrated O 
effects O 
. O 
The O 
high O 
frequency O 
of O 
expression O 
of O 
P-gp O 
in O 
CRC O 
presents O 
an O 
adventitious O 
target O 
for O 
complementing O 
ceramide B-FAMILY 
-based O 
therapies O 
, O 
a O 
strategy O 
that O 
could O 
hold O 
promise O 
for O 
treatment O 
of O 
resistant O 
disease O 
. O 

of O 
Src O 
and O 
the O 
actin O 
cytoskeleton O 
in O 
the O 
antitumorigenic O 
action O 
of O 
adenosine B-SYSTEMATIC 
dialdehyde I-SYSTEMATIC 
. O 

is O 
an O 
important O 
reaction O 
that O 
transfers O 
a O 
methyl B-SYSTEMATIC 
group O 
in O 
S-adenosylmethionine B-TRIVIAL 
( O 
SAM B-ABBREVIATION 
) O 
to O 
substrates O 
such O 
as O 
DNA O 
, O 
RNA O 
, O 
and O 
proteins O 
. O 
It O 
is O 
known O 
that O 
transmethylation O 
plays O 
critical O 
roles O 
in O 
various O 
cellular O 
responses O 
. O 
In O 
this O 
study O 
, O 
we O 
examined O 
the O 
effects O 
of O 
transmethylation O 
on O 
tumorigenic O 
responses O 
and O 
its O 
regulatory O 
mechanism O 
using O 
an O 
upregulation O 
strategy O 
of O 
adenosylhomocysteine B-TRIVIAL 
( O 
SAH B-ABBREVIATION 
) O 
acting O 
as O 
a O 
negative O 
feedback O 
inhibitor O 
. O 
Treatment O 
with O 
adenosine B-SYSTEMATIC 
dialdehyde I-SYSTEMATIC 
( O 
AdOx B-ABBREVIATION 
) O 
, O 
an O 
inhibitor O 
of O 
transmethylation O 
- O 
suppressive O 
adenosylhomocysteine B-TRIVIAL 
( O 
SAH B-ABBREVIATION 
) O 
hydrolase O 
( O 
SAHH O 
) O 
, O 
enhanced O 
the O 
level O 
of O 
SAH B-ABBREVIATION 
and O 
effectively O 
blocked O 
the O 
proliferation O 
, O 
migration O 
, O 
and O 
invasion O 
of O 
cancer O 
cells O 
; O 
the O 
treatment O 
also O 
induced O 
the O 
differentiation O 
of O 
C6 O 
glioma O 
cells O 
and O 
suppressed O 
the O 
neovascular O 
genesis O 
of O 
eggs O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Through O 
immunoblotting O 
analysis O 
, O 
it O 
was O 
found O 
that O 
AdOx B-ABBREVIATION 
was O 
capable O 
of O 
indirectly O 
diminishing O 
the O 
phosphorylation O 
of O 
oncogenic O 
Src O 
and O 
its O 
kinase O 
activity O 
. O 
Interestingly O 
, O 
AdOx B-ABBREVIATION 
disrupted O 
actin O 
cytoskeleton O 
structures O 
, O 
leading O 
to O 
morphological O 
changes O 
, O 
and O 
suppressed O 
the O 
formation O 
of O 
a O 
signaling O 
complex O 
composed O 
of O 
Src O 
and O 
p85 O 
/ O 
PI3K O 
, O 
which O 
is O 
linked O 
to O 
various O 
tumorigenic O 
responses O 
. O 
In O 
agreement O 
with O 
these O 
data O 
, O 
the O 
exogenous O 
treatment O 
of O 
SAH B-ABBREVIATION 
or O 
inhibition O 
of O 
SAHH O 
by O 
specific O 
siRNA O 
or O 
another O 
type O 
of O 
inhibitor O 
, O 
3-deazaadenosine B-SYSTEMATIC 
( O 
DAZA B-ABBREVIATION 
) O 
, O 
similarly O 
resulted O 
in O 
antitumorigenic O 
responses O 
, O 
suppressive O 
activity O 
on O 
Src O 
, O 
the O 
alteration O 
of O 
actin O 
cytoskeleton O 
, O 
and O 
a O 
change O 
of O 
the O 
colocalization O 
pattern O 
between O 
actin O 
and O 
Src O 
. O 
Taken O 
together O 
, O 
these O 
results O 
suggest O 
that O 
SAH B-ABBREVIATION 
/ O 
SAHH O 
- O 
mediated O 
transmethylation O 
could O 
be O 
linked O 
to O 
the O 
tumorigenic O 
processes O 
through O 
cross O 
- O 
regulation O 
between O 
the O 
actin O 
cytoskeleton O 
and O 
Src O 
kinase O 
activity O 
. O 

of O 
derivatives O 
of O 
methyl B-SYSTEMATIC 
rosmarinate I-SYSTEMATIC 
and O 
their O 
inhibitory O 
activities O 
against O 
matrix O 
metalloproteinase-1 O 
( O 
MMP-1 O 
) O 
. O 

series O 
of O 
MMP-1 O 
inhibitors O 
have O 
been O 
identified O 
based O 
upon O 
a O 
methyl B-SYSTEMATIC 
rosmarinate I-SYSTEMATIC 
scaffold O 
using O 
structure O 
- O 
based O 
drug O 
design O 
methods O 
. O 
The O 
best O 
compound O 
in O 
the O 
series O 
showed O 
an O 
IC50 O 
value O 
of O 
0.4 O 
μM O 
. O 
A O 
docking O 
study O 
was O 
conducted O 
for O 
compound O 
(S)-10n O 
in O 
order O 
to O 
investigate O 
its O 
binding O 
interactions O 
with O 
MMP-1 O 
. O 
The O 
structure O 
- O 
activity O 
relationships O 
( O 
SAR O 
) O 
were O 
also O 
briefly O 
discussed O 
. O 
Useful O 
SAR O 
was O 
established O 
which O 
provides O 
important O 
guidelines O 
for O 
the O 
design O 
of O 
future O 
generations O 
of O 
potent O 
inhibitors O 
against O 
MMP-1 O 
. O 

, O 
synthesis O 
and O 
anticancer O 
properties O 
of O 
5-arylbenzoxepins B-FAMILY 
as O 
conformationally O 
restricted O 
isocombretastatin B-TRIVIAL 
A-4 I-TRIVIAL 
analogs O 
. O 

series O 
of O 
novel O 
benzoxepins B-FAMILY 
6 O 
was O 
designed O 
and O 
prepared O 
as O 
rigid- O 
isoCA-4 B-ABBREVIATION 
analogs O 
according O 
to O 
a O 
convergent O 
strategy O 
using O 
the O 
coupling O 
of O 
N-tosylhydrazones B-FAMILY 
with O 
aryl B-FAMILY 
iodides I-FAMILY 
under O 
palladium B-SYSTEMATIC 
catalysis O 
. O 
The O 
most O 
potent O 
compound O 
6b O 
, O 
having O 
the O 
greatest O 
resemblance O 
to O 
CA-4 B-ABBREVIATION 
and O 
isoCA-4 B-ABBREVIATION 
displayed O 
antiproliferative O 
activity O 
at O 
nanomolar O 
concentrations O 
against O 
various O 
cancer O 
cell O 
lines O 
and O 
inhibited O 
tubulin O 
assembly O 
at O 
a O 
micromolar O 
range O 
. O 
In O 
addition O 
, O 
benzoxepin B-FAMILY 
6b O 
led O 
to O 
the O 
arrest O 
of O 
HCT116 O 
, O 
K562 O 
, O 
H1299 O 
and O 
MDA-MB231 O 
cancer O 
cell O 
lines O 
in O 
the O 
G2 O 
/ O 
M O 
phase O 
of O 
the O 
cell O 
cycle O 
, O 
and O 
strongly O 
induced O 
apoptosis O 
at O 
low O 
concentrations O 
. O 
Docking O 
studies O 
demonstrated O 
that O 
benzoxepin B-FAMILY 
6b O 
adopt O 
an O 
orientation O 
similar O 
to O 
that O 
of O 
isoCA-4 B-ABBREVIATION 
at O 
the O 
colchicine O 
binding O 
site O 
on O 
β-tubulin O 
. O 

of O 
lapachol B-TRIVIAL 
, O 
β-lapachone B-TRIVIAL 
and O 
related O 
synthetic O 
1,4-naphthoquinones B-FAMILY 
against O 
oesophageal O 
cancer O 
cells O 
. O 

have O 
been O 
found O 
to O 
have O 
a O 
wide O 
range O 
of O 
biological O 
activities O 
, O 
including O 
cytotoxicity O 
to O 
cancer O 
cells O 
. O 
The O 
secondary O 
metabolites O 
lapachol O 
, O 
α- B-MULTIPLE 
and I-MULTIPLE 
β-lapachone I-MULTIPLE 
and O 
a O 
series O 
of O 
25 O 
related O 
synthetic O 
1,4-naphthoquinones B-FAMILY 
were O 
screened O 
against O 
the O 
oesophageal O 
cancer O 
cell O 
line O 
( O 
WHCO1 O 
) O 
. O 
Most O 
of O 
the O 
compounds O 
exhibited O 
enhanced O 
cytotoxicity O 
( O 
IC50 O 
1.6-11.7 O 
μM O 
) O 
compared O 
to O 
the O 
current O 
drug O 
of O 
choice O 
cisplatin B-TRIVIAL 
( O 
IC50 O 
= O 
16.5 O 
μM O 
) O 
. O 
This O 
study O 
also O 
established O 
that O 
the O 
two O 
new O 
synthetic O 
halogenated O 
compounds O 
12a O 
and O 
16a O 
( O 
IC50 O 
= O 
3 O 
and O 
7.3 O 
μM O 
) O 
and O 
the O 
previously O 
reported O 
compound O 
11a O 
( O 
IC50 O 
= O 
3.9 O 
μM O 
) O 
, O 
were O 
non-toxic O 
to O 
NIH3T3 O 
normal O 
fibroblast O 
cells O 
. O 
Cell O 
death O 
of O 
oesophageal O 
cancer O 
cells O 
by O 
processes O 
involving O 
PARP O 
cleavage O 
caused O 
by O 
11a O 
was O 
shown O 
to O 
be O 
associated O 
with O 
elevated O 
c-Jun O 
levels O 
, O 
suggesting O 
a O 
role O 
for O 
this O 
pathway O 
in O 
the O 
mechanism O 
of O 
action O 
of O 
this O 
cohort O 
of O 
naphthoquinone B-FAMILY 
compounds O 
. O 

of O 
an O 
MIF-1 B-ABBREVIATION 
analogue O 
containing O 
enantiopure O 
(S)-α-trifluoromethyl-proline B-SYSTEMATIC 
and O 
biological O 
evaluation O 
on O 
nociception O 
. O 

synthesis O 
and O 
the O 
effect O 
of O 
a O 
novel O 
MIF-1 B-ABBREVIATION 
analogue O 
on O 
nociception O 
during O 
acute O 
pain O 
in O 
rat O 
model O 
are O 
reported O 
. O 
The O 
synthesis O 
of O 
this O 
enantiopure O 
trifluoromethyl B-SYSTEMATIC 
group O 
containing O 
tripeptide B-FAMILY 
was O 
performed O 
through O 
a O 
peptide O 
coupling O 
reaction O 
between O 
the O 
HCl O 
. O 
Leu-Gly-NH2 O 
and O 
the O 
(S)-α-Tfm- B-TRIVIAL 
proline I-TRIVIAL 
. O 
The O 
analgesic O 
effect O 
of O 
the O 
CF3-(MIF-1) B-FORMULA 
2 O 
has O 
been O 
evaluated O 
in O 
vivo O 
on O 
rat O 
model O 
by O 
paw O 
pressure O 
( O 
PP O 
) O 
and O 
hot O 
plate O 
( O 
HP O 
) O 
tests O 
and O 
compared O 
to O 
the O 
native O 
peptide O 
MIF-1 B-ABBREVIATION 
. O 
Highest O 
analgesic O 
effect O 
was O 
observed O 
with O 
CF3-(MIF-1) B-FORMULA 
2 O 
only O 
in O 
PP O 
test O 
. O 
In O 
order O 
to O 
study O 
the O 
mechanisms O 
of O 
nociception O 
induced O 
by O 
the O 
studied O 
peptides O 
, O 
the O 
involvement O 
of O 
the O 
opioid O 
and O 
the O 
nitric B-SYSTEMATIC 
oxideergic O 
systems O 
was O 
investigated O 
. O 
The O 
results O 
are O 
in O 
favor O 
of O 
a O 
participation O 
of O 
both O 
system O 
since O 
pretreatment O 
, O 
20 O 
min O 
before O 
injection O 
of O 
the O 
CF3-(MIF-1) B-FORMULA 
2 O 
, O 
with O 
the O 
non-competitive O 
antagonist O 
of O 
opiate O 
receptors O 
naloxone B-TRIVIAL 
, O 
the O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
NOS O 
) O 
inhibitor O 
l-N(G)-nitroarginine B-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
l-NAME B-ABBREVIATION 
) O 
or O 
the O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
donor O 
l-arginine B-TRIVIAL 
( O 
l-Arg B-FORMULA 
) O 
significantly O 
decreased O 
the O 
pain O 
perception O 
in O 
PP O 
and O 
HP O 
tests O 
. O 

, O 
characterization O 
, O 
cytotoxicity O 
and O 
antimicrobial O 
studies O 
on O 
bis(N-furfuryl-N-(2-phenylethyl)dithiocarbamato-S,S')zinc B-SYSTEMATIC 
(II) I-SYSTEMATIC 
and O 
its O 
nitrogen B-SYSTEMATIC 
donor O 
adducts O 
. O 

Zn(fpedtc)2 B-FORMULA 
] O 
( O 
1 O 
) O 
, O 
[ O 
Zn(fpedtc)2(py) B-FORMULA 
] O 
( O 
2 O 
) O 
, O 
[ O 
Zn(fpedtc)2(1,10-phen) B-FORMULA 
] O 
( O 
3 O 
) O 
and O 
[ O 
Zn(fpedtc)2(2,2'-bipy) B-FORMULA 
] O 
( O 
4 O 
) O 
( O 
where O 
fpedtc B-ABBREVIATION 
= O 
N-furfuryl-N-(2-phenylethyl)dithiocarbamate B-SYSTEMATIC 
, O 
py O 
= O 
pyridine B-SYSTEMATIC 
, O 
1,10-phen B-SYSTEMATIC 
= O 
1,10-phenanthroline B-SYSTEMATIC 
and O 
2,2'-bipy B-SYSTEMATIC 
= O 
2,2'-bipyridine B-SYSTEMATIC 
) O 
were O 
synthesized O 
. O 
Characterization O 
of O 
the O 
complexes O 
were O 
achieved O 
by O 
IR O 
and O 
NMR O 
( O 
(1)H B-FORMULA 
and O 
(13)C B-FORMULA 
) O 
spectra O 
and O 
in O 
addition O 
, O 
for O 
2 O 
and O 
3 O 
, O 
by O 
X-ray O 
crystallography O 
. O 
Single O 
crystal O 
X-ray O 
structural O 
analysis O 
of O 
2 O 
and O 
3 O 
showed O 
that O 
complex O 
2 O 
is O 
almost O 
half O 
way O 
between O 
trigonal O 
bipyramidal O 
and O 
square O 
pyramidal O 
and O 
complex O 
3 O 
has O 
a O 
distorted O 
octahedral O 
geometry O 
. O 
Zn B-FORMULA 
- O 
N B-FORMULA 
distances O 
in O 
2 O 
is O 
shorter O 
than O 
that O 
found O 
in O 
a O 
six O 
coordinate O 
complex O 
3 O 
due O 
to O 
the O 
change O 
in O 
coordination O 
number O 
. O 
These O 
complexes O 
were O 
also O 
screened O 
for O 
in O 
vitro O 
antibacterial O 
and O 
antifungal O 
activities O 
and O 
significant O 
activities O 
have O 
been O 
found O 
. O 
In O 
vitro O 
cytotoxic O 
activity O 
of O 
all O 
the O 
synthesized O 
complexes O 
was O 
evaluated O 
on O 
HeLa O 
cell O 
line O 
. O 
Complex O 
1 O 
exhibits O 
maximum O 
inhibitory O 
effect O 
at O 
a O 
concentration O 
of O 
40 O 
μg O 
mL(-1) O 
on O 
HeLa O 
cell O 
line O 
. O 

agmatine B-FAMILY 
dipeptide I-FAMILY 
inhibitors O 
against O 
the O 
West O 
Nile O 
virus O 
NS2B O 
/ O 
NS3 O 
protease O 
: O 
A O 
P3 O 
and O 
N-cap O 
optimization O 
study O 
. O 

communication O 
describes O 
the O 
synthesis O 
and O 
inhibitory O 
activities O 
of O 
thirty O 
- O 
seven O 
novel O 
C B-FORMULA 
-terminal O 
agmatine B-FAMILY 
dipeptides I-FAMILY 
used O 
as O 
screening O 
compounds O 
to O 
study O 
the O 
structure O 
- O 
activity O 
relationship O 
between O 
active O 
- O 
site O 
peptidomimetics O 
and O 
the O 
West O 
Nile O 
virus O 
( O 
WNV O 
) O 
NS2B O 
/ O 
NS3 O 
serine B-TRIVIAL 
protease O 
. O 
Our O 
efforts O 
lead O 
to O 
the O 
discovery O 
of O 
a O 
novel O 
agmatine B-FAMILY 
dipeptide I-FAMILY 
inhibitor O 
( O 
compound O 
33 O 
, O 
IC50 O 
2.6 O 
± O 
0.3 O 
μM O 
) O 
with O 
improved O 
inhibitory O 
activity O 
in O 
comparison O 
to O 
the O 
most O 
potent O 
inhibitor O 
described O 
in O 
our O 
recent O 
report O 
[ O 
IC50 O 
4.7 O 
± O 
1.2 O 
μM O 
; O 
Lim O 
et O 
al O 
. O 
, O 
Eur O 
. O 
J O 
. O 
Med O 
. O 
Chem O 
. O 
46 O 
( O 
2011 O 
) O 
3130-3134 O 
] O 
. O 
In O 
addition O 
, O 
our O 
study O 
cleared O 
the O 
contention O 
surrounding O 
the O 
previous O 
X-ray O 
co O 
- O 
crystallization O 
study O 
and O 
an O 
enzyme O 
inhibition O 
report O 
on O 
the O 
binding O 
conformation O 
adopted O 
by O 
active O 
- O 
site O 
peptide O 
aldehydes B-FAMILY 
. O 
Our O 
data O 
should O 
provide O 
valuable O 
insights O 
into O 
the O 
design O 
of O 
future O 
peptidomimetic O 
antivirals O 
against O 
WNV O 
infections O 
. O 

, O 
pharmacological O 
evaluation O 
and O 
QSAR O 
modeling O 
of O 
mono O 
- O 
substituted O 
4-phenylpiperidines B-FAMILY 
and O 
4-phenylpiperazines B-FAMILY 
. O 

series O 
of O 
mono B-MULTIPLE 
- I-MULTIPLE 
substituted I-MULTIPLE 
4-phenylpiperidines I-MULTIPLE 
and I-MULTIPLE 
-piperazines I-MULTIPLE 
4-phenylpiperidines B-MULTIPLE 
and I-MULTIPLE 
-piperazines I-MULTIPLE 
have O 
been O 
synthesized O 
and O 
their O 
effects O 
on O 
the O 
dopaminergic O 
system O 
tested O 
in O 
vivo O 
. O 
The O 
structure O 
activity O 
relationship O 
( O 
SAR O 
) O 
revealed O 
that O 
the O 
position O 
and O 
physicochemical O 
character O 
of O 
the O 
aromatic O 
substituent O 
proved O 
to O 
be O 
critical O 
for O 
the O 
levels O 
of O 
3,4-dihydroxyphenylacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DOPAC B-ABBREVIATION 
) O 
in O 
the O 
brain O 
of O 
freely O 
moving O 
rats O 
. O 
In O 
order O 
to O 
investigate O 
how O 
the O 
structural O 
properties O 
of O 
these O 
compounds O 
affect O 
the O 
response O 
, O 
a O 
set O 
of O 
tabulated O 
and O 
calculated O 
physicochemical O 
descriptors O 
were O 
modeled O 
against O 
the O 
in O 
vivo O 
effects O 
using O 
partial O 
least O 
square O 
( O 
PLS O 
) O 
regression O 
. O 
Furthermore O 
, O 
the O 
binding O 
affinities O 
to O 
the O 
dopamine B-TRIVIAL 
D2 O 
( O 
DA O 
D2 O 
) O 
receptor O 
and O 
monoamine B-FAMILY 
oxidase O 
A O 
( O 
MAO O 
A O 
) O 
enzyme O 
were O 
determined O 
for O 
a O 
chosen O 
subset O 
and O 
QSAR O 
models O 
using O 
the O 
same O 
descriptors O 
as O 
in O 
the O 
in O 
vivo O 
model O 
were O 
produced O 
to O 
investigate O 
the O 
mechanisms O 
leading O 
to O 
the O 
observed O 
DOPAC B-ABBREVIATION 
response O 
. O 
These O 
models O 
, O 
in O 
combination O 
with O 
a O 
strong O 
correlation O 
between O 
the O 
levels O 
of O 
striatal O 
DOPAC B-ABBREVIATION 
and O 
the O 
affinities O 
to O 
DA O 
D2 O 
and O 
MAO O 
A O 
, O 
provides O 
a O 
comprehensive O 
understanding O 
of O 
the O 
biological O 
response O 
for O 
compounds O 
in O 
this O 
class O 
. O 

and O 
temporal O 
control O 
of O 
drug O 
release O 
has O 
for O 
long O 
been O 
a O 
main O 
focus O 
in O 
the O 
development O 
of O 
novel O 
drug O 
carriers O 
. O 
Polymersomes O 
, O 
which O 
can O 
load O 
both O 
hydrophilic O 
and O 
hydrophobic O 
species O 
and O 
, O 
at O 
the O 
same O 
time O 
, O 
be O 
tailored O 
to O 
respond O 
to O 
a O 
desired O 
stimulus O 
, O 
have O 
drawn O 
much O 
attention O 
over O 
the O 
last O 
decade O 
. O 
Here O 
we O 
describe O 
polymersomes O 
able O 
to O 
encapsulate O 
up O 
to O 
6% O 
( O 
w O 
/ O 
w O 
) O 
of O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
together O 
with O 
30% O 
( O 
w O 
/ O 
w O 
) O 
of O 
superparamagnetic O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
( O 
USPIO O 
; O 
γ-Fe(2)O(3) B-FORMULA 
) O 
. O 
Upon O 
internalization O 
in O 
HeLa O 
cells O 
and O 
when O 
a O 
high O 
frequency O 
AC O 
magnetic O 
field O 
( O 
14mT O 
at O 
750kHz O 
) O 
was O 
applied O 
, O 
the O 
developed O 
delivery O 
system O 
elicited O 
an O 
18% O 
increase O 
in O 
cell O 
toxicity O 
, O 
associated O 
with O 
augmented O 
DOX B-ABBREVIATION 
release O 
kinetics O 
. O 
In O 
order O 
to O 
ensure O 
that O 
the O 
observed O 
cytotoxicity O 
arose O 
from O 
the O 
increased O 
doxorubicin B-TRIVIAL 
release O 
and O 
not O 
from O 
a O 
pure O 
magnetic O 
hyperthermia O 
effect O 
, O 
polymersomes O 
loaded O 
with O 
magnetic O 
nanoparticles O 
alone O 
were O 
also O 
tested O 
. O 
In O 
this O 
case O 
, O 
no O 
increased O 
toxicity O 
was O 
observed O 
. O 
We O 
hypothesize O 
that O 
the O 
magnetic O 
field O 
is O 
inducing O 
a O 
very O 
local O 
hyperthermia O 
effect O 
at O 
the O 
level O 
of O 
the O 
polymersome O 
membrane O 
, O 
increasing O 
drug O 
release O 
. O 
This O 
approach O 
opens O 
new O 
perspectives O 
in O 
the O 
development O 
of O 
smart O 
delivery O 
systems O 
able O 
to O 
release O 
drug O 
upon O 
demand O 
and O 
therefore O 
, O 
improving O 
treatment O 
control O 
. O 

fasudil B-TRIVIAL 
, O 
a O 
rho-kinase O 
inhibitor O 
, O 
for O 
prolonged O 
pulmonary O 
preferential O 
vasodilation O 
in O 
pulmonary O 
arterial O 
hypertension O 
. O 

pharmacological O 
interventions O 
for O 
pulmonary O 
arterial O 
hypertension O 
( O 
PAH O 
) O 
require O 
continuous O 
infusions O 
, O 
multiple O 
inhalations O 
, O 
or O 
oral O 
administration O 
of O 
drugs O 
that O 
act O 
on O 
various O 
pathways O 
involved O 
in O 
the O 
pathogenesis O 
of O 
PAH O 
. O 
However O 
, O 
invasive O 
methods O 
of O 
administration O 
, O 
short O 
duration O 
of O 
action O 
, O 
and O 
lack O 
of O 
pulmonary O 
selectivity O 
result O 
in O 
noncompliance O 
and O 
poor O 
patient O 
outcomes O 
. O 
In O 
this O 
study O 
, O 
we O 
tested O 
the O 
hypothesis O 
that O 
encapsulation O 
of O 
an O 
investigational O 
anti-PAH O 
molecule O 
fasudil B-TRIVIAL 
( O 
HA-1077 B-IDENTIFIER 
) O 
, O 
a O 
Rho-kinase O 
inhibitor O 
, O 
into O 
liposomal O 
vesicles O 
results O 
in O 
prolonged O 
vasodilation O 
in O 
distal O 
pulmonary O 
arterioles O 
. O 
Liposomes O 
were O 
prepared O 
by O 
hydration O 
and O 
extrusion O 
method O 
and O 
fasudil B-TRIVIAL 
was O 
loaded O 
by O 
ammonium B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
-induced O 
transmembrane O 
electrochemical O 
gradient O 
. O 
Liposomes O 
were O 
then O 
characterized O 
for O 
various O 
physicochemical O 
properties O 
. O 
Optimized O 
formulations O 
were O 
tested O 
for O 
pulmonary O 
absorption O 
and O 
their O 
pharmacological O 
efficacy O 
in O 
a O 
monocrotaline B-TRIVIAL 
( O 
MCT B-ABBREVIATION 
) O 
induced O 
rat O 
model O 
of O 
PAH O 
. O 
The O 
entrapment O 
efficiency O 
of O 
optimized O 
liposomal O 
fasudil B-TRIVIAL 
formulations O 
was O 
between O 
68.1±0.8% O 
and O 
73.6±2.3% O 
, O 
and O 
the O 
cumulative O 
release O 
at O 
37°C O 
was O 
98-99% O 
over O 
a O 
period O 
of O 
5 O 
days O 
. O 
Compared O 
to O 
intravenous O 
(IV) O 
fasudil B-TRIVIAL 
, O 
a O 
~10 O 
fold O 
increase O 
in O 
the O 
terminal O 
plasma O 
half O 
- O 
life O 
was O 
observed O 
when O 
liposomal O 
fasudil B-TRIVIAL 
was O 
administered O 
as O 
aerosols O 
. O 
The O 
t1 O 
/ O 
2 O 
of O 
IV O 
fasudil B-TRIVIAL 
was O 
0.39±0.12 O 
h O 
. O 
and O 
when O 
given O 
as O 
liposomes O 
via O 
pulmonary O 
route O 
, O 
the O 
t1 O 
/ O 
2 O 
extended O 
to O 
4.71±0.72 O 
h O 
. O 
One O 
h O 
after O 
intratracheal O 
instillation O 
of O 
liposomal O 
fasudil B-TRIVIAL 
, O 
mean O 
pulmonary O 
arterial O 
pressure O 
( O 
MPAP O 
) O 
was O 
reduced O 
by O 
37.6±5.7% O 
and O 
continued O 
to O 
decrease O 
for O 
about O 
3 O 
h O 
, O 
suggesting O 
that O 
liposomal O 
formulations O 
produced O 
pulmonary O 
preferential O 
vasodilation O 
in O 
MCT B-ABBREVIATION 
induced O 
PAH O 
rats O 
. O 
Overall O 
, O 
this O 
study O 
established O 
the O 
proof O 
- O 
of O 
- O 
principle O 
that O 
aerosolized O 
liposomal O 
fasudil B-TRIVIAL 
is O 
a O 
feasible O 
option O 
for O 
a O 
non-invasive O 
, O 
controlled O 
release O 
and O 
pulmonary O 
preferential O 
treatment O 
of O 
PAH O 
. O 

development O 
of O 
malignant O 
melanoma O 
is O 
a O 
highly O 
complex O 
process O 
, O 
which O 
is O 
still O 
poorly O 
understood O 
. O 
A O 
majority O 
of O 
human O 
melanomas O 
are O 
found O 
to O 
express O 
a O 
few O 
oncogenic O 
proteins O 
, O 
such O 
as O 
mutant O 
RAS O 
and O 
BRAF O 
variants O 
. O 
However O 
, O 
these O 
oncogenes O 
are O 
also O 
found O 
in O 
nevi O 
, O 
and O 
it O 
is O 
now O 
a O 
well O 
- O 
accepted O 
fact O 
that O 
their O 
expression O 
alone O 
leads O 
to O 
senescence O 
. O 
This O 
renders O 
the O 
understanding O 
of O 
senescence O 
escape O 
mechanisms O 
an O 
important O 
point O 
to O 
understand O 
tumor O 
development O 
. O 
Here O 
, O 
we O 
approached O 
the O 
question O 
of O 
senescence O 
evasion O 
by O 
expressing O 
the O 
transcription O 
factor O 
v-myc O 
myelocytomatosis O 
viral O 
oncogene O 
homolog O 
( O 
c-MYC O 
) O 
, O 
which O 
is O 
known O 
to O 
act O 
synergistically O 
with O 
many O 
oncogenes O 
, O 
in O 
melanocytes O 
. O 
We O 
observed O 
that O 
MYC O 
drives O 
the O 
evasion O 
of O 
reactive- O 
oxygen B-SYSTEMATIC 
stress O 
- O 
induced O 
melanocyte O 
senescence O 
, O 
caused O 
by O 
activated O 
receptor O 
tyrosine B-TRIVIAL 
kinase O 
signaling O 
. O 
Conversely O 
, O 
MIZ1 O 
, O 
the O 
growth O 
suppressing O 
interaction O 
partner O 
of O 
MYC O 
, O 
is O 
involved O 
in O 
mediating O 
melanocyte O 
senescence O 
. O 
Both O 
, O 
MYC O 
overexpression O 
and O 
Miz1 O 
knockdown O 
led O 
to O 
a O 
strong O 
reduction O 
of O 
endogenous O 
reactive- O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
DNA O 
damage O 
and O 
senescence O 
. O 
We O 
identified O 
the O 
cystathionase O 
( O 
CTH O 
) O 
gene O 
product O 
as O 
mediator O 
of O 
the O 
ROS O 
- O 
related O 
MYC O 
and O 
MIZ1 O 
effects O 
. O 
Blocking O 
CTH O 
enzymatic O 
activity O 
in O 
MYC-overexpressing O 
and O 
Miz1 O 
knockdown O 
cells O 
increased O 
intracellular O 
stress O 
and O 
senescence O 
. O 
Importantly O 
, O 
pharmacological O 
inhibition O 
of O 
CTH O 
in O 
human O 
melanoma O 
cells O 
also O 
reconstituted O 
senescence O 
in O 
the O 
majority O 
of O 
cell O 
lines O 
, O 
and O 
CTH O 
knockdown O 
reduced O 
tumorigenic O 
effects O 
such O 
as O 
proliferation O 
, O 
H(2)O(2) B-FORMULA 
resistance O 
and O 
soft O 
agar O 
growth O 
. O 
Thus O 
, O 
we O 
identified O 
CTH O 
as O 
new O 
MYC O 
target O 
gene O 
with O 
an O 
important O 
function O 
in O 
senescence O 
evasion.Oncogene O 
advance O 
online O 
publication O 
, O 
28 O 
January O 
2013 O 
; O 
doi O 
: O 
10.1038 O 
/ O 
onc.2012.641 O 
. O 

for O 
5-HT2C O 
receptor O 
functional O 
selectivity O 
in O 
vivo O 
utilizing O 
structurally O 
diverse O 
, O 
selective O 
5-HT2C O 
receptor O 
ligands O 
and O 
the O 
2,5-dimethoxy-4-iodoamphetamine B-SYSTEMATIC 
elicited O 
head O 
- O 
twitch O 
response O 
model O 
. O 

are O 
seemingly O 
conflicting O 
data O 
in O 
the O 
literature O 
regarding O 
the O 
role O 
of O 
serotonin B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
) O 
5-HT2C O 
receptors O 
in O 
the O 
mouse O 
head O 
- O 
twitch O 
response O 
( O 
HTR O 
) O 
elicited O 
by O 
the O 
hallucinogenic O 
5-HT2A O 
/ O 
2B O 
/ O 
2C O 
receptor O 
agonist O 
2,5-dimethoxy-4-iodoamphetamine B-SYSTEMATIC 
( O 
DOI B-ABBREVIATION 
) O 
. O 
Namely O 
, O 
both O 
5-HT2C O 
receptor O 
agonists O 
and O 
antagonists O 
, O 
regarding O 
5-HT2C O 
receptor O 
- O 
mediated O 
Gq-phospholipase O 
C O 
( O 
PLC O 
) O 
signaling O 
, O 
reportedly O 
attenuate O 
the O 
HTR O 
response O 
. O 
The O 
present O 
experiments O 
tested O 
the O 
hypothesis O 
that O 
both O 
classes O 
of O 
5-HT2C O 
receptor O 
compounds O 
could O 
attenuate O 
the O 
DOI B-ABBREVIATION 
-elicited-HTR O 
in O 
a O 
single O 
strain O 
of O 
mice O 
, O 
C57Bl O 
/ O 
6J O 
. O 
The O 
expected O 
results O 
were O 
considered O 
in O 
accordance O 
with O 
ligand O 
functional O 
selectivity O 
. O 
Commercially O 
- O 
available O 
5-HT2C O 
agonists O 
( O 
CP B-IDENTIFIER 
809101 I-IDENTIFIER 
, O 
Ro B-IDENTIFIER 
60-0175 I-IDENTIFIER 
, O 
WAY B-IDENTIFIER 
161503 I-IDENTIFIER 
, O 
mCPP B-ABBREVIATION 
, O 
and O 
1-methylpsilocin B-SYSTEMATIC 
) O 
, O 
novel O 
4-phenyl-2-N,N-dimethyl-aminotetralin B-SYSTEMATIC 
( O 
PAT B-ABBREVIATION 
) O 
- O 
type O 
5-HT2C O 
agonists O 
( O 
with O 
5-HT2A O 
/ O 
2B O 
antagonist O 
activity O 
) O 
, O 
and O 
antagonists O 
selective O 
for O 
5-HT2A O 
( O 
M100907 B-IDENTIFIER 
) O 
, O 
5-HT2C O 
( O 
SB-242084 B-IDENTIFIER 
) O 
, O 
and O 
5-HT2B O 
/ O 
2C O 
( O 
SB-206553 B-IDENTIFIER 
) O 
receptors O 
attenuated O 
the O 
DOI B-ABBREVIATION 
-elicited-HTR O 
. O 
In O 
contrast O 
, O 
there O 
were O 
differential O 
effects O 
on O 
locomotion O 
across O 
classes O 
of O 
compounds O 
. O 
The O 
5-HT2C O 
agonists O 
and O 
M100907 B-IDENTIFIER 
decreased O 
locomotion O 
, O 
SB-242084 B-IDENTIFIER 
increased O 
locomotion O 
, O 
SB-206553 B-IDENTIFIER 
resulted O 
in O 
dose O 
- O 
dependent O 
biphasic O 
effects O 
on O 
locomotion O 
, O 
and O 
the O 
PATs O 
did O 
not O 
alter O 
locomotion O 
. O 
In O 
vitro O 
molecular O 
pharmacology O 
studies O 
showed O 
that O 
5-HT2C O 
agonists O 
potent O 
for O 
attenuating O 
the O 
DOI B-ABBREVIATION 
-elicited-HTR O 
also O 
reduced O 
the O 
efficacy O 
of O 
DOI B-ABBREVIATION 
to O 
activate O 
mouse O 
5-HT2C O 
receptor O 
- O 
mediated O 
PLC O 
signaling O 
in O 
HEK O 
cells O 
. O 
Although O 
there O 
were O 
differences O 
in O 
affinities O 
of O 
a O 
few O 
compounds O 
at O 
mouse O 
compared O 
to O 
human O 
5-HT2A O 
or O 
5-HT2C O 
receptors O 
, O 
all O 
compounds O 
tested O 
retained O 
their O 
selectivity O 
for O 
either O 
receptor O 
, O 
regardless O 
of O 
receptor O 
species O 
. O 
Results O 
indicate O 
that O 
5-HT2C O 
receptor O 
agonists O 
and O 
antagonists O 
attenuate O 
the O 
DOI B-ABBREVIATION 
-elicited-HTR O 
in O 
C57Bl O 
/ O 
6J O 
mice O 
, O 
and O 
suggest O 
that O 
structurally O 
diverse O 
5-HT2C O 
ligands O 
result O 
in O 
different O 
5-HT2C O 
receptor O 
signaling O 
outcomes O 
compared O 
to O 
DOI B-ABBREVIATION 
. O 

objective O 
of O 
this O 
study O 
was O 
to O 
investigate O 
if O 
the O 
increase O 
in O 
apparent O 
solubility O 
induced O 
by O 
liposomalization O 
or O 
micellization O 
of O 
the O 
poorly O 
soluble O 
drug O 
hydrocortisone B-TRIVIAL 
( O 
HC O 
) O 
would O 
lead O 
to O 
an O 
enhancement O 
of O 
its O 
permeability O 
through O 
biological O 
membranes O 
. O 
For O 
this O 
purpose O 
phosphatidylcholine B-FAMILY 
liposome O 
formulations O 
as O 
well O 
as O 
d-α-tocopheryl B-FAMILY 
polyethylene I-FAMILY 
glycol I-FAMILY 
1000 I-FAMILY 
succinate I-FAMILY 
( O 
TPGS B-ABBREVIATION 
) O 
micelle O 
dispersions O 
and O 
polyvinylpyrrolidone B-SYSTEMATIC 
( O 
PVP B-ABBREVIATION 
) O 
supersaturated O 
solutions O 
were O 
prepared O 
in O 
order O 
to O 
increase O 
the O 
apparent O 
solubility O 
of O 
HC O 
. O 
Both O 
the O 
apparent O 
solubility O 
of O 
hydrocortisone B-TRIVIAL 
( O 
i.e O 
. O 
amount O 
of O 
drug O 
entrapped O 
plus O 
non-entrapped O 
in O 
the O 
carriers O 
) O 
as O 
well O 
as O 
the O 
concentration O 
of O 
molecularly O 
dissolved O 
drug O 
( O 
i.e O 
. O 
fraction O 
non-entrapped O 
into O 
carriers O 
, O 
truly O 
molecularly O 
dissolved O 
fraction O 
) O 
were O 
characterized O 
. O 
Subsequently O 
, O 
the O 
permeability O 
of O 
hydrocortisone B-TRIVIAL 
was O 
assessed O 
for O 
each O 
type O 
of O 
formulation O 
using O 
the O 
in O 
vitro O 
sheep O 
nasal O 
mucosa O 
permeability O 
assay O 
. O 
In O 
all O 
formulations O 
where O 
solubilizing O 
agents O 
are O 
present O 
, O 
an O 
enhanced O 
flux O 
of O 
HC O 
( O 
compared O 
to O 
the O 
pure O 
drug O 
powder O 
suspension O 
) O 
is O 
observed O 
. O 
The O 
expected O 
linear O 
correlation O 
between O 
apparent O 
solubilities O 
and O 
fluxes O 
was O 
not O 
found O 
, O 
whereas O 
, O 
the O 
concentrations O 
of O 
molecularly O 
dissolved O 
HC O 
were O 
found O 
to O 
be O 
directly O 
proportional O 
to O 
the O 
respective O 
fluxes O 
. O 
This O 
is O 
an O 
experimental O 
proof O 
for O 
the O 
hypothesis O 
that O 
, O 
of O 
all O 
the O 
strategies O 
to O 
increase O 
the O 
apparent O 
solubility O 
of O 
poorly O 
soluble O 
drugs O 
, O 
enhancement O 
of O 
the O 
molecularly O 
dissolved O 
drug O 
concentration O 
( O 
induction O 
of O 
true O 
supersaturation O 
) O 
would O 
lead O 
to O 
better O 
permeation O 
though O 
membranes O 
. O 

constitute O 
a O 
diverse O 
class O 
of O 
chemicals O 
used O 
for O 
the O 
protection O 
of O 
agricultural O 
products O 
. O 
Several O 
lines O 
of O 
evidence O 
demonstrate O 
that O 
organochlorine B-FAMILY 
and O 
organophosphate B-FAMILY 
pesticides O 
can O 
cause O 
malignant O 
transformation O 
of O 
cells O 
in O 
in O 
vitro O 
and O 
in O 
vivo O 
models O 
. O 
In O 
the O 
current O 
minireview O 
a O 
comprehensive O 
summary O 
of O 
recent O 
in O 
vitro O 
findings O 
is O 
presented O 
along O 
with O 
data O 
reported O 
from O 
human O 
population O 
studies O 
, O 
regarding O 
the O 
impact O 
of O 
pesticide O 
exposure O 
on O 
activation O 
or O 
dysregulation O 
of O 
oncogenes O 
and O 
tumor O 
suppressor O 
genes O 
. O 
Substantial O 
mechanistic O 
work O 
suggests O 
that O 
pesticides O 
are O 
capable O 
of O 
inducing O 
mutations O 
in O 
oncogenes O 
and O 
increase O 
their O 
transcriptional O 
expression O 
in O 
vitro O 
, O 
whereas O 
human O 
population O 
studies O 
indicate O 
associations O 
between O 
pesticide O 
exposure O 
levels O 
and O 
mutation O 
occurrence O 
in O 
cancer O 
- O 
related O 
genes O 
. O 
Further O 
work O 
is O 
required O 
to O 
fully O 
explore O 
the O 
exact O 
mechanisms O 
by O 
which O 
pesticide O 
exposure O 
affects O 
the O 
integrity O 
and O 
normal O 
function O 
of O 
oncogenes O 
and O 
tumor O 
suppressor O 
genes O 
in O 
human O 
populations O 
. O 

increases O 
liking O 
and O 
consumption O 
of O 
novel O 
- O 
flavored O 
yogurt O 
. O 

: O 
Caffeine B-TRIVIAL 
has O 
been O 
shown O 
to O 
increase O 
preference O 
for O 
beverages O 
with O 
which O 
it O 
is O 
paired O 
; O 
however O 
, O 
it O 
is O 
not O 
known O 
if O 
caffeine B-TRIVIAL 
alters O 
liking O 
for O 
foods O 
with O 
which O 
it O 
is O 
paired O 
indirectly O 
. O 
OBJECTIVES O 
: O 
The O 
purpose O 
of O 
the O 
current O 
experiment O 
was O 
to O 
test O 
the O 
hypothesis O 
that O 
a O 
caffeinated O 
beverage O 
paired O 
with O 
a O 
novel O 
- O 
flavored O 
yogurt O 
will O 
increase O 
preference O 
for O 
that O 
yogurt O 
compared O 
to O 
one O 
paired O 
with O 
placebo O 
. O 
We O 
also O 
tested O 
the O 
hypothesis O 
that O 
liking O 
would O 
increase O 
more O 
when O 
caffeine B-TRIVIAL 
was O 
paired O 
with O 
high O 
energy O 
density O 
yogurt O 
. O 
METHODS O 
: O 
Men O 
and O 
women O 
( O 
n O 
= O 
62 O 
) O 
were O 
randomized O 
to O 
receive O 
a O 
beverage O 
containing O 
placebo O 
( O 
PLA O 
) O 
or O 
caffeine B-TRIVIAL 
( O 
CAF B-ABBREVIATION 
) O 
and O 
to O 
consume O 
a O 
low O 
( O 
LED O 
) O 
or O 
high O 
energy O 
density O 
( O 
HED O 
) O 
, O 
novel O 
- O 
flavored O 
yogurt O 
. O 
Participants O 
rated O 
, O 
ranked O 
, O 
and O 
consumed O 
seven O 
novel O 
- O 
flavored O 
yogurts O 
and O 
then O 
had O 
a O 
target O 
yogurt O 
paired O 
with O 
either O 
PLA O 
or O 
CAF B-ABBREVIATION 
over O 
four O 
consecutive O 
days O 
. O 
RESULTS O 
: O 
In O 
general O 
, O 
yogurt O 
liking O 
increased O 
over O 
time O 
, O 
the O 
HED O 
yogurt O 
was O 
liked O 
more O 
than O 
the O 
LED O 
yogurt O 
, O 
and O 
yogurt O 
paired O 
with O 
caffeine B-TRIVIAL 
was O 
liked O 
more O 
than O 
yogurt O 
paired O 
with O 
placebo O 
. O 
Participants O 
showed O 
a O 
significant O 
increase O 
in O 
liking O 
of O 
LED O 
yogurt O 
paired O 
with O 
caffeine B-TRIVIAL 
compared O 
to O 
those O 
with O 
LED O 
yogurt O 
paired O 
with O 
placebo O 
. O 
CONCLUSIONS O 
: O 
Caffeine B-TRIVIAL 
administration O 
may O 
increase O 
liking O 
and O 
consumption O 
of O 
novel O 
- O 
flavored O 
foods O 
, O 
particularly O 
if O 
the O 
food O 
is O 
not O 
highly O 
liked O 
at O 
baseline O 
. O 
This O 
suggests O 
that O 
caffeine B-TRIVIAL 
pairing O 
may O 
be O 
a O 
way O 
to O 
increase O 
liking O 
of O 
LED O 
foods O 
, O 
such O 
as O 
vegetables O 
and O 
fruit O 
. O 

of O 
repeated O 
exposure O 
to O 
MDMA B-ABBREVIATION 
on O 
5HT1a O 
autoreceptor O 
function O 
: O 
behavioral O 
and O 
neurochemical O 
responses O 
to O 
8-OHDPAT B-SYSTEMATIC 
. O 

consistent O 
effect O 
of O 
repeated O 
exposure O 
to O 
3,4 B-SYSTEMATIC 
methylenedioxymethamphetamine I-SYSTEMATIC 
( O 
MDMA B-ABBREVIATION 
) O 
is O 
a O 
decrease O 
in O 
the O 
tissue O 
levels O 
of O 
serotonin B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
) O 
. O 
A O 
variety O 
of O 
behavioural O 
and O 
neurochemical O 
tests O 
were O 
conducted O 
to O 
determine O 
whether O 
the O 
tissue O 
deficits O 
were O 
accompanied O 
by O 
an O 
increased O 
sensitivity O 
of O 
the O 
5-HT1a O 
autoreceptor O 
. O 
Tests O 
were O 
conducted O 
2 O 
weeks O 
following O 
MDMA B-ABBREVIATION 
exposure O 
( O 
four O 
injections O 
of O 
10 O 
mg O 
/ O 
kg O 
, O 
IP O 
, O 
administered O 
at O 
2-h O 
intervals O 
in O 
a O 
single O 
day O 
) O 
. O 
The O 
response O 
to O 
the O 
5-HT1a O 
agonist O 
, O 
8-OHDPAT B-SYSTEMATIC 
( O 
0.003-0.5 O 
mg O 
/ O 
kg O 
, O 
SC O 
) O 
, O 
was O 
assessed O 
using O 
lower O 
lip O 
retraction O 
( O 
LLR O 
) O 
, O 
hypoactivity O 
, O 
and O 
5-hydroxytryptophan B-SYSTEMATIC 
( O 
5-HTP B-SYSTEMATIC 
) O 
accumulation O 
following O 
decarboxylase O 
inhibition O 
. O 
The O 
8-OHDPAT B-SYSTEMATIC 
produced O 
a O 
dose O 
- O 
dependent O 
increase O 
in O 
LLR O 
and O 
hypoactivity O 
, O 
but O 
these O 
effects O 
were O 
comparable O 
for O 
MDMA B-ABBREVIATION 
and O 
saline O 
pretreated O 
groups O 
. O 
MDMA B-ABBREVIATION 
decreased O 
tissue O 
levels O 
of O 
5-HT B-SYSTEMATIC 
and O 
the O 
accumulation O 
of O 
5-HTP B-SYSTEMATIC 
, O 
but O 
these O 
effects O 
were O 
not O 
reflected O 
in O 
the O 
changes O 
in O 
autoreceptor O 
sensitivity O 
. O 
The O 
data O 
suggest O 
that O 
the O 
decrease O 
in O 
tissue O 
levels O 
of O 
5-HT B-SYSTEMATIC 
produced O 
by O 
MDMA B-ABBREVIATION 
is O 
accompanied O 
by O 
a O 
decrease O 
in O 
tryptophan B-TRIVIAL 
hydroxylase O 
activity O 
but O 
cannot O 
be O 
explained O 
by O 
supersensitivity O 
of O 
the O 
5-HT1a O 
autoreceptor O 
. O 

elucidate O 
the O 
compositional O 
changes O 
of O 
the O 
amygdala O 
with O 
aging O 
, O 
the O 
authors O 
investigated O 
age O 
- O 
related O 
differences O 
of O 
elements O 
in O 
human O 
amygdalae O 
. O 
In O 
addition O 
, O 
the O 
relationships O 
between O 
the O 
amygdala O 
and O 
other O 
brain O 
regions O 
were O 
investigated O 
from O 
a O 
viewpoint O 
of O 
elements O 
. O 
After O 
ordinary O 
dissections O 
at O 
Nara O 
Medical O 
University O 
were O 
finished O 
, O 
the O 
amygdalae O 
were O 
removed O 
from O 
the O 
cerebra O 
of O 
the O 
subjects O 
who O 
consisted O 
of O 
22 O 
men O 
and O 
23 O 
women O 
, O 
ranging O 
in O 
age O 
from O 
70 O 
to O 
101 O 
years O 
. O 
In O 
addition O 
, O 
the O 
hippocampus O 
, O 
dentate O 
gyrus O 
, O 
mammillary O 
body O 
of O 
the O 
limbic O 
system O 
and O 
the O 
caudate O 
nucleus O 
, O 
putamen O 
, O 
and O 
globus O 
pallidus O 
of O 
the O 
basal O 
ganglia O 
were O 
also O 
removed O 
from O 
the O 
identical O 
cerebra O 
. O 
After O 
the O 
brain O 
samples O 
were O 
incinerated O 
with O 
nitric B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
perchloric B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
the O 
element O 
contents O 
were O 
determined O 
by O 
inductively O 
coupled O 
plasma O 
- O 
atomic O 
emission O 
spectrometry O 
. O 
It O 
was O 
found O 
that O 
both O 
the O 
Ca B-FORMULA 
and O 
Mg B-FORMULA 
contents O 
increased O 
significantly O 
in O 
the O 
amygdalae O 
with O 
aging O 
, O 
but O 
the O 
other O 
five O 
element O 
contents O 
( O 
P B-FORMULA 
, O 
S B-FORMULA 
, O 
Zn B-FORMULA 
, O 
Fe B-FORMULA 
, O 
and O 
Na B-FORMULA 
) O 
did O 
not O 
change O 
significantly O 
in O 
the O 
amygdalae O 
with O 
aging O 
. O 
Regarding O 
the O 
relationships O 
among O 
elements O 
, O 
very O 
significant O 
or O 
significant O 
direct O 
correlations O 
were O 
found O 
among O 
the O 
Ca B-FORMULA 
, O 
P B-FORMULA 
, O 
and O 
Mg B-FORMULA 
contents O 
in O 
the O 
amygdalae O 
. O 
To O 
explore O 
the O 
relationships O 
between O 
the O 
amygdala O 
and O 
either O 
other O 
limbic O 
system O 
or O 
basal O 
ganglia O 
, O 
the O 
correlations O 
between O 
seven O 
elements O 
of O 
the O 
amygdala O 
and O 
hippocampus O 
, O 
dentate O 
gyrus O 
, O 
or O 
mammillary O 
body O 
, O 
and O 
between O 
those O 
of O 
the O 
amygdala O 
and O 
caudate O 
nucleus O 
, O 
putamen O 
, O 
or O 
globus O 
pallidus O 
which O 
derived O 
from O 
the O 
identical O 
cerebra O 
, O 
were O 
analyzed O 
with O 
Pearson's O 
correlation O 
. O 
It O 
was O 
found O 
that O 
regarding O 
the O 
four O 
elements O 
of O 
Ca B-FORMULA 
, O 
P B-FORMULA 
, O 
Mg B-FORMULA 
, O 
and O 
Fe B-FORMULA 
, O 
a O 
close O 
relationship O 
existed O 
between O 
the O 
amygdala O 
and O 
hippocampus O 
, O 
globus O 
pallidus O 
, O 
or O 
mammillary O 
body O 
. O 

the O 
pandemic O 
of O 
type O 
2 O 
diabetes O 
spreads O 
globally O 
, O 
clinicians O 
face O 
many O 
challenges O 
in O 
treating O 
an O 
increasingly O 
diverse O 
patient O 
population O 
varying O 
in O 
age O 
, O 
comorbidities O 
, O 
and O 
socioeconomic O 
status O 
. O 
Current O 
therapies O 
for O 
type O 
2 O 
diabetes O 
are O 
often O 
unable O 
to O 
alter O 
the O 
natural O 
course O 
of O 
the O 
disease O 
and O 
provide O 
durable O 
glycemic O 
control O 
, O 
and O 
side O 
effects O 
in O 
the O 
context O 
of O 
individual O 
patient O 
characteristics O 
often O 
limit O 
treatment O 
choices O 
. O 
This O 
often O 
results O 
in O 
the O 
progression O 
to O 
insulin O 
use O 
and O 
complex O 
regimens O 
that O 
are O 
difficult O 
to O 
maintain O 
. O 
Therefore O 
, O 
a O 
number O 
of O 
agents O 
are O 
being O 
developed O 
to O 
better O 
address O 
the O 
pathogenesis O 
of O 
type O 
2 O 
diabetes O 
and O 
to O 
overcome O 
limitations O 
of O 
current O 
therapies O 
. O 
The O 
hope O 
is O 
to O 
provide O 
more O 
options O 
for O 
glucose B-TRIVIAL 
lowering O 
and O 
complication O 
reduction O 
with O 
less O 
risk O 
for O 
hypoglycemia O 
and O 
other O 
adverse O 
effects O 
. O 
These O 
agents O 
include O 
newer O 
incretin O 
- O 
based O 
therapies O 
and O 
PPAR O 
agonists O 
, O 
as O 
well O 
as O 
new O 
therapeutic O 
classes O 
such O 
as O 
sodium B-SYSTEMATIC 
-coupled O 
glucose B-TRIVIAL 
cotransporter O 
2 O 
inhibitors O 
, O 
free O 
fatty B-FAMILY 
acid I-FAMILY 
receptor O 
agonists O 
, O 
11-β-hydroxysteroid B-FAMILY 
dehydrogenase O 
type O 
1 O 
inhibitors O 
, O 
glucokinase O 
activators O 
, O 
and O 
several O 
others O 
that O 
may O 
enter O 
clinical O 
use O 
over O 
the O 
next O 
decade O 
. O 
Herein O 
we O 
review O 
these O 
agents O 
that O 
are O 
advancing O 
through O 
clinical O 
trials O 
and O 
describe O 
the O 
rationale O 
behind O 
their O 
use O 
, O 
mechanisms O 
of O 
action O 
, O 
and O 
potential O 
for O 
glucose B-TRIVIAL 
lowering O 
, O 
as O 
well O 
as O 
what O 
is O 
known O 
of O 
their O 
limitations O 
. O 

pharmacokinetics O 
of O 
piperacillin B-TRIVIAL 
/ O 
tazobactam B-TRIVIAL 
in O 
neonates O 
and O 
young O 
infants O 
. O 

: O 
To O 
develop O 
population O 
pharmacokinetic O 
( O 
PK O 
) O 
models O 
for O 
piperacillin B-TRIVIAL 
/ O 
tazobactam B-TRIVIAL 
in O 
neonates O 
and O 
infants O 
of O 
less O 
than O 
2 O 
months O 
of O 
age O 
in O 
order O 
to O 
determine O 
the O 
appropriate O 
dosing O 
regimen O 
and O 
provide O 
a O 
rational O 
basis O 
for O 
the O 
development O 
of O 
preliminary O 
dosing O 
guidelines O 
suitable O 
for O 
this O 
population O 
. O 
METHODS O 
: O 
A O 
two O 
- O 
stage O 
, O 
open O 
- O 
label O 
study O 
was O 
conducted O 
in O 
neonates O 
and O 
infants O 
less O 
than O 
2 O 
months O 
of O 
age O 
in O 
the O 
neonatal O 
intensive O 
care O 
unit O 
( O 
NICU O 
) O 
. O 
A O 
total O 
of O 
207 O 
piperacillin B-TRIVIAL 
and O 
204 O 
tazobactam B-TRIVIAL 
concentration O 
- O 
time O 
data O 
sets O 
from O 
71 O 
patients O 
were O 
analyzed O 
using O 
a O 
nonlinear O 
mixed O 
- O 
effect O 
modeling O 
approach O 
( O 
NONMEM O 
VII O 
) O 
. O 
PK O 
models O 
were O 
developed O 
for O 
piperacillin B-TRIVIAL 
and O 
tazobactam B-TRIVIAL 
. O 
The O 
final O 
models O 
were O 
evaluated O 
using O 
both O 
bootstrap O 
and O 
visual O 
predictive O 
checks O 
. O 
External O 
model O 
evaluations O 
were O 
made O 
in O 
20 O 
additional O 
patients O 
. O 
RESULTS O 
: O 
For O 
neonates O 
and O 
young O 
infants O 
less O 
than O 
2 O 
months O 
of O 
age O 
, O 
the O 
median O 
central O 
clearance O 
was O 
0.133 O 
and O 
0.149 O 
L O 
/ O 
h O 
/ O 
kg O 
for O 
piperacillin B-TRIVIAL 
and O 
tazobactam B-TRIVIAL 
, O 
respectively O 
. O 
Postmenstrual O 
age O 
( O 
PMA O 
) O 
was O 
identified O 
as O 
the O 
most O 
significant O 
covariate O 
on O 
central O 
clearance O 
of O 
piperacillin B-TRIVIAL 
and O 
tazobactam B-TRIVIAL 
. O 
However O 
, O 
the O 
combination O 
of O 
current O 
bodyweight O 
( O 
BW O 
) O 
and O 
postnatal O 
age O 
proved O 
to O 
be O 
superior O 
to O 
PMA O 
alone O 
. O 
BW O 
was O 
the O 
most O 
important O 
covariate O 
for O 
apparent O 
central O 
volume O 
of O 
distribution O 
. O 
Both O 
internal O 
and O 
external O 
evaluations O 
supported O 
the O 
prediction O 
of O 
the O 
final O 
piperacillin B-TRIVIAL 
and O 
tazobactam B-TRIVIAL 
PK O 
models O 
. O 
The O 
dosing O 
strategy O 
44.44 O 
/ O 
5.56 O 
mg O 
/ O 
kg O 
/ O 
dose O 
piperacillin B-TRIVIAL 
/ O 
tazobactam B-TRIVIAL 
every O 
8 O 
or O 
12 O 
h O 
evaluated O 
in O 
this O 
study O 
achieved O 
the O 
pharmacodynamic O 
target O 
( O 
free O 
piperacillin B-TRIVIAL 
concentrations O 
> O 
4 O 
mg O 
/ O 
L O 
for O 
more O 
than O 
50 O 
% O 
of O 
the O 
dosing O 
interval O 
) O 
in O 
about O 
67 O 
% O 
of O 
infants O 
. O 
CONCLUSIONS O 
: O 
Population O 
PK O 
models O 
accurately O 
described O 
the O 
PK O 
profiles O 
of O 
piperacillin B-TRIVIAL 
/ O 
tazobactam B-TRIVIAL 
in O 
infants O 
less O 
than O 
2 O 
months O 
of O 
age O 
. O 
The O 
results O 
indicated O 
that O 
higher O 
doses O 
or O 
more O 
frequent O 
dosing O 
regimens O 
may O 
be O 
required O 
for O 
controlling O 
infection O 
in O 
this O 
population O 
in O 
NICU O 
. O 

- O 
healing O 
coating O 
based O 
on O 
metallopolymers O 
are O 
prepared O 
and O 
fully O 
characterized O 
. O 
Iron B-SYSTEMATIC 
bisterpyridine I-SYSTEMATIC 
complexes O 
are O 
incorporated O 
into O 
a O 
polymer O 
network O 
based O 
on O 
methacrylates B-FAMILY 
, O 
resulting O 
in O 
self O 
- O 
healing O 
properties O 
of O 
these O 
materials O 
. O 
Moreover O 
, O 
the O 
influence O 
of O 
the O 
comonomers O 
on O 
the O 
thermal O 
properties O 
is O 
studied O 
in O 
detail O 
. O 

discovery O 
of O 
phenylbenzamide B-SYSTEMATIC 
derivatives O 
as O 
Grb7 O 
- O 
based O 
antitumor O 
agents O 
. O 

is O 
a O 
non-catalytic O 
protein O 
, O 
the O 
overexpression O 
of O 
which O 
has O 
been O 
associated O 
with O 
the O 
proliferative O 
and O 
migratory O 
potentials O 
of O 
cancer O 
cells O 
. O 
Virtual O 
screening O 
strategies O 
involving O 
a O 
shape O 
- O 
based O 
similarity O 
search O 
, O 
molecular O 
docking O 
, O 
and O 
2D-similarity O 
searches O 
complemented O 
by O 
experimental O 
binding O 
studies O 
( O 
Thermofluor O 
and O 
isothermal O 
titration O 
calorimetry O 
) O 
resulted O 
in O 
the O 
identification O 
of O 
nine O 
novel O 
phenylbenzamide B-SYSTEMATIC 
-based O 
antagonists O 
of O 
the O 
Grb7 O 
SH2 O 
domain O 
. O 
Moderate O 
binding O 
affinities O 
were O 
observed O 
, O 
ranging O 
from O 
K(d)=32.3 O 
μM O 
for O 
lead O 
phenylbenzamide B-SYSTEMATIC 
NSC B-IDENTIFIER 
104999 I-IDENTIFIER 
( O 
1 O 
) O 
to O 
K(d)=1.1 O 
μM O 
for O 
a O 
structurally O 
related O 
compound O 
, O 
NSC B-IDENTIFIER 
57148 I-IDENTIFIER 
( O 
2 O 
) O 
. O 
Deconvolution O 
of O 
the O 
affinity O 
data O 
into O 
its O 
components O 
revealed O 
differences O 
in O 
lead O 
binding O 
, O 
from O 
being O 
entropy O 
based O 
( O 
lead O 
1 O 
) O 
to O 
enthalpically O 
driven O 
( O 
NSC B-IDENTIFIER 
100874 I-IDENTIFIER 
( O 
3 O 
) O 
, O 
NSC B-IDENTIFIER 
55158 I-IDENTIFIER 
( O 
4 O 
) O 
, O 
and O 
compound O 
2 O 
) O 
. O 
Finally O 
, O 
the O 
lead O 
compound O 
1 O 
was O 
found O 
to O 
decrease O 
the O 
growth O 
of O 
MDA-MB-468 O 
breast O 
cancer O 
cells O 
, O 
with O 
an O 
IC(50) O 
value O 
of O 
39.9 O 
μM O 
. O 
It O 
is O 
expected O 
that O 
these O 
structures O 
will O 
serve O 
as O 
novel O 
leads O 
in O 
the O 
development O 
of O 
Grb7 O 
- O 
based O 
anticancer O 
therapeutics O 
. O 

( O 
PDEs O 
) O 
degrade O 
cyclic B-FAMILY 
nucleotides I-FAMILY 
, O 
signalling O 
molecules O 
that O 
play O 
important O 
roles O 
in O 
synaptic O 
plasticity O 
and O 
memory O 
. O 
Inhibition O 
of O 
PDEs O 
may O 
therefore O 
enhance O 
synaptic O 
plasticity O 
and O 
memory O 
as O 
a O 
result O 
of O 
elevated O 
levels O 
of O 
these O 
signalling O 
molecules O 
, O 
and O 
this O 
has O 
led O 
to O 
interest O 
in O 
PDE O 
inhibitors O 
as O 
cognitive O 
enhancers O 
. O 
The O 
development O 
of O 
new O 
mouse O 
models O 
in O 
which O 
PDE O 
subtypes O 
have O 
been O 
selectively O 
knocked O 
out O 
and O 
increasing O 
selectivity O 
of O 
PDE O 
antagonists O 
means O 
that O 
this O 
field O 
is O 
currently O 
expanding O 
. O 
Roles O 
for O 
PDE2 O 
, O 
4 O 
, O 
5 O 
and O 
9 O 
in O 
synaptic O 
plasticity O 
have O 
so O 
far O 
been O 
demonstrated O 
and O 
we O 
review O 
these O 
studies O 
here O 
in O 
the O 
context O 
of O 
cyclic B-FAMILY 
nucleotide I-FAMILY 
signalling O 
more O 
generally O 
. O 
The O 
role O 
of O 
other O 
PDE O 
families O 
in O 
synaptic O 
plasticity O 
has O 
not O 
yet O 
been O 
investigated O 
, O 
and O 
this O 
area O 
promises O 
to O 
advance O 
our O 
understanding O 
of O 
cyclic B-FAMILY 
nucleotide I-FAMILY 
signalling O 
in O 
synaptic O 
plasticity O 
in O 
the O 
future O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
GluR-dep O 
synaptic O 
plasticity O 
' O 
. O 

induces O 
senescence O 
in O 
colorectal O 
cancer O 
cells O 
by O 
inducing O 
lamin O 
B1 O 
expression O 
. O 

cancer O 
is O 
a O 
leading O 
cause O 
of O 
cancer O 
mortality O 
with O 
a O 
complex O 
carcinogenesis O 
that O 
includes O 
reduced O 
cellular O 
senescence O 
. O 
Lamin O 
proteins O 
are O 
decreased O 
in O 
senescing O 
cells O 
, O 
and O 
frequently O 
decreased O 
in O 
malignancies O 
. O 
This O 
study O 
identified O 
a O 
new O 
drug O 
candidate O 
for O 
colorectal O 
cancer O 
that O 
appears O 
to O 
target O 
cell O 
senescence O 
via O 
a O 
lamin O 
protein O 
. O 
β-Asarone B-TRIVIAL 
( O 
1-propenyl-2,4,5-methoxybenzol B-SYSTEMATIC 
) O 
is O 
a O 
compound O 
from O 
the O 
traditional O 
medical O 
herb O 
Acorus O 
calamus O 
Linn O 
. O 
This O 
study O 
tested O 
the O 
in O 
vitro O 
and O 
in O 
vivo O 
effects O 
of O 
β-asarone B-TRIVIAL 
on O 
colorectal O 
cancer O 
cells O 
by O 
testing O 
cell O 
viability O 
using O 
human O 
colorectal O 
cell O 
lines O 
HT29 O 
and O 
SW480 O 
in O 
MTT B-ABBREVIATION 
assays O 
; O 
tumorigenesis O 
using O 
xenografts O 
in O 
nude O 
mice O 
and O 
a O 
mouse O 
model O 
of O 
colorectal O 
cancer O 
; O 
cell O 
senescence O 
using O 
senescence O 
- O 
associated O 
β-galactosidase O 
activity O 
; O 
and O 
expression O 
of O 
cancer O 
and O 
senescence O 
- O 
related O 
proteins O 
, O 
specifically O 
lamins O 
, O 
Oct-1 O 
, O 
p53 O 
, O 
p21 O 
, O 
and O 
p15 O 
, O 
by O 
Western O 
blot O 
. O 
β-Asarone B-TRIVIAL 
appeared O 
to O 
increase O 
expression O 
of O 
lamin O 
B1 O 
, O 
p53 O 
, O 
p21 O 
, O 
but O 
not O 
lamin O 
A O 
/ O 
C O 
. O 
β-Asarone B-TRIVIAL 
regulates O 
p15 O 
expression O 
by O 
regulation O 
of O 
Oct-1 O 
binding O 
. O 
Collectively O 
, O 
the O 
results O 
suggested O 
that O 
β-asarone B-TRIVIAL 
inhibits O 
colon O 
cancer O 
formation O 
in O 
vivo O 
and O 
in O 
vitro O 
by O 
inducing O 
senescence O 
. O 
Since O 
β-asarone B-TRIVIAL 
induced O 
lamin O 
B1 O 
expression O 
, O 
a O 
model O 
is O 
proposed O 
in O 
which O 
β-asarone B-TRIVIAL 
inhibits O 
colorectal O 
cancer O 
by O 
inducing O 
senescence O 
through O 
lamin O 
B1 O 
. O 

effect O 
on O 
NO B-FORMULA 
production O 
of O 
triterpenes B-FAMILY 
from O 
the O 
fruiting O 
bodies O 
of O 
Ganoderma O 
lucidum O 
. O 

new O 
lanostane B-FAMILY 
triterpenes I-FAMILY 
, O 
butyl B-SYSTEMATIC 
lucidenate I-SYSTEMATIC 
P I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
butyl B-SYSTEMATIC 
lucidenate I-SYSTEMATIC 
D(2) I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
butyl B-SYSTEMATIC 
lucidenate I-SYSTEMATIC 
E(2) I-SYSTEMATIC 
( O 
3 O 
) O 
and O 
butyl B-SYSTEMATIC 
lucidenate I-SYSTEMATIC 
Q I-SYSTEMATIC 
( O 
4 O 
) O 
along O 
with O 
11 O 
known O 
compounds O 
( O 
5- O 
15 O 
) O 
were O 
isolated O 
from O 
the O 
fruiting O 
bodies O 
of O 
Ganoderma O 
lucidum O 
. O 
Their O 
chemical O 
structures O 
were O 
established O 
mainly O 
by O 
1D O 
and O 
2D O 
NMR O 
techniques O 
and O 
mass O 
spectrometry O 
. O 
Their O 
anti-inflammatory O 
activity O 
was O 
evaluated O 
against O 
LPS-induced O 
NO B-FORMULA 
production O 
in O 
macrophage O 
RAW O 
264.7 O 
cells O 
. O 
Compounds O 
1 O 
, O 
3 O 
, O 
4 O 
, O 
9 O 
, O 
10 O 
and O 
15 O 
showed O 
inhibitory O 
potency O 
with O 
IC(50) O 
values O 
of O 
7.4 O 
, O 
6.4 O 
, O 
4.3 O 
, O 
9.4 O 
, O 
9.2 O 
and O 
4.5 O 
μM O 
, O 
respectively O 
. O 
Compounds O 
1 O 
, O 
3 O 
and O 
15 O 
dose O 
- O 
dependently O 
reduced O 
the O 
LPS-induced O 
iNOS O 
expressions O 
. O 
Preincubation O 
of O 
cell O 
with O 
1 O 
, O 
3 O 
and O 
15 O 
significantly O 
suppressed O 
LPS-induced O 
expression O 
of O 
COX-2 O 
protein O 
. O 

transmission O 
is O 
essential O 
for O 
early O 
development O 
of O 
the O 
central O 
nervous O 
system O 
. O 
However O 
, O 
the O 
mechanisms O 
that O 
regulate O 
early O 
synaptic O 
transmission O 
in O 
the O 
cerebral O 
cortex O 
are O 
unclear O 
. O 
PKMζ O 
is O 
a O 
kinase O 
essential O 
for O 
the O 
maintenance O 
of O 
LTP O 
. O 
We O 
show O 
for O 
the O 
first O 
time O 
that O 
inhibition O 
of O 
PKMζ O 
produces O 
a O 
profound O 
depression O 
of O 
basal O 
synaptic O 
transmission O 
in O 
neonatal O 
, O 
but O 
not O 
adult O 
, O 
rat O 
perirhinal O 
cortex O 
. O 
This O 
suggests O 
that O 
synapses O 
in O 
early O 
development O 
are O 
in O 
a O 
constitutive O 
LTP O 
- O 
like O 
state O 
. O 
Furthermore O 
, O 
basal O 
synaptic O 
transmission O 
in O 
immature O 
, O 
but O 
not O 
mature O 
, O 
perirhinal O 
cortex O 
relies O 
on O 
persistent O 
activity O 
of O 
metabotropic O 
glutamate B-TRIVIAL 
( O 
mGlu O 
) O 
receptor O 
, O 
PI3Kinase O 
and O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
( O 
mTOR O 
) O 
. O 
Thus O 
early O 
in O 
development O 
, O 
cortical O 
synapses O 
exist O 
in O 
an O 
LTP O 
- O 
like O 
state O 
maintained O 
by O 
tonically O 
active O 
mGlu O 
receptor- O 
, O 
mTOR- O 
and O 
PKMζ- O 
dependent O 
cascades O 
. O 
These O 
results O 
provide O 
new O 
understanding O 
of O 
the O 
molecular O 
mechanisms O 
that O 
control O 
synapses O 
during O 
development O 
and O 
may O 
aid O 
our O 
understanding O 
of O 
developmental O 
disorders O 
such O 
as O 
autism O 
and O 
schizophrenia O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

effects O 
caused O 
by O 
therapeutic O 
drugs O 
are O 
a O 
serious O 
and O 
costly O 
health O 
concern O 
. O 
Despite O 
the O 
body's O 
systemic O 
responses O 
to O 
therapeutics O 
, O 
the O 
liver O 
is O 
often O 
the O 
focus O 
of O 
damage O 
and O 
is O 
usually O 
the O 
focus O 
of O 
studies O 
of O 
toxic O 
effects O 
due O 
to O 
its O 
active O 
roles O 
in O 
the O 
metabolism O 
of O 
xenobiotics O 
. O 
It O 
is O 
extremely O 
difficult O 
, O 
however O 
, O 
to O 
assess O 
systemic O 
responses O 
with O 
currently O 
available O 
methods O 
. O 
Comprehensive O 
cataloging O 
of O 
cell O 
- O 
free O 
circulating O 
RNAs O 
using O 
next O 
- O 
generation O 
sequencing O 
technology O 
may O 
open O 
a O 
window O 
to O 
assess O 
drug O 
- O 
associated O 
adverse O 
effects O 
at O 
the O 
systems O 
level O 
. O 
To O 
explore O 
this O 
potential O 
, O 
we O 
conducted O 
an O 
RNA O 
profiling O 
study O 
using O 
the O 
well O 
- O 
characterized O 
acetaminophen B-TRIVIAL 
overdose O 
mouse O 
model O 
on O 
liver O 
and O 
plasma O 
with O 
microarray O 
and O 
next O 
- O 
generation O 
sequencing O 
platforms O 
, O 
respectively O 
. O 
After O 
drug O 
treatment O 
, O 
the O 
levels O 
of O 
a O 
number O 
of O 
transcripts O 
, O 
both O 
endogenous O 
and O 
exogenous O 
RNAs O 
, O 
showed O 
significant O 
changes O 
in O 
plasma O 
, O 
reflecting O 
not O 
only O 
the O 
classical O 
liver O 
injury O 
induced O 
by O 
acetaminophen B-TRIVIAL 
overdose O 
but O 
also O 
damage O 
in O 
tissues O 
other O 
than O 
the O 
liver O 
. O 
The O 
changes O 
in O 
exogenous O 
RNAs O 
also O 
reflect O 
alteration O 
on O 
dieting O 
behavior O 
after O 
acetaminophen B-TRIVIAL 
overdose O 
. O 
Besides O 
reporting O 
an O 
extensive O 
list O 
of O 
circulating O 
RNA O 
- O 
based O 
biomarker O 
candidates O 
, O 
this O 
study O 
illustrates O 
the O 
possibility O 
of O 
using O 
circulating O 
RNAs O 
to O 
assess O 
global O 
effects O 
of O 
therapeutics O 
. O 
This O 
could O 
also O 
lead O 
to O 
a O 
new O 
approach O 
for O 
a O 
more O 
comprehensive O 
assessment O 
of O 
the O 
efficacy O 
and O 
safety O 
of O 
therapeutics O 
. O 

of O 
p-glycoprotein O 
mediated O 
multidrug O 
resistance O 
by O 
stemofoline B-TRIVIAL 
derivatives O 
. O 

to O 
chemotherapy O 
in O 
cancer O 
patients O 
has O 
been O 
correlated O 
to O 
the O 
overexpression O 
of O 
the O 
ATP B-ABBREVIATION 
-binding O 
cassette O 
( O 
ABC O 
) O 
drug O 
transporters O 
including O 
P-glycoprotein O 
( O 
P-gp O 
) O 
that O 
actively O 
efflux O 
chemotherapeutic O 
drugs O 
from O 
cancer O 
cells O 
. O 
We O 
examined O 
the O 
mutidrug O 
resistance O 
reversing O 
property O 
of O 
stemofoline B-TRIVIAL 
derivatives O 
in O 
drug O 
- O 
resistance O 
human O 
cervical O 
carcinoma O 
( O 
KB-V1 O 
) O 
and O 
human O 
leukemic O 
( O 
K562 O 
/ O 
Adr O 
) O 
cell O 
lines O 
that O 
overexpress O 
P-gp O 
. O 
Didehydrostemofoline B-TRIVIAL 
and O 
eleven O 
of O 
its O 
derivatives O 
were O 
synthesized O 
and O 
the O 
cytotoxicity O 
and O 
their O 
effect O 
on O 
doxorubicin B-TRIVIAL 
, O 
vinblastine B-TRIVIAL 
and O 
paclitaxel B-TRIVIAL 
sensitivity O 
in O 
drug O 
resistant O 
( O 
KB-V1 O 
and O 
K562 O 
/ O 
Adr O 
) O 
and O 
drug O 
sensitive O 
( O 
KB-3-1 O 
and O 
K562 O 
) O 
cell O 
lines O 
by O 
a O 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
MTT B-ABBREVIATION 
) O 
assay O 
were O 
determined O 
. O 
We O 
found O 
that O 
three O 
out O 
of O 
the O 
twelve O 
stemofoline B-TRIVIAL 
derivatives O 
including O 
OH-A1 B-FORMULA 
, O 
NH-B6 B-FORMULA 
and O 
NH-D6 B-FORMULA 
showed O 
commitment O 
efficiency O 
to O 
increase O 
sensitivity O 
to O 
doxorubicin B-TRIVIAL 
, O 
vinblastine B-TRIVIAL 
and O 
paclitaxel B-TRIVIAL 
in O 
KB-V1 O 
cells O 
and O 
increase O 
sensitivity O 
to O 
doxorubicin B-TRIVIAL 
, O 
and O 
paclitaxel B-TRIVIAL 
in O 
K562 O 
/ O 
Adr O 
cells O 
whereas O 
the O 
effects O 
have O 
not O 
been O 
seen O 
in O 
their O 
parental O 
sensitive O 
cancer O 
cell O 
lines O 
( O 
KB-3-1 O 
and O 
K562 O 
) O 
. O 
These O 
results O 
indicate O 
that O 
stemofoline B-TRIVIAL 
derivatives O 
reversed O 
P-gp O 
- O 
mediated O 
multidrug O 
resistance O 
in O 
vitro O 
, O 
and O 
thus O 
could O 
be O 
developed O 
as O 
effective O 
chemosensitizers O 
to O 
treat O 
multidrug O 
- O 
resistant O 
cancers O 
. O 
The O 
molecular O 
mechanism O 
of O 
modulation O 
of O 
P-gp O 
would O 
be O 
further O 
determined O 
. O 

have O 
previously O 
reported O 
that O 
pyrroloquinoline B-SYSTEMATIC 
quinone I-SYSTEMATIC 
( O 
PQQ B-ABBREVIATION 
) O 
prevents O 
the O 
amyloid O 
formation O 
of O 
α-synuclein O 
, O 
amyloid O 
β(1-42) O 
(Aβ(1-42)) O 
, O 
and O 
mouse O 
prion O 
protein O 
. O 
Moreover O 
, O 
PQQ B-ABBREVIATION 
-modified O 
α-synuclein O 
and O 
a O 
proteolytic O 
fragment O 
of O 
the O 
PQQ B-ABBREVIATION 
-modified O 
α-synuclein O 
are O 
able O 
to O 
inhibit O 
the O 
amyloid O 
formation O 
of O 
α-synuclein O 
. O 
Here O 
, O 
we O 
identified O 
the O 
peptide O 
sequences O 
that O 
play O 
an O 
important O 
role O 
as O 
PQQ B-ABBREVIATION 
-modified O 
specific O 
peptide O 
inhibitors O 
of O 
α-synuclein O 
. O 
We O 
demonstrate O 
that O 
the O 
PQQ B-ABBREVIATION 
-modified O 
α-Syn(36-46) O 
peptide O 
, O 
which O 
is O 
a O 
partial O 
sequence O 
of O 
α-synuclein O 
, O 
prevented O 
α-synuclein O 
amyloid O 
fibril O 
formation O 
but O 
did O 
not O 
inhibit O 
Aβ(1-42) O 
fibril O 
formation O 
. O 
In O 
addition O 
, O 
the O 
α-synuclein O 
partial O 
peptide O 
modified O 
with O 
other O 
small O 
- O 
molecule O 
inhibitors O 
, O 
Baicalein B-TRIVIAL 
and O 
epigallocatechin B-TRIVIAL 
gallate I-TRIVIAL 
( O 
EGCG B-ABBREVIATION 
) O 
, O 
prevented O 
α-synuclein O 
fibril O 
formation O 
. O 
Currently O 
reported O 
quinone B-FAMILY 
amyloid O 
inhibitors O 
do O 
not O 
have O 
selectivity O 
toward O 
protein O 
molecules O 
. O 
Therefore O 
, O 
our O 
achievements O 
provide O 
a O 
novel O 
strategy O 
for O 
the O 
development O 
of O 
targeted O 
specific O 
amyloid O 
formation O 
inhibitors O 
: O 
the O 
combination O 
of O 
quinone B-FAMILY 
compounds O 
with O 
specific O 
peptide O 
sequence O 
from O 
target O 
proteins O 
involved O 
in O 
amyloid O 
formation O 
. O 

and O 
biological O 
evaluation O 
of O 
xanthine B-TRIVIAL 
derivatives O 
on O 
dipeptidyl O 
peptidase O 
4 O 
. O 

series O 
of O 
xanthine B-TRIVIAL 
derivatives O 
in O 
which O 
a O 
methylene B-SYSTEMATIC 
was O 
inserted O 
at O 
position O 
8 O 
of O 
xanthine B-TRIVIAL 
scaffold O 
was O 
synthesized O 
and O 
evaluated O 
as O 
inhibitors O 
of O 
dipeptidyl O 
peptidase O 
4 O 
( O 
DPP-4 O 
) O 
for O 
the O 
treatment O 
of O 
type O 
2 O 
diabetes O 
. O 
As O 
the O 
results O 
of O 
structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
study O 
of O 
the O 
series O 
, O 
the O 
compounds O 
with O 
4-methyl-quinazoline-2-yl-methyl B-SYSTEMATIC 
group O 
at O 
N-1 O 
position O 
and O 
2-aminoethylaminomethyl B-SYSTEMATIC 
group O 
gave O 
better O 
activities O 
. O 
Compounds O 
H4 O 
and O 
H9 O 
showed O 
good O 
DPP-4 O 
inhibition O 
and O 
more O 
than O 
100-fold O 
selectivity O 
over O 
DPP-7 O 
and O 
DPP-8 O 
. O 

, O 
DNA O 
binding O 
and O 
antitumor O 
evaluation O 
of O 
styelsamine B-FAMILY 
and O 
cystodytin B-FAMILY 
analogues O 
. O 

series O 
of O 
N-14 O 
sidechain O 
substituted O 
analogues O 
of O 
styelsamine B-FAMILY 
( O 
pyrido[4,3,2-mn]acridine B-SYSTEMATIC 
) O 
and O 
cystodytin B-FAMILY 
( O 
pyrido[4,3,2-mn]acridin-4-one B-SYSTEMATIC 
) O 
alkaloids O 
have O 
been O 
prepared O 
and O 
evaluated O 
for O 
their O 
DNA O 
binding O 
affinity O 
and O 
antiproliferative O 
activity O 
towards O 
a O 
panel O 
of O 
human O 
tumor O 
cell O 
lines O 
. O 
Overall O 
it O 
was O 
found O 
that O 
styelsamine B-FAMILY 
analogues O 
were O 
stronger O 
DNA O 
binders O 
, O 
with O 
the O 
natural O 
products O 
styelsamines B-MULTIPLE 
B I-MULTIPLE 
and I-MULTIPLE 
D I-MULTIPLE 
having O 
particularly O 
high O 
affinity O 
( O 
K(app) O 
5.33 O 
× O 
10(6) O 
and O 
3.64 O 
× O 
10(6) O 
M(-1) O 
, O 
respectively O 
) O 
. O 
In O 
comparison O 
, O 
the O 
cystodytin B-FAMILY 
iminoquinone I-FAMILY 
alkaloids I-FAMILY 
showed O 
lower O 
affinity O 
for O 
DNA O 
, O 
but O 
were O 
typically O 
just O 
as O 
active O 
as O 
styelsamine B-FAMILY 
analogues O 
at O 
inhibiting O 
proliferation O 
of O 
tumor O 
cells O 
in O 
vitro O 
. O 
Sub O 
- O 
panel O 
selectivity O 
towards O 
non-small O 
cell O 
lung O 
, O 
melanoma O 
and O 
renal O 
cancer O 
cell O 
lines O 
were O 
observed O 
for O 
a O 
number O 
of O 
the O 
analogues O 
. O 
Correlation O 
was O 
observed O 
between O 
whole O 
cell O 
activity O 
and O 
clogP O 
, O 
with O 
the O 
most O 
potent O 
antiproliferative O 
activity O 
being O 
observed O 
for O 
3-phenylpropanamide B-SYSTEMATIC 
analogues O 
37 O 
and O 
41 O 
( O 
NCI O 
panel O 
average O 
GI(50) O 
0.4 O 
μM O 
and O 
0.32 O 
μM O 
, O 
respectively O 
) O 
with O 
clogP O 
~4.0-4.5 O 
. O 

in O 
the O 
α O 
5 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
subunit O 
gene O 
predicts O 
cigarette O 
smoking O 
intensity O 
as O 
a O 
function O 
of O 
nicotine B-TRIVIAL 
content O 
. O 

single O 
- O 
nucleotide O 
polymorphism O 
( O 
SNP O 
) O 
in O 
the O 
α5 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
subunit O 
gene O 
, O 
rs16969968 O 
, O 
has O 
been O 
repeatedly O 
associated O 
with O 
both O 
smoking O 
and O 
respiratory O 
health O 
phenotypes O 
. O 
However O 
, O 
there O 
remains O 
considerable O 
debate O 
as O 
to O 
whether O 
associations O 
with O 
lung O 
cancer O 
are O 
mediated O 
through O 
effects O 
on O 
smoking O 
behavior O 
. O 
Preclinical O 
studies O 
suggest O 
that O 
α5 O 
receptor O 
subunit O 
expression O 
and O 
function O 
may O 
have O 
a O 
direct O 
role O 
in O 
nicotine B-TRIVIAL 
titration O 
during O 
self O 
administration O 
. O 
The O 
present O 
study O 
investigated O 
the O 
association O 
of O 
CHRNA5 O 
polymorphisms O 
and O 
smoking O 
topography O 
in O 
66 O 
smokers O 
asked O 
to O 
smoke O 
four O 
nicotine B-TRIVIAL 
-containing O 
( O 
nicotine B-TRIVIAL 
yield=0.60 O 
mg O 
) O 
and O 
four O 
placebo O 
( O 
nicotine B-TRIVIAL 
yield O 
< O 
0.05 O 
mg O 
) O 
cigarettes O 
, O 
during O 
separate O 
experimental O 
sessions O 
. O 
Genotype O 
at O 
rs16969968 O 
predicted O 
nicotine B-TRIVIAL 
titration O 
, O 
with O 
homozygotes O 
for O 
the O 
major O 
allele O 
( O 
G O 
: O 
G O 
) O 
displaying O 
significantly O 
reduced O 
puff O 
volume O 
in O 
response O 
to O 
nicotine B-TRIVIAL 
, O 
whereas O 
minor O 
allele O 
carriers O 
( O 
A O 
: O 
G O 
or O 
A O 
: O 
A O 
) O 
produced O 
equivalent O 
puff O 
volumes O 
for O 
placebo O 
and O 
nicotine B-TRIVIAL 
cigarettes O 
. O 
The O 
present O 
results O 
suggest O 
that O 
puff O 
volume O 
may O 
be O 
a O 
more O 
powerful O 
objective O 
phenotype O 
of O 
smoking O 
behavior O 
than O 
self O 
- O 
reported O 
cigarettes O 
per O 
day O 
and O 
nicotine B-TRIVIAL 
dependence O 
. O 
Further O 
, O 
these O 
results O 
suggest O 
that O 
the O 
association O 
between O 
rs16969968 O 
and O 
lung O 
cancer O 
may O 
be O 
mediated O 
by O 
the O 
quantity O 
of O 
smoke O 
inhaled.The O 
Pharmacogenomics O 
Journal O 
advance O 
online O 
publication O 
, O 
29 O 
January O 
2013 O 
; O 
doi O 
: O 
10.1038 O 
/ O 
tpj.2012.50 O 
. O 

pH O 
mapping O 
in O 
microfluidic O 
devices O 
by O 
integrating O 
adaptive O 
coatings O 
based O 
on O 
polyaniline B-SYSTEMATIC 
with O 
colorimetric O 
imaging O 
techniques O 
. O 

this O 
paper O 
we O 
present O 
a O 
microfluidic O 
device O 
that O 
has O 
integrated O 
pH O 
optical O 
sensing O 
capabilities O 
based O 
on O 
polyaniline B-SYSTEMATIC 
. O 
The O 
optical O 
properties O 
of O 
polyaniline B-SYSTEMATIC 
coatings O 
change O 
in O 
response O 
to O 
the O 
pH O 
of O 
the O 
solution O 
that O 
is O 
flushed O 
inside O 
the O 
microchannel O 
offering O 
the O 
possibility O 
of O 
monitoring O 
pH O 
in O 
continuous O 
flow O 
over O 
a O 
wide O 
pH O 
range O 
throughout O 
the O 
entire O 
channel O 
length O 
. O 
This O 
work O 
also O 
features O 
an O 
innovative O 
detection O 
system O 
for O 
spatial O 
localisation O 
of O 
chemical O 
pH O 
gradients O 
along O 
microfluidic O 
channels O 
through O 
the O 
use O 
of O 
a O 
low O 
cost O 
optical O 
device O 
. O 
Specifically O 
, O 
the O 
use O 
of O 
a O 
microfluidic O 
channel O 
coated O 
with O 
polyaniline B-SYSTEMATIC 
is O 
shown O 
to O 
respond O 
colorimetrically O 
to O 
pH O 
and O 
that O 
effect O 
is O 
detected O 
by O 
the O 
detection O 
system O 
, O 
even O 
when O 
pH O 
gradients O 
are O 
induced O 
within O 
the O 
channel O 
. O 
This O 
study O 
explores O 
the O 
capability O 
of O 
detecting O 
this O 
gradient O 
by O 
means O 
of O 
imaging O 
techniques O 
and O 
the O 
mapping O 
of O 
the O 
camera's O 
response O 
to O 
its O 
corresponding O 
pH O 
after O 
a O 
successful O 
calibration O 
process O 
. O 
The O 
provision O 
of O 
an O 
inherently O 
responsive O 
channel O 
means O 
that O 
changes O 
in O 
the O 
pH O 
of O 
a O 
sample O 
moving O 
through O 
the O 
system O 
can O 
be O 
detected O 
dynamically O 
using O 
digital O 
imaging O 
along O 
the O 
entire O 
channel O 
length O 
in O 
real O 
time O 
, O 
without O 
the O 
need O 
to O 
add O 
reagents O 
to O 
the O 
sample O 
. O 
This O 
approach O 
is O 
generic O 
and O 
can O 
be O 
applied O 
to O 
other O 
chemically O 
responsive O 
coatings O 
immobilised O 
on O 
microchannels O 
. O 

standard O 
tests O 
assess O 
toxic O 
effects O 
by O 
exposing O 
an O 
organism O 
to O 
high O 
concentrations O 
over O 
defined O 
periods O 
of O 
time O 
. O 
To O 
evaluate O 
toxicity O 
under O 
field O 
conditions O 
such O 
as O 
fluctuating O 
and O 
pulsed O 
exposures O 
, O 
process O 
- O 
based O 
toxicokinetic O 
/ O 
toxicodynamic O 
( O 
TK O 
/ O 
TD O 
) O 
models O 
may O 
be O 
used O 
for O 
extrapolation O 
from O 
the O 
existing O 
evidence O 
. O 
A O 
TK O 
/ O 
TD O 
model O 
was O 
developed O 
that O 
simulates O 
the O 
effect O 
on O 
growth O 
of O 
the O 
green O 
algae O 
Scenedesmus O 
vacuolatus O 
continuously O 
exposed O 
to O 
the O 
model O 
chemicals O 
norflurazon B-TRIVIAL 
, O 
triclosan B-TRIVIAL 
, O 
and O 
N-phenyl-2-naphthylamine B-SYSTEMATIC 
. O 
A O 
pharmacological O 
time O 
- O 
response O 
model O 
describing O 
the O 
effects O 
of O 
anticancer O 
treatments O 
on O 
cancer O 
cell O 
growth O 
was O 
adapted O 
and O 
modified O 
to O 
model O 
the O 
affected O 
growth O 
of O 
synchronized O 
algae O 
cells O 
. O 
The O 
TK O 
/ O 
TD O 
model O 
simulates O 
the O 
temporal O 
effect O 
course O 
by O 
linking O 
the O 
ambient O 
concentration O 
of O 
a O 
chemical O 
to O 
the O 
observable O 
adverse O 
effect O 
via O 
an O 
internal O 
concentration O 
and O 
a O 
sequence O 
of O 
biological O 
events O 
in O 
the O 
organism O 
. O 
The O 
parameters O 
of O 
the O 
toxicodynamic O 
model O 
are O 
related O 
to O 
the O 
growth O 
characteristics O 
of O 
algae O 
cells O 
, O 
a O 
no O 
effect O 
concentration O 
, O 
the O 
chemical O 
efficacy O 
as O 
well O 
as O 
the O 
ability O 
of O 
recovery O 
and O 
repair O 
, O 
and O 
the O 
delay O 
during O 
damage O 
propagation O 
. O 
The O 
TK O 
/ O 
TD O 
model O 
fits O 
well O 
to O 
the O 
observed O 
algae O 
growth O 
. O 
The O 
effect O 
propagation O 
through O 
cumulative O 
cell O 
damage O 
explained O 
the O 
observed O 
delayed O 
responses O 
better O 
than O 
just O 
the O 
toxicokinetics O 
. O 
The O 
TK O 
/ O 
TD O 
model O 
could O 
facilitate O 
the O 
link O 
between O 
several O 
effect O 
levels O 
within O 
damage O 
propagation O 
, O 
which O 
prospectively O 
may O 
be O 
helpful O 
to O 
model O 
adverse O 
outcome O 
pathways O 
and O 
time O 
- O 
dependent O 
mixture O 
effects O 
. O 
Environ O 
. O 
Toxicol O 
. O 
Chem O 
. O 
2013;32 O 
: O 
1161-1172 O 
. O 
© O 
2013 O 
SETAC O 
. O 

fatty O 
liver O 
disease O 
( O 
NAFLD O 
) O 
is O 
characterized O 
by O 
the O 
accumulation O 
of O 
triglycerides B-FAMILY 
in O 
hepatocytes O 
in O 
the O 
absence O 
of O 
excessive O 
alcohol B-FAMILY 
intake O 
, O 
ranging O 
in O 
severity O 
from O 
simple O 
steatosis O 
to O 
nonalcoholic O 
steatohepatitis O 
( O 
NASH O 
) O 
. O 
Nonalcoholic O 
steatohepatitis O 
can O 
ultimately O 
progress O 
to O 
cirrhosis O 
and O 
hepatocellular O 
carcinoma O 
. O 
NAFLD O 
is O 
associated O 
with O 
cardiometabolic O 
risk O 
factors O 
and O 
is O 
the O 
most O 
common O 
chronic O 
liver O 
disease O 
among O 
adults O 
in O 
the O 
Western O 
Hemisphere O 
. O 
Although O 
simple O 
steatosis O 
is O 
generally O 
considered O 
a O 
self O 
- O 
limiting O 
disease O 
, O 
evidence O 
suggests O 
an O 
increased O 
risk O 
of O 
cardiovascular O 
disease O 
, O 
and O 
, O 
less O 
conclusively O 
, O 
mortality O 
, O 
among O 
individuals O 
with O 
NAFLD O 
and O 
/ O 
or O 
NASH O 
. O 
The O 
current O 
standard O 
of O 
care O 
for O 
the O 
treatment O 
of O 
patients O 
with O 
NAFLD O 
focuses O 
on O 
lifestyle O 
interventions O 
, O 
particularly O 
diet O 
and O 
exercise O 
. O 
There O 
is O 
a O 
lack O 
of O 
consensus O 
regarding O 
the O 
most O 
effective O 
and O 
appropriate O 
pharmacologic O 
therapy O 
. O 
A O 
PubMed O 
search O 
was O 
conducted O 
using O 
the O 
medical O 
subject O 
heading O 
terms O 
" O 
fatty O 
liver O 
" O 
and O 
" O 
steatohepatitis O 
. O 
" O 
This O 
review O 
focuses O 
on O 
the O 
current O 
pharmacologic O 
options O 
available O 
for O 
treating O 
adults O 
with O 
NAFLD O 
and O 
/ O 
or O 
NASH O 
. O 
Continued O 
investigation O 
of O 
drugs O 
or O 
combinations O 
that O 
improve O 
NAFLD O 
progression O 
is O 
crucial O 
. O 
Clinicians O 
, O 
particularly O 
pharmacists O 
, O 
must O 
take O 
an O 
active O 
role O 
in O 
identification O 
and O 
appropriate O 
selection O 
of O 
pharmacotherapy O 
for O 
NAFLD O 
. O 

-Modified O 
Macroporous O 
Poly(Glycidyl B-FAMILY 
Methacrylate I-FAMILY 
) I-FAMILY 
and O 
Poly(2-Hydroxyethyl B-FAMILY 
Methacrylate I-FAMILY 
) I-FAMILY 
Microspheres O 
to O 
Reduce O 
Non-Specific O 
Protein O 
Adsorption O 
. O 

minimize O 
non-specific O 
protein O 
adsorption O 
on O 
macroporous O 
poly(glycidyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
and O 
poly(2-hydroxyethyl B-FAMILY 
methacrylate I-FAMILY 
) I-FAMILY 
microspheres O 
containing O 
amino B-FAMILY 
and O 
/ O 
or O 
carboxyl B-SYSTEMATIC 
groups O 
, O 
the O 
microspheres O 
are O 
coated O 
with O 
α,ω-bis-carboxy B-FAMILY 
poly(ethylene I-FAMILY 
glycol I-FAMILY 
) I-FAMILY 
and O 
amino B-FAMILY 
-terminated O 
poly(ethylene B-FAMILY 
glycol I-FAMILY 
- I-FAMILY 
co I-FAMILY 
- I-FAMILY 
propylene I-FAMILY 
glycol I-FAMILY 
) I-FAMILY 
or O 
α-methoxy-ω-amino B-FAMILY 
poly(ethylene I-FAMILY 
glycol I-FAMILY 
) I-FAMILY 
. O 
Adsorption O 
of O 
bovine O 
serum O 
albumin O 
( O 
BSA O 
) O 
, O 
γ-globulin O 
, O 
( B-FORMULA 
125 I-FORMULA 
) I-FORMULA 
I I-FORMULA 
-BSA O 
, O 
pepsin O 
, O 
and O 
chymotrypsin O 
on O 
neat O 
and O 
PEGylated O 
microspheres O 
is O 
determined O 
by O 
UV-VIS O 
spectroscopy O 
of O 
supernatants O 
and O 
eluates O 
or O 
by O 
measurement O 
of O 
radioactivity O 
in O 
an O 
ionization O 
chamber O 
. O 
Neat O 
and O 
PEGylated O 
microspheres O 
adsorb O 
0.8-70% O 
and O 
0.02-44% O 
of O 
protein O 
, O 
respectively O 
. O 

electronic O 
structure O 
of O 
individual O 
hybrid O 
particles O 
was O 
studied O 
by O 
nanoscale O 
near O 
- O 
edge O 
X-ray O 
absorption O 
spectromicroscopy O 
. O 
The O 
colloidal O 
particles O 
consist O 
of O 
a O 
solid O 
polystyrene B-SYSTEMATIC 
core O 
and O 
a O 
cross O 
- O 
linked O 
poly-N-(isopropylacrylamide) B-FAMILY 
shell O 
with O 
embedded O 
crystalline O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
TiO(2) B-FORMULA 
) O 
nanoparticles O 
( O 
d O 
= O 
6 O 
± O 
3 O 
nm O 
) O 
. O 
The O 
TiO(2) B-FORMULA 
particles O 
are O 
generated O 
in O 
the O 
carrier O 
network O 
by O 
a O 
sol O 
- O 
gel O 
process O 
at O 
room O 
temperature O 
. O 
The O 
hybrid O 
particles O 
were O 
imaged O 
with O 
photon O 
energy O 
steps O 
of O 
0.1 O 
eV O 
in O 
their O 
hydrated O 
environment O 
with O 
a O 
cryo O 
transmission O 
X-ray O 
microscope O 
( O 
TXM O 
) O 
at O 
the O 
Ti B-FORMULA 
L(2,3)-edge O 
. O 
By O 
analyzing O 
the O 
image O 
stacks O 
, O 
the O 
obtained O 
near O 
- O 
edge O 
X-ray O 
absorption O 
fine O 
structure O 
( O 
NEXAFS O 
) O 
spectra O 
of O 
our O 
individual O 
hybrid O 
particles O 
show O 
clearly O 
that O 
our O 
synthesis O 
generates O 
TiO(2) B-FORMULA 
in O 
the O 
anastase O 
phase O 
. O 
Additionally O 
, O 
our O 
spectromicroscopy O 
method O 
permits O 
the O 
determination O 
of O 
the O 
density O 
distribution O 
of O 
TiO(2) B-FORMULA 
in O 
single O 
carrier O 
particles O 
. O 
Therefore O 
, O 
NEXAFS O 
spectroscopy O 
combined O 
with O 
TXM O 
presents O 
a O 
unique O 
method O 
to O 
get O 
in O 
- O 
depth O 
insight O 
into O 
the O 
electronic O 
structure O 
of O 
hybrid O 
materials O 
. O 

explore O 
the O 
acceptor O 
regioselectivity O 
of O 
OleD O 
- O 
catalyzed O 
glucosylation O 
, O 
the O 
products O 
of O 
OleD O 
- O 
catalyzed O 
reactions O 
with O 
six O 
structurally O 
diverse O 
acceptors O 
flavones B-FAMILY 
- O 
( O 
daidzein B-TRIVIAL 
) O 
, O 
isoflavones B-FAMILY 
( O 
flavopiridol B-TRIVIAL 
) O 
, O 
stilbenes B-FAMILY 
( O 
resveratrol B-TRIVIAL 
) O 
, O 
indole B-FAMILY 
alkaloids I-FAMILY 
( O 
10-hydroxycamptothecin B-SYSTEMATIC 
) O 
, O 
and O 
steroids B-FAMILY 
( O 
2-methoxyestradiol B-SYSTEMATIC 
)-were O 
determined O 
. O 
This O 
study O 
highlights O 
the O 
first O 
synthesis O 
of O 
flavopiridol B-TRIVIAL 
and O 
2-methoxyestradiol B-FAMILY 
glucosides I-FAMILY 
and O 
confirms O 
the O 
ability O 
of O 
OleD O 
to O 
glucosylate B-TRIVIAL 
both O 
aromatic O 
and O 
aliphatic O 
nucleophiles O 
. O 
In O 
all O 
cases O 
, O 
molecular O 
dynamics O 
simulations O 
were O 
consistent O 
with O 
the O 
determined O 
product O 
distribution O 
and O 
suggest O 
the O 
potential O 
to O 
develop O 
a O 
virtual O 
screening O 
model O 
to O 
identify O 
additional O 
OleD O 
substrates O 
. O 

fibroin O 
cryogels O 
with O 
remarkable O 
properties O 
were O 
obtained O 
from O 
frozen O 
fibroin O 
solutions O 
( O 
4.2-12.6% O 
) O 
at O 
subzero O 
temperatures O 
between O 
-5 O 
and O 
-22 O 
°C O 
. O 
This O 
was O 
achieved O 
by O 
the O 
addition O 
of O 
ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
diglycidyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
EGDE B-ABBREVIATION 
) O 
into O 
the O 
cryogelation O 
system O 
. O 
EGDE B-ABBREVIATION 
triggers O 
the O 
conformational O 
transition O 
of O 
fibroin O 
from O 
random O 
coil O 
to O 
β-sheet O 
structure O 
and O 
hence O 
fibroin O 
gelation O 
. O 
One O 
of O 
the O 
unique O 
features O 
of O 
fibroin O 
cryogels O 
is O 
their O 
elasticity O 
that O 
allows O 
them O 
to O 
resist O 
complete O 
compression O 
without O 
any O 
crack O 
development O 
, O 
during O 
which O 
water O 
inside O 
the O 
cryogel O 
is O 
removed O 
. O 
The O 
compressed O 
cryogel O 
immediately O 
swells O 
during O 
unloading O 
to O 
recover O 
its O 
original O 
shape O 
. O 
The O 
scaffolds O 
obtained O 
by O 
freeze O 
- O 
drying O 
of O 
the O 
cryogels O 
consist O 
of O 
regular O 
, O 
interconnected O 
pores O 
of O 
diameters O 
ranging O 
from O 
50 O 
to O 
10 O 
μm O 
that O 
could O 
be O 
regulated O 
by O 
the O 
synthesis O 
parameters O 
. O 
The O 
mechanical O 
compressive O 
strength O 
and O 
the O 
modulus O 
of O 
the O 
scaffolds O 
increase O 
with O 
decreasing O 
pore O 
diameter O 
, O 
that O 
is O 
, O 
with O 
decreasing O 
gelation O 
temperature O 
or O 
, O 
with O 
increasing O 
fibroin O 
or O 
EGDE B-ABBREVIATION 
concentrations O 
in O 
the O 
feed O 
. O 
The O 
scaffolds O 
produced O 
at O 
12.6% O 
fibroin O 
exhibit O 
a O 
very O 
high O 
compressive O 
modulus O 
( O 
50 O 
MPa O 
) O 
making O 
them O 
good O 
candidates O 
as O 
bone O 
scaffold O 
materials O 
. O 

- O 
by O 
- O 
layer O 
( O 
LBL O 
) O 
assembly O 
is O 
an O 
attractive O 
platform O 
for O 
controlled O 
release O 
of O 
biologics O 
given O 
its O 
mild O 
fabrication O 
process O 
and O 
versatility O 
in O 
coating O 
substrates O 
of O 
any O 
shape O 
. O 
Proteins O 
can O 
be O 
incorporated O 
into O 
LBL O 
coatings O 
by O 
sequentially O 
depositing O 
oppositely O 
charged O 
polyelectrolytes O 
, O 
which O 
self O 
- O 
assemble O 
into O 
nanoscale O 
films O 
on O 
medical O 
devices O 
or O 
tissue O 
engineering O 
scaffolds O 
. O 
However O 
, O 
previously O 
reported O 
LBL O 
platforms O 
often O 
require O 
the O 
use O 
of O 
a O 
few O 
hundred O 
layers O 
to O 
avoid O 
burst O 
release O 
, O 
which O 
hinders O 
their O 
broad O 
translation O 
due O 
to O 
the O 
lengthy O 
fabrication O 
process O 
, O 
cost O 
, O 
and O 
batch O 
- O 
to O 
- O 
batch O 
variability O 
. O 
Here O 
we O 
report O 
a O 
biodegradable O 
LBL O 
platform O 
composed O 
of O 
only O 
10 O 
layers O 
with O 
tunable O 
protein O 
release O 
kinetics O 
, O 
which O 
is O 
an O 
order O 
of O 
magnitude O 
less O 
than O 
previously O 
reported O 
LBL O 
platforms O 
. O 
We O 
performed O 
a O 
combinatorial O 
study O 
to O 
examine O 
the O 
effects O 
of O 
polymer O 
chemistry O 
and O 
order O 
of O 
deposition O 
of O 
poly(β-amino) B-FAMILY 
esters I-FAMILY 
on O 
protein O 
release O 
kinetics O 
under O 
81 O 
LBL O 
assembly O 
conditions O 
. O 
Using O 
the O 
optimal O 
" O 
polyelectrolyte O 
couples O 
" O 
for O 
constructing O 
the O 
LBL O 
film O 
, O 
basic O 
fibroblast O 
growth O 
factor O 
( O 
bFGF O 
) O 
was O 
released O 
gradually O 
over O 
14 O 
days O 
with O 
retained O 
biological O 
activity O 
to O 
stimulate O 
cell O 
proliferation O 
. O 
The O 
method O 
reported O 
herein O 
is O 
applicable O 
for O 
coating O 
various O 
substrates O 
including O 
metals O 
, O 
polymers O 
, O 
and O 
ceramics O 
and O 
may O 
be O 
used O 
for O 
a O 
broad O 
range O 
of O 
biomedical O 
and O 
tissue O 
engineering O 
applications O 
. O 

silicon B-SYSTEMATIC 
dots O 
self O 
- O 
assembled O 
on O 
aluminum B-SYSTEMATIC 
nitride I-SYSTEMATIC 
/ O 
Si B-FORMULA 
( I-FORMULA 
111 I-FORMULA 
) I-FORMULA 
. O 

nanoscale O 
dots O 
are O 
synthesized O 
on O 
AlN B-FORMULA 
/ O 
Si(111) B-FORMULA 
by O 
molecular O 
beam O 
epitaxy O 
. O 
A O 
dot O 
density O 
of O 
2.2 O 
× O 
10(11) O 
cm(-2) O 
with O 
a O 
mean O 
radius O 
of O 
5.6 O 
± O 
2.8 O 
nm O 
is O 
obtained O 
in O 
Volmer-Weber O 
growth O 
mode O 
. O 
A O 
double O 
Si B-FORMULA 
coverage O 
leads O 
to O 
a O 
decrease O 
in O 
dot O 
density O 
and O 
increase O 
in O 
dot O 
size O 
. O 
The O 
dot O 
orientations O 
are O 
[ O 
11[overline]0]( O 
Si B-FORMULA 
) O 
( O 
or O 
[ O 
1[overline]10]( O 
Si B-FORMULA 
) O 
) O 
/ O 
/ O 
[ O 
112[overline]0]( O 
AlN B-FORMULA 
) O 
and O 
(111)(Si) B-FORMULA 
/ O 
/ O 
( O 
0001)( O 
AlN B-FORMULA 
) O 
, O 
which O 
are O 
similar O 
( O 
or O 
identical O 
) O 
to O 
the O 
orientation O 
of O 
AlN B-FORMULA 
relative O 
to O 
the O 
Si B-FORMULA 
substrate O 
. O 

of O 
posaconazole B-TRIVIAL 
. O 

: O 
The O 
increasing O 
number O 
of O 
invasive O 
fungal O 
infections O 
( O 
IFI O 
) O 
among O 
immunocompromised O 
hosts O 
is O 
a O 
significant O 
clinical O 
issue O 
. O 
Diagnosis O 
of O 
IFI O 
, O 
choosing O 
among O 
the O 
available O 
antifungal O 
drugs O 
, O 
and O 
the O 
high O 
morbidity O 
/ O 
mortality O 
associated O 
with O 
IFI O 
pose O 
clinical O 
challenges O 
for O 
healthcare O 
providers O 
. O 
Besides O 
efficacy O 
, O 
a O 
thorough O 
knowledge O 
of O 
the O 
pharmacokinetics O 
, O 
drug O 
- O 
drug O 
interactions O 
and O 
safety O 
profile O 
of O 
the O 
antifungal O 
drugs O 
is O 
critical O 
for O 
appropriate O 
drug O 
selection O 
. O 
Among O 
the O 
commonly O 
used O 
triazoles B-FAMILY 
, O 
the O 
recently O 
released O 
posaconazole B-TRIVIAL 
is O 
relatively O 
less O 
well O 
investigated O 
in O 
terms O 
of O 
its O 
safety O 
. O 
With O 
expanding O 
clinical O 
use O 
of O 
posaconazole B-TRIVIAL 
, O 
the O 
present O 
review O 
examines O 
the O 
safety O 
of O 
the O 
drug O 
and O 
its O 
propensity O 
for O 
drug O 
- O 
drug O 
interaction O 
. O 
AREAS O 
COVERED O 
: O 
This O 
paper O 
mainly O 
discusses O 
the O 
safety O 
profile O 
of O 
posaconazole B-TRIVIAL 
, O 
its O 
adverse O 
effects O 
and O 
drug O 
- O 
drug O 
interaction O 
. O 
EXPERT O 
OPINION O 
: O 
Posaconazole B-TRIVIAL 
is O 
generally O 
safe O 
and O 
well O 
tolerated O 
. O 
Lack O 
of O 
an O 
intravenous O 
formulation O 
and O 
unpredictable O 
bioavailability O 
of O 
the O 
suspension O 
form O 
are O 
significant O 
factors O 
limiting O 
the O 
widespread O 
use O 
of O 
posaconazole B-TRIVIAL 
. O 

transfer O 
and O 
adsorption O 
equilibrium O 
for O 
low O 
volatility O 
alkanes B-FAMILY 
in O 
BPL O 
activated O 
carbon B-SYSTEMATIC 
. O 

structure O 
of O 
a O 
molecule O 
and O 
its O 
concentration O 
can O 
strongly O 
influence O 
diffusional O 
properties O 
for O 
transport O 
in O 
nanoporous O 
materials O 
. O 
We O 
study O 
mass O 
transfer O 
of O 
alkanes B-FAMILY 
in O 
BPL O 
activated O 
carbon B-SYSTEMATIC 
using O 
the O 
concentration O 
- O 
swing O 
frequency O 
response O 
method O 
, O 
which O 
can O 
easily O 
discriminate O 
among O 
mass O 
transfer O 
mechanisms O 
. O 
We O 
measure O 
concentration O 
- O 
dependent O 
diffusion O 
rates O 
for O 
n-hexane B-SYSTEMATIC 
, O 
n-octane B-SYSTEMATIC 
, O 
n-decane B-SYSTEMATIC 
, O 
2,7-dimethyloctane B-SYSTEMATIC 
, O 
and O 
cyclodecane B-SYSTEMATIC 
, O 
which O 
have O 
different O 
carbon B-SYSTEMATIC 
numbers O 
and O 
geometries O 
: O 
straight O 
chain O 
, O 
branched O 
chain O 
, O 
and O 
cyclic O 
. O 
Micropore O 
diffusion O 
is O 
determined O 
to O 
be O 
the O 
controlling O 
mass O 
transfer O 
resistance O 
except O 
at O 
low O 
relative O 
saturation O 
for O 
n-decane B-SYSTEMATIC 
, O 
where O 
an O 
external O 
mass O 
transfer O 
resistance O 
also O 
becomes O 
important O 
, O 
showing O 
that O 
the O 
controlling O 
mass O 
transfer O 
mechanism O 
can O 
change O 
with O 
system O 
concentration O 
. O 
Micropore O 
diffusion O 
coefficients O 
are O 
found O 
to O 
be O 
strongly O 
concentration O 
dependent O 
. O 
Adsorption O 
isotherm O 
slopes O 
obtained O 
from O 
measured O 
isotherms O 
, O 
the O 
concentration O 
- O 
swing O 
frequency O 
response O 
method O 
, O 
and O 
a O 
predictive O 
method O 
show O 
reasonably O 
good O 
agreement O 
. O 

, O 
synthesis O 
, O 
and O 
structure O 
- O 
activity O 
relationship O 
studies O 
of O 
tryptanthrins B-FAMILY 
as O 
antitubercular O 
agents O 
. O 

natural O 
product O 
tryptanthrin B-TRIVIAL 
( O 
1a O 
) O 
represents O 
a O 
potential O 
lead O 
for O 
new O 
tuberculosis O 
( O 
TB O 
) O 
drugs O 
since O 
tryptanthrin B-TRIVIAL 
and O 
its O 
synthetic O 
analogues O 
possess O 
potent O 
in O 
vitro O 
activity O 
against O 
Mycobacterium O 
tuberculosis O 
( O 
Mtb O 
) O 
. O 
However O 
, O 
in O 
spite O 
of O 
their O 
in O 
vitro O 
activity O 
, O 
none O 
of O 
these O 
agents O 
have O 
been O 
shown O 
to O 
be O 
efficacious O 
in O 
vivo O 
against O 
animal O 
models O 
of O 
TB O 
. O 
Described O 
herein O 
are O 
syntheses O 
of O 
new O 
tryptanthrin B-TRIVIAL 
analogues O 
together O 
with O 
a O 
systematic O 
investigation O 
of O 
their O 
in O 
vitro O 
antitubercular O 
activity O 
and O 
ADME O 
properties O 
followed O 
by O 
pharmacokinetic O 
characterization O 
in O 
rodents O 
for O 
the O 
most O 
promising O 
compounds O 
. O 
Those O 
with O 
the O 
best O 
potency O 
and O 
oral O 
bioavailability O 
were O 
progressed O 
to O 
evaluations O 
of O 
efficacy O 
against O 
acute O 
murine O 
TB O 
. O 
The O 
work O 
aimed O 
to O 
prove O 
the O 
concept O 
that O 
this O 
compound O 
class O 
can O 
limit O 
growth O 
of O 
Mtb O 
during O 
infection O 
as O 
well O 
as O 
to O 
establish O 
the O 
SAR O 
for O 
in O 
vitro O 
activity O 
against O 
Mtb O 
and O 
the O 
range O 
of O 
in O 
vitro O 
ADME O 
parameters O 
for O 
this O 
class O 
of O 
natural O 
products O 
. O 
Novel O 
C-11-deoxy O 
( O 
5b O 
) O 
and O 
A-ring O 
- O 
saturated O 
( O 
6 O 
) O 
tryptanthrin B-TRIVIAL 
analogues O 
were O 
discovered O 
that O 
maintained O 
activity O 
against O 
Mtb O 
and O 
showed O 
improved O 
solubility O 
compared O 
to O 
tryptanthrin B-TRIVIAL 
as O 
well O 
as O 
evidence O 
of O 
oral O 
bioavailability O 
in O 
rodents O 
. O 
However O 
, O 
neither O 
5b O 
nor O 
6 O 
demonstrated O 
efficacy O 
against O 
acute O 
murine O 
TB O 
following O 
administration O 
at O 
doses O 
up O 
to O 
400 O 
mg O 
/ O 
kg O 
daily O 
for O 
4 O 
weeks O 
. O 
Although O 
5b O 
and O 
6 O 
failed O 
to O 
inhibit O 
replication O 
or O 
kill O 
Mtb O 
in O 
vivo O 
, O 
they O 
illuminate O 
a O 
path O 
to O 
new O 
structural O 
variations O 
of O 
the O 
tryptanthrin B-TRIVIAL 
scaffold O 
that O 
may O 
maximize O 
the O 
potential O 
of O 
this O 
class O 
of O 
compounds O 
against O 
TB O 
. O 

nickel B-SYSTEMATIC 
bis(dithiolene) I-SYSTEMATIC 
complex O 
nanosheet O 
. O 

π-conjugated O 
nanosheet O 
comprising O 
planar O 
nickel B-SYSTEMATIC 
bis(dithiolene) I-SYSTEMATIC 
complexes O 
was O 
synthesized O 
by O 
a O 
bottom O 
- O 
up O 
method O 
. O 
A O 
liquid O 
- O 
liquid O 
interfacial O 
reaction O 
using O 
benzenehexathiol B-SYSTEMATIC 
in O 
the O 
organic O 
phase O 
and O 
nickel B-SYSTEMATIC 
(II) I-SYSTEMATIC 
acetate I-SYSTEMATIC 
in O 
the O 
aqueous O 
phase O 
produced O 
a O 
semiconducting O 
bulk O 
material O 
with O 
a O 
thickness O 
of O 
several O 
micrometers O 
. O 
Powder O 
X-ray O 
diffraction O 
analysis O 
revealed O 
that O 
the O 
crystalline O 
portion O 
of O 
the O 
bulk O 
material O 
comprised O 
a O 
staggered O 
stack O 
of O 
nanosheets O 
. O 
A O 
single O 
- O 
layer O 
nanosheet O 
was O 
successfully O 
realized O 
using O 
a O 
gas-liquid O 
interfacial O 
reaction O 
. O 
Atomic O 
force O 
microscopy O 
and O 
scanning O 
tunneling O 
microscopy O 
confirmed O 
that O 
the O 
π-conjugated O 
nanosheet O 
was O 
single O 
- O 
layered O 
. O 
Modulation O 
of O 
the O 
oxidation O 
state O 
of O 
the O 
nanosheet O 
was O 
possible O 
using O 
chemical O 
redox O 
reactions O 
. O 

vitro O 
and O 
mechanistic O 
studies O 
of O 
an O 
antiamyloidogenic O 
self O 
- O 
assembled O 
cyclic B-TRIVIAL 
D,L-α- I-TRIVIAL 
peptide I-TRIVIAL 
architecture O 
. O 

of O 
the O 
Aβ O 
protein O 
and O 
its O 
subsequent O 
aggregation O 
into O 
toxic O 
oligomers O 
are O 
related O 
to O 
Alzheimer's O 
disease O 
. O 
Although O 
peptides O 
of O 
various O 
sequences O 
can O 
self O 
- O 
assemble O 
into O 
amyloid O 
structures O 
, O 
these O 
structures O 
share O 
common O 
three O 
- O 
dimensional O 
features O 
that O 
may O 
promote O 
their O 
cross O 
- O 
reaction O 
. O 
Given O 
the O 
significant O 
similarities O 
between O 
amyloids O 
and O 
the O 
architecture O 
of O 
self O 
- O 
assembled O 
cyclic B-TRIVIAL 
D,L-α- I-TRIVIAL 
peptide I-TRIVIAL 
, O 
we O 
hypothesized O 
that O 
the O 
latter O 
may O 
bind O 
and O 
stabilize O 
a O 
nontoxic O 
form O 
of O 
Aβ O 
, O 
thereby O 
preventing O 
its O 
aggregation O 
into O 
toxic O 
forms O 
. O 
By O 
screening O 
a O 
focused O 
library O 
of O 
six O 
- O 
residue O 
cyclic B-FAMILY 
D,L-α- I-FAMILY 
peptides I-FAMILY 
and O 
optimizing O 
the O 
activity O 
of O 
a O 
lead O 
peptide O 
, O 
we O 
found O 
one O 
cyclic B-TRIVIAL 
D,L-α- I-TRIVIAL 
peptide I-TRIVIAL 
( O 
CP-2 B-ABBREVIATION 
) O 
that O 
interacts O 
strongly O 
with O 
Aβ O 
and O 
inhibits O 
its O 
aggregation O 
. O 
In O 
transmission O 
electron O 
microscopy O 
, O 
optimized O 
thioflavin B-TRIVIAL 
T I-TRIVIAL 
and O 
cell O 
survival O 
assays O 
, O 
CP-2 B-ABBREVIATION 
inhibits O 
the O 
formation O 
of O 
Aβ O 
aggregates O 
, O 
entirely O 
disassembles O 
preformed O 
aggregated O 
and O 
fibrillar O 
Aβ O 
, O 
and O 
protects O 
rat O 
pheochromocytoma O 
PC12 O 
cells O 
from O 
Aβ O 
toxicity O 
, O 
without O 
inducing O 
any O 
toxicity O 
by O 
itself O 
. O 
Using O 
various O 
immunoassays O 
, O 
circular O 
dichroism O 
spectroscopy O 
, O 
photoinduced O 
cross O 
- O 
linking O 
of O 
unmodified O 
proteins O 
( O 
PICUP O 
) O 
combined O 
with O 
SDS B-ABBREVIATION 
/ O 
PAGE O 
, O 
and O 
NMR O 
, O 
we O 
probed O 
the O 
mechanisms O 
underlying O 
CP-2 B-ABBREVIATION 
' O 
s O 
antiamyloidogenic O 
activity O 
. O 
NMR O 
spectroscopy O 
indicates O 
that O 
CP-2 B-ABBREVIATION 
interacts O 
with O 
Aβ O 
through O 
its O 
self O 
- O 
assembled O 
conformation O 
and O 
induces O 
weak O 
secondary O 
structure O 
in O 
Aβ O 
. O 
Upon O 
coincubation O 
, O 
CP-2 B-ABBREVIATION 
changes O 
the O 
aggregation O 
pathway O 
of O 
Aβ O 
and O 
alters O 
its O 
oligomer O 
distribution O 
by O 
stabilizing O 
small O 
oligomers O 
( O 
1-3 O 
mers O 
) O 
. O 
Our O 
results O 
support O 
studies O 
suggesting O 
that O 
toxic O 
early O 
oligomeric O 
states O 
of O 
Aβ O 
may O 
be O 
composed O 
of O 
antiparallel O 
β- O 
peptide O 
structures O 
and O 
that O 
the O 
interaction O 
of O 
Aβ O 
with O 
CP-2 B-ABBREVIATION 
promotes O 
formation O 
of O 
more O 
benign O 
parallel O 
β-structures O 
. O 
Further O 
studies O 
will O 
show O 
whether O 
these O 
kinds O 
of O 
abiotic O 
cyclic B-FAMILY 
D,L-α- I-FAMILY 
peptides I-FAMILY 
are O 
also O 
beneficial O 
as O 
an O 
intervention O 
in O 
related O 
in O 
vivo O 
models O 
. O 

effects O 
of O 
a O 
special O 
carbohydrate B-FAMILY 
-whey O 
protein O 
cake O 
after O 
exhaustive O 
cycling O 
in O 
humans O 
. O 

exercise O 
induces O 
increased O 
levels O 
of O 
pro O 
- O 
inflammatory O 
and O 
anti-inflammatory O 
cytokines O 
. O 
Thus O 
, O 
the O 
purpose O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
effects O 
of O 
a O 
special O 
cake O 
( O 
consisting O 
of O 
carbohydrate B-FAMILY 
to O 
whey O 
protein O 
3.5 O 
: O 
1 O 
) O 
vs O 
. O 
an O 
isocaloric O 
carbohydrate B-FAMILY 
cake O 
on O 
inflammatory O 
markers O 
after O 
exhaustive O 
cycling O 
in O 
humans O 
. O 
Nine O 
subjects O 
received O 
either O 
the O 
experimental O 
or O 
placebo O 
cake O 
in O 
a O 
counterbalanced O 
fashion O 
using O 
a O 
crossover O 
, O 
double O 
- O 
blind O 
, O 
repeated O 
- O 
measures O 
design O 
. O 
They O 
performed O 
one O 
trial O 
involving O 
a O 
2h O 
exercise O 
on O 
a O 
cycle O 
ergometer O 
at O 
60-65% O 
VO2max O 
followed O 
by O 
a O 
4h O 
recovery O 
and O 
then O 
a O 
second O 
trial O 
involving O 
an O 
1h O 
exercise O 
at O 
60-65% O 
VO2max O 
which O 
was O 
increased O 
at O 
95% O 
VO2max O 
. O 
Blood O 
samples O 
were O 
collected O 
pre O 
- O 
exercise O 
, O 
30min O 
and O 
4h O 
post O 
- O 
exercise O 
, O 
post O 
- O 
time O 
Trial O 
and O 
48h O 
post O 
- O 
time O 
Trial O 
. O 
Cakes O 
were O 
consumed O 
immediately O 
post O 
- O 
exercise O 
and O 
every O 
1h O 
for O 
the O 
next O 
3h O 
. O 
The O 
results O 
showed O 
that O 
consumption O 
of O 
the O 
experimental O 
cake O 
reduced O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
, O 
4h O 
post O 
- O 
exercise O 
, O 
the O 
pro O 
- O 
inflammatory O 
protein O 
levels O 
IL-6 O 
and O 
CRP O 
compared O 
to O 
the O 
control O 
group O 
by O 
50% O 
and O 
46% O 
respectively O 
. O 
Moreover O 
, O 
in O 
the O 
experimental O 
cake O 
group O 
, O 
the O 
level O 
of O 
the O 
anti-inflammatory O 
cytokine O 
IL-10 O 
was O 
higher O 
by O 
118% O 
, O 
4h O 
post O 
- O 
exercise O 
, O 
compared O 
to O 
the O 
control O 
group O 
but O 
not O 
statistically O 
significant O 
. O 

absorption O 
spectroscopy O 
and O 
energy O 
storage O 
of O 
Ni B-FORMULA 
-doped O 
cobalt B-SYSTEMATIC 
nitride I-SYSTEMATIC 
, O 
(Ni(0.33)Co(0.67))N B-FORMULA 
, O 
prepared O 
by O 
a O 
simple O 
synthesis O 
route O 
. O 

nitride I-FAMILY 
(Ni(0.33)Co(0.67))N B-FORMULA 
nanoparticles O 
are O 
prepared O 
by O 
nitridation O 
using O 
NiCo(2)O(4) B-FORMULA 
as O 
a O 
precursor O 
material O 
by O 
heating O 
at O 
335 O 
°C O 
for O 
2 O 
h O 
in O 
flowing O 
NH(3) B-FORMULA 
+ O 
N(2) B-FORMULA 
gas O 
and O 
characterized O 
by O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
, O 
field O 
emission O 
- O 
scanning O 
electron O 
microscopy O 
( O 
FE-SEM O 
) O 
, O 
high O 
resolution O 
- O 
transmission O 
electron O 
microscopy O 
( O 
HR-TEM O 
) O 
, O 
along O 
with O 
selective O 
area O 
electron O 
diffraction O 
( O 
SAED O 
) O 
and O 
X-ray O 
absorption O 
spectroscopy O 
( O 
XAS O 
) O 
techniques O 
. O 
The O 
X-ray O 
absorption O 
near O 
edge O 
structure O 
( O 
XANES O 
) O 
at O 
the O 
Co B-FORMULA 
K-edge O 
showed O 
that O 
the O 
oxidation O 
state O 
of O 
cobalt B-SYSTEMATIC 
is O 
close O 
to O 
3+ O 
. O 
The O 
(Ni(0.33)Co(0.67))N B-FORMULA 
showed O 
a O 
shift O 
in O 
edge O 
energy O 
towards O 
lower O 
values O 
due O 
to O 
Ni B-FORMULA 
-doping O 
to O 
cobalt O 
site O 
. O 
The O 
Li B-FORMULA 
-storage O 
behaviour O 
of O 
(Ni(0.33)Co(0.67))N B-FORMULA 
nanoparticles O 
was O 
evaluated O 
by O 
galvanostatic O 
cycling O 
and O 
cyclic O 
voltammetry O 
in O 
the O 
cells O 
with O 
Li B-FORMULA 
-metal O 
as O 
counter O 
electrode O 
in O 
the O 
voltage O 
range O 
of O 
0.005-3.0 O 
V O 
at O 
ambient O 
temperature O 
. O 
When O 
cycled O 
at O 
250 O 
mA O 
g(-1) O 
, O 
the O 
first O 
- O 
cycle O 
reversible O 
capacity O 
of O 
700 O 
( O 
±5 O 
) O 
mA O 
h O 
g(-1) O 
( O 
~1.9 O 
moles O 
of O 
Li B-FORMULA 
) O 
is O 
obtained O 
. O 
It O 
showed O 
an O 
initial O 
decrease O 
in O 
capacity O 
until O 
the O 
10(th) O 
cycle O 
and O 
a O 
stable O 
capacity O 
of O 
400 O 
( O 
±5 O 
) O 
mA O 
h O 
g(-1) O 
( O 
~1.09 O 
moles O 
of O 
Li B-FORMULA 
) O 
is O 
observed O 
at O 
the O 
end O 
of O 
the O 
50(th) O 
cycle O 
. O 
Excellent O 
rate O 
capability O 
is O 
also O 
shown O 
when O 
cycling O 
at O 
500 O 
mA O 
g(-1) O 
( O 
up O 
to O 
50 O 
cycles O 
) O 
. O 
The O 
materials O 
showed O 
excellent O 
Li B-FORMULA 
-ion O 
insertion O 
/ O 
extraction O 
, O 
with O 
the O 
coulombic O 
efficiency O 
reaching O 
almost O 
99% O 
in O 
the O 
range O 
of O 
10-50 O 
cycles O 
. O 
The O 
average O 
charge O 
and O 
discharge O 
potentials O 
are O 
~2.03 O 
and O 
~1.0 O 
V O 
, O 
respectively O 
for O 
the O 
decomposition O 
/ O 
formation O 
of O 
Li(3)N B-FORMULA 
as O 
determined O 
by O 
electroanalytical O 
techniques O 
. O 

- O 
assembly O 
of O 
mesoporous O 
CuO B-FORMULA 
nanosheets-CNT O 
3D-network O 
composites O 
for O 
lithium B-SYSTEMATIC 
-ion O 
batteries O 
. O 

facile O 
, O 
flexible O 
and O 
large O 
- O 
scale O 
technique O 
was O 
proposed O 
to O 
prepare O 
a O 
CuO B-FORMULA 
-CNT O 
3D-network O 
composite O 
with O 
the O 
aid O 
of O 
electrostatic O 
interactions O 
in O 
aqueous O 
solution O 
. O 
The O 
composite O 
greatly O 
improves O 
the O 
electrochemical O 
performance O 
. O 
At O 
a O 
rate O 
of O 
0.1 O 
C O 
, O 
the O 
cycling O 
discharge O 
capacity O 
of O 
the O 
optimal O 
composite O 
is O 
more O 
than O 
2.3 O 
times O 
of O 
that O 
of O 
unmodified O 
mesoporous O 
CuO B-FORMULA 
nanosheets O 
as O 
the O 
active O 
material O 
in O 
an O 
anode O 
after O 
40 O 
cycles O 
. O 

structure O 
of O 
solid O 
- O 
ionic O 
liquid O 
( O 
IL O 
) O 
interfaces O 
has O 
been O 
characterised O 
with O 
unprecedented O 
clarity O 
by O 
employing O 
a O 
range O 
of O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
imaging O 
techniques O 
and O 
tip O 
pressures O 
appropriate O 
for O 
the O 
system O 
under O 
study O 
. O 
Soft O 
contact O 
and O 
amplitude-modulation O 
( O 
AM O 
) O 
AFM O 
imaging O 
have O 
been O 
used O 
to O 
elucidate O 
the O 
lateral O 
structure O 
of O 
ILs O 
adsorbed O 
onto O 
mica O 
, O 
and O 
in O 
the O 
near O 
surface O 
ion O 
layers O 
. O 
Data O 
is O 
presented O 
for O 
ethylammonium B-SYSTEMATIC 
nitrate I-SYSTEMATIC 
( O 
EAN B-ABBREVIATION 
) O 
and O 
1-ethyl-3-methylimidazolium B-SYSTEMATIC 
bis(trifluoro-methylsulfonyl)imide I-SYSTEMATIC 
( O 
EMIm B-ABBREVIATION 
TFSI I-ABBREVIATION 
) O 
. O 
Whereas O 
EAN B-ABBREVIATION 
is O 
a O 
protic O 
IL O 
that O 
forms O 
a O 
nanostructured O 
sponge O 
phase O 
in O 
the O 
bulk O 
, O 
EMIm B-ABBREVIATION 
TFSI I-ABBREVIATION 
is O 
aprotic O 
and O 
has O 
weak O 
( O 
or O 
absent O 
) O 
bulk O 
association O 
structure O 
. O 
Comparison O 
of O 
results O 
obtained O 
for O 
the O 
two O 
liquids O 
elucidates O 
how O 
the O 
strength O 
of O 
bulk O 
liquid O 
morphology O 
effects O 
lateral O 
organisation O 
at O 
the O 
surface O 
, O 
and O 
any O 
effect O 
of O 
IL O 
class O 
, O 
i.e O 
. O 
protic O 
versus O 
aprotic O 
. O 
Imaging O 
reveals O 
EAN B-ABBREVIATION 
self O 
assembles O 
at O 
the O 
solid O 
surface O 
in O 
a O 
worm O 
- O 
like O 
morphology O 
, O 
whereas O 
EMIm B-ABBREVIATION 
cations O 
adsorb O 
in O 
a O 
more O 
isolated O 
fashion O 
, O 
but O 
still O 
in O 
rows O 
templated O 
by O 
the O 
mica O 
surface O 
. O 
To O 
the O 
authors O 
' O 
knowledge O 
, O 
the O 
wormlike O 
structures O 
present O 
at O 
the O 
EAN B-ABBREVIATION 
-mica O 
interface O 
are O 
the O 
smallest O 
self O 
- O 
assembled O 
aggregates O 
ever O 
imaged O 
on O 
a O 
solid O 
surface O 
. O 

the O 
last O 
15 O 
years O 
, O 
some O 
16 O 
open O 
and O 
controlled O 
clinical O 
trials O 
for O 
potential O 
treatments O 
of O 
mitochondrial O 
diseases O 
have O 
been O 
reported O 
or O 
are O 
in O 
progress O 
, O 
and O 
are O 
summarized O 
and O 
reviewed O 
herein O 
. O 
These O 
include O 
trials O 
of O 
administering O 
dichloroacetate B-SYSTEMATIC 
( O 
an O 
activator O 
of O 
pyruvate B-TRIVIAL 
dehydrogenase O 
complex O 
) O 
, O 
arginine B-TRIVIAL 
or O 
citrulline B-TRIVIAL 
( O 
precursors O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
) O 
, O 
coenzyme B-TRIVIAL 
Q10 I-TRIVIAL 
( O 
CoQ10 B-ABBREVIATION 
; O 
part O 
of O 
the O 
electron O 
transport O 
chain O 
and O 
an O 
antioxidant O 
) O 
, O 
idebenone B-TRIVIAL 
( O 
a O 
synthetic O 
analogue O 
of O 
CoQ10 B-ABBREVIATION 
) O 
, O 
EPI-743 B-IDENTIFIER 
( O 
a O 
novel O 
oral O 
potent O 
2-electron O 
redox O 
cycling O 
agent O 
) O 
, O 
creatine B-TRIVIAL 
( O 
a O 
precursor O 
of O 
phosphocreatine B-SYSTEMATIC 
) O 
, O 
combined O 
administration O 
( O 
of O 
creatine B-TRIVIAL 
, O 
α-lipoate B-TRIVIAL 
, O 
and O 
CoQ10 B-ABBREVIATION 
) O 
, O 
and O 
exercise O 
training O 
( O 
to O 
increase O 
muscle O 
mitochondria O 
) O 
. O 
These O 
trials O 
have O 
included O 
patients O 
with O 
various O 
mitochondrial O 
disorders O 
, O 
a O 
selected O 
subcategory O 
of O 
mitochondrial O 
disorders O 
, O 
or O 
specific O 
mitochondrial O 
disorders O 
( O 
Leber O 
hereditary O 
optic O 
neuropathy O 
or O 
mitochondrial O 
encephalopathy O 
, O 
lactic O 
acidosis O 
, O 
and O 
stroke O 
- O 
like O 
episodes O 
) O 
. O 
The O 
trial O 
designs O 
have O 
varied O 
from O 
open O 
- O 
label O 
/ O 
uncontrolled O 
, O 
open O 
- O 
label O 
/ O 
controlled O 
, O 
or O 
double O 
- O 
blind O 
/ O 
placebo O 
- O 
controlled O 
/ O 
crossover O 
. O 
Primary O 
outcomes O 
have O 
ranged O 
from O 
single O 
, O 
clinically O 
- O 
relevant O 
scores O 
to O 
multiple O 
measures O 
. O 
Eight O 
of O 
these O 
trials O 
have O 
been O 
well O 
- O 
controlled O 
, O 
completed O 
trials O 
. O 
Of O 
these O 
only O 
1 O 
( O 
treatment O 
with O 
creatine O 
) O 
showed O 
a O 
significant O 
change O 
in O 
primary O 
outcomes O 
, O 
but O 
this O 
was O 
not O 
reproduced O 
in O 
2 O 
subsequent O 
trials O 
with O 
creatine B-TRIVIAL 
with O 
different O 
patients O 
. O 
One O 
trial O 
( O 
idebenone B-TRIVIAL 
treatment O 
of O 
Leber O 
hereditary O 
optic O 
neuropathy O 
) O 
did O 
not O 
show O 
significant O 
improvement O 
in O 
the O 
primary O 
outcome O 
, O 
but O 
there O 
was O 
significant O 
improvement O 
in O 
a O 
subgroup O 
of O 
patients O 
. O 
Despite O 
the O 
paucity O 
of O 
benefits O 
found O 
so O 
far O 
, O 
well O 
- O 
controlled O 
clinical O 
trials O 
are O 
essential O 
building O 
blocks O 
in O 
the O 
continuing O 
search O 
for O 
more O 
effective O 
treatment O 
of O 
mitochondrial O 
disease O 
, O 
and O 
current O 
trials O 
based O 
on O 
information O 
gained O 
from O 
these O 
prior O 
experiences O 
are O 
in O 
progress O 
. O 
Because O 
of O 
difficulties O 
in O 
recruiting O 
sufficient O 
mitochondrial O 
disease O 
patients O 
and O 
the O 
relatively O 
large O 
expense O 
of O 
conducting O 
such O 
trials O 
, O 
advantageous O 
strategies O 
include O 
crossover O 
designs O 
( O 
where O 
possible O 
) O 
, O 
multicenter O 
collaboration O 
, O 
and O 
the O 
selection O 
of O 
very O 
few O 
, O 
clinically O 
relevant O 
, O 
primary O 
outcomes O 
. O 

syndrome O 
( O 
BTHS O 
) O 
is O 
an O 
X O 
- O 
linked O 
mitochondrial O 
defect O 
characterised O 
by O 
dilated O 
cardiomyopathy O 
, O 
neutropaenia O 
and O 
3-methylglutaconic O 
aciduria O 
( O 
3-MGCA O 
) O 
. O 
We O 
report O 
on O 
two O 
affected O 
brothers O 
with O 
c.646G O 
> O 
A O 
( O 
p.G216R O 
) O 
TAZ O 
gene O 
mutations O 
. O 
The O 
pathogenicity O 
of O 
the O 
mutation O 
, O 
as O 
indicated O 
by O 
the O 
structure O 
- O 
based O 
functional O 
analyses O 
, O 
was O 
further O 
confirmed O 
by O 
abnormal O 
monolysocardiolipin B-TRIVIAL 
/ O 
cardiolipin B-TRIVIAL 
ratio O 
in O 
dry O 
blood O 
spots O 
of O 
the O 
patients O 
as O 
well O 
as O 
the O 
occurrence O 
of O 
this O 
mutation O 
in O 
another O 
reported O 
BTHS O 
proband O 
. O 
In O 
both O 
brothers O 
, O 
2D-echocardiography O 
revealed O 
some O 
features O 
of O 
left O 
ventricular O 
noncompaction O 
( O 
LVNC O 
) O 
despite O 
marked O 
differences O 
in O 
the O 
course O 
of O 
the O 
disease O 
; O 
the O 
eldest O 
child O 
presented O 
with O 
isolated O 
cardiomyopathy O 
from O 
late O 
infancy O 
, O 
whereas O 
the O 
youngest O 
showed O 
severe O 
lactic O 
acidosis O 
without O 
3-MGCA O 
during O 
the O 
neonatal O 
period O 
. O 
An O 
examination O 
of O 
the O 
patients O 
' O 
fibroblast O 
cultures O 
revealed O 
that O 
extremely O 
low O 
mitochondrial O 
membrane O 
potentials O 
( O 
mtΔΨ O 
about O 
50 O 
% O 
of O 
the O 
control O 
value O 
) O 
dominated O 
other O 
unspecific O 
mitochondrial O 
changes O 
detected O 
( O 
respiratory O 
chain O 
dysfunction O 
, O 
abnormal O 
ROS O 
production O 
and O 
depressed O 
antioxidant O 
defense O 
) O 
. O 
1 O 
) O 
Our O 
studies O 
confirm O 
generalised O 
mitochondrial O 
dysfunction O 
in O 
the O 
skeletal O 
muscle O 
and O 
the O 
fibroblasts O 
of O 
BTHS O 
patients O 
, O 
especially O 
a O 
severe O 
impairment O 
in O 
the O 
mtΔΨ O 
and O 
the O 
inhibition O 
of O 
complex O 
V O 
activity O 
. O 
It O 
can O 
be O 
hypothesised O 
that O 
impaired O 
mtΔΨ O 
and O 
mitochondrial O 
ATP B-ABBREVIATION 
synthase O 
activity O 
may O 
contribute O 
to O 
episodes O 
of O 
cardiac O 
arrhythmia O 
that O 
occurred O 
unexpectedly O 
in O 
BTHS O 
patients O 
. O 
2 O 
) O 
Severe O 
lactic O 
acidosis O 
without O 
3-methylglutaconic O 
aciduria O 
in O 
male O 
neonates O 
as O 
well O 
as O 
an O 
asymptomatic O 
mild O 
left O 
ventricular O 
noncompaction O 
may O 
characterise O 
the O 
ranges O 
of O 
natural O 
history O 
of O 
Barth O 
syndrome O 
. O 

solution O 
synthesis O 
of O 
Ag B-FORMULA 
@ O 
Pt B-FORMULA 
core O 
- O 
shell O 
nanoparticles O 
with O 
dendritic O 
Pt B-FORMULA 
shells O 
. O 

@ O 
Pt B-FORMULA 
nanoparticles O 
with O 
various O 
dendritic O 
Pt B-FORMULA 
shells O 
were O 
successfully O 
synthesized O 
by O 
using O 
nonionic O 
surfactants O 
at O 
room O 
temperature O 
. O 
Our O 
recent O 
study O 
demonstrated O 
that O 
the O 
addition O 
of O 
nonionic O 
surfactant O 
plays O 
an O 
important O 
key O 
role O 
in O 
the O 
synthesis O 
of O 
dendritic O 
Pt B-FORMULA 
nanostructures O 
( O 
J O 
. O 
Am O 
. O 
Chem O 
. O 
Soc O 
. O 
, O 
2010 O 
, O 
132 O 
, O 
13636 O 
) O 
. O 
Here O 
we O 
extend O 
this O 
synthetic O 
concept O 
to O 
prepare O 
various O 
Ag B-FORMULA 
@ O 
Pt B-FORMULA 
nanoarchitectures O 
. O 
The O 
different O 
nanostructured O 
Pt B-FORMULA 
shells O 
on O 
the O 
Ag B-FORMULA 
core O 
were O 
confirmed O 
by O 
ultraviolet O 
- O 
visible O 
absorption O 
spectroscopy O 
and O 
transmission O 
electron O 
microscopy O 
. O 
As O 
a O 
preliminary O 
electrochemical O 
application O 
, O 
the O 
obtained O 
Ag B-FORMULA 
@ O 
Pt B-FORMULA 
nanostructures O 
were O 
applied O 
in O 
the O 
methanol B-SYSTEMATIC 
oxidation O 
reaction O 
( O 
MOR O 
) O 
in O 
0.5 O 
M O 
H(2)SO(4) B-FORMULA 
solution O 
containing O 
0.5 O 
M O 
methanol B-SYSTEMATIC 
. O 
The O 
Ag B-FORMULA 
@ O 
Pt B-FORMULA 
nanoparticles O 
with O 
thin O 
dendritic O 
Pt B-FORMULA 
shells O 
show O 
superior O 
CO B-FORMULA 
-tolerance O 
performance O 
with O 
a O 
I(f) O 
/ O 
I(b) O 
value O 
reaching O 
3.71 O 
. O 
Our O 
Ag B-FORMULA 
@ O 
Pt B-FORMULA 
nanostructures O 
with O 
good O 
CO B-FORMULA 
tolerant O 
activity O 
will O 
be O 
prominent O 
catalysts O 
for O 
MOR O 
. O 

mechanistic O 
study O 
of O 
the O 
electrochemical O 
oxygen B-SYSTEMATIC 
reduction O 
on O 
the O 
model O 
semiconductor O 
n- O 
Ge B-FORMULA 
( O 
100 O 
) O 
by O 
ATR-IR O 
and O 
DFT O 
. O 

electrochemical O 
oxygen B-SYSTEMATIC 
reduction O 
reaction O 
( O 
ORR O 
) O 
on O 
a O 
n- O 
Ge B-FORMULA 
( O 
100 O 
) O 
surface O 
in O 
0.1 O 
M O 
HClO4 B-FORMULA 
was O 
investigated O 
in O 
situ O 
and O 
operando O 
using O 
a O 
combination O 
of O 
attenuated O 
total O 
reflection O 
infrared O 
( O 
ATR-IR O 
) O 
spectroscopy O 
and O 
density O 
functional O 
( O 
DFT O 
) O 
calculations O 
. O 
The O 
vibrational O 
modes O 
of O 
the O 
detected O 
intermediates O 
were O 
assigned O 
based O 
on O 
DFT O 
calculations O 
of O 
solvated O 
model O 
clusters O 
such O 
as O 
Ge B-FORMULA 
-bound O 
superoxides B-FAMILY 
and O 
peroxides B-FAMILY 
. O 
ATR-IR O 
shows O 
the O 
Ge B-FORMULA 
-bound O 
superoxide B-TRIVIAL 
with O 
a O 
transition O 
dipole O 
moment O 
oriented O 
at O 
( O 
28 O 
± O 
10)° O 
with O 
respect O 
to O 
the O 
surface O 
normal O 
. O 
At O 
slightly O 
negative O 
potentials O 
, O 
the O 
surface O 
- O 
bound O 
peroxide B-SYSTEMATIC 
is O 
identified O 
by O 
an O 
OOH B-FORMULA 
bending O 
mode O 
as O 
a O 
further O 
intermediate O 
, O 
oriented O 
at O 
a O 
similar O 
angle O 
. O 
At O 
strongly O 
negative O 
potentials O 
, O 
a O 
surface O 
- O 
bound O 
perchlorate O 
is O 
found O 
. O 
The O 
findings O 
indicate O 
a O 
multistep O 
mechanism O 
of O 
the O 
ORR O 
. O 
The O 
reaction O 
is O 
furthermore O 
coupled O 
with O 
the O 
hydrogen B-SYSTEMATIC 
evolution O 
reaction O 
( O 
HER O 
) O 
. O 

interference O 
( O 
RNAi O 
) O 
is O 
a O 
powerful O 
tool O 
for O 
functional O 
genomics O 
with O 
the O 
capacity O 
to O 
comprehensively O 
analyze O 
host O 
- O 
pathogen O 
interactions O 
. O 
High O 
- O 
throughput O 
RNAi O 
screening O 
is O 
used O 
to O 
systematically O 
perturb O 
cellular O 
pathways O 
and O 
discover O 
therapeutic O 
targets O 
, O 
but O 
the O 
method O 
can O 
be O 
tedious O 
and O 
requires O 
extensive O 
capital O 
equipment O 
and O 
expensive O 
reagents O 
. O 
To O 
aid O 
in O 
the O 
development O 
of O 
an O 
inexpensive O 
miniaturized O 
RNAi O 
screening O 
platform O 
, O 
we O 
have O 
developed O 
a O 
two O 
part O 
microfluidic O 
system O 
for O 
patterning O 
and O 
screening O 
gene O 
targets O 
on O 
- O 
chip O 
to O 
examine O 
cellular O 
pathways O 
involved O 
in O 
virus O 
entry O 
and O 
infection O 
. O 
First O 
, O 
a O 
multilayer O 
polydimethylsiloxane B-SYSTEMATIC 
( O 
PDMS B-ABBREVIATION 
) O 
- O 
based O 
spotting O 
device O 
was O 
used O 
to O 
array O 
siRNA O 
molecules O 
into O 
96 O 
microwells O 
targeting O 
markers O 
of O 
endocytosis O 
, O 
along O 
with O 
siRNA O 
controls O 
. O 
By O 
using O 
a O 
PDMS B-ABBREVIATION 
-based O 
spotting O 
device O 
, O 
we O 
remove O 
the O 
need O 
for O 
a O 
microarray O 
printer O 
necessary O 
to O 
perform O 
previously O 
described O 
small O 
scale O 
( O 
e.g O 
. O 
cellular O 
microarrays O 
) O 
and O 
microchip O 
- O 
based O 
RNAi O 
screening O 
, O 
while O 
still O 
minimizing O 
reagent O 
usage O 
tenfold O 
compared O 
to O 
conventional O 
screening O 
. O 
Second O 
, O 
the O 
siRNA O 
spotted O 
array O 
was O 
transferred O 
to O 
a O 
reversibly O 
sealed O 
PDMS B-ABBREVIATION 
-based O 
screening O 
platform O 
containing O 
microchannels O 
designed O 
to O 
enable O 
efficient O 
cell O 
loading O 
and O 
transfection O 
of O 
mammalian O 
cells O 
while O 
preventing O 
cross O 
- O 
contamination O 
between O 
experimental O 
conditions O 
. O 
Validation O 
of O 
the O 
screening O 
platform O 
was O 
examined O 
using O 
Vesicular O 
stomatitis O 
virus O 
and O 
emerging O 
pathogen O 
Rift O 
Valley O 
fever O 
virus O 
, O 
which O 
demonstrated O 
virus O 
entry O 
pathways O 
of O 
clathrin O 
- O 
mediated O 
endocytosis O 
and O 
caveolae O 
- O 
mediated O 
endocytosis O 
, O 
respectively O 
. O 
The O 
techniques O 
here O 
are O 
adaptable O 
to O 
other O 
well O 
- O 
characterized O 
infection O 
pathways O 
with O 
a O 
potential O 
for O 
large O 
scale O 
screening O 
in O 
high O 
containment O 
biosafety O 
laboratories O 
. O 

is O 
a O 
primary O 
fuel O 
for O 
generating O 
energy O 
in O 
basic O 
daily O 
activities O 
. O 
Thus O 
, O 
glucose B-TRIVIAL 
homeostasis O 
is O 
tightly O 
regulated O 
by O 
counter O 
- O 
regulatory O 
hormones O 
such O 
as O 
glucagon O 
, O 
cortisol O 
, O 
and O 
insulin O 
, O 
which O 
affect O 
key O 
organs O 
including O 
liver O 
, O 
skeletal O 
muscle O 
, O 
pancreas O 
, O 
and O 
adipocytes O 
. O 
Among O 
metabolic O 
tissues O 
, O 
liver O 
plays O 
a O 
critical O 
role O 
in O 
controlling O 
glucose B-TRIVIAL 
production O 
under O 
various O 
hormonal O 
and O 
metabolic O 
cues O 
. O 
Under O 
fasting O 
, O 
acute O 
activation O 
of O 
both O 
glycogenolysis O 
and O 
gluconeogenesis O 
is O 
achieved O 
by O 
post O 
- O 
translational O 
modification O 
or O 
allosteric O 
activation O 
of O 
key O 
rate O 
- O 
limiting O 
enzymes O 
, O 
thereby O 
enabling O 
enhanced O 
glucose B-TRIVIAL 
production O 
from O 
the O 
liver O 
to O 
maintain O 
glucose B-TRIVIAL 
homeostasis O 
. O 
More O 
prolonged O 
fasting O 
or O 
starvation O 
leads O 
to O 
the O 
chronic O 
activation O 
of O 
gluconeogenesis O 
that O 
requires O 
increased O 
expression O 
of O 
key O 
enzymes O 
in O 
the O 
pathway O 
, O 
which O 
is O 
turned O 
off O 
under O 
feeding O 
conditions O 
by O 
the O 
molecular O 
events O 
that O 
are O 
initiated O 
by O 
insulin O 
. O 
This O 
process O 
is O 
normally O 
achieved O 
by O 
the O 
regulation O 
of O 
gene O 
expression O 
at O 
the O 
level O 
of O 
transcription O 
. O 
Recently O 
, O 
the O 
transcriptional O 
regulators O 
of O 
hepatic O 
gluconeogenesis O 
are O 
considered O 
as O 
potential O 
therapeutic O 
targets O 
for O 
the O 
treatment O 
of O 
type O 
2 O 
diabetes O 
. O 
In O 
this O 
review O 
, O 
we O 
would O 
like O 
to O 
discuss O 
the O 
current O 
knowledge O 
regarding O 
the O 
key O 
transcriptional O 
activators O 
and O 
inhibitors O 
of O 
hepatic O 
gluconeogenic O 
program O 
to O 
provide O 
the O 
better O 
insight O 
into O 
the O 
control O 
of O 
glycemia O 
in O 
the O 
disease O 
status O 
. O 

of O 
cytochrome O 
P4502B6 O 
in O 
methadone B-TRIVIAL 
metabolism O 
and O 
clearance O 
. O 

N B-FORMULA 
-demethylation O 
in O 
vitro O 
is O 
catalyzed O 
by O 
hepatic O 
cytochrome O 
P4502B6 O 
( O 
CYP2B6 O 
) O 
and O 
CYP3A4 O 
, O 
but O 
clinical O 
disposition O 
is O 
often O 
attributed O 
to O 
CYP3A4 O 
. O 
This O 
investigation O 
tested O 
the O 
hypothesis O 
that O 
CYP2B6 O 
is O 
a O 
prominent O 
CYP O 
isoform O 
responsible O 
for O 
clinical O 
methadone B-TRIVIAL 
N B-FORMULA 
-demethylation O 
and O 
clearance O 
, O 
using O 
the O 
in O 
vivo O 
mechanism O 
- O 
based O 
CYP2B6 O 
inhibitor O 
ticlopidine B-TRIVIAL 
, O 
given O 
orally O 
for O 
4 O 
days O 
. O 
A O 
preliminary O 
clinical O 
investigation O 
with O 
the O 
CYP3A4 O 
/ O 
5 O 
substrate O 
probe O 
alfentanil B-TRIVIAL 
established O 
that O 
ticlopidine B-TRIVIAL 
did O 
not O 
inhibit O 
intestinal O 
or O 
hepatic O 
CYP3A4 O 
/ O 
5 O 
. O 
Subjects O 
received O 
intravenous O 
plus O 
oral O 
( O 
deuterium B-SYSTEMATIC 
-labeled O 
) O 
racemic B-TRIVIAL 
methadone I-TRIVIAL 
before O 
and O 
after O 
ticlopidine B-TRIVIAL 
. O 
Ticlopidine B-TRIVIAL 
significantly O 
and O 
stereoselectively O 
( O 
S O 
> O 
R O 
) O 
inhibited O 
methadone B-TRIVIAL 
N B-FORMULA 
-demethylation O 
, O 
decreasing O 
plasma O 
metabolite/ O 
methadone B-TRIVIAL 
area O 
under O 
the O 
curve O 
ratios O 
and O 
metabolite O 
formation O 
clearances O 
. O 
Ticlopidine B-TRIVIAL 
also O 
significantly O 
increased O 
the O 
dose O 
- O 
adjusted O 
plasma O 
area O 
under O 
the O 
curve O 
for O 
R- B-MULTIPLE 
and I-MULTIPLE 
S-methadone I-MULTIPLE 
by O 
20% O 
and O 
60% O 
, O 
respectively O 
, O 
after O 
both O 
intravenous O 
and O 
oral O 
dosing O 
. O 
CYP2B6 O 
inhibition O 
reduces O 
methadone B-TRIVIAL 
N B-FORMULA 
-demethylation O 
and O 
clearance O 
, O 
and O 
alters O 
methadone B-TRIVIAL 
concentrations O 
, O 
demonstrating O 
an O 
important O 
role O 
for O 
CYP2B6 O 
in O 
clinical O 
methadone B-TRIVIAL 
disposition O 
. O 

acid I-SYSTEMATIC 
(bio)isosteres O 
in O 
drug O 
design O 
. O 

carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
functional O 
group O 
can O 
be O 
an O 
important O 
constituent O 
of O 
a O 
pharmacophore O 
, O 
however O 
, O 
the O 
presence O 
of O 
this O 
moiety O 
can O 
also O 
be O 
responsible O 
for O 
significant O 
drawbacks O 
, O 
including O 
metabolic O 
instability O 
, O 
toxicity O 
, O 
as O 
well O 
as O 
limited O 
passive O 
diffusion O 
across O 
biological O 
membranes O 
. O 
To O 
avoid O 
some O 
of O 
these O 
shortcomings O 
while O 
retaining O 
the O 
desired O 
attributes O 
of O 
the O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
moiety O 
, O 
medicinal O 
chemists O 
often O 
investigate O 
the O 
use O 
of O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
(bio)isosteres O 
. O 
The O 
same O 
type O 
of O 
strategy O 
can O 
also O 
be O 
effective O 
for O 
a O 
variety O 
other O 
purposes O 
, O 
for O 
example O 
, O 
to O 
increase O 
the O 
selectivity O 
of O 
a O 
biologically O 
active O 
compound O 
or O 
to O 
create O 
new O 
intellectual O 
property O 
. O 
Several O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
isosteres O 
have O 
been O 
reported O 
, O 
however O 
, O 
the O 
outcome O 
of O 
any O 
isosteric O 
replacement O 
cannot O 
be O 
readily O 
predicted O 
as O 
this O 
strategy O 
is O 
generally O 
found O 
to O 
be O 
dependent O 
upon O 
the O 
particular O 
context O 
( O 
i.e O 
. O 
, O 
the O 
characteristic O 
properties O 
of O 
the O 
drug O 
and O 
the O 
drug O 
- O 
target O 
) O 
. O 
As O 
a O 
result O 
, O 
screening O 
of O 
a O 
panel O 
of O 
isosteres O 
is O 
typically O 
required O 
. O 
In O 
this O 
context O 
, O 
the O 
discovery O 
and O 
development O 
of O 
novel O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
surrogates O 
that O 
could O 
complement O 
the O 
existing O 
palette O 
of O 
isosteres O 
remains O 
an O 
important O 
area O 
of O 
research O 
. O 
The O 
goal O 
of O 
this O 
Minireview O 
is O 
to O 
provide O 
an O 
overview O 
of O 
the O 
most O 
commonly O 
employed O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
(bio)isosteres O 
and O 
to O 
present O 
representative O 
examples O 
demonstrating O 
the O 
use O 
and O 
utility O 
of O 
each O 
isostere O 
in O 
drug O 
design O 
. O 

- O 
induced O 
osteomalacia O 
( O 
TIO O 
) O 
is O 
a O 
rare O 
disorder O 
of O 
phosphate B-SYSTEMATIC 
wasting O 
due O 
to O 
fibroblast O 
growth O 
factor-23 O 
(FGF23)-secreting O 
tumors O 
that O 
are O 
often O 
difficult O 
to O 
locate O 
. O 
We O 
present O 
a O 
systematic O 
approach O 
to O 
tumor O 
localization O 
and O 
post O 
- O 
operative O 
biochemical O 
changes O 
in O 
31 O 
subjects O 
with O 
TIO O 
. O 
All O 
had O 
failed O 
either O 
initial O 
, O 
or O 
re O 
- O 
localization O 
( O 
in O 
case O 
of O 
recurrence O 
or O 
metastases O 
at O 
outside O 
institutions O 
) O 
. O 
Functional O 
imaging O 
with O 
( B-SYSTEMATIC 
111 I-SYSTEMATIC 
) I-SYSTEMATIC 
Indium I-SYSTEMATIC 
- O 
octreotide O 
with O 
single O 
photon O 
emission O 
computed O 
tomography O 
( O 
octreo-SPECT O 
or O 
SPECT O 
/ O 
CT O 
) O 
, O 
and O 
( B-SYSTEMATIC 
18 I-SYSTEMATIC 
) I-SYSTEMATIC 
fluorodeoxyglucose I-SYSTEMATIC 
positron O 
emission O 
tomography O 
/ O 
CT O 
( O 
FDG-PET O 
/ O 
CT O 
) O 
were O 
performed O 
, O 
followed O 
by O 
anatomic O 
imaging O 
( O 
CT,MRI O 
) O 
. O 
Selective O 
venous O 
sampling O 
( O 
VS O 
) O 
was O 
performed O 
when O 
multiple O 
suspicious O 
lesions O 
were O 
identified O 
or O 
high O 
surgical O 
risk O 
was O 
a O 
concern O 
. O 
Tumors O 
were O 
localized O 
in O 
20 O 
/ O 
31 O 
subjects O 
( O 
64.5% O 
) O 
. O 
Nineteen O 
of O 
20 O 
subjects O 
underwent O 
octreo-SPECT O 
imaging O 
, O 
and O 
16 O 
/ O 
20 O 
FDG-PET O 
/ O 
CT O 
imaging O 
. O 
Eighteen O 
of O 
19 O 
( O 
95% O 
) O 
were O 
positive O 
on O 
octreo-SPECT O 
, O 
and O 
14 O 
/ O 
16 O 
( O 
88% O 
) O 
on O 
FDG-PET O 
/ O 
CT O 
. O 
Twelve O 
of O 
20 O 
subjects O 
underwent O 
VS O 
; O 
10 O 
/ O 
12 O 
( O 
83% O 
) O 
were O 
positive O 
. O 
Sensitivity O 
, O 
specificity O 
, O 
positive O 
predictive O 
value O 
( O 
PPV O 
) O 
, O 
and O 
negative O 
predictive O 
value O 
( O 
NPV O 
) O 
were O 
: O 
sensitivity=0.95 O 
, O 
specificity=0.64 O 
, O 
PPV=0.82 O 
and O 
NPV=0.88 O 
for O 
octreo-SPECT O 
; O 
sensitivity=0.88 O 
, O 
specificity=0.36 O 
, O 
PPV=0.62 O 
and O 
NPV=0.50 O 
for O 
FDG-PET O 
/ O 
CT O 
. O 
Fifteen O 
subjects O 
had O 
their O 
tumor O 
resected O 
at O 
our O 
institution O 
, O 
and O 
were O 
disease O 
- O 
free O 
at O 
last O 
follow O 
- O 
up O 
. O 
Serum O 
phosphorus B-SYSTEMATIC 
returned O 
to O 
normal O 
in O 
all O 
subjects O 
within O 
1-5 O 
days O 
. O 
In O 
10 O 
subjects O 
who O 
were O 
followed O 
for O 
at O 
least O 
7 O 
days O 
postoperatively O 
, O 
intact O 
FGF23 O 
( O 
iFGF23 O 
) O 
decreased O 
to O 
near O 
undetectable O 
within O 
hours O 
and O 
returned O 
to O 
the O 
normal O 
range O 
within O 
5 O 
days O 
. O 
C B-FORMULA 
-terminal O 
FGF23 O 
( O 
cFGF23 O 
) O 
decreased O 
immediately O 
but O 
remained O 
elevated O 
, O 
yielding O 
a O 
markedly O 
elevated O 
cFGF23 O 
/ O 
iFGF23 O 
ratio O 
. O 
Serum O 
1,25-dihydroxyvitamin B-SYSTEMATIC 
D(3) I-SYSTEMATIC 
( O 
1,25D B-SYSTEMATIC 
) O 
rose O 
and O 
exceeded O 
the O 
normal O 
range O 
. O 
In O 
this O 
systematic O 
approach O 
to O 
TIO O 
tumor O 
localization O 
Octreo-SPECT O 
was O 
more O 
sensitive O 
and O 
specific O 
, O 
but O 
in O 
many O 
cases O 
FDG-PET O 
/ O 
CT O 
was O 
complementary O 
. O 
VS O 
can O 
discriminate O 
between O 
multiple O 
suspicious O 
lesions O 
and O 
increase O 
certainty O 
prior O 
to O 
surgery O 
. O 
Sustained O 
elevations O 
in O 
cFGF23 O 
and O 
1,25D B-SYSTEMATIC 
were O 
observed O 
, O 
suggesting O 
novel O 
regulation O 
of O 
FGF23 O 
processing O 
and O 
1,25D B-SYSTEMATIC 
generation O 
. O 
© O 
2013 O 
American O 
Society O 
for O 
Bone O 
and O 
Mineral O 
Research O 
. O 

Oxide I-SYSTEMATIC 
-Based O 
Fluorescent O 
Biosensor O 
for O 
Protein O 
Detection O 
via O 
Terminal O 
Protection O 
of O 
Small-Molecule O 
- O 
Linked O 
DNA O 
. O 

fluorescence O 
method O 
for O 
protein O 
detection O 
is O 
developed O 
based O 
on O 
terminal O 
protection O 
of O 
small O 
- O 
molecule O 
- O 
linked O 
DNA O 
by O 
target O 
protein O 
and O 
a O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
-assisted O 
DNA O 
assay O 
strategy O 
. O 
This O 
design O 
results O 
in O 
fluorescence O 
- O 
enhanced O 
detection O 
that O 
is O 
sensitive O 
and O 
selective O 
for O 
the O 
target O 
protein O 
. O 

potently O 
induces O 
endoplasmic O 
reticulum O 
stress O 
- O 
mediated O 
apoptosis O 
in O 
BRAFV600E O 
melanoma O 
cells O 
. O 

V600E O 
mutation O 
in O 
the O 
kinase O 
BRAF O 
is O 
frequently O 
detected O 
in O 
melanomas O 
and O 
results O 
in O 
constitutive O 
activation O 
of O 
BRAF O 
, O 
which O 
then O 
promotes O 
cell O 
proliferation O 
by O 
the O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
signaling O 
pathway O 
. O 
Although O 
the O 
BRAFV600E O 
kinase O 
inhibitor O 
vemurafenib B-TRIVIAL 
has O 
remarkable O 
antitumor O 
activity O 
in O 
patients O 
with O 
BRAFV600E-mutated O 
melanoma O 
, O 
its O 
effects O 
are O 
limited O 
by O 
the O 
onset O 
of O 
drug O 
resistance O 
. O 
We O 
found O 
that O 
exposure O 
of O 
melanoma O 
cell O 
lines O 
with O 
the O 
BRAFV600E O 
mutation O 
to O 
vemurafenib B-TRIVIAL 
decreased O 
the O 
abundance O 
of O 
antiapoptotic O 
proteins O 
and O 
induced O 
intrinsic O 
mitochondrial O 
apoptosis O 
. O 
Vemurafenib B-TRIVIAL 
-treated O 
melanoma O 
cells O 
showed O 
increased O 
cytosolic O 
concentration O 
of O 
calcium B-SYSTEMATIC 
, O 
a O 
potential O 
trigger O 
for O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
stress O 
, O 
which O 
can O 
lead O 
to O 
apoptosis O 
. O 
Consistent O 
with O 
an O 
ER O 
stress O 
- O 
induced O 
response O 
, O 
vemurafenib B-TRIVIAL 
decreased O 
the O 
abundance O 
of O 
the O 
ER O 
chaperone O 
protein O 
glucose B-TRIVIAL 
-regulated O 
protein O 
78 O 
, O 
increased O 
the O 
abundance O 
of O 
the O 
spliced O 
isoform O 
of O 
the O 
transcription O 
factor O 
X-box O 
binding O 
protein O 
1 O 
( O 
XBP1 O 
) O 
( O 
which O 
transcriptionally O 
activates O 
genes O 
involved O 
in O 
ER O 
stress O 
responses O 
) O 
, O 
increased O 
the O 
phosphorylation O 
of O 
the O 
translation O 
initiation O 
factor O 
eIF2α O 
( O 
which O 
would O 
be O 
expected O 
to O 
inhibit O 
protein O 
synthesis O 
) O 
, O 
and O 
induced O 
the O 
expression O 
of O 
ER O 
stress O 
- O 
related O 
genes O 
. O 
Knockdown O 
of O 
the O 
ER O 
stress O 
response O 
protein O 
activating O 
transcription O 
factor O 
4 O 
( O 
ATF4 O 
) O 
significantly O 
reduced O 
vemurafenib B-TRIVIAL 
-induced O 
apoptosis O 
. O 
Moreover O 
, O 
the O 
ER O 
stress O 
inducer O 
thapsigargin B-TRIVIAL 
prevented O 
invasive O 
growth O 
of O 
tumors O 
formed O 
from O 
vemurafenib B-TRIVIAL 
-sensitive O 
melanoma O 
cells O 
in O 
vivo O 
. O 
In O 
melanoma O 
cells O 
with O 
low O 
sensitivity O 
or O 
resistance O 
to O 
vemurafenib B-TRIVIAL 
, O 
combination O 
treatment O 
with O 
thapsigargin B-TRIVIAL 
augmented O 
or O 
induced O 
apoptosis O 
. O 
Thus O 
, O 
thapsigargin B-TRIVIAL 
or O 
other O 
inducers O 
of O 
ER O 
stress O 
may O 
be O 
useful O 
in O 
combination O 
therapies O 
to O 
overcome O 
vemurafenib B-TRIVIAL 
resistance O 
. O 

growth O 
factor O 
β O 
integrates O 
Smad O 
3 O 
to O 
mechanistic O 
target O 
of O 
rapamycin B-TRIVIAL 
complexes O 
to O 
arrest O 
deptor O 
abundance O 
for O 
glomerular O 
mesangial O 
cell O 
hypertrophy O 
. O 

many O 
renal O 
diseases O 
, O 
transforming O 
growth O 
factor O 
β O 
(TGFβ)-stimulated O 
canonical O 
Smad O 
3 O 
and O 
noncanonical O 
mechanistic O 
target O 
of O 
rapamycin B-TRIVIAL 
( O 
mTOR O 
) O 
promote O 
increased O 
protein O 
synthesis O 
and O 
mesangial O 
cell O 
hypertrophy O 
. O 
The O 
cellular O 
underpinnings O 
involving O 
these O 
signaling O 
molecules O 
to O 
regulate O 
mesangial O 
cell O 
hypertrophy O 
are O 
not O 
fully O 
understood O 
. O 
Deptor O 
has O 
recently O 
been O 
identified O 
as O 
an O 
mTOR O 
interacting O 
protein O 
and O 
functions O 
as O 
an O 
endogenous O 
inhibitor O 
of O 
the O 
kinase O 
activity O 
for O 
both O 
TORC1 O 
and O 
TORC2 O 
. O 
Prolonged O 
incubation O 
of O 
mesangial O 
cells O 
with O 
TGFβ O 
reduced O 
the O 
levels O 
of O 
deptor O 
concomitant O 
with O 
an O 
increase O 
in O 
TORC1 O 
and O 
TORC2 O 
activity O 
. O 
Sustained O 
TGFβ O 
activation O 
was O 
required O 
to O 
inhibit O 
association O 
of O 
deptor O 
with O 
mTOR O 
, O 
whereas O 
rapid O 
activation O 
had O 
no O 
effect O 
. O 
Using O 
the O 
mTOR O 
inhibitor O 
PP242 B-IDENTIFIER 
, I-IDENTIFIER 
we O 
found O 
that O 
TGFβ-induced O 
both O 
early O 
and O 
sustained O 
activation O 
of O 
TORC1 O 
and O 
TORC2 O 
was O 
necessary O 
for O 
deptor O 
suppression O 
. O 
PP242 B-IDENTIFIER 
-induced O 
reversal O 
of O 
deptor O 
suppression O 
by O 
TGFβ O 
was O 
associated O 
with O 
a O 
significant O 
inhibition O 
of O 
TGFβ-stimulated O 
protein O 
synthesis O 
and O 
hypertrophy O 
. O 
Interestingly O 
, O 
expression O 
of O 
siRNA O 
against O 
Smad O 
3 O 
or O 
Smad O 
7 O 
, O 
which O 
blocks O 
TGFβ O 
receptor O 
- O 
specific O 
Smad O 
3 O 
signaling O 
, O 
prevented O 
TGFβ-induced O 
suppression O 
of O 
deptor O 
abundance O 
and O 
TORC1 O 
/ O 
2 O 
activities O 
. O 
Furthermore O 
, O 
overexpression O 
of O 
Smad O 
3 O 
decreased O 
deptor O 
expression O 
similar O 
to O 
TGFβ O 
stimulation O 
concomitant O 
with O 
increased O 
TORC1 O 
and O 
TORC2 O 
activities O 
. O 
Finally O 
, O 
knockdown O 
of O 
deptor O 
reversed O 
Smad O 
7- O 
mediated O 
inhibition O 
of O 
protein O 
synthesis O 
and O 
mesangial O 
cell O 
hypertrophy O 
induced O 
by O 
TGFβ O 
. O 
These O 
data O 
reveal O 
the O 
requirement O 
of O 
both O 
early O 
and O 
late O 
activation O 
of O 
mTOR O 
for O 
TGFβ-induced O 
protein O 
synthesis O 
. O 
Our O 
results O 
support O 
that O 
TGFβ-stimulated O 
Smad O 
3 O 
acts O 
as O 
a O 
key O 
node O 
to O 
instill O 
a O 
feedback O 
loop O 
between O 
deptor O 
down O 
- O 
regulation O 
and O 
TORC1 O 
/ O 
2 O 
activation O 
in O 
driving O 
mesangial O 
cell O 
hypertrophy O 
. O 

the O 
magnetic O 
properties O 
of O 
metal B-FAMILY 
oxide I-FAMILY 
nanocrystal O 
heterostructures O 
by O 
cation O 
exchange O 
. O 

three O 
types O 
of O 
colloidal O 
magnetic O 
nanocrystals O 
, O 
we O 
demonstrate O 
that O 
postsynthetic O 
cation O 
exchange O 
enables O 
tuning O 
of O 
the O 
nanocrystal's O 
magnetic O 
properties O 
and O 
achieving O 
characteristics O 
not O 
obtainable O 
by O 
conventional O 
synthetic O 
routes O 
. O 
While O 
the O 
cation O 
exchange O 
procedure O 
, O 
performed O 
in O 
solution O 
phase O 
approach O 
, O 
was O 
restricted O 
so O 
far O 
to O 
chalcogenide O 
based O 
semiconductor O 
nanocrystals O 
, O 
here O 
ferrite B-FAMILY 
-based O 
nanocrystals O 
were O 
subjected O 
to O 
a O 
Fe(2+) B-FORMULA 
to O 
Co(2+) B-FORMULA 
cation O 
exchange O 
procedure O 
. O 
This O 
allows O 
tracing O 
of O 
the O 
compositional O 
modifications O 
by O 
systematic O 
and O 
detailed O 
magnetic O 
characterization O 
. O 
In O 
homogeneous O 
magnetite O 
nanocrystals O 
and O 
in O 
gold O 
/ O 
magnetite O 
core O 
shell O 
nanocrystals O 
the O 
cation O 
exchange O 
increases O 
the O 
coercivity O 
field O 
, O 
the O 
remanence O 
magnetization O 
, O 
as O 
well O 
as O 
the O 
superparamagnetic O 
blocking O 
temperature O 
. O 
For O 
core O 
/ O 
shell O 
nanoheterostructures O 
a O 
selective O 
doping O 
of O 
either O 
the O 
shell O 
or O 
predominantly O 
of O 
the O 
core O 
with O 
Co(2+) B-FORMULA 
is O 
demonstrated O 
. O 
By O 
applying O 
the O 
cation O 
exchange O 
to O 
FeO B-FORMULA 
/ O 
CoFe(2)O(4) B-FORMULA 
core O 
/ O 
shell O 
nanocrystals O 
the O 
Neél O 
temperature O 
of O 
the O 
core O 
material O 
is O 
increased O 
and O 
exchange O 
- O 
bias O 
effects O 
are O 
enhanced O 
so O 
that O 
vertical O 
shifts O 
of O 
the O 
hysteresis O 
loops O 
are O 
obtained O 
which O 
are O 
superior O 
to O 
those O 
in O 
any O 
other O 
system O 
. O 

studies O 
have O 
shown O 
a O 
correlation O 
between O 
chronic O 
biomass O 
smoke O 
exposure O 
and O 
increased O 
respiratory O 
infection O 
. O 
Pulmonary O 
macrophages O 
are O 
instrumental O 
in O 
both O 
the O 
innate O 
and O 
the O 
adaptive O 
immune O 
responses O 
to O 
respiratory O 
infection O 
. O 
In O 
the O 
present O 
study O 
, O 
in O 
vitro O 
systems O 
were O 
utilized O 
where O 
alveolar O 
macrophages O 
( O 
AM O 
) O 
and O 
bone O 
marrow O 
- O 
derived O 
macrophages O 
( O 
BMdM O 
) O 
were O 
exposed O 
to O 
concentrated O 
wood O 
smoke O 
- O 
derived O 
particulate O 
matter O 
( O 
WS-PM O 
) O 
and O 
mice O 
were O 
exposed O 
in O 
vivo O 
to O 
either O 
concentrated O 
WS-PM O 
or O 
inhaled O 
WS O 
. O 
In O 
vivo O 
studies O 
demonstrated O 
that O 
WS-exposed O 
mice O 
inoculated O 
with O 
Streptococcus O 
pneumoniae O 
had O 
a O 
higher O 
bacterial O 
load O 
24 O 
h O 
post O 
- O 
exposure O 
, O 
and O 
corresponding O 
AM O 
were O 
found O 
to O 
have O 
decreased O 
lymphocyte O 
activation O 
activity O 
. O 
Additionally O 
, O 
while O 
classic O 
markers O 
of O 
inflammation O 
( O 
cellular O 
infiltration O 
, O 
total O 
protein O 
, O 
neutrophils O 
) O 
were O 
not O 
affected O 
, O 
there O 
were O 
changes O 
in O 
pulmonary O 
macrophages O 
populations O 
, O 
including O 
significant O 
decreases O 
in O 
macrophages O 
expressing O 
markers O 
of O 
activation O 
in O 
WS-exposed O 
mice O 
. O 
The O 
lymphocyte O 
activation O 
activity O 
of O 
WS-PM-exposed O 
AM O 
was O 
significantly O 
suppressed O 
, O 
but O 
the O 
phagocytic O 
activity O 
appeared O 
unchanged O 
. O 
In O 
an O 
effort O 
to O 
determine O 
a O 
pathway O 
for O 
WS-induced O 
suppression O 
, O 
RelB O 
activation O 
, O 
assessed O 
by O 
nuclear O 
translocation O 
, O 
was O 
observed O 
in O 
AM O 
exposed O 
to O 
either O 
inhaled O 
WS O 
or O 
instilled O 
WS-PM O 
. O 
Finally O 
, O 
an O 
analysis O 
of O 
WS-PM O 
fractions O 
determined O 
the O 
presence O 
of O 
4-5 O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PAHs B-ABBREVIATION 
) O 
, O 
and O 
preliminary O 
work O 
suggests O 
a O 
potential O 
role O 
for O 
these O 
PAHs B-ABBREVIATION 
to O 
alter O 
macrophage O 
functions O 
. O 
These O 
studies O 
show O 
a O 
decreased O 
ability O 
of O 
WS-exposed O 
pulmonary O 
macrophages O 
to O 
effectively O 
mount O 
a O 
defense O 
against O 
infection O 
, O 
the O 
effect O 
lasts O 
at O 
least O 
a O 
week O 
post O 
- O 
exposure O 
, O 
and O 
appears O 
to O 
be O 
mediated O 
via O 
RelB O 
activation O 
. O 

of O 
superconducting O 
nanocables O 
of O 
FeSe B-FORMULA 
encapsulated O 
in O 
carbonaceous O 
shell O 
. O 

recent O 
discovery O 
of O 
superconductivity O 
in O 
iron B-SYSTEMATIC 
selenide I-SYSTEMATIC 
has O 
attracted O 
considerable O 
attention O 
due O 
to O 
the O 
simplicity O 
of O 
composition O 
, O 
unconventional O 
nature O 
of O 
superconductivity O 
, O 
and O 
ease O 
of O 
synthesis O 
. O 
We O 
have O 
synthesized O 
superconducting O 
FeSe B-FORMULA 
nanowires O 
with O 
a O 
simple O 
catalyst O 
- O 
aided O 
vapor O 
transport O 
reaction O 
at O 
800 O 
°C O 
in O 
an O 
inert O 
atmosphere O 
. O 
The O 
precursors O 
were O 
chosen O 
to O 
be O 
elemental O 
Se B-FORMULA 
and O 
iron B-SYSTEMATIC 
acetylacetonate I-SYSTEMATIC 
[ O 
Fe(III)(C₅H₈O₂)₃ B-FORMULA 
] O 
. O 
These O 
vaporized O 
very O 
easily O 
, O 
thereby O 
facilitating O 
transport O 
, O 
and O 
also O 
contributed O 
to O 
the O 
formation O 
of O 
a O 
carbonaceous O 
shell O 
encapsulating O 
the O 
FeSe B-FORMULA 
nanowires O 
. O 
The O 
superconductivity O 
of O 
these O 
nanocables O 
was O 
confirmed O 
through O 
magnetic O 
measurements O 
and O 
a O 
T(c) O 
of O 
≈8 O 
K O 
was O 
obtained O 
for O 
an O 
ensemble O 
of O 
nanocables O 
. O 
The O 
length O 
of O 
FeSe B-FORMULA 
filling O 
inside O 
the O 
carbon B-SYSTEMATIC 
nanofibers O 
could O 
be O 
varied O 
by O 
controlling O 
the O 
reaction O 
conditions O 
while O 
the O 
diameter O 
of O 
nanowires O 
was O 
dependent O 
on O 
the O 
thickness O 
of O 
Au-Pd B-FORMULA 
coating O 
used O 
as O 
a O 
catalyst O 
. O 
Extensive O 
analysis O 
through O 
high O 
- O 
resolution O 
microscopy O 
revealed O 
that O 
there O 
was O 
considerable O 
lattice O 
contraction O 
of O 
FeSe B-FORMULA 
in O 
the O 
nanocable O 
up O 
to O 
about O 
3.6% O 
along O 
the O 
c-direction O 
leading O 
to O 
a O 
reduced O 
spacing O 
between O 
the O 
( O 
1 O 
) O 
lattice O 
planes O 
. O 
Interestingly O 
, O 
this O 
compression O 
was O 
more O 
pronounced O 
near O 
the O 
catalyst- O 
FeSe B-FORMULA 
interface O 
and O 
was O 
reduced O 
further O 
along O 
the O 
length O 
of O 
the O 
nanocable O 
. O 
The O 
presence O 
of O 
carbon B-SYSTEMATIC 
nanofibers O 
as O 
a O 
shell O 
around O 
the O 
FeSe B-FORMULA 
protected O 
the O 
FeSe B-FORMULA 
nanowires O 
from O 
both O 
atmospheric O 
O₂ B-FORMULA 
and O 
moisture O 
attack O 
, O 
as O 
was O 
evident O 
from O 
the O 
very O 
long O 
ambient O 
condition O 
shelf O 
life O 
of O 
these O 
nanocables O 
, O 
and O 
also O 
makes O 
them O 
more O 
stable O 
under O 
e-beam O 
irradiation O 
. O 

, O 
a O 
natural O 
product O 
derived O 
from O 
soybeans O 
, O 
ameliorates O 
polyglutamine B-FAMILY 
-mediated O 
motor O 
neuron O 
disease O 
. O 

and O 
bulbar O 
muscular O 
atrophy O 
( O 
SBMA O 
) O 
is O 
an O 
inherited O 
motor O 
neuron O 
disease O 
caused O 
by O 
the O 
expansion O 
of O 
a O 
polyglutamine B-FAMILY 
( O 
polyQ B-ABBREVIATION 
) O 
tract O 
within O 
the O 
androgen B-FAMILY 
receptor O 
( O 
AR O 
) O 
gene O 
. O 
The O 
pathologic O 
features O 
of O 
SBMA O 
are O 
motor O 
neuron O 
loss O 
in O 
the O 
spinal O 
cord O 
and O 
brainstem O 
, O 
and O 
diffuse O 
nuclear O 
accumulation O 
and O 
nuclear O 
inclusions O 
of O 
mutant O 
AR O 
in O 
residual O 
motor O 
neurons O 
and O 
certain O 
visceral O 
organs O 
. O 
AR-associated O 
coregulator O 
70 O 
( O 
ARA70 O 
) O 
was O 
the O 
first O 
coregulator O 
of O 
AR O 
to O 
be O 
identified O 
, O 
and O 
it O 
has O 
been O 
shown O 
to O 
interact O 
with O 
AR O 
and O 
increase O 
its O 
protein O 
stability O 
. O 
Here O 
, O 
we O 
report O 
that O 
genistein B-TRIVIAL 
, O 
an O 
isoflavone B-FAMILY 
found O 
in O 
soy O 
, O 
disrupts O 
the O 
interaction O 
between O 
AR O 
and O 
ARA70 O 
and O 
promotes O 
the O 
degradation O 
of O 
mutant O 
AR O 
in O 
neuronal O 
cells O 
and O 
transgenic O 
mouse O 
models O 
of O 
SBMA O 
. O 
We O 
also O 
demonstrate O 
that O 
dietary O 
genistein B-TRIVIAL 
ameliorates O 
behavioral O 
abnormalities O 
, O 
improves O 
spinal O 
cord O 
and O 
muscle O 
pathology O 
, O 
and O 
decreases O 
the O 
amounts O 
of O 
monomeric O 
AR O 
and O 
high O 
- O 
molecular O 
- O 
weight O 
mutant O 
AR O 
protein O 
aggregates O 
in O 
SBMA O 
transgenic O 
mice O 
. O 
Thus O 
, O 
genistein B-TRIVIAL 
treatment O 
may O 
be O 
a O 
potential O 
therapeutic O 
approach O 
for O 
alleviating O 
the O 
symptoms O 
of O 
SBMA O 
by O 
disrupting O 
the O 
interactions O 
between O 
AR O 
and O 
ARA70 O 
. O 

T(g) O 
bio O 
- O 
based O 
aliphatic O 
polyesters B-FAMILY 
from O 
bicyclic B-TRIVIAL 
D-mannitol I-TRIVIAL 
. O 

carbohydrate B-FAMILY 
-based O 
diol B-SYSTEMATIC 
2,4 B-SYSTEMATIC 
: I-SYSTEMATIC 
3,5-di-O-methylene-d-mannitol I-SYSTEMATIC 
( O 
Manx O 
) O 
has O 
been O 
used O 
to O 
obtain O 
aliphatic O 
polyesters B-FAMILY 
. O 
Manx O 
is O 
a O 
symmetric O 
bicyclic O 
compound O 
consisting O 
of O 
two O 
fused O 
1,3-dioxane B-SYSTEMATIC 
rings O 
and O 
bearing O 
two O 
primary O 
hydroxyl B-SYSTEMATIC 
groups O 
. O 
In O 
terms O 
of O 
stiffness O 
, O 
it O 
is O 
comparable O 
to O 
the O 
widely O 
known O 
isosorbide B-TRIVIAL 
, O 
but O 
it O 
affords O 
the O 
additional O 
advantages O 
of O 
being O 
much O 
more O 
reactive O 
in O 
polycondensation O 
and O 
capable O 
of O 
producing O 
stereoregular O 
polymers O 
with O 
fairly O 
high O 
molecular O 
weights O 
. O 
A O 
fully O 
bio O 
- O 
based O 
homopolyester O 
( O 
PManxS O 
) O 
has O 
been O 
synthesized O 
by O 
polycondensation O 
in O 
the O 
melt O 
from O 
dimethyl B-SYSTEMATIC 
succinate I-SYSTEMATIC 
and O 
Manx O 
. O 
The O 
high O 
thermal O 
stability O 
of O 
PManxS O 
, O 
its O 
relatively O 
high O 
glass O 
transition O 
temperature O 
( O 
Tg O 
= O 
68 O 
°C O 
) O 
and O 
elastic O 
modulus O 
, O 
and O 
its O 
enhanced O 
sensitivity O 
to O 
the O 
action O 
of O 
lipases O 
point O 
to O 
PManxS O 
as O 
a O 
polyester B-FAMILY 
of O 
exceptional O 
interest O 
for O 
those O 
applications O 
where O 
biodegradability O 
and O 
molecular O 
stiffness O 
are O 
priority O 
requirements O 
. O 
In O 
addition O 
, O 
random O 
copolyesters O 
( O 
PBxManxyS O 
) O 
covering O 
a O 
broad O 
range O 
of O 
compositions O 
have O 
been O 
obtained O 
using O 
mixtures O 
of O 
Manx O 
and O 
1,4-butanediol B-SYSTEMATIC 
in O 
the O 
reaction O 
with O 
dimethyl B-SYSTEMATIC 
succinate I-SYSTEMATIC 
. O 
All O 
PBxManxyS O 
were O 
semicrystalline O 
and O 
displayed O 
Tg O 
values O 
from O 
-29 O 
to O 
+ O 
51 O 
°C O 
steadily O 
increasing O 
with O 
the O 
content O 
in O 
Manx O 
units O 
. O 
The O 
stress O 
- O 
strain O 
behavior O 
of O 
these O 
copolyesters O 
largely O 
depended O 
on O 
their O 
content O 
in O 
Manx O 
and O 
they O 
were O 
enzymatically O 
degraded O 
faster O 
than O 
PBS O 
. O 

and O 
corticosterone B-TRIVIAL 
on O 
testicular O 
steroidogenesis O 
and O 
antioxidant O 
system O 
of O 
epididymal O 
sperm O 
in O 
rats O 
. O 

dibenzo-p-dioxin I-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
, O 
an O 
endocrine O 
- O 
disrupting O 
environmental O 
pollutant O 
, O 
has O 
been O 
found O 
to O 
cause O 
male O 
reproductive O 
toxicity O 
. O 
Glucocorticoids O 
have O 
been O 
found O 
to O 
influence O 
the O 
metabolic O 
pathway O 
of O 
TCDD B-ABBREVIATION 
. O 
Stress O 
, O 
which O 
affects O 
the O 
male O 
reproductive O 
function O 
, O 
is O 
marked O 
by O 
an O 
increase O 
in O 
the O 
level O 
and O 
activity O 
of O 
glucocorticoids O 
in O 
the O 
body O 
. O 
The O 
present O 
study O 
was O 
carried O 
out O 
to O 
understand O 
the O 
effect O 
of O 
TCDD B-ABBREVIATION 
on O 
testicular O 
steroidogenesis O 
and O 
sperm O 
antioxidant O 
system O 
under O 
the O 
influence O 
of O 
increased O 
level O 
of O 
corticosterone B-TRIVIAL 
in O 
the O 
body O 
. O 
Adult O 
male O 
rats O 
were O 
treated O 
with O 
either O 
TCDD B-ABBREVIATION 
( O 
100 O 
ng O 
/ O 
kg O 
bw/ O 
day O 
) O 
or O 
corticosterone B-TRIVIAL 
( O 
3 O 
mg O 
/ O 
kg O 
bw O 
/ O 
day O 
) O 
or O 
both O 
for O 
15 O 
days O 
. O 
Treatment O 
with O 
either O 
TCDD B-ABBREVIATION 
or O 
corticosterone O 
was O 
found O 
to O 
suppress O 
the O 
levels O 
of O 
steroidogenic O 
acute O 
regulatory O 
protein O 
and O 
androgen O 
- O 
binding O 
protein O 
and O 
reduce O 
the O 
activities O 
of O 
steroidogenic O 
enzymes O 
in O 
testis O 
while O 
increasing O 
oxidative O 
stress O 
in O 
ventral O 
prostate O 
, O 
seminal O 
vesicles O 
and O 
epididymal O 
sperm O 
. O 
In O 
rats O 
treated O 
with O 
both O 
TCDD B-ABBREVIATION 
and O 
corticosterone B-TRIVIAL 
, O 
the O 
suppression O 
of O 
testicular O 
steroidogenesis O 
and O 
increase O 
in O 
oxidative O 
stress O 
observed O 
in O 
ventral O 
prostate O 
, O 
seminal O 
vesicles O 
and O 
epididymal O 
sperm O 
were O 
significant O 
as O 
compared O 
to O 
TCDD B-ABBREVIATION 
alone O 
treated O 
rats O 
. O 
The O 
levels O 
of O 
Fas O 
and O 
FasL O 
proteins O 
were O 
also O 
increased O 
in O 
rats O 
subjected O 
to O 
either O 
TCDD B-ABBREVIATION 
or O 
corticosterone B-TRIVIAL 
treatment O 
. O 
In O 
rats O 
treated O 
with O 
both O 
compounds O 
, O 
the O 
increase O 
observed O 
in O 
testicular O 
levels O 
of O 
Fas O 
and O 
FasL O 
was O 
significant O 
as O 
compared O 
to O 
TCDD B-ABBREVIATION 
alone O 
treated O 
rats O 
. O 
Effect O 
of O 
TCDD B-ABBREVIATION 
on O 
testicular O 
steroidogenesis O 
and O 
antioxidant O 
system O 
of O 
epididymal O 
sperm O 
may O 
get O 
enhanced O 
under O 
increased O 
level O 
of O 
glucocorticoids O 
in O 
the O 
body O 
. O 

: O 
synthetic O 
developments O 
and O 
applications O 
. O 

have O 
attracted O 
considerable O 
worldwide O 
attention O 
over O 
the O 
last O 
few O 
decades O 
. O 
Since O 
the O 
discovery O 
of O 
these O 
pigments O 
, O 
chemists O 
, O 
biologists O 
, O 
medical O 
professionals O 
and O 
material O 
scientists O 
have O 
devoted O 
pronounced O 
efforts O 
in O 
order O 
to O 
develop O 
synthetic O 
methods O 
and O 
discover O 
useful O 
applications O 
for O 
these O 
compounds O 
. O 
Nowadays O 
, O 
tetrabenzoporphyrins B-FAMILY 
occupy O 
a O 
prominent O 
position O 
in O 
porphyrin B-FAMILY 
chemistry O 
, O 
and O 
this O 
review O 
is O 
intended O 
to O 
cover O 
the O 
main O 
synthetic O 
methods O 
and O 
applications O 
of O 
these O 
compounds O 
. O 

binding O 
or O 
the O 
fraction O 
of O 
drug O 
unbound O 
in O 
an O 
in O 
vitro O 
incubation O 
, O 
fuinc O 
, O 
is O 
an O 
important O 
parameter O 
to O 
predict O 
or O 
measure O 
in O 
the O 
pursuit O 
of O 
accurate O 
clearance O 
predictions O 
from O 
in O 
vitro O 
data O 
. O 
Here O 
we O 
describe O 
a O 
method O 
for O 
fuinc O 
determination O 
directly O 
in O 
the O 
hepatocyte O 
intrinsic O 
clearance O 
( O 
CLint O 
) O 
assay O 
with O 
emphasis O 
on O 
compounds O 
that O 
are O 
actively O 
transported O 
into O 
hepatocytes O 
, O 
hypothesizing O 
that O 
for O 
such O 
compounds O 
the O 
typical O 
protocol O 
of O 
1 O 
million O 
hepatocytes O 
/ O 
ml O 
systematically O 
underestimates O 
the O 
maximum O 
attainable O 
unbound O 
intracellular O 
drug O 
concentration O 
. O 
Using O 
the O 
transporter O 
substrate O 
atorvastatin B-TRIVIAL 
as O 
a O 
test O 
compound O 
, O 
incubations O 
were O 
performed O 
and O 
a O 
mathematical O 
model O 
applied O 
to O 
describe O 
metabolism O 
, O 
distribution O 
, O 
and O 
binding O 
at O 
different O 
hepatocyte O 
concentrations O 
. O 
From O 
these O 
investigations O 
it O 
was O 
evident O 
that O 
, O 
since O 
binding O 
is O 
more O 
extensive O 
intracellularly O 
than O 
in O 
the O 
medium O 
, O 
increased O 
partitioning O 
into O 
the O 
cellular O 
volume O 
, O 
due O 
to O 
active O 
uptake O 
, O 
increases O 
the O 
total O 
amount O 
of O 
atorvastatin B-TRIVIAL 
bound O 
in O 
the O 
incubation O 
. O 
Consequently O 
, O 
a O 
significant O 
lowering O 
of O 
the O 
hepatocyte O 
concentration O 
impacts O 
the O 
free O 
drug O 
concentration O 
in O 
the O 
incubation O 
and O 
increases O 
the O 
observed O 
rate O 
of O 
metabolism O 
and O 
therefore O 
observed O 
CLint O 
( O 
that O 
is O 
, O 
when O 
viewed O 
from O 
the O 
media O 
drug O 
concentration O 
) O 
. O 
The O 
applicability O 
of O 
the O 
findings O 
was O 
tested O 
for O 
a O 
series O 
of O 
11 O 
actively O 
transported O 
zwitterions O 
for O 
which O 
standard O 
rat O 
hepatocyte O 
metabolic O 
CLint O 
data O 
( O 
1 O 
million O 
cells O 
/ O 
ml O 
incubation O 
) O 
poorly O 
predicted O 
in O 
vivo O 
clearance O 
( O 
average O 
fold O 
error O 
of O 
5.4 O 
) O 
. O 
Using O 
metabolic O 
CLint O 
determined O 
at O 
a O 
lower O 
hepatocyte O 
concentration O 
( O 
0.125 O 
million O 
cells O 
/ O 
ml O 
) O 
considerably O 
improved O 
clearance O 
predictions O 
( O 
average O 
fold O 
error O 
of O 
2.3 O 
) O 
. O 

of O 
the O 
toxicokinetics O 
of O 
petroleum B-FAMILY 
hydrocarbon I-FAMILY 
distillates O 
with O 
the O 
earthworm O 
Eisenia O 
andrei O 
. O 

Canada O 
- O 
wide O 
standards O 
for O 
petroleum B-FAMILY 
hydrocarbons I-FAMILY 
in O 
soils O 
regulate O 
petroleum B-FAMILY 
hydrocarbons I-FAMILY 
based O 
on O 
four O 
distillate O 
ranges O 
: O 
F1 O 
( O 
C6-C10 O 
) O 
, O 
F2 O 
( O 
> O 
C10-C16 O 
) O 
, O 
F3 O 
( O 
> O 
C16-C34 O 
) O 
, O 
and O 
F4 O 
( O 
> O 
C34 O 
) O 
. O 
Previous O 
toxicity O 
tests O 
with O 
earthworms O 
and O 
F2 O 
, O 
as O 
well O 
as O 
two O 
subfractions O 
of O 
F3 O 
, O 
F3a O 
( O 
> O 
C16-C23 O 
) O 
and O 
F3a O 
( O 
> O 
C23-C34 O 
) O 
, O 
indicate O 
that O 
test O 
durations O 
might O 
not O 
be O 
sufficiently O 
long O 
to O 
reach O 
threshold O 
effect O 
concentrations O 
, O 
likely O 
because O 
of O 
the O 
differing O 
toxicokinetics O 
for O 
each O 
distillate O 
. O 
A O 
study O 
was O 
conducted O 
to O 
determine O 
the O 
toxicokinetics O 
of O 
both O 
aliphatic O 
and O 
aromatic O 
fractions O 
of O 
F2 O 
, O 
F3a O 
, O 
and O 
F3b O 
with O 
the O 
earthworm O 
Eisenia O 
andrei O 
. O 
Peak O 
accumulation O 
curves O 
were O 
observed O 
for O 
F2 O 
aliphatics O 
and O 
aromatics O 
and O 
F3a O 
aromatics O 
, O 
likely O 
as O 
a O 
result O 
of O 
changes O 
in O 
exposure O 
concentration O 
over O 
the O 
test O 
duration O 
via O 
loss O 
or O 
a O 
decrease O 
in O 
the O 
bioavailable O 
fraction O 
. O 
Biota-soil O 
accumulation O 
factors O 
were O 
> O 
1 O 
for O 
total O 
F2 O 
aliphatics O 
and O 
aromatics O 
and O 
F3a O 
aromatics O 
as O 
well O 
as O 
for O 
several O 
individual O 
polyaromatic B-FAMILY 
hydrocarbons I-FAMILY 
for O 
each O 
distillate O 
. O 
Aromatics O 
were O 
disproportionately O 
accumulated O 
over O 
aliphatics O 
and O 
were O 
the O 
main O 
contributors O 
to O 
toxicity O 
; O 
therefore O 
, O 
aromatics O 
and O 
aliphatics O 
should O 
be O 
regulated O 
separately O 
. O 
The O 
toxicokinetics O 
were O 
used O 
to O 
interpret O 
previous O 
toxicity O 
data O 
. O 
Higher O 
molecular O 
weight O 
distillates O 
need O 
longer O 
- O 
than O 
- O 
standard O 
test O 
durations O 
to O 
determine O 
toxicity O 
, O 
so O 
toxicity O 
test O 
results O 
from O 
fixed O 
, O 
standard O 
- O 
duration O 
tests O 
are O 
not O 
strictly O 
comparable O 
for O 
these O 
petroleum O 
distillates O 
. O 
Environ O 
. O 
Toxicol O 
. O 
Chem O 
. O 
2013;32 O 
: O 
1006-1015 O 
. O 
© O 
2013 O 
SETAC O 
. O 

polyphenols B-FAMILY 
enhance O 
positive O 
mood O 
states O 
but O 
not O 
cognitive O 
performance O 
: O 
a O 
randomized O 
, O 
placebo O 
- O 
controlled O 
trial O 
. O 

study O 
aimed O 
to O 
examine O 
the O 
acute O 
and O 
sub O 
- O 
chronic O 
effects O 
of O 
cocoa O 
polyphenols B-FAMILY 
on O 
cognition O 
and O 
mood O 
. O 
In O 
a O 
randomized O 
, O 
double O 
- O 
blind O 
study O 
, O 
healthy O 
middle O 
- O 
aged O 
participants O 
received O 
a O 
dark O 
chocolate O 
drink O 
mix O 
standardized O 
to O 
contain O 
500 O 
mg O 
, O 
250 O 
mg O 
or O 
0 O 
mg O 
of O 
polyphenols B-FAMILY 
( O 
placebo O 
) O 
in O 
a O 
parallel O 
- O 
groups O 
design O 
. O 
Participants O 
consumed O 
their O 
assigned O 
treatment O 
once O 
daily O 
for O 
30 O 
days O 
. O 
Cognition O 
was O 
measured O 
with O 
the O 
Cognitive O 
Drug O 
Research O 
system O 
and O 
self O 
- O 
rated O 
mood O 
with O 
the O 
Bond-Lader O 
Visual O 
Analogue O 
Scale O 
. O 
Participants O 
were O 
tested O 
at O 
baseline O 
, O 
at O 
1 O 
, O 
2.5 O 
and O 
4 O 
h O 
after O 
a O 
single O 
acute O 
dose O 
and O 
again O 
after O 
receiving O 
30 O 
days O 
of O 
treatment O 
. O 
In O 
total O 
, O 
72 O 
participants O 
completed O 
the O 
trial O 
. O 
After O 
30 O 
days O 
, O 
the O 
high O 
dose O 
of O 
treatment O 
significantly O 
increased O 
self O 
- O 
rated O 
calmness O 
and O 
contentedness O 
relative O 
to O 
placebo O 
. O 
Mood O 
was O 
unchanged O 
by O 
treatment O 
acutely O 
while O 
cognition O 
was O 
unaffected O 
by O 
treatment O 
at O 
all O 
time O 
points O 
. O 
This O 
randomized O 
controlled O 
trial O 
is O 
perhaps O 
the O 
first O 
to O 
demonstrate O 
the O 
positive O 
effects O 
of O 
cocoa O 
polyphenols B-FAMILY 
on O 
mood O 
in O 
healthy O 
participants O 
. O 
This O 
provides O 
a O 
rationale O 
for O 
exploring O 
whether O 
cocoa O 
polyphenols B-FAMILY 
can O 
ameliorate O 
the O 
symptoms O 
associated O 
with O 
clinical O 
anxiety O 
or O 
depression O 
. O 

addicts O 
consume O 
large O 
quantities O 
of O 
refined O 
sugars B-FAMILY 
. O 
This O 
study O 
investigated O 
the O 
effect O 
of O 
opiate O 
use O 
and O 
antagonism O 
on O 
sweet O 
taste O 
in O 
opiate O 
- O 
maintained O 
drug O 
users O 
and O 
detoxified O 
former O 
chronic O 
opiate O 
users O 
, O 
using O 
a O 
within O 
- O 
subject O 
design O 
. O 
Seven O 
opiate O 
users O 
received O 
methadone B-TRIVIAL 
and O 
seven O 
buprenorphine B-TRIVIAL 
maintenance O 
. O 
Six O 
detoxified O 
subjects O 
received O 
naltrexone B-TRIVIAL 
. O 
Sucrose B-TRIVIAL 
recognition O 
thresholds O 
and O 
measurements O 
of O 
pleasantness O 
and O 
intensity O 
were O 
determined O 
before O 
and O 
four O 
hours O 
after O 
1 O 
) O 
a O 
single O 
dose O 
of O 
methadone B-TRIVIAL 
or O 
buprenorphine B-TRIVIAL 
or O 
2 O 
) O 
naltrexone B-TRIVIAL 
. O 
Control O 
data O 
were O 
taken O 
from O 
a O 
cohort O 
of O 
healthy O 
volunteers O 
including O 
smokers O 
. O 
All O 
measures O 
of O 
sweet O 
and O 
salt O 
taste O 
perception O 
were O 
significantly O 
greater O 
in O 
opiate O 
users O 
and O 
recently O 
detoxified O 
subjects O 
compared O 
to O 
control O 
subjects O 
, O 
with O 
the O 
exception O 
of O 
sweet O 
pleasantness O 
, O 
which O 
returned O 
to O 
control O 
level O 
after O 
detoxification O 
. O 
Acute O 
methadone B-TRIVIAL 
administration O 
reduced O 
salt O 
thresholds O 
and O 
unpleasantness O 
to O 
control O 
levels O 
. O 
Increased O 
sweet O 
thresholds O 
and O 
salt O 
unpleasantness O 
in O 
detoxified O 
subjects O 
were O 
reversed O 
by O 
acute O 
opioid O 
antagonism O 
, O 
returning O 
to O 
control O 
levels O 
. O 
These O 
results O 
suggest O 
that O 
opiate O 
use O 
and O 
antagonism O 
alters O 
taste O 
perception O 
. O 
Some O 
of O 
the O 
alterations O 
reverse O 
on O 
detoxification O 
( O 
sweet O 
pleasantness O 
) O 
, O 
and O 
others O 
can O 
be O 
reversed O 
by O 
opioid O 
antagonism O 
( O 
sweet O 
threshold O 
, O 
salt O 
unpleasantness O 
) O 
. O 
Changes O 
in O 
taste O 
perception O 
may O 
underlie O 
altered O 
consumption O 
of O 
refined O 
sugars B-FAMILY 
in O 
opiate O 
users O 
. O 

A-F I-MULTIPLE 
, O 
new O 
triterpene B-FAMILY 
glycosides I-FAMILY 
from O 
Cimicifuga O 
heracleifolia O 
, O 
and O 
their O 
inhibitory O 
activities O 
against O 
hypoxia O 
and O 
reoxygenation O 
. O 

new O 
9,19-cycloartane B-FAMILY 
triterpene I-FAMILY 
glycosides I-FAMILY 
, O 
heracleifolinosides B-MULTIPLE 
A-F I-MULTIPLE 
( O 
1-6 O 
) O 
, O 
and O 
one O 
new O 
chromone O 
, O 
norkhelloside B-TRIVIAL 
( O 
7 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
rhizome O 
of O 
Cimicifuga O 
heracleifolia O 
, O 
together O 
with O 
15 O 
known O 
compounds O 
( O 
8-22 O 
) O 
. O 
The O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
elucidated O 
by O 
means O 
of O 
spectroscopic O 
methods O 
including O 
2D O 
NMR O 
and O 
mass O 
spectrometry O 
. O 
The O 
extracts O 
of O 
C O 
. O 
heracleifolia O 
and O 
all O 
the O 
isolated O 
compounds O 
were O 
tested O 
for O 
activities O 
against O 
hypoxia O 
and O 
reoxygenation O 
injury O 
in O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
. O 
Heracleifolinoside B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
is O 
effectively O 
resistant O 
to O 
hypoxia O 
and O 
reoxygenation O 
- O 
induced O 
human O 
umbilical O 
vein O 
endothelial O 
cell O 
injury O 
, O 
with O 
cell O 
viabilities O 
of O 
61.95 O 
± O 
2.04 O 
% O 
, O 
77.04 O 
± O 
4.44 O 
% O 
, O 
and O 
83.65 O 
± O 
3.29 O 
% O 
at O 
concentrations O 
of O 
1 O 
, O 
10 O 
, O 
and O 
100 O 
µM O 
, O 
respectively O 
. O 

for O 
conformational O 
relaxation O 
of O 
flexible O 
conjugated O 
polymers O 
: O 
application O 
to O 
p-phenylenevinylene B-FAMILY 
trimers I-FAMILY 
in O 
nonpolar O 
solvents O 
. O 

of O 
flexible O 
conjugated O 
polymers O 
is O 
invariably O 
followed O 
by O 
a O 
fast O 
conformational O 
/ O 
torsional O 
relaxation O 
towards O 
a O 
configuration O 
favouring O 
coplanarity O 
of O 
the O 
conjugated O 
segments O 
. O 
In O 
general O 
, O 
the O 
experimental O 
relaxation O 
rate O 
constant O 
(k(CR)) O 
depends O 
on O 
the O 
solvent O 
viscosity O 
( O 
η O 
) O 
and O 
temperature O 
( O 
T O 
) O 
, O 
and O 
is O 
not O 
proportional O 
to O 
T O 
/ O 
η O 
. O 
A O 
theory O 
capable O 
of O 
explaining O 
the O 
observed O 
dependence O 
of O 
k(CR) O 
on O 
T O 
and O 
η O 
over O 
a O 
wide O 
range O 
of O 
these O 
variables O 
is O 
not O 
available O 
. O 
This O 
gap O 
is O 
filled O 
here O 
by O 
presenting O 
a O 
stochastic O 
model O 
that O 
includes O 
the O 
participation O 
of O 
the O 
oligomer O 
side O 
chain O 
in O 
storing O 
and O 
dissipating O 
the O 
stresses O 
induced O 
by O 
photoexcitation O 
. O 
The O 
model O 
is O 
able O 
to O 
account O 
for O 
the O 
softening O 
of O 
solute O 
- O 
solvent O 
interactions O 
and O 
its O 
predictions O 
are O 
found O 
to O 
be O 
in O 
excellent O 
agreement O 
with O 
the O 
observed O 
relaxation O 
rate O 
constants O 
of O 
a O 
series O 
of O 
substituted O 
p-phenylenevinylene B-FAMILY 
trimers I-FAMILY 
[ O 
ChemPhysChem O 
2009 O 
, O 
10 O 
, O 
448-454 O 
] O 
on O 
T O 
, O 
η O 
and O 
the O 
size O 
of O 
the O 
side O 
- O 
chains O 
. O 

: O 
Janus O 
kinases O 
( O 
JAKs O 
) O 
comprise O 
a O 
family O 
of O 
four O 
enzymes O 
, O 
JAK1 O 
, O 
JAK2 O 
, O 
JAK3 O 
and O 
tyrosine B-TRIVIAL 
kinase O 
2 O 
( O 
TYK2 O 
) O 
, O 
centrally O 
implicated O 
in O 
cell O 
signaling O 
processes O 
important O 
in O 
cancer O 
and O 
immune O 
- O 
inflammatory O 
diseases O 
. O 
Progression O 
in O 
the O 
field O 
has O 
taken O 
a O 
recent O 
step O 
forward O 
with O 
the O 
approval O 
of O 
ruxolitinib B-TRIVIAL 
( O 
Jakafi B-TRIVIAL 
) O 
, O 
a O 
selective O 
inhibitor O 
of O 
JAK1 O 
/ O 
2 O 
and O 
very O 
recently O 
tofacitinib B-TRIVIAL 
( O 
Xeljanz B-TRIVIAL 
) O 
, O 
a O 
pan-JAK O 
inhibitor O 
. O 
There O 
are O 
many O 
new O 
JAK O 
family O 
enzyme O 
inhibitors O 
in O 
the O 
clinic O 
now O 
with O 
a O 
range O 
of O 
selectivity O 
profiles O 
. O 
More O 
selective O 
JAK2 O 
or O 
JAK3 O 
compounds O 
are O 
now O 
coming O 
through O 
in O 
considerable O 
numbers O 
and O 
this O 
review O 
attempts O 
to O 
provide O 
an O 
update O 
of O 
the O 
recent O 
patent O 
literature O 
of O 
those O 
new O 
compounds O 
. O 
An O 
overview O 
is O 
given O 
on O 
the O 
diversity O 
of O 
core O 
structures O 
employed O 
for O 
inhibitor O 
design O 
showing O 
that O 
the O 
vast O 
majority O 
of O 
compounds O 
are O 
based O 
on O 
classic O 
ATP B-ABBREVIATION 
-competitive O 
kinase O 
inhibitor O 
heterocycles O 
. O 
AREAS O 
COVERED O 
: O 
This O 
review O 
updates O 
new O 
patents O 
claiming O 
JAK2 O 
and O 
/ O 
or O 
JAK3 O 
inhibitors O 
published O 
from O 
2010 O 
to O 
2012 O 
. O 
Pre-2010 O 
patents O 
have O 
been O 
extensively O 
covered O 
in O 
previous O 
reviews O 
. O 
Comments O 
on O 
the O 
context O 
of O 
each O 
chemical O 
series O 
are O 
given O 
where O 
applicable O 
to O 
orientate O 
the O 
readers O 
on O 
the O 
bewildering O 
array O 
of O 
molecular O 
designs O 
now O 
available O 
. O 
This O 
review O 
does O 
not O 
cover O 
JAK1 O 
or O 
TYK2 O 
inhibitors O 
but O 
mention O 
is O 
made O 
of O 
these O 
where O 
they O 
occur O 
within O 
series O 
of O 
JAK2 O 
/ O 
3 O 
inhibitors O 
. O 
Given O 
the O 
overlap O 
between O 
many O 
pharmacophores O 
, O 
it O 
was O 
not O 
possible O 
to O 
completely O 
separate O 
inhibitors O 
of O 
JAK2 O 
from O 
JAK3 O 
, O 
hence O 
the O 
material O 
is O 
organized O 
by O 
JAK2 O 
, O 
JAK3 O 
and O 
JAK2 O 
/ O 
3 O 
and O 
within O 
each O 
section O 
by O 
alphabetical O 
order O 
of O 
the O 
patent O 
assignee O 
, O 
some O 
companies O 
having O 
published O 
five O 
or O 
more O 
patents O 
, O 
such O 
as O 
Ambit O 
( O 
10 O 
) O 
, O 
Incyte O 
( O 
9 O 
) O 
, O 
Galapagos O 
( O 
7 O 
) O 
, O 
Almirall O 
( O 
6 O 
) O 
and O 
Biocryst O 
( O 
5 O 
) O 
. O 
A O 
total O 
of O 
98 O 
patents O 
are O 
reviewed O 
herein O 
. O 
EXPERT O 
OPINION O 
: O 
JAK O 
inhibitor O 
therapy O 
is O 
entering O 
a O 
significant O 
new O 
era O 
with O 
the O 
advent O 
on O 
the O 
market O 
of O 
the O 
JAK1 O 
/ O 
2 O 
inhibitor O 
ruxolitinib B-TRIVIAL 
and O 
the O 
pan-JAK O 
inhibitor O 
tofacitinib B-TRIVIAL 
, O 
with O 
unprecedented O 
speed O 
of O 
development O 
. O 
Selectivity O 
against O 
the O 
four O 
individual O 
JAK O 
family O 
enzymes O 
, O 
JAK1 O 
, O 
2 O 
, O 
3 O 
and O 
TYK2 O 
, O 
is O 
now O 
a O 
key O 
goal O 
since O 
they O 
each O 
play O 
subtly O 
different O 
roles O 
in O 
cytokine O 
- O 
induced O 
cell O 
signaling O 
. O 
The O 
future O 
looks O 
bright O 
for O 
patients O 
as O 
many O 
new O 
drugs O 
are O 
being O 
developed O 
and O 
now O 
combinations O 
of O 
JAK O 
inhibitors O 
with O 
other O 
targeted O 
agents O 
are O 
being O 
studied O 
in O 
the O 
clinic O 
. O 
These O 
advances O 
are O 
expected O 
to O 
lead O 
to O 
further O 
significant O 
progress O 
improving O 
patient O 
outcomes O 
and O 
quality O 
of O 
life O 
. O 

of O 
glycine B-TRIVIAL 
in O 
the O 
cylindrical O 
nanopores O 
of O 
anodic O 
aluminum B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
AAO B-ABBREVIATION 
) O 
revealed O 
the O 
formation O 
of O 
metastable O 
β-glycine B-TRIVIAL 
in O 
pores O 
having O 
diameters O 
less O 
than O 
200 O 
nm O 
. O 
Two O 
- O 
dimensional O 
X-ray O 
microdiffraction O 
indicated O 
that O 
the O 
[ O 
10 O 
] O 
axis O 
of O 
the O 
embedded O 
β-glycine B-TRIVIAL 
nanocrystals O 
coincided O 
with O 
the O 
pore O 
direction O 
, O 
identical O 
to O 
behavior O 
observed O 
previously O 
in O 
the O 
cylindrical O 
nanopores O 
of O 
polymer O 
monoliths O 
. O 
Whereas O 
the O 
β-glycine B-TRIVIAL 
nanocrystals O 
were O 
stable O 
indefinitely O 
in O 
ambient O 
air O 
and O 
persisted O 
upon O 
heating O 
, O 
they O 
transformed O 
to O 
the O 
α O 
polymorph O 
upon O 
standing O 
at O 
room O 
temperature O 
and O 
90% O 
relative O 
humidity O 
( O 
RH O 
) O 
. O 
The O 
α-glycine B-TRIVIAL 
nanocrystals O 
were O 
oriented O 
with O 
the O 
[ O 
10 O 
] O 
axis O 
nearly O 
perpendicular O 
to O 
the O 
pore O 
direction O 
, O 
reflecting O 
a O 
nearly O 
90° O 
rotation O 
of O 
the O 
glycine B-TRIVIAL 
molecules O 
during O 
the O 
transition O 
. O 
When O 
the O 
β-glycine B-TRIVIAL 
nanocrystals O 
were O 
formed O 
in O 
the O 
AAO B-ABBREVIATION 
cylinders O 
in O 
the O 
presence O 
of O 
small O 
amounts O 
of O 
racemic O 
hydrophobic O 
amino B-FAMILY 
acid I-FAMILY 
auxiliaries O 
, O 
which O 
are O 
known O 
to O 
bind O 
selectively O 
to O 
the O 
( O 
10 O 
) O 
and O 
( O 
10 O 
) O 
faces O 
on O 
the O 
fast O 
- O 
growing O 
end O 
of O 
β-glycine B-TRIVIAL 
enantiomorphs O 
, O 
the O 
β O 
→ O 
α O 
phase O 
transition O 
at O 
90% O 
RH O 
was O 
suppressed O 
. O 
In O 
contrast O 
, O 
β-glycine B-TRIVIAL 
nanocrystals O 
grown O 
in O 
the O 
presence O 
of O 
an O 
enantiopure O 
amino B-FAMILY 
acid I-FAMILY 
auxiliary O 
, O 
which O 
binds O 
to O 
the O 
fast O 
- O 
growing O 
end O 
of O 
only O 
one O 
of O 
the O 
enantiomorphs O 
, O 
thus O 
suppressing O 
its O 
formation O 
and O 
leaving O 
the O 
other O 
enantiomorph O 
unperturbed O 
, O 
transformed O 
into O 
the O 
α O 
polymorph O 
under O 
the O 
same O 
conditions O 
. O 
This O 
observation O 
confirms O 
that O 
binding O 
of O 
an O 
amino B-FAMILY 
acid I-FAMILY 
to O 
the O 
{ O 
10 O 
} O 
faces O 
is O 
stereoselective O 
and O 
that O 
access O 
of O 
water O 
to O 
these O 
faces O 
is O 
essential O 
for O 
the O 
transition O 
to O 
the O 
α O 
polymorph O 
. O 

impact O 
of O 
functionalization O 
on O 
the O 
stability O 
, O 
work O 
function O 
, O 
and O 
photoluminescence O 
of O 
reduced B-SYSTEMATIC 
graphene I-SYSTEMATIC 
oxide I-SYSTEMATIC 
. O 

graphene I-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
rGO B-ABBREVIATION 
) O 
is O 
a O 
promising O 
material O 
for O 
a O 
variety O 
of O 
thin O 
- O 
film O 
optoelectronic O 
applications O 
. O 
Two O 
main O 
barriers O 
to O 
its O 
widespread O 
use O 
are O 
the O 
lack O 
of O 
( O 
1 O 
) O 
fabrication O 
protocols O 
leading O 
to O 
tailored O 
functionalization O 
of O 
the O 
graphene B-TRIVIAL 
sheet O 
with O 
oxygen B-SYSTEMATIC 
-containing O 
chemical O 
groups O 
, O 
and O 
( O 
2 O 
) O 
understanding O 
of O 
the O 
impact O 
of O 
such O 
functional O 
groups O 
on O 
the O 
stability O 
and O 
on O 
the O 
optical O 
and O 
electronic O 
properties O 
of O 
rGO B-ABBREVIATION 
. O 
We O 
carry O 
out O 
classical O 
molecular O 
dynamics O 
and O 
density O 
functional O 
theory O 
calculations O 
on O 
a O 
large O 
set O 
of O 
realistic O 
rGO B-ABBREVIATION 
structures O 
to O 
decompose O 
the O 
effects O 
of O 
different O 
functional O 
groups O 
on O 
the O 
stability O 
, O 
work O 
function O 
, O 
and O 
photoluminescence O 
. O 
Our O 
calculations O 
indicate O 
the O 
metastable O 
nature O 
of O 
carbonyl B-FAMILY 
-rich O 
rGO B-ABBREVIATION 
and O 
its O 
favorable O 
transformation O 
to O 
hydroxyl B-SYSTEMATIC 
-rich O 
rGO B-ABBREVIATION 
at O 
room O 
temperature O 
via O 
carbonyl B-FAMILY 
-to- O 
hydroxyl B-SYSTEMATIC 
conversion O 
reactions O 
near O 
carbon B-SYSTEMATIC 
vacancies O 
and O 
holes O 
. O 
We O 
demonstrate O 
a O 
significant O 
tunability O 
in O 
the O 
work O 
function O 
of O 
rGO B-ABBREVIATION 
up O 
to O 
2.5 O 
eV O 
by O 
altering O 
the O 
composition O 
of O 
oxygen B-SYSTEMATIC 
-containing O 
functional O 
groups O 
for O 
a O 
fixed O 
oxygen B-SYSTEMATIC 
concentration O 
, O 
and O 
of O 
the O 
photoluminescence O 
emission O 
by O 
modulating O 
the O 
fraction O 
of O 
epoxy B-SYSTEMATIC 
and O 
carbonyl B-FAMILY 
groups O 
. O 
Taken O 
together O 
, O 
our O 
results O 
guide O 
the O 
application O 
of O 
tailored O 
rGO B-ABBREVIATION 
structures O 
in O 
devices O 
for O 
optoelectronics O 
and O 
renewable O 
energy O 
. O 

contrasting O 
activity O 
of O 
iodido B-SYSTEMATIC 
versus O 
chlorido B-SYSTEMATIC 
ruthenium I-SYSTEMATIC 
and O 
osmium B-MULTIPLE 
arene I-MULTIPLE 
azo- I-MULTIPLE 
and I-MULTIPLE 
imino I-MULTIPLE 
- I-MULTIPLE 
pyridine I-MULTIPLE 
anticancer O 
complexes O 
: O 
control O 
of O 
cell O 
selectivity O 
, O 
cross O 
- O 
resistance O 
, O 
p53 O 
dependence O 
, O 
and O 
apoptosis O 
pathway O 
. O 

half O 
- O 
sandwich O 
complexes O 
[ B-FAMILY 
M(p-cymene)(azo I-FAMILY 
/ I-FAMILY 
imino-pyridine)X](+ I-FAMILY 
) I-FAMILY 
where O 
M B-FORMULA 
= I-FORMULA 
Ru I-FORMULA 
(II) I-FORMULA 
or I-FORMULA 
Os I-FORMULA 
(II) I-FORMULA 
Ru B-FORMULA 
(II) I-FORMULA 
or O 
Os B-FORMULA 
(II) I-FORMULA 
and O 
X B-FORMULA 
═ I-FORMULA 
Cl I-FORMULA 
or I-FORMULA 
I I-FORMULA 
Cl B-FORMULA 
or O 
I B-FORMULA 
, O 
exhibit O 
potent O 
antiproliferative O 
activity O 
toward O 
a O 
range O 
of O 
cancer O 
cells O 
. O 
Not O 
only O 
are O 
the O 
iodido B-SYSTEMATIC 
complexes O 
more O 
potent O 
than O 
the O 
chlorido B-SYSTEMATIC 
analogues O 
, O 
but O 
they O 
are O 
not O 
cross O 
- O 
resistant O 
with O 
the O 
clinical O 
platinum B-SYSTEMATIC 
drugs O 
cisplatin B-TRIVIAL 
and O 
oxaliplatin B-TRIVIAL 
. O 
They O 
are O 
also O 
more O 
selective O 
for O 
cancer O 
cells O 
versus O 
normal O 
cells O 
( O 
fibroblasts O 
) O 
and O 
show O 
high O 
accumulation O 
in O 
cell O 
membranes O 
. O 
They O 
arrest O 
cell O 
growth O 
in O 
G1 O 
phase O 
in O 
contrast O 
to O 
cisplatin B-TRIVIAL 
( O 
S O 
phase O 
) O 
with O 
a O 
high O 
incidence O 
of O 
late O 
- O 
stage O 
apoptosis O 
. O 
The O 
iodido B-SYSTEMATIC 
complexes O 
retain O 
potency O 
in O 
p53 O 
mutant O 
colon O 
cells O 
. O 
All O 
complexes O 
activate O 
caspase O 
3 O 
. O 
In O 
general O 
, O 
antiproliferative O 
activity O 
is O 
greatly O 
enhanced O 
by O 
low O 
levels O 
of O 
the O 
glutathione B-TRIVIAL 
synthase O 
inhibitor O 
l-buthionine B-TRIVIAL 
sulfoxime I-TRIVIAL 
. O 
The O 
work O 
illustrates O 
how O 
subtle O 
changes O 
to O 
the O 
design O 
of O 
low O 
- O 
spin O 
d(6) O 
metal O 
complexes O 
can O 
lead O 
to O 
major O 
changes O 
in O 
cellular O 
metabolism O 
and O 
to O 
potent O 
complexes O 
with O 
novel O 
mechanisms O 
of O 
anticancer O 
activity O 
. O 

Cu B-FORMULA 
(I) I-FORMULA 
-niobate O 
semiconductor O 
with O 
a O 
low O 
- O 
temperature O 
, O 
nanoparticle O 
- O 
mediated O 
synthesis O 
. O 

nanoparticle O 
synthetic O 
strategy O 
for O 
the O 
preparation O 
of O 
a O 
new O 
metastable O 
Cu B-FORMULA 
(I) I-FORMULA 
- O 
niobate B-SYSTEMATIC 
is O 
described O 
, O 
and O 
that O 
involves O 
multipored O 
Li₃NbO₄ B-FORMULA 
nanoparticles O 
as O 
a O 
precursor O 
. O 
A O 
hydrothermal O 
reaction O 
of O 
HNbO₃ B-FORMULA 
and O 
LiOH·H₂O B-FORMULA 
in O 
PEG200 B-ABBREVIATION 
and O 
water O 
at O 
∼180 O 
°C O 
yields O 
∼15-40 O 
nm O 
Li₃NbO₄ B-FORMULA 
particles O 
. O 
These O 
particles O 
are O 
subsequently O 
used O 
in O 
a O 
solvothermal O 
copper B-SYSTEMATIC 
(I) I-SYSTEMATIC 
-exchange O 
reaction O 
with O 
excess O 
CuCl B-FORMULA 
at O 
150 O 
°C O 
. O 
Heating O 
these O 
products O 
within O 
the O 
used O 
CuCl B-FORMULA 
flux O 
( O 
mp O 
= O 
430 O 
°C O 
) O 
to O 
450 O 
°C O 
for O 
30 O 
min O 
yields O 
∼4-12 O 
nm O 
Cu₂Nb₈O₂₁ B-FORMULA 
crystalline O 
nanoparticles O 
, O 
and O 
for O 
a O 
heating O 
time O 
of O 
24 O 
h O 
yields O 
μm-sized O 
, O 
rod O 
- O 
shaped O 
crystals O 
. O 
The O 
new O 
structure O 
was O 
characterized O 
by O 
single O 
- O 
crystal O 
X-ray O 
diffraction O 
to O 
have O 
a O 
condensed O 
network O 
consisting O 
of O 
NbO₇ B-FORMULA 
polyhedra O 
and O 
chains O 
of O 
elongated O 
CuO₄ B-FORMULA 
tetrahedra O 
. O 
The O 
compound O 
thermally O 
decomposes O 
starting O 
at O 
∼250 O 
°C O 
and O 
higher O 
temperatures O 
, O 
depending O 
on O 
the O 
particle O 
sizes O 
, O 
owing O 
to O 
the O 
loss O 
of O 
the O 
weakly O 
coordinated O 
Cu B-FORMULA 
(I) I-FORMULA 
cations O 
from O 
the O 
structure O 
and O 
a O 
concurrent O 
disproportionation O 
reaction O 
at O 
its O 
surfaces O 
. O 
Thus O 
, O 
conventional O 
solid O 
- O 
state O 
reactions O 
involving O 
higher O 
temperatures O 
and O 
bulk O 
reagents O 
have O 
proven O 
unsatisfactory O 
for O 
its O 
synthesis O 
. O 
The O 
measured O 
bandgap O 
size O 
is O 
∼1.43-1.65 O 
eV O 
( O 
indirect O 
) O 
and O 
shows O 
a O 
dependence O 
on O 
the O 
particle O 
sizes O 
. O 
Electronic O 
structure O 
calculations O 
based O 
on O 
density O 
functional O 
theory O 
show O 
that O 
the O 
bandgap O 
transition O 
results O 
from O 
the O 
excitation O 
of O 
electrons O 
at O 
the O 
band O 
edges O 
between O 
filled O 
Cu B-FORMULA 
(I) I-FORMULA 
3d¹⁰-orbitals O 
and O 
empty O 
Nb B-FORMULA 
(V) I-FORMULA 
4d⁰-orbitals O 
, O 
respectively O 
. O 
The O 
p- O 
type O 
nature O 
of O 
the O 
Cu₂Nb₈O₂₁ B-FORMULA 
particles O 
was O 
confirmed O 
in O 
photoelectrochemical O 
measurements O 
on O 
polycrystalline O 
films O 
that O 
show O 
a O 
strong O 
photocathodic O 
current O 
under O 
visible O 
- O 
light O 
irradiation O 
in O 
aqueous O 
solutions O 
. O 
These O 
results O 
demonstrate O 
the O 
general O 
utility O 
of O 
reactive O 
nanoscale O 
precursors O 
in O 
the O 
synthetic O 
discovery O 
of O 
new O 
Cu B-FORMULA 
(I) I-FORMULA 
-based O 
semiconducting O 
oxides B-FAMILY 
and O 
which O 
also O 
show O 
promise O 
for O 
use O 
in O 
solar O 
energy O 
conversion O 
applications O 
. O 

- O 
assembled O 
structures O 
of O 
brush O 
block O 
copolymers O 
( O 
BrBCPs O 
) O 
with O 
polylactide B-FAMILY 
( O 
PLA B-ABBREVIATION 
) O 
and O 
polystyrene B-SYSTEMATIC 
( O 
PS O 
) O 
side O 
chains O 
were O 
studied O 
. O 
The O 
polynorbornene B-FAMILY 
-backbone O 
- O 
based O 
BrBCPs O 
containing O 
approximately O 
equal O 
volume O 
fractions O 
of O 
each O 
block O 
self O 
- O 
assembled O 
into O 
highly O 
ordered O 
lamellae O 
with O 
domain O 
spacing O 
ranging O 
from O 
20 O 
to O 
240 O 
nm O 
by O 
varying O 
molecular O 
weight O 
of O 
the O 
backbone O 
in O 
the O 
bulk O 
state O 
, O 
as O 
revealed O 
by O 
small O 
- O 
angle O 
X-ray O 
scattering O 
( O 
SAXS O 
) O 
. O 
The O 
domain O 
size O 
increased O 
approximately O 
linearly O 
with O 
backbone O 
length O 
, O 
which O 
indicated O 
an O 
extended O 
conformation O 
of O 
the O 
backbone O 
in O 
the O 
ordered O 
state O 
. O 
In O 
situ O 
SAXS O 
measurements O 
suggested O 
that O 
the O 
BrBCPs O 
self O 
- O 
assemble O 
with O 
an O 
extremely O 
fast O 
manner O 
which O 
could O 
be O 
attributed O 
to O 
a O 
reduced O 
number O 
of O 
entanglements O 
between O 
chains O 
. O 
The O 
strong O 
segregation O 
theory O 
and O 
Monte O 
Carlo O 
simulation O 
also O 
confirmed O 
this O 
near O 
- O 
linear O 
dependence O 
of O 
the O 
domain O 
spacing O 
on O 
backbone O 
length O 
, O 
rationalizing O 
experimental O 
results O 
. O 

new O 
compounds O 
, O 
(-)-petrosynoic B-MULTIPLE 
acids I-MULTIPLE 
A-D I-MULTIPLE 
( O 
1-4 O 
) O 
, O 
and O 
five O 
known O 
congeners O 
, O 
pellynols B-MULTIPLE 
A I-MULTIPLE 
( I-MULTIPLE 
5 I-MULTIPLE 
) I-MULTIPLE 
, I-MULTIPLE 
C I-MULTIPLE 
( I-MULTIPLE 
6 I-MULTIPLE 
) I-MULTIPLE 
, I-MULTIPLE 
D I-MULTIPLE 
( I-MULTIPLE 
7 I-MULTIPLE 
) I-MULTIPLE 
, I-MULTIPLE 
F I-MULTIPLE 
( I-MULTIPLE 
8 I-MULTIPLE 
) I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
I I-MULTIPLE 
( O 
9 O 
) O 
, O 
were O 
isolated O 
from O 
a O 
Petrosia O 
sp O 
. O 
marine O 
sponge O 
collected O 
in O 
American O 
Samoa O 
. O 
Isolation O 
work O 
was O 
guided O 
by O 
cytotoxicity O 
against O 
human O 
lung O 
cancer O 
cells O 
( O 
H460 O 
) O 
. O 
The O 
structures O 
of O 
the O 
C31-C33 B-FAMILY 
polyacetylenes I-FAMILY 
( O 
1-9 O 
) O 
were O 
determined O 
on O 
the O 
basis O 
of O 
1D- O 
and O 
2D-NMR O 
analysis O 
, O 
mass O 
spectrometry O 
, O 
and O 
comparison O 
of O 
specific O 
rotation O 
values O 
. O 
Compounds O 
1-9 O 
were O 
found O 
to O 
be O 
broadly O 
cytotoxic O 
with O 
limited O 
selectivity O 
for O 
cancer O 
cells O 
, O 
as O 
they O 
were O 
all O 
moderately O 
active O 
against O 
the O 
A2058 O 
( O 
melanoma O 
) O 
, O 
H522-T1 O 
( O 
lung O 
) O 
, O 
and O 
H460 O 
( O 
lung O 
) O 
human O 
cancer O 
cell O 
lines O 
as O 
well O 
as O 
IMR-90 O 
quiescent O 
human O 
fibroblast O 
cells O 
. O 

droplets O 
loaded O 
with O 
surfactant O 
propel O 
themselves O 
with O 
a O 
velocity O 
up O 
to O 
6 O 
mm O 
s(-1) O 
when O 
they O 
are O 
placed O 
in O 
an O 
aqueous O 
phase O 
of O 
NaOH B-FORMULA 
solution O 
or O 
buffer O 
solution O 
. O 
The O 
required O 
driving O 
force O 
for O 
such O 
motion O 
is O 
generated O 
on O 
the O 
interface O 
of O 
the O 
droplets O 
by O 
the O 
change O 
in O 
interfacial O 
tension O 
, O 
due O 
to O 
deprotonation O 
of O 
the O 
surfactant O 
. O 
This O 
force O 
induces O 
Marangoni O 
convection O 
, O 
which O 
gives O 
rise O 
to O 
a O 
circulating O 
flow O 
inside O 
the O 
droplets O 
. O 
The O 
droplets O 
begin O 
to O 
move O 
when O 
the O 
axis O 
of O 
this O 
circulation O 
deviates O 
from O 
the O 
vertical O 
line O 
. O 
This O 
motion O 
depends O 
on O 
the O 
pH O 
condition O 
of O 
the O 
aqueous O 
phase O 
. O 
When O 
the O 
initial O 
value O 
of O 
pH O 
is O 
adjusted O 
such O 
that O 
the O 
pH O 
exceeds O 
the O 
threshold O 
at O 
the O 
equilibrium O 
state O 
, O 
the O 
droplets O 
move O 
spontaneously O 
. O 
It O 
was O 
seen O 
that O 
the O 
droplets O 
were O 
independent O 
of O 
the O 
material O 
of O 
the O 
solid O 
substrates O 
because O 
the O 
droplets O 
were O 
not O 
directly O 
in O 
contact O 
with O 
the O 
surface O 
of O 
the O 
substrate O 
. O 
The O 
condition O 
for O 
the O 
onset O 
of O 
this O 
spontaneous O 
motion O 
was O 
verified O 
by O 
comparing O 
the O 
prediction O 
from O 
the O 
linear O 
stability O 
analysis O 
with O 
experiments O 
. O 
The O 
stability O 
analysis O 
overestimates O 
the O 
value O 
of O 
the O 
driving O 
force O 
, O 
causing O 
instability O 
. O 

polyesters B-FAMILY 
with O 
composition O 
- O 
dependent O 
thermomechanical O 
properties O 
: O 
synthesis O 
and O 
characterization O 
of O 
poly(butylene B-FAMILY 
succinate I-FAMILY 
- I-FAMILY 
co I-FAMILY 
- I-FAMILY 
butylene I-FAMILY 
azelate I-FAMILY 
) I-FAMILY 
. O 

friendly O 
poly(butylenesuccinate-co-butyleneazelate) B-FAMILY 
( O 
P(BS-co-BAz)s B-FAMILY 
) O 
aliphatic B-FAMILY 
copolyesters I-FAMILY 
with O 
composition O 
- O 
dependent O 
thermomechanical O 
properties O 
were O 
synthesized O 
from O 
succinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
SuA B-ABBREVIATION 
) O 
, O 
1,4-butanediol B-SYSTEMATIC 
( O 
BDO B-ABBREVIATION 
) O 
, O 
and O 
dimethylazelate B-SYSTEMATIC 
( O 
DMAz B-ABBREVIATION 
) O 
through O 
a O 
two O 
- O 
step O 
polycondensation O 
reaction O 
. O 
The O 
molar O 
SuA B-ABBREVIATION 
/ O 
AzA B-ABBREVIATION 
ratio O 
was O 
varied O 
from O 
4 O 
: O 
1 O 
to O 
1 O 
: O 
4 O 
, O 
and O 
the O 
chemical O 
structure O 
and O 
molecular O 
characteristics O 
of O 
resulting O 
(co)polyesters B-FAMILY 
were O 
characterized O 
by O 
NMR O 
and O 
SEC O 
, O 
whereas O 
thermal O 
properties O 
and O 
crystallinity O 
were O 
studied O 
by O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
, O 
dynamic O 
mechanical O 
thermal O 
analyses O 
( O 
DMTA O 
) O 
, O 
and O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
. O 
A O 
good O 
agreement O 
between O 
theoretical O 
and O 
experimental O 
SuA B-ABBREVIATION 
/ O 
AzA B-ABBREVIATION 
molar O 
ratios O 
in O 
the O 
copolyesters B-FAMILY 
was O 
achieved O 
, O 
together O 
with O 
the O 
recovery O 
of O 
semicrystalline O 
random O 
copolymers O 
of O 
uniform O 
composition O 
along O 
the O 
chains O 
. O 
NMR O 
, O 
DSC O 
, O 
DMTA O 
, O 
and O 
XRD O 
results O 
show O 
that O 
depending O 
on O 
their O 
composition O 
the O 
P(BS-co-BAz) B-FAMILY 
copolyesters I-FAMILY 
might O 
find O 
applications O 
from O 
elastomers O 
to O 
high O 
- O 
impact O 
thermoplastics O 
. O 

, O 
in O 
vitro O 
evaluation O 
and O 
study O 
of O 
variables O 
on O 
tri O 
- O 
layered O 
gastro O 
- O 
retentive O 
delivery O 
system O 
of O 
diltiazem B-FORMULA 
HCl I-FORMULA 
. O 

Context O 
: O 
Tri O 
- O 
layered O 
floating O 
tablets O 
using O 
only O 
one O 
grade O 
of O 
polyethylene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
PEO B-ABBREVIATION 
) O 
would O 
enable O 
easy O 
manufacturing O 
, O 
reproducibility O 
and O 
controlled O 
release O 
for O 
highly O 
soluble O 
drugs O 
. O 
Objective O 
: O 
To O 
evaluate O 
the O 
potential O 
of O 
PEO B-ABBREVIATION 
as O 
a O 
sole O 
polymer O 
for O 
the O 
controlled O 
release O 
and O 
to O 
study O 
the O 
effect O 
of O 
formulation O 
variables O 
on O 
release O 
and O 
gastric O 
retention O 
of O 
highly O 
soluble O 
Diltiazem B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
DTZ B-ABBREVIATION 
) O 
. O 
Methods O 
: O 
Tablets O 
were O 
compressed O 
with O 
middle O 
layer O 
consisting O 
of O 
drug O 
and O 
polymer O 
while O 
outer O 
layers O 
consisted O 
of O 
polymer O 
with O 
sodium B-SYSTEMATIC 
bicarbonate I-SYSTEMATIC 
. O 
Design O 
of O 
formulation O 
to O 
obtain O 
12 O 
h O 
, O 
zero O 
- O 
order O 
release O 
and O 
rapid O 
floatation O 
was O 
done O 
by O 
varying O 
the O 
grades O 
, O 
quantity O 
of O 
PEO B-ABBREVIATION 
and O 
sodium B-SYSTEMATIC 
bicarbonate I-SYSTEMATIC 
. O 
Dissolution O 
data O 
were O 
fitted O 
in O 
drug O 
release O 
models O 
and O 
swelling O 
/ O 
erosion O 
studies O 
were O 
undertaken O 
to O 
verify O 
the O 
drug O 
release O 
mechanism O 
. O 
Effect O 
of O 
formulation O 
variables O 
and O 
tablet O 
surface O 
morphology O 
using O 
scanning O 
electron O 
microscopy O 
were O 
studied O 
. O 
Results O 
and O 
discussion O 
: O 
The O 
optimized O 
formula O 
passed O 
the O 
criteria O 
of O 
USP O 
dissolution O 
test O 
I O 
and O 
exhibited O 
floating O 
lag O 
- O 
time O 
of O 
3-4 O 
min O 
. O 
Drug O 
release O 
was O 
faster O 
from O 
low O 
molecular O 
weight O 
( O 
MW O 
) O 
PEO B-ABBREVIATION 
as O 
compared O 
to O 
high O 
MW O 
. O 
With O 
an O 
increase O 
in O 
the O 
amount O 
of O 
sodium B-SYSTEMATIC 
bicarbonate I-SYSTEMATIC 
, O 
faster O 
buoyancy O 
was O 
achieved O 
due O 
to O 
the O 
increased O 
CO(2) B-FORMULA 
gas O 
formation O 
. O 
Drug O 
release O 
followed O 
zero O 
- O 
order O 
and O 
gave O 
a O 
good O 
fit O 
to O 
the O 
Korsmeyer-Peppas O 
model O 
, O 
which O 
suggested O 
that O 
drug O 
release O 
was O 
due O 
to O 
diffusion O 
through O 
polymer O 
swelling O 
. O 
Conclusion O 
: O 
Zero O 
- O 
order O 
, O 
controlled O 
release O 
profile O 
with O 
the O 
desired O 
buoyancy O 
can O 
be O 
achieved O 
by O 
using O 
optimum O 
formula O 
quantities O 
of O 
sodium B-SYSTEMATIC 
bicarbonate I-SYSTEMATIC 
and O 
polymer O 
. O 
The O 
tri O 
- O 
layered O 
system O 
shows O 
promising O 
delivery O 
of O 
DTZ B-ABBREVIATION 
, O 
and O 
possibly O 
other O 
water O 
- O 
soluble O 
drugs O 
. O 

: O 
At O 
present O 
, O 
the O 
key O 
public O 
health O 
concern O 
is O 
to O 
define O 
the O 
way O 
in O 
which O 
the O 
next O 
influenza O 
pandemic O 
should O 
be O 
controlled O 
. O 
While O 
influenza O 
vaccines O 
are O 
available O 
, O 
their O 
effectiveness O 
could O 
be O 
significantly O 
reduced O 
if O 
new O 
strains O 
differ O 
significantly O 
from O 
those O 
of O 
the O 
vaccines O 
. O 
Therefore O 
, O 
antiviral O 
drugs O 
play O 
an O 
important O 
role O 
in O 
the O 
prevention O 
and O 
management O 
of O 
influenza O 
. O 
The O 
influenza O 
neuraminidase O 
( O 
nan O 
) O 
, O 
a O 
surface O 
- O 
glycoprotein O 
enzyme O 
involved O 
in O 
releasing O 
the O 
virus O 
from O 
the O 
host O 
cell O 
, O 
has O 
been O 
considered O 
as O 
an O 
essential O 
therapeutic O 
target O 
for O 
treatment O 
and O 
prophylaxis O 
of O 
influenza O 
infection O 
. O 
It O 
is O 
a O 
highly O 
conserved O 
feature O 
of O 
the O 
active O 
site O 
across O 
all O 
influenza O 
A O 
and O 
B O 
viruses O 
and O 
is O 
of O 
particular O 
interest O 
because O 
compounds O 
nan O 
inhibitors O 
( O 
NAIs O 
) O 
can O 
be O 
cross O 
- O 
reactive O 
against O 
multiple O 
types O 
and O 
subtypes O 
of O 
influenza O 
. O 
Currently O 
, O 
there O 
are O 
two O 
NAI O 
drugs O 
which O 
are O 
licensed O 
worldwide O 
: O 
oseltamivir B-TRIVIAL 
and O 
zanamivir B-TRIVIAL 
, O 
and O 
two O 
more O 
drugs O 
which O 
have O 
received O 
recent O 
approval O 
in O 
Japan O 
: O 
peramivir B-TRIVIAL 
and O 
laninamivir B-TRIVIAL 
. O 
Sudden O 
changes O 
in O 
NAI O 
susceptibility O 
have O 
stressed O 
the O 
urgent O 
need O 
in O 
searching O 
for O 
novel O 
inhibitors O 
. O 
AREAS O 
COVERED O 
: O 
In O 
this O 
review O 
, O 
a O 
potential O 
pitfall O 
in O 
nan O 
- O 
based O 
assays O 
and O 
the O 
progress O 
in O 
the O 
chemical O 
synthesis O 
of O 
all O 
patented O 
NAIs O 
from O 
February O 
2006 O 
to O 
July O 
2012 O 
are O 
discussed O 
. O 
EXPERT O 
OPINION O 
: O 
Both O 
nan O 
enzyme O 
inhibition O 
and O 
X-ray O 
crystallography O 
data O 
have O 
suggested O 
that O 
the O 
strategy O 
of O 
designing O 
NAIs O 
binding O 
to O 
the O 
highly O 
conserved O 
region O 
of O 
nan O 
can O 
lead O 
to O 
inhibitors O 
that O 
are O 
effective O 
against O 
all O 
influenza O 
nan O 
subtypes O 
. O 
A O 
number O 
of O 
new O 
synthetic O 
entries O 
having O 
unique O 
structural O 
frameworks O 
that O 
were O 
designed O 
based O 
on O 
computational O 
study O 
of O 
X-ray O 
structures O 
of O 
nan O 
. O 
They O 
strongly O 
exhibited O 
the O 
activity O 
of O 
nan O 
in O 
the O 
low O 
nanomolar O 
range O 
such O 
as O 
phosphonate B-SYSTEMATIC 
congeners O 
of O 
zanamivir B-TRIVIAL 
and O 
oseltarmivir B-TRIVIAL 
. O 
Screening O 
strategies O 
based O 
on O 
the O 
chemical O 
diversity O 
of O 
natural O 
products O 
have O 
revealed O 
that O 
flavonoids B-FAMILY 
are O 
the O 
most O 
prominent O 
scaffolds O 
possessing O 
nan O 
inhibitory O 
activity O 
. O 
However O 
, O 
these O 
substituted O 
phenyl-benzopyrane B-SYSTEMATIC 
compounds O 
have O 
been O 
reported O 
to O 
exert O 
a O 
considerable O 
quenching O 
effect O 
, O 
causing O 
false O 
- O 
positive O 
results O 
in O 
the O 
commonly O 
used O 
method O 
of O 
enzyme O 
- O 
based O 
nan O 
inhibition O 
assays O 
, O 
and O 
thus O 
, O 
reliability O 
of O 
the O 
flavonoid B-FAMILY 
-based O 
NAIs O 
reported O 
in O 
the O 
literature O 
. O 

, O 
plasma O 
and O 
erythrocyte O 
levels O 
of O 
thiamine B-TRIVIAL 
and O 
its O 
phosphate B-FAMILY 
esters I-FAMILY 
in O 
rats O 
with O 
acute O 
ethanol B-SYSTEMATIC 
intoxication O 
: O 
a O 
comparison O 
of O 
thiamine B-TRIVIAL 
and O 
benfotiamine B-TRIVIAL 
administration O 
. O 

and O 
benfotiamine B-TRIVIAL 
are O 
vitamin B-TRIVIAL 
B1 I-TRIVIAL 
and O 
pro B-TRIVIAL 
- I-TRIVIAL 
vitamin I-TRIVIAL 
B1 I-TRIVIAL 
substances O 
, O 
respectively O 
. O 
Vitamin B-TRIVIAL 
B1 I-TRIVIAL 
plays O 
an O 
essential O 
role O 
in O 
energy O 
metabolism O 
, O 
and O 
its O 
deficiency O 
leads O 
to O 
neurologic O 
and O 
cardiovascular O 
pathologies O 
, O 
as O 
seen O 
in O 
alcoholics B-FAMILY 
. O 
This O 
study O 
presents O 
new O 
data O 
about O 
the O 
effects O 
of O 
thiamine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
or O 
benfotiamine B-TRIVIAL 
treatment O 
given O 
to O 
rats O 
with O 
acute O 
alcohol B-FAMILY 
intoxication O 
, O 
on O 
the O 
distribution O 
of O 
thiamine B-TRIVIAL 
and O 
its O 
phosphate B-FAMILY 
esters I-FAMILY 
in O 
liver O 
, O 
plasma O 
and O 
erythrocytes O 
. O 
The O 
treatments O 
were O 
effective O 
in O 
increasing O 
thiamine B-TRIVIAL 
levels O 
in O 
plasma O 
, O 
erythrocytes O 
and O 
liver O 
cells O 
. O 
The O 
benfotiamine B-TRIVIAL 
-treated O 
group O 
had O 
its O 
total O 
plasma O 
thiamine B-TRIVIAL 
increased O 
by O 
100% O 
. O 
In O 
erythrocytes O 
, O 
thiamine B-TRIVIAL 
levels O 
were O 
4- O 
and O 
25-fold O 
higher O 
in O 
the O 
groups O 
treated O 
with O 
thiamine B-TRIVIAL 
and O 
benfotiamine B-TRIVIAL 
, O 
respectively O 
, O 
compared O 
with O 
the O 
untreated O 
groups O 
. O 
Liver O 
thiamine B-TRIVIAL 
was O 
increased O 
by O 
60% O 
in O 
the O 
treated O 
groups O 
compared O 
with O 
the O 
untreated O 
groups O 
. O 
Thus O 
, O 
we O 
verified O 
the O 
high O 
bioavailability O 
especially O 
of O 
benfotiamine B-TRIVIAL 
within O 
6h O 
of O 
ethanol B-SYSTEMATIC 
administration O 
. O 

- O 
term O 
assessment O 
of O 
toxicological O 
aspects O 
, O 
oxidative O 
and O 
inflammatory O 
response O 
to O 
dietary O 
melon O 
superoxide B-TRIVIAL 
dismutase O 
in O 
rats O 
. O 

protective O 
effects O 
of O 
SODB O 
, O 
a O 
gastro O 
- O 
resistant O 
encapsulated O 
melon O 
superoxide B-TRIVIAL 
dismutase O 
, O 
on O 
haematological O 
and O 
biochemical O 
parameters O 
and O 
inflammatory O 
and O 
oxidative O 
status O 
, O 
were O 
evaluated O 
in O 
the O 
blood O 
and O 
liver O 
tissue O 
. O 
The O 
study O 
consisted O 
in O 
a O 
28-day O 
experiment O 
on O 
rats O 
supplemented O 
with O 
three O 
doses O 
( O 
10 O 
, O 
40 O 
and O 
160USOD O 
/ O 
day O 
) O 
of O 
SODB-M O 
, O 
SODB-D O 
or O 
SODB-S O 
, O 
different O 
depending O 
on O 
the O 
nature O 
of O 
the O 
coating O 
( O 
palm O 
oil O 
, O 
shellac O 
or O 
gum O 
Arabic O 
respectively O 
) O 
. O 
No O 
mortality O 
, O 
abnormal O 
clinical O 
signs O 
, O 
behavioural O 
changes O 
or O 
macroscopic O 
findings O 
were O 
observed O 
whatever O 
the O 
groups O 
. O 
Haematological O 
parameters O 
( O 
total O 
red O 
blood O 
cell O 
count O 
, O 
haemoglobin O 
content O 
, O 
haematocrit O 
, O 
red O 
cell O 
indices O 
, O 
white O 
blood O 
cell O 
count O 
and O 
platelets O 
count O 
) O 
were O 
not O 
modified O 
in O 
SODB O 
treated O 
- O 
groups O 
. O 
No O 
marked O 
change O 
was O 
recorded O 
in O 
biochemical O 
parameters O 
( O 
plasma O 
urea B-TRIVIAL 
, O 
creatinine B-TRIVIAL 
, O 
lipids O 
, O 
electrolytes O 
, O 
bilirubin B-TRIVIAL 
, O 
transaminases O 
and O 
gamma-glutamyl B-SYSTEMATIC 
transferase O 
) O 
. O 
The O 
liver O 
endogenous O 
antioxidant O 
enzymes O 
( O 
copper B-SYSTEMATIC 
/ O 
zinc B-SYSTEMATIC 
and O 
manganese B-SYSTEMATIC 
superoxide I-SYSTEMATIC 
dismutase O 
) O 
expressions O 
were O 
significantly O 
increased O 
in O 
the O 
rats O 
receiving O 
the O 
highest O 
dose O 
of O 
SODB O 
( O 
160USOD O 
/ O 
day O 
) O 
whatever O 
the O 
coating O 
. O 
Moreover O 
, O 
interleukin-6 O 
, O 
a O 
marker O 
of O 
inflammation O 
, O 
was O 
significantly O 
decreased O 
in O 
these O 
high O 
dose O 
- O 
treated O 
- O 
groups O 
. O 
The O 
present O 
study O 
indicates O 
that O 
dietary O 
supplementation O 
of O 
SODB O 
on O 
rats O 
has O 
no O 
harmful O 
side O 
effects O 
and O 
could O 
be O 
beneficial O 
especially O 
at O 
high O 
doses O 
. O 

and O 
natural O 
killer O 
cell O 
activity O 
of O 
Korean O 
red O 
ginseng O 
( O 
Panax O 
ginseng O 
) O 
and O 
urushiol B-TRIVIAL 
( O 
Rhus O 
vernicifera O 
Stokes O 
) O 
on O 
non-alcoholic O 
fatty O 
liver O 
disease O 
of O 
rat O 
. O 

and O 
immunologic O 
effects O 
of O 
the O 
Korea O 
red O 
ginseng O 
( O 
KRG O 
; O 
Panax O 
ginseng O 
) O 
and O 
urushiol B-TRIVIAL 
( O 
Rhus O 
vernicifera O 
Stokes O 
) O 
on O 
non-alcoholic O 
fatty O 
liver O 
disease O 
( O 
NAFLD O 
) O 
were O 
evaluated O 
. O 
Forty O 
- O 
five O 
rats O 
( O 
five O 
Long-Evans O 
Tokushima O 
Otsuka O 
and O 
40 O 
Otsuka O 
Long-Evans O 
Tokushima O 
Fatty O 
[ O 
OLETF O 
] O 
rats O 
) O 
received O 
chew O 
diets O 
for O 
10months O 
; O 
after O 
this O 
period O 
. O 
The O 
OLETF O 
rats O 
were O 
divided O 
into O 
the O 
following O 
four O 
groups O 
according O 
to O 
diet O 
for O 
2months O 
: O 
NAFLD O 
( O 
chew O 
) O 
, O 
KRG O 
( O 
chew O 
+ O 
KRG O 
[ O 
200mg O 
/ O 
kg O 
/ O 
day O 
] O 
) O 
, O 
urushiol B-TRIVIAL 
( O 
chew+ O 
urushiol B-TRIVIAL 
[ O 
0.5mg O 
/ O 
kg O 
/ O 
day O 
] O 
) O 
, O 
and O 
ursodeoxycholic B-TRIVIAL 
acid I-TRIVIAL 
( O 
UDCA B-ABBREVIATION 
) O 
( O 
chew+ O 
UDCA B-ABBREVIATION 
[ O 
15mg O 
/ O 
kg O 
/ O 
day O 
] O 
) O 
groups O 
. O 
Liver O 
function O 
, O 
lipid O 
profiles O 
and O 
anti-oxidant O 
activity O 
of O 
liver O 
and O 
serum O 
, O 
natural O 
killer O 
( O 
NK O 
) O 
cell O 
activity O 
, O 
and O 
pathology O 
were O 
compared O 
. O 
In O 
KRG O 
and O 
urushiol B-TRIVIAL 
groups O 
, O 
the O 
level O 
of O 
serum O 
triglyceride B-FAMILY 
( O 
[ O 
302.0±70.4 O 
and O 
275.2±63.8 O 
] O 
vs O 
. O 
527.7±153.3mg O 
/ O 
dL O 
) O 
were O 
lower O 
compared O 
with O 
that O 
of O 
NAFLD O 
group O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
levels O 
of O 
HDL- O 
cholesterol B-TRIVIAL 
( O 
liver O 
tissue O 
: O 
[ O 
4.8±0.2 O 
and O 
4.8±0.5 O 
] O 
vs O 
. O 
4.2±0.2mg O 
/ O 
g O 
) O 
and O 
NK O 
cell O 
activity O 
( O 
[ O 
3485±910 O 
and O 
3559±910 O 
] O 
vs O 
. O 
2486±619 O 
counts O 
) O 
were O 
significantly O 
higher O 
than O 
those O 
of O 
the O 
NAFLD O 
group O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
Inflammation O 
with O 
neutrophil O 
infiltration O 
was O 
observed O 
in O 
only O 
two O 
rats O 
in O 
the O 
NAFLD O 
group O 
. O 
These O 
results O 
suggest O 
that O 
2months O 
of O 
oral O 
KRG O 
or O 
urushiol B-TRIVIAL 
administration O 
improves O 
lipid O 
profiles O 
and O 
stimulates O 
NK O 
cell O 
activity O 
, O 
while O 
inhibiting O 
steatohepatitis O 
in O 
OLEFT O 
rats O 
. O 

and O 
Fas O 
/ O 
FasL O 
pathways O 
are O 
involved O 
in O 
9-Methoxycamptothecin B-SYSTEMATIC 
-induced O 
apoptosis O 
in O 
cancer O 
cells O 
with O 
oxidative O 
stress O 
and O 
G2 O 
/ O 
M O 
cell O 
cycle O 
arrest O 
. O 

( O 
MCPT B-ABBREVIATION 
) O 
has O 
been O 
recently O 
reported O 
to O 
have O 
a O 
strong O 
anticancer O 
activity O 
. O 
However O 
, O 
its O 
detailed O 
mechanism O 
of O 
action O 
in O 
human O 
cancer O 
cells O 
has O 
not O 
been O 
well O 
clarified O 
. O 
The O 
results O 
showed O 
that O 
MCPT B-ABBREVIATION 
induced O 
cytotoxicity O 
in O 
seven O 
human O 
cancer O 
cell O 
lines O 
in O 
a O 
dose O 
dependent O 
manner O 
after O 
72h O 
, O 
with O 
A2780 O 
and O 
Hela O 
cell O 
lines O 
more O 
sensitive O 
, O 
so O 
the O 
two O 
cell O 
lines O 
were O 
chosen O 
to O 
do O 
further O 
studies O 
. O 
MCPT B-ABBREVIATION 
induced O 
strong O 
G2 O 
/ O 
M O 
arrest O 
in O 
both O 
A2780 O 
cells O 
and O 
Hela O 
cells O 
after O 
24h O 
, O 
following O 
by O 
substantial O 
sub-G1 O 
arrest O 
( O 
indicating O 
apoptosis O 
) O 
. O 
The O 
apoptosis O 
was O 
verified O 
by O 
staining O 
with O 
Annexin O 
V- O 
FITC B-ABBREVIATION 
and O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
. O 
ROS O 
generation O 
increased O 
significantly O 
in O 
MCPT B-ABBREVIATION 
-induced O 
apoptosis O 
. O 
Meanwhile O 
, O 
the O 
apoptosis O 
appeared O 
to O 
be O 
dependent O 
on O 
caspase-3 O 
, O 
-8 O 
and O 
-9 O 
in O 
A2780 O 
cells O 
, O 
and O 
caspase-3 O 
in O 
Hela O 
cells O 
. O 
In O 
addition O 
, O 
MCPT B-ABBREVIATION 
induced O 
up O 
- O 
regulation O 
expression O 
of O 
most O 
of O 
seventeen O 
genes O 
in O 
both O 
cell O 
lines O 
. O 
Western O 
blot O 
verified O 
that O 
changes O 
of O 
TNFα O 
, O 
Fas O 
, O 
P53 O 
and O 
P27 O 
protein O 
level O 
were O 
consistent O 
with O 
their O 
gene O 
expression O 
changes O 
. O 
Taken O 
together O 
, O 
MCPT B-ABBREVIATION 
plays O 
an O 
important O 
role O 
in O 
tumor O 
growth O 
suppression O 
by O 
inducing O 
apoptosis O 
in O 
both O 
cell O 
lines O 
via O 
extrinsic O 
and O 
intrinsic O 
apoptotic O 
pathways O 
, O 
and O 
has O 
the O 
potential O 
to O 
be O 
developed O 
into O 
an O 
antitumor O 
agent O 
. O 

dysplasia O 
( O 
DTD O 
) O 
is O 
a O 
chondrodysplasia O 
caused O 
by O 
mutations O 
in O 
the O 
SLC26A2 O 
gene O 
, O 
leading O 
to O 
reduced O 
intracellular O 
sulfate B-SYSTEMATIC 
pool O 
in O 
chondrocytes O 
, O 
osteoblasts O 
and O 
fibroblasts O 
. O 
Hence O 
, O 
proteoglycans O 
are O 
undersulfated O 
in O 
the O 
cartilage O 
and O 
bone O 
of O 
DTD O 
patients O 
. O 
To O 
characterize O 
the O 
bone O 
phenotype O 
of O 
this O 
skeletal O 
dysplasia O 
we O 
used O 
the O 
Slc26a2 O 
knock O 
- O 
in O 
mouse O 
( O 
dtd O 
mouse O 
) O 
, O 
that O 
was O 
previously O 
validated O 
as O 
an O 
animal O 
model O 
of O 
DTD O 
in O 
humans O 
. O 
X-rays O 
, O 
bone O 
densitometry O 
, O 
static O 
and O 
dynamic O 
histomorphometry O 
, O 
and O 
in O 
vitro O 
studies O 
revealed O 
a O 
primary O 
bone O 
defect O 
in O 
the O 
dtd O 
mouse O 
model O 
. O 
We O 
showed O 
in O 
vivo O 
that O 
this O 
primary O 
bone O 
defect O 
in O 
dtd O 
mice O 
is O 
due O 
to O 
decreased O 
bone O 
accrual O 
associated O 
with O 
a O 
decreased O 
trabecular O 
and O 
periosteal O 
appositional O 
rate O 
at O 
the O 
cell O 
level O 
in O 
one O 
month O 
- O 
old O 
mice O 
. O 
Although O 
the O 
osteoclast O 
number O 
evaluated O 
by O 
histomorphometry O 
was O 
not O 
different O 
in O 
dtd O 
compared O 
to O 
wild O 
- O 
type O 
mice O 
, O 
urine O 
analysis O 
of O 
deoxypyridinoline B-SYSTEMATIC 
cross O 
- O 
links O 
and O 
serum O 
levels O 
of O 
type O 
I O 
collagen O 
C B-FORMULA 
-terminal O 
telopeptides O 
showed O 
a O 
higher O 
resorption O 
rate O 
in O 
dtd O 
mice O 
compared O 
to O 
wild O 
- O 
type O 
littermates O 
. O 
Electron O 
microscopy O 
studies O 
showed O 
that O 
collagen O 
fibrils O 
in O 
bone O 
were O 
thinner O 
and O 
less O 
organized O 
in O 
dtd O 
compared O 
to O 
wild O 
- O 
type O 
mice O 
. O 
These O 
data O 
suggest O 
that O 
the O 
low O 
bone O 
mass O 
observed O 
in O 
mutant O 
mice O 
could O 
possibly O 
be O 
linked O 
to O 
the O 
different O 
bone O 
matrix O 
compositions O 
/ O 
organizations O 
in O 
dtd O 
mice O 
triggering O 
changes O 
in O 
osteoblast O 
and O 
osteoclast O 
activities O 
. O 
Overall O 
, O 
these O 
results O 
suggest O 
that O 
proteoglycan O 
undersulfation O 
not O 
only O 
affects O 
the O 
properties O 
of O 
hyaline O 
cartilage O 
, O 
but O 
can O 
also O 
lead O 
to O 
unbalanced O 
bone O 
modeling O 
and O 
remodeling O 
activities O 
, O 
demonstrating O 
the O 
importance O 
of O 
proteoglycan O 
sulfation O 
in O 
bone O 
homeostasis O 
. O 

/ O 
Ref-1 O 
prevents O 
oxidative O 
inactivation O 
of O 
ERK O 
for O 
G1-to-S O 
progression O 
following O 
lead B-SYSTEMATIC 
acetate I-SYSTEMATIC 
exposure O 
. O 

/ O 
apyrimidinic O 
endonuclease O 
1 O 
( O 
APE1 O 
) O 
/ O 
redox O 
effector O 
factor-1 O 
is O 
a O 
multifunctional O 
enzyme O 
involved O 
in O 
DNA O 
base O 
excision O 
repair O 
and O 
protein O 
redox O 
regulation O 
. O 
Previously O 
, O 
we O 
have O 
showed O 
that O 
lead B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
Pb B-FORMULA 
) O 
elicits O 
EGFR O 
activation O 
to O 
initiate O 
the O 
SFK O 
/ O 
PKCα O 
/ O 
Ras O 
/ O 
Raf-1 O 
/ O 
MKK1 O 
/ O 
2 O 
/ O 
ERK O 
signaling O 
cascade O 
functioning O 
against O 
genotoxicity O 
. O 
Here O 
, O 
we O 
explore O 
whether O 
APE1 O 
and O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
affect O 
ERK O 
signaling O 
and O 
cell O 
cycle O 
progression O 
following O 
Pb B-FORMULA 
exposure O 
. O 
We O 
found O 
that O 
Pb B-FORMULA 
induced O 
APE1 O 
expression O 
and O 
ROS O 
generation O 
in O 
CL3 O 
human O 
lung O 
cancer O 
cells O 
. O 
The O 
Pb B-FORMULA 
-elicited O 
ROS O 
levels O 
and O 
cytotoxicity O 
were O 
further O 
enhanced O 
by O 
introducing O 
small O 
interfering O 
RNA O 
specific O 
for O 
APE1 O 
( O 
siAPE1 O 
) O 
. O 
E3330 O 
, O 
an O 
inhibitor O 
of O 
APE1 O 
redox O 
activity O 
, O 
also O 
augmented O 
the O 
ROS O 
levels O 
and O 
cytotoxicity O 
in O 
Pb B-FORMULA 
-treated O 
cells O 
. O 
Intriguingly O 
, O 
the O 
capability O 
of O 
Pb B-FORMULA 
to O 
activate O 
ERK O 
was O 
abolished O 
under O 
siAPE1 O 
or O 
E3330 O 
co O 
- O 
treatments O 
; O 
conversely O 
, O 
forced O 
expression O 
of O 
APE1 O 
up O 
- O 
regulated O 
the O 
ERK O 
activation O 
by O 
Pb B-FORMULA 
or O 
serum O 
in O 
both O 
Cys B-FORMULA 
65-redox O 
activity O 
dependent O 
and O 
independent O 
manners O 
. O 
Moreover O 
, O 
APE1 O 
formed O 
complex O 
with O 
ERK2 O 
, O 
and O 
its O 
redox O 
activity O 
could O 
rescue O 
ERK O 
oxidative O 
inactivation O 
. O 
APE1 O 
redox O 
activity O 
also O 
facilitated O 
the O 
Cyclin O 
D1 O 
expression O 
and O 
G1-to-S O 
progression O 
following O 
Pb B-FORMULA 
exposure O 
. O 
In O 
summary O 
, O 
the O 
results O 
indicate O 
that O 
APE1 O 
is O 
a O 
direct O 
redox O 
regulator O 
of O 
ERK O 
for O 
maintaining O 
the O 
kinase O 
activity O 
to O 
promote O 
cell O 
proliferation O 
. O 

, O 
quantitative O 
structure O 
- O 
activity O 
relationship O 
and O 
biological O 
evaluation O 
of O 
1,3,4-oxadiazole B-SYSTEMATIC 
derivatives O 
possessing O 
diphenylamine B-SYSTEMATIC 
moiety O 
as O 
potential O 
anticancer O 
agents O 
. O 

of O 
2,5- B-FAMILY 
disubstituted-1,3,4-oxadiazole I-FAMILY 
( O 
2a-c O 
) O 
, O 
3- B-FAMILY 
substituted I-FAMILY 
aminomethyl-5 I-FAMILY 
- I-FAMILY 
substituted-1,3,4-oxadiazole-2(3H)-thione I-FAMILY 
( O 
4a-m O 
) O 
and O 
2- B-FAMILY 
substituted I-FAMILY 
thio-5 I-FAMILY 
- I-FAMILY 
substituted-1,3,4-oxadiazole I-FAMILY 
( O 
5a O 
, O 
b O 
) O 
had O 
been O 
described O 
. O 
All O 
the O 
synthesized O 
derivatives O 
were O 
screened O 
for O 
anticancer O 
activity O 
against O 
HT29 O 
and O 
MCF7 O 
cancer O 
cell O 
lines O 
using O 
Sulfo-Rodamine B-TRIVIAL 
B I-TRIVIAL 
( O 
SRB B-ABBREVIATION 
) O 
standard O 
method O 
. O 
Most O 
of O 
the O 
tested O 
compounds O 
exploited O 
potent O 
antiproliferative O 
activity O 
against O 
HT29 O 
cancer O 
cell O 
line O 
rather O 
than O 
MCF7 O 
cancer O 
cell O 
line O 
. O 
Compounds O 
2a-c O 
, O 
4f O 
and O 
5a O 
exhibited O 
potent O 
cytotoxicity O 
( O 
IC(50) O 
1.3-2.0 O 
µM O 
) O 
and O 
selectivity O 
against O 
HT29 O 
cancer O 
cell O 
line O 
. O 
Quantitative O 
structure O 
- O 
activity O 
relationship O 
( O 
QSAR O 
) O 
study O 
was O 
applied O 
to O 
find O 
a O 
correlation O 
between O 
the O 
experimental O 
antiproliferative O 
activities O 
of O 
the O 
newly O 
synthesized O 
oxadiazole B-FAMILY 
derivatives O 
with O 
their O 
physicochemical O 
parameter O 
and O 
topological O 
index O 
. O 

present O 
study O 
systematically O 
and O 
simultaneously O 
investigates O 
the O 
influence O 
of O 
process O 
variables O 
of O 
spray O 
- O 
drying O 
on O 
the O 
properties O 
of O 
solid O 
self O 
- O 
microemulsifying O 
drug O 
delivery O 
system O 
( O 
SMEDDS O 
) O 
using O 
design O 
of O 
experiment O 
( O 
DOE O 
) O 
and O 
optimizes O 
them O 
in O 
order O 
to O 
produce O 
solid-SMEDDS O 
satisfying O 
pre O 
- O 
defined O 
powder O 
quality O 
attributes O 
. O 
Flurbiprofen B-TRIVIAL 
-loaded O 
liquid-SMEDDS O 
was O 
dispersed O 
in O 
dextran O 
and O 
spray O 
- O 
dried O 
. O 
After O 
preliminary O 
screening O 
, O 
the O 
independent O 
factors O 
selected O 
according O 
to O 
three O 
- O 
factor O 
, O 
three O 
- O 
level O 
Box-Behnken O 
design O 
were O 
inlet O 
temperature O 
(X(1)) O 
, O 
feed O 
rate O 
(X(2)) O 
and O 
carrier O 
concentration O 
(X(3)) O 
. O 
The O 
responses O 
used O 
to O 
compute O 
the O 
effects O 
of O 
independent O 
factors O 
were O 
moisture O 
content O 
(Y(1)) O 
, O 
yield O 
(Y(2)) O 
, O 
drug O 
content O 
(Y(3)) O 
and O 
droplet O 
size O 
(Y(4)) O 
of O 
the O 
micro O 
- O 
emulsion O 
. O 
SMEDDS O 
powder O 
characteristics O 
such O 
as O 
morphology O 
, O 
thermal O 
behavior O 
, O 
crystallinity O 
and O 
flowability O 
were O 
also O 
considered O 
. O 
Models O 
were O 
developed O 
and O 
model O 
fitting O 
analysis O 
showed O 
an O 
adequate O 
fit O 
for O 
all O 
responses O 
, O 
indicating O 
good O 
predictability O 
. O 
Significant O 
effects O 
of O 
processing O 
parameters O 
on O 
powder O 
characteristics O 
were O 
observed O 
. O 
The O 
spray O 
- O 
drying O 
process O 
parameters O 
were O 
optimized O 
as O 
inlet O 
temperature O 
( O 
134°C O 
) O 
, O 
feed O 
rate O 
( O 
5% O 
) O 
and O 
carrier O 
concentration O 
( O 
0.6% O 
) O 
to O 
produce O 
solid-SMEDDS O 
with O 
acceptable O 
moisture O 
content O 
( O 
0.72±0.02% O 
) O 
, O 
yield O 
( O 
58.5±2.9% O 
) O 
, O 
drug O 
content O 
( O 
70.1±2.7 O 
mg O 
/ O 
g O 
) O 
and O 
droplet O 
size O 
( O 
166.8±13.8 O 
nm O 
) O 
. O 
Validation O 
of O 
the O 
optimization O 
process O 
in O 
five O 
batches O 
showed O 
experimental O 
value O 
very O 
close O 
to O 
the O 
predicted O 
one O 
, O 
ensuring O 
the O 
reproducibility O 
of O 
the O 
developed O 
models O 
. O 
Furthermore O 
, O 
optimized O 
parameters O 
resulted O 
a O 
highly O 
crystalline O 
flurbiprofen B-TRIVIAL 
changed O 
to O 
an O 
amorphous O 
form O 
. O 
In O 
conclusion O 
, O 
this O 
study O 
demonstrated O 
the O 
applicability O 
of O 
the O 
DOE O 
approach O 
for O 
optimizing O 
the O 
process O 
parameters O 
to O 
manufacture O 
solid-SMEDDS O 
with O 
desired O 
quality O 
attributes O 
. O 

compounds O 
as O 
adult O 
T-cell O 
leukemia O 
cell O 
proliferation O 
inhibitors O 
. O 

forms O 
of O 
adult O 
T-cell O 
leukemia O 
( O 
ATL O 
) O 
respond O 
poorly O 
to O 
conventional O 
anticancer O 
chemotherapy O 
, O 
and O 
new O 
lead O 
compounds O 
are O 
required O 
for O 
the O 
development O 
of O 
drugs O 
to O 
treat O 
this O 
fatal O 
disease O 
. O 
Recently O 
, O 
we O 
developed O 
ATL O 
cell O 
- O 
selective O 
proliferation O 
inhibitors O 
based O 
on O 
a O 
tetrahydrotetramethylnaphthalene B-SYSTEMATIC 
( O 
TMN B-ABBREVIATION 
) O 
skeleton O 
1 O 
, O 
and O 
here O 
we O 
report O 
the O 
design O 
and O 
synthesis O 
of O 
silicon B-SYSTEMATIC 
analogs O 
of O 
TMN B-ABBREVIATION 
derivatives O 
. O 
Among O 
them O 
, O 
compound O 
13 O 
showed O 
the O 
most O 
potent O 
growth O 
- O 
inhibitory O 
activity O 
towards O 
the O 
ATL O 
cell O 
line O 
S1T O 
, O 
though O 
its O 
selectivity O 
for O 
S1T O 
over O 
the O 
non-ATL O 
cell O 
line O 
MOLT-4 O 
was O 
only O 
moderate O 
. O 
This O 
result O 
, O 
as O 
well O 
as O 
computational O 
studies O 
, O 
suggests O 
that O 
sila O 
- O 
substitution O 
( O 
C B-FORMULA 
/ O 
Si B-FORMULA 
exchange O 
) O 
is O 
useful O 
for O 
structure O 
optimization O 
of O 
these O 
inhibitors O 
. O 

anomalous O 
stability O 
of O 
magic O 
- O 
number O 
metal O 
clusters O 
has O 
been O 
associated O 
with O 
closed O 
geometric O 
and O 
electronic O 
shells O 
and O 
the O 
opening O 
of O 
HOMO-LUMO O 
gaps O 
. O 
Despite O 
this O 
enhanced O 
stability O 
, O 
magic O 
- O 
number O 
clusters O 
are O 
known O 
to O 
decay O 
and O 
react O 
in O 
the O 
condensed O 
phase O 
to O 
form O 
other O 
products O 
. O 
Improving O 
our O 
understanding O 
of O 
their O 
decay O 
mechanisms O 
and O 
developing O 
strategies O 
to O 
control O 
or O 
eliminate O 
cluster O 
instability O 
is O 
a O 
priority O 
, O 
to O 
develop O 
a O 
more O 
complete O 
theory O 
of O 
their O 
stability O 
, O 
to O 
avoid O 
studying O 
mixtures O 
of O 
clusters O 
produced O 
by O 
the O 
decay O 
of O 
purified O 
materials O 
, O 
and O 
to O 
enable O 
technology O 
development O 
. O 
Silver B-SYSTEMATIC 
clusters O 
are O 
sufficiently O 
reactive O 
to O 
facilitate O 
the O 
study O 
of O 
the O 
ambient O 
temporal O 
stability O 
of O 
magic O 
- O 
number O 
metal O 
clusters O 
and O 
to O 
begin O 
to O 
understand O 
their O 
decay O 
mechanisms O 
. O 
Here O 
, O 
the O 
solution O 
phase O 
stability O 
of O 
a O 
series O 
of O 
silver B-SYSTEMATIC 
: O 
glutathione B-TRIVIAL 
( O 
Ag B-FORMULA 
: O 
SG O 
) O 
clusters O 
was O 
studied O 
as O 
a O 
function O 
of O 
size O 
, O 
pH O 
and O 
chemical O 
environment O 
. O 
Cluster O 
stability O 
was O 
found O 
to O 
be O 
a O 
non-monotonic O 
function O 
of O 
size O 
. O 
Electrophoretic O 
separations O 
showed O 
that O 
the O 
dominant O 
mechanism O 
involved O 
the O 
redistribution O 
of O 
mass O 
toward O 
smaller O 
sizes O 
, O 
where O 
the O 
products O 
were O 
almost O 
exclusively O 
previously O 
known O 
cluster O 
sizes O 
. O 
Optical O 
absorption O 
spectra O 
showed O 
that O 
the O 
smaller O 
clusters O 
evolved O 
toward O 
the O 
two O 
most O 
stable O 
cluster O 
sizes O 
. O 
The O 
net O 
surface O 
charge O 
was O 
found O 
to O 
play O 
an O 
important O 
role O 
in O 
cluster O 
stabilization O 
although O 
charge O 
screening O 
had O 
no O 
effect O 
on O 
stability O 
, O 
contrary O 
to O 
DLVO O 
theory O 
. O 
The O 
decay O 
mechanism O 
was O 
found O 
to O 
involve O 
the O 
loss O 
of O 
Ag(+) B-FORMULA 
ions O 
and O 
silver B-FAMILY 
glutathionates I-FAMILY 
. O 
Clusters O 
could O 
be O 
stabilized O 
by O 
the O 
addition O 
of O 
Ag(+) B-FORMULA 
ions O 
and O 
destabilized O 
by O 
either O 
the O 
addition O 
of O 
glutathione B-TRIVIAL 
or O 
the O 
removal O 
of O 
Ag(+) B-FORMULA 
ions O 
. O 
Clusters O 
were O 
also O 
found O 
to O 
be O 
most O 
stable O 
in O 
near O 
neutral O 
pH O 
, O 
where O 
they O 
had O 
a O 
net O 
negative O 
surface O 
charge O 
. O 
These O 
results O 
provide O 
new O 
mechanistic O 
insights O 
into O 
the O 
control O 
of O 
post O 
- O 
synthesis O 
stability O 
and O 
chemical O 
decay O 
of O 
magic O 
- O 
number O 
metal O 
clusters O 
, O 
which O 
could O 
be O 
used O 
to O 
develop O 
design O 
principles O 
for O 
synthesizing O 
specific O 
cluster O 
species O 
. O 

role O 
of O 
cortisol B-TRIVIAL 
and O 
psychopathy O 
in O 
the O 
cycle O 
of O 
violence O 
. O 

: O 
Child O 
abuse O 
and O 
neglect O 
are O 
universal O 
risk O 
factors O 
for O 
delinquency O 
, O 
violence O 
, O 
and O 
aggression O 
; O 
this O 
phenomenon O 
is O 
known O 
as O 
the O 
cycle O 
of O 
violence O 
. O 
Additional O 
factors O 
- O 
psychopathy O 
, O 
impulsiveness O 
, O 
and O 
disruptions O 
in O 
the O 
hypothalamic O 
- O 
pituitary O 
- O 
adrenal O 
( O 
HPA O 
) O 
axis O 
- O 
play O 
a O 
role O 
in O 
aggressive O 
behavior O 
but O 
have O 
rarely O 
been O 
examined O 
in O 
the O 
same O 
conceptual O 
and O 
experimental O 
framework O 
. O 
OBJECTIVES O 
: O 
We O 
sought O 
to O 
examine O 
the O 
above O 
- O 
mentioned O 
risk O 
factors O 
for O 
aggression O 
in O 
a O 
prospective O 
study O 
employing O 
psychopharmacologic O 
and O 
psychometric O 
techniques O 
. O 
METHODS O 
: O 
Sixty O 
- O 
seven O 
adult O 
participants O 
were O 
given O 
an O 
acute O 
dose O 
of O 
20 O 
mg O 
cortisol B-TRIVIAL 
in O 
a O 
placebo O 
- O 
controlled O 
, O 
within O 
- O 
subject O 
, O 
counter O 
- O 
balanced O 
dosing O 
design O 
. O 
Salivary O 
cortisol B-TRIVIAL 
was O 
measured O 
at O 
baseline O 
and O 
at O 
regular O 
intervals O 
across O 
a O 
5 O 
h O 
testing O 
period O 
. O 
Following O 
dosing O 
, O 
state O 
- O 
aggressive O 
behavior O 
was O 
measured O 
by O 
a O 
laboratory O 
task O 
, O 
the O 
Point-Subtraction O 
Aggression O 
Paradigm O 
. O 
History O 
of O 
child O 
abuse O 
/ O 
neglect O 
, O 
psychopathy O 
, O 
impulsivity O 
, O 
and O 
a O 
trait O 
measure O 
of O 
aggression O 
were O 
assessed O 
through O 
self O 
- O 
report O 
questionnaires O 
. O 
RESULTS O 
: O 
Using O 
multiple O 
regression O 
, O 
a O 
model O 
including O 
abuse O 
/ O 
neglect O 
, O 
psychopathy O 
, O 
impulsivity O 
, O 
and O 
baseline O 
cortisol B-TRIVIAL 
explained O 
58 O 
% O 
of O 
the O 
variance O 
in O 
trait O 
aggression O 
and O 
26 O 
% O 
of O 
the O 
variance O 
in O 
state O 
aggression O 
. O 
Abuse O 
/ O 
neglect O 
predicted O 
diminished O 
HPA-axis O 
reactivity O 
and O 
HPA-axis O 
reactivity O 
showed O 
a O 
trend O 
toward O 
predicting O 
state O 
and O 
trait O 
aggression O 
, O 
although O 
it O 
was O 
not O 
a O 
significant O 
mediating O 
variable O 
between O 
abuse O 
/ O 
neglect O 
and O 
aggression O 
. O 
CONCLUSIONS O 
: O 
The O 
results O 
indicate O 
that O 
child O 
maltreatment O 
, O 
psychopathy O 
and O 
HPA-axis O 
reactivity O 
interact O 
to O 
provide O 
a O 
confluence O 
over O 
aggressive O 
behavior O 
, O 
and O 
intervention O 
efforts O 
need O 
to O 
consider O 
all O 
these O 
factors O 
. O 

Facile O 
Synthesis O 
of O 
Double-Shelled O 
SnO2 B-FORMULA 
Yolk-Shell-Structured O 
Powders O 
by O 
Continuous O 
Process O 
as O 
Anode O 
Materials O 
for O 
Li B-FORMULA 
-ion O 
Batteries O 
. O 

- O 
shelled O 
SnO2 B-FORMULA 
yolk O 
- O 
shell O 
- O 
structured O 
powders O 
are O 
prepared O 
by O 
applying O 
a O 
new O 
facile O 
one O 
- O 
pot O 
process O 
. O 
Carbon B-SYSTEMATIC 
- O 
SnO2 B-FORMULA 
composite O 
powder O 
particles O 
are O 
first O 
formed O 
as O 
an O 
intermediate O 
product O 
inside O 
a O 
tubular O 
reactor O 
. O 
Step O 
- O 
by O 
- O 
step O 
combustion O 
of O 
carbon B-SYSTEMATIC 
from O 
outside O 
the O 
composite O 
powder O 
particles O 
forms O 
the O 
double O 
- O 
shelled O 
SnO2 B-FORMULA 
yolk O 
- O 
shell O 
- O 
structured O 
powder O 
particles O 
. O 
The O 
SnO2 B-FORMULA 
yolk O 
- O 
shell O 
- O 
structured O 
powders O 
show O 
excellent O 
electrochemical O 
properties O 
. O 

SENSOR O 
TRIO O 
: O 
Fluorogenic O 
DNA O 
sensors O 
were O 
developed O 
for O 
distinct O 
classes O 
of O 
nucleases O 
: O 
3'-exonucleases O 
, O 
5'-exonucleases O 
, O 
and O 
endonucleases O 
. O 
The O 
highly O 
selective O 
sensors O 
, O 
built O 
from O 
very O 
small O 
modified O 
DNA O 
oligomers O 
containing O 
the O 
unnatural O 
fluorescent O 
base O 
pyrene B-SYSTEMATIC 
, O 
and O 
employing O 
thymine B-TRIVIAL 
as O 
a O 
quencher O 
, O 
were O 
found O 
to O 
function O 
in O 
a O 
variety O 
of O 
complex O 
biological O 
media O 
. O 

supplementation O 
protects O 
against O 
diet O 
- O 
induced O 
diabetes O 
in O 
wild O 
type O 
mice O 
by O 
enhancing O 
insulin O 
secretion O 
. O 

dysfunction O 
is O 
both O 
a O 
contributing O 
mechanism O 
and O 
complication O 
of O 
diabetes O 
, O 
and O 
oxidative O 
stress O 
contributes O 
to O 
that O 
dysfunction O 
. O 
Mitochondrial O 
manganese B-SYSTEMATIC 
- O 
superoxide B-TRIVIAL 
dismutase O 
( O 
MnSOD O 
) O 
is O 
a O 
metalloenzyme O 
that O 
provides O 
antioxidant O 
protection O 
. O 
We O 
have O 
previously O 
shown O 
in O 
a O 
mouse O 
model O 
of O 
hereditary O 
iron O 
overload O 
that O 
cytosolic O 
iron B-SYSTEMATIC 
levels O 
affected O 
mitochondrial O 
manganese B-SYSTEMATIC 
availability O 
, O 
Mn B-FORMULA 
SOD O 
activity O 
, O 
and O 
insulin O 
secretion O 
. O 
We O 
therefore O 
sought O 
to O 
determine O 
the O 
metallation O 
status O 
of O 
Mn B-FORMULA 
SOD O 
in O 
wild O 
- O 
type O 
mice O 
and O 
whether O 
altering O 
that O 
status O 
affected O 
β-cell O 
function O 
. O 
129 O 
/ O 
SvEVTac O 
mice O 
given O 
supplemental O 
manganese O 
exhibited O 
a O 
73% O 
increase O 
in O 
hepatic O 
Mn B-FORMULA 
SOD O 
activity O 
and O 
increased O 
metallation O 
of O 
Mn B-FORMULA 
SOD O 
. O 
To O 
determine O 
whether O 
manganese O 
supplementation O 
offered O 
glucose B-TRIVIAL 
homeostasis O 
under O 
a O 
situation O 
of O 
β-cell O 
stress O 
, O 
we O 
challenged O 
C57BL O 
/ O 
6J O 
mice O 
, O 
which O 
are O 
more O 
susceptible O 
to O 
diet O 
- O 
induced O 
diabetes O 
, O 
with O 
a O 
high O 
- O 
fat O 
diet O 
for O 
12 O 
weeks O 
. O 
Manganese B-SYSTEMATIC 
was O 
supplemented O 
or O 
not O 
for O 
the O 
final O 
8 O 
weeks O 
on O 
that O 
diet O 
, O 
after O 
which O 
we O 
examined O 
glucose B-TRIVIAL 
tolerance O 
and O 
the O 
function O 
of O 
isolated O 
islets O 
. O 
Liver O 
mitochondria O 
from O 
manganese B-SYSTEMATIC 
-injected O 
C57BL O 
/ O 
6J O 
mice O 
had O 
similar O 
increases O 
in O 
Mn B-FORMULA 
SOD O 
activity O 
( O 
81% O 
) O 
and O 
metallation O 
as O 
were O 
seen O 
in O 
129 O 
/ O 
SvEVTac O 
mice O 
. O 
The O 
manganese B-SYSTEMATIC 
-treated O 
group O 
fed O 
high O 
fat O 
had O 
improved O 
glucose B-TRIVIAL 
tolerance O 
( O 
24% O 
decrease O 
in O 
fasting O 
glucose B-TRIVIAL 
and O 
41% O 
decrease O 
in O 
area O 
under O 
the O 
glucose B-TRIVIAL 
curve O 
) O 
, O 
comparable O 
with O 
mice O 
on O 
normal O 
chow O 
and O 
increased O 
serum O 
insulin O 
levels O 
. O 
Isolated O 
islets O 
from O 
the O 
manganese B-SYSTEMATIC 
-treated O 
group O 
exhibited O 
improved O 
insulin O 
secretion O 
, O 
decreased O 
lipid O 
peroxidation O 
, O 
and O 
improved O 
mitochondrial O 
function O 
. O 
In O 
conclusion O 
, O 
Mn B-FORMULA 
SOD O 
metallation O 
and O 
activity O 
can O 
be O 
augmented O 
with O 
manganese B-SYSTEMATIC 
supplementation O 
in O 
normal O 
mice O 
on O 
normal O 
chow O 
, O 
and O 
manganese B-SYSTEMATIC 
treatment O 
can O 
increase O 
insulin O 
secretion O 
to O 
improve O 
glucose B-TRIVIAL 
tolerance O 
under O 
conditions O 
of O 
dietary O 
stress O 
. O 

simple O 
and O 
sensitive O 
method O 
for O 
determination O 
of O 
vitamins B-MULTIPLE 
D(3) I-MULTIPLE 
and I-MULTIPLE 
K(1) I-MULTIPLE 
in O 
rat O 
plasma O 
: O 
application O 
for O 
an O 
in O 
vivo O 
pharmacokinetic O 
study O 
. O 

Purpose O 
: O 
To O 
develop O 
and O 
to O 
validate O 
a O 
simple O 
but O 
sensitive O 
method O 
for O 
determination O 
of O 
vitamins B-MULTIPLE 
D(3) I-MULTIPLE 
and I-MULTIPLE 
K(1) I-MULTIPLE 
in O 
rat O 
plasma O 
. O 
Methods O 
: O 
The O 
sample O 
treatment O 
included O 
protein O 
precipitation O 
by O 
cold O 
acetonitrile B-SYSTEMATIC 
, O 
evaporation O 
, O 
reconstitution O 
with O 
methanol B-SYSTEMATIC 
and O 
filtration O 
. O 
The O 
chromatography O 
conditions O 
included O 
Xterra O 
RP18 O 
3.5 O 
µm O 
4.6 O 
× O 
100 O 
mm O 
column O 
at O 
ambient O 
temperature O 
and O 
mobile O 
phase O 
consisting O 
of O 
methanol B-SYSTEMATIC 
/ O 
water O 
( O 
93 O 
/ O 
7 O 
, O 
v O 
/ O 
v O 
) O 
at O 
0.5 O 
mL O 
/ O 
min O 
flow O 
rate O 
. O 
Vitamin B-TRIVIAL 
D(3) I-TRIVIAL 
and O 
probucol B-TRIVIAL 
were O 
detected O 
at O 
265 O 
nm O 
and O 
vitamin B-TRIVIAL 
K(1) I-TRIVIAL 
at O 
239 O 
nm O 
. O 
Rats O 
were O 
administered O 
intravenously O 
by O 
0.1 O 
mg O 
/ O 
kg O 
of O 
vitamin B-MULTIPLE 
D(3) I-MULTIPLE 
or I-MULTIPLE 
K(1) I-MULTIPLE 
and O 
the O 
blood O 
samples O 
were O 
withdrawn O 
pre O 
- O 
administration O 
and O 
at O 
pre O 
- O 
determined O 
time O 
points O 
post O 
- O 
administration O 
. O 
The O 
pharmacokinetic O 
analysis O 
was O 
performed O 
using O 
a O 
non-compartmental O 
approach O 
. O 
Results O 
: O 
The O 
calibration O 
curves O 
in O 
rat O 
plasma O 
were O 
linear O 
up O 
to O 
5000 O 
ng O 
/ O 
mL O 
for O 
both O 
vitamins B-FAMILY 
. O 
The O 
limit O 
of O 
quantification O 
( O 
LOQ O 
) O 
was O 
20 O 
ng O 
/ O 
mL O 
for O 
vitamin B-TRIVIAL 
D(3) I-TRIVIAL 
and O 
40 O 
ng O 
/ O 
mL O 
for O 
K(1) O 
. O 
Inter- O 
and O 
intra O 
- O 
day O 
precision O 
and O 
accuracy O 
were O 
below O 
15% O 
. O 
The O 
pharmacokinetic O 
parameters O 
of O 
vitamin B-TRIVIAL 
D(3) I-TRIVIAL 
following O 
intravenous O 
administration O 
were O 
: O 
AUC(0-∞) O 
= O 
11323 O 
± O 
1081 O 
h O 
× O 
ng O 
/ O 
mL O 
, O 
V(d) O 
= O 
218 O 
± O 
80 O 
mL O 
/ O 
kg O 
, O 
CL O 
= O 
8.9 O 
± O 
0.8 O 
mL O 
/ O 
h O 
/ O 
kg O 
, O 
t(1 O 
/ O 
2) O 
= O 
16.8 O 
± O 
5 O 
h O 
; O 
and O 
of O 
vitamin B-TRIVIAL 
K(1) I-TRIVIAL 
: O 
AUC(0-∞) O 
= O 
2495 O 
± O 
297 O 
h O 
× O 
ng O 
/ O 
mL O 
, O 
V(d) O 
= O 
60 O 
±24 O 
mL O 
/ O 
kg O 
, O 
CL O 
= O 
40.5 O 
± O 
5.1 O 
mL O 
/ O 
h O 
/ O 
kg O 
, O 
t(1 O 
/ O 
2) O 
= O 
1.1 O 
±0.5 O 
h O 
. O 
Conclusion O 
: O 
The O 
developed O 
HPLC-UV O 
assay O 
is O 
a O 
simple O 
and O 
sensitive O 
method O 
for O 
the O 
determination O 
of O 
vitamins B-MULTIPLE 
D(3) I-MULTIPLE 
and I-MULTIPLE 
K(1) I-MULTIPLE 
in O 
rat O 
plasma O 
. O 
A O 
higher O 
dose O 
of O 
vitamin B-TRIVIAL 
K(1) I-TRIVIAL 
should O 
be O 
used O 
in O 
future O 
studies O 
for O 
accurate O 
estimation O 
of O 
pharmacokinetic O 
parameters O 
. O 
The O 
data O 
show O 
the O 
suitability O 
of O 
the O 
assay O 
for O 
pharmacokinetic O 
studies O 
in O 
rats O 
. O 

microparticles O 
are O 
extensively O 
used O 
in O 
the O 
purification O 
of O 
biomolecules O 
due O 
to O 
the O 
speed O 
and O 
ease O 
of O 
magnetic O 
separation O 
. O 
It O 
is O 
desirable O 
that O 
the O 
microparticles O 
used O 
in O 
biological O 
affinity O 
separations O 
have O 
both O 
high O 
surface O 
area O 
and O 
high O 
magnetic O 
mobility O 
to O 
facilitate O 
a O 
high O 
binding O 
capacity O 
of O 
target O 
biomolecules O 
and O 
their O 
rapid O 
removal O 
from O 
solution O 
, O 
respectively O 
. O 
Scaling O 
laws O 
for O 
conventional O 
spherical O 
superparamagnetic O 
microparticles O 
are O 
such O 
that O 
increasing O 
the O 
microparticle O 
specific O 
surface O 
area O 
results O 
in O 
a O 
significant O 
decrease O 
in O 
the O 
magnetic O 
mobility O 
. O 
More O 
favorable O 
combinations O 
of O 
these O 
key O 
parameters O 
can O 
be O 
found O 
if O 
alternative O 
microparticle O 
morphologies O 
are O 
developed O 
for O 
use O 
in O 
affinity O 
separations O 
. O 
Emulsion O 
- O 
templated O 
self O 
- O 
assembly O 
of O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
into O 
microparticles O 
using O 
oil O 
- O 
in O 
- O 
water O 
emulsions O 
was O 
carried O 
out O 
using O 
a O 
modified O 
Couette O 
shear O 
mixer O 
with O 
separate O 
inlet O 
ports O 
for O 
the O 
oil O 
and O 
aqueous O 
phases O 
, O 
enabling O 
high O 
throughput O 
microparticle O 
synthesis O 
. O 
By O 
controlling O 
the O 
dissolved O 
nanoparticle O 
concentration O 
and O 
nanoparticle O 
surface O 
activity O 
at O 
the O 
droplet O 
interfaces O 
, O 
the O 
resulting O 
microparticles O 
were O 
tuned O 
to O 
spherical O 
, O 
dimpled O 
, O 
or O 
crumpled O 
morphologies O 
. O 
The O 
specific O 
binding O 
capacity O 
and O 
magnetic O 
mobility O 
of O 
each O 
type O 
of O 
microparticle O 
were O 
measured O 
by O 
a O 
peroxidase O 
- O 
based O 
colorimetric O 
assay O 
and O 
by O 
their O 
magnetic O 
field O 
- O 
induced O 
motion O 
in O 
a O 
viscous O 
fluid O 
, O 
respectively O 
. O 
Superparamagnetic O 
microparticles O 
with O 
dimpled O 
and O 
crumpled O 
morphologies O 
were O 
found O 
to O 
have O 
higher O 
specific O 
binding O 
capacities O 
compared O 
to O 
spherical O 
microparticles O 
, O 
while O 
maintaining O 
high O 
magnetic O 
field O 
velocities O 
due O 
to O 
their O 
high O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
content O 
. O 
Superparamagnetic O 
microparticles O 
with O 
these O 
novel O 
morphologies O 
would O 
make O 
excellent O 
tools O 
for O 
affinity O 
- O 
based O 
bioseparations O 
where O 
binding O 
capacity O 
and O 
magnetic O 
mobility O 
are O 
key O 
factors O 
. O 

of O 
astatine B-SYSTEMATIC 
(III) I-SYSTEMATIC 
hydrolyzed O 
species O 
: O 
experiments O 
and O 
relativistic O 
calculations O 
. O 

work O 
aims O 
to O 
resolve O 
some O 
controversies O 
about O 
astatine B-SYSTEMATIC 
(III) I-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
species O 
present O 
in O 
oxidant O 
aqueous O 
solution O 
. O 
AtO(+) B-FORMULA 
is O 
the O 
dominant O 
species O 
existing O 
under O 
oxidizing O 
and O 
acidic O 
pH O 
conditions O 
. O 
This O 
is O 
consistent O 
with O 
high O 
- O 
performance O 
ion O 
- O 
exchange O 
chromatography O 
data O 
showing O 
the O 
existence O 
of O 
one O 
species O 
holding O 
one O 
positive O 
charge O 
. O 
A O 
change O 
in O 
speciation O 
occurs O 
as O 
the O 
pH O 
changes O 
from O 
1 O 
to O 
4 O 
, O 
while O 
remaining O 
under O 
oxidizing O 
conditions O 
. O 
Dynamic O 
experiments O 
with O 
ion O 
- O 
exchange O 
resins O 
evidence O 
the O 
existence O 
of O 
a O 
neutral O 
species O 
witnessed O 
by O 
its O 
elution O 
in O 
the O 
void O 
volume O 
. O 
Batch O 
- O 
experiments O 
using O 
a O 
competition O 
method O 
show O 
the O 
exchange O 
of O 
one O 
proton O 
indicating O 
the O 
formation O 
of O 
the O 
AtO(OH) B-FORMULA 
species O 
. O 
The O 
hydrolysis O 
thermodynamic O 
constant O 
, O 
extrapolated O 
to O 
zero O 
ionic O 
strength O 
, O 
was O 
determined O 
to O 
be O 
10(-1.9) O 
. O 
This O 
value O 
is O 
supported O 
by O 
two O 
- O 
component O 
relativistic O 
quantum O 
calculations O 
and O 
therefore O 
allows O 
disclosing O 
unambiguously O 
the O 
structure O 
of O 
the O 
formed O 
species O 
. O 

specificity O 
of O 
polymer O 
conjugates O 
based O 
on O 
N-(2-hydroxypropyl)methacrylamide B-SYSTEMATIC 
( O 
HPMA B-ABBREVIATION 
) O 
bearing O 
cytostatic O 
drugs O 
for O 
cancer O 
cells O 
could O 
be O 
significantly O 
increased O 
by O 
the O 
incorporation O 
of O 
a O 
suitable O 
targeting O 
ligand O 
, O 
such O 
as O 
a O 
monoclonal O 
antibody O 
( O 
mAb O 
) O 
. O 
However O 
, O 
direct O 
binding O 
of O 
the O 
protein O 
to O 
the O 
polymer O 
carrier O 
could O 
cause O 
considerable O 
problems O 
, O 
such O 
as O 
decreasing O 
the O 
binding O 
capacity O 
of O 
mAb O 
to O 
its O 
target O 
. O 
Here O 
, O 
we O 
introduce O 
a O 
novel O 
strategy O 
of O 
joining O 
a O 
targeting O 
moiety O 
to O 
a O 
polymeric O 
conjugate O 
with O 
cytostatic O 
drug O 
. O 
The O 
scFv O 
of O 
B1 O 
mAb O 
( O 
specific O 
for O 
BCL1 O 
leukemia O 
cells O 
) O 
was O 
tagged O 
with O 
peptide O 
K O 
( O 
(VAALKEK)4 O 
) O 
. O 
Peptide O 
E O 
( O 
(VAALEKE)4 O 
) O 
, O 
which O 
forms O 
a O 
stable O 
coiled O 
coil O 
structure O 
heterodimer O 
with O 
peptide O 
K O 
, O 
was O 
assembled O 
with O 
the O 
HPMA B-ABBREVIATION 
copolymers O 
bearing O 
doxorubicin B-TRIVIAL 
. O 
Such O 
targeted O 
polymeric O 
conjugates O 
possess O 
very O 
selective O 
and O 
high O 
binding O 
activity O 
toward O 
BCL1 O 
cells O 
. O 
Similarly O 
, O 
targeted O 
polymeric O 
conjugates O 
exert O 
approximately O 
100 O 
times O 
higher O 
cytostatic O 
activity O 
toward O 
BCL1 O 
cells O 
in O 
comparison O 
to O 
nontargeted O 
conjugates O 
in O 
vitro O 
. O 
At O 
the O 
same O 
time O 
, O 
the O 
conjugates O 
have O 
comparable O 
and O 
rather O 
low O 
cytostatic O 
activity O 
for O 
38C13 O 
cells O 
, O 
which O 
are O 
used O 
as O 
a O 
negative O 
control O 
, O 
in O 
vitro O 
. O 

D2 O 
receptor O 
activation O 
leads O 
to O 
an O 
up O 
- O 
regulation O 
of O 
glial O 
cell O 
line O 
- O 
derived O 
neurotrophic O 
factor O 
via O 
Gβγ-Erk1 O 
/ O 
2-dependent O 
induction O 
of O 
Zif268 O 
. O 

cell O 
line O 
- O 
derived O 
neurotrophic O 
factor O 
( O 
GDNF O 
) O 
is O 
a O 
potent O 
growth O 
factor O 
essential O 
to O 
the O 
development O 
, O 
survival O 
, O 
and O 
function O 
of O 
dopaminergic O 
neurons O 
( O 
Airaksinen O 
and O 
Saarma O 
2002 O 
) O 
. O 
The O 
molecular O 
mechanisms O 
underlying O 
GDNF O 
expression O 
remain O 
elusive O 
; O 
thus O 
, O 
we O 
set O 
out O 
to O 
identify O 
a O 
signaling O 
pathway O 
that O 
governs O 
GDNF O 
levels O 
. O 
We O 
found O 
that O 
treatment O 
of O 
both O 
differentiated O 
dopaminergic O 
- O 
like O 
SH-SY5Y O 
cells O 
and O 
rat O 
midbrain O 
slices O 
with O 
the O 
dopamine B-TRIVIAL 
D2 O 
receptor O 
( O 
D2R O 
) O 
agonist O 
, O 
quinpirole B-TRIVIAL 
, O 
triggered O 
an O 
increase O 
in O 
the O 
expression O 
of O 
GDNF O 
that O 
was O 
temporally O 
preceded O 
by O 
an O 
increase O 
in O 
the O 
levels O 
of O 
zinc B-SYSTEMATIC 
-finger O 
protein O 
268 O 
( O 
Zif268 O 
) O 
, O 
a O 
DNA O 
- O 
binding O 
transcription O 
factor O 
encoded O 
by O 
an O 
immediate O 
- O 
early O 
gene O 
. O 
Moreover O 
, O 
the O 
D2R O 
inhibitor O 
raclopride B-TRIVIAL 
blocked O 
the O 
increase O 
of O 
both O 
GDNF O 
and O 
Zif268 O 
expression O 
following O 
potassium B-SYSTEMATIC 
-evoked O 
dopamine B-TRIVIAL 
release O 
in O 
SH-SY5Y O 
cells O 
. O 
We O 
used O 
adenoviral O 
delivery O 
of O 
small O 
hairpin O 
RNA O 
( O 
shRNA O 
) O 
targeting O 
Zif268 O 
to O 
down O 
- O 
regulate O 
its O 
expression O 
and O 
found O 
that O 
Zif268 O 
is O 
specifically O 
required O 
for O 
the O 
D2R O 
- O 
mediated O 
up O 
- O 
regulation O 
of O 
GDNF O 
. O 
Furthermore O 
, O 
the O 
D2R O 
- O 
mediated O 
induction O 
of O 
GDNF O 
and O 
Zif268 O 
expression O 
was O 
dependent O 
on O 
Gβγ O 
- O 
mediated O 
signaling O 
and O 
activation O 
of O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
1 O 
/ O 
2 O 
. O 
Importantly O 
, O 
using O 
chromatin O 
immunoprecipitation O 
assay O 
, O 
we O 
identified O 
a O 
direct O 
association O 
of O 
Zif268 O 
with O 
the O 
GDNF O 
promoter O 
. O 
These O 
results O 
suggest O 
that O 
D2R O 
activation O 
induces O 
a O 
Gβγ- O 
and O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
1 O 
/ O 
2-dependent O 
increase O 
in O 
the O 
level O 
of O 
Zif268 O 
, O 
which O 
functions O 
to O 
directly O 
up O 
- O 
regulate O 
the O 
expression O 
of O 
GDNF O 
. O 

protein O 
motions O 
are O 
coupled O 
to O 
enzyme O 
H B-FORMULA 
-transfer O 
reactions O 
. O 

of O 
fast O 
protein O 
dynamics O 
to O 
enzyme O 
chemistry O 
is O 
controversial O 
and O 
has O 
ignited O 
considerable O 
debate O 
, O 
especially O 
over O 
the O 
past O 
15 O 
years O 
in O 
relation O 
to O 
enzyme O 
- O 
catalyzed O 
H B-FORMULA 
-transfer O 
. O 
H B-FORMULA 
-transfer O 
can O 
occur O 
by O 
quantum O 
tunneling O 
, O 
and O 
the O 
temperature O 
dependence O 
of O 
kinetic O 
isotope O 
effects O 
( O 
KIEs O 
) O 
has O 
emerged O 
as O 
the O 
" O 
gold O 
standard O 
" O 
descriptor O 
of O 
these O 
reactions O 
. O 
The O 
anomalous O 
temperature O 
dependence O 
of O 
KIEs O 
is O 
often O 
rationalized O 
by O 
invoking O 
fast O 
motions O 
to O 
facilitate O 
H B-FORMULA 
-transfer O 
, O 
yet O 
crucially O 
, O 
direct O 
evidence O 
for O 
coupled O 
motions O 
is O 
lacking O 
. O 
The O 
fast O 
motions O 
hypothesis O 
underpinning O 
the O 
temperature O 
dependence O 
of O 
KIEs O 
is O 
based O 
on O 
inference O 
. O 
Here O 
, O 
we O 
have O 
perturbed O 
vibrational O 
motions O 
in O 
pentaerythritol B-SYSTEMATIC 
tetranitrate I-SYSTEMATIC 
reductase O 
( O 
PETNR O 
) O 
by O 
isotopic O 
substitution O 
where O 
all O 
non O 
- O 
exchangeable O 
atoms O 
were O 
replaced O 
with O 
the O 
corresponding O 
heavy O 
isotope O 
( O 
(13)C B-FORMULA 
, O 
(15)N B-FORMULA 
, O 
and O 
(2)H B-FORMULA 
) O 
. O 
The O 
KIE O 
temperature O 
dependence O 
is O 
perturbed O 
by O 
heavy O 
isotope O 
labeling O 
, O 
demonstrating O 
a O 
direct O 
link O 
between O 
( O 
promoting O 
) O 
vibrations O 
in O 
the O 
protein O 
and O 
the O 
observed O 
KIE O 
. O 
Further O 
we O 
show O 
that O 
temperature O 
- O 
independent O 
KIEs O 
do O 
not O 
necessarily O 
rule O 
out O 
a O 
role O 
for O 
fast O 
dynamics O 
coupled O 
to O 
reaction O 
chemistry O 
. O 
We O 
show O 
causality O 
between O 
fast O 
motions O 
and O 
enzyme O 
chemistry O 
and O 
demonstrate O 
how O 
this O 
impacts O 
on O 
experimental O 
KIEs O 
for O 
enzyme O 
reactions O 
. O 

isomerizations O 
of O 
proline B-TRIVIAL 
residues O 
are O 
key O 
to O 
bradykinin B-TRIVIAL 
conformations O 
. O 

recent O 
ion O 
mobility O 
- O 
mass O 
spectrometry O 
( O 
IM-MS O 
) O 
study O 
of O 
the O 
nonapeptide O 
bradykinin B-TRIVIAL 
( O 
BK O 
, O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
Arg B-FORMULA 
(1)- O 
Pro B-FORMULA 
(2)- O 
Pro B-FORMULA 
(3)- O 
Gly B-FORMULA 
(4)- O 
Phe B-FORMULA 
(5)- O 
Ser B-FORMULA 
(6)- O 
Pro B-FORMULA 
(7)- O 
Phe B-FORMULA 
(8)- O 
Arg B-FORMULA 
( O 
9 O 
) O 
) O 
found O 
evidence O 
for O 
10 O 
populations O 
of O 
conformations O 
that O 
depend O 
upon O 
the O 
solution O 
composition O 
[ O 
J O 
. O 
Am O 
. O 
Chem O 
. O 
Soc O 
. O 
2011 O 
, O 
133 O 
, O 
13810 O 
] O 
. O 
Here O 
, O 
the O 
role O 
of O 
the O 
three O 
proline B-TRIVIAL 
residues O 
( O 
Pro B-FORMULA 
( O 
2 O 
) O 
, O 
Pro B-FORMULA 
( O 
3 O 
) O 
, O 
and O 
Pro B-FORMULA 
( O 
7 O 
) O 
) O 
in O 
establishing O 
these O 
conformations O 
is O 
investigated O 
using O 
a O 
series O 
of O 
seven O 
analogue O 
peptides O 
in O 
which O 
combinations O 
of O 
alanine B-TRIVIAL 
residues O 
are O 
substituted O 
for O 
prolines B-FAMILY 
. O 
IM-MS O 
distributions O 
of O 
the O 
analogue O 
peptides O 
, O 
when O 
compared O 
to O 
the O 
distribution O 
for O 
BK O 
, O 
indicate O 
the O 
multiple O 
structures O 
are O 
associated O 
with O 
different O 
combinations O 
of O 
cis O 
and O 
trans O 
forms O 
of O 
the O 
three O 
proline B-TRIVIAL 
residues O 
. O 
These O 
data O 
are O 
used O 
to O 
assign O 
the O 
structures O 
to O 
different O 
peptide O 
populations O 
that O 
are O 
observed O 
under O 
various O 
solution O 
conditions O 
. O 
The O 
assignments O 
also O 
show O 
the O 
connectivity O 
between O 
structures O 
when O 
collisional O 
activation O 
is O 
used O 
to O 
convert O 
one O 
state O 
into O 
another O 
. O 

: O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
utility O 
of O 
remnant O 
uptake O 
on O 
postoperative O 
radioiodine B-SYSTEMATIC 
scans O 
as O 
an O 
oncologic O 
indicator O 
after O 
thyroidectomy O 
for O 
differentiated O 
thyroid O 
cancer O 
( O 
DTC O 
) O 
. O 
METHODS O 
: O 
We O 
conducted O 
a O 
retrospective O 
review O 
of O 
patients O 
undergoing O 
total O 
thyroidectomy O 
for O 
DTC O 
and O 
subsequent O 
radioactive O 
iodine B-SYSTEMATIC 
( O 
RAI O 
) O 
treatment O 
. O 
Of O 
the O 
eight O 
surgeons O 
included O 
, O 
three O 
were O 
considered O 
high O 
volume O 
, O 
performing O 
at O 
least O 
20 O 
thyroidectomies O 
per O 
year O 
. O 
Patients O 
with O 
distant O 
metastases O 
at O 
diagnosis O 
or O 
poorly O 
differentiated O 
variants O 
were O 
excluded O 
. O 
To O 
control O 
for O 
the O 
effect O 
of O 
varying O 
RAI O 
doses O 
, O 
the O 
remnant O 
uptake O 
was O 
analyzed O 
as O 
a O 
ratio O 
of O 
the O 
percentage O 
uptake O 
to O 
the O 
dose O 
received O 
( O 
uptake O 
to O 
dose O 
ratio O 
, O 
UDR O 
) O 
. O 
Multivariate O 
logistic O 
regression O 
was O 
used O 
to O 
determine O 
the O 
influence O 
of O 
UDR O 
on O 
recurrence O 
. O 
RESULTS O 
: O 
Of O 
the O 
223 O 
patients O 
who O 
met O 
inclusion O 
criteria O 
, O 
21 O 
patients O 
( O 
9.42% O 
) O 
experienced O 
a O 
recurrence O 
. O 
Those O 
who O 
recurred O 
had O 
a O 
ten O 
- O 
fold O 
higher O 
UDR O 
compared O 
to O 
those O 
who O 
did O 
not O 
recur O 
( O 
0.03 O 
vs O 
. O 
0.003 O 
, O 
p O 
= O 
0.001 O 
) O 
. O 
Similarly O 
, O 
patients O 
with O 
increasing O 
postoperative O 
thyroglobulin O 
measurements O 
( O 
0.339 O 
vs O 
. O 
0.003 O 
, O 
p O 
< O 
0.001 O 
) O 
also O 
had O 
significantly O 
greater O 
UDRs O 
compared O 
to O 
those O 
with O 
stable O 
thyroglobulin O 
. O 
The O 
UDRs O 
of O 
high O 
volume O 
surgeons O 
were O 
significantly O 
smaller O 
than O 
low O 
volume O 
surgeons O 
( O 
0.003 O 
vs O 
. O 
0.025 O 
, O 
p O 
= O 
0.002 O 
) O 
. O 
When O 
combined O 
with O 
other O 
known O 
predictors O 
for O 
recurrence O 
, O 
UDR O 
( O 
OR O 
3.71 O 
, O 
C.I O 
1.05 O 
- O 
13.1 O 
, O 
p O 
= O 
0.041 O 
) O 
was O 
significantly O 
associated O 
with O 
recurrence O 
. O 
High O 
volume O 
surgeons O 
maintained O 
a O 
low O 
level O 
of O 
permanent O 
complications O 
across O 
all O 
UDRs O 
whereas O 
low O 
volume O 
surgeons O 
had O 
greater O 
permanent O 
complications O 
associated O 
with O 
higher O 
uptake O 
. O 

and O 
biological O 
evaluation O 
of O 
5-nitropyrimidine B-SYSTEMATIC 
analogs O 
with O 
azabicyclic B-FAMILY 
substituents O 
as O 
GPR119 O 
agonists O 
. O 

analogs O 
substituted O 
with O 
conformationally O 
restricted O 
azabicyclic B-MULTIPLE 
amines I-MULTIPLE 
and I-MULTIPLE 
alcohols I-MULTIPLE 
were O 
prepared O 
and O 
evaluated O 
their O 
agonistic O 
activity O 
against O 
human O 
GPR119 O 
. O 
The O 
analogs O 
bearing O 
endo-azabicyclic B-MULTIPLE 
amines I-MULTIPLE 
and I-MULTIPLE 
alcohols I-MULTIPLE 
( O 
7 O 
, O 
8 O 
, O 
11 O 
, O 
and O 
12 O 
) O 
exhibited O 
full O 
agonistic O 
activities O 
while O 
the O 
analogs O 
with O 
exo-azabicyclic B-MULTIPLE 
amines I-MULTIPLE 
and I-MULTIPLE 
alcohols I-MULTIPLE 
were O 
proved O 
as O 
partial O 
agonists O 
( O 
9 O 
, O 
10 O 
, O 
13 O 
, O 
and O 
14 O 
) O 
regardless O 
of O 
their O 
EC(50) O 
values O 
. O 
5-Nitropyrimidine B-SYSTEMATIC 
analogs O 
with O 
(2-fluoro-4-methylsulfonyl)phenylamino B-SYSTEMATIC 
group O 
( O 
8 O 
, O 
10 O 
, O 
12 O 
, O 
14 O 
) O 
showed O 
more O 
potent O 
GPR119 O 
activation O 
activities O 
than O 
the O 
analogs O 
without O 
fluorine B-SYSTEMATIC 
in O 
all O 
cases O 
( O 
7 O 
, O 
9 O 
, O 
11 O 
, O 
13 O 
) O 
. O 

/ O 
LNA O 
aptamers O 
: O 
CE-SELEX O 
using O 
a O 
DNA O 
- O 
based O 
library O 
of O 
full O 
- O 
length O 
2'-O,4'-C-methylene- B-FAMILY 
bridged I-FAMILY 
/ I-FAMILY 
linked I-FAMILY 
bicyclic I-FAMILY 
ribonucleotides I-FAMILY 
. O 

- O 
based O 
aptamers O 
that O 
contain O 
2'-O,4'-C-methylene- B-FAMILY 
bridged I-FAMILY 
/ I-FAMILY 
linked I-FAMILY 
bicyclic I-FAMILY 
ribonucleotides I-FAMILY 
( O 
B O 
/ O 
L O 
nucleotides B-FAMILY 
) O 
over O 
the O 
entire O 
length O 
were O 
successfully O 
obtained O 
using O 
a O 
capillary O 
electrophoresis O 
systematic O 
evolution O 
of O 
ligands O 
by O 
exponential O 
enrichment O 
( O 
CE-SELEX O 
) O 
method O 
. O 
A O 
modified O 
DNA O 
library O 
was O 
prepared O 
with O 
an O 
enzyme O 
mix O 
of O 
KOD O 
Dash O 
and O 
KOD O 
mutant O 
DNA O 
polymerases O 
. O 
Forty O 
2'-O,4'-C- O 
methylene B-SYSTEMATIC 
bridged O 
/ O 
locked O 
nucleic O 
acid O 
( O 
2',4'-BNA O 
/ O 
LNA O 
) O 
aptamers O 
were O 
isolated O 
from O 
an O 
enriched O 
pool O 
and O 
classified O 
into O 
six O 
groups O 
according O 
to O 
their O 
sequence O 
. O 
2',4'-BNA O 
/ O 
LNA O 
aptamers O 
of O 
groups O 
V O 
and O 
VI O 
bound O 
human O 
thrombin O 
with O 
K(d) O 
values O 
in O 
the O 
range O 
of O 
several O 
10 O 
nanomolar O 
levels O 
. O 

neonatal O 
Fc O 
receptor O 
, O 
FcRn O 
, O 
prolongs O 
the O 
half O 
- O 
life O 
of O 
IgG O 
in O 
the O 
serum O 
and O 
represents O 
a O 
potential O 
therapeutic O 
target O 
for O 
the O 
treatment O 
of O 
autoimmune O 
disease O 
. O 
Small O 
molecules O 
that O 
block O 
the O 
protein O 
- O 
protein O 
interactions O 
of O 
human O 
IgG-human O 
FcRn O 
may O 
lower O 
pathogenic O 
autoantibodies O 
and O 
provide O 
effective O 
treatment O 
. O 
A O 
novel O 
class O 
of O 
quinoxalines B-FAMILY 
has O 
been O 
discovered O 
as O 
antagonists O 
of O 
the O 
IgG O 
: O 
FcRn O 
protein O 
- O 
protein O 
interaction O 
through O 
optimization O 
of O 
a O 
hit O 
derived O 
from O 
a O 
virtual O 
ligand O 
- O 
based O 
screen O 
. O 

/ I-MULTIPLE 
S-Hydroxyvoacamine I-MULTIPLE 
, O 
a O 
potent O 
acetylcholinesterase O 
inhibitor O 
from O 
Tabernaemontana O 
divaricata O 
. O 

by O 
the O 
acetylcholinesterase O 
inhibiting O 
activity O 
, O 
the O 
bisindole B-FAMILY 
alkaloid I-FAMILY 
3'-R B-MULTIPLE 
/ I-MULTIPLE 
S-hydroxyvoacamine I-MULTIPLE 
was O 
isolated O 
from O 
a O 
stem O 
extract O 
of O 
Tabernaemontana O 
divaricata O 
, O 
a O 
plant O 
used O 
in O 
Thailand O 
in O 
traditional O 
rejuvenation O 
remedies O 
for O 
improving O 
the O 
memory O 
. O 
The O 
structure O 
of O 
the O 
alkaloid O 
was O 
elucidated O 
by O 
extensive O 
use O 
of O 
NMR O 
spectroscopy O 
and O 
the O 
complete O 
assignment O 
of O 
the O 
(1)H B-FORMULA 
and O 
(13)C B-FORMULA 
NMR O 
spectra O 
is O 
reported O 
. O 
The O 
alkaloid O 
acted O 
as O 
a O 
non-competitive O 
inhibitor O 
against O 
AChE O 
with O 
an O 
IC50 O 
value O 
of O 
7.00±1.99μM O 
. O 
An O 
HPLC O 
method O 
was O 
developed O 
for O 
the O 
quantitative O 
analysis O 
of O 
the O 
AChE O 
inhibitor O 
. O 
It O 
suggested O 
that O 
there O 
was O 
12.4% O 
( O 
w O 
/ O 
w O 
) O 
of O 
3'-R B-MULTIPLE 
/ I-MULTIPLE 
S-hydroxyvoacamine I-MULTIPLE 
in O 
the O 
alkaloid O 
enriched O 
fraction O 
of O 
T O 
. O 
divaricata O 
stem O 
. O 

marsupials O 
and O 
men O 
: O 
" O 
Backdoor O 
" O 
dihydrotestosterone B-SYSTEMATIC 
synthesis O 
in O 
male O 
sexual O 
differentiation O 
. O 

development O 
of O 
the O 
fetal O 
bipotential O 
gonad O 
into O 
a O 
testis O 
, O 
male O 
genital O 
differentiation O 
requires O 
testicular O 
androgens B-FAMILY 
. O 
Fetal O 
Leydig O 
cells O 
produce O 
testosterone B-TRIVIAL 
that O 
is O 
converted O 
to O 
dihydrotestosterone B-SYSTEMATIC 
in O 
genital O 
skin O 
, O 
resulting O 
in O 
labio O 
- O 
scrotal O 
fusion O 
. O 
An O 
alternative O 
' O 
backdoor O 
' O 
pathway O 
of O 
dihydrotestosterone B-SYSTEMATIC 
synthesis O 
that O 
bypasses O 
testosterone B-TRIVIAL 
has O 
been O 
described O 
in O 
marsupials O 
, O 
but O 
its O 
relevance O 
to O 
human O 
biology O 
has O 
been O 
uncertain O 
. O 
The O 
classic O 
and O 
backdoor O 
pathways O 
share O 
many O 
enzymes O 
, O 
but O 
a O 
3α-reductase O 
, O 
AKR1C2 O 
, O 
is O 
unique O 
to O 
the O 
backdoor O 
pathway O 
. O 
Human O 
AKR1C2 O 
mutations O 
cause O 
disordered O 
sexual O 
differentiation O 
, O 
lending O 
weight O 
to O 
the O 
idea O 
that O 
both O 
pathways O 
are O 
required O 
for O 
normal O 
human O 
male O 
genital O 
development O 
. O 
These O 
observations O 
indicate O 
that O 
fetal O 
dihydrotestosterone B-SYSTEMATIC 
acts O 
both O 
as O 
a O 
hormone O 
and O 
as O 
a O 
paracrine O 
factor O 
, O 
substantially O 
revising O 
the O 
classic O 
paradigm O 
for O 
fetal O 
male O 
sexual O 
development O 
. O 

- O 
range O 
interactions O 
in O 
the O 
alpha O 
subunit O 
of O 
tryptophan B-TRIVIAL 
synthase O 
help O 
to O 
coordinate O 
ligand O 
binding O 
, O 
catalysis O 
, O 
and O 
substrate O 
channeling O 
. O 

α-subunit O 
of O 
tryptophan B-TRIVIAL 
synthase O 
( O 
αTS O 
) O 
catalyzes O 
the O 
conversion O 
of O 
indole-3-glycerol B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
to O 
d-glyceraldehyde-3-phosphate B-SYSTEMATIC 
and O 
indole B-SYSTEMATIC 
. O 
We O 
propose O 
that O 
allosteric O 
networks O 
intrinsic O 
to O 
αTS O 
are O 
modulated O 
by O 
the O 
binding O 
of O 
the O 
β-subunit O 
to O 
regulate O 
αTS O 
function O 
. O 
Understanding O 
these O 
long O 
- O 
range O 
amino B-FAMILY 
acid I-FAMILY 
networks O 
in O 
αTS O 
thus O 
gives O 
insight O 
into O 
the O 
coordination O 
of O 
the O 
two O 
active O 
sites O 
within O 
TS O 
. O 
In O 
this O 
study O 
, O 
we O 
have O 
used O 
Ala B-FORMULA 
residues O 
as O 
probes O 
for O 
structural O 
and O 
dynamic O 
changes O 
of O 
αTS O 
throughout O 
its O 
catalytic O 
cycle O 
, O 
in O 
the O 
absence O 
of O 
the O 
β-subunit O 
. O 
Projection O 
analysis O 
of O 
the O 
chemical O 
shift O 
changes O 
by O 
site O 
- O 
specific O 
amino B-FAMILY 
acid I-FAMILY 
substitutions O 
and O 
ligand O 
titrations O 
indicates O 
that O 
αTS O 
has O 
three O 
important O 
conformational O 
states O 
: O 
ligand O 
- O 
free O 
, O 
glyceraldehyde-3-phosphate B-SYSTEMATIC 
-bound(like) O 
, O 
and O 
the O 
active O 
states O 
. O 
The O 
amino B-FAMILY 
acid I-FAMILY 
networks O 
within O 
these O 
conformations O 
are O 
different O 
, O 
as O 
suggested O 
by O 
chemical O 
shift O 
correlation O 
analysis O 
. O 
In O 
particular O 
, O 
there O 
are O 
long O 
- O 
range O 
connections O 
, O 
only O 
in O 
the O 
active O 
state O 
, O 
between O 
Ala B-FORMULA 
47 O 
, O 
which O 
reports O 
on O 
structural O 
and O 
dynamic O 
changes O 
associated O 
with O 
the O 
general O 
acid O 
/ O 
base O 
Glu B-FORMULA 
49 O 
, O 
and O 
residues O 
within O 
the O 
β2α2 O 
loop O 
, O 
which O 
contains O 
the O 
catalytically O 
important O 
Asp B-FORMULA 
60 O 
residue O 
. O 
These O 
long O 
- O 
range O 
interactions O 
are O 
likely O 
important O 
for O 
coordinating O 
chemical O 
catalysis O 
. O 
In O 
the O 
free O 
state O 
, O 
but O 
not O 
in O 
the O 
active O 
state O 
, O 
there O 
are O 
connections O 
between O 
the O 
β2α2 O 
and O 
β6α6 O 
loops O 
that O 
likely O 
help O 
to O 
coordinate O 
substrate O 
binding O 
. O 
Changes O 
in O 
the O 
allosteric O 
networks O 
are O 
also O 
accompanied O 
by O 
protein O 
dynamic O 
changes O 
. O 
During O 
catalytic O 
turnover O 
, O 
the O 
protein O 
becomes O 
more O 
rigid O 
on O 
the O 
millisecond O 
timescale O 
and O 
the O 
active O 
- O 
site O 
dynamics O 
are O 
driven O 
to O 
a O 
faster O 
nanosecond O 
timescale O 
. O 

of O 
the O 
mouse O 
promoter O 
region O 
of O 
the O 
acyl-CoA B-ABBREVIATION 
synthetase O 
4 O 
gene O 
: O 
role O 
of O 
Sp1 O 
and O 
CREB O 
. O 

synthetase O 
4 O 
( O 
Acsl4 O 
) O 
is O 
involved O 
in O 
several O 
cellular O 
functions O 
including O 
steroidogenesis O 
, O 
synaptic O 
development O 
and O 
cancer O 
metastasis O 
. O 
Although O 
the O 
expression O 
of O 
Acsl4 O 
seems O 
to O 
be O 
regulated O 
by O 
tissue- O 
and O 
cell O 
- O 
specific O 
factors O 
as O 
well O 
as O 
pituitary O 
hormones O 
and O 
growth O 
factors O 
, O 
the O 
transcriptional O 
mechanisms O 
involved O 
remain O 
unknown O 
. O 
We O 
demonstrated O 
hCG O 
and O 
cAMP B-ABBREVIATION 
regulation O 
of O 
Acsl4 O 
mRNA O 
in O 
mouse O 
steroidogenic O 
MA-10 O 
Leydig O 
cells O 
. O 
We O 
characterized O 
the O 
transcription O 
initiation O 
site O 
and O 
promoter O 
of O 
the O 
Acsl4 O 
mouse O 
gene O 
and O 
identified O 
three O 
alternative O 
splice O 
variants O 
present O 
in O 
MA-10 O 
cells O 
. O 
Sequence O 
analysis O 
of O 
a O 
1.5-kb O 
fragment O 
of O 
the O 
Acsl4 O 
promoter O 
revealed O 
the O 
absence O 
of O 
a O 
TATA O 
box O 
and O 
the O 
presence O 
of O 
many O 
putative O 
binding O 
sites O 
for O 
transcription O 
factors O 
including O 
Sp1 O 
and O 
CREB O 
. O 
Functional O 
characterization O 
revealed O 
that O 
the O 
specificity O 
protein O 
/ O 
Krüppel O 
- O 
like O 
factor O 
Sp1 O 
binding O 
site O 
in O 
the O 
proximal O 
promoter O 
is O 
involved O 
in O 
basal O 
activity O 
and O 
that O 
the O 
cAMP B-ABBREVIATION 
response O 
element O 
- O 
binding O 
site O 
is O 
involved O 
in O 
cAMP B-ABBREVIATION 
stimulation O 
of O 
Acsl4 O 
transcription O 
. O 

and O 
biological O 
evaluation O 
of O 
thieno B-FAMILY 
[2',3':4,5]pyrimido[1,2-b][1,2,4]triazines I-FAMILY 
and O 
thieno[2,3-d][1,2,4]triazolo[1,5-a]pyrimidines B-FAMILY 
as O 
anti-inflammatory O 
and O 
analgesic O 
agents O 
. O 

new O 
series O 
of O 
thieno[2',3':4,5]pyrimido[1,2-b][1,2,4]triazines B-FAMILY 
and O 
thieno[2,3-d][1,2,4]triazolo[1,5-a]pyrimidines B-FAMILY 
was O 
synthesized O 
. O 
The O 
newly O 
synthesized O 
compounds O 
were O 
evaluated O 
for O 
their O 
anti-inflammatory O 
and O 
analgesic O 
activity O 
using O 
diclofenac B-FORMULA 
Na I-FORMULA 
as O 
a O 
reference O 
standard O 
. O 
Additionally O 
, O 
the O 
ulcerogenic O 
effects O 
and O 
acute O 
toxicity O 
( O 
ALD50 O 
) O 
values O 
of O 
the O 
active O 
compounds O 
were O 
also O 
determined O 
. O 
In O 
general O 
, O 
the O 
thieno[2,3-d][1,2,4]triazolo[1,5-a]pyrimidine B-SYSTEMATIC 
derivatives O 
exhibited O 
better O 
biological O 
activities O 
than O 
the O 
thieno[2',3':4,5]pyrimido[1,2-b][1,2,4]triazines B-FAMILY 
. O 
Collectively O 
, O 
the O 
thienotriazolopyrimidine B-SYSTEMATIC 
derivatives O 
9 O 
, O 
13 O 
and O 
14a O 
were O 
proved O 
to O 
display O 
distinctive O 
anti-inflammatory O 
activity O 
at O 
the O 
acute O 
and O 
subacute O 
models O 
as O 
well O 
as O 
good O 
analgesic O 
profile O 
with O 
a O 
delayed O 
onset O 
of O 
action O 
. O 
Moreover O 
, O 
they O 
revealed O 
good O 
gastrointestinal O 
safety O 
profile O 
and O 
are O 
well O 
tolerated O 
by O 
experimental O 
animals O 
with O 
high O 
safety O 
margin O 
( O 
ALD50 O 
> O 
0.3 O 
g O 
/ O 
kg O 
) O 
. O 

insight O 
into O 
the O 
inhibition O 
mechanism O 
of O 
cyrtominetin B-TRIVIAL 
to O 
α-hemolysin O 
by O 
molecular O 
dynamics O 
simulation O 
. O 

protein O 
α-hemolysin O 
( O 
α-HL O 
) O 
is O 
a O 
self O 
- O 
assembling O 
exotoxin O 
that O 
binds O 
to O 
the O 
membrane O 
of O 
a O 
susceptible O 
host O 
cell O 
. O 
In O 
this O 
paper O 
, O 
experimental O 
studies O 
show O 
that O 
cyrtominetin B-TRIVIAL 
( O 
CTM B-ABBREVIATION 
) O 
can O 
inhibit O 
the O 
hemolytic O 
activity O 
of O 
α-HL O 
. O 
To O 
understand O 
how O 
CTM B-ABBREVIATION 
can O 
affect O 
hemolytic O 
activity O 
, O 
molecular O 
dynamics O 
simulations O 
were O 
carried O 
out O 
for O 
α-HL- O 
CTM B-ABBREVIATION 
complex O 
and O 
these O 
results O 
were O 
compared O 
with O 
the O 
crystal O 
structure O 
of O 
monomeric O 
α-HL O 
. O 
With O 
this O 
approach O 
, O 
the O 
analysis O 
revealed O 
that O 
the O 
inhibition O 
of O 
CTM B-ABBREVIATION 
involves O 
CTM B-ABBREVIATION 
directly O 
binding O 
to O 
α-HL O 
. O 
Due O 
to O 
the O 
binding O 
of O 
CTM B-ABBREVIATION 
, O 
the O 
conformation O 
of O 
the O 
critical O 
" O 
Loop O 
" O 
region O 
was O 
restrained O 
. O 
This O 
mechanism O 
was O 
confirmed O 
by O 
the O 
experimental O 
data O 
. O 
These O 
findings O 
indicate O 
that O 
CTM B-ABBREVIATION 
hinders O 
the O 
lysis O 
activity O 
of O 
α-HL O 
through O 
a O 
novel O 
mechanism O 
. O 

of O 
environmentally O 
relevant O 
concentrations O 
of O 
vinclozolin B-TRIVIAL 
on O 
quality O 
, O 
DNA O 
integrity O 
, O 
and O 
antioxidant O 
responses O 
of O 
sterlet O 
Acipenser O 
ruthenus O 
spermatozoa O 
. O 

effects O 
of O 
vinclozolin B-TRIVIAL 
( O 
VIN B-ABBREVIATION 
) O 
, O 
an O 
anti-androgenic O 
fungicide O 
, O 
on O 
quality O 
, O 
oxidative O 
stress O 
, O 
DNA O 
integrity O 
, O 
and O 
ATP B-ABBREVIATION 
level O 
of O 
sterlet O 
( O 
Acipenser O 
ruthenus O 
) O 
spermatozoa O 
were O 
investigated O 
in O 
vitro O 
. O 
Fish O 
spermatozoa O 
were O 
incubated O 
with O 
different O 
concentrations O 
of O 
vinclozolin B-TRIVIAL 
( O 
0.5 O 
, O 
2 O 
, O 
10 O 
, O 
15 O 
, O 
20 O 
and O 
50μg O 
/ O 
l O 
) O 
for O 
2h O 
. O 
A O 
dose O 
- O 
dependent O 
reduction O 
in O 
spermatozoa O 
motility O 
and O 
velocity O 
was O 
observed O 
at O 
concentrations O 
of O 
2-50μg O 
/ O 
l O 
. O 
A O 
dramatic O 
increase O 
in O 
DNA O 
fragmentation O 
was O 
recorded O 
at O 
concentrations O 
10μg O 
/ O 
l O 
and O 
above O 
. O 
After O 
2h O 
exposure O 
at O 
higher O 
test O 
concentrations O 
( O 
10-50μg O 
/ O 
l O 
) O 
, O 
oxidative O 
stress O 
was O 
apparent O 
, O 
as O 
reflected O 
by O 
significantly O 
higher O 
levels O 
of O 
protein O 
and O 
lipid O 
oxidation O 
and O 
significantly O 
greater O 
superoxide B-TRIVIAL 
dismutase O 
activity O 
. O 
Intracellular O 
ATP B-ABBREVIATION 
content O 
of O 
spermatozoa O 
decreased O 
with O 
increasing O 
concentrations O 
of O 
VIN B-ABBREVIATION 
. O 
The O 
results O 
demonstrated O 
that O 
VIN B-ABBREVIATION 
can O 
induce O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
stress O 
in O 
fish O 
spermatozoa O 
, O 
which O 
could O 
impair O 
the O 
sperm O 
quality O 
, O 
DNA O 
integrity O 
, O 
ATP B-ABBREVIATION 
content O 
, O 
and O 
the O 
antioxidant O 
defense O 
system O 
. O 

and O 
utilization O 
of O 
oxidized O 
guanine B-FAMILY 
nucleotides I-FAMILY 
in O 
the O 
synthesis O 
of O 
RNA O 
and O 
its O 
precursors O 
. O 

oxygen B-SYSTEMATIC 
species O 
are O 
produced O 
as O 
side O 
products O 
of O 
oxygen B-SYSTEMATIC 
utilization O 
and O 
can O 
lead O 
to O 
the O 
oxidation O 
of O 
nucleic O 
acids O 
and O 
their O 
precursor O 
nucleotides B-FAMILY 
. O 
Among O 
the O 
various O 
oxidized O 
bases O 
, O 
8-oxo-7,8-dihydroguanine B-SYSTEMATIC 
seems O 
to O 
be O 
the O 
most O 
critical O 
during O 
the O 
transfer O 
of O 
genetic O 
information O 
because O 
it O 
can O 
pair O 
with O 
both O 
cytosine B-TRIVIAL 
and O 
adenine B-TRIVIAL 
. O 
During O 
the O 
de O 
novo O 
synthesis O 
of O 
guanine B-FAMILY 
nucleotides I-FAMILY 
, O 
GMP B-ABBREVIATION 
is O 
formed O 
first O 
, O 
and O 
it O 
is O 
converted O 
to O 
GDP B-ABBREVIATION 
by O 
guanylate B-TRIVIAL 
kinase O 
. O 
This O 
enzyme O 
hardly O 
acts O 
on O 
an O 
oxidized O 
form O 
of O 
GMP B-ABBREVIATION 
( O 
8-oxo-GMP B-SYSTEMATIC 
) O 
formed O 
by O 
the O 
oxidation O 
of O 
GMP B-ABBREVIATION 
or O 
by O 
the O 
cleavage O 
of O 
8-oxo-GDP B-SYSTEMATIC 
and O 
8-oxo-GTP B-SYSTEMATIC 
by O 
MutT O 
protein O 
. O 
Although O 
the O 
formation O 
of O 
8-oxo-GDP B-SYSTEMATIC 
from O 
8-oxo-GMP B-SYSTEMATIC 
is O 
thus O 
prevented O 
, O 
8-oxo-GDP B-SYSTEMATIC 
itself O 
may O 
be O 
produced O 
by O 
the O 
oxidation O 
of O 
GDP B-ABBREVIATION 
by O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
. O 
The O 
8-oxo-GDP B-SYSTEMATIC 
thus O 
formed O 
can O 
be O 
converted O 
to O 
8-oxo-GTP B-SYSTEMATIC 
because O 
nucleoside-diphosphate B-FAMILY 
kinase O 
and O 
adenylate B-TRIVIAL 
kinase O 
, O 
both O 
of O 
which O 
catalyze O 
the O 
conversion O 
of O 
GDP B-ABBREVIATION 
to O 
GTP B-ABBREVIATION 
, O 
do O 
not O 
discriminate O 
8-oxo-GDP B-SYSTEMATIC 
from O 
normal O 
GDP B-ABBREVIATION 
. O 
The O 
8-oxo-GTP B-SYSTEMATIC 
produced O 
in O 
this O 
way O 
and O 
by O 
the O 
oxidation O 
of O 
GTP B-ABBREVIATION 
can O 
be O 
used O 
for O 
RNA O 
synthesis O 
. O 
This O 
misincorporation O 
is O 
prevented O 
by O 
MutT O 
protein O 
, O 
which O 
has O 
the O 
potential O 
to O 
cleave O 
8-oxo-GTP B-SYSTEMATIC 
as O 
well O 
as O 
8-oxo-GDP B-SYSTEMATIC 
to O 
8-oxo-GMP B-SYSTEMATIC 
. O 
When O 
(14)C-labeled B-SYSTEMATIC 
8-oxo-GTP I-SYSTEMATIC 
was O 
applied O 
to O 
CaCl2 B-FORMULA 
-permeabilized O 
cells O 
of O 
a O 
mutT(-) O 
mutant O 
strain O 
, O 
it O 
could O 
be O 
incorporated O 
into O 
RNA O 
at O 
4% O 
of O 
the O 
rate O 
for O 
GTP B-ABBREVIATION 
. O 
Escherichia O 
coli O 
cells O 
appear O 
to O 
possess O 
mechanisms O 
to O 
prevent O 
misincorporation O 
of O 
8-oxo-7,8-dihydroguanine B-SYSTEMATIC 
into O 
RNA O 
. O 

modulates O 
spontaneous O 
nerve O 
growth O 
factor O 
production O 
and O 
stretch O 
- O 
induced O 
ATP B-ABBREVIATION 
release O 
in O 
human O 
urothelium O 
. O 

urothelium O 
plays O 
a O 
crucial O 
role O 
in O 
integrating O 
urinary O 
bladder O 
sensory O 
outputs O 
, O 
responding O 
to O 
mechanical O 
stress O 
and O 
chemical O 
stimulation O 
by O 
producing O 
several O 
diffusible O 
mediators O 
, O 
including O 
ATP B-ABBREVIATION 
and O 
, O 
possibly O 
, O 
neurotrophin O 
nerve O 
growth O 
factor O 
( O 
NGF O 
) O 
. O 
Such O 
urothelial O 
mediators O 
activate O 
underlying O 
afferents O 
and O 
thus O 
may O 
contribute O 
to O 
normal O 
bladder O 
sensation O 
and O 
possibly O 
to O 
the O 
development O 
of O 
bladder O 
overactivity O 
. O 
The O 
muscle O 
- O 
contracting O 
and O 
pain O 
- O 
inducing O 
peptide O 
bradykinin B-TRIVIAL 
is O 
produced O 
in O 
various O 
inflammatory O 
and O 
non-inflammatory O 
pathologies O 
associated O 
with O 
bladder O 
overactivity O 
, O 
but O 
the O 
effect O 
of O 
bradykinin B-TRIVIAL 
on O 
human O 
urothelial O 
function O 
has O 
not O 
yet O 
been O 
characterized O 
. O 
The O 
human O 
urothelial O 
cell O 
line O 
UROtsa O 
expresses O 
mRNA O 
for O 
both O 
B1 O 
and O 
B2 O 
subtypes O 
of O 
bradykinin B-TRIVIAL 
receptors O 
, O 
as O 
determined O 
by O 
real O 
- O 
time O 
PCR O 
. O 
Bradykinin B-TRIVIAL 
concentration O 
- O 
dependently O 
( O 
pEC50=8.3 O 
, O 
Emax O 
4434±277nM O 
) O 
increased O 
urothelial O 
intracellular O 
calcium O 
levels O 
and O 
induced O 
phosphorylation O 
of O 
the O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
ERK1 O 
/ O 
2 O 
. O 
Activation O 
of O 
both O 
bradykinin B-TRIVIAL 
-induced O 
signaling O 
pathways O 
was O 
completely O 
abolished O 
by O 
the O 
B2 O 
antagonist O 
icatibant O 
( O 
1μM O 
) O 
, O 
but O 
not O 
the O 
B1 O 
antagonist O 
R715 O 
( O 
1μM O 
) O 
. O 
Bradykinin B-TRIVIAL 
-induced O 
( O 
100nM O 
) O 
B2 O 
receptor O 
activation O 
markedly O 
increased O 
( O 
192±13% O 
of O 
control O 
levels O 
) O 
stretch O 
- O 
induced O 
ATP B-ABBREVIATION 
release O 
from O 
UROtsa O 
in O 
hypotonic O 
medium O 
, O 
the O 
effect O 
being O 
dependent O 
on O 
intracellular O 
calcium O 
elevations O 
. O 
UROtsa O 
cells O 
also O 
expressed O 
mRNA O 
and O 
protein O 
for O 
NGF O 
and O 
spontaneously O 
released O 
NGF O 
to O 
the O 
medium O 
in O 
the O 
course O 
of O 
hours O 
( O 
11.5±1.4pgNGF O 
/ O 
mgprotein O 
/ O 
h O 
) O 
. O 
Bradykinin B-TRIVIAL 
increased O 
NGF O 
mRNA O 
expression O 
and O 
accelerated O 
urothelial O 
NGF O 
release O 
to O 
127±5% O 
in O 
a O 
protein O 
kinase O 
C- O 
and O 
ERK1 O 
/ O 
2-dependent O 
manner O 
. O 
Finally O 
, O 
bradykinin B-TRIVIAL 
up O 
- O 
regulated O 
mRNA O 
for O 
transient-receptor O 
potential O 
vanilloid O 
( O 
TRPV1 O 
) O 
sensory O 
ion O 
channel O 
in O 
UROtsa O 
. O 
In O 
conclusion O 
, O 
we O 
show O 
that O 
bradykinin B-TRIVIAL 
represents O 
a O 
versatile O 
modulator O 
of O 
human O 
urothelial O 
phenotype O 
, O 
accelerating O 
stretch O 
- O 
induced O 
ATP B-ABBREVIATION 
release O 
, O 
spontaneous O 
release O 
of O 
NGF O 
, O 
as O 
well O 
as O 
expression O 
of O 
sensory O 
ion O 
channel O 
TRPV1 O 
. O 
Bradykinin B-TRIVIAL 
-induced O 
changes O 
in O 
urothelial O 
sensory O 
function O 
might O 
contribute O 
to O 
the O 
development O 
of O 
bladder O 
dysfunction O 
. O 

ameliorates O 
adriamycin B-TRIVIAL 
-induced O 
cardiac O 
fibrosis O 
via O 
activation O 
of O 
a O 
BRCA1-dependent O 
anti-oxidant O 
pathway O 
. O 

cardiotoxicity O 
of O 
adriamycin B-TRIVIAL 
greatly O 
limits O 
its O 
application O 
in O 
the O 
treatment O 
of O 
cancer O 
. O 
Heart O 
failure O 
that O 
is O 
caused O 
by O 
adriamycin B-TRIVIAL 
-treatment O 
induced O 
cardiac O 
fibrosis O 
is O 
a O 
major O 
cause O 
of O 
death O 
in O 
patients O 
who O 
are O 
treated O 
with O 
this O 
medication O 
. O 
The O 
severe O 
oxidative O 
stress O 
that O 
is O 
induced O 
by O 
adriamycin B-TRIVIAL 
is O 
considered O 
to O 
be O 
one O 
of O 
the O 
primary O 
mechanisms O 
by O 
which O 
fibrogenesis O 
of O 
cardiac O 
tissue O 
occurs O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
demonstrate O 
that O 
3,3'-diindolymethane B-SYSTEMATIC 
( O 
DIM B-ABBREVIATION 
) O 
exhibits O 
a O 
significant O 
anti-fibrosis O 
effect O 
on O 
cardiac O 
tissue O 
in O 
an O 
animal O 
model O 
of O 
adriamycin B-TRIVIAL 
-induced O 
cardiac O 
fibrosis O 
( O 
AICF O 
) O 
. O 
Further O 
studies O 
demonstrated O 
that O 
DIM B-ABBREVIATION 
is O 
able O 
to O 
dramatically O 
up O 
- O 
regulate O 
the O 
expression O 
of O 
breast O 
cancer O 
type O 
1 O 
susceptibility O 
protein O 
( O 
BRCA1 O 
) O 
in O 
cardiac O 
tissue O 
and O 
fibroblast O 
, O 
which O 
subsequently O 
activate O 
the O 
transcription O 
factor O 
Nuclear O 
factor O 
( O 
erythroid O 
- O 
derived O 
2 O 
) O 
- O 
like O 
2 O 
( O 
Nrf2 O 
) O 
. O 
The O 
upregulation O 
of O 
this O 
transcription O 
factor O 
resulted O 
in O 
the O 
expression O 
of O 
several O 
anti-oxidant O 
genes O 
in O 
the O 
cell O 
. O 
Because O 
DIM B-ABBREVIATION 
is O 
a O 
safe O 
food O 
additive O 
that O 
has O 
been O 
used O 
for O 
decades O 
, O 
our O 
findings O 
suggest O 
that O 
there O 
is O 
a O 
great O 
potential O 
for O 
this O 
chemical O 
to O 
be O 
developed O 
into O 
a O 
clinical O 
medication O 
for O 
the O 
treatment O 
of O 
adriamycin B-TRIVIAL 
-induced O 
heart O 
failure O 
during O 
cancer O 
therapy O 
. O 

evidence O 
suggests O 
that O 
the O 
PI3K O 
/ O 
AKT O 
pathway O 
is O 
a O 
pro O 
- O 
survival O 
signalling O 
system O 
in O 
neurons O 
. O 
Therefore O 
, O 
the O 
inhibition O 
of O 
this O 
pathway O 
may O 
be O 
implicated O 
in O 
the O 
degeneration O 
of O 
neurons O 
in O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
, O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
, O 
and O 
other O 
neurological O 
disorders O 
. O 
Here O 
we O 
study O 
the O 
participation O 
of O 
the O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
pathway O 
on O 
apoptosis O 
induced O 
by O 
PI3K O 
/ O 
AKT O 
inhibition O 
in O 
cultured O 
cerebellar O 
granule O 
cells O 
( O 
CGCs O 
) O 
. O 
LY294002 B-IDENTIFIER 
, O 
a O 
specific O 
PI3K O 
/ O 
AKT O 
inhibitor O 
, O 
selectively O 
activated O 
the O 
p38 O 
MAPK O 
kinase O 
pathway O 
and O 
enhanced O 
c-Jun O 
phosphorylation O 
, O 
but O 
did O 
not O 
activate O 
JNK O 
. O 
The O 
pharmacological O 
inhibitors O 
SB203580 B-IDENTIFIER 
( O 
p38 O 
inhibitor O 
) O 
and O 
SP600125 B-IDENTIFIER 
( O 
a O 
JNK O 
inhibitor O 
) O 
protected O 
primary O 
cultures O 
of O 
rat O 
CGCs O 
from O 
LY294002 B-IDENTIFIER 
-induced O 
apoptosis O 
. O 
Furthermore O 
, O 
both O 
compounds O 
decreased O 
the O 
phosphorylation O 
of O 
c-Jun O 
and O 
lowered O 
mRNA O 
levels O 
of O 
the O 
pro O 
- O 
apoptotic O 
gene O 
dp5 O 
, O 
a O 
direct O 
target O 
of O 
c-Jun O 
. O 
Taken O 
together O 
, O 
our O 
data O 
demonstrate O 
that O 
PI3K O 
/ O 
AKT O 
inhibition O 
induces O 
neuronal O 
apoptosis O 
, O 
a O 
process O 
that O 
is O 
mediated O 
by O 
the O 
activation O 
of O 
p38 O 
MAPK O 
/ O 
c-Jun O 
/ O 
dp5 O 
. O 

and O 
strain O 
contributions O 
to O 
the O 
variability O 
of O 
buprenorphine B-TRIVIAL 
-related O 
respiratory O 
toxicity O 
in O 
mice O 
. O 

most O 
deaths O 
from O 
asphyxia O 
related O 
to O 
buprenorphine B-TRIVIAL 
( O 
BUP B-ABBREVIATION 
) O 
overdose O 
have O 
been O 
reported O 
in O 
males O 
, O 
higher O 
plasma O 
concentrations O 
of O 
BUP B-ABBREVIATION 
and O 
its O 
toxic O 
metabolite O 
norbuprenorphine B-TRIVIAL 
( O 
NBUP B-ABBREVIATION 
) O 
have O 
been O 
observed O 
in O 
females O 
. O 
We O 
previously O 
demonstrated O 
that O 
P-glycoprotein O 
( O 
P-gp O 
) O 
modulation O 
at O 
the O 
blood O 
- O 
brain O 
barrier O 
( O 
BBB O 
) O 
contributes O 
highly O 
to O 
BUP B-ABBREVIATION 
-related O 
respiratory O 
toxicity O 
, O 
by O 
limiting O 
NBUP B-ABBREVIATION 
entrance O 
into O 
the O 
brain O 
. O 
In O 
this O 
work O 
, O 
we O 
sought O 
to O 
investigate O 
the O 
role O 
of O 
P-gp O 
- O 
mediated O 
transport O 
at O 
the O 
BBB O 
in O 
gender O 
and O 
strain O 
- O 
related O 
variability O 
of O 
BUP B-ABBREVIATION 
and O 
NBUP B-ABBREVIATION 
-induced O 
respiratory O 
effects O 
in O 
mice O 
. O 
Ventilation O 
was O 
studied O 
using O 
plethysmography O 
, O 
P-gp O 
expression O 
using O 
western O 
blot O 
, O 
and O 
transport O 
at O 
the O 
BBB O 
using O 
in O 
situ O 
cerebral O 
perfusion O 
. O 
In O 
male O 
Fvb O 
and O 
Swiss O 
mice O 
, O 
BUP B-ABBREVIATION 
was O 
responsible O 
for O 
ceiling O 
respiratory O 
effects O 
. O 
NBUP B-ABBREVIATION 
-related O 
reduction O 
in O 
minute O 
volume O 
was O 
dose O 
- O 
dependent O 
but O 
more O 
marked O 
in O 
Fvb O 
( O 
p O 
< O 
0.01 O 
at O 
1mg O 
/ O 
kg O 
NBUP B-ABBREVIATION 
and O 
p O 
< O 
0.001 O 
at O 
3 O 
and O 
9mg O 
/ O 
kg O 
NBUP B-ABBREVIATION 
) O 
than O 
in O 
Swiss O 
mice O 
( O 
p O 
< O 
0.001 O 
at O 
9mg O 
/ O 
kg O 
NBUP B-ABBREVIATION 
) O 
. O 
Female O 
Fvb O 
mice O 
were O 
more O 
susceptible O 
to O 
BUP B-ABBREVIATION 
than O 
males O 
with O 
significantly O 
increased O 
inspiratory O 
time O 
( O 
p O 
< O 
0.05 O 
) O 
and O 
to O 
NBUP B-ABBREVIATION 
with O 
significantly O 
increased O 
expiratory O 
time O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
Following O 
BUP B-ABBREVIATION 
administration O 
, O 
plasma O 
BUP B-ABBREVIATION 
concentrations O 
were O 
significantly O 
higher O 
( O 
p O 
< O 
0.01 O 
) O 
and O 
plasma O 
NBUP B-ABBREVIATION 
concentrations O 
significantly O 
lower O 
( O 
p O 
< O 
0.001 O 
) O 
in O 
Fvb O 
mice O 
compared O 
to O 
Swiss O 
mice O 
. O 
Plasma O 
BUP B-ABBREVIATION 
concentrations O 
were O 
significantly O 
higher O 
( O 
p O 
< O 
0.05 O 
) O 
and O 
plasma O 
NBUP B-ABBREVIATION 
concentrations O 
significantly O 
lower O 
( O 
p O 
< O 
0.01 O 
) O 
in O 
male O 
compared O 
to O 
female O 
Fvb O 
mice O 
. O 
In O 
contrast O 
, O 
following O 
NBUP B-ABBREVIATION 
administration O 
, O 
comparable O 
plasma O 
NBUP B-ABBREVIATION 
concentrations O 
were O 
observed O 
in O 
both O 
genders O 
and O 
strains O 
. O 
No O 
differences O 
in O 
P-gp O 
expression O 
or O 
BUP B-ABBREVIATION 
and O 
NBUP B-ABBREVIATION 
transport O 
across O 
the O 
BBB O 
were O 
observed O 
between O 
male O 
and O 
female O 
Fvb O 
mice O 
as O 
well O 
as O 
between O 
Swiss O 
and O 
Fvb O 
mice O 
. O 
Our O 
results O 
suggest O 
that O 
P-gp O 
- O 
mediated O 
transport O 
across O 
the O 
BBB O 
does O 
not O 
play O 
a O 
key O 
- O 
role O 
in O 
gender O 
and O 
strain O 
- O 
related O 
variability O 
in O 
BUP B-ABBREVIATION 
and O 
NBUP B-ABBREVIATION 
-induced O 
respiratory O 
toxicity O 
in O 
mice O 
. O 
Both O 
gender- O 
and O 
strain O 
- O 
related O 
differences O 
in O 
respiratory O 
effects O 
of O 
BUP B-ABBREVIATION 
could O 
be O 
attributed O 
to O 
BUP B-ABBREVIATION 
itself O 
rather O 
than O 
to O 
its O 
metabolite O 
, O 
NBUP B-ABBREVIATION 
. O 

in O 
skeletal O 
muscle O 
proteolytic O 
gene O 
expression O 
after O 
prophylactic O 
supplementation O 
of O 
EGCG B-ABBREVIATION 
and O 
NAC B-ABBREVIATION 
and O 
eccentric O 
damage O 
. O 

: O 
The O 
impact O 
of O 
prophylactic O 
supplementation O 
of O 
N-acetyl-cysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
and O 
epigallocatechin B-TRIVIAL 
gallate I-TRIVIAL 
( O 
EGCG B-ABBREVIATION 
) O 
on O 
intramuscular O 
expression O 
of O 
proteolytic O 
genes O 
after O 
unaccustomed O 
eccentric O 
muscle O 
contractions O 
was O 
investigated O 
. O 
METHODS O 
: O 
Thirty O 
apparently O 
healthy O 
males O 
( O 
mean±SD O 
: O 
20.0±1.8years O 
, O 
175±7.1cm O 
, O 
76.1±16.9kg O 
) O 
ingested O 
daily O 
either O 
1800mg O 
of O 
NAC B-ABBREVIATION 
or O 
1800mg O 
of O 
EGCG B-ABBREVIATION 
( O 
98% O 
total O 
polyphenols B-FAMILY 
, O 
80% O 
total O 
catechins B-FAMILY 
, O 
and O 
50% O 
EGCG B-ABBREVIATION 
) O 
, O 
or O 
1000mg O 
of O 
a O 
glucomannan O 
placebo O 
( O 
PLA O 
) O 
in O 
a O 
double O 
blind O 
, O 
prophylactic O 
fashion O 
for O 
14days O 
. O 
Subjects O 
then O 
completed O 
an O 
unaccustomed O 
eccentric O 
exercise O 
bout O 
( O 
100 O 
repetitions O 
at O 
30°s(-1) O 
) O 
using O 
the O 
dominant O 
knee O 
extensors O 
. O 
Skeletal O 
muscle O 
biopsies O 
were O 
collected O 
from O 
the O 
vastus O 
lateralis O 
at O 
baseline O 
and O 
both O 
6 O 
and O 
24h O 
after O 
exercise O 
. O 
The O 
expression O 
of O 
proteolytic O 
genes O 
[ O 
i.e O 
. O 
, O 
muscle O 
ring O 
- O 
finger O 
1 O 
( O 
MuRF1 O 
) O 
, O 
atrogin-1 O 
, O 
α- O 
type O 
20S O 
subunit O 
C2 O 
( O 
HC2 O 
) O 
, O 
α- O 
type O 
20S O 
subunit O 
C3 O 
( O 
HC3 O 
) O 
, O 
ubiquitin O 
protein O 
ligase O 
3B O 
( O 
UBE3B O 
) O 
, O 
μ-calpain O 
, O 
and O 
m-calpain O 
] O 
was O 
quantified O 
using O 
real O 
- O 
time O 
RT-PCR O 
. O 
Separate O 
3×3 O 
( O 
group×time O 
) O 
repeated O 
measures O 
ANOVAs O 
were O 
used O 
to O 
analyze O 
changes O 
in O 
gene O 
expression O 
over O 
time O 
between O 
groups O 
. O 
RESULTS O 
: O 
No O 
significant O 
group×time O 
interactions O 
were O 
detected O 
between O 
groups O 
for O 
the O 
expression O 
of O 
any O 
of O 
the O 
atrogenes O 
or O 
calpains O 
( O 
p O 
> O 
0.05 O 
) O 
. O 
Significant O 
main O 
effects O 
for O 
time O 
identified O 
increases O 
in O 
MuRF1 O 
( O 
6h O 
: O 
5.3±10.8 O 
fold O 
; O 
p=0.046 O 
) O 
, O 
UBE3B O 
( O 
6h O 
: O 
5.3±7.7 O 
fold O 
; O 
p=0.006 O 
; O 
24h O 
: O 
3.3±4.5 O 
fold O 
; O 
p=0.005 O 
) O 
, O 
and O 
m-calpain O 
expression O 
( O 
6h O 
: O 
2.7±4.4 O 
fold O 
; O 
p=0.045 O 
) O 
in O 
all O 
participants O 
following O 
exercise O 
. O 
Increases O 
approached O 
significance O 
in O 
HC2 O 
( O 
6h O 
: O 
1.9±2.4 O 
fold O 
; O 
p=0.079 O 
; O 
24h O 
: O 
1.6±1.9 O 
fold O 
; O 
p=0.084 O 
) O 
and O 
m-calpain O 
expression O 
( O 
24h O 
: O 
1.8±2.3 O 
fold O 
; O 
p=0.084 O 
) O 
following O 
exercise O 
. O 
CONCLUSIONS O 
: O 
Prophylactic O 
supplementation O 
of O 
NAC B-ABBREVIATION 
and O 
EGCG B-ABBREVIATION 
did O 
not O 
impact O 
acute O 
changes O 
in O 
skeletal O 
muscle O 
proteolytic O 
gene O 
expression O 
following O 
eccentric O 
exercise O 
. O 
Eccentric O 
muscle O 
contractions O 
elevated O 
MuRF1 O 
and O 
UBE3B O 
, O 
while O 
m-calpain O 
and O 
HC2 O 
mRNA O 
tended O 
to O 
increase O 
. O 

major O 
histocompatibility O 
complex O 
class O 
II O 
( O 
MHC-II O 
) O 
surface O 
expression O 
on O 
antigen O 
presenting O 
cells O 
( O 
APCs O 
) O 
is O 
associated O 
with O 
dysregulated O 
immune O 
homeostasis O 
. O 
Lead O 
( O 
Pb B-FORMULA 
) O 
is O 
known O 
to O 
increase O 
MHC-II O 
surface O 
expression O 
on O 
murine O 
peritoneal O 
macrophages O 
ex O 
vivo O 
at O 
concentrations O 
exceeding O 
25 O 
μM O 
. O 
Little O 
data O 
exist O 
examining O 
this O 
effect O 
at O 
physiologically O 
relevant O 
concentrations O 
. O 
To O 
address O 
this O 
deficit O 
, O 
we O 
examined O 
the O 
effects O 
of O 
Pb B-FORMULA 
on O 
MHC-II O 
surface O 
expression O 
, O 
secondary O 
T-cell O 
activation O 
markers O 
( O 
CD80 O 
, O 
CD86 O 
, O 
CD40 O 
) O 
, O 
cell O 
viability O 
, O 
cellular O 
metabolic O 
activity O 
, O 
and O 
β-hexosaminidase O 
activity O 
in O 
RAW O 
267.4 O 
macrophage O 
cell O 
lines O 
, O 
with O 
changes O 
in O 
cell O 
ultrastructure O 
evaluated O 
by O 
electron O 
and O 
confocal O 
microscopy O 
. O 
Pb B-FORMULA 
induced O 
an O 
increase O 
in O 
MHC-II O 
, O 
CD86 O 
, O 
and O 
lysosome O 
- O 
associated O 
LAMP-1 O 
and O 
LAMP-2 O 
surface O 
mean O 
expression O 
during O 
one O 
doubling O 
cycle O 
( O 
17 O 
h O 
) O 
, O 
which O 
was O 
mirrored O 
by O 
increased O 
β-hexosaminidase O 
activity O 
. O 
Although O 
cell O 
viability O 
was O 
unaffected O 
, O 
cellular O 
metabolism O 
was O 
inhibited O 
. O 
Electron O 
microscopy O 
revealed O 
evidence O 
of O 
lipid O 
vacuolization O 
, O 
macroautophagy O 
and O 
myelin O 
figure O 
formation O 
in O 
cells O 
cultured O 
with O 
either O 
Pb B-FORMULA 
or O 
LPS O 
. O 
Confocal O 
microscopy O 
with O 
antibodies O 
against O 
LC3B O 
showed O 
a O 
punctate O 
pattern O 
consistent O 
with O 
the O 
presence O 
of O 
mature O 
autophagosomes O 
. O 
Collectively O 
, O 
these O 
data O 
suggest O 
that O 
2.5-5.0 O 
μM O 
Pb B-FORMULA 
increased O 
MHC-II O 
surface O 
expression O 
by O 
inhibiting O 
metabolic O 
activity O 
, O 
inducing O 
autophagy O 
, O 
and O 
increasing O 
MHC-II O 
trafficking O 
in O 
a O 
macrophage O 
cell O 
line O 
. O 

developmental O 
toxicity O 
studies O 
on O 
diundecyl B-MULTIPLE 
and I-MULTIPLE 
ditridecyl I-MULTIPLE 
phthalates I-MULTIPLE 
in O 
Sprague-Dawley O 
rats O 
. O 

study O 
evaluates O 
the O 
developmental O 
toxicity O 
of O 
two O 
high O 
molecular O 
weight O 
dialkyl B-FAMILY 
phthalate I-FAMILY 
esters I-FAMILY 
, O 
diundecyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DUDP B-ABBREVIATION 
) O 
and O 
ditridecyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DTDP B-ABBREVIATION 
) O 
. O 
Sprague-Dawley O 
rats O 
were O 
administered O 
0 O 
, O 
0.25 O 
, O 
0.5 O 
, O 
or O 
1g O 
/ O 
kg O 
/ O 
day O 
of O 
DUDP B-ABBREVIATION 
or O 
DTDP B-ABBREVIATION 
, O 
by O 
gavage O 
, O 
on O 
gestation O 
days O 
6-20 O 
. O 
DUDP B-ABBREVIATION 
and O 
DTDP B-ABBREVIATION 
had O 
no O 
adverse O 
effects O 
on O 
maternal O 
body O 
weight O 
and O 
food O 
consumption O 
. O 
The O 
number O 
of O 
live O 
fetuses O 
, O 
percent O 
of O 
post O 
- O 
implantation O 
loss O 
and O 
of O 
resorptions O 
, O 
fetal O 
sex O 
, O 
and O 
fetal O 
body O 
weights O 
were O 
not O 
affected O 
by O 
either O 
phthalate B-FAMILY 
. O 
There O 
was O 
no O 
evidence O 
of O 
teratogenicity O 
, O 
whatever O 
treatment O 
. O 
Small O 
decreases O 
in O 
the O 
anogenital O 
distance O 
of O 
male O 
fetuses O 
were O 
noted O 
at O 
0.5 O 
and O 
1g O 
DUDP B-ABBREVIATION 
/ O 
kg O 
/ O 
day O 
. O 
The O 
incidence O 
of O 
fetuses O 
with O 
supernumerary O 
lumbar O 
ribs O 
was O 
significantly O 
higher O 
than O 
control O 
at O 
0.5 O 
and O 
1g O 
DUDP B-ABBREVIATION 
/ O 
kg O 
/ O 
day O 
. O 
Thus O 
, O 
DTDP B-ABBREVIATION 
was O 
not O 
developmentally O 
toxic O 
up O 
to O 
1g O 
/ O 
kg O 
/ O 
day O 
and O 
there O 
were O 
signs O 
of O 
DUDP B-ABBREVIATION 
-induced O 
fetal O 
effects O 
at O 
0.5 O 
and O 
1g O 
/ O 
kg O 
/ O 
day O 
. O 

dosing O 
of O 
warfarin B-TRIVIAL 
and O 
other O 
coumarin B-TRIVIAL 
anticoagulants O 
: O 
the O 
role O 
of O 
genetic O 
polymorphisms O 
. O 

anticoagulants O 
, O 
which O 
include O 
warfarin B-TRIVIAL 
, O 
acenocoumarol B-TRIVIAL 
and O 
phenprocoumon B-TRIVIAL 
, O 
are O 
among O 
the O 
most O 
widely O 
prescribed O 
drugs O 
worldwide O 
. O 
There O 
is O 
now O 
a O 
large O 
body O 
of O 
published O 
data O 
showing O 
that O 
genotype O 
for O 
certain O 
common O 
polymorphisms O 
in O 
the O 
genes O 
encoding O 
the O 
target O 
vitamin B-FAMILY 
K I-FAMILY 
epoxide I-FAMILY 
reductase O 
( O 
G-1639A O 
/ O 
C1173T O 
) O 
and O 
the O 
main O 
metabolizing O 
enzyme O 
CYP2C9 O 
( O 
CYP2C9*2 O 
and O 
*3 O 
alleles O 
) O 
are O 
important O 
determinants O 
of O 
the O 
individual O 
coumarin B-TRIVIAL 
anticoagulant O 
dose O 
requirement O 
. O 
Additional O 
less O 
common O 
polymorphisms O 
in O 
these O 
genes O 
together O 
with O 
polymorphisms O 
in O 
other O 
genes O 
relevant O 
to O 
blood O 
coagulation O 
such O 
as O 
the O 
cytochrome O 
P450 O 
CYP4F2 O 
, O 
gamma-glutamyl B-SYSTEMATIC 
carboxylase O 
, O 
calumenin O 
and O 
cytochrome O 
P450 O 
oxidoreductase O 
may O 
also O 
be O 
significant O 
predictors O 
of O 
dose O 
, O 
especially O 
in O 
ethnic O 
groups O 
such O 
as O 
Africans O 
where O 
there O 
have O 
been O 
fewer O 
genetic O 
studies O 
compared O 
with O 
European O 
populations O 
. O 
Using O 
relevant O 
genotypes O 
to O 
calculate O 
starting O 
dose O 
may O 
improve O 
safety O 
during O 
the O 
initiation O 
period O 
. O 
Various O 
algorithms O 
for O 
dose O 
calculation O 
, O 
which O 
also O 
take O 
patient O 
age O 
and O 
other O 
characteristics O 
into O 
consideration O 
, O 
have O 
been O 
developed O 
for O 
all O 
three O 
widely O 
used O 
coumarin B-TRIVIAL 
anticoagulants O 
and O 
are O 
now O 
being O 
tested O 
in O 
ongoing O 
large O 
randomised O 
clinical O 
trials O 
. O 
One O 
recently O 
completed O 
study O 
has O 
provided O 
encouraging O 
results O 
suggesting O 
that O 
calculation O 
of O 
warfarin B-TRIVIAL 
dose O 
on O 
the O 
basis O 
of O 
individual O 
patient O 
genotype O 
leads O 
to O 
few O 
adverse O 
events O 
and O 
a O 
higher O 
proportion O 
of O 
time O 
within O 
the O 
therapeutic O 
coagulation O 
rate O 
window O 
, O 
but O 
these O 
findings O 
still O 
need O 
confirmation O 
. O 

of O 
caffeine B-TRIVIAL 
and O 
alcohol B-FAMILY 
on O 
mood O 
and O 
performance O 
changes O 
following O 
consumption O 
of O 
lager O 
. O 

: O 
The O 
present O 
study O 
examined O 
whether O 
caffeine B-TRIVIAL 
would O 
modify O 
the O 
behavioural O 
effects O 
of O 
alcohol B-FAMILY 
. O 
OBJECTIVES O 
: O 
The O 
aim O 
of O 
the O 
study O 
was O 
to O 
determine O 
whether O 
caffeine B-TRIVIAL 
modifies O 
the O 
effects O 
of O 
alcohol B-FAMILY 
on O 
mood O 
and O 
psychomotor O 
performance O 
and O 
to O 
identify O 
possible O 
dose O 
- O 
response O 
and O 
temporal O 
relationships O 
. O 
METHODS O 
: O 
A O 
double O 
- O 
blind O 
study O 
examined O 
the O 
effects O 
of O 
three O 
successive O 
lager O 
drinks O 
( O 
330 O 
ml O 
each O 
) O 
in O 
the O 
early O 
afternoon O 
on O 
mood O 
and O 
psychomotor O 
performance O 
assessed O 
at O 
30-min O 
intervals O 
over O 
a O 
2-h O 
period O 
. O 
Participants O 
carried O 
out O 
a O 
baseline O 
session O 
and O 
were O 
then O 
randomly O 
assigned O 
to O 
one O 
of O 
six O 
conditions O 
formed O 
by O 
combining O 
three O 
different O 
doses O 
of O 
caffeine B-TRIVIAL 
( O 
0 O 
, O 
62.5 O 
and O 
125 O 
mg O 
per O 
drink O 
) O 
with O 
either O 
no O 
alcohol B-FAMILY 
or O 
4.3 O 
% O 
alcohol B-FAMILY 
. O 
One O 
hundred O 
and O 
forty O 
- O 
six O 
young O 
adults O 
( O 
65 O 
male O 
, O 
81 O 
female O 
; O 
age O 
range O 
18-30 O 
years O 
) O 
participated O 
in O 
the O 
study O 
. O 
Mood O 
( O 
alertness O 
, O 
hedonic O 
tone O 
and O 
anxiety O 
) O 
was O 
assessed O 
before O 
and O 
after O 
performing O 
simple O 
reaction O 
time O 
and O 
choice O 
reaction O 
time O 
tasks O 
. O 
RESULTS O 
: O 
Alcohol B-SYSTEMATIC 
was O 
associated O 
with O 
higher O 
hedonic O 
tone O 
( O 
p O 
< O 
0.005 O 
) O 
, O 
reduced O 
anxiety O 
( O 
p O 
< O 
0.05 O 
) O 
and O 
reduced O 
alertness O 
( O 
p O 
< O 
0.005 O 
) O 
. O 
Caffeine B-TRIVIAL 
had O 
no O 
modifying O 
effect O 
on O 
hedonic O 
tone O 
or O 
anxiety O 
. O 
However O 
, O 
the O 
highest O 
dose O 
of O 
caffeine B-TRIVIAL 
did O 
remove O 
the O 
effect O 
of O 
alcohol B-FAMILY 
on O 
alertness O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Effects O 
of O 
alcohol B-FAMILY 
and O 
caffeine B-TRIVIAL 
were O 
found O 
on O 
the O 
performance O 
tasks O 
( O 
all O 
p O 
values O 
< O 
0.05 O 
) O 
but O 
these O 
were O 
independent O 
effects O 
. O 
CONCLUSIONS O 
: O 
The O 
results O 
from O 
the O 
present O 
study O 
confirm O 
that O 
caffeine B-TRIVIAL 
does O 
not O 
remove O 
the O 
negative O 
effects O 
of O 
alcohol B-FAMILY 
on O 
performance O 
although O 
high O 
doses O 
counteract O 
the O 
drop O 
in O 
subjective O 
alertness O 
produced O 
by O 
alcohol B-FAMILY 
. O 

- O 
induced O 
human O 
hepatotoxicity O 
is O 
difficult O 
to O 
predict O 
using O 
the O 
current O 
in O 
vitro O 
systems O 
. O 
In O 
this O 
study O 
, O 
long O 
- O 
term O 
3D O 
organotypic O 
cultures O 
of O 
the O 
human O 
hepatoma O 
HepaRG O 
cell O 
line O 
were O 
prepared O 
using O 
a O 
high O 
- O 
throughput O 
hanging O 
drop O 
method O 
. O 
The O 
organotypic O 
cultures O 
were O 
maintained O 
for O 
3 O 
weeks O 
and O 
assessed O 
for O 
( O 
1 O 
) O 
liver O 
specific O 
functions O 
, O 
including O 
phase O 
I O 
enzyme O 
and O 
transporter O 
activities O 
, O 
( O 
2 O 
) O 
expression O 
of O 
liver O 
- O 
specific O 
proteins O 
, O 
and O 
( O 
3 O 
) O 
responses O 
to O 
three O 
drugs O 
( O 
acetaminophen B-TRIVIAL 
, O 
troglitazone B-TRIVIAL 
, O 
and O 
rosiglitazone B-TRIVIAL 
) O 
. O 
Our O 
results O 
show O 
that O 
the O 
organotypic O 
cultures O 
maintain O 
high O 
liver O 
- O 
specific O 
functionality O 
during O 
3 O 
weeks O 
of O 
culture O 
. O 
The O 
immunohistochemistry O 
analyses O 
illustrate O 
that O 
the O 
organotypic O 
cultures O 
express O 
liver O 
- O 
specific O 
markers O 
such O 
as O 
albumin O 
, O 
CYP3A4 O 
, O 
CYP2E1 O 
, O 
and O 
MRP-2 O 
throughout O 
the O 
cultivation O 
period O 
. O 
Accordingly O 
, O 
the O 
production O 
rates O 
of O 
albumin O 
and O 
glucose B-TRIVIAL 
, O 
as O 
well O 
as O 
CYP2E1 O 
activity O 
, O 
were O 
significantly O 
higher O 
in O 
the O 
3D O 
versus O 
the O 
2D O 
cultures O 
. O 
Toxicity O 
studies O 
show O 
that O 
the O 
organotypic O 
cultures O 
are O 
more O 
sensitive O 
to O 
acetaminophen B-TRIVIAL 
- O 
and O 
rosiglitazone B-TRIVIAL 
-induced O 
toxicity O 
but O 
less O 
sensitive O 
to O 
troglitazone B-TRIVIAL 
-induced O 
toxicity O 
than O 
the O 
2D O 
cultures O 
. O 
Furthermore O 
, O 
the O 
EC50 O 
value O 
( O 
2.7mM O 
) O 
for O 
acetaminophen B-TRIVIAL 
on O 
the O 
3D O 
cultures O 
was O 
similar O 
to O 
in O 
vivo O 
toxicity O 
. O 
In O 
summary O 
, O 
the O 
results O 
from O 
our O 
study O 
suggest O 
that O 
the O 
3D O 
organotypic O 
HepaRG O 
culture O 
is O 
a O 
promising O 
in O 
vitro O 
tool O 
for O 
more O 
accurate O 
assessment O 
of O 
acute O 
and O 
also O 
possibly O 
for O 
chronic O 
drug O 
- O 
induced O 
hepatotoxicity O 
. O 

is O 
a O 
systemic O 
inflammatory O 
response O 
to O 
infection O 
. O 
A O 
common O 
end O 
- O 
feature O 
, O 
these O 
patients O 
regularly O 
suffer O 
from O 
is O 
the O 
so O 
- O 
called O 
multiple O 
organ O 
dysfunction O 
syndrome O 
, O 
an O 
often O 
fatal O 
consequence O 
of O 
organ O 
hypoperfusion O 
, O 
coagulopathy O 
, O 
immune O 
dysregulation O 
, O 
and O 
mitochondrial O 
dysfunction O 
. O 
Microvascular O 
dysfunction O 
critically O 
contributes O 
to O 
the O 
morbidity O 
and O 
mortality O 
of O 
this O 
disease O 
. O 
The O 
angiopoietin O 
( O 
Angpt O 
) O 
/ O 
Tie2 O 
system O 
consists O 
of O 
the O 
transmembrane O 
endothelial O 
tyrosine B-TRIVIAL 
kinase O 
Tie2 O 
and O 
its O 
circulating O 
ligands O 
( O 
Angpt-1 O 
, O 
-2 O 
, O 
and O 
-3 O 
/ O 
4 O 
) O 
. O 
The O 
balance O 
between O 
the O 
canonical O 
agonist O 
Angpt-1 O 
and O 
its O 
competitive O 
inhibitor O 
, O 
Angpt-2 O 
, O 
regulates O 
basal O 
endothelial O 
barrier O 
function O 
and O 
the O 
leakage O 
and O 
vascular O 
inflammation O 
that O 
develop O 
in O 
response O 
to O 
pathogens O 
and O 
cytokines O 
. O 
Here O 
we O 
summarize O 
recent O 
work O 
in O 
mice O 
and O 
men O 
to O 
highlight O 
the O 
therapeutic O 
potential O 
in O 
this O 
pathway O 
to O 
prevent O 
or O 
even O 
reverse O 
microvascular O 
dysfunction O 
in O 
this O 
deadly O 
disease O 
. O 

( O 
GPI O 
) O 
enriches O 
GPI-anchored O 
proteins O 
( O 
GPI-AP O 
) O 
in O 
lipid O 
rafts O 
by O 
intimate O 
interaction O 
of O 
its O 
lipid O 
moiety O 
with O 
sphingolipids B-FAMILY 
and O 
cholesterol B-TRIVIAL 
. O 
In O 
addition O 
to O 
such O 
lipid O 
- O 
lipid O 
interactions O 
, O 
it O 
has O 
been O 
reported O 
that O 
GPI O 
may O 
interact O 
with O 
protein O 
moiety O 
linked O 
to O 
GPI O 
and O 
affect O 
protein O 
conformations O 
because O 
GPI O 
delipidation O 
reduced O 
immunoreactivities O 
of O 
protein O 
. O 
Here O 
, O 
we O 
report O 
that O 
GPI-APs O 
that O 
have O 
not O 
undergone O 
fatty B-FAMILY 
acid I-FAMILY 
remodeling O 
exhibit O 
reduced O 
immunoreactivities O 
in O 
Western O 
blotting O 
, O 
similar O 
to O 
delipidated O 
proteins O 
, O 
compared O 
with O 
normal O 
remodeled O 
GPI-APs O 
. O 
In O 
contrast O 
, O 
immunostaining O 
in O 
flow O 
cytometry O 
and O 
immunoprecipitation O 
did O 
not O 
show O 
significant O 
differences O 
between O 
remodeled O 
and O 
unremodeled O 
GPI-APs O 
. O 
Moreover O 
, O 
detection O 
with O 
premixed O 
primary O 
/ O 
secondary O 
antibody O 
complexes O 
or O 
Fab O 
fragments O 
eliminated O 
this O 
difference O 
in O 
Western O 
blotting O 
. O 
These O 
results O 
indicate O 
that O 
normally O 
remodeled O 
GPI O 
enhanced O 
oligomerization O 
of O 
GPI-APs O 
and O 
that O 
inefficient O 
oligomerization O 
of O 
unremodeled O 
GPI-APs O 
was O 
responsible O 
for O 
reduced O 
immunoreactivities O 
. O 
Moreover O 
, O 
the O 
reduction O 
in O 
immunoreactivities O 
of O 
delipidated O 
GPI-APs O 
was O 
most O 
likely O 
caused O 
by O 
the O 
same O 
effect O 
. O 
Finally O 
, O 
by O 
chemical O 
cross O 
- O 
linking O 
of O 
surface O 
proteins O 
in O 
living O 
cells O 
and O 
cell O 
killing O 
assay O 
using O 
a O 
pore O 
- O 
forming O 
bacterial O 
toxin O 
, O 
we O 
showed O 
that O 
enhanced O 
oligomerization O 
by O 
GPI-remodeling O 
occurs O 
under O 
a O 
physiological O 
membrane O 
environment O 
. O 
Thus O 
, O 
this O 
study O 
clarifies O 
the O 
significance O 
of O 
GPI O 
fatty B-FAMILY 
acid I-FAMILY 
remodeling O 
in O 
oligomerization O 
of O 
GPI-APs O 
and O 
provides O 
useful O 
information O 
for O 
technical O 
studies O 
of O 
these O 
cell O 
components O 
. O 

Modifications O 
to O 
Tetrahydropyridine-3-carboxylate B-FAMILY 
Esters I-FAMILY 
en O 
Route O 
to O 
the O 
Discovery O 
of O 
M(5)-Preferring O 
Muscarinic O 
Receptor O 
Orthosteric O 
Antagonists O 
. O 

M(5) O 
muscarinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
is O 
suggested O 
to O 
be O 
a O 
potential O 
pharmacotherapeutic O 
target O 
for O 
the O 
treatment O 
of O 
drug O 
abuse O 
. O 
We O 
describe O 
herein O 
the O 
discovery O 
of O 
a O 
series O 
of O 
M(5)-preferring O 
orthosteric O 
antagonists O 
based O 
on O 
the O 
scaffold O 
of O 
1,2,5,6-tetrahydropyridine-3-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
Compound O 
56 O 
, O 
the O 
most O 
selective O 
compound O 
in O 
this O 
series O 
, O 
possesses O 
an O 
11-fold O 
selectivity O 
for O 
the O 
M(5) O 
over O 
M(1) O 
receptor O 
and O 
shows O 
little O 
activity O 
at O 
M(2)-M(4) O 
. O 
This O 
compound O 
, O 
although O 
exhibiting O 
modest O 
affinity O 
( O 
K O 
(i) O 
= O 
2.24 O 
μM O 
) O 
for O 
the O 
[(3)H]N-methylscopolamine B-SYSTEMATIC 
binding O 
site O 
on O 
the O 
M(5) O 
receptor O 
, O 
is O 
potent O 
( O 
IC(50) O 
= O 
0.45 O 
nM O 
) O 
in O 
inhibiting O 
oxotremorine B-TRIVIAL 
-evoked O 
[(3)H]DA B-SYSTEMATIC 
release O 
from O 
rat O 
striatal O 
slices O 
. O 
Further O 
, O 
a O 
homology O 
model O 
of O 
human O 
M(5) O 
receptor O 
based O 
on O 
the O 
crystal O 
structure O 
of O 
the O 
rat O 
M(3) O 
receptor O 
was O 
constructed O 
, O 
and O 
docking O 
studies O 
of O 
compounds O 
28 O 
and O 
56 O 
were O 
performed O 
in O 
an O 
attempt O 
to O 
understand O 
the O 
possible O 
binding O 
mode O 
of O 
these O 
novel O 
analogues O 
to O 
the O 
receptor O 
. O 

molecule O 
antivirulents O 
targeting O 
the O 
iron B-SYSTEMATIC 
-regulated O 
heme B-FAMILY 
oxygenase O 
( O 
HemO O 
) O 
of O 
P O 
. O 
aeruginosa O 
. O 

require O 
iron B-SYSTEMATIC 
for O 
survival O 
and O 
virulence O 
and O 
employ O 
several O 
mechanisms O 
including O 
utilization O 
of O 
the O 
host O 
heme B-FAMILY 
containing O 
proteins O 
. O 
The O 
final O 
step O 
in O 
releasing O 
iron B-SYSTEMATIC 
is O 
the O 
oxidative O 
cleavage O 
of O 
heme B-FAMILY 
by O 
HemO O 
. O 
A O 
recent O 
computer O 
aided O 
drug O 
design O 
( O 
CADD O 
) O 
study O 
identified O 
several O 
inhibitors O 
of O 
the O 
bacterial O 
HemOs O 
. O 
Herein O 
we O 
report O 
the O 
near O 
complete O 
HN B-FORMULA 
, O 
N B-FORMULA 
, O 
CO B-FORMULA 
, O 
Cα O 
, O 
and O 
Cβ O 
chemical O 
shift O 
assignment O 
of O 
the O 
P O 
. O 
aeruginosa O 
HemO O 
in O 
the O 
absence O 
and O 
presence O 
of O 
inhibitors O 
(E)-3-(4-(phenylamino)phenylcarbamoyl)acrylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
3 O 
) O 
and O 
(E)-N'-(4-(dimethylamino)benzylidene) B-SYSTEMATIC 
diazenecarboximidhydrazide I-SYSTEMATIC 
( O 
5 O 
) O 
. O 
The O 
NMR O 
data O 
confirm O 
that O 
the O 
inhibitors O 
bind O 
within O 
the O 
heme B-FAMILY 
pocket O 
of O 
HemO O 
consistent O 
with O 
in O 
silico O 
molecular O 
dynamic O 
simulations O 
. O 
Both O 
inhibitors O 
and O 
the O 
phenoxy B-SYSTEMATIC 
derivative O 
of O 
3 O 
have O 
activity O 
against O 
P O 
. O 
aeruginosa O 
clinical O 
isolates O 
. O 
Furthermore O 
, O 
5 O 
showed O 
antimicrobial O 
activity O 
in O 
the O 
in O 
vivo O 
C O 
. O 
elegans O 
curing O 
assay O 
. O 
Thus O 
, O 
targeting O 
virulence O 
mechanisms O 
required O 
within O 
the O 
host O 
is O 
a O 
viable O 
antimicrobial O 
strategy O 
for O 
the O 
development O 
of O 
novel O 
antivirulants O 
. O 

inhibition O 
of O 
HIV-1 O 
reverse O 
transcriptase O 
: O 
a O 
first O 
step O 
in O 
designing O 
a O 
bifunctional O 
triphosphate B-SYSTEMATIC 
. O 

onset O 
of O 
resistance O 
to O 
approved O 
anti-AIDS O 
drugs O 
by O 
HIV O 
necessitates O 
the O 
search O 
for O 
novel O 
inhibitors O 
of O 
HIV-1 O 
reverse O 
transcriptase O 
( O 
RT O 
) O 
. O 
Developing O 
single O 
molecular O 
agents O 
concurrently O 
occupying O 
the O 
nucleoside B-FAMILY 
and O 
nonnucleoside O 
binding O 
sites O 
in O 
RT O 
is O 
an O 
intriguing O 
idea O 
but O 
the O 
proof O 
of O 
concept O 
has O 
so O 
far O 
been O 
elusive O 
. O 
As O 
a O 
first O 
step O 
, O 
we O 
describe O 
molecular O 
modeling O 
to O 
guide O 
focused O 
chemical O 
syntheses O 
of O 
conjugates O 
having O 
nucleoside B-FAMILY 
( O 
d4T B-ABBREVIATION 
) O 
and O 
nonnucleoside O 
( O 
TIBO B-ABBREVIATION 
) O 
moieties O 
tethered O 
by O 
a O 
flexible O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
linker O 
. O 
A O 
triphosphate B-SYSTEMATIC 
of O 
d4T-6PEG-TIBO B-ABBREVIATION 
conjugate O 
was O 
successfully O 
synthesized O 
that O 
is O 
recognized O 
as O 
a O 
substrate O 
by O 
HIV-1 O 
RT O 
and O 
incorporated O 
into O 
a O 
double O 
- O 
stranded O 
DNA O 
. O 

: O 
The O 
clinical O 
significance O 
of O 
the O 
measurement O 
of O 
serum O 
PCSK9 O 
( O 
proprotein O 
subtilisin O 
kexin O 
type O 
9 O 
) O 
is O 
not O 
well O 
defined O 
. O 
This O 
study O 
investigated O 
the O 
association O 
between O 
serum O 
PCSK9 O 
levels O 
and O 
atherosclerosis O 
assessed O 
by O 
carotid O 
intima O 
media O 
thickness O 
( O 
IMT O 
) O 
in O 
hypertensive O 
patients O 
. O 
METHODS O 
: O 
A O 
total O 
of O 
126 O 
hypertensive O 
patients O 
over O 
the O 
age O 
of O 
45 O 
were O 
enrolled O 
. O 
The O 
maximum O 
carotid O 
IMT O 
( O 
max-IMT O 
) O 
and O 
the O 
mean O 
carotid O 
IMT O 
( O 
mean-IMT O 
) O 
were O 
measured O 
at O 
the O 
time O 
of O 
enrollment O 
. O 
Clinical O 
and O 
laboratory O 
parameters O 
including O 
serum O 
PCSK9 O 
were O 
analyzed O 
. O 
RESULTS O 
: O 
Patients O 
were O 
divided O 
into O 
tertiles O 
based O 
on O 
serum O 
PCSK9 O 
levels O 
. O 
After O 
adjusting O 
for O 
age O 
, O 
sex O 
, O 
total O 
cholesterol B-TRIVIAL 
, O 
HDL-cholesterol O 
and O 
triglyceride B-FAMILY 
, O 
max-IMT O 
was O 
significantly O 
increased O 
in O 
the O 
highest O 
tertile O 
of O 
serum O 
PCSK9 O 
( O 
0.969±0.033 O 
vs O 
0.959±0.033 O 
vs O 
1.077±0.033mm O 
, O 
respectively O 
; O 
P=0.026 O 
) O 
. O 
Mean-IMT O 
showed O 
a O 
tendency O 
to O 
increase O 
across O 
the O 
tertile O 
groups O 
( O 
0.773±0.025 O 
vs O 
0.790±0.026 O 
vs O 
0.856±0.025mm O 
, O 
respectively O 
; O 
P=0.059 O 
) O 
. O 
Multivariate O 
regression O 
analysis O 
revealed O 
that O 
serum O 
PCSK9 O 
was O 
independently O 
associated O 
with O 
carotid O 
IMT O 
( O 
max-IMT O 
: O 
β=0.212 O 
, O 
P=0.016 O 
; O 
mean-IMT O 
: O 
β=0.184 O 
, O 
P=0.04 O 
) O 
. O 
CONCLUSION O 
: O 
The O 
present O 
study O 
is O 
the O 
first O 
to O 
report O 
the O 
association O 
between O 
serum O 
PCSK9 O 
levels O 
and O 
carotid O 
IMT O 
in O 
hypertensive O 
patients O 
. O 
These O 
results O 
suggest O 
that O 
serum O 
PCSK9 O 
may O 
have O 
a O 
certain O 
role O 
in O 
early O 
pathogenesis O 
of O 
atherosclerosis O 
. O 

effect O 
of O 
amphetamine B-TRIVIAL 
and O 
concomitant O 
ionotropic O 
glutamate B-TRIVIAL 
receptors O 
blockade O 
in O 
the O 
ventral O 
striatum O 
on O 
spatial O 
learning O 
in O 
mice O 
. O 

: O 
Accumulating O 
evidence O 
supports O 
the O 
involvement O 
of O 
the O 
ventral O 
striatum O 
( O 
VS O 
) O 
in O 
spatial O 
information O 
processing O 
. O 
The O 
multiple O 
cortical O 
glutamatergic O 
and O 
mesolimbic O 
dopaminergic O 
( O 
DAergic O 
) O 
afferences O 
on O 
the O 
same O 
neurons O 
in O 
the O 
ventral O 
striatum O 
provide O 
the O 
neuroanatomical O 
substrate O 
for O 
glutamate B-TRIVIAL 
and O 
dopamine B-TRIVIAL 
functional O 
interaction O 
. O 
However O 
, O 
there O 
is O 
little O 
evidence O 
in O 
the O 
literature O 
on O 
how O 
this O 
interaction O 
affects O 
the O 
ability O 
to O 
encode O 
spatial O 
information O 
. O 
OBJECTIVE O 
: O 
First O 
, O 
we O 
evaluated O 
the O 
effect O 
of O 
intra-VS O 
bilateral O 
infusion O 
of O 
different O 
doses O 
of O 
amphetamine B-TRIVIAL 
( O 
0.3 O 
, O 
0.75 O 
, O 
and O 
1.5 O 
μg O 
/ O 
side O 
) O 
on O 
the O 
ability O 
to O 
detect O 
spatial O 
novelty O 
in O 
mice O 
. O 
Next O 
, O 
we O 
examined O 
the O 
impact O 
produced O 
on O 
the O 
same O 
abilities O 
by O 
intra-VS O 
infusion O 
of O 
ineffective O 
doses O 
of O 
amphetamine B-TRIVIAL 
( O 
0.3 O 
μg O 
/ O 
side O 
) O 
in O 
association O 
with O 
N-methyl-D-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
( O 
3.125 O 
ng O 
/ O 
side O 
) O 
or O 
α-amino-3-hydroxy-5-methylisoxazole-4-propionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
AMPA B-ABBREVIATION 
) O 
( O 
0.25 O 
ng O 
/ O 
side O 
) O 
receptor O 
antagonist O 
. O 
RESULTS O 
: O 
The O 
results O 
show O 
that O 
infusion O 
of O 
amphetamine B-TRIVIAL 
impairs O 
detection O 
of O 
spatial O 
novelty O 
, O 
affecting O 
also O 
exploratory O 
activity O 
and O 
marginally O 
the O 
detection O 
of O 
nonspatial O 
novelty O 
. O 
In O 
contrast O 
, O 
an O 
association O 
of O 
subthreshold O 
doses O 
of O 
amphetamine B-TRIVIAL 
with O 
NMDA B-ABBREVIATION 
or O 
AMPA B-ABBREVIATION 
receptor O 
antagonists O 
exerted O 
a O 
selective O 
effect O 
on O 
reactivity O 
to O 
a O 
spatial O 
change O 
. O 
CONCLUSIONS O 
: O 
These O 
findings O 
demonstrate O 
that O 
enhanced O 
DAergic O 
activity O 
in O 
the O 
VS O 
enhances O 
glutamate B-TRIVIAL 
receptor O 
antagonist O 
- O 
induced O 
impairment O 
in O 
learning O 
and O 
memory O 
. O 

phosphatase O 
2A O 
is O 
one O 
of O 
four O 
major O 
classes O 
of O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
phosphatases O 
. O 
Overexpression O 
of O 
brain O 
- O 
specific O 
regulatory O 
subunit O 
PPP2R2 O 
in O 
neuron O 
cells O 
is O 
implicated O 
in O 
pathogenesis O 
. O 
The O 
alternative O 
splicing O 
of O 
PPP2R2B O 
encodes O 
two O 
isoforms O 
. O 
They O 
are O 
subunit O 
of O 
cytoplasmic O 
specific O 
Bβ1 O 
and O 
mitochondria O 
- O 
targeted O 
Bβ2 O 
. O 
The O 
two O 
constructs O 
were O 
transfected O 
into O 
human O 
neuroblastoma O 
cells O 
, O 
SK-N-SH O 
, O 
respectively O 
, O 
and O 
the O 
stable O 
clones O 
overexpressing O 
either O 
Bβ1 O 
or O 
Bβ2 O 
established O 
. O 
We O 
have O 
reported O 
that O 
Bβ2 O 
clones O 
are O 
sensitive O 
to O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
treatment O 
by O 
inducing O 
autophagic O 
cell O 
death O 
. O 
To O 
study O 
more O 
on O 
the O 
onset O 
of O 
neuropathogenesis O 
under O 
strain O 
, O 
both O 
clones O 
were O 
exposed O 
to O 
different O 
environmental O 
stress O 
, O 
e.g O 
. O 
starvation O 
and O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
stress O 
. O 
To O 
learn O 
how O 
PPP2R2B O 
overexpression O 
responds O 
to O 
starvation O 
, O 
cells O 
were O 
incubated O 
in O 
Hank's O 
buffered O 
salt O 
solution O 
of O 
deprived O 
nutrient O 
. O 
Cell O 
death O 
was O 
induced O 
in O 
Bβ1 O 
clones O 
after O 
6 O 
h O 
starvation O 
, O 
but O 
not O 
in O 
Bβ2 O 
clones O 
. O 
The O 
pharmacological O 
inhibitor O 
, O 
Bafilomycin B-TRIVIAL 
A1 I-TRIVIAL 
, O 
rescued O 
the O 
cell O 
death O 
while O 
suppressing O 
autophagy O 
. O 
On O 
the O 
other O 
hand O 
, O 
to O 
assess O 
how O 
cells O 
respond O 
to O 
ER O 
stress O 
, O 
the O 
cells O 
were O 
treated O 
with O 
0.1 O 
μM O 
of O 
N B-FORMULA 
-glycosylation O 
inhibitor O 
, O 
tunicamycin B-TRIVIAL 
( O 
TM O 
) O 
. O 
In O 
contrast O 
with O 
Bβ1 O 
, O 
the O 
apoptotic O 
cell O 
death O 
appeared O 
in O 
Bβ2 O 
after O 
48 O 
h O 
treatment O 
. O 
The O 
formation O 
of O 
autophagolysosome O 
was O 
detected O 
in O 
Bβ2 O 
following O 
12 O 
h O 
treatment O 
with O 
TM O 
as O 
evidenced O 
by O 
lysotracker O 
and O 
GFP-LC3 O 
staining O 
for O 
fluorescence O 
microscopy O 
analysis O 
. O 
The O 
autophagy O 
inhibitor O 
, O 
3-methyladenine B-SYSTEMATIC 
, O 
salvaged O 
the O 
final O 
apoptosis O 
. O 
The O 
stable O 
cell O 
lines O 
with O 
ectopically O 
transfected O 
PPP2R2B O 
genes O 
encoding O 
isoforms O 
of O 
brain O 
- O 
specific O 
regulatory O 
subunit O 
exhibit O 
distinct O 
apoptosis O 
under O 
different O 
stressors O 
. O 
The O 
induced O 
autophagic O 
apoptotic O 
cell O 
death O 
is O 
related O 
to O 
mitochondrial O 
membrane O 
potential O 
drop O 
and O 
ROS O 
generation O 
. O 
Disturbance O 
of O 
autophagy O 
alleviates O 
the O 
induced O 
cell O 
death O 
. O 
The O 
results O 
promised O 
a O 
good O 
model O 
for O 
understanding O 
the O 
onset O 
in O 
pathogenesis O 
under O 
stress O 
in O 
neuron O 
cells O 
with O 
aberrant O 
PPP2R2B O 
expression O 
. O 

review O 
of O 
fabrication O 
and O 
applications O 
of O 
carbon B-SYSTEMATIC 
nanotube O 
film O 
- O 
based O 
flexible O 
electronics O 
. O 

electronics O 
offer O 
a O 
wide-variety O 
of O 
applications O 
such O 
as O 
flexible O 
circuits O 
, O 
flexible O 
displays O 
, O 
flexible O 
solar O 
cells O 
, O 
skin O 
- O 
like O 
pressure O 
sensors O 
, O 
and O 
conformable O 
RFID O 
tags O 
. O 
Carbon B-SYSTEMATIC 
nanotubes O 
( O 
CNTs O 
) O 
are O 
a O 
promising O 
material O 
for O 
flexible O 
electronics O 
, O 
both O 
as O 
the O 
channel O 
material O 
in O 
field O 
- O 
effect O 
transistors O 
( O 
FETs O 
) O 
and O 
as O 
transparent O 
electrodes O 
, O 
due O 
to O 
their O 
high O 
intrinsic O 
carrier O 
mobility O 
, O 
conductivity O 
, O 
and O 
mechanical O 
flexibility O 
. O 
In O 
this O 
feature O 
article O 
, O 
we O 
review O 
the O 
recent O 
progress O 
of O 
CNTs O 
in O 
flexible O 
electronics O 
by O 
describing O 
both O 
the O 
processing O 
and O 
the O 
applications O 
of O 
CNT O 
- O 
based O 
flexible O 
devices O 
. O 
To O 
employ O 
CNTs O 
as O 
the O 
channel O 
material O 
in O 
FETs O 
, O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWNTs O 
) O 
are O 
used O 
. O 
There O 
are O 
generally O 
two O 
methods O 
of O 
depositing O 
SWNTs O 
on O 
flexible O 
substrates O 
- O 
transferring O 
CVD-grown O 
SWNTs O 
or O 
solution O 
- O 
depositing O 
SWNTs O 
. O 
Since O 
CVD-grown O 
SWNTs O 
can O 
be O 
highly O 
aligned O 
, O 
they O 
often O 
outperform O 
solution O 
- O 
processed O 
SWNT O 
films O 
that O 
are O 
typically O 
in O 
the O 
form O 
of O 
random O 
network O 
. O 
However O 
, O 
solution O 
- O 
based O 
SWNTs O 
can O 
be O 
printed O 
at O 
a O 
large O 
- O 
scale O 
and O 
at O 
low O 
- O 
cost O 
, O 
rendering O 
them O 
more O 
appropriate O 
for O 
manufacturing O 
. O 
In O 
either O 
case O 
, O 
the O 
removal O 
of O 
metallic O 
SWNTs O 
in O 
an O 
effective O 
and O 
a O 
scalable O 
manner O 
is O 
critical O 
, O 
which O 
must O 
still O 
be O 
developed O 
and O 
optimized O 
. O 
Nevertheless O 
, O 
promising O 
results O 
demonstrating O 
SWNT O 
- O 
based O 
flexible O 
circuits O 
, O 
displays O 
, O 
RF-devices O 
, O 
and O 
biochemical O 
sensors O 
have O 
been O 
reported O 
by O 
various O 
research O 
groups O 
, O 
proving O 
insight O 
into O 
the O 
exciting O 
possibilities O 
of O 
SWNT O 
- O 
based O 
FETs O 
. O 
In O 
using O 
carbon B-SYSTEMATIC 
nanotubes O 
as O 
transparent O 
electrodes O 
( O 
TEs O 
) O 
, O 
two O 
main O 
strategies O 
have O 
been O 
implemented O 
to O 
fabricate O 
highly O 
conductive O 
, O 
transparent O 
, O 
and O 
mechanically O 
compliant O 
films O 
- O 
superaligned O 
films O 
of O 
CNTs O 
drawn O 
from O 
vertically O 
grown O 
CNT O 
forests O 
using O 
the O 
" O 
dry O 
- O 
drawing O 
" O 
technique O 
and O 
the O 
deposition O 
or O 
embedding O 
of O 
CNTs O 
onto O 
flexible O 
or O 
stretchable O 
substrates O 
. O 
The O 
main O 
challenge O 
for O 
CNT O 
based O 
TEs O 
is O 
to O 
fabricate O 
films O 
that O 
are O 
both O 
highly O 
conductive O 
and O 
transparent O 
. O 
These O 
CNT O 
based O 
TEs O 
have O 
been O 
used O 
in O 
stretchable O 
and O 
flexible O 
pressure O 
, O 
strain O 
, O 
and O 
chemical O 
and O 
biological O 
sensors O 
. O 
In O 
addition O 
, O 
they O 
have O 
also O 
been O 
used O 
as O 
the O 
anode O 
and O 
cathode O 
in O 
flexible O 
light O 
emitting O 
diodes O 
, O 
solar O 
cells O 
, O 
and O 
supercapacitors O 
. O 
In O 
summary O 
, O 
there O 
are O 
a O 
number O 
of O 
challenges O 
yet O 
to O 
overcome O 
to O 
optimize O 
the O 
processing O 
and O 
performance O 
of O 
CNT O 
- O 
based O 
flexible O 
electronics O 
; O 
nonetheless O 
, O 
CNTs O 
remain O 
a O 
highly O 
suitable O 
candidate O 
for O 
various O 
flexible O 
electronic O 
applications O 
in O 
the O 
near O 
future O 
. O 

Serum-Resistant O 
Low-Generation O 
Polyamidoamine B-SYSTEMATIC 
with O 
PEI B-TRIVIAL 
423 I-TRIVIAL 
Outer O 
Layer O 
for O 
Gene O 
Delivery O 
Vector O 
. O 

new O 
derivative O 
of O 
polyamidoamine B-FAMILY 
and O 
polyethylenimine B-SYSTEMATIC 
, O 
G2.5- O 
PEI B-TRIVIAL 
423 I-TRIVIAL 
or O 
G1.5- O 
PEI B-TRIVIAL 
423 I-TRIVIAL 
, O 
is O 
prepared O 
by O 
an O 
amidation O 
reaction O 
of O 
PAMAM B-ABBREVIATION 
G2.5 O 
or O 
PAMAM B-ABBREVIATION 
G1.5 O 
using O 
PEI B-TRIVIAL 
423 I-TRIVIAL 
. O 
The O 
polycations O 
show O 
a O 
great O 
ability O 
to O 
combine O 
with O 
pDNA O 
to O 
form O 
complexes O 
, O 
which O 
protect O 
the O 
pDNA O 
from O 
nuclease O 
degradation O 
. O 
The O 
polymers O 
display O 
stronger O 
buffer O 
capacity O 
and O 
lower O 
cytotoxicity O 
. O 
The O 
complexes O 
have O 
particle O 
sizes O 
of O 
120-180 O 
nm O 
and O 
zeta O 
potentials O 
of O 
20-40 O 
mV O 
. O 
The O 
G2.5- O 
PEI B-TRIVIAL 
423 I-TRIVIAL 
complexes O 
display O 
much O 
higher O 
transfection O 
efficiencies O 
than O 
PAMAM B-ABBREVIATION 
G5 O 
and O 
Lipo-2k O 
, O 
and O 
the O 
G1.5- O 
PEI B-TRIVIAL 
423 I-TRIVIAL 
complexes O 
display O 
higher O 
transfection O 
efficiencies O 
than O 
PAMAM B-ABBREVIATION 
G4 O 
and O 
PEI B-ABBREVIATION 
-25k O 
. O 
The O 
complexes O 
possess O 
better O 
serum O 
- O 
resistant O 
capacity O 
. O 
The O 
G2.5- O 
PEI B-TRIVIAL 
423 I-TRIVIAL 
has O 
a O 
great O 
potential O 
to O 
be O 
used O 
as O 
a O 
serum O 
- O 
resistant O 
gene O 
vector O 
. O 

pharmacokinetics O 
of O 
atorvastatin B-TRIVIAL 
and O 
its O 
active O 
metabolites O 
in O 
children O 
and O 
adolescents O 
with O 
heterozygous O 
familial O 
hypercholesterolemia O 
: O 
selective O 
use O 
of O 
informative O 
prior O 
distributions O 
from O 
adults O 
. O 

population O 
pharmacokinetics O 
( O 
PPK O 
) O 
of O 
atorvastatin B-TRIVIAL 
and O 
its O 
principal O 
active O 
metabolite O 
, O 
o-hydroxyatorvastatin B-SYSTEMATIC 
, O 
were O 
described O 
in O 
6-17 O 
years O 
old O 
pediatric O 
hypercholesterolemia O 
patients O 
with O 
a O 
2-compartment O 
model O 
for O 
both O 
parent O 
and O 
metabolite O 
. O 
Informative O 
prior O 
distributions O 
on O 
selected O 
parameters O 
, O 
based O 
on O 
adult O 
data O 
, O 
were O 
required O 
to O 
stabilize O 
the O 
model O 
and O 
were O 
implemented O 
using O 
a O 
Bayesian O 
penalty O 
term O 
on O 
the O 
likelihood O 
function O 
in O 
the O 
nonlinear O 
mixed O 
effects O 
model O 
( O 
NONMEM O 
VI O 
with O 
PRIOR O 
) O 
. O 
Concentrations O 
below O 
the O 
limit O 
of O 
quantitation O 
were O 
treated O 
as O 
censored O 
data O 
using O 
a O 
conditional O 
likelihood O 
function O 
. O 
Atorvastatin B-TRIVIAL 
apparent O 
oral O 
clearance O 
( O 
CL O 
/ O 
F O 
) O 
was O 
described O 
as O 
a O 
function O 
of O 
body O 
weight O 
using O 
an O 
allometric O 
equation O 
. O 
Based O 
on O 
the O 
final O 
model O 
, O 
the O 
typical O 
CL O 
/ O 
F O 
estimates O 
for O 
a O 
Tanner O 
Stage O 
1 O 
patient O 
( O 
35 O 
kg O 
weight O 
) O 
and O 
Tanner O 
Stage O 
≥ O 
2 O 
( O 
50 O 
kg O 
weight O 
) O 
, O 
would O 
be O 
553 O 
and O 
543 O 
L O 
/ O 
hour O 
, O 
respectively O 
. O 
When O 
scaled O 
allometrically O 
, O 
CL O 
/ O 
F O 
was O 
similar O 
to O 
values O 
reported O 
for O 
adults O 
. O 
Variability O 
in O 
atorvastatin B-TRIVIAL 
PK O 
was O 
primarily O 
affected O 
by O 
weight O 
. O 

effects O 
of O 
clopidogrel B-TRIVIAL 
and O 
clarithromycin B-TRIVIAL 
on O 
the O 
enantioselective O 
pharmacokinetics O 
of O 
sibutramine B-TRIVIAL 
and O 
its O 
active O 
metabolites O 
in O 
healthy O 
subjects O 
. O 

this O 
study O 
, O 
we O 
assessed O 
the O 
effects O 
of O 
clopidogrel B-TRIVIAL 
and O 
clarithromycin B-TRIVIAL 
, O 
known O 
CYP2B6 O 
and O 
CYP3A O 
inhibitors O 
, O 
respectively O 
, O 
on O 
the O 
enantioselective O 
disposition O 
of O 
racemic B-TRIVIAL 
sibutramine I-TRIVIAL 
in O 
conjunction O 
with O 
CYP2B6 O 
polymorphisms O 
in O 
humans O 
. O 
Sibutramine B-TRIVIAL 
showed O 
enantioselective O 
plasma O 
profiles O 
with O 
consistently O 
higher O 
concentrations O 
of O 
R-enantiomers O 
. O 
Clopidogrel B-TRIVIAL 
and O 
clarithromycin B-TRIVIAL 
significantly O 
increased O 
the O 
sibutramine B-TRIVIAL 
plasma O 
concentration O 
, O 
but O 
their O 
effects O 
differed O 
between O 
enantiomers O 
; O 
a O 
2.2-fold O 
versus O 
4.1-fold O 
increase O 
in O 
the O 
AUC O 
in O 
S-enantiomer O 
and O 
1.8-fold O 
versus O 
2.0-fold O 
for O 
the O 
R-enantiomer O 
, O 
respectively O 
. O 
The O 
AUCs O 
of O 
S- O 
and O 
R-desmethyl O 
metabolites O 
changed O 
significantly O 
during O 
the O 
clopidogrel B-TRIVIAL 
phase O 
( O 
P O 
< O 
0.001 O 
and O 
P O 
< O 
0.001 O 
, O 
respectively O 
) O 
but O 
not O 
during O 
the O 
clarithromycin B-TRIVIAL 
phase O 
( O 
P O 
= O 
0.099 O 
and O 
P O 
= O 
0.09 O 
, O 
respectively O 
) O 
. O 
Exposure O 
to O 
sibutramine B-TRIVIAL 
was O 
higher O 
in O 
subjects O 
with O 
the O 
CYP2B6*6 O 
/ O 
*6 O 
genotype O 
, O 
but O 
no O 
statistical O 
difference O 
was O 
observed O 
among O 
the O 
CYP2B6 O 
genotypes O 
. O 
These O 
results O 
suggest O 
that O 
the O 
enantioselective O 
disposition O 
of O 
sibutramine B-TRIVIAL 
and O 
its O 
active O 
metabolites O 
are O 
influenced O 
by O 
the O 
altered O 
genetic O 
and O 
environmental O 
factors O 
of O 
CYP2B6 O 
and O 
CYP3A O 
activity O 
in O 
vivo O 
. O 

of O 
edge O 
States O 
in O 
covalently O 
bonded O 
zigzag O 
edges O 
of O 
graphene B-TRIVIAL 
on O 
ir(111) B-FORMULA 
. O 

zigzag O 
edges O 
of O 
graphene B-TRIVIAL 
on O 
Ir(111) B-FORMULA 
are O 
studied O 
by O 
ab O 
initio O 
simulations O 
and O 
low O 
- O 
temperature O 
scanning O 
tunneling O 
spectroscopy O 
, O 
providing O 
information O 
about O 
their O 
structural O 
, O 
electronic O 
, O 
and O 
magnetic O 
properties O 
. O 
No O 
edge O 
state O 
is O 
found O 
to O 
exist O 
, O 
which O 
is O 
explained O 
in O 
terms O 
of O 
the O 
interplay O 
between O 
a O 
strong O 
geometrical O 
relaxation O 
at O 
the O 
edge O 
and O 
a O 
hybridization O 
of O 
the O 
d O 
orbitals O 
of O 
Ir O 
atoms O 
with O 
the O 
graphene B-TRIVIAL 
orbitals O 
at O 
the O 
edge O 
. O 

of O 
efflux O 
transporters O 
involved O 
in O 
distribution O 
and O 
disposition O 
of O 
apixaban B-TRIVIAL 
. O 

studies O 
reported O 
here O 
were O 
conducted O 
to O 
investigate O 
the O 
transport O 
characteristics O 
of O 
apixaban B-TRIVIAL 
( O 
1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide B-SYSTEMATIC 
) O 
and O 
to O 
understand O 
the O 
impact O 
of O 
transporters O 
on O 
apixaban O 
distribution O 
and O 
disposition O 
. O 
In O 
human O 
permeability O 
glycoprotein O 
(P-gp)- O 
and O 
breast O 
cancer O 
resistance O 
protein O 
(BCRP)-cDNA-transfected O 
cell O 
monolayers O 
as O 
well O 
as O 
Caco-2 O 
cell O 
monolayers O 
, O 
the O 
apparent O 
efflux O 
ratio O 
of O 
basolateral O 
- O 
to O 
- O 
apical O 
( O 
PcB-A O 
) O 
versus O 
apical O 
- O 
to O 
- O 
basolateral O 
permeability O 
( O 
PcA-B O 
) O 
of O 
apixaban B-TRIVIAL 
was O 
> O 
10 O 
. O 
The O 
P-gp- O 
and O 
BCRP-facilitated O 
transport O 
of O 
apixaban B-TRIVIAL 
was O 
concentration- O 
and O 
time O 
- O 
dependent O 
and O 
did O 
not O 
show O 
saturation O 
over O 
a O 
wide O 
range O 
of O 
concentrations O 
( O 
1-100 O 
μM O 
) O 
. O 
The O 
efflux O 
transport O 
of O 
apixaban B-TRIVIAL 
was O 
also O 
demonstrated O 
by O 
the O 
lower O 
mucosal O 
- O 
to O 
- O 
serosal O 
permeability O 
than O 
that O 
of O 
the O 
serosal O 
- O 
to O 
- O 
mucosal O 
direction O 
in O 
isolated O 
rat O 
jejunum O 
segments O 
. O 
Apixaban B-TRIVIAL 
did O 
not O 
inhibit O 
digoxin B-TRIVIAL 
transport O 
in O 
Caco-2 O 
cells O 
. O 
Ketoconazole B-TRIVIAL 
decreased O 
the O 
P-gp O 
- O 
mediated O 
apixaban O 
efflux O 
in O 
Caco-2 O 
and O 
the O 
P-gp-cDNA-transfected O 
cell O 
monolayers O 
, O 
but O 
did O 
not O 
affect O 
the O 
apixaban B-TRIVIAL 
efflux O 
to O 
a O 
meaningful O 
extent O 
in O 
the O 
BCRP-cDNA-transfected O 
cell O 
monolayers O 
. O 
Coincubation O 
of O 
a O 
P-gp O 
inhibitor O 
( O 
ketoconazole B-TRIVIAL 
or O 
cyclosporin B-TRIVIAL 
A I-TRIVIAL 
) O 
and O 
a O 
BCRP O 
inhibitor O 
( O 
Ko134 B-IDENTIFIER 
) O 
provided O 
more O 
complete O 
inhibition O 
of O 
apixaban O 
efflux O 
in O 
Caco-2 O 
cells O 
than O 
separate O 
inhibition O 
by O 
individual O 
inhibitors O 
. O 
Naproxen B-TRIVIAL 
inhibited O 
apixaban B-TRIVIAL 
efflux O 
in O 
Caco-2 O 
cells O 
but O 
showed O 
only O 
a O 
minimal O 
effect O 
on O 
apixaban B-TRIVIAL 
transport O 
in O 
the O 
BCRP-transfected O 
cells O 
. O 
Naproxen B-TRIVIAL 
was O 
the O 
first O 
nonsteroidal O 
antiinflammatory O 
drug O 
that O 
was O 
demonstrated O 
as O 
a O 
weak O 
P-gp O 
inhibitor O 
. O 
These O 
results O 
demonstrate O 
that O 
apixaban B-TRIVIAL 
is O 
a O 
substrate O 
for O 
efflux O 
transporters O 
P-gp O 
and O 
BCRP O 
, O 
which O 
can O 
help O 
explain O 
its O 
low O 
brain O 
penetration O 
, O 
and O 
low O 
fetal O 
exposures O 
and O 
high O 
milk O 
excretion O 
in O 
rats O 
. O 

- O 
relaxivity O 
and O 
luminescent O 
silica B-TRIVIAL 
nanoparticles O 
as O 
multimodal O 
agents O 
for O 
molecular O 
imaging O 
. O 

design O 
and O 
synthesis O 
of O 
a O 
new O 
bimodal O 
contrast O 
agent O 
for O 
magnetic O 
resonance O 
imaging O 
and O 
optical O 
imaging O 
is O 
reported O 
. O 
Tunable O 
- O 
sized O 
silica B-TRIVIAL 
nanoparticles O 
were O 
synthesized O 
by O 
a O 
microemulsion O 
- O 
mediated O 
pathway O 
and O 
used O 
as O 
carriers O 
for O 
paramagnetic O 
and O 
luminescent O 
probes O 
. O 
The O 
near O 
- O 
infrared O 
luminescent O 
agent O 
was O 
a O 
ruthenium B-SYSTEMATIC 
complex O 
that O 
was O 
directly O 
entrapped O 
in O 
the O 
silica B-TRIVIAL 
shell O 
to O 
provide O 
photoluminescence O 
enhancement O 
and O 
to O 
make O 
it O 
highly O 
photostable O 
as O 
it O 
was O 
protected O 
from O 
the O 
surrounding O 
environment O 
. O 
The O 
paramagnetic O 
activity O 
came O 
from O 
a O 
Gd-DTPA B-FORMULA 
derivative O 
that O 
was O 
grafted O 
on O 
the O 
silica B-TRIVIAL 
surface O 
. O 
NMRD O 
profiles O 
showed O 
a O 
strong O 
relaxivity O 
enhancement O 
( O 
increase O 
of O 
432% O 
in O 
the O 
r1 O 
value O 
at O 
20 O 
MHz O 
) O 
when O 
the O 
paramagnetic O 
complex O 
was O 
grafted O 
at O 
the O 
nanoparticle O 
surface O 
, O 
because O 
of O 
a O 
reduction O 
of O 
its O 
mobility O 
. O 
Polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
was O 
also O 
grafted O 
at O 
the O 
nanoparticle O 
surface O 
to O 
enhance O 
the O 
nanoparticle O 
residence O 
time O 
in O 
the O 
bloodstream O 
. O 
A O 
thorough O 
characterization O 
of O 
the O 
material O 
confirmed O 
its O 
potential O 
as O 
a O 
very O 
effective O 
bimodal O 
contrast O 
agent O 
. O 

Hyperthyroidism O 
is O 
not O 
a O 
rare O 
entity O 
in O 
pregnancy O 
and O 
85% O 
of O 
these O 
cases O 
attributed O 
to O 
Graves' O 
disease O 
( O 
GD O 
) O 
. O 
There O 
is O 
no O 
therapeutic O 
modality O 
for O 
GD O 
considered O 
as O 
totally O 
safe O 
in O 
pregnancy O 
. O 
Fetal O 
and O 
neonatal O 
risks O 
of O 
maternal O 
hyperthyroid O 
disease O 
are O 
related O 
to O 
the O 
hyperthyroidism O 
itself O 
and O 
/ O 
or O 
to O 
the O 
medical O 
treatment O 
of O 
the O 
disease O 
. O 
There O 
are O 
no O 
data O 
supporting O 
an O 
association O 
between O 
congenital O 
anomalies O 
in O 
the O 
fetus O 
and O 
propylthiouracil B-SYSTEMATIC 
( O 
PTU B-ABBREVIATION 
) O 
. O 
Hepatotoxicity O 
, O 
cytopenias O 
- O 
especially O 
agranulocytosis O 
and O 
quite O 
rarely O 
, O 
angioedema O 
, O 
may O 
be O 
seen O 
as O 
side O 
effects O 
of O 
PTU B-ABBREVIATION 
. O 
In O 
this O 
case O 
report O 
, O 
we O 
examine O 
an O 
instance O 
of O 
Graves' O 
hyperthyroidism O 
diagnosed O 
during O 
pregnancy O 
. O 
In O 
this O 
case O 
, O 
a O 
serious O 
side O 
effect O 
during O 
anti-thyroid O 
drug O 
usage O 
was O 
encountered O 
, O 
eventually O 
resulting O 
in O 
surgery O 
in O 
the O 
second O 
trimester O 
. O 
This O 
intervention O 
was O 
assisted O 
by O 
the O 
use O 
of O 
plasmapheresis O 
to O 
obtain O 
rapid O 
normalization O 
of O 
serum O 
thyroid B-FAMILY 
hormone I-FAMILY 
levels O 
. O 

affects O 
bioenergetics O 
of O 
liver O 
mitochondria O 
and O 
promotes O 
mitochondrial O 
permeability O 
transition O 
: O 
Potential O 
mechanisms O 
of O 
hepatotoxicity O 
. O 

is O 
a O 
synthetic O 
retinoid O 
used O 
for O 
severe O 
extensive O 
psoriasis O 
and O 
it O 
has O 
been O 
shown O 
to O 
be O 
an O 
effective O 
and O 
a O 
safe O 
therapeutic O 
drug O 
for O 
other O 
diseases O 
including O 
cancer O 
when O 
used O 
in O 
combination O 
with O 
other O 
agents O 
. O 
However O 
, O 
cases O 
of O 
acitretin B-TRIVIAL 
-associated O 
liver O 
injury O 
have O 
been O 
documented O 
, O 
but O 
the O 
possible O 
mechanisms O 
of O 
acitretin B-TRIVIAL 
-associated O 
hepatotoxicity O 
and O 
apoptosis O 
are O 
not O 
entirely O 
clarified O 
. O 
This O 
study O 
reports O 
that O 
mitochondrial O 
dysfunctions O 
may O 
play O 
an O 
important O 
role O 
in O 
liver O 
injury O 
and O 
apoptosis O 
induced O 
by O 
this O 
retinoid B-FAMILY 
. O 
Acitretin B-TRIVIAL 
( O 
5-20μM O 
) O 
impaired O 
mitochondrial O 
phosphorylation O 
efficiency O 
as O 
demonstrated O 
by O 
the O 
decrease O 
in O 
the O 
state O 
3 O 
respiration O 
and O 
ATP B-ABBREVIATION 
levels O 
, O 
and O 
by O 
the O 
increase O 
in O 
the O 
lag O 
phase O 
of O 
ADP B-ABBREVIATION 
phosphorylation O 
cycle O 
, O 
without O 
affecting O 
the O 
membrane O 
potential O 
. O 
Acitretin B-TRIVIAL 
induced O 
Ca(2+) B-FORMULA 
-mediated O 
mitochondrial O 
permeability O 
transition O 
( O 
MPT O 
) O 
and O 
decreased O 
the O 
adenine B-TRIVIAL 
nucleotide I-TRIVIAL 
translocase O 
( O 
ANT O 
) O 
content O 
. O 
Acitretin B-TRIVIAL 
-induced O 
MPT O 
was O 
not O 
prevented O 
by O 
thiol B-FAMILY 
group O 
protecting O 
and O 
antioxidant O 
agents O 
, O 
excluding O 
the O 
involvement O 
of O 
oxidative O 
stress O 
mechanisms O 
. O 
However O 
, O 
MPT O 
was O 
prevented O 
by O 
ANT O 
ligands O 
ATP B-ABBREVIATION 
, O 
ADP B-ABBREVIATION 
, O 
tamoxifen B-TRIVIAL 
and O 
4-hydroxytamoxifen B-SYSTEMATIC 
, O 
implying O 
that O 
the O 
MPT O 
induction O 
by O 
acitretin O 
is O 
mediated O 
by O 
the O 
ANT O 
. O 
ANT O 
plays O 
a O 
major O 
role O 
in O 
promoting O 
apoptosis O 
and O 
ATP B-ABBREVIATION 
synthesis O 
, O 
and O 
it O 
is O 
still O 
considered O 
as O 
a O 
structural O 
component O 
of O 
the O 
pore O 
with O 
a O 
regulatory O 
role O 
in O 
MPT O 
formation O 
. O 
Therefore O 
, O 
our O 
results O 
, O 
including O 
the O 
decrease O 
in O 
the O 
state O 
3 O 
respiration O 
and O 
the O 
increase O 
in O 
the O 
lag O 
phase O 
of O 
phosphorylation O 
cycle O 
, O 
the O 
ATP B-ABBREVIATION 
depletion O 
and O 
the O 
induction O 
of O 
Ca(2+) B-FORMULA 
-mediated O 
MPT O 
, O 
indicate O 
that O 
acitretin B-TRIVIAL 
-associated O 
liver O 
toxicity O 
and O 
apoptosis O 
is O 
possibly O 
related O 
with O 
mitochondrial O 
dysfunctions O 
due O 
to O 
interactions O 
with O 
the O 
ANT O 
. O 
Additionally O 
, O 
the O 
combination O 
of O 
acitretin B-TRIVIAL 
with O 
other O 
drugs O 
, O 
such O 
as O 
antiestrogens O 
, O 
which O 
are O 
able O 
to O 
inhibit O 
the O 
MPT O 
, O 
may O 
contribute O 
to O 
decrease O 
the O 
toxicity O 
induced O 
by O 
acitretin B-TRIVIAL 
. O 

can O 
cause O 
steroid B-FAMILY 
-induced O 
diabetes O 
or O 
accelerate O 
the O 
progression O 
to O 
diabetes O 
by O 
creating O 
systemic O 
insulin O 
resistance O 
and O 
decreasing O 
functional O 
β-cell O 
mass O 
, O 
which O 
is O 
influenced O 
by O 
changes O 
in O 
β-cell O 
function O 
, O 
growth O 
, O 
and O 
death O 
. O 
The O 
synthetic O 
glucocorticoid O 
agonist O 
dexamethasone B-TRIVIAL 
( O 
Dex B-ABBREVIATION 
) O 
is O 
deleterious O 
to O 
functional O 
β-cell O 
mass O 
by O 
decreasing O 
β-cell O 
function O 
, O 
survival O 
, O 
and O 
proliferation O 
. O 
However O 
, O 
the O 
mechanism O 
by O 
which O 
Dex B-ABBREVIATION 
decreases O 
β-cell O 
proliferation O 
is O 
unknown O 
. O 
Interestingly O 
, O 
Dex B-ABBREVIATION 
induces O 
the O 
transcription O 
of O 
an O 
antiproliferative O 
factor O 
and O 
negative O 
regulator O 
of O 
epidermal O 
growth O 
factor O 
receptor O 
signaling O 
, O 
Mig6 O 
( O 
also O 
known O 
as O 
gene O 
33 O 
, O 
RALT O 
, O 
and O 
Errfi1 O 
) O 
. O 
We O 
, O 
therefore O 
, O 
hypothesized O 
that O 
Dex B-ABBREVIATION 
impairs O 
β-cell O 
proliferation O 
by O 
increasing O 
the O 
expression O 
of O 
Mig6 O 
and O 
thereby O 
decreasing O 
downstream O 
signaling O 
of O 
epidermal O 
growth O 
factor O 
receptor O 
. O 
We O 
found O 
that O 
Dex B-ABBREVIATION 
induced O 
Mig6 O 
and O 
decreased O 
[(3)H]thymidine B-SYSTEMATIC 
incorporation O 
, O 
an O 
index O 
of O 
cellular O 
replication O 
, O 
in O 
mouse O 
, O 
rat O 
, O 
and O 
human O 
islets O 
. O 
Using O 
adenovirally O 
delivered O 
small O 
interfering O 
RNA O 
targeted O 
to O 
Mig6 O 
in O 
rat O 
islets O 
, O 
we O 
were O 
able O 
to O 
limit O 
the O 
induction O 
of O 
Mig6 O 
upon O 
exposure O 
to O 
Dex B-ABBREVIATION 
, O 
compared O 
with O 
islets O 
treated O 
with O 
a O 
control O 
virus O 
, O 
and O 
completely O 
rescued O 
the O 
Dex B-ABBREVIATION 
-mediated O 
impairment O 
in O 
replication O 
. O 
We O 
demonstrated O 
that O 
both O 
Dex B-ABBREVIATION 
and O 
overexpression O 
of O 
Mig6 O 
attenuated O 
the O 
phosphorylation O 
of O 
ERK1 O 
/ O 
2 O 
and O 
blocked O 
the O 
G(1) O 
/ O 
S O 
transition O 
of O 
the O 
cell O 
cycle O 
. O 
In O 
conclusion O 
, O 
Mig6 O 
functions O 
as O 
a O 
molecular O 
brake O 
for O 
β-cell O 
proliferation O 
during O 
glucocorticoid O 
treatment O 
in O 
β-cells O 
, O 
and O 
thus O 
, O 
Mig6 O 
may O 
be O 
a O 
novel O 
target O 
for O 
preventing O 
glucocorticoid O 
- O 
induced O 
impairments O 
in O 
functional O 
β-cell O 
mass O 
. O 

of O 
cytosolic O 
glutathione B-TRIVIAL 
peroxidase O 
and O 
phospholipid- O 
hydroperoxide B-FAMILY 
glutathione B-TRIVIAL 
peroxidase O 
genes O 
in O 
rainbow O 
trout O 
( O 
Oncorhynchus O 
mykiss O 
) O 
and O 
their O 
modulation O 
by O 
in O 
vitro O 
selenium B-SYSTEMATIC 
exposure O 
. O 

( O 
Se B-FORMULA 
) O 
is O 
an O 
oligonutrient O 
with O 
both O 
essential O 
biological O 
functions O 
and O 
recognized O 
harmful O 
effects O 
. O 
As O 
the O 
selenocysteine B-TRIVIAL 
( O 
SeCys B-FORMULA 
) O 
amino B-FAMILY 
acid I-FAMILY 
, O 
selenium B-SYSTEMATIC 
is O 
integrated O 
in O 
several O 
Se B-FORMULA 
-containing O 
proteins O 
( O 
selenoproteins O 
) O 
, O 
many O 
of O 
which O 
are O 
fundamental O 
for O 
cell O 
homeostasis O 
. O 
Nevertheless O 
, O 
selenium O 
may O 
exert O 
toxic O 
effects O 
at O 
levels O 
marginally O 
above O 
those O 
required O 
, O 
mainly O 
through O 
the O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
. O 
The O 
selenium B-SYSTEMATIC 
chemical O 
speciation O 
can O 
strongly O 
affect O 
the O 
bioavailability O 
of O 
this O 
metal O 
and O 
its O 
impact O 
on O 
metabolism O 
, O 
dictating O 
the O 
levels O 
that O 
can O 
be O 
beneficial O 
or O 
detrimental O 
towards O 
an O 
organism O 
. O 
Glutathione B-TRIVIAL 
peroxidase O 
( O 
GPxs O 
) O 
is O 
the O 
largest O 
and O 
the O 
most O 
studied O 
selenoprotein O 
family O 
. O 
Cytosolic O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
cGPx O 
, O 
GPx1 O 
) O 
and O 
phospholipid O 
hydroperoxide B-FAMILY 
glutathione B-TRIVIAL 
peroxidase O 
( O 
PHGPx O 
, O 
GPx4 O 
) O 
are O 
widely O 
distributed O 
throughout O 
tissues O 
, O 
and O 
play O 
a O 
pivotal O 
role O 
in O 
regulating O 
the O 
oxidative O 
status O 
in O 
the O 
cell O 
. O 
In O 
this O 
study O 
we O 
have O 
cloned O 
GPx1 O 
and O 
GPx4 O 
genes O 
in O 
rainbow O 
trout O 
( O 
Oncorhynchus O 
mykiss O 
) O 
. O 
The O 
constitutive O 
mRNA O 
expression O 
of O 
these O 
GPx O 
genes O 
was O 
examined O 
in O 
18 O 
trout O 
tissues O 
and O 
their O 
responsiveness O 
to O 
Se O 
availability O 
was O 
analysed O 
using O 
a O 
rainbow O 
trout O 
liver O 
cell O 
line O 
( O 
RTL O 
) O 
. O 
An O 
inorganic O 
( O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
, O 
Na2SeO3 B-FORMULA 
) O 
and O 
organic O 
( O 
selenocysteine B-TRIVIAL 
, O 
Cys-Se-Se-Cys B-FORMULA 
) O 
selenocompound O 
have O 
been O 
used O 
as O 
Se B-FORMULA 
sources O 
. O 
GPx1 O 
activity O 
was O 
also O 
tested O 
to O 
verify O 
the O 
impact O 
of O 
transcript O 
changes O 
on O 
the O 
enzymatic O 
function O 
of O 
these O 
molecules O 
. O 
To O 
understand O 
if O 
the O 
results O 
obtained O 
from O 
the O 
transcript O 
expression O 
analysis O 
were O 
due O 
to O 
Se B-FORMULA 
bioavailability O 
or O 
generation O 
of O 
ROS O 
, O 
the O 
cytoxicity O 
of O 
the O 
two O 
selenocompounds O 
was O 
tested O 
by O 
measuring O 
the O 
impact O 
of O 
Se B-FORMULA 
on O 
cell O 
membrane O 
integrity O 
. O 
Lastly O 
, O 
Se B-FORMULA 
availability O 
was O 
quantified O 
by O 
mass O 
spectrophotometry O 
to O 
determine O 
the O 
amount O 
of O 
Se B-FORMULA 
in O 
the O 
cell O 
culture O 
media O 
, O 
the O 
Se B-FORMULA 
background O 
due O 
to O 
the O 
foetal O 
calf O 
serum O 
supplement O 
and O 
the O 
contribution O 
from O 
the O 
two O 
selenocompounds O 
used O 
in O 
the O 
treatments O 
. O 
Three O 
isoforms O 
of O 
genes O 
for O 
both O 
GPx1 O 
( O 
GPx1a O 
, O 
1b1 O 
and O 
1b2 O 
) O 
and O 
GPx4 O 
( O 
GPx4a1 O 
, O 
a2 O 
and O 
b O 
) O 
have O 
been O 
identified O 
. O 
The O 
discovery O 
of O 
a O 
third O 
gene O 
encoding O 
for O 
GPx1 O 
and O 
GPx4 O 
hints O 
that O 
salmonids O 
may O 
have O 
the O 
biggest O 
selenoproteome O 
amongst O 
all O 
vertebrates O 
. O 
Transcripts O 
of O 
GPx4 O 
genes O 
were O 
more O 
highly O 
expressed O 
in O 
most O 
tissues O 
examined O 
in O 
vivo O 
( O 
except O 
blood O 
, O 
head O 
kidney O 
and O 
spleen O 
) O 
, O 
whereas O 
those O 
of O 
the O 
GPx1 O 
genes O 
were O 
more O 
responsive O 
to O 
selenium B-SYSTEMATIC 
exposure O 
in O 
vitro O 
, O 
especially O 
to O 
the O 
organic O 
form O 
. O 
Interestingly O 
, O 
GPx1a O 
was O 
the O 
most O 
sensitive O 
to O 
selenium B-SYSTEMATIC 
availability O 
in O 
non O 
stressful O 
conditions O 
, O 
whereas O 
GPx1b1 O 
and O 
GPx1b2 O 
were O 
highly O 
induced O 
by O 
exposure O 
to O 
selenium B-SYSTEMATIC 
levels O 
that O 
had O 
some O 
toxic O 
effects O 
on O 
the O 
cells O 
. O 
Although O 
the O 
different O 
concentrations O 
tested O 
of O 
the O 
two O 
selenocompounds O 
modulate O 
GPx1 O 
transcript O 
expression O 
to O 
various O 
degrees O 
, O 
no O 
significant O 
change O 
of O 
GPx1 O 
enzymatic O 
activity O 
was O 
detectable O 
. O 
Our O 
results O 
lead O 
us O 
to O 
conclude O 
that O 
trout O 
GPx1 O 
transcripts O 
expression O 
level O 
may O 
represent O 
a O 
sensitive O 
biomarker O 
for O 
selenium B-SYSTEMATIC 
intake O 
, O 
helping O 
to O 
evaluate O 
if O 
selenium B-SYSTEMATIC 
concentration O 
and O 
chemical O 
speciation O 
impact O 
on O 
cell O 
homeostasis O 
. O 

of O 
activated O 
nucleoside B-FAMILY 
analogs O 
for O 
the O 
treatment O 
of O 
drug O 
- O 
resistant O 
tumors O 
by O 
oral O 
delivery O 
of O 
nanogel O 
- O 
drug O 
conjugates O 
. O 

majority O 
of O 
nanoencapsulated O 
drugs O 
that O 
have O 
shown O 
promise O 
in O 
cancer O 
chemotherapy O 
are O 
administered O 
intravenously O 
. O 
Development O 
of O 
effective O 
oral O 
nanoformulations O 
presents O 
a O 
very O 
challenging O 
medical O 
goal O 
. O 
Here O 
, O 
we O 
describe O 
successful O 
applications O 
of O 
innovative O 
polymeric O 
nanogels O 
in O 
the O 
form O 
of O 
conjugates O 
with O 
activated O 
nucleoside B-FAMILY 
analogs O 
for O 
oral O 
administration O 
in O 
cancer O 
chemotherapy O 
. O 
Previously O 
, O 
we O 
reported O 
the O 
synthesis O 
of O 
amphiphilic O 
polyvinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
and O 
dextrin O 
- O 
based O 
nanogel O 
conjugates O 
with O 
the O 
phosphorylated B-SYSTEMATIC 
5-FU I-SYSTEMATIC 
nucleoside I-SYSTEMATIC 
Floxuridine B-TRIVIAL 
and O 
demonstrated O 
their O 
enhanced O 
activity O 
against O 
regular O 
and O 
drug O 
- O 
resistant O 
cancers O 
( O 
T.H O 
. O 
Senanayake O 
, O 
G O 
. O 
Warren O 
, O 
S.V O 
. O 
Vinogradov O 
, O 
Novel O 
anticancer O 
polymeric O 
conjugates O 
of O 
activated O 
nucleoside B-FAMILY 
analogs O 
, O 
Bioconjug O 
. O 
Chem O 
. O 
22 O 
( O 
2011 O 
) O 
1983-1993 O 
) O 
. O 
In O 
this O 
study O 
, O 
we O 
synthesized O 
and O 
evaluated O 
oral O 
applications O 
of O 
nanogel O 
conjugates O 
of O 
a O 
protected O 
Gemcitabine B-TRIVIAL 
, O 
the O 
drug O 
never O 
used O 
in O 
oral O 
therapies O 
. O 
These O 
conjugates O 
were O 
able O 
to O 
quickly O 
release O 
an O 
active O 
form O 
of O 
the O 
drug O 
( O 
Gemcitabine B-MULTIPLE 
5'-mono- I-MULTIPLE 
, I-MULTIPLE 
di- I-MULTIPLE 
and I-MULTIPLE 
triphosphates I-MULTIPLE 
) O 
by O 
specific O 
enzymatic O 
activities O 
, O 
or O 
slowly O 
during O 
hydrolysis O 
. O 
Gemcitabine B-TRIVIAL 
conjugates O 
demonstrated O 
up O 
to O 
127 O 
times O 
higher O 
in O 
vitro O 
efficacy O 
than O 
the O 
free O 
drug O 
against O 
various O 
cancer O 
cells O 
, O 
including O 
the O 
lines O 
resistant O 
to O 
nucleoside B-FAMILY 
analogs O 
. O 
Surprisingly O 
, O 
these O 
nanogel O 
- O 
drug O 
conjugates O 
were O 
relatively O 
stable O 
in O 
gastric O 
conditions O 
and O 
able O 
to O 
actively O 
penetrate O 
through O 
the O 
gastrointestinal O 
barrier O 
based O 
on O 
permeability O 
studies O 
in O 
Caco-2 O 
cell O 
model O 
. O 
In O 
tumor O 
xenograft O 
models O 
of O 
several O 
drug O 
- O 
resistant O 
human O 
cancers O 
, O 
we O 
observed O 
an O 
efficient O 
inhibition O 
of O 
tumor O 
growth O 
and O 
extended O 
the O 
life O 
- O 
span O 
of O 
the O 
animals O 
by O 
3 O 
times O 
that O 
of O 
the O 
control O 
with O 
orally O 
treated O 
Gemcitabine B-TRIVIAL 
- O 
or O 
Floxuridine B-TRIVIAL 
-nanogel O 
conjugates O 
. O 
Thus O 
, O 
we O 
have O 
demonstrated O 
a O 
potential O 
of O 
therapeutic O 
nanogel O 
conjugates O 
with O 
the O 
activated O 
and O 
stabilized O 
Gemcitabine B-TRIVIAL 
as O 
a O 
successful O 
oral O 
drug O 
form O 
against O 
Gemcitabine B-TRIVIAL 
-resistant O 
and O 
other O 
drug O 
- O 
resistant O 
tumors O 
. O 

and O 
synthesis O 
of O 
imidazole B-SYSTEMATIC 
and O 
triazole B-FAMILY 
derivatives O 
as O 
Lp-PLA₂ O 
inhibitors O 
and O 
the O 
unexpected O 
discovery O 
of O 
highly O 
potent O 
quaternary B-FAMILY 
ammonium I-FAMILY 
salts I-FAMILY 
. O 

Lp-PLA(2) O 
inhibitors O 
were O 
synthesized O 
by O 
the O 
bioisosteric O 
replacement O 
of O 
the O 
amide B-FAMILY 
group O 
of O 
Darapladib B-TRIVIAL 
with O 
an O 
imidazole B-SYSTEMATIC 
or O 
a O 
triazole B-FAMILY 
. O 
Unfortunately O 
, O 
the O 
inhibitory O 
activities O 
of O 
these O 
derivatives O 
were O 
lower O 
than O 
that O 
of O 
Darapladib B-TRIVIAL 
. O 
But O 
interestingly O 
, O 
a O 
series O 
of O 
quaternary B-FAMILY 
ammonium I-FAMILY 
salts I-FAMILY 
that O 
were O 
isolated O 
as O 
by O 
- O 
products O 
during O 
this O 
synthetic O 
work O 
were O 
found O 
with O 
high O 
potency O 
. O 
Of O 
these O 
by O 
- O 
products O 
, O 
compound O 
22c O 
showed O 
a O 
similar O 
profile O 
to O 
Darapladib B-TRIVIAL 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

and O 
antibacterial O 
activities O 
of O 
new O 
piperidine B-SYSTEMATIC 
substituted O 
(5R)-[1,2,3]triazolylmethyl B-MULTIPLE 
and I-MULTIPLE 
(5R)-[(4-F-[1,2,3]triazolyl)methyl] I-MULTIPLE 
oxazolidinones I-MULTIPLE 
. O 

novel O 
series O 
of O 
5(R)-[1,2,3]triazolylmethyl B-MULTIPLE 
and I-MULTIPLE 
(5R)-[(4-F-[1,2,3]triazolyl)methyl]oxazolidinones I-MULTIPLE 
having O 
various O 
piperidine B-SYSTEMATIC 
group O 
were O 
synthesized O 
and O 
evaluated O 
antibacterial O 
activity O 
against O 
clinically O 
isolated O 
resistant O 
strains O 
of O 
Gram O 
- O 
positive O 
and O 
Gram O 
- O 
negative O 
bacteria O 
. O 
The O 
compound O 
12a O 
having O 
exo-cyanoethylidene B-SYSTEMATIC 
group O 
in O 
the O 
4- O 
position O 
of O 
piperidine B-SYSTEMATIC 
ring O 
was O 
found O 
to O 
be O 
two O 
to O 
threefold O 
more O 
potent O 
than O 
the O 
linezolid B-TRIVIAL 
against O 
penicillin B-FAMILY 
-resistant O 
Staphylococcus O 
pneumonia O 
and O 
Staphylococcus O 
agalactiae O 
, O 
and O 
also O 
exhibited O 
reduced O 
MAO-B O 
inhibitory O 
activity O 
. O 

analysis O 
of O 
transcriptomics O 
and O 
metabonomics O 
profiles O 
in O 
aflatoxin B-TRIVIAL 
B1 I-TRIVIAL 
-induced O 
hepatotoxicity O 
in O 
rat O 
. O 

aim O 
of O 
this O 
work O 
was O 
to O 
identify O 
mechanisms O 
and O 
potential O 
biomarkers O 
for O 
predicting O 
the O 
development O 
and O 
progression O 
of O 
aflatoxin B-TRIVIAL 
B1 I-TRIVIAL 
( O 
AFB1 B-ABBREVIATION 
)-induced O 
acute O 
hepatotoxicity O 
. O 
In O 
this O 
study O 
, O 
microarray O 
analysis O 
and O 
metabolites O 
profiles O 
were O 
used O 
to O 
identify O 
shifts O 
in O 
gene O 
expression O 
and O 
metabolite O 
levels O 
associated O 
with O 
the O 
affected O 
physiological O 
processes O 
of O 
rats O 
treated O 
with O 
AFB1 B-ABBREVIATION 
. O 
Histopathological O 
examinations O 
and O 
serum O 
biochemical O 
analysis O 
were O 
simultaneously O 
performed O 
; O 
the O 
results O 
indicated O 
that O 
hepatotoxicity O 
occurred O 
in O 
higher O 
dosage O 
groups O 
. O 
However O 
, O 
gene O 
expression O 
analysis O 
and O 
metabolite O 
profiles O 
are O 
more O 
sensitive O 
than O 
general O 
toxicity O 
studies O 
for O 
detecting O 
AFB1 B-ABBREVIATION 
-induced O 
acute O 
hepatotoxicity O 
as O 
the O 
patterns O 
of O 
low O 
- O 
dose O 
AFB1 B-ABBREVIATION 
-treated O 
rats O 
in O 
these O 
two O 
technique O 
platforms O 
were O 
more O 
similar O 
to O 
the O 
rats O 
in O 
higher O 
dosage O 
groups O 
than O 
to O 
the O 
control O 
rats O 
. O 
Integrated O 
analysis O 
of O 
the O 
results O 
from O 
general O 
toxicity O 
studies O 
, O 
transcriptomics O 
and O 
metabonomics O 
profiles O 
suggested O 
that O 
p53 O 
signaling O 
pathway O 
induced O 
by O 
oxidative O 
damage O 
was O 
the O 
crucial O 
step O 
in O 
AFB1 B-ABBREVIATION 
-induced O 
acute O 
hepatotoxicity O 
, O 
whereas O 
gluconeogenesis O 
and O 
lipid O 
metabolism O 
disorder O 
were O 
found O 
to O 
be O 
the O 
major O 
metabolic O 
effects O 
after O 
acute O 
AFB1 B-ABBREVIATION 
exposure O 
. O 
The O 
genes O 
and O 
metabolites O 
significantly O 
affected O 
in O 
common O 
in O 
rat O 
liver O 
or O 
serum O 
of O 
three O 
doses O 
AFB1 B-ABBREVIATION 
treatments O 
served O 
as O 
potential O 
biomarkers O 
for O 
detecting O 
AFB1 B-ABBREVIATION 
-induced O 
acute O 
hepatotoxicity O 
. O 

is O 
a O 
light O 
- O 
gated O 
ion O 
channel O 
, O 
which O 
has O 
been O 
studied O 
intensively O 
over O 
the O 
last O 
decade O 
. O 
Vibrational O 
spectroscopic O 
experiments O 
started O 
to O 
shed O 
light O 
on O 
the O 
structural O 
changes O 
, O 
that O 
occur O 
during O 
the O 
photocycle O 
, O 
especially O 
in O 
the O 
hydrogen B-SYSTEMATIC 
-bonded O 
network O 
surrounding O 
the O 
protonated O 
D156 O 
and O 
C128 O 
- O 
the O 
DC O 
gate O 
. O 
However O 
, O 
the O 
interpretation O 
of O 
these O 
experiments O 
was O 
only O 
based O 
on O 
homology O 
models O 
. O 
Since O 
then O 
, O 
an O 
X-ray O 
structure O 
and O 
better O 
computational O 
models O 
became O 
available O 
. O 
In O 
this O 
article O 
, O 
we O 
show O 
that O 
in O 
combination O 
with O 
a O 
recent O 
reparametrization O 
, O 
the O 
approximate O 
DFT O 
method O 
, O 
DFTB O 
, O 
is O 
able O 
to O 
describe O 
the O 
effects O 
of O 
hydrogen B-SYSTEMATIC 
bonding O 
on O 
the O 
C B-FORMULA 
[ O 
double O 
bond O 
, O 
length O 
as O 
m-dash O 
] O 
O B-FORMULA 
stretch O 
vibration O 
in O 
carboxylic B-FAMILY 
acids I-FAMILY 
reliably O 
and O 
agrees O 
well O 
with O 
full O 
DFT O 
results O 
. O 
We O 
apply O 
DFTB O 
in O 
a O 
QM O 
/ O 
MM O 
framework O 
to O 
perform O 
vibrational O 
analysis O 
of O 
buried O 
aspartic B-FAMILY 
acids I-FAMILY 
in O 
bacteriorhodopsin O 
and O 
channelrhodopsin-2 O 
. O 
Using O 
this O 
approach O 
, O 
we O 
can O 
simulate O 
the O 
FTIR O 
spectral O 
difference O 
between O 
D115 O 
in O 
the O 
dark O 
- O 
adapted O 
and O 
K O 
states O 
of O 
bacteriorhodopsin O 
. O 
The O 
FTIR O 
experiments O 
on O 
the O 
DC O 
gate O 
in O 
channelrhodopsin-2 O 
are O 
well O 
described O 
using O 
an O 
indirect O 
model O 
, O 
where O 
D156 O 
and O 
C128 O 
are O 
bridged O 
via O 
a O 
water O 
molecule O 
. O 

and O 
evaluation O 
of O 
sustained O 
- O 
release O 
doxazosin B-TRIVIAL 
mesylate I-TRIVIAL 
pellets O 
. O 

mesylate I-TRIVIAL 
( O 
DXM B-ABBREVIATION 
) O 
sustained O 
release O 
pellets O 
were O 
prepared O 
by O 
an O 
extrusion O 
- O 
spheronization O 
and O 
fluid O 
- O 
bed O 
coating O 
technique O 
. O 
The O 
core O 
pellets O 
containing O 
DXM B-ABBREVIATION 
were O 
prepared O 
by O 
extrusion O 
- O 
spheronization O 
technique O 
, O 
and O 
coated O 
by O 
a O 
fluid O 
- O 
bed O 
coater O 
to O 
control O 
the O 
release O 
of O 
DXM B-ABBREVIATION 
. O 
The O 
factors O 
affecting O 
to O 
properties O 
of O 
pellets O 
, O 
such O 
as O 
diluent O 
content O 
, O 
type O 
and O 
coating O 
level O 
of O 
coating O 
agents O 
and O 
plasticizers O 
were O 
studied O 
in O 
the O 
present O 
study O 
. O 
Polymethacrylate B-FAMILY 
derivatives O 
( O 
Eudragit B-TRIVIAL 
® O 
RS O 
PO O 
and O 
RL O 
PO O 
) O 
were O 
used O 
for O 
coating O 
agents O 
, O 
and O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
6000 I-SYSTEMATIC 
( O 
PEG B-TRIVIAL 
6000 I-TRIVIAL 
) O 
, O 
triethyl B-SYSTEMATIC 
citrate I-SYSTEMATIC 
( O 
TEC B-ABBREVIATION 
) O 
and O 
castor O 
oil O 
were O 
as O 
plasticizers O 
. O 
To O 
evaluate O 
the O 
properties O 
of O 
prepared O 
pellets O 
, O 
the O 
size O 
of O 
prepared O 
pellets O 
was O 
investigated O 
by O 
sieve O 
analysis O 
technique O 
and O 
the O 
morphology O 
of O 
pellets O 
was O 
evaluated O 
by O 
scanning O 
electron O 
microscopy O 
. O 
Through O 
the O 
dissolution O 
test O 
, O 
factors O 
that O 
have O 
an O 
effect O 
on O 
the O 
dissolution O 
of O 
the O 
drug O 
were O 
evaluated O 
. O 
As O 
the O 
content O 
ratio O 
of O 
microcrystalline O 
cellulose O 
( O 
MCC O 
) O 
had O 
increased O 
, O 
the O 
dissolution O 
was O 
proportionally O 
sustained O 
. O 
Eudragit B-TRIVIAL 
® O 
RS O 
PO O 
had O 
more O 
marked O 
sustaining O 
effect O 
on O 
the O 
dissolution O 
rate O 
than O 
Eudragit B-TRIVIAL 
® O 
RL O 
PO O 
, O 
and O 
the O 
effect O 
was O 
more O 
pronounced O 
with O 
the O 
increased O 
coating O 
level O 
. O 
PEG B-TRIVIAL 
6000 I-TRIVIAL 
was O 
an O 
appropriate O 
plasticizer O 
for O 
DXM B-ABBREVIATION 
pellets O 
, O 
and O 
increasing O 
the O 
content O 
of O 
PEG B-TRIVIAL 
6000 I-TRIVIAL 
, O 
was O 
also O 
slightly O 
decreasing O 
the O 
dissolution O 
rate O 
. O 

H-J I-MULTIPLE 
, O 
3,6- B-FAMILY 
Disubstituted I-FAMILY 
α-Pyrones I-FAMILY 
from O 
the O 
Marine O 
Actinomycete O 
Nocardiopsis O 
sp O 
. O 
KMF-001 O 
. O 

new O 
3,6- B-FAMILY 
disubstituted I-FAMILY 
α-pyrones I-FAMILY 
, O 
nocapyrones B-MULTIPLE 
H-J I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
marine O 
actinomycete O 
Nocardiopsis O 
sp O 
. O 
KMF-001 O 
. O 
Their O 
structures O 
were O 
assigned O 
to O 
be O 
3-alkylated B-FAMILY 
6-(1-methyl-1-propenyl)-2H-pyran-2-ones I-FAMILY 
on O 
the O 
basis O 
of O 
UV O 
, O 
MS O 
, O 
NMR O 
, O 
and O 
high O 
resolution O 
(HR)-FAB-MS O 
analyses O 
. O 
Nocapyrone B-TRIVIAL 
H I-TRIVIAL 
( O 
1 O 
) O 
reduced O 
the O 
pro O 
- O 
inflammatory O 
factor O 
such O 
as O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
, O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
( O 
PGE2 B-ABBREVIATION 
) O 
and O 
interleukin-1β O 
( O 
IL-1β O 
) O 
. O 
Moreover O 
, O 
nocapyrone B-TRIVIAL 
H I-TRIVIAL 
showed O 
5.82% O 
stronger O 
inhibitory O 
effect O 
on O 
NO B-FORMULA 
production O 
than O 
chrysin O 
at O 
a O 
concentration O 
of O 
10 O 
µm O 
in O 
lipopolysaccharide O 
(LPS)-stimulated O 
BV-2 O 
microglial O 
cells O 
. O 

vitro O 
- O 
in O 
vivo O 
correlation O 
of O 
the O 
inhibition O 
potency O 
of O 
sodium B-SYSTEMATIC 
- O 
glucose B-TRIVIAL 
cotransporter O 
inhibitors O 
in O 
rat O 
: O 
a O 
pharmacokinetic O 
and O 
pharmacodynamic O 
modeling O 
approach O 
. O 

evaluate O 
the O 
relationship O 
between O 
the O 
in O 
vitro O 
and O 
in O 
vivo O 
potency O 
of O 
sodium B-SYSTEMATIC 
- O 
glucose B-TRIVIAL 
cotransporter O 
( O 
SGLT O 
) O 
inhibitors O 
, O 
a O 
pharmacokinetic O 
and O 
pharmacodynamic O 
( O 
PK-PD O 
) O 
study O 
was O 
performed O 
using O 
normal O 
rats O 
. O 
A O 
highly O 
selective O 
SGLT2 O 
inhibitor O 
, O 
tofogliflozin B-TRIVIAL 
, O 
and O 
four O 
other O 
inhibitors O 
with O 
different O 
in O 
vitro O 
inhibition O 
potency O 
to O 
SGLT2 O 
and O 
selectivity O 
toward O 
SGLT2 O 
, O 
versus O 
SGLT1 O 
were O 
used O 
as O 
test O 
compounds O 
, O 
and O 
the O 
time O 
courses O 
for O 
urinary O 
glucose B-TRIVIAL 
excretion O 
( O 
UGE O 
) O 
and O 
the O 
plasma O 
glucose B-TRIVIAL 
and O 
compound O 
concentrations O 
were O 
monitored O 
after O 
administration O 
of O 
the O 
compounds O 
. O 
A O 
PK-PD O 
analysis O 
of O 
the O 
UGE O 
caused O 
by O 
SGLT O 
inhibition O 
was O 
performed O 
on O 
the O 
basis O 
of O 
a O 
nonlinear O 
parallel O 
tube O 
model O 
that O 
took O 
into O 
consideration O 
the O 
consecutive O 
reabsorption O 
by O 
different O 
glucose B-TRIVIAL 
transport O 
properties O 
of O 
SGLT2 O 
and O 
SGLT1 O 
. O 
The O 
model O 
adequately O 
captured O 
the O 
time O 
course O 
of O 
cumulative O 
UGE O 
caused O 
by O 
SGLT O 
inhibition O 
; O 
then O 
, O 
the O 
in O 
vivo O 
inhibition O 
constants O 
( O 
Ki O 
) O 
of O 
inhibitors O 
for O 
both O 
SGLT1 O 
and O 
SGLT2 O 
were O 
estimated O 
. O 
The O 
in O 
vivo O 
selectivity O 
toward O 
SGLT2 O 
showed O 
a O 
good O 
correlation O 
with O 
the O 
in O 
vitro O 
data O 
( O 
r O 
= O 
0.985 O 
; O 
P O 
< O 
0.05 O 
) O 
, O 
with O 
in O 
vivo O 
Ki O 
values O 
for O 
SGLT2 O 
in O 
the O 
range O 
of O 
0.3-3.4-fold O 
the O 
in O 
vitro O 
data O 
. O 
This O 
suggests O 
that O 
in O 
vitro O 
inhibition O 
potency O 
to O 
both O 
SGLT2 O 
and O 
SGLT1 O 
is O 
reflected O 
in O 
vivo O 
. O 
Furthermore O 
, O 
the O 
complementary O 
role O 
of O 
SGLT1 O 
to O 
SGLT2 O 
and O 
how O 
selectivity O 
toward O 
SGLT2 O 
affects O 
the O 
inhibitory O 
potency O 
for O 
renal O 
glucose B-TRIVIAL 
reabsorption O 
were O 
discussed O 
using O 
the O 
PK-PD O 
model O 
. O 

-Based O 
Nanomaterials O 
: O 
Synthesis O 
and O 
Application O 
in O 
Lithium B-SYSTEMATIC 
-Ion O 
Batteries O 
. O 

development O 
of O 
new O 
electrode O 
materials O 
for O 
lithium B-SYSTEMATIC 
-ion O 
batteries O 
( O 
LIBs O 
) O 
has O 
always O 
been O 
a O 
focal O 
area O 
of O 
materials O 
science O 
, O 
as O 
the O 
current O 
technology O 
may O 
not O 
be O 
able O 
to O 
meet O 
the O 
high O 
energy O 
demands O 
for O 
electronic O 
devices O 
with O 
better O 
performance O 
. O 
Among O 
all O 
the O 
metal B-FAMILY 
oxides I-FAMILY 
, O 
tin B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
SnO(2) B-FORMULA 
) O 
is O 
regarded O 
as O 
a O 
promising O 
candidate O 
to O 
serve O 
as O 
the O 
anode O 
material O 
for O 
LIBs O 
due O 
to O 
its O 
high O 
theoretical O 
capacity O 
. O 
Here O 
, O 
a O 
thorough O 
survey O 
is O 
provided O 
of O 
the O 
synthesis O 
of O 
SnO(2) B-FORMULA 
-based O 
nanomaterials O 
with O 
various O 
structures O 
and O 
chemical O 
compositions O 
, O 
and O 
their O 
application O 
as O 
negative O 
electrodes O 
for O 
LIBs O 
. O 
It O 
covers O 
SnO(2) B-FORMULA 
with O 
different O 
morphologies O 
ranging O 
from O 
1D O 
nanorods O 
/ O 
nanowires O 
/ O 
nanotubes O 
, O 
to O 
2D O 
nanosheets O 
, O 
to O 
3D O 
hollow O 
nanostructures O 
. O 
Nanocomposites O 
consisting O 
of O 
SnO(2) B-FORMULA 
and O 
different O 
carbonaceous O 
supports O 
, O 
e.g O 
. O 
, O 
amorphous O 
carbon B-SYSTEMATIC 
, O 
carbon B-SYSTEMATIC 
nanotubes O 
, O 
graphene B-TRIVIAL 
, O 
are O 
also O 
investigated O 
. O 
The O 
use O 
of O 
Sn B-FORMULA 
-based O 
nanomaterials O 
as O 
the O 
anode O 
material O 
for O 
LIBs O 
will O 
be O 
briefly O 
discussed O 
as O 
well O 
. O 
The O 
aim O 
of O 
this O 
review O 
is O 
to O 
provide O 
an O 
in O 
- O 
depth O 
and O 
rational O 
understanding O 
such O 
that O 
the O 
electrochemical O 
properties O 
of O 
SnO(2) B-FORMULA 
-based O 
anodes O 
can O 
be O 
effectively O 
enhanced O 
by O 
making O 
proper O 
nanostructures O 
with O 
optimized O 
chemical O 
composition O 
. O 
By O 
focusing O 
on O 
SnO(2) B-FORMULA 
, O 
the O 
hope O 
is O 
that O 
such O 
concepts O 
and O 
strategies O 
can O 
be O 
extended O 
to O 
other O 
potential O 
metal B-FAMILY 
oxides I-FAMILY 
, O 
such O 
as O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
or O 
iron B-FAMILY 
oxides I-FAMILY 
, O 
thus O 
shedding O 
some O 
light O 
on O 
the O 
future O 
development O 
of O 
high O 
- O 
performance O 
metal B-FAMILY 
- I-FAMILY 
oxide I-FAMILY 
based O 
negative O 
electrodes O 
for O 
LIBs O 
. O 

- O 
on O 
therapy O 
with O 
the O 
DPP-4 O 
inhibitor O 
sitagliptin B-TRIVIAL 
improves O 
glycemic O 
control O 
in O 
insulin O 
- O 
treated O 
Japanese O 
patients O 
with O 
type O 
2 O 
diabetes O 
mellitus O 
. O 

effect O 
of O 
add O 
- O 
on O 
therapy O 
with O 
sitagliptin B-TRIVIAL 
on O 
glycemic O 
control O 
was O 
prospectively O 
investigated O 
in O 
patients O 
with O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
receiving O 
insulin O 
alone O 
or O 
insulin O 
combined O 
with O 
oral O 
antidiabetic O 
drugs O 
. O 
Seventy O 
- O 
one O 
patients O 
were O 
evaluated O 
( O 
38 O 
men O 
and O 
33 O 
women O 
aged O 
63.9±10.2 O 
years O 
) O 
. O 
They O 
were O 
divided O 
into O 
three O 
groups O 
, O 
which O 
were O 
45 O 
patients O 
receiving O 
premixed O 
insulin O 
twice O 
daily O 
, O 
15 O 
patients O 
receiving O 
multiple O 
daily O 
insulin O 
injections O 
, O 
and O 
11 O 
patients O 
receiving O 
basal O 
insulin O 
with O 
oral O 
antidiabetic O 
drugs O 
( O 
basal O 
insulin O 
therapy O 
) O 
. O 
Concomitant O 
oral O 
drugs O 
included O 
sulfonylureas B-FAMILY 
, O 
α-glucosidase O 
inhibitors O 
and O 
metformin B-TRIVIAL 
. O 
The O 
hemoglobin O 
A1c O 
( O 
HbA1c O 
) O 
of O 
all O 
patients O 
improved O 
significantly O 
from O 
8.1±1.2% O 
to O 
7.6±1.1% O 
after O 
12 O 
weeks O 
of O 
add O 
- O 
on O 
therapy O 
with O 
sitagliptin B-TRIVIAL 
( O 
p O 
< O 
0.01 O 
) O 
, O 
and O 
the O 
insulin O 
dosage O 
was O 
reduced O 
from O 
27.3±15.8 O 
U O 
/ O 
day O 
to O 
24.5±16.5 O 
U O 
/ O 
day O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
Body O 
weight O 
did O 
not O 
change O 
after O 
the O 
start O 
of O 
concomitant O 
therapy O 
and O 
severe O 
hypoglycemia O 
was O 
not O 
observed O 
. O 
The O 
baseline O 
HbA1c O 
and O 
glycated O 
albumin O 
levels O 
were O 
identified O 
as O 
factors O 
that O 
predicted O 
the O 
response O 
to O 
add O 
- O 
on O 
therapy O 
with O 
sitagliptin B-TRIVIAL 
. O 
These O 
findings O 
suggest O 
that O 
add O 
- O 
on O 
therapy O 
with O 
sitagliptin B-TRIVIAL 
can O 
be O 
expected O 
to O 
achieve O 
improvement O 
of O 
poor O 
glycemic O 
control O 
irrespective O 
of O 
a O 
patient's O 
demographic O 
profile O 
. O 
Stratified O 
analysis O 
based O 
on O 
the O 
insulin O 
regimen O 
revealed O 
a O 
stronger O 
antidiabetic O 
effect O 
and O 
a O 
high O 
efficacy O 
of O 
sitagliptin B-TRIVIAL 
when O 
it O 
was O 
added O 
to O 
basal O 
insulin O 
therapy O 
. O 
The O 
results O 
of O 
this O 
investigation O 
confirmed O 
that O 
add O 
- O 
on O 
therapy O 
with O 
sitagliptin B-TRIVIAL 
to O 
various O 
insulin O 
regimens O 
could O 
improve O 
glycemic O 
control O 
without O 
severe O 
hypoglycemia O 
and O 
/ O 
or O 
weight O 
gain O 
. O 

question O 
of O 
the O 
contribution O 
of O 
CYP21A2 O 
heterozygosity O 
to O 
the O 
development O 
of O 
polycystic O 
ovary O 
syndrome O 
( O 
PCOS O 
) O 
has O 
repeatedly O 
been O 
raised O 
in O 
the O 
literature O 
. O 
The O 
available O 
data O 
, O 
however O 
, O 
do O 
not O 
offer O 
a O 
satisfactory O 
answer O 
. O 
The O 
discrepancy O 
must O 
be O 
attributed O 
, O 
primarily O 
, O 
to O 
the O 
small O 
number O 
of O 
subjects O 
in O 
the O 
various O 
studies O 
, O 
the O 
type O 
of O 
selected O 
phenotype O 
, O 
and O 
the O 
number O 
of O 
searched O 
mutations O 
. O 
The O 
aim O 
of O 
the O 
study O 
was O 
to O 
define O 
the O 
contribution O 
of O 
CYP21A2 O 
heterozygous O 
mutations O 
to O 
the O 
pathogenesis O 
of O 
PCOS O 
. O 
We O 
searched O 
for O 
14 O 
molecular O 
defects O 
of O 
the O 
CYP21A2 O 
gene O 
in O 
197 O 
PCOS O 
women O 
, O 
employing O 
allele O 
specific O 
PCR O 
. O 
Androgen B-FAMILY 
levels O 
were O 
determined O 
at O 
baseline O 
by O 
appropriate O 
methodology O 
in O 
the O 
follicular O 
phase O 
. O 
PCOS O 
women O 
with O 
17-hydroxyprogesterone B-SYSTEMATIC 
( O 
17OHP B-SYSTEMATIC 
) O 
basal O 
values O 
> O 
2 O 
ng O 
/ O 
ml O 
and O 
/ O 
or O 
post-ACTH O 
> O 
10 O 
ng O 
/ O 
ml O 
were O 
excluded O 
. O 
Appropriate O 
controls O 
were O 
included O 
. O 
The O 
frequency O 
of O 
the O 
CYP21A2 O 
heterozygous O 
mutations O 
in O 
PCOS O 
women O 
and O 
in O 
controls O 
was O 
7.6% O 
and O 
5.9% O 
, O 
respectively O 
[ O 
p-value O 
( O 
PCOS O 
vs O 
. O 
controls O 
) O 
: O 
0.663 O 
] O 
. O 
Homozygosity O 
for O 
CYP21A2 O 
gene O 
defects O 
was O 
not O 
detected O 
. O 
In O 
conclusion O 
, O 
the O 
contribution O 
of O 
CYP21A2 O 
heterozygous O 
mutations O 
to O 
the O 
pathogenesis O 
of O 
PCOS O 
is O 
not O 
substantiated O 
by O 
our O 
data O 
. O 
Moreover O 
, O 
17-hydroxyprogesterone B-SYSTEMATIC 
values O 
of O 
< O 
10 O 
ng O 
/ O 
ml O 
post-ACTH O 
exclude O 
homozygosity O 
of O 
CYP21A2 O 
mutations O 
. O 

inhibition O 
of O 
human O 
carboxylesterases O 
by O 
acyl B-FAMILY 
glucuronides I-FAMILY 
. O 

hydrolyze O 
esters B-FAMILY 
, O 
amides B-FAMILY 
, O 
and O 
thioesters B-FAMILY 
to O 
produce O 
carboxylic B-FAMILY 
acids I-FAMILY 
and O 
resulting O 
alcohols B-FAMILY 
, O 
amines B-FAMILY 
, O 
and O 
thiols B-FAMILY 
, O 
respectively O 
. O 
Uridine B-SYSTEMATIC 
5'-diphosphate I-SYSTEMATIC 
- O 
glucuronosyltransferases O 
are O 
colocalized O 
with O 
carboxylesterases O 
and O 
have O 
the O 
potential O 
to O 
further O 
metabolize O 
carboxylic B-FAMILY 
acids I-FAMILY 
to O 
acyl B-FAMILY 
glucuronides I-FAMILY 
, O 
but O 
it O 
is O 
currently O 
unknown O 
if O 
acyl B-FAMILY 
glucuronides I-FAMILY 
, O 
being O 
esters B-FAMILY 
, O 
also O 
interact O 
with O 
carboxylesterases O 
. O 
Objective O 
: O 
This O 
study O 
explores O 
the O 
ability O 
of O 
acyl B-FAMILY 
glucuronides I-FAMILY 
to O 
act O 
as O 
substrates O 
or O 
inhibitors O 
of O 
human O 
carboxylesterases O 
1 O 
( O 
hCES1 O 
) O 
and O 
2 O 
( O 
hCES2 O 
) O 
. O 
Methods O 
: O 
The O 
stability O 
of O 
six O 
acyl B-FAMILY 
glucuronides I-FAMILY 
in O 
the O 
presence O 
of O 
hCES1 O 
, O 
hCES2 O 
, O 
and O 
buffer O 
alone O 
( O 
100 O 
mM O 
potassium B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
, O 
pH O 
7.4 O 
, O 
37°C O 
) O 
were O 
investigated O 
. O 
Reversible O 
inhibition O 
of O 
4-nitrophenyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
hydrolysis O 
by O 
the O 
acyl B-FAMILY 
glucuronides I-FAMILY 
was O 
also O 
studied O 
. O 
Diclofenac-β-d-glucuronide B-SYSTEMATIC 
was O 
used O 
to O 
explore O 
potential O 
time O 
- O 
dependent O 
inactivation O 
. O 
Results O 
: O 
The O 
chemical O 
stability O 
half O 
- O 
life O 
values O 
for O 
CGP B-SYSTEMATIC 
47292-β-d-glucuronide I-SYSTEMATIC 
, O 
diclofenac-β-d-glucuronide B-SYSTEMATIC 
, O 
(R)-naproxen-β-d-glucuronide B-SYSTEMATIC 
, O 
(S)-naproxen-β-d-glucuronide B-SYSTEMATIC 
, O 
ibuprofen-β-d-glucuronide B-SYSTEMATIC 
( I-SYSTEMATIC 
racemic I-SYSTEMATIC 
) I-SYSTEMATIC 
, O 
clopidogrel-β-d-glucuronide B-SYSTEMATIC 
, O 
and O 
valproate-β-d-glucuronide B-SYSTEMATIC 
were O 
found O 
to O 
be O 
0.252 O 
, O 
0.537 O 
, O 
0.996 O 
, O 
1.77 O 
, O 
3.67 O 
, O 
5.02 O 
, O 
and O 
15.2 O 
hours O 
, O 
respectively O 
. O 
Diclofenac-β-d-glucuronide B-SYSTEMATIC 
, O 
clopidogrel-β-d-glucuronide B-SYSTEMATIC 
, O 
ibuprofen-β-d-glucuronide B-SYSTEMATIC 
, O 
(R)-naproxen-β-d-glucuronide B-SYSTEMATIC 
, O 
and O 
(S)-naproxen-β-d-glucuronide B-SYSTEMATIC 
selectively O 
inhibited O 
hCES1 O 
, O 
with O 
Ki O 
values O 
of O 
4.32 O 
± O 
0.47 O 
, O 
24.8 O 
± O 
4.2 O 
, O 
355 O 
± O 
38 O 
, O 
468 O 
± O 
21 O 
, O 
707 O 
± O 
64 O 
µM O 
, O 
respectively O 
, O 
but O 
did O 
not O 
significantly O 
inhibit O 
hCES2 O 
. O 
Valproate-β-d-glucuronide B-SYSTEMATIC 
and O 
CGP B-SYSTEMATIC 
47292-β-d-glucuronide I-SYSTEMATIC 
did O 
not O 
inhibit O 
either O 
hCES O 
. O 
Time O 
- O 
dependent O 
inactivation O 
of O 
hCES1 O 
by O 
diclofenac-β-d-glucuronide B-SYSTEMATIC 
was O 
not O 
observed O 
. O 
Lastly O 
, O 
both O 
hCES1 O 
and O 
hCES2 O 
were O 
shown O 
not O 
to O 
catalyze O 
the O 
hydrolysis O 
of O 
the O 
acyl B-FAMILY 
glucuronides I-FAMILY 
studied O 
. O 
Conclusion O 
: O 
Drug O 
- O 
drug O 
interaction O 
studies O 
may O 
be O 
warranted O 
for O 
drugs O 
that O 
metabolize O 
to O 
acyl B-FAMILY 
glucuronides I-FAMILY 
due O 
to O 
the O 
potential O 
inhibition O 
of O 
hCESs O 
. O 

effects O 
of O 
ketamine B-TRIVIAL 
administration O 
for O 
2 O 
weeks O 
in O 
rats O 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
the O 
long O 
- O 
term O 
and O 
high O 
- O 
dose O 
application O 
of O 
ketamine B-TRIVIAL 
on O 
the O 
liver O 
by O 
employing O 
histologic O 
and O 
biochemical O 
methods O 
. O 
A O 
total O 
of O 
30 O 
male O 
rats O 
were O 
randomly O 
assigned O 
to O 
control O 
and O 
four O 
treatment O 
groups O 
( O 
n O 
: O 
6 O 
) O 
. O 
Saline O 
for O 
control O 
group O 
and O 
different O 
doses O 
of O 
ketamine B-TRIVIAL 
for O 
four O 
treatment O 
groups O 
( O 
40 O 
, O 
60 O 
, O 
80 O 
and O 
100 O 
mg O 
kg(-1) O 
) O 
were O 
administered O 
intraperitoneal O 
twice O 
a O 
day O 
for O 
2 O 
weeks O 
. O 
Immunohistological O 
staining O 
, O 
light O 
and O 
electron O 
microscopy O 
were O 
used O 
to O 
study O 
tissue O 
specimens O 
. O 
Histopathological O 
changes O 
were O 
more O 
severe O 
and O 
diverse O 
in O 
groups O 
80 O 
and O 
100 O 
mg O 
kg(-1) O 
day(-1) O 
, O 
and O 
the O 
least O 
significant O 
change O 
was O 
observed O 
in O 
groups O 
40 O 
and O 
60 O 
mg O 
kg(-1) O 
day(-1) O 
. O 
The O 
most O 
important O 
ultrastructural O 
changes O 
were O 
seen O 
in O 
mitochondria O 
and O 
in O 
the O 
rough O 
endoplasmic O 
reticulum O 
. O 
The O 
immunoreactivity O 
of O 
calcineurin O 
was O 
determined O 
as O 
different O 
. O 
Prolonged O 
use O 
of O 
ketamine B-TRIVIAL 
caused O 
hepatocellualar O 
toxicity O 
and O 
histological O 
changes O 
in O 
hepatocytes O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
in O 
all O 
experimental O 
groups O 
. O 

cytotoxic O 
activity O 
of O 
crude O 
extracts O 
and O 
their O 
fractions O 
from O 
leaves O 
and O 
roots O 
of O 
G O 
. O 
pohliana O 
was O 
assessed O 
against O 
nine O 
human O 
cancer O 
cell O 
lines O 
: O 
melanoma O 
( O 
UACC-62 O 
) O 
, O 
breast O 
( O 
MCF-7 O 
) O 
, O 
breast O 
expressing O 
the O 
multidrug O 
resistance O 
phenotype O 
( O 
NCI-ADR O 
) O 
, O 
lung O 
( O 
NCI-460 O 
) O 
, O 
prostate O 
( O 
PCO-3 O 
) O 
, O 
kidney O 
( O 
786-0 O 
) O 
, O 
ovarian O 
( O 
OVCAR O 
) O 
, O 
colon O 
( O 
HT-29 O 
) O 
and O 
leukaemia O 
( O 
K-562 O 
) O 
. O 
The O 
hexane B-SYSTEMATIC 
fraction O 
from O 
leaves O 
( O 
HL O 
) O 
and O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
EAR O 
) O 
, O 
chloroform B-TRIVIAL 
( O 
CR O 
) O 
and O 
hydromethanolic O 
( O 
HMR O 
) O 
fractions O 
from O 
roots O 
were O 
the O 
most O 
active O 
fractions O 
against O 
K-562 O 
with O 
GI(50) O 
values O 
being O 
lower O 
than O 
1 O 
μg O 
mL(- O 
1) O 
. O 
Also O 
, O 
CR O 
and O 
HMR O 
fractions O 
were O 
active O 
against O 
UACC-62 O 
cell O 
line O 
in O 
the O 
same O 
order O 
of O 
magnitude O 
. O 
The O 
phytochemical O 
study O 
of O 
the O 
CR O 
fraction O 
allowed O 
identifying O 
the O 
known O 
iridoids B-FAMILY 
secoxyloganin B-TRIVIAL 
, O 
sweroside B-TRIVIAL 
and O 
loganin B-TRIVIAL 
. O 

and O 
electron O 
momentum O 
spectroscopy O 
of O 
tetrahydrofuran B-SYSTEMATIC 
from O 
a O 
molecular O 
dynamical O 
perspective O 
. O 

results O 
of O 
experimental O 
studies O 
of O 
the O 
valence O 
electronic O 
structure O 
of O 
tetrahydrofuran B-SYSTEMATIC 
employing O 
He B-FORMULA 
I O 
photoelectron O 
spectroscopy O 
as O 
well O 
as O 
Electron O 
Momentum O 
Spectroscopy O 
( O 
EMS O 
) O 
have O 
been O 
reinterpreted O 
on O 
the O 
basis O 
of O 
Molecular O 
Dynamical O 
simulations O 
employing O 
the O 
classical O 
MM3 O 
force O 
field O 
and O 
large O 
- O 
scale O 
quantum O 
mechanical O 
simulations O 
employing O 
Born-Oppenheimer O 
Molecular O 
Dynamics O 
in O 
conjunction O 
with O 
the O 
dispersion O 
corrected O 
ωB97XD O 
exchange O 
- O 
correlation O 
functional O 
. O 
Analysis O 
of O 
the O 
produced O 
atomic O 
trajectories O 
demonstrates O 
the O 
importance O 
of O 
thermal O 
deviations O 
from O 
the O 
lowest O 
energy O 
path O 
for O 
pseudorotation O 
, O 
in O 
the O 
form O 
of O 
considerable O 
variations O 
of O 
the O 
ring O 
- O 
puckering O 
amplitude O 
. O 
These O 
deviations O 
are O 
found O 
to O 
have O 
a O 
significant O 
influence O 
on O 
several O 
outer O 
- O 
valence O 
electron O 
momentum O 
distributions O 
, O 
as O 
well O 
as O 
on O 
the O 
He B-FORMULA 
I O 
photoelectron O 
spectrum O 
. O 

inhibits O 
the O 
maturation O 
of O 
cathepsin O 
D O 
in O 
mammalian O 
cells O 
. O 

( O 
AZA-1 B-ABBREVIATION 
) O 
inhibits O 
endocytosis O 
, O 
but O 
the O 
consequences O 
of O 
this O 
alteration O 
on O 
cellular O 
processes O 
are O 
unknown O 
. O 
We O 
hypothesized O 
that O 
the O 
inhibition O 
of O 
endocytosis O 
is O 
a O 
key O 
step O 
of O 
the O 
mode O 
of O 
action O 
of O 
AZA-1 B-ABBREVIATION 
, O 
leading O 
to O 
perturbation O 
of O 
cellular O 
processes O 
dependent O 
on O 
proper O 
functioning O 
of O 
endocytic O 
machinery O 
. O 
We O 
tested O 
this O 
working O 
hypothesis O 
by O 
probing O 
whether O 
AZA-1 B-ABBREVIATION 
can O 
alter O 
the O 
maturation O 
of O 
cathepsin O 
D O 
in O 
MCF-7 O 
epithelial O 
cells O 
, O 
as O 
a O 
model O 
system O 
. O 
We O 
found O 
that O 
cell O 
treatment O 
with O 
AZA-1 B-ABBREVIATION 
inhibited O 
the O 
conversion O 
of O 
52 O 
kDa O 
procathepsin O 
D O 
into O 
the O 
mature O 
30 O 
kDa O 
protein O 
. O 
The O 
effects O 
induced O 
by O 
AZA-1 B-ABBREVIATION 
were O 
similar O 
to O 
those O 
elicited O 
by O 
chlorpromazine B-TRIVIAL 
and O 
other O 
agents O 
preventing O 
proper O 
maturation O 
of O 
lysosomal O 
enzymes O 
, O 
indicating O 
that O 
the O 
inhibition O 
of O 
endocytic O 
transfer O 
of O 
proforms O 
to O 
late O 
endosomes O 
/ O 
lysosomess O 
is O 
responsible O 
for O 
the O 
effect O 
induced O 
by O 
the O 
toxin O 
. O 
By O 
immunofluorescence O 
microscopy O 
, O 
we O 
found O 
no O 
colocalization O 
of O 
cathepsin O 
D O 
and O 
the O 
early O 
endosomal O 
marker O 
EEA-1 O 
in O 
control O 
cells O 
, O 
where O 
most O 
of O 
cathepsin O 
D O 
resides O 
in O 
late O 
endosomes O 
/ O 
lysosomes O 
. O 
Co-localization O 
of O 
cathepsin O 
D O 
and O 
EEA-1 O 
immunoreactivity O 
, O 
in O 
turn O 
, O 
was O 
found O 
in O 
cells O 
exposed O 
to O 
AZA-1 B-ABBREVIATION 
, O 
indicating O 
that O 
the O 
toxin O 
blocks O 
protein O 
maturation O 
at O 
the O 
early O 
steps O 
of O 
endocytosis O 
, O 
causing O 
accumulation O 
of O 
procathepsin O 
D O 
in O 
early O 
endosomes O 
. O 
The O 
molecular O 
alteration O 
induced O 
by O 
AZA-1 B-ABBREVIATION 
involved O 
both O 
secreted O 
and O 
intracellular O 
pools O 
of O 
procathepsin O 
D O 
, O 
showing O 
that O 
the O 
toxin O 
effect O 
does O 
not O 
result O 
from O 
a O 
general O 
impairment O 
of O 
vesicular O 
trafficking O 
but O 
is O 
the O 
outcome O 
of O 
a O 
perturbed O 
centripetal O 
process O 
. O 
Furthermore O 
, O 
AZA-1 B-ABBREVIATION 
was O 
found O 
to O 
inhibit O 
procathepsin O 
D O 
maturation O 
also O 
in O 
normal O 
fibroblasts O 
, O 
showing O 
that O 
this O 
molecular O 
response O 
is O 
induced O 
by O 
this O 
toxin O 
in O 
different O 
cell O 
types O 
. O 
The O 
data O 
we O 
obtained O 
corroborated O 
our O 
hypothesis O 
and O 
provide O 
a O 
unified O 
molecular O 
frame O 
for O 
the O 
mode O 
of O 
action O 
of O 
AZAs B-ABBREVIATION 
in O 
animal O 
models O 
, O 
involving O 
a O 
primary O 
alteration O 
of O 
endocytic O 
processes O 
. O 

fabrication O 
of O 
hexagonally O 
close O 
- O 
packed O 
Langmuir-Blodgett O 
silica B-TRIVIAL 
particulate O 
monolayers O 
from O 
binary O 
surfactant O 
and O 
solvent O 
systems O 
. O 

describe O 
a O 
controllable O 
method O 
to O 
fabricate O 
hexagonally O 
close O 
- O 
packed O 
Langmuir-Blodgett O 
( O 
LB O 
) O 
monolayers O 
with O 
stearic B-TRIVIAL 
acid I-TRIVIAL 
( O 
SA O 
) O 
as O 
co O 
- O 
surfactant O 
and O 
methanol B-SYSTEMATIC 
as O 
co O 
- O 
solvent O 
. O 
The O 
optimal O 
SA O 
concentrations O 
and O 
volume O 
ratios O 
of O 
chloroform B-TRIVIAL 
to O 
methanol B-SYSTEMATIC 
are O 
0.8 O 
mg O 
/ O 
mL O 
and O 
3 O 
: O 
1 O 
for O 
particles O 
of O 
140 O 
nm O 
, O 
0.5 O 
mg O 
/ O 
mL O 
and O 
4 O 
: O 
1 O 
for O 
particles O 
of O 
300 O 
nm O 
, O 
and O 
0.05 O 
mg O 
/ O 
mL O 
and O 
5 O 
: O 
1 O 
for O 
particles O 
of O 
550 O 
nm O 
, O 
respectively O 
. O 
Additionally O 
, O 
SEM O 
detections O 
of O 
the O 
monolayers O 
transferred O 
at O 
different O 
surface O 
pressures O 
indicate O 
that O 
the O 
monolayers O 
deposited O 
from O 
the O 
binary O 
systems O 
are O 
more O 
compressible O 
. O 
The O 
experimental O 
results O 
indicate O 
that O 
the O 
interparticle O 
repulsions O 
and O 
particle O 
- O 
water O 
interactions O 
can O 
be O 
enhanced O 
without O 
decreasing O 
the O 
particle O 
hydrophobicity O 
by O 
adding O 
SA O 
and O 
methanol B-SYSTEMATIC 
; O 
thus O 
, O 
particulate O 
monolayers O 
with O 
large O 
hexagonally O 
close O 
- O 
packed O 
domains O 
composed O 
of O 
small O 
silica B-TRIVIAL 
particles O 
can O 
be O 
successfully O 
fabricated O 
using O 
LB O 
technique O 
. O 
We O 
propose O 
that O 
the O 
enhanced O 
interparticle O 
repulsion O 
is O 
attributed O 
to O 
the O 
Columbic O 
repulsion O 
resulting O 
from O 
the O 
attachment O 
of O 
SA O 
molecules O 
to O 
the O 
CTAB B-ABBREVIATION 
modified O 
particles O 
around O 
the O 
three O 
phase O 
contact O 
line O 
. O 

from O 
the O 
rhizomes O 
of O 
Curcuma O 
heyneana O 
. O 

new O 
germacranes B-FAMILY 
[ O 
heyneanones B-MULTIPLE 
A-D I-MULTIPLE 
( O 
1-4 O 
) O 
] O 
, O 
three O 
new O 
guaianes B-FAMILY 
[ O 
4,10-epizedoarondiol B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
15-hydroxyprocurcumenol B-SYSTEMATIC 
( O 
6 O 
) O 
, O 
12-hydroxycurcumenol B-SYSTEMATIC 
( O 
7 O 
) O 
] O 
, O 
and O 
two O 
new O 
spirolactones B-FAMILY 
[ O 
curcumanolides B-FAMILY 
C O 
( O 
8 O 
) O 
and O 
D O 
( O 
9 O 
) O 
] O 
were O 
isolated O 
from O 
the O 
rhizomes O 
of O 
Curcuma O 
heyneana O 
together O 
with O 
13 O 
known O 
sesquiterpenes B-FAMILY 
and O 
two O 
known O 
labdane B-TRIVIAL 
-type O 
diterpenes B-FAMILY 
. O 
Among O 
the O 
isolated O 
compounds O 
, O 
heyneanone B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
, O 
heyneanone B-TRIVIAL 
C I-TRIVIAL 
( O 
3 O 
) O 
, O 
4,10-epizedoarondiol B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
procurcumenol B-TRIVIAL 
( O 
16 O 
) O 
, O 
aerugidiol B-TRIVIAL 
( O 
17 O 
) O 
, O 
zerumin B-TRIVIAL 
A I-TRIVIAL 
( O 
23 O 
) O 
, O 
and O 
(E)-15,16-bisnorlabda-8(17),11-dien-13-one B-SYSTEMATIC 
( O 
24 O 
) O 
inhibited O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
1B O 
( O 
PTP1B O 
) O 
with O 
IC(50) O 
values O 
of O 
42.5 O 
, O 
35.2 O 
, O 
35.1 O 
, O 
45.6 O 
, O 
35.7 O 
, O 
10.4 O 
, O 
and O 
14.7 O 
μM O 
, O 
respectively O 
. O 

aim O 
of O 
this O 
work O 
was O 
to O 
develop O 
a O 
targeted O 
drug O 
delivery O 
system O 
with O 
potentials O 
for O 
intravesical O 
instilled O 
chemotherapy O 
of O 
superficial O 
bladder O 
cancer O 
. O 
The O 
amphiphilic O 
diblock O 
copolymer O 
poly(ε-caprolactone)-b-poly(ethylene B-FAMILY 
oxide I-FAMILY 
) I-FAMILY 
( O 
PCL-b-PEO B-ABBREVIATION 
) O 
was O 
first O 
conjugated O 
with O 
the O 
cyclic B-TRIVIAL 
( I-TRIVIAL 
Arginine-Glycine-Aspartic I-TRIVIAL 
acid-d-Phenylalanine-Lysine I-TRIVIAL 
) I-TRIVIAL 
(c(RGDfK)) O 
and O 
fluorescein B-SYSTEMATIC 
isothiocyannate I-SYSTEMATIC 
( O 
FITC B-ABBREVIATION 
) O 
via O 
the O 
functional O 
terminal O 
groups O 
of O 
hydrophilic O 
block O 
, O 
and O 
then O 
assembled O 
into O 
micelles O 
. O 
The O 
interaction O 
between O 
micelles O 
and O 
various O 
model O 
cells O 
was O 
well O 
studied O 
by O 
means O 
of O 
confocal O 
laser O 
scanning O 
microscopy O 
and O 
flow O 
cytometry O 
. O 
The O 
c(RGDfK) O 
on O 
the O 
surface O 
of O 
the O 
micelle O 
was O 
confirmed O 
by O 
(1)H B-FORMULA 
NMR O 
analysis O 
and O 
cell O 
affinity O 
with O 
human O 
glioblastoma O 
- O 
astrocytoma O 
cells O 
( O 
U87MG O 
) O 
. O 
The O 
cell O 
viability O 
of O 
bladder O 
cancer O 
cells O 
( O 
T-24 O 
cells O 
) O 
after O 
incubation O 
with O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
loaded O 
polymeric O 
micelles O 
was O 
evaluated O 
by O 
in O 
vitro O 
cytotoxicity O 
assay O 
. O 
The O 
results O 
revealed O 
that O 
c(RGDfK) O 
modified O 
micelles O 
showed O 
strong O 
affinity O 
to O 
T-24 O 
cells O 
and O 
strong O 
inhibitory O 
effect O 
on O 
the O 
proliferation O 
of O 
T-24 O 
cells O 
when O 
doxorubicin B-TRIVIAL 
drug O 
was O 
loaded O 
, O 
indicating O 
the O 
high O 
affinity O 
of O 
c(RGDfK) O 
to O 
bladder O 
cancer O 
cells O 
. O 
The O 
c(RGDfK) O 
modified O 
micelles O 
assembled O 
from O 
PCL-b-PEO B-ABBREVIATION 
diblock O 
copolymers O 
developed O 
in O 
this O 
study O 
are O 
of O 
great O 
potentials O 
as O 
nano O 
- O 
scaled O 
drug O 
delivery O 
system O 
for O 
intravesical O 
instilled O 
chemotherapy O 
of O 
superficial O 
bladder O 
cancer O 
. O 

-hydroxylase O 
inhibition O 
preserves O 
endothelial O 
cell O 
function O 
in O 
a O 
rat O 
model O 
of O 
vascular O 
ischemia O 
reperfusion O 
injury O 
. O 

protocols O 
of O 
vascular O 
grafts O 
need O 
further O 
improvement O 
against O 
ischemia O 
- O 
reperfusion O 
( O 
IR O 
) O 
injury O 
. O 
Hypoxia O 
elicits O 
a O 
variety O 
of O 
complex O 
cellular O 
responses O 
by O 
altering O 
the O 
activity O 
of O 
many O 
signaling O 
pathways O 
, O 
such O 
as O 
the O 
oxygen B-SYSTEMATIC 
-dependent O 
prolyl B-TRIVIAL 
-hyroxylase O 
domain O 
- O 
containing O 
enzyme O 
( O 
PHD O 
) O 
. O 
Reduction O 
of O 
PHD O 
activity O 
during O 
hypoxia O 
leads O 
to O 
stabilization O 
and O 
accumulation O 
of O 
hypoxia O 
inducible O 
factor O 
( O 
HIF O 
) O 
1α O 
. O 
We O 
examined O 
the O 
effects O 
of O 
PHD O 
inhibiton O 
by O 
dimethyloxalylglycine B-SYSTEMATIC 
on O 
the O 
vasomotor O 
responses O 
of O 
isolated O 
rat O 
aorta O 
and O 
aortic O 
vascular O 
smooth O 
muscle O 
cells O 
( O 
VSMCs O 
) O 
in O 
a O 
model O 
of O 
cold O 
ischemia O 
/ O 
warm O 
reperfusion O 
. O 
Aortic O 
segments O 
underwent O 
24 O 
hours O 
of O 
cold O 
ischemic O 
preservation O 
in O 
saline O 
or O 
DMOG B-ABBREVIATION 
( O 
dimethyloxalylglycine B-SYSTEMATIC 
)-supplemented O 
saline O 
solution O 
. O 
We O 
investigated O 
endothelium O 
- O 
dependent O 
and O 
-independent O 
vasorelaxations O 
. O 
To O 
simulate O 
IR O 
injury O 
, O 
hypochlorite B-SYSTEMATIC 
( O 
NaOCl B-FORMULA 
) O 
was O 
added O 
during O 
warm O 
reperfusion O 
. O 
VSMCs O 
were O 
incubated O 
in O 
NaCl B-FORMULA 
or O 
DMOG B-ABBREVIATION 
solution O 
at O 
4°C O 
for O 
24 O 
hours O 
after O 
the O 
medium O 
was O 
changed O 
for O 
a O 
supplied O 
standard O 
medium O 
at O 
37°C O 
for O 
6 O 
hours O 
. O 
Apoptosis O 
was O 
assessed O 
using O 
the O 
TUNEL O 
method O 
. O 
Gene O 
expression O 
analysis O 
was O 
performed O 
using O 
quantitative O 
real O 
- O 
time O 
polymerase O 
chain O 
reaction O 
. O 
Cold O 
ischemic O 
preservation O 
and O 
NaOCl B-FORMULA 
induced O 
severe O 
endothelial O 
dysfunction O 
, O 
which O 
was O 
significantly O 
improved O 
by O 
DMOG B-ABBREVIATION 
supplementation O 
( O 
maximal O 
relaxation O 
of O 
aortic O 
segments O 
to O 
acetylcholine B-SYSTEMATIC 
: O 
control O 
95% O 
± O 
1% O 
versus O 
NaOCl B-FORMULA 
44% O 
± O 
4% O 
versus O 
DMOG B-ABBREVIATION 
68% O 
± O 
5% O 
) O 
. O 
Number O 
of O 
TUNEL-positive O 
cell O 
nuclei O 
was O 
significantly O 
higher O 
in O 
the O 
NaOCl B-FORMULA 
group O 
, O 
and O 
DMOG B-ABBREVIATION 
treatment O 
significantly O 
decreased O 
apoptosis O 
. O 
Inducible O 
heme B-FAMILY 
-oxygenase O 
1 O 
mRNA O 
expressions O 
were O 
significantly O 
higher O 
in O 
the O 
DMOG B-ABBREVIATION 
group O 
. O 
Pharmacological O 
modulation O 
of O 
oxygen B-SYSTEMATIC 
sensing O 
system O 
by O 
DMOG B-ABBREVIATION 
in O 
an O 
in O 
vitro O 
model O 
of O 
vascular O 
IR O 
effectively O 
preserved O 
endothelial O 
function O 
. O 
Inhibition O 
of O 
PHDs O 
could O 
therefore O 
be O 
a O 
new O 
therapeutic O 
avenue O 
for O 
protecting O 
endothelium O 
and O 
vascular O 
muscle O 
cells O 
against O 
IR O 
injury O 
. O 

of O 
A1 O 
adenosine B-TRIVIAL 
receptor O 
agonist O 
tecadenoson B-TRIVIAL 
by O 
human O 
and O 
mouse O 
nucleoside B-FAMILY 
transporters O 
: O 
evidence O 
for O 
blood O 
- O 
brain O 
barrier O 
transport O 
by O 
murine O 
equilibrative O 
nucleoside B-FAMILY 
transporter O 
1 O 
mENT1 O 
. O 

high O 
density O 
of O 
A1 O 
adenosine B-TRIVIAL 
receptors O 
in O 
the O 
brain O 
results O 
in O 
significant O 
potential O 
for O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
- O 
related O 
adverse O 
effects O 
with O 
A1 O 
agonists O 
. O 
Tecadenoson B-TRIVIAL 
is O 
a O 
selective O 
A1 O 
adenosine B-TRIVIAL 
receptor O 
agonist O 
with O 
close O 
similarity O 
to O 
adenosine B-TRIVIAL 
. O 
We O 
studied O 
the O 
binding O 
and O 
transmembrane O 
transport O 
of O 
tecadenoson B-TRIVIAL 
by O 
recombinant O 
human O 
equilibrative O 
nucleoside B-FAMILY 
transporters O 
( O 
hENTs O 
) O 
hENT1 O 
and O 
hENT2 O 
, O 
and O 
human O 
concentrative O 
nucleoside B-FAMILY 
transporters O 
( O 
hCNTs O 
) O 
hCNT1 O 
, O 
hCNT2 O 
, O 
and O 
hCNT3 O 
in O 
vitro O 
and O 
by O 
mouse O 
mENT1 O 
in O 
vivo O 
. O 
Binding O 
affinities O 
of O 
the O 
five O 
recombinant O 
human O 
nucleoside B-FAMILY 
transporters O 
for O 
tecadenoson B-TRIVIAL 
differed O 
( O 
hENT1 O 
> O 
hCNT1 O 
> O 
hCNT3 O 
> O 
hENT2 O 
> O 
hCNT2 O 
) O 
, O 
and O 
tecadenoson B-TRIVIAL 
was O 
transported O 
largely O 
by O 
hENT1 O 
. O 
Pretreatment O 
of O 
mice O 
with O 
a O 
phosphorylated O 
prodrug O 
of O 
nitrobenzylmercaptopurine B-SYSTEMATIC 
riboside O 
, O 
an O 
inhibitor O 
of O 
mENT1 O 
, O 
significantly O 
decreased O 
brain O 
exposure O 
to O 
tecadenoson B-TRIVIAL 
compared O 
with O 
that O 
of O 
the O 
untreated O 
( O 
control O 
) O 
group O 
, O 
suggesting O 
involvement O 
of O 
mENT1 O 
in O 
transport O 
of O 
tecadenoson B-TRIVIAL 
across O 
the O 
blood O 
- O 
brain O 
barrier O 
( O 
BBB O 
) O 
. O 
In O 
summary O 
, O 
ENT1 O 
was O 
shown O 
to O 
mediate O 
the O 
transport O 
of O 
tecadenoson B-TRIVIAL 
in O 
vitro O 
with O 
recombinant O 
and O 
native O 
human O 
protein O 
and O 
in O 
vivo O 
with O 
mice O 
. O 
The O 
micromolar O 
apparent O 
Km O 
value O 
of O 
tecadenoson B-TRIVIAL 
for O 
transport O 
by O 
native O 
hENT1 O 
in O 
cultured O 
cells O 
suggests O 
that O 
hENT1 O 
will O 
not O 
be O 
saturated O 
at O 
clinically O 
relevant O 
( O 
i.e O 
. O 
, O 
nanomolar O 
) O 
concentrations O 
of O 
tecadenoson B-TRIVIAL 
, O 
and O 
that O 
hENT1 O 
- O 
mediated O 
passage O 
across O 
the O 
BBB O 
may O 
contribute O 
to O 
the O 
adverse O 
CNS O 
effects O 
observed O 
in O 
clinical O 
trials O 
. O 
In O 
contrast O 
, O 
in O 
cases O 
in O 
which O 
a O 
CNS O 
effect O 
is O 
desired O 
, O 
the O 
present O 
results O 
illustrate O 
that O 
synthetic O 
A1 O 
agonists O 
that O 
are O 
transported O 
by O 
hENT1 O 
could O 
be O 
used O 
to O 
target O 
CNS O 
disorders O 
because O 
of O 
enhanced O 
delivery O 
to O 
the O 
brain O 
. O 

herein O 
presented O 
complete O 
structure O 
of O 
the O 
core O 
oligosaccharide O 
of O 
lipopolysaccharide O 
( O 
LPS O 
) O 
P O 
. O 
shigelloides O 
Polish O 
Collection O 
of O 
Microorganisms O 
( O 
PCM O 
) O 
2231 O 
( O 
serotype O 
O17 O 
) O 
was O 
investigated O 
by O 
(1)H B-FORMULA 
, O 
(13)C B-FORMULA 
NMR O 
spectroscopy O 
, O 
mass O 
spectrometry O 
, O 
chemical O 
analyses O 
and O 
serological O 
methods O 
. O 
The O 
core O 
oligosaccharide O 
is O 
composed O 
of O 
an O 
undecasaccharide O 
, O 
which O 
represents O 
the O 
second O 
core O 
type O 
identified O 
for O 
P O 
. O 
shigelloides O 
serotype O 
O17 O 
LPS O 
. O 
This O 
structure O 
is O 
similar O 
to O 
that O 
of O 
the O 
core O 
oligosaccharide O 
of O 
P O 
. O 
shigelloides O 
strains O 
302-73 O 
( O 
serotype O 
O1 O 
) O 
and O 
7-63 O 
( O 
serotype O 
O17 O 
) O 
and O 
differs O 
from O 
these O 
only O 
by O 
one O 
sugar B-FAMILY 
residue O 
. O 
Serological O 
screening O 
of O 
55 O 
strains O 
of O 
P O 
. O 
shigelloides O 
with O 
the O 
use O 
of O 
serum O 
against O 
identified O 
core O 
oligosaccharide O 
conjugated O 
with O 
bovine O 
serum O 
albumin O 
( O 
BSA O 
) O 
indicated O 
the O 
presence O 
of O 
similar O 
structures O 
in O 
the O 
LPS O 
core O 
region O 
of O 
28 O 
O-serotypes O 
. O 
This O 
observation O 
suggests O 
that O 
the O 
core O 
oligosaccharide O 
structure O 
present O 
in O 
strain O 
PCM O 
2231 O 
could O 
be O 
the O 
most O 
common O 
type O 
among O 
P O 
. O 
shigelloides O 
lipopolysaccharides O 
. O 

casbane B-FAMILY 
diterpenoids I-FAMILY 
from O 
a O 
South O 
China O 
Sea O 
soft O 
coral O 
, O 
Sinularia O 
sp O 
. O 

new O 
casbane B-FAMILY 
diterpenoids I-FAMILY 
, O 
named O 
as O 
sinularcasbanes B-MULTIPLE 
A-F I-MULTIPLE 
( O 
1-6 O 
) O 
, O 
along O 
with O 
six O 
known O 
analogues O 
7-12 O 
, O 
were O 
isolated O 
from O 
a O 
South O 
China O 
Sea O 
soft O 
coral O 
, O 
Sinularia O 
sp O 
. O 
The O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
elucidated O 
by O 
extensive O 
spectroscopic O 
analysis O 
and O 
by O 
comparison O 
with O 
data O 
reported O 
in O 
the O 
literature O 
. O 
All O 
compounds O 
were O 
evaluated O 
for O 
their O 
cytotoxicity O 
against O 
selected O 
cancer O 
cell O 
lines O 
and O 
the O 
inhibition O 
of O 
lipopolysaccharide O 
(LPS)-induced O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
production O 
in O 
mouse O 
peritoneal O 
macrophages O 
. O 

has O 
been O 
recently O 
reported O 
that O 
for O 
some O 
suspensions O 
of O 
magnetic O 
nanoparticles O 
the O 
transverse O 
proton O 
relaxation O 
rate O 
, O 
R(2) O 
, O 
is O 
dependent O 
on O 
the O 
time O 
that O 
the O 
sample O 
is O 
exposed O 
to O 
an O 
applied O 
magnetic O 
field O 
. O 
This O 
time O 
dependence O 
has O 
been O 
linked O 
to O 
the O 
formation O 
of O 
linear O 
aggregates O 
or O 
chains O 
in O 
an O 
applied O 
magnetic O 
field O 
via O 
numerical O 
modeling O 
. O 
It O 
is O 
widely O 
known O 
that O 
chain O 
formation O 
occurs O 
in O 
more O 
concentrated O 
ferrofluids O 
systems O 
and O 
that O 
this O 
has O 
an O 
affect O 
on O 
the O 
ferrofluid O 
properties O 
. O 
In O 
this O 
work O 
we O 
examine O 
the O 
relationships O 
between O 
colloidal O 
stability O 
, O 
the O 
formation O 
of O 
these O 
linear O 
structures O 
, O 
and O 
changes O 
observed O 
in O 
the O 
proton O 
transverse O 
relaxation O 
rate O 
of O 
aqueous O 
suspensions O 
of O 
magnetic O 
particles O 
. O 
A O 
series O 
of O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
with O 
varying O 
stabilizing O 
ligand O 
brush O 
lengths O 
were O 
synthesized O 
. O 
These O 
systems O 
were O 
characterized O 
with O 
dynamic O 
light O 
scattering O 
, O 
transmission O 
electron O 
microscopy O 
, O 
dark O 
- O 
field O 
optical O 
microscopy O 
, O 
and O 
proton O 
transverse O 
relaxation O 
rate O 
measurements O 
. O 
The O 
dark O 
field O 
optical O 
microscopy O 
and O 
R(2) O 
measurements O 
were O 
made O 
in O 
similar O 
magnetic O 
fields O 
over O 
the O 
same O 
time O 
scale O 
so O 
as O 
to O 
correlate O 
the O 
reduction O 
of O 
the O 
transverse O 
relaxivity O 
with O 
the O 
formation O 
of O 
linear O 
aggregates O 
. O 
Our O 
results O 
indicate O 
that O 
varying O 
the O 
ligand O 
length O 
has O 
a O 
direct O 
effect O 
on O 
the O 
colloidal O 
arrangement O 
of O 
the O 
system O 
in O 
a O 
magnetic O 
field O 
, O 
producing O 
differences O 
in O 
the O 
rate O 
and O 
size O 
of O 
chain O 
formation O 
, O 
and O 
hence O 
systematic O 
changes O 
in O 
transverse O 
relaxation O 
rates O 
over O 
time O 
. O 
With O 
increasing O 
ligand O 
brush O 
length O 
, O 
attractive O 
inter O 
- O 
particle O 
interactions O 
are O 
reduced O 
, O 
which O 
results O 
in O 
slower O 
aggregate O 
formation O 
and O 
shorter O 
linear O 
aggregate O 
length O 
. O 
These O 
results O 
have O 
implications O 
for O 
the O 
stabilization O 
, O 
characterization O 
and O 
potentially O 
the O 
toxicity O 
of O 
magnetic O 
nanoparticle O 
systems O 
used O 
in O 
biomedical O 
applications O 
. O 

of O 
toxicity O 
between O 
the O 
different O 
- O 
type O 
TiO(2) B-FORMULA 
nanowires O 
in O 
vivo O 
and O 
in O 
vitro O 
. O 

this O 
study O 
, O 
we O 
compared O 
their O 
toxicity O 
in O 
vivo O 
and O 
in O 
vitro O 
based O 
on O 
the O 
physicochemical O 
properties O 
of O 
three O 
different O 
types O 
of O 
TiO(2) B-FORMULA 
nanowires O 
, O 
H(2)Ti(3)O(7) B-FORMULA 
nanowires O 
( O 
1HTO O 
) O 
, O 
hydrothermal O 
treatment O 
( O 
2HTO O 
) O 
, O 
and O 
calcination O 
( O 
3HTO O 
) O 
of O 
1HTO O 
. O 
The O 
surface O 
of O 
1HTO O 
was O 
smooth O 
, O 
and O 
the O 
surface O 
of O 
2HTO O 
was O 
much O 
rougher O 
. O 
The O 
negative O 
charge O 
on O 
the O 
surface O 
increased O 
in O 
the O 
order O 
of O 
2HTO O 
, O 
3HTO O 
, O 
and O 
1HTO O 
, O 
whereas O 
the O 
surface O 
area O 
increased O 
in O 
the O 
order O 
of O 
3HTO O 
, O 
1HTO O 
, O 
and O 
2HTO O 
. O 
The O 
lung O 
is O 
a O 
main O 
exposure O 
route O 
of O 
nanoparticles O 
. O 
On O 
day O 
28 O 
after O 
a O 
single O 
instillation O 
( O 
1 O 
mg O 
/ O 
kg O 
) O 
, O 
three O 
nanowires O 
induced O 
a O 
Th2 O 
- O 
type O 
inflammatory O 
response O 
together O 
with O 
the O 
relative O 
increase O 
in O 
CD4(+) O 
T O 
cells O 
, O 
especially O 
by O 
2HTO O 
. O 
In O 
vitro O 
, O 
three O 
TiO(2) B-FORMULA 
nanowires O 
( O 
10 O 
μg O 
/ O 
ml O 
) O 
commonly O 
induced O 
the O 
generation O 
of O 
cell O 
debris O 
in O 
eight O 
cell O 
lines O 
which O 
may O 
be O 
the O 
potential O 
target O 
organ O 
of O 
nanoparticles O 
, O 
especially O 
by O 
2HTO O 
. O 
It O 
seemed O 
that O 
the O 
generation O 
of O 
cell O 
debris O 
coincides O 
with O 
the O 
increase O 
in O 
autophagosome O 
- O 
like O 
vacuoles O 
in O 
the O 
cytosol O 
. O 
In O 
further O 
study O 
using O 
BEAS-2B O 
cells O 
originated O 
from O 
the O 
lung O 
, O 
the O 
protein O 
amount O 
from O 
cells O 
exposed O 
to O 
2HTO O 
decreased O 
more O 
clearly O 
although O 
the O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
was O 
less O 
compared O 
to O 
1HTO O 
and O 
3HTO O 
. O 
Based O 
on O 
these O 
results O 
, O 
we O 
suggest O 
that O 
surface O 
area O 
may O 
act O 
as O 
an O 
important O 
factor O 
depends O 
on O 
the O 
biological O 
response O 
by O 
TiO(2) B-FORMULA 
nanowires O 
. O 
Furthermore O 
, O 
the O 
increase O 
in O 
autophagosome O 
- O 
like O 
vacuoles O 
may O 
be O 
an O 
important O 
cause O 
of O 
cell O 
death O 
by O 
nanoparticles O 
with O 
ROS O 
. O 

effects O 
of O 
BMY-14802 B-IDENTIFIER 
against O 
L-DOPA B-ABBREVIATION 
- O 
and O 
dopamine B-TRIVIAL 
agonist O 
- O 
induced O 
dyskinesia O 
in O 
the O 
hemiparkinsonian O 
rat O 
. O 

: O 
L-DOPA B-ABBREVIATION 
continues O 
to O 
be O 
the O 
primary O 
treatment O 
for O 
patients O 
with O 
Parkinson's O 
disease O 
; O 
however O 
, O 
the O 
benefits O 
of O 
long O 
- O 
term O 
treatment O 
are O 
often O 
accompanied O 
by O 
debilitating O 
side O 
effects O 
known O 
as O 
dyskinesias O 
. O 
In O 
recent O 
years O 
, O 
several O 
5-HT(1A) O 
receptor O 
agonists O 
have O 
been O 
found O 
to O 
reduce O 
dyskinesia O 
in O 
clinical O 
and O 
experimental O 
models O 
of O 
PD O 
. O 
The O 
purported O 
sigma-1 O 
antagonist O 
, O 
BMY-14802 B-IDENTIFIER 
has O 
been O 
previously O 
demonstrated O 
to O 
reduce O 
L-DOPA B-ABBREVIATION 
induced O 
dyskinesia O 
in O 
a O 
5-HT(1A) O 
receptor O 
dependent O 
manner O 
. O 
OBJECTIVE O 
: O 
In O 
the O 
present O 
study O 
, O 
we O 
extend O 
these O 
findings O 
by O 
examining O 
the O 
anti-dyskinetic O 
potential O 
of O 
BMY-14802 B-IDENTIFIER 
against O 
L-DOPA B-ABBREVIATION 
, O 
the O 
D(1) O 
receptor O 
agonist O 
SKF81297 B-IDENTIFIER 
and O 
the O 
D(2) O 
receptor O 
agonist O 
, O 
quinpirole B-TRIVIAL 
, O 
in O 
the O 
hemi O 
- O 
parkinsonian O 
rat O 
model O 
. O 
In O 
addition O 
, O 
the O 
receptor O 
specificity O 
of O 
BMY-14802 B-IDENTIFIER 
' O 
s O 
effects O 
was O 
evaluated O 
using O 
WAY-100635 B-IDENTIFIER 
, O 
a O 
5-HT(1A) O 
receptor O 
antagonist O 
. O 
RESULTS O 
: O 
Results O 
confirmed O 
the O 
dose O 
- O 
dependent O 
( O 
20 O 
> O 
10 O 
> O 
5 O 
mg O 
/ O 
kg O 
) O 
anti-dyskinetic O 
effects O 
of O 
BMY-14802 B-IDENTIFIER 
against O 
L-DOPA B-ABBREVIATION 
with O 
preservation O 
of O 
anti-parkinsonian O 
efficacy O 
at O 
10 O 
mg O 
/ O 
kg O 
. O 
BMY-14802 B-IDENTIFIER 
at O 
10 O 
and O 
20 O 
mg O 
/ O 
kg O 
also O 
reduced O 
dyskinesia O 
induced O 
by O 
both O 
D(1) O 
and O 
D(2) O 
receptor O 
agonists O 
. O 
Additionally O 
, O 
BMY-14802 B-IDENTIFIER 
' O 
s O 
anti-dyskinetic O 
effects O 
against O 
L-DOPA B-ABBREVIATION 
, O 
but O 
not O 
SKF81297 B-IDENTIFIER 
or O 
quinpirole B-TRIVIAL 
, O 
were O 
reversed O 
by O 
WAY-100635 B-IDENTIFIER 
( O 
0.5 O 
mg O 
/ O 
kg O 
) O 
. O 
CONCLUSION O 
: O 
Collectively O 
, O 
these O 
findings O 
demonstrate O 
that O 
BMY-14802 B-IDENTIFIER 
provides O 
anti-dyskinetic O 
relief O 
against O 
L-DOPA B-ABBREVIATION 
and O 
direct O 
DA O 
agonist O 
in O 
a O 
preclinical O 
model O 
of O 
PD O 
, O 
acting O 
via O 
multiple O 
receptor O 
systems O 
and O 
supports O 
the O 
utility O 
of O 
such O 
compounds O 
for O 
the O 
improved O 
treatment O 
of O 
PD O 
. O 

: O 
Prostate O 
smooth O 
muscle O 
plays O 
an O 
important O 
role O 
in O 
the O 
physiological O 
ejection O 
of O 
prostatic O 
fluid O 
and O 
also O 
in O 
the O 
pathogenesis O 
of O 
benign O 
prostate O 
hyperplasia O 
. O 
Although O 
mouse O 
is O 
the O 
best O 
genetically O 
engineered O 
animal O 
model O 
to O 
identify O 
potential O 
molecular O 
targets O 
for O 
human O 
diseases O 
, O 
only O 
fragmentary O 
information O 
is O 
available O 
for O 
basic O 
mechanism O 
of O 
mouse O 
prostate O 
contraction O 
. O 
METHODS O 
: O 
Small O 
smooth O 
muscle O 
tubular O 
rings O 
were O 
excised O 
from O 
four O 
mouse O 
prostate O 
lobes O 
to O 
measure O 
their O 
isometric O 
contractions O 
. O 
High O 
K(+) B-FORMULA 
, O 
noradrenaline B-TRIVIAL 
( O 
nan O 
) O 
, O 
or O 
acetylcholine B-SYSTEMATIC 
( O 
ACh B-ABBREVIATION 
) O 
was O 
applied O 
with O 
and O 
without O 
various O 
antagonists O 
and O 
/ O 
or O 
inhibitors O 
to O 
examine O 
the O 
contractile O 
signaling O 
pathways O 
. O 
RESULTS O 
: O 
Maximum O 
amplitude O 
of O 
agonist O 
- O 
induced O 
contractions O 
varied O 
greatly O 
with O 
different O 
lobes O 
but O 
not O 
with O 
different O 
locations O 
or O 
orientations O 
within O 
each O 
lobe O 
. O 
Both O 
nan O 
and O 
ACh B-ABBREVIATION 
produced O 
large O 
contractions O 
in O 
ventral O 
and O 
dorsal O 
rings O 
, O 
whereas O 
only O 
small O 
contractions O 
were O 
elicited O 
in O 
lateral O 
and O 
anterior O 
rings O 
. O 
Combination O 
of O 
alpha-1 O 
and O 
muscarinic O 
antagonists O 
suppressed O 
K(+) B-FORMULA 
depolarization O 
- O 
induced O 
contraction O 
potently O 
in O 
ventral O 
rings O 
, O 
but O 
slightly O 
in O 
anterior O 
rings O 
. O 
Blocking O 
of O 
either O 
Ca(2+) B-FORMULA 
-release O 
or O 
Ca(2+) B-FORMULA 
-influx O 
reduced O 
agonist O 
- O 
induced O 
contraction O 
of O 
ventral O 
rings O 
, O 
however O 
, O 
a O 
considerable O 
amount O 
of O 
contractility O 
remained O 
even O 
with O 
both O 
blockers O 
. O 
Inhibitors O 
of O 
ROCK O 
and O 
PKC O 
partially O 
inhibited O 
NA-induced O 
contractions O 
, O 
whereas O 
a O 
combination O 
of O 
Ca(2+) B-FORMULA 
-blockers O 
and O 
Ca(2+) B-FORMULA 
-sensitization O 
inhibitors O 
strongly O 
suppressed O 
the O 
contraction O 
. O 
CONCLUSIONS O 
: O 
The O 
ejection O 
of O 
prostatic O 
fluid O 
is O 
differentially O 
regulated O 
in O 
each O 
prostate O 
lobe O 
. O 
In O 
ventral O 
prostate O 
smooth O 
muscle O 
, O 
Ca(2+) B-FORMULA 
-release O 
, O 
Ca(2+) B-FORMULA 
-influx O 
, O 
and O 
ROCK- O 
and O 
PKC O 
- O 
mediated O 
Ca(2+) B-FORMULA 
-sensitizations O 
are O 
all O 
involved O 
in O 
NA-induced O 
contractions O 
. O 
This O 
finding O 
is O 
a O 
useful O 
step O 
toward O 
the O 
understanding O 
of O 
the O 
phenotypic O 
changes O 
in O 
the O 
smooth O 
muscle O 
of O 
BPH O 
prostate O 
. O 
Prostate O 
© O 
2013 O 
Wiley O 
Periodicals O 
, O 
Inc O 
. O 

: O 
Prostatic O 
inflammation O 
has O 
been O 
linked O 
to O 
a O 
number O 
of O 
prostatic O 
diseases O 
such O 
as O 
benign O 
prostatic O 
hyperplasia O 
( O 
BPH O 
) O 
, O 
prostatitis O 
syndromes O 
, O 
and O 
prostate O 
cancer O 
. O 
Major O 
unanswered O 
questions O 
include O 
what O 
pathogenic O 
mechanisms O 
, O 
such O 
as O 
bacterial O 
infections O 
, O 
may O 
drive O 
the O 
accumulation O 
of O 
inflammatory O 
infiltrates O 
in O 
the O 
human O 
prostate O 
, O 
and O 
how O 
inflammation O 
might O 
contribute O 
to O 
disease O 
. O 
To O 
study O 
this O 
potential O 
link O 
in O 
an O 
in O 
vivo O 
system O 
, O 
we O 
developed O 
a O 
mouse O 
model O 
of O 
long O 
- O 
term O 
bacteria O 
- O 
induced O 
chronic O 
inflammation O 
of O 
the O 
prostate O 
using O 
a O 
human O 
prostatectomy O 
- O 
derived O 
strain O 
of O 
Propionibacterium O 
acnes O 
. O 
METHODS O 
: O 
C57BL O 
/ O 
6J O 
mice O 
were O 
inoculated O 
, O 
via O 
urethral O 
catheterization O 
, O 
with O 
vehicle O 
control O 
or O 
a O 
prostatectomy O 
- O 
derived O 
strain O 
of O 
P O 
. O 
acnes O 
( O 
PA2 O 
) O 
. O 
Animals O 
were O 
assessed O 
at O 
2 O 
days O 
, O 
1 O 
, O 
2 O 
, O 
or O 
8 O 
weeks O 
post O 
- O 
inoculation O 
via O 
histology O 
and O 
immunohistochemistry O 
( O 
IHC O 
) O 
. O 
RESULTS O 
: O 
PA2 O 
inoculation O 
resulted O 
in O 
severe O 
acute O 
and O 
chronic O 
inflammation O 
confined O 
to O 
the O 
dorsal O 
lobe O 
of O 
the O 
prostate O 
. O 
Chronic O 
inflammation O 
persisted O 
for O 
at O 
least O 
8 O 
weeks O 
post O 
- O 
inoculation O 
. O 
Inflammatory O 
lesions O 
were O 
associated O 
with O 
an O 
increase O 
in O 
the O 
Ki-67 O 
proliferative O 
index O 
, O 
and O 
diminished O 
Nkx3.1 O 
and O 
androgen B-FAMILY 
receptor O 
( O 
AR O 
) O 
production O 
. O 
Interestingly O 
, O 
the O 
observed O 
response O 
required O 
live O 
bacteria O 
and O 
both O 
IHC O 
and O 
in O 
situ O 
hybridization O 
assays O 
for O 
P O 
. O 
acnes O 
indicated O 
a O 
potential O 
intracellular O 
presence O 
of O 
P O 
. O 
acnes O 
in O 
prostate O 
epithelial O 
cells O 
. O 
CONCLUSIONS O 
: O 
To O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
mouse O 
model O 
of O 
long O 
- O 
term O 
prostatic O 
inflammation O 
induced O 
by O 
P O 
. O 
acnes O 
, O 
and O 
more O 
generally O 
, O 
any O 
prostatectomy O 
- O 
derived O 
bacterial O 
isolate O 
. O 
This O 
model O 
may O 
serve O 
as O 
a O 
valuable O 
preclinical O 
model O 
of O 
chronic O 
prostatic O 
inflammation O 
that O 
can O 
be O 
used O 
to O 
mechanistically O 
study O 
the O 
link O 
between O 
inflammation O 
and O 
prostatic O 
disease O 
. O 
Prostate O 
© O 
2013 O 
Wiley O 
Periodicals O 
, O 
Inc O 
. O 

4 O 
inhibitors O 
augment O 
the O 
ability O 
of O 
formoterol B-TRIVIAL 
to O 
enhance O 
glucocorticoid O 
- O 
dependent O 
gene O 
transcription O 
in O 
human O 
airway O 
epithelial O 
cells O 
: O 
a O 
novel O 
mechanism O 
for O 
the O 
clinical O 
efficacy O 
of O 
roflumilast B-TRIVIAL 
in O 
severe O 
chronic O 
obstructive O 
pulmonary O 
disease O 
. O 

- O 
hoc O 
analysis O 
of O 
two O 
phase O 
III O 
clinical O 
studies O 
found O 
that O 
the O 
phosphodiesterase O 
4 O 
( O 
PDE4 O 
) O 
inhibitor O 
, O 
roflumilast B-TRIVIAL 
, O 
reduced O 
exacerbation O 
frequency O 
in O 
patients O 
with O 
severe O 
chronic O 
obstructive O 
pulmonary O 
disease O 
( O 
COPD O 
) O 
who O 
were O 
taking O 
inhaled O 
corticosteroids O 
( O 
ICS O 
) O 
concomitantly O 
, O 
whereas O 
patients O 
not O 
taking O 
ICS O 
derived O 
no O 
such O 
benefit O 
. O 
In O 
contrast O 
, O 
in O 
two O 
different O 
trials O 
also O 
performed O 
in O 
patients O 
with O 
severe O 
COPD O 
, O 
roflumilast B-TRIVIAL 
reduced O 
exacerbation O 
rates O 
in O 
the O 
absence O 
of O 
ICS O 
, O 
indicating O 
that O 
PDE4 O 
inhibition O 
alone O 
is O 
sufficient O 
for O 
therapeutic O 
activity O 
to O 
be O 
realized O 
. O 
Given O 
that O 
roflumilast B-TRIVIAL 
is O 
recommended O 
as O 
an O 
" O 
add O 
- O 
on O 
" O 
medication O 
to O 
patients O 
with O 
severe O 
disease O 
who O 
will O 
inevitably O 
be O 
taking O 
a O 
long O 
- O 
acting O 
β2-adrenoceptor O 
agonist O 
( O 
LABA O 
) O 
/ O 
ICS O 
combination O 
therapy O 
, O 
we O 
tested O 
the O 
hypothesis O 
that O 
roflumilast B-TRIVIAL 
augments O 
the O 
ability O 
of O 
glucocorticoids O 
to O 
induce O 
genes O 
with O 
anti-inflammatory O 
activity O 
. O 
Using O 
a O 
glucocorticoid O 
response O 
element O 
( O 
GRE O 
) O 
luciferase O 
reporter O 
transfected O 
into O 
human O 
airway O 
epithelial O 
cells O 
[ O 
both O 
bronchial O 
epithelium O 
+ O 
adenovirus O 
12 O 
- O 
SV40 O 
hybrid O 
( O 
BEAS-2B O 
) O 
cells O 
and O 
primary O 
cultures O 
] O 
, O 
roflumilast B-TRIVIAL 
enhanced O 
fluticasone B-SYSTEMATIC 
propionate I-SYSTEMATIC 
-induced O 
GRE-dependent O 
transcription O 
. O 
Roflumilast B-TRIVIAL 
also O 
produced O 
a O 
sinistral O 
displacement O 
of O 
the O 
concentration O 
- O 
response O 
curves O 
that O 
described O 
the O 
augmentation O 
of O 
GRE-dependent O 
transcription O 
by O 
the O 
LABA O 
formoterol B-TRIVIAL 
. O 
In O 
BEAS-2B O 
cells O 
and O 
primary O 
airway O 
epithelia O 
, O 
roflumilast B-TRIVIAL 
interacted O 
with O 
formoterol B-TRIVIAL 
in O 
a O 
positive O 
cooperative O 
manner O 
to O 
enhance O 
the O 
expression O 
of O 
several O 
glucocorticoid O 
- O 
inducible O 
genes O 
that O 
have O 
anti-inflammatory O 
potential O 
. O 
We O 
suggest O 
that O 
the O 
ability O 
of O 
roflumilast B-TRIVIAL 
and O 
formoterol B-TRIVIAL 
to O 
interact O 
in O 
this O 
way O 
supports O 
the O 
concept O 
that O 
these O 
drugs O 
together O 
may O 
impart O 
clinical O 
benefit O 
beyond O 
that O 
achievable O 
by O 
an O 
ICS O 
alone O 
, O 
a O 
PDE4 O 
inhibitor O 
alone O 
, O 
or O 
an O 
ICS O 
/ O 
LABA O 
combination O 
therapy O 
. O 
Roflumilast B-TRIVIAL 
may O 
, O 
therefore O 
, O 
be O 
especially O 
effective O 
in O 
patients O 
with O 
severe O 
COPD O 
. O 

binds O 
to O 
the O 
TAU5 O 
motif O 
and O 
inhibits O 
constitutively O 
active O 
androgen B-FAMILY 
receptor O 
splice O 
variants O 
. O 

: O 
Aberrant O 
activation O 
of O 
the O 
androgen B-FAMILY 
receptor O 
( O 
AR O 
) O 
is O 
a O 
major O 
factor O 
highly O 
relevant O 
to O 
castration O 
- O 
resistant O 
progression O 
of O 
prostate O 
cancer O 
( O 
PCa O 
) O 
. O 
FOXO1 O 
, O 
a O 
key O 
downstream O 
effector O 
of O 
PTEN O 
, O 
inhibits O 
androgen B-FAMILY 
-independent O 
activation O 
of O 
the O 
AR O 
. O 
However O 
, O 
the O 
underlying O 
mechanism O 
remains O 
elusive O 
. O 
METHODS O 
: O 
The O 
inhibitory O 
effect O 
of O 
FOXO1 O 
on O 
full O 
- O 
length O 
and O 
constitutively O 
active O 
splice O 
variants O 
of O 
the O 
AR O 
was O 
examined O 
by O 
luciferase O 
reporter O 
assays O 
and O 
real O 
- O 
time O 
reverse O 
transcription O 
polymerase O 
chain O 
reaction O 
( O 
RT-qPCR O 
) O 
. O 
In O 
vitro O 
protein O 
binding O 
assays O 
and O 
western O 
blot O 
analyses O 
were O 
used O 
to O 
determine O 
the O 
regions O 
in O 
FOXO1 O 
and O 
AR O 
responsible O 
for O 
their O 
interaction O 
. O 
RESULTS O 
: O 
We O 
found O 
that O 
a O 
putative O 
transcription O 
repression O 
domain O 
in O 
the O 
NH2 B-FORMULA 
-terminus O 
of O 
FOXO1 O 
is O 
dispensable O 
for O 
FOXO1 O 
inhibition O 
of O 
the O 
AR O 
. O 
In O 
vitro O 
protein O 
binding O 
assays O 
showed O 
that O 
FOXO1 O 
binds O 
to O 
the O 
transcription O 
activation O 
unit O 
5 O 
( O 
TAU5 O 
) O 
motif O 
in O 
the O 
AR O 
NH2 B-FORMULA 
-terminal O 
domain O 
( O 
NTD O 
) O 
, O 
a O 
region O 
required O 
for O 
recruitment O 
of O 
p160 O 
activators O 
including O 
SRC-1 O 
. O 
Ectopic O 
expression O 
of O 
SRC-1 O 
augmented O 
transcriptional O 
activity O 
of O 
some O 
, O 
but O 
not O 
all O 
AR O 
splice O 
variants O 
examined O 
. O 
Forced O 
expression O 
of O 
FOXO1 O 
blocked O 
the O 
effect O 
of O 
SRC-1 O 
on O 
AR O 
variants O 
' O 
transcriptional O 
activity O 
by O 
decreasing O 
the O 
binding O 
of O 
SRC-1 O 
to O 
the O 
AR O 
NTD O 
. O 
Ectopic O 
expression O 
of O 
FOXO1 O 
inhibited O 
expression O 
of O 
endogenous O 
genes O 
activated O 
primarily O 
by O 
alternatively O 
spliced O 
AR O 
variants O 
in O 
human O 
castration O 
- O 
resistant O 
PCa O 
22Rv1 O 
cells O 
. O 
CONCLUSIONS O 
: O 
FOXO1 O 
binds O 
to O 
the O 
TAU5 O 
motif O 
in O 
the O 
AR O 
NTD O 
and O 
inhibits O 
ligand O 
- O 
independent O 
activation O 
of O 
AR O 
splice O 
variants O 
, O 
suggesting O 
the O 
PTEN O 
/ O 
FOXO1 O 
pathway O 
as O 
a O 
potential O 
therapeutic O 
target O 
for O 
inhibition O 
of O 
aberrant O 
AR O 
activation O 
and O 
castration O 
- O 
resistant O 
PCa O 
growth O 
. O 
Prostate O 
© O 
2013 O 
Wiley O 
Periodicals O 
, O 
Inc O 
. O 

Muscular O 
Atrophy O 
( O 
SMA O 
) O 
is O 
due O 
to O 
the O 
loss O 
of O 
the O 
survival O 
motor O 
neuron O 
gene O 
1 O 
( O 
SMN1 O 
) O 
, O 
resulting O 
in O 
motor O 
neuron O 
( O 
MN O 
) O 
degeneration O 
, O 
muscle O 
atrophy O 
and O 
loss O 
of O 
motor O 
function O 
. O 
While O 
SMN2 O 
encodes O 
a O 
protein O 
identical O 
to O 
SMN1 O 
, O 
a O 
single O 
nucleotide B-FAMILY 
difference O 
in O 
exon O 
7 O 
causes O 
most O 
of O 
the O 
SMN2 O 
- O 
derived O 
transcripts O 
to O 
be O 
alternatively O 
spliced O 
resulting O 
in O 
a O 
truncated O 
and O 
unstable O 
protein O 
( O 
SMNΔ7 O 
) O 
. O 
SMA O 
patients O 
retain O 
at O 
least O 
one O 
SMN2 O 
copy O 
, O 
making O 
it O 
an O 
important O 
target O 
for O 
therapeutics O 
. O 
Many O 
of O 
the O 
existing O 
SMA O 
models O 
are O 
very O 
severe O 
, O 
with O 
animals O 
typically O 
living O 
less O 
than O 
2 O 
weeks O 
. O 
Here O 
, O 
we O 
present O 
a O 
novel O 
intermediate O 
mouse O 
model O 
of O 
SMA O 
based O 
upon O 
the O 
human O 
genomic O 
SMN2 O 
gene O 
. O 
Genetically O 
, O 
this O 
model O 
is O 
similar O 
to O 
the O 
well O 
- O 
characterized O 
SMNΔ7 O 
model O 
; O 
however O 
, O 
we O 
have O 
manipulated O 
the O 
SMNΔ7 O 
transgene O 
to O 
encode O 
a O 
modestly O 
more O 
functional O 
protein O 
referred O 
to O 
as O 
SMN O 
read O 
- O 
through O 
(SMN(RT)) O 
. O 
By O 
introducing O 
the O 
SMN(RT) O 
transgene O 
onto O 
the O 
background O 
of O 
a O 
severe O 
mouse O 
model O 
of O 
SMA O 
( O 
SMN2(+ O 
/ O 
+ O 
);Smn(- O 
/ O 
- O 
) O 
) O 
, O 
disease O 
severity O 
was O 
significantly O 
decreased O 
based O 
upon O 
a O 
battery O 
of O 
phenotypic O 
parameters O 
, O 
including O 
MN O 
pathology O 
and O 
a O 
significant O 
extension O 
in O 
survival O 
. O 
Importantly O 
, O 
there O 
is O 
not O 
a O 
full O 
phenotypic O 
correction O 
, O 
allowing O 
for O 
the O 
examination O 
of O 
a O 
broad O 
range O 
of O 
therapeutics O 
, O 
including O 
SMN2-dependent O 
and O 
SMN O 
- O 
independent O 
pathways O 
. O 
This O 
novel O 
animal O 
model O 
serves O 
as O 
an O 
important O 
biological O 
and O 
therapeutic O 
model O 
for O 
less O 
severe O 
forms O 
of O 
SMA O 
and O 
provides O 
an O 
in O 
vivo O 
validation O 
of O 
the O 
SMN(RT) O 
protein O 
. O 

Au102(pMBA)44 B-FORMULA 
nanocluster O 
becomes O 
a O 
superatom O 
paramagnet O 
after O 
chemical O 
oxidation O 
. O 
Solutions O 
of O 
paramagnetic O 
Au102(pMBA)44 B-FORMULA 
heat O 
in O 
an O 
oscillating O 
magnetic O 
field O 
component O 
of O 
an O 
RF O 
field O 
, O 
but O 
not O 
in O 
the O 
electric O 
component O 
. O 
Combined O 
, O 
these O 
experiments O 
suggest O 
that O 
paramagnetic O 
Au102(pMBA)44 B-FORMULA 
heats O 
through O 
interactions O 
of O 
spin O 
magnetic O 
moment O 
with O 
an O 
external O 
oscillating O 
magnetic O 
field O 
. O 
These O 
results O 
may O 
clarify O 
some O 
current O 
controversy O 
regarding O 
gold O 
nanoparticle O 
heating O 
in O 
radiofrequency O 
fields O 
. O 

signature O 
of O 
singlet O 
open O 
- O 
shell O 
character O 
on O 
the O 
optically O 
allowed O 
singlet O 
excitation O 
energy O 
and O 
singlet O 
- O 
triplet O 
energy O 
gap O 
is O 
theoretically O 
illuminated O 
for O 
open O 
- O 
shell O 
singlet O 
molecules O 
. O 
On O 
the O 
basis O 
of O 
a O 
two O 
- O 
site O 
diradical O 
model O 
with O 
two O 
electrons O 
in O 
two O 
orbitals O 
, O 
the O 
linear O 
dependence O 
of O 
these O 
excitation O 
energies O 
on O 
the O 
transfer O 
integral O 
, O 
which O 
is O 
equivalent O 
to O 
the O 
energy O 
gap O 
between O 
the O 
highest O 
occupied O 
( O 
HOMO O 
) O 
and O 
the O 
lowest O 
unoccupied O 
( O 
LUMO O 
) O 
molecular O 
orbitals O 
in O 
the O 
Hückel O 
theory O 
, O 
is O 
found O 
to O 
be O 
broken O 
down O 
in O 
the O 
high O 
diradical O 
character O 
region O 
due O 
to O 
an O 
increase O 
in O 
electron O 
correlation O 
in O 
the O 
open O 
- O 
shell O 
singlet O 
ground O 
state O 
. O 
A O 
series O 
of O 
polyacenes B-FAMILY 
shows O 
the O 
similar O 
behavior O 
of O 
the O 
optically O 
allowed O 
singlet O 
excitation O 
energies O 
obtained O 
by O 
time O 
- O 
dependent O 
spin O 
- O 
flip O 
density O 
functional O 
theory O 
calculations O 
and O 
experiments O 
, O 
which O 
bears O 
testimony O 
to O 
the O 
singlet O 
open O 
- O 
shell O 
character O 
in O 
long O 
polyacenes O 
. O 

report O 
the O 
acquisition O 
and O 
interpretation O 
of O 
nuclear O 
magnetic O 
resonance O 
( O 
NMR O 
) O 
J-spectra O 
at O 
zero O 
magnetic O 
field O 
for O 
a O 
series O 
of O 
benzene B-SYSTEMATIC 
derivatives O 
, O 
demonstrating O 
the O 
analytical O 
capabilities O 
of O 
zero O 
- O 
field O 
NMR O 
. O 
The O 
zeroth O 
- O 
order O 
spectral O 
patterns O 
do O 
not O 
overlap O 
, O 
which O 
allows O 
for O 
straightforward O 
determination O 
of O 
the O 
spin O 
interactions O 
of O 
substituent O 
functional O 
groups O 
. O 
Higher O 
- O 
order O 
effects O 
cause O 
additional O 
line O 
splittings O 
, O 
revealing O 
additional O 
molecular O 
information O 
. O 
We O 
demonstrate O 
resonance O 
linewidths O 
as O 
narrow O 
as O 
11 O 
mHz O 
, O 
permitting O 
resolution O 
of O 
minute O 
frequency O 
differences O 
and O 
precise O 
determination O 
of O 
long O 
- O 
range O 
J-couplings O 
. O 
The O 
measurement O 
of O 
J-couplings O 
with O 
the O 
high O 
precision O 
offered O 
by O 
zero O 
- O 
field O 
NMR O 
may O 
allow O 
further O 
refinements O 
in O 
the O 
determination O 
of O 
molecular O 
structure O 
and O 
conformation O 
. O 

supramolecular O 
host O 
assembly O 
[Ga4L6](12-) B-FAMILY 
[ O 
1 O 
; O 
L O 
= O 
1,5-bis(2,3-dihydroxybenzamido)naphthalene B-SYSTEMATIC 
] O 
contains O 
a O 
flexible O 
, O 
hydrophobic O 
interior O 
cavity O 
that O 
can O 
encapsulate O 
cationic O 
guest O 
molecules O 
and O 
catalyze O 
a O 
variety O 
of O 
chemical O 
transformations O 
. O 
The O 
Ar-CH2 B-FORMULA 
bond O 
rotational O 
barrier O 
for O 
encapsulated O 
ortho- B-FAMILY 
substituted I-FAMILY 
benzyl I-FAMILY 
phosphonium I-FAMILY 
guest O 
molecules O 
is O 
sensitive O 
to O 
the O 
size O 
and O 
shape O 
of O 
the O 
host O 
interior O 
space O 
. O 
Here O 
we O 
examine O 
how O 
changes O 
in O 
bulk O 
solvent O 
( O 
water O 
, O 
methanol B-SYSTEMATIC 
, O 
or O 
DMF B-ABBREVIATION 
) O 
or O 
applied O 
pressure O 
( O 
up O 
to O 
150 O 
MPa O 
) O 
affect O 
the O 
rotational O 
dynamics O 
of O 
encapsulated O 
benzyl B-SYSTEMATIC 
phosphonium I-SYSTEMATIC 
guests O 
, O 
as O 
a O 
way O 
to O 
probe O 
changes O 
in O 
host O 
cavity O 
size O 
or O 
flexibility O 
. O 
When O 
host O 
1 O 
is O 
dissolved O 
in O 
organic O 
solvents O 
with O 
large O 
solvent O 
internal O 
pressures O 
( O 
∂U O 
/ O 
∂V)T O 
, O 
we O 
find O 
that O 
the O 
free O 
energy O 
barrier O 
to O 
Ar-CH2 B-FORMULA 
bond O 
rotation O 
increases O 
by O 
1-2 O 
kcal O 
/ O 
mol O 
, O 
compared O 
with O 
that O 
in O 
aqueous O 
solution O 
. O 
Likewise O 
, O 
when O 
external O 
pressure O 
is O 
applied O 
to O 
the O 
host O 
- O 
guest O 
complex O 
in O 
solution O 
, O 
the O 
bond O 
rotational O 
rates O 
for O 
the O 
encapsulated O 
guests O 
decrease O 
. O 
The O 
magnitude O 
of O 
these O 
rate O 
changes O 
and O 
the O 
volumes O 
of O 
activation O 
obtained O 
using O 
either O 
solvent O 
internal O 
pressure O 
or O 
applied O 
external O 
pressure O 
are O 
very O 
similar O 
. O 
NOE O 
distance O 
measurements O 
reveal O 
shorter O 
average O 
host O 
- O 
guest O 
distances O 
( O 
~0.3 O 
Å O 
) O 
in O 
organic O 
versus O 
aqueous O 
solution O 
. O 
These O 
experiments O 
demonstrate O 
that O 
increasing O 
solvent O 
internal O 
pressure O 
or O 
applied O 
external O 
pressure O 
reduces O 
the O 
host O 
cavity O 
size O 
or O 
flexibility O 
, O 
resulting O 
in O 
more O 
restricted O 
motions O 
for O 
encapsulated O 
guest O 
molecules O 
. O 
Changing O 
bulk O 
solvent O 
or O 
external O 
pressure O 
might O 
therefore O 
be O 
used O 
to O 
tune O 
the O 
physical O 
properties O 
or O 
reactivity O 
of O 
guest O 
molecules O 
encapsulated O 
in O 
a O 
flexible O 
supramolecular O 
host O 
. O 

characterization O 
in O 
rats O 
revealed O 
immediate O 
secretion O 
of O 
AZD7903 B-NO_CLASS 
into O 
the O 
stomach O 
after O 
IV O 
dosing O 
. O 

1 O 
. O 
The O 
distribution O 
of O 
AZD7903 B-NO_CLASS 
and O 
/ O 
or O 
its O 
metabolites O 
was O 
studied O 
in O 
rats O 
following O 
a O 
single O 
p.o O 
. O 
or O 
i.v O 
. O 
dose O 
using O 
quantitative O 
whole O 
- O 
body O 
autoradiography O 
( O 
QWBA O 
) O 
. O 
At O 
5 O 
min O 
after O 
i.v O 
. O 
administration O 
of O 
the O 
(14)C B-FORMULA 
compound O 
, O 
high O 
levels O 
of O 
radioactivity O 
were O 
observed O 
in O 
the O 
fundus O 
of O 
the O 
stomach O 
compared O 
to O 
blood O 
and O 
plasma O 
and O 
the O 
rest O 
of O 
the O 
stomach O 
, O 
indicating O 
an O 
active O 
secretion O 
of O 
(14)C B-FORMULA 
material O 
into O 
the O 
stomach O 
. O 
2 O 
. O 
Also O 
, O 
excretion O 
and O 
pharmacokinetics O 
were O 
studied O 
following O 
p.o O 
. O 
and O 
i.v O 
. O 
dosage O 
in O 
rats O 
. O 
The O 
radioactivity O 
was O 
mainly O 
excreted O 
via O 
feces O 
, O 
and O 
even O 
in O 
i.v O 
. O 
administered O 
bile O 
- O 
duct O 
cannulated O 
( O 
BDC O 
) O 
animals O 
a O 
significant O 
part O 
of O 
radioactivity O 
( O 
26% O 
in O 
males O 
and O 
57% O 
in O 
females O 
) O 
was O 
recovered O 
in O 
the O 
feces O 
in O 
the O 
form O 
of O 
parent O 
compound O 
and O 
two O 
minor O 
metabolic O 
products O 
. O 
3 O 
. O 
The O 
compound O 
was O 
well O 
absorbed O 
( O 
F% O 
98 O 
in O 
males O 
and O 
76 O 
in O 
females O 
) O 
, O 
and O 
showed O 
low O 
clearance O 
in O 
plasma O 
( O 
0.14 O 
L O 
/ O 
h O 
/ O 
kg O 
in O 
males O 
and O 
0.03 O 
L O 
/ O 
h O 
/ O 
kg O 
in O 
females O 
) O 
and O 
low O 
- O 
intermediate O 
Vd(ss) O 
( O 
0.7 O 
L O 
/ O 
kg O 
) O 
. O 
Clear O 
differences O 
in O 
metabolic O 
pathways O 
( O 
qualitative O 
) O 
and O 
rates O 
( O 
quantitative O 
) O 
and O 
consequently O 
in O 
PK O 
parameters O 
between O 
sexes O 
were O 
observed O 
. O 
4 O 
. O 
In O 
summary O 
, O 
the O 
results O 
indicate O 
AZD7903 B-NO_CLASS 
being O 
substrate O 
for O 
a O 
transporter O 
protein O 
and O 
support O 
the O 
hypothesis O 
that O 
the O 
differences O 
in O 
disposition O 
between O 
sexes O 
are O 
due O 
to O 
differences O 
in O 
metabolic O 
pathways O 
and O 
rates O 
. O 

: O 
We O 
evaluated O 
prevalence O 
and O 
severity O 
of O 
angiographic O 
coronary O 
artery O 
disease O 
( O 
CAD O 
) O 
according O 
to O 
groups O 
by O 
metabolically O 
obese O 
( O 
MO O 
) O 
and O 
/ O 
or O 
weight O 
status O 
. O 
MATERIAL O 
/ O 
METHODS O 
: O 
Normal O 
weight O 
was O 
defined O 
as O 
body O 
mass O 
index O 
( O 
BMI O 
, O 
kg O 
/ O 
m(2) O 
) O 
< O 
25 O 
and O 
obesity O 
was O 
defined O 
as O 
BMI≥25 O 
. O 
The O 
MO O 
was O 
determined O 
using O 
the O 
National O 
Cholesterol B-TRIVIAL 
Education O 
Program-Adult O 
Treatment O 
Panel O 
III O 
classification O 
with O 
Korean O 
- O 
specific O 
cutoffs O 
for O 
abdominal O 
obesity O 
. O 
Therefore O 
, O 
a O 
total O 
of O 
856 O 
subjects O 
were O 
categorized O 
as O 
follows O 
: O 
( O 
1 O 
) O 
metabolically O 
healthy O 
and O 
normal O 
weight O 
( O 
MHNW O 
) O 
; O 
( O 
2 O 
) O 
metabolically O 
obese O 
but O 
normal O 
weight O 
( O 
MONW O 
) O 
; O 
( O 
3 O 
) O 
metabolically O 
healthy O 
but O 
obese O 
( O 
MHO O 
) O 
; O 
and O 
( O 
4 O 
) O 
metabolically O 
abnormally O 
obese O 
( O 
MAO O 
) O 
. O 
The O 
presence O 
of O 
obstructive O 
lesion≥50% O 
of O 
coronary O 
artery O 
was O 
considered O 
as O 
an O 
angiographic O 
CAD O 
and O 
the O 
Gensini O 
scoring O 
system O 
was O 
used O 
for O 
the O 
severity O 
. O 
RESULTS O 
: O 
MONW O 
or O 
MO O 
showed O 
a O 
higher O 
prevalence O 
of O 
CAD O 
than O 
MHNW O 
or O 
non-MO O 
after O 
adjustment O 
for O 
age O 
and O 
sex O 
, O 
respectively O 
( O 
MONW O 
, O 
odds O 
ratio O 
[OR]=1.69 O 
, O 
95% O 
confidence O 
interval O 
[ O 
CI O 
] O 
: O 
1.13-2.51 O 
and O 
MO O 
, O 
OR=1.44 O 
, O 
95% O 
CI O 
: O 
1.09-1.91 O 
) O 
. O 
In O 
subjects O 
without O 
diabetes O 
mellitus O 
( O 
DM O 
) O 
, O 
MONW O 
or O 
MO O 
showed O 
a O 
marginally O 
higher O 
prevalence O 
of O 
CAD O 
( O 
MONW O 
, O 
OR=1.58 O 
, O 
95% O 
CI O 
: O 
0.96-2.61 O 
and O 
MO O 
, O 
OR=1.41 O 
, O 
95% O 
CI O 
: O 
0.96-2.08 O 
) O 
. O 
MONW O 
was O 
independently O 
associated O 
with O 
a O 
higher O 
severity O 
of O 
angiographic O 
CAD O 
than O 
MHNW O 
after O 
age O 
, O 
sex O 
, O 
glomerular O 
filtration O 
rate O 
, O 
smoking O 
status O 
, O 
high O 
sensitive O 
C-reactive O 
protein O 
, O 
and O 
use O 
of O 
anti-platelet O 
and O 
anti-angina O 
drugs O 
( O 
β=0.118 O 
, O 
P=0.005 O 
) O 
. O 
And O 
MO O 
was O 
associated O 
with O 
a O 
higher O 
severity O 
of O 
angiographic O 
CAD O 
than O 
non-MO O 
after O 
adjustment O 
for O 
age O 
and O 
sex O 
( O 
β=0.077 O 
, O 
P=0.024 O 
) O 
. O 
The O 
above O 
associations O 
were O 
also O 
consistent O 
in O 
subjects O 
without O 
DM O 
( O 
MONW O 
, O 
β=0.147 O 
, O 
P=0.003 O 
and O 
MO O 
, O 
β=0.129 O 
, O 
P=0.005 O 
) O 
. O 
CONCLUSIONS O 
: O 
MONW O 
or O 
MO O 
is O 
associated O 
with O 
both O 
the O 
prevalence O 
and O 
severity O 
of O 
angiographic O 
CAD O 
after O 
adjustment O 
for O 
age O 
and O 
sex O 
and O 
MONW O 
is O 
independently O 
associated O 
with O 
the O 
severity O 
of O 
angiographic O 
CAD O 
irrespective O 
of O 
DM O 
. O 
Therefore O 
, O 
subjects O 
with O 
MO O 
but O 
normal O 
weight O 
( O 
MONW O 
) O 
should O 
be O 
carefully O 
examined O 
for O 
angiographic O 
CAD O 
. O 

trajectory O 
and O 
statistical O 
quantum O 
calculations O 
for O 
the O 
C B-FORMULA 
+ O 
OH B-FORMULA 
→ O 
CO B-FORMULA 
+ O 
H B-FORMULA 
reaction O 
on O 
the O 
first O 
excited O 
1(2)A″ O 
potential O 
energy O 
surface O 
. O 

report O 
quasiclassical O 
trajectory O 
dynamical O 
calculations O 
for O 
the O 
C B-FORMULA 
( O 
(3)P O 
) O 
+ O 
OH B-FORMULA 
( O 
X(2)Π O 
) O 
→ O 
CO B-FORMULA 
( O 
a(3)Π O 
) O 
+ O 
H B-FORMULA 
( O 
(2)S O 
) O 
using O 
a O 
recently O 
developed O 
ab O 
initio O 
potential O 
energy O 
surface O 
for O 
the O 
first O 
electronic O 
state O 
of O 
HCO B-FORMULA 
of O 
1(2)A″ O 
symmetry O 
. O 
The O 
dependence O 
of O 
integral O 
cross O 
sections O 
on O 
the O 
collision O 
energy O 
was O 
determined O 
. O 
Product O 
energy O 
and O 
angular O 
distributions O 
have O 
also O 
been O 
calculated O 
. O 
Integral O 
cross O 
sections O 
show O 
no O 
energy O 
threshold O 
and O 
decrease O 
as O 
the O 
collision O 
energy O 
increases O 
. O 
The O 
comparison O 
with O 
results O 
obtained O 
from O 
a O 
statistical O 
quantum O 
method O 
seems O 
to O 
confirm O 
that O 
the O 
reaction O 
is O 
mainly O 
dominated O 
by O 
an O 
indirect O 
mechanism O 
in O 
which O 
a O 
long O 
- O 
lived O 
intermediate O 
complex O 
is O 
involved O 
. O 

far O 
, O 
there O 
is O 
limited O 
information O 
on O 
biotransformation O 
mechanisms O 
and O 
products O 
of O 
polar O 
contaminants O 
in O 
freshwater O 
crustaceans O 
. O 
In O 
the O 
present O 
study O 
, O 
metabolites O 
of O 
biocides O 
and O 
pharmaceuticals O 
formed O 
in O 
Gammarus O 
pulex O 
and O 
Daphnia O 
magna O 
were O 
identified O 
using O 
liquid O 
chromatography O 
- O 
high O 
resolution O 
mass O 
spectrometry O 
. O 
Different O 
confidence O 
levels O 
were O 
assigned O 
to O 
the O 
identification O 
of O 
metabolites O 
without O 
reference O 
standards O 
using O 
a O 
framework O 
based O 
on O 
the O 
background O 
evidence O 
used O 
for O 
structure O 
elucidation O 
. O 
Twenty O 
- O 
five O 
metabolites O 
were O 
tentatively O 
identified O 
for O 
irgarol B-TRIVIAL 
, O 
terbutryn B-TRIVIAL 
, O 
tramadol B-TRIVIAL 
, O 
and O 
venlafaxine B-TRIVIAL 
in O 
G O 
. O 
pulex O 
( O 
21 O 
via O 
oxidation O 
and O 
4 O 
via O 
conjugation O 
reactions O 
) O 
and O 
11 O 
metabolites O 
in O 
D O 
. O 
magna O 
( O 
7 O 
via O 
oxidation O 
and O 
4 O 
via O 
conjugation O 
reactions O 
) O 
, O 
while O 
no O 
evidence O 
of O 
metabolites O 
for O 
clarithromycin B-TRIVIAL 
and O 
valsartan B-TRIVIAL 
was O 
found O 
. O 
Of O 
the O 
360 O 
metabolites O 
predicted O 
for O 
the O 
four O 
parent O 
compounds O 
using O 
pathway O 
prediction O 
systems O 
and O 
expert O 
knowledge O 
, O 
23 O 
products O 
were O 
true O 
positives O 
, O 
while O 
2 O 
identified O 
metabolites O 
were O 
unexpected O 
products O 
. O 
Observed O 
oxidative O 
reactions O 
included O 
N B-FORMULA 
- O 
and O 
O B-FORMULA 
-demethylation O 
, O 
hydroxylation O 
, O 
and O 
N B-FORMULA 
-oxidation O 
. O 
Glutathione B-TRIVIAL 
conjugation O 
of O 
selected O 
biocides O 
followed O 
by O 
subsequent O 
reactions O 
forming O 
cysteine B-TRIVIAL 
conjugates O 
was O 
described O 
for O 
the O 
first O 
time O 
in O 
freshwater O 
invertebrates O 
. O 

, O 
Characterization O 
, O 
and O 
Sulfonamide B-SYSTEMATIC 
and O 
Thiol B-SYSTEMATIC 
Inhibition O 
Studies O 
of O 
an O 
α-Carbonic O 
Anhydrase O 
from O 
Trypanosoma O 
cruzi O 
, O 
the O 
Causative O 
Agent O 
of O 
Chagas O 
Disease O 
. O 

α-carbonic O 
anhydrase O 
( O 
CA O 
, O 
EC O 
4.2.1.1 O 
) O 
has O 
been O 
identified O 
, O 
cloned O 
, O 
and O 
characterized O 
from O 
the O 
unicellular O 
protozoan O 
Trypanosoma O 
cruzi O 
, O 
the O 
causative O 
agent O 
of O 
Chagas O 
disease O 
. O 
The O 
enzyme O 
( O 
TcCA O 
) O 
has O 
a O 
very O 
high O 
catalytic O 
activity O 
for O 
the O 
CO(2) B-FORMULA 
hydration O 
reaction O 
, O 
being O 
similar O 
kinetically O 
to O 
the O 
human O 
( O 
h O 
) O 
isoform O 
hCA O 
II O 
, O 
although O 
it O 
is O 
devoid O 
of O 
the O 
His B-FORMULA 
64 O 
proton O 
shuttle O 
. O 
A O 
large O 
number O 
of O 
aromatic B-MULTIPLE 
/ I-MULTIPLE 
heterocyclic I-MULTIPLE 
sulfonamides I-MULTIPLE 
and O 
some O 
5-mercapto-1,3,4-thiadiazoles B-FAMILY 
were O 
investigated O 
as O 
TcCA O 
inhibitors O 
. O 
The O 
aromatic B-FAMILY 
sulfonamides I-FAMILY 
were O 
weak O 
inhibitors O 
( O 
K O 
(I) O 
values O 
of O 
192 O 
nM O 
to O 
84 O 
μM O 
) O 
, O 
whereas O 
some O 
heterocyclic O 
compounds O 
inhibited O 
the O 
enzyme O 
with O 
K O 
(I) O 
values O 
in O 
the O 
range O 
61.6-93.6 O 
nM O 
. O 
The O 
thiols B-FAMILY 
were O 
the O 
most O 
potent O 
in O 
vitro O 
inhibitors O 
( O 
K O 
(I) O 
values O 
of O 
21.1-79.0 O 
nM O 
) O 
, O 
and O 
some O 
of O 
them O 
also O 
inhibited O 
the O 
epimastigotes O 
growth O 
of O 
two O 
T O 
. O 
cruzi O 
strains O 
in O 
vivo O 
. O 

, O 
toxicokinetic O 
and O 
gastroprotective O 
evaluation O 
of O 
the O 
benzaldehyde B-SYSTEMATIC 
semicarbazone I-SYSTEMATIC 
. O 

semicarbazone I-SYSTEMATIC 
( O 
BS O 
) O 
has O 
presented O 
positive O 
results O 
in O 
several O 
pharmacological O 
models O 
, O 
including O 
anticonvulsivant O 
and O 
anti-inflammatory O 
models O 
. O 
The O 
present O 
study O 
evaluated O 
the O 
preclinical O 
toxicity O 
( O 
acute O 
and O 
subchronic O 
) O 
, O 
as O 
well O 
as O 
the O 
toxicokinetic O 
and O 
gastroprotective O 
effects O 
of O 
BS O 
against O 
ethanol B-SYSTEMATIC 
lesions O 
. O 
Oral O 
doses O 
of O 
300 O 
and O 
2000mg O 
/ O 
kg O 
were O 
used O 
in O 
the O 
preclinical O 
acute O 
toxicity O 
study O 
; O 
100 O 
, O 
200 O 
, O 
and O 
300mg O 
/ O 
kg O 
were O 
used O 
in O 
both O 
the O 
subchronic O 
toxicity O 
evaluation O 
and O 
the O 
gastric O 
study O 
; O 
and O 
300mg O 
/ O 
kg O 
was O 
used O 
in O 
the O 
toxicokinetic O 
study O 
. O 
No O 
impact O 
from O 
the O 
dose O 
of O 
300mg O 
/ O 
kg O 
could O 
be O 
identified O 
; O 
while O 
, O 
one O 
animal O 
died O 
at O 
2000mg O 
/ O 
kg O 
in O 
the O 
acute O 
toxicity O 
test O 
. O 
In O 
the O 
subchronic O 
toxicity O 
test O 
, O 
changes O 
in O 
the O 
biochemical O 
parameters O 
of O 
the O 
liver O 
, O 
as O 
well O 
as O 
in O 
the O 
histopatological O 
evaluation O 
, O 
demonstrated O 
that O 
BS O 
is O 
a O 
hepatotoxic O 
drug O 
. O 
BS O 
proved O 
to O 
be O 
effective O 
for O 
moderate O 
and O 
severe O 
gastric O 
lesions O 
. O 
In O 
the O 
toxicokinetics O 
study O 
, O 
BS O 
presented O 
a O 
low O 
concentration O 
and O 
rapid O 
plasma O 
disappearance O 
. O 
Several O 
results O 
also O 
indicate O 
that O 
BS O 
is O 
likely O 
to O 
be O 
mostly O 
eliminated O 
from O 
the O 
liver O 
and O 
may O 
well O 
undergo O 
a O 
first O 
- O 
pass O 
effect O 
after O 
oral O 
absorption O 
. O 
It O 
was O 
impossible O 
to O 
estimate O 
the O 
noobserved O 
- O 
adverse O 
- O 
effect O 
- O 
levels O 
( O 
NOAEL O 
) O 
and O 
lowest O 
- O 
observed O 
- O 
adverse O 
- O 
effect O 
- O 
levels O 
( O 
LOAEL O 
) O 
due O 
to O 
the O 
presence O 
of O 
hepatotoxicity O 
in O 
all O 
tested O 
doses O 
. O 

of O 
Li B-FORMULA 
- O 
Mn B-FORMULA 
- O 
O B-FORMULA 
mesocrystals O 
with O 
controlled O 
crystal O 
phases O 
through O 
topotactic O 
transformation O 
of O 
MnCO₃ B-FORMULA 
. O 

of O 
Li B-FORMULA 
- O 
Mn B-FORMULA 
- O 
O B-FORMULA 
compounds O 
, O 
such O 
as O 
LiMn2O4 B-FORMULA 
, O 
Li2MnO3 B-FORMULA 
, O 
and O 
LiMnO2 B-FORMULA 
- O 
Li2MnO3 B-FORMULA 
, O 
consisting O 
of O 
oriented O 
nanoscale O 
units O 
were O 
selectively O 
produced O 
under O 
hydrothermal O 
conditions O 
from O 
biomimetically O 
prepared O 
MnCO3 B-FORMULA 
mesocrystals O 
. O 
Topotactic O 
transformation O 
through O 
the O 
intermediate O 
phase O 
of O 
Mn5O8 B-FORMULA 
inheriting O 
a O 
hierarchical O 
structure O 
of O 
the O 
MnCO3 B-FORMULA 
precursor O 
was O 
essential O 
for O 
the O 
formation O 
of O 
the O 
mesocrystal O 
compounds O 
. O 
The O 
crystal O 
phases O 
were O 
successfully O 
controlled O 
by O 
varying O 
the O 
conditions O 
for O 
the O 
hydrothermal O 
reactions O 
. O 
The O 
Li B-FORMULA 
- O 
Mn B-FORMULA 
- O 
O B-FORMULA 
mesocrystals O 
have O 
considerable O 
potential O 
as O 
cathodes O 
of O 
Li B-FORMULA 
-ion O 
batteries O 
. O 

tegmental O 
area O 
GABA B-ABBREVIATION 
neurons O 
and O 
opiate O 
motivation O 
. O 

: O 
Past O 
research O 
has O 
demonstrated O 
that O 
when O 
an O 
animal O 
changes O 
from O 
a O 
previously O 
drug O 
- O 
naive O 
to O 
an O 
opiate O 
- O 
dependent O 
and O 
withdrawn O 
state O 
, O 
morphine B-TRIVIAL 
' O 
s O 
motivational O 
effects O 
are O 
switched O 
from O 
a O 
tegmental O 
pedunculopontine O 
nucleus O 
(TPP)-dependent O 
to O 
a O 
dopamine B-TRIVIAL 
-dependent O 
pathway O 
. O 
Interestingly O 
, O 
a O 
corresponding O 
change O 
is O 
observed O 
in O 
ventral O 
tegmental O 
area O 
( O 
VTA O 
) O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
receptors O 
, O 
which O 
change O 
from O 
mediating O 
hyperpolarization O 
of O 
VTA O 
GABA B-ABBREVIATION 
neurons O 
to O 
mediating O 
depolarization O 
. O 
OBJECTIVES O 
: O 
The O 
present O 
study O 
investigated O 
whether O 
pharmacological O 
manipulation O 
of O 
VTA O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
receptor O 
activity O 
could O 
directly O 
influence O 
the O 
mechanisms O 
underlying O 
opiate O 
motivation O 
. O 
RESULTS O 
: O 
Using O 
an O 
unbiased O 
place O 
conditioning O 
procedure O 
, O 
we O 
demonstrated O 
that O 
in O 
Wistar O 
rats O 
, O 
intra-VTA O 
administration O 
of O 
furosemide B-TRIVIAL 
, O 
a O 
Cl(-) B-FORMULA 
cotransporter O 
inhibitor O 
, O 
was O 
able O 
to O 
promote O 
a O 
switch O 
in O 
the O 
mechanisms O 
underlying O 
morphine B-TRIVIAL 
' O 
s O 
motivational O 
properties O 
, O 
one O 
which O 
is O 
normally O 
observed O 
only O 
after O 
chronic O 
opiate O 
exposure O 
. O 
This O 
behavioral O 
switch O 
was O 
prevented O 
by O 
intra-VTA O 
administration O 
of O 
acetazolamide B-TRIVIAL 
, O 
an O 
inhibitor O 
of O 
the O 
bicarbonate B-SYSTEMATIC 
ion O 
- O 
producing O 
carbonic O 
anhydrase O 
enzyme O 
. O 
Electrophysiological O 
recordings O 
of O 
mouse O 
VTA O 
showed O 
that O 
furosemide B-TRIVIAL 
reduced O 
the O 
sensitivity O 
of O 
VTA O 
GABA B-ABBREVIATION 
neurons O 
to O 
inhibition O 
by O 
the O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
receptor O 
agonist O 
muscimol B-TRIVIAL 
, O 
instead O 
increasing O 
the O 
firing O 
rate O 
of O 
a O 
significant O 
subset O 
of O 
these O 
GABA B-ABBREVIATION 
neurons O 
. O 
CONCLUSIONS O 
: O 
Our O 
results O 
suggest O 
that O 
the O 
carbonic O 
anhydrase O 
enzyme O 
may O 
constitute O 
part O 
of O 
a O 
common O 
VTA O 
GABA B-ABBREVIATION 
neuron O 
- O 
based O 
biological O 
pathway O 
responsible O 
for O 
controlling O 
the O 
mechanisms O 
underlying O 
opiate O 
motivation O 
, O 
supporting O 
the O 
hypothesis O 
that O 
VTA O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
receptor O 
hyperpolarization O 
or O 
depolarization O 
is O 
responsible O 
for O 
selecting O 
TPP- O 
or O 
dopamine B-TRIVIAL 
-dependent O 
motivational O 
outputs O 
, O 
respectively O 
. O 

of O 
monocarboxylate B-SYSTEMATIC 
transporter O 
inhibition O 
on O 
the O 
oral O 
toxicokinetics O 
/ O 
toxicodynamics O 
of O 
γ-hydroxybutyrate B-SYSTEMATIC 
and O 
γ-butyrolactone B-SYSTEMATIC 
. O 

depression O 
and O 
death O 
secondary O 
to O 
respiratory O 
arrest O 
have O 
occurred O 
after O 
oral O 
overdoses O 
of O 
γ-hydroxybutyrate B-SYSTEMATIC 
( O 
GHB B-ABBREVIATION 
) O 
and O 
its O 
precursor O 
γ-butyrolactone B-SYSTEMATIC 
( O 
GBL B-ABBREVIATION 
) O 
. O 
GHB B-ABBREVIATION 
is O 
a O 
substrate O 
for O 
monocarboxylate B-SYSTEMATIC 
transporters O 
( O 
MCTs O 
) O 
, O 
and O 
increasing O 
GHB B-ABBREVIATION 
renal O 
clearance O 
or O 
decreasing O 
GHB B-ABBREVIATION 
absorption O 
via O 
MCT O 
inhibition O 
represents O 
a O 
potential O 
treatment O 
strategy O 
for O 
GHB B-ABBREVIATION 
/ O 
GBL B-ABBREVIATION 
overdose O 
. O 
In O 
these O 
studies O 
, O 
GHB B-ABBREVIATION 
and O 
GBL B-ABBREVIATION 
were O 
administered O 
in O 
doses O 
of O 
1.92 O 
, O 
5.77 O 
, O 
and O 
14.4 O 
mmol O 
/ O 
kg O 
orally O 
with O 
and O 
without O 
MCT O 
inhibition O 
to O 
determine O 
effects O 
of O 
this O 
treatment O 
strategy O 
on O 
the O 
oral O 
toxicokinetics O 
and O 
toxicodynamics O 
of O 
GHB B-ABBREVIATION 
and O 
GBL B-ABBREVIATION 
. O 
The O 
competitive O 
MCT O 
inhibitor O 
l-lactate B-TRIVIAL 
was O 
administered O 
by O 
intravenous O 
infusion O 
starting O 
1 O 
hour O 
after O 
GHB B-ABBREVIATION 
and O 
GBL B-ABBREVIATION 
administration O 
. O 
Oral O 
administration O 
of O 
l-lactate B-TRIVIAL 
and O 
the O 
MCT O 
inhibitor O 
luteolin O 
was O 
also O 
evaluated O 
. O 
Respiratory O 
depression O 
was O 
measured O 
using O 
plethysmography O 
. O 
Intravenous O 
l-lactate B-TRIVIAL 
, O 
but O 
not O 
oral O 
treatments O 
, O 
significantly O 
increased O 
GHB B-ABBREVIATION 
renal O 
and O 
/ O 
or O 
oral O 
clearances O 
. O 
At O 
the O 
low O 
dose O 
of O 
GHB B-ABBREVIATION 
and O 
GBL B-ABBREVIATION 
, O 
i.v O 
. O 
l-lactate B-TRIVIAL 
increased O 
GHB B-ABBREVIATION 
renal O 
clearance O 
. O 
Due O 
to O 
the O 
increased O 
contribution O 
of O 
renal O 
clearance O 
to O 
total O 
clearance O 
at O 
the O 
moderate O 
dose O 
, O 
increased O 
renal O 
clearance O 
translated O 
to O 
an O 
increase O 
in O 
oral O 
clearance O 
. O 
At O 
the O 
highest O 
GHB B-ABBREVIATION 
dose O 
, O 
oral O 
clearance O 
was O 
increased O 
without O 
a O 
significant O 
change O 
in O 
renal O 
clearance O 
. O 
The O 
lack O 
of O 
effect O 
of O 
i.v O 
. O 
l-lactate B-TRIVIAL 
on O 
renal O 
clearance O 
after O 
a O 
high O 
oral O 
GHB B-ABBREVIATION 
dose O 
suggests O 
possible O 
effects O 
of O 
i.v O 
. O 
l-lactate B-TRIVIAL 
on O 
MCT O 
- O 
mediated O 
absorption O 
. O 
The O 
resulting O 
increases O 
in O 
oral O 
clearance O 
improved O 
respiratory O 
depression O 
. O 
Intravenous O 
l-lactate B-TRIVIAL 
also O 
reduced O 
mortality O 
with O 
the O 
high O 
GBL B-ABBREVIATION 
dose O 
. O 
These O 
data O 
indicate O 
i.v O 
. O 
l-lactate B-TRIVIAL 
represents O 
a O 
potential O 
treatment O 
strategy O 
in O 
oral O 
overdose O 
of O 
GHB B-ABBREVIATION 
and O 
GBL B-ABBREVIATION 
. O 

treatment O 
and O 
emotional O 
processing O 
: O 
can O 
we O 
dissociate O 
the O 
roles O 
of O 
serotonin B-TRIVIAL 
and O 
noradrenaline B-TRIVIAL 
? O 

ability O 
to O 
match O 
individual O 
patients O 
to O 
tailored O 
treatments O 
has O 
the O 
potential O 
to O 
greatly O 
improve O 
outcomes O 
for O 
individuals O 
suffering O 
from O 
major O 
depression O 
. O 
In O 
particular O 
, O 
while O 
the O 
vast O 
majority O 
of O 
antidepressant O 
treatments O 
affect O 
either O 
serotonin B-TRIVIAL 
or O 
noradrenaline B-TRIVIAL 
or O 
a O 
combination O 
of O 
these O 
two O 
neurotransmitters O 
, O 
it O 
is O 
not O 
known O 
whether O 
there O 
are O 
particular O 
patients O 
or O 
symptom O 
profiles O 
which O 
respond O 
preferentially O 
to O 
the O 
potentiation O 
of O 
serotonin B-TRIVIAL 
over O 
noradrenaline B-TRIVIAL 
or O 
vice O 
versa O 
. O 
Experimental O 
medicine O 
models O 
suggest O 
that O 
the O 
primary O 
mode O 
of O 
action O 
of O 
these O 
treatments O 
may O 
be O 
to O 
remediate O 
negative O 
biases O 
in O 
emotional O 
processing O 
. O 
Such O 
models O 
may O 
provide O 
a O 
useful O 
framework O 
for O 
interrogating O 
the O 
specific O 
actions O 
of O 
antidepressants O 
. O 
Here O 
, O 
we O 
therefore O 
review O 
evidence O 
from O 
studies O 
examining O 
the O 
effects O 
of O 
drugs O 
which O 
potentiate O 
serotonin B-TRIVIAL 
, O 
noradrenaline B-TRIVIAL 
or O 
a O 
combination O 
of O 
both O 
neurotransmitters O 
on O 
emotional O 
processing O 
. O 
These O 
results O 
suggest O 
that O 
antidepressants O 
targeting O 
serotonin B-TRIVIAL 
and O 
noradrenaline B-TRIVIAL 
may O 
have O 
some O 
specific O 
actions O 
on O 
emotion O 
and O 
reward O 
processing O 
which O 
could O 
be O 
used O 
to O 
improve O 
tailoring O 
of O 
treatment O 
or O 
to O 
understand O 
the O 
effects O 
of O 
dual O 
- O 
reuptake O 
inhibition O 
. O 
Specifically O 
, O 
serotonin B-TRIVIAL 
may O 
be O 
particularly O 
important O 
in O 
alleviating O 
distress O 
symptoms O 
, O 
while O 
noradrenaline B-TRIVIAL 
may O 
be O 
especially O 
relevant O 
to O 
anhedonia O 
. O 
The O 
data O 
reviewed O 
here O 
also O 
suggest O 
that O 
noradrenergic O 
- O 
based O 
treatments O 
may O 
have O 
earlier O 
effects O 
on O 
emotional O 
memory O 
that O 
those O 
which O 
affect O 
serotonin B-TRIVIAL 
. O 

pulse O 
frequency O 
- O 
dependent O 
stimulation O 
of O 
FSHβ O 
transcription O 
is O 
mediated O 
via O 
activation O 
of O 
PKA O 
and O 
CREB O 
. O 

of O 
pituitary O 
FSH O 
and O 
LH O 
, O 
under O 
the O 
control O 
of O 
pulsatile O 
GnRH B-ABBREVIATION 
, O 
is O 
essential O 
for O 
fertility O 
. O 
cAMP B-ABBREVIATION 
response O 
element O 
- O 
binding O 
protein O 
( O 
CREB O 
) O 
has O 
been O 
implicated O 
in O 
the O 
regulation O 
of O 
FSHβ O 
gene O 
expression O 
, O 
but O 
the O 
molecular O 
mechanisms O 
by O 
which O 
pulsatile O 
GnRH B-ABBREVIATION 
regulates O 
CREB O 
activation O 
remain O 
poorly O 
understood O 
. O 
We O 
hypothesized O 
that O 
CREB O 
is O 
activated O 
by O 
a O 
distinct O 
signaling O 
pathway O 
in O 
response O 
to O 
pulsatile O 
GnRH B-ABBREVIATION 
in O 
a O 
frequency O 
- O 
dependent O 
manner O 
to O 
dictate O 
the O 
FSHβ O 
transcriptional O 
response O 
. O 
GnRH B-ABBREVIATION 
stimulation O 
of O 
CREB O 
phosphorylation O 
( O 
pCREB O 
) O 
in O 
the O 
gonadotrope O 
- O 
derived O 
LβT2 O 
cell O 
line O 
was O 
attenuated O 
by O 
a O 
protein O 
kinase O 
A O 
( O 
PKA O 
) O 
inhibitor O 
, O 
H89 B-IDENTIFIER 
. O 
A O 
dominant O 
negative O 
PKA O 
( O 
DNPKA O 
) O 
reduced O 
GnRH B-ABBREVIATION 
-stimulated O 
pCREB O 
and O 
markedly O 
decreased O 
GnRH B-ABBREVIATION 
stimulation O 
of O 
FSHβ O 
mRNA O 
and O 
FSHβLUC O 
activity O 
, O 
but O 
had O 
little O 
effect O 
on O 
LHβLUC O 
activity O 
, O 
indicating O 
relative O 
specificity O 
of O 
this O 
pathway O 
. O 
In O 
perifusion O 
studies O 
, O 
FSHβ O 
mRNA O 
levels O 
and O 
FSHβLUC O 
activities O 
were O 
increased O 
by O 
pulsatile O 
GnRH B-ABBREVIATION 
, O 
with O 
significantly O 
greater O 
increases O 
at O 
low O 
compared O 
with O 
high O 
pulse O 
frequencies O 
. O 
DNPKA O 
markedly O 
reduced O 
these O 
GnRH B-ABBREVIATION 
-stimulated O 
FSHβ O 
responses O 
at O 
both O 
low O 
and O 
high O 
pulse O 
frequencies O 
. O 
Correlating O 
with O 
FSHβ O 
activation O 
, O 
both O 
PKA O 
activity O 
and O 
levels O 
of O 
pCREB O 
were O 
increased O 
to O 
a O 
greater O 
extent O 
by O 
low O 
compared O 
with O 
high O 
GnRH B-ABBREVIATION 
pulse O 
frequencies O 
, O 
and O 
the O 
induction O 
of O 
pCREB O 
was O 
also O 
attenuated O 
by O 
overexpression O 
of O 
DNPKA O 
at O 
both O 
low O 
and O 
high O 
pulse O 
frequencies O 
. O 
Taken O 
together O 
, O 
these O 
data O 
indicate O 
that O 
a O 
PKA O 
- O 
mediated O 
signaling O 
pathway O 
mediates O 
GnRH B-ABBREVIATION 
activation O 
of O 
CREB O 
at O 
low O 
- O 
pulse O 
frequencies O 
, O 
playing O 
a O 
significant O 
role O 
in O 
the O 
decoding O 
of O 
the O 
hypothalamic O 
GnRH B-ABBREVIATION 
signal O 
to O 
result O 
in O 
frequency O 
- O 
dependent O 
FSHβ O 
activation O 
. O 

To O 
investigate O 
the O 
relationship O 
between O 
different O 
degrees O 
of O 
subclinical O 
myocardial O 
necrosis O 
, O 
glycemic O 
control O 
, O 
and O 
long O 
- O 
term O 
adverse O 
clinical O 
outcomes O 
within O 
a O 
stable O 
patient O 
population O 
with O 
diabetes O 
mellitus O 
. O 
RESEARCH O 
DESIGN O 
AND O 
METHODS O 
We O 
examined O 
1275 O 
stable O 
patients O 
with O 
diabetes O 
mellitus O 
undergoing O 
elective O 
diagnostic O 
coronary O 
angiography O 
with O 
cardiac O 
troponin O 
I O 
( O 
cTnI O 
) O 
levels O 
below O 
the O 
diagnostic O 
cut O 
- O 
off O 
for O 
defining O 
myocardial O 
infarction O 
( O 
MI O 
) O 
( O 
< O 
0.03 O 
ng O 
/ O 
mL O 
) O 
. O 
The O 
relationship O 
of O 
subclinical O 
myocardial O 
necrosis O 
( O 
cTnI O 
0.009-0.029 O 
ng O 
/ O 
mL O 
) O 
with O 
incident O 
major O 
adverse O 
cardiovascular O 
events O 
( O 
MACE O 
; O 
defined O 
as O 
any O 
death O 
, O 
MI O 
, O 
or O 
stroke O 
) O 
over O 
3 O 
years O 
of O 
follow O 
- O 
up O 
was O 
examined O 
. O 
RESULTS O 
Subclinical O 
myocardial O 
necrosis O 
was O 
observed O 
in O 
22% O 
of O 
patients O 
. O 
A O 
strong O 
association O 
was O 
observed O 
between O 
the O 
magnitude O 
of O 
subclinical O 
myocardial O 
necrosis O 
and O 
risk O 
of O 
3-year O 
incident O 
MACE O 
( O 
hazard O 
ratio O 
, O 
1.98 O 
; O 
95% O 
confidence O 
interval O 
, O 
1.48-2.65 O 
; O 
P O 
< O 
0.001 O 
) O 
and O 
remained O 
statistically O 
significant O 
even O 
after O 
adjustment O 
for O 
traditional O 
risk O 
factors O 
, O 
high O 
- O 
sensitivity O 
C-reactive O 
protein O 
, O 
and O 
creatinine O 
clearance O 
. O 
Only O 
a O 
weak O 
correlation O 
was O 
observed O 
between O 
the O 
presence O 
of O 
subclinical O 
myocardial O 
necrosis O 
and O 
either O 
glycemic O 
control O 
( O 
r O 
= O 
0.06 O 
; O 
P O 
= O 
0.044 O 
for O 
hemoglobin O 
A1c O 
versus O 
cTnI O 
) O 
or O 
insulin O 
resistance O 
( O 
r O 
= O 
0.04 O 
; O 
P O 
= O 
0.094 O 
for O 
glucose B-TRIVIAL 
-to O 
- O 
insulin O 
ratio O 
versus O 
cTnI O 
) O 
. O 
CONCLUSIONS O 
The O 
presence O 
of O 
detectable O 
subclinical O 
myocardial O 
necrosis O 
in O 
stable O 
patients O 
with O 
diabetes O 
mellitus O 
is O 
associated O 
with O 
heightened O 
long O 
- O 
term O 
risk O 
for O 
MACE O 
, O 
independent O 
of O 
traditional O 
risk O 
factors O 
and O 
glycemic O 
control O 
. O 

evaluate O 
the O 
effect O 
of O 
removal O 
of O 
the O 
duodenum O 
on O 
the O 
complex O 
interplay O 
between O 
incretins O 
, O 
insulin O 
, O 
and O 
glucagon O 
in O 
nondiabetic O 
subjects.RESEARCH O 
DESIGN O 
AND O 
METHODSFor O 
evaluation O 
of O 
hormonal O 
secretion O 
and O 
insulin O 
sensitivity O 
, O 
10 O 
overweight O 
patients O 
without O 
type O 
2 O 
diabetes O 
( O 
age O 
61 O 
± O 
19.3 O 
years O 
and O 
BMI O 
27.9 O 
± O 
5.3 O 
kg O 
/ O 
m(2) O 
) O 
underwent O 
a O 
mixed O 
- O 
meal O 
test O 
and O 
a O 
hyperinsulinemic O 
- O 
euglycemic O 
clamp O 
before O 
and O 
after O 
pylorus O 
- O 
preserving O 
pancreatoduodenectomy O 
for O 
ampulloma.RESULTSAll O 
patients O 
experienced O 
a O 
reduction O 
in O 
insulin O 
( O 
P O 
= O 
0.002 O 
) O 
, O 
C- O 
peptide O 
( O 
P O 
= O 
0.0002 O 
) O 
, O 
and O 
gastric O 
inhibitory O 
peptide O 
( O 
GIP O 
) O 
secretion O 
( O 
P O 
= O 
0.0004 O 
) O 
, O 
while O 
both O 
fasting O 
and O 
postprandial O 
glucose B-TRIVIAL 
levels O 
increased O 
( O 
P O 
= O 
0.0001 O 
) O 
; O 
GLP-1 O 
and O 
glucagon O 
responses O 
to O 
the O 
mixed O 
meal O 
increased O 
significantly O 
after O 
surgery O 
( O 
P O 
= O 
0.02 O 
and O 
0.031 O 
) O 
. O 
While O 
changes O 
in O 
GIP O 
levels O 
did O 
not O 
correlate O 
with O 
insulin O 
, O 
glucagon O 
, O 
and O 
glucose B-TRIVIAL 
levels O 
, O 
the O 
increase O 
in O 
GLP-1 O 
secretion O 
was O 
inversely O 
related O 
to O 
the O 
postsurgery O 
decrease O 
in O 
insulin O 
secretion O 
( O 
R(2) O 
= O 
0.56 O 
; O 
P O 
= O 
0.012 O 
) O 
but O 
not O 
to O 
the O 
increased O 
glucagon O 
secretion O 
, O 
which O 
correlated O 
inversely O 
with O 
the O 
reduction O 
of O 
insulin O 
( O 
R(2) O 
= O 
0.46 O 
; O 
P O 
= O 
0.03 O 
) O 
and O 
C- O 
peptide O 
( O 
R(2) O 
= O 
0.37 O 
; O 
P O 
= O 
0.04 O 
) O 
. O 
Given O 
that O 
the O 
remaining O 
pancreas O 
presumably O 
has O 
preserved O 
intraislet O 
anatomy O 
, O 
insulin O 
secretory O 
capacity O 
, O 
and O 
α- O 
and O 
β-cell O 
interplay O 
, O 
our O 
data O 
suggest O 
that O 
the O 
increased O 
glucagon O 
secretion O 
is O 
related O 
to O 
decreased O 
systemic O 
insulin.CONCLUSIONSPylorus O 
- O 
preserving O 
pancreatoduodenectomy O 
was O 
associated O 
with O 
a O 
decrease O 
in O 
GIP O 
and O 
a O 
remarkable O 
increase O 
in O 
GLP-1 O 
levels O 
, O 
which O 
was O 
not O 
translated O 
into O 
increased O 
insulin O 
secretion O 
. O 
Rather O 
, O 
the O 
hypoinsulinemia O 
may O 
have O 
caused O 
an O 
increase O 
in O 
glucagon O 
secretion O 
. O 

Interactions O 
between O 
Monoamine B-SYSTEMATIC 
Oxidase O 
A O 
Inhibitor O 
Harmaline B-TRIVIAL 
and O 
5-Methoxy-N,N-Dimethyltryptamine B-SYSTEMATIC 
, O 
and O 
the O 
Impact O 
of O 
CYP2D6 O 
Status O 
. O 

( O 
5-MeO-DMT B-SYSTEMATIC 
or O 
street O 
name O 
" O 
5-MEO B-SYSTEMATIC 
" O 
) O 
is O 
a O 
newer O 
designer O 
drug O 
belonging O 
to O 
a O 
group O 
of O 
naturally O 
occurring O 
indolealkylamines B-FAMILY 
. O 
Our O 
recent O 
study O 
has O 
demonstrated O 
that O 
coadministration O 
of O 
monoamine B-FAMILY 
oxidase O 
A O 
( O 
MAO-A O 
) O 
inhibitor O 
harmaline B-TRIVIAL 
( O 
5 O 
mg O 
/ O 
kg O 
) O 
increases O 
systemic O 
exposure O 
to O 
5-MeO-DMT B-SYSTEMATIC 
( O 
2 O 
mg O 
/ O 
kg O 
) O 
and O 
active O 
metabolite O 
bufotenine O 
. O 
This O 
study O 
is O 
aimed O 
at O 
delineating O 
harmaline B-TRIVIAL 
and O 
5-MeO-DMT B-SYSTEMATIC 
pharmacokinetic O 
( O 
PK O 
) O 
interactions O 
at O 
multiple O 
dose O 
levels O 
, O 
as O 
well O 
as O 
the O 
impact O 
of O 
CYP2D6 O 
that O 
affects O 
harmaline B-TRIVIAL 
PK O 
and O 
determines O 
5-MeO-DMT B-SYSTEMATIC 
O B-FORMULA 
-demethylation O 
to O 
produce O 
bufotenine B-TRIVIAL 
. O 
Our O 
data O 
revealed O 
that O 
inhibition O 
of O 
MAO-A O 
- O 
mediated O 
metabolic O 
elimination O 
by O 
harmaline B-TRIVIAL 
( O 
2 O 
, O 
5 O 
, O 
and O 
15 O 
mg O 
/ O 
kg O 
) O 
led O 
to O 
a O 
sharp O 
increase O 
in O 
systemic O 
and O 
cerebral O 
exposure O 
to O 
5-MeO-DMT B-SYSTEMATIC 
( O 
2 O 
and O 
10 O 
mg O 
/ O 
kg O 
) O 
at O 
all O 
dose O 
combinations O 
. O 
A O 
more O 
pronounced O 
effect O 
on O 
5-MeO-DMT B-SYSTEMATIC 
PK O 
was O 
associated O 
with O 
greater O 
exposure O 
to O 
harmaline B-TRIVIAL 
in O 
wild O 
- O 
type O 
mice O 
than O 
CYP2D6-humanized O 
( O 
Tg-CYP2D6 O 
) O 
mice O 
. O 
Harmaline B-TRIVIAL 
( O 
5 O 
mg O 
/ O 
kg O 
) O 
also O 
increased O 
blood O 
and O 
brain O 
bufotenine B-TRIVIAL 
concentrations O 
that O 
were O 
generally O 
higher O 
in O 
Tg-CYP2D6 O 
mice O 
. O 
Surprisingly O 
, O 
greater O 
harmaline B-TRIVIAL 
dose O 
( O 
15 O 
mg O 
/ O 
kg O 
) O 
reduced O 
bufotenine B-TRIVIAL 
levels O 
. O 
The O 
in O 
vivo O 
inhibitory O 
effect O 
of O 
harmaline B-TRIVIAL 
on O 
CYP2D6 O 
- O 
catalyzed O 
bufotenine B-TRIVIAL 
formation O 
was O 
confirmed O 
by O 
in O 
vitro O 
study O 
using O 
purified O 
CYP2D6 O 
. O 
Given O 
these O 
findings O 
, O 
a O 
unified O 
PK O 
model O 
including O 
the O 
inhibition O 
of O 
MAO-A- O 
and O 
CYP2D6 O 
- O 
catalyzed O 
5-MeO-DMT B-SYSTEMATIC 
metabolism O 
by O 
harmaline B-TRIVIAL 
was O 
developed O 
to O 
describe O 
blood O 
harmaline B-TRIVIAL 
, O 
5-MeO-DMT B-SYSTEMATIC 
, O 
and O 
bufotenine B-TRIVIAL 
PK O 
profiles O 
in O 
both O 
wild O 
- O 
type O 
and O 
Tg-CYP2D6 O 
mouse O 
models O 
. O 
This O 
PK O 
model O 
may O 
be O 
further O 
employed O 
to O 
predict O 
harmaline B-TRIVIAL 
and O 
5-MeO-DMT B-SYSTEMATIC 
PK O 
interactions O 
at O 
various O 
doses O 
, O 
define O 
the O 
impact O 
of O 
CYP2D6 O 
status O 
, O 
and O 
drive O 
harmaline B-TRIVIAL 
- O 
5-MeO-DMT B-SYSTEMATIC 
pharmacodynamics O 
. O 

Polyester B-FAMILY 
Hydrogels O 
with O 
Controlled O 
Drug O 
Release O 
and O 
Cell O 
Adhesion O 
Properties O 
. O 

polyesters B-FAMILY 
( O 
HPE O 
) O 
have O 
a O 
high O 
efficiency O 
to O 
encapsulate O 
bioactive O 
agents O 
, O 
including O 
drugs O 
, O 
genes O 
, O 
and O 
proteins O 
, O 
due O 
to O 
their O 
globe O 
- O 
like O 
nanostructure O 
. O 
However O 
, O 
the O 
use O 
of O 
these O 
highly O 
branched O 
polymeric O 
systems O 
for O 
tissue O 
engineering O 
applications O 
has O 
not O 
been O 
broadly O 
investigated O 
. O 
Here O 
, O 
we O 
report O 
synthesis O 
and O 
characterization O 
of O 
photocrosslinkable O 
HPE O 
hydrogels O 
with O 
sustained O 
drug O 
release O 
characteristics O 
for O 
cellular O 
therapies O 
. O 
These O 
HPE O 
can O 
encapsulate O 
hydrophobic O 
drug O 
molecules O 
within O 
the O 
HPE O 
cavities O 
due O 
to O 
the O 
presence O 
of O 
a O 
hydrophobic O 
inner O 
structure O 
that O 
is O 
otherwise O 
difficult O 
to O 
achieve O 
in O 
conventional O 
hydrogels O 
. O 
The O 
functionalization O 
of O 
HPE O 
with O 
photocrosslinkable O 
acrylate B-SYSTEMATIC 
moieties O 
renders O 
the O 
formation O 
of O 
hydrogels O 
with O 
a O 
highly O 
porous O 
interconnected O 
structure O 
and O 
mechanically O 
tough O 
network O 
. O 
The O 
compressive O 
modulus O 
of O 
HPE O 
hydrogels O 
was O 
tunable O 
by O 
changing O 
the O 
crosslinking O 
density O 
. O 
The O 
feasibility O 
of O 
using O 
these O 
HPE O 
networks O 
for O 
cellular O 
therapies O 
was O 
investigated O 
by O 
evaluating O 
cell O 
adhesion O 
, O 
spreading O 
, O 
and O 
proliferation O 
on O 
hydrogel O 
surface O 
. O 
Highly O 
crosslinked O 
and O 
mechanically O 
stiff O 
HPE O 
hydrogels O 
have O 
higher O 
cell O 
adhesion O 
, O 
spreading O 
, O 
and O 
proliferation O 
compared O 
to O 
soft O 
and O 
complaint O 
HPE O 
hydrogels O 
. O 
Overall O 
, O 
we O 
showed O 
that O 
hydrogels O 
made O 
from O 
HPE O 
could O 
be O 
used O 
for O 
biomedical O 
applications O 
that O 
require O 
spatial O 
control O 
of O 
cell O 
adhesion O 
and O 
controlled O 
release O 
of O 
hydrophobic O 
clues O 
. O 

- O 
pot O 
, O 
exchange O 
- O 
free O 
, O 
room O 
- O 
temperature O 
synthesis O 
of O 
sub-10 O 
nm O 
aqueous O 
, O 
noninteracting O 
, O 
and O 
stable O 
zwitterated B-SYSTEMATIC 
iron I-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
. O 

aqueous O 
dispersions O 
of O 
superparamagnetic O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
were O 
synthesized O 
in O 
one O 
step O 
in O 
the O 
presence O 
of O 
a O 
zwitterionic B-FAMILY 
siloxane I-FAMILY 
as O 
the O 
stabilizing O 
/ O 
capping O 
/ O 
solubilizing O 
ligand O 
. O 
The O 
hydrodynamic O 
diameter O 
of O 
the O 
particles O 
was O 
tuned O 
by O 
controlling O 
the O 
concentration O 
of O 
zwitterion B-FAMILY 
siloxane I-FAMILY 
, O 
which O 
ultimately O 
yielded O 
monodisperse O 
nanoparticles O 
small O 
enough O 
for O 
renal O 
filtration O 
( O 
< O 
6 O 
nm O 
diameter O 
) O 
. O 
The O 
zwitterated O 
nanoparticles O 
were O 
readily O 
dispersed O 
and O 
stable O 
in O 
aqueous O 
media O 
in O 
the O 
pH O 
range O 
6-9 O 
but O 
exhibited O 
lower O 
magnetization O 
values O 
than O 
nonzwitterated O 
materials O 
due O 
to O 
amorphous O 
content O 
and O 
spin O 
canting O 
, O 
typical O 
for O 
particles O 
of O 
such O 
size O 
. O 
Turbidimetry O 
and O 
light O 
scattering O 
studies O 
revealed O 
no O 
interaction O 
between O 
the O 
particles O 
and O 
proteins O 
, O 
suggesting O 
the O 
materials O 
will O 
circulate O 
well O 
in O 
vivo O 
. O 

diterpenoids I-FAMILY 
with O 
isomerized O 
isospongian B-TRIVIAL 
skeleton O 
and O 
labdane B-FAMILY 
diterpenoids I-FAMILY 
from O 
the O 
fruits O 
of O 
Amomum O 
kravanh O 
. O 

novel O 
diterpenoids B-FAMILY 
, O 
including O 
three O 
tetracyclic B-FAMILY 
diterpenes I-FAMILY 
with O 
isomerized O 
isospongian B-TRIVIAL 
skeletons O 
, O 
kravanhins B-MULTIPLE 
A-C I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
and O 
kravanhin B-TRIVIAL 
D I-TRIVIAL 
( O 
4 O 
) O 
, O 
and O 
three O 
new O 
labdane B-FAMILY 
diterpenes I-FAMILY 
( O 
5-7 O 
) O 
were O 
isolated O 
from O 
the O 
fruits O 
of O 
Amomum O 
kravanh O 
. O 
Compounds O 
1-4 O 
had O 
unprecedented O 
isospongian B-FAMILY 
diterpene I-FAMILY 
skeletons O 
with O 
a O 
trans-anti-cis O 
fused O 
tricyclic O 
ring O 
system O 
. O 
The O 
structures O 
of O 
compounds O 
1-7 O 
were O 
established O 
on O 
the O 
basis O 
of O 
extensive O 
analysis O 
of O 
NMR O 
spectra O 
, O 
CD O 
, O 
and O 
X-ray O 
crystallography O 
. O 
Compound O 
2 O 
showed O 
inhibitory O 
activity O 
on O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
in O 
lipopolysaccharide-induced O 
RAW264.7 O 
macrophages O 
with O 
an O 
IC(50) O 
value O 
of O 
36.2 O 
μM O 
. O 

pharmacogenetics O 
in O 
rheumatoid O 
arthritis O 
: O 
a O 
status O 
report O 
. O 

( O 
MTX B-ABBREVIATION 
) O 
, O 
an O 
antifolate O 
drug O 
, O 
is O 
the O 
first O 
- O 
line O 
disease O 
- O 
modifying O 
agent O 
for O 
the O 
treatment O 
of O 
rheumatoid O 
arthritis O 
( O 
RA O 
) O 
worldwide O 
. O 
MTX B-ABBREVIATION 
has O 
excellent O 
long O 
- O 
term O 
efficacy O 
, O 
tolerability O 
and O 
safety O 
. O 
Early O 
initiation O 
of O 
MTX B-ABBREVIATION 
in O 
patients O 
with O 
RA O 
controls O 
joint O 
destruction O 
and O 
slows O 
progression O 
of O 
disease O 
. O 
However O 
, O 
the O 
clinical O 
response O 
to O 
MTX B-ABBREVIATION 
and O 
frequency O 
of O 
adverse O 
effects O 
from O 
the O 
drug O 
exhibit O 
marked O 
interpatient O 
variability O 
. O 
Over O 
the O 
past O 
decade O 
, O 
there O 
has O 
been O 
a O 
quest O 
to O 
identify O 
genetic O 
markers O 
that O 
reliably O 
predict O 
MTX B-ABBREVIATION 
efficacy O 
and O 
toxicity O 
and O 
help O 
optimize O 
MTX B-ABBREVIATION 
therapy O 
in O 
RA O 
; O 
that O 
is O 
, O 
the O 
field O 
of O 
MTX B-ABBREVIATION 
pharmacogenetics O 
. O 
This O 
review O 
will O 
summarize O 
key O 
pharmacogenetic O 
studies O 
examining O 
SNPs O 
in O 
the O 
genes O 
encoding O 
enzymes O 
in O 
the O 
MTX B-ABBREVIATION 
cellular O 
pathway O 
and O 
their O 
association O 
with O 
MTX B-ABBREVIATION 
response O 
in O 
RA O 
. O 
As O 
evident O 
from O 
this O 
review O 
, O 
MTX B-ABBREVIATION 
pharmacogenetics O 
in O 
RA O 
remains O 
a O 
muddled O 
field O 
, O 
mostly O 
due O 
to O 
inconsistent O 
results O 
from O 
several O 
small O 
underpowered O 
studies O 
. O 

sol O 
- O 
to O 
- O 
gel O 
transformation O 
of O 
uracil B-TRIVIAL 
gelators O 
: O 
specific O 
colorimetric O 
and O 
fluorimetric O 
sensor O 
for O 
fluoride B-SYSTEMATIC 
ions O 
. O 

new O 
type O 
of O 
anthracene B-SYSTEMATIC 
organogelator O 
based O 
on O 
uracil B-TRIVIAL 
was O 
obtained O 
using O 
organic O 
aromatic O 
solvents O 
, O 
cyclohexane B-SYSTEMATIC 
, O 
DMSO B-ABBREVIATION 
, O 
ethanol B-SYSTEMATIC 
, O 
and O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
. O 
It O 
was O 
further O 
characterized O 
by O 
field O 
- O 
emission O 
scanning O 
electron O 
microscopy O 
and O 
transmission O 
electron O 
microscopy O 
. O 
Specifically O 
, O 
the O 
resulting O 
organogels O 
were O 
demonstrated O 
to O 
be O 
promising O 
colorimetric O 
and O 
fluorescent O 
sensors O 
toward O 
fluoride O 
ions O 
with O 
high O 
sensitivity O 
and O 
selectivity O 
, O 
accompanying O 
the O 
disruption O 
of O 
the O 
gelators O 
. O 
Spectroscopic O 
study O 
and O 
(1)H B-FORMULA 
NMR O 
titration O 
experiment O 
revealed O 
that O 
the O 
deprotonation O 
of O 
the O 
hydrogen B-SYSTEMATIC 
atom O 
on O 
the O 
N B-FORMULA 
position O 
of O 
uracil B-TRIVIAL 
moiety O 
by O 
fluoride B-SYSTEMATIC 
ions O 
is O 
responsible O 
for O 
the O 
recognition O 
events O 
, O 
evidenced O 
by O 
immediate O 
transformation O 
from O 
the O 
sol O 
phase O 
to O 
the O 
gel O 
state O 
upon O 
adding O 
a O 
small O 
amount O 
of O 
a O 
proton O 
solvent O 
, O 
methanol B-SYSTEMATIC 
. O 
The O 
process O 
is O 
reversible O 
, O 
with O 
zero O 
loss O 
in O 
sensing O 
activity O 
and O 
sol O 
- O 
to O 
- O 
gel O 
transformation O 
ability O 
even O 
after O 
five O 
runs O 
. O 

standards O 
of O 
medical O 
care O 
in O 
diabetes O 
recommend O 
that O 
statin O 
therapy O 
is O 
added O 
to O 
lifestyle O 
therapy O 
for O 
diabetic O 
patients O 
with O 
overt O 
cardiovascular O 
disease O 
( O 
LDL O 
cholesterol B-TRIVIAL 
goal O 
< O 
70 O 
mg O 
/ O 
dl O 
) O 
, O 
or O 
without O 
cardiovascular O 
disease O 
who O 
are O 
over O 
the O 
age O 
of O 
40 O 
years O 
and O 
who O 
have O 
one O 
or O 
more O 
other O 
cardiovascular O 
disease O 
risk O 
factors O 
( O 
LDL O 
cholesterol B-TRIVIAL 
goal O 
< O 
100 O 
mg O 
/ O 
dl O 
) O 
. O 
In O 
order O 
to O 
reach O 
strict O 
LDL O 
targets O 
, O 
high O 
doses O 
of O 
statins O 
may O 
be O 
required O 
. O 
However O 
, O 
the O 
frequency O 
of O 
statin O 
associated O 
adverse O 
effects O 
and O 
statin O 
intolerance O 
in O 
clinical O 
practice O 
is O 
high O 
( O 
up O 
to O 
10-15% O 
of O 
statin O 
users O 
) O 
especially O 
at O 
muscle O 
level O 
. O 
The O 
review O 
overviews O 
: O 
1 O 
) O 
the O 
known O 
or O 
hypothesised O 
mechanisms O 
through O 
which O 
causal O 
and O 
contributing O 
factors O 
are O 
associated O 
with O 
adverse O 
effects O 
in O 
diabetic O 
people O 
, O 
and O 
2 O 
) O 
the O 
rationale O 
of O 
strategies O 
for O 
managing O 
statin O 
intolerant O 
patients O 
. O 

kinase O 
: O 
an O 
old O 
topic O 
brings O 
new O 
perspectives O 
. O 

kinase O 
( O 
TMPK O 
) O 
is O 
a O 
key O 
enzyme O 
for O 
pyrimidine B-SYSTEMATIC 
synthesis O 
that O 
catalyzes O 
the O 
phosphorylation O 
of O 
thymidine B-SYSTEMATIC 
5'-monophosphate I-SYSTEMATIC 
( O 
dTMP B-TRIVIAL 
) O 
in O 
the O 
presence O 
of O 
ATP B-ABBREVIATION 
and O 
Mg(2+) B-FORMULA 
to O 
form O 
thymidine B-SYSTEMATIC 
5'-diphosphate I-SYSTEMATIC 
( O 
dTDP B-TRIVIAL 
) O 
, O 
which O 
is O 
then O 
converted O 
to O 
thymidine B-SYSTEMATIC 
5'-triphosphate I-SYSTEMATIC 
( O 
dTTP B-TRIVIAL 
) O 
by O 
nucleoside-diphosphate B-FAMILY 
kinase O 
( O 
NDK O 
) O 
. O 
TMPK O 
has O 
an O 
important O 
function O 
in O 
cell O 
proliferation O 
and O 
its O 
enzyme O 
kinetics O 
and O 
related O 
structures O 
have O 
been O 
determined O 
in O 
various O 
organisms O 
. O 
TMPK O 
is O 
well O 
recognized O 
as O 
a O 
potential O 
drug O 
target O 
, O 
with O 
the O 
most O 
notable O 
function O 
being O 
in O 
the O 
activation O 
of O 
anti-HIV O 
nucleoside B-FAMILY 
prodrugs O 
. O 
Recent O 
studies O 
have O 
shown O 
that O 
TMPK O 
is O 
a O 
validated O 
target O 
for O 
antibiotic O 
development O 
against O 
gram O 
- O 
positive O 
bacterium O 
of O 
Staphylococcus O 
aureus O 
. O 
In O 
addition O 
, O 
inhibition O 
of O 
human O 
TMPK O 
increases O 
the O 
potential O 
of O 
anticancer O 
agent O 
doxorubicin B-TRIVIAL 
toward O 
colon O 
cancer O 
cells O 
regardless O 
of O 
p53 O 
status O 
. O 
Following O 
the O 
rapid O 
expanding O 
knowledge O 
on O 
TMPKs O 
and O 
the O 
rising O 
interests O 
in O 
TMPKs O 
as O 
a O 
drug O 
target O 
, O 
in O 
this O 
review O 
we O 
try O 
to O 
describe O 
current O 
research O 
on O 
TMPKs O 
in O 
various O 
organisms O 
of O 
eukaryotes O 
, O 
prokaryotes O 
and O 
viruses O 
and O 
to O 
provide O 
information O 
for O 
designing O 
new O 
potential O 
inhibitors O 
against O 
TMPKs O 
. O 

of O 
highly O 
fluorescent O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
- O 
and O 
zwitterion O 
- O 
functionalized O 
gold O 
nanoclusters O 
. O 

have O 
prepared O 
and O 
characterized O 
a O 
new O 
set O 
of O 
highly O 
fluorescent O 
gold O 
nanoclusters O 
( O 
AuNCs O 
) O 
using O 
one O 
- O 
step O 
aqueous O 
reduction O 
of O 
a O 
gold O 
precursor O 
in O 
the O 
presence O 
of O 
bidentate O 
ligands O 
made O 
of O 
lipoic B-TRIVIAL 
acid I-TRIVIAL 
anchoring O 
groups O 
, O 
appended O 
with O 
either O 
a O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
short O 
chain O 
or O 
a O 
zwitterion O 
group O 
. O 
The O 
AuNCs O 
fluoresce O 
in O 
the O 
red O 
to O 
near O 
- O 
infrared O 
region O 
of O 
the O 
optical O 
spectrum O 
with O 
emission O 
centered O 
at O 
∼750 O 
nm O 
and O 
a O 
quantum O 
yield O 
of O 
∼10-14% O 
, O 
and O 
they O 
exhibit O 
long O 
fluorescence O 
lifetimes O 
( O 
up O 
to O 
∼300 O 
ns O 
) O 
. O 
Dispersions O 
of O 
these O 
AuNCs O 
exhibit O 
great O 
long O 
- O 
term O 
colloidal O 
stability O 
, O 
over O 
a O 
wide O 
range O 
of O 
pHs O 
( O 
2-13 O 
) O 
and O 
in O 
the O 
presence O 
of O 
high O 
electrolyte O 
concentrations O 
, O 
and O 
a O 
strong O 
resistance O 
to O 
reducing O 
agents O 
such O 
as O 
glutathione B-TRIVIAL 
. O 
The O 
growth O 
strategy O 
further O 
permitted O 
the O 
controlled O 
, O 
in O 
situ O 
functionalization O 
of O 
the O 
NCs O 
with O 
reactive O 
groups O 
( O 
e.g O 
. O 
, O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
or O 
amine B-SYSTEMATIC 
) O 
, O 
making O 
these O 
nanoclusters O 
compatible O 
with O 
common O 
and O 
simple O 
- O 
to O 
- O 
implement O 
coupling O 
strategies O 
, O 
such O 
as O 
carbodiimide B-SYSTEMATIC 
chemistry O 
. O 
These O 
properties O 
combined O 
make O 
these O 
fluorescent O 
NCs O 
greatly O 
promising O 
for O 
use O 
in O 
various O 
imaging O 
and O 
sensing O 
applications O 
where O 
NIR O 
and O 
long O 
- O 
lived O 
excitations O 
are O 
desired O 
. O 

superlattice O 
polymorphs O 
to O 
internanoparticle O 
distance O 
, O 
packing O 
density O 
, O 
and O 
surface O 
lattice O 
in O 
assemblies O 
of O 
PbS B-FORMULA 
nanoparticles O 
. O 

of O 
3.5 O 
nm O 
PbS B-FORMULA 
nanoparticles O 
( O 
NPs O 
) O 
nucleate O 
in O 
three O 
dominant O 
superlattice O 
polymorphs O 
: O 
amorphous O 
, O 
body O 
- O 
centered O 
- O 
cubic O 
( O 
bcc O 
) O 
and O 
face O 
- O 
centered O 
- O 
cubic O 
( O 
fcc O 
) O 
phase O 
. O 
This O 
superlattice O 
relationship O 
can O 
be O 
controlled O 
by O 
the O 
inter-NP O 
distance O 
without O 
changing O 
the O 
NP O 
size O 
. O 
Upon O 
increase O 
of O 
inter-NP O 
distance O 
, O 
the O 
packing O 
density O 
decreases O 
, O 
and O 
the O 
capping O 
molecules O 
at O 
NP O 
surfaces O 
change O 
in O 
structure O 
and O 
accordingly O 
modify O 
the O 
surface O 
energy O 
. O 
The O 
driving O 
force O 
for O 
NP O 
assembly O 
develops O 
from O 
an O 
entropic O 
maximization O 
to O 
a O 
reduction O 
of O 
total O 
free O 
energy O 
through O 
multiple O 
interactions O 
between O 
surface O 
molecules O 
and O 
NPs O 
and O 
resulting O 
variation O 
of O 
surface O 
molecules O 
. O 
Upon O 
long O 
- O 
term O 
aging O 
and O 
additional O 
thermal O 
treatment O 
, O 
fcc O 
undergoes O 
a O 
tetragonal O 
distortion O 
and O 
subsequently O 
transforms O 
to O 
bcc O 
phase O 
, O 
and O 
simultaneously O 
, O 
the O 
NPs O 
embedded O 
in O 
supercrystals O 
reduce O 
surface O 
energy O 
primarily O 
in O 
{ O 
200 O 
} O 
facets O 
. O 
Linking O 
molecule-NP O 
interactions O 
with O 
a O 
series O 
of O 
changes O 
of O 
packing O 
density O 
and O 
surface O 
lattice O 
spacings O 
of O 
NPs O 
allows O 
for O 
an O 
interpretation O 
of O 
principles O 
governing O 
the O 
nucleation O 
, O 
structure O 
stability O 
, O 
and O 
transformation O 
of O 
PbS B-FORMULA 
NP-assembled O 
supercrystals O 
. O 

microbiota O 
regulates O 
bile B-FAMILY 
acid I-FAMILY 
metabolism O 
by O 
reducing O 
the O 
levels O 
of O 
tauro-beta-muricholic B-TRIVIAL 
acid I-TRIVIAL 
, O 
a O 
naturally O 
occurring O 
FXR O 
antagonist O 
. O 

acids I-FAMILY 
are O 
synthesized O 
from O 
cholesterol B-TRIVIAL 
in O 
the O 
liver O 
and O 
further O 
metabolized O 
by O 
the O 
gut O 
microbiota O 
into O 
secondary O 
bile B-FAMILY 
acids I-FAMILY 
. O 
Bile B-FAMILY 
acid I-FAMILY 
synthesis O 
is O 
under O 
negative O 
feedback O 
control O 
through O 
activation O 
of O 
the O 
nuclear O 
receptor O 
farnesoid O 
X O 
receptor O 
( O 
FXR O 
) O 
in O 
the O 
ileum O 
and O 
liver O 
. O 
Here O 
we O 
profiled O 
the O 
bile B-FAMILY 
acid I-FAMILY 
composition O 
throughout O 
the O 
enterohepatic O 
system O 
in O 
germ O 
- O 
free O 
( O 
GF O 
) O 
and O 
conventionally O 
raised O 
( O 
CONV-R O 
) O 
mice O 
. O 
We O 
confirmed O 
a O 
dramatic O 
reduction O 
in O 
muricholic B-FAMILY 
acid I-FAMILY 
, O 
but O 
not O 
cholic B-TRIVIAL 
acid I-TRIVIAL 
, O 
levels O 
in O 
CONV-R O 
mice O 
. O 
Rederivation O 
of O 
Fxr O 
- O 
deficient O 
mice O 
as O 
GF O 
demonstrated O 
that O 
the O 
gut O 
microbiota O 
regulated O 
expression O 
of O 
fibroblast O 
growth O 
factor O 
15 O 
in O 
the O 
ileum O 
and O 
cholesterol B-TRIVIAL 
7α-hydroxylase O 
( O 
CYP7A1 O 
) O 
in O 
the O 
liver O 
by O 
FXR-dependent O 
mechanisms O 
. O 
Importantly O 
, O 
we O 
identified O 
tauro B-MULTIPLE 
- I-MULTIPLE 
conjugated I-MULTIPLE 
beta- I-MULTIPLE 
and I-MULTIPLE 
alpha-muricholic I-MULTIPLE 
acids I-MULTIPLE 
as O 
FXR O 
antagonists O 
. O 
These O 
studies O 
suggest O 
that O 
the O 
gut O 
microbiota O 
not O 
only O 
regulates O 
secondary O 
bile B-FAMILY 
acid I-FAMILY 
metabolism O 
but O 
also O 
inhibits O 
bile B-FAMILY 
acid I-FAMILY 
synthesis O 
in O 
the O 
liver O 
by O 
alleviating O 
FXR O 
inhibition O 
in O 
the O 
ileum O 
. O 

modulates O 
calcium B-SYSTEMATIC 
signaling O 
during O 
RANKL O 
- O 
mediated O 
osteoclast O 
differentiation O 
. O 

maturation O 
and O 
function O 
primarily O 
depend O 
on O 
receptor O 
activator O 
of O 
NF-κB O 
ligand O 
( O 
RANKL O 
) O 
- O 
mediated O 
induction O 
of O 
nuclear O 
factor O 
of O 
activated O 
T O 
cells O 
c1 O 
( O 
NFATc1 O 
) O 
, O 
which O 
is O 
further O 
activated O 
via O 
increased O 
intracellular O 
calcium B-SYSTEMATIC 
( O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
) O 
oscillation O 
. O 
However O 
, O 
the O 
coordination O 
mechanism O 
that O 
mediates O 
Ca(2+) B-FORMULA 
oscillation O 
during O 
osteoclastogenesis O 
remains O 
ill O 
defined O 
. O 
Here O 
, O 
we O 
identified O 
transmembrane O 
protein O 
64 O 
( O 
Tmem64 O 
) O 
as O 
a O 
regulator O 
of O 
Ca(2+) B-FORMULA 
oscillation O 
during O 
osteoclastogenesis O 
. O 
We O 
found O 
that O 
Tmem64-deficient O 
mice O 
exhibit O 
increased O 
bone O 
mass O 
due O 
in O 
part O 
to O 
impaired O 
osteoclast O 
formation O 
. O 
Using O 
in O 
vitro O 
osteoclast O 
culture O 
systems O 
, O 
we O 
show O 
here O 
that O 
Tmem64 O 
interacts O 
with O 
sarcoplasmic O 
endoplasmic O 
reticulum O 
Ca(2+) B-FORMULA 
ATPase O 
2 O 
( O 
SERCA2 O 
) O 
and O 
modulates O 
its O 
activity O 
. O 
Consequently O 
, O 
Tmem64 O 
deficiency O 
significantly O 
diminishes O 
RANKL-induced O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
oscillation O 
, O 
which O 
results O 
in O 
reduced O 
Ca(2+) B-FORMULA 
/ O 
calmodulin O 
- O 
dependent O 
protein O 
kinases O 
( O 
CaMK O 
) O 
IV O 
and O 
mitochondrial O 
ROS O 
, O 
both O 
of O 
which O 
contribute O 
to O 
achieving O 
the O 
CREB O 
activity O 
necessary O 
for O 
osteoclast O 
formation O 
. O 
These O 
data O 
demonstrate O 
that O 
Tmem64 O 
is O 
a O 
positive O 
modulator O 
of O 
osteoclast O 
differentiation O 
via O 
SERCA2-dependent O 
Ca(2+) B-FORMULA 
signaling O 
. O 

is O 
essential O 
for O 
heme B-FAMILY 
transport O 
from O 
the O 
phagolysosome O 
of O 
macrophages O 
during O 
erythrophagocytosis O 
. O 

humans O 
have O 
about O 
25 O 
trillion O 
red O 
blood O 
cells O 
( O 
RBCs O 
) O 
, O 
and O 
each O 
second O 
we O 
recycle O 
about O 
5 O 
million O 
RBCs O 
by O 
erythrophagocytosis O 
( O 
EP O 
) O 
in O 
macrophages O 
of O 
the O 
reticuloendothelial O 
system O 
. O 
Despite O 
the O 
central O 
role O 
for O 
EP O 
in O 
mammalian O 
iron B-SYSTEMATIC 
metabolism O 
, O 
the O 
molecules O 
and O 
pathways O 
responsible O 
for O 
heme B-FAMILY 
trafficking O 
during O 
EP O 
remain O 
unknown O 
. O 
Here O 
, O 
we O 
show O 
that O 
the O 
mammalian O 
homolog O 
of O 
HRG1 O 
, O 
a O 
transmembrane O 
heme B-FAMILY 
permease O 
in O 
C. O 
elegans O 
, O 
is O 
essential O 
for O 
macrophage O 
iron B-SYSTEMATIC 
homeostasis O 
and O 
transports O 
heme B-FAMILY 
from O 
the O 
phagolysosome O 
to O 
the O 
cytoplasm O 
during O 
EP O 
. O 
HRG1 O 
is O 
strongly O 
expressed O 
in O 
macrophages O 
of O 
the O 
reticuloendothelial O 
system O 
and O 
specifically O 
localizes O 
to O 
the O 
phagolysosomal O 
membranes O 
during O 
EP O 
. O 
Depletion O 
of O 
Hrg1 O 
in O 
mouse O 
macrophages O 
causes O 
attenuation O 
of O 
heme B-FAMILY 
transport O 
from O 
the O 
phagolysosomal O 
compartment O 
. O 
Importantly O 
, O 
missense O 
polymorphisms O 
in O 
human O 
HRG1 O 
are O 
defective O 
in O 
heme B-FAMILY 
transport O 
. O 
Our O 
results O 
reveal O 
HRG1 O 
as O 
the O 
long O 
- O 
sought O 
heme B-FAMILY 
transporter O 
for O 
heme B-FAMILY 
- O 
iron B-SYSTEMATIC 
recycling O 
in O 
macrophages O 
and O 
suggest O 
that O 
genetic O 
variations O 
in O 
HRG1 O 
could O 
be O 
modifiers O 
of O 
human O 
iron B-SYSTEMATIC 
metabolism O 
. O 

coli O 
K12 O 
cells O 
suspended O 
in O 
apple O 
cider O 
were O 
treated O 
by O 
manothermosonication O 
( O 
MTS O 
, O 
400 O 
kPa O 
/ O 
59 O 
°C O 
) O 
, O 
thermosonication O 
( O 
TS O 
, O 
100 O 
kPa O 
/ O 
59 O 
°C O 
) O 
, O 
and O 
manosonication O 
( O 
MS O 
, O 
400 O 
kPa O 
/ O 
55 O 
°C O 
) O 
for O 
up O 
to O 
4 O 
min O 
. O 
A O 
5-log O 
reduction O 
was O 
achieved O 
in O 
1.4 O 
min O 
by O 
MTS O 
, O 
3.8 O 
min O 
by O 
TS O 
, O 
and O 
2.5 O 
min O 
by O 
MS O 
. O 
The O 
inactivation O 
curves O 
of O 
the O 
E O 
. O 
coli O 
exhibited O 
a O 
fast O 
initial O 
reduction O 
followed O 
by O 
a O 
slow O 
inactivation O 
section O 
. O 
The O 
Weibull O 
, O 
log O 
- O 
logistic O 
, O 
and O 
biphasic O 
linear O 
models O 
showed O 
a O 
good O 
fit O 
of O 
the O 
inactivation O 
data O 
. O 
Quality O 
analyses O 
were O 
conducted O 
with O 
raw O 
apple O 
cider O 
( O 
control O 
) O 
, O 
thermally O 
- O 
pasteurized O 
( O 
TP O 
) O 
, O 
and O 
MTS- O 
, O 
TS- O 
, O 
and O 
MS O 
- O 
treated O 
cider O 
samples O 
over O 
a O 
3-week O 
period O 
at O 
refrigeration O 
temperature O 
. O 
Titratable O 
acidity O 
and O 
pH O 
did O 
not O 
differ O 
among O 
any O 
of O 
the O 
samples O 
. O 
During O 
storage O 
, O 
the O 
turbidity O 
value O 
of O 
the O 
control O 
was O 
the O 
highest O 
, O 
followed O 
by O 
TP O 
, O 
TS O 
, O 
MTS O 
and O 
MS O 
. O 
All O 
color O 
parameters O 
of O 
the O 
TP O 
sample O 
were O 
significantly O 
different O 
from O 
those O 
receiving O 
the O 
other O 
treatments O 
. O 
The O 
control O 
and O 
sonicated O 
samples O 
showed O 
similar O 
color O 
parameters O 
during O 
storage O 
. O 
In O 
total O 
, O 
97 O 
aroma O 
compounds O 
were O 
identified O 
in O 
the O 
control O 
, O 
TS- O 
, O 
MS- O 
, O 
and O 
MTS O 
- O 
treated O 
cider O 
samples O 
, O 
while O 
95 O 
aroma O 
compounds O 
were O 
found O 
in O 
the O 
TP O 
at O 
Week O 
0 O 
. O 
Among O 
all O 
the O 
aroma O 
compounds O 
, O 
9 O 
key O 
ones O 
were O 
identified O 
in O 
all O 
samples O 
, O 
including O 
ethyl B-SYSTEMATIC 
2-methylbutanoate I-SYSTEMATIC 
, O 
butyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
1-butanol B-SYSTEMATIC 
, O 
ethyl B-SYSTEMATIC 
hexanoate I-SYSTEMATIC 
, O 
1-hexanol B-SYSTEMATIC 
, O 
butanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
β-damascenone B-TRIVIAL 
, O 
hexanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
and O 
octanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
The O 
profiles O 
of O 
the O 
key O 
aroma O 
compounds O 
in O 
all O 
sonicated O 
samples O 
were O 
more O 
similar O 
to O 
the O 
control O 
than O 
the O 
TP O 
sample O 
at O 
Weeks O 
0 O 
and O 
3 O 
. O 

applications O 
of O 
bisphosphonates B-FAMILY 
. O 

their O 
discovery O 
over O 
100 O 
years O 
ago O 
, O 
bisphosphonates B-FAMILY 
have O 
been O 
used O 
industrially O 
as O 
corrosion O 
inhibitors O 
and O 
complexing O 
agents O 
. O 
With O 
the O 
discovery O 
of O 
their O 
pharmacological O 
activity O 
in O 
the O 
late O 
1960s O 
, O 
implicating O 
their O 
high O 
affinity O 
for O 
hydroxyapatite B-TRIVIAL 
, O 
bisphosphonates B-FAMILY 
have O 
been O 
employed O 
in O 
the O 
treatment O 
of O 
bone O 
diseases O 
and O 
as O 
targeting O 
agents O 
for O 
colloids O 
and O 
drugs O 
. O 
They O 
have O 
notably O 
been O 
investigated O 
for O 
the O 
treatment O 
of O 
Paget's O 
disease O 
, O 
osteoporosis O 
, O 
bone O 
metastases O 
, O 
malignancy O 
- O 
associated O 
hypercalcemia O 
, O 
and O 
pediatric O 
bone O 
diseases O 
. O 
Currently O 
, O 
they O 
are O 
first O 
- O 
line O 
medications O 
for O 
several O 
of O 
these O 
diseases O 
and O 
are O 
taken O 
by O 
millions O 
of O 
patients O 
worldwide O 
, O 
mostly O 
postmenopausal O 
women O 
. O 
A O 
major O 
problem O 
associated O 
with O 
their O 
use O 
is O 
their O 
low O 
oral O 
bioavailability O 
. O 
Several O 
delivery O 
systems O 
have O 
been O 
proposed O 
to O 
improve O 
their O 
absorption O 
and O 
to O 
direct O 
them O 
to O 
sites O 
other O 
than O 
bone O 
tissues O 
. O 
Beyond O 
their O 
important O 
pharmacological O 
role O 
, O 
the O 
medical O 
applications O 
of O 
bisphosphonates B-FAMILY 
are O 
numerous O 
. O 
In O 
addition O 
, O 
their O 
metal O 
- O 
chelating O 
properties O 
have O 
been O 
exploited O 
to O 
coat O 
and O 
stabilize O 
implants O 
, O 
nanoparticulates O 
, O 
and O 
contrast O 
agents O 
. O 
In O 
this O 
contribution O 
, O 
we O 
review O 
the O 
pharmacological O 
and O 
clinical O 
uses O 
of O 
bisphosphonates B-FAMILY 
and O 
highlight O 
their O 
novel O 
applications O 
in O 
the O 
pharmaceutical O 
and O 
biomedical O 
fields O 
. O 

alleviates O 
hepatocyte O 
steatosis O 
through O 
activating O 
AMPK O 
signaling O 
pathway O 
. O 

, O 
an O 
effective O 
compound O 
derived O 
from O 
foxtail O 
- O 
like O 
sophora O 
herb O 
and O 
seed O 
, O 
has O 
been O 
reported O 
that O 
it O 
can O 
alleviate O 
non-alcoholic O 
steatohepatitis O 
( O 
NASH O 
) O 
in O 
rats O 
and O 
affect O 
adipocytokine O 
synthesis O 
. O 
Meanwhile O 
, O 
adipocytokines O 
could O 
adjust O 
hepatic O 
lipid O 
metabolism O 
through O 
AMPK O 
signaling O 
pathway O 
. O 
In O 
the O 
work O 
presented O 
here O 
, O 
primary O 
hepatocytes O 
were O 
isolated O 
from O 
specific O 
pathogen O 
- O 
free O 
male O 
SD O 
rats O 
and O 
incubated O 
with O 
200 O 
μmol O 
/ O 
L O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
for O 
24h O 
to O 
induce O 
steatotic O 
model O 
, O 
then O 
treated O 
with O 
sophocarpine B-TRIVIAL 
for O 
72 O 
h O 
. O 
Oil O 
red O 
staining O 
was O 
performed O 
to O 
evaluate O 
steatosis O 
, O 
total O 
RNA O 
and O 
protein O 
of O 
primary O 
hepatocytes O 
were O 
extracted O 
for O 
real O 
- O 
time O 
RT-PCR O 
and O 
western O 
blot O 
analysis O 
. O 
A O 
cluster O 
of O 
aberrances O 
were O 
observed O 
in O 
the O 
model O 
group O 
, O 
including O 
hepatocyte O 
steatosis O 
, O 
increased O 
leptin O 
and O 
decreased O 
adiponectin O 
mRNA O 
expressions O 
. O 
While O 
sophocarpine B-TRIVIAL 
treatment O 
resulted O 
in O 
: O 
significant O 
improvement O 
of O 
steatosis O 
( O 
> O 
50% O 
decrease O 
) O 
, O 
decrease O 
of O 
leptin O 
expression O 
( O 
< O 
0.57-fold O 
) O 
and O 
increase O 
of O 
adiponectin O 
expression O 
( O 
> O 
1.48-fold O 
) O 
. O 
Moreover O 
, O 
compared O 
with O 
the O 
model O 
group O 
, O 
sophocarpine B-TRIVIAL 
could O 
significantly O 
increase O 
P-AMPKα O 
( O 
> O 
5.82-fold O 
) O 
, O 
AMPKα O 
( O 
> O 
1.29-fold O 
) O 
and O 
ACC O 
( O 
> O 
3.27-fold O 
) O 
protein O 
expressions O 
, O 
and O 
reduce O 
P-ACC O 
( O 
< O 
0.30-fold O 
) O 
and O 
HNF-4α O 
( O 
< O 
0.20-fold O 
) O 
protein O 
expression O 
. O 
The O 
mRNA O 
expression O 
of O 
Srebp-1c O 
was O 
downregulated O 
significantly O 
simultaneously O 
( O 
< O 
0.68-fold O 
) O 
. O 
We O 
concluded O 
that O 
sophocarpine B-TRIVIAL 
could O 
alleviate O 
hepatocyte O 
steatosis O 
and O 
the O 
potential O 
mechanism O 
might O 
be O 
the O 
activated O 
signaling O 
pathway O 
of O 
AMPK O 
. O 

inhibits O 
UVB-induced O 
immunosuppression O 
in O 
mouse O 
skin O 
. O 
To O 
identify O 
the O 
molecular O 
mechanisms O 
underlying O 
this O 
effect O 
, O 
we O 
used O 
an O 
adoptive O 
transfer O 
approach O 
in O 
which O 
dendritic O 
cells O 
( O 
DCs O 
) O 
from O 
the O 
draining O 
lymph O 
nodes O 
of O 
donor O 
mice O 
that O 
had O 
been O 
UVB-exposed O 
and O 
sensitized O 
to O 
2,4,-dinitrofluorobenzene B-SYSTEMATIC 
( O 
DNFB B-ABBREVIATION 
) O 
were O 
transferred O 
into O 
naïve O 
recipient O 
mice O 
. O 
The O 
contact O 
hypersensitivity O 
( O 
CHS O 
) O 
response O 
of O 
the O 
recipient O 
mice O 
to O 
DNFB B-ABBREVIATION 
was O 
then O 
measured O 
. O 
When O 
DCs O 
were O 
obtained O 
from O 
UVB-exposed O 
donor O 
mice O 
that O 
were O 
not O 
treated O 
with O 
silymarin O 
, O 
the O 
CHS O 
response O 
was O 
suppressed O 
confirming O 
the O 
role O 
of O 
DCs O 
in O 
the O 
UVB-induced O 
immunosuppression O 
. O 
Silymarin O 
treatment O 
of O 
UVB-exposed O 
donor O 
mice O 
relieved O 
this O 
suppression O 
of O 
the O 
CHS O 
response O 
in O 
the O 
recipients O 
. O 
Silymarin O 
treatment O 
was O 
associated O 
with O 
rapid O 
repair O 
of O 
UVB-induced O 
cyclobutane B-FAMILY 
pyrimidine I-FAMILY 
dimers I-FAMILY 
( O 
CPDs B-FAMILY 
) O 
in O 
DCs O 
and O 
silymarin O 
treatment O 
did O 
not O 
prevent O 
UV-induced O 
immunosuppression O 
in O 
XPA-deficient O 
mice O 
which O 
are O 
unable O 
to O 
repair O 
UV-induced O 
DNA O 
damage O 
. O 
The O 
CHS O 
response O 
in O 
mice O 
receiving O 
DCs O 
from O 
silymarin O 
- O 
treated O 
UV-exposed O 
donor O 
mice O 
also O 
was O 
associated O 
with O 
enhanced O 
secretion O 
of O 
Th1 O 
- O 
type O 
cytokines O 
and O 
stimulation O 
of O 
T O 
cells O 
. O 
Adoptive O 
transfer O 
of O 
T O 
cells O 
revealed O 
that O 
transfer O 
of O 
either O 
CD8(+) O 
or O 
CD4(+) O 
cells O 
from O 
silymarin O 
- O 
treated O 
, O 
UVB-exposed O 
donors O 
resulted O 
in O 
enhancement O 
of O 
the O 
CHS O 
response O 
. O 
Cell O 
culture O 
study O 
showed O 
enhanced O 
secretion O 
of O 
IL-2 O 
and O 
IFNγ O 
by O 
CD8(+) O 
T O 
cells O 
, O 
and O 
reduced O 
secretion O 
of O 
Th2 O 
cytokines O 
by O 
CD4(+) O 
T O 
cells O 
, O 
obtained O 
from O 
silymarin O 
- O 
treated O 
UVB-exposed O 
mice O 
. O 
These O 
data O 
suggest O 
that O 
DNA O 
repair O 
- O 
dependent O 
functional O 
activation O 
of O 
DCs O 
, O 
a O 
reduction O 
in O 
CD4(+) O 
regulatory O 
T-cell O 
activity O 
, O 
and O 
stimulation O 
of O 
CD8(+) O 
effector O 
T O 
cells O 
contribute O 
to O 
silymarin O 
- O 
mediated O 
inhibition O 
of O 
UVB-induced O 
immunosuppression O 
. O 

for O 
oxysterol B-FAMILY 
analysis O 
: O 
Past O 
, O 
present O 
and O 
future O 
. O 

are O 
oxidised O 
forms O 
of O 
cholesterol B-TRIVIAL 
or O 
its O 
precursors O 
. O 
In O 
this O 
article O 
we O 
will O 
concentrate O 
specifically O 
on O 
those O 
formed O 
in O 
mammalian O 
systems O 
. O 
Oxidation O 
may O 
be O 
catalysed O 
by O 
endogenous O 
enzymes O 
or O 
through O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
forming O 
a O 
myriad O 
of O 
potential O 
products O 
. O 
A O 
number O 
of O 
these O 
products O 
are O 
biologically O 
active O 
, O 
and O 
oxysterols B-FAMILY 
may O 
have O 
roles O 
in O 
cholesterol B-TRIVIAL 
homeostasis O 
, O 
neurogenesis O 
, O 
protein O 
prenylation O 
and O 
in O 
the O 
immune O 
system O 
. O 
Oxysterols B-FAMILY 
are O 
also O 
implicated O 
in O 
aetiology O 
of O 
disease O 
states O 
including O 
atherosclerosis O 
, O 
neurodegenerative O 
and O 
inflammatory O 
diseases O 
. O 
Reports O 
indicating O 
the O 
levels O 
of O 
oxysterols B-FAMILY 
in O 
plasma O 
, O 
cerebrospinal O 
fluid O 
and O 
various O 
tissues O 
are O 
in O 
many O 
cases O 
unrealistic O 
owing O 
to O 
a O 
lack O 
of O 
attention O 
to O 
the O 
possibility O 
of O 
autoxidation O 
, O 
a O 
process O 
by O 
which O 
oxysterols B-FAMILY 
are O 
formed O 
from O 
cholesterol B-TRIVIAL 
by O 
oxygen B-SYSTEMATIC 
in O 
air O 
. O 
This O 
article O 
comprises O 
a O 
critical O 
assessment O 
of O 
the O 
technical O 
difficulties O 
of O 
oxysterol B-FAMILY 
analysis O 
, O 
highlights O 
methodologies O 
utilising O 
best O 
practise O 
and O 
discusses O 
newer O 
procedures O 
. O 

regulates O 
transcription O 
of O 
the O 
ion O 
uptake O 
Na+ B-FORMULA 
/ O 
Cl- B-FORMULA 
cotransporter O 
( O 
ncc O 
) O 
gene O 
in O 
zebrafish O 
gill O 
. O 

( O 
PRL O 
) O 
is O 
a O 
well O 
- O 
known O 
regulator O 
of O 
ion O 
and O 
water O 
transport O 
within O 
osmoregulatory O 
tissues O 
across O 
vertebrate O 
species O 
, O 
yet O 
how O 
PRL O 
acts O 
on O 
some O 
of O 
its O 
target O 
tissues O 
remains O 
poorly O 
understood O 
. O 
Using O 
zebrafish O 
as O 
a O 
model O 
, O 
we O 
show O 
that O 
ionocytes O 
in O 
the O 
gill O 
directly O 
respond O 
to O 
systemic O 
PRL O 
to O 
regulate O 
mechanisms O 
of O 
ion O 
uptake O 
. O 
Ion O 
- O 
poor O 
conditions O 
led O 
to O 
increases O 
in O 
the O 
expression O 
of O 
PRL O 
receptor O 
( O 
prlra O 
) O 
, O 
Na(+) B-FORMULA 
/ O 
Cl(-) B-FORMULA 
cotransporter O 
( O 
ncc O 
; O 
slc12a10.2 O 
) O 
, O 
Na(+) B-FORMULA 
/ O 
H(+) B-FORMULA 
exchanger O 
( O 
nhe3b O 
; O 
slc9a3.2 O 
) O 
, O 
and O 
epithelial O 
Ca(2+) B-FORMULA 
channel O 
( O 
ecac O 
; O 
trpv6 O 
) O 
transcripts O 
within O 
the O 
gill O 
. O 
Intraperitoneal O 
injection O 
of O 
ovine O 
PRL O 
( O 
oPRL O 
) O 
increased O 
ncc O 
and O 
prlra O 
transcripts O 
, O 
but O 
did O 
not O 
affect O 
nhe3b O 
or O 
ecac O 
. O 
Consistent O 
with O 
direct O 
PRL O 
action O 
in O 
the O 
gill O 
, O 
addition O 
of O 
oPRL O 
to O 
cultured O 
gill O 
filaments O 
stimulated O 
ncc O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
, O 
an O 
effect O 
blocked O 
by O 
a O 
pure O 
human O 
PRL O 
receptor O 
antagonist O 
( O 
Δ1-9-G129R-hPRL O 
) O 
. O 
These O 
results O 
suggest O 
that O 
PRL O 
signaling O 
through O 
PRL O 
receptors O 
in O 
the O 
gill O 
regulates O 
the O 
expression O 
of O 
ncc O 
, O 
thereby O 
linking O 
this O 
pituitary O 
hormone O 
with O 
an O 
effector O 
of O 
Cl(-) B-FORMULA 
uptake O 
in O 
zebrafish O 
for O 
the O 
first O 
time O 
. O 

inhibitors O 
of O 
matrix O 
metalloproteinases O 
( O 
MMPs O 
) O 
, O 
designed O 
previously O 
, O 
as O 
well O 
as O 
tissue O 
inhibitors O 
of O 
metalloproteinases O 
( O 
TIMPs O 
) O 
lack O 
enzyme O 
selectivity O 
, O 
which O 
has O 
been O 
a O 
major O 
obstacle O 
for O 
developing O 
inhibitors O 
into O 
safe O 
and O 
effective O 
MMP-targeted O 
drugs O 
. O 
Here O 
we O 
designed O 
a O 
fusion O 
protein O 
named O 
APP-IP-TIMP-2 O 
, O 
in O 
which O 
the O 
ten O 
amino B-FAMILY 
acid I-FAMILY 
residue O 
sequence O 
of O 
APP O 
- O 
derived O 
MMP-2 O 
selective O 
inhibitory O 
peptide O 
( O 
APP-IP O 
) O 
is O 
added O 
to O 
the O 
N B-FORMULA 
terminus O 
of O 
TIMP-2 O 
. O 
The O 
APP-IP O 
and O 
TIMP-2 O 
regions O 
of O 
the O 
fusion O 
protein O 
are O 
designed O 
to O 
interact O 
with O 
the O 
active O 
site O 
and O 
the O 
hemopexin O 
- O 
like O 
domain O 
of O 
MMP-2 O 
, O 
respectively O 
. O 
The O 
reactive O 
site O 
of O 
the O 
TIMP-2 O 
region O 
, O 
which O 
has O 
broad O 
specificity O 
against O 
MMPs O 
, O 
is O 
blocked O 
by O 
the O 
APP-IP O 
adduct O 
. O 
The O 
recombinant O 
APP-IP-TIMP-2 O 
showed O 
strong O 
inhibitory O 
activity O 
toward O 
MMP-2 O 
( O 
Ki(app) O 
= O 
0.68 O 
pm O 
) O 
, O 
whereas O 
its O 
inhibitory O 
activity O 
toward O 
MMP-1 O 
, O 
MMP-3 O 
, O 
MMP-7 O 
, O 
MMP-8 O 
, O 
MMP-9 O 
, O 
or O 
MT1-MMP O 
was O 
six O 
orders O 
of O 
magnitude O 
or O 
more O 
weaker O 
( O 
IC50 O 
> O 
1 O 
μm O 
) O 
. O 
The O 
fusion O 
protein O 
inhibited O 
the O 
activation O 
of O 
pro-MMP-2 O 
in O 
the O 
concanavalin O 
A-stimulated O 
HT1080 O 
cells O 
, O 
degradation O 
of O 
type O 
IV O 
collagen O 
by O 
the O 
cells O 
, O 
and O 
the O 
migration O 
of O 
stimulated O 
cells O 
. O 
Compared O 
with O 
the O 
decapeptide B-FAMILY 
APP-IP O 
( O 
t&frac12 O 
; O 
= O 
30 O 
min O 
) O 
, O 
APP-IP-TIMP-2 O 
( O 
t&frac12 O 
; O 
≫ O 
96 O 
h O 
) O 
showed O 
a O 
much O 
longer O 
half O 
- O 
life O 
in O 
cultured O 
tumor O 
cells O 
. O 
Therefore O 
, O 
the O 
fusion O 
protein O 
may O 
be O 
a O 
useful O 
tool O 
to O 
evaluate O 
contributions O 
of O 
proteolytic O 
activity O 
of O 
MMP-2 O 
in O 
various O 
pathophysiological O 
processes O 
. O 
It O 
may O 
also O 
be O 
developed O 
as O 
an O 
effective O 
anti-tumor O 
drug O 
with O 
restricted O 
side O 
effects O 
. O 

activity O 
of O 
a O 
family O 
scorpiand O 
- O 
like O 
azamacrocycles O 
against O 
Leishmania O 
infantum O 
and O 
Leishmania O 
braziliensis O 
was O 
studied O 
using O 
promastigotes O 
, O 
axenic O 
and O 
intracellular O 
amastigotes O 
forms O 
. O 
All O 
the O 
compounds O 
are O 
more O 
active O 
and O 
less O 
toxic O 
than O 
meglumine B-TRIVIAL 
antimoniate I-TRIVIAL 
( O 
Glucantime B-TRIVIAL 
) O 
. O 
Moreover O 
, O 
the O 
data O 
on O 
infection O 
rates O 
and O 
amastigotes O 
showed O 
that O 
compounds O 
P2Py O 
, O 
PN O 
and O 
P3Py O 
are O 
the O 
most O 
active O 
against O 
both O 
species O 
of O 
Leishmania O 
. O 
On O 
the O 
other O 
hand O 
, O 
studies O 
on O 
the O 
inhibitory O 
effect O 
of O 
these O 
compounds O 
on O 
SOD O 
enzymes O 
showed O 
that O 
while O 
the O 
inhibition O 
of O 
the O 
Fe B-FORMULA 
-SOD O 
enzyme O 
of O 
the O 
promastigote O 
forms O 
of O 
the O 
parasites O 
is O 
remarkable O 
, O 
the O 
inhibition O 
of O 
human O 
CuZn B-FORMULA 
-SOD O 
and O 
Mn B-FORMULA 
-SOD O 
from O 
Escherichia O 
coli O 
is O 
negligible O 
. O 
The O 
ultrastructural O 
alterations O 
observed O 
in O 
treated O 
promastigote O 
forms O 
confirmed O 
that O 
the O 
compounds O 
having O 
the O 
highest O 
activity O 
were O 
those O 
causing O 
the O 
largest O 
cell O 
damage O 
. O 
The O 
modifications O 
observed O 
by O 
(1)H B-FORMULA 
NMR O 
, O 
and O 
the O 
amounts O 
of O 
catabolites O 
excreted O 
by O 
the O 
parasites O 
after O 
treatment O 
with O 
the O 
compounds O 
, O 
suggested O 
that O 
the O 
catabolic O 
mechanism O 
could O 
depend O 
on O 
the O 
structure O 
of O 
the O 
side O 
chains O 
linked O 
to O 
the O 
aza B-SYSTEMATIC 
-scorpiand O 
macrocycles O 
. O 

modulates O 
expression O 
of O 
DNA O 
methyltranferases O 
and O 
methyl B-SYSTEMATIC 
CpG I-SYSTEMATIC 
-/ O 
CpG B-ABBREVIATION 
domain O 
- O 
binding O 
proteins O 
in O 
murine O 
embryonic O 
fibroblasts O 
. O 

alcohol B-FAMILY 
syndrome O 
( O 
FAS O 
) O 
, O 
presenting O 
with O 
a O 
constellation O 
of O 
neuro- O 
/ O 
psychological O 
, O 
craniofacial O 
and O 
cardiac O 
abnormalities O 
, O 
occurs O 
frequently O 
in O 
offspring O 
of O 
women O 
who O 
consume O 
alcohol B-FAMILY 
during O 
pregnancy O 
, O 
with O 
a O 
prevalence O 
of O 
1-3 O 
per O 
1000 O 
livebirths O 
. O 
The O 
present O 
study O 
was O 
designed O 
to O 
test O 
the O 
hypothesis O 
that O 
alcohol B-FAMILY 
alters O 
global O 
DNA O 
methylation O 
, O 
and O 
modulates O 
expression O 
of O 
the O 
DNA O 
methyltransferases O 
( O 
DNMTs O 
) O 
and O 
various O 
methyl B-SYSTEMATIC 
CpG I-SYSTEMATIC 
-binding O 
proteins O 
. O 
Murine O 
embryonic O 
fibroblasts O 
( O 
MEFs O 
) O 
, O 
utilized O 
as O 
an O 
in O 
vitro O 
embryonic O 
model O 
system O 
, O 
demonstrated O 
∼5% O 
reduction O 
in O 
global O 
DNA O 
methylation O 
following O 
exposure O 
to O 
200mM O 
ethanol B-SYSTEMATIC 
. O 
In O 
addition O 
, O 
ethanol B-SYSTEMATIC 
induced O 
degradation O 
of O 
DNA O 
methyltransferases O 
( O 
DNMT-1 O 
, O 
DNMT-3a O 
, O 
and O 
DNMT-3b O 
) O 
, O 
as O 
well O 
as O 
the O 
methyl B-SYSTEMATIC 
CpG I-SYSTEMATIC 
-binding O 
proteins O 
( O 
MeCP-2 O 
, O 
MBD-2 O 
and O 
MBD-3 O 
) O 
, O 
in O 
MEF O 
cells O 
by O 
the O 
proteasomal O 
pathway O 
. O 
Such O 
degradation O 
could O 
be O 
completely O 
rescued O 
by O 
pretreatment O 
of O 
MEF O 
cells O 
with O 
the O 
proteasomal O 
inhibitor O 
, O 
MG-132 B-IDENTIFIER 
. O 
These O 
data O 
support O 
a O 
potential O 
epigenetic O 
molecular O 
mechanism O 
underlying O 
the O 
pathogenesis O 
of O 
FAS O 
during O 
mammalian O 
development O 
. O 

hepatocyte O 
cultures O 
are O 
now O 
considered O 
as O 
convenient O 
models O 
for O 
in O 
vitro O 
analyzing O 
liver O 
drug O 
transport O 
. O 
However O 
, O 
if O 
primary O 
human O 
and O 
rat O 
hepatocytes O 
have O 
been O 
well O 
- O 
characterized O 
with O 
respect O 
to O 
drug O 
transporter O 
expression O 
and O 
regulation O 
, O 
much O 
less O 
is O 
known O 
for O 
primary O 
mouse O 
hepatocytes O 
. O 
The O 
present O 
study O 
was O 
therefore O 
designed O 
to O 
gain O 
insights O 
about O 
this O 
point O 
. O 
The O 
profile O 
of O 
sinusoidal O 
and O 
canalicular O 
drug O 
transporter O 
mRNA O 
expression O 
in O 
short O 
time O 
(4h)-cultured O 
mouse O 
hepatocytes O 
was O 
found O 
to O 
be O 
highly O 
correlated O 
with O 
that O 
of O 
freshly O 
isolated O 
hepatocytes O 
; O 
by O 
contrast O 
, O 
those O 
of O 
counterparts O 
cultured O 
for O 
a O 
longer O 
time O 
( O 
until O 
4days O 
) O 
either O 
in O 
monolayer O 
configurations O 
on O 
plastic O 
or O 
collagen O 
or O 
in O 
sandwich O 
configuration O 
with O 
matrigel O 
were O 
profoundly O 
altered O 
: O 
uptake O 
drug O 
transporters O 
such O 
as O 
Oct1 O 
, O 
Oatps O 
and O 
Oat2 O 
were O 
thus O 
down O 
- O 
regulated O 
, O 
whereas O 
most O 
of O 
efflux O 
transporters O 
such O 
as O 
Mdr1a O 
/ O 
b O 
, O 
Mrp3 O 
, O 
Mrp4 O 
and O 
Bcrp O 
were O 
induced O 
. O 
Moreover O 
, O 
short O 
time O 
- O 
cultured O 
hepatocytes O 
exhibited O 
the O 
highest O 
levels O 
of O 
sinusoidal O 
influx O 
transporter O 
activities O 
. O 
Transporter O 
- O 
mediated O 
drug O 
secretion O 
into O 
canalicular O 
networks O 
was O 
however O 
only O 
observed O 
in O 
sandwich O 
- O 
cultured O 
hepatocytes O 
. O 
Mouse O 
hepatocytes O 
cultured O 
either O 
in O 
monolayer O 
or O 
sandwich O 
configurations O 
were O 
finally O 
shown O 
to O 
exhibit O 
up O 
- O 
regulation O 
of O 
referent O 
transporters O 
in O 
response O 
to O 
exposure O 
to O 
prototypical O 
activators O 
of O 
the O 
drug O 
sensing O 
receptors O 
pregnane B-TRIVIAL 
X O 
receptor O 
, O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
or O 
constitutive O 
androstane B-TRIVIAL 
receptor O 
. O 
Taken O 
together O 
, O 
these O 
data O 
demonstrate O 
the O 
feasibility O 
of O 
using O 
primary O 
mouse O 
hepatocytes O 
for O 
investigating O 
potential O 
interactions O 
of O 
xenobiotics O 
with O 
hepatic O 
transporter O 
activity O 
or O 
regulation O 
, O 
provided O 
that O 
adequate O 
culture O 
conditions O 
are O 
retained O 
. O 

and O 
NF-κB-dependent O 
induction O 
of O 
interleukin-6 O 
by O 
co O 
- O 
exposure O 
to O 
the O 
environmental O 
contaminant O 
benzanthracene B-SYSTEMATIC 
and O 
the O 
cytokine O 
tumor O 
necrosis O 
factor-α O 
in O 
human O 
mammary O 
MCF-7 O 
cells O 
. O 

to O 
environmental O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PAHs B-ABBREVIATION 
) O 
and O 
interleukin O 
(IL)-1β O 
induces O 
expression O 
of O 
the O 
tumor O 
- O 
promoting O 
cytokine O 
IL-6 O 
in O 
cancer O 
cells O 
. O 
The O 
present O 
study O 
was O 
designed O 
to O 
determine O 
whether O 
such O 
an O 
IL-6 O 
up O 
- O 
regulation O 
also O 
occurs O 
in O 
response O 
to O 
co O 
- O 
treatment O 
by O 
PAHs B-ABBREVIATION 
and O 
tumor O 
necrosis O 
factor O 
(TNF)-α O 
, O 
an O 
inflammatory O 
cytokine O 
commonly O 
found O 
in O 
tumor O 
microenvironment O 
. O 
Co-exposure O 
to O 
the O 
prototypical O 
PAH B-ABBREVIATION 
benzanthracene B-SYSTEMATIC 
( O 
BZA B-ABBREVIATION 
) O 
and O 
TNF-α O 
was O 
found O 
to O 
markedly O 
induce O 
mRNA O 
expression O 
and O 
secretion O 
of O 
IL-6 O 
in O 
human O 
breast O 
cancer O 
cells O 
MCF-7 O 
, O 
whereas O 
exposure O 
to O 
either O 
BZA B-ABBREVIATION 
or O 
TNF-α O 
alone O 
was O 
without O 
significant O 
effect O 
. O 
Co O 
- O 
treatment O 
by O 
BZA B-ABBREVIATION 
and O 
TNF-α O 
- O 
containing O 
conditioned O 
media O 
from O 
human O 
inflammatory O 
macrophages O 
similarly O 
up O 
- O 
regulated O 
IL-6 O 
expression O 
in O 
MCF-7 O 
cells O 
. O 
BZA B-ABBREVIATION 
/ O 
TNF-α O 
- O 
mediated O 
IL-6 O 
induction O 
in O 
MCF-7 O 
cells O 
was O 
counteracted O 
by O 
silencing O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AhR O 
) O 
, O 
known O 
to O 
mediates O 
most O 
of O 
PAH B-ABBREVIATION 
effects O 
. O 
IL-6 O 
up O 
- O 
regulation O 
was O 
moreover O 
associated O 
with O 
NF-κB O 
activation O 
and O 
was O 
abolished O 
by O 
using O 
chemical O 
NF-κB O 
inhibitors O 
or O 
knocking O 
- O 
down O 
expression O 
of O 
the O 
p65 O 
/ O 
RelA O 
NF-κB O 
subunit O 
. O 
Taken O 
together O 
, O 
these O 
data O 
indicate O 
that O 
co O 
- O 
exposure O 
to O 
BZA B-ABBREVIATION 
/ O 
TNF-α O 
induces O 
IL-6 O 
expression O 
by O 
AhR- O 
and O 
NF-κB-dependent O 
pathways O 
in O 
MCF-7 O 
cancer O 
cells O 
. O 
This O 
regulation O 
of O 
IL-6 O 
by O 
environmental O 
PAHs B-ABBREVIATION 
, O 
that O 
is O 
dependent O 
of O 
inflammatory O 
cytokine O 
microenvironment O 
, O 
may O 
contribute O 
to O 
the O 
well O 
- O 
known O 
carcinogenic O 
properties O 
of O 
these O 
organic O 
pollutants O 
. O 

prevents O 
protein O 
nitration O 
and O 
glycolytic O 
block O 
of O 
proliferation O 
in O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
insulted O 
cultured O 
neuronal O 
precursor O 
cells O 
( O 
NPCs O 
) O 
: O 
Implications O 
on O 
CNS O 
regeneration O 
. O 

along O 
with O 
optimal O 
proliferation O 
of O 
neuronal O 
precursors O 
determines O 
the O 
outcomes O 
of O 
the O 
endogenous O 
cellular O 
repair O 
in O 
CNS O 
. O 
Cellular O 
- O 
oxidation O 
based O 
cell O 
death O 
has O 
been O 
described O 
in O 
several O 
neurodegenerative O 
disorders O 
. O 
Therefore O 
, O 
this O 
study O 
was O 
aimed O 
at O 
the O 
identification O 
of O 
the O 
potent O 
targets O 
of O 
oxidative O 
damage O 
to O 
the O 
neuronal O 
precursors O 
and O 
its O 
effective O 
prevention O 
by O 
a O 
natural O 
flavonoid O 
, O 
Quercetin B-TRIVIAL 
. O 
Neuronal O 
precursor O 
cells O 
( O 
NPCs O 
) O 
, O 
Nestin+ O 
and O 
GFAP O 
( O 
Glial O 
fibrillary O 
acidic O 
protein)+ O 
were O 
isolated O 
and O 
cultured O 
from O 
adult O 
rat O 
SVZ O 
( O 
subventricular O 
zone O 
) O 
. O 
These O 
cells O 
were O 
challenged O 
with O 
a O 
single O 
dose O 
of O 
H2O2 B-FORMULA 
( O 
50μM O 
) O 
and O 
/ O 
or O 
pre O 
- O 
treated O 
with O 
different O 
concentrations O 
of O 
Quercetin B-TRIVIAL 
. O 
H2O2 B-FORMULA 
severely O 
limited O 
the O 
cellular O 
viability O 
and O 
expansion O 
of O 
the O 
neurospheres O 
. O 
Cellular O 
- O 
oxidation O 
studies O 
revealed O 
reduction O 
in O 
glutathione B-TRIVIAL 
dependent O 
redox O 
buffering O 
along O 
with O 
depletion O 
of O 
enzymatic O 
cellular O 
antioxidants O 
that O 
might O 
potentiate O 
the O 
nitrite B-SYSTEMATIC 
( O 
NO2(-) B-FORMULA 
) O 
and O 
superoxide B-TRIVIAL 
anion O 
( O 
O2(-) B-FORMULA 
) O 
mediated O 
peroxynitrite B-SYSTEMATIC 
( O 
ONOO(-) B-FORMULA 
) O 
formation O 
and O 
irreversible O 
protein O 
nitration O 
. O 
We O 
identified O 
depleted O 
PK-M2 O 
( O 
M2 O 
isoform O 
of O 
pyruvate B-TRIVIAL 
kinase O 
) O 
activity O 
and O 
apoptosis O 
of O 
NPCs O 
revealed O 
by O 
the O 
genomic O 
DNA O 
fragmentation O 
and O 
elevated O 
PARP O 
( O 
poly B-FAMILY 
ADP I-FAMILY 
ribose I-FAMILY 
polymerase O 
) O 
activity O 
along O 
with O 
increased O 
Caspase O 
activity O 
initiated O 
by O 
severely O 
depolarised O 
mitochondrial O 
membranes O 
. O 
However O 
, O 
the O 
pre O 
- O 
treatment O 
of O 
Quercetin B-TRIVIAL 
in O 
a O 
dose O 
- O 
response O 
manner O 
prevented O 
these O 
changes O 
and O 
restored O 
the O 
expansion O 
of O 
neurospheres O 
preferably O 
by O 
neutralizing O 
the O 
oxidative O 
conditions O 
and O 
thereby O 
reducing O 
peroxynitrite B-SYSTEMATIC 
formation O 
, O 
protein O 
nitration O 
and O 
PK-M2 O 
depletion O 
. O 
Our O 
results O 
unravel O 
the O 
potential O 
interactions O 
of O 
oxidative O 
environment O 
and O 
respiration O 
in O 
the O 
survival O 
and O 
activation O 
of O 
precursors O 
and O 
offer O 
a O 
promise O 
shown O 
by O 
a O 
natural O 
flavonoid B-FAMILY 
in O 
the O 
protective O 
strategy O 
for O 
neuronal O 
precursors O 
of O 
adult O 
brain O 
. O 

Golgi O 
apparatus O 
undergoes O 
morphological O 
changes O 
under O 
stress O 
or O 
malignant O 
transformation O 
, O 
but O 
the O 
precise O 
mechanisms O 
are O 
not O 
known O 
. O 
We O 
recently O 
showed O 
that O 
non-muscle O 
myosin O 
IIA O 
( O 
NMIIA O 
) O 
binds O 
to O 
the O 
cytoplasmic O 
tail O 
of O 
Core O 
2 O 
N B-FORMULA 
-acetylglucosaminyltransferase O 
mucus O 
- O 
type O 
( O 
C2GnT-M O 
) O 
and O 
transports O 
it O 
to O 
the O 
endoplasmic O 
reticulum O 
for O 
recycling O 
. O 
Here O 
, O 
we O 
report O 
that O 
Golgi O 
fragmentation O 
induced O 
by O 
brefeldin B-TRIVIAL 
A I-TRIVIAL 
( O 
BFA B-ABBREVIATION 
) O 
or O 
coatomer O 
protein O 
( O 
β-COP O 
) O 
knockdown O 
( O 
KD O 
) O 
in O 
Panc1-bC2GnT-M O 
( O 
c-Myc O 
) O 
cells O 
is O 
accompanied O 
by O 
the O 
increased O 
association O 
of O 
NMIIA O 
with O 
C2GnT-M O 
and O 
its O 
degradation O 
by O 
proteasomes O 
. O 
Golgi O 
fragmentation O 
is O 
prevented O 
by O 
inhibition O 
or O 
KD O 
of O 
NMIIA O 
. O 
Using O 
multiple O 
approaches O 
, O 
we O 
have O 
shown O 
that O 
the O 
speed O 
of O 
BFA B-ABBREVIATION 
-induced O 
Golgi O 
fragmentation O 
is O 
positively O 
correlated O 
with O 
the O 
levels O 
of O 
this O 
enzyme O 
in O 
the O 
Golgi O 
. O 
The O 
observation O 
is O 
reproduced O 
in O 
LNCaP O 
cells O 
which O 
express O 
high O 
levels O 
of O 
two O 
endogenous O 
glycosyltransferases-C2GnT-L O 
and O 
β-galactoside O 
α2,3 O 
sialyltransferase O 
1 O 
. O 
NMIIA O 
is O 
found O 
to O 
form O 
complexes O 
with O 
these O 
two O 
enzymes O 
but O 
not O 
Golgi O 
matrix O 
proteins O 
. O 
The O 
KD O 
of O 
both O 
enzymes O 
or O 
the O 
prevention O 
of O 
Golgi O 
glycosyltransferases O 
from O 
exiting O 
endoplasmic O 
reticulum O 
reduced O 
Golgi O 
- O 
associated O 
NMIIA O 
and O 
decreased O 
the O 
BFA B-ABBREVIATION 
-induced O 
fragmentation O 
. O 
Interestingly O 
, O 
the O 
fragmented O 
Golgi O 
detected O 
in O 
colon O 
cancer O 
HT-29 O 
cells O 
can O 
be O 
restored O 
to O 
a O 
compact O 
morphology O 
after O 
inhibition O 
or O 
KD O 
of O 
NMIIA O 
. O 
The O 
Golgi O 
disorganization O 
induced O 
by O 
the O 
microtubule O 
or O 
actin O 
destructive O 
agent O 
is O 
NMIIA O 
- O 
independent O 
and O 
does O 
not O 
affect O 
the O 
levels O 
of O 
glycosyltransferases O 
. O 
We O 
conclude O 
that O 
NMIIA O 
interacts O 
with O 
Golgi O 
residential O 
but O 
not O 
matrix O 
proteins O 
, O 
and O 
this O 
interaction O 
is O 
responsible O 
for O 
Golgi O 
fragmentation O 
induced O 
by O 
β-COP O 
KD O 
or O 
BFA B-ABBREVIATION 
treatment O 
. O 
This O 
is O 
a O 
novel O 
non-enzymatic O 
function O 
of O 
Golgi O 
glycosyltransferases O 
. O 

active O 
efflux O 
by O 
p-glycoprotein O 
and O 
breast O 
cancer O 
resistance O 
protein O 
at O 
the O 
blood O 
- O 
brain O 
barrier O 
leads O 
to O 
nonlinear O 
distribution O 
of O 
elacridar B-TRIVIAL 
to O 
the O 
central O 
nervous O 
system O 
. O 

study O 
objective O 
was O 
to O 
investigate O 
factors O 
that O 
affect O 
the O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
distribution O 
of O 
elacridar B-TRIVIAL 
. O 
Elacridar B-TRIVIAL 
inhibits O 
transport O 
mediated O 
by O 
P-glycoprotein O 
( O 
P-gp O 
) O 
and O 
breast O 
cancer O 
resistance O 
protein O 
( O 
Bcrp O 
) O 
and O 
has O 
been O 
used O 
to O 
study O 
the O 
influence O 
of O 
transporters O 
on O 
brain O 
distribution O 
of O 
chemotherapeutics O 
. O 
Adequate O 
distribution O 
of O 
elacridar B-TRIVIAL 
across O 
the O 
blood O 
- O 
brain O 
barrier O 
( O 
BBB O 
) O 
and O 
into O 
the O 
brain O 
parenchyma O 
is O 
necessary O 
to O 
target O 
tumor O 
cells O 
in O 
the O 
brain O 
that O 
overexpress O 
transporters O 
and O 
reside O 
behind O 
an O 
intact O 
BBB O 
. O 
We O 
examined O 
the O 
role O 
of O 
P-gp O 
and O 
Bcrp O 
on O 
brain O 
penetration O 
of O 
elacridar B-TRIVIAL 
using O 
Friend O 
leukemia O 
virus O 
strain O 
B O 
wild O 
- O 
type O 
, O 
Mdr1a O 
/ O 
b(- O 
/ O 
- O 
) O 
, O 
Bcrp1(- O 
/ O 
- O 
) O 
, O 
and O 
Mdr1a O 
/ O 
b(- O 
/ O 
-)Bcrp1(- O 
/ O 
- O 
) O 
mice O 
. O 
Initially O 
, O 
the O 
mice O 
were O 
administered O 
2.5 O 
mg O 
/ O 
kg O 
of O 
elacridar B-TRIVIAL 
intravenously O 
, O 
and O 
the O 
plasma O 
and O 
brain O 
concentrations O 
were O 
determined O 
. O 
The O 
brain O 
- O 
to O 
- O 
plasma O 
partition O 
coefficient O 
of O 
elacridar B-TRIVIAL 
in O 
the O 
wild O 
- O 
type O 
mice O 
was O 
0.82 O 
, O 
as O 
compared O 
with O 
3.5 O 
in O 
Mdr1a O 
/ O 
b(- O 
/ O 
- O 
) O 
mice O 
, O 
6.6 O 
in O 
Bcrp1(- O 
/ O 
- O 
) O 
mice O 
, O 
and O 
15 O 
in O 
Mdr1a O 
/ O 
b(- O 
/ O 
-)Bcrp1(- O 
/ O 
- O 
) O 
mice O 
, O 
indicating O 
that O 
both O 
P-gp O 
and O 
Bcrp O 
limit O 
the O 
brain O 
distribution O 
of O 
elacridar B-TRIVIAL 
. O 
The O 
four O 
genotypes O 
were O 
then O 
administered O 
increasing O 
doses O 
of O 
elacridar B-TRIVIAL 
, O 
and O 
the O 
CNS O 
distribution O 
of O 
elacridar B-TRIVIAL 
was O 
determined O 
. O 
The O 
observed O 
and O 
model O 
predicted O 
maximum O 
brain O 
- O 
to O 
- O 
plasma O 
ratios O 
( O 
Emax O 
) O 
at O 
the O 
highest O 
dose O 
were O 
not O 
significantly O 
different O 
in O 
all O 
genotypes O 
. O 
However O 
, O 
the O 
ED50 O 
was O 
lower O 
for O 
Mdr1a O 
/ O 
b(- O 
/ O 
- O 
) O 
mice O 
compared O 
with O 
Bcrp1(- O 
/ O 
- O 
) O 
mice O 
. O 
These O 
findings O 
correlate O 
with O 
the O 
relative O 
expression O 
of O 
P-gp O 
and O 
Bcrp O 
at O 
the O 
BBB O 
in O 
these O 
mice O 
and O 
demonstrate O 
the O 
quantitative O 
enhancement O 
in O 
elacridar O 
CNS O 
distribution O 
as O 
a O 
function O 
of O 
its O 
dose O 
. O 
Overall O 
, O 
this O 
study O 
provides O 
useful O 
concepts O 
for O 
future O 
applications O 
of O 
elacridar B-TRIVIAL 
as O 
an O 
adjuvant O 
therapy O 
to O 
improve O 
targeting O 
of O 
chemotherapeutic O 
agents O 
to O 
tumor O 
cells O 
in O 
the O 
brain O 
parenchyma O 
. O 

layer O 
deposition O 
of O 
a O 
submonolayer O 
catalyst O 
for O 
the O 
enhanced O 
photoelectrochemical O 
performance O 
of O 
water O 
oxidation O 
with O 
hematite B-TRIVIAL 
. O 

photoanodes O 
were O 
coated O 
with O 
an O 
ultrathin O 
cobalt B-SYSTEMATIC 
oxide I-SYSTEMATIC 
layer O 
by O 
atomic O 
layer O 
deposition O 
( O 
ALD O 
) O 
. O 
The O 
optimal O 
coating-1 O 
ALD O 
cycle O 
, O 
which O 
amounts O 
to O 
< O 
1 O 
monolayer O 
of O 
Co(OH)2 B-FORMULA 
/ O 
Co3O4 B-FORMULA 
-resulted O 
in O 
significantly O 
enhanced O 
photoelectrochemical O 
water O 
oxidation O 
performance O 
. O 
A O 
stable O 
, O 
100-200 O 
mV O 
cathodic O 
shift O 
in O 
the O 
photocurrent O 
onset O 
potential O 
was O 
observed O 
that O 
is O 
correlated O 
to O 
an O 
order O 
of O 
magnitude O 
reduction O 
in O 
the O 
resistance O 
to O 
charge O 
transfer O 
at O 
the O 
Fe2O3 B-FORMULA 
/ O 
H2O B-FORMULA 
interface O 
. O 
Furthermore O 
, O 
the O 
optical O 
transparency O 
of O 
the O 
ultrathin O 
Co(OH)2 B-FORMULA 
/ O 
Co3O4 B-FORMULA 
coating O 
establishes O 
it O 
as O 
a O 
particularly O 
advantageous O 
treatment O 
for O 
nanostructured O 
water O 
oxidation O 
photoanodes O 
. O 
The O 
photocurrent O 
of O 
catalyst O 
- O 
coated O 
nanostructured O 
inverse O 
opal O 
scaffold O 
hematite B-TRIVIAL 
photoanodes O 
reached O 
0.81 O 
and O 
2.1 O 
mA O 
/ O 
cm(2) O 
at O 
1.23 O 
and O 
1.53 O 
V O 
, O 
respectively O 
. O 

detailed O 
look O 
at O 
the O 
reaction O 
mechanisms O 
of O 
substituted O 
carbenes B-FAMILY 
with O 
water O 
. O 

competitive O 
reaction O 
mechanisms O 
for O 
the O 
gas-phase O 
chemical O 
transformation O 
of O 
singlet O 
chlorocarbene B-SYSTEMATIC 
into O 
chloromethanol B-SYSTEMATIC 
in O 
the O 
presence O 
of O 
one O 
and O 
two O 
water O 
molecules O 
are O 
examined O 
in O 
detail O 
. O 
An O 
analysis O 
of O 
bond O 
orders O 
and O 
bond O 
order O 
derivatives O 
as O 
well O 
as O 
of O 
properties O 
of O 
bond O 
critical O 
points O 
in O 
the O 
electron O 
densities O 
along O 
the O 
intrinsic O 
reaction O 
coordinates O 
( O 
IRCs O 
for O 
intermediates O 
→ O 
transition O 
state O 
( O 
TS O 
) O 
→ O 
products O 
) O 
suggests O 
that O 
, O 
from O 
the O 
perspective O 
of O 
bond O 
breaking O 
/ O 
formation O 
, O 
both O 
reactions O 
should O 
be O 
considered O 
to O 
be O 
highly O 
nonsynchronous O 
, O 
concerted O 
processes O 
. O 
Both O 
transition O 
states O 
are O 
early O 
, O 
resembling O 
the O 
intermediates O 
, O 
yielding O 
rate O 
constants O 
whose O 
magnitudes O 
are O 
mostly O 
influenced O 
by O 
structural O 
changes O 
and O 
to O 
a O 
lesser O 
degree O 
by O 
bond O 
breaking O 
/ O 
formation O 
. O 
For O 
the O 
case O 
of O 
one O 
water O 
molecule O 
, O 
most O 
of O 
the O 
energy O 
in O 
the O 
reactants O 
region O 
of O 
the O 
IRC O 
is O 
used O 
for O 
structural O 
changes O 
, O 
while O 
the O 
transition O 
state O 
region O 
encompasses O 
the O 
majority O 
of O 
electron O 
activity O 
, O 
except O 
for O 
the O 
formation O 
of O 
the O 
C-O B-FORMULA 
bond O 
, O 
which O 
extends O 
well O 
into O 
the O 
products O 
region O 
. O 
In O 
the O 
case O 
of O 
two O 
water O 
molecules O 
, O 
very O 
little O 
electron O 
flux O 
and O 
comparatively O 
less O 
work O 
required O 
for O 
structural O 
changes O 
is O 
noticed O 
in O 
the O 
reactants O 
region O 
, O 
leading O 
to O 
an O 
earlier O 
transition O 
state O 
and O 
therefore O 
to O 
a O 
smaller O 
activation O 
energy O 
and O 
to O 
a O 
larger O 
rate O 
constant O 
. O 
This O 
, O 
together O 
with O 
evidence O 
gathered O 
from O 
other O 
sources O 
, O 
allows O 
us O 
to O 
provide O 
plausible O 
explanations O 
for O 
the O 
observed O 
difference O 
in O 
rate O 
constants O 
. O 

and O 
micelles O 
find O 
various O 
applications O 
as O 
potential O 
solubilizers O 
in O 
extraction O 
processes O 
or O 
in O 
drug O 
delivery O 
systems O 
. O 
Thermodynamic O 
and O 
transport O 
processes O 
governing O 
the O 
interactions O 
of O 
different O 
kinds O 
of O 
solutes O 
in O 
liposomes O 
or O 
micelles O 
can O 
be O 
analyzed O 
regarding O 
the O 
free O 
energy O 
profiles O 
of O 
the O 
solutes O 
in O 
the O 
system O 
. O 
However O 
, O 
free O 
energy O 
profiles O 
in O 
heterogeneous O 
systems O 
such O 
as O 
micelles O 
are O 
experimentally O 
almost O 
not O 
accessible O 
. O 
Therefore O 
, O 
the O 
development O 
of O 
predictive O 
methods O 
is O 
desirable O 
. O 
Molecular O 
dynamics O 
( O 
MD O 
) O 
simulations O 
reliably O 
simulate O 
the O 
structure O 
and O 
dynamics O 
of O 
lipid O 
membranes O 
and O 
micelles O 
, O 
whereas O 
COSMO-RS O 
accurately O 
reproduces O 
solvation O 
free O 
energies O 
in O 
different O 
solvents O 
. O 
For O 
the O 
first O 
time O 
, O 
free O 
energy O 
profiles O 
in O 
micellar O 
systems O 
, O 
as O 
well O 
as O 
mixed O 
lipid O 
bilayers O 
, O 
are O 
investigated O 
, O 
taking O 
advantage O 
of O 
both O 
methods O 
: O 
MD O 
simulations O 
and O 
COSMO-RS O 
, O 
referred O 
to O 
as O 
COSMOmic O 
( O 
Klamt O 
, O 
A O 
. O 
; O 
Huniar O 
, O 
U O 
. O 
; O 
Spycher O 
, O 
S O 
. O 
; O 
Keldenich O 
, O 
J O 
. O 
COSMOmic O 
: O 
A O 
Mechanistic O 
Approach O 
to O 
the O 
Calculation O 
of O 
Membrane-Water O 
Partition O 
Coefficients O 
and O 
Internal O 
Distributions O 
within O 
Membranes O 
and O 
Micelles O 
. O 
J O 
. O 
Phys O 
. O 
Chem O 
. O 
B O 
2008 O 
, O 
112 O 
, O 
12148-12157 O 
) O 
. O 
All O 
- O 
atom O 
molecular O 
dynamics O 
simulations O 
of O 
the O 
system O 
SDS B-ABBREVIATION 
/ O 
water O 
and O 
CTAB B-ABBREVIATION 
/ O 
water O 
have O 
been O 
applied O 
in O 
order O 
to O 
retrieve O 
representative O 
micelle O 
structures O 
for O 
further O 
analysis O 
with O 
COSMOmic O 
. O 
For O 
the O 
system O 
CTAB B-ABBREVIATION 
/ O 
water O 
, O 
different O 
surfactant O 
concentrations O 
were O 
considered O 
, O 
which O 
results O 
in O 
different O 
micelle O 
sizes O 
. O 
Free O 
energy O 
profiles O 
of O 
more O 
than O 
200 O 
solutes O 
were O 
predicted O 
and O 
validated O 
by O 
means O 
of O 
experimental O 
partition O 
coefficients O 
. O 
To O 
our O 
knowledge O 
, O 
these O 
are O 
the O 
first O 
quantitative O 
predictions O 
of O 
micelle O 
/ O 
water O 
partition O 
coefficients O 
, O 
which O 
are O 
based O 
on O 
whole O 
free O 
energy O 
profiles O 
from O 
molecular O 
methods O 
. O 
Further O 
, O 
the O 
partitioning O 
in O 
lipid O 
bilayer O 
systems O 
containing O 
different O 
hydrophobic O 
tail O 
groups O 
( O 
DOPC B-ABBREVIATION 
( O 
1,2-dioleoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
) O 
, O 
SOPC B-ABBREVIATION 
( O 
stearoyl-oleoylphosphatidylcholine B-TRIVIAL 
) O 
, O 
DMPC B-ABBREVIATION 
( O 
1,2-dimyristoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
) O 
, O 
and O 
POPC B-ABBREVIATION 
( O 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
) O 
) O 
as O 
well O 
as O 
mixed O 
bilayers O 
was O 
calculated O 
. O 
Experimental O 
partition O 
coefficients O 
( O 
log O 
P O 
) O 
were O 
reproduced O 
with O 
a O 
root O 
- O 
mean O 
- O 
square O 
error O 
( O 
RMSE O 
) O 
of O 
0.62 O 
. O 
To O 
determine O 
the O 
influence O 
of O 
cholesterol B-TRIVIAL 
as O 
an O 
important O 
component O 
of O 
cellular O 
membranes O 
, O 
free O 
energy O 
profiles O 
in O 
the O 
presence O 
of O 
cholesterol B-TRIVIAL 
were O 
calculated O 
and O 
shown O 
to O 
be O 
in O 
good O 
agreement O 
with O 
experimental O 
data O 
. O 

adsorption O 
of O 
polyacrylamide B-SYSTEMATIC 
-based O 
polymers O 
on O 
anisotropic O 
Basal O 
planes O 
of O 
kaolinite B-TRIVIAL 
using O 
quartz B-TRIVIAL 
crystal O 
microbalance O 
. O 

crystal O 
microbalance O 
with O 
dissipation O 
( O 
QCM-D O 
) O 
was O 
applied O 
to O 
investigate O 
the O 
adsorption O 
characteristics O 
of O 
polyacrylamide B-SYSTEMATIC 
-based O 
polymers O 
( O 
PAMs B-FAMILY 
) O 
on O 
anisotropic O 
basal O 
planes O 
of O 
kaolinite B-TRIVIAL 
. O 
Kaolinite B-TRIVIAL 
basal O 
planes O 
were O 
differentiated O 
by O 
depositing O 
kaolinite B-TRIVIAL 
nanoparticles O 
( O 
KNPs O 
) O 
on O 
silica B-TRIVIAL 
and O 
alumina B-TRIVIAL 
sensors O 
in O 
solutions O 
of O 
controlled O 
pH O 
values O 
. O 
Adsorption O 
of O 
an O 
in O 
- O 
house O 
synthesized O 
organic O 
- O 
inorganic O 
Al(OH)3-PAM B-FORMULA 
( O 
Al-PAM B-FORMULA 
) O 
as O 
an O 
example O 
of O 
cationic O 
hybrid O 
PAM B-ABBREVIATION 
and O 
a O 
commercially O 
available O 
partially O 
hydrolyzed O 
polyacrylamide B-SYSTEMATIC 
( O 
MF1011 B-IDENTIFIER 
) O 
as O 
an O 
example O 
of O 
anionic B-ABBREVIATION 
PAM I-ABBREVIATION 
was O 
studied O 
. O 
Cationic B-ABBREVIATION 
Al-PAM I-ABBREVIATION 
was O 
found O 
to O 
adsorb O 
irreversibly O 
and O 
preferentially O 
on O 
tetrahedral O 
silica B-TRIVIAL 
basal O 
planes O 
of O 
kaolinite B-TRIVIAL 
. O 
In O 
contrast O 
, O 
anionic B-IDENTIFIER 
MF1011 I-IDENTIFIER 
adsorbed O 
strongly O 
on O 
aluminum B-SYSTEMATIC 
- I-SYSTEMATIC 
hydroxy I-SYSTEMATIC 
basal O 
planes O 
, O 
while O 
its O 
adsorption O 
on O 
tetrahedral O 
silica B-TRIVIAL 
basal O 
planes O 
was O 
weak O 
and O 
reversible O 
. O 
Adsorption O 
study O 
revealed O 
that O 
both O 
electrostatic O 
attraction O 
and O 
hydrogen B-SYSTEMATIC 
-bonding O 
mechanisms O 
contribute O 
to O 
adsorption O 
of O 
PAMs B-FAMILY 
on O 
kaolinite B-TRIVIAL 
. O 
The O 
adsorbed O 
Al-PAM B-FORMULA 
layer O 
was O 
able O 
to O 
release O 
trapped O 
water O 
overtime O 
and O 
became O 
more O 
compact O 
, O 
while O 
MF1011 B-IDENTIFIER 
film O 
became O 
more O 
dissipative O 
as O 
backbones O 
stretched O 
out O 
from O 
kaolinite B-TRIVIAL 
surface O 
with O 
minimal O 
overlapping O 
. O 
Experimental O 
results O 
obtained O 
from O 
this O 
study O 
provide O 
clear O 
insights O 
into O 
the O 
phenomenon O 
that O 
governs O 
flocculation O 
- O 
based O 
solid O 
- O 
liquid O 
separation O 
processes O 
using O 
multicomponent O 
flocculants O 
of O 
anionic O 
and O 
cationic O 
nature O 
. O 

effects O 
of O 
cluster O 
size O 
and O 
air O 
exposure O 
on O 
oxygen B-SYSTEMATIC 
reduction O 
and O 
carbon B-SYSTEMATIC 
oxidation O 
electrocatalysis O 
by O 
size O 
- O 
selected O 
Pt(n) B-FAMILY 
( O 
n O 
≤ O 
11 O 
) O 
on O 
glassy B-TRIVIAL 
carbon I-TRIVIAL 
electrodes O 
. O 

Pt(n) B-FAMILY 
/ O 
glassy B-TRIVIAL 
carbon I-TRIVIAL 
electrodes O 
( O 
Pt(n) B-FAMILY 
/ O 
GCE O 
) O 
were O 
prepared O 
by O 
deposition O 
of O 
mass O 
- O 
selected O 
Pt(n)(+) B-FAMILY 
( O 
n O 
≤ O 
11 O 
) O 
on O 
GCE O 
substrates O 
in O 
ultrahigh O 
vacuum O 
. O 
Electrocatalysis O 
under O 
conditions O 
appropriate O 
for O 
the O 
oxygen B-SYSTEMATIC 
reduction O 
reaction O 
( O 
ORR O 
) O 
was O 
studied O 
, O 
for O 
samples O 
both O 
in O 
situ O 
with O 
no O 
exposure O 
to O 
laboratory O 
air O 
and O 
with O 
air O 
exposure O 
prior O 
to O 
electrochemical O 
measurements O 
. O 
Of O 
the O 
small O 
clusters O 
, O 
only O 
a O 
few O 
cluster O 
sizes O 
show O 
the O 
expected O 
ORR O 
activity O 
, O 
and O 
in O 
those O 
cases O 
, O 
the O 
activity O 
per O 
Pt B-FORMULA 
atom O 
is O 
similar O 
to O 
that O 
seen O 
under O 
identical O 
conditions O 
with O 
a O 
conventionally O 
prepared O 
electrode O 
with O 
Pt B-FORMULA 
nanoparticles O 
grown O 
on O 
a O 
GCE O 
. O 
For O 
other O 
small O 
Pt(n) B-FAMILY 
on O 
GCE O 
, O 
any O 
ORR O 
signal O 
is O 
overwhelmed O 
by O 
large O 
oxidative O 
currents O 
attributed O 
to O 
catalysis O 
of O 
carbon B-SYSTEMATIC 
oxidation O 
by O 
water O 
. O 
If O 
the O 
samples O 
are O 
exposed O 
to O 
air O 
prior O 
to O 
electrochemistry O 
, O 
both O 
ORR O 
and O 
carbon B-SYSTEMATIC 
oxidation O 
signals O 
are O 
absent O 
, O 
and O 
instead O 
only O 
small O 
capacitive O 
currents O 
or O 
currents O 
attributed O 
to O 
redox O 
chemistry O 
of O 
adventitious O 
organic O 
adsorbates O 
are O 
observed O 
, O 
indicating O 
that O 
air O 
exposure O 
results O 
in O 
passivation O 
of O 
the O 
small O 
Pt B-FORMULA 
clusters O 
. O 

of O 
chronic O 
dietary O 
selenomethionine B-SYSTEMATIC 
exposure O 
on O 
repeat O 
swimming O 
performance O 
, O 
aerobic O 
metabolism O 
and O 
methionine B-TRIVIAL 
catabolism O 
in O 
adult O 
zebrafish O 
( O 
Danio O 
rerio O 
) O 
. O 

a O 
previous O 
study O 
we O 
reported O 
impaired O 
swimming O 
performance O 
and O 
greater O 
stored O 
energy O 
in O 
adult O 
zebrafish O 
( O 
Danio O 
rerio O 
) O 
after O 
chronic O 
dietary O 
exposure O 
to O 
selenomethionine B-SYSTEMATIC 
( O 
SeMet B-FORMULA 
) O 
. O 
The O 
goal O 
of O 
the O 
present O 
study O 
was O 
to O 
further O 
investigate O 
effects O 
of O 
chronic O 
exposure O 
to O 
dietary O 
SeMet B-FORMULA 
on O 
repeat O 
swimming O 
performance O 
, O 
oxygen B-SYSTEMATIC 
consumption O 
( O 
MO2 O 
) O 
, O 
metabolic O 
capacities O 
( O 
standard O 
metabolic O 
rate O 
[ O 
SMR O 
] O 
, O 
active O 
metabolic O 
rate O 
[ O 
AMR O 
] O 
, O 
factorial O 
aerobic O 
scope O 
[ O 
F-AS O 
] O 
and O 
cost O 
of O 
transport O 
[ O 
COT O 
] O 
) O 
and O 
gene O 
expression O 
of O 
energy O 
metabolism O 
and O 
methionine B-TRIVIAL 
catabolism O 
enzymes O 
in O 
adult O 
zebrafish O 
. O 
Fish O 
were O 
fed O 
SeMet B-FORMULA 
at O 
measured O 
concentrations O 
of O 
1.3 O 
, O 
3.4 O 
, O 
9.8 O 
or O 
27.5 O 
μg O 
Se B-FORMULA 
/g O 
dry O 
mass O 
( O 
d.m O 
. O 
) O 
for O 
90 O 
d O 
. O 
At O 
the O 
end O 
of O 
the O 
exposure O 
period O 
, O 
fish O 
from O 
each O 
treatment O 
group O 
were O 
divided O 
into O 
three O 
subgroups O 
: O 
( O 
a O 
) O 
no O 
swim O 
, O 
( O 
b O 
) O 
swim O 
, O 
and O 
( O 
c O 
) O 
repeat O 
swim O 
. O 
Fish O 
from O 
the O 
no O 
swim O 
group O 
were O 
euthanized O 
immediately O 
at O 
90 O 
d O 
and O 
whole O 
body O 
triglycerides B-FAMILY 
, O 
glycogen O 
and O 
lactate B-FAMILY 
, O 
and O 
gene O 
expression O 
of O 
energy O 
metabolism O 
and O 
methionine B-TRIVIAL 
catabolism O 
enzymes O 
were O 
determined O 
. O 
Individual O 
fish O 
from O 
the O 
swim O 
group O 
were O 
placed O 
in O 
a O 
swim O 
tunnel O 
respirometer O 
and O 
swimming O 
performance O 
was O 
assessed O 
by O 
determining O 
the O 
critical O 
swimming O 
speed O 
(U(crit)) O 
. O 
After O 
both O 
Ucrit O 
and O 
MO2 O 
analyses O 
, O 
fish O 
were O 
euthanized O 
and O 
whole O 
body O 
energy O 
stores O 
and O 
lactate B-FAMILY 
were O 
determined O 
. O 
Similarly O 
, O 
individual O 
fish O 
from O 
the O 
repeat O 
swim O 
group O 
were O 
subjected O 
to O 
two O 
U(crit) O 
tests O 
( O 
U(crit-1) O 
and O 
U(crit-2) O 
) O 
performed O 
with O 
a O 
60 O 
min O 
recovery O 
period O 
between O 
tests O 
, O 
followed O 
by O 
determination O 
of O 
energy O 
stores O 
and O 
lactate B-FAMILY 
. O 
Impaired O 
swim O 
performance O 
was O 
observed O 
in O 
fish O 
fed O 
SeMet B-FORMULA 
at O 
concentrations O 
greater O 
than O 
3 O 
μg O 
Se B-FORMULA 
/g O 
in O 
the O 
diet O 
. O 
However O 
, O 
within O 
each O 
dietary O 
Se B-FORMULA 
treatment O 
group O 
, O 
no O 
significant O 
differences O 
between O 
single O 
and O 
repeat O 
U(crits) O 
were O 
observed O 
. O 
Oxygen B-SYSTEMATIC 
consumption O 
, O 
SMR O 
and O 
COT O 
were O 
significantly O 
greater O 
, O 
and O 
F-AS O 
was O 
significantly O 
lesser O 
, O 
in O 
fish O 
fed O 
SeMet B-FORMULA 
. O 
Whole O 
body O 
triglycerides B-FAMILY 
were O 
proportional O 
to O 
the O 
concentration O 
of O 
SeMet B-FORMULA 
in O 
the O 
diet O 
. O 
While O 
swimming O 
resulted O 
in O 
lesser O 
concentrations O 
of O 
glycogen O 
in O 
the O 
body O 
, O 
exposure O 
to O 
SeMet B-FORMULA 
in O 
the O 
diet O 
had O 
no O 
significant O 
effect O 
on O 
glycogen O 
content O 
. O 
Exposure O 
to O 
SeMet B-FORMULA 
significantly O 
down O 
- O 
regulated O 
mRNA O 
abundance O 
of O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
1B O 
( O 
PTP O 
1B O 
) O 
in O 
muscle O 
, O 
and O 
β-hydroxyacyl B-SYSTEMATIC 
coenzyme I-SYSTEMATIC 
A I-SYSTEMATIC 
dehydrogenase O 
( O 
HOAD O 
) O 
, O 
sterol B-FAMILY 
regulatory O 
element O 
binding O 
protein O 
1 O 
( O 
SREBP O 
1 O 
) O 
and O 
methionine B-TRIVIAL 
adenosyltransferase O 
1 O 
alpha O 
( O 
MAT O 
1A O 
) O 
in O 
liver O 
of O 
adult O 
zebrafish O 
. O 
Overall O 
the O 
results O 
of O 
this O 
study O 
suggest O 
chronic O 
exposure O 
of O 
adult O 
zebrafish O 
to O 
SeMet B-FORMULA 
in O 
the O 
diet O 
can O 
cause O 
both O 
cellular O 
and O 
organismal O 
effects O 
that O 
could O 
affect O 
fitness O 
and O 
survivability O 
of O 
fish O 
. O 

attachment O 
to O 
the O 
dipeptide O 
dialanine B-TRIVIAL 
: O 
influence O 
of O 
methylation O 
on O 
site O 
selective O 
dissociation O 
reactions O 
. O 

phase O 
dissociative O 
electron O 
attachment O 
( O 
DEA O 
) O 
measurements O 
with O 
methyl-dialanine B-SYSTEMATIC 
, O 
C(7)H(14)N(2)O(3) B-FORMULA 
, O 
are O 
performed O 
in O 
a O 
crossed O 
electron O 
- O 
molecular O 
beam O 
experiment O 
at O 
high O 
energy O 
resolution O 
( O 
∼120 O 
meV O 
) O 
. O 
Anion O 
efficiency O 
yields O 
as O 
a O 
function O 
of O 
the O 
incident O 
electron O 
energy O 
are O 
obtained O 
for O 
the O 
most O 
abundant O 
fragments O 
up O 
to O 
electron O 
energies O 
of O 
∼15 O 
eV O 
. O 
There O 
is O 
no O 
evidence O 
of O 
molecular O 
anion O 
formation O 
whereas O 
the O 
dehydrogenated O 
closed O 
shell O 
anion O 
(M-H)(-) O 
is O 
one O 
of O 
the O 
most O 
dominant O 
reaction O 
products O 
. O 
Quantum O 
chemical O 
calculations O 
are O 
performed O 
to O 
investigate O 
the O 
electron O 
attachment O 
process O 
and O 
to O 
elucidate O 
site O 
selective O 
bond O 
cleavage O 
in O 
the O 
(M-H)(-) O 
DEA-channel O 
. O 
Previous O 
DEA O 
studies O 
on O 
dialanine B-TRIVIAL 
have O 
shown O 
that O 
(M-H)(-) O 
formation O 
proceeds O 
through O 
abstraction O 
of O 
a O 
hydrogen B-SYSTEMATIC 
atom O 
from O 
the O 
carboxyl B-SYSTEMATIC 
and O 
amide B-FAMILY 
groups O 
, O 
contributing O 
to O 
two O 
distinct O 
resonances O 
at O 
0.81 O 
and O 
1.17 O 
eV O 
, O 
respectively O 
[ O 
D O 
. O 
Gschliesser O 
, O 
V O 
. O 
Vizcaino O 
, O 
M O 
. O 
Probst O 
, O 
P O 
. O 
Scheier O 
and O 
S O 
. O 
Denifl O 
, O 
Chem.-Eur O 
. O 
J O 
. O 
, O 
2012 O 
, O 
18 O 
, O 
4613-4619 O 
] O 
. O 
Here O 
we O 
show O 
that O 
by O 
methylation O 
of O 
the O 
carboxyl B-SYSTEMATIC 
group O 
, O 
all O 
( O 
calculated O 
) O 
thresholds O 
for O 
H B-FORMULA 
-loss O 
from O 
the O 
different O 
sites O 
in O 
the O 
dialanine B-TRIVIAL 
molecule O 
are O 
shifted O 
up O 
to O 
a O 
maximum O 
of O 
1.4 O 
eV O 
. O 
The O 
lowest O 
lying O 
resonance O 
observed O 
experimentally O 
for O 
(M-H)(-) O 
remains O 
operative O 
from O 
the O 
amide B-FAMILY 
group O 
at O 
the O 
electron O 
energy O 
of O 
2.4 O 
eV O 
due O 
to O 
the O 
methylation O 
. O 
We O 
further O 
study O 
methylation O 
- O 
induced O 
effects O 
on O 
the O 
unimolecular O 
dissociation O 
leading O 
to O 
a O 
variety O 
of O 
negatively O 
charged O 
DEA O 
products O 
. O 

the O 
dielectric O 
response O 
of O 
graphene B-TRIVIAL 
via O 
dual O 
- O 
band O 
plasmonic O 
nanoresonators O 
. O 

this O 
article O 
, O 
we O 
use O 
optical O 
transmission O 
spectroscopy O 
to O 
measure O 
the O 
changes O 
in O 
the O 
resonance O 
features O 
of O 
a O 
Au B-FORMULA 
plasmonic O 
nanoresonator O 
array O 
consisting O 
of O 
concentric O 
ring O 
/ O 
disc O 
cavity O 
elements O 
, O 
when O 
graphene O 
is O 
introduced O 
as O 
an O 
encapsulating O 
medium O 
. O 
We O 
show O 
that O 
by O 
using O 
finite O 
element O 
modelling O 
to O 
best O 
reproduce O 
our O 
experimental O 
results O 
the O 
dielectric O 
response O 
of O 
the O 
graphene B-TRIVIAL 
film O 
can O 
be O 
determined O 
. O 
We O 
discuss O 
the O 
potential O 
of O 
such O 
structures O 
for O 
chemical O 
sensing O 
applications O 
. O 

to O 
microbicide O 
gel O 
use O 
is O 
critical O 
to O 
optimizing O 
effectiveness O 
in O 
preventing O 
human O 
immunodeficiency O 
virus O 
transmission O 
. O 
The O 
authors O 
hypothesized O 
that O 
ester B-FAMILY 
taggants O 
added O 
to O 
vaginal O 
gels O 
would O 
generate O 
exhaled O 
alcohol B-FAMILY 
and O 
ketone B-SYSTEMATIC 
metabolites O 
and O 
provide O 
a O 
" O 
breath O 
test O 
" O 
for O 
vaginal O 
gel O 
use O 
. O 
This O 
2-arm O 
( O 
vaginal O 
and O 
dermal O 
) O 
, O 
randomized O 
, O 
participant O 
- O 
blinded O 
, O 
pilot O 
study O 
tested O 
this O 
hypothesis O 
. O 
On O 
8 O 
visits O 
, O 
healthy O 
women O 
( O 
n O 
= O 
8 O 
) O 
received O 
intravaginal O 
taggant O 
( O 
2-butyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
2-pentyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
isopropyl B-SYSTEMATIC 
butyrate I-SYSTEMATIC 
, O 
or O 
2-pentyl B-SYSTEMATIC 
butyrate I-SYSTEMATIC 
; O 
30 O 
mg O 
) O 
formulated O 
in O 
hydroxyethylcellulose O 
or O 
tenofovir B-TRIVIAL 
placebo O 
gel O 
. O 
A O 
second O 
group O 
( O 
n O 
= O 
4 O 
) O 
of O 
women O 
received O 
the O 
same O 
formulations O 
administered O 
dermally O 
on O 
the O 
forearm O 
to O 
determine O 
if O 
skin O 
administration O 
might O 
confound O 
the O 
system O 
. O 
Breath O 
samples O 
were O 
collected O 
using O 
bags O 
before O 
and O 
after O 
taggant O 
administration O 
for O 
1 O 
hour O 
. O 
Samples O 
were O 
measured O 
using O 
a O 
miniature O 
gas O 
chromatograph O 
and O 
/ O 
or O 
gas O 
chromatography O 
- O 
mass O 
spectroscopy O 
for O 
ester O 
taggant O 
, O 
alcohol B-FAMILY 
, O 
and O 
ketone B-SYSTEMATIC 
concentrations O 
. O 
After O 
vaginal O 
administration O 
, O 
2-butyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
2-pentyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
and O 
metabolites O 
were O 
observed O 
in O 
breath O 
, O 
whereas O 
isopropyl B-SYSTEMATIC 
butyrate I-SYSTEMATIC 
, O 
2-pentyl B-SYSTEMATIC 
butyrate I-SYSTEMATIC 
, O 
and O 
metabolites O 
were O 
not O 
. O 
Some O 
women O 
reported O 
self O 
- O 
resolving O 
, O 
mild O 
burning O 
( O 
24 O 
/ O 
64 O 
visits O 
) O 
with O 
vaginal O 
administration O 
or O 
a O 
" O 
bubblegum O 
" O 
taste O 
( O 
7 O 
/ O 
64 O 
visits O 
) O 
. O 
No O 
taggants O 
or O 
metabolites O 
were O 
detected O 
following O 
dermal O 
application O 
. O 
A O 
" O 
breath O 
test O 
" O 
for O 
adherence O 
to O 
antiretroviral O 
vaginal O 
gel O 
application O 
appears O 
physiologically O 
and O 
technically O 
feasible O 
. O 

of O 
intravenous O 
voriconazole B-TRIVIAL 
in O 
obese O 
patients O 
: O 
implications O 
of O 
CYP2C19 O 
homozygous O 
poor O 
metabolizer O 
genotype O 
. O 

is O 
a O 
paucity O 
of O 
pharmacokinetic O 
studies O 
describing O 
weight O 
- O 
based O 
dosing O 
of O 
intravenous O 
voriconazole B-TRIVIAL 
in O 
obese O 
patients O 
. O 
In O 
this O 
case O 
report O 
, O 
we O 
describe O 
the O 
pharmacokinetics O 
of O 
intravenous O 
voriconazole B-TRIVIAL 
in O 
an O 
obese O 
CYP2C19 O 
homozygous O 
poor O 
metabolizer O 
and O 
review O 
previously O 
reported O 
data O 
regarding O 
the O 
use O 
of O 
intravenous O 
voriconazole B-TRIVIAL 
in O 
obese O 
patients O 
. O 
A O 
17-year- O 
old O 
obese O 
Hispanic O 
male O 
patient O 
( O 
body O 
mass O 
index O 
35 O 
kg O 
/ O 
m(2) O 
) O 
received O 
intravenous O 
voriconazole B-TRIVIAL 
for O 
the O 
treatment O 
of O 
suspected O 
aspergillosis O 
. O 
After O 
2.5 O 
days O 
of O 
voriconazole B-TRIVIAL 
4 O 
mg O 
/ O 
kg O 
intravenously O 
every O 
12 O 
hours O 
based O 
on O 
adjusted O 
body O 
weight O 
, O 
the O 
voriconazole B-TRIVIAL 
area O 
under O 
the O 
serum O 
concentration O 
- O 
time O 
curve O 
over O 
the O 
course O 
of O 
a O 
single O 
( O 
12-hr O 
) O 
dosing O 
interval O 
and O 
trough O 
concentration O 
were O 
86100 O 
ng O 
· O 
hr O 
/ O 
ml O 
and O 
6.2 O 
µg O 
/ O 
ml O 
, O 
respectively O 
. O 
Six O 
days O 
later O 
, O 
the O 
voriconazole B-TRIVIAL 
dosage O 
was O 
decreased O 
. O 
A O 
trough O 
concentration O 
measured O 
just O 
before O 
the O 
dosage O 
reduction O 
( O 
after O 
8.5 O 
days O 
of O 
voriconazole B-TRIVIAL 
4 O 
mg O 
/ O 
kg O 
intravenously O 
every O 
12 O 
hours O 
based O 
on O 
adjusted O 
body O 
weight O 
) O 
remained O 
elevated O 
at O 
5.8 O 
µg O 
/ O 
ml O 
. O 
Genotyping O 
revealed O 
a O 
CYP2C19 O 
homozygous O 
poor O 
metabolizer O 
( O 
CYP2C19*2 O 
/ O 
*2 O 
) O 
. O 
Voriconazole B-TRIVIAL 
was O 
subsequently O 
discontinued O 
due O 
to O 
QTc O 
prolongation O 
. O 
These O 
data O 
and O 
those O 
from O 
two O 
recent O 
publications O 
suggest O 
that O 
voriconazole B-TRIVIAL 
does O 
not O 
distribute O 
extensively O 
into O 
human O 
adipose O 
tissue O 
and O 
that O 
obese O 
patients O 
should O 
be O 
dosed O 
on O 
an O 
adjusted O 
body O 
weight O 
basis O 
. O 
If O 
an O 
obese O 
patient O 
dosed O 
on O 
total O 
body O 
weight O 
is O 
also O 
a O 
CYP2C19 O 
poor O 
metabolizer O 
, O 
serum O 
voriconazole B-TRIVIAL 
concentrations O 
will O 
be O 
further O 
elevated O 
, O 
potentially O 
leading O 
to O 
drug O 
- O 
induced O 
toxicity O 
. O 

geochemistry O 
in O 
a O 
biostimulated O 
aquifer O 
: O 
An O 
aqueous O 
speciation O 
study O 
. O 

microbial O 
growth O 
through O 
the O 
use O 
of O 
acetate O 
injection O 
wells O 
at O 
the O 
former O 
uranium O 
mill O 
site O 
in O 
Rifle O 
, O 
Colorado O 
, O 
USA O 
, O 
has O 
been O 
shown O 
to O 
decrease O 
dissolved O 
uranium B-SYSTEMATIC 
(VI) I-SYSTEMATIC 
concentrations O 
through O 
bacterial O 
reduction O 
to O 
immobile O 
uranium B-SYSTEMATIC 
(IV) I-SYSTEMATIC 
. O 
Bioreduction O 
also O 
changed O 
the O 
redox O 
chemistry O 
of O 
site O 
groundwater O 
, O 
altering O 
the O 
mobility O 
of O 
several O 
other O 
redox O 
- O 
sensitive O 
elements O 
present O 
in O 
the O 
subsurface O 
, O 
including O 
iron B-SYSTEMATIC 
, O 
sulfur B-SYSTEMATIC 
, O 
and O 
arsenic B-SYSTEMATIC 
. O 
Following O 
acetate B-SYSTEMATIC 
amendment O 
at O 
the O 
site O 
, O 
elevated O 
concentrations O 
of O 
arsenic B-SYSTEMATIC 
in O 
the O 
groundwater O 
were O 
observed O 
. O 
Ion O 
chromatography O 
- O 
inductively O 
coupled O 
plasma O 
- O 
mass O 
spectrometry O 
was O 
used O 
to O 
determine O 
the O 
aqueous O 
arsenic B-SYSTEMATIC 
speciation O 
. O 
Upgradient O 
samples O 
, O 
unexposed O 
to O 
acetate B-SYSTEMATIC 
, O 
showed O 
low O 
levels O 
of O 
arsenic B-SYSTEMATIC 
( O 
≈1 O 
μM O 
) O 
, O 
with O 
greater O 
than O 
90% O 
as O 
arsenate B-SYSTEMATIC 
( O 
As[V] B-FORMULA 
) O 
and O 
a O 
small O 
amount O 
of O 
arsenite B-SYSTEMATIC 
( O 
As[III] B-FORMULA 
) O 
. O 
Downgradient O 
acetate B-SYSTEMATIC 
-stimulated O 
water O 
samples O 
had O 
much O 
higher O 
levels O 
of O 
arsenic B-SYSTEMATIC 
( O 
up O 
to O 
8 O 
μM O 
) O 
, O 
and O 
4 O 
additional O 
thioarsenic B-SYSTEMATIC 
species O 
were O 
present O 
under O 
sulfate B-SYSTEMATIC 
-reducing O 
conditions O 
. O 
These O 
thioarsenic B-SYSTEMATIC 
species O 
demonstrate O 
a O 
strong O 
correlation O 
between O 
arsenic B-SYSTEMATIC 
release O 
and O 
sulfide B-SYSTEMATIC 
concentrations O 
in O 
groundwater O 
, O 
and O 
their O 
formation O 
may O 
explain O 
the O 
elevated O 
total O 
arsenic B-SYSTEMATIC 
concentrations O 
. O 
An O 
alternative O 
remediation O 
approach O 
, O 
enhanced O 
flushing O 
of O 
uranium B-SYSTEMATIC 
, O 
was O 
accomplished O 
by O 
addition O 
of O 
bicarbonate B-SYSTEMATIC 
and O 
did O 
not O 
result O 
in O 
highly O 
elevated O 
arsenic B-SYSTEMATIC 
concentrations O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1216-1223 O 
. O 
© O 
2013 O 
SETAC O 
. O 

Lignan B-FAMILY 
(-)-Cubebin B-TRIVIAL 
Inhibits O 
Vascular O 
Contraction O 
and O 
Induces O 
Relaxation O 
Via O 
Nitric B-SYSTEMATIC 
Oxide I-SYSTEMATIC 
Activation O 
in O 
Isolated O 
Rat O 
Aorta O 
. O 

, O 
the O 
most O 
abundant O 
lignan B-FAMILY 
in O 
Piper O 
cubeba O 
, O 
has O 
been O 
described O 
as O 
having O 
several O 
effects O 
as O 
trypanocidal O 
, O 
antimycobacterial O 
, O 
antispasmodic O 
, O 
antimicrobial O 
, O 
anti-inflammatory O 
, O 
and O 
analgesic O 
. O 
This O 
study O 
investigated O 
the O 
vasorelaxant O 
effect O 
produced O 
by O 
(-)-cubebin B-TRIVIAL 
in O 
isolated O 
rat O 
aortic O 
rings O 
pre O 
- O 
contracted O 
with O 
phenylephrine B-TRIVIAL 
( O 
Phe B-FORMULA 
) O 
, O 
and O 
the O 
possible O 
mechanism O 
involved O 
in O 
this O 
event O 
was O 
evaluated O 
. O 
Endothelium O 
- O 
dependent O 
relaxation O 
was O 
evoked O 
by O 
acetylcholine B-SYSTEMATIC 
and O 
(-)-cubebin B-TRIVIAL 
in O 
intact O 
aortic O 
rings O 
, O 
while O 
endothelium O 
- O 
independent O 
vasorelaxation O 
was O 
elicited O 
by O 
sodium B-SYSTEMATIC 
nitroprusside I-SYSTEMATIC 
and O 
(-)-cubebin B-TRIVIAL 
in O 
denuded O 
rings O 
. O 
Cumulative O 
concentration O 
- O 
response O 
curves O 
for O 
Phe B-FORMULA 
( O 
10(-10) O 
-10(-5) O 
M O 
) O 
were O 
determined O 
for O 
endothelium O 
- O 
intact O 
and O 
endothelium O 
- O 
denuded O 
aortic O 
rings O 
in O 
either O 
the O 
presence O 
or O 
absence O 
of O 
(-)-cubebin B-TRIVIAL 
. O 
Dose O 
- O 
response O 
curves O 
were O 
also O 
constructed O 
for O 
pre O 
- O 
incubation O 
of O 
vascular O 
rings O 
with O 
Nω-nitro-L-arginine B-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
L-NAME B-ABBREVIATION 
) O 
( O 
a O 
non-specific O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
inhibitor O 
) O 
, O 
indomethacin B-TRIVIAL 
( O 
an O 
unspecific O 
cyclooxygenase O 
inhibitor O 
) O 
, O 
and O 
1H-[1,2,4] B-SYSTEMATIC 
oxadiazolo I-SYSTEMATIC 
[4,3-a]quinoxalin-1-one I-SYSTEMATIC 
( O 
ODQ B-ABBREVIATION 
) O 
( O 
a O 
guanylyl O 
cyclase O 
inhibitor O 
) O 
. O 
(-)-Cubebin B-TRIVIAL 
was O 
found O 
to O 
exert O 
a O 
vasorelaxant O 
effect O 
irrespective O 
of O 
the O 
presence O 
of O 
endothelium O 
, O 
which O 
was O 
abolished O 
by O 
pretreatment O 
with O 
L-NAME B-ABBREVIATION 
and O 
ODQ B-ABBREVIATION 
, O 
but O 
not O 
with O 
indomethacin B-TRIVIAL 
. O 
In O 
addition O 
, O 
(-)-cubebin B-TRIVIAL 
was O 
able O 
to O 
reduce O 
Phe B-FORMULA 
contraction O 
in O 
the O 
case O 
of O 
intact O 
rings O 
. O 
These O 
results O 
suggest O 
that O 
(-)-cubebin B-TRIVIAL 
promotes O 
vasorelaxation O 
via O 
NO B-FORMULA 
/ O 
cGMP B-ABBREVIATION 
pathway O 
in O 
rat O 
aorta O 
, O 
without O 
prostacyclin B-TRIVIAL 
involvement O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

Attenuates O 
Neuronal O 
Apoptosis O 
in O 
Hydrogen B-SYSTEMATIC 
Peroxide I-SYSTEMATIC 
-Treated O 
Astrocytes O 
Through O 
the O 
Up-Regulation O 
of O 
Neurotrophic O 
Factors O 
. O 

apoptosis O 
induced O 
by O 
oxidative O 
stress O 
is O 
a O 
prominent O 
feature O 
of O 
neurodegenerative O 
disorders O 
. O 
[6]-shogaol B-TRIVIAL 
, O 
a O 
bio O 
- O 
active O 
compound O 
in O 
ginger O 
, O 
possesses O 
potent O 
anti-inflammatory O 
actions O 
and O 
has O 
recently O 
emerged O 
as O 
a O 
potential O 
therapeutic O 
agent O 
for O 
neurodegenerative O 
disorders O 
. O 
However O 
, O 
the O 
effects O 
of O 
[6]-shogaol B-TRIVIAL 
on O 
astroglial O 
apoptosis O 
following O 
exogenously O 
induced O 
oxidative O 
stress O 
has O 
not O 
yet O 
been O 
investigated O 
. O 
Here O 
, O 
we O 
show O 
that O 
the O 
anti-apoptotic O 
activity O 
of O 
[6]-shogaol B-TRIVIAL 
in O 
astrocytes O 
following O 
exposure O 
to O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
H(2) B-FORMULA 
O(2) I-FORMULA 
) O 
involves O 
a O 
marked O 
up O 
- O 
regulation O 
of O 
neurotrophic O 
factors O 
such O 
as O 
nerve O 
growth O 
factor O 
, O 
glial O 
cell O 
line O 
- O 
derived O 
neurotrophic O 
factor O 
, O 
and O 
brain O 
- O 
derived O 
neurotrophic O 
factor O 
. O 
Astrocytes O 
co O 
- O 
treated O 
with O 
[6]-shogaol B-TRIVIAL 
and O 
H(2) B-FORMULA 
O(2) I-FORMULA 
for O 
1 O 
h O 
showed O 
decrease O 
in O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
production O 
compared O 
with O 
those O 
only O 
treated O 
with O 
H(2) B-FORMULA 
O(2) I-FORMULA 
. O 
Moreover O 
, O 
[6]-shogaol B-TRIVIAL 
counteracted O 
the O 
reduced O 
expression O 
of O 
ERK1 O 
/ O 
2 O 
in O 
H(2) B-FORMULA 
O(2) I-FORMULA 
-treated O 
astrocytes O 
and O 
protected O 
these O 
cells O 
from O 
oxidative O 
stress O 
and O 
apoptosis O 
by O 
attenuating O 
the O 
impairment O 
of O 
mitochondrial O 
function O 
proteins O 
such O 
as O 
Bcl-2 O 
and O 
Bcl-xL O 
. O 
Additionally O 
, O 
[6]-shogaol B-TRIVIAL 
inhibits O 
the O 
expression O 
of O 
the O 
apoptotic O 
proteins O 
Bax O 
and O 
caspase-3 O 
in O 
H(2) B-FORMULA 
O(2) I-FORMULA 
-treated O 
astrocytes O 
. O 
This O 
data O 
suggest O 
that O 
following O 
oxidative O 
stress O 
, O 
[6]-shogaol B-TRIVIAL 
protects O 
astrocytes O 
from O 
oxidative O 
damage O 
through O 
the O 
up O 
- O 
regulating O 
levels O 
of O 
neurotrophic O 
factors O 
. O 
These O 
findings O 
provide O 
further O 
support O 
for O 
the O 
use O 
of O 
[6]-shogaol B-TRIVIAL 
as O 
a O 
therapeutic O 
agent O 
in O 
neurodegenerative O 
disorders O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

vivo O 
Antimalarial O 
Activity O 
of O 
a O 
Labdane B-FAMILY 
Diterpenoid I-FAMILY 
from O 
the O 
Leaves O 
of O 
Otostegia O 
integrifolia O 
Benth O 
. O 

Ethiopian O 
traditional O 
medicine O 
, O 
the O 
leaves O 
of O 
Otostegia O 
integrifolia O 
Benth O 
. O 
are O 
used O 
for O 
the O 
treatment O 
of O 
several O 
diseases O 
including O 
malaria O 
. O 
In O 
an O 
ongoing O 
search O 
for O 
effective O 
, O 
safe O 
and O 
cheap O 
antimalarial O 
agents O 
from O 
plants O 
, O 
the O 
80% O 
methanol B-SYSTEMATIC 
leaf O 
extract O 
O O 
. O 
integrifolia O 
was O 
tested O 
for O 
its O 
in O 
vivo O 
antimalarial O 
activity O 
, O 
in O 
a O 
4-day O 
suppressive O 
assay O 
against O 
Plasmodium O 
berghei O 
. O 
Activity O 
- O 
guided O 
fractionation O 
of O 
this O 
extract O 
which O 
showed O 
potent O 
antiplasmodial O 
activity O 
resulted O 
in O 
the O 
isolation O 
of O 
a O 
labdane B-FAMILY 
diterpenoid I-FAMILY 
identified O 
as O 
otostegindiol B-TRIVIAL 
. O 
Otostegindiol B-TRIVIAL 
displayed O 
a O 
significant O 
( O 
P O 
< O 
0.001 O 
) O 
antimalarial O 
activity O 
at O 
doses O 
of O 
25 O 
, O 
50 O 
and O 
100 O 
mg O 
/ O 
kg O 
with O 
chemosuppression O 
values O 
of O 
50.13 O 
, O 
65.58 O 
and O 
73.16% O 
, O 
respectively O 
. O 
Acute O 
toxicity O 
studies O 
revealed O 
that O 
the O 
crude O 
extract O 
possesses O 
no O 
toxicity O 
in O 
mice O 
up O 
to O 
a O 
maximum O 
dose O 
of O 
5000 O 
mg O 
/ O 
kg O 
suggesting O 
the O 
relative O 
safety O 
of O 
the O 
plant O 
when O 
administered O 
orally O 
. O 
The O 
results O 
of O 
the O 
present O 
study O 
indicate O 
that O 
otostegindiol B-TRIVIAL 
is O 
among O 
the O 
antimalarial O 
principles O 
in O 
this O 
medicinal O 
plant O 
, O 
and O 
further O 
support O 
claims O 
for O 
the O 
traditional O 
medicinal O 
use O 
of O 
the O 
plant O 
for O 
the O 
treatment O 
of O 
malaria O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

the O 
Interplay O 
Between O 
Ligand O 
Derivatisation O 
and O 
Cation O 
Type O 
in O 
the O 
Assembly O 
of O 
Hybrid O 
Polyoxometalate B-FAMILY 
Mn B-FORMULA 
-Andersons O 
. O 

a O 
library O 
of O 
hybrid O 
Mn B-FORMULA 
-Anderson O 
polyoxometalates B-FAMILY 
anions O 
are O 
presented O 
: O 
1 O 
, O 
[ B-FORMULA 
( I-FORMULA 
MnMo(6) I-FORMULA 
O(18) I-FORMULA 
)((OCH(2 I-FORMULA 
) I-FORMULA 
)(3 I-FORMULA 
) I-FORMULA 
-C-(CH(2) I-FORMULA 
)(7 I-FORMULA 
) I-FORMULA 
CHCH(2) I-FORMULA 
)(2 I-FORMULA 
) I-FORMULA 
](3- I-FORMULA 
) I-FORMULA 
; O 
compound O 
2 O 
, O 
[ B-FORMULA 
( I-FORMULA 
MnMo(6) I-FORMULA 
O(18) I-FORMULA 
)((OCH(2 I-FORMULA 
) I-FORMULA 
)(3 I-FORMULA 
) I-FORMULA 
C-NHCH(2) I-FORMULA 
C(16) I-FORMULA 
H(9) I-FORMULA 
)(2 I-FORMULA 
) I-FORMULA 
](3- I-FORMULA 
) I-FORMULA 
; O 
compound O 
3 O 
, O 
[ B-FORMULA 
( I-FORMULA 
MnMo(6) I-FORMULA 
O(18) I-FORMULA 
)((OCH(2 I-FORMULA 
) I-FORMULA 
)(3 I-FORMULA 
) I-FORMULA 
C-(CH(2) I-FORMULA 
)(7 I-FORMULA 
) I-FORMULA 
CHCH(2) I-FORMULA 
)(1 I-FORMULA 
) I-FORMULA 
( I-FORMULA 
( I-FORMULA 
OCH(2) I-FORMULA 
)(3 I-FORMULA 
) I-FORMULA 
C-NHCH(2) I-FORMULA 
C(16) I-FORMULA 
H(9) I-FORMULA 
)(1 I-FORMULA 
) I-FORMULA 
](3- I-FORMULA 
) I-FORMULA 
; O 
compound O 
4 O 
, O 
[ B-FORMULA 
( I-FORMULA 
MnMo(6) I-FORMULA 
O(18) I-FORMULA 
)((OCH(2 I-FORMULA 
) I-FORMULA 
)(3 I-FORMULA 
) I-FORMULA 
C-NHC(O)CH(2) I-FORMULA 
CHCH(2) I-FORMULA 
)(2 I-FORMULA 
) I-FORMULA 
](3- I-FORMULA 
) I-FORMULA 
and O 
compounds O 
5-9 O 
, O 
[ B-FAMILY 
( I-FAMILY 
MnMo(6) I-FAMILY 
O(18) I-FAMILY 
)((OCH(2 I-FAMILY 
) I-FAMILY 
)(3 I-FAMILY 
) I-FAMILY 
C-NHC(O)(CH(2) I-FAMILY 
)(x I-FAMILY 
) I-FAMILY 
CH(3) I-FAMILY 
)(2 I-FAMILY 
) I-FAMILY 
] I-FAMILY 
[ B-FORMULA 
( I-FORMULA 
MnMo(6) I-FORMULA 
O(18) I-FORMULA 
)((OCH(2 I-FORMULA 
) I-FORMULA 
)(3 I-FORMULA 
) I-FORMULA 
C-NHC(O)(CH(2) I-FORMULA 
)(x I-FORMULA 
) I-FORMULA 
CH(3) I-FORMULA 
)(2 I-FORMULA 
) I-FORMULA 
] I-FORMULA 
) I-FORMULA 
, O 
where O 
x O 
= O 
4 O 
, O 
10 O 
, O 
12 O 
, O 
14 O 
, O 
and O 
18 O 
respectively O 
. O 
The O 
compounds O 
resulting O 
from O 
the O 
cation O 
exchange O 
of O 
the O 
anions O 
1-9 O 
to O 
give O 
TBA B-ABBREVIATION 
( O 
a O 
) O 
and O 
DMDOA B-ABBREVIATION 
( O 
b O 
) O 
salts O 
, O 
and O 
additionally O 
for O 
compounds O 
1 O 
, O 
2 O 
and O 
3 O 
, O 
tetraphenylphosphonium B-SYSTEMATIC 
( O 
PPh(4) B-FORMULA 
) O 
( O 
c O 
) O 
salts O 
, O 
are O 
explored O 
at O 
the O 
air O 
/ O 
water O 
interface O 
using O 
scanning O 
force O 
microscopy O 
, O 
showing O 
a O 
range O 
of O 
architectures O 
including O 
hexagonal O 
structures O 
, O 
nanofibers O 
and O 
other O 
supramolecular O 
forms O 
. O 
Additionally O 
the O 
solid O 
- O 
state O 
structures O 
for O 
compounds O 
1c O 
, O 
2c O 
, O 
4a O 
, O 
6a O 
, O 
9a O 
, O 
are O 
presented O 
for O 
the O 
first O 
time O 
and O 
these O 
investigations O 
demonstrate O 
the O 
delicate O 
interplay O 
between O 
the O 
structure O 
of O 
the O 
covalently O 
derivatised O 
hybrid O 
organo O 
- O 
clusters O 
as O 
well O 
as O 
the O 
ion O 
- O 
exchange O 
cation O 
types O 
. O 

cocktail O 
study O 
evaluated O 
the O 
interaction O 
potential O 
of O 
the O 
oral O 
lavender O 
oil O 
preparation O 
silexan O 
with O 
major O 
P450 O 
( O 
cytochrome O 
P450 O 
) O 
enzymes O 
. O 
Subjects O 
and O 
Methods O 
: O 
Sixteen O 
healthy O 
male O 
or O 
female O 
Caucasians O 
completed O 
this O 
double O 
- O 
blind O 
, O 
randomized O 
, O 
2-fold O 
crossover O 
study O 
. O 
Silexan O 
( O 
160 O 
mg O 
) O 
or O 
placebo O 
were O 
administered O 
once O 
daily O 
for O 
11 O 
days O 
. O 
Additionally O 
, O 
on O 
day O 
11 O 
of O 
both O 
study O 
periods O 
, O 
150 O 
mg O 
caffeine B-TRIVIAL 
( O 
CYP1A2 O 
) O 
, O 
125 O 
mg O 
tolbutamide B-TRIVIAL 
( O 
CYP2C9 O 
) O 
, O 
20 O 
mg O 
omeprazole B-TRIVIAL 
( O 
CYP2C19 O 
) O 
, O 
30 O 
mg O 
dextromethorphan-HBr B-FORMULA 
( O 
CYP2D6 O 
) O 
, O 
and O 
2 O 
mg O 
midazolam B-TRIVIAL 
( O 
CYP3A4 O 
) O 
were O 
administered O 
orally O 
. O 
Formal O 
interaction O 
was O 
excluded O 
if O 
the O 
90% O 
confidence O 
interval O 
( O 
CI O 
) O 
for O 
the O 
silexan O 
over O 
placebo O 
ratios O 
for O 
phenotyping O 
metrics O 
( O 
primary O 
: O 
AUC0-t O 
) O 
was O 
within O 
a O 
0.70-1.43 O 
range O 
. O 
Results O 
: O 
According O 
to O 
the O 
AUC0-t O 
comparisons O 
, O 
silexan O 
had O 
no O 
relevant O 
effect O 
on O 
CYP1A2 O 
, O 
2C9 O 
, O 
2D6 O 
, O 
and O 
3A4 O 
activity O 
. O 
Secondary O 
phenotyping O 
metrics O 
confirmed O 
this O 
result O 
. O 
Mean O 
ratios O 
for O 
all O 
omeprazole B-TRIVIAL 
-derived O 
metrics O 
were O 
close O 
to O 
unity O 
. O 
The O 
90% O 
CI O 
for O 
the O 
AUC0-t O 
ratio O 
of O 
omeprazole B-TRIVIAL 
but O 
not O 
for O 
omeprazole B-TRIVIAL 
/ O 
5-OH-omeprazole B-SYSTEMATIC 
plasma O 
ratio O 
3 O 
hours O 
post O 
- O 
dose O 
or O 
omeprazole B-TRIVIAL 
/ O 
5-OH-omeprazole B-SYSTEMATIC 
AUC0-t O 
ratio O 
( O 
secondary O 
CYP2C19 O 
metrics O 
) O 
was O 
above O 
the O 
predefined O 
threshold O 
of O 
1.43 O 
, O 
probably O 
caused O 
by O 
the O 
inherent O 
high O 
variability O 
of O 
omeprazole B-TRIVIAL 
pharmacokinetics O 
. O 
Silexan O 
and O 
the O 
phenotyping O 
drugs O 
were O 
well O 
tolerated O 
. O 
Repeated O 
silexan O 
( O 
160 O 
mg O 
/ O 
day O 
) O 
administration O 
has O 
no O 
clinically O 
relevant O 
inhibitory O 
or O 
inducing O 
effects O 
on O 
the O 
CYP1A2 O 
, O 
2C9 O 
, O 
2C19 O 
, O 
2D6 O 
, O 
and O 
3A4 O 
enzymes O 
in O 
vivo O 
. O 

- O 
induced O 
changes O 
in O 
the O 
micellization O 
and O 
degradation O 
properties O 
of O 
poly(lactic B-FAMILY 
acid)-block-poly(ethylene I-FAMILY 
glycol I-FAMILY 
) I-FAMILY 
copolymers O 
. O 

acid)-block-poly(ethylene I-FAMILY 
glycol I-FAMILY 
) I-FAMILY 
copolymers O 
( O 
PLA-b-PEG B-ABBREVIATION 
) O 
featuring O 
varying O 
tacticities O 
( O 
atactic O 
, O 
heterotactic O 
, O 
isotactic O 
) O 
in O 
the O 
PLA B-ABBREVIATION 
block O 
were O 
synthesized O 
and O 
investigated O 
for O 
their O 
micellar O 
stability O 
, O 
degradation O 
, O 
and O 
thermal O 
properties O 
. O 
Utilizing O 
tin B-SYSTEMATIC 
(II) I-SYSTEMATIC 
bis(2-ethylhexanoate) I-SYSTEMATIC 
, O 
aluminum B-SYSTEMATIC 
salan I-SYSTEMATIC 
, O 
and O 
aluminum B-SYSTEMATIC 
salen I-SYSTEMATIC 
catalysts O 
, O 
the O 
copolymers O 
were O 
synthesized O 
through O 
the O 
ring O 
- O 
opening O 
polymerization O 
of O 
d- O 
, O 
l- O 
, O 
rac- O 
, O 
or O 
a O 
blend O 
of O 
l- B-MULTIPLE 
and I-MULTIPLE 
rac I-MULTIPLE 
- I-MULTIPLE 
lactide I-MULTIPLE 
using O 
monomethoxy-poly(ethylene B-FAMILY 
glycol I-FAMILY 
) I-FAMILY 
as O 
a O 
macroinitiator O 
. O 
The O 
critical O 
micelle O 
concentration O 
, O 
which O 
reflects O 
the O 
micellar O 
stability O 
, O 
was O 
probed O 
using O 
a O 
fluorescence O 
spectroscopic O 
method O 
with O 
pyrene B-SYSTEMATIC 
as O 
the O 
probe O 
. O 
The O 
copolymers O 
were O 
degraded O 
in O 
a O 
methanolic O 
solution O 
of O 
1,5,7-triaza-bicyclo[4.4.0]dec-5-ene B-SYSTEMATIC 
and O 
the O 
degradation O 
was O 
measured O 
by O 
(1)H B-FORMULA 
NMR O 
spectroscopic O 
and O 
gel O 
permeation O 
chromatographic O 
analyses O 
. O 
Differential O 
scanning O 
calorimetry O 
and O 
thermogravimetric O 
analysis O 
provided O 
information O 
on O 
the O 
thermal O 
properties O 
of O 
the O 
copolymers O 
. O 
Atactic O 
and O 
heterotactic O 
microstructures O 
in O 
the O 
PLA B-ABBREVIATION 
block O 
resulted O 
in O 
lower O 
micellar O 
stability O 
, O 
as O 
well O 
as O 
faster O 
degradation O 
and O 
shorter O 
erosion O 
time O 
compared O 
to O 
polymers O 
with O 
high O 
isotactic O 
enchainment O 
( O 
Pm O 
) O 
. O 
By O 
modification O 
of O 
the O 
Pm O 
, O 
micellar O 
stability O 
, O 
degradation O 
, O 
and O 
erosion O 
rates O 
of O 
the O 
copolymers O 
can O 
be O 
tuned O 
to O 
specific O 
biomedical O 
applications O 
. O 
Interestingly O 
, O 
while O 
tin B-SYSTEMATIC 
(II) I-SYSTEMATIC 
bis(2-ethylhexanoate) I-SYSTEMATIC 
and O 
aluminum B-SYSTEMATIC 
salan I-SYSTEMATIC 
-catalyzed O 
PLA-b-PEG B-ABBREVIATION 
copolymers O 
exhibited O 
similar O 
micellization O 
behavior O 
, O 
the O 
aluminum B-SYSTEMATIC 
salen I-SYSTEMATIC 
-catalyzed O 
PLA-b-PEG B-ABBREVIATION 
exhibited O 
unique O 
behavior O 
at O 
high O 
micelle O 
concentration O 
in O 
the O 
presence O 
of O 
the O 
pyrene B-SYSTEMATIC 
probe O 
. O 
This O 
unique O 
behavior O 
can O 
be O 
attributed O 
to O 
the O 
disintegration O 
of O 
the O 
micelles O 
through O 
the O 
interactions O 
of O 
long O 
isotactic O 
stereoblock O 
segments O 
. O 

B12 I-TRIVIAL 
and O 
homocysteine B-TRIVIAL 
status O 
during O 
pregnancy O 
in O 
the O 
metformin B-TRIVIAL 
in O 
gestational O 
diabetes O 
trial O 
: O 
responses O 
to O 
maternal O 
metformin B-TRIVIAL 
compared O 
with O 
insulin O 
treatment(†) O 

: O 
The O 
aim O 
of O 
the O 
study O 
is O 
to O 
compare O 
the O 
effects O 
of O 
metformin B-TRIVIAL 
and O 
insulin O 
treatment O 
for O 
gestational O 
diabetes O 
mellitus O 
( O 
GDM O 
) O 
on O 
vitamin B-TRIVIAL 
B12 I-TRIVIAL 
and O 
homocysteine B-TRIVIAL 
( O 
Hcy B-ABBREVIATION 
) O 
status O 
. O 
METHODS O 
: O 
Women O 
with O 
GDM O 
, O 
who O 
met O 
criteria O 
for O 
insulin O 
treatment O 
, O 
were O 
randomly O 
assigned O 
to O 
metformin B-TRIVIAL 
( O 
n O 
= O 
89 O 
) O 
or O 
insulin O 
( O 
n O 
= O 
91 O 
) O 
in O 
the O 
Adelaide O 
cohort O 
of O 
the O 
metformin B-TRIVIAL 
in O 
gestational O 
diabetes O 
( O 
MiG O 
) O 
trial O 
. O 
Fasting O 
serum O 
total O 
vitamin B-TRIVIAL 
B12 I-TRIVIAL 
( O 
TB12 O 
) O 
, O 
holotranscobalamin O 
( O 
HoloTC O 
) O 
, O 
a O 
marker O 
of O 
functional O 
B12 O 
status O 
and O 
plasma O 
Hcy B-ABBREVIATION 
concentrations O 
were O 
measured O 
at O 
20-34 O 
weeks O 
( O 
at O 
randomization O 
) O 
and O 
36 O 
weeks O 
gestation O 
, O 
then O 
at O 
6-8 O 
weeks O 
postpartum O 
. O 
RESULTS O 
: O 
Circulating O 
TB12 O 
, O 
HoloTC O 
and O 
Hcy B-ABBREVIATION 
were O 
similar O 
in O 
both O 
treatment O 
groups O 
at O 
each O 
time O 
point O 
. O 
Women O 
who O 
were O 
taking O 
dietary O 
folate B-TRIVIAL 
supplements O 
at O 
randomization O 
had O 
higher O 
serum O 
TB12 O 
and O 
HoloTC O 
at O 
randomization O 
than O 
those O 
not O 
taking O 
folate B-TRIVIAL 
. O 
Overall O 
, O 
serum O 
TB12 O 
fell O 
more O 
between O 
randomization O 
and O 
36 O 
weeks O 
gestation O 
in O 
the O 
metformin B-TRIVIAL 
group O 
than O 
in O 
the O 
insulin O 
group O 
( O 
metformin B-TRIVIAL 
: O 
-19.7 O 
± O 
4.7 O 
pmol O 
/ O 
l O 
, O 
insulin O 
: O 
-6.4 O 
± O 
3.6 O 
pmol O 
/ O 
l O 
, O 
p O 
= O 
0.004 O 
) O 
. O 
The O 
decrease O 
in O 
serum O 
TB12 O 
during O 
treatment O 
was O 
greater O 
with O 
increasing O 
treatment O 
duration O 
in O 
metformin B-TRIVIAL 
-treated O 
( O 
p O 
< O 
0.001 O 
) O 
, O 
but O 
not O 
in O 
insulin O 
- O 
treated O 
women O 
. O 
CONCLUSIONS O 
: O 
Total O 
, O 
but O 
not O 
bioavailable O 
, O 
vitamin B-TRIVIAL 
B12 I-TRIVIAL 
stores O 
were O 
depleted O 
during O 
pregnancy O 
to O 
a O 
greater O 
extent O 
in O 
metformin B-TRIVIAL 
-treated O 
than O 
in O 
insulin O 
- O 
treated O 
women O 
with O 
GDM O 
, O 
but O 
neither O 
analyte O 
differed O 
between O 
groups O 
at O 
any O 
stage O 
. O 
This O 
adds O 
further O 
evidence O 
supporting O 
metformin B-TRIVIAL 
as O 
a O 
safe O 
alternative O 
treatment O 
to O 
insulin O 
in O 
GDM O 
. O 
Further O 
investigation O 
is O 
needed O 
to O 
evaluate O 
whether O 
women O 
treated O 
with O 
metformin B-TRIVIAL 
for O 
longer O 
periods O 
in O 
pregnancy O 
require O 
additional O 
B12 O 
or O 
other O 
supplementation O 
. O 

developed O 
a O 
model O 
for O 
hole O 
migration O 
along O 
relatively O 
short O 
DNA O 
hairpins O 
with O 
fewer O 
that O 
seven O 
adenine B-TRIVIAL 
( O 
A O 
) O 
: O 
thymine B-TRIVIAL 
( O 
T O 
) O 
base O 
pairs O 
. O 
The O 
model O 
was O 
used O 
to O 
simulate O 
hole O 
migration O 
along O 
poly(A)-poly(T) O 
sequences O 
with O 
a O 
particular O 
emphasis O 
on O 
the O 
impact O 
of O 
partial O 
hole O 
localization O 
on O 
the O 
different O 
rate O 
processes O 
. O 
The O 
simulations O 
, O 
performed O 
within O 
the O 
framework O 
of O 
the O 
stochastic O 
surrogate O 
Hamiltonian O 
approach O 
, O 
give O 
values O 
for O 
the O 
arrival O 
rate O 
in O 
good O 
agreement O 
with O 
experimental O 
data O 
. O 
Theoretical O 
results O 
obtained O 
for O 
hairpins O 
with O 
fewer O 
than O 
three O 
A O 
: O 
T O 
base O 
pairs O 
suggest O 
that O 
hole O 
transfer O 
along O 
short O 
hairpins O 
occurs O 
via O 
superexchange O 
. O 
This O 
mechanism O 
is O 
characterized O 
by O 
the O 
exponential O 
distance O 
dependence O 
of O 
the O 
arrival O 
rate O 
on O 
the O 
donor O 
/ O 
acceptor O 
distance O 
, O 
k(a) O 
≃ O 
e(-βR) O 
, O 
with O 
β O 
= O 
0.9 O 
Å(-1) O 
. O 
For O 
longer O 
systems O 
, O 
up O 
to O 
six O 
A O 
: O 
T O 
pairs O 
, O 
the O 
distance O 
dependence O 
follows O 
a O 
power O 
law O 
k(a) O 
≃ O 
R(-η) O 
with O 
η O 
= O 
2 O 
. O 
Despite O 
this O 
seemingly O 
clear O 
signature O 
of O 
unbiased O 
hopping O 
, O 
our O 
simulations O 
show O 
the O 
complete O 
delocalization O 
of O 
the O 
hole O 
density O 
along O 
the O 
entire O 
hairpin O 
. O 
According O 
to O 
our O 
analysis O 
, O 
the O 
hole O 
transfer O 
along O 
relatively O 
long O 
sequences O 
may O 
proceed O 
through O 
a O 
mechanism O 
which O 
is O 
distinct O 
from O 
both O 
coherent O 
single O 
- O 
step O 
superexchange O 
and O 
incoherent O 
multistep O 
hopping O 
. O 
The O 
criterion O 
for O 
the O 
validity O 
of O 
this O 
mechanism O 
intermediate O 
between O 
superexchange O 
and O 
hopping O 
is O 
proposed O 
. O 
The O 
impact O 
of O 
partial O 
localization O 
on O 
the O 
rate O 
of O 
hole O 
transfer O 
between O 
neighboring O 
A O 
bases O 
was O 
also O 
investigated O 
. O 

insight O 
into O 
artifactual O 
phenomena O 
during O 
in O 
vitro O 
toxicity O 
assessment O 
of O 
engineered O 
nanoparticles O 
: O 
study O 
of O 
TNF-α O 
adsorption O 
on O 
alumina B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticle O 
. O 

can O 
be O 
adsorbed O 
on O 
nanoparticles O 
( O 
NPs O 
) O 
and O 
degraded O 
during O 
in O 
vitro O 
toxicity O 
assays O 
. O 
These O 
artifactual O 
phenomena O 
could O 
lead O 
to O 
misinterpretation O 
of O 
biological O 
activity O 
, O 
such O 
as O 
false O 
- O 
negative O 
results O 
. O 
To O 
avoid O 
possible O 
underestimation O 
of O 
cytokine O 
release O 
after O 
contact O 
between O 
NP O 
and O 
cells O 
, O 
we O 
propose O 
a O 
methodology O 
to O 
account O 
for O 
these O 
artifactual O 
phenomena O 
and O 
lead O 
to O 
accurate O 
measurements O 
. O 
We O 
focused O 
on O 
the O 
pro O 
- O 
inflammatory O 
cytokine O 
tumor O 
necrosis O 
factor O 
TNF-α O 
. O 
We O 
studied O 
well O 
- O 
characterized O 
boehmite B-TRIVIAL 
engineered O 
NP O 
[ O 
aluminum B-SYSTEMATIC 
oxide I-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
, O 
AlO(OH) B-FORMULA 
] O 
. O 
The O 
rate O 
of O 
TNF-α O 
degradation O 
and O 
its O 
adsorption O 
( O 
on O 
boehmite B-TRIVIAL 
and O 
on O 
the O 
walls O 
of O 
wells O 
) O 
were O 
determined O 
in O 
cell O 
- O 
free O 
conditions O 
by O 
adding O 
a O 
known O 
TNF-α O 
concentration O 
( O 
1500 O 
pg O 
/ O 
ml O 
) O 
under O 
various O 
experimental O 
conditions O 
. O 
After O 
a O 
24-h O 
incubation O 
, O 
we O 
quantified O 
that O 
7 O 
wt.% O 
of O 
the O 
initial O 
TNF-α O 
was O 
degraded O 
over O 
time O 
, O 
6 O 
wt.% O 
adsorbed O 
on O 
the O 
walls O 
of O 
96-well O 
plates O 
, O 
and O 
13 O 
wt.% O 
adsorbed O 
on O 
the O 
boehmite B-TRIVIAL 
surface O 
. O 
Finally O 
, O 
boehmite B-TRIVIAL 
NP O 
were O 
incubated O 
with O 
murine O 
macrophages O 
( O 
RAW O 
264.7 O 
cell O 
line O 
) O 
. O 
The O 
release O 
of O 
TNF-α O 
was O 
assessed O 
for O 
boehmite B-TRIVIAL 
NP O 
and O 
the O 
experimental O 
data O 
were O 
corrected O 
considering O 
the O 
artifactual O 
phenomena O 
, O 
which O 
accounted O 
for O 
about O 
20-30% O 
of O 
the O 
total O 
. O 

CoA B-ABBREVIATION 
-Reductase O 
inhibitors O 
, O 
also O 
known O 
as O 
statins O 
, O 
are O 
currently O 
the O 
most O 
powerful O 
cholesterol B-TRIVIAL 
-lowering O 
drugs O 
available O 
on O 
the O 
market O 
. O 
Clinical O 
trials O 
and O 
experimental O 
evidence O 
suggest O 
that O 
statins O 
have O 
anti-atherosclerotic O 
effects O 
. O 
These O 
are O 
in O 
part O 
consequence O 
of O 
lipid O 
lowering O 
but O 
also O 
result O 
from O 
pleiotropic O 
actions O 
of O 
the O 
drugs O 
. O 
In O 
this O 
article O 
, O 
the O 
anti-atherosclerotic O 
actions O 
of O 
statins O 
will O 
be O 
reviewed O 
. O 

of O 
mitochondrial O 
carnitine B-TRIVIAL 
/ O 
acylcarnitine B-SYSTEMATIC 
transporter O 
by O 
H2O2 B-FORMULA 
: O 
Molecular O 
mechanism O 
and O 
possible O 
implication O 
in O 
pathophysiology O 
. O 

inhibits O 
the O 
[(3)H]carnitine B-SYSTEMATIC 
/ O 
carnitine B-TRIVIAL 
antiport O 
catalysed O 
by O 
the O 
mitochondrial O 
carnitine B-TRIVIAL 
/ O 
acylcarnitine B-SYSTEMATIC 
transporter O 
reconstituted O 
in O 
proteoliposomes O 
. O 
The O 
inhibition O 
was O 
reversed O 
by O 
dithioerythritol B-SYSTEMATIC 
, O 
N-acetylcysteine B-SYSTEMATIC 
and O 
l-cysteine B-TRIVIAL 
. O 
Inhibition O 
time O 
- O 
dependence O 
revealed O 
a O 
faster O 
and O 
a O 
slower O 
reaction O 
stages O 
with O 
orders O 
of O 
reaction O 
of O 
1 O 
and O 
1.9 O 
, O 
respectively O 
. O 
Inhibition O 
was O 
tested O 
on O 
mutants O 
in O 
which O 
one O 
or O 
more O 
of O 
the O 
six O 
Cys B-FORMULA 
residues O 
had O 
been O 
substituted O 
with O 
Ser B-FORMULA 
or O 
with O 
Val B-ABBREVIATION 
. O 
The O 
four O 
replacement O 
mutant O 
C23S O 
/ O 
C58S O 
/ O 
C89S O 
/ O 
C283S O 
containing O 
C136 O 
and O 
C155 O 
was O 
inhibited O 
as O 
the O 
wild O 
- O 
type O 
. O 
Mutants O 
C23V O 
/ O 
C58V O 
/ O 
C155V O 
/ O 
C89S O 
/ O 
C283S O 
and O 
C23V O 
/ O 
C58V O 
/ O 
C136V O 
/ O 
C89S O 
/ O 
C283S O 
containing O 
only O 
C136 O 
or O 
C155 O 
, O 
respectively O 
, O 
were O 
inhibited O 
at O 
a O 
much O 
lower O 
extent O 
respect O 
to O 
the O 
wild O 
- O 
type O 
, O 
while O 
the O 
mutant O 
C136S O 
/ O 
C155S O 
in O 
which O 
the O 
two O 
Cys B-FORMULA 
were O 
substituted O 
and O 
the O 
C-less O 
protein O 
were O 
virtually O 
insensitive O 
to O 
inhibition O 
. O 
DTE B-ABBREVIATION 
reversed O 
the O 
inhibition O 
of O 
the O 
H2O2 B-FORMULA 
sensitive O 
proteins O 
except O 
that O 
in O 
the O 
case O 
of O 
the O 
mutants O 
containing O 
only O 
C136 O 
or O 
C155 O 
after O 
long O 
time O 
of O 
incubation O 
with O 
H2O2 B-FORMULA 
. O 
The O 
IC50 O 
values O 
obtained O 
by O 
dose O 
- O 
response O 
curves O 
of O 
H2O2 B-FORMULA 
inhibition O 
were O 
0.17mM O 
for O 
the O 
wild O 
- O 
type O 
, O 
0.39mM O 
for O 
the O 
four O 
replacement O 
mutant O 
containing O 
C136 O 
and O 
C155 O 
, O 
2.23 O 
or O 
1.8mM O 
in O 
the O 
five O 
replacement O 
mutants O 
containing O 
the O 
single O 
C136 O 
or O 
C155 O 
, O 
respectively O 
. O 
Carnitine B-TRIVIAL 
and O 
acetylcarnitine B-SYSTEMATIC 
protected O 
the O 
protein O 
from O 
the O 
inhibition O 
by O 
H2O2 B-FORMULA 
. O 
Inhibition O 
kinetics O 
showed O 
a O 
competitive O 
behaviour O 
of O 
H2O2 B-FORMULA 
respect O 
to O 
carnitine B-TRIVIAL 
. O 
All O 
the O 
data O 
concur O 
to O 
demonstrate O 
that O 
H2O2 B-FORMULA 
interacts O 
with O 
C136 O 
and O 
C155 O 
and O 
completely O 
inactivates O 
the O 
transporter O 
by O 
inducing O 
the O 
formation O 
of O 
a O 
disulphide B-SYSTEMATIC 
. O 

and O 
hepatic O 
responses O 
of O 
the O 
freshwater O 
fish O 
Hoplias O 
malabaricus O 
after O 
saxitoxin B-TRIVIAL 
exposure O 
. O 

bioaccumulation O 
of O 
saxitoxins B-FAMILY 
( O 
STX B-ABBREVIATION 
) O 
in O 
the O 
trophic O 
chain O 
, O 
mainly O 
in O 
freshwater O 
, O 
are O 
not O 
completely O 
known O 
. O 
This O 
work O 
aimed O 
to O 
elucidate O 
the O 
effects O 
of O 
STX B-ABBREVIATION 
on O 
Hoplias O 
malabaricus O 
through O 
trophic O 
bioassay O 
. O 
The O 
fish O 
were O 
fed O 
once O 
every O 
five O 
days O 
with O 
Astyanax O 
sp O 
. O 
before O 
being O 
subjected O 
to O 
an O 
intraperitoneal O 
inoculation O 
with O 
the O 
lysate O 
of O 
Cylindrospermopsis O 
raciborskii O 
culture O 
containing O 
97% O 
STX B-ABBREVIATION 
and O 
3% O 
by O 
neosaxitoxin B-TRIVIAL 
and O 
gonyautoxin B-FAMILY 
during O 
20 O 
days O 
. O 
The O 
animal's O 
liver O 
was O 
assessed O 
using O 
biomarkers O 
as O 
activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
catalase O 
( O 
CAT O 
) O 
, O 
glutathione B-TRIVIAL 
S-transferase O 
( O 
GST O 
) O 
, O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
, O 
and O 
concentrations O 
of O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
and O 
lipoperoxidation O 
( O 
LPO O 
) O 
and O 
protein O 
carbonylation O 
( O 
PCO O 
) O 
. O 
In O 
the O 
blood O 
was O 
analyzed O 
the O 
genotoxic O 
and O 
hematological O 
parameters O 
. O 
The O 
hepatosomatic O 
index O 
and O 
the O 
relative O 
condition O 
factor O 
did O 
not O 
show O 
a O 
significant O 
difference O 
between O 
the O 
exposed O 
and O 
control O 
groups O 
. O 
The O 
values O 
of O 
mean O 
corpuscular O 
hemoglobin O 
concentration O 
and O 
mean O 
corpuscular O 
hemoglobin O 
increased O 
in O 
the O 
STX B-ABBREVIATION 
group O 
. O 
The O 
hepatic O 
tissue O 
from O 
both O 
groups O 
exhibited O 
a O 
typical O 
pattern O 
that O 
have O 
been O 
already O 
described O 
for O 
most O 
teleost O 
fish O 
. O 
The O 
results O 
suggested O 
the O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
with O 
increased O 
activity O 
of O 
GPx O 
and O 
concentrations O 
of O 
LPO O 
and O 
GSH B-ABBREVIATION 
; O 
whereas O 
the O 
specific O 
activity O 
of O 
SOD O 
decreased O 
. O 
However O 
, O 
no O 
changes O 
were O 
observed O 
in O 
the O 
CAT O 
, O 
PCO O 
, O 
and O 
DNA O 
damage O 
. O 
Although O 
the O 
STX B-ABBREVIATION 
effects O 
are O 
known O 
as O 
neurotoxic O 
, O 
this O 
cyanotoxin O 
caused O 
liver O 
biochemical O 
alterations O 
that O 
can O 
be O 
considered O 
ecologically O 
relevant O 
. O 

composition O 
of O 
dog O 
foods O 
using O 
nitric B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
simulated O 
gastric O 
digestions O 
. O 

dry O 
dog O 
foods O 
obtained O 
commercially O 
in O 
the O 
United O 
States O 
were O 
digested O 
using O 
microwave O 
assisted O 
nitric B-SYSTEMATIC 
acid I-SYSTEMATIC 
digestion O 
and O 
a O 
simulated O 
gastric O 
digestion O 
. O 
Digests O 
were O 
analysed O 
for O 
23 O 
elements O 
using O 
inductively O 
coupled O 
plasma O 
- O 
mass O 
spectrometry O 
. O 
Data O 
, O 
expressed O 
as O 
dry O 
matter O 
concentrations O 
, O 
were O 
compared O 
to O 
published O 
nitric B-SYSTEMATIC 
acid I-SYSTEMATIC 
digestion O 
results O 
. O 
Nitric B-SYSTEMATIC 
acid I-SYSTEMATIC 
data O 
obtained O 
in O 
the O 
present O 
study O 
were O 
not O 
statistically O 
different O 
from O 
published O 
data O 
, O 
with O 
the O 
exception O 
of O 
Mo B-FORMULA 
, O 
Sn B-FORMULA 
, O 
Sb B-FORMULA 
, O 
Tl B-FORMULA 
and O 
Th B-FORMULA 
. O 
However O 
, O 
significant O 
differences O 
in O 
individual O 
intra O 
- O 
sample O 
results O 
were O 
observed O 
between O 
published O 
studies O 
and O 
the O 
present O 
work O 
. O 
Simulated O 
gastric O 
digestions O 
demonstrated O 
lower O 
extraction O 
efficiencies O 
( O 
< O 
50% O 
nitric O 
acid O 
digestions O 
) O 
that O 
were O 
statistically O 
significant O 
. O 
Much O 
lower O 
bioavailability O 
was O 
observed O 
for O 
Al B-FORMULA 
, O 
Ba B-FORMULA 
and O 
Pb B-FORMULA 
. O 
In O 
general O 
, O 
elemental O 
concentrations O 
were O 
determined O 
to O 
be O 
lower O 
than O 
the O 
appropriate O 
Mineral O 
Tolerance O 
Limit O 
or O 
consistent O 
with O 
background O 
concentrations O 
in O 
foodstuffs O 
. O 
Evaluation O 
against O 
Reference O 
Doses O 
( O 
RfDs O 
) O 
showed O 
concentrations O 
for O 
many O 
elements O 
obtained O 
by O 
nitric B-SYSTEMATIC 
acid I-SYSTEMATIC 
digestion O 
to O 
be O 
above O 
RfD O 
levels O 
. O 
However O 
, O 
the O 
respective O 
simulated O 
gastric O 
digestion O 
data O 
were O 
below O 
or O 
only O 
moderately O 
elevated O 
above O 
RfDs O 
. O 
Only O 
arsenic O 
displayed O 
median O 
and O 
maximum O 
concentrations O 
at O 
factors O 
of O 
five O 
and O 
ten O 
above O 
the O 
relevant O 
RfD O 
. O 

differences O 
in O 
age O 
- O 
related O 
diseases O 
and O 
cancer O 
could O 
stem O 
from O 
differences O 
in O 
diet O 
. O 
To O 
characterize O 
DNA O 
strand O 
- O 
breaking O 
activities O 
in O 
selected O 
foods O 
/ O 
beverages O 
, O 
flavorings O 
, O 
and O 
some O 
of O 
their O 
constituent O 
chemicals O 
, O 
we O 
used O 
p53R O 
cells O 
, O 
a O 
cellular O 
assay O 
sensitive O 
to O 
such O 
breaks O 
. O 
Substances O 
testing O 
positive O 
included O 
reference O 
chemicals O 
: O 
quinacrine B-TRIVIAL 
( O 
peak O 
response O 
, O 
51× O 
) O 
and O 
etoposide B-TRIVIAL 
( O 
33× O 
) O 
; O 
flavonoids B-FAMILY 
: O 
EGCG B-ABBREVIATION 
( O 
19× O 
) O 
, O 
curcumin B-TRIVIAL 
( O 
12× O 
) O 
, O 
apigenin B-TRIVIAL 
( O 
9× O 
) O 
, O 
and O 
quercetin B-TRIVIAL 
( O 
7× O 
) O 
; O 
beverages O 
: O 
chamomile O 
( O 
11× O 
) O 
, O 
green O 
( O 
21× O 
) O 
, O 
and O 
black O 
tea O 
( O 
26× O 
) O 
and O 
coffee O 
( O 
3-29× O 
) O 
; O 
and O 
liquid O 
smoke O 
( O 
4-28× O 
) O 
. O 
Damage O 
occurred O 
at O 
dietary O 
concentrations O 
: O 
etoposide B-TRIVIAL 
near O 
5μg O 
/ O 
ml O 
produced O 
responses O 
similar O 
to O 
a O 
1 O 
: O 
1000 O 
dilution O 
of O 
liquid O 
smoke O 
, O 
a O 
1 O 
: O 
20 O 
dilution O 
of O 
coffee O 
, O 
and O 
a O 
1 O 
: O 
5 O 
dilution O 
of O 
tea O 
. O 
Pyrogallol B-TRIVIAL 
-related O 
chemicals O 
and O 
tannins B-FAMILY 
are O 
present O 
in O 
dietary O 
sources O 
and O 
individually O 
produced O 
strong O 
activity O 
: O 
pyrogallol B-TRIVIAL 
( O 
30× O 
) O 
, O 
3-methoxycatechol B-SYSTEMATIC 
( O 
25× O 
) O 
, O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
( O 
21× O 
) O 
, O 
and O 
1,2,4-benzenetriol B-SYSTEMATIC 
( O 
21× O 
) O 
. O 
From O 
structure O 
- O 
activity O 
relationships O 
, O 
high O 
activities O 
depended O 
on O 
specific O 
orientations O 
of O 
hydroxyls B-FAMILY 
on O 
the O 
benzene B-SYSTEMATIC 
ring O 
. O 
Responses O 
accompanied O 
cellular O 
signals O 
characteristic O 
of O 
DNA O 
breaks O 
such O 
as O 
H2AX O 
phosphorylation O 
. O 
Breaks O 
were O 
also O 
directly O 
detected O 
by O 
comet O 
assay O 
. O 
Cellular O 
toxicological O 
effects O 
of O 
foods O 
and O 
flavorings O 
could O 
guide O 
epidemiologic O 
and O 
experimental O 
studies O 
of O 
potential O 
disease O 
risks O 
from O 
DNA O 
strand O 
- O 
breaking O 
chemicals O 
in O 
diets O 
. O 

synthesis O 
and O 
SAR O 
of O 
calcitonin O 
gene O 
- O 
related O 
peptide O 
( O 
CGRP O 
) O 
receptor O 
antagonists O 
derived O 
from O 
tyrosine B-TRIVIAL 
surrogates O 
. O 
Part O 
2 O 
. O 

substituted O 
indazole B-SYSTEMATIC 
and O 
benzoxazolone B-SYSTEMATIC 
amino B-FAMILY 
acids I-FAMILY 
were O 
investigated O 
as O 
d-tyrosine B-TRIVIAL 
surrogates O 
in O 
highly O 
potent O 
CGRP O 
receptor O 
antagonists O 
. O 
Compound O 
3 O 
, O 
derived O 
from O 
the O 
7-methylindazole B-SYSTEMATIC 
core O 
, O 
afforded O 
a O 
30-fold O 
increase O 
in O 
CGRP O 
binding O 
potency O 
compared O 
with O 
its O 
unsubstituted O 
indazole B-SYSTEMATIC 
analog O 
1 O 
. O 
When O 
dosed O 
at O 
0.03mg O 
/ O 
kg O 
SC O 
, O 
compound O 
2 O 
( O 
a O 
racemic O 
mixture O 
of O 
3 O 
and O 
its O 
(S)-enantiomer O 
) O 
demonstrated O 
robust O 
inhibition O 
of O 
CGRP-induced O 
increases O 
in O 
mamoset O 
facial O 
blood O 
flow O 
up O 
to O 
105min O 
. O 
The O 
compound O 
possesses O 
a O 
favorable O 
predictive O 
in O 
vitro O 
toxicology O 
profile O 
, O 
and O 
good O 
aqueous O 
solubility O 
. O 
When O 
dosed O 
as O 
a O 
nasal O 
spray O 
in O 
rabbits O 
, O 
3 O 
was O 
rapidly O 
absorbed O 
and O 
showed O 
good O 
intranasal O 
bioavailability O 
( O 
42% O 
) O 
. O 

extrusion O 
of O 
wet O 
masses O 
was O 
studied O 
as O 
a O 
novel O 
technology O 
for O 
the O 
production O 
of O 
dosage O 
forms O 
for O 
oral O 
drug O 
delivery O 
. O 
Extrusion O 
was O 
carried O 
out O 
with O 
a O 
ram O 
extruder O 
. O 
Formulations O 
contained O 
either O 
microcrystalline O 
cellulose O 
( O 
MCC O 
) O 
or O 
dicalcium B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
( O 
DCP B-ABBREVIATION 
) O 
as O 
diluent O 
, O 
hydroxypropyl O 
methylcellulose O 
( O 
HPMC O 
) O 
, O 
lactose B-TRIVIAL 
, O 
and O 
water O 
. O 
Extrudates O 
were O 
characterized O 
for O 
their O 
tensile O 
strength O 
, O 
Young's O 
modulus O 
of O 
elasticity O 
, O 
water O 
absorption O 
, O 
gel O 
forming O 
capacity O 
, O 
and O 
release O 
of O 
two O 
model O 
drugs O 
, O 
coumarin B-TRIVIAL 
( O 
COU B-ABBREVIATION 
) O 
and O 
propranolol B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
PRO B-ABBREVIATION 
) O 
. O 
Cohesive O 
extrudates O 
could O 
be O 
produced O 
with O 
both O 
filling O 
materials O 
( O 
MCC O 
and O 
DCP B-ABBREVIATION 
) O 
when O 
HPMC O 
was O 
included O 
as O 
a O 
binder O 
at O 
low O 
amounts O 
( O 
3.3-4.5% O 
w O 
/ O 
w O 
dry O 
weight O 
) O 
. O 
Employing O 
more O 
HPMC O 
, O 
the O 
elasticity O 
of O 
the O 
wet O 
masses O 
increased O 
which O 
resulted O 
in O 
distinct O 
surface O 
defects O 
. O 
For O 
MCC O 
, O 
the O 
maximum O 
HPMC O 
amount O 
that O 
could O 
be O 
included O 
in O 
the O 
formulations O 
( O 
15% O 
w O 
/ O 
w O 
dry O 
weight O 
) O 
did O 
not O 
affect O 
the O 
mechanical O 
properties O 
or O 
decrease O 
the O 
drug O 
release O 
significantly O 
. O 
For O 
DCP B-ABBREVIATION 
extrudates O 
, O 
the O 
maximally O 
effective O 
HPMC O 
amount O 
was O 
30% O 
( O 
w O 
/ O 
w O 
dry O 
weight O 
) O 
with O 
influence O 
on O 
both O 
the O 
mechanical O 
properties O 
and O 
drug O 
release O 
. O 
This O 
study O 
suggests O 
that O 
laminar O 
extrusion O 
of O 
wet O 
masses O 
is O 
a O 
feasible O 
technique O 
for O 
the O 
production O 
of O 
dosage O 
forms O 
for O 
oral O 
drug O 
delivery O 
. O 

this O 
study O 
, O 
the O 
stabilization O 
effects O 
of O 
three O 
polymers O 
on O 
four O 
model O 
drugs O 
( O 
felodipine B-TRIVIAL 
, O 
fenofibrate B-TRIVIAL 
, O 
carbamazepine B-TRIVIAL 
, O 
and O 
celecoxib B-TRIVIAL 
) O 
under O 
saturated O 
humidity O 
were O 
investigated O 
. O 
Three O 
different O 
types O 
of O 
thin O 
films O 
( O 
solid O 
dispersions O 
, O 
drug O 
films O 
with O 
a O 
polymer O 
film O 
coating O 
and O 
drug O 
films O 
laid O 
on O 
top O 
of O 
polymer O 
coated O 
surfaces O 
) O 
were O 
prepared O 
and O 
compared O 
with O 
films O 
containing O 
the O 
drug O 
alone O 
. O 
ATR-FTIR O 
spectroscopy O 
, O 
polarised O 
light O 
microscopy O 
( O 
PLM O 
) O 
, O 
scanning O 
electron O 
microscopy O 
( O 
SEM O 
) O 
and O 
nano O 
- O 
thermal O 
analysis O 
( O 
nano-TA O 
) O 
were O 
performed O 
on O 
the O 
model O 
systems O 
after O 
storage O 
under O 
saturated O 
humidity O 
. O 
The O 
recrystallisation O 
tendency O 
of O 
the O 
drug O 
in O 
the O 
drug O 
containing O 
thin O 
films O 
was O 
found O 
to O 
be O 
strongly O 
related O 
to O 
the O 
intrinsic O 
crystallization O 
tendency O 
of O 
the O 
drug O 
film O 
alone O 
and O 
the O 
strength O 
of O 
drug O 
- O 
polymer O 
interactions O 
. O 
Additionally O 
, O 
under O 
high O 
humidity O 
, O 
the O 
glass O 
transition O 
temperature O 
of O 
the O 
polymer O 
is O 
no O 
longer O 
an O 
indicator O 
of O 
its O 
drug O 
stabilization O 
capability O 
. O 
Instead O 
, O 
it O 
is O 
the O 
hygroscobicity O 
of O 
the O 
polymer O 
that O 
appears O 
to O 
be O 
the O 
most O 
important O 
parameter O 
. O 
Amongst O 
the O 
polymers O 
tested O 
in O 
this O 
study O 
, O 
EUDRAGIT B-FAMILY 
E I-FAMILY 
PO I-FAMILY 
was O 
found O 
to O 
have O 
the O 
greatest O 
inhibitory O 
effect O 
on O 
crystallization O 
, O 
whilst O 
PVP B-TRIVIAL 
K30 I-TRIVIAL 
was O 
found O 
to O 
have O 
the O 
least O 
protective O 
effect O 
; O 
presumably O 
because O 
of O 
its O 
hygroscopic O 
nature O 
. O 

prevents O 
insulin O 
aggregation O 
and O 
fragmentation O 
during O 
copper B-SYSTEMATIC 
catalyzed O 
oxidation O 
. O 

catalyzed O 
oxidation O 
via O 
the O 
oxidative O 
system O 
Cu(2+) B-FORMULA 
/ O 
ascorbate B-TRIVIAL 
is O 
known O 
to O 
induce O 
aggregation O 
of O 
therapeutic O 
proteins O 
, O 
resulting O 
in O 
enhanced O 
immunogenicity O 
. O 
Hence O 
, O 
inclusion O 
of O 
antioxidants O 
in O 
protein O 
formulations O 
is O 
of O 
great O 
interest O 
. O 
In O 
this O 
study O 
, O 
using O 
recombinant O 
human O 
insulin O 
( O 
insulin O 
) O 
as O 
a O 
model O 
, O 
we O 
investigated O 
the O 
ability O 
of O 
several O 
excipients O 
, O 
in O 
particular O 
triethylenetetramine B-SYSTEMATIC 
( O 
TETA B-ABBREVIATION 
) O 
, O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
and O 
ethylenediamine B-SYSTEMATIC 
tetraacetic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
EDTA B-ABBREVIATION 
) O 
, O 
for O 
their O 
ability O 
to O 
prevent O 
protein O 
oxidation O 
, O 
aggregation O 
, O 
and O 
fragmentation O 
. O 
Insulin O 
( O 
1mg O 
/ O 
ml O 
) O 
was O 
oxidized O 
with O 
40μM O 
Cu(2+) B-FORMULA 
and O 
4mM O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
in O 
absence O 
or O 
presence O 
of O 
excipients O 
. O 
Among O 
the O 
excipients O 
studied O 
, O 
1mM O 
of O 
TETA B-ABBREVIATION 
, O 
EDTA B-ABBREVIATION 
, O 
or O 
GSH B-ABBREVIATION 
prevented O 
insulin O 
aggregation O 
upon O 
metal O 
catalyzed O 
oxidation O 
( O 
MCO O 
) O 
for O 
3h O 
at O 
room O 
temperature O 
, O 
based O 
on O 
size O 
exclusion O 
chromatography O 
( O 
SEC O 
) O 
. O 
At O 
lower O 
concentration O 
( O 
100μM O 
) O 
, O 
for O 
72h O 
at O 
+ O 
4°C O 
, O 
TETA B-ABBREVIATION 
was O 
the O 
only O 
one O 
to O 
inhibit O 
almost O 
completely O 
oxidation O 
- O 
induced O 
insulin O 
aggregation O 
, O 
fragmentation O 
, O 
and O 
structural O 
changes O 
, O 
as O 
indicated O 
by O 
SEC O 
, O 
nanoparticle O 
tracking O 
analysis O 
, O 
light O 
obscuration O 
particle O 
counting O 
, O 
intrinsic O 
/ O 
extrinsic O 
fluorescence O 
, O 
circular O 
dichroism O 
, O 
and O 
chemical O 
derivatization O 
. O 
In O 
contrast O 
, O 
GSH B-ABBREVIATION 
had O 
a O 
slight O 
pro O 
- O 
oxidant O 
effect O 
, O 
as O 
demonstrated O 
by O 
the O 
higher O 
percentage O 
of O 
aggregates O 
and O 
a O 
more O 
severe O 
structural O 
damage O 
, O 
whereas O 
EDTA B-ABBREVIATION 
offered O 
substantially O 
less O 
protection O 
. O 
TETA B-ABBREVIATION 
also O 
protected O 
a O 
monoclonal O 
IgG1 O 
against O 
MCO-induced O 
aggregation O 
, O 
suggesting O 
its O 
general O 
applicability O 
. O 
In O 
conclusion O 
, O 
TETA B-ABBREVIATION 
is O 
a O 
potential O 
candidate O 
excipient O 
for O 
inclusion O 
in O 
formulations O 
of O 
oxidation O 
- O 
sensitive O 
proteins O 
. O 

and O 
Nrf2-inducing O 
activity O 
of O 
the O 
isothiocyanates B-FAMILY 
iberverin B-TRIVIAL 
, O 
iberin B-TRIVIAL 
and O 
cheirolin B-TRIVIAL 
. O 

studies O 
have O 
reported O 
a O 
potent O 
induction O 
of O 
Nuclear O 
factor O 
( O 
erythroid O 
- O 
derived O 
2 O 
) O 
- O 
like O 
2 O 
(Nrf2)-dependent O 
gene O 
expression O 
by O 
the O 
isothiocyanate O 
sulforaphane B-TRIVIAL 
. O 
However O 
, O 
little O 
is O 
known O 
regarding O 
the O 
Nrf2-inducing O 
activities O 
of O 
the O 
lower O 
structure O 
- O 
related O 
sulforaphane B-TRIVIAL 
homologues O 
, O 
such O 
as O 
iberverin B-TRIVIAL 
, O 
iberin B-TRIVIAL 
and O 
cheirolin B-TRIVIAL 
, O 
which O 
exhibit O 
different O 
sulfur O 
oxidation O 
states O 
. O 
Therefore O 
, O 
in O 
this O 
study O 
we O 
synthesized O 
the O 
isothiocyanates B-FAMILY 
iberverin B-TRIVIAL 
, O 
iberin B-TRIVIAL 
and O 
cheirolin B-TRIVIAL 
with O 
a O 
high O 
yield O 
and O 
purity O 
and O 
determined O 
their O 
Nrf2-inducing O 
activity O 
in O 
NIH3T3 O 
fibroblasts O 
. O 
Iberverin B-TRIVIAL 
, O 
iberin B-TRIVIAL 
and O 
cheirolin B-TRIVIAL 
significantly O 
induced O 
Nrf2 O 
nuclear O 
translocation O 
. O 
The O 
increase O 
in O 
nuclear O 
Nrf2 O 
levels O 
was O 
accompanied O 
by O 
a O 
significant O 
increase O 
in O 
heme O 
oxygenase O 
1 O 
( O 
HO-1 O 
) O 
and O 
γ-glutamylcysteine B-SYSTEMATIC 
synthetase O 
( O 
γGCS O 
) O 
mRNA O 
and O 
protein O 
levels O 
. O 
Overall O 
, O 
iberverin B-TRIVIAL 
, O 
iberin B-TRIVIAL 
and O 
cheirolin B-TRIVIAL 
exhibited O 
a O 
similar O 
potency O 
to O 
sulforaphane B-TRIVIAL 
in O 
inducing O 
Nrf2-dependent O 
gene O 
- O 
expression O 
. O 
Furthermore O 
, O 
our O 
data O 
suggest O 
that O 
the O 
induction O 
of O 
Nrf2 O 
by O 
iberverin B-TRIVIAL 
, O 
iberin B-TRIVIAL 
and O 
cheirolin B-TRIVIAL 
may O 
have O 
occurred O 
via O 
an O 
extracellular O 
signal O 
- O 
related O 
kinase O 
(ERK)-dependent O 
signal O 
- O 
transduction O 
pathway O 
. O 

food O 
contaminant O 
deoxynivalenol B-TRIVIAL 
activates O 
the O 
mitogen O 
activated O 
protein O 
kinases O 
in O 
the O 
intestine O 
: O 
interest O 
of O 
ex O 
vivo O 
models O 
as O 
an O 
alternative O 
to O 
in O 
vivo O 
experiments O 
. O 

induce O 
changes O 
in O 
the O 
intestinal O 
barrier O 
function O 
through O 
decreased O 
expression O 
of O 
cell O 
junction O 
proteins O 
and O 
apoptosis O 
of O 
enterocytes O 
. O 
The O 
mitogen O 
activated O 
protein O 
kinases O 
( O 
MAPK O 
) O 
play O 
an O 
important O 
role O 
in O 
the O 
signaling O 
pathways O 
of O 
cell O 
turnover O 
and O 
differentiation O 
. O 
Using O 
ex O 
vivo O 
and O 
in O 
vivo O 
approaches O 
, O 
the O 
purpose O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
ability O 
of O 
low O 
doses O 
of O 
DON B-ABBREVIATION 
to O 
induce O 
histological O 
changes O 
in O 
the O 
intestine O 
and O 
to O 
activate O 
the O 
MAPK O 
ERK O 
1 O 
/ O 
2 O 
, O 
p38 O 
and O 
JNK O 
. O 
Twelve O 
weaning O 
piglets O 
received O 
during O 
four O 
weeks O 
a O 
control O 
diet O 
or O 
a O 
DON B-ABBREVIATION 
-contaminated O 
diet O 
( O 
2.3 O 
mg O 
DON B-ABBREVIATION 
/ O 
kg O 
feed O 
) O 
. O 
Six O 
weaning O 
piglets O 
were O 
used O 
to O 
prepare O 
jejunal O 
explants O 
( O 
ex O 
vivo O 
model O 
) O 
. O 
Explants O 
were O 
exposed O 
during O 
4 O 
h O 
to O 
vehicle O 
, O 
5 O 
or O 
10 O 
μM O 
DON B-ABBREVIATION 
. O 
Intestinal O 
changes O 
were O 
graded O 
using O 
a O 
histological O 
score O 
. O 
Pigs O 
fed O 
a O 
DON B-ABBREVIATION 
-diet O 
and O 
explants O 
exposed O 
to O 
DON B-ABBREVIATION 
showed O 
a O 
significant O 
decrease O 
in O 
the O 
jejunal O 
score O 
. O 
In O 
both O 
models O 
, O 
the O 
toxin O 
significantly O 
enhanced O 
phosphorylation O 
of O 
ERK O 
1 O 
/ O 
2 O 
and O 
p38 O 
, O 
whereas O 
the O 
increased O 
phosphorylation O 
of O 
JNK O 
was O 
non O 
significant O 
. O 
Taken O 
together O 
these O 
results O 
indicate O 
that O 
in O 
vivo O 
or O 
ex O 
vivo O 
exposure O 
of O 
intestinal O 
tissue O 
to O 
DON B-ABBREVIATION 
lead O 
to O 
similar O 
intestinal O 
lesions O 
and O 
activation O 
of O 
MAPK O 
. O 
These O 
effects O 
could O 
impair O 
the O 
homeostasis O 
of O 
intestinal O 
tissue O 
in O 
the O 
aspects O 
of O 
barrier O 
function O 
and O 
immune O 
protection O 
. O 
The O 
similarity O 
of O 
the O 
in O 
vivo O 
and O 
ex O 
vivo O 
results O 
provides O 
also O 
strong O 
evidence O 
that O 
the O 
jejunal O 
explant O 
model O 
is O 
a O 
good O 
alternative O 
for O 
toxicological O 
studies O 
in O 
intestinal O 
tissue O 
. O 

-induced O 
connexin43 O 
gap O 
junction O 
disassembly O 
in O 
rat O 
astrocytes O 
involves O 
protein O 
kinase O 
Cβ O 
. O 

, O 
a O 
phenanthroindolizidine B-FAMILY 
alkaloid I-FAMILY 
derived O 
from O 
Cryptocaryachinensis O 
and O 
Ficusseptica O 
in O 
the O 
Asclepiadaceae O 
milkweed O 
family O 
, O 
is O 
cytotoxic O 
for O 
various O 
cancer O 
cell O 
lines O 
. O 
In O 
this O 
study O 
, O 
we O 
demonstrated O 
that O 
treatment O 
of O 
rat O 
primary O 
astrocytes O 
with O 
antofine B-TRIVIAL 
induced O 
dose O 
- O 
dependent O 
inhibition O 
of O 
gap O 
junction O 
intercellular O 
communication O 
( O 
GJIC O 
) O 
, O 
as O 
assessed O 
by O 
scrape O 
- O 
loading O 
6-carboxyfluorescein B-SYSTEMATIC 
dye O 
transfer O 
. O 
Levels O 
of O 
Cx43 O 
protein O 
were O 
also O 
decreased O 
in O 
a O 
dose- O 
and O 
time O 
- O 
dependent O 
manner O 
following O 
antofine B-TRIVIAL 
treatment O 
. O 
Double O 
- O 
labeling O 
immunofluorescence O 
microscopy O 
showed O 
that O 
antofine B-TRIVIAL 
( O 
10ng O 
/ O 
ml O 
) O 
induced O 
endocytosis O 
of O 
surface O 
gap O 
junctions O 
into O 
the O 
cytoplasm O 
, O 
where O 
Cx43 O 
was O 
co O 
- O 
localized O 
with O 
the O 
early O 
endosome O 
marker O 
EEA1 O 
. O 
Inhibition O 
of O 
lysosomes O 
or O 
proteasomes O 
by O 
co O 
- O 
treatment O 
with O 
antofine B-TRIVIAL 
and O 
their O 
respective O 
specific O 
inhibitors O 
, O 
NH4Cl B-FORMULA 
or O 
MG132 B-IDENTIFIER 
, O 
partially O 
inhibited O 
the O 
antofine O 
- O 
induced O 
decrease O 
in O 
Cx43 O 
protein O 
levels O 
, O 
but O 
did O 
not O 
inhibit O 
the O 
antofine O 
- O 
induced O 
inhibition O 
of O 
GJIC O 
. O 
After O 
30min O 
of O 
treatment O 
, O 
antofine O 
induced O 
a O 
rapid O 
increase O 
in O 
the O 
intracellular O 
Ca(2+) B-FORMULA 
concentration O 
and O 
activation O 
of O 
protein O 
kinase O 
C O 
(PKC)α O 
/ O 
βII O 
, O 
which O 
was O 
maintained O 
for O 
at O 
least O 
6h O 
. O 
Co O 
- O 
treatment O 
of O 
astrocytes O 
with O 
antofine B-TRIVIAL 
and O 
the O 
intracellular O 
Ca(2+) B-FORMULA 
chelator O 
BAPTA-AM B-ABBREVIATION 
prevented O 
downregulation O 
of O 
Cx43 O 
and O 
inhibition O 
of O 
GJIC O 
. O 
Moreover O 
, O 
co O 
- O 
treatment O 
with O 
antofine B-TRIVIAL 
and O 
a O 
specific O 
PKCβ O 
inhibitor O 
prevented O 
endocytosis O 
of O 
gap O 
junctions O 
, O 
downregulation O 
of O 
Cx43 O 
, O 
and O 
inhibition O 
of O 
GJIC O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
indicate O 
that O 
antofine B-TRIVIAL 
induces O 
Cx43 O 
gap O 
junction O 
disassembly O 
by O 
the O 
PKCβ O 
signaling O 
pathway O 
. O 
Inhibition O 
of O 
GJIC O 
by O 
antofine B-TRIVIAL 
may O 
undermine O 
the O 
neuroprotective O 
effect O 
of O 
astrocytes O 
in O 
CNS O 
. O 

impact O 
of O 
antiretroviral O 
therapy O 
( O 
ART O 
) O 
on O 
the O 
natural O 
history O 
of O 
HIV-1 O 
infection O 
has O 
resulted O 
in O 
dramatic O 
reductions O 
in O 
disease O 
- O 
associated O 
morbidity O 
and O 
mortality O 
. O 
Additionally O 
, O 
the O 
epidemiology O 
of O 
HIV-1 O 
infection O 
worldwide O 
is O 
changing O 
, O 
as O 
women O 
now O 
represent O 
a O 
substantial O 
proportion O 
of O 
infected O 
adults O 
. O 
As O 
more O 
highly O 
effective O 
and O 
tolerable O 
antiretroviral O 
regimens O 
become O 
available O 
, O 
and O 
as O 
the O 
prevention O 
of O 
mother O 
- O 
to O 
- O 
child O 
transmission O 
becomes O 
an O 
attainable O 
goal O 
in O 
the O 
management O 
of O 
HIV-infected O 
individuals O 
, O 
more O 
and O 
more O 
HIV-positive O 
women O 
are O 
choosing O 
to O 
become O 
pregnant O 
and O 
have O 
children O 
. O 
Consequently O 
, O 
it O 
is O 
important O 
to O 
consider O 
the O 
efficacy O 
and O 
safety O 
of O 
antiretroviral O 
agents O 
in O 
pregnancy O 
. O 
Protease O 
inhibitors O 
are O 
a O 
common O 
class O 
of O 
medication O 
used O 
in O 
the O 
treatment O 
of O 
HIV-1 O 
infection O 
and O 
are O 
increasingly O 
being O 
used O 
in O 
pregnancy O 
. O 
However O 
, O 
several O 
studies O 
have O 
raised O 
concerns O 
regarding O 
pharmacokinetic O 
alterations O 
in O 
pregnancy O 
, O 
particularly O 
in O 
the O 
third O 
trimester O 
, O 
which O 
results O 
in O 
suboptimal O 
drug O 
concentrations O 
and O 
a O 
theoretically O 
higher O 
risk O 
of O 
virologic O 
failure O 
and O 
perinatal O 
transmission O 
. O 
Drug O 
level O 
reductions O 
have O 
been O 
observed O 
with O 
each O 
individual O 
protease O 
inhibitor O 
and O 
dose O 
adjustments O 
in O 
pregnancy O 
are O 
suggested O 
for O 
certain O 
agents O 
. O 
Furthermore O 
, O 
studies O 
have O 
also O 
raised O 
concerns O 
regarding O 
the O 
safety O 
of O 
protease O 
inhibitors O 
in O 
pregnancy O 
, O 
particularly O 
as O 
they O 
may O 
increase O 
the O 
risk O 
of O 
pre O 
- O 
term O 
birth O 
and O 
metabolic O 
disturbances O 
. O 
Overall O 
, O 
protease O 
inhibitors O 
are O 
safe O 
and O 
effective O 
for O 
the O 
treatment O 
of O 
HIV-infected O 
pregnant O 
women O 
. O 
Specifically O 
, O 
ritonavir B-TRIVIAL 
-boosted O 
lopinavir B-TRIVIAL 
- O 
and O 
atazanavir B-TRIVIAL 
-based O 
regimens O 
are O 
preferred O 
in O 
pregnancy O 
, O 
while O 
ritonavir B-TRIVIAL 
-boosted O 
darunavir B-TRIVIAL 
- O 
and O 
saquinavir B-TRIVIAL 
-based O 
therapies O 
are O 
reasonable O 
alternatives O 
. O 
This O 
paper O 
reviews O 
the O 
use O 
of O 
protease O 
inhibitors O 
in O 
pregnancy O 
, O 
focusing O 
on O 
pharmacokinetic O 
and O 
safety O 
considerations O 
, O 
and O 
outlines O 
the O 
recommendations O 
for O 
use O 
of O 
this O 
class O 
of O 
medication O 
in O 
the O 
HIV-1-infected O 
pregnant O 
woman O 
. O 

To O 
develop O 
and O 
validate O 
a O 
risk O 
engine O 
that O 
calculates O 
the O 
risks O 
of O 
macro- O 
and O 
microvascular O 
complications O 
in O 
type O 
2 O 
diabetes O 
. O 
RESEARCH O 
DESIGN O 
AND O 
METHODS O 
We O 
analyzed O 
pooled O 
data O 
from O 
two O 
clinical O 
trials O 
on O 
1748 O 
Japanese O 
type O 
2 O 
diabetic O 
patients O 
without O 
diabetes O 
complications O 
other O 
than O 
mild O 
diabetic O 
retinopathy O 
with O 
a O 
median O 
follow O 
- O 
up O 
of O 
7.2 O 
years O 
. O 
End O 
points O 
were O 
coronary O 
heart O 
disease O 
( O 
CHD O 
) O 
, O 
stroke O 
, O 
noncardiovascular O 
mortality O 
, O 
overt O 
nephropathy O 
defined O 
by O 
persistent O 
proteinuria O 
, O 
and O 
progression O 
of O 
retinopathy O 
. O 
We O 
fit O 
a O 
multistate O 
Cox O 
regression O 
model O 
to O 
derive O 
an O 
algorithm O 
for O 
prediction O 
. O 
The O 
predictive O 
accuracy O 
of O 
the O 
calculated O 
5-year O 
risks O 
was O 
cross O 
- O 
validated O 
. O 
RESULTS O 
Sex O 
, O 
age O 
, O 
HbA1c O 
, O 
years O 
after O 
diagnosis O 
, O 
BMI O 
, O 
systolic O 
blood O 
pressure O 
, O 
non-HDL O 
cholesterol B-TRIVIAL 
, O 
albumin-to- O 
creatinine B-TRIVIAL 
ratio O 
, O 
atrial O 
fibrillation O 
, O 
current O 
smoker O 
, O 
and O 
leisure O 
- O 
time O 
physical O 
activity O 
were O 
risk O 
factors O 
for O 
macro- O 
and O 
microvascular O 
complications O 
and O 
were O 
incorporated O 
into O 
the O 
risk O 
engine O 
. O 
The O 
observed O 
- O 
to O 
- O 
predicted O 
( O 
O O 
/ O 
P O 
) O 
ratios O 
for O 
each O 
event O 
were O 
between O 
0.93 O 
and O 
1.08 O 
, O 
and O 
Hosmer-Lemeshow O 
tests O 
showed O 
no O 
significant O 
deviations O 
between O 
observed O 
and O 
predicted O 
events O 
. O 
In O 
contrast O 
, O 
the O 
UK O 
Prospective O 
Diabetes O 
Study O 
( O 
UKPDS O 
) O 
risk O 
engine O 
overestimated O 
CHD O 
risk O 
( O 
O O 
/ O 
P O 
ratios O 
: O 
0.3 O 
for O 
CHD O 
and O 
0.72 O 
for O 
stroke O 
) O 
. O 
C O 
statistics O 
in O 
our O 
Japanese O 
patients O 
were O 
high O 
for O 
CHD O 
, O 
noncardiovascular O 
mortality O 
, O 
and O 
overt O 
nephropathy O 
( O 
0.725 O 
, O 
0.696 O 
, O 
and O 
0.767 O 
) O 
but O 
moderate O 
for O 
stroke O 
and O 
progression O 
of O 
retinopathy O 
( O 
0.636 O 
and O 
0.614 O 
) O 
. O 
By O 
combining O 
macro- O 
and O 
microvascular O 
risks O 
, O 
the O 
classification O 
of O 
low- O 
and O 
high O 
- O 
risk O 
patients O 
was O 
improved O 
by O 
a O 
net O 
reclassification O 
improvement O 
of O 
5.7% O 
( O 
P O 
= O 
0.02 O 
) O 
. O 
CONCLUSIONS O 
The O 
risk O 
engine O 
accurately O 
predicts O 
macro- O 
and O 
microvascular O 
complications O 
and O 
would O 
provide O 
helpful O 
information O 
in O 
risk O 
classification O 
and O 
health O 
economic O 
simulations O 
. O 

is O 
an O 
angiogenic O 
and O 
lymphangiogenic O 
glycoprotein O 
that O 
can O 
be O 
proteolytically O 
processed O 
generating O 
various O 
forms O 
differing O 
in O 
subunit O 
composition O 
due O 
to O 
the O 
presence O 
or O 
absence O 
of O 
N B-FORMULA 
- O 
and O 
C B-FORMULA 
-terminal O 
propeptides O 
. O 
These O 
propeptides O 
flank O 
the O 
central O 
VEGF O 
homology O 
domain O 
, O 
that O 
contains O 
the O 
binding O 
sites O 
for O 
VEGF O 
receptors O 
( O 
VEGFRs O 
) O 
, O 
but O 
their O 
biological O 
functions O 
were O 
unclear O 
. O 
Characterization O 
of O 
propeptide O 
function O 
will O 
be O 
important O 
to O 
clarify O 
which O 
forms O 
of O 
VEGF-D O 
are O 
biologically O 
active O 
and O 
therefore O 
clinically O 
relevant O 
. O 
Here O 
we O 
use O 
VEGF-D O 
mutants O 
deficient O 
in O 
either O 
propeptide O 
, O 
and O 
in O 
the O 
capacity O 
to O 
process O 
the O 
remaining O 
propeptide O 
, O 
to O 
monitor O 
the O 
functions O 
of O 
these O 
domains O 
. O 
We O 
report O 
for O 
the O 
first O 
time O 
that O 
VEGF-D O 
binds O 
heparin O 
, O 
and O 
that O 
the O 
C B-FORMULA 
-terminal O 
propeptide O 
significantly O 
enhances O 
this O 
interaction O 
( O 
removal O 
of O 
this O 
propeptide O 
from O 
full O 
- O 
length O 
VEGF-D O 
completely O 
prevents O 
heparin O 
binding O 
) O 
. O 
We O 
also O 
show O 
that O 
removal O 
of O 
either O 
the O 
N B-FORMULA 
- O 
or O 
C B-FORMULA 
-terminal O 
propeptide O 
is O 
required O 
for O 
VEGF-D O 
to O 
drive O 
formation O 
of O 
VEGFR-2 O 
/ O 
VEGFR-3 O 
heterodimers O 
which O 
have O 
recently O 
been O 
shown O 
to O 
positively O 
regulate O 
angiogenic O 
sprouting O 
. O 
The O 
mature O 
form O 
of O 
VEGF-D O 
, O 
lacking O 
both O 
propeptides O 
, O 
can O 
also O 
promote O 
formation O 
of O 
these O 
receptor O 
heterodimers O 
. O 
In O 
a O 
mouse O 
tumor O 
model O 
, O 
removal O 
of O 
only O 
the O 
C B-FORMULA 
-terminal O 
propeptide O 
from O 
full O 
- O 
length O 
VEGF-D O 
was O 
sufficient O 
to O 
enhance O 
angiogenesis O 
and O 
tumor O 
growth O 
. O 
In O 
contrast O 
, O 
removal O 
of O 
both O 
propeptides O 
is O 
required O 
for O 
high O 
rates O 
of O 
lymph O 
node O 
metastasis O 
. O 
The O 
findings O 
reported O 
here O 
show O 
that O 
the O 
propeptides O 
profoundly O 
influence O 
molecular O 
interactions O 
of O 
VEGF-D O 
with O 
VEGF O 
receptors O 
, O 
co O 
- O 
receptors O 
, O 
and O 
heparin O 
, O 
and O 
its O 
effects O 
on O 
tumor O 
biology O 
. O 

immunoreactive O 
11-ketotestosterone B-SYSTEMATIC 
concentrations O 
in O 
sheep O 
feces O 
after O 
acth O 
challenge O 
. O 

and O 
related O 
substances O 
are O 
important O 
metabolites O 
of O 
cortisol B-TRIVIAL 
and O 
are O 
excreted O 
via O 
feces O 
in O 
ruminants O 
. O 
To O 
investigate O 
whether O 
11-ketotestosterone B-SYSTEMATIC 
( O 
11-KT B-ABBREVIATION 
) O 
or O 
its O 
immunoreactive O 
metabolites O 
are O 
formed O 
and O 
excreted O 
in O 
ruminant O 
feces O 
, O 
an O 
enzyme O 
immunoassay O 
( O 
EIA O 
) O 
was O 
developed O 
and O 
validated O 
. O 
The O 
antibody O 
was O 
raised O 
in O 
rabbits O 
against O 
11-KT-3-CMO B-SYSTEMATIC 
: O 
bovine O 
serum O 
albumin O 
with O 
biotinylated B-SYSTEMATIC 
11-KT I-SYSTEMATIC 
as O 
a O 
label O 
. O 
The O 
assay O 
showed O 
a O 
sensitivity O 
of O 
0.3 O 
pg O 
/ O 
well O 
. O 
To O 
validate O 
the O 
assay O 
biologically O 
, O 
6 O 
rams O 
were O 
injected O 
with O 
a O 
synthetic O 
analogue O 
of O 
the O 
adrenocorticotropic O 
hormone O 
( O 
Synacthen O 
, O 
2 O 
µg O 
/ O 
kg O 
body O 
wt O 
) O 
. O 
An O 
aliquot O 
was O 
collected O 
of O 
each O 
fecal O 
portion O 
spontaneously O 
defecated O 
8 O 
h O 
before O 
Synacthen O 
injection O 
to O 
24 O 
h O 
after O 
injection O 
and O 
stored O 
at O 
-20 O 
°C O 
until O 
analysis O 
. O 
Samples O 
( O 
0.5 O 
g O 
) O 
were O 
extracted O 
using O 
80% O 
methanol B-SYSTEMATIC 
and O 
immunoreactive O 
metabolites O 
measured O 
using O 
the O 
11-KT B-ABBREVIATION 
EIA O 
and O 
an O 
already O 
established O 
11,17-dioxoandrostane B-SYSTEMATIC 
( O 
11,17-DOA B-SYSTEMATIC 
) O 
EIA O 
. O 
High O 
- O 
performance O 
liquid O 
chromatography O 
separation O 
revealed O 
no O 
peak O 
in O 
the O 
same O 
elution O 
position O 
as O 
authentic O 
11-KT B-ABBREVIATION 
; O 
therefore O 
, O 
reacting O 
substances O 
were O 
referred O 
to O 
as O 
11-KT B-ABBREVIATION 
equivalents O 
. O 
In O 
the O 
case O 
of O 
11-KT B-ABBREVIATION 
immunoreactive O 
substances O 
, O 
the O 
values O 
increased O 
from O 
baseline O 
( O 
median O 
, O 
136 O 
ng O 
/ O 
g O 
feces O 
) O 
to O 
a O 
peak O 
concentration O 
( O 
median O 
, O 
424 O 
ng O 
/ O 
g O 
) O 
10 O 
to O 
14 O 
h O 
after O 
Synacthen O 
injection O 
and O 
declined O 
afterwards O 
. O 
Concentrations O 
of O 
11,17-DOA B-SYSTEMATIC 
showed O 
the O 
same O 
pattern O 
, O 
but O 
the O 
values O 
were O 
2 O 
to O 
4 O 
times O 
higher O 
. O 
From O 
this O 
data O 
, O 
the O 
authors O 
conclude O 
that O 
11-KT B-ABBREVIATION 
-like O 
substances O 
, O 
specifically O 
C19 B-FAMILY 
O3 I-FAMILY 
-androgens I-FAMILY 
with O 
a O 
17ß-hydroxy B-SYSTEMATIC 
group O 
, O 
were O 
present O 
in O 
the O 
feces O 
. O 
These O 
substances O 
originate O 
from O 
the O 
adrenals O 
and O 
are O 
most O 
likely O 
cortisol B-TRIVIAL 
metabolites O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1332-1336 O 
. O 
© O 
2013 O 
SETAC O 
. O 

of O 
organosolv O 
lignin O 
from O 
olive O 
tree O 
clippings O 
and O 
its O 
valorization O 
to O 
simple O 
phenolic B-FAMILY 
compounds O 
. O 

valorization O 
practices O 
have O 
attracted O 
a O 
great O 
deal O 
of O 
interest O 
in O 
recent O 
years O 
due O 
to O 
the O 
large O 
excess O 
of O 
lignin O 
produced O 
by O 
the O 
pulp O 
and O 
paper O 
industry O 
, O 
together O 
with O 
second O 
- O 
generation O 
bioethanol O 
plants O 
. O 
In O 
this O 
work O 
, O 
a O 
new O 
lignin O 
valorization O 
approach O 
is O 
proposed O 
. O 
It O 
involves O 
ultrafiltration O 
as O 
a O 
fractionation O 
process O 
to O 
separate O 
different O 
molecular O 
weight O 
lignin O 
fractions O 
followed O 
by O 
a O 
hydrogen B-SYSTEMATIC 
-free O 
, O 
mild O 
, O 
hydrogenolytic O 
, O 
heterogeneously O 
catalyzed O 
methodology O 
assisted O 
by O 
microwave O 
irradiation O 
to O 
obtain O 
simple O 
phenolic B-FAMILY 
, O 
monomeric O 
products O 
by O 
depolymerization O 
using O 
a O 
nickel O 
- O 
based O 
catalyst O 
. O 
The O 
main O 
products O 
obtained O 
were O 
desaspidinol B-TRIVIAL 
, O 
syringaldehyde B-TRIVIAL 
, O 
and O 
syringol B-TRIVIAL 
; O 
this O 
proves O 
the O 
efficiency O 
of O 
the O 
depolymerization O 
conditions O 
applied O 
. O 
The O 
concentration O 
of O 
these O 
observed O 
compounds O 
increased O 
when O 
the O 
molecular O 
weights O 
of O 
the O 
lignin O 
fractions O 
increased O 
. O 
The O 
applied O 
depolymerization O 
conditions O 
, O 
which O 
take O 
advantage O 
of O 
the O 
use O 
of O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
as O 
a O 
hydrogen B-SYSTEMATIC 
-donating O 
solvent O 
, O 
did O 
not O 
generate O 
any O 
biochar O 
in O 
the O 
systems O 
. O 

microRNA O 
targets O 
in O 
the O 
coding O 
region O 
is O 
difficult O 
due O 
to O 
the O 
overwhelming O 
signal O 
encoding O 
the O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
. O 
Here O 
, O 
we O 
introduce O 
an O 
algorithm O 
( O 
called O 
PACCMIT-CDS O 
) O 
that O 
finds O 
potential O 
microRNA O 
targets O 
within O 
coding O 
sequences O 
by O 
searching O 
for O 
conserved O 
motifs O 
that O 
are O 
complementary O 
to O 
the O 
microRNA O 
seed O 
region O 
and O 
also O 
overrepresented O 
in O 
comparison O 
with O 
a O 
background O 
model O 
preserving O 
both O 
codon O 
usage O 
and O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
. O 
Precision O 
and O 
sensitivity O 
of O 
PACCMIT-CDS O 
are O 
evaluated O 
using O 
PAR-CLIP O 
and O 
proteomics O 
data O 
sets O 
. O 
Thanks O 
to O 
the O 
properly O 
constructed O 
background O 
, O 
the O 
new O 
algorithm O 
achieves O 
a O 
lower O 
rate O 
of O 
false O 
positives O 
and O 
better O 
ranking O 
of O 
predictions O 
than O 
do O 
currently O 
available O 
algorithms O 
, O 
which O 
were O 
designed O 
to O 
find O 
microRNA O 
targets O 
within O 
3 O 
' O 
UTRs O 
. O 

nonionic O 
inhibitor O 
with O 
high O 
specificity O 
for O 
the O 
UDP-Gal B-ABBREVIATION 
donor O 
binding O 
site O 
of O 
human O 
blood O 
group O 
B O 
galactosyltransferase O 
: O 
design O 
, O 
synthesis O 
, O 
and O 
characterization O 
. O 

( O 
1 O 
) O 
was O 
designed O 
and O 
synthesized O 
as O 
a O 
nonionic O 
inhibitor O 
for O 
the O 
donor O 
binding O 
site O 
of O 
human O 
blood O 
group O 
B O 
galactosyltransferase O 
( O 
GTB O 
) O 
. O 
Enzymatic O 
characterization O 
showed O 
1 O 
to O 
be O 
extremely O 
specific O 
, O 
as O 
the O 
highly O 
homologous O 
human O 
N B-FORMULA 
-acetylgalactosaminyltransferase O 
( O 
GTA O 
) O 
is O 
not O 
inhibited O 
. O 
The O 
binding O 
epitope O 
of O 
1 O 
demonstrates O 
a O 
high O 
involvement O 
of O 
the O 
arabinityl B-TRIVIAL 
linker O 
, O 
whereas O 
the O 
galactose B-TRIVIAL 
residue O 
is O 
only O 
making O 
contact O 
to O 
the O 
protein O 
via O 
its O 
C-2 O 
site O 
, O 
which O 
is O 
very O 
important O 
for O 
the O 
discrimination O 
between O 
galactose B-TRIVIAL 
and O 
N-acetylgalactosamine B-SYSTEMATIC 
, O 
the O 
substrate O 
transferred O 
by O 
GTA O 
. O 
The O 
approach O 
can O 
generate O 
highly O 
specific O 
glycosyltransferase O 
inhibitors O 
. O 

- O 
like O 
polypeptides O 
( O 
ELPs O 
) O 
are O 
protein O 
polymers O 
that O 
reversibly O 
phase O 
separate O 
in O 
response O 
to O 
increased O 
temperature O 
, O 
pressure O 
, O 
concentration O 
, O 
ionic O 
strength O 
, O 
and O 
molecular O 
weight O 
. O 
If O 
it O 
were O 
possible O 
to O 
engineer O 
their O 
phase O 
separation O 
to O 
respond O 
to O 
specific O 
molecular O 
substrates O 
, O 
ELP O 
fusion O 
proteins O 
might O 
be O 
engineered O 
as O 
biosensors O 
, O 
smart O 
biomaterials O 
, O 
diagnostic O 
imaging O 
agents O 
, O 
and O 
targeted O 
therapies O 
. O 
What O 
has O 
been O 
lacking O 
is O 
a O 
strategy O 
to O 
design O 
ELPs O 
to O 
respond O 
to O 
specific O 
substrates O 
. O 
To O 
address O 
this O 
deficiency O 
, O 
we O 
report O 
that O 
ELP O 
fusion O 
proteins O 
phase O 
separate O 
in O 
response O 
to O 
chemical O 
inducers O 
of O 
dimerization O 
( O 
CID O 
) O 
. O 
The O 
rationale O 
is O 
that O 
ELP O 
phase O 
separation O 
depends O 
on O 
molecular O 
weight O 
, O 
concentration O 
, O 
and O 
local O 
hydrophobicity O 
; O 
therefore O 
, O 
processes O 
that O 
affect O 
these O 
properties O 
, O 
including O 
noncovalent O 
dimerization O 
, O 
can O 
be O 
tuned O 
to O 
produce O 
isothermal O 
phase O 
separation O 
. O 
To O 
test O 
this O 
hypothesis O 
, O 
constructs O 
were O 
evaluated O 
consisting O 
of O 
an O 
immunophilin O 
: O 
human O 
FK-506 B-IDENTIFIER 
binding O 
protein O 
12 O 
( O 
FKBP O 
) O 
attached O 
to O 
an O 
ELP O 
. O 
Under O 
stoichiometric O 
binding O 
of O 
a O 
CID O 
, O 
the O 
fusion O 
protein O 
homodimerizes O 
and O 
triggers O 
phase O 
separation O 
. O 
This O 
dimerization O 
is O 
reversible O 
upon O 
saturation O 
with O 
excess O 
CID O 
or O 
competitive O 
binding O 
of O 
a O 
small O 
lipophilic O 
macrolide O 
to O 
FKBP O 
. O 
By O 
modulating O 
the O 
ELP O 
molecular O 
weight O 
, O 
phase O 
separation O 
was O 
tuned O 
for O 
isothermal O 
response O 
to O 
CID O 
at O 
physiological O 
ionic O 
strength O 
and O 
temperature O 
( O 
37 O 
°C O 
) O 
. O 
To O 
interpret O 
the O 
relationship O 
between O 
transition O 
temperature O 
and O 
equilibrium O 
binding O 
constants O 
, O 
an O 
empirical O 
mathematical O 
model O 
was O 
employed O 
. O 
To O 
the O 
best O 
of O 
our O 
knowledge O 
, O 
this O 
report O 
is O 
the O 
first O 
demonstration O 
of O 
reversible O 
ELP O 
switching O 
in O 
response O 
to O 
controlled O 
dimerization O 
. O 
Due O 
to O 
its O 
simplicity O 
, O 
this O 
strategy O 
may O 
be O 
useful O 
to O 
design O 
ELP O 
fusion O 
proteins O 
that O 
respond O 
to O 
specific O 
dimeric O 
biological O 
entities O 
. O 

thin O 
films O 
in O 
nanodevices O 
may O 
absorb O 
moisture O 
, O 
leading O 
to O 
physical O 
changes O 
and O 
property O 
/ O 
performance O 
degradation O 
, O 
such O 
as O 
altered O 
data O 
storage O 
and O 
readout O 
in O 
resistance O 
random O 
access O 
memory O 
. O 
Here O 
we O 
demonstrate O 
using O 
a O 
nanometallic O 
memory O 
that O 
such O 
degradation O 
proceeds O 
via O 
nanoporosity O 
, O 
which O 
facilitates O 
water O 
wetting O 
in O 
otherwise O 
nonwetting O 
dielectrics O 
. O 
Electric O 
degradation O 
only O 
occurs O 
when O 
the O 
device O 
is O 
in O 
the O 
charge O 
- O 
storage O 
state O 
, O 
which O 
provides O 
a O 
nanoscale O 
dielectrophoretic O 
force O 
directing O 
H2O B-FORMULA 
to O 
internal O 
field O 
centers O 
( O 
sites O 
of O 
trapped O 
charge O 
) O 
to O 
enable O 
bond O 
rupture O 
and O 
charged O 
hydroxyl B-SYSTEMATIC 
formation O 
. O 
While O 
these O 
processes O 
are O 
dramatically O 
enhanced O 
by O 
an O 
external O 
DC O 
or O 
AC O 
field O 
and O 
electron O 
- O 
donating O 
electrodes O 
, O 
they O 
can O 
be O 
completely O 
prevented O 
by O 
eliminating O 
nanoporosity O 
, O 
depositing O 
a O 
barrier O 
layer O 
, O 
or O 
using O 
an O 
oxidation O 
- O 
resistant O 
electrode O 
. O 
These O 
findings O 
provide O 
insight O 
for O 
understanding O 
high O 
- O 
performance O 
memory O 
and O 
field O 
- O 
assisted O 
degradation O 
of O 
nanodevices O 
. O 

of O 
oxidant O 
- O 
antioxidant O 
status O 
in O 
oral O 
toxicity O 
of O 
fish O 
oil O 
methyl B-FAMILY 
esters I-FAMILY 
and O 
diesel O 
fuel O 
in O 
male O 
rats O 
. O 

study O 
was O 
conducted O 
to O 
compare O 
the O 
effects O 
of O 
oral O 
toxicity O 
induced O 
by O 
fish O 
oil O 
biodiesel O 
and O 
diesel O 
fuel O 
. O 
Diesel O 
and O 
fish O 
oil O 
biodiesel O 
were O 
administered O 
by O 
oral O 
gavage O 
to O 
rats O 
. O 
For O 
this O 
purpose O 
, O 
35 O 
rats O 
were O 
divided O 
into O 
five O 
groups O 
. O 
Sunflower O 
oil O 
of O 
250 O 
mg O 
kg(-1) O 
was O 
administered O 
to O 
the O 
rats O 
in O 
the O 
control O 
group O 
by O 
oral O 
gavage O 
. O 
The O 
rats O 
in O 
the O 
D250 O 
and O 
D500 O 
groups O 
were O 
administered O 
by O 
oral O 
gavage O 
250 O 
mg O 
kg(-1) O 
and O 
500 O 
mg O 
kg(-1) O 
of O 
diesel O 
fuel O 
dissolved O 
in O 
equal O 
amounts O 
of O 
sunflower O 
oil O 
, O 
respectively O 
. O 
The O 
rats O 
in O 
the O 
F250 O 
and O 
F500 O 
groups O 
were O 
administered O 
by O 
oral O 
gavage O 
250 O 
mg O 
kg(-1) O 
and O 
500 O 
mg O 
kg(-1) O 
of O 
fish O 
oil O 
biodiesel O 
dissolved O 
in O 
equal O 
amounts O 
of O 
sunflower O 
oil O 
, O 
respectively O 
. O 
At O 
the O 
end O 
of O 
the O 
study O 
, O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
and O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
levels O 
were O 
measured O 
in O 
the O 
whole O 
blood O 
; O 
catalase O 
( O 
CAT O 
) O 
activity O 
level O 
was O 
measured O 
in O 
erythrocytes O 
; O 
and O 
nitrite B-SYSTEMATIC 
( O 
NO(2) B-FORMULA 
) O 
and O 
nitrate B-SYSTEMATIC 
( O 
NO(3) B-FORMULA 
) O 
levels O 
were O 
measured O 
in O 
the O 
serum O 
. O 
It O 
was O 
observed O 
that O 
the O 
whole O 
blood O 
MDA B-ABBREVIATION 
levels O 
of O 
the O 
diesel O 
groups O 
were O 
considerably O 
different O 
from O 
those O 
in O 
the O 
control O 
and O 
fish O 
oil O 
biodiesel O 
groups O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
GSH B-ABBREVIATION 
levels O 
in O 
the O 
control O 
group O 
were O 
observed O 
to O 
be O 
considerably O 
different O 
from O 
those O 
in O 
all O 
other O 
groups O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
Serum O 
NO(3) B-FORMULA 
concentrations O 
in O 
the O 
diesel O 
groups O 
were O 
found O 
to O 
be O 
considerably O 
different O 
from O 
those O 
in O 
the O 
control O 
and O 
biodiesel O 
groups O 
. O 
Serum O 
NO(2) B-FORMULA 
concentrations O 
in O 
one O 
of O 
the O 
diesel O 
groups O 
were O 
significantly O 
different O 
from O 
those O 
in O 
the O 
control O 
and O 
biodiesel O 
groups O 
( O 
p O 
< O 
0.01 O 
and O 
p O 
< O 
0.05 O 
, O 
respectively O 
) O 
. O 
The O 
CAT O 
activity O 
of O 
the O 
control O 
group O 
was O 
observed O 
to O 
be O 
different O 
from O 
that O 
in O 
the O 
other O 
groups O 
. O 
According O 
to O 
these O 
results O 
, O 
both O 
fish O 
oil O 
biodiesel O 
and O 
diesel O 
fuel O 
are O 
thought O 
to O 
cause O 
lipid O 
peroxidation O 
. O 
It O 
was O 
observed O 
that O 
fish O 
oil O 
biodiesel O 
does O 
not O 
induce O 
as O 
much O 
oxidative O 
damage O 
as O 
does O 
the O 
diesel O 
fuel O 
. O 
It O 
is O 
suggested O 
that O 
fish O 
oil O 
biodiesel O 
should O 
be O 
preferred O 
as O 
an O 
alternative O 
to O 
the O 
diesel O 
. O 

of O 
tocopherol B-FAMILY 
on O 
biochemical O 
blood O 
parameters O 
in O 
pleuritis O 
- O 
induced O 
rats O 
treated O 
with O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
effect O 
of O 
tocopherol B-FAMILY 
on O 
pleuritis O 
- O 
induced O 
rats O 
exposed O 
to O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
. O 
Rats O 
were O 
treated O 
with O 
a O 
single O 
TCDD B-ABBREVIATION 
dose O 
of O 
5 O 
μg O 
/ O 
kg O 
body O 
weight O 
( O 
b.w O 
. O 
) O 
and O 
then O 
for O 
3 O 
weeks O 
they O 
were O 
daily O 
supplemented O 
with O 
tocopherol B-FAMILY 
at O 
a O 
dose O 
of O 
30 O 
mg O 
/ O 
kg O 
b.w O 
. O 
The O 
inflammation O 
was O 
initiated O 
by O 
intrapleural O 
injection O 
of O 
a O 
single O 
dose O 
of O 
1% O 
carrageenin O 
solution O 
in O 
a O 
volume O 
of O 
0.15 O 
ml O 
. O 
Changes O 
in O 
biochemical O 
blood O 
parameters O 
were O 
measured O 
three O 
times O 
at O 
the O 
24th O 
, O 
72nd O 
and O 
120th O 
hour O 
of O 
pleuritis O 
and O 
the O 
blood O 
was O 
collected O 
from O 
20 O 
animals O 
of O 
each O 
group O 
of O 
rats O 
( O 
group O 
with O 
the O 
control O 
inflammation O 
; O 
group O 
treated O 
with O 
TCDD B-ABBREVIATION 
and O 
with O 
control O 
inflammation O 
; O 
group O 
treated O 
with O 
TCDD B-ABBREVIATION 
, O 
supplemented O 
with O 
tocopherol O 
and O 
with O 
the O 
inflammation O 
) O 
. O 
The O 
following O 
biochemical O 
parameters O 
were O 
measured O 
: O 
tumor O 
necrosis O 
factor O 
( O 
TNF O 
) O 
, O 
interleukin-1 O 
( O 
IL-1 O 
) O 
, O 
IL-2 O 
, O 
IL-4 O 
, O 
IL-6 O 
, O 
procollagen O 
, O 
telopeptide O 
, O 
fibrinogen O 
, O 
cholesterol B-TRIVIAL 
, O 
urea B-TRIVIAL 
, O 
creatinine B-TRIVIAL 
, O 
aspartate B-TRIVIAL 
aminotransferase O 
( O 
AspAT O 
) O 
and O 
alanine B-TRIVIAL 
aminotransferase O 
( O 
AlAT O 
) O 
. O 
Daily O 
supplementation O 
of O 
tocopherol B-FAMILY 
caused O 
significant O 
changes O 
in O 
the O 
level O 
of O 
TNF O 
, O 
IL-1 O 
, O 
IL-4 O 
, O 
IL-6 O 
, O 
urea B-TRIVIAL 
, O 
creatinine B-TRIVIAL 
, O 
AspAT O 
and O 
AlAT O 
. O 
According O 
to O 
the O 
results O 
of O 
these O 
studies O 
, O 
we O 
suggest O 
that O 
tocopherol B-FAMILY 
supplementation O 
in O 
high O 
doses O 
could O 
act O 
as O 
a O 
protective O 
treatment O 
to O 
improve O 
liver O 
metabolism O 
. O 

study O 
describes O 
the O 
cytotoxic O 
and O 
phytotoxic O 
activities O 
of O 
the O 
crude O 
extract O 
of O 
Heliotropium O 
strigosum O 
and O 
its O 
resultant O 
fractions O 
. O 
In O 
brine O 
shrimp O 
toxicology O 
assays O 
, O 
profound O 
cytotoxicity O 
was O 
displayed O 
by O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
LD(50) O 
8.3 O 
μg O 
/ O 
ml O 
) O 
and O 
chloroform B-TRIVIAL 
( O 
LD(50) O 
8.8 O 
μg O 
/ O 
ml O 
) O 
fractions O 
, O 
followed O 
by O 
relatively O 
weak O 
crude O 
methanolic O 
extract O 
of O 
H O 
. O 
strigosum O 
( O 
LD(50) O 
909 O 
μg O 
/ O 
ml O 
) O 
and O 
n-hexane B-SYSTEMATIC 
fraction O 
( O 
LD(50) O 
1000 O 
μg O 
/ O 
ml O 
) O 
. O 
In O 
case O 
of O 
phytotoxicity O 
activity O 
against O 
Lemna O 
acquinoctialis O 
, O 
highest O 
phytotoxic O 
effect O 
was O 
showed O 
by O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
fraction O 
( O 
LD(50) O 
91 O 
μg O 
/ O 
ml O 
) O 
, O 
while O 
chloroform B-TRIVIAL 
fraction O 
, O 
plant O 
crude O 
extract O 
and O 
n-hexane B-SYSTEMATIC 
, O 
respectively O 
, O 
caused O 
50% O 
, O 
30.76 O 
± O 
1.1% O 
and O 
30.7 O 
± O 
1.1% O 
inhibitory O 
action O 
at O 
maximum O 
concentration O 
used O 
, O 
that O 
is O 
, O 
1000 O 
μg O 
/ O 
ml O 
. O 
These O 
data O 
indicates O 
that O 
H O 
. O 
strigosum O 
exhibits O 
cytotoxic O 
and O 
phytotoxic O 
potential O 
, O 
which O 
explore O 
its O 
use O 
as O 
anticancer O 
and O 
herbicidal O 
medicine O 
. O 
The O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
and O 
chloroform B-TRIVIAL 
fractions O 
were O 
more O 
potent O 
for O 
the O 
evaluated O 
toxicity O 
effects O 
, O 
thus O 
recommended O 
for O 
isolation O 
and O 
identification O 
of O 
the O 
active O 
compounds O 
. O 

(II) I-FAMILY 
polypyridyl I-FAMILY 
complexes O 
as O 
G-quadruplex O 
inducing O 
and O 
stabilizing O 
ligands O 
in O 
telomeric O 
DNA O 
. O 

ruthenium B-FAMILY 
(ii) I-FAMILY 
polypyridyl I-FAMILY 
complexes O 
[Ru(phen)2(4idip)](ClO4)2 B-FORMULA 
() O 
and O 
[Ru(bpy)2(4idip)](ClO4)2 B-FORMULA 
() O 
( O 
phen B-ABBREVIATION 
= O 
1,10-phenanthroline B-SYSTEMATIC 
, O 
bpy B-ABBREVIATION 
= O 
2,2'-bipyridine B-SYSTEMATIC 
, O 
4idip B-SYSTEMATIC 
= O 
4-indoleimidazo[4,5-f][1,10]phenanthroline B-SYSTEMATIC 
) O 
designed O 
as O 
telomeric O 
G-quadruplex O 
ligands O 
have O 
been O 
synthesized O 
and O 
characterized O 
. O 
The O 
interaction O 
of O 
human O 
telomeric O 
G-quadruplex O 
DNA O 
( O 
HTG21 O 
) O 
with O 
the O 
designed O 
ligands O 
was O 
explored O 
by O 
fluorescence O 
analysis O 
, O 
absorption O 
spectroscopy O 
, O 
continuous O 
variation O 
, O 
circular O 
dichroism O 
spectroscopy O 
, O 
fluorescence O 
resonance O 
energy O 
transfer O 
( O 
FRET O 
) O 
melting O 
assay O 
, O 
polymerase O 
chain O 
reaction O 
( O 
PCR O 
) O 
stop O 
assay O 
, O 
telomerase O 
repeat O 
amplification O 
protocol O 
( O 
TRAP O 
) O 
, O 
and O 
visual O 
studies O 
. O 
The O 
results O 
showed O 
that O 
both O 
complexes O 
could O 
induce O 
and O 
stabilize O 
different O 
G-quadruplex O 
structures O 
by O 
using O 
a O 
1 O 
: O 
1 O 
[ O 
quadruplex O 
] O 
/ O 
[ O 
complex O 
] O 
binding O 
mode O 
ratio O 
. O 
Complex O 
exhibited O 
higher O 
interaction O 
ability O 
and O 
better O 
G-quadruplex O 
selectivity O 
than O 
duplex O 
DNA O 
. O 
Furthermore O 
, O 
both O 
ruthenium B-SYSTEMATIC 
complexes O 
led O 
to O 
the O 
inhibition O 
of O 
the O 
enzyme O 
telomerase O 
, O 
and O 
complex O 
was O 
the O 
significantly O 
better O 
inhibitor O 
. O 

: O 
The O 
head O 
- O 
twitch O 
response O 
( O 
HTR O 
) O 
is O 
a O 
rapid O 
side-to O 
- O 
side O 
rotational O 
head O 
movement O 
that O 
occurs O 
in O 
rats O 
and O 
mice O 
after O 
administration O 
of O 
serotonergic O 
hallucinogens O 
and O 
other O 
5-HT B-SYSTEMATIC 
( O 
2A O 
) O 
agonists O 
. O 
The O 
HTR O 
is O 
widely O 
used O 
as O 
a O 
behavioral O 
assay O 
for O 
5-HT B-SYSTEMATIC 
( O 
2A O 
) O 
activation O 
and O 
to O 
probe O 
for O 
interactions O 
between O 
the O 
5-HT B-SYSTEMATIC 
( O 
2A O 
) O 
receptor O 
and O 
other O 
transmitter O 
systems O 
. O 
OBJECTIVE O 
: O 
High O 
- O 
speed O 
video O 
recordings O 
were O 
used O 
to O 
analyze O 
the O 
head O 
movement O 
that O 
occurs O 
during O 
head O 
twitches O 
in O 
C57BL O 
/ O 
6J O 
mice O 
. O 
Experiments O 
were O 
also O 
conducted O 
in O 
C57BL O 
/ O 
6J O 
mice O 
to O 
determine O 
whether O 
a O 
head O 
- O 
mounted O 
magnet O 
and O 
a O 
magnetometer O 
coil O 
could O 
be O 
used O 
to O 
detect O 
the O 
HTR O 
induced O 
by O 
serotonergic O 
hallucinations O 
based O 
on O 
the O 
dynamics O 
of O 
the O 
response O 
. O 
RESULTS O 
: O 
Head O 
movement O 
during O 
the O 
HTR O 
was O 
highly O 
rhythmic O 
and O 
occurred O 
within O 
a O 
specific O 
frequency O 
range O 
( O 
mean O 
head O 
movement O 
frequency O 
of O 
90.3 O 
Hz O 
) O 
. O 
Head O 
twitches O 
produced O 
wave O 
- O 
like O 
oscillations O 
of O 
magnetometer O 
coil O 
voltage O 
that O 
matched O 
the O 
frequency O 
of O 
head O 
movement O 
during O 
the O 
response O 
. O 
The O 
magnetometer O 
coil O 
detected O 
the O 
HTR O 
induced O 
by O 
the O 
serotonergic O 
hallucinogens O 
2,5-dimethoxy-4-iodoamphetamine B-SYSTEMATIC 
( O 
DOI B-ABBREVIATION 
; O 
0.25 O 
, O 
0.5 O 
, O 
and O 
1 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
and O 
lysergic B-SYSTEMATIC 
acid I-SYSTEMATIC 
diethylamide I-SYSTEMATIC 
( O 
LSD B-ABBREVIATION 
; O 
0.05 O 
, O 
0.1 O 
, O 
0.2 O 
, O 
and O 
0.4 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
with O 
extremely O 
high O 
sensitivity O 
and O 
specificity O 
. O 
Magnetometer O 
coil O 
recordings O 
demonstrated O 
that O 
the O 
non-hallucinogenic O 
compounds O 
(+)-amphetamine B-TRIVIAL 
( O 
2.5 O 
and O 
5 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
and O 
lisuride B-TRIVIAL 
( O 
0.8 O 
, O 
1.6 O 
, O 
and O 
3.2 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
did O 
not O 
induce O 
the O 
HTR O 
. O 
CONCLUSIONS O 
: O 
These O 
studies O 
confirm O 
that O 
a O 
magnetometer O 
coil O 
can O 
be O 
used O 
to O 
detect O 
the O 
HTR O 
induced O 
by O 
hallucinogens O 
. O 
The O 
use O 
of O 
magnetometer O 
- O 
based O 
HTR O 
detection O 
provides O 
a O 
high O 
- O 
throughput O 
, O 
semi-automated O 
assay O 
for O 
this O 
behavior O 
, O 
and O 
offers O 
several O 
advantages O 
over O 
traditional O 
assessment O 
methods O 
. O 

Excretion O 
Dynamic O 
during O 
Subacute O 
Oral O 
Exposure O 
to O 
Different O 
Pb B-FORMULA 
Species O 
in O 
Rattus O 
norvegicus O 
. O 

excretion O 
is O 
a O 
basic O 
means O 
of O 
detoxification O 
upon O 
ingestion O 
of O 
Pb B-FORMULA 
-contaminated O 
feed O 
. O 
In O 
order O 
to O 
determine O 
a O 
time O 
course O 
of O 
Pb B-FORMULA 
elimination O 
after O 
oral O 
exposure O 
to O 
two O 
different O 
forms O 
of O 
this O 
heavy O 
metal O 
( O 
lead B-SYSTEMATIC 
acetate I-SYSTEMATIC 
vs O 
. O 
phyto O 
- O 
bound O 
Pb B-FORMULA 
) O 
, O 
a O 
feeding O 
study O 
was O 
carried O 
out O 
in O 
experimental O 
rats O 
using O 
the O 
Pb B-FORMULA 
phyto O 
- O 
hyperaccumulator O 
Pistia O 
stratiotes O 
as O 
a O 
model O 
diet O 
. O 
The O 
effect O 
of O 
starvation O 
on O 
Pb B-FORMULA 
excretion O 
was O 
further O 
studied O 
in O 
rats O 
that O 
were O 
fed O 
plant O 
material O 
. O 
Twelve O 
Pb B-FORMULA 
doses O 
( O 
7 O 
μg O 
Pb B-FORMULA 
/ O 
1 O 
g O 
BW O 
) O 
were O 
administered O 
orally O 
over O 
a O 
5-week O 
period O 
. O 
Faeces O 
samples O 
were O 
collected O 
24 O 
and O 
72 O 
h O 
post O 
- O 
exposure O 
. O 
Inductively O 
coupled O 
plasma O 
optical O 
emission O 
spectrometry O 
and O 
electrothermal O 
absorption O 
spectrometry O 
methods O 
were O 
used O 
for O 
determination O 
of O 
heavy O 
metal O 
concentrations O 
. O 
Up O 
to O 
53 O 
% O 
of O 
ingested O 
Pb B-FORMULA 
was O 
rapidly O 
eliminated O 
from O 
the O 
exposed O 
rats O 
via O 
faeces O 
within O 
24 O 
h O 
after O 
exposure O 
. O 
Faecal O 
excretion O 
in O 
exposed O 
rats O 
differed O 
significantly O 
when O 
compared O 
to O 
that O 
of O 
the O 
control O 
group O 
. O 
Fasting O 
before O 
exposure O 
reduced O 
Pb B-FORMULA 
excretion O 
by O 
up O 
to O 
50 O 
% O 
. O 
Faecal O 
excretions O 
of O 
both O 
examined O 
Pb B-FORMULA 
forms O 
exhibited O 
almost O 
identical O 
patterns O 
. O 
Considerable O 
differences O 
were O 
revealed O 
concerning O 
total O 
excretion O 
levels O 
; O 
lead B-SYSTEMATIC 
acetate I-SYSTEMATIC 
was O 
excreted O 
in O 
amount O 
greater O 
extent O 
than O 
those O 
of O 
phytobound O 
Pb B-FORMULA 
. O 
Results O 
of O 
our O 
study O 
suggest O 
that O 
Pb B-FORMULA 
forms O 
occurring O 
in O 
the O 
P O 
. O 
stratiotes O 
tissues O 
are O 
absorbed O 
through O 
the O 
gastrointestinal O 
tract O 
to O 
a O 
greater O 
extent O 
than O 
Pb B-FORMULA 
from O 
lead B-SYSTEMATIC 
acetate I-SYSTEMATIC 
. O 
Therefore O 
, O 
higher O 
portions O 
of O 
ingested O 
Pb B-FORMULA 
can O 
be O 
available O 
for O 
potential O 
accumulation O 
in O 
tissues O 
of O 
exposed O 
subjects O 
. O 

sanguinea O 
and O 
Echinacea O 
pallida O 
extracts O 
stimulate O 
glucuronidation O 
and O 
basolateral O 
transfer O 
of O 
Bauer O 
alkamides B-FAMILY 
8 O 
and O 
10 O 
and O 
ketone B-SYSTEMATIC 
24 O 
and O 
inhibit O 
P-glycoprotein O 
transporter O 
in O 
Caco-2 O 
cells O 
. O 

use O 
of O 
Echinacea O 
as O 
a O 
medicinal O 
herb O 
is O 
prominent O 
in O 
the O 
United O 
States O 
, O 
and O 
many O 
studies O 
have O 
assessed O 
the O 
effectiveness O 
of O 
Echinacea O 
as O 
an O 
immunomodulator O 
. O 
We O 
hypothesized O 
that O 
Bauer O 
alkamides B-FAMILY 
8 O 
, O 
10 O 
, O 
and O 
11 O 
and O 
ketone B-SYSTEMATIC 
24 O 
were O 
absorbed O 
similarly O 
either O 
as O 
pure O 
compounds O 
or O 
from O 
Echinacea O 
sanguinea O 
and O 
Echinacea O 
pallida O 
ethanol B-SYSTEMATIC 
extracts O 
, O 
and O 
that O 
these O 
Echinacea O 
extracts O 
could O 
inhibit O 
the O 
P-glycoprotein O 
transporter O 
in O 
Caco-2 O 
human O 
intestinal O 
epithelial O 
cells O 
. O 
Using O 
HPLC O 
analysis O 
, O 
the O 
permeation O 
rate O 
of O 
Bauer O 
alkamides B-FAMILY 
by O 
passive O 
diffusion O 
across O 
Caco-2 O 
cells O 
corresponded O 
with O 
compound O 
hydrophilicity O 
( O 
alkamide B-FAMILY 
8 O 
> O 
10 O 
> O 
11 O 
) O 
, O 
independent O 
of O 
the O 
plant O 
extract O 
matrix O 
. O 
Both O 
Echinacea O 
ethanol B-SYSTEMATIC 
extracts O 
stimulated O 
apparent O 
glucuronidation O 
and O 
basolateral O 
efflux O 
of O 
glucuronides O 
of O 
alkamides B-FAMILY 
8 O 
and O 
10 O 
but O 
not O 
alkamide B-FAMILY 
11 O 
. O 
Bauer O 
ketone B-SYSTEMATIC 
24 O 
was O 
totally O 
metabolized O 
to O 
more O 
hydrophilic O 
metabolites O 
when O 
administered O 
as O 
a O 
single O 
compound O 
, O 
but O 
was O 
also O 
glucuronidated O 
when O 
present O 
in O 
Echinacea O 
extracts O 
. O 
Bauer O 
alkamides B-FAMILY 
8 O 
, O 
10 O 
, O 
and O 
11 O 
( O 
175-230 O 
µM O 
) O 
and O 
ethanol B-SYSTEMATIC 
extracts O 
of O 
E O 
. O 
sanguinea O 
( O 
1 O 
mg O 
/ O 
mL O 
, O 
containing O 
~ O 
90 O 
µM O 
total O 
alkamides B-FAMILY 
) O 
and O 
E O 
. O 
pallida O 
( O 
5 O 
mg O 
/ O 
mL O 
, O 
containing O 
285 O 
µM O 
total O 
alkamides O 
) O 
decreased O 
the O 
efflux O 
of O 
the O 
P-glycoprotein O 
transporter O 
probe O 
calcein-AM O 
from O 
Caco-2 O 
cells O 
. O 
These O 
results O 
suggest O 
that O 
other O 
constituents O 
in O 
these O 
Echinacea O 
extracts O 
facilitated O 
the O 
metabolism O 
and O 
efflux O 
of O 
alkamides B-FAMILY 
and O 
ketones B-FAMILY 
, O 
which O 
might O 
improve O 
therapeutic O 
benefits O 
. O 
Alkamides B-FAMILY 
and O 
Echinacea O 
extracts O 
might O 
be O 
useful O 
in O 
potentiating O 
some O 
chemotherapeutics O 
, O 
which O 
are O 
substrates O 
for O 
the O 
P-glycoprotein O 
transporter O 
. O 

south O 
coast O 
of O 
Laizhou O 
Bay O 
, O 
in O 
northeastern O 
China O 
, O 
is O 
a O 
production O 
area O 
for O 
halogenated O 
flame O 
retardants O 
( O 
HFR O 
) O 
. O 
In O 
2007 O 
, O 
the O 
authors O 
measured O 
serum O 
concentrations O 
of O 
polybrominated B-FAMILY 
diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
in O 
Laizhou O 
Bay O 
residents O 
. O 
To O 
assess O 
the O 
PBDE B-ABBREVIATION 
concentration O 
trend O 
, O 
and O 
determine O 
the O 
concentrations O 
of O 
the O 
emerging O 
flame O 
retardants O 
Dechlorane B-TRIVIAL 
Plus I-TRIVIAL 
( O 
DP O 
) O 
and O 
bis(2-ethylhexyl)-3,4,5,6-tetrabromophthalate B-SYSTEMATIC 
( O 
TBPH B-ABBREVIATION 
) O 
, O 
the O 
authors O 
measured O 
the O 
concentrations O 
of O 
8 O 
PBDE B-ABBREVIATION 
congeners O 
, O 
2 O 
DP O 
isomers O 
, O 
and O 
TBPH B-ABBREVIATION 
in O 
10 O 
composite O 
samples O 
, O 
which O 
were O 
pooled O 
from O 
the O 
serum O 
collected O 
from O 
305 O 
Laizhou O 
Bay O 
residents O 
in O 
October O 
2011 O 
. O 
The O 
average O 
concentration O 
of O 
the O 
total O 
PBDE B-ABBREVIATION 
( O 
∑8 O 
PBDE B-ABBREVIATION 
) O 
concentration O 
in O 
all O 
serum O 
pools O 
was O 
240 O 
ng O 
/ O 
g O 
lipid O 
weight O 
, O 
and O 
the O 
highest O 
serum O 
pool O 
concentration O 
( O 
in O 
the O 
30- O 
to O 
39-yr- O 
old O 
male O 
group O 
) O 
was O 
780 O 
ng O 
/ O 
g O 
lipid O 
weight O 
. O 
Brominated B-SYSTEMATIC 
diphenyl I-SYSTEMATIC 
ether-209 I-SYSTEMATIC 
was O 
the O 
dominant O 
congener O 
, O 
accounting O 
for O 
87% O 
of O 
∑8 O 
PBDE B-ABBREVIATION 
. O 
Compared O 
with O 
a O 
previous O 
study O 
, O 
∑8 O 
PBDE B-ABBREVIATION 
serum O 
concentrations O 
in O 
the O 
present O 
study O 
showed O 
no O 
change O 
in O 
order O 
of O 
magnitude O 
, O 
but O 
the O 
relative O 
contribution O 
of O 
BDE-209 B-IDENTIFIER 
to O 
∑8 O 
PBDE B-ABBREVIATION 
was O 
higher O 
. O 
The O 
average O 
concentration O 
of O 
∑DP O 
in O 
all O 
serum O 
pools O 
was O 
3.6 O 
ng O 
/ O 
g O 
lipid O 
weight O 
, O 
ranging O 
from O 
1.4 O 
ng O 
/ O 
g O 
lipid O 
weight O 
( O 
in O 
the O 
50- O 
to O 
59-yr- O 
old O 
male O 
group O 
) O 
to O 
11 O 
ng O 
/ O 
g O 
lipid O 
weight O 
( O 
in O 
the O 
20- O 
to O 
29-yr- O 
old O 
male O 
group O 
) O 
. O 
The O 
concentration O 
of O 
DP O 
was O 
lower O 
than O 
in O 
other O 
reported O 
studies O 
. O 
The O 
study O 
also O 
detected O 
TBPH B-ABBREVIATION 
in O 
the O 
30- O 
to O 
39-yr- O 
old O 
female O 
group O 
, O 
suggesting O 
that O 
TBPH B-ABBREVIATION 
, O 
as O 
an O 
emerging O 
HFR O 
, O 
requires O 
further O 
monitoring O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1242-1247 O 
. O 
© O 
2013 O 
SETAC O 
. O 

and O 
NMR O 
studies O 
of O 
novel O 
chromone-2-carboxamide B-SYSTEMATIC 
derivatives O 
. O 

are O 
heterocyclic O 
compounds O 
of O 
natural O 
or O 
synthetic O 
origin O 
that O 
possess O 
relevant O 
pharmacological O 
activities O 
. O 
Versatile O 
functionalization O 
of O 
the O 
chromone B-TRIVIAL 
nucleus O 
allows O 
attaining O 
of O 
a O 
chemical O 
diversity O 
suitable O 
to O 
perform O 
structure O 
- O 
activity O 
relationships O 
in O 
drug O 
discovery O 
and O 
development O 
programs O 
. O 
Accordingly O 
, O 
the O 
synthesis O 
and O 
identification O 
of O 
novel O 
chromone B-SYSTEMATIC 
carboxamide I-SYSTEMATIC 
derivatives O 
with O 
electron O 
- O 
donating O 
and O 
electron O 
- O 
withdrawing O 
substituents O 
in O 
different O 
positions O 
of O 
the O 
exocyclic O 
ring O 
are O 
reported O 
in O 
this O 
work O 
. O 
Their O 
complete O 
structural O 
characterization O 
was O 
performed O 
using O 
one O 
- O 
dimensional O 
and O 
two O 
- O 
dimensional O 
resonance O 
techniques O 
. O 
The O 
data O 
acquired O 
are O 
useful O 
for O 
a O 
prompt O 
analysis O 
of O 
related O 
compounds O 
that O 
encompass O 
our O 
integrated O 
medicinal O 
chemistry O 
sketch O 
. O 

new O 
insights O 
into O 
the O 
complexities O 
of O 
endochondral O 
fracture O 
repair O 
emerge O 
, O 
the O 
temporal O 
role O 
of O 
osteoclast O 
activity O 
remains O 
ambiguous O 
. O 
With O 
numerous O 
anti-resorptive O 
agents O 
available O 
to O 
treat O 
bone O 
disease O 
, O 
understanding O 
their O 
impact O 
on O 
bone O 
repair O 
is O 
vital O 
. O 
Further O 
, O 
in O 
light O 
of O 
recent O 
work O 
suggesting O 
osteoclast O 
activity O 
may O 
not O 
be O 
necessary O 
during O 
early O 
endochondral O 
fracture O 
union O 
, O 
we O 
hypothesize O 
instead O 
a O 
pivotal O 
role O 
of O 
MMP O 
secreting O 
cells O 
in O 
driving O 
this O 
process O 
. O 
While O 
the O 
role O 
of O 
MMPs O 
in O 
fracture O 
healing O 
has O 
been O 
examined O 
, O 
no O 
directly O 
comparative O 
experiments O 
exist O 
. O 
We O 
examined O 
a O 
number O 
of O 
anti-resorptive O 
treatments O 
to O 
either O 
block O 
osteoclast O 
activity O 
, O 
including O 
the O 
potent O 
bisphosphonates B-FAMILY 
zoledronic B-TRIVIAL 
acid I-TRIVIAL 
( O 
ZA O 
) O 
and O 
clodronate B-TRIVIAL 
( O 
CLOD B-ABBREVIATION 
) O 
, O 
which O 
work O 
via O 
differing O 
mechanisms O 
, O 
or O 
antagonize O 
osteoclastogenesis O 
with O 
recombinant O 
OPG O 
( O 
HuOPG-Fc O 
) O 
, O 
comparing O 
these O 
directly O 
to O 
an O 
inhibitor O 
of O 
matrix O 
metalloproteinase O 
( O 
MMP O 
) O 
activity O 
( O 
MMI270 O 
) O 
. O 
Endochondral O 
ossification O 
to O 
union O 
occurred O 
normally O 
in O 
all O 
anti-resorptive O 
groups O 
. O 
In O 
contrast O 
, O 
MMP O 
inhibition O 
greatly O 
impaired O 
endochondral O 
union O 
, O 
significantly O 
delaying O 
cartilage O 
callus O 
removal O 
. O 
MMP O 
inhibition O 
also O 
produced O 
smaller O 
, O 
denser O 
hard O 
calluses O 
. O 
Hard O 
callus O 
remodeling O 
was O 
, O 
as O 
expected O 
, O 
delayed O 
with O 
ZA O 
, O 
CLOD B-ABBREVIATION 
and O 
OPG O 
treatment O 
at O 
4 O 
and O 
6 O 
weeks O 
, O 
resulting O 
in O 
larger O 
more O 
mineralized O 
calluses O 
at O 
6 O 
weeks O 
. O 
As O 
a O 
result O 
of O 
reduced O 
hard O 
callus O 
turnover O 
, O 
bone O 
formation O 
was O 
reduced O 
with O 
anti-resorptive O 
agents O 
at O 
these O 
time O 
points O 
. O 
These O 
results O 
confirm O 
that O 
the O 
achievement O 
of O 
endochondral O 
fracture O 
union O 
occurs O 
independently O 
of O 
osteoclast O 
activity O 
. O 
Alternatively O 
, O 
MMP O 
secretion O 
by O 
invading O 
cells O 
is O 
obligatory O 
to O 
endochondral O 
union O 
. O 
This O 
study O 
provides O 
new O 
insight O 
into O 
cellular O 
contributions O 
to O 
bone O 
repair O 
and O 
may O 
abate O 
concerns O 
regarding O 
anti-resorptive O 
therapies O 
impeding O 
initial O 
fracture O 
union O 
. O 
© O 
2013 O 
American O 
Society O 
for O 
Bone O 
and O 
Mineral O 
Research O 
. O 

and O 
risk O 
of O 
subtrochanteric O 
, O 
femoral O 
shaft O 
, O 
and O 
atypical O 
femur O 
fracture O 
: O 
A O 
systematic O 
review O 
and O 
meta-analysis O 
. O 

there O 
is O 
strong O 
evidence O 
that O 
bisphosphonates B-FAMILY 
prevent O 
certain O 
types O 
of O 
osteoporotic O 
fractures O 
, O 
there O 
are O 
concerns O 
that O 
these O 
medications O 
may O 
be O 
associated O 
with O 
rare O 
atypical O 
femoral O 
fractures O 
( O 
AFF O 
) O 
. O 
Recent O 
published O 
studies O 
examining O 
this O 
potential O 
association O 
are O 
conflicting O 
in O 
regards O 
to O 
the O 
existence O 
and O 
strength O 
of O 
this O 
association O 
. O 
We O 
conducted O 
a O 
systematic O 
review O 
and O 
meta-analysis O 
of O 
published O 
studies O 
examining O 
the O 
association O 
of O 
bisphosphonates B-FAMILY 
with O 
subtrochanteric O 
, O 
femoral O 
shaft O 
, O 
and O 
AFF O 
. O 
The O 
random O 
- O 
effects O 
model O 
was O 
used O 
to O 
calculate O 
the O 
pooled O 
estimates O 
of O 
adjusted O 
risk O 
ratios O 
( O 
RR O 
) O 
. O 
Subgroup O 
analysis O 
was O 
performed O 
by O 
study O 
design O 
, O 
for O 
studies O 
that O 
used O 
validated O 
outcome O 
definitions O 
for O 
AFF O 
, O 
and O 
for O 
studies O 
reporting O 
on O 
duration O 
of O 
bisphosphonate B-SYSTEMATIC 
use O 
. O 
Eleven O 
studies O 
were O 
included O 
in O 
the O 
meta-analysis O 
: O 
five O 
case O 
- O 
control O 
and O 
six O 
cohort O 
studies O 
. O 
Bisphosphonate B-SYSTEMATIC 
exposure O 
was O 
associated O 
with O 
an O 
increased O 
risk O 
of O 
subtrochanteric O 
, O 
femoral O 
shaft O 
, O 
and O 
AFF O 
with O 
adjusted O 
RR O 
of O 
1.7 O 
( O 
95% O 
CI O 
1.22-2.37 O 
) O 
. O 
Subgroup O 
analysis O 
of O 
studies O 
using O 
the O 
ASBMR-criteria O 
to O 
define O 
AFF O 
suggests O 
a O 
higher O 
risk O 
of O 
AFF O 
with O 
bisphosphonate B-SYSTEMATIC 
use O 
with O 
RR O 
of O 
11.78 O 
( O 
95% O 
CI O 
0.39-359.69 O 
) O 
as O 
compared O 
to O 
studies O 
using O 
mainly O 
diagnosis O 
codes O 
( O 
RR O 
1.62 O 
, O 
95% O 
CI O 
1.18-2.22 O 
) O 
, O 
although O 
there O 
is O 
a O 
wide O 
confidence O 
interval O 
and O 
severe O 
heterogeneity O 
( O 
I(2) O 
= O 
96.15% O 
) O 
in O 
this O 
subgroup O 
analysis O 
. O 
Subgroup O 
analysis O 
of O 
studies O 
examining O 
at O 
least O 
5 O 
years O 
of O 
bisphosphonate B-SYSTEMATIC 
use O 
showed O 
adjusted O 
RR O 
of O 
1.62 O 
( O 
95% O 
CI O 
1.29-2.04 O 
) O 
. O 
This O 
meta-analysis O 
suggests O 
there O 
is O 
an O 
increased O 
risk O 
of O 
subtrochanteric O 
, O 
femoral O 
shaft O 
, O 
and O 
AFF O 
among O 
bisphosphonate B-SYSTEMATIC 
users O 
. O 
Further O 
research O 
examining O 
the O 
risk O 
of O 
AFF O 
with O 
long O 
- O 
term O 
use O 
of O 
bisphosphonates B-FAMILY 
is O 
indicated O 
as O 
there O 
was O 
limited O 
data O 
in O 
this O 
subgroup O 
. O 
The O 
public O 
health O 
implication O 
of O 
this O 
observed O 
increase O 
in O 
AFF O 
risk O 
is O 
not O 
clear O 
. O 
© O 
2013 O 
American O 
Society O 
for O 
Bone O 
and O 
Mineral O 
Research O 
. O 

inhibition O 
of O 
archaeal O 
family-D O 
DNA O 
polymerase O 
by O 
uracil B-TRIVIAL 
. O 

family-D O 
DNA O 
polymerase O 
is O 
inhibited O 
by O 
the O 
presence O 
of O 
uracil B-TRIVIAL 
in O 
DNA O 
template O 
strands O 
. O 
When O 
the O 
enzyme O 
encounters O 
uracil B-TRIVIAL 
, O 
following O 
three O 
parameters O 
change O 
: O 
DNA O 
binding O 
increases O 
roughly O 
2-fold O 
, O 
the O 
rate O 
of O 
polymerization O 
slows O 
by O 
a O 
factor O 
of O 
∼5 O 
and O 
3'-5 O 
' O 
proof O 
- O 
reading O 
exonuclease O 
activity O 
is O 
stimulated O 
by O 
a O 
factor O 
of O 
∼2 O 
. O 
Together O 
these O 
changes O 
result O 
in O 
a O 
significant O 
decrease O 
in O 
polymerization O 
activity O 
and O 
a O 
reduction O 
in O 
net O 
DNA O 
synthesis O 
. O 
Pol O 
D O 
appears O 
to O 
interact O 
with O 
template O 
strand O 
uracil B-TRIVIAL 
irrespective O 
of O 
its O 
distance O 
ahead O 
of O 
the O 
replication O 
fork O 
. O 
Polymerization O 
does O 
not O 
stop O 
at O 
a O 
defined O 
location O 
relative O 
to O 
uracil B-TRIVIAL 
, O 
rather O 
a O 
general O 
decrease O 
in O 
DNA O 
synthesis O 
is O 
observed O 
. O 
' O 
Trans' O 
inhibition O 
, O 
the O 
slowing O 
of O 
Pol O 
D O 
by O 
uracil B-TRIVIAL 
on O 
a O 
DNA O 
strand O 
not O 
being O 
replicated O 
is O 
also O 
observed O 
. O 
It O 
is O 
proposed O 
that O 
Pol O 
D O 
is O 
able O 
to O 
interact O 
with O 
uracil B-TRIVIAL 
by O 
looping O 
out O 
the O 
single O 
- O 
stranded O 
template O 
, O 
allowing O 
simultaneous O 
contact O 
of O 
both O 
the O 
base O 
and O 
the O 
primer O 
- O 
template O 
junction O 
to O 
give O 
a O 
polymerase-DNA O 
complex O 
with O 
diminished O 
extension O 
ability O 
. O 

derived O 
suppressor O 
cells O 
( O 
MDSCs O 
) O 
are O 
a O 
heterogeneous O 
population O 
of O 
myeloid O 
progenitors O 
that O 
can O 
play O 
a O 
major O 
role O 
in O 
tumour O 
development O 
and O 
chronic O 
inflammation O 
. O 
The O 
importance O 
of O 
the O 
suppressive O 
function O 
ofMDSCs O 
was O 
first O 
suggested O 
by O 
studies O 
involving O 
cancer O 
patients O 
and O 
cancer O 
- O 
bearing O 
mice O 
. O 
In O 
addition O 
, O 
recent O 
studies O 
have O 
demonstrated O 
that O 
MDSCs O 
can O 
also O 
be O 
involved O 
in O 
many O 
other O 
pathological O 
conditions O 
. O 
MDSCs O 
have O 
unique O 
ways O 
of O 
abrogatingan O 
immune O 
response O 
in O 
addition O 
to O 
those O 
utilised O 
by O 
other O 
immune O 
- O 
suppressive O 
cell O 
types O 
, O 
for O 
example O 
via O 
the O 
induction O 
of O 
arginase-1 O 
and O 
consequent O 
upregulation O 
in O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
production O 
. O 
Due O 
to O 
their O 
heterogeneity,they O 
further O 
can O 
express O 
a O 
variety O 
of O 
lineage O 
markers O 
, O 
which O 
overlap O 
with O 
other O 
myeloid O 
cell O 
types O 
such O 
as O 
Gr1,CD11b O 
, O 
MHCIIlo O 
, O 
Ly6C O 
and O 
Ly6G O 
, O 
making O 
it O 
difficult O 
to O 
identify O 
them O 
by O 
surface O 
phenotype O 
alone O 
. O 
The O 
disparity O 
between O 
mouse O 
and O 
human O 
MDSCs O 
further O 
complicates O 
the O 
identification O 
of O 
these O 
elusive O 
cell O 
populations O 
. O 
In O 
this O 
review O 
, O 
we O 
will O 
summarise O 
the O 
recent O 
updates O 
on O 
the O 
methods O 
for O 
eliciting O 
and O 
studying O 
different O 
MDSC O 
subsets O 
, O 
including O 
newly O 
proposed O 
surface O 
phenotypes O 
, O 
as O 
well O 
as O 
insights O 
into O 
how O 
their O 
function O 
is O 
being O 
characterised O 
in O 
both O 
mice O 
and O 
humans O 
. O 
In O 
addition O 
, O 
exciting O 
new O 
discoveries O 
suggesting O 
their O 
involvement O 
across O 
a O 
number O 
of O 
different O 
pathological O 
settings O 
, O 
such O 
as O 
sepsis O 
, O 
autoimmunity O 
and O 
Leishmaniasis O 
, O 
will O 
be O 
discussed O 
. O 

growth O 
factor O 
receptor-4 O 
( O 
FGFR4 O 
) O 
is O 
a O 
tyrosine B-TRIVIAL 
kinase O 
with O 
a O 
range O 
of O 
important O 
physiological O 
functions O 
. O 
However O 
, O 
it O 
is O 
also O 
frequently O 
mutated O 
in O 
various O 
cancers O 
and O 
is O 
now O 
generating O 
significant O 
interest O 
as O 
a O 
potential O 
therapeutic O 
target O 
. O 
Unfortunately O 
, O 
biochemical O 
characterization O 
of O 
its O 
role O 
in O 
disease O 
, O 
and O 
further O 
evaluation O 
as O 
a O 
drug O 
target O 
is O 
hampered O 
by O 
lack O 
of O 
a O 
specific O 
inhibitor O 
. O 
We O 
aimed O 
to O 
discover O 
new O 
inhibitors O 
for O 
FGFR4 O 
ab O 
initio O 
using O 
a O 
strategy O 
combining O 
in O 
silico O 
, O 
in O 
vitro O 
and O 
cell O 
- O 
based O 
assays O 
. O 
We O 
used O 
the O 
homologous O 
FGFR1 O 
to O 
calculate O 
docking O 
scores O 
of O 
a O 
chemically O 
- O 
diverse O 
library O 
of O 
approximately O 
2000 O 
potential O 
kinase O 
inhibitors O 
. O 
Nineteen O 
potential O 
inhibitors O 
and O 
ten O 
randomly- O 
selected O 
negative O 
controls O 
were O 
taken O 
forward O 
for O 
in O 
vitro O 
FGFR4 O 
kinase O 
assays O 
. O 
All O 
compounds O 
with O 
good O 
docking O 
scores O 
significantly O 
inhibited O 
FGFR4 O 
kinase O 
activity O 
, O 
some O 
with O 
sub O 
- O 
micromolar O 
( O 
most O 
potent O 
being O 
V4-015 B-IDENTIFIER 
with O 
an O 
IC(50) O 
of O 
0.04 O 
μM O 
) O 
. O 
Four O 
of O 
these O 
compounds O 
also O 
demonstrated O 
substantial O 
activity O 
in O 
cellular O 
assays O 
using O 
the O 
FGFR4- O 
overexpressing O 
breast O 
carcinoma O 
cell O 
line O 
, O 
MDA-MB453 O 
. O 
Through O 
immunoblot O 
assays O 
, O 
these O 
compounds O 
were O 
shown O 
to O 
block O 
the O 
phosphorylation O 
of O 
the O 
FGFR4 O 
adaptor O 
protein O 
, O 
FGFR O 
substrate O 
protein-2α O 
( O 
FRS2α O 
) O 
. O 
The O 
most O 
potent O 
compound O 
to O 
date O 
, O 
V4-015 B-IDENTIFIER 
, O 
suppressed O 
proliferation O 
of O 
MDA-MB453 O 
cells O 
at O 
sub O 
- O 
micromolar O 
concentrations O 
, O 
activated O 
the O 
pro O 
- O 
apoptotic O 
caspases O 
3 O 
/ O 
7 O 
and O 
inhibited O 
cellular O 
migration O 
. O 
While O 
achieving O 
complete O 
selectivity O 
of O 
this O 
compound O 
for O 
FGFR4 O 
will O 
require O 
further O 
lead O 
optimization O 
, O 
this O 
study O 
has O 
successfully O 
identified O 
new O 
chemical O 
scaffolds O 
with O 
unprecedented O 
FGFR4 O 
inhibition O 
capacities O 
that O 
will O 
support O 
mechanism O 
of O 
action O 
studies O 
and O 
future O 
anti-cancer O 
drug O 
design O 
. O 

bronchodilators O 
, O 
including O 
beta2-agonists O 
and O 
antimuscaric O 
receptor O 
antagonists O 
, O 
are O 
the O 
mainstay O 
of O 
pharmacotherapy O 
in O 
chronic O 
obstructive O 
pulmonary O 
disease O 
( O 
COPD O 
) O 
. O 
The O 
short O 
- O 
acting O 
beta2-agonists O 
, O 
including O 
salbutamol B-TRIVIAL 
, O 
and O 
fenoterol B-TRIVIAL 
, O 
have O 
a O 
rapid O 
onset O 
of O 
action O 
, O 
a O 
bronchodilating O 
effect O 
for O 
3-6 O 
h O 
and O 
are O 
used O 
on O 
demand O 
. O 
The O 
longacting O 
beta2-agonists O 
( O 
LABAs O 
) O 
, O 
including O 
salmeterol B-TRIVIAL 
and O 
formoterol B-TRIVIAL 
, O 
have O 
12-hour O 
duration O 
of O 
action O 
and O 
are O 
used O 
with O 
a O 
twice O 
- O 
daily O 
dosing O 
regimen O 
for O 
long O 
- O 
term O 
COPD O 
treatment O 
. O 
Unlike O 
salmeterol B-TRIVIAL 
, O 
formoterol B-TRIVIAL 
has O 
a O 
rapid O 
onset O 
of O 
action O 
. O 
Pharmacological O 
characteristics O 
required O 
by O 
novel O 
inhaled O 
LABAs O 
include O 
24 O 
h O 
bronchodilator O 
effect O 
in O 
vivo O 
which O 
would O 
make O 
them O 
suitable O 
for O 
once O 
daily O 
administration O 
( O 
ultra-LABA O 
) O 
, O 
high O 
potency O 
and O 
selectivity O 
for O 
beta2-adrenoceptors O 
, O 
rapid O 
onset O 
of O 
action O 
, O 
low O 
oral O 
bioavailability O 
( O 
< O 
5% O 
) O 
after O 
inhalation O 
, O 
and O 
high O 
systemic O 
clearance O 
. O 
Indacaterol B-TRIVIAL 
, O 
which O 
has O 
been O 
approved O 
for O 
long O 
- O 
term O 
treatment O 
of O 
COPD O 
in O 
Europe O 
and O 
in O 
the O 
USA O 
, O 
has O 
a O 
24-h O 
duration O 
of O 
action O 
and O 
a O 
once O 
- O 
daily O 
dosing O 
regimen O 
. O 
Newer O 
ultra-LABAs O 
, O 
including O 
olodaterol B-TRIVIAL 
, O 
vilanterol B-TRIVIAL 
, O 
milveterol B-TRIVIAL 
, O 
carmoterol B-TRIVIAL 
, O 
and O 
abediterol B-TRIVIAL 
, O 
are O 
in O 
development O 
. O 
Combination O 
with O 
ICS O 
( O 
fluticasone B-TRIVIAL 
/ O 
salmeterol B-TRIVIAL 
, O 
budesonide B-TRIVIAL 
/ O 
formoterol B-TRIVIAL 
, O 
beclomethasone B-TRIVIAL 
/ O 
formoterol B-TRIVIAL 
) O 
appears O 
to O 
provide O 
an O 
additional O 
benefit O 
over O 
the O 
monocomponent O 
therapy O 
, O 
although O 
the O 
extent O 
of O 
this O 
benefit O 
is O 
variable O 
and O 
often O 
not O 
clinically O 
significant O 
in O 
all O 
the O 
endpoints O 
assessed O 
. O 
In O 
patients O 
with O 
COPD O 
, O 
treatment O 
with O 
ICS O 
is O 
associated O 
with O 
increased O 
risk O 
of O 
pneumonia O 
which O 
should O 
be O 
carefully O 
considered O 
when O 
assessing O 
the O 
risk O 
/ O 
benefit O 
ratio O 
of O 
ICS O 
/ O 
LABA O 
combinations O 
. O 
Subphenotyping O 
of O 
patients O 
with O 
COPD O 
( O 
e.g O 
. O 
, O 
frequent O 
exacerbations O 
, O 
sputum O 
eosinophilia O 
, O 
mixed O 
asthma O 
/ O 
COPD O 
phenotype O 
) O 
might O 
help O 
identify O 
those O 
patients O 
who O 
are O 
most O 
likely O 
to O 
benefit O 
from O 
addition O 
of O 
ICS O 
to O 
bronchodilating O 
treatment O 
. O 
Ultra-LABA/ O 
long O 
- O 
acting O 
muscarinic O 
receptor O 
antagonist O 
( O 
LAMA O 
) O 
combination O 
treatment O 
is O 
under O 
development O 
and O 
is O 
likely O 
to O 
become O 
a O 
standard O 
pharmacological O 
strategy O 
for O 
COPD O 
. O 
Dual O 
- O 
pharmacology O 
inhaled O 
muscarinic O 
antagonist-beta2 O 
agonist O 
( O 
MABA O 
) O 
molecules O 
provide O 
a O 
new O 
approach O 
to O 
the O 
treatment O 
of O 
COPD O 
. O 

therapeutic O 
potential O 
of O 
allosteric O 
ligands O 
for O 
free O 
fatty B-FAMILY 
acid I-FAMILY 
sensitive O 
GPCRs O 
. O 

protein O 
coupled O 
receptors O 
( O 
GPCRs O 
) O 
are O 
the O 
most O 
historically O 
successful O 
therapeutic O 
targets O 
. O 
Despite O 
this O 
success O 
there O 
are O 
many O 
important O 
aspects O 
of O 
GPCR O 
pharmacology O 
and O 
function O 
that O 
have O 
yet O 
to O 
be O 
exploited O 
to O 
their O 
full O 
therapeutic O 
potential O 
. O 
One O 
in O 
particular O 
that O 
has O 
been O 
gaining O 
attention O 
in O 
recent O 
times O 
is O 
that O 
of O 
GPCR O 
ligands O 
that O 
bind O 
to O 
allosteric O 
sites O 
on O 
the O 
receptor O 
distinct O 
from O 
the O 
orthosteric O 
site O 
of O 
the O 
endogenous O 
ligand O 
. O 
As O 
therapeutics O 
, O 
allosteric O 
ligands O 
possess O 
many O 
theoretical O 
advantages O 
over O 
their O 
orthosteric O 
counterparts O 
, O 
including O 
more O 
complex O 
modes O 
of O 
action O 
, O 
improved O 
safety O 
, O 
more O 
physiologically O 
appropriate O 
responses O 
, O 
better O 
target O 
selectivity O 
, O 
and O 
reduced O 
likelihood O 
of O 
desensitisation O 
and O 
tachyphylaxis O 
. O 
Despite O 
these O 
advantages O 
, O 
the O 
development O 
of O 
allosteric O 
ligands O 
is O 
often O 
difficult O 
from O 
a O 
medicinal O 
chemistry O 
standpoint O 
due O 
to O 
the O 
more O 
complex O 
challenge O 
of O 
identifying O 
allosteric O 
leads O 
and O 
their O 
often O 
flat O 
or O 
confusing O 
SAR O 
. O 
The O 
present O 
review O 
will O 
consider O 
the O 
advantages O 
and O 
challenges O 
associated O 
with O 
allosteric O 
GPCR O 
ligands O 
, O 
and O 
examine O 
how O 
the O 
particular O 
properties O 
of O 
these O 
ligands O 
may O 
be O 
exploited O 
to O 
uncover O 
the O 
therapeutic O 
potential O 
for O 
free O 
fatty B-FAMILY 
acid I-FAMILY 
sensitive O 
GPCRs O 
. O 

polymerases O 
replicate O 
DNA O 
by O 
catalyzing O 
the O 
template O 
- O 
directed O 
polymerization O 
of O 
deoxynucleoside B-FAMILY 
triphosphate I-FAMILY 
( O 
dNTP B-ABBREVIATION 
) O 
substrates O 
onto O 
the O 
3 O 
' O 
end O 
of O 
a O 
growing O 
DNA O 
primer O 
strand O 
. O 
Many O 
DNA O 
polymerases O 
also O 
possess O 
a O 
separate O 
3'-5 O 
' O 
exonuclease O 
activity O 
that O 
is O 
used O 
to O 
remove O 
misincorporated O 
nucleotides B-FAMILY 
from O 
the O 
nascent O 
DNA O 
( O 
proofreading O 
) O 
. O 
The O 
polymerase O 
( O 
pol O 
) O 
and O 
exonuclease O 
( O 
exo O 
) O 
activities O 
are O 
spatially O 
separated O 
in O 
different O 
enzyme O 
domains O 
, O 
indicating O 
that O 
a O 
mechanism O 
must O 
exist O 
to O 
transfer O 
the O 
growing O 
primer O 
terminus O 
from O 
one O 
site O 
to O 
the O 
other O 
. O 
Here O 
we O 
report O 
a O 
single O 
- O 
molecule O 
Förster O 
resonance O 
energy O 
transfer O 
( O 
smFRET O 
) O 
system O 
that O 
directly O 
monitors O 
the O 
movement O 
of O 
a O 
DNA O 
substrate O 
between O 
the O 
pol O 
and O 
exo O 
sites O 
of O 
DNA O 
polymerase O 
I O 
Klenow O 
fragment O 
( O 
KF O 
) O 
. O 
FRET O 
trajectories O 
recorded O 
during O 
the O 
encounter O 
between O 
single O 
polymerase O 
and O 
DNA O 
molecules O 
reveal O 
that O 
DNA O 
can O 
channel O 
between O 
the O 
pol O 
and O 
exo O 
sites O 
in O 
both O 
directions O 
while O 
remaining O 
closely O 
associated O 
with O 
the O 
enzyme O 
( O 
intramolecular O 
transfer O 
) O 
. O 
In O 
addition O 
, O 
it O 
is O 
evident O 
from O 
the O 
trajectories O 
that O 
DNA O 
can O 
also O 
dissociate O 
from O 
one O 
site O 
and O 
subsequently O 
rebind O 
at O 
the O 
other O 
( O 
intermolecular O 
transfer O 
) O 
. O 
Rate O 
constants O 
for O 
each O 
pathway O 
have O 
been O 
determined O 
by O 
dwell O 
- O 
time O 
analysis O 
, O 
revealing O 
that O 
intramolecular O 
transfer O 
is O 
the O 
faster O 
of O 
the O 
two O 
pathways O 
. O 
Unexpectedly O 
, O 
a O 
mispaired O 
primer O 
terminus O 
accesses O 
the O 
exo O 
site O 
more O 
frequently O 
when O 
dNTP B-ABBREVIATION 
substrates O 
are O 
also O 
present O 
in O 
solution O 
, O 
which O 
is O 
expected O 
to O 
enhance O 
proofreading O 
. O 
Together O 
, O 
these O 
results O 
explain O 
how O 
the O 
separate O 
pol O 
and O 
exo O 
activities O 
of O 
KF O 
are O 
physically O 
coordinated O 
to O 
achieve O 
efficient O 
proofreading O 
. O 

patent O 
application O 
WO2012082947 O 
claims O 
novel O 
compounds O 
as O 
agonists O 
of O 
a O 
plasma O 
membrane O 
- O 
bound O 
bile O 
acid O 
receptor O 
TGR5 O 
. O 
By O 
activating O 
TGR5 O 
, O 
the O 
agonists O 
improve O 
glycemic O 
control O 
and O 
enhance O 
energy O 
expenditure O 
. O 
The O 
basic O 
generic O 
claim O 
of O 
the O 
patent O 
covers O 
pyrazole B-SYSTEMATIC 
derivatives O 
, O 
different O 
permutations O 
on O 
the O 
core O 
pyrazole B-SYSTEMATIC 
ring O 
are O 
covered O 
in O 
the O 
subsidiary O 
claims O 
. O 
The O 
claimed O 
compounds O 
are O 
human O 
TGR5 O 
agonists O 
having O 
potency O 
in O 
the O 
nM O 
range O 
. O 

and O 
structure O 
- O 
activity O 
relationships O 
of O 
indazole B-FAMILY 
arylsulfonamides I-FAMILY 
as O 
allosteric O 
CC-chemokine O 
receptor O 
4 O 
( O 
CCR4 O 
) O 
antagonists O 
. O 

series O 
of O 
indazole B-FAMILY 
arylsulfonamides I-FAMILY 
were O 
synthesized O 
and O 
examined O 
as O 
human O 
CCR4 O 
antagonists O 
. O 
Methoxy B-SYSTEMATIC 
- O 
or O 
hydroxyl B-SYSTEMATIC 
-containing O 
groups O 
were O 
the O 
more O 
potent O 
indazole B-SYSTEMATIC 
C4 O 
substituents O 
. O 
Only O 
small O 
groups O 
were O 
tolerated O 
at O 
C5 O 
, O 
C6 O 
, O 
or O 
C7 O 
, O 
with O 
the O 
C6 O 
analogues O 
being O 
preferred O 
. O 
The O 
most O 
potent O 
N3- O 
substituent O 
was O 
5-chlorothiophene-2-sulfonamide B-SYSTEMATIC 
. O 
N1 O 
meta- O 
substituted O 
benzyl B-SYSTEMATIC 
groups O 
possessing O 
an O 
α-amino- O 
3-[(methylamino)acyl] B-SYSTEMATIC 
-group O 
were O 
the O 
most O 
potent O 
N1- O 
substituents O 
. O 
Strongly O 
basic O 
amino B-FAMILY 
groups O 
had O 
low O 
oral O 
absorption O 
in O 
vivo O 
. O 
Less O 
basic O 
analogues O 
, O 
such O 
as O 
morpholines B-FAMILY 
, O 
had O 
good O 
oral O 
absorption O 
; O 
however O 
, O 
they O 
also O 
had O 
high O 
clearance O 
. O 
The O 
most O 
potent O 
compound O 
with O 
high O 
absorption O 
in O 
two O 
species O 
was O 
analogue O 
6 O 
( O 
GSK2239633A B-IDENTIFIER 
) O 
, O 
which O 
was O 
selected O 
for O 
further O 
development O 
. O 
Aryl B-FAMILY 
sulfonamide I-FAMILY 
antagonists O 
bind O 
to O 
CCR4 O 
at O 
an O 
intracellular O 
allosteric O 
site O 
denoted O 
site O 
II O 
. O 
X-ray O 
diffraction O 
studies O 
on O 
two O 
indazole B-FAMILY 
sulfonamide I-FAMILY 
fragments O 
suggested O 
the O 
presence O 
of O 
an O 
important O 
intramolecular O 
interaction O 
in O 
the O 
active O 
conformation O 
. O 

- O 
based O 
discovery O 
of O 
pyrazolobenzothiazine B-SYSTEMATIC 
derivatives O 
as O 
inhibitors O 
of O 
hepatitis O 
C O 
virus O 
replication O 
. O 

NS5B O 
RNA-dependent O 
RNA O 
polymerase O 
is O 
an O 
attractive O 
target O 
for O 
the O 
development O 
of O 
novel O 
and O 
selective O 
inhibitors O 
of O 
hepatitis O 
C O 
virus O 
replication O 
. O 
To O 
identify O 
novel O 
structural O 
hits O 
as O 
anti-HCV O 
agents O 
, O 
we O 
performed O 
structure O 
- O 
based O 
virtual O 
screening O 
of O 
our O 
in O 
- O 
house O 
library O 
followed O 
by O 
rational O 
drug O 
design O 
, O 
organic O 
synthesis O 
, O 
and O 
biological O 
testing O 
. O 
These O 
studies O 
led O 
to O 
the O 
identification O 
of O 
pyrazolobenzothiazine B-SYSTEMATIC 
scaffold O 
as O 
a O 
suitable O 
template O 
for O 
obtaining O 
novel O 
anti-HCV O 
agents O 
targeting O 
the O 
NS5B O 
polymerase O 
. O 
The O 
best O 
compound O 
of O 
this O 
series O 
was O 
the O 
meta-fluoro-N-1-phenyl B-SYSTEMATIC 
pyrazolobenzothiazine I-SYSTEMATIC 
derivative O 
4a O 
, O 
which O 
exhibited O 
an O 
EC50 O 
= O 
3.6 O 
μM O 
, O 
EC90 O 
= O 
25.6 O 
μM O 
, O 
and O 
CC50 O 
> O 
180 O 
μM O 
in O 
the O 
Huh O 
9-13 O 
replicon O 
system O 
, O 
thus O 
providing O 
a O 
good O 
starting O 
point O 
for O 
further O 
hit O 
evolution O 
. O 

arsenic B-SYSTEMATIC 
treatment O 
alters O 
cytochrome O 
P450 O 
expression O 
and O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
metabolism O 
in O 
lung O 
, O 
liver O 
and O 
kidney O 
of O 
C57Bl O 
/ O 
6 O 
mice O 
. O 

1 O 
. O 
Arsenic B-SYSTEMATIC 
( O 
As B-FORMULA 
(III) I-FORMULA 
) O 
toxicity O 
has O 
received O 
increasing O 
attention O 
as O 
human O 
exposure O 
to O 
arsenic B-SYSTEMATIC 
is O 
associated O 
with O 
pulmonary O 
, O 
hepatic O 
and O 
renal O 
toxicities O 
. O 
Therefore O 
, O 
in O 
the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
effect O 
of O 
acute O 
As B-FORMULA 
(III) I-FORMULA 
treatment O 
on O 
pulmonary O 
, O 
hepatic O 
and O 
renal O 
cytochrome O 
( O 
CYP O 
) O 
P450 O 
- O 
mediated O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
metabolism O 
. O 
2 O 
. O 
Our O 
results O 
demonstrated O 
that O 
acute O 
As B-FORMULA 
(III) I-FORMULA 
treatment O 
( O 
12.5 O 
mg O 
/ O 
kg O 
) O 
altered O 
CYP O 
epoxygenases O 
, O 
CYP O 
ω-hydroxylases O 
and O 
EPHX2 O 
mRNA O 
levels O 
that O 
were O 
isozyme O 
and O 
tissue O 
specific O 
. O 
3 O 
. O 
Furthermore O 
, O 
As B-FORMULA 
(III) I-FORMULA 
increased O 
the O 
formation O 
of O 
epoxyeicosatrienoic B-FAMILY 
acids I-FAMILY 
( O 
EETs B-ABBREVIATION 
) O 
in O 
the O 
kidney O 
without O 
affecting O 
their O 
levels O 
in O 
the O 
lung O 
or O 
liver O 
. O 
In O 
addition O 
, O 
acute O 
As B-FORMULA 
(III) I-FORMULA 
treatment O 
increased O 
dihydroxyeicosatrienoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DHETs B-FAMILY 
) O 
formation O 
in O 
the O 
lung O 
, O 
while O 
it O 
did O 
not O 
affect O 
liver O 
DHETs B-FAMILY 
formation O 
and O 
decreased O 
kidney O 
DHETs B-FAMILY 
formation O 
. O 
4 O 
. O 
As B-FORMULA 
(III) I-FORMULA 
also O 
increased O 
total O 
epoxygenases O 
activity O 
in O 
the O 
lung O 
while O 
it O 
decreased O 
its O 
levels O 
in O 
the O 
kidney O 
and O 
had O 
no O 
effect O 
on O 
the O 
liver O 
. O 
Furthermore O 
, O 
As B-FORMULA 
(III) I-FORMULA 
increased O 
20-hydroxyeicosatetraenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
formation O 
in O 
the O 
liver O 
while O 
it O 
decreased O 
its O 
formation O 
in O 
the O 
kidney O 
. O 
5 O 
. O 
Lastly O 
, O 
As B-FORMULA 
(III) I-FORMULA 
increased O 
soluble O 
epoxide B-SYSTEMATIC 
hydrolase O 
activity O 
in O 
the O 
lung O 
, O 
while O 
it O 
decreased O 
its O 
levels O 
in O 
the O 
kidney O 
and O 
had O 
no O 
effect O 
on O 
the O 
liver O 
. O 
In O 
conclusion O 
, O 
this O 
is O 
the O 
first O 
demonstration O 
that O 
As B-FORMULA 
(III) I-FORMULA 
alters O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
metabolism O 
in O 
a O 
tissue O 
specific O 
manner O 
. O 

recognition O 
of O 
the O 
S23906-1 B-IDENTIFIER 
-DNA O 
adduct O 
by O 
nuclear O 
proteins O 
: O 
direct O 
involvement O 
of O 
glyceraldehyde-3-phosphate B-SYSTEMATIC 
dehydrogenase O 
(GAPDH)1 O 
. O 

a O 
view O 
to O 
develop O 
new O 
DNA O 
alkylating O 
antitumour O 
drugs O 
, O 
evaluating O 
the O 
precise O 
mechanism O 
of O 
action O 
and O 
the O 
molecular O 
/ O 
cellular O 
consequences O 
of O 
the O 
alkylation O 
is O 
a O 
point O 
of O 
major O 
interest O 
. O 
The O 
benzo-b-acronycine B-SYSTEMATIC 
derivative O 
S23906-1 B-IDENTIFIER 
alkylates O 
guanine B-FAMILY 
nucleobases I-FAMILY 
in O 
the O 
minor O 
groove O 
of O 
the O 
DNA O 
helix O 
and O 
presents O 
an O 
original O 
ability O 
to O 
locally O 
open O 
the O 
double O 
helix O 
of O 
DNA O 
, O 
which O 
appears O 
to O 
be O 
associated O 
with O 
its O 
cytotoxic O 
activity O 
. O 
However O 
, O 
the O 
molecular O 
mechanism O 
linking O 
adduct O 
formation O 
to O 
cellular O 
consequences O 
is O 
not O 
precisely O 
known O 
. O 
The O 
objective O 
of O 
the O 
present O 
study O 
was O 
to O 
identify O 
proteins O 
involved O 
in O 
the O 
recognition O 
and O 
mechanism O 
of O 
action O 
of O 
S23906 B-IDENTIFIER 
-DNA O 
adducts O 
. O 
We O 
found O 
that O 
GAPDH O 
( O 
glyceraldehyde-3-phosphate B-SYSTEMATIC 
dehydrogenase O 
) O 
is O 
a O 
protein O 
that O 
binds O 
to O 
S23906 B-IDENTIFIER 
-alkylated O 
single O 
- O 
stranded O 
, O 
double O 
- O 
stranded O 
and O 
telomeric O 
sequences O 
in O 
a O 
drug O 
- O 
dependent O 
and O 
DNA O 
sequence O 
/ O 
structure O 
- O 
dependent O 
manner O 
. O 
We O 
used O 
the O 
CASTing O 
( O 
cyclic O 
amplification O 
of O 
sequence O 
targeting O 
) O 
method O 
to O 
identify O 
GAPDH O 
DNA O 
- O 
binding O 
selectivity O 
and O 
then O 
evaluated O 
its O 
binding O 
to O 
such O 
selected O 
S23906 B-IDENTIFIER 
-alkylated O 
sequences O 
. O 
At O 
the O 
cellular O 
level O 
, O 
alkylation O 
of O 
S23906-1 B-IDENTIFIER 
results O 
in O 
an O 
increase O 
in O 
the O 
binding O 
of O 
GAPDH O 
and O 
its O 
protein O 
partner O 
HMG O 
( O 
high O 
- O 
mobility O 
group O 
) O 
B1 O 
to O 
the O 
chromatin O 
. O 
Regarding O 
the O 
multiple O 
roles O 
of O 
GAPDH O 
in O 
apoptosis O 
and O 
DNA O 
repair O 
, O 
the O 
cytotoxic O 
and O 
apoptotic O 
activities O 
of O 
GAPDH O 
were O 
evaluated O 
and O 
present O 
opposite O 
effects O 
in O 
two O 
different O 
cellular O 
models O 
. O 

and O 
cancer O 
stem O 
cell O 
- O 
based O 
activity O 
of O 
substituted O 
5-morpholino-7H-thieno[3,2-b]pyran-7-ones B-FAMILY 
designed O 
as O 
next O 
generation O 
PI3K O 
inhibitors O 
. O 

of O 
the O 
phosphatidylinositol-3-kinase O 
( O 
PI3K O 
) O 
pathway O 
in O 
a O 
wide O 
range O 
of O 
tumors O 
has O 
made O 
PI3K O 
a O 
consensus O 
target O 
to O 
inhibit O 
as O 
illustrated O 
by O 
more O 
than O 
15 O 
inhibitors O 
now O 
in O 
clinical O 
trials O 
. O 
Our O 
previous O 
work O 
, O 
built O 
on O 
the O 
early O 
pioneering O 
multikinase O 
inhibitor O 
LY294002 B-IDENTIFIER 
, O 
resulted O 
in O 
the O 
only O 
PI3K O 
vascular O 
- O 
targeted O 
PI3K O 
inhibitor O 
prodrug O 
, O 
SF1126 B-IDENTIFIER 
, O 
which O 
has O 
now O 
completed O 
Phase O 
I O 
clinical O 
trials O 
. O 
This O 
inhibitor O 
has O 
properties O 
that O 
impart O 
more O 
in O 
vivo O 
activity O 
than O 
should O 
be O 
warranted O 
by O 
its O 
enzymatic O 
potency O 
, O 
which O 
in O 
general O 
is O 
much O 
lower O 
than O 
other O 
clinical O 
stage O 
PI3K O 
inhibitors O 
. O 
We O 
embarked O 
on O 
the O 
exploration O 
of O 
scaffolds O 
that O 
retained O 
such O 
properties O 
while O 
simultaneously O 
exhibiting O 
an O 
increased O 
potency O 
toward O 
PI3K O 
. O 
This O 
work O 
resulted O 
in O 
the O 
discovery O 
of O 
the O 
5-morpholino-7H-thieno[3,2-b]pyran-7-one B-SYSTEMATIC 
system O 
as O 
the O 
foundation O 
of O 
a O 
new O 
compound O 
class O 
of O 
potential O 
PI3K O 
inhibitors O 
having O 
improved O 
potency O 
toward O 
PI3K O 
. O 
The O 
synthesis O 
and O 
cancer O 
stem O 
cell O 
- O 
based O 
activity O 
of O 
these O 
compounds O 
are O 
reported O 
herein O 
. O 

superparamagnets O 
: O 
highly O 
elastic O 
and O 
degradable O 
poly(N-isopropylacrylamide) B-SYSTEMATIC 
-superparamagnetic O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticle O 
( O 
SPION O 
) O 
composite O 
hydrogels O 
. O 

, O 
in O 
situ O 
- O 
gelling O 
magnetic O 
composite O 
materials O 
have O 
been O 
fabricated O 
by O 
using O 
aldehyde B-SYSTEMATIC 
-functionalized O 
dextran O 
to O 
cross O 
- O 
link O 
superparamagnetic O 
nanoparticles O 
surface O 
- O 
functionalized O 
with O 
hydrazide B-SYSTEMATIC 
-functionalized O 
poly(N-isopropylacrylamide) B-SYSTEMATIC 
( O 
pNIPAM B-ABBREVIATION 
) O 
. O 
The O 
resulting O 
composites O 
exhibit O 
high O 
water O 
contents O 
( O 
82-88 O 
wt.% O 
) O 
while O 
also O 
displaying O 
significantly O 
higher O 
elasticities O 
( O 
G O 
' O 
> O 
60 O 
kPa O 
) O 
than O 
other O 
injectable O 
hydrogels O 
previously O 
reported O 
. O 
The O 
composites O 
hydrolytically O 
degrade O 
via O 
slow O 
hydrolysis O 
of O 
the O 
hydrazone B-FAMILY 
cross O 
- O 
link O 
at O 
physiological O 
temperature O 
and O 
pH O 
into O 
degradation O 
products O 
that O 
show O 
no O 
significant O 
cytotoxicity O 
. O 
Subcutaneous O 
injections O 
indicate O 
only O 
minor O 
chronic O 
inflammation O 
associated O 
with O 
material O 
degradation O 
, O 
with O 
no O 
fibrous O 
capsule O 
formation O 
evident O 
. O 
Drug O 
release O 
experiments O 
indicate O 
the O 
potential O 
of O 
these O 
materials O 
to O 
facilitate O 
pulsatile O 
, O 
" O 
on O 
- O 
demand O 
" O 
changes O 
in O 
drug O 
release O 
upon O 
the O 
application O 
of O 
an O 
external O 
oscillating O 
magnetic O 
field O 
. O 
The O 
injectable O 
but O 
high O 
- O 
strength O 
and O 
externally O 
triggerable O 
nature O 
of O 
these O 
materials O 
, O 
coupled O 
with O 
their O 
biological O 
degradability O 
and O 
inertness O 
, O 
suggest O 
potential O 
biological O 
applications O 
in O 
tissue O 
engineering O 
and O 
drug O 
delivery O 
. O 

species O 
colonizes O 
the O 
stomach O 
and O 
are O 
associated O 
with O 
the O 
development O 
of O 
gastritis O 
disease O 
. O 
Drugs O 
for O 
treatment O 
of O 
Helicobacter O 
infection O 
relieve O 
pain O 
or O 
gastritis O 
symptoms O 
but O 
they O 
are O 
not O 
targeted O 
specifically O 
to O 
Helicobacter O 
pylori O 
. O 
Therefore O 
, O 
there O 
is O 
dire O 
need O 
for O 
discovery O 
of O 
new O 
drug O 
targets O 
and O 
drugs O 
for O 
the O 
treatment O 
of O 
H O 
. O 
pylori O 
. O 
The O 
main O 
objective O 
of O 
this O 
study O 
is O 
to O 
screen O 
the O 
potential O 
drug O 
targets O 
by O 
in O 
silico O 
analysis O 
for O 
the O 
potent O 
strains O 
of O 
H O 
. O 
pylori O 
which O 
include O 
HpB38 O 
, O 
HpP12 O 
, O 
HpG27 O 
, O 
Hpshi470 O 
and O 
HpSJM180 O 
. O 
Genome O 
and O 
metabolic O 
pathways O 
of O 
pathogen O 
H O 
. O 
pylori O 
and O 
the O 
host O 
Homosapien O 
sapiens O 
are O 
compared O 
and O 
genes O 
which O 
were O 
unique O 
to O 
H O 
. O 
pylori O 
were O 
filtered O 
and O 
catalogued O 
. O 
These O 
unique O 
genes O 
were O 
subjected O 
to O 
gene O 
property O 
analysis O 
to O 
identify O 
the O 
potentiality O 
of O 
the O 
drug O 
targets O 
. O 
Among O 
the O 
total O 
number O 
of O 
genes O 
analysed O 
in O 
different O 
strains O 
of O 
H O 
. O 
pylori O 
nearly O 
558 O 
, O 
569 O 
, O 
539 O 
, O 
569 O 
, O 
567 O 
number O 
of O 
genes O 
in O 
HpB38 O 
, O 
HpP12 O 
, O 
HpG27 O 
, O 
Hpshi470 O 
and O 
HpSJM180 O 
found O 
qualified O 
as O 
unique O 
molecules O 
and O 
among O 
them O 
17 O 
qualified O 
as O 
potential O 
drug O 
targets O 
. O 
Membrane O 
fusion O 
protein O 
of O 
hefABC O 
efflux O 
system O 
, O 
50 O 
S O 
ribosomal O 
protein O 
L33 O 
, O 
Hydrogenase O 
expression O 
protein O 
/ O 
formation O 
of O 
HypD O 
, O 
Cag O 
pathogenecity O 
island O 
protein O 
X O 
, O 
Apolipoprotein O 
N B-SYSTEMATIC 
acyl I-SYSTEMATIC 
transferase O 
, O 
DNA O 
methyalse O 
, O 
Histone O 
like O 
binding O 
protein O 
, O 
Peptidoglycan O 
- O 
associated O 
lipoprotein O 
OprL O 
were O 
found O 
to O 
be O 
critical O 
drug O 
targets O 
to O 
H O 
. O 
pylori O 
. O 
Three O 
( O 
hefABC O 
efflux O 
system O 
, O 
Hydrogenase O 
expression O 
protein O 
/ O 
formation O 
of O 
HypD O 
, O 
Cag O 
pathogenecity O 
island O 
protein O 
X O 
) O 
of O 
the O 
17 O 
predicted O 
drug O 
targets O 
are O 
already O 
experimentally O 
validated O 
either O 
genetically O 
or O 
biochemically O 
lending O 
credence O 
to O 
our O 
unique O 
approach O 
. O 

the O 
structural O 
determinants O 
of O 
heteroarylnitrile B-FAMILY 
scaffold O 
- O 
based O 
derivatives O 
as O 
falcipain-2 O 
inhibitors O 
by O 
in O 
silico O 
methods O 
. O 

indicates O 
that O 
cysteine B-TRIVIAL 
protease O 
falcipain-2 O 
plays O 
essential O 
role O 
in O 
malaria O 
parasites O 
; O 
therefore O 
the O 
potent O 
and O 
selective O 
inhibitors O 
of O 
falcipain-2 O 
may O 
be O 
therapeutically O 
useful O 
drugs O 
for O 
treatment O 
of O 
various O 
forms O 
of O 
malaria O 
parasite O 
plasmodium O 
. O 
In O 
order O 
to O 
understand O 
the O 
structure O 
- O 
activity O 
correlation O 
of O 
falcipain-2 O 
inhibitors O 
, O 
a O 
set O 
of O 
ligand- O 
and O 
receptor O 
- O 
based O 
3D-QSAR O 
models O 
were O 
, O 
for O 
the O 
first O 
time O 
, O 
developed O 
in O 
the O 
present O 
work O 
employing O 
Comparative O 
Molecular O 
Field O 
Analysis O 
( O 
CoMFA O 
) O 
and O 
Comparative O 
Molecular O 
Similarity O 
Index O 
Analysis O 
( O 
CoMSIA O 
) O 
for O 
240 O 
promising O 
molecules O 
. O 
Based O 
on O 
the O 
ligand O 
- O 
based O 
alignment O 
, O 
an O 
optimal O 
3D-QSAR O 
model O 
was O 
obtained O 
with O 
good O 
predictive O 
power O 
of O 
Q(2) O 
= O 
0.501 O 
, O 
R(2) O 
ncv O 
= O 
0.89 O 
, O 
SEE O 
= O 
0.282 O 
, O 
F O 
= O 
153.522 O 
and O 
R(2) O 
pred O 
= O 
0.768 O 
. O 
And O 
the O 
contour O 
maps O 
intuitively O 
suggest O 
where O 
to O 
modify O 
the O 
molecular O 
structures O 
in O 
order O 
to O 
improve O 
the O 
binding O 
affinity O 
. O 
In O 
addition O 
, O 
docking O 
analysis O 
and O 
molecular O 
dynamics O 
simulation O 
( O 
MD O 
) O 
study O 
were O 
also O 
carried O 
out O 
on O 
the O 
dataset O 
with O 
purpose O 
of O 
exploring O 
the O 
detailed O 
binding O 
modes O 
of O 
ligand O 
in O 
the O 
falcipain-2 O 
binding O 
pocket O 
. O 
The O 
combination O 
of O 
docking O 
analysis O 
and O 
MD O 
simulation O 
shows O 
that O 
Gly B-FORMULA 
83 O 
, O 
Trp B-FORMULA 
43 O 
and O 
Ala B-FORMULA 
175 O 
which O 
formed O 
several O 
H B-FORMULA 
-bonds O 
are O 
crucial O 
for O 
falcipain-2 O 
inhibitors O 
. O 
The O 
analysis O 
of O 
the O 
best O 
QSAR O 
model O 
reveals O 
the O 
structural O 
features O 
related O 
to O 
the O 
activity O 
, O 
and O 
provides O 
an O 
insight O 
into O 
molecular O 
mechanisms O 
of O 
inhibition O 
and O 
possible O 
modification O 
of O 
the O 
molecules O 
for O 
better O 
activity O 
. O 

etiopathology O 
of O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
is O 
extremely O 
complex O 
and O 
heterogeneous O 
, O 
often O 
associated O 
with O 
comorbidities O 
. O 
As O 
a O 
result O 
it O 
may O 
be O 
unlikely O 
that O 
AD O 
may O 
be O 
mitigated O 
by O 
drug O 
acting O 
on O 
a O 
single O 
specific O 
target O 
. O 
The O 
current O 
tendency O 
in O 
drug O 
design O 
and O 
discovery O 
in O 
AD O 
is O 
the O 
rational O 
design O 
or O 
" O 
serendipitous O 
" O 
discovery O 
of O 
new O 
drug O 
entities O 
challenging O 
multiple O 
targets O 
. O 
Since O 
two O 
of O 
the O 
presently O 
approved O 
drugs O 
for O 
AD O 
are O 
based O 
on O 
natural O 
products O 
( O 
galantamine B-TRIVIAL 
and O 
the O 
physostigmine B-TRIVIAL 
-derivative O 
rivastigmine B-TRIVIAL 
) O 
, O 
many O 
plants O 
are O 
now O 
under O 
investigation O 
as O 
a O 
potential O 
source O 
of O 
new O 
drugs O 
. O 
Multifunctional O 
drugs O 
often O 
have O 
their O 
origin O 
in O 
natural O 
sources O 
. O 
This O 
review O 
is O 
limited O 
to O 
plant O 
chemicals O 
having O 
different O 
targets O 
with O 
actual O 
( O 
galantamine B-TRIVIAL 
) O 
or O 
promising O 
( O 
drugs O 
from O 
Crocus O 
sativus O 
, O 
Ginkgo O 
biloba O 
, O 
Salvia O 
species O 
, O 
and O 
Huperzia O 
serrata O 
) O 
clinical O 
evidence O 
in O 
people O 
with O 
dementia O 
or O 
AD O 
. O 

epigenetic O 
reprogramming O 
occurs O 
during O 
mammalian O 
germ O 
cell O 
development O 
, O 
although O 
the O 
targets O 
of O 
this O 
process O 
, O 
including O 
DNA O 
demethylation O 
and O 
de O 
novo O 
methylation O 
, O 
remain O 
poorly O 
understood O 
. O 
We O 
performed O 
genome O 
- O 
wide O 
DNA O 
methylation O 
analysis O 
in O 
male O 
and O 
female O 
mouse O 
primordial O 
germ O 
cells O 
at O 
embryonic O 
days O 
10.5 O 
, O 
13.5 O 
, O 
and O 
16.5 O 
by O 
whole O 
- O 
genome O 
shotgun O 
bisulfite B-SYSTEMATIC 
sequencing O 
. O 
Our O 
high O 
- O 
resolution O 
DNA O 
methylome O 
maps O 
demonstrated O 
gender O 
- O 
specific O 
differences O 
in O 
CpG B-ABBREVIATION 
methylation O 
at O 
genome O 
- O 
wide O 
and O 
gene O 
- O 
specific O 
levels O 
during O 
fetal O 
germline O 
progression O 
. O 
There O 
was O 
extensive O 
intra- O 
and O 
intergenic O 
hypomethylation O 
with O 
erasure O 
of O 
methylation O 
marks O 
at O 
imprinted O 
, O 
X O 
- O 
linked O 
, O 
or O 
germline O 
- O 
specific O 
genes O 
during O 
gonadal O 
sex O 
determination O 
and O 
partial O 
methylation O 
at O 
particular O 
retrotransposons O 
. O 
Following O 
global O 
demethylation O 
and O 
sex O 
determination O 
, O 
CpG B-ABBREVIATION 
sites O 
switched O 
to O 
de O 
novo O 
methylation O 
in O 
males O 
, O 
but O 
the O 
X O 
- O 
linked O 
genes O 
appeared O 
resistant O 
to O 
the O 
wave O 
of O 
de O 
novo O 
methylation O 
. O 
Significant O 
differential O 
methylation O 
at O 
a O 
subset O 
of O 
imprinted O 
loci O 
was O 
identified O 
in O 
both O 
genders O 
, O 
and O 
non- O 
CpG B-ABBREVIATION 
methylation O 
occurred O 
only O 
in O 
male O 
gonocytes O 
. O 
Our O 
data O 
establish O 
the O 
basis O 
for O 
future O 
studies O 
on O 
the O 
role O 
of O 
epigenetic O 
modifications O 
in O 
germline O 
development O 
and O 
other O 
biological O 
processes O 
. O 

from O 
a O 
mangrove O 
rhizosphere O 
soil O 
- O 
derived O 
fungus O 
Aspergillus O 
terreus O 
Gwq-48 O 
with O 
anti-influenza O 
A O 
viral O 
( O 
H1N1 O 
) O 
activity O 
. O 

new O 
butenolide B-FAMILY 
isoaspulvinone B-TRIVIAL 
E I-TRIVIAL 
( O 
1 O 
) O 
, O 
together O 
with O 
two O 
known O 
butenolides B-FAMILY 
aspulvinone B-TRIVIAL 
E I-TRIVIAL 
( O 
2 O 
) O 
and O 
pulvic B-TRIVIAL 
acid I-TRIVIAL 
( O 
3 O 
) O 
were O 
isolated O 
from O 
the O 
marine O 
- O 
derived O 
fungus O 
, O 
Aspergillus O 
terreus O 
Gwq-48 O 
. O 
They O 
showed O 
significant O 
anti-influenza O 
A O 
H1N1 O 
virus O 
activities O 
, O 
with O 
IC50 O 
values O 
of O 
32.3 O 
, O 
56.9 O 
, O 
and O 
29.1μg O 
/ O 
mL O 
, O 
respectively O 
. O 
Moreover O 
, O 
only O 
compound O 
1 O 
exhibited O 
effective O 
inhibitory O 
activity O 
against O 
H1N1 O 
viral O 
neuraminidase O 
( O 
nan O 
) O 
, O 
and O 
docking O 
of O 
two O 
isomers O 
( O 
1-2 O 
) O 
into O 
the O 
active O 
sites O 
of O 
nan O 
showed O 
that O 
the O 
E O 
double O 
bond O 
Δ(5(10)) O 
was O 
essential O 
to O 
achieve O 
activity O 
. O 

novel O 
fluorogenic O 
substrate O 
for O 
dinuclear O 
Zn B-FORMULA 
(II) I-FORMULA 
-containing O 
metallo-β-lactamases O 
. O 

an O 
effort O 
to O 
prepare O 
a O 
fluorogenic O 
substrate O 
to O 
be O 
used O 
in O 
activity O 
assays O 
with O 
metallo-β-lactamases O 
, O 
(6R,7R)-8-oxo-7-(2-oxo-2H-chromene-3-carboxamido)-3-((4-(2-oxo-2H-chromene-3-carboxamido)-phenylthio)methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
CA O 
) O 
was O 
synthesized O 
and O 
characterized O 
. O 
CA O 
exhibited O 
a O 
fluorescence O 
quantum O 
yield O 
( O 
φ O 
) O 
of O 
0.0059 O 
, O 
two O 
fluorescence O 
lifetimes O 
of O 
3.63×10(-10) O 
and O 
5.38×10(-9)s O 
, O 
and O 
fluorescence O 
intensity O 
that O 
is O 
concentration O 
- O 
dependent O 
. O 
Steady O 
- O 
state O 
kinetic O 
assays O 
revealed O 
that O 
CA O 
is O 
a O 
substrate O 
for O 
metallo-β-lactamases O 
( O 
MβLs O 
) O 
L1 O 
and O 
CcrA O 
, O 
exhibiting O 
Km O 
and O 
kcat O 
values O 
of O 
18μM O 
and O 
5s(-1) O 
and O 
11μM O 
and O 
17s(-1) O 
, O 
respectively O 
. O 

and O 
physicochemical O 
properties O 
of O 
new O 
tripodal O 
amphiphiles O 
bearing O 
fatty B-FAMILY 
acids I-FAMILY 
as O 
a O 
hydrophobic O 
group O 
. O 

fatty I-FAMILY 
acids I-FAMILY 
( O 
FA O 
) O 
were O 
grafted O 
using O 
tyrosine B-TRIVIAL 
as O 
a O 
spacer O 
group O 
to O 
the O 
cyclotriphosphazene B-TRIVIAL 
ring O 
along O 
with O 
equimolar O 
hydrophilic O 
methoxy B-FAMILY 
poly(ethylene I-FAMILY 
glycol I-FAMILY 
) I-FAMILY 
( O 
MPEG B-ABBREVIATION 
) O 
in O 
cis-nongeminal O 
way O 
. O 
Seven O 
new O 
cyclotriphosphazene B-TRIVIAL 
amphiphiles O 
were O 
prepared O 
from O 
combinations O 
of O 
hydrophilic O 
MPEGs B-FAMILY 
with O 
different O 
molecular O 
weights O 
of O 
350 O 
, O 
550 O 
, O 
750 O 
and O 
1000 O 
and O 
four O 
different O 
fatty B-FAMILY 
acids I-FAMILY 
of O 
different O 
hydrophobicity O 
including O 
lauric B-MULTIPLE 
, I-MULTIPLE 
myristic I-MULTIPLE 
, I-MULTIPLE 
palmitic I-MULTIPLE 
and I-MULTIPLE 
stearic I-MULTIPLE 
acids I-MULTIPLE 
. O 
These O 
steric O 
amphiphiles O 
bearing O 
fatty B-FAMILY 
acids I-FAMILY 
as O 
a O 
hydrophobic O 
group O 
were O 
found O 
to O 
form O 
more O 
stable O 
micelles O 
with O 
very O 
low O 
critical O 
micelle O 
concentrations O 
( O 
CMC O 
) O 
( O 
2.95-7.80mg O 
/ O 
L O 
) O 
compared O 
with O 
oligopeptide O 
analogues O 
, O 
and O 
their O 
highly O 
hydrophobic O 
core O 
environment O 
is O 
unique O 
and O 
potentially O 
useful O 
for O 
various O 
biomedical O 
applications O 
. O 

determination O 
of O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
in O 
food O 
samples O 
at O 
graphene B-TRIVIAL 
modified O 
glassy O 
carbon B-SYSTEMATIC 
electrode O 
based O 
on O 
the O 
enhancement O 
effect O 
of O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulphonate I-SYSTEMATIC 
. O 

paper O 
describes O 
a O 
novel O 
electrochemical O 
method O 
for O 
the O 
determination O 
of O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
in O 
food O 
samples O 
based O 
on O 
the O 
electrochemical O 
catalytic O 
activity O 
of O 
graphene B-TRIVIAL 
modified O 
glassy O 
carbon B-SYSTEMATIC 
electrode O 
( O 
GMGCE O 
) O 
and O 
the O 
enhancement O 
effect O 
of O 
an O 
anionic O 
surfactant O 
: O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulphonate I-SYSTEMATIC 
( O 
SDS B-ABBREVIATION 
) O 
. O 
Using O 
pH O 
6 O 
phosphate B-SYSTEMATIC 
buffer O 
solution O 
( O 
PBS O 
) O 
as O 
supporting O 
electrolyte O 
and O 
in O 
the O 
presence O 
of O 
1.5 O 
× O 
10(-4)mol O 
L(-1) O 
SDS B-ABBREVIATION 
, O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
yielded O 
a O 
well O 
- O 
defined O 
and O 
sensitive O 
oxidation O 
peak O 
at O 
a O 
GMGCE O 
. O 
The O 
oxidation O 
peak O 
current O 
of O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
remarkably O 
increased O 
in O 
the O 
presence O 
of O 
SDS B-ABBREVIATION 
. O 
The O 
experimental O 
parameters O 
, O 
such O 
as O 
supporting O 
electrolyte O 
, O 
concentration O 
of O 
SDS B-ABBREVIATION 
, O 
and O 
accumulation O 
time O 
, O 
were O 
optimised O 
for O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
determination O 
. O 
The O 
oxidation O 
peak O 
current O 
showed O 
a O 
linear O 
relationship O 
with O 
the O 
concentrations O 
of O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
in O 
the O 
range O 
of O 
7.5 O 
× O 
10(-8)-7.50 O 
× O 
10(-6)mol O 
L(-1) O 
, O 
with O 
the O 
detection O 
limit O 
of O 
4 O 
× O 
10(-8)mol O 
L(-1) O 
. O 
This O 
new O 
voltammetric O 
method O 
was O 
successfully O 
used O 
to O 
determine O 
Sudan B-TRIVIAL 
I I-TRIVIAL 
in O 
food O 
products O 
such O 
as O 
ketchup O 
and O 
chili O 
sauce O 
with O 
satisfactory O 
results O 
. O 

inhibits O 
dimethylnitrosamine B-SYSTEMATIC 
-induced O 
liver O 
fibrosis O 
in O 
rats O 
. O 

, O 
found O 
in O 
grapes O 
and O 
berries O 
, O 
exhibits O 
pleiotropic O 
effects O 
, O 
including O 
anti-inflammatory O 
, O 
antioxidant O 
, O 
and O 
anti-proliferative O 
activities O 
. O 
This O 
study O 
was O 
conducted O 
to O 
investigate O 
the O 
effect O 
of O 
pterostilbene B-TRIVIAL 
on O 
liver O 
fibrosis O 
and O 
the O 
potential O 
underlying O 
mechanism O 
for O 
such O 
effect O 
. O 
Sprague-Dawley O 
rats O 
were O 
intraperitoneally O 
given O 
dimethyl B-SYSTEMATIC 
n-nitrosamine I-SYSTEMATIC 
( O 
DMN B-ABBREVIATION 
) O 
( O 
10mg O 
/ O 
kg O 
) O 
3 O 
days O 
per O 
week O 
for O 
4 O 
weeks O 
. O 
Pterostilbene B-TRIVIAL 
( O 
10 O 
or O 
20mg O 
/ O 
kg O 
) O 
was O 
administered O 
by O 
oral O 
gavage O 
daily O 
. O 
Liver O 
function O 
, O 
morphology O 
, O 
histochemistry O 
, O 
and O 
fibrotic O 
parameters O 
were O 
examined O 
. O 
Pterostilbene B-TRIVIAL 
supplementation O 
alleviated O 
the O 
DMN B-ABBREVIATION 
-induced O 
changes O 
in O 
the O 
serum O 
levels O 
of O 
alanine O 
transaminase O 
and O 
aspartate O 
transaminase O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Fibrotic O 
status O 
and O 
the O 
activation O 
of O 
hepatic O 
stellate O 
cells O 
were O 
improved O 
upon O 
pterostilbene B-TRIVIAL 
supplementation O 
as O 
evidenced O 
by O 
histopathological O 
examination O 
as O 
well O 
as O 
the O 
expression O 
of O 
α-smooth O 
muscle O 
actin O 
( O 
α-SMA O 
) O 
, O 
transforming O 
growth O 
factor-β1 O 
( O 
TGF-β1 O 
) O 
, O 
and O 
matrix O 
metalloproteinase O 
2 O 
( O 
MMP2 O 
) O 
. O 
These O 
data O 
demonstrated O 
that O 
pterostilbene B-TRIVIAL 
exhibited O 
hepatoprotective O 
effects O 
on O 
experimental O 
fibrosis O 
, O 
potentially O 
by O 
inhibiting O 
the O 
TGF-β1 O 
/ O 
Smad O 
signaling O 
. O 

, O 
boiling O 
of O 
vegetables O 
is O 
assumed O 
leading O 
to O 
lower O 
nutritional O 
values O 
because O 
of O 
leaching O 
effects O 
and O 
activity O 
loss O 
of O 
bioactive O 
compounds O 
. O 
Kale O 
( O 
Brassica O 
oleracea O 
var O 
. O 
sabellica O 
) O 
reveals O 
a O 
great O 
diversity O 
of O 
flavonoids B-FAMILY 
, O 
which O 
have O 
been O 
shown O 
to O 
be O 
good O 
antioxidants O 
. O 
As O 
Brassica O 
vegetables O 
are O 
mainly O 
consumed O 
cooked O 
, O 
the O 
influence O 
of O 
boiling O 
on O 
kale's O 
flavonoids B-FAMILY 
and O 
their O 
antioxidant O 
activity O 
was O 
investigated O 
. O 
Therefore O 
, O 
three O 
kale O 
cultivars O 
were O 
cooked O 
at O 
100°C O 
for O 
2 O 
and O 
4h O 
prior O 
to O 
analysis O 
. O 
The O 
total O 
phenolic O 
content O 
( O 
TPC O 
) O 
and O 
the O 
total O 
antioxidant O 
activity O 
( O 
TEAC O 
assay O 
and O 
EPR O 
spectrometry O 
) O 
of O 
each O 
cultivar O 
were O 
determined O 
and O 
revealed O 
no O 
change O 
, O 
independent O 
of O 
cooking O 
time O 
, O 
although O 
kale O 
samples O 
visually O 
altered O 
. O 
Using O 
the O 
HPLC-UV O 
/ O 
Vis-online-TEAC O 
approach O 
, O 
distinct O 
changes O 
in O 
composition O 
and O 
antioxidant O 
activity O 
of O 
the O 
flavonoids B-FAMILY 
were O 
detectable O 
. O 
Thus O 
, O 
it O 
was O 
observable O 
, O 
that O 
the O 
antioxidant O 
activities O 
of O 
the O 
reaction O 
products O 
compensated O 
the O 
" O 
loss O 
" O 
of O 
the O 
antioxidant O 
activity O 
of O 
the O 
original O 
compounds O 
of O 
the O 
uncooked O 
material O 
. O 

liquid O 
- O 
liquid O 
microextraction O 
combined O 
with O 
field O 
- O 
amplified O 
sample O 
stacking O 
in O 
capillary O 
electrophoresis O 
for O 
the O 
determination O 
of O 
non- O 
steroidal B-FAMILY 
anti-inflammatory O 
drugs O 
in O 
milk O 
and O 
dairy O 
products O 
. O 

liquid O 
- O 
liquid O 
microextraction O 
( O 
DLLME O 
) O 
was O 
coupled O 
with O 
field O 
- O 
amplified O 
sample O 
stacking O 
in O 
capillary O 
electrophoresis O 
( O 
FASS O 
) O 
for O 
the O 
determination O 
of O 
five O 
non- O 
steroidal B-FAMILY 
anti-inflammatory O 
drugs O 
( O 
NSAIDs O 
) O 
in O 
bovine O 
milk O 
and O 
dairy O 
products O 
. O 
After O 
extraction O 
, O 
the O 
enriched O 
analytes O 
were O 
back O 
- O 
extracted O 
into O 
a O 
basic O 
aqueous O 
solution O 
for O 
injection O 
into O 
CE O 
. O 
Under O 
optimum O 
conditions O 
, O 
enrichment O 
factors O 
were O 
in O 
the O 
range O 
46-229 O 
. O 
Limits O 
of O 
detection O 
of O 
the O 
analytes O 
ranged O 
from O 
3 O 
to O 
13.1 O 
μg O 
kg(-1) O 
for O 
all O 
matrices O 
analysed O 
. O 
Calibration O 
graphs O 
showed O 
good O 
linearity O 
with O 
coefficients O 
of O 
determination O 
(R(2))≥ O 
0.9915 O 
and O 
relative O 
standard O 
deviations O 
( O 
RSD% O 
) O 
of O 
the O 
analyses O 
in O 
the O 
range O 
of O 
0.6-6.2% O 
( O 
n=5 O 
) O 
. O 
Recoveries O 
of O 
all O 
NSAIDs O 
from O 
bottled O 
milk O 
, O 
raw O 
milk O 
, O 
yogurt O 
and O 
white O 
cheese O 
samples O 
were O 
in O 
the O 
ranges O 
of O 
86.6-109.3% O 
, O 
84.3-100.5% O 
, O 
77.4-107.3% O 
, O 
and O 
90.9-101.6% O 
, O 
respectively O 
. O 
DLLME-FASS-CE O 
was O 
demonstrated O 
to O 
be O 
a O 
rapid O 
and O 
convenient O 
method O 
for O 
the O 
determination O 
of O 
NSAIDs O 
in O 
milk O 
and O 
dairy O 
products O 
. O 

activities O 
of O 
the O 
synthesized O 
thiol B-FAMILY 
-contained O 
peptides O 
derived O 
from O 
computer O 
- O 
aided O 
pepsin O 
hydrolysis O 
of O 
yam O 
tuber O 
storage O 
protein O 
, O 
dioscorin B-TRIVIAL 
. O 

previous O 
report O 
showed O 
that O 
yam O 
dioscorin B-TRIVIAL 
and O 
its O 
peptic O 
hydrolysates O 
exhibit O 
radical O 
scavenging O 
activities O 
; O 
however O 
, O 
the O 
functions O 
of O 
these O 
peptic O 
hydrolases O 
are O 
still O 
under O 
investigation O 
. O 
In O 
this O 
study O 
, O 
the O 
thiol B-FAMILY 
-containing O 
peptides O 
derived O 
from O 
computer O 
- O 
aided O 
simulation O 
of O 
pepsin O 
hydrolysis O 
of O 
dioscorin B-TRIVIAL 
, O 
namely O 
, O 
KTCGNGME O 
( O 
diotide1 O 
) O 
, O 
PPCSE O 
( O 
diotide2 O 
) O 
, O 
CDDRVIRTPLT O 
( O 
diotide3 O 
) O 
, O 
KTCGY O 
( O 
diotide4 O 
) O 
, O 
and O 
PPCTE O 
( O 
diotide5 O 
) O 
were O 
synthesized O 
to O 
compare O 
their O 
antioxidant O 
activities O 
with O 
GSH B-ABBREVIATION 
and O 
/ O 
or O 
carnosine B-TRIVIAL 
by O 
examining O 
hydroxyl B-SYSTEMATIC 
radical O 
scavenging O 
activity O 
by O 
electron O 
spin O 
resonance O 
spectrometry O 
, O 
anti-low- O 
density O 
lipoprotein O 
peroxidation O 
, O 
anti- O 
AAPH B-ABBREVIATION 
-induced O 
hemolysis O 
, O 
and O 
oxygen B-SYSTEMATIC 
radical O 
absorbance O 
capacity O 
activity O 
. O 
We O 
found O 
that O 
while O 
all O 
the O 
synthesized O 
diotides O 
showed O 
antioxidant O 
activity O 
, O 
diotide4 O 
exhibited O 
the O 
highest O 
levels O 
. O 
Moreover O 
, O 
all O 
diotides O 
( O 
100 O 
μM O 
) O 
showed O 
protective O 
effects O 
against O 
methylglyoxal B-SYSTEMATIC 
-induced O 
human O 
umbilical O 
vein O 
endothelial O 
cell O 
death O 
. O 
These O 
results O 
suggest O 
that O 
thiol B-FAMILY 
-containing O 
diotides O 
derived O 
from O 
dioscorin B-TRIVIAL 
hydrolysis O 
exhibit O 
antioxidant O 
activities O 
and O 
reveal O 
the O 
benefits O 
of O 
yam O 
tuber O 
as O 
an O 
antioxidant O 
- O 
rich O 
food O 
. O 

wheat O 
hull O 
( O 
husk O 
) O 
is O 
a O 
valuable O 
source O 
for O 
tricin B-TRIVIAL 
, O 
a O 
potential O 
selective O 
cytotoxic O 
agent O 
. O 

flavone B-TRIVIAL 
, O 
tricin B-TRIVIAL 
( O 
5,7,4'-trihydroxy-3',5'-dimethoxyflavone B-SYSTEMATIC 
) O 
has O 
great O 
potential O 
as O 
an O 
anticancer O 
agent O 
, O 
due O 
to O 
its O 
specific O 
chemopreventive O 
activity O 
. O 
In O 
spite O 
of O 
these O 
characteristics O 
, O 
its O 
use O 
in O 
preclinical O 
studies O 
is O 
still O 
limited O 
, O 
mainly O 
because O 
of O 
its O 
limited O 
availability O 
and O 
high O 
production O 
cost O 
. O 
Tricin B-TRIVIAL 
is O 
found O 
mainly O 
in O 
cereal O 
grains O 
, O 
such O 
as O 
wheat O 
, O 
rice O 
, O 
barley O 
, O 
oat O 
and O 
maize O 
. O 
However O 
, O 
its O 
concentration O 
in O 
these O 
plants O 
is O 
not O 
sufficient O 
for O 
commercial O 
use O 
. O 
To O 
find O 
a O 
reliable O 
, O 
rich O 
source O 
of O 
tricin B-TRIVIAL 
, O 
we O 
investigated O 
its O 
distribution O 
in O 
different O 
parts O 
of O 
wheat O 
( O 
Triticum O 
aestivum O 
) O 
and O 
designed O 
an O 
efficient O 
method O 
for O 
its O 
isolation O 
and O 
purification O 
. O 
The O 
highest O 
amount O 
( O 
770 O 
± O 
157 O 
mg O 
/ O 
kg O 
dry O 
weight O 
) O 
was O 
found O 
in O 
the O 
husks O 
of O 
winter O 
wheat O 
. O 
This O 
concentration O 
is O 
one O 
of O 
the O 
highest O 
in O 
any O 
plant O 
species O 
and O 
is O 
considered O 
as O 
a O 
cheap O 
source O 
of O 
natural O 
tricin B-TRIVIAL 
. O 
The O 
purified O 
wheat O 
husks O 
tricin B-TRIVIAL 
was O 
found O 
to O 
be O 
a O 
selective O 
potent O 
inhibitor O 
of O 
two O 
cancer O 
cell O 
lines O 
of O 
liver O 
and O 
pancreas O 
, O 
while O 
having O 
no O 
side O 
effects O 
on O 
normal O 
cells O 
. O 
This O 
selective O 
action O 
suggests O 
that O 
tricin B-TRIVIAL 
could O 
be O 
considered O 
as O 
a O 
potential O 
candidate O 
for O 
pre O 
- O 
clinical O 
trials O 
as O 
a O 
chemopreventive O 
agent O 
. O 
In O 
addition O 
, O 
fibre O 
- O 
rich O 
crude O 
wheat O 
husk O 
could O 
be O 
used O 
as O 
a O 
natural O 
chemopreventive O 
agent O 
in O 
food O 
supplement O 
. O 

and O 
Chardonnay O 
grapevines O 
were O 
treated O 
with O 
an O 
oak O 
extract O 
in O 
order O 
to O 
determine O 
the O 
effect O 
on O 
glycosidic O 
aroma O 
precursors O 
. O 
Grapevines O 
were O 
treated O 
at O 
three O 
different O 
timings O 
of O 
the O 
veraison O 
( O 
treatment O 
1 O 
, O 
2 O 
and O 
3 O 
) O 
. O 
Aglycons O 
were O 
obtained O 
by O 
enzymatic O 
hydrolysis O 
, O 
and O 
these O 
were O 
identified O 
and O 
quantified O 
by O 
means O 
of O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
( O 
GC-MS O 
) O 
. O 
Results O 
suggest O 
that O 
after O 
the O 
applications O 
the O 
majority O 
of O 
compounds O 
from O 
the O 
oak O 
extract O 
were O 
assimilated O 
and O 
stored O 
as O 
glycosidic O 
forms O 
in O 
both O 
cultivars O 
. O 
Also O 
, O 
other O 
compounds O 
not O 
present O 
in O 
the O 
extract O 
were O 
affected O 
, O 
with O 
a O 
different O 
behaviour O 
observed O 
depending O 
on O 
the O 
timing O 
of O 
application O 
and O 
the O 
variety O 
. O 
In O 
general O 
, O 
C6 B-FORMULA 
compounds O 
, O 
alcohols B-FAMILY 
, O 
terpenes B-FAMILY 
, O 
phenols B-FAMILY 
and O 
C13-norisoprenoids B-FAMILY 
in O 
Syrah O 
showed O 
a O 
decrease O 
and O 
in O 
Chardonnay O 
an O 
increase O 
. O 
Thus O 
, O 
this O 
study O 
proved O 
a O 
change O 
in O 
the O 
glycosidic O 
aroma O 
profile O 
in O 
grapes O 
after O 
the O 
oak O 
application O 
, O 
so O 
these O 
treated O 
grapes O 
could O 
produce O 
wines O 
with O 
different O 
aromatic O 
quality O 
. O 

NMR O 
- O 
based O 
metabolic O 
fingerprinting O 
of O 
urine O 
metabolites O 
after O 
consumption O 
of O 
lingonberries O 
( O 
Vaccinium O 
vitis O 
- O 
idaea O 
) O 
with O 
a O 
high O 
- O 
fat O 
meal O 
. O 

use O 
of O 
NMR O 
metabolomics O 
in O 
clinical O 
trials O 
is O 
growing O 
; O 
however O 
, O 
reports O 
of O 
postprandial O 
experiments O 
in O 
humans O 
are O 
scarce O 
. O 
The O 
present O 
study O 
investigated O 
whether O 
consumption O 
of O 
lingonberries O 
as O 
a O 
supplement O 
to O 
an O 
oil O 
- O 
rich O 
meal O 
modifies O 
the O 
postprandial O 
fingerprints O 
of O 
human O 
urine O 
. O 
Urine O 
samples O 
were O 
analysed O 
by O 
(1)H B-FORMULA 
NMR O 
, O 
and O 
untargeted O 
multivariate O 
analysis O 
was O 
applied O 
to O 
the O 
data O 
for O 
comprehensive O 
fingerprinting O 
. O 
A O 
clear O 
separation O 
of O 
postprandial O 
lingonberry O 
meal O 
samples O 
was O 
revealed O 
. O 
To O 
evaluate O 
statistical O 
differences O 
, O 
a O 
targeted O 
approach O 
was O 
applied O 
for O 
the O 
informative O 
spectral O 
areas O 
. O 
Significantly O 
( O 
p O 
< O 
0.05 O 
) O 
increased O 
levels O 
of O 
polyphenol B-FAMILY 
metabolites O 
, O 
hippuric B-TRIVIAL 
acid I-TRIVIAL 
and O 
4-hydroxyhippuric B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
and O 
decreased O 
creatinine B-TRIVIAL 
and O 
dimethylamine B-SYSTEMATIC 
levels O 
were O 
the O 
major O 
explanations O 
for O 
the O 
grouping O 
of O 
the O 
postprandial O 
samples O 
after O 
the O 
different O 
meals O 
. O 
Thus O 
, O 
inclusion O 
of O 
polyphenol B-FAMILY 
-rich O 
lingonberry O 
powder O 
in O 
a O 
rapeseed O 
oil O 
- O 
rich O 
meal O 
modifies O 
the O 
metabolic O 
profile O 
of O 
urine O 
which O 
may O 
be O 
used O 
to O 
reveal O 
both O 
consumption O 
of O 
berries O 
and O 
health O 
- O 
promoting O 
changes O 
in O 
the O 
common O 
metabolism O 
. O 

determination O 
of O 
Mn2+ B-FORMULA 
and O 
Fe3+ B-FORMULA 
as O 
4,4'[(4-cholorophenyl)methylene] B-SYSTEMATIC 
bis(3-methyl-1-phenyl-1H-pyrazol-5-ol) I-SYSTEMATIC 
complexes O 
in O 
some O 
foods O 
, O 
vegetable O 
and O 
water O 
samples O 
by O 
artificial O 
neural O 
networks O 
. O 

simple O 
and O 
sensitive O 
spectrophotometric O 
method O 
to O 
the O 
simultaneous O 
determination O 
of O 
Mn(2+) B-FORMULA 
and O 
Fe(3+) B-FORMULA 
in O 
foods O 
, O 
vegetable O 
and O 
water O 
sample O 
with O 
the O 
aid O 
of O 
artificial O 
neural O 
networks O 
( O 
ANNs O 
) O 
is O 
described O 
. O 
It O 
relies O 
on O 
the O 
complexation O 
of O 
analytes O 
with O 
recently O 
synthesised O 
bis O 
pyrazol B-SYSTEMATIC 
base O 
ligand O 
as O 
4,4'[(4-cholorophenyl)methylene] B-SYSTEMATIC 
bis(3-methyl-1-phenyl-1H-pyrazol-5-ol) I-SYSTEMATIC 
( O 
CMBPP B-ABBREVIATION 
) O 
. O 
The O 
analytical O 
data O 
show O 
that O 
the O 
ratio O 
of O 
ligand O 
to O 
metal O 
in O 
metal O 
complexes O 
is O 
1 O 
: O 
1 O 
and O 
1 O 
: O 
2 O 
for O 
Fe(3+) B-FORMULA 
and O 
Mn(2+) B-FORMULA 
, O 
respectively O 
. O 
It O 
was O 
found O 
that O 
the O 
complexation O 
reactions O 
are O 
completed O 
at O 
pH O 
6.7 O 
and O 
5 O 
min O 
after O 
mixing O 
. O 
The O 
results O 
showed O 
that O 
Mn(2+) B-FORMULA 
and O 
Fe(3+) B-FORMULA 
could O 
be O 
determined O 
simultaneously O 
in O 
the O 
range O 
of O 
0.20-7.5 O 
and O 
0.30-9.0 O 
mgl(-1) O 
, O 
respectively O 
. O 
The O 
analytical O 
characteristics O 
of O 
the O 
method O 
such O 
as O 
the O 
detection O 
limit O 
and O 
the O 
relative O 
standard O 
error O 
predictions O 
were O 
calculated O 
. O 
The O 
data O 
obtained O 
from O 
synthetic O 
mixtures O 
of O 
the O 
metal O 
ions O 
were O 
processed O 
by O 
radial O 
basis O 
function O 
networks O 
( O 
RBFNs O 
) O 
and O 
feed O 
forward O 
neural O 
networks O 
( O 
FFNNs O 
) O 
. O 
The O 
optimal O 
conditions O 
of O 
the O 
neural O 
networks O 
were O 
obtained O 
by O 
adjusting O 
various O 
parameters O 
by O 
trial O 
- O 
and O 
- O 
error O 
. O 
Under O 
the O 
working O 
conditions O 
, O 
the O 
proposed O 
methods O 
were O 
successfully O 
applied O 
to O 
the O 
simultaneous O 
determination O 
of O 
elements O 
in O 
different O 
water O 
, O 
tablet O 
, O 
rice O 
, O 
tea O 
leaves O 
, O 
tomato O 
, O 
cabbage O 
and O 
lettuce O 
samples O 
. O 

exchange O 
technology O 
has O 
been O 
applied O 
to O 
adjust O 
the O 
pH O 
of O 
red O 
wine O 
and O 
improve O 
its O 
tartaric O 
and O 
oxidative O 
stability O 
. O 
Ion O 
exchange O 
appears O 
to O 
be O 
a O 
useful O 
technique O 
to O 
achieve O 
these O 
objectives O 
. O 
Regarding O 
the O 
effect O 
of O 
ion O 
exchange O 
on O 
organoleptic O 
characteristics O 
and O 
the O 
quality O 
of O 
the O 
obtained O 
wines O 
, O 
a O 
slight O 
decrease O 
in O 
both O 
anthocyanin B-FAMILY 
and O 
tannin B-FAMILY 
contents O 
was O 
observed O 
along O 
with O 
a O 
small O 
drop O 
in O 
the O 
aromatic O 
content O 
. O 
However O 
, O 
the O 
treated O 
wines O 
had O 
lower O 
hue O 
and O 
higher O 
colour O 
intensity O 
and O 
gave O 
better O 
punctuations O 
in O 
the O 
sensory O 
evaluation O 
. O 
These O 
results O 
confirm O 
that O 
ion O 
exchange O 
is O 
an O 
interesting O 
technique O 
for O 
application O 
in O 
red O 
winemaking O 
. O 

analytical O 
investigation O 
of O 
phospholipids O 
and O 
triglycerides B-FAMILY 
in O 
offshore O 
farmed O 
gilthead O 
sea O 
bream O 
( O 
Sparus O 
aurata O 
) O 
fed O 
commercial O 
diets O 
. O 

this O 
work O 
, O 
a O 
quantitative O 
characterisation O 
of O 
lipid O 
( O 
both O 
triglycerides B-FAMILY 
and O 
phospholipids O 
) O 
rearrangements O 
in O 
the O 
muscle O 
of O 
offshore O 
- O 
raised O 
gilthead O 
sea O 
bream O 
was O 
carried O 
out O 
as O 
a O 
function O 
of O 
fish O 
growth O 
between O 
April O 
and O 
September O 
. O 
Relative O 
percentages O 
of O 
lipid O 
classes O 
and O 
f O 
atty B-FAMILY 
acids I-FAMILY 
/ O 
acyls B-FAMILY 
composition O 
of O 
the O 
commercial O 
feeds O 
and O 
fish O 
dorsal O 
muscles O 
were O 
assessed O 
by O 
means O 
of O 
an O 
interdisciplinary O 
analytical O 
approach O 
. O 
A O 
combination O 
of O 
preparative O 
chemistry O 
and O 
experimental O 
results O 
from O 
NMR O 
spectroscopy O 
, O 
GC O 
, O 
3D-TLC O 
as O 
well O 
as O 
proximate O 
analysis O 
permitted O 
the O 
observed O 
growth O 
parameters O 
in O 
key O 
metabolic O 
events O 
to O 
be O 
linked O 
with O 
fish O 
fattening O 
and O 
lipid O 
turnover O 
. O 
While O 
defined O 
effects O 
of O 
feed O 
composition O 
on O 
fatty B-FAMILY 
acid I-FAMILY 
profiles O 
of O 
fillets O 
were O 
ascertained O 
, O 
the O 
relative O 
increase O 
of O 
fatty B-FAMILY 
acyls I-FAMILY 
in O 
triglycerides B-FAMILY 
and O 
phospholipids O 
were O 
also O 
estimated O 
enabling O 
detailed O 
evaluation O 
of O 
TAG O 
: O 
PL O 
ratio O 
in O 
adult O 
offshore O 
- O 
farmed O 
gilthead O 
sea O 
bream O 
. O 
NMR O 
was O 
also O 
used O 
to O 
quantify O 
PUFA B-ABBREVIATION 
regiospecific O 
distribution O 
in O 
TAG B-ABBREVIATION 
and O 
PL O 
. O 

, O 
fast O 
, O 
and O 
efficient O 
process O 
for O 
producing O 
and O 
purifying O 
trehalulose B-TRIVIAL 
. O 

new O 
property O 
of O 
recombinant O 
trehalose B-TRIVIAL 
synthase O 
( O 
GTase O 
) O 
from O 
Thermus O 
thermophilus O 
HB-8 O 
( O 
ATCC O 
27634 O 
) O 
was O 
found O 
and O 
described O 
in O 
this O 
study O 
. O 
GTase O 
can O 
act O 
on O 
sucrose B-TRIVIAL 
and O 
catalyze O 
trehalulose B-TRIVIAL 
formation O 
without O 
isomaltose B-TRIVIAL 
, O 
isomaltulose B-TRIVIAL 
, O 
or O 
isomelezitose B-TRIVIAL 
, O 
releasing O 
small O 
amounts O 
of O 
glucose B-TRIVIAL 
and O 
fructose B-TRIVIAL 
as O 
byproducts O 
. O 
Maximum O 
trehalulose B-TRIVIAL 
yield O 
( O 
approximately O 
81% O 
) O 
was O 
obtained O 
at O 
an O 
optimum O 
temperature O 
of O 
65°C O 
and O 
was O 
independent O 
of O 
substrate O 
concentration O 
. O 
A O 
simple O 
, O 
fast O 
, O 
and O 
efficient O 
method O 
of O 
producing O 
and O 
purifying O 
trehalulose B-TRIVIAL 
is O 
then O 
described O 
. O 
In O 
the O 
first O 
step O 
, O 
GTase O 
catalyzed O 
trehalulose B-TRIVIAL 
formation O 
using O 
a O 
20% O 
sucrose B-TRIVIAL 
substrate O 
. O 
Miscellaneous O 
sugars B-FAMILY 
were O 
then O 
rapidly O 
removed O 
, O 
while O 
trehalulose B-TRIVIAL 
was O 
completely O 
preserved O 
by O 
Saccharomyces O 
cerevisiae O 
cells O 
. O 
Finally O 
, O 
the O 
cells O 
were O 
separated O 
by O 
centrifugation O 
, O 
and O 
salt O 
ions O 
were O 
removed O 
by O 
an O 
ion O 
- O 
exchange O 
resin O 
, O 
subsequently O 
obtaining O 
a O 
high O 
- O 
purity O 
trehalulose B-TRIVIAL 
solution O 
. O 
A O 
trehalulose B-TRIVIAL 
recovery O 
rate O 
of O 
over O 
95% O 
was O 
achieved O 
using O 
this O 
process O 
. O 
This O 
method O 
has O 
a O 
simple O 
process O 
, O 
fast O 
separation O 
efficiency O 
, O 
and O 
low O 
investment O 
in O 
production O 
equipment O 
, O 
so O 
greatly O 
to O 
improve O 
production O 
efficiency O 
and O 
reduce O 
production O 
costs O 
. O 

impact O 
of O 
peeling O 
and O 
three O 
cooking O 
treatments O 
( O 
boiling O 
, O 
baking O 
and O 
microwaving O 
) O 
on O 
the O 
content O 
of O 
selected O 
phytochemicals O 
in O 
white- O 
, O 
yellow- O 
, O 
red- O 
and O 
purple O 
- O 
fleshed O 
potatoes O 
was O 
investigated O 
. O 
Ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
contents O 
were O 
determined O 
by O 
HPLC-DAD O 
, O 
total O 
anthocyanin B-FAMILY 
content O 
by O 
pH-differential O 
spectrophotometry O 
, O 
glycoalkaloid B-FAMILY 
, O 
α-chaconine B-TRIVIAL 
and O 
α-solanine B-TRIVIAL 
contents O 
by O 
HPLC-ESI O 
/ O 
MS O 
/ O 
MS O 
. O 
All O 
cooking O 
treatments O 
reduced O 
ascorbic B-TRIVIAL 
and I-TRIVIAL 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
contents O 
, O 
total O 
glycoalkaloids B-FAMILY 
, O 
α-chaconine B-TRIVIAL 
and O 
α-solanine B-TRIVIAL 
with O 
the O 
exception O 
of O 
total O 
anthocyanins B-FAMILY 
. O 
The O 
losses O 
of O 
ascorbic B-MULTIPLE 
and I-MULTIPLE 
chlorogenic I-MULTIPLE 
acids I-MULTIPLE 
were O 
minimised O 
with O 
boiling O 
and O 
total O 
anthocyanin B-FAMILY 
levels O 
retained O 
the O 
highest O 
. O 
Boiling O 
of O 
peeled O 
tubers O 
decreased O 
contents O 
of O 
total O 
glycoalkaloids B-FAMILY 
( O 
α-chaconine B-MULTIPLE 
and I-MULTIPLE 
α-solanine I-MULTIPLE 
) O 
and O 
appeared O 
as O 
the O 
most O 
favourable O 
among O 
the O 
three O 
tested O 
methods O 
. O 
Moreover O 
, O 
due O 
to O 
higher O 
initial O 
levels O 
, O 
red- O 
and O 
purple O 
- O 
fleshed O 
cultivars O 
retained O 
higher O 
amounts O 
of O 
antioxidants O 
( O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
, O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
and O 
total O 
anthocyanin B-FAMILY 
) O 
after O 
boiling O 
and O 
may O 
be O 
healthier O 
as O 
compared O 
with O 
white O 
or O 
yellow O 
cultivars O 
. O 

modified O 
QuEChERS O 
method O 
for O 
simultaneous O 
determination O 
of O 
124 O 
pesticide O 
residues O 
in O 
rice O 
was O 
established O 
and O 
validated O 
. O 
The O 
rice O 
samples O 
were O 
initially O 
extracted O 
with O 
acetonitrile B-SYSTEMATIC 
( O 
MeCN B-FORMULA 
) O 
, O 
and O 
the O 
targeted O 
pesticides O 
were O 
purified O 
following O 
the O 
dispersive O 
solid O 
phase O 
extraction O 
( O 
d-SPE O 
) O 
cleanup O 
method O 
and O 
detected O 
by O 
gas O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
( O 
GC-MS O 
/ O 
MS O 
) O 
. O 
The O 
efficiency O 
of O 
citrate B-FAMILY 
-buffered O 
and O 
unbuffered O 
method O 
in O 
liquid O 
extraction O 
procedure O 
was O 
compared O 
; O 
the O 
amount O 
of O 
primary B-MULTIPLE 
secondary I-MULTIPLE 
amine I-MULTIPLE 
( O 
PSA B-ABBREVIATION 
) O 
was O 
optimised O 
. O 
In O 
the O 
method O 
validation O 
, O 
correlation O 
coefficients O 
(r(2)) O 
were O 
higher O 
than O 
0.99 O 
with O 
the O 
linear O 
ranging O 
from O 
10 O 
to O 
200 O 
μg O 
kg(-1) O 
. O 
At O 
the O 
fortification O 
levels O 
of O 
20-200 O 
μg O 
kg(-1) O 
, O 
average O 
recoveries O 
ranged O 
from O 
70% O 
to O 
122.7% O 
with O 
the O 
RSD O 
< O 
20% O 
. O 

activity O 
of O 
phytosteryl B-FAMILY 
phenolates I-FAMILY 
in O 
different O 
model O 
systems O 
. O 

part O 
of O 
a O 
comprehensive O 
study O 
of O 
the O 
physiochemical O 
and O 
biological O 
properties O 
of O 
phytosteryl B-FAMILY 
phenolates I-FAMILY 
, O 
successfully O 
synthesized O 
chemoenzymatically O 
in O 
our O 
lab O 
, O 
their O 
antioxidant O 
activity O 
was O 
evaluated O 
using O 
three O 
different O 
in O 
vitro O 
model O 
systems O 
, O 
namely O 
bulk O 
oil O 
model O 
system O 
, O 
β-carotene B-TRIVIAL 
- O 
linoleate B-TRIVIAL 
model O 
system O 
and O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
( O 
LDL-C O 
) O 
oxidation O 
assay O 
. O 
In O 
the O 
bulk O 
oil O 
system O 
, O 
phytosteryl B-FAMILY 
phenolates I-FAMILY 
showed O 
similar O 
or O 
lower O 
antioxidant O 
activity O 
compared O 
with O 
those O 
of O 
phenolic B-FAMILY 
acids I-FAMILY 
. O 
However O 
, O 
in O 
β-carotene B-TRIVIAL 
- O 
linoleate B-TRIVIAL 
assay O 
, O 
an O 
emulsion O 
model O 
system O 
, O 
phytosteryl B-FAMILY 
phenolates I-FAMILY 
showed O 
enhanced O 
antioxidant O 
activity O 
except O 
phytosteryl B-FAMILY 
ferulates I-FAMILY 
. O 
Moderate O 
inhibitory O 
effect O 
of O 
LDL-C O 
oxidation O 
by O 
phytosteryl B-FAMILY 
phenolates I-FAMILY 
was O 
observed O 
. O 
These O 
findings O 
demonstrate O 
that O 
use O 
of O 
multidimensional O 
antioxidant O 
activity O 
determinations O 
with O 
differing O 
reaction O 
mechanisms O 
is O 
necessary O 
to O 
provide O 
an O 
overall O 
understanding O 
of O 
the O 
mechanisms O 
of O 
antioxidant O 
action O 
of O 
phytosteryl B-FAMILY 
phenolates I-FAMILY 
. O 

nanosilver O 
- O 
based O 
spectrophotometry O 
method O 
for O 
sensitive O 
determination O 
of O 
tartrazine B-TRIVIAL 
in O 
food O 
samples O 
. O 

new O 
method O 
is O 
reported O 
for O 
sensitive O 
determination O 
of O 
tartrazine B-TRIVIAL 
in O 
the O 
food O 
samples O 
. O 
The O 
method O 
is O 
based O 
on O 
the O 
catalytic O 
effect O 
of O 
silver B-SYSTEMATIC 
nanoparticle O 
( O 
AgNPs O 
) O 
on O 
the O 
oxidation O 
reaction O 
of O 
tartrazine B-TRIVIAL 
by O 
potassium B-SYSTEMATIC 
iodate I-SYSTEMATIC 
in O 
the O 
acetate B-SYSTEMATIC 
buffer O 
medium O 
. O 
The O 
reaction O 
is O 
followed O 
spectrophotometrically O 
by O 
measuring O 
the O 
change O 
in O 
absorbance O 
( O 
ΔA O 
) O 
at O 
420 O 
nm O 
using O 
a O 
fixed O 
time O 
method O 
( O 
70 O 
s O 
) O 
. O 
The O 
reaction O 
variables O 
were O 
optimised O 
in O 
order O 
to O 
achieve O 
the O 
highest O 
sensitivity O 
. O 
The O 
thirty O 
six O 
criterion O 
detection O 
limit O 
was O 
0.3 O 
ng O 
/ O 
mL O 
, O 
and O 
the O 
relative O 
standard O 
deviation O 
for O 
ten O 
replicate O 
measurements O 
of O 
30 O 
ng O 
/ O 
mL O 
of O 
tartrazine B-TRIVIAL 
was O 
0.98% O 
( O 
n=10 O 
) O 
. O 
The O 
method O 
was O 
successfully O 
applied O 
to O 
the O 
determination O 
of O 
tartrazine B-TRIVIAL 
in O 
lemon O 
, O 
and O 
papaya O 
- O 
flavoured O 
gelatin O 
, O 
candy O 
, O 
and O 
in O 
fruit O 
syrup O 
. O 

tubers O 
of O 
Lactuca O 
tuberosa O 
as O 
a O 
source O 
of O 
antioxidant O 
phenolic B-FAMILY 
compounds O 
and O 
new O 
furofuran B-FAMILY 
lignans I-FAMILY 
. O 

the O 
root O 
tubers O 
of O 
Lactuca O 
tuberosa O 
, O 
a O 
wild O 
edible O 
plant O 
species O 
, O 
nine O 
phenolic B-FAMILY 
compounds O 
were O 
isolated O 
, O 
including O 
two O 
new O 
furofuran B-FAMILY 
lignan I-FAMILY 
glucosides I-FAMILY 
, O 
named O 
lactuberin B-TRIVIAL 
A I-TRIVIAL 
and O 
lactuberin B-TRIVIAL 
B I-TRIVIAL 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
spectroscopic O 
methods O 
, O 
especially O 
HRESIMS O 
and O 
2D O 
NMR O 
techniques O 
. O 
This O 
is O 
the O 
first O 
time O 
that O 
compounds O 
belonging O 
to O 
the O 
epi O 
series O 
of O 
2,6-diaryl-3,7-dioxabicyclo[3.3.0]octane B-FAMILY 
type O 
furofuran B-FAMILY 
lignans I-FAMILY 
have O 
been O 
found O 
in O 
Lactuca O 
species O 
. O 
The O 
total O 
phenolic O 
content O 
of O 
the O 
root O 
tuber O 
extract O 
was O 
evaluated O 
and O 
its O 
major O 
phenolic B-FAMILY 
constituents O 
, O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
, O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
and O 
3,5 B-SYSTEMATIC 
dicaffeoylquinic I-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
known O 
to O 
possess O 
antioxidant O 
activity O 
, O 
were O 
quantified O 
. O 
Additionally O 
, O 
the O 
root O 
tuber O 
extract O 
showed O 
DPPH B-ABBREVIATION 
radical O 
scavenging O 
activity O 
implying O 
its O 
potential O 
as O 
functional O 
food O 
. O 

characterisation O 
of O 
soluble O 
apple O 
polysaccharides O 
, O 
and O 
their O 
antioxidant O 
and O 
hepatoprotective O 
effects O 
on O 
acute O 
CCl4 B-FORMULA 
-caused O 
liver O 
damage O 
in O 
mice O 
. O 

- O 
soluble O 
apple O 
peel O 
polysaccharides O 
( O 
APP O 
) O 
and O 
apple O 
flesh O 
polysaccharides O 
( O 
AFP O 
) O 
were O 
isolated O 
from O 
Pink O 
Lady O 
fruits O 
, O 
and O 
their O 
in O 
vitro O 
antioxidant O 
capacities O 
were O 
characterised O 
by O 
DPPH B-ABBREVIATION 
() O 
, O 
HO B-FORMULA 
() O 
, O 
and O 
O(2)(-) B-FORMULA 
systems O 
, O 
and O 
ferric B-SYSTEMATIC 
-reducing O 
antioxidant O 
power O 
assay O 
. O 
Oral O 
administration O 
of O 
APP O 
at O 
250 O 
and O 
500 O 
mg O 
/ O 
kg O 
bw O 
in O 
mice O 
was O 
shown O 
to O 
be O 
as O 
effective O 
as O 
AFP O 
in O 
lowering O 
the O 
CCl(4) B-FORMULA 
-caused O 
increases O 
of O 
serum O 
alanine B-TRIVIAL 
aminotransferase O 
, O 
aspartate B-TRIVIAL 
aminotransferase O 
and O 
lactic O 
dehydrogenase O 
activities O 
, O 
and O 
hepatic O 
malondialdehyde B-TRIVIAL 
level O 
, O 
and O 
antagonising O 
the O 
decreases O 
in O 
antioxidant O 
superoxide B-TRIVIAL 
dismutase O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
activities O 
caused O 
by O 
CCl(4) B-FORMULA 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Histopathological O 
examinations O 
further O 
confirmed O 
that O 
both O 
APP O 
and O 
AFP O 
could O 
protect O 
the O 
liver O 
from O 
CCl(4) B-FORMULA 
-induced O 
histological O 
alteration O 
. O 
HPLC O 
analysis O 
also O 
showed O 
similar O 
profiles O 
of O 
monosaccharide O 
composition O 
for O 
APP O 
and O 
AFP O 
with O 
arabinose B-TRIVIAL 
, O 
galactose B-TRIVIAL 
and O 
galacturonic B-TRIVIAL 
acid I-TRIVIAL 
being O 
main O 
component O 
monosaccharides O 
. O 
All O 
of O 
these O 
findings O 
demonstrate O 
that O 
the O 
extracts O 
of O 
both O 
APP O 
and O 
AFP O 
possess O 
antioxidant O 
and O 
hepatoprotective O 
potential O 
. O 

the O 
interactions O 
between O 
free O 
phenols B-FAMILY 
, O 
L-ascorbic B-TRIVIAL 
acid I-TRIVIAL 
, O 
apple O 
polyphenoloxidase O 
and O 
oxygen B-SYSTEMATIC 
during O 
a O 
thermal O 
treatment O 
. O 

kinetics O 
of O 
degradation O 
of O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
( O 
CG O 
) O 
, O 
( B-TRIVIAL 
- I-TRIVIAL 
) I-TRIVIAL 
epicatechin I-TRIVIAL 
( O 
EPI B-ABBREVIATION 
) O 
, O 
L-ascorbic B-TRIVIAL 
acid I-TRIVIAL 
( O 
AA O 
) O 
and O 
polyphenoloxidase O 
( O 
PPO O 
) O 
activity O 
from O 
Marie-Ménard O 
apple O 
in O 
pH O 
3.8 O 
solutions O 
at O 
20 O 
and O 
50°C O 
were O 
investigated O 
to O 
provide O 
information O 
on O 
the O 
impact O 
of O 
the O 
presence O 
of O 
CG O 
, O 
EPI B-ABBREVIATION 
and O 
/ O 
or O 
AA O 
on O 
PPO O 
thermostability O 
. O 
The O 
effect O 
of O 
the O 
heat O 
treatment O 
on O 
their O 
degradation O 
by O 
enzymatic O 
and O 
/ O 
or O 
nonenzymatic O 
ways O 
was O 
also O 
studied O 
. O 
Stoechiokinetic O 
reactions O 
on O 
the O 
basis O 
of O 
experimental O 
data O 
and O 
literature O 
and O 
determination O 
of O 
the O 
kinetic O 
constants O 
( O 
k O 
) O 
at O 
20 O 
and O 
50°C O 
were O 
elaborated O 
before O 
modelling O 
the O 
interaction O 
among O 
reactants O 
, O 
by O 
fitting O 
the O 
reaction O 
curves O 
to O 
predictive O 
model O 
. O 
Apple O 
PPO O 
was O 
thermolabile O 
, O 
denaturing O 
after O 
10min O 
at O 
70°C O 
. O 
Losses O 
of O 
PPO O 
activity O 
were O 
favoured O 
by O 
the O 
presence O 
of O 
EPI B-ABBREVIATION 
in O 
model O 
solutions O 
, O 
compared O 
with O 
CG O 
, O 
due O 
to O 
the O 
formation O 
of O 
o-quinones B-FAMILY 
of O 
EPI B-ABBREVIATION 
( O 
QEPI O 
) O 
lowering O 
PPO O 
stability O 
. O 
Temperature O 
quickened O 
both O 
enzymatic O 
phenol B-SYSTEMATIC 
oxidations O 
before O 
PPO O 
deteriorated O 
and O 
the O 
whole O 
set O 
of O 
the O 
chemical O 
reactions O 
, O 
including O 
the O 
production O 
of O 
secondary O 
oxidation O 
products O 
and O 
CG O 
or O 
EPI B-ABBREVIATION 
regeneration O 
. O 
Results O 
also O 
confirmed O 
that O 
AA O 
in O 
excess O 
induced O 
a O 
fast O 
regeneration O 
of O 
CG O 
and O 
EPI B-ABBREVIATION 
from O 
the O 
corresponding O 
o-quinones B-FAMILY 
formed O 
enzymatically O 
via O 
redox O 
chemical O 
reactions O 
. O 

sumac O 
( O 
Rhus O 
hirta O 
L O 
. O 
) O 
is O 
a O 
native O 
tree O 
in O 
Eastern O 
Canada O 
whose O 
fruit O 
has O 
been O 
used O 
by O 
aboriginal O 
peoples O 
to O 
treat O 
various O 
illnesses O 
, O 
and O 
has O 
recently O 
been O 
found O 
to O 
be O 
a O 
good O 
source O 
of O 
antioxidants O 
. O 
However O 
, O 
the O 
phytochemical O 
composition O 
of O 
R O 
. O 
hirta O 
is O 
not O 
known O 
. O 
In O 
this O 
study O 
, O 
we O 
used O 
Four O 
highly O 
accepted O 
assays O 
and O 
confirmed O 
its O 
FRAP O 
, O 
ORAC O 
, O 
β-CLAMS O 
and O 
PCL O 
values O 
to O 
be O 
79.95 O 
μmol O 
AAE O 
/ O 
g O 
DW O 
, O 
1544 O 
μmol O 
TE O 
/ O 
g O 
DW O 
, O 
RAA O 
129% O 
and O 
4513 O 
μmol O 
TE O 
/ O 
g O 
DW O 
, O 
respectively O 
. O 
The O 
antioxidant O 
activities O 
correlated O 
positively O 
to O 
the O 
total O 
polyphenols B-FAMILY 
content O 
, O 
which O 
was O 
higher O 
in O 
the O 
ethanolic O 
extract O 
( O 
81.6 O 
mg O 
GAE/ O 
g O 
DW O 
) O 
compared O 
to O 
the O 
water O 
extract O 
( O 
46.3mg O 
GAE O 
/ O 
g O 
DW O 
) O 
, O 
suggesting O 
polyphenols B-FAMILY 
play O 
an O 
important O 
role O 
. O 
Quantitative O 
data O 
from O 
UHPLC O 
and O 
qualitative O 
studies O 
using O 
HPLC-DAD-MS O 
showed O 
that O 
in O 
addition O 
to O 
commonly O 
found O 
phenolic B-FAMILY 
acids I-FAMILY 
, O 
flavonoids B-FAMILY 
and O 
anthocyanins B-FAMILY 
, O 
R O 
. O 
hirta O 
fruit O 
contained O 
a O 
novel O 
group O 
of O 
unique O 
anthocyanins B-FAMILY 
with O 
aglycones O 
( O 
anthocyanidins B-FAMILY 
) O 
at O 
449 O 
, O 
419 O 
and O 
433 O 
Da O 
. O 
Further O 
studies O 
on O 
the O 
identification O 
and O 
their O 
health O 
beneficial O 
effects O 
are O 
being O 
conducted O 
. O 

between O 
the O 
evolution O 
of O 
the O 
percentage O 
in O 
weight O 
of O 
polar O 
compounds O 
and O 
that O 
of O 
the O 
molar O 
percentage O 
of O 
acyl B-FAMILY 
groups O 
of O 
edible O 
oils O 
submitted O 
to O 
frying O 
temperature O 
. O 

evolution O 
of O 
the O 
molar O 
percentage O 
of O 
several O 
kinds O 
of O 
acyl B-FAMILY 
groups O 
of O 
extra O 
virgin O 
olive O 
, O 
sunflower O 
and O 
virgin O 
linseed O 
oils O 
was O 
monitored O 
throughout O 
heating O 
at O 
frying O 
temperature O 
by O 
means O 
of O 
(1)H B-FORMULA 
nuclear O 
magnetic O 
resonance O 
. O 
Likewise O 
, O 
the O 
evolution O 
of O 
the O 
percentage O 
in O 
weight O 
of O 
the O 
polar O 
compounds O 
of O 
the O 
same O 
oils O 
under O 
the O 
same O 
heating O 
conditions O 
was O 
also O 
determined O 
. O 
Relationships O 
between O 
both O 
sets O 
of O 
parameters O 
, O 
in O 
each O 
oil O 
and O 
in O 
the O 
oils O 
as O 
a O 
group O 
, O 
were O 
studied O 
. O 
An O 
equation O 
which O 
is O 
able O 
to O 
accurately O 
predict O 
the O 
percentage O 
in O 
weight O 
of O 
the O 
polar O 
compounds O 
, O 
throughout O 
the O 
heating O 
at O 
frying O 
temperature O 
, O 
of O 
any O 
one O 
of O 
these O 
three O 
oils O 
, O 
from O 
the O 
molar O 
percentage O 
of O 
triunsaturated O 
, O 
diunsaturated O 
and O 
monounsaturated O 
acyl B-FAMILY 
groups O 
, O 
was O 
obtained O 
. O 
In O 
this O 
way O 
both O 
molar O 
percentage O 
of O 
acyl B-FAMILY 
groups O 
and O 
percentage O 
in O 
weight O 
of O 
polar O 
compounds O 
can O 
be O 
obtained O 
in O 
a O 
few O 
minutes O 
that O 
registration O 
of O 
the O 
(1)H B-FORMULA 
NMR O 
spectrum O 
of O 
the O 
oil O 
takes O 
, O 
in O 
addition O 
to O 
the O 
rest O 
of O 
information O 
provided O 
by O 
this O 
technique O 
. O 
The O 
study O 
reveals O 
the O 
close O 
relationships O 
between O 
percentage O 
in O 
weight O 
of O 
polar O 
compounds O 
and O 
the O 
composition O 
expressed O 
in O 
terms O 
of O 
molar O 
percentages O 
of O 
acyl B-FAMILY 
groups O 
in O 
edible O 
oils O 
heated O 
at O 
frying O 
temperature O 
. O 

new O 
optoelectronic O 
nose O 
for O 
the O 
shelf O 
- O 
life O 
assessment O 
of O 
fresh O 
sea O 
bream O 
in O 
cold O 
storage O 
has O 
been O 
developed O 
. O 
The O 
chromogenic O 
array O 
used O 
eight O 
sensing O 
materials O 
( O 
based O 
on O 
aluminium B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
silica B-TRIVIAL 
gel I-TRIVIAL 
) O 
containing O 
pH O 
indicators O 
, O 
Lewis B-FAMILY 
acids I-FAMILY 
and O 
an O 
oxidation O 
- O 
reduction O 
indicator O 
. O 
The O 
colour O 
changes O 
of O 
the O 
sensor O 
array O 
were O 
characteristic O 
of O 
sea O 
bream O 
spoilage O 
. O 
Colour O 
modulations O 
were O 
measured O 
on O 
day O 
0 O 
and O 
for O 
the O 
samples O 
held O 
in O 
cold O 
storage O 
for O 
2 O 
, O 
4 O 
, O 
7 O 
, O 
9 O 
and O 
11 O 
days O 
. O 
Determination O 
of O 
moisture O 
content O 
, O 
pH O 
, O 
total O 
volatile O 
basic O 
nitrogen B-SYSTEMATIC 
( O 
TVB- O 
N B-FORMULA 
) O 
, O 
drip O 
loss O 
, O 
ATP B-ABBREVIATION 
-related O 
compounds O 
and O 
K(1)-value O 
and O 
microbial O 
( O 
mesophilic O 
bacteria O 
and O 
Enterobacteriaceae O 
) O 
analyses O 
were O 
carried O 
out O 
on O 
the O 
same O 
days O 
. O 
The O 
changes O 
in O 
the O 
chromogenic O 
arrays O 
data O 
were O 
processed O 
by O 
statistical O 
analysis O 
( O 
PCA O 
) O 
. O 
Moreover O 
, O 
PLS O 
statistical O 
studies O 
allowed O 
the O 
creation O 
of O 
models O 
to O 
correlate O 
the O 
chromogenic O 
data O 
with O 
concentrations O 
of O 
mesophilic O 
and O 
Enterobacteriaceae O 
. O 
The O 
results O 
suggest O 
the O 
feasibility O 
of O 
this O 
system O 
to O 
help O 
develop O 
optoelectronic O 
noses O 
for O 
fish O 
freshness O 
monitoring O 
. O 

water- O 
alcohol B-FAMILY 
extract O 
of O 
Citrus O 
grandis O 
whole O 
fruits O 
has O 
beneficial O 
metabolic O 
effects O 
in O 
the O 
obese O 
Zucker O 
rats O 
fed O 
with O 
high O 
fat O 
/ O 
high O 
cholesterol B-TRIVIAL 
diet O 
. O 

studies O 
suggest O 
that O 
citrus O 
fruits O 
and O 
compounds O 
such O 
as O 
flavonoids B-FAMILY 
, O 
limonoids O 
and O 
pectins O 
have O 
health O 
promoting O 
effects O 
. O 
Our O 
aim O 
was O 
to O 
study O 
the O 
effects O 
of O 
Citrus O 
grandis O 
( O 
L O 
. O 
) O 
Osbeck O 
var O 
. O 
tomentosa O 
hort O 
. O 
fruit O 
extract O 
on O 
the O 
energy O 
metabolism O 
. O 
A O 
whole O 
fruit O 
powder O 
from O 
dry O 
water O 
and O 
alcohol B-FAMILY 
extracts O 
of O 
C O 
. O 
grandis O 
containing O 
19% O 
naringin B-TRIVIAL 
flavonoid O 
was O 
prepared O 
. O 
The O 
effects O 
of O 
the O 
citrus O 
extract O 
were O 
followed O 
in O 
the O 
obese O 
Zucker O 
rats O 
fed O 
with O 
the O 
HFD O 
. O 
The O 
circulatory O 
levels O 
of O 
GLP-1 O 
decreased O 
significantly O 
by O 
the O 
extract O 
in O 
comparison O 
to O 
the O 
HFD O 
group O 
, O 
whereas O 
the O 
decreased O 
ghrelin O 
levels O 
were O 
reversed O 
. O 
The O 
levels O 
of O 
PYY O 
were O 
decreased O 
in O 
all O 
HFD O 
groups O 
. O 
The O 
leptin O 
amounts O 
decreased O 
but O 
not O 
significantly O 
whereas O 
insulin O 
and O 
amylin O 
were O 
unchanged O 
. O 
The O 
cholesterol B-TRIVIAL 
and O 
glucose B-TRIVIAL 
levels O 
were O 
somewhat O 
but O 
not O 
systematically O 
improved O 
in O 
the O 
HFD O 
fed O 
rats O 
. O 
Further O 
studies O 
are O 
needed O 
to O 
identify O 
the O 
active O 
compounds O 
and O 
their O 
mechanisms O 
. O 

were O 
subjected O 
to O 
treatments O 
like O 
defatting O 
, O 
hydrothermal O 
cooking O 
and O 
kilning O 
, O 
milled O 
into O 
flour O 
and O 
then O 
the O 
control O 
and O 
treated O 
flours O 
were O 
incorporated O 
into O 
wheat O 
flour O 
at O 
25% O 
and O 
50% O 
levels O 
and O 
chapatti O 
making O 
behaviour O 
and O 
antioxidant O 
properties O 
were O 
studied O 
. O 
The O 
treatments O 
significantly O 
affected O 
the O 
antioxidant O 
properties O 
of O 
oats O 
. O 
Incorporating O 
oat O 
flours O 
to O 
wheat O 
increased O 
total O 
phenolic O 
content O 
but O 
lowered O 
the O 
antioxidant O 
activity O 
however O 
both O 
were O 
decreased O 
significantly O 
upon O 
baking O 
. O 
The O 
reducing O 
power O 
of O 
the O 
oat O 
blended O 
flour O 
was O 
higher O 
than O 
the O 
wheat O 
flours O 
and O 
ranged O 
from O 
8 O 
to O 
15.5 O 
μmol O 
AAE O 
/ O 
g O 
and O 
was O 
further O 
increased O 
upon O 
baking O 
. O 
The O 
metal O 
chelating O 
activity O 
of O 
flour O 
blends O 
varied O 
from O 
62.0% O 
to O 
73.8% O 
and O 
further O 
increased O 
upon O 
baking O 
. O 
After O 
baking O 
the O 
total O 
flavonoid B-FAMILY 
content O 
was O 
lowered O 
and O 
ranged O 
from O 
308 O 
to O 
389 O 
μg O 
CE O 
/ O 
g O 
. O 
The O 
non-enzymatic O 
browning O 
index O 
significantly O 
increased O 
up O 
to O 
27.6% O 
upon O 
baking O 
. O 

, O 
a O 
potent O 
bioactive O 
stilbene B-TRIVIAL 
, O 
as O 
major O 
phenolic B-FAMILY 
component O 
in O 
Rhodomyrtus O 
tomentosa O 
. O 

sim O 
fruit O 
( O 
Rhodomyrtus O 
tomentosa O 
) O 
has O 
long O 
been O 
used O 
in O 
folk O 
medicine O 
to O 
treat O 
diarrhoea O 
, O 
dysentery O 
, O 
and O 
to O 
boost O 
the O 
immune O 
system O 
. O 
The O 
purpose O 
of O 
this O 
work O 
was O 
to O 
determine O 
its O 
phenolic O 
profile O 
and O 
to O 
evaluate O 
the O 
changes O 
of O 
content O 
during O 
maturation O 
, O 
as O 
well O 
as O 
the O 
variations O 
induced O 
by O 
environmental O 
conditions O 
. O 
Using O 
HPLC-ESI-HR-MS O 
, O 
19 O 
phenolic B-FAMILY 
compounds O 
( O 
PCs O 
) O 
were O 
tentatively O 
characterised O 
and O 
included O 
stilbenes B-FAMILY 
and O 
ellagitannins O 
as O 
major O 
components O 
, O 
followed O 
by O 
anthocyanins B-FAMILY 
, O 
flavonols B-FAMILY 
, O 
and O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
. O 
PCs O 
were O 
then O 
further O 
quantified O 
by O 
HPLC-DAD O 
. O 
Piceatannol B-TRIVIAL 
, O 
a O 
promising O 
health O 
- O 
promoting O 
stilbene B-TRIVIAL 
component O 
, O 
was O 
the O 
major O 
PC O 
in O 
the O 
fruit O 
with O 
a O 
concentration O 
of O 
2.3mg O 
/ O 
g O 
dry O 
weight O 
at O 
full O 
maturity O 
stage O 
. O 
This O 
concentration O 
is O 
1000-2000 O 
times O 
higher O 
than O 
that O 
of O 
red O 
grapes O 
, O 
a O 
major O 
source O 
of O 
stilbene B-TRIVIAL 
in O 
the O 
human O 
diet O 
. O 
During O 
maturation O 
, O 
the O 
contents O 
in O 
piceatannol B-TRIVIAL 
and O 
other O 
stilbenes B-FAMILY 
, O 
ellagitannins O 
, O 
and O 
flavonols B-FAMILY 
decreased O 
while O 
the O 
anthocyanin B-FAMILY 
content O 
increased O 
. O 
Shade-grown O 
sim O 
fruits O 
showed O 
significantly O 
higher O 
piceatannol B-TRIVIAL 
levels O 
than O 
sun O 
- O 
exposed O 
fruits O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
highlight O 
the O 
potential O 
of O 
sim O 
, O 
an O 
under O 
- O 
utilised O 
plant O 
species O 
from O 
South-East O 
Asia O 
, O 
as O 
a O 
source O 
of O 
health O 
- O 
promoting O 
fruits O 
. O 

hypocholesterolemic O 
and O 
antioxidant O 
activities O 
of O 
various O 
extracts O 
( O 
water O 
, O 
methanol B-SYSTEMATIC 
, O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
hexane B-SYSTEMATIC 
, O 
dichloro B-SYSTEMATIC 
- I-SYSTEMATIC 
methane I-SYSTEMATIC 
) O 
of O 
fenugreek O 
seeds O 
were O 
investigated O 
in O 
cholesterol B-TRIVIAL 
-fed O 
rats O 
. O 
Only O 
the O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
reduced O 
total O 
cholesterol B-TRIVIAL 
, O 
triglycerides B-FAMILY 
, O 
and O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
( O 
LDL-C O 
) O 
and O 
increased O 
high O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
( O 
HDL-C O 
) O 
compared O 
with O 
those O 
of O 
rats O 
fed O 
a O 
cholesterol B-TRIVIAL 
-rich O 
diet O 
( O 
HCD O 
) O 
. O 
Furthermore O 
, O 
the O 
content O 
of O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
-reactive O 
substances O 
( O 
TBARS O 
) O 
, O 
and O 
catalase O 
and O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
in O 
liver O 
, O 
heart O 
and O 
kidney O 
decreased O 
significantly O 
after O 
oral O 
administration O 
of O 
the O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
, O 
compared O 
with O 
those O 
of O 
HCD-fed O 
rats O 
. O 
The O 
phenolic B-FAMILY 
and O 
flavonoïd B-FAMILY 
contents O 
were O 
highest O 
in O 
the O 
methanol B-SYSTEMATIC 
and O 
the O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extracts O 
. O 
These O 
results O 
showed O 
that O 
the O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
of O 
the O 
fenugreek O 
seeds O 
had O 
a O 
significant O 
hypocholesterolemic O 
effect O 
and O 
antioxidant O 
activity O 
in O 
cholesterol B-TRIVIAL 
-fed O 
rats O 
, O 
whether O 
this O 
is O 
partly O 
due O 
to O 
the O 
presence O 
of O 
flavonoïds B-FAMILY 
in O 
the O 
extract O 
needs O 
further O 
study O 
. O 

non-lichenized O 
ascomycete O 
Bulgaria O 
inquinans O 
( O 
Fries O 
) O 
, O 
growing O 
in O 
the O 
Changbai O 
Mountain O 
of O 
China O 
, O 
has O 
been O 
used O 
as O 
medicinal O 
diet O 
for O 
many O 
years O 
. O 
In O 
a O 
previous O 
study O 
, O 
we O 
have O 
reported O 
that O 
a O 
heteropolysaccharide O 
BIWS-4b O 
from O 
the O 
fruit O 
bodies O 
of O 
B O 
. O 
inquinans O 
( O 
Fries O 
) O 
exhibited O 
markedly O 
antimalarial O 
and O 
immunostimulating O 
activities O 
. O 
In O 
this O 
paper O 
, O 
the O 
structural O 
features O 
and O 
antioxidant O 
activity O 
of O 
BIWS-4b O 
were O 
investigated O 
. O 
The O 
results O 
showed O 
that O 
BIWS-4b O 
contains O 
an O 
α-(1→2) O 
, O 
(1→6)-mannan O 
core O 
to O 
which O 
the O 
glucogalactan O 
chains O 
are O 
attached O 
. O 
The O 
glucogalactan O 
chains O 
were O 
composed O 
of O 
(1→6)- O 
, O 
(1→5)- O 
and O 
( O 
1→5,6 O 
) O 
- O 
linked O 
β-Galf B-ABBREVIATION 
, O 
( O 
1→4 O 
) O 
- O 
linked O 
and O 
non-reducing O 
terminal O 
β-Glcp B-ABBREVIATION 
units O 
, O 
and O 
might O 
be O 
attached O 
to O 
the O 
mannan O 
core O 
at O 
the O 
O-2 O 
positions O 
of O 
α-Manp B-ABBREVIATION 
units O 
. O 
The O 
antioxidant O 
assays O 
showed O 
that O 
BIWS-4b O 
exhibited O 
good O 
activities O 
, O 
including O 
free O 
radicals O 
scavenging O 
effects O 
, O 
ferrous B-SYSTEMATIC 
ion O 
- O 
chelating O 
ability O 
and O 
reducing O 
power O 
. O 
Thus O 
, O 
BIWS-4b O 
could O 
be O 
used O 
as O 
a O 
natural O 
antioxidant O 
agent O 
for O 
food O 
and O 
pharmaceutical O 
industries O 
. O 

of O 
different O 
freezing O 
treatments O 
on O 
the O 
biogenic O 
amine B-SYSTEMATIC 
and O 
quality O 
changes O 
of O 
bighead O 
carp O 
( O 
Aristichthys O 
nobilis O 
) O 
heads O 
during O 
ice O 
storage O 
. O 

effects O 
of O 
different O 
freezing O 
treatments O 
on O 
the O 
quality O 
changes O 
of O 
bighead O 
carp O 
heads O 
were O 
evaluated O 
in O 
terms O 
of O 
pH O 
value O 
, O 
TBARS O 
, O 
TVB-N O 
, O 
K-value O 
, O 
biogenic O 
amine B-SYSTEMATIC 
, O 
total O 
aerobic O 
counts O 
( O 
TACs O 
) O 
, O 
drip O 
loss O 
, O 
cooking O 
loss O 
and O 
electrical O 
conductivity O 
( O 
EC O 
) O 
during O 
ice O 
storage O 
. O 
Fish O 
heads O 
were O 
stored O 
at O 
-40°C O 
( O 
T1 O 
) O 
, O 
-40°C O 
for O 
12h O 
and O 
then O 
-18°C O 
( O 
T2 O 
) O 
, O 
-18°C O 
( O 
T3 O 
) O 
for O 
3months O 
prior O 
to O 
ice O 
storage O 
. O 
No O 
significant O 
differences O 
were O 
observed O 
among O 
T1 O 
, O 
T2 O 
and O 
T3 O 
for O 
drip O 
loss O 
, O 
cooking O 
loss O 
and O 
EC O 
( O 
p O 
> O 
0.05 O 
) O 
. O 
T2 O 
showed O 
lower O 
TACs O 
, O 
pH O 
value O 
, O 
TBARS O 
and O 
TVB-N O 
than O 
T3 O 
did O 
. O 
Significant O 
lower O 
value O 
of O 
spermine B-TRIVIAL 
and O 
spermidine B-TRIVIAL 
were O 
observed O 
in O 
T1 O 
, O 
T2 O 
and O 
T3 O 
than O 
those O 
of O 
control O 
group O 
( O 
fresh O 
) O 
from O 
9th O 
to O 
18th O 
day O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Drip O 
loss O 
was O 
significantly O 
correlated O 
with O 
TBARS O 
, O 
pH O 
value O 
, O 
TVB-N O 
, O 
and O 
TACs O 
in O 
groups O 
T1 O 
, O 
T2 O 
and O 
T3 O 
( O 
p O 
< O 
0.05 O 
) O 
. O 

of O 
carrot O 
β-carotene B-TRIVIAL 
in O 
presence O 
of O 
oil O 
during O 
thermal O 
and O 
combined O 
thermal O 
/ O 
high O 
pressure O 
processing O 
. O 

effect O 
of O 
thermal O 
processing O 
( O 
85-130°C O 
) O 
and O 
combined O 
thermal O 
/ O 
high O 
pressure O 
processing O 
( O 
100°C O 
combined O 
with O 
0.1 O 
to O 
700 O 
MPa O 
and O 
700 O 
MPa O 
combined O 
with O 
85-115°C O 
) O 
on O 
β-carotene B-TRIVIAL 
isomerisation O 
in O 
an O 
olive O 
oil O 
/ O 
carrot O 
emulsion O 
and O 
pure O 
olive O 
oil O 
phase O 
enriched O 
with O 
carrot O 
β-carotene B-TRIVIAL 
was O 
investigated O 
. O 
Thermal O 
processing O 
always O 
resulted O 
in O 
an O 
increase O 
in O 
the O 
contribution O 
of O 
the O 
cis- O 
isomers O 
, O 
with O 
the O 
increase O 
being O 
more O 
pronounced O 
at O 
higher O 
temperatures O 
. O 
In O 
the O 
oil O 
/ O 
carrot O 
emulsion O 
, O 
less O 
β-carotene B-TRIVIAL 
isomerisation O 
was O 
observed O 
during O 
combined O 
thermal O 
/ O 
high O 
pressure O 
processing O 
compared O 
to O 
thermal O 
processing O 
. O 
This O 
effect O 
was O 
attributed O 
to O 
strengthening O 
of O 
the O 
carrot O 
cell O 
walls O 
under O 
high O 
pressure O 
, O 
thereby O 
hindering O 
the O 
transfer O 
of O 
β-carotene B-TRIVIAL 
to O 
the O 
oil O 
phase O 
and O 
lowering O 
its O 
susceptibility O 
to O 
isomerisation O 
. O 
In O 
an O 
oil O 
phase O 
enriched O 
with O 
β-carotene B-TRIVIAL 
, O 
β-carotene B-TRIVIAL 
isomerisation O 
was O 
not O 
influenced O 
by O 
the O 
applied O 
pressure O 
at O 
100°C O 
and O 
became O 
almost O 
temperature O 
insensitive O 
at O 
700 O 
MPa O 
. O 

activity O 
of O 
Filipendula O 
ulmaria O 
constituents O 
on O 
recombinant O 
human O 
histidine B-TRIVIAL 
decarboxylase O 
. O 

decarboxylase O 
( O 
HDC O 
) O 
catalyses O 
the O 
formation O 
of O 
histamine B-TRIVIAL 
, O 
a O 
bioactive O 
amine B-SYSTEMATIC 
. O 
Agents O 
that O 
control O 
HDC O 
activity O 
are O 
beneficial O 
for O 
treating O 
histamine B-TRIVIAL 
-mediated O 
symptoms O 
, O 
such O 
as O 
allergies O 
and O 
stomach O 
ulceration O 
. O 
We O 
searched O 
for O 
inhibitors O 
of O 
HDC O 
from O 
the O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
of O 
the O 
petal O 
of O 
Filipendula O 
ulmaria O 
, O 
also O 
called O 
meadowsweet O 
. O 
Rugosin B-TRIVIAL 
D I-TRIVIAL 
, O 
rugosin B-TRIVIAL 
A I-TRIVIAL 
, O 
rugosin B-SYSTEMATIC 
A I-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
a O 
novel O 
compound O 
) O 
, O 
and O 
tellimagrandin B-TRIVIAL 
II I-TRIVIAL 
were O 
the O 
main O 
components O 
; O 
these O 
4 O 
ellagitannins O 
exhibited O 
a O 
non-competitive O 
type O 
of O 
inhibition O 
, O 
with O 
K O 
(i) O 
values O 
of O 
approximately O 
0.35-1 O 
μM O 
. O 
These O 
K O 
(i) O 
values O 
are O 
nearly O 
equal O 
to O 
that O 
of O 
histidine B-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
K(i)=0.46 O 
μM O 
) O 
, O 
an O 
existing O 
substrate O 
analogue O 
inhibitor O 
. O 
Our O 
results O 
show O 
that O 
food O 
products O 
contain O 
potent O 
HDC O 
inhibitors O 
and O 
that O 
these O 
active O 
food O 
constituents O 
might O 
be O 
useful O 
for O 
designing O 
clinically O 
available O 
HDC O 
inhibitors O 
. O 

phenolics B-FAMILY 
, O 
radical O 
scavenging O 
activity O 
( O 
RSA O 
) O 
on O 
DPPH B-ABBREVIATION 
, O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
content O 
and O 
chelating O 
activity O 
on O 
Fe(2+) B-FORMULA 
of O 
Pleurotus O 
citrinopileatus O 
, O 
Pleurotus O 
djamor O 
, O 
Pleurotus O 
eryngii O 
, O 
Pleurotus O 
flabellatus O 
, O 
Pleurotus O 
florida O 
, O 
Pleurotus O 
ostreatus O 
, O 
Pleurotus O 
sajor O 
- O 
caju O 
and O 
Hypsizygus O 
ulmarius O 
have O 
been O 
evaluated O 
. O 
The O 
assayed O 
mushrooms O 
contained O 
3.94-21.67 O 
mg O 
TAE O 
of O 
phenolics B-FAMILY 
, O 
13.63-69.67% O 
DPPH B-ABBREVIATION 
scavenging O 
activity O 
, O 
3.76-6.76 O 
mg O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
60.25-82.7% O 
chelating O 
activity O 
. O 
Principal O 
Component O 
Analysis O 
( O 
PCA O 
) O 
revealed O 
that O 
significantly O 
higher O 
total O 
phenolics B-FAMILY 
, O 
RSA O 
on O 
DPPH B-ABBREVIATION 
and O 
growth O 
/ O 
day O 
was O 
present O 
in O 
P O 
. O 
eryngii O 
whereas O 
P O 
. O 
citrinopileatus O 
showed O 
higher O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
chelating O 
activity O 
. O 
Agglomerative O 
hierarchical O 
clustering O 
analysis O 
revealed O 
that O 
studied O 
mushroom O 
species O 
fall O 
into O 
two O 
clusters O 
; O 
Cluster O 
I O 
included O 
P O 
. O 
djamor O 
, O 
P O 
. O 
eryngii O 
and O 
P O 
. O 
flabellatus O 
, O 
while O 
Cluster O 
II O 
included O 
H O 
. O 
ulmarius O 
, O 
P O 
. O 
sajor O 
- O 
caju O 
, O 
P O 
. O 
citrinopileatus O 
, O 
P O 
. O 
ostreatus O 
and O 
P O 
. O 
florida O 
. O 
Enhanced O 
yield O 
of O 
P O 
. O 
eryngii O 
was O 
achieved O 
on O 
spent O 
compost O 
casing O 
material O 
. O 
Use O 
of O 
casing O 
materials O 
enhanced O 
yield O 
by O 
21-107% O 
over O 
non-cased O 
substrate O 
. O 

between O 
lysozyme O 
and O 
procyanidin B-FAMILY 
: O 
multilevel O 
structural O 
nature O 
and O 
effect O 
of O 
carbohydrates B-FAMILY 
. O 

interaction O 
of O 
procyanidins B-FAMILY 
with O 
proteins O 
has O 
aroused O 
extensive O 
attention O 
due O 
to O 
its O 
important O 
relationship O 
with O 
the O 
bioavailability O 
and O 
astringent O 
property O 
of O 
polyphenols B-FAMILY 
. O 
In O 
the O 
present O 
work O 
, O 
we O 
have O 
investigated O 
the O 
interactions O 
of O 
lysozyme O 
with O 
procyanidin B-FAMILY 
dimer O 
( O 
B3 O 
) O 
using O 
various O 
biophysical O 
approaches O 
, O 
which O 
aims O 
to O 
provide O 
insights O 
into O 
the O 
mechanism O 
of O 
protein/ O 
polyphenol B-FAMILY 
aggregation O 
. O 
Procyanidin B-TRIVIAL 
B3 I-TRIVIAL 
spontaneously O 
binds O 
lysozyme O 
, O 
inducing O 
the O 
multilevel O 
structural O 
changes O 
in O 
lysozyme O 
and O 
the O 
formation O 
of O 
insoluble O 
complexes O 
. O 
The O 
relationship O 
between O 
lysozyme O 
aggregation O 
and O 
the O 
loss O 
of O 
enzymatic O 
activity O 
was O 
monitored O 
using O 
dynamic O 
light O 
scattering O 
and O 
fluorescence O 
quenching O 
. O 
The O 
influences O 
of O 
two O 
carbohydrates B-FAMILY 
( O 
gum O 
arabic O 
and O 
sucrose B-TRIVIAL 
) O 
on O 
lysozyme O 
/ O 
B3 O 
aggregation O 
were O 
also O 
studied O 
. O 
Gum O 
arabic O 
effectively O 
inhibited O 
the O 
formation O 
of O 
insoluble O 
aggregates O 
, O 
but O 
was O 
unable O 
to O 
restore O 
the O 
fluorescence O 
and O 
activity O 
of O 
lysozyme O 
. O 
However O 
, O 
sucrose O 
concomitantly O 
decreased O 
the O 
aggregate O 
size O 
with O 
the O 
recovery O 
of O 
fluorescence O 
and O 
lysozyme O 
activity O 
. O 
These O 
results O 
proposed O 
two O 
probable O 
mechanisms O 
by O 
which O 
these O 
two O 
carbohydrates B-FAMILY 
inhibit O 
protein/ O 
polyphenol B-FAMILY 
aggregation O 
. O 

milk O 
with O 
low O 
levels O 
of O 
added O 
β-mercaptoethanol B-SYSTEMATIC 
( O 
SM-ME O 
) O 
and O 
untreated O 
skim O 
milk O 
( O 
SM O 
) O 
were O 
heated O 
and O 
then O 
made O 
into O 
acid O 
gels O 
. O 
Acid O 
gels O 
prepared O 
from O 
heated O 
SM-ME O 
had O 
markedly O 
higher O 
firmness O 
and O 
contained O 
more O 
protein O 
connections O 
than O 
acid O 
gels O 
prepared O 
from O 
heated O 
SM O 
. O 
Electrophoretic O 
analyses O 
of O 
the O 
milks O 
showed O 
that O 
the O 
levels O 
of O 
β-lactoglobulin O 
and O 
α-lactalbumin O 
associated O 
with O 
the O 
casein O 
micelles O 
increased O 
with O 
increasing O 
β-ME O 
concentration O 
. O 
The O 
levels O 
of O 
disulphide B-SYSTEMATIC 
-linked O 
whey O 
proteins O 
were O 
higher O 
in O 
SM-ME O 
than O 
in O 
SM O 
. O 
This O 
suggested O 
that O 
there O 
may O 
be O 
higher O 
levels O 
of O 
initiators O 
for O 
thiol B-FAMILY 
- O 
disulphide B-SYSTEMATIC 
exchange O 
reactions O 
, O 
resulting O 
in O 
an O 
increase O 
in O 
the O 
rate O 
of O 
the O 
reactions O 
and O 
the O 
formation O 
of O 
greater O 
numbers O 
of O 
small O 
aggregates O 
, O 
in O 
SM-ME O 
than O 
in O 
SM O 
. O 
Consequently O 
, O 
acid O 
gels O 
made O 
from O 
SM-ME O 
may O 
have O 
more O 
bonds O 
and O 
more O 
particles O 
participating O 
in O 
the O 
network O 
, O 
resulting O 
in O 
firmer O 
gels O 
, O 
than O 
acid O 
gels O 
made O 
from O 
SM O 
. O 

novel O 
colloidal O 
gold O 
- O 
based O 
lateral O 
flow O 
immunoassay O 
for O 
rapid O 
simultaneous O 
detection O 
of O 
cyromazine B-TRIVIAL 
and O 
melamine B-TRIVIAL 
in O 
foods O 
of O 
animal O 
origin O 
. O 

rapid O 
and O 
sensitive O 
lateral O 
flow O 
immunoassay O 
( O 
LFIA O 
) O 
based O 
on O 
competitive O 
format O 
was O 
developed O 
and O 
validated O 
for O 
simultaneous O 
detection O 
of O 
cyromazine B-TRIVIAL 
( O 
CA O 
) O 
and O 
melamine B-TRIVIAL 
( O 
MA O 
) O 
in O 
foods O 
of O 
animal O 
origin O 
. O 
With O 
this O 
method O 
, O 
the O 
cut O 
- O 
off O 
value O 
for O 
the O 
two O 
test O 
lines O 
were O 
achieved O 
at O 
25 O 
ng O 
/ O 
g O 
, O 
which O 
was O 
lower O 
than O 
the O 
maximum O 
residue O 
levels O 
( O 
MRLs O 
) O 
established O 
for O 
CA O 
and O 
MA O 
. O 
At O 
three O 
fortified O 
levels O 
( O 
50 O 
, O 
100 O 
, O 
and O 
150 O 
ng O 
/ O 
g O 
) O 
, O 
the O 
recoveries O 
for O 
CA O 
and O 
MA O 
ranged O 
from O 
73.9% O 
to O 
104.2% O 
with O 
the O 
relative O 
standard O 
deviation O 
( O 
RSD O 
) O 
less O 
than O 
11.9% O 
, O 
based O 
on O 
within O 
day O 
and O 
interday O 
analysis O 
. O 
The O 
lower O 
detection O 
limit O 
for O 
CA O 
and O 
MA O 
in O 
matrix O 
sample O 
were O 
0.22 O 
ng O 
/ O 
ml O 
and O 
0.26 O 
ng O 
/ O 
ml O 
, O 
respectively O 
, O 
which O 
were O 
lower O 
than O 
those O 
of O 
published O 
literatures O 
. O 
A O 
parallel O 
analysis O 
of O 
CA O 
and O 
MA O 
in O 
real O 
samples O 
conducted O 
by O 
HPLC O 
showed O 
comparable O 
results O 
to O 
those O 
obtained O 
from O 
LFIA O 
. O 
The O 
results O 
of O 
LFIA O 
were O 
in O 
good O 
agreement O 
with O 
those O 
of O 
high O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
in O 
the O 
analysis O 
of O 
CA O 
and O 
MA O 
in O 
foods O 
of O 
animal O 
origin O 
, O 
demonstrating O 
the O 
practical O 
applicability O 
of O 
the O 
developed O 
assay O 
in O 
real O 
samples O 
. O 
Overall O 
, O 
to O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
report O 
of O 
quantitative O 
or O 
semi-quantitative O 
simultaneous O 
detection O 
for O 
CA O 
and O 
MA O 
by O 
immunochromatographic O 
assay O 
. O 

amino B-FAMILY 
acid I-FAMILY 
profiles O 
of O 
heat O 
- O 
processed O 
fresh O 
Elaeis O 
guineensis O 
and O 
Raphia O 
hookeri O 
wines O 
. O 

amino B-FAMILY 
acid I-FAMILY 
( O 
AA O 
) O 
profiles O 
of O 
heat O 
- O 
processed O 
fresh O 
Elaeis O 
guineensis O 
and O 
Raphia O 
hookeri O 
wines O 
were O 
studied O 
. O 
Heating O 
their O 
fresh O 
wines O 
to O 
85°C O 
, O 
cooling O 
and O 
diluting O 
to O 
original O 
volumes O 
distilled O 
off O 
ethanol B-SYSTEMATIC 
, O 
but O 
did O 
not O 
change O 
their O 
moisture O 
and O 
nitrogen B-SYSTEMATIC 
contents O 
. O 
R O 
. O 
hookeri O 
wine O 
contained O 
more O 
( O 
p O 
< O 
0.05 O 
) O 
Phe B-FORMULA 
, O 
Val B-ABBREVIATION 
, O 
Ala B-FORMULA 
, O 
Gly B-FORMULA 
, O 
Pro B-FORMULA 
, O 
Asp B-FORMULA 
, O 
Asn B-FORMULA 
, O 
His B-FORMULA 
and O 
Lys B-FORMULA 
than O 
E O 
. O 
guineensis O 
wine O 
which O 
contained O 
more O 
( O 
p O 
< O 
0.05 O 
) O 
Met B-FORMULA 
, O 
Cys B-FORMULA 
, O 
Glu B-FORMULA 
, O 
Gln B-FORMULA 
, O 
Ser B-FORMULA 
and O 
Arg B-FORMULA 
. O 
Tyrosine B-TRIVIAL 
, O 
Leu B-FORMULA 
, O 
Ile B-FORMULA 
and O 
Thr B-FORMULA 
contents O 
did O 
not O 
vary O 
( O 
p O 
> O 
0.05 O 
) O 
. O 
Glycine B-TRIVIAL 
and O 
Pro B-FORMULA 
contents O 
were O 
low O 
suggesting O 
high O 
globular O 
protein O 
concentrations O 
. O 
∑basic O 
AA O 
/ O 
∑acidic O 
AA O 
ratios O 
were O 
> O 
1 O 
suggesting O 
high O 
basic O 
protein O 
contents O 
. O 
The O 
E O 
. O 
guineensis O 
and O 
R O 
. O 
hookeri O 
wines O 
contained O 
58.25 O 
± O 
0.56% O 
and O 
56.79 O 
± O 
0.4% O 
essential O 
AAs B-FAMILY 
, O 
respectively O 
. O 
Essential O 
AA O 
scores O 
suggested O 
Leu B-FORMULA 
as O 
their O 
limiting O 
AA O 
. O 
In O 
conclusion O 
, O 
the O 
wines O 
can O 
adequately O 
meet O 
daily O 
nitrogen B-SYSTEMATIC 
and O 
essential O 
AA O 
needs O 
when O 
a O 
70 O 
kg O 
adult O 
drinks O 
1425.45 O 
ml O 
. O 

aim O 
of O 
the O 
study O 
was O 
to O 
investigate O 
the O 
effect O 
on O 
the O 
antioxidant O 
properties O 
and O 
sensory O 
value O 
of O 
bread O 
of O 
adding O 
ground O 
onion O 
skin O 
( O 
OS O 
) O 
. O 
For O 
a O 
determination O 
of O 
bioaccessibility O 
and O 
bioavailability O 
in O 
vitro O 
the O 
human O 
gastrointestinal O 
tract O 
model O 
was O 
used O 
. O 
OS O 
contained O 
mastication O 
- O 
extractable O 
quercetin B-TRIVIAL 
( O 
4.6 O 
mg O 
/ O 
g O 
) O 
. O 
Quercetin B-TRIVIAL 
from O 
OS O 
was O 
highly O 
bioaccessible O 
during O 
in O 
vitro O 
conditions O 
, O 
but O 
only O 
approximately O 
4% O 
of O 
quercetin B-TRIVIAL 
released O 
during O 
simulated O 
digestion O 
was O 
bioavailable O 
in O 
vitro O 
. O 
The O 
antioxidant O 
potential O 
of O 
bread O 
with O 
OS O 
was O 
significantly O 
higher O 
than O 
the O 
activity O 
noted O 
in O 
the O 
control O 
. O 
In O 
particular O 
, O 
OS O 
addition O 
significantly O 
fortificated O 
bread O 
with O 
bioaccessible O 
lipid O 
oxidation O 
preventers O 
and O 
compounds O 
with O 
reducing O 
and O 
chelating O 
abilities O 
. O 
The O 
2-3% O 
OS O 
addition O 
caused O 
significant O 
improvement O 
of O 
antioxidant O 
abilities O 
( O 
further O 
increases O 
in O 
the O 
OS O 
supplement O 
did O 
not O 
increase O 
the O 
activity O 
of O 
bread O 
) O 
. O 
Sensory O 
evaluation O 
showed O 
that O 
replacement O 
of O 
wheat O 
flour O 
in O 
bread O 
with O 
up O 
to O 
3% O 
OS O 
powder O 
gave O 
satisfactory O 
consumer O 
acceptability O 
. O 

of O 
total O 
iron B-SYSTEMATIC 
in O 
food O 
samples O 
after O 
flow O 
injection O 
preconcentration O 
on O 
polyurethane B-SYSTEMATIC 
foam O 
functionalized O 
with O 
N,N-bis(salicylidene)-1,3-propanediamine B-SYSTEMATIC 
. O 

highly O 
selective O 
flow O 
injection O 
sorption O 
system O 
was O 
developed O 
for O 
the O 
fast O 
determination O 
of O 
total O 
iron B-SYSTEMATIC 
in O 
food O 
samples O 
. O 
Iron B-SYSTEMATIC 
(III) I-SYSTEMATIC 
was O 
reduced O 
to O 
iron B-SYSTEMATIC 
(II) I-SYSTEMATIC 
by O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
preconcentrated O 
on O 
a O 
mini O 
- O 
column O 
packed O 
with O 
polyurethane B-SYSTEMATIC 
foam O 
( O 
PUF O 
) O 
functionalized O 
with O 
N,N-bis(salicylidene)-1,3-propanediamine B-SYSTEMATIC 
( O 
SPDA B-ABBREVIATION 
) O 
. O 
The O 
retained O 
Fe B-FORMULA 
(II) I-FORMULA 
was O 
eluted O 
with O 
hydrochloric B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
subsequently O 
reacted O 
to O 
2,4,6-tri(2'-pyridyl)-1,3,5-triazine B-SYSTEMATIC 
( O 
TPTZ B-ABBREVIATION 
) O 
then O 
measured O 
at O 
593 O 
nm O 
. O 
The O 
procedure O 
has O 
resulted O 
preconcentration O 
factor O 
36 O 
, O 
sample O 
frequency O 
20 O 
h(-1) O 
and O 
detection O 
limit O 
18 O 
μg O 
L(-1) O 
. O 
The O 
precision O 
( O 
RSD O 
) O 
was O 
found O 
to O 
be O 
5.7% O 
and O 
3.1% O 
at O 
concentration O 
levels O 
0.1 O 
and O 
5 O 
μg O 
mL(-1) O 
iron B-SYSTEMATIC 
(II) I-SYSTEMATIC 
, O 
respectively O 
. O 
Finally O 
, O 
the O 
method O 
was O 
successfully O 
applied O 
to O 
determination O 
of O 
total O 
iron B-SYSTEMATIC 
in O 
reference O 
material O 
and O 
food O 
samples O 
. O 

of O 
blanching O 
on O 
polyphenol B-FAMILY 
stability O 
of O 
innovative O 
paste O 
- O 
like O 
parsley O 
( O 
Petroselinum O 
crispum O 
( O 
Mill O 
. O 
) O 
Nym O 
ex O 
A O 
. O 
W O 
. O 
Hill O 
) O 
and O 
marjoram O 
( O 
Origanum O 
majorana O 
L O 
. O 
) O 
products O 
. O 

herbs O 
were O 
water- O 
and O 
steam O 
- O 
blanched O 
at O 
90-100°C O 
and O 
100°C O 
, O 
respectively O 
, O 
for O 
1-10 O 
min O 
and O 
30 O 
s O 
to O 
7 O 
min O 
for O 
parsley O 
and O 
marjoram O 
, O 
respectively O 
, O 
and O 
subsequently O 
minced O 
to O 
obtain O 
a O 
paste O 
. O 
For O 
the O 
first O 
time O 
, O 
phenolic B-FAMILY 
compounds O 
of O 
unheated O 
marjoram O 
were O 
characterised O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
coupled O 
to O 
mass O 
spectrometry O 
( O 
HPLC-MS O 
) O 
. O 
Hereby O 
, O 
10 O 
phenolics B-FAMILY 
were O 
detected O 
. O 
Among O 
them O 
, O 
apigenin B-TRIVIAL 
- I-TRIVIAL 
glucuronide I-TRIVIAL 
, O 
lucenin-2 B-TRIVIAL 
and O 
lithospermic B-TRIVIAL 
acid I-TRIVIAL 
were O 
tentatively O 
identified O 
for O 
the O 
first O 
time O 
. O 
In O 
unheated O 
parsley O 
, O 
apart O 
from O 
the O 
major O 
compound O 
apiin B-TRIVIAL 
, O 
10 O 
further O 
phenolics B-FAMILY 
were O 
characterised O 
including O 
several O 
p-coumaric B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
which O 
were O 
newly O 
detected O 
. O 
Except O 
for O 
apiin B-TRIVIAL 
, O 
short O 
- O 
time O 
steam- O 
and O 
water O 
- O 
blanching O 
( O 
1 O 
min O 
) O 
, O 
respectively O 
, O 
did O 
not O 
cause O 
significant O 
losses O 
of O 
phenolic B-FAMILY 
compounds O 
, O 
and O 
thus O 
proved O 
to O 
be O 
the O 
most O 
suitable O 
measures O 
to O 
ensure O 
polyphenol B-FAMILY 
retention O 
. O 
Consequently O 
, O 
blanching O 
is O 
a O 
recommendable O 
initial O 
operation O 
in O 
the O 
processing O 
of O 
parsley O 
and O 
marjoram O 
into O 
novel O 
paste O 
- O 
like O 
products O 
. O 

compounds O 
and O 
antioxidant O 
activities O 
of O 
selected O 
species O 
of O 
seaweeds O 
from O 
Danish O 
coast O 
. O 

and O 
ethanolic O 
extracts O 
of O 
16 O 
species O 
of O 
seaweeds O 
collected O 
along O 
the O 
Danish O 
coasts O 
were O 
screened O 
for O 
antioxidant O 
activities O 
using O 
four O 
in O 
vitro O 
antioxidant O 
assays O 
( O 
2,2-diphenyl-1-picrylhydrazyl B-SYSTEMATIC 
radical O 
scavenging O 
activity O 
, O 
reducing O 
power O 
, O 
ferrous B-SYSTEMATIC 
ion O 
- O 
chelating O 
and O 
liposome O 
model O 
system O 
) O 
. O 
Furthermore O 
their O 
effectiveness O 
in O 
retarding O 
lipid O 
peroxidation O 
in O 
fish O 
oil O 
was O 
evaluated O 
by O 
an O 
accelerated O 
stability O 
test O 
. O 
Significant O 
differences O 
were O 
observed O 
in O 
total O 
and O 
individual O 
phenolic O 
content O 
and O 
the O 
antioxidant O 
activities O 
of O 
seaweed O 
species O 
evaluated O 
. O 
Ethanol B-SYSTEMATIC 
was O 
more O 
efficient O 
for O 
polyphenol B-FAMILY 
extraction O 
than O 
water O 
. O 
Polysiphonia O 
fucoides O 
and O 
all O 
the O 
Fucus O 
species O 
tested O 
showed O 
highest O 
radical O 
scavenging O 
activity O 
, O 
reducing O 
power O 
, O 
inhibition O 
of O 
oxidation O 
in O 
liposome O 
model O 
system O 
and O 
in O 
fish O 
oil O 
and O 
were O 
high O 
in O 
phenolic O 
content O 
. O 
These O 
seaweeds O 
could O 
be O 
potential O 
rich O 
sources O 
of O 
natural O 
antioxidants O 
for O 
protection O 
of O 
foods O 
against O 
oxidation O 
. O 
In O 
general O 
, O 
the O 
various O 
antioxidative O 
assays O 
correlated O 
well O 
with O 
the O 
total O 
phenolic O 
content O 
, O 
indicating O 
that O 
algal O 
polyphenols B-FAMILY 
are O 
active O 
components O 
in O 
these O 
extracts O 
. O 
However O 
, O 
in O 
some O 
of O 
the O 
antioxidative O 
assays O 
some O 
species O 
with O 
low O 
total O 
phenolic O 
content O 
also O 
showed O 
good O 
antioxidative O 
effects O 
indicating O 
that O 
some O 
other O 
co O 
- O 
extracted O 
active O 
compounds O 
such O 
as O 
pigments O 
and O 
tocopherols B-FAMILY 
in O 
ethanolic O 
extracts O 
and O 
sulphated O 
polysaccharides O 
, O 
proteins O 
or O 
peptides O 
in O 
water O 
extracts O 
may O 
also O 
contribute O 
to O 
the O 
overall O 
antioxidant O 
properties O 
and O 
this O 
needs O 
further O 
investigation O 
. O 

study O 
aimed O 
to O 
quantify O 
the O 
effects O 
of O 
grape O 
maturity O 
on O 
wine O 
alcohol O 
, O 
phenolics B-FAMILY 
, O 
flavour O 
compounds O 
and O 
polysaccharides O 
in O 
Vitis O 
vinifera O 
L O 
. O 
cv O 
Cabernet O 
Sauvignon O 
. O 
Grapes O 
were O 
harvested O 
at O 
juice O 
soluble O 
solids O 
from O 
20 O 
to O 
26 O 
°Brix O 
which O 
corresponded O 
to O 
a O 
range O 
of O 
wine O 
ethanol B-SYSTEMATIC 
concentrations O 
between O 
12% O 
and O 
15.5% O 
. O 
Grape O 
anthocyanin B-FAMILY 
and O 
skin O 
tannin B-FAMILY 
concentration O 
increased O 
as O 
ripening O 
progressed O 
, O 
while O 
seed O 
tannin B-FAMILY 
declined O 
. O 
In O 
the O 
corresponding O 
wines O 
, O 
monomeric O 
anthocyanin B-FAMILY 
and O 
wine O 
tannin B-FAMILY 
concentration O 
increased O 
with O 
harvest O 
date O 
, O 
consistent O 
with O 
an O 
enhanced O 
extraction O 
of O 
skin O 
- O 
derived O 
phenolics B-FAMILY 
. O 
In O 
wines O 
, O 
there O 
was O 
an O 
observed O 
increase O 
in O 
yeast O 
- O 
derived O 
metabolites O 
, O 
including O 
volatile O 
esters B-FAMILY 
, O 
dimethyl B-SYSTEMATIC 
sulfide I-SYSTEMATIC 
, O 
glycerol B-TRIVIAL 
and O 
mannoproteins O 
with O 
harvest O 
date O 
. O 
Wine O 
volatiles O 
which O 
were O 
significantly O 
influenced O 
by O 
harvest O 
date O 
were O 
isobutyl B-SYSTEMATIC 
methoxypyrazine I-SYSTEMATIC 
, O 
C(6) O 
alcohols B-FAMILY 
and O 
hexyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
all O 
of O 
which O 
decreased O 
as O 
ripening O 
progressed O 
. O 
The O 
implications O 
of O 
harvest O 
date O 
for O 
wine O 
composition O 
is O 
discussed O 
in O 
terms O 
of O 
both O 
grape O 
composition O 
and O 
yeast O 
metabolism O 
. O 

/ O 
H B-FORMULA 
exchange O 
in O 
C-H B-FORMULA 
bonds O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
: O 
implication O 
for O 
geographical O 
discrimination O 
of O 
food O 
materials O 
. O 

stable O 
isotope O 
analysis O 
of O 
non O 
- O 
exchangeable O 
hydrogen B-SYSTEMATIC 
in O 
food O 
materials O 
has O 
been O 
believed O 
as O 
a O 
powerful O 
tool O 
for O 
tracing O 
geographical O 
origins O 
and O 
delivery O 
of O 
the O 
materials O 
. O 
However O 
, O 
little O 
information O 
is O 
available O 
for O 
the O 
D B-FORMULA 
/ O 
H B-FORMULA 
exchanges O 
even O 
in O 
hydrophobic O 
molecules O 
, O 
which O 
leads O 
to O 
potential O 
uncertainty O 
on O 
the O 
observed O 
results O 
. O 
To O 
further O 
evaluate O 
the O 
reliability O 
of O 
hydrogen B-SYSTEMATIC 
isotopes O 
of O 
organic O 
molecules O 
, O 
we O 
examined O 
the O 
isotope O 
exchangeability O 
in O 
fatty B-FAMILY 
acids I-FAMILY 
within O 
phospholipid O 
bilayers O 
exposed O 
to O 
D(2)O B-FORMULA 
for O 
12h O 
. O 
The O 
results O 
indicate O 
that O 
the O 
isotope O 
ratio O 
is O 
clearly O 
increased O 
during O 
all O 
examines O 
( O 
e.g O 
. O 
, O 
93-328 O 
‰ O 
in O 
50% O 
D(2)O B-FORMULA 
) O 
, O 
in O 
which O 
its O 
magnitude O 
depends O 
on O 
type O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
and O 
state O 
of O 
bilayers O 
. O 
However O 
, O 
these O 
results O 
also O 
indicate O 
very O 
clearly O 
that O 
the O 
observed O 
exchange O 
rate O 
is O 
negligible O 
if O 
samples O 
are O 
exposed O 
to O 
natural O 
abundance O 
of O 
deuterium B-SYSTEMATIC 
( O 
0.0156% O 
) O 
in O 
natural O 
and O 
laboratory O 
environments O 
before O 
/ O 
during O 
analysis O 
. O 

potential O 
to O 
intensify O 
sulforaphane B-TRIVIAL 
formation O 
in O 
cooked O 
broccoli O 
( O 
Brassica O 
oleracea O 
var O 
. O 
italica O 
) O 
using O 
mustard O 
seeds O 
( O 
Sinapis O 
alba O 
) O 
. O 

, O 
a O 
naturally O 
occurring O 
cancer O 
chemopreventive O 
, O 
is O 
the O 
hydrolysis O 
product O 
of O 
glucoraphanin B-TRIVIAL 
, O 
the O 
main O 
glucosinolate B-FAMILY 
in O 
broccoli O 
. O 
The O 
hydrolysis O 
requires O 
myrosinase O 
isoenzyme O 
to O 
be O 
present O 
in O 
sufficient O 
activity O 
; O 
however O 
, O 
processing O 
leads O 
to O 
its O 
denaturation O 
and O 
hence O 
reduced O 
hydrolysis O 
. O 
In O 
this O 
study O 
, O 
the O 
effect O 
of O 
adding O 
mustard O 
seeds O 
, O 
which O 
contain O 
a O 
more O 
resilient O 
isoform O 
of O 
myrosinase O 
, O 
to O 
processed O 
broccoli O 
was O 
investigated O 
with O 
a O 
view O 
to O 
intensify O 
the O 
formation O 
of O 
sulforaphane B-TRIVIAL 
. O 
Thermal O 
inactivation O 
of O 
myrosinase O 
from O 
both O 
broccoli O 
and O 
mustard O 
seeds O 
was O 
studied O 
. O 
Thermal O 
degradation O 
of O 
broccoli O 
glucoraphanin B-TRIVIAL 
was O 
investigated O 
in O 
addition O 
to O 
the O 
effects O 
of O 
thermal O 
processing O 
on O 
the O 
formation O 
of O 
sulforaphane B-TRIVIAL 
and O 
sulforaphane B-SYSTEMATIC 
nitrile I-SYSTEMATIC 
. O 
Limited O 
thermal O 
degradation O 
of O 
glucoraphanin B-TRIVIAL 
( O 
less O 
than O 
12% O 
) O 
was O 
observed O 
when O 
broccoli O 
was O 
placed O 
in O 
vacuum O 
sealed O 
bag O 
( O 
sous O 
vide O 
) O 
and O 
cooked O 
in O 
a O 
water O 
bath O 
at O 
100°C O 
for O 
8 O 
and O 
12 O 
min O 
. O 
Boiling O 
broccoli O 
in O 
water O 
prevented O 
the O 
formation O 
of O 
any O 
significant O 
levels O 
of O 
sulforaphane B-TRIVIAL 
due O 
to O 
inactivated O 
myrosinase O 
. O 
However O 
, O 
addition O 
of O 
powdered O 
mustard O 
seeds O 
to O 
the O 
heat O 
processed O 
broccoli O 
significantly O 
increased O 
the O 
formation O 
of O 
sulforaphane B-TRIVIAL 
. O 

of O 
thermal O 
heating O 
on O 
some O 
lignans B-FAMILY 
in O 
flax O 
seeds O 
, O 
sesame O 
seeds O 
and O 
rye O 
. O 

of O 
lignan B-FAMILY 
rich O 
food O 
is O 
presumed O 
to O 
have O 
positive O 
effects O 
on O 
human O 
health O 
. O 
As O 
numerous O 
foods O 
are O 
consumed O 
mainly O 
in O 
processed O 
form O 
it O 
is O 
important O 
to O 
investigate O 
the O 
changes O 
of O 
the O 
lignan B-FAMILY 
content O 
during O 
processing O 
. O 
To O 
this O 
end O 
, O 
unheated O 
and O 
heated O 
sesame O 
seeds O 
, O 
sesame O 
products O 
, O 
rye O 
grains O 
, O 
rye O 
flour O 
, O 
rye O 
bread O 
and O 
flax O 
seeds O 
were O 
extracted O 
by O 
sonication O 
with O 
ethanol B-SYSTEMATIC 
/ O 
water O 
( O 
70 O 
: O 
30 O 
, O 
v O 
: O 
v O 
) O 
or O 
sodium B-SYSTEMATIC 
methoxide I-SYSTEMATIC 
. O 
The O 
extracts O 
were O 
additionally O 
hydrolysed O 
enzymatically O 
( O 
β-glucuronidase O 
/ O 
arylsulphatase O 
, O 
cellulase O 
) O 
, O 
the O 
compounds O 
separated O 
on O 
a O 
reversed O 
phase O 
column O 
by O 
gradient O 
elution O 
and O 
detected O 
by O 
UV O 
/ O 
ESI-MS O 
in O 
the O 
negative O 
ionisation O 
multiple O 
reaction O 
monitoring O 
mode O 
( O 
MRM O 
) O 
. O 
Secoisolariciresinol B-TRIVIAL 
, O 
lariciresinol B-TRIVIAL 
, O 
pinoresinol B-TRIVIAL 
, O 
7-hydroxymatairesinol B-SYSTEMATIC 
, O 
syringaresinol B-TRIVIAL 
, O 
isolariciresinol B-TRIVIAL 
, O 
secoisolariciresinol B-FAMILY 
diglycoside I-FAMILY 
, O 
lariciresinol B-FAMILY 
monoglycoside I-FAMILY 
, O 
pinoresinol B-MULTIPLE 
mono- I-MULTIPLE 
, I-MULTIPLE 
di- I-MULTIPLE 
and I-MULTIPLE 
triglycoside I-MULTIPLE 
, O 
sesaminol B-TRIVIAL 
, O 
sesaminol B-FAMILY 
triglycoside I-FAMILY 
, O 
sesamolinol B-TRIVIAL 
and O 
sesamolinol B-FAMILY 
diglycoside I-FAMILY 
were O 
identified O 
. O 
Moderate O 
heating O 
at O 
100°C O 
did O 
not O 
degrade O 
the O 
lignan O 
aglycones O 
and O 
glycosides O 
in O 
dry O 
foods O 
. O 
In O 
contrast O 
, O 
heating O 
was O 
responsible O 
for O 
the O 
better O 
extractability O 
of O 
the O 
lignans B-FAMILY 
. O 
If O 
samples O 
with O 
high O 
moisture O 
content O 
were O 
heated O 
, O 
the O 
degradation O 
of O 
the O 
lignans B-FAMILY 
in O 
sesame O 
seeds O 
and O 
rye O 
was O 
observed O 
already O 
at O 
100°C O 
. O 
Higher O 
roasting O 
temperatures O 
caused O 
degradation O 
of O 
aglycones O 
and O 
glycosides O 
. O 
Especially O 
at O 
250°C O 
, O 
lignans O 
were O 
degraded O 
rapidly O 
in O 
sesame O 
seeds O 
and O 
rye O 
but O 
not O 
in O 
flax O 
seeds O 
. O 

studies O 
from O 
our O 
lab O 
showed O 
that O 
increase O 
in O 
AngII O 
in O 
H9c2 O 
cells O 
causes O 
elevated O 
IGFII O 
and O 
IGFIIR O 
through O 
MEK O 
and O 
JNK O 
, O 
leading O 
to O 
rise O 
in O 
intracellular O 
calcium B-SYSTEMATIC 
, O 
calcineurin O 
activation O 
by O 
PLC-β3 O 
via O 
Gαq O 
, O 
insertion O 
into O 
mitochondrial O 
membranes O 
of O 
Bad O 
, O 
and O 
apoptosis O 
via O 
caspases O 
9 O 
and O 
3 O 
. O 
Codonopsis O 
pilosula O 
is O 
traditionally O 
used O 
to O 
lower O 
blood O 
pressure O 
. O 
The O 
purpose O 
of O 
our O 
study O 
is O 
to O 
investigate O 
if O 
C O 
. O 
pilosula O 
attenuates O 
AngII O 
plus O 
Leu B-FORMULA 
(27)-IGFII-induced O 
calcium B-SYSTEMATIC 
influx O 
and O 
apoptosis O 
in O 
H9c2 O 
cardiomyoblasts O 
. O 
C O 
. O 
pilosula O 
significantly O 
attenuated O 
AngII O 
induced O 
IGFIIR O 
promoter O 
activity O 
. O 
Leu B-FORMULA 
(27)-IGFII O 
was O 
applied O 
to O 
enhance O 
the O 
AngII O 
effect O 
. O 
C O 
. O 
pilosula O 
also O 
reversed O 
Ca(2+) B-FORMULA 
influx O 
, O 
MOMP O 
and O 
apoptosis O 
increased O 
by O 
AngII O 
plus O 
Leu B-FORMULA 
(27)-IGFII O 
. O 
Molecular O 
markers O 
in O 
IGFIIR O 
apoptotic O 
pathway O 
( O 
IGFIIR O 
, O 
calcineurin O 
, O 
etc O 
. O 
) O 
and O 
IGFIIR-Gαq O 
association O 
were O 
downregulated O 
by O 
C O 
. O 
pilosula O 
. O 
However O 
, O 
p-Bad( O 
Ser B-FORMULA 
136 O 
) O 
and O 
Bcl-2 O 
were O 
increased O 
. O 
Therefore O 
, O 
C O 
. O 
pilosula O 
suppresses O 
AngII O 
plus O 
Leu B-FORMULA 
(27)-IGFII-induced O 
IGFII O 
/ O 
IGFIIR O 
pathway O 
in O 
myocardial O 
cells O 
. O 

ketchup O 
, O 
barbeque O 
sauce O 
, O 
sweet O 
chili O 
sauce O 
, O 
and O 
spaghetti O 
sauce O 
were O 
gamma O 
irradiated O 
at O 
0 O 
, O 
1 O 
, O 
5 O 
, O 
and O 
10 O 
kGy O 
. O 
Electron O 
spin O 
resonance O 
( O 
ESR O 
) O 
technique O 
was O 
used O 
to O 
characterize O 
the O 
irradiated O 
sauces O 
, O 
targeting O 
radiation O 
- O 
induced O 
cellulose O 
radicals O 
and O 
using O 
a O 
modified O 
sample O 
pretreatment O 
method O 
. O 
The O 
samples O 
were O 
first O 
washed O 
with O 
water O 
, O 
and O 
then O 
the O 
residues O 
were O 
extracted O 
with O 
alcohol B-FAMILY 
. O 
The O 
non-irradiated O 
sauces O 
exhibited O 
the O 
single O 
central O 
signal O 
, O 
whose O 
intensity O 
showed O 
a O 
significant O 
increase O 
on O 
irradiation O 
. O 
The O 
ESR O 
spectra O 
from O 
the O 
radiation O 
- O 
induced O 
cellulose O 
radicals O 
, O 
with O 
two O 
side O 
peaks O 
( O 
g=2.02012 O 
and O 
g=1.98516 O 
) O 
equally O 
spaced O 
( O 
± O 
3 O 
mT O 
) O 
from O 
the O 
central O 
signal O 
, O 
were O 
also O 
observed O 
in O 
the O 
irradiated O 
sauces O 
. O 
The O 
improvements O 
in O 
the O 
central O 
( O 
natural O 
) O 
and O 
radiation O 
- O 
induced O 
( O 
two O 
side O 
peaks O 
corresponding O 
to O 
the O 
cellulose O 
radicals O 
) O 
signal O 
intensities O 
were O 
obvious O 
, O 
when O 
compared O 
with O 
routine O 
freeze O 
- O 
drying O 
and O 
alcoholic O 
- O 
extraction O 
techniques O 
. O 

of O 
tartrazine B-TRIVIAL 
in O 
beverage O 
samples O 
by O 
stopped O 
- O 
flow O 
analysis O 
and O 
three O 
- O 
way O 
multivariate O 
calibration O 
of O 
non-linear O 
kinetic O 
- O 
spectrophotometric O 
data O 
. O 

performance O 
of O 
MCR-ALS O 
was O 
studied O 
in O 
the O 
modeling O 
of O 
non-linear O 
kinetic O 
- O 
spectrophotometric O 
data O 
acquired O 
by O 
a O 
stopped O 
- O 
flow O 
system O 
for O 
the O 
quantitation O 
of O 
tartrazine B-TRIVIAL 
in O 
the O 
presence O 
of O 
brilliant B-MULTIPLE 
blue I-MULTIPLE 
and I-MULTIPLE 
sunset I-MULTIPLE 
yellow I-MULTIPLE 
FCF I-MULTIPLE 
as O 
possible O 
interferents O 
. O 
In O 
the O 
present O 
work O 
, O 
MCR-ALS O 
and O 
U-PCA O 
/ O 
RBL O 
were O 
firstly O 
applied O 
to O 
remove O 
the O 
contribution O 
of O 
unexpected O 
components O 
not O 
included O 
in O 
the O 
calibration O 
set O 
. O 
Secondly O 
, O 
a O 
polynomial O 
function O 
was O 
used O 
to O 
model O 
the O 
non-linear O 
data O 
obtained O 
by O 
the O 
implementation O 
of O 
the O 
algorithms O 
. O 
MCR-ALS O 
was O 
the O 
only O 
strategy O 
that O 
allowed O 
the O 
determination O 
of O 
tartrazine B-TRIVIAL 
in O 
test O 
samples O 
accurately O 
. O 
Therefore O 
, O 
it O 
was O 
applied O 
for O 
the O 
analysis O 
of O 
tartrazine B-TRIVIAL 
in O 
beverage O 
samples O 
with O 
minimum O 
sample O 
preparation O 
and O 
short O 
analysis O 
time O 
. O 
The O 
proposed O 
method O 
was O 
validated O 
by O 
comparison O 
with O 
a O 
chromatographic O 
procedure O 
published O 
in O 
the O 
literature O 
. O 
Mean O 
recovery O 
values O 
between O 
98% O 
and O 
100% O 
and O 
relative O 
errors O 
of O 
prediction O 
values O 
between O 
4% O 
and O 
9% O 
were O 
indicative O 
of O 
the O 
good O 
performance O 
of O 
the O 
method O 
. O 

of O 
ferrous B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
fortification O 
in O 
germinated O 
brown O 
rice O 
on O 
seed O 
iron B-SYSTEMATIC 
concentration O 
and O 
bioavailability O 
. O 

present O 
study O 
evaluated O 
the O 
effectiveness O 
of O 
germination O 
and O 
iron B-SYSTEMATIC 
fortification O 
on O 
iron B-SYSTEMATIC 
concentration O 
and O 
bioavailability O 
of O 
brown O 
rice O 
. O 
Iron B-SYSTEMATIC 
fortification O 
during O 
germination O 
process O 
with O 
0.05-2 O 
g O 
/ O 
L O 
ferrous B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
increased O 
the O 
iron B-SYSTEMATIC 
concentration O 
in O 
germinated O 
brown O 
rice O 
from O 
1.1 O 
to O 
15.6 O 
times O 
than O 
those O 
in O 
raw O 
brown O 
rice O 
. O 
Based O 
on O 
the O 
recommended O 
dietary O 
allowance O 
of O 
iron B-SYSTEMATIC 
, O 
maximum O 
germination O 
rate O 
and O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
we O 
recommend O 
the O 
brown O 
rice O 
fortified O 
with O 
0.25 O 
g O 
/ O 
L O 
FeSO(4) B-FORMULA 
as O 
a O 
suitable O 
fortification O 
level O 
to O 
use O 
in O 
germination O 
process O 
. O 
Iron B-SYSTEMATIC 
fortification O 
during O 
the O 
germination O 
process O 
has O 
a O 
positive O 
effect O 
on O 
iron B-SYSTEMATIC 
concentration O 
and O 
bioavailability O 
. O 
A O 
significant O 
difference O 
was O 
observed O 
among O 
the O 
cultivars O 
in O 
respect O 
to O 
the O 
capacity O 
for O 
iron B-SYSTEMATIC 
accumulation O 
and O 
bioavailability O 
. O 
Germination O 
alone O 
could O 
improve O 
in O 
vitro O 
iron B-SYSTEMATIC 
solubility O 
, O 
but O 
had O 
no O 
effect O 
on O 
iron B-SYSTEMATIC 
bioavailability O 
in O 
Caco-2 O 
cell O 
, O 
the O 
additional O 
fortification O 
process O 
should O 
be O 
combined O 
to O 
get O 
high O 
amount O 
of O 
bioavailable O 
iron B-SYSTEMATIC 
from O 
the O 
brown O 
rice O 
. O 

of O 
human O 
breast O 
cancer O 
cells O 
induced O 
by O 
microencapsulated O 
betulinic B-TRIVIAL 
acid I-TRIVIAL 
from O 
sour O 
jujube O 
fruits O 
through O 
the O 
mitochondria O 
transduction O 
pathway O 
. O 

acid I-TRIVIAL 
( O 
BA O 
) O 
, O 
a O 
natural O 
pentacyclic B-FAMILY 
triterpenoid I-FAMILY 
, O 
was O 
isolated O 
from O 
sour O 
jujube O 
fruits O 
for O 
the O 
first O 
time O 
. O 
An O 
inclusion O 
complex O 
comprising O 
BA O 
and O 
β-cyclodextrin B-TRIVIAL 
( O 
β-CD B-ABBREVIATION 
) O 
was O 
formed O 
to O 
improve O 
the O 
dissolution O 
of O 
BA O 
, O 
but O 
little O 
is O 
known O 
about O 
its O 
anticancer O 
effect O 
. O 
In O 
this O 
study O 
, O 
the O 
anti-proliferative O 
and O 
apoptosis O 
mechanisms O 
of O 
BA-β-CD B-ABBREVIATION 
on O 
human O 
breast O 
cancer O 
MCF-7 O 
cells O 
were O 
further O 
investigated O 
. O 
Experimental O 
results O 
confirmed O 
that O 
the O 
complexation O 
model O 
inhibited O 
the O 
growth O 
of O 
MCF-7 O 
cells O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
, O 
arrested O 
cell O 
cycle O 
in O 
the O 
G2 O 
/ O 
M O 
phase O 
and O 
induced O 
apoptosis O 
via O 
the O 
mitochondria O 
transduction O 
pathway O 
. O 
Gene O 
and O 
protein O 
analyses O 
showed O 
that O 
the O 
complexation O 
model O 
significantly O 
inhibited O 
Bcl-2 O 
expression O 
and O 
promoted O 
Bax O 
expression O 
, O 
causing O 
caspase-3 O 
and O 
caspase-9 O 
cascade O 
activation O 
. O 
These O 
findings O 
corroborated O 
evidence O 
on O 
microencapsulated O 
BA O 
as O 
an O 
apoptosis O 
inducer O 
in O 
MCF-7 O 
cells O 
. O 
Thus O 
, O 
sour O 
jujube O 
fruits O 
may O 
have O 
potential O 
use O 
as O 
a O 
breast O 
cancer O 
chemotherapeutic O 
agent O 
. O 

of O 
stevioside B-TRIVIAL 
to O 
improve O 
the O 
edulcorant O 
quality O 
by O 
lower O 
substitution O 
using O 
cornstarch O 
hydrolyzate O 
and O 
CGTase O 
. O 

is O 
an O 
abundant O 
sweetener O 
extracted O 
from O 
Stevia O 
rebaudiana O 
leaf O 
with O 
a O 
bitter O 
aftertaste O 
. O 
Enzymatic O 
transglycosylation O 
of O 
stevioside B-TRIVIAL 
is O 
a O 
solution O 
to O 
improve O 
the O 
edulcorant O 
quality O 
of O 
stevioside B-TRIVIAL 
, O 
but O 
highly O 
derivatised O 
stevioside B-TRIVIAL 
coming O 
with O 
high O 
conversion O 
of O 
stevioside B-TRIVIAL 
is O 
undesired O 
. O 
In O 
this O 
experiment O 
, O 
the O 
transglycosylation O 
of O 
stevioside B-TRIVIAL 
was O 
investigated O 
by O 
using O 
a O 
commercial O 
cyclodextrin O 
glucanotransferase O 
and O 
cornstarch O 
hydrolyzate O 
. O 
With O 
controlled O 
parameters O 
, O 
the O 
product O 
was O 
mainly O 
composed O 
of O 
mono- B-MULTIPLE 
and I-MULTIPLE 
di I-MULTIPLE 
- I-MULTIPLE 
glucosylated I-MULTIPLE 
stevioside I-MULTIPLE 
while O 
the O 
highest O 
stevioside B-TRIVIAL 
conversion O 
reached O 
77.11% O 
. O 
Neither O 
kinetic O 
nor O 
thermodynamic O 
factor O 
stimulated O 
the O 
formation O 
of O 
high O 
substituted O 
steviosides B-FAMILY 
. O 
The O 
simultaneous O 
hydrolysis O 
in O 
the O 
reaction O 
might O 
inhibit O 
the O 
yield O 
of O 
highly O 
substituted O 
steviosides B-FAMILY 
. O 

serum O 
vitamin B-FAMILY 
D I-FAMILY 
levels O 
reduce O 
the O 
risk O 
for O 
nonalcoholic O 
fatty O 
liver O 
disease O 
in O 
healthy O 
men O 
independent O 
of O 
metabolic O 
syndrome O 
. O 

studies O 
suggest O 
an O 
association O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
with O 
obesity O 
, O 
diabetes O 
and O 
cardiovascular O 
diseases O 
. O 
We O 
analyzed O 
the O 
association O 
of O 
serum O 
vitamin B-FAMILY 
D I-FAMILY 
level O 
assessed O 
by O 
25-hydroxyvitamin B-SYSTEMATIC 
D(3) I-SYSTEMATIC 
{ O 
25(OH)D(3) B-SYSTEMATIC 
} O 
with O 
nonalcoholic O 
fatty O 
liver O 
disease O 
( O 
NAFLD O 
) O 
in O 
apparently O 
healthy O 
men O 
. O 
We O 
performed O 
a O 
cross O 
- O 
sectional O 
study O 
of O 
6567 O 
Korean O 
men O 
who O 
participated O 
in O 
a O 
health O 
screening O 
program O 
, O 
evaluating O 
the O 
association O 
of O 
serum O 
25(OH)D(3) B-SYSTEMATIC 
levels O 
with O 
the O 
risk O 
of O 
NAFLD O 
assessed O 
by O 
abdominal O 
ultrasonogram O 
. O 
Of O 
the O 
participants O 
, O 
43.6% O 
had O 
NAFLD O 
and O 
21.1% O 
had O 
metabolic O 
syndrome O 
. O 
Age O 
, O 
serum O 
calcium B-SYSTEMATIC 
, O 
and O 
aspartate B-TRIVIAL 
aminotransferase O 
levels O 
showed O 
weak O 
but O 
significant O 
positive O 
correlations O 
with O 
25(OH)D(3) B-SYSTEMATIC 
level O 
; O 
total O 
cholesterol B-TRIVIAL 
, O 
triglycerides B-FAMILY 
, O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
and O 
fasting O 
insulin O 
level O 
showed O 
weak O 
but O 
significant O 
negative O 
correlations O 
with O 
25(OH)D(3) B-SYSTEMATIC 
level O 
. O 
The O 
mean O 
25(OH)D(3) B-SYSTEMATIC 
level O 
was O 
significantly O 
lower O 
in O 
participants O 
with O 
NAFLD O 
than O 
in O 
those O 
without O 
( O 
38.7 O 
± O 
9 O 
vs O 
. O 
39.7 O 
± O 
9.7 O 
nmol O 
/ O 
L O 
, O 
p O 
< O 
0.001 O 
) O 
. O 
When O 
participants O 
were O 
divided O 
into O 
tertiles O 
based O 
on O 
mean O 
25(OH)D(3) B-SYSTEMATIC 
level O 
, O 
the O 
proportion O 
with O 
NAFLD O 
significantly O 
increased O 
as O 
mean O 
25(OH)D(3) B-SYSTEMATIC 
level O 
decreased O 
( O 
40 O 
, O 
45 O 
and O 
45.9% O 
, O 
p O 
for O 
linear O 
trend O 
< O 
0.001 O 
) O 
. O 
Multiple O 
logistic O 
regression O 
analyses O 
with O 
NAFLD O 
as O 
the O 
dependent O 
variable O 
showed O 
that O 
the O 
tertiles O 
with O 
lower O 
25(OH)D(3) B-SYSTEMATIC 
levels O 
had O 
a O 
significantly O 
increased O 
risk O 
for O 
NAFLD O 
compared O 
with O 
the O 
highest O 
tertile O 
, O 
even O 
after O 
adjusting O 
for O 
body O 
mass O 
index O 
and O 
metabolic O 
syndrome O 
( O 
OR O 
1.247 O 
and O 
1.408 O 
vs O 
. O 
the O 
highest O 
tertile O 
, O 
p O 
< O 
0.001 O 
) O 
. O 
Thus O 
, O 
participants O 
with O 
higher O 
serum O 
25(OH)D(3) B-SYSTEMATIC 
showed O 
a O 
significantly O 
reduced O 
risk O 
for O 
NAFLD O 
compared O 
with O 
the O 
low O 
25(OH)D(3) B-SYSTEMATIC 
groups O 
, O 
independent O 
of O 
obesity O 
and O 
metabolic O 
syndrome O 
. O 

- O 
learning O 
theories O 
of O 
substance O 
use O 
propose O 
that O 
members O 
of O 
peer O 
groups O 
influence O 
the O 
drug O 
use O 
of O 
other O 
members O 
by O 
selectively O 
modeling O 
, O 
reinforcing O 
, O 
and O 
punishing O 
either O 
abstinence O 
- O 
related O 
or O 
drug O 
- O 
related O 
behaviors O 
. O 
The O 
objective O 
of O 
the O 
present O 
study O 
was O 
to O 
examine O 
the O 
social O 
influences O 
on O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
in O 
isolated O 
and O 
socially O 
housed O 
rats O 
, O 
under O 
conditions O 
where O 
the O 
socially O 
housed O 
rats O 
were O 
tested O 
simultaneously O 
with O 
their O 
partner O 
in O 
the O 
same O 
chamber O 
. O 
To O 
this O 
end O 
, O 
male O 
rats O 
were O 
obtained O 
at O 
weaning O 
and O 
housed O 
in O 
isolated O 
or O 
pair O 
- O 
housed O 
conditions O 
for O 
6 O 
weeks O 
. O 
Rats O 
were O 
then O 
implanted O 
with O 
intravenous O 
catheters O 
and O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
was O 
examined O 
in O 
custom O 
- O 
built O 
operant O 
conditioning O 
chambers O 
that O 
allowed O 
two O 
rats O 
to O 
be O 
tested O 
simultaneously O 
. O 
For O 
some O 
socially O 
housed O 
subjects O 
, O 
both O 
rats O 
had O 
simultaneous O 
access O 
to O 
cocaine B-TRIVIAL 
; O 
for O 
others O 
, O 
only O 
one O 
rat O 
of O 
the O 
pair O 
had O 
access O 
to O 
cocaine B-TRIVIAL 
. O 
An O 
econometric O 
analysis O 
was O 
applied O 
to O 
the O 
data O 
, O 
and O 
the O 
reinforcing O 
strength O 
of O 
cocaine B-TRIVIAL 
was O 
measured O 
by O 
examining O 
consumption O 
( O 
i.e O 
. O 
quantity O 
demanded O 
) O 
and O 
elasticity O 
of O 
demand O 
as O 
a O 
function O 
of O 
price O 
, O 
which O 
was O 
manipulated O 
by O 
varying O 
the O 
dose O 
and O 
ratio O 
requirements O 
on O 
a O 
fixed O 
ratio O 
schedule O 
of O 
reinforcement O 
. O 
Cocaine B-TRIVIAL 
consumption O 
decreased O 
as O 
a O 
function O 
of O 
price O 
in O 
all O 
groups O 
. O 
Elasticity O 
of O 
demand O 
did O 
not O 
vary O 
across O 
groups O 
, O 
but O 
consumption O 
was O 
significantly O 
lower O 
in O 
socially O 
housed O 
rats O 
paired O 
with O 
a O 
rat O 
without O 
access O 
to O 
cocaine B-TRIVIAL 
. O 
These O 
data O 
suggest O 
that O 
the O 
presence O 
of O 
an O 
abstaining O 
peer O 
decreases O 
the O 
reinforcing O 
strength O 
of O 
cocaine B-TRIVIAL 
, O 
thus O 
supporting O 
the O 
development O 
of O 
social O 
interventions O 
in O 
drug O 
abuse O 
prevention O 
and O 
treatment O 
programs O 
. O 

of O 
Gβγ-subunit O 
signaling O 
potentiates O 
morphine B-TRIVIAL 
-induced O 
antinociception O 
but O 
not O 
respiratory O 
depression O 
, O 
constipation O 
, O 
locomotion O 
, O 
and O 
reward O 
. O 

of O 
Gβγ-subunit O 
signaling O 
to O 
phospholipase O 
C O 
β3 O 
has O 
been O 
shown O 
to O 
potentiate O 
morphine B-TRIVIAL 
-mediated O 
antinociception O 
while O 
attenuating O 
the O 
development O 
of O 
tolerance O 
and O 
dependence O 
in O 
mice O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
effect O 
of O 
Gβγ-subunit O 
inhibition O 
on O 
antinociception O 
and O 
other O 
pharmacological O 
effects O 
, O 
such O 
as O 
respiratory O 
depression O 
, O 
constipation O 
, O 
and O 
hyperlocomotion O 
, O 
mediated O 
by O 
the O 
μ-opioid O 
receptor O 
. O 
The O 
Gβγ-subunit O 
inhibitor O 
, O 
gallein B-TRIVIAL 
, O 
was O 
administered O 
to O 
C57BL O 
/ O 
6J O 
mice O 
by O 
intraperitoneal O 
injection O 
before O 
morphine B-TRIVIAL 
, O 
and O 
data O 
were O 
compared O 
with O 
mice O 
treated O 
with O 
vehicle O 
, O 
morphine B-TRIVIAL 
, O 
or O 
gallein B-TRIVIAL 
alone O 
. O 
Morphine B-TRIVIAL 
-induced O 
antinociception O 
was O 
measured O 
using O 
the O 
55°C O 
warm O 
- O 
water O 
tail O 
- O 
withdrawal O 
test O 
. O 
Pretreatment O 
with O 
gallein B-TRIVIAL 
produced O 
a O 
dose O 
- O 
dependent O 
potentiation O 
of O 
morphine B-TRIVIAL 
-mediated O 
antinociception O 
, O 
producing O 
up O 
to O 
a O 
10-fold O 
leftward O 
shift O 
in O 
the O 
morphine B-TRIVIAL 
dose O 
- O 
response O 
curve O 
and O 
extending O 
the O 
duration O 
of O 
antinociception O 
induced O 
by O 
a O 
single O 
dose O 
of O 
morphin B-TRIVIAL 
e O 
. O 
Gallein B-TRIVIAL 
pretreatment O 
also O 
prevented O 
acute O 
antinociceptive O 
tolerance O 
induced O 
by O 
morphine B-TRIVIAL 
. O 
In O 
contrast O 
, O 
the O 
dose O 
- O 
dependent O 
respiratory O 
depression O 
and O 
hyperlocomotion O 
induced O 
by O 
morphine B-TRIVIAL 
were O 
not O 
potentiated O 
by O 
gallein B-TRIVIAL 
pretreatment O 
. O 
Similarly O 
, O 
gallein B-TRIVIAL 
pretreatment O 
did O 
not O 
potentiate O 
morphine B-TRIVIAL 
-conditioned O 
place O 
preference O 
responses O 
or O 
morphine B-TRIVIAL 
-induced O 
constipation O 
, O 
as O 
measured O 
as O 
a O 
reduction O 
in O 
excreta O 
. O 
These O 
results O 
suggest O 
that O 
selectively O 
inhibiting O 
Gβγ O 
- O 
mediated O 
signaling O 
may O 
selectively O 
increase O 
μ-opioid O 
receptor O 
- O 
mediated O 
antinociception O 
without O 
matching O 
increases O 
in O 
adverse O 
physiological O 
effects O 
. O 

alleviates O 
neuronal O 
storage O 
of O 
cholesterol B-TRIVIAL 
in O 
Niemann-Pick O 
C O 
disease O 
without O 
evidence O 
of O 
detectable O 
blood O 
- O 
brain O 
barrier O 
permeability O 
. O 

type O 
C O 
disease O 
is O 
an O 
inherited O 
autosomal O 
recessive O 
neurodegenerative O 
disorder O 
characterised O 
by O 
the O 
accumulation O 
of O 
unesterified O 
cholesterol B-TRIVIAL 
and O 
sphingolipids B-FAMILY 
within O 
the O 
endosomal O 
/ O 
lysosomal O 
compartments O 
. O 
It O 
has O 
been O 
observed O 
that O 
the O 
administration O 
of O 
hydroxypropyl-β-cyclodextrin B-SYSTEMATIC 
( O 
HPBCD B-ABBREVIATION 
) O 
delays O 
onset O 
of O 
clinical O 
symptoms O 
and O 
reduces O 
accumulation O 
of O 
cholesterol B-TRIVIAL 
and O 
gangliosides B-FAMILY 
within O 
neuronal O 
cells O 
. O 
It O 
was O 
assumed O 
that O 
HPBCD B-ABBREVIATION 
exerts O 
its O 
action O 
by O 
readily O 
entering O 
the O 
CNS O 
and O 
directly O 
interacting O 
with O 
neurones O 
and O 
other O 
brain O 
cells O 
to O 
facilitate O 
removal O 
of O 
stored O 
cholesterol B-TRIVIAL 
from O 
the O 
late O 
endosomal O 
/ O 
lysosomal O 
compartment O 
. O 
Here O 
, O 
we O 
present O 
evidence O 
that O 
refutes O 
this O 
hypothesis O 
. O 
We O 
use O 
two O 
well O 
established O 
techniques O 
for O 
accurately O 
measuring O 
brain O 
uptake O 
of O 
solutes O 
from O 
blood O 
and O 
show O 
that O 
there O 
is O 
no O 
significant O 
crossing O 
of O 
HPBCD B-ABBREVIATION 
into O 
the O 
brain O 
. O 
The O 
two O 
techniques O 
are O 
brain O 
in O 
situ O 
perfusion O 
and O 
intraperitoneal O 
injection O 
followed O 
by O 
multi O 
- O 
time O 
- O 
point O 
regression O 
analysis O 
. O 
Neither O 
study O 
demonstrates O 
significant O 
, O 
time O 
- O 
dependent O 
uptake O 
of O 
HPBCD B-ABBREVIATION 
in O 
either O 
adult O 
or O 
neonatal O 
mice O 
. O 
However O 
, O 
the O 
volume O 
of O 
distribution O 
available O 
to O 
HPBCD B-ABBREVIATION 
( O 
0.113 O 
± O 
0.01 O 
ml O 
/ O 
g O 
) O 
exceeds O 
the O 
accepted O 
values O 
for O 
plasma O 
and O 
vascular O 
volume O 
of O 
the O 
brain O 
. O 
In O 
fact O 
, O 
it O 
is O 
nearly O 
three O 
times O 
larger O 
than O 
that O 
for O 
sucrose B-TRIVIAL 
( O 
0.039 O 
± O 
0.006 O 
ml O 
/ O 
g O 
) O 
. O 
We O 
propose O 
that O 
this O 
indicates O 
cell O 
surface O 
binding O 
of O 
HPBCD B-ABBREVIATION 
to O 
the O 
endothelium O 
of O 
the O 
cerebral O 
vasculature O 
and O 
may O 
provide O 
a O 
mechanism O 
for O 
the O 
mobilisation O 
and O 
clearance O 
of O 
cholesterol B-TRIVIAL 
from O 
the O 
CNS O 
. O 

postmenopausal O 
women O 
, O 
adipositas O 
represents O 
a O 
serious O 
risk O 
factor O 
for O 
cancer O 
development O 
and O 
progression O 
. O 
White O 
adipose O 
tissue O 
secretes O 
the O 
16 O 
kDa O 
hormone O 
leptin O 
which O 
plays O 
a O 
key O 
role O 
in O 
the O 
regulation O 
of O 
appetite O 
and O 
metabolism O 
. O 
An O 
increasing O 
number O 
of O 
reports O 
indicate O 
that O 
leptin O 
also O 
interferes O 
with O 
signal O 
transduction O 
pathways O 
implicated O 
in O 
the O 
development O 
of O 
breast O 
cancer O 
. O 
In O 
our O 
previous O 
study O 
, O 
we O 
identified O 
the O 
estrogen B-FAMILY 
receptor O 
alpha O 
( O 
ERα O 
) O 
as O 
a O 
relevant O 
enhancer O 
of O 
leptin O 
- O 
induced O 
signal O 
transduction O 
leading O 
to O 
transactivation O 
of O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
3 O 
( O 
Stat3 O 
) O 
. O 
The O 
purpose O 
of O 
this O 
study O 
is O 
the O 
investigation O 
of O 
specific O 
target O 
gene O 
expression O 
in O 
response O 
to O 
leptin O 
- O 
mediated O 
Stat3 O 
signaling O 
. O 
We O 
performed O 
a O 
comprehensive O 
microarray O 
analysis O 
of O 
ERα-positive O 
and O 
ERα-negative O 
MDA-MB-231 O 
cells O 
upon O 
leptin O 
treatment O 
and O 
identified O 
49 O 
genes O 
which O 
showed O 
a O 
significant O 
ERα-dependent O 
regulation O 
in O 
leptin O 
- O 
treated O 
MDA-MB-231 O 
cells O 
. O 
There O 
was O 
no O 
intersection O 
with O 
genes O 
which O 
were O 
merely O 
up- O 
or O 
downregulated O 
by O 
ERα O 
expression O 
and O 
only O 
9 O 
and O 
11 O 
genes O 
overlapping O 
targets O 
which O 
were O 
regulated O 
by O 
leptin O 
stimulation O 
either O 
in O 
ERα-expressing O 
or O 
ERα-negative O 
MDA-MB-231 O 
cells O 
, O 
respectively O 
. O 
To O 
demonstrate O 
the O 
specificity O 
, O 
expression O 
of O 
three O 
target O 
genes O 
was O 
validated O 
by O 
quantitative O 
real O 
- O 
time O 
PCR O 
. O 
In O 
conclusion O 
, O 
these O 
data O 
imply O 
that O 
leptin O 
can O 
induce O 
a O 
different O 
set O 
of O 
target O 
genes O 
dependent O 
on O 
ERα O 
expression O 
, O 
which O 
might O 
contribute O 
to O 
the O 
development O 
and O 
progression O 
of O 
cancer O 
diseases O 
. O 

-doped O 
silicon B-SYSTEMATIC 
nanocrystals O 
exhibiting O 
mid O 
- O 
infrared O 
localized O 
surface O 
plasmon O 
resonance O 
. O 

surface O 
plasmon O 
resonances O 
( O 
LSPRs O 
) O 
enable O 
tailoring O 
of O 
the O 
optical O 
response O 
of O 
nanomaterials O 
through O 
their O 
free O 
carrier O 
concentration O 
, O 
morphology O 
, O 
and O 
dielectric O 
environment O 
. O 
Recent O 
efforts O 
to O 
expand O 
the O 
spectral O 
range O 
of O 
usable O 
LSPR O 
frequencies O 
into O 
the O 
infrared O 
successfully O 
demonstrated O 
LSPRs O 
in O 
doped O 
semiconductor O 
nanocrystals O 
. O 
Despite O 
silicon B-SYSTEMATIC 
' O 
s O 
importance O 
for O 
electronic O 
and O 
photonic O 
applications O 
, O 
no O 
LSPRs O 
have O 
been O 
reported O 
for O 
doped O 
silicon B-SYSTEMATIC 
nanocrystals O 
. O 
Here O 
we O 
demonstrate O 
doped O 
silicon B-SYSTEMATIC 
nanocrystals O 
synthesized O 
via O 
a O 
nonthermal O 
plasma O 
technique O 
that O 
exhibits O 
tunable O 
LSPRs O 
in O 
the O 
energy O 
range O 
of O 
0.07-0.3 O 
eV O 
or O 
mid O 
- O 
infrared O 
wavenumbers O 
of O 
600-2500 O 
cm(-1) O 
. O 

the O 
potential O 
ophthalmic O 
applications O 
of O 
pilocarpine B-TRIVIAL 
entrapped O 
into O 
polyvinylpyrrolidone B-SYSTEMATIC 
- O 
poly(acrylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
nanogel O 
dispersions O 
prepared O 
by O 
γ O 
radiation O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
improve O 
the O 
stability O 
and O 
bioavailability O 
of O 
pilocarpine B-TRIVIAL 
in O 
order O 
to O 
maintain O 
an O 
adequate O 
concentration O 
of O 
the O 
pilocarpine B-TRIVIAL 
at O 
the O 
site O 
of O 
action O 
for O 
prolonged O 
period O 
of O 
time O 
. O 
Thus O 
, O 
pH-sensitive O 
polyvinylpyrrolidone B-SYSTEMATIC 
- O 
poly(acrylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PVP B-ABBREVIATION 
/ O 
PAAc B-ABBREVIATION 
) O 
nanogels O 
prepared O 
by O 
γ O 
radiation O 
- O 
induced O 
polymerization O 
of O 
acrylic B-TRIVIAL 
acid I-TRIVIAL 
( O 
AAc B-ABBREVIATION 
) O 
in O 
an O 
aqueous O 
solution O 
of O 
polyvinylpyrrolidone B-SYSTEMATIC 
( O 
PVP B-ABBREVIATION 
) O 
as O 
a O 
template O 
polymer O 
were O 
used O 
to O 
encapsulate O 
pilocarpine B-TRIVIAL 
. O 
Factors O 
affecting O 
size O 
and O 
encapsulation O 
efficiency O 
were O 
optimized O 
to O 
obtain O 
nanogel O 
suitable O 
for O 
entrapping O 
drug O 
efficiently O 
. O 
The O 
PVP B-ABBREVIATION 
/ O 
PAAc B-ABBREVIATION 
nanogel O 
particles O 
were O 
characterized O 
by O 
dynamic O 
light O 
scattering O 
( O 
DLS O 
) O 
, O 
zeta O 
potential O 
, O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
( O 
FTIR O 
) O 
, O 
and O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
, O 
and O 
their O 
size O 
can O 
be O 
controlled O 
by O 
the O 
feed O 
composition O 
and O 
concentration O 
as O 
well O 
as O 
the O 
irradiation O 
dose O 
. O 
Pilocarpine B-TRIVIAL 
was O 
loaded O 
into O 
the O 
nanogel O 
particles O 
through O 
electrostatic O 
interactions O 
where O 
the O 
AAc B-ABBREVIATION 
-rich O 
nanogels O 
exhibited O 
the O 
highest O 
loading O 
efficiency O 
. O 
The O 
transmittance O 
, O 
mucoadhesion O 
, O 
and O 
rheological O 
characteristics O 
of O 
the O 
nanogel O 
particles O 
were O 
studied O 
to O 
evaluate O 
their O 
ocular O 
applicability O 
. O 
The O 
in O 
vitro O 
release O 
study O 
conducted O 
in O 
simulated O 
tear O 
fluid O 
showed O 
a O 
relatively O 
long O 
sustained O 
release O 
of O 
pilocarpine B-TRIVIAL 
from O 
the O 
prepared O 
PVP B-ABBREVIATION 
/ O 
PAAc B-ABBREVIATION 
nanogel O 
particles O 
if O 
compared O 
with O 
pilocarpine B-TRIVIAL 
in O 
solution O 
. O 

Surface O 
Acoustic O 
Wave O 
Immunosensing O 
System O 
on O 
a O 
PEG B-ABBREVIATION 
/ O 
Aptamer O 
Hybridized O 
Surface O 
. O 

- O 
free O 
immunoassay O 
systems O 
have O 
the O 
advantages O 
of O 
procedural O 
simplicity O 
and O 
a O 
low O 
construction O 
cost O 
of O 
surfaces O 
for O 
immunosensing O 
. O 
When O 
label O 
- O 
free O 
immunoassay O 
systems O 
are O 
considered O 
, O 
the O 
nonspecific O 
adsorption O 
of O 
unwanted O 
materials O 
should O 
be O 
eliminated O 
unless O 
it O 
aids O 
in O 
the O 
detection O 
of O 
error O 
. O 
PEG B-ABBREVIATION 
is O 
well O 
- O 
known O 
as O 
a O 
blocking O 
agent O 
for O 
the O 
prevention O 
of O 
the O 
adsorption O 
of O 
nonspecific O 
binding O 
materials O 
when O 
coimmobilized O 
with O 
ligands O 
for O 
targets O 
such O 
as O 
antibodies O 
and O 
oligonucleotides O 
. O 
The O 
construction O 
strategy O 
for O 
PEG B-ABBREVIATION 
/ O 
ligand O 
coimmobilized O 
surfaces O 
is O 
an O 
important O 
point O 
in O 
the O 
preparation O 
of O 
a O 
high O 
- O 
performance O 
assays O 
because O 
the O 
physiological O 
condition O 
of O 
the O 
ligand O 
depends O 
strongly O 
on O 
its O 
interaction O 
with O 
the O 
PEG B-ABBREVIATION 
chain O 
. O 
In O 
this O 
report O 
, O 
we O 
investigate O 
the O 
interaction O 
between O 
thrombin O 
and O 
a O 
thrombin O 
- O 
binding O 
aptamer O 
( O 
TBA O 
) O 
on O 
a O 
PEG B-ABBREVIATION 
/ O 
TBA O 
coimmobilized O 
surface O 
by O 
using O 
a O 
shear O 
horizontal O 
surface O 
acoustic O 
wave O 
( O 
SAW O 
) O 
sensor O 
. O 
The O 
thrombin-TBA O 
binding O 
property O 
shows O 
remarkable O 
differences O 
with O 
changes O 
in O 
the O 
PEG B-ABBREVIATION 
density O 
and O 
the O 
distance O 
from O 
the O 
gold O 
surface O 
to O 
the O 
aptamer O 
. O 

of O 
the O 
bifunctional O 
chelator O 
on O 
the O 
pharmacokinetic O 
properties O 
of O 
99mTc(CO)3 B-FORMULA 
-labeled O 
cyclic B-TRIVIAL 
α-melanocyte I-TRIVIAL 
stimulating I-TRIVIAL 
hormone I-TRIVIAL 
analog O 
. O 

at O 
the O 
design O 
of O 
specific O 
melanocortin-1 O 
receptor O 
( O 
MC1R O 
) O 
targeted O 
imaging O 
probes O 
, O 
we O 
report O 
on O 
the O 
effect O 
of O 
different O 
azolyl B-SYSTEMATIC 
-ring O 
substitution O 
patterns O 
( O 
carboxylate B-SYSTEMATIC 
at O 
the O 
4- O 
position O 
and O 
/ O 
or O 
methyl B-SYSTEMATIC 
groups O 
at O 
the O 
3,5 O 
positions O 
) O 
of O 
pyrazolyl-diamine B-SYSTEMATIC 
bifunctional O 
chelators O 
(Pz(2)-Pz(4)) O 
on O 
the O 
pharmacokinetic O 
profile O 
of O 
the O 
(99m)Tc(CO)3 B-FORMULA 
-labeled O 
lactam B-SYSTEMATIC 
bridge- O 
cyclized B-TRIVIAL 
α-melanocyte I-TRIVIAL 
stimulating I-TRIVIAL 
hormone I-TRIVIAL 
derivative O 
, O 
βAlaNleCycMSH(hex) B-FORMULA 
. O 
Three O 
pyrazolyl-diamine B-SYSTEMATIC 
-containing O 
chelators O 
were O 
conjugated O 
to O 
βAlaNleCycMSHhex B-FORMULA 
, O 
with O 
the O 
resulting O 
peptide O 
conjugates O 
displaying O 
subnanomolar O 
MC1R O 
binding O 
affinity O 
. O 
Biodistribution O 
studies O 
in O 
B16F1 O 
melanoma O 
- O 
bearing O 
mice O 
show O 
that O 
all O 
radiopeptides O 
present O 
a O 
good O 
melanoma O 
uptake O 
. O 
The O 
introduction O 
of O 
a O 
carboxylate B-SYSTEMATIC 
group O 
in O 
the O 
azolyl B-SYSTEMATIC 
-ring O 
leads O 
to O 
a O 
remarkable O 
reduction O 
of O 
the O 
kidney O 
( O 
> O 
89% O 
) O 
and O 
liver O 
( O 
> O 
91% O 
) O 
accumulation O 
for O 
(99m)Tc(CO)3-Pz(3)-βAlaNleCycMSH(hex) B-FORMULA 
and O 
(99m)Tc(CO)3-Pz(4)-βAlaNleCycMSH(hex) B-FORMULA 
when O 
compared O 
to O 
the O 
radiopeptide O 
(99m)Tc(CO)3-Pz(1)-βAlaNleCycMSH(hex) B-FORMULA 
, O 
where O 
that O 
group O 
is O 
absent O 
. O 
The O 
good O 
tumor O 
uptake O 
and O 
favorable O 
tumor O 
- O 
to O 
- O 
nontarget O 
- O 
organs O 
ratios O 
of O 
(99m)Tc(CO)3-Pz(3)-βAlaNleCycMSH(hex) B-FORMULA 
and O 
(99m)Tc(CO)3-Pz(4)-βAlaNleCycMSH(hex) B-FORMULA 
highlights O 
the O 
potential O 
of O 
both O 
compounds O 
as O 
melanoma O 
imaging O 
agents O 
. O 

, O 
an O 
Inhibitor O 
of O 
VEGF O 
Receptor O 
Tyrosine B-TRIVIAL 
Kinases O 
Isolated O 
from O 
the O 
Culture O 
Broth O 
of O 
Streptomyces O 
sp O 
. O 

new O 
inhibitor O 
of O 
VEGF O 
receptor O 
tyrosine B-TRIVIAL 
kinases O 
, O 
vegfrecine B-TRIVIAL 
( O 
1 O 
) O 
, O 
was O 
isolated O 
from O 
the O 
culture O 
broth O 
of O 
Streptomyces O 
sp O 
. O 
MK931-CF8 O 
. O 
The O 
molecular O 
structure O 
of O 
1 O 
was O 
determined O 
by O 
NMR O 
and O 
MS O 
analysis O 
combined O 
with O 
synthesis O 
. O 
Compound O 
1 O 
showed O 
potent O 
inhibitory O 
activity O 
against O 
vascular O 
endothelial O 
growth O 
factor O 
receptor O 
( O 
VEGFR O 
) O 
tyrosine O 
kinases O 
in O 
in O 
vitro O 
enzyme O 
assays O 
, O 
but O 
platelet O 
- O 
derived O 
growth O 
factor O 
receptors O 
( O 
PDGFRs O 
) O 
, O 
fibroblast O 
growth O 
factor O 
receptor O 
( O 
FGFR O 
) O 
, O 
and O 
epidermal O 
growth O 
factor O 
receptor O 
( O 
EGFR O 
) O 
responded O 
only O 
weakly O 
. O 
Compound O 
1 O 
is O 
a O 
promising O 
new O 
selective O 
VEGFR O 
inhibitor O 
for O 
investigating O 
new O 
treatments O 
of O 
cancer O 
and O 
inflammatory O 
diseases O 
. O 

of O 
dimethylarsinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
to O 
the O 
highly O 
toxic O 
dimethylarsinous B-SYSTEMATIC 
acid I-SYSTEMATIC 
by O 
rats O 
and O 
rat O 
liver O 
cytosol O 
. O 

acid I-SYSTEMATIC 
( O 
DMAs B-FORMULA 
(V) I-FORMULA 
) O 
, O 
the O 
major O 
urinary O 
metabolite O 
of O 
inorganic O 
arsenic B-SYSTEMATIC 
, O 
is O 
weakly O 
cytotoxic O 
, O 
whereas O 
its O 
reduced O 
form O 
, O 
dimethylarsinous B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DMAs B-FORMULA 
(III) I-FORMULA 
) O 
, O 
is O 
highly O 
toxic O 
. O 
Although O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
omega O 
1 O 
( O 
GSTO1 O 
) O 
and O 
arsenic B-SYSTEMATIC 
methyltransferase O 
have O 
been O 
shown O 
or O 
thought O 
to O 
catalyze O 
DMAs B-FORMULA 
(V) I-FORMULA 
reduction O 
, O 
their O 
role O 
in O 
DMAs B-FORMULA 
(V) I-FORMULA 
reduction O 
in O 
vivo O 
, O 
or O 
in O 
cell O 
extracts O 
is O 
uncertain O 
. O 
Therefore O 
, O 
the O 
reduction O 
of O 
DMAs B-FORMULA 
(V) I-FORMULA 
to O 
DMAs B-FORMULA 
(III) I-FORMULA 
in O 
rats O 
and O 
in O 
rat O 
liver O 
cytosol O 
was O 
studied O 
to O 
better O 
understand O 
its O 
mechanism O 
. O 
To O 
assess O 
DMAs B-FORMULA 
(V) I-FORMULA 
reduction O 
in O 
rats O 
, O 
a O 
novel O 
procedure O 
was O 
devised O 
based O 
on O 
following O 
the O 
accumulation O 
of O 
red O 
blood O 
cell O 
( O 
RBC O 
) O 
- O 
bound O 
dimethylarsenic B-SYSTEMATIC 
( O 
DMAs B-FORMULA 
) O 
, O 
which O 
represents O 
DMAs B-FORMULA 
(III) I-FORMULA 
, O 
in O 
the O 
blood O 
of O 
DMAs B-FORMULA 
(V) I-FORMULA 
-injected O 
anesthetized O 
rats O 
. O 
These O 
studies O 
indicated O 
that O 
rats O 
reduced O 
DMAs B-FORMULA 
(V) I-FORMULA 
to O 
DMAs B-FORMULA 
(III) I-FORMULA 
to O 
a O 
significant O 
extent O 
, O 
as O 
in O 
90 O 
min O 
31% O 
of O 
the O 
injected O 
50 O 
μmol O 
/ O 
kg O 
DMAs B-FORMULA 
(V) I-FORMULA 
dose O 
was O 
converted O 
to O 
DMAs B-FORMULA 
(III) I-FORMULA 
that O 
was O 
sequestered O 
by O 
the O 
circulating O 
erythrocytes O 
. O 
Pretreatment O 
of O 
rats O 
with O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
depletors O 
( O 
phorone B-TRIVIAL 
or O 
BSO B-ABBREVIATION 
) O 
delayed O 
the O 
elimination O 
of O 
DMAs B-FORMULA 
(V) I-FORMULA 
and O 
the O 
accumulation O 
of O 
RBC O 
- O 
bound O 
DMAs B-FORMULA 
, O 
whereas O 
the O 
indirect O 
methyltransferase O 
inhibitor O 
periodate B-SYSTEMATIC 
-oxidized O 
adenosine B-TRIVIAL 
was O 
without O 
effect O 
. O 
Assessment O 
of O 
DMAs B-FORMULA 
(V) I-FORMULA 
-reducing O 
activity O 
of O 
rat O 
liver O 
cytosol O 
revealed O 
that O 
reduction O 
of O 
DMAs B-FORMULA 
(V) I-FORMULA 
required O 
cytosolic O 
protein O 
and O 
GSH B-ABBREVIATION 
and O 
was O 
inhibited O 
by O 
thiol B-FAMILY 
reagents O 
, O 
GSSG B-ABBREVIATION 
and O 
dehydroascorbate B-SYSTEMATIC 
. O 
Although O 
thioredoxin O 
reductase O 
( O 
TRR O 
) O 
inhibitors O 
( O 
aurothioglucose B-SYSTEMATIC 
and O 
Sb B-FORMULA 
(III) I-FORMULA 
) O 
inhibited O 
cytosolic O 
DMAs B-FORMULA 
(V) I-FORMULA 
reduction O 
, O 
recombinant O 
rat O 
TRR O 
plus O 
NADPH B-ABBREVIATION 
, O 
alone O 
or O 
when O 
added O 
to O 
the O 
cytosol O 
, O 
failed O 
to O 
support O 
DMAs B-FORMULA 
(V) I-FORMULA 
reduction O 
. O 
On O 
ultrafiltration O 
of O 
the O 
cytosol O 
through O 
a O 
3 O 
kDa O 
filter O 
, O 
the O 
reducing O 
activity O 
in O 
the O 
retentate O 
was O 
lost O 
but O 
was O 
largely O 
restored O 
by O 
NADPH B-ABBREVIATION 
. O 
Such O 
experiments O 
also O 
suggested O 
that O 
the O 
reducing O 
enzyme O 
was O 
larger O 
than O 
100 O 
kDa O 
and O 
was O 
not O 
GSTO1 O 
. O 
In O 
summary O 
, O 
reduction O 
of O 
DMAs B-FORMULA 
(V) I-FORMULA 
to O 
the O 
highly O 
toxic O 
DMAs B-FORMULA 
(III) I-FORMULA 
in O 
rats O 
and O 
rat O 
liver O 
cytosol O 
is O 
a O 
GSH B-ABBREVIATION 
-dependent O 
enzymatic O 
process O 
, O 
yet O 
its O 
mechanism O 
remains O 
uncertain O 
. O 

- O 
scale O 
spinning O 
assembly O 
of O 
neat O 
, O 
morphology O 
- O 
defined O 
, O 
graphene B-TRIVIAL 
-based O 
hollow O 
fibers O 
. O 

- O 
scale O 
assembly O 
of O 
graphenes B-FAMILY 
in O 
a O 
well O 
- O 
controlled O 
macroscopic O 
fashion O 
is O 
important O 
for O 
practical O 
applications O 
. O 
We O 
have O 
developed O 
a O 
facile O 
and O 
straightforward O 
approach O 
for O 
continuous O 
fabrication O 
of O 
neat O 
, O 
morphology O 
- O 
defined O 
, O 
graphene B-TRIVIAL 
-based O 
hollow O 
fibers O 
( O 
HFs O 
) O 
via O 
a O 
coaxial O 
two O 
- O 
capillary O 
spinning O 
strategy O 
. O 
With O 
a O 
high O 
throughput O 
, O 
HFs O 
and O 
necklace O 
- O 
like O 
HFs O 
of O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
have O 
been O 
well O 
- O 
controlled O 
produced O 
with O 
the O 
ease O 
of O 
functionalization O 
and O 
conversion O 
to O 
graphene B-TRIVIAL 
HFs O 
via O 
simply O 
thermal O 
or O 
chemical O 
reduction O 
. O 
This O 
work O 
paves O 
the O 
way O 
toward O 
the O 
mass O 
production O 
of O 
graphene B-TRIVIAL 
-based O 
HFs O 
with O 
desirable O 
functionalities O 
and O 
morphologies O 
for O 
many O 
of O 
important O 
applications O 
in O 
fluidics O 
, O 
catalysis O 
, O 
purification O 
, O 
separation O 
, O 
and O 
sensing O 
. O 

of O 
novel O 
7-membered B-SYSTEMATIC 
cyclic I-SYSTEMATIC 
amide I-SYSTEMATIC 
derivatives O 
that O 
inhibit O 
1 O 
1beta-hydroxysteroid B-FAMILY 
dehydrogenase O 
type O 
1 O 
. O 

series O 
of O 
novel O 
5-trans-hydroxyadamantan-2-yl-5,6,7,8-tetrahydropyrazolo[4,3-c]azepin-4(1H)-ones B-FAMILY 
that O 
inhibit O 
11beta-hydroxysteroid B-FAMILY 
dehydrogenase O 
type O 
1 O 
are O 
described O 
. O 
We O 
discovered O 
these O 
7-membered B-SYSTEMATIC 
cyclic I-SYSTEMATIC 
amide I-SYSTEMATIC 
derivatives O 
by O 
introducing O 
a O 
distinctive O 
linker O 
through O 
pharmacophore O 
analysis O 
of O 
known O 
ligands O 
included O 
in O 
X-ray O 
co O 
- O 
crystal O 
structures O 
. O 
Further O 
optimization O 
using O 
docking O 
studies O 
led O 
to O 
highly O 
potent O 
inhibitors O 
15b O 
and O 
27 O 
, O 
which O 
furthermore O 
showed O 
the O 
potent O 
efficacy O 
in O 
in O 
vivo O 
studies O 
. O 

tagging O 
of O 
a O 
drug O 
target O 
using O 
5-sulfonyl B-SYSTEMATIC 
tetrazole I-SYSTEMATIC 
. O 

modification O 
is O 
one O 
of O 
the O 
most O 
promising O 
strategies O 
to O 
identify O 
cellular O 
receptors O 
of O 
bioactive O 
small O 
molecules O 
. O 
Here O 
we O 
report O 
that O 
receptor O 
proteins O 
can O 
be O 
chemically O 
tagged O 
using O 
a O 
5-sulfonyl B-SYSTEMATIC 
tetrazole I-SYSTEMATIC 
probe O 
. O 
5-Sulfonyl B-SYSTEMATIC 
tetrazole I-SYSTEMATIC 
easily O 
accepted O 
nucleophilic O 
attack O 
of O 
thiol B-FAMILY 
groups O 
, O 
while O 
5-sulfinyl B-SYSTEMATIC 
tetrazole I-SYSTEMATIC 
did O 
not O 
. O 
These O 
functional O 
groups O 
were O 
introduced O 
into O 
probe O 
molecules O 
of O 
a O 
natural O 
product O 
. O 
Cyclosporine B-TRIVIAL 
A I-TRIVIAL 
, O 
an O 
immunosuppressant O 
produced O 
by O 
a O 
microbe O 
, O 
was O 
derivatized O 
to O 
possess O 
5-sulfonyl B-SYSTEMATIC 
tetrazole I-SYSTEMATIC 
and O 
a O 
tag O 
group O 
, O 
which O 
enabled O 
chemical O 
tagging O 
of O 
cyclophilin O 
A O 
, O 
the O 
cellular O 
receptor O 
of O 
cyclosporine B-TRIVIAL 
A I-TRIVIAL 
. O 
Cyclosporine B-TRIVIAL 
A I-TRIVIAL 
derivative O 
possessing O 
5-sulfinyl B-SYSTEMATIC 
tetrazole I-SYSTEMATIC 
could O 
not O 
tag O 
cyclophilin O 
A O 
. O 
This O 
technique O 
will O 
allow O 
efficient O 
identification O 
of O 
cellular O 
receptors O 
of O 
bioactive O 
small O 
molecules O 
. O 

α-carbonic O 
anhydrase O 
( O 
CA O 
, O 
EC O 
4.2.1.1 O 
) O 
has O 
been O 
recently O 
cloned O 
and O 
characterized O 
in O 
the O 
human O 
pathogenic O 
bacterium O 
Vibrio O 
cholerae O 
, O 
denominated O 
VchCA O 
( O 
Del O 
Prete O 
et O 
al O 
. O 
J O 
. O 
Med O 
. O 
Chem.2012 O 
, O 
55 O 
, O 
10742 O 
) O 
. O 
This O 
enzyme O 
shows O 
a O 
good O 
catalytic O 
activity O 
for O 
the O 
CO2 B-FORMULA 
hydration O 
reaction O 
, O 
comparable O 
to O 
that O 
of O 
the O 
human O 
( O 
h O 
) O 
isoform O 
hCA O 
I O 
. O 
Many O 
inorganic O 
anions O 
and O 
several O 
small O 
molecules O 
were O 
investigated O 
as O 
VchCA O 
inhibitors O 
. O 
Inorganic O 
anions O 
such O 
as O 
cyanate B-SYSTEMATIC 
, O 
cyanide B-SYSTEMATIC 
, O 
hydrogen B-SYSTEMATIC 
sulfide I-SYSTEMATIC 
, O 
hydrogen B-SYSTEMATIC 
sulfite I-SYSTEMATIC 
, O 
and O 
trithiocarbonate B-SYSTEMATIC 
were O 
effective O 
VchCA O 
inhibitors O 
with O 
inhibition O 
constants O 
in O 
the O 
range O 
of O 
33-88μM O 
. O 
Other O 
effective O 
inhibitors O 
were O 
diethyldithiocarbamate B-SYSTEMATIC 
, O 
sulfamide B-SYSTEMATIC 
, O 
sulfamate B-SYSTEMATIC 
, O 
phenylboronic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
phenylarsonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
with O 
KIs O 
of O 
7-43μM O 
. O 
Halides B-FAMILY 
( O 
bromide B-SYSTEMATIC 
, O 
iodide B-SYSTEMATIC 
) O 
, O 
bicarbonate B-SYSTEMATIC 
and O 
carbonate B-FAMILY 
were O 
much O 
less O 
effective O 
VchCA O 
inhibitors O 
, O 
with O 
KIs O 
in O 
the O 
range O 
of O 
4.64-28.0mM O 
. O 
The O 
resistance O 
of O 
VchCA O 
to O 
bicarbonate B-SYSTEMATIC 
inhibition O 
may O 
represent O 
an O 
evolutionary O 
adaptation O 
of O 
this O 
enzyme O 
to O 
living O 
in O 
an O 
environment O 
rich O 
in O 
this O 
ion O 
, O 
such O 
as O 
the O 
gastrointestinal O 
tract O 
, O 
as O 
bicarbonate B-SYSTEMATIC 
is O 
a O 
virulence O 
enhancer O 
of O 
this O 
bacterium O 
. O 

of O 
tetrazole O 
analogues O 
of O 
phosphonohydroxamic B-FAMILY 
acids I-FAMILY 
: O 
an O 
attempt O 
to O 
improve O 
the O 
inhibitory O 
activity O 
against O 
the O 
DXR O 
. O 

work O 
is O 
focused O 
on O 
the O 
design O 
of O 
new O 
antimicrobial O 
drugs O 
and O 
on O 
the O 
development O 
of O 
lipophilic O 
inhibitors O 
of O 
the O 
DXR O 
, O 
the O 
second O 
enzyme O 
of O 
the O 
MEP O 
pathway O 
for O 
the O 
biosynthesis O 
of O 
isoprene B-TRIVIAL 
units O 
in O 
most O 
bacteria O 
, O 
by O 
replacing O 
the O 
phosphonate B-SYSTEMATIC 
group O 
of O 
fosmidomycin B-TRIVIAL 
derivatives O 
by O 
a O 
tetrazoyl B-SYSTEMATIC 
moiety O 
capable O 
of O 
multiple O 
hydrogen B-SYSTEMATIC 
bonding O 
. O 
The O 
N B-FORMULA 
- O 
and O 
C B-FORMULA 
-substituted O 
tetrazole B-FAMILY 
analogues O 
of O 
phosphonohydroxamate B-SYSTEMATIC 
inhibitors O 
were O 
synthesized O 
and O 
tested O 
on O 
the O 
DXR O 
of O 
Escherichia O 
coli O 
. O 
This O 
work O 
points O 
out O 
the O 
hypothesis O 
that O 
the O 
phosphonate B-SYSTEMATIC 
/ O 
phosphate B-SYSTEMATIC 
recognition O 
site O 
might O 
be O 
too O 
rigid O 
to O 
accommodate O 
other O 
functional O 
groups O 
. O 

and O 
docking O 
studies O 
of O 
pentacycloundecylamines B-FAMILY 
at O 
the O 
sigma-1 O 
( O 
σ1 O 
) O 
receptor O 
. O 

( O 
PCU B-ABBREVIATION 
) O 
derived O 
compounds O 
have O 
been O 
shown O 
to O 
be O 
promising O 
lead O 
structures O 
for O 
the O 
development O 
of O 
novel O 
drug O 
candidates O 
aimed O 
at O 
a O 
variety O 
of O 
neurodegenerative O 
and O 
psychiatric O 
diseases O 
. O 
Here O 
we O 
show O 
for O 
the O 
first O 
time O 
a O 
3D O 
quantitative O 
structure O 
- O 
activity O 
relationship O 
( O 
3D-QSAR O 
) O 
for O 
a O 
series O 
of O 
aza-PCU B-SYSTEMATIC 
-derived O 
compounds O 
with O 
activity O 
at O 
the O 
sigma-1 O 
( O 
σ1 O 
) O 
receptor O 
. O 
A O 
comparative O 
molecular O 
field O 
analysis O 
( O 
CoMFA O 
) O 
model O 
was O 
developed O 
with O 
a O 
partial O 
least O 
squares O 
cross O 
validated O 
(q(2)) O 
regression O 
value O 
of O 
0.6 O 
, O 
and O 
a O 
non-cross O 
validated O 
r(2) O 
of O 
0.9 O 
. O 
The O 
CoMFA O 
model O 
was O 
effective O 
at O 
predicting O 
the O 
sigma-1 O 
activities O 
of O 
a O 
test O 
set O 
with O 
an O 
r(2) O 
> O 
0.7 O 
. O 
We O 
also O 
describe O 
here O 
the O 
docking O 
of O 
the O 
PCU B-ABBREVIATION 
-derived O 
compounds O 
into O 
a O 
homology O 
model O 
of O 
the O 
sigma-1 O 
( O 
σ1 O 
) O 
receptor O 
, O 
which O 
was O 
developed O 
to O 
gain O 
insight O 
into O 
binding O 
of O 
these O 
cage O 
compounds O 
to O 
the O 
receptor O 
. O 
Based O 
on O 
docking O 
studies O 
we O 
evaluated O 
in O 
a O 
[(3)H]pentazocine B-SYSTEMATIC 
binding O 
assay O 
an O 
oxa-PCU B-SYSTEMATIC 
, O 
NGP1-01 B-IDENTIFIER 
( O 
IC50=1.78μM O 
) O 
and O 
its O 
phenethyl B-SYSTEMATIC 
derivative O 
( O 
IC50=1.54μM O 
) O 
. O 
Results O 
from O 
these O 
studies O 
can O 
be O 
used O 
to O 
develop O 
new O 
compounds O 
with O 
specific O 
affinity O 
for O 
the O 
sigma-1(σ1) O 
receptor O 
. O 

of O 
antibacterial O 
mode O 
of O 
action O 
for O 
traditional O 
and O 
amphiphilic O 
aminoglycosides B-FAMILY 
. O 

represents O 
a O 
class O 
of O 
versatile O 
and O 
broad O 
spectrum O 
antibacterial O 
agents O 
. O 
In O 
an O 
effort O 
to O 
revive O 
the O 
antibacterial O 
activity O 
against O 
aminoglycoside B-FAMILY 
resistant O 
bacteria O 
, O 
our O 
laboratory O 
has O 
developed O 
two O 
new O 
classes O 
of O 
aminoglycoside B-FAMILY 
, O 
pyranmycin B-TRIVIAL 
and O 
amphiphilic O 
neomycin B-TRIVIAL 
( O 
NEOF004 B-IDENTIFIER 
) O 
. O 
The O 
former O 
resembles O 
the O 
traditional O 
aminoglycoside B-FAMILY 
, O 
neomycin B-TRIVIAL 
. O 
The O 
latter O 
, O 
albeit O 
derived O 
from O 
neomycin B-TRIVIAL 
, O 
appears O 
to O 
exert O 
antibacterial O 
action O 
via O 
a O 
different O 
mode O 
of O 
action O 
. O 
In O 
order O 
to O 
discern O 
that O 
these O 
aminoglycoside B-FAMILY 
derivatives O 
have O 
distinct O 
antibacterial O 
mode O 
of O 
action O 
, O 
RNA O 
- O 
binding O 
affinity O 
and O 
fluorogenic O 
dye O 
were O 
employed O 
. O 
These O 
studies O 
, O 
together O 
with O 
our O 
previous O 
investigation O 
, O 
confirm O 
that O 
pyranmycin O 
exhibit O 
the O 
traditional O 
antibacterial O 
mode O 
of O 
action O 
of O 
aminoglycosides B-FAMILY 
by O 
binding O 
toward O 
the O 
bacterial O 
rRNA O 
. O 
On O 
the O 
other O 
hand O 
, O 
the O 
amphiphilic O 
neomycin B-TRIVIAL 
, O 
NEOF004 B-IDENTIFIER 
disrupts O 
the O 
bacterial O 
cell O 
wall O 
. O 
In O 
a O 
broader O 
perspective O 
, O 
it O 
verifies O 
that O 
structurally O 
modified O 
neomycin B-TRIVIAL 
can O 
exert O 
different O 
antibacterial O 
mode O 
of O 
action O 
leading O 
to O 
the O 
revival O 
of O 
activity O 
against O 
aminoglycoside B-FAMILY 
resistant O 
bacteria O 
. O 

order O 
to O 
develop O 
potent O 
and O 
selective O 
focal O 
adhesion O 
kinase O 
( O 
FAK O 
) O 
inhibitors O 
, O 
synthetic O 
studies O 
on O 
pyrazolo[4,3-c][2,1]benzothiazines B-FAMILY 
targeted O 
for O 
the O 
FAK O 
allosteric O 
site O 
were O 
carried O 
out O 
. O 
Based O 
on O 
the O 
X-ray O 
structural O 
analysis O 
of O 
the O 
co O 
- O 
crystal O 
of O 
the O 
lead O 
compound O 
, O 
8-(4-ethylphenyl)-5-methyl-1,5-dihydropyrazolo[4,3-c][2,1]benzothiazine B-SYSTEMATIC 
4,4-dioxide I-SYSTEMATIC 
1 O 
with O 
FAK O 
, O 
we O 
designed O 
and O 
prepared O 
1,5-dimethyl-1,5-dihydropyrazolo[4,3-c][2,1]benzothiazin B-SYSTEMATIC 
derivatives O 
which O 
selectively O 
inhibited O 
kinase O 
activity O 
of O 
FAK O 
without O 
affecting O 
seven O 
other O 
kinases O 
. O 
The O 
optimized O 
compound O 
, O 
N-(4-tert-butylbenzyl)-1,5-dimethyl-1,5-dihydropyrazolo[4,3-c][2,1]benzothiazin-8-amine B-SYSTEMATIC 
4,4-dioxide I-SYSTEMATIC 
30 O 
possessed O 
significant O 
FAK O 
kinase O 
inhibitory O 
activities O 
both O 
in O 
cell O 
- O 
free O 
( O 
IC50=0.64μM O 
) O 
and O 
in O 
cellular O 
assays O 
( O 
IC50=7.1μM O 
) O 
. O 
These O 
results O 
clearly O 
demonstrated O 
a O 
potential O 
of O 
FAK O 
allosteric O 
inhibitors O 
as O 
antitumor O 
agents O 
. O 

of O 
black O 
cohosh O 
triterpene B-FAMILY 
glycosides I-FAMILY 
and O 
polyphenols B-FAMILY 
: O 
Potential O 
clinical O 
relevance O 
. O 

to O 
a O 
clinical O 
trial O 
of O 
black O 
cohosh O 
for O 
menopausal O 
hot O 
flashes O 
, O 
the O 
long O 
- O 
term O 
stability O 
of O 
the O 
black O 
cohosh O 
, O 
over O 
the O 
duration O 
of O 
the O 
clinical O 
trial O 
, O 
was O 
examined O 
. O 
Analytical O 
results O 
showed O 
that O 
the O 
major O 
constituents O 
, O 
both O 
triterpene B-FAMILY 
glycosides I-FAMILY 
and O 
polyphenols B-FAMILY 
, O 
were O 
stable O 
over O 
the O 
3-year O 
period O 
of O 
testing O 
. O 
These O 
results O 
indicate O 
that O 
a O 
black O 
cohosh O 
product O 
stored O 
for O 
several O 
years O 
in O 
a O 
controlled O 
environment O 
does O 
not O 
undergo O 
significant O 
changes O 
in O 
its O 
major O 
constituents O 
. O 
These O 
results O 
have O 
implications O 
not O 
only O 
for O 
clinical O 
research O 
in O 
natural O 
products O 
, O 
but O 
for O 
basic O 
science O 
, O 
as O 
well O 
as O 
the O 
dietary O 
supplements O 
industry O 
. O 

of O 
profenofos B-TRIVIAL 
to O 
4-bromo-2-chlorophenol B-SYSTEMATIC 
, O 
a O 
specific O 
and O 
sensitive O 
exposure O 
biomarker O 
. O 

is O 
a O 
direct O 
acting O 
phosphorothioate B-SYSTEMATIC 
organophosphorus B-FAMILY 
( O 
OP O 
) O 
pesticide O 
capable O 
of O 
inhibiting O 
β-esterases O 
such O 
as O 
acetylcholinesterase O 
, O 
butyrylcholinesterase O 
, O 
and O 
carboxylesterase O 
. O 
Profenofos B-TRIVIAL 
is O 
known O 
to O 
be O 
detoxified O 
to O 
the O 
biologically O 
inactive O 
metabolite O 
, O 
4-bromo-2-chlorophenol B-SYSTEMATIC 
( O 
BCP B-ABBREVIATION 
) O 
; O 
however O 
, O 
limited O 
data O 
are O 
available O 
regarding O 
the O 
use O 
of O 
urinary O 
BCP B-ABBREVIATION 
as O 
an O 
exposure O 
biomarker O 
in O 
humans O 
. O 
A O 
pilot O 
study O 
conducted O 
in O 
Egyptian O 
agriculture O 
workers O 
, O 
demonstrated O 
that O 
urinary O 
BCP B-ABBREVIATION 
levels O 
prior O 
to O 
application O 
( O 
3.3-30.0μg O 
/ O 
g O 
creatinine B-TRIVIAL 
) O 
were O 
elevated O 
to O 
34.5-3566μg O 
/ O 
g O 
creatinine B-TRIVIAL 
during O 
the O 
time O 
workers O 
were O 
applying O 
profenofos B-TRIVIAL 
to O 
cotton O 
fields O 
. O 
Subsequently O 
, O 
the O 
in O 
vitro O 
enzymatic O 
formation O 
of O 
BCP B-ABBREVIATION 
was O 
examined O 
using O 
pooled O 
human O 
liver O 
microsomes O 
and O 
recombinant O 
human O 
cytochrome O 
P-450s O 
( O 
CYPs O 
) O 
incubated O 
with O 
profenofos B-TRIVIAL 
. O 
Of O 
the O 
nine O 
human O 
CYPs O 
studied O 
, O 
only O 
CYPs O 
3A4 O 
, O 
2B6 O 
, O 
and O 
2C19 O 
were O 
able O 
to O 
metabolize O 
profenofos B-TRIVIAL 
to O 
BCP B-ABBREVIATION 
. O 
Kinetic O 
studies O 
indicated O 
that O 
CYP O 
2C19 O 
has O 
the O 
lowest O 
Km O 
, O 
0.516μM O 
followed O 
by O 
2B6 O 
( O 
Km=1.02μM O 
) O 
and O 
3A4 O 
( O 
Km=18.9μM O 
) O 
. O 
The O 
Vmax O 
for O 
BCP B-ABBREVIATION 
formation O 
was O 
47.9 O 
, O 
25.1 O 
, O 
and O 
19.2nmol O 
/ O 
min O 
/ O 
nmol O 
CYP O 
for O 
CYP2B6 O 
, O 
2C19 O 
, O 
and O 
3A4 O 
, O 
respectively O 
. O 
Intrinsic O 
clearance O 
( O 
Vmax O 
/ O 
Km O 
) O 
values O 
of O 
48.8 O 
, O 
46.9 O 
, O 
and O 
1.02ml O 
/ O 
min O 
/ O 
nmol O 
CYP O 
2C19 O 
, O 
2B6 O 
, O 
and O 
3A4 O 
, O 
respectively O 
, O 
indicate O 
that O 
CYP2C19 O 
and O 
CYP2B6 O 
are O 
primarily O 
responsible O 
for O 
the O 
detoxification O 
of O 
profenofos B-TRIVIAL 
. O 
These O 
findings O 
support O 
the O 
use O 
of O 
urinary O 
BCP B-ABBREVIATION 
as O 
a O 
biomarker O 
of O 
exposure O 
to O 
profenofos B-TRIVIAL 
in O 
humans O 
and O 
suggest O 
polymorphisms O 
in O 
CYP O 
2C19 O 
and O 
CYP O 
2B6 O 
as O 
potential O 
biomarkers O 
of O 
susceptibility O 
. O 

- O 
stimulating O 
hormone O 
( O 
FSH O 
) O 
activates O 
FSH O 
receptors O 
( O 
FSHR O 
) O 
in O 
granulosa O 
cells O 
to O 
induce O 
follicle O 
differentiation O 
, O 
growth O 
and O 
estradiol B-TRIVIAL 
production O 
. O 
FSH O 
is O 
used O 
clinically O 
to O 
treat O 
female O 
infertility O 
and O 
is O 
administered O 
by O 
injection O 
. O 
To O 
increase O 
patient O 
convenience O 
and O 
compliance O 
, O 
compound O 
homogeneity O 
and O 
composition O 
, O 
low O 
molecular O 
weight O 
( O 
LMW O 
) O 
, O 
orally O 
bioavailable O 
, O 
FSHR O 
agonists O 
are O 
now O 
being O 
developed O 
to O 
replace O 
FSH O 
. O 
In O 
this O 
study O 
, O 
we O 
present O 
the O 
signaling O 
mechanisms O 
of O 
a O 
newly O 
developed O 
LMW O 
dihydropyridine B-SYSTEMATIC 
agonist O 
of O 
the O 
FSHR O 
, O 
Org B-IDENTIFIER 
214444-0 I-IDENTIFIER 
. O 
Org B-IDENTIFIER 
214444-0 I-IDENTIFIER 
is O 
shown O 
to O 
be O 
a O 
stereoselective O 
, O 
nanomolar O 
potent O 
FSHR O 
agonist O 
and O 
selective O 
over O 
the O 
structurally O 
related O 
LHR O 
and O 
TSHR O 
. O 
Org B-IDENTIFIER 
214444-0 I-IDENTIFIER 
is O 
an O 
allosteric O 
agonist O 
interacting O 
with O 
the O 
transmembrane O 
region O 
of O 
the O 
FSHR O 
. O 
When O 
co O 
- O 
incubated O 
with O 
FSH O 
, O 
Org B-IDENTIFIER 
214444-0 I-IDENTIFIER 
augments O 
FSH's O 
potency O 
in O 
binding O 
( O 
6.5-fold O 
) O 
and O 
adenylyl O 
cyclase/ O 
cAMP B-ABBREVIATION 
activation O 
( O 
3.5-fold O 
) O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 
Like O 
FSH O 
, O 
Org B-IDENTIFIER 
214444-0 I-IDENTIFIER 
induces O 
FSHR O 
internalization O 
and O 
is O 
only O 
marginally O 
effective O 
in O 
stimulating O 
phospholipase O 
C O 
. O 
Moreover O 
, O 
Org B-IDENTIFIER 
214444-0 I-IDENTIFIER 
stimulates O 
cAMP B-ABBREVIATION 
and O 
estradiol B-TRIVIAL 
production O 
in O 
human O 
granulosa O 
cells O 
in O 
culture O 
and O 
supports O 
the O 
follicular O 
phase O 
in O 
mature O 
female O 
rats O 
. O 
We O 
conclude O 
that O 
Org B-IDENTIFIER 
214444-0 I-IDENTIFIER 
is O 
a O 
bonafide O 
FSHR O 
agonist O 
. O 

high O 
- O 
throughput O 
- O 
compatible O 
, O 
fluorescence O 
anisotropy O 
- O 
based O 
assay O 
for O 
ATP B-ABBREVIATION 
-dependent O 
supercoiled O 
DNA O 
relaxation O 
by O 
human O 
topoisomerase O 
IIα O 
. O 

novel O 
, O 
high O 
- O 
throughput O 
- O 
compatible O 
assay O 
for O 
the O 
ATP B-ABBREVIATION 
-dependent O 
supercoiled O 
DNA O 
relaxing O 
activity O 
of O 
human O 
topoisomerase O 
IIα O 
( O 
hTopoIIα O 
) O 
is O 
described O 
. O 
The O 
principle O 
of O 
detection O 
is O 
the O 
preferential O 
binding O 
of O 
the O 
oligodeoxyribonucleotide O 
BODIPY B-ABBREVIATION 
- O 
TMR B-ABBREVIATION 
-5'-TTCTTCTTCT-3 O 
' O 
to O 
relaxed O 
double O 
- O 
stranded O 
plasmid O 
containing O 
the O 
triplex O 
forming O 
sequence O 
(TTC)9 O 
versus O 
the O 
supercoiled O 
plasmid O 
. O 
Binding O 
of O 
the O 
oligonucleotide O 
to O 
the O 
plasmid O 
increases O 
the O 
fluorescence O 
anisotropy O 
of O 
the O 
BODIPY B-ABBREVIATION 
- O 
TMR B-ABBREVIATION 
label O 
. O 
Optimization O 
of O 
the O 
assay O 
conditions O 
was O 
conducted O 
to O 
maximize O 
the O 
signal O 
and O 
the O 
activity O 
of O 
the O 
topoisomerase O 
. O 
The O 
multiwell O 
assay O 
plate O 
- O 
based O 
fluorescence O 
anisotropy O 
assay O 
gave O 
the O 
same O 
values O 
for O 
the O 
potencies O 
of O 
several O 
previously O 
reported O 
inhibitors O 
of O 
hTopoIIα O 
as O 
a O 
gel O 
electrophoresis O 
- O 
based O 
assay O 
of O 
DNA O 
relaxation O 
. O 

and O 
synthesis O 
of O 
bicyclic B-MULTIPLE 
pyrazinone I-MULTIPLE 
and I-MULTIPLE 
pyrimidinone I-MULTIPLE 
amides I-MULTIPLE 
as O 
potent O 
TF-FVIIa O 
inhibitors O 
. O 

pyrazinone I-MULTIPLE 
and I-MULTIPLE 
pyrimidinone I-MULTIPLE 
amides I-MULTIPLE 
were O 
designed O 
and O 
synthesized O 
as O 
potent O 
TF-FVIIa O 
inhibitors O 
. O 
SAR O 
demonstrated O 
that O 
the O 
S2 O 
and O 
S3 O 
pockets O 
of O 
FVIIa O 
prefer O 
to O 
bind O 
small O 
, O 
lipophilic O 
groups O 
. O 
An O 
X-ray O 
crystal O 
structure O 
of O 
optimized O 
compound O 
9b O 
bound O 
in O 
the O 
active O 
site O 
of O 
FVIIa O 
showed O 
that O 
the O 
bicyclic O 
scaffold O 
provides O 
5 O 
hydrogen B-SYSTEMATIC 
bonding O 
interactions O 
in O 
addition O 
to O 
projecting O 
groups O 
for O 
interactions O 
within O 
the O 
S1 O 
, O 
S2 O 
and O 
S3 O 
pockets O 
. O 
Compound O 
9b O 
showed O 
excellent O 
FVIIa O 
potency O 
, O 
good O 
selectivity O 
against O 
FIXa O 
, O 
Xa O 
, O 
XIa O 
and O 
chymotrypsin O 
, O 
and O 
good O 
clotting O 
activity O 
. O 

synthesis O 
of O 
anacardic B-FAMILY 
acid I-FAMILY 
analogues O 
and O 
their O 
antibacterial O 
activities O 
. O 

acid I-FAMILY 
derivatives O 
exhibit O 
a O 
broad O 
range O 
of O 
biological O 
activities O 
. O 
In O 
this O 
report O 
, O 
an O 
efficient O 
method O 
for O 
the O 
synthesis O 
of O 
anacardic B-FAMILY 
acid I-FAMILY 
derivatives O 
was O 
explored O 
, O 
and O 
a O 
small O 
set O 
of O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
variants O 
synthesised O 
retaining O 
a O 
constant O 
hydrophobic O 
element O 
( O 
a O 
naphthyl B-SYSTEMATIC 
tail O 
) O 
. O 
The O 
naphthyl B-SYSTEMATIC 
side O 
chain O 
was O 
introduced O 
via O 
Wittig O 
reaction O 
and O 
the O 
aldehyde B-SYSTEMATIC 
installed O 
using O 
directed O 
ortho-metalation O 
reaction O 
of O 
the O 
substituted O 
o-anisic B-FAMILY 
acids I-FAMILY 
. O 
The O 
failure O 
of O 
ortho-metalation O 
using O 
unprotected O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
group O 
compelled O 
us O 
to O 
use O 
directed O 
ortho-metalation O 
in O 
which O 
a O 
tertiary B-SYSTEMATIC 
amide I-SYSTEMATIC 
was O 
used O 
as O 
a O 
strong O 
ortho-directing O 
group O 
. O 
In O 
the O 
initial O 
route O 
, O 
tertiary B-SYSTEMATIC 
amide I-SYSTEMATIC 
cleavage O 
during O 
final O 
step O 
was O 
challenging O 
, O 
but O 
cleaving O 
the O 
tertiary B-SYSTEMATIC 
amide I-SYSTEMATIC 
before O 
Wittig O 
reaction O 
was O 
beneficial O 
. O 
The O 
Wittig O 
reaction O 
with O 
protected O 
carboxylic B-SYSTEMATIC 
group O 
( O 
methyl B-SYSTEMATIC 
ester I-SYSTEMATIC 
) O 
resulted O 
in O 
side-products O 
whereas O 
using O 
sodium B-SYSTEMATIC 
salt O 
resulted O 
in O 
higher O 
yields O 
. O 
The O 
novel O 
compounds O 
were O 
screened O 
for O 
antibacterial O 
activity O 
and O 
cytotoxicity O 
. O 
Although O 
substitution O 
on O 
the O 
salicylic B-TRIVIAL 
head O 
group O 
enhanced O 
antibacterial O 
activities O 
they O 
also O 
enhanced O 
cytotoxicity O 
. O 

piperidinyl B-FAMILY 
glycinyl I-FAMILY 
2-cyano-4,5-methano I-FAMILY 
pyrrolidines I-FAMILY 
as O 
potent O 
and O 
stable O 
dipeptidyl O 
peptidase O 
IV O 
inhibitors O 
. O 

and O 
structure O 
- O 
activity O 
relationship O 
of O 
a O 
series O 
of O 
substituted O 
piperidinyl B-SYSTEMATIC 
glycine I-SYSTEMATIC 
2-cyano-4,5-methano I-SYSTEMATIC 
pyrroline I-SYSTEMATIC 
DPP-IV O 
inhibitors O 
are O 
described O 
. O 
Improvement O 
of O 
the O 
inhibitory O 
activity O 
and O 
chemical O 
stability O 
of O 
this O 
series O 
of O 
compounds O 
was O 
respectively O 
achieved O 
by O 
the O 
introduction O 
of O 
bulky O 
groups O 
at O 
the O 
4- O 
position O 
and O 
1- O 
position O 
of O 
the O 
piperidinyl B-SYSTEMATIC 
glycine I-SYSTEMATIC 
, O 
leading O 
to O 
a O 
series O 
of O 
potent O 
and O 
stable O 
DPP-IV O 
inhibitors O 
. O 

inducible O 
factor-1α O 
( O 
HIF-1α O 
) O 
is O 
a O 
transcription O 
factor O 
found O 
in O 
mammalian O 
cells O 
under O 
hypoxia O 
. O 
While O 
HIF-1α O 
in O 
hypoxia O 
translocates O 
to O 
the O 
nucleus O 
where O 
it O 
transcribes O 
the O 
target O 
genes O 
including O 
vascular O 
endothelial O 
growth O 
factor O 
( O 
VEGF O 
) O 
mRNA O 
, O 
HIF-1α O 
is O 
degraded O 
under O 
normoxia O 
, O 
which O 
involves O 
its O 
proline B-TRIVIAL 
hydroxylation O 
and O 
subsequent O 
binding O 
to O 
the O 
von O 
Hippel-Lindau O 
protein-Elongin O 
B-Elogin O 
C O 
( O 
VBC O 
) O 
complex O 
. O 
Previously O 
, O 
peptide O 
inhibitors O 
against O 
this O 
interaction O 
between O 
hydroxylated O 
HIF-1α O 
and O 
VBC O 
have O 
been O 
developed O 
to O 
stabilize O 
the O 
transcriptional O 
activity O 
of O 
HIF-1α O 
by O 
preventing O 
the O 
degradation O 
of O 
the O 
protein O 
even O 
under O 
normoxia O 
. O 
Despite O 
the O 
specific O 
inhibition O 
by O 
these O 
peptides O 
, O 
their O 
poor O 
inhibition O 
potency O 
needs O 
to O 
be O 
improved O 
for O 
further O 
clinical O 
application O 
. O 
In O 
this O 
work O 
, O 
we O 
have O 
designed O 
and O 
prepared O 
a O 
streptavidin O 
- O 
based O 
multivalent O 
peptide O 
inhibitor O 
against O 
the O 
HIF-1α-VBC O 
complexation O 
. O 
We O 
have O 
evaluated O 
the O 
potency O 
of O 
the O 
multivalent O 
peptide O 
in O 
terms O 
of O 
stabilization O 
of O 
HIF-1α O 
and O 
the O 
downstream O 
effect O 
. O 
As O 
the O 
result O 
, O 
we O 
have O 
found O 
that O 
the O 
inhibitor O 
showed O 
about O 
13-fold O 
lowered O 
IC50 O 
value O 
compared O 
with O 
that O 
of O 
the O 
corresponding O 
monovalent O 
peptide O 
, O 
thereby O 
activating O 
HIF-1α O 
and O 
leading O 
to O 
up O 
- O 
regulation O 
of O 
VEGF O 
protein O 
at O 
the O 
cellular O 
level O 
. O 

α3β4* O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
subtype O 
mediates O 
nicotine B-TRIVIAL 
reward O 
and O 
physical O 
nicotine B-TRIVIAL 
withdrawal O 
signs O 
independently O 
of O 
the O 
α5 O 
subunit O 
in O 
the O 
mouse O 
. O 

15q25 O 
gene O 
cluster O 
contains O 
genes O 
that O 
code O 
for O 
the O 
α5 O 
, O 
α3 O 
, O 
and O 
β4 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
nAChRs O 
) O 
subunits O 
, O 
and O 
in O 
human O 
genetic O 
studies O 
, O 
has O 
shown O 
the O 
most O 
robust O 
association O 
with O 
smoking O 
behavior O 
and O 
nicotine B-TRIVIAL 
dependence O 
to O 
date O 
. O 
The O 
limited O 
available O 
animal O 
studies O 
implicate O 
a O 
role O 
for O 
the O 
α5 O 
and O 
β4 O 
nAChR O 
subunits O 
in O 
nicotine B-TRIVIAL 
dependence O 
and O 
withdrawal O 
; O 
however O 
studies O 
focusing O 
on O 
the O 
behavioral O 
role O 
of O 
the O 
α3β4* O 
nAChR O 
receptor O 
subtype O 
in O 
nicotine B-TRIVIAL 
dependence O 
are O 
lacking O 
. O 
Because O 
of O 
the O 
apparent O 
role O 
of O 
the O 
α3β4* O 
nAChR O 
subtype O 
in O 
nicotine B-TRIVIAL 
dependence O 
, O 
the O 
goal O 
of O 
the O 
current O 
study O 
was O 
to O 
better O 
evaluate O 
the O 
involvement O 
of O 
this O 
subtype O 
in O 
nicotine B-TRIVIAL 
mediated O 
behavioral O 
responses O 
. O 
Using O 
the O 
selective O 
α3β4* O 
nAChR O 
antagonist O 
, O 
α-conotoxin O 
AuIB O 
, O 
we O 
assessed O 
the O 
role O 
of O 
α3β4* O 
nAChRs O 
in O 
acute O 
nicotine B-TRIVIAL 
, O 
nicotine B-TRIVIAL 
reward O 
, O 
and O 
physical O 
and O 
affective O 
nicotine B-TRIVIAL 
withdrawal O 
. O 
Because O 
α5 O 
has O 
also O 
been O 
implicated O 
in O 
nicotine B-TRIVIAL 
dependence O 
behaviors O 
in O 
mice O 
and O 
can O 
form O 
functional O 
receptors O 
with O 
α3β4* O 
, O 
we O 
also O 
evaluated O 
the O 
role O 
of O 
the O 
α3β4α5* O 
nAChR O 
subtype O 
in O 
nicotine B-TRIVIAL 
reward O 
and O 
somatic O 
nicotine B-TRIVIAL 
withdrawal O 
signs O 
by O 
blocking O 
the O 
α3β4* O 
nAChR O 
subtype O 
in O 
α5 O 
nAChR O 
knockout O 
mice O 
with O 
AuIB O 
. O 
AuIB O 
had O 
no O 
significant O 
effect O 
on O 
acute O 
nicotine B-TRIVIAL 
behaviors O 
, O 
but O 
dose O 
- O 
dependently O 
attenuated O 
nicotine B-TRIVIAL 
reward O 
and O 
physical O 
withdrawal O 
signs O 
, O 
with O 
no O 
significant O 
effect O 
in O 
affective O 
withdrawal O 
measures O 
. O 
Interestingly O 
, O 
AuIB O 
also O 
attenuated O 
nicotine B-TRIVIAL 
reward O 
and O 
somatic O 
signs O 
in O 
α5 O 
nAChR O 
knockout O 
mice O 
. O 
This O 
study O 
shows O 
that O 
α3β4* O 
nAChRs O 
mediate O 
nicotine B-TRIVIAL 
reward O 
and O 
physical O 
nicotine B-TRIVIAL 
withdrawal O 
, O 
but O 
not O 
acute O 
nicotine B-TRIVIAL 
behaviors O 
or O 
affective O 
nicotine B-TRIVIAL 
withdrawal O 
signs O 
in O 
mice O 
. O 
The O 
α5 O 
subunit O 
is O 
not O 
required O 
in O 
the O 
receptor O 
assembly O 
to O 
mediate O 
these O 
effects O 
. O 
Our O 
findings O 
suggest O 
an O 
important O 
role O 
for O 
the O 
α3β4* O 
nAChR O 
subtype O 
in O 
nicotine B-TRIVIAL 
reward O 
and O 
physical O 
aspects O 
of O 
the O 
nicotine B-TRIVIAL 
withdrawal O 
syndrome O 
. O 

serum O 
albumin O 
- O 
based O 
design O 
of O 
a O 
diflunisal B-TRIVIAL 
prodrug O 
. O 

cyclooxygenase-2 O 
inhibitor O 
, O 
diflunisal B-TRIVIAL 
, O 
is O 
used O 
in O 
the O 
clinic O 
for O 
its O 
anti-inflammatory O 
activity O 
. O 
About O 
99% O 
of O 
a O 
dose O 
of O 
diflunisal B-TRIVIAL 
is O 
unavailable O 
for O 
reaction O 
with O 
the O 
target O 
enzyme O 
, O 
because O 
diflunisal B-TRIVIAL 
strongly O 
binds O 
to O 
human O 
serum O 
albumin O 
( O 
HSA O 
) O 
. O 
To O 
reduce O 
the O 
binding O 
affinity O 
of O 
diflunisal B-TRIVIAL 
to O 
albumin O 
, O 
we O 
designed O 
and O 
synthesized O 
the O 
prodrug O 
acetyldiflunisal B-SYSTEMATIC 
. O 
The O 
crystal O 
structure O 
of O 
HSA O 
complexed O 
with O 
fatty B-FAMILY 
acid I-FAMILY 
and O 
acetyldiflunisal B-SYSTEMATIC 
revealed O 
that O 
acetyldiflunisal B-SYSTEMATIC 
binds O 
to O 
the O 
IIA O 
subdomain O 
and O 
that O 
upon O 
binding O 
, O 
it O 
acetylates O 
lysine B-TRIVIAL 
199 O 
. O 
Mass O 
spectrometry O 
confirmed O 
that O 
acetyldiflunisal B-SYSTEMATIC 
acetylates O 
Lys B-FORMULA 
199 O 
. O 
The O 
acetylated O 
albumin O 
had O 
twofold O 
weaker O 
binding O 
affinity O 
for O 
diflunisal B-TRIVIAL 
as O 
demonstrated O 
by O 
fluorescence O 
quenching O 
. O 
Reduced O 
binding O 
affinity O 
means O 
that O 
diflunisal B-TRIVIAL 
is O 
more O 
easily O 
released O 
from O 
acetylated O 
albumin O 
into O 
the O 
circulation O 
. O 
Therefore O 
, O 
lower O 
doses O 
of O 
acetyldiflunisal B-SYSTEMATIC 
compared O 
to O 
diflunisal B-TRIVIAL 
will O 
be O 
required O 
. O 
Taken O 
together O 
, O 
our O 
results O 
not O 
only O 
provide O 
a O 
template O 
for O 
design O 
of O 
HSA O 
- O 
based O 
prodrugs O 
, O 
but O 
also O 
pave O 
the O 
way O 
toward O 
more O 
effective O 
use O 
of O 
diflunisal B-TRIVIAL 
in O 
the O 
clinic O 
. O 

water O 
- O 
soluble O 
low O 
molecular O 
weight O 
polysaccharide O 
( O 
SCPP11 O 
) O 
was O 
extracted O 
and O 
purified O 
using O 
DEAE-cellulose O 
and O 
Sephadex O 
G-100 O 
column O 
from O 
Schisandra O 
chinensis O 
( O 
Turcz O 
. O 
) O 
Baill O 
. O 
Its O 
in O 
vivo O 
and O 
in O 
vitro O 
antitumor O 
and O 
immunomodulatory O 
activity O 
were O 
investigated O 
. O 
The O 
results O 
showed O 
that O 
SCPP11 O 
with O 
a O 
molecular O 
weight O 
of O 
3.4×10(3)Da O 
exhibited O 
indirect O 
cyctotoxic O 
activity O 
against O 
tumor O 
cells O 
in O 
vitro O 
, O 
but O 
could O 
significantly O 
inhibit O 
the O 
growth O 
of O 
Heps O 
cells O 
in O 
vivo O 
at O 
dose O 
of O 
50mg O 
/ O 
kg O 
, O 
and O 
its O 
inhibition O 
rate O 
is O 
higher O 
than O 
that O 
in O 
the O 
positive O 
group O 
. O 
Moreover O 
, O 
SCPP11 O 
could O 
ameliorate O 
the O 
hematological O 
and O 
biochemical O 
parameters O 
to O 
almost O 
normal O 
and O 
no O 
significant O 
changes O 
in O 
organ O 
weight O 
, O 
and O 
could O 
increase O 
the O 
body O 
weight O 
. O 
In O 
addition O 
, O 
SCPP11 O 
( O 
at O 
50mg O 
/ O 
kg O 
) O 
could O 
also O 
increased O 
in O 
thymus O 
indexes O 
as O 
well O 
as O 
IL-2 O 
and O 
TNF-α O 
levels O 
in O 
serum O 
in O 
vivo O 
and O 
significantly O 
enhance O 
the O 
phagocytosis O 
activity O 
and O 
the O 
productions O 
of O 
NO B-FORMULA 
of O 
RAW264.7 O 
in O 
vitro O 
. O 
The O 
results O 
indicated O 
that O 
antitumor O 
properties O 
of O 
SCPP11 O 
might O 
be O 
achieved O 
by O 
improving O 
immune O 
response O 
. O 
It O 
could O 
be O 
explored O 
as O 
a O 
potential O 
adjuvant O 
against O 
cancer O 
used O 
in O 
the O 
health O 
food O 
and O 
pharmaceutical O 
therapy O 
. O 

fraction O 
from O 
citrus O 
peels O 
attenuates O 
alcoholic O 
liver O 
disease O 
in O 
mice O 
. O 

study O 
aimed O 
to O 
demonstrate O 
protective O 
activities O 
of O 
the O 
narirutin B-TRIVIAL 
fraction O 
from O 
peels O 
of O 
Citrus O 
unshiu O 
against O 
ethanol B-SYSTEMATIC 
-induced O 
hepatic O 
damage O 
through O 
an O 
animal O 
study O 
. O 
Citrus O 
narirutin B-TRIVIAL 
fraction O 
( O 
CNF O 
) O 
, O 
contained O 
75% O 
of O 
narirutin B-TRIVIAL 
, O 
was O 
obtained O 
by O 
an O 
ultra O 
- O 
sonicated O 
extraction O 
and O 
further O 
purification O 
. O 
ICR O 
mice O 
were O 
divided O 
into O 
four O 
groups O 
; O 
normaldiet O 
control O 
, O 
ethanol B-SYSTEMATIC 
control O 
( O 
6.5g O 
ethanol B-SYSTEMATIC 
/ O 
kg O 
) O 
, O 
low-CNF O 
( O 
ethanol B-SYSTEMATIC 
+ O 
150mg O 
CNF O 
/ O 
kg O 
) O 
and O 
high-CNF O 
( O 
ethanol B-SYSTEMATIC 
+ O 
300mg O 
CNF O 
/ O 
kg O 
) O 
groups O 
. O 
Consumption O 
of O 
alcohol B-FAMILY 
for O 
8weeks O 
induced O 
severe O 
liver O 
damage O 
with O 
increases O 
in O 
prognostic O 
indicators O 
such O 
as O 
aspartate B-TRIVIAL 
transaminase O 
, O 
alanine O 
transaminase O 
in O 
serum O 
whereas O 
co O 
- O 
administration O 
of O 
CNF O 
suppressed O 
their O 
increases O 
. O 
Excessive O 
accumulations O 
in O 
liver O 
TG O 
and O 
TC O 
in O 
ethanol B-SYSTEMATIC 
control O 
group O 
were O 
also O 
suppressed O 
by O 
co O 
- O 
administration O 
of O 
CNF O 
. O 
Co-administration O 
of O 
CNF O 
maintained O 
SOD O 
activity O 
, O 
GSH B-ABBREVIATION 
and O 
malondialdehyde B-TRIVIAL 
levels O 
close O 
to O 
those O 
of O 
the O 
normal O 
diet O 
group O 
. O 
Chronic O 
consumption O 
of O 
alcohol B-FAMILY 
also O 
stimulated O 
abrupt O 
increases O 
in O 
pro O 
- O 
inflammatory O 
cytokines O 
such O 
as O 
nuclear O 
factor O 
(NF)-κB O 
, O 
tumor O 
necrosis O 
factor O 
(TNF)-α O 
and O 
interleukin O 
(IL)-1β O 
in O 
liver O 
otherwise O 
co O 
- O 
administration O 
of O 
CNF O 
effectively O 
suppressed O 
production O 
of O 
these O 
cytokines O 
dose O 
- O 
dependently O 
. O 
These O 
results O 
indicate O 
that O 
co O 
- O 
administration O 
of O 
CNF O 
with O 
alcohol B-FAMILY 
can O 
alleviate O 
alcohol B-FAMILY 
induced O 
liver O 
damage O 
through O 
preventing O 
lipid O 
formation O 
, O 
protecting O 
antioxidant O 
system O 
and O 
suppressing O 
productions O 
of O 
pro O 
- O 
inflammatory O 
cytokines O 
. O 

has O 
been O 
a O 
steep O 
increase O 
in O 
the O 
prevalence O 
of O 
dementia O 
in O 
recent O 
decades O 
, O 
which O 
has O 
roughly O 
followed O 
an O 
increase O 
in O 
pesticide O 
use O 
some O 
decades O 
earlier O 
, O 
a O 
time O 
when O 
it O 
is O 
probable O 
that O 
current O 
dementia O 
patients O 
could O 
have O 
been O 
exposed O 
to O 
pesticides O 
. O 
This O 
raises O 
the O 
question O 
whether O 
pesticides O 
contribute O 
to O 
dementia O 
pathogenesis O 
. O 
Indeed O 
, O 
many O 
studies O 
have O 
found O 
increased O 
prevalence O 
of O 
cognitive O 
, O 
behavioral O 
and O 
psychomotor O 
dysfunction O 
in O 
individuals O 
chronically O 
exposed O 
to O 
pesticides O 
. O 
Furthermore O 
, O 
evidence O 
from O 
recent O 
studies O 
shows O 
a O 
possible O 
association O 
between O 
chronic O 
pesticide O 
exposure O 
and O 
an O 
increased O 
prevalence O 
of O 
dementia O 
, O 
including O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
dementia O 
. O 
At O 
the O 
cellular O 
and O 
molecular O 
level O 
, O 
the O 
mechanism O 
of O 
action O 
of O 
many O 
classes O 
of O 
pesticides O 
suggests O 
that O 
these O 
compounds O 
could O 
be O 
, O 
at O 
least O 
partly O 
, O 
accountable O 
for O 
the O 
neurodegeneration O 
accompanying O 
AD O 
and O 
other O 
dementias O 
. O 
For O 
example O 
, O 
organophosphates B-FAMILY 
, O 
which O 
inhibit O 
acetylcholinesterase O 
as O 
do O 
the O 
drugs O 
used O 
in O 
treating O 
AD O 
symptoms O 
, O 
have O 
also O 
been O 
shown O 
to O 
lead O 
to O 
microtubule O 
derangements O 
and O 
tau O 
hyperphosphorylation O 
, O 
a O 
hallmark O 
of O 
AD O 
. O 
This O 
emerging O 
association O 
is O 
of O 
considerable O 
public O 
health O 
importance O 
, O 
given O 
the O 
increasing O 
dementia O 
prevalence O 
and O 
pesticide O 
use O 
. O 
Here O 
we O 
review O 
the O 
epidemiological O 
links O 
between O 
dementia O 
and O 
pesticide O 
exposure O 
and O 
discuss O 
the O 
possible O 
pathophysiological O 
mechanisms O 
and O 
clinical O 
implications O 
of O 
this O 
association O 
. O 

of O 
the O 
cysteine B-TRIVIAL 
S B-FORMULA 
-conjugate O 
sulfoxides B-FAMILY 
of O 
trichloroethylene B-SYSTEMATIC 
and O 
tetrachloroethylene B-SYSTEMATIC 
in O 
the O 
Ames O 
test O 
. O 

nephrotoxicity O 
and O 
nephrocarcinogenicity O 
of O 
trichloroethylene B-SYSTEMATIC 
( O 
TCE B-ABBREVIATION 
) O 
and O 
tetrachloroethylene B-SYSTEMATIC 
( O 
PCE B-ABBREVIATION 
) O 
are O 
believed O 
to O 
be O 
mediated O 
primarily O 
through O 
the O 
cysteine B-TRIVIAL 
S B-FORMULA 
-conjugate O 
β-lyase- O 
dependent O 
bioactivation O 
of O 
the O 
corresponding O 
cysteine B-TRIVIAL 
S B-FORMULA 
-conjugate O 
metabolites O 
S-(1,2-dichlorovinyl)-l-cysteine B-SYSTEMATIC 
( O 
DCVC B-ABBREVIATION 
) O 
and O 
S-(1,2,2-trichlorovinyl)-l-cysteine B-SYSTEMATIC 
( O 
TCVC B-ABBREVIATION 
) O 
, O 
respectively O 
. O 
DCVC B-ABBREVIATION 
and O 
TCVC B-ABBREVIATION 
have O 
previously O 
been O 
demonstrated O 
to O 
be O 
mutagenic O 
by O 
the O 
Ames O 
Salmonella O 
mutagenicity O 
assay O 
, O 
and O 
reduction O 
in O 
mutagenicity O 
was O 
observed O 
upon O 
treatment O 
with O 
the O 
β-lyase O 
inhibitor O 
aminooxyacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
AOAA B-ABBREVIATION 
) O 
. O 
Because O 
DCVC B-ABBREVIATION 
and O 
TCVC B-ABBREVIATION 
can O 
also O 
be O 
bioactivated O 
through O 
sulfoxidation O 
to O 
yield O 
the O 
potent O 
nephrotoxicants O 
S-(1,2-dichlorovinyl)-l-cysteine B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
( O 
DCVCS B-ABBREVIATION 
) O 
and O 
S-(1,2,2-trichlorovinyl)-l-cysteine B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
( O 
TCVCS B-ABBREVIATION 
) O 
, O 
respectively O 
, O 
the O 
mutagenic O 
potential O 
of O 
these O 
two O 
sulfoxides B-FAMILY 
was O 
investigated O 
using O 
the O 
Ames O 
Salmonella O 
typhimurium O 
TA100 O 
mutagenicity O 
assay O 
. O 
The O 
results O 
show O 
both O 
DCVCS B-ABBREVIATION 
and O 
TCVCS B-ABBREVIATION 
were O 
mutagenic O 
, O 
and O 
TCVCS B-ABBREVIATION 
exhibited O 
3-fold O 
higher O 
mutagenicity O 
than O 
DCVCS B-ABBREVIATION 
. O 
However O 
, O 
DCVCS B-ABBREVIATION 
and O 
TCVCS B-ABBREVIATION 
mutagenic O 
activity O 
was O 
approximately O 
700-fold O 
and O 
30-fold O 
lower O 
than O 
DCVC B-ABBREVIATION 
and O 
TCVC B-ABBREVIATION 
, O 
respectively O 
. O 
DCVC B-ABBREVIATION 
and O 
DCVCS B-ABBREVIATION 
appeared O 
to O 
induce O 
toxicity O 
in O 
TA100 O 
, O 
as O 
evidenced O 
by O 
increased O 
microcolony O 
formation O 
and O 
decreased O 
mutant O 
frequency O 
above O 
threshold O 
concentrations O 
. O 
TCVC B-ABBREVIATION 
and O 
TCVCS B-ABBREVIATION 
were O 
not O 
toxic O 
in O 
TA100 O 
. O 
The O 
toxic O 
effects O 
of O 
DCVC B-ABBREVIATION 
limited O 
the O 
sensitivity O 
of O 
TA100 O 
to O 
DCVC B-ABBREVIATION 
mutagenic O 
effects O 
and O 
rendered O 
it O 
difficult O 
to O 
investigate O 
the O 
effects O 
of O 
AOAA B-ABBREVIATION 
on O 
DCVC B-ABBREVIATION 
mutagenic O 
activity O 
. O 
Collectively O 
, O 
these O 
results O 
suggest O 
that O 
DCVCS B-ABBREVIATION 
and O 
TCVCS B-ABBREVIATION 
exerted O 
a O 
definite O 
but O 
weak O 
mutagenicity O 
in O 
the O 
TA100 O 
strain O 
. O 
Therefore O 
, O 
despite O 
their O 
potent O 
nephrotoxicity O 
, O 
DCVCS B-ABBREVIATION 
and O 
TCVCS B-ABBREVIATION 
are O 
not O 
likely O 
to O 
play O 
a O 
major O 
role O 
in O 
DCVC B-ABBREVIATION 
or O 
TCVC B-ABBREVIATION 
mutagenicity O 
in O 
this O 
strain O 
. O 

synthesis O 
and O 
biological O 
evaluation O 
of O 
indeno[2,1-e]pyrazolo[3,4-b]pyrazin-5-one B-SYSTEMATIC 
and O 
related O 
derivatives O 
. O 

synthesis O 
of O 
indeno[2,1-e]pyrazolo[3,4-b]pyrazin-5-one B-SYSTEMATIC 
was O 
achieved O 
by O 
intramolecular O 
Friedel-Crafts O 
reaction O 
of O 
the O 
acid B-FAMILY 
chloride I-FAMILY 
3-methyl-1,6-diphenyl-1H-pyrazolo[3,4-b] B-SYSTEMATIC 
pyrazine-5-carboxylic I-SYSTEMATIC 
acid I-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
4 O 
) O 
using O 
AlCl3 B-FORMULA 
in O 
boiling O 
CS2 B-FORMULA 
. O 
Compound O 
4 O 
proved O 
to O 
be O 
a O 
versatile O 
compound O 
for O 
the O 
synthesis O 
of O 
several O 
Indenopyrazolopyrazinone B-FAMILY 
derivatives O 
. O 
The O 
antibacterial O 
and O 
antifungal O 
activities O 
of O 
selected O 
derivatives O 
were O 
evaluated O 
. O 

of O 
nanoparticles O 
of O 
TiO2 B-FORMULA 
on O 
food O 
depletion O 
and O 
life O 
- O 
history O 
responses O 
of O 
Daphnia O 
magna O 
. O 

extent O 
to O 
which O 
different O 
forms O 
of O 
nanoparticles O 
of O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
nano- O 
TiO2 B-FORMULA 
) O 
aggregated O 
with O 
microalgae O 
, O 
decreased O 
food O 
levels O 
and O 
hence O 
impaired O 
growth O 
, O 
reproduction O 
and O 
fitness O 
of O 
Daphnia O 
magna O 
individuals O 
were O 
studied O 
. O 
Treatments O 
included O 
three O 
different O 
types O 
of O 
nano- O 
TiO2 B-FORMULA 
differing O 
in O 
their O 
coating O 
or O 
crystalline O 
structure O 
but O 
of O 
similar O 
primary O 
size O 
( O 
20 O 
nm O 
) O 
plus O 
a O 
micron O 
- O 
sized O 
bulk O 
material O 
, O 
two O 
exposure O 
levels O 
( O 
1 O 
, O 
10mg O 
/ O 
l O 
) O 
and O 
two O 
food O 
ration O 
levels O 
of O 
the O 
microalgae O 
Chlorella O 
vulgaris O 
that O 
included O 
a O 
non O 
limiting O 
( O 
1.5 O 
μgC O 
/ O 
ml O 
) O 
and O 
a O 
limiting O 
one O 
( O 
0.3 O 
μgC O 
/ O 
ml O 
) O 
. O 
Effects O 
were O 
assessed O 
using O 
standardized O 
chronic O 
tests O 
and O 
assays O 
that O 
maximized O 
food O 
depletion O 
in O 
the O 
water O 
column O 
under O 
semi-static O 
and O 
re O 
- O 
suspension O 
conditions O 
. O 
Results O 
indicated O 
that O 
the O 
high O 
ion O 
levels O 
in O 
culture O 
medium O 
lead O 
to O 
the O 
aggregation O 
of O 
nanoparticles O 
followed O 
by O 
particle O 
destabilization O 
. O 
Nanoparticle O 
aggregates O 
interacted O 
with O 
the O 
algae O 
cells O 
, O 
forming O 
clusters O 
. O 
Large O 
TiO2 B-FORMULA 
-algae O 
agglomerates O 
settled O 
readily O 
dramatically O 
depleting O 
the O 
concentration O 
of O 
available O 
food O 
for O 
D O 
. O 
magna O 
. O 
At O 
limiting O 
food O 
rations O 
food O 
depletion O 
by O 
nanoparticle O 
aggregation O 
had O 
dramatic O 
effects O 
on O 
reproduction O 
and O 
fitness O 
of O 
exposed O 
D O 
. O 
magna O 
at O 
1mg O 
/ O 
l O 
irrespectively O 
of O 
the O 
particle O 
form O 
. O 
At O 
high O 
food O 
rations O 
effects O 
were O 
only O 
observed O 
for O 
one O 
of O 
the O 
nano- O 
TiO2 B-FORMULA 
, O 
P-25 B-NO_CLASS 
, O 
at O 
high O 
exposure O 
levels O 
( O 
10 O 
mg O 
/ O 
l O 
) O 
under O 
both O 
semi-static O 
and O 
particle O 
re O 
- O 
suspension O 
conditions O 
, O 
which O 
suggest O 
that O 
P-25 B-NO_CLASS 
effects O 
were O 
mediated O 
by O 
clogging O 
the O 
gut O 
and O 
hence O 
diminishing O 
food O 
acquisition O 
. O 
These O 
results O 
indicate O 
that O 
nano- O 
TiO2 B-FORMULA 
may O 
affect O 
the O 
transfer O 
of O 
energy O 
throughout O 
the O 
planktonic O 
aquatic O 
food O 
webs O 
increasing O 
the O 
settlement O 
of O 
edible O 
particles O 
from O 
the O 
water O 
column O 
. O 

laboratory O 
based O 
studies O 
have O 
shown O 
that O 
oil O 
sands O 
process O 
- O 
affected O 
waters O 
( O 
OSPWs O 
) O 
containing O 
high O 
concentrations O 
of O 
naphthenic B-FAMILY 
acids I-FAMILY 
( O 
> O 
25 O 
mg O 
/ O 
l O 
) O 
have O 
adverse O 
effects O 
on O 
the O 
reproductive O 
physiology O 
of O 
fish O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
assess O 
the O 
reproductive O 
development O 
and O 
health O 
of O 
a O 
wild O 
population O 
of O 
fathead O 
minnows O 
( O 
Pimephales O 
promelas O 
) O 
inhabiting O 
an O 
OSPW O 
pond O 
that O 
has O 
moderate O 
concentrations O 
of O 
naphthenic B-FAMILY 
acids I-FAMILY 
( O 
~10 O 
mg O 
/ O 
l O 
) O 
. O 
Fathead O 
minnows O 
were O 
collected O 
at O 
various O 
times O 
during O 
the O 
period O 
of O 
2006 O 
through O 
2008 O 
from O 
Demonstration O 
Pond O 
( O 
OSPW O 
) O 
located O 
at O 
Syncrude O 
Canada O 
Ltd O 
. O 
, O 
and O 
two O 
reference O 
sites O 
, O 
Beaver O 
Creek O 
reservoir O 
and O 
Poplar O 
Creek O 
reservoir O 
, O 
which O 
are O 
all O 
north O 
of O 
Fort O 
McMurray O 
, O 
AB O 
, O 
Canada O 
. O 
Condition O 
factor O 
, O 
gill O 
histopathology O 
, O 
gonadosomatic O 
indices O 
, O 
liver O 
somatic O 
indices O 
, O 
male O 
secondary O 
sexual O 
characteristics O 
, O 
and O 
plasma O 
sex O 
steroids B-FAMILY 
were O 
examined O 
. O 
Depending O 
on O 
the O 
time O 
of O 
year O 
that O 
fathead O 
minnows O 
were O 
collected O 
, O 
there O 
were O 
differences O 
in O 
the O 
condition O 
factor O 
, O 
gonadosomatic O 
indices O 
, O 
liver O 
somatic O 
indices O 
, O 
and O 
secondary O 
sexual O 
characteristics O 
of O 
fathead O 
minnows O 
( O 
in O 
males O 
) O 
from O 
Demonstration O 
Pond O 
when O 
compared O 
to O 
the O 
fathead O 
minnows O 
from O 
the O 
reference O 
sites O 
. O 
In O 
comparison O 
to O 
reference O 
fish O 
, O 
lower O 
concentrations O 
of O 
11-ketotestosterone B-SYSTEMATIC 
were O 
measured O 
in O 
the O 
plasma O 
of O 
male O 
fathead O 
minnows O 
collected O 
from O 
Demonstration O 
Pond O 
in O 
June O 
2006 O 
and O 
July O 
2007 O 
. O 
Black O 
spot O 
disease O 
and O 
Ligula O 
intestinalis O 
were O 
prevalent O 
in O 
fathead O 
minnows O 
from O 
the O 
reference O 
sites O 
but O 
were O 
not O 
observed O 
in O 
fathead O 
minnows O 
from O 
Demonstration O 
Pond O 
. O 
The O 
opercula O 
of O 
fathead O 
minnows O 
from O 
Demonstration O 
Pond O 
also O 
differed O 
from O 
those O 
of O 
reference O 
fish O 
. O 
An O 
examination O 
of O 
the O 
gills O 
of O 
fathead O 
minnows O 
from O 
Demonstration O 
Pond O 
revealed O 
that O 
were O 
a O 
number O 
of O 
proliferative O 
and O 
degenerative O 
alterations O 
relative O 
to O 
reference O 
fish O 
. O 
Even O 
though O 
the O 
fathead O 
minnow O 
population O 
has O 
been O 
maintained O 
in O 
this O 
OSPW O 
pond O 
since O 
1993 O 
, O 
the O 
results O 
of O 
this O 
study O 
demonstrate O 
that O 
the O 
OSPW O 
continues O 
to O 
affect O 
the O 
reproductive O 
development O 
and O 
health O 
of O 
the O 
fathead O 
minnows O 
compared O 
to O 
fish O 
collected O 
at O 
reference O 
sites O 
. O 

correlated O 
SERS O 
measurements O 
with O 
scanning O 
electron O 
microscopy O 
: O 
an O 
assessment O 
of O 
the O 
problem O 
arising O 
from O 
the O 
deposition O 
of O 
amorphous O 
carbon B-SYSTEMATIC 
. O 

surface O 
- O 
enhanced O 
Raman O 
scattering O 
( O 
SERS O 
) O 
substrates O 
with O 
nonspherical O 
symmetry O 
, O 
it O 
is O 
critical O 
to O 
correlate O 
spectroscopy O 
measurements O 
with O 
imaging O 
by O 
scanning O 
electron O 
microscopy O 
( O 
SEM O 
) O 
. O 
However O 
, O 
the O 
deposition O 
of O 
carbon B-SYSTEMATIC 
resulting O 
from O 
e-beam O 
exposure O 
during O 
SEM O 
imaging O 
contaminates O 
the O 
surface O 
of O 
nanoparticles O 
, O 
potentially O 
preventing O 
their O 
further O 
functionalization O 
with O 
Raman O 
probe O 
molecules O 
. O 
In O 
addition O 
, O 
the O 
deposited O 
carbon B-SYSTEMATIC 
leads O 
to O 
unwanted O 
background O 
SERS O 
signals O 
. O 
In O 
this O 
study O 
, O 
we O 
systematically O 
investigated O 
the O 
deposition O 
of O 
carbon B-SYSTEMATIC 
during O 
SEM O 
imaging O 
and O 
examined O 
how O 
it O 
affects O 
the O 
functionalization O 
of O 
nanoparticles O 
with O 
probe O 
molecules O 
and O 
impacts O 
the O 
detection O 
of O 
SERS O 
signals O 
. O 
Significantly O 
, O 
we O 
found O 
that O 
the O 
carbon B-SYSTEMATIC 
could O 
be O 
removed O 
or O 
replaced O 
from O 
the O 
surface O 
of O 
Ag B-FORMULA 
nanoparticles O 
through O 
chemical O 
or O 
physical O 
means O 
, O 
rendering O 
the O 
nanoparticles O 
the O 
capability O 
for O 
correlated O 
SEM O 
/ O 
SERS O 
studies O 
. O 

scat O 
namely O 
as O 
Scatophagus O 
argus O 
is O 
a O 
venomous O 
aquarium O 
fish O 
belonging O 
to O 
Scatophagidae O 
family O 
. O 
It O 
can O 
induce O 
painful O 
wounds O 
in O 
injured O 
hand O 
with O 
partial O 
paralysis O 
to O 
whom O 
that O 
touch O 
the O 
spines O 
. O 
Dorsal O 
and O 
ventral O 
rough O 
spines O 
contain O 
cells O 
that O 
produce O 
venom O 
with O 
toxic O 
activities O 
. O 
According O 
to O 
unpublished O 
data O 
collected O 
from O 
local O 
hospitals O 
in O 
southern O 
coastal O 
region O 
of O 
Iran O 
, O 
S O 
. O 
argus O 
is O 
reported O 
as O 
a O 
venomous O 
fish O 
. O 
Envenomation O 
induces O 
clinical O 
symptoms O 
such O 
as O 
local O 
pain O 
, O 
partial O 
paralysis O 
, O 
erythema O 
and O 
itching O 
. O 
In O 
the O 
present O 
study O 
green O 
scat O 
( O 
spotted O 
scat O 
) O 
was O 
collected O 
from O 
Persian O 
Gulf O 
coastal O 
waters O 
. O 
SDS B-ABBREVIATION 
-PAGE O 
indicated O 
12 O 
distinct O 
bands O 
in O 
the O 
venom O 
ranged O 
between O 
7 O 
and O 
250 O 
kDa O 
. O 
The O 
crude O 
venom O 
had O 
hemolytic O 
activity O 
on O 
human O 
erythrocytes O 
( O 
1% O 
) O 
with O 
an O 
LC100 O 
( O 
Lytic O 
Concentration O 
) O 
of O 
about O 
1.7 O 
μg O 
. O 
The O 
crude O 
venom O 
can O 
release O 
813 O 
μg O 
protein O 
from O 
0.5% O 
casein O 
. O 
Phospholipase O 
C O 
activity O 
was O 
recorded O 
at O 
3.125 O 
μg O 
of O 
total O 
venom O 
. O 
Our O 
findings O 
showed O 
that O 
the O 
edematic O 
activity O 
remained O 
over O 
24 O 
h O 
after O 
injection O 
. O 
The O 
results O 
demonstrated O 
that O 
crude O 
venom O 
extracted O 
from O 
Iranian O 
coastal O 
border O 
has O 
different O 
toxic O 
and O 
enzymatic O 
activities O 
. O 
This O 
study O 
is O 
pending O 
to O 
further O 
investigation O 
on O 
animal O 
model O 
regarding O 
protein O 
purification O 
and O 
in O 
vivo O 
studies O 
. O 

evaluation O 
of O 
the O 
serotonin B-TRIVIAL 
system O 
and O 
perseverative O 
, O 
compulsive O 
, O 
stereotypical O 
, O 
and O 
hyperactive O 
behaviors O 
in O 
dopamine B-TRIVIAL 
transporter O 
( O 
DAT O 
) O 
knockout O 
mice O 
. O 

: O 
Mice O 
lacking O 
the O 
dopamine B-TRIVIAL 
transporter O 
( O 
DAT O 
) O 
display O 
major O 
behavioral O 
alterations O 
that O 
include O 
hyperactivity O 
, O 
perseverative O 
locomotor O 
patterns O 
, O 
and O 
reduced O 
prepulse O 
inhibition O 
of O 
the O 
acoustic O 
startle O 
reflex O 
. O 
OBJECTIVES O 
: O 
The O 
objectives O 
of O 
this O 
study O 
were O 
to O 
investigate O 
perseverative O 
, O 
compulsive O 
, O 
stereotypical O 
, O 
and O 
hyperactive O 
behaviors O 
, O 
as O 
well O 
as O 
serotonin B-TRIVIAL 
and O 
its O 
involvement O 
with O 
these O 
behaviors O 
, O 
in O 
DAT O 
gene O 
- O 
altered O 
mice O 
. O 
RESULTS O 
: O 
In O 
the O 
open O 
field O 
, O 
mean O 
turn O 
angle O 
and O 
meandering O 
were O 
decreased O 
in O 
DAT O 
knockout O 
( O 
DAT-KO O 
) O 
mice O 
. O 
DAT-KO O 
mice O 
displayed O 
increased O 
hyperactivity O 
, O 
increased O 
velocity O 
, O 
less O 
time O 
immobile O 
, O 
and O 
a O 
failure O 
to O 
habituate O 
over O 
time O 
in O 
the O 
open O 
field O 
unlike O 
their O 
DAT O 
wildtype O 
( O 
DAT-WT O 
) O 
and O 
heterozygous O 
( O 
DAT-HET O 
) O 
littermates O 
. O 
DAT-KO O 
mice O 
buried O 
fewer O 
marbles O 
than O 
DAT-WT O 
and O 
-HET O 
mice O 
in O 
an O 
assessment O 
of O 
compulsive O 
- O 
like O 
behaviors O 
, O 
likely O 
due O 
to O 
extreme O 
hyperactivity O 
and O 
related O 
inattention O 
. O 
Stereotypical O 
head O 
weaving O 
was O 
increased O 
in O 
untreated O 
DAT-KO O 
mice O 
. O 
Following O 
administration O 
of O 
the O 
5-HT B-SYSTEMATIC 
( O 
1A O 
/ O 
7 O 
) O 
agonist O 
8-hydroxy-2-(di-n-propylamino)tetralin B-SYSTEMATIC 
( O 
8-OH-DPAT B-SYSTEMATIC 
) O 
, O 
stereotypical O 
head O 
weaving O 
and O 
forepaw O 
treading O 
were O 
increased O 
more O 
in O 
DAT-KO O 
mice O 
than O 
in O 
DAT-WT O 
or O 
-HET O 
mice O 
. O 
By O 
contrast O 
, O 
head O 
twitches O 
induced O 
by O 
treatment O 
with O 
the O 
5-HT B-SYSTEMATIC 
( O 
2A O 
/ O 
2C O 
) O 
agonist O 
(±)-2,5-dimethoxy-4-iodophenyl-2-aminopropane B-SYSTEMATIC 
( O 
DOI B-ABBREVIATION 
) O 
were O 
similar O 
in O 
mice O 
of O 
all O 
three O 
DAT O 
genotypes O 
. O 
5-HT B-SYSTEMATIC 
( O 
1A O 
) O 
autoreceptor O 
function O 
was O 
intact O 
in O 
DAT-KO O 
mice O 
. O 
Compared O 
to O 
DAT-WT O 
mice O 
, O 
serotonin B-TRIVIAL 
levels O 
were O 
increased O 
in O 
DAT-HET O 
and O 
-KO O 
mice O 
in O 
frontal O 
cortex O 
and O 
hippocampus O 
, O 
respectively O 
, O 
and O 
serotonin O 
turnover O 
rates O 
were O 
increased O 
∼30 O 
% O 
in O 
the O 
striatum O 
of O 
DAT-KO O 
mice O 
. O 
CONCLUSIONS O 
: O 
These O 
findings O 
extend O 
and O 
confirm O 
prior O 
behavioral O 
and O 
biochemical O 
characterization O 
of O 
DAT-KO O 
mice O 
. O 
Hyperactivity O 
, O 
stereotypy O 
, O 
and O 
perseverative O 
behaviors O 
are O 
increased O 
in O 
these O 
mice O 
, O 
with O 
brain O 
- O 
area O 
specific O 
increases O 
in O 
serotonin B-TRIVIAL 
levels O 
and O 
serotonin B-TRIVIAL 
turnover O 
, O 
and O 
marked O 
increases O 
in O 
postsynaptic O 
5-HT B-SYSTEMATIC 
( O 
1A O 
) O 
receptor O 
- O 
mediated O 
stereotypic O 
responses O 
. O 

dots O 
exhibit O 
less O 
bioaccumulation O 
than O 
free O 
cadmium B-SYSTEMATIC 
and O 
selenium B-SYSTEMATIC 
in O 
the O 
earthworm O 
Eisenia O 
andrei O 
. O 

present O 
study O 
addresses O 
the O 
bioaccumulation O 
behavior O 
of O 
cadmium B-SYSTEMATIC 
selenide I-SYSTEMATIC 
quantum O 
dots O 
by O 
Eisenia O 
andrei O 
earthworms O 
in O 
a O 
terrestrial O 
environment O 
. O 
Earthworms O 
were O 
exposed O 
to O 
quantum O 
dot O 
- O 
treated O 
soil O 
for O 
up O 
to O 
4 O 
wk O 
and O 
analyzed O 
for O 
cadmium B-SYSTEMATIC 
and O 
selenium B-SYSTEMATIC 
concentration O 
using O 
inductively O 
coupled O 
plasma O 
mass O 
spectrometry O 
. O 
Results O 
were O 
compared O 
with O 
those O 
from O 
earthworms O 
exposed O 
to O 
cadmium B-SYSTEMATIC 
nitrate I-SYSTEMATIC 
and O 
selenious B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
as O 
positive O 
controls O 
, O 
and O 
those O 
exposed O 
in O 
untreated O 
soil O 
( O 
negative O 
control O 
) O 
. O 
Earthworms O 
exposed O 
to O 
quantum O 
dots O 
showed O 
significant O 
bioaccumulation O 
of O 
cadmium B-SYSTEMATIC 
and O 
selenium B-SYSTEMATIC 
( O 
5.3- O 
and O 
1.5-fold O 
higher O 
concentration O 
over O 
negative O 
controls O 
, O 
respectively O 
) O 
after O 
4 O 
wk O 
. O 
Over O 
the O 
same O 
4 O 
wk O 
, O 
positive O 
control O 
earthworms O 
accumulated O 
9.2- O 
and O 
2.2-fold O 
higher O 
cadmium B-SYSTEMATIC 
and O 
selenium B-SYSTEMATIC 
, O 
respectively O 
, O 
than O 
negative O 
controls O 
for O 
a O 
much O 
more O 
substantial O 
final O 
body O 
burden O 
of O 
the O 
2 O 
elements O 
. O 
The O 
concentrations O 
also O 
increased O 
with O 
exposure O 
time O 
; O 
cadmium B-SYSTEMATIC 
concentrations O 
increased O 
from O 
3600 O 
± O 
310 O 
ng O 
/ O 
g O 
to O 
8080 O 
± O 
660 O 
ng O 
/ O 
g O 
, O 
from O 
1 O 
to O 
4 O 
wk O 
, O 
suggesting O 
that O 
further O 
bioaccumulation O 
may O 
take O 
place O 
with O 
even O 
longer O 
exposure O 
time O 
. O 
The O 
molar O 
ratio O 
of O 
cadmium B-SYSTEMATIC 
to O 
selenium B-SYSTEMATIC 
in O 
the O 
quantum O 
dot O 
- O 
exposed O 
worms O 
( O 
6.2 O 
) O 
is O 
closer O 
to O 
the O 
ratios O 
seen O 
in O 
positive O 
control O 
worms O 
( O 
7.2 O 
) O 
than O 
to O 
the O 
pure O 
quantum O 
dots O 
( O 
1.8 O 
) O 
, O 
which O 
implies O 
that O 
quantum O 
dots O 
are O 
taken O 
up O 
predominantly O 
in O 
the O 
degraded O 
form O 
. O 
The O 
results O 
suggest O 
that O 
chemical O 
modification O 
of O 
quantum O 
dots O 
to O 
protect O 
them O 
from O 
environmental O 
degradation O 
could O 
potentially O 
reduce O 
bioaccumulation O 
of O 
the O 
nanoparticles O 
by O 
earthworms O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1288-1294 O 
. O 
© O 
2013 O 
SETAC O 
. O 

advances O 
in O 
molecular O 
organic O 
photovoltaics O 
( O 
OPVs O 
) O 
have O 
shown O 
10% O 
power O 
conversion O 
efficiency O 
( O 
PCE O 
) O 
for O 
single O 
- O 
junction O 
cells O 
, O 
which O 
put O 
them O 
in O 
direct O 
competition O 
with O 
PVs O 
based O 
on O 
amorphous O 
silicon B-SYSTEMATIC 
. O 
Incorporation O 
of O 
plasmonic O 
nanostructures O 
for O 
light O 
trapping O 
in O 
these O 
thin O 
- O 
film O 
devices O 
offers O 
an O 
attractive O 
solution O 
to O 
realize O 
higher O 
- O 
efficiency O 
OPVs O 
with O 
PCE≫10% O 
. O 
This O 
article O 
reviews O 
recent O 
progress O 
on O 
plasmonic O 
- O 
enhanced O 
OPV O 
devices O 
using O 
metallic O 
nanoparticles O 
, O 
and O 
one O 
- O 
dimensional O 
( O 
1D O 
) O 
and O 
two O 
- O 
dimensional O 
( O 
2D O 
) O 
patterned O 
periodic O 
nanostructures O 
. O 
We O 
discuss O 
the O 
benefits O 
of O 
using O 
various O 
plasmonic O 
nanostructures O 
for O 
broad O 
- O 
band O 
, O 
polarization O 
- O 
insensitive O 
and O 
angle O 
- O 
independent O 
absorption O 
enhancement O 
, O 
and O 
their O 
integration O 
with O 
one O 
or O 
two O 
electrode(s) O 
of O 
an O 
OPV O 
device O 
. O 

the O 
Stability O 
of O 
Graphene B-TRIVIAL 
Layers O 
by O 
Phthalocyanine B-TRIVIAL 
-Based O 
oPPV O 
Oligomers O 
Towards O 
Photo- O 
and O 
Redoxactive O 
Materials O 
. O 

contrast O 
to O 
pristine O 
zinc B-SYSTEMATIC 
phthalocyanine I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
zinc B-SYSTEMATIC 
phthalocyanine I-SYSTEMATIC 
based O 
oPPV B-ABBREVIATION 
-oligomers O 
( O 
2-4 O 
) O 
of O 
different O 
chain O 
lengths O 
interact O 
tightly O 
and O 
reversibly O 
with O 
graphite B-TRIVIAL 
, O 
affording O 
stable O 
and O 
finely O 
dispersed O 
suspensions O 
of O 
mono- O 
to O 
few O 
- O 
layer O 
graphene B-TRIVIAL 
-nanographene O 
(NG)-that O 
are O 
photoactive O 
. O 
The O 
p- O 
type O 
character O 
of O 
the O 
oPPV O 
backbones O 
and O 
the O 
increasing O 
length O 
of O 
the O 
oPPV O 
backbones O 
facilitate O 
the O 
overall O 
π-π O 
interactions O 
with O 
the O 
graphene B-TRIVIAL 
layers O 
. O 
In O 
NG O 
/ O 
2 O 
, O 
NG O 
/ O 
3 O 
, O 
and O 
NG O 
/ O 
4 O 
hybrids O 
, O 
strong O 
electronic O 
coupling O 
between O 
the O 
individual O 
components O 
gives O 
rise O 
to O 
charge O 
transfer O 
from O 
the O 
photoexcited O 
zinc B-FAMILY 
phthalocyanines I-FAMILY 
to O 
NG O 
to O 
form O 
hundreds O 
of O 
picoseconds O 
lived O 
charge O 
transfer O 
states O 
. O 
The O 
resulting O 
features O 
, O 
namely O 
photo- O 
and O 
redoxactivity O 
, O 
serve O 
as O 
incentives O 
to O 
construct O 
and O 
to O 
test O 
novel O 
solar O 
cells O 
. O 
Solar O 
cells O 
made O 
out O 
of O 
NG O 
/ O 
4 O 
feature O 
stable O 
and O 
repeatable O 
photocurrent O 
generation O 
during O 
several O 
' O 
on O 
- O 
off O 
' O 
cycles O 
of O 
illumination O 
with O 
monochromatic O 
IPCE O 
values O 
of O 
around O 
1% O 
. O 

and O 
Superoleophilic O 
PVDF B-ABBREVIATION 
Membranes O 
for O 
Effective O 
Separation O 
of O 
Water-in-Oil O 
Emulsions O 
with O 
High O 
Flux O 
. O 

and O 
highly O 
compressible O 
graphene B-TRIVIAL 
aerogels O 
. O 

converted O 
graphene B-TRIVIAL 
aerogels O 
with O 
ultralight O 
density O 
and O 
high O 
compressibility O 
are O 
prepared O 
by O 
diamine B-SYSTEMATIC 
-mediated O 
functionalization O 
and O 
assembly O 
, O 
followed O 
by O 
microwave O 
irradiation O 
. O 
The O 
resulting O 
graphene B-TRIVIAL 
aerogels O 
with O 
density O 
as O 
low O 
as O 
3 O 
mg O 
cm(-3) O 
show O 
excellent O 
resilience O 
and O 
can O 
completely O 
recover O 
after O 
more O 
than O 
90% O 
compression O 
. O 
The O 
ultralight O 
graphene B-TRIVIAL 
aerogels O 
possessing O 
high O 
elasticity O 
are O 
promising O 
as O 
compliant O 
and O 
energy O 
- O 
absorbing O 
materials O 
. O 

arborescens O 
Miller O 
, O 
belonging O 
to O 
the O 
Aloe O 
genus O 
( O 
Liliaceae O 
family O 
) O 
, O 
is O 
one O 
of O 
the O 
main O 
varieties O 
of O 
Aloe O 
used O 
worldwide O 
. O 
Although O 
less O 
characterized O 
than O 
the O 
commonest O 
Aloe O 
vera O 
, O 
Aloe O 
arborescens O 
is O 
known O 
to O 
be O 
richer O 
in O 
beneficial O 
phytotherapeutic O 
, O 
anticancer O 
, O 
and O 
radio O 
- O 
protective O 
properties O 
. O 
It O 
is O 
commonly O 
used O 
as O 
a O 
pharmaceutical O 
ingredient O 
for O 
its O 
effect O 
in O 
burn O 
treatment O 
and O 
ability O 
to O 
increase O 
skin O 
wound O 
healing O 
properties O 
. O 
However O 
, O 
very O 
few O 
studies O 
have O 
addressed O 
the O 
biological O 
effects O 
of O 
Aloe O 
at O 
molecular O 
level O 
. O 
The O 
aim O 
of O 
the O 
research O 
is O 
to O 
provide O 
evidences O 
for O 
the O 
antiproliferative O 
properties O 
of O 
Aloe O 
arborescens O 
crude O 
leaf O 
extract O 
using O 
an O 
integrated O 
proteomic O 
and O 
cellular O 
biological O 
approach O 
. O 
We O 
analysed O 
the O 
composition O 
of O 
an O 
Aloe O 
arborescens O 
leaf O 
extract O 
by O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
analysis O 
. O 
We O 
found O 
it O 
rich O 
in O 
Aloe- O 
emodin B-TRIVIAL 
, O 
a O 
hydroxylanthraquinone B-SYSTEMATIC 
with O 
known O 
antitumoral O 
activity O 
and O 
in O 
several O 
compounds O 
with O 
anti-oxidant O 
properties O 
. O 
Accordingly O 
, O 
we O 
show O 
that O 
the O 
Aloe O 
extract O 
has O 
antiproliferative O 
effects O 
on O 
several O 
human O 
transformed O 
cell O 
lines O 
and O 
exhibits O 
prodifferentiative O 
effects O 
on O 
both O 
primary O 
and O 
immortalized O 
human O 
keratinocyte O 
. O 
Proteomic O 
analysis O 
of O 
whole O 
cell O 
extracts O 
revealed O 
the O 
presence O 
of O 
proteins O 
with O 
a O 
strong O 
antiproliferative O 
and O 
antimicrobial O 
activity O 
specifically O 
induced O 
in O 
human O 
keratinocytes O 
by O 
Aloe O 
treatment O 
supporting O 
its O 
application O 
as O 
a O 
therapeutical O 
agent O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

and O 
apoptosis O 
- O 
inducing O 
activities O 
of O 
steviol B-TRIVIAL 
and O 
isosteviol B-TRIVIAL 
derivatives O 
against O 
human O 
cancer O 
cell O 
lines O 
. O 

steviol B-TRIVIAL 
derivatives O 
, O 
i.e O 
. O 
, O 
2-18 O 
, O 
and O 
19 O 
isosteviol B-TRIVIAL 
derivatives O 
, O 
i.e O 
. O 
, O 
19-37 O 
, O 
were O 
prepared O 
from O 
a O 
diterpenoid B-FAMILY 
glycoside I-FAMILY 
, O 
stevioside B-TRIVIAL 
( O 
1 O 
) O 
. O 
Upon O 
evaluation O 
of O 
the O 
cytotoxic O 
activities O 
of O 
these O 
compounds O 
against O 
leukemia O 
( O 
HL60 O 
) O 
, O 
lung O 
( O 
A549 O 
) O 
, O 
stomach O 
( O 
AZ521 O 
) O 
, O 
and O 
breast O 
( O 
SK-BR-3 O 
) O 
cancer O 
cell O 
lines O 
, O 
nine O 
steviol B-TRIVIAL 
derivatives O 
, O 
i.e O 
. O 
, O 
5-9 O 
and O 
11-14 O 
, O 
and O 
five O 
isosteviol B-TRIVIAL 
derivatives O 
, O 
i.e O 
. O 
, O 
28-32 O 
, O 
exhibited O 
activities O 
with O 
single O 
- O 
digit O 
micromolar O 
IC(50) O 
values O 
against O 
one O 
or O 
more O 
cell O 
lines O 
. O 
All O 
of O 
these O 
active O 
compounds O 
possess O 
C(19)- O 
O-acyl B-FAMILY 
group O 
, O 
and O 
among O 
which O 
, O 
ent-kaur-16-ene-13,19-diol B-SYSTEMATIC 
19-O-4',4',4'-trifluorocrotonate I-SYSTEMATIC 
( O 
14 O 
) O 
exhibited O 
potent O 
cytotoxicities O 
against O 
four O 
cell O 
lines O 
with O 
IC(50) O 
values O 
in O 
the O 
range O 
of O 
1.2-4.1 O 
μM O 
. O 
Compound O 
14 O 
induced O 
typical O 
apoptotic O 
cell O 
death O 
in O 
HL60 O 
cells O 
upon O 
evaluation O 
of O 
the O 
apoptosis O 
- O 
inducing O 
activity O 
by O 
flow O 
- O 
cytometric O 
analysis O 
. O 
These O 
results O 
suggested O 
that O 
acylation O 
of O 
the O 
19- O 
OH B-FORMULA 
group O 
of O 
kaurane B-TRIVIAL 
- O 
and O 
beyerane B-TRIVIAL 
-type O 
diterpenoids B-FAMILY 
might O 
be O 
useful O 
for O 
enhancement O 
of O 
their O 
cytotoxicities O 
with O 
apoptosis O 
- O 
inducing O 
activity O 
. O 

sumatrensis O 
( O 
Retz O 
. O 
) O 
E.WALKER O 
( O 
Asteraceae O 
) O 
is O 
a O 
spontaneous O 
annual O 
herb O 
, O 
fairly O 
widespread O 
throughout O 
Tunisia O 
, O 
which O 
has O 
rarely O 
been O 
studied O 
or O 
valued O 
in O 
any O 
sector O 
. O 
Essential O 
oils O 
were O 
obtained O 
by O 
hydrodistillation O 
of O 
different O 
parts O 
( O 
flower O 
heads O 
, O 
leaves O 
, O 
stems O 
, O 
and O 
roots O 
) O 
of O 
C O 
. O 
sumatrensis O 
plants O 
, O 
which O 
were O 
collected O 
in O 
autumn O 
( O 
November O 
2007 O 
) O 
at O 
the O 
flowering O 
stage O 
in O 
the O 
area O 
of O 
Monastir O 
, O 
Tunisia O 
. O 
In O 
total O 
, O 
98 O 
compounds O 
, O 
representing O 
88.1-99.3% O 
of O 
the O 
oil O 
composition O 
, O 
were O 
identified O 
by O 
GC-FID O 
and O 
GC O 
/ O 
MS O 
analyses O 
. O 
The O 
root O 
essential O 
oil O 
was O 
distinguished O 
by O 
its O 
high O 
content O 
in O 
acetylenes B-FAMILY 
( O 
matricaria B-TRIVIAL 
ester I-TRIVIAL 
, O 
4 O 
; O 
74.3% O 
) O 
, O 
while O 
those O 
from O 
flower O 
heads O 
and O 
leaves O 
were O 
dominated O 
by O 
oxygenated O 
sesquiterpenes B-FAMILY 
( O 
61.1 O 
and O 
50.3% O 
, O 
resp O 
. O 
) O 
. O 
The O 
oils O 
of O 
C O 
. O 
sumatrensis O 
from O 
Tunisia O 
belonged O 
to O 
a O 
matricaria B-TRIVIAL 
ester I-TRIVIAL 
/ O 
caryophyllene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
chemotype O 
. O 
All O 
the O 
oils O 
were O 
evaluated O 
for O 
antibacterial O 
, O 
antifungal O 
, O 
and O 
allelopathic O 
activities O 
. O 
The O 
results O 
indicate O 
that O 
the O 
leaf O 
oil O 
exhibited O 
significant O 
in O 
vitro O 
antibacterial O 
activity O 
against O 
Enterococcus O 
faecalis O 
, O 
Staphylococcus O 
aureus O 
, O 
and O 
Proteus O 
mirabilis O 
and O 
that O 
the O 
C O 
. O 
sumatrensis O 
oils O 
isolated O 
from O 
the O 
aerial O 
parts O 
presented O 
high O 
mycelia O 
- O 
growth O 
inhibition O 
of O 
Candida O 
albicans O 
and O 
the O 
filamentous O 
fungi O 
tested O 
. O 
Moreover O 
, O 
the O 
essential O 
oils O 
of O 
the O 
different O 
plant O 
parts O 
inhibited O 
the O 
shoot O 
and O 
root O 
growth O 
of O 
Raphanus O 
sativus O 
( O 
radish O 
) O 
seedlings O 
. O 
Indeed O 
, O 
the O 
inhibition O 
of O 
the O 
hypocotyl O 
growth O 
varied O 
from O 
28.6 O 
to O 
90.1% O 
and O 
that O 
of O 
the O 
radicle O 
from O 
42.3 O 
to O 
96.2% O 
. O 

N B-FORMULA 
-oxidation O 
by O 
CYP2E1 O 
in O 
human O 
liver O 
microsomes O 
. O 

nicotinamide B-TRIVIAL 
, O 
a O 
form O 
of O 
vitamin B-TRIVIAL 
B(3) I-TRIVIAL 
, O 
is O 
metabolized O 
through O 
two O 
enzymatic O 
systems O 
and O 
eventually O 
excreted O 
from O 
the O 
body O 
. O 
The O 
first O 
system O 
starts O 
with O 
the O 
methylation O 
of O 
nicotinamide B-TRIVIAL 
by O 
nicotinamide B-TRIVIAL 
N B-FORMULA 
-methyltransferase O 
, O 
which O 
can O 
subsequently O 
be O 
oxidized O 
by O 
aldehyde B-SYSTEMATIC 
oxidase O 
. O 
The O 
second O 
enzymatic O 
system O 
oxidizes O 
nicotinamide B-TRIVIAL 
to O 
nicotinamide B-SYSTEMATIC 
N-oxide I-SYSTEMATIC 
. O 
It O 
is O 
located O 
in O 
the O 
endoplasmic O 
reticulum O 
of O 
hepatocytes O 
but O 
the O 
precise O 
enzyme O 
is O 
unknown O 
. O 
We O 
have O 
used O 
human O 
liver O 
microsomes O 
in O 
combination O 
with O 
selective O 
cytochrome O 
P450 O 
inhibitors O 
, O 
specific O 
substrates O 
, O 
and O 
antibodies O 
to O 
identify O 
CYP2E1 O 
as O 
the O 
main O 
activity O 
producing O 
nicotinamide B-SYSTEMATIC 
N-oxide I-SYSTEMATIC 
. O 
Our O 
results O 
suggest O 
the O 
potential O 
use O 
of O 
nicotinamide B-SYSTEMATIC 
N-oxide I-SYSTEMATIC 
as O 
a O 
biomarker O 
of O 
CYP2E1 O 
activity O 
from O 
urine O 
or O 
blood O 
samples O 
. O 

response O 
of O 
individual O 
Au-Ag B-FORMULA 
@ O 
SiO₂ B-FORMULA 
heterodimers O 
. O 

optical O 
extinction O 
response O 
of O 
individual O 
Au-Ag B-FORMULA 
@ O 
SiO2 B-FORMULA 
heterodimers O 
whose O 
individual O 
morphologies O 
are O 
determined O 
by O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
is O 
investigated O 
using O 
spatial O 
modulation O 
spectroscopy O 
. O 
The O 
extinction O 
spectra O 
show O 
two O 
resonances O 
spectrally O 
close O 
to O 
the O 
surface O 
plasmon O 
resonances O 
of O 
the O 
constituting O 
Au B-FORMULA 
and O 
Ag B-FORMULA 
@ O 
SiO2 B-FORMULA 
core O 
- O 
shell O 
particles O 
. O 
The O 
interparticle O 
electromagnetic O 
coupling O 
is O 
demonstrated O 
to O 
induce O 
a O 
large O 
increase O 
of O 
the O 
optical O 
extinction O 
of O 
the O 
dimer O 
around O 
its O 
Au B-FORMULA 
-like O 
surface O 
plasmon O 
resonance O 
for O 
light O 
polarized O 
along O 
its O 
axis O 
, O 
as O 
compared O 
to O 
that O 
for O 
perpendicular O 
polarization O 
and O 
to O 
that O 
of O 
an O 
isolated O 
Au B-FORMULA 
nanoparticle O 
. O 
For O 
spherical O 
particles O 
, O 
this O 
interaction O 
also O 
leads O 
to O 
comparable O 
shifts O 
with O 
light O 
polarization O 
of O 
the O 
two O 
dimer O 
resonances O 
, O 
an O 
effect O 
masked O 
or O 
even O 
reversed O 
for O 
particles O 
significantly O 
deviating O 
from O 
sphericity O 
. O 
Both O 
amplitude O 
and O 
spectral O 
effects O 
are O 
found O 
to O 
be O 
in O 
excellent O 
quantitative O 
agreement O 
with O 
numerical O 
simulations O 
when O 
using O 
the O 
TEM-measured O 
dimer O 
morphology O 
( O 
i.e O 
. O 
, O 
size O 
, O 
shape O 
, O 
and O 
orientation O 
of O 
the O 
individual O 
dimers O 
) O 
, O 
stressing O 
the O 
importance O 
of O 
individual O 
morphology O 
characterization O 
for O 
interpreting O 
heterodimer O 
optical O 
response O 
. O 

polar O 
copper B-SYSTEMATIC 
- O 
boron B-SYSTEMATIC 
one O 
- O 
electron O 
σ- O 
bond O 
. O 

all O 
chemical O 
bonds O 
consist O 
of O 
one O 
or O 
several O 
pairs O 
of O 
electrons O 
shared O 
by O 
two O 
atoms O 
. O 
Examples O 
of O 
σ- O 
bonds O 
made O 
of O 
a O 
single O 
electron O 
delocalized O 
over O 
two O 
neighboring O 
atoms O 
were O 
until O 
recently O 
found O 
only O 
in O 
gas-phase O 
cations O 
such O 
as O 
H2(+) B-FORMULA 
and O 
Li2(+) B-FORMULA 
and O 
in O 
highly O 
unstable O 
species O 
generated O 
in O 
solid O 
matrices O 
. O 
Only O 
in O 
the O 
past O 
decade O 
was O 
bona O 
fide O 
one O 
- O 
electron O 
bonding O 
observed O 
for O 
molecules O 
in O 
fluid O 
solution O 
. O 
Here O 
we O 
report O 
the O 
isolation O 
and O 
structural O 
characterization O 
of O 
a O 
thermally O 
stable O 
compound O 
featuring O 
a O 
Cu-B B-FORMULA 
one O 
- O 
electron O 
bond O 
, O 
as O 
well O 
as O 
its O 
oxidized O 
( O 
nonbonded O 
) O 
and O 
reduced O 
( O 
two O 
- O 
electrons O 
- O 
bonded O 
) O 
congeners O 
. O 
This O 
triad O 
provides O 
an O 
excellent O 
opportunity O 
to O 
study O 
the O 
degree O 
of O 
σ- O 
bonding O 
in O 
a O 
metalloboratrane B-FAMILY 
as O 
a O 
function O 
of O 
electron O 
count O 
. O 

H(2)S B-FORMULA 
and O 
NO B-FORMULA 
Interplay O 
: O 
Hydrogen B-SYSTEMATIC 
Sulfide I-SYSTEMATIC 
and O 
Nitroprusside B-SYSTEMATIC 
React O 
Directly O 
to O 
Give O 
Nitroxyl B-SYSTEMATIC 
( O 
HNO B-FORMULA 
) O 
. O 
A O 
New O 
Pharmacological O 
Source O 
of O 
HNO B-FORMULA 
. O 

sulfide I-SYSTEMATIC 
( O 
H(2)S B-FORMULA 
) O 
has O 
been O 
increasingly O 
recognized O 
as O 
an O 
important O 
signaling O 
molecule O 
that O 
regulates O 
both O 
blood O 
pressure O 
and O 
neuronal O 
activity O 
. O 
Attention O 
has O 
been O 
drawn O 
to O 
its O 
interactions O 
with O 
another O 
gasotransmitter O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
. O 
Here O 
, O 
we O 
provide O 
evidence O 
that O 
the O 
physiological O 
effects O 
observed O 
upon O 
the O 
application O 
of O 
sodium B-SYSTEMATIC 
nitroprusside I-SYSTEMATIC 
( O 
SNP B-ABBREVIATION 
) O 
and O 
H(2)S B-FORMULA 
can O 
be O 
ascribed O 
to O 
the O 
generation O 
of O 
nitroxyl B-SYSTEMATIC 
( O 
HNO B-FORMULA 
) O 
, O 
which O 
is O 
a O 
direct O 
product O 
of O 
the O 
reaction O 
between O 
SNP B-ABBREVIATION 
and O 
H(2)S B-FORMULA 
, O 
not O 
a O 
consequence O 
of O 
released O 
NO B-FORMULA 
subsequently O 
reacting O 
with O 
H(2)S B-FORMULA 
. O 
Intracellular O 
HNO B-FORMULA 
formation O 
has O 
been O 
confirmed O 
, O 
and O 
the O 
subsequent O 
release O 
of O 
calcitonin O 
gene O 
- O 
related O 
peptide O 
from O 
a O 
mouse O 
heart O 
has O 
been O 
demonstrated O 
. O 
Unlike O 
with O 
other O 
thiols B-FAMILY 
, O 
SNP B-ABBREVIATION 
reacts O 
with O 
H(2)S B-FORMULA 
in O 
the O 
same O 
way O 
as O 
rhodanese O 
, O 
i.e O 
. O 
, O 
the O 
cyanide B-SYSTEMATIC 
transforms O 
into O 
a O 
thiocyanate B-SYSTEMATIC 
. O 
These O 
findings O 
shed O 
new O 
light O 
on O 
how O 
H(2)S B-FORMULA 
is O 
understood O 
to O 
interact O 
with O 
nitroprusside B-SYSTEMATIC 
. O 
Additionally O 
, O 
they O 
offer O 
a O 
new O 
and O 
convenient O 
pharmacological O 
source O 
of O 
HNO B-FORMULA 
for O 
therapeutic O 
purposes O 
. O 

new O 
compounds O 
, O 
5β-pregnane-2α,6α,20(S)-triol B-SYSTEMATIC 
( O 
1 O 
) O 
and O 
8-hydroxyl-3-methoxyl-2(1H)-quinolone B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
were O 
isolated O 
from O 
Scolopendra O 
multidens O 
Newport O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
spectroscopic O 
methods O 
including O 
1D O 
and O 
2D O 
NMR O 
and O 
HR-TOF-MS O 
. O 

conjugated O 
one O 
- O 
dimensional O 
nanowires O 
prepared O 
by O 
topochemical O 
polymerization O 
of O 
a O 
butadiynes B-FAMILY 
-containing O 
star O 
- O 
shaped O 
molecule O 
in O 
the O 
xerogel O 
state O 
. O 

star O 
- O 
shaped O 
molecule O 
with O 
three O 
butadiyne B-SYSTEMATIC 
moieties O 
attached O 
to O 
a O 
central O 
phenyl B-SYSTEMATIC 
core O 
was O 
self O 
- O 
assembled O 
via O 
organogel O 
formation O 
in O 
different O 
solvents O 
and O 
subjected O 
to O 
UV O 
irradiation O 
in O 
its O 
xerogels O 
form O 
to O 
give O 
a O 
soluble O 
conjugated O 
1D O 
nanowire O 
made O 
of O 
three O 
connected O 
polydiacetylene B-FAMILY 
( O 
PDA B-ABBREVIATION 
) O 
chains O 
. O 
The O 
resulting O 
polymer O 
has O 
a O 
slightly O 
lower O 
optical O 
band O 
gap O 
than O 
its O 
linear O 
counterpart O 
and O 
presents O 
no O 
chromism O 
property O 
, O 
indicative O 
of O 
the O 
rigid O 
nature O 
of O 
the O 
polymer O 
thus O 
obtained O 
. O 

/ O 
anti-IL-2 O 
mAb O 
immunocomplexes O 
were O 
described O 
to O 
have O 
dramatically O 
higher O 
activity O 
than O 
free O 
IL-2 O 
in O 
vivo O 
. O 
We O 
designed O 
protein O 
chimera O 
consisting O 
of O 
IL-2 O 
linked O 
to O 
light O 
chain O 
of O 
anti-IL-2 O 
mAb O 
S4B6 O 
through O 
flexible O 
oligopeptide O 
spacer O 
(Gly4Ser)3 O 
. O 
This O 
protein O 
chimera O 
mimics O 
the O 
structure O 
of O 
IL-2 O 
/ O 
S4B6 O 
mAb O 
immunocomplexes O 
but O 
eliminates O 
general O 
disadvantages O 
of O 
immunocomplexes O 
like O 
possible O 
excess O 
of O 
either O 
IL-2 O 
or O 
anti-IL-2 O 
mAb O 
and O 
their O 
dissociation O 
to O 
antibody O 
and O 
IL-2 O 
at O 
low O 
concentrations O 
. O 
This O 
novel O 
kind O 
of O 
protein O 
chimera O 
is O 
characterized O 
by O 
an O 
intramolecular O 
interaction O 
between O 
IL-2 O 
and O 
binding O 
site O 
of O 
S4B6 O 
mAb O 
similarly O 
as O 
in O 
IL-2 O 
/ O 
S4B6 O 
mAb O 
immunocomplexes O 
. O 
Our O 
protein O 
chimera O 
has O 
biological O 
activity O 
comparable O 
to O 
IL-2 O 
/ O 
S4B6 O 
mAb O 
immunocomplexes O 
in O 
vitro O 
, O 
as O 
shown O 
by O 
stimulation O 
of O 
proliferation O 
of O 
purified O 
and O 
activated O 
OT-I O 
CD8(+) O 
T O 
cells O 
. O 
The O 
protein O 
chimera O 
exerts O 
higher O 
stimulatory O 
activity O 
to O 
drive O 
expansion O 
of O 
purified O 
CFSE B-ABBREVIATION 
-labeled O 
OT-I O 
CD8(+) O 
T O 
cells O 
activated O 
by O 
an O 
injection O 
of O 
a O 
low O 
dose O 
of O 
SIINFEKL O 
peptide O 
than O 
IL-2 O 
/ O 
S4B6 O 
mAb O 
immunocomplexes O 
in O 
vivo O 
. O 

effects O 
of O 
treadmill O 
running O 
( O 
8weeks O 
, O 
5 O 
times O 
/ O 
week O 
, O 
1h O 
/ O 
day O 
at O 
27m O 
/ O 
min O 
) O 
, O 
caloric O 
restriction O 
, O 
and O 
cocoa O 
supplementation O 
on O 
brain O 
function O 
and O 
oxidative O 
stress O 
markers O 
were O 
tested O 
. O 
The O 
Morris O 
maze O 
test O 
was O 
used O 
to O 
appraise O 
rat O 
memory O 
. O 
Regular O 
exercise O 
significantly O 
improved O 
spatial O 
learning O 
performance O 
. O 
The O 
level O 
of O 
oxidative O 
stress O 
was O 
measured O 
by O 
the O 
concentration O 
of O 
carbonylated O 
proteins O 
. O 
The O 
free O 
radical O 
concentration O 
increased O 
in O 
brain O 
of O 
the O 
training O 
groups O 
but O 
not O 
the O 
controls O 
. O 
The O 
content O 
of O 
reactive O 
carbonyl B-FAMILY 
derivates O 
did O 
not O 
change O 
with O 
exercise O 
, O 
suggesting O 
that O 
the O 
increased O 
production O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
were O 
well O 
tolerated O 
in O 
this O 
experimental O 
model O 
. O 
Caloric O 
restriction O 
( O 
CR O 
) O 
decreased O 
the O 
accumulation O 
of O 
free O 
radicals O 
in O 
the O 
frontal O 
lobe O 
. O 
The O 
protein O 
content O 
of O 
brain O 
- O 
derived O 
neutrophic O 
factors O 
( O 
BDNFs O 
) O 
was O 
evaluated O 
and O 
changes O 
did O 
not O 
occur O 
either O 
with O 
exercise O 
or O 
cocoa O 
supplementation O 
treatments O 
. O 
These O 
data O 
did O 
not O 
show O 
significant O 
effects O 
of O 
the O 
administration O 
of O 
cocoa O 
( O 
2% O 
w O 
/ O 
w O 
) O 
on O 
the O 
concentration O 
of O 
ROS O 
, O 
BDNF O 
or O 
on O 
spatial O 
memory O 
. O 
Conversely O 
, O 
exercise O 
and O 
CR O 
can O 
play O 
a O 
role O 
in O 
ROS O 
generation O 
and O 
brain O 
function O 
. O 

neurobehavioral O 
impact O 
of O 
manganese B-SYSTEMATIC 
: O 
Results O 
and O 
challenges O 
obtained O 
by O 
a O 
meta-analysis O 
of O 
individual O 
participant O 
data O 
. O 

from O 
a O 
meta-analysis O 
of O 
aggregated O 
data O 
provoked O 
a O 
new O 
analysis O 
using O 
individual O 
data O 
on O 
the O 
neuropsychological O 
performance O 
of O 
occupationally O 
exposed O 
workers O 
. O 
Data O 
from O 
eight O 
studies O 
examining O 
579 O 
exposed O 
and O 
433 O 
reference O 
participants O 
were O 
included O 
, O 
28 O 
performance O 
variables O 
analyzed O 
. O 
The O 
performance O 
scores O 
were O 
adjusted O 
for O 
well O 
- O 
known O 
individual O 
- O 
level O 
covariates O 
; O 
the O 
influence O 
of O 
possible O 
, O 
but O 
unknown O 
study O 
- O 
level O 
covariates O 
was O 
attenuated O 
by O 
means O 
of O 
a O 
z-normalization O 
. O 
Associations O 
between O 
performance O 
and O 
exposure O 
were O 
estimated O 
by O 
ANOVAs O 
and O 
ANCOVAs O 
, O 
the O 
latter O 
representing O 
multi O 
- O 
level O 
models O 
. O 
Four O 
cognitive O 
and O 
motor O 
performance O 
variables O 
each O 
indicated O 
significantly O 
lower O 
performances O 
of O 
exposed O 
individuals O 
when O 
confounding O 
was O 
considered O 
; O 
slowed O 
motor O 
performances O 
and O 
deficits O 
in O 
attention O 
and O 
short O 
- O 
term O 
memory O 
were O 
found O 
. O 
Performance O 
on O 
a O 
single O 
test O 
was O 
significantly O 
related O 
to O 
the O 
biomarker O 
manganese B-SYSTEMATIC 
in O 
blood O 
. O 
The O 
outcomes O 
on O 
susceptibility O 
were O 
weak O 
. O 
The O 
slowing O 
of O 
responses O 
was O 
the O 
most O 
distinct O 
feature O 
of O 
performances O 
of O 
exposed O 
workers O 
. O 
It O 
remains O 
unclear O 
, O 
whether O 
this O 
result O 
is O 
related O 
to O 
the O 
employed O 
tests O 
or O 
provides O 
important O 
information O 
about O 
early O 
stages O 
of O 
the O 
neurotoxic O 
impairment O 
. O 
More O 
specific O 
cognitive O 
tests O 
need O 
to O 
be O 
employed O 
to O 
answer O 
this O 
question O 
. O 
The O 
lack O 
of O 
dose O 
- O 
response O 
relationships O 
was O 
related O 
to O 
features O 
of O 
the O 
biomarker O 
: O 
it O 
does O 
not O 
reflect O 
the O 
Mn B-FORMULA 
in O 
brain O 
responsible O 
for O 
changes O 
in O 
performances O 
. O 

femoral O 
fractures O 
( O 
AFFs O 
) O 
have O 
been O 
well O 
defined O 
clinically O 
and O 
epidemiologically O 
. O 
Less O 
clear O 
are O 
the O 
underlying O 
mechanisms O 
responsible O 
. O 
This O 
commentary O 
points O 
out O 
the O 
likely O 
sources O 
of O 
decreased O 
resistance O 
to O 
fracture O 
using O 
lessons O 
from O 
bone O 
material O 
studies O 
and O 
biomechanics O 
. O 
We O 
hypothesize O 
that O 
the O 
key O 
element O 
in O 
the O 
cascade O 
of O 
events O 
leading O 
to O 
failure O 
of O 
the O 
largest O 
and O 
strongest O 
bone O 
in O 
the O 
human O 
body O 
is O 
long O 
- O 
term O 
suppression O 
of O 
normal O 
bone O 
turnover O 
caused O 
by O 
exposure O 
to O 
potent O 
anti-remodeling O 
agents O 
, O 
most O 
notably O 
the O 
bisphosphonates B-FAMILY 
( O 
BPs B-ABBREVIATION 
) O 
. O 
Suppressed O 
bone O 
turnover O 
produces O 
changes O 
in O 
bone O 
that O 
alter O 
its O 
material O 
quality O 
and O 
these O 
changes O 
could O 
lead O 
to O 
adverse O 
effects O 
on O 
its O 
mechanical O 
function O 
. O 
At O 
the O 
submicroscopic O 
[ O 
< O 
1μm O 
] O 
level O 
of O 
collagen O 
fibrils O 
, O 
suppression O 
of O 
bone O 
turnover O 
allows O 
continued O 
addition O 
of O 
non-enzymatic O 
cross O 
links O 
that O 
can O 
reduce O 
collagen's O 
plasticity O 
and O 
this O 
in O 
turn O 
contributes O 
to O 
reduced O 
bone O 
toughness O 
. O 
Further O 
, O 
adverse O 
changes O 
in O 
hydroxyapatite O 
crystalline O 
structure O 
and O 
composition O 
can O 
occur O 
, O 
perhaps O 
increasing O 
collagen's O 
brittleness O 
. O 
At O 
the O 
microscopic O 
level O 
[ O 
~1-500μm O 
] O 
of O 
the O 
bone O 
- O 
matrix O 
structure O 
, O 
suppressed O 
bone O 
turnover O 
allows O 
full O 
mineralization O 
of O 
cortical O 
bone O 
osteons O 
and O 
results O 
in O 
a O 
microstructure O 
of O 
bone O 
that O 
is O 
more O 
homogeneous O 
. O 
Both O 
brittleness O 
and O 
loss O 
of O 
heterogeneity O 
allow O 
greater O 
progression O 
of O 
microscopic O 
cracks O 
that O 
can O 
occur O 
with O 
usual O 
physical O 
activity O 
; O 
in O 
crack O 
mechanical O 
terms O 
, O 
normal O 
mechanisms O 
that O 
dissipate O 
crack O 
tip O 
growth O 
energy O 
are O 
greatly O 
reduced O 
and O 
crack O 
progression O 
is O 
less O 
impeded O 
. O 
Further O 
, O 
the O 
targeted O 
repair O 
of O 
cracks O 
by O 
newly O 
activated O 
BMUs O 
appears O 
to O 
be O 
preferentially O 
suppressed O 
by O 
BPs B-ABBREVIATION 
. O 
We O 
further O 
hypothesize O 
that O 
it O 
is O 
not O 
necessary O 
to O 
have O 
accumulation O 
of O 
many O 
cracks O 
to O 
produce O 
an O 
AFF O 
, O 
just O 
one O 
that O 
progresses O 
- O 
one O 
that O 
is O 
not O 
stopped O 
by O 
bone's O 
several O 
protective O 
mechanisms O 
and O 
is O 
allowed O 
to O 
penetrate O 
through O 
a O 
homogeneous O 
environment O 
. O 
The O 
remarkable O 
straight O 
transverse O 
fracture O 
line O 
is O 
an O 
indicator O 
of O 
the O 
slow O 
progression O 
of O 
a O 
" O 
mother O 
crack O 
" O 
and O 
the O 
failure O 
of O 
usual O 
mechanisms O 
to O 
bridge O 
or O 
deflect O 
the O 
crack O 
. O 
Research O 
in O 
AFF O 
mechanisms O 
has O 
been O 
focused O 
at O 
the O 
organ O 
level O 
, O 
describing O 
the O 
clinical O 
presentation O 
and O 
radiologic O 
appearance O 
. O 
Although O 
today O 
we O 
have O 
not O 
yet O 
connected O 
all O 
the O 
dots O 
in O 
the O 
pathophysiology O 
of O 
BP-induced O 
AFF O 
, O 
recent O 
advances O 
in O 
measuring O 
bone O 
mechanical O 
qualities O 
at O 
the O 
submicroscopic O 
and O 
tissue O 
levels O 
allow O 
us O 
to O 
explain O 
how O 
spontaneous O 
catastrophic O 
failure O 
of O 
the O 
femur O 
can O 
occur O 
. O 

novel O 
model O 
of O 
infected O 
nail O 
plate O 
for O 
testing O 
the O 
efficacy O 
of O 
topical O 
antifungal O 
formulations O 
has O 
been O 
developed O 
. O 
This O 
model O 
utilized O 
keratin O 
film O 
made O 
of O 
human O 
hair O 
keratin O 
as O 
a O 
nail O 
plate O 
model O 
. O 
Subsequent O 
to O 
infection O 
by O 
Trichophyton O 
rubrum O 
, O 
the O 
common O 
causative O 
agent O 
of O 
onychomycosis O 
, O 
keratin O 
films O 
as O 
infected O 
nail O 
plate O 
models O 
were O 
treated O 
with O 
selected O 
topical O 
formulations O 
, O 
that O 
is O 
cream O 
, O 
gel O 
, O 
and O 
nail O 
lacquer O 
. O 
Bovine O 
hoof O 
was O 
compared O 
to O 
keratin O 
film O 
. O 
In O 
contrast O 
to O 
the O 
common O 
antifungal O 
susceptibility O 
test O 
, O 
the O 
antifungal O 
drugs O 
tested O 
were O 
applied O 
as O 
ready O 
- O 
to O 
- O 
use O 
formulations O 
because O 
the O 
vehicle O 
may O 
modify O 
and O 
control O 
the O 
drug O 
action O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Extrapolating O 
the O 
potency O 
of O 
an O 
antifungal O 
drug O 
from O 
an O 
in O 
vitro O 
susceptibility O 
test O 
only O 
would O 
not O 
be O 
representative O 
of O 
the O 
in O 
vivo O 
situation O 
since O 
these O 
drugs O 
are O 
applied O 
as O 
ready O 
- O 
to O 
- O 
use O 
formulations O 
, O 
for O 
example O 
as O 
a O 
nail O 
lacquer O 
. O 
Although O 
terbinafine B-TRIVIAL 
has O 
been O 
acknowledged O 
to O 
be O 
the O 
most O 
effective O 
antifungal O 
agent O 
against O 
T O 
. O 
rubrum O 
, O 
its O 
antifungal O 
efficacy O 
was O 
improved O 
by O 
its O 
incorporation O 
into O 
an O 
optimal O 
formulation O 
. O 
Different O 
gels O 
proved O 
superior O 
to O 
cream O 
. O 
Therefore O 
, O 
this O 
study O 
is O 
able O 
to O 
discriminate O 
between O 
efficacies O 
of O 
different O 
topical O 
antifungal O 
formulations O 
based O 
on O 
their O 
activities O 
against O 
T O 
. O 
rubrum O 
. O 

affects O 
the O 
oral O 
toxicity O 
of O 
poly(amidoamine) B-SYSTEMATIC 
dendrimers O 
. O 

( O 
PAMAM B-ABBREVIATION 
) O 
dendrimers O 
have O 
been O 
evaluated O 
for O 
the O 
influence O 
of O 
surface O 
functionality O 
and O 
size O 
on O 
the O 
epithelial O 
barrier O 
of O 
the O 
gut O 
with O 
the O 
goal O 
of O 
identifying O 
safe O 
carriers O 
that O 
can O 
be O 
used O 
for O 
oral O 
drug O 
delivery O 
. O 
Limited O 
studies O 
are O 
conducted O 
to O 
date O 
, O 
however O 
, O 
to O 
assess O 
the O 
toxicity O 
of O 
PAMAM B-ABBREVIATION 
dendrimers O 
in O 
vivo O 
when O 
administered O 
by O 
the O 
oral O 
route O 
. O 
The O 
goal O 
of O 
this O 
research O 
was O 
to O 
conduct O 
an O 
oral O 
acute O 
toxicity O 
study O 
of O 
PAMAM B-ABBREVIATION 
dendrimers O 
as O 
a O 
function O 
of O 
size O 
and O 
charge O 
in O 
immune O 
competent O 
CD-1 O 
mice O 
. O 
Maximum O 
tolerated O 
doses O 
( O 
MTD O 
) O 
of O 
PAMAM B-ABBREVIATION 
dendrimers O 
as O 
a O 
function O 
of O 
size O 
and O 
surface O 
functionality O 
were O 
established O 
and O 
clinical O 
signs O 
of O 
toxicity O 
monitored O 
. O 
Results O 
demonstrate O 
that O 
positively O 
charged O 
dendrimers O 
caused O 
more O 
toxicity O 
, O 
whereas O 
their O 
anionic O 
counterparts O 
were O 
tolerated O 
at O 
ten O 
times O 
higher O 
doses O 
. O 
Severe O 
signs O 
of O 
toxicity O 
observed O 
for O 
large O 
( O 
G7 O 
) O 
cationic O 
amine B-SYSTEMATIC 
- O 
or O 
hydroxyl B-SYSTEMATIC 
-terminated O 
dendrimers O 
include O 
hemobilia O 
and O 
spleenomegaly O 
. O 
The O 
MTD O 
for O 
these O 
dendrimers O 
ranged O 
from O 
30mg O 
/ O 
kg O 
to O 
200mg O 
/ O 
kg O 
. O 
Anionic O 
G6.5 O 
or O 
smaller O 
molecular O 
weight O 
carboxyl B-SYSTEMATIC 
- O 
, O 
amine B-SYSTEMATIC 
- O 
, O 
or O 
hydroxyl B-SYSTEMATIC 
-terminated O 
dendrimers O 
( O 
G3.5- O 
COOH B-FORMULA 
, O 
G4- O 
NH2 B-FORMULA 
, O 
G4- O 
OH B-FORMULA 
) O 
on O 
the O 
other O 
hand O 
were O 
tolerated O 
at O 
doses O 
of O 
up O 
to O 
500mg O 
/ O 
kg O 
( O 
300mg O 
/ O 
kg O 
in O 
some O 
cases O 
) O 
with O 
minimal O 
or O 
no O 
signs O 
of O 
toxicity O 
. O 
Establishing O 
the O 
MTD O 
of O 
orally O 
delivered O 
PAMAM B-ABBREVIATION 
dendrimers O 
and O 
the O 
influence O 
of O 
surface O 
functionality O 
and O 
size O 
on O 
toxicity O 
aids O 
in O 
the O 
rational O 
design O 
of O 
PAMAM B-ABBREVIATION 
-drug O 
conjugates O 
for O 
oral O 
drug O 
delivery O 
applications O 
. O 

of O 
mitochondrial O 
glutathione B-TRIVIAL 
status O 
and O 
cellular O 
energetics O 
in O 
primary O 
cultures O 
of O 
proximal O 
tubular O 
cells O 
from O 
remnant O 
kidney O 
of O 
uninephrectomized O 
rats O 
. O 

renal O 
hypertrophy O 
following O 
reduction O 
in O 
renal O 
mass O 
leads O 
to O 
a O 
hypermetabolic O 
state O 
and O 
increases O 
in O 
basal O 
mitochondrial O 
oxidative O 
stress O 
and O 
susceptibility O 
to O 
several O 
nephrotoxicants O 
. O 
Previous O 
studies O 
provide O 
conflicting O 
data O 
on O 
whether O 
renal O 
mitochondria O 
after O 
reduction O 
in O 
renal O 
mass O 
undergo O 
proliferation O 
or O 
hypertrophy O 
or O 
both O 
. O 
In O 
the O 
present O 
study O 
, O 
our O 
goal O 
was O 
to O 
determine O 
whether O 
mitochondria O 
of O 
hypertrophied O 
kidney O 
undergo O 
hypertrophy O 
or O 
proliferation O 
after O 
uninephrectomy O 
using O 
the O 
uninephrectomized O 
( O 
NPX O 
) O 
rat O 
model O 
. O 
Renal O 
proximal O 
tubular O 
( O 
PT O 
) O 
cells O 
from O 
NPX O 
rats O 
exhibited O 
increased O 
mitochondrial O 
density O 
, O 
membrane O 
potential O 
and O 
protein O 
but O 
no O 
significant O 
difference O 
in O 
mitochondrial O 
DNA O 
, O 
as O 
compared O 
to O 
PT O 
cells O 
from O 
control O 
rats O 
. O 
Our O 
previous O 
studies O 
showed O 
that O 
overexpression O 
of O 
two O 
mitochondrial O 
anion O 
transporters O 
, O 
the O 
dicarboxylate B-SYSTEMATIC 
( O 
DIC B-ABBREVIATION 
, O 
Slc25a10 O 
) O 
and O 
oxoglutarate B-SYSTEMATIC 
( O 
OGC B-ABBREVIATION 
, O 
Slc25a11 O 
) O 
carriers O 
, O 
in O 
NRK-52E O 
cells O 
resulted O 
in O 
increased O 
mitochondrial O 
uptake O 
of O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
and O 
protection O 
from O 
chemically O 
induced O 
apoptosis O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
overexpressed O 
DIC B-ABBREVIATION 
- O 
and O 
OGC B-ABBREVIATION 
-cDNA O 
plasmids O 
to O 
assess O 
their O 
function O 
in O 
renal O 
PT O 
cells O 
after O 
compensatory O 
renal O 
hypertrophy O 
. O 
PT O 
cells O 
from O 
NPX O 
rats O 
that O 
were O 
first O 
preincubated O 
with O 
GSH B-ABBREVIATION 
were O 
protected O 
from O 
cytotoxicity O 
due O 
to O 
the O 
mitochondrial O 
inhibitor O 
antimycin B-TRIVIAL 
A I-TRIVIAL 
by O 
overexpression O 
of O 
either O 
of O 
the O 
two O 
mitochondrial O 
GSH B-ABBREVIATION 
transporters O 
. O 
Our O 
present O 
results O 
provide O 
further O 
evidence O 
that O 
compensatory O 
renal O 
hypertrophy O 
is O 
associated O 
primarily O 
with O 
mitochondrial O 
hypertrophy O 
and O 
hyperpolarization O 
and O 
that O 
manipulation O 
of O 
mitochondrial O 
GSH B-ABBREVIATION 
transporters O 
in O 
PT O 
cells O 
of O 
hypertrophied O 
kidney O 
can O 
alter O 
susceptibility O 
to O 
chemically O 
induced O 
injury O 
under O 
appropriate O 
conditions O 
and O 
may O 
be O 
a O 
suitable O 
therapeutic O 
approach O 
. O 

of O 
transition O 
and O 
post O 
- O 
transition O 
metals O 
to O 
incorporate O 
into O 
copper B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
copper B-SYSTEMATIC 
bismuth I-SYSTEMATIC 
oxide I-SYSTEMATIC 
for O 
photoelectrochemical O 
hydrogen B-SYSTEMATIC 
evolution O 
. O 

new O 
dispenser O 
and O 
scanner O 
system O 
is O 
used O 
to O 
create O 
and O 
screen O 
Bi B-FORMULA 
-M- O 
Cu B-FORMULA 
oxide B-SYSTEMATIC 
arrays O 
for O 
cathodic O 
photoactivity O 
, O 
where O 
M O 
represents O 
1 O 
of O 
22 O 
different O 
transition O 
and O 
post O 
- O 
transition O 
metals O 
. O 
Over O 
3000 O 
unique O 
Bi B-FORMULA 
: O 
M O 
: O 
Cu B-FORMULA 
atomic O 
ratios O 
are O 
screened O 
. O 
Of O 
the O 
22 O 
metals O 
tested O 
, O 
10 O 
show O 
a O 
M- O 
Cu B-SYSTEMATIC 
oxide I-SYSTEMATIC 
with O 
higher O 
photoactivity O 
than O 
CuO B-FORMULA 
and O 
10 O 
show O 
a O 
Bi B-FORMULA 
-M- O 
Cu B-FORMULA 
oxide B-SYSTEMATIC 
with O 
higher O 
photoactivity O 
than O 
CuBi2O4 B-FORMULA 
. O 
Cd B-FORMULA 
, O 
Zn B-FORMULA 
, O 
Sn B-FORMULA 
, O 
and O 
Co B-FORMULA 
produce O 
the O 
most O 
photoactive O 
M- O 
Cu B-FORMULA 
oxides B-FAMILY 
, O 
all O 
showing O 
a O 
200-300% O 
improvement O 
in O 
photocurrent O 
over O 
CuO B-FORMULA 
. O 
Ag B-FORMULA 
, O 
Cd B-FORMULA 
, O 
and O 
Zn B-FORMULA 
produce O 
the O 
highest O 
photoactivity O 
Bi B-FORMULA 
-M- O 
Cu B-FORMULA 
oxides B-FAMILY 
with O 
a O 
200-400% O 
improvement O 
over O 
CuBi2O4 B-FORMULA 
. O 
Most O 
notable O 
is O 
a O 
Bi-Ag-Cu B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
Bi B-FORMULA 
: O 
Ag B-FORMULA 
: O 
Cu B-FORMULA 
atomic O 
ratio O 
of O 
22 O 
: O 
3 O 
: O 
11 O 
) O 
which O 
shows O 
4 O 
times O 
higher O 
photocurrent O 
than O 
CuBi2O4 B-FORMULA 
. O 
This O 
material O 
is O 
capable O 
of O 
evolving O 
hydrogen B-SYSTEMATIC 
under O 
illumination O 
in O 
neutral O 
electrolyte O 
solutions O 
at O 
0.6 O 
V O 
vs O 
. O 
RHE O 
when O 
Pt B-FORMULA 
is O 
added O 
to O 
the O 
surface O 
as O 
an O 
electrocatalyst O 
. O 

structural O 
mapping O 
of O 
mutations O 
causing O 
succinyl-CoA B-TRIVIAL 
: O 
3-ketoacid O 
CoA O 
transferase O 
( O 
SCOT O 
) O 
deficiency O 
. O 

: O 
3-ketoacid O 
CoA O 
transferase O 
( O 
SCOT O 
) O 
deficiency O 
is O 
a O 
rare O 
inherited O 
metabolic O 
disorder O 
of O 
ketone B-SYSTEMATIC 
metabolism O 
, O 
characterized O 
by O 
ketoacidotic O 
episodes O 
and O 
often O 
permanent O 
ketosis O 
. O 
To O 
date O 
there O 
are O 
∼20 O 
disease O 
- O 
associated O 
alleles O 
on O 
the O 
OXCT1 O 
gene O 
that O 
encodes O 
the O 
mitochondrial O 
enzyme O 
SCOT O 
. O 
SCOT O 
catalyzes O 
the O 
first O 
, O 
rate O 
- O 
limiting O 
step O 
of O 
ketone B-SYSTEMATIC 
body O 
utilization O 
in O 
peripheral O 
tissues O 
, O 
by O 
transferring O 
a O 
CoA B-ABBREVIATION 
moiety O 
from O 
succinyl-CoA B-TRIVIAL 
to O 
form O 
acetoacetyl-CoA B-SYSTEMATIC 
, O 
for O 
entry O 
into O 
the O 
tricarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
cycle O 
for O 
energy O 
production O 
. O 
We O 
have O 
determined O 
the O 
crystal O 
structure O 
of O 
human O 
SCOT O 
, O 
providing O 
a O 
molecular O 
understanding O 
of O 
the O 
reported O 
mutations O 
based O 
on O 
their O 
potential O 
structural O 
effects O 
. O 
An O 
interactive O 
version O 
of O 
this O 
manuscript O 
( O 
which O 
may O 
contain O 
additional O 
mutations O 
appended O 
after O 
acceptance O 
of O 
this O 
manuscript O 
) O 
may O 
be O 
found O 
on O 
the O 
web O 
address O 
: O 
http O 
: O 
/ O 
/ O 
www.thesgc.org O 
/ O 
jimd O 
/ O 
SCOT O 
. O 

Methacrylamide B-SYSTEMATIC 
Hydrogels O 
as O 
Potential O 
Biomaterials O 
for O 
Fabrication O 
of O 
Tissue-Engineered O 
Cartilage O 
Constructs O 
. O 

methacrylamide B-SYSTEMATIC 
( O 
gelMA O 
) O 
hydrogels O 
are O 
shown O 
to O 
support O 
chondrocyte O 
viability O 
and O 
differentiation O 
and O 
give O 
wide O 
ranging O 
mechanical O 
properties O 
depending O 
on O 
several O 
cross O 
- O 
linking O 
parameters O 
. O 
Polymer O 
concentration O 
, O 
UV O 
exposure O 
time O 
, O 
and O 
thermal O 
gelation O 
prior O 
to O 
UV O 
exposure O 
allow O 
for O 
control O 
over O 
hydrogel O 
stiffness O 
and O 
swelling O 
properties O 
. O 
GelMA O 
solutions O 
have O 
a O 
low O 
viscosity O 
at O 
37 O 
°C O 
, O 
which O 
is O 
incompatible O 
with O 
most O 
biofabrication O 
approaches O 
. O 
However O 
, O 
incorporation O 
of O 
hyaluronic O 
acid O 
( O 
HA O 
) O 
and O 
/ O 
or O 
co O 
- O 
deposition O 
with O 
thermoplastics O 
allows O 
gelMA O 
to O 
be O 
used O 
in O 
biofabrication O 
processes O 
. O 
These O 
attributes O 
may O 
allow O 
engineered O 
constructs O 
to O 
match O 
the O 
natural O 
functional O 
variations O 
in O 
cartilage O 
mechanical O 
and O 
geometrical O 
properties O 
. O 

, O 
we O 
describe O 
the O 
first O 
report O 
on O 
a O 
new O 
class O 
of O 
disk O 
- O 
shaped O 
and O 
quite O 
monodisperse O 
water O 
- O 
soluble O 
nanomaterials O 
that O 
we O 
named O 
glyconanosomes O 
( O 
GNS O 
) O 
. O 
GNSs O 
were O 
obtained O 
by O 
sliding O 
out O 
the O 
cylindrical O 
structures O 
formed O 
upon O 
self O 
- O 
organization O 
and O 
photopolymerization O 
of O 
glycolipid O 
1 O 
on O 
single O 
- O 
walled O 
carbon O 
nanotube O 
( O 
SWCNT O 
) O 
sidewalls O 
. O 
GNSs O 
present O 
a O 
sheltered O 
hydrophobic O 
inner O 
cavity O 
formed O 
by O 
the O 
carbonated O 
tails O 
, O 
surrounded O 
by O 
PEG B-ABBREVIATION 
and O 
lactose O 
moieties O 
. O 
The O 
amphiphilic O 
character O 
of O 
GNSs O 
allows O 
the O 
water O 
solubility O 
of O 
insoluble O 
hydrophobic O 
cargos O 
such O 
as O 
a O 
perylene B-SYSTEMATIC 
- I-SYSTEMATIC 
bisimide I-SYSTEMATIC 
derivative O 
, O 
[60]fullerene B-TRIVIAL 
, O 
or O 
the O 
anti-carcinogenic O 
drug O 
camptothecin B-TRIVIAL 
( O 
CPT B-ABBREVIATION 
) O 
. O 
GNS/ O 
C60 B-TRIVIAL 
inclusion O 
complexes O 
are O 
able O 
to O 
establish O 
specific O 
interactions O 
between O 
peanut O 
agglutinin O 
( O 
PNA O 
) O 
lectin O 
and O 
the O 
lactose O 
moiety O 
surrounding O 
the O 
complexes O 
, O 
while O 
CPT B-ABBREVIATION 
solubilized O 
by O 
GNS O 
shows O 
higher O 
cytotoxicity O 
toward O 
MCF7 O 
- O 
type O 
breast O 
cancer O 
cells O 
than O 
CPT B-ABBREVIATION 
alone O 
. O 
Thus O 
, O 
GNS O 
represents O 
an O 
attractive O 
extension O 
of O 
nanoparticle O 
- O 
based O 
drug O 
delivery O 
systems O 
. O 

new O 
lanostanoid B-FAMILY 
triterpenes I-FAMILY 
from O 
the O 
fruiting O 
bodies O 
of O 
Ganoderma O 
tropicum O 
. O 

new O 
lanostanoid B-FAMILY 
triterpenes I-FAMILY 
, O 
3β,7β,15β-trihydroxy-11,23-dioxo-lanost-8,16-dien-26-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
3β,7β,15β-trihydroxy-11,23-dioxo-lanost-8,16-dien-26-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
and O 
3β,15β-dihydroxy-7,11,23-trioxo-lanost-8,16-dien-26-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
3 O 
) O 
were O 
isolated O 
from O 
the O 
EtOAc B-FORMULA 
extract O 
of O 
the O 
fruiting O 
bodies O 
of O 
Ganoderma O 
tropicum O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
1D O 
and O 
2D O 
NMR O 
spectroscopy O 
as O 
well O 
as O 
MS O 
. O 
The O 
bioassay O 
of O 
inhibitory O 
activity O 
against O 
acetylcholinesterase O 
( O 
AChE O 
) O 
of O 
these O 
isolates O 
was O 
evaluated O 
and O 
compound O 
2 O 
exhibited O 
definite O 
inhibitory O 
activity O 
against O 
AChE O 
. O 

combining O 
in O 
situ O 
and O 
ex O 
situ O 
transmission O 
electron O 
microscopy O 
measurements O 
, O 
we O 
examine O 
the O 
factors O 
that O 
control O 
the O 
morphology O 
of O 
" O 
hybrid O 
" O 
nanowires O 
that O 
include O 
group O 
III-V O 
and O 
group O 
IV O 
materials O 
. O 
We O 
focus O 
on O 
one O 
materials O 
pair O 
, O 
GaP B-FORMULA 
/ O 
Si B-FORMULA 
, O 
for O 
which O 
we O 
use O 
a O 
wide O 
range O 
of O 
growth O 
parameters O 
. O 
We O 
show O 
through O 
video O 
imaging O 
that O 
nanowire O 
morphology O 
depends O 
on O 
growth O 
conditions O 
, O 
but O 
that O 
a O 
general O 
pattern O 
emerges O 
where O 
either O 
single O 
kinks O 
or O 
inclined O 
defects O 
form O 
some O 
distance O 
after O 
the O 
heterointerface O 
. O 
We O 
show O 
that O 
pure O 
Si B-FORMULA 
nanowires O 
can O 
be O 
made O 
to O 
exhibit O 
the O 
same O 
kinks O 
and O 
defects O 
by O 
changing O 
their O 
droplet O 
volume O 
. O 
From O 
this O 
we O 
derive O 
a O 
model O 
where O 
droplet O 
geometry O 
drives O 
growth O 
morphology O 
and O 
discuss O 
optimization O 
strategies O 
. O 
We O 
finally O 
discuss O 
morphology O 
control O 
for O 
material O 
pairs O 
where O 
the O 
second O 
material O 
kinks O 
immediately O 
at O 
the O 
heterointerface O 
and O 
show O 
that O 
an O 
interlayer O 
between O 
segments O 
can O 
enable O 
the O 
growth O 
of O 
unkinked O 
hybrid O 
nanowires O 
. O 

effect O 
of O 
rosmarinic B-TRIVIAL 
acid I-TRIVIAL 
on O 
multidrug O 
resistance O 
in O 
SGC7901/ O 
Adr B-ABBREVIATION 
cell O 
. O 

resistance O 
( O 
MDR O 
) O 
has O 
been O 
a O 
major O 
problem O 
in O 
cancer O 
chemotherapy O 
. O 
In O 
this O 
study O 
, O 
the O 
aim O 
was O 
to O 
explore O 
the O 
reversal O 
effect O 
and O 
its O 
potential O 
mechanism O 
of O 
rosmarinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
RA O 
) O 
on O 
SGC7901 O 
/ O 
Adr O 
cells O 
. O 
3-(4,5-Dimethylthiazol)-2,5-diphenyl B-SYSTEMATIC 
tetrazolium I-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
MTT B-ABBREVIATION 
) O 
assay O 
was O 
used O 
to O 
investigate O 
the O 
reversal O 
index O 
of O 
RA O 
in O 
SGC7901/ O 
Adr B-ABBREVIATION 
cell O 
line O 
. O 
The O 
intracellular O 
accumulation O 
of O 
adriamycin B-TRIVIAL 
, O 
rhodamine123 B-TRIVIAL 
( O 
Rh123 B-ABBREVIATION 
) O 
, O 
and O 
the O 
expression O 
of O 
P-glycoprotein O 
( O 
P-gp O 
) O 
were O 
assayed O 
by O 
flow O 
cytometry O 
. O 
The O 
influence O 
of O 
RA O 
on O 
the O 
transcription O 
of O 
MDR1 O 
gene O 
was O 
determined O 
by O 
reverse O 
transcription O 
- O 
polymerase O 
chain O 
reaction O 
. O 
The O 
results O 
showed O 
that O 
RA O 
could O 
reverse O 
the O 
MDR O 
of O 
SGC7901/ O 
Adr B-ABBREVIATION 
cells O 
, O 
increase O 
the O 
intracellular O 
accumulation O 
of O 
Adr B-ABBREVIATION 
and O 
Rh123 B-ABBREVIATION 
, O 
and O 
decrease O 
the O 
transcription O 
of O 
MDR1 O 
gene O 
and O 
the O 
expression O 
of O 
P-gp O 
in O 
SGC7901 O 
/ O 
Adr O 
cells O 
. O 
These O 
results O 
indicated O 
that O 
RA O 
was O 
a O 
potential O 
multidrug O 
resistance O 
- O 
reversing O 
agent O 
and O 
warranted O 
further O 
investigations O 
. O 

new O 
piperidine B-FAMILY 
alkaloids I-FAMILY 
from O 
Streptomyces O 
sp O 
. O 
NEAU-Z4 O 
. O 

new O 
piperidine B-FAMILY 
alkaloids I-FAMILY 
, O 
streptazones B-FAMILY 
E O 
( O 
1 O 
) O 
and O 
F O 
( O 
2 O 
) O 
, O 
were O 
isolated O 
from O 
Streptomyces O 
sp O 
. O 
NEAU-Z4 O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
MS O 
and O 
NMR O 
analysis O 
. O 

, O 
cytotoxicity O 
and O 
in O 
vitro O 
antileishmanial O 
activity O 
of O 
naphthothiazoles B-FAMILY 
. O 

leishmaniasis O 
is O 
a O 
spectral O 
disease O 
caused O 
by O 
the O 
protozoan O 
Leishmania O 
spp O 
, O 
which O 
threatens O 
millions O 
of O 
people O 
worldwide O 
. O 
Current O 
treatments O 
exhibit O 
high O 
toxicity O 
and O 
there O 
is O 
no O 
vaccine O 
available O 
. O 
The O 
need O 
for O 
new O 
lead O 
compounds O 
with O 
leishmanicidal O 
activity O 
is O 
urgent O 
. O 
Considering O 
that O 
many O 
lead O 
leishmanicidal O 
compounds O 
contain O 
a O 
quinoidal B-FAMILY 
scaffold O 
and O 
the O 
thiazole B-SYSTEMATIC 
heterocyclic O 
ring O 
is O 
found O 
in O 
a O 
number O 
of O 
antimicrobial O 
drugs O 
, O 
we O 
proposed O 
a O 
hybridization O 
approach O 
to O 
generate O 
a O 
diverse O 
set O 
of O 
semi-synthetic O 
heterocycles O 
with O 
antileishmanial O 
activity O 
. O 
We O 
found O 
that O 
almost O 
all O 
synthesized O 
compounds O 
demonstrated O 
potent O 
activity O 
against O 
promastigotes O 
of O 
Leishmania O 
( O 
Viannia O 
) O 
braziliensis O 
and O 
reduced O 
the O 
survival O 
index O 
of O 
Leishmania O 
amastigotes O 
in O 
mammalian O 
macrophages O 
. O 
Furthermore O 
, O 
the O 
compounds O 
were O 
not O 
cytotoxic O 
to O 
macrophages O 
at O 
5-fold O 
higher O 
concentrations O 
than O 
the O 
EC(50) O 
for O 
promastigotes O 
. O 
All O 
molecules O 
fulfilled O 
Lipinski's O 
Rule O 
of O 
Five O 
, O 
which O 
predicts O 
efficient O 
orally O 
absorption O 
and O 
permeation O 
through O 
biological O 
membranes O 
, O 
the O 
in O 
silico O 
pharmacokinetic O 
profile O 
confirmed O 
these O 
characteristics O 
. O 
The O 
potent O 
and O 
selective O 
activity O 
of O 
semi-synthetic O 
naphthothiazoles B-FAMILY 
against O 
promastigotes O 
and O 
amastigotes O 
reveals O 
that O 
the O 
2-amino-naphthothiazole B-SYSTEMATIC 
ring O 
may O 
represent O 
a O 
scaffold O 
for O 
the O 
design O 
of O 
compounds O 
with O 
leishmanicidal O 
properties O 
and O 
encourage O 
the O 
development O 
of O 
drug O 
formulation O 
and O 
new O 
compounds O 
for O 
further O 
studies O 
in O 
vivo O 
. O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
A O 
/ O 
S O 
. O 

new O 
sesquiterpenes B-FAMILY 
from O 
cultures O 
of O 
the O 
basidiomycete O 
Agaricus O 
arvensis O 
. O 

new O 
drimane B-TRIVIAL 
sesquiterpenoids B-FAMILY 
, O 
11,12-dihydroxy-15-drimeneoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
1 O 
) O 
and O 
3α,11,15-trihydroxydrimene B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
were O 
isolated O 
from O 
cultures O 
of O 
the O 
basidiomycete O 
Agaricus O 
arvensis O 
, O 
together O 
with O 
one O 
known O 
compound O 
3β,11,12-trihydroxydrimene B-SYSTEMATIC 
( O 
3 O 
) O 
. O 
Their O 
structures O 
were O 
established O 
by O 
means O 
of O 
spectroscopic O 
analysis O 
. O 

as O 
a O 
potential O 
target O 
by O 
which O 
berberine B-TRIVIAL 
induce O 
cell O 
cycle O 
arrest O 
in O 
human O 
hepatoma O 
Bel7402 O 
cells O 
. O 

is O 
an O 
isoquinoline B-FAMILY 
alkaloid I-FAMILY 
that O 
has O 
drawn O 
extensive O 
attention O 
since O 
it O 
possesses O 
various O 
biological O 
activities O 
. O 
Several O 
mechanisms O 
have O 
been O 
proposed O 
to O 
interpret O 
the O 
anticancer O 
activity O 
of O 
berberine B-TRIVIAL 
. O 
However O 
, O 
these O 
explanations O 
are O 
mostly O 
based O 
on O 
its O 
downstream O 
- O 
regulated O 
genes O 
or O 
proteins O 
, O 
information O 
on O 
the O 
direct O 
target O 
proteins O 
that O 
mediate O 
the O 
antiproliferative O 
action O 
of O 
berberine B-TRIVIAL 
remain O 
unclear O 
. O 
In O 
the O 
present O 
study O 
, O 
a O 
computational O 
pipeline O 
based O 
on O 
a O 
ligand O 
- O 
protein O 
inverse O 
docking O 
program O 
and O 
mining O 
of O 
the O 
" O 
Connectivity O 
MAP O 
" O 
data O 
was O 
adopted O 
to O 
explore O 
the O 
potential O 
target O 
proteins O 
for O 
berberine B-TRIVIAL 
. O 
The O 
results O 
showed O 
that O 
four O 
proteins O 
, O 
i.e O 
. O 
, O 
calmodulin O 
, O 
cytochrome O 
P450 O 
3A4 O 
, O 
sex O 
hormone O 
- O 
binding O 
globulin O 
and O 
carbonic O 
anhydrase O 
II O 
, O 
were O 
suggested O 
to O 
be O 
the O 
potential O 
targets O 
of O 
berberine B-TRIVIAL 
. O 
The O 
anti-calmodulin O 
property O 
of O 
berberine B-TRIVIAL 
was O 
demonstrated O 
with O 
an O 
in O 
vitro O 
phosphodiesterase O 
activity O 
assay O 
. O 
Flow O 
cytometric O 
analysis O 
found O 
that O 
G1 O 
cell O 
cycle O 
arrest O 
induced O 
by O 
berberine B-TRIVIAL 
in O 
Bel7402 O 
cells O 
was O 
enhanced O 
by O 
cotreatment O 
with O 
calmodulin O 
inhibitors O 
. O 
Western O 
blotting O 
results O 
indicated O 
that O 
berberine B-TRIVIAL 
treatment O 
decreased O 
phosphorylation O 
of O 
calmodulin O 
kinase O 
II O 
and O 
blocked O 
subsequent O 
MEK1 O 
activation O 
as O 
well O 
as O 
p27 O 
protein O 
degradation O 
. O 
These O 
results O 
suggested O 
that O 
calmodulin O 
might O 
play O 
crucial O 
roles O 
in O 
berberine B-TRIVIAL 
-induced O 
cell O 
cycle O 
arrest O 
in O 
cancer O 
cells O 
. O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
A O 
/ O 
S O 
. O 

new O 
sesquiterpenoids B-FAMILY 
from O 
the O 
fungus O 
Ceriporia O 
alachuana O 
. O 

new O 
sesquiterpenoids B-FAMILY 
, O 
tremulenolide B-TRIVIAL 
D I-TRIVIAL 
( O 
1 O 
) O 
and O 
muurolane-10β,15-diol B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
together O 
with O 
four O 
known O 
sesquiterpenoids B-FAMILY 
, O 
tremulenediol B-TRIVIAL 
A I-TRIVIAL 
( O 
3 O 
) O 
, O 
2β-hydroxy-α-candinol B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
epicubenol B-TRIVIAL 
( O 
5 O 
) O 
, O 
and O 
3β-hydroxy-δ-candinol B-SYSTEMATIC 
( O 
6 O 
) O 
, O 
were O 
isolated O 
from O 
cultures O 
of O 
the O 
fungus O 
Ceriporia O 
alachuana O 
. O 
The O 
structures O 
of O 
new O 
compounds O 
were O 
determined O 
by O 
extensive O 
spectroscopic O 
analyses O 
. O 
Structurally O 
, O 
compounds O 
1 O 
and O 
3 O 
are O 
tremulane B-TRIVIAL 
-type O 
sesquiterpenoids B-FAMILY 
with O 
an O 
unusual O 
perhydroazulene B-SYSTEMATIC 
carbon B-SYSTEMATIC 
skeleton O 
. O 

have O 
investigated O 
the O 
adsorption O 
and O 
organization O 
at O 
the O 
air O 
/ O 
water O 
interface O 
of O 
catanionic O 
molecules O 
released O 
from O 
a O 
dispersion O 
of O 
solid O 
- O 
like O 
catanionic O 
vesicles O 
composed O 
of O 
myristic B-TRIVIAL 
acid I-TRIVIAL 
and O 
cetyl B-SYSTEMATIC 
trimethylammonium I-SYSTEMATIC 
chloride I-SYSTEMATIC 
at O 
the O 
2 O 
: O 
1 O 
ratio O 
. O 
These O 
vesicles O 
were O 
shown O 
recently O 
to O 
be O 
promising O 
foam O 
stabilizers O 
. O 
Using O 
Brewster O 
angle O 
microscopy O 
, O 
we O 
observed O 
the O 
formation O 
of O 
a O 
catanionic O 
monolayer O 
at O 
the O 
air O 
/ O 
water O 
interface O 
composed O 
of O 
liquid O 
- O 
condensed O 
domains O 
in O 
a O 
liquid O 
- O 
expanded O 
matrix O 
. O 
Further O 
adsorption O 
of O 
catanionic O 
molecules O 
forced O 
them O 
to O 
pack O 
, O 
thereby O 
forming O 
a O 
very O 
dense O 
monolayer O 
that O 
prevented O 
further O 
vesicle O 
rupture O 
by O 
avoiding O 
contact O 
of O 
the O 
vesicles O 
with O 
air O 
. O 
Moreover O 
, O 
confocal O 
fluorescence O 
microscopy O 
revealed O 
the O 
presence O 
of O 
layers O 
of O 
intact O 
vesicles O 
that O 
were O 
progressively O 
creaming O 
toward O 
this O 
catanionic O 
monolayer O 
; O 
the O 
surface O 
tension O 
of O 
the O 
vesicle O 
dispersion O 
remained O 
constant O 
upon O 
creaming O 
. O 
The O 
catanionic O 
monolayer O 
behaved O 
as O 
a O 
soft O 
glassy O 
material O 
, O 
an O 
amorphous O 
solid O 
with O 
time- O 
and O 
temperature O 
- O 
dependent O 
properties O 
. O 
Using O 
interfacial O 
oscillatory O 
rheology O 
, O 
we O 
found O 
that O 
the O 
monolayer O 
relaxed O 
mechanical O 
stresses O 
in O 
seconds O 
and O 
melted O 
at O 
a O 
temperature O 
very O 
close O 
to O 
the O 
melting O 
transition O 
temperature O 
of O 
the O 
vesicle O 
bilayers O 
. O 
These O 
results O 
have O 
potential O 
application O 
in O 
the O 
design O 
of O 
smart O 
foams O 
that O 
have O 
temperature O 
- O 
tunable O 
stability O 
. O 

new O 
phenyl-ethanediols B-FAMILY 
from O 
the O 
fruiting O 
bodies O 
of O 
the O 
mushroom O 
Fomes O 
fomentarius O 
. O 

new O 
phenyl-ethanediols B-FAMILY 
, O 
(1R)-(3-ethenylphenyl)-1,2-ethanediol B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
(1R)-(3-formylphenyl)-1,2-ethanediol B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
and O 
(1R)-(3-acetophenyl)-1,2-ethanediol B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
fruiting O 
bodies O 
of O 
the O 
mushroom O 
Fomes O 
fomentarius O 
, O 
together O 
with O 
two O 
related O 
known O 
compounds O 
, O 
(3-ethylphenyl)-1,2-ethanediol B-SYSTEMATIC 
( O 
4 O 
) O 
and O 
(4-acetophenyl)-1,2-ethanediol B-SYSTEMATIC 
( O 
5 O 
) O 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
spectroscopic O 
methods O 
including O 
extensive O 
2D O 
NMR O 
techniques O 
. O 
Compounds O 
1-3 O 
showed O 
weak O 
antimicrobial O 
activity O 
. O 

- O 
mediated O 
autophagy O 
adjustment O 
is O 
involved O 
in O 
the O 
protection O 
of O 
silibinin B-TRIVIAL 
against O 
murine O 
dermal O 
inflammation O 
and O 
epidermal O 
apoptosis O 
induced O 
by O 
UVB O 
irradiation O 
. O 

in O 
murine O 
dermal O 
cells O 
is O 
retarded O 
by O 
ultraviolet O 
B O 
( O 
UVB O 
) O 
irradiation O 
- O 
induced O 
autophagic O 
intervention O 
while O 
simultaneously O 
epidermal O 
cells O 
commit O 
apoptosis O 
, O 
during O 
which O 
inflammatory O 
cytokines O 
released O 
from O 
the O 
lost O 
epidermal O 
cells O 
promote O 
immune O 
responses O 
of O 
dermal O 
inflammatory O 
cells O 
, O 
forming O 
morphological O 
symptoms O 
of O 
acute O 
cutaneous O 
diseases O 
. O 
Autophagy O 
is O 
involved O 
in O 
prevention O 
or O 
provocation O 
of O 
apoptosis O 
of O 
dermal O 
or O 
epidermal O 
cells O 
of O 
UVB-irradiated O 
mice O 
via O 
modulation O 
of O 
intracellular O 
metabolism O 
, O 
intervening O 
the O 
balance O 
between O 
cell O 
death O 
and O 
survival O 
in O 
dermis O 
and O 
epidermis O 
. O 
p53 O 
expressed O 
in O 
immune O 
system O 
affects O 
autophagy O 
function O 
through O 
activating O 
or O 
inactivating O 
genes O 
encoding O 
apoptotic O 
factors O 
and O 
inflammatory O 
cytokines O 
. O 
Silibinin B-TRIVIAL 
protects O 
dermal O 
and O 
epidermal O 
cells O 
of O 
UVB O 
irradiated O 
skin O 
against O 
abnormally O 
autophagy O 
- O 
mediated O 
apoptosis O 
adjustments O 
. O 
In O 
this O 
study O 
, O 
how O 
UVB O 
irradiation O 
intervenes O 
autophagy O 
in O 
dermal O 
and O 
epidermal O 
cells O 
as O 
well O 
as O 
how O 
silibinin B-TRIVIAL 
protects O 
UVB O 
irradiated O 
skin O 
through O 
physiological O 
recovering O 
of O 
autophagy O 
function O 
in O 
dermis O 
and O 
epidermis O 
are O 
focused O 
and O 
elucidated O 
preliminarily O 
. O 
Silibinin B-TRIVIAL 
treatment O 
( O 
50 O 
mg O 
/ O 
kg O 
/ O 
day O 
for O 
4 O 
days O 
) O 
reversed O 
dermal O 
and O 
epidermal O 
autophagy O 
levels O 
from O 
UVB O 
irradiation O 
- O 
induced O 
improper O 
autophagy O 
intervention O 
, O 
repaired O 
the O 
balance O 
between O 
cell O 
survival O 
and O 
death O 
in O 
dermis O 
and O 
epidermis O 
, O 
and O 
protected O 
skin O 
against O 
damage O 
through O 
mediation O 
of O 
p53 O 
activation O 
in O 
dermal O 
and O 
epidermal O 
cells O 
. O 

new O 
coumarin B-FAMILY 
glycosides I-FAMILY 
from O 
Chimonanthus O 
nitens O 
. O 

new O 
coumarin B-FAMILY 
glycosides I-FAMILY 
, O 
namely O 
nitensosides B-MULTIPLE 
A-B I-MULTIPLE 
( O 
1-2 O 
) O 
, O 
together O 
with O 
six O 
known O 
compounds O 
, O 
scopolin B-TRIVIAL 
( O 
3 O 
) O 
, O 
5,6,7-trimethoxycoumarin B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
d-calycanthine B-TRIVIAL 
( O 
5 O 
) O 
, O 
calycanthoside B-TRIVIAL 
( O 
6 O 
) O 
, O 
xeroboside B-TRIVIAL 
( O 
7 O 
) O 
, O 
and O 
scopoletin B-TRIVIAL 
( O 
8 O 
) O 
, O 
were O 
isolated O 
from O 
Chimonanthus O 
nitens O 
. O 
The O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
elucidated O 
by O 
comprehensive O 
analysis O 
of O 
IR O 
, O 
MS O 
, O 
and O 
NMR O 
spectroscopic O 
data O 
. O 
Compounds O 
3 O 
, O 
4 O 
, O 
7 O 
, O 
and O 
8 O 
showed O 
moderate O 
inhibitory O 
activity O 
against O 
Micrococcus O 
luteus O 
. O 

Spectroscopy O 
and O 
Electronic O 
Structure O 
of O 
Copper B-SYSTEMATIC 
Acetylide I-SYSTEMATIC 
, O 
CuCCH B-FORMULA 
. O 

optical O 
spectrum O 
of O 
the O 
linear O 
CuCCH B-FORMULA 
molecule O 
has O 
been O 
investigated O 
for O 
the O 
first O 
time O 
, O 
using O 
resonant O 
two O 
- O 
photon O 
ionization O 
spectroscopy O 
employing O 
ArF B-FAMILY 
( O 
193 O 
nm O 
) O 
or O 
F2 B-FORMULA 
( O 
157 O 
nm O 
) O 
excimer O 
radiation O 
for O 
photoionization O 
. O 
Scans O 
over O 
the O 
range O 
19 O 
400-25 O 
200 O 
cm(-1) O 
were O 
conducted O 
, O 
leading O 
to O 
the O 
observation O 
of O 
three O 
electronic O 
band O 
systems O 
. O 
These O 
are O 
identified O 
as O 
the O 
[ O 
20.2 O 
] O 
ã1 O 
← O 
X̃ O 
(1)Σ(+) O 
, O 
the O 
[ O 
23.1 O 
] O 
Ã O 
(1)Σ(+) O 
← O 
X̃ O 
(1)Σ(+) O 
, O 
and O 
the O 
[ O 
24.7 O 
] O 
B̃ O 
(1)Π O 
← O 
X̃ O 
(1)Σ(+) O 
systems O 
, O 
although O 
only O 
the O 
first O 
two O 
have O 
been O 
rotationally O 
resolved O 
. O 
The O 
ã1 O 
state O 
is O 
tentatively O 
assigned O 
as O 
having O 
(3)Π1 O 
symmetry O 
, O 
becoming O 
optically O 
accessible O 
through O 
spin O 
- O 
orbit O 
interaction O 
with O 
the O 
B̃ O 
(1)Π O 
state O 
. O 
Vibrational O 
assignments O 
have O 
provided O 
the O 
frequency O 
of O 
the O 
Cu-C B-FORMULA 
stretching O 
mode O 
, O 
ν3 O 
, O 
in O 
the O 
ground O 
and O 
all O 
three O 
excited O 
states O 
, O 
along O 
with O 
both O 
bending O 
modes O 
, O 
ν4 O 
and O 
ν5 O 
, O 
in O 
the O 
Ã O 
(1)Σ(+) O 
and O 
B̃ O 
(1)Π O 
states O 
, O 
and O 
the O 
Cu-C≡C B-FORMULA 
bending O 
mode O 
, O 
ν5 O 
, O 
in O 
the O 
ground O 
state O 
. O 
Comparisons O 
are O 
made O 
to O 
the O 
known O 
electronic O 
states O 
of O 
CuF B-FORMULA 
, O 
CuCl B-FORMULA 
, O 
CuBr B-FORMULA 
, O 
and O 
CuI B-FORMULA 
, O 
and O 
it O 
is O 
argued O 
that O 
like O 
these O 
molecules O 
, O 
the O 
CuCCH B-FORMULA 
molecule O 
is O 
essentially O 
ionic O 
in O 
both O 
the O 
ground O 
and O 
excited O 
states O 
, O 
with O 
the O 
ground O 
state O 
correlating O 
diabatically O 
to O 
Cu(+) B-FORMULA 
( O 
3d(10) O 
, O 
(1)S O 
) O 
+ O 
CCH(-) B-FORMULA 
( O 
X̃ O 
(1)Σ(+) O 
) O 
and O 
the O 
excited O 
states O 
correlating O 
diabatically O 
to O 
Cu(+) B-FORMULA 
( O 
3d(9)4s(1) O 
, O 
(1,3)D O 
) O 
+ O 
CCH(-) B-FORMULA 
( O 
X̃ O 
(1)Σ(+) O 
) O 
. O 

adsorption O 
of O 
human O 
serum O 
fibrinogen O 
on O 
polystyrene O 
latex O 
particles O 
was O 
studied O 
using O 
the O 
microelectrophoretic O 
and O 
concentration O 
depletion O 
methods O 
. O 
Measurements O 
were O 
carried O 
out O 
for O 
pH O 
3.5 O 
and O 
an O 
ionic O 
strength O 
range O 
of O 
10(-3) O 
to O 
0.15 O 
M O 
NaCl B-FORMULA 
. O 
The O 
electrophoretic O 
mobility O 
of O 
latex O 
was O 
determined O 
as O 
a O 
function O 
of O 
the O 
amount O 
of O 
adsorbed O 
fibrinogen O 
( O 
surface O 
concentration O 
) O 
. O 
A O 
monotonic O 
increase O 
in O 
the O 
electrophoretic O 
mobility O 
( O 
zeta O 
potential O 
) O 
of O 
the O 
latex O 
was O 
observed O 
, O 
indicating O 
a O 
significant O 
adsorption O 
of O 
fibrinogen O 
on O 
latex O 
for O 
all O 
ionic O 
strengths O 
. O 
No O 
changes O 
in O 
the O 
latex O 
mobility O 
were O 
observed O 
for O 
prolonged O 
time O 
periods O 
, O 
suggesting O 
the O 
irreversibility O 
of O 
fibrinogen O 
adsorption O 
. O 
The O 
maximum O 
coverage O 
of O 
fibrinogen O 
on O 
latex O 
particles O 
was O 
precisely O 
determined O 
using O 
the O 
depletion O 
method O 
. O 
The O 
residual O 
protein O 
concentration O 
after O 
making O 
contact O 
with O 
latex O 
particles O 
was O 
determined O 
by O 
electrokinetic O 
measurements O 
and O 
AFM O 
imaging O 
where O 
the O 
surface O 
coverage O 
of O 
fibrinogen O 
on O 
mica B-TRIVIAL 
was O 
quantitatively O 
determined O 
. O 
The O 
maximum O 
fibrinogen O 
coverage O 
increased O 
monotonically O 
with O 
ionic O 
strength O 
from O 
1.8 O 
mg O 
m(-2) O 
for O 
10(-3) O 
M O 
NaCl O 
to O 
3.6 O 
mg O 
m(-2) O 
for O 
0.15 O 
M O 
NaCl O 
. O 
The O 
increase O 
in O 
the O 
maximum O 
coverage O 
was O 
interpreted O 
in O 
terms O 
of O 
the O 
reduced O 
electrostatic O 
repulsion O 
among O 
adsorbed O 
fibrinogen O 
molecules O 
. O 
The O 
experimental O 
data O 
agree O 
with O 
theoretical O 
simulations O 
made O 
by O 
assuming O 
a O 
3D O 
unoriented O 
adsorption O 
of O 
fibrinogen O 
. O 
The O 
stability O 
of O 
fibrinogen O 
monolayers O 
on O 
latex O 
was O 
also O 
determined O 
in O 
ionic O 
strength O 
cycling O 
experiments O 
. O 
It O 
was O 
revealed O 
that O 
cyclic O 
variations O 
in O 
NaCl B-FORMULA 
concentration O 
between O 
10(-3) O 
and O 
0.15 O 
M O 
induced O 
no O 
changes O 
in O 
the O 
latex O 
electrophoretic O 
mobility O 
, O 
suggesting O 
that O 
there O 
were O 
no O 
irreversible O 
molecule O 
orientation O 
changes O 
in O 
the O 
monolayers O 
. O 
On O 
the O 
basis O 
of O 
these O 
experimental O 
data O 
, O 
a O 
robust O 
procedure O 
of O 
preparing O 
fibrinogen O 
monolayers O 
on O 
latex O 
particles O 
of O 
well O 
- O 
controlled O 
coverage O 
was O 
proposed O 
. O 

new O 
type O 
of O 
protective O 
surface O 
layer O 
for O 
high O 
- O 
capacity O 
Ni B-FORMULA 
-based O 
cathode O 
materials O 
: O 
nanoscaled O 
surface O 
pillaring O 
layer O 
. O 

solid O 
solution O 
series O 
of O 
lithium B-FAMILY 
nickel I-FAMILY 
metal I-FAMILY 
oxides I-FAMILY 
, O 
Li[Ni(1-x)M(x)]O2 B-FAMILY 
( O 
with O 
M O 
= O 
Co B-FORMULA 
, O 
Mn B-FORMULA 
, O 
and O 
Al B-FORMULA 
) O 
have O 
been O 
investigated O 
intensively O 
to O 
enhance O 
the O 
inherent O 
structural O 
instability O 
of O 
LiNiO2 B-FORMULA 
. O 
However O 
, O 
when O 
a O 
voltage O 
range O 
of O 
Ni B-FORMULA 
-based O 
cathode O 
materials O 
was O 
increased O 
up O 
to O 
> O 
4.5 O 
V O 
, O 
phase O 
transitions O 
occurring O 
above O 
4.3 O 
V O 
resulted O 
in O 
accelerated O 
formation O 
of O 
the O 
trigonal O 
phase O 
( O 
P3m1 O 
) O 
and O 
NiO B-FORMULA 
phases O 
, O 
leading O 
to O 
and O 
pulverization O 
of O 
the O 
cathode O 
during O 
cycling O 
at O 
60 O 
°C O 
. O 
In O 
an O 
attempt O 
to O 
overcome O 
these O 
problems O 
, O 
LiNi0.62Co0.14Mn0.24O2 B-FORMULA 
cathode O 
material O 
with O 
pillar O 
layers O 
in O 
which O 
Ni(2+) B-FORMULA 
ions O 
were O 
resided O 
in O 
Li B-FORMULA 
slabs O 
near O 
the O 
surface O 
having O 
a O 
thickness O 
of O 
∼10 O 
nm O 
was O 
prepared O 
using O 
a O 
polyvinylpyrrolidone B-SYSTEMATIC 
( O 
PVP B-ABBREVIATION 
) O 
functionalized O 
Mn B-FORMULA 
precursor O 
coating O 
on O 
Ni0.7Co0.15Mn0.15(OH)2 B-FORMULA 
. O 
We O 
confirmed O 
the O 
formation O 
of O 
a O 
pillar O 
layer O 
via O 
various O 
analysis O 
methods O 
( O 
XPS O 
, O 
HRTEM O 
, O 
and O 
STEM O 
) O 
. O 
This O 
material O 
showed O 
excellent O 
structural O 
stability O 
due O 
to O 
a O 
pillar O 
layer O 
, O 
corresponding O 
to O 
85% O 
capacity O 
retention O 
between O 
3 O 
and O 
4.5 O 
V O 
at O 
60 O 
°C O 
after O 
100 O 
cycles O 
. O 
In O 
addition O 
, O 
the O 
amount O 
of O 
heat O 
generation O 
was O 
decreased O 
by O 
40% O 
, O 
compared O 
to O 
LiNi0.70Co0.15Mn0.15O2 B-FORMULA 
. O 

phenolics B-FAMILY 
from O 
Seriphidium O 
stenocephalum O 
. O 

separation O 
of O 
the O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
soluble O 
part O 
of O 
the O 
methanolic O 
extract O 
from O 
Seriphidium O 
stenocephalum O 
yielded O 
three O 
new O 
compounds O 
: O 
stenocepflavone B-TRIVIAL 
( O 
1 O 
) O 
, O 
stenocepflavan B-TRIVIAL 
( O 
2 O 
) O 
, O 
and O 
stenocephol B-TRIVIAL 
( O 
3 O 
) O 
, O 
together O 
with O 
cirsimaritin B-TRIVIAL 
( O 
4 O 
) O 
, O 
5,7,5'-trihydroxy-3',4',6-trimethoxyflavone B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
5,6,7,5'-tetrahydroxy-4'-methoxyflavone B-SYSTEMATIC 
( O 
6 O 
) O 
, O 
and O 
axillaroside B-TRIVIAL 
( O 
7 O 
) O 
. O 
All O 
isolates O 
were O 
characterized O 
with O 
the O 
help O 
of O 
spectroscopic O 
data O 
including O 
1D O 
, O 
2D O 
NMR O 
, O 
and O 
high O 
resolution O 
mass O 
spectrometry O 
and O 
/ O 
or O 
in O 
comparison O 
with O 
the O 
related O 
compounds O 
in O 
literature O 
. O 
All O 
compounds O 
were O 
tested O 
for O 
in O 
vitro O 
enzyme O 
inhibitory O 
activities O 
against O 
acetylcholinesterase O 
, O 
butyrylcholinesterase O 
, O 
and O 
lipoxygenase O 
. O 
Compounds O 
1 O 
and O 
4-7 O 
exhibited O 
significant O 
activity O 
against O 
all O 
the O 
tested O 
enzymes O 
, O 
whereas O 
compounds O 
2 O 
and O 
3 O 
were O 
found O 
inactive O 
. O 

review O 
gives O 
an O 
overview O 
of O 
flow O 
cytometry O 
applications O 
to O 
toxicological O 
studies O 
of O 
several O 
physiological O 
target O 
sites O 
of O 
mycotoxins O 
on O 
different O 
mammalian O 
cell O 
lines O 
. O 
Mycotoxins O 
are O 
secondary O 
metabolites O 
of O 
fungi O 
that O 
may O 
be O 
present O 
in O 
food O 
, O 
feed O 
, O 
air O 
and O 
water O 
. O 
The O 
increasing O 
presence O 
of O 
mycotoxins O 
in O 
crops O 
, O 
their O 
wide O 
distribution O 
in O 
the O 
food O 
chain O 
, O 
and O 
their O 
potential O 
for O 
toxicity O 
demonstrate O 
the O 
need O 
for O 
further O 
knowledge O 
. O 
Flow O 
cytometry O 
has O 
become O 
a O 
valuable O 
tool O 
in O 
mycotoxin O 
studies O 
in O 
recent O 
years O 
for O 
the O 
rapid O 
analysis O 
of O 
single O 
cells O 
in O 
a O 
mixture O 
. O 
In O 
toxicology O 
, O 
the O 
power O 
of O 
these O 
methods O 
lies O 
in O 
the O 
possibility O 
of O 
determining O 
a O 
wide O 
range O 
of O 
cell O 
parameters O 
, O 
providing O 
valuable O 
information O 
to O 
elucidate O 
cell O 
growth O 
and O 
viability O 
, O 
metabolic O 
activity O 
, O 
mitochondrial O 
membrane O 
potential O 
and O 
membrane O 
integrity O 
mechanisms O 
. O 
There O 
are O 
studies O 
using O 
flow O 
cytometry O 
technique O 
on O 
Alternaria O 
, O 
Aspergillus O 
, O 
Fusarium O 
and O 
Penicillium O 
mycotoxins O 
including O 
information O 
about O 
cell O 
type O 
, O 
assay O 
conditions O 
and O 
functional O 
parameters O 
. O 
Most O 
of O 
the O 
studies O 
collected O 
in O 
the O 
literature O 
are O 
on O 
deoxynivalenol B-TRIVIAL 
and O 
zearalenone B-TRIVIAL 
mycotoxins O 
. O 
Cell O 
cycle O 
analysis O 
and O 
apoptosis O 
are O 
the O 
processes O 
more O 
widely O 
investigated O 
. O 

ovary O 
syndrome O 
( O 
PCOS O 
) O 
is O 
considered O 
a O 
complex O 
multifactorial O 
disorder O 
resulting O 
from O 
the O 
interaction O 
of O 
genetic O 
, O 
environmental O 
, O 
and O 
lifestyle O 
influences O 
. O 
Nontargeted O 
proteomics O 
and O 
metabolomics O 
have O 
been O 
used O 
in O 
the O 
past O 
years O 
with O 
the O 
aim O 
of O 
identifying O 
molecules O 
potentially O 
involved O 
in O 
the O 
pathophysiology O 
of O 
this O 
frequent O 
disorder O 
. O 
The O 
biomolecules O 
identified O 
so O 
far O 
participate O 
in O 
many O 
metabolic O 
pathways O 
, O 
including O 
energy O 
metabolism O 
( O 
glucose B-TRIVIAL 
and O 
lipid O 
metabolism O 
) O 
, O 
protein O 
metabolic O 
processes O 
and O 
protein O 
folding O 
, O 
cytoskeleton O 
structure O 
, O 
immune O 
response O 
, O 
inflammation O 
and O 
iron O 
metabolism O 
, O 
fibrinolysis O 
and O 
thrombosis O 
, O 
oxidative O 
stress O 
and O 
intracellular O 
calcium B-SYSTEMATIC 
metabolism O 
. O 
These O 
molecules O 
provide O 
key O 
information O 
about O 
molecular O 
functions O 
altered O 
in O 
PCOS O 
and O 
raise O 
questions O 
concerning O 
their O 
precise O 
role O 
in O 
the O 
pathogenesis O 
of O 
this O 
syndrome O 
. O 
The O 
biomolecules O 
identified O 
by O 
nontargeted O 
proteomic O 
and O 
metabolomic O 
approaches O 
should O 
be O 
considered O 
as O 
candidates O 
in O 
future O 
studies O 
aiming O 
to O 
define O 
specific O 
molecular O 
phenotypes O 
of O 
PCOS O 
. O 

polyphenols B-FAMILY 
from O 
Nigerian O 
mistletoe O 
Loranthus O 
micranthus O 
( O 
Linn O 
. O 
) O 
parasitizing O 
on O 
Hevea O 
brasiliensis O 
. O 

new O 
phenolic B-FAMILY 
glycosides I-FAMILY 
, O 
linamarin B-TRIVIAL 
gallate I-TRIVIAL 
( O 
1 O 
) O 
and O 
walsuraside B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
, O 
together O 
with O 
nine O 
known O 
compounds O 
, O 
catechin B-TRIVIAL 
( O 
3 O 
) O 
, O 
epicatechin B-TRIVIAL 
( O 
4 O 
) O 
, O 
epicatechin B-SYSTEMATIC 
3-O-gallate I-SYSTEMATIC 
( O 
5 O 
) O 
, O 
epicatechin B-SYSTEMATIC 
3-O-(3-O-methyl)gallate I-SYSTEMATIC 
( O 
6 O 
) O 
, O 
epicatechin B-SYSTEMATIC 
3-O-(3,5-O-dimethyl)gallate I-SYSTEMATIC 
( O 
7 O 
) O 
, O 
epicatechin B-SYSTEMATIC 
3-O-(3,4,5-O-trimethyl)gallate I-SYSTEMATIC 
( O 
8 O 
) O 
, O 
quercetin B-SYSTEMATIC 
3-O-β-d-glucopyranoside I-SYSTEMATIC 
( O 
9 O 
) O 
, O 
rutin B-TRIVIAL 
( O 
10 O 
) O 
, O 
and O 
peltatoside B-TRIVIAL 
( O 
11 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
leafy O 
twigs O 
of O 
Nigerian O 
mistletoe O 
Loranthus O 
micranthus O 
( O 
Linn O 
. O 
) O 
parasitic O 
on O 
Hevea O 
brasiliensis O 
. O 
Compound O 
1 O 
was O 
characterized O 
as O 
an O 
unusual O 
cyanogenic B-FAMILY 
glycoside I-FAMILY 
, O 
while O 
compound O 
8 O 
was O 
isolated O 
for O 
the O 
first O 
time O 
from O 
a O 
natural O 
source O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
a O 
cyanogenic B-FAMILY 
glycoside I-FAMILY 
from O 
mistletoes O 
. O 
The O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
unambiguously O 
elucidated O 
by O 
1D O 
( O 
(1)H B-FORMULA 
, O 
(13)C B-FORMULA 
) O 
, O 
2D O 
NMR O 
( O 
COSY O 
, O 
HSQC O 
, O 
and O 
HMBC O 
) O 
and O 
by O 
mass O 
spectroscopy O 
. O 
The O 
antioxidant O 
activities O 
of O 
the O 
isolated O 
compounds O 
( O 
1-11 O 
) O 
were O 
evaluated O 
using O 
the O 
2 B-SYSTEMATIC 
, I-SYSTEMATIC 
2-diphenyl-1-picrylhydrazyl I-SYSTEMATIC 
( O 
DPPH B-ABBREVIATION 
) O 
assay O 
. O 

neuroprotector O 
kynurenic B-TRIVIAL 
acid I-TRIVIAL 
increases O 
neuronal O 
cell O 
survival O 
through O 
neprilysin O 
induction O 
. O 

acid I-TRIVIAL 
( O 
KYNA B-ABBREVIATION 
) O 
, O 
one O 
of O 
the O 
main O 
product O 
of O 
the O 
kynurenine B-TRIVIAL 
pathway O 
originating O 
from O 
tryptophan B-TRIVIAL 
, O 
is O 
considered O 
to O 
be O 
neuroprotective O 
. O 
Dysregulation O 
of O 
KYNA B-ABBREVIATION 
activity O 
is O 
thought O 
to O 
be O 
involved O 
in O 
neurodegenerative O 
diseases O 
, O 
the O 
physiopathology O 
of O 
which O 
evokes O 
excitotoxicity O 
, O 
oxidative O 
stress O 
and O 
/ O 
or O 
protein O 
aggregation O 
. O 
The O 
neuroprotective O 
effect O 
of O 
KYNA B-ABBREVIATION 
is O 
generally O 
attributed O 
to O 
its O 
antagonistic O 
action O 
on O 
NMDA B-ABBREVIATION 
receptors O 
. O 
However O 
, O 
this O 
single O 
target O 
action O 
appears O 
insufficient O 
to O 
support O 
KYNA B-ABBREVIATION 
beneficial O 
effects O 
against O 
complex O 
neurodegenerative O 
processes O 
including O 
neuroinflammation O 
, O 
β-amyloid O 
peptide O 
( O 
Aβ O 
) O 
toxicity O 
and O 
apoptosis O 
. O 
Novel O 
insights O 
are O 
therefore O 
required O 
to O 
elucidate O 
KYNA B-ABBREVIATION 
neuroprotective O 
mechanisms O 
. O 
Here O 
, O 
we O 
combined O 
cellular O 
, O 
biochemical O 
, O 
molecular O 
and O 
pharmacological O 
approaches O 
to O 
demonstrate O 
that O 
low O 
micromolar O 
concentrations O 
of O 
KYNA B-ABBREVIATION 
strongly O 
induce O 
neprilysin O 
( O 
NEP O 
) O 
gene O 
expression O 
, O 
protein O 
level O 
and O 
enzymatic O 
activity O 
increase O 
in O 
human O 
neuroblastoma O 
SH-SY5Y O 
cells O 
. O 
Furthermore O 
, O 
our O 
studies O 
revealed O 
that O 
KYNA B-ABBREVIATION 
exerts O 
a O 
protective O 
effect O 
on O 
SH-SY5Y O 
cells O 
by O 
increasing O 
their O 
viability O 
through O 
a O 
mechanism O 
independent O 
from O 
NMDA B-ABBREVIATION 
receptors O 
. O 
Interestingly O 
, O 
KYNA B-ABBREVIATION 
also O 
induced O 
NEP O 
activity O 
and O 
neuroprotection O 
in O 
mouse O 
cortical O 
neuron O 
cultures O 
the O 
viability O 
of O 
which O 
was O 
more O 
promoted O 
than O 
SH-SY5Y O 
cell O 
survival O 
under O 
KYNA B-ABBREVIATION 
treatment O 
. O 
KYNA B-ABBREVIATION 
-evoked O 
neuroprotection O 
disappeared O 
in O 
the O 
presence O 
of O 
thiorphan B-TRIVIAL 
, O 
an O 
inhibitor O 
of O 
NEP O 
activity O 
. O 
NEP O 
is O 
a O 
well O 
characterized O 
metallopeptidase O 
whose O 
deregulation O 
leads O 
to O 
cerebral O 
Aβ O 
accumulation O 
and O 
neuronal O 
death O 
in O 
Alzheimer's O 
disease O 
. O 
Therefore O 
, O 
our O 
results O 
suggest O 
that O 
a O 
part O 
of O 
the O 
neuroprotective O 
role O 
of O 
KYNA B-ABBREVIATION 
may O 
depend O 
on O 
its O 
ability O 
to O 
induce O 
the O 
expression O 
and O 
/ O 
or O 
activity O 
of O 
the O 
amyloid O 
- O 
degrading O 
enzyme O 
NEP O 
in O 
nerve O 
cells O 
. O 

chemistry O 
has O 
recently O 
emerged O 
as O 
a O 
promising O 
way O 
to O 
modulate O 
protein O 
functions O 
, O 
but O 
devising O 
molecules O 
that O 
will O 
interact O 
with O 
a O 
protein O 
in O 
the O 
desired O 
manner O 
is O 
difficult O 
as O 
many O 
competing O 
interactions O 
exist O 
in O 
a O 
biological O 
environment O 
( O 
with O 
solvents O 
, O 
salts O 
or O 
different O 
sites O 
for O 
the O 
target O 
biomolecule O 
) O 
. O 
We O 
now O 
show O 
that O 
lysine B-TRIVIAL 
-specific O 
molecular O 
tweezers O 
bind O 
to O 
a O 
14-3-3 O 
adapter O 
protein O 
and O 
modulate O 
its O 
interaction O 
with O 
partner O 
proteins O 
. O 
The O 
tweezers O 
inhibit O 
binding O 
between O 
the O 
14-3-3 O 
protein O 
and O 
two O 
partner O 
proteins O 
-- O 
a O 
phosphorylated O 
( O 
C-Raf O 
) O 
protein O 
and O 
an O 
unphosphorylated O 
one O 
( O 
ExoS O 
) O 
-- O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 
Protein O 
crystallography O 
shows O 
that O 
this O 
effect O 
arises O 
from O 
the O 
binding O 
of O 
the O 
tweezers O 
to O 
a O 
single O 
surface O 
- O 
exposed O 
lysine B-TRIVIAL 
( O 
Lys B-FORMULA 
214 O 
) O 
of O 
the O 
14-3-3 O 
protein O 
in O 
the O 
proximity O 
of O 
its O 
central O 
channel O 
, O 
which O 
normally O 
binds O 
the O 
partner O 
proteins O 
. O 
A O 
combination O 
of O 
structural O 
analysis O 
and O 
computer O 
simulations O 
provides O 
rules O 
for O 
the O 
tweezers O 
' O 
binding O 
preferences O 
, O 
thus O 
allowing O 
us O 
to O 
predict O 
their O 
influence O 
on O 
this O 
type O 
of O 
protein O 
- O 
protein O 
interactions O 
. O 

inhibits O 
NADPH B-ABBREVIATION 
oxidase O 
activation O 
and O 
protects O 
endothelial O 
function O 
in O 
the O 
rat O 
aorta O 
: O 
Implications O 
for O 
vascular O 
aging O 
. O 

aging O 
is O 
characterized O 
by O 
up O 
- O 
regulation O 
of O 
NADPH B-ABBREVIATION 
oxidase O 
, O 
oxidative O 
stress O 
and O 
endothelial O 
dysfunction O 
. O 
Previous O 
studies O 
demonstrate O 
that O 
the O 
activity O 
of O 
the O 
evolutionarily O 
conserved O 
NAD(+) B-ABBREVIATION 
-dependent O 
deacetylase O 
SIRT1 O 
declines O 
with O 
age O 
and O 
that O 
pharmacological O 
activators O 
of O 
SIRT1 O 
confer O 
significant O 
anti-aging O 
cardiovascular O 
effects O 
. O 
To O 
determine O 
whether O 
dysregulation O 
of O 
SIRT1 O 
promotes O 
NADPH B-ABBREVIATION 
oxidase O 
- O 
dependent O 
production O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
and O 
impairs O 
endothelial O 
function O 
we O 
assessed O 
the O 
effects O 
of O 
three O 
structurally O 
different O 
inhibitors O 
of O 
SIRT1 O 
( O 
nicotinamide B-TRIVIAL 
, O 
sirtinol B-TRIVIAL 
, O 
EX527 B-IDENTIFIER 
) O 
in O 
aorta O 
segments O 
isolated O 
from O 
young O 
Wistar O 
rats O 
. O 
Inhibition O 
of O 
SIRT1 O 
induced O 
endothelial O 
dysfunction O 
, O 
as O 
shown O 
by O 
the O 
significantly O 
reduced O 
relaxation O 
to O 
the O 
endothelium O 
- O 
dependent O 
vasodilators O 
acetylcholine B-SYSTEMATIC 
and O 
the O 
calcium B-SYSTEMATIC 
ionophore O 
A23187 B-IDENTIFIER 
. O 
Endothelial O 
dysfunction O 
induced O 
by O 
SIRT1 O 
inhibition O 
was O 
prevented O 
by O 
treatment O 
of O 
the O 
vessels O 
with O 
the O 
NADPH B-ABBREVIATION 
oxidase O 
inhibitor O 
apocynin B-TRIVIAL 
or O 
superoxide B-TRIVIAL 
dismutase O 
. O 
Inhibition O 
of O 
SIRT1 O 
significantly O 
increased O 
vascular O 
superoxide B-TRIVIAL 
production O 
, O 
enhanced O 
NADPH B-ABBREVIATION 
oxidase O 
activity O 
, O 
and O 
mRNA O 
expression O 
of O 
its O 
subunits O 
p22(phox) O 
and O 
NOX4 O 
, O 
which O 
were O 
prevented O 
by O 
resveratrol B-TRIVIAL 
. O 
Peroxisome O 
proliferator O 
- O 
activated O 
receptor-α O 
( O 
PPARα O 
) O 
activation O 
mimicked O 
the O 
effects O 
of O 
resveratrol B-TRIVIAL 
while O 
PPARα O 
inhibition O 
prevented O 
the O 
effects O 
of O 
this O 
SIRT1 O 
activator O 
. O 
SIRT1 O 
co O 
- O 
precipitated O 
with O 
PPARα O 
and O 
nicotinamide B-TRIVIAL 
increased O 
the O 
acetylation O 
of O 
the O 
PPARα O 
coactivator O 
PGC-1α O 
, O 
which O 
was O 
suppressed O 
by O 
resveratrol B-TRIVIAL 
. O 
In O 
conclusion O 
, O 
impaired O 
activity O 
of O 
SIRT1 O 
induces O 
endothelial O 
dysfunction O 
and O 
up O 
- O 
regulates O 
NADPH B-ABBREVIATION 
oxidase O 
- O 
derived O 
ROS O 
production O 
in O 
the O 
vascular O 
wall O 
, O 
mimicking O 
the O 
vascular O 
aging O 
phenotype O 
. O 
Moreover O 
, O 
a O 
new O 
mechanism O 
for O 
controlling O 
endothelial O 
function O 
after O 
SIRT1 O 
activation O 
involves O 
a O 
decreased O 
PGC-1α O 
acetylation O 
and O 
the O 
subsequent O 
PPARα O 
activation O 
, O 
resulting O 
in O 
both O 
decreased O 
NADPH B-ABBREVIATION 
oxidase O 
- O 
driven O 
ROS O 
production O 
and O 
NO B-FORMULA 
inactivation O 
. O 

block O 
/ O 
homo-mixed O 
polyplex O 
micelle O 
, O 
comprising O 
of O 
cationic O 
homo O 
polymer O 
: O 
poly{N'-[N-(2-aminoethyl)-2-aminoethyl]aspartamide} B-FAMILY 
P[Asp(DET)] B-ABBREVIATION 
and O 
block O 
copolymer O 
: O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
(PEG)-b-P[Asp(DET)] B-ABBREVIATION 
, O 
has O 
been O 
reported O 
to O 
exhibit O 
the O 
efficient O 
transgene O 
expression O 
in O 
vivo O 
by O 
intratracheal O 
and O 
systemic O 
administration O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
potential O 
of O 
immunogene O 
therapy O 
by O 
intraperitoneal O 
( O 
i.p O 
. O 
) O 
administration O 
of O 
block O 
/ O 
homo O 
polyplex O 
micelles O 
for O 
peritoneal O 
dissemination O 
. O 
For O 
evaluation O 
of O 
transgene O 
expression O 
in O 
vivo O 
, O 
block O 
/ O 
homo O 
polyplex O 
micelles O 
showed O 
12-fold O 
higher O 
level O 
in O 
luciferase O 
expression O 
evaluated O 
by O 
bioluminescence O 
imaging O 
system O 
at O 
24h O 
after O 
the O 
i.p O 
. O 
administration O 
compared O 
with O 
block O 
polyplex O 
micelles O 
composed O 
with O 
only O 
PEG-b-P[Asp(DET)] B-ABBREVIATION 
in O 
nude O 
mice O 
bearing O 
peritoneal O 
dissemination O 
. O 
The O 
distribution O 
of O 
block O 
/ O 
homo O 
polyplex O 
micelles O 
and O 
intracellular O 
uptake O 
of O 
pDNA O 
was O 
observed O 
in O 
tumor O 
nodules O 
. O 
The O 
tumor O 
growth O 
and O 
the O 
prolonged O 
survival O 
rate O 
for O 
the O 
mice O 
harboring O 
disseminated O 
pancreatic O 
cancer O 
more O 
significantly O 
compared O 
with O 
the O 
mock O 
. O 
The O 
antitumor O 
effect O 
of O 
GM-CSF O 
gene O 
therapy O 
was O 
mediated O 
via O 
the O 
activation O 
of O 
natural O 
killer O 
cells O 
. O 
For O 
safety O 
evaluation O 
, O 
block O 
/ O 
homo O 
polyplex O 
micelles O 
indicated O 
almost O 
no O 
adverse O 
events O 
for O 
patho O 
- O 
physical O 
findings O 
and O 
blood O 
examinations O 
in O 
mice O 
and O 
cynomolgus O 
monkeys O 
, O 
although O 
slight O 
increases O 
in O 
serum O 
fibrinogen O 
were O 
observed O 
in O 
the O 
monkey O 
model O 
. O 
In O 
conclusion O 
, O 
block O 
/ O 
homo O 
polyplex O 
micelle O 
- O 
based O 
immunogene O 
therapy O 
via O 
i.p O 
. O 
administration O 
may O 
be O 
a O 
safe O 
and O 
effective O 
approach O 
for O 
suppressing O 
intractable O 
peritoneal O 
dissemination O 
. O 

glucose B-TRIVIAL 
environment O 
enhanced O 
oxidative O 
stress O 
and O 
increased O 
interleukin-8 O 
secretion O 
from O 
keratinocytes O 
: O 
New O 
insights O 
on O 
impaired O 
diabetic O 
wound O 
healing O 
. O 

wound O 
healing O 
frequently O 
occurs O 
in O 
patients O 
with O 
diabetes O 
. O 
Interluekin-8 O 
( O 
IL-8 O 
) O 
production O 
by O 
keratinocyte O 
is O 
responsible O 
for O 
recruiting O 
neutrophils O 
during O 
healing O 
. O 
Intense O 
inflammation O 
is O 
associated O 
with O 
diabetic O 
wounds O 
while O 
reduction O 
of O 
neutrophil O 
infiltration O 
is O 
associated O 
with O 
enhanced O 
healing O 
. O 
We O 
hypothesized O 
that O 
increased O 
neutrophil O 
recruitment O 
by O 
keratinocytes O 
may O 
contribute O 
to O 
the O 
delayed O 
healing O 
of O 
diabetic O 
wound O 
. O 
Using O 
cultured O 
human O 
keratinocytes O 
and O 
diabetic O 
rat O 
model O 
, O 
the O 
current O 
study O 
showed O 
that O 
high- O 
glucose B-TRIVIAL 
environment O 
enhanced O 
IL-8 O 
production O 
via O 
epidermal O 
growth O 
factor O 
receptor O 
( O 
EGFR O 
) O 
-extracelluar O 
signal O 
- O 
regulated O 
kinase O 
( O 
ERK O 
) O 
pathway O 
in O 
a O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
(ROS)-dependent O 
manner O 
in O 
keratinocytes O 
. O 
In O 
addition O 
, O 
diabetic O 
rat O 
skin O 
showed O 
enhanced O 
EGFR O 
, O 
ERK O 
and O 
IL-8 O 
expression O 
as O 
compared O 
to O 
control O 
rats O 
. O 
The O 
dermal O 
neutrophil O 
infiltration O 
of O 
the O 
wound O 
, O 
as O 
represented O 
by O 
expression O 
of O 
myeloperoxidase O 
level O 
, O 
was O 
also O 
significantly O 
higher O 
in O 
diabetic O 
rats O 
. O 
Treating O 
diabetic O 
rats O 
with O 
dapsone B-TRIVIAL 
, O 
an O 
agent O 
known O 
to O 
inhibit O 
neutrophil O 
function O 
, O 
was O 
associated O 
with O 
improved O 
healing O 
. O 
In O 
conclusion O 
, O 
IL-8 O 
production O 
and O 
neutrophil O 
infiltration O 
are O 
increased O 
in O 
high- O 
glucose B-TRIVIAL 
environment O 
due O 
to O 
elevated O 
ROS O 
level O 
and O 
contributed O 
to O 
impaired O 
wound O 
healing O 
in O 
diabetic O 
skin O 
. O 
Targeting O 
these O 
dysfunctions O 
may O 
present O 
novel O 
therapeutic O 
approaches O 
. O 

and O 
early O 
life O 
stages O 
are O 
critical O 
periods O 
characterized O 
by O 
severe O 
alterations O 
of O 
the O 
redox O 
balance O 
and O 
by O 
" O 
physiological O 
" O 
genomic O 
changes O 
in O 
lung O 
cells O 
, O 
which O 
may O 
be O 
responsible O 
for O 
cancer O 
and O 
other O 
diseases O 
in O 
adulthood O 
. O 
Oxidative O 
stress O 
is O 
a O 
major O 
mechanism O 
accounting O 
for O 
the O 
carcinogenicity O 
of O 
cigarette O 
smoke O 
( O 
CS O 
) O 
, O 
which O 
becomes O 
more O 
potently O 
carcinogenic O 
in O 
mice O 
when O 
exposure O 
starts O 
at O 
birth O 
and O 
continues O 
early O 
in O 
life O 
. O 
We O 
compared O 
herewith O 
a O 
variety O 
of O 
end O 
- O 
points O 
related O 
to O 
oxidative O 
stress O 
, O 
mitochondrial O 
alterations O 
, O 
and O 
cell O 
turnover O 
in O 
the O 
lung O 
of O 
Swiss O 
H O 
mice O 
, O 
either O 
sham O 
- O 
exposed O 
or O 
CS-exposed O 
for O 
4 O 
weeks O 
, O 
starting O 
either O 
at O 
birth O 
or O 
at O 
4 O 
months O 
of O 
age O 
. O 
The O 
results O 
showed O 
that O 
the O 
physiological O 
levels O 
of O 
certain O 
end O 
- O 
points O 
are O 
affected O 
by O 
age O 
. O 
In O 
fact O 
, O 
the O 
baseline O 
proportion O 
of O 
hypodiploid O 
cells O 
and O 
the O 
mitochondrial O 
potential O 
and O 
mass O 
were O 
higher O 
in O 
adults O 
, O 
whereas O 
8-hydroxy-2'-deoxyguanosine B-SYSTEMATIC 
( O 
8-oxo-dGuo B-SYSTEMATIC 
) O 
levels O 
, O 
the O 
proportion O 
of O 
necrotic O 
cells O 
, O 
and O 
the O 
extent O 
of O 
autophagy O 
were O 
higher O 
early O 
in O 
life O 
. O 
Adult O 
mice O 
were O 
more O 
responsive O 
to O 
CS O 
by O 
increasing O 
the O 
proportion O 
of O 
necrotic O 
cells O 
and O 
of O 
cells O 
in O 
S O 
/ O 
G2 O 
phase O 
, O 
whereas O 
young O 
mice O 
maintained O 
a O 
high O 
extent O 
of O 
autophagy O 
, O 
exhibited O 
a O 
greater O 
increase O 
of O 
lipid O 
peroxidation O 
products O 
and O 
8-oxo-dGuo B-SYSTEMATIC 
levels O 
, O 
and O 
had O 
a O 
higher O 
frequency O 
of O 
micronucleated O 
cells O 
. O 
In O 
addition O 
, O 
exposure O 
to O 
CS O 
affected O 
the O 
mitochondrial O 
potential O 
/ O 
mass O 
, O 
especially O 
in O 
young O 
mice O 
. O 
In O 
conclusion O 
, O 
these O 
data O 
provide O 
evidence O 
that O 
oxidative O 
stress O 
and O 
the O 
resulting O 
DNA O 
damage O 
provide O 
a O 
major O 
contribution O 
to O 
the O 
high O 
susceptibility O 
of O 
mice O 
to O 
CS O 
early O 
in O 
life O 
. O 

influence O 
of O 
salinity O 
on O 
acute O 
nickel B-SYSTEMATIC 
toxicity O 
to O 
the O 
two O 
euryhaline O 
fish O 
species O 
, O 
Fundulus O 
heteroclitus O 
and O 
Kryptolebias O 
marmoratus O 
. O 

( O 
Ni B-FORMULA 
) O 
is O 
a O 
common O 
pollutant O 
found O 
in O 
aquatic O 
environments O 
and O 
may O 
be O 
harmful O 
at O 
elevated O 
concentrations O 
. O 
Increasing O 
salinity O 
has O 
been O 
shown O 
to O 
decrease O 
the O 
bioavailability O 
and O 
toxicity O 
of O 
other O 
metals O 
to O 
aquatic O 
organisms O 
. O 
In O 
the O 
present O 
study O 
, O 
acute O 
Ni B-FORMULA 
toxicity O 
experiments O 
( O 
96-h O 
) O 
were O 
conducted O 
at O 
various O 
salinities O 
( O 
0-36 O 
ppt O 
) O 
to O 
determine O 
the O 
effects O 
of O 
salinity O 
on O 
Ni B-FORMULA 
toxicity O 
to O 
2 O 
euryhaline O 
fish O 
species O 
, O 
Kryptolebias O 
marmoratus O 
and O 
Fundulus O 
heteroclitus O 
. O 
Nickel B-SYSTEMATIC 
concentrations O 
causing O 
lethality O 
to O 
50% O 
of O 
the O 
fish O 
ranged O 
from O 
2 O 
mg O 
/ O 
L O 
in O 
moderately O 
hard O 
freshwater O 
to O 
66.6 O 
mg O 
/ O 
L O 
in O 
36 O 
ppt O 
saltwater O 
. O 
Nickel B-SYSTEMATIC 
toxicity O 
to O 
F O 
. O 
heteroclitus O 
decreased O 
linearly O 
with O 
increasing O 
salinity O 
; O 
however O 
, O 
Ni B-FORMULA 
toxicity O 
to O 
K O 
. O 
marmoratus O 
was O 
only O 
lowered O 
by O 
salinities O 
above O 
6 O 
ppt O 
, O 
demonstrating O 
potential O 
physiological O 
differences O 
between O 
the O 
2 O 
species O 
when O 
they O 
are O 
functioning O 
as O 
freshwater O 
fish O 
. O 
Furthermore O 
, O 
the O 
authors O 
investigated O 
the O 
influence O 
of O 
Mg(2+) B-FORMULA 
, O 
Ca(2+) B-FORMULA 
, O 
Na(+) B-FORMULA 
, O 
and O 
Cl(-) B-FORMULA 
on O 
Ni B-FORMULA 
toxicity O 
to O 
F O 
. O 
heteroclitus O 
. O 
Freshwater O 
with O 
up O 
to O 
120 O 
mg O 
/ O 
L O 
Ca(2+) B-FORMULA 
as O 
CaSO4 B-FORMULA 
, O 
250 O 
mg O 
/ O 
L O 
Mg(2+) B-FORMULA 
as O 
MgSO4 B-FORMULA 
, O 
or O 
250 O 
mg O 
/ O 
L O 
Na(+) B-FORMULA 
as O 
NaHCO3 B-FORMULA 
did O 
not O 
provide O 
protection O 
against O 
Ni B-FORMULA 
toxicity O 
. O 
Alternatively O 
, O 
250 O 
mg O 
/ O 
L O 
Na(+) B-FORMULA 
, O 
as O 
NaCl B-FORMULA 
, O 
was O 
protective O 
against O 
Ni B-FORMULA 
toxicity O 
; O 
and O 
the O 
extent O 
of O 
protection O 
was O 
similar O 
to O 
that O 
demonstrated O 
from O 
salt O 
water O 
with O 
the O 
same O 
Cl(-) B-FORMULA 
concentration O 
. O 
These O 
results O 
suggest O 
that O 
Cl(-) B-FORMULA 
is O 
the O 
predominant O 
ion O 
responsible O 
for O 
reducing O 
Ni B-FORMULA 
toxicity O 
to O 
K O 
. O 
marmoratus O 
and O 
F O 
. O 
heteroclitus O 
in O 
higher O 
salinity O 
waters O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1354-1359 O 
. O 
© O 
2013 O 
SETAC O 
. O 

of O 
phytotoxicity O 
and O 
genotoxicity O 
of O 
nitrobenzene B-SYSTEMATIC 
with O 
A O 
battery O 
of O 
Vicia O 
Faba O 
assay O 
system O 
. O 

( O 
NB O 
) O 
is O 
an O 
important O 
organic O 
compound O 
intermediate O 
that O 
is O 
used O 
widely O 
in O 
industry O 
. O 
In O 
the O 
present O 
study O 
, O 
to O 
evaluate O 
the O 
phytotoxicity O 
and O 
genotoxicity O 
of O 
NB O 
on O 
plants O 
, O 
Vicia O 
faba O 
was O 
exposed O 
to O 
increasing O 
concentrations O 
of O 
NB O 
( O 
5 O 
mg O 
L(-1) O 
, O 
10 O 
mg O 
L(-1) O 
, O 
25 O 
mg O 
L(-1) O 
, O 
50 O 
mg O 
L(-1) O 
, O 
and O 
100 O 
mg O 
L(-1) O 
) O 
. O 
The O 
data O 
revealed O 
that O 
germination O 
rate O 
and O 
radicle O 
length O 
of O 
V O 
. O 
faba O 
seedlings O 
were O 
promoted O 
by O 
low O 
NB O 
concentrations O 
and O 
short O 
exposure O 
periods O 
, O 
whereas O 
these O 
parameters O 
were O 
inhibited O 
at O 
greater O 
NB O 
concentrations O 
and O 
longer O 
exposures O 
. O 
When O 
assessed O 
by O 
mitotic O 
index O 
, O 
micronucleus O 
, O 
and O 
chromosomal O 
aberration O 
assays O 
, O 
NB O 
showed O 
dose O 
- O 
dependent O 
genotoxicity O 
at O 
0 O 
mg O 
L(-1) O 
to O 
50 O 
mg O 
L(-1) O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1426-1432 O 
. O 
© O 
2013 O 
SETAC O 
. O 

sanctum O 
L O 
. O 
( O 
Lamiaceae O 
) O 
is O 
found O 
throughout O 
India O 
and O 
in O 
many O 
parts O 
of O 
world O 
. O 
O O 
. O 
sanctum O 
is O 
used O 
for O 
the O 
treatment O 
of O 
various O 
health O 
indications O 
. O 
In O 
this O 
lieu O 
, O 
it O 
is O 
of O 
prime O 
importance O 
to O 
investigate O 
the O 
safety O 
aspects O 
of O 
the O 
plant O 
. O 
Hence O 
, O 
the O 
present O 
study O 
was O 
conducted O 
to O 
investigate O 
the O 
possible O 
genotoxic O 
potential O 
and O 
acute O 
oral O 
toxicity O 
of O 
the O 
extract O 
of O 
O O 
. O 
sanctum O 
( O 
OciBest O 
™ O 
) O 
. O 
The O 
standard O 
battery O 
of O 
in O 
vitro O 
genotoxicity O 
tests O 
, O 
namely O 
bacterial O 
reverse O 
mutation O 
, O 
chromosome O 
aberration O 
and O 
micronucleus O 
( O 
MN O 
) O 
tests O 
were O 
employed O 
to O 
assess O 
the O 
possible O 
mutagenic O 
activity O 
. O 
The O 
results O 
showed O 
that O 
OciBest O 
™ O 
( O 
7.9-2500.0 O 
µg O 
/ O 
mL O 
) O 
did O 
not O 
increase O 
the O 
number O 
of O 
histidine B-TRIVIAL 
revertant O 
colonies O 
in O 
Salmonella O 
typhimurium O 
strains O 
( O 
TA98 O 
and O 
TAMix O 
) O 
with O 
and O 
without O 
exogenous O 
metabolic O 
activation O 
( O 
S9 O 
) O 
. O 
OciBest O 
™ O 
( O 
10.0-100.0 O 
µg O 
/ O 
mL O 
) O 
did O 
not O 
show O 
structural O 
chromosomal O 
aberrations O 
or O 
increase O 
in O 
MN O 
induction O 
, O 
with O 
and O 
without O 
S9 O 
, O 
at O 
the O 
tested O 
dose O 
range O 
in O 
both O 
4-h O 
and O 
18-h O 
exposure O 
cell O 
cultures O 
. O 
Thus O 
, O 
OciBest O 
™ O 
is O 
not O 
genotoxic O 
in O 
bacterial O 
reverse O 
mutation O 
, O 
chromosomal O 
aberration O 
and O 
MN O 
tests O 
. O 
In O 
an O 
acute O 
oral O 
toxicity O 
test O 
, O 
rats O 
were O 
treated O 
with O 
5 O 
g O 
/ O 
kg O 
of O 
OciBest O 
™ O 
and O 
observed O 
for O 
signs O 
of O 
toxicity O 
for O 
14 O 
days O 
and O 
the O 
results O 
did O 
not O 
show O 
any O 
treatment O 
- O 
related O 
toxic O 
effects O 
to O 
Wistar O 
rats O 
. O 

prevents O 
doxorubucine B-TRIVIAL 
-induced O 
cardiotoxicity O 
in O 
rats O 
. O 

study O 
is O 
designed O 
to O 
observe O 
the O 
effects O 
of O 
N-acetylcysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
on O 
doxorubucine B-TRIVIAL 
-induced O 
cardiac O 
toxicity O 
in O 
rats O 
both O 
histologically O 
and O 
biochemically O 
. O 
Totally O 
32 O 
rats O 
divided O 
equally O 
into O 
four O 
groups O 
were O 
studied O 
. O 
The O 
first O 
group O 
received O 
only O 
200 O 
mg O 
/ O 
kg O 
NAC B-ABBREVIATION 
intraperitoneal O 
( O 
i.p O 
. O 
) O 
once O 
every O 
24 O 
h O 
for O 
5 O 
days O 
( O 
group O 
1 O 
) O 
; O 
the O 
second O 
group O 
received O 
20 O 
mg O 
/ O 
kg O 
doxorubucine B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
i.p O 
. O 
single O 
dose O 
plus O 
NAC B-ABBREVIATION 
200 O 
mg O 
/ O 
kg O 
i.p O 
. O 
once O 
every O 
24 O 
h O 
for O 
5 O 
days O 
( O 
group O 
2 O 
) O 
; O 
the O 
third O 
group O 
received O 
DOX B-ABBREVIATION 
20 O 
mg O 
/ O 
kg O 
DOX B-ABBREVIATION 
i.p O 
. O 
single O 
dose O 
( O 
group O 
3 O 
) O 
and O 
the O 
fourth O 
group O 
, O 
which O 
is O 
also O 
the O 
control O 
group O 
, O 
received O 
saline O 
( O 
group O 
4 O 
) O 
. O 
Following O 
24 O 
h O 
of O 
the O 
final O 
dose O 
, O 
blood O 
samples O 
were O 
drawn O 
from O 
a O 
portal O 
vein O 
and O 
heart O 
tissue O 
were O 
obtained O 
. O 
Tissue O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
reactive O 
substance O 
( O 
TBARS O 
) O 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
levels O 
were O 
highest O 
in O 
the O 
DOX B-ABBREVIATION 
group O 
. O 
In O 
the O 
DOX B-ABBREVIATION 
-treated O 
rats O 
, O 
serum O 
TBARS O 
, O 
NO B-FORMULA 
, O 
aspartate B-TRIVIAL 
transaminase O 
, O 
lactate B-FAMILY 
dehydrogenase O 
and O 
creatine B-TRIVIAL 
kinase O 
levels O 
were O 
highest O 
when O 
compared O 
with O 
other O 
groups O 
. O 
Except O 
for O 
serum O 
superoxide B-TRIVIAL 
dismutase O 
levels O 
, O 
all O 
other O 
parameters O 
differed O 
significantly O 
between O 
the O 
DOX B-ABBREVIATION 
plus O 
NAC B-ABBREVIATION 
group O 
and O 
the O 
DOX B-ABBREVIATION 
group O 
. O 
In O 
the O 
DOX B-ABBREVIATION 
plus O 
NAC B-ABBREVIATION 
group O 
, O 
general O 
architecture O 
was O 
preserved O 
better O 
than O 
the O 
DOX B-ABBREVIATION 
group O 
and O 
myofibril O 
loss O 
was O 
minimal O 
compared O 
with O 
the O 
DOX B-ABBREVIATION 
group O 
. O 
NAC B-ABBREVIATION 
demonstrated O 
, O 
both O 
biochemically O 
and O 
histologically O 
, O 
to O 
be O 
effective O 
in O 
the O 
prevention O 
of O 
DOX B-ABBREVIATION 
-induced O 
cardiotoxicity O 
in O 
rat O 
models O 
. O 
Evaluation O 
of O 
NAC B-ABBREVIATION 
' O 
s O 
effect O 
on O 
DOX B-ABBREVIATION 
toxicity O 
warrants O 
further O 
clinical O 
trials O 
on O 
cancer O 
patients O 
. O 

GABA B-ABBREVIATION 
-Enhancing O 
Therapy O 
against O 
Seizures O 
in O 
a O 
Mouse O 
Model O 
of O 
Dravet O 
Syndrome O 
. O 

remain O 
uncontrolled O 
in O 
30% O 
of O 
patients O 
with O 
epilepsy O 
, O 
even O 
with O 
concurrent O 
use O 
of O 
multiple O 
drugs O 
, O 
and O 
uncontrolled O 
seizures O 
result O 
in O 
increased O 
morbidity O 
and O 
mortality O 
. O 
An O 
extreme O 
example O 
is O 
Dravet O 
syndrome O 
( O 
DS O 
) O 
, O 
an O 
infantile O 
- O 
onset O 
severe O 
epilepsy O 
caused O 
by O 
heterozygous O 
loss O 
of O 
function O 
mutations O 
in O 
SCN1A O 
, O 
the O 
gene O 
encoding O 
the O 
brain O 
type-I O 
voltage O 
- O 
gated O 
sodium B-SYSTEMATIC 
channel O 
NaV1.1 O 
. O 
Studies O 
in O 
Scn1a O 
heterozygous O 
knockout O 
mice O 
demonstrate O 
reduced O 
excitability O 
of O 
GABAergic O 
interneurons O 
, O 
suggesting O 
that O 
enhancement O 
of O 
GABA B-ABBREVIATION 
signaling O 
may O 
improve O 
seizure O 
control O 
and O 
comorbidities O 
. O 
We O 
studied O 
the O 
efficacy O 
of O 
two O 
GABA B-ABBREVIATION 
-enhancing O 
drugs O 
, O 
clonazepam B-TRIVIAL 
and O 
tiagabine B-TRIVIAL 
, O 
alone O 
and O 
in O 
combination O 
, O 
against O 
thermally O 
evoked O 
myoclonic O 
and O 
generalized O 
tonic O 
- O 
clonic O 
seizures O 
. O 
Clonazepam B-TRIVIAL 
, O 
a O 
positive O 
allosteric O 
modulator O 
of O 
GABA B-ABBREVIATION 
-A O 
receptors O 
, O 
protected O 
against O 
myoclonic O 
and O 
generalized O 
tonic O 
- O 
clonic O 
seizures O 
. O 
Tiagabine B-TRIVIAL 
, O 
a O 
presynaptic O 
GABA B-ABBREVIATION 
reuptake O 
inhibitor O 
, O 
was O 
protective O 
against O 
generalized O 
tonic O 
- O 
clonic O 
seizures O 
but O 
only O 
minimally O 
protective O 
against O 
myoclonic O 
seizures O 
and O 
enhanced O 
myoclonic O 
seizure O 
susceptibility O 
at O 
high O 
doses O 
. O 
Combined O 
therapy O 
with O 
clonazepam B-TRIVIAL 
and O 
tiagabine B-TRIVIAL 
was O 
synergistic O 
against O 
generalized O 
tonic O 
- O 
clonic O 
seizures O 
but O 
was O 
additive O 
against O 
myoclonic O 
seizures O 
. O 
Toxicity O 
determined O 
by O 
rotorod O 
testing O 
was O 
additive O 
for O 
combination O 
therapy O 
. O 
The O 
synergistic O 
actions O 
of O 
clonazepam B-TRIVIAL 
and O 
tiagabine B-TRIVIAL 
gave O 
enhanced O 
seizure O 
protection O 
and O 
reduced O 
toxicity O 
, O 
suggesting O 
that O 
combination O 
therapy O 
may O 
be O 
well O 
tolerated O 
and O 
effective O 
for O 
seizures O 
in O 
DS O 
. O 

of O 
glyco- O 
acridine B-TRIVIAL 
derivatives O 
to O 
lysozyme O 
leads O 
to O 
inhibition O 
of O 
amyloid O 
fibrillization O 
. O 

amyloid O 
- O 
related O 
diseases O 
are O 
at O 
the O 
center O 
of O 
intense O 
research O 
efforts O 
, O 
no O 
feasible O 
cure O 
is O 
currently O 
available O 
for O 
these O 
diseases O 
. O 
The O 
experimental O 
and O 
computational O 
techniques O 
were O 
used O 
to O 
study O 
the O 
ability O 
of O 
glyco- O 
acridines B-FAMILY 
to O 
prevent O 
lysozyme O 
amyloid O 
fibrillization O 
in O 
vitro O 
. O 
Fluorescence O 
spectroscopy O 
and O 
atomic O 
force O 
microscopy O 
have O 
shown O 
that O 
glyco- O 
acridines B-FAMILY 
inhibit O 
amyloid O 
aggregation O 
of O 
lysozyme O 
; O 
the O 
inhibition O 
efficiency O 
characterized O 
by O 
the O 
half O 
- O 
maximal O 
inhibition O 
concentration O 
IC50 O 
was O 
affected O 
by O 
the O 
structure O 
and O 
concentration O 
of O 
the O 
derivative O 
. O 
We O 
next O 
investigated O 
relationship O 
between O 
the O 
binding O 
affinity O 
and O 
the O 
inhibitory O 
activity O 
of O 
the O 
compounds O 
. O 
The O 
semiempirical O 
quantum O 
PM6-DH+ O 
method O 
provided O 
a O 
good O 
correlation O 
pointing O 
to O 
the O 
importance O 
of O 
quantum O 
effects O 
on O 
the O 
binding O 
of O 
glyco- O 
acridine B-TRIVIAL 
derivatives O 
to O 
lysozyme O 
. O 
The O 
contribution O 
of O 
linkers O 
may O 
be O 
explained O 
by O 
the O 
valence O 
bond O 
theory O 
. O 
Our O 
data O 
provide O 
a O 
basis O 
for O 
the O 
development O 
of O 
new O 
small O 
molecule O 
inhibitors O 
effective O 
in O 
therapy O 
of O 
amyloid O 
- O 
related O 
diseases O 
. O 

essential O 
oils O 
from O 
three O 
samples O 
: O 
stems O 
, O 
leaves O 
and O 
inflorescences O 
of O 
Thymus O 
maroccanus O 
Ball O 
, O 
obtained O 
by O 
hydrodistillation O 
, O 
were O 
analysed O 
by O 
gas O 
chromatography O 
and O 
gas O 
chromatography O 
coupled O 
to O 
mass O 
spectrometry O 
. O 
The O 
oils O 
of O 
stems O 
, O 
leaves O 
and O 
inflorescences O 
afforded O 
68 O 
, O 
49 O 
and O 
51 O 
constituents O 
, O 
respectively O 
. O 
Quantitative O 
and O 
qualitative O 
differences O 
have O 
been O 
found O 
between O 
the O 
analysed O 
parts O 
. O 
The O 
most O 
abundant O 
components O 
in O 
the O 
stems O 
oil O 
included O 
carvacrol B-TRIVIAL 
( O 
60.8% O 
) O 
, O 
α-terpineol B-TRIVIAL 
( O 
4.7% O 
) O 
and O 
p-cymene B-TRIVIAL 
( O 
2.4% O 
) O 
, O 
while O 
carvacrol B-TRIVIAL 
( O 
33% O 
) O 
, O 
p-cymene B-TRIVIAL 
( O 
25.3% O 
) O 
and O 
α-pinene B-TRIVIAL 
( O 
11.6% O 
) O 
were O 
the O 
main O 
components O 
in O 
the O 
leaves O 
. O 
In O 
the O 
inflorescences O 
, O 
carvacrol B-TRIVIAL 
( O 
84.9% O 
) O 
is O 
the O 
major O 
component O 
. O 
Antibacterial O 
activity O 
of O 
the O 
T O 
. O 
maroccanus O 
Ball O 
leaves O 
oil O 
was O 
tested O 
against O 
eight O 
Gram O 
- O 
positive O 
and O 
Gram O 
- O 
negative O 
bacteria O 
by O 
the O 
disc O 
diffusion O 
method O 
. O 
The O 
values O 
of O 
inhibition O 
zones O 
for O 
bacterial O 
strains O 
, O 
which O 
were O 
sensitive O 
to O 
the O 
essential O 
oil O 
of O 
T O 
. O 
maroccanus O 
leaves O 
, O 
were O 
in O 
the O 
range O 
of O 
11-43 O 
mm O 
. O 

mechanics O 
/ O 
molecular O 
mechanics O 
modeling O 
of O 
fatty B-FAMILY 
acid I-FAMILY 
fatty B-FAMILY 
acid I-FAMILY 
amide I-FAMILY 
amide B-FAMILY 
hydrolase O 
reactivation O 
distinguishes O 
substrate O 
from O 
irreversible O 
covalent O 
inhibitors O 
. O 

and O 
urea B-TRIVIAL 
derivatives O 
are O 
important O 
classes O 
of O 
fatty B-FAMILY 
acid I-FAMILY 
fatty B-FAMILY 
acid I-FAMILY 
amide I-FAMILY 
amide B-FAMILY 
hydrolase O 
( O 
FAAH O 
) O 
inhibitors O 
that O 
carbamoylate B-SYSTEMATIC 
the O 
active O 
- O 
site O 
nucleophile O 
Ser B-FORMULA 
241 O 
. O 
In O 
the O 
present O 
work O 
, O 
the O 
reactivation O 
mechanism O 
of O 
carbamoylated O 
FAAH O 
is O 
investigated O 
by O 
means O 
of O 
a O 
quantum O 
mechanics O 
/ O 
molecular O 
mechanics O 
( O 
QM O 
/ O 
MM O 
) O 
approach O 
. O 
The O 
potential O 
energy O 
surfaces O 
for O 
decarbamoylation O 
of O 
FAAH O 
covalent O 
adducts O 
, O 
derived O 
from O 
the O 
O B-FORMULA 
-aryl O 
carbamate O 
URB597 B-IDENTIFIER 
and O 
from O 
the O 
N B-FORMULA 
-piperazinylurea O 
JNJ1661610 B-IDENTIFIER 
, O 
were O 
calculated O 
and O 
compared O 
to O 
that O 
for O 
deacylation O 
of O 
FAAH O 
acylated O 
by O 
the O 
substrate O 
oleamide B-TRIVIAL 
. O 
Calculations O 
show O 
that O 
a O 
carbamic B-SYSTEMATIC 
group O 
bound O 
to O 
Ser B-FORMULA 
241 O 
prevents O 
efficient O 
stabilization O 
of O 
transition O 
states O 
of O 
hydrolysis O 
, O 
leading O 
to O 
large O 
increments O 
in O 
the O 
activation O 
barrier O 
. O 
Moreover O 
, O 
the O 
energy O 
barrier O 
for O 
the O 
piperazine B-SYSTEMATIC 
carboxylate I-SYSTEMATIC 
was O 
significantly O 
lower O 
than O 
that O 
for O 
the O 
cyclohexyl B-SYSTEMATIC 
carbamate I-SYSTEMATIC 
derived O 
from O 
URB597 B-IDENTIFIER 
. O 
This O 
is O 
consistent O 
with O 
experimental O 
data O 
showing O 
slowly O 
reversible O 
FAAH O 
inhibition O 
for O 
the O 
N-piperazinylurea B-SYSTEMATIC 
inhibitor O 
and O 
irreversible O 
inhibition O 
for O 
URB597 B-IDENTIFIER 
. O 

to O 
their O 
versatility O 
and O 
cost O 
- O 
effectiveness O 
, O 
gel O 
electrophoretic O 
methods O 
provide O 
an O 
important O 
set O 
of O 
tools O 
for O 
the O 
analysis O 
of O 
therapeutic O 
proteins O 
. O 
As O 
an O 
increasing O 
number O 
of O 
biosimilar O 
pharmaceuticals O 
are O 
entering O 
the O 
market O 
, O 
techniques O 
are O 
required O 
that O 
allow O 
reliable O 
demonstration O 
of O 
comparability O 
of O 
these O 
products O 
with O 
the O 
reference O 
products O 
. O 
Isoelectric O 
focusing O 
, O 
SDS B-ABBREVIATION 
-PAGE O 
, O 
native O 
PAGE O 
and O 
2D O 
electrophoresis O 
( O 
2D-PAGE O 
) O 
have O 
been O 
frequently O 
applied O 
for O 
this O 
purpose O 
. O 
Supplementary O 
techniques O 
are O 
fluorophore O 
- O 
assisted O 
carbohydrate B-FAMILY 
electrophoresis O 
and O 
sarcosyl B-TRIVIAL 
-PAGE O 
. O 
Of O 
additional O 
importance O 
is O 
the O 
comparison O 
of O 
recombinant O 
with O 
endogenously O 
synthesized O 
glycoproteins O 
. O 
Reagent O 
array O 
analysis O 
combined O 
with O 
SDS B-ABBREVIATION 
-PAGE O 
and O 
western O 
blotting O 
proved O 
especially O 
useful O 
for O 
this O 
purpose O 
. O 
As O 
an O 
example O 
for O 
the O 
application O 
of O 
these O 
methods O 
, O 
the O 
analysis O 
of O 
recombinant O 
originator O 
erythropoietins O 
and O 
some O 
of O 
their O 
biosimilar O 
counterparts O 
is O 
described O 
. O 

-zwitterion O 
organic O 
- O 
inorganic O 
nanocomposite O 
with O 
antimicrobial O 
and O 
antiadhesive O 
capabilities O 
. O 

this O 
work O 
, O 
we O 
demonstrate O 
a O 
convenient O 
, O 
efficient O 
, O 
and O 
environmentally O 
benign O 
strategy O 
to O 
achieving O 
antimicrobial O 
and O 
antiadhesive O 
purposes O 
using O 
a O 
silver B-SYSTEMATIC 
-zwitterion O 
nanocomposite O 
. O 
The O 
synthesis O 
of O 
the O 
nanocomposite O 
relies O 
on O 
loading O 
zwitterionic O 
polymer O 
brushes O 
with O 
Ag(+) B-FORMULA 
precursor O 
ions O 
, O 
followed O 
by O 
their O 
in O 
situ O 
reduction O 
to O 
Ag B-FORMULA 
nanoparticle O 
by O 
ultraviolet O 
( O 
UV O 
) O 
irradiation O 
. O 
Both O 
poly(sulfobetaine B-FAMILY 
methacrylate I-FAMILY 
) I-FAMILY 
( O 
pSBMA B-ABBREVIATION 
) O 
and O 
poly(carboxybetaine B-FAMILY 
methacrylate I-FAMILY 
) I-FAMILY 
( O 
pCBMA B-ABBREVIATION 
) O 
have O 
been O 
studied O 
as O 
matrices O 
for O 
the O 
embedding O 
of O 
silver B-SYSTEMATIC 
. O 
Well O 
- O 
dispersed O 
silver B-SYSTEMATIC 
nanoparticles O 
are O 
embedded O 
into O 
pCBMA B-ABBREVIATION 
matrices O 
. O 
The O 
obtained O 
pCBMA B-ABBREVIATION 
- O 
silver B-SYSTEMATIC 
hybrid O 
( O 
CB- O 
Ag B-FORMULA 
) O 
is O 
capable O 
of O 
killing O 
bacteria O 
upon O 
contact O 
and O 
releasing O 
dead O 
bacteria O 
under O 
wet O 
conditions O 
. O 
Results O 
suggest O 
the O 
feasibility O 
of O 
using O 
this O 
nanocomposite O 
system O 
as O 
a O 
robust O 
and O 
reliable O 
antimicrobial O 
and O 
antiadhesive O 
platform O 
for O 
the O 
prevention O 
of O 
microbial O 
colonization O 
. O 

, O 
in O 
vitro O 
antiplatelet O 
activity O 
and O 
molecular O 
modelling O 
studies O 
of O 
10- B-FAMILY 
substituted I-FAMILY 
2-(1-piperazinyl)pyrimido[1,2-a]benzimidazol-4(10H)-ones I-FAMILY 
. O 

multistep O 
preparation O 
of O 
the O 
new O 
10- B-FAMILY 
substituted I-FAMILY 
2-(1-piperazinyl)pyrimido[1,2-a]benzimidazol-4(10H)-ones I-FAMILY 
6a-o O 
, O 
and O 
of O 
the O 
two O 
isomers O 
10-ethyl-2-(diethylamino)pyrimido[1,2-a]benzimidazol-4(10H)-one B-SYSTEMATIC 
6p O 
and O 
10-ethyl-4-(diethylamino)pyrimido[1,2-a]benzimidazol-2(10H)-one B-SYSTEMATIC 
13 O 
, O 
as O 
well O 
as O 
the O 
in O 
vitro O 
evaluation O 
of O 
their O 
inhibitory O 
activity O 
on O 
human O 
platelet O 
aggregation O 
induced O 
in O 
platelet O 
- O 
rich O 
plasma O 
by O 
ADP B-ABBREVIATION 
, O 
collagen O 
or O 
the O 
Ca(2+) B-FORMULA 
ionophore O 
A23187 B-IDENTIFIER 
were O 
here O 
described O 
. O 
Nine O 
out O 
of O 
fifteen O 
2-(1-piperazinyl) B-SYSTEMATIC 
derivatives O 
( O 
6g-o O 
) O 
showed O 
good O 
inhibitory O 
properties O 
towards O 
all O 
the O 
platelet O 
aggregation O 
agonists O 
used O 
. O 
Moreover O 
, O 
a O 
molecular O 
modelling O 
study O 
has O 
been O 
performed O 
on O 
two O 
of O 
the O 
best O 
compounds O 
of O 
this O 
series O 
( O 
6i O 
and O 
6o O 
) O 
to O 
confirm O 
in O 
silico O 
their O 
interactions O 
with O 
the O 
catalytic O 
site O 
of O 
human O 
platelet O 
PDE3 O 
, O 
using O 
the O 
X-ray O 
data O 
of O 
the O 
PDE3B O 
isoform O 
in O 
complex O 
with O 
an O 
inhibitor O 
. O 

and O 
biological O 
evaluation O 
of O 
novel O 
pyranochalcone B-FAMILY 
derivatives O 
as O 
a O 
new O 
class O 
of O 
microtubule O 
stabilizing O 
agents O 
. O 

- O 
five O 
novel O 
pyranochalcone B-FAMILY 
derivatives O 
were O 
synthesized O 
and O 
evaluated O 
for O 
their O 
in O 
vitro O 
and O 
in O 
vivo O 
antiproliferative O 
activities O 
. O 
Among O 
them O 
, O 
compound O 
10i O 
exhibited O 
superior O 
potent O 
activity O 
against O 
21 O 
tumor O 
cell O 
lines O 
including O 
multidrug O 
resistant O 
phenotype O 
with O 
the O 
IC50 O 
values O 
ranged O 
from O 
0.09 O 
to O 
1.3 O 
μM O 
. O 
In O 
addition O 
, O 
10i O 
significantly O 
induced O 
cell O 
cycle O 
arrest O 
in O 
G2 O 
/ O 
M O 
phase O 
, O 
promoted O 
tubulin O 
polymerization O 
into O 
microtubules O 
and O 
caused O 
microtubule O 
stabilization O 
. O 
Further O 
studies O 
confirmed O 
that O 
10i O 
significantly O 
suppressed O 
the O 
growth O 
of O 
tumor O 
volume O 
in O 
HepG2 O 
xenograft O 
tumor O 
model O 
. O 
Our O 
study O 
demonstrated O 
that O 
10i O 
could O 
have O 
beneficial O 
antitumor O 
activity O 
as O 
a O 
novel O 
microtubule O 
stabilizing O 
agent O 
. O 

- O 
quantum O 
(1)H B-FORMULA 
NMR O 
spectroscopy O 
has O 
been O 
finding O 
a O 
renewed O 
interest O 
for O 
its O 
possible O 
applications O 
in O 
the O 
analysis O 
of O 
mixtures O 
of O 
small O 
molecules O 
, O 
due O 
to O 
its O 
simplification O 
properties O 
. O 
A O 
crucial O 
aspect O 
of O 
this O 
application O 
of O 
multiple O 
- O 
quantum O 
NMR O 
is O 
the O 
sensitivity O 
of O 
the O 
spectrum O 
intensity O 
to O 
the O 
molecular O 
structure O 
and O 
to O 
the O 
parameterization O 
of O 
the O 
experiment O 
, O 
which O 
could O 
result O 
in O 
the O 
missing O 
of O 
some O 
components O 
. O 
We O 
demonstrate O 
that O 
a O 
general O 
scheme O 
to O 
overcome O 
this O 
drawback O 
consists O 
in O 
varying O 
the O 
experiment O 
parameterizations O 
over O 
a O 
small O 
number O 
of O 
values O 
, O 
selected O 
according O 
the O 
values O 
of O 
the O 
couplings O 
and O 
the O 
relaxation O 
rates O 
. O 

apiospermum O 
is O 
a O 
soil O 
fungus O 
which O 
can O 
cause O 
severe O 
and O 
often O 
fatal O 
cerebral O 
infections O 
in O 
both O 
immunocompetent O 
patients O 
in O 
the O 
event O 
of O 
near O 
drowning O 
and O 
immunosuppressed O 
patients O 
such O 
as O 
lung O 
transplant O 
recipients O 
. O 
Because O 
of O 
the O 
low O 
susceptibility O 
of O 
this O 
fungus O 
to O 
antifungal O 
drugs O 
, O 
and O 
the O 
low O 
permeability O 
of O 
the O 
blood O 
- O 
brain O 
barrier O 
( O 
BBB O 
) O 
, O 
therapeutic O 
drug O 
monitoring O 
is O 
necessary O 
to O 
reach O 
an O 
effective O 
tissue O 
concentration O 
with O 
limited O 
side O 
effects O 
. O 
Indeed O 
, O 
diffusion O 
of O 
the O 
drug O 
in O 
the O 
brain O 
is O 
dependent O 
on O 
several O 
parameters O 
, O 
such O 
as O 
the O 
integrity O 
of O 
the O 
BBB O 
and O 
the O 
activity O 
of O 
efflux O 
pumps O 
. O 
To O 
evaluate O 
drug O 
diffusion O 
, O 
two O 
experimental O 
models O 
were O 
developed O 
in O 
immunocompetent O 
and O 
immunosuppressed O 
rats O 
. O 
Inocula O 
were O 
administered O 
via O 
the O 
penile O 
vein O 
and O 
a O 
clinical O 
scale O 
( O 
0-9 O 
) O 
was O 
established O 
, O 
based O 
on O 
weight O 
and O 
clinical O 
and O 
neurologic O 
signs O 
evaluated O 
by O 
the O 
tail O 
suspension O 
test O 
. O 
Cerebral O 
involvement O 
was O 
confirmed O 
by O 
magnetic O 
resonance O 
imaging O 
and O 
histologic O 
examination O 
of O 
brain O 
sections O 
after O 
hematoxylin B-TRIVIAL 
- O 
eosin B-FAMILY 
-safran O 
or O 
silver B-SYSTEMATIC 
staining O 
. O 
Voriconazole B-TRIVIAL 
or O 
posaconazole B-TRIVIAL 
was O 
given O 
to O 
the O 
rats O 
at O 
doses O 
ranging O 
from O 
10 O 
to O 
75 O 
mg O 
/ O 
kg O 
/ O 
day O 
via O 
i.v O 
. O 
or O 
oral O 
routes O 
, O 
respectively O 
. O 
Whatever O 
the O 
immune O 
status O 
, O 
the O 
effective O 
doses O 
( O 
defined O 
by O 
a O 
doubling O 
of O 
the O 
survival O 
time O 
and O 
the O 
absence O 
of O 
neurologic O 
sequelae O 
) O 
were O 
30 O 
mg O 
/ O 
kg O 
/ O 
day O 
for O 
voriconazole B-TRIVIAL 
and O 
50 O 
mg O 
/ O 
kg O 
/ O 
day O 
for O 
posaconazole B-TRIVIAL 
. O 
Overall O 
, O 
the O 
results O 
demonstrated O 
that O 
these O 
models O 
may O 
constitute O 
valuable O 
tools O 
for O 
the O 
performance O 
of O 
pharmacokinetic O 
and O 
pharmacodynamic O 
studies O 
for O 
pharmacokinetic O 
- O 
pharmacodynamic O 
modeling O 
. O 

toxic O 
stress O 
by O 
atrazine B-TRIVIAL 
in O 
a O 
marine O 
consumer O 
- O 
resource O 
system O 
. O 

present O 
study O 
combines O 
short O 
- O 
term O 
experiments O 
with O 
food O 
chain O 
modeling O 
to O 
explore O 
the O 
long O 
- O 
term O 
effects O 
of O 
the O 
herbicide O 
atrazine B-TRIVIAL 
on O 
consumer O 
- O 
resource O 
dynamics O 
in O 
a O 
marine O 
intertidal O 
ecosystem O 
. O 
Short O 
- O 
term O 
( O 
28 O 
d O 
) O 
lab O 
experiments O 
indicated O 
that O 
the O 
intrinsic O 
rate O 
of O 
increase O 
( O 
r O 
) O 
and O 
carrying O 
capacity O 
( O 
K O 
) O 
of O 
the O 
marine O 
diatom O 
Seminavis O 
robusta O 
decreased O 
with O 
increasing O 
atrazine B-TRIVIAL 
exposure O 
. O 
This O 
decrease O 
did O 
not O 
show O 
the O 
concave O 
shape O 
expected O 
from O 
the O 
lifetime O 
productivity O 
for O 
nonexposed O 
diatoms O 
and O 
from O 
single O 
- O 
species O 
toxicity O 
data O 
in O 
the O 
literature O 
but O 
instead O 
was O 
described O 
best O 
by O 
a O 
linear O 
model O 
. O 
These O 
experimentally O 
observed O 
atrazine B-TRIVIAL 
-induced O 
decreases O 
of O 
r O 
and O 
K O 
were O 
used O 
to O 
parameterize O 
a O 
Rosenzweig-MacArthur O 
model O 
representing O 
a O 
simple O 
food O 
chain O 
including O 
the O 
tested O 
diatom O 
and O 
its O 
grazer O 
, O 
the O 
harpacticoid O 
copepod O 
Delavalia O 
palustris O 
var O 
. O 
palustris O 
. O 
Stable O 
oscillation O 
zoo O 
- O 
phytobenthos O 
systems O 
were O 
produced O 
at O 
diatom O 
exposures O 
of O 
0 O 
, O 
100 O 
, O 
and O 
150 O 
µg O 
/ O 
L O 
atrazine B-TRIVIAL 
. O 
An O 
atrazine B-TRIVIAL 
concentration O 
of O 
150 O 
µg O 
/ O 
L O 
contributed O 
to O 
a O 
15% O 
increase O 
of O 
the O 
oscillation O 
periods O 
of O 
both O 
diatoms O 
and O 
copepods O 
as O 
well O 
as O 
a O 
52% O 
reduction O 
of O 
oscillation O 
amplitudes O 
compared O 
with O 
the O 
control O 
situation O 
. O 
Although O 
the O 
amplitudes O 
of O 
copepods O 
increased O 
only O 
7% O 
at O 
150 O 
µg O 
/ O 
L O 
atrazine B-TRIVIAL 
, O 
the O 
maximum O 
and O 
minimum O 
copepod O 
densities O 
at O 
that O 
concentration O 
were O 
reduced O 
61 O 
and O 
63% O 
, O 
respectively O 
. O 
The O 
effects O 
of O 
atrazine B-TRIVIAL 
on O 
periodicity O 
and O 
amplitudes O 
were O 
robust O 
to O 
20% O 
changes O 
in O 
the O 
food O 
- O 
chain O 
model O 
parameters O 
that O 
represented O 
allometric O 
relationships O 
. O 
The O 
simulations O 
in O 
the O 
present O 
study O 
suggest O 
food O 
chain O 
- O 
mediated O 
indirect O 
effects O 
on O 
zoobenthos O 
populations O 
, O 
indicating O 
a O 
reduced O 
diatom O 
and O 
copepod O 
availability O 
throughout O 
the O 
year O 
. O 
Environ O 
. O 
Toxicol O 
. O 
Chem O 
. O 
2013;32 O 
: O 
1088-1095 O 
. O 
© O 
2013 O 
SETAC O 
. O 

effects O 
of O 
the O 
phosphodiesterase O 
type O 
5 O 
inhibitor O 
vardenafil B-TRIVIAL 
on O 
cognitive O 
performance O 
in O 
healthy O 
adults O 
: O 
a O 
behavioral- O 
electroencephalography O 
study O 
. O 

type O 
5 O 
inhibitors O 
( O 
PDE5-Is O 
) O 
improve O 
cognitive O 
performance O 
of O 
rodents O 
, O 
but O 
the O 
few O 
human O 
studies O 
investigating O 
their O 
effects O 
did O 
not O 
systematically O 
investigate O 
cognitive O 
effects O 
and O 
the O 
results O 
have O 
been O 
quite O 
contradictory O 
. O 
Therefore O 
, O 
we O 
examined O 
whether O 
the O 
PDE5-I O 
vardenafil B-TRIVIAL 
improves O 
memory O 
and O 
executive O 
functioning O 
and O 
affect O 
electroencephalography O 
( O 
EEG O 
) O 
in O 
healthy O 
young O 
adults O 
. O 
Participants O 
were O 
selected O 
out O 
of O 
a O 
group O 
of O 
volunteers O 
, O 
based O 
on O 
their O 
performance O 
on O 
a O 
memory O 
screening O 
and O 
they O 
were O 
orally O 
treated O 
with O 
vardenafil B-TRIVIAL 
( O 
10-20 O 
mg O 
or O 
placebo O 
) O 
. O 
Memory O 
and O 
executive O 
functioning O 
were O 
tested O 
while O 
EEG O 
activity O 
was O 
recorded O 
. O 
Additionally O 
, O 
a O 
simple O 
reaction O 
time O 
task O 
and O 
questionnaires O 
addressing O 
various O 
complaints O 
were O 
presented O 
. O 
No O 
prominent O 
effects O 
of O 
vardenafil B-TRIVIAL 
on O 
cognition O 
were O 
found O 
: O 
participants O 
only O 
made O 
more O 
mistakes O 
on O 
a O 
reaction O 
time O 
task O 
after O 
20 O 
mg O 
vardenafil B-TRIVIAL 
. O 
During O 
encoding O 
of O 
words O 
, O 
the O 
P300 O 
was O 
generally O 
smaller O 
after O 
vardenafil B-TRIVIAL 
treatment O 
. O 
Furthermore O 
, O 
the O 
N400 O 
was O 
larger O 
after O 
vardenafil B-TRIVIAL 
10 O 
mg O 
than O 
placebo O 
treatment O 
in O 
a O 
spatial O 
memory O 
task O 
at O 
Fz O 
. O 
Finally O 
, O 
headache O 
and O 
feeling O 
weak O 
were O 
reported O 
more O 
after O 
vardenafil B-TRIVIAL 
treatment O 
. O 
Vardenafil B-TRIVIAL 
did O 
not O 
affect O 
cognitive O 
performance O 
of O 
healthy O 
adults O 
and O 
showed O 
only O 
some O 
incidental O 
effects O 
on O 
ERPs O 
. O 
These O 
findings O 
in O 
humans O 
do O 
not O 
corroborate O 
the O 
cognition O 
- O 
enhancing O 
effects O 
of O 
PDE5-Is O 
in O 
healthy O 
animals O 
. O 

of O 
the O 
anti- O 
dopamine B-TRIVIAL 
D2 O 
and O 
anti- O 
serotonin B-TRIVIAL 
5-HT2A O 
activities O 
of O 
chlorpromazine B-TRIVIAL 
, O 
bromperidol B-TRIVIAL 
, O 
haloperidol B-TRIVIAL 
and O 
second O 
- O 
generation O 
antipsychotics O 
parent O 
compounds O 
and O 
metabolites O 
thereof O 
. O 

- O 
generation O 
antipsychotics O 
, O 
which O 
have O 
become O 
the O 
standard O 
drug O 
therapies O 
for O 
schizophrenia O 
, O 
are O 
known O 
to O 
have O 
a O 
serotonin B-TRIVIAL 
5-HT2A O 
receptor O 
blocking O 
effect O 
in O 
addition O 
to O 
a O 
dopamine B-TRIVIAL 
D2 O 
receptor O 
blocking O 
effect O 
. O 
However O 
, O 
although O 
chlorpromazine B-TRIVIAL 
( O 
CPZ B-ABBREVIATION 
) O 
has O 
a O 
5-HT2A O 
receptor O 
blocking O 
effect O 
and O 
has O 
the O 
profile O 
of O 
a O 
second O 
- O 
generation O 
antipsychotic O 
in O 
vitro O 
, O 
it O 
loses O 
this O 
pharmacological O 
profile O 
in O 
vivo O 
. O 
In O 
order O 
to O 
elucidate O 
the O 
differences O 
between O 
the O 
in O 
vivo O 
and O 
in O 
vitro O 
pharmacological O 
characteristics O 
of O 
CPZ B-ABBREVIATION 
, O 
we O 
used O 
a O 
radioreceptor O 
assay O 
to O 
measure O 
the O 
anti-D2 O 
activity O 
and O 
the O 
anti-5-HT2A O 
activity O 
of O 
CPZ B-ABBREVIATION 
and O 
five O 
major O 
metabolites O 
of O 
CPZ B-ABBREVIATION 
, O 
and O 
compared O 
the O 
results O 
to O 
the O 
anti-D2 O 
activity O 
and O 
anti-5-HT2A O 
activity O 
of O 
risperidone B-TRIVIAL 
, O 
zotepine B-TRIVIAL 
, O 
perospirone B-TRIVIAL 
, O 
the O 
major O 
metabolites O 
of O 
each O 
of O 
these O 
drugs O 
, O 
and O 
olanzapine B-TRIVIAL 
, O 
bromperidol B-TRIVIAL 
, O 
and O 
haloperidol B-TRIVIAL 
. O 
The O 
subjects O 
were O 
182 O 
patients O 
who O 
had O 
received O 
diagnoses O 
of O 
schizophrenia O 
based O 
on O 
the O 
DSM-IV O 
criteria O 
. O 
The O 
results O 
revealed O 
that O 
CPZ B-ABBREVIATION 
exhibited O 
little O 
anti-5-HT2A O 
activity O 
, O 
regardless O 
of O 
the O 
anti-D2 O 
activity O 
level O 
, O 
and O 
that O 
none O 
of O 
the O 
metabolites O 
possessed O 
anti-5-HT2A O 
activity O 
. O 
However O 
, O 
both O 
the O 
parent O 
compounds O 
and O 
the O 
metabolites O 
of O 
each O 
of O 
the O 
second O 
- O 
generation O 
antipsychotics O 
possessed O 
both O 
anti-D2 O 
activity O 
and O 
anti-5-HT2A O 
activity O 
. O 
This O 
clarified O 
that O 
, O 
unlike O 
second O 
- O 
generation O 
antipsychotics O 
, O 
the O 
reason O 
CPZ B-ABBREVIATION 
loses O 
its O 
second O 
- O 
generation O 
antipsychotic O 
profiles O 
in O 
vivo O 
is O 
because O 
it O 
does O 
not O 
have O 
any O 
metabolites O 
that O 
possess O 
anti-5-HT2A O 
activity O 
. O 

- O 
solid O 
growth O 
of O 
high O 
optical O 
quality O 
MoS₂ B-FORMULA 
monolayers O 
with O 
near O 
- O 
unity O 
valley O 
polarization O 
. O 

of O 
transition B-FAMILY 
metal I-FAMILY 
dichalcogenides I-FAMILY 
( O 
TMDCs B-FAMILY 
) O 
are O 
atomically O 
thin O 
direct O 
- O 
gap O 
semiconductors O 
with O 
potential O 
applications O 
in O 
nanoelectronics O 
, O 
optoelectronics O 
, O 
and O 
electrochemical O 
sensing O 
. O 
Recent O 
theoretical O 
and O 
experimental O 
efforts O 
suggest O 
that O 
they O 
are O 
ideal O 
systems O 
for O 
exploiting O 
the O 
valley O 
degrees O 
of O 
freedom O 
of O 
Bloch O 
electrons O 
. O 
For O 
example O 
, O 
Dirac O 
valley O 
polarization O 
has O 
been O 
demonstrated O 
in O 
mechanically O 
exfoliated O 
monolayer O 
MoS2 B-FORMULA 
samples O 
by O 
polarization O 
- O 
resolved O 
photoluminescence O 
, O 
although O 
polarization O 
has O 
rarely O 
been O 
seen O 
at O 
room O 
temperature O 
. O 
Here O 
we O 
report O 
a O 
new O 
method O 
for O 
synthesizing O 
high O 
optical O 
quality O 
monolayer O 
MoS2 B-FORMULA 
single O 
crystals O 
up O 
to O 
25 O 
μm O 
in O 
size O 
on O 
a O 
variety O 
of O 
standard O 
insulating O 
substrates O 
( O 
SiO2 B-FORMULA 
, O 
sapphire B-TRIVIAL 
, O 
and O 
glass O 
) O 
using O 
a O 
catalyst O 
- O 
free O 
vapor O 
- O 
solid O 
growth O 
mechanism O 
. O 
The O 
technique O 
is O 
simple O 
and O 
reliable O 
, O 
and O 
the O 
optical O 
quality O 
of O 
the O 
crystals O 
is O 
extremely O 
high O 
, O 
as O 
demonstrated O 
by O 
the O 
fact O 
that O 
the O 
valley O 
polarization O 
approaches O 
unity O 
at O 
30 O 
K O 
and O 
persists O 
at O 
35% O 
even O 
at O 
room O 
temperature O 
, O 
suggesting O 
a O 
virtual O 
absence O 
of O 
defects O 
. O 
This O 
will O 
allow O 
greatly O 
improved O 
optoelectronic O 
TMDC B-ABBREVIATION 
monolayer O 
devices O 
to O 
be O 
fabricated O 
and O 
studied O 
routinely O 
. O 

derivatives O 
as O 
new O 
potent O 
and O 
selective O 
human O 
A3 O 
Adenosine B-TRIVIAL 
receptor O 
antagonists O 
. O 
Molecular O 
modeling O 
studies O 
and O 
pharmacological O 
evaluation O 
. O 

the O 
basis O 
of O 
our O 
previously O 
reported O 
2-arylpyrazolo[4,3-d]pyrimidin-7-ones B-FAMILY 
, O 
a O 
set O 
of O 
2-arylpyrazolo[4,3-d]pyrimidin-7-amines B-FAMILY 
were O 
designed O 
as O 
new O 
human O 
( O 
h O 
) O 
A3 O 
adenosine B-TRIVIAL 
receptor O 
( O 
AR O 
) O 
antagonists O 
. O 
Lipophilic O 
groups O 
with O 
different O 
steric O 
bulk O 
were O 
introduced O 
at O 
the O 
5- O 
position O 
of O 
the O 
bicyclic O 
scaffold O 
( O 
R5 O 
= O 
Me B-FORMULA 
, O 
Ph B-FORMULA 
, O 
CH2Ph B-FORMULA 
) O 
, O 
and O 
different O 
acyl B-FAMILY 
and O 
carbamoyl B-SYSTEMATIC 
moieties O 
( O 
R7 O 
) O 
were O 
appended O 
on O 
the O 
7-amino B-SYSTEMATIC 
group O 
, O 
as O 
well O 
as O 
a O 
para-methoxy B-SYSTEMATIC 
group O 
inserted O 
on O 
the O 
2-phenyl B-SYSTEMATIC 
ring O 
. O 
The O 
presence O 
of O 
acyl B-FAMILY 
groups O 
turned O 
out O 
to O 
be O 
of O 
paramount O 
importance O 
for O 
an O 
efficient O 
and O 
selective O 
binding O 
at O 
the O 
hA3 O 
AR O 
. O 
In O 
fact O 
, O 
most O 
of O 
the O 
7-acylamino B-SYSTEMATIC 
derivatives O 
showed O 
low O 
nanomolar O 
affinity O 
( O 
Ki O 
= O 
2.5-45 O 
nM O 
) O 
and O 
high O 
selectivity O 
toward O 
this O 
receptor O 
. O 
A O 
few O 
selected O 
pyrazolo[4,3-d]pyrimidin-7-amides B-FAMILY 
were O 
effective O 
in O 
counteracting O 
oxaliplatin B-TRIVIAL 
-induced O 
apoptosis O 
in O 
rat O 
astrocyte O 
cell O 
cultures O 
, O 
an O 
in O 
vitro O 
model O 
of O 
neurotoxicity O 
. O 
Through O 
an O 
in O 
silico O 
receptor O 
- O 
driven O 
approach O 
the O 
obtained O 
binding O 
data O 
were O 
rationalized O 
and O 
the O 
molecular O 
bases O 
of O 
the O 
observed O 
hA3 O 
AR O 
affinity O 
and O 
hA3 O 
versus O 
hA2A O 
AR O 
selectivity O 
were O 
explained O 
. O 

Configurations O 
of O 
Fungal O 
and O 
Plant O 
Metabolites O 
by O 
Chiroptical O 
Methods O 
. O 
ORD O 
, O 
ECD O 
, O 
and O 
VCD O 
Studies O 
on O 
Phyllostin B-TRIVIAL 
, O 
Scytolide B-TRIVIAL 
, O 
and O 
Oxysporone B-TRIVIAL 
. O 

absolute O 
configuration O 
( O 
AC O 
) O 
of O 
the O 
bioactive O 
metabolites O 
phyllostin B-TRIVIAL 
( O 
1 O 
) O 
and O 
scytolide B-TRIVIAL 
( O 
2 O 
) O 
, O 
two O 
hexahydro-1,4-benzodioxines B-FAMILY 
produced O 
by O 
Phyllosticta O 
cirsii O 
, O 
and O 
oxysporone B-TRIVIAL 
( O 
3 O 
) O 
, O 
a O 
dihydrofuropyranone B-SYSTEMATIC 
recently O 
isolated O 
from O 
a O 
strain O 
of O 
Diplodia O 
africana O 
, O 
has O 
been O 
assigned O 
by O 
computational O 
analysis O 
of O 
their O 
optical O 
rotatory O 
dispersion O 
( O 
ORD O 
) O 
, O 
electronic O 
circular O 
dichroism O 
( O 
ECD O 
) O 
, O 
and O 
vibrational O 
circular O 
dichroism O 
( O 
VCD O 
) O 
spectra O 
. O 
Computational O 
prediction O 
of O 
ORD O 
, O 
ECD O 
, O 
and O 
VCD O 
allowed O 
us O 
to O 
assign O 
( O 
3S,4aR,8S,8aR O 
) O 
AC O 
to O 
naturally O 
occurring O 
(-)-1 O 
, O 
while O 
( O 
4aR,8S,8aR O 
) O 
AC O 
was O 
assigned O 
to O 
(-)-2 O 
employing O 
only O 
ECD O 
and O 
VCD O 
, O 
because O 
in O 
this O 
case O 
ORD O 
analysis O 
turned O 
out O 
to O 
be O 
unsuitable O 
for O 
AC O 
assignment O 
. O 
Theoretical O 
prediction O 
of O 
both O 
ORD O 
and O 
ECD O 
spectra O 
of O 
3 O 
led O 
to O 
assignment O 
of O 
( O 
4S,5R,6R O 
) O 
AC O 
to O 
(+)-3 O 
. O 
In O 
this O 
case O 
a O 
satisfactory O 
agreement O 
between O 
experimental O 
and O 
calculated O 
VCD O 
spectra O 
was O 
obtained O 
only O 
after O 
taking O 
into O 
account O 
solvent O 
effects O 
. O 
This O 
study O 
shows O 
that O 
in O 
the O 
case O 
of O 
flexible O 
and O 
complex O 
natural O 
products O 
only O 
a O 
concerted O 
application O 
of O 
more O 
than O 
a O 
single O 
chiroptical O 
technique O 
permits O 
unambiguous O 
assignment O 
of O 
absolute O 
configuration O 
. O 

angle O 
X-ray O 
scattering O 
( O 
SAXS O 
) O 
is O 
employed O 
to O 
characterize O 
the O 
inner O 
structure O 
and O 
shape O 
of O 
aqueous O 
nanocrystalline O 
cellulose O 
suspensions O 
using O 
the O 
generalized O 
indirect O 
Fourier O 
transformation O 
( O 
GIFT O 
) O 
. O 
The O 
use O 
of O 
the O 
GIFT O 
approach O 
provides O 
a O 
single O 
fitting O 
procedure O 
for O 
the O 
determination O 
of O 
intra- O 
and O 
interparticle O 
interactions O 
due O 
to O 
a O 
simultaneous O 
treatment O 
of O 
the O 
form O 
factor O 
P(q) O 
and O 
the O 
structure O 
factor O 
S(q) O 
. O 
Moreover O 
, O 
GIFT O 
allows O 
for O 
the O 
determination O 
of O 
particle O 
charges O 
and O 
polydispersity O 
indices O 
. O 
As O 
test O 
material O 
, O 
aqueous O 
nanocrystalline O 
cellulose O 
suspensions O 
( O 
aNCS O 
) O 
prepared O 
by O 
the O 
H2SO4 B-FORMULA 
route O 
have O 
been O 
investigated O 
and O 
characterized O 
( O 
SAXS O 
, O 
dynamic O 
light O 
scattering O 
, O 
zeta O 
potential O 
) O 
. O 

of O 
difluoromethyl B-FAMILY 
ketones I-FAMILY 
as O 
agonists O 
of O 
the O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
type O 
B O 
( O 
GABAB O 
) O 
receptor O 
. O 

design O 
, O 
synthesis O 
, O 
biological O 
evaluation O 
, O 
and O 
in O 
vivo O 
studies O 
of O 
difluoromethyl B-FAMILY 
ketones I-FAMILY 
as O 
GABAB O 
agonists O 
that O 
are O 
not O 
structurally O 
analogous O 
to O 
known O 
GABAB O 
agonists O 
, O 
such O 
as O 
baclofen B-TRIVIAL 
or O 
3-aminopropyl B-SYSTEMATIC 
phosphinic I-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
are O 
presented O 
. O 
The O 
difluoromethyl B-FAMILY 
ketones I-FAMILY 
were O 
assembled O 
in O 
three O 
synthetic O 
steps O 
using O 
a O 
trifluoroacetate B-SYSTEMATIC 
-release O 
aldol O 
reaction O 
. O 
Following O 
evaluation O 
at O 
clinically O 
relevant O 
GABA B-ABBREVIATION 
receptors O 
, O 
we O 
have O 
identified O 
a O 
difluoromethyl B-SYSTEMATIC 
ketone I-SYSTEMATIC 
that O 
is O 
a O 
potent O 
GABAB O 
agonist O 
, O 
obtained O 
its O 
X-ray O 
structure O 
, O 
and O 
presented O 
preliminary O 
in O 
vivo O 
data O 
in O 
alcohol B-FAMILY 
-preferring O 
mice O 
. O 
The O 
behavioral O 
studies O 
in O 
mice O 
demonstrated O 
that O 
this O 
compound O 
tended O 
to O 
reduce O 
the O 
acoustic O 
startle O 
response O 
, O 
which O 
is O 
consistent O 
with O 
an O 
anxiolytic O 
profile O 
. O 
Structure O 
- O 
activity O 
investigations O 
determined O 
that O 
replacing O 
the O 
fluorines B-FAMILY 
of O 
the O 
difluoromethyl B-SYSTEMATIC 
ketone I-SYSTEMATIC 
with O 
hydrogens B-FAMILY 
resulted O 
in O 
an O 
inactive O 
analogue O 
. O 
Resolution O 
of O 
the O 
individual O 
enantiomers O 
of O 
the O 
difluoromethyl B-SYSTEMATIC 
ketone I-SYSTEMATIC 
provided O 
a O 
compound O 
with O 
full O 
biological O 
activity O 
at O 
concentrations O 
less O 
than O 
an O 
order O 
of O 
magnitude O 
greater O 
than O 
the O 
pharmaceutical O 
, O 
baclofen B-TRIVIAL 
. O 

-modulated O 
cobalt B-SYSTEMATIC 
nanocatalysts O 
for O 
low O 
- O 
temperature O 
aqueous O 
- O 
phase O 
Fischer-Tropsch O 
synthesis O 
. O 

synthesis O 
( O 
FTS O 
) O 
is O 
an O 
important O 
catalytic O 
process O 
for O 
liquid O 
fuel O 
generation O 
, O 
which O 
converts O 
coal O 
/ O 
shale O 
gas O 
/ O 
biomass O 
- O 
derived O 
syngas O 
( O 
a O 
mixture O 
of O 
CO B-FORMULA 
and O 
H2 B-FORMULA 
) O 
to O 
oil O 
. O 
While O 
FTS O 
is O 
thermodynamically O 
favored O 
at O 
low O 
temperature O 
, O 
it O 
is O 
desirable O 
to O 
develop O 
a O 
new O 
catalytic O 
system O 
that O 
could O 
allow O 
working O 
at O 
a O 
relatively O 
low O 
reaction O 
temperature O 
. O 
In O 
this O 
article O 
, O 
we O 
present O 
a O 
one O 
- O 
step O 
hydrogenation O 
- O 
reduction O 
route O 
for O 
the O 
synthesis O 
of O 
Pt-Co B-FORMULA 
nanoparticles O 
( O 
NPs O 
) O 
which O 
were O 
found O 
to O 
be O 
excellent O 
catalysts O 
for O 
aqueous O 
- O 
phase O 
FTS O 
at O 
433 O 
K O 
. O 
Coupling O 
with O 
atomic O 
- O 
resolution O 
scanning O 
transmission O 
electron O 
microscopy O 
( O 
STEM O 
) O 
and O 
theoretical O 
calculations O 
, O 
the O 
outstanding O 
activity O 
is O 
rationalized O 
by O 
the O 
formation O 
of O 
Co B-FORMULA 
overlayer O 
structures O 
on O 
Pt B-FORMULA 
NPs O 
or O 
Pt-Co B-FORMULA 
alloy O 
NPs O 
. O 
The O 
improved O 
energetics O 
and O 
kinetics O 
from O 
the O 
change O 
of O 
the O 
transition O 
states O 
imposed O 
by O 
the O 
lattice O 
mismatch O 
between O 
the O 
two O 
metals O 
are O 
concluded O 
to O 
be O 
the O 
key O 
factors O 
responsible O 
for O 
the O 
dramatically O 
improved O 
FTS O 
performance O 
. O 

study O 
elucidates O 
the O 
role O 
of O 
metabolic O 
remodeling O 
in O 
cardiac O 
dysfunction O 
induced O 
by O 
hyperthyroidism O 
. O 
Cardiac O 
hypertrophy O 
, O 
structural O 
remodeling O 
, O 
and O 
expression O 
of O 
the O 
genes O 
associated O 
with O 
fatty B-FAMILY 
acid I-FAMILY 
metabolism O 
were O 
examined O 
in O 
rats O 
treated O 
with O 
triiodothyronine B-TRIVIAL 
( O 
T3 O 
) O 
alone O 
( O 
8 O 
μg O 
/ O 
100 O 
g O 
body O 
weight O 
( O 
BW O 
) O 
, O 
i.p O 
. O 
) O 
for O 
15 O 
days O 
or O 
along O 
with O 
a O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
alpha O 
agonist O 
bezafibrate B-TRIVIAL 
( O 
Bzf B-ABBREVIATION 
; O 
30 O 
μg O 
/ O 
100 O 
g O 
BW O 
, O 
oral O 
) O 
and O 
were O 
found O 
to O 
improve O 
in O 
the O 
Bzf B-ABBREVIATION 
co O 
- O 
treated O 
condition O 
. O 
Ultrastructure O 
of O 
mitochondria O 
was O 
damaged O 
in O 
T3 O 
- O 
treated O 
rat O 
heart O 
, O 
which O 
was O 
prevented O 
by O 
Bzf B-ABBREVIATION 
co O 
- O 
administration O 
. O 
Hyperthyroidism O 
- O 
induced O 
oxidative O 
stress O 
, O 
reduction O 
in O 
cytochrome O 
c O 
oxidase O 
activity O 
, O 
and O 
myocardial O 
ATP B-ABBREVIATION 
concentration O 
were O 
also O 
significantly O 
checked O 
by O 
Bzf B-ABBREVIATION 
. O 
Heart O 
function O 
studied O 
at O 
different O 
time O 
points O 
during O 
the O 
course O 
of O 
T3 O 
treatment O 
shows O 
an O 
initial O 
improvement O 
and O 
then O 
a O 
gradual O 
but O 
progressive O 
decline O 
with O 
time O 
, O 
which O 
is O 
prevented O 
by O 
Bzf B-ABBREVIATION 
co O 
- O 
treatment O 
. O 
In O 
summary O 
, O 
the O 
results O 
demonstrate O 
that O 
hyperthyroidism O 
inflicts O 
structural O 
and O 
functional O 
damage O 
to O 
mitochondria O 
, O 
leading O 
to O 
energy O 
depletion O 
and O 
cardiac O 
dysfunction O 
. O 

stems O 
, O 
leaves O 
and O 
flowers O 
of O 
Cyclopia O 
have O 
been O 
consumed O 
as O 
a O 
herbal O 
tea O 
' O 
honeybush O 
tea O 
' O 
to O 
treat O 
various O 
medical O 
ailments O 
since O 
the O 
19th O 
century O 
. O 
Plant O 
polyphenols B-FAMILY 
are O 
reported O 
to O 
inhibit O 
adipogenesis O 
in O 
cell O 
and O 
animal O 
models O 
of O 
obesity O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
assess O 
the O 
effect O 
of O 
hot O 
water O 
extracts O 
of O 
two O 
Cyclopia O 
species O 
, O 
C O 
. O 
maculata O 
and O 
C O 
. O 
subternata O 
on O 
obesity O 
in O 
an O 
in O 
vitro O 
model O 
. O 
The O 
total O 
polyphenol B-FAMILY 
content O 
of O 
unfermented O 
C O 
. O 
subternata O 
, O 
unfermented O 
C O 
. O 
maculata O 
and O 
fermented O 
C O 
. O 
maculata O 
extracts O 
was O 
25.6 O 
, O 
22.4 O 
and O 
10.8g O 
GAE O 
/ O 
100g O 
, O 
respectively O 
. O 
The O 
major O 
compounds O 
present O 
in O 
the O 
extracts O 
were O 
: O 
the O 
flavonoid B-FAMILY 
, O 
phloretin-3',5'-di-C-glucoside B-SYSTEMATIC 
in O 
C O 
. O 
subternata O 
, O 
the O 
xanthone B-TRIVIAL 
, O 
mangiferin B-TRIVIAL 
in O 
unfermented O 
C O 
. O 
maculata O 
and O 
the O 
flavanone B-TRIVIAL 
, O 
hesperidin O 
in O 
fermented O 
C O 
. O 
maculata O 
. O 
All O 
of O 
the O 
plant O 
extracts O 
inhibited O 
intracellular O 
triglyceride B-FAMILY 
and O 
fat O 
accumulation O 
, O 
and O 
decreased O 
PPARγ2 O 
expression O 
. O 
The O 
higher O 
concentrations O 
of O 
unfermented O 
C O 
. O 
maculata O 
( O 
800 O 
and O 
1600μg O 
/ O 
ml O 
) O 
and O 
C O 
. O 
subternata O 
( O 
1600μg O 
/ O 
ml O 
) O 
were O 
cytotoxic O 
in O 
terms O 
of O 
decreased O 
mitochondrial O 
dehydrogenase O 
activity O 
. O 
Both O 
fermented O 
and O 
unfermented O 
C O 
. O 
maculata O 
, O 
at O 
concentrations O 
greater O 
than O 
100μg O 
/ O 
ml O 
, O 
decreased O 
cellular O 
ATP B-ABBREVIATION 
content O 
. O 
Cyclopia O 
maculata O 
and O 
C O 
. O 
subternata O 
inhibit O 
adipogenesis O 
in O 
vitro O 
, O 
suggesting O 
their O 
potential O 
as O 
anti-obesity O 
agents O 
. O 

the O 
mode O 
of O 
action O 
of O 
an O 
obesogen O 
: O 
Mechanistic O 
analysis O 
of O 
the O 
model O 
obesogen O 
tributyltin B-SYSTEMATIC 
in O 
the O 
3T3-L1 O 
cell O 
line O 
. O 

compounds O 
are O 
chemicals O 
that O 
have O 
an O 
influence O 
on O 
obesity O 
development O 
. O 
This O 
study O 
was O 
designed O 
to O 
unravel O 
the O 
molecular O 
mechanisms O 
of O 
the O 
model O 
obesogen O 
TBT B-ABBREVIATION 
, O 
using O 
microarray O 
analysis O 
in O 
the O 
3T3-L1 O 
in O 
vitro O 
system O 
, O 
and O 
to O 
evaluate O 
the O 
use O 
of O 
toxicogenomics O 
for O 
obesogen O 
screening O 
. O 
The O 
microarray O 
results O 
revealed O 
enrichment O 
of O 
Gene O 
Ontology O 
terms O 
involved O 
in O 
energy O 
and O 
fat O 
metabolism O 
after O 
10days O 
of O 
TBT B-ABBREVIATION 
exposure O 
. O 
Pathway O 
analysis O 
unveiled O 
PPAR O 
signalling O 
pathway O 
as O 
the O 
sole O 
pathway O 
significantly O 
enriched O 
after O 
1day O 
and O 
the O 
most O 
significantly O 
enriched O 
pathway O 
after O 
10days O 
of O 
exposure O 
. O 
To O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
study O 
delivering O 
an O 
in O 
depth O 
mechanistic O 
outline O 
of O 
the O 
mode O 
of O 
action O 
of O 
TBT B-ABBREVIATION 
as O 
an O 
obesogen O 
, O 
combining O 
effects O 
on O 
both O 
cell O 
physiological O 
and O 
gene O 
expression O 
level O 
. O 
Furthermore O 
, O 
our O 
results O 
show O 
that O 
combining O 
transcriptomics O 
with O 
3T3-L1 O 
cells O 
is O 
a O 
promising O 
tool O 
for O 
screening O 
of O 
potential O 
obesogenic O 
compounds O 
. O 

effects O 
of O 
cannabidiol B-TRIVIAL 
on O 
the O 
antigen O 
- O 
induced O 
contraction O 
of O 
airways O 
smooth O 
muscle O 
in O 
the O 
guinea O 
- O 
pig O 
. O 

has O 
been O 
demonstrated O 
to O 
have O 
beneficial O 
effects O 
in O 
the O 
airways O 
, O 
but O 
its O 
psychoactive O 
effects O 
preclude O 
its O 
therapeutic O 
use O 
for O 
the O 
treatment O 
of O 
airways O 
diseases O 
. O 
In O 
the O 
present O 
study O 
we O 
have O 
investigated O 
the O 
effects O 
of O 
(-)-cannabidiol B-TRIVIAL 
, O 
a O 
non-psychoactive O 
component O 
of O 
cannabis O 
for O 
its O 
actions O 
on O 
bronchial O 
smooth O 
muscle O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Guinea O 
- O 
pig O 
bronchial O 
smooth O 
muscle O 
contractions O 
induced O 
by O 
exogenously O 
applied O 
spasmogens O 
were O 
measured O 
isometrically O 
. O 
In O 
addition O 
, O 
contractile O 
responses O 
of O 
bronchial O 
smooth O 
muscle O 
from O 
ovalbumin O 
- O 
sensitized O 
guinea O 
- O 
pigs O 
were O 
investigated O 
in O 
the O 
absence O 
or O 
presence O 
of O 
(-)-cannabidiol B-TRIVIAL 
. O 
Furthermore O 
, O 
the O 
effect O 
of O 
(-)-cannabidiol B-TRIVIAL 
against O 
ovalbumin O 
- O 
induced O 
airway O 
obstruction O 
was O 
investigated O 
in O 
vivo O 
in O 
ovalbumin O 
- O 
sensitized O 
guinea O 
- O 
pigs O 
. O 
(-)-Cannabidiol B-TRIVIAL 
did O 
not O 
influence O 
the O 
bronchial O 
smooth O 
muscle O 
contraction O 
induced O 
by O 
carbachol B-TRIVIAL 
, O 
histamine B-TRIVIAL 
or O 
neurokinin O 
A O 
. O 
In O 
contrast O 
, O 
(-)-cannabidiol B-TRIVIAL 
inhibited O 
anandamide B-TRIVIAL 
- O 
and O 
virodhamine B-TRIVIAL 
-induced O 
responses O 
of O 
isolated O 
bronchi O 
. O 
A O 
fatty B-FAMILY 
acid I-FAMILY 
amide I-FAMILY 
hydrolase O 
inhibitor O 
, O 
phenylmethanesulfonyl B-SYSTEMATIC 
fluoride I-SYSTEMATIC 
reversed O 
the O 
inhibitory O 
effect O 
of O 
(-)-cannabidiol B-TRIVIAL 
on O 
anandamide B-TRIVIAL 
-induced O 
contractions O 
. O 
In O 
addition O 
, O 
(-)-cannabidiol B-TRIVIAL 
inhibited O 
the O 
contractile O 
response O 
of O 
bronchi O 
obtained O 
from O 
allergic O 
guinea O 
- O 
pigs O 
induced O 
by O 
ovalbumin O 
. O 
In O 
vivo O 
, O 
(-)-cannabidiol B-TRIVIAL 
reduced O 
ovalbumin O 
- O 
induced O 
airway O 
obstruction O 
. O 
In O 
conclusion O 
, O 
our O 
results O 
suggest O 
that O 
cannabidiol B-TRIVIAL 
can O 
influence O 
antigen O 
- O 
induced O 
airway O 
smooth O 
muscle O 
tone O 
suggesting O 
that O 
this O 
molecule O 
may O 
have O 
beneficial O 
effects O 
in O 
the O 
treatment O 
of O 
obstructive O 
airway O 
disorders O 
. O 

infusions O 
of O 
low O 
- O 
dose O 
ketamine B-TRIVIAL 
for O 
major O 
depression O 
. O 

: O 
Single O 
infusions O 
of O 
ketamine B-TRIVIAL 
have O 
been O 
used O 
successfully O 
to O 
achieve O 
improvement O 
in O 
depressed O 
patients O 
. O 
Side O 
effects O 
during O 
the O 
infusions O 
have O 
been O 
common O 
. O 
It O 
is O 
not O 
known O 
whether O 
serial O 
infusions O 
or O 
lower O 
infusion O 
rates O 
result O 
in O 
greater O 
efficacy O 
. O 
Methods O 
: O 
Ten O 
depressed O 
patients O 
were O 
treated O 
with O 
twice O 
weekly O 
ketamine B-TRIVIAL 
infusions O 
of O 
ketamine B-TRIVIAL 
0.5 O 
mg O 
/ O 
kg O 
administered O 
over O 
100 O 
min O 
until O 
either O 
remission O 
was O 
achieved O 
or O 
four O 
infusions O 
were O 
given O 
. O 
Side O 
effects O 
were O 
assessed O 
with O 
the O 
Young O 
Mania O 
Rating O 
Scale O 
( O 
YMRS O 
) O 
and O 
the O 
Brief O 
Psychiatric O 
Rating O 
Scale O 
( O 
BPRS O 
) O 
. O 
Patients O 
were O 
followed O 
naturalistically O 
at O 
weekly O 
intervals O 
for O 
four O 
weeks O 
after O 
completion O 
of O 
the O 
infusions O 
. O 
Results O 
: O 
Five O 
of O 
10 O 
patients O 
achieved O 
remission O 
status O 
. O 
There O 
were O 
no O 
significant O 
increases O 
on O 
the O 
BPRS O 
or O 
YMRS O 
. O 
Two O 
of O 
the O 
remitting O 
patients O 
sustained O 
their O 
improvement O 
throughout O 
the O 
four O 
week O 
follow O 
- O 
up O 
period O 
. O 
Conclusions O 
: O 
Ketamine B-TRIVIAL 
infusions O 
at O 
a O 
lower O 
rate O 
than O 
previously O 
reported O 
have O 
demonstrated O 
similar O 
efficacy O 
and O 
excellent O 
tolerability O 
and O 
may O 
be O 
more O 
practically O 
available O 
for O 
routine O 
clinical O 
care O 
. O 
Serial O 
ketamine B-TRIVIAL 
infusions O 
appear O 
to O 
be O 
more O 
effective O 
than O 
a O 
single O 
infusion O 
. O 
Further O 
research O 
to O 
test O 
relapse O 
prevention O 
strategies O 
with O 
continuation O 
ketamine B-TRIVIAL 
infusions O 
is O 
indicated O 
. O 

effect O 
of O 
calcium B-SYSTEMATIC 
channel O 
blockers O 
against O 
toxicity O 
of O 
lead O 
exposure O 
in O 
mice O 
. O 

to O 
lead O 
( O 
Pb B-FORMULA 
) O 
can O 
induce O 
kidney O 
damage O 
, O 
which O 
is O 
related O 
to O 
induction O 
of O 
oxidative O 
damage O 
and O 
disturbance O 
of O 
intracellular O 
calcium B-SYSTEMATIC 
homeostasis O 
. O 
Pb B-FORMULA 
can O 
readily O 
permeate O 
through O 
dihydropyridine O 
- O 
sensitive O 
L- O 
type O 
calcium B-SYSTEMATIC 
channels O 
and O 
accumulate O 
within O 
cells O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
investigate O 
protective O 
effects O 
of O 
calcium B-SYSTEMATIC 
channel O 
blockers O 
( O 
CCBs O 
) O 
verapamil B-TRIVIAL 
and O 
nimodipine B-TRIVIAL 
on O 
nephrotoxicity O 
induced O 
by O 
Pb B-SYSTEMATIC 
acetate I-SYSTEMATIC 
in O 
mice O 
. O 
One O 
hundred O 
and O 
twenty O 
male O 
mice O 
were O 
randomly O 
divided O 
into O 
6 O 
groups O 
: O 
control O 
, O 
Pb B-FORMULA 
, O 
low O 
- O 
dose O 
verapamil B-TRIVIAL 
, O 
high O 
- O 
dose O 
verapamil B-TRIVIAL 
, O 
low O 
- O 
dose O 
nimodipine B-TRIVIAL 
and O 
high O 
- O 
dose O 
nimodipine B-TRIVIAL 
( O 
n=20 O 
per O 
group O 
) O 
. O 
Pb B-SYSTEMATIC 
acetate I-SYSTEMATIC 
was O 
injected O 
intraperitoneally O 
( O 
i.p O 
. O 
) O 
at O 
40 O 
mg O 
/ O 
kg O 
body O 
weight O 
/ O 
day O 
for O 
10 O 
days O 
to O 
establish O 
the O 
Pb B-FORMULA 
toxicity O 
model O 
. O 
While O 
control O 
mice O 
received O 
saline O 
, O 
mice O 
of O 
the O 
treated O 
groups O 
simultaneously O 
received O 
i.p O 
. O 
injections O 
of O 
verapamil B-TRIVIAL 
or O 
nimodipine B-TRIVIAL 
daily O 
for O 
10 O 
days O 
. O 
Both O 
verapamil B-TRIVIAL 
and O 
nimodipine B-TRIVIAL 
showed O 
protection O 
against O 
Pb B-FORMULA 
-induced O 
kidney O 
injury O 
, O 
including O 
alleviation O 
of O 
renal O 
pathological O 
damage O 
and O 
decreasing O 
the O 
level O 
of O 
Pb B-FORMULA 
in O 
kidney O 
homogenate O 
and O 
extent O 
of O 
apoptosis O 
in O 
nephrocytes O 
. O 
Moreover O 
, O 
verapamil B-TRIVIAL 
and O 
nimodipine B-TRIVIAL 
significantly O 
down O 
- O 
regulated O 
levels O 
of O 
blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
and O 
creatinine B-TRIVIAL 
in O 
the O 
serum O 
. O 
In O 
addition O 
, O 
verapamil B-TRIVIAL 
and O 
nimodipine B-TRIVIAL 
administration O 
decreased O 
malondialdehyde B-TRIVIAL 
content O 
and O 
increased O 
activities O 
of O 
super B-TRIVIAL 
oxide I-TRIVIAL 
dismutase O 
activity O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
in O 
the O 
kidney O 
homogenate O 
. O 
The O 
findings O 
in O 
the O 
present O 
study O 
implicate O 
the O 
therapeutic O 
potential O 
of O 
CCBs O 
for O 
Pb B-FORMULA 
-induced O 
nephrotoxicity O 
, O 
which O 
were O 
at O 
least O 
partly O 
due O 
to O 
the O 
decrease O 
of O 
Pb B-FORMULA 
uptake O 
and O 
inhibition O 
of O 
lipid O 
peroxidation O 
. O 

damage O 
detected O 
by O 
genotoxicity O 
biomarkers O 
such O 
as O 
the O 
Comet O 
assay O 
is O 
not O 
always O 
a O 
reliable O 
indicator O 
of O 
the O 
consequences O 
that O 
genotoxic O 
agents O 
can O 
have O 
on O 
the O 
genome O 
integrity O 
of O 
the O 
exposed O 
organisms O 
. O 
Therefore O 
, O 
to O 
reveal O 
the O 
existence O 
of O 
more O 
permanent O 
alterations O 
of O 
DNA O 
structure O 
after O 
genotoxic O 
stress O 
, O 
the O 
RTG-2 O 
rainbow O 
trout O 
cell O 
line O 
was O 
exposed O 
for O 
3days O 
to O 
benzo[a]pyrene B-SYSTEMATIC 
( O 
B[a]P B-ABBREVIATION 
, O 
0.1-10μM O 
) O 
and O 
ethyl B-SYSTEMATIC 
methanesulfonate I-SYSTEMATIC 
( O 
EMS B-ABBREVIATION 
, O 
0.1-1mM O 
) O 
followed O 
by O 
3days O 
of O 
recovery O 
period O 
. O 
Primary O 
DNA O 
damage O 
was O 
evaluated O 
by O 
the O 
Comet O 
assay O 
and O 
DNA O 
alterations O 
were O 
assessed O 
using O 
AFLP O 
( O 
amplified O 
fragment O 
length O 
polymorphism O 
) O 
. O 
Qualitative O 
and O 
quantitative O 
modifications O 
in O 
AFLP O 
profiles O 
were O 
analyzed O 
in O 
order O 
to O 
detect O 
genetic O 
alterations O 
arising O 
from O 
mutation O 
events O 
and O 
/ O 
or O 
DNA O 
damage O 
. O 
Significant O 
induction O 
in O 
DNA O 
damage O 
measured O 
by O 
the O 
Comet O 
assay O 
was O 
noticed O 
after O 
B[a]P B-ABBREVIATION 
treatment O 
at O 
all O 
concentrations O 
but O 
values O 
returned O 
to O 
the O 
control O 
level O 
after O 
recovery O 
. O 
Exposure O 
to O 
EMS O 
induced O 
significant O 
DNA O 
damage O 
only O 
at O 
the O 
highest O 
concentration O 
and O 
damage O 
persisted O 
after O 
the O 
recovery O 
period O 
. O 
AFLP O 
profiles O 
detected O 
DNA O 
alterations O 
even O 
when O 
Comet O 
assay O 
indicated O 
complete O 
DNA O 
repair O 
, O 
revealing O 
more O 
persistent O 
damage O 
. O 
Since O 
such O 
DNA O 
damage O 
can O 
impair O 
its O 
structure O 
and O 
function O 
, O 
Comet O 
assay O 
results O 
should O 
preferably O 
be O 
supplemented O 
with O 
other O 
methods O 
in O 
order O 
to O 
predict O 
the O 
consequences O 
of O 
genotoxic O 
insult O 
more O 
accurately O 
. O 

tests O 
to O 
assess O 
skin O 
sensitization O 
hazard O 
are O 
in O 
peer O 
- O 
review O 
for O 
pre O 
- O 
validation O 
. O 
These O 
tests O 
, O 
as O 
well O 
as O 
the O 
animal O 
tests O 
they O 
aim O 
to O 
replace O 
, O 
were O 
developed O 
( O 
and O 
validated O 
) O 
for O 
the O 
testing O 
of O 
pure O 
substances O 
. O 
However O 
, O 
in O 
the O 
cosmetic O 
field O 
, O 
active O 
ingredients O 
are O 
often O 
mixtures O 
from O 
natural O 
sources O 
. O 
It O 
is O 
therefore O 
important O 
to O 
understand O 
which O 
tests O 
could O 
be O 
used O 
to O 
evaluate O 
their O 
safety O 
. O 
Here O 
we O 
describe O 
a O 
proof O 
- O 
of O 
- O 
concept O 
study O 
to O 
test O 
whether O 
the O 
KeratinoSens(™) O 
assay O 
is O 
able O 
to O 
detect O 
sensitizing O 
constituents O 
within O 
botanical O 
mixtures O 
. O 
Four O 
extracts O 
were O 
spiked O 
with O 
different O 
doses O 
of O 
the O 
sensitizers O 
citral B-TRIVIAL 
, O 
cinnamic B-TRIVIAL 
aldehyde I-TRIVIAL 
and O 
isoeugenol B-TRIVIAL 
. O 
The O 
tested O 
extracts O 
were O 
negative O 
in O 
the O 
test O 
whereas O 
they O 
became O 
positive O 
in O 
most O 
cases O 
when O 
spiked O 
with O 
the O 
sensitizers O 
. O 
Analysis O 
of O 
the O 
results O 
from O 
the O 
samples O 
spiked O 
with O 
different O 
doses O 
allowed O 
the O 
determination O 
of O 
the O 
minimal O 
level O 
of O 
sensitizers O 
being O 
detectable O 
. O 
The O 
contribution O 
to O 
sensitization O 
potential O 
of O 
doses O 
of O 
2% O 
and O 
above O 
of O 
the O 
spiked O 
sensitizers O 
were O 
reliably O 
detected O 
. O 
There O 
were O 
limitations O 
for O 
an O 
extract O 
with O 
high O 
cytotoxicity O 
, O 
in O 
which O 
case O 
detection O 
of O 
the O 
artificially O 
spiked O 
sensitizers O 
proved O 
difficult O 
. O 
This O 
study O 
gives O 
a O 
proof O 
of O 
principle O 
for O 
testing O 
of O 
mixtures O 
in O 
the O 
KeratinoSens(™) O 
assay O 
and O 
indicates O 
how O 
sensitive O 
the O 
assay O 
is O 
to O 
detect O 
minor O 
components O 
with O 
sensitizing O 
potential O 
. O 

effect O 
of O 
developmental O 
exposure O 
to O 
chlorpyrifos B-TRIVIAL 
on O 
late O 
- O 
stage O 
neurogenesis O 
in O 
the O 
hippocampal O 
dentate O 
gyrus O 
in O 
mouse O 
offspring O 
. O 

effect O 
of O 
developmental O 
exposure O 
to O 
chlorpyrifos B-TRIVIAL 
( O 
CPF B-ABBREVIATION 
) O 
on O 
hippocampal O 
neurogenesis O 
was O 
examined O 
in O 
male O 
mice O 
after O 
maternal O 
dietary O 
exposure O 
to O 
CPF B-ABBREVIATION 
at O 
0 O 
, O 
4 O 
, O 
20 O 
, O 
or O 
100ppm O 
from O 
gestation O 
day O 
10 O 
to O 
postnatal O 
day O 
( O 
PND O 
) O 
21 O 
. O 
Cholinesterase O 
activity O 
was O 
dose O 
- O 
dependently O 
decreased O 
in O 
red O 
blood O 
cells O 
at O 
≥ O 
4ppm O 
and O 
in O 
the O 
brain O 
at O 
100ppm O 
both O 
in O 
dams O 
and O 
offspring O 
on O 
PND O 
21 O 
. O 
Immunohistochemically O 
, O 
doublecortin(+) O 
cells O 
were O 
decreased O 
at O 
≥ O 
20ppm O 
in O 
the O 
subgranular O 
zone O 
( O 
SGZ O 
) O 
of O 
the O 
dentate O 
gyrus O 
, O 
and O 
NeuN(+)-expressing O 
mature O 
neurons O 
were O 
decreased O 
at O 
100ppm O 
in O 
the O 
hilus O 
on O 
PND O 
21 O 
. O 
There O 
were O 
no O 
differences O 
in O 
the O 
numbers O 
of O 
progenitor O 
populations O 
expressing O 
Tbr2 O 
or O 
M1 O 
muscarinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
. O 
Transcript O 
levels O 
of O 
Dcx O 
also O 
decreased O 
at O 
≥ O 
20ppm O 
, O 
and O 
those O 
of O 
Pcna O 
, O 
Casp3 O 
, O 
Bax O 
, O 
Bcl2 O 
, O 
Pax6 O 
and O 
Tbr2 O 
were O 
unchanged O 
in O 
the O 
dentate O 
gyrus O 
by O 
real O 
- O 
time O 
RT-PCR O 
. O 
At O 
PND O 
77 O 
, O 
hippocampal O 
neurogenesis O 
was O 
unchanged O 
. O 
These O 
results O 
suggest O 
that O 
developmental O 
CPF B-ABBREVIATION 
exposure O 
directly O 
but O 
transiently O 
suppresses O 
maturation O 
of O 
late O 
- O 
stage O 
granule O 
cell O 
lineages O 
in O 
the O 
SGZ O 
and O 
affects O 
interneuron O 
populations O 
in O 
the O 
hilus O 
. O 

pro O 
- O 
apoptotic O 
BCL-2 O 
family O 
member O 
BOK O 
is O 
widely O 
expressed O 
and O 
resembles O 
the O 
multi-BH O 
domain O 
proteins O 
BAX O 
and O 
BAK O 
based O 
on O 
its O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
. O 
The O 
genomic O 
region O 
encoding O 
BOK O 
was O 
reported O 
to O 
be O 
frequently O 
deleted O 
in O 
human O 
cancer O 
and O 
it O 
has O 
therefore O 
been O 
hypothesized O 
that O 
BOK O 
functions O 
as O 
a O 
tumor O 
suppressor O 
. O 
However O 
, O 
little O 
is O 
known O 
about O 
the O 
molecular O 
functions O 
of O 
BOK O 
. O 
We O 
show O 
that O 
enforced O 
expression O 
of O 
BOK O 
activates O 
the O 
intrinsic O 
( O 
mitochondrial O 
) O 
apoptotic O 
pathway O 
in O 
BAX O 
/ O 
BAK-proficient O 
cells O 
but O 
fails O 
to O 
kill O 
cells O 
lacking O 
both O 
BAX O 
and O 
BAK O 
or O 
sensitize O 
them O 
to O 
cytotoxic O 
insults O 
. O 
Interestingly O 
, O 
major O 
portions O 
of O 
endogenous O 
BOK O 
are O 
localized O 
to O 
and O 
partially O 
inserted O 
into O 
the O 
membranes O 
of O 
the O 
Golgi O 
apparatus O 
as O 
well O 
as O 
the O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
and O 
associated O 
membranes O 
. O 
The O 
C B-FORMULA 
-terminal O 
transmembrane O 
domain O 
of O 
BOK O 
thereby O 
constitutes O 
a O 
' O 
tail O 
- O 
anchor O 
' O 
specific O 
for O 
targeting O 
to O 
the O 
Golgi O 
and O 
ER O 
. O 
Overexpression O 
of O 
full O 
- O 
length O 
BOK O 
causes O 
early O 
fragmentation O 
of O 
ER O 
and O 
Golgi O 
compartments O 
. O 
A O 
role O 
for O 
BOK O 
on O 
the O 
Golgi O 
apparatus O 
and O 
the O 
ER O 
is O 
supported O 
by O 
an O 
abnormal O 
response O 
of O 
Bok O 
- O 
deficient O 
cells O 
to O 
the O 
Golgi O 
/ O 
ER O 
stressor O 
brefeldin B-TRIVIAL 
A I-TRIVIAL 
. O 
Based O 
on O 
these O 
results O 
, O 
we O 
propose O 
that O 
major O 
functions O 
of O 
BOK O 
are O 
exerted O 
at O 
the O 
Golgi O 
and O 
ER O 
membranes O 
and O 
that O 
BOK O 
induces O 
apoptosis O 
in O 
a O 
manner O 
dependent O 
on O 
BAX O 
and O 
BAK O 
. O 

stretch O 
induces O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
and O 
soluble O 
guanylate B-TRIVIAL 
cyclase O 
in O 
pulmonary O 
artery O 
smooth O 
muscle O 
cells O 
. O 

the O 
pulmonary O 
vasculature O 
, O 
mechanical O 
forces O 
such O 
as O 
cyclic O 
stretch O 
induce O 
changes O 
in O 
vascular O 
signaling O 
, O 
tone O 
and O 
remodeling O 
. O 
Nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
is O 
a O 
potent O 
regulator O 
of O 
soluble O 
guanylate B-TRIVIAL 
cyclase O 
( O 
sGC O 
) O 
, O 
which O 
drives O 
cGMP B-ABBREVIATION 
production O 
, O 
causing O 
vasorelaxation O 
. O 
Pulmonary O 
artery O 
smooth O 
muscle O 
cells O 
( O 
PASMCs O 
) O 
express O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
, O 
and O 
while O 
iNOS O 
expression O 
increases O 
during O 
late O 
gestation O 
, O 
little O 
is O 
known O 
about O 
how O 
cyclic O 
stretch O 
impacts O 
this O 
pathway O 
. O 
In O 
this O 
study O 
, O 
PASMC O 
were O 
subjected O 
to O 
cyclic O 
stretch O 
of O 
20% O 
amplitude O 
and O 
frequency O 
of O 
1 O 
Hz O 
for O 
24 O 
h O 
and O 
compared O 
to O 
control O 
cells O 
maintained O 
under O 
static O 
conditions O 
. O 
Cyclic O 
stretch O 
significantly O 
increased O 
cytosolic O 
oxidative O 
stress O 
as O 
compared O 
to O 
static O 
cells O 
( O 
62.9 O 
± O 
5.9% O 
vs O 
. O 
33.3 O 
± O 
5.7% O 
maximal O 
oxidation O 
) O 
, O 
as O 
measured O 
by O 
the O 
intracellular O 
redox O 
sensor O 
roGFP O 
. O 
Cyclic O 
stretch O 
also O 
increased O 
sGCβ O 
protein O 
expression O 
( O 
2.5 O 
± O 
0.9-fold O 
) O 
, O 
sGC O 
activity O 
( O 
1.5 O 
± O 
0.2-fold O 
) O 
and O 
cGMP B-ABBREVIATION 
levels O 
( O 
1.8 O 
± O 
0.2-fold O 
) O 
, O 
as O 
well O 
as O 
iNOS O 
mRNA O 
and O 
protein O 
expression O 
( O 
3 O 
± O 
0.9 O 
and O 
2.6 O 
± O 
0.7-fold O 
, O 
respectively O 
) O 
relative O 
to O 
control O 
cells O 
. O 
An O 
antioxidant O 
, O 
recombinant O 
human O 
superoxide B-TRIVIAL 
dismutase O 
( O 
rhSOD O 
) O 
, O 
significantly O 
decreased O 
stretch O 
- O 
induced O 
cytosolic O 
oxidative O 
stress O 
, O 
but O 
did O 
not O 
block O 
stretch O 
- O 
induced O 
sGC O 
activity O 
. O 
Inhibition O 
of O 
iNOS O 
with O 
1400 O 
W O 
or O 
an O 
iNOS-specific O 
siRNA O 
inhibited O 
stretch O 
- O 
induced O 
sGC O 
activity O 
by O 
30% O 
and O 
68% O 
respectively O 
vs O 
. O 
static O 
controls O 
. O 
In O 
conclusion O 
, O 
cyclic O 
stretch O 
increases O 
sGC O 
expression O 
and O 
activity O 
in O 
an O 
iNOS-dependent O 
manner O 
in O 
PASMC O 
from O 
fetal O 
lambs O 
. O 
The O 
mechanism O 
that O 
produces O 
iNOS O 
and O 
sGC O 
upregulation O 
is O 
not O 
yet O 
known O 
, O 
but O 
we O 
speculate O 
these O 
effects O 
represent O 
an O 
early O 
compensatory O 
mechanism O 
to O 
counteract O 
the O 
effects O 
of O 
stretch O 
- O 
induced O 
oxidative O 
stress O 
. O 
A O 
better O 
understanding O 
of O 
the O 
interplay O 
between O 
these O 
two O 
distinct O 
pathways O 
could O 
provide O 
key O 
insights O 
into O 
future O 
avenues O 
to O 
treat O 
infants O 
with O 
pulmonary O 
hypertension O 
. O 

interfacial O 
- O 
organized O 
monolayer O 
water O 
film O 
( O 
MWF O 
) O 
induced O 
" O 
two O 
- O 
step O 
" O 
aggregation O 
of O 
nanographene B-TRIVIAL 
: O 
both O 
in O 
stacking O 
and O 
sliding O 
assembly O 
pathways O 
. O 

computational O 
investigation O 
was O 
carried O 
out O 
to O 
understand O 
the O 
aggregation O 
of O 
nanoscale O 
graphene B-TRIVIAL 
with O 
two O 
typical O 
pathways O 
of O 
stacking O 
assembly O 
and O 
sliding O 
assembly O 
in O 
water O 
. O 
The O 
interfacial O 
- O 
organized O 
monolayer O 
water O 
film O 
( O 
MWF O 
) O 
induced O 
" O 
two O 
- O 
step O 
" O 
aggregation O 
of O 
nanographene B-TRIVIAL 
in O 
both O 
stacking O 
and O 
sliding O 
assembly O 
pathways O 
was O 
reported O 
for O 
the O 
first O 
time O 
. O 
By O 
means O 
of O 
potential O 
mean O 
forces O 
( O 
PMFs O 
) O 
calculation O 
, O 
no O 
energy O 
barrier O 
was O 
observed O 
during O 
the O 
sliding O 
assembly O 
of O 
two O 
graphene B-TRIVIAL 
nanosheets O 
, O 
while O 
the O 
PMF O 
profiles O 
could O 
be O 
impacted O 
by O 
the O 
contact O 
forms O 
of O 
nanographene B-TRIVIAL 
and O 
the O 
MWF O 
within O 
the O 
interplate O 
of O 
two O 
graphene B-TRIVIAL 
nanosheets O 
. O 
To O 
explore O 
the O 
potential O 
physical O 
basis O 
of O 
the O 
" O 
hindering O 
role O 
" O 
of O 
self O 
- O 
organized O 
interfacial O 
water O 
, O 
the O 
dynamical O 
and O 
structural O 
properties O 
as O 
well O 
as O 
the O 
status O 
of O 
hydrogen B-SYSTEMATIC 
bonds O 
( O 
H B-FORMULA 
-bonds O 
) O 
for O 
interfacial O 
water O 
were O 
investigated O 
. O 
We O 
found O 
that O 
the O 
compact O 
, O 
ordered O 
structure O 
and O 
abundant O 
H B-FORMULA 
-bonds O 
of O 
the O 
MWF O 
could O 
be O 
taken O 
as O 
the O 
fundamental O 
aspects O 
of O 
the O 
" O 
hindering O 
role O 
" O 
of O 
interfacial O 
water O 
for O 
the O 
hydrophobic O 
assembly O 
of O 
nanographene B-TRIVIAL 
. O 
These O 
findings O 
are O 
displaying O 
a O 
potential O 
to O 
further O 
understand O 
the O 
hydrophobic O 
assembly O 
which O 
mostly O 
dominate O 
the O 
behaviors O 
of O 
nanomaterials O 
, O 
proteins O 
etc O 
. O 
in O 
aqueous O 
solutions O 
. O 

inhibition O 
of O 
canonical O 
wnt O 
signaling O 
disrupts O 
prostatic O 
bud O 
formation O 
in O 
mouse O 
urogenital O 
sinus O 
. O 

mice O 
, O 
in O 
utero O 
exposure O 
to O 
2,3,7,8-tetrachlorodibenzo-p- B-SYSTEMATIC 
dioxin I-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
reduces O 
the O 
number O 
of O 
dorsolateral O 
prostatic O 
buds O 
resulting O 
in O 
a O 
smaller O 
dorsolateral O 
prostate O 
and O 
prevents O 
formation O 
of O 
ventral O 
buds O 
culminating O 
in O 
ventral O 
prostate O 
agenesis O 
. O 
The O 
genes O 
and O 
signaling O 
pathways O 
affected O 
by O 
TCDD B-ABBREVIATION 
that O 
are O 
responsible O 
for O 
disrupting O 
prostate O 
development O 
are O 
largely O 
unknown O 
. O 
Here O 
we O 
show O 
that O 
treatment O 
of O 
urogenital O 
sinus O 
( O 
UGS O 
) O 
organ O 
cultures O 
with O 
known O 
inhibitors O 
of O 
canonical O 
Wnt O 
signaling O 
also O 
inhibits O 
prostatic O 
bud O 
formation O 
. O 
In O 
support O 
of O 
the O 
hypothesis O 
that O 
TCDD B-ABBREVIATION 
decreases O 
canonical O 
Wnt O 
signaling O 
, O 
we O 
identify O 
inhibitory O 
effects O 
of O 
TCDD B-ABBREVIATION 
on O 
multiple O 
components O 
of O 
the O 
canonical O 
Wnt O 
signaling O 
pathway O 
in O 
the O 
UGS O 
that O 
temporally O 
coincide O 
with O 
the O 
inhibitory O 
effect O 
of O 
TCDD B-ABBREVIATION 
on O 
prostatic O 
bud O 
formation O 
: O 
( O 
1 O 
) O 
expression O 
of O 
R-spondins O 
( O 
Rspo2 O 
and O 
Rspo3 O 
) O 
that O 
promote O 
canonical O 
Wnt O 
signaling O 
is O 
reduced O 
; O 
( O 
2 O 
) O 
expression O 
of O 
Lef1 O 
, O 
Tcf1 O 
, O 
and O 
Wif1 O 
, O 
established O 
canonical O 
Wnt O 
target O 
genes O 
, O 
is O 
decreased O 
; O 
( O 
3 O 
) O 
expression O 
of O 
Lgr5 O 
, O 
a O 
RSPO O 
receptor O 
that O 
activates O 
canonical O 
Wnt O 
signaling O 
, O 
is O 
reduced O 
; O 
and O 
( O 
4 O 
) O 
expression O 
of O 
Dickkopfs O 
( O 
Dkks O 
) O 
, O 
inhibitors O 
of O 
canonical O 
Wnt O 
signaling O 
, O 
is O 
not O 
increased O 
by O 
TCDD B-ABBREVIATION 
. O 
Thus O 
, O 
the O 
TCDD B-ABBREVIATION 
-induced O 
reduction O 
in O 
canonical O 
Wnt O 
signaling O 
is O 
associated O 
with O 
a O 
decrease O 
in O 
activators O 
( O 
Rspo2 O 
and O 
Rspo3 O 
) O 
rather O 
than O 
an O 
increase O 
in O 
inhibitors O 
( O 
Dkk1 O 
and O 
Dkk2 O 
) O 
of O 
the O 
pathway O 
. O 
This O 
study O 
focuses O 
on O 
determining O 
whether O 
treatment O 
of O 
TCDD B-ABBREVIATION 
-exposed O 
UGS O 
organ O 
cultures O 
with O 
RSPO2 O 
and O 
/ O 
or O 
RSPO3 O 
is O 
capable O 
of O 
rescuing O 
the O 
inhibitory O 
effects O 
of O 
TCDD B-ABBREVIATION 
on O 
canonical O 
Wnt O 
signaling O 
and O 
prostatic O 
bud O 
formation O 
. O 
We O 
discovered O 
that O 
each O 
RSPO O 
alone O 
or O 
in O 
combination O 
partially O 
rescues O 
TCDD B-ABBREVIATION 
inhibition O 
of O 
both O 
canonical O 
Wnt O 
signaling O 
and O 
prostatic O 
bud O 
formation O 
. O 

for O 
fertility O 
is O 
based O 
on O 
two O 
conditions O 
, O 
namely O 
on O 
evidence O 
of O 
an O 
adverse O 
effect O 
on O 
sexual O 
function O 
and O 
fertility O 
and O 
that O 
the O 
effect O 
is O 
not O 
secondary O 
to O 
other O 
toxic O 
effects O 
. O 
To O 
decide O 
on O 
an O 
adverse O 
effect O 
is O 
a O 
relatively O 
simple O 
day O 
- O 
to O 
- O 
day O 
decision O 
in O 
toxicology O 
but O 
whether O 
this O 
effect O 
is O 
secondary O 
often O 
leads O 
to O 
serious O 
controversy O 
. O 
As O 
the O 
seminiferous O 
epithelium O 
operates O 
on O 
the O 
verge O 
of O 
hypoxia O 
, O 
oxygen B-SYSTEMATIC 
deficit O 
can O 
lead O 
to O 
secondary O 
impairment O 
of O 
testicular O 
function O 
. O 
This O 
is O 
well O 
known O 
from O 
healthy O 
mountaineers O 
exposing O 
themselves O 
to O 
high O 
altitude O 
. O 
They O 
have O 
reduced O 
blood O 
oxygen B-SYSTEMATIC 
content O 
that O 
goes O 
in O 
parallel O 
with O 
impairment O 
of O 
testicular O 
function O 
and O 
this O 
effect O 
remains O 
for O 
some O 
time O 
in O 
spite O 
of O 
a O 
compensatory O 
polycythaemia O 
. O 
Similar O 
findings O 
are O 
described O 
for O 
experimental O 
animals O 
exposed O 
to O 
hypobaric O 
oxygen B-SYSTEMATIC 
/ O 
high O 
altitude O 
. O 
In O 
addition O 
, O 
testicular O 
function O 
is O 
affected O 
in O 
severe O 
diseases O 
in O 
humans O 
associated O 
with O 
systemic O 
oxygen B-SYSTEMATIC 
deficit O 
like O 
chronic O 
obstructive O 
pulmonary O 
disease O 
, O 
sickle O 
cell O 
disease O 
or O 
beta-thalassaemia O 
as O 
well O 
as O 
in O 
transgenic O 
animals O 
simulating O 
haemolytic O 
anaemia O 
or O 
sickle O 
cell O 
disease O 
. O 
The O 
problem O 
of O 
insufficient O 
oxygen B-SYSTEMATIC 
supply O 
as O 
the O 
underlying O 
cause O 
for O 
testicular O 
impairment O 
has O 
received O 
relatively O 
little O 
attention O 
in O 
toxicology O 
, O 
mainly O 
because O 
blood O 
oxygen B-SYSTEMATIC 
content O 
is O 
generally O 
not O 
measured O 
in O 
these O 
animal O 
experiments O 
. O 
The O 
difficulties O 
associated O 
with O 
the O 
decision O 
whether O 
testicular O 
toxicity O 
is O 
primary O 
or O 
secondary O 
to O 
hypoxia O 
are O 
exemplified O 
by O 
the O 
results O 
of O 
inhalation O 
studies O 
with O 
nickel B-SYSTEMATIC 
subsulphide I-SYSTEMATIC 
and O 
gallium B-SYSTEMATIC 
arsenide I-SYSTEMATIC 
( O 
GaAs B-FORMULA 
) O 
. O 
Both O 
of O 
these O 
particulate O 
substances O 
lead O 
to O 
severe O 
lung O 
toxicity O 
that O 
might O 
impair O 
oxygen B-SYSTEMATIC 
uptake O 
, O 
but O 
testicular O 
toxicity O 
is O 
only O 
observed O 
with O 
GaAs B-FORMULA 
. O 
This O 
may O 
first O 
be O 
explained O 
by O 
different O 
effects O 
on O 
the O 
blood O 
: O 
nickel B-SYSTEMATIC 
subsulphide I-SYSTEMATIC 
inhalation O 
leads O 
to O 
a O 
compensatory O 
erythropoiesis O 
that O 
may O 
mitigate O 
pulmonary O 
lack O 
of O 
oxygen B-SYSTEMATIC 
uptake O 
. O 
In O 
contrast O 
, O 
GaAs B-FORMULA 
exposure O 
is O 
associated O 
with O 
microcytic O 
haemolytic O 
anaemia O 
thereby O 
aggravating O 
any O 
possible O 
oxygen B-SYSTEMATIC 
undersupply O 
. O 
Furthermore O 
, O 
the O 
predominant O 
pulmonary O 
effect O 
caused O 
by O 
GaAs B-FORMULA 
( O 
but O 
not O 
by O 
nickel B-SYSTEMATIC 
subsulphide I-SYSTEMATIC 
) O 
is O 
alveolar O 
proteinosis O 
. O 
Pulmonary O 
alveolar O 
proteinosis O 
is O 
also O 
known O 
as O 
a O 
severe O 
disease O 
in O 
humans O 
associated O 
with O 
hypoxaemia O 
. O 
Therefore O 
, O 
we O 
conclude O 
that O 
the O 
testicular O 
effects O 
observed O 
after O 
GaAs B-FORMULA 
are O 
secondary O 
to O 
hypoxaemia O 
caused O 
by O 
the O 
combination O 
of O 
pulmonary O 
proteinosis O 
and O 
haemolytic O 
anaemia O 
. O 
This O 
publication O 
tries O 
to O 
raise O 
awareness O 
to O 
the O 
severe O 
consequences O 
of O 
hypoxaemia O 
on O 
testicular O 
function O 
that O 
may O 
already O 
be O 
caused O 
by O 
reduced O 
oxygen B-SYSTEMATIC 
pressure O 
at O 
high O 
altitude O 
without O 
any O 
chemical O 
exposure O 
. O 

sodium B-SYSTEMATIC 
nitroprusside I-SYSTEMATIC 
alleviates O 
arsenic B-SYSTEMATIC 
-induced O 
oxidative O 
stress O 
in O 
wheat O 
( O 
Triticum O 
aestivum O 
L O 
. O 
) O 
seedlings O 
by O 
enhancing O 
antioxidant O 
defense O 
and O 
glyoxalase O 
system O 
. O 

present O 
study O 
investigates O 
the O 
possible O 
regulatory O 
role O 
of O 
exogenous O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
in O 
mitigating O 
oxidative O 
stress O 
in O 
wheat O 
seedlings O 
exposed O 
to O 
arsenic B-SYSTEMATIC 
( O 
As B-FORMULA 
) O 
. O 
Seedlings O 
were O 
treated O 
with O 
NO B-FORMULA 
donor O 
( O 
0.25 O 
mM O 
sodium B-SYSTEMATIC 
nitroprusside I-SYSTEMATIC 
, O 
SNP B-ABBREVIATION 
) O 
and O 
As B-FORMULA 
( O 
0.25 O 
and O 
0.5 O 
mM O 
Na2HAsO4·7H2O B-FORMULA 
) O 
separately O 
and O 
/ O 
or O 
in O 
combination O 
and O 
grown O 
for O 
72 O 
h O 
. O 
Relative O 
water O 
content O 
( O 
RWC O 
) O 
and O 
chlorophyll B-FAMILY 
( O 
chl B-ABBREVIATION 
) O 
content O 
were O 
decreased O 
by O 
As B-FORMULA 
treatment O 
but O 
proline B-TRIVIAL 
( O 
Pro B-FORMULA 
) O 
content O 
was O 
increased O 
. O 
The O 
ascorbate B-TRIVIAL 
( O 
AsA B-ABBREVIATION 
) O 
content O 
was O 
decreased O 
significantly O 
with O 
increased O 
As B-FORMULA 
concentration O 
. O 
The O 
imposition O 
of O 
As B-FORMULA 
caused O 
marked O 
increase O 
in O 
the O 
MDA B-ABBREVIATION 
and O 
H2O2 B-FORMULA 
content O 
. O 
The O 
amount O 
of O 
reduced O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
and O 
glutathione B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
( O 
GSSG B-ABBREVIATION 
) O 
significantly O 
increased O 
with O 
an O 
increase O 
in O 
the O 
level O 
of O 
As B-FORMULA 
( O 
both O 
0.25 O 
and O 
0.5 O 
mM O 
) O 
, O 
while O 
the O 
GSH B-ABBREVIATION 
/ O 
GSSG B-ABBREVIATION 
ratio O 
decreased O 
at O 
higher O 
concentration O 
( O 
0.5 O 
mM O 
) O 
. O 
The O 
ascorbate B-TRIVIAL 
peroxidase O 
and O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
activities O 
consistently O 
increased O 
with O 
an O 
increase O 
in O 
the O 
As B-FORMULA 
concentration O 
, O 
while O 
glutathione B-TRIVIAL 
reductase O 
( O 
GR O 
) O 
activities O 
increased O 
only O 
at O 
0.25 O 
mM O 
. O 
The O 
monodehydroascorbate B-SYSTEMATIC 
reductase O 
( O 
MDHAR O 
) O 
and O 
catalase O 
( O 
CAT O 
) O 
activities O 
were O 
not O 
changed O 
upon O 
exposure O 
to O 
As B-FORMULA 
. O 
The O 
activities O 
of O 
dehydroascorbate B-SYSTEMATIC 
reductase O 
( O 
DHAR O 
) O 
and O 
glyoxalase O 
I O 
( O 
Gly O 
I O 
) O 
decreased O 
at O 
any O 
levels O 
of O 
As B-FORMULA 
, O 
while O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPX O 
) O 
and O 
glyoxalase O 
II O 
( O 
Gly O 
II O 
) O 
activities O 
decreased O 
only O 
upon O 
0.5 O 
mM O 
As B-FORMULA 
. O 
Exogenous O 
NO B-FORMULA 
alone O 
had O 
little O 
influence O 
on O 
the O 
non-enzymatic O 
and O 
enzymatic O 
components O 
compared O 
to O 
the O 
control O 
seedlings O 
. O 
These O 
inhibitory O 
effects O 
of O 
As B-FORMULA 
were O 
markedly O 
recovered O 
by O 
supplementation O 
with O 
SNP B-ABBREVIATION 
; O 
that O 
is O 
, O 
the O 
treatment O 
with O 
SNP B-ABBREVIATION 
increased O 
the O 
RWC O 
, O 
chl B-ABBREVIATION 
and O 
Pro B-FORMULA 
contents O 
; O 
AsA B-ABBREVIATION 
and O 
GSH B-ABBREVIATION 
contents O 
and O 
the O 
GSH B-ABBREVIATION 
/ O 
GSSG B-ABBREVIATION 
ratio O 
as O 
well O 
as O 
the O 
activities O 
of O 
MDHAR O 
, O 
DHAR O 
, O 
GR O 
, O 
GPX O 
, O 
CAT O 
, O 
Gly O 
I O 
and O 
Gly O 
II O 
in O 
the O 
seedlings O 
subjected O 
to O 
As B-FORMULA 
stress O 
. O 
These O 
results O 
suggest O 
that O 
the O 
exogenous O 
application O 
of O 
NO B-FORMULA 
rendered O 
the O 
plants O 
more O 
tolerant O 
to O 
As B-FORMULA 
-induced O 
oxidative O 
damage O 
by O 
enhancing O 
their O 
antioxidant O 
defense O 
and O 
glyoxalase O 
system O 
. O 

fibrosis O 
is O 
associated O 
with O 
most O 
cardiac O 
diseases O 
. O 
Fibrosis O 
is O 
an O 
accumulation O 
of O 
excessive O 
extracellular O 
matrix O 
proteins O 
( O 
ECM O 
) O 
synthesized O 
by O 
cardiac O 
fibroblasts O 
and O 
myofibroblasts O 
. O 
Fibroblasts O 
are O 
the O 
most O 
prevalent O 
cell O 
type O 
in O 
the O 
heart O 
, O 
comprising O 
75% O 
of O 
cardiac O 
cells O 
. O 
Myofibroblasts O 
are O 
hardly O 
present O 
in O 
healthy O 
normal O 
heart O 
tissue O 
, O 
but O 
appear O 
abundantly O 
in O 
diseased O 
hearts O 
. O 
Cardiac O 
fibroblasts O 
are O 
activated O 
by O 
a O 
variety O 
of O 
pathological O 
stimuli O 
, O 
such O 
as O 
myocardial O 
injury O 
, O 
oxidative O 
stress O 
, O 
mechanical O 
stretch O 
, O 
and O 
elevated O 
autocrine O 
- O 
paracrine O 
mediators O 
, O 
thereby O 
undergoing O 
proliferation O 
, O 
differentiation O 
to O 
myofibroblasts O 
, O 
and O 
production O 
of O 
various O 
cytokines O 
and O 
ECM O 
proteins O 
. O 
A O 
number O 
of O 
signaling O 
pathways O 
and O 
bioactive O 
molecules O 
are O 
involved O 
and O 
work O 
in O 
concert O 
to O 
activate O 
fibroblasts O 
and O 
myofibroblasts O 
in O 
the O 
fibrogenesis O 
cascade O 
. O 
Fibroblasts O 
and O 
myofibroblasts O 
are O 
not O 
only O 
principal O 
ECM O 
producers O 
, O 
but O 
also O 
play O 
a O 
central O 
role O 
in O 
fibrogenesis O 
and O 
myocardial O 
remodeling O 
in O 
fibrotic O 
heart O 
disease O 
. O 
Thus O 
, O 
understanding O 
the O 
biological O 
processes O 
of O 
cardiac O 
fibroblasts O 
will O 
provide O 
novel O 
insights O 
into O 
the O 
underlying O 
mechanisms O 
of O 
fibrosis O 
and O 
provide O 
potential O 
targets O 
for O 
developing O 
antifibrotic O 
drugs O 
. O 
Recent O 
studies O 
demonstrate O 
that O 
Ca2+ B-FORMULA 
signal O 
is O 
essential O 
for O 
fibroblast O 
proliferation O 
, O 
differentiation O 
, O 
and O 
ECM O 
- O 
protein O 
production O 
. O 
This O 
review O 
focuses O 
on O 
the O 
recent O 
advances O 
in O 
understanding O 
molecular O 
mechanisms O 
of O 
Ca2+ B-FORMULA 
signaling O 
in O 
cardiac O 
fibrogenesis O 
, O 
and O 
potential O 
role O 
of O 
Ca2+ B-FORMULA 
-permeable O 
channels O 
, O 
in O 
particular O 
, O 
the O 
transient O 
potential O 
( O 
TRP O 
) O 
channels O 
in O 
fibrotic O 
heart O 
disease O 
. O 
TRP O 
channels O 
are O 
highly O 
expressed O 
in O 
cardiac O 
fibroblasts O 
. O 
TRPM7 O 
has O 
been O 
shown O 
to O 
be O 
essential O 
in O 
TGFβ1 O 
mediated O 
fibrogenesis O 
, O 
and O 
TRPC3 O 
has O 
been O 
demonstrated O 
to O 
play O 
an O 
essential O 
role O 
in O 
regulating O 
fibroblast O 
function O 
. O 
Thus O 
, O 
the O 
Ca2+ B-FORMULA 
-permeable O 
TRP O 
channels O 
may O 
serve O 
as O 
potential O 
novel O 
targets O 
for O 
developing O 
anti-fibrotic O 
drugs O 
. O 

recent O 
years O 
, O 
research O 
on O 
the O 
roles O 
of O 
TRP O 
channels O 
in O 
vascular O 
function O 
and O 
disease O 
has O 
undergone O 
a O 
rapid O 
expansion O 
from O 
tens O 
of O 
reports O 
published O 
in O 
the O 
early O 
2000s O 
to O 
several O 
hundreds O 
of O 
papers O 
published O 
to O 
date O 
. O 
Multiple O 
TRP O 
subtypes O 
are O 
expressed O 
in O 
vascular O 
smooth O 
muscle O 
cells O 
and O 
endothelial O 
cells O 
, O 
where O 
they O 
form O 
diverse O 
non-selective O 
cation O 
channels O 
permeable O 
to O 
Ca2+ B-FORMULA 
. O 
These O 
channels O 
mediate O 
Ca2+ B-FORMULA 
entry O 
following O 
receptor O 
stimulation O 
, O 
Ca2+ B-FORMULA 
store O 
depletion O 
and O 
mechanical O 
stimulation O 
of O 
vascular O 
myocytes O 
and O 
endothelial O 
cells O 
. O 
The O 
complex O 
molecular O 
composition O 
and O 
signalling O 
pathways O 
leading O 
to O 
the O 
activation O 
of O 
various O 
vascular O 
TRP O 
channels O 
and O 
the O 
growing O 
evidence O 
for O 
their O 
involvement O 
in O 
various O 
vascular O 
disorders O 
, O 
including O 
dysregulation O 
of O 
vascular O 
tone O 
and O 
hypertension O 
, O 
impaired O 
endothelium O 
- O 
dependent O 
vasodilatation O 
, O 
increased O 
endothelial O 
permeability O 
, O 
occlusive O 
vascular O 
disease O 
, O 
vascular O 
injury O 
and O 
oxidative O 
stress O 
, O 
are O 
summarised O 
and O 
discussed O 
in O 
this O 
review O 
. O 

Receptor O 
Potential O 
( O 
TRP O 
) O 
channels O 
affect O 
several O 
inflammatory O 
and O 
neoplastic O 
conditions O 
. O 
About O 
thirty O 
TRPs O 
have O 
been O 
identified O 
to O 
date O 
and O 
divided O 
into O 
seven O 
families O 
: O 
TRPC O 
( O 
Canonical O 
) O 
, O 
TRPV O 
( O 
Vanilloid B-FAMILY 
) O 
, O 
TRPM O 
( O 
Melastatin O 
) O 
, O 
TRPML O 
( O 
Mucolipin O 
) O 
, O 
TRPP O 
( O 
Polycystin O 
) O 
, O 
and O 
TRPA O 
( O 
Ankyrin O 
transmembrane O 
protein O 
) O 
and O 
TRPN O 
( O 
NomPClike O 
) O 
. O 
Among O 
these O 
, O 
the O 
TRPC O 
, O 
TRPM O 
, O 
and O 
TRPV O 
families O 
have O 
been O 
mainly O 
correlated O 
with O 
malignant O 
growth O 
and O 
progression O 
. O 
The O 
aim O 
of O 
this O 
review O 
is O 
to O 
summarize O 
data O 
reported O 
so O 
far O 
on O 
the O 
expression O 
and O 
functional O 
role O 
of O 
TRP O 
channels O 
in O 
different O 
types O 
of O 
cancers O 
. O 
TRP O 
channels O 
have O 
been O 
recently O 
implicated O 
in O 
the O 
triggering O 
of O 
enhanced O 
proliferation O 
, O 
aberrant O 
differentiation O 
, O 
and O 
resistance O 
to O 
apoptotic O 
cell O 
death O 
, O 
leading O 
to O 
uncontrolled O 
tumor O 
growth O 
and O 
progression O 
. O 
Depending O 
on O 
cancer O 
stage O 
, O 
up O 
and O 
down O 
- O 
regulation O 
of O 
TRP O 
mRNAs O 
and O 
protein O 
expression O 
have O 
been O 
reported O 
. O 
These O 
changes O 
have O 
been O 
shown O 
to O 
exhibit O 
cancer O 
promoting O 
( O 
oncogenic O 
) O 
or O 
inhibiting O 
/ O 
delaying O 
( O 
tumor O 
suppressor O 
) O 
effects O 
. O 
We O 
are O 
only O 
at O 
the O 
beginning O 
, O 
and O 
more O 
detailed O 
study O 
on O 
the O 
physiopathologic O 
role O 
of O 
TRP O 
channels O 
is O 
required O 
to O 
understand O 
how O 
the O 
deregulation O 
of O 
TRP O 
channel O 
expression O 
and O 
function O 
contributes O 
to O 
tumor O 
development O 
and O 
progression O 
. O 
It O 
is O 
hoped O 
that O 
greater O 
knowledge O 
about O 
TRP O 
biology O 
will O 
enable O 
future O 
development O 
of O 
new O 
chemotherapeutic O 
agents O 
for O 
specific O 
TRP O 
targets O 
, O 
and O 
the O 
use O 
of O 
TRP O 
channels O 
as O 
evaluable O 
markers O 
in O 
diagnostic O 
and O 
/ O 
or O 
prognostic O 
analysis O 
. O 

between O 
structural O 
, O 
spectroscopic O 
, O 
and O 
reactivity O 
properties O 
within O 
a O 
series O 
of O 
structurally O 
analogous O 
metastable O 
manganese(III)-alkylperoxo B-FAMILY 
complexes I-FAMILY 
. O 

- I-FAMILY 
peroxos I-FAMILY 
are O 
proposed O 
as O 
key O 
intermediates O 
in O 
a O 
number O 
of O 
important O 
biochemical O 
and O 
synthetic O 
transformations O 
. O 
Our O 
understanding O 
of O 
the O 
structural O 
, O 
spectroscopic O 
, O 
and O 
reactivity O 
properties O 
of O 
these O 
metastable O 
species O 
is O 
limited O 
, O 
however O 
, O 
and O 
correlations O 
between O 
these O 
properties O 
have O 
yet O 
to O 
be O 
established O 
experimentally O 
. O 
Herein O 
we O 
report O 
the O 
crystallographic O 
structures O 
of O 
a O 
series O 
of O 
structurally O 
related O 
metastable O 
Mn(III)-OOR B-FAMILY 
compounds O 
, O 
and O 
examine O 
their O 
spectroscopic O 
and O 
reactivity O 
properties O 
. O 
The O 
four O 
reported O 
Mn(III)-OOR B-FAMILY 
compounds O 
extend O 
the O 
number O 
of O 
known O 
end O 
- O 
on O 
Mn(III)-(η(1)-peroxos) B-FAMILY 
to O 
six O 
. O 
The O 
ligand O 
backbone O 
is O 
shown O 
to O 
alter O 
the O 
metal O 
- O 
ligand O 
distances O 
and O 
modulate O 
the O 
electronic O 
properties O 
key O 
to O 
bonding O 
and O 
activation O 
of O 
the O 
peroxo O 
. O 
The O 
mechanism O 
of O 
thermal O 
decay O 
of O 
these O 
metastable O 
species O 
is O 
examined O 
via O 
variable O 
- O 
temperature O 
kinetics O 
. O 
Strong O 
correlations O 
between O 
structural O 
( O 
O-O B-FORMULA 
and O 
Mn B-FORMULA 
··· O 
N(py,quin) B-FORMULA 
distances O 
) O 
, O 
spectroscopic O 
( O 
E(πv*( O 
O-O B-FORMULA 
) O 
→ O 
Mn B-FORMULA 
CT O 
band O 
) O 
, O 
ν( O 
O-O B-FORMULA 
) O 
) O 
, O 
and O 
kinetic O 
( O 
ΔH(‡) O 
and O 
ΔS(‡) O 
) O 
parameters O 
for O 
these O 
complexes O 
provide O 
compelling O 
evidence O 
for O 
rate O 
- O 
limiting O 
O-O B-FORMULA 
bond O 
cleavage O 
. O 
Products O 
identified O 
in O 
the O 
final O 
reaction O 
mixtures O 
of O 
Mn(III)-OOR B-FAMILY 
decay O 
are O 
consistent O 
with O 
homolytic O 
O-O B-FORMULA 
bond O 
scission O 
. O 
The O 
N-heterocyclic B-FAMILY 
amines I-FAMILY 
and O 
ligand O 
backbone O 
( O 
Et O 
vs O 
Pr O 
) O 
are O 
found O 
to O 
modulate O 
structural O 
and O 
reactivity O 
properties O 
, O 
and O 
O-O B-FORMULA 
bond O 
activation O 
is O 
shown O 
, O 
both O 
experimentally O 
and O 
theoretically O 
, O 
to O 
track O 
with O 
metal O 
ion O 
Lewis O 
acidity O 
. O 
The O 
peroxo B-SYSTEMATIC 
O-O I-SYSTEMATIC 
bond O 
is O 
shown O 
to O 
gradually O 
become O 
more O 
activated O 
as O 
the O 
N-heterocyclic B-FAMILY 
amines I-FAMILY 
move O 
closer O 
to O 
the O 
metal O 
ion O 
causing O 
a O 
decrease O 
in O 
π-donation O 
from O 
the O 
peroxo O 
πv*( O 
O-O B-FORMULA 
) O 
orbital O 
. O 
The O 
reported O 
work O 
represents O 
one O 
of O 
very O 
few O 
examples O 
of O 
experimentally O 
verified O 
relationships O 
between O 
structure O 
and O 
function O 
. O 

discrimination O 
through O 
oxidant O 
selection O 
in O 
low O 
- O 
temperature O 
atomic O 
layer O 
deposition O 
of O 
crystalline O 
iron B-FAMILY 
oxides I-FAMILY 
. O 

over O 
the O 
oxidation O 
state O 
and O 
crystalline O 
phase O 
of O 
thin O 
- O 
film O 
iron B-FAMILY 
oxides I-FAMILY 
was O 
achieved O 
by O 
low O 
- O 
temperature O 
atomic O 
layer O 
deposition O 
( O 
ALD O 
) O 
, O 
utilizing O 
a O 
novel O 
iron B-SYSTEMATIC 
precursor O 
, O 
bis(2,4-methylpentadienyl)iron B-SYSTEMATIC 
. O 
This O 
low O 
- O 
temperature O 
( O 
T O 
= O 
120 O 
°C O 
) O 
route O 
to O 
conformal O 
deposition O 
of O 
crystalline O 
Fe3O4 B-FORMULA 
or O 
α-Fe2O3 B-FORMULA 
thin O 
films O 
is O 
determined O 
by O 
the O 
choice O 
of O 
oxygen B-SYSTEMATIC 
source O 
selected O 
for O 
the O 
second O 
surface O 
half O 
- O 
reaction O 
. O 
The O 
approach O 
employs O 
ozone O 
to O 
produce O 
fully O 
oxidized O 
α-Fe2O3 B-FORMULA 
or O 
a O 
milder O 
oxidant O 
, O 
H2O2 B-FORMULA 
, O 
to O 
generate O 
the O 
Fe(2+) B-FORMULA 
/ O 
Fe(3+) B-FORMULA 
spinel O 
, O 
Fe3O4 B-FORMULA 
. O 
Both O 
processes O 
show O 
self O 
- O 
limiting O 
surface O 
reactions O 
and O 
deposition O 
rates O 
of O 
at O 
least O 
0.6 O 
Å O 
/ O 
cycle O 
, O 
a O 
significantly O 
high O 
growth O 
rate O 
at O 
such O 
mild O 
conditions O 
. O 
We O 
utilized O 
this O 
process O 
to O 
prepare O 
conformal O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
thin O 
films O 
on O 
a O 
porous O 
framework O 
, O 
for O 
which O 
α-Fe2O3 B-FORMULA 
is O 
active O 
for O 
photocatalytic O 
water O 
splitting O 
. O 

on O 
an O 
(S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
AMPA B-ABBREVIATION 
) O 
receptor O 
antagonist O 
IKM-159 B-IDENTIFIER 
: O 
asymmetric O 
synthesis O 
, O 
neuroactivity O 
, O 
and O 
structural O 
characterization O 
. O 

was O 
developed O 
and O 
identified O 
as O 
a O 
member O 
of O 
a O 
new O 
class O 
of O 
heterotricyclic O 
glutamate B-TRIVIAL 
analogues O 
that O 
act O 
as O 
AMPA B-ABBREVIATION 
receptor O 
- O 
selective O 
antagonists O 
. O 
However O 
, O 
it O 
was O 
not O 
known O 
which O 
enantiomer O 
of O 
IKM-159 B-IDENTIFIER 
was O 
responsible O 
for O 
its O 
pharmacological O 
activities O 
. O 
Here O 
, O 
we O 
report O 
in O 
vivo O 
and O 
in O 
vitro O 
neuronal O 
activities O 
of O 
both O 
enantiomers O 
of O 
IKM-159 B-IDENTIFIER 
prepared O 
by O 
enantioselective O 
asymmetric O 
synthesis O 
. O 
By O 
employment O 
of O 
(R)-2-amino-2-(4-methoxyphenyl)ethanol B-SYSTEMATIC 
as O 
a O 
chiral O 
auxiliary O 
, O 
(2R)-IKM-159 B-IDENTIFIER 
and O 
the O 
(2S)-counterpart O 
were O 
successfully O 
synthesized O 
in O 
0.70% O 
and O 
1.5% O 
yields O 
, O 
respectively O 
, O 
over O 
a O 
total O 
of O 
18 O 
steps O 
. O 
Both O 
behavioral O 
and O 
electrophysiological O 
assays O 
showed O 
that O 
the O 
biological O 
activity O 
observed O 
for O 
the O 
racemic O 
mixture O 
was O 
reproduced O 
only O 
with O 
(2R)-IKM-159 B-IDENTIFIER 
, O 
whereas O 
the O 
(2S)-counterpart O 
was O 
inactive O 
in O 
both O 
assays O 
. O 
Racemic B-IDENTIFIER 
IKM-159 I-IDENTIFIER 
was O 
crystallized O 
with O 
the O 
ligand O 
- O 
binding O 
domain O 
of O 
GluA2 O 
, O 
and O 
the O 
structure O 
revealed O 
a O 
complex O 
containing O 
(2R)-IKM-159 B-IDENTIFIER 
at O 
the O 
glutamate O 
binding O 
site O 
. O 
(2R)-IKM-159 B-IDENTIFIER 
locks O 
the O 
GluA2 O 
in O 
an O 
open O 
form O 
, O 
consistent O 
with O 
a O 
pharmacological O 
action O 
as O 
competitive O 
antagonist O 
of O 
AMPA O 
receptors O 
. O 

new O 
guaianolide B-FAMILY 
from O 
Artemisia O 
roxburghiana O 
. O 

new O 
member O 
of O 
5αH,6βH,7αH,11αH-guaian-12,6α-olides B-FAMILY 
, O 
11-epi-8α-hydroxyarborescin B-SYSTEMATIC 
, O 
together O 
with O 
a O 
mixture O 
of O 
(24R)- B-MULTIPLE 
and I-MULTIPLE 
(24S)-cycloart-25-en-3b,24-diols I-MULTIPLE 
, O 
palmitic B-TRIVIAL 
acid I-TRIVIAL 
and O 
1-octacosanol B-SYSTEMATIC 
were O 
isolated O 
from O 
the O 
leaves O 
of O 
Artemisia O 
roxburghiana O 
Bess O 
. O 
( O 
Asteraceae O 
) O 
of O 
Vietnam O 
. O 
Their O 
structures O 
were O 
determined O 
on O 
the O 
basis O 
of O 
spectroscopic O 
methods O 
. O 

microspheres O 
bearing O 
poly(ε-caprolactone) B-FAMILY 
grafts O 
of O 
different O 
molecular O 
weights O 
were O 
investigated O 
to O 
evaluate O 
the O 
effect O 
of O 
graft O 
length O 
on O 
the O 
interfacial O 
properties O 
. O 
Surface O 
force O 
and O 
friction O 
measurements O 
were O 
performed O 
using O 
an O 
atomic O 
force O 
microscope O 
in O 
colloidal O 
probe O 
mode O 
. O 
The O 
maximum O 
interaction O 
distance O 
and O 
adhesion O 
is O 
dependent O 
on O 
the O 
temperature O 
and O 
the O 
time O 
in O 
contact O 
via O 
a O 
diffusion O 
controlled O 
mechanism O 
. O 
The O 
effects O 
are O 
highest O 
for O 
the O 
longer O 
grafts O 
, O 
and O 
molecular O 
weight O 
thresholds O 
were O 
found O 
to O 
lie O 
between O 
21 O 
and O 
34 O 
kDa O 
at O 
25 O 
°C O 
and O 
between O 
9 O 
and O 
21 O 
kDa O 
at O 
40 O 
°C O 
. O 
The O 
interpenetration O 
of O 
the O 
graft O 
into O 
a O 
matrix O 
leads O 
to O 
" O 
hidden O 
length O 
" O 
contributions O 
to O 
adhesion O 
, O 
analogous O 
to O 
those O 
in O 
natural O 
biocomposites O 
. O 
The O 
nanotribology O 
results O 
display O 
Amontonian O 
behavior O 
, O 
and O 
the O 
friction O 
force O 
at O 
zero O 
applied O 
load O 
is O 
higher O 
at O 
the O 
graft O 
- O 
graft O 
interface O 
than O 
for O 
a O 
bare O 
cellulose O 
sphere O 
interacting O 
with O 
the O 
graft O 
. O 
These O 
results O 
clearly O 
demonstrate O 
the O 
benefits O 
of O 
the O 
grafted O 
polymer O 
layer O 
on O 
the O 
adhesion O 
, O 
toughness O 
, O 
and O 
resistance O 
to O 
shear O 
in O 
the O 
design O 
of O 
cellulosic O 
nanobiocomposites O 
. O 

Induces O 
Epithelial-to-Mesenchymal O 
Transition O 
and O 
Cancer O 
Stem O 
Cell O 
- O 
like O 
Properties O 
in O 
Aldehyde B-SYSTEMATIC 
Dehydroghenase-Negative O 
Thyroid O 
Cancer O 
Cells O 
. O 

: O 
Epithelial O 
- O 
to O 
- O 
mesenchymal O 
transition O 
( O 
EMT O 
) O 
has O 
been O 
thought O 
to O 
play O 
a O 
critical O 
role O 
in O 
invasion O 
and O 
metastasis O 
of O 
cancer O 
and O 
to O 
be O 
associated O 
with O 
cancer O 
stem O 
cell O 
( O 
CSC O 
) O 
properties O 
. O 
It O 
is O 
not O 
clear O 
if O 
there O 
is O 
a O 
link O 
between O 
EMT O 
and O 
CSCs O 
in O 
thyroid O 
cancers O 
. O 
We O 
therefore O 
investigated O 
CSC O 
properties O 
of O 
thyroid O 
cancers O 
that O 
underwent O 
EMT O 
. O 
Method O 
: O 
To O 
induce O 
EMT O 
( O 
spindle O 
- O 
like O 
cell O 
morphology O 
, O 
loss O 
and O 
acquisition O 
of O 
expression O 
of O 
an O 
epithelial O 
marker O 
E-cadherin O 
and O 
a O 
mesenchymal O 
marker O 
vimentin O 
, O 
respectively O 
) O 
in O 
an O 
epithelial O 
type O 
thyroid O 
cancer O 
cell O 
line O 
ACT-1 O 
, O 
we O 
used O 
transforming O 
growth O 
factor O 
- O 
beta O 
( O 
TGF-beta O 
) O 
, O 
BRAFV600E O 
and O 
/ O 
or O 
Snail O 
homolog O 
1 O 
( O 
SNAI1 O 
, O 
also O 
known O 
as O 
SNAIL O 
) O 
. O 
CSC O 
properties O 
were O 
analyzed O 
with O 
assays O 
for O 
cell O 
proliferation O 
, O 
chemosensitivity O 
, O 
in O 
vitro O 
and O 
in O 
vivo O 
tumor O 
formation O 
ability O 
, O 
cell O 
surface O 
antigens O 
and O 
intracellular O 
aldehyde B-SYSTEMATIC 
dehydrogenase O 
( O 
ALDH O 
; O 
a O 
known O 
CSC O 
marker O 
) O 
activities O 
. O 
Results O 
: O 
EMT O 
was O 
induced O 
most O 
efficiently O 
by O 
SNAIL O 
( O 
ACT-SNAIL O 
cells O 
) O 
, O 
whereas O 
TGF-beta O 
and O 
BRAFV600E O 
were O 
less O 
efficient O 
. O 
ACT-SNAIL O 
cells O 
showed O 
slightly O 
but O 
significantly O 
enhanced O 
tumor O 
formation O 
ability O 
in O 
in O 
vitro O 
sphere O 
assay O 
( O 
~3 O 
fold O 
) O 
but O 
not O 
in O 
vivo O 
subcutaneous O 
tumor O 
growth O 
assay O 
, O 
and O 
showed O 
comparable O 
chemosensitivity O 
, O 
as O 
compared O 
to O 
the O 
parental O 
ACT-1 O 
cells O 
. O 
However O 
, O 
of O 
interest O 
, O 
although O 
in O 
vitro O 
sphere O 
formation O 
ability O 
of O 
ALDH+ O 
cells O 
was O 
almost O 
unchanged O 
after O 
SNAIL O 
induction O 
, O 
SNAIL O 
overexpression O 
induced O 
much O 
higher O 
( O 
~14 O 
fold O 
) O 
spheres O 
in O 
ALDH- O 
cells O 
. O 
Thus O 
, O 
ALDH O 
was O 
no O 
longer O 
a O 
CSC O 
marker O 
in O 
ACT-SNAIL O 
cells O 
. O 
Conclusions O 
: O 
All O 
these O 
data O 
indicate O 
that O 
EMT O 
confers O 
CSC O 
properties O 
in O 
ALDH- O 
cells O 
and O 
appears O 
to O 
influence O 
the O 
ability O 
of O 
ALDH O 
to O 
enrich O 
CSCs O 
. O 

Activation O 
of O 
Polycyclic B-FAMILY 
Aromatic I-FAMILY 
Hydrocarbons I-FAMILY 
and O 
Aryl B-MULTIPLE 
and I-MULTIPLE 
Heterocyclic I-MULTIPLE 
Amines I-MULTIPLE 
by O 
Human O 
Cytochromes O 
P450 O 
2A13 O 
and O 
2A6 O 
. O 

cytochrome O 
P450 O 
( O 
P450 O 
) O 
2A13 O 
was O 
found O 
to O 
interact O 
with O 
several O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PAHs B-ABBREVIATION 
) O 
to O 
produce O 
Type O 
I O 
binding O 
spectra O 
, O 
including O 
acenaphthene B-TRIVIAL 
, O 
acenaphthylene B-TRIVIAL 
, O 
benzo[c]phenanthrene B-SYSTEMATIC 
, O 
fluoranthene B-SYSTEMATIC 
, O 
fluoranthene-2,3-diol B-SYSTEMATIC 
, O 
and O 
1-nitropyrene B-SYSTEMATIC 
. O 
P450 O 
2A6 O 
also O 
interacted O 
with O 
acenaphthene B-TRIVIAL 
and O 
acenaphthylene B-TRIVIAL 
, O 
but O 
not O 
with O 
fluoranthene B-SYSTEMATIC 
, O 
fluoranthene-2,3-diol B-SYSTEMATIC 
, O 
or O 
1-nitropyrene B-SYSTEMATIC 
. O 
P450 O 
1B1 O 
is O 
well O 
- O 
known O 
to O 
oxidize O 
many O 
carcinogenic O 
PAHs B-ABBREVIATION 
, O 
and O 
we O 
found O 
that O 
several O 
PAHs B-ABBREVIATION 
( O 
i.e O 
. O 
, O 
7,12-dimethylbenz[a]anthracene B-SYSTEMATIC 
, O 
7,12-dimethylbenz[a]anthracene-5,6-diol B-SYSTEMATIC 
, O 
benzo[c]phenanthrene B-SYSTEMATIC 
, O 
fluoranthene B-SYSTEMATIC 
, O 
fluoranthene-2,3-diol B-SYSTEMATIC 
, O 
5-methylchrysene B-SYSTEMATIC 
, O 
benz[a]pyrene-4,5-diol B-SYSTEMATIC 
, O 
benzo[a]pyrene-7,8-diol B-SYSTEMATIC 
, O 
1-nitropyrene B-SYSTEMATIC 
, O 
2-aminoanthracene B-SYSTEMATIC 
, O 
2-aminofluorene B-SYSTEMATIC 
, O 
and O 
2-acetylaminofluorene B-SYSTEMATIC 
) O 
interacted O 
with O 
P450 O 
1B1 O 
, O 
producing O 
Reverse O 
Type O 
I O 
binding O 
spectra O 
. O 
Metabolic O 
activation O 
of O 
PAHs B-ABBREVIATION 
and O 
aryl- B-MULTIPLE 
and I-MULTIPLE 
heterocyclic I-MULTIPLE 
amines I-MULTIPLE 
to O 
genotoxic O 
products O 
was O 
examined O 
in O 
Salmonella O 
typhimurium O 
NM2009 O 
, O 
and O 
we O 
found O 
that O 
P450 O 
2A13 O 
and O 
2A6 O 
( O 
as O 
well O 
as O 
P450 O 
1B1 O 
) O 
were O 
able O 
to O 
activate O 
several O 
of O 
these O 
procarcinogens O 
. O 
The O 
former O 
two O 
enzymes O 
were O 
particularly O 
active O 
in O 
catalyzing O 
2-aminofluorene B-SYSTEMATIC 
and O 
2-aminoanthracene B-SYSTEMATIC 
activation O 
, O 
and O 
molecular O 
docking O 
simulations O 
supported O 
the O 
results O 
with O 
these O 
procarcinogens O 
, O 
in O 
terms O 
of O 
binding O 
in O 
the O 
active O 
sites O 
of O 
P450 O 
2A13 O 
and O 
2A6 O 
. O 
These O 
results O 
suggest O 
that O 
P450 O 
2A O 
enzymes O 
, O 
as O 
well O 
as O 
P450 O 
Family O 
1 O 
enzymes O 
including O 
P450 O 
1B1 O 
, O 
are O 
major O 
enzymes O 
involved O 
in O 
activating O 
PAHs B-ABBREVIATION 
and O 
aryl- B-MULTIPLE 
and I-MULTIPLE 
heterocyclic I-MULTIPLE 
amines I-MULTIPLE 
, O 
as O 
well O 
as O 
tobacco O 
- O 
related O 
nitrosamines B-FAMILY 
. O 

properties O 
of O 
farnesoids B-FAMILY 
: O 
the O 
new O 
steroids B-FAMILY 
? O 

acid I-SYSTEMATIC 
( O 
FTS B-ABBREVIATION 
) O 
is O 
a O 
potent O 
non-toxic O 
anticancer O 
drug O 
that O 
targets O 
oncogenic O 
and O 
pathologically O 
activated O 
Ras O 
. O 
The O 
mechanism O 
of O 
action O 
of O 
FTS B-ABBREVIATION 
is O 
well O 
understood O 
. O 
It O 
interferes O 
with O 
the O 
binding O 
of O 
activated O 
Ras O 
proteins O 
to O 
their O 
escort O 
chaperons O 
and O 
with O 
Ras O 
tethering O 
to O 
the O 
plasma O 
membrane O 
. O 
This O 
agent O 
has O 
been O 
evaluated O 
successfully O 
in O 
phase O 
II O 
clinical O 
trials O 
of O 
pancreatic O 
and O 
lung O 
cancer O 
patients O 
. O 
It O 
is O 
generally O 
agreed O 
that O 
Ras O 
proteins O 
play O 
an O 
important O 
role O 
in O 
cancer O 
, O 
but O 
they O 
also O 
drive O 
activation O 
of O 
the O 
immune O 
system O 
. O 
Therefore O 
we O 
hypothesized O 
that O 
inhibiting O 
Ras O 
might O 
be O 
beneficial O 
in O 
autoimmune O 
and O 
inflammatory O 
conditions O 
. O 
Over O 
the O 
past O 
decade O 
we O 
have O 
extensively O 
studied O 
the O 
effects O 
of O 
FTS B-ABBREVIATION 
in O 
multiple O 
animal O 
models O 
of O 
such O 
diseases O 
. O 
We O 
were O 
able O 
to O 
show O 
potent O 
anti-inflammatory O 
properties O 
of O 
FTS B-ABBREVIATION 
in O 
autoimmune O 
disease O 
models O 
such O 
as O 
systemic O 
lupus O 
erythematous O 
, O 
antiphospholipd O 
syndrome O 
, O 
Guillain-Barré O 
syndrome O 
, O 
multiple O 
sclerosis O 
, O 
and O 
inflammatory O 
bowel O 
diseases O 
. O 
Its O 
potential O 
was O 
also O 
shown O 
in O 
type O 
I O 
and O 
type O 
II O 
diabetes O 
. O 
Animal O 
models O 
of O 
contact O 
dermatitis O 
, O 
allergic O 
inflammation O 
, O 
and O 
proliferative O 
nephritis O 
were O 
studied O 
as O 
well O 
. O 
We O 
have O 
also O 
investigated O 
the O 
molecular O 
mechanisms O 
, O 
signaling O 
pathways O 
, O 
and O 
inflammatory O 
mediators O 
underlying O 
these O 
conditions O 
. O 
In O 
this O 
review O 
we O 
summarize O 
our O 
( O 
and O 
others O 
) O 
published O 
data O 
, O 
and O 
conclude O 
that O 
FTS B-ABBREVIATION 
has O 
great O 
potential O 
as O 
a O 
safe O 
anti-inflammatory O 
drug O 
. O 

advances O 
in O 
carbon B-SYSTEMATIC 
nanotubes O 
as O 
delivery O 
systems O 
for O 
anticancer O 
drugs O 
. O 

associated O 
with O 
the O 
administration O 
of O 
anticancer O 
drugs O 
, O 
such O 
as O 
limited O 
solubility O 
, O 
poor O 
biodistribution,lack O 
of O 
selectivity O 
, O 
and O 
healthy O 
tissue O 
damage O 
, O 
can O 
be O 
overcome O 
by O 
the O 
implementation O 
of O 
drug O 
delivery O 
systems O 
. O 
A O 
wide O 
range O 
of O 
materials O 
, O 
including O 
liposomes O 
, O 
microspheres O 
, O 
polymers O 
and O 
recently O 
, O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
CNTs O 
) O 
, O 
have O 
been O 
investigated O 
for O 
delivering O 
anticancer O 
drugs O 
on O 
the O 
purpose O 
of O 
reducing O 
the O 
number O 
of O 
necessary O 
administrations O 
, O 
providing O 
more O 
localized O 
and O 
better O 
use O 
of O 
the O 
active O 
agents O 
, O 
and O 
increasing O 
patient O 
compliance O 
. O 
Carbon B-SYSTEMATIC 
nanotubes O 
( O 
CNTs O 
) O 
have O 
attracted O 
particular O 
attention O 
as O 
carriers O 
of O 
biologically O 
relevant O 
molecules O 
due O 
to O 
their O 
unique O 
physical O 
, O 
chemical O 
and O 
physiological O 
properties O 
. O 
The O 
exact O 
relationship O 
between O 
the O 
physical O 
- O 
chemical O 
properties O 
of O 
carbon B-SYSTEMATIC 
nanotubes O 
, O 
their O 
cell O 
to O 
- O 
cell O 
interactions O 
, O 
reactivity O 
, O 
and O 
biological O 
/ O 
systemic O 
consequences O 
are O 
relevant O 
issues O 
and O 
it O 
is O 
important O 
to O 
know O 
suchinter O 
- O 
relationships O 
beforehand O 
to O 
employ O 
the O 
benefits O 
of O 
these O 
nanomaterials O 
without O 
the O 
hazardous O 
consequences O 
. O 
The O 
purpose O 
of O 
this O 
review O 
is O 
to O 
present O 
highlight O 
of O 
recent O 
developments O 
in O 
the O 
application O 
of O 
carbon B-SYSTEMATIC 
nanotubes O 
as O 
cargoes O 
for O 
anti O 
cancer O 
drugs O 
and O 
in O 
the O 
diagnosis O 
of O 
cancer O 
diseases O 
. O 

Resistance O 
in O 
Cancer O 
: O 
Insights O 
into O 
the O 
Molecular O 
Mechanisms O 
of O 
a O 
DNA-Damaging O 
Drug O 
. O 

of O 
DNA O 
topoisomerase O 
I O 
is O 
the O 
mechanism O 
by O 
which O 
camptothecins B-FAMILY 
interfere O 
with O 
tumor O 
growth O 
. O 
Although O 
the O 
clinical O 
use O 
of O 
camptothecins B-FAMILY 
has O 
had O 
a O 
significant O 
impact O 
on O 
cancer O 
therapy O 
, O 
de O 
novo O 
or O 
acquired O 
clinical O 
resistance O 
to O 
these O 
drugs O 
is O 
common O 
. O 
Clinical O 
resistance O 
to O 
camptothecins B-FAMILY 
is O 
still O 
a O 
poorly O 
understood O 
phenomenon O 
, O 
likely O 
involving O 
pharmacological O 
and O 
tumor O 
- O 
related O 
factors O 
. O 
Experimental O 
models O 
including O 
yeast O 
and O 
mammalian O 
cell O 
cultures O 
suggest O 
three O 
general O 
mechanisms O 
of O 
camptothecin B-TRIVIAL 
resistance O 
: O 
i O 
) O 
reduced O 
cellular O 
accumulation O 
of O 
drugs O 
, O 
ii O 
) O 
alteration O 
in O 
the O 
structure O 
/ O 
expression O 
of O 
topoisomerase O 
I O 
, O 
and O 
iii O 
) O 
alterations O 
in O 
the O 
cellular O 
response O 
to O 
camptothecin B-TRIVIAL 
-DNA-ternary O 
complex O 
formation O 
. O 
Some O 
lines O 
of O 
evidence O 
have O 
also O 
suggested O 
links O 
between O 
cellular O 
camptothecin B-TRIVIAL 
resistance O 
, O 
the O 
existence O 
of O 
a O 
subset O 
of O 
tumor O 
- O 
initiating O 
cells O 
and O 
miRNA O 
deregulation O 
. O 
In O 
this O 
regard O 
, O 
a O 
better O 
definition O 
of O 
the O 
molecular O 
events O 
clarifying O 
the O 
regulation O 
of O 
tumorigenesis O 
and O 
gene O 
expression O 
might O 
contribute O 
to O 
gain O 
insight O 
into O 
the O 
molecular O 
mechanisms O 
on O 
the O 
basis O 
of O 
camptothecin B-TRIVIAL 
resistance O 
of O 
tumors O 
and O 
to O 
identify O 
new O 
molecular O 
tools O 
for O 
targeting O 
cancer O 
cells O 
. O 
The O 
relevance O 
of O 
these O 
mechanisms O 
to O 
clinical O 
drug O 
resistance O 
has O 
not O 
yet O 
been O 
completely O 
defined O 
, O 
but O 
their O 
evaluation O 
in O 
clinical O 
specimens O 
should O 
help O 
to O 
define O 
personalized O 
treatments O 
including O 
camptothecins B-FAMILY 
as O 
single O 
agents O 
or O 
in O 
combination O 
with O 
other O 
cytotoxic O 
and O 
target O 
- O 
specific O 
anticancer O 
agents O 
. O 
The O 
present O 
review O 
focuses O 
on O 
the O 
cellular/ O 
molecular O 
aspects O 
involved O 
in O 
resistance O 
of O 
tumor O 
cells O 
to O 
camptothecins B-FAMILY 
, O 
including O 
the O 
potential O 
role O 
of O 
cancer O 
stem O 
cells O 
and O 
deregulated O 
miRNAs O 
, O 
and O 
on O 
the O 
approaches O 
proposed O 
for O 
overcoming O 
resistance O 
. O 

agonists O 
to O 
the O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
(PPAR)γ O 
, O 
such O 
as O 
Rosiglitazone B-TRIVIAL 
, O 
have O 
been O 
associated O 
with O 
a O 
series O 
of O 
undesired O 
side O 
effects O 
, O 
such O 
as O 
weight O 
gain O 
, O 
fluid O 
retention O 
, O 
cardiac O 
hypertrophy O 
, O 
and O 
hepatotoxicity O 
. O 
Nevertheless O 
, O 
PPARγ O 
is O 
involved O 
in O 
the O 
expression O 
of O 
genes O 
that O 
control O 
glucose B-TRIVIAL 
and O 
lipid O 
metabolism O 
and O 
is O 
an O 
important O 
target O 
for O 
drugs O 
against O 
type O 
2 O 
diabetes O 
, O 
dyslipidemia O 
, O 
atherosclerosis O 
, O 
and O 
cardiovascular O 
disease O 
. O 
In O 
an O 
effort O 
to O 
identify O 
novel O 
PPARγ O 
ligands O 
with O 
an O 
improved O 
pharmacological O 
profile O 
, O 
emphasis O 
has O 
shifted O 
to O 
selective O 
ligands O 
with O 
partial O 
agonist O 
binding O 
properties O 
. O 
Toward O 
this O 
end O 
we O 
applied O 
an O 
integrated O 
in O 
silico O 
/ O 
in O 
vitro O 
workflow O 
, O 
based O 
on O 
pharmacophore- O 
and O 
structure O 
- O 
based O 
virtual O 
screening O 
of O 
the O 
ZINC O 
library O 
, O 
coupled O 
with O 
competitive O 
binding O 
and O 
transactivation O 
assays O 
, O 
and O 
adipocyte O 
differentiation O 
and O 
gene O 
expression O 
studies O 
. O 
Hit O 
compound O 
9 O 
was O 
identified O 
as O 
the O 
most O 
potent O 
ligand O 
( O 
IC50 O 
= O 
0.3 O 
μM O 
) O 
and O 
a O 
relatively O 
poor O 
inducer O 
of O 
adipocyte O 
differentiation O 
. O 
The O 
binding O 
mode O 
of O 
compound O 
9 O 
was O 
confirmed O 
by O 
molecular O 
dynamics O 
simulation O 
, O 
and O 
the O 
calculated O 
free O 
energy O 
of O 
binding O 
was O 
-8.4 O 
kcal O 
/ O 
mol O 
. O 
A O 
novel O 
functional O 
group O 
, O 
the O 
carbonitrile B-SYSTEMATIC 
group O 
, O 
was O 
identified O 
to O 
be O 
a O 
key O 
substituent O 
in O 
the O 
ligand O 
- O 
protein O 
interactions O 
. O 
Further O 
studies O 
on O 
the O 
transcriptional O 
regulation O 
properties O 
of O 
compound O 
9 O 
revealed O 
a O 
gene O 
regulatory O 
profile O 
that O 
was O 
to O 
a O 
large O 
extent O 
unique O 
, O 
however O 
functionally O 
closer O 
to O 
that O 
of O 
a O 
partial O 
agonist O 
. O 

insights O 
into O 
the O 
structural O 
and O 
chemical O 
changes O 
in O 
mixed O 
- O 
anion O 
FeOF B-FORMULA 
electrodes O 
by O 
using O 
operando O 
PDF O 
and O 
NMR O 
spectroscopy O 
. O 

analysis O 
of O 
operando O 
X-ray O 
pair O 
distribution O 
function O 
( O 
PDF O 
) O 
data O 
is O 
combined O 
with O 
Li B-FORMULA 
NMR O 
spectroscopy O 
to O 
gain O 
comprehensive O 
insights O 
into O 
the O 
electrochemical O 
reaction O 
mechanism O 
of O 
high O 
- O 
performance O 
iron B-SYSTEMATIC 
oxyfluoride I-SYSTEMATIC 
electrodes O 
. O 
While O 
the O 
full O 
discharge O 
capacity O 
could O 
be O 
recovered O 
upon O 
charge O 
, O 
implying O 
reversibility O 
of O 
the O 
electrochemical O 
reaction O 
, O 
the O 
atomic O 
structure O 
of O 
the O 
electrode O 
formed O 
after O 
cycling O 
( O 
discharge O 
- O 
charge O 
) O 
differs O 
from O 
the O 
pristine O 
uncycled O 
electrode O 
material O 
. O 
Instead O 
, O 
the O 
" O 
active O 
" O 
electrode O 
that O 
forms O 
upon O 
cycling O 
is O 
a O 
nanocomposite O 
of O 
an O 
amorphous O 
rutile O 
phase O 
and O 
a O 
nanoscale O 
rock O 
salt O 
phase O 
. O 
Bond O 
valence O 
sum O 
analysis O 
, O 
based O 
on O 
the O 
precise O 
structural O 
parameters O 
( O 
bond O 
lengths O 
and O 
coordination O 
number O 
) O 
extracted O 
from O 
the O 
in O 
situ O 
PDF O 
data O 
, O 
suggests O 
that O 
anion O 
partitioning O 
occurs O 
during O 
the O 
electrochemical O 
reaction O 
, O 
with O 
the O 
rutile O 
phase O 
being O 
F B-FORMULA 
-rich O 
and O 
the O 
rock O 
salt O 
phase O 
being O 
O B-FORMULA 
-rich O 
. O 
The O 
F B-FORMULA 
- O 
and O 
O B-FORMULA 
-rich O 
phases O 
react O 
sequentially O 
; O 
Fe B-FORMULA 
in O 
a O 
F B-FORMULA 
-rich O 
environment O 
reacts O 
preferentially O 
during O 
both O 
discharge O 
and O 
charge O 
. O 

by O 
co O 
- O 
crystal O 
structures O 
of O 
compounds O 
15 O 
, O 
22 O 
and O 
30 O 
, O 
an O 
SBDD O 
approach O 
led O 
to O 
the O 
discovery O 
of O 
the O 
6-methyl B-SYSTEMATIC 
pyridone I-SYSTEMATIC 
series O 
as O 
a O 
novel O 
class O 
of O 
GKAs O 
that O 
potently O 
activate O 
GK O 
in O 
enzyme O 
and O 
cell O 
assays O 
. O 
Anti-diabetic O 
OGTT O 
efficacy O 
was O 
demonstrated O 
with O 
54 O 
in O 
a O 
mouse O 
model O 
of O 
type O 
2 O 
diabetes O 
. O 

role O 
of O 
omega-3 O 
derived O 
resolvins B-FAMILY 
in O 
arthritis O 
. O 

polyunsaturated I-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
PUFAs B-ABBREVIATION 
) O 
are O 
known O 
to O 
alleviate O 
joint O 
stiffness O 
and O 
pain O 
in O 
rheumatoid O 
arthritis O 
patients O 
. O 
However O 
, O 
the O 
mechanisms O 
by O 
which O 
omega-3s O 
exert O 
their O 
beneficial O 
effects O 
has O 
not O 
been O 
fully O 
explored O 
. O 
Herein O 
we O 
discuss O 
a O 
novel O 
class O 
of O 
bioactive O 
lipid O 
mediators O 
, O 
which O 
are O 
enzymatically O 
biosynthesized O 
in O 
vivo O 
from O 
omega-3 B-SYSTEMATIC 
eicosapentaenoic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
EPA B-ABBREVIATION 
) O 
and O 
docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DHA B-ABBREVIATION 
) O 
, O 
termed O 
resolvins B-FAMILY 
. O 
These O 
lipid O 
mediators O 
exert O 
anti-inflammatory O 
and O 
pro O 
- O 
resolving O 
properties O 
and O 
are O 
log O 
- O 
orders O 
more O 
potent O 
than O 
their O 
precursors O 
. O 
We O 
also O 
highlight O 
that O 
formation O 
of O 
pro O 
- O 
resolving O 
mediators O 
can O 
be O 
enhanced O 
by O 
widely O 
used O 
anti-inflammatory O 
and O 
cardioprotective O 
drugs O 
( O 
aspirin B-TRIVIAL 
and O 
statins O 
) O 
via O 
the O 
modification O 
of O 
cyclooxygenase-2 O 
enzymatic O 
activity O 
. O 
These O 
bioactive O 
pro O 
- O 
resolving O 
lipid O 
mediators O 
provide O 
further O 
rationale O 
for O 
the O 
beneficial O 
effects O 
of O 
dietary O 
supplementation O 
with O 
fish O 
oils O 
, O 
and O 
offer O 
new O 
avenues O 
for O 
developing O 
therapeutics O 
for O 
inflammatory O 
conditions O 
such O 
as O 
rheumatoid O 
arthritis O 
. O 

one O 
- O 
pot O 
domino O 
synthesis O 
and O 
discovery O 
of O 
highly O 
functionalized O 
dihydrobenzo[b]thiophenes B-FAMILY 
as O 
AChE O 
inhibitors O 
. O 

library O 
of O 
novel O 
5-amino-2,7-diaryl-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitriles B-FAMILY 
have O 
been O 
synthesized O 
regioselectively O 
in O 
good O 
yields O 
through O 
the O 
one O 
- O 
pot O 
domino O 
reactions O 
of O 
5-aryldihydro-3(2H)-thiophenones B-FAMILY 
, O 
malononitrile B-TRIVIAL 
and O 
aromatic B-FAMILY 
aldehydes I-FAMILY 
in O 
the O 
presence O 
of O 
morpholine B-SYSTEMATIC 
. O 
This O 
transformation O 
presumably O 
involves O 
Knoevenagel O 
condensation-Michael O 
addition O 
- O 
intramolecular O 
Thorpe-Ziegler O 
cyclization-Tautomerization-Elimination O 
sequence O 
of O 
reactions O 
. O 
These O 
compounds O 
were O 
evaluated O 
for O 
their O 
acetylcholinesterase O 
( O 
AChE O 
) O 
inhibitory O 
activity O 
and O 
5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile B-SYSTEMATIC 
was O 
found O 
to O 
be O 
the O 
most O 
potent O 
against O 
AChE O 
with O 
IC50 O 
4.16 O 
μmol O 
/ O 
L O 
. O 

to O 
aniline B-SYSTEMATIC 
: O 
an O 
exceptional O 
biologically O 
driven O 
rearrangement O 
. O 

and O 
cytotoxicity O 
evaluation O 
of O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
. O 

derivatives O 
of O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
1 O 
) O 
have O 
been O 
synthesized O 
and O 
evaluated O 
for O 
their O 
inhibitory O 
activities O 
against O 
the O 
growth O 
of O 
prostate O 
PC3 O 
, O 
breast O 
MCF-7 O 
, O 
lung O 
A549 O 
, O 
and O 
gastric O 
BGC-823 O 
cancer O 
cells O 
by O 
MTT B-ABBREVIATION 
assays O 
. O 
Within O 
these O 
series O 
of O 
derivatives O 
, O 
compound O 
17 O 
exhibited O 
the O 
most O 
potent O 
cytotoxicity O 
against O 
PC3 O 
cell O 
line O 
( O 
IC50=0.39 O 
μM O 
) O 
and O 
compound O 
28 O 
displayed O 
the O 
best O 
activity O 
against O 
A549 O 
cell O 
line O 
( O 
IC50=0.22 O 
μM O 
) O 
. O 
SAR O 
analysis O 
indicates O 
that O 
H B-FORMULA 
-donor O 
substitution O 
at O 
C-3 O 
position O 
of O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
may O 
be O 
advantageous O 
for O 
improvement O 
of O 
cytotoxicity O 
against O 
PC3 O 
, O 
A549 O 
and O 
MCF-7 O 
cell O 
lines O 
. O 

derivatives O 
as O 
fluorescent O 
pigment O 
dyeing O 
substrates O 
and O 
their O 
application O 
for O 
the O 
assay O 
of O 
β-d-galactosidase O 
activities O 
. O 

derivatives O 
were O 
synthesized O 
as O 
novel O 
artificial O 
fluorescent O 
pigment O 
dyeing O 
substrates O 
for O 
β-d-galactosidase O 
. O 
The O 
substrates O 
, O 
which O 
exhibited O 
non-fluorescence O 
or O 
weak O 
fluorescence O 
in O 
solution O 
phase O 
, O 
were O 
smoothly O 
hydrolyzed O 
by O 
β-d-galactosidase O 
from O 
Aspergillus O 
oryzae O 
and O 
yielded O 
a O 
water O 
- O 
insoluble O 
strong O 
fluorescent O 
pigment O 
. O 
The O 
difference O 
of O 
fluorescent O 
intensity O 
exhibited O 
a O 
linear O 
relationship O 
with O 
the O 
amount O 
of O 
enzyme O 
. O 

Q10 I-TRIVIAL 
protects O 
Pc12 O 
cells O 
from O 
cisplatin B-TRIVIAL 
-induced O 
DNA O 
damage O 
and O 
neurotoxicity O 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
neuroprotective O 
effect O 
of O 
a O 
water O 
- O 
soluble O 
formulation O 
of O 
coenzyme B-TRIVIAL 
Q10 I-TRIVIAL 
( O 
WS- O 
CoQ10 B-ABBREVIATION 
) O 
in O 
PC12 O 
cells O 
exposed O 
to O 
cisplatin B-TRIVIAL 
, O 
a O 
chemotherapeutic O 
agent O 
with O 
a O 
dose O 
- O 
limiting O 
factor O 
due O 
to O 
neurotoxicity O 
. O 
In O 
the O 
cytokinesis O 
- O 
block O 
micronucleus O 
cytome O 
assay O 
( O 
CBMN O 
Cyt O 
) O 
, O 
WS- O 
CoQ10 B-ABBREVIATION 
( O 
at O 
concentrations O 
of O 
0.1 O 
, O 
0.5 O 
and O 
1.0μgmL(-1) O 
) O 
protected O 
PC12 O 
cells O 
from O 
cisplatin B-TRIVIAL 
-induced O 
DNA O 
damage O 
(0.1μgmL(-1)) O 
, O 
reducing O 
the O 
frequency O 
of O 
micronuclei O 
( O 
MNi O 
) O 
and O 
nuclear O 
buds O 
( O 
NBUDs O 
) O 
. O 
WS- O 
CoQ10 B-ABBREVIATION 
did O 
not O 
alter O 
the O 
mRNA O 
expression O 
levels O 
of O 
Tp53 O 
( O 
at O 
a O 
concentration O 
of O 
1.0μgmL(-1) O 
) O 
and O 
exhibited O 
neuroprotective O 
activity O 
by O 
stimulating O 
cisplatin B-TRIVIAL 
-inhibited O 
neurite O 
outgrowth O 
in O 
nerve O 
growth O 
factor O 
(NGF)-differentiated O 
PC12 O 
cells O 
( O 
at O 
a O 
concentration O 
of O 
0.1μgmL(-1) O 
) O 
. O 
In O 
conclusion O 
, O 
WS- O 
CoQ10 B-ABBREVIATION 
protected O 
the O 
PC12 O 
cells O 
from O 
cisplatin B-TRIVIAL 
-induced O 
DNA O 
damage O 
and O 
neurotoxicity O 
. O 
Moreover O 
, O 
the O 
neuroprotective O 
effects O 
of O 
WS- O 
CoQ10 B-ABBREVIATION 
suggest O 
a O 
possible O 
application O 
in O 
chemotherapeutic O 
protocols O 
. O 

and O 
Sensitive O 
Determination O 
of O 
Timosaponin B-TRIVIAL 
AIII I-TRIVIAL 
in O 
Rat O 
Plasma O 
by O 
LC-MS O 
/ O 
MS O 
and O 
Its O 
Pharmacokinetic O 
Application O 
. O 

rapid O 
sensitive O 
and O 
selective O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
( O 
LC-MS O 
/ O 
MS O 
) O 
method O 
was O 
developed O 
for O 
determination O 
of O 
timosaponin B-TRIVIAL 
AIII I-TRIVIAL 
( O 
TA-III B-ABBREVIATION 
) O 
in O 
rat O 
plasma O 
, O 
using O 
ginsenoside B-TRIVIAL 
Re I-TRIVIAL 
as O 
an O 
internal O 
standard O 
( O 
IS O 
) O 
. O 
TA-III B-ABBREVIATION 
and O 
the O 
IS O 
were O 
detected O 
in O 
MRM O 
mode O 
with O 
a O 
negative O 
ionization O 
electrospray O 
mass O 
spectrometer O 
. O 
The O 
calibration O 
curves O 
were O 
linear O 
over O 
the O 
concentration O 
ranges O 
from O 
11.14 O 
to O 
1114 O 
ng O 
/ O 
mL O 
and O 
the O 
lower O 
limit O 
of O 
quantification O 
( O 
LLOQ O 
) O 
was O 
11.14 O 
ng O 
/ O 
mL O 
. O 
Intra O 
- O 
day O 
and O 
inter O 
- O 
day O 
precisions O 
( O 
RSD O 
) O 
were O 
within O 
10% O 
, O 
and O 
accuracy O 
ranged O 
from O 
6.4% O 
to O 
9.1% O 
. O 
The O 
extraction O 
recovery O 
at O 
three O 
concentrations O 
ranged O 
from O 
92.3% O 
to O 
95.5% O 
. O 
The O 
validated O 
method O 
was O 
successfully O 
applied O 
to O 
monitor O 
the O 
concentrations O 
of O 
TA-III B-ABBREVIATION 
in O 
rat O 
plasma O 
after O 
intragastric O 
administration O 
. O 
The O 
best O 
fit O 
pharmacokinetic O 
model O 
to O 
estimate O 
the O 
pharmacokinetic O 
parameters O 
was O 
a O 
single O 
compartment O 
model O 
with O 
weight O 
of O 
1 O 
/ O 
x2 O 
for O 
oral O 
administration O 
groups O 
of O 
rats O 
for O 
TA-III B-ABBREVIATION 
. O 

resistance O 
is O 
a O 
major O 
cause O 
of O 
chemotherapy O 
failure O 
. O 
Recent O 
studies O 
indicate O 
that O 
drug O 
resistance O 
can O 
be O 
rapidly O 
induced O 
by O 
some O 
soluble O 
factors O 
, O 
such O 
as O 
cytokines O 
, O 
chemokines O 
, O 
growth O 
factors O 
, O 
and O 
cell O 
adhesion O 
factors O 
in O 
the O 
tumor O 
microenvironment O 
. O 
Osteopontin O 
( O 
OPN O 
) O 
, O 
an O 
extracellular O 
matrix O 
protein O 
, O 
has O 
a O 
functional O 
arginine B-TRIVIAL 
- O 
glycine B-TRIVIAL 
- O 
aspartic B-TRIVIAL 
acid I-TRIVIAL 
( O 
RGD O 
) O 
domain O 
for O 
binding O 
to O 
integrin O 
. O 
Here O 
we O 
found O 
OPN O 
expression O 
to O 
be O 
upregulated O 
by O 
hypoxic O 
condition O 
in O 
PC-3 O 
prostate O 
tumor O 
cells O 
. O 
OPN O 
increased O 
the O 
mRNA O 
and O 
protein O 
expression O 
of O 
p-glycoprotein O 
( O 
P-gp O 
) O 
, O 
a O 
subfamily O 
of O 
ATP B-ABBREVIATION 
-binding O 
cassette O 
transporter O 
in O 
a O 
concentration- O 
and O 
time O 
- O 
dependent O 
manner O 
. O 
The O 
increase O 
in O 
P-gp O 
transporter O 
by O 
OPN O 
was O 
mediated O 
by O 
binding O 
to O 
αvβ3 O 
integrin O 
. O 
Daunomycin B-TRIVIAL 
( O 
DUN B-ABBREVIATION 
) O 
, O 
a O 
chemotherapeutic O 
agent O 
with O 
autofluorescence O 
, O 
was O 
used O 
to O 
evaluate O 
the O 
pump O 
activity O 
, O 
and O 
OPN O 
increased O 
the O 
drug O 
pumping O 
- O 
out O 
activity O 
. O 
OPN O 
inhibited O 
DUN B-ABBREVIATION 
-induced O 
cell O 
death O 
, O 
which O 
was O 
antagonized O 
by O 
αvβ3 O 
monoclonal O 
antibody O 
. O 
Long O 
- O 
term O 
treatment O 
with O 
DUN B-ABBREVIATION 
further O 
enhanced O 
the O 
expression O 
of O 
OPN O 
. O 
Knockdown O 
of O 
endogenous O 
OPN O 
potentiated O 
the O 
DUN B-ABBREVIATION 
-induced O 
apoptosis O 
of O 
PC-3 O 
cells O 
. O 
Furthermore O 
, O 
knockdown O 
of O 
OPN O 
enhanced O 
cell O 
death O 
caused O 
by O 
other O 
drugs O 
, O 
including O 
paclitaxel B-TRIVIAL 
, O 
doxorubicin B-TRIVIAL 
, O 
actinomycin-D B-TRIVIAL 
, O 
and O 
rapamycin B-TRIVIAL 
, O 
which O 
are O 
also O 
P-gp O 
substrates O 
. O 
The O 
animal O 
studies O 
also O 
showed O 
that O 
OPN O 
knockdown O 
enhanced O 
the O 
cytotoxic O 
action O 
of O 
DUN B-ABBREVIATION 
. O 
These O 
results O 
indicate O 
that O 
OPN O 
is O 
a O 
potential O 
therapeutic O 
target O 
for O 
cancer O 
therapy O 
to O 
reduce O 
drug O 
resistance O 
in O 
sensitive O 
tumors O 
. O 

A I-TRIVIAL 
, O 
a O 
marine O 
- O 
derived O 
tetranorditerpenoid B-FAMILY 
, O 
induces O 
G2 O 
/ O 
M O 
arrest O 
in O 
human O 
NCI-H460 O 
lung O 
carcinoma O 
cells O 
, O 
is O 
mediated O 
by O 
p53-p21 O 
stabilization O 
and O 
modulated O 
by O 
Ras O 
/ O 
Raf O 
/ O 
MEK O 
/ O 
ERK O 
signaling O 
pathway O 
. O 

we O 
first O 
demonstrate O 
that O 
asperolide B-TRIVIAL 
A I-TRIVIAL 
, O 
a O 
very O 
recently O 
reported O 
marine O 
- O 
derived O 
tetranorditerpenoid B-FAMILY 
, O 
leads O 
to O 
the O 
inhibition O 
of O 
NCI-H460 O 
lung O 
carcinoma O 
cell O 
proliferation O 
by O 
G2 O 
/ O 
M O 
arrest O 
with O 
the O 
activation O 
of O 
the O 
Ras O 
/ O 
Raf O 
/ O 
MEK O 
/ O 
ERK O 
signaling O 
and O 
p53-dependent O 
p21 O 
pathway O 
. O 
Treatment O 
with O 
35 O 
μM O 
asperolide B-TRIVIAL 
A I-TRIVIAL 
( O 
2 O 
× O 
IC(50) O 
) O 
resulted O 
in O 
a O 
significant O 
increase O 
in O 
the O 
proportion O 
of O 
G2 O 
/ O 
M O 
phase O 
cells O 
, O 
about O 
a O 
2.9-fold O 
increase O 
during O 
48 O 
h O 
. O 
Immunoblot O 
assays O 
demonstrated O 
time O 
- O 
dependent O 
inhibition O 
of O 
G2 O 
/ O 
M O 
regulatory O 
proteins O 
. O 
Moreover O 
, O 
asperolide B-TRIVIAL 
A I-TRIVIAL 
significantly O 
activated O 
MAP O 
kinases O 
( O 
ERK1 O 
/ O 
2 O 
, O 
JNK O 
and O 
p38 O 
MAP O 
kinase O 
) O 
by O 
phosphorylation O 
, O 
and O 
only O 
the O 
inhibition O 
of O 
ERK O 
activation O 
by O 
PD98059 B-IDENTIFIER 
reversed O 
downregulation O 
of O 
G2 O 
/ O 
M O 
regulatory O 
proteins O 
CDC2 O 
, O 
and O 
suppressed O 
upregulation O 
of O 
p21 O 
and O 
p-p53 O 
levels O 
. O 
Transfection O 
of O 
cells O 
with O 
dominant O 
- O 
negative O 
Ras O 
( O 
RasN17 O 
) O 
mutant O 
genes O 
up O 
- O 
regulated O 
asperolide B-TRIVIAL 
A I-TRIVIAL 
-induced O 
the O 
decrease O 
of O 
cyclin O 
B1 O 
and O 
CDC2 O 
, O 
suppressed O 
Raf O 
, O 
ERK O 
activity O 
and O 
p53-p21 O 
expression O 
, O 
and O 
at O 
last O 
, O 
abolished O 
G2 O 
/ O 
M O 
arrest O 
. O 
This O 
study O 
indicates O 
that O 
asperolide B-TRIVIAL 
A I-TRIVIAL 
-induced O 
G2 O 
/ O 
M O 
arrest O 
in O 
human O 
NCI-H460 O 
lung O 
carcinoma O 
cells O 
relys O 
on O 
the O 
participation O 
of O 
the O 
Ras O 
/ O 
Raf O 
/ O 
MEK O 
/ O 
ERK O 
signaling O 
pathway O 
in O 
p53-p21 O 
stabilization O 
. O 
An O 
in O 
vivo O 
study O 
with O 
asperolide B-TRIVIAL 
A I-TRIVIAL 
illustrated O 
a O 
marked O 
inhibition O 
of O 
tumor O 
growth O 
, O 
and O 
little O 
toxcity O 
compared O 
to O 
Cisplatin B-TRIVIAL 
therapy O 
. O 
Overall O 
, O 
these O 
findings O 
provide O 
potential O 
effectiveness O 
and O 
a O 
theoretical O 
basis O 
for O 
the O 
therapeutic O 
use O 
of O 
asperolide B-TRIVIAL 
A I-TRIVIAL 
in O 
the O 
treatment O 
of O 
malignancies O 
. O 

of O 
monophosphoryl B-TRIVIAL 
lipid I-TRIVIAL 
A I-TRIVIAL 
producing O 
Escherichia O 
coli O 
mutants O 
and O 
comparison O 
of O 
immuno O 
- O 
stimulatory O 
activities O 
of O 
their O 
lipopolysaccharides O 
. O 

lipid B-TRIVIAL 
A I-TRIVIAL 
moiety O 
of O 
Escherichia O 
coli O 
lipopolysaccharide O 
is O 
a O 
hexaacylated B-FAMILY 
disaccharide I-FAMILY 
of O 
glucosamine B-TRIVIAL 
phosphorylated O 
at O 
the O 
1- O 
and O 
4'- O 
positions O 
. O 
It O 
can O 
be O 
recognized O 
by O 
the O 
TLR4 O 
/ O 
MD-2 O 
complex O 
of O 
mammalian O 
immune O 
cells O 
, O 
leading O 
to O 
release O 
of O 
proinflammatory O 
cytokines O 
. O 
The O 
toxicity O 
of O 
lipid B-TRIVIAL 
A I-TRIVIAL 
depends O 
on O 
its O 
structure O 
. O 
In O 
this O 
study O 
, O 
two O 
E O 
. O 
coli O 
mutants O 
, O 
HW001 O 
and O 
HW002 O 
, O 
were O 
constructed O 
by O 
deleting O 
or O 
integrating O 
key O 
genes O 
related O 
to O 
lipid B-TRIVIAL 
A I-TRIVIAL 
biosynthesis O 
in O 
the O 
chromosome O 
of O 
E O 
. O 
coli O 
W3110 O 
. O 
HW001 O 
was O 
constructed O 
by O 
deleting O 
lacI O 
and O 
replacing O 
lacZ O 
with O 
the O 
Francisella O 
novicida O 
lpxE O 
gene O 
in O 
the O 
chromosome O 
and O 
only O 
synthesizes O 
monophosphoryl B-TRIVIAL 
lipid I-TRIVIAL 
A I-TRIVIAL 
. O 
HW002 O 
was O 
constructed O 
by O 
deleting O 
lpxM O 
in O 
HW001 O 
and O 
synthesizes O 
only O 
the O 
pentaacylated B-TRIVIAL 
monophosphoryl I-TRIVIAL 
lipid I-TRIVIAL 
A I-TRIVIAL 
. O 
The O 
structures O 
of O 
lipid B-TRIVIAL 
A I-TRIVIAL 
made O 
in O 
HW001 O 
and O 
HW002 O 
were O 
confirmed O 
by O 
thin O 
layer O 
chromatography O 
and O 
electrospray O 
ionization O 
mass O 
spectrometry O 
. O 
HW001 O 
and O 
HW002 O 
grew O 
as O 
well O 
as O 
the O 
wild O 
- O 
type O 
W3110 O 
. O 
LPS O 
purified O 
from O 
HW001 O 
or O 
HW002 O 
was O 
used O 
to O 
stimulate O 
murine O 
macrophage O 
RAW264.7 O 
cells O 
, O 
and O 
less O 
TNF-α O 
were O 
released O 
. O 
This O 
study O 
provides O 
a O 
feasible O 
way O 
to O 
produce O 
interesting O 
lipid B-TRIVIAL 
A I-TRIVIAL 
species O 
in O 
E O 
. O 
coli O 
. O 

- O 
aged O 
people O 
with O 
diabetes O 
have O 
been O 
reported O 
to O 
have O 
significantly O 
higher O 
risks O 
of O 
cardiovascular O 
events O 
than O 
people O 
without O 
diabetes O 
. O 
However O 
, O 
recent O 
falls O 
in O 
cardiovascular O 
disease O 
rates O 
and O 
more O 
active O 
management O 
of O 
risk O 
factors O 
may O 
have O 
abolished O 
the O 
increased O 
risk O 
. O 
We O 
aimed O 
to O 
provide O 
an O 
up O 
- O 
to O 
- O 
date O 
assessment O 
of O 
the O 
relative O 
risks O 
associated O 
with O 
type O 
2 O 
diabetes O 
of O 
all O 
- O 
cause O 
and O 
cardiovascular O 
mortality O 
in O 
middle O 
- O 
aged O 
people O 
in O 
the O 
U.K.RESEARCH O 
DESIGN O 
AND O 
METHODSUsing O 
data O 
from O 
the O 
General O 
Practice O 
Research O 
Database O 
, O 
from O 
2004 O 
to O 
2010 O 
, O 
we O 
conducted O 
a O 
cohort O 
study O 
of O 
87098 O 
people O 
, O 
40-65 O 
years O 
of O 
age O 
at O 
baseline O 
, O 
comparing O 
21798 O 
with O 
type O 
2 O 
diabetes O 
and O 
65300 O 
without O 
diabetes O 
, O 
matched O 
on O 
age O 
, O 
sex O 
, O 
and O 
general O 
practice O 
. O 
We O 
produced O 
hazard O 
ratios O 
( O 
HRs O 
) O 
for O 
mortality O 
and O 
compared O 
rates O 
of O 
blood O 
pressure O 
testing O 
, O 
cholesterol B-TRIVIAL 
monitoring O 
, O 
and O 
use O 
of O 
aspirin B-TRIVIAL 
, O 
statins O 
, O 
and O 
antihypertensive O 
drugs.RESULTSPeople O 
with O 
type O 
2 O 
diabetes O 
, O 
compared O 
with O 
people O 
without O 
diabetes O 
, O 
had O 
a O 
twofold O 
increased O 
risk O 
of O 
all O 
- O 
cause O 
mortality O 
( O 
HR O 
2.07 O 
[ O 
95% O 
CI O 
1.95-2.20 O 
] O 
, O 
adjusted O 
for O 
smoking O 
) O 
and O 
a O 
threefold O 
increased O 
risk O 
of O 
cardiovascular O 
mortality O 
( O 
3.25 O 
[ O 
2.87-3.68 O 
] O 
, O 
adjusted O 
for O 
smoking O 
) O 
. O 
Women O 
had O 
a O 
higher O 
relative O 
risk O 
than O 
men O 
, O 
and O 
people O 
< O 
55 O 
years O 
of O 
age O 
had O 
a O 
higher O 
relative O 
risk O 
than O 
those O 
> O 
55 O 
years O 
of O 
age O 
. O 
Monitoring O 
and O 
medication O 
rates O 
were O 
higher O 
in O 
those O 
with O 
diabetes O 
( O 
all O 
P O 
< O 
0.001).CONCLUSIONSDespite O 
efforts O 
to O 
manage O 
risk O 
factors O 
, O 
administer O 
effective O 
treatments O 
, O 
and O 
develop O 
new O 
therapies O 
, O 
middle O 
- O 
aged O 
people O 
with O 
type O 
2 O 
diabetes O 
remain O 
at O 
significantly O 
increased O 
risk O 
of O 
death O 
. O 

effect O 
of O 
therapeutic O 
strategies O 
on O 
cardiovascular O 
( O 
CV O 
) O 
disease O 
can O 
be O 
evaluated O 
by O 
monitoring O 
changes O 
in O 
CV O 
risk O 
biomarkers O 
. O 
This O 
study O 
investigated O 
the O 
effect O 
of O 
a O 
structured O 
self O 
- O 
monitoring O 
of O 
blood O 
glucose B-TRIVIAL 
( O 
SMBG O 
) O 
protocol O 
and O 
the O 
resulting O 
improvements O 
in O 
glycemic O 
control O 
on O 
changes O 
in O 
high O 
- O 
sensitivity O 
C-reactive O 
protein O 
( O 
hs-CRP O 
) O 
in O 
insulin-naïve O 
patients O 
with O 
type O 
2 O 
diabetes.RESEARCH O 
DESIGN O 
AND O 
METHODSThe O 
Structured O 
Testing O 
Program O 
( O 
STeP O 
) O 
study O 
was O 
a O 
prospective O 
, O 
cluster O 
- O 
randomized O 
, O 
multicenter O 
trial O 
in O 
which O 
483 O 
poorly O 
controlled O 
, O 
insulin-naïve O 
patients O 
with O 
type O 
2 O 
diabetes O 
were O 
randomized O 
to O 
active O 
control O 
( O 
ACG O 
) O 
or O 
structured O 
testing O 
( O 
STG O 
) O 
that O 
included O 
quarterly O 
structured O 
SMBG O 
. O 
Changes O 
in O 
A1C O 
, O 
hs-CRP O 
, O 
and O 
glycemic O 
variability O 
( O 
STG O 
subjects O 
only O 
) O 
were O 
measured O 
at O 
baseline O 
and O 
quarterly.RESULTSReductions O 
in O 
geometric O 
mean O 
hs-CRP O 
values O 
were O 
significantly O 
greater O 
in O 
the O 
STG O 
group O 
at O 
months O 
3 O 
( O 
P O 
= O 
0.005 O 
) O 
, O 
6 O 
( O 
P O 
= O 
0.0003 O 
) O 
, O 
and O 
12 O 
( O 
P O 
= O 
0.04 O 
) O 
than O 
in O 
the O 
ACG O 
group O 
. O 
STG O 
patients O 
at O 
high O 
CV O 
risk O 
( O 
> O 
3 O 
mg O 
/ O 
L O 
) O 
showed O 
significantly O 
greater O 
reductions O 
in O 
hs-CRP O 
levels O 
than O 
ACG O 
patients O 
at O 
high O 
CV O 
risk O 
: O 
-3.64 O 
mg O 
/ O 
dL O 
( O 
95% O 
CI O 
-4.21 O 
to O 
-3.06 O 
) O 
versus O 
-2.18 O 
mg O 
/ O 
dL O 
( O 
-2.93 O 
to O 
-1.43 O 
) O 
, O 
respectively O 
( O 
P O 
= O 
0.002 O 
) O 
. O 
There O 
was O 
a O 
strong O 
correlation O 
between O 
reductions O 
in O 
hs-CRP O 
and O 
A1C O 
in O 
both O 
groups O 
: O 
standardized O 
coefficient O 
( O 
β O 
) O 
was O 
0.25 O 
for O 
the O 
entire O 
cohort O 
( O 
P O 
< O 
0.0001 O 
) O 
, O 
0.31 O 
for O 
STG O 
( O 
P O 
< O 
0.0001 O 
) O 
, O 
and O 
0.16 O 
for O 
ACG O 
( O 
P O 
= O 
0.02).CONCLUSIONSReductions O 
in O 
hs-CRP O 
level O 
are O 
associated O 
with O 
reductions O 
in O 
A1C O 
but O 
not O 
reductions O 
in O 
lipids O 
or O 
glycemic O 
variability O 
. O 
Comprehensive O 
structured O 
SMBG O 
- O 
based O 
interventions O 
that O 
lower O 
A1C O 
may O 
translate O 
into O 
improvements O 
in O 
CV O 
risk O 
, O 
as O 
evidenced O 
by O 
levels O 
of O 
the O 
biomarker O 
hs-CRP O 
. O 

venoms O 
and O 
secretions O 
have O 
been O 
screened O 
, O 
in O 
our O 
research O 
group O 
, O 
to O 
discover O 
, O 
identify O 
and O 
isolate O 
peptide O 
molecules O 
active O 
in O 
the O 
mammalian O 
haemostatic O 
system O 
. O 
As O 
result O 
, O 
this O 
kind O 
of O 
research O 
has O 
provided O 
a O 
portfolio O 
of O 
promising O 
drug O 
candidates O 
. O 
These O 
novel O 
recombinant O 
proteins O 
have O 
turned O 
out O 
to O 
be O 
multifunctional O 
molecules O 
, O 
and O 
are O 
currently O 
under O 
different O 
development O 
phases O 
. O 
Lopap O 
from O 
bristles O 
of O 
the O 
Lonomia O 
obliqua O 
moth O 
caterpillar O 
, O 
for O 
instance O 
, O 
is O 
a O 
prothrombin O 
activator O 
which O 
belongs O 
to O 
the O 
lipocalin O 
family O 
. O 
It O 
displays O 
serine B-TRIVIAL 
protease O 
- O 
like O 
activity O 
with O 
procoagulant O 
effect O 
, O 
and O 
also O 
induces O 
cytokine O 
secretion O 
and O 
antiapoptotic O 
pathways O 
in O 
human O 
cultured O 
endothelial O 
cells O 
. O 
Furthermore O 
, O 
a O 
Lopap O 
- O 
derived O 
peptide O 
has O 
showed O 
to O 
induce O 
collagen O 
synthesis O 
in O 
fibroblast O 
culture O 
and O 
in O 
animal O 
dermis O 
. O 
Here O 
, O 
the O 
molecular O 
properties O 
( O 
steric O 
, O 
electronic O 
, O 
hydrophobic O 
, O 
geometric O 
) O 
, O 
which O 
are O 
strongly O 
dependent O 
on O 
chemical O 
structure O 
, O 
were O 
investigated O 
by O 
applying O 
chemometric O 
and O 
computational O 
chemistry O 
methods O 
. O 
It O 
was O 
considered O 
different O 
patterns O 
of O 
amino B-FAMILY 
acid I-FAMILY 
substitution O 
related O 
to O 
the O 
lipocalins O 
' O 
motif O 
2 O 
, O 
which O 
was O 
recently O 
shown O 
to O 
modulate O 
cell O 
survival O 
. O 
The O 
calculated O 
molecular O 
properties O 
were O 
generally O 
maintained O 
in O 
all O 
investigated O 
peptides O 
extracted O 
from O 
three O 
- O 
dimensional O 
structures O 
of O 
Protein O 
Data O 
Bank O 
( O 
1t0v O 
, O 
1bbp O 
, O 
1kxo O 
, O 
2hzr O 
, O 
1iiu O 
, O 
1jyj O 
, O 
1gka O 
, O 
1s44 O 
, O 
3ebw O 
) O 
when O 
compared O 
to O 
Lopap O 
- O 
derived O 
peptide O 
, O 
specially O 
the O 
molecular O 
shape O 
and O 
electronic O 
density O 
distribution O 
, O 
validating O 
the O 
lipocalin O 
sequence O 
signature O 
previously O 
reported O 
. O 
Indeed O 
, O 
those O 
two O 
properties O 
are O 
quite O 
important O 
for O 
the O 
molecular O 
recognition O 
process O 
. O 

in O 
morphometry O 
and O 
association O 
between O 
whole O 
- O 
body O 
fatty B-FAMILY 
acids I-FAMILY 
and O 
steroid B-FAMILY 
hormone O 
profiles O 
in O 
relation O 
to O 
bioaccumulation O 
patterns O 
in O 
salmon O 
larvae O 
exposed O 
to O 
perfluorooctane B-MULTIPLE 
sulfonic I-MULTIPLE 
or I-MULTIPLE 
perfluorooctane I-MULTIPLE 
carboxylic I-MULTIPLE 
acids I-MULTIPLE 
. O 

the O 
present O 
study O 
, O 
we O 
have O 
used O 
salmon O 
embryos O 
whose O 
continuous O 
exposure O 
to O 
waterborne O 
PFOA B-ABBREVIATION 
or O 
PFOS B-ABBREVIATION 
at O 
100 O 
μg O 
/ O 
L O 
started O 
as O 
freshly O 
fertilized O 
eggs O 
, O 
and O 
lasted O 
for O 
a O 
total O 
of O 
52 O 
days O 
. O 
PFOS B-ABBREVIATION 
and O 
PFOA B-ABBREVIATION 
were O 
dissolved O 
in O 
methanol B-SYSTEMATIC 
( O 
carrier O 
vehicle O 
) O 
whose O 
concentration O 
never O 
exceeded O 
0.01% O 
of O 
total O 
tank O 
volume O 
. O 
Samples O 
were O 
collected O 
at O 
day O 
21 O 
, O 
28 O 
, O 
35 O 
, O 
52 O 
, O 
49 O 
and O 
56 O 
after O 
the O 
start O 
of O 
the O 
exposure O 
. O 
Note O 
that O 
days O 
49 O 
and O 
56 O 
represent O 
end O 
of O 
exposure O 
and O 
1 O 
week O 
after O 
a O 
recovery O 
period O 
, O 
respectively O 
. O 
Tissue O 
bioaccumulations O 
were O 
determined O 
by O 
HPLC O 
/ O 
MS O 
/ O 
MS O 
, O 
steroid B-FAMILY 
hormones O 
, O 
fatty B-FAMILY 
acids I-FAMILY 
( O 
FAs B-ABBREVIATION 
) O 
and O 
lipids O 
were O 
determined O 
by O 
GC-MS O 
, O 
while O 
mRNA O 
expression O 
levels O 
of O 
genes O 
were O 
determined O 
by O 
qPCR O 
in O 
whole O 
body O 
homogenate O 
. O 
We O 
observed O 
that O 
PFOS B-ABBREVIATION 
and O 
PFOA B-ABBREVIATION 
showed O 
a O 
steady O 
increase O 
in O 
whole O 
body O 
burden O 
during O 
the O 
exposure O 
period O 
, O 
with O 
a O 
slight O 
decrease O 
after O 
the O 
recovery O 
period O 
. O 
Calculated O 
somatic O 
indexes O 
showed O 
that O 
PFOA B-ABBREVIATION 
produced O 
increases O 
in O 
heart- O 
, O 
thymus- O 
, O 
liver- O 
and O 
kidney O 
somatic O 
indexes O 
( O 
HSI O 
, O 
TSI O 
, O 
LSI O 
and O 
KSI O 
) O 
. O 
PFOA B-ABBREVIATION 
and O 
PFOS B-ABBREVIATION 
exposure O 
produced O 
significant O 
decreases O 
in O 
whole O 
body O 
dehydroepiandrosterone B-TRIVIAL 
( O 
DHEA B-ABBREVIATION 
) O 
, O 
estrone O 
and O 
testosterone B-TRIVIAL 
at O 
sampling O 
day O 
21 O 
and O 
a O 
strong O 
increase O 
of O 
cortisol B-TRIVIAL 
and O 
cholesterol B-TRIVIAL 
at O 
the O 
end O 
of O 
recovery O 
period O 
( O 
day O 
56 O 
) O 
. O 
PFOA B-ABBREVIATION 
and O 
PFOS B-ABBREVIATION 
effects O 
differed O 
with O 
DHEA B-ABBREVIATION 
and O 
estrone B-TRIVIAL 
. O 
While O 
PFOS B-ABBREVIATION 
decreased O 
DHEA B-ABBREVIATION 
levels O 
, O 
PFOA B-ABBREVIATION 
produced O 
an O 
increase O 
at O 
day O 
49 O 
, O 
and O 
while O 
PFOS B-ABBREVIATION 
decreased O 
estrone B-TRIVIAL 
, O 
PFOA B-ABBREVIATION 
produced O 
a O 
slight O 
increase O 
at O 
day O 
56 O 
. O 
We O 
observed O 
changes O 
in O 
FA O 
composition O 
that O 
predominantly O 
involved O 
increases O 
in O 
FA B-FAMILY 
methyl I-FAMILY 
esters I-FAMILY 
( O 
FAMEs B-FAMILY 
) O 
, O 
mono- B-MULTIPLE 
and I-MULTIPLE 
poly I-MULTIPLE 
- I-MULTIPLE 
unsaturated I-MULTIPLE 
FA I-MULTIPLE 
( O 
MUFA B-ABBREVIATION 
and O 
PUFA B-ABBREVIATION 
) O 
and O 
a O 
decrease O 
in O 
n-3 O 
/ O 
n-6 O 
PUFA B-ABBREVIATION 
ratio O 
by O 
both O 
PFOA B-ABBREVIATION 
and O 
PFOS B-ABBREVIATION 
. O 
Particularly O 
, O 
an O 
increase O 
in O 
- O 
pentadecenoic B-SYSTEMATIC 
MUFA I-SYSTEMATIC 
( O 
15 O 
: O 
1 O 
) O 
, O 
two O 
n-3 O 
PUFAs B-ABBREVIATION 
α-linolenic B-TRIVIAL 
acid I-TRIVIAL 
[ O 
ALA B-ABBREVIATION 
: O 
18 O 
: O 
3 O 
n3 O 
] O 
and O 
eicosapentaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
[ O 
EPA B-ABBREVIATION 
: O 
20 O 
: O 
5 O 
n-3 O 
] O 
and O 
n-6 O 
PUFA B-ABBREVIATION 
: O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
[ O 
ARA B-ABBREVIATION 
: O 
20 O 
: O 
4 O 
n6 O 
] O 
, O 
docosapentaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DPA B-ABBREVIATION 
) O 
by O 
PFOA B-ABBREVIATION 
and O 
PFOS B-ABBREVIATION 
were O 
observed O 
. O 
These O 
effects O 
were O 
associated O 
with O 
changes O 
in O 
mRNA O 
expression O 
of O 
FA O 
elongase O 
( O 
FAE O 
) O 
, O 
Δ5-desaturase O 
( O 
FAD5 O 
) O 
and O 
Δ6-desaturase O 
( O 
FAD6 O 
) O 
genes O 
. O 
In O 
summary O 
, O 
the O 
changes O 
in O 
hormonal O 
and O 
FA O 
profiles O 
may O 
represent O 
cellular O 
and O 
/ O 
or O 
physiological O 
adaptation O 
to O 
continuous O 
PFOS B-ABBREVIATION 
and O 
PFOA B-ABBREVIATION 
exposure O 
by O 
increasing O 
membrane O 
fluidity O 
, O 
and O 
/ O 
or O 
overt O 
developmental O 
effects O 
. O 
The O 
present O 
findings O 
provide O 
some O 
potential O 
insights O 
and O 
basis O 
for O 
a O 
better O 
understanding O 
on O 
the O 
possible O 
mechanisms O 
of O 
PFCs O 
toxicity O 
in O 
fish O 
. O 

1 O 
( O 
FDX1 O 
; O 
adrenodoxin O 
) O 
is O 
an O 
iron B-SYSTEMATIC 
- O 
sulfur B-SYSTEMATIC 
protein O 
that O 
is O 
involved O 
in O 
various O 
metabolic O 
processes O 
, O 
including O 
steroid B-FAMILY 
steroid B-FAMILY 
hormone I-FAMILY 
synthesis O 
in O 
mammalian O 
tissues O 
. O 
We O 
investigated O 
the O 
transcriptional O 
regulation O 
of O 
FDX1 O 
in O 
ovarian O 
granulosa O 
cells O 
. O 
Previously O 
, O 
we O 
reported O 
that O 
the O 
NR5A O 
family O 
, O 
including O 
steroidogenic O 
factor-1 O 
( O 
SF-1 O 
) O 
and O 
liver O 
receptor O 
homolog-1 O 
could O 
induce O 
differentiation O 
of O 
human O 
mesenchymal O 
stem O 
cells O 
( O 
hMSCs O 
) O 
into O 
steroidogenic O 
cells O 
. O 
A O 
ChIP O 
assay O 
showed O 
that O 
SF-1 O 
could O 
bind O 
to O 
the O 
FDX1 O 
promoter O 
in O 
differentiated O 
hMSCs O 
. O 
Luciferase O 
reporter O 
assays O 
showed O 
that O 
transcription O 
of O 
FDX1 O 
was O 
synergistically O 
activated O 
by O 
the O 
NR5A O 
family O 
and O 
8Br-cAMP B-SYSTEMATIC 
treatment O 
through O 
two O 
SF-1 O 
binding O 
sites O 
and O 
a O 
CRE O 
- O 
like O 
sequence O 
in O 
a O 
human O 
ovarian O 
granulosa O 
cell O 
line O 
, O 
KGN O 
. O 
Knockdown O 
of O 
FDX1 O 
attenuated O 
progesterone B-TRIVIAL 
production O 
in O 
KGN O 
cells O 
. O 
These O 
results O 
indicate O 
transcription O 
of O 
FDX1 O 
is O 
regulated O 
by O 
the O 
NR5A O 
family O 
and O 
cAMP B-ABBREVIATION 
signaling O 
, O 
and O 
participates O 
in O 
steroid B-FAMILY 
steroid B-FAMILY 
hormone I-FAMILY 
production O 
in O 
ovarian O 
granulosa O 
cells O 
. O 

by O 
statins B-FAMILY 
of O 
membrane O 
raft O 
- O 
redox O 
signaling O 
in O 
coronary O 
arterial O 
endothelium O 
. O 

raft O 
(MR)-redox O 
signaling O 
platforms O 
associated O 
with O 
NADPH B-ABBREVIATION 
oxidase O 
are O 
involved O 
in O 
coronary O 
endothelial O 
dysfunction O 
. O 
Here O 
, O 
we O 
studied O 
whether O 
statins B-FAMILY 
interfere O 
with O 
the O 
formation O 
of O 
MR-redox O 
signaling O 
platforms O 
to O 
protect O 
the O 
coronary O 
arterial O 
endothelium O 
from O 
oxidized O 
low O 
- O 
density O 
lipoprotein O 
(OxLDL)-induced O 
injury O 
and O 
from O 
acute O 
hypercholesterolemia O 
. O 
In O 
cultured O 
human O 
coronary O 
arterial O 
endothelial O 
cells O 
, O 
confocal O 
microscopy O 
detected O 
the O 
formation O 
of O 
an O 
MRs O 
clustering O 
when O 
they O 
were O 
exposed O 
to O 
OxLDL O 
, O 
and O 
such O 
MR O 
platform O 
formation O 
was O 
inhibited O 
markedly O 
by O 
statins B-FAMILY 
, O 
including O 
pravastatin B-TRIVIAL 
and O 
simvastatin B-TRIVIAL 
. O 
In O 
these O 
MR O 
clusters O 
, O 
NADPH B-ABBREVIATION 
oxidase O 
subunits O 
gp91(phox) O 
and O 
p47(phox) O 
were O 
aggregated O 
and O 
were O 
markedly O 
blocked O 
by O 
both O 
statins B-FAMILY 
. O 
In O 
addition O 
, O 
colocalization O 
of O 
acid O 
sphingomyelinase O 
( O 
ASM O 
) O 
and O 
ceramide B-FAMILY 
was O 
induced O 
by O 
OxLDL O 
, O 
which O 
was O 
blocked O 
by O 
statins B-FAMILY 
. O 
Electron O 
spin O 
resonance O 
spectrometry O 
showed O 
that O 
OxLDL-induced O 
superoxide B-TRIVIAL 
( O 
O2(.-) B-FORMULA 
) O 
production O 
in O 
the O 
MR O 
fractions O 
was O 
substantially O 
reduced O 
by O 
statins B-FAMILY 
. O 
In O 
coronary O 
artery O 
intima O 
of O 
mice O 
with O 
acute O 
hypercholesterolemia O 
, O 
confocal O 
microscopy O 
revealed O 
a O 
colocalization O 
of O 
gp91(phox) O 
, O 
p47(phox) O 
, O 
ASM O 
, O 
or O 
ceramide B-FAMILY 
in O 
MR O 
clusters O 
. O 
Such O 
colocalization O 
was O 
rarely O 
observed O 
in O 
the O 
arteries O 
of O 
normal O 
mice O 
or O 
significantly O 
reduced O 
by O 
pretreatment O 
of O 
hypercholesterolemic O 
mice O 
with O 
statins B-FAMILY 
. O 
Furthermore O 
, O 
O2(.-) B-FORMULA 
production O 
in O 
situ O 
was O 
3-fold O 
higher O 
in O 
the O 
coronary O 
arteries O 
from O 
hypercholesterolemic O 
mice O 
than O 
in O 
those O 
from O 
normal O 
mice O 
, O 
and O 
such O 
increase O 
was O 
inhibited O 
by O 
statins B-FAMILY 
. O 
Our O 
results O 
indicate O 
that O 
blockade O 
of O 
MR-redox O 
signaling O 
platform O 
formation O 
in O 
endothelial O 
cell O 
membrane O 
may O 
be O 
another O 
important O 
therapeutic O 
mechanism O 
of O 
statins B-FAMILY 
in O 
preventing O 
endothelial O 
injury O 
and O 
atherosclerosis O 
and O 
may O 
be O 
associated O 
with O 
their O 
direct O 
action O 
on O 
membrane O 
cholesterol B-TRIVIAL 
structure O 
and O 
function O 
. O 

of O 
acetylsalicylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
other O 
nonsteroidal O 
anti-inflammatory O 
agents O 
: O 
clinical O 
implications O 
. O 

: O 
Pharmacogenomics O 
investigates O 
interindividual O 
genetic O 
variability O 
in O 
the O 
DNA O 
sequence O 
of O 
drug O 
targets O 
, O 
drug O 
- O 
metabolizing O 
enzymes O 
or O 
disease O 
genes O 
, O 
RNA O 
expression O 
, O 
or O 
protein O 
translation O 
of O 
genes O 
affecting O 
drug O 
response O 
and O 
drug O 
safety O 
. O 
Aspirin B-TRIVIAL 
and O 
other O 
nonsteroidal O 
anti-inflammatory O 
drugs O 
( O 
NSAIDs O 
) O 
are O 
among O 
the O 
most O 
commonly O 
prescribed O 
medications O 
with O 
well O 
- O 
documented O 
variation O 
in O 
patient O 
response O 
in O 
terms O 
of O 
efficacy O 
and O 
safety O 
. O 
This O 
variation O 
may O 
in O 
part O 
be O 
explained O 
by O 
pharmacogenomics O 
. O 
METHODS O 
: O 
In O 
this O 
paper O 
I O 
review O 
data O 
on O 
the O 
pharmacogenomics O 
of O 
aspirin O 
and O 
other O 
NSAIDs O 
focusing O 
on O 
clinical O 
implications O 
. O 
RESULTS O 
: O 
Existing O 
scientific O 
evidence O 
supports O 
the O 
pharmacogenomic O 
basis O 
of O 
interindividual O 
variation O 
in O 
treatment O 
response O 
to O 
aspirin O 
and O 
NSAIDs O 
, O 
with O 
clinical O 
implications O 
for O 
antiplatelet O 
action O 
, O 
cancer O 
chemoprevention O 
, O 
and O 
drug O 
safety O 
. O 
However O 
, O 
further O 
research O 
efforts O 
are O 
needed O 
before O 
knowledge O 
on O 
the O 
pharmacogenomics O 
of O 
aspirin B-TRIVIAL 
and O 
NSAIDs O 
can O 
be O 
implemented O 
in O 
clinical O 
practice O 
. O 
CONCLUSION O 
: O 
The O 
outcome O 
of O 
these O 
research O 
efforts O 
would O 
be O 
anticipated O 
to O 
have O 
added O 
value O 
for O 
both O 
science O 
and O 
society O 
, O 
contributing O 
to O 
the O 
enhanced O 
efficacy O 
and O 
safety O 
of O 
these O 
agents O 
through O 
patient O 
selection O 
. O 

- O 
enhanced O 
Raman O 
scattering O 
spectra O 
of O 
adsorbates O 
on O 
Cu₂O B-FORMULA 
nanospheres O 
: O 
charge O 
- O 
transfer O 
and O 
electromagnetic O 
enhancement O 
. O 

- O 
enhanced O 
Raman O 
scattering O 
( O 
SERS O 
) O 
spectra O 
of O 
4-mercaptobenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
4-MBA B-SYSTEMATIC 
) O 
have O 
been O 
investigated O 
on O 
the O 
surface O 
of O 
Cu2O B-FORMULA 
nanospheres O 
. O 
The O 
SERS O 
signals O 
were O 
believed O 
to O 
originate O 
from O 
the O 
static O 
chemical O 
enhancement O 
, O 
resonant O 
chemical O 
enhancement O 
and O 
electromagnetic O 
enhancement O 
. O 
The O 
coupling O 
between O 
the O 
adsorbates O 
and O 
the O 
semiconductor O 
, O 
evidenced O 
by O 
the O 
shift O 
in O 
absorption O 
spectrum O 
of O 
modified O 
Cu2O B-FORMULA 
and O 
the O 
enhancement O 
of O 
non-totally O 
symmetric O 
modes O 
of O 
the O 
4-MBA B-SYSTEMATIC 
and O 
4-mercaptopyridine B-SYSTEMATIC 
( O 
4-MPY B-SYSTEMATIC 
) O 
molecules O 
, O 
were O 
invoked O 
to O 
explain O 
the O 
experimental O 
results O 
. O 
Furthermore O 
, O 
simulations O 
were O 
employed O 
to O 
investigate O 
the O 
nature O 
of O 
the O 
enhancement O 
mechanisms O 
operative O 
between O 
the O 
molecules O 
and O 
the O 
semiconductor O 
. O 
Density O 
functional O 
theory O 
( O 
DFT O 
) O 
calculations O 
suggested O 
a O 
charge O 
transfer O 
( O 
CT O 
) O 
transition O 
process O 
between O 
the O 
molecules O 
and O 
the O 
Cu2O B-FORMULA 
nanospheres O 
. O 
Three O 
- O 
dimensional O 
finite O 
- O 
difference O 
time O 
domain O 
( O 
3D-FDTD O 
) O 
simulations O 
were O 
conducted O 
to O 
map O 
out O 
the O 
electromagnetic O 
field O 
around O 
the O 
Cu2O B-FORMULA 
nanospheres O 
. O 
The O 
experimental O 
and O 
simulation O 
results O 
have O 
revealed O 
the O 
promise O 
of O 
the O 
Cu2O B-FORMULA 
nanospheres O 
as O 
a O 
good O 
SERS O 
substrate O 
and O 
the O 
prospect O 
of O 
using O 
the O 
SERS O 
substrate O 
as O 
a O 
valuable O 
tool O 
for O 
in O 
situ O 
investigation O 
and O 
assay O 
of O 
the O 
adsorption O 
behavior O 
on O 
semiconductor O 
surfaces O 
. O 

characteristics O 
of O 
genistin B-TRIVIAL 
-induced O 
inhibitory O 
effects O 
on O 
intestinal O 
motility O 
. O 

belongs O 
to O 
isoflavones B-FAMILY 
. O 
Based O 
on O 
the O 
facts O 
that O 
genistin B-TRIVIAL 
exerts O 
inhibitory O 
effects O 
on O 
the O 
contractility O 
of O 
vascular O 
smooth O 
muscle,the O 
present O 
study O 
was O 
designed O 
to O 
characterize O 
the O 
effects O 
of O 
genistin B-TRIVIAL 
on O 
intestinal O 
contractility O 
and O 
evaluate O 
its O 
potential O 
clinical O 
implication O 
. O 
Ex O 
vivo O 
[ O 
isolated O 
jejunal O 
segment O 
( O 
IJS O 
) O 
of O 
rat O 
] O 
, O 
in O 
vitro O 
, O 
and O 
in O 
vivo O 
assays O 
were O 
used O 
in O 
the O 
study O 
. O 
The O 
results O 
indicated O 
that O 
genistin B-TRIVIAL 
( O 
5-80 O 
μmol O 
/ O 
L O 
) O 
inhibited O 
the O 
contraction O 
of O 
IJS O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
and O 
inhibited O 
the O 
increased O 
- O 
contractility O 
of O 
IJS O 
induced O 
by O 
acetylcholine B-SYSTEMATIC 
( O 
ACh B-ABBREVIATION 
) O 
, O 
histamine B-TRIVIAL 
, O 
high O 
Ca(2+) B-FORMULA 
, O 
and O 
erythromycin B-TRIVIAL 
, O 
respectively O 
. O 
The O 
inhibitory O 
effects O 
of O 
genistin B-TRIVIAL 
were O 
correlated O 
with O 
the O 
stimulation O 
of O 
alpha O 
adrenergic O 
and O 
beta O 
adrenergic O 
receptors O 
since O 
these O 
inhibitory O 
effects O 
were O 
significantly O 
blocked O 
in O 
the O 
presence O 
of O 
phentolamine B-TRIVIAL 
and O 
propranolol B-TRIVIAL 
respectively O 
. O 
No O 
further O 
inhibitory O 
effects O 
of O 
genistin B-TRIVIAL 
were O 
observed O 
in O 
the O 
presence O 
of O 
verapamil B-TRIVIAL 
or O 
in O 
Ca(2+) B-FORMULA 
-free O 
condition O 
, O 
indicating O 
genistin B-TRIVIAL 
-induced O 
inhibitory O 
effects O 
are O 
Ca(2+) B-FORMULA 
-dependent O 
. O 
Genistin B-TRIVIAL 
decreased O 
myosin O 
light O 
chain O 
kinase O 
( O 
MLCK O 
) O 
protein O 
contents O 
and O 
MLCK O 
mRNA O 
expression O 
in O 
IJS O 
, O 
and O 
inhibited O 
both O 
phosphorylation O 
and O 
Mg(2+) B-FORMULA 
-ATPase O 
activity O 
of O 
purified O 
myosin O 
, O 
implicating O 
that O 
the O 
decrease O 
of O 
MLCK O 
contents O 
and O 
inhibition O 
of O 
MLCK O 
activity O 
are O 
involved O 
in O 
the O 
genistin B-TRIVIAL 
-induced O 
inhibitory O 
effects O 
. O 
The O 
study O 
suggests O 
the O 
potential O 
clinical O 
implications O 
of O 
genistin B-TRIVIAL 
in O 
relieving O 
intestinal O 
hypercontractility O 
. O 

pharmacokinetics O 
and O 
pharmacodynamics O 
of O 
zaleplon B-TRIVIAL 
delivered O 
as O 
a O 
thermally O 
generated O 
aerosol O 
in O 
a O 
single O 
breath O 
to O 
volunteers O 
. O 

, O 
pharmacodynamics O 
, O 
safety O 
, O 
and O 
tolerability O 
of O 
inhaled O 
zaleplon B-TRIVIAL 
were O 
assessed O 
in O 
healthy O 
volunteers O 
. O 
Forty O 
participants O 
received O 
0.5 O 
, O 
1 O 
, O 
2 O 
, O 
or O 
4 O 
mg O 
zaleplon B-TRIVIAL 
or O 
placebo O 
as O 
a O 
thermally O 
generated O 
aerosol O 
in O 
a O 
randomized O 
, O 
double O 
- O 
blind O 
, O 
parallel O 
- O 
group O 
, O 
dose O 
escalation O 
study O 
. O 
Blood O 
was O 
collected O 
up O 
to O 
24 O 
hours O 
after O 
dosing O 
, O 
and O 
sedation O 
was O 
assessed O 
up O 
to O 
8 O 
hours O 
. O 
Following O 
inhalation O 
, O 
the O 
observed O 
median O 
time O 
to O 
maximum O 
plasma O 
concentrations O 
( O 
25% O 
, O 
75% O 
) O 
was O 
1.89 O 
( O 
1.45 O 
, O 
3.08 O 
) O 
minutes O 
and O 
the O 
mean O 
( O 
SD O 
) O 
elimination O 
half O 
- O 
life O 
was O 
1.24 O 
( O 
0.24 O 
) O 
hours O 
. O 
The O 
equilibration O 
half O 
- O 
life O 
for O 
sedation O 
( O 
t(1 O 
/ O 
2 O 
) O 
k(e0) O 
) O 
was O 
1.16 O 
( O 
0.62 O 
, O 
2.17 O 
) O 
minutes O 
. O 
The O 
zaleplon B-TRIVIAL 
AUC O 
was O 
dose O 
proportional O 
across O 
doses O 
, O 
with O 
a O 
slope O 
( O 
90% O 
confidence O 
interval O 
) O 
of O 
log-AUC O 
versus O 
log O 
- O 
dose O 
of O 
0.92 O 
( O 
0.82 O 
, O 
1.02 O 
) O 
. O 
No O 
clinically O 
significant O 
changes O 
were O 
noted O 
in O 
laboratory O 
values O 
, O 
vital O 
signs O 
, O 
or O 
spirometry O 
. O 
The O 
most O 
common O 
adverse O 
events O 
were O 
dizziness O 
, O 
somnolence O 
, O 
euphoria O 
, O 
headache O 
, O 
and O 
visual O 
disturbance O 
. O 
Zaleplon B-TRIVIAL 
inhalation O 
represents O 
a O 
safe O 
, O 
well O 
- O 
tolerated O 
means O 
of O 
rapidly O 
achieving O 
effective O 
plasma O 
concentrations O 
. O 

studies O 
have O 
pinpointed O 
the O 
significant O 
contribution O 
of O 
liver O 
- O 
mediated O 
drug O 
metabolism O 
and O 
transport O 
to O 
the O 
complexity O 
of O 
drug O 
- O 
induced O 
liver O 
injury O 
( O 
DILI O 
) O 
. O 
Phase O 
I O 
cytochrome O 
P450 O 
( O 
CYP450 O 
) O 
enzymes O 
can O 
lead O 
to O 
altered O 
drug O 
metabolism O 
and O 
formation O 
of O 
toxic O 
metabolites O 
, O 
whilst O 
Phase O 
II O 
enzymes O 
are O 
also O 
associated O 
with O 
DILI O 
. O 
The O 
emerging O 
role O 
of O 
hepatic O 
transporters O 
in O 
regulating O 
the O 
movement O 
of O 
endogenous O 
and O 
exogenous O 
chemicals O 
( O 
e.g O 
. O 
, O 
bile B-FAMILY 
acids I-FAMILY 
and O 
drugs O 
) O 
across O 
cellular O 
and O 
tissue O 
membranes O 
is O 
critical O 
in O 
determining O 
the O 
pathophysiology O 
of O 
liver O 
disease O 
as O 
well O 
as O 
drug O 
toxicity O 
and O 
efficacy O 
. O 
Genetic O 
and O 
environmental O 
factors O 
can O 
have O 
a O 
significant O 
impact O 
on O 
drug O 
metabolism O 
and O 
transporter O 
proteins O 
, O 
consequently O 
increasing O 
the O 
risk O 
of O 
DILI O 
in O 
susceptible O 
individuals O 
. O 
The O 
assessment O 
of O 
these O 
factors O 
therefore O 
represents O 
an O 
important O 
approach O 
for O 
predicting O 
and O 
preventing O 
DILI O 
, O 
by O 
better O 
understanding O 
the O 
pharmacological O 
profile O 
of O 
a O 
specific O 
drug O 
. O 
This O 
review O 
focuses O 
on O 
the O 
mechanisms O 
of O 
DILI O 
associated O 
with O 
drug O 
metabolism O 
and O 
hepatic O 
transport O 
, O 
and O 
how O 
they O 
can O 
be O 
influenced O 
by O 
underlying O 
factors O 
. O 

of O 
excipients O 
on O 
acetaminophen B-TRIVIAL 
metabolism O 
and O 
its O 
implications O 
for O 
prevention O 
of O 
liver O 
injury O 
. O 

poisoning O 
is O 
the O 
most O 
frequent O 
cause O 
of O 
acute O 
hepatic O 
failure O 
in O 
the O 
US O 
. O 
Toxicity O 
requires O 
reductive O 
metabolism O 
of O 
acetaminophen B-TRIVIAL 
, O 
primarily O 
via O 
CYP2E1 O 
. O 
Liquid O 
acetaminophen B-TRIVIAL 
preparations O 
contain O 
propylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
, O 
a O 
common O 
excipient O 
that O 
has O 
been O 
shown O 
to O 
reduce O 
hepatocellular O 
injury O 
in O 
vitro O 
and O 
in O 
rodents O 
. O 
Children O 
are O 
less O 
susceptible O 
to O 
acetaminophen B-TRIVIAL 
toxicity O 
for O 
unclear O 
reasons O 
. O 
We O 
conducted O 
a O 
pharmacokinetic O 
single O 
- O 
blinded O 
crossover O 
study O 
of O 
15 O 
healthy O 
adult O 
volunteers O 
comparing O 
the O 
CYP2E1 O 
and O 
conjugative O 
metabolism O 
of O 
a O 
15 O 
mg O 
/ O 
kg O 
dose O 
of O 
liquid O 
versus O 
solid O 
preparations O 
of O 
acetaminophen B-TRIVIAL 
. O 
Measured O 
AUC's O 
for O 
the O 
CYP2E1 O 
metabolites O 
were O 
16-17% O 
lower O 
and O 
extrapolated O 
AUC's O 
were O 
25-28% O 
lower O 
in O 
the O 
liquid O 
formulation O 
arm O 
while O 
there O 
was O 
no O 
difference O 
in O 
conjugative O 
metabolite O 
production O 
. O 
The O 
formation O 
rate O 
constants O 
for O 
reductive O 
metabolites O 
were O 
equivalent O 
between O 
solid O 
and O 
liquid O 
formulations O 
indicating O 
that O 
enzyme O 
inhibition O 
was O 
competitive O 
. O 
Propylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
, O 
an O 
established O 
CYP2E1 O 
competitive O 
antagonist O 
, O 
was O 
detected O 
in O 
the O 
liquid O 
formulation O 
but O 
not O 
solid O 
formulation O 
arm O 
. O 
Since O 
children O 
tend O 
to O 
ingest O 
liquid O 
preparations O 
, O 
the O 
protective O 
effect O 
of O 
this O 
excipient O 
could O 
explain O 
their O 
decreased O 
susceptibility O 
to O 
acetaminophen B-TRIVIAL 
toxicity O 
. O 
A O 
less O 
hepatotoxic O 
formulation O 
of O 
acetaminophen B-TRIVIAL 
could O 
potentially O 
be O 
developed O 
if O 
co O 
- O 
formulated O 
with O 
a O 
CYP2E1 O 
inhibitor O 
. O 

of O 
cilostazol B-TRIVIAL 
to O 
conventional O 
dual O 
antiplatelet O 
therapy O 
reduces O 
the O 
risk O 
of O 
cardiac O 
events O 
and O 
restenosis O 
after O 
drug O 
- O 
eluting O 
stent O 
implantation O 
: O 
a O 
meta-analysis O 
. O 

meta-analysis O 
was O 
performed O 
to O 
compare O 
the O 
risk O 
of O 
cardiac O 
events O 
and O 
restenosis O 
between O 
triple O 
antiplatelet O 
therapy O 
( O 
TAT O 
, O 
addition O 
of O 
cilostazol B-TRIVIAL 
to O 
aspirin B-TRIVIAL 
and O 
clopidogrel B-TRIVIAL 
) O 
and O 
conventional O 
dual O 
antiplatelet O 
therapy O 
( O 
DAT O 
, O 
aspirin B-TRIVIAL 
and O 
clopidogrel B-TRIVIAL 
) O 
in O 
drug O 
- O 
eluting O 
stents O 
( O 
DES O 
) O 
implantation O 
patients O 
. O 
We O 
performed O 
PUBMED O 
, O 
MEDLINE O 
, O 
EMBASE O 
, O 
and O 
Cochrane O 
CENTRAL O 
searches O 
for O 
randomized O 
clinical O 
trials O 
of O 
TAT O 
versus O 
DAT O 
in O 
patients O 
after O 
DES O 
implantation O 
. O 
Five O 
clinical O 
trials O 
were O 
involved O 
in O 
the O 
study O 
. O 
TAT O 
was O 
associated O 
with O 
a O 
36% O 
reduction O 
in O 
major O 
adverse O 
cardiac O 
events O 
( O 
MACE O 
; O 
odds O 
ratio O 
(OR) O 
= O 
0.64 O 
; O 
95% O 
confidence O 
interval O 
(CI) O 
= O 
0.51-0.81 O 
, O 
P O 
< O 
0.01 O 
) O 
, O 
a O 
40% O 
reduction O 
( O 
OR O 
= O 
0.6 O 
, O 
95% O 
CI O 
= O 
0.44-0.80 O 
; O 
P O 
< O 
0.01 O 
) O 
in O 
target O 
vessel O 
revascularization O 
( O 
TVR O 
) O 
, O 
a O 
44% O 
reduction O 
( O 
OR O 
= O 
0.56 O 
, O 
95% O 
CI O 
= O 
0.34-0.91 O 
; O 
P O 
= O 
0.02 O 
) O 
in O 
target O 
lesion O 
revascularization O 
( O 
TLR O 
) O 
and O 
a O 
47% O 
/ O 
44% O 
reduction O 
in O 
in O 
- O 
segment O 
/ O 
in O 
- O 
stent O 
restenosis O 
( O 
P O 
< O 
0.01 O 
) O 
and O 
lower O 
in O 
- O 
segment O 
/ O 
in O 
- O 
stent O 
late O 
loss O 
( O 
P O 
< O 
0.01 O 
) O 
. O 
As O 
regards O 
to O 
the O 
safety O 
assessment O 
, O 
there O 
was O 
no O 
significant O 
difference O 
about O 
the O 
risk O 
of O 
stent O 
thrombosis O 
and O 
bleeding O 
between O 
TAT O 
and O 
DAT O 
group O 
, O 
while O 
the O 
risk O 
of O 
gastrointestinal O 
trouble O 
was O 
significantly O 
higher O 
in O 
TAT O 
group O 
( O 
OR O 
= O 
2.46 O 
, O 
95% O 
CI O 
= O 
1.25-4.86 O 
; O 
P O 
< O 
0.01 O 
) O 
. O 
Addition O 
of O 
cilostazol B-TRIVIAL 
to O 
DAT O 
reduced O 
the O 
incidence O 
of O 
MACE O 
, O 
TVR O 
, O 
and O 
TLR O 
after O 
DES O 
implantation O 
. O 
TAT O 
also O 
reduced O 
the O 
risk O 
of O 
restenosis O 
and O 
late O 
loss O 
in O 
patients O 
after O 
DES O 
implantation O 
. O 

sativa O 
L O 
. O 
seeds O 
( O 
N O 
. O 
sativa O 
) O 
have O 
been O 
used O 
as O 
a O 
traditional O 
remedy O 
for O 
a O 
wide O 
range O 
of O 
diseases O 
including O 
hypertension O 
. O 
The O 
present O 
study O 
was O 
performed O 
to O 
explore O 
the O 
effects O 
of O 
N O 
. O 
sativa O 
oil O 
on O 
blood O 
pressure O 
( O 
BP O 
) O 
in O 
healthy O 
volunteers O 
. O 
In O 
a O 
double O 
- O 
blind O 
, O 
randomized O 
study O 
, O 
70 O 
healthy O 
volunteers O 
aged O 
34 O 
to O 
63 O 
years O 
with O 
systolic O 
BP O 
from O 
110 O 
to O 
140 O 
mmHg O 
and O 
diastolic O 
BP O 
from O 
60 O 
to O 
90 O 
mmHg O 
were O 
randomly O 
allocated O 
to O 
receive O 
2.5 O 
mL O 
N O 
. O 
sativa O 
oil O 
or O 
placebo O 
two O 
times O 
a O 
day O 
for O 
8 O 
weeks O 
. O 
The O 
systolic O 
and O 
diastolic O 
BPs O 
, O 
body O 
mass O 
index O 
and O 
blood O 
levels O 
of O 
aspartate B-TRIVIAL 
transaminase O 
, O 
alanine B-TRIVIAL 
transaminase O 
, O 
alkaline O 
phosphatase O 
, O 
creatinine B-TRIVIAL 
and O 
blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
were O 
determined O 
at O 
baseline O 
and O 
endpoint O 
. O 
Results O 
showed O 
that O 
in O 
N O 
. O 
sativa O 
oil O 
treated O 
group O 
the O 
systolic O 
and O 
diastolic O 
BPs O 
decreased O 
significantly O 
compared O 
with O 
baseline O 
and O 
placebo O 
group O 
at O 
the O 
endpoint O 
. O 
Other O 
parameters O 
did O 
not O 
significantly O 
change O 
in O 
both O 
groups O 
at O 
the O 
endpoint O 
. O 
No O 
adverse O 
effects O 
were O 
reported O 
. O 
In O 
conclusion O 
, O 
oral O 
daily O 
administration O 
of O 
5 O 
mL O 
N O 
. O 
sativa O 
oil O 
to O 
healthy O 
volunteers O 
for O 
8 O 
weeks O 
lowers O 
systolic O 
and O 
diastolic O 
BPs O 
without O 
any O 
adverse O 
effects O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

accessible O 
fluorescent O 
probes O 
for O 
sensitive O 
biological O 
imaging O 
of O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
. O 

peroxide I-SYSTEMATIC 
is O 
a O 
major O 
component O 
of O 
oxygen B-SYSTEMATIC 
metabolism O 
in O 
biological O 
systems O 
that O 
, O 
when O 
present O 
in O 
high O 
concentrations O 
, O 
can O 
lead O 
to O 
oxidative O 
stress O 
in O 
cells O 
. O 
Noninvasive O 
molecular O 
imaging O 
of O 
H(2)O(2) B-FORMULA 
using O 
fluorogenic O 
systems O 
represents O 
an O 
effective O 
way O 
to O 
detect O 
and O 
measure O 
the O 
accumulation O 
of O 
this O 
metabolite O 
. O 
Herein O 
, O 
we O 
detail O 
the O 
development O 
of O 
robust O 
H(2)O(2) B-FORMULA 
-sensitive O 
fluorescent O 
probes O 
using O 
a O 
boronic B-SYSTEMATIC 
ester I-SYSTEMATIC 
trigger O 
appended O 
to O 
the O 
fluorophore O 
through O 
a O 
benzyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
linkage O 
. O 
A O 
major O 
advantage O 
of O 
the O 
probes O 
presented O 
here O 
is O 
their O 
synthetic O 
accessibility O 
, O 
with O 
only O 
one O 
step O 
needed O 
to O 
generate O 
the O 
probes O 
on O 
the O 
gram O 
scale O 
. O 
The O 
sensitivity O 
of O 
the O 
probes O 
was O 
evaluated O 
in O 
simulated O 
physiological O 
conditions O 
, O 
showing O 
micromolar O 
sensitivity O 
to O 
H(2)O(2) B-FORMULA 
. O 
The O 
probes O 
were O 
tested O 
in O 
biological O 
model O 
systems O 
, O 
demonstrating O 
effective O 
imaging O 
of O 
unstimulated O 
, O 
endogenous O 
H(2)O(2) B-FORMULA 
levels O 
in O 
RAW O 
264.7 O 
cells O 
and O 
murine O 
brain O 
tissue O 
. O 

for O 
management O 
of O 
Cushing's O 
syndrome O 
. O 

syndrome O 
is O 
a O 
debilitating O 
endocrine O 
disorder O 
caused O 
by O 
elevated O 
circulating O 
glucocorticoid O 
levels O 
. O 
Although O 
uncommon O 
, O 
Cushing's O 
syndrome O 
is O 
associated O 
with O 
significant O 
morbidity O 
necessitating O 
rapid O 
reversal O 
of O 
hypercortisolemia O 
. O 
Primary O 
therapy O 
for O 
most O 
patients O 
with O 
Cushing's O 
syndrome O 
is O 
surgical O 
, O 
but O 
many O 
patients O 
will O 
require O 
additional O 
treatments O 
with O 
radiation O 
or O 
drugs O 
. O 
Although O 
several O 
options O 
for O 
drug O 
therapy O 
exist O 
, O 
few O 
are O 
readily O 
available O 
and O 
all O 
have O 
dose O 
- O 
limiting O 
adverse O 
effects O 
. O 
Mifepristone B-TRIVIAL 
( O 
RU B-IDENTIFIER 
486 I-IDENTIFIER 
) O 
, O 
a O 
first O 
- O 
in O 
- O 
class O 
glucocorticoid O 
receptor O 
antagonist O 
, O 
was O 
approved O 
by O 
the O 
United O 
States O 
Food O 
and O 
Drug O 
Administration O 
in O 
2012 O 
for O 
use O 
in O 
Cushing's O 
syndrome O 
to O 
control O 
hyperglycemia O 
in O 
patients O 
who O 
are O 
not O 
surgical O 
candidates O 
or O 
have O 
not O 
achieved O 
remission O 
from O 
surgery O 
. O 
The O 
drug O 
is O 
approved O 
for O 
oral O 
once O 
- O 
daily O 
administration O 
. O 
In O 
its O 
pivotal O 
trial O 
, O 
60% O 
of O 
patients O 
responded O 
to O 
mifepristone B-TRIVIAL 
with O 
significant O 
improvements O 
in O 
glycemic O 
control O 
and O 
38% O 
had O 
a O 
reduction O 
in O 
diastolic O 
blood O 
pressure O 
. O 
The O 
most O 
common O 
adverse O 
events O 
were O 
nausea O 
, O 
fatigue O 
, O 
headache O 
, O 
endometrial O 
hyperplasia O 
, O 
and O 
hypokalemia O 
. O 
Adrenal O 
insufficiency O 
occurred O 
in O 
fewer O 
than O 
5% O 
of O 
patients O 
. O 
The O 
recommended O 
starting O 
dosage O 
of O 
mifepristone B-TRIVIAL 
is O 
300 O 
mg O 
/ O 
day O 
. O 
The O 
dosage O 
may O 
be O 
increased O 
every O 
2-4 O 
weeks O 
up O 
to O 
a O 
maximum O 
of O 
1200 O 
mg O 
/ O 
day O 
, O 
although O 
it O 
should O 
not O 
exceed O 
20 O 
mg O 
/ O 
kg O 
/ O 
day O 
. O 
Significant O 
drug O 
- O 
drug O 
interactions O 
exist O 
due O 
to O 
mifepristone B-TRIVIAL 
' O 
s O 
effects O 
on O 
a O 
number O 
of O 
cytochrome O 
P450 O 
enzymes O 
. O 
Despite O 
its O 
limitations O 
, O 
mifepristone B-TRIVIAL 
is O 
a O 
welcome O 
addition O 
and O 
an O 
appropriate O 
alternative O 
to O 
the O 
available O 
drug O 
therapy O 
for O 
Cushing's O 
syndrome O 
. O 

/ O 
Vis O 
spectra O 
of O 
subporphyrazines B-FAMILY 
and O 
subphthalocyanines B-FAMILY 
with O 
aluminum B-SYSTEMATIC 
and O 
gallium B-SYSTEMATIC 
: O 
a O 
time O 
- O 
dependent O 
DFT O 
study O 
. O 

UV O 
/ O 
Vis O 
spectra O 
of O 
selected O 
substituted O 
subporphyrazines B-FAMILY 
( O 
SubPz B-ABBREVIATION 
) O 
and O 
subphthalocyanines B-FAMILY 
( O 
SubPc B-ABBREVIATION 
) O 
with O 
aluminum B-SYSTEMATIC 
and O 
gallium B-SYSTEMATIC 
as O 
central O 
atoms O 
are O 
analyzed O 
through O 
time O 
- O 
dependent O 
DFT O 
calculations O 
in O 
chloroform B-TRIVIAL 
. O 
The O 
results O 
are O 
compared O 
with O 
previous O 
results O 
with O 
boron B-SYSTEMATIC 
as O 
the O 
central O 
atom O 
to O 
analyze O 
the O 
photochemical O 
properties O 
of O 
these O 
two O 
families O 
of O 
compounds O 
on O 
varying O 
the O 
metal O 
along O 
the O 
same O 
group O 
. O 
The O 
absorptions O 
of O 
SubPz B-ABBREVIATION 
( O 
Al B-FORMULA 
, O 
Ga B-FORMULA 
) O 
are O 
redshifted O 
or O 
blueshifted O 
with O 
respect O 
to O 
SubPz B-ABBREVIATION 
( O 
B O 
) O 
depending O 
on O 
the O 
nature O 
of O 
the O 
R O 
substituents O 
of O 
the O 
molecule O 
, O 
whereas O 
the O 
absorptions O 
of O 
SubPc B-ABBREVIATION 
( O 
Al B-FORMULA 
, O 
Ga B-FORMULA 
) O 
structures O 
are O 
redshifted O 
and O 
with O 
smaller O 
energy O 
gaps O 
with O 
respect O 
to O 
SubPc B-ABBREVIATION 
( O 
B O 
) O 
for O 
all O 
kinds O 
of O 
R O 
substituents O 
. O 
Looking O 
at O 
their O 
absorption O 
spectra O 
, O 
these O 
systems O 
with O 
aluminum B-SYSTEMATIC 
and O 
gallium B-SYSTEMATIC 
may O 
also O 
have O 
, O 
as O 
in O 
the O 
case O 
of O 
boron B-SYSTEMATIC 
, O 
promising O 
photochemical O 
properties O 
. O 

tea O 
hot O 
- O 
water O 
extract O 
activates O 
Akt O 
and O 
induces O 
insulin O 
- O 
independent O 
glucose B-TRIVIAL 
transport O 
in O 
rat O 
skeletal O 
muscle O 
. O 

muscle O 
is O 
a O 
major O 
organ O 
that O 
is O 
important O 
for O 
whole O 
- O 
body O 
glucose B-TRIVIAL 
metabolism O 
. O 
We O 
found O 
that O 
when O 
isolated O 
rat O 
epitrochlearis O 
muscle O 
was O 
incubated O 
with O 
a O 
Pu-erh O 
tea O 
hot O 
- O 
water O 
extract O 
( O 
PTE O 
) O 
for O 
30 O 
min O 
, O 
the O 
rate O 
of O 
3-O-methyl-D-glucose B-SYSTEMATIC 
( O 
3MG B-SYSTEMATIC 
) O 
transport O 
increased O 
in O 
the O 
absence O 
of O 
insulin O 
. O 
This O 
activation O 
was O 
associated O 
with O 
an O 
increase O 
in O 
Ser B-FORMULA 
( O 
473 O 
) O 
phosphorylation O 
of O 
Akt O 
, O 
a O 
signaling O 
intermediary O 
leading O 
to O 
insulin O 
- O 
dependent O 
glucose B-TRIVIAL 
transport O 
, O 
but O 
not O 
Tyr B-FORMULA 
( O 
458 O 
) O 
phosphorylation O 
of O 
phosphoinositide O 
3-kinase O 
p85 O 
, O 
an O 
upstream O 
molecule O 
of O 
Akt O 
. O 
PTE-stimulated O 
3MG O 
transport O 
was O 
also O 
not O 
accompanied O 
by O 
Thr B-FORMULA 
( O 
172 O 
) O 
phosphorylation O 
of O 
the O 
catalytic O 
α-subunit O 
of O 
5'- O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
. O 
Gallic B-TRIVIAL 
acid I-TRIVIAL 
, O 
a O 
water O 
- O 
soluble O 
ingredient O 
in O 
Pu-erh O 
tea O 
, O 
stimulated O 
Akt O 
phosphorylation O 
, O 
but O 
not O 
AMPK O 
phosphorylation O 
. O 
These O 
results O 
suggest O 
that O 
Pu-erh O 
tea O 
potentially O 
promotes O 
skeletal O 
muscle O 
glucose B-TRIVIAL 
transport O 
at O 
least O 
in O 
part O 
by O 
activating O 
Akt O 
. O 

, O 
biological O 
evaluation O 
, O 
and O 
structure O 
- O 
activity O 
and O 
-selectivity O 
relationships O 
of O 
6'- B-FAMILY 
substituted I-FAMILY 
(E)-2-(benzofuran-3(2H)-ylidene)-N-methylacetamides I-FAMILY 
, O 
a O 
novel O 
class O 
of O 
potent O 
and O 
selective O 
monoamine B-FAMILY 
oxidase O 
inhibitors O 
. O 

use O 
of O 
selective O 
inhibitors O 
of O 
monoamine B-FAMILY 
oxidase O 
A O 
( O 
MAO-A O 
) O 
and O 
B O 
( O 
MAO-B O 
) O 
holds O 
a O 
therapeutic O 
relevance O 
in O 
the O 
treatment O 
of O 
depressive O 
disorders O 
and O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
, O 
respectively O 
. O 
Here O 
, O 
the O 
discovery O 
of O 
a O 
new O 
class O 
of O 
compounds O 
acting O 
as O 
monoamine B-FAMILY 
oxidase O 
inhibitors O 
( O 
MAO-Is O 
) O 
and O 
bearing O 
a O 
6'- B-FAMILY 
substituted I-FAMILY 
(E)-2-(benzofuran-3(2H)-ylidene)-N-alkylacetamide I-FAMILY 
skeleton O 
is O 
reported O 
. O 
6'-Sulfonyloxy B-SYSTEMATIC 
derivatives O 
exhibited O 
outstanding O 
affinities O 
to O 
MAO-A O 
( O 
7 O 
nM O 
< O 
IC50 O 
< O 
49 O 
nM O 
, O 
much O 
higher O 
than O 
moclobemide B-TRIVIAL 
) O 
and O 
a O 
pronounced O 
MAO-A O 
/ O 
B O 
selectivity O 
. O 
The O 
corresponding O 
6'-benzyloxy B-SYSTEMATIC 
derivatives O 
showed O 
potent O 
MAO-B O 
inhibition O 
and O 
inverted O 
selectivity O 
profile O 
. O 
The O 
rigid O 
E-geometry O 
of O 
the O 
exocyclic O 
double O 
bond O 
allowed O 
a O 
more O 
efficient O 
binding O 
conformation O 
compared O 
to O 
more O 
flexible O 
and O 
less O 
active O 
2-(1-benzofuran-3-yl)-N-methylacetamide B-SYSTEMATIC 
isomers O 
and O 
4-N-methylcarboxamidomethylcoumarin B-SYSTEMATIC 
analogues O 
. O 
Focused O 
structural O 
modifications O 
and O 
docking O 
simulations O 
enabled O 
the O 
identification O 
of O 
key O 
molecular O 
determinants O 
for O 
high O 
affinity O 
toward O 
both O 
MAO O 
isoforms O 
. O 
These O 
novel O 
MAO-Is O 
may O 
represent O 
promising O 
hits O 
for O 
the O 
development O 
of O 
safer O 
therapeutic O 
agents O 
with O 
a O 
potential O 
against O 
depression O 
, O 
PD O 
, O 
and O 
other O 
age O 
- O 
related O 
neurodegenerative O 
pathologies O 
. O 

new O 
member O 
of O 
short O 
chain O 
α-neurotoxic O 
protein O 
family O 
from O 
venom O 
of O 
the O 
Mexican O 
coral O 
snake O 
, O 
Micrurus O 
laticollaris O 
, O 
was O 
characterized O 
. O 
This O 
protein O 
, O 
named O 
MlatA1 O 
, O 
possesses O 
61 O 
amino B-FAMILY 
acids I-FAMILY 
with O 
8 O 
conserved O 
cysteine B-TRIVIAL 
residues O 
, O 
sharing O 
30-91% O 
sequence O 
identity O 
with O 
other O 
fully O 
sequenced O 
Micrurus O 
toxins O 
. O 
MlatA1 O 
( O 
LD50i.v O 
. O 
= O 
0.064 O 
mg O 
/ O 
kg O 
) O 
antagonizes O 
with O 
both O 
fetal O 
and O 
adult O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
nAChR O 
) O 
as O 
well O 
as O 
α-7 O 
neuronal O 
nAChR O 
in O 
a O 
dose O 
- O 
dependent O 
way O 
. O 
Specific O 
rabbit O 
anti-Mlat O 
serum O 
( O 
titer O 
higher O 
than O 
18000 O 
) O 
does O 
not O 
show O 
any O 
protective O 
ability O 
against O 
this O 
toxin O 
, O 
nevertheless O 
it O 
was O 
able O 
to O 
recognize O 
protein O 
bands O 
in O 
six O 
out O 
of O 
twelve O 
Micrurus O 
venoms O 
showing O 
the O 
existence O 
of O 
two O 
distinct O 
antigenic O 
groups O 
for O 
α-neurotoxins O 
in O 
North O 
American O 
coral O 
snakes O 
species O 
. O 
The O 
MlatA1 O 
gene O 
was O 
cloned O 
and O 
used O 
to O 
produce O 
recombinant O 
toxin O 
( O 
rMlatA1 O 
) O 
that O 
was O 
recognized O 
by O 
rabbit O 
anti-native O 
toxin O 
but O 
was O 
depleted O 
of O 
toxic O 
activity O 
. O 

Microsecond O 
Sugar B-FAMILY 
Ring O 
Flexing O 
Encode O 
3D-Shape O 
and O 
Bioactivity O 
in O 
the O 
Heparanome O 
? O 

biological O 
information O 
encoded O 
in O 
carbohydrate B-FAMILY 
sequences O 
dwarfs O 
that O 
of O 
proteins O 
and O 
nucleic O 
acids O 
. O 
Deciphering O 
structure O 
- O 
function O 
relationships O 
in O 
heparin O 
and O 
heparan O 
sulfate B-SYSTEMATIC 
( O 
the O 
heparanome O 
) O 
is O 
further O 
compounded O 
by O 
extreme O 
sequence O 
diversity O 
, O 
experimental O 
difficulties O 
, O 
and O 
the O 
computational O 
cost O 
of O 
rigorous O 
modeling O 
. O 
Here O 
we O 
perform O 
unbiased O 
microsecond O 
dynamics O 
simulations O 
of O 
11 O 
heparanome O 
oligosaccharides O 
( O 
55 O 
microseconds O 
total O 
) O 
to O 
investigate O 
the O 
effect O 
of O 
sequence O 
on O 
3D-structure O 
and O 
to O 
underpin O 
a O 
coarse O 
- O 
grained O 
model O 
that O 
is O 
consistent O 
with O 
long O 
- O 
time O 
scale O 
experimentally O 
validated O 
atomic O 
motions O 
in O 
water O 
. O 
Pyranose B-SYSTEMATIC 
ring O 
flexing O 
( O 
puckering O 
) O 
in O 
2-O-sulfo-α-l-iduronic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
which O 
underlies O 
heparin O 
- O 
mediated O 
anticoagulation O 
, O 
was O 
modulated O 
by O 
polymerization O 
( O 
chain O 
position O 
and O 
adjacent O 
residues O 
) O 
, O 
which O 
is O 
supported O 
by O 
previous O 
experiments O 
. O 
Furthermore O 
, O 
in O 
coarse O 
- O 
grained O 
simulations O 
, O 
inclusion O 
of O 
puckering O 
was O 
essential O 
to O 
predict O 
macroscopic O 
hydrodynamic O 
properties O 
of O 
heparan O 
sulfate B-SYSTEMATIC 
chains O 
containing O 
hundreds O 
of O 
monosaccharaides B-FAMILY 
. O 
Our O 
structural O 
findings O 
and O 
model O 
enable O 
rational O 
molecular O 
design O 
, O 
and O 
we O 
propose O 
that O 
, O 
in O 
the O 
heparanome O 
, O 
puckering O 
, O 
polymer O 
3D-shape O 
, O 
and O 
bioactivity O 
are O 
inextricably O 
linked O 
. O 

of O 
formulation O 
design O 
space O 
, O 
in O 
vitro O 
bioactivity O 
and O 
in O 
vivo O 
biodistribution O 
for O 
hydrophilic O 
drug O 
loaded O 
PLGA B-ABBREVIATION 
/ O 
PEO-PPO-PEO B-ABBREVIATION 
nanoparticles O 
using O 
OFAT O 
experiments O 
. O 

nanoprecipitation O 
method O 
was O 
used O 
for O 
improved O 
incorporation O 
of O 
hydrophilic O 
drug O 
( O 
irinotecan B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
) O 
into O 
the O 
PLGA B-ABBREVIATION 
/ O 
PEO-PPO-PEO B-ABBREVIATION 
blended O 
and O 
blended O 
/ O 
adsorbed O 
nanoparticles O 
. O 
One O 
factor O 
at O 
a O 
time O 
( O 
OFAT O 
) O 
variation O 
experiments O 
were O 
conducted O 
in O 
order O 
to O 
determine O 
key O 
formulation O 
factors O 
( O 
concentration O 
and O 
volume O 
of O 
drug O 
solution O 
, O 
evaporation O 
rate O 
and O 
PLGA B-ABBREVIATION 
/ O 
PEO-PPO-PEO B-ABBREVIATION 
ratio O 
) O 
influencing O 
nanoparticle O 
properties O 
( O 
particle O 
size O 
and O 
size O 
distribution O 
, O 
encapsulation O 
efficiency O 
, O 
drug O 
content O 
, O 
zeta O 
potential O 
, O 
drug O 
dissolution O 
rate O 
, O 
as O 
well O 
as O 
protein O 
binding O 
capacity O 
) O 
. O 
The O 
insight O 
into O 
in O 
vivo O 
behavior O 
of O 
prepared O 
nanoparticles O 
and O 
their O 
potential O 
for O 
effective O 
anticancer O 
treatment O 
was O 
gained O 
by O 
performing O 
biodistribution O 
and O 
cell O 
culture O 
studies O 
as O 
part O 
of O 
OFAT O 
experiments O 
. O 
The O 
mean O 
particle O 
size O 
, O 
mainly O 
dependent O 
upon O 
PLGA B-ABBREVIATION 
/ O 
PEO-PPO-PEO B-ABBREVIATION 
ratio O 
, O 
was O 
in O 
the O 
range O 
of O 
112-125nm O 
, O 
with O 
narrow O 
unimodal O 
distribution O 
( O 
PDI∼0.1 O 
) O 
. O 
Encapsulation O 
efficiency O 
( O 
32-63% O 
) O 
was O 
impacted O 
by O 
evaporation O 
rate O 
and O 
PLGA B-ABBREVIATION 
/ O 
PEO-PPO-PEO B-ABBREVIATION 
ratio O 
. O 
Drug O 
content O 
( O 
0.2-1.51% O 
) O 
and O 
controlled O 
release O 
properties O 
were O 
related O 
to O 
the O 
influence O 
of O 
all O 
tested O 
formulation O 
factors O 
. O 
Structural O 
information O 
for O 
the O 
studied O 
nanoparticles O 
was O 
obtained O 
using O 
DSC O 
and O 
FT-IR O 
spectroscopy O 
. O 
Zeta O 
potential O 
values O 
indicated O 
that O 
presence O 
of O 
PEO-PPO-PEO B-ABBREVIATION 
in O 
the O 
formulations O 
shielded O 
the O 
high O 
surface O 
negative O 
charge O 
of O 
PLGA B-ABBREVIATION 
. O 
PEO-PPO-PEO B-ABBREVIATION 
surface O 
coverage O 
of O 
PLGA B-ABBREVIATION 
/ O 
PEO-PPO-PEO B-ABBREVIATION 
blended O 
as O 
well O 
as O 
blended O 
/ O 
adsorbed O 
nanoparticles O 
depended O 
upon O 
amount O 
of O 
used O 
PEO-PPO-PEO B-ABBREVIATION 
during O 
preparation O 
procedure O 
and O 
was O 
related O 
to O 
the O 
protein O 
resistant O 
characteristics O 
of O 
nanoparticles O 
. O 
Results O 
from O 
in O 
vivo O 
studies O 
evidenced O 
prolonged O 
blood O 
circulation O 
time O 
of O 
the O 
prepared O 
nanoparticles O 
, O 
while O 
cell O 
culture O 
studies O 
indicated O 
higher O 
in O 
vitro O 
bioefficacy O 
compared O 
to O 
free O 
drug O 
. O 
Performed O 
experiments O 
defined O 
possible O 
design O 
space O 
and O 
justified O 
further O 
optimization O 
of O 
formulation O 
using O 
experimental O 
design O 
studies O 
. O 

for O 
preventive O 
effects O 
of O 
cocoa O 
and O 
cocoa O 
polyphenols B-FAMILY 
in O 
cancer O 
. O 

of O 
cancer O 
through O 
the O 
diet O 
is O 
receiving O 
increasing O 
interest O 
, O 
and O 
cocoa O 
because O 
of O 
its O 
polyphenolic B-FAMILY 
compounds O 
has O 
become O 
an O 
important O 
potential O 
chemopreventive O 
and O 
therapeutic O 
natural O 
agent O 
. O 
Cocoa O 
and O 
its O 
main O 
polyphenols B-FAMILY 
have O 
been O 
reported O 
to O 
interfere O 
at O 
the O 
initiation O 
, O 
promotion O 
and O 
progression O 
of O 
cancer O 
. O 
Cocoa O 
flavonoids B-FAMILY 
have O 
been O 
demonstrated O 
to O 
influence O 
several O 
important O 
biological O 
functions O 
in O 
vitro O 
and O 
in O 
vivo O 
by O 
their O 
free O 
radical O 
scavenging O 
ability O 
or O 
through O 
the O 
regulation O 
of O 
signal O 
transduction O 
pathways O 
to O 
stimulate O 
apoptosis O 
and O 
to O 
inhibit O 
inflammation O 
, O 
cellular O 
proliferation O 
, O 
apoptosis O 
, O 
angiogenesis O 
and O 
metastasis O 
. O 
Nevertheless O 
, O 
these O 
molecular O 
mechanisms O 
of O 
action O 
are O 
not O 
completely O 
characterized O 
and O 
many O 
features O 
remain O 
to O 
be O 
elucidated O 
. O 
The O 
aim O 
of O 
this O 
review O 
is O 
to O 
provide O 
insights O 
into O 
the O 
molecular O 
basis O 
of O 
the O 
potential O 
chemopreventive O 
activity O 
of O 
cocoa O 
and O 
its O 
polyphenolic B-FAMILY 
components O 
by O 
summarizing O 
cell O 
culture O 
and O 
animal O 
models O 
studies O 
, O 
as O 
well O 
as O 
interventional O 
and O 
epidemiological O 
studies O 
on O 
humans O 
. O 

and O 
antioxidant O 
effects O 
of O 
a O 
beverage O 
containing O 
silymarin O 
and O 
arginine B-TRIVIAL 
. O 
A O 
pilot O 
, O 
human O 
intervention O 
cross O 
- O 
over O 
trial O 
. O 

study O 
objective O 
was O 
to O 
investigate O 
the O 
potential O 
of O 
a O 
beverage O 
containing O 
silymarin O 
and O 
l-arginine B-TRIVIAL 
to O 
alter O 
basic O 
physiological O 
and O 
urodynamic O 
parameters O 
in O 
22 O 
normal O 
healthy O 
men O 
aged O 
38-59years O 
. O 
The O 
volunteers O 
drank O 
500ml O 
/ O 
day O 
beverage O 
without O 
silymarin O 
and O 
l-arginine B-TRIVIAL 
for O 
10days O 
followed O 
, O 
after O 
a O 
7-day O 
washout O 
period O 
, O 
by O 
the O 
beverage O 
with O 
400mg O 
silymarin O 
and O 
295mg O 
l-arginine B-TRIVIAL 
for O 
10days O 
. O 
Blood O 
and O 
urine O 
samples O 
were O 
collected O 
on O 
days O 
0 O 
, O 
10 O 
and O 
27 O 
. O 
The O 
beverages O 
were O 
well O 
- O 
tolerated O 
with O 
no O 
adverse O 
effects O 
. O 
Most O 
of O 
the O 
biochemical O 
, O 
hematological O 
and O 
urodynamic O 
parameters O 
remained O 
unchanged O 
. O 
Total O 
antioxidant O 
capacity O 
, O 
total O 
level O 
of O 
antioxidants O 
, O 
lipoperoxidation O 
products O 
( O 
malondialdehyde B-TRIVIAL 
) O 
, O 
advanced O 
oxidation O 
products O 
of O 
proteins O 
in O 
plasma O 
and O 
glutathione B-TRIVIAL 
, O 
glutathione B-TRIVIAL 
peroxidase O 
, O 
glutathione B-TRIVIAL 
reductase O 
, O 
superoxide B-TRIVIAL 
dismutase O 
and O 
catalase O 
levels O 
in O 
erythrocytes O 
were O 
not O 
influenced O 
. O 
Serum O 
γ-glutamyl O 
transferase O 
, O 
malondialdehyde B-TRIVIAL 
level O 
and O 
activity O 
of O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
in O 
erythrocytes O 
were O 
lowered O 
at O 
day O 
27 O 
and O 
the O 
concentration O 
of O 
total O 
plasma O 
SH B-FORMULA 
-groups O 
was O 
higher O 
on O 
day O 
10 O 
. O 
Using O 
an O 
ex O 
vivo O 
system O 
, O 
we O 
found O 
that O 
silymarin/ O 
silybin B-TRIVIAL 
at O 
10-100μM O 
is O 
able O 
to O 
adsorb O 
onto O 
human O 
erythrocytes O 
and O 
the O 
complexes O 
displayed O 
antioxidant O 
properties O 
as O 
studied O 
using O 
ex O 
situ O 
square O 
- O 
wave O 
voltammetry O 
. O 
The O 
trial O 
showed O 
that O 
silymarin O 
in O 
vivo O 
may O 
protect O 
erythrocytes O 
against O 
oxidative O 
damage O 
. O 

inhibits O 
sodium B-SYSTEMATIC 
metabisulfite I-SYSTEMATIC 
induced O 
oxidative O 
stress O 
and O 
apoptosis O 
in O 
rat O 
gastric O 
mucosa O 
. O 

study O 
aimed O 
to O 
investigate O 
the O 
effect O 
of O 
ghrelin O 
administration O 
on O 
sulfite B-SYSTEMATIC 
induced O 
oxidative O 
and O 
apoptotic O 
changes O 
in O 
rat O 
gastric O 
mucosa O 
. O 
Forty O 
male O 
albino O 
Wistar O 
rats O 
were O 
randomized O 
into O 
control O 
( O 
C O 
) O 
, O 
sodium B-SYSTEMATIC 
metabisulfite I-SYSTEMATIC 
( O 
Na2S2O5 B-FORMULA 
) O 
treated O 
( O 
S O 
) O 
, O 
ghrelin O 
treated O 
( O 
G O 
) O 
and O 
, O 
Na2S2O5 B-FORMULA 
+ O 
ghrelin O 
treated O 
( O 
SG O 
) O 
groups O 
. O 
Sodium B-SYSTEMATIC 
metabisulfite I-SYSTEMATIC 
( O 
100mg O 
/ O 
kg O 
/ O 
day O 
) O 
was O 
given O 
by O 
gastric O 
gavage O 
and O 
, O 
ghrelin O 
( O 
20μg O 
/ O 
kg O 
/ O 
day O 
) O 
was O 
given O 
intraperitoneally O 
for O 
5weeks O 
. O 
Plasma- O 
S B-FORMULA 
- O 
sulfonate B-SYSTEMATIC 
level O 
was O 
increased O 
in O 
S O 
and O 
SG O 
groups O 
. O 
Na2S2O5 B-FORMULA 
administration O 
significantly O 
elevated O 
total O 
oxidant O 
status O 
( O 
TOS O 
) O 
levels O 
while O 
depleting O 
total O 
antioxidant O 
status O 
( O 
TAS O 
) O 
levels O 
in O 
gastric O 
mucosa O 
. O 
Ghrelin O 
significantly O 
decreased O 
gastric O 
TOS O 
levels O 
in O 
the O 
SG O 
group O 
compared O 
with O 
the O 
S O 
group O 
. O 
Additionally O 
, O 
TAS O 
levels O 
were O 
found O 
to O 
be O 
higher O 
in O 
SG O 
group O 
in O 
reference O 
to O 
S O 
group O 
. O 
Na2S2O5 B-FORMULA 
administration O 
also O 
markedly O 
increased O 
the O 
number O 
of O 
apoptotic O 
cells O 
, O 
cleaved O 
caspase-3 O 
and O 
PAR O 
expression O 
( O 
PARP O 
activity O 
indicator O 
) O 
and O 
, O 
decreased O 
Ki67 O 
expression O 
( O 
cell O 
proliferation O 
index O 
) O 
in O 
gastric O 
mucosal O 
cells O 
. O 
Ghrelin O 
treatment O 
decreased O 
the O 
number O 
apoptotic O 
cells O 
, O 
cytochrome O 
C O 
release O 
, O 
PAR O 
and O 
, O 
caspase-3 O 
expressions O 
while O 
increasing O 
Ki67 O 
expression O 
in O 
gastric O 
mucosa O 
exposed O 
to O 
Na2S2O5 B-FORMULA 
. O 
In O 
conclusion O 
, O 
we O 
suggest O 
that O 
ghrelin O 
treatment O 
might O 
ameliorate O 
ingested- O 
Na2S2O5 B-FORMULA 
induced O 
gastric O 
mucosal O 
injury O 
stemming O 
from O 
apoptosis O 
and O 
oxidative O 
stress O 
in O 
rats O 
. O 

A I-FAMILY 
and O 
retinoid B-FAMILY 
signaling O 
: O 
genomic O 
and O 
non-genomic O 
effects O 
. O 

A I-FAMILY 
or O 
retinol B-TRIVIAL 
is O 
arguably O 
the O 
most O 
multifunctional O 
vitamin B-FAMILY 
in O 
the O 
human O 
body O 
as O 
it O 
is O 
essential O 
from O 
embryogenesis O 
to O 
adulthood O 
. O 
The O 
pleiotropic O 
effects O 
of O 
vitamin B-FAMILY 
A I-FAMILY 
are O 
exerted O 
mainly O 
by O 
one O 
active O 
metabolite O 
, O 
all B-TRIVIAL 
- I-TRIVIAL 
trans I-TRIVIAL 
retinoic I-TRIVIAL 
acid I-TRIVIAL 
( O 
atRA B-ABBREVIATION 
) O 
, O 
which O 
regulates O 
the O 
expression O 
of O 
a O 
battery O 
of O 
target O 
genes O 
through O 
several O 
families O 
of O 
nuclear O 
receptors O 
( O 
RARs O 
, O 
RXRs O 
and O 
PPARβ O 
/ O 
δ O 
) O 
, O 
polymorphic O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
( O 
RA O 
) O 
response O 
elements O 
and O 
multiple O 
coregulators O 
. O 
It O 
also O 
involves O 
extra O 
nuclear O 
and O 
non-transcriptional O 
effects O 
such O 
as O 
the O 
activation O 
of O 
kinase O 
cascades O 
, O 
which O 
are O 
integrated O 
in O 
the O 
nucleus O 
via O 
the O 
phosphorylation O 
of O 
several O 
actors O 
of O 
RA O 
signaling O 
. O 
However O 
, O 
vitamin B-FAMILY 
A I-FAMILY 
itself O 
proved O 
recently O 
to O 
be O 
active O 
and O 
RARs O 
to O 
be O 
present O 
in O 
the O 
cytosol O 
to O 
regulate O 
translation O 
and O 
cell O 
plasticity O 
. O 
All O 
these O 
new O 
concepts O 
expand O 
the O 
scope O 
of O 
the O 
biologic O 
functions O 
of O 
vitamin B-FAMILY 
A I-FAMILY 
and O 
RA O 
. O 

and O 
antiproliferative O 
activity O 
evaluation O 
of O 
imidazole B-SYSTEMATIC 
-based O 
indeno[1,2-b]quinoline-9,11-dione B-SYSTEMATIC 
derivatives O 
. O 

series O 
of O 
new O 
imidazole B-SYSTEMATIC 
substituted O 
indeno[1,2-b]quinoline-9,11-dione B-SYSTEMATIC 
derivatives O 
were O 
synthesized O 
and O 
evaluated O 
for O 
their O 
antiproliferative O 
effects O 
on O 
HeLa O 
, O 
LS180 O 
, O 
MCF-7 O 
and O 
Jurkat O 
human O 
cancer O 
cell O 
lines O 
. O 
Antiproliferative O 
effects O 
were O 
evaluated O 
using O 
MTT B-ABBREVIATION 
assay O 
. O 
Prepared O 
compounds O 
exhibited O 
weak O 
to O 
good O 
antiproliferative O 
activity O 
in O 
evaluated O 
cell O 
lines O 
. O 
Prepared O 
compounds O 
were O 
more O 
potent O 
in O 
Jurkat O 
cell O 
line O 
when O 
compared O 
to O 
LS180 O 
, O 
HeLa O 
and O 
MCF-7 O 
cell O 
lines O 
. O 
Compounds O 
29 O 
( O 
IC16 O 
= O 
0.7 O 
μM O 
) O 
and O 
31 O 
( O 
IC16 O 
= O 
1.7 O 
μM O 
) O 
and O 
33 O 
( O 
IC16 O 
= O 
1.7 O 
μM O 
) O 
were O 
found O 
to O 
be O 
the O 
most O 
potent O 
molecules O 
on O 
Jurkat O 
cell O 
lines O 
. O 
Moreover O 
; O 
it O 
was O 
found O 
that O 
some O 
of O 
the O 
tested O 
compounds O 
bearing O 
imidazole-2-yl B-SYSTEMATIC 
moiety O 
on O 
the O 
C11- O 
position O 
of O 
dihydropyridine B-SYSTEMATIC 
ring O 
exhibited O 
superior O 
antiproliferative O 
activity O 
in O 
comparison O 
to O 
cis-platin B-TRIVIAL 
especially O 
in O 
Jurkat O 
cell O 
line O 
( O 
compounds O 
29 O 
, O 
31 O 
, O 
and O 
33 O 
) O 
. O 
It O 
seemed O 
that O 
the O 
introduction O 
of O 
electron O 
- O 
withdrawing O 
groups O 
on O 
the O 
imidazole B-SYSTEMATIC 
ring O 
enhanced O 
the O 
antiproliferative O 
potential O 
of O 
these O 
compounds O 
( O 
compounds O 
27 O 
, O 
29 O 
and O 
31 O 
) O 
. O 
The O 
results O 
of O 
this O 
study O 
proposed O 
that O 
some O 
of O 
the O 
imidazole B-SYSTEMATIC 
substituted O 
indeno[1,2-b]quinoline-9,11-dione B-SYSTEMATIC 
compounds O 
may O 
act O 
as O 
efficient O 
anticancer O 
agents O 
in O 
vitro O 
, O 
emphasizing O 
their O 
potential O 
role O 
as O 
a O 
source O 
for O 
rational O 
design O 
of O 
potent O 
antiproliferative O 
agents O 
. O 

- O 
inducible O 
factors O 
( O 
HIFs O 
) O 
are O 
master O 
regulators O 
of O 
angiogenesis O 
and O 
cellular O 
adaptation O 
in O 
hypoxic O 
microenvironments O 
. O 
Accumulating O 
evidence O 
indicates O 
that O 
HIFs O 
also O 
regulate O 
cell O 
survival O 
, O 
glucose B-TRIVIAL 
metabolism O 
, O 
microenvironmental O 
remodeling O 
, O 
cancer O 
metastasis O 
, O 
and O 
tumor O 
progression O 
, O 
and O 
thus O 
, O 
HIFs O 
are O 
viewed O 
as O 
therapeutic O 
targets O 
in O 
many O 
diseases O 
. O 
Epigenetic O 
changes O 
are O 
involved O 
in O 
the O 
switching O 
' O 
on O 
' O 
and O 
' O 
off O 
' O 
of O 
many O 
genes O 
, O 
and O 
it O 
has O 
been O 
suggested O 
that O 
the O 
DNA O 
hypermethylation O 
of O 
specific O 
gene O 
promoters O 
, O 
histone O 
modifications O 
( O 
acetylation O 
, O 
phosphorylation O 
, O 
and O 
methylation O 
) O 
and O 
small O 
interfering O 
or O 
micro O 
RNAs O 
be O 
regarded O 
epigenetic O 
gene O 
targets O 
for O 
the O 
regulation O 
of O 
disease O 
- O 
associated O 
cellular O 
changes O 
. O 
Furthermore O 
, O 
the O 
hypoxic O 
microenvironment O 
is O 
one O 
of O 
the O 
most O 
important O 
cellular O 
stress O 
stimuli O 
in O 
terms O 
of O 
the O 
regulation O 
of O 
cellular O 
epigenetic O 
status O 
via O 
histone O 
modification O 
. O 
Therefore O 
, O 
drug O 
development O 
and O 
therapeutic O 
approaches O 
to O 
ischemic O 
diseases O 
or O 
cancer O 
for O 
targeting O 
HIFs O 
by O 
modulation O 
of O 
epigenetic O 
status O 
become O 
an O 
attractive O 
area O 
. O 
Here O 
, O 
the O 
authors O 
provide O 
a O 
review O 
of O 
the O 
literature O 
regarding O 
the O 
targeting O 
of O 
HIF O 
, O 
a O 
key O 
modulator O 
of O 
hypoxic O 
- O 
cell O 
response O 
under O 
various O 
disease O 
conditions O 
, O 
by O 
modulating O 
histone O 
or O 
DNA O 
using O 
endogenous O 
small O 
RNAs O 
or O 
exogenous O 
chemicals O 
. O 

stability O 
and O 
elastic O 
properties O 
of O 
chromium B-FAMILY 
borides I-FAMILY 
with O 
various O 
stoichiometries O 
. O 

stability O 
is O 
important O 
to O 
the O 
application O 
of O 
materials O 
. O 
By O 
first O 
- O 
principles O 
calculations O 
, O 
we O 
establish O 
the O 
phase O 
stability O 
of O 
chromium B-FAMILY 
borides I-FAMILY 
with O 
various O 
stoichiometries O 
. O 
Moreover O 
, O 
the O 
phases O 
of O 
CrB3 B-FORMULA 
and O 
CrB4 B-FORMULA 
have O 
been O 
predicted O 
by O 
using O 
a O 
newly O 
developed O 
particle O 
swarm O 
optimization O 
( O 
PSO O 
) O 
algorithm O 
. O 
Formation O 
enthalpy O 
- O 
pressure O 
diagrams O 
reveal O 
that O 
the O 
MoB B-FORMULA 
-type O 
structure O 
is O 
more O 
energetically O 
favorable O 
than O 
the O 
TiI B-FORMULA 
-type O 
structure O 
for O 
CrB B-FORMULA 
. O 
For O 
CrB2 B-FORMULA 
, O 
the O 
WB2 B-FORMULA 
-type O 
structure O 
is O 
preferred O 
at O 
zero O 
pressure O 
. O 
The O 
predicted O 
new O 
phase O 
of O 
CrB3 B-FORMULA 
belongs O 
to O 
the O 
hexagonal O 
P-6m2 O 
space O 
group O 
and O 
it O 
transforms O 
into O 
an O 
orthorhombic O 
phase O 
as O 
the O 
pressure O 
exceeds O 
93 O 
GPa O 
. O 
The O 
predicted O 
CrB4 B-FORMULA 
( O 
space O 
group O 
: O 
Pnnm O 
) O 
phase O 
is O 
more O 
energetically O 
favorable O 
than O 
the O 
previously O 
proposed O 
Immm O 
structure O 
. O 
The O 
mechanical O 
and O 
thermodynamic O 
stabilities O 
of O 
predicted O 
CrB3 B-FORMULA 
and O 
CrB4 B-FORMULA 
are O 
verified O 
by O 
the O 
calculated O 
elastic O 
constants O 
and O 
formation O 
enthalpies O 
. O 
The O 
full O 
phonon O 
dispersion O 
calculations O 
confirm O 
the O 
dynamic O 
stability O 
of O 
WB2 B-FORMULA 
-type O 
CrB2 B-FORMULA 
and O 
predicted O 
CrB3 B-FORMULA 
. O 
The O 
large O 
shear O 
moduli O 
, O 
large O 
Young's O 
moduli O 
, O 
low O 
Poisson O 
ratios O 
, O 
and O 
low O 
bulk O 
and O 
shear O 
modulus O 
ratios O 
of O 
CrB4 B-FORMULA 
PSC O 
and O 
CrB4 B-FORMULA 
PSD O 
indicate O 
that O 
they O 
are O 
potential O 
hard O 
materials O 
. O 
Analyses O 
of O 
Debye O 
temperature O 
, O 
electronic O 
localization O 
function O 
, O 
and O 
electronic O 
structure O 
provide O 
further O 
understanding O 
of O 
the O 
chemical O 
and O 
physical O 
properties O 
of O 
these O 
borides O 
. O 

- O 
inspired O 
histidine B-TRIVIAL 
-based O 
transient O 
network O 
metal O 
coordination O 
hydrogels O 
. O 

network O 
hydrogels O 
cross O 
- O 
linked O 
through O 
histidine B-TRIVIAL 
-divalent O 
cation O 
coordination O 
bonds O 
were O 
studied O 
by O 
conventional O 
rheologic O 
methods O 
using O 
histidine B-TRIVIAL 
-modified O 
star O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
polymers O 
. O 
These O 
materials O 
were O 
inspired O 
by O 
the O 
mussel O 
, O 
which O 
is O 
thought O 
to O 
use O 
histidine B-TRIVIAL 
-metal O 
coordination O 
bonds O 
to O 
impart O 
self O 
- O 
healing O 
properties O 
in O 
the O 
mussel O 
byssal O 
thread O 
. O 
Hydrogel O 
viscoelastic O 
mechanical O 
properties O 
were O 
studied O 
as O 
a O 
function O 
of O 
metal O 
, O 
pH O 
, O 
concentration O 
, O 
and O 
ionic O 
strength O 
. O 
The O 
equilibrium O 
metal O 
- O 
binding O 
constants O 
were O 
determined O 
by O 
dilute O 
solution O 
potentiometric O 
titration O 
of O 
monofunctional O 
histidine B-TRIVIAL 
-modified O 
methoxy-PEG B-FAMILY 
and O 
were O 
found O 
to O 
be O 
consistent O 
with O 
binding O 
constants O 
of O 
small O 
molecule O 
analogs O 
previously O 
studied O 
. O 
pH-dependent O 
speciation O 
curves O 
were O 
then O 
calculated O 
using O 
the O 
equilibrium O 
constants O 
determined O 
by O 
potentiometric O 
titration O 
, O 
providing O 
insight O 
into O 
the O 
pH O 
dependence O 
of O 
histidine B-TRIVIAL 
-metal O 
ion O 
coordination O 
and O 
guiding O 
the O 
design O 
of O 
metal O 
coordination O 
hydrogels O 
. O 
Gel O 
relaxation O 
dynamics O 
were O 
found O 
to O 
be O 
uncorrelated O 
with O 
the O 
equilibrium O 
constants O 
measured O 
, O 
but O 
were O 
correlated O 
to O 
the O 
expected O 
coordination O 
bond O 
dissociation O 
rate O 
constants O 
. O 

product O 
drug O 
discovery O 
programs O 
often O 
rely O 
on O 
the O 
use O 
of O 
silica B-TRIVIAL 
( O 
Si B-FORMULA 
) O 
gel O 
, O 
reversed O 
- O 
phase O 
media O 
, O 
or O 
size O 
- O 
exclusion O 
resins O 
( O 
e.g O 
. O 
, O 
RP-C(18) O 
, O 
Sephadex O 
LH-20 O 
) O 
for O 
compound O 
purification O 
. O 
The O 
synthetic O 
polymer O 
- O 
based O 
sorbent O 
Diaion B-FAMILY 
HP20SS I-FAMILY 
( O 
cross O 
- O 
linked O 
polystyrene B-SYSTEMATIC 
matrix O 
) O 
is O 
used O 
as O 
an O 
alternative O 
to O 
prepare O 
purified O 
natural O 
product O 
libraries O 
. O 
To O 
evaluate O 
the O 
impact O 
of O 
chromatographic O 
media O 
on O 
the O 
isolation O 
of O 
biologically O 
active O 
, O 
yet O 
chromatographically O 
unstable O 
natural O 
products O 
, O 
Diaion B-FAMILY 
HP20SS I-FAMILY 
was O 
evaluated O 
side-by O 
- O 
side O 
with O 
normal O 
- O 
phase O 
sorbents O 
for O 
irreversible O 
binding O 
of O 
extract O 
constituents O 
and O 
their O 
effects O 
on O 
bioactivity O 
. O 
An O 
array O 
of O 
chemically O 
diverse O 
natural O 
product O 
- O 
rich O 
extracts O 
was O 
selected O 
as O 
a O 
test O 
panel O 
, O 
and O 
a O 
cell O 
- O 
based O 
reporter O 
assay O 
for O 
hypoxia O 
- O 
inducible O 
factor-1 O 
( O 
HIF-1 O 
) O 
was O 
employed O 
to O 
monitor O 
potential O 
change(s) O 
in O 
bioactivity O 
. O 
Silica O 
gel O 
caused O 
significant O 
irreversible O 
binding O 
of O 
three O 
out O 
of O 
10 O 
extracts O 
. O 
Curcuma O 
longa O 
, O 
Saururus O 
cernuus O 
, O 
and O 
Citrus O 
reticulata O 
extracts O 
showed O 
decreased O 
HIF-1 O 
inhibitory O 
activity O 
after O 
elution O 
through O 
Si B-FORMULA 
gel O 
. O 
An O 
additional O 
nonpolar O 
column O 
wash O 
of O 
HP20SS B-FAMILY 
with O 
EtOAc B-FORMULA 
retained O 
considerable O 
bioactivities O 
of O 
active O 
extracts O 
. O 
In O 
general O 
, O 
Si B-FORMULA 
gel O 
produced O 
the O 
greatest O 
loss O 
of O 
bioactivity O 
. O 
However O 
, O 
HP20SS B-FAMILY 
elution O 
reduced O 
significantly O 
HIF-1 O 
inhibitory O 
activity O 
of O 
certain O 
extracts O 
( O 
e.g O 
. O 
, O 
Asimina O 
triloba O 
) O 
. O 

new O 
pentacyclic B-SYSTEMATIC 
phenol I-SYSTEMATIC 
and O 
other O 
constituents O 
from O 
the O 
root O 
bark O 
of O 
Bauhinia O 
racemosa O 
Lamk O 
. O 

work O 
reported O 
the O 
isolation O 
of O 
one O 
unknown O 
( O 
1 O 
) O 
and O 
10 O 
known O 
compounds O 
( O 
2-11 O 
) O 
from O 
the O 
root O 
bark O 
of O 
Bauhinia O 
racemosa O 
Lamk O 
. O 
( O 
family O 
: O 
Caesalpiniaceae O 
) O 
. O 
Racemosolone B-TRIVIAL 
( O 
1 O 
) O 
was O 
characterised O 
as O 
a O 
pentacyclic B-FAMILY 
phenolic I-FAMILY 
compound O 
possessing O 
an O 
unusual O 
skeleton O 
with O 
a O 
cycloheptane B-SYSTEMATIC 
ring O 
and O 
a O 
rare O 
furopyran B-FAMILY 
moiety O 
. O 
The O 
structure O 
elucidation O 
was O 
carried O 
out O 
on O 
the O 
basis O 
of O 
UV O 
, O 
infrared O 
( O 
IR O 
) O 
, O 
HR-ESI-MS O 
, O 
1D O 
and O 
2D O 
NMR O 
spectra O 
and O 
finally O 
confirmed O 
by O 
the O 
single O 
crystal O 
X-ray O 
analysis O 
. O 
The O 
known O 
compounds O 
were O 
characterised O 
as O 
n-tetracosane B-SYSTEMATIC 
, O 
β-sitosteryl B-TRIVIAL 
stearate I-TRIVIAL 
, O 
eicosanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
stigmasterol B-TRIVIAL 
, O 
β-sitosterol B-TRIVIAL 
, O 
racemosol B-TRIVIAL 
, O 
octacosyl B-TRIVIAL 
ferulate I-TRIVIAL 
, O 
de-O-methyl B-SYSTEMATIC 
racemosol I-SYSTEMATIC 
, O 
lupeol B-TRIVIAL 
and O 
1,7,8,12b-tetrahydro-2,2,4-trimethyl-2H-benzo[6,7]cyclohepta B-SYSTEMATIC 
[ I-SYSTEMATIC 
1,2,3-de I-SYSTEMATIC 
] I-SYSTEMATIC 
[ I-SYSTEMATIC 
1 I-SYSTEMATIC 
] I-SYSTEMATIC 
benzopyran-5,10,11 I-SYSTEMATIC 
triol I-SYSTEMATIC 
on O 
the O 
basis O 
of O 
spectroscopic O 
data O 
comparison O 
with O 
the O 
literature O 
value O 
. O 
Compounds O 
with O 
skeleton O 
similar O 
to O 
1 O 
have O 
never O 
been O 
reported O 
from O 
any O 
natural O 
or O 
other O 
source O 
. O 

reactions O 
observed O 
by O 
picosecond O 
pulse O 
radiolysis O 
in O 
highly O 
concentrated O 
bromide B-SYSTEMATIC 
aqueous O 
solutions O 
. O 

formation O 
of O 
the O 
well O 
- O 
known O 
product O 
Br3(-) B-FORMULA 
, O 
observed O 
in O 
the O 
steady O 
- O 
state O 
radiolysis O 
of O 
highly O 
concentrated O 
Br(-) B-FORMULA 
aqueous O 
solutions O 
, O 
has O 
now O 
been O 
directly O 
observed O 
at O 
ultrashort O 
times O 
corresponding O 
to O 
the O 
relaxation O 
of O 
the O 
spur O 
. O 
The O 
transient O 
absorption O 
induced O 
by O 
picosecond O 
pulse O 
radiolysis O 
of O 
6 O 
M O 
Br(-) B-FORMULA 
aqueous O 
solution O 
was O 
probed O 
simultaneously O 
at O 
260 O 
nm O 
with O 
the O 
third O 
harmonic O 
laser O 
wave O 
and O 
from O 
350 O 
to O 
750 O 
nm O 
with O 
a O 
supercontinuum O 
generated O 
by O 
the O 
fundamental O 
laser O 
wave O 
. O 
This O 
approach O 
allows O 
several O 
transient O 
radiolytic O 
species O 
to O 
be O 
followed O 
in O 
parallel O 
, O 
particularly O 
the O 
solvated O 
electron O 
, O 
BrOH(-•) B-FORMULA 
, O 
Br2(-•) B-FORMULA 
, O 
and O 
Br3(-) B-FORMULA 
. O 
The O 
kinetics O 
measured O 
within O 
4 O 
ns O 
at O 
260 O 
and O 
370 O 
nm O 
clearly O 
exhibit O 
that O 
the O 
decay O 
of O 
Br2(•-) B-FORMULA 
is O 
correlated O 
with O 
the O 
formation O 
of O 
Br3(-) B-FORMULA 
. O 
In O 
highly O 
concentrated O 
Br(-) B-FORMULA 
solutions O 
, O 
the O 
OH(•) B-FORMULA 
radical O 
is O 
fully O 
replaced O 
by O 
Br2(•-) B-FORMULA 
, O 
and O 
the O 
spur O 
kinetics O 
of O 
OH(•) B-FORMULA 
radical O 
in O 
pure O 
water O 
is O 
comparable O 
with O 
that O 
of O 
Br2(-•) B-FORMULA 
. O 
Model O 
calculations O 
indicate O 
that O 
the O 
main O 
OH(•) B-FORMULA 
radical O 
combination O 
product O 
H2O2 B-FORMULA 
in O 
pure O 
water O 
has O 
formation O 
kinetics O 
similar O 
to O 
that O 
of O 
Br3(-) B-FORMULA 
in O 
6 O 
M O 
Br(-) B-FORMULA 
solutions O 
. O 
Moreover O 
, O 
they O 
point O 
out O 
that O 
oxidation O 
of O 
Br(-) B-FORMULA 
occurs O 
within O 
the O 
electron O 
pulse O 
both O 
by O 
direct O 
energy O 
absorption O 
and O 
by O 
scavenging O 
of O 
the O 
water O 
radical O 
cation O 
, O 
H2O(•+) B-FORMULA 
. O 

the O 
dynamic O 
mechanical O 
response O 
of O 
tissue O 
, O 
cells O 
, O 
membranes O 
, O 
proteins O 
, O 
nucleic O 
acids O 
, O 
and O 
carbohydrates B-FAMILY 
to O 
external O 
perturbations O 
is O 
important O 
to O 
understand O 
various O 
biological O 
and O 
biotechnological O 
problems O 
. O 
Atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
- O 
based O 
approaches O 
are O 
the O 
most O 
frequently O 
used O 
nanotechnologies O 
to O 
determine O 
the O 
mechanical O 
properties O 
of O 
biological O 
samples O 
that O 
range O 
in O 
size O 
from O 
microscopic O 
to O 
(sub)nanoscopic O 
. O 
However O 
, O 
the O 
dynamic O 
nature O 
of O 
biomechanical O 
properties O 
has O 
barely O 
been O 
addressed O 
by O 
AFM O 
imaging O 
. O 
In O 
this O 
work O 
, O 
we O 
characterizethe O 
viscoelastic O 
properties O 
of O 
the O 
native O 
light O 
- O 
driven O 
proton O 
pump O 
bacteriorhodopsin O 
of O 
the O 
purple O 
membrane O 
of O 
Halobacterium O 
salinarum O 
. O 
Using O 
force O 
- O 
distance O 
curve O 
( O 
F-D O 
) O 
- O 
based O 
AFM O 
we O 
imaged O 
purple O 
membranes O 
while O 
force O 
probing O 
their O 
mechanical O 
response O 
over O 
a O 
wide O 
range O 
of O 
loading O 
rates O 
( O 
from O 
∼0.5 O 
to O 
100 O 
μN O 
/ O 
s O 
) O 
. O 
Our O 
results O 
show O 
that O 
the O 
mechanical O 
stiffness O 
of O 
protein O 
and O 
membrane O 
increases O 
with O 
the O 
loading O 
rate O 
up O 
to O 
a O 
factor O 
of O 
10 O 
( O 
from O 
∼0.3 O 
to O 
3.2 O 
N O 
/ O 
m O 
) O 
. O 
In O 
addition O 
, O 
the O 
electrostatic O 
repulsion O 
between O 
AFM O 
tip O 
and O 
sample O 
can O 
alter O 
the O 
mechanical O 
stiffness O 
measured O 
by O 
AFM O 
up O 
to O 
∼60% O 
( O 
from O 
∼0.8 O 
to O 
1.3 O 
N O 
/ O 
m).These O 
findings O 
indicate O 
that O 
the O 
mechanical O 
response O 
of O 
membranes O 
and O 
proteins O 
and O 
probably O 
of O 
other O 
biomolecular O 
systems O 
should O 
be O 
determined O 
at O 
different O 
loading O 
rates O 
to O 
fully O 
understand O 
their O 
properties O 
. O 

a O 
viable O 
new O 
drug O 
candidate O 
is O 
difficult O 
. O 
Developing O 
one O 
that O 
is O 
a O 
small O 
molecule O 
kinase O 
inhibitor O 
that O 
binds O 
competitively O 
with O 
respect O 
to O 
ATP B-ABBREVIATION 
with O 
superb O 
selectivity O 
is O 
even O 
more O 
difficult O 
, O 
which O 
makes O 
the O 
design O 
and O 
optimization O 
work O 
described O 
by O 
Jimenez O 
et O 
al O 
. O 
( O 
J O 
. O 
Med O 
. O 
Chem O 
. O 
, O 
DOI O 
: O 
10.1021 O 
/ O 
jm301465a O 
) O 
particularly O 
remarkable O 
. O 
They O 
took O 
a O 
lead O 
from O 
a O 
high O 
- O 
throughput O 
screen O 
against O 
protein O 
kinase O 
C O 
θ O 
( O 
PKCθ O 
) O 
through O 
a O 
series O 
of O 
optimization O 
steps O 
, O 
culminating O 
in O 
the O 
demonstration O 
of O 
in O 
vivo O 
activity O 
in O 
mice O 
. O 
Having O 
identified O 
and O 
improved O 
the O 
hinge O 
- O 
binding O 
" O 
warhead O 
" O 
at O 
one O 
end O 
of O 
their O 
lead O 
molecule O 
, O 
they O 
proceeded O 
to O 
use O 
structure O 
- O 
based O 
design O 
tools O 
to O 
guide O 
modification O 
of O 
the O 
other O 
end O 
to O 
enhance O 
selectivity O 
over O 
a O 
closely O 
related O 
isoform O 
of O 
the O 
kinase O 
. O 
With O 
that O 
accomplished O 
, O 
they O 
used O 
a O 
series O 
of O 
protection O 
and O 
deprotection O 
maneuvers O 
to O 
modify O 
the O 
central O 
portion O 
of O 
the O 
series O 
scaffold O 
to O 
further O 
enhance O 
potency O 
against O 
the O 
target O 
while O 
also O 
improving O 
pharmacokinetic O 
properties O 
. O 
The O 
project O 
was O 
a O 
success O 
at O 
the O 
preclinical O 
level O 
: O 
oral O 
administration O 
of O 
the O 
ultimate O 
analogue O 
obtained O 
was O 
effective O 
at O 
suppressing O 
interleukin-2 O 
induction O 
in O 
mice O 
. O 

of O 
Palytoxin B-TRIVIAL 
Binding O 
to O 
HaCaT O 
Cells O 
Using O 
a O 
Monoclonal O 
Anti- O 
Palytoxin B-TRIVIAL 
Antibody O 
. O 

( O 
PLTX B-ABBREVIATION 
) O 
is O 
the O 
reference O 
compound O 
for O 
a O 
group O 
of O 
potent O 
marine O 
biotoxins O 
, O 
for O 
which O 
the O 
molecular O 
target O 
is O 
Na+ B-FORMULA 
/ O 
K+ B-FORMULA 
-ATPase O 
. O 
Indeed O 
, O 
ouabain B-TRIVIAL 
( O 
OUA B-ABBREVIATION 
) O 
, O 
a O 
potent O 
blocker O 
of O 
the O 
pump O 
, O 
is O 
used O 
to O 
inhibit O 
some O 
PLTX B-ABBREVIATION 
effects O 
in O 
vitro O 
. O 
However O 
, O 
in O 
an O 
effort O 
to O 
explain O 
incomplete O 
inhibition O 
of O 
PLTX B-ABBREVIATION 
cytotoxicity O 
, O 
some O 
studies O 
suggest O 
the O 
possibility O 
of O 
two O 
different O 
binding O 
sites O 
on O 
Na+ B-FORMULA 
/ O 
K+ B-FORMULA 
-ATPase O 
. O 
Hence O 
, O 
this O 
study O 
was O 
performed O 
to O 
characterize O 
PLTX B-ABBREVIATION 
binding O 
to O 
intact O 
HaCaT O 
keratinocytes O 
and O 
to O 
investigate O 
the O 
ability O 
of O 
OUA B-ABBREVIATION 
to O 
compete O 
for O 
this O 
binding O 
. O 
PLTX B-ABBREVIATION 
binding O 
to O 
HaCaT O 
cells O 
was O 
demonstrated O 
by O 
immunocytochemical O 
analysis O 
after O 
10 O 
min O 
exposure O 
. O 
An O 
anti- O 
PLTX B-ABBREVIATION 
monoclonal O 
antibody O 
- O 
based O 
ELISA O 
showed O 
that O 
the O 
binding O 
was O 
saturable O 
and O 
reversible O 
, O 
with O 
a O 
K(d) O 
of O 
3 O 
× O 
10-10 O 
M O 
. O 
However O 
, O 
kinetic O 
experiments O 
revealed O 
that O 
PLTX B-ABBREVIATION 
binding O 
dissociation O 
was O 
incomplete O 
, O 
suggesting O 
an O 
additional O 
, O 
OUA B-ABBREVIATION 
-insensitive O 
, O 
PLTX B-ABBREVIATION 
binding O 
site O 
. O 
Competitive O 
experiments O 
suggested O 
that O 
OUA B-ABBREVIATION 
acts O 
as O 
a O 
negative O 
allosteric O 
modulator O 
against O 
high O 
PLTX B-ABBREVIATION 
concentrations O 
( O 
0.3-1.0 O 
× O 
10-7 O 
M O 
) O 
and O 
possibly O 
as O 
a O 
non-competitive O 
antagonist O 
against O 
low O 
PLTX B-ABBREVIATION 
concentrations O 
( O 
0.1-3.0 O 
× O 
10-9 O 
M O 
) O 
. O 
Antagonism O 
was O 
supported O 
by O 
PLTX B-ABBREVIATION 
cytotoxicity O 
inhibition O 
at O 
OUA B-ABBREVIATION 
concentrations O 
that O 
displaced O 
PLTX B-ABBREVIATION 
binding O 
( O 
1 O 
× O 
10-5 O 
M O 
) O 
. O 
However O 
, O 
this O 
inhibition O 
was O 
incomplete O 
, O 
supporting O 
the O 
existence O 
of O 
both O 
OUA B-ABBREVIATION 
-sensitive O 
and O 
-insensitive O 
PLTX B-ABBREVIATION 
binding O 
sites O 
. O 

of O 
photobleaching O 
, O 
oxidation O 
and O 
metal O 
induced O 
fluorescence O 
quenching O 
of O 
DNA-templated O 
silver B-SYSTEMATIC 
nanoclusters O 
. O 

- O 
atom O 
noble O 
metal O 
nanoclusters O 
have O 
attracted O 
a O 
lot O 
of O 
interest O 
due O 
to O 
their O 
potential O 
applications O 
in O 
biosensor O 
development O 
, O 
imaging O 
and O 
catalysis O 
. O 
DNA-templated O 
silver B-SYSTEMATIC 
nanoclusters O 
( O 
AgNCs O 
) O 
are O 
of O 
particular O 
interest O 
as O 
different O 
emission O 
colors O 
can O 
be O 
obtained O 
by O 
changing O 
the O 
DNA O 
sequence O 
. O 
A O 
popular O 
analytical O 
application O 
is O 
fluorescence O 
quenching O 
by O 
Hg(2+) B-FORMULA 
, O 
where O 
d(10)-d(10) O 
metallophilic O 
interaction O 
has O 
often O 
been O 
proposed O 
for O 
associating O 
Hg(2+) B-FORMULA 
with O 
nanoclusters O 
. O 
However O 
, O 
it O 
cannot O 
explain O 
the O 
lack O 
of O 
response O 
to O 
other O 
d(10) O 
ions O 
such O 
as O 
Zn(2+) B-FORMULA 
and O 
Cd(2+) B-FORMULA 
. O 
In O 
our O 
effort O 
to O 
elucidate O 
the O 
quenching O 
mechanism O 
, O 
we O 
studied O 
a O 
total O 
of O 
eight O 
AgNCs O 
prepared O 
by O 
different O 
hairpin O 
DNA O 
sequences O 
; O 
they O 
showed O 
different O 
sensitivity O 
to O 
Hg(2+) B-FORMULA 
, O 
and O 
DNA O 
with O 
a O 
larger O 
cytosine B-TRIVIAL 
loop O 
size O 
produced O 
more O 
sensitive O 
AgNCs O 
. O 
In O 
all O 
the O 
cases O 
, O 
samples O 
strongly O 
quenched O 
by O 
Hg(2+) B-FORMULA 
were O 
also O 
more O 
easily O 
photobleached O 
. O 
Light O 
of O 
shorter O 
wavelengths O 
bleached O 
AgNCs O 
more O 
potently O 
, O 
and O 
photobleached O 
samples O 
can O 
be O 
recovered O 
by O 
NaBH4 B-FORMULA 
. O 
Strong O 
fluorescence O 
quenching O 
was O 
also O 
observed O 
with O 
high O 
redox O 
potential O 
metal O 
ions O 
such O 
as O 
Ag(+) B-FORMULA 
, O 
Au(3+) B-FORMULA 
, O 
Cu(2+) B-FORMULA 
and O 
Hg(2+) B-FORMULA 
, O 
but O 
not O 
with O 
low O 
redox O 
potential O 
ions O 
. O 
Such O 
metal O 
induced O 
quenching O 
cannot O 
be O 
recovered O 
by O 
NaBH4 B-FORMULA 
. O 
Electronic O 
absorption O 
and O 
mass O 
spectrometry O 
studies O 
offered O 
further O 
insights O 
into O 
the O 
oxidation O 
reaction O 
. O 
Our O 
results O 
correlate O 
many O 
important O 
experimental O 
observations O 
and O 
will O 
fuel O 
the O 
further O 
growth O 
of O 
this O 
field O 
. O 

the O 
accuracy O 
of O 
explicitly O 
correlated O 
methods O 
to O 
generate O 
potential O 
energy O 
surfaces O 
for O 
scattering O 
calculations O 
and O 
clustering O 
: O 
application O 
to O 
the O 
HCl B-FORMULA 
- O 
He B-FORMULA 
complex O 
. O 

closely O 
compare O 
the O 
accuracy O 
of O 
multidimensional O 
potential O 
energy O 
surfaces O 
( O 
PESs O 
) O 
generated O 
by O 
the O 
recently O 
developed O 
explicitly O 
correlated O 
coupled O 
cluster O 
( O 
CCSD(T)-F12 O 
) O 
methods O 
in O 
connection O 
with O 
the O 
cc-pVXZ-F12 O 
( O 
X O 
= O 
D O 
, O 
T O 
) O 
and O 
aug-cc-pVTZ O 
basis O 
sets O 
and O 
those O 
deduced O 
using O 
the O 
well O 
- O 
established O 
orbital O 
- O 
based O 
coupled O 
cluster O 
techniques O 
employing O 
correlation O 
consistent O 
atomic O 
basis O 
sets O 
( O 
aug-cc-pVXZ O 
, O 
X O 
= O 
T O 
, O 
Q O 
, O 
5 O 
) O 
and O 
extrapolated O 
to O 
the O 
complete O 
basis O 
set O 
( O 
CBS O 
) O 
limit O 
. O 
This O 
work O 
is O 
performed O 
on O 
the O 
benchmark O 
rare O 
gas- O 
hydrogen B-FAMILY 
halide I-FAMILY 
interaction O 
( O 
HCl B-FORMULA 
- O 
He B-FORMULA 
) O 
system O 
. O 
These O 
PESs O 
are O 
then O 
incorporated O 
into O 
quantum O 
close O 
- O 
coupling O 
scattering O 
dynamical O 
calculations O 
in O 
order O 
to O 
check O 
the O 
impact O 
of O 
the O 
accuracy O 
of O 
the O 
PES O 
on O 
the O 
scattering O 
calculations O 
. O 
For O 
this O 
system O 
, O 
we O 
deduced O 
inelastic O 
collisional O 
data O 
including O 
(de-)excitation O 
collisional O 
and O 
pressure O 
broadening O 
cross O 
sections O 
. O 
Our O 
work O 
shows O 
that O 
the O 
CCSD(T)-F12 O 
/ O 
aug-cc-pVTZ O 
PES O 
describes O 
correctly O 
the O 
repulsive O 
wall O 
, O 
the O 
van O 
der O 
Waals O 
minimum O 
and O 
long O 
range O 
internuclear O 
distances O 
whereas O 
cc-pVXZ-F12 O 
( O 
X O 
= O 
D,T O 
) O 
basis O 
sets O 
are O 
not O 
diffuse O 
enough O 
for O 
that O 
purposes O 
. O 
Interestingly O 
, O 
the O 
collision O 
cross O 
sections O 
deduced O 
from O 
the O 
CCSD(T)-F12 O 
/ O 
aug-cc-pVTZ O 
PES O 
are O 
in O 
excellent O 
agreement O 
with O 
those O 
obtained O 
with O 
CCSD(T) O 
/ O 
CBS O 
methodology O 
. O 
The O 
position O 
of O 
the O 
resonances O 
and O 
the O 
general O 
shape O 
of O 
these O 
cross O 
sections O 
almost O 
coincide O 
. O 
Since O 
the O 
cost O 
of O 
the O 
electronic O 
structure O 
computations O 
is O 
reduced O 
by O 
several O 
orders O 
of O 
magnitude O 
when O 
using O 
CCSD(T)-F12 O 
/ O 
aug-cc-pVTZ O 
compared O 
to O 
CCSD(T) O 
/ O 
CBS O 
methodology O 
, O 
this O 
approach O 
can O 
be O 
recommended O 
as O 
an O 
alternative O 
for O 
generation O 
of O 
PESs O 
of O 
molecular O 
clusters O 
and O 
for O 
the O 
interpretation O 
of O 
accurate O 
scattering O 
experiments O 
as O 
well O 
as O 
for O 
a O 
wide O 
production O 
of O 
collisional O 
data O 
to O 
be O 
included O 
in O 
astrophysical O 
and O 
atmospherical O 
models O 
. O 

alters O 
the O 
integrity O 
of O 
cell O 
membrane O 
and O 
acts O 
against O 
the O 
nosocomial O 
pathogen O 
Proteus O 
mirabilis O 
. O 

, O 
a O 
member O 
of O 
the O 
phenylpropanoids O 
class O 
of O 
chemical O 
compounds O 
, O 
is O 
a O 
clear O 
to O 
pale O 
yellow O 
oily O 
liquid O 
extracted O 
from O 
certain O 
essential O 
oils O 
especially O 
from O 
clove O 
oil O 
, O 
nutmeg O 
, O 
cinnamon O 
, O 
and O 
bay O 
leaf O 
. O 
The O 
antibacterial O 
activity O 
of O 
eugenol B-TRIVIAL 
and O 
its O 
mechanism O 
of O 
bactericidal O 
action O 
against O 
Proteus O 
mirabilis O 
were O 
evaluated O 
. O 
Treatment O 
with O 
eugenol B-TRIVIAL 
at O 
their O 
minimum O 
inhibitory O 
concentration O 
[ O 
0.125 O 
% O 
( O 
v O 
/ O 
v O 
) O 
] O 
and O 
minimum O 
bactericidal O 
concentration O 
[ O 
0.25 O 
% O 
( O 
v O 
/ O 
v O 
) O 
] O 
reduced O 
the O 
viability O 
and O 
resulted O 
in O 
complete O 
inhibition O 
of O 
P O 
. O 
mirabilis O 
. O 
A O 
strong O 
bactericidal O 
effect O 
on O 
P O 
. O 
mirabilis O 
was O 
also O 
evident O 
, O 
as O 
eugenol B-TRIVIAL 
inactivated O 
the O 
bacterial O 
population O 
within O 
30 O 
min O 
exposure O 
. O 
Chemo O 
- O 
attractant O 
property O 
and O 
the O 
observance O 
of O 
highest O 
antibacterial O 
activity O 
at O 
alkaline O 
pH O 
suggest O 
that O 
eugenol B-TRIVIAL 
can O 
work O 
more O 
effectively O 
when O 
given O 
in O 
vivo O 
. O 
Eugenol B-TRIVIAL 
inhibits O 
the O 
virulence O 
factors O 
produced O 
by O 
P O 
. O 
mirabilis O 
as O 
observed O 
by O 
swimming O 
motility O 
, O 
swarming O 
behavior O 
and O 
urease O 
activity O 
. O 
It O 
interacts O 
with O 
cellular O 
membrane O 
of O 
P O 
. O 
mirabilis O 
and O 
makes O 
it O 
highly O 
permeable O 
, O 
forming O 
nonspecific O 
pores O 
on O 
plasma O 
membrane O 
, O 
which O 
in O 
turn O 
directs O 
the O 
release O 
of O 
260 O 
nm O 
absorbing O 
materials O 
and O 
uptake O 
of O 
more O 
crystal B-TRIVIAL 
violet I-TRIVIAL 
from O 
the O 
medium O 
into O 
the O 
cells O 
. O 
SDS B-ABBREVIATION 
- O 
polyacrylamide B-SYSTEMATIC 
gel O 
, O 
scanning O 
electron O 
microscopy O 
and O 
Fourier O 
transform O 
infrared O 
analysis O 
further O 
proves O 
the O 
disruptive O 
action O 
of O 
eugenol B-TRIVIAL 
on O 
the O 
plasma O 
membrane O 
of O 
P O 
. O 
mirabilis O 
. O 
The O 
findings O 
reveal O 
that O 
eugenol B-TRIVIAL 
shows O 
an O 
excellent O 
bactericidal O 
activity O 
against O 
P O 
. O 
mirabilis O 
by O 
altering O 
the O 
integrity O 
of O 
cell O 
membrane O 
. O 

constituents O 
from O 
Parakmeria O 
yunnanensis O 
and O 
their O 
anti-HIV-1 O 
activity O 
. O 

new O 
phenolic B-FAMILY 
compounds O 
, O 
yunnanensins B-MULTIPLE 
A-C I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
together O 
with O 
fourteen O 
known O 
ones O 
( O 
4-17 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
leaves O 
and O 
stems O 
of O 
Parakmeria O 
yunnanensis O 
. O 
The O 
structures O 
of O 
new O 
compounds O 
were O 
established O 
on O 
the O 
basis O 
of O 
extensive O 
spectroscopic O 
analyses O 
. O 
Several O 
compounds O 
showed O 
weak O 
anti-HIV-1 O 
activity O 
. O 

inhibition O 
of O 
an O 
apicoplastic O 
aminoacyl B-SYSTEMATIC 
-tRNA O 
synthetase O 
from O 
Plasmodium O 
falciparum O 
. O 

resistance O 
of O 
malaria O 
parasites O 
to O 
available O 
drugs O 
continues O 
to O 
grow O 
, O 
and O 
this O 
makes O 
the O 
need O 
for O 
new O 
antimalarial O 
therapies O 
pressing O 
. O 
Aminoacyl B-SYSTEMATIC 
-tRNA O 
synthetases O 
( O 
ARSs O 
) O 
are O 
essential O 
enzymes O 
and O 
well O 
- O 
established O 
antibacterial O 
targets O 
and O 
so O 
constitute O 
a O 
promising O 
set O 
of O 
targets O 
for O 
the O 
development O 
of O 
new O 
antimalarials O 
. O 
Despite O 
their O 
potential O 
as O 
drug O 
targets O 
, O 
apicoplastic O 
ARSs O 
remain O 
unexplored O 
. O 
We O 
have O 
characterized O 
the O 
lysylation O 
system O 
of O 
Plasmodium O 
falciparum O 
, O 
and O 
designed O 
, O 
synthesized O 
, O 
and O 
tested O 
a O 
set O 
of O 
inhibitors O 
based O 
on O 
the O 
structure O 
of O 
the O 
natural O 
substrate O 
intermediate O 
: O 
lysyl-adenylate B-TRIVIAL 
. O 
Here O 
we O 
demonstrate O 
that O 
selective O 
inhibition O 
of O 
apicoplastic O 
ARSs O 
is O 
feasible O 
and O 
describe O 
new O 
compounds O 
that O 
that O 
specifically O 
inhibit O 
Plasmodium O 
apicoplastic O 
lysyl B-TRIVIAL 
-tRNA O 
synthetase O 
and O 
show O 
antimalarial O 
activities O 
in O 
the O 
micromolar O 
range O 
. O 

neonicotinoid O 
imidacloprid B-TRIVIAL 
shows O 
high O 
chronic O 
toxicity O 
to O 
mayfly O 
nymphs O 
. O 

present O 
study O 
evaluated O 
the O 
acute O 
and O 
chronic O 
toxicity O 
of O 
imidacloprid B-TRIVIAL 
to O 
a O 
range O 
of O 
freshwater O 
arthropods O 
. O 
Mayfly O 
and O 
caddisfly O 
species O 
were O 
most O 
sensitive O 
to O 
short O 
- O 
term O 
imidacloprid B-TRIVIAL 
exposures O 
( O 
10 O 
tests O 
) O 
, O 
whereas O 
the O 
mayflies O 
showed O 
by O 
far O 
the O 
most O 
sensitive O 
response O 
to O 
long O 
- O 
term O 
exposure O 
of O 
all O 
seven O 
arthropod O 
species O 
tested O 
( O 
28-d O 
EC10 O 
values O 
of O 
approximately O 
0.03 O 
µg O 
/ O 
L O 
) O 
. O 
The O 
results O 
indicated O 
a O 
high O 
aquatic O 
risk O 
of O 
chronic O 
exposure O 
of O 
imidacloprid B-TRIVIAL 
to O 
mayflies O 
. O 
Environ O 
. O 
Toxicol O 
. O 
Chem O 
. O 
2013;32 O 
: O 
1096-1100 O 
. O 
© O 
2013 O 
SETAC O 
. O 

of O 
modified O 
- O 
release O 
prednisone B-TRIVIAL 
tablets O 
in O 
healthy O 
subjects O 
and O 
patients O 
with O 
rheumatoid O 
arthritis O 
. O 

rheumatoid O 
arthritis O 
( O 
RA O 
) O 
, O 
nocturnal O 
release O 
of O 
proinflammatory O 
cytokines O 
is O 
not O 
adequately O 
counteracted O 
by O 
endogenous O 
glucocorticoid O 
and O 
is O 
associated O 
with O 
symptoms O 
of O 
morning O 
stiffness O 
and O 
pain O 
. O 
Taking O 
exogenous O 
glucocorticoid O 
during O 
the O 
night O 
reduces O 
morning O 
stiffness O 
significantly O 
more O 
than O 
treatment O 
at O 
the O 
conventional O 
time O 
in O 
the O 
morning O 
, O 
although O 
waking O 
to O 
take O 
tablets O 
is O 
unacceptable O 
for O 
patients O 
. O 
Modified O 
- O 
release O 
prednisone B-TRIVIAL 
tablets O 
were O 
developed O 
to O 
allow O 
administration O 
at O 
bedtime O 
for O 
programmed O 
delivery O 
of O 
glucocorticoid O 
during O 
the O 
night O 
. O 
Single O 
- O 
center O 
crossover O 
studies O 
were O 
conducted O 
, O 
each O 
in O 
≤ O 
24 O 
healthy O 
subjects O 
, O 
to O 
compare O 
the O 
pharmacokinetics O 
of O 
a O 
single O 
5-mg O 
oral O 
dose O 
of O 
modified O 
- O 
release O 
prednisone B-TRIVIAL 
and O 
conventional O 
prednisone B-TRIVIAL 
, O 
as O 
well O 
as O 
the O 
effect O 
of O 
food O 
on O 
bioavailability O 
. O 
There O 
was O 
no O 
substantial O 
difference O 
in O 
pharmacokinetic O 
parameters O 
of O 
the O 
formulations O 
apart O 
from O 
the O 
programmed O 
delay O 
in O 
release O 
of O 
glucocorticoid O 
from O 
the O 
modified O 
- O 
release O 
tablets O 
( O 
C(max) O 
97% O 
, O 
AUC(0-∞) O 
101% O 
, O 
90% O 
confidence O 
intervals O 
within O 
the O 
requisite O 
range O 
for O 
bioequivalence O 
) O 
. O 
Administration O 
after O 
a O 
full O 
or O 
light O 
meal O 
did O 
not O 
affect O 
pharmacokinetic O 
characteristics O 
, O 
but O 
bioavailability O 
was O 
reduced O 
under O 
fasted O 
conditions O 
. O 
Pharmacokinetic O 
evaluation O 
in O 
9 O 
patients O 
with O 
RA O 
confirmed O 
that O 
modified O 
- O 
release O 
prednisone B-TRIVIAL 
tablets O 
taken O 
at O 
bedtime O 
( O 
around O 
22 O 
: O 
0 O 
h O 
) O 
with O 
or O 
after O 
an O 
evening O 
meal O 
result O 
in O 
programmed O 
release O 
of O 
glucocorticoid O 
4 O 
to O 
6 O 
hours O 
after O 
intake O 
. O 

of O 
the O 
Catalytic O 
Function O 
of O 
Human O 
Hydroxysteroid B-FAMILY 
Sulfotransferase O 
hSULT2A1 O 
by O 
Formation O 
of O 
Disulfide B-SYSTEMATIC 
Bonds O 
. O 

human O 
cytosolic O 
sulfotransferase O 
hSULT2A1 O 
catalyzes O 
the O 
sulfation O 
of O 
a O 
broad O 
range O 
of O 
xenobiotics O 
, O 
as O 
well O 
as O 
endogenous O 
hydroxysteroids B-FAMILY 
and O 
bile B-FAMILY 
acids I-FAMILY 
. O 
Reversible O 
modulation O 
of O 
the O 
catalytic O 
activity O 
of O 
this O 
enzyme O 
could O 
play O 
important O 
roles O 
in O 
its O 
physiologic O 
functions O 
. O 
Whereas O 
other O 
mammalian O 
sulfotransferases O 
are O 
known O 
to O 
be O 
reversibly O 
altered O 
by O 
changes O 
in O 
their O 
redox O 
environment O 
, O 
this O 
has O 
not O 
been O 
previously O 
shown O 
for O 
hSULT2A1 O 
. O 
We O 
have O 
examined O 
the O 
hypothesis O 
that O 
the O 
formation O 
of O 
disulfide B-SYSTEMATIC 
bonds O 
in O 
hSULT2A1 O 
can O 
reversibly O 
regulate O 
the O 
catalytic O 
function O 
of O 
the O 
enzyme O 
. O 
Three O 
thiol B-FAMILY 
oxidants O 
were O 
used O 
as O 
model O 
compounds O 
to O 
investigate O 
their O 
effects O 
on O 
homogeneous O 
preparations O 
of O 
hSULT2A1 O 
: O 
glutathione B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
, O 
5,5'-dithiobis(2-nitrobenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
, O 
and O 
1,1'-azobis(N,N-dimethylformamide B-SYSTEMATIC 
) O 
( O 
diamide B-SYSTEMATIC 
) O 
. O 
Examination O 
of O 
the O 
effects O 
of O 
disulfide B-SYSTEMATIC 
bond O 
formation O 
with O 
these O 
agents O 
indicated O 
that O 
the O 
activity O 
of O 
the O 
enzyme O 
is O 
reversibly O 
altered O 
. O 
Studies O 
on O 
the O 
kinetics O 
of O 
the O 
hSULT2A1 O 
- O 
catalyzed O 
sulfation O 
of O 
dehydroepiandrosterone B-TRIVIAL 
( O 
DHEA B-ABBREVIATION 
) O 
showed O 
the O 
effects O 
of O 
disulfide B-SYSTEMATIC 
bond O 
formation O 
on O 
the O 
substrate O 
inhibition O 
characteristics O 
of O 
the O 
enzyme O 
. O 
The O 
effects O 
of O 
these O 
agents O 
on O 
the O 
binding O 
of O 
substrates O 
and O 
products O 
, O 
liquid O 
chromatography O 
- O 
mass O 
spectrometry O 
identification O 
of O 
the O 
disulfides B-FAMILY 
formed O 
, O 
and O 
structural O 
modeling O 
of O 
the O 
modified O 
enzyme O 
were O 
examined O 
. O 
Our O 
results O 
indicate O 
that O 
conformational O 
changes O 
at O 
cysteines B-FAMILY 
near O 
the O 
nucleotide B-FAMILY 
binding O 
site O 
affect O 
the O 
binding O 
of O 
both O 
the O 
nucleotide B-FAMILY 
and O 
DHEA B-ABBREVIATION 
to O 
the O 
enzyme O 
, O 
with O 
the O 
specific O 
effects O 
dependent O 
on O 
the O 
structure O 
of O 
the O 
resulting O 
disulfide B-SYSTEMATIC 
. O 
Thus O 
, O 
the O 
formation O 
of O 
disulfide B-SYSTEMATIC 
bonds O 
in O 
hSULT2A1 O 
is O 
a O 
potentially O 
important O 
reversible O 
mechanism O 
for O 
alterations O 
in O 
the O 
rates O 
of O 
sulfation O 
of O 
both O 
endogenous O 
and O 
xenobiotic O 
substrates O 
. O 

transition O 
from O 
unicellular O 
to O 
multicellular O 
life O 
, O 
which O 
occurred O 
several O 
times O 
during O 
evolution O 
, O 
requires O 
tight O 
interaction O 
and O 
communication O 
of O 
neighboring O 
cells O 
. O 
The O 
multicellular O 
cyanobacterium O 
Nostoc O 
punctiforme O 
ATCC O 
29133 O 
forms O 
filaments O 
of O 
hundreds O 
of O 
interacting O 
cells O 
exchanging O 
metabolites O 
and O 
signal O 
molecules O 
and O 
is O 
able O 
to O 
differentiate O 
specialized O 
cells O 
in O 
response O 
to O 
environmental O 
stimuli O 
. O 
Mutation O 
of O 
cell O 
wall O 
amidase O 
AmiC2 O 
leads O 
to O 
a O 
severe O 
phenotype O 
with O 
formation O 
of O 
aberrant O 
septa O 
in O 
the O 
distorted O 
filaments O 
, O 
which O 
completely O 
lack O 
cell O 
communication O 
and O 
potential O 
for O 
cell O 
differentiation O 
. O 
Here O 
we O 
demonstrate O 
the O 
function O 
of O 
the O 
amidase O 
AmiC2 O 
in O 
formation O 
of O 
cell O 
- O 
joining O 
structures O 
. O 
The O 
AmiC2 O 
protein O 
localizes O 
to O 
the O 
young O 
septum O 
between O 
cells O 
and O 
shows O 
bona O 
fide O 
amidase O 
activity O 
in O 
vivo O 
and O 
in O 
vitro O 
. O 
Vancomycin B-TRIVIAL 
staining O 
identified O 
the O 
overall O 
septum O 
morphology O 
in O 
living O 
cells O 
. O 
By O 
electron O 
microscopy O 
of O 
isolated O 
peptidoglycan O 
sacculi O 
, O 
the O 
submicroscopic O 
structure O 
of O 
the O 
cell O 
junctions O 
could O 
be O 
visualized O 
, O 
revealing O 
a O 
novel O 
function O 
for O 
a O 
cell O 
wall O 
amidase O 
: O 
AmiC2 O 
drills O 
holes O 
into O 
the O 
cross O 
- O 
walls O 
, O 
forming O 
an O 
array O 
of O 
∼155 O 
nanopores O 
with O 
a O 
diameter O 
of O 
∼20 O 
nm O 
each O 
. O 
These O 
nanopores O 
seem O 
to O 
constitute O 
a O 
framework O 
for O 
cell O 
- O 
joining O 
proteins O 
, O 
penetrating O 
the O 
cell O 
wall O 
. O 
The O 
entire O 
array O 
of O 
junctional O 
nanopores O 
appears O 
as O 
a O 
novel O 
bacterial O 
organelle O 
, O 
establishing O 
multicellularity O 
in O 
a O 
filamentous O 
prokaryote.-Lehner O 
, O 
J O 
. O 
, O 
Berendt O 
, O 
S O 
. O 
, O 
Dörsam O 
, O 
B O 
. O 
, O 
Pérez O 
, O 
R O 
. O 
, O 
Forchhammer O 
, O 
K O 
. O 
, O 
Maldener O 
, O 
I O 
. O 
Prokaryotic O 
multicellularity O 
: O 
a O 
nanopore O 
array O 
for O 
bacterial O 
cell O 
communication O 
. O 

, O 
pharmacokinetics O 
, O 
tissue O 
distribution O 
and O 
antitumor O 
activity O 
of O 
honokiol B-TRIVIAL 
submicron O 
lipid O 
emulsions O 
in O 
tumor O 
- O 
burdened O 
mice O 
. O 

, O 
isolated O 
from O 
the O 
Chinese O 
traditional O 
herb O 
magnolia O 
, O 
is O 
a O 
poorly O 
water O 
- O 
soluble O 
component O 
and O 
has O 
been O 
found O 
to O 
have O 
anti-tumor O 
properties O 
. O 
In O 
the O 
current O 
study O 
, O 
honokiol B-TRIVIAL 
submicron O 
lipid O 
emulsions O 
( O 
HK-SLEs O 
) O 
were O 
prepared O 
by O 
high O 
pressure O 
homogenization O 
technology O 
. O 
After O 
HK-SLEs O 
were O 
physically O 
characterized O 
, O 
their O 
pharmacokinetics O 
, O 
tissue O 
distribution O 
and O 
antitumor O 
activity O 
after O 
intravenous O 
( O 
i.v O 
. O 
) O 
administration O 
to O 
tumor O 
- O 
burdened O 
mice O 
were O 
examined O 
, O 
using O 
honokiol B-TRIVIAL 
solution O 
( O 
HK-SOL O 
) O 
as O 
the O 
control O 
. O 
The O 
results O 
showed O 
that O 
the O 
mean O 
particle O 
size O 
, O 
zeta O 
potential O 
, O 
pH O 
value O 
, O 
osmolality O 
, O 
drug O 
loading O 
(DL)% O 
and O 
entrapment O 
efficiency O 
(EE)% O 
of O 
HK-SLEs O 
were O 
186.6 O 
+ O 
/ O 
- O 
1.7 O 
nm O 
, O 
-35.65 O 
+ O 
/ O 
- O 
0.67 O 
mV O 
, O 
7.22 O 
+ O 
/ O 
- O 
0.26 O 
, O 
298 O 
+ O 
/ O 
- O 
2.3 O 
mOsm O 
/ O 
L O 
, O 
7.1 O 
+ O 
/ O 
- O 
0.2% O 
and O 
95.5 O 
+ O 
/ O 
- O 
0.2% O 
, O 
respectively O 
. O 
HK-SLEs O 
were O 
stable O 
for O 
at O 
least O 
12 O 
months O 
when O 
stored O 
at O 
4 O 
+ O 
/ O 
- O 
2 O 
degrees O 
C O 
. O 
The O 
pharmacokinetic O 
results O 
showed O 
that O 
the O 
drug O 
concentration O 
- O 
time O 
curves O 
of O 
HK-SLEs O 
and O 
HK-SOL O 
could O 
both O 
be O 
described O 
by O 
an O 
open O 
two O 
- O 
compartment O 
model O 
. O 
The O 
half O 
- O 
life O 
of O 
HK-SLEs O 
( O 
t1 O 
/ O 
2(alpha) O 
= O 
8.014 O 
min O 
, O 
t1 O 
/ O 
2(beta) O 
= O 
35.784 O 
min O 
) O 
was O 
remarkably O 
prolonged O 
compared O 
to O 
that O 
of O 
HK-SOL O 
( O 
t1 O 
/ O 
2(alpha) O 
= O 
4.318 O 
min O 
, O 
t1 O 
/ O 
2(beta) O 
= O 
15.522 O 
min O 
) O 
. O 
HK-SLEs O 
exhibited O 
a O 
greater O 
AUC O 
and O 
reduced O 
plasma O 
clearance O 
. O 
The O 
tissue O 
distribution O 
results O 
indicated O 
that O 
HK-SLEs O 
have O 
better O 
targeting O 
properties O 
to O 
lung O 
and O 
tumor O 
tissues O 
compared O 
with O 
those O 
of O 
HK-SOL O 
. O 
Both O 
HK-SLEs O 
and O 
HK-SOL O 
tended O 
to O 
accumulate O 
in O 
brain O 
tissue O 
. O 
In O 
vivo O 
study O 
showed O 
that O 
HK-SLEs O 
treatment O 
caused O 
significant O 
inhibition O 
of O 
mouse O 
sarcoma O 
S180 O 
tumor O 
growth O 
compared O 
to O 
HK-SOL O 
. O 
These O 
results O 
suggest O 
that O 
HK-SLEs O 
might O 
be O 
an O 
effective O 
parenteral O 
carrier O 
for O 
honokiol B-TRIVIAL 
delivery O 
in O 
cancer O 
treatment O 
. O 

and O 
Ydc1p O 
are O 
alkaline O 
ceramide O 
hydrolases O 
, O 
which O 
reside O 
in O 
the O 
ER O 
. O 
Ypc1p O 
can O 
catalyze O 
the O 
reverse O 
reaction O 
, O 
i.e O 
. O 
the O 
condensation O 
of O 
free O 
fatty B-FAMILY 
acids I-FAMILY 
with O 
phytosphingosine B-TRIVIAL 
or O 
dihydrosphingosine B-SYSTEMATIC 
and O 
overexpression O 
of O 
YPC1 O 
or O 
YDC1 O 
can O 
provide O 
enough O 
ceramide B-FAMILY 
synthesis O 
as O 
to O 
rescue O 
the O 
viability O 
of O 
cells O 
lacking O 
the O 
normal O 
acyl-CoA B-ABBREVIATION 
-dependent O 
ceramide O 
synthases O 
. O 
To O 
better O 
understand O 
the O 
coexistence O 
of O 
acyl-CoA B-ABBREVIATION 
dependent O 
ceramide B-FAMILY 
synthases O 
and O 
ceramidases B-FAMILY 
in O 
the O 
ER O 
we O 
investigated O 
the O 
membrane O 
topology O 
of O 
Ypc1p O 
by O 
probing O 
cysteine B-TRIVIAL 
accessibility O 
of O 
natural O 
and O 
substituted O 
cysteines B-FAMILY 
with O 
membrane O 
non-permeating O 
mass O 
- O 
tagged O 
probes O 
. O 
The O 
N B-FORMULA 
- O 
and O 
C B-FORMULA 
-terminal O 
ends O 
of O 
Ypc1p O 
are O 
oriented O 
towards O 
the O 
lumen O 
and O 
cytosol O 
, O 
respectively O 
. O 
Two O 
of O 
the O 
5 O 
natural O 
cysteines B-FAMILY 
, O 
Cys27 O 
and O 
Cys219 O 
, O 
are O 
essential O 
for O 
enzymatic O 
activity O 
and O 
form O 
a O 
disulfide B-SYSTEMATIC 
bridge O 
. O 
The O 
data O 
allow O 
inferring O 
that O 
all O 
amino B-FAMILY 
acids I-FAMILY 
of O 
Ypc1p O 
that O 
are O 
conserved O 
in O 
the O 
pfam O 
PF05875 O 
ceramidase O 
motif O 
and O 
the O 
CREST O 
superfamily O 
are O 
located O 
in O 
or O 
near O 
the O 
ER O 
lumen O 
. O 
Microsomal O 
assays O 
using O 
a O 
lysine B-TRIVIAL 
-specific O 
reagent O 
show O 
that O 
the O 
reverse O 
ceramidase O 
activity O 
can O 
only O 
be O 
blocked O 
when O 
the O 
reagent O 
has O 
access O 
to O 
Ypc1p O 
from O 
the O 
lumenal O 
side O 
. O 
Overall O 
the O 
data O 
suggest O 
that O 
the O 
active O 
site O 
of O 
Ypc1p O 
resides O 
at O 
the O 
lumenal O 
side O 
of O 
the O 
ER O 
membrane O 
. O 

engineering O 
of O 
single O 
molecules O 
into O 
higher O 
- O 
order O 
hierarchical O 
assemblies O 
is O 
a O 
current O 
research O 
focus O 
in O 
molecular O 
materials O 
chemistry O 
. O 
Molecules O 
containing O 
π-conjugated O 
units O 
are O 
an O 
important O 
class O 
of O 
building O 
blocks O 
because O 
their O 
self O 
- O 
assembly O 
is O 
not O 
only O 
of O 
fundamental O 
interest O 
, O 
but O 
also O 
the O 
key O 
to O 
fabricating O 
functional O 
systems O 
for O 
organic O 
electronic O 
and O 
photovoltaic O 
applications O 
. O 
Functionalizing O 
the O 
π-cores O 
with O 
" O 
alkyl B-FAMILY 
chains O 
" O 
is O 
a O 
common O 
strategy O 
in O 
the O 
molecular O 
design O 
that O 
can O 
give O 
the O 
system O 
desirable O 
properties O 
, O 
such O 
as O 
good O 
solubility O 
in O 
organic O 
solvents O 
for O 
solution O 
processing O 
. O 
Moreover O 
, O 
the O 
alkylated-π O 
system O 
can O 
regulate O 
the O 
self O 
- O 
assembly O 
behavior O 
by O 
fine O 
- O 
tuning O 
the O 
intermolecular O 
forces O 
. O 
The O 
optimally O 
assembled O 
structures O 
can O 
then O 
exhibit O 
advanced O 
functions O 
. O 
However O 
, O 
while O 
some O 
general O 
rules O 
have O 
been O 
revealed O 
, O 
a O 
comprehensive O 
understanding O 
of O 
the O 
function O 
played O 
by O 
the O 
attached O 
alkyl B-FAMILY 
chains O 
is O 
still O 
lacking O 
, O 
and O 
current O 
methodology O 
is O 
system O 
- O 
specific O 
in O 
many O 
cases O 
. O 
Better O 
clarification O 
of O 
this O 
issue O 
requires O 
contributions O 
from O 
carefully O 
designed O 
libraries O 
of O 
alkylated-π O 
molecular O 
systems O 
in O 
both O 
self O 
- O 
assembly O 
and O 
nonassembly O 
materialization O 
strategies O 
. O 
Here O 
, O 
based O 
on O 
recent O 
efforts O 
toward O 
this O 
goal O 
, O 
we O 
show O 
the O 
power O 
of O 
the O 
alkyl B-FAMILY 
chains O 
in O 
controlling O 
the O 
self O 
- O 
assembly O 
of O 
soft O 
molecular O 
materials O 
and O 
their O 
resulting O 
optoelectronic O 
properties O 
. O 
The O 
design O 
of O 
alkylated-C60 B-FAMILY 
is O 
selected O 
from O 
our O 
recent O 
research O 
achievements O 
, O 
as O 
the O 
most O 
attractive O 
example O 
of O 
such O 
alkylated-π O 
systems O 
. O 
Some O 
other O 
closely O 
related O 
systems O 
composed O 
of O 
alkyl B-FAMILY 
chains O 
and O 
π- O 
units O 
are O 
also O 
reviewed O 
to O 
indicate O 
the O 
universality O 
of O 
the O 
methodology O 
. O 
Finally O 
, O 
as O 
a O 
contrast O 
to O 
the O 
self O 
- O 
assembled O 
molecular O 
materials O 
, O 
nonassembled O 
, O 
solvent-free O 
, O 
novel O 
functional O 
liquid O 
materials O 
are O 
discussed O 
. O 
In O 
doing O 
so O 
, O 
a O 
new O 
journey O 
toward O 
the O 
ultimate O 
organic O 
" O 
soft O 
" O 
materials O 
is O 
introduced O 
, O 
based O 
on O 
alkylated-π O 
molecular O 
design O 
. O 

method O 
for O 
the O 
separation O 
and O 
recovery O 
of O 
endocrine O 
- O 
disrupting O 
compound O 
bisphenol B-TRIVIAL 
AP I-TRIVIAL 
from O 
wastewater O 
. O 

removal O 
of O 
bisphenol B-TRIVIAL 
AP I-TRIVIAL 
( O 
BPAP B-ABBREVIATION 
) O 
by O 
a O 
multiwalled O 
carbon B-SYSTEMATIC 
nanotube O 
( O 
MWCNT O 
) O 
was O 
investigated O 
. O 
BPAP B-ABBREVIATION 
, O 
representing O 
typical O 
scenarios O 
for O 
the O 
BPAP B-ABBREVIATION 
-MWCNT O 
interactions O 
, O 
was O 
employed O 
as O 
a O 
probe O 
molecule O 
. O 
It O 
was O 
found O 
that O 
BPAP B-ABBREVIATION 
exhibited O 
great O 
adsorptive O 
affinity O 
to O 
MWCNT O 
, O 
and O 
the O 
adsorption O 
kinetics O 
equilibrium O 
was O 
arrived O 
within O 
4 O 
min O 
following O 
the O 
pseudo O 
- O 
second O 
- O 
order O 
model O 
. O 
The O 
overall O 
rate O 
process O 
was O 
mainly O 
controlled O 
by O 
the O 
external O 
mass O 
transfer O 
. O 
The O 
hydrogen B-SYSTEMATIC 
bond O 
, O 
hydrophobic O 
, O 
and O 
π-π O 
stacking O 
interactions O 
were O 
dominant O 
factors O 
for O 
the O 
strong O 
adsorption O 
of O 
BPAP B-ABBREVIATION 
, O 
instead O 
of O 
the O 
pH O 
ionic O 
strength O 
and O 
other O 
ionic O 
species O 
in O 
contaminated O 
water O 
. O 
The O 
MWCNT O 
has O 
higher O 
stability O 
within O 
8 O 
removal O 
- O 
regeneration O 
recycles O 
, O 
and O 
up O 
to O 
95% O 
of O 
recovery O 
could O 
be O 
obtained O 
by O 
eluting O 
the O 
adsorbed O 
BPAP B-ABBREVIATION 
on O 
MWCNT O 
adsorbent O 
using O 
ethanol B-SYSTEMATIC 
/ O 
sodium B-SYSTEMATIC 
hydrate I-SYSTEMATIC 
solution O 
. O 
The O 
results O 
of O 
the O 
experiment O 
on O 
real O 
samples O 
verified O 
the O 
effectiveness O 
for O 
the O 
recovery O 
and O 
removal O 
of O 
BPAP B-ABBREVIATION 
from O 
wastewater O 
samples O 
. O 

insulin O 
analog O 
therapy O 
is O 
the O 
most O 
common O 
method O 
of O 
introducing O 
insulin O 
replacement O 
therapy O 
for O 
the O 
majority O 
of O 
patients O 
with O 
type O 
2 O 
diabetes O 
mellitus O 
. O 
Long O 
- O 
acting O 
insulin O 
analogs O 
provide O 
relatively O 
peakless O 
and O 
more O 
physiologic O 
insulin O 
replacement O 
therapy O 
than O 
neutral O 
protaminated O 
Hagedorn O 
insulin O 
. O 
Recently O 
2 O 
new O 
basal O 
insulin O 
analogs O 
have O 
been O 
developed O 
with O 
superior O 
pharmacokinetic O 
and O 
pharmacodynamics O 
properties O 
; O 
insulin O 
degludec O 
and O 
a O 
pegylated O 
insulin O 
lispro O 
. O 
These O 
agents O 
are O 
generally O 
well O 
tolerated O 
and O 
have O 
been O 
evaluated O 
in O 
both O 
type O 
1 O 
and O 
type O 
2 O 
diabetes O 
. O 
In O 
this O 
article O 
we O 
review O 
the O 
results O 
of O 
clinical O 
trials O 
assessing O 
the O 
efficacy O 
, O 
safety O 
and O 
tolerability O 
of O 
these O 
newer O 
longer O 
- O 
acting O 
insulin O 
analogs O 
. O 
In O 
general O 
rates O 
of O 
hypoglycaemia O 
in O 
these O 
trials O 
were O 
low O 
, O 
glucose B-TRIVIAL 
control O 
was O 
comparable O 
to O 
currently O 
available O 
basal O 
insulin O 
analogs O 
, O 
and O 
rates O 
of O 
nocturnal O 
hypoglycaemia O 
were O 
significantly O 
and O 
substantially O 
lower O 
. O 
While O 
further O 
study O 
will O 
be O 
required O 
, O 
advances O 
in O 
basal O 
insulin O 
replacement O 
may O 
offer O 
important O 
advantages O 
over O 
existing O 
options O 
for O 
starting O 
insulin O 
strategies O 
. O 

observation O 
of O 
a O 
bent O 
carbonyl B-FAMILY 
ligand O 
in O 
a O 
19-electron O 
transition B-FAMILY 
metal I-FAMILY 
complex O 
. O 

photochemistry O 
of O 
[CpRu(CO)2]2 B-FORMULA 
in O 
P(OMe)3 B-FORMULA 
/ O 
CH2Cl2 B-FORMULA 
solution O 
has O 
been O 
studied O 
using O 
picosecond O 
time O 
- O 
resolved O 
infrared O 
( O 
TRIR O 
) O 
spectroscopy O 
. O 
Photolysis O 
at O 
400 O 
nm O 
leads O 
to O 
the O 
formation O 
of O 
17-electron O 
CpRu(CO)2(•) B-FORMULA 
radicals O 
, O 
which O 
react O 
on O 
the O 
picosecond O 
time O 
scale O 
to O 
form O 
19-electron O 
CpRu(CO)2P(OMe)3(•) B-FORMULA 
adducts O 
. O 
The O 
TRIR O 
spectra O 
of O 
this O 
adduct O 
display O 
an O 
unusually O 
low O 
CO B-FORMULA 
stretching O 
frequency O 
for O 
the O 
antisymmetric O 
CO B-FORMULA 
stretching O 
mode O 
, O 
suggesting O 
that O 
one O 
carbonyl B-FAMILY 
ligand O 
adopts O 
a O 
bent O 
configuration O 
to O 
avoid O 
a O 
19-electron O 
count O 
at O 
the O 
metal O 
center O 
. O 
This O 
spectral O 
assignment O 
is O 
supported O 
by O 
analogous O 
experiments O 
on O 
[CpFe(CO)2]2 B-FORMULA 
in O 
the O 
same O 
solvent O 
, O 
combined O 
with O 
DFT O 
studies O 
on O 
the O 
structures O 
of O 
the O 
19-electron O 
adducts O 
. O 
The O 
DFT O 
results O 
predict O 
a O 
bent O 
CO B-FORMULA 
ligand O 
in O 
CpRu(CO)2P(OMe)3(•) B-FORMULA 
, O 
whereas O 
approximately O 
linear O 
Fe-C-O B-FORMULA 
bond O 
angles O 
are O 
predicted O 
for O 
CpFe(CO)2P(OMe)3(•) B-FORMULA 
. O 
The O 
observation O 
of O 
a O 
bent O 
CO B-FORMULA 
ligand O 
in O 
the O 
19-electron O 
ruthenium B-SYSTEMATIC 
adduct O 
is O 
a O 
surprising O 
result O 
, O 
and O 
it O 
provides O 
new O 
insight O 
into O 
the O 
solution O 
- O 
phase O 
behavior O 
of O 
19-electron O 
complexes O 
. O 
TRIR O 
spectra O 
were O 
also O 
collected O 
for O 
[CpRu(CO)2]2 B-FORMULA 
in O 
neat O 
CH2Cl2 B-FORMULA 
, O 
and O 
it O 
is O 
interesting O 
to O 
note O 
that O 
no O 
singly O 
bridged O 
[CpRu(CO)]2(μ-CO) B-FORMULA 
photoproduct O 
was O 
observed O 
to O 
form O 
following O 
400- O 
or O 
267-nm O 
excitation O 
, O 
despite O 
previous O 
observations O 
of O 
this O 
species O 
on O 
longer O 
time O 
scales O 
. O 

responsive O 
hyaluronic O 
Acid O 
nanocapsules O 
containing O 
polyhexanide B-FAMILY 
and O 
their O 
exposure O 
to O 
bacteria O 
to O 
prevent O 
infection O 
. O 

nanodevices O 
could O 
bring O 
coatings O 
of O 
plastic O 
materials O 
and O 
wound O 
dressings O 
a O 
big O 
step O 
forward O 
if O 
the O 
release O 
of O 
the O 
antibacterial O 
agents O 
could O 
be O 
triggered O 
by O 
the O 
presence O 
of O 
the O 
bacteria O 
themselves O 
. O 
Here O 
, O 
we O 
show O 
that O 
novel O 
hyaluronic O 
acid O 
( O 
HA O 
) O 
- O 
based O 
nanocapsules O 
containing O 
the O 
antimicrobial O 
agent O 
polyhexanide B-FAMILY 
are O 
specifically O 
cleaved O 
in O 
the O 
presence O 
of O 
hyaluronidase O 
, O 
a O 
factor O 
of O 
pathogenicity O 
and O 
invasion O 
for O 
bacteria O 
like O 
Staphylococcus O 
aureus O 
and O 
Escherichia O 
coli O 
. O 
This O 
resulted O 
in O 
an O 
efficient O 
killing O 
of O 
the O 
pathogenic O 
bacteria O 
by O 
the O 
antimicrobial O 
agent O 
. O 
The O 
formation O 
of O 
different O 
polymeric O 
nanocapsules O 
was O 
achieved O 
through O 
a O 
polyaddition O 
reaction O 
in O 
inverse O 
miniemulsion O 
. O 
After O 
the O 
synthesis O 
, O 
the O 
nanocapsules O 
were O 
transferred O 
to O 
an O 
aqueous O 
medium O 
and O 
investigated O 
in O 
terms O 
of O 
size O 
, O 
size O 
distribution O 
, O 
functionality O 
, O 
and O 
morphology O 
using O 
dynamic O 
light O 
scattering O 
, O 
zeta O 
potential O 
measurements O 
and O 
scanning O 
electron O 
microscopy O 
. O 
The O 
enzyme O 
triggered O 
release O 
of O 
a O 
model O 
dye O 
and O 
the O 
antimicrobial O 
polyhexanide B-FAMILY 
was O 
monitored O 
using O 
fluorescence O 
and O 
UV O 
spectroscopy O 
. O 
The O 
stability O 
of O 
the O 
nanocapsules O 
in O 
several O 
biological O 
media O 
was O 
tested O 
and O 
the O 
interaction O 
of O 
nanocapsules O 
with O 
human O 
serum O 
protein O 
was O 
studied O 
using O 
isothermal O 
titration O 
calorimetry O 
. O 
The O 
antibacterial O 
effectiveness O 
is O 
demonstrated O 
by O 
determination O 
of O 
the O 
antibacterial O 
activity O 
and O 
determination O 
of O 
the O 
minimal O 
bactericidal O 
concentration O 
( O 
MBC O 
) O 
. O 

, O 
optimization O 
, O 
in O 
vivo O 
pharmacokinetic O 
, O 
behavioral O 
and O 
biochemical O 
estimations O 
of O 
minocycline B-TRIVIAL 
loaded O 
chitosan O 
nanoparticles O 
for O 
enhanced O 
brain O 
uptake O 
. O 

minocycline B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
MH O 
) O 
, O 
at O 
higher O 
doses O 
, O 
is O 
useful O 
in O 
the O 
treatment O 
of O 
neurodegenerative O 
disorders O 
and O 
owing O 
to O 
its O 
antioxidant O 
potential O 
, O 
it O 
may O 
have O 
nootropic O 
effects O 
. O 
MH O 
loaded O 
nanoparticles O 
( O 
MHNP O 
) O 
were O 
coated O 
with O 
tween B-FAMILY 
80 I-FAMILY 
( O 
cMHNP O 
) O 
to O 
improve O 
its O 
brain O 
uptake O 
followed O 
by O 
their O 
optimization O 
employing O 
two O 
factor O 
- O 
three O 
level O 
(3(2)) O 
central O 
composite O 
design O 
( O 
CCD O 
) O 
in O 
order O 
to O 
minimize O 
particle O 
size O 
and O 
maximize O 
drug O 
entrapment O 
efficiency O 
( O 
DEE O 
) O 
and O 
validated O 
. O 
The O 
optimized O 
formulations O 
were O 
further O 
subjected O 
to O 
in O 
vitro O 
drug O 
release O 
study O 
; O 
in O 
vivo O 
biodistribution O 
studies O 
in O 
male O 
wistar O 
rats O 
. O 
The O 
pharmacodynamic O 
study O 
was O 
carried O 
out O 
using O 
elevated O 
plus O 
maze O 
( O 
EPM O 
) O 
and O 
Morris O 
water O 
maze O 
( O 
MWM O 
) O 
behavioral O 
models O 
for O 
nootropic O 
activity O 
in O 
swiss O 
albino O 
mice O 
; O 
and O 
biochemical O 
estimations O 
( O 
acetylcholine B-SYSTEMATIC 
esterase O 
, O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
, O 
malondialdehyde B-TRIVIAL 
and O 
brain O 
nitrite B-SYSTEMATIC 
level O 
) O 
. O 
After O 
intravenous O 
( O 
i.v O 
. O 
) O 
administration O 
, O 
the O 
concentration O 
of O 
MH O 
in O 
brain O 
of O 
cMHNP O 
( O 
6.21±0.64 O 
µg O 
/ O 
mL O 
) O 
treated O 
rats O 
was O 
significantly O 
higher O 
with O 
MH O 
solution O 
treated O 
( O 
0.70±0.06 O 
µg O 
/ O 
mL O 
) O 
as O 
well O 
as O 
MHNP O 
( O 
1.03±0.12 O 
µg O 
/ O 
mL O 
) O 
treated O 
animals O 
. O 
Pharmacodynamic O 
studies O 
revealed O 
a O 
significant O 
improvement O 
in O 
memory O 
of O 
MH O 
, O 
MHNP O 
and O 
cMHNP O 
treated O 
swiss O 
albino O 
mice O 
than O 
saline O 
treated O 
control O 
group O 
. O 
However O 
, O 
cMHNP O 
revealed O 
maximum O 
decrease O 
in O 
transfer O 
latency O 
( O 
TL O 
) O 
in O 
EPM O 
and O 
maximum O 
increase O 
in O 
time O 
spent O 
in O 
target O 
quadrant O 
( O 
TSTQ O 
) O 
in O 
MWM O 
. O 
Although O 
cMHNP O 
did O 
not O 
produce O 
significant O 
change O 
in O 
brain O 
acetylcholinesterase O 
, O 
but O 
, O 
significantly O 
increased O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
, O 
malondialdehyde B-TRIVIAL 
and O 
reduced O 
brain O 
nitrite B-SYSTEMATIC 
level O 
as O 
compared O 
to O 
saline O 
, O 
MH O 
solution O 
and O 
MHNP O 
treated O 
groups O 
. O 
The O 
results O 
suggest O 
that O 
cMHNP O 
is O 
a O 
promising O 
candidate O 
for O 
improved O 
brain O 
uptake O 
of O 
MH O 
with O 
better O 
nootropic O 
effect O 
. O 

of O 
7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole B-SYSTEMATIC 
( O 
TASP0382088 B-IDENTIFIER 
) O 
: O 
a O 
potent O 
and O 
selective O 
transforming O 
growth O 
factor-β O 
type O 
I O 
receptor O 
inhibitor O 
as O 
a O 
topical O 
drug O 
for O 
alopecia O 
. O 

11 O 
( O 
TASP0382088 B-IDENTIFIER 
) O 
was O 
synthesized O 
and O 
evaluated O 
as O 
transforming O 
growth O 
factor-β O 
( O 
TGF-β O 
) O 
type O 
I O 
receptor O 
( O 
also O 
known O 
as O 
activin O 
receptor O 
- O 
like O 
kinase O 
5 O 
or O 
ALK5 O 
) O 
inhibitor O 
. O 
Compound O 
11 O 
, O 
a O 
potent O 
and O 
selective O 
ALK5 O 
inhibitor O 
, O 
exhibited O 
good O 
enzyme O 
inhibitory O 
activity O 
( O 
IC50=4.8 O 
nM O 
) O 
as O 
well O 
as O 
inhibitory O 
activity O 
against O 
TGF-β-induced O 
Smad2 O 
/ O 
3 O 
phosphorylation O 
at O 
a O 
cellular O 
level O 
( O 
IC50=17 O 
nM O 
) O 
. O 
The O 
introduction O 
of O 
a O 
methoxy B-SYSTEMATIC 
group O 
to O 
the O 
benzothiazole B-SYSTEMATIC 
ring O 
in O 
1 O 
and O 
the O 
break O 
up O 
of O 
the O 
planarity O 
between O 
the O 
imidazole B-SYSTEMATIC 
ring O 
and O 
the O 
thiazole B-SYSTEMATIC 
ring O 
improved O 
the O 
solubility O 
in O 
the O 
lotion O 
base O 
of O 
11 O 
. O 
Furthermore O 
, O 
the O 
topical O 
application O 
of O 
3% O 
11 O 
lotion O 
significantly O 
inhibited O 
Smad2 O 
phosphorylation O 
in O 
mouse O 
skin O 
at O 
8 O 
h O 
after O 
application O 
( O 
71% O 
inhibition O 
, O 
compared O 
with O 
vehicle O 
- O 
treated O 
animals O 
) O 
. O 

- O 
organizing O 
map O 
analysis O 
using O 
multivariate O 
data O 
from O 
theophylline B-TRIVIAL 
tablets O 
predicted O 
by O 
a O 
thin O 
- O 
plate O 
spline O 
interpolation O 
. O 

" O 
quality O 
by O 
design O 
" O 
concept O 
in O 
pharmaceutical O 
formulation O 
development O 
requires O 
the O 
establishment O 
of O 
a O 
science O 
- O 
based O 
rationale O 
and O 
a O 
design O 
space O 
. O 
We O 
integrated O 
thin O 
- O 
plate O 
spline O 
( O 
TPS O 
) O 
interpolation O 
and O 
Kohonen's O 
self O 
- O 
organizing O 
map O 
( O 
SOM O 
) O 
to O 
visualize O 
the O 
latent O 
structure O 
underlying O 
causal O 
factors O 
and O 
pharmaceutical O 
responses O 
. O 
As O 
a O 
model O 
pharmaceutical O 
product O 
, O 
theophylline B-TRIVIAL 
tablets O 
were O 
prepared O 
based O 
on O 
a O 
standard O 
formulation O 
. O 
The O 
tensile O 
strength O 
, O 
disintegration O 
time O 
, O 
and O 
stability O 
of O 
these O 
variables O 
were O 
measured O 
as O 
response O 
variables O 
. O 
These O 
responses O 
were O 
predicted O 
quantitatively O 
based O 
on O 
nonlinear O 
TPS O 
. O 
A O 
large O 
amount O 
of O 
data O 
on O 
these O 
tablets O 
was O 
generated O 
and O 
classified O 
into O 
several O 
clusters O 
using O 
an O 
SOM O 
. O 
The O 
experimental O 
values O 
of O 
the O 
responses O 
were O 
predicted O 
with O 
high O 
accuracy O 
, O 
and O 
the O 
data O 
generated O 
for O 
the O 
tablets O 
were O 
classified O 
into O 
several O 
distinct O 
clusters O 
. O 
The O 
SOM O 
feature O 
map O 
allowed O 
us O 
to O 
analyze O 
the O 
global O 
and O 
local O 
correlations O 
between O 
causal O 
factors O 
and O 
tablet O 
characteristics O 
. O 
The O 
results O 
of O 
this O 
study O 
suggest O 
that O 
increasing O 
the O 
proportion O 
of O 
microcrystalline O 
cellulose O 
( O 
MCC O 
) O 
improved O 
the O 
tensile O 
strength O 
and O 
the O 
stability O 
of O 
tensile O 
strength O 
of O 
these O 
theophylline B-TRIVIAL 
tablets O 
. O 
In O 
addition O 
, O 
the O 
proportion O 
of O 
MCC O 
has O 
an O 
optimum O 
value O 
for O 
disintegration O 
time O 
and O 
stability O 
of O 
disintegration O 
. O 
Increasing O 
the O 
proportion O 
of O 
magnesium B-SYSTEMATIC 
stearate I-SYSTEMATIC 
extended O 
disintegration O 
time O 
. O 
Increasing O 
the O 
compression O 
force O 
improved O 
tensile O 
strength O 
, O 
but O 
degraded O 
the O 
stability O 
of O 
disintegration O 
. O 
This O 
technique O 
provides O 
a O 
better O 
understanding O 
of O 
the O 
relationships O 
between O 
causal O 
factors O 
and O 
pharmaceutical O 
responses O 
in O 
theophylline B-TRIVIAL 
tablet O 
formulations O 
. O 

of O 
aromatic O 
components O 
with O 
excellent O 
fragrance O 
properties O 
and O 
biological O 
activities O 
: O 
β-ionols B-FAMILY 
with O 
antimelanogenetic O 
effects O 
and O 
their O 
asymmetric O 
syntheses O 
. O 

enantiomers O 
of O 
dihydro-β-ionol B-SYSTEMATIC 
and O 
β-ionol B-TRIVIAL 
, O 
contained O 
in O 
the O 
aromatic O 
components O 
of O 
Osmanthus O 
flower O 
and O 
of O 
Hakuto O 
peach O 
, O 
were O 
obtained O 
with O 
high O 
optical O 
purity O 
by O 
lipase O 
- O 
catalyzed O 
kinetic O 
resolution O 
of O 
the O 
racemates O 
. O 
It O 
was O 
found O 
that O 
all O 
these O 
enantiomers O 
had O 
different O 
characteristic O 
favorable O 
scents O 
and O 
high O 
antimelanogenetic O 
effects O 
. O 
The O 
absolute O 
configuration O 
and O 
the O 
enantiomer O 
ratios O 
of O 
dihydro-β-ionol B-SYSTEMATIC 
in O 
the O 
aromatic O 
components O 
of O 
Osmanthus O 
flower O 
and O 
of O 
Hakuto O 
peach O 
were O 
determined O 
. O 
The O 
asymmetric O 
synthesis O 
of O 
(R)-dihydro-β-ionol B-SYSTEMATIC 
, O 
one O 
of O 
the O 
most O 
valuable O 
raw O 
materials O 
for O 
fragrance O 
and O 
flavor O 
, O 
was O 
performed O 
from O 
inexpensive O 
β-ionone B-TRIVIAL 
via O 
lipase O 
- O 
catalyzed O 
dynamic O 
kinetic O 
resolution O 
followed O 
by O 
reduction O 
. O 

new O 
orcinol B-TRIVIAL 
-conjugated O 
hydrolysable O 
tannins B-FAMILY 
from O 
the O 
leaves O 
of O 
Cleyera O 
japonica O 
. O 

new O 
orcinol B-TRIVIAL 
( O 
3-hydroxy-5-methylphenol B-SYSTEMATIC 
)-conjugated O 
hydrolysable O 
tannins B-FAMILY 
, O 
together O 
with O 
two O 
known O 
compounds O 
were O 
isolated O 
from O 
the O 
leaves O 
of O 
Cleyera O 
japonica O 
( O 
CJ O 
) O 
, O 
and O 
have O 
been O 
tentatively O 
named O 
cleyeratannin B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
, O 
cleyeratannin B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
and O 
cleyeratannin B-TRIVIAL 
C I-TRIVIAL 
( O 
3 O 
) O 
. O 
The O 
chemical O 
structures O 
of O 
these O 
compounds O 
were O 
elucidated O 
using O 
1 O 
dimensional O 
( O 
1D O 
) O 
/ O 
2D O 
NMR O 
and O 
high O 
resolution O 
FAB-MS O 
, O 
and O 
the O 
absolute O 
configuration O 
was O 
confirmed O 
by O 
circular O 
dichroism O 
( O 
CD O 
) O 
. O 
To O 
evaluate O 
their O 
anti-oxidative O 
activities O 
, O 
1,1-diphenyl-2-picrylhydrazyl B-SYSTEMATIC 
( O 
DPPH B-ABBREVIATION 
) O 
/ O 
free O 
radical O 
scavenging O 
activity O 
and O 
nitroblue B-TRIVIAL 
tetrazolium I-TRIVIAL 
( O 
NBT B-ABBREVIATION 
)/ O 
superoxide B-TRIVIAL 
anion O 
scavenging O 
activity O 
were O 
determined O 
. O 

represses O 
androgen B-FAMILY 
receptor O 
transactivation O 
in O 
prostate O 
cancer O 
. O 

receptor O 
( O 
AR O 
) O 
signaling O 
is O 
essential O 
for O 
prostate O 
cancer O 
( O 
PCa O 
) O 
development O 
in O 
humans O 
. O 
The O 
initiation O 
of O 
prostate O 
malignancy O 
and O 
progression O 
to O 
a O 
castration O 
- O 
resistant O 
stage O 
are O 
largely O 
contributed O 
by O 
the O 
modulation O 
of O 
AR O 
activity O 
through O 
its O 
coregulatory O 
proteins O 
. O 
We O 
and O 
others O 
previously O 
reported O 
that O 
p14 O 
alternative O 
reading O 
frame O 
( O 
ARF O 
) O 
expression O 
is O 
positively O 
correlated O 
with O 
the O 
disease O 
progression O 
and O 
severity O 
of O 
PCa O 
. O 
Here O 
, O 
we O 
provide O 
evidence O 
that O 
p14ARF O 
physically O 
interacts O 
with O 
AR O 
and O 
functions O 
as O 
an O 
AR O 
corespressor O 
in O 
both O 
an O 
androgen B-FAMILY 
-dependent O 
and O 
androgen B-FAMILY 
-independent O 
manner O 
. O 
Endogenous O 
ARF O 
( O 
p14ARF O 
in O 
human O 
and O 
p19ARF O 
in O 
mouse O 
) O 
and O 
AR O 
colocalize O 
in O 
both O 
human O 
PCa O 
cells O 
in O 
vitro O 
and O 
PCa O 
tissues O 
of O 
mouse O 
and O 
human O 
in O 
vivo O 
. O 
Overexpression O 
of O 
p14ARF O 
in O 
PCa O 
cells O 
significantly O 
attenuates O 
the O 
activities O 
of O 
androgen B-FAMILY 
response O 
region O 
(ARR2)-probasin O 
and O 
prostate O 
- O 
specific O 
antigen O 
( O 
PSA O 
) O 
promoters O 
. O 
The O 
forced O 
expression O 
of O 
p14ARF O 
in O 
cells O 
resulted O 
in O 
a O 
suppression O 
of O 
PSA O 
and O 
NK O 
transcription O 
factor O 
locus O 
1 O 
( O 
NKX3.1 O 
) O 
expression O 
. O 
Conversely O 
, O 
knockdown O 
of O 
endogenous O 
p14ARF O 
in O 
human O 
PCa O 
cells O 
with O 
short O 
hairpin O 
RNA O 
enhanced O 
AR O 
transactivation O 
activities O 
in O 
a O 
dose O 
- O 
dependent O 
and O 
p53 O 
- O 
independent O 
manner O 
. O 
Furthermore O 
, O 
we O 
demonstrated O 
that O 
p14ARF O 
binds O 
to O 
both O 
the O 
N B-FORMULA 
-terminal O 
domain O 
and O 
the O 
ligand O 
- O 
binding O 
domain O 
of O 
AR O 
, O 
and O 
the O 
human O 
double O 
minute O 
2 O 
( O 
HDM2 O 
) O 
- O 
binding O 
motif O 
of O 
p14ARF O 
is O 
required O 
for O 
the O 
interaction O 
of O 
p14ARF O 
and O 
AR O 
proteins O 
. O 
p14ARF O 
perturbs O 
the O 
androgen B-FAMILY 
-induced O 
interaction O 
between O 
the O 
N B-FORMULA 
terminus O 
and O 
C B-FORMULA 
terminus O 
of O 
AR O 
. O 
Most O 
importantly O 
, O 
we O 
observed O 
that O 
the O 
expression O 
of O 
PSA O 
is O 
reversely O 
correlated O 
with O 
p14ARF O 
in O 
human O 
prostate O 
tissues O 
. O 
Taken O 
together O 
, O 
our O 
results O 
reveal O 
a O 
novel O 
function O 
of O 
ARF O 
in O 
modulation O 
of O 
AR O 
transactivation O 
in O 
PCa O 
. O 

phosphoethanolamine I-FAMILY 
biosynthesis O 
in O 
Drosophila O 
is O 
mediated O 
by O 
a O 
unique O 
ethanolamine B-SYSTEMATIC 
phosphotransferase O 
in O 
the O 
Golgi O 
lumen O 
. O 

( O 
SM O 
) O 
is O 
a O 
vital O 
component O 
of O 
mammalian O 
membranes O 
, O 
providing O 
mechanical O 
stability O 
and O 
a O 
structural O 
framework O 
for O 
plasma O 
membrane O 
organization O 
. O 
Its O 
production O 
involves O 
the O 
transfer O 
of O 
phosphocholine B-SYSTEMATIC 
from O 
phosphatidylcholine B-FAMILY 
onto O 
ceramide B-FAMILY 
, O 
a O 
reaction O 
catalyzed O 
by O 
SM O 
synthase O 
in O 
the O 
Golgi O 
lumen O 
. O 
Drosophila O 
lacks O 
SM O 
and O 
instead O 
synthesizes O 
the O 
SM O 
analogue O 
ceramide B-FAMILY 
phosphoethanolamine I-FAMILY 
( O 
CPE B-ABBREVIATION 
) O 
as O 
the O 
principal O 
membrane O 
sphingolipid B-FAMILY 
. O 
The O 
corresponding O 
CPE B-ABBREVIATION 
synthase O 
shares O 
mechanistic O 
features O 
with O 
enzymes O 
mediating O 
phospholipid O 
biosynthesis O 
via O 
the O 
Kennedy O 
pathway O 
. O 
Using O 
a O 
functional O 
cloning O 
strategy O 
, O 
we O 
here O 
identified O 
a O 
CDP B-ABBREVIATION 
- O 
ethanolamine B-SYSTEMATIC 
: O 
ceramide B-FAMILY 
ethanolamine B-SYSTEMATIC 
phosphotransferase O 
as O 
the O 
enzyme O 
responsible O 
for O 
CPE B-ABBREVIATION 
production O 
in O 
Drosophila O 
. O 
CPE B-ABBREVIATION 
synthase O 
constitutes O 
a O 
new O 
branch O 
within O 
the O 
CDP B-ABBREVIATION 
- O 
alcohol B-FAMILY 
phosphotransferase O 
superfamily O 
with O 
homologues O 
in O 
Arthropoda O 
( O 
insects O 
, O 
spiders O 
, O 
mites O 
, O 
scorpions O 
) O 
, O 
Cnidaria O 
( O 
Hydra O 
, O 
sea O 
anemones O 
) O 
, O 
and O 
Mollusca O 
( O 
oysters O 
) O 
but O 
not O 
in O 
most O 
other O 
animal O 
phyla O 
. O 
The O 
enzyme O 
resides O 
in O 
the O 
Golgi O 
complex O 
with O 
its O 
active O 
site O 
facing O 
the O 
lumen O 
, O 
contrary O 
to O 
the O 
membrane O 
topology O 
of O 
other O 
CDP B-ABBREVIATION 
- O 
alcohol B-FAMILY 
phosphotransferases O 
. O 
Our O 
findings O 
open O 
up O 
an O 
important O 
new O 
avenue O 
to O 
address O 
the O 
biological O 
role O 
of O 
CPE B-ABBREVIATION 
, O 
an O 
enigmatic O 
membrane O 
constituent O 
of O 
a O 
wide O 
variety O 
of O 
invertebrate O 
and O 
marine O 
organisms O 
. O 

gas-phase O 
reaction O 
of O 
methane B-SYSTEMATIC 
sulfonic I-SYSTEMATIC 
acid I-SYSTEMATIC 
with O 
the O 
hydroxyl B-SYSTEMATIC 
radical O 
without O 
and O 
with O 
water O 
vapor O 
. O 

gas O 
phase O 
reaction O 
between O 
methane B-SYSTEMATIC 
sulfonic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
CH3SO3H B-FORMULA 
; O 
MSA B-ABBREVIATION 
) O 
and O 
the O 
hydroxyl B-SYSTEMATIC 
radical O 
( O 
HO B-FORMULA 
) O 
, O 
without O 
and O 
with O 
a O 
water O 
molecule O 
, O 
was O 
investigated O 
with O 
DFT-B3LYP O 
and O 
CCSD(T)-F12 O 
methods O 
. O 
For O 
the O 
bare O 
reaction O 
we O 
have O 
found O 
two O 
reaction O 
mechanisms O 
, O 
involving O 
proton O 
coupled O 
electron O 
transfer O 
and O 
hydrogen B-SYSTEMATIC 
atom O 
transfer O 
processes O 
that O 
produce O 
CH3SO3 B-FORMULA 
and O 
H2O B-FORMULA 
. O 
We O 
also O 
found O 
a O 
third O 
reaction O 
mechanism O 
involving O 
the O 
double O 
proton O 
transfer O 
process O 
, O 
where O 
the O 
products O 
and O 
reactants O 
are O 
identical O 
. O 
The O 
computed O 
rate O 
constant O 
for O 
the O 
oxidation O 
process O 
is O 
8.3 O 
× O 
10(-15) O 
cm(3) O 
s(-1) O 
molecule(-1) O 
. O 
CH3SO3H B-FORMULA 
forms O 
two O 
very O 
stable O 
complexes O 
with O 
water O 
with O 
computed O 
binding O 
energies O 
of O 
about O 
10 O 
kcal O 
mol(-1) O 
. O 
The O 
presence O 
of O 
a O 
single O 
water O 
molecule O 
makes O 
the O 
reaction O 
between O 
CH3SO3H B-FORMULA 
and O 
HO B-FORMULA 
much O 
more O 
complex O 
, O 
introducing O 
a O 
new O 
reaction O 
that O 
consists O 
in O 
the O 
interchange O 
of O 
H2O B-FORMULA 
between O 
HO B-FORMULA 
and O 
CH3SO3H B-FORMULA 
. O 
Our O 
kinetic O 
calculations O 
show O 
that O 
99.5% O 
of O 
the O 
reaction O 
involves O 
this O 
interchange O 
of O 
the O 
water O 
molecule O 
and O 
, O 
consequently O 
, O 
water O 
vapor O 
does O 
not O 
play O 
any O 
role O 
in O 
the O 
oxidation O 
reaction O 
of O 
methane B-SYSTEMATIC 
sulfonic I-SYSTEMATIC 
acid I-SYSTEMATIC 
by O 
the O 
hydroxyl B-SYSTEMATIC 
radical O 
. O 

in O 
thermoresponsive O 
polymers O 
has O 
steadily O 
grown O 
over O 
many O 
decades O 
, O 
and O 
a O 
great O 
deal O 
of O 
work O 
has O 
been O 
dedicated O 
to O 
developing O 
temperature O 
sensitive O 
macromolecules O 
that O 
can O 
be O 
crafted O 
into O 
new O 
smart O 
materials O 
. O 
However O 
, O 
the O 
overwhelming O 
majority O 
of O 
previously O 
reported O 
temperature O 
- O 
responsive O 
polymers O 
are O 
based O 
on O 
poly(N-isopropylacrylamide) B-SYSTEMATIC 
( O 
PNIPAM B-ABBREVIATION 
) O 
, O 
despite O 
the O 
fact O 
that O 
a O 
wide O 
range O 
of O 
other O 
thermoresponsive O 
polymers O 
have O 
demonstrated O 
similar O 
promise O 
for O 
the O 
preparation O 
of O 
adaptive O 
materials O 
. O 
Herein O 
, O 
we O 
aim O 
to O 
highlight O 
recent O 
results O 
that O 
involve O 
thermoresponsive O 
systems O 
that O 
have O 
not O 
yet O 
been O 
as O 
fully O 
considered O 
. O 
Many O 
of O 
these O 
(co)polymers O 
represent O 
clear O 
opportunities O 
for O 
advancements O 
in O 
emerging O 
biomedical O 
and O 
materials O 
fields O 
due O 
to O 
their O 
increased O 
biocompatibility O 
and O 
tuneable O 
response O 
. O 
By O 
highlighting O 
recent O 
examples O 
of O 
newly O 
developed O 
thermoresponsive O 
polymer O 
systems O 
, O 
we O 
hope O 
to O 
promote O 
the O 
development O 
of O 
new O 
generations O 
of O 
smart O 
materials O 
. O 

a I-TRIVIAL 
in O 
the O 
active O 
branch O 
of O 
the O 
reaction O 
center O 
of O 
rhodobacter O 
sphaeroides O 
is O 
not O 
disturbed O 
by O 
the O 
protein O 
matrix O 
as O 
shown O 
by O 
13C B-FORMULA 
photo-CIDNP O 
MAS O 
NMR O 
. O 

electronic O 
structure O 
of O 
bacteriopheophytin B-TRIVIAL 
a I-TRIVIAL 
( O 
BPhe B-ABBREVIATION 
a I-ABBREVIATION 
) O 
, O 
the O 
primary O 
electron O 
acceptor O 
( O 
ΦA O 
) O 
in O 
photosynthetic O 
reaction O 
centers O 
( O 
RCs O 
) O 
of O 
the O 
purple O 
bacterium O 
Rhodobacter O 
sphaeroides O 
, O 
is O 
investigated O 
by O 
photochemically O 
induced O 
dynamic O 
nuclear O 
polarization O 
( O 
photo-CIDNP O 
) O 
magic O 
- O 
angle O 
spinning O 
( O 
MAS O 
) O 
NMR O 
spectroscopy O 
at O 
atomic O 
resolution O 
. O 
By O 
using O 
various O 
isotope O 
labeling O 
systems O 
, O 
introduced O 
by O 
adding O 
different O 
(13)C B-FORMULA 
selectively O 
labeled O 
δ-aminolevulinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
precursors O 
in O 
the O 
growing O 
medium O 
of O 
R O 
. O 
sphaeroides O 
wild O 
type O 
( O 
WT O 
) O 
, O 
we O 
were O 
able O 
to O 
extract O 
light O 
- O 
induced O 
(13)C B-FORMULA 
NMR O 
signals O 
originating O 
from O 
the O 
primary O 
electron O 
acceptor O 
. O 
The O 
assignments O 
are O 
backed O 
by O 
theoretical O 
calculations O 
. O 
By O 
comparison O 
of O 
these O 
chemical O 
shifts O 
to O 
those O 
obtained O 
from O 
monomeric O 
BPhe B-ABBREVIATION 
a I-ABBREVIATION 
in O 
solution O 
, O 
it O 
is O 
demonstrated O 
that O 
ΦA O 
in O 
the O 
active O 
branch O 
appears O 
to O 
be O 
electronically O 
close O 
to O 
free O 
bacteriopheophytin B-TRIVIAL 
. O 
Hence O 
, O 
there O 
is O 
little O 
effect O 
of O 
the O 
protein O 
surrounding O 
on O 
the O 
cofactor O 
functionally O 
which O 
contributes O 
with O 
its O 
standard O 
redox O 
potential O 
to O 
the O 
electron O 
transfer O 
process O 
that O 
is O 
asymmetric O 
. O 

enantioselective O 
rhodium B-SYSTEMATIC 
-catalyzed O 
[ O 
2 O 
+ O 
2 O 
+ O 
2 O 
] O 
cycloaddition O 
of O 
diynes B-FAMILY 
to O 
sulfonimines B-FAMILY 
. O 

new O 
asymmetric O 
[ O 
2 O 
+ O 
2 O 
+ O 
2 O 
] O 
cycloaddition O 
of O 
diynes B-FAMILY 
to O 
sulfonimines B-FAMILY 
under O 
rhodium B-SYSTEMATIC 
catalysis O 
that O 
provides O 
the O 
corresponding O 
enantioenriched O 
1,2-dihydropyridines B-FAMILY 
in O 
good O 
yields O 
is O 
described O 
. O 

and O 
its O 
derivatives O 
: O 
a O 
review O 
on O 
recent O 
progress O 
in O 
biological O 
activities O 
. O 

1,3,4-thiadiazole B-SYSTEMATIC 
nucleus O 
is O 
one O 
of O 
the O 
most O 
important O 
and O 
well O 
- O 
known O 
heterocyclic O 
nuclei O 
, O 
which O 
is O 
a O 
common O 
and O 
integral O 
feature O 
of O 
a O 
variety O 
of O 
natural O 
products O 
and O 
medicinal O 
agents O 
. O 
Thiadiazole B-SYSTEMATIC 
nucleus O 
is O 
present O 
as O 
a O 
core O 
structural O 
component O 
in O 
an O 
array O 
of O 
drug O 
categories O 
such O 
as O 
antimicrobial O 
, O 
anti-inflammatory O 
, O 
analgesic O 
, O 
antiepileptic O 
, O 
antiviral O 
, O 
antineoplastic O 
, O 
and O 
antitubercular O 
agents O 
. O 
The O 
broad O 
and O 
potent O 
activity O 
of O 
thiadiazole B-SYSTEMATIC 
and O 
their O 
derivatives O 
has O 
established O 
them O 
as O 
pharmacologically O 
significant O 
scaffolds O 
. O 
In O 
this O 
study O 
, O 
an O 
attempt O 
has O 
been O 
made O 
with O 
recent O 
research O 
findings O 
on O 
this O 
nucleus O 
, O 
to O 
review O 
the O 
structural O 
modifications O 
on O 
different O 
thiadiazole B-SYSTEMATIC 
derivatives O 
for O 
various O 
pharmacological O 
activities O 
. O 

: O 
The O 
mGlu2 O 
receptor O 
, O 
which O 
belongs O 
to O 
the O 
group O 
II O 
subfamily O 
of O 
metabotropic O 
glutamate B-TRIVIAL 
receptors O 
( O 
mGlu O 
) O 
along O 
with O 
the O 
mGlu3 O 
receptor O 
, O 
has O 
proven O 
to O 
be O 
of O 
particular O 
importance O 
in O 
neuropharmacology O 
. O 
Preferentially O 
expressed O 
on O 
presynaptic O 
nerve O 
terminals O 
, O 
the O 
mGlu2 O 
receptor O 
negatively O 
modulates O 
glutamate B-TRIVIAL 
and O 
GABA B-ABBREVIATION 
release O 
and O 
is O 
widely O 
distributed O 
in O 
the O 
brain O 
. O 
High O 
levels O 
of O 
mGlu2 O 
receptors O 
are O 
seen O 
in O 
brain O 
areas O 
such O 
as O 
prefrontal O 
cortex O 
, O 
hippocampus O 
and O 
amygdala O 
where O 
glutamate B-TRIVIAL 
hyperfunction O 
may O 
be O 
implicated O 
in O 
disorders O 
and O 
diseases O 
such O 
as O 
anxiety O 
and O 
schizophrenia O 
. O 
Given O 
the O 
promise O 
offered O 
by O 
mGlu2 O 
/ O 
3 O 
receptor O 
activation O 
, O 
there O 
is O 
increased O 
interest O 
in O 
identifying O 
small O 
molecules O 
which O 
activate O 
the O 
receptor O 
. O 
A O 
preferred O 
approach O 
is O 
via O 
positive O 
allosteric O 
modulators O 
( O 
PAMs O 
) O 
which O 
bind O 
at O 
an O 
alternative O 
site O 
to O 
agonists O 
. O 
Areas O 
covered O 
: O 
This O 
review O 
covers O 
the O 
patent O 
applications O 
which O 
were O 
published O 
between O 
April O 
2009 O 
and O 
December O 
2012 O 
on O 
PAMs O 
of O 
the O 
mGlu2 O 
, O 
and O 
it O 
is O 
a O 
continuation O 
of O 
an O 
earlier O 
review O 
published O 
in O 
this O 
journal O 
. O 
Expert O 
opinion O 
: O 
Advances O 
in O 
medicinal O 
chemistry O 
and O 
pharmacology O 
have O 
set O 
the O 
stage O 
in O 
the O 
field O 
of O 
mGlu2 O 
receptor O 
PAMs O 
. O 
Compounds O 
currently O 
advancing O 
in O 
clinical O 
trials O 
will O 
soon O 
establish O 
the O 
therapeutic O 
potential O 
of O 
this O 
allosteric O 
approach O 
. O 

of O 
a O 
pre O 
- O 
export O 
enzyme O 
- O 
chaperone O 
complex O 
on O 
the O 
twin- O 
arginine B-TRIVIAL 
transport O 
pathway O 
. O 

Tat O 
( O 
twin- O 
arginine B-TRIVIAL 
translocation O 
) O 
system O 
is O 
a O 
protein O 
targeting O 
pathway O 
utilized O 
by O 
prokaryotes O 
and O 
chloroplasts O 
. O 
Tat O 
substrates O 
are O 
produced O 
with O 
distinctive O 
N B-FORMULA 
-terminal O 
signal O 
peptides O 
and O 
are O 
translocated O 
as O 
fully O 
folded O 
proteins O 
. O 
In O 
Escherichia O 
coli O 
, O 
Tat O 
- O 
dependent O 
proteins O 
often O 
contain O 
redox O 
cofactors O 
that O 
must O 
be O 
loaded O 
before O 
translocation O 
. O 
Trimethylamine B-SYSTEMATIC 
N-oxide I-SYSTEMATIC 
reductase O 
( O 
TorA O 
) O 
is O 
a O 
model O 
bacterial O 
Tat O 
substrate O 
and O 
is O 
a O 
molybdenum B-SYSTEMATIC 
cofactor O 
- O 
dependent O 
enzyme O 
. O 
Co-ordination O 
of O 
cofactor O 
loading O 
and O 
translocation O 
of O 
TorA O 
is O 
directed O 
by O 
the O 
TorD O 
protein O 
, O 
which O 
is O 
a O 
cytoplasmic O 
chaperone O 
known O 
to O 
interact O 
physically O 
with O 
the O 
TorA O 
signal O 
peptide O 
. O 
In O 
the O 
present O 
study O 
, O 
a O 
pre O 
- O 
export O 
TorAD O 
complex O 
has O 
been O 
characterized O 
using O 
biochemical O 
and O 
biophysical O 
techniques O 
, O 
including O 
SAXS O 
( O 
small O 
- O 
angle O 
X-ray O 
scattering O 
) O 
. O 
A O 
stable O 
, O 
cofactor O 
- O 
free O 
TorAD O 
complex O 
was O 
isolated O 
, O 
which O 
revealed O 
a O 
1 O 
: O 
1 O 
binding O 
stoichiometry O 
. O 
Surprisingly O 
, O 
a O 
TorAD O 
complex O 
with O 
similar O 
architecture O 
can O 
be O 
isolated O 
in O 
the O 
complete O 
absence O 
of O 
the O 
39-residue O 
TorA O 
signal O 
peptide O 
. O 
The O 
present O 
study O 
demonstrates O 
that O 
two O 
high O 
- O 
affinity O 
binding O 
sites O 
for O 
TorD O 
are O 
present O 
on O 
TorA O 
, O 
and O 
that O 
a O 
single O 
TorD O 
protein O 
binds O 
both O 
of O 
those O 
simultaneously O 
. O 
Further O 
characterization O 
suggested O 
that O 
the O 
C B-FORMULA 
-terminal O 
' O 
Domain O 
IV O 
' O 
of O 
TorA O 
remained O 
solvent-exposed O 
in O 
the O 
cofactor O 
- O 
free O 
pre O 
- O 
export O 
TorAD O 
complex O 
. O 
It O 
is O 
possible O 
that O 
correct O 
folding O 
of O 
Domain O 
IV O 
upon O 
cofactor O 
loading O 
is O 
the O 
trigger O 
for O 
TorD O 
release O 
and O 
subsequent O 
export O 
of O 
TorA O 
. O 

Nanocrystalline O 
Domains O 
Formed O 
from O 
Phosphorylated B-TRIVIAL 
Serine I-TRIVIAL 
-Rich O 
Motifs O 
in O 
Caddisfly O 
Larval O 
Silk O 
: O 
A O 
Solid O 
State O 
NMR O 
and O 
XRD O 
Study O 
. O 

silks O 
spun O 
by O 
aquatic O 
caddisfly O 
( O 
order O 
Trichoptera O 
) O 
larvae O 
are O 
used O 
to O 
build O 
both O 
intricate O 
protective O 
shelters O 
and O 
food O 
harvesting O 
nets O 
underwater O 
. O 
In O 
this O 
study O 
, O 
we O 
use O 
(13)C B-FORMULA 
and O 
(31)P B-FORMULA 
solid O 
- O 
state O 
NMR O 
and O 
wide O 
angle O 
X-ray O 
diffraction O 
( O 
WAXD O 
) O 
as O 
tools O 
to O 
elucidate O 
molecular O 
protein O 
structure O 
of O 
caddisfly O 
larval O 
silk O 
from O 
the O 
species O 
Hesperophylax O 
consimilis O 
. O 
Caddisfly O 
larval O 
silk O 
is O 
a O 
fibroin O 
protein O 
based O 
biopolymer O 
containing O 
mostly O 
repetitive O 
amino B-FAMILY 
acid I-FAMILY 
motifs O 
. O 
NMR O 
and O 
X-ray O 
results O 
provide O 
strong O 
supporting O 
evidence O 
for O 
a O 
structural O 
model O 
in O 
which O 
phosphorylated B-TRIVIAL 
serine I-TRIVIAL 
repeats O 
(pSX)4 O 
complex O 
with O 
divalent O 
cations O 
Ca(2+) B-FORMULA 
and O 
Mg(2+) B-FORMULA 
to O 
form O 
rigid O 
nanocrystalline O 
β-sheet O 
structures O 
in O 
caddisfly O 
silk O 
. O 
(13)C B-FORMULA 
NMR O 
data O 
suggests O 
that O 
both O 
phosphorylated B-TRIVIAL 
serine I-TRIVIAL 
and O 
neighboring O 
valine B-TRIVIAL 
residues O 
exist O 
in O 
a O 
β-sheet O 
conformation O 
while O 
glycine B-TRIVIAL 
and O 
leucine B-TRIVIAL 
residues O 
common O 
in O 
GGX O 
repeats O 
likely O 
reside O 
in O 
random O 
coil O 
conformations O 
. O 
Additionally O 
, O 
(31)P B-FORMULA 
chemical O 
shift O 
anisotropy O 
( O 
CSA O 
) O 
analysis O 
indicates O 
that O 
the O 
phosphates B-FAMILY 
on O 
phosphoserine B-SYSTEMATIC 
residues O 
are O 
doubly O 
ionized O 
, O 
and O 
are O 
charge O 
- O 
stabilized O 
by O 
divalent O 
cations O 
. O 
Positively O 
charged O 
arginine B-TRIVIAL 
side O 
chains O 
also O 
likely O 
play O 
a O 
role O 
in O 
charge O 
stabilization O 
. O 
Finally O 
, O 
WAXD O 
results O 
finds O 
that O 
the O 
silk O 
is O 
at O 
least O 
7-8% O 
crystalline O 
, O 
with O 
β-sheet O 
interplane O 
spacings O 
of O 
3.7 O 
and O 
4.5 O 
Å O 
. O 

( O 
jet O 
fuel O 
JP-8 O 
) O 
induce O 
epigenetic O 
transgenerational O 
inheritance O 
of O 
obesity O 
, O 
reproductive O 
disease O 
and O 
sperm O 
epimutations O 
. O 

compounds O 
have O 
been O 
shown O 
to O 
promote O 
epigenetic O 
transgenerational O 
inheritance O 
of O 
disease O 
. O 
The O 
current O 
study O 
was O 
designed O 
to O 
determine O 
if O 
a O 
hydrocarbon B-FAMILY 
mixture O 
involving O 
jet O 
fuel O 
( O 
JP-8 O 
) O 
promotes O 
epigenetic O 
transgenerational O 
inheritance O 
of O 
disease O 
. O 
Gestating O 
F0 O 
generation O 
female O 
rats O 
were O 
transiently O 
exposed O 
during O 
the O 
fetal O 
gonadal O 
development O 
period O 
. O 
The O 
direct O 
exposure O 
F1 O 
generation O 
had O 
an O 
increased O 
incidence O 
of O 
kidney O 
abnormalities O 
in O 
both O 
females O 
and O 
males O 
, O 
prostate O 
and O 
pubertal O 
abnormalities O 
in O 
males O 
, O 
and O 
primordial O 
follicle O 
loss O 
and O 
polycystic O 
ovarian O 
disease O 
in O 
females O 
. O 
The O 
first O 
transgenerational O 
generation O 
is O 
the O 
F3 O 
generation O 
, O 
and O 
the O 
jet O 
fuel O 
lineage O 
had O 
an O 
increased O 
incidence O 
of O 
primordial O 
follicle O 
loss O 
and O 
polycystic O 
ovarian O 
disease O 
in O 
females O 
, O 
and O 
obesity O 
in O 
both O 
females O 
and O 
males O 
. O 
Analysis O 
of O 
the O 
jet O 
fuel O 
lineage O 
F3 O 
generation O 
sperm O 
epigenome O 
identified O 
33 O 
differential O 
DNA O 
methylation O 
regions O 
, O 
termed O 
epimutations O 
. O 
Observations O 
demonstrate O 
hydrocarbons B-FAMILY 
can O 
promote O 
epigenetic O 
transgenerational O 
inheritance O 
of O 
disease O 
and O 
sperm O 
epimutations O 
, O 
potential O 
biomarkers O 
for O 
ancestral O 
exposures O 
. O 

and O 
evaluation O 
of O 
nicotinamide B-TRIVIAL 
derivative O 
as O 
anti-angiogenic O 
agents O 
. O 

, O 
we O 
have O 
found O 
that O 
BRN-103 B-IDENTIFIER 
, O 
a O 
nicotinamide B-TRIVIAL 
derivative O 
, O 
inhibits O 
vascular O 
endothelial O 
growth O 
factor O 
( O 
VEGF O 
) O 
- O 
mediated O 
angiogenesis O 
signaling O 
in O 
human O 
endothelial O 
cells O 
. O 
During O 
our O 
continuous O 
efforts O 
to O 
identify O 
more O 
potent O 
anti-angiogenic O 
agents O 
, O 
we O 
synthesized O 
various O 
nicotinamide B-TRIVIAL 
derivatives O 
and O 
evaluated O 
their O 
anti-angiogenic O 
effects O 
. O 
We O 
found O 
that O 
2-{1-[1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl]piperidin-4-ylamino}-N-(3-chlorophenyl) B-SYSTEMATIC 
pyridine-3-carboxamide I-SYSTEMATIC 
( O 
BRN-250 B-IDENTIFIER 
) O 
significantly O 
inhibited O 
human O 
umbilical O 
vascular O 
endothelial O 
cells O 
( O 
HUVECs O 
) O 
proliferation O 
, O 
migration O 
, O 
tube O 
formation O 
, O 
and O 
microvessel O 
growth O 
in O 
a O 
concentration O 
range O 
of O 
10-100 O 
nM O 
. O 
Furthermore O 
, O 
BRN-250 B-IDENTIFIER 
inhibited O 
the O 
VEGF-induced O 
phosphorylation O 
and O 
intracellular O 
tyrosine B-TRIVIAL 
kinase O 
activity O 
of O 
VEGF O 
receptor O 
2 O 
( O 
VEGFR2 O 
) O 
and O 
the O 
activation O 
of O 
its O 
downstream O 
AKT O 
pathway O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
suggest O 
that O 
BRN-250 B-IDENTIFIER 
be O 
considered O 
a O 
potential O 
lead O 
compound O 
for O 
cancer O 
therapy O 
. O 

Wnt O 
signal O 
transduction O 
pathway O 
is O 
dysregulated O 
in O 
many O 
highly O 
prevalent O 
diseases O 
, O 
including O 
cancer O 
. O 
Unfortunately O 
, O 
drug O 
discovery O 
efforts O 
have O 
been O 
hampered O 
by O 
the O 
paucity O 
of O 
targets O 
and O 
drug O 
- O 
like O 
lead O 
molecules O 
amenable O 
to O 
drug O 
discovery O 
. O 
Recently O 
, O 
we O 
reported O 
the O 
FDA-approved O 
anthelmintic O 
drug O 
Niclosamide B-TRIVIAL 
inhibits O 
Wnt O 
/ O 
β-catenin O 
signaling O 
by O 
a O 
unique O 
mechanism O 
, O 
though O 
the O 
target O 
responsible O 
remains O 
unknown O 
. O 
We O 
interrogated O 
the O 
mechanism O 
and O 
structure O 
- O 
activity O 
relationships O 
to O 
understand O 
drivers O 
of O 
potency O 
and O 
to O 
assist O 
target O 
identification O 
efforts O 
. O 
We O 
found O 
inhibition O 
of O 
Wnt O 
signaling O 
by O 
Niclosamide B-TRIVIAL 
appears O 
unique O 
among O 
the O 
structurally O 
- O 
related O 
anthelmintic O 
agents O 
tested O 
and O 
found O 
the O 
potency O 
and O 
functional O 
response O 
was O 
dependent O 
on O 
small O 
changes O 
in O 
the O 
chemical O 
structure O 
of O 
Niclosamide B-TRIVIAL 
. O 
Overall O 
, O 
these O 
findings O 
support O 
efforts O 
to O 
identify O 
the O 
target O 
of O 
Niclosamide B-TRIVIAL 
inhibition O 
of O 
Wnt O 
/ O 
β-catenin O 
signaling O 
and O 
the O 
discovery O 
of O 
potent O 
and O 
selective O 
modulators O 
to O 
treat O 
human O 
disease O 
. O 

acid I-TRIVIAL 
and O 
its O 
octadecatrienoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
geoisomers O 
induce O 
apoptosis O 
selectively O 
in O 
cancerous O 
human O 
prostate O 
cells O 
: O 
a O 
mechanistic O 
and O 
3-D O 
structure O 
- O 
activity O 
study O 
. O 

- O 
derived O 
non-essential O 
fatty B-FAMILY 
acids I-FAMILY 
are O 
important O 
dietary O 
nutrients O 
, O 
and O 
some O 
are O 
purported O 
to O 
have O 
chemopreventive O 
properties O 
against O 
various O 
cancers O 
, O 
including O 
that O 
of O 
the O 
prostate O 
. O 
In O 
this O 
study O 
, O 
we O 
determined O 
the O 
ability O 
of O 
seven O 
dietary O 
C-18 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
to O 
cause O 
cytotoxicity O 
and O 
induce O 
apoptosis O 
in O 
various O 
types O 
of O 
human O 
prostate O 
cancer O 
cells O 
. O 
These O 
fatty B-FAMILY 
acids I-FAMILY 
included O 
jacaric B-MULTIPLE 
and I-MULTIPLE 
punicic I-MULTIPLE 
acid I-MULTIPLE 
found O 
in O 
jacaranda O 
and O 
pomegranate O 
seed O 
oil O 
, O 
respectively O 
, O 
three O 
octadecatrienoic O 
geometric O 
isomers O 
( O 
alpha- B-MULTIPLE 
and I-MULTIPLE 
beta-calendic I-MULTIPLE 
and I-MULTIPLE 
catalpic I-MULTIPLE 
acid I-MULTIPLE 
) O 
and O 
two O 
mono B-FAMILY 
- I-FAMILY 
unsaturated I-FAMILY 
C-18 I-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
trans- B-MULTIPLE 
and I-MULTIPLE 
cis-vaccenic I-MULTIPLE 
acid I-MULTIPLE 
) O 
. O 
Jacaric B-TRIVIAL 
acid I-TRIVIAL 
and O 
four O 
of O 
its O 
octadecatrienoic O 
geoisomers O 
selectively O 
induced O 
apoptosis O 
in O 
hormone O 
- O 
dependent O 
( O 
LNCaP O 
) O 
and O 
-independent O 
( O 
PC-3 O 
) O 
human O 
prostate O 
cancer O 
cells O 
, O 
whilst O 
not O 
affecting O 
the O 
viability O 
of O 
normal O 
human O 
prostate O 
epithelial O 
cells O 
( O 
RWPE-1 O 
) O 
. O 
Jacaric B-TRIVIAL 
acid I-TRIVIAL 
induced O 
concentration- O 
and O 
time O 
- O 
depedent O 
LNCaP O 
cell O 
death O 
through O 
activation O 
of O 
intrinsic O 
and O 
extrinsic O 
apoptotic O 
pathways O 
resulting O 
in O 
cleavage O 
of O 
PARP-1 O 
, O 
modulation O 
of O 
pro- O 
and O 
antiapoptotic O 
Bcl-2 O 
family O 
of O 
proteins O 
and O 
increased O 
cleavage O 
of O 
caspase-3 O 
, O 
-8 O 
and O 
-9 O 
. O 
Moreover O 
, O 
activation O 
of O 
a O 
cell O 
death O 
- O 
inducing O 
signalling O 
cascade O 
involving O 
death O 
receptor O 
5 O 
was O 
observed O 
. O 
Jacaric B-TRIVIAL 
acid I-TRIVIAL 
induced O 
apoptosis O 
in O 
PC-3 O 
cells O 
by O 
activation O 
of O 
the O 
intrinsic O 
pathway O 
only O 
. O 
The O 
spatial O 
conformation O 
cis O 
, O 
trans O 
, O 
cis O 
of O 
jacaric B-MULTIPLE 
and I-MULTIPLE 
punicic I-MULTIPLE 
acid I-MULTIPLE 
was O 
shown O 
to O 
play O 
a O 
key O 
role O 
in O 
the O 
increased O 
potency O 
and O 
efficacy O 
of O 
these O 
two O 
fatty B-FAMILY 
acids I-FAMILY 
in O 
comparison O 
to O 
the O 
five O 
other O 
C-18 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
tested O 
. O 
Three O 
- O 
dimensional O 
conformational O 
analysis O 
using O 
the O 
PubChem O 
Database O 
( O 
http O 
: O 
/ O 
/ O 
pubchem.ncbi.nlm.nih.gov O 
) O 
showed O 
that O 
the O 
cytotoxic O 
potency O 
of O 
the O 
C-18 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
was O 
related O 
to O 
their O 
degree O 
of O 
conformational O 
similarity O 
to O 
our O 
cytotoxic O 
reference O 
compound O 
, O 
punicic B-TRIVIAL 
acid I-TRIVIAL 
, O 
based O 
on O 
optimized O 
shape O 
( O 
ST O 
) O 
and O 
feature O 
( O 
CT O 
) O 
similarity O 
scores O 
, O 
with O 
jacaric B-TRIVIAL 
acid I-TRIVIAL 
being O 
most O 
' O 
biosimilar O 
' O 
( O 
ST(ST-opt)=0.81 O 
; O 
CT(CT-opt)=0.45 O 
) O 
. O 
This O 
3-D O 
analysis O 
of O 
structural O 
similarity O 
enabled O 
us O 
to O 
rank O 
geoisomeric O 
fatty B-FAMILY 
acids I-FAMILY 
according O 
to O 
cytotoxic O 
potency O 
, O 
whereas O 
a O 
2-D O 
positional O 
assessment O 
of O 
cis O 
/ O 
trans O 
structure O 
did O 
not O 
. O 
Our O 
findings O 
provide O 
mechanistic O 
evidence O 
that O 
nutrition O 
- O 
derived O 
non-essential O 
fatty B-FAMILY 
acids I-FAMILY 
have O 
chemopreventive O 
biological O 
activities O 
and O 
Exhibit O 
3-D O 
structure O 
- O 
activity O 
relationships O 
that O 
could O 
be O 
exploited O 
to O 
develop O 
new O 
strategies O 
for O 
the O 
prevention O 
or O 
treatment O 
of O 
prostate O 
cancer O 
regardless O 
of O 
hormone O 
dependency O 
. O 

and O 
anti-acetylcholinesterase O 
properties O 
of O 
novel O 
β- B-MULTIPLE 
and I-MULTIPLE 
γ- I-MULTIPLE 
substituted I-MULTIPLE 
alkoxy I-MULTIPLE 
organophosphonates I-MULTIPLE 
. O 

organophosphate B-FAMILY 
( O 
OP O 
) O 
insecticides O 
and O 
chemical O 
agents O 
inhibit O 
acetylcholinesterase O 
( O 
AChE O 
) O 
to O 
form O 
OP-AChE O 
adducts O 
. O 
Whereas O 
the O 
structure O 
of O 
the O 
OP O 
correlates O 
with O 
the O 
rate O 
of O 
inhibition O 
, O 
the O 
structure O 
of O 
the O 
OP-AChE O 
adduct O 
influences O 
the O 
rate O 
at O 
which O 
post O 
- O 
inhibitory O 
reactivation O 
or O 
aging O 
phenomena O 
occurs O 
. O 
In O 
this O 
report O 
, O 
we O 
prepared O 
a O 
panel O 
of O 
β- B-MULTIPLE 
substituted I-MULTIPLE 
ethoxy I-MULTIPLE 
and I-MULTIPLE 
γ- I-MULTIPLE 
substituted I-MULTIPLE 
propoxy I-MULTIPLE 
phosphonoesters I-MULTIPLE 
of O 
the O 
type O 
p-NO(2)PhO-P(X)(R)[(O(CH(2))(n)Z] B-FAMILY 
( O 
R=Me B-FORMULA 
, I-FORMULA 
Et I-FORMULA 
; I-FORMULA 
X=O I-FORMULA 
, I-FORMULA 
S I-FORMULA 
; I-FORMULA 
n=2 I-FORMULA 
, I-FORMULA 
3 I-FORMULA 
; I-FORMULA 
Z=halogen I-FORMULA 
, I-FORMULA 
OTs I-FORMULA 
Me B-FORMULA 
, O 
Et B-FORMULA 
; O 
X= O 
O B-FORMULA 
, O 
S B-FORMULA 
; O 
n=2 O 
, O 
3 O 
; O 
Z= O 
halogen B-FAMILY 
, O 
OTs B-FORMULA 
) O 
and O 
examined O 
the O 
inhibition O 
of O 
three O 
AChEs O 
by O 
select O 
structures O 
in O 
the O 
panel O 
. O 
The O 
β-fluoroethoxy B-SYSTEMATIC 
methylphosphonate I-SYSTEMATIC 
analog O 
( O 
R=Me B-FORMULA 
, I-FORMULA 
Z=F I-FORMULA 
, I-FORMULA 
n=2 I-FORMULA 
Me B-FORMULA 
, O 
Z= O 
F B-FORMULA 
, O 
n=2 O 
) O 
was O 
the O 
most O 
potent O 
anti-AChE O 
compound O 
comparable O 
( O 
ki O 
∼6 O 
× O 
10(6)M(-1)min(-1) O 
) O 
to O 
paraoxon B-TRIVIAL 
against O 
EEAChE O 
. O 
Analogs O 
with O 
Z=Br B-FORMULA 
, I-FORMULA 
I I-FORMULA 
, I-FORMULA 
or I-FORMULA 
OTs I-FORMULA 
Br B-FORMULA 
, O 
I B-FORMULA 
, O 
or O 
OTs B-FORMULA 
were O 
weak O 
inhibitors O 
of O 
the O 
AChEs O 
, O 
and O 
methyl B-FAMILY 
phosphonates I-FAMILY 
( O 
R=Me B-FORMULA 
Me B-FORMULA 
) O 
were O 
more O 
potent O 
than O 
the O 
corresponding O 
ethyl B-FAMILY 
phosphonates I-FAMILY 
( O 
R=Et B-FORMULA 
Et B-FORMULA 
) O 
. O 
As O 
expected O 
, O 
analogs O 
with O 
a O 
thionate B-SYSTEMATIC 
linkage O 
( O 
PS O 
) O 
were O 
poor O 
inhibitors O 
of O 
the O 
AChEs O 
. O 

derivatives O 
with O 
novel O 
terminal O 
tertiary B-SYSTEMATIC 
amide I-SYSTEMATIC 
substitution O 
for O 
treatment O 
of O 
bovine O 
viral O 
diarrhea O 
virus O 
( O 
BVDV O 
) O 
, O 
Dengue O 
, O 
and O 
Tacaribe O 
virus O 
infections O 
. O 

N-alkyldeoxynojirimycins B-FAMILY 
( O 
NADNJs B-FAMILY 
) O 
with O 
two O 
hydrophobic O 
groups O 
attached O 
to O 
a O 
nitrogen O 
linker O 
on O 
the O 
alkyl B-FAMILY 
chain O 
were O 
designed O 
. O 
A O 
novel O 
NADNJ B-ABBREVIATION 
containing O 
a O 
terminal O 
tertiary B-SYSTEMATIC 
carboxamide I-SYSTEMATIC 
moiety O 
was O 
discovered O 
that O 
was O 
a O 
potent O 
inhibitor O 
against O 
BVDV O 
. O 
Further O 
optimization O 
resulted O 
in O 
a O 
structurally O 
more O 
stable O 
lead O 
compound O 
24 O 
with O 
a O 
submicromolar O 
EC50 O 
against O 
BVDV O 
, O 
Dengue O 
, O 
and O 
Tacaribe O 
; O 
and O 
low O 
cytotoxicity O 
. O 

Substituted-2-amino-6-boronohexanoic I-FAMILY 
acids I-FAMILY 
as O 
arginase O 
inhibitors O 
. O 

at O 
the O 
alpha O 
center O 
of O 
the O 
known O 
human O 
arginase O 
inhibitor O 
2-amino-6-boronohexanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
ABH B-ABBREVIATION 
) O 
is O 
acceptable O 
in O 
the O 
active O 
site O 
pockets O 
of O 
both O 
human O 
arginase O 
I O 
and O 
arginase O 
II O 
. O 
In O 
particular O 
, O 
substituents O 
with O 
a O 
tertiary B-SYSTEMATIC 
amine I-SYSTEMATIC 
linked O 
via O 
a O 
two O 
carbon B-SYSTEMATIC 
chain O 
show O 
improved O 
inhibitory O 
potency O 
for O 
both O 
enzyme O 
isoforms O 
. O 
This O 
potency O 
improvement O 
can O 
be O 
rationalized O 
by O 
X-ray O 
crystallography O 
, O 
which O 
shows O 
a O 
water O 
- O 
mediated O 
contact O 
between O 
the O 
basic O 
nitrogen B-SYSTEMATIC 
and O 
the O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
side O 
chain O 
of O 
Asp B-FORMULA 
200 O 
, O 
which O 
is O 
situated O 
at O 
the O 
mouth O 
of O 
the O 
active O 
site O 
pocket O 
of O 
arginase O 
II O 
( O 
Asp B-FORMULA 
181 O 
in O 
arginase O 
I O 
) O 
. O 
We O 
believe O 
that O 
this O 
is O 
the O 
first O 
literature O 
report O 
of O 
compounds O 
with O 
improved O 
arginase O 
inhibitory O 
activity O 
, O 
relative O 
to O 
ABH B-ABBREVIATION 
, O 
and O 
represents O 
a O 
promising O 
starting O 
point O 
for O 
further O 
optimization O 
of O 
in O 
vitro O 
potency O 
and O 
the O 
identification O 
of O 
better O 
tool O 
molecules O 
for O 
in O 
vivo O 
investigations O 
of O 
the O 
potential O 
pathophysiological O 
roles O 
of O 
arginases O 
. O 

- O 
sulfur B-SYSTEMATIC 
containing O 
antioxidant O 
conjugates O 
as O 
potential O 
prodrugs O 
to O 
improve O 
the O 
treatment O 
of O 
Alzheimer's O 
disease O 
. O 

approved O 
treatments O 
for O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
exploit O 
mainly O 
a O 
symptomatic O 
approach O 
based O 
on O 
the O 
use O 
of O 
cholinesterase O 
inhibitors O 
or O 
N-methyl-d-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
receptor O 
antagonists O 
. O 
Natural O 
antioxidant O 
compounds O 
, O 
able O 
to O 
pass O 
through O 
the O 
blood O 
- O 
brain O 
barrier O 
( O 
BBB O 
) O 
, O 
have O 
been O 
extensively O 
studied O 
as O 
useful O 
neuroprotective O 
agents O 
. O 
A O 
novel O 
approach O 
towards O 
excitotoxicity O 
protection O 
and O 
oxidative O 
stress O 
associated O 
with O 
excess O 
β O 
amyloid O 
( O 
Aβ O 
) O 
preservation O 
in O 
AD O 
is O 
represented O 
by O 
selective O 
glutamatergic O 
antagonists O 
that O 
possess O 
as O 
well O 
antioxidant O 
capabilities O 
. O 
In O 
the O 
present O 
work O 
, O 
GSH B-ABBREVIATION 
( O 
1 O 
) O 
or O 
(R)-α-lipoic B-TRIVIAL 
acid I-TRIVIAL 
( O 
LA O 
) O 
( O 
2 O 
) O 
have O 
been O 
covalently O 
linked O 
with O 
the O 
NMDA B-ABBREVIATION 
receptor O 
antagonists O 
memantine B-TRIVIAL 
( O 
MEM B-ABBREVIATION 
) O 
. O 
The O 
new O 
conjugates O 
, O 
proposed O 
as O 
potential O 
antialzheimer O 
drugs O 
, O 
should O 
act O 
both O 
as O 
glutamate B-TRIVIAL 
receptor O 
antagonists O 
and O 
radical O 
scavenging O 
agents O 
. O 
The O 
physico O 
- O 
chemical O 
properties O 
and O 
" O 
in O 
vitro O 
" O 
membrane O 
permeability O 
, O 
the O 
enzymatic O 
and O 
chemical O 
stability O 
, O 
the O 
demonstrated O 
" O 
in O 
vitro O 
" O 
antioxidant O 
activity O 
associated O 
to O 
the O 
capacity O 
to O 
inhibit O 
Aβ(1-42) O 
aggregation O 
makes O 
at O 
least O 
compound O 
2 O 
a O 
promising O 
candidate O 
for O 
treatment O 
of O 
AD O 
patients O 
. O 

delivery O 
of O 
Photofrin B-TRIVIAL 
® O 
by O 
PLL-g-PEG B-ABBREVIATION 
for O 
photodynamic O 
therapy O 
. O 

® O 
( O 
porfimer B-SYSTEMATIC 
sodium I-SYSTEMATIC 
) O 
is O 
a O 
photosensitive O 
reagent O 
used O 
for O 
photodynamic O 
therapy O 
( O 
PDT O 
) O 
of O 
tumors O 
and O 
dysplasias O 
. O 
Because O 
only O 
photo O 
- O 
irradiated O 
sites O 
are O 
damaged O 
, O 
PDT O 
is O 
less O 
invasive O 
than O 
systemic O 
treatments O 
. O 
However O 
, O 
a O 
photosensitive O 
reaction O 
is O 
a O 
major O 
side O 
effect O 
of O 
systemically O 
delivered O 
Photofrin B-TRIVIAL 
. O 
To O 
enhance O 
localization O 
of O 
Photofrin B-TRIVIAL 
to O 
tumors O 
, O 
we O 
have O 
formulated O 
Photofrin B-TRIVIAL 
with O 
the O 
tumor O 
- O 
localizing O 
graft O 
copolymer O 
poly(ethylene B-FAMILY 
glycol)-grafted I-FAMILY 
poly(l-lysine) I-FAMILY 
, O 
PLL-g-PEG B-ABBREVIATION 
. O 
We O 
demonstrate O 
that O 
Photofrin B-TRIVIAL 
preferentially O 
interacts O 
with O 
PLL-g-PEG B-ABBREVIATION 
through O 
both O 
ionic O 
and O 
hydrophobic O 
interactions O 
. O 
The O 
serum O 
competitive O 
study O 
showed O 
that O 
the O 
highly O 
PEG-grafted B-ABBREVIATION 
PLL I-ABBREVIATION 
is O 
better O 
for O 
preventing O 
serum O 
binding O 
to O 
the O 
Photofrin B-TRIVIAL 
/ O 
PLL-g-PEG B-ABBREVIATION 
complex O 
. O 
In O 
tumor O 
- O 
bearing O 
mice O 
, O 
formulation O 
of O 
Photofrin B-TRIVIAL 
with O 
PLL-g-PEG B-ABBREVIATION 
enhanced O 
tumor O 
localization O 
of O 
Photofrin B-TRIVIAL 
as O 
twice O 
as O 
Photofrin B-TRIVIAL 
alone O 
and O 
concomitantly O 
suppressed O 
the O 
photosensitivity O 
reaction O 
drastically O 
. O 

of O 
the O 
effect O 
of O 
increasing O 
the O 
number O 
of O 
intra- O 
disulfide B-SYSTEMATIC 
amino I-SYSTEMATIC 
functional O 
groups O 
on O 
the O 
performance O 
of O 
small O 
molecule O 
cyclic O 
polyamine B-FAMILY 
disulfide I-FAMILY 
vectors O 
. O 

structure O 
- O 
activity O 
relationships O 
is O 
vital O 
if O 
the O 
efficacy O 
of O 
non-viral O 
vectors O 
is O 
to O 
match O 
that O 
of O 
their O 
viral O 
counter O 
- O 
parts O 
. O 
Recently O 
, O 
we O 
reported O 
on O 
the O 
ability O 
of O 
a O 
series O 
of O 
small O 
molecule O 
, O 
cyclic B-FAMILY 
polyamine I-FAMILY 
disulfides I-FAMILY 
to O 
condense O 
and O 
cage O 
plasmid O 
DNA O 
( O 
pDNA O 
) O 
by O 
a O 
process O 
of O 
thermodynamically O 
controlled O 
template O 
polymerization O 
, O 
leading O 
to O 
a O 
series O 
of O 
corresponding O 
pDNA-polyplex O 
nanoparticles O 
able O 
to O 
mediate O 
high O 
levels O 
of O 
transfection O 
with O 
no O 
associated O 
cytotoxicities O 
. O 
The O 
leading O 
cyclic B-FAMILY 
polyamine I-FAMILY 
disulfide I-FAMILY 
was O 
shown O 
to O 
be O 
the O 
spermine B-SYSTEMATIC 
tetra I-SYSTEMATIC 
- I-SYSTEMATIC 
amine I-SYSTEMATIC 
disulfide I-SYSTEMATIC 
( O 
TetraN-3,4,3 B-SYSTEMATIC 
) O 
. O 
Herein O 
we O 
report O 
on O 
the O 
significantly O 
more O 
challenging O 
syntheses O 
of O 
cyclic B-FAMILY 
disulfides I-FAMILY 
with O 
longer O 
polyamine O 
motifs O 
. O 
Two O 
new O 
cyclic B-FAMILY 
polyamine I-FAMILY 
disulfides I-FAMILY 
, O 
based O 
on O 
hexa- B-MULTIPLE 
and I-MULTIPLE 
octa I-MULTIPLE 
- I-MULTIPLE 
amine I-MULTIPLE 
inserts O 
, O 
were O 
prepared O 
and O 
their O 
transfection O 
efficacies O 
and O 
cytotoxicities O 
compared O 
with O 
our O 
previously O 
reported O 
cyclic B-MULTIPLE 
tri- I-MULTIPLE 
and I-MULTIPLE 
tetra I-MULTIPLE 
- I-MULTIPLE 
amine I-MULTIPLE 
disulfides I-MULTIPLE 
. O 
The O 
new O 
cyclic B-MULTIPLE 
hexa- I-MULTIPLE 
and I-MULTIPLE 
octa I-MULTIPLE 
- I-MULTIPLE 
amine I-MULTIPLE 
disulfides I-MULTIPLE 
prove O 
more O 
effective O 
at O 
transfection O 
in O 
vitro O 
, O 
especially O 
of O 
lung O 
epithelial O 
A549 O 
cell O 
line O 
. O 
By O 
contrast O 
, O 
our O 
original O 
cyclic B-SYSTEMATIC 
tetra I-SYSTEMATIC 
- I-SYSTEMATIC 
amine I-SYSTEMATIC 
disulfide I-SYSTEMATIC 
remains O 
the O 
most O 
efficient O 
agent O 
for O 
the O 
transfection O 
of O 
lung O 
epithelial O 
cells O 
in O 
vivo O 
following O 
intra O 
- O 
nasal O 
administration O 
. O 
Hypothetical O 
mechanistic O 
reasons O 
are O 
presented O 
to O 
explain O 
this O 
outcome O 
. O 
Our O 
data O 
in O 
toto O 
support O 
the O 
concept O 
of O 
shorter O 
cyclic B-FAMILY 
polyamine I-FAMILY 
disulfides I-FAMILY 
as O 
preferred O 
agents O 
for O 
polycation O 
- O 
mediated O 
controlled O 
condensation O 
and O 
functional O 
delivery O 
of O 
pDNA O 
to O 
lung O 
epithelial O 
cells O 
in O 
vivo O 
. O 

of O 
Escherichia O 
coli O 
( O 
STEC O 
) O 
causing O 
Uremic O 
Hemolytic O 
Syndrome O 
( O 
UHS O 
) O 
generate O 
oxidative O 
stress O 
in O 
human O 
blood O 
with O 
more O 
production O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
than O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
. O 
Shiga O 
toxin O 
( O 
Stx O 
) O 
together O 
with O 
the O 
hemolysin O 
( O 
Hly O 
) O 
increased O 
lipid O 
oxidation O 
, O 
as O 
evaluated O 
by O 
malondialdehyde B-TRIVIAL 
MDA B-ABBREVIATION 
and O 
oxidation O 
of O 
proteins O 
. O 
The O 
addition O 
of O 
Ziziphus O 
mistol O 
Griseb O 
extracts O 
decreased O 
NO B-FORMULA 
, O 
ROS O 
, O 
MDA B-ABBREVIATION 
and O 
simultaneously O 
caused O 
an O 
increase O 
in O 
the O 
degradation O 
of O 
oxidized O 
proteins O 
to O 
advanced O 
oxidation O 
protein O 
products O 
( O 
AOPPs O 
) O 
in O 
controls O 
and O 
samples O 
with O 
toxins O 
. O 
Furthermore O 
, O 
the O 
nitrosylated O 
proteins O 
/ O 
AOPP O 
ratio O 
was O 
reduced O 
, O 
due O 
to O 
the O 
increase O 
of O 
AOPP O 
. O 
Z O 
. O 
mistol O 
Griseb O 
extracts O 
exhibited O 
a O 
high O 
proportion O 
of O 
polyphenols B-FAMILY 
and O 
flavonoids B-FAMILY 
, O 
with O 
evident O 
correlation O 
with O 
ferrous B-SYSTEMATIC 
reduction O 
antioxidant O 
potential O 
( O 
FRAP O 
) O 
. O 
The O 
plasma O 
of O 
eight O 
children O 
with O 
UHS O 
showed O 
oxidative O 
stress O 
and O 
NO B-FORMULA 
stimulus O 
, O 
comparable O 
to O 
the O 
effect O 
of O 
toxins O 
during O 
the O 
assays O 
in O 
vitro O 
. O 
UHS O 
children O 
presented O 
high O 
levels O 
of O 
nitrosylated O 
proteins O 
respect O 
to O 
control O 
children O 
of O 
similar O 
age O 
. O 
Although O 
the O 
degradation O 
of O 
oxidized O 
proteins O 
to O 
AOPP O 
rose O 
in O 
UHS O 
children O 
, O 
the O 
nitrosylated O 
proteins O 
/ O 
AOPP O 
rate O 
increased O 
as O 
a O 
consequence O 
of O 
the O 
elevated O 
nitrosative O 
stress O 
observed O 
in O 
these O 
patients O 
. O 

- O 
month O 
subchronic O 
intramuscular O 
toxicity O 
study O 
of O 
rotigotine B-TRIVIAL 
-loaded O 
microspheres O 
in O 
SD O 
rats O 
. O 

dopaminergic O 
stimulation O 
( O 
CDS O 
) O 
has O 
been O 
an O 
important O 
strategy O 
of O 
drug O 
development O 
for O 
the O 
treatment O 
of O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
. O 
Rotigotine B-TRIVIAL 
is O 
a O 
non- O 
ergoline B-TRIVIAL 
D3 O 
/ O 
D2 O 
/ O 
D1 O 
dopamine B-TRIVIAL 
agonist O 
for O 
treating O 
PD O 
. O 
As O 
a O 
new O 
treatment O 
option O 
for O 
CDS O 
, O 
rotigotine B-TRIVIAL 
-loaded O 
microspheres O 
( O 
RoMS O 
) O 
, O 
a O 
long O 
- O 
acting O 
sustained O 
- O 
release O 
microspheres O 
for O 
injection O 
with O 
poly(lactide-co-glycolide) B-SYSTEMATIC 
as O 
drug O 
carrier O 
, O 
are O 
now O 
being O 
evaluated O 
in O 
clinical O 
trial O 
. O 
In O 
this O 
study O 
, O 
subchronic O 
toxicity O 
of O 
RoMS O 
in O 
SD O 
rats O 
has O 
been O 
characterized O 
via O 
intramuscular O 
administration O 
with O 
RoMS O 
( O 
0-240mg O 
/ O 
kg O 
/ O 
week O 
) O 
on O 
a O 
consecutive O 
weekly O 
dosing O 
schedule O 
for O 
3months O 
followed O 
by O 
1-month O 
recovery O 
period O 
. O 
The O 
No O 
Observed O 
Adverse O 
Effect O 
Level O 
( O 
NOAEL O 
) O 
was O 
45mg O 
/ O 
kg O 
/ O 
week O 
. O 
One O 
male O 
at O 
240mg O 
/ O 
kg O 
died O 
from O 
an O 
extensive O 
pulmonary O 
embolism O 
. O 
The O 
major O 
toxicological O 
effects O 
were O 
associated O 
with O 
the O 
dopamine B-TRIVIAL 
agonist O 
- O 
related O 
pharmacodynamic O 
properties O 
of O 
rotigotine B-TRIVIAL 
( O 
e.g O 
. O 
hyperactivity O 
and O 
stereotype O 
, O 
enlarged O 
ovary O 
, O 
sporadic O 
gastric O 
mucous O 
membrane O 
lesions O 
, O 
decreased O 
body O 
weight O 
, O 
food O 
consumption O 
and O 
prolactin O 
, O 
and O 
increased O 
mononuclear O 
cell O 
, O 
neutrophil O 
granulocyte O 
, O 
aspartate B-TRIVIAL 
aminotransferase O 
and O 
alanine B-TRIVIAL 
aminotransferase O 
) O 
and O 
foreign O 
body O 
removal O 
reaction O 
induced O 
by O 
poly(lactide-co-glycolide) B-SYSTEMATIC 
and O 
carboxymethycellulose O 
sodium B-SYSTEMATIC 
. O 
At O 
the O 
end O 
of O 
recovery O 
period O 
, O 
all O 
findings O 
had O 
recovered O 
to O 
a O 
normal O 
level O 
or O 
to O 
a O 
certain O 
degree O 
except O 
foreign O 
body O 
reaction O 
at O 
injection O 
sites O 
. O 
RoMS O 
has O 
exhibited O 
high O 
safety O 
on O 
SD O 
rats O 
. O 

cell O 
- O 
penetrating O 
peptide O 
suppresses O 
the O 
hypoxia O 
inducible O 
factor-1 O 
function O 
by O 
binding O 
to O 
the O 
helix O 
- O 
loop O 
- O 
helix O 
domain O 
of O 
the O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
nuclear O 
translocator O 
. O 

heterodimeric O 
hypoxia O 
inducible O 
factor-1 O 
( O 
HIF-1 O 
) O 
complex O 
is O 
composed O 
of O 
the O 
hypoxia O 
inducible O 
factor-1 O 
alpha O 
( O 
HIF-1α O 
) O 
and O 
the O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
nuclear O 
translocator O 
( O 
ARNT O 
) O 
. O 
Activation O 
of O 
the O 
HIF-1 O 
function O 
is O 
essential O 
for O 
tumor O 
growth O 
and O 
metastasis O 
. O 
We O 
previously O 
showed O 
that O 
transfection O 
of O 
a O 
plasmid O 
containing O 
an O 
ARNT-interacting O 
peptide O 
( O 
Ainp1 O 
) O 
cDNA O 
suppresses O 
the O 
HIF-1 O 
signaling O 
in O 
Hep3B O 
cells O 
. O 
Here O 
we O 
generated O 
TAT O 
fusion O 
of O 
the O 
Ainp1 O 
peptide O 
( O 
6His B-FORMULA 
-TAT-Ainp1 O 
) O 
to O 
determine O 
whether O 
and O 
how O 
the O 
Ainp1 O 
peptide O 
suppresses O 
the O 
HIF-1 O 
function O 
. O 
The O 
bacterially O 
expressed O 
6His B-FORMULA 
-TAT-Ainp1 O 
was O 
purified O 
under O 
denatured O 
condition O 
and O 
then O 
refolded O 
by O 
limited O 
dialysis O 
. O 
The O 
refolded O 
6His B-FORMULA 
-TAT-Ainp1 O 
interacts O 
with O 
the O 
helix O 
- O 
loop O 
- O 
helix O 
( O 
HLH O 
) O 
domain O 
of O 
ARNT O 
in O 
a O 
similar O 
fashion O 
as O 
the O 
native O 
6His B-FORMULA 
-Ainp1 O 
. O 
6His B-FORMULA 
-TAT-Ainp1 O 
colocalizes O 
with O 
ARNT O 
in O 
the O 
nucleus O 
of O 
HeLa O 
and O 
Hep3B O 
cells O 
after O 
protein O 
transduction O 
. O 
The O 
transduced O 
protein O 
reaches O 
the O 
maximum O 
intracellular O 
levels O 
within O 
2h O 
while O 
remains O 
detectable O 
up O 
to O 
96h O 
in O 
HeLa O 
cells O 
. O 
At O 
2μM O 
concentration O 
, O 
6His B-FORMULA 
-TAT-Ainp1 O 
is O 
not O 
cytotoxic O 
in O 
HeLa O 
cells O 
but O 
suppresses O 
the O 
cobalt B-SYSTEMATIC 
chloride I-SYSTEMATIC 
-activated O 
, O 
hypoxia O 
responsive O 
enhancer O 
- O 
driven O 
luciferase O 
expression O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
In O 
addition O 
, O 
it O 
decreases O 
the O 
cobalt B-SYSTEMATIC 
chloride I-SYSTEMATIC 
-dependent O 
induction O 
of O 
the O 
HIF-1 O 
target O 
genes O 
at O 
both O 
the O 
message O 
( O 
vascular O 
endothelial O 
growth O 
factor O 
and O 
aldolase O 
C O 
) O 
and O 
protein O 
( O 
carbonic O 
anhydrase O 
IX O 
and O 
glucose B-TRIVIAL 
transporter O 
1 O 
) O 
levels O 
. O 
The O 
protein O 
levels O 
of O 
HIF-1α O 
and O 
ARNT O 
are O 
not O 
altered O 
in O 
the O 
presence O 
of O 
6His B-FORMULA 
-TAT-Ainp1 O 
. O 
In O 
summary O 
, O 
we O 
provided O 
evidence O 
to O 
support O 
that O 
the O 
Ainp1 O 
peptide O 
directly O 
suppresses O 
the O 
HIF-1 O 
function O 
by O 
interacting O 
with O 
the O 
ARNT O 
HLH O 
domain O 
, O 
and O 
in O 
turn O 
interfering O 
with O 
the O 
heterodimerization O 
of O 
HIF-1α O 
and O 
ARNT O 
. O 

assessment O 
of O 
vaccine O 
adjuvant O 
squalene B-TRIVIAL 
. O 

genotoxic O 
potential O 
of O 
the O 
vaccine O 
adjuvant O 
Squalene B-TRIVIAL 
was O 
assessed O 
by O 
the O 
chromosomal O 
aberrations O 
( O 
CAs O 
) O 
, O 
sister O 
chromatid O 
exchanges O 
( O 
SCEs O 
) O 
and O 
micronucleus O 
( O 
MNs O 
) O 
tests O 
in O 
human O 
lymphocytes O 
and O 
comet O 
assay O 
in O 
both O 
human O 
and O 
rat O 
lymphocytes O 
. O 
Five O 
different O 
concentrations O 
of O 
squalene B-TRIVIAL 
( O 
1250-20,000μg O 
/ O 
ml O 
for O 
human O 
lymphocytes O 
and O 
0.07-1.12mg O 
/ O 
kg O 
for O 
rat O 
lymphocytes O 
) O 
were O 
studied O 
. O 
Squalene B-TRIVIAL 
did O 
not O 
affect O 
the O 
CAs O 
and O 
MN O 
frequency O 
, O 
in O 
all O 
treatments O 
in O 
vitro O 
. O 
A O 
significant O 
increase O 
in O 
SCEs O 
was O 
observed O 
in O 
almost O 
all O 
concentrations O 
at O 
24h O 
treatment O 
. O 
Squalene B-TRIVIAL 
did O 
not O 
affect O 
significantly O 
the O 
comet O 
tail O 
length O 
( O 
CTL O 
) O 
( O 
except O 
2500μg O 
/ O 
ml O 
) O 
and O 
comet O 
tail O 
intensity O 
( O 
CTI O 
) O 
at O 
all O 
treatments O 
in O 
vitro O 
. O 
In O 
rats O 
, O 
squalene B-TRIVIAL 
significantly O 
increased O 
and O 
decreased O 
CTL O 
and O 
CTI O 
in O 
some O 
doses O 
. O 
Although O 
there O 
are O 
increasing O 
and O 
reduction O 
in O 
the O 
effect O 
, O 
squalene B-TRIVIAL 
cannot O 
be O 
regarded O 
as O 
genotoxic O 
in O 
human O 
lymphocytes O 
. O 
However O 
, O 
further O 
in O 
vivo O 
studies O 
are O 
required O 
to O 
be O 
sure O 
on O 
the O 
effect O 
. O 

- O 
sized O 
particulate O 
adjuvants O 
such O 
as O 
ISCOMs O 
, O 
polystyrene B-SYSTEMATIC 
nanoparticles O 
and O 
virus O 
- O 
like O 
particles O 
have O 
been O 
shown O 
to O 
target O 
dendritic O 
cells O 
, O 
resulting O 
in O 
the O 
activation O 
of O 
T O 
and O 
B O 
cells O 
in O 
vivo O 
. O 
Using O 
an O 
ovine O 
pseudo O 
- O 
afferent O 
lymph O 
cannulation O 
model O 
to O 
capture O 
APC O 
that O 
traffic O 
from O 
the O 
site O 
of O 
injection O 
to O 
the O 
local O 
lymph O 
node O 
, O 
we O 
show O 
that O 
40-50nm O 
nanoparticles O 
are O 
taken O 
up O 
at O 
the O 
site O 
of O 
injection O 
by O 
dendritic O 
cells O 
( O 
DCs O 
) O 
migrating O 
to O 
the O 
draining O 
lymph O 
node O 
. O 
These O 
DCs O 
can O 
express O 
CD11c O 
, O 
CD1b O 
, O 
CD5 O 
, O 
MHC O 
class O 
II O 
and O 
CD8 O 
. O 
Nanoparticles O 
transported O 
by O 
DCs O 
migrating O 
from O 
the O 
site O 
of O 
injection O 
to O 
the O 
local O 
lymph O 
node O 
therefore O 
needs O 
to O 
be O 
considered O 
as O 
a O 
new O 
mechanism O 
underlying O 
the O 
immunogenicity O 
of O 
virus O 
- O 
sized O 
vaccine O 
delivery O 
systems O 
. O 

and O 
genotoxic O 
effects O 
of O 
Roundup B-TRIVIAL 
on O 
tadpoles O 
of O 
the O 
Indian O 
skittering O 
frog O 
( O 
Euflictis O 
cyanophlyctis O 
) O 
in O 
the O 
presence O 
and O 
absence O 
of O 
predator O 
stress O 
. O 

, O 
a O 
post O 
emergent O 
herbicide O 
, O 
has O 
become O 
the O 
backbone O 
of O 
no O 
- O 
till O 
agriculture O 
and O 
is O 
considered O 
safe O 
for O 
animals O 
. O 
However O 
, O 
the O 
impact O 
of O 
glyphosate B-TRIVIAL 
on O 
non-target O 
organisms O 
, O 
especially O 
on O 
amphibians O 
, O 
is O 
the O 
subject O 
of O 
major O 
concern O 
and O 
debate O 
in O 
recent O 
times O 
. O 
We O 
examined O 
the O 
toxic O 
and O 
genotoxic O 
effects O 
of O 
Roundup B-TRIVIAL 
, O 
a O 
commercial O 
formulation O 
of O 
glyphosate B-TRIVIAL 
, O 
in O 
the O 
tadpoles O 
of O 
the O 
Indian O 
skittering O 
frog O 
( O 
Euflictis O 
cyanophlyctis O 
) O 
. O 
Roundup B-TRIVIAL 
at O 
different O 
concentrations O 
( O 
0 O 
, O 
1 O 
, O 
2 O 
, O 
3 O 
, O 
4 O 
and O 
8mg O 
acid O 
equivalent O 
( O 
ae O 
) O 
/ O 
L O 
) O 
, O 
tested O 
in O 
a O 
2×6 O 
factorial O 
design O 
in O 
the O 
presence O 
and O 
absence O 
of O 
predator O 
stress O 
, O 
induced O 
concentration O 
- O 
dependent O 
lethality O 
in O 
tadpoles O 
. O 
The O 
96-h O 
LC50 O 
for O 
Roundup B-TRIVIAL 
in O 
the O 
absence O 
and O 
presence O 
of O 
predator O 
stress O 
were O 
3.76mgae O 
/ O 
L O 
and O 
3.39mgae O 
/ O 
L O 
, O 
respectively O 
. O 
The O 
10-day O 
LC50 O 
value O 
for O 
Roundup B-TRIVIAL 
was O 
significantly O 
lower O 
, O 
2.12mgae O 
/ O 
L O 
and O 
1.91mgae O 
/ O 
L O 
in O 
the O 
absence O 
and O 
presence O 
of O 
predator O 
stress O 
, O 
respectively O 
. O 
Lower O 
concentrations O 
of O 
Roundup B-TRIVIAL 
( O 
1 O 
, O 
2 O 
and O 
3mgae O 
/ O 
L O 
) O 
induced O 
the O 
formation O 
of O 
micronuclei O 
( O 
MN O 
) O 
in O 
the O 
erythrocytes O 
of O 
tadpoles O 
at O 
24-h O 
( O 
F3,56=10.286 O 
, O 
p O 
< O 
0.001 O 
) O 
, O 
48-h O 
( O 
F3,56=48.255 O 
, O 
p O 
< O 
0.001 O 
) O 
, O 
72-h O 
( O 
F3,56=118.933 O 
, O 
p O 
< O 
0.001 O 
) O 
and O 
96-h O 
( O 
F3,56=85.414 O 
, O 
p O 
< O 
0.001 O 
) O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 
Presence O 
of O 
predator O 
stress O 
apparently O 
increased O 
the O 
toxicity O 
and O 
genotoxicity O 
of O 
Roundup B-TRIVIAL 
; O 
but O 
these O 
effects O 
were O 
not O 
statistically O 
significant O 
. O 
These O 
findings O 
suggest O 
that O 
Roundup B-TRIVIAL 
at O 
environmentally O 
relevant O 
concentrations O 
has O 
lethal O 
and O 
genotoxic O 
impact O 
on O 
E O 
. O 
cyanophlyctis O 
; O 
which O 
may O 
have O 
long O 
- O 
term O 
fitness O 
consequence O 
to O 
the O 
species O 
. O 

and O 
biochemical O 
activities O 
of O 
antiproliferative O 
amino B-FAMILY 
acid I-FAMILY 
and O 
phosphate B-SYSTEMATIC 
derivatives O 
of O 
microtubule O 
- O 
disrupting O 
β-lactam B-FAMILY 
combretastatins I-FAMILY 
. O 

synthesis O 
and O 
biochemical O 
activities O 
of O 
novel O 
water O 
- O 
soluble O 
β-lactam B-TRIVIAL 
analogues O 
of O 
combretastatin B-TRIVIAL 
A-4 I-TRIVIAL 
are O 
described O 
. O 
The O 
first O 
series O 
of O 
compounds O 
investigated O 
, O 
β-lactam B-FAMILY 
phosphate I-FAMILY 
esters I-FAMILY 
7a O 
, O 
8a O 
and O 
9a O 
, O 
exhibited O 
potent O 
antiproliferative O 
activity O 
and O 
caused O 
microtubule O 
disruption O 
in O 
human O 
breast O 
carcinoma O 
- O 
derived O 
MCF-7 O 
cells O 
. O 
They O 
did O 
not O 
inhibit O 
tubulin O 
polymerisation O 
in O 
vitro O 
, O 
indicating O 
that O 
biotransformation O 
was O 
necessary O 
for O 
their O 
antiproliferative O 
and O 
tubulin O 
binding O 
effects O 
in O 
MCF-7 O 
cells O 
. O 
The O 
second O 
series O 
of O 
compounds O 
, O 
β-lactam B-FAMILY 
amino I-FAMILY 
acid I-FAMILY 
amides I-FAMILY 
( O 
including O 
10k O 
and O 
11l O 
) O 
displayed O 
potent O 
antiproliferative O 
activity O 
in O 
MCF-7 O 
cells O 
, O 
disrupted O 
microtubules O 
in O 
MCF-7 O 
cells O 
and O 
also O 
inhibited O 
the O 
polymerisation O 
of O 
tubulin O 
in O 
vitro O 
. O 
This O 
indicates O 
that O 
the O 
β-lactam B-FAMILY 
amides I-FAMILY 
did O 
not O 
require O 
metabolic O 
activation O 
to O 
have O 
antiproliferative O 
effects O 
, O 
in O 
contrast O 
to O 
the O 
phosphate B-SYSTEMATIC 
series O 
. O 
Both O 
series O 
of O 
compounds O 
caused O 
mitotic O 
catastrophe O 
and O 
apoptosis O 
in O 
MCF-7 O 
cells O 
. O 
Molecular O 
modelling O 
studies O 
indicated O 
potential O 
binding O 
conformations O 
for O 
the O 
β-lactam B-FAMILY 
amino I-FAMILY 
acid I-FAMILY 
amides I-FAMILY 
10k O 
and O 
11l O 
in O 
the O 
colchicine B-TRIVIAL 
-binding O 
site O 
of O 
tubulin O 
. O 
Due O 
to O 
their O 
aqueous O 
solubility O 
and O 
potent O 
biochemical O 
effects O 
, O 
these O 
compounds O 
are O 
promising O 
candidates O 
for O 
further O 
development O 
as O 
microtubule O 
- O 
disrupting O 
agents O 
. O 

, O 
evaluation O 
and O 
absolute O 
configuration O 
assignment O 
of O 
novel O 
dihydropyrimidin-2-ones B-FAMILY 
as O 
picomolar O 
sodium B-SYSTEMATIC 
iodide I-SYSTEMATIC 
symporter O 
inhibitors O 
. O 

small O 
library O 
of O 
dihydropyrimidin-2-ones B-FAMILY 
( O 
DHPMs B-FAMILY 
) O 
was O 
synthesized O 
and O 
evaluated O 
for O 
their O 
potency O 
to O 
block O 
iodide B-SYSTEMATIC 
entrapment O 
in O 
rat O 
thyroid O 
cells O 
. O 
Synthesis O 
was O 
achieved O 
using O 
the O 
multicomponent O 
Biginelli O 
reaction O 
. O 
Twelve O 
compounds O 
were O 
tested O 
for O 
the O 
inhibition O 
of O 
sodium B-SYSTEMATIC 
iodide I-SYSTEMATIC 
symporter O 
( O 
NIS O 
) O 
in O 
a O 
cell O 
- O 
based O 
assay O 
. O 
One O 
newly O 
synthesized O 
derivative O 
exhibited O 
a O 
remarkably O 
strong O 
activity O 
, O 
with O 
a O 
half O 
- O 
maximum O 
inhibitory O 
concentration O 
value O 
( O 
IC50 O 
) O 
of O 
65 O 
pM O 
. O 
Three O 
DHPMs B-FAMILY 
were O 
further O 
resolved O 
from O 
racemates O 
using O 
chiral O 
HPLC O 
and O 
absolute O 
configurations O 
were O 
assigned O 
using O 
circular O 
dichroism O 
spectroscopy O 
. O 
Biological O 
evaluation O 
showed O 
that O 
most O 
of O 
the O 
activity O 
against O 
NIS O 
resides O 
in O 
one O 
enantiomer O 
. O 
This O 
study O 
provides O 
new O 
insights O 
for O 
the O 
development O 
of O 
anti-thyroid O 
drugs O 
, O 
as O 
well O 
as O 
for O 
the O 
synthesis O 
of O 
novel O 
pharmacological O 
tools O 
designed O 
to O 
investigate O 
iodide B-SYSTEMATIC 
transport O 
mechanisms O 
at O 
cellular O 
and O 
molecular O 
levels O 
. O 

of O 
chronic O 
heroin B-TRIVIAL 
and O 
cocaine B-TRIVIAL 
administration O 
on O 
global O 
DNA O 
methylation O 
in O 
brain O 
and O 
liver O 
. O 

abuse O 
is O 
associated O 
with O 
epigenetic O 
changes O 
, O 
such O 
as O 
histone O 
modifications O 
and O 
DNA O 
methylation O 
. O 
The O 
purpose O 
of O 
the O 
present O 
study O 
was O 
to O 
examine O 
the O 
effect O 
of O 
chronic O 
cocaine B-TRIVIAL 
and O 
heroin B-TRIVIAL 
administration O 
on O 
global O 
DNA O 
methylation O 
in O 
brain O 
and O 
liver O 
. O 
Male O 
, O 
8 O 
week O 
old O 
, O 
C57BL O 
/ O 
6J O 
mice O 
received O 
heroin B-TRIVIAL 
in O 
a O 
chronic O 
' O 
intermittent O 
' O 
escalating O 
dose O 
paradigm O 
, O 
or O 
cocaine B-TRIVIAL 
in O 
a O 
chronic O 
escalating O 
dose O 
' O 
binge O 
' O 
paradigm O 
, O 
which O 
mimic O 
the O 
human O 
pattern O 
of O 
opioid O 
or O 
cocaine B-TRIVIAL 
abuse O 
respectively O 
. O 
Following O 
sacrifice O 
, O 
livers O 
and O 
brains O 
were O 
removed O 
and O 
DNA O 
was O 
extracted O 
from O 
them O 
. O 
The O 
extracted O 
DNA O 
was O 
hydrolyzed O 
and O 
2'-deoxycytidine B-SYSTEMATIC 
and O 
5-methyl-2'-deoxycytidine B-SYSTEMATIC 
were O 
determined O 
by O 
HPLC-UV O 
. O 
The O 
% O 
5-methyl-2'-deoxycytidine B-SYSTEMATIC 
content O 
of O 
DNA O 
was O 
significantly O 
higher O 
in O 
the O 
brain O 
compared O 
to O 
the O 
liver O 
. O 
There O 
were O 
no O 
differences O 
between O 
the O 
control O 
animals O 
and O 
the O 
cocaine B-TRIVIAL 
or O 
heroin B-TRIVIAL 
treated O 
animals O 
in O 
neither O 
of O 
the O 
tissues O 
examined O 
, O 
which O 
is O 
surprising O 
since O 
cocaine B-TRIVIAL 
administration O 
induced O 
gross O 
morphological O 
changes O 
in O 
the O 
liver O 
. O 
Moreover O 
, O 
there O 
was O 
no O 
difference O 
in O 
the O 
% O 
5-methyl-2'-deoxycytidine B-SYSTEMATIC 
content O 
of O 
DNA O 
between O 
the O 
cocaine B-TRIVIAL 
and O 
the O 
heroin B-TRIVIAL 
treated O 
animals O 
. O 
The O 
global O 
DNA O 
methylation O 
status O 
in O 
the O 
brain O 
and O 
liver O 
of O 
mice O 
chronically O 
treated O 
with O 
cocaine B-TRIVIAL 
or O 
heroin B-TRIVIAL 
remains O 
unaffected O 
, O 
but O 
this O 
finding O 
cannot O 
exclude O 
the O 
existence O 
of O 
anatomical O 
region O 
or O 
gene O 
- O 
specific O 
methylation O 
differences O 
. O 
This O 
is O 
the O 
first O 
time O 
that O 
global O 
DNA O 
methylation O 
in O 
the O 
liver O 
and O 
whole O 
brain O 
has O 
been O 
studied O 
following O 
chronic O 
cocaine B-TRIVIAL 
or O 
heroin B-TRIVIAL 
treatment O 
. O 

design O 
, O 
synthesis O 
and O 
QSAR O 
study O 
of O 
vasorelaxant O 
active O 
3-pyridinecarbonitriles B-SYSTEMATIC 
incorporating O 
1H-benzimidazol-2-yl B-SYSTEMATIC 
function O 
. O 

variety O 
of O 
2-alkoxy-4-aryl-6-(1H-benzimidazol-2-yl)-3-pyridinecarbonitriles B-FAMILY 
4a-r O 
were O 
prepared O 
via O 
either O 
regioselective O 
reaction O 
of O 
3-aryl-1-(1H-benzimidazol-2-yl)-2-propen-1-ones B-FAMILY 
3 O 
with O 
malononitrile B-TRIVIAL 
or O 
ylidenemalononitriles B-FAMILY 
6 O 
with O 
2-acetyl-1H-benzimidazoles B-FAMILY 
1 O 
in O 
the O 
presence O 
of O 
sodium B-FAMILY 
alkoxide I-FAMILY 
in O 
the O 
corresponding O 
alcohol B-FAMILY 
. O 
All O 
the O 
synthesized O 
compounds O 
showed O 
significant O 
vasodilation O 
properties O 
using O 
isolated O 
thoracic O 
aortic O 
rings O 
of O 
rats O 
pre O 
- O 
contracted O 
with O 
norepinephrine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
standard O 
technique O 
. O 
Compounds O 
4d O 
, O 
4p O 
, O 
4l O 
, O 
and O 
4f O 
exhibited O 
remarkable O 
activity O 
compared O 
with O 
prazosin B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
, O 
which O 
was O 
used O 
as O 
a O 
reference O 
standard O 
in O 
the O 
present O 
study O 
. O 
QSAR O 
studies O 
revealed O 
a O 
good O 
predictive O 
and O 
statistically O 
significant O 
3 O 
descriptor O 
model O 
( O 
r(2) O 
= O 
0.913 O 
, O 
radjusted(2)=0.8808 O 
, O 
rprediction(2)=0.7911 O 
) O 
. O 

antifolates O 
, O 
part O 
3 O 
: O 
Synthesis O 
, O 
biological O 
evaluation O 
and O 
molecular O 
modeling O 
study O 
of O 
some O 
new O 
2-heteroarylthio-quinazolin-4-ones B-FAMILY 
. O 

new O 
series O 
of O 
2-heteroarylthio-6- B-FAMILY 
substituted-quinazolin-4-one I-FAMILY 
analogs O 
was O 
designed O 
, O 
synthesized O 
, O 
and O 
evaluated O 
for O 
their O 
in O 
vitro O 
DHFR O 
inhibition O 
, O 
antimicrobial O 
, O 
and O 
antitumor O 
activities O 
. O 
Compounds O 
21 O 
, O 
25 O 
, O 
and O 
39 O 
proved O 
to O 
be O 
active O 
DHFR O 
inhibitors O 
with O 
IC50 O 
range O 
of O 
0.3-0.8 O 
μM O 
. O 
Compounds O 
25 O 
, O 
28 O 
, O 
33 O 
, O 
35 O 
and O 
36 O 
showed O 
broad O 
spectrum O 
antimicrobial O 
activity O 
comparable O 
to O 
the O 
known O 
antibiotic O 
gentamicin B-FAMILY 
. O 
Compound O 
29 O 
showed O 
broad O 
spectrum O 
antitumor O 
activity O 
toward O 
several O 
tumor O 
cell O 
lines O 
with O 
GI O 
values O 
range O 
of O 
25.8-41.2% O 
. O 
Molecular O 
modeling O 
studies O 
concluded O 
that O 
recognition O 
with O 
key O 
amino B-FAMILY 
acid I-FAMILY 
Arg B-FORMULA 
38 O 
and O 
Lys B-FORMULA 
31 O 
are O 
essential O 
for O 
binding O 
and O 
biological O 
activities O 
. O 
Flexible O 
alignment O 
; O 
electrostatic O 
and O 
hydrophobic O 
mappings O 
revealed O 
that O 
the O 
obtained O 
model O 
could O 
be O 
useful O 
for O 
the O 
development O 
of O 
new O 
DHFR O 
inhibitors O 
. O 

the O 
present O 
study O 
, O 
a O 
quantitative O 
dietary O 
exposure O 
assessment O 
of O 
mycotoxins O 
and O 
their O 
masked O 
forms O 
was O 
conducted O 
on O 
a O 
national O 
representative O 
sample O 
of O 
the O 
Belgian O 
population O 
using O 
the O 
contamination O 
data O 
of O 
cereal O 
- O 
based O 
foods O 
. O 
Cereal O 
- O 
based O 
food O 
products O 
( O 
n=174 O 
) O 
were O 
analysed O 
for O 
the O 
occurrence O 
of O 
deoxynivalenol B-TRIVIAL 
, O 
3-acetyldeoxynivalenol B-SYSTEMATIC 
, O 
15-acetyldeoxynivalenol B-SYSTEMATIC 
, O 
zearalenone B-TRIVIAL 
, O 
α-zearalenol B-TRIVIAL 
, O 
β-zearalenol B-TRIVIAL 
, O 
T-2-toxin B-TRIVIAL 
, O 
HT-2-toxin B-TRIVIAL 
, O 
and O 
their O 
respective O 
masked O 
forms O 
, O 
including O 
, O 
deoxynivalenol-3-glucoside B-SYSTEMATIC 
, O 
zearalenone-4-glucoside B-SYSTEMATIC 
, O 
α-zearalenol-4-glucoside B-SYSTEMATIC 
, O 
β-zearalenol-4-glucoside B-SYSTEMATIC 
and O 
zearalenone-4-sulfate B-SYSTEMATIC 
. O 
Fibre O 
- O 
enriched O 
bread O 
, O 
bran O 
- O 
enriched O 
bread O 
, O 
breakfast O 
cereals O 
, O 
popcorn O 
and O 
oatmeal O 
were O 
collected O 
in O 
Belgian O 
supermarkets O 
according O 
to O 
a O 
structured O 
sampling O 
plan O 
and O 
analysed O 
during O 
the O 
period O 
from O 
April O 
2010 O 
to O 
October O 
2011 O 
. O 
The O 
habitual O 
intake O 
of O 
these O 
food O 
groups O 
was O 
estimated O 
from O 
a O 
national O 
representative O 
food O 
intake O 
survey O 
. O 
According O 
to O 
a O 
probabilistic O 
exposure O 
analysis O 
, O 
the O 
mean O 
( O 
and O 
P95 O 
) O 
mycotoxin O 
intake O 
for O 
the O 
sum O 
of O 
the O 
deoxynivalenol B-TRIVIAL 
-equivalents O 
, O 
zearalenone B-TRIVIAL 
-equivalents O 
, O 
and O 
the O 
sum O 
of O 
HT-2-and B-MULTIPLE 
T-2-toxin I-MULTIPLE 
for O 
all O 
cereal O 
- O 
based O 
foods O 
was O 
0.1162 O 
( O 
0.4047 O 
, O 
P95 O 
) O 
, O 
0.0447 O 
( O 
0.1568 O 
, O 
P95 O 
) O 
and O 
0.0258 O 
( O 
0.0924 O 
, O 
P95 O 
) O 
μg O 
kg(-1)body O 
weight O 
day(-1) O 
, O 
respectively O 
. O 
These O 
values O 
were O 
below O 
the O 
tolerable O 
daily O 
intake O 
( O 
TDI O 
) O 
levels O 
for O 
deoxynivalenol B-TRIVIAL 
, O 
zearalenone B-TRIVIAL 
and O 
the O 
sum O 
of O 
T-2 B-MULTIPLE 
and I-MULTIPLE 
HT-2 I-MULTIPLE 
toxin I-MULTIPLE 
( O 
1 O 
, O 
0.25 O 
and O 
0.1 O 
μg O 
kg(-1)body O 
weight O 
day(-1) O 
, O 
respectively O 
) O 
. O 
The O 
absolute O 
level O 
exceeding O 
the O 
TDI O 
for O 
all O 
cereal O 
- O 
based O 
foods O 
was O 
calculated O 
, O 
and O 
recorded O 
0.85% O 
, O 
2.75% O 
and O 
4.11% O 
of O 
the O 
Belgian O 
population O 
, O 
respectively O 
. O 

new O 
triterpenoids B-FAMILY 
, O 
( B-SYSTEMATIC 
24R I-SYSTEMATIC 
/ I-SYSTEMATIC 
S)-24-hydroxy-3α I-SYSTEMATIC 
10α-epoxy-9-eip-cucurbita-25-ene I-SYSTEMATIC 
( O 
1a O 
, O 
b O 
) O 
, O 
as O 
well O 
as O 
six O 
known O 
compounds O 
( O 
3-8 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
extraction O 
of O 
Fructus O 
Viticis O 
Negundo O 
. O 
Their O 
structures O 
were O 
established O 
on O 
the O 
basis O 
of O 
spectral O 
analysis O 
. O 
In O 
addition O 
, O 
all O 
the O 
compounds O 
were O 
tested O 
for O 
inhibitory O 
effect O 
against O 
K-562 O 
and O 
A-549 O 
cell O 
lines O 
. O 

vitro O 
nanotoxicity O 
of O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
- O 
dendrimer O 
nanocomplexes O 
against O 
murine O 
myoblast O 
cells O 
. O 

- O 
wall O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWCNTs O 
) O 
and O 
polyamidoamine B-FAMILY 
dendrimers O 
( O 
PAMAM O 
) O 
have O 
been O 
proposed O 
for O 
a O 
variety O 
of O 
biomedical O 
applications O 
. O 
The O 
combination O 
of O 
both O 
molecules O 
makes O 
this O 
new O 
composite O 
nanomaterial O 
highly O 
functionalizable O 
and O 
versatile O 
to O 
theranostic O 
and O 
drug O 
- O 
delivery O 
systems O 
. O 
However O 
, O 
recent O 
toxicological O 
studies O 
have O 
shown O 
that O 
nanomaterials O 
such O 
as O 
SWCNTs O 
and O 
PAMAM O 
may O 
have O 
high O 
toxicity O 
in O 
biological O 
environments O 
. O 
Aiming O 
to O 
elucidate O 
such O 
behavior O 
, O 
in O 
vitro O 
studies O 
with O 
different O 
cultured O 
cells O 
have O 
been O 
conducted O 
in O 
the O 
past O 
few O 
years O 
. O 
This O 
study O 
focuses O 
on O 
the O 
effects O 
of O 
SWCNT-PAMAM O 
nanomaterials O 
and O 
their O 
individual O 
components O 
on O 
the O 
C2C12 O 
murine O 
cell O 
line O 
, O 
which O 
is O 
a O 
mixed O 
population O 
of O 
stem O 
and O 
progenitor O 
cells O 
. O 
The O 
interactions O 
between O 
the O 
cells O 
and O 
the O 
nanomaterials O 
were O 
studied O 
with O 
different O 
techniques O 
usually O 
employed O 
in O 
toxicological O 
analyses O 
. O 
The O 
results O 
showed O 
that O 
SWCNT-PAMAM O 
and O 
PAMAM O 
inhibited O 
the O 
proliferation O 
and O 
caused O 
DNA O 
damage O 
of O 
C2C12 O 
cells O 
. O 
Data O 
from O 
flow O 
cytometry O 
revealed O 
a O 
less O 
toxicity O 
in O 
C2C12 O 
cells O 
exposed O 
to O 
SWCNT O 
compared O 
to O 
the O 
other O 
nanomaterials O 
. O 
The O 
results O 
indicated O 
that O 
the O 
toxicity O 
of O 
SWCNT O 
, O 
SWCNT-PAMAM O 
and O 
PAMAM O 
in O 
C2C12 O 
cells O 
can O 
be O 
strongly O 
correlated O 
with O 
the O 
charge O 
of O 
the O 
nanomaterials O 
. O 

suppression O 
of O 
hematopoiesis O 
function O 
in O 
Balb O 
/ O 
c O 
mice O 
induced O 
by O 
prolonged O 
exposure O 
of O 
microcystin-LR B-TRIVIAL 
. O 

( O 
MCs O 
) O 
cause O 
normocytic O 
anemia O 
in O 
patients O 
in O 
a O 
hemodialysis O 
unit O 
in O 
Caruaru O 
, O 
Brazil O 
in O 
1996 O 
, O 
but O 
the O 
underlying O 
mechanisms O 
are O 
still O 
unclear O 
. O 
In O 
the O 
present O 
study O 
, O 
Balb O 
/ O 
c O 
mice O 
were O 
intraperitoneally O 
injected O 
with O 
microcystin-LR B-TRIVIAL 
( O 
MC-LR B-ABBREVIATION 
) O 
at O 
the O 
doses O 
of O 
0.5 O 
, O 
2 O 
and O 
8μg O 
/ O 
kg O 
body O 
weight O 
( O 
bw O 
) O 
every O 
48h O 
for O 
30d O 
. O 
After O 
the O 
prolonged O 
exposure O 
of O 
MC-LR B-ABBREVIATION 
, O 
significant O 
decreases O 
of O 
red O 
blood O 
cell O 
count O 
( O 
RBC O 
) O 
, O 
hemoglobin O 
( O 
Hb O 
) O 
and O 
hematocrit O 
( O 
Ht O 
) O 
were O 
observed O 
in O 
2 O 
and O 
8μg O 
/ O 
kg O 
bw O 
groups O 
, O 
but O 
erythrocyte O 
mean O 
corpuscular O 
volume O 
( O 
MCV O 
) O 
showed O 
no O 
significant O 
changes O 
. O 
Significantly O 
elevated O 
micronucleus O 
frequency O 
was O 
observed O 
in O 
bone O 
marrow O 
cells O 
( O 
BMCs O 
) O 
in O 
all O 
MC-LR B-ABBREVIATION 
treatments O 
. O 
The O 
proliferation O 
of O 
BMCs O 
significantly O 
declined O 
in O 
both O 
2 O 
and O 
8μg O 
/ O 
kg O 
bw O 
groups O 
. O 
Serum O 
levels O 
of O 
some O 
hematopoietic O 
growth O 
factors O 
significantly O 
changed O 
in O 
8μg O 
/ O 
kg O 
bw O 
group O 
, O 
mainly O 
including O 
granulocyte O 
- O 
macrophage O 
( O 
GM-CSF O 
) O 
, O 
erythropoietin O 
( O 
EPO O 
) O 
, O 
interleukin-3 O 
( O 
IL-3 O 
) O 
and O 
TNF-α O 
. O 
The O 
transcriptional O 
levels O 
of O 
these O 
4 O 
genes O 
in O 
BMCs O 
were O 
also O 
significantly O 
changed O 
in O 
8μg O 
/ O 
kg O 
bw O 
group O 
. O 
MC-LR B-ABBREVIATION 
exposure O 
significantly O 
increased O 
the O 
apoptosis O 
rates O 
in O 
all O 
MC-LR B-ABBREVIATION 
treatments O 
. O 
The O 
present O 
study O 
indicates O 
prolonged O 
exposure O 
of O 
MC-LR B-ABBREVIATION 
induces O 
normocytic O 
anemia O 
, O 
and O 
the O 
disturbed O 
hematopoietic O 
growth O 
factors O 
and O 
BMCs O 
apoptosis O 
are O 
responsible O 
for O 
this O 
normocytic O 
anemia O 
. O 

of O 
the O 
adjuvant O 
effect O 
of O 
silver B-SYSTEMATIC 
nanoparticles O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

immunological O 
adjuvant O 
effect O 
of O 
silver B-SYSTEMATIC 
nanoparticles O 
( O 
AgNPs O 
) O 
was O 
investigated O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
The O 
in O 
vivo O 
adjuvant O 
effect O 
of O 
AgNPs O 
was O 
evaluated O 
with O 
model O 
antigen O 
ovalbumin O 
( O 
OVA O 
) O 
and O 
bovine O 
serum O 
albumin O 
( O 
BSA O 
) O 
in O 
mice O 
by O 
intraperitoneal O 
and O 
subcutaneous O 
immunization O 
. O 
Serum O 
antigen O 
- O 
specific O 
IgG O 
level O 
significantly O 
increased O 
in O 
AgNPs O 
- O 
treated O 
mice O 
comparing O 
to O 
the O 
control O 
group O 
. O 
AgNPs O 
induced O 
the O 
increase O 
of O 
IgG1 O 
/ O 
IgG2a O 
ratio O 
and O 
antigen O 
- O 
specific O 
IgE O 
, O 
indicating O 
that O 
AgNPs O 
elicited O 
Th2-biased O 
immune O 
responses O 
. O 
By O 
in O 
vitro O 
assay O 
, O 
the O 
mechanism O 
of O 
adjuvant O 
effect O 
was O 
explored O 
. O 
After O 
48h O 
treatment O 
with O 
AgNPs O 
, O 
both O 
the O 
number O 
of O 
leukocytes O 
and O 
levels O 
of O 
cytokines O 
TNF-α O 
and O 
IFN-γ O 
in O 
abdominal O 
lavage O 
fluid O 
of O 
mice O 
increased O 
. O 
The O 
expression O 
of O 
the O 
major O 
histocompatibility O 
complex O 
class O 
II O 
molecule O 
on O 
the O 
surface O 
of O 
peritoneal O 
macrophages O 
significantly O 
increased O 
. O 
AgNPs O 
can O 
be O 
easily O 
phagocytosed O 
by O 
peritoneal O 
macrophages O 
, O 
while O 
do O 
not O 
affect O 
antigen O 
uptake O 
by O 
the O 
cell O 
. O 
We O 
therefore O 
conclude O 
that O 
AgNPs O 
have O 
significant O 
adjuvant O 
effect O 
and O 
the O 
mechanism O 
of O 
this O 
effect O 
is O 
mainly O 
ascribed O 
to O 
the O 
recruitment O 
and O 
activation O 
of O 
local O 
leukocytes O 
and O 
especially O 
macrophages O 
. O 
For O 
the O 
first O 
time O 
we O 
found O 
the O 
remarkable O 
adjuvant O 
effect O 
of O 
AgNPs O 
, O 
and O 
the O 
result O 
is O 
beneficial O 
for O 
the O 
future O 
applications O 
, O 
especially O 
in O 
biomedicine O 
. O 

(II) I-SYSTEMATIC 
complexes O 
with O 
mono-aminophosphonate B-SYSTEMATIC 
ester I-SYSTEMATIC 
targeting O 
group O 
that O 
induce O 
apoptosis O 
through O 
G1 O 
cell O 
- O 
cycle O 
arrest O 
: O 
Synthesis O 
, O 
crystal O 
structure O 
and O 
antitumour O 
activity O 
. O 

new O 
platinum B-SYSTEMATIC 
(II) I-SYSTEMATIC 
complexes O 
with O 
mono-aminophosphonate B-SYSTEMATIC 
ester I-SYSTEMATIC 
were O 
synthesized O 
and O 
characterized O 
by O 
elemental O 
analysis O 
, O 
(1)H B-FORMULA 
NMR O 
, O 
ESI-MS O 
as O 
well O 
as O 
single O 
crystal O 
X-ray O 
diffraction O 
analysis O 
. O 
They O 
are O 
mononuclear O 
structures O 
. O 
In O 
all O 
the O 
crystal O 
structures O 
of O 
complexes O 
1-6 O 
, O 
the O 
platinum B-SYSTEMATIC 
centre O 
adopts O 
an O 
approximately O 
square O 
- O 
planar O 
geometry O 
, O 
which O 
were O 
found O 
to O 
possess O 
excellent O 
solubility O 
in O 
both O 
organic O 
solvents O 
and O 
water O 
and O 
exhibit O 
considerable O 
cytotoxicity O 
against O 
MG-63 O 
, O 
SK-OV-3 O 
and O 
HepG2 O 
cell O 
lines O 
, O 
but O 
low O 
cytotoxicity O 
towards O 
normal O 
human O 
liver O 
cell O 
HL-7702 O 
. O 
In O 
contrast O 
to O 
cisplatin B-TRIVIAL 
, O 
their O 
antitumour O 
activities O 
are O 
achieved O 
through O 
the O 
induction O 
of O 
cell O 
apoptosis O 
by O 
G1 O 
cell O 
- O 
cycle O 
arrest O 
. O 

of O 
Both O 
Protein O 
Kinase O 
A O 
( O 
PKA O 
) O 
Type O 
I O 
and O 
PKA O 
Type O 
II O 
Isozymes O 
Is O 
Required O 
for O 
Retinoid B-FAMILY 
-Induced O 
Maturation O 
of O 
Acute O 
Promyelocytic O 
Leukemia O 
Cells O 
. O 

promyelocytic O 
leukemia O 
( O 
APL O 
) O 
is O 
characterized O 
by O 
granulopoietic O 
differentiation O 
arrest O 
at O 
the O 
promyelocytic O 
stage O 
. O 
In O 
most O 
cases O 
, O 
this O 
defect O 
can O 
be O 
overcome O 
by O 
treatment O 
with O 
all-trans-retinoic B-TRIVIAL 
acid I-TRIVIAL 
( O 
ATRA B-ABBREVIATION 
) O 
, O 
leading O 
to O 
complete O 
clinical O 
remission O 
. O 
Cyclic B-TRIVIAL 
AMP I-TRIVIAL 
signaling O 
has O 
a O 
key O 
role O 
in O 
retinoid B-FAMILY 
treatment O 
efficacy O 
: O 
it O 
enhances O 
ATRA B-ABBREVIATION 
-induced O 
maturation O 
in O 
ATRA B-ABBREVIATION 
-sensitive O 
APL O 
cells O 
( O 
including O 
NB4 O 
cells O 
) O 
and O 
restores O 
it O 
in O 
some O 
ATRA B-ABBREVIATION 
-resistant O 
cells O 
( O 
including O 
NB4-LR1 O 
cells O 
) O 
. O 
We O 
show O 
that O 
the O 
two O 
cell O 
types O 
express O 
identical O 
levels O 
of O 
the O 
Cα O 
catalytic O 
subunit O 
and O 
comparable O 
global O 
cAMP B-ABBREVIATION 
-dependent O 
protein O 
kinase O 
A O 
( O 
PKA O 
) O 
enzyme O 
activity O 
. O 
However O 
, O 
the O 
maturation O 
- O 
resistant O 
NB4-LR1 O 
cells O 
have O 
a O 
PKA O 
isozyme O 
switch O 
: O 
compared O 
with O 
the O 
NB4 O 
cells O 
, O 
they O 
have O 
decreased O 
content O 
of O 
the O 
juxtanuclearly O 
located O 
PKA O 
regulatory O 
subunit O 
IIα O 
and O 
PKA O 
regulatory O 
subunit O 
IIβ O 
, O 
and O 
a O 
compensatory O 
increase O 
of O 
the O 
generally O 
cytoplasmically O 
distributed O 
PKA-RIα O 
. O 
Furthermore O 
, O 
the O 
PKA O 
regulatory O 
subunit O 
II O 
exists O 
mainly O 
in O 
the O 
less O 
cAMP B-ABBREVIATION 
-responsive O 
nonautophosphorylated O 
state O 
in O 
the O 
NB4-LR1 O 
cells O 
. O 
By O 
the O 
use O 
of O 
isozyme O 
- O 
specific O 
cAMP B-ABBREVIATION 
analog O 
pairs O 
, O 
we O 
show O 
that O 
both O 
PKA-I O 
and O 
PKA-II O 
must O 
be O 
activated O 
to O 
achieve O 
maturation O 
in O 
NB4-LR1 O 
as O 
well O 
as O 
NB4 O 
cells O 
. O 
Therefore O 
, O 
special O 
attention O 
should O 
be O 
paid O 
to O 
activating O 
not O 
only O 
PKA-I O 
but O 
also O 
PKA-II O 
in O 
attempts O 
to O 
enhance O 
ATRA B-ABBREVIATION 
-induced O 
APL O 
maturation O 
in O 
a O 
clinical O 
setting O 
. O 

: O 
Alexithymia O 
is O 
a O 
personality O 
trait O 
characterized O 
by O 
difficulty O 
indentifying O 
and O 
describing O 
subjective O 
emotional O 
experiences O 
. O 
Decreased O 
aptitude O 
in O 
the O 
perception O 
, O 
evaluation O 
, O 
and O 
communication O 
of O 
affectively O 
laden O 
mental O 
states O 
has O 
been O 
associated O 
with O 
reduced O 
emotion O 
regulation O 
, O 
more O 
severe O 
drug O 
craving O 
in O 
addicts O 
, O 
and O 
structural O 
/ O 
functional O 
alterations O 
in O 
insula O 
and O 
anterior O 
cingulate O 
cortex O 
( O 
ACC O 
) O 
. O 
The O 
insula O 
and O 
ACC O 
represent O 
sites O 
of O 
convergence O 
between O 
the O 
putative O 
neural O 
substrates O 
of O 
alexithymia O 
and O 
those O 
perpetuating O 
cigarette O 
smoking O 
. O 
OBJECTIVES O 
: O 
We O 
examined O 
the O 
interrelations O 
between O 
alexithymia O 
, O 
tobacco O 
craving O 
, O 
and O 
insula O 
/ O 
ACC O 
neurocircuitry O 
using O 
resting O 
- O 
state O 
functional O 
connectivity O 
( O 
rsFC O 
) O 
. O 
METHODS O 
: O 
Overnight O 
- O 
deprived O 
smokers O 
( O 
n O 
= O 
24 O 
) O 
and O 
nonsmokers O 
( O 
n O 
= O 
20 O 
) O 
completed O 
six O 
neuroimaging O 
assessments O 
on O 
different O 
days O 
both O 
in O 
the O 
absence O 
of O 
, O 
and O 
following O 
, O 
varenicline B-TRIVIAL 
and O 
/ O 
or O 
nicotine B-TRIVIAL 
administration O 
. O 
In O 
this O 
secondary O 
analysis O 
of O 
data O 
from O 
a O 
larger O 
study O 
, O 
we O 
assessed O 
trait O 
alexithymia O 
and O 
state O 
tobacco O 
craving O 
using O 
self O 
- O 
reports O 
and O 
examined O 
the O 
rsFC O 
of O 
bilateral O 
insular O 
subregions O 
( O 
anterior O 
, O 
middle O 
, O 
posterior O 
) O 
and O 
dorsal O 
ACC O 
. O 
RESULTS O 
: O 
Higher O 
alexithymia O 
in O 
smokers O 
predicted O 
reduced O 
rsFC O 
strength O 
between O 
the O 
right O 
anterior O 
insula O 
( O 
aI O 
) O 
and O 
ventromedial O 
prefrontal O 
cortex O 
( O 
vmPFC O 
) O 
. O 
Higher O 
alexithymia O 
also O 
predicted O 
more O 
severe O 
tobacco O 
craving O 
during O 
nicotine B-TRIVIAL 
withdrawal O 
. O 
Critically O 
, O 
the O 
identified O 
aI-vmPFC O 
circuit O 
fully O 
mediated O 
this O 
alexithymia O 
- O 
craving O 
relation O 
. O 
That O 
is O 
, O 
elevated O 
alexithymia O 
predicted O 
decreased O 
aI-vmPFC O 
rsFC O 
and O 
, O 
in O 
turn O 
, O 
decreased O 
aI-vmPFC O 
rsFC O 
predicted O 
increased O 
craving O 
during O 
withdrawal O 
. O 
A O 
moderated O 
mediation O 
analysis O 
indicated O 
that O 
this O 
aI-vmPFC O 
mediational O 
effect O 
was O 
not O 
observed O 
following O 
drug O 
administration O 
. O 
CONCLUSIONS O 
: O 
These O 
results O 
suggest O 
that O 
a O 
weakened O 
right O 
aI-vmPFC O 
functional O 
circuit O 
confers O 
increased O 
liability O 
for O 
tobacco O 
craving O 
during O 
smoking O 
abstinence O 
. O 
Individual O 
differences O 
in O 
alexithymia O 
and O 
/ O 
or O 
aI-vmPFC O 
functional O 
coupling O 
may O 
be O 
relevant O 
factors O 
for O 
smoking O 
cessation O 
success O 
. O 

behavioural O 
effects O 
of O 
bupropion B-TRIVIAL 
and O 
naltrexone B-TRIVIAL 
, O 
alone O 
and O 
in O 
combination O 
, O 
in O 
non-deprived O 
male O 
rats O 
presented O 
with O 
palatable O 
mash O 
. O 

: O 
In O 
appetite O 
research O 
, O 
drugs O 
frequently O 
progress O 
to O 
clinical O 
trials O 
on O 
the O 
basis O 
of O 
outcome O 
( O 
reduced O 
food O 
intake O 
/ O 
body O 
weight O 
gain O 
) O 
with O 
insufficient O 
attention O 
to O 
process O 
( O 
behavioural O 
analysis O 
) O 
. O 
Although O 
bupropion B-TRIVIAL 
and O 
naltrexone B-TRIVIAL 
( O 
alone O 
and O 
in O 
combination O 
) O 
reduce O 
food O 
consumption O 
in O 
rodents O 
and O 
humans O 
, O 
their O 
effects O 
on O 
behaviour O 
during O 
feeding O 
tests O 
have O 
not O 
been O 
thoroughly O 
investigated O 
. O 
OBJECTIVES O 
: O 
This O 
study O 
aimed O 
to O 
assess O 
the O 
behavioural O 
specificity O 
of O 
anorectic O 
responses O 
to O 
bupropion B-TRIVIAL 
, O 
naltrexone B-TRIVIAL 
and O 
their O 
combination O 
. O 
METHODS O 
: O 
Video O 
analysis O 
was O 
employed O 
to O 
characterise O 
the O 
behavioural O 
effects O 
of O 
acute O 
systemic O 
treatment O 
with O 
bupropion B-TRIVIAL 
( O 
10.0-40.0 O 
mg O 
/ O 
kg O 
) O 
, O 
naltrexone B-TRIVIAL 
( O 
0.1-3.0 O 
mg O 
/ O 
kg O 
) O 
and O 
combined O 
bupropion B-TRIVIAL 
( O 
20 O 
mg O 
/ O 
kg O 
) O 
plus O 
naltrexone B-TRIVIAL 
( O 
0.1-1.0 O 
mg O 
/ O 
kg O 
) O 
in O 
non-deprived O 
male O 
rats O 
exposed O 
for O 
1 O 
h O 
to O 
palatable O 
mash O 
. O 
Particular O 
attention O 
was O 
paid O 
to O 
the O 
behavioural O 
satiety O 
sequence O 
( O 
BSS O 
) O 
. O 
RESULTS O 
: O 
In O 
experiment O 
1 O 
, O 
the O 
anorectic O 
response O 
to O 
40 O 
mg O 
/ O 
kg O 
bupropion B-TRIVIAL 
was O 
associated O 
with O 
significant O 
psychomotor O 
stimulation O 
and O 
a O 
complete O 
disruption O 
of O 
the O 
BSS O 
. O 
In O 
experiment O 
2 O 
, O 
the O 
anorectic O 
response O 
to O 
3 O 
mg O 
/ O 
kg O 
naltrexone B-TRIVIAL 
was O 
associated O 
with O 
an O 
accelerated O 
but O 
otherwise O 
normal O 
BSS O 
. O 
In O 
experiment O 
3 O 
, O 
the O 
co O 
- O 
administration O 
of O 
20 O 
mg O 
/ O 
kg O 
bupropion B-TRIVIAL 
and O 
naltrexone B-TRIVIAL 
( O 
0.1 O 
and O 
1 O 
mg O 
/ O 
kg O 
) O 
not O 
only O 
produced O 
an O 
additive O 
anorectic O 
profile O 
( O 
including O 
a O 
reduced O 
rate O 
of O 
eating O 
) O 
, O 
but O 
the O 
addition O 
of O 
the O 
opioid O 
receptor O 
antagonist O 
also O 
concurrently O 
attenuated O 
the O 
psychomotor O 
stimulant O 
response O 
to O 
the O 
atypical O 
antidepressant O 
. O 
CONCLUSIONS O 
: O 
Low O 
- O 
dose O 
co O 
- O 
treatment O 
with O 
naltrexone B-TRIVIAL 
and O 
bupropion B-TRIVIAL 
produces O 
a O 
stronger O 
suppression O 
of O 
appetite O 
than O 
that O 
seen O 
with O 
either O 
agent O 
alone O 
and O 
has O 
the O 
additional O 
advantage O 
of O 
reducing O 
some O 
of O 
the O 
unwanted O 
effects O 
of O 
bupropion B-TRIVIAL 
. O 

evaluate O 
the O 
vegetative O 
periodic O 
effect O 
of O 
rhizosphere O 
on O 
the O 
patterns O 
of O 
metal O 
bioaccumulation O 
, O 
the O 
concentrations O 
of O 
Mg B-FORMULA 
, O 
K B-FORMULA 
, O 
Ca B-FORMULA 
, O 
Mn B-FORMULA 
, O 
Zn B-FORMULA 
, O 
Fe B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Cr B-FORMULA 
, O 
Ni B-FORMULA 
, O 
Cd B-FORMULA 
and O 
Pb B-FORMULA 
in O 
the O 
corresponding O 
rhizosphere O 
soil O 
and O 
tissues O 
of O 
Phragmites O 
australis O 
growing O 
in O 
the O 
Sun O 
Island O 
wetland O 
( O 
Harbin O 
, O 
China O 
) O 
were O 
compared O 
. O 
The O 
concentrations O 
of O 
Zn B-FORMULA 
, O 
Fe B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Cr B-FORMULA 
, O 
Ni B-FORMULA 
, O 
Cd B-FORMULA 
and O 
Pb B-FORMULA 
in O 
roots O 
were O 
higher O 
than O 
in O 
shoots O 
, O 
suggesting O 
that O 
roots O 
are O 
the O 
primary O 
accumulation O 
organs O 
for O 
these O 
metals O 
and O 
there O 
exists O 
an O 
exclusion O 
strategy O 
for O 
metal O 
tolerance O 
. O 
In O 
contrast O 
, O 
the O 
rest O 
of O 
the O 
metals O 
showed O 
an O 
opposite O 
trend O 
, O 
suggesting O 
that O 
they O 
were O 
not O 
restricted O 
in O 
roots O 
. O 
Harvesting O 
would O 
particularly O 
be O 
an O 
effective O 
method O 
to O 
remove O 
Mn B-FORMULA 
from O 
the O 
environment O 
. O 
The O 
concentrations O 
of O 
metals O 
in O 
shoots O 
were O 
generally O 
higher O 
in O 
autumn O 
than O 
in O 
summer O 
, O 
suggesting O 
that O 
Ph O 
. O 
australis O 
possesses O 
an O 
efficient O 
root O 
- O 
to O 
- O 
shoot O 
translocation O 
system O 
, O 
which O 
is O 
activated O 
at O 
the O 
end O 
of O 
the O 
growing O 
season O 
and O 
allows O 
more O 
metals O 
into O 
the O 
senescent O 
tissues O 
. O 
Furthermore O 
, O 
metal O 
bioaccumulation O 
of O 
Ph O 
. O 
australis O 
was O 
affected O 
by O 
vegetative O 
periodic O 
variation O 
through O 
the O 
changing O 
of O 
physicochemical O 
and O 
microbial O 
conditions O 
. O 
The O 
rhizospheric O 
microbial O 
characteristics O 
were O 
significantly O 
related O 
to O 
the O 
concentrations O 
of O 
Mg B-FORMULA 
, O 
K B-FORMULA 
, O 
Zn B-FORMULA 
, O 
Fe B-FORMULA 
and O 
Cu B-FORMULA 
, O 
suggesting O 
that O 
microbial O 
influence O 
on O 
metal O 
accumulation O 
is O 
specific O 
and O 
selective O 
, O 
not O 
eurytopic O 
. O 

soy O 
and O 
soy O 
isoflavones B-FAMILY 
are O 
neuroprotective O 
in O 
experimental O 
cerebral O 
ischemia O 
. O 
Because O 
these O 
isoflavones B-FAMILY 
have O 
estrogenic O 
properties O 
, O 
we O 
hypothesized O 
that O 
, O 
like O 
estrogens B-FAMILY 
, O 
they O 
would O 
inhibit O 
acute O 
vascular O 
injury O 
and O 
the O 
detrimental O 
acute O 
increase O 
in O 
hypoxia O 
- O 
induced O 
vascular O 
endothelial O 
growth O 
factor O 
( O 
VEGF O 
) O 
that O 
leads O 
to O 
cerebral O 
edema O 
after O 
stroke O 
. O 
Mature O 
ovariectomized O 
female O 
Sprague O 
Dawley O 
rats O 
were O 
fed O 
soy O 
- O 
free O 
or O 
soy O 
- O 
containing O 
diets O 
for O 
4 O 
weeks O 
followed O 
by O 
90 O 
minutes O 
of O 
transient O 
middle O 
cerebral O 
artery O 
occlusion O 
. O 
Similar O 
to O 
estrogens B-FAMILY 
, O 
dietary O 
soy O 
significantly O 
reduced O 
cerebral O 
edema O 
and O 
vascular O 
apoptosis O 
24 O 
hours O 
after O 
stroke O 
. O 
Soy O 
also O 
inhibited O 
the O 
ischemia O 
- O 
induced O 
increase O 
in O 
cortical O 
VEGF O 
and O 
VEGF O 
receptor O 
(VEGFR)-2 O 
protein O 
expression O 
observed O 
4 O 
and O 
24 O 
hours O 
after O 
stroke O 
, O 
although O 
mRNA O 
levels O 
increased O 
. O 
The O 
reduction O 
in O 
VEGF O 
/ O 
VEGFR-2 O 
was O 
associated O 
both O 
with O 
decreases O 
in O 
receptor O 
phosphorylation O 
and O 
signaling O 
to O 
AKT O 
and O 
endothelial O 
nitric O 
oxide O 
synthase O 
. O 
Furthermore O 
degradation O 
of O 
the O 
VEGFR-2 O 
was O 
increased O 
with O 
dietary O 
soy O 
. O 
The O 
primary O 
ischemic O 
stimulus O 
for O 
VEGF O 
, O 
hypoxia O 
- O 
inducible O 
factor O 
1α O 
( O 
HIF1α O 
) O 
, O 
was O 
similarly O 
reduced O 
by O 
dietary O 
soy O 
4 O 
hours O 
after O 
transient O 
middle O 
cerebral O 
artery O 
occlusion O 
in O 
both O 
the O 
cortex O 
and O 
striatum O 
. O 
The O 
inhibition O 
of O 
HIF1α O 
activity O 
was O 
further O 
confirmed O 
by O 
a O 
significant O 
decrease O 
in O 
the O 
HIF1α-activated O 
apoptotic O 
mediator O 
BCL2 O 
/ O 
adenovirus O 
E1B O 
19 O 
kDa O 
protein O 
- O 
interacting O 
protein O 
3 O 
( O 
Nip3 O 
- O 
like O 
protein O 
X O 
) O 
. O 
These O 
data O 
suggest O 
that O 
soy O 
isoflavones B-FAMILY 
target O 
events O 
early O 
in O 
the O 
ischemic O 
cascade O 
as O 
part O 
of O 
their O 
neuroprotective O 
actions O 
and O 
counterbalance O 
some O 
of O 
the O 
detrimental O 
effects O 
of O 
the O 
endogenous O 
response O 
to O 
cerebral O 
injury O 
. O 

, O 
antigenotoxic O 
and O 
antioxidant O 
properties O 
of O 
methanol B-SYSTEMATIC 
extracts O 
obtained O 
from O 
Peltigera O 
horizontalis O 
and O 
Peltigera O 
praetextata O 
. O 

, O 
there O 
is O 
a O 
big O 
need O 
to O 
reduce O 
genotoxic O 
effects O 
of O 
mutagenic O 
and O 
carcinogenic O 
agents O 
in O 
environment O 
, O 
which O 
are O 
increased O 
by O 
the O 
technological O 
development O 
. O 
Lichens O 
produce O 
a O 
wide O 
variety O 
of O 
unique O 
metabolites O 
due O 
to O 
being O 
in O 
various O 
extreme O 
areas O 
and O 
being O 
symbiotic O 
organisms O 
of O 
fungi O 
and O 
algae O 
. O 
Therefore O 
, O 
this O 
study O 
was O 
planned O 
to O 
search O 
new O 
sources O 
having O 
antimutagenic O 
activity O 
by O 
researching O 
two O 
different O 
lichen O 
species O 
and O 
to O 
determine O 
whether O 
their O 
usage O 
is O 
safe O 
. O 
With O 
this O 
respect O 
, O 
the O 
mutagenic O 
and O 
antimutagenic O 
properties O 
of O 
methanol B-SYSTEMATIC 
extracts O 
of O 
the O 
lichens O 
were O 
determined O 
by O 
the O 
bacterial O 
reverse O 
mutation O 
and O 
sister O 
chromatid O 
exchange O 
assays O 
. O 
Furthermore O 
, O 
the O 
malondialdehyde B-TRIVIAL 
level O 
, O 
superoxide B-TRIVIAL 
dismutase O 
, O 
glutathione B-TRIVIAL 
and O 
glutathione B-TRIVIAL 
peroxidase O 
activities O 
against O 
aflatoxin B-TRIVIAL 
B1 I-TRIVIAL 
were O 
determined O 
for O 
understanding O 
the O 
ways O 
in O 
which O 
the O 
lichens O 
showed O 
their O 
genotoxic O 
properties O 
. O 

kidney O 
disease O 
( O 
CKD O 
) O 
patients O 
may O 
have O 
high O 
rates O 
of O 
bone O 
loss O 
and O 
fractures O 
, O 
but O 
microarchitectural O 
and O 
biochemical O 
mechanisms O 
of O 
bone O 
loss O 
in O 
CKD O 
patients O 
have O 
not O 
been O 
fully O 
described O 
. O 
In O 
this O 
longitudinal O 
study O 
of O 
53 O 
patients O 
with O 
CKD O 
Stages O 
2-5D O 
, O 
we O 
used O 
dual O 
energy O 
X-ray O 
absorptiometry O 
( O 
DXA O 
) O 
, O 
high O 
resolution O 
peripheral O 
quantitative O 
computed O 
tomography O 
( O 
HRpQCT O 
) O 
and O 
biochemical O 
markers O 
of O 
bone O 
metabolism O 
to O 
elucidate O 
effects O 
of O 
CKD O 
on O 
the O 
skeleton O 
. O 
Median O 
follow O 
- O 
up O 
was O 
1.5 O 
years O 
( O 
Range O 
0.9 O 
to O 
4.3 O 
years O 
) O 
; O 
bone O 
changes O 
were O 
annualized O 
and O 
compared O 
to O 
baseline O 
. O 
By O 
DXA O 
, O 
there O 
were O 
significant O 
declines O 
in O 
areal O 
bone O 
mineral O 
density O 
( O 
BMD O 
) O 
of O 
the O 
total O 
hip O 
and O 
ultradistal O 
radius O 
: O 
-1.3% O 
( O 
95% O 
CI O 
: O 
-2.1 O 
to O 
-0.6 O 
) O 
and O 
-2.4% O 
( O 
95% O 
CI O 
: O 
-4 O 
to O 
-0.9 O 
) O 
, O 
respectively O 
. O 
By O 
HRpQCT O 
at O 
the O 
distal O 
radius O 
, O 
there O 
were O 
significant O 
declines O 
in O 
cortical O 
area O 
, O 
density O 
and O 
thickness O 
, O 
and O 
increases O 
in O 
porosity O 
: O 
-2.9% O 
( O 
95% O 
CI O 
-3.7 O 
to O 
-2.2 O 
) O 
, O 
-1.3% O 
( O 
95% O 
CI O 
-1.6 O 
to O 
-0.6 O 
) O 
, O 
-2.8% O 
( O 
95% O 
CI O 
-3.6 O 
to O 
-1.9 O 
) O 
, O 
and O 
+ O 
4.2% O 
( O 
95% O 
CI O 
2 O 
to O 
6.4 O 
) O 
respectively O 
. O 
Radius O 
trabecular O 
area O 
increased O 
significantly O 
: O 
+ O 
0.4% O 
( O 
95% O 
CI O 
0.2 O 
to O 
0.6 O 
) O 
, O 
without O 
significant O 
changes O 
in O 
trabecular O 
density O 
or O 
microarchitecture O 
. O 
Elevated O 
time O 
- O 
averaged O 
levels O 
of O 
parathyroid O 
hormone O 
( O 
PTH O 
) O 
and O 
bone O 
turnover O 
markers O 
predicted O 
cortical O 
deterioration O 
. O 
Higher O 
levels O 
of O 
serum O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
predicted O 
decreases O 
in O 
trabecular O 
network O 
heterogeneity O 
. O 
These O 
data O 
suggest O 
that O 
significant O 
cortical O 
loss O 
occurs O 
with O 
CKD O 
, O 
which O 
is O 
mediated O 
by O 
hyperparathyroidism O 
and O 
elevated O 
turnover O 
. O 
Future O 
investigations O 
are O 
required O 
to O 
determine O 
whether O 
these O 
cortical O 
losses O 
can O 
be O 
attenuated O 
by O 
treatments O 
that O 
reduce O 
PTH O 
levels O 
and O 
remodeling O 
rates O 
. O 
© O 
2013 O 
American O 
Society O 
for O 
Bone O 
and O 
Mineral O 
Research O 
. O 

flavonol B-TRIVIAL 
and O 
diterpenoids B-FAMILY 
from O 
the O 
endophytic O 
fungus O 
Aspergillus O 
sp O 
. O 
YXf3 O 
. O 

new O 
flavonol B-TRIVIAL 
, O 
chlorflavonin B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
, O 
four O 
new O 
diterpenoids B-FAMILY 
, O 
aspergiloids B-MULTIPLE 
E-H I-MULTIPLE 
( O 
3 O 
, O 
5-7 O 
) O 
, O 
together O 
with O 
eight O 
known O 
compounds O 
( O 
2 O 
, O 
4 O 
, O 
8-13 O 
) O 
were O 
isolated O 
from O 
solid O 
fermentation O 
of O 
Aspergillus O 
sp O 
. O 
( O 
strain O 
no O 
. O 
YXf3 O 
) O 
, O 
an O 
endophytic O 
fungus O 
from O 
Ginkgo O 
biloba O 
. O 
Their O 
structures O 
were O 
determined O 
through O 
detailed O 
spectroscopic O 
analysis O 
combined O 
with O 
comparison O 
of O 
NMR O 
spectra O 
data O 
with O 
reported O 
ones O 
. O 
All O 
of O 
them O 
were O 
screened O 
on O 
cytotoxicity O 
against O 
KB O 
, O 
SGC-7901 O 
, O 
SW1116 O 
, O 
and O 
A549 O 
cell O 
lines O 
; O 
compounds O 
4 O 
, O 
9-11 O 
exhibited O 
moderate O 
activities O 
with O 
IC50 O 
values O 
ranging O 
from O 
6.74 O 
to O 
46.64 O 
µM O 
. O 

role O 
of O 
self O 
- O 
assembled O 
monolayers O 
in O 
carbon B-SYSTEMATIC 
nanomaterial O 
- O 
based O 
field O 
- O 
effect O 
transistors O 
. O 

self O 
- O 
assembly O 
is O 
a O 
promising O 
technology O 
for O 
creating O 
reliable O 
functional O 
films O 
in O 
optoelectronic O 
devices O 
with O 
full O 
control O 
of O 
thickness O 
and O 
even O 
spatial O 
resolution O 
. O 
In O 
particular O 
, O 
rationally O 
designed O 
self O 
- O 
assembled O 
monolayers O 
( O 
SAMs O 
) O 
play O 
an O 
important O 
role O 
in O 
modifying O 
the O 
electrode O 
/ O 
semiconductor O 
and O 
semiconductor O 
/ O 
dielectric O 
interfaces O 
in O 
field O 
- O 
effect O 
transistors O 
. O 
Carbon B-SYSTEMATIC 
nanomaterials O 
, O 
especially O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
and O 
graphene B-TRIVIAL 
, O 
have O 
attracted O 
intense O 
interest O 
in O 
recent O 
years O 
due O 
to O 
their O 
remarkable O 
physicochemical O 
properties O 
. O 
The O 
combination O 
of O 
the O 
advantages O 
of O 
both O 
SAMs O 
and O 
carbon B-SYSTEMATIC 
nanomaterials O 
has O 
been O 
opening O 
up O 
a O 
thriving O 
research O 
field O 
. O 
In O 
this O 
Review O 
article O 
, O 
the O 
unique O 
role O 
of O 
SAMs O 
acting O 
as O 
either O 
active O 
or O 
auxiliary O 
layers O 
in O 
carbon B-SYSTEMATIC 
nanomaterials O 
- O 
based O 
field O 
- O 
effect O 
transistors O 
is O 
highlighted O 
for O 
tuning O 
the O 
substrate O 
effect O 
, O 
controlling O 
the O 
carrier O 
type O 
and O 
density O 
in O 
the O 
conducting O 
channel O 
, O 
and O 
even O 
installing O 
new O 
functionalities O 
. O 
The O 
combination O 
of O 
molecular O 
self O 
- O 
assembly O 
and O 
molecular O 
engineering O 
with O 
materials O 
fabrication O 
could O 
incorporate O 
diverse O 
molecular O 
functionalities O 
into O 
electrical O 
nanocircuits O 
, O 
thus O 
speeding O 
the O 
development O 
of O 
nanometer O 
/ O 
molecular O 
electronics O 
in O 
the O 
future O 
. O 

of O 
Isoidide B-TRIVIAL 
through O 
Epimerization O 
of O 
Isosorbide B-TRIVIAL 
using O 
Ruthenium B-SYSTEMATIC 
on O 
Carbon B-SYSTEMATIC 
. O 

highly O 
efficient O 
procedure O 
for O 
obtaining O 
resin O 
- O 
grade O 
isoidide B-TRIVIAL 
through O 
catalytic O 
epimerization O 
of O 
isosorbide B-TRIVIAL 
using O 
a O 
ruthenium B-SYSTEMATIC 
-on- O 
carbon B-SYSTEMATIC 
( O 
Ru B-FORMULA 
/ O 
C B-FORMULA 
) O 
catalyst O 
is O 
reported O 
. O 
A O 
comprehensive O 
reaction O 
- O 
parameter O 
variation O 
study O 
involving O 
substrate O 
concentration O 
, O 
catalyst O 
( O 
type O 
of O 
metal O 
, O 
support O 
, O 
and O 
loading O 
) O 
, O 
initial O 
pH O 
value O 
, O 
hydrogen B-SYSTEMATIC 
pressure O 
, O 
solvent O 
, O 
and O 
reaction O 
temperature O 
demonstrates O 
that O 
superior O 
performance O 
and O 
high O 
selectivity O 
can O 
be O 
achieved O 
. O 
Epimerization O 
of O 
isosorbide B-TRIVIAL 
in O 
water O 
( O 
pH O 
8 O 
) O 
at O 
220 O 
°C O 
, O 
under O 
40 O 
bar O 
of O 
hydrogen B-SYSTEMATIC 
, O 
and O 
using O 
a O 
Ru B-FORMULA 
/ O 
C B-FORMULA 
catalyst O 
( O 
5 O 
% O 
Ru B-FORMULA 
) O 
for O 
2 O 
h O 
results O 
in O 
a O 
thermodynamic O 
equilibrium O 
mixture O 
containing O 
55 O 
% O 
isoidide B-TRIVIAL 
, O 
40 O 
% O 
isosorbide B-TRIVIAL 
, O 
and O 
5 O 
% O 
isomannide B-TRIVIAL 
. O 
In O 
comparison O 
with O 
previously O 
reported O 
nickel B-SYSTEMATIC 
-based O 
catalysts O 
, O 
the O 
Ru B-FORMULA 
/ O 
C B-FORMULA 
catalyst O 
is O 
advantageous O 
because O 
it O 
is O 
highly O 
active O 
( O 
as O 
low O 
as O 
360 O 
ppm O 
Ru B-FORMULA 
) O 
and O 
recyclable O 
. O 
High O 
purity O 
isoidide B-TRIVIAL 
is O 
obtained O 
by O 
high O 
- O 
vacuum O 
distillation O 
of O 
an O 
equilibrium O 
mixture O 
on O 
a O 
200 O 
g O 
scale O 
. O 
The O 
high O 
substrate O 
loading O 
( O 
50 O 
wt O 
% O 
in O 
water O 
) O 
, O 
high O 
selectivity O 
, O 
and O 
the O 
possibility O 
for O 
substrate O 
reuse O 
makes O 
this O 
procedure O 
highly O 
atom O 
efficient O 
and O 
therefore O 
, O 
highly O 
attractive O 
for O 
industrial O 
use O 
. O 

and O 
impairment O 
in O 
brain O 
development O 
and O 
function O 
in O 
rat O 
offspring O 
after O 
maternal O 
exposure O 
to O 
methylmercury B-SYSTEMATIC 
. O 

exposure O 
to O 
the O 
neurotoxin O 
methylmercury B-SYSTEMATIC 
( O 
MeHg B-FORMULA 
) O 
has O 
been O 
shown O 
to O 
have O 
adverse O 
effects O 
on O 
neural O 
development O 
of O 
the O 
offspring O 
in O 
man O 
. O 
Little O 
is O 
known O 
about O 
the O 
underlying O 
mechanisms O 
by O 
which O 
MeHg B-FORMULA 
affects O 
the O 
developing O 
brain O 
. O 
To O 
explore O 
the O 
neurodevelopmental O 
defects O 
and O 
the O 
underlying O 
mechanism O 
associated O 
with O 
MeHg B-FORMULA 
exposure O 
, O 
the O 
cerebellum O 
and O 
cerebrum O 
of O 
Wistar O 
rat O 
pups O 
were O 
analyzed O 
by O 
[(18)F]FDG B-SYSTEMATIC 
PET O 
functional O 
imaging O 
, O 
field O 
potential O 
analysis O 
, O 
and O 
microarray O 
gene O 
expression O 
profiling O 
. O 
Female O 
rat O 
pups O 
were O 
exposed O 
to O 
MeHg B-FORMULA 
via O 
maternal O 
diet O 
during O 
intrauterinal O 
and O 
lactational O 
period O 
( O 
from O 
gestational O 
day O 
6 O 
to O 
postnatal O 
day O 
(PND)10 O 
) O 
, O 
and O 
their O 
brain O 
tissues O 
were O 
sampled O 
for O 
the O 
analysis O 
at O 
weaning O 
( O 
PND18-21 O 
) O 
and O 
adulthood O 
( O 
PND61-70 O 
) O 
. O 
The O 
[(18)F]FDG B-SYSTEMATIC 
PET O 
imaging O 
and O 
field O 
potential O 
analysis O 
suggested O 
a O 
delay O 
in O 
brain O 
activity O 
and O 
impaired O 
neural O 
function O 
by O 
MeHg B-FORMULA 
. O 
Genome O 
- O 
wide O 
transcriptome O 
analysis O 
substantiated O 
these O 
findings O 
by O 
showing O 
( O 
1 O 
) O 
a O 
delay O 
in O 
the O 
onset O 
of O 
gene O 
expression O 
related O 
to O 
neural O 
development O 
, O 
and O 
( O 
2 O 
) O 
alterations O 
in O 
pathways O 
related O 
to O 
both O 
structural O 
and O 
functional O 
aspects O 
of O 
nervous O 
system O 
development O 
. O 
The O 
latter O 
included O 
changes O 
in O 
gene O 
expression O 
of O 
developmental O 
regulators O 
, O 
developmental O 
phase O 
- O 
associated O 
genes O 
, O 
small O 
GTPase O 
signaling O 
molecules O 
, O 
and O 
representatives O 
of O 
all O 
processes O 
required O 
for O 
synaptic O 
transmission O 
. O 
These O 
findings O 
were O 
observed O 
at O 
dose O 
levels O 
at O 
which O 
only O 
marginal O 
changes O 
in O 
conventional O 
developmental O 
toxicity O 
endpoints O 
were O 
detected O 
. O 
Therefore O 
, O 
the O 
approaches O 
applied O 
in O 
this O 
study O 
are O 
promising O 
in O 
terms O 
of O 
yielding O 
increased O 
sensitivity O 
compared O 
with O 
classical O 
developmental O 
toxicity O 
tests O 
. O 

T I-TRIVIAL 
and O 
its O 
photoirradiative O 
derivatives O 
: O 
exploring O 
their O 
spectroscopic O 
properties O 
in O 
the O 
absence O 
and O 
presence O 
of O 
amyloid O 
fibrils O 
. O 

this O 
work O 
, O 
we O 
found O 
that O 
, O 
during O 
storage O 
or O 
after O 
UV O 
irradiation O 
, O 
ThT B-ABBREVIATION 
is O 
demethylated O 
or O 
oxidized O 
, O 
forming O 
three O 
derivatives O 
. O 
These O 
three O 
derivatives O 
were O 
purified O 
by O 
high O 
performance O 
liquid O 
chromatography O 
and O 
characterized O 
by O 
mass O 
and O 
nuclear O 
magnetic O 
resonance O 
spectroscopy O 
and O 
the O 
spectroscopic O 
properties O 
of O 
pure O 
ThT B-ABBREVIATION 
and O 
the O 
derivatives O 
carefully O 
compared O 
. O 
Our O 
results O 
show O 
that O 
the O 
emission O 
peak O 
at O 
450 O 
nm O 
results O 
from O 
oxidized O 
ThT B-ABBREVIATION 
and O 
not O 
from O 
the O 
monomeric O 
form O 
of O 
ThT B-ABBREVIATION 
, O 
as O 
previously O 
proposed O 
. O 
The O 
partial O 
conversion O 
of O 
ThT B-ABBREVIATION 
into O 
oxidized O 
and O 
demethylated O 
derivatives O 
has O 
an O 
effect O 
on O 
amyloid O 
detection O 
using O 
ThT B-ABBREVIATION 
assay O 
. O 
Irradiated O 
ThT B-ABBREVIATION 
has O 
the O 
same O 
lag O 
time O 
as O 
pure O 
ThT B-ABBREVIATION 
in O 
the O 
amyloidogenesis O 
of O 
insulin O 
, O 
but O 
the O 
intensity O 
of O 
the O 
emitted O 
fluorescence O 
is O 
significantly O 
decreased O 
. O 

radiation O 
( O 
SR O 
) O 
, O 
which O 
combines O 
extremely O 
high O 
intensity O 
, O 
high O 
collimation O 
, O 
tunability O 
, O 
and O 
continuous O 
energy O 
spectrum O 
, O 
allows O 
the O 
development O 
of O 
advanced O 
X-ray O 
based O 
techniques O 
that O 
are O 
becoming O 
a O 
uniquely O 
useful O 
tool O 
in O 
life O 
science O 
research O 
, O 
along O 
providing O 
exciting O 
opportunities O 
in O 
biomedical O 
imaging O 
and O 
radiotherapy O 
. O 
This O 
review O 
summarize O 
emerging O 
techniques O 
and O 
their O 
potential O 
to O 
greatly O 
enhance O 
the O 
exploration O 
of O 
dynamical O 
biological O 
process O 
occurring O 
across O 
various O 
spatial O 
and O 
temporal O 
regimes O 
, O 
from O 
whole O 
body O 
physiology O 
, O 
down O 
to O 
the O 
location O 
of O 
individual O 
chemical O 
species O 
within O 
single O 
cells O 
. O 
In O 
recent O 
years O 
pediatric O 
research O 
and O 
clinic O 
practice O 
have O 
started O 
to O 
profit O 
from O 
these O 
new O 
opportunities O 
, O 
particularly O 
by O 
extending O 
the O 
diagnostic O 
and O 
therapeutic O 
capabilities O 
of O 
these O 
X-ray O 
based O 
techniques O 
. O 
In O 
diagnosis O 
, O 
technical O 
advances O 
in O 
DEI O 
and O 
KES O 
imaging O 
modalities O 
have O 
been O 
demonstrated O 
as O 
particularly O 
valuable O 
for O 
children O 
and O 
women O 
since O 
SR O 
allows O 
dose O 
minimization O 
, O 
with O 
significant O 
reductions O 
compared O 
to O 
conventional O 
approaches O 
. O 
However O 
, O 
the O 
greatest O 
expectations O 
are O 
in O 
the O 
field O 
of O 
SR O 
based O 
radiotherapy O 
, O 
increasingly O 
studies O 
are O 
demonstrating O 
SR O 
radiotherapy O 
provides O 
improved O 
chances O 
of O 
recovery O 
; O 
this O 
is O 
especially O 
the O 
case O 
for O 
pediatric O 
patients O 
. O 
In O 
addition O 
, O 
we O 
report O 
on O 
the O 
applicability O 
of O 
advanced O 
X-ray O 
microscopy O 
techniques O 
that O 
offer O 
exceptional O 
spatial O 
and O 
quantitative O 
resolution O 
in O 
elemental O 
detection O 
. O 
These O 
techniques O 
, O 
which O 
are O 
useful O 
for O 
in O 
vitro O 
studies O 
, O 
will O 
be O 
particularly O 
advantageous O 
where O 
investigators O 
seek O 
deeper O 
understanding O 
of O 
diseases O 
where O 
mismetabolism O 
of O 
metals O 
, O 
either O 
physiological O 
important O 
( O 
i.e O 
. O 
Cu B-FORMULA 
, O 
Zn B-FORMULA 
) O 
or O 
outright O 
toxic O 
( O 
i.e O 
. O 
Pb B-FORMULA 
) O 
, O 
underlies O 
pathogenesis O 
. O 

is O 
certainly O 
one O 
of O 
the O 
scientific O 
and O 
technological O 
challenges O 
of O 
the O 
coming O 
years O 
. O 
In O 
particular O 
, O 
biodegradable O 
nanoparticles O 
formulated O 
from O 
poly B-FAMILY 
( I-FAMILY 
D,L-lactide-co- I-FAMILY 
glycolide I-FAMILY 
) I-FAMILY 
( O 
PLGA B-ABBREVIATION 
) O 
have O 
been O 
extensively O 
investigated O 
for O 
sustained O 
and O 
targeted O 
delivery O 
of O 
different O 
agents O 
, O 
including O 
recombinant O 
proteins O 
, O 
plasmid O 
DNA O 
, O 
and O 
low O 
molecular O 
weight O 
compounds O 
. O 
PLGA B-ABBREVIATION 
NPs O 
present O 
some O 
very O 
attractive O 
properties O 
such O 
as O 
biodegradability O 
and O 
biocompatibility O 
, O 
protection O 
of O 
drug O 
from O 
degradation O 
, O 
possibility O 
of O 
sustained O 
release O 
, O 
and O 
the O 
possibility O 
to O 
modify O 
surface O 
properties O 
to O 
target O 
nanoparticles O 
to O 
specific O 
organs O 
or O 
cells O 
. O 
Moreover O 
, O 
PLGA B-ABBREVIATION 
NPs O 
have O 
received O 
the O 
FDA O 
and O 
European O 
Medicine O 
Agency O 
approval O 
in O 
drug O 
delivery O 
systems O 
for O 
parenteral O 
administration O 
, O 
thus O 
reducing O 
the O 
time O 
for O 
human O 
clinical O 
applications O 
. O 
This O 
review O 
in O 
particular O 
deals O 
on O 
surface O 
modification O 
of O 
PLGA B-ABBREVIATION 
NPs O 
and O 
their O 
possibility O 
of O 
clinical O 
applications O 
, O 
including O 
treatment O 
for O 
brain O 
pathologies O 
such O 
as O 
brain O 
tumors O 
and O 
Lysosomal O 
Storage O 
Disorders O 
with O 
neurological O 
involvement O 
. O 
Since O 
a O 
great O 
number O 
of O 
pharmacologically O 
active O 
molecules O 
are O 
not O 
able O 
to O 
cross O 
the O 
Blood-Brain O 
Barrier O 
( O 
BBB O 
) O 
and O 
reach O 
the O 
Central O 
Nervous O 
System O 
( O 
CNS O 
) O 
, O 
new O 
brain O 
targeted O 
polymeric O 
PLGA B-ABBREVIATION 
NPs O 
modified O 
with O 
glycopeptides O 
( O 
g7- O 
NPs O 
) O 
have O 
been O 
recently O 
produced O 
. O 
In O 
this O 
review O 
several O 
in O 
vivo O 
biodistribution O 
studies O 
and O 
pharmacological O 
proof O 
- O 
of O 
evidence O 
of O 
brain O 
delivery O 
of O 
model O 
drugs O 
are O 
reported O 
, O 
demonstrating O 
the O 
ability O 
of O 
g7-NPs O 
to O 
create O 
BBB O 
interaction O 
and O 
trigger O 
an O 
efficacious O 
BBB O 
crossing O 
. O 
Moreover O 
, O 
another O 
relevant O 
development O 
of O 
NPs O 
surface O 
engineering O 
was O 
achieved O 
by O 
conjugating O 
to O 
the O 
surface O 
of O 
g7-NPs O 
, O 
some O 
specific O 
and O 
selective O 
antibodies O 
to O 
drive O 
NPs O 
directly O 
to O 
a O 
specific O 
cell O 
type O 
once O 
inside O 
the O 
CNS O 
parenchyma O 
. O 

-exposed O 
macrophages O 
induce O 
IL-8 O 
release O 
from O 
airway O 
epithelial O 
cells O 
through O 
NF-κB O 
and O 
AP-1 O 
pathways O 
. O 

, O 
a O 
highly O 
toxic O 
α B-SYSTEMATIC 
, I-SYSTEMATIC 
β- I-SYSTEMATIC 
unsaturated I-SYSTEMATIC 
aldehyde I-SYSTEMATIC 
, O 
is O 
a O 
major O 
component O 
of O 
cigarette O 
smoke O 
and O 
a O 
ubiquitous O 
environmental O 
pollutant O 
. O 
Crotonaldehyde B-TRIVIAL 
exposure O 
is O 
known O 
to O 
have O 
adverse O 
effects O 
on O 
respiratory O 
health O 
, O 
but O 
the O 
underlying O 
mechanisms O 
remain O 
obscure O 
. O 
To O 
examine O 
the O 
interaction O 
between O 
macrophages O 
and O 
airway O 
epithelial O 
cells O 
after O 
exposure O 
to O 
crotonaldehyde B-TRIVIAL 
, O 
BEAS-2B O 
and O 
A549 O 
cells O 
were O 
treated O 
with O 
conditioned O 
media O 
from O 
a O 
human O 
monocytic O 
leukemia O 
cell O 
line O 
( O 
THP-1 O 
) O 
cells O 
stimulated O 
with O 
crotonaldehyde B-TRIVIAL 
. O 
We O 
demonstrate O 
that O 
conditioned O 
media O 
from O 
THP-1 O 
cells O 
stimulated O 
with O 
crotonaldehyde B-TRIVIAL 
increased O 
interleukin O 
(IL)-8 O 
production O 
, O 
enhanced O 
nuclear O 
factor O 
(NF)-κB O 
and O 
AP-1 O 
DNA O 
- O 
binding O 
activity O 
in O 
BEAS-2B O 
and O 
A549 O 
cells O 
. O 
Analysis O 
of O 
these O 
conditioned O 
media O 
revealed O 
marked O 
increases O 
in O 
tumor O 
necrosis O 
factor O 
(TNF)-α O 
, O 
IL-1β O 
and O 
IL-8 O 
levels O 
. O 
Preincubation O 
of O 
conditioned O 
media O 
with O 
either O 
TNF-α- O 
or O 
IL-1β-neutralizing O 
antibodies O 
reduced O 
IL-8 O 
production O 
. O 
Furthermore O 
, O 
BEAS-2B O 
and O 
A549 O 
cells O 
directly O 
treated O 
with O 
crotonaldehyde B-TRIVIAL 
induced O 
increase O 
in O 
IL-8 O 
production O 
. O 
These O 
data O 
suggest O 
that O 
crotonaldehyde B-TRIVIAL 
is O 
capable O 
of O 
directly O 
stimulating O 
the O 
production O 
of O 
IL-8 O 
in O 
both O 
macrophages O 
and O 
airway O 
epithelial O 
cells O 
. O 
Crotonaldehyde B-TRIVIAL 
-stimulated O 
macrophages O 
also O 
amplify O 
the O 
inflammatory O 
response O 
by O 
enhancing O 
IL-8 O 
release O 
from O 
airway O 
epithelial O 
cells O 
mediated O 
by O 
NF-κB O 
and O 
AP-1 O 
pathways O 
through O 
a O 
mechanism O 
involving O 
TNF-α O 
and O 
IL-1β O 
. O 
These O 
findings O 
indicate O 
that O 
crotonaldehyde B-TRIVIAL 
can O 
cause O 
lung O 
inflammatory O 
response O 
via O 
multiple O 
mechanisms O 
, O 
and O 
may O 
contribute O 
to O 
chronic O 
airway O 
inflammation O 
in O 
smokers O 
. O 

- O 
acute O 
, O 
moderate O 
- O 
dose O 
, O 
but O 
not O 
short O 
- O 
term O 
, O 
low O 
- O 
dose O 
dietary O 
pre O 
- O 
exposure O 
of O 
mice O 
to O 
perfluorooctanoate B-SYSTEMATIC 
aggravates O 
concanavalin O 
A-induced O 
hepatitis O 
. O 

of O 
mice O 
to O 
perfluorooctanoate B-SYSTEMATIC 
( O 
PFOA B-ABBREVIATION 
) O 
evokes O 
pronounced O 
hepatomegaly O 
along O 
with O 
significant O 
alterations O 
in O 
both O 
the O 
histological O 
structure O 
and O 
immune O 
status O 
of O 
the O 
liver O 
. O 
The O 
present O 
study O 
was O 
designed O 
to O 
evaluate O 
the O 
effects O 
of O 
this O 
perfluorochemical O 
on O 
immune O 
- O 
mediated O 
liver O 
damage O 
. O 
In O 
this O 
connection O 
, O 
the O 
influence O 
of O 
both O 
sub O 
- O 
acute O 
( O 
10 O 
days O 
) O 
, O 
moderate O 
- O 
dose O 
( O 
0.002% O 
w O 
/ O 
w=3±0.7mg O 
/ O 
kg O 
body O 
weight O 
/ O 
day O 
) O 
and O 
short O 
- O 
term O 
( O 
28 O 
days O 
) O 
, O 
low O 
- O 
dose O 
( O 
0.00005% O 
w O 
/ O 
w=70±2μg O 
/ O 
kg O 
body O 
weight O 
/ O 
day O 
) O 
dietary O 
pretreatment O 
with O 
PFOA B-ABBREVIATION 
on O 
the O 
development O 
of O 
concanavalin O 
A O 
( O 
Con O 
A)-induced O 
liver O 
damage O 
in O 
mice O 
was O 
examined O 
. O 
With O 
sub O 
- O 
acute O 
, O 
moderate O 
, O 
but O 
not O 
short O 
- O 
term O 
, O 
low O 
- O 
dose O 
exposure O 
, O 
PFOA B-ABBREVIATION 
aggravated O 
the O 
acute O 
liver O 
damage O 
caused O 
by O 
Con O 
A O 
, O 
i.e O 
. O 
, O 
elevated O 
serum O 
levels O 
of O 
transaminases O 
and O 
led O 
to O 
more O 
pronounced O 
damage O 
of O 
hepatic O 
tissue O 
. O 
This O 
aggravation O 
was O 
associated O 
with O 
significantly O 
enhanced O 
hepatic O 
level O 
of O 
interleukin-6 O 
( O 
IL-6 O 
) O 
, O 
but O 
unaltered O 
hepatic O 
levels O 
of O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
( O 
TNF-α O 
) O 
, O 
interferon O 
- O 
gamma O 
( O 
IFN-γ O 
) O 
and O 
interleukin-4 O 
( O 
IL-4 O 
) O 
. O 
Moreover O 
, O 
hepatic O 
DNA O 
fragmentation O 
was O 
not O 
changed O 
by O 
sub O 
- O 
acute O 
exposure O 
to O 
the O 
moderate O 
- O 
dose O 
. O 
Our O 
findings O 
imply O 
that O 
exposure O 
to O 
PFOA B-ABBREVIATION 
may O 
sensitize O 
hepatic O 
parenchymal O 
cells O 
to O 
other O 
toxicants O 
that O 
activate O 
the O 
hepatic O 
immune O 
system O 
and O 
thereby O 
aggravate O 
liver O 
injury O 
during O 
acute O 
inflammation O 
. O 

and O 
Anti-inflammatory O 
Meroterpenoids B-FAMILY 
from O 
the O 
Brown O 
Alga O 
Cystoseira O 
usneoides O 
. O 

chemical O 
study O 
of O 
the O 
alga O 
Cystoseira O 
usneoides O 
has O 
led O 
to O 
the O 
isolation O 
of O 
six O 
new O 
meroterpenoids B-FAMILY 
, O 
cystodiones B-MULTIPLE 
A-F I-MULTIPLE 
( O 
1-6 O 
) O 
, O 
together O 
with O 
six O 
known O 
related O 
compounds O 
( O 
7-12 O 
) O 
. O 
The O 
structures O 
of O 
the O 
new O 
metabolites O 
have O 
been O 
established O 
by O 
spectroscopic O 
techniques O 
. O 
In O 
antioxidant O 
assays O 
all O 
of O 
the O 
tested O 
meroterpenes B-FAMILY 
, O 
and O 
in O 
particular O 
cystodiones B-MULTIPLE 
A I-MULTIPLE 
( I-MULTIPLE 
1 I-MULTIPLE 
) I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
( O 
2 O 
) O 
, O 
6-cis-amentadione-1'-methyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
7 O 
) O 
, O 
and O 
amentadione-1'-methyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
8 O 
) O 
, O 
exhibited O 
strong O 
radical O 
- O 
scavenging O 
activity O 
. O 
In O 
anti-inflammatory O 
assays O 
, O 
usneoidone B-TRIVIAL 
Z I-TRIVIAL 
( O 
11 O 
) O 
and O 
its O 
corresponding O 
6E O 
isomer O 
( O 
12 O 
) O 
showed O 
significant O 
activity O 
as O 
inhibitors O 
of O 
the O 
production O 
of O 
the O 
proinflammatory O 
cytokine O 
TNF-α O 
in O 
LPS-stimulated O 
THP-1 O 
human O 
macrophages O 
. O 

oxide I-SYSTEMATIC 
nanoparticle O 
induced O 
autophagic O 
cell O 
death O 
and O 
mitochondrial O 
damage O 
via O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
generation O 
. O 

oxide I-SYSTEMATIC 
nanoparticles O 
( O 
ZnO B-FORMULA 
-np O 
) O 
are O 
used O 
in O 
an O 
increasing O 
number O 
of O 
industrial O 
products O 
such O 
as O 
paint O 
, O 
coating O 
and O 
cosmetics O 
, O 
and O 
in O 
other O 
biological O 
applications O 
. O 
There O 
have O 
been O 
many O 
suggestions O 
of O 
a O 
ZnO B-FORMULA 
-np O 
toxicity O 
paradigm O 
but O 
the O 
underlying O 
molecular O 
mechanisms O 
about O 
the O 
toxicity O 
of O 
ZnO B-FORMULA 
-np O 
remain O 
unclear O 
. O 
This O 
study O 
was O 
done O 
to O 
determine O 
the O 
potential O 
toxicity O 
of O 
ZnO B-FORMULA 
-np O 
and O 
to O 
assess O 
the O 
toxicity O 
mechanism O 
in O 
normal O 
skin O 
cells O 
. O 
Synthesized O 
ZnO B-FORMULA 
-np O 
generated O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
as O 
determined O 
by O 
electron O 
spin O 
resonance O 
. O 
After O 
uptake O 
into O 
cells O 
, O 
ZnO B-FORMULA 
-np O 
induced O 
ROS O 
in O 
a O 
concentration- O 
and O 
time O 
- O 
dependent O 
manner O 
. O 
To O 
demonstrate O 
ZnO B-FORMULA 
-np O 
toxicity O 
mechanism O 
related O 
to O 
ROS O 
, O 
we O 
detected O 
abnormal O 
autophagic O 
vacuoles O 
accumulation O 
and O 
mitochondria O 
dysfunction O 
after O 
ZnO B-FORMULA 
-np O 
treatment O 
. O 
Furthermore O 
mitochondria O 
membrane O 
potential O 
and O 
adenosine-5'-triphosphate B-SYSTEMATIC 
( O 
ATP B-ABBREVIATION 
) O 
production O 
are O 
decreased O 
for O 
culture O 
with O 
ZnO B-FORMULA 
-np O 
. O 
We O 
conclude O 
that O 
ZnO B-FORMULA 
-np O 
leads O 
to O 
cell O 
death O 
through O 
autophagic O 
vacuole O 
accumulation O 
and O 
mitochondria O 
damage O 
in O 
normal O 
skin O 
cells O 
via O 
ROS O 
induction O 
. O 
Accordingly O 
, O 
ZnO B-FORMULA 
-np O 
may O 
cause O 
toxicity O 
and O 
the O 
results O 
highlight O 
and O 
need O 
for O 
careful O 
regulation O 
of O 
ZnO B-FORMULA 
-np O 
production O 
and O 
use O 
. O 

vitro O 
and O 
in O 
vivo O 
evaluation O 
of O 
superparamagnetic O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
coated O 
by O 
bisphosphonates B-FAMILY 
: O 
The O 
effects O 
of O 
electrical O 
charge O 
and O 
molecule O 
length O 
. O 

coating O 
properties O 
are O 
often O 
considered O 
to O 
be O 
determining O 
factors O 
for O 
in O 
vivo O 
characteristics O 
of O 
superparamagnetic O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
, O 
used O 
as O 
contrast O 
agent O 
in O 
Magnetic O 
Resonance O 
Imaging O 
( O 
MRI O 
) O 
. O 
To O 
investigate O 
the O 
electrical O 
charge O 
( O 
modified O 
by O 
zero O 
, O 
one O 
or O 
two O 
ammonium B-SYSTEMATIC 
groups O 
) O 
and O 
the O 
molecule O 
length O 
( O 
3 O 
, O 
5 O 
or O 
7 O 
methylene B-SYSTEMATIC 
chains O 
) O 
effects O 
of O 
bisphosphonate B-SYSTEMATIC 
-type O 
coatings O 
, O 
we O 
assessed O 
the O 
complement O 
activation O 
, O 
in O 
vivo O 
plasma O 
and O 
tissue O 
relaxation O 
time O 
alterations O 
of O 
intravenously O 
injected O 
small O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
( O 
< O 
25nm O 
) O 
on O 
male O 
healthy O 
Wistar O 
rats O 
. O 
The O 
presence O 
of O 
ammonium B-SYSTEMATIC 
groups O 
induces O 
a O 
weak O 
activation O 
of O 
the O 
complement O 
whatever O 
the O 
size O 
and O 
the O 
concentration O 
of O 
particles O 
, O 
whereas O 
hydroxyethylenebisphosphonate B-SYSTEMATIC 
( O 
HEBP B-ABBREVIATION 
) O 
- O 
coated O 
particles O 
are O 
poor O 
complement O 
activators O 
only O 
at O 
the O 
lowest O 
concentration O 
. O 
In O 
vivo O 
, O 
HEBP B-ABBREVIATION 
-coated O 
nanoparticles O 
have O 
the O 
greatest O 
prolonged O 
relaxation O 
time O 
effects O 
, O 
despite O 
their O 
higher O 
negative O 
electrical O 
charge O 
, O 
contrary O 
to O 
two O 
ammonium B-SYSTEMATIC 
bearing O 
coatings O 
. O 
No O 
significant O 
differences O 
were O 
observed O 
between O 
mono-ammonium B-SYSTEMATIC 
molecular O 
coatings O 
. O 

hydrogel O 
materials O 
of O 
interest O 
are O 
homogeneous O 
on O 
the O 
micrometer O 
scale O 
. O 
Electrospinning O 
, O 
the O 
formation O 
of O 
sub O 
- O 
micrometer O 
to O 
micrometer O 
diameter O 
fibers O 
by O 
a O 
jet O 
of O 
fluid O 
formed O 
under O 
an O 
electric O 
field O 
, O 
is O 
one O 
process O 
being O 
explored O 
to O 
create O 
rich O 
microstructures O 
. O 
However O 
, O 
electrospinning O 
a O 
hydrogel O 
system O 
as O 
it O 
reacts O 
requires O 
an O 
understanding O 
of O 
the O 
gelation O 
kinetics O 
and O 
corresponding O 
rheology O 
near O 
the O 
liquid O 
- O 
solid O 
transition O 
. O 
In O 
this O 
study O 
, O 
we O 
correlate O 
the O 
structure O 
of O 
electrospun O 
fibers O 
of O 
a O 
covalently O 
cross O 
- O 
linked O 
hydrogelator O 
with O 
the O 
corresponding O 
gelation O 
transition O 
and O 
kinetics O 
. O 
Polyethylene B-FAMILY 
oxide I-FAMILY 
( O 
PEO B-ABBREVIATION 
) O 
is O 
used O 
as O 
a O 
carrier O 
polymer O 
in O 
a O 
chemically O 
cross O 
- O 
linking O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
-high O 
molecular O 
weight O 
heparin O 
( O 
PEG B-ABBREVIATION 
-HMWH O 
) O 
hydrogel O 
. O 
Using O 
measurements O 
of O 
gelation O 
kinetics O 
from O 
multiple O 
particle O 
tracking O 
microrheology O 
( O 
MPT O 
) O 
, O 
we O 
correlate O 
the O 
material O 
rheology O 
with O 
the O 
the O 
formation O 
of O 
stable O 
fibers O 
. O 
An O 
equilibrated O 
, O 
cross O 
- O 
linked O 
hydrogel O 
is O 
then O 
spun O 
and O 
the O 
PEO B-ABBREVIATION 
is O 
dissolved O 
. O 
In O 
both O 
cases O 
, O 
microstructural O 
features O 
of O 
the O 
electrospun O 
fibers O 
are O 
retained O 
, O 
confirming O 
the O 
covalent O 
nature O 
of O 
the O 
network O 
. O 
The O 
ability O 
to O 
spin O 
fibers O 
of O 
a O 
cross O 
- O 
linking O 
hydrogel O 
system O 
ultimately O 
enables O 
the O 
engineering O 
of O 
materials O 
and O 
microstructural O 
length O 
scales O 
suitable O 
for O 
biological O 
applications O 
. O 

vivo O 
binding O 
of O 
the O 
dopamine B-TRIVIAL 
-1 O 
receptor O 
PET O 
tracers O 
[(11)C]NNC112 B-SYSTEMATIC 
and O 
[ B-SYSTEMATIC 
(11)C]SCH23390 I-SYSTEMATIC 
: O 
a O 
comparison O 
study O 
in O 
individuals O 
with O 
schizophrenia O 
. O 

: O 
A O 
deficit O 
in O 
dopamine B-TRIVIAL 
-1 O 
( O 
D1 O 
) O 
receptor O 
function O 
in O 
the O 
prefrontal O 
cortex O 
is O 
suggested O 
to O 
play O 
a O 
role O 
in O 
the O 
cognitive O 
dysfunction O 
observed O 
in O 
patients O 
with O 
schizophrenia O 
. O 
However O 
, O 
the O 
results O 
from O 
positron O 
emission O 
tomography O 
imaging O 
studies O 
of O 
D1 O 
receptor O 
levels O 
in O 
individuals O 
with O 
schizophrenia O 
are O 
mixed O 
. O 
OBJECTIVES O 
: O 
The O 
aim O 
of O 
this O 
investigation O 
was O 
to O 
determine O 
whether O 
the O 
in O 
vivo O 
characteristics O 
of O 
the O 
different O 
D1 O 
receptor O 
tracers O 
used O 
in O 
previous O 
reports O 
, O 
[(11)C]SCH23390 B-SYSTEMATIC 
and O 
[(11)C]NNC112 B-SYSTEMATIC 
, O 
may O 
have O 
contributed O 
to O 
these O 
discrepancies O 
reported O 
in O 
the O 
literature O 
. O 
METHODS O 
: O 
Eight O 
patients O 
with O 
schizophrenia O 
and O 
12 O 
healthy O 
control O 
subjects O 
were O 
scanned O 
with O 
both O 
[(11)C]SCH23390 B-SYSTEMATIC 
and O 
[(11)C]NNC112 B-SYSTEMATIC 
. O 
RESULTS O 
: O 
[(11)C]SCH23390 B-SYSTEMATIC 
and O 
[(11)C]NNC112 B-SYSTEMATIC 
binding O 
potentials O 
in O 
both O 
patients O 
and O 
control O 
subjects O 
were O 
compared O 
and O 
no O 
tracer O 
by O 
diagnosis O 
interactions O 
were O 
observed O 
. O 
CONCLUSIONS O 
: O 
The O 
results O 
of O 
this O 
study O 
suggest O 
that O 
differences O 
in O 
the O 
binding O 
of O 
[(11)C]SCH23390 B-SYSTEMATIC 
and O 
[(11)C]NNC112 B-SYSTEMATIC 
observed O 
in O 
previous O 
studies O 
are O 
not O 
due O 
to O 
differences O 
in O 
the O 
in O 
vivo O 
behavior O 
of O 
these O 
tracers O 
. O 

proteoglycan O 
decorin O 
modulates O 
leukocyte O 
recruitment O 
during O 
delayed O 
- O 
type O 
hypersensitivity O 
responses O 
. O 
Decorin O 
- O 
deficient O 
( O 
Dcn(- O 
/ O 
- O 
) O 
) O 
mice O 
show O 
reduced O 
edema O 
formation O 
during O 
the O 
first O 
24 O 
h O 
with O 
a O 
concurrent O 
attenuated O 
recruitment O 
of O 
CD8(+) O 
leukocytes O 
in O 
the O 
inflamed O 
Dcn(- O 
/ O 
- O 
) O 
ears O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
elucidate O 
the O 
molecular O 
pathways O 
affected O 
by O 
the O 
loss O 
of O 
decorin O 
. O 
In O 
vivo O 
, O 
reduced O 
numbers O 
of O 
CD8(+) O 
cells O 
in O 
Dcn(- O 
/ O 
- O 
) O 
ears O 
correlated O 
with O 
a O 
reduced O 
interferon-γ O 
( O 
Ifn-γ O 
) O 
and O 
CXCL-10 O 
expression O 
. O 
In O 
vitro O 
, O 
Dcn(- O 
/ O 
- O 
) O 
lymphocytes O 
displayed O 
an O 
increased O 
adhesion O 
to O 
brain O 
microvascular O 
( O 
bEnd.3 O 
) O 
endothelial O 
cells O 
. O 
Decorin O 
treatment O 
of O 
bEnd.3 O 
increased O 
Icam1 O 
and O 
down O 
- O 
regulated O 
Vcam1 O 
expression O 
after O 
TNF-α O 
stimulation O 
. O 
However O 
, O 
Dcn(- O 
/ O 
- O 
) O 
and O 
wild O 
- O 
type O 
lymphocytes O 
produced O 
IFN-γ O 
after O 
activation O 
with O 
CD3ε O 
. O 
Upon O 
incubation O 
with O 
decorin O 
, O 
endothelial O 
cells O 
and O 
fibroblasts O 
responded O 
differently O 
to O 
IFN-γ O 
and O 
TNF-α O 
; O 
CCL2 O 
in O 
bEnd.3 O 
cells O 
was O 
more O 
prominently O 
up O 
- O 
regulated O 
by O 
TNF-α O 
compared O 
with O 
IFN-γ O 
. O 
Notably O 
, O 
both O 
factors O 
were O 
more O 
potent O 
in O 
the O 
presence O 
of O 
decorin O 
. O 
Compared O 
with O 
TNF-α O 
, O 
IFN-γ O 
treatment O 
induced O 
significantly O 
more O 
CXCL-10 O 
, O 
and O 
both O 
factors O 
increased O 
synthesis O 
of O 
CXCL-10 O 
in O 
the O 
presence O 
of O 
decorin O 
. O 
The O 
response O 
to O 
IFN-γ O 
was O 
similar O 
in O 
Dcn(- O 
/ O 
- O 
) O 
and O 
wild O 
- O 
type O 
fibroblasts O 
, O 
an O 
additional O 
source O 
of O 
CXCL-10 O 
. O 
However O 
, O 
addition O 
of O 
decorin O 
yielded O 
significantly O 
more O 
CXCL-10 O 
. O 
Notably O 
, O 
decorin O 
increased O 
the O 
stability O 
of O 
IFN-γ O 
in O 
vitro O 
and O 
potentiated O 
IFN-γ-induced O 
activation O 
of O 
STAT-1 O 
. O 
Furthermore O 
, O 
only O 
dermatan O 
sulfate B-SYSTEMATIC 
influenced O 
IFN-γ O 
signaling O 
by O 
significantly O 
increasing O 
CXCL-10 O 
expression O 
in O 
contrast O 
to O 
decorin O 
protein O 
core O 
alone O 
. O 
Our O 
data O 
demonstrate O 
that O 
decorin O 
modulates O 
delayed O 
- O 
type O 
hypersensitivity O 
responses O 
by O 
augmenting O 
the O 
induction O 
of O 
downstream O 
effector O 
cytokines O 
of O 
IFN-γ O 
and O 
TNF-α O 
, O 
thereby O 
influencing O 
the O 
recruitment O 
of O 
CD8(+) O 
lymphocytes O 
into O 
the O 
inflamed O 
tissue O 
. O 

, O 
a O 
Natural O 
Selective O 
Ligand O 
and O 
Partial O 
Agonist O 
for O 
the O 
α4β2 O 
Nicotinic O 
Receptor O 
Subtype O 
. O 

( O 
1 O 
) O 
, O 
a O 
rare O 
alkaloid O 
extracted O 
from O 
Laburnum O 
anagyroides O 
seeds O 
( O 
∼4 O 
mg O 
from O 
1 O 
kg O 
) O 
, O 
was O 
shown O 
to O 
bind O 
with O 
high O 
affinity O 
( O 
Ki O 
, O 
293 O 
nM O 
) O 
to O 
the O 
α4β2 O 
nicotinic O 
receptor O 
subtype O 
, O 
which O 
is O 
, O 
respectively O 
, O 
126 O 
and O 
136 O 
times O 
higher O 
than O 
to O 
the O 
α3β4 O 
( O 
Ki O 
37 O 
μM O 
) O 
and O 
α7 O 
subtypes O 
( O 
Ki O 
40 O 
μM O 
) O 
. O 
When O 
its O 
ability O 
to O 
release O 
[(3)H]-dopamine B-SYSTEMATIC 
from O 
striatal O 
slices O 
was O 
tested O 
in O 
a O 
functional O 
assay O 
, O 
compound O 
1 O 
behaved O 
as O 
a O 
partial O 
agonist O 
with O 
an O 
EC50 O 
of O 
5.8 O 
μM O 
and O 
an O 
Emax O 
that O 
was O 
43% O 
that O 
of O 
nicotine B-TRIVIAL 
. O 
When O 
incubated O 
with O 
nicotine B-TRIVIAL 
in O 
the O 
same O 
assay O 
, O 
1 O 
prevented O 
a O 
maximal O 
effect O 
from O 
being O 
reached O 
. O 

report O 
on O 
the O 
use O 
of O 
characteristic O 
prompt O 
γ-fluorescence O 
after O 
neutron O 
capture O 
induced O 
by O 
an O 
evanescent O 
neutron O 
wave O 
to O 
probe O 
densities O 
and O 
depth O 
profiles O 
of O 
labeled O 
molecules O 
at O 
solid O 
/ O 
liquid O 
interfaces O 
. O 
In O 
contrast O 
to O 
classical O 
scattering O 
techniques O 
and O 
X-ray O 
fluorescence O 
, O 
this O 
method O 
of O 
" O 
grazing O 
- O 
incidence O 
neutron O 
- O 
induced O 
fluorescence O 
" O 
combines O 
direct O 
chemical O 
specificity O 
, O 
provided O 
by O 
the O 
label O 
, O 
with O 
sensitivity O 
to O 
the O 
interface O 
, O 
inherent O 
to O 
the O 
evanescent O 
wave O 
. O 
We O 
demonstrate O 
that O 
the O 
formation O 
of O 
a O 
supported O 
lipid O 
membrane O 
can O 
be O 
quantitatively O 
monitored O 
from O 
the O 
characteristic O 
fluorescence O 
of O 
(157)Gd(3+) B-FORMULA 
ions O 
bound O 
to O 
the O 
headgroup O 
of O 
chelator O 
lipids O 
. O 
Moreover O 
, O 
we O 
were O 
able O 
to O 
localize O 
the O 
(157)Gd(3+) B-FORMULA 
ions O 
along O 
the O 
surface O 
normal O 
with O 
nanometer O 
precision O 
. O 
This O 
first O 
proof O 
of O 
principle O 
with O 
a O 
well O 
- O 
defined O 
model O 
system O 
suggests O 
that O 
the O 
method O 
has O 
a O 
great O 
potential O 
for O 
biology O 
and O 
soft O 
matter O 
studies O 
where O 
spatial O 
resolution O 
and O 
chemical O 
sensitivity O 
are O 
required O 
. O 

systematic O 
study O 
was O 
undertaken O 
to O 
gain O 
more O 
insight O 
into O 
the O 
mechanism O 
of O 
transdermal O 
delivery O 
of O 
nanoencapsulated O 
model O 
dyes O 
across O 
microneedle O 
( O 
MN O 
) O 
- O 
treated O 
skin O 
, O 
a O 
complex O 
process O 
not O 
yet O 
explored O 
. O 
Rhodamine B-TRIVIAL 
B I-TRIVIAL 
( O 
Rh B-ABBREVIATION 
B I-ABBREVIATION 
) O 
and O 
fluorescein B-TRIVIAL 
isothiocyanate I-TRIVIAL 
( O 
FITC B-ABBREVIATION 
) O 
as O 
model O 
hydrophilic O 
and O 
hydrophobic O 
small O 
/ O 
medium O 
- O 
size O 
molecules O 
, O 
respectively O 
, O 
were O 
encapsulated O 
in O 
poly B-FAMILY 
lactic I-FAMILY 
- I-FAMILY 
co I-FAMILY 
- I-FAMILY 
glycolic I-FAMILY 
acid I-FAMILY 
( O 
PLGA B-ABBREVIATION 
) O 
nanoparticles O 
( O 
NPs O 
) O 
and O 
delivered O 
through O 
full O 
thickness O 
porcine O 
skin O 
pretreated O 
with O 
MN O 
array O 
. O 
Permeation O 
through O 
MN O 
- O 
treated O 
skin O 
was O 
affected O 
by O 
physicochemical O 
characteristics O 
of O 
NPs O 
and O 
the O 
encapsulated O 
dyes O 
. O 
Dye O 
flux O 
was O 
enhanced O 
by O 
smaller O 
particle O 
size O 
, O 
hydrophilicity O 
, O 
and O 
negative O 
zeta O 
potential O 
of O 
NPs O 
. O 
Regarding O 
encapsulated O 
dyes O 
, O 
solubility O 
at O 
physiological O 
pH O 
and O 
potential O 
interaction O 
with O 
skin O 
proteins O 
proved O 
to O 
outweigh O 
molecular O 
weight O 
as O 
determinants O 
of O 
skin O 
permeation O 
. O 
Data O 
were O 
verified O 
using O 
confocal O 
laser O 
scanning O 
microscopy O 
imaging O 
. O 
Findings O 
coupled O 
with O 
the O 
literature O 
data O 
are O 
supportive O 
of O 
a O 
mechanism O 
involving O 
influx O 
of O 
NPs O 
, O 
particularly O 
of O 
smaller O 
size O 
, O 
deep O 
into O 
MN-created O 
channels O 
, O 
generating O 
depot O 
dye O 
- O 
rich O 
reservoirs O 
. O 
Molecular O 
diffusion O 
of O 
the O 
released O 
dye O 
across O 
viable O 
skin O 
layers O 
proceeds O 
at O 
a O 
rate O 
determined O 
by O 
its O 
molecular O 
characteristics O 
. O 
Data O 
obtained O 
provide O 
mechanistic O 
information O 
of O 
importance O 
to O 
the O 
development O 
of O 
formulation O 
strategies O 
for O 
more O 
effective O 
intradermal O 
and O 
transdermal O 
MN O 
- O 
mediated O 
delivery O 
of O 
nanoencapsulated O 
therapeutic O 
agents O 
. O 

between O 
aflatoxin B-TRIVIAL 
M1 I-TRIVIAL 
content O 
of O 
breast O 
milk O 
, O 
dietary O 
exposure O 
to O 
aflatoxin B-TRIVIAL 
B1 I-TRIVIAL 
and O 
socioeconomic O 
status O 
of O 
lactating O 
mothers O 
in O 
Ogun O 
State O 
, O 
Nigeria O 
. O 

M1 I-TRIVIAL 
( O 
AF B-ABBREVIATION 
M1 I-ABBREVIATION 
) O 
, O 
a O 
hydroxylated O 
metabolite O 
of O 
AF B-ABBREVIATION 
B1 I-ABBREVIATION 
, O 
is O 
an O 
important O 
toxin O 
that O 
can O 
contaminate O 
the O 
milk O 
of O 
lactating O 
mothers O 
. O 
A O 
correlation O 
study O 
was O 
conducted O 
to O 
determine O 
the O 
relationship O 
between O 
AF B-ABBREVIATION 
M1 I-ABBREVIATION 
content O 
of O 
breast O 
milk O 
, O 
dietary O 
exposure O 
to O 
AF B-ABBREVIATION 
B1 I-ABBREVIATION 
and O 
socioeconomic O 
status O 
of O 
lactating O 
mothers O 
in O 
the O 
three O 
Senatorial O 
districts O 
of O 
Ogun O 
State O 
, O 
Nigeria O 
. O 
Equal O 
amounts O 
of O 
breast O 
milk O 
( O 
20ml O 
) O 
and O 
food O 
rations O 
( O 
40kg O 
) O 
obtained O 
from O 
50 O 
volunteer O 
lactating O 
mothers O 
and O 
eighty O 
- O 
two O 
frequently O 
consumed O 
food O 
commodities O 
in O 
the O 
preceding O 
month O 
were O 
used O 
for O 
the O 
study O 
. O 
The O 
level O 
of O 
contamination O 
of O 
the O 
foods O 
by O 
AF B-ABBREVIATION 
B1 I-ABBREVIATION 
was O 
low O 
( O 
0.16-0.33μg O 
/ O 
kg O 
) O 
and O 
differed O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
across O 
the O 
state O 
but O 
did O 
not O 
exceed O 
the O 
EU O 
limit O 
of O 
2μg O 
/ O 
kg O 
. O 
The O 
occurrence O 
level O 
of O 
AF B-ABBREVIATION 
B1 I-ABBREVIATION 
was O 
however O 
high O 
( O 
93.75-94.45% O 
) O 
and O 
was O 
more O 
pronounced O 
in O 
Ogun O 
East O 
Senatorial O 
district O 
( O 
94.45% O 
) O 
. O 
Eighty O 
- O 
two O 
percent O 
of O 
the O 
breast O 
milk O 
was O 
contaminated O 
with O 
AF B-ABBREVIATION 
M1 I-ABBREVIATION 
( O 
3.49-35ng O 
/ O 
l O 
) O 
and O 
16% O 
exceeded O 
the O 
EU O 
limit O 
of O 
25ng O 
/ O 
l O 
while O 
a O 
100% O 
occurrence O 
risk O 
was O 
recorded O 
in O 
Ogun O 
Central O 
Senatorial O 
district O 
. O 
The O 
socioeconomic O 
status O 
of O 
the O 
mothers O 
also O 
significantly O 
influenced O 
their O 
dietary O 
exposure O 
and O 
exposure O 
risk O 
of O 
the O 
sucklings O 
to O 
AF B-ABBREVIATION 
M1 I-ABBREVIATION 
. O 

Assessment O 
of O 
Ketamine B-TRIVIAL 
. O 

: O 
Ketamine B-TRIVIAL 
is O 
used O 
as O 
a O 
general O 
anesthetic O 
, O 
and O 
recent O 
data O 
suggest O 
that O 
anesthetics O 
can O 
cause O 
neurodegeneration O 
and O 
/ O 
or O 
neuroprotection O 
. O 
The O 
precise O 
mechanisms O 
are O 
not O 
completely O 
understood O 
. O 
AIMS O 
: O 
This O 
review O 
is O 
to O 
examine O 
the O 
work O 
on O 
ketamine B-TRIVIAL 
and O 
to O 
address O 
how O 
developmental O 
biology O 
may O 
be O 
utilized O 
when O 
combined O 
with O 
biochemical O 
, O 
pathological O 
, O 
and O 
pharmacokinetic O 
assessments O 
to O 
produce O 
a O 
bridging O 
model O 
that O 
may O 
decrease O 
the O 
uncertainty O 
in O 
extrapolating O 
preclinical O 
data O 
to O 
human O 
conditions O 
. O 
RESULTS O 
: O 
Advantages O 
of O 
using O 
preclinical O 
models O 
to O 
study O 
critical O 
issues O 
related O 
to O 
ketamine B-TRIVIAL 
anesthesia O 
have O 
been O 
described O 
. O 
These O 
include O 
the O 
relationships O 
between O 
ketamine B-TRIVIAL 
-induced O 
neurotoxicity O 
/ O 
protection O 
and O 
the O 
preclinical O 
models O 
/ O 
approaches O 
in O 
elucidating O 
mechanisms O 
associated O 
with O 
ketamine B-TRIVIAL 
exposure O 
. O 
CONCLUSIONS O 
: O 
The O 
discussions O 
focus O 
on O 
the O 
following O 
: O 
( O 
1 O 
) O 
the O 
doses O 
and O 
time O 
- O 
course O 
over O 
which O 
ketamine B-TRIVIAL 
is O 
associated O 
with O 
damage O 
to O 
, O 
or O 
protection O 
of O 
, O 
neural O 
cells O 
, O 
( O 
2 O 
) O 
how O 
ketamine B-TRIVIAL 
directs O 
or O 
signals O 
neural O 
cells O 
to O 
undergo O 
apoptosis O 
or O 
necrosis O 
, O 
( O 
3 O 
) O 
how O 
such O 
exposures O 
can O 
trigger O 
mitochondrial O 
dysfunction O 
, O 
( O 
4 O 
) O 
how O 
antioxidants O 
and O 
knockdowns O 
of O 
specific O 
transcription O 
modulators O 
or O 
receptors O 
affect O 
neurotoxicity O 
induced O 
by O 
ketamine B-TRIVIAL 
, O 
and O 
( O 
5 O 
) O 
whether O 
the O 
potential O 
neural O 
damage O 
can O 
be O 
monitored O 
after O 
ketamine B-TRIVIAL 
exposure O 
in O 
living O 
animals O 
using O 
positron O 
emission O 
tomography O 
. O 

cycle O 
arrest O 
, O 
extracellular O 
matrix O 
changes O 
and O 
intrinsic O 
apoptosis O 
in O 
human O 
melanoma O 
cells O 
are O 
induced O 
by O 
Boron B-SYSTEMATIC 
Neutron O 
Capture O 
Therapy O 
. O 

Neutron O 
Capture O 
Therapy O 
( O 
BNCT O 
) O 
involves O 
the O 
selective O 
accumulation O 
of O 
boron O 
carriers O 
in O 
tumor O 
tissue O 
followed O 
by O 
irradiation O 
with O 
a O 
thermal O 
or O 
epithermal O 
neutron O 
beam O 
. O 
This O 
therapy O 
is O 
therefore O 
a O 
cellular O 
irradiation O 
suited O 
to O 
treat O 
tumors O 
that O 
have O 
infiltrated O 
into O 
healthy O 
tissues O 
. O 
BNCT O 
has O 
been O 
used O 
clinically O 
to O 
treat O 
patients O 
with O 
cutaneous O 
melanomas O 
which O 
have O 
a O 
high O 
mortality O 
. O 
Human O 
normal O 
melanocytes O 
and O 
melanoma O 
cells O 
were O 
treated O 
with O 
BNCT O 
at O 
different O 
boronophenylalanine B-SYSTEMATIC 
concentrations O 
for O 
signaling O 
pathways O 
analysis O 
. O 
BNCT O 
induced O 
few O 
morphological O 
alterations O 
in O 
normal O 
melanocytes O 
, O 
with O 
a O 
negligible O 
increase O 
in O 
free O 
radical O 
production O 
. O 
Melanoma O 
cells O 
treated O 
with O 
BNCT O 
showed O 
significant O 
extracellular O 
matrix O 
( O 
ECM O 
) O 
changes O 
and O 
a O 
significant O 
cyclin O 
D1 O 
decrease O 
, O 
suggesting O 
cell O 
death O 
by O 
necrosis O 
and O 
apoptosis O 
and O 
cell O 
cycle O 
arrest O 
, O 
respectively O 
. O 
BNCT O 
also O 
induced O 
a O 
significant O 
increase O 
in O 
cleaved O 
caspase-3 O 
and O 
a O 
decrease O 
in O 
the O 
mitochondrial O 
electrical O 
potential O 
with O 
selectivity O 
for O 
melanoma O 
cells O 
. O 
Normal O 
melanocytes O 
had O 
no O 
significant O 
differences O 
due O 
to O 
BNCT O 
treatment O 
, O 
confirming O 
the O 
data O 
from O 
the O 
literature O 
regarding O 
the O 
selectivity O 
of O 
BNCT O 
. O 
The O 
results O 
from O 
this O 
study O 
suggest O 
that O 
some O 
signaling O 
pathways O 
are O 
involved O 
in O 
human O 
melanoma O 
treatment O 
by O 
BNCT O 
, O 
such O 
as O 
cell O 
cycle O 
arrest O 
, O 
ECM O 
changes O 
and O 
intrinsic O 
apoptosis O 
. O 

free O 
rapamycin B-TRIVIAL 
loaded O 
drug O 
eluting O 
stent O 
: O 
In O 
vitro O 
and O 
in O 
vivo O 
evaluation O 
. O 

the O 
search O 
for O 
improving O 
the O 
performance O 
of O 
drug O 
eluting O 
stent O 
( O 
DES O 
) O 
various O 
developments O 
are O 
in O 
progress O 
worldwide O 
including O 
use O 
of O 
carrier O 
free O 
DES O 
, O 
use O 
of O 
biodegradable O 
polymers O 
, O 
biodegradable O 
stents O 
etc O 
. O 
In O 
this O 
work O 
, O 
carrier O 
free- O 
rapamycin B-TRIVIAL 
( O 
RM O 
) O 
coated O 
DES O 
has O 
been O 
prepared O 
, O 
and O 
evaluated O 
by O 
in O 
vitro O 
and O 
in O 
vivo O 
procedures O 
necessary O 
for O 
clinical O 
development O 
. O 
In O 
vitro O 
drug O 
release O 
from O 
the O 
developed O 
stents O 
was O 
carried O 
in O 
different O 
release O 
media O 
, O 
normal O 
saline- O 
isopropanol B-SYSTEMATIC 
( O 
NS-IP O 
) O 
, O 
phosphate B-SYSTEMATIC 
buffer O 
( O 
PB O 
) O 
, O 
phosphate B-SYSTEMATIC 
buffer O 
saline O 
( O 
PBS O 
) O 
and O 
in O 
human O 
plasma O 
. O 
Simultaneously O 
, O 
drug O 
released O 
at O 
site O 
of O 
implantation O 
and O 
biocompatibility O 
of O 
developed O 
stents O 
was O 
determined O 
after O 
subcutaneous O 
implantation O 
in O 
the O 
SD O 
rats O 
. O 
Developed O 
stent O 
coating O 
method O 
enables O 
fabrication O 
of O 
controllable O 
and O 
homogeneous O 
crystalline O 
RM O 
coatings O 
on O 
stent O 
scaffolds O 
. O 
Continuous O 
release O 
of O 
RM O 
was O 
observed O 
in O 
different O 
release O 
conditions O 
with O 
different O 
release O 
rate O 
, O 
maximum O 
in O 
NS-IP O 
and O 
least O 
in O 
PB O 
. O 
Similarly O 
, O 
after O 
subcutaneous O 
implantation O 
of O 
these O 
stents O 
, O 
RM O 
was O 
found O 
in O 
surrounding O 
tissues O 
and O 
in O 
implanted O 
stent O 
up O 
to O 
28days O 
. O 
Biocompatibility O 
studies O 
showed O 
no O 
evidence O 
for O 
presence O 
of O 
necrosis O 
, O 
foreign O 
body O 
giant O 
cell O 
reaction O 
or O 
any O 
type O 
of O 
increased O 
severity O 
of O 
inflammatory O 
reaction O 
, O 
proving O 
potential O 
of O 
developed O 
stents O 
for O 
further O 
clinical O 
development O 
. O 

as O 
in O 
situ O 
formed O 
diffusion O 
barriers O 
in O 
multimaterial O 
drug O 
carriers O 
. O 

hydrogels O 
typically O 
release O 
their O 
drug O 
payload O 
rapidly O 
due O 
to O 
their O 
high O 
water O 
content O 
and O 
the O 
diffusivity O 
for O 
drug O 
molecules O 
. O 
This O 
study O 
proposes O 
a O 
multimaterial O 
system O 
to O 
sustain O 
the O 
release O 
by O 
covering O 
the O 
hydrogel O 
with O 
a O 
poly(alkyl-2-cyanoacrylate) B-FAMILY 
[ O 
PACA B-ABBREVIATION 
] O 
- O 
based O 
film O 
, O 
which O 
should O 
be O 
formed O 
by O 
an O 
in O 
situ O 
polymerization O 
on O 
the O 
hydrogel O 
surface O 
initiated O 
upon O 
contact O 
with O 
water O 
. O 
A O 
series O 
of O 
PACA B-ABBREVIATION 
-hydrogel O 
hybrid O 
systems O 
with O 
increasing O 
PACA B-ABBREVIATION 
side O 
chain O 
hydrophobicity O 
was O 
prepared O 
using O 
physically O 
crosslinked O 
alginate O 
films O 
and O 
hydrophilic O 
diclofenac B-SYSTEMATIC 
sodium I-SYSTEMATIC 
as O 
model O 
hydrogel O 
/ O 
drug O 
system O 
. O 
Successful O 
synthesis O 
of O 
PACA B-ABBREVIATION 
at O 
the O 
hydrogel O 
surface O 
was O 
confirmed O 
and O 
the O 
PACA B-ABBREVIATION 
layer O 
was O 
identified O 
to O 
be O 
most O 
homogeneous O 
for O 
poly(n-butyl-2-cyanoacrylate) B-FAMILY 
on O 
both O 
the O 
micro- O 
and O 
nanolevel O 
. O 
At O 
the O 
same O 
time O 
, O 
the O 
diclofenac B-TRIVIAL 
release O 
from O 
the O 
hybrid O 
systems O 
was O 
substantially O 
sustained O 
from O 
~1day O 
for O 
unmodified O 
hydrogels O 
up O 
to O 
> O 
14days O 
depending O 
on O 
the O 
type O 
of O 
PACA B-ABBREVIATION 
employed O 
as O 
diffusion O 
barrier O 
. O 
Overall O 
, O 
in O 
situ O 
polymerized O 
PACA B-ABBREVIATION 
films O 
on O 
hydrogels O 
may O 
be O 
widely O 
applicable O 
to O 
various O 
hydrogel O 
matrices O 
, O 
different O 
matrix O 
sizes O 
as O 
well O 
as O 
more O 
complex O 
shaped O 
hydrogel O 
carriers O 
. O 

/ O 
HYPOTHESIS O 
: O 
Cholecystokinin O 
( O 
CCK O 
) O 
and O 
leptin O 
are O 
important O 
hormones O 
with O 
effects O 
on O 
energy O 
balance O 
. O 
The O 
present O 
study O 
assessed O 
the O 
biological O 
effects O 
of O 
(pGlu-Gln)-CCK-8 O 
and O 
[D-Leu-4]-OB3 O 
, O 
smaller O 
isoforms O 
of O 
CCK O 
and O 
leptin O 
, O 
respectively O 
. O 
METHODS O 
: O 
The O 
actions O 
and O 
overall O 
therapeutic O 
use O 
of O 
(pGlu-Gln)-CCK-8 O 
and O 
[D-Leu-4]-OB3 O 
, O 
alone O 
and O 
in O 
combination O 
, O 
were O 
evaluated O 
in O 
normal O 
and O 
high O 
- O 
fat O 
- O 
fed O 
mice O 
. O 
RESULTS O 
: O 
(pGlu-Gln)-CCK-8 O 
had O 
prominent O 
( O 
p O 
< O 
0.01 O 
to O 
p O 
< O 
0.001 O 
) O 
, O 
acute O 
feeding O 
- O 
suppressive O 
effects O 
, O 
which O 
were O 
significantly O 
augmented O 
( O 
p O 
< O 
0.05 O 
to O 
p O 
< O 
0.01 O 
) O 
by O 
[D-Leu-4]-OB3 O 
. O 
In O 
agreement O 
, O 
the O 
acute O 
dose O 
- O 
dependent O 
glucose B-TRIVIAL 
-lowering O 
and O 
insulinotropic O 
actions O 
of O 
(pGlu-Gln)-CCK-8 O 
were O 
significantly O 
enhanced O 
by O 
concurrent O 
administration O 
of O 
[D-Leu-4]-OB3 O 
. O 
Twice O 
daily O 
injection O 
of O 
(pGlu-Gln)-CCK-8 O 
alone O 
and O 
in O 
combination O 
with O 
[D-Leu-4]-OB3 O 
in O 
high O 
- O 
fat O 
- O 
fed O 
mice O 
for O 
18 O 
days O 
decreased O 
body O 
weight O 
( O 
p O 
< O 
0.05 O 
to O 
p O 
< O 
0.001 O 
) O 
, O 
energy O 
intake O 
( O 
p O 
< O 
0.01 O 
) O 
, O 
circulating O 
triacylglycerol B-FAMILY 
( O 
p O 
< O 
0.01 O 
) O 
, O 
non-fasting O 
glucose O 
( O 
p O 
< O 
0.05 O 
to O 
p O 
< O 
0.001 O 
) O 
and O 
triacylglycerol B-FAMILY 
deposition O 
in O 
liver O 
and O 
adipose O 
tissue O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
All O 
treatment O 
regimens O 
improved O 
glucose B-TRIVIAL 
tolerance O 
( O 
p O 
< O 
0.05 O 
to O 
p O 
< O 
0.001 O 
) O 
and O 
insulin O 
sensitivity O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
Combined O 
treatment O 
with O 
(pGlu-Gln)-CCK-8 O 
and O 
[D-Leu-4]-OB3 O 
resulted O 
in O 
significantly O 
lowered O 
plasma O 
insulin O 
levels O 
, O 
normalisation O 
of O 
circulating O 
LDL- O 
cholesterol B-TRIVIAL 
and O 
decreased O 
triacylglycerol B-FAMILY 
deposition O 
in O 
muscle O 
. O 
These O 
effects O 
were O 
superior O 
to O 
either O 
treatment O 
regimen O 
alone O 
. O 
There O 
were O 
no O 
changes O 
in O 
overall O 
locomotor O 
activity O 
or O 
respiratory O 
exchange O 
ratio O 
, O 
but O 
treatment O 
with O 
(pGlu-Gln)-CCK-8 O 
significantly O 
reduced O 
( O 
p O 
< O 
0.001 O 
) O 
energy O 
expenditure O 
. O 
CONCLUSIONS O 
/ O 
INTERPRETATION O 
: O 
These O 
studies O 
highlight O 
the O 
potential O 
of O 
(pGlu-Gln)-CCK-8 O 
alone O 
and O 
in O 
combination O 
with O 
[D-Leu-4]-OB3 O 
in O 
the O 
treatment O 
of O 
obesity O 
and O 
diabetes O 
. O 

of O 
surface O 
morphology O 
on O 
friction O 
of O 
graphene B-TRIVIAL 
on O 
various O 
substrates O 
. O 

friction O 
of O 
graphene B-TRIVIAL 
on O 
various O 
substrates O 
, O 
such O 
as O 
SiO2 B-FORMULA 
, O 
h-BN O 
, O 
bulk O 
- O 
like O 
graphene B-TRIVIAL 
, O 
and O 
mica B-TRIVIAL 
, O 
was O 
investigated O 
to O 
characterize O 
the O 
adhesion O 
level O 
between O 
graphene B-TRIVIAL 
and O 
the O 
underlying O 
surface O 
. O 
The O 
friction O 
of O 
graphene B-TRIVIAL 
on O 
SiO2 B-FORMULA 
decreased O 
with O 
increasing O 
thickness O 
and O 
converged O 
around O 
the O 
penta O 
- O 
layers O 
due O 
to O 
incomplete O 
contact O 
between O 
the O 
two O 
surfaces O 
. O 
However O 
, O 
the O 
friction O 
of O 
graphene B-TRIVIAL 
on O 
an O 
atomically O 
flat O 
substrate O 
, O 
such O 
as O 
h-BN O 
or O 
bulk O 
- O 
like O 
graphene B-TRIVIAL 
, O 
was O 
low O 
and O 
comparable O 
to O 
that O 
of O 
bulk O 
- O 
like O 
graphene B-TRIVIAL 
. O 
In O 
contrast O 
, O 
the O 
friction O 
of O 
graphene B-TRIVIAL 
folded O 
onto O 
bulk O 
- O 
like O 
graphene B-TRIVIAL 
was O 
indistinguishable O 
from O 
that O 
of O 
mono O 
- O 
layer O 
graphene B-TRIVIAL 
on O 
SiO2 B-FORMULA 
despite O 
the O 
ultra O 
- O 
smoothness O 
of O 
bulk O 
- O 
like O 
graphene B-TRIVIAL 
. O 
The O 
characterization O 
of O 
the O 
graphene B-TRIVIAL 
' O 
s O 
roughness O 
before O 
and O 
after O 
folding O 
showed O 
that O 
the O 
corrugation O 
of O 
graphene B-TRIVIAL 
induced O 
by O 
SiO2 B-FORMULA 
morphology O 
was O 
preserved O 
even O 
after O 
it O 
was O 
folded O 
onto O 
an O 
atomically O 
flat O 
substrate O 
. O 
In O 
addition O 
, O 
graphene B-TRIVIAL 
deposited O 
on O 
mica B-TRIVIAL 
, O 
when O 
folded O 
, O 
preserved O 
the O 
same O 
corrugation O 
level O 
as O 
before O 
the O 
folding O 
event O 
. O 
Our O 
friction O 
measurements O 
revealed O 
that O 
graphene B-TRIVIAL 
, O 
once O 
exfoliated O 
from O 
the O 
bulk O 
crystal O 
, O 
tends O 
to O 
maintain O 
its O 
corrugation O 
level O 
even O 
after O 
it O 
is O 
folded O 
onto O 
an O 
atomically O 
flat O 
substrate O 
and O 
that O 
ultra O 
- O 
flatness O 
in O 
both O 
graphene B-TRIVIAL 
and O 
the O 
substrate O 
is O 
required O 
to O 
achieve O 
the O 
intimate O 
contact O 
necessary O 
for O 
strong O 
adhesion O 
. O 

drugs O 
directed O 
against O 
the O 
microtubule O 
, O 
including O 
taxanes B-FAMILY 
and O 
vinca B-FAMILY 
alkaloids I-FAMILY 
, O 
have O 
been O 
the O 
backbone O 
of O 
many O 
chemotherapy O 
regimes O 
for O 
decades O 
. O 
These O 
drugs O 
have O 
, O 
however O 
, O 
significant O 
limitations O 
, O 
which O 
have O 
prompted O 
the O 
development O 
of O 
novel O 
microtubule O 
targeting O 
agents O 
( O 
MTAs O 
) O 
. O 
This O 
article O 
will O 
discuss O 
MTAs O 
for O 
anticancer O 
therapies O 
and O 
recent O 
debates O 
regarding O 
their O 
mechanisms O 
of O 
action O 
. O 
Furthermore O 
, O 
the O 
limitations O 
of O 
taxanes B-FAMILY 
, O 
including O 
hypersensitivity O 
reactions O 
, O 
neurotoxicity O 
, O 
drug O 
resistance O 
and O 
lack O 
of O 
validated O 
biomarkers O 
to O 
guide O 
therapy O 
will O 
be O 
discussed O 
, O 
all O 
of O 
which O 
have O 
driven O 
the O 
development O 
of O 
novel O 
agents O 
. O 
The O 
mechanisms O 
of O 
action O 
and O 
drug O 
development O 
of O 
new O 
generations O 
of O 
MTAs O 
will O 
also O 
be O 
outlined O 
. O 
Agents O 
demonstrating O 
utility O 
in O 
Phase O 
III O 
clinical O 
trials O 
, O 
including O 
eribulin B-TRIVIAL 
, O 
ixabepilone B-TRIVIAL 
, O 
cabazitaxel B-TRIVIAL 
and O 
trastuzumab- O 
DM1 B-ABBREVIATION 
will O 
be O 
highlighted O 
, O 
as O 
well O 
as O 
novel O 
agents O 
currently O 
in O 
development O 
and O 
future O 
directions O 
for O 
MTAs O 
. O 

- O 
infused O 
textured O 
solid O 
substrates O 
are O 
gaining O 
remarkable O 
interest O 
as O 
a O 
new O 
class O 
of O 
omni O 
- O 
repellent O 
nonfouling O 
materials O 
and O 
surface O 
coatings O 
. O 
We O 
investigated O 
the O 
effect O 
of O 
the O 
length O 
scale O 
and O 
hierarchy O 
of O 
the O 
surface O 
topography O 
of O 
the O 
underlying O 
substrates O 
on O 
their O 
ability O 
to O 
retain O 
the O 
lubricant O 
under O 
high O 
shear O 
conditions O 
, O 
which O 
is O 
important O 
for O 
maintaining O 
nonwetting O 
properties O 
under O 
application O 
- O 
relevant O 
conditions O 
. O 
By O 
comparing O 
the O 
lubricant O 
loss O 
, O 
contact O 
angle O 
hysteresis O 
, O 
and O 
sliding O 
angles O 
for O 
water O 
and O 
ethanol B-SYSTEMATIC 
droplets O 
on O 
flat O 
, O 
microscale O 
, O 
nanoscale O 
, O 
and O 
hierarchically O 
textured O 
surfaces O 
subjected O 
to O 
various O 
spinning O 
rates O 
( O 
from O 
100 O 
to O 
10 O 
0 O 
rpm O 
) O 
, O 
we O 
show O 
that O 
lubricant O 
- O 
infused O 
textured O 
surfaces O 
with O 
uniform O 
nanofeatures O 
provide O 
the O 
most O 
shear O 
- O 
tolerant O 
liquid O 
- O 
repellent O 
behavior O 
, O 
unlike O 
lotus O 
leaf O 
- O 
inspired O 
superhydrophobic O 
surfaces O 
, O 
which O 
generally O 
favor O 
hierarchical O 
structures O 
for O 
improved O 
pressure O 
stability O 
and O 
low O 
contact O 
angle O 
hysteresis O 
. O 
On O 
the O 
basis O 
of O 
these O 
findings O 
, O 
we O 
present O 
generalized O 
, O 
low O 
- O 
cost O 
, O 
and O 
scalable O 
methods O 
to O 
manufacture O 
uniform O 
or O 
regionally O 
patterned O 
nanotextured O 
coatings O 
on O 
arbitrary O 
materials O 
and O 
complex O 
shapes O 
. O 
After O 
functionalization O 
and O 
lubrication O 
, O 
these O 
coatings O 
show O 
robust O 
, O 
shear O 
- O 
tolerant O 
omniphobic O 
behavior O 
, O 
transparency O 
, O 
and O 
nonfouling O 
properties O 
against O 
highly O 
contaminating O 
media O 
. O 

of O 
stachydrine B-TRIVIAL 
on O 
endoplasmic O 
reticulum O 
stress O 
- O 
induced O 
apoptosis O 
in O 
rat O 
kidney O 
after O 
unilateral O 
ureteral O 
obstruction O 
. O 

study O 
aimed O 
at O 
determining O 
the O 
effect O 
of O 
stachydrine B-TRIVIAL 
on O 
the O 
PERK O 
, O 
CHOP O 
, O 
and O 
caspase-3 O 
in O 
rat O 
kidney O 
with O 
RIF O 
. O 
Rats O 
were O 
randomly O 
divided O 
into O 
control O 
group O 
, O 
model O 
group O 
, O 
enalapril B-TRIVIAL 
group O 
, O 
high O 
stachydrine B-TRIVIAL 
group O 
, O 
medium O 
stachydrine B-TRIVIAL 
group O 
, O 
and O 
low O 
stachydrine B-TRIVIAL 
group O 
. O 
RIF O 
models O 
of O 
five O 
groups O 
were O 
developed O 
by O 
unilateral O 
ureteral O 
obstruction O 
except O 
the O 
control O 
group O 
. O 
The O 
rats O 
were O 
sacrificed O 
12 O 
days O 
after O 
surgery O 
and O 
blood O 
samples O 
were O 
collected O 
. O 
Serum O 
creatinine B-TRIVIAL 
( O 
Scr O 
) O 
and O 
blood O 
urea O 
nitrogen B-SYSTEMATIC 
( O 
BUN O 
) O 
levels O 
were O 
detected O 
. O 
Renal O 
tubular O 
damage O 
index O 
was O 
determined O 
by O 
HE O 
staining O 
. O 
The O 
area O 
percentage O 
of O 
RIF O 
was O 
determined O 
by O 
the O 
Masson O 
method O 
. O 
Expressions O 
of O 
PERK O 
, O 
CHOP O 
, O 
and O 
caspase-3 O 
in O 
kidney O 
were O 
determined O 
by O 
immunohistochemistry O 
. O 
Tubulointerstitial O 
injury O 
index O 
, O 
RIF O 
, O 
serum O 
Scr O 
, O 
BUN O 
level O 
, O 
and O 
expressions O 
of O 
PERK O 
, O 
CHOP O 
, O 
and O 
caspase-3 O 
were O 
different O 
between O 
the O 
model O 
and O 
treatment O 
groups O 
( O 
P O 
< O 
0.05 O 
; O 
P O 
< O 
0.01 O 
) O 
. O 
The O 
expressions O 
of O 
PERK O 
, O 
CHOP O 
, O 
and O 
caspase-3 O 
in O 
nephridial O 
tissue O 
were O 
reduced O 
( O 
P O 
< O 
0.05 O 
) O 
, O 
tubulointerstitial O 
injury O 
and O 
RIF O 
were O 
reduced O 
( O 
P O 
< O 
0.05 O 
) O 
, O 
and O 
Scr O 
and O 
BUN O 
were O 
lower O 
( O 
P O 
< O 
0.05 O 
) O 
in O 
the O 
high O 
stachydrine B-TRIVIAL 
group O 
than O 
those O 
in O 
the O 
enalapril B-TRIVIAL 
group O 
. O 
The O 
expressions O 
of O 
PERK O 
, O 
CHOP O 
, O 
and O 
caspase-3 O 
were O 
reduced O 
in O 
the O 
endoplasmic O 
reticulum O 
stress O 
- O 
related O 
apoptosis O 
pathway O 
after O 
stachydrine B-TRIVIAL 
treatment O 
. O 
Consequently O 
, O 
apoptosis O 
was O 
prevented O 
, O 
and O 
RIF O 
was O 
inhibited O 
. O 

, O 
a O 
new O 
flavonoid B-FAMILY 
with O 
a O 
methyl B-SYSTEMATIC 
benzoate I-SYSTEMATIC 
substituent O 
from O 
Selaginella O 
uncinata O 
. O 

( O 
1 O 
) O 
, O 
a O 
new O 
flavonoid B-FAMILY 
, O 
together O 
with O 
four O 
known O 
compounds O 
( O 
2-5 O 
) O 
, O 
was O 
isolated O 
from O 
Selaginella O 
uncinata O 
( O 
Desv O 
. O 
) O 
Spring O 
. O 
Compounds O 
2 O 
and O 
3 O 
were O 
isolated O 
from O 
the O 
genus O 
selaginella O 
for O 
the O 
first O 
time O 
. O 
The O 
structure O 
of O 
the O 
new O 
compound O 
was O 
determined O 
as O 
methyl B-SYSTEMATIC 
3-(5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-6-yl)-4-methoxybenzoate I-SYSTEMATIC 
by O 
means O 
of O 
spectroscopic O 
evidence O 
, O 
including O 
UV O 
, O 
IR O 
, O 
1D O 
and O 
2D O 
NMR O 
analyses O 
as O 
well O 
as O 
HR-ESI-MS O 
. O 
These O 
compounds O 
( O 
1-5 O 
) O 
were O 
evaluated O 
for O 
the O 
antioxidant O 
activity O 
in O 
1,1-diphenyl-2-picrylhydrazyl B-SYSTEMATIC 
assay O 
system O 
. O 

antiviral O 
effect O 
of O 
7-hydroxyisoflavone B-SYSTEMATIC 
against O 
Enterovirus O 
71 O 
in O 
vitro O 
. O 

71 O 
( O 
EV71 O 
) O 
is O 
the O 
major O 
causative O 
agent O 
of O 
hand O 
foot O 
and O 
mouth O 
disease O 
. O 
And O 
EV71 O 
causes O 
epidemics O 
worldwide O 
, O 
particularly O 
in O 
the O 
Asia-Pacific O 
region O 
. O 
Unfortunately O 
, O 
currently O 
there O 
is O 
no O 
approved O 
vaccine O 
or O 
antiviral O 
drug O 
for O 
EV71-induced O 
disease O 
prevention O 
and O 
therapy O 
. O 
In O 
screening O 
for O 
anti-EV71 O 
candidates O 
, O 
we O 
found O 
that O 
7-hydroxyisoflavone B-SYSTEMATIC 
was O 
active O 
against O 
EV71 O 
. O 
7-Hydroxyisoflavone B-SYSTEMATIC 
exhibited O 
strong O 
antiviral O 
activity O 
against O 
three O 
different O 
EV71 O 
strains O 
. O 
The O 
50% O 
inhibitory O 
concentration O 
range O 
was O 
between O 
3.25 O 
and O 
4.92 O 
μM O 
by O 
cytopathic O 
effect O 
assay O 
. O 
7-Hydroxyisoflavone B-SYSTEMATIC 
could O 
reduce O 
EV71 O 
viral O 
RNA O 
and O 
protein O 
synthesis O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Time O 
course O 
study O 
showed O 
that O 
treatment O 
of O 
Vero O 
cells O 
with O 
7-hydroxyisoflavone B-SYSTEMATIC 
at O 
indicated O 
times O 
after O 
EV71 O 
inoculation O 
( O 
0-6 O 
h O 
) O 
resulted O 
in O 
significant O 
antiviral O 
activity O 
. O 
Results O 
showed O 
that O 
7-hydroxyisoflavone B-SYSTEMATIC 
acted O 
at O 
an O 
early O 
step O 
of O 
EV71 O 
replication O 
. O 
7-Hydroxyisoflavone B-SYSTEMATIC 
also O 
exhibited O 
strong O 
antiviral O 
activity O 
against O 
coxsackievirus O 
B2 O 
, O 
B3 O 
, O 
and O 
B6 O 
. O 
In O 
short O 
, O 
7-hydroxyisoflavone B-SYSTEMATIC 
may O 
be O 
used O 
as O 
a O 
lead O 
compound O 
for O 
anti-EV71 O 
drug O 
development O 
. O 

new O 
tri-nor-eudesmanolides B-FAMILY 
from O 
Inula O 
racemosa O 
. O 

new O 
tri-nor-eudesmane B-TRIVIAL 
-type O 
sesquiterpenoids B-FAMILY 
were O 
isolated O 
from O 
the O 
roots O 
of O 
Inula O 
racemosa O 
, O 
and O 
their O 
structures O 
were O 
elucidated O 
as O 
8-oxo-tri-nor-eudesm-6-en-5α-ol B-SYSTEMATIC 
( O 
1 O 
) O 
and O 
tri-nor-eudesm-5-en-7β,8β-diol B-SYSTEMATIC 
( O 
2 O 
) O 
. O 
The O 
cytotoxic O 
activity O 
of O 
compound O 
1 O 
against O 
five O 
human O 
cancer O 
cell O 
lines O 
had O 
been O 
tested O 
, O 
but O 
exhibited O 
no O 
cytotoxic O 
activity O 
. O 

Phonon O 
Scattering O 
from O 
Sub-10 O 
nm O 
Surface O 
Roughness O 
Wavelengths O 
in O 
Metal O 
- O 
Assisted O 
Chemically O 
Etched O 
Si B-FORMULA 
Nanowires O 
. O 

dependence O 
in O 
phonon O 
surface O 
scattering O 
is O 
a O 
debated O 
topic O 
in O 
fundamental O 
phonon O 
physics O 
. O 
Recent O 
experiments O 
and O 
theory O 
suggest O 
such O 
a O 
phenomenon O 
, O 
but O 
an O 
independent O 
agreement O 
between O 
the O 
two O 
remains O 
elusive O 
. O 
We O 
report O 
low O 
- O 
temperature O 
dependence O 
of O 
thermal O 
conductivity O 
in O 
silicon B-SYSTEMATIC 
nanowires O 
fabricated O 
using O 
a O 
two O 
- O 
step O 
, O 
metal O 
- O 
assisted O 
chemical O 
etch O 
. O 
By O 
reducing O 
etch O 
rates O 
down O 
to O 
0.5 O 
nm O 
/ O 
s O 
from O 
the O 
typical O 
> O 
100 O 
nm O 
/ O 
s O 
, O 
we O 
report O 
controllable O 
roughening O 
of O 
nanowire O 
surfaces O 
and O 
selectively O 
focus O 
on O 
moderate O 
roughness O 
scales O 
rather O 
than O 
the O 
extreme O 
scales O 
investigated O 
previously O 
. O 
This O 
critically O 
enables O 
direct O 
comparison O 
with O 
perturbation O 
- O 
based O 
spectral O 
scattering O 
theory O 
. O 
Using O 
experimentally O 
characterized O 
surface O 
roughness O 
, O 
we O 
show O 
that O 
a O 
multiple O 
scattering O 
theory O 
provides O 
excellent O 
agreement O 
and O 
explanation O 
of O 
the O 
observed O 
low O 
- O 
temperature O 
dependence O 
of O 
rough O 
surface O 
nanowires O 
. O 
The O 
theory O 
does O 
not O 
employ O 
any O 
fitting O 
parameters O 
. O 
A O 
5-10 O 
nm O 
roughness O 
correlation O 
length O 
is O 
typical O 
in O 
metal O 
- O 
assisted O 
chemical O 
etching O 
and O 
resonantly O 
scatters O 
dominant O 
phonons O 
in O 
silicon B-SYSTEMATIC 
, O 
leading O 
to O 
the O 
observed O 
∼T(1.6-2.4) O 
behavior O 
. O 
Our O 
work O 
provides O 
fundamental O 
and O 
quantitative O 
insight O 
into O 
spectral O 
phonon O 
scattering O 
from O 
rough O 
surfaces O 
. O 
This O 
advances O 
applications O 
of O 
nanowires O 
in O 
thermoelectric O 
energy O 
conversion O 
. O 

new O 
flavanol B-FAMILY 
from O 
Cynomorium O 
songaricum O 
. O 

new O 
flavanol B-FAMILY 
, O 
named O 
songarin B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
, O 
was O 
isolated O 
from O 
Cynomorium O 
songaricum O 
Rupr O 
. O 
The O 
structure O 
was O 
established O 
on O 
the O 
basis O 
of O 
spectroscopic O 
methods O 
including O 
2D O 
NMR O 
techniques O 
. O 
Compound O 
1 O 
displayed O 
the O 
protective O 
effect O 
against O 
d-galactosamine B-TRIVIAL 
-induced O 
HepG2 O 
damage O 
and O 
reduced O 
the O 
damage O 
from O 
58.64% O 
to O 
22.26% O 
. O 

, O 
challenges O 
, O 
and O 
opportunities O 
in O 
two O 
- O 
dimensional O 
materials O 
beyond O 
graphene B-TRIVIAL 
. O 

' O 
s O 
success O 
has O 
shown O 
that O 
it O 
is O 
possible O 
to O 
create O 
stable O 
, O 
single O 
and O 
few O 
- O 
atom O 
- O 
thick O 
layers O 
of O 
van O 
der O 
Waals O 
materials O 
, O 
and O 
also O 
that O 
these O 
materials O 
can O 
exhibit O 
fascinating O 
and O 
technologically O 
useful O 
properties O 
. O 
Here O 
we O 
review O 
the O 
state O 
- O 
of O 
- O 
the O 
- O 
art O 
of O 
2D O 
materials O 
beyond O 
graphene B-TRIVIAL 
. O 
Initially O 
, O 
we O 
will O 
outline O 
the O 
different O 
chemical O 
classes O 
of O 
2D O 
materials O 
and O 
discuss O 
the O 
various O 
strategies O 
to O 
prepare O 
single O 
- O 
layer O 
, O 
few O 
- O 
layer O 
, O 
and O 
multilayer O 
assembly O 
materials O 
in O 
solution O 
, O 
on O 
substrates O 
, O 
and O 
on O 
the O 
wafer O 
scale O 
. O 
Additionally O 
, O 
we O 
present O 
an O 
experimental O 
guide O 
for O 
identifying O 
and O 
characterizing O 
single O 
- O 
layer O 
- O 
thick O 
materials O 
, O 
as O 
well O 
as O 
outlining O 
emerging O 
techniques O 
that O 
yield O 
both O 
local O 
and O 
global O 
information O 
. O 
We O 
describe O 
the O 
differences O 
that O 
occur O 
in O 
the O 
electronic O 
structure O 
between O 
the O 
bulk O 
and O 
the O 
single O 
layer O 
and O 
discuss O 
various O 
methods O 
of O 
tuning O 
their O 
electronic O 
properties O 
by O 
manipulating O 
the O 
surface O 
. O 
Finally O 
, O 
we O 
highlight O 
the O 
properties O 
and O 
advantages O 
of O 
single- O 
, O 
few- O 
, O 
and O 
many O 
- O 
layer O 
2D O 
materials O 
in O 
field O 
- O 
effect O 
transistors O 
, O 
spin- O 
and O 
valley O 
- O 
tronics O 
, O 
thermoelectrics O 
, O 
and O 
topological O 
insulators O 
, O 
among O 
many O 
other O 
applications O 
. O 

Targets O 
of O 
Thioacetamide B-SYSTEMATIC 
Metabolites O 
in O 
Rat O 
Hepatocytes O 
. O 

( O 
TA O 
) O 
has O 
long O 
been O 
known O 
as O 
a O 
hepatotoxicant O 
whose O 
bioactivation O 
requires O 
S B-FORMULA 
-oxidation O 
to O 
thioacetamide B-SYSTEMATIC 
S-oxide I-SYSTEMATIC 
( O 
TASO B-ABBREVIATION 
) O 
and O 
then O 
to O 
the O 
very O 
reactive O 
S,S-dioxide B-SYSTEMATIC 
( O 
TASO2 B-FORMULA 
) O 
. O 
The O 
latter O 
can O 
tautomerize O 
to O 
form O 
acylating O 
species O 
capable O 
of O 
covalently O 
modifying O 
cellular O 
nucleophiles O 
including O 
phosphatidylethanolamine B-SYSTEMATIC 
( O 
PE O 
) O 
lipids O 
and O 
protein O 
lysine B-TRIVIAL 
side O 
chains O 
. O 
Isolated O 
hepatocytes O 
efficiently O 
oxidize O 
TA O 
to O 
TASO B-ABBREVIATION 
but O 
experience O 
little O 
covalent O 
binding O 
or O 
cytotoxicity O 
because O 
TA O 
is O 
a O 
very O 
potent O 
inhibitor O 
of O 
the O 
oxidation O 
of O 
TASO B-ABBREVIATION 
to O 
TASO2 B-FORMULA 
. O 
However O 
, O 
hepatocytes O 
treated O 
with O 
TASO B-ABBREVIATION 
show O 
extensive O 
covalent O 
binding O 
to O 
both O 
lipids O 
and O 
proteins O 
accompanied O 
by O 
extensive O 
cytotoxicity O 
. O 
In O 
this O 
work O 
, O 
we O 
treated O 
rat O 
hepatocytes O 
with O 
[(14)C]-TASO B-SYSTEMATIC 
and O 
submitted O 
the O 
mitochondrial O 
, O 
microsomal O 
, O 
and O 
cytosolic O 
fractions O 
to O 
2DGE O 
, O 
which O 
revealed O 
a O 
total O 
of O 
321 O 
radioactive O 
protein O 
spots O 
. O 
To O 
facilitate O 
the O 
identification O 
of O 
target O 
proteins O 
and O 
adducted O 
peptides O 
, O 
we O 
also O 
treated O 
cells O 
with O 
a O 
mixture O 
of O 
TASO B-ABBREVIATION 
/ O 
[(13)C2D3]-TASO B-SYSTEMATIC 
. O 
Using O 
a O 
combination O 
of O 
1DGE- O 
and O 
2DGE O 
- O 
based O 
proteomic O 
approaches O 
, O 
we O 
identified O 
187 O 
modified O 
peptides O 
( O 
174 O 
acetylated O 
, O 
50 O 
acetimidoylated O 
, O 
and O 
37 O 
in O 
both O 
forms O 
) O 
from O 
a O 
total O 
of O 
88 O 
nonredundant O 
target O 
proteins O 
. O 
Among O 
the O 
latter O 
, O 
57 O 
are O 
also O 
known O 
targets O 
of O 
at O 
least O 
one O 
other O 
hepatotoxin O 
. O 
The O 
formation O 
of O 
both O 
amide B-FAMILY 
- O 
and O 
amidine B-SYSTEMATIC 
-type O 
adducts O 
to O 
protein O 
lysine B-TRIVIAL 
side O 
chains O 
is O 
in O 
contrast O 
to O 
the O 
exclusive O 
formation O 
of O 
amidine B-SYSTEMATIC 
-type O 
adducts O 
with O 
PE O 
phospholipids O 
. O 
Thiobenzamide B-SYSTEMATIC 
( O 
TB O 
) O 
undergoes O 
the O 
same O 
two O 
- O 
step O 
oxidative O 
bioactivation O 
as O 
TA O 
, O 
and O 
it O 
also O 
gives O 
rise O 
to O 
both O 
amide B-FAMILY 
and O 
amidine B-SYSTEMATIC 
adducts O 
on O 
protein O 
lysine B-TRIVIAL 
side O 
chains O 
but O 
only O 
amidine B-SYSTEMATIC 
adducts O 
to O 
PE O 
lipids O 
. O 
Despite O 
their O 
similarity O 
in O 
functional O 
group O 
chemical O 
reactivity O 
, O 
only O 
38 O 
of O 
62 O 
known O 
TB O 
target O 
proteins O 
are O 
found O 
among O 
the O 
88 O 
known O 
targets O 
of O 
TASO B-ABBREVIATION 
. O 
The O 
potential O 
roles O 
of O 
protein O 
modification O 
by O 
TASO B-ABBREVIATION 
in O 
triggering O 
cytotoxicity O 
are O 
discussed O 
in O 
terms O 
of O 
enzyme O 
inhibition O 
, O 
protein O 
folding O 
, O 
and O 
chaperone O 
function O 
, O 
and O 
the O 
emerging O 
role O 
of O 
protein O 
acetylation O 
in O 
intracellular O 
signaling O 
and O 
the O 
regulation O 
of O 
biochemical O 
pathways O 
. O 

as O 
a O 
template O 
for O 
structure O 
- O 
based O 
drug O 
design O 
: O 
identification O 
of O 
new O 
pyrazole B-SYSTEMATIC 
series O 
of O 
irreversible O 
KAT O 
II O 
inhibitors O 
with O 
improved O 
lipophilic O 
efficiency O 
. O 

structure O 
- O 
based O 
design O 
, O 
synthesis O 
, O 
and O 
biological O 
evaluation O 
of O 
a O 
new O 
pyrazole B-SYSTEMATIC 
series O 
of O 
irreversible O 
KAT O 
II O 
inhibitors O 
are O 
described O 
herein O 
. O 
The O 
modification O 
of O 
the O 
inhibitor O 
scaffold O 
of O 
1 O 
and O 
2 O 
from O 
a O 
dihydroquinolinone B-SYSTEMATIC 
core O 
to O 
a O 
tetrahydropyrazolopyridinone B-SYSTEMATIC 
core O 
led O 
to O 
discovery O 
of O 
a O 
new O 
series O 
of O 
potent O 
KAT O 
II O 
inhibitors O 
with O 
excellent O 
physicochemical O 
properties O 
. O 
Compound O 
20 O 
is O 
the O 
most O 
potent O 
and O 
lipophilically O 
efficient O 
of O 
these O 
new O 
pyrazole B-SYSTEMATIC 
analogs O 
, O 
with O 
a O 
k(inact) O 
/ O 
K O 
(i) O 
value O 
of O 
112000 O 
M(-1)s(-1) O 
and O 
lipophilic O 
efficiency O 
( O 
LipE O 
) O 
of O 
8.53 O 
. O 
The O 
X-ray O 
crystal O 
structure O 
of O 
20 O 
with O 
KAT O 
II O 
demonstrates O 
key O 
features O 
that O 
contribute O 
to O 
this O 
remarkable O 
potency O 
and O 
binding O 
efficiency O 
. O 

, O 
synthesis O 
and O 
antithrombotic O 
evaluation O 
of O 
novel O 
dabigatran B-TRIVIAL 
prodrugs O 
containing O 
methyl B-SYSTEMATIC 
ferulate I-SYSTEMATIC 
. O 

novel O 
series O 
of O 
prodrugs O 
containing O 
dabigatran B-TRIVIAL 
and O 
methyl B-SYSTEMATIC 
(E)-3-(4-hydroxy-2-methoxyphenyl)propenoate I-SYSTEMATIC 
( O 
methyl B-SYSTEMATIC 
ferulate I-SYSTEMATIC 
) O 
were O 
synthesized O 
. O 
All O 
of O 
them O 
reveal O 
the O 
effect O 
of O 
thrombin O 
- O 
induced O 
anti-platelet O 
aggregation O 
in O 
vitro O 
. O 
In O 
addition O 
, O 
in O 
vivo O 
experiment O 
shows O 
that O 
one O 
of O 
the O 
target O 
compounds O 
, O 
X-2 O 
( O 
ED50=3.7 O 
± O 
1 O 
μmol O 
/ O 
kg O 
) O 
possesses O 
a O 
more O 
potent O 
activity O 
for O 
inhibiting O 
venous O 
thrombosis O 
than O 
that O 
of O 
dabigatran B-TRIVIAL 
etexilate I-TRIVIAL 
( O 
ED50=7.8 O 
± O 
1.5 O 
μmol O 
/ O 
kg O 
) O 
. O 

new O 
series O 
of O 
N2- B-FAMILY 
substituted-5-(p-toluenesulfonylamino)phthalimide I-FAMILY 
analogues O 
as O 
α-glucosidase O 
inhibitors O 
. O 

members O 
of O 
a O 
new O 
family O 
of O 
non- O 
sugar B-FAMILY 
-type O 
α-glycosidase O 
inhibitors O 
, O 
bearing O 
a O 
5-(p-toluenesulfonylamino)phthalimide B-SYSTEMATIC 
moiety O 
and O 
various O 
substituent O 
at O 
the O 
N2 O 
position O 
, O 
were O 
synthesized O 
and O 
their O 
activities O 
were O 
investigated O 
. O 
The O 
newly O 
synthesized O 
compounds O 
displayed O 
different O 
inhibition O 
profile O 
towards O 
yeast O 
α-glycosidase O 
and O 
rat O 
intestinal O 
α-glycosidase O 
. O 
Almost O 
all O 
the O 
compounds O 
had O 
strong O 
inhibitory O 
activities O 
against O 
yeast O 
α-glycosidase O 
. O 
Regarding O 
rat O 
intestinal O 
α-glycosidase O 
, O 
only O 
analogs O 
with O 
N2-aromatic O 
substituents O 
displayed O 
varying O 
degrees O 
of O 
inhibitory O 
activities O 
on O 
rat O 
intestinal O 
maltase O 
and O 
lactase O 
and O 
nearly O 
all O 
compounds O 
showed O 
no O 
inhibition O 
against O 
rat O 
intestinal O 
α-amylase O 
. O 
Structure O 
- O 
activity O 
relationship O 
studies O 
indicated O 
that O 
5-(p-toluenesulfonylamino)phthalimide B-SYSTEMATIC 
moiety O 
is O 
a O 
favorable O 
scaffold O 
to O 
exert O 
the O 
α-glucosidase O 
inhibitory O 
activity O 
and O 
substituents O 
at O 
the O 
N2 O 
position O 
have O 
considerable O 
influence O 
on O 
the O 
efficacy O 
of O 
the O 
inhibition O 
activities O 
. O 

synthesis O 
and O 
antimicrobial O 
activity O 
of O 
some O 
novel O 
S-β-d-glucosides B-FAMILY 
of O 
5-aryl-1,2,4-triazole-3-thiones B-FAMILY 
derivatives O 
. O 

series O 
of O 
3-S-β-d-glucosides-4-arylideneamino-5-aryl-1,2,4-triazoles B-FAMILY 
were O 
rationally O 
designed O 
and O 
synthesized O 
according O 
to O 
the O 
principle O 
of O 
superposition O 
of O 
bioactive O 
substructures O 
by O 
the O 
combination O 
of O 
1,2,4-triazole B-SYSTEMATIC 
, O 
Schiff B-FAMILY 
base I-FAMILY 
and O 
glucosides B-FAMILY 
. O 
The O 
structures O 
of O 
the O 
target O 
compounds O 
have O 
been O 
characterized O 
by O 
(1)H B-FORMULA 
NMR O 
, O 
(13)C B-FORMULA 
NMR O 
, O 
IR O 
, O 
MS O 
and O 
HRMS O 
. O 
All O 
the O 
newly O 
synthesized O 
compounds O 
have O 
been O 
evaluated O 
for O 
their O 
antimicrobial O 
activities O 
in O 
vitro O 
against O 
Staphylococcus O 
aureus O 
( O 
ATCC O 
6538 O 
) O 
, O 
Escherichia O 
coli O 
( O 
ATCC O 
8099 O 
) O 
as O 
well O 
as O 
Monilia O 
albican O 
( O 
ATCC O 
10231 O 
) O 
. O 
The O 
bioactive O 
assay O 
showed O 
that O 
most O 
of O 
the O 
tested O 
compounds O 
displayed O 
variable O 
inhibitory O 
effects O 
on O 
the O 
growth O 
of O 
the O 
Gram O 
- O 
positive O 
bacterial O 
strain O 
( O 
Staphylococcus O 
aureus O 
) O 
, O 
Gram O 
- O 
negative O 
bacterial O 
strains O 
( O 
Escherichia O 
coli O 
) O 
and O 
fungal O 
strains O 
( O 
Monilia O 
albican O 
) O 
. O 
All O 
the O 
target O 
compounds O 
exhibited O 
better O 
antifungal O 
activity O 
than O 
antibacterial O 
activity O 
. O 
Especially O 
, O 
compounds O 
6b O 
, O 
6c O 
, O 
6f O 
, O 
6j O 
, O 
6k O 
and O 
6l O 
showed O 
excellent O 
activity O 
against O 
fungus O 
Monilia O 
albican O 
with O 
MIC O 
values O 
of O 
16 O 
μg O 
/ O 
mL O 
. O 

bed O 
nucleus O 
of O 
the O 
stria O 
terminalis O 
( O 
BNST O 
) O 
is O 
a O 
group O 
of O 
inter O 
- O 
connected O 
subnuclei O 
that O 
play O 
critical O 
roles O 
in O 
stress O 
- O 
reward O 
interactions O 
. O 
An O 
interesting O 
feature O 
of O 
this O 
brain O 
region O 
is O 
the O 
massive O 
noradrenergic O 
input O 
that O 
it O 
receives O 
. O 
Important O 
roles O 
for O 
norepinephrine B-TRIVIAL 
in O 
this O 
region O 
have O 
been O 
documented O 
in O 
a O 
number O 
of O 
stress O 
and O 
reward O 
related O 
behaviors O 
. O 
This O 
work O 
has O 
been O 
paralleled O 
over O 
the O 
last O 
several O 
years O 
by O 
efforts O 
to O 
understand O 
the O 
actions O 
of O 
norepinephrine B-TRIVIAL 
on O 
neuronal O 
function O 
in O 
the O 
region O 
. O 
In O 
this O 
review O 
, O 
we O 
will O 
summarize O 
the O 
current O 
state O 
of O 
these O 
research O 
areas O 
. O 

functional O 
interactions O 
between O 
the O 
metabotropic O 
glutamate B-TRIVIAL 
2 O 
( O 
mGlu2 O 
) O 
and O 
5-hydroxytryptamine2A O 
( O 
5-HT2A O 
) O 
neurotransmitter O 
receptors O 
have O 
been O 
established O 
based O 
on O 
electrophysiological O 
, O 
biochemical O 
and O 
behavioral O 
evidence O 
. O 
Over O 
the O 
last O 
several O 
years O 
, O 
dimerization O 
between O 
5-HT2A O 
and O 
mGlu2 O 
receptors O 
has O 
been O 
proposed O 
to O 
account O 
for O 
the O 
functional O 
cross O 
- O 
talk O 
between O 
these O 
two O 
receptors O 
in O 
the O 
prefrontal O 
cortex O 
. O 
The O 
pros O 
and O 
cons O 
for O 
the O 
existence O 
of O 
a O 
heteromeric O 
complex O 
between O 
5-HT2A O 
and O 
mGlu2 O 
receptors O 
will O 
be O 
reviewed O 
here O 
. O 
First O 
, O 
the O 
fundamental O 
criteria O 
needing O 
to O 
establish O 
evidence O 
for O 
heteromeric O 
complexes O 
will O 
be O 
reviewed O 
. O 
Then O 
, O 
the O 
in O 
vitro O 
evidence O 
for O 
and O 
against O 
heteromeric O 
complexes O 
between O 
5-HT2A O 
and O 
mGlu2 O 
receptors O 
will O 
be O 
discussed O 
in O 
regard O 
to O 
physical O 
and O 
functional O 
interactions O 
. O 
Finally O 
, O 
the O 
data O 
with O 
native O 
in O 
situ O 
mGlu2 O 
and O 
5-HT2A O 
receptors O 
will O 
be O 
discussed O 
with O 
respect O 
to O 
whether O 
heteromeric O 
complexes O 
or O 
a O 
simple O 
functional O 
interaction O 
between O 
two O 
distinct O 
GPCRs O 
based O 
on O 
brain O 
network O 
activity O 
is O 
the O 
more O 
simple O 
explanation O 
for O 
a O 
range O 
of O 
in O 
vivo O 
data O 
. O 

of O 
P-glycoprotein O 
- O 
mediated O 
multidrug O 
resistance O 
is O 
induced O 
by O 
mollugin B-TRIVIAL 
in O 
MCF-7 O 
/ O 
adriamycin O 
cells O 
. O 

( O 
P-gp O 
) O 
, O 
an O 
important O 
efflux O 
transporter O 
, O 
is O 
encoded O 
by O 
the O 
MDR1 O 
class O 
of O 
genes O 
and O 
is O 
a O 
central O 
element O 
of O 
the O 
multidrug O 
resistance O 
( O 
MDR O 
) O 
phenomenon O 
in O 
cancer O 
cells O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
whether O 
mollugin B-TRIVIAL 
, O 
purified O 
from O 
roots O 
of O 
Rubica O 
cordifolia O 
L O 
. O 
, O 
down O 
- O 
regulated O 
MDR1 O 
expression O 
in O 
MCF-7/ O 
adriamycin B-TRIVIAL 
( O 
MCF-7 O 
/ O 
adr O 
) O 
cells O 
, O 
a O 
human O 
breast O 
multidrug O 
- O 
resistant O 
cancer O 
cell O 
line O 
. O 
Mollugin B-TRIVIAL 
treatment O 
significantly O 
inhibited O 
MDR1 O 
expression O 
by O 
blocking O 
MDR1 O 
transcription O 
. O 
Mollugin B-TRIVIAL 
treatment O 
also O 
significantly O 
increased O 
intracellular O 
accumulation O 
of O 
the O 
fluorescently O 
- O 
tagged O 
P-gp O 
substrate O 
, O 
rhodamine-123 B-TRIVIAL 
. O 
The O 
suppression O 
of O 
MDR1 O 
promoter O 
activity O 
and O 
protein O 
expression O 
was O 
mediated O 
through O 
mollugin B-TRIVIAL 
-induced O 
activation O 
of O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
. O 
Furthermore O 
, O 
mollugin B-TRIVIAL 
inhibited O 
MDR1 O 
expression O 
through O 
the O 
suppression O 
of O 
NF-κB O 
and O 
CREB O 
activation O 
. O 
Interestingly O 
, O 
mollugin B-TRIVIAL 
also O 
inhibited O 
COX-2 O 
expression O 
. O 
These O 
results O 
suggest O 
that O 
mollugin B-TRIVIAL 
treatment O 
enhanced O 
suppression O 
of O 
P-gp O 
expression O 
by O 
inhibiting O 
the O 
NF-κB O 
signaling O 
pathway O 
and O 
COX-2 O 
expression O 
, O 
as O 
well O 
as O 
attenuating O 
CRE O 
transcriptional O 
activity O 
through O 
AMPK O 
activation O 
. O 

effects O 
exerted O 
in O 
vitro O 
by O 
polyphenols B-FAMILY 
- O 
quercetin B-TRIVIAL 
, O 
epigallocatechin B-TRIVIAL 
gallate I-TRIVIAL 
and O 
curcumin B-TRIVIAL 
- O 
on O 
HUVEC O 
and O 
Jurkat O 
cells O 
, O 
relevant O 
for O 
diabetes O 
mellitus O 
. O 

are O 
largely O 
studied O 
for O 
their O 
beneficial O 
action O 
in O 
various O 
pathologies O 
, O 
but O 
the O 
correlation O 
with O 
their O 
effects O 
on O 
cell O 
membranes O 
is O 
still O 
elusive O 
. O 
In O 
the O 
present O 
study O 
we O 
assessed O 
the O 
effects O 
exerted O 
in O 
vitro O 
by O 
quercetin B-TRIVIAL 
, O 
epigallocatechin B-TRIVIAL 
gallate I-TRIVIAL 
and O 
curcumin B-TRIVIAL 
on O 
membrane O 
fluidity O 
and O 
transmembrane O 
potential O 
of O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
and O 
Jurkat O 
T O 
lymphoblasts O 
, O 
in O 
experimental O 
conditions O 
mimicking O 
diabetes O 
mellitus O 
, O 
i.e O 
. O 
high O 
glucose B-TRIVIAL 
conditions O 
or O 
increased O 
concentration O 
of O 
advanced O 
glycation O 
end O 
products O 
. O 
Results O 
showed O 
that O 
the O 
investigated O 
polyphenols B-FAMILY 
had O 
beneficial O 
effects O 
on O 
cell O 
membranes O 
altered O 
in O 
diabetic O 
conditions O 
, O 
by O 
restoring O 
transmembrane O 
potential O 
and O 
by O 
membrane O 
" O 
stiffening O 
" O 
. O 
Moreover O 
, O 
they O 
limited O 
the O 
release O 
of O 
pro O 
- O 
inflammatory O 
factors O 
, O 
like O 
monocyte O 
chemotactic O 
protein-1 O 
. O 
These O 
effects O 
were O 
more O 
obvious O 
for O 
cells O 
exposed O 
to O 
advanced O 
glycation O 
end O 
products O 
specific O 
for O 
the O 
late O 
stages O 
of O 
diabetes O 
. O 
Apparently O 
, O 
the O 
inhibitory O 
action O 
of O 
polyphenols B-FAMILY 
on O 
lipid O 
peroxidation O 
was O 
associated O 
with O 
a O 
decrease O 
of O 
membrane O 
fluidity O 
. O 
Concluding O 
, O 
our O 
in O 
vitro O 
study O 
highlighted O 
the O 
potential O 
beneficial O 
action O 
of O 
polyphenols B-FAMILY 
mainly O 
in O 
the O 
late O 
stages O 
of O 
diabetes O 
, O 
exerted O 
at O 
the O 
level O 
of O 
membrane O 
fluidity O 
and O 
transmembrane O 
potential O 
, O 
accompanied O 
by O 
an O 
anti-inflammatory O 
effect O 
on O 
endothelial O 
and O 
immune O 
cells O 
. O 

confers O 
cisplatin B-TRIVIAL 
resistance O 
in O 
gastric O 
cancer O 
cells O 
by O 
regulating O 
PTEN O 
. O 

to O 
chemotherapy O 
is O 
a O 
major O 
obstacle O 
for O 
the O 
effective O 
treatment O 
of O 
cancers O 
. O 
The O 
mechanism O 
of O 
chemo O 
- O 
resistance O 
is O 
still O 
poorly O 
understood O 
, O 
however O 
, O 
mounting O 
evidence O 
supports O 
a O 
role O 
for O 
microRNAs O 
( O 
miRNAs O 
) O 
in O 
modulating O 
key O 
cellular O 
pathways O 
mediating O 
response O 
to O 
chemotherapy O 
. O 
microRNA-21 O 
( O 
miR-21 O 
) O 
has O 
been O 
implicated O 
in O 
many O 
cancers O 
and O 
contributed O 
to O 
chemo O 
- O 
resistance O 
, O 
but O 
its O 
role O 
in O 
gastric O 
cancer O 
drug O 
resistance O 
still O 
remains O 
unexplored O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
whether O 
miR-21 O 
mediated O 
resistance O 
of O 
the O 
gastric O 
cancer O 
cell O 
line O 
SGC7901 O 
to O 
the O 
chemotherapeutic O 
agent O 
cisplatin B-TRIVIAL 
( O 
DDP B-ABBREVIATION 
) O 
. O 
Our O 
study O 
found O 
that O 
the O 
expression O 
of O 
miR-21 O 
upregulated O 
in O 
the O 
cisplatin B-TRIVIAL 
resistant O 
cell O 
line O 
SGC7901/ O 
DDP B-ABBREVIATION 
compared O 
to O 
its O 
parental O 
line O 
SGC7901 O 
. O 
Moreover O 
, O 
over O 
- O 
expression O 
of O 
miR-21 O 
significantly O 
decreased O 
antiproliferative O 
effects O 
and O 
apoptosis O 
induced O 
by O 
cisplatin B-TRIVIAL 
, O 
while O 
knockdown O 
of O 
miR-21 O 
dramatically O 
increased O 
antiproliferative O 
effects O 
and O 
apoptosis O 
induction O 
by O 
cisplatin B-TRIVIAL 
. O 
In O 
addition O 
, O 
miR-21 O 
induced O 
cell O 
survival O 
and O 
cisplatin B-TRIVIAL 
resistance O 
through O 
downregulating O 
the O 
expression O 
of O 
phosphatase O 
and O 
tension O 
homolog O 
deleted O 
on O 
chromosome O 
10 O 
( O 
PTEN O 
) O 
and O 
activation O 
of O 
Akt O 
pathway O 
. O 
Inhibition O 
of O 
Akt O 
using O 
PI3K O 
inhibitor O 
LY B-IDENTIFIER 
294002 I-IDENTIFIER 
could O 
abrogate O 
miR-21 O 
induced O 
cell O 
survival O 
. O 
These O 
results O 
suggest O 
that O 
miR-21 O 
may O 
provide O 
a O 
novel O 
mechanism O 
for O 
understanding O 
cisplatin B-TRIVIAL 
resistance O 
in O 
gastric O 
cancer O 
by O 
modulating O 
PTEN O 
/ O 
PI3K O 
/ O 
Akt O 
pathway O 
. O 

induces O 
disruption O 
of O 
cardiomyocyte O 
adherens O 
junctions O 
. O 

serum O 
levels O 
of O 
p-cresol B-TRIVIAL 
in O 
chronic O 
kidney O 
disease O 
populations O 
have O 
been O 
associated O 
with O 
increased O 
cardiovascular O 
mortality O 
. O 
However O 
, O 
studies O 
on O 
how O 
p-cresol B-TRIVIAL 
affects O 
intercellular O 
junctions O 
between O 
cardiomyocytes O 
were O 
limited O 
. O 
This O 
study O 
investigated O 
the O 
effect O 
of O 
p-cresol B-TRIVIAL 
on O 
adherens O 
junction O 
( O 
AJ O 
) O 
of O 
neonatal O 
cultured O 
cardiomyocytes O 
and O 
its O 
underlying O 
mechanism O 
. O 
A O 
loss O 
of O 
N-cadherin O 
and O 
p120-catenin O 
( O 
p120ctn O 
) O 
immunostaining O 
from O 
cell O 
- O 
cell O 
contact O 
sites O 
was O 
noted O 
by O 
p-cresol B-TRIVIAL 
treatment O 
. O 
In O 
addition O 
, O 
p-cresol B-TRIVIAL 
disrupted O 
AJs O 
by O 
inducing O 
formation O 
of O 
intercellular O 
gaps O 
. O 
Our O 
previous O 
study O 
has O 
revealed O 
that O 
p-cresol B-TRIVIAL 
increased O 
intracellular O 
calcium B-SYSTEMATIC 
levels O 
and O 
activated O 
protein O 
kinase O 
Cα O 
( O 
PKCα O 
) O 
by O 
phosphorylation O 
. O 
The O 
PKCα O 
activation O 
was O 
involved O 
in O 
the O 
p-cresol B-TRIVIAL 
-mediated O 
AJ O 
disassembly O 
, O 
since O 
pharmacological O 
inhibition O 
of O 
PKCα O 
abolished O 
the O 
above O 
- O 
mentioned O 
p-cresol B-TRIVIAL 
effect O 
. O 
This O 
PKCα O 
activation O 
also O 
led O 
to O 
the O 
serine B-TRIVIAL 
dephosphorylation O 
of O 
p120ctn O 
and O 
caused O 
the O 
dissociation O 
of O 
p120ctn O 
from O 
N-cadherin O 
. O 
This O 
hypothesis O 
was O 
further O 
confirmed O 
in O 
H9c2 O 
cells O 
by O 
siRNA O 
approach O 
. O 
SiRNA O 
knockdown O 
of O 
PKCα O 
prevented O 
p-cresol B-TRIVIAL 
-induced O 
serine O 
dephosphorylation O 
of O 
p120ctn O 
and O 
splitting O 
of O 
AJ O 
. O 
In O 
conclusion O 
, O 
p-cresol B-TRIVIAL 
caused O 
PKCα-dependent O 
AJ O 
disassembly O 
of O 
cardiomyocytes O 
, O 
which O 
might O 
be O 
related O 
to O 
asychronized O 
contraction O 
. O 

zinc B-SYSTEMATIC 
-finger O 
missense O 
mutations O 
lead O 
to O 
hypomorphic O 
alleles O 
and O 
a O 
mild O 
Mowat-Wilson O 
syndrome O 
. O 

syndrome O 
( O 
MWS O 
) O 
is O 
a O 
severe O 
intellectual O 
disability O 
(ID)-distinctive O 
facial O 
gestalt O 
- O 
multiple O 
congenital O 
anomaly O 
syndrome O 
, O 
commonly O 
associating O 
microcephaly O 
, O 
epilepsy O 
, O 
corpus O 
callosum O 
agenesis O 
, O 
conotruncal O 
heart O 
defects O 
, O 
urogenital O 
malformations O 
and O 
Hirschsprung O 
disease O 
( O 
HSCR O 
) O 
. O 
MWS O 
is O 
caused O 
by O 
de O 
novo O 
heterozygous O 
mutations O 
in O 
the O 
ZEB2 O 
gene O 
. O 
The O 
majority O 
of O 
mutations O 
lead O 
to O 
haplo O 
- O 
insufficiency O 
through O 
premature O 
stop O 
codons O 
or O 
large O 
gene O 
deletions O 
. O 
Only O 
three O 
missense O 
mutations O 
have O 
been O 
reported O 
so O 
far O 
; O 
none O 
of O 
which O 
resides O 
in O 
a O 
known O 
functional O 
domain O 
of O 
ZEB2 O 
. O 
In O 
this O 
study O 
, O 
we O 
report O 
and O 
analyze O 
the O 
functional O 
consequences O 
of O 
three O 
novel O 
missense O 
mutations O 
, O 
p.Tyr1055Cys O 
, O 
p.Ser1071Pro O 
and O 
p.His1045Arg O 
, O 
identified O 
in O 
the O 
highly O 
conserved O 
C- O 
zinc B-SYSTEMATIC 
-finger O 
( O 
C-ZF O 
) O 
domain O 
of O 
ZEB2 O 
. O 
Patients' O 
phenotype O 
included O 
the O 
facial O 
gestalt O 
of O 
MWS O 
and O 
moderate O 
ID O 
, O 
but O 
no O 
microcephaly O 
, O 
heart O 
defects O 
or O 
HSCR O 
. O 
In O 
vitro O 
studies O 
showed O 
that O 
all O 
the O 
three O 
mutations O 
prevented O 
binding O 
and O 
repression O 
of O 
the O 
E-cadherin O 
promoter O 
, O 
a O 
characterized O 
ZEB2 O 
target O 
gene O 
. O 
Taking O 
advantage O 
of O 
the O 
zebrafish O 
morphant O 
technology O 
, O 
we O 
performed O 
rescue O 
experiments O 
using O 
wild O 
- O 
type O 
( O 
WT O 
) O 
and O 
mutant O 
human O 
ZEB2 O 
mRNAs O 
. O 
Variable O 
, O 
mutation O 
- O 
dependent O 
, O 
embryo O 
rescue O 
, O 
correlating O 
with O 
the O 
severity O 
of O 
patients O 
' O 
phenotype O 
, O 
was O 
observed O 
. O 
Our O 
data O 
provide O 
evidence O 
that O 
these O 
missense O 
mutations O 
cause O 
a O 
partial O 
loss O 
of O 
function O 
of O 
ZEB2 O 
, O 
suggesting O 
that O 
its O 
role O 
is O 
not O 
restricted O 
to O 
repression O 
of O 
E-cadherin O 
. O 
Functional O 
domains O 
other O 
than O 
C-ZF O 
may O 
play O 
a O 
role O 
in O 
early O 
embryonic O 
development O 
. O 
Finally O 
, O 
these O 
findings O 
broaden O 
the O 
clinical O 
spectrum O 
of O 
ZEB2 O 
mutations O 
, O 
indicating O 
that O 
MWS O 
ought O 
to O 
be O 
considered O 
in O 
patients O 
with O 
lesser O 
degrees O 
of O 
ID O 
and O 
a O 
suggestive O 
facial O 
gestalt O 
, O 
even O 
in O 
the O 
absence O 
of O 
congenital O 
malformation O 
. O 

vasorelaxant O 
analogs O 
from O 
chemical O 
modification O 
and O 
biotransformation O 
of O 
isosteviol B-TRIVIAL 
. O 

( O 
1 O 
) O 
has O 
been O 
reported O 
to O 
exhibit O 
moderate O 
vasorelaxant O 
activity O 
. O 
In O 
order O 
to O 
enhance O 
the O 
bioactivity O 
of O 
this O 
compound O 
, O 
chemical O 
modification O 
of O 
1 O 
to O 
the O 
dihydro O 
analog O 
, O 
ent-16β-hydroxybeyeran-19-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
was O 
undertaken O 
. O 
Compound O 
2 O 
was O 
then O 
converted O 
to O 
the O 
corresponding O 
acetate B-SYSTEMATIC 
derivative O 
, O 
ent-16β-acetoxybeyeran-19-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
3 O 
) O 
. O 
Biotransformation O 
of O 
compounds O 
1-3 O 
by O 
the O 
fungus O 
Cunninghamella O 
echinulata O 
NRRL O 
1386 O 
was O 
investigated O 
and O 
the O 
metabolites O 
4-9 O 
were O 
obtained O 
. O 
The O 
substrates O 
and O 
their O 
metabolites O 
were O 
subjected O 
to O 
in O 
vitro O 
rat O 
aorta O 
relaxant O 
activity O 
evaluation O 
. O 
The O 
metabolite O 
4 O 
, O 
ent-7α-hydroxy-16-ketobeyeran-19-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
exhibited O 
the O 
most O 
highly O 
potent O 
activity O 
, O 
with O 
EC50 O 
of O 
3.46 O 
nM O 
, O 
whereas O 
the O 
parent O 
compound O 
1 O 
showed O 
relatively O 
low O 
activity O 
( O 
EC50 O 
57.41 O 
nM O 
) O 
. O 
A O 
17-fold O 
increase O 
in O 
vasorelaxant O 
activity O 
of O 
the O 
analog O 
4 O 
relative O 
to O 
compound O 
1 O 
is O 
of O 
particular O 
significant O 
. O 
Compound O 
4 O 
exerted O 
vasorelaxant O 
activity O 
at O 
particularly O 
low O 
concentration O 
and O 
the O 
vasorelaxant O 
profile O 
reached O 
maximum O 
at O 
relatively O 
low O 
concentration O 
, O 
especially O 
when O 
compared O 
with O 
acetylcholine B-SYSTEMATIC 
, O 
the O 
positive O 
control O 
. O 

novel O 
insulin O 
mimetic O 
vanadium B-FAMILY 
- I-FAMILY 
flavonol I-FAMILY 
complex O 
: O 
Synthesis O 
, O 
characterization O 
and O 
in O 
vivo O 
evaluation O 
in O 
STZ B-ABBREVIATION 
-induced O 
rats O 
. O 

1985 O 
, O 
when O 
Heyliger O 
et O 
al O 
. O 
, O 
first O 
demonstrated O 
a O 
serendipitous O 
discovery O 
that O 
oral O 
administration O 
of O 
0.8 O 
mg O 
/ O 
ml O 
of O 
sodium B-SYSTEMATIC 
orthovanadate I-SYSTEMATIC 
in O 
drinking O 
water O 
to O 
streptozotocin B-TRIVIAL 
-induced O 
diabetic O 
rats O 
resulted O 
in O 
normoglycemia O 
, O 
numerous O 
extensive O 
studies O 
have O 
been O 
pursued O 
on O 
the O 
anti-diabetic O 
and O 
insulinomimetic O 
actions O 
of O 
vanadium B-SYSTEMATIC 
. O 
The O 
acceptance O 
of O 
vanadium B-SYSTEMATIC 
compounds O 
as O 
promising O 
therapeutic O 
antidiabetic O 
agents O 
has O 
been O 
slowed O 
due O 
to O 
the O 
concern O 
for O 
chronic O 
toxicity O 
associated O 
with O 
vanadium B-SYSTEMATIC 
accumulation O 
. O 
In O 
order O 
to O 
circumvent O 
the O 
toxic O 
effects O 
of O 
vanadium B-SYSTEMATIC 
, O 
we O 
have O 
taken O 
up O 
a O 
combinational O 
approach O 
wherein O 
a O 
novel O 
vanadium B-FAMILY 
- I-FAMILY 
flavonol I-FAMILY 
complex O 
was O 
synthesized O 
, O 
characterized O 
and O 
its O 
toxic O 
as O 
well O 
as O 
insulin O 
mimetic O 
potential O 
was O 
evaluated O 
in O 
STZ B-ABBREVIATION 
-induced O 
experimental O 
diabetes O 
in O 
rats O 
. O 
The O 
results O 
indicate O 
that O 
the O 
complex O 
is O 
non-toxic O 
and O 
possess O 
anti-diabetic O 
activity O 
. O 

: O 
A O 
novel O 
target O 
for O 
non-genomic O 
estrogen B-FAMILY 
action O 
in O 
the O 
cardiovascular O 
system O 
. O 

key O 
to O 
harnessing O 
the O 
enormous O 
therapeutic O 
potential O 
of O 
estrogens B-FAMILY 
is O 
understanding O 
the O 
diversity O 
of O 
estrogen B-FAMILY 
receptors O 
and O 
their O 
signaling O 
mechanisms O 
. O 
In O 
addition O 
to O 
the O 
classic O 
nuclear O 
estrogen B-FAMILY 
receptors O 
( O 
i.e O 
. O 
, O 
ERα O 
and O 
ERβ O 
) O 
, O 
over O 
the O 
past O 
decade O 
a O 
novel O 
G O 
- O 
protein O 
- O 
coupled O 
estrogen B-FAMILY 
receptor O 
( O 
GPER O 
) O 
has O 
been O 
discovered O 
in O 
cancer O 
and O 
other O 
cell O 
types O 
. O 
More O 
recently O 
, O 
this O 
non-genomic O 
signaling O 
mechanism O 
has O 
been O 
found O 
in O 
blood O 
vessels O 
, O 
and O 
mediates O 
vasodilatory O 
responses O 
to O 
estrogen B-FAMILY 
and O 
estrogen B-FAMILY 
-like O 
agents O 
; O 
however O 
, O 
downstream O 
signaling O 
events O 
involved O 
acute O 
estrogen B-FAMILY 
action O 
remain O 
unclear O 
. O 
The O 
purpose O 
of O 
this O 
review O 
is O 
to O 
discuss O 
the O 
latest O 
knowledge O 
concerning O 
GPER O 
modulation O 
of O 
cardiovascular O 
function O 
, O 
with O 
a O 
particular O 
emphasis O 
upon O 
how O 
activation O 
of O 
this O 
receptor O 
could O 
mediate O 
acute O 
estrogen B-FAMILY 
effects O 
in O 
the O 
heart O 
and O 
blood O 
vessels O 
( O 
i.e O 
. O 
, O 
vascular O 
tone O 
, O 
cell O 
growth O 
and O 
differentiation O 
, O 
apoptosis O 
, O 
endothelial O 
function O 
, O 
myocardial O 
protection O 
) O 
. O 
Understanding O 
the O 
role O 
of O 
GPER O 
in O 
estrogen B-FAMILY 
signaling O 
may O 
help O 
resolve O 
some O 
of O 
the O 
controversies O 
associated O 
with O 
estrogen B-FAMILY 
and O 
cardiovascular O 
function O 
. O 
Moreover O 
, O 
a O 
more O 
thorough O 
understanding O 
of O 
GPER O 
function O 
could O 
also O 
open O 
significant O 
opportunities O 
for O 
the O 
development O 
of O 
new O 
pharmacological O 
strategies O 
that O 
would O 
provide O 
the O 
cardiovascular O 
benefits O 
of O 
estrogen B-FAMILY 
while O 
limiting O 
the O 
potentially O 
dangerous O 
side O 
effects O 
. O 

abacavir B-TRIVIAL 
bioactivation O 
in O 
humans O 
: O 
Screening O 
for O 
an O 
aldehyde B-SYSTEMATIC 
metabolite O 
. O 

anti-HIV O 
drug O 
abacavir B-TRIVIAL 
is O 
associated O 
with O 
idiosyncratic O 
hypersensitivity O 
reactions O 
and O 
cardiotoxicity O 
. O 
Although O 
the O 
mechanism O 
underlying O 
abacavir B-TRIVIAL 
-toxicity O 
is O 
not O 
fully O 
understood O 
, O 
drug O 
bioactivation O 
to O 
reactive O 
metabolites O 
may O 
be O 
involved O 
. O 
This O 
work O 
was O 
aimed O 
at O 
identifying O 
abacavir B-TRIVIAL 
-protein O 
adducts O 
in O 
the O 
hemoglobin O 
of O 
HIV O 
patients O 
as O 
biomarkers O 
of O 
abacavir B-TRIVIAL 
bioactivation O 
and O 
protein O 
modification O 
. O 
The O 
protocol O 
received O 
prior O 
approval O 
from O 
the O 
Hospital O 
Ethics O 
Committee O 
, O 
patients O 
gave O 
their O 
written O 
informed O 
consent O 
and O 
adherence O 
was O 
controlled O 
through O 
a O 
questionnaire O 
. O 
Abacavir B-TRIVIAL 
-derived O 
Edman O 
adducts O 
with O 
the O 
N B-FORMULA 
-terminal O 
valine B-TRIVIAL 
of O 
hemoglobin O 
were O 
analyzed O 
by O 
an O 
established O 
liquid O 
chromatography O 
- O 
electrospray O 
ionization O 
- O 
tandem O 
mass O 
spectrometry O 
method O 
. O 
Abacavir B-TRIVIAL 
- O 
valine B-TRIVIAL 
adducts O 
were O 
detected O 
in O 
three O 
out O 
of O 
ten O 
patients O 
. O 
This O 
work O 
represents O 
the O 
first O 
evidence O 
of O 
abacavir B-TRIVIAL 
-protein O 
adduct O 
formation O 
in O 
humans O 
. O 
The O 
data O 
confirm O 
the O 
ability O 
of O 
abacavir B-TRIVIAL 
to O 
modify O 
self O 
- O 
proteins O 
and O 
suggest O 
that O 
the O 
molecular O 
mechanism(s) O 
of O 
some O 
abacavir B-TRIVIAL 
-induced O 
adverse O 
reactions O 
may O 
require O 
bioactivation O 
. O 

history O 
of O 
alcoholism O 
interacts O 
with O 
alcohol B-FAMILY 
to O 
affect O 
brain O 
regions O 
involved O 
in O 
behavioral O 
inhibition O 
. O 

: O 
Impulsive O 
behavior O 
is O 
associated O 
with O 
both O 
alcohol B-FAMILY 
use O 
disorders O 
and O 
a O 
family O 
history O 
of O 
alcoholism O 
( O 
FHA O 
) O 
. O 
One O 
operational O 
definition O 
of O 
impulsive O 
behavior O 
is O 
the O 
stop O 
- O 
signal O 
task O 
( O 
SST O 
) O 
which O 
measures O 
the O 
time O 
needed O 
to O 
stop O 
a O 
ballistic O 
hand O 
movement O 
. O 
OBJECTIVE O 
: O 
Employ O 
functional O 
magnetic O 
resonance O 
imaging O 
( O 
fMRI O 
) O 
to O 
study O 
right O 
frontal O 
responses O 
to O 
stop O 
signals O 
in O 
heavy O 
drinking O 
subjects O 
with O 
and O 
without O 
FHA O 
, O 
and O 
as O 
a O 
function O 
of O 
alcohol B-FAMILY 
exposure O 
. O 
METHODS O 
: O 
Twenty O 
- O 
two O 
family O 
history O 
- O 
positive O 
( O 
FHP O 
; O 
age O 
= O 
22.7 O 
years O 
, O 
SD O 
= O 
1.9 O 
) O 
and O 
18 O 
family O 
history O 
- O 
negative O 
( O 
FHN O 
; O 
age O 
= O 
23.7 O 
, O 
SD O 
= O 
1.8 O 
) O 
subjects O 
performed O 
the O 
SST O 
in O 
fMRI O 
in O 
two O 
randomized O 
visits O 
: O 
once O 
during O 
intravenous O 
infusion O 
of O 
alcohol B-FAMILY 
, O 
clamped O 
at O 
a O 
steady O 
- O 
state O 
breath O 
alcohol B-FAMILY 
( O 
BrAC O 
) O 
concentration O 
of O 
60 O 
mg O 
/ O 
dL O 
, O 
and O 
once O 
during O 
infusion O 
of O 
placebo O 
saline O 
. O 
An O 
independent O 
reference O 
group O 
( O 
n O 
= O 
13 O 
, O 
age O 
= O 
23.7 O 
, O 
SD O 
= O 
1.8 O 
) O 
was O 
used O 
to O 
identify O 
a O 
priori O 
right O 
prefrontal O 
regions O 
activated O 
by O 
successful O 
inhibition O 
( O 
Inh O 
) O 
trials O 
, O 
relative O 
to O 
" O 
Go O 
" O 
trials O 
that O 
carried O 
no O 
need O 
for O 
inhibition O 
[ O 
Inh O 
> O 
Go O 
] O 
. O 
RESULTS O 
: O 
FHA O 
interacted O 
with O 
alcohol B-FAMILY 
exposure O 
in O 
right O 
prefrontal O 
cortex O 
, O 
where O 
alcohol B-FAMILY 
reduced O 
[ O 
Inh O 
> O 
Go O 
] O 
activation O 
in O 
FHN O 
subjects O 
but O 
not O 
in O 
FHP O 
subjects O 
. O 
Within O 
this O 
right O 
frontal O 
cortical O 
region O 
, O 
stop O 
- O 
signal O 
reaction O 
time O 
also O 
correlated O 
negatively O 
with O 
[ O 
Inh O 
> O 
Go O 
] O 
activation O 
, O 
suggesting O 
that O 
the O 
[ O 
Inh O 
> O 
Go O 
] O 
activity O 
was O 
related O 
to O 
inhibitory O 
behavior O 
. O 
CONCLUSIONS O 
: O 
The O 
results O 
are O 
consistent O 
with O 
the O 
low O 
level O 
of O 
response O 
theory O 
( O 
Schuckit O 
, O 
J O 
Stud O 
Alcohol B-SYSTEMATIC 
55 O 
: O 
149-158 O 
, O 
1980 O 
; O 
Quinn O 
and O 
Fromme O 
, O 
Alcohol B-SYSTEMATIC 
Clin O 
Exp O 
Res O 
35 O 
: O 
1759-1770 O 
, O 
2011 O 
) O 
, O 
with O 
FHP O 
being O 
less O 
sensitive O 
to O 
alcohol B-FAMILY 
' O 
s O 
effects O 
. O 

carboxylic I-FAMILY 
acids I-FAMILY 
: O 
non O 
- O 
proteinogenic O 
amino B-FAMILY 
acids I-FAMILY 
for O 
medicinal O 
chemists O 
. O 

formation O 
from O 
D-glucose B-SYSTEMATIC 
of O 
both O 
enantiomers O 
of O 
2,4-dideoxy-2,4-iminoribonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
is O 
the O 
first O 
chemical O 
synthesis O 
of O 
unprotected O 
3-hydroxyazetidine B-FAMILY 
carboxylic I-FAMILY 
acids I-FAMILY 
. O 
The O 
long O 
- O 
term O 
stability O 
of O 
3-hydroxyazetidine B-FAMILY 
amides I-FAMILY 
is O 
established O 
at O 
acidic O 
and O 
neutral O 
pH O 
and O 
implies O 
their O 
value O 
as O 
non O 
- O 
proteinogenic O 
amino B-FAMILY 
acid I-FAMILY 
components O 
of O 
peptides O 
, O 
providing O 
medicinal O 
chemists O 
with O 
a O 
new O 
class O 
of O 
peptide O 
isosteres O 
. O 
The O 
structure O 
of O 
N,3-O-dibenzyl-2,4-dideoxy-2,4-imino-D-ribonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
was O 
established O 
by O 
X-ray O 
crystallographic O 
analysis O 
. O 
An O 
N-methylazetidine B-SYSTEMATIC 
amide I-SYSTEMATIC 
derivative O 
is O 
a O 
specific O 
inhibitor O 
of O 
β-hexosaminidases O 
at O 
the O 
micromolar O 
level O 
, O 
and O 
is O 
only O 
the O 
second O 
example O 
of O 
potent O 
inhibition O 
of O 
any O 
glycosidase O 
by O 
an O 
amide B-FAMILY 
of O 
a O 
sugar B-FAMILY 
amino I-FAMILY 
acid I-FAMILY 
related O 
to O 
an O 
iminosugar B-FAMILY 
. O 

Role O 
of O 
Surface O 
Chemistry O 
on O 
the O 
Toxicity O 
of O 
Ag B-FORMULA 
Nanoparticles O 
. O 

role O 
of O 
surface O 
chemistry O 
on O 
the O 
toxicity O 
of O 
Ag B-FORMULA 
nanoparticles O 
is O 
investigated O 
using O 
Saccharomyces O 
cerevisiae O 
yeast O 
as O 
a O 
platform O 
for O 
evaluation O 
. O 
Combining O 
the O 
shape O 
- O 
controlled O 
synthesis O 
of O 
Ag B-FORMULA 
nanoparticles O 
with O 
a O 
comprehensive O 
characterization O 
of O 
their O 
physicochemical O 
properties O 
, O 
an O 
understanding O 
is O 
formed O 
of O 
the O 
correlation O 
between O 
the O 
physicochemical O 
parameters O 
of O 
nanoparticles O 
and O 
the O 
inhibition O 
growth O 
of O 
yeast O 
cells O 
upon O 
the O 
introduction O 
of O 
nanoparticles O 
into O 
the O 
cell O 
culture O 
system O 
. O 
Capping O 
agents O 
, O 
surface O 
facets O 
, O 
and O 
sample O 
stability O 
- O 
the O 
three O 
experimental O 
parameters O 
that O 
are O 
inherent O 
from O 
the O 
wet O 
- O 
chemical O 
synthesis O 
of O 
Ag B-FORMULA 
nanoparticles O 
- O 
have O 
a O 
strong O 
impact O 
on O 
toxicity O 
evaluation O 
. O 
Hence O 
, O 
it O 
is O 
important O 
to O 
characterize O 
surface O 
properties O 
of O 
Ag B-FORMULA 
nanoparticles O 
in O 
the O 
nature O 
of O 
biological O 
media O 
and O 
to O 
understand O 
the O 
role O 
that O 
surface O 
chemistry O 
may O 
interplay O 
to O 
correlate O 
the O 
physicochemical O 
properties O 
of O 
nanoparticles O 
with O 
their O 
biological O 
response O 
upon O 
exposure O 
. O 
This O 
work O 
demonstrates O 
the O 
great O 
importance O 
of O 
surface O 
chemistry O 
in O 
designing O 
experiments O 
for O 
reliable O 
toxicity O 
evaluation O 
and O 
in O 
mitigating O 
the O 
toxicity O 
of O 
Ag B-FORMULA 
nanoparticles O 
for O 
their O 
safe O 
use O 
in O 
future O 
commercialization O 
. O 

of O 
Phenylthiolate B-SYSTEMATIC 
- O 
and O 
Methylthiolate B-SYSTEMATIC 
-Adatom O 
Species O 
at O 
Low O 
Coverage O 
on O 
the O 
Au(111) B-FORMULA 
Surface O 
. O 

scanning O 
tunneling O 
microscopy O 
we O 
observed O 
reaction O 
products O 
of O 
two O 
chemisorbed O 
thiolate B-SYSTEMATIC 
species O 
, O 
methylthiolate B-SYSTEMATIC 
and O 
phenylthiolate B-SYSTEMATIC 
, O 
on O 
the O 
Au(111) B-FORMULA 
surface O 
. O 
Despite O 
the O 
apparent O 
stability O 
, O 
organometallic B-FAMILY 
complexes O 
of O 
methylthiolate B-SYSTEMATIC 
and O 
phenylthiolate B-SYSTEMATIC 
with O 
the O 
gold O 
- O 
adatom O 
( O 
RS-Au-SR B-FAMILY 
, O 
with O 
R O 
- O 
the O 
hydrocarbon B-FAMILY 
group O 
) O 
undergo O 
a O 
stoichiometric O 
exchange O 
reaction O 
, O 
forming O 
hybridized O 
CH3S-Au-SPh B-FORMULA 
complexes O 
. O 
Complementary O 
density O 
functional O 
theory O 
calculations O 
suggest O 
that O 
the O 
reaction O 
is O 
most O 
likely O 
mediated O 
by O 
a O 
monothiolate O 
RS-Au B-FAMILY 
complex O 
bonded O 
to O 
the O 
gold O 
surface O 
, O 
which O 
forms O 
a O 
trithiolate B-SYSTEMATIC 
RS-Au-(SR)-Au-SR B-FAMILY 
complex O 
as O 
a O 
key O 
intermediate O 
. O 
This O 
work O 
therefore O 
reveals O 
the O 
novel O 
chemical O 
reactivity O 
of O 
the O 
low O 
- O 
coverage O 
" O 
striped O 
" O 
phase O 
of O 
alkanethiols B-FAMILY 
on O 
gold O 
and O 
strongly O 
points O 
to O 
the O 
involvement O 
of O 
monoadatom O 
thiolate B-SYSTEMATIC 
intermediates O 
in O 
this O 
reaction O 
. O 
By O 
extension O 
, O 
such O 
intermediates O 
may O 
be O 
involved O 
in O 
the O 
self O 
- O 
assembly O 
process O 
itself O 
, O 
shedding O 
new O 
light O 
on O 
this O 
long O 
- O 
standing O 
problem O 
. O 

d4 O 
dopamine B-TRIVIAL 
receptors O 
: O 
implications O 
for O 
drug O 
discovery O 
and O 
therapeutic O 
development O 
. O 

wealth O 
of O 
preclinical O 
and O 
clinical O 
literature O 
has O 
established O 
functional O 
associations O 
of O 
CNS O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
and O 
its O 
multiple O 
G O 
protein O 
- O 
coupled O 
receptor O 
( O 
GPCR O 
) O 
types O 
in O 
the O 
integration O 
of O 
key O 
neurological O 
processes O 
linked O 
to O 
complex O 
behavioral O 
activities O 
. O 
Conversely O 
, O 
an O 
equivalent O 
vast O 
literature O 
supports O 
the O 
role O 
of O 
aberrant O 
CNS O 
DA O 
expression O 
and O 
DA O 
receptor O 
signaling O 
in O 
the O 
etiology O 
and O 
persistence O 
of O 
major O 
psychiatric O 
illnesses O 
and O 
has O 
established O 
selective O 
targeting O 
of O 
DA-ergic O 
systems O 
as O 
a O 
cornerstone O 
of O 
pharmacotherapeutic O 
intervention O 
and O 
current O 
neuroleptic O 
drug O 
development O 
. O 
The O 
present O 
short O 
review O 
focuses O 
on O 
potential O 
functional O 
/ O 
behavioral O 
alterations O 
linked O 
to O 
polymorphisms O 
in O 
the O 
primary O 
DNA O 
sequence O 
of O 
the O 
DA O 
receptor O 
type O 
4 O 
( O 
DRD4 O 
) O 
gene O 
in O 
reference O 
to O 
major O 
psychiatric O 
illnesses O 
. O 
The O 
potential O 
clinical O 
relevance O 
of O 
major O 
polymorphisms O 
of O 
the O 
DRD4 O 
gene O 
are O 
discussed O 
within O 
the O 
context O 
of O 
practical O 
aspects O 
of O 
typical O 
and O 
atypical O 
neuroleptic O 
drug O 
usage O 
within O 
afflicted O 
populations O 
of O 
psychiatric O 
patients O 
. O 
It O 
is O 
anticipated O 
that O 
additional O 
complementary O 
molecular O 
, O 
biochemical O 
, O 
and O 
behavioral O 
studies O 
of O 
DRD4 O 
gene O 
polymorphisms O 
will O 
provide O 
essential O 
information O 
for O 
selective O 
targeting O 
of O 
heterogeneous O 
populations O 
of O 
CNS O 
D4 O 
receptors O 
and O 
advance O 
drug O 
discovery O 
and O 
therapeutic O 
development O 
efforts O 
for O 
highly O 
efficacious O 
treatment O 
of O 
psychiatric O 
illnesses O 
. O 

Antibody O 
to O 
Soman B-TRIVIAL 
- O 
Tyrosine B-TRIVIAL 
. O 

forms O 
a O 
stable O 
, O 
covalent O 
bond O 
with O 
tyrosine B-TRIVIAL 
411 O 
of O 
human O 
albumin O 
, O 
with O 
tyrosines B-FAMILY 
257 O 
and O 
593 O 
in O 
human O 
transferrin O 
, O 
and O 
with O 
tyrosine B-TRIVIAL 
in O 
many O 
other O 
proteins O 
. O 
The O 
pinacolyl B-TRIVIAL 
group O 
of O 
soman B-TRIVIAL 
is O 
retained O 
, O 
suggesting O 
that O 
pinacolyl B-SYSTEMATIC 
methylphosphonate I-SYSTEMATIC 
bound O 
to O 
tyrosine B-TRIVIAL 
could O 
generate O 
specific O 
antibodies O 
. O 
Tyrosine B-TRIVIAL 
in O 
the O 
pentapeptide B-FAMILY 
RYGRK O 
was O 
covalently O 
modified O 
with O 
soman B-TRIVIAL 
simply O 
by O 
adding O 
soman B-TRIVIAL 
to O 
the O 
peptide O 
. O 
The O 
phosphonylated O 
- O 
peptide O 
was O 
linked O 
to O 
keyhole O 
limpet O 
hemocyanin O 
, O 
and O 
the O 
conjugate O 
was O 
injected O 
into O 
rabbits O 
. O 
The O 
polyclonal O 
antiserum O 
recognized O 
soman B-TRIVIAL 
-labeled O 
human O 
albumin O 
, O 
soman B-TRIVIAL 
-mouse O 
albumin O 
, O 
and O 
soman B-TRIVIAL 
human O 
transferrin O 
but O 
not O 
nonphosphonylated O 
control O 
proteins O 
. O 
The O 
soman B-TRIVIAL 
-labeled O 
tyrosines B-FAMILY 
in O 
these O 
proteins O 
are O 
surrounded O 
by O 
different O 
amino B-FAMILY 
acid I-FAMILY 
sequences O 
, O 
suggesting O 
that O 
the O 
polyclonal O 
recognizes O 
soman B-TRIVIAL 
- O 
tyrosine B-TRIVIAL 
independent O 
of O 
the O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
. O 
Antiserum O 
obtained O 
after O 
4 O 
antigen O 
injections O 
over O 
a O 
period O 
of O 
18 O 
weeks O 
was O 
tested O 
in O 
a O 
competition O 
ELISA O 
where O 
it O 
had O 
an O 
IC50 O 
of O 
10(-11) O 
M O 
. O 
The O 
limit O 
of O 
detection O 
on O 
Western O 
blots O 
was O 
0.01 O 
μg O 
( O 
15 O 
picomoles O 
) O 
of O 
soman B-TRIVIAL 
-labeled O 
albumin O 
. O 
In O 
conclusion O 
, O 
a O 
high O 
- O 
affinity O 
, O 
polyclonal O 
antibody O 
that O 
specifically O 
recognizes O 
soman B-TRIVIAL 
adducts O 
on O 
tyrosine B-TRIVIAL 
in O 
a O 
variety O 
of O 
proteins O 
has O 
been O 
produced O 
. O 
Such O 
an O 
antibody O 
could O 
be O 
useful O 
for O 
identifying O 
secondary O 
targets O 
of O 
soman B-TRIVIAL 
toxicity O 
. O 

, O 
functional O 
spheres O 
based O 
on O 
oxidative O 
coupling O 
assembly O 
of O 
green O 
tea O 
polyphenols B-FAMILY 
. O 

luminescent O 
, O 
monodisperse O 
, O 
smooth O 
, O 
porous O 
and O 
hollow O 
spheres O 
were O 
simply O 
prepared O 
by O 
Cu(2+) B-FORMULA 
and O 
temperature O 
mediated O 
oxidative O 
coupling O 
assembly O 
of O 
green O 
tea O 
polyphenols B-FAMILY 
in O 
water O 
. O 
These O 
polymeric O 
tea O 
polyphenol B-FAMILY 
spheres O 
are O 
GSH B-ABBREVIATION 
responsive O 
, O 
acid O 
resistant O 
but O 
alkali O 
- O 
responsive O 
, O 
ideally O 
used O 
as O 
platform O 
for O 
controlled O 
delivery O 
of O 
functional O 
guests O 
. O 

growth O 
of O 
rubrene B-TRIVIAL 
film O 
enhanced O 
by O 
vertical O 
ordering O 
in O 
cadmium B-SYSTEMATIC 
arachidate I-SYSTEMATIC 
multilayer O 
substrate O 
. O 

growth O 
of O 
highly O 
crystalline O 
rubrene B-TRIVIAL 
thin O 
films O 
for O 
organic O 
field O 
effect O 
transistor O 
( O 
OFET O 
) O 
application O 
remains O 
a O 
challenge O 
. O 
Here O 
, O 
we O 
report O 
on O 
the O 
vapor O 
- O 
deposited O 
growth O 
of O 
rubrene B-TRIVIAL 
films O 
on O 
the O 
substrates O 
made O 
of O 
cadmium B-SYSTEMATIC 
arachidate I-SYSTEMATIC 
( O 
CdA B-FORMULA 
) O 
multilayers O 
deposited O 
onto O 
SiO2 B-FORMULA 
/ O 
Si B-FORMULA 
( O 
100 O 
) O 
via O 
the O 
Langmuir-Blodgett O 
technique O 
. O 
The O 
CdA B-FORMULA 
films O 
, O 
containing O 
2n O 
+ O 
1 O 
layers O 
, O 
with O 
integer O 
n O 
ranging O 
from O 
0 O 
to O 
4 O 
, O 
are O 
surface O 
- O 
terminated O 
identically O 
by O 
the O 
methyl B-SYSTEMATIC 
group O 
but O 
exhibit O 
the O 
thickness O 
- O 
dependent O 
morphology O 
. O 
The O 
morphology O 
and O 
structure O 
of O 
both O 
CdA B-FORMULA 
and O 
rubrene B-TRIVIAL 
films O 
are O 
characterized O 
by O 
X-ray O 
reflectivity O 
( O 
XRR O 
) O 
, O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
, O 
near O 
- O 
edge O 
X-ray O 
absorption O 
fine O 
structure O 
( O 
NEXAFS O 
) O 
spectroscopy O 
, O 
and O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
. O 
Crystalline O 
rubrene B-TRIVIAL 
films O 
, O 
evidenced O 
by O 
XRD O 
and O 
marked O 
by O 
platelet O 
features O 
in O 
AFM O 
images O 
, O 
become O 
observable O 
when O 
grown O 
onto O 
the O 
CdA B-FORMULA 
layer O 
thicker O 
than O 
5L O 
. O 
XRD O 
data O 
show O 
that O 
vertical O 
ordering O 
, O 
that O 
is O 
, O 
ordering O 
along O 
surface O 
normal O 
, O 
of O 
CdA B-FORMULA 
multilayer O 
substrates O 
exerts O 
a O 
strong O 
influence O 
in O 
promoting O 
the O 
crystalline O 
growth O 
of O 
rubrene B-TRIVIAL 
films O 
. O 
This O 
promoted O 
growth O 
is O 
not O 
due O 
to O 
the O 
surface O 
energy O 
of O 
CdA B-FORMULA 
layer O 
but O 
derived O 
from O 
the O 
additional O 
interaction O 
localized O 
between O 
rubrene B-TRIVIAL 
and O 
CdA B-FORMULA 
island O 
sidewall O 
and O 
presumably O 
strengthened O 
by O 
a O 
close O 
dimensional O 
match O 
between O 
the O 
a-axis O 
of O 
rubrene B-TRIVIAL 
lattice O 
and O 
the O 
layer O 
spacing O 
of O 
CdA B-FORMULA 
multilayer O 
. O 
The O 
best O 
OFET O 
mobility O 
is O 
recorded O 
for O 
9L O 
CdA B-FORMULA 
substrate O 
and O 
reaches O 
6.7 O 
× O 
10(-2) O 
cm(2) O 
V(-1) O 
s(-1) O 
, O 
presumably O 
limited O 
by O 
the O 
roughness O 
of O 
the O 
interface O 
between O 
CdA B-FORMULA 
and O 
rubrene B-TRIVIAL 
films O 
. O 

Small O 
Molecule O 
Inhibitors O 
of O 
Calcium B-SYSTEMATIC 
-Dependent O 
Protein O 
Kinase O 
1 O 
to O 
Prevent O 
Infection O 
by O 
Toxoplasma O 
gondii O 
. O 

gondii O 
is O 
sensitive O 
to O 
bulky O 
pyrazolo B-SYSTEMATIC 
[ I-SYSTEMATIC 
3,4-d I-SYSTEMATIC 
] I-SYSTEMATIC 
pyrimidine I-SYSTEMATIC 
( O 
PP O 
) O 
inhibitors O 
due O 
to O 
the O 
presence O 
of O 
a O 
Gly B-FORMULA 
gatekeeper O 
in O 
the O 
essential O 
calcium B-SYSTEMATIC 
dependent O 
protein O 
kinase O 
1 O 
( O 
CDPK1 O 
) O 
. O 
Here O 
we O 
synthesized O 
a O 
number O 
of O 
new O 
derivatives O 
of O 
3-methyl-benzyl-PP B-SYSTEMATIC 
( O 
3-MB-PP B-SYSTEMATIC 
, O 
or O 
1 O 
) O 
. O 
The O 
potency O 
of O 
PP O 
analogues O 
in O 
inhibiting O 
CDPK1 O 
enzyme O 
activity O 
in O 
vitro O 
( O 
low O 
nM O 
IC50 O 
values O 
) O 
and O 
blocking O 
parasite O 
growth O 
in O 
host O 
cell O 
monolayers O 
in O 
vivo O 
( O 
low O 
μM O 
EC50 O 
values O 
) O 
were O 
highly O 
correlated O 
and O 
occurred O 
in O 
a O 
CDPK1-specific O 
manner O 
. O 
Chemical O 
modification O 
of O 
the O 
PP O 
scaffold O 
to O 
increase O 
half O 
- O 
life O 
in O 
the O 
presence O 
of O 
microsomes O 
in O 
vitro O 
led O 
to O 
identification O 
of O 
compounds O 
with O 
enhanced O 
stability O 
while O 
retaining O 
activity O 
. O 
Several O 
of O 
these O 
more O 
potent O 
compounds O 
were O 
able O 
to O 
prevent O 
lethal O 
infection O 
with O 
T O 
. O 
gondii O 
in O 
the O 
mouse O 
model O 
. O 
Collectively O 
, O 
the O 
strategies O 
outlined O 
here O 
provide O 
a O 
route O 
for O 
development O 
of O 
more O 
effective O 
compounds O 
for O 
treatment O 
of O 
toxoplasmosis O 
and O 
perhaps O 
related O 
parasitic O 
diseases O 
. O 

newly O 
synthesized O 
sinapic B-TRIVIAL 
Acid I-TRIVIAL 
derivative O 
inhibits O 
endothelial O 
activation O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

of O 
oxidative O 
stress O 
and O 
inflammation O 
in O 
vascular O 
endothelial O 
cells O 
( O 
ECs O 
) O 
may O 
represent O 
a O 
new O 
therapeutic O 
strategy O 
against O 
endothelial O 
activation O 
. O 
Sinapic B-TRIVIAL 
acid I-TRIVIAL 
( O 
SA O 
) O 
, O 
a O 
phenylpropanoid B-SYSTEMATIC 
compound O 
, O 
is O 
found O 
in O 
natural O 
herbs O 
and O 
high O 
- O 
bran O 
cereals O 
and O 
has O 
moderate O 
antioxidant O 
activity O 
. O 
We O 
aimed O 
to O 
develop O 
new O 
SA O 
agents O 
with O 
the O 
properties O 
of O 
antioxidation O 
and O 
blocking O 
EC O 
activation O 
for O 
possible O 
therapy O 
of O 
cardiovascular O 
disease O 
. O 
We O 
designed O 
and O 
synthesized O 
10 O 
SA O 
derivatives O 
according O 
to O 
their O 
chemical O 
structures O 
. O 
Preliminary O 
screening O 
of O 
the O 
compounds O 
involved O 
scavenging O 
hydroxyl B-SYSTEMATIC 
radicals O 
and O 
2,2-diphenyl-1-picrylhydrazyl B-SYSTEMATIC 
( O 
DPPH(⋅) B-ABBREVIATION 
) O 
, O 
croton O 
oil O 
- O 
induced O 
ear O 
edema O 
in O 
mice O 
, O 
and O 
analysis O 
of O 
the O 
mRNA O 
expression O 
of O 
adhesion O 
molecules O 
in O 
ECs O 
. O 
1-Acetyl-sinapic B-SYSTEMATIC 
acyl-4-(3'-chlorine-)benzylpiperazine I-SYSTEMATIC 
( O 
SA9 B-ABBREVIATION 
) O 
had O 
the O 
strongest O 
antioxidant O 
and O 
anti-inflammatory O 
activities O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Thus O 
, O 
the O 
effect O 
of O 
SA9 B-ABBREVIATION 
was O 
further O 
studied O 
. O 
SA9 B-ABBREVIATION 
inhibited O 
tumor O 
necrosis O 
factor O 
α-induced O 
upregulation O 
of O 
adhesion O 
molecules O 
in O 
ECs O 
at O 
both O 
mRNA O 
and O 
protein O 
levels O 
, O 
as O 
well O 
as O 
the O 
consequent O 
monocyte O 
adhesion O 
to O 
ECs O 
. O 
In O 
vivo O 
, O 
result O 
of O 
face O 
- O 
to O 
- O 
face O 
immunostaining O 
showed O 
that O 
SA9 O 
reduced O 
lipopolysaccharide-induced O 
expression O 
of O 
intercellular O 
adhesion O 
molecule-1 O 
in O 
mouse O 
aortic O 
intima O 
. O 
To O 
study O 
the O 
molecular O 
mechanism O 
, O 
results O 
from O 
luciferase O 
assay O 
, O 
nuclear O 
translocation O 
of O 
NF-κB O 
, O 
and O 
Western O 
blot O 
indicated O 
that O 
the O 
mechanism O 
of O 
the O 
anti-inflammatory O 
effects O 
of O 
SA9 B-ABBREVIATION 
might O 
be O 
suppression O 
of O 
intracellular O 
generation O 
of O 
ROS O 
and O 
inhibition O 
of O 
NF-κB O 
activation O 
in O 
ECs O 
. O 
SA9 B-ABBREVIATION 
is O 
a O 
prototype O 
of O 
a O 
novel O 
class O 
of O 
antioxidant O 
with O 
anti-inflammatory O 
effects O 
in O 
ECs O 
. O 
It O 
may O 
represent O 
a O 
new O 
therapeutic O 
approach O 
for O 
preventing O 
endothelial O 
activation O 
in O 
cardiovascular O 
disorders O 
. O 

of O 
Transport O 
Activities O 
of O 
3β-Hydroxy-Δ(5)-bile B-FAMILY 
Acids I-FAMILY 
in O 
Bile B-FAMILY 
Salt I-FAMILY 
Export O 
Pump O 
and O 
Multidrug O 
Resistance-Associated O 
Proteins O 
Using O 
LC-MS O 
/ O 
MS O 
. O 

method O 
has O 
been O 
developed O 
for O 
the O 
measurement O 
of O 
transport O 
activities O 
in O 
membrane O 
vesicles O 
obtained O 
from O 
Sf9 O 
cells O 
for O 
3β-hydroxy-Δ(5)-bile B-FAMILY 
acids I-FAMILY 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
- O 
electrospray O 
ionization O 
- O 
tandem O 
mass O 
spectrometry O 
. O 
Calibration O 
curves O 
for O 
the O 
bile B-FAMILY 
acids I-FAMILY 
were O 
linear O 
over O 
the O 
range O 
of O 
10 O 
to O 
2000 O 
pmol O 
/ O 
mL O 
, O 
and O 
the O 
detection O 
limit O 
was O 
less O 
than O 
1 O 
pmol O 
/ O 
mL O 
for O 
3β-hydroxy-Δ(5)-bile B-FAMILY 
acids I-FAMILY 
using O 
selected O 
reaction O 
monitoring O 
analysis O 
. O 
The O 
analytical O 
method O 
was O 
applied O 
to O 
measurements O 
of O 
transport O 
activities O 
in O 
membrane O 
vesicles O 
obtained O 
from O 
human O 
multidrug O 
resistance O 
- O 
associated O 
protein O 
2- O 
, O 
3- O 
, O 
and O 
human O 
bile B-FAMILY 
salt I-FAMILY 
export O 
pump O 
- O 
expressing O 
Sf9 O 
cells O 
for O 
conjugated O 
3β-hydroxy-Δ(5)-bile B-FAMILY 
acids I-FAMILY 
. O 
The O 
present O 
study O 
demonstrated O 
that O 
human O 
multidrug O 
resistance O 
- O 
associated O 
protein O 
3 O 
vesicles O 
accepted O 
conjugated O 
3β-hydroxy-Δ(5)-bile B-FAMILY 
acids I-FAMILY 
along O 
with O 
common O 
bile B-FAMILY 
acids I-FAMILY 
such O 
as O 
glycocholic B-TRIVIAL 
acid I-TRIVIAL 
and O 
taurolithocholic B-SYSTEMATIC 
acid I-SYSTEMATIC 
3-sulfate I-SYSTEMATIC 
. O 

trial O 
was O 
conducted O 
to O 
investigate O 
the O 
effect O 
of O 
chest O 
physiotherapy O 
in O 
different O 
positions O 
on O 
the O 
heart O 
and O 
the O 
respiratory O 
system O 
after O 
coronary O 
artery O 
bypass O 
surgery O 
. O 
Patients O 
are O 
divided O 
into O 
two O 
groups O 
of O 
30 O 
patients O 
each O 
in O 
the O 
study O 
. O 
To O 
the O 
patients O 
in O 
the O 
first O 
group O 
( O 
30 O 
patients O 
) O 
, O 
percussion O 
- O 
vibration O 
was O 
performed O 
in O 
the O 
45° O 
supine O 
position O 
, O 
while O 
slightly O 
laterally O 
lying O 
and O 
endotracheal O 
aspiration O 
was O 
performed O 
in O 
the O 
supine O 
position O 
. O 
To O 
the O 
patients O 
in O 
the O 
second O 
group O 
( O 
30 O 
patients O 
) O 
, O 
percussion O 
- O 
vibration O 
was O 
performed O 
in O 
the O 
0° O 
supine O 
position O 
, O 
while O 
slightly O 
laterally O 
lying O 
and O 
endotracheal O 
aspiration O 
was O 
performed O 
in O 
the O 
supine O 
position O 
. O 
The O 
procedures O 
are O 
repeated O 
two O 
times O 
for O 
all O 
patients O 
and O 
their O 
means O 
were O 
taken O 
. O 
The O 
pre- O 
and O 
postapplication O 
values O 
of O 
patients O 
were O 
measured O 
from O 
central O 
venous O 
and O 
arterial O 
catheters O 
and O 
the O 
values O 
of O 
patient O 
monitors O 
were O 
recorded O 
. O 
Comparison O 
of O 
the O 
two O 
groups O 
in O 
terms O 
of O 
respiratory O 
values O 
did O 
not O 
reveal O 
a O 
significant O 
difference O 
, O 
but O 
chest O 
physiotherapy O 
with O 
the O 
head O 
of O 
the O 
bed O 
at O 
0° O 
was O 
determined O 
to O 
improve O 
cardiac O 
functions O 
. O 
Evaluation O 
of O 
the O 
groups O 
in O 
terms O 
of O 
pre- O 
and O 
postphysiotherapy O 
applications O 
showed O 
a O 
significant O 
increase O 
in O 
mixed O 
venous O 
oxygen B-SYSTEMATIC 
saturation O 
in O 
both O 
groups O 
. O 
Chest O 
physiotherapy O 
with O 
the O 
head O 
of O 
the O 
bed O 
elevated O 
to O 
45° O 
may O 
be O 
recommended O 
in O 
patients O 
who O 
carry O 
a O 
risk O 
of O 
pulmonary O 
complications O 
and O 
who O 
are O 
candidates O 
for O 
chest O 
physiotherapy O 
at O 
an O 
early O 
stage O 
. O 

new O 
anti-inflammatory O 
triterpene B-FAMILY 
saponin I-FAMILY 
isolated O 
from O 
Anabasis O 
setifera O 
. O 

bio O 
- O 
guided O 
fractionation O 
of O 
Anabasis O 
setifera O 
Moq O 
. O 
( O 
Chenopodiaceae O 
) O 
for O 
anti-inflammatory O 
activity O 
was O 
carried O 
out O 
using O 
carrageenin O 
rat O 
paw O 
edema O 
model O 
in O 
rats O 
. O 
On O 
the O 
basis O 
of O 
percent O 
edema O 
inhibition O 
after O 
3 O 
h O 
of O 
carrageenin O 
injection O 
, O 
n-butanol B-SYSTEMATIC 
fraction O 
showed O 
promising O 
activity O 
through O 
a O 
significant O 
( O 
p O 
< O 
0.05 O 
) O 
decrease O 
in O 
paw O 
volume O 
by O 
85.6 O 
% O 
from O 
control O 
using O 
indomethacin B-TRIVIAL 
as O 
reference O 
standard O 
. O 
Moreover O 
, O 
the O 
n-butanol B-SYSTEMATIC 
fraction O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
decreased O 
PGE2 B-ABBREVIATION 
and O 
TNF-α O 
in O 
the O 
exudates O 
of O 
rat O 
paw O 
edema O 
. O 
Chemical O 
investigation O 
of O 
n-butanol B-SYSTEMATIC 
fraction O 
afforded O 
α-amyrin B-SYSTEMATIC 
3-O-glucopyranoside I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
patuletin B-SYSTEMATIC 
7-O-glucopyranoside I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
myricitrin B-TRIVIAL 
( O 
3 O 
) O 
and O 
a O 
new O 
oleanane B-FAMILY 
triterpene I-FAMILY 
saponin I-FAMILY 
derivative O 
( O 
4 O 
) O 
, O 
sophradiol B-SYSTEMATIC 
3-O-α-L-(1)C4-rhamnopyranosyl-(1'''→4'')-O-β-D-(4)C1-galactopyranosyl I-SYSTEMATIC 
(1''→6')-O-β-D-(4)C1-glucopyranoside I-SYSTEMATIC 
. O 
The O 
structure O 
of O 
the O 
new O 
compound O 
was O 
determined O 
by O 
comprehensive O 
analyses O 
of O 
their O 
1D O 
and O 
2D O 
NMR O 
, O 
mass O 
spectral O 
data O 
and O 
comparison O 
with O 
previously O 
known O 
analogs O 
. O 
Only O 
compound O 
4 O 
revealed O 
a O 
significant O 
( O 
p O 
< O 
0.05 O 
) O 
inhibition O 
of O 
cyclooxygenase O 
1 O 
and O 
2 O 
( O 
COX O 
) O 
activities O 
. O 

Myocardial O 
Infarction O 
During O 
Regadenoson B-TRIVIAL 
Myocardial O 
Perfusion O 
Imaging O 
. O 

stress O 
testing O 
uses O 
vasodilators O 
to O 
provide O 
objective O 
evidence O 
of O 
myocardial O 
ischemia O 
. O 
Adenosine B-TRIVIAL 
and O 
dipyridamole B-TRIVIAL 
are O 
nonselective O 
adenosine B-TRIVIAL 
receptor O 
agonists O 
that O 
have O 
been O 
associated O 
with O 
myocardial O 
infarction O 
( O 
MI O 
) O 
during O 
intravenous O 
infusion O 
. O 
Mechanisms O 
postulated O 
for O 
this O 
effect O 
include O 
coronary O 
steal O 
, O 
transmural O 
steal O 
, O 
global O 
hypotension O 
, O 
and O 
direct O 
vasoconstriction O 
. O 
Regadenoson B-TRIVIAL 
, O 
a O 
direct O 
A2A O 
agonist O 
, O 
was O 
approved O 
for O 
use O 
in O 
stress O 
testing O 
in O 
2008 O 
. O 
We O 
describe O 
a O 
68-year- O 
old O 
man O 
who O 
presented O 
to O 
our O 
institution O 
with O 
typical O 
angina O 
, O 
relieved O 
by O 
nitroglycerin B-SYSTEMATIC 
. O 
He O 
did O 
not O 
have O 
electrocardiogram O 
( O 
ECG O 
) O 
changes O 
suggestive O 
of O 
myocardial O 
pathology O 
, O 
and O 
laboratory O 
testing O 
did O 
not O 
reveal O 
a O 
significant O 
rise O 
in O 
troponin-I O 
levels O 
. O 
To O 
further O 
assess O 
the O 
etiology O 
of O 
his O 
symptoms O 
, O 
he O 
underwent O 
a O 
pharmacologic O 
stress O 
test O 
with O 
regadenoson B-TRIVIAL 
followed O 
by O 
technetium B-SYSTEMATIC 
99 I-SYSTEMATIC 
m I-SYSTEMATIC 
sestamibi I-SYSTEMATIC 
. O 
Six O 
minutes O 
after O 
regadenoson B-TRIVIAL 
infusion O 
, O 
the O 
patient O 
developed O 
severe O 
retrosternal O 
chest O 
pain O 
accompanied O 
by O 
ST O 
elevations O 
on O 
ECG O 
. O 
Sublingual O 
nitroglycerin B-SYSTEMATIC 
was O 
administered O 
that O 
resolved O 
both O 
the O 
pain O 
and O 
ECG O 
changes O 
. O 
The O 
patient O 
subsequently O 
underwent O 
urgent O 
coronary O 
angiography O 
and O 
was O 
found O 
to O 
have O 
a O 
95% O 
critical O 
stenosis O 
involving O 
the O 
left O 
anterior O 
descending O 
artery O 
. O 
We O 
conclude O 
this O 
case O 
represents O 
a O 
MI O 
secondary O 
to O 
coronary O 
steal O 
phenomenon O 
induced O 
by O 
regadenoson B-TRIVIAL 
infusion O 
. O 
Clinicians O 
should O 
be O 
aware O 
this O 
adverse O 
effect O 
can O 
occur O 
despite O 
the O 
improved O 
side-effect O 
profile O 
of O 
regadenoson B-TRIVIAL 
. O 
Continuous O 
monitoring O 
of O 
vital O 
signs O 
and O 
the O 
ECG O 
with O 
regular O 
assessment O 
of O 
symptoms O 
is O 
imperative O 
to O 
identify O 
this O 
rare O 
but O 
potentially O 
devastating O 
adverse O 
event O 
. O 

Efficiency O 
of O 
the O 
Metal O 
Catalysts O 
in O 
the O 
Nucleophilic O 
Substitution O 
of O 
Alcohols B-FAMILY 
is O 
Dependent O 
on O 
the O 
Nucleophile O 
and O 
Not O 
on O 
the O 
Electrophile O 
. O 

this O 
study O 
, O 
we O 
investigate O 
the O 
effect O 
of O 
the O 
electrophiles O 
and O 
the O 
nucleophiles O 
for O 
eight O 
catalysts O 
in O 
the O 
catalytic O 
SN O 
1 O 
type O 
substitution O 
of O 
alcohols B-FAMILY 
with O 
different O 
degree O 
of O 
activation O 
by O 
sulfur B-SYSTEMATIC 
- O 
, O 
carbon B-SYSTEMATIC 
- O 
, O 
oxygen B-SYSTEMATIC 
- O 
, O 
and O 
nitrogen B-SYSTEMATIC 
-centered O 
nucleophiles O 
. O 
The O 
catalysts O 
do O 
not O 
show O 
any O 
general O 
variance O 
in O 
efficiency O 
or O 
selectivity O 
with O 
respect O 
to O 
the O 
alcohols B-FAMILY 
and O 
follow O 
the O 
trend O 
of O 
alcohol B-FAMILY 
reactivity O 
. O 
However O 
, O 
when O 
it O 
comes O 
to O 
the O 
nucleophile O 
, O 
the O 
eight O 
catalysts O 
show O 
general O 
and O 
specific O 
variances O 
in O 
the O 
efficiency O 
and O 
selectivity O 
to O 
perform O 
the O 
desired O 
substitution O 
. O 
Interestingly O 
, O 
the O 
selectivity O 
of O 
the O 
alcohols B-FAMILY 
to O 
produce O 
the O 
desired O 
substitution O 
products O 
was O 
found O 
to O 
be O 
independent O 
of O 
the O 
electrophilicity O 
of O 
the O 
generated O 
carbocations O 
but O 
highly O 
dependent O 
on O 
the O 
ease O 
of O 
formation O 
of O 
the O 
cation O 
. O 
Catalysts O 
based O 
on O 
iron B-SYSTEMATIC 
(III) I-SYSTEMATIC 
, O 
bismuth B-SYSTEMATIC 
(III) I-SYSTEMATIC 
, O 
and O 
gold B-SYSTEMATIC 
(III) I-SYSTEMATIC 
show O 
higher O 
conversions O 
for O 
S B-FORMULA 
- O 
, O 
C B-FORMULA 
- O 
, O 
and O 
N B-FORMULA 
-centered O 
nucleophiles O 
, O 
and O 
Bi B-FORMULA 
(III) I-FORMULA 
was O 
the O 
most O 
efficient O 
catalyst O 
in O 
all O 
combinations O 
. O 
Catalysts O 
based O 
on O 
rhenium B-SYSTEMATIC 
(I) I-SYSTEMATIC 
or O 
rhenium B-SYSTEMATIC 
(VII) I-SYSTEMATIC 
, O 
palladium B-SYSTEMATIC 
(II) I-SYSTEMATIC 
, O 
and O 
lanthanum B-SYSTEMATIC 
(III) I-SYSTEMATIC 
were O 
the O 
most O 
efficient O 
in O 
performing O 
the O 
nucleophilic O 
substitution O 
on O 
the O 
various O 
alcohols B-FAMILY 
with O 
the O 
O B-FORMULA 
-centered O 
nucleophiles O 
. O 
These O 
catalysts O 
generate O 
the O 
symmetrical O 
ether O 
as O 
a O 
by O 
- O 
product O 
from O 
the O 
reactions O 
of O 
S B-FORMULA 
- O 
, O 
C B-FORMULA 
- O 
, O 
and O 
N B-FORMULA 
-centered O 
nucleophiles O 
as O 
well O 
, O 
resulting O 
in O 
lower O 
chemoselectivity O 
. O 

and O 
Spin O 
States O 
of O 
FeS B-FORMULA 
( O 
0 O 
/ O 
- O 
) O 
, O 
FeS2 B-FORMULA 
( O 
0 O 
/ O 
- O 
) O 
, O 
Fe2 B-FORMULA 
S2 I-FORMULA 
( O 
0 O 
/ O 
- O 
) O 
, O 
Fe3 B-FORMULA 
S4 I-FORMULA 
( O 
0 O 
/ O 
- O 
) O 
, O 
and O 
Fe4 B-FORMULA 
S4 I-FORMULA 
( O 
0 O 
/ O 
- O 
) O 
Clusters O 
. O 

structures O 
and O 
energies O 
of O 
the O 
electronic O 
ground O 
states O 
of O 
the O 
FeS B-FORMULA 
( O 
0 O 
/ O 
- O 
) O 
, O 
FeS2 B-FORMULA 
( O 
0 O 
/ O 
- O 
) O 
, O 
Fe2 B-FORMULA 
S2 I-FORMULA 
( O 
0 O 
/ O 
- O 
) O 
, O 
Fe3 B-FORMULA 
S4 I-FORMULA 
( O 
0 O 
/ O 
- O 
) O 
, O 
and O 
Fe4 B-FORMULA 
S4 I-FORMULA 
( O 
0 O 
/ O 
- O 
) O 
neutral O 
and O 
anionic O 
clusters O 
have O 
been O 
computed O 
systematically O 
with O 
nine O 
computational O 
methods O 
in O 
combination O 
with O 
seven O 
basis O 
sets O 
. O 
The O 
computed O 
adiabatic O 
electronic O 
affinities O 
( O 
AEA O 
) O 
have O 
been O 
compared O 
with O 
available O 
experimental O 
data O 
. O 
Most O 
reasonable O 
agreements O 
between O 
theory O 
and O 
experiment O 
have O 
been O 
found O 
for O 
both O 
hybrid O 
B3LYP O 
and O 
B3PW91 O 
functionals O 
in O 
conjugation O 
with O 
6-311 O 
+ O 
G* O 
and O 
QZVP O 
basis O 
sets O 
. O 
Detailed O 
comparisons O 
between O 
the O 
available O 
experimental O 
and O 
computed O 
AEA O 
data O 
at O 
the O 
B3LYP O 
/ O 
6-311 O 
+ O 
G* O 
level O 
identified O 
the O 
electronic O 
ground O 
state O 
of O 
( O 
5 O 
) O 
Δ O 
for O 
FeS B-FORMULA 
, O 
( O 
4 O 
) O 
Δ O 
for O 
FeS(-) B-FORMULA 
, O 
( O 
5 O 
) O 
B2 O 
for O 
FeS2 B-FORMULA 
, O 
( O 
6 O 
) O 
A1 O 
for O 
FeS2 B-FORMULA 
( I-FORMULA 
- I-FORMULA 
) I-FORMULA 
, O 
( O 
1 O 
) O 
A1 O 
for O 
Fe2 B-FORMULA 
S2 I-FORMULA 
, O 
( O 
8 O 
) O 
A O 
' O 
for O 
Fe2 B-FORMULA 
S2 I-FORMULA 
( I-FORMULA 
- I-FORMULA 
) I-FORMULA 
, O 
( O 
5 O 
) O 
A O 
' O 
' O 
for O 
Fe3 B-FORMULA 
S4 I-FORMULA 
, O 
( O 
6 O 
) O 
A O 
' O 
' O 
for O 
Fe3 B-FORMULA 
S4 I-FORMULA 
( I-FORMULA 
- I-FORMULA 
) I-FORMULA 
, O 
( O 
1 O 
) O 
A1 O 
for O 
Fe4 B-FORMULA 
S4 I-FORMULA 
, O 
and O 
( O 
1 O 
) O 
A2 O 
for O 
Fe4 B-FORMULA 
S4 I-FORMULA 
( I-FORMULA 
- I-FORMULA 
) I-FORMULA 
. O 
In O 
addition O 
, O 
Fe2 B-FORMULA 
S2 I-FORMULA 
, O 
Fe3 B-FORMULA 
S4 I-FORMULA 
, O 
Fe3 B-FORMULA 
S4 I-FORMULA 
( I-FORMULA 
- I-FORMULA 
) I-FORMULA 
, O 
Fe4 B-FORMULA 
S4 I-FORMULA 
, O 
and O 
Fe4 B-FORMULA 
S4 I-FORMULA 
( I-FORMULA 
- I-FORMULA 
) I-FORMULA 
are O 
antiferromagnetic O 
at O 
the O 
B3LYP O 
/ O 
6-311 O 
+ O 
G* O 
level O 
. O 
The O 
magnetic O 
properties O 
are O 
discussed O 
on O 
the O 
basis O 
of O 
natural O 
bond O 
orbital O 
analysis O 
. O 

cAMP B-ABBREVIATION 
-dependent O 
Protein O 
Kinase O 
( O 
PKA O 
) O 
Regulates O 
Multiple O 
Aspects O 
of O 
Cellular O 
Events O 
by O 
Phosphorylating O 
the O 
Whi3 O 
Cell O 
Cycle O 
Regulator O 
in O 
Budding O 
Yeast O 
. O 

Start O 
/ O 
G1 O 
phase O 
in O 
the O 
cell O 
cycle O 
is O 
an O 
important O 
period O 
during O 
which O 
cells O 
determine O 
their O 
developmental O 
fate O 
, O 
onset O 
of O 
mitotic O 
progression O 
, O 
or O 
the O 
switch O 
to O 
developmental O 
stages O 
in O 
response O 
to O 
both O 
external O 
and O 
internal O 
signals O 
. O 
In O 
the O 
budding O 
yeast O 
Saccharomyces O 
cerevisiae O 
, O 
Whi3 O 
, O 
a O 
negative O 
regulator O 
of O 
the O 
G1 O 
cyclins O 
, O 
has O 
been O 
identified O 
as O 
a O 
positive O 
regulator O 
of O 
cell O 
size O 
control O 
and O 
is O 
involved O 
in O 
the O 
regulation O 
of O 
Start O 
. O 
However O 
, O 
the O 
regulatory O 
pathway O 
of O 
Whi3 O 
governing O 
the O 
response O 
to O 
multiple O 
signals O 
remains O 
largely O 
unknown O 
. O 
Here O 
, O 
we O 
show O 
that O 
Whi3 O 
is O 
phosphorylated O 
by O 
the O 
Ras/ O 
cAMP B-ABBREVIATION 
-dependent O 
protein O 
kinase O 
( O 
PKA O 
) O 
and O 
that O 
phosphorylation O 
of O 
Ser B-FORMULA 
-568 O 
in O 
Whi3 O 
by O 
PKA O 
plays O 
an O 
inhibitory O 
role O 
in O 
Whi3 O 
function O 
. O 
Phosphorylation O 
of O 
Whi3 O 
by O 
PKA O 
led O 
to O 
its O 
decreased O 
interaction O 
with O 
CLN3 O 
G1 O 
cyclin O 
mRNA O 
and O 
was O 
required O 
for O 
the O 
promotion O 
of O 
G1 O 
/ O 
S O 
progression O 
. O 
Furthermore O 
, O 
we O 
demonstrate O 
that O 
the O 
phosphomimetic O 
S568D O 
mutation O 
of O 
Whi3 O 
prevented O 
the O 
developmental O 
fate O 
switch O 
to O 
sporulation O 
or O 
invasive O 
growth O 
. O 
Thus O 
, O 
PKA O 
modulated O 
the O 
function O 
of O 
Whi3 O 
by O 
phosphorylation O 
, O 
thus O 
implicating O 
PKA O 
- O 
mediated O 
modulation O 
of O 
Whi3 O 
in O 
multiple O 
cellular O 
events O 
. O 

of O 
dilution O 
of O 
aqueous O 
solutions O 
of O 
aliphatic B-MULTIPLE 
6,12- I-MULTIPLE 
and I-MULTIPLE 
12,12-ionene I-MULTIPLE 
bromides I-MULTIPLE 
and I-MULTIPLE 
fluorides I-MULTIPLE 
and O 
enthalpies O 
of O 
mixing O 
with O 
low O 
molecular O 
- O 
weight O 
salts O 
, O 
such O 
as O 
sodium B-MULTIPLE 
fluoride I-MULTIPLE 
and I-MULTIPLE 
bromide I-MULTIPLE 
, O 
are O 
determined O 
. O 
In O 
the O 
second O 
part O 
of O 
the O 
study O 
, O 
the O 
various O 
x,y-ionenes O 
( O 
x O 
, O 
y O 
are O 
numbers O 
of O 
methylene B-SYSTEMATIC 
groups O 
between O 
the O 
adjacent O 
charges O 
) O 
with O 
fluoride B-SYSTEMATIC 
, O 
bromide B-SYSTEMATIC 
, O 
and O 
iodide B-SYSTEMATIC 
counterions O 
are O 
mixed O 
with O 
aqueous O 
sodium B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
solution O 
. O 
The O 
polyelectrolytes O 
examined O 
in O 
this O 
part O 
of O 
the O 
work O 
are O 
3,3- B-MULTIPLE 
, I-MULTIPLE 
6,9- I-MULTIPLE 
, I-MULTIPLE 
6,12- I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
12,12-ionenes I-MULTIPLE 
. O 
A O 
comparison O 
with O 
theoretical O 
results O 
, O 
based O 
on O 
the O 
Poisson-Boltzmann O 
cell O 
model O 
, O 
is O 
presented O 
. O 
The O 
theory O 
predicts O 
for O 
the O 
enthalpy O 
of O 
dilution O 
to O 
be O 
exothermic O 
and O 
the O 
enthalpy O 
of O 
mixing O 
endothermic O 
, O 
while O 
experiments O 
show O 
that O 
signs O 
of O 
the O 
heat O 
effects O 
depend O 
on O 
the O 
nature O 
of O 
the O 
counterion O 
of O 
the O 
added O 
salt O 
, O 
as O 
also O 
on O 
the O 
hydrophobicity O 
( O 
numbers O 
x O 
, O 
y O 
of O 
methylene B-SYSTEMATIC 
groups O 
) O 
of O 
the O 
ionene O 
. O 
We O 
show O 
that O 
the O 
salts O 
when O 
ordered O 
by O 
heat O 
effects O 
produced O 
by O 
mixing O 
of O 
NaF B-FORMULA 
and O 
NaBr B-FORMULA 
with O 
3,3- B-MULTIPLE 
, I-MULTIPLE 
6,9- I-MULTIPLE 
, I-MULTIPLE 
or I-MULTIPLE 
6,12-ionene I-MULTIPLE 
fluorides I-MULTIPLE 
and I-MULTIPLE 
bromides I-MULTIPLE 
follow O 
the O 
opposite O 
ordering O 
than O 
in O 
the O 
case O 
when O 
the O 
same O 
alkali B-FAMILY 
halide I-FAMILY 
salts O 
are O 
mixed O 
with O 
more O 
hydrophobic O 
12,12-ionene B-SYSTEMATIC 
salts O 
. O 
The O 
results O 
for O 
the O 
enthalpy O 
of O 
mixing O 
of O 
ionenes O 
under O 
study O 
with O 
Na2SO4 B-FORMULA 
follow O 
the O 
same O 
order O 
as O 
obtained O 
for O 
monovalent O 
salts O 
. O 

this O 
contribution O 
we O 
have O 
tried O 
to O 
investigate O 
whether O 
the O 
mechanical O 
properties O 
of O 
the O 
reverse O 
micellar O 
( O 
RM O 
) O 
interface O 
dictate O 
the O 
physical O 
properties O 
of O 
entrapped O 
water O 
molecules O 
in O 
the O 
RM O 
waterpool O 
. O 
We O 
choose O 
AOT B-ABBREVIATION 
/ O 
Igepal-520 B-TRIVIAL 
/ O 
cyclohexane B-SYSTEMATIC 
( O 
Cy O 
) O 
mixed O 
RM O 
as O 
a O 
model O 
system O 
which O 
exhibits O 
synergistic O 
water O 
solubilization O 
behavior O 
as O 
a O 
function O 
of O 
interfacial O 
stoichiometry O 
. O 
Such O 
a O 
phenomenon O 
associates O 
systematic O 
modification O 
of O 
the O 
interface O 
curvature O 
. O 
Dynamic O 
light O 
scattering O 
( O 
DLS O 
) O 
studies O 
reveal O 
linear O 
increase O 
in O 
the O 
droplet O 
size O 
and O 
aggregation O 
number O 
of O 
the O 
RMs O 
with O 
increasing O 
XIgepal O 
( O 
mole O 
fraction O 
of O 
Igepal B-TRIVIAL 
in O 
the O 
surfactant O 
mixture O 
) O 
. O 
FTIR O 
study O 
in O 
the O 
3000-3800 O 
cm(-1) O 
region O 
identifies O 
that O 
the O 
relative O 
population O 
of O 
the O 
surface O 
- O 
bound O 
water O 
molecules O 
is O 
higher O 
in O 
AOT B-ABBREVIATION 
RM O 
compared O 
to O 
that O 
in O 
Igepal B-TRIVIAL 
RM O 
, O 
and O 
in O 
mixed O 
systems O 
it O 
also O 
follows O 
a O 
linear O 
trend O 
with O 
XIgepal O 
. O 
Water O 
relaxation O 
dynamics O 
as O 
probed O 
by O 
time O 
- O 
resolved O 
fluorescence O 
spectroscopy O 
using O 
Coumarin-500 B-TRIVIAL 
also O 
reveals O 
an O 
overall O 
linear O 
trend O 
with O 
no O 
characteristic O 
feature O 
around O 
the O 
solubilization O 
inflation O 
point O 
. O 
Our O 
study O 
clearly O 
identifies O 
that O 
the O 
physical O 
properties O 
of O 
water O 
in O 
RM O 
are O 
mostly O 
governed O 
by O 
the O 
interfacial O 
stoichiometry O 
and O 
water O 
content O 
, O 
and O 
merely O 
bares O 
any O 
dependence O 
on O 
the O 
mechanical O 
properties O 
of O 
the O 
interface O 
. O 

of O 
(R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
congeners O 
as O 
highly O 
potent O 
inhibitors O 
of O 
human O 
arginases O 
I O 
and O 
II O 
for O 
treatment O 
of O 
myocardial O 
reperfusion O 
injury O 
. O 

efforts O 
to O 
identify O 
treatments O 
for O 
myocardial O 
ischemia O 
reperfusion O 
injury O 
have O 
resulted O 
in O 
the O 
discovery O 
of O 
a O 
novel O 
series O 
of O 
highly O 
potent O 
α,α- B-FAMILY 
disubstituted I-FAMILY 
amino I-FAMILY 
acid I-FAMILY 
-based O 
arginase O 
inhibitors O 
. O 
The O 
lead O 
candidate O 
, O 
(R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
compound O 
9 O 
, O 
inhibits O 
human O 
arginases O 
I O 
and O 
II O 
with O 
IC50s O 
of O 
223 O 
and O 
509 O 
nM O 
, O 
respectively O 
, O 
and O 
is O 
active O 
in O 
a O 
recombinant O 
cellular O 
assay O 
overexpressing O 
human O 
arginase O 
I O 
( O 
CHO O 
cells O 
) O 
. O 
It O 
is O 
28% O 
orally O 
bioavailable O 
and O 
significantly O 
reduces O 
the O 
infarct O 
size O 
in O 
a O 
rat O 
model O 
of O 
myocardial O 
ischemia O 
/ O 
reperfusion O 
injury O 
. O 
Herein O 
, O 
we O 
report O 
the O 
design O 
, O 
synthesis O 
, O 
and O 
structure O 
- O 
activity O 
relationships O 
( O 
SAR O 
) O 
for O 
this O 
novel O 
series O 
of O 
inhibitors O 
along O 
with O 
pharmacokinetic O 
and O 
in O 
vivo O 
efficacy O 
data O 
for O 
compound O 
9 O 
and O 
X-ray O 
crystallography O 
data O 
for O 
selected O 
lead O 
compounds O 
cocrystallized O 
with O 
arginases O 
I O 
and O 
II O 
. O 

, O 
Synthesis O 
, O 
and O 
Biological O 
Evaluation O 
of O 
a O 
Series O 
of O 
Benzo[de][1,7]naphthyridin-7(8H)-ones B-FAMILY 
Bearing O 
a O 
Functionalized O 
Longer O 
Chain O 
Appendage O 
as O 
Novel O 
PARP1 O 
Inhibitors O 
. O 

series O 
of O 
benzo[de][1,7]naphthyridin-7(8H)-ones B-FAMILY 
possessing O 
a O 
functionalized O 
long O 
- O 
chain O 
appendage O 
have O 
been O 
designed O 
and O 
evaluated O 
as O 
novel O 
PARP1 O 
inhibitors O 
. O 
The O 
initial O 
effort O 
led O 
to O 
the O 
first O 
- O 
generation O 
PARP1 O 
inhibitor O 
26 O 
bearing O 
a O 
terminal O 
phthalazin-1(2H)-one B-SYSTEMATIC 
framework O 
and O 
showing O 
remarkably O 
high O 
PARP1 O 
inhibitory O 
activity O 
( O 
0.31 O 
nM O 
) O 
but O 
only O 
moderate O 
potency O 
in O 
the O 
cell O 
. O 
Further O 
effort O 
generated O 
the O 
second O 
- O 
generation O 
lead O 
41 O 
, O 
showing O 
high O 
potency O 
against O 
both O 
the O 
PARP1 O 
enzyme O 
and O 
BRCA-deficient O 
cells O 
, O 
especially O 
for O 
the O 
BRCA1-deficient O 
MDA-MB-436 O 
cells O 
( O 
CC50 O 
< O 
0.26 O 
nM O 
) O 
. O 
Mechanistic O 
studies O 
revealed O 
that O 
the O 
new O 
PARP1 O 
inhibitors O 
significantly O 
inhibited O 
H2O2 B-FORMULA 
-triggered O 
PARylation O 
in O 
SKOV3 O 
cells O 
, O 
induced O 
cellular O 
accumulation O 
of O 
DNA O 
double O 
- O 
strand O 
breaks O 
, O 
and O 
impaired O 
cell O 
- O 
cycle O 
progression O 
in O 
BRCA2-deficient O 
cells O 
. O 
Significant O 
potentiation O 
on O 
the O 
cytotoxicity O 
of O 
Temozolomide B-TRIVIAL 
was O 
also O 
observed O 
. O 
The O 
unique O 
structural O 
character O 
and O 
exceptionally O 
high O 
potency O 
of O 
41 O 
made O 
it O 
stand O 
out O 
as O 
a O 
promising O 
drug O 
candidate O 
worthy O 
for O 
further O 
evaluation O 
. O 

Magnetic O 
Shape O 
Anisotropy O 
in O 
BiFeO3 B-FORMULA 
- O 
CoFe2O4 B-FORMULA 
Self-Assembled O 
Thin O 
Films O 
. O 

report O 
growth O 
of O 
various O 
phase O 
architectures O 
of O 
self O 
- O 
assembled O 
BiFeO3 B-FORMULA 
- O 
CoFe2O4 B-FORMULA 
( O 
BFO B-ABBREVIATION 
- O 
CFO B-ABBREVIATION 
) O 
thin O 
films O 
on O 
differently O 
oriented O 
SrTiO3 B-FORMULA 
( O 
STO B-ABBREVIATION 
) O 
substrates O 
. O 
CFO B-ABBREVIATION 
forms O 
segregated O 
square O 
, O 
stripe O 
, O 
and O 
triangular O 
nanopillars O 
embedded O 
in O 
a O 
coherent O 
BFO B-ABBREVIATION 
matrix O 
on O 
(001)- O 
, O 
(110)- O 
, O 
and O 
(111)-oriented O 
STO B-ABBREVIATION 
substrates O 
, O 
respectively O 
. O 
Nanostructures O 
with O 
an O 
aspect O 
ratio O 
of O 
up O 
to O 
5 O 
: O 
1 O 
with O 
a O 
prominent O 
magnetic O 
anisotropy O 
were O 
obtained O 
on O 
both O 
( O 
1 O 
) O 
and O 
( O 
110 O 
) O 
STO B-ABBREVIATION 
along O 
out O 
- O 
of O 
- O 
plane O 
and O 
in O 
- O 
plane O 
directions O 
. O 
Magnetic O 
easy O 
axis O 
rotation O 
from O 
in O 
- O 
plane O 
to O 
out O 
- O 
of O 
- O 
plane O 
directions O 
was O 
realized O 
through O 
aspect O 
ratio O 
control O 
. O 
An O 
intractable O 
in O 
- O 
plane O 
anisotropy O 
was O 
fixed O 
in O 
CFO B-ABBREVIATION 
on O 
( O 
111 O 
) O 
STO B-ABBREVIATION 
due O 
to O 
the O 
triangular O 
shape O 
of O 
the O 
ferromagnetic O 
phase O 
nanopillars O 
. O 
These O 
studies O 
established O 
a O 
detailed O 
relationship O 
of O 
magnetic O 
anisotropy O 
with O 
specific O 
shape O 
and O 
dimensions O 
of O 
ordered O 
magnetic O 
arrays O 
. O 
The O 
results O 
suggest O 
a O 
way O 
to O 
effectively O 
control O 
the O 
magnetic O 
anisotropy O 
in O 
patterned O 
ferromagnetic O 
oxide B-SYSTEMATIC 
arrays O 
with O 
tunable O 
shape O 
, O 
aspect O 
ratio O 
, O 
and O 
elastic O 
strain O 
conditions O 
of O 
the O 
nanostructures O 
. O 

of O 
different O 
sized O 
nanoparticles O 
assessed O 
by O 
positron O 
emission O 
tomography O 
: O 
a O 
general O 
strategy O 
for O 
direct O 
activation O 
of O 
metal B-FAMILY 
oxide I-FAMILY 
particles O 
. O 

extraordinary O 
small O 
size O 
of O 
NPs O 
makes O 
them O 
difficult O 
to O 
detect O 
and O 
quantify O 
once O 
distributed O 
in O 
a O 
material O 
or O 
biological O 
system O 
. O 
We O 
present O 
a O 
simple O 
and O 
straightforward O 
method O 
for O 
the O 
direct O 
proton O 
beam O 
activation O 
of O 
synthetic O 
or O 
commercially O 
available O 
aluminum B-SYSTEMATIC 
oxide I-SYSTEMATIC 
NPs O 
( O 
Al2O3 B-FORMULA 
NPs O 
) O 
via O 
the O 
(16)O B-FORMULA 
( O 
p,α O 
) O 
(13)N B-FORMULA 
nuclear O 
reaction O 
in O 
order O 
to O 
assess O 
their O 
biological O 
fate O 
using O 
positron O 
emission O 
tomography O 
( O 
PET O 
) O 
. O 
The O 
radiolabeling O 
of O 
the O 
NPs O 
does O 
not O 
alter O 
their O 
surface O 
or O 
structural O 
properties O 
as O 
demonstrated O 
by O 
TEM O 
, O 
DLS O 
, O 
and O 
ζ-potential O 
measurements O 
. O 
The O 
incorporation O 
of O 
radioactive O 
(13)N B-FORMULA 
atoms O 
in O 
the O 
Al2O3 B-FORMULA 
NPs O 
allowed O 
the O 
study O 
of O 
the O 
biodistribution O 
of O 
the O 
metal B-FAMILY 
oxide I-FAMILY 
NPs O 
in O 
rats O 
after O 
intravenous O 
administration O 
via O 
PET O 
. O 
Despite O 
the O 
short O 
half O 
- O 
life O 
of O 
(13)N B-FORMULA 
( O 
9.97 O 
min O 
) O 
, O 
the O 
accumulation O 
of O 
NPs O 
in O 
different O 
organs O 
could O 
be O 
measured O 
during O 
the O 
first O 
68 O 
min O 
after O 
administration O 
. O 
The O 
percentage O 
amount O 
of O 
radioactivity O 
per O 
organ O 
was O 
calculated O 
to O 
evaluate O 
the O 
relative O 
amount O 
of O 
NPs O 
per O 
organ O 
. O 
This O 
simple O 
and O 
robust O 
activation O 
strategy O 
can O 
be O 
applied O 
to O 
any O 
synthetic O 
or O 
commercially O 
available O 
metal B-FAMILY 
oxide I-FAMILY 
particle O 
. O 

synthesis O 
and O 
characterization O 
of O 
nano O 
- O 
sized O 
lead B-SYSTEMATIC 
(II) I-SYSTEMATIC 
3D O 
coordination O 
polymer O 
: O 
Precursor O 
for O 
the O 
synthesis O 
of O 
lead B-SYSTEMATIC 
(II) I-SYSTEMATIC 
oxybromide I-SYSTEMATIC 
nanoparticles O 
. O 

of O 
a O 
three O 
- O 
dimensional O 
coordination O 
polymer O 
, O 
[Pb(L)(μ2-Br)(H2O)]n B-FAMILY 
( O 
1 O 
) O 
, O 
( O 
L(-)= O 
1H-1,2,4-triazole-3-carboxylate B-SYSTEMATIC 
) O 
, O 
have O 
been O 
synthesized O 
by O 
an O 
ultrasonic O 
method O 
and O 
characterized O 
by O 
scanning O 
electron O 
microscopy O 
, O 
X-ray O 
powder O 
diffraction O 
, O 
IR O 
spectroscopy O 
and O 
elemental O 
analyses O 
. O 
The O 
thermal O 
stability O 
of O 
compound O 
1 O 
both O 
its O 
bulk O 
and O 
nano O 
- O 
size O 
has O 
been O 
studied O 
by O 
thermal O 
gravimetric O 
( O 
TG O 
) O 
and O 
differential O 
thermal O 
( O 
DTA O 
) O 
analyses O 
and O 
compared O 
each O 
other O 
. O 
Concentration O 
of O 
initial O 
reagents O 
effects O 
and O 
the O 
role O 
of O 
power O 
ultrasound O 
irradiation O 
on O 
size O 
and O 
morphology O 
of O 
nano O 
- O 
structured O 
compound O 
1 O 
, O 
have O 
been O 
studied O 
. O 
Calcination O 
of O 
the O 
compound O 
1 O 
at O 
500°C O 
under O 
air O 
atmosphere O 
yields O 
Pb3O2Br2 B-FORMULA 
nanoparticles O 
. O 

targeting O 
property O 
of O 
a O 
Lu-177 B-FORMULA 
-labeled O 
lactam B-SYSTEMATIC 
bridge O 
- O 
cyclized O 
alpha-MSH O 
peptide O 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
melanoma O 
targeting O 
property O 
of O 
(177)Lu-DOTA-GGNle-CycMSHhex B-FORMULA 
in O 
B16 O 
/ O 
F1 O 
melanoma O 
- O 
bearing O 
C57 O 
mice O 
. O 
(177)Lu-DOTA-GGNle-CycMSHhex B-FORMULA 
exhibited O 
high O 
receptor O 
- O 
mediated O 
melanoma O 
uptake O 
and O 
fast O 
urinary O 
clearance O 
. O 
The O 
tumor O 
uptake O 
of O 
(177)Lu-DOTA-GGNle-CycMSHhex B-FORMULA 
was O 
20.25 O 
± O 
4.59 O 
and O 
21.63 O 
± O 
6.27% O 
ID O 
/ O 
g O 
at O 
0.5 O 
and O 
2h O 
post O 
- O 
injection O 
, O 
respectively O 
. O 
Approximately O 
83% O 
of O 
injected O 
dose O 
cleared O 
out O 
the O 
body O 
via O 
urinary O 
system O 
at O 
2h O 
post O 
- O 
injection O 
. O 
(177)Lu-DOTA-GGNle-CycMSHhex B-FORMULA 
showed O 
high O 
tumor O 
to O 
normal O 
organ O 
uptake O 
ratios O 
except O 
for O 
the O 
kidneys O 
. O 
The O 
tumor O 
/ O 
kidney O 
uptake O 
ratios O 
of O 
(177)Lu-DOTA-GGNle-CycMSHhex B-FORMULA 
were O 
2.76 O 
and O 
1.74 O 
at O 
2 O 
and O 
24h O 
post O 
- O 
injection O 
. O 
The O 
melanoma O 
lesions O 
were O 
clearly O 
visualized O 
by O 
SPECT O 
/ O 
CT O 
using O 
(177)Lu-DOTA-GGNle-CycMSHhex B-FORMULA 
as O 
an O 
imaging O 
probe O 
at O 
2h O 
post O 
- O 
injection O 
. O 
Overall O 
, O 
high O 
melanoma O 
uptake O 
coupled O 
with O 
fast O 
urinary O 
clearance O 
of O 
(177)Lu-DOTA-GGNle-CycMSHhex B-FORMULA 
underscored O 
its O 
potential O 
for O 
melanoma O 
treatment O 
in O 
the O 
future O 
. O 

tyrosine B-TRIVIAL 
kinase O 
inhibitor O 
pharmacophore O 
model O 
derived O 
from O 
a O 
series O 
of O 
phenylaminopyrimidine B-SYSTEMATIC 
-based O 
( O 
PAP B-ABBREVIATION 
) O 
derivatives O 
. O 

reveal O 
novel O 
insights O 
into O 
the O 
inhibition O 
of O 
BCR-ABL O 
tyrosine B-TRIVIAL 
kinase O 
, O 
pharmacophore O 
mapping O 
studies O 
were O 
performed O 
for O 
a O 
series O 
of O 
phenylaminopyrimidine B-SYSTEMATIC 
-based O 
( O 
PAP B-ABBREVIATION 
) O 
derivatives O 
, O 
including O 
imatinib B-TRIVIAL 
( O 
Gleevec O 
) O 
. O 
A O 
seven O 
- O 
point O 
pharmacophore O 
model O 
with O 
one O 
hydrophobic O 
group O 
( O 
H O 
) O 
, O 
two O 
hydrogen B-SYSTEMATIC 
bond O 
donors O 
( O 
D O 
) O 
and O 
four O 
aromatic O 
rings O 
( O 
R O 
) O 
was O 
developed O 
using O 
phase O 
( O 
pharmacophore O 
alignment O 
& O 
scoring O 
engine O 
) O 
. O 
The O 
pharmacophore O 
hypothesis O 
yielded O 
a O 
statistically O 
significant O 
3D-QSAR O 
model O 
, O 
with O 
a O 
correlation O 
coefficient O 
of O 
0.886 O 
and O 
a O 
survival O 
score O 
of O 
4.97 O 
for O 
training O 
set O 
molecules O 
. O 
The O 
model O 
showed O 
excellent O 
predictive O 
power O 
, O 
with O 
a O 
correlation O 
coefficient O 
of O 
Q(2)=0.768 O 
for O 
an O 
external O 
test O 
set O 
of O 
ten O 
molecules O 
. O 
The O 
results O 
obtained O 
from O 
our O 
studies O 
provide O 
a O 
valuable O 
tool O 
for O 
designing O 
new O 
lead O 
molecules O 
with O 
potent O 
activity O 
. O 

- O 
dependent O 
effects O 
of O 
corticosterone B-TRIVIAL 
on O 
reward O 
- O 
based O 
decision O 
- O 
making O 
in O 
a O 
rodent O 
model O 
of O 
the O 
Iowa O 
Gambling O 
Task O 
. O 

hormones O 
, O 
released O 
after O 
stress O 
, O 
are O 
known O 
to O 
change O 
neuronal O 
activity O 
in O 
two O 
time O 
- O 
domains O 
: O 
within O 
minutes O 
via O 
non-genomic O 
pathways O 
and O 
with O 
a O 
delay O 
of O 
> O 
1 O 
h O 
through O 
pathways O 
involving O 
transcriptional O 
regulation O 
. O 
Recent O 
evidence O 
in O 
rodents O 
and O 
humans O 
indicates O 
that O 
these O 
two O 
modes O 
of O 
corticosteroid O 
action O 
differently O 
affect O 
cognitive O 
tasks O 
. O 
Here O 
, O 
we O 
investigated O 
whether O 
reward O 
- O 
based O 
decision O 
- O 
making O 
, O 
in O 
a O 
rat O 
model O 
of O 
the O 
Iowa O 
Gambling O 
Task O 
( O 
rIGT O 
) O 
, O 
is O 
also O 
differently O 
altered O 
by O 
rapid O 
versus O 
delayed O 
actions O 
of O 
corticosterone B-TRIVIAL 
. O 
We O 
targeted O 
the O 
rapid O 
and O 
delayed O 
time O 
domain O 
by O 
injecting O 
corticosterone B-TRIVIAL 
( O 
CORT B-ABBREVIATION 
, O 
1 O 
mg O 
/ O 
kg O 
, O 
s.c O 
. O 
) O 
at O 
30 O 
min O 
( O 
rapid O 
) O 
or O 
180 O 
min O 
( O 
delayed O 
) O 
respectively O 
prior O 
to O 
behavioural O 
testing O 
, O 
during O 
the O 
final O 
3 O 
days O 
of O 
the O 
behavioural O 
paradigm O 
. O 
In O 
saline O 
treated O 
rats O 
, O 
the O 
number O 
of O 
visits O 
to O 
the O 
disadvantageous O 
arm O 
decreased O 
over O 
trial O 
blocks O 
, O 
whilst O 
this O 
was O 
attenuated O 
when O 
CORT B-ABBREVIATION 
was O 
administered O 
30 O 
min O 
before O 
testing O 
. O 
This O 
attenuation O 
was O 
associated O 
with O 
a O 
significantly O 
increased O 
c-Fos O 
expression O 
in O 
the O 
lateral O 
orbitofrontal O 
cortex O 
and O 
insular O 
cortex O 
, O 
and O 
a O 
trend O 
for O 
an O 
increase O 
in O 
the O 
infralimbic O 
cortex O 
. O 
The O 
rapid O 
corticosteroid O 
effect O 
contrasted O 
with O 
treatment O 
180 O 
min O 
before O 
testing O 
, O 
where O 
the O 
number O 
of O 
visits O 
to O 
the O 
disadvantageous O 
arm O 
as O 
well O 
as O 
c-Fos O 
labelling O 
was O 
not O 
affected O 
. O 
These O 
findings O 
indicate O 
that O 
rapid O 
corticosteroid O 
actions O 
impair O 
reward O 
- O 
based O 
decision O 
- O 
making O 
. O 

of O 
the O 
Antibiotic O 
Phosacetamycin B-TRIVIAL 
via O 
a O 
New O 
Mass O 
Spectrometry O 
- O 
Based O 
Method O 
for O 
Phosphonic B-SYSTEMATIC 
Acid I-SYSTEMATIC 
Detection O 
. O 

occurring O 
phosphonates B-FAMILY 
such O 
as O 
phosphinothricin B-TRIVIAL 
( O 
Glufosinate B-TRIVIAL 
, O 
a O 
commercially O 
used O 
herbicide O 
) O 
and O 
fosfomycin B-TRIVIAL 
( O 
Monurol B-TRIVIAL 
, O 
a O 
clinically O 
used O 
antibiotic O 
) O 
have O 
proved O 
to O 
be O 
potent O 
and O 
useful O 
biocides O 
. O 
Yet O 
this O 
class O 
of O 
natural O 
products O 
is O 
still O 
an O 
under O 
explored O 
family O 
of O 
secondary O 
metabolites O 
. O 
Discovery O 
of O 
the O 
biosynthetic O 
pathways O 
responsible O 
for O 
the O 
production O 
of O 
these O 
compounds O 
has O 
been O 
simplified O 
by O 
using O 
gene O 
based O 
screening O 
approaches O 
, O 
but O 
detection O 
and O 
identification O 
of O 
the O 
natural O 
products O 
the O 
genes O 
produce O 
have O 
been O 
hampered O 
by O 
a O 
lack O 
of O 
high O 
- O 
throughput O 
methods O 
for O 
screening O 
potential O 
producers O 
under O 
various O 
culture O 
conditions O 
. O 
Here O 
, O 
we O 
present O 
an O 
efficient O 
mass O 
- O 
spectrometric O 
method O 
for O 
the O 
selective O 
detection O 
of O 
natural O 
products O 
containing O 
phosphonate B-SYSTEMATIC 
and O 
phosphinate B-SYSTEMATIC 
functional O 
groups O 
. O 
We O 
have O 
used O 
this O 
method O 
to O 
identify O 
a O 
new O 
phosphonate B-SYSTEMATIC 
metabolite O 
, O 
phosacetamycin B-TRIVIAL 
, O 
whose O 
structure O 
, O 
biological O 
activity O 
, O 
and O 
biosynthetic O 
gene O 
cluster O 
are O 
reported O 
. O 

present O 
study O 
determined O 
the O 
anti-Mycobacterium O 
tuberculosis O 
activities O 
of O 
supercritical O 
CO2 B-FORMULA 
extracts O 
, O 
neolignans B-FAMILY 
eupomatenoid-5 B-TRIVIAL 
( O 
1 O 
) O 
, O 
conocarpan B-TRIVIAL 
( O 
4 O 
) O 
and O 
eupomatenoid-3 B-TRIVIAL 
( O 
7 O 
) O 
and O 
their O 
derivatives O 
( O 
2 O 
, O 
3 O 
, O 
5 O 
, O 
6 O 
, O 
and O 
8 O 
) O 
from O 
Piper O 
regnellii O 
, O 
as O 
well O 
as O 
their O 
cytotoxicities O 
. O 
The O 
supercritical O 
CO2 B-FORMULA 
extract O 
from O 
leaves O 
was O 
purified O 
by O 
chromatographic O 
methods O 
, O 
yielding O 
compounds O 
( O 
1 O 
) O 
, O 
( O 
4 O 
) O 
and O 
( O 
7 O 
) O 
, O 
which O 
were O 
identified O 
by O 
(1)H B-FORMULA 
NMR O 
and O 
comparison O 
with O 
literature O 
data O 
. O 
Anti-M O 
. O 
tuberculosis O 
activity O 
( O 
H37Rv O 
and O 
clinical O 
isolates O 
) O 
was O 
evaluated O 
using O 
a O 
resazurin O 
microtiter O 
assay O 
plate O 
( O 
REMA O 
) O 
to O 
determine O 
the O 
MIC O 
. O 
The O 
cytotoxicity O 
assay O 
was O 
carried O 
out O 
in O 
macrophages O 
J774G.8 O 
by O 
sulforhodamine B-TRIVIAL 
B I-TRIVIAL 
colorimetric O 
assay O 
. O 
The O 
supercritical O 
CO2 B-FORMULA 
extracts O 
from O 
leaves O 
and O 
stems O 
, O 
and O 
compound O 
( O 
4 O 
) O 
showed O 
activity O 
against O 
M O 
. O 
tuberculosis O 
( O 
MIC O 
15.6μg O 
/ O 
ml O 
) O 
. O 
Compound O 
( O 
1 O 
) O 
showed O 
the O 
best O 
activity O 
( O 
MIC O 
1.9μg O 
/ O 
ml O 
) O 
, O 
with O 
good O 
SI O 
. O 
Compounds O 
( O 
7 O 
) O 
and O 
( O 
8 O 
) O 
showed O 
low O 
activity O 
against O 
M O 
. O 
tuberculosis O 
H37Rv O 
. O 
The O 
derivative O 
compounds O 
did O 
not O 
show O 
increased O 
anti-M O 
. O 
tuberculosis O 
activity O 
. O 
This O 
is O 
the O 
first O 
report O 
, O 
to O 
our O 
knowledge O 
, O 
to O 
describe O 
neolignans B-FAMILY 
from O 
P O 
. O 
regnellii O 
with O 
activity O 
against O 
M O 
. O 
tuberculosis O 
, O 
and O 
compound O 
( O 
1 O 
) O 
is O 
a O 
potential O 
candidate O 
for O 
future O 
antituberculosis O 
drugs O 
. O 

of O 
fatty B-FAMILY 
acids I-FAMILY 
as O 
a O 
continuous O 
process O 
for O 
the O 
development O 
of O 
controlled O 
release O 
multiparticulate O 
dosage O 
forms O 
. O 

this O 
study O 
, O 
prilling O 
was O 
evaluated O 
as O 
a O 
technique O 
for O 
the O 
development O 
of O 
multiparticulate O 
dosage O 
forms O 
using O 
the O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
stearic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
behenic B-TRIVIAL 
acid I-TRIVIAL 
as O 
potential O 
matrix O 
formers O 
to O 
control O 
the O 
release O 
of O 
metoprolol B-TRIVIAL 
tartrate I-TRIVIAL 
( O 
MPT B-ABBREVIATION 
) O 
, O 
a O 
highly O 
water O 
soluble O 
drug O 
. O 
The O 
in O 
vitro O 
drug O 
release O 
was O 
dependent O 
on O 
the O 
drug O 
load O 
, O 
type O 
of O 
fatty B-FAMILY 
acid I-FAMILY 
, O 
and O 
pH O 
of O 
the O 
dissolution O 
medium O 
. O 
Higher O 
drug O 
loads O 
resulted O 
in O 
faster O 
release O 
with O 
behenic B-TRIVIAL 
acid I-TRIVIAL 
releasing O 
drug O 
over O 
longer O 
periods O 
relative O 
to O 
stearic B-TRIVIAL 
acid I-TRIVIAL 
. O 
The O 
in O 
vitro O 
drug O 
release O 
was O 
pH-dependent O 
at O 
low O 
drug O 
load O 
with O 
the O 
release O 
being O 
slower O 
at O 
lower O 
pH O 
. O 
Due O 
to O 
ionization O 
of O 
the O 
fatty B-FAMILY 
acid I-FAMILY 
at O 
pH O 
7.4 O 
, O 
drug O 
release O 
was O 
susceptible O 
to O 
the O 
ionic O 
strength O 
at O 
this O 
pH O 
value O 
. O 
Solid O 
state O 
characterization O 
indicated O 
that O 
the O 
crystalline O 
state O 
of O 
the O 
fatty B-FAMILY 
acids I-FAMILY 
was O 
not O 
affected O 
by O 
thermal O 
processing O 
via O 
prilling O 
, O 
while O 
the O 
crystallinity O 
of O 
MPT B-ABBREVIATION 
was O 
decreased O 
. O 
During O 
storage O 
, O 
the O 
amorphous O 
MPT B-ABBREVIATION 
fraction O 
recrystallized O 
in O 
the O 
entire O 
matrix O 
. O 
Drug O 
release O 
from O 
behenic B-TRIVIAL 
acid I-TRIVIAL 
matrices O 
was O 
increased O 
during O 
storage O 
at O 
40°C O 
; O 
however O 
, O 
no O 
polymorphism O 
of O 
behenic B-TRIVIAL 
acid I-TRIVIAL 
was O 
detected O 
. O 
The O 
bioavailability O 
of O 
MPT B-ABBREVIATION 
, O 
after O 
oral O 
administration O 
to O 
dogs O 
as O 
prills O 
containing O 
30% O 
and O 
40% O 
MPT B-ABBREVIATION 
using O 
behenic B-TRIVIAL 
acid I-TRIVIAL 
as O 
matrix O 
former O 
, O 
was O 
not O 
significantly O 
different O 
from O 
a O 
commercial O 
sustained O 
release O 
reference O 
formulation O 
, O 
although O 
the O 
40% O 
MPT B-ABBREVIATION 
prills O 
showed O 
a O 
burst O 
release O 
. O 

and O 
evaluation O 
of O 
3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines B-FAMILY 
as O 
Bcl-2 O 
inhibitory O 
anticancer O 
agents O 
. O 

series O 
of O 
substituted O 
3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines B-FAMILY 
has O 
been O 
synthesised O 
and O 
tested O 
in O 
vitro O 
as O 
potential O 
pro O 
- O 
apoptotic O 
Bcl-2-inhibitory O 
anticancer O 
agents O 
. O 
Synthesis O 
of O 
the O 
target O 
compounds O 
was O 
readily O 
accomplished O 
in O 
good O 
yields O 
through O 
a O 
cyclisation O 
reaction O 
between O 
indole-3-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
hydrazide I-SYSTEMATIC 
and O 
carbon B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
under O 
basic O 
conditions O 
, O 
followed O 
by O 
S B-FORMULA 
-benzylation O 
. O 
Active O 
compounds O 
, O 
such O 
as O 
the O 
nitrobenzyl B-SYSTEMATIC 
analogue O 
6c O 
, O 
were O 
found O 
to O 
exhibit O 
sub O 
- O 
micromolar O 
IC50 O 
values O 
in O 
Bcl-2 O 
expressing O 
human O 
cancer O 
cell O 
lines O 
. O 
Molecular O 
modelling O 
and O 
ELISA O 
studies O 
further O 
implicated O 
anti-apoptotic O 
Bcl-2 O 
as O 
a O 
candidate O 
molecular O 
target O 
underpinning O 
anticancer O 
activity O 
. O 

- O 
nitrogen B-SYSTEMATIC 
co O 
- O 
doped O 
three O 
- O 
dimensional O 
carbon B-SYSTEMATIC 
foams O 
with O 
hierarchical O 
pore O 
structures O 
as O 
efficient O 
metal O 
- O 
free O 
electrocatalysts O 
for O 
oxygen B-SYSTEMATIC 
reduction O 
reactions O 
. O 

the O 
good O 
progress O 
in O 
developing O 
doped O 
carbon O 
catalysts O 
for O 
oxygen B-SYSTEMATIC 
-reduction O 
reaction O 
( O 
ORR O 
) O 
, O 
the O 
current O 
metal O 
- O 
free O 
carbon B-SYSTEMATIC 
catalysts O 
are O 
still O 
far O 
from O 
satisfactory O 
for O 
large O 
- O 
scale O 
applications O 
of O 
fuel O 
cell O 
. O 
Developing O 
new O 
metal O 
free O 
doped O 
carbon B-SYSTEMATIC 
materials O 
with O 
abundance O 
active O 
sites O 
as O 
well O 
as O 
excellent O 
electron O 
transfer O 
and O 
reactant O 
transport O 
rate O 
towards O 
ORR O 
may O 
be O 
a O 
potential O 
solution O 
. O 
Herein O 
, O 
we O 
develop O 
a O 
novel O 
three O 
- O 
dimensional O 
( O 
3D O 
) O 
sulfur B-SYSTEMATIC 
- I-SYSTEMATIC 
nitrogen I-SYSTEMATIC 
co I-SYSTEMATIC 
- I-SYSTEMATIC 
doped I-SYSTEMATIC 
carbon I-SYSTEMATIC 
foams O 
( O 
S B-FORMULA 
- O 
N B-FORMULA 
-CF O 
) O 
with O 
hierarchical O 
pore O 
structures O 
, O 
using O 
a O 
convenient O 
, O 
economical O 
, O 
and O 
scalable O 
method O 
. O 
The O 
experimental O 
results O 
have O 
demonstrated O 
that O 
the O 
obtained O 
3D O 
S B-FORMULA 
- O 
N B-FORMULA 
-CF O 
exhibited O 
better O 
catalytic O 
activity O 
, O 
longer O 
- O 
term O 
stability O 
and O 
higher O 
methanol B-SYSTEMATIC 
tolerance O 
than O 
a O 
commercial O 
Pt B-FORMULA 
/ O 
C B-FORMULA 
catalyst O 
. O 
Such O 
excellent O 
performances O 
may O 
be O 
attributed O 
to O 
the O 
synergistic O 
effect O 
, O 
which O 
includes O 
high O 
catalytic O 
sites O 
for O 
ORR O 
provided O 
by O 
high O 
S B-FORMULA 
- O 
N B-FORMULA 
heteroatom O 
loading O 
, O 
excellent O 
reactant O 
transport O 
caused O 
by O 
hierarchical O 
pore O 
structures O 
and O 
high O 
electron O 
transfer O 
rate O 
provided O 
by O 
3D O 
continuous O 
networks O 
. O 
Our O 
results O 
not O 
only O 
develop O 
a O 
new O 
type O 
of O 
catalysts O 
with O 
excellent O 
electrocatalytic O 
performance O 
by O 
a O 
commercially O 
valid O 
route O 
, O 
but O 
also O 
provide O 
useful O 
information O 
for O 
further O 
clarification O 
of O 
the O 
relationship O 
between O 
the O 
microstructures O 
of O 
metal O 
- O 
free O 
carbon B-SYSTEMATIC 
materials O 
and O 
catalyst O 
properties O 
for O 
ORR O 
. O 
More O 
importantly O 
, O 
the O 
idea O 
to O 
design O 
hierarchical O 
pore O 
structures O 
could O 
be O 
applied O 
to O 
other O 
catalytic O 
materials O 
and O 
serve O 
as O 
a O 
general O 
strategy O 
for O 
improving O 
the O 
activity O 
of O 
various O 
ORR O 
catalysts O 
. O 

of O 
Two O 
β-Secretase O 
Inhibitors O 
Including O 
Ring O 
Opening O 
and O 
Contraction O 
of O 
a O 
Pyrimidine B-SYSTEMATIC 
Ring O 
. O 

, O 
the O 
discovery O 
of O 
the O 
aminoisoindoles B-FAMILY 
as O 
potent O 
and O 
selective O 
inhibitors O 
of O 
β-secretase O 
was O 
reported O 
, O 
including O 
the O 
close O 
structural O 
analogs O 
compound O 
(S)-1-pyridin-4-yl-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine B-SYSTEMATIC 
[ O 
(S)-25 O 
] O 
and O 
(S)-1-(2-(difluoromethyl)pyridin-4-yl)-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine B-SYSTEMATIC 
hemifumarate I-SYSTEMATIC 
( O 
AZD3839 B-IDENTIFIER 
) O 
, O 
the O 
latter O 
being O 
recently O 
progressed O 
to O 
the O 
clinic O 
. O 
The O 
biotransformation O 
of O 
(S)-25 O 
was O 
investigated O 
in O 
vitro O 
and O 
in O 
vivo O 
in O 
rat O 
, O 
rabbit O 
, O 
and O 
human O 
and O 
compared O 
with O 
AZD3839 B-IDENTIFIER 
to O 
further O 
understand O 
the O 
metabolic O 
fate O 
of O 
these O 
compounds O 
. O 
In O 
vitro O 
, O 
CYP3A4 O 
was O 
the O 
major O 
responsible O 
enzyme O 
and O 
metabolized O 
both O 
compounds O 
to O 
a O 
large O 
extent O 
in O 
the O 
commonly O 
shared O 
pyridine B-SYSTEMATIC 
and O 
pyrimidine B-SYSTEMATIC 
rings O 
. O 
The O 
main O 
proposed O 
metabolic O 
pathways O 
in O 
various O 
in O 
vitro O 
systems O 
were O 
N B-FORMULA 
-oxidation O 
of O 
the O 
pyridine B-SYSTEMATIC 
and O 
/ O 
or O 
pyrimidine B-SYSTEMATIC 
ring O 
and O 
conversion O 
to O 
4-pyrimidone B-SYSTEMATIC 
and O 
pyrimidine-2,4-dione B-SYSTEMATIC 
. O 
Both O 
compounds O 
were O 
extensively O 
metabolized O 
, O 
and O 
more O 
than O 
90% O 
was O 
excreted O 
in O 
feces O 
after O 
intravenous O 
administration O 
of O 
radiolabeled O 
compound O 
to O 
the O 
rat O 
. O 
Here O 
, O 
the O 
main O 
pathways O 
were O 
N B-FORMULA 
-oxidation O 
of O 
the O 
pyridine B-SYSTEMATIC 
and O 
/ O 
or O 
pyrimidine B-SYSTEMATIC 
ring O 
and O 
a O 
ring O 
contraction O 
of O 
the O 
pyrimidine B-SYSTEMATIC 
ring O 
into O 
an O 
imidazole B-SYSTEMATIC 
ring O 
. O 
Ring O 
- O 
contracted O 
metabolites O 
accounted O 
for O 
25% O 
of O 
the O 
total O 
metabolism O 
in O 
the O 
rat O 
for O 
(S)-25 O 
, O 
whereas O 
the O 
contribution O 
was O 
much O 
smaller O 
for O 
AZD3839 B-IDENTIFIER 
. O 
This O 
metabolic O 
pathway O 
was O 
not O 
foreseen O 
on O 
the O 
basis O 
of O 
the O 
obtained O 
in O 
vitro O 
data O 
. O 
In O 
conclusion O 
, O 
we O 
discovered O 
an O 
unusual O 
metabolic O 
pathway O 
of O 
aryl-pyrimidine B-FAMILY 
-containing O 
compounds O 
by O 
a O 
ring O 
- O 
opening O 
reaction O 
followed O 
by O 
elimination O 
of O 
a O 
carbon B-SYSTEMATIC 
atom O 
and O 
a O 
ring O 
closure O 
to O 
form O 
an O 
imidazole B-SYSTEMATIC 
ring O 
. O 

experimental O 
and O 
theoretical O 
studies O 
have O 
established O 
that O 
electrokinetic O 
and O 
aggregation O 
properties O 
of O 
soft O 
MS2 O 
phages O 
are O 
not O 
only O 
governed O 
by O 
the O 
physico O 
- O 
chemical O 
features O 
of O 
their O 
proteinaceous O 
outer O 
surface O 
but O 
are O 
also O 
significantly O 
impacted O 
by O 
those O 
of O 
their O 
inner O 
RNA O 
component O 
( O 
Dika O 
et O 
al O 
. O 
Appl O 
. O 
Environ O 
. O 
Microbiol O 
. O 
, O 
2011 O 
, O 
14 O 
, O 
4939-4948 O 
) O 
. O 
These O 
conclusions O 
contradict O 
the O 
recent O 
findings O 
of O 
Nguyen O 
et O 
al O 
. O 
( O 
Soft O 
Matter O 
, O 
2011 O 
, O 
7 O 
, O 
10449-10456 O 
) O 
who O 
reported O 
identical O 
electrokinetic O 
and O 
aggregation O 
characteristics O 
for O 
MS2 O 
and O 
corresponding O 
virus O 
like O 
particles O 
( O 
VLPs O 
) O 
that O 
lack O 
the O 
internal O 
RNA O 
component O 
. O 
We O 
demonstrate O 
here O 
that O 
this O 
contradiction O 
originates O 
from O 
the O 
different O 
purification O 
methods O 
adopted O 
prior O 
to O 
measurements O 
. O 
More O 
generally O 
, O 
we O 
show O 
that O 
stability O 
and O 
electrohydrodynamics O 
of O 
viruses O 
differ O 
according O 
to O 
purification O 
by O 
(i) O 
dialysis O 
, O 
(ii) O 
isopycnic O 
centrifugation O 
in O 
the O 
cesium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
gradient O 
, O 
and O 
(iii) O 
precipitation O 
using O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
. O 
Methods O 
(i) O 
and O 
(iii) O 
lead O 
to O 
aggregation O 
of O 
MS2 O 
phages O 
at O 
pH O 
≤ O 
4 O 
and O 
pH O 
≤ O 
6 O 
in O 
1-100 O 
mM O 
NaNO3 O 
solutions O 
, O 
respectively O 
, O 
while O 
under O 
such O 
conditions O 
aggregation O 
is O 
not O 
observed O 
for O 
MS2 O 
and O 
VLP O 
suspensions O 
prepared O 
according O 
to O 
(ii) O 
. O 
In O 
addition O 
, O 
VLPs O 
prepared O 
following O 
methods O 
(i) O 
and O 
(iii) O 
aggregate O 
only O 
at O 
the O 
isoelectric O 
point O 
( O 
pH O 
~ O 
3-4 O 
) O 
in O 
1 O 
mM O 
NaNO3 B-SYSTEMATIC 
solution O 
. O 
Electrophoretic O 
mobility O 
data O 
of O 
stable O 
MS2 O 
and O 
VLP O 
particles O 
were O 
further O 
examined O 
using O 
a O 
recent O 
formalism O 
for O 
electrokinetics O 
of O 
soft O 
multilayered O 
colloids O 
. O 
The O 
analysis O 
qualitatively O 
shows O 
how O 
the O 
purification O 
protocol O 
may O 
affect O 
either O 
the O 
outer O 
particle O 
surface O 
properties O 
and O 
/ O 
or O 
the O 
inner O 
particle O 
content O 
. O 
Finally O 
, O 
the O 
non-DLVO O 
aggregation O 
behavior O 
of O 
MS2 O 
and O 
VLPs O 
purified O 
via O 
the O 
above O 
protocols O 
is O 
discussed O 
in O 
terms O 
of O 
the O 
possible O 
change O 
in O 
corresponding O 
interparticular O 
interactions O 
. O 

antipsychotic O 
- O 
like O 
effects O 
of O 
the O 
mGlu O 
group O 
III O 
orthosteric O 
agonist O 
, O 
LSP1-2111 B-IDENTIFIER 
, O 
involves O 
5-HT1A O 
signalling O 
. O 

: O 
Several O 
studies O 
have O 
suggested O 
that O 
modulation O 
of O 
the O 
glutamatergic O 
system O 
via O 
metabotropic O 
glutamate B-TRIVIAL 
receptors O 
( O 
mGlu O 
) O 
could O 
be O 
a O 
new O 
way O 
to O 
achieve O 
antipsychotic O 
- O 
like O 
activity O 
. O 
LSP1-2111 B-IDENTIFIER 
, O 
the O 
group O 
III O 
mGlu O 
receptor O 
orthosteric O 
agonist O 
, O 
with O 
a O 
high O 
affinity O 
towards O 
mGlu4 O 
receptors O 
, O 
was O 
previously O 
shown O 
to O 
exhibit O 
antipsychotic O 
- O 
like O 
action O 
in O 
animal O 
models O 
displaying O 
positive O 
symptoms O 
of O 
schizophrenia O 
. O 
OBJECTIVES O 
: O 
Here O 
, O 
we O 
decided O 
to O 
investigate O 
the O 
possible O 
role O 
of O 
LSP1-2111 B-IDENTIFIER 
in O 
models O 
of O 
negative O 
( O 
social O 
interaction O 
) O 
and O 
cognitive O 
( O 
NOR O 
) O 
symptoms O 
of O 
psychosis O 
. O 
We O 
also O 
investigated O 
the O 
involvement O 
of O 
5-HT1A O 
receptors O 
in O 
the O 
LSP1-2111 B-IDENTIFIER 
-induced O 
antipsychotic O 
effects O 
. O 
Apart O 
from O 
the O 
above O 
- O 
mentioned O 
models O 
of O 
negative O 
and O 
cognitive O 
symptoms O 
, O 
MK-801 B-IDENTIFIER 
and O 
amphetamine B-TRIVIAL 
-induced O 
hyperactivity O 
tests O 
, O 
plus O 
the O 
DOI B-ABBREVIATION 
-induced O 
head O 
twitches O 
in O 
mice O 
as O 
models O 
for O 
positive O 
symptoms O 
of O 
psychosis O 
, O 
were O 
used O 
in O 
this O 
part O 
of O 
the O 
investigations O 
. O 
RESULTS O 
: O 
LSP1-2111 B-IDENTIFIER 
( O 
0.5 O 
, O 
2 O 
, O 
and O 
5 O 
mg/ O 
kg O 
) O 
dose O 
- O 
dependently O 
inhibited O 
MK-801 B-IDENTIFIER 
-induced O 
deficits O 
in O 
social O 
interaction O 
and O 
NOR O 
tests O 
. O 
The O 
effects O 
of O 
the O 
drug O 
were O 
antagonized O 
by O 
5-HT1A O 
antagonist O 
, O 
WAY100635 B-IDENTIFIER 
( O 
0.1 O 
mg O 
/ O 
kg O 
) O 
. O 
A O 
similar O 
inhibition O 
of O 
LSP1-2111 B-IDENTIFIER 
-induced O 
effects O 
was O 
observed O 
in O 
models O 
of O 
positive O 
symptoms O 
of O 
schizophrenia O 
. O 
Moreover O 
, O 
the O 
concomitant O 
administration O 
of O 
subeffective O 
doses O 
of O 
LSP1-2111 B-IDENTIFIER 
( O 
0.3-0.5 O 
mg O 
/ O 
kg O 
) O 
with O 
a O 
subeffective O 
dose O 
of O 
5-HT1A O 
agonist O 
, O 
(R)-(+)-8-Hydroxy-DPAT B-SYSTEMATIC 
( O 
0.01 O 
mg O 
/ O 
kg O 
) O 
, O 
induced O 
a O 
clear O 
antipsychotic O 
- O 
like O 
effect O 
in O 
all O 
of O 
the O 
procedures O 
used O 
. O 
CONCLUSIONS O 
: O 
Altogether O 
, O 
we O 
propose O 
that O 
the O 
activation O 
of O 
group O 
III O 
mGlu O 
receptors O 
may O 
be O 
a O 
promising O 
target O 
for O 
the O 
development O 
of O 
novel O 
antipsychotic O 
drugs O 
, O 
towards O 
not O 
only O 
positive O 
but O 
also O 
negative O 
and O 
cognitive O 
symptoms O 
. O 
The O 
action O 
of O 
the O 
compound O 
is O 
5-HT1A-dependent O 
. O 

synthesis O 
of O 
a O 
chromene B-TRIVIAL 
analog O 
for O 
use O 
as O 
a O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
receptor O 
alpha O 
antagonist O 
lead O 
compound O 
. O 

acid I-TRIVIAL 
receptor O 
alpha O 
( O 
RARα O 
) O 
selective O 
compounds O 
may O 
guide O 
the O 
design O 
of O 
drugs O 
that O 
can O 
be O 
used O 
in O 
conjunction O 
with O 
hormonal O 
adjuvant O 
therapy O 
in O 
the O 
treatment O 
of O 
breast O 
cancer O 
. O 
Herein O 
we O 
report O 
a O 
modified O 
synthesis O 
of O 
a O 
known O 
RARα O 
antagonist O 
, O 
2-fluoro-4-[[[8-bromo-2,2-dimethyl-4-(4-methylphenyl)chroman-6-yl]carbonyl]amino]benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
a O 
synthesis O 
of O 
its O 
unknown O 
, O 
desfluoro O 
analog O 
, O 
4-[[[8-bromo-2,2-dimethyl-4-(4-methylphenyl)chroman-6-yl]carbonyl]amino]benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
The O 
modified O 
route O 
allows O 
for O 
facile O 
reaction O 
workups O 
, O 
increased O 
yields O 
, O 
lower O 
cost O 
and O 
incorporates O 
a O 
green O 
alternative O 
step O 
. O 
Structure O 
- O 
activity O 
relationship O 
studies O 
determined O 
through O 
functional O 
cell O 
- O 
based O 
assays O 
, O 
demonstrated O 
antagonism O 
to O 
RARα O 
for O 
both O 
compounds O 
. O 
Molecular O 
modeling O 
within O 
the O 
RARα O 
binding O 
pocket O 
was O 
used O 
to O 
compare O 
binding O 
interactions O 
of O 
the O 
desfluoro O 
analog O 
to O 
a O 
known O 
RAR O 
antagonist O 
. O 

of O 
decacationic B-FAMILY 
[60]fullerene I-FAMILY 
decaiodides I-FAMILY 
giving O 
photoinduced O 
production O 
of O 
superoxide B-TRIVIAL 
radicals O 
and O 
effective O 
PDT-mediation O 
on O 
antimicrobial O 
photoinactivation O 
. O 

report O 
a O 
novel O 
class O 
of O 
highly O 
water O 
- O 
soluble O 
decacationic B-FAMILY 
methano[60]fullerene I-FAMILY 
decaiodides I-FAMILY 
C60[ B-FAMILY 
> I-FAMILY 
M(C3N6(+)C3)2]-(I(-))10 I-FAMILY 
[ O 
1- O 
(I(-))10 B-FORMULA 
] O 
capable O 
of O 
co O 
- O 
producing O 
singlet O 
oxygen B-SYSTEMATIC 
( O 
Type-II O 
) O 
and O 
highly O 
reactive O 
hydroxyl B-SYSTEMATIC 
radicals O 
, O 
formed O 
from O 
superoxide B-TRIVIAL 
radicals O 
in O 
Type-I O 
photosensitizing O 
reactions O 
, O 
upon O 
illumination O 
at O 
both O 
UVA O 
and O 
white O 
light O 
wavelengths O 
. O 
The O 
O2(-)· B-FORMULA 
-production O 
efficiency O 
of O 
1- O 
(I(-))10 B-FORMULA 
was O 
confirmed O 
by O 
using O 
an O 
O2(-)· B-FORMULA 
-reactive O 
bis(2,4-dinitrobenzenesulfonyl)tetrafluorofluorescein B-SYSTEMATIC 
probe O 
and O 
correlated O 
to O 
the O 
photoinduced O 
electron O 
- O 
transfer O 
event O 
going O 
from O 
iodide B-SYSTEMATIC 
anions O 
to O 
( B-FAMILY 
3)C60*[ I-FAMILY 
> I-FAMILY 
M(C3N6(+)C3)2 I-FAMILY 
] I-FAMILY 
leading O 
to O 
C60(-)·[ B-FAMILY 
> I-FAMILY 
M(C3N6(+)C3)2 I-FAMILY 
] I-FAMILY 
. O 
Incorporation O 
of O 
a O 
defined O 
number O 
( O 
ten O 
) O 
of O 
quaternary B-SYSTEMATIC 
ammonium I-SYSTEMATIC 
cationic O 
charges O 
per O 
C60 B-TRIVIAL 
in O 
1 O 
was O 
aimed O 
to O 
enhance O 
its O 
ability O 
to O 
target O 
pathogenic O 
Gram O 
- O 
positive O 
and O 
Gram O 
- O 
negative O 
bacterial O 
cells O 
. O 
We O 
used O 
the O 
well O 
- O 
characterized O 
malonato[60]fullerene B-SYSTEMATIC 
diester I-SYSTEMATIC 
monoadduct O 
C60[ B-FAMILY 
> I-FAMILY 
M(t-Bu)2 I-FAMILY 
] I-FAMILY 
as O 
the O 
starting O 
fullerene B-TRIVIAL 
derivative O 
to O 
provide O 
a O 
better O 
synthetic O 
route O 
to O 
C60[ B-FAMILY 
> I-FAMILY 
M(C3N6(+)C3)2 I-FAMILY 
] I-FAMILY 
via O 
transesterification O 
reaction O 
under O 
trifluoroacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
catalyzed O 
conditions O 
. O 
These O 
compounds O 
may O 
be O 
used O 
as O 
effective O 
photosensitizers O 
and O 
nano-PDT O 
drugs O 
for O 
photoinactivation O 
of O 
pathogens O 
. O 

, O 
antimicrobial O 
, O 
antiquorum O 
- O 
sensing O 
, O 
antitumor O 
and O 
cytotoxic O 
activities O 
of O 
new O 
series O 
of O 
fused O 
[1,3,4]thiadiazoles B-FAMILY 
. O 

series O 
of O 
[1,3,4]thiadiazolo[3,2-a]pyrimidines B-FAMILY 
, O 
benzo[h][1,3,4]thiadiazolo[2,3-b]quinazolines B-FAMILY 
, O 
benzothiadiazolotriazocine B-SYSTEMATIC 
, O 
and O 
imidazo[2,1-b][1,3,4]thiadiazoles B-FAMILY 
have O 
been O 
synthesized O 
and O 
characterized O 
by O 
analytical O 
and O 
spectrometrical O 
methods O 
( O 
IR O 
, O 
MS O 
, O 
(1)H B-FORMULA 
and O 
(13)C B-FORMULA 
NMR O 
) O 
. O 
Twenty O 
of O 
the O 
synthesized O 
compounds O 
were O 
screened O 
for O 
antibacterial O 
activity O 
against O 
Escherichia O 
coli O 
, O 
Staphylococcus O 
aureus O 
and O 
Bacillus O 
cereus O 
. O 
They O 
were O 
found O 
to O 
be O 
either O 
moderately O 
active O 
, O 
slightly O 
active O 
or O 
inactive O 
against O 
the O 
tested O 
microorganisms O 
. O 
The O 
antifungal O 
activity O 
of O 
these O 
compounds O 
were O 
also O 
tested O 
against O 
Candida O 
albicans O 
, O 
Aspergillus O 
fumigatus O 
293 O 
and O 
Aspergillus O 
flavus O 
3375 O 
. O 
Compounds O 
3g O 
, O 
h O 
showed O 
potent O 
antifungal O 
activity O 
against O 
C. O 
albicans O 
. O 
In O 
addition O 
, O 
the O 
same O 
compounds O 
were O 
tested O 
for O 
antiquorum O 
- O 
sensing O 
activity O 
against O 
Chromobacterium O 
violacium O 
ATCC O 
12472 O 
, O 
where O 
compounds O 
3b,c O 
, O 
3f-h O 
, O 
6b-d O 
, O 
9 O 
, O 
10 O 
and O 
12 O 
demonstrated O 
acceptable O 
activity O 
. O 
Compounds O 
3d O 
, O 
9 O 
and O 
10 O 
were O 
screened O 
for O 
antitumor O 
activity O 
at O 
National O 
Cancer O 
Institute O 
, O 
USA O 
. O 
The O 
in O 
vitro O 
cytotoxic O 
activity O 
of O 
eighteen O 
of O 
the O 
synthesized O 
compounds O 
was O 
studied O 
by O 
brine O 
shrimp O 
lethality O 
bioassay O 
, O 
and O 
results O 
indicated O 
that O 
compounds O 
6c O 
, O 
13 O 
, O 
3h O 
, O 
6d O 
and O 
3d O 
have O 
the O 
highest O 
cytotoxic O 
activity O 
. O 

using O 
microwave O 
irradiation O 
and O 
antibacterial O 
evaluation O 
of O 
new O 
N,O-acetals B-FAMILY 
and O 
N,S-acetals B-FAMILY 
derived O 
from O 
2-amino-1,4-naphthoquinones B-FAMILY 
. O 

paper O 
describes O 
a O 
novel O 
series O 
of O 
N,O-acetals B-FAMILY 
and O 
N,S-acetals B-FAMILY 
( O 
7a-o O 
) O 
derived O 
from O 
2-amino-1,4-naphthoquinones B-FAMILY 
that O 
were O 
synthesized O 
and O 
evaluated O 
as O 
potential O 
antimicrobial O 
agents O 
. O 
These O 
compounds O 
were O 
obtained O 
in O 
good O 
yields O 
using O 
microwave O 
irradiation O 
, O 
and O 
several O 
of O 
them O 
showed O 
promising O 
antibacterial O 
profiles O 
. O 
Three O 
of O 
our O 
biologically O 
active O 
2-amino-1,4-naphthoquinone B-SYSTEMATIC 
N,O-acetals B-FAMILY 
and O 
N,S-acetals B-FAMILY 
tested O 
against O 
hospital O 
bacterial O 
strains O 
were O 
identified O 
as O 
potential O 
lead O 
compounds O 
. O 
Characterization O 
of O 
all O 
compounds O 
was O 
performed O 
using O 
one O 
- O 
dimensional O 
NMR O 
techniques O 
( O 
(1)H B-FORMULA 
, O 
(13)C B-FORMULA 
-APT O 
) O 
, O 
IR O 
spectra O 
, O 
elemental O 
analyses O 
and O 
high O 
- O 
resolution O 
electrospray O 
ionization O 
mass O 
spectrometry O 
( O 
HR-ESI-MS O 
) O 
. O 

supplementation O 
influenced O 
levels O 
of O 
triglyceride B-FAMILY 
and O 
luteunizing O 
hormone O 
in O 
Korean O 
postmenopausal O 
women O 
. O 

conducted O 
a O 
double O 
- O 
blind O 
, O 
randomized O 
, O 
placebo O 
- O 
controlled O 
trial O 
to O 
evaluate O 
the O 
effects O 
of O 
soy O 
- O 
derived O 
isoflavone B-FAMILY 
on O 
blood O 
glucose B-TRIVIAL 
, O 
lipid O 
profiles O 
, O 
and O 
sex O 
hormones O 
related O 
to O 
cardiovascular O 
disease O 
in O 
Korean O 
postmenopausal O 
women O 
. O 
One O 
hundred O 
thirteen O 
postmenopausal O 
women O 
were O 
recruited O 
from O 
the O 
Seoul O 
metropolitan O 
area O 
. O 
To O 
confirm O 
postmenopausal O 
and O 
gynecologic O 
status O 
, O 
the O 
subjects O 
were O 
clinically O 
examined O 
by O 
a O 
gynecologist O 
using O 
ultra O 
sound O 
and O 
X-ray O 
. O 
Finally O 
, O 
85 O 
postmenopausal O 
women O 
whose O 
follicle O 
- O 
stimulating O 
hormone O 
( O 
FSH O 
) O 
levels O 
were O 
higher O 
than O 
40 O 
IU O 
/ O 
ml O 
were O 
enrolled O 
. O 
Subjects O 
received O 
either O 
70 O 
mg O 
isoflavone B-FAMILY 
or O 
placebo O 
capsules O 
daily O 
for O 
12 O 
weeks O 
. O 
As O 
a O 
result O 
, O 
the O 
values O 
of O 
fasting O 
glucose B-TRIVIAL 
, O 
insulin O 
and O 
HOMA-IR O 
, O 
as O 
well O 
as O 
those O 
of O 
TC O 
, O 
LDL-C O 
, O 
HDL-C O 
and O 
FFA O 
, O 
were O 
not O 
different O 
between O 
the O 
groups O 
after O 
supplementation O 
. O 
However O 
, O 
triglyceride B-FAMILY 
( O 
TG O 
) O 
levels O 
in O 
the O 
treatment O 
group O 
decreased O 
significantly O 
compared O 
with O 
those O 
of O 
the O 
placebo O 
group O 
( O 
p O 
= O 
0.0215 O 
) O 
. O 
The O 
levels O 
of O 
luteinizing O 
hormone O 
( O 
LH O 
) O 
significantly O 
decreased O 
in O 
the O 
treatment O 
group O 
( O 
p O 
= O 
0.027 O 
) O 
; O 
however O 
, O 
the O 
levels O 
of O 
FSH O 
, O 
estrone B-TRIVIAL 
and O 
estradiol B-TRIVIAL 
were O 
not O 
changed O 
after O 
intervention O 
. O 
In O 
conclusion O 
, O 
isoflavone B-FAMILY 
supplement O 
of O 
70 O 
mg O 
/ O 
day O 
for O 
12 O 
weeks O 
decreased O 
blood O 
levels O 
of O 
TG O 
and O 
LH O 
in O 
Korean O 
postmenopausal O 
women O 
. O 

speciation O 
and O 
spatial O 
and O 
interspecies O 
differences O 
of O 
metal O 
concentrations O 
in O 
mollusks O 
and O 
crustaceans O 
from O 
a O 
South O 
China O 
estuary O 
. O 

speciation O 
and O 
concentrations O 
were O 
determined O 
in O 
mollusks O 
and O 
crustaceans O 
in O 
the O 
intertidal O 
zone O 
from O 
twelve O 
locations O 
in O 
Zhanjiang O 
estuary O 
, O 
South O 
China O 
. O 
Metal O 
concentrations O 
( O 
Ag B-FORMULA 
, O 
As B-FORMULA 
, O 
Cd B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Hg B-FORMULA 
, O 
Ni B-FORMULA 
, O 
Pb B-FORMULA 
, O 
and O 
Zn B-FORMULA 
) O 
were O 
also O 
concurrently O 
determined O 
in O 
these O 
species O 
. O 
Arsenic B-SYSTEMATIC 
speciation O 
analysis O 
showed O 
that O 
the O 
less O 
- O 
toxic O 
arsenobetaine B-TRIVIAL 
( O 
AsB B-ABBREVIATION 
) O 
constituted O 
80.6-98.8 O 
% O 
of O 
all O 
As O 
compounds O 
, O 
and O 
dimethylarsinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DMA B-ABBREVIATION 
) O 
constituted O 
0.47-3.44 O 
% O 
. O 
Monomethylarsonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
MMA B-ABBREVIATION 
) O 
and O 
As B-FORMULA 
(V) I-FORMULA 
were O 
only O 
detected O 
in O 
the O 
whelk O 
Drupa O 
fiscella O 
and O 
the O 
crab O 
Heteropilumnus O 
ciliatus O 
, O 
respectively O 
. O 
Arsenite B-SYSTEMATIC 
[ O 
As B-FORMULA 
(III) I-FORMULA 
] O 
was O 
not O 
detected O 
in O 
any O 
of O 
the O 
sampled O 
specimens O 
, O 
but O 
there O 
were O 
also O 
unidentified O 
other O 
As B-FORMULA 
species O 
. O 
A O 
strong O 
spatial O 
variation O 
of O 
metals O 
in O 
the O 
oyster O 
Saccostrea O 
cucullata O 
was O 
found O 
in O 
the O 
estuary O 
, O 
confirming O 
that O 
oysters O 
can O 
be O 
used O 
as O 
a O 
good O 
biomonitor O 
of O 
metal O 
contamination O 
in O 
the O 
studied O 
area O 
. O 
The O 
concentrations O 
of O 
eight O 
metals O 
in O 
the O 
studied O 
mollusks O 
and O 
crustaceans O 
clearly O 
revealed O 
that O 
these O 
invertebrates O 
accumulated O 
different O 
metals O 
to O 
different O 
degrees O 
. O 
Furthermore O 
, O 
As B-FORMULA 
, O 
Cd B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Hg B-FORMULA 
, O 
and O 
Pb B-FORMULA 
contents O 
in O 
mollusks O 
and O 
crustacean O 
samples O 
were O 
below O 
the O 
Food O 
and O 
Agricultural O 
Organization O 
( O 
FAO O 
) O 
safe O 
concentrations O 
, O 
thus O 
there O 
was O 
no O 
obvious O 
health O 
risk O 
from O 
the O 
intake O 
of O 
the O 
metals O 
through O 
marine O 
mollusks O 
and O 
crustaceans O 
consumption O 
. O 

inhibition O 
of O 
Eph O 
receptors O 
enhances O 
glucose B-TRIVIAL 
-stimulated O 
insulin O 
secretion O 
from O 
mouse O 
and O 
human O 
pancreatic O 
islets O 
. O 

/ O 
HYPOTHESIS O 
: O 
Type O 
2 O 
diabetes O 
is O 
characterised O 
by O 
impaired O 
glucose B-TRIVIAL 
-stimulated O 
insulin O 
secretion O 
( O 
GSIS O 
) O 
from O 
pancreatic O 
islets O 
. O 
Since O 
erythropoietin O 
- O 
producing O 
hepatoma O 
(Eph)-ephrin O 
bidirectional O 
signalling O 
fine O 
- O 
tunes O 
GSIS O 
from O 
pancreatic O 
beta O 
cells O 
, O 
we O 
investigated O 
Eph O 
receptor O 
tyrosine B-TRIVIAL 
kinases O 
( O 
RTK O 
) O 
as O 
potential O 
drug O 
targets O 
for O 
selectively O 
increasing O 
GSIS O 
. O 
METHODS O 
: O 
Insulin O 
secretion O 
assays O 
were O 
carried O 
out O 
using O 
mouse O 
and O 
human O 
pancreatic O 
islets O 
as O 
well O 
as O 
mouse O 
insulinoma O 
( O 
MIN6 O 
) O 
cells O 
in O 
the O 
presence O 
or O 
absence O 
of O 
two O 
Eph O 
RTK O 
inhibitors O 
. O 
Furthermore O 
, O 
the O 
most O 
potent O 
inhibitor O 
was O 
injected O 
into O 
mice O 
to O 
evaluate O 
its O 
effects O 
on O 
glucose B-TRIVIAL 
tolerance O 
and O 
plasma O 
insulin O 
levels O 
. O 
RESULTS O 
: O 
We O 
showed O 
that O 
the O 
Eph O 
RTK O 
inhibitors O 
selectively O 
increased O 
GSIS O 
from O 
MIN6 O 
cells O 
as O 
well O 
as O 
mouse O 
and O 
human O 
islets O 
. O 
Our O 
results O 
also O 
showed O 
that O 
the O 
insulin O 
secretory O 
effects O 
of O 
these O 
compounds O 
required O 
Eph O 
- O 
ephrin O 
signalling O 
. O 
Finally O 
, O 
pharmacological O 
inhibition O 
of O 
Eph O 
receptor O 
signalling O 
improved O 
glucose B-TRIVIAL 
tolerance O 
in O 
mice O 
. O 
CONCLUSIONS O 
/ O 
INTERPRETATION O 
: O 
We O 
showed O 
for O 
the O 
first O 
time O 
that O 
Eph O 
RTKs O 
represent O 
targets O 
for O 
small O 
molecules O 
to O 
selectively O 
increase O 
GSIS O 
and O 
improve O 
glucose B-TRIVIAL 
tolerance O 
. O 

of O 
Strontium B-SYSTEMATIC 
on O 
Collagen O 
Content O 
and O 
Expression O 
of O 
Related O 
Genes O 
in O 
Rat O 
Chondrocytes O 
Cultured O 
In O 
Vitro O 
. O 

stimulates O 
cartilage O 
matrix O 
formation O 
in O 
vitro O 
. O 
However O 
, O 
the O 
mechanisms O 
governing O 
these O 
effects O 
have O 
not O 
yet O 
been O 
extensively O 
reported O 
. O 
In O 
this O 
study O 
, O 
chondrocytes O 
were O 
isolated O 
from O 
rat O 
articular O 
cartilage O 
by O 
enzymatic O 
digestion O 
and O 
cultured O 
for O 
24-72 O 
h O 
with O 
1-5 O 
mM O 
strontium B-SYSTEMATIC 
. O 
We O 
investigated O 
the O 
effects O 
of O 
different O 
concentrations O 
of O 
strontium B-SYSTEMATIC 
on O 
collagen O 
content O 
, O 
type O 
II O 
collagen O 
, O 
insulin O 
- O 
like O 
growth O 
factor O 
( O 
IGF-1 O 
) O 
and O 
matrix O 
metalloproteinase O 
(MMP)-13 O 
expression O 
in O 
rat O 
cultured O 
articular O 
chondrocytes O 
in O 
vitro O 
. O 
The O 
collagen O 
content O 
of O 
the O 
chondrocytes O 
, O 
determined O 
as O 
hydroxyproline B-SYSTEMATIC 
, O 
was O 
measured O 
by O 
a O 
colorimetry O 
method O 
. O 
Type O 
II O 
collagen O 
, O 
IGF-1 O 
, O 
and O 
MMP-13 O 
mRNA O 
abundance O 
and O 
protein O 
expression O 
levels O 
were O 
determined O 
by O 
real O 
- O 
time O 
polymerase O 
chain O 
reaction O 
( O 
real O 
- O 
time O 
PCR O 
) O 
and O 
western O 
blot O 
, O 
respectively O 
. O 
The O 
results O 
showed O 
that O 
collagen O 
content O 
from O 
the O 
chondrocytes O 
extracellular O 
matrix O 
increased O 
with O 
increasing O 
strontium B-SYSTEMATIC 
concentration O 
. O 
Moreover O 
, O 
3 O 
and O 
5 O 
mM O 
strontium B-SYSTEMATIC 
strongly O 
stimulated O 
protein O 
expression O 
and O 
mRNA O 
levels O 
of O 
type O 
II O 
collagen O 
and O 
IGF-1 O 
. O 
Conversely O 
, O 
MMP-13 O 
expression O 
in O 
chondrocytes O 
decreased O 
dose O 
- O 
dependently O 
with O 
increasing O 
strontium B-SYSTEMATIC 
concentration O 
. O 
These O 
results O 
should O 
provide O 
insight O 
into O 
the O 
ability O 
of O 
strontium B-SYSTEMATIC 
to O 
promote O 
chondrocyte O 
extracellular O 
matrix O 
synthesis O 
. O 
Strontium B-SYSTEMATIC 
could O 
promote O 
collagen O 
synthesis O 
and O 
suppress O 
collagen O 
degradation O 
via O 
the O 
repression O 
of O 
MMP-13 O 
expression O 
. O 

of O 
nicotine B-TRIVIAL 
pretreatment O 
on O 
arsenic B-SYSTEMATIC 
-induced O 
oxidative O 
stress O 
in O 
male O 
Wistar O 
rats O 
. O 

are O 
commonly O 
exposed O 
to O 
nicotine B-TRIVIAL 
, O 
one O 
of O 
the O 
most O 
important O 
lifestyle O 
chemicals O 
. O 
The O 
occurrence O 
of O 
high O 
levels O 
of O 
arsenic B-SYSTEMATIC 
in O 
the O 
groundwater O 
of O 
the O 
southeast O 
region O 
of O 
Asia O 
has O 
received O 
much O 
attention O 
in O 
the O 
past O 
decade O 
and O 
has O 
become O 
a O 
global O 
health O 
concern O 
. O 
Predominant O 
occurrence O 
of O 
both O 
these O 
chemicals O 
and O 
ease O 
of O 
their O 
human O 
exposure O 
led O 
us O 
to O 
investigate O 
the O 
effect O 
of O 
nicotine B-TRIVIAL 
, O 
a O 
major O 
tobacco O 
alkaloid O 
, O 
on O 
arsenic B-SYSTEMATIC 
toxicity O 
. O 
Adult O 
male O 
rats O 
were O 
pre O 
- O 
exposed O 
to O 
two O 
different O 
doses O 
of O 
nicotine B-TRIVIAL 
( O 
0.75 O 
and O 
3 O 
mg O 
/ O 
kg O 
, O 
intraperitoneally O 
) O 
for O 
7 O 
days O 
followed O 
by O 
30 O 
days O 
of O 
arsenic B-SYSTEMATIC 
exposure O 
( O 
50 O 
ppm O 
sodium B-SYSTEMATIC 
arsenite I-SYSTEMATIC 
in O 
drinking O 
water O 
) O 
. O 
Nicotine B-TRIVIAL 
pre O 
- O 
exposure O 
resulted O 
in O 
an O 
increased O 
brain O 
arsenic B-SYSTEMATIC 
accumulation O 
and O 
a O 
decreased O 
liver O 
arsenic B-SYSTEMATIC 
concentration O 
. O 
Arsenic B-SYSTEMATIC 
also O 
caused O 
a O 
significant O 
oxidative O 
stress O 
in O 
the O 
blood O 
, O 
brain O 
and O 
liver O 
of O 
the O 
exposed O 
rats O 
. O 
Glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
, O 
a O 
phase O 
II O 
enzyme O 
, O 
was O 
inhibited O 
by O 
both O 
arsenic B-SYSTEMATIC 
and O 
nicotine B-TRIVIAL 
but O 
no O 
such O 
inhibition O 
was O 
noted O 
in O 
arsenic B-SYSTEMATIC 
-treated O 
animals O 
pre O 
- O 
exposed O 
to O 
nicotine B-TRIVIAL 
. O 
Upon O 
nicotine B-TRIVIAL 
pre O 
- O 
exposure O 
, O 
brain O 
acetylcholinesterase O 
increased O 
, O 
while O 
monoamine O 
oxidase O 
( O 
MAO O 
) O 
decreased O 
. O 
The O 
toxic O 
effects O 
of O 
MAO O 
significantly O 
attenuated O 
with O 
nicotine B-TRIVIAL 
pre O 
- O 
exposure O 
. O 
The O 
present O 
study O 
suggests O 
that O 
nicotine B-TRIVIAL 
may O 
not O 
be O 
the O 
major O 
contributing O 
factor O 
for O 
the O 
previously O 
reported O 
synergistic O 
toxic O 
interaction O 
between O 
tobacco O 
and O 
arsenic B-SYSTEMATIC 
. O 
Nicotine B-TRIVIAL 
pre O 
- O 
exposure O 
in O 
arsenic B-SYSTEMATIC 
-exposed O 
animals O 
revealed O 
interesting O 
toxicokinetics O 
and O 
oxidative O 
stress O 
modulating O 
interactions O 
in O 
the O 
brain O 
and O 
liver O 
of O 
rats O 
, O 
which O 
requires O 
further O 
exploration O 
. O 

- O 
disrupting O 
chemicals O 
can O 
affect O 
reproduction O 
and O 
development O 
in O 
humans O 
and O 
wildlife O 
. O 
We O 
developed O 
a O 
computational O 
model O 
of O 
the O 
hypothalamic O 
- O 
pituitary O 
- O 
gonadal O 
( O 
HPG O 
) O 
axis O 
in O 
female O 
fathead O 
minnows O 
to O 
predict O 
dose O 
- O 
response O 
and O 
time O 
- O 
course O 
( O 
DRTC O 
) O 
behaviors O 
for O 
endocrine O 
effects O 
of O 
the O 
aromatase O 
inhibitor O 
, O 
fadrozole B-TRIVIAL 
( O 
FAD B-ABBREVIATION 
) O 
. O 
The O 
model O 
describes O 
adaptive O 
responses O 
to O 
endocrine O 
stress O 
involving O 
regulated O 
secretion O 
of O 
a O 
generic O 
gonadotropin O 
( O 
LH O 
/ O 
FSH O 
) O 
from O 
the O 
hypothalamic O 
- O 
pituitary O 
complex O 
. O 
For O 
model O 
development O 
, O 
we O 
used O 
plasma O 
17β-estradiol B-SYSTEMATIC 
( O 
E2 O 
) O 
concentrations O 
and O 
ovarian O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
19A O 
aromatase O 
mRNA O 
data O 
from O 
two O 
time O 
- O 
course O 
experiments O 
, O 
each O 
of O 
which O 
included O 
both O 
an O 
exposure O 
and O 
a O 
depuration O 
phase O 
, O 
and O 
plasma O 
E2 O 
data O 
from O 
a O 
third O 
4-day O 
study O 
. O 
Model O 
parameters O 
were O 
estimated O 
using O 
E2 O 
concentrations O 
for O 
0 O 
, O 
0.5 O 
, O 
and O 
3 O 
µg O 
/ O 
l O 
FAD B-ABBREVIATION 
exposure O 
concentrations O 
, O 
and O 
good O 
fits O 
to O 
these O 
data O 
were O 
obtained O 
. O 
The O 
model O 
accurately O 
predicted O 
CYP19A O 
mRNA O 
fold O 
changes O 
for O 
controls O 
and O 
three O 
FAD B-ABBREVIATION 
doses O 
( O 
0 O 
, O 
0.5 O 
, O 
and O 
3 O 
µg O 
/ O 
l O 
) O 
and O 
plasma O 
E2 O 
dose O 
response O 
from O 
the O 
4-day O 
study O 
. O 
Comparing O 
the O 
model O 
- O 
predicted O 
DRTC O 
with O 
experimental O 
data O 
provided O 
insight O 
into O 
how O 
the O 
feedback O 
control O 
mechanisms O 
in O 
the O 
HPG O 
axis O 
mediate O 
these O 
changes O 
: O 
specifically O 
, O 
adaptive O 
changes O 
in O 
plasma O 
E2 O 
levels O 
occurring O 
during O 
exposure O 
and O 
" O 
overshoot O 
" O 
occurring O 
postexposure O 
. O 
This O 
study O 
demonstrates O 
the O 
value O 
of O 
mechanistic O 
modeling O 
to O 
examine O 
and O 
predict O 
dynamic O 
behaviors O 
in O 
perturbed O 
systems O 
. O 
As O 
this O 
work O 
progresses O 
, O 
we O 
will O 
obtain O 
a O 
refined O 
understanding O 
of O 
how O 
adaptive O 
responses O 
within O 
the O 
vertebrate O 
HPG O 
axis O 
affect O 
DRTC O 
behaviors O 
for O 
aromatase O 
inhibitors O 
and O 
other O 
types O 
of O 
endocrine O 
- O 
active O 
chemicals O 
and O 
apply O 
that O 
knowledge O 
in O 
support O 
of O 
risk O 
assessments O 
. O 

novel O 
nontoxic O 
inhibitor O 
of O 
the O 
activation O 
of O 
NADPH B-ABBREVIATION 
oxidase O 
reduces O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
production O 
in O 
mouse O 
lung O 
. O 

( O 
MJ33 B-IDENTIFIER 
) O 
is O 
a O 
fluorinated O 
phospholipid O 
analog O 
that O 
inhibits O 
the O 
phospholipase O 
A2 O 
( O 
PLA2 O 
) O 
activity O 
of O 
peroxiredoxin O 
6 O 
( O 
Prdx6 O 
) O 
. O 
Prdx6 O 
PLA2 O 
activity O 
is O 
required O 
for O 
activation O 
of O 
NADPH B-ABBREVIATION 
oxidase O 
2 O 
and O 
subsequent O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
. O 
In O 
vitro O 
, O 
MJ33 B-IDENTIFIER 
inhibited O 
agonist O 
- O 
stimulated O 
production O 
of O 
ROS O 
by O 
the O 
isolated O 
perfused O 
mouse O 
lung O 
, O 
lung O 
microvascular O 
endothelial O 
cells O 
, O 
and O 
polymorphonuclear O 
leukocytes O 
. O 
MJ33 B-IDENTIFIER 
( O 
0.02-0.5 O 
µmol O 
MJ33 B-IDENTIFIER 
/ O 
kg O 
body O 
weight O 
) O 
in O 
mixed O 
unilamellar O 
liposomes O 
was O 
administered O 
to O 
C57BL O 
/ O 
6 O 
mice O 
by O 
either O 
intratracheal O 
( O 
i.t O 
. O 
) O 
or O 
i.v O 
. O 
routes O 
. O 
Lung O 
MJ33 B-IDENTIFIER 
content O 
, O 
measured O 
by O 
liquid O 
chromatography O 
/ O 
mass O 
spectroscopy O 
, O 
showed O 
uptake O 
of O 
67-87% O 
of O 
the O 
injected O 
dose O 
for O 
i.t O 
. O 
and O 
23-42% O 
for O 
i.v O 
. O 
administration O 
at O 
4 O 
hours O 
postinjection O 
. O 
PLA2 O 
activity O 
of O 
lung O 
homogenates O 
was O 
markedly O 
inhibited O 
( O 
> O 
85% O 
) O 
at O 
4 O 
hours O 
postadministration O 
. O 
Both O 
MJ33 B-IDENTIFIER 
content O 
and O 
PLA2 O 
activity O 
gradually O 
returned O 
to O 
near O 
control O 
levels O 
over O 
the O 
subsequent O 
24-72 O 
hours O 
. O 
Mice O 
treated O 
with O 
MJ33 B-IDENTIFIER 
at O 
12.5-25 O 
µmol O 
/ O 
kg O 
did O 
not O 
show O 
changes O 
( O 
compared O 
with O 
control O 
) O 
in O 
clinical O 
symptomatology O 
, O 
body O 
weight O 
, O 
hematocrit O 
, O 
and O 
histology O 
of O 
lung O 
, O 
liver O 
, O 
and O 
kidney O 
during O 
a O 
30- O 
to O 
50-day O 
observation O 
period O 
. O 
Thus O 
, O 
the O 
toxic O 
dose O 
of O 
MJ33 B-IDENTIFIER 
was O 
> O 
25 O 
µmol O 
/ O 
kg O 
, O 
whereas O 
the O 
PLA2 O 
inhibitory O 
dose O 
was O 
approximately O 
0.02 O 
µmol O 
/ O 
kg O 
, O 
indicating O 
a O 
high O 
margin O 
of O 
safety O 
. O 
MJ33 B-IDENTIFIER 
administered O 
to O 
mice O 
prior O 
to O 
lung O 
isolation O 
markedly O 
reduced O 
ROS O 
production O 
and O 
tissue O 
lipid O 
and O 
protein O 
oxidation O 
during O 
ischemia O 
followed O 
by O 
reperfusion O 
. O 
Thus O 
, O 
MJ33 B-IDENTIFIER 
could O 
be O 
useful O 
as O 
a O 
therapeutic O 
agent O 
to O 
prevent O 
ROS O 
- O 
mediated O 
tissue O 
injury O 
associated O 
with O 
lung O 
inflammation O 
or O 
in O 
harvested O 
lungs O 
prior O 
to O 
transplantation O 
. O 

ring O 
/ O 
chain O 
equilibrium O 
in O 
nanoconfined O 
sulfur B-SYSTEMATIC 
. O 

effect O 
of O 
nanoconfinement O 
on O 
the O 
thermodynamics O 
of O 
free O 
radical O 
polymerization O 
of O 
sulfur B-SYSTEMATIC 
is O 
examined O 
. O 
We O 
extend O 
Tobolsky O 
and O 
Eisenberg's O 
model O 
of O 
bulk O 
sulfur B-SYSTEMATIC 
polymerization O 
to O 
nanopores O 
accounting O 
for O 
the O 
confinement O 
entropy O 
of O 
the O 
chains O 
and O 
ring O 
using O 
scaling O 
reported O 
in O 
literature O 
. O 
The O 
model O 
quantitatively O 
captures O 
literature O 
data O 
from O 
Yannopoulos O 
and O 
co O 
- O 
workers O 
for O 
the O 
extent O 
of O 
polymerization O 
versus O 
temperature O 
for O 
bulk O 
sulfur B-SYSTEMATIC 
polymerization O 
and O 
for O 
polymerization O 
in O 
20 O 
, O 
7.5 O 
, O 
and O 
2.5 O 
nm O 
diameter O 
Gelsil B-NO_CLASS 
nanopores O 
, O 
assuming O 
that O 
the O 
change O 
of O 
entropy O 
of O 
nanoconfined O 
chains O 
scales O 
with O 
molecular O 
size O 
to O 
the O 
second O 
power O 
and O 
with O 
nanopore O 
diameter O 
to O 
either O 
the O 
-3 O 
or O 
-3.8 O 
power O 
, O 
the O 
former O 
of O 
which O 
fits O 
slightly O 
better O 
. O 
The O 
scaling O 
, O 
which O 
is O 
valid O 
for O 
strong O 
confinement O 
in O 
spherical O 
pores O 
, O 
predicts O 
that O 
the O 
propagation O 
equilibrium O 
constant O 
will O 
depend O 
on O 
both O 
nanopore O 
size O 
and O 
chain O 
length O 
, O 
such O 
that O 
the O 
average O 
chain O 
length O 
decreases O 
significantly O 
upon O 
confinement O 
. O 

genus O 
Capsicum O 
( O 
pepper O 
) O 
comprises O 
a O 
large O 
number O 
of O 
wild O 
and O 
cultivated O 
species O 
. O 
The O 
plants O 
are O 
grown O 
all O 
over O 
the O 
world O 
, O 
primarily O 
in O 
tropical O 
and O 
subtropical O 
countries O 
. O 
The O 
fruits O 
are O 
an O 
excellent O 
source O 
of O 
health O 
- O 
related O 
compounds O 
, O 
such O 
as O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
( O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
) O 
, O 
carotenoids O 
( O 
provitamin O 
A O 
) O 
, O 
tocopherols B-FAMILY 
( O 
vitamin B-FAMILY 
E I-FAMILY 
) O 
, O 
flavonoids B-FAMILY 
, O 
and O 
capsaicinoids B-FAMILY 
. O 
Pepper O 
fruits O 
have O 
been O 
used O 
for O 
fresh O 
and O 
cooked O 
consumption O 
, O 
as O 
well O 
as O 
for O 
medicinal O 
purposes O 
, O 
such O 
as O 
treatment O 
of O 
asthma O 
, O 
coughs O 
, O 
sore O 
throats O 
, O 
and O 
toothache O 
. O 
Depending O 
on O 
its O 
uses O 
, O 
there O 
are O 
several O 
main O 
characters O 
important O 
for O 
product O 
quality O 
; O 
pungency O 
, O 
bright O 
attractive O 
colors O 
, O 
highly O 
concentrated O 
extracts O 
, O 
and O 
a O 
small O 
number O 
of O 
seeds O 
are O 
the O 
main O 
characters O 
on O 
which O 
quality O 
is O 
based O 
and O 
priced O 
. O 
Herein O 
, O 
a O 
general O 
overview O 
of O 
biochemical O 
composition O 
, O 
medical O 
properties O 
of O 
these O 
compounds O 
, O 
and O 
characteristics O 
of O 
quality O 
attributes O 
of O 
pepper O 
fruits O 
is O 
presented O 
. O 

Adducts O 
in O 
Aldehyde B-SYSTEMATIC 
Dehydrogenase-Positive O 
Lung O 
Stem O 
Cells O 
of O 
A O 
/ O 
J O 
Mice O 
Treated O 
with O 
the O 
Tobacco O 
Specific O 
Lung O 
Carcinogen O 
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone B-SYSTEMATIC 
( O 
NNK B-TRIVIAL 
) O 
. O 

cancer O 
is O 
the O 
leading O 
cause O 
of O 
cancer O 
death O 
in O 
the O 
world O 
. O 
Evidence O 
suggests O 
that O 
lung O 
cancer O 
could O 
originate O 
from O 
mutations O 
accumulating O 
in O 
a O 
subpopulation O 
of O 
self O 
- O 
renewing O 
cells O 
, O 
lung O 
stem O 
cells O 
. O 
Aldehyde B-SYSTEMATIC 
dehydrogenase O 
( O 
ALDH O 
) O 
is O 
a O 
marker O 
of O 
stem O 
cells O 
. O 
To O 
investigate O 
the O 
presence O 
of O 
DNA O 
modifications O 
in O 
these O 
cells O 
, O 
we O 
isolated O 
ALDH-positive O 
lung O 
cells O 
from O 
A O 
/ O 
J O 
mice O 
exposed O 
to O 
the O 
lung O 
carcinogen O 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone B-SYSTEMATIC 
. O 
Using O 
LC-NSI-HRMS O 
/ O 
MS-PRM O 
, O 
O(6)-methyl-G B-SYSTEMATIC 
, O 
7-POB-G B-SYSTEMATIC 
, O 
and O 
O(2)-POB-dT B-FORMULA 
were O 
positively O 
identified O 
in O 
ALDH-positive O 
cell O 
DNA O 
. O 
This O 
is O 
the O 
first O 
example O 
of O 
detection O 
of O 
carcinogen-DNA O 
adducts O 
in O 
lung O 
stem O 
cells O 
, O 
supporting O 
the O 
hypothesis O 
of O 
their O 
role O 
in O 
lung O 
carcinogenesis O 
. O 

and O 
efficacy O 
of O 
polycalcium B-FAMILY 
for O 
improving O 
biomarkers O 
of O 
bone O 
metabolism O 
: O 
a O 
4-week O 
open O 
- O 
label O 
clinical O 
study O 
. O 

is O 
a O 
mixture O 
of O 
Polycan O 
and O 
calcium B-SYSTEMATIC 
lactate I-SYSTEMATIC 
- I-SYSTEMATIC 
gluconate I-SYSTEMATIC 
1 O 
: O 
9 O 
( O 
w O 
/ O 
w O 
) O 
with O 
demonstrated O 
antiosteoporosis O 
activity O 
in O 
vitro O 
and O 
in O 
vivo O 
studies O 
. O 
These O 
studies O 
were O 
a O 
4-week O 
open O 
- O 
label O 
, O 
single O 
- O 
center O 
trial O 
to O 
evaluate O 
the O 
efficacy O 
of O 
oral O 
Polycalcium B-FAMILY 
on O 
bone O 
metabolism O 
and O 
safety O 
. O 
In O 
total O 
, O 
30 O 
healthy O 
women O 
( O 
range O 
40-60 O 
years O 
) O 
were O 
administered O 
400 O 
mg O 
of O 
Polycalcium B-FAMILY 
for O 
4 O 
weeks O 
. O 
The O 
primary O 
efficacy O 
parameter O 
was O 
urinary O 
deoxypyridinoline B-SYSTEMATIC 
( O 
DPYR B-ABBREVIATION 
) O 
levels O 
, O 
and O 
serum O 
osteocalcin O 
( O 
OSC O 
) O 
, O 
bone O 
- O 
specific O 
alkaline O 
phosphatase O 
( O 
BALP O 
) O 
, O 
urinary O 
cross O 
- O 
linked O 
C B-FORMULA 
-telopeptide O 
of O 
type-1 O 
collagen O 
( O 
CTx O 
) O 
, O 
urinary O 
cross O 
- O 
linked O 
N B-FORMULA 
-telopeptide O 
of O 
type-1 O 
collagen O 
( O 
NTx O 
) O 
, O 
calcium B-SYSTEMATIC 
( O 
Ca B-FORMULA 
) O 
, O 
and O 
phosphorus B-SYSTEMATIC 
( O 
P B-FORMULA 
) O 
levels O 
, O 
which O 
were O 
evaluated O 
for O 
comparison O 
before O 
and O 
after O 
administration O 
of O 
Polycalcium B-FAMILY 
. O 
After O 
4 O 
weeks O 
of O 
Polycalcium B-FAMILY 
administration O 
, O 
27 O 
subjects O 
completed O 
the O 
test O 
plan O 
. O 
Three O 
subjects O 
withdrew O 
their O 
consent O 
to O 
participate O 
. O 
The O 
values O 
of O 
blood O 
OSC O 
, O 
BALP O 
, O 
serum O 
Ca B-FORMULA 
, O 
and O 
serum O 
P B-FORMULA 
from O 
baseline O 
to O 
4 O 
weeks O 
of O 
treatment O 
were O 
changed O 
by O 
-28.44% O 
, O 
14.37% O 
, O 
6.11% O 
, O 
and O 
1.42% O 
, O 
respectively O 
. O 
Biomarkers O 
of O 
bone O 
resorption O 
: O 
urinary O 
DPYR B-ABBREVIATION 
, O 
serum O 
CTx O 
, O 
serum O 
NTx O 
, O 
urinary O 
Ca B-FORMULA 
, O 
and O 
urinary O 
P B-FORMULA 
, O 
at O 
baseline O 
after O 
4 O 
weeks O 
of O 
treatment O 
were O 
changed O 
by O 
-13.40% O 
, O 
6.67% O 
, O 
-5.13% O 
, O 
-22.43% O 
, O 
and O 
-3.04% O 
, O 
respectively O 
. O 
Additionally O 
, O 
when O 
considering O 
the O 
subjects O 
' O 
adverse O 
effects O 
and O 
the O 
results O 
of O 
the O 
blood O 
and O 
urine O 
tests O 
over O 
the O 
4-week O 
trial O 
period O 
, O 
the O 
dose O 
of O 
400 O 
mg O 
Polycalcium B-FAMILY 
showed O 
efficacy O 
for O 
improving O 
bone O 
metabolism O 
and O 
was O 
well O 
tolerated O 
and O 
safe O 
. O 
Polycalcium B-FAMILY 
was O 
apparently O 
safe O 
and O 
efficacious O 
. O 

and O 
gram O 
- O 
scale O 
synthesis O 
of O 
BMS-593214 B-IDENTIFIER 
, O 
a O 
potent O 
, O 
selective O 
FVIIa O 
inhibitor O 
. O 

6-amidinotetrahydroquinoline B-SYSTEMATIC 
screening O 
hit O 
was O 
driven O 
to O 
a O 
structurally O 
novel O 
, O 
potent O 
, O 
and O 
selective O 
FVIIa O 
inhibitor O 
through O 
a O 
combination O 
of O 
library O 
synthesis O 
and O 
rational O 
design O 
. O 
An O 
efficient O 
gram O 
- O 
scale O 
synthesis O 
of O 
the O 
active O 
enantiomer O 
BMS-593214 B-IDENTIFIER 
was O 
developed O 
, O 
which O 
required O 
significant O 
optimization O 
of O 
the O 
key O 
Povarov O 
annulation O 
. O 
Importantly O 
, O 
BMS-593214 B-IDENTIFIER 
showed O 
antithrombotic O 
efficacy O 
in O 
a O 
rabbit O 
arterial O 
thrombosis O 
model O 
. O 
A O 
crystal O 
structure O 
of O 
BMS-593214 B-IDENTIFIER 
bound O 
to O 
FVIIa O 
highlights O 
key O 
contacts O 
with O 
Asp B-FORMULA 
189 O 
, O 
Lys B-FORMULA 
192 O 
, O 
and O 
the O 
S2 O 
pocket O 
. O 

regulates O 
mTORC1 O 
activity O 
and O 
autophagy O 
through O 
controlling O 
the O 
degradation O 
of O 
amino-acid B-FAMILY 
transporter O 
PAT4 O 
. O 

is O 
an O 
evolutionarily O 
conserved O 
catabolic O 
mechanism O 
that O 
targets O 
intracellular O 
molecules O 
and O 
damaged O 
organelles O 
to O 
lysosomes O 
. O 
Autophagy O 
is O 
achieved O 
by O 
a O 
series O 
of O 
membrane O 
trafficking O 
events O 
, O 
but O 
their O 
regulatory O 
mechanisms O 
are O 
poorly O 
understood O 
. O 
Here O 
, O 
we O 
report O 
small O 
GTPase O 
Rab12 O 
as O 
a O 
new O 
type O 
of O 
autophagic O 
regulator O 
that O 
controls O 
the O 
degradation O 
of O 
an O 
amino-acid B-FAMILY 
transporter O 
. O 
Knockdown O 
of O 
Rab12 O 
results O 
in O 
inhibition O 
of O 
autophagy O 
and O 
in O 
increased O 
activity O 
of O 
mTORC1 O 
( O 
mammalian O 
/ O 
mechanistic O 
target O 
of O 
rapamycin B-TRIVIAL 
complex O 
1 O 
) O 
, O 
an O 
upstream O 
regulator O 
of O 
autophagy O 
. O 
We O 
also O 
found O 
that O 
Rab12 O 
promotes O 
constitutive O 
degradation O 
of O 
PAT4 O 
( O 
proton O 
- O 
coupled O 
amino-acid B-FAMILY 
transporter O 
4 O 
) O 
, O 
whose O 
accumulation O 
in O 
Rab12-knockdown O 
cells O 
modulates O 
mTORC1 O 
activity O 
and O 
autophagy O 
. O 
Our O 
findings O 
reveal O 
a O 
new O 
mechanism O 
of O 
regulation O 
of O 
mTORC1 O 
signalling O 
and O 
autophagy O 
, O 
that O 
is O 
, O 
quality O 
control O 
of O 
PAT4 O 
by O 
Rab12 O 
. O 

Reveals O 
a O 
Cysteine B-TRIVIAL 
-Dependent O 
Desensitization O 
Mechanism O 
of O 
TRPA1 O 
. O 

transient O 
receptor O 
potential O 
ankyrin O 
1 O 
( O 
TRPA1 O 
) O 
nonselective O 
cation O 
channel O 
has O 
a O 
conserved O 
function O 
as O 
a O 
noxious O 
chemical O 
sensor O 
throughout O 
much O 
of O 
Metazoa O 
. O 
Electrophilic O 
chemicals O 
activate O 
both O 
insect O 
and O 
vertebrate O 
TRPA1 O 
via O 
covalent O 
modification O 
of O 
cysteine B-TRIVIAL 
residues O 
in O 
the O 
amino B-FAMILY 
-terminal O 
region O 
. O 
Although O 
naturally O 
occurring O 
electrophilic O 
plant O 
compounds O 
, O 
such O 
as O 
mustard O 
oil O 
and O 
cinnamaldehyde B-TRIVIAL 
, O 
are O 
TRPA1 O 
agonists O 
, O 
it O 
is O 
unknown O 
whether O 
arthropod O 
- O 
produced O 
electrophiles O 
activate O 
mammalian O 
TRPA1 O 
. O 
We O 
characterized O 
the O 
effects O 
of O 
the O 
electrophilic O 
arthropod O 
defensive O 
compound O 
para-benzoquinone B-SYSTEMATIC 
( O 
pBQN B-ABBREVIATION 
) O 
on O 
the O 
human O 
TRPA1 O 
channel O 
. O 
We O 
used O 
whole O 
- O 
cell O 
recordings O 
of O 
human O 
embryonic O 
kidney O 
cells O 
heterologously O 
expressing O 
either O 
wild O 
- O 
type O 
TRPA1 O 
or O 
TRPA1 O 
with O 
three O 
serine B-TRIVIAL 
-substituted O 
cysteines B-FAMILY 
crucial O 
for O 
electrophile O 
activation O 
( O 
C621S O 
, O 
C641S O 
, O 
C665S O 
) O 
. O 
We O 
found O 
that O 
pBQN B-ABBREVIATION 
activates O 
TRPA1 O 
starting O 
at O 
10 O 
nM O 
and O 
peaking O 
at O 
300 O 
nM O 
; O 
higher O 
concentrations O 
caused O 
rapid O 
activation O 
followed O 
by O 
a O 
fast O 
decline O 
. O 
Activation O 
by O 
pBQN B-ABBREVIATION 
required O 
reactivity O 
with O 
cysteine B-TRIVIAL 
residues O 
, O 
but O 
ones O 
that O 
are O 
distinct O 
from O 
those O 
previously O 
reported O 
to O 
be O 
the O 
key O 
targets O 
of O 
electrophiles O 
. O 
The O 
current O 
reduction O 
we O 
found O 
at O 
higher O 
pBQN B-ABBREVIATION 
concentrations O 
was O 
a O 
cysteine O 
- O 
dependent O 
desensitization O 
of O 
TRPA1 O 
, O 
and O 
did O 
not O 
require O 
prior O 
activation O 
. O 
The O 
cysteines B-FAMILY 
required O 
for O 
desensitization O 
are O 
not O 
accessible O 
to O 
all O 
electrophiles O 
as O 
iodoacetamide B-SYSTEMATIC 
and O 
internally O 
applied O 
2-(trimethylammonium)ethyl B-SYSTEMATIC 
methanesulfonate I-SYSTEMATIC 
failed O 
to O 
cause O 
desensitization O 
( O 
despite O 
large O 
activation O 
) O 
. O 
Interestingly O 
, O 
following O 
pBQN B-ABBREVIATION 
desensitization O 
, O 
wild O 
- O 
type O 
TRPA1 O 
had O 
dramatically O 
reduced O 
response O 
to O 
the O 
nonelectrophile O 
agonist O 
carvacrol B-TRIVIAL 
, O 
whereas O 
the O 
triple O 
cysteine B-TRIVIAL 
mutant O 
TRPA1 O 
retained O 
its O 
full O 
response O 
. O 
Our O 
results O 
suggest O 
that O 
modification O 
of O 
multiple O 
cysteine B-TRIVIAL 
residues O 
by O 
electrophilic O 
compounds O 
can O 
generate O 
both O 
activation O 
and O 
desensitization O 
of O 
the O 
TRPA1 O 
channel O 
. O 

kinetics O 
and O 
inhibition O 
is O 
important O 
for O 
a O 
wide O 
range O 
of O 
disciplines O 
including O 
pharmacology O 
, O 
medicine O 
and O 
industrial O 
bioprocess O 
technology O 
. O 
We O 
present O 
a O 
novel O 
microdroplet O 
- O 
based O 
device O 
for O 
extensive O 
characterization O 
of O 
the O 
reaction O 
kinetics O 
of O 
enzyme O 
substrate O 
inhibitor O 
systems O 
in O 
a O 
single O 
experiment O 
utilizing O 
an O 
integrated O 
droplet O 
picoinjector O 
for O 
bioanalysis O 
. O 
This O 
device O 
enables O 
the O 
scanning O 
of O 
multiple O 
fluorescently O 
- O 
barcoded O 
inhibitor O 
concentrations O 
and O 
substrate O 
conditions O 
in O 
a O 
single O 
, O 
highly O 
time O 
- O 
resolved O 
experiment O 
yielding O 
the O 
Michaelis O 
constant O 
( O 
Km O 
) O 
, O 
the O 
turnover O 
number O 
( O 
kcat O 
) O 
and O 
the O 
enzyme O 
inhibitor O 
dissociation O 
constants O 
( O 
ki O 
, O 
ki O 
' O 
) O 
. O 
Using O 
this O 
device O 
we O 
determine O 
Km O 
and O 
kcat O 
for O 
β-galactosidase O 
and O 
the O 
fluorogenic O 
substrate O 
Resorufin B-SYSTEMATIC 
β-d-galactopyranoside I-SYSTEMATIC 
( O 
RBG B-ABBREVIATION 
) O 
to O 
be O 
442 O 
μM O 
and O 
1070 O 
s(-1) O 
, O 
respectively O 
. O 
Furthermore O 
, O 
we O 
examine O 
the O 
inhibitory O 
effects O 
of O 
isopropyl-β-d-thiogalactopyranoside B-SYSTEMATIC 
( O 
IPTG B-ABBREVIATION 
) O 
on O 
β-galactosidase O 
. O 
This O 
system O 
has O 
a O 
number O 
of O 
potential O 
applications O 
, O 
for O 
example O 
it O 
could O 
be O 
used O 
to O 
screen O 
inhibitors O 
to O 
pharmaceutically O 
relevant O 
enzymes O 
and O 
to O 
characterize O 
engineered O 
enzyme O 
variants O 
for O 
biofuels O 
production O 
, O 
in O 
both O 
cases O 
acquiring O 
detailed O 
information O 
about O 
the O 
enzyme O 
catalysis O 
and O 
enzyme O 
inhibitor O 
interaction O 
at O 
high O 
throughput O 
and O 
low O 
cost O 
. O 

study O 
of O 
parabens B-FAMILY 
and O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
in O 
surface O 
water O 
and O 
fish O 
brain O 
tissue O 
from O 
the O 
Greater O 
Pittsburgh O 
Area O 
. O 

from O 
xenoestrogens B-FAMILY 
has O 
been O 
discovered O 
in O 
the O 
aquatic O 
environment O 
of O 
the O 
Greater O 
Pittsburgh O 
Area O 
and O 
is O 
suspected O 
to O 
be O 
caused O 
by O 
the O 
failing O 
sewer O 
system O 
. O 
Personal O 
care O 
products O 
and O 
plasticizers O 
have O 
the O 
potential O 
to O 
enter O 
the O 
water O 
supply O 
though O 
treated O 
and O 
untreated O 
sewage O 
. O 
Many O 
of O 
these O 
compounds O 
are O 
suspected O 
xenoestrogens B-FAMILY 
. O 
Paraben B-FAMILY 
detection O 
in O 
surface O 
waters O 
was O 
as O 
follows O 
: O 
methyl B-SYSTEMATIC 
paraben I-SYSTEMATIC 
ranged O 
between O 
2.2 O 
to O 
17.3 O 
ppt O 
; O 
ethyl B-SYSTEMATIC 
paraben I-SYSTEMATIC 
was O 
not O 
detectable O 
; O 
propyl B-SYSTEMATIC 
paraben I-SYSTEMATIC 
was O 
detected O 
at O 
9.2 O 
and O 
12 O 
ppt O 
; O 
butyl B-SYSTEMATIC 
paraben I-SYSTEMATIC 
was O 
detected O 
at O 
0.2 O 
ppt O 
. O 
BPA B-ABBREVIATION 
was O 
detected O 
between O 
0.6 O 
and O 
15.4 O 
ppt O 
. O 
Estrogenic O 
potential O 
of O 
extracts O 
from O 
fish O 
brain O 
tissue O 
was O 
tested O 
via O 
Bromodeoxyuridine B-SYSTEMATIC 
MCF-7 O 
analysis O 
and O 
paired O 
with O 
HPLC-MS O 
to O 
investigate O 
the O 
presence O 
of O 
xenoestrogens B-FAMILY 
. O 
All O 
samples O 
were O 
non-detectable O 
for O 
parabens O 
. O 
BPA B-ABBREVIATION 
was O 
detected O 
in O 
44 O 
of O 
the O 
58 O 
samples O 
, O 
with O 
a O 
range O 
from O 
non-detectable O 
to O 
120 O 
pg O 
/ O 
g O 
. O 
BCFs O 
were O 
calculated O 
. O 
Results O 
were O 
statistically O 
significant O 
for O 
location O 
of O 
capture O 
( O 
p O 
< O 
0.05 O 
) O 
and O 
correlation O 
existed O 
between O 
estrogenicity O 
and O 
BPA B-ABBREVIATION 
. O 

induces O 
apoptosis O 
and O 
Rho O 
kinase O 
- O 
dependent O 
cell O 
blebbing O 
in O 
Jurkat O 
cells O 
. O 

sulfide I-SYSTEMATIC 
( O 
H2S B-FORMULA 
) O 
is O 
a O 
toxic O 
gaseous O 
substance O 
, O 
and O 
accidental O 
exposure O 
to O 
high O 
concentrations O 
of O 
H2S B-FORMULA 
has O 
been O 
reported O 
to O 
be O 
lethal O 
to O 
humans O 
. O 
Inhaled O 
and O 
absorbed O 
H2S B-FORMULA 
is O 
partially O 
dissolved O 
within O 
the O 
circulation O 
and O 
causes O 
toxic O 
effects O 
on O 
lymphocytes O 
. O 
However O 
, O 
the O 
mechanisms O 
involved O 
in O 
H2S B-FORMULA 
toxicity O 
have O 
not O 
been O 
well O 
documented O 
. O 
In O 
this O 
study O 
, O 
we O 
examined O 
the O 
cellular O 
uptake O 
and O 
injury O 
of O 
sulfide B-SYSTEMATIC 
-exposed O 
human O 
T O 
lymphocytes O 
( O 
Jurkat O 
) O 
. O 
Cells O 
were O 
exposed O 
to O 
a O 
H2S B-FORMULA 
donor O 
, O 
sodium B-SYSTEMATIC 
hydroxysulfide I-SYSTEMATIC 
( O 
NaHS B-FORMULA 
) O 
, O 
at O 
pH O 
6 O 
, O 
7 O 
, O 
or O 
8 O 
for O 
1 O 
h O 
at O 
37 O 
°C O 
in O 
a O 
sealed O 
conical O 
tube O 
to O 
avoid O 
the O 
loss O 
of O 
dissolved O 
H2S B-FORMULA 
gas O 
. O 
Cytotoxicity O 
and O 
cellular O 
sulfide B-SYSTEMATIC 
concentrations O 
increased O 
dramatically O 
as O 
the O 
pH O 
of O 
the O 
NaHS B-FORMULA 
solution O 
decreased O 
. O 
Sulfide B-SYSTEMATIC 
enhanced O 
the O 
cleavage O 
of O 
caspase-3 O 
and O 
poly B-SYSTEMATIC 
( I-SYSTEMATIC 
ADP-ribose I-SYSTEMATIC 
) I-SYSTEMATIC 
polymerase O 
and O 
induced O 
early O 
cellular O 
apoptosis O 
. O 
A O 
pan O 
- O 
caspase O 
inhibitor O 
reduced O 
sulfide B-SYSTEMATIC 
-induced O 
apoptosis O 
. O 
These O 
results O 
indicate O 
that O 
sulfide B-SYSTEMATIC 
induces O 
pH-dependent O 
and O 
caspase O 
- O 
dependent O 
apoptosis O 
. O 
We O 
also O 
found O 
that O 
blebbing O 
of O 
the O 
plasma O 
membrane O 
occurred O 
in O 
sulfide B-SYSTEMATIC 
-exposed O 
cells O 
. O 
Both O 
ROCK-1 O 
and O 
ROCK-2 O 
( O 
Rho O 
kinases O 
) O 
were O 
activated O 
by O 
sulfide B-SYSTEMATIC 
, O 
and O 
sulfide B-SYSTEMATIC 
-induced O 
cell O 
blebbing O 
was O 
suppressed O 
by O 
a O 
ROCK O 
inhibitor O 
, O 
suggesting O 
that O 
a O 
Rho O 
pathway O 
is O 
involved O 
in O 
sulfide B-SYSTEMATIC 
-induced O 
blebbing O 
in O 
lymphocytes O 
. O 

Between O 
Lipids O 
, O 
Lipoproteins O 
Composition O 
of O 
HDL O 
Particles O 
and O 
Triglyceride B-FAMILY 
-Rich O 
Lipoproteins O 
, O 
and O 
LCAT O 
and O 
CETP O 
Activity O 
in O 
Post O 
- O 
renal O 
Transplant O 
Patients O 
. O 

- O 
density O 
lipoprotein O 
( O 
HDL O 
) O 
remodeling O 
within O 
the O 
plasma O 
compartment O 
and O 
the O 
association O 
between O 
lecithin- O 
cholesterol B-TRIVIAL 
acyltransferase O 
( O 
LCAT O 
) O 
and O 
cholesterol B-FAMILY 
ester I-FAMILY 
transfer O 
protein O 
( O 
CETP O 
) O 
activity O 
, O 
and O 
lipid O 
, O 
lipoprotein O 
concentrations O 
and O 
composition O 
were O 
investigated O 
. O 
The O 
aim O 
was O 
to O 
examine O 
the O 
high O 
sensitivity O 
of O 
C-reactive O 
protein O 
( O 
hsCRP O 
) O 
, O 
lipid O 
, O 
apolipoprotein O 
B O 
( O 
apoB O 
) O 
, O 
apoAI O 
, O 
total O 
apoAII O 
, O 
apoAIInonB O 
, O 
apoB O 
- O 
containing O 
apoAII O 
( O 
apoB O 
: O 
AII O 
) O 
, O 
total O 
apoCIII O 
, O 
apoCIIInonB O 
, O 
apoB O 
- O 
containing O 
apoCIII O 
( O 
apoB O 
: O 
CIII O 
) O 
concentration O 
and O 
LCAT O 
and O 
CETP O 
activity O 
to O 
gain O 
an O 
insight O 
into O 
the O 
association O 
between O 
them O 
and O 
LCAT O 
and O 
CETP O 
, O 
57 O 
post O 
- O 
renal O 
transplant O 
( O 
Tx O 
) O 
patients O 
with O 
and O 
without O 
statin O 
therapy O 
and O 
in O 
15 O 
healthy O 
subjects O 
. O 
Tx O 
patients O 
had O 
moderate O 
hypertriglyceridemia O 
, O 
hypercholesterolemia O 
, O 
and O 
dyslipoproteinemia O 
, O 
disturbed O 
triglyceride B-FAMILY 
-rich O 
lipoproteins O 
( O 
TRLs O 
) O 
and O 
HDL O 
composition O 
, O 
decreased O 
LCAT O 
, O 
and O 
slightly O 
increased O 
hsCRP O 
but O 
no O 
CETP O 
activity O 
. O 
Spearman's O 
correlation O 
test O 
showed O 
the O 
association O 
between O 
lipids O 
and O 
lipoproteins O 
and O 
LCAT O 
or O 
CETP O 
, O 
and O 
multiple O 
ridge O 
stepwise O 
forward O 
regression O 
showed O 
that O 
immunosuppressive O 
therapy O 
in O 
Tx O 
patients O 
can O 
disturb O 
HDL O 
and O 
TRLs O 
composition O 
. O 
The O 
results O 
suggest O 
that O 
inhibition O 
or O 
activation O 
of O 
LCAT O 
is O 
due O 
, O 
in O 
part O 
, O 
to O 
HDL-associated O 
lipoprotein O 
. O 
Lipoprotein O 
composition O 
of O 
apoAI O 
, O 
apoAIInonB O 
, O 
and O 
apoCIIInonB O 
in O 
HDL O 
particle O 
and O 
apoB O 
: O 
AII O 
TRLs O 
can O 
contribute O 
to O 
decrease O 
LCAT O 
mass O 
in O 
Tx O 
patients O 
. O 
Tx O 
patients O 
without O 
statin B-FAMILY 
and O 
with O 
lower O 
triglycerides B-FAMILY 
but O 
higher O 
HDL O 
cholesterol B-TRIVIAL 
concentration O 
and O 
disturbed O 
lipoprotein O 
composition O 
of O 
ApoAI O 
and O 
apoAII O 
in O 
HDL O 
particle O 
can O 
decrease O 
LCAT O 
, O 
increase O 
LDL O 
cholesterol B-TRIVIAL 
, O 
aggravate O 
renal O 
graft O 
, O 
and O 
accelerate O 
atherosclerosis O 
and O 
chronic O 
heart O 
diseases O 
. O 

mitochondriotropic O 
derivatives O 
antagonize O 
nitrate B-SYSTEMATIC 
tolerance O 
and O 
endothelial O 
dysfunction O 
of O 
isolated O 
rat O 
aorta O 
rings O 
. O 

use O 
of O 
glyceryl B-SYSTEMATIC 
trinitrate I-SYSTEMATIC 
is O 
limited O 
by O 
serious O 
side O 
effects O 
, O 
inter O 
alia O 
tolerance O 
and O 
endothelial O 
dysfunction O 
of O 
coronary O 
and O 
resistance O 
arteries O 
. O 
The O 
natural O 
flavonoid O 
quercetin B-TRIVIAL 
has O 
been O 
shown O 
to O 
counteract O 
the O 
development O 
of O 
glyceryl B-SYSTEMATIC 
trinitrate I-SYSTEMATIC 
tolerance O 
in O 
vitro O 
. O 
Two O 
mitochondriotropic O 
, O 
4-O-triphenylphosphoniumbutyl B-SYSTEMATIC 
derivatives O 
of O 
quercetin B-TRIVIAL 
( O 
QTA-3BTPI B-SYSTEMATIC 
and O 
Q-3BTPI B-SYSTEMATIC 
) O 
were O 
compared O 
to O 
quercetin B-TRIVIAL 
for O 
protection O 
against O 
glyceryl B-SYSTEMATIC 
trinitrate I-SYSTEMATIC 
-induced O 
tolerance O 
and O 
endothelial O 
dysfunction O 
of O 
isolated O 
rat O 
aorta O 
rings O 
. O 
Both O 
QTA-3BTPI B-SYSTEMATIC 
and O 
Q-3BTPI B-SYSTEMATIC 
significantly O 
counteracted O 
the O 
reduced O 
vascular O 
responsiveness O 
to O 
both O 
glyceryl B-SYSTEMATIC 
trinitrate I-SYSTEMATIC 
and O 
acetylcholine B-SYSTEMATIC 
caused O 
by O 
prolonged O 
exposure O 
of O 
the O 
vessel O 
to O 
glyceryl B-SYSTEMATIC 
trinitrate I-SYSTEMATIC 
itself O 
, O 
their O 
potency O 
being O 
much O 
greater O 
than O 
that O 
of O 
quercetin B-TRIVIAL 
. O 
QTA-3BTPI B-SYSTEMATIC 
, O 
however O 
, O 
turned O 
out O 
to O 
cause O 
endothelial O 
dysfunction O 
per O 
se O 
. O 
Since O 
Q-3BTPI B-SYSTEMATIC 
antagonized O 
in O 
vitro O 
nitrate B-SYSTEMATIC 
tolerance O 
and O 
endothelial O 
dysfunction O 
of O 
vessels O 
, O 
this O 
encourages O 
assessing O 
whether O 
this O 
effect O 
is O 
displayed O 
also O 
in O 
vivo O 
during O 
long O 
- O 
term O 
glyceryl B-SYSTEMATIC 
trinitrate I-SYSTEMATIC 
treatment O 
. O 

pentacyclic B-FAMILY 
triterpenoids I-FAMILY 
from O 
Prinsepia O 
utilis O 
. O 

investigation O 
of O 
the O 
aerial O 
parts O 
of O 
Prinsepia O 
utilis O 
Royle O 
resulted O 
in O 
the O 
isolation O 
and O 
identification O 
of O 
ten O 
pentacyclic B-FAMILY 
triterpenoids I-FAMILY 
, O 
including O 
two O 
new O 
triterpenoids B-FAMILY 
, O 
2α-O-trans-p-coumaroyl-3β,19α-dihydroxy-urs-12-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
1 O 
) O 
and O 
2α-O-cis-p-coumaroyl-3β,19α-dihydroxy-urs-12-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
along O 
with O 
eight O 
known O 
pentacyclic B-FAMILY 
triterpenoids I-FAMILY 
( O 
3-10 O 
) O 
. O 
The O 
structures O 
were O 
elucidated O 
by O 
extensive O 
spectroscopic O 
methods O 
and O 
by O 
comparison O 
to O 
previously O 
reported O 
spectroscopic O 
data O 
. O 
Most O 
of O 
these O 
compounds O 
showed O 
significant O 
cytotoxic O 
activities O 
against O 
four O 
human O 
cancer O 
cell O 
lines O 
( O 
A549 O 
, O 
HCT116 O 
, O 
MDA-MB-231 O 
, O 
and O 
CCRF-CEM O 
) O 
, O 
and O 
the O 
structure O 
- O 
activity O 
relationships O 
are O 
also O 
discussed O 
. O 

constitute O 
an O 
attractive O 
research O 
topic O 
due O 
to O 
their O 
estrogenic O 
profile O 
and O 
their O 
biological O 
involvement O 
in O 
woman's O 
health O 
. O 
Therefore O 
, O 
numerous O 
studies O 
are O 
currently O 
performed O 
in O 
natural O 
products O 
chemistry O 
area O 
aiming O 
at O 
the O 
discovery O 
of O 
novel O 
phytoestrogens O 
. O 
The O 
main O 
classes O 
of O 
phytoestrogens O 
are O 
flavonoids B-FAMILY 
( O 
flavonols B-FAMILY 
, O 
flavanones B-FAMILY 
) O 
, O 
isoflavonoids B-FAMILY 
( O 
isoflavones B-FAMILY 
, O 
coumestans B-FAMILY 
) O 
, O 
lignans B-FAMILY 
, O 
stilbenoids B-FAMILY 
as O 
well O 
as O 
miscellaneous O 
chemical O 
groups O 
abundant O 
in O 
several O 
edible O 
and O 
/ O 
or O 
medicinal O 
plants O 
, O 
belonging O 
mostly O 
to O 
the O 
Leguminosae O 
family O 
. O 
As O 
for O 
other O 
bioactives O 
, O 
the O 
detection O 
of O 
new O 
structures O 
and O 
more O 
potent O 
plant O 
- O 
derived O 
phytoestrogens O 
typically O 
follows O 
the O 
general O 
approaches O 
currently O 
available O 
in O 
the O 
natural O 
product O 
discovery O 
process O 
. O 
Plant O 
- O 
based O 
approaches O 
selected O 
from O 
traditional O 
medicine O 
knowledge O 
and O 
bioguided O 
concepts O 
are O 
routinely O 
employed O 
. O 
However O 
, O 
these O 
approaches O 
are O 
associated O 
with O 
serious O 
disadvantages O 
such O 
as O 
time O 
- O 
consuming O 
, O 
repeated O 
, O 
and O 
labor O 
intensive O 
processes O 
as O 
well O 
as O 
lack O 
of O 
specificity O 
and O 
reproducibility O 
. O 
In O 
recent O 
years O 
, O 
the O 
natural O 
products O 
chemistry O 
became O 
more O 
technology O 
- O 
driven O 
, O 
and O 
several O 
different O 
strategies O 
have O 
been O 
developed O 
. O 
Structure O 
- O 
oriented O 
procedures O 
and O 
miniaturized O 
approaches O 
employing O 
advanced O 
hyphenated O 
analytical O 
platforms O 
have O 
recently O 
emerged O 
. O 
They O 
facilitate O 
significantly O 
not O 
only O 
the O 
discovery O 
of O 
novel O 
phytoestrogens O 
but O 
also O 
the O 
dereplication O 
procedure O 
leading O 
to O 
the O 
anticipation O 
of O 
major O 
drawbacks O 
in O 
natural O 
products O 
discovery O 
. O 
In O 
this O 
review O 
, O 
apart O 
from O 
the O 
traditional O 
concepts O 
followed O 
in O 
phytochemistry O 
for O 
the O 
discovery O 
of O 
novel O 
biologically O 
active O 
compounds O 
, O 
recent O 
applications O 
in O 
the O 
field O 
of O 
extraction O 
, O 
analysis O 
, O 
fractionation O 
, O 
and O 
identification O 
of O 
phytoestrogens O 
will O 
be O 
discussed O 
. O 
Moreover O 
, O 
specific O 
methodologies O 
combining O 
identification O 
of O 
actives O 
and O 
biological O 
evaluation O 
in O 
parallel O 
, O 
such O 
as O 
liquid O 
chromatography O 
- O 
biochemical O 
detection O 
, O 
frontal O 
affinity O 
chromatography O 
- O 
mass O 
spectrometry O 
and O 
pulsed O 
ultrafiltration-MS O 
will O 
also O 
be O 
presented O 
. O 
Finally O 
, O 
miniaturized O 
methods O 
( O 
microchip O 
and O 
biosensor O 
) O 
will O 
be O 
also O 
discussed.With O 
the O 
current O 
review O 
, O 
we O 
attempt O 
to O 
give O 
a O 
wide O 
and O 
holistic O 
overview O 
of O 
the O 
different O 
approaches O 
which O 
could O 
be O 
employed O 
in O 
the O 
discovery O 
of O 
new O 
phytoestrogens O 
. O 
On O 
the O 
other O 
hand O 
, O 
we O 
anticipate O 
to O 
attract O 
more O 
scientists O 
to O 
the O 
area O 
of O 
phytoestrogens O 
and O 
to O 
indicate O 
the O 
need O 
of O 
multidisciplinary O 
concepts O 
. O 

Units O 
Important O 
for O 
Activity O 
of O 
a O 
Novel O 
- O 
type O 
Phosphoserine B-SYSTEMATIC 
Phosphatase O 
from O 
Hydrogenobacter O 
thermophilus O 
TK-6 O 
Revealed O 
by O 
Crystal O 
Structure O 
Analysis O 
. O 

- O 
type O 
serine B-TRIVIAL 
-synthesizing O 
enzymes O 
, O 
termed O 
metal O 
- O 
independent O 
phosphoserine B-SYSTEMATIC 
phosphatases O 
( O 
iPSPs O 
) O 
, O 
were O 
recently O 
identified O 
and O 
characterized O 
from O 
Hydrogenobacter O 
thermophilus O 
, O 
a O 
chemolithoautotrophic O 
bacterium O 
belonging O 
to O 
the O 
order O 
Aquificales O 
. O 
iPSPs O 
are O 
cofactor O 
- O 
dependent O 
phosphoglycerate B-SYSTEMATIC 
mutase O 
( O 
dPGM O 
) O 
- O 
like O 
phosphatases O 
that O 
have O 
significant O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
similarity O 
to O 
dPGMs O 
but O 
lack O 
phosphoglycerate B-SYSTEMATIC 
mutase O 
activity O 
. O 
Genes O 
coding O 
dPGM O 
- O 
like O 
phosphatases O 
have O 
been O 
identified O 
in O 
a O 
broad O 
range O 
of O 
organisms O 
; O 
however O 
, O 
predicting O 
the O 
function O 
of O 
the O 
corresponding O 
proteins O 
based O 
on O 
sequence O 
information O 
alone O 
is O 
difficult O 
due O 
to O 
their O 
diverse O 
substrate O 
preferences O 
. O 
Here O 
, O 
we O 
determined O 
the O 
crystal O 
structure O 
of O 
iPSP1 O 
from O 
H O 
. O 
thermophilus O 
in O 
the O 
apo O 
- O 
form O 
and O 
in O 
complex O 
with O 
its O 
substrate O 
l-phosphoserine B-SYSTEMATIC 
to O 
find O 
structural O 
units O 
important O 
for O 
its O 
phosphatase O 
activity O 
toward O 
l-phosphoserine B-SYSTEMATIC 
. O 
Structural O 
and O 
biochemical O 
characterization O 
of O 
iPSP1 O 
revealed O 
that O 
the O 
side O 
chains O 
of O 
His B-FORMULA 
( O 
85 O 
) O 
and O 
C B-FORMULA 
-terminal O 
region O 
characteristic O 
of O 
iPSP1 O 
are O 
responsible O 
for O 
the O 
PSP O 
activity O 
. O 
The O 
importance O 
of O 
these O 
structural O 
units O 
for O 
PSP O 
activity O 
was O 
confirmed O 
by O 
high O 
PSP O 
activity O 
observed O 
in O 
two O 
novel O 
dPGM O 
- O 
like O 
proteins O 
from O 
Cyanobacteria O 
and O 
Chloroflexus O 
in O 
which O 
the O 
two O 
structural O 
units O 
were O 
conserved O 
. O 
We O 
anticipate O 
that O 
our O 
present O 
findings O 
will O 
facilitate O 
understanding O 
of O 
the O 
serine B-TRIVIAL 
biosynthesis O 
pathways O 
of O 
organisms O 
that O 
lack O 
gene(s) O 
encoding O 
conventional O 
PSPs O 
, O 
as O 
the O 
structural O 
information O 
revealed O 
here O 
will O 
help O 
to O 
identify O 
iPSP O 
from O 
sequence O 
databases O 
. O 

as O 
Potent O 
and O 
Selective O 
Ligands O 
for O 
A1 O 
Adenosine B-TRIVIAL 
Receptors O 
. O 

series O 
of O 
N-[9-(ortho-fluorobenzyl)-2-phenyl-8-azapurin-6-yl]-amides B-FAMILY 
were O 
synthesised O 
and O 
tested O 
for O 
their O 
affinity O 
toward O 
A1 O 
, O 
A2A O 
and O 
A3 O 
adenosine B-TRIVIAL 
receptor O 
subtypes O 
. O 
Biological O 
results O 
demonstrated O 
that O 
the O 
introduction O 
of O 
a O 
fluorine B-SYSTEMATIC 
atom O 
at O 
the O 
ortho O 
position O 
of O 
the O 
9-benzyl B-SYSTEMATIC 
group O 
generally O 
enhanced O 
affinity O 
toward O 
A1 O 
subtype O 
and O 
did O 
not O 
significantly O 
affect O 
A2A O 
and O 
A3 O 
affinity O 
. O 
Very O 
interesting O 
is O 
the O 
compound O 
bearing O 
a O 
meta-fluorophenyl B-SYSTEMATIC 
substituent O 
on O 
the O 
carbonyl B-SYSTEMATIC 
carbon I-SYSTEMATIC 
of O 
the O 
amide B-FAMILY 
group O 
, O 
which O 
shows O 
significantly O 
high O 
A1 O 
/ O 
A2A O 
-A3 O 
selectivity O 
. O 
Compounds O 
of O 
this O 
new O 
series O 
, O 
together O 
with O 
the O 
previously O 
published O 
analogs O 
without O 
the O 
fluorine B-SYSTEMATIC 
atom O 
on O 
the O 
9-benzyl B-SYSTEMATIC 
group O 
, O 
constituted O 
the O 
starting O 
dataset O 
for O 
the O 
development O 
of O 
QSAR O 
models O 
. O 
The O 
models O 
obtained O 
were O 
able O 
to O 
rationally O 
describe O 
the O 
affinity O 
trends O 
resulting O 
from O 
biological O 
testing O 
, O 
and O 
to O 
enable O 
investigation O 
of O 
the O 
role O 
of O 
different O 
substituents O 
on O 
the O 
8-azapurine B-SYSTEMATIC 
scaffold O 
, O 
as O 
well O 
as O 
the O 
influence O 
of O 
the O 
newly O 
introduced O 
fluorine B-SYSTEMATIC 
atom O 
on O 
the O 
benzyl B-SYSTEMATIC 
moiety O 
. O 
The O 
said O 
QSAR O 
models O 
can O 
also O 
assist O 
in O 
the O 
design O 
of O 
new O 
compounds O 
selectively O 
active O 
on O 
A1 O 
adenosine B-TRIVIAL 
receptors O 
. O 
Furthermore O 
, O 
a O 
molecular O 
docking O 
study O 
was O 
carried O 
out O 
in O 
order O 
to O 
assess O 
hypothetical O 
binding O 
mode O 
of O 
N-[9-(ortho-fluorobenzyl)-2-phenyl-8-azapurin-6-yl]-amides B-FAMILY 
to O 
A1 O 
adenosine B-TRIVIAL 
receptors O 
. O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
A O 
/ O 
S O 
. O 

Properties O 
and O 
Supernucleophilicity O 
of O 
Oxime B-SYSTEMATIC 
-Functionalized O 
Surfactants O 
: O 
Hydrolytic O 
Catalysts O 
toward O 
Dephosphorylation O 
of O 
Di- B-MULTIPLE 
and I-MULTIPLE 
Triphosphate I-MULTIPLE 
Esters I-MULTIPLE 
. O 

and O 
kinetic O 
studies O 
have O 
been O 
performed O 
to O 
understand O 
the O 
hydrolytic O 
potencies O 
of O 
the O 
series O 
of O 
oxime B-SYSTEMATIC 
-functionalized O 
surfactants O 
, O 
viz O 
. O 
, O 
3- B-FAMILY 
hydroxyiminomethyl-1-alkylpyridinium I-FAMILY 
bromide I-FAMILY 
( O 
alkyl B-FAMILY 
= O 
CnH2n B-FAMILY 
+ I-FAMILY 
1 I-FAMILY 
, O 
n O 
= O 
10 O 
, O 
12 O 
, O 
14 O 
, O 
16 O 
, O 
18 O 
) O 
in O 
the O 
cleavage O 
of O 
phosphate B-FAMILY 
esters I-FAMILY 
, O 
p-nitrophenyl B-SYSTEMATIC 
diphenyl I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
( O 
PNPDPP B-ABBREVIATION 
) O 
and O 
bis(2,4-dinitrophenyl) B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
( O 
BNDPP B-ABBREVIATION 
) O 
, O 
in O 
mixed O 
micelles O 
with O 
cetylpyridinium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
CPB B-ABBREVIATION 
) O 
. O 
Micellization O 
and O 
surface O 
properties O 
of O 
mixed O 
micelles O 
functional O 
surfactants O 
with O 
CPB B-ABBREVIATION 
were O 
studied O 
by O 
conductivity O 
and O 
surface O 
tension O 
measurements O 
. O 
Acid O 
dissociation O 
constants O 
( O 
pKa O 
) O 
were O 
determined O 
, O 
the O 
effect O 
of O 
functional O 
surfactant O 
alkyl B-FAMILY 
chain O 
length O 
and O 
pH O 
on O 
the O 
observed O 
rate O 
constant O 
( O 
kobs O 
) O 
for O 
phosphate B-SYSTEMATIC 
ester I-SYSTEMATIC 
cleavage O 
has O 
been O 
discussed O 
, O 
and O 
the O 
effect O 
of O 
substrate O 
on O 
the O 
supernucleophilicities O 
of O 
the O 
studied O 
oximes B-FAMILY 
was O 
monitored O 
. O 
Functionalized O 
oxime B-SYSTEMATIC 
-based O 
surfactants O 
were O 
proved O 
to O 
be O 
supernucleophiles O 
to O 
attack O 
on O 
the O 
P═O B-FORMULA 
center O 
of O 
tri- B-MULTIPLE 
and I-MULTIPLE 
diphosphate I-MULTIPLE 
esters I-MULTIPLE 
. O 
Oximes B-FAMILY 
with O 
hexadecyl B-SYSTEMATIC 
alkyl B-FAMILY 
chain O 
length O 
( O 
3-C16 B-MULTIPLE 
) O 
showed O 
maximum O 
micellar O 
effect O 
on O 
the O 
rate O 
constants O 
toward O 
PNPDPP B-ABBREVIATION 
. O 
Micellar O 
effects O 
were O 
analyzed O 
in O 
terms O 
of O 
the O 
pseudophase O 
model O 
. O 

concise O 
total O 
synthesis O 
of O 
the O 
natural O 
carbazole B-SYSTEMATIC 
clauraila O 
A O 
. O 

short O 
and O 
efficient O 
total O 
synthesis O 
of O 
naturally O 
occurring O 
carbazole B-SYSTEMATIC 
clauraila B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
is O 
described O 
. O 
The O 
approach O 
is O 
designed O 
on O 
the O 
basis O 
of O 
the O 
key O 
regioselective O 
Diels-Alder O 
reaction O 
of O 
the O 
properly O 
substituted O 
exo-2-oxazolidinone B-SYSTEMATIC 
diene I-SYSTEMATIC 
3 O 
with O 
acrolein B-TRIVIAL 
( O 
4 O 
) O 
to O 
give O 
the O 
corresponding O 
adduct O 
2 O 
. O 
The O 
latter O 
is O 
converted O 
to O 
functionalised O 
diarylamine B-FAMILY 
8 O 
, O 
which O 
is O 
cyclised O 
to O 
the O 
desired O 
carbazole B-SYSTEMATIC 
1 O 
through O 
a O 
Pd B-FORMULA 
-promoted O 
or O 
-catalysed O 
double O 
C-H B-FORMULA 
bond O 
activation O 
process O 
in O 
a O 
fairly O 
good O 
overall O 
yield O 
. O 

fatty B-FAMILY 
acid I-FAMILY 
binding O 
protein-4 O 
and O 
retinol B-TRIVIAL 
binding O 
protein-4 O 
in O 
polycystic O 
ovary O 
syndrome O 
: O 
response O 
to O 
simvastatin B-TRIVIAL 
and O 
metformin B-TRIVIAL 
therapies O 
. O 

Free O 
fatty B-FAMILY 
acid I-FAMILY 
binding O 
protein-4 O 
( O 
FABP4 O 
) O 
and O 
retinol B-TRIVIAL 
binding O 
protein-4 O 
( O 
RBP4 O 
) O 
contribute O 
to O 
metabolic O 
syndrome O 
. O 
We O 
investigated O 
serum O 
FABP4 O 
and O 
RBP4 O 
responses O 
to O 
insulin O 
sensitizing O 
and O 
lipid O 
lowering O 
therapies O 
in O 
polycystic O 
ovary O 
syndrome O 
( O 
PCOS O 
) O 
. O 
Sixty O 
- O 
two O 
healthy O 
, O 
untreated O 
women O 
with O 
PCOS O 
( O 
age O 
25.1 O 
± O 
3.6 O 
years O 
, O 
BMI O 
: O 
24 O 
± O 
4.7 O 
kg O 
/ O 
m(2) O 
) O 
were O 
randomized O 
to O 
metformin B-TRIVIAL 
( O 
n O 
= O 
24 O 
) O 
, O 
simvastatin B-TRIVIAL 
( O 
n O 
= O 
20 O 
) O 
or O 
metformin B-TRIVIAL 
plus O 
simvastatin B-TRIVIAL 
( O 
n O 
= O 
18 O 
) O 
for O 
3 O 
months O 
. O 
Anthropometric O 
measures O 
, O 
fasting O 
blood O 
tests O 
and O 
oral O 
glucose B-TRIVIAL 
tolerance O 
tests O 
( O 
OGTT O 
) O 
were O 
obtained O 
at O 
the O 
baseline O 
and O 
the O 
end O 
. O 
At O 
the O 
baseline O 
serum O 
FABP4 O 
correlated O 
with O 
obesity O 
( O 
BMI O 
: O 
r O 
= O 
0.63 O 
, O 
p O 
< O 
0.001 O 
) O 
, O 
insulin O 
resistance O 
( O 
fasting O 
insulin O 
: O 
r O 
= O 
0.44 O 
, O 
p O 
= O 
0.0002 O 
; O 
QUICKI O 
: O 
r O 
= O 
-0.3 O 
, O 
p O 
= O 
0.02 O 
; O 
OGTT-insulin O 
sensitivity O 
index O 
: O 
r O 
= O 
-0.27 O 
, O 
p O 
= O 
0.04 O 
) O 
, O 
dyslipidemia O 
( O 
HDL O 
: O 
r O 
= O 
-0.26 O 
, O 
p O 
= O 
0.03 O 
) O 
and O 
hyperandrogenemia O 
( O 
free O 
- O 
testosterone O 
: O 
r O 
= O 
0.23 O 
, O 
p O 
= O 
0.03 O 
; O 
SHBG O 
: O 
r O 
= O 
-0.28 O 
, O 
p O 
= O 
0.03 O 
) O 
; O 
while O 
RBP4 O 
correlated O 
with O 
total- O 
cholesterol B-TRIVIAL 
( O 
r O 
= O 
0.33 O 
, O 
p O 
= O 
0.009 O 
) O 
. O 
Multiple O 
regression O 
analysis O 
indicated O 
that O 
t O 
best O 
predictors O 
of O 
serum O 
FABP4 O 
and O 
RBP4 O 
were O 
BMI O 
( O 
β O 
= O 
1.02 O 
, O 
p O 
= O 
0.0003 O 
) O 
and O 
total O 
cholesterol B-TRIVIAL 
( O 
β O 
= O 
2326 O 
, O 
p O 
= O 
0.01 O 
) O 
, O 
respectively O 
. O 
Simvastatin B-TRIVIAL 
, O 
alone O 
or O 
with O 
metformin B-TRIVIAL 
did O 
not O 
affect O 
serum O 
FABP4 O 
or O 
RBP4 O 
. O 
Serum O 
FABP4 O 
related O 
to O 
the O 
obesity O 
, O 
insulin O 
resistance O 
and O 
inflammation O 
while O 
RBP4 O 
related O 
to O 
lipids O 
. O 
Insulin O 
sensitizing O 
and O 
lipid O 
lowering O 
therapies O 
did O 
not O 
affect O 
FABP4 O 
or O 
RBP4 O 
levels O 
in O 
PCOS O 
. O 

Conformations O 
of O 
a O 
Membrane O 
Supported O 
Zinc B-SYSTEMATIC 
Porphyrin I-SYSTEMATIC 
Tweezer O 
by O 
2D O 
Fluorescence O 
Spectroscopy O 
. O 

studied O 
the O 
equilibrium O 
conformations O 
of O 
a O 
zinc B-SYSTEMATIC 
porphyrin I-SYSTEMATIC 
tweezer O 
composed O 
of O 
two O 
carboxylphenyl B-SYSTEMATIC 
-functionalized O 
zinc B-SYSTEMATIC 
tetraphenyl I-SYSTEMATIC 
porphyrin I-SYSTEMATIC 
subunits O 
connected O 
by O 
a O 
1,4-butyndiol B-SYSTEMATIC 
spacer O 
, O 
which O 
was O 
suspended O 
inside O 
the O 
amphiphilic O 
regions O 
of O 
1,2-distearoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
( O 
DSPC B-ABBREVIATION 
) O 
liposomes O 
. O 
By O 
combining O 
phase O 
- O 
modulation O 
two O 
- O 
dimensional O 
fluorescence O 
spectroscopy O 
( O 
2D O 
FS O 
) O 
with O 
linear O 
absorbance O 
and O 
fluorimetry O 
, O 
we O 
determined O 
that O 
the O 
zinc B-SYSTEMATIC 
porphyrin I-SYSTEMATIC 
tweezer O 
adopts O 
a O 
mixture O 
of O 
folded O 
and O 
extended O 
conformations O 
in O 
the O 
membrane O 
. O 
By O 
fitting O 
an O 
exciton O 
- O 
coupling O 
model O 
to O 
a O 
series O 
of O 
data O 
sets O 
recorded O 
over O 
a O 
range O 
of O 
temperatures O 
( O 
17-85 O 
°C O 
) O 
and O 
at O 
different O 
laser O 
center O 
wavelengths O 
, O 
we O 
determined O 
that O 
the O 
folded O 
form O 
of O 
the O 
tweezer O 
is O 
stabilized O 
by O 
a O 
favorable O 
change O 
in O 
the O 
entropy O 
of O 
the O 
local O 
membrane O 
environment O 
. O 
Our O 
results O 
provide O 
insights O 
toward O 
understanding O 
the O 
balance O 
of O 
thermodynamic O 
factors O 
that O 
govern O 
molecular O 
assembly O 
in O 
membranes O 
. O 

MRI O 
labeling O 
of O 
endothelial O 
progenitor O 
cells O 
: O 
Design O 
of O 
thiolated O 
surface O 
stabilized O 
superparamagnetic O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
design O 
thiolated O 
surface O 
stabilized O 
superparamagnetic O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
( O 
TSS-SPIONs O 
) O 
for O 
efficient O 
internalization O 
with O 
high O 
MRI O 
sensitivity O 
. O 
TSS-SPIONs O 
were O 
developed O 
by O 
chelation O 
between O 
thiolated O 
chitosan- O 
thioglycolic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
chitosan- O 
TGA B-ABBREVIATION 
) O 
hydrogel O 
and O 
iron B-SYSTEMATIC 
ions O 
( O 
Fe(2+) B-FORMULA 
/ O 
Fe(3+) B-FORMULA 
) O 
. O 
Likely O 
, O 
unmodified O 
chitosan O 
hydrogel O 
SPIONs O 
( O 
UC-SPIONs O 
) O 
and O 
uncoated O 
SPIONs O 
were O 
used O 
as O 
control O 
. O 
Moreover O 
, O 
TSS-SPIONs O 
were O 
investigated O 
regarding O 
to O 
their O 
iron B-SYSTEMATIC 
core O 
size O 
, O 
hydrodynamic O 
diameter O 
, O 
zeta O 
potential O 
, O 
iron B-SYSTEMATIC 
contents O 
, O 
molar O 
relaxivities O 
( O 
r1 O 
and O 
r2 O 
) O 
, O 
and O 
cellular O 
internalization O 
. O 
TSS-SPIONs O 
demonstrated O 
an O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
core O 
diameter O 
( O 
crystallite O 
size O 
by O 
XRD O 
) O 
of O 
3.1±0.02nm O 
, O 
a O 
hydrodynamic O 
diameter O 
of O 
94±20nm O 
, O 
a O 
zeta O 
potential O 
of O 
+ O 
21±5mV O 
, O 
and O 
an O 
iron B-SYSTEMATIC 
content O 
of O 
3.6±0.9mg O 
/ O 
mL O 
. O 
In O 
addition O 
, O 
internalization O 
of O 
TSS-SPIONs O 
into O 
human O 
endothelial O 
progenitor O 
cells O 
( O 
EPC O 
) O 
from O 
umbilical O 
cord O 
blood O 
was O 
more O 
than O 
threefold O 
and O 
17-fold O 
higher O 
in O 
contrast O 
to O 
UC-SPIONs O 
and O 
SPIONs O 
, O 
respectively O 
. O 
With O 
twofold O 
lower O 
incubation O 
iron B-SYSTEMATIC 
concentration O 
of O 
TSS-SPIONs O 
, O 
more O 
than O 
threefold O 
higher O 
internalization O 
was O 
achieved O 
as O 
compared O 
to O 
Resovist O 
® O 
. O 
Also O 
, O 
cell O 
viability O 
of O 
more O 
than O 
90% O 
was O 
observed O 
in O 
the O 
presence O 
of O 
TSS-SPIONs O 
after O 
24h O 
. O 
The O 
molar O 
MR O 
relaxivities O 
( O 
r2 O 
) O 
value O 
at O 
1.5T O 
was O 
threefold O 
higher O 
than O 
that O 
of O 
Resovist O 
® O 
and O 
demonstrated O 
that O 
TSS-SPIONs O 
have O 
the O 
potential O 
as O 
very O 
effective O 
T2 O 
contrast O 
- O 
enhancement O 
agent O 
. O 
According O 
to O 
these O 
findings O 
, O 
TSS-SPIONs O 
with O 
efficient O 
internalization O 
, O 
lower O 
cytotoxicity O 
, O 
and O 
high O 
MRI O 
sensitivity O 
seem O 
to O 
be O 
promising O 
for O 
cell O 
tracking O 
. O 

for O 
the O 
recognition O 
of O 
dilysine B-TRIVIAL 
retrieval O 
motifs O 
by O 
coatomer O 
. O 

dilysine B-TRIVIAL 
motifs O 
on O 
transmembrane O 
proteins O 
are O 
captured O 
by O 
coatomer O 
α-COP O 
and O 
β'-COP O 
subunits O 
and O 
packaged O 
into O 
COPI O 
- O 
coated O 
vesicles O 
for O 
Golgi-to-ER O 
retrieval O 
. O 
Numerous O 
ER O 
/ O 
Golgi O 
proteins O 
contain O 
K(x)Kxx O 
motifs O 
, O 
but O 
the O 
rules O 
for O 
their O 
recognition O 
are O 
unclear O 
. O 
We O 
present O 
crystal O 
structures O 
of O 
α-COP O 
and O 
β'-COP O 
bound O 
to O 
a O 
series O 
of O 
naturally O 
occurring O 
retrieval O 
motifs O 
- O 
encompassing O 
KKxx O 
, O 
KxKxx O 
and O 
non-canonical O 
RKxx O 
and O 
viral O 
KxHxx O 
sequences O 
. O 
Binding O 
experiments O 
show O 
that O 
α-COP O 
and O 
β'-COP O 
have O 
generally O 
the O 
same O 
specificity O 
for O 
KKxx O 
and O 
KxKxx O 
, O 
but O 
only O 
β'-COP O 
recognizes O 
the O 
RKxx O 
signal O 
. O 
Dilysine B-TRIVIAL 
motif O 
recognition O 
involves O 
lysine B-TRIVIAL 
side-chain O 
interactions O 
with O 
two O 
acidic O 
patches O 
. O 
Surprisingly O 
, O 
however O 
, O 
KKxx O 
and O 
KxKxx O 
motifs O 
bind O 
differently O 
, O 
with O 
their O 
lysine B-TRIVIAL 
residues O 
transposed O 
at O 
the O 
binding O 
patches O 
. O 
We O 
derive O 
rules O 
for O 
retrieval O 
motif O 
recognition O 
from O 
key O 
structural O 
features O 
: O 
the O 
reversed O 
binding O 
modes O 
, O 
the O 
recognition O 
of O 
the O 
C B-FORMULA 
-terminal O 
carboxylate B-SYSTEMATIC 
group O 
which O 
enforces O 
lysine B-TRIVIAL 
positional O 
context O 
, O 
and O 
the O 
tolerance O 
of O 
the O 
acidic O 
patches O 
for O 
non- O 
lysine B-TRIVIAL 
residues O 
. O 

and O 
regression O 
based O 
quantitative O 
structure O 
- O 
toxicity O 
relationship O 
( O 
QSTR O 
) O 
as O 
well O 
as O 
toxicophore O 
models O 
were O 
developed O 
for O 
the O 
first O 
time O 
on O 
basal O 
cytotoxicity O 
data O 
( O 
in O 
vitro O 
3T3 O 
neutral O 
red O 
uptake O 
data O 
) O 
of O 
a O 
diverse O 
series O 
of O 
chemicals O 
( O 
including O 
drugs O 
and O 
environmental O 
pollutants O 
) O 
collected O 
from O 
the O 
ACuteTox O 
database O 
( O 
http O 
: O 
/ O 
/ O 
www.acutetox.eu/ O 
) O 
. O 
Statistically O 
significant O 
QSTR O 
models O 
were O 
obtained O 
using O 
linear O 
discriminant O 
analysis O 
( O 
classification O 
) O 
and O 
partial O 
least O 
squares O 
( O 
regression O 
) O 
methodologies O 
. O 
Generated O 
toxicophore O 
models O 
showed O 
four O 
important O 
features O 
responsible O 
for O 
basal O 
cytotoxicity O 
: O 
(i) O 
two O 
hydrophobic O 
aliphatic O 
groups O 
( O 
HYD O 
Aliphatic O 
) O 
, O 
(ii) O 
ring O 
aromatic O 
group O 
( O 
RA O 
) O 
and O 
(iii) O 
hydrogen B-SYSTEMATIC 
bond O 
donor O 
( O 
HBD O 
) O 
. O 
The O 
most O 
predictive O 
hypothesis O 
( O 
Hypo O 
1 O 
) O 
had O 
a O 
correlation O 
coefficient O 
of O 
0.932 O 
for O 
the O 
training O 
set O 
, O 
a O 
low O 
rms O 
deviation O 
of O 
1.105 O 
, O 
and O 
an O 
acceptable O 
cost O 
difference O 
of O 
62.8 O 
bits O 
, O 
which O 
represents O 
a O 
true O 
correlation O 
and O 
a O 
good O 
predictivity O 
. O 
QSTR O 
and O 
toxicophore O 
models O 
were O 
rigorously O 
validated O 
internally O 
as O 
well O 
as O 
externally O 
along O 
with O 
the O 
randomization O 
test O 
to O 
nullify O 
the O 
possibilities O 
of O 
chance O 
correlation O 
. O 
Our O 
in O 
silico O 
models O 
enable O 
to O 
identify O 
the O 
essential O 
structural O 
attributes O 
and O 
quantify O 
the O 
prime O 
molecular O 
pre O 
- O 
requisites O 
which O 
were O 
chiefly O 
responsible O 
for O 
in O 
vitro O 
basal O 
cytotoxicity O 
. O 
The O 
developed O 
models O 
were O 
also O 
implemented O 
to O 
screen O 
basal O 
cytotoxicity O 
for O 
huge O 
number O 
DrugBank O 
database O 
( O 
http O 
: O 
/ O 
/ O 
www.drugbank.ca/ O 
) O 
compounds O 
. O 

modulates O 
spatial O 
recognition O 
memory O 
in O 
male O 
rats O 
. O 

growing O 
body O 
of O 
research O 
indicates O 
that O 
testosterone B-TRIVIAL 
influences O 
spatial O 
cognition O 
in O 
male O 
rats O 
; O 
however O 
, O 
the O 
overwhelming O 
majority O 
of O 
studies O 
have O 
been O 
conducted O 
on O 
tasks O 
motivated O 
by O 
either O 
food O 
deprivation O 
or O 
water O 
escape O 
. O 
The O 
hippocampus O 
- O 
dependent O 
version O 
of O 
the O 
Y-maze O 
task O 
, O 
which O 
characterizes O 
spatial O 
recognition O 
memory O 
, O 
capitalizes O 
on O 
the O 
propensity O 
of O 
rats O 
to O 
gravitate O 
toward O 
novel O 
spatial O 
environments O 
and O 
is O 
not O 
contingent O 
upon O 
either O 
appetite O 
or O 
the O 
stress O 
associated O 
with O 
water O 
escape O 
, O 
two O 
factors O 
also O 
affected O 
by O 
testosterone B-TRIVIAL 
. O 
Accordingly O 
, O 
the O 
aim O 
of O 
the O 
current O 
study O 
was O 
to O 
examine O 
the O 
effects O 
of O 
orchidectomy O 
and O 
subsequent O 
testosterone B-TRIVIAL 
treatment O 
on O 
spatial O 
recognition O 
memory O 
. O 
Orchidectomy O 
did O 
not O 
impact O 
spatial O 
recognition O 
memory O 
when O 
the O 
delay O 
between O 
the O 
information O 
and O 
retention O 
trials O 
of O 
the O 
Y-maze O 
task O 
was O 
24h O 
. O 
Alternatively O 
, O 
on O 
the O 
second O 
Y-maze O 
task O 
, O 
which O 
featured O 
a O 
48-h O 
delay O 
between O 
trials O 
, O 
orchidectomy O 
reduced O 
, O 
and O 
treatments O 
that O 
produced O 
higher O 
levels O 
of O 
testosterone B-TRIVIAL 
restored O 
, O 
preference O 
for O 
the O 
arm O 
associated O 
with O 
the O 
novel O 
spatial O 
environment O 
. O 
Importantly O 
, O 
there O 
were O 
no O 
differences O 
in O 
activity O 
levels O 
as O 
a O 
function O 
of O 
orchidectomy O 
or O 
testosterone B-TRIVIAL 
treatment O 
on O 
either O 
of O 
the O 
two O 
tasks O 
. O 
Consistent O 
with O 
previous O 
findings O 
, O 
orchidectomy O 
attenuated O 
, O 
and O 
testosterone B-TRIVIAL 
treatment O 
restored O 
, O 
both O 
body O 
weight O 
gain O 
and O 
the O 
relative O 
weight O 
of O 
the O 
androgen B-FAMILY 
-sensitive O 
ischiocavernosus O 
muscle O 
, O 
which O 
confirmed O 
the O 
efficacy O 
of O 
orchidectomy O 
and O 
testosterone B-TRIVIAL 
treatments O 
on O 
physiological O 
outcomes O 
. O 
Therefore O 
, O 
testosterone B-TRIVIAL 
influenced O 
spatial O 
cognition O 
on O 
a O 
task O 
that O 
minimized O 
the O 
influence O 
of O 
non-mnemonic O 
factors O 
and O 
took O 
advantage O 
of O 
the O 
innate O 
preference O 
of O 
rodents O 
to O 
seek O 
out O 
novel O 
spatial O 
environments O 
. O 

LIN28A O 
and O 
LIN28B O 
are O 
RNA O 
- O 
binding O 
proteins O 
( O 
RBPs O 
) O 
conserved O 
in O 
animals O 
with O 
important O 
roles O 
during O 
development O 
and O 
stem O 
cell O 
reprogramming O 
. O 
We O 
used O 
Photoactivatable- O 
Ribonucleoside B-FAMILY 
-Enhanced O 
Crosslinking O 
and O 
Immunoprecipitation O 
( O 
PAR-CLIP O 
) O 
in O 
HEK293 O 
cells O 
and O 
identified O 
a O 
largely O 
overlapping O 
set O 
of O 
∼3000 O 
mRNAs O 
at O 
∼9500 O 
sites O 
located O 
in O 
the O 
3 O 
' O 
UTR O 
and O 
CDS O 
. O 
In O 
vitro O 
and O 
in O 
vivo O 
, O 
LIN28 O 
preferentially O 
bound O 
single O 
- O 
stranded O 
RNA O 
containing O 
a O 
uridine B-TRIVIAL 
-rich O 
element O 
and O 
one O 
or O 
more O 
flanking O 
guanosines B-FAMILY 
and O 
appeared O 
to O 
be O 
able O 
to O 
disrupt O 
base O 
- O 
pairing O 
to O 
access O 
these O 
elements O 
when O 
embedded O 
in O 
predicted O 
secondary O 
structure O 
. O 
In O 
HEK293 O 
cells O 
, O 
LIN28 O 
protein O 
binding O 
mildly O 
stabilized O 
target O 
mRNAs O 
and O 
increased O 
protein O 
abundance O 
. O 
The O 
top O 
targets O 
were O 
its O 
own O 
mRNAs O 
and O 
those O 
of O 
other O 
RBPs O 
and O 
cell O 
cycle O 
regulators O 
. O 
Alteration O 
of O 
LIN28 O 
protein O 
levels O 
also O 
negatively O 
regulated O 
the O 
abundance O 
of O 
some O 
but O 
not O 
all O 
let-7 O 
miRNA O 
family O 
members O 
, O 
indicating O 
sequence O 
- O 
specific O 
binding O 
of O 
let-7 O 
precursors O 
to O 
LIN28 O 
proteins O 
and O 
competition O 
with O 
cytoplasmic O 
miRNA O 
biogenesis O 
factors O 
. O 

tacrine B-TRIVIAL 
-related O 
drugs O 
as O 
potential O 
candidates O 
for O 
the O 
treatment O 
of O 
Alzheimer's O 
disease O 
. O 

summary O 
of O 
the O 
recently O 
published O 
efforts O 
on O 
tacrine B-TRIVIAL 
derivatives O 
as O 
a O 
renewed O 
potential O 
therapeutic O 
approach O 
for O 
the O 
treatment O 
of O 
Alzheimer's O 
disease O 
is O 
presented O 
. O 

, O 
receptor O 
binding O 
and O 
activity O 
of O 
iso B-MULTIPLE 
and I-MULTIPLE 
azakainoids I-MULTIPLE 
. O 

syntheses O 
for O 
the O 
production O 
of O 
an O 
unsubstituted O 
azakainoid B-TRIVIAL 
are O 
described O 
. O 
The O 
1,3-dipolar O 
cycloaddition O 
of O 
diazomethane B-SYSTEMATIC 
with O 
trans-dibenzyl B-SYSTEMATIC 
glutaconate I-SYSTEMATIC 
yields O 
a O 
1-pyrazoline B-SYSTEMATIC 
, O 
which O 
may O 
be O 
reduced O 
directly O 
to O 
the O 
pyrazolidine B-SYSTEMATIC 
. O 
An O 
unexpected O 
trans-cis O 
isomerization O 
is O 
observed O 
during O 
Hg B-FORMULA 
/ O 
Al B-FORMULA 
reduction O 
of O 
the O 
1-pyrazoline B-SYSTEMATIC 
NN B-FORMULA 
bond O 
. O 
Alternatively O 
, O 
when O 
TMS B-SYSTEMATIC 
diazomethane I-SYSTEMATIC 
is O 
used O 
as O 
the O 
dipole O 
, O 
the O 
resulting O 
2-pyrazoline B-SYSTEMATIC 
obtained O 
after O 
desilylation O 
may O 
be O 
reduced O 
with O 
NaCNBH3 B-FORMULA 
to O 
provide O 
the O 
trans B-TRIVIAL 
azakainate I-TRIVIAL 
analog O 
exclusively O 
. O 
The O 
synthesis O 
of O 
an O 
unsubstituted O 
isokainoid B-TRIVIAL 
via O 
Michael O 
addition O 
is O 
also O 
described O 
. O 
Glutamate B-TRIVIAL 
receptor O 
binding O 
assays O 
revealed O 
that O 
the O 
azakaniod B-TRIVIAL 
has O 
a O 
moderate O 
affinity O 
for O 
unspecified O 
glutamate B-TRIVIAL 
receptors O 
. O 
Membrane O 
depolarization O 
of O 
Aplysia O 
neurons O 
upon O 
application O 
of O 
the O 
azakainoid B-TRIVIAL 
demonstrates O 
that O 
it O 
is O 
an O 
ionotropic O 
glutamate B-TRIVIAL 
receptor O 
agonist O 
. O 

of O 
a O 
sucrose B-TRIVIAL 
-derived O 
contrast O 
agent O 
for O 
magnetic O 
resonance O 
imaging O 
of O 
the O 
GI O 
tract O 
. O 

scaffold O 
bearing O 
eight O 
terminal O 
alkyne B-FAMILY 
groups O 
was O 
synthesized O 
from O 
sucrose B-TRIVIAL 
, O 
and O 
copies O 
of O 
an O 
azide B-SYSTEMATIC 
-terminated O 
Gd-DOTA B-FORMULA 
complex O 
were O 
attached O 
via O 
copper B-SYSTEMATIC 
(I) I-SYSTEMATIC 
-catalyzed O 
azide-alkyne B-FAMILY 
cycloaddition O 
. O 
The O 
resulting O 
contrast O 
agent O 
( O 
CA O 
) O 
was O 
administered O 
by O 
gavage O 
to O 
C3H O 
mice O 
. O 
Passage O 
of O 
the O 
CA O 
through O 
the O 
gastrointestinal O 
( O 
GI O 
) O 
tract O 
was O 
followed O 
by O 
T1-weighted O 
magnetic O 
resonance O 
imaging O 
( O 
MRI O 
) O 
over O 
a O 
period O 
of O 
47h O 
, O 
by O 
which O 
time O 
the O 
CA O 
had O 
exited O 
the O 
GI O 
tract O 
. O 
No O 
evidence O 
for O 
leakage O 
of O 
the O 
CA O 
from O 
the O 
GI O 
tract O 
was O 
observed O 
. O 
Thus O 
, O 
a O 
new O 
, O 
orally O 
administered O 
CA O 
for O 
MRI O 
of O 
the O 
GI O 
tract O 
has O 
been O 
developed O 
and O 
successfully O 
demonstrated O 
. O 

and O 
Anti-Inflammatory O 
Eunicellin B-TRIVIAL 
-Based O 
Diterpenoids B-FAMILY 
from O 
the O 
Soft O 
Coral O 
Cladiella O 
krempfi O 
. O 

new O 
eunicellin B-TRIVIAL 
-based O 
diterpenoids B-FAMILY 
, O 
krempfielins B-MULTIPLE 
E-I I-MULTIPLE 
( O 
1-5 O 
) O 
and O 
seven O 
known O 
compounds O 
( O 
6-12 O 
) O 
were O 
isolated O 
from O 
the O 
organic O 
extract O 
of O 
a O 
Taiwanese O 
soft O 
coral O 
Cladiella O 
krempfi O 
. O 
The O 
structures O 
of O 
the O 
new O 
metabolites O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
extensive O 
spectroscopic O 
analysis O 
. O 
Metabolites O 
5 O 
, O 
6 O 
, O 
10 O 
and O 
12 O 
were O 
shown O 
to O 
exhibit O 
cytotoxicity O 
against O 
a O 
limited O 
panel O 
of O 
cancer O 
cell O 
lines O 
. O 
Furthermore O 
, O 
compounds O 
6 O 
and O 
10 O 
could O 
potently O 
inhibit O 
the O 
accumulation O 
of O 
the O 
pro O 
- O 
inflammatory O 
iNOS O 
protein O 
, O 
and O 
6 O 
and O 
12 O 
could O 
significantly O 
reduce O 
the O 
expression O 
of O 
COX-2 O 
protein O 
in O 
LPS-stimulated O 
RAW264.7 O 
macrophage O 
cells O 
. O 

Azalomycin B-TRIVIAL 
F I-TRIVIAL 
Analogs O 
from O 
Mangrove O 
Streptomyces O 
sp O 
. O 
211726 O 
with O 
Activity O 
against O 
Microbes O 
and O 
Cancer O 
Cells O 
. O 

new O 
azalomycin B-TRIVIAL 
F I-TRIVIAL 
analogs O 
( O 
1-7 O 
) O 
were O 
isolated O 
from O 
the O 
broth O 
of O 
mangrove O 
Streptomyces O 
sp O 
. O 
211726 O 
, O 
and O 
respectively O 
identified O 
as O 
25-malonyl B-SYSTEMATIC 
demalonylazalomycin I-SYSTEMATIC 
F5a I-SYSTEMATIC 
monoester I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
23-valine B-SYSTEMATIC 
demalonylazalomycin I-SYSTEMATIC 
F5a I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
23-(6-methyl)heptanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
demalonylazalomycins I-SYSTEMATIC 
F3a I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
3 O 
) O 
, O 
F4a B-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
4 O 
) O 
and O 
F5a B-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
5 O 
) O 
, O 
23-(9-methyl)decanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
demalonylazalomycin I-SYSTEMATIC 
F4a I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
6 O 
) O 
and O 
23-(10-methyl)undecanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
demalony I-SYSTEMATIC 
lazalomycin I-SYSTEMATIC 
F4a I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
7 O 
) O 
. O 
Their O 
structures O 
were O 
established O 
by O 
their O 
spectroscopic O 
data O 
and O 
by O 
comparing O 
with O 
those O 
of O 
azalomycins B-MULTIPLE 
F3a I-MULTIPLE 
, I-MULTIPLE 
F4a I-MULTIPLE 
and I-MULTIPLE 
F5a I-MULTIPLE 
. O 
Biological O 
assays O 
exhibited O 
that O 
1-7 O 
showed O 
broad O 
- O 
spectrum O 
antimicrobial O 
and O 
anti O 
HCT-116 O 
activities O 
. O 

Hepatobiliary O 
Disposition O 
: O 
Mechanisms O 
of O 
Hepatic O 
Uptake O 
and O 
Disposition O 
of O 
Generated O 
Metabolites O 
. O 

is O 
an O 
orally O 
active O 
tyrosine B-TRIVIAL 
kinase O 
inhibitor O 
used O 
in O 
the O 
treatment O 
of O 
renal O 
and O 
hepatocellular O 
carcinoma O 
. O 
This O 
study O 
was O 
designed O 
to O 
establish O 
whether O 
transport O 
proteins O 
are O 
involved O 
in O 
the O 
hepatic O 
uptake O 
of O 
sorafenib B-TRIVIAL 
, O 
and O 
to O 
determine O 
the O 
extent O 
of O 
biliary O 
excretion O 
of O 
sorafenib B-TRIVIAL 
/ O 
metabolites O 
in O 
human O 
hepatocytes O 
. O 
Initial O 
uptake O 
was O 
assessed O 
in O 
freshly O 
isolated O 
, O 
suspended O 
human O 
hepatocytes O 
in O 
the O 
presence O 
of O 
inhibitors O 
and O 
modulators O 
. O 
[(14)C]Sorafenib B-SYSTEMATIC 
( O 
1 O 
μM O 
) O 
uptake O 
at O 
4°C O 
was O 
~61-63% O 
of O 
the O 
uptake O 
at O 
37°C O 
, O 
suggesting O 
a O 
high O 
degree O 
of O 
passive O 
diffusion O 
. O 
Hepatocyte O 
uptake O 
of O 
[(14)C]sorafenib B-SYSTEMATIC 
was O 
not O 
Na(+) B-FORMULA 
-dependent O 
or O 
influenced O 
by O 
the O 
organic O 
anion O 
transporter O 
2 O 
( O 
OAT2 O 
) O 
inhibitor O 
ketoprofen B-TRIVIAL 
. O 
However O 
, O 
initial O 
[(14)C]sorafenib B-SYSTEMATIC 
hepatocyte O 
uptake O 
was O 
reduced O 
by O 
46 O 
and O 
30% O 
compared O 
to O 
control O 
values O 
in O 
the O 
presence O 
of O 
the O 
organic O 
anion O 
transporting O 
polypeptide O 
( O 
OATP O 
) O 
inhibitor O 
rifamycin B-TRIVIAL 
SV I-TRIVIAL 
, O 
and O 
the O 
organic O 
cation O 
transporter O 
( O 
OCT O 
) O 
inhibitor O 
decynium B-TRIVIAL 
22 I-TRIVIAL 
, O 
respectively O 
. O 
[(14)C]Sorafenib B-SYSTEMATIC 
( O 
0.5 O 
to O 
5 O 
μM O 
) O 
uptake O 
was O 
significantly O 
higher O 
in O 
hOCT1-transfected O 
CHO O 
cells O 
compared O 
to O 
mock O 
cells O 
, O 
and O 
inhibited O 
by O 
the O 
general O 
OCT O 
inhibitor O 
, O 
MPP(+) B-ABBREVIATION 
. O 
OCT1 O 
- O 
mediated O 
uptake O 
was O 
saturable O 
with O 
a O 
Km O 
of O 
3.8 O 
± O 
2.53 O 
μM O 
and O 
Vmax O 
of O 
116 O 
± O 
42 O 
pmol O 
/ O 
mg O 
/ O 
min O 
. O 
The O 
biliary O 
excretion O 
index O 
( O 
BEI O 
) O 
and O 
in O 
vitro O 
biliary O 
clearance O 
( O 
Clbiliary O 
) O 
of O 
sorafenib B-TRIVIAL 
( O 
1 O 
μM O 
) O 
in O 
sandwich O 
- O 
cultured O 
human O 
hepatocytes O 
were O 
low O 
( O 
~11% O 
and O 
11 O 
ml O 
/ O 
min O 
/ O 
kg O 
, O 
respectively O 
) O 
. O 
Results O 
suggest O 
that O 
sorafenib B-TRIVIAL 
uptake O 
in O 
human O 
hepatocytes O 
occurs O 
via O 
passive O 
diffusion O 
, O 
and O 
by O 
OCT1 O 
and O 
a O 
rifamycin B-FAMILY 
-sensitive O 
transporter O 
. O 
Sorafenib B-TRIVIAL 
undergoes O 
modest O 
biliary O 
excretion O 
, O 
predominantly O 
as O 
glucuronide O 
conjugate(s) O 
. O 

photovoltaic O 
performance O 
of O 
a O 
dye O 
- O 
sensitized O 
solar O 
cell O 
using O 
graphene B-TRIVIAL 
- O 
TiO2 B-FORMULA 
photoanode O 
prepared O 
by O 
a O 
novel O 
in O 
situ O 
simultaneous O 
reduction O 
- O 
hydrolysis O 
technique O 
. O 

photovoltaic O 
performance O 
of O 
a O 
DSSC O 
using O 
graphene B-TRIVIAL 
- O 
TiO2 B-FORMULA 
photoelectrodes O 
prepared O 
by O 
our O 
recent O 
in O 
situ O 
simultaneous O 
reduction O 
- O 
hydrolysis O 
technique O 
( O 
Adv O 
. O 
Funct O 
. O 
Mater O 
. O 
, O 
2012 O 
, O 
DOI O 
: O 
10.1002 O 
/ O 
adfm.201202349 O 
, O 
in O 
press O 
) O 
was O 
achieved O 
. O 
The O 
DSSCs O 
based O 
on O 
the O 
G-TiO2 B-FORMULA 
nanocomposites O 
improved O 
their O 
overall O 
energy O 
conversion O 
efficiency O 
to O 
7.1% O 
. O 
The O 
results O 
prove O 
that O 
the O 
promoting O 
effect O 
of O 
graphene B-TRIVIAL 
is O 
strongly O 
dependent O 
on O 
its O 
content O 
; O 
namely O 
, O 
the O 
efficiency O 
of O 
DSSCs O 
increases O 
and O 
then O 
decreases O 
with O 
increasing O 
graphene B-TRIVIAL 
content O 
in O 
TiO2 B-FORMULA 
- O 
graphene B-TRIVIAL 
composites O 
. O 
Excessive O 
graphene B-TRIVIAL 
in O 
the O 
nanocomposite O 
leads O 
to O 
a O 
decrease O 
of O 
the O 
light O 
harvest O 
of O 
dye O 
molecules O 
and O 
thus O 
a O 
negative O 
effect O 
on O 
the O 
power O 
conversion O 
efficiency O 
of O 
DSSCs O 
. O 

of O 
treatment O 
with O 
a O 
carbon B-SYSTEMATIC 
monoxide I-SYSTEMATIC 
-releasing O 
molecule O 
and O 
a O 
heme O 
oxygenase O 
1 O 
inducer O 
in O 
the O 
antinociceptive O 
effects O 
of O 
morphine B-TRIVIAL 
in O 
different O 
models O 
of O 
acute O 
and O 
chronic O 
pain O 
in O 
mice O 
. O 

: O 
Treatment O 
with O 
a O 
carbon B-SYSTEMATIC 
monoxide I-SYSTEMATIC 
-releasing O 
molecule O 
( O 
tricarbonyldichlororuthenium B-SYSTEMATIC 
(II) I-SYSTEMATIC 
dimer O 
, O 
CORM-2 B-ABBREVIATION 
) O 
or O 
a O 
classical O 
heme O 
oxygenase O 
1 O 
inducer O 
( O 
cobalt B-SYSTEMATIC 
protoporphyrin I-SYSTEMATIC 
IX I-SYSTEMATIC 
, O 
CoPP B-FORMULA 
) O 
has O 
potent O 
anti-inflammatory O 
effects O 
, O 
but O 
the O 
role O 
played O 
by O 
these O 
treatments O 
in O 
the O 
antinociceptive O 
effects O 
of O 
morphine B-TRIVIAL 
during O 
acute O 
and O 
chronic O 
pain O 
was O 
not O 
evaluated O 
. O 
OBJECTIVES O 
: O 
In O 
wild O 
type O 
( O 
WT O 
) O 
, O 
neuronal O 
( O 
NOS1-KO O 
) O 
, O 
or O 
inducible O 
( O 
NOS2-KO O 
) O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthases O 
knockout O 
mice O 
, O 
we O 
evaluated O 
the O 
effects O 
of O 
CORM-2 B-ABBREVIATION 
and O 
CoPP B-FORMULA 
treatments O 
in O 
the O 
antinociceptive O 
actions O 
of O 
morphine B-TRIVIAL 
and O 
their O 
interaction O 
with O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
during O 
acute O 
, O 
visceral O 
, O 
and O 
chronic O 
inflammatory O 
or O 
neuropathic O 
pain O 
. O 
METHODS O 
: O 
Acute O 
and O 
visceral O 
pain O 
was O 
assessed O 
through O 
formalin B-TRIVIAL 
and O 
acid B-SYSTEMATIC 
acetic I-SYSTEMATIC 
writhing O 
tests O 
. O 
Chronic O 
inflammatory O 
pain O 
induced O 
by O 
the O 
intra O 
- O 
articular O 
administration O 
of O 
complete O 
Freund's O 
adjuvant O 
and O 
neuropathic O 
pain O 
by O 
partial O 
ligation O 
of O 
sciatic O 
nerve O 
were O 
evaluated O 
by O 
measuring O 
allodynia O 
and O 
hyperalgesia O 
using O 
the O 
von O 
Frey O 
filaments O 
, O 
plantar O 
, O 
or O 
cold O 
plate O 
tests O 
. O 
RESULTS O 
: O 
While O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
synthetized O 
by O 
NOS1 O 
and O 
/ O 
or O 
NOS2 O 
, O 
increased O 
the O 
local O 
antinociceptive O 
effects O 
of O 
morphine B-TRIVIAL 
during O 
acute O 
and O 
chronic O 
pain O 
, O 
it O 
decreased O 
the O 
inhibitory O 
effects O 
of O 
morphine B-TRIVIAL 
after O 
visceral O 
pain O 
. O 
Moreover O 
, O 
while O 
CORM-2 B-ABBREVIATION 
or O 
CoPP B-FORMULA 
treatments O 
did O 
not O 
alter O 
or O 
reduced O 
the O 
antinociceptive O 
effects O 
of O 
morphine B-TRIVIAL 
during O 
acute O 
and O 
visceral O 
pain O 
, O 
both O 
treatments O 
improved O 
the O 
local O 
antiallodynic O 
and O 
antihyperalgesic O 
effects O 
of O 
morphine B-TRIVIAL 
after O 
chronic O 
inflammatory O 
or O 
neuropathic O 
pain O 
in O 
WT O 
, O 
but O 
not O 
in O 
KO O 
mice O 
. O 
CONCLUSIONS O 
: O 
CORM-2 B-ABBREVIATION 
and O 
CoPP B-FORMULA 
treatments O 
improved O 
the O 
local O 
antinociceptive O 
effects O 
of O 
morphine B-TRIVIAL 
during O 
chronic O 
inflammatory O 
and O 
neuropathic O 
pain O 
by O 
interaction O 
with O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthetized O 
by O 
NOS1 O 
and O 
NOS2 O 
isoforms O 
. O 

is O 
an O 
inhibitor O 
and O 
its O 
boron B-SYSTEMATIC 
dipyrromethene I-SYSTEMATIC 
derivative O 
is O 
a O 
fluorescent O 
recognition O 
agent O 
for O 
botulinum O 
neurotoxin O 
subtype O 
a O 
. O 

A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
: O 
Absolute O 
Configuration O 
and O 
NF-κB O 
Transcriptional O 
Inhibitory O 
Activity O 
. O 

new O 
metabolites O 
, O 
embellicines B-MULTIPLE 
A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
( O 
1 O 
and O 
2 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
EtOAc B-FORMULA 
extract O 
of O 
the O 
fungus O 
Embellisia O 
eureka O 
, O 
an O 
endophyte O 
of O 
the O 
Moroccan O 
plant O 
Cladanthus O 
arabicus O 
( O 
Asteraceae O 
) O 
. O 
The O 
structures O 
of O 
these O 
new O 
compounds O 
were O 
determined O 
on O 
the O 
basis O 
of O 
extensive O 
one- O 
and O 
two O 
- O 
dimensional O 
NMR O 
spectroscopy O 
as O 
well O 
as O 
by O 
high O 
- O 
resolution O 
mass O 
spectrometry O 
. O 
The O 
absolute O 
configuration O 
of O 
embellicine B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
was O 
determined O 
by O 
TDDFT O 
ECD O 
calculations O 
of O 
solution O 
conformers O 
, O 
whereas O 
that O 
of O 
embellicine B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
was O 
deduced O 
based O 
on O 
ROESY O 
correlations O 
and O 
on O 
biogenetic O 
considerations O 
in O 
comparison O 
to O 
1 O 
. O 
Both O 
embellicines B-FAMILY 
( O 
1 O 
and O 
2 O 
) O 
are O 
cytostatic O 
, O 
cytotoxic O 
, O 
and O 
inhibit O 
NF-κB O 
transcriptional O 
activity O 
, O 
indicating O 
that O 
inhibition O 
of O 
NF-κB O 
may O 
be O 
a O 
possible O 
mechanism O 
of O 
action O 
of O 
these O 
compounds O 
. O 
Embellicine B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
was O 
the O 
most O 
active O 
compound O 
encountered O 
in O 
this O 
study O 
and O 
acts O 
at O 
nanomolar O 
concentrations O 
without O 
affecting O 
tumor O 
microenvironment O 
. O 

-coated O 
viral O 
nanoforests O 
as O 
sodium B-SYSTEMATIC 
-ion O 
battery O 
anodes O 
. O 

as O 
a O 
high O 
- O 
capacity O 
alloy O 
host O 
for O 
Na B-FORMULA 
-ion O 
chemistry O 
, O 
a O 
forest O 
of O 
Sn B-FORMULA 
nanorods O 
with O 
a O 
unique O 
core O 
- O 
shell O 
structure O 
was O 
synthesized O 
on O 
viral O 
scaffolds O 
, O 
which O 
were O 
genetically O 
engineered O 
to O 
ensure O 
a O 
nearly O 
vertical O 
alignment O 
upon O 
self O 
- O 
assembly O 
onto O 
a O 
metal O 
substrate O 
. O 
The O 
interdigital O 
spaces O 
thus O 
formed O 
between O 
individual O 
rods O 
effectively O 
accommodated O 
the O 
volume O 
expansion O 
and O 
contraction O 
of O 
the O 
alloy O 
upon O 
sodiation O 
/ O 
desodiation O 
, O 
while O 
additional O 
carbon B-SYSTEMATIC 
-coating O 
engineered O 
over O 
these O 
nanorods O 
further O 
suppressed O 
Sn B-FORMULA 
aggregation O 
during O 
extended O 
electrochemical O 
cycling O 
. O 
Due O 
to O 
the O 
unique O 
nanohierarchy O 
of O 
multiple O 
functional O 
layers O 
, O 
the O 
resultant O 
3D O 
nanoforest O 
of O 
C B-FORMULA 
/ O 
Sn B-FORMULA 
/ O 
Ni B-FORMULA 
/ O 
TMV1cys O 
, O 
binder O 
- O 
free O 
composite O 
electrode O 
already O 
and O 
evenly O 
assembled O 
on O 
a O 
stainless O 
steel B-TRIVIAL 
current O 
collector O 
, O 
exhibited O 
supreme O 
capacity O 
utilization O 
and O 
cycling O 
stability O 
toward O 
Na B-FORMULA 
-ion O 
storage O 
and O 
release O 
. O 
An O 
initial O 
capacity O 
of O 
722 O 
mA·h O 
( O 
g O 
Sn B-FORMULA 
)(-1 O 
) O 
along O 
with O 
405 O 
mA·h O 
( O 
g O 
Sn B-FORMULA 
)(-1 O 
) O 
retained O 
after O 
150 O 
deep O 
cycles O 
demonstrates O 
the O 
longest O 
- O 
cycling O 
nano- O 
Sn B-FORMULA 
anode O 
material O 
for O 
Na B-FORMULA 
-ion O 
batteries O 
reported O 
in O 
the O 
literature O 
to O 
date O 
and O 
marks O 
a O 
significant O 
performance O 
improvement O 
for O 
neat O 
Sn B-FORMULA 
material O 
as O 
alloy O 
host O 
for O 
Na B-FORMULA 
-ion O 
chemistry O 
. O 

modulation O 
of O 
microtubule O 
stability O 
contributes O 
to O 
anthracene B-SYSTEMATIC 
general O 
anesthesia O 
. O 

, O 
we O 
identified O 
1-aminoanthracene B-SYSTEMATIC 
as O 
a O 
fluorescent O 
general O 
anesthetic O 
. O 
To O 
investigate O 
the O 
mechanism O 
of O 
action O 
, O 
a O 
photoactive O 
analogue O 
, O 
1-azidoanthracene B-SYSTEMATIC 
, O 
was O 
synthesized O 
. O 
Administration O 
of O 
1-azidoanthracene B-SYSTEMATIC 
to O 
albino O 
stage O 
40-47 O 
tadpoles O 
was O 
found O 
to O 
immobilize O 
animals O 
upon O 
near-UV O 
irradiation O 
of O 
the O 
forebrain O 
region O 
. O 
The O 
immobilization O 
was O 
often O 
reversible O 
, O 
but O 
it O 
was O 
characterized O 
by O 
a O 
longer O 
duration O 
consistent O 
with O 
covalent O 
attachment O 
of O 
the O 
ligand O 
to O 
functionally O 
important O 
targets O 
. O 
IEF O 
/ O 
SDS-PAGE O 
examination O 
of O 
irradiated O 
tadpole O 
brain O 
homogenate O 
revealed O 
labeled O 
protein O 
, O 
identified O 
by O 
mass O 
spectrometry O 
as O 
β-tubulin O 
. O 
In O 
vitro O 
assays O 
with O 
aminoanthracene B-SYSTEMATIC 
-cross O 
- O 
linked O 
tubulin O 
indicated O 
inhibition O 
of O 
microtubule O 
polymerization O 
, O 
similar O 
to O 
colchicine B-TRIVIAL 
. O 
Tandem O 
mass O 
spectrometry O 
confirmed O 
anthracene B-SYSTEMATIC 
binding O 
near O 
the O 
colchicine B-TRIVIAL 
site O 
. O 
Stage O 
40-47 O 
tadpoles O 
were O 
also O 
incubated O 
1 O 
h O 
with O 
microtubule O 
stabilizing O 
agents O 
, O 
epothilone B-TRIVIAL 
D I-TRIVIAL 
or O 
discodermolide B-TRIVIAL 
, O 
followed O 
by O 
dosing O 
with O 
1-aminoanthracene B-SYSTEMATIC 
. O 
The O 
effective O 
concentration O 
of O 
1-aminoanthracene B-SYSTEMATIC 
required O 
to O 
immobilize O 
the O 
tadpoles O 
was O 
significantly O 
increased O 
in O 
the O 
presence O 
of O 
either O 
microtubule O 
stabilizing O 
agent O 
. O 
Epothilone B-TRIVIAL 
D I-TRIVIAL 
similarly O 
mitigated O 
the O 
effects O 
of O 
a O 
clinical O 
neurosteroid O 
general O 
anesthetic O 
, O 
allopregnanolone B-TRIVIAL 
, O 
believed O 
to O 
occupy O 
the O 
colchicine B-TRIVIAL 
site O 
in O 
tubulin O 
. O 
We O 
conclude O 
that O 
neuronal O 
microtubules O 
are O 
" O 
on O 
- O 
pathway O 
" O 
targets O 
for O 
anthracene B-SYSTEMATIC 
general O 
anesthetics O 
and O 
may O 
also O 
represent O 
functional O 
targets O 
for O 
some O 
neurosteroid O 
general O 
anesthetics O 
. O 

the O 
Role O 
of O 
the O 
Protein O 
Environment O 
for O 
[ B-FORMULA 
FeFe I-FORMULA 
] I-FORMULA 
-Hydrogenase O 
: O 
A O 
New O 
Application O 
of O 
Coarse-Graining O 
. O 

enzymes O 
are O 
natural O 
biocatalysts O 
that O 
might O 
be O 
harnessed O 
to O 
reduce O 
the O 
cost O 
of O 
hydrogen B-SYSTEMATIC 
gas O 
production O 
. O 
[ B-FORMULA 
FeFe I-FORMULA 
] I-FORMULA 
-hydrogenases O 
are O 
the O 
most O 
effective O 
of O 
three O 
such O 
enzymes O 
at O 
catalyzing O 
H(+) B-FORMULA 
reduction O 
. O 
In O 
this O 
study O 
, O 
we O 
develop O 
and O 
apply O 
a O 
novel O 
combination O 
of O 
all O 
- O 
atom O 
molecular O 
dynamics O 
and O 
coarse O 
- O 
grained O 
( O 
CG O 
) O 
analysis O 
to O 
characterize O 
two O 
important O 
steps O 
of O 
the O 
catalytic O 
cycle O 
of O 
[ B-FORMULA 
FeFe I-FORMULA 
] I-FORMULA 
-hydrogenase O 
. O 
The O 
first O 
is O 
the O 
electron O 
transport O 
through O 
FeS B-FORMULA 
clusters O 
to O 
the O 
active O 
site O 
. O 
We O 
use O 
a O 
Marcus O 
formulation O 
to O 
compute O 
the O 
free O 
energy O 
and O 
the O 
reorganization O 
energy O 
of O 
three O 
electron O 
transport O 
steps O 
and O 
decompose O 
these O 
values O 
into O 
contributions O 
from O 
the O 
CG O 
protein O 
sites O 
and O 
the O 
solvent O 
. O 
The O 
three O 
- O 
step O 
transport O 
process O 
is O 
found O 
to O 
be O 
downhill O 
with O 
relative O 
free O 
energies O 
of O 
-11.7 O 
for O 
the O 
first O 
step O 
, O 
-14.8 O 
for O 
the O 
second O 
step O 
, O 
and O 
-17.1 O 
kcal O 
/ O 
mol O 
for O 
the O 
third O 
step O 
. O 
The O 
electron O 
- O 
transport O 
process O 
is O 
also O 
found O 
to O 
activate O 
a O 
water O 
channel O 
suggesting O 
a O 
coupled O 
mechanism O 
for O 
proton O 
and O 
electron O 
transport O 
to O 
the O 
active O 
site O 
. O 
The O 
channel O 
opening O 
is O 
orchestrated O 
by O 
three O 
CG O 
sites O 
located O 
in O 
the O 
active O 
- O 
site O 
domain O 
of O 
the O 
protein O 
with O 
one O 
of O 
the O 
sites O 
also O 
contributing O 
a O 
strong O 
attractive O 
electrostatic O 
potential O 
( O 
ESP O 
) O 
to O 
help O 
shuttle O 
protons O 
to O 
the O 
active O 
site O 
. O 
Overall O 
, O 
our O 
CG O 
analysis O 
points O 
to O 
a O 
concerted O 
mechanism O 
of O 
electron O 
and O 
proton O 
delivery O 
to O 
the O 
active O 
site O 
in O 
these O 
proteins O 
thus O 
providing O 
important O 
insight O 
for O 
the O 
development O 
of O 
biomimetic O 
devices O 
. O 

search O 
of O 
a O 
basis O 
for O 
the O 
impressive O 
potency O 
of O 
an O 
endoprotease O 
that O 
cleaves O 
SNAP-25 O 
, O 
botulinum O 
neurotoxin O 
type O 
A O 
( O 
BoNT O 
/ O 
A O 
) O 
, O 
in O 
treating O 
numerous O 
diseases O 
due O 
to O 
hyper O 
- O 
active O 
autonomic O 
nerves O 
, O 
truncation O 
of O 
its O 
target O 
and O 
inhibition O 
of O 
neurotransmission O 
were O 
studied O 
in O 
rat O 
sympathetic O 
neurons O 
. O 
Tetrodotoxin B-TRIVIAL 
-sensitive O 
spontaneous O 
cholinergic O 
neurotransmission O 
was O 
blocked O 
> O 
80% O 
by O 
1 O 
pM O 
BoNT O 
/ O 
A O 
despite O 
cleaving O 
< O 
20% O 
of O 
the O 
SNAP-25 O 
. O 
A O 
maximum O 
cleavage O 
of O 
∼60% O 
SNAP-25 O 
could O 
be O 
achieved O 
with O 
> O 
1 O 
nM O 
BoNT O 
/ O 
A O 
, O 
despite O 
an O 
absence O 
of O 
non-cleavable O 
SNAP-25 O 
in O 
the O 
detergent-solubilised O 
neurons O 
. O 
In O 
contrast O 
, O 
BoNT O 
/ O 
E O 
( O 
100 O 
nM O 
) O 
truncated O 
nearly O 
all O 
the O 
SNAP-25 O 
in O 
the O 
intact O 
cells O 
, O 
but O 
was O 
unable O 
to O 
block O 
neurotransmission O 
at O 
low O 
concentrations O 
like O 
BoNT O 
/ O 
A O 
. O 
Chimeras O 
created O 
by O 
inserting O 
the O 
acceptor O 
- O 
binding O 
HC O 
domain O 
of O 
BoNT O 
/ O 
A O 
into O 
BoNT O 
/ O 
E O 
still O 
cleaved O 
all O 
the O 
SNAP-25 O 
, O 
indicating O 
ubiquitous O 
expression O 
of O 
BoNT O 
/ O 
A O 
acceptors O 
. O 
Accordingly O 
, O 
SV2 O 
and O 
SNAP-25 O 
were O 
found O 
to O 
be O 
co O 
- O 
expressed O 
and O 
broadly O 
co O 
- O 
localised O 
in O 
neurons O 
, O 
but O 
absent O 
from O 
non-neuronal O 
cells O 
. O 
On O 
the O 
other O 
hand O 
, O 
partial O 
cleavage O 
by O 
the O 
BoNT O 
/ O 
A O 
protease O 
persisted O 
upon O 
replacing O 
its O 
HC O 
with O 
counterparts O 
from O 
BoNT O 
/ O 
E O 
or O 
BoNT O 
/ O 
B O 
. O 
Moreover O 
, O 
limited O 
cleavage O 
of O 
SNAP-25 O 
was O 
conferred O 
onto O 
the O 
protease O 
from O 
BoNT O 
/ O 
E O 
when O 
fused O 
to O 
the O 
N B-FORMULA 
-terminus O 
of O 
BoNT O 
/ O 
A O 
. O 
Thus O 
, O 
the O 
BoNT O 
/ O 
A O 
protease O 
is O 
uniquely O 
well O 
- O 
adapted O 
for O 
selectively O 
inactivating O 
the O 
SNAP-25 O 
directly O 
involved O 
in O 
neurotransmission O 
; O 
this O 
together O 
with O 
the O 
toxin's O 
acceptor O 
and O 
its O 
target O 
being O 
localised O 
on O 
the O 
peri O 
- O 
somatic O 
boutons O 
likely O 
contribute O 
to O 
its O 
exceptional O 
therapeutic O 
utility O 
in O 
the O 
clinic O 
. O 

modifications O 
of O 
polymethacrylates B-FAMILY 
: O 
Impact O 
on O 
thermal O 
behavior O 
and O 
release O 
characteristics O 
of O 
glassy O 
solid O 
solutions O 
. O 

such O 
as O 
Eudragit B-TRIVIAL 
® O 
polymers O 
are O 
well O 
established O 
as O 
drug O 
delivery O 
matrix O 
. O 
Here O 
, O 
we O 
synthesize O 
several O 
Eudragit B-FAMILY 
E I-FAMILY 
PO I-FAMILY 
( O 
n-butyl B-SYSTEMATIC 
- O 
, O 
dimethylaminoethyl B-SYSTEMATIC 
- O 
, O 
methyl-methacrylate B-SYSTEMATIC 
- O 
terpolymer B-FAMILY 
) O 
analogues O 
via O 
free O 
radical O 
polymerization O 
. O 
These O 
polymers O 
are O 
processed O 
via O 
hot O 
melt O 
extrusion O 
, O 
followed O 
by O 
injection O 
molding O 
and O 
evaluated O 
as O 
carriers O 
to O 
produce O 
immediate O 
release O 
solid O 
solution O 
tablets O 
. O 
Three O 
chemical O 
modifications O 
increased O 
the O 
glass O 
transition O 
temperature O 
of O 
the O 
polymer O 
: O 
( O 
a O 
) O 
substitution O 
of O 
n-butyl B-SYSTEMATIC 
by O 
t-butyl B-SYSTEMATIC 
groups O 
, O 
( O 
b O 
) O 
reduction O 
of O 
the O 
dimethylaminoethyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
( O 
DMAEMA B-ABBREVIATION 
) O 
content O 
, O 
and O 
( O 
c O 
) O 
incorporation O 
of O 
a O 
bulky O 
isobornyl B-TRIVIAL 
repeating O 
unit O 
. O 
These O 
structural O 
modifications O 
revealed O 
the O 
possibility O 
to O 
increase O 
the O 
mechanical O 
stability O 
of O 
the O 
tablets O 
via O 
altering O 
the O 
polymer O 
Tg O 
without O 
influencing O 
the O 
drug O 
release O 
characteristics O 
and O 
glassy O 
solid O 
solution O 
forming O 
properties O 
. O 
The O 
presence O 
of O 
DMAEMA B-ABBREVIATION 
units O 
proved O 
to O 
be O 
crucial O 
with O 
respect O 
to O 
API O 
/ O 
polymer O 
interaction O 
( O 
essential O 
in O 
creating O 
glassy O 
solid O 
solutions O 
) O 
and O 
drug O 
release O 
characteristics O 
. O 
Moreover O 
, O 
these O 
chemical O 
modifications O 
accentuate O 
the O 
need O 
for O 
a O 
more O 
rational O 
design O 
of O 
( O 
methacrylate B-TRIVIAL 
) O 
polymer O 
matrix O 
excipients O 
for O 
drug O 
formulation O 
via O 
hot O 
melt O 
extrusion O 
and O 
injection O 
molding O 
. O 

in O 
fishes O 
from O 
Augusta O 
Bay O 
( O 
southern O 
Italy O 
) O 
: O 
Risk O 
assessment O 
and O 
health O 
implication O 
. O 

study O 
reports O 
on O 
the O 
total O 
mercury B-SYSTEMATIC 
( O 
HgT O 
) O 
concentrations O 
measured O 
in O 
the O 
muscles O 
and O 
livers O 
of O 
several O 
benthic O 
, O 
demersal O 
and O 
pelagic O 
fish O 
species O 
caught O 
inside O 
and O 
outside O 
of O 
Augusta O 
Bay O 
( O 
southern O 
Italy O 
) O 
, O 
a O 
semi-enclosed O 
marine O 
area O 
, O 
highly O 
contaminated O 
by O 
the O 
uncontrolled O 
( O 
since O 
the O 
1950s O 
to O 
1978s O 
) O 
discharge O 
of O 
the O 
largest O 
European O 
petrochemical O 
plant O 
. O 
Mercury B-SYSTEMATIC 
levels O 
in O 
fish O 
tissues O 
are O 
discussed O 
with O 
regard O 
to O 
specific O 
habitat O 
, O 
size O 
and O 
/ O 
or O 
age O 
of O 
the O 
specimens O 
and O 
HgT O 
distribution O 
in O 
the O 
bottom O 
sediments O 
. O 
Results O 
suggest O 
a O 
still O 
active O 
Hg B-FORMULA 
release O 
mechanism O 
from O 
the O 
polluted O 
sediments O 
to O 
the O 
marine O 
environment O 
. O 
Also O 
, O 
the O 
high O 
HgT O 
concentrations O 
measured O 
in O 
fishes O 
caught O 
in O 
the O 
external O 
area O 
of O 
the O 
bay O 
imply O 
a O 
potential O 
role O 
of O 
Augusta O 
Bay O 
as O 
a O 
pollutant O 
source O 
for O 
the O 
Mediterranean O 
ecosystem O 
. O 
Finally O 
, O 
values O 
of O 
hazard O 
target O 
quotient O 
( O 
THQ O 
) O 
and O 
estimated O 
weekly O 
intake O 
( O 
EWI O 
) O 
demonstrate O 
that O 
consumption O 
of O 
fishes O 
caught O 
inside O 
the O 
bay O 
represents O 
a O 
serious O 
risk O 
for O 
human O 
health O 
. O 
Also O 
, O 
data O 
indicate O 
that O 
intake O 
of O 
fishes O 
caught O 
from O 
the O 
external O 
area O 
of O 
the O 
bay O 
, O 
especially O 
for O 
that O 
concern O 
demersal O 
and O 
benthic O 
species O 
, O 
could O 
be O 
represent O 
a O 
significant O 
component O 
of O 
risk O 
for O 
the O 
local O 
population O 
. O 

hydrogen I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
catalyzed O 
convenient O 
synthesis O 
of O 
2,5-dimethyl-N- B-FAMILY 
substituted I-FAMILY 
pyrroles I-FAMILY 
under O 
ultrasonic O 
irradiation O 
. O 

liquid O 
[HMIM]HSO4 B-FORMULA 
was O 
found O 
to O 
be O 
an O 
efficient O 
catalyst O 
for O 
the O 
synthesis O 
of O 
N- B-FAMILY 
substituted I-FAMILY 
pyrroles I-FAMILY 
through O 
the O 
reaction O 
of O 
2,5-hexanedione B-SYSTEMATIC 
with O 
amines B-FAMILY 
under O 
ultrasonic O 
irradiation O 
at O 
room O 
temperature O 
. O 
These O 
reactions O 
proceed O 
with O 
good O 
yields O 
under O 
short O 
reaction O 
time O 
. O 
Furthermore O 
, O 
the O 
green O 
catalytic O 
system O 
can O 
be O 
recycled O 
specific O 
times O 
with O 
no O 
decreases O 
in O 
yields O 
and O 
reaction O 
rates O 
. O 

Radix O 
attenuates O 
dimethylnitrosamine B-SYSTEMATIC 
-induced O 
liver O 
fibrosis O 
in O 
rats O 
by O 
inducing O 
Nrf2 O 
- O 
mediated O 
antioxidant O 
enzymes O 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
anti-fibrotic O 
effects O 
of O 
the O 
aqueous O 
extract O 
of O 
the O 
Platycodi O 
Radix O 
root O 
( O 
Changkil O 
: O 
CK O 
) O 
on O 
dimethylnitrosamine B-SYSTEMATIC 
( O 
DMN B-ABBREVIATION 
)-induced O 
liver O 
fibrosis O 
in O 
rats O 
. O 
DMN B-ABBREVIATION 
treatment O 
for O 
4weeks O 
led O 
to O 
marked O 
liver O 
fibrosis O 
as O 
assessed O 
by O 
serum O 
biochemistry O 
, O 
histopathological O 
examination O 
, O 
and O 
hepatic O 
lipid O 
peroxidation O 
and O 
collagen O 
content O 
. O 
CK O 
significantly O 
inhibited O 
DMN B-ABBREVIATION 
-induced O 
increases O 
in O 
serum O 
alanine B-TRIVIAL 
aminotransferase O 
( O 
ALT O 
) O 
and O 
aspartate B-TRIVIAL 
aminotransferase O 
( O 
AST O 
) O 
activities O 
, O 
fibrosis O 
score O 
, O 
and O 
hepatic O 
malondialdehyde B-TRIVIAL 
and O 
collagen O 
content O 
. O 
CK O 
also O 
inhibited O 
DMN B-ABBREVIATION 
-induced O 
reductions O 
in O 
rat O 
body O 
and O 
liver O 
weights O 
. O 
Reverse O 
transcription O 
polymerase O 
chain O 
reaction O 
( O 
RT-PCR O 
) O 
and O 
western O 
blot O 
analyses O 
revealed O 
that O 
CK O 
inhibited O 
DMN B-ABBREVIATION 
-induced O 
increases O 
in O 
matrix O 
metalloproteinase-13 O 
( O 
MMP-13 O 
) O 
, O 
tissue O 
inhibitor O 
of O 
metalloproteinase-1 O 
( O 
TIMP-1 O 
) O 
, O 
and O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
mRNA O 
, O 
and O 
collagen O 
type O 
I O 
and O 
α-smooth O 
muscle O 
actin O 
protein O 
. O 
DMN B-ABBREVIATION 
-induced O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
expression O 
and O 
nuclear O 
factor O 
- O 
kappa O 
B O 
( O 
NF-κB O 
) O 
activation O 
was O 
reduced O 
by O 
CK O 
treatment O 
. O 
Furthermore O 
, O 
CK O 
induced O 
activation O 
of O 
nuclear O 
erythroid O 
2- O 
related O 
factor O 
2 O 
( O 
Nrf2 O 
) O 
- O 
mediated O 
antioxidant O 
enzymes O 
such O 
as O 
γ-glutamylcysteine B-SYSTEMATIC 
synthetase O 
( O 
γ-GCS O 
) O 
, O 
heme B-FAMILY 
oxygenase-1 O 
( O 
HO-1 O 
) O 
, O 
NAD(P)H B-ABBREVIATION 
quinone B-FAMILY 
oxidoreductase O 
1 O 
( O 
NQO1 O 
) O 
, O 
and O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
( O 
GST O 
) O 
in O 
HepG2 O 
cells O 
. O 
These O 
results O 
demonstrated O 
that O 
CK O 
attenuates O 
DMN B-ABBREVIATION 
-induced O 
liver O 
fibrosis O 
through O 
the O 
activation O 
of O 
Nrf2 O 
- O 
mediated O 
antioxidant O 
enzymes O 
. O 

determination O 
and O 
bioaccessibility O 
study O 
of O 
ethyl B-SYSTEMATIC 
lauroyl I-SYSTEMATIC 
arginate I-SYSTEMATIC 
( O 
LAE B-ABBREVIATION 
) O 
from O 
a O 
LAE B-ABBREVIATION 
based O 
antimicrobial O 
food O 
packaging O 
material O 
. O 

lauroyl I-SYSTEMATIC 
arginate I-SYSTEMATIC 
( O 
LAE B-ABBREVIATION 
, O 
ethyl-N-dodecanoyl-L-arginate B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
) O 
is O 
a O 
strong O 
antimicrobial O 
agent O 
that O 
was O 
included O 
as O 
an O 
active O 
compound O 
in O 
an O 
antimicrobial O 
food O 
packaging O 
material O 
. O 
The O 
potential O 
existence O 
of O 
non-intentionally O 
added O 
substances O 
( O 
NIASs O 
) O 
such O 
as O 
impurities O 
must O 
therefore O 
be O 
checked O 
before O 
launching O 
any O 
food O 
contact O 
material O 
onto O 
the O 
market O 
. O 
For O 
this O 
reason O 
, O 
an O 
untargeted O 
analysis O 
of O 
the O 
migration O 
was O 
performed O 
in O 
both O 
food O 
simulants O 
and O 
fresh O 
chicken O 
breast O 
fillets O 
wrapped O 
with O 
the O 
active O 
material O 
. O 
The O 
analysis O 
was O 
performed O 
by O 
liquid O 
chromatography O 
coupled O 
to O 
mass O 
spectrometry O 
detection O 
with O 
a O 
quadrupole O 
- O 
time O 
- O 
of O 
- O 
flight O 
analyzer O 
, O 
LC-MS(QTOF) O 
, O 
for O 
the O 
identification O 
of O 
nonvolatile O 
substances O 
. O 
The O 
migration O 
values O 
found O 
for O 
LAE B-ABBREVIATION 
were O 
0.94±0.14 O 
and O 
1.62±0.70μg O 
/ O 
g O 
in O 
ethanol B-SYSTEMATIC 
10% O 
v O 
/ O 
v O 
( O 
simulant O 
A O 
) O 
and O 
in O 
ethanol B-SYSTEMATIC 
95% O 
v O 
/ O 
v O 
( O 
simulant O 
D O 
) O 
, O 
respectively O 
, O 
and O 
0.93±0.17μg O 
/ O 
g O 
in O 
chicken O 
. O 
Other O 
migrants O 
such O 
as O 
dipropylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
methyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
or O 
tributyl-o-acetylcitrate B-SYSTEMATIC 
, O 
both O 
coming O 
from O 
the O 
coating O 
were O 
also O 
found O 
, O 
but O 
none O 
of O 
them O 
have O 
potential O 
adverse O 
effects O 
. O 
Bioaccessibility O 
studies O 
showed O 
that O 
after O 
a O 
simulated O 
gastrointestinal O 
digestion O 
, O 
LAE B-ABBREVIATION 
was O 
not O 
available O 
anymore O 
for O 
subsequent O 
intestinal O 
absorption O 
and O 
new O 
toxic O 
compounds O 
were O 
not O 
formed O 
. O 

telluride I-SYSTEMATIC 
quantum O 
dots O 
cause O 
oxidative O 
stress O 
leading O 
to O 
extrinsic O 
and O 
intrinsic O 
apoptosis O 
in O 
hepatocellular O 
carcinoma O 
HepG2 O 
cells O 
. O 

mechanisms O 
of O 
toxicity O 
related O 
to O 
human O 
hepatocellular O 
carcinoma O 
HepG2 O 
cell O 
exposures O 
to O 
cadmium B-SYSTEMATIC 
telluride I-SYSTEMATIC 
quantum O 
dots O 
( O 
CdTe B-FORMULA 
-QDs O 
) O 
were O 
investigated O 
. O 
CdTe B-FORMULA 
-QDs O 
caused O 
cytotoxicity O 
in O 
HepG2 O 
cells O 
in O 
a O 
dose- O 
and O 
time O 
- O 
dependent O 
manner O 
. O 
Treated O 
cells O 
showed O 
an O 
increase O 
in O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
. O 
Altered O 
antioxidant O 
levels O 
were O 
demonstrated O 
by O 
depletion O 
of O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
, O 
a O 
decreased O 
ratio O 
of O 
reduced O 
glutathione B-TRIVIAL 
to O 
oxidized B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSH B-ABBREVIATION 
/ O 
GSSG B-ABBREVIATION 
) O 
and O 
an O 
increased O 
NF-E2 O 
- O 
related O 
Factor O 
2 O 
( O 
Nrf2 O 
) O 
activation O 
. O 
Enzyme O 
assays O 
showed O 
that O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
activity O 
was O 
elevated O 
whereas O 
catalase O 
( O 
CAT O 
) O 
and O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
( O 
GST O 
) O 
activities O 
were O 
depressed O 
. O 
Further O 
analyses O 
revealed O 
that O 
CdTe B-FORMULA 
-QD O 
exposure O 
resulted O 
in O 
apoptosis O 
, O 
indicated O 
by O 
changes O 
in O 
levels O 
of O 
caspase-3 O 
activity O 
, O 
poly B-SYSTEMATIC 
ADP-ribose I-SYSTEMATIC 
polymerase O 
( O 
PARP O 
) O 
cleavage O 
and O 
phosphatidylserine B-FAMILY 
externalization O 
. O 
Extrinsic O 
apoptotic O 
pathway O 
markers O 
such O 
as O 
Fas O 
levels O 
and O 
caspase-8 O 
activity O 
increased O 
as O 
a O 
result O 
of O 
CdTe B-FORMULA 
-QD O 
exposure O 
. O 
Involvement O 
of O 
the O 
intrinsic O 
/ O 
mitochondrial O 
apoptotic O 
pathway O 
was O 
indicated O 
by O 
decreased O 
levels O 
of O 
B-cell O 
lymphoma O 
2 O 
( O 
Bcl2 O 
) O 
protein O 
and O 
mitochondrial O 
cytochrome O 
c O 
, O 
and O 
by O 
increased O 
levels O 
of O 
mitochondrial O 
Bcl-2-associated O 
X O 
protein O 
( O 
Bax O 
) O 
and O 
cytosolic O 
cytochrome O 
c O 
. O 
Further O 
, O 
mitogen O 
- O 
activated O 
protein O 
kinases O 
( O 
MAPKs O 
) O 
such O 
as O 
c-Jun O 
N B-FORMULA 
-terminal O 
kinases O 
( O 
JNK O 
) O 
, O 
extracellular O 
signal O 
- O 
regulated O 
kinases O 
( O 
Erk1 O 
/ O 
2 O 
) O 
, O 
and O 
p38 O 
were O 
all O 
activated O 
. O 
Our O 
findings O 
reveal O 
that O 
CdTe B-FORMULA 
-QDs O 
cause O 
oxidative O 
stress O 
, O 
interfere O 
with O 
antioxidant O 
defenses O 
and O 
activate O 
protein O 
kinases O 
, O 
leading O 
to O 
apoptosis O 
via O 
both O 
extrinsic O 
and O 
intrinsic O 
pathways O 
. O 
Since O 
the O 
effects O 
of O 
CdTe B-FORMULA 
-QDs O 
on O 
selected O 
biomarkers O 
were O 
similar O 
or O 
greater O 
compared O 
to O 
those O 
of O 
CdCl2 B-FORMULA 
at O 
equivalent O 
concentrations O 
of O 
cadmium B-SYSTEMATIC 
, O 
the O 
study O 
suggests O 
that O 
the O 
toxicity O 
of O 
CdTe B-FORMULA 
-QDs O 
arises O 
from O 
a O 
combination O 
of O 
the O 
effects O 
of O 
cadmium O 
and O 
ROS O 
generated O 
from O 
the O 
NPs O 
. O 

of O 
rat O 
liver O 
branched O 
- O 
chain O 
alpha-keto B-SYSTEMATIC 
acid I-SYSTEMATIC 
dehydrogenase O 
activity O 
by O 
low O 
doses O 
of O 
bezafibrate B-TRIVIAL 
. O 

branched O 
- O 
chain O 
alpha-ketoacid B-SYSTEMATIC 
dehydrogenase O 
complex O 
( O 
BCKDH O 
) O 
catalyzes O 
the O 
regulatory O 
step O 
of O 
oxidative O 
catabolism O 
of O 
indispensable O 
branched O 
- O 
chain O 
amino B-FAMILY 
acids I-FAMILY 
( O 
BCAA O 
) O 
. O 
The O 
activity O 
of O 
the O 
BCKDH O 
complex O 
is O 
regulated O 
by O 
a O 
reversible O 
phosphorylation O 
, O 
end O 
- O 
product O 
inhibition O 
and O 
by O 
changes O 
in O 
the O 
gene O 
expression O 
of O 
BCKDH O 
component O 
enzymes O 
. O 
It O 
has O 
been O 
shown O 
previously O 
that O 
a O 
high O 
dose O 
of O 
bezafibrate B-TRIVIAL 
( O 
an O 
agent O 
added O 
to O 
rat O 
chow O 
at O 
final O 
concentration O 
of O 
0.5% O 
) O 
changes O 
mRNA O 
levels O 
of O 
BCKDH O 
- O 
related O 
enzymes O 
and O 
increases O 
dephosphorylation O 
of O 
the O 
complex O 
leading O 
to O 
stimulation O 
of O 
liver O 
BCKDH O 
activity O 
and O 
the O 
enhanced O 
BCAA O 
catabolism O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
determine O 
an O 
in O 
vivo O 
effect O 
of O 
low O 
, O 
clinically O 
relevant O 
doses O 
of O 
bezafibrate B-TRIVIAL 
on O 
BCKDH O 
activity O 
in O 
rat O 
liver O 
. O 
Bezafibrate B-TRIVIAL 
was O 
administrated O 
for O 
14 O 
days O 
by O 
gastric O 
gavage O 
to O 
Wistar O 
male O 
rats O 
( O 
fed O 
low O 
- O 
protein O 
chow O 
; O 
8% O 
protein O 
) O 
at O 
one O 
of O 
the O 
following O 
daily O 
doses O 
of O 
5 O 
, O 
10 O 
and O 
20mg O 
/ O 
kgb.wt O 
. O 
The O 
control O 
group O 
was O 
given O 
the O 
vehicle O 
( O 
0.3% O 
methylcellulose O 
) O 
only O 
. O 
The O 
actual O 
BCKDH O 
and O 
total O 
BCKDH O 
activities O 
were O 
assayed O 
spectrophotometrically O 
before O 
and O 
after O 
incubation O 
with O 
a O 
broad O 
- O 
specificity O 
phosphatase O 
, O 
respectively O 
. O 
The O 
mRNA O 
levels O 
of O 
the O 
selected O 
genes O 
( O 
BCKDH O 
catalytic O 
subunits O 
and O 
regulatory O 
enzymes O 
) O 
were O 
quantified O 
by O 
means O 
of O 
semi-quantitative O 
RT-PCR O 
. O 
Current O 
catalytic O 
activity O 
of O 
BCKDH O 
( O 
described O 
as O 
BCKDH O 
activity O 
state O 
- O 
the O 
proportion O 
of O 
the O 
BCKDH O 
complex O 
in O 
its O 
active O 
dephosphorylated O 
form O 
) O 
increased O 
by O 
2.1±0.2 O 
, O 
2.3±0.2 O 
and O 
2.7±0.2 O 
fold O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
Changes O 
in O 
BCKDH O 
activity O 
did O 
not O 
correspond O 
with O 
changes O 
in O 
mRNA O 
levels O 
of O 
the O 
complex O 
catalytic O 
subunits O 
. O 
Moreover O 
, O 
mRNA O 
levels O 
of O 
regulatory O 
enzymes O 
remained O 
unaltered O 
. O 
Initially O 
bezafibrate B-TRIVIAL 
caused O 
a O 
transient O 
insignificant O 
reduction O 
in O 
body O 
weight O 
, O 
but O 
it O 
had O 
no O 
effect O 
on O 
the O 
final O 
body O 
weight O 
. O 
The O 
highest O 
dose O 
of O 
bezafibrate B-TRIVIAL 
induced O 
hepatomegaly O 
. O 
In O 
conclusion O 
, O 
these O 
data O 
indicate O 
that O 
under O 
conditions O 
of O 
dietary O 
protein O 
restriction O 
low O 
, O 
clinically O 
relevant O 
doses O 
of O 
bezafibrate B-TRIVIAL 
have O 
a O 
similar O 
adverse O 
effect O 
on O 
rat O 
liver O 
BCKDH O 
activity O 
and O 
BCAA O 
degradation O 
rate O 
as O 
the O 
high O 
experimental O 
dose O 
. O 
Up-regulation O 
of O 
liver O 
BCKDH O 
activity O 
by O 
low O 
doses O 
of O 
bezafibrate B-TRIVIAL 
appears O 
to O 
result O 
mainly O 
from O 
changes O 
in O 
phosphorylation O 
status O 
of O 
the O 
complex O 
( O 
increased O 
dephosphorylation O 
) O 
and O 
is O 
not O 
associated O 
with O 
elevations O 
in O 
mRNA O 
levels O 
of O 
BCKDH O 
enzymatic O 
components O 
. O 

in O 
CYP2D6 O 
and O 
CYP2C19 O 
affect O 
the O 
efficacy O 
and O 
safety O 
of O 
tricyclics O 
, O 
with O 
some O 
drugs O 
being O 
affected O 
by O 
CYP2D6 O 
only O 
, O 
and O 
others O 
by O 
both O 
polymorphic O 
enzymes O 
. O 
Amitriptyline B-TRIVIAL 
, O 
clomipramine B-TRIVIAL 
, O 
doxepin B-TRIVIAL 
, O 
imipramine B-TRIVIAL 
, O 
and O 
trimipramine B-TRIVIAL 
are O 
demethylated O 
by O 
CYP2C19 O 
to O 
pharmacologically O 
active O 
metabolites O 
. O 
These O 
drugs O 
and O 
their O 
metabolites O 
, O 
along O 
with O 
desipramine B-TRIVIAL 
and O 
nortriptyline B-TRIVIAL 
, O 
undergo O 
hydroxylation O 
by O 
CYP2D6 O 
to O 
less O 
active O 
metabolites O 
. O 
Evidence O 
from O 
published O 
literature O 
is O 
presented O 
for O 
CYP2D6 O 
and O 
CYP2C19 O 
genotype O 
- O 
directed O 
dosing O 
of O 
tricyclic O 
antidepressants O 
. O 

Explanation O 
for O 
Allolactose B-TRIVIAL 
( O 
lac O 
Operon O 
Inducer O 
) O 
Synthesis O 
by O 
lacZ O 
β-Galactosidase O 
and O 
the O 
Evolutionary O 
Relationship O 
between O 
Allolactose B-TRIVIAL 
Synthesis O 
and O 
the O 
lac O 
Repressor O 
. O 

( O 
lacZ O 
) O 
has O 
bifunctional O 
activity O 
. O 
It O 
hydrolyzes O 
lactose B-TRIVIAL 
to O 
galactose B-TRIVIAL 
and O 
glucose B-TRIVIAL 
and O 
catalyzes O 
the O 
intramolecular O 
isomerization O 
of O 
lactose B-TRIVIAL 
to O 
allolactose B-TRIVIAL 
, O 
the O 
lac O 
operon O 
inducer O 
. O 
β-Galactosidase O 
promotes O 
the O 
isomerization O 
by O 
means O 
of O 
an O 
acceptor O 
site O 
that O 
binds O 
glucose B-TRIVIAL 
after O 
its O 
cleavage O 
from O 
lactose B-TRIVIAL 
and O 
thus O 
delays O 
its O 
exit O 
from O 
the O 
site O 
. O 
However O 
, O 
because O 
of O 
its O 
relatively O 
low O 
affinity O 
for O 
glucose B-TRIVIAL 
, O 
details O 
of O 
this O 
site O 
have O 
remained O 
elusive O 
. O 
We O 
present O 
structural O 
data O 
mapping O 
the O 
glucose B-TRIVIAL 
site O 
based O 
on O 
a O 
substituted O 
enzyme O 
( O 
G794A-β-galactosidase O 
) O 
that O 
traps O 
allolactose B-TRIVIAL 
. O 
Various O 
lines O 
of O 
evidence O 
indicate O 
that O 
the O 
glucose B-TRIVIAL 
of O 
the O 
trapped O 
allolactose B-TRIVIAL 
is O 
in O 
the O 
acceptor O 
position O 
. O 
The O 
evidence O 
includes O 
structures O 
with O 
Bis-Tris B-SYSTEMATIC 
( I-SYSTEMATIC 
2,2-bis(hydroxymethyl)-2,2',2″-nitrilotriethanol I-SYSTEMATIC 
) I-SYSTEMATIC 
and O 
l-ribose B-TRIVIAL 
in O 
the O 
site O 
and O 
kinetic O 
binding O 
studies O 
with O 
substituted O 
β-galactosidases O 
. O 
The O 
site O 
is O 
composed O 
of O 
Asn B-FORMULA 
-102 O 
, O 
His B-FORMULA 
-418 O 
, O 
Lys B-FORMULA 
-517 O 
, O 
Ser B-FORMULA 
-796 O 
, O 
Glu B-FORMULA 
-797 O 
, O 
and O 
Trp B-FORMULA 
-999 O 
. O 
Ser B-FORMULA 
-796 O 
and O 
Glu B-FORMULA 
-797 O 
are O 
part O 
of O 
a O 
loop O 
( O 
residues O 
795-803 O 
) O 
that O 
closes O 
over O 
the O 
active O 
site O 
. O 
This O 
loop O 
appears O 
essential O 
for O 
the O 
bifunctional O 
nature O 
of O 
the O 
enzyme O 
because O 
it O 
helps O 
form O 
the O 
glucose B-TRIVIAL 
binding O 
site O 
. O 
In O 
addition O 
, O 
because O 
the O 
loop O 
is O 
mobile O 
, O 
glucose B-TRIVIAL 
binding O 
is O 
transient O 
, O 
allowing O 
the O 
release O 
of O 
some O 
glucose B-TRIVIAL 
. O 
Bioinformatics O 
studies O 
showed O 
that O 
the O 
residues O 
important O 
for O 
interacting O 
with O 
glucose B-TRIVIAL 
are O 
only O 
conserved O 
in O 
a O 
subset O 
of O 
related O 
enzymes O 
. O 
Thus O 
, O 
intramolecular O 
isomerization O 
is O 
not O 
a O 
universal O 
feature O 
of O 
β-galactosidases O 
. O 
Genomic O 
analyses O 
indicated O 
that O 
lac O 
repressors O 
were O 
co O 
- O 
selected O 
only O 
within O 
the O 
conserved O 
subset O 
. O 
This O 
shows O 
that O 
the O 
glucose B-TRIVIAL 
binding O 
site O 
of O 
β-galactosidase O 
played O 
an O 
important O 
role O 
in O 
lac O 
operon O 
evolution O 
. O 

II O 
type O 
1 O 
receptor O 
antagonists O 
( O 
ARBs O 
) O 
have O 
become O 
an O 
important O 
drug O 
class O 
in O 
the O 
treatment O 
of O 
hypertension O 
and O 
heart O 
failure O 
and O 
the O 
protection O 
from O 
diabetic O 
nephropathy O 
. O 
Eight O 
ARBs O 
are O 
clinically O 
available O 
[ O 
azilsartan B-TRIVIAL 
, O 
candesartan B-TRIVIAL 
, O 
eprosartan B-TRIVIAL 
, O 
irbesartan B-TRIVIAL 
, O 
losartan B-TRIVIAL 
, O 
olmesartan B-TRIVIAL 
, O 
telmisartan B-TRIVIAL 
, O 
valsartan B-TRIVIAL 
] O 
. O 
Azilsartan B-TRIVIAL 
( O 
in O 
some O 
countries O 
) O 
, O 
candesartan B-TRIVIAL 
, O 
and O 
olmesartan B-TRIVIAL 
are O 
orally O 
administered O 
as O 
prodrugs O 
, O 
whereas O 
the O 
blocking O 
action O 
of O 
some O 
is O 
mediated O 
through O 
active O 
metabolites O 
. O 
On O 
the O 
basis O 
of O 
their O 
chemical O 
structures O 
, O 
ARBs O 
use O 
different O 
binding O 
pockets O 
in O 
the O 
receptor O 
, O 
which O 
are O 
associated O 
with O 
differences O 
in O 
dissociation O 
times O 
and O 
, O 
in O 
most O 
cases O 
, O 
apparently O 
insurmountable O 
antagonism O 
. O 
The O 
physicochemical O 
differences O 
between O 
ARBs O 
also O 
manifest O 
in O 
different O 
tissue O 
penetration O 
, O 
including O 
passage O 
through O 
the O 
blood O 
- O 
brain O 
barrier O 
. O 
Differences O 
in O 
binding O 
mode O 
and O 
tissue O 
penetration O 
are O 
also O 
associated O 
with O 
differences O 
in O 
pharmacokinetic O 
profile O 
, O 
particularly O 
duration O 
of O 
action O 
. O 
Although O 
generally O 
highly O 
specific O 
for O 
angiotensin O 
II O 
type O 
1 O 
receptors O 
, O 
some O 
ARBs O 
, O 
particularly O 
telmisartan B-TRIVIAL 
, O 
are O 
partial O 
agonists O 
at O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor-γ O 
. O 
All O 
of O 
these O 
properties O 
are O 
comprehensively O 
reviewed O 
in O 
this O 
article O 
. O 
Although O 
there O 
is O 
general O 
consensus O 
that O 
a O 
continuous O 
receptor O 
blockade O 
over O 
a O 
24-hour O 
period O 
is O 
desirable O 
, O 
the O 
clinical O 
relevance O 
of O 
other O 
pharmacological O 
differences O 
between O 
individual O 
ARBs O 
remains O 
to O 
be O 
assessed O 
. O 

OH B-FORMULA 
oxidation O 
of O 
biomass O 
burning O 
organic O 
aerosol O 
surrogate O 
compounds O 
: O 
assessment O 
of O 
volatilisation O 
products O 
and O 
the O 
role O 
of O 
OH B-FORMULA 
concentration O 
on O 
the O 
reactive O 
uptake O 
kinetics O 
. O 

reactive O 
uptake O 
coefficients O 
( O 
γ O 
) O 
of O 
OH B-FORMULA 
by O 
levoglucosan B-TRIVIAL 
, O 
abietic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
nitroguaiacol B-SYSTEMATIC 
serving O 
as O 
surrogate O 
compounds O 
for O 
biomass O 
burning O 
aerosol O 
have O 
been O 
determined O 
employing O 
a O 
chemical O 
ionisation O 
mass O 
spectrometer O 
coupled O 
to O 
a O 
rotating O 
- O 
wall O 
flow O 
- O 
tube O 
reactor O 
over O 
a O 
wide O 
range O 
of O 
[ O 
OH B-FORMULA 
] O 
∼10(7)-10(11) O 
molecule O 
cm(-3) O 
. O 
Volatilisation O 
products O 
of O 
these O 
organic O 
substrates O 
due O 
to O 
heterogeneous O 
oxidation O 
by O 
OH B-FORMULA 
have O 
been O 
determined O 
at O 
1 O 
atm O 
using O 
a O 
high O 
resolution O 
proton O 
transfer O 
reaction O 
time O 
- O 
of O 
- O 
flight O 
mass O 
spectrometer O 
( O 
HR-PTR-ToF-MS O 
) O 
. O 
γ O 
range O 
within O 
0.05-1 O 
for O 
[ O 
OH B-FORMULA 
] O 
= O 
2.6 O 
× O 
10(7)-3 O 
× O 
10(9) O 
molecule O 
cm(-3) O 
for O 
all O 
investigated O 
organic O 
compounds O 
, O 
but O 
decrease O 
to O 
0.008-0.034 O 
for O 
[ O 
OH B-FORMULA 
] O 
= O 
4.1 O 
× O 
10(10)-6.7 O 
× O 
10(10) O 
molecule O 
cm(-3) O 
. O 
γ O 
as O 
a O 
function O 
of O 
[ O 
OH B-FORMULA 
] O 
can O 
be O 
described O 
by O 
a O 
Langmuir-Hinshelwood O 
model O 
, O 
neglecting O 
bulk O 
processes O 
, O 
suggesting O 
that O 
despite O 
its O 
strong O 
reactivity O 
, O 
OH B-FORMULA 
is O 
mobile O 
on O 
surfaces O 
prior O 
to O 
reaction O 
. O 
The O 
best O 
fit O 
Langmuir-Hinshelwood O 
parameters O 
on O 
average O 
are O 
K( O 
OH B-FORMULA 
) O 
= O 
3.81 O 
× O 
10(-10) O 
cm(3) O 
molecule(-1) O 
and O 
k(s) O 
= O 
9.71 O 
× O 
10(-17) O 
cm(2) O 
molecule(-1) O 
s(-1) O 
for O 
all O 
of O 
the O 
investigated O 
organic O 
compounds O 
. O 
Volatilised O 
products O 
have O 
been O 
identified O 
indicating O 
enhancements O 
over O 
background O 
of O 
50% O 
up O 
to O 
a O 
factor O 
of O 
15 O 
. O 
Amongst O 
the O 
common O 
volatile O 
organic O 
compounds O 
( O 
VOCs O 
) O 
identified O 
between O 
levoglucosan B-TRIVIAL 
, O 
abietic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
nitroguaiacol B-SYSTEMATIC 
were O 
methanol B-SYSTEMATIC 
, O 
acetaldehyde B-SYSTEMATIC 
, O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
and O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
VOCs O 
having O 
the O 
greatest O 
enhancement O 
over O 
background O 
were O 
glucic B-TRIVIAL 
acid I-TRIVIAL 
from O 
levoglucosan B-TRIVIAL 
, O 
glycolic B-TRIVIAL 
acid I-TRIVIAL 
from O 
abietic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
methanol B-SYSTEMATIC 
and O 
nitric B-SYSTEMATIC 
acid I-SYSTEMATIC 
from O 
nitroguaiacol B-SYSTEMATIC 
. O 
Reaction O 
mechanisms O 
leading O 
to O 
the O 
formation O 
of O 
glucic B-TRIVIAL 
acid I-TRIVIAL 
, O 
glycolic B-TRIVIAL 
acid I-TRIVIAL 
, O 
methanol B-SYSTEMATIC 
, O 
and O 
nitric B-SYSTEMATIC 
acid I-SYSTEMATIC 
are O 
proposed O 
. O 
Estimated O 
lower O 
limits O 
of O 
atmospheric O 
lifetimes O 
of O 
biomass O 
burning O 
aerosol O 
particles O 
, O 
200 O 
nm O 
in O 
diameter O 
, O 
by O 
heterogeneous O 
OH B-FORMULA 
oxidation O 
under O 
fresh O 
biomass O 
burning O 
plume O 
conditions O 
are O 
∼2 O 
days O 
and O 
up O 
to O 
∼2 O 
weeks O 
for O 
atmospheric O 
background O 
conditions O 
. O 
However O 
, O 
estimated O 
lifetimes O 
depend O 
crucially O 
on O 
[ O 
OH B-FORMULA 
] O 
and O 
corresponding O 
γ O 
, O 
emphasising O 
the O 
need O 
to O 
determine O 
γ O 
under O 
relevant O 
conditions O 
. O 

: O 
To O 
determine O 
whether O 
baseline O 
characteristics O 
, O 
especially O 
haemoglobin O 
A1c O 
( O 
HbA1c O 
) O 
, O 
predict O 
the O 
likelihood O 
of O 
reaching O 
HbA1c O 
≤ O 
7.0% O 
or O 
the O 
risk O 
of O 
experiencing O 
hypoglycaemia O 
after O 
the O 
addition O 
of O 
insulin O 
glargine O 
to O 
oral O 
therapy O 
in O 
type O 
2 O 
diabetes O 
. O 
METHODS O 
: O 
Pooled O 
patient-level O 
data O 
from O 
12 O 
prospective O 
, O 
randomized O 
, O 
controlled O 
studies O 
that O 
used O 
insulin O 
glargine O 
in O 
a O 
treat O 
- O 
to O 
- O 
target O 
titration O 
regimen O 
seeking O 
fasting O 
glucose B-TRIVIAL 
levels O 
≤ O 
5.5 O 
mmol O 
/ O 
l O 
( O 
100 O 
mg O 
/ O 
dl O 
) O 
were O 
analysed O 
. O 
Baseline O 
characteristics O 
were O 
evaluated O 
by O 
logistic O 
regression O 
models O 
as O 
predictors O 
of O 
reaching O 
a O 
target O 
HbA1c O 
≤ O 
7.0% O 
or O 
experiencing O 
confirmed O 
hypoglycaemia O 
. O 
The O 
effect O 
of O 
prior O 
glycaemic O 
control O 
was O 
further O 
explored O 
by O 
analysis O 
of O 
categorical O 
ranges O 
of O 
baseline O 
HbA1c O 
. O 
RESULTS O 
: O 
Of O 
2312 O 
participants O 
, O 
95% O 
completed O 
24 O 
weeks O 
of O 
treatment O 
. O 
Lower O 
HbA1c O 
at O 
baseline O 
was O 
independently O 
associated O 
with O 
reaching O 
HbA1c O 
target O 
[ O 
adjusted O 
odds O 
ratio O 
( O 
OR O 
) O 
for O 
1% O 
difference O 
: O 
0.538 O 
, O 
p O 
< O 
0.0001 O 
] O 
and O 
also O 
with O 
likelihood O 
of O 
experiencing O 
confirmed O 
hypoglycaemic O 
events O 
( O 
adjusted O 
OR O 
: O 
0.835 O 
, O 
p O 
< O 
0.0001 O 
) O 
at O 
week O 
24 O 
. O 
In O 
an O 
unadjusted O 
analysis O 
by O 
baseline O 
HbA1c O 
range O 
, O 
the O 
strong O 
association O 
between O 
baseline O 
control O 
and O 
attaining O 
target O 
HbA1c O 
was O 
confirmed O 
( O 
75% O 
with O 
baseline O 
HbA1c O 
< O 
8.0% O 
, O 
60% O 
with O 
baseline O 
HbA1c O 
≥ O 
8 O 
and O 
< O 
9.0% O 
and O 
38% O 
with O 
baseline O 
HbA1c O 
≥ O 
9.0% O 
attained O 
HbA1c O 
≤ O 
7.0% O 
) O 
. O 
The O 
incidence O 
of O 
hypoglycaemia O 
confirmed O 
< O 
3.9 O 
mmol O 
/ O 
l O 
( O 
70 O 
mg O 
/ O 
dl O 
) O 
was O 
higher O 
in O 
the O 
lower O 
baseline O 
HbA1c O 
ranges O 
but O 
severe O 
hypoglycaemia O 
was O 
infrequent O 
at O 
all O 
baseline O 
HbA1c O 
levels O 
. O 
CONCLUSIONS O 
: O 
Systematically O 
titrated O 
insulin O 
glargine O 
, O 
added O 
to O 
oral O 
agents O 
, O 
was O 
effective O 
over O 
a O 
wide O 
range O 
of O 
baseline O 
HbA1c O 
. O 
Lower O 
baseline O 
HbA1c O 
was O 
the O 
best O 
clinical O 
predictor O 
of O 
achieving O 
HbA1c O 
≤ O 
7.0% O 
and O 
also O 
associated O 
with O 
higher O 
risk O 
of O 
glucose B-TRIVIAL 
-confirmed O 
hypoglycaemia O 
. O 
Severe O 
hypoglycaemia O 
was O 
infrequent O 
using O 
this O 
treatment O 
approach O 
. O 

, O 
crystal O 
structure O 
and O 
biological O 
evaluation O 
of O 
a O 
main O 
group O 
seven O 
- O 
coordinated O 
bismuth B-SYSTEMATIC 
(III) I-SYSTEMATIC 
complex O 
with O 
2-acetylpyridine B-SYSTEMATIC 
N4-phenylthiosemicarbazone I-SYSTEMATIC 
. O 

to O 
now O 
, O 
bismuth B-SYSTEMATIC 
(III) I-SYSTEMATIC 
complexes O 
with O 
thiosemicarbazones B-FAMILY 
have O 
been O 
comparatively O 
rare O 
. O 
Here O 
, O 
a O 
main O 
group O 
seven O 
- O 
coordinated O 
bismuth B-SYSTEMATIC 
(III) I-SYSTEMATIC 
complex O 
[ O 
Bi(L)(NO3)2(CH3CH2OH) B-FAMILY 
] O 
( O 
1 O 
) O 
( O 
HL O 
= O 
2-acetylpyridine B-SYSTEMATIC 
N(4)-phenylthiosemicarbazone I-SYSTEMATIC 
) O 
has O 
been O 
synthesized O 
and O 
characterized O 
by O 
elemental O 
analysis O 
, O 
IR O 
, O 
(1)H B-FORMULA 
NMR O 
and O 
single O 
- O 
crystal O 
X-ray O 
diffraction O 
studies O 
. O 
The O 
cytotoxicity O 
data O 
suggest O 
that O 
1 O 
exhibits O 
higher O 
in O 
vitro O 
antiproliferative O 
activity O 
in O 
four O 
human O 
cancer O 
cells O 
tested O 
. O 
Its O 
possible O 
apoptotic O 
mechanism O 
has O 
been O 
evaluated O 
in O 
HepG2 O 
cells O 
. O 
Compound O 
1 O 
promotes O 
a O 
dose O 
- O 
dependent O 
apoptosis O 
in O 
HepG2 O 
cells O 
and O 
the O 
apoptosis O 
is O 
associated O 
with O 
an O 
increase O 
in O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
production O 
and O 
reduction O 
of O 
mitochondrial O 
membrane O 
potential O 
( O 
MMP O 
) O 
. O 

and O 
synthesis O 
of O 
N-(thiophen-2-yl) B-SYSTEMATIC 
benzamide I-SYSTEMATIC 
derivatives O 
as O 
BRAF(V600E) O 
inhibitors O 
. O 

V600E O 
BRAF O 
kinase O 
mutation O 
, O 
which O 
activates O 
the O 
downstream O 
MAPK O 
signaling O 
pathway O 
, O 
commonly O 
occurs O 
in O 
about O 
8% O 
of O 
all O 
human O 
malignancies O 
and O 
about O 
50% O 
of O 
all O 
melanomas O 
. O 
In O 
this O 
study O 
, O 
we O 
employed O 
virtual O 
screening O 
and O 
chemical O 
synthesis O 
to O 
identify O 
a O 
series O 
of O 
N-(thiophen-2-yl) B-SYSTEMATIC 
benzamide I-SYSTEMATIC 
derivatives O 
as O 
potent O 
BRAF(V600E) O 
inhibitors O 
. O 
Structure O 
- O 
activity O 
relationship O 
studies O 
of O 
these O 
derivatives O 
revealed O 
that O 
compounds O 
b40 O 
and O 
b47 O 
are O 
the O 
two O 
most O 
potent O 
BRAF(V600E) O 
inhibitors O 
in O 
this O 
series O 
. O 

chemistry O 
of O 
CF3O2 B-FORMULA 
: O 
a O 
theoretical O 
study O 
on O 
mechanisms O 
and O 
pathways O 
of O 
the O 
CF3O2 B-FORMULA 
+ O 
IO B-FORMULA 
reaction O 
. O 

mechanisms O 
and O 
reaction O 
pathways O 
for O 
the O 
CF3O2 B-FORMULA 
+ O 
IO B-FORMULA 
reaction O 
have O 
been O 
investigated O 
by O 
quantum O 
chemistry O 
methods O 
. O 
It O 
has O 
been O 
found O 
that O 
the O 
title O 
reaction O 
takes O 
place O 
on O 
both O 
the O 
singlet O 
and O 
triplet O 
potential O 
energy O 
surfaces O 
( O 
PES O 
) O 
. O 
On O 
the O 
singlet O 
PES O 
, O 
the O 
most O 
important O 
products O 
include O 
CF3OOOI B-FORMULA 
, O 
CF3OOIO B-FORMULA 
, O 
CF3OIO2 B-FORMULA 
, O 
and O 
CF2O B-FORMULA 
+ O 
FIO2 B-FORMULA 
, O 
while O 
other O 
products O 
such O 
as O 
CF2O B-FORMULA 
+ O 
FOIO B-FORMULA 
, O 
CF2O B-FORMULA 
+ O 
FOOI B-FORMULA 
, O 
CF3OOI B-FORMULA 
+ O 
O B-FORMULA 
( O 
(3)P O 
) O 
, O 
CF3OI B-FORMULA 
+ O 
O2 B-FORMULA 
( O 
(1)Δ O 
and O 
(3)Σ O 
) O 
, O 
and O 
CF3O B-FORMULA 
+ O 
OIO B-FORMULA 
are O 
negligible O 
due O 
to O 
high O 
barriers O 
or O 
unstable O 
formations O 
. O 
On O 
the O 
triplet O 
PES O 
, O 
CF3O B-FORMULA 
+ O 
OIO B-FORMULA 
is O 
the O 
dominant O 
product O 
with O 
a O 
lower O 
barrier O 
. O 
As O 
for O 
FIO2 B-FORMULA 
and O 
it O 
isomers O 
, O 
the O 
most O 
stable O 
one O 
is O 
FIO2 B-FORMULA 
. O 
TDDFT O 
( O 
Time O 
Dependent O 
Density O 
Functional O 
Theory O 
) O 
calculation O 
indicates O 
that O 
CF3OOOI B-FORMULA 
, O 
CF3OOIO B-FORMULA 
and O 
CF3OIO2 B-FORMULA 
undergo O 
photolysis O 
easily O 
under O 
sunlight O 
. O 
Moreover O 
, O 
a O 
minor O 
contribution O 
relative O 
to O 
hydrogen B-SYSTEMATIC 
is O 
found O 
in O 
the O 
CX3O2 B-FAMILY 
+ O 
IO B-FORMULA 
( O 
X O 
= O 
H B-FORMULA 
and O 
F B-FORMULA 
) O 
reactions O 
. O 

nicotine B-TRIVIAL 
training O 
doses O 
in O 
mice O 
as O 
a O 
basis O 
for O 
differentiating O 
the O 
effects O 
of O 
smoking O 
cessation O 
aids O 
. O 

: O 
Receptor O 
mechanisms O 
underlying O 
the O 
behavioral O 
effects O 
of O 
clinically O 
used O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
agonists O 
have O 
not O 
been O 
fully O 
established O 
. O 
OBJECTIVE O 
: O 
Drug O 
discrimination O 
was O 
used O 
to O 
compare O 
receptor O 
mechanisms O 
underlying O 
the O 
effects O 
of O 
smoking O 
cessation O 
aids O 
. O 
METHODS O 
: O 
Separate O 
groups O 
of O 
male O 
C57BL O 
/ O 
6J O 
mice O 
discriminated O 
0.56 O 
, O 
1 O 
, O 
or O 
1.78 O 
mg O 
/ O 
kg O 
of O 
nicotine B-TRIVIAL 
base O 
. O 
Nicotine B-TRIVIAL 
, O 
varenicline B-TRIVIAL 
, O 
and O 
cytisine B-TRIVIAL 
were O 
administered O 
alone O 
, O 
in O 
combination O 
with O 
each O 
other O 
, O 
and O 
in O 
combination O 
with O 
mecamylamine B-TRIVIAL 
and O 
dihydro-β-erythroidine B-SYSTEMATIC 
( O 
DHβE B-ABBREVIATION 
) O 
. O 
Midazolam B-TRIVIAL 
and O 
morphine B-TRIVIAL 
were O 
tested O 
to O 
examine O 
sensitivity O 
to O 
non-nicotinics O 
. O 
RESULTS O 
: O 
The O 
ED50 O 
value O 
of O 
nicotine B-TRIVIAL 
to O 
produce O 
discriminative O 
stimulus O 
effects O 
systematically O 
increased O 
as O 
training O 
dose O 
increased O 
. O 
Varenicline B-TRIVIAL 
and O 
cytisine B-TRIVIAL 
did O 
not O 
fully O 
substitute O 
for O 
nicotine B-TRIVIAL 
and O 
, O 
as O 
compared O 
with O 
nicotine B-TRIVIAL 
, O 
their O 
ED50 O 
values O 
varied O 
less O 
systematically O 
as O 
a O 
function O 
of O 
nicotine B-TRIVIAL 
training O 
dose O 
. O 
Morphine B-TRIVIAL 
did O 
not O 
substitute O 
for O 
nicotine B-TRIVIAL 
, O 
whereas O 
midazolam B-TRIVIAL 
substituted O 
for O 
the O 
low O 
and O 
not O 
the O 
higher O 
training O 
doses O 
of O 
nicotine B-TRIVIAL 
. O 
As O 
training O 
dose O 
increased O 
, O 
the O 
dose O 
of O 
mecamylamine B-TRIVIAL 
needed O 
to O 
produce O 
a O 
significant O 
rightward O 
shift O 
in O 
the O 
nicotine O 
dose O 
- O 
effect O 
function O 
also O 
increased O 
. O 
DHβE B-ABBREVIATION 
antagonized O 
nicotine B-TRIVIAL 
in O 
animals O 
discriminating O 
the O 
smallest O 
dose O 
of O 
nicotine B-TRIVIAL 
. O 
Varenicline B-TRIVIAL 
did O 
not O 
antagonize O 
the O 
effects O 
of O 
nicotine B-TRIVIAL 
, O 
whereas O 
cytisine B-TRIVIAL 
produced O 
a O 
modest O 
though O 
significant O 
antagonism O 
of O 
nicotine B-TRIVIAL 
. O 
CONCLUSIONS O 
: O 
These O 
results O 
suggest O 
that O 
differences O 
in O 
pharmacologic O 
mechanism O 
between O 
nicotine B-TRIVIAL 
, O 
varenicline B-TRIVIAL 
, O 
and O 
cytisine B-TRIVIAL 
include O 
not O 
only O 
differences O 
in O 
efficacy O 
at O 
a O 
common O 
subtype O 
of O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
, O 
but O 
also O 
differential O 
affinity O 
and O 
/ O 
or O 
efficacy O 
at O 
multiple O 
receptor O 
subtypes O 
. O 

enhancing O 
effects O 
of O 
nicotine B-TRIVIAL 
via O 
smoking O 
. O 

: O 
In O 
animals O 
, O 
nicotine B-TRIVIAL 
enhances O 
reinforcement O 
from O 
stimuli O 
unrelated O 
to O 
nicotine B-TRIVIAL 
intake O 
. O 
Human O 
research O 
is O 
suggestive O 
but O 
has O 
not O 
clearly O 
shown O 
a O 
similar O 
influence O 
of O 
nicotine B-TRIVIAL 
. O 
OBJECTIVES O 
: O 
We O 
assessed O 
acute O 
effects O 
of O 
nicotine B-TRIVIAL 
via O 
smoking O 
on O 
enhancement O 
of O 
positive O 
( O 
money O 
, O 
music O 
) O 
or O 
negative O 
( O 
termination O 
of O 
noise O 
) O 
reinforcers O 
, O 
or O 
no O 
" O 
reward O 
" O 
( O 
control O 
) O 
. O 
These O 
different O 
rewards O 
determined O 
the O 
generalizability O 
of O 
nicotine B-TRIVIAL 
effects O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Dependent O 
( O 
n O 
= O 
25 O 
) O 
and O 
nondependent O 
( O 
n O 
= O 
27 O 
) O 
smokers O 
participated O 
in O 
three O 
sessions O 
, O 
each O 
after O 
overnight O 
abstinence O 
. O 
Using O 
a O 
within O 
- O 
subjects O 
design O 
, O 
sessions O 
involved O 
no O 
smoking O 
or O 
smoking O 
denicotinized O 
( O 
0.05 O 
mg O 
) O 
or O 
nicotine B-TRIVIAL 
( O 
0.6 O 
mg O 
) O 
Quest O 
( O 
R O 
) O 
brand O 
cigarettes O 
. O 
For O 
comparison O 
, O 
a O 
fourth O 
session O 
involved O 
no O 
abstinence O 
prior O 
to O 
smoking O 
one's O 
own O 
brand O 
to O 
gauge O 
responses O 
under O 
typical O 
nicotine B-TRIVIAL 
satiation O 
. O 
Reinforcement O 
was O 
assessed O 
by O 
responses O 
on O 
a O 
simple O 
operant O 
computer O 
task O 
for O 
the O 
rewards O 
, O 
each O 
available O 
singly O 
on O 
a O 
progressive O 
ratio O 
schedule O 
during O 
separate O 
trials O 
. O 
RESULTS O 
: O 
The O 
reinforcing O 
effect O 
of O 
music O 
, O 
but O 
not O 
other O 
rewards O 
, O 
was O 
greater O 
due O 
to O 
the O 
nicotine B-TRIVIAL 
cigarette O 
, O 
compared O 
to O 
the O 
denicotinized O 
cigarette O 
or O 
no O 
smoking O 
. O 
Reinforcement O 
enhancing O 
effects O 
of O 
nicotine B-TRIVIAL 
did O 
not O 
differ O 
between O 
dependent O 
and O 
nondependent O 
groups O 
, O 
indicating O 
no O 
influence O 
of O 
withdrawal O 
relief O 
. O 
Responding O 
due O 
to O 
acute O 
nicotine B-TRIVIAL 
after O 
abstinence O 
was O 
very O 
similar O 
to O 
responding O 
to O 
one's O 
own O 
brand O 
after O 
no O 
abstinence O 
. O 
CONCLUSIONS O 
: O 
Acute O 
nicotine B-TRIVIAL 
intake O 
per O 
se O 
from O 
smoking O 
after O 
abstinence O 
enhances O 
the O 
reinforcing O 
value O 
of O 
rewards O 
unassociated O 
with O 
smoking O 
, O 
perhaps O 
in O 
a O 
manner O 
comparable O 
to O 
ad O 
lib O 
smoking O 
after O 
no O 
abstinence O 
. O 
Nicotine B-TRIVIAL 
' O 
s O 
reinforcement O 
enhancing O 
effects O 
may O 
be O 
specific O 
to O 
certain O 
rewards O 
, O 
perhaps O 
those O 
sensory O 
in O 
nature O 
. O 

Coating O 
of O 
Hydrous B-SYSTEMATIC 
Ruthenium I-SYSTEMATIC 
Oxide I-SYSTEMATIC 
on O 
Mesoporous O 
Silica B-TRIVIAL 
Nanoparticles O 
to O 
Develop O 
High-Performance O 
Supercapacitors O 
. O 

efficient O 
evaporation O 
- O 
induced O 
coating O 
method O 
combining O 
microwave O 
- O 
assisted O 
hydrothermal O 
transformation O 
and O 
annealing O 
is O 
developed O 
to O 
fabricate O 
an O 
ideal O 
electrode O 
material O 
from O 
composites O 
with O 
a O 
layer O 
of O 
hydrous B-FORMULA 
RuO2 I-FORMULA 
on O 
mesoporous O 
silica B-TRIVIAL 
nanoparticles O 
( O 
MSNs O 
) O 
, O 
for O 
a O 
high O 
- O 
performance O 
supercapacitor O 
. O 
Total O 
and O 
RuO2 B-FORMULA 
-based O 
specific O 
capacitances O 
are O 
as O 
high O 
as O 
1125 O 
and O 
2000 O 
F O 
g(-1) O 
, O 
respectively O 
. O 

growth O 
and O 
its O 
persistence O 
within O 
wounds O 
have O 
recently O 
been O 
suggested O 
as O 
contributing O 
factors O 
to O 
impaired O 
healing O 
. O 
The O 
goal O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
anti-biofilm O 
effects O 
of O 
several O 
honey O 
samples O 
of O 
different O 
botanical O 
origin O 
, O 
including O 
manuka O 
honey O 
against O 
Proteus O 
mirabilis O 
and O 
Enterobacter O 
cloacae O 
wound O 
isolates O 
. O 
Quantification O 
of O 
biofilm O 
formation O 
was O 
carried O 
out O 
using O 
a O 
microtiter O 
plate O 
assay O 
. O 
All O 
honeys O 
at O 
a O 
sub O 
- O 
inhibitory O 
concentration O 
of O 
10% O 
( O 
w O 
/ O 
v O 
) O 
significantly O 
reduced O 
the O 
biofilm O 
development O 
of O 
both O 
isolates O 
. O 
Similarly O 
, O 
at O 
a O 
concentration O 
of O 
50% O 
( O 
w O 
/ O 
v O 
) O 
, O 
each O 
of O 
the O 
honeys O 
caused O 
significant O 
partial O 
detachment O 
of O 
Pr O 
. O 
mirabilis O 
biofilm O 
after O 
24 O 
h O 
. O 
On O 
the O 
other O 
hand O 
, O 
no O 
honey O 
was O 
able O 
to O 
significantly O 
detach O 
Ent O 
. O 
cloacae O 
biofilm O 
. O 
In O 
addition O 
, O 
treatment O 
of O 
Ent O 
. O 
cloacae O 
and O 
Pr O 
. O 
mirabilis O 
biofilms O 
with O 
all O 
honeys O 
resulted O 
in O 
a O 
significant O 
decrease O 
in O 
colony O 
- O 
forming O 
units O 
per O 
well O 
values O 
in O 
a O 
range O 
of O 
0.35-1.16 O 
and O 
1.2-7.5 O 
log O 
units O 
, O 
respectively O 
. O 
Of O 
the O 
tested O 
honeys O 
, O 
manuka O 
honey O 
possessed O 
the O 
most O 
potent O 
anti-biofilm O 
properties O 
. O 
Furthermore O 
, O 
methylglyoxal B-SYSTEMATIC 
, O 
an O 
antibacterial O 
compound O 
of O 
manuka O 
honey O 
, O 
was O 
shown O 
to O 
be O 
responsible O 
for O 
killing O 
biofilm O 
- O 
embedded O 
wound O 
bacteria O 
. O 
These O 
findings O 
suggest O 
that O 
manuka O 
honey O 
could O 
be O 
used O 
as O 
a O 
potential O 
therapy O 
for O 
the O 
treatment O 
of O 
wounds O 
containing O 
Pr O 
. O 
mirabilis O 
or O 
Ent O 
. O 
cloacae O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

- O 
processible O 
highly O 
conducting O 
fullerenes B-FAMILY 
. O 

of O 
solution O 
- O 
processible O 
organic O 
semiconductors O 
: O 
highly O 
conductive O 
fullerenes B-FAMILY 
are O 
demonstrated O 
through O 
solution O 
- O 
processed O 
fulleropyrrolidinium B-SYSTEMATIC 
iodide I-SYSTEMATIC 
( O 
FPI B-ABBREVIATION 
) O 
and O 
FPI B-ABBREVIATION 
-doped O 
PCBM B-ABBREVIATION 
to O 
reach O 
a O 
high O 
conductivity O 
( O 
3.2 O 
S O 
/ O 
m O 
) O 
. O 
The O 
n-doping O 
proceeds O 
via O 
anion O 
- O 
induced O 
electron O 
transfer O 
between O 
the O 
iodide B-SYSTEMATIC 
on O 
FPI B-ABBREVIATION 
and O 
the O 
fullerene B-TRIVIAL 
in O 
the O 
solid O 
state O 
. O 

of O 
the O 
Green O 
Tea O 
Leaf O 
Extract O 
on O 
Neurotoxicity O 
of O 
Aluminium B-SYSTEMATIC 
Chloride I-SYSTEMATIC 
in O 
Rats O 
. O 

may O 
have O 
an O 
important O 
role O 
in O 
the O 
aetiology O 
/ O 
pathogenesis O 
/ O 
precipitation O 
of O 
Alzheimer's O 
disease O 
. O 
Because O 
green O 
tea O 
( O 
Camellia O 
sinensis O 
L O 
. O 
) O 
reportedly O 
has O 
health O 
- O 
promoting O 
effects O 
in O 
the O 
central O 
nervous O 
system O 
, O 
we O 
evaluated O 
the O 
effects O 
of O 
green O 
tea O 
leaf O 
extract O 
( O 
GTLE O 
) O 
on O 
aluminium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
AlCl3 B-FORMULA 
) O 
neurotoxicity O 
in O 
rats O 
. O 
All O 
solutions O 
were O 
injected O 
into O 
the O 
cornu O 
ammonis O 
region O 
1 O 
hippocampal O 
region O 
. O 
We O 
measured O 
the O 
performance O 
of O 
active O 
avoidance O 
( O 
AA O 
) O 
tasks O 
, O 
various O 
enzyme O 
activities O 
and O 
total O 
glutathione B-TRIVIAL 
content O 
( O 
TGC O 
) O 
in O 
the O 
forebrain O 
cortex O 
( O 
FbC O 
) O 
, O 
striatum O 
, O 
basal O 
forebrain O 
( O 
BFb O 
) O 
, O 
hippocampus O 
, O 
brain O 
stem O 
and O 
cerebellum O 
. O 
AlCl3 B-FORMULA 
markedly O 
reduced O 
AA O 
performance O 
and O 
activities O 
of O 
cytochrome O 
c O 
oxidase O 
( O 
COX O 
) O 
and O 
acetylcholinesterase O 
( O 
AChE O 
) O 
in O 
all O 
regions O 
. O 
It O 
decreased O 
TGC O 
in O 
the O 
FbC O 
, O 
striatum O 
, O 
BFb O 
, O 
hippocampus O 
, O 
brain O 
stem O 
and O 
cerebellum O 
, O 
and O 
increased O 
superoxide B-TRIVIAL 
dismutase O 
activity O 
in O 
the O 
FbC O 
, O 
cerebellum O 
and O 
BFb O 
. O 
GTLE O 
pretreatment O 
completely O 
reversed O 
the O 
damaging O 
effects O 
of O 
AlCl3 B-FORMULA 
on O 
AA O 
and O 
superoxide B-TRIVIAL 
dismutase O 
activity O 
, O 
markedly O 
corrected O 
COX O 
and O 
AChE O 
activities O 
, O 
and O 
moderately O 
improved O 
TGC O 
. O 
GTLE O 
alone O 
increased O 
COX O 
and O 
AChE O 
activities O 
in O 
almost O 
all O 
regions O 
. O 
GTLE O 
reduces O 
AlCl3 B-FORMULA 
neurotoxicity O 
probably O 
via O 
antioxidative O 
effects O 
and O 
improves O 
mitochondrial O 
and O 
cholinergic O 
synaptic O 
functions O 
through O 
the O 
actions O 
of O 
(-)-epigallocatechin B-TRIVIAL 
gallate I-TRIVIAL 
and O 
(-)-epicatechin B-SYSTEMATIC 
, O 
compounds O 
most O 
abundantly O 
found O 
in O 
GTLE O 
. O 
Our O 
results O 
suggest O 
that O 
green O 
tea O 
might O 
be O 
beneficial O 
in O 
Alzheimer's O 
disease O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

squalamine O 
mimics O 
: O 
synthesis O 
and O 
antibacterial O 
activities O 
of O 
head O 
- O 
to O 
- O 
tail O 
dimeric O 
sterol B-FAMILY 
- O 
polyamine B-FAMILY 
conjugates O 
. O 

dimeric O 
sterol B-FAMILY 
- O 
polyamine B-FAMILY 
conjugates O 
have O 
been O 
synthesized O 
from O 
the O 
homo- O 
and O 
hetero O 
- O 
connection O 
of O 
monomeric O 
sterol B-FAMILY 
- O 
polyamine B-FAMILY 
analogs O 
in O 
a O 
head O 
- O 
to O 
- O 
tail O 
manner O 
. O 
These O 
dimeric O 
conjugates O 
show O 
strong O 
antibacterial O 
activity O 
against O 
a O 
broad O 
spectrum O 
of O 
Gram O 
- O 
positive O 
bacteria O 
, O 
whereas O 
their O 
corresponding O 
activities O 
against O 
Gram O 
- O 
negative O 
bacteria O 
are O 
relatively O 
moderate O 
. O 
Though O 
no O 
significant O 
difference O 
was O 
observed O 
in O 
the O 
activities O 
of O 
these O 
conjugates O 
, O 
cholic B-TRIVIAL 
acid I-TRIVIAL 
-containing O 
dimeric O 
conjugates O 
generally O 
exhibit O 
higher O 
activities O 
than O 
the O 
corresponding O 
deoxycholic B-TRIVIAL 
acid I-TRIVIAL 
-derived O 
analogs O 
. O 
This O 
is O 
in O 
contrast O 
to O 
the O 
finding O 
that O 
a O 
monomeric O 
deoxycholic B-TRIVIAL 
acid I-TRIVIAL 
- O 
spermine B-TRIVIAL 
conjugate O 
was O 
more O 
active O 
than O 
the O 
corresponding O 
cholic B-TRIVIAL 
acid I-TRIVIAL 
-derived O 
analog O 
. O 

and O 
Structure-Activity O 
Relationship O 
Studies O 
of O 
Derivatives O 
of O 
the O 
Dual O 
Aromatase-Sulfatase O 
Inhibitor O 
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl B-SYSTEMATIC 
sulfamate I-SYSTEMATIC 
. O 

sulfamate I-SYSTEMATIC 
and O 
its O 
ortho-halogenated O 
( O 
F B-FORMULA 
, O 
Cl B-FORMULA 
, O 
Br B-FORMULA 
) O 
derivatives O 
are O 
first O 
- O 
generation O 
dual O 
aromatase O 
and O 
sulfatase O 
inhibitors O 
( O 
DASIs O 
) O 
. O 
Structure O 
- O 
activity O 
relationship O 
studies O 
were O 
performed O 
on O 
these O 
compounds O 
, O 
and O 
various O 
modifications O 
were O 
made O 
to O 
their O 
structures O 
involving O 
relocation O 
of O 
the O 
halogen B-FAMILY 
atom O 
, O 
introduction O 
of O 
more O 
halogen B-FAMILY 
atoms O 
, O 
replacement O 
of O 
the O 
halogen B-FAMILY 
with O 
another O 
group O 
, O 
replacement O 
of O 
the O 
methylene B-SYSTEMATIC 
linker O 
with O 
a O 
difluoromethylene B-SYSTEMATIC 
linker O 
, O 
replacement O 
of O 
the O 
para-cyanophenyl B-SYSTEMATIC 
ring O 
with O 
other O 
ring O 
structures O 
, O 
and O 
replacement O 
of O 
the O 
triazolyl B-SYSTEMATIC 
group O 
with O 
an O 
imidazolyl B-SYSTEMATIC 
group O 
. O 
The O 
most O 
potent O 
in O 
vitro O 
DASI O 
discovered O 
is O 
an O 
imidazole B-SYSTEMATIC 
derivative O 
with O 
IC50 O 
values O 
against O 
aromatase O 
and O 
steroid B-FAMILY 
sulfatase O 
in O 
a O 
JEG-3 O 
cell O 
preparation O 
of O 
0.2 O 
and O 
2.5 O 
nM O 
, O 
respectively O 
. O 
The O 
parent O 
phenol B-SYSTEMATIC 
of O 
this O 
compound O 
inhibits O 
aromatase O 
with O 
an O 
IC50 O 
value O 
of O 
0.028 O 
nM O 
in O 
the O 
same O 
assay O 
. O 

and O 
P2Y O 
nucleotide B-FAMILY 
receptors O 
as O 
targets O 
in O 
cardiovascular O 
disease O 
. O 

nucleotides B-FAMILY 
have O 
widespread O 
actions O 
in O 
the O 
cardiovascular O 
system O 
, O 
but O 
it O 
is O 
only O 
recently O 
that O 
the O 
P2X O 
and O 
P2Y O 
receptor O 
subtypes O 
, O 
at O 
which O 
they O 
act O 
, O 
have O 
been O 
identified O 
and O 
subtype O 
- O 
selective O 
agonists O 
and O 
antagonists O 
developed O 
. O 
These O 
advances O 
have O 
greatly O 
increased O 
our O 
understanding O 
of O 
the O 
physiological O 
and O 
pathophysiological O 
functions O 
of O 
P2X O 
and O 
P2Y O 
receptors O 
, O 
but O 
investigation O 
of O 
the O 
clinical O 
usefulness O 
of O 
selective O 
ligands O 
is O 
at O 
an O 
early O 
stage O 
. O 
Nonetheless O 
, O 
the O 
evidence O 
considered O 
in O 
this O 
review O 
demonstrates O 
clearly O 
that O 
various O 
cardiovascular O 
disorders O 
, O 
including O 
vasospasm O 
, O 
hypertension O 
, O 
congestive O 
heart O 
failure O 
and O 
cardiac O 
damage O 
during O 
ischemic O 
episodes O 
, O 
may O 
be O 
viable O 
targets O 
. O 
With O 
further O 
development O 
of O 
novel O 
, O 
selective O 
agonists O 
and O 
antagonists O 
, O 
our O 
understanding O 
will O 
continue O 
to O 
improve O 
and O 
further O 
therapeutic O 
applications O 
are O 
likely O 
to O 
be O 
discovered O 
. O 

- O 
derivatized O 
polymers O 
, O 
such O 
as O 
poly(allylurea) B-FAMILY 
( O 
PU O 
) O 
and O 
poly(L-citrulline) B-FAMILY 
derivatives O 
, O 
exhibited O 
upper O 
critical O 
solution O 
temperature O 
( O 
UCST O 
) O 
behavior O 
under O 
physiological O 
buffer O 
conditions O 
as O 
we O 
previously O 
reported O 
. O 
The O 
PU O 
derivatives O 
having O 
amino B-FAMILY 
groups O 
( O 
PU-Am B-ABBREVIATION 
) O 
also O 
showed O 
UCST O 
behavior O 
. O 
In O 
this O 
study O 
, O 
we O 
modified O 
the O 
amino B-FAMILY 
groups O 
of O 
the O 
polymer O 
with O 
succinyl B-SYSTEMATIC 
anhydride I-SYSTEMATIC 
( O 
PU-Su B-ABBREVIATION 
) O 
or O 
acetyl B-SYSTEMATIC 
anhydride I-SYSTEMATIC 
( O 
PU-Ac B-ABBREVIATION 
) O 
to O 
determine O 
the O 
effects O 
of O 
these O 
ionic O 
groups O 
on O 
the O 
UCST O 
behavior O 
and O 
to O 
control O 
interactions O 
between O 
the O 
PU O 
derivatives O 
and O 
biocomponents O 
such O 
as O 
proteins O 
and O 
cells O 
. O 
Succinylation O 
of O 
PU-Am B-ABBREVIATION 
resulted O 
in O 
a O 
significant O 
decrease O 
in O 
phase O 
separation O 
temperature O 
( O 
Tp O 
) O 
, O 
whereas O 
acetylation O 
of O 
PU-Am B-ABBREVIATION 
resulted O 
in O 
an O 
increase O 
in O 
Tp O 
. O 
As O 
expected O 
, O 
the O 
Tp O 
of O 
PU-Am B-ABBREVIATION 
and O 
PU-Su B-ABBREVIATION 
changed O 
when O 
the O 
pH O 
of O 
the O 
solution O 
was O 
changed O 
. O 
The O 
Tp O 
of O 
PU-Am B-ABBREVIATION 
increased O 
at O 
higher O 
pH O 
, O 
whereas O 
that O 
of O 
PU-Su B-ABBREVIATION 
increased O 
at O 
lower O 
pH O 
, O 
indicating O 
that O 
ionic O 
charge O 
decreases O 
Tp O 
of O 
PU O 
derivatives O 
by O 
increasing O 
osmotic O 
pressure O 
and O 
by O 
increasing O 
hydrophilicity O 
of O 
the O 
polymer O 
chains O 
. O 
Interestingly O 
, O 
these O 
groups O 
did O 
not O 
significantly O 
change O 
UCST O 
when O 
these O 
groups O 
were O 
nonionic O 
. O 
We O 
then O 
examined O 
capture O 
and O 
separation O 
of O 
particular O 
proteins O 
from O 
a O 
protein O 
mixture O 
by O 
cooling O 
- O 
induced O 
phase O 
separation O 
. O 
Selective O 
and O 
rapid O 
capture O 
of O 
particular O 
proteins O 
from O 
protein O 
mixture O 
by O 
PU O 
derivatives O 
was O 
shown O 
, O 
indicating O 
that O 
the O 
ureido O 
- O 
derivatized O 
polymers O 
are O 
potential O 
media O 
for O 
bioseparation O 
under O 
biofriendly O 
conditions O 
. O 

have O 
constructed O 
a O 
novel O 
class O 
of O 
" O 
double O 
- O 
hydrophobic O 
" O 
block O 
polypeptides O 
based O 
on O 
the O 
hydrophobic O 
domains O 
found O 
in O 
native O 
elastin O 
, O 
an O 
extracellular O 
matrix O 
protein O 
responsible O 
for O 
the O 
elasticity O 
and O 
resilience O 
of O 
tissues O 
. O 
The O 
block O 
polypeptides O 
comprise O 
proline B-TRIVIAL 
-rich O 
poly(VPGXG) O 
and O 
glycine B-TRIVIAL 
-rich O 
poly(VGGVG) O 
, O 
both O 
of O 
which O 
dehydrate O 
at O 
higher O 
temperature O 
but O 
form O 
distinct O 
secondary O 
structures O 
, O 
β-turn O 
and O 
β-sheet O 
respectively O 
. O 
In O 
water O 
at O 
45 O 
°C O 
, O 
the O 
block O 
polypeptides O 
initially O 
assemble O 
into O 
nanoparticles O 
rich O 
in O 
β-turn O 
structures O 
, O 
which O 
further O 
connect O 
into O 
long O 
( O 
> O 
10 O 
μm O 
) O 
, O 
beaded O 
nanofibers O 
along O 
with O 
the O 
increase O 
in O 
the O 
β-sheet O 
content O 
. O 
The O 
nanofibers O 
obtained O 
are O 
well O 
- O 
dispersed O 
in O 
water O 
, O 
and O 
show O 
thermoresponsive O 
properties O 
. O 
Polypeptides O 
comprising O 
each O 
block O 
component O 
assemble O 
into O 
different O 
morphologies O 
, O 
showing O 
that O 
the O 
conjugation O 
of O 
poly(VPGXG) O 
and O 
poly(VGGVG) O 
plays O 
a O 
role O 
for O 
beaded O 
fiber O 
formation O 
. O 
These O 
results O 
may O 
provide O 
innovative O 
ideas O 
for O 
designing O 
peptide O 
- O 
based O 
materials O 
but O 
also O 
opportunities O 
for O 
developing O 
novel O 
materials O 
useful O 
for O 
tissue O 
engineering O 
and O 
drug O 
delivery O 
systems O 
. O 

of O 
the O 
volatile O 
oil O 
from O 
Carum O 
carvi O 
of O 
Tunisia O 
and O 
Lithuania O 
by O 
supercritical O 
carbon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
: O 
chemical O 
composition O 
and O 
antiulcerogenic O 
activity O 
. O 

study O 
investigates O 
whether O 
the O 
essential O 
oil O 
prepared O 
from O 
Carum O 
carvi O 
seeds O 
exhibits O 
antiulcerogenic O 
activity O 
. O 
Its O 
volatile O 
oil O 
was O 
obtained O 
by O 
supercritical O 
fluid O 
extraction O 
( O 
SFE O 
) O 
and O 
by O 
hydrodistillation O 
. O 
The O 
essential O 
oils O 
were O 
analysed O 
by O 
GC-MS O 
to O 
monitor O 
their O 
composition O 
. O 
The O 
chemical O 
analysis O 
revealed O 
that O 
the O 
essential O 
oils O 
extracted O 
under O 
SFE O 
conditions O 
had O 
high O 
carvone B-TRIVIAL 
and O 
limonene B-TRIVIAL 
contents O 
. O 
The O 
antiulcerogenic O 
activity O 
was O 
evaluated O 
by O 
the O 
HCl B-FORMULA 
/ O 
ethanol B-SYSTEMATIC 
method O 
, O 
which O 
causes O 
injury O 
to O 
the O 
gastric O 
mucosa O 
. O 
Three O 
treated O 
groups O 
received O 
the O 
essential O 
oil O 
( O 
100-300 O 
mg O 
/ O 
kg O 
) O 
. O 
The O 
reference O 
group O 
received O 
omeprazole B-TRIVIAL 
( O 
30 O 
mg O 
/ O 
kg O 
) O 
and O 
the O 
control O 
group O 
received O 
NaCl B-FORMULA 
. O 
After O 
30 O 
min O 
, O 
all O 
groups O 
were O 
treated O 
with O 
HCl B-FORMULA 
/ O 
EtOH B-FORMULA 
for O 
gastric O 
ulcer O 
induction O 
. O 
The O 
results O 
show O 
C O 
. O 
carvi O 
essential O 
oil O 
enhanced O 
a O 
significant O 
inhibition O 
of O 
47% O 
, O 
81% O 
and O 
88% O 
, O 
respectively O 
, O 
for O 
three O 
doses O 
of O 
essential O 
oil O 
used O 
, O 
which O 
was O 
similar O 
to O 
that O 
induced O 
by O 
omeprazole B-TRIVIAL 
( O 
95% O 
) O 
( O 
p O 
< O 
0.005 O 
) O 
. O 

patterns O 
of O 
biomolecules O 
and O 
cells O 
has O 
been O 
applied O 
widely O 
in O 
many O 
fields O 
associated O 
with O 
the O 
life O 
sciences O 
, O 
including O 
diagnostics O 
. O 
In O 
these O 
applications O 
it O 
has O 
become O 
increasingly O 
apparent O 
that O 
the O 
spatiotemporal O 
arrangement O 
of O 
biological O 
molecules O 
in O 
vitro O 
is O 
important O 
for O 
the O 
investigation O 
of O 
the O 
cellular O 
functions O 
found O 
in O 
vivo O 
. O 
However O 
, O 
the O 
cell O 
patterning O 
techniques O 
often O 
used O 
are O 
limited O 
to O 
creating O 
2D O 
functional O 
surfaces O 
on O 
glass O 
and O 
silicon B-SYSTEMATIC 
. O 
In O 
addition O 
, O 
in O 
general O 
, O 
these O 
procedures O 
are O 
not O 
easy O 
to O 
implement O 
in O 
conventional O 
biological O 
laboratories O 
. O 
Here O 
, O 
we O 
show O 
the O 
formation O 
of O 
a O 
living O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
layer O 
that O 
can O 
be O 
patterned O 
with O 
visible O 
light O 
on O 
plastic O 
surfaces O 
. O 
This O 
new O 
and O 
simple O 
method O 
can O 
be O 
expanded O 
to O 
pattern O 
multiple O 
types O 
of O 
biomolecule O 
on O 
either O 
a O 
previously O 
formed O 
PEG B-ABBREVIATION 
layer O 
or O 
a O 
plastic O 
substrate O 
. O 
Using O 
common O 
plastic O 
wares O 
( O 
i.e O 
. O 
, O 
polyethylene B-SYSTEMATIC 
films O 
and O 
polystyrene B-SYSTEMATIC 
cell O 
culture O 
Petri O 
- O 
dishes O 
) O 
, O 
we O 
demonstrate O 
that O 
these O 
PEG B-ABBREVIATION 
-modified O 
surfaces O 
have O 
a O 
high O 
resistance O 
to O 
protein O 
adsorption O 
and O 
cell O 
adhesion O 
, O 
while O 
at O 
the O 
same O 
time O 
, O 
being O 
capable O 
of O 
undergoing O 
further O 
molecular O 
grafting O 
with O 
bioactive O 
motifs O 
. O 
With O 
a O 
photomask O 
and O 
a O 
fluid O 
delivery O 
system O 
, O 
we O 
illustrate O 
a O 
flexible O 
way O 
to O 
immobilize O 
biological O 
functions O 
with O 
a O 
high O 
degree O 
of O 
2D O 
and O 
3D O 
spatial O 
control O 
. O 
We O 
anticipate O 
that O 
our O 
method O 
can O 
be O 
easily O 
implemented O 
in O 
a O 
typical O 
life O 
science O 
laboratory O 
( O 
without O 
the O 
need O 
for O 
specialized O 
lithography O 
equipment O 
) O 
offering O 
the O 
prospect O 
of O 
imparting O 
desirable O 
properties O 
to O 
plastic O 
products O 
, O 
for O 
example O 
, O 
the O 
creation O 
of O 
functional O 
microenvironments O 
in O 
biological O 
studies O 
or O 
reducing O 
biological O 
adhesion O 
to O 
surfaces O 
. O 

Rearrangement O 
in O 
the O 
Formation O 
of O 
Jet-Cooled O 
Complexes O 
of O 
Chiral O 
(S)-1,2,3,4-Tetrahydro-3-isoquinolinemethanol B-SYSTEMATIC 
with O 
Methyl B-SYSTEMATIC 
Lactate I-SYSTEMATIC 
: O 
Chirality O 
Effect O 
in O 
Conformer O 
Selection O 
. O 

jet O 
- O 
cooled O 
complexes O 
between O 
the O 
two O 
enantiomers O 
of O 
methyl B-SYSTEMATIC 
lactate I-SYSTEMATIC 
( O 
ML O 
) O 
and O 
(S)-1,2,3,4-tetrahydro-3-isoquinolinemethanol B-SYSTEMATIC 
( O 
THIQM B-ABBREVIATION 
) O 
are O 
studied O 
by O 
double O 
resonance O 
spectroscopy O 
combined O 
with O 
ab O 
initio O 
calculations O 
. O 
Both O 
diastereomer O 
complexes O 
exist O 
in O 
different O 
isomers O 
, O 
involving O 
either O 
direct O 
addition O 
of O 
THIQM B-ABBREVIATION 
on O 
ML O 
with O 
no O 
structural O 
rearrangement O 
of O 
the O 
subunits O 
or O 
formation O 
of O 
very O 
stable O 
structures O 
involving O 
multiple O 
intermolecular O 
hydrogen B-SYSTEMATIC 
bonds O 
and O 
extensive O 
deformation O 
of O 
the O 
subunits O 
. O 
Competition O 
between O 
these O 
two O 
processes O 
and O 
its O 
dependence O 
upon O 
chirality O 
are O 
discussed O 
. O 
It O 
is O 
shown O 
that O 
the O 
most O 
stable O 
form O 
of O 
the O 
chromophore O 
( O 
THIQMI B-ABBREVIATION 
with O 
an O 
OH B-FORMULA 
··· O 
N B-FORMULA 
hydrogen B-SYSTEMATIC 
bond O 
) O 
prefers O 
to O 
directly O 
stick O 
to O 
ML O 
to O 
form O 
the O 
addition O 
complex O 
whereas O 
the O 
second O 
conformer O 
( O 
THIQMII B-ABBREVIATION 
with O 
NH B-FORMULA 
··· O 
O B-FORMULA 
hydrogen B-SYSTEMATIC 
bond O 
) O 
rearranges O 
to O 
form O 
a O 
strongly O 
bound O 
structure O 
. O 
The O 
two O 
structures O 
are O 
formed O 
for O 
the O 
homochiral O 
as O 
well O 
the O 
heterochiral O 
complex O 
, O 
however O 
with O 
different O 
relative O 
abundance O 
. O 
This O 
shows O 
an O 
enantioselective O 
binding O 
preference O 
of O 
ML O 
for O 
one O 
of O 
the O 
conformers O 
of O 
the O 
chromophore O 
. O 

nonionic O 
amphiphiles O 
forming O 
monolayers O 
, O 
bilayers O 
, O 
micelles O 
, O 
or O 
biomembranes O 
create O 
a O 
positive O 
dipole O 
potential O 
at O 
the O 
boundary O 
with O 
water O 
. O 
In O 
a O 
series O 
of O 
papers O 
we O 
have O 
reported O 
on O 
Langmuir O 
monolayers O 
with O 
CF3 B-FORMULA 
terminals O 
of O 
the O 
polar O 
heads O 
, O 
which O 
show O 
a O 
negative O 
surface O 
dipole O 
potential O 
ΔV O 
( O 
Petrov O 
, O 
J O 
. O 
G O 
. O 
; O 
Andreeva O 
, O 
T O 
. O 
D O 
. O 
; O 
Kurt O 
, O 
D O 
. O 
K O 
. O 
; O 
Möhwald O 
, O 
H O 
. O 
J O 
. O 
Phys O 
. O 
Chem O 
. O 
B O 
2005 O 
, O 
109 O 
, O 
14102 O 
) O 
. O 
Here O 
we O 
use O 
vibrational O 
sum O 
frequency O 
spectroscopy O 
( O 
SF O 
) O 
to O 
study O 
the O 
origin O 
of O 
the O 
opposite O 
ΔV O 
signs O 
of O 
Langmuir O 
films O 
of O 
CH3(CH2)20COCH2CH3 B-FORMULA 
( O 
ethyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
, O 
EE O 
) O 
and O 
CH3(CH2)20COCH2CF3 B-FORMULA 
( O 
fluorinated B-SYSTEMATIC 
ethyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
, O 
FEE B-ABBREVIATION 
) O 
. O 
The O 
vibrational O 
sum O 
frequency O 
spectra O 
are O 
recorded O 
at O 
the O 
same O 
film O 
density O 
of O 
the O 
S-phase O 
of O 
the O 
EE O 
and O 
FEE B-ABBREVIATION 
monolayers O 
and O 
analyzed O 
in O 
the O 
spectral O 
regions O 
of O 
OH B-FORMULA 
, O 
COC B-FORMULA 
, O 
CH3 B-FORMULA 
, O 
and O 
CF3 B-FORMULA 
stretching O 
vibrations O 
because O 
these O 
functional O 
groups O 
could O 
be O 
responsible O 
for O 
the O 
different O 
dipole O 
potentials O 
. O 
We O 
compare O 
the O 
rearrangement O 
of O 
the O 
pure O 
water O 
surface O 
by O 
EE O 
and O 
FEE B-ABBREVIATION 
monolayers O 
and O 
the O 
conformations O 
of O 
EE O 
and O 
FEE B-ABBREVIATION 
polar O 
heads O 
. O 
The O 
analysis O 
is O 
performed O 
according O 
to O 
the O 
three O 
- O 
capacitor O 
model O 
of O 
the O 
dipole O 
potential O 
of O 
Langmuir O 
monolayers O 
( O 
Demchak O 
, O 
R O 
. O 
T O 
. O 
; O 
Fort O 
, O 
T O 
. O 
, O 
Jr O 
. O 
J O 
. O 
Colloid O 
Interface O 
Sci O 
. O 
1974 O 
, O 
46 O 
, O 
191 O 
) O 
. O 
The O 
results O 
show O 
that O 
reversal O 
of O 
the O 
ΔV O 
sign O 
caused O 
by O 
fluorination O 
of O 
the O 
polar O 
heads O 
originates O 
from O 
the O 
upward O 
- O 
oriented O 
CF3 B-FORMULA 
terminals O 
of O 
the O 
FEE B-ABBREVIATION 
heads O 
, O 
whose O 
negative O 
normal O 
dipole O 
moment O 
component O 
determines O 
the O 
negative O 
dipole O 
potential O 
of O 
the O 
FEE B-ABBREVIATION 
monolayer O 
. O 

of O 
CN-columns O 
for O 
the O 
analysis O 
of O 
γ-oryzanol B-TRIVIAL 
and O 
its O 
p-coumarate B-TRIVIAL 
and O 
caffeate B-TRIVIAL 
derivatives O 
by O 
normal O 
phase O 
HPLC O 
and O 
a O 
validated O 
method O 
of O 
quantitation O 
. O 

is O 
an O 
important O 
phytochemical O 
used O 
in O 
pharmaceutical O 
, O 
alimentary O 
and O 
cosmetic O 
preparations O 
. O 
The O 
present O 
article O 
, O 
for O 
the O 
first O 
time O 
, O 
discloses O 
the O 
performances O 
of O 
NP-HPLC O 
in O 
separating O 
γ-oryzanol B-TRIVIAL 
components O 
and O 
develops O 
a O 
validated O 
method O 
for O 
its O 
routine O 
quantification O 
. O 
The O 
analysis O 
is O 
performed O 
on O 
a O 
cyanopropyl B-SYSTEMATIC 
bonded O 
column O 
using O 
the O 
hexane B-SYSTEMATIC 
/ O 
MTBE B-ABBREVIATION 
gradient O 
elution O 
and O 
UV O 
detection O 
at O 
325 O 
nm O 
. O 
The O 
method O 
allows O 
: O 
the O 
separation O 
of O 
steryl B-TRIVIAL 
ferulate I-TRIVIAL 
, O 
p-coumarate B-TRIVIAL 
and O 
caffeate B-FAMILY 
esters I-FAMILY 
, O 
the O 
separation O 
of O 
cis- O 
from O 
trans-ferulate B-TRIVIAL 
isomers O 
, O 
the O 
splitting O 
of O 
steroid B-FAMILY 
moieties O 
into O 
saturated O 
and O 
unsaturated O 
at O 
the O 
side O 
chain O 
. O 
The O 
optimised O 
method O 
provides O 
excellent O 
linear O 
response O 
( O 
R(2)=0.99997 O 
) O 
, O 
high O 
precision O 
( O 
RSD O 
< O 
1.0% O 
) O 
and O 
satisfactory O 
accuracy O 
( O 
R(∗)=70-86% O 
) O 
. O 
In O 
conclusion O 
, O 
the O 
established O 
method O 
presents O 
the O 
details O 
of O 
the O 
procedure O 
and O 
the O 
experimental O 
conditions O 
in O 
order O 
to O 
achieve O 
the O 
required O 
precision O 
and O 
instrumental O 
accuracy O 
. O 
The O 
method O 
is O 
fast O 
and O 
sensitive O 
and O 
it O 
could O 
be O 
a O 
suitable O 
tool O 
for O 
quality O 
assurance O 
and O 
determination O 
of O 
origin O 
. O 

salted O 
and O 
dried O 
product O 
of O 
tuna O 
roe O 
( O 
bottarga O 
) O 
is O 
a O 
seafood O 
characteristic O 
of O 
the O 
Mediterranean O 
area O 
and O 
exported O 
all O 
over O 
the O 
world O 
. O 
Samples O 
of O 
bottarga O 
from O 
bluefin O 
tunas O 
( O 
Thunnus O 
thynnus O 
, O 
L O 
. O 
) O 
caught O 
in O 
the O 
southwest O 
Mediterranean O 
sea O 
were O 
analysed O 
. O 
The O 
samples O 
were O 
characterised O 
by O 
high O 
content O 
of O 
marine O 
wax O 
esters B-FAMILY 
( O 
55-67 O 
mol% O 
of O 
lipid O 
classes O 
) O 
, O 
of O 
docosahexaenoic B-SYSTEMATIC 
( O 
22 O 
: O 
6 O 
n-3 O 
, O 
25 O 
w% O 
) O 
and O 
oleic B-TRIVIAL 
( O 
18 O 
: O 
1 O 
n-9 O 
, O 
19 O 
w% O 
) O 
fatty B-FAMILY 
acids I-FAMILY 
. O 
Cholesterol B-TRIVIAL 
was O 
detected O 
as O 
7-9 O 
w% O 
of O 
lipids O 
. O 
Free O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
index O 
of O 
lipid O 
hydrolysis O 
, O 
represented O 
32-39 O 
mol% O 
over O 
total O 
fatty B-FAMILY 
acids I-FAMILY 
. O 
Among O 
metabolites O 
, O 
nutrients O 
as O 
taurine B-TRIVIAL 
, O 
nicotinamide B-TRIVIAL 
and O 
β-alanine B-TRIVIAL 
, O 
were O 
found O 
. O 
The O 
microflora O 
comprised O 
staphylococci O 
, O 
enterococci O 
( O 
2.2 O 
log(10)CFU O 
/ O 
g O 
) O 
and O 
lactic B-TRIVIAL 
acid I-TRIVIAL 
bacteria O 
( O 
3 O 
log(10) O 
CFU O 
/ O 
g O 
) O 
. O 
The O 
food O 
- O 
borne O 
pathogens O 
Staphylococcus O 
aureus O 
, O 
Listeria O 
monocytogenes O 
and O 
Salmonella O 
spp O 
. O 
were O 
not O 
detected O 
. O 
These O 
findings O 
indicate O 
tuna O 
bottarga O 
as O 
valuable O 
source O 
of O 
nutrients O 
. O 

, O 
dimeric B-FAMILY 
catechins I-FAMILY 
, O 
inhibit O 
peptide O 
transport O 
across O 
Caco-2 O 
cell O 
monolayers O 
via O 
down O 
- O 
regulation O 
of O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
- O 
mediated O 
peptide O 
transporter O 
PEPT1 O 
. O 

the O 
small O 
intestine O 
, O 
peptide O 
transporter O 
1 O 
( O 
PEPT1 O 
) O 
plays O 
a O 
role O 
in O 
the O 
transport O 
of O 
di- B-MULTIPLE 
and I-MULTIPLE 
tripeptides I-MULTIPLE 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
whether O 
theaflavins B-FAMILY 
( O 
TFs B-FAMILY 
) O 
affect O 
the O 
absorption O 
of O 
small O 
peptides O 
in O 
human O 
intestinal O 
Caco-2 O 
cells O 
, O 
since O 
TFs B-FAMILY 
do O 
not O 
penetrate O 
through O 
the O 
cells O 
and O 
might O 
be O 
involved O 
in O 
intestinal O 
transport O 
systems O 
. O 
In O 
transport O 
experiments O 
, O 
the O 
transport O 
of O 
glycyl-sarcosine B-TRIVIAL 
( O 
Gly-Sar B-FORMULA 
, O 
a O 
model O 
molecule O 
for O 
PEPT1 O 
transport O 
) O 
and O 
other O 
dipeptides B-FAMILY 
( O 
Val-Tyr B-FORMULA 
and O 
Ile-Phe B-FORMULA 
) O 
were O 
significantly O 
reduced O 
( O 
P O 
< O 
0.05 O 
) O 
in O 
TFs B-FAMILY 
-pretreated O 
cells O 
. O 
In O 
TF B-SYSTEMATIC 
3'-O-gallate I-SYSTEMATIC 
-pretreated O 
cells O 
, O 
Western O 
blot O 
analysis O 
revealed O 
attenuated O 
expression O 
of O 
PEPT1 O 
transporter O 
and O 
Gly-Sar B-FORMULA 
transport O 
was O 
completely O 
ameliorated O 
by O 
10 O 
μM O 
Compound B-TRIVIAL 
C I-TRIVIAL 
, O 
an O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
inhibitor O 
. O 
In O 
conclusion O 
, O 
the O 
present O 
study O 
demonstrated O 
that O 
TFs B-FAMILY 
inhibit O 
peptide O 
transport O 
across O 
Caco-2 O 
cell O 
monolayers O 
, O 
probably O 
through O 
suppression O 
of O 
AMPK O 
- O 
mediated O 
PEPT1 O 
expression O 
, O 
which O 
should O 
be O 
considered O 
a O 
new O 
bioactivity O 
of O 
TFs B-FAMILY 
in O 
black O 
tea O 
. O 

this O 
study O 
, O 
aqueous O 
enzymatic O 
process O 
( O 
AEP O 
) O 
assisted O 
by O 
microwave O 
extraction O 
( O 
ME O 
) O 
of O 
oil O 
from O 
yellow O 
horn O 
( O 
Xanthoceras O 
sorbifolia O 
Bunge O 
. O 
) O 
seed O 
kernel O 
was O 
investigated O 
. O 
Central O 
composite O 
design O 
( O 
CCD O 
) O 
and O 
response O 
surface O 
methodology O 
( O 
RSM O 
) O 
were O 
used O 
to O 
optimise O 
an O 
enzyme O 
cocktail O 
( O 
cellulase O 
, O 
hemicellulase O 
, O 
pectinase O 
) O 
for O 
AEP O 
. O 
The O 
main O 
factors O 
of O 
ME O 
were O 
also O 
studied O 
. O 
A O 
maximal O 
oil O 
extraction O 
yield O 
of O 
55.8% O 
was O 
achieved O 
under O 
optimal O 
conditions O 
. O 
Moreover O 
, O 
scanning O 
electron O 
microscope O 
( O 
SEM O 
) O 
was O 
applied O 
to O 
characterise O 
the O 
extraction O 
process O 
. O 
Analysing O 
chemical O 
composition O 
of O 
the O 
extracted O 
oil O 
by O 
GC-MS O 
showed O 
that O 
the O 
content O 
of O 
unsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
by O 
this O 
emerging O 
method O 
( O 
91.18% O 
) O 
was O 
similar O 
to O 
that O 
by O 
conventional O 
organic O 
solvent O 
extraction O 
( O 
88.76% O 
) O 
. O 
In O 
addition O 
, O 
the O 
main O 
physicochemical O 
properties O 
and O 
antioxidant O 
activities O 
of O 
yellow O 
horn O 
oil O 
were O 
measured O 
to O 
evaluate O 
its O 
quality O 
. O 
The O 
present O 
research O 
supported O 
necessary O 
data O 
for O 
the O 
green O 
extraction O 
method O 
of O 
edible O 
oil O 
in O 
food O 
industry O 
. O 

the O 
effect O 
of O 
high O 
pressure O 
and O 
transglutaminase O 
treatment O 
of O 
milk O 
on O 
the O 
evolution O 
of O 
flavour O 
compounds O 
during O 
lactic B-TRIVIAL 
acid I-TRIVIAL 
fermentation O 
using O 
PTR-ToF-MS O 
. O 

this O 
study O 
, O 
the O 
effects O 
of O 
thermal O 
or O 
high O 
hydrostatic O 
pressure O 
( O 
HHP O 
) O 
treatment O 
of O 
a O 
milk O 
base O 
in O 
the O 
absence O 
or O 
presence O 
of O 
a O 
transglutaminase O 
( O 
TGase O 
) O 
protein O 
cross O 
- O 
linking O 
step O 
on O 
the O 
flavour O 
development O 
of O 
yoghurt O 
were O 
investigated O 
. O 
The O 
presence O 
of O 
several O 
tentatively O 
identified O 
volatile O 
flavour O 
compounds O 
( O 
VOCs O 
) O 
, O 
both O 
during O 
the O 
enzymatic O 
treatment O 
and O 
the O 
lactic B-TRIVIAL 
acid I-TRIVIAL 
fermentation O 
of O 
the O 
milk O 
base O 
, O 
were O 
monitored O 
using O 
a O 
proton O 
transfer O 
reaction O 
time O 
- O 
of O 
- O 
flight O 
mass O 
spectrometer O 
( O 
PTR-ToF-MS O 
) O 
. O 
The O 
formation O 
of O 
the O 
major O 
flavour O 
compounds O 
( O 
acetaldehyde B-SYSTEMATIC 
, O 
diacetyl B-SYSTEMATIC 
, O 
acetoin B-TRIVIAL 
, O 
and O 
2-butanone B-SYSTEMATIC 
) O 
followed O 
a O 
sigmoidal O 
trend O 
described O 
by O 
the O 
modified O 
Gompertz O 
model O 
. O 
The O 
HHP O 
treatment O 
of O 
milk O 
increased O 
significantly O 
the O 
volatile O 
compound O 
formation O 
rate O 
whereas O 
it O 
did O 
not O 
affect O 
the O 
duration O 
of O 
the O 
lag O 
phase O 
of O 
formation O 
, O 
with O 
the O 
exception O 
of O 
acetaldehyde B-SYSTEMATIC 
and O 
diacetyl B-SYSTEMATIC 
formation O 
. O 
On O 
the O 
contrary O 
, O 
the O 
TGase O 
cross O 
- O 
linking O 
of O 
milk O 
did O 
not O 
significantly O 
modify O 
the O 
formation O 
rate O 
of O 
the O 
volatile O 
compounds O 
but O 
shortened O 
the O 
duration O 
of O 
the O 
lag O 
phase O 
of O 
their O 
formation O 
. O 

and O 
characterisation O 
of O 
two O 
enzymes O 
related O 
to O 
endogenous O 
formaldehyde B-SYSTEMATIC 
in O 
Lentinula O 
edodes O 
. O 

this O 
study O 
, O 
γ-glutamyl B-TRIVIAL 
transpeptidase O 
( O 
GGT O 
) O 
and O 
l-cysteine B-SYSTEMATIC 
sulphoxide I-SYSTEMATIC 
lyase O 
( O 
C-S O 
lyase O 
) O 
were O 
purified O 
from O 
the O 
fruiting O 
body O 
of O 
Lentinula O 
edodes O 
in O 
three O 
steps O 
and O 
then O 
characterised O 
. O 
We O 
found O 
that O 
GGT O 
together O 
with O 
C-S O 
lyase O 
caused O 
the O 
generation O 
of O 
endogenous O 
formaldehyde B-SYSTEMATIC 
in O 
L O 
. O 
edodes O 
. O 
GGT O 
was O 
composed O 
of O 
a O 
large O 
subunit O 
of O 
41 O 
kDa O 
and O 
a O 
small O 
subunit O 
of O 
25 O 
kDa O 
, O 
and O 
C-S O 
lyase O 
was O 
composed O 
of O 
two O 
identical O 
subunits O 
of O 
46 O 
kDa O 
, O 
as O 
determined O 
by O 
SDS B-ABBREVIATION 
-PAGE O 
. O 
GGT O 
was O 
stable O 
at O 
pH O 
8.0-10.0 O 
with O 
an O 
optimum O 
pH O 
of O 
8.8 O 
, O 
and O 
was O 
stable O 
at O 
20-50°C O 
with O 
an O 
optimum O 
activity O 
at O 
37°C O 
. O 
C-S O 
lyase O 
was O 
stable O 
at O 
pH O 
8.0-9.0 O 
with O 
an O 
optimum O 
pH O 
of O 
8.5 O 
, O 
and O 
was O 
stable O 
at O 
20-60°C O 
with O 
an O 
optimum O 
activity O 
at O 
40°C O 
. O 
The O 
present O 
work O 
supports O 
the O 
study O 
of O 
the O 
mechanism O 
of O 
endogenous O 
formaldehyde B-SYSTEMATIC 
in O 
L O 
. O 
edodes O 
. O 

of O 
synthesis O 
of O 
oligosaccharides O 
derived O 
from O 
lactulose B-TRIVIAL 
( O 
fructosyl-galacto B-FAMILY 
- I-FAMILY 
oligosaccharides I-FAMILY 
) O 
with O 
β-galactosidases O 
of O 
different O 
origin O 
. O 

synthesis O 
of O 
fructosyl-galacto B-FAMILY 
- I-FAMILY 
oligosaccharides I-FAMILY 
from O 
lactulose B-TRIVIAL 
was O 
performed O 
with O 
commercial O 
β-galactosidase O 
preparations O 
from O 
Aspergillus O 
oryzae O 
, O 
Kluyveromyces O 
lactis O 
and O 
Bacillus O 
circulans O 
. O 
The O 
enzyme O 
from O 
A O 
. O 
oryzae O 
produced O 
the O 
highest O 
yield O 
and O 
specific O 
productivity O 
of O 
synthesis O 
, O 
being O 
selected O 
for O 
further O 
studies O 
. O 
Optimization O 
of O 
fructosyl-galacto B-FAMILY 
- I-FAMILY 
oligosaccharides I-FAMILY 
synthesis O 
was O 
carried O 
out O 
using O 
response O 
surface O 
methodology O 
, O 
considering O 
temperature O 
and O 
initial O 
sugar B-FAMILY 
concentration O 
as O 
variables O 
and O 
yield O 
and O 
specific O 
productivity O 
as O 
response O 
parameters O 
. O 
Maximum O 
yield O 
of O 
0.41 O 
g O 
g(-1) O 
fructosyl-galacto B-FAMILY 
- I-FAMILY 
oligosaccharides I-FAMILY 
was O 
obtained O 
at O 
70°C O 
and O 
60% O 
w O 
/ O 
w O 
lactulose B-TRIVIAL 
concentration O 
, O 
while O 
maximum O 
specific O 
productivity O 
of O 
1.2 O 
g O 
h(-1)mg(-1) O 
was O 
obtained O 
at O 
70°C O 
and O 
40% O 
w O 
/ O 
w O 
lactulose B-TRIVIAL 
concentration O 
. O 

cancer O 
resistance O 
protein O 
( O 
BCRP O 
/ O 
ABCG2 O 
) O 
plays O 
an O 
important O 
role O 
in O 
determining O 
the O 
absorption O 
and O 
disposition O 
of O 
consumed O 
xenobiotics O 
including O 
various O 
drugs O 
and O 
dietary O 
phytochemicals O 
and O 
is O 
also O 
one O 
of O 
the O 
prominent O 
efflux O 
transporters O 
involved O 
in O 
multidrug O 
resistance O 
( O 
MDR O 
) O 
. O 
In O 
this O 
study O 
, O 
we O 
have O 
investigated O 
the O 
interactions O 
between O 
ABCG2 O 
and O 
56 O 
naturally O 
- O 
occurring O 
phytochemicals O 
including O 
phenolic B-FAMILY 
acids I-FAMILY 
, O 
flavonoids B-FAMILY 
, O 
triterpenes B-FAMILY 
and O 
other O 
common O 
dietary O 
phytochemicals O 
, O 
as O 
well O 
as O 
two O 
non O 
plant O 
- O 
based O 
compounds O 
( O 
hippuric B-TRIVIAL 
acid I-TRIVIAL 
and O 
propyl B-SYSTEMATIC 
gallate I-SYSTEMATIC 
) O 
using O 
cell- O 
and O 
membrane O 
- O 
based O 
transport O 
inhibition O 
assays O 
. O 
Of O 
the O 
non- O 
flavonoid B-FAMILY 
phytochemicals O 
tested O 
, O 
berberine B-TRIVIAL 
, O 
celastrol B-TRIVIAL 
, O 
ellagic B-TRIVIAL 
acid I-TRIVIAL 
, O 
limonin B-TRIVIAL 
, O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
, O 
propyl B-SYSTEMATIC 
gallate I-SYSTEMATIC 
, O 
sinapic B-TRIVIAL 
acid I-TRIVIAL 
and O 
ursolic B-TRIVIAL 
acid I-TRIVIAL 
demonstrated O 
significant O 
inhibition O 
of O 
ABCG2 O 
- O 
mediated O 
transport O 
. O 
Chrysoeriol B-TRIVIAL 
, O 
laricitrin B-TRIVIAL 
, O 
myricetin B-SYSTEMATIC 
3',4',5'-trimethylether I-SYSTEMATIC 
, O 
pinocembrin B-TRIVIAL 
, O 
quercitrin B-TRIVIAL 
, O 
tamarixetin B-TRIVIAL 
, O 
tricetin B-TRIVIAL 
and O 
tricetin B-SYSTEMATIC 
3',4',5'-trimethylether I-SYSTEMATIC 
were O 
also O 
identified O 
as O 
novel O 
flavonoid B-FAMILY 
ABCG2 O 
inhibitors O 
. O 
The O 
identified O 
inhibitory O 
activity O 
of O 
dietary O 
phytochemicals O 
on O 
ABCG2 O 
provides O 
a O 
framework O 
for O 
further O 
investigation O 
of O 
ABCG2-modulated O 
phytochemical O 
bioavailability O 
, O 
MDR O 
, O 
and O 
possible O 
food O 
- O 
drug O 
interactions O 
. O 

- O 
induced O 
changes O 
in O 
arabinotriose B-TRIVIAL 
, O 
a O 
model O 
of O 
coffee O 
arabinogalactan O 
side O 
chains O 
. O 

processing O 
can O 
promote O 
reactions O 
that O 
change O 
the O 
structure O 
of O 
food O 
constituents O 
, O 
often O 
by O 
unknown O 
mechanisms O 
, O 
such O 
as O 
those O 
occurring O 
in O 
arabinose B-TRIVIAL 
residues O 
of O 
coffee O 
arabinogalactan O 
side O 
chains O 
. O 
Aiming O 
to O 
know O 
more O 
about O 
these O 
modifications O 
, O 
the O 
structurally O 
related O 
α-(1→5)-l-arabinotriose B-SYSTEMATIC 
was O 
roasted O 
at O 
200°C O 
and O 
the O 
products O 
obtained O 
were O 
identified O 
by O 
ESI-MS O 
and O 
MALDI-MS O 
and O 
characterised O 
by O 
ESI-MS(n) O 
. O 
Depolymerised O 
and O 
polymerised O 
oligosaccharides O 
with O 
up O 
to O 
16 O 
residues O 
and O 
new O 
types O 
of O 
linkages O 
were O 
formed O 
. O 
Also O 
, O 
products O 
resulting O 
from O 
dehydration O 
, O 
oxidation O 
, O 
and O 
cleavage O 
of O 
a O 
carbon B-SYSTEMATIC 
- O 
carbon B-SYSTEMATIC 
bond O 
at O 
the O 
reducing O 
end O 
of O 
the O 
corresponding O 
non O 
- O 
modified O 
oligosaccharide O 
were O 
formed O 
, O 
probably O 
promoting O 
the O 
release O 
of O 
formaldehyde B-SYSTEMATIC 
, O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
glycolaldehyde B-TRIVIAL 
, O 
glyoxal B-TRIVIAL 
, O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
glycolic B-TRIVIAL 
acid I-TRIVIAL 
, O 
glyceraldehyde B-TRIVIAL 
, O 
2-hydroxypropanedialdehyde B-SYSTEMATIC 
and O 
lactic O 
acid O 
. O 
As O 
many O 
of O 
these O 
compounds O 
have O 
been O 
reported O 
to O 
occur O 
in O 
roasted O 
coffee O 
beans O 
and O 
/ O 
or O 
brews O 
, O 
it O 
can O 
be O 
suggested O 
that O 
the O 
degradation O 
of O 
coffee O 
arabinogalactan O 
side O 
chains O 
can O 
contribute O 
to O 
their O 
formation O 
upon O 
roasting O 
. O 

protein O 
isolate O 
( O 
PPI O 
) O 
was O 
phosphorylated O 
with O 
sodium B-SYSTEMATIC 
trimetaphosphate I-SYSTEMATIC 
( O 
STMP B-ABBREVIATION 
) O 
at O 
ambient O 
temperature O 
and O 
various O 
reaction O 
pH O 
( O 
5.2 O 
, O 
6.2 O 
, O 
8 O 
and O 
10.5 O 
) O 
to O 
improve O 
the O 
functional O 
properties O 
without O 
impairing O 
the O 
nutritional O 
availability O 
. O 
Changes O 
in O 
chemical O 
composition O 
( O 
total O 
and O 
coagulable O 
protein O 
content O 
, O 
ash O 
and O 
minerals O 
content O 
and O 
amino B-FAMILY 
acid I-FAMILY 
composition O 
) O 
, O 
functional O 
properties O 
( O 
protein O 
solubility O 
index O 
, O 
emulsifying O 
activity O 
and O 
foaming O 
capacity O 
, O 
water O 
and O 
oil O 
absorption O 
capacity O 
) O 
and O 
phosphorus B-SYSTEMATIC 
were O 
determined O 
. O 
The O 
chemical O 
composition O 
and O 
functional O 
properties O 
of O 
phosphorylated O 
potato O 
protein O 
isolate O 
( O 
PP-PPI O 
) O 
were O 
significantly O 
different O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
PP-PPI O 
at O 
pH O 
5.2 O 
was O 
characterised O 
by O 
the O 
highest O 
content O 
of O 
all O 
amino B-FAMILY 
acids I-FAMILY 
, O 
whereas O 
, O 
PP-PPI O 
under O 
alkaline O 
conditions O 
( O 
pH O 
10.5 O 
) O 
caused O 
decrease O 
in O 
these O 
compounds O 
. O 
PP-PPI O 
at O 
pH O 
8 O 
had O 
the O 
highest O 
oil O 
absorption O 
capacity O 
, O 
emulsion O 
activity O 
and O 
foam O 
capacity O 
, O 
whereas O 
, O 
PP-PPI O 
at O 
pH O 
10.5 O 
had O 
the O 
highest O 
WAC O 
. O 

of O 
the O 
odour O 
- O 
active O 
cyclic O 
diketone O 
cis-2,6-dimethyl-1,4-cyclohexanedione B-SYSTEMATIC 
in O 
roasted O 
Arabica O 
coffee O 
brew O 
. O 

investigated O 
odour O 
- O 
active O 
trace O 
compounds O 
in O 
roasted O 
Brazilian O 
Arabica O 
coffee O 
. O 
Aroma O 
dilution O 
extract O 
analysis O 
( O 
AEDA O 
) O 
applied O 
to O 
the O 
volatile O 
oil O 
extracted O 
from O 
roasted O 
coffee O 
brew O 
revealed O 
34 O 
odour O 
- O 
active O 
compounds O 
. O 
Among O 
these O 
, O 
a O 
pungent-smelling O 
unknown O 
odour O 
- O 
active O 
compound O 
was O 
determined O 
. O 
The O 
volatile O 
oil O 
was O 
fractioned O 
by O 
silica B-TRIVIAL 
gel I-TRIVIAL 
column O 
chromatography O 
. O 
Gas O 
chromatography O 
- O 
olfactometry O 
( O 
GC-O O 
) O 
and O 
multidimensional O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
( O 
MDGC-MS O 
) O 
of O 
the O 
fraction O 
which O 
contained O 
a O 
significant O 
amount O 
of O 
the O 
target O 
unknown O 
compound O 
revealed O 
the O 
cyclic O 
1,4-diketone O 
, O 
cis-2,6-dimethyl-1,4-cyclohexanedione B-SYSTEMATIC 
, O 
which O 
had O 
a O 
pungent O 
odour O 
, O 
and O 
was O 
thus O 
first O 
identified O 
in O 
roasted O 
coffee O 
. O 
Model O 
experiments O 
revealed O 
that O 
cis-2,6-dimethyl-1,4-cyclohexanedione B-SYSTEMATIC 
was O 
formed O 
via O 
thermal O 
degradation O 
of O 
sugars B-FAMILY 
, O 
especially O 
monosaccharides B-FAMILY 
, O 
under O 
alkaline O 
conditions O 
. O 
Further O 
, O 
we O 
demonstrated O 
that O 
2-hydroxy-3-pentanone B-SYSTEMATIC 
and O 
1-hydroxy-2-propanone B-SYSTEMATIC 
, O 
thermal O 
degradation O 
products O 
of O 
monosaccharides B-FAMILY 
, O 
were O 
closely O 
related O 
to O 
the O 
formation O 
of O 
cis-2,6-dimethyl-1,4-cyclohexanedione B-SYSTEMATIC 
. O 

of O 
major O 
phlorotannins B-FAMILY 
in O 
Eisenia O 
bicyclis O 
using O 
hydrophilic O 
interaction O 
chromatography O 
: O 
seasonal O 
variation O 
and O 
extraction O 
characteristics O 
. O 

this O 
study O 
, O 
a O 
hydrophilic O 
interaction O 
chromatography O 
( O 
HILIC O 
) O 
condition O 
was O 
developed O 
for O 
the O 
simultaneous O 
determination O 
of O 
five O 
major O 
phlorotannins B-FAMILY 
from O 
an O 
extract O 
of O 
Eisenia O 
bicyclis O 
( O 
Kjellman O 
) O 
Setchell O 
with O 
good O 
linearity O 
( O 
r(2) O 
> O 
0.999 O 
) O 
. O 
Based O 
on O 
this O 
method O 
, O 
the O 
seasonal O 
variations O 
and O 
extraction O 
characteristics O 
, O 
in O 
terms O 
of O 
total O 
extraction O 
yield O 
and O 
the O 
content O 
of O 
the O 
phlorotannins B-FAMILY 
, O 
were O 
investigated O 
under O 
various O 
extraction O 
conditions O 
. O 
In O 
results O 
, O 
the O 
yields O 
and O 
phlorotannins B-FAMILY 
were O 
increased O 
two O 
- O 
to O 
- O 
four O 
times O 
in O 
summer O 
( O 
June-October O 
) O 
and O 
then O 
, O 
were O 
decreased O 
to O 
normal O 
levels O 
in O 
winter O 
( O 
November-March O 
) O 
. O 
In O 
the O 
extraction O 
of O 
E O 
. O 
bicyclis O 
, O 
ethanol B-SYSTEMATIC 
percentage O 
in O 
water O 
, O 
extraction O 
time O 
and O 
washing O 
time O 
significantly O 
affected O 
the O 
yield O 
of O 
the O 
extract O 
and O 
the O 
phlorotannins B-FAMILY 
, O 
whereas O 
the O 
temperature O 
and O 
the O 
sample O 
/ O 
solvent O 
ratio O 
impacted O 
the O 
extraction O 
to O 
a O 
lesser O 
degree O 
. O 
These O 
results O 
will O 
be O 
useful O 
information O 
in O 
the O 
application O 
of O 
this O 
macroalga O 
in O 
the O 
commercial O 
areas O 
related O 
to O 
nutraceuticals O 
, O 
pharmaceuticals O 
, O 
and O 
cosmeceuticals O 
. O 

of O 
dietary O 
carnosic B-TRIVIAL 
acid I-TRIVIAL 
on O 
the O 
fatty B-FAMILY 
acid I-FAMILY 
profile O 
and O 
flavour O 
stability O 
of O 
meat O 
from O 
fattening O 
lambs O 
. O 

- O 
two O 
lambs O 
were O 
fed O 
with O 
barley O 
straw O 
supplemented O 
by O 
a O 
concentrate O 
alone O 
, O 
or O 
a O 
concentrate O 
enriched O 
with O 
either O 
vitamin B-FAMILY 
E I-FAMILY 
( O 
VITE B-ABBREVIATION 
6 O 
: O 
0.6 O 
g O 
kg(-1) O 
feed O 
concentrate O 
) O 
or O 
carnosic B-TRIVIAL 
acid I-TRIVIAL 
( O 
CARN B-ABBREVIATION 
6 O 
: O 
0.6 O 
g O 
kg(-1) O 
feed O 
concentrate O 
; O 
or O 
CARN B-ABBREVIATION 
12 O 
: O 
1.2 O 
g O 
kg(-1) O 
feed O 
concentrate O 
) O 
. O 
In O 
order O 
to O 
elucidate O 
the O 
influence O 
of O 
the O 
dietary O 
supplementation O 
of O 
carnosic O 
compared O 
with O 
a O 
reference O 
diet O 
antioxidant O 
( O 
vitamin B-FAMILY 
E I-FAMILY 
) O 
, O 
the O 
animals O 
were O 
slaughtered O 
and O 
the O 
longissimus O 
thoracis O 
were O 
lyophilised O 
to O 
determine O 
the O 
FAs B-ABBREVIATION 
profile O 
and O 
the O 
phenolic B-FAMILY 
compounds O 
. O 
In O 
addition O 
, O 
longissimus O 
lumborum O 
slices O 
were O 
stored O 
in O 
a O 
modified O 
atmosphere O 
package O 
for O 
3 O 
days O 
and O 
then O 
grilled O 
to O 
determine O 
volatile O 
compounds O 
. O 
Dietary O 
carnosic B-TRIVIAL 
acid I-TRIVIAL 
did O 
not O 
modify O 
the O 
FAs B-ABBREVIATION 
profile O 
, O 
but O 
had O 
a O 
clear O 
effect O 
on O 
the O 
production O 
of O 
volatile O 
compounds O 
, O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
These O 
results O 
have O 
implications O 
for O 
the O 
food O 
industry O 
, O 
since O 
dietary O 
carnosic B-TRIVIAL 
acid I-TRIVIAL 
seems O 
to O 
extend O 
the O 
shelf O 
life O 
of O 
lamb O 
meat O 
. O 

microwave O 
- O 
assisted O 
hydrolysis O 
of O 
ellagitannins O 
and O 
quantification O 
as O 
ellagic B-TRIVIAL 
acid I-TRIVIAL 
equivalents O 
. O 

health O 
- O 
promoting O 
effects O 
of O 
ellagic B-TRIVIAL 
acid I-TRIVIAL 
and O 
its O 
intestinal O 
degradation O 
products O 
are O 
well O 
- O 
known O 
. O 
In O 
plants O 
, O 
ellagic B-TRIVIAL 
acid I-TRIVIAL 
mainly O 
appears O 
in O 
the O 
form O 
of O 
its O 
precursors O 
, O 
the O 
so O 
- O 
called O 
ellagitannins O 
. O 
Therefore O 
, O 
determination O 
of O 
total O 
ellagic B-TRIVIAL 
acid I-TRIVIAL 
content O 
has O 
been O 
accomplished O 
by O 
cleaving O 
ellagitannins O 
with O 
high O 
temperatures O 
and O 
strong O 
acids O 
. O 
Microwave O 
- O 
assisted O 
extraction O 
( O 
MAE O 
) O 
has O 
been O 
shown O 
to O 
be O 
a O 
very O 
effective O 
and O 
quick O 
extraction O 
technique O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
establish O 
an O 
MAE O 
- O 
based O 
method O 
for O 
a O 
rapid O 
hydrolysis O 
of O 
ellagitannins O 
and O 
to O 
compare O 
this O 
method O 
with O 
a O 
conventional O 
acid O 
hydrolysis O 
. O 
For O 
this O 
purpose O 
, O 
strawberries O 
( O 
Fragaria O 
x O 
ananassa O 
) O 
, O 
which O 
have O 
been O 
identified O 
as O 
a O 
major O 
source O 
of O 
ellagitannins O 
in O 
human O 
diet O 
, O 
were O 
used O 
as O 
a O 
model O 
. O 
The O 
newly O 
developed O 
MAE O 
method O 
was O 
quicker O 
, O 
less O 
chemical O 
- O 
consuming O 
and O 
more O 
effective O 
in O 
hydrolysing O 
ellagitannins O 
. O 

degradation O 
kinetics O 
of O 
the O 
major O 
blood O 
orange O 
xanthophylls O 
( O 
cis-violaxanthin B-TRIVIAL 
, O 
lutein B-TRIVIAL 
, O 
β-cryptoxanthin B-TRIVIAL 
, O 
zeaxanthin B-TRIVIAL 
and O 
cis-antheraxanthin B-TRIVIAL 
) O 
were O 
investigated O 
at O 
45 O 
, O 
60 O 
, O 
75 O 
, O 
and O 
90°C O 
in O 
real O 
juice O 
and O 
three O 
model O 
systems O 
formulated O 
to O 
evaluate O 
the O 
impact O 
of O 
xanthophyll O 
form O 
( O 
esterified O 
or O 
free O 
) O 
and O 
pH O 
( O 
acid O 
or O 
neutral O 
) O 
. O 
Xanthophylls O 
were O 
monitored O 
by O 
HPLC-DAD O 
and O 
kinetic O 
parameters O 
were O 
identified O 
by O 
non-linear O 
regression O 
. O 
A O 
second O 
order O 
model O 
best O 
fitted O 
the O 
degradation O 
curves O 
of O 
xanthophylls O 
. O 
All O 
degradation O 
rates O 
were O 
the O 
lowest O 
in O 
real O 
juice O 
. O 
Esterified O 
forms O 
were O 
more O 
stable O 
than O 
were O 
the O 
free O 
forms O 
. O 
In O 
all O 
acidic O 
media O 
, O 
β-cryptoxanthin B-TRIVIAL 
exhibited O 
the O 
lowest O 
degradation O 
rates O 
followed O 
by O 
lutein B-TRIVIAL 
and O 
zeaxanthin B-TRIVIAL 
. O 
In O 
comparison O 
, O 
the O 
epoxy B-SYSTEMATIC 
carotenoids O 
cis-violaxanthin B-TRIVIAL 
and O 
cis-antheraxanthin B-TRIVIAL 
degraded O 
around O 
3-fold O 
faster O 
in O 
their O 
esterified O 
form O 
. O 
In O 
their O 
free O 
form O 
, O 
cis-antheraxanthin B-TRIVIAL 
degraded O 
30-fold O 
faster O 
while O 
cis-violaxanthin B-TRIVIAL 
instantaneously O 
disappeared O 
because O 
of O 
the O 
isomerisation O 
of O 
its O 
5,6-epoxy B-SYSTEMATIC 
groups O 
into O 
5,8-epoxy B-SYSTEMATIC 
. O 
By O 
contrast O 
, O 
in O 
neutral O 
medium O 
, O 
free O 
epoxy B-SYSTEMATIC 
-xanthophylls O 
were O 
about O 
2-fold O 
more O 
stable O 
than O 
were O 
the O 
free O 
hydroxy B-SYSTEMATIC 
xanthophylls O 
lutein B-TRIVIAL 
, O 
zeaxanthin B-TRIVIAL 
and O 
β-cryptoxanthin B-TRIVIAL 
. O 
Kinetic O 
behaviours O 
of O 
xanthophylls O 
were O 
closely O 
dependent O 
on O 
their O 
chemical O 
structures O 
. O 

and O 
body O 
mass O 
index O 
modify O 
the O 
effect O 
of O 
increasing O 
amounts O 
of O 
caffeinated O 
coffee O 
on O 
postprandial O 
glucose B-TRIVIAL 
and O 
insulin O 
concentrations O 
; O 
a O 
randomized O 
, O 
controlled O 
, O 
clinical O 
trial O 
. O 

: O 
To O 
examine O 
the O 
effects O 
of O 
different O 
coffee O 
amounts O 
on O 
blood O 
glucose B-TRIVIAL 
and O 
insulin O 
concentrations O 
of O 
healthy O 
volunteers O 
, O 
and O 
to O 
assess O 
potential O 
effect O 
modification O 
by O 
sex O 
and O 
body O 
mass O 
index O 
category O 
. O 
MATERIALS O 
/ O 
METHODS O 
: O 
Thirty O 
- O 
three O 
volunteers O 
[ O 
16♀ O 
/ O 
17♂ O 
, O 
16 O 
normal O 
- O 
weight O 
and O 
17 O 
overweight O 
/ O 
obese O 
, O 
27.3±7.2 O 
( O 
19-44 O 
) O 
y O 
] O 
took O 
part O 
in O 
this O 
randomized O 
, O 
crossover O 
study O 
. O 
Ιn O 
the O 
morning O 
of O 
each O 
experimental O 
day O 
volunteers O 
received O 
a O 
standardized O 
meal O 
along O 
with O 
200mL O 
of O 
water O 
or O 
instant O 
coffee O 
containing O 
either O 
3 O 
or O 
6mg O 
of O 
caffeine B-TRIVIAL 
/ O 
kg O 
body O 
weight O 
. O 
Blood O 
samples O 
were O 
obtained O 
and O 
analyzed O 
for O 
glucose B-TRIVIAL 
and O 
insulin O 
concentrations O 
in O 
the O 
fasting O 
state O 
, O 
immediately O 
after O 
meal O 
/ O 
drink O 
consumption O 
and O 
at O 
standard O 
time O 
points O 
for O 
the O 
next O 
3h O 
thereafter O 
. O 
RESULTS O 
: O 
Coffee O 
delayed O 
the O 
rise O 
of O 
insulin O 
in O 
response O 
to O 
the O 
standardized O 
meal O 
and O 
the O 
fall O 
of O 
glucose B-TRIVIAL 
concentrations O 
from O 
its O 
maximum O 
levels O 
in O 
the O 
entire O 
study O 
sample O 
. O 
Glucose B-TRIVIAL 
incremental O 
area O 
under O 
the O 
curve O 
( O 
IAUC O 
) O 
was O 
significantly O 
different O 
between O 
interventions O 
( O 
P=.009 O 
) O 
with O 
both O 
coffee O 
amounts O 
inducing O 
a O 
greater O 
area O 
compared O 
to O 
water O 
. O 
Secondary O 
, O 
subgroup O 
analysis O 
at O 
the O 
nominal O 
level O 
showed O 
that O 
this O 
might O 
be O 
more O 
evident O 
among O 
females O 
( O 
PIAUC=.05 O 
) O 
and O 
overweight O 
/ O 
obese O 
participants O 
( O 
PIAUC=.03 O 
) O 
. O 
Furthermore O 
, O 
coffee O 
, O 
mainly O 
the O 
6mg O 
dose O 
, O 
could O 
be O 
lowering O 
insulin O 
concentrations O 
the O 
first O 
30min O 
after O 
its O 
consumption O 
compared O 
to O 
water O 
in O 
men O 
and O 
overweight O 
/ O 
obese O 
participants O 
. O 
CONCLUSIONS O 
: O 
Coffee O 
exerts O 
an O 
acute O 
effect O 
on O 
postprandial O 
glucose B-TRIVIAL 
and O 
insulin O 
concentrations O 
. O 
This O 
effect O 
may O 
be O 
modified O 
by O 
sex O 
and O 
overweight O 
/ O 
obese O 
status O 
. O 
Future O 
research O 
is O 
necessary O 
to O 
elucidate O 
underlying O 
mechanisms O 
. O 

, O 
preliminary O 
structure O 
- O 
activity O 
relationships O 
, O 
and O 
in O 
vitro O 
biological O 
evaluation O 
of O 
6-aryl-3-amino-thieno[2,3-b]pyridine B-FAMILY 
derivatives O 
as O 
potential O 
anti-inflammatory O 
agents O 
. O 

our O 
previous O 
study O 
, O 
a O 
series O 
of O 
6-aryl-3-amino-thieno[2,3-b]pyridine B-FAMILY 
derivatives O 
exhibited O 
potent O 
antiproliferative O 
activities O 
and O 
an O 
unique O 
hepatocellular O 
carcinoma O 
(HCC)-specific O 
anticancer O 
activity O 
was O 
also O 
observed O 
. O 
In O 
further O 
anti-inflammatory O 
research O 
, O 
thienopyridine B-SYSTEMATIC 
derivative O 
1a O 
showed O 
potent O 
inhibition O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
production O 
. O 
So O 
a O 
series O 
of O 
thienopyridine B-SYSTEMATIC 
analogues O 
of O 
1a O 
were O 
synthesized O 
and O 
evaluated O 
for O 
anti-inflammatory O 
activities O 
. O 
The O 
structure O 
- O 
activity O 
relationships O 
( O 
SARs O 
) O 
revealed O 
that O 
the O 
most O 
potent O 
analogues O 
1f O 
and O 
1o O 
were O 
identified O 
as O 
potent O 
inhibitors O 
of O 
NO B-FORMULA 
production O 
with O 
IC50 O 
values O 
of O 
3.3 O 
and O 
3.24 O 
μM O 
, O 
respectively O 
. O 
These O 
results O 
suggest O 
that O 
these O 
6-aryl-3-amino-thieno[2,3-b]pyridine B-FAMILY 
derivatives O 
might O 
potentially O 
constitute O 
a O 
novel O 
class O 
of O 
anti-inflammatory O 
agents O 
, O 
which O 
require O 
further O 
studies O 
. O 

toxin O 
A O 
( O 
BTX-A O 
) O 
is O 
approved O 
for O 
treatment O 
of O 
chronic O 
migraine O 
and O 
has O 
been O 
investigated O 
in O 
various O 
other O 
painful O 
conditions O 
. O 
Recent O 
evidence O 
demonstrated O 
retrograde O 
axonal O 
transport O 
and O 
suggested O 
the O 
involvement O 
of O 
CNS O 
in O 
antinociceptive O 
effect O 
of O 
BTX-A O 
. O 
However O 
, O 
the O 
mechanism O 
of O 
BTX-A O 
central O 
antinociceptive O 
action O 
is O 
unknown O 
. O 
In O 
this O 
study O 
we O 
investigated O 
the O 
potential O 
role O 
of O 
opioid O 
receptors O 
in O 
BTX-A's O 
antinociceptive O 
activity O 
. O 
In O 
formalin B-TRIVIAL 
-induced O 
inflammatory O 
pain O 
we O 
assessed O 
the O 
effect O 
of O 
opioid O 
antagonists O 
on O 
antinociceptive O 
activity O 
of O 
BTX-A O 
. O 
Naltrexone B-TRIVIAL 
was O 
injected O 
subcutaneously O 
( O 
0.02-2 O 
mg O 
/ O 
kg O 
) O 
or O 
intrathecally O 
( O 
0.07 O 
μg O 
/ O 
10 O 
μl-350 O 
μg O 
/ O 
10 O 
μl O 
) O 
, O 
while O 
selective O 
μ-antagonist O 
naloxonazine B-TRIVIAL 
was O 
administered O 
intraperitoneally O 
( O 
5 O 
mg O 
/ O 
kg O 
) O 
prior O 
to O 
nociceptive O 
testing O 
. O 
The O 
influence O 
of O 
naltrexone B-TRIVIAL 
( O 
2 O 
mg O 
/ O 
kg O 
s.c O 
. O 
) O 
on O 
BTX-A O 
antinociceptive O 
activity O 
was O 
examined O 
additionally O 
in O 
an O 
experimental O 
neuropathy O 
induced O 
by O 
partial O 
sciatic O 
nerve O 
transection O 
. O 
To O 
investigate O 
the O 
effects O 
of O 
naltrexone B-TRIVIAL 
and O 
BTX-A O 
on O 
neuronal O 
activation O 
in O 
spinal O 
cord O 
, O 
c-Fos O 
expression O 
was O 
immunohistochemically O 
examined O 
in O 
a O 
model O 
of O 
formalin B-TRIVIAL 
-induced O 
pain O 
. O 
Antinociceptive O 
effects O 
of O 
BTX-A O 
in O 
formalin B-TRIVIAL 
and O 
sciatic O 
nerve O 
transection O 
- O 
induced O 
pain O 
were O 
prevented O 
by O 
non-selective O 
opioid O 
antagonist O 
naltrexone B-TRIVIAL 
. O 
Similarly O 
, O 
BTX-A-induced O 
pain O 
reduction O 
was O 
abolished O 
by O 
low O 
dose O 
of O 
intrathecal O 
naltrexone B-TRIVIAL 
and O 
by O 
selective O 
μ-antagonist O 
naloxonazine B-TRIVIAL 
. O 
BTX-A-induced O 
decrease O 
in O 
dorsal O 
horn O 
c-Fos O 
expression O 
was O 
prevented O 
by O 
naltrexone B-TRIVIAL 
. O 
Prevention O 
of O 
BTX-A O 
effects O 
on O 
pain O 
and O 
c-Fos O 
expression O 
by O 
opioid O 
antagonists O 
suggest O 
that O 
the O 
central O 
antinociceptive O 
action O 
of O 
BTX-A O 
might O 
be O 
associated O 
with O 
the O 
activity O 
of O 
endogenous O 
opioid O 
system O 
( O 
involving O 
μ-opioid O 
receptor O 
) O 
. O 
These O 
results O 
provide O 
first O 
insights O 
into O 
the O 
mechanism O 
of O 
BTX-A's O 
central O 
antinociceptive O 
activity O 
. O 

do O 
in O 
- O 
vitro O 
release O 
profiles O 
of O 
nanosuspensions O 
from O 
Alzet O 
® O 
pumps O 
correspond O 
to O 
the O 
in O 
- O 
vivo O 
situation O 
? O 
A O 
case O 
study O 
on O 
radiolabeled B-TRIVIAL 
fenofibrate I-TRIVIAL 
. O 

research O 
and O 
development O 
sufficiently O 
high O 
and O 
constant O 
plasma O 
levels O 
of O 
drug O 
candidates O 
are O 
often O 
requested O 
, O 
but O 
simple O 
solutions O 
of O 
hydrophobic O 
drugs O 
delivered O 
from O 
the O 
commonly O 
used O 
micro O 
- O 
osmotic O 
pumps O 
cannot O 
meet O 
these O 
demands O 
. O 
Nanosuspensions O 
released O 
from O 
implanted O 
osmotic O 
devices O 
can O 
be O 
a O 
strategy O 
to O 
overcome O 
this O 
challenge O 
but O 
little O 
is O 
known O 
about O 
their O 
pharmacokinetic O 
behavior O 
after O 
subcutaneous O 
application O 
. O 
In O 
the O 
current O 
study O 
, O 
four O 
different O 
nanosuspension O 
formulations O 
containing O 
iodinated B-TRIVIAL 
fenofibrate I-TRIVIAL 
were O 
prepared O 
, O 
physicochemically O 
characterized O 
and O 
investigated O 
concerning O 
their O 
in O 
- O 
vitro O 
release O 
kinetics O 
from O 
osmotic O 
pumps O 
. O 
One O 
nanosuspension O 
of O 
lower O 
viscosity O 
exhibited O 
thereby O 
an O 
unexpectedly O 
first O 
order O 
release O 
kinetics O 
, O 
whereas O 
the O 
higher O 
viscous O 
counterpart O 
was O 
released O 
in O 
the O 
expected O 
zero O 
- O 
order O 
manner O 
. O 
To O 
assess O 
the O 
relation O 
of O 
the O 
in O 
- O 
vitro O 
release O 
kinetics O 
to O 
the O 
in O 
- O 
vivo O 
fate O 
of O 
nanosuspensions O 
, O 
various O 
[ B-SYSTEMATIC 
(131)I I-SYSTEMATIC 
] I-SYSTEMATIC 
iodinated I-SYSTEMATIC 
fenofibrate I-SYSTEMATIC 
formulations O 
were O 
subcutaneously O 
applied O 
to O 
mice O 
. O 
The O 
biodistribution O 
was O 
followed O 
by O 
means O 
of O 
γ-scintigraphy O 
and O 
γ-scintillation O 
. O 
Two O 
different O 
nanosuspensions O 
released O 
from O 
osmotic O 
pumps O 
were O 
compared O 
to O 
bolus O 
injections O 
of O 
a O 
nanosuspension O 
and O 
an O 
organic O 
drug O 
solution O 
. O 
The O 
distribution O 
and O 
elimination O 
of O 
the O 
bolus O 
injected O 
drug O 
solution O 
were O 
almost O 
completed O 
within O 
48h O 
. O 
In O 
contrast O 
, O 
a O 
long O 
lasting O 
( O 
> O 
1week O 
) O 
depot O 
at O 
the O 
injection O 
site O 
was O 
formed O 
by O 
the O 
bolus O 
injected O 
nanosuspension O 
. O 
Ex O 
vivo O 
examination O 
of O 
the O 
organs O 
showed O 
a O 
sustained O 
, O 
but O 
exponential O 
decrease O 
of O 
the O 
radiolabel O 
concentration O 
. O 
More O 
constant O 
drug O 
levels O 
in O 
the O 
organs O 
were O 
achieved O 
within O 
the O 
nanosuspensions O 
released O 
from O 
osmotic O 
pumps O 
. O 
The O 
organ O 
levels O 
of O 
[ B-SYSTEMATIC 
(131)I I-SYSTEMATIC 
] I-SYSTEMATIC 
labeled I-SYSTEMATIC 
fenofibrate I-SYSTEMATIC 
were O 
found O 
to O 
be O 
more O 
constant O 
in O 
case O 
of O 
the O 
pump O 
with O 
the O 
higher O 
viscous O 
nanosuspension O 
in O 
contrast O 
to O 
the O 
lower O 
viscous O 
counterpart O 
. O 
However O 
, O 
the O 
very O 
different O 
release O 
profiles O 
of O 
the O 
lower O 
and O 
higher O 
viscous O 
nanosuspension O 
observed O 
in O 
- O 
vitro O 
were O 
not O 
observed O 
in O 
- O 
vivo O 
, O 
as O 
both O 
pumps O 
showed O 
zero O 
order O 
release O 
. O 
In O 
conclusion O 
, O 
nanosuspensions O 
of O 
poorly O 
soluble O 
compounds O 
released O 
from O 
subcutaneously O 
implanted O 
osmotic O 
pumps O 
can O 
be O 
a O 
suitable O 
approach O 
in O 
pharmacokinetic O 
studies O 
. O 
Although O 
the O 
in O 
- O 
vivo O 
release O 
of O 
nanosuspensions O 
differed O 
in O 
the O 
expected O 
release O 
profile O 
from O 
the O 
in O 
- O 
vitro O 
test O 
results O 
, O 
these O 
in O 
- O 
vitro O 
release O 
tests O 
present O 
a O 
valuable O 
tool O 
for O 
the O 
pre O 
- O 
selection O 
of O 
suitable O 
nanosuspension O 
candidates O 
. O 

of O 
block O 
copolymers O 
for O 
the O 
coordinated O 
delivery O 
of O 
doxorubicin B-TRIVIAL 
and O 
magnetite B-TRIVIAL 
nanocubes O 
. O 

nanoparticles O 
combine O 
drug O 
and O 
imaging O 
agent O 
together O 
to O 
assign O 
both O 
therapeutic O 
and O 
diagnostic O 
functions O 
. O 
However O 
, O 
particle O 
aggregation O 
/ O 
dissociation O 
and O 
/ O 
or O 
major O 
differences O 
in O 
the O 
bio O 
- O 
distribution O 
and O 
targeting O 
capability O 
of O 
drugs O 
and O 
imaging O 
probes O 
are O 
main O 
obstacles O 
for O 
the O 
efficient O 
, O 
coordinated O 
delivery O 
of O 
multiple O 
agents O 
, O 
unless O 
the O 
different O 
agents O 
can O 
be O 
tightly O 
bound O 
and O 
well O 
- O 
protected O 
during O 
their O 
circulation O 
in O 
vivo O 
. O 
In O 
this O 
paper O 
, O 
we O 
report O 
the O 
coordinated O 
in O 
vivo O 
delivery O 
of O 
anti-cancer O 
drugs O 
and O 
imaging O 
agents O 
by O 
chemically O 
loading O 
doxorubicin B-TRIVIAL 
and O 
magnetite B-TRIVIAL 
nanocubes O 
( O 
MNs O 
) O 
in O 
the O 
core O 
of O 
polymeric O 
nanoparticles O 
. O 
Living O 
polymerization O 
, O 
nitroxide B-SYSTEMATIC 
-mediated O 
radical O 
polymerization O 
( O 
NMP O 
) O 
, O 
was O 
applied O 
to O 
construct O 
the O 
optimal O 
polymers O 
to O 
co O 
- O 
deliver O 
doxorubicin B-TRIVIAL 
and O 
MNs O 
. O 
The O 
resulting O 
diblock O 
polymers O 
consisted O 
of O 
one O 
block O 
with O 
triethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
brushes O 
and O 
another O 
block O 
with O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
groups O 
to O 
bind O 
doxorubicin B-TRIVIAL 
and O 
Fe3O4 B-FORMULA 
MNs O 
. O 
The O 
optimal O 
polymer O 
has O 
narrow O 
polydispersity O 
( O 
PDI=1.2 O 
) O 
and O 
high O 
doxorubicin B-TRIVIAL 
/ O 
MN O 
loading O 
( O 
30wt.% O 
/ O 
28wt.% O 
) O 
. O 
Core O 
- O 
shell O 
particles O 
were O 
obtained O 
with O 
good O 
stability O 
and O 
a O 
suitable O 
particle O 
size O 
of O 
~100nm O 
. O 
The O 
doxorubicin B-TRIVIAL 
and O 
MNs O 
loaded O 
in O 
this O 
polymeric O 
system O 
showed O 
highly O 
coordinated O 
bio O 
- O 
distribution O 
in O 
the O 
balb O 
/ O 
C O 
mice O 
model O 
. O 
This O 
system O 
may O 
have O 
important O 
impact O 
on O 
the O 
design O 
of O 
effective O 
and O 
stable O 
dual O 
- O 
agent O 
co O 
- O 
delivery O 
systems O 
. O 

efficacy O 
of O 
protein O 
- O 
based O 
therapeutics O 
with O 
indications O 
in O 
the O 
treatment O 
of O 
lymphatic O 
diseases O 
is O 
expected O 
to O 
be O 
improved O 
by O 
enhancing O 
lymphatic O 
disposition O 
. O 
This O 
study O 
was O 
therefore O 
aimed O 
at O 
examining O 
whether O 
PEGylation O 
can O 
usefully O 
be O 
applied O 
to O 
improve O 
the O 
lymphatic O 
uptake O 
of O 
interferon O 
α2 O 
and O 
whether O 
this O 
ultimately O 
translates O 
into O 
improved O 
therapeutic O 
efficacy O 
against O 
lymph O 
- O 
resident O 
cancer O 
. O 
The O 
lymphatic O 
pharmacokinetics O 
of O 
interferon O 
α2b O 
( O 
IFN O 
, O 
19kDa O 
) O 
and O 
PEGylated O 
interferon O 
α2b O 
( O 
IFN- O 
PEG12 B-TRIVIAL 
, O 
31kDa O 
) O 
or O 
α2a O 
( O 
IFN- O 
PEG40 B-TRIVIAL 
, O 
60kDa O 
) O 
was O 
examined O 
in O 
thoracic O 
lymph O 
duct O 
cannulated O 
rats O 
. O 
IFN O 
was O 
poorly O 
absorbed O 
from O 
the O 
SC O 
injection O 
site O 
( O 
Fabs O 
36% O 
) O 
and O 
showed O 
little O 
uptake O 
into O 
lymph O 
after O 
SC O 
or O 
IV O 
administration O 
( O 
≤ O 
1% O 
) O 
. O 
In O 
contrast O 
, O 
IFN- O 
PEG12 B-TRIVIAL 
was O 
efficiently O 
absorbed O 
from O 
the O 
SC O 
injection O 
site O 
( O 
Fabs O 
82% O 
) O 
and O 
approximately O 
20% O 
and O 
8% O 
of O 
the O 
injected O 
dose O 
was O 
recovered O 
in O 
thoracic O 
lymph O 
over O 
30h O 
after O 
SC O 
or O 
IV O 
administration O 
respectively O 
. O 
IFN- O 
PEG40 B-TRIVIAL 
, O 
however O 
, O 
was O 
incompletely O 
absorbed O 
from O 
the O 
SC O 
injection O 
site O 
( O 
Fabs O 
23% O 
) O 
and O 
showed O 
similar O 
lymphatic O 
access O 
after O 
SC O 
administration O 
to O 
IFN- O 
PEG12 B-TRIVIAL 
( O 
21% O 
) O 
. O 
The O 
recovery O 
of O 
IFN-PEG40 O 
in O 
thoracic O 
lymph O 
after O 
IV O 
administration O 
, O 
however O 
, O 
was O 
significantly O 
greater O 
( O 
29% O 
) O 
when O 
compared O 
to O 
IV O 
IFN- O 
PEG12 B-TRIVIAL 
. O 
The O 
anti-tumour O 
efficacy O 
of O 
interferon O 
against O 
axillary O 
metastases O 
of O 
a O 
highly O 
lymph O 
- O 
metastatic O 
variant O 
of O 
human O 
breast O 
MDA-MB-231 O 
carcinoma O 
was O 
significantly O 
increased O 
by O 
SC O 
administration O 
of O 
lymph O 
- O 
targeted O 
IFN- O 
PEG12 B-TRIVIAL 
when O 
compared O 
to O 
the O 
administration O 
of O 
IFN O 
on O 
the O 
ipsilateral O 
side O 
to O 
the O 
axillary O 
metastasis O 
. O 
Optimal O 
PEGylation O 
may O 
therefore O 
represent O 
a O 
viable O 
approach O 
to O 
improving O 
the O 
lymphatic O 
disposition O 
and O 
efficacy O 
of O 
therapeutic O 
proteins O 
against O 
lymphatic O 
diseases O 
. O 

stress O 
responses O 
in O 
zebrafish O 
Danio O 
rerio O 
after O 
subchronic O 
exposure O 
to O 
atrazine B-TRIVIAL 
. O 

is O 
one O 
of O 
the O 
most O 
used O 
pesticides O 
all O 
over O 
the O 
world O 
and O 
it O 
is O 
frequently O 
detected O 
in O 
surface O 
water O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
if O 
zebrafish O 
exposure O 
to O 
atrazine B-TRIVIAL 
could O 
induce O 
oxidative O 
stress O 
and O 
changes O 
in O 
detoxifying O 
system O 
. O 
Juvenile O 
fish O 
were O 
exposed O 
to O 
sublethal O 
concentrations O 
of O 
0.3 O 
, O 
3 O 
, O 
30 O 
, O 
or O 
90μgL(-1) O 
for O 
28days O 
. O 
The O 
level O 
of O 
oxidized O 
lipids O 
increased O 
in O 
experimental O 
groups O 
exposed O 
to O 
atrazine B-TRIVIAL 
at O 
30 O 
and O 
90μgL(-1) O 
compared O 
to O 
control O 
. O 
Activity O 
of O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
decreased O 
in O 
group O 
with O 
the O 
highest O 
concentration O 
compared O 
to O 
control O 
. O 
A O 
significant O 
decline O 
was O 
observed O 
in O 
catalase O 
activity O 
in O 
all O 
experimental O 
groups O 
compared O 
to O 
control O 
. O 
Activity O 
of O 
superoxide B-TRIVIAL 
dismutase O 
increased O 
only O 
in O 
experimental O 
group O 
exposed O 
to O 
atrazine B-TRIVIAL 
at O 
30μgL(-1) O 
compared O 
to O 
control O 
. O 
Activity O 
of O 
glutathione B-TRIVIAL 
peroxidase O 
and O 
reductase O 
( O 
GR O 
) O 
increased O 
in O 
experimental O 
groups O 
exposed O 
to O 
atrazine B-TRIVIAL 
at O 
0.3 O 
( O 
only O 
for O 
GR O 
activity O 
) O 
and O 
90μgL(-1) O 
compared O 
to O 
control O 
. O 
Our O 
results O 
showed O 
that O 
atrazine B-TRIVIAL 
exposure O 
had O 
profound O 
influence O 
on O 
the O 
oxidative O 
stress O 
markers O 
and O 
detoxifying O 
enzyme O 
of O 
the O 
exposed O 
zebrafish O 
. O 
The O 
changes O 
in O 
antioxidant O 
enzyme O 
activities O 
could O 
be O 
an O 
adaptive O 
response O 
to O 
protect O 
the O 
fish O 
from O 
the O 
atrazine B-TRIVIAL 
-induced O 
toxicity O 
. O 

dots O 
( O 
QDs O 
) O 
are O 
nano O 
- O 
sized O 
semiconductors O 
. O 
Previously O 
, O 
intratracheal O 
instillation O 
of O 
QD705s O 
induces O 
persistent O 
inflammation O 
in O 
mouse O 
lungs O 
. O 
In O 
our O 
present O 
study O 
, O 
QD705-COOH O 
and O 
QD705- O 
PEG B-ABBREVIATION 
activated O 
NF-κB O 
and O 
increased O 
monocyte O 
chemotactic O 
protein-1 O 
( O 
MCP-1 O 
) O 
expression O 
in O 
macrophages O 
RAW264.7 O 
via O 
MyD88 O 
dependent O 
Toll O 
- O 
like O 
receptor O 
( O 
TLR O 
) O 
signaling O 
pathways O 
. O 
MyD88 O 
is O 
an O 
adapter O 
protein O 
for O 
most O 
TLRs O 
to O 
activate O 
NF-κB O 
. O 
Silencing O 
expression O 
of O 
MyD88 O 
or O 
p65 O 
with O 
siRNA O 
or O 
co O 
- O 
treatment O 
with O 
a O 
NF-κB O 
inhibitor O 
tremendously O 
abolished O 
QD705s-induced O 
NF-κB O 
activity O 
and O 
MCP-1 O 
expression O 
. O 
The O 
involved O 
TLRs O 
might O 
locate O 
either O 
on O 
the O 
cell O 
surface O 
or O 
inside O 
of O 
cells O 
. O 
Co O 
- O 
treatment O 
with O 
a O 
TLR4 O 
inhibitor O 
completely O 
prevented O 
MCP-1 O 
induction O 
by O 
QD705- O 
PEG B-ABBREVIATION 
. O 
Nevertheless O 
, O 
QD705- O 
COOH B-FORMULA 
readily O 
entered O 
cells O 
, O 
and O 
co O 
- O 
treatment O 
with O 
either O 
inhibitors O 
of O 
endocytosis O 
or O 
intracellular O 
TLRs O 
prevented O 
MCP-1 O 
induction O 
. O 
These O 
findings O 
indicate O 
that O 
, O 
depending O 
on O 
their O 
surface O 
modification O 
, O 
OD705s O 
activate O 
MyD88 O 
dependent-TLRs O 
at O 
the O 
surface O 
or O 
inside O 
of O 
the O 
cells O 
, O 
which O 
is O 
an O 
important O 
mechanism O 
for O 
nanoparticles O 
- O 
induced O 
inflammatory O 
responses O 
. O 
But O 
other O 
MyD88 O 
- O 
independent O 
pathways O 
may O 
also O 
involve O 
in O 
these O 
responses O 
. O 

of O 
thienopyridines B-FAMILY 
on O 
human O 
neutrophil O 
granulocytes O 
and O 
lymphocytes O 
. O 

can O 
cause O 
neutropenia O 
and O 
agranulocytosis O 
. O 
The O 
aim O 
of O 
the O 
current O 
investigations O 
was O 
to O 
compare O 
cytotoxicity O 
of O 
ticlopidine B-TRIVIAL 
, O 
clopidogrel B-TRIVIAL 
, O 
clopidogrel B-SYSTEMATIC 
carboxylate I-SYSTEMATIC 
and O 
prasugrel B-TRIVIAL 
for O 
human O 
neutrophil O 
granulocytes O 
with O 
the O 
toxicity O 
for O 
lymphocytes O 
and O 
to O 
investigate O 
underlying O 
mechanisms O 
. O 
For O 
granulocytes O 
, O 
clopidogrel B-TRIVIAL 
, O 
ticlopidine B-TRIVIAL 
, O 
clopidogrel B-SYSTEMATIC 
carboxylate I-SYSTEMATIC 
and O 
prasugrel B-TRIVIAL 
were O 
concentration O 
- O 
dependently O 
toxic O 
starting O 
at O 
10μM O 
. O 
Cytotoxicity O 
could O 
be O 
prevented O 
by O 
the O 
myeloperoxidase O 
inhibitor O 
rutin B-TRIVIAL 
, O 
but O 
not O 
by O 
the O 
cytochrome O 
P450 O 
inhibitor O 
ketoconazole B-TRIVIAL 
. O 
All O 
compounds O 
were O 
also O 
toxic O 
for O 
lymphocytes O 
, O 
but O 
cytotoxicity O 
started O 
at O 
100μM O 
and O 
could O 
not O 
be O 
prevented O 
by O 
rutin B-TRIVIAL 
or O 
ketoconazole B-TRIVIAL 
. O 
Granulocytes O 
metabolized O 
ticlopidine B-TRIVIAL 
, O 
clopidogrel B-TRIVIAL 
, O 
clopidogrel B-SYSTEMATIC 
carboxylate I-SYSTEMATIC 
and O 
prasugrel B-TRIVIAL 
, O 
and O 
metabolization O 
was O 
inhibited O 
by O 
rutin B-TRIVIAL 
, O 
but O 
not O 
by O 
ketoconazole B-TRIVIAL 
. O 
Metabolism O 
of O 
these O 
compounds O 
by O 
lymphocytes O 
was O 
much O 
slower O 
and O 
could O 
not O 
be O 
inhibited O 
by O 
ketoconazole B-TRIVIAL 
or O 
rutin B-TRIVIAL 
. O 
In O 
neutrophils O 
, O 
all O 
compounds O 
investigated O 
decreased O 
the O 
electrical O 
potential O 
across O 
the O 
inner O 
mitochondrial O 
membrane O 
, O 
were O 
associated O 
with O 
cellular O 
accumulation O 
of O 
ROS O 
, O 
mitochondrial O 
loss O 
of O 
cytochrome O 
c O 
and O 
induction O 
of O 
apoptosis O 
starting O 
at O 
10μM O 
. O 
All O 
of O 
these O 
effects O 
could O 
be O 
inhibited O 
by O 
rutin B-TRIVIAL 
, O 
but O 
not O 
by O 
ketoconazole B-TRIVIAL 
. O 
Similar O 
findings O 
were O 
obtained O 
in O 
lymphocytes O 
; O 
but O 
compared O 
to O 
neutrophils O 
, O 
the O 
effects O 
were O 
detectable O 
only O 
at O 
higher O 
concentrations O 
and O 
were O 
not O 
inhibited O 
by O 
rutin B-TRIVIAL 
. O 
In O 
conclusion O 
, O 
ticlopidine B-TRIVIAL 
, O 
clopidogrel B-TRIVIAL 
, O 
clopidogrel B-SYSTEMATIC 
carboxylate I-SYSTEMATIC 
and O 
prasugrel B-TRIVIAL 
are O 
toxic O 
for O 
both O 
granulocytes O 
and O 
lymphocytes O 
. O 
In O 
granulocytes O 
, O 
cytotoxicity O 
is O 
more O 
accentuated O 
than O 
in O 
lymphocytes O 
and O 
depends O 
on O 
metabolization O 
by O 
myeloperoxidase O 
. O 
These O 
findings O 
suggest O 
a O 
mitochondrial O 
mechanism O 
for O 
cytotoxicity O 
for O 
both O 
myeloperoxidase O 
- O 
associated O 
metabolites O 
and O 
, O 
at O 
higher O 
concentrations O 
, O 
also O 
for O 
the O 
parent O 
compounds O 
. O 

and O 
antifungal O 
activity O 
of O 
C-21 O 
steroids B-FAMILY 
with O 
an O 
aromatic O 
D O 
ring O 
. O 

analogues O 
of O 
salpichrolides B-FAMILY 
with O 
a O 
simplified O 
side O 
chain O 
( O 
6-11 O 
) O 
were O 
synthesized O 
using O 
a O 
new O 
methodology O 
to O 
obtain O 
steroids B-FAMILY 
with O 
an O 
aromatic O 
D-ring O 
. O 
The O 
key O 
step O 
was O 
the O 
elimination O 
of O 
HBr B-FORMULA 
in O 
a O 
vicinal B-FAMILY 
dibromo I-FAMILY 
D-homosteroid I-FAMILY 
by O 
treatment O 
with O 
1,4-diazabicyclo[2.2.2]octane B-SYSTEMATIC 
( O 
DABCO B-ABBREVIATION 
) O 
. O 
All O 
new O 
compounds O 
were O 
completely O 
characterized O 
by O 
2D O 
NMR O 
techniques O 
and O 
tested O 
on O 
two O 
fungal O 
pathogenic O 
species O 
, O 
Fusarium O 
virguliforme O 
and O 
Fusarium O 
solani O 
. O 

vitro O 
, O 
ex O 
vivo O 
and O 
in O 
vivo O 
examination O 
of O 
buccal O 
absorption O 
of O 
metoprolol B-TRIVIAL 
with O 
varying O 
pH O 
in O 
TR146 O 
cell O 
culture O 
, O 
porcine O 
buccal O 
mucosa O 
and O 
Göttingen O 
minipigs O 
. O 

work O 
studied O 
the O 
buccal O 
absorption O 
of O 
metoprolol B-TRIVIAL 
in O 
vitro O 
, O 
ex O 
vivo O 
and O 
in O 
vivo O 
as O 
a O 
function O 
of O 
buffered O 
pH O 
at O 
7.4 O 
, O 
8.5 O 
, O 
9 O 
and O 
9.5 O 
. O 
Permeability O 
studies O 
showed O 
a O 
correlation O 
( O 
r(2)=0.92 O 
) O 
between O 
in O 
vitro O 
TR146 O 
cell O 
culture O 
and O 
ex O 
vivo O 
porcine O 
buccal O 
mucosa O 
in O 
a O 
modified O 
Ussing O 
chamber O 
. O 
A O 
higher O 
apparent O 
permeability O 
was O 
observed O 
at O 
higher O 
pH O 
values O 
, O 
i.e O 
. O 
the O 
more O 
compound O 
that O 
was O 
unionised O 
the O 
higher O 
the O 
permeability O 
. O 
In O 
vivo O 
studies O 
were O 
conducted O 
in O 
anaesthetised O 
Göttingen O 
mini O 
- O 
pigs O 
. O 
A O 
clear O 
influence O 
of O 
pH O 
on O 
the O 
absorption O 
was O 
seen O 
and O 
a O 
significant O 
higher O 
absolute O 
bioavailability O 
was O 
obtained O 
after O 
buccal O 
dosing O 
( O 
58-107% O 
) O 
compared O 
to O 
oral O 
( O 
3% O 
) O 
administration O 
, O 
ranging O 
58-107% O 
and O 
3% O 
, O 
respectively O 
. O 
Macroscopically O 
, O 
no O 
local O 
toxic O 
effects O 
were O 
observed O 
by O 
visual O 
inspection O 
of O 
mini O 
- O 
pig O 
cheeks O 
. O 
A O 
very O 
clear O 
level O 
C O 
in O 
vitro O 
in O 
vivo O 
correlation O 
( O 
r(2)=0.98 O 
) O 
was O 
obtained O 
between O 
the O 
observed O 
in O 
vitro O 
permeabilities O 
and O 
the O 
bioavailability O 
observed O 
in O 
vivo O 
, O 
suggesting O 
that O 
the O 
two O 
in O 
vitro O 
models O 
have O 
good O 
predictive O 
power O 
for O 
drug O 
delivery O 
, O 
which O 
could O 
be O 
a O 
useful O 
tool O 
for O 
future O 
formulation O 
developments O 
intended O 
for O 
buccal O 
delivery O 
. O 

bowel O 
disease O 
( O 
IBD O 
) O 
is O 
a O 
chronic O 
relapsing O 
inflammation O 
of O 
the O 
gastrointestinal O 
tract O 
. O 
The O 
cytokine O 
TNF-alpha O 
( O 
TNF-α O 
) O 
plays O 
a O 
pivotal O 
role O 
in O 
mediating O 
this O 
inflammatory O 
response O 
. O 
RNA O 
interference O 
( O 
RNAi O 
) O 
holds O 
great O 
promise O 
for O 
the O 
specific O 
and O 
selective O 
silencing O 
of O 
aberrantly O 
expressed O 
genes O 
, O 
such O 
as O 
TNF-α O 
in O 
IBD O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
efficacy O 
of O 
an O 
amphiphilic O 
cationic O 
cyclodextrin O 
( O 
CD O 
) O 
vector O 
for O 
effective O 
TNF-α O 
siRNA O 
delivery O 
to O 
macrophage O 
cells O 
and O 
to O 
mice O 
with O 
induced O 
acute O 
- O 
colitis O 
. O 
The O 
stability O 
of O 
CD.siRNA O 
was O 
examined O 
by O 
gel O 
electrophoresis O 
in O 
biorelevant O 
media O 
reflecting O 
colonic O 
fluids O 
. O 
RAW264.7 O 
cells O 
were O 
transfected O 
with O 
CD.TNF-α O 
siRNA O 
, O 
stimulated O 
with O 
lipopolysaccharide O 
( O 
LPS O 
) O 
and O 
TNF-α O 
and O 
IL-6 O 
responses O 
were O 
measured O 
by O 
PCR O 
and O 
ELISA O 
. O 
Female O 
C57BL O 
/ O 
6 O 
mice O 
were O 
exposed O 
to O 
dextran O 
sodium B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
( O 
DSS O 
) O 
and O 
treated O 
by O 
intrarectal O 
administration O 
with O 
either O 
CD.siRNA O 
TNF-α O 
or O 
a O 
control O 
solution O 
. O 
In O 
vitro O 
, O 
siRNA O 
in O 
CD O 
nanocomplexes O 
remained O 
intact O 
and O 
stable O 
in O 
both O 
fed O 
and O 
fasted O 
simulated O 
colonic O 
fluids O 
. O 
RAW264.7 O 
cells O 
transfected O 
with O 
CD.TNF-α O 
siRNA O 
and O 
stimulated O 
with O 
LPS O 
displayed O 
a O 
significant O 
reduction O 
in O 
both O 
gene O 
and O 
protein O 
levels O 
of O 
TNF-α O 
and O 
IL-6 O 
. O 
CD.TNF-α O 
siRNA O 
- O 
treated O 
mice O 
revealed O 
a O 
mild O 
amelioration O 
in O 
clinical O 
signs O 
of O 
colitis O 
, O 
but O 
significant O 
reductions O 
in O 
total O 
colon O 
weight O 
and O 
colonic O 
mRNA O 
expression O 
of O 
TNF-α O 
and O 
IL-6 O 
compared O 
to O 
DSS-control O 
mice O 
were O 
detected O 
. O 
This O 
data O 
indicates O 
the O 
clinical O 
potential O 
of O 
a O 
local O 
CD O 
- O 
based O 
TNF-α O 
siRNA O 
delivery O 
system O 
for O 
the O 
treatment O 
of O 
IBD O 
. O 

Basis O 
for O 
the O 
ATP B-ABBREVIATION 
-Induced O 
Isomerization O 
of O 
Kinesin O 
. O 

superfamily O 
proteins O 
( O 
KIFs O 
) O 
are O 
microtubule O 
- O 
based O 
molecular O 
motors O 
driven O 
by O 
the O 
energy O 
derived O 
from O 
the O 
hydrolysis O 
of O 
ATP B-ABBREVIATION 
. O 
Previous O 
studies O 
have O 
revealed O 
that O 
the O 
ATP B-ABBREVIATION 
binding O 
step O 
is O 
crucial O 
both O 
for O 
the O 
power O 
stroke O 
to O 
produce O 
motility O 
and O 
for O 
the O 
inter O 
- O 
domain O 
regulation O 
of O 
ATPase O 
activity O 
to O 
guarantee O 
the O 
processive O 
movement O 
of O 
dimeric O 
KIFs O 
. O 
Here O 
, O 
we O 
report O 
the O 
first O 
crystal O 
structure O 
of O 
KIF4 O 
complexed O 
with O 
the O 
non-hydrolyzable O 
ATP B-ABBREVIATION 
analog O 
, O 
AMPPNP B-ABBREVIATION 
( O 
adenylyl B-SYSTEMATIC 
imidodiphosphate I-SYSTEMATIC 
) O 
, O 
at O 
1.7Å O 
resolution O 
. O 
By O 
combining O 
our O 
structure O 
with O 
previously O 
solved O 
KIF1A O 
structures O 
complexed O 
with O 
two O 
ATP B-ABBREVIATION 
analogs O 
, O 
molecular O 
snapshots O 
during O 
ATP B-ABBREVIATION 
binding O 
reveal O 
that O 
the O 
closure O 
of O 
the O 
nucleotide B-FAMILY 
-binding O 
pocket O 
during O 
ATP B-ABBREVIATION 
binding O 
is O 
achieved O 
by O 
closure O 
of O 
the O 
backdoor O 
. O 
Closure O 
of O 
the O 
backdoor O 
stabilizes O 
two O 
mobile O 
regions O 
, O 
switch O 
I O 
and O 
switch O 
II O 
, O 
to O 
generate O 
the O 
phosphate B-SYSTEMATIC 
tube O 
from O 
which O 
hydrolyzed O 
phosphate B-SYSTEMATIC 
is O 
released O 
. O 
Through O 
the O 
stabilization O 
of O 
switch O 
II O 
, O 
the O 
local O 
conformational O 
change O 
at O 
the O 
catalytic O 
center O 
is O 
further O 
relayed O 
to O 
the O 
neck O 
- O 
linker O 
element O 
that O 
fully O 
docks O 
to O 
the O 
catalytic O 
core O 
to O 
produce O 
the O 
power O 
stroke O 
. O 
Because O 
the O 
neck O 
linker O 
is O 
a O 
sole O 
element O 
that O 
connects O 
the O 
partner O 
heads O 
in O 
dimeric O 
KIFs O 
, O 
this O 
tight O 
structural O 
coordination O 
between O 
the O 
catalytic O 
center O 
and O 
neck O 
linker O 
enables O 
inter O 
- O 
domain O 
communication O 
between O 
the O 
partner O 
heads O 
. O 
This O 
study O 
also O 
revealed O 
the O 
putative O 
microtubule O 
- O 
binding O 
site O 
of O 
KIF4 O 
, O 
thus O 
providing O 
structural O 
insights O 
that O 
describe O 
the O 
specific O 
binding O 
of O 
KIF4 O 
to O 
the O 
microtubule O 
. O 

in O 
cancer O 
cell O 
proliferation O 
and O 
death O 
. O 

have O 
been O 
shown O 
to O 
interfere O 
with O 
proliferation O 
and O 
cause O 
the O 
death O 
of O 
many O 
cancer O 
cell O 
types O 
, O 
such O 
as O 
leukaemia O 
, O 
glioblastoma O 
, O 
colon O 
, O 
breast O 
and O 
prostate O 
cancer O 
cells O 
, O 
while O 
they O 
have O 
little O 
or O 
no O 
effect O 
on O 
senescent O 
cells O 
. O 
The O 
mechanisms O 
by O 
which O 
oxysterols B-FAMILY 
may O 
influence O 
proliferation O 
are O 
manifold O 
: O 
they O 
control O 
the O 
transcription O 
and O 
the O 
turnover O 
of O 
the O 
key O 
enzyme O 
in O 
cholesterol B-TRIVIAL 
synthesis O 
, O 
3-hydroxy-3-methylglutaryl B-SYSTEMATIC 
CoA I-SYSTEMATIC 
reductase O 
, O 
by O 
binding O 
to O 
Insig-1 O 
, O 
Insig-2 O 
and O 
liver O 
X O 
receptors O 
. O 
Oxysterols B-FAMILY 
are O 
thought O 
to O 
be O 
generated O 
in O 
proportion O 
to O 
the O 
rate O 
of O 
cholesterol B-TRIVIAL 
synthesis O 
. O 
Although O 
there O 
is O 
no O 
consensus O 
about O 
the O 
mechanism O 
by O 
which O 
these O 
oxysterols B-FAMILY 
are O 
generated O 
in O 
vivo O 
, O 
it O 
clearly O 
has O 
to O 
be O 
ubiquitous O 
. O 
The O 
25- O 
and O 
the O 
27- O 
cholesterol B-TRIVIAL 
hydroxylases O 
, O 
present O 
in O 
almost O 
all O 
tissues O 
, O 
are O 
possible O 
candidates O 
. O 
Cholesterol B-TRIVIAL 
uptake O 
from O 
lipoproteins O 
, O 
intracellular O 
vesicle O 
transport O 
and O 
lipid O 
transfer O 
are O 
also O 
modified O 
by O 
oxysterols B-FAMILY 
. O 
Oxysterols B-FAMILY 
interfere O 
with O 
ERK O 
, O 
hedgehog O 
and O 
wnt O 
pathways O 
of O 
proliferation O 
and O 
differentiation O 
. O 
When O 
administered O 
in O 
vitro O 
to O 
cancer O 
cell O 
lines O 
, O 
oxysterols B-FAMILY 
invariably O 
both O 
slow O 
down O 
proliferation O 
and O 
provoke O 
cell O 
death O 
. O 
Perhaps O 
is O 
it O 
sufficient O 
to O 
stop O 
proliferation O 
of O 
a O 
cancer O 
to O 
provoke O 
its O 
eradication O 
. O 
Therefore O 
, O 
the O 
two O 
facets O 
of O 
oxysterol B-FAMILY 
action O 
that O 
seem O 
important O 
for O 
cancer O 
treatment O 
, O 
cytostaticity O 
and O 
cytotoxicity O 
, O 
will O 
be O 
discussed O 
. O 

proliferation O 
of O 
cardiac O 
fibroblasts O 
is O 
implicated O 
in O 
the O 
pathogenesis O 
of O 
myocardial O 
remodeling O 
and O 
fibrosis O 
. O 
Intermediate O 
- O 
conductance O 
calcium B-SYSTEMATIC 
-activated O 
K(+) B-FORMULA 
channels O 
( O 
KCa3.1 O 
channels O 
) O 
have O 
important O 
roles O 
in O 
cell O 
proliferation O 
. O 
However O 
, O 
it O 
is O 
unknown O 
whether O 
angiotensin O 
II O 
( O 
Ang O 
II O 
) O 
, O 
a O 
potent O 
profibrotic O 
molecule O 
, O 
would O 
regulate O 
KCa3.1 O 
channels O 
in O 
cardiac O 
fibroblasts O 
and O 
participate O 
in O 
cell O 
proliferation O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
whether O 
KCa3.1 O 
channels O 
were O 
regulated O 
by O 
Ang O 
II O 
, O 
and O 
how O 
the O 
channel O 
activity O 
mediated O 
cell O 
proliferation O 
in O 
cultured O 
adult O 
rat O 
cardiac O 
fibroblasts O 
using O 
electrophysiology O 
and O 
biochemical O 
approaches O 
. O 
It O 
was O 
found O 
that O 
mRNA O 
, O 
protein O 
, O 
and O 
current O 
density O 
of O 
KCa3.1 O 
channels O 
were O 
greatly O 
enhanced O 
in O 
cultured O 
cardiac O 
fibroblasts O 
treated O 
with O 
1μM O 
Ang O 
II O 
, O 
and O 
the O 
effects O 
were O 
countered O 
by O 
the O 
angiotensin O 
type O 
1 O 
receptor O 
( O 
AT1R O 
) O 
blocker O 
losartan O 
, O 
the O 
p38-MAPK O 
inhibitor O 
SB203580 B-IDENTIFIER 
, O 
the O 
ERK1 O 
/ O 
2 O 
inhibitor O 
PD98059 B-IDENTIFIER 
, O 
and O 
the O 
PI3K O 
/ O 
Akt O 
inhibitor O 
LY294002 B-IDENTIFIER 
. O 
Ang O 
II O 
stimulated O 
cell O 
proliferation O 
and O 
the O 
effect O 
was O 
antagonized O 
by O 
the O 
KCa3.1 O 
blocker O 
TRAM-34 B-TRIVIAL 
and O 
siRNA O 
targeting O 
KCa3.1 O 
. O 
In O 
addition O 
, O 
Ang O 
II-induced O 
increase O 
of O 
KCa3.1 O 
expression O 
was O 
attenuated O 
by O 
transfection O 
of O 
activator O 
protein-1 O 
( O 
AP-1 O 
) O 
decoy O 
oligodeoxynucleotides O 
. O 
These O 
results O 
demonstrate O 
for O 
the O 
first O 
time O 
that O 
Ang O 
II O 
stimulates O 
cell O 
proliferation O 
mediated O 
by O 
upregulating O 
KCa3.1 O 
channels O 
via O 
interacting O 
with O 
the O 
AT1R O 
and O 
activating O 
AP-1 O 
complex O 
through O 
ERK1 O 
/ O 
2 O 
, O 
p38-MAPK O 
and O 
PI3K O 
/ O 
Akt O 
signaling O 
pathways O 
in O 
cultured O 
adult O 
rat O 
cardiac O 
fibroblasts O 
. O 

and O 
estrogen B-FAMILY 
play O 
an O 
important O 
role O 
in O 
the O 
pathogenesis O 
of O 
benign O 
prostatic O 
hyperplasia O 
( O 
BPH O 
) O 
. O 
Estrogen B-FAMILY 
exerts O 
its O 
action O 
through O 
two O 
distinct O 
estrogen B-FAMILY 
receptors O 
( O 
ERs O 
) O 
either O 
ER-α O 
or O 
ER-β O 
. O 
The O 
phytoestrogenic O 
property O 
of O 
silymarin O 
( O 
SIL O 
) O 
has O 
been O 
previously O 
characterized O 
. O 
Thus O 
, O 
this O 
study O 
examined O 
the O 
protective O 
effect O 
of O 
SIL O 
against O 
testosterone B-TRIVIAL 
-induced O 
BPH O 
in O 
rats O 
. O 
In O 
an O 
initial O 
dose O 
- O 
response O 
study O 
, O 
SIL O 
in O 
a O 
dose O 
of O 
50mg O 
/ O 
kg O 
was O 
the O 
most O 
effective O 
in O 
preventing O 
the O 
rise O 
in O 
prostate O 
weight O 
, O 
prostate O 
weight O 
/ O 
body O 
weight O 
ratio O 
and O 
histopathologic O 
changes O 
induced O 
by O 
testosterone B-TRIVIAL 
. O 
Testosterone B-TRIVIAL 
significantly O 
decreased O 
ER-β O 
and O 
increased O 
ER-α O 
and O 
AR O 
expressions O 
as O 
compared O 
to O 
the O 
control O 
group O 
and O 
these O 
effects O 
were O 
significantly O 
ameliorated O 
by O 
SIL O 
. O 
Furthermore O 
, O 
SIL O 
significantly O 
protected O 
against O 
testosterone B-TRIVIAL 
-provoked O 
decline O 
in O 
mRNA O 
expression O 
of O 
P21(WAF1 O 
/ O 
Cip1 O 
) O 
and O 
Bax O 
/ O 
Bcl O 
- O 
xl O 
ratio O 
as O 
well O 
as O 
caspase-3 O 
activity O 
. O 
SIL O 
minimized O 
the O 
number O 
of O 
proliferating O 
cell O 
nuclear O 
antigen O 
( O 
PCNA O 
) O 
positive O 
cells O 
as O 
compared O 
to O 
testosterone B-TRIVIAL 
-treated O 
group O 
. O 
Moreover O 
, O 
SIL O 
significantly O 
blunted O 
the O 
inducible O 
NF-κB O 
expression O 
and O 
restored O 
the O 
oxidative O 
status O 
to O 
within O 
normal O 
values O 
in O 
the O 
prostatic O 
tissues O 
. O 
Collectively O 
these O 
findings O 
elucidate O 
the O 
effectiveness O 
of O 
SIL O 
in O 
preventing O 
testosterone B-TRIVIAL 
-induced O 
BPH O 
in O 
rats O 
. O 
This O 
could O 
be O 
attributed O 
, O 
at O 
least O 
partly O 
, O 
to O 
its O 
phytoestrogenic O 
, O 
pro O 
- O 
apoptotic O 
and O 
anti-oxidative O 
properties O 
. O 

exposure O 
- O 
induced O 
neurobehavioral O 
alterations O 
among O 
Chinese O 
workers O 
. O 

-containing O 
products O 
are O 
manufactured O 
and O 
widely O 
used O 
in O 
the O 
modern O 
industry O 
. O 
Yet O 
the O 
neurobehavioral O 
toxicity O 
due O 
to O 
occupational O 
exposure O 
to O 
vanadium B-SYSTEMATIC 
remained O 
elusive O 
. O 
This O 
cross O 
- O 
sectional O 
study O 
was O 
designed O 
to O 
examine O 
the O 
neurotoxic O 
effects O 
of O 
occupational O 
vanadium B-SYSTEMATIC 
exposure O 
. O 
A O 
total O 
of O 
463 O 
vanadium B-SYSTEMATIC 
-exposed O 
workers O 
( O 
exposed O 
group O 
) O 
and O 
251 O 
non-exposed O 
workers O 
( O 
control O 
group O 
) O 
were O 
recruited O 
from O 
a O 
Steel O 
and O 
Iron B-SYSTEMATIC 
Group O 
in O 
Sichuan O 
, O 
China O 
. O 
A O 
WHO-recommended O 
neurobehavioral O 
core O 
test O 
battery O 
( O 
NCTB O 
) O 
and O 
event O 
- O 
related O 
auditory O 
evoked O 
potentials O 
test O 
( O 
P300 O 
) O 
were O 
used O 
to O 
assess O 
the O 
neurobehavioral O 
functions O 
of O 
all O 
study O 
subjects O 
. O 
A O 
general O 
linear O 
model O 
was O 
used O 
to O 
compare O 
outcome O 
scores O 
between O 
the O 
two O 
groups O 
while O 
controlling O 
for O 
possible O 
confounders O 
. O 
The O 
exposed O 
group O 
showed O 
a O 
statistically O 
significant O 
neurobehavioral O 
alteration O 
more O 
than O 
the O 
control O 
group O 
in O 
the O 
NCTB O 
tests O 
. O 
The O 
exposed O 
workers O 
also O 
exhibited O 
an O 
increased O 
anger O 
- O 
hostility O 
, O 
depression O 
- O 
dejection O 
and O 
fatigue O 
- O 
inertia O 
on O 
the O 
profile O 
of O 
mood O 
states O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Performances O 
in O 
the O 
simple O 
reaction O 
time O 
, O 
digit O 
span O 
, O 
benton O 
visual O 
retention O 
and O 
pursuit O 
aiming O 
were O 
also O 
poorer O 
among O 
exposed O 
workers O 
as O 
compared O 
to O 
unexposed O 
control O 
workers O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Some O 
of O 
these O 
poor O 
performances O 
in O 
tests O 
were O 
also O 
significantly O 
related O 
to O 
workers O 
' O 
exposure O 
duration O 
. O 
P300 O 
latencies O 
were O 
longer O 
in O 
the O 
exposed O 
group O 
than O 
in O 
the O 
control O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Longer O 
mean O 
reaction O 
times O 
and O 
more O 
counting O 
errors O 
were O 
also O 
found O 
in O 
the O 
exposed O 
workers O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Given O 
the O 
findings O 
of O 
our O 
study O 
and O 
the O 
limitations O 
of O 
neurobehavioral O 
workplace O 
testing O 
, O 
we O 
found O 
evidence O 
of O 
altered O 
neurobehavioral O 
outcomes O 
by O 
occupational O 
exposure O 
to O 
vanadium B-SYSTEMATIC 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
oxidative O 
stability O 
of O 
sardine O 
muscle O 
lipids O 
as O 
related O 
to O 
the O 
storage O 
conditions O 
. O 
Whole O 
sardines O 
were O 
stored O 
at O 
4°C O 
for O 
4h O 
under O 
light O 
exposure O 
and O 
at O 
dark O 
. O 
The O 
lowest O 
levels O 
of O 
peroxide B-SYSTEMATIC 
value O 
( O 
PV O 
) O 
, O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
reactive O 
substances O 
( O 
TBARs O 
) O 
, O 
cholesterol B-TRIVIAL 
oxidation O 
products O 
( O 
COPs O 
) O 
and O 
the O 
highest O 
level O 
of O 
polyunsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
PUFAs B-ABBREVIATION 
) O 
content O 
, O 
especially O 
PUFA B-ABBREVIATION 
PUFA B-ABBREVIATION 
n-3 I-ABBREVIATION 
, O 
were O 
found O 
in O 
the O 
untreated O 
sardines O 
( O 
time O 
zero O 
) O 
. O 
After O 
light O 
exposure O 
, O 
PUFA B-ABBREVIATION 
dramatically O 
dropped O 
( O 
up O 
to O 
a O 
19% O 
decrease O 
) O 
and O 
a O 
marked O 
increase O 
of O 
PV O 
( O 
11.8meq O 
O2 B-FORMULA 
/ O 
kg O 
fat O 
) O 
, O 
TBARs O 
( O 
3.7mg O 
MDA O 
/ O 
kg O 
meat O 
) O 
and O 
COPs O 
( O 
3.7μg O 
/ O 
g O 
muscle O 
) O 
was O 
observed O 
; O 
under O 
darkness O 
, O 
the O 
values O 
of O 
the O 
oxidation O 
parameters O 
were O 
similar O 
to O 
those O 
found O 
in O 
untreated O 
sardines O 
. O 
Although O 
cholesterol B-TRIVIAL 
oxidation O 
rate O 
did O 
not O 
exceed O 
0.9% O 
, O 
further O 
research O 
is O 
required O 
about O 
toxicity O 
levels O 
of O 
the O 
single O 
COPs O 
, O 
to O 
better O 
understand O 
if O 
the O 
COPs O 
levels O 
found O 
in O 
untreated O 
and O 
photoxidized O 
muscle O 
( O 
0.62-3.72μg O 
/ O 
g O 
of O 
muscle O 
) O 
do O 
not O 
represent O 
a O 
risk O 
for O 
human O 
health O 
. O 

of O 
purified O 
decolorized O 
( O 
low O 
anthraquinone B-SYSTEMATIC 
) O 
whole O 
leaf O 
Aloe O 
vera O 
( O 
L O 
) O 
Burm O 
. O 
f O 
. O 
juice O 
in O 
a O 
3-month O 
drinking O 
water O 
toxicity O 
study O 
in O 
F344 O 
rats O 
. O 

( O 
purified O 
, O 
low O 
anthraquinone O 
) O 
whole O 
leaf O 
Aloe O 
vera O 
( O 
L O 
. O 
) O 
Burm O 
. O 
f O 
. O 
juice O 
was O 
administered O 
at O 
concentrations O 
of O 
0% O 
, O 
0.5% O 
, O 
1% O 
and O 
2% O 
in O 
the O 
drinking O 
water O 
of O 
F344Du O 
® O 
rats O 
for O 
3months O 
without O 
any O 
adverse O 
effect O 
. O 
The O 
no O 
- O 
observed O 
- O 
adverse O 
- O 
effect O 
level O 
( O 
NOAEL O 
) O 
in O 
this O 
study O 
was O 
considered O 
to O 
be O 
> O 
2%w O 
/ O 
v O 
( O 
> O 
1845mg O 
/ O 
kg O 
bodyweight O 
/ O 
day O 
for O 
males O 
and O 
> O 
2920mg O 
/ O 
kg O 
bodyweight O 
for O 
females O 
) O 
. O 
The O 
test O 
material O 
contained O 
total O 
anthraquinones B-FAMILY 
at O 
< O 
0.1parts O 
per O 
million O 
. O 
In O 
the O 
present O 
study O 
there O 
was O 
a O 
complete O 
absence O 
of O 
any O 
histological O 
alteration O 
in O 
samples O 
from O 
the O 
cecum O 
, O 
colon O 
( O 
proximal O 
, O 
mid O 
and O 
distal O 
regions O 
) O 
. O 
Similar O 
concentrations O 
of O 
non-decolorized O 
( O 
unpurified O 
, O 
high O 
anthraquinone B-SYSTEMATIC 
) O 
Aloe O 
vera O 
extracts O 
tested O 
in O 
other O 
studies O 
have O 
resulted O 
in O 
an O 
increased O 
incidence O 
and O 
severity O 
of O 
diarrhea O 
and O 
colon O 
adenomas O 
and O 
carcinomas O 
. O 
The O 
results O 
of O 
this O 
study O 
supports O 
the O 
assertion O 
that O 
the O 
high O 
levels O 
of O 
anthraquinone B-SYSTEMATIC 
present O 
in O 
orally O 
administered O 
, O 
non-purified O 
whole O 
leaf O 
Aloe O 
vera O 
extract O 
may O 
be O 
responsible O 
for O 
the O 
adverse O 
effects O 
observed O 
on O 
the O 
colon O 
. O 

activity O 
induction O 
in O 
peripheral O 
blood O 
lymphocytes O 
, O 
liver O 
and O 
brain O 
tissues O 
of O 
rats O 
orally O 
exposed O 
to O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
. O 

is O 
known O 
in O 
terms O 
of O 
multi O 
- O 
matrix O 
cytochrome O 
P450 O 
activity O 
induction O 
under O 
repeated O 
oral O 
exposure O 
to O 
planar O 
halogenated B-MULTIPLE 
and I-MULTIPLE 
polycyclic I-MULTIPLE 
aromatic I-MULTIPLE 
hydrocarbons I-MULTIPLE 
( O 
PHH O 
, O 
PAH B-ABBREVIATION 
) O 
. O 
In O 
the O 
present O 
study O 
, O 
60 O 
rats O 
were O 
daily O 
exposed O 
, O 
during O 
28days O 
, O 
to O 
oral O 
ingestion O 
of O 
a O 
mixture O 
consisting O 
of O 
phenanthrene B-SYSTEMATIC 
, O 
pyrene B-SYSTEMATIC 
and O 
benzo(a)pyrene B-SYSTEMATIC 
at O 
0 O 
, O 
6 O 
or O 
600μg O 
/ O 
day O 
. O 
EROD B-ABBREVIATION 
activity O 
, O 
reflecting O 
almost O 
exclusively O 
CYP1A1 O 
and O 
CYP1B1 O 
activities O 
, O 
was O 
measured O 
in O 
brain O 
and O 
liver O 
microsomes O 
as O 
well O 
as O 
in O 
peripheral O 
blood O 
lymphocytes O 
( O 
PBLs O 
) O 
. O 
All O 
induction O 
kinetics O 
could O 
be O 
appropriately O 
fitted O 
using O 
logistic O 
- O 
like O 
models O 
. O 
After O 
28days O 
of O 
exposure O 
to O 
a O 
6μg O 
/ O 
day O 
dose O 
, O 
EROD B-ABBREVIATION 
activity O 
was O 
found O 
to O 
be O 
91 O 
, O 
152 O 
and O 
94-fold O 
increased O 
in O 
lymphocytes O 
, O 
liver O 
and O 
brain O 
, O 
respectively O 
, O 
compared O 
to O 
day O 
0 O 
. O 
Plateau O 
activities O 
could O 
be O 
appropriately O 
fitted O 
versus O 
ingested O 
doses O 
using O 
Hill O 
or O 
Michaelis-Menten O 
models O 
. O 
Correlations O 
between O 
matrices O 
made O 
it O 
possible O 
to O 
conclude O 
that O 
EROD B-ABBREVIATION 
activity O 
in O 
PBL O 
should O 
be O 
considered O 
as O 
a O 
sensitive O 
, O 
convenient O 
and O 
non-destructive O 
approach O 
for O 
(i) O 
evaluating O 
EROD B-ABBREVIATION 
activity O 
in O 
liver O 
, O 
which O 
was O 
found O 
to O 
represent O 
98% O 
of O 
the O 
observed O 
EROD B-ABBREVIATION 
activities O 
in O 
the O 
three O 
tested O 
matrices O 
and O 
(ii) O 
evaluating O 
oral O 
exposure O 
of O 
homogeneous O 
groups O 
of O 
farm O 
animals O 
( O 
race O 
, O 
diet O 
) O 
to O 
CYP O 
inducing O 
PAH O 
and O 
PHH B-ABBREVIATION 
. O 

chiral O 
ferrocenylpyrazolo[1,5-a][1,4]diazepin-4-one B-SYSTEMATIC 
derivatives O 
- O 
Synthesis O 
, O 
characterization O 
and O 
inhibition O 
against O 
lung O 
cancer O 
cells O 
. O 

series O 
of O 
novel O 
2-ferrocenyl-7-hydroxy-5-phenethyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one B-SYSTEMATIC 
derivatives O 
with O 
optical O 
activity O 
( O 
2 O 
) O 
was O 
synthesized O 
in O 
the O 
microwave O 
- O 
assisted O 
condition O 
and O 
characterized O 
by O 
means O 
of O 
IR O 
, O 
(1)H B-FORMULA 
NMR O 
and O 
mass O 
spectroscopy O 
, O 
and O 
furthermore O 
confirmed O 
by O 
X-ray O 
analysis O 
of O 
a O 
representative O 
compound O 
(R)-2a O 
. O 
Preliminary O 
biological O 
evaluation O 
showed O 
that O 
some O 
compounds O 
could O 
suppress O 
the O 
growth O 
of O 
A549 O 
, O 
H322 O 
and O 
H1299 O 
lung O 
cancer O 
cells O 
. O 
Among O 
the O 
tested O 
compounds O 
, O 
2b-d O 
were O 
more O 
effective O 
and O 
might O 
perform O 
their O 
action O 
through O 
cell O 
cycle O 
arrest O 
for O 
A549 O 
cell O 
. O 
Whereas O 
these O 
compounds O 
inhibited O 
growth O 
of O 
H1299 O 
and O 
H322 O 
cells O 
by O 
inducing O 
apoptosis O 
. O 
The O 
anti-tumor O 
activities O 
of O 
these O 
compounds O 
were O 
related O 
to O 
the O 
nature O 
of O 
substituents O 
in O 
benzene O 
moiety O 
. O 
In O 
addition O 
, O 
the O 
results O 
indicated O 
also O 
that O 
compounds O 
2b-d O 
possessed O 
notable O 
cytotoxicity O 
and O 
selectivity O 
for O 
A549 O 
vs O 
H1299 O 
and O 
H322 O 
lung O 
cancer O 
cells O 
. O 

and O 
evaluation O 
of O 
7,8-dehydrorutaecarpine B-SYSTEMATIC 
derivatives O 
as O 
potential O 
multifunctional O 
agents O 
for O 
the O 
treatment O 
of O 
Alzheimer's O 
disease O 
. O 

series O 
of O 
7,8-dehydrorutaecarpine B-SYSTEMATIC 
derivatives O 
were O 
synthesized O 
and O 
characterized O 
as O 
potential O 
multifunctional O 
agents O 
for O 
treatment O 
of O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
. O 
All O 
of O 
these O 
synthetic O 
compounds O 
showed O 
high O 
acetylcholinesterase O 
( O 
AChE O 
) O 
inhibitory O 
activity O 
with O 
IC50 O 
values O 
ranged O 
from O 
0.6 O 
to O 
196.7 O 
nM O 
, O 
and O 
good O 
selectivity O 
for O 
AChE O 
over O 
butyrylcholinesterase O 
( O 
BuChE O 
) O 
( O 
125- O 
to O 
3225-fold O 
) O 
. O 
A O 
Lineweaver-Burk O 
plot O 
and O 
molecular O 
modeling O 
study O 
indicated O 
these O 
compounds O 
could O 
bind O 
to O 
both O 
catalytic O 
active O 
site O 
and O 
the O 
peripheral O 
anionic O 
site O 
of O 
AChE O 
. O 
Besides O 
, O 
compounds O 
showed O 
higher O 
activity O 
of O 
inhibiting O 
AChE-induced O 
amyloid O 
- O 
beta O 
( O 
Aβ O 
) O 
aggregation O 
than O 
curcumin B-TRIVIAL 
, O 
higher O 
anti-oxidative O 
activity O 
than O 
Trolox B-TRIVIAL 
, O 
and O 
could O 
also O 
be O 
good O 
metal O 
chelators O 
. O 
Considering O 
their O 
low O 
cytotoxicity O 
, O 
our O 
results O 
indicated O 
that O 
these O 
derivatives O 
provide O 
good O 
templates O 
for O 
developing O 
new O 
multifunctional O 
agents O 
for O 
AD O 
treatment O 
. O 

receptors O 
in O 
the O 
stimulation O 
of O 
mesolimbic O 
dopamine B-TRIVIAL 
activity O 
by O 
ethanol B-SYSTEMATIC 
and O 
morphine B-TRIVIAL 
in O 
Long-Evans O 
rats O 
: O 
a O 
delayed O 
effect O 
of O 
ethanol B-SYSTEMATIC 
. O 

: O 
Naltrexone B-TRIVIAL 
, O 
a O 
non-selective O 
opioid O 
antagonist O 
, O 
decreases O 
the O 
euphoria O 
and O 
positive O 
subjective O 
responses O 
to O 
alcohol B-FAMILY 
in O 
heavy O 
drinkers O 
. O 
It O 
has O 
been O 
proposed O 
that O 
the O 
μ-opioid O 
receptor O 
plays O 
a O 
role O 
in O 
ethanol B-SYSTEMATIC 
reinforcement O 
through O 
modulation O 
of O 
ethanol B-SYSTEMATIC 
-stimulated O 
mesolimbic O 
dopamine B-TRIVIAL 
release O 
. O 
OBJECTIVES O 
: O 
To O 
investigate O 
the O 
ability O 
of O 
naltrexone B-TRIVIAL 
and O 
β-funaltrexamine B-TRIVIAL 
, O 
an O 
irreversible O 
μ-opioid O 
specific O 
antagonist O 
, O 
to O 
inhibit O 
ethanol B-SYSTEMATIC 
-stimulated O 
and O 
morphine B-TRIVIAL 
-stimulated O 
mesolimbic O 
dopamine B-TRIVIAL 
release O 
, O 
and O 
to O 
determine O 
whether O 
opioid O 
receptors O 
on O 
mesolimbic O 
neurons O 
contribute O 
to O 
these O 
mechanisms O 
. O 
METHODS O 
: O 
Ethanol B-SYSTEMATIC 
-naïve O 
male O 
Long O 
Evans O 
rats O 
were O 
given O 
opioid O 
receptor O 
antagonists O 
either O 
intravenously O 
, O 
subcutaneously O 
, O 
or O 
intracranially O 
into O 
the O 
ventral O 
tegmental O 
area O 
( O 
VTA O 
) O 
, O 
followed O 
by O 
intravenous O 
administration O 
of O 
ethanol B-SYSTEMATIC 
or O 
morphine B-TRIVIAL 
. O 
We O 
measured O 
extracellular O 
dopamine B-TRIVIAL 
in O 
vivo O 
using O 
microdialysis O 
probes O 
inserted O 
into O 
the O 
nucleus O 
accumbens O 
shell O 
( O 
n O 
= O 
114 O 
) O 
. O 
RESULTS O 
: O 
Administration O 
of O 
naltrexone B-TRIVIAL 
( O 
intravenously O 
) O 
and O 
β-funaltrexamine B-TRIVIAL 
( O 
subcutaneously O 
) O 
, O 
as O 
well O 
as O 
intracranial O 
injection O 
of O 
naltrexone B-TRIVIAL 
into O 
the O 
VTA O 
did O 
not O 
prevent O 
the O 
initiation O 
of O 
dopamine B-TRIVIAL 
release O 
by O 
intravenous O 
ethanol B-SYSTEMATIC 
administration O 
, O 
but O 
prevented O 
it O 
from O 
being O 
as O 
prolonged O 
. O 
In O 
contrast O 
, O 
morphine B-TRIVIAL 
-stimulated O 
mesolimbic O 
dopamine B-TRIVIAL 
release O 
was O 
effectively O 
suppressed O 
. O 
CONCLUSIONS O 
: O 
Our O 
results O 
provide O 
novel O 
evidence O 
that O 
there O 
are O 
two O 
distinct O 
mechanisms O 
that O 
mediate O 
ethanol B-SYSTEMATIC 
-stimulated O 
mesolimbic O 
dopamine B-TRIVIAL 
release O 
( O 
an O 
initial O 
phase O 
and O 
a O 
delayed O 
phase O 
) O 
, O 
and O 
that O 
opioid O 
receptor O 
activation O 
is O 
required O 
to O 
maintain O 
the O 
delayed O 
- O 
phase O 
dopamine B-TRIVIAL 
release O 
. O 
Moreover O 
, O 
μ-opioid O 
receptors O 
account O 
for O 
this O 
delayed O 
- O 
phase O 
dopamine B-TRIVIAL 
response O 
, O 
and O 
the O 
VTA O 
is O 
potentially O 
the O 
site O 
of O 
action O 
of O 
this O 
mechanism O 
. O 
We O 
conclude O 
that O 
μ-opioid O 
receptors O 
play O 
different O 
roles O 
in O 
the O 
mechanisms O 
of O 
stimulation O 
of O 
mesolimbic O 
dopamine B-TRIVIAL 
activity O 
by O 
ethanol B-SYSTEMATIC 
and O 
morphine B-TRIVIAL 
. O 

antidepressant O 
- O 
like O 
response O 
to O 
lithium B-SYSTEMATIC 
treatment O 
between O 
mouse O 
strains O 
: O 
effects O 
of O 
sex O 
, O 
maternal O 
care O 
, O 
and O 
mixed O 
genetic O 
background O 
. O 

: O 
Lithium B-SYSTEMATIC 
is O 
a O 
mood O 
stabilizer O 
with O 
both O 
antidepressant O 
and O 
antimanic O 
properties O 
, O 
however O 
its O 
mechanism O 
of O 
action O 
is O 
unclear O 
. O 
Identifying O 
the O 
genetic O 
factors O 
that O 
influence O 
lithium B-SYSTEMATIC 
' O 
s O 
therapeutic O 
actions O 
will O 
be O 
an O 
important O 
step O 
to O 
assist O 
in O 
identifying O 
such O 
mechanisms O 
. O 
We O 
previously O 
reported O 
that O 
lithium B-SYSTEMATIC 
treatment O 
of O 
male O 
mice O 
has O 
antidepressant O 
- O 
like O 
effects O 
in O 
the O 
C57BL O 
/ O 
6J O 
strain O 
but O 
that O 
such O 
effects O 
were O 
absent O 
in O 
the O 
BALB O 
/ O 
cJ O 
strain O 
. O 
OBJECTIVES O 
: O 
This O 
study O 
aimed O 
to O 
assess O 
the O 
roles O 
of O 
both O 
genetic O 
and O 
non-genetic O 
factors O 
such O 
as O 
sex O 
and O 
non-shared O 
environmental O 
conditions O 
that O 
may O 
mediate O 
differential O 
behavioral O 
responses O 
to O 
lithium B-SYSTEMATIC 
. O 
METHODS O 
: O 
Mice O 
were O 
treated O 
with O 
lithium B-SYSTEMATIC 
for O 
10 O 
days O 
and O 
then O 
tested O 
in O 
the O 
forced O 
swim O 
test O 
followed O 
by O 
lithium B-SYSTEMATIC 
discontinuation O 
and O 
retesting O 
to O 
assess O 
effects O 
of O 
lithium B-SYSTEMATIC 
withdrawal O 
. O 
We O 
also O 
assessed O 
effects O 
of O 
sex O 
and O 
cross O 
- O 
fostering O 
on O 
lithium B-SYSTEMATIC 
response O 
between O 
the O 
C57BL O 
/ O 
6J O 
and O 
BALB O 
/ O 
cJ O 
strains O 
, O 
and O 
antidepressant O 
- O 
like O 
effects O 
of O 
lithium B-SYSTEMATIC 
in O 
the O 
hybrid O 
CB6F1 O 
/ O 
J O 
strain O 
that O 
is O 
derived O 
from O 
C57BL O 
/ O 
6J O 
and O 
BALB O 
/ O 
cJ O 
parental O 
strains O 
. O 
RESULTS O 
: O 
Neither O 
sex O 
nor O 
maternal O 
care O 
significantly O 
influenced O 
the O 
differential O 
antidepressant O 
- O 
like O 
response O 
to O 
lithium B-SYSTEMATIC 
. O 
Withdrawal O 
from O 
lithium B-SYSTEMATIC 
treatment O 
reversed O 
antidepressant O 
- O 
like O 
effects O 
in O 
the O 
C57BL O 
/ O 
6J O 
strain O 
but O 
had O 
no O 
effects O 
in O 
BALB O 
/ O 
cJ O 
mice O 
. O 
Lithium B-SYSTEMATIC 
treatment O 
did O 
not O 
result O 
in O 
antidepressant O 
- O 
like O 
effects O 
in O 
the O 
CB6F1 O 
/ O 
J O 
strain O 
. O 
CONCLUSIONS O 
: O 
Genetic O 
factors O 
are O 
likely O 
primarily O 
responsible O 
for O 
differential O 
antidepressant O 
- O 
like O 
effects O 
of O 
lithium B-SYSTEMATIC 
in O 
the O 
C57BL O 
/ O 
6J O 
and O 
BALB O 
/ O 
cJ O 
strains O 
. O 
Future O 
studies O 
identifying O 
such O 
genetic O 
factors O 
may O 
help O 
to O 
elucidate O 
the O 
neurobiological O 
mechanisms O 
of O 
lithium B-SYSTEMATIC 
' O 
s O 
therapeutic O 
actions O 
. O 

dependent O 
patients O 
have O 
weak O 
negative O 
rather O 
than O 
strong O 
positive O 
implicit O 
alcohol B-FAMILY 
associations O 
. O 

: O 
Alcohol B-SYSTEMATIC 
dependence O 
is O 
characterised O 
by O 
motivational O 
conflict O 
( O 
or O 
ambivalence O 
) O 
in O 
controlled O 
cognitive O 
processes O 
, O 
but O 
it O 
is O 
unclear O 
if O 
ambivalence O 
also O 
exists O 
within O 
automatic O 
cognitive O 
processes O 
, O 
and O 
if O 
ambivalence O 
operates O 
between O 
controlled O 
and O 
automatic O 
processes O 
. O 
OBJECTIVE O 
: O 
To O 
investigate O 
ambivalence O 
operating O 
within O 
and O 
between O 
controlled O 
and O 
automatic O 
processes O 
in O 
alcohol B-FAMILY 
dependence O 
. O 
METHOD O 
: O 
Alcohol B-SYSTEMATIC 
-dependent O 
patients O 
who O 
had O 
recently O 
completed O 
inpatient O 
alcohol B-FAMILY 
detoxification O 
( O 
N O 
= O 
47 O 
) O 
and O 
social O 
drinking O 
controls O 
( O 
N O 
= O 
40 O 
) O 
completed O 
unipolar O 
implicit O 
association O 
tests O 
and O 
self O 
- O 
report O 
measures O 
of O 
alcohol B-FAMILY 
approach O 
and O 
avoidance O 
motivation O 
and O 
alcohol B-FAMILY 
outcome O 
expectancies O 
. O 
RESULTS O 
: O 
As O 
predicted O 
, O 
both O 
positive O 
and O 
negative O 
alcohol B-FAMILY 
outcome O 
expectancies O 
were O 
stronger O 
in O 
alcohol B-FAMILY 
-dependent O 
patients O 
compared O 
to O 
controls O 
, O 
indicative O 
of O 
ambivalence O 
. O 
Groups O 
did O 
not O 
differ O 
on O 
implicit O 
alcohol B-FAMILY 
-positive O 
associations O 
, O 
but O 
alcohol B-FAMILY 
-dependent O 
participants O 
had O 
significantly O 
weaker O 
alcohol B-FAMILY 
-negative O 
associations O 
than O 
controls O 
. O 
Regression O 
analyses O 
revealed O 
that O 
implicit O 
negative O 
associations O 
accounted O 
for O 
unique O 
variance O 
in O 
group O 
membership O 
after O 
controlling O 
for O 
alcohol B-FAMILY 
outcome O 
expectancies O 
. O 
CONCLUSIONS O 
: O 
Our O 
findings O 
demonstrate O 
that O 
alcohol B-FAMILY 
dependent O 
patients O 
possess O 
weak O 
automatic O 
alcohol B-FAMILY 
-negative O 
associations O 
but O 
not O 
strong O 
automatic O 
alcohol B-FAMILY 
-positive O 
associations O 
, O 
and O 
they O 
suggest O 
the O 
presence O 
of O 
conflict O 
between O 
controlled O 
and O 
automatic O 
processes O 
with O 
regard O 
to O 
negative O 
alcohol B-FAMILY 
cognitions O 
. O 

effects O 
of O 
two O 
fungicides O 
( O 
copper B-SYSTEMATIC 
and O 
dimethomorph B-TRIVIAL 
) O 
on O 
their O 
phytoremediation O 
using O 
Lemna O 
minor O 
. O 

of O 
two O 
fungicides O 
, O 
copper B-SYSTEMATIC 
and O 
dimethomorph B-TRIVIAL 
( O 
( B-SYSTEMATIC 
E,Z)4-[3-(4-chlorophenyl)-3-(3-4dimethoxyphenyl I-SYSTEMATIC 
) I-SYSTEMATIC 
acryloyl I-SYSTEMATIC 
] I-SYSTEMATIC 
morpholine I-SYSTEMATIC 
) O 
on O 
Lemna O 
minor O 
growth O 
and O 
phytoremediation O 
were O 
evaluated O 
. O 
The O 
toxicity O 
of O 
copper B-SYSTEMATIC 
and O 
dimethomorph B-TRIVIAL 
alone O 
and O 
in O 
combination O 
, O 
was O 
assessed O 
by O 
growth O 
inhibition O 
of O 
L O 
. O 
minor O 
cultures O 
after O 
96 O 
and O 
168 O 
h O 
. O 
Copper B-SYSTEMATIC 
had O 
a O 
severe O 
impact O 
on O 
growth O 
( O 
max O 
. O 
inhibition O 
: O 
90 O 
% O 
at O 
1000 O 
μg O 
L(-1) O 
) O 
while O 
dimethomorph B-TRIVIAL 
( O 
as O 
pure O 
ingredient O 
or O 
formulated O 
as O 
Forum B-TRIVIAL 
) O 
did O 
not O 
( O 
inhibition O 
< O 
45 O 
% O 
at O 
1000 O 
μg O 
L(-1) O 
) O 
after O 
168 O 
h O 
of O 
treatment O 
. O 
When O 
both O 
chemicals O 
were O 
combined O 
, O 
synergism O 
was O 
observed O 
after O 
96 O 
h O 
of O 
exposure O 
to O 
copper B-SYSTEMATIC 
and O 
Forum B-TRIVIAL 
. O 
However O 
, O 
this O 
interaction O 
was O 
a O 
simple O 
additivity O 
after O 
168 O 
h O 
. O 
Additivity O 
was O 
also O 
observed O 
when O 
the O 
pure O 
active O 
ingredient O 
( O 
dimethomorph B-TRIVIAL 
) O 
replaced O 
Forum B-TRIVIAL 
in O 
the O 
mixture O 
of O 
copper B-SYSTEMATIC 
and O 
dimethomorph B-TRIVIAL 
at O 
96 O 
and O 
168 O 
h O 
. O 
L O 
. O 
minor O 
showed O 
an O 
excellent O 
performance O 
in O 
removing O 
copper B-SYSTEMATIC 
from O 
the O 
medium O 
since O 
after O 
96 O 
h O 
, O 
36 O 
, O 
60 O 
, O 
and O 
76 O 
% O 
removal O 
were O 
reached O 
for O 
10 O 
, O 
20 O 
, O 
and O 
30 O 
μg O 
L(-1) O 
of O 
Cu B-FORMULA 
respectively O 
. O 
Copper B-SYSTEMATIC 
accumulated O 
in O 
the O 
plants O 
. O 
The O 
removal O 
of O 
copper B-SYSTEMATIC 
increased O 
with O 
Forum B-TRIVIAL 
concentration O 
. O 
After O 
96 O 
h O 
copper B-SYSTEMATIC 
( O 
10 O 
μg O 
L(-1) O 
initial O 
concentration O 
) O 
elimination O 
increased O 
from O 
36.39 O 
± O 
5.86-60.70 O 
± O 
6.06 O 
% O 
when O 
Forum B-TRIVIAL 
concentration O 
increased O 
from O 
0 O 
to O 
500 O 
μg O 
L(-1) O 
. O 
Accumulation O 
of O 
copper B-SYSTEMATIC 
in O 
plants O 
was O 
also O 
increased O 
by O 
Forum B-TRIVIAL 
but O 
not O 
by O 
the O 
active O 
ingredient O 
alone O 
. O 
Depuration O 
of O 
Forum O 
by O 
L O 
. O 
minor O 
varied O 
between O 
10 O 
and O 
40 O 
% O 
after O 
96 O 
h O 
and O 
it O 
was O 
generally O 
more O 
efficient O 
than O 
that O 
of O 
the O 
pure O 
ingredient O 
. O 
This O 
depuration O 
decreased O 
in O 
the O 
presence O 
of O 
copper B-SYSTEMATIC 
possibly O 
due O 
to O 
the O 
metal O 
toxicity O 
. O 

out O 
Semiconducting O 
Single-Walled O 
Carbon B-SYSTEMATIC 
Nanotube O 
Arrays O 
by O 
Washing O 
off O 
Metallic O 
Tubes O 
Using O 
SDS B-ABBREVIATION 
Aqueous O 
Solution O 
. O 

single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
( O 
s-SWNT O 
) O 
arrays O 
are O 
produced O 
via O 
a O 
procedure O 
analogous O 
to O 
a O 
surfactant O 
- O 
assisted O 
decontamination O 
process O 
. O 
Aligned O 
individual O 
SWNT O 
arrays O 
grow O 
on O 
a O 
quartz B-TRIVIAL 
surface O 
as O 
a O 
mixture O 
of O 
metallic O 
SWNTs O 
( O 
m-SWNTs O 
) O 
and O 
s-SWNTs O 
. O 
They O 
are O 
immersed O 
in O 
a O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
SDS B-ABBREVIATION 
) O 
solution O 
, O 
and O 
the O 
SDS B-ABBREVIATION 
molecules O 
selectively O 
adsorb O 
onto O 
m-SWNTs O 
. O 
This O 
SDS B-ABBREVIATION 
coating O 
minimizes O 
the O 
interaction O 
between O 
m-SWNTs O 
and O 
the O 
substrate O 
, O 
thus O 
the O 
m-SWNTs O 
are O 
easily O 
washed O 
off O 
during O 
ultrasonication O 
while O 
the O 
s-SWNT O 
arrays O 
remain O 
on O 
the O 
substrate O 
. O 
The O 
percentage O 
of O 
s-SWNTs O 
in O 
the O 
arrays O 
can O 
be O 
higher O 
than O 
90% O 
. O 

Oxygen B-SYSTEMATIC 
Reduction O 
Behavior O 
of O 
Selectively O 
Deposited O 
Platinum B-SYSTEMATIC 
Atoms O 
on O 
Gold O 
Nanoparticles O 
. O 

-supported O 
Pt B-FORMULA 
@ O 
Au B-FORMULA 
" O 
core O 
- O 
shell O 
" O 
nanoparticles O 
with O 
varying O 
surface O 
concentration O 
of O 
platinum B-SYSTEMATIC 
atoms O 
have O 
been O 
synthesized O 
using O 
a O 
novel O 
redox O 
- O 
mediated O 
synthesis O 
approach O 
. O 
The O 
synthesis O 
technique O 
allows O 
for O 
a O 
selective O 
deposition O 
of O 
platinum B-SYSTEMATIC 
atoms O 
on O 
the O 
surface O 
of O 
prefabricated O 
gold O 
nanoparticles O 
. O 
Energy O 
dispersive O 
spectroscopic O 
analyses O 
in O 
a O 
scanning O 
electron O 
microscope O 
reveal O 
that O 
the O 
platinum B-SYSTEMATIC 
to O 
gold O 
atomic O 
ratios O 
are O 
close O 
to O 
the O 
nominal O 
values O 
, O 
validating O 
the O 
synthesis O 
scheme O 
. O 
X-ray O 
diffraction O 
data O 
indicate O 
an O 
un O 
- O 
alloyed O 
structure O 
. O 
The O 
platinum B-SYSTEMATIC 
to O 
gold O 
surface O 
atomic O 
ratio O 
determined O 
from O 
cyclic O 
voltammetry O 
and O 
copper B-SYSTEMATIC 
under O 
- O 
potential O 
deposition O 
experiments O 
reveal O 
good O 
agreement O 
with O 
the O 
calculated O 
values O 
at O 
low O 
platinum B-SYSTEMATIC 
concentration O 
. O 
However O 
, O 
there O 
is O 
an O 
increase O 
in O 
non-uniformity O 
in O 
the O 
deposition O 
process O 
upon O 
increasing O 
the O 
platinum B-SYSTEMATIC 
concentration O 
. O 
Koutecky-Levich O 
analysis O 
of O 
the O 
samples O 
indicates O 
a O 
transition O 
of O 
the O 
total O 
number O 
of O 
electrons O 
transferred O 
( O 
n O 
) O 
in O 
the O 
electrochemical O 
oxygen B-SYSTEMATIC 
reduction O 
reaction O 
from O 
two O 
to O 
four O 
electrons O 
upon O 
increasing O 
the O 
surface O 
concentration O 
of O 
platinum B-SYSTEMATIC 
atoms O 
. O 
Furthermore O 
, O 
the O 
data O 
indicate O 
that O 
isolated O 
platinum B-SYSTEMATIC 
atoms O 
can O 
reduce O 
molecular O 
oxygen B-SYSTEMATIC 
but O 
via O 
a O 
two O 
- O 
electron O 
route O 
. O 
Moreover O 
, O 
successful O 
four O 
- O 
electron O 
reduction O 
of O 
molecular O 
oxygen B-SYSTEMATIC 
requires O 
clusters O 
of O 
platinum B-SYSTEMATIC 
atoms O 
. O 

of O 
phenyleneethynylene B-SYSTEMATIC 
-doped O 
poly(pphenylenebutadiynylene) B-FAMILY 
s I-FAMILY 
for O 
live O 
cell O 
imaging O 
. O 

developed O 
a O 
new O 
synthetic O 
approach O 
to O 
high O 
molecular O 
weight O 
poly(p-phenylenebutadiynylene) B-FAMILY 
s I-FAMILY 
( O 
PPBs B-FAMILY 
) O 
by O 
increasing O 
backbone O 
flexibility O 
. O 
The O 
introduction O 
of O 
a O 
small O 
amount O 
of O 
flexible O 
units O 
along O 
the O 
backbone O 
improved O 
both O 
the O 
physical O 
and O 
photophysical O 
properties O 
of O 
the O 
polymers O 
. O 
These O 
materials O 
were O 
successfully O 
fabricated O 
into O 
conjugated O 
polymer O 
nanoparticles O 
( O 
CPNs O 
) O 
and O 
used O 
for O 
fluorescent O 
live O 
cell O 
imaging O 
for O 
the O 
first O 
time O 
. O 

resilin O 
, O 
the O 
rubber O 
- O 
like O 
protein O 
that O 
exists O 
in O 
specialized O 
compartments O 
of O 
most O 
arthropods O 
, O 
possesses O 
excellent O 
mechanical O 
properties O 
such O 
as O 
low O 
stiffness O 
, O 
high O 
resilience O 
and O 
effective O 
energy O 
storage O 
. O 
Recombinantly O 
- O 
engineered O 
resilin O 
- O 
like O 
polypeptides O 
( O 
RLPs O 
) O 
that O 
possess O 
the O 
favorable O 
attributes O 
of O 
native O 
resilin O 
would O 
be O 
attractive O 
candidates O 
for O 
the O 
modular O 
design O 
of O 
biomaterials O 
for O 
engineering O 
mechanically O 
active O 
tissues O 
. O 
Based O 
on O 
our O 
previous O 
success O 
in O 
creating O 
a O 
novel O 
RLP O 
- O 
based O 
hydrogel O 
and O 
demonstrating O 
useful O 
mechanical O 
and O 
cell O 
- O 
adhesive O 
properties O 
, O 
we O 
have O 
produced O 
a O 
suite O 
of O 
new O 
RLP O 
- O 
based O 
constructs O 
, O 
each O 
equipped O 
with O 
12 O 
repeats O 
of O 
the O 
putative O 
resilin O 
consensus O 
sequence O 
and O 
a O 
single O 
, O 
distinct O 
biologically O 
active O 
domain O 
. O 
This O 
approach O 
allows O 
independent O 
control O 
over O 
the O 
concentrations O 
of O 
cell O 
- O 
binding O 
, O 
MMP-sensitive O 
, O 
and O 
polysaccharide-sequestration O 
domains O 
in O 
hydrogels O 
comprising O 
mixtures O 
of O 
the O 
various O 
RLPs O 
. O 
The O 
high O 
purity O 
, O 
molecular O 
weight O 
and O 
correct O 
compositions O 
of O 
each O 
new O 
polypeptide O 
have O 
been O 
confirmed O 
via O 
high O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
, O 
sodium B-FAMILY 
dodecyl I-FAMILY 
sulfate I-FAMILY 
polyacrylamide I-FAMILY 
gel I-FAMILY 
electrophoresis O 
( O 
SDS B-ABBREVIATION 
-PAGE O 
) O 
, O 
matrix O 
- O 
assisted O 
laser O 
desorption O 
/ O 
ionization O 
mass O 
spectrometry O 
( O 
MALDI-MS O 
) O 
, O 
and O 
amino B-FAMILY 
acid I-FAMILY 
analysis O 
. O 
These O 
RLP O 
- O 
based O 
polypeptides O 
exhibit O 
largely O 
random O 
- O 
coil O 
conformation O 
, O 
both O 
in O 
solution O 
and O 
in O 
the O 
cross O 
- O 
linked O 
hydrogels O 
, O 
as O 
indicated O 
by O 
circular O 
dichroic O 
and O 
infrared O 
spectroscopic O 
analyses O 
. O 
Hydrogels O 
of O 
various O 
compositions O 
, O 
with O 
a O 
range O 
of O 
elastic O 
moduli O 
( O 
1kPa O 
to O 
25kPa O 
) O 
can O 
be O 
produced O 
from O 
these O 
polypeptides O 
, O 
and O 
the O 
activity O 
of O 
the O 
cell O 
- O 
binding O 
and O 
matrix O 
metalloproteinase O 
( O 
MMP O 
) O 
sensitive O 
domains O 
was O 
confirmed O 
. O 
Tris(hydroxymethyl B-SYSTEMATIC 
phosphine I-SYSTEMATIC 
) I-SYSTEMATIC 
cross O 
- O 
linked O 
RLP O 
hydrogels O 
were O 
able O 
to O 
maintain O 
their O 
mechanical O 
integrity O 
as O 
well O 
as O 
the O 
viability O 
of O 
encapsulated O 
primary O 
human O 
mesenchymal O 
stem O 
cells O 
( O 
MSCs O 
) O 
. O 
These O 
results O 
validate O 
the O 
promising O 
properties O 
of O 
these O 
RLP O 
- O 
based O 
elastomeric O 
biomaterials O 
. O 

Basis O 
for O 
Enzyme O 
I O 
Inhibition O 
by O 
α-Ketoglutarate B-TRIVIAL 
. O 

new O 
bacterial O 
strains O 
in O 
which O 
carbon B-SYSTEMATIC 
and O 
nitrogen B-SYSTEMATIC 
metabolism O 
are O 
uncoupled O 
is O 
potentially O 
very O 
useful O 
for O 
optimizing O 
yields O 
of O 
microbial O 
produced O 
chemicals O 
from O 
renewable O 
carbon B-SYSTEMATIC 
sources O 
. O 
However O 
, O 
the O 
mechanisms O 
that O 
balance O 
carbon B-SYSTEMATIC 
and O 
nitrogen B-SYSTEMATIC 
consumption O 
in O 
bacteria O 
are O 
poorly O 
understood O 
. O 
Recently O 
, O 
α-ketoglutarate B-TRIVIAL 
( O 
αKG B-ABBREVIATION 
) O 
, O 
the O 
carbon B-SYSTEMATIC 
substrate O 
for O 
ammonia B-SYSTEMATIC 
assimilation O 
, O 
has O 
been O 
observed O 
to O 
inhibit O 
Escherichia O 
coli O 
enzyme O 
I O 
( O 
EI O 
) O 
, O 
the O 
first O 
component O 
of O 
the O 
bacterial O 
phosphotransferase O 
system O 
( O 
PTS O 
) O 
, O 
thereby O 
providing O 
a O 
direct O 
biochemical O 
link O 
between O 
central O 
carbon B-SYSTEMATIC 
and O 
nitrogen B-SYSTEMATIC 
metabolism O 
. O 
Here O 
we O 
investigate O 
the O 
EI- O 
αKG B-ABBREVIATION 
interaction O 
by O 
NMR O 
and O 
enzymatic O 
assays O 
. O 
We O 
show O 
that O 
αKG B-ABBREVIATION 
binds O 
with O 
a O 
KD O 
of O 
∼2.2 O 
mM O 
at O 
the O 
active O 
site O 
of O 
EI O 
, O 
acting O 
as O 
a O 
competitive O 
inhibitor O 
. O 
In O 
addition O 
, O 
we O 
use O 
molecular O 
docking O 
simulations O 
to O 
derive O 
a O 
structural O 
model O 
of O 
the O 
enzyme O 
- O 
inhibitor O 
complex O 
that O 
is O 
fully O 
consistent O 
with O 
NMR O 
and O 
analytical O 
ultracentrifugation O 
data O 
. O 
We O 
expect O 
that O 
the O 
EI- O 
αKG B-ABBREVIATION 
structure O 
presented O 
here O 
will O 
provide O 
a O 
starting O 
point O 
for O 
structure O 
- O 
based O 
design O 
of O 
EI O 
mutants O 
resistant O 
to O 
αKG B-ABBREVIATION 
. O 

- O 
shen O 
, O 
radix O 
Codonopsis O 
is O 
one O 
of O 
the O 
best O 
- O 
known O 
traditional O 
Chinese O 
medicines O 
and O 
is O 
used O 
mainly O 
as O 
a O 
tonic O 
agent O 
. O 
Nine O 
commercial O 
products O 
belong O 
to O 
three O 
species O 
of O 
Codonopsis O 
genus O 
, O 
Codonopsis O 
tangshen O 
, O 
Codonopsis O 
pilosula O 
var O 
. O 
modesta O 
and O 
a O 
cultivated O 
species O 
of O 
Codonopsis O 
pilosula O 
, O 
which O 
were O 
purchased O 
from O 
drug O 
stores O 
in O 
Taipei O 
and O 
Taichung O 
, O 
Taiwan O 
. O 
To O 
determine O 
the O 
chemical O 
differences O 
between O 
samples O 
of O 
Dang O 
- O 
shen O 
, O 
a O 
method O 
combining O 
solvent O 
partition O 
and O 
HPLC-UV O 
was O 
used O 
. O 
An O 
enriched O 
fraction O 
of O 
n-butanol B-SYSTEMATIC 
was O 
obtained O 
, O 
after O 
partition O 
. O 
Then O 
, O 
the O 
chemical O 
profile O 
was O 
determined O 
using O 
a O 
C18 O 
reversed O 
column O 
chromatography O 
in O 
a O 
gradient O 
solvent O 
system O 
with O 
10-40% O 
acetonitrile B-SYSTEMATIC 
in O 
0.1% O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
for O 
60 O 
min O 
. O 
A O 
comparison O 
of O 
the O 
constituents O 
in O 
the O 
nine O 
commercial O 
products O 
of O 
Dang O 
- O 
shen O 
showed O 
that O 
compounds O 
codonopyrrolidum B-MULTIPLE 
A I-MULTIPLE 
, I-MULTIPLE 
B I-MULTIPLE 
and O 
codonoside B-TRIVIAL 
A I-TRIVIAL 
only O 
exist O 
in O 
C O 
. O 
tangshen O 
, O 
but O 
not O 
in O 
C O 
. O 
pilosula O 
var O 
. O 
modesta O 
and O 
C O 
. O 
pilosula O 
. O 
A O 
predominate O 
compound O 
, O 
codonopyrrolidum B-TRIVIAL 
A I-TRIVIAL 
, O 
can O 
be O 
used O 
to O 
distinguish O 
the O 
herbs O 
, O 
C O 
. O 
tangshen O 
from O 
C O 
. O 
pilosula O 
var O 
. O 
modesta O 
and O 
C O 
. O 
pilosula O 
. O 
Low O 
secondary O 
metabolite O 
content O 
was O 
found O 
in O 
the O 
cultivated O 
species O 
of O 
C O 
. O 
pilosula O 
. O 

is O 
one O 
of O 
the O 
main O 
factors O 
that O 
hinders O 
the O 
performance O 
of O 
probes O 
for O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
, O 
including O 
for O 
the O 
widely O 
used O 
amplitude O 
modulation O 
( O 
AM-AFM O 
) O 
mode O 
. O 
Unfortunately O 
, O 
a O 
comprehensive O 
scientific O 
understanding O 
of O 
nanoscale O 
wear O 
is O 
lacking O 
. O 
We O 
have O 
developed O 
a O 
protocol O 
for O 
conducting O 
consistent O 
and O 
quantitative O 
AM-AFM O 
wear O 
experiments O 
. O 
The O 
protocol O 
involves O 
controlling O 
the O 
tip O 
- O 
sample O 
interaction O 
regime O 
during O 
AM-AFM O 
scanning O 
, O 
determining O 
the O 
tip O 
- O 
sample O 
contact O 
geometry O 
, O 
calculating O 
the O 
peak O 
repulsive O 
force O 
and O 
normal O 
stress O 
over O 
the O 
course O 
of O 
the O 
wear O 
test O 
, O 
and O 
quantifying O 
the O 
wear O 
volume O 
using O 
high O 
- O 
resolution O 
transmission O 
electron O 
microscopy O 
imaging O 
. O 
The O 
peak O 
repulsive O 
tip O 
- O 
sample O 
interaction O 
force O 
is O 
estimated O 
from O 
a O 
closed O 
- O 
form O 
equation O 
accompanied O 
by O 
an O 
effective O 
tip O 
radius O 
measurement O 
procedure O 
, O 
which O 
combines O 
transmission O 
electron O 
microscopy O 
and O 
blind O 
tip O 
reconstruction O 
. O 
The O 
contact O 
stress O 
is O 
estimated O 
by O 
applying O 
Derjaguin-Müller-Toporov O 
contact O 
mechanics O 
model O 
and O 
also O 
numerically O 
solving O 
a O 
general O 
contact O 
mechanics O 
model O 
recently O 
developed O 
for O 
the O 
adhesive O 
contact O 
of O 
arbitrary O 
axisymmetric O 
punch O 
shapes O 
. O 
We O 
discuss O 
the O 
important O 
role O 
that O 
the O 
assumed O 
tip O 
shape O 
geometry O 
plays O 
in O 
calculating O 
both O 
the O 
interaction O 
forces O 
and O 
the O 
contact O 
stresses O 
. O 
Contact O 
stresses O 
are O 
significantly O 
affected O 
by O 
the O 
tip O 
geometry O 
while O 
the O 
peak O 
repulsive O 
force O 
is O 
mainly O 
determined O 
by O 
experimentally O 
controlled O 
parameters O 
, O 
specifically O 
, O 
the O 
free O 
oscillation O 
amplitude O 
and O 
amplitude O 
ratio O 
. O 
The O 
applicability O 
of O 
this O 
protocol O 
is O 
demonstrated O 
experimentally O 
by O 
assessing O 
the O 
performance O 
of O 
diamond B-TRIVIAL 
-like O 
carbon B-SYSTEMATIC 
-coated O 
and O 
silicon B-SYSTEMATIC 
- I-SYSTEMATIC 
nitride I-SYSTEMATIC 
-coated O 
silicon B-SYSTEMATIC 
probes O 
scanned O 
over O 
ultrananocrystalline O 
diamond B-TRIVIAL 
substrates O 
in O 
repulsive O 
mode O 
AM-AFM O 
. O 
There O 
is O 
no O 
sign O 
of O 
fracture O 
or O 
plastic O 
deformation O 
in O 
the O 
case O 
of O 
diamond B-TRIVIAL 
-like O 
carbon B-SYSTEMATIC 
; O 
wear O 
could O 
be O 
characterized O 
as O 
a O 
gradual O 
atom O 
- O 
by O 
- O 
atom O 
process O 
. O 
In O 
contrast O 
, O 
silicon B-SYSTEMATIC 
nitride I-SYSTEMATIC 
wears O 
through O 
removal O 
of O 
the O 
cluster O 
of O 
atoms O 
and O 
plastic O 
deformation O 
. O 

to O 
Reinforced O 
State O 
by O 
Percolating O 
Domains O 
of O 
Intercalated O 
Brush O 
- O 
Modified O 
Cellulose O 
Nanocrystals O 
and O 
Poly(butadiene) B-FAMILY 
in O 
Cross O 
- O 
Linked O 
Composites O 
Based O 
on O 
Thiol B-FAMILY 
- I-FAMILY 
ene I-FAMILY 
Click O 
Chemistry O 
. O 

classic O 
nanocomposite O 
approach O 
aims O 
at O 
percolation O 
of O 
low O 
fraction O 
of O 
exfoliated O 
individual O 
reinforcing O 
nanoscale O 
elements O 
within O 
a O 
polymeric O 
matrix O 
. O 
By O 
contrast O 
, O 
many O 
of O 
the O 
mechanically O 
excellent O 
biological O 
nanocomposites O 
involve O 
self O 
- O 
assembled O 
and O 
space O 
- O 
filled O 
structures O 
of O 
hard O 
reinforcing O 
and O 
soft O 
toughening O 
domains O 
, O 
with O 
high O 
weight O 
fraction O 
of O 
reinforcements O 
. O 
Here O 
we O 
inspect O 
a O 
new O 
concept O 
toward O 
mimicking O 
such O 
structures O 
by O 
studying O 
whether O 
percolation O 
of O 
intercalated O 
domains O 
consisting O 
of O 
alternating O 
rigid O 
and O 
reinforcing O 
, O 
and O 
soft O 
rubbery O 
domains O 
could O 
allow O 
a O 
transition O 
to O 
a O 
reinforced O 
state O 
. O 
Toward O 
that O 
, O 
we O 
present O 
the O 
functionalization O 
of O 
rigid O 
native O 
cellulose O 
nanocrystals O 
( O 
CNCs O 
) O 
by O 
esterification O 
with O 
a O 
dense O 
hydrocarbon B-FAMILY 
chain O 
brush O 
containing O 
cross O 
- O 
linkable O 
double O 
bonds O 
. O 
Composite O 
films O 
with O 
0-80 O 
wt O 
% O 
of O 
such O 
modified O 
CNCs O 
( O 
mCNCs O 
) O 
within O 
a O 
poly(butadiene) B-FAMILY 
( O 
PBD B-ABBREVIATION 
) O 
rubber O 
matrix O 
were O 
prepared O 
via O 
cross O 
- O 
linking O 
by O 
UV-light O 
initiated O 
thiol B-FAMILY 
- I-FAMILY 
ene I-FAMILY 
click O 
reaction O 
. O 
Transmission O 
electron O 
microscopy O 
showed O 
structures O 
at O 
two O 
length O 
scales O 
, O 
where O 
the O 
mCNCs O 
and O 
PBD B-ABBREVIATION 
form O 
domains O 
having O 
internal O 
aligned O 
self O 
- O 
assemblies O 
of O 
alternating O 
hard O 
mCNCs O 
and O 
soft O 
PBD B-ABBREVIATION 
with O 
periodicity O 
of O 
ca O 
. O 
40 O 
nm O 
, O 
and O 
where O 
additional O 
PBD B-ABBREVIATION 
connects O 
such O 
domains O 
. O 
Increasing O 
the O 
weight O 
fraction O 
of O 
mCNCs O 
causes O 
an O 
uncommon O 
abrupt O 
transition O 
from O 
PBD B-ABBREVIATION 
-dominated O 
soft O 
materials O 
to O 
significantly O 
reinforced O 
mCNC-dominated O 
mechanical O 
properties O 
, O 
suggesting O 
that O 
the O 
intercalated O 
self O 
- O 
assembled O 
mCNC/ O 
PBD B-ABBREVIATION 
domains O 
percolate O 
in O 
PBD B-ABBREVIATION 
upon O 
passing O 
30-35 O 
wt O 
% O 
of O 
mCNCs O 
. O 
Maximum O 
stress O 
of O 
16 O 
MPa O 
at O 
mCNC O 
fraction O 
of O 
80 O 
wt O 
% O 
was O 
obtained O 
. O 
The O 
mechanical O 
properties O 
of O 
the O 
composites O 
show O 
exceptional O 
insensitivity O 
to O 
air O 
humidity O 
. O 
The O 
shown O 
simple O 
concept O 
of O 
percolative O 
intercalated O 
nanocomposites O 
suggests O 
searching O 
for O 
more O 
general O 
biomimetic O 
compositions O 
involving O 
several O 
deformation O 
mechanisms O 
for O 
improved O 
mechanical O 
properties O 
. O 

this O 
work O 
, O 
Family O 
1 O 
cellulose O 
binding O 
modules O 
CBMCel7A O 
and O 
CBMCel6A O 
were O 
heterologously O 
expressed O 
and O 
purified O 
from O 
Escherichia O 
coli O 
, O 
and O 
the O 
binding O 
properties O 
between O 
these O 
CBMs O 
and O 
cellulose O 
substrates O 
were O 
studied O 
. O 
Cellulose O 
nanowhiskers O 
( O 
CNWs O 
, O 
the O 
crystalline O 
portion O 
of O 
cellulose O 
) O 
, O 
microcrystalline O 
cellulose O 
Avicel O 
PH101 O 
( O 
partially O 
crystalline O 
cellulose O 
) O 
, O 
and O 
phosphoric B-SYSTEMATIC 
acid I-SYSTEMATIC 
swollen O 
cellulose O 
( O 
PASC O 
, O 
amorphous O 
cellulose O 
) O 
were O 
used O 
as O 
representative O 
models O 
for O 
cellulose O 
to O 
better O 
understand O 
the O 
binding O 
interactions O 
between O 
the O 
CBMs O 
and O 
different O 
regions O 
of O 
native O 
cellulose O 
. O 
Isothermal O 
titration O 
calorimetry O 
( O 
ITC O 
) O 
was O 
combined O 
with O 
adsorption O 
- O 
isotherm O 
experiment O 
to O 
analyze O 
the O 
thermodynamics O 
of O 
CBM O 
binding O 
to O 
various O 
cellulose O 
substrates O 
. O 
N2 B-FORMULA 
adsorption O 
and O 
static O 
light O 
scattering O 
( O 
SLS O 
) O 
data O 
were O 
used O 
to O 
estimate O 
the O 
accessible O 
surface O 
area O 
of O 
cellulose O 
which O 
was O 
then O 
used O 
for O 
ITC O 
data O 
analysis O 
. O 
A O 
new O 
method O 
of O 
determining O 
the O 
cellulose O 
molarity O 
based O 
on O 
the O 
available O 
surface O 
area O 
for O 
CBM O 
binding O 
was O 
developed O 
, O 
which O 
allows O 
different O 
cellulose O 
substrates O 
to O 
be O 
compared O 
for O 
binding O 
experiments O 
. O 
The O 
ITC O 
results O 
showed O 
that O 
the O 
binding O 
constant O 
( O 
Ka O 
) O 
to O 
crystalline O 
CNWs O 
was O 
∼10(5) O 
M(-1) O 
for O 
CBMCel7A O 
, O 
while O 
∼10(6) O 
M(-1) O 
for O 
CBMCel6A O 
, O 
suggesting O 
a O 
higher O 
binding O 
affinity O 
of O 
CBMCel6A O 
to O 
CNWs O 
. O 
For O 
Avicel O 
, O 
lower O 
binding O 
constants O 
for O 
both O 
CBMs O 
were O 
observed O 
, O 
and O 
weak O 
bindings O 
to O 
PASC O 
were O 
characterized O 
, O 
suggesting O 
that O 
the O 
binding O 
between O 
CBMCel7A,Cel6A O 
and O 
cellulose O 
to O 
some O 
extent O 
relates O 
to O 
the O 
crystallinity O 
of O 
cellulose O 
. O 
Additionally O 
, O 
the O 
binding O 
reactions O 
were O 
driven O 
by O 
a O 
favorable O 
enthalpy O 
change O 
, O 
offset O 
partially O 
by O 
an O 
unfavorable O 
entropy O 
change O 
. O 
It O 
is O 
suggested O 
that O 
CBMCel6A O 
preferentially O 
binds O 
to O 
the O 
reducing O 
end O 
of O 
cellulose O 
chain O 
, O 
while O 
CBMCel7A O 
does O 
not O 
show O 
such O 
end O 
binding O 
specificities O 
. O 
Cello O 
- O 
oligosaccharides O 
less O 
than O 
two O 
glucose B-TRIVIAL 
units O 
did O 
not O 
bind O 
with O 
CBMs O 
, O 
and O 
improved O 
binding O 
affinities O 
were O 
observed O 
for O 
cello O 
- O 
oligosaccharides O 
with O 
longer O 
glucose B-TRIVIAL 
units O 
. O 

of O 
prolonged O 
exposure O 
to O 
microcystin-LR B-TRIVIAL 
in O 
mice O 
. O 

effects O 
of O 
prolonged O 
exposure O 
to O 
microcystins O 
( O 
MCs O 
) O 
on O 
health O 
are O 
not O 
yet O 
sufficiently O 
understood O 
and O 
this O 
type O 
of O 
poisoning O 
is O 
often O 
undiagnosed O 
. O 
Even O 
though O 
chronic O 
exposure O 
has O 
been O 
linked O 
with O 
liver O 
cancer O 
and O 
alterations O 
have O 
been O 
described O 
in O 
liver O 
damage O 
marker O 
enzymes O 
in O 
exposed O 
populations O 
, O 
there O 
are O 
not O 
profile O 
parameters O 
that O 
indicate O 
prolonged O 
exposure O 
to O 
microcystins O 
. O 
The O 
aim O 
of O 
this O 
work O 
is O 
to O 
determine O 
, O 
based O 
on O 
an O 
animal O 
model O 
of O 
prolonged O 
exposure O 
to O 
successive O 
i.p O 
. O 
doses O 
of O 
25 O 
μg O 
MC-LR B-ABBREVIATION 
/ O 
kg O 
body O 
weight O 
, O 
several O 
plasma O 
parameters O 
which O 
could O 
be O 
useful O 
as O 
exposure O 
biomarkers O 
. O 
Hemoglobin O 
( O 
Hb O 
) O 
and O 
methemoglobin O 
( O 
MetHb O 
) O 
levels O 
were O 
determined O 
on O 
blood O 
samples O 
. O 
We O 
also O 
studied O 
plasma O 
levels O 
of O 
hydroperoxides B-FAMILY 
( O 
ROOHs B-FAMILY 
) O 
, O 
α-tocopherol B-TRIVIAL 
, O 
glutathione B-TRIVIAL 
and O 
lipid O 
profile O 
as O 
well O 
as O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
and O 
catalase O 
( O 
CAT O 
) O 
erythrocyte O 
activities O 
. O 
In O 
addition O 
, O 
the O 
determination O 
of O 
MC-LR B-ABBREVIATION 
levels O 
in O 
liver O 
, O 
kidney O 
, O 
plasma O 
, O 
urine O 
and O 
feces O 
of O 
treated O 
mice O 
was O 
carried O 
out O 
. O 
We O 
found O 
that O 
alteration O 
in O 
MetHb O 
, O 
ROOHs B-FAMILY 
, O 
glutathione B-TRIVIAL 
, O 
α-tocopherol B-TRIVIAL 
levels O 
, O 
SOD O 
activity O 
and O 
plasma O 
lipid O 
profile O 
, O 
correlates O 
with O 
those O 
expected O 
if O 
the O 
alteration O 
derived O 
from O 
hepatic O 
damage O 
. O 
The O 
alterated O 
plasma O 
paramenters O 
together O 
with O 
MC-LR B-ABBREVIATION 
determination O 
could O 
be O 
used O 
as O 
biomarkers O 
, O 
helpful O 
tools O 
in O 
screening O 
and O 
epidemiological O 
studies O 
. O 

/ O 
MS O 
Determination O 
of O 
Isoprostanes B-FAMILY 
in O 
Plasma O 
Samples O 
Collected O 
from O 
Mice O 
Exposed O 
to O 
Doxorubicin B-TRIVIAL 
or O 
Tert-Butyl B-SYSTEMATIC 
Hydroperoxide I-SYSTEMATIC 
. O 

are O 
stable O 
products O 
of O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
peroxidation O 
and O 
are O 
regarded O 
as O 
the O 
most O 
reliable O 
markers O 
of O 
oxidative O 
stress O 
in O 
vivo O 
. O 
Here O 
we O 
describe O 
the O 
LC-MS O 
/ O 
MS O 
procedure O 
enabling O 
simultaneous O 
determination O 
of O 
four O 
regioisomers O 
( O 
8-iso B-SYSTEMATIC 
prostaglandin I-SYSTEMATIC 
F2α I-SYSTEMATIC 
, O 
8-iso-15(R)-prostaglandin B-SYSTEMATIC 
F2α I-SYSTEMATIC 
, O 
11β-prostaglandin B-SYSTEMATIC 
F2α I-SYSTEMATIC 
, O 
15(R)-prostaglandin B-TRIVIAL 
F2α I-TRIVIAL 
) O 
in O 
plasma O 
samples O 
collected O 
from O 
mice O 
. O 
The O 
four O 
plasma O 
isoprostanes B-FAMILY 
are O 
determined O 
by O 
LC-ESI-MS O 
/ O 
MS O 
with O 
deuterated O 
8-iso-PGF2α-d4 B-SYSTEMATIC 
as O 
an O 
internal O 
standard O 
( O 
I.S O 
. O 
) O 
. O 
For O 
plasma O 
samples O 
spiked O 
with O 
the O 
isoprostanes B-FAMILY 
at O 
a O 
level O 
of O 
200 O 
pg O 
/ O 
mL O 
each O 
, O 
the O 
method O 
imprecision O 
has O 
been O 
below O 
7.1% O 
and O 
mean O 
inaccuracy O 
equaled O 
8.7% O 
. O 
The O 
applicability O 
of O 
the O 
proposed O 
approach O 
has O 
been O 
verified O 
by O 
the O 
assessment O 
of O 
changes O 
in O 
isoprostane B-FAMILY 
levels O 
in O 
plasma O 
samples O 
derived O 
from O 
mice O 
exposed O 
to O 
tert-butyl B-SYSTEMATIC 
hydroperoxide I-SYSTEMATIC 
( O 
TBHP B-ABBREVIATION 
) O 
, O 
a O 
model O 
inducer O 
of O 
oxidative O 
stress O 
, O 
or O 
to O 
antitumor O 
drug O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
known O 
for O 
potent O 
stimulation O 
of O 
redox O 
cycling O 
. O 
Compared O 
to O 
the O 
control O 
group O 
of O 
mice O 
, O 
both O 
oxidative O 
stress O 
inducers O 
tested O 
increased O 
the O 
levels O 
of O 
three O 
out O 
of O 
four O 
isoprostanes O 
in O 
exposed O 
animals O 
; O 
11β-prostaglandin B-SYSTEMATIC 
F2α I-SYSTEMATIC 
being O 
the O 
exception O 
. O 
The O 
greatest O 
rise O 
was O 
observed O 
in O 
the O 
case O 
of O 
15(R)-prostaglandin B-TRIVIAL 
F2α I-TRIVIAL 
, O 
by O 
about O 
50% O 
and O 
70% O 
in O 
plasma O 
samples O 
derived O 
from O 
mice O 
exposed O 
to O 
DOX B-ABBREVIATION 
and O 
TBHP B-ABBREVIATION 
, O 
respectively O 
. O 

acid I-TRIVIAL 
impairs O 
glucose B-TRIVIAL 
homeostasis O 
and O 
inhibits O 
insulin O 
secretion O 
in O 
high O 
- O 
fat O 
diet O 
obese O 
mice O 
. O 

/ O 
HYPOTHESIS O 
: O 
Lysophosphatidic B-TRIVIAL 
acid I-TRIVIAL 
( O 
LPA B-ABBREVIATION 
) O 
is O 
a O 
lipid O 
mediator O 
produced O 
by O 
adipocytes O 
that O 
acts O 
via O 
specific O 
G O 
- O 
protein O 
- O 
coupled O 
receptors O 
; O 
its O 
synthesis O 
is O 
modulated O 
in O 
obesity O 
. O 
We O 
previously O 
reported O 
that O 
reducing O 
adipocyte O 
LPA B-ABBREVIATION 
production O 
in O 
high O 
- O 
fat O 
diet O 
(HFD)-fed O 
obese O 
mice O 
is O 
associated O 
with O 
improved O 
glucose B-TRIVIAL 
tolerance O 
, O 
suggesting O 
a O 
negative O 
impact O 
of O 
LPA B-ABBREVIATION 
on O 
glucose B-TRIVIAL 
homeostasis O 
. O 
Here O 
, O 
our O 
aim O 
was O 
to O 
test O 
this O 
hypothesis O 
. O 
METHODS O 
: O 
First O 
, O 
glucose B-TRIVIAL 
tolerance O 
and O 
plasma O 
insulin O 
were O 
assessed O 
after O 
acute O 
( O 
30 O 
min O 
) O 
injection O 
of O 
LPA B-ABBREVIATION 
( O 
50 O 
mg O 
/ O 
kg O 
) O 
or O 
of O 
the O 
LPA1 O 
/ O 
LPA3 O 
receptor O 
antagonist O 
Ki16425 O 
( O 
5 O 
mg O 
kg(-1) O 
day(-1) O 
, O 
i.p O 
. O 
) O 
in O 
non-obese O 
mice O 
fed O 
a O 
normal O 
diet O 
( O 
ND O 
) O 
and O 
in O 
obese O 
/ O 
prediabetic O 
( O 
defined O 
as O 
glucose B-TRIVIAL 
-intolerant O 
) O 
HFD O 
mice O 
. O 
Glucose B-TRIVIAL 
and O 
insulin O 
tolerance O 
, O 
pancreas O 
morphology O 
, O 
glycogen O 
storage O 
, O 
glucose B-TRIVIAL 
oxidation O 
and O 
glucose B-TRIVIAL 
transport O 
were O 
then O 
studied O 
after O 
chronic O 
treatment O 
( O 
3 O 
weeks O 
) O 
of O 
HFD O 
mice O 
with O 
Ki16425 O 
. O 
RESULTS O 
: O 
In O 
ND O 
and O 
HFD O 
mice O 
, O 
LPA B-ABBREVIATION 
acutely O 
impaired O 
glucose B-TRIVIAL 
tolerance O 
by O 
inhibiting O 
glucose B-TRIVIAL 
-induced O 
insulin O 
secretion O 
. O 
These O 
effects O 
were O 
blocked O 
by O 
pre O 
- O 
injection O 
of O 
Ki16425 O 
( O 
5 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
. O 
Inhibition O 
of O 
glucose B-TRIVIAL 
-induced O 
insulin O 
secretion O 
by O 
LPA B-ABBREVIATION 
also O 
occurred O 
in O 
isolated O 
mouse O 
islets O 
. O 
Plasma O 
LPA B-ABBREVIATION 
was O 
higher O 
in O 
HFD O 
mice O 
than O 
in O 
ND O 
mice O 
and O 
Ki16425 O 
transiently O 
improved O 
glucose B-TRIVIAL 
tolerance O 
. O 
The O 
beneficial O 
effect O 
of O 
Ki16425 O 
became O 
permanent O 
after O 
chronic O 
treatment O 
and O 
was O 
associated O 
with O 
increased O 
pancreatic O 
islet O 
mass O 
and O 
higher O 
fasting O 
insulinaemia O 
. O 
Chronic O 
treatment O 
with O 
Ki16425 O 
also O 
improved O 
insulin O 
tolerance O 
and O 
increased O 
liver O 
glycogen O 
storage O 
and O 
basal O 
glucose B-TRIVIAL 
use O 
in O 
skeletal O 
muscle O 
. O 
CONCLUSIONS O 
/ O 
INTERPRETATION O 
: O 
Exogenous O 
and O 
endogenous O 
LPA B-ABBREVIATION 
exerts O 
a O 
deleterious O 
effect O 
on O 
glucose B-TRIVIAL 
disposal O 
through O 
a O 
reduction O 
of O 
plasma O 
insulin O 
; O 
pharmacological O 
blockade O 
of O 
LPA B-ABBREVIATION 
receptors O 
improves O 
glucose B-TRIVIAL 
homeostasis O 
in O 
obese O 
/ O 
prediabetic O 
mice O 
. O 

levels O 
of O 
trait O 
impulsiveness O 
and O 
a O 
less O 
effective O 
response O 
inhibition O 
are O 
linked O 
to O 
more O 
intense O 
cue O 
- O 
elicited O 
craving O 
for O 
alcohol B-FAMILY 
in O 
alcohol B-FAMILY 
-dependent O 
patients O 
. O 

: O 
Cue O 
- O 
elicited O 
craving O 
is O 
a O 
well O 
- O 
researched O 
phenomenon O 
in O 
alcohol B-FAMILY 
literature O 
. O 
However O 
, O 
not O 
all O 
alcohol B-FAMILY 
-dependent O 
people O 
display O 
the O 
same O 
reactivity O 
to O 
alcohol B-FAMILY 
cues O 
. O 
Personality O 
factors O 
such O 
as O 
multiple O 
impulsivity O 
traits O 
may O 
be O 
responsible O 
for O 
individual O 
differences O 
in O 
cue O 
reactivity O 
by O 
modulating O 
its O 
intensity O 
. O 
Nevertheless O 
, O 
there O 
has O 
been O 
a O 
scarcity O 
of O 
empirical O 
studies O 
testing O 
this O 
assumption O 
in O 
alcohol B-FAMILY 
literature O 
. O 
OBJECTIVES O 
: O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
the O 
effects O 
of O 
response O 
inhibition O 
and O 
trait O 
impulsiveness O 
on O 
cue O 
- O 
elicited O 
craving O 
for O 
alcohol B-FAMILY 
in O 
alcohol B-FAMILY 
-dependent O 
drinkers O 
. O 
METHODS O 
: O 
Participants O 
( O 
n O 
= O 
41 O 
) O 
were O 
inpatients O 
of O 
the O 
private O 
clinic O 
U-Center O 
, O 
Netherlands O 
. O 
Alcohol B-SYSTEMATIC 
exposure O 
took O 
place O 
in O 
a O 
real O 
bar O 
- O 
restaurant O 
close O 
to O 
the O 
premises O 
of O 
the O 
clinic O 
, O 
and O 
participants O 
were O 
exposed O 
to O 
real O 
alcohol B-FAMILY 
cues O 
. O 
Response O 
inhibition O 
was O 
assessed O 
with O 
the O 
stop O 
- O 
signal O 
task O 
and O 
trait O 
impulsiveness O 
with O 
the O 
Barratt O 
impulsivity O 
scale O 
version O 
11 O 
. O 
RESULTS O 
: O 
The O 
cue O 
exposure O 
was O 
successful O 
as O 
alcohol B-FAMILY 
-dependent O 
patients O 
experienced O 
higher O 
craving O 
for O 
alcohol B-FAMILY 
when O 
exposed O 
to O 
alcohol B-FAMILY 
rather O 
than O 
to O 
neutral O 
cues O 
. O 
Additionally O 
, O 
both O 
response O 
inhibition O 
and O 
trait O 
impulsiveness O 
predicted O 
cue O 
- O 
elicited O 
craving O 
for O 
alcohol B-FAMILY 
. O 
Trait O 
impulsiveness O 
predicted O 
both O 
the O 
absolute O 
craving O 
in O 
the O 
bar O 
- O 
restaurant O 
and O 
the O 
increase O 
in O 
cue O 
- O 
elicited O 
craving O 
during O 
the O 
whole O 
alcohol B-FAMILY 
cue O 
exposure O 
, O 
while O 
response O 
inhibition O 
predicted O 
only O 
the O 
former O 
. O 
CONCLUSIONS O 
: O 
The O 
results O 
clearly O 
implicate O 
both O 
trait O 
impulsiveness O 
and O 
response O 
inhibition O 
in O 
the O 
modulation O 
of O 
cue O 
- O 
elicited O 
craving O 
in O 
alcohol B-FAMILY 
dependence O 
. O 
Theoretical O 
and O 
methodological O 
issues O 
in O 
the O 
findings O 
and O 
their O 
clinical O 
implications O 
in O 
alcohol B-FAMILY 
treatment O 
and O 
relapse O 
are O 
discussed O 
. O 

Basis O 
for O 
Sialic B-FAMILY 
Acid I-FAMILY 
-dependent O 
Receptor O 
Recognition O 
by O 
the O 
Plasmodium O 
falciparum O 
Invasion O 
Protein O 
Erythrocyte O 
- O 
binding O 
Antigen-140 O 
/ O 
BAEBL O 
. O 

falciparum O 
erythrocyte O 
invasion O 
is O 
dependent O 
on O 
high O 
affinity O 
recognition O 
of O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
on O 
cell O 
surface O 
receptors O 
. O 
The O 
erythrocyte O 
binding O 
- O 
like O 
( O 
EBL O 
) O 
family O 
of O 
invasion O 
ligands O 
mediates O 
recognition O 
of O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
on O 
erythrocyte O 
glycoproteins O 
. O 
Erythrocyte O 
- O 
binding O 
antigen-140 O 
( O 
PfEBA-140 O 
/ O 
BAEBL O 
) O 
is O 
a O 
critical O 
EBL O 
ligand O 
that O 
binds O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
on O 
its O 
receptor O 
glycophorin O 
C O 
. O 
We O 
present O 
here O 
the O 
crystal O 
structure O 
of O 
the O 
two O 
- O 
domain O 
receptor O 
- O 
binding O 
region O 
of O 
PfEBA-140 O 
in O 
complex O 
with O 
a O 
glycan O 
containing O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
. O 
The O 
structure O 
identifies O 
two O 
glycan O 
- O 
binding O 
pockets O 
unique O 
to O 
PfEBA-140 O 
and O 
not O 
shared O 
by O 
other O 
EBL O 
ligands O 
. O 
Specific O 
molecular O 
interactions O 
that O 
enable O 
receptor O 
engagement O 
are O 
identified O 
and O 
reveal O 
that O 
the O 
glycan O 
binding O 
mode O 
is O 
distinct O 
from O 
that O 
of O 
apicomplexan O 
and O 
viral O 
cell O 
surface O 
recognition O 
ligands O 
as O 
well O 
as O 
host O 
immune O 
factors O 
that O 
bind O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
. O 
Erythrocyte O 
binding O 
experiments O 
elucidated O 
essential O 
glycan O 
contact O 
residues O 
and O 
identified O 
divergent O 
functional O 
roles O 
for O 
each O 
receptor O 
- O 
binding O 
site O 
. O 
One O 
of O 
four O 
polymorphisms O 
proposed O 
to O 
affect O 
receptor O 
binding O 
was O 
localized O 
to O 
a O 
glycan O 
- O 
binding O 
site O 
, O 
providing O 
a O 
structural O 
basis O 
for O 
altered O 
erythrocyte O 
engagement O 
. O 
The O 
studies O 
described O 
here O 
provide O 
the O 
first O 
full O 
description O 
of O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
-dependent O 
molecular O 
interactions O 
at O 
the O 
P O 
. O 
falciparum O 
erythrocyte O 
invasion O 
interface O 
and O 
define O 
a O 
framework O 
for O 
development O 
of O 
PfEBA-140 O 
- O 
based O 
therapeutics O 
, O 
vaccines O 
, O 
and O 
diagnostics O 
assessing O 
vaccine O 
efficacy O 
and O 
natural O 
immunity O 
to O 
infection O 
. O 

albicans O 
and O 
Pseudomonas O 
aeruginosa O 
are O 
able O 
to O 
form O 
pathogenic O 
polymicrobial O 
communities O 
. O 
P O 
. O 
aeruginosa O 
colonizes O 
and O 
kills O 
hyphae O 
but O 
is O 
unable O 
to O 
attach O 
to O 
yeast O 
. O 
It O 
is O 
unknown O 
why O 
the O 
interaction O 
of O 
P O 
. O 
aeruginosa O 
is O 
different O 
with O 
yeast O 
than O 
with O 
hyphae O 
. O 
Here O 
we O 
aim O 
to O 
evaluate O 
the O 
role O 
of O 
P O 
. O 
aeruginosa O 
chitin O 
- O 
binding O 
protein O 
( O 
CbpD O 
) O 
in O 
its O 
physical O 
interaction O 
with O 
C O 
. O 
albicans O 
hyphae O 
or O 
yeast O 
, O 
based O 
on O 
surface O 
thermodynamic O 
and O 
atomic O 
force O 
microscopic O 
analyses O 
. O 
A O 
P O 
. O 
aeruginosa O 
mutant O 
lacking O 
CbpD O 
was O 
unable O 
to O 
express O 
strong O 
adhesion O 
forces O 
with O 
hyphae O 
( O 
-2.9 O 
nN O 
) O 
as O 
compared O 
with O 
the O 
parent O 
strain O 
P O 
. O 
aeruginosa O 
PAO1 O 
( O 
-4.8 O 
nN O 
) O 
and O 
showed O 
less O 
adhesion O 
to O 
hyphae O 
. O 
Also O 
blocking O 
of O 
CbpD O 
using O 
N-acetyl-glucosamine B-SYSTEMATIC 
yielded O 
a O 
lower O 
adhesion O 
force O 
( O 
-4.3 O 
nN O 
) O 
with O 
hyphae O 
. O 
Strong O 
adhesion O 
forces O 
were O 
restored O 
after O 
complementing O 
the O 
expression O 
of O 
CbpD O 
in O 
P O 
. O 
aeruginosa O 
PAO1 O 
ΔcbpD O 
yielding O 
an O 
adhesion O 
force O 
of O 
-5.1 O 
nN O 
. O 
These O 
observations O 
were O 
confirmed O 
with O 
microscopic O 
evaluation O 
of O 
adhesion O 
tests O 
. O 
Regardless O 
of O 
the O 
absence O 
or O 
presence O 
of O 
CbpD O 
on O 
the O 
bacterial O 
cell O 
surfaces O 
, O 
or O 
their O 
blocking O 
, O 
P O 
. O 
aeruginosa O 
experienced O 
favorable O 
thermodynamic O 
conditions O 
for O 
adhesion O 
with O 
hyphae O 
, O 
which O 
were O 
absent O 
with O 
yeast O 
. O 
In O 
addition O 
, O 
adhesion O 
forces O 
with O 
yeast O 
were O 
less O 
than O 
0.5 O 
nN O 
in O 
all O 
cases O 
. O 
Concluding O 
, O 
CbpD O 
in O 
P O 
. O 
aeruginosa O 
is O 
responsible O 
for O 
strong O 
physical O 
interactions O 
with O 
C O 
. O 
albicans O 
hyphae O 
. O 
The O 
development O 
of O 
this O 
interaction O 
requires O 
time O 
due O 
to O 
the O 
fact O 
that O 
CbpDs O 
have O 
to O 
invade O 
the O 
outermost O 
mannoprotein O 
layer O 
on O 
the O 
hyphal O 
cell O 
surfaces O 
. O 
In O 
order O 
to O 
do O 
this O 
, O 
thermodynamic O 
conditions O 
at O 
the O 
outermost O 
cell O 
surfaces O 
have O 
to O 
be O 
favorable O 
. O 

this O 
work O 
, O 
degradable O 
cationic O 
shell O 
cross O 
- O 
linked O 
knedel O 
- O 
like O 
( O 
deg-cSCK O 
) O 
nanoparticles O 
were O 
developed O 
as O 
an O 
alternative O 
platform O 
to O 
replace O 
similar O 
nondegradable O 
cSCK O 
nanoparticles O 
that O 
have O 
been O 
utilized O 
for O 
nucleic O 
acids O 
delivery O 
. O 
An O 
amphiphilic O 
diblock O 
copolymer O 
poly(acrylamidoethylamine)90-block-poly(dl-lactide)40 B-FAMILY 
( O 
PAEA90-b-PDLLA40 B-ABBREVIATION 
) O 
was O 
synthesized O 
, O 
self O 
- O 
assembled O 
in O 
aqueous O 
solution O 
, O 
and O 
shell O 
cross O 
- O 
linked O 
using O 
a O 
hydrolyzable O 
cross O 
- O 
linker O 
to O 
afford O 
deg-cSCKs O 
with O 
an O 
average O 
core O 
diameter O 
of O 
45 O 
± O 
7 O 
nm O 
. O 
These O 
nanoparticles O 
were O 
fluorescently O 
labeled O 
for O 
in O 
vitro O 
tracking O 
. O 
The O 
enzymatic- O 
and O 
hydrolytic O 
- O 
degradability O 
, O 
siRNA O 
binding O 
affinity O 
, O 
cell O 
uptake O 
and O 
cytotoxicity O 
of O 
the O 
deg-cSCKs O 
were O 
evaluated O 
. O 
Esterase O 
- O 
catalyzed O 
hydrolysis O 
of O 
the O 
nanoparticles O 
resulted O 
in O 
the O 
degradation O 
of O 
ca O 
. O 
24% O 
of O 
the O 
PDLLA B-ABBREVIATION 
core O 
into O 
lactic B-TRIVIAL 
acid I-TRIVIAL 
within O 
5 O 
d O 
, O 
as O 
opposed O 
to O 
only O 
ca O 
. O 
9% O 
degradation O 
from O 
aqueous O 
solutions O 
of O 
the O 
deg-cSCK O 
nanoparticles O 
in O 
the O 
absence O 
of O 
enzyme O 
. O 
Cellular O 
uptake O 
of O 
deg-cSCKs O 
was O 
efficient O 
, O 
while O 
exhibiting O 
low O 
cytotoxicity O 
with O 
LD50 O 
values O 
of O 
ca O 
. O 
90 O 
and O 
30 O 
μg O 
/ O 
mL O 
in O 
RAW O 
264.7 O 
mouse O 
macrophages O 
and O 
MLE O 
12 O 
cell O 
lines O 
, O 
respectively O 
, O 
ca O 
. O 
5- O 
to O 
6-fold O 
lower O 
than O 
the O 
cytotoxicity O 
observed O 
for O 
nondegradable O 
cSCK O 
analogs O 
. O 
Additionally O 
, O 
deg-cSCKs O 
were O 
able O 
to O 
complex O 
siRNA O 
at O 
an O 
N O 
/ O 
P O 
ratio O 
as O 
low O 
as O 
2 O 
, O 
and O 
were O 
efficiently O 
able O 
to O 
facilitate O 
cellular O 
uptake O 
of O 
the O 
complexed O 
nucleic O 
acids O 
. O 

Nanocarriers O 
with O 
Hydrogen B-SYSTEMATIC 
Peroxide I-SYSTEMATIC 
-Triggered O 
Drug O 
Release O 
for O 
Cancer O 
Treatment O 
. O 

is O 
an O 
important O 
modality O 
in O 
cancer O 
treatment O 
. O 
The O 
major O 
challenge O 
of O 
recent O 
works O 
in O 
this O 
research O 
field O 
is O 
to O 
develop O 
new O 
types O 
of O 
smart O 
nanocarriers O 
that O 
can O 
respond O 
selectively O 
to O 
cancer O 
cell O 
- O 
specific O 
conditions O 
and O 
realize O 
rapid O 
drug O 
release O 
in O 
target O 
cells O 
. O 
In O 
the O 
present O 
study O 
, O 
a O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
- O 
responsive O 
nanocarrier O 
has O 
been O 
successfully O 
self O 
- O 
assembled O 
from O 
an O 
amphiphilic O 
hyperbranched O 
polymer O 
consisting O 
of O 
alternative O 
hydrophobic O 
selenide B-SYSTEMATIC 
groups O 
and O 
hydrophilic O 
phosphate B-SYSTEMATIC 
segments O 
in O 
the O 
dendritic O 
backbone O 
. O 
Because O 
the O 
hydrophobic O 
selenide B-SYSTEMATIC 
groups O 
transformed O 
into O 
the O 
hydrophilic O 
selenone B-FAMILY 
groups O 
after O 
oxidation O 
under O 
the O 
exclusive O 
oxidative O 
microenvironment O 
within O 
cancer O 
cells O 
, O 
the O 
amphiphilic O 
hyperbranched O 
precursors O 
become O 
hydrophilic O 
ones O 
. O 
As O 
a O 
result O 
, O 
the O 
nanocarriers O 
were O 
rapidly O 
disassembled O 
in O 
target O 
cells O 
, O 
resulting O 
in O 
fast O 
intracellular O 
drug O 
release O 
. O 
The O 
hydrophilic O 
products O 
of O 
oxidation O 
can O 
be O 
degraded O 
into O 
harmless O 
small O 
molecular O 
species O 
via O 
the O 
enzymatic O 
digestion O 
of O 
the O 
phosphate B-SYSTEMATIC 
segments O 
and O 
then O 
eliminated O 
by O 
renal O 
excretion O 
. O 
Meanwhile O 
, O 
the O 
reactive O 
selenium B-SYSTEMATIC 
-containing O 
nanocarrier O 
possesses O 
a O 
potent O 
intrinsic O 
anticancer O 
effect O 
since O 
selenium B-SYSTEMATIC 
compounds O 
can O 
produce O 
antitumor O 
metabolites O 
which O 
induce O 
apoptosis O 
of O 
cancer O 
cells O 
efficiently O 
. O 
Therefore O 
, O 
this O 
type O 
of O 
therapeutic O 
nanocarriers O 
with O 
a O 
unique O 
drug O 
release O 
mechanism O 
based O 
on O 
an O 
amphiphilic O 
- O 
to O 
- O 
hydrophilic O 
transition O 
provides O 
a O 
new O 
platform O 
for O 
targeted O 
drug O 
delivery O 
and O 
combined O 
therapy O 
. O 

anhydrase O 
inhibitors O 
: O 
Inhibition O 
of O 
the O 
β-class O 
enzyme O 
from O 
the O 
pathogenic O 
yeast O 
Candida O 
glabrata O 
with O 
sulfonamides B-FAMILY 
, O 
sulfamates B-FAMILY 
and O 
sulfamides B-FAMILY 
. O 

fungal O 
pathogen O 
Candida O 
glabrata O 
encodes O 
for O 
a O 
β-carbonic O 
anhydrase O 
( O 
CA O 
, O 
EC O 
4.2.1.1 O 
) O 
, O 
CgNce103 O 
, O 
recently O 
discovered O 
. O 
Only O 
anions O 
have O 
been O 
investigated O 
as O 
CgNce103 O 
inhibitors O 
up O 
until O 
now O 
. O 
Here O 
we O 
report O 
the O 
first O 
sulfonamides B-FAMILY 
inhibition O 
study O 
of O 
this O 
enzyme O 
. O 
Simple O 
sulfonamides B-FAMILY 
showed O 
weak O 
or O 
moderate O 
CgNce103 O 
inhibitory O 
properties O 
, O 
whereas O 
acetazolamide B-TRIVIAL 
, O 
and O 
a O 
series O 
of O 
4- B-FAMILY 
substituted I-FAMILY 
ureido I-FAMILY 
- I-FAMILY 
benzene I-FAMILY 
- I-FAMILY 
sulfonamides I-FAMILY 
, O 
sulfamates B-FAMILY 
and O 
sulfamides B-FAMILY 
showed O 
effective O 
CgNce103 O 
inhibitory O 
properties O 
, O 
with O 
KIs O 
in O 
the O 
range O 
of O 
4.1-115nM O 
, O 
being O 
also O 
ineffective O 
as O 
human O 
CA O 
II O 
inhibitors O 
. O 
As O 
there O 
is O 
significant O 
resistance O 
of O 
C O 
. O 
glabrata O 
clinical O 
isolates O 
to O 
many O 
classical O 
antifungal O 
agents O 
, O 
inhibition O 
of O 
the O 
β-CA O 
from O 
this O 
organism O 
may O 
allow O 
an O 
interesting O 
means O 
of O 
controlling O 
the O 
pathogen O 
growth O 
, O 
eventually O 
leading O 
to O 
antifungals O 
with O 
a O 
novel O 
mechanism O 
of O 
action O 
. O 

present O 
a O 
programmable O 
, O 
biocompatible O 
technique O 
for O 
dynamically O 
concentrating O 
and O 
patterning O 
particles O 
and O 
cells O 
in O 
a O 
microfluidic O 
device O 
. O 
Since O 
our O 
technique O 
utilizes O 
opto O 
- O 
thermally O 
generated O 
, O 
acoustically O 
activated O 
, O 
surface O 
bubbles O 
, O 
we O 
name O 
it O 
" O 
optoacoustic O 
tweezers O 
" O 
. O 
The O 
optoacoustic O 
tweezers O 
are O 
capable O 
of O 
concentrating O 
particles O 
/ O 
cells O 
at O 
any O 
prescribed O 
locations O 
in O 
a O 
microfluidic O 
chamber O 
without O 
the O 
use O 
of O 
permanent O 
structures O 
, O 
rendering O 
it O 
particularly O 
useful O 
for O 
the O 
formation O 
of O 
flexible O 
, O 
complex O 
cell O 
patterns O 
. O 
Additionally O 
, O 
this O 
technique O 
has O 
demonstrated O 
excellent O 
biocompatibility O 
and O 
can O 
be O 
conveniently O 
integrated O 
with O 
other O 
microfluidic O 
units O 
. O 
In O 
our O 
experiments O 
, O 
micro O 
- O 
bubbles O 
were O 
generated O 
by O 
focusing O 
a O 
405 O 
nm O 
diode O 
laser O 
onto O 
a O 
gold O 
- O 
coated O 
glass O 
chamber O 
. O 
By O 
properly O 
tuning O 
the O 
laser O 
, O 
we O 
demonstrate O 
precise O 
control O 
over O 
the O 
position O 
and O 
size O 
of O 
the O 
generated O 
bubbles O 
. O 
Acoustic O 
waves O 
were O 
then O 
applied O 
to O 
activate O 
the O 
surface O 
bubbles O 
, O 
causing O 
them O 
to O 
oscillate O 
at O 
an O 
optimized O 
frequency O 
. O 
The O 
resulting O 
acoustic O 
radiation O 
force O 
allowed O 
us O 
to O 
locally O 
trap O 
particles O 
/ O 
cells O 
, O 
including O 
15 O 
μm O 
polystyrene B-SYSTEMATIC 
beads O 
and O 
HeLa O 
cells O 
, O 
around O 
each O 
bubble O 
. O 
Cell O 
- O 
adhesion O 
tests O 
were O 
also O 
conducted O 
after O 
cell O 
concentrating O 
to O 
confirm O 
the O 
biocompatibility O 
of O 
this O 
technique O 
. O 

pharmacokinetics O 
of O 
intramuscular O 
artesunate B-TRIVIAL 
in O 
african O 
children O 
with O 
severe O 
malaria O 
: O 
implications O 
for O 
a O 
practical O 
dosing O 
regimen O 
. O 

artesunate B-TRIVIAL 
( O 
ARS B-ABBREVIATION 
) O 
is O 
the O 
drug O 
of O 
choice O 
for O 
the O 
treatment O 
of O 
severe O 
malaria O 
. O 
Pharmacokinetics O 
data O 
on O 
intramuscular O 
ARS B-ABBREVIATION 
are O 
limited O 
with O 
respect O 
to O 
the O 
main O 
treatment O 
group O 
that O 
carries O 
the O 
highest O 
mortality O 
, O 
namely O 
, O 
critically O 
ill O 
children O 
with O 
severe O 
malaria O 
. O 
A O 
population O 
pharmacokinetic O 
study O 
of O 
ARS B-ABBREVIATION 
and O 
dihydroartemisinin B-SYSTEMATIC 
( O 
DHA B-ABBREVIATION 
) O 
was O 
conducted O 
from O 
sparse O 
sampling O 
in O 
70 O 
Tanzanian O 
children O 
of O 
ages O 
6 O 
months O 
to O 
11 O 
years O 
. O 
All O 
the O 
children O 
had O 
been O 
admitted O 
with O 
severe O 
falciparum O 
malaria O 
and O 
were O 
treated O 
with O 
intramuscular O 
ARS B-ABBREVIATION 
( O 
2.4 O 
mg O 
/ O 
kg O 
at O 
0 O 
, O 
12 O 
, O 
and O 
24 O 
h O 
) O 
. O 
Venous O 
plasma O 
concentration O 
- O 
time O 
profiles O 
were O 
characterized O 
using O 
nonlinear O 
mixed O 
- O 
effects O 
modeling O 
( O 
NONMEM O 
) O 
. O 
A O 
one O 
- O 
compartment O 
disposition O 
model O 
accurately O 
described O 
first O 
- O 
dose O 
population O 
pharmacokinetics O 
of O 
ARS B-ABBREVIATION 
and O 
DHA B-ABBREVIATION 
. O 
Body O 
weight O 
significantly O 
affected O 
clearance O 
and O 
apparent O 
volume O 
of O 
distribution O 
( O 
P O 
< O 
0.001 O 
) O 
, O 
resulting O 
in O 
lower O 
ARS B-ABBREVIATION 
and O 
DHA B-ABBREVIATION 
exposure O 
levels O 
in O 
smaller O 
children O 
. O 
An O 
adapted O 
dosing O 
regimen O 
including O 
a O 
practical O 
dosing O 
table O 
per O 
weight O 
band O 
is O 
proposed O 
for O 
young O 
children O 
based O 
on O 
the O 
pharmacokinetic O 
model O 
. O 

copper B-SYSTEMATIC 
hyperaccumulation O 
phenotype O 
correlates O 
with O 
pathogenesis O 
in O 
Cryptococcus O 
neoformans O 
. O 

neoformans O 
is O 
a O 
major O 
human O 
pathogen O 
and O 
a O 
cause O 
of O 
meningoencephalitis O 
in O 
immunocompromised O 
patients O 
. O 
Many O 
factors O 
contribute O 
to O 
the O 
extraordinary O 
survivability O 
and O 
pathogenicity O 
of O 
this O 
fungus O 
in O 
humans O 
, O 
including O 
copper B-SYSTEMATIC 
homeostasis O 
pathways O 
. O 
Previous O 
work O 
has O 
shown O 
that O 
deletion O 
of O 
the O 
copper B-SYSTEMATIC 
-dependent O 
regulator O 
Cuf1 O 
results O 
in O 
decreased O 
virulence O 
and O 
dissemination O 
in O 
brain O 
infection O 
, O 
suggesting O 
that O 
copper B-SYSTEMATIC 
acquisition O 
is O 
important O 
to O 
the O 
persistence O 
of O 
this O 
pathogen O 
. O 
Here O 
, O 
we O 
show O 
that O 
the O 
minimal O 
copper B-SYSTEMATIC 
quota O 
of O 
C O 
. O 
neoformans O 
is O 
maintained O 
at O 
a O 
high O 
level O 
even O 
when O 
grown O 
under O 
conditions O 
of O 
stringent O 
copper B-SYSTEMATIC 
limitation O 
. O 
Intriguingly O 
, O 
when O 
this O 
fungal O 
pathogen O 
is O 
grown O 
in O 
standard O 
and O 
copper B-SYSTEMATIC 
-enriched O 
media O 
, O 
it O 
sequesters O 
even O 
higher O 
levels O 
of O 
this O 
essential O 
metal O 
, O 
achieving O 
levels O 
that O 
are O 
far O 
higher O 
than O 
non-pathogenic O 
S O 
. O 
cerevisiae O 
. O 
The O 
hypothesis O 
that O 
copper B-SYSTEMATIC 
acquisition O 
plays O 
an O 
essential O 
role O 
in O 
virulence O 
is O 
further O 
corroborated O 
by O 
the O 
findings O 
that O 
a O 
hypovirulent O 
CUF1-deletant O 
strain O 
of O 
C O 
. O 
neoformans O 
retrieved O 
from O 
infected O 
mice O 
contains O 
almost O 
a O 
6-fold O 
lower O 
concentration O 
of O 
intracellular O 
copper B-SYSTEMATIC 
than O 
the O 
pathogenic O 
wild O 
- O 
type O 
strain O 
. O 
The O 
concentration O 
difference O 
arises O 
in O 
part O 
from O 
larger O 
- O 
sized O 
cuf1Δ O 
cell O 
. O 
Under O 
in O 
vitro O 
growth O 
conditions O 
, O 
the O 
size O 
of O 
the O 
cuf1Δ O 
cells O 
is O 
normal O 
and O 
the O 
hypertrophy O 
phenotype O 
is O 
readily O 
induced O 
in O 
vitro O 
under O 
conditions O 
of O 
copper B-SYSTEMATIC 
starvation O 
. O 
Taken O 
together O 
, O 
these O 
data O 
suggest O 
that O 
acquisition O 
of O 
extraordinary O 
levels O 
of O 
copper B-SYSTEMATIC 
is O 
an O 
important O 
factor O 
in O 
the O 
survivability O 
of O 
the O 
pathogen O 
in O 
the O 
copper B-SYSTEMATIC 
-deplete O 
environment O 
of O 
infection O 
, O 
and O 
effective O 
copper B-SYSTEMATIC 
concentration O 
may O 
play O 
an O 
important O 
role O 
in O 
the O 
pathogenesis O 
of O 
C O 
. O 
neoformans O 
. O 

of O 
voltage O 
polarity O 
and O 
amplitude O 
on O 
electroforming O 
of O 
TiO2 B-FORMULA 
based O 
memristive O 
devices O 
. O 

/ O 
TiO2 B-FORMULA 
/ O 
Pt B-FORMULA 
/ O 
Ti B-FORMULA 
memristive O 
devices O 
were O 
electrically O 
formed O 
to O 
either O 
the O 
ON O 
or O 
OFF O 
state O 
using O 
voltages O 
of O 
the O 
same O 
polarity O 
but O 
with O 
different O 
amplitudes O 
. O 
The O 
forming O 
step O 
dictated O 
the O 
subsequent O 
switching O 
behaviour O 
. O 
A O 
qualitative O 
model O 
based O 
on O 
the O 
creation O 
and O 
migration O 
of O 
oxygen B-SYSTEMATIC 
vacancies O 
was O 
proposed O 
to O 
explain O 
the O 
experimental O 
results O 
. O 

Artemisinin B-TRIVIAL 
the O 
Only O 
Antiplasmodial O 
Compound O 
in O 
the O 
Artemisia O 
annua O 
Tea O 
Infusion O 
? O 
An O 
in O 
Vitro O 
Study O 
. O 

our O 
ongoing O 
investigation O 
into O 
Artemisia O 
annua O 
for O 
the O 
treatment O 
of O 
malaria O 
, O 
we O 
decided O 
to O 
study O 
the O 
possibility O 
that O 
synergism O 
might O 
enhance O 
the O 
efficacy O 
of O 
artemisinin B-TRIVIAL 
. O 
Our O 
main O 
objective O 
was O 
to O 
test O 
tea O 
infusions O 
and O 
nonpolar O 
extracts O 
prepared O 
from O 
different O 
A. O 
annua O 
varieties O 
against O 
Plasmodium O 
falciparum O 
in O 
vitro O 
in O 
order O 
to O 
determine O 
if O 
synergism O 
will O 
increase O 
the O 
effectiveness O 
of O 
artemisinin B-TRIVIAL 
in O 
the O 
samples O 
as O 
compared O 
to O 
pure O 
artemisinin B-TRIVIAL 
. O 
We O 
found O 
that O 
the O 
IC50 O 
of O 
artemisinin B-TRIVIAL 
in O 
the O 
tea O 
and O 
nonpolar O 
extracts O 
was O 
not O 
significantly O 
different O 
to O 
the O 
IC50 O 
of O 
pure O 
artemisinin B-TRIVIAL 
. O 
We O 
could O 
show O 
that O 
the O 
year O 
and O 
country O 
of O 
harvest O 
or O 
storage O 
conditions O 
did O 
not O 
have O 
any O 
influence O 
on O 
the O 
activity O 
and O 
that O 
it O 
narrowly O 
followed O 
the O 
concentration O 
of O 
artemisinin B-TRIVIAL 
in O 
all O 
the O 
extracts O 
. O 
In O 
conclusion O 
, O 
based O 
on O 
these O 
in O 
vitro O 
results O 
, O 
artemisinin B-TRIVIAL 
seems O 
to O 
be O 
the O 
only O 
active O 
antiplasmodial O 
compound O 
in O 
A. O 
annua O 
. O 

extract O 
is O 
a O 
long O 
used O 
medicinal O 
product O 
and O 
, O 
regarding O 
hormonal O 
activities O 
, O 
in O 
1999 O 
a O 
number O 
of O 
prenylflavanones B-FAMILY 
have O 
been O 
identified O 
as O 
its O 
major O 
constituents O 
with O 
8-prenylnaringenin B-SYSTEMATIC 
( O 
8-PN B-SYSTEMATIC 
) O 
being O 
the O 
main O 
active O 
estrogenic O 
compound O 
. O 
There O 
have O 
been O 
several O 
in O 
vivo O 
studies O 
performed O 
that O 
demonstrate O 
the O 
potential O 
of O 
hop O 
extract O 
and O 
the O 
single O 
compound O 
8-PN B-SYSTEMATIC 
to O 
alleviate O 
climacteric O 
symptoms O 
like O 
osteoporosis O 
, O 
vasomotoric O 
complaints O 
, O 
and O 
sexual O 
motivation O 
. O 
On O 
the O 
other O 
hand O 
, O 
only O 
a O 
few O 
clinical O 
studies O 
have O 
been O 
performed O 
so O 
far O 
, O 
and O 
these O 
mainly O 
focused O 
on O 
menopausal O 
discomforts O 
, O 
especially O 
hot O 
flushes O 
, O 
yielding O 
rather O 
inconclusive O 
results O 
. O 
Despite O 
preferentially O 
activating O 
estrogen B-FAMILY 
receptor O 
α O 
, O 
8-PN B-SYSTEMATIC 
is O 
only O 
slightly O 
uterotrophic O 
, O 
but O 
it O 
also O 
elucidates O 
estrogenic O 
effects O 
on O 
the O 
mammary O 
gland O 
. O 
In O 
conclusion O 
, O 
although O 
hop O 
extract O 
and O 
especially O 
8-PN B-SYSTEMATIC 
are O 
promising O 
candidates O 
as O 
a O 
relief O 
for O 
climacteric O 
symptoms O 
, O 
data O 
on O 
the O 
safety O 
and O 
efficacy O 
is O 
still O 
scarce O 
. O 

Ameliorates O 
Insulin O 
Resistance O 
Induced O 
by O 
High O 
Insulin O 
and O 
High O 
Glucose B-TRIVIAL 
through O 
the O 
mTOR O 
and O 
Signal O 
Pathway O 
. O 

mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
is O 
crucial O 
in O 
the O 
regulation O 
of O 
cell O 
growth O 
and O 
metabolism O 
. O 
Recent O 
studies O 
suggest O 
that O 
the O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
and O 
its O 
downstream O 
70-kDa O 
ribosomal O 
S6 O 
kinase O 
1 O 
negatively O 
modulate O 
the O 
insulin O 
- O 
signaling O 
pathway O 
, O 
which O 
is O 
considered O 
the O 
main O 
cause O 
of O 
insulin O 
resistance O 
. O 
The O 
aim O 
of O 
this O 
study O 
is O 
to O 
investigate O 
the O 
effects O 
of O 
cardamonin B-TRIVIAL 
, O 
a O 
potential O 
inhibitor O 
of O 
the O 
mammalian O 
target O 
of O 
the O 
rapamycin B-TRIVIAL 
, O 
on O 
insulin O 
- O 
resistant O 
vascular O 
smooth O 
muscle O 
cells O 
and O 
the O 
molecular O 
mechanisms O 
involved O 
. O 
Vascular O 
smooth O 
muscle O 
cells O 
were O 
cultured O 
with O 
high O 
glucose B-TRIVIAL 
and O 
high O 
insulin O 
to O 
induce O 
insulin O 
resistance O 
. O 
The O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
was O 
overstimulated O 
in O 
cells O 
that O 
were O 
incubated O 
with O 
high O 
glucose B-TRIVIAL 
and O 
high O 
insulin O 
, O 
as O 
reflected O 
by O 
the O 
excessive O 
activation O 
of O 
S6 O 
kinase O 
1 O 
. O 
Insulin O 
- O 
resistant O 
vascular O 
smooth O 
muscle O 
cells O 
displayed O 
hyperphosphorylation O 
of O 
insulin O 
receptor O 
substrate-1 O 
at O 
Ser B-FORMULA 
residues O 
636 O 
/ O 
639 O 
, O 
which O 
decreased O 
the O 
activity O 
of O 
insulin O 
receptor O 
substrate-1 O 
. O 
Also O 
, O 
the O 
activation O 
of O 
protein O 
kinase O 
B O 
and O 
phosphorylation O 
of O 
glycogen O 
synthesis O 
kinase-3β O 
were O 
inhibited O 
. O 
Cardamonin B-TRIVIAL 
increased O 
the O 
2-deoxyglucose B-SYSTEMATIC 
uptake O 
and O 
glycogen O 
concentration O 
, O 
which O 
was O 
reduced O 
by O 
insulin O 
resistance O 
. O 
As O 
with O 
rapamycin B-TRIVIAL 
, O 
cardamonin B-TRIVIAL 
inhibited O 
the O 
activity O 
of O 
the O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
and O 
S6 O 
kinase O 
1 O 
, O 
decreased O 
the O 
Ser B-FORMULA 
636 O 
/ O 
639 O 
phosphorylation O 
of O 
insulin O 
receptor O 
substrate-1 O 
and O 
increased O 
the O 
activation O 
of O 
protein O 
kinase O 
B O 
. O 
Both O 
of O 
them O 
increased O 
the O 
Ser B-FORMULA 
9 O 
phosphorylation O 
of O 
glycogen O 
synthesis O 
kinase-3β O 
and O 
decreased O 
the O 
expression O 
of O 
glycogen O 
synthesis O 
kinase-3β O 
. O 
However O 
, O 
neither O 
cardamonin B-TRIVIAL 
nor O 
rapamycin B-TRIVIAL 
increased O 
the O 
expression O 
of O 
glucose B-TRIVIAL 
transport O 
4 O 
which O 
decreased O 
in O 
insulin O 
- O 
resistant O 
vascular O 
smooth O 
muscle O 
cells O 
. O 
This O 
study O 
suggests O 
that O 
cardamonin B-TRIVIAL 
inhibited O 
the O 
activity O 
of O 
the O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
and O 
eliminated O 
the O 
negative O 
feedback O 
of O 
the O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
and O 
S6 O 
kinase O 
1 O 
on O 
the O 
insulin O 
- O 
signaling O 
pathway O 
. O 

: O 
Quinone B-FAMILY 
Oxidoreductase O 
1 O 
Inducer O 
Activity O 
of O 
Some O 
Saudi O 
Arabian O 
Medicinal O 
Plants O 
. O 

plants O 
are O 
a O 
rich O 
source O 
of O 
biologically O 
- O 
active O 
phytochemicals O 
and O 
have O 
been O 
used O 
in O 
traditional O 
medicine O 
for O 
centuries O 
. O 
Specific O 
phytochemicals O 
and O 
extracts O 
of O 
their O 
plant O 
sources O 
have O 
the O 
ability O 
to O 
reduce O 
the O 
risk O 
for O 
chronic O 
degenerative O 
diseases O 
by O 
induction O 
of O 
enzymes O 
involved O 
in O 
xenobiotic O 
metabolism O 
, O 
many O 
of O 
which O 
also O 
have O 
antioxidant O 
and O 
anti-inflammatory O 
functions O 
. O 
One O 
such O 
multifunctional O 
cytoprotective O 
enzyme O 
is O 
NAD(P)H B-ABBREVIATION 
: O 
quinone B-FAMILY 
oxidoreductase O 
. O 
In O 
this O 
study O 
, O 
we O 
prepared O 
extracts O 
of O 
27 O 
Saudi O 
Arabian O 
medicinal O 
plants O 
which O 
belong O 
to O 
18 O 
different O 
plant O 
families O 
and O 
tested O 
their O 
ability O 
to O 
induce O 
NAD(P)H B-ABBREVIATION 
: O 
quinone B-FAMILY 
oxidoreductase O 
in O 
murine O 
hepatoma O 
cells O 
grown O 
in O 
microtiter O 
plate O 
wells O 
. O 
In O 
addition O 
to O 
the O 
Brassicaceae O 
, O 
a O 
known O 
source O 
of O 
NAD(P)H B-ABBREVIATION 
: O 
quinone B-FAMILY 
oxidoreductase O 
inducer O 
activity O 
, O 
we O 
found O 
substantial O 
inducer O 
activity O 
in O 
extracts O 
from O 
the O 
Apiaceae O 
, O 
Apocynaceae O 
, O 
and O 
the O 
Asteraceae O 
families O 
. O 
Five O 
out O 
of O 
a O 
total O 
of O 
eight O 
active O 
extracts O 
are O 
from O 
plants O 
which O 
belong O 
to O 
the O 
Asteraceae O 
family O 
. O 
We O 
further O 
show O 
that O 
artemisinin B-TRIVIAL 
, O 
an O 
agent O 
which O 
is O 
used O 
clinically O 
for O 
the O 
treatment O 
of O 
malaria O 
, O 
contributes O 
but O 
does O 
not O 
fully O 
account O 
for O 
the O 
inducer O 
activity O 
of O 
the O 
extract O 
of O 
Artemisia O 
monosperma O 
. O 
In O 
contrast O 
to O 
artemisinin B-TRIVIAL 
, O 
deoxyartemisinin B-SYSTEMATIC 
is O 
inactive O 
in O 
this O 
assay O 
, O 
demonstrating O 
the O 
critical O 
role O 
of O 
the O 
endoperoxide O 
moiety O 
of O 
artemisinin B-TRIVIAL 
for O 
inducer O 
activity O 
. O 
Thus O 
, O 
the O 
NAD(P)H B-ABBREVIATION 
: O 
quinone B-FAMILY 
oxidoreductase O 
inducer O 
activity O 
of O 
extracts O 
of O 
some O 
Saudi O 
Arabian O 
medicinal O 
plants O 
indicates O 
the O 
presence O 
of O 
specific O 
phytochemicals O 
which O 
have O 
the O 
potential O 
to O 
protect O 
against O 
chronic O 
degenerative O 
diseases O 
. O 

protective O 
effects O 
of O 
ω-3 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
on O 
doxorubicin B-TRIVIAL 
-induced O 
hepatotoxicity O 
and O 
nephrotoxicity O 
in O 
rats O 
. O 

study O 
aims O 
to O 
evaluate O 
the O 
protective O 
effects O 
of O 
ω-3 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
FAs B-ABBREVIATION 
) O 
on O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
)-induced O 
hepatotoxicity O 
and O 
nephrotoxicity O 
in O 
rats O 
. O 
A O 
total O 
of O 
24 O 
adult O 
male O 
Sprague O 
Dawley O 
rats O 
were O 
divided O 
into O 
three O 
groups O 
. O 
Control O 
group O 
was O 
given O 
only O 
saline O 
by O 
intragastric O 
gavage O 
. O 
DOX B-ABBREVIATION 
group O 
received O 
DOX B-ABBREVIATION 
at O 
the O 
dose O 
of O 
30 O 
mg O 
/ O 
kg O 
intraperitoneally O 
on O 
day O 
28 O 
. O 
DOX-ω-3 B-SYSTEMATIC 
FA I-SYSTEMATIC 
group O 
was O 
given O 
as O 
ω-3 B-FAMILY 
FAs I-FAMILY 
at O 
the O 
dose O 
of O 
400 O 
mg O 
/ O 
kg O 
daily O 
by O 
intragastric O 
gavage O 
for O 
30 O 
days O 
and O 
received O 
DOX B-ABBREVIATION 
at O 
the O 
dose O 
of O 
30 O 
mg O 
/ O 
kg O 
intraperitoneally O 
on O 
day O 
28 O 
. O 
At O 
the O 
end O 
of O 
the O 
30-day O 
experimental O 
period O 
, O 
the O 
serum O 
, O 
liver O 
and O 
kidney O 
tissue O 
specimens O 
were O 
taken O 
from O 
the O 
animals O 
by O 
giving O 
a O 
general O 
anesthesia O 
. O 
Glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
and O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
levels O 
in O 
serum O 
and O 
GSH B-ABBREVIATION 
and O 
MDA B-ABBREVIATION 
levels O 
and O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GSH B-ABBREVIATION 
-Px O 
) O 
activities O 
in O 
liver O 
and O 
kidney O 
tissues O 
were O 
measured O 
spectrophotometrically O 
. O 
In O 
our O 
study O 
, O 
a O 
significant O 
increase O 
in O 
MDA B-ABBREVIATION 
levels O 
was O 
observed O 
in O 
rats O 
when O 
given O 
a O 
dose O 
of O 
DOX B-ABBREVIATION 
and O 
a O 
significant O 
decrease O 
in O 
the O 
levels O 
of O 
GSH B-ABBREVIATION 
, O 
SOD O 
and O 
GSH B-ABBREVIATION 
-Px O 
activities O 
in O 
serum O 
, O 
liver O 
and O 
kidney O 
tissues O 
was O 
determined O 
when O 
compared O 
with O 
control O 
group O 
. O 
In O 
addition O 
, O 
a O 
significant O 
decrease O 
in O 
MDA B-ABBREVIATION 
levels O 
was O 
observed O 
in O 
rats O 
when O 
a O 
dose O 
of O 
ω-3 B-FAMILY 
FAs I-FAMILY 
was O 
given O 
with O 
DOX B-ABBREVIATION 
and O 
a O 
significant O 
increase O 
was O 
determined O 
in O 
the O 
levels O 
of O 
GSH B-ABBREVIATION 
, O 
SOD O 
and O 
GSH B-ABBREVIATION 
-Px O 
activities O 
in O 
serum O 
, O 
liver O 
and O 
kidney O 
tissues O 
, O 
when O 
compared O 
with O 
DOX B-ABBREVIATION 
group O 
. O 
We O 
concluded O 
that O 
ω-3 B-SYSTEMATIC 
FA I-SYSTEMATIC 
had O 
favorable O 
effects O 
in O 
rat O 
liver O 
and O 
kidney O 
tissues O 
by O 
preventing O 
oxidative O 
damage O 
. O 

of O 
Beclomethasone B-SYSTEMATIC 
Dipropionate I-SYSTEMATIC 
by O 
Cytochrome O 
P450 O 
3A O 
Enzymes O 
. O 

glucocorticoids O 
, O 
such O 
as O 
beclomethasone B-SYSTEMATIC 
dipropionate I-SYSTEMATIC 
( O 
BDP B-ABBREVIATION 
) O 
, O 
are O 
the O 
mainstay O 
treatment O 
of O 
asthma O 
. O 
However O 
, O 
∼30% O 
of O 
patients O 
exhibit O 
little O 
to O 
no O 
benefit O 
from O 
treatment O 
. O 
It O 
has O 
been O 
postulated O 
that O 
glucocorticoid O 
resistance O 
, O 
or O 
insensitivity O 
, O 
is O 
attributable O 
to O 
individual O 
differences O 
in O 
glucocorticoid O 
receptor O 
- O 
mediated O 
processes O 
. O 
It O 
is O 
possible O 
that O 
variations O 
in O 
cytochrome O 
P450 O 
3A O 
enzyme O 
- O 
mediated O 
metabolism O 
of O 
BDP B-ABBREVIATION 
may O 
contribute O 
to O 
this O 
phenomenon O 
. O 
This O 
hypothesis O 
was O 
explored O 
by O 
evaluating O 
the O 
contributions O 
of O 
CYP3A4 O 
, O 
3A5 O 
, O 
3A7 O 
, O 
and O 
esterase O 
enzymes O 
in O 
the O 
metabolism O 
of O 
BDP B-ABBREVIATION 
in O 
vitro O 
and O 
relating O 
metabolism O 
to O 
changes O 
in O 
CYP3A O 
enzyme O 
mRNA O 
expression O 
via O 
the O 
glucocorticoid O 
receptor O 
in O 
lung O 
and O 
liver O 
cells O 
. O 
CYP3A4 O 
and O 
CYP3A5 O 
metabolized O 
BDP B-ABBREVIATION 
via O 
hydroxylation O 
( O 
[ O 
M4 O 
] O 
and O 
[ O 
M6 O 
] O 
) O 
and O 
dehydrogenation O 
([M5]) O 
at O 
similar O 
rates O 
; O 
CYP3A7 O 
did O 
not O 
metabolize O 
BDP B-ABBREVIATION 
. O 
A O 
new O 
metabolite O 
[ O 
M6 O 
] O 
, O 
formed O 
by O 
the O 
combined O 
action O 
of O 
esterases O 
and O 
CYP3A4 O 
hydroxylation O 
, O 
was O 
also O 
characterized O 
. O 
To O 
validate O 
the O 
results O 
observed O 
using O 
microsomes O 
and O 
recombinant O 
enzymes O 
, O 
studies O 
were O 
also O 
conducted O 
using O 
A549 O 
lung O 
and O 
DPX2 O 
liver O 
cells O 
. O 
Both O 
liver O 
and O 
lung O 
cells O 
produced O 
esterase O 
- O 
dependent O 
metabolites O 
[ O 
M1-M3 O 
] O 
, O 
with O 
[ O 
M1 O 
] O 
correlating O 
with O 
CYP3A5 O 
mRNA O 
induction O 
in O 
A549 O 
cells O 
. O 
Liver O 
cells O 
produced O 
both O 
hydroxylated O 
and O 
dehydrogenated O 
metabolites O 
[ O 
M4 O 
, O 
M5 O 
, O 
and O 
M6 O 
] O 
, O 
but O 
lung O 
cells O 
produced O 
only O 
the O 
dehydrogenated O 
metabolite O 
[ O 
M5 O 
] O 
. O 
These O 
studies O 
show O 
that O 
CYP3A4 O 
and O 
CYP3A5 O 
metabolize O 
BDP B-ABBREVIATION 
to O 
inactive O 
metabolites O 
and O 
suggest O 
that O 
differences O 
in O 
the O 
expression O 
or O 
function O 
of O 
these O 
enzymes O 
in O 
the O 
lung O 
and O 
/ O 
or O 
liver O 
could O 
influence O 
BDP B-ABBREVIATION 
disposition O 
in O 
humans O 
. O 

Tumor O 
Suppressor O 
Kruppel O 
- O 
Like O 
Factor O 
6 O 
is O 
a O 
Novel O 
Aryl B-FAMILY 
Hydrocarbon I-FAMILY 
Receptor O 
DNA O 
Binding O 
Partner O 
. O 

Aryl B-FAMILY 
Hydrocarbon I-FAMILY 
Receptor O 
( O 
AhR O 
) O 
is O 
a O 
ligand O 
mediated O 
basic O 
helix O 
- O 
loop O 
- O 
helix O 
transcription O 
factor O 
of O 
Per O 
/ O 
Arnt O 
/ O 
Sim O 
family O 
that O 
regulates O 
adaptive O 
and O 
toxic O 
responses O 
to O 
variety O 
of O 
chemical O 
pollutants O 
including O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PAH B-ABBREVIATION 
) O 
and O 
halogenated B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
, O 
most O 
notably O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
. O 
Ligand O 
activation O 
leads O 
to O 
AhR O 
nuclear O 
translocation O 
and O 
binding O 
to O 
a O 
xenobiotic O 
response O 
element O 
( O 
XRE O 
) O 
in O 
association O 
with O 
the O 
aryl O 
receptor O 
nuclear O 
translocator O 
( O 
Arnt O 
) O 
to O 
regulate O 
gene O 
expression O 
. O 
Several O 
recent O 
genome O 
- O 
wide O 
transcriptional O 
studies O 
identified O 
numerous O 
AhR O 
target O 
genes O 
that O 
lack O 
the O 
canonical O 
XRE O 
recognition O 
site O 
in O 
the O 
promoter O 
regions O 
. O 
Characterization O 
of O 
one O 
such O 
target O 
gene O 
, O 
the O 
Plasminogen O 
Activator O 
Inhibitor O 
1 O 
( O 
PAI-1 O 
) O 
identified O 
a O 
novel O 
non-consensus O 
XRE O 
( O 
NC-XRE O 
) O 
that O 
confers O 
TCDD B-ABBREVIATION 
responsiveness O 
independently O 
of O 
the O 
Arnt O 
protein O 
. O 
Studies O 
reported O 
here O 
show O 
that O 
the O 
NC-XRE O 
is O 
a O 
recognition O 
site O 
for O 
the O 
AhR O 
and O 
a O 
new O 
binding O 
partner O 
, O 
the O 
Kruppel O 
- O 
like O 
Factor O 
( O 
KLF O 
) O 
family O 
member O 
KLF6 O 
. O 
In O 
vivo O 
chromatin O 
immunoprecipitations O 
and O 
in O 
vitro O 
DNA O 
binding O 
studies O 
demonstrate O 
that O 
the O 
AhR O 
and O 
KLF6 O 
proteins O 
form O 
an O 
obligatory O 
heterodimer O 
necessary O 
for O 
NC-XRE O 
binding O 
. O 
Mutational O 
analyzes O 
show O 
that O 
the O 
protein O 
- O 
protein O 
interactions O 
involve O 
the O 
AhR O 
C-terminus O 
and O 
KLF6 O 
N-terminus O 
, O 
respectively O 
. O 
Moreover O 
, O 
NC-XRE O 
binding O 
depends O 
on O 
the O 
5 O 
' O 
basic O 
region O 
in O 
KLF6 O 
rather O 
than O 
the O 
previously O 
characterized O 
zinc B-SYSTEMATIC 
finger O 
DNA O 
binding O 
domain O 
. O 
Collectively O 
, O 
the O 
results O 
unmask O 
a O 
novel O 
AhR O 
signaling O 
mechanism O 
distinct O 
from O 
the O 
canonical O 
XRE-driven O 
process O 
that O 
will O 
enrich O 
our O 
future O 
understanding O 
of O 
AhR O 
biology O 
. O 

Inhibits O 
Collagen O 
Production O 
of O 
Nasal O 
Polyp O 
- O 
Derived O 
Fibroblasts O 
. O 

polyps O 
are O 
chronic O 
inflammatory O 
conditions O 
characterized O 
by O 
myofibroblast O 
differentiation O 
and O 
extracelluar O 
matrix O 
accumulation O 
. O 
The O 
major O 
catechin B-TRIVIAL 
from O 
green O 
tea O 
is O 
(-)-epigallocatechin-3-gallate B-TRIVIAL 
( O 
EGCG B-ABBREVIATION 
) O 
, O 
which O 
has O 
garnered O 
attention O 
for O 
its O 
potential O 
to O 
prevent O 
oxidative O 
stress O 
- O 
related O 
diseases O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
twofold O 
: O 
(i) O 
to O 
determine O 
the O 
effect O 
of O 
EGCG B-ABBREVIATION 
on O 
fibroblast O 
differentiation O 
into O 
myofibroblasts O 
and O 
extracellular O 
matrix O 
accumulation O 
in O 
transforming O 
growth O 
factor O 
(TGF)-β1-induced O 
nasal O 
polyp O 
- O 
derived O 
fibroblasts O 
( O 
NPDFs O 
) O 
and O 
(ii) O 
to O 
determine O 
if O 
the O 
antioxidative O 
effect O 
of O 
EGCG B-ABBREVIATION 
on O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
production O 
in O 
TGF-β1-induced O 
NPDFs O 
is O 
involved O 
in O 
the O 
aforementioned O 
processes O 
. O 
TGF-β1-induced O 
NPDFs O 
were O 
treated O 
with O 
or O 
without O 
EGCG B-ABBREVIATION 
. O 
α-smooth O 
muscle O 
actin O 
( O 
α-SMA O 
) O 
and O 
collagen O 
type O 
I O 
mRNA O 
were O 
analyzed O 
by O 
reverse O 
transcription O 
- O 
polymerase O 
chain O 
reaction O 
. O 
α-SMA O 
protein O 
was O 
also O 
detected O 
using O 
immunofluorescent O 
staining O 
. O 
The O 
amount O 
of O 
total O 
soluble O 
collagen O 
was O 
analyzed O 
by O 
Sircol B-TRIVIAL 
collagen O 
assay O 
. O 
ROS O 
activity O 
was O 
measured O 
by O 
the O 
nitroblue B-TRIVIAL 
tetrazolium I-TRIVIAL 
reduction O 
assay O 
and O 
visualized O 
by O 
fluorescent O 
microscopy O 
. O 
EGCG B-ABBREVIATION 
significantly O 
inhibited O 
expressions O 
of O 
α-SMA O 
and O 
collagen O 
type O 
I O 
mRNA O 
and O 
reduced O 
α-SMA O 
and O 
collagen O 
protein O 
levels O 
at O 
concentrations O 
of O 
10-20 O 
µg O 
/ O 
mL O 
. O 
EGCG B-ABBREVIATION 
also O 
inhibited O 
TGF-β1-induced O 
ROS O 
production O 
at O 
the O 
same O 
concentrations O 
. O 
These O 
results O 
suggest O 
the O 
possibility O 
that O 
EGCG B-ABBREVIATION 
may O 
be O 
effective O 
at O 
inhibiting O 
the O 
development O 
of O 
nasal O 
polyps O 
through O 
an O 
anti-oxidant O 
effect O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

Effects O 
of O 
Puerarin B-TRIVIAL 
on O 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine B-SYSTEMATIC 
induced O 
Parkinson's O 
Disease O 
Model O 
in O 
Mice O 
. O 

, O 
an O 
active O 
component O 
of O 
Pueraria O 
montana O 
var O 
. O 
lobata O 
( O 
Willd O 
. O 
) O 
Sanjappa O 
& O 
Pradeep O 
is O 
well O 
- O 
known O 
for O 
its O 
anti-oxidative O 
and O 
neuroprotective O 
activities O 
. O 
Although O 
anti-Parkinson's O 
disease O 
activity O 
of O 
puerarin B-TRIVIAL 
was O 
reported O 
in O 
both O 
of O 
in O 
vivo O 
and O 
in O 
vitro O 
model O 
, O 
detailed O 
mechanisms O 
are O 
not O 
clarified O 
. O 
In O 
this O 
study O 
, O 
we O 
addressed O 
that O 
puerarin B-TRIVIAL 
attenuated O 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine B-SYSTEMATIC 
( O 
MPTP B-ABBREVIATION 
)-induced O 
behavioral O 
deficits O 
, O 
dopaminergic O 
neuronal O 
degeneration O 
and O 
dopamine B-TRIVIAL 
depletion O 
. O 
Puerarin B-TRIVIAL 
administration O 
enhanced O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
activity O 
, O 
glial O 
cell O 
line O 
- O 
derived O 
neurotrophic O 
factor O 
( O 
GDNF O 
) O 
expression O 
and O 
PI3K O 
/ O 
Akt O 
pathway O 
activation O 
, O 
which O 
might O 
ameliorate O 
MPTP B-ABBREVIATION 
injection O 
- O 
induced O 
progressive O 
elevation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
formation O 
in O 
mice O 
. O 
In O 
addition O 
to O 
the O 
effect O 
on O 
ROS O 
, O 
puerarin B-TRIVIAL 
ameliorated O 
MPTP B-ABBREVIATION 
-reduced O 
lysosome O 
- O 
associated O 
membrane O 
protein O 
type O 
2A O 
( O 
Lamp O 
2A O 
) O 
expression O 
. O 
Taken O 
together O 
, O 
our O 
data O 
demonstrate O 
that O 
puerarin B-TRIVIAL 
attenuates O 
MPTP B-ABBREVIATION 
-induced O 
dopaminergic O 
neuronal O 
degeneration O 
via O 
modulating O 
GDNF O 
expression O 
, O 
PI3K O 
/ O 
Akt O 
pathway O 
and O 
GSH B-ABBREVIATION 
activation O 
, O 
which O 
subsequently O 
ameliorate O 
MPTP B-ABBREVIATION 
-induced O 
ROS O 
formation O 
and O 
decrease O 
of O 
Lamp O 
2A O 
expression O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

synthases O 
( O 
AHASs O 
) O 
, O 
which O 
catalyze O 
the O 
first O 
step O 
in O 
the O 
biosynthesis O 
of O 
branched O 
- O 
chain O 
amino B-FAMILY 
acids I-FAMILY 
, O 
are O 
composed O 
of O 
a O 
catalytic O 
subunit O 
( O 
CSU O 
) O 
and O 
a O 
regulatory O 
subunit O 
( O 
RSU O 
) O 
. O 
The O 
CSU O 
harbors O 
the O 
catalytic O 
site O 
, O 
and O 
the O 
RSU O 
is O 
responsible O 
for O 
the O 
activation O 
and O 
feedback O 
regulation O 
of O 
the O 
CSU O 
. O 
Previous O 
results O 
from O 
Chipman O 
and O 
co O 
- O 
workers O 
and O 
our O 
lab O 
have O 
shown O 
that O 
heterologous O 
activation O 
can O 
be O 
achieved O 
among O 
isozymes O 
of O 
Escherichia O 
coli O 
AHAS O 
. O 
It O 
would O 
be O 
interesting O 
to O 
find O 
the O 
minimum O 
peptide O 
of O 
ilvH O 
( O 
the O 
RSU O 
of O 
E O 
. O 
coli O 
AHAS O 
III O 
) O 
that O 
could O 
activate O 
other O 
E O 
. O 
coli O 
CSUs O 
, O 
or O 
even O 
those O 
of O 
## O 
species O 
. O 
In O 
this O 
paper O 
, O 
C B-FORMULA 
-terminal O 
, O 
N B-FORMULA 
-terminal O 
, O 
and O 
C B-FORMULA 
- O 
and O 
N B-FORMULA 
-terminal O 
truncation O 
mutants O 
of O 
ilvH O 
were O 
constructed O 
. O 
The O 
minimum O 
peptide O 
to O 
activate O 
ilvI O 
( O 
the O 
CSU O 
of O 
E O 
. O 
coli O 
AHAS O 
III O 
) O 
was O 
found O 
to O 
be O 
ΔN O 
14-ΔC O 
89 O 
. O 
Moreover O 
, O 
this O 
peptide O 
could O 
not O 
only O 
activate O 
its O 
homologous O 
ilvI O 
and O 
heterologous O 
ilvB O 
( O 
CSU O 
of O 
E O 
. O 
coli O 
AHAS O 
I O 
) O 
, O 
but O 
also O 
heterologously O 
activate O 
the O 
CSUs O 
of O 
AHAS O 
from O 
Saccharomyces O 
cerevisiae O 
, O 
Arabidopsis O 
thaliana O 
, O 
and O 
Nicotiana O 
plumbaginifolia O 
. O 
However O 
, O 
this O 
peptide O 
totally O 
lost O 
its O 
ability O 
for O 
feedback O 
regulation O 
by O 
valine B-TRIVIAL 
, O 
thus O 
suggesting O 
different O 
elements O 
for O 
enzymatic O 
activation O 
and O 
feedback O 
regulation O 
. O 
Additionally O 
, O 
the O 
apparent O 
dissociation O 
constant O 
( O 
Kd O 
) O 
of O 
ΔN O 
14-ΔC O 
89 O 
when O 
binding O 
CSUs O 
of O 
different O 
species O 
was O 
found O 
to O 
be O 
9.3-66.5 O 
μM O 
by O 
using O 
microscale O 
thermophoresis O 
. O 
The O 
ability O 
of O 
this O 
peptide O 
to O 
activate O 
different O 
CSUs O 
does O 
not O 
correlate O 
well O 
with O 
its O 
binding O 
ability O 
( O 
Kd O 
) O 
to O 
these O 
CSUs O 
, O 
thus O 
implying O 
that O 
key O 
interactions O 
by O 
specific O 
residues O 
is O 
more O 
important O 
than O 
binding O 
ability O 
in O 
promoting O 
enzymatic O 
reactions O 
. O 
The O 
high O 
sequence O 
similarity O 
of O 
the O 
peptide O 
ΔN O 
14-ΔC O 
89 O 
to O 
RSUs O 
across O 
species O 
hints O 
that O 
this O 
peptide O 
represents O 
the O 
minimum O 
activation O 
motif O 
in O 
RSU O 
and O 
that O 
it O 
regulates O 
all O 
AHASs O 
. O 

meso-tetra(2,6-dichloro-3-sulfonatophenyl)porphyrinate B-SYSTEMATIC 
of O 
manganese B-SYSTEMATIC 
(III) I-SYSTEMATIC 
chloride I-SYSTEMATIC 
[ B-FORMULA 
Mn-(TDCPPS)Cl I-FORMULA 
] I-FORMULA 
biomimetic O 
catalyst O 
immobilized O 
on O 
spacer O 
- O 
functionalized O 
kaolinite B-TRIVIAL 
clay O 
mineral O 
was O 
employed O 
in O 
the O 
oxidative O 
coupling O 
reaction O 
of O 
a O 
dissolved O 
humic O 
acid O 
( O 
HA O 
) O 
suprastructure O 
with O 
either O 
chemical O 
( O 
H2O2 B-FORMULA 
) O 
or O 
UV-light O 
oxidation O 
. O 
The O 
changes O 
in O 
molecular O 
size O 
of O 
humic O 
matter O 
subjected O 
to O 
catalyzed O 
oxidative O 
reaction O 
were O 
followed O 
by O 
high O 
- O 
performance O 
size O 
exclusion O 
chromatography O 
( O 
HPSEC O 
) O 
with O 
UV-vis O 
and O 
refractive O 
index O 
( O 
RI O 
) O 
detectors O 
in O 
series O 
, O 
and O 
by O 
thermogravimetric O 
( O 
TGA O 
) O 
analysis O 
. O 
Both O 
the O 
enhanced O 
molecular O 
size O 
shown O 
by O 
differences O 
between O 
HPSEC O 
chromatograms O 
of O 
humic O 
reaction O 
mixtures O 
at O 
either O 
pH O 
6 O 
or O 
3.5 O 
and O 
the O 
increase O 
of O 
thermogravimetric O 
stability O 
suggest O 
that O 
the O 
heterogeneous O 
biomimetic O 
catalysis O 
promoted O 
the O 
stabilization O 
of O 
humic O 
conformations O 
by O 
new O 
intermolecular O 
covalent O 
bonds O 
during O 
oxidative O 
coupling O 
. O 
The O 
similarity O 
between O 
chemical O 
and O 
light O 
- O 
induced O 
oxidation O 
results O 
suggests O 
potential O 
multiple O 
applications O 
of O 
the O 
kaolinite B-TRIVIAL 
-supported O 
heterogeneous O 
catalyst O 
in O 
controlling O 
the O 
reactivity O 
of O 
natural O 
organic O 
matter O 
within O 
biogeochemical O 
cycles O 
and O 
environmental O 
reactions O 
. O 

Potencies O 
and O 
Relative O 
Toxicities O 
of O 
γ-Coniceine B-TRIVIAL 
and O 
N-Methylconiine B-SYSTEMATIC 
Enantiomers O 
. O 

, O 
coniine B-TRIVIAL 
, O 
and O 
N-methylconiine B-SYSTEMATIC 
are O 
toxic O 
alkaloids O 
present O 
in O 
poison O 
hemlock O 
( O 
Conium O 
maculatum O 
) O 
. O 
We O 
previously O 
reported O 
the O 
comparison O 
of O 
the O 
relative O 
potencies O 
of O 
(+)- B-MULTIPLE 
and I-MULTIPLE 
(-)-coniine I-MULTIPLE 
enantiomers O 
. O 
In O 
this O 
study O 
, O 
we O 
synthesized O 
γ-coniceine B-TRIVIAL 
and O 
the O 
enantiomers O 
of O 
N-methylconiine B-SYSTEMATIC 
and O 
determined O 
the O 
biological O 
activity O 
of O 
γ-coniceine B-TRIVIAL 
and O 
each O 
of O 
the O 
N-methylconiine B-SYSTEMATIC 
enantiomers O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
The O 
relative O 
potencies O 
of O 
these O 
piperidine B-FAMILY 
alkaloids I-FAMILY 
on O 
cells O 
expressing O 
human O 
fetal O 
muscle O 
- O 
type O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
had O 
the O 
rank O 
order O 
of O 
γ-coniceine B-TRIVIAL 
> O 
(-)-N-methylconiine B-SYSTEMATIC 
> O 
(±)-N-methylconiine B-SYSTEMATIC 
> O 
(+)-N-methylconiine B-SYSTEMATIC 
. O 
The O 
relative O 
lethalities O 
of O 
γ-coniceine B-TRIVIAL 
and O 
(-)- B-MULTIPLE 
, I-MULTIPLE 
(±)- I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
(+)-N-methylconiine I-MULTIPLE 
in O 
vivo O 
using O 
a O 
mouse O 
bioassay O 
were O 
4.4 O 
, O 
16.1 O 
, O 
17.8 O 
, O 
and O 
19.2 O 
mg O 
/ O 
kg O 
, O 
respectively O 
. O 
The O 
results O 
from O 
this O 
study O 
suggest O 
γ-coniceine B-TRIVIAL 
is O 
a O 
more O 
potent O 
agonist O 
than O 
the O 
enantiomers O 
of O 
N-methylconiine B-SYSTEMATIC 
and O 
that O 
there O 
is O 
a O 
stereoselective O 
difference O 
in O 
the O 
in O 
vitro O 
potencies O 
of O 
the O 
enantiomers O 
of O 
N-methylconiine B-SYSTEMATIC 
that O 
correlates O 
with O 
the O 
relative O 
toxicities O 
of O 
the O 
enantiomers O 
in O 
vivo O 
. O 

Chemistry O 
of O 
Oxide B-SYSTEMATIC 
Nanomaterials O 
with O 
High O 
Surface O 
Area O 
: O 
Ordered O 
Mesoporous O 
Thin O 
Films O 
of O 
the O 
Oxygen B-SYSTEMATIC 
Storage O 
Catalyst O 
CeO2-ZrO2 O 
. O 

we O 
report O 
the O 
electrical O 
transport O 
properties O 
of O 
a O 
series O 
of O 
ordered O 
mesoporous O 
ceria B-SYSTEMATIC 
- I-SYSTEMATIC 
zirconia I-SYSTEMATIC 
( O 
CexZr1-xO2 B-FAMILY 
, O 
referred O 
to O 
as O 
mp- O 
CZO B-ABBREVIATION 
) O 
thin O 
films O 
with O 
both O 
a O 
cubic O 
structure O 
of O 
( O 
17 O 
± O 
2 O 
) O 
nm O 
diameter O 
pores O 
and O 
nanocrystalline O 
walls O 
. O 
Samples O 
over O 
the O 
whole O 
range O 
of O 
composition O 
, O 
including O 
bare O 
CeO2 B-FORMULA 
and O 
ZrO2 B-FORMULA 
, O 
were O 
fabricated O 
by O 
templating O 
strategies O 
using O 
the O 
large O 
diblock O 
copolymer O 
KLE B-FAMILY 
as O 
the O 
structure O 
- O 
directing O 
agent O 
. O 
Both O 
the O 
nanoscale O 
structure O 
and O 
the O 
chemical O 
composition O 
of O 
the O 
mesoporous O 
materials O 
were O 
analyzed O 
by O 
a O 
combination O 
of O 
scanning O 
and O 
transmission O 
electron O 
microscopy O 
, O 
grazing O 
incidence O 
small O 
- O 
angle O 
X-ray O 
scattering O 
, O 
X-ray O 
photoelectron O 
spectroscopy O 
, O 
and O 
time O 
- O 
of O 
- O 
flight O 
secondary O 
ion O 
mass O 
spectrometry O 
. O 
The O 
total O 
conductivity O 
as O 
a O 
function O 
of O 
the O 
film O 
composition O 
, O 
temperature O 
, O 
and O 
oxygen B-SYSTEMATIC 
partial O 
pressure O 
was O 
measured O 
using O 
impedance O 
spectroscopy O 
. O 
The O 
mesoporous O 
solid O 
solutions O 
of O 
CeO2 B-FORMULA 
- O 
ZrO2 B-FORMULA 
prepared O 
in O 
this O 
work O 
showed O 
a O 
higher O 
stability O 
against O 
thermal O 
ripening O 
than O 
both O 
binary O 
oxides O 
, O 
making O 
them O 
ideal O 
model O 
systems O 
to O 
study O 
both O 
the O 
charge O 
transport O 
properties O 
and O 
the O 
oxygen O 
storage O 
at O 
elevated O 
temperatures O 
. O 
We O 
find O 
that O 
the O 
redox O 
properties O 
of O 
nanocrystalline O 
mp- O 
CZO B-ABBREVIATION 
thin O 
films O 
differ O 
significantly O 
from O 
those O 
of O 
bulk O 
CZO B-ABBREVIATION 
materials O 
reported O 
in O 
the O 
literature O 
and O 
, O 
therefore O 
, O 
propose O 
a O 
defect O 
chemical O 
model O 
of O 
surface O 
regions O 
. O 

of O 
the O 
Ganglioside B-TRIVIAL 
GM1 I-TRIVIAL 
and O 
Cholesterol B-TRIVIAL 
Detected O 
by O 
Secondary O 
Ion O 
Mass O 
Spectrometry O 
. O 

characterization O 
of O 
the O 
lateral O 
organization O 
of O 
components O 
in O 
biological O 
membranes O 
and O 
the O 
evolution O 
of O 
this O 
arrangement O 
in O 
response O 
to O 
external O 
triggers O 
remain O 
a O 
major O 
challenge O 
. O 
The O 
concept O 
of O 
lipid O 
rafts O 
is O 
widely O 
invoked O 
; O 
however O 
, O 
direct O 
evidence O 
of O 
the O 
existence O 
of O 
these O 
ephemeral O 
entities O 
remains O 
elusive O 
. O 
We O 
report O 
here O 
the O 
use O 
of O 
secondary O 
ion O 
mass O 
spectrometry O 
( O 
SIMS O 
) O 
to O 
image O 
the O 
cholesterol B-TRIVIAL 
-dependent O 
cohesive O 
phase O 
separation O 
of O 
the O 
ganglioside B-TRIVIAL 
GM1 I-TRIVIAL 
into O 
nano- O 
and O 
microscale O 
assemblies O 
in O 
a O 
canonical O 
lipid O 
raft O 
composition O 
of O 
lipids O 
. O 
This O 
assembly O 
of O 
domains O 
was O 
interrogated O 
in O 
a O 
model O 
membrane O 
system O 
composed O 
of O 
palmitoyl B-TRIVIAL 
sphingomyelin I-TRIVIAL 
( O 
PSM B-ABBREVIATION 
) O 
, O 
cholesterol B-TRIVIAL 
, O 
and O 
an O 
unsaturated O 
lipid O 
( O 
dioleoylphosphatidylcholine B-TRIVIAL 
, O 
DOPC B-ABBREVIATION 
) O 
. O 
Orthogonal O 
isotopic O 
labeling O 
of O 
every O 
lipid O 
bilayer O 
component O 
and O 
monofluorination O 
of O 
GM1 B-ABBREVIATION 
allowed O 
generation O 
of O 
molecule O 
specific O 
images O 
using O 
a O 
NanoSIMS O 
. O 
Simultaneous O 
detection O 
of O 
six O 
different O 
ion O 
species O 
in O 
SIMS O 
, O 
including O 
secondary O 
electrons O 
, O 
was O 
used O 
to O 
generate O 
ion O 
ratio O 
images O 
whose O 
signal O 
intensity O 
values O 
could O 
be O 
correlated O 
to O 
composition O 
through O 
the O 
use O 
of O 
calibration O 
curves O 
from O 
standard O 
samples O 
. O 
Images O 
of O 
this O 
system O 
provide O 
the O 
first O 
direct O 
, O 
molecule O 
specific O 
, O 
visual O 
evidence O 
for O 
the O 
colocalization O 
of O 
cholesterol B-TRIVIAL 
and O 
GM1 B-ABBREVIATION 
in O 
supported O 
lipid O 
bilayers O 
and O 
further O 
indicate O 
the O 
presence O 
of O 
three O 
compositionally O 
distinct O 
phases O 
: O 
( O 
1 O 
) O 
the O 
interdomain O 
region O 
; O 
( O 
2 O 
) O 
micrometer O 
- O 
scale O 
domains O 
( O 
d O 
> O 
3 O 
μm O 
) O 
; O 
( O 
3 O 
) O 
nanometer O 
- O 
scale O 
domains O 
( O 
d O 
= O 
100 O 
nm O 
to O 
1 O 
μm O 
) O 
localized O 
within O 
the O 
micrometer O 
- O 
scale O 
domains O 
and O 
the O 
interdomain O 
region O 
. O 
PSM B-ABBREVIATION 
-rich O 
, O 
nanometer O 
- O 
scale O 
domains O 
prefer O 
to O 
partition O 
within O 
the O 
more O 
ordered O 
, O 
cholesterol B-TRIVIAL 
-rich/ O 
DOPC B-ABBREVIATION 
-poor/ O 
GM1 B-ABBREVIATION 
-rich O 
micrometer O 
- O 
scale O 
phase O 
, O 
while O 
GM1 B-ABBREVIATION 
-rich O 
, O 
nanometer O 
- O 
scale O 
domains O 
prefer O 
to O 
partition O 
within O 
the O 
surrounding O 
, O 
disordered O 
, O 
cholesterol B-TRIVIAL 
-poor/ O 
PSM B-ABBREVIATION 
-rich/ O 
DOPC B-ABBREVIATION 
-rich O 
interdomain O 
phase O 
. O 

and O 
Absolute O 
Configuration O 
of O 
Methyl B-SYSTEMATIC 
(3R)-Malonyl-(13S)-hydroxycheilanth-17-en-19-oate I-SYSTEMATIC 
, O 
a O 
Sesterterpene B-FAMILY 
Derivative O 
from O 
the O 
Roots O 
of O 
Aletris O 
farinosa O 
. O 

report O 
the O 
isolation O 
and O 
structure O 
elucidation O 
of O 
a O 
new O 
cheilanthane B-TRIVIAL 
sesterterpene B-FAMILY 
from O 
the O 
roots O 
of O 
Aletris O 
farinosa O 
that O 
possesses O 
an O 
unusual O 
malonate B-SYSTEMATIC 
half I-SYSTEMATIC 
- I-SYSTEMATIC 
ester I-SYSTEMATIC 
functional O 
group O 
. O 
The O 
structure O 
of O 
1 O 
was O 
determined O 
via O 
mass O 
spectrometry O 
and O 
1D O 
and O 
2D O 
NMR O 
spectroscopy O 
, O 
while O 
its O 
absolute O 
configuration O 
was O 
determined O 
via O 
X-ray O 
crystallographic O 
analysis O 
performed O 
on O 
its O 
methyl B-SYSTEMATIC 
ester I-SYSTEMATIC 
derivative O 
2 O 
. O 

activity O 
of O 
Pd B-FORMULA 
(II) I-FORMULA 
complexes O 
with O 
mono- B-MULTIPLE 
and I-MULTIPLE 
disubstituted I-MULTIPLE 
pyridines I-MULTIPLE 
-Experimental O 
and O 
theoretical O 
studies O 
. O 

to O 
the O 
similarity O 
between O 
Pd B-FORMULA 
and O 
Pt B-FORMULA 
, O 
the O 
complexes O 
of O 
palladium B-SYSTEMATIC 
(II) I-SYSTEMATIC 
can O 
be O 
considered O 
as O 
potential O 
anticancer O 
agents O 
. O 
Activity O 
of O 
six O 
PdCl2(X2Py)2 B-FAMILY 
complexes O 
( O 
Py B-FORMULA 
= O 
pyridine B-SYSTEMATIC 
, O 
and O 
X= O 
CH3 B-FORMULA 
or O 
Cl B-FORMULA 
) O 
was O 
measured O 
by O 
MTT B-ABBREVIATION 
test O 
using O 
MCF7 O 
, O 
CCRF-SB O 
, O 
PC3 O 
and O 
human O 
B-lymphoblastoid O 
cell O 
lines O 
. O 
We O 
found O 
that O 
the O 
effect O 
of O 
PdCl2(XnPy)2 B-FAMILY 
was O 
cell O 
- O 
specific O 
and O 
time O 
- O 
dependent O 
. O 
Obtained O 
results O 
were O 
discussed O 
and O 
compared O 
with O 
the O 
activation O 
parameters O 
calculated O 
for O 
the O 
hydrolysis O 
of O 
PdCl2(XnPy)2 B-FAMILY 
, O 
indicating O 
a O 
correlation O 
between O 
viability O 
of O 
MCF7 O 
and O 
CCRF-SB O 
cells O 
and O 
rates O 
of O 
hydrolysis O 
of O 
the O 
Pd B-FORMULA 
(II) I-FORMULA 
complexes O 
. O 

Androgen B-FAMILY 
Metabolite O 
, O 
5α-Androstane-3β,17β-Diol B-SYSTEMATIC 
( O 
3β-Diol B-SYSTEMATIC 
) O 
, O 
Activates O 
the O 
Oxytocin B-TRIVIAL 
Promoter O 
Through O 
an O 
Estrogen B-FAMILY 
Receptor-β O 
Pathway O 
. O 

has O 
been O 
shown O 
to O 
suppress O 
the O 
acute O 
stress O 
- O 
induced O 
activation O 
of O 
the O 
hypothalamic O 
- O 
pituitary O 
- O 
adrenal O 
axis O 
; O 
however O 
, O 
the O 
mechanisms O 
underlying O 
this O 
response O 
remain O 
unclear O 
. O 
The O 
hypothalamic O 
- O 
pituitary O 
- O 
adrenal O 
axis O 
is O 
regulated O 
by O 
a O 
neuroendocrine O 
subpopulation O 
of O 
medial O 
parvocellular O 
neurons O 
in O 
the O 
paraventricular O 
nucleus O 
of O 
the O 
hypothalamus O 
( O 
PVN O 
) O 
. O 
These O 
neurons O 
are O 
devoid O 
of O 
androgen B-FAMILY 
receptors O 
( O 
ARs O 
) O 
. O 
Therefore O 
, O 
a O 
possibility O 
is O 
that O 
the O 
PVN O 
target O 
neurons O 
respond O 
to O 
a O 
metabolite O 
in O 
the O 
testosterone B-TRIVIAL 
catabolic O 
pathway O 
via O 
an O 
AR O 
- O 
independent O 
mechanism O 
. O 
The O 
dihydrotestosterone B-SYSTEMATIC 
metabolite O 
, O 
5α-androstane-3β,17β-diol B-SYSTEMATIC 
( O 
3β-diol B-SYSTEMATIC 
) O 
, O 
binds O 
and O 
activates O 
estrogen B-FAMILY 
receptor-β O 
( O 
ER-β O 
) O 
, O 
the O 
predominant O 
ER O 
in O 
the O 
PVN O 
. O 
In O 
the O 
PVN O 
, O 
ER-β O 
is O 
coexpressed O 
with O 
oxytocin B-TRIVIAL 
( O 
OT O 
) O 
. O 
Therefore O 
, O 
we O 
tested O 
the O 
hypothesis O 
that O 
3β-diol B-SYSTEMATIC 
regulates O 
OT O 
expression O 
through O 
ER-β O 
activation O 
. O 
Treatment O 
of O 
ovariectomized O 
rats O 
with O 
estradiol B-SYSTEMATIC 
benzoate I-SYSTEMATIC 
or O 
3β-diol B-SYSTEMATIC 
for O 
4 O 
days O 
increased O 
OT O 
mRNA O 
selectively O 
in O 
the O 
midcaudal O 
, O 
but O 
not O 
rostral O 
PVN O 
compared O 
with O 
vehicle O 
- O 
treated O 
controls O 
. O 
3β-Diol B-SYSTEMATIC 
treatment O 
also O 
increased O 
OT O 
mRNA O 
in O 
the O 
hypothalamic O 
N38 O 
cell O 
line O 
in O 
vitro O 
. O 
The O 
functional O 
interactions O 
between O 
3β-diol B-SYSTEMATIC 
and O 
ER-β O 
with O 
the O 
human O 
OT O 
promoter O 
were O 
examined O 
using O 
an O 
OT O 
promoter O 
- O 
luciferase O 
reporter O 
construct O 
( O 
OT-luc O 
) O 
. O 
In O 
a O 
dose O 
- O 
dependent O 
manner O 
, O 
3β-diol B-SYSTEMATIC 
treatment O 
increased O 
OT-luc O 
activity O 
when O 
cells O 
were O 
cotransfected O 
with O 
ER-β O 
, O 
but O 
not O 
ER-α O 
. O 
The O 
3β-diol B-SYSTEMATIC 
-induced O 
OT-luc O 
activity O 
was O 
reduced O 
by O 
deletion O 
of O 
the O 
promoter O 
region O 
containing O 
the O 
composite O 
hormone O 
response O 
element O 
( O 
cHRE O 
) O 
. O 
Point O 
mutations O 
of O 
the O 
cHRE O 
also O 
prevented O 
OT-luc O 
activation O 
by O 
3β-diol B-SYSTEMATIC 
. O 
These O 
results O 
indicate O 
that O 
3β-diol B-SYSTEMATIC 
induces O 
OT O 
promoter O 
activity O 
via O 
ER-β-cHRE O 
interactions O 
. O 

study O 
aimed O 
to O 
investigate O 
the O 
implication O 
of O 
some O 
apoptotic O 
and O 
lipid O 
peroxidation O 
markers O 
in O 
preeclampsia O 
( O 
PE O 
) O 
. O 
A O 
total O 
of O 
25 O 
women O 
with O 
PE O 
and O 
25 O 
age- O 
and O 
parity O 
- O 
matched O 
normal O 
pregnant O 
women O 
were O 
enrolled O 
in O 
this O 
study O 
. O 
The O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
level O 
, O 
caspase-9 O 
activity O 
and O 
the O 
percentage O 
of O 
DNA O 
fragmentation O 
were O 
significantly O 
higher O 
in O 
placental O 
tissue O 
of O 
PE O 
than O 
in O 
control O 
women O 
. O 
The O 
serum O 
level O 
of O 
MDA B-ABBREVIATION 
was O 
significantly O 
elevated O 
in O 
women O 
with O 
PE O 
having O 
delivery O 
by O 
cesarean O 
section O 
( O 
CS O 
) O 
than O 
in O 
women O 
with O 
PE O 
having O 
vaginal O 
delivery O 
. O 
In O 
vitro O 
study O 
demonstrated O 
that O 
the O 
addition O 
of O 
0.5 O 
mM O 
Fe(2+) B-FORMULA 
and O 
0.1 O 
mM O 
ascorbate B-TRIVIAL 
caused O 
increase O 
in O 
the O 
production O 
of O 
MDA B-ABBREVIATION 
level O 
in O 
placental O 
tissue O 
with O 
PE O 
than O 
normal O 
placentas O 
, O 
and O 
vitamin B-FAMILY 
E I-FAMILY 
( O 
100 O 
µM O 
) O 
caused O 
lower O 
inhibition O 
of O 
in O 
vitro O 
lipid O 
peroxidation O 
in O 
placental O 
tissue O 
with O 
PE O 
when O 
compared O 
with O 
normal O 
tissue O 
. O 
The O 
activity O 
of O 
caspase-9 O 
and O 
percentage O 
of O 
DNA O 
fragmentation O 
were O 
associated O 
with O 
the O 
severity O 
of O 
the O 
PE O 
and O 
both O 
could O 
differentiate O 
between O 
PE O 
and O 
control O 
women O 
with O 
88% O 
and O 
100% O 
sensitivity O 
and O 
96% O 
and O 
100% O 
specificity O 
, O 
respectively O 
. O 
The O 
activities O 
of O 
caspase-8 O 
and O 
/ O 
or O 
-9 O 
were O 
positively O 
correlated O 
with O 
the O 
maternal O 
age O 
but O 
only O 
caspase-8 O 
was O 
negatively O 
correlated O 
with O 
neonatal O 
birth O 
weight O 
and O 
placental O 
weight O 
. O 
In O 
conclusion O 
, O 
the O 
elevations O 
of O 
MDA B-ABBREVIATION 
, O 
caspase-9 O 
activity O 
and O 
the O 
percentage O 
of O 
DNA O 
fragmentation O 
in O 
the O 
placentas O 
of O 
women O 
with O 
PE O 
implicate O 
the O 
involvement O 
of O 
lipid O 
peroxidation O 
and O 
apoptosis O 
in O 
PE O 
. O 
The O 
placenta O 
represents O 
a O 
considerable O 
source O 
of O 
the O 
elevated O 
circulating O 
MDA B-ABBREVIATION 
in O 
PE O 
. O 

-dependent O 
suicidal O 
erythrocyte O 
death O 
following O 
zearalenone B-TRIVIAL 
exposure O 
. O 

, O 
a O 
cereal O 
mycotoxin O 
with O 
mycoestrogen O 
activity O 
and O 
effect O 
on O 
fertility O 
, O 
is O 
known O 
to O 
trigger O 
apoptosis O 
of O 
a O 
variety O 
of O 
nucleated O 
cell O 
types O 
including O 
hematopoietic O 
progenitor O 
cells O 
. O 
In O 
analogy O 
to O 
apoptosis O 
of O 
nucleated O 
cells O 
, O 
eryptosis O 
, O 
the O 
suicidal O 
death O 
of O 
erythrocytes O 
, O 
leads O 
to O 
cell O 
shrinkage O 
and O 
cell O 
membrane O 
scrambling O 
with O 
phosphatidylserine O 
exposure O 
at O 
the O 
erythrocyte O 
surface O 
. O 
The O 
most O 
important O 
stimulator O 
of O 
eryptosis O 
is O 
an O 
increase O 
in O 
cytosolic O 
Ca(2+) B-FORMULA 
activity O 
( O 
[ O 
Ca(2+) B-FORMULA 
]i O 
) O 
. O 
The O 
present O 
study O 
explored O 
whether O 
zearalenone B-TRIVIAL 
triggers O 
eryptosis O 
. O 
Erythrocyte O 
volume O 
was O 
estimated O 
from O 
forward O 
scatter O 
, O 
phosphatidylserine O 
exposure O 
at O 
the O 
erythrocyte O 
surface O 
from O 
annexin-V O 
binding O 
, O 
hemolysis O 
from O 
hemoglobin O 
release O 
, O 
and O 
[ O 
Ca(2+) B-FORMULA 
]i O 
from O 
Fluo3 B-TRIVIAL 
fluorescence O 
. O 
A O 
48-h O 
exposure O 
to O 
zearalenone B-TRIVIAL 
( O 
≥ O 
25 O 
μM O 
) O 
was O 
followed O 
by O 
a O 
significant O 
increase O 
in O 
[ O 
Ca(2+) B-FORMULA 
]i O 
and O 
annexin-V O 
binding O 
, O 
and O 
a O 
significant O 
decrease O 
in O 
forward O 
scatter O 
. O 
The O 
effect O 
on O 
annexin-V O 
binding O 
was O 
significantly O 
blunted O 
in O 
the O 
nominal O 
absence O 
of O 
extracellular O 
Ca(2+) B-FORMULA 
. O 
Zearalenone B-TRIVIAL 
stimulates O 
the O 
suicidal O 
erythrocyte O 
death O 
, O 
an O 
effect O 
at O 
least O 
partially O 
due O 
to O 
stimulation O 
of O 
Ca(2+) B-FORMULA 
entry O 
. O 

DNA O 
damage O 
is O 
involved O 
in O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
-induced O 
G2 O 
arrest O 
through O 
ataxia O 
telangiectasia O 
- O 
mutated O 
( O 
ATM O 
) O 
pathways O 
in O 
human O 
gastric O 
epithelium O 
GES-1 O 
cells O 
in O 
vitro O 
. O 

A I-TRIVIAL 
( O 
OTA B-ABBREVIATION 
) O 
, O 
one O 
of O 
the O 
most O 
abundant O 
mycotoxin O 
food O 
contaminants O 
, O 
is O 
classified O 
as O 
" O 
possibly O 
carcinogenic O 
to O 
humans O 
. O 
" O 
Our O 
previous O 
study O 
showed O 
that O 
OTA B-ABBREVIATION 
could O 
induce O 
a O 
G2 O 
arrest O 
in O 
immortalized O 
human O 
gastric O 
epithelium O 
cells O 
( O 
GES-1 O 
) O 
. O 
To O 
explore O 
the O 
putative O 
roles O 
of O 
oxidative O 
DNA O 
damage O 
and O 
the O 
ataxia O 
telangiectasia O 
- O 
mutated O 
( O 
ATM O 
) O 
pathways O 
on O 
the O 
OTA B-ABBREVIATION 
-induced O 
G2 O 
arrest O 
, O 
the O 
current O 
study O 
systematically O 
evaluated O 
the O 
roles O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
production O 
, O 
DNA O 
damage O 
, O 
and O 
ATM-dependent O 
pathway O 
activation O 
on O 
the O 
OTA B-ABBREVIATION 
-induced O 
G2 O 
phase O 
arrest O 
in O 
GES-1 O 
cells O 
. O 
The O 
results O 
showed O 
that O 
OTA B-ABBREVIATION 
exposure O 
elevated O 
intracellular O 
ROS O 
production O 
, O 
which O 
directly O 
induced O 
DNA O 
damage O 
and O 
increased O 
the O 
levels O 
of O 
8-OHdG B-SYSTEMATIC 
and O 
DNA O 
double O 
- O 
strand O 
breaks O 
( O 
DSBs O 
) O 
. O 
In O 
addition O 
, O 
it O 
was O 
found O 
that O 
OTA B-ABBREVIATION 
treatment O 
induced O 
the O 
phosphorylation O 
of O 
the O 
ATM O 
protein O 
, O 
as O 
well O 
as O 
its O 
downstream O 
molecules O 
Chk2 O 
and O 
p53 O 
, O 
in O 
response O 
to O 
DNA O 
DSBs O 
. O 
Inhibition O 
of O 
ATM O 
by O 
the O 
pharmacological O 
inhibitor O 
caffeine O 
or O 
siRNA O 
effectively O 
prevented O 
the O 
activation O 
of O 
ATM-dependent O 
pathways O 
and O 
rescued O 
the O 
G2 O 
arrest O 
elicited O 
by O 
OTA B-ABBREVIATION 
. O 
Finally O 
, O 
pretreatment O 
with O 
the O 
antioxidant O 
N-acetyl-L-cysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
reduced O 
the O 
OTA B-ABBREVIATION 
-induced O 
DNA O 
DSBs O 
, O 
ATM O 
phosphorylation O 
, O 
and O 
G2 O 
arrest O 
. O 
In O 
conclusion O 
, O 
the O 
results O 
of O 
this O 
study O 
suggested O 
that O 
OTA B-ABBREVIATION 
-induced O 
oxidative O 
DNA O 
damage O 
triggered O 
the O 
ATM-dependent O 
pathways O 
, O 
which O 
ultimately O 
elicited O 
a O 
G2 O 
arrest O 
in O 
GES-1 O 
cells O 
. O 

mitochondrial O 
disorders O 
are O 
clinically O 
and O 
genetically O 
heterogeneous O 
, O 
caused O 
by O 
an O 
alteration(s) O 
in O 
either O 
mitochondrial O 
DNA O 
or O 
nuclear O 
DNA O 
, O 
and O 
affect O 
the O 
respiratory O 
chain's O 
ability O 
to O 
undergo O 
oxidative O 
phosphorylation O 
, O 
leading O 
to O 
decreased O 
production O 
of O 
adenosine B-SYSTEMATIC 
triphosphophate I-SYSTEMATIC 
and O 
subsequent O 
energy O 
failure O 
. O 
These O 
disorders O 
may O 
present O 
at O 
any O 
age O 
, O 
but O 
children O 
tend O 
to O 
have O 
an O 
acute O 
onset O 
of O 
disease O 
compared O 
with O 
subacute O 
or O 
slowly O 
progressive O 
presentation O 
in O 
adults O 
. O 
Varying O 
organ O 
involvement O 
also O 
contributes O 
to O 
the O 
phenotypic O 
spectrum O 
seen O 
in O 
these O 
disorders O 
. O 
The O 
childhood O 
presentation O 
of O 
primary O 
mitochondrial O 
disease O 
is O 
mainly O 
due O 
to O 
nuclear O 
DNA O 
mutations O 
, O 
with O 
mitochondrial O 
DNA O 
mutations O 
being O 
less O 
frequent O 
in O 
childhood O 
and O 
more O 
prominent O 
in O 
adulthood O 
disease O 
. O 
The O 
clinician O 
should O 
be O 
aware O 
of O 
the O 
pediatric O 
presentation O 
of O 
mitochondrial O 
disease O 
and O 
have O 
an O 
understanding O 
of O 
the O 
myriad O 
of O 
nuclear O 
genes O 
responsible O 
for O 
these O 
disorders O 
. O 
The O 
nuclear O 
genes O 
can O 
be O 
best O 
understood O 
by O 
utilizing O 
a O 
classification O 
system O 
of O 
location O 
and O 
function O 
within O 
the O 
mitochondria O 
. O 

of O 
Gentamicin B-FAMILY 
on O 
the O 
Proteomes O 
of O 
Aerobic O 
and O 
Oxygen B-SYSTEMATIC 
-Limited O 
Escherichia O 
coli O 
. O 

key O 
role O 
of O 
the O 
bacterial O 
ribosome O 
makes O 
it O 
an O 
important O 
target O 
for O 
antibacterial O 
agents O 
. O 
Indeed O 
, O 
a O 
large O 
number O 
of O 
clinically O 
useful O 
antibiotics O 
target O 
this O 
complex O 
translational O 
ribonucleoprotein O 
machinery O 
. O 
Unfortunately O 
, O 
the O 
development O 
of O 
resistant O 
bacterial O 
strains O 
has O 
compromised O 
the O 
effectiveness O 
of O 
most O 
classes O 
of O 
antibacterial O 
agent O 
, O 
including O 
the O 
classes O 
that O 
target O 
the O 
ribosome O 
. O 
Combinations O 
of O 
two O 
or O 
more O 
drugs O 
can O 
be O 
used O 
to O 
help O 
overcome O 
resistance O 
, O 
and O 
in O 
certain O 
circumstances O 
their O 
action O 
may O 
be O 
synergistic O 
. O 
In O 
this O 
study O 
we O 
have O 
used O 
proteomic O 
techniques O 
to O 
establish O 
the O 
effects O 
of O 
gentamicin B-FAMILY 
on O 
the O 
proteomes O 
of O 
aerobic O 
and O 
oxygen B-SYSTEMATIC 
-limited O 
Escherichia O 
coli O 
. O 
Ribosomal O 
proteins O 
L1 O 
, O 
L9 O 
, O 
L10 O 
, O 
and O 
S2 O 
were O 
found O 
to O 
be O 
up O 
- O 
regulated O 
in O 
both O 
conditions O 
, O 
and O 
we O 
postulate O 
that O 
these O 
are O 
candidate O 
drug O 
targets O 
for O 
the O 
development O 
of O 
synergistic O 
combinations O 
with O 
gentamicin B-FAMILY 
. O 

: O 
The O 
atherogenic O 
effects O 
of O 
hypothyroidism O 
on O 
lipid O 
metabolism O 
could O 
result O 
, O 
in O 
part O 
, O 
from O 
the O 
reduced O 
clearance O 
of O 
remnant O 
lipoproteins O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
expression O 
of O 
hepatic O 
low O 
- O 
density O 
lipoprotein O 
receptor O 
- O 
related O 
protein O 
1 O 
( O 
LRP1 O 
) O 
, O 
a O 
receptor O 
for O 
remnant O 
lipoproteins O 
, O 
in O 
hypothyroidism O 
and O 
the O 
effect O 
of O 
triiodothyronine B-TRIVIAL 
( O 
T3 O 
) O 
treatment O 
on O 
hepatic O 
LRP1 O 
expression O 
. O 
Methods O 
: O 
C57BL O 
/ O 
6 O 
mice O 
were O 
fed O 
a O 
normal O 
diet O 
( O 
control O 
group O 
) O 
or O 
a O 
low O 
iodine B-SYSTEMATIC 
diet O 
supplemented O 
with O 
0.15 O 
% O 
propylthiouracil B-SYSTEMATIC 
( O 
PTU B-ABBREVIATION 
/ O 
LI O 
group O 
) O 
for O 
4 O 
weeks O 
. O 
Mice O 
in O 
PTU B-ABBREVIATION 
/ O 
LI O 
group O 
were O 
injected O 
intraperitoneally O 
with O 
T3 O 
( O 
0 O 
, O 
30 O 
, O 
and O 
150 O 
μg O 
/ O 
kg O 
of O 
body O 
weight O 
) O 
for O 
7 O 
days O 
. O 
HepG2 O 
cells O 
were O 
incubated O 
in O 
fetal O 
bovine O 
serum O 
( O 
FBS O 
) O 
or O 
charcoal O 
- O 
stripped O 
FBS O 
( O 
CSS O 
) O 
with O 
various O 
concentrations O 
of O 
T3 O 
. O 
The O 
expression O 
and O 
function O 
of O 
LRP1 O 
in O 
liver O 
samples O 
and O 
cells O 
were O 
analyzed O 
. O 
Results O 
: O 
Hypothyroidism O 
was O 
successfully O 
induced O 
in O 
PTU B-ABBREVIATION 
/ O 
LI O 
group O 
mice O 
. O 
Hepatic O 
LRP1 O 
protein O 
expression O 
was O 
lower O 
in O 
the O 
PTU B-ABBREVIATION 
/ O 
LI O 
group O 
than O 
the O 
control O 
group O 
. O 
T3 O 
treatment O 
up O 
- O 
regulated O 
hepatic O 
LRP1 O 
protein O 
expression O 
in O 
PTU B-ABBREVIATION 
/ O 
LI O 
group O 
mice O 
. O 
LRP1 O 
expression O 
in O 
HepG2 O 
cells O 
was O 
reduced O 
after O 
incubation O 
in O 
media O 
containing O 
CSS O 
, O 
which O 
mimics O 
hypothyroidism O 
in O 
vitro O 
, O 
and O 
was O 
recovered O 
by O 
T3 O 
treatment O 
. O 
The O 
protein O 
expression O 
of O 
LRP1 O 
in O 
HepG2 O 
cells O 
was O 
increased O 
by O 
T3 O 
treatment O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
up O 
to O 
2 O 
nM O 
T3 O 
. O 
However O 
, O 
LRP1 O 
mRNA O 
transcription O 
was O 
not O 
affected O 
by O 
hypothyroidism O 
conditions O 
or O 
T3 O 
treatment O 
, O 
either O 
in O 
liver O 
samples O 
or O 
HepG2 O 
cells O 
. O 
T3 O 
treatment O 
on O 
HepG2 O 
cells O 
increased O 
cellular O 
uptake O 
of O 
lipid O 
- O 
conjugated O 
apolipoprotein O 
E O 
through O 
LRP1 O 
. O 
Conclusions O 
: O 
Our O 
data O 
demonstrate O 
that O 
hepatic O 
LRP1 O 
expression O 
and O 
function O 
decrease O 
in O 
hypothyroidism O 
and O 
are O 
regulated O 
by O 
thyroid B-FAMILY 
hormone I-FAMILY 
. O 
These O 
results O 
suggest O 
that O 
in O 
hypothyroidism O 
, O 
decreased O 
expression O 
of O 
hepatic O 
LRP1 O 
may O 
be O 
associated O 
with O 
reduced O 
clearance O 
of O 
circulating O 
remnant O 
lipoproteins O 
. O 

solvent O 
quality O 
of O 
an O 
aqueous O 
mixture O 
of O 
two O 
good O 
solvents O 
, O 
urea B-TRIVIAL 
and O 
guanidinium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
GdmCl B-FORMULA 
) O 
, O 
for O 
a O 
hydrophobic O 
polymer O 
was O 
investigated O 
using O 
atomistic O 
molecular O 
dynamics O 
simulations O 
. O 
A O 
counterintuitive O 
collapse O 
of O 
the O 
polymer O 
was O 
found O 
, O 
suggesting O 
that O 
mixing O 
the O 
two O 
denaturants O 
reduces O 
the O 
solvent O 
quality O 
. O 
This O 
cononsolvency O 
of O 
the O 
polymer O 
in O 
the O 
urea B-TRIVIAL 
+ O 
GdmCl B-FORMULA 
mixture O 
is O 
found O 
to O 
be O 
caused O 
by O 
the O 
preferential O 
adsorption O 
of O 
urea B-TRIVIAL 
on O 
the O 
polymer O 
. O 
The O 
polymer O 
collapses O 
as O 
a O 
result O 
of O 
indirect O 
long O 
- O 
range O 
interactions O 
between O 
monomers O 
resulting O 
from O 
the O 
presence O 
of O 
urea B-TRIVIAL 
clouds O 
surrounding O 
them O 
. O 
Surprisingly O 
, O 
urea B-TRIVIAL 
behaves O 
as O 
the O 
better O 
solvent O 
in O 
the O 
mixture O 
not O 
because O 
there O 
exists O 
a O 
stronger O 
affinity O 
of O 
the O 
polymer O 
for O 
urea B-TRIVIAL 
. O 
Instead O 
, O 
attractive O 
interactions O 
between O 
two O 
unlike O 
denaturant O 
molecules O 
combined O 
with O 
the O 
direct O 
dispersion O 
interactions O 
of O 
the O 
polymer O 
with O 
both O 
denaturants O 
determine O 
the O 
solvent O 
quality O 
of O 
the O 
mixture O 
. O 

diverse O 
applications O 
utilize O 
hydrogels O 
as O 
carriers O 
, O 
sensors O 
, O 
and O 
actuators O 
, O 
and O 
these O 
applications O 
rely O 
on O 
the O 
refined O 
control O 
of O 
physical O 
properties O 
of O 
the O 
hydrogel O 
, O 
such O 
as O 
elastic O 
modulus O 
and O 
degree O 
of O 
swelling O 
. O 
Often O 
, O 
hydrogel O 
properties O 
are O 
interdependent O 
; O 
for O 
example O 
, O 
when O 
elastic O 
modulus O 
is O 
increased O 
, O 
degree O 
of O 
swelling O 
is O 
decreased O 
. O 
Controlling O 
these O 
inverse O 
dependencies O 
remains O 
a O 
major O 
barrier O 
for O 
broader O 
hydrogel O 
applications O 
. O 
We O 
hypothesized O 
that O 
polymer O 
cross O 
- O 
linkers O 
with O 
varied O 
chain O 
flexibility O 
would O 
allow O 
us O 
to O 
tune O 
the O 
inverse O 
dependency O 
between O 
the O 
elastic O 
modulus O 
and O 
the O 
degree O 
of O 
swelling O 
of O 
the O 
hydrogels O 
. O 
We O 
examined O 
this O 
hypothesis O 
by O 
using O 
alginate O 
and O 
poly(acrylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PAA B-ABBREVIATION 
) O 
modified O 
with O 
a O 
controlled O 
number O 
of O 
methacrylic B-TRIVIAL 
groups O 
as O 
model O 
inflexible O 
and O 
flexible O 
cross O 
- O 
linkers O 
, O 
respectively O 
. O 
Interestingly O 
, O 
the O 
polyacrylamide B-SYSTEMATIC 
hydrogel O 
cross O 
- O 
linked O 
by O 
the O 
inflexible O 
alginate O 
methacrylates O 
exhibited O 
less O 
dependency O 
between O 
the O 
degree O 
of O 
swelling O 
and O 
the O 
elastic O 
modulus O 
than O 
the O 
hydrogel O 
cross O 
- O 
linked O 
by O 
flexible O 
PAA B-ABBREVIATION 
methacrylates B-FAMILY 
. O 
This O 
critical O 
role O 
of O 
the O 
cross-linker's O 
inflexibility O 
was O 
related O 
to O 
the O 
difference O 
of O 
the O 
degree O 
of O 
hydrophobic O 
association O 
between O 
polymer O 
cross O 
- O 
linkers O 
, O 
as O 
confirmed O 
with O 
pyrene B-SYSTEMATIC 
probes O 
added O 
in O 
pregel O 
solutions O 
. O 
Furthermore O 
, O 
hydrogels O 
cross O 
- O 
linked O 
with O 
alginate O 
methacrylates B-FAMILY 
could O 
tune O 
the O 
projection O 
area O 
of O 
adhered O 
cells O 
by O 
solely O 
altering O 
elastic O 
moduli O 
. O 
In O 
contrast O 
, O 
gels O 
cross O 
- O 
linked O 
with O 
PAA B-ABBREVIATION 
methacrylates B-FAMILY 
failed O 
to O 
modulate O 
the O 
cellular O 
adhesion O 
morphology O 
due O 
to O 
a O 
lower O 
, O 
and O 
smaller O 
, O 
elastic O 
modulus O 
range O 
to O 
be O 
controlled O 
. O 
Overall O 
, O 
the O 
results O 
of O 
this O 
study O 
will O 
significantly O 
advance O 
the O 
controllability O 
of O 
hydrogel O 
properties O 
and O 
greatly O 
enhance O 
the O 
performance O 
of O 
hydrogels O 
in O 
various O 
biological O 
applications O 
. O 

basic O 
science O 
and O 
clinical O 
use O 
of O 
morphine B-TRIVIAL 
and O 
other O 
" O 
opioid O 
" O 
drugs O 
are O 
based O 
almost O 
exclusively O 
on O 
the O 
extracts O 
or O 
analogues O 
of O 
compounds O 
isolated O 
from O 
a O 
single O 
source O 
, O 
the O 
opium O 
poppy O 
( O 
Papaver O 
somniferum O 
) O 
. O 
However O 
, O 
it O 
now O 
appears O 
that O 
biological O 
diversity O 
has O 
evolved O 
an O 
alternative O 
source O 
. O 
Specifically O 
, O 
at O 
least O 
two O 
alkaloids O 
isolated O 
from O 
the O 
plant O 
Mitragyna O 
speciosa O 
, O 
mitragynine B-TRIVIAL 
( O 
(E)-2-[(2S,3S)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[3,2-h]quinolizin-2-yl]-3-methoxyprop-2-enoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
; O 
9-methoxy B-SYSTEMATIC 
coryantheidine I-SYSTEMATIC 
; O 
MG O 
) O 
and O 
7-hydroxymitragynine B-SYSTEMATIC 
( O 
7-OH-MG B-SYSTEMATIC 
) O 
, O 
and O 
several O 
synthetic O 
analogues O 
of O 
these O 
natural O 
products O 
display O 
centrally O 
mediated O 
( O 
supraspinal O 
and O 
spinal O 
) O 
antinociceptive O 
( O 
analgesic O 
) O 
activity O 
in O 
various O 
pain O 
models O 
. O 
Several O 
characteristics O 
of O 
these O 
compounds O 
suggest O 
a O 
classic O 
" O 
opioid O 
" O 
mechanism O 
of O 
action O 
: O 
nanomolar O 
affinity O 
for O 
opioid O 
receptors O 
, O 
competitive O 
interaction O 
with O 
the O 
opioid O 
receptor O 
antagonist O 
naloxone B-TRIVIAL 
, O 
and O 
two O 
- O 
way O 
analgesic O 
cross O 
- O 
tolerance O 
with O 
morphine B-TRIVIAL 
. O 
However O 
, O 
other O 
characteristics O 
of O 
the O 
compounds O 
suggest O 
novelty O 
, O 
particularly O 
chemical O 
structure O 
and O 
possible O 
greater O 
separation O 
from O 
side O 
effects O 
. O 
We O 
review O 
the O 
chemical O 
and O 
pharmacological O 
properties O 
of O 
these O 
compounds O 
. O 

and O 
hepatic O 
first O 
- O 
pass O 
extraction O 
of O 
the O 
11β-HSD1 O 
inhibitor O 
AMG B-IDENTIFIER 
221 I-IDENTIFIER 
in O 
rats O 
with O 
chronic O 
vascular O 
catheters O 
. O 

1 O 
. O 
A O 
catheterized O 
rat O 
model O 
was O 
used O 
to O 
define O 
the O 
intestinal O 
and O 
hepatic O 
components O 
of O 
oral O 
bioavailability O 
for O 
an O 
11β-HSD1 O 
inhibitor O 
, O 
AMG B-IDENTIFIER 
221 I-IDENTIFIER 
. O 
These O 
data O 
were O 
integrated O 
with O 
standard O 
in O 
vivo O 
metabolism O 
studies O 
to O 
elucidate O 
the O 
components O 
contributing O 
to O 
the O 
oral O 
disposition O 
of O 
a O 
novel O 
drug O 
candidate O 
. O 
2 O 
. O 
Intestinal O 
and O 
hepatic O 
extraction O 
ratios O 
of O 
AMG B-IDENTIFIER 
221 I-IDENTIFIER 
obtained O 
using O 
a O 
five O 
- O 
catheter O 
rat O 
model O 
were O 
0.56 O 
and O 
0.32 O 
, O 
respectively O 
. O 
Therefore O 
, O 
both O 
intestinal O 
and O 
hepatic O 
extraction O 
contributed O 
to O 
the O 
first O 
- O 
pass O 
component O 
of O 
oral O 
bioavailability O 
. O 
There O 
was O 
no O 
evidence O 
for O 
significant O 
gut O 
extraction O 
of O 
systemically O 
administered O 
drug O 
. O 
3 O 
. O 
Mass O 
balance O 
data O 
and O 
in O 
vivo O 
metabolite O 
characterization O 
obtained O 
after O 
administration O 
of O 
[ B-SYSTEMATIC 
(14)C I-SYSTEMATIC 
] I-SYSTEMATIC 
AMG I-SYSTEMATIC 
221 I-SYSTEMATIC 
to O 
rat O 
showed O 
that O 
AMG B-IDENTIFIER 
221 I-IDENTIFIER 
was O 
completely O 
absorbed O 
from O 
the O 
gut O 
lumen O 
following O 
an O 
oral O 
dose O 
, O 
primarily O 
excreted O 
in O 
urine O 
and O 
was O 
almost O 
completely O 
metabolized O 
prior O 
to O 
excretion O 
. O 
4 O 
. O 
Hepatic O 
bioavailability O 
( O 
FH O 
) O 
, O 
measured O 
in O 
two O 
animals O 
at O 
various O 
time O 
points O 
after O 
oral O 
dose O 
administration O 
was O 
somewhat O 
variable O 
but O 
generally O 
characterized O 
by O 
an O 
initial O 
reduction O 
during O 
the O 
absorption O 
phase O 
followed O 
by O 
an O 
increase O 
during O 
the O 
elimination O 
phase O 
, O 
consistent O 
with O 
hepatic O 
distribution O 
of O 
AMG B-IDENTIFIER 
221 I-IDENTIFIER 
. O 
5 O 
. O 
The O 
five O 
- O 
catheter O 
rat O 
model O 
afforded O 
estimates O 
of O 
hepatic O 
and O 
intestinal O 
contribution O 
to O 
oral O 
bioavailability O 
that O 
were O 
used O 
with O 
other O 
data O 
to O 
define O 
the O 
preclinical O 
ADME O 
characteristics O 
of O 
a O 
drug O 
candidate O 
. O 

and O 
biological O 
activities O 
of O 
some O 
novel O 
aminomethyl B-SYSTEMATIC 
derivatives O 
of O 
4- B-FAMILY 
substituted-5-(2-thienyl)-2,4-dihydro-3H-1,2,4-triazole-3-thiones I-FAMILY 
. O 

novel O 
series O 
of O 
compounds O 
were O 
synthesized O 
by O 
cyclic O 
condensation O 
reaction O 
of O 
substituted O 
isothiocyanate B-FAMILY 
( O 
2a-c O 
) O 
with O 
2-thiophenecarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
hydrazide I-SYSTEMATIC 
( O 
1 O 
) O 
in O 
the O 
presence O 
of O 
ethyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
, O 
to O 
obtain O 
intermediate O 
thiosemicarbazides B-FAMILY 
( O 
3a-c O 
) O 
, O 
which O 
were O 
further O 
treated O 
with O 
sodium B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
in O 
the O 
presence O 
of O 
ethanol B-SYSTEMATIC 
to O 
obtain O 
triazole B-FAMILY 
derivatives O 
( O 
4a-c O 
) O 
. O 
The O 
latter O 
were O 
refluxed O 
with O 
substituted O 
secondary B-FAMILY 
amines I-FAMILY 
and O 
formaldehyde B-SYSTEMATIC 
for O 
6-10 O 
h O 
to O 
afford O 
Mannich B-FAMILY 
bases I-FAMILY 
( O 
5a-k O 
) O 
. O 
The O 
synthesized O 
compounds O 
were O 
characterized O 
on O 
the O 
basis O 
of O 
their O 
spectral O 
( O 
IR O 
, O 
(13)C B-FORMULA 
and O 
(1)H B-FORMULA 
NMR O 
) O 
data O 
and O 
evaluated O 
for O 
biological O 
activities O 
. O 
Some O 
of O 
the O 
compounds O 
were O 
found O 
to O 
exhibit O 
significant O 
antimicrobial O 
and O 
antioxidant O 
activity O 
. O 

, O 
modeling O 
, O 
synthesis O 
and O 
biological O 
activity O 
evaluation O 
of O 
camptothecin B-TRIVIAL 
-linked O 
platinum B-SYSTEMATIC 
anticancer O 
agents O 
. O 

design O 
, O 
modeling O 
, O 
synthesis O 
and O 
biological O 
activity O 
evaluation O 
of O 
two O 
hybrid O 
agents O 
formed O 
by O 
7-oxyiminomethylcamptothecin B-SYSTEMATIC 
derivatives O 
and O 
diaminedichloro B-SYSTEMATIC 
- I-SYSTEMATIC 
platinum I-SYSTEMATIC 
(II) I-SYSTEMATIC 
complex O 
are O 
reported O 
. O 
The O 
compounds O 
showed O 
growth O 
inhibitory O 
activity O 
against O 
a O 
panel O 
of O 
human O 
tumor O 
cell O 
lines O 
, O 
including O 
sublines O 
resistant O 
to O 
topotecan B-TRIVIAL 
and O 
platinum B-SYSTEMATIC 
compounds O 
. O 
The O 
derivatives O 
were O 
active O 
in O 
all O 
the O 
tested O 
cell O 
lines O 
, O 
and O 
compound O 
1b O 
, O 
the O 
most O 
active O 
one O 
, O 
was O 
able O 
to O 
overcome O 
cisplatin B-TRIVIAL 
resistance O 
in O 
the O 
osteosarcoma O 
U2OS O 
/ O 
Pt O 
cell O 
line O 
. O 
Platinum B-SYSTEMATIC 
-containing O 
camptothecins B-FAMILY 
produced O 
platinum B-SYSTEMATIC 
-DNA O 
adducts O 
and O 
topoisomerase O 
I O 
- O 
mediated O 
DNA O 
damage O 
with O 
cleavage O 
pattern O 
and O 
persistence O 
similar O 
to O 
SN38 B-IDENTIFIER 
, O 
the O 
active O 
principle O 
of O 
irinotecan B-TRIVIAL 
. O 
Compound O 
1b O 
exhibited O 
an O 
appreciable O 
antitumor O 
activity O 
in O 
vivo O 
against O 
human O 
H460 O 
tumor O 
xenograft O 
, O 
comparable O 
to O 
that O 
of O 
irinotecan B-TRIVIAL 
at O 
lower O 
well O 
- O 
tolerated O 
dose O 
levels O 
and O 
superior O 
to O 
cisplatin B-TRIVIAL 
. O 
The O 
results O 
support O 
the O 
interpretation O 
that O 
the O 
diaminedichloro B-SYSTEMATIC 
- I-SYSTEMATIC 
platinum I-SYSTEMATIC 
(II) I-SYSTEMATIC 
complex O 
conjugated O 
via O 
an O 
oxyiminomethyl B-SYSTEMATIC 
linker O 
at O 
the O 
7- O 
position O 
of O 
the O 
camptothecin B-TRIVIAL 
resulted O 
in O 
a O 
new O 
class O 
of O 
effective O 
antitumor O 
compounds O 
. O 

silica B-TRIVIAL 
-supported O 
lipid O 
bilayers O 
( O 
protocells O 
) O 
for O 
DNA O 
cargo O 
delivery O 
to O 
the O 
spinal O 
cord O 
. O 

mesoporous O 
silica B-TRIVIAL 
nanoparticles O 
( O 
' O 
protocells O 
' O 
) O 
that O 
support O 
surface O 
lipid O 
bilayers O 
recently O 
characterized O 
in O 
vitro O 
as O 
carrier O 
constructs O 
for O 
small O 
drug O 
and O 
DNA O 
delivery O 
are O 
reported O 
here O 
as O 
highly O 
biocompatible O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
, O 
involving O 
the O 
brain O 
and O 
spinal O 
cord O 
following O 
spinal O 
delivery O 
into O 
the O 
lumbosacral O 
subarachnoid O 
space O 
( O 
intrathecal O 
; O 
i.t O 
. O 
) O 
. O 
Specifically O 
, O 
positively O 
charged O 
, O 
1 B-SYSTEMATIC 
, I-SYSTEMATIC 
2-Dioleoyl-3-Trimethylammonium-Propane I-SYSTEMATIC 
( O 
DOTAP B-ABBREVIATION 
)- O 
cholesterol B-TRIVIAL 
( O 
DOTAP B-ABBREVIATION 
: O 
Chol B-ABBREVIATION 
) O 
liposome O 
- O 
formulated O 
protocells O 
revealed O 
stable O 
in O 
vitro O 
cargo O 
release O 
kinetics O 
and O 
cellular O 
interleukin-10 O 
( O 
IL-10 O 
) O 
transgene O 
transfection O 
. O 
Recent O 
approaches O 
using O 
synthetic O 
non-viral O 
vector O 
platforms O 
to O 
deliver O 
the O 
pain O 
- O 
suppressive O 
therapeutic O 
transgene O 
, O 
IL-10 O 
, O 
to O 
the O 
spinal O 
subarachnoid O 
space O 
have O 
yielded O 
promising O 
results O 
in O 
animal O 
models O 
of O 
peripheral O 
neuropathy O 
, O 
a O 
condition O 
involving O 
aberrant O 
neuronal O 
communication O 
within O 
sensory O 
pathways O 
in O 
the O 
nervous O 
system O 
. O 
Non-viral O 
drug O 
and O 
gene O 
delivery O 
protocell O 
platforms O 
offer O 
potential O 
flexibility O 
because O 
cargo O 
release O 
- O 
rates O 
can O 
be O 
pH-dependent O 
. O 
We O 
report O 
here O 
that O 
i.t O 
. O 
delivery O 
of O 
protocells O 
, O 
with O 
modified O 
chemistry O 
supporting O 
a O 
surface O 
coating O 
of O 
DOTAP B-ABBREVIATION 
: O 
Chol B-ABBREVIATION 
liposomes O 
and O 
containing O 
the O 
IL-10 O 
transgene O 
, O 
results O 
in O 
functional O 
suppression O 
of O 
pain O 
- O 
related O 
behavior O 
in O 
rats O 
for O 
extended O 
periods O 
. O 
This O 
study O 
is O 
the O 
first O 
demonstration O 
that O 
protocell O 
vectors O 
offer O 
amenable O 
and O 
enduring O 
in O 
vivo O 
biological O 
characteristics O 
that O 
can O 
be O 
applied O 
to O 
spinal O 
gene O 
delivery O 
. O 

characterization O 
of O 
domestic O 
oral O 
tobacco O 
products O 
: O 
Total O 
nicotine B-TRIVIAL 
, O 
pH O 
, O 
unprotonated O 
nicotine B-TRIVIAL 
and O 
tobacco O 
- O 
specific O 
N-nitrosamines B-FAMILY 
. O 

the O 
United O 
States O 
, O 
moist O 
snuff O 
has O 
been O 
studied O 
more O 
widely O 
than O 
other O 
distinct O 
categories O 
of O 
oral O 
tobacco O 
. O 
In O 
this O 
study O 
, O 
we O 
measured O 
pH O 
, O 
moisture O 
, O 
nicotine B-TRIVIAL 
( O 
total O 
and O 
unprotonated O 
) O 
, O 
and O 
tobacco O 
- O 
specific O 
N-nitrosamines B-FAMILY 
( O 
TSNAs O 
) O 
for O 
other O 
established O 
( O 
twist O 
, O 
loose O 
leaf O 
, O 
plug O 
, O 
and O 
dry O 
snuff O 
without O 
pouch O 
) O 
and O 
emerging O 
oral O 
tobacco O 
products O 
( O 
dry O 
snuff O 
pouch O 
, O 
US-made O 
snus O 
, O 
and O 
dissolvable O 
tobacco O 
) O 
. O 
Among O 
the O 
seven O 
product O 
categories O 
, O 
product O 
pH O 
ranged O 
from O 
4.7 O 
to O 
7.9 O 
, O 
and O 
total O 
nicotine B-TRIVIAL 
concentration O 
spanned O 
from O 
3.9 O 
to O 
40.1mg O 
/ O 
g O 
. O 
The O 
most O 
readily O 
absorbable O 
form O 
of O 
nicotine B-TRIVIAL 
( O 
unprotonated O 
nicotine B-TRIVIAL 
) O 
varied O 
more O 
than O 
350-fold O 
, O 
ranging O 
from O 
0.01 O 
to O 
3.7mg O 
/ O 
g O 
. O 
While O 
the O 
highest O 
total O 
nicotine B-TRIVIAL 
concentrations O 
were O 
observed O 
in O 
twist O 
products O 
, O 
snus O 
and O 
dissolvable O 
tobacco O 
had O 
the O 
highest O 
unprotonated O 
nicotine B-TRIVIAL 
levels O 
. O 
Among O 
all O 
products O 
, O 
total O 
TSNA O 
concentrations O 
ranged O 
from O 
313 O 
to O 
76,500ng O 
/ O 
g O 
with O 
dry O 
snuff O 
having O 
the O 
highest O 
total O 
TSNA O 
concentrations O 
. O 
This O 
study O 
demonstrates O 
the O 
diversity O 
among O 
oral O 
tobacco O 
products O 
and O 
highlights O 
the O 
potential O 
of O 
these O 
products O 
to O 
deliver O 
a O 
wide O 
range O 
of O 
nicotine B-TRIVIAL 
and O 
carcinogenic O 
TSNAs O 
. O 
Characterizing O 
the O 
chemical O 
content O 
of O 
these O 
products O 
may O 
be O 
helpful O 
in O 
further O 
understanding O 
the O 
risk O 
of O 
marketing O 
these O 
products O 
to O 
oral O 
tobacco O 
users O 
and O 
smokers O 
as O 
an O 
alternative O 
and O 
discrete O 
form O 
of O 
tobacco O 
. O 

, O 
synthesis O 
and O 
structure O 
- O 
activity O 
relationships O 
of O 
3,5-diaryl-1H-pyrazoles B-FAMILY 
as O 
inhibitors O 
of O 
arylamine B-FAMILY 
N B-FORMULA 
-acetyltransferase O 
. O 

synthesis O 
and O 
inhibitory O 
potencies O 
of O 
a O 
novel O 
series O 
of O 
3,5-diaryl-1H-pyrazoles B-FAMILY 
as O 
specific O 
inhibitors O 
of O 
prokaryotic O 
arylamine B-FAMILY 
N B-FORMULA 
-acetyltransferase O 
enzymes O 
is O 
described O 
. O 
The O 
series O 
is O 
based O 
on O 
hit O 
compound O 
1 B-FAMILY 
3,5-diaryl-1H-pyrazole I-FAMILY 
identified O 
from O 
a O 
high O 
- O 
throughout O 
screen O 
that O 
has O 
been O 
carried O 
out O 
previously O 
and O 
found O 
to O 
inhibit O 
the O 
growth O 
of O 
Mycobacterium O 
tuberculosis O 
. O 

is O 
a O 
highly O 
conserved O 
protein O 
complex O 
related O 
to O 
cohesin O 
and O 
condensin O 
involved O 
in O 
the O 
structural O 
maintenance O 
of O 
chromosomes O 
. O 
In O 
yeasts O 
the O 
Smc5-6 O 
complex O 
is O 
essential O 
for O 
proliferation O 
and O 
is O 
involved O 
in O 
DNA O 
repair O 
and O 
homologous O 
recombination O 
. O 
siRNA O 
depletion O 
of O 
genes O 
involved O 
in O 
the O 
Smc5-6 O 
complex O 
in O 
cultured O 
mammalian O 
cells O 
results O 
in O 
sensitivity O 
to O 
some O 
DNA O 
damaging O 
agents O 
. O 
In O 
order O 
to O 
gain O 
further O 
insight O 
into O 
its O 
role O 
in O 
mammals O 
we O 
have O 
generated O 
mice O 
mutated O 
in O 
the O 
Smc6 O 
gene O 
. O 
A O 
complete O 
knockout O 
resulted O 
in O 
early O 
embryonic O 
lethality O 
, O 
demonstrating O 
that O 
this O 
gene O 
is O 
essential O 
in O 
mammals O 
. O 
However O 
, O 
mutation O 
of O 
the O 
highly O 
conserved O 
serine B-TRIVIAL 
-994 O 
to O 
alanine B-TRIVIAL 
in O 
the O 
ATP B-ABBREVIATION 
hydrolysis O 
motif O 
in O 
the O 
SMC6 O 
C- O 
terminal O 
domain O 
, O 
resulted O 
in O 
mice O 
with O 
a O 
surprisingly O 
mild O 
phenotype O 
. O 
With O 
the O 
neo O 
gene O 
selection O 
marker O 
in O 
the O 
intron O 
following O 
the O 
mutation O 
, O 
resulting O 
in O 
reduced O 
expression O 
of O 
the O 
SMC6 O 
gene O 
, O 
the O 
mice O 
were O 
reduced O 
in O 
size O 
, O 
but O 
fertile O 
and O 
had O 
normal O 
lifespans O 
. O 
When O 
the O 
neo O 
gene O 
was O 
removed O 
, O 
the O 
mice O 
had O 
normal O 
size O 
, O 
but O 
detailed O 
phenotypic O 
analysis O 
revealed O 
minor O 
abnormalities O 
in O 
glucose B-TRIVIAL 
tolerance O 
, O 
haematopoiesis O 
, O 
nociception O 
and O 
global O 
gene O 
expression O 
patterns O 
. O 
Embryonic O 
fibroblasts O 
derived O 
from O 
the O 
ser B-FORMULA 
994 O 
mutant O 
mice O 
were O 
not O 
sensitive O 
to O 
killing O 
by O 
a O 
range O 
of O 
DNA O 
damaging O 
agents O 
, O 
but O 
they O 
were O 
sensitive O 
to O 
the O 
induction O 
of O 
sister O 
chromatid O 
exchanges O 
induced O 
by O 
ultraviolet O 
light O 
or O 
mitomycin B-TRIVIAL 
C I-TRIVIAL 
. O 
They O 
also O 
accumulated O 
more O 
oxidative O 
damage O 
than O 
wild O 
- O 
type O 
cells O 
. O 

evidence O 
for O 
surface O 
freezing O 
in O 
supercooled O 
n-alkane B-FAMILY 
nanodroplets O 
. O 

chain O 
length O 
( O 
16 O 
≤ O 
i≤ O 
50 O 
) O 
n-alkanes B-FAMILY 
are O 
known O 
to O 
surface O 
freeze O 
at O 
temperatures O 
that O 
are O 
up O 
to O 
three O 
degrees O 
higher O 
than O 
the O 
equilibrium O 
melting O 
point O 
[ O 
B O 
. O 
M O 
. O 
Ocko O 
et O 
al O 
. O 
, O 
Phys O 
. O 
Rev O 
. O 
E O 
, O 
1997 O 
, O 
55 O 
, O 
3164-3182 O 
] O 
. O 
Our O 
recent O 
experimental O 
results O 
suggest O 
that O 
highly O 
supercooled O 
nanodroplets O 
of O 
n-octane B-SYSTEMATIC 
and O 
n-nonane B-SYSTEMATIC 
also O 
surface O 
freeze O 
, O 
and O 
subsequently O 
bulk O 
crystallization O 
occurs O 
. O 
The O 
data O 
yield O 
surface O 
and O 
bulk O 
nucleation O 
rates O 
on O 
the O 
order O 
of O 
∼10(15) O 
cm(-2) O 
s(-1) O 
and O 
∼10(22) O 
cm(-3) O 
s(-1) O 
, O 
respectively O 
, O 
at O 
temperatures O 
between O 
180 O 
K O 
and O 
200 O 
K O 
. O 
Molecular O 
dynamics O 
simulations O 
at O 
the O 
united O 
atom O 
level O 
were O 
used O 
to O 
follow O 
the O 
freezing O 
of O 
a O 
supercooled O 
n-octane B-SYSTEMATIC 
drop O 
and O 
show O 
that O 
an O 
ordered O 
monolayer O 
develops O 
on O 
the O 
surface O 
of O 
the O 
droplet O 
almost O 
immediately O 
, O 
and O 
the O 
rest O 
of O 
the O 
droplet O 
then O 
freezes O 
in O 
a O 
layer O 
- O 
by O 
- O 
layer O 
manner O 
. O 

influences O 
of O 
compositional O 
asymmetry O 
on O 
the O 
two O 
- O 
photon O 
photoluminescence O 
and O 
the O 
second O 
harmonic O 
generation O 
processes O 
in O 
weakly O 
coupled O 
plasmonic O 
dimers O 
were O 
addressed O 
. O 
Au-Au B-FORMULA 
homodimer O 
and O 
Au-Ag B-FORMULA 
heterodimer O 
arrays O 
produced O 
using O 
electron O 
- O 
beam O 
lithography O 
were O 
investigated O 
using O 
confocal O 
nonlinear O 
optical O 
imaging O 
and O 
spectroscopy O 
. O 
Compared O 
to O 
the O 
Au-Au B-FORMULA 
homodimers O 
, O 
the O 
Au-Ag B-FORMULA 
dimers O 
showed O 
slightly O 
broadened O 
two O 
- O 
photon O 
photoluminescence O 
near O 
the O 
X O 
symmetry O 
point O 
at O 
the O 
first O 
Brillouin O 
zone O 
of O 
Au B-FORMULA 
, O 
whilst O 
that O 
from O 
the O 
L O 
symmetry O 
point O 
stayed O 
the O 
same O 
. O 
Additionally O 
, O 
weakly O 
coupled O 
Au-Ag B-FORMULA 
heterodimers O 
generated O 
strong O 
second O 
harmonic O 
signals O 
which O 
were O 
invisible O 
in O 
the O 
Au-Au B-FORMULA 
homodimers O 
. O 
The O 
observations O 
highlighted O 
the O 
importance O 
of O 
compositional O 
asymmetry O 
in O 
the O 
non-linear O 
optical O 
studies O 
of O 
plasmonic O 
dimers O 
. O 

X O 
Receptor O 
Mediates O 
Dyslipidemia O 
Induced O 
by O 
the O 
HIV O 
Protease O 
Inhibitor O 
Amprenavir B-TRIVIAL 
in O 
Mice O 
. O 

protease O 
inhibitors O 
( O 
PIs O 
) O 
have O 
been O 
used O 
successfully O 
in O 
extending O 
the O 
lifespan O 
of O 
people O 
infected O 
with O 
HIV O 
. O 
The O 
use O 
of O 
PIs O 
has O 
also O 
been O 
associated O 
with O 
dyslipidemia O 
and O 
an O 
increased O 
risk O 
of O 
cardiovascular O 
disease O 
but O 
the O 
underlying O 
mechanisms O 
remain O 
elusive O 
. O 
Several O 
PIs O 
have O 
been O 
implicated O 
to O 
activate O 
the O 
nuclear O 
receptor O 
pregnane B-TRIVIAL 
X O 
receptor O 
( O 
PXR O 
) O 
, O 
which O 
acts O 
as O 
a O 
xenobiotic O 
sensor O 
to O 
regulate O 
xenobiotic O 
metabolism O 
in O 
the O 
liver O 
and O 
intestine O 
. O 
Recent O 
studies O 
indicate O 
that O 
PXR O 
may O 
also O 
play O 
an O 
important O 
role O 
in O 
the O 
regulation O 
of O 
lipid O 
homeostasis O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
identified O 
amprenavir B-TRIVIAL 
, O 
a O 
widely O 
used O 
HIV O 
PI O 
, O 
as O 
a O 
potent O 
PXR-selective O 
agonist O 
. O 
Computational O 
docking O 
studies O 
combined O 
with O 
site O 
- O 
direct O 
mutagenesis O 
identified O 
several O 
key O 
residues O 
within O 
the O 
ligand O 
binding O 
pocket O 
of O 
PXR O 
that O 
constitute O 
points O 
of O 
interaction O 
with O 
amprenavir B-TRIVIAL 
. O 
Amprenavir B-TRIVIAL 
efficiently O 
activated O 
PXR O 
and O 
induced O 
PXR O 
target O 
gene O 
expression O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Short O 
- O 
term O 
exposure O 
to O 
amprenavir B-TRIVIAL 
significantly O 
increased O 
plasma O 
total O 
cholesterol B-TRIVIAL 
and O 
atherogenic O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
levels O 
in O 
wild O 
- O 
type O 
mice O 
, O 
but O 
not O 
in O 
PXR-deficient O 
mice O 
. O 
Amprenavir B-TRIVIAL 
-mediated O 
PXR O 
activation O 
stimulated O 
the O 
expression O 
of O 
several O 
key O 
intestinal O 
genes O 
involved O 
in O 
lipid O 
homeostasis O 
. O 
These O 
findings O 
provide O 
critical O 
mechanistic O 
insight O 
for O 
understanding O 
the O 
impact O 
of O 
PIs O 
on O 
cardiovascular O 
disease O 
and O 
demonstrate O 
a O 
potential O 
role O 
of O 
PXR O 
in O 
mediating O 
adverse O 
effects O 
of O 
HIV O 
PIs O 
in O 
humans O 
. O 

( O 
sialidases O 
) O 
catalyze O 
the O 
removal O 
of O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
residues O 
from O 
sialylated O 
glycoconjugates O 
. O 
We O 
now O 
report O 
that O 
mammalian O 
neuraminidase O 
1 O 
( O 
Neu1 O 
) O 
, O 
in O 
addition O 
to O 
its O 
catabolic O 
function O 
in O 
lysosomes O 
, O 
is O 
transported O 
to O 
the O 
cell O 
surface O 
where O 
it O 
is O 
involved O 
in O 
regulation O 
of O 
insulin O 
signaling O 
. O 
Insulin O 
binding O 
to O 
its O 
receptor O 
rapidly O 
induces O 
interaction O 
of O 
the O 
receptor O 
with O 
Neu1 O 
, O 
which O 
hydrolyzes O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
residues O 
in O 
the O 
glycan O 
chains O 
of O 
the O 
receptor O 
and O 
, O 
consequently O 
, O 
induces O 
its O 
activation O 
. O 
Cells O 
from O 
sialidosis O 
patients O 
with O 
a O 
genetic O 
deficiency O 
of O 
Neu1 O 
show O 
impairment O 
of O 
insulin O 
- O 
induced O 
phosphorylation O 
of O 
downstream O 
protein O 
kinase O 
AKT O 
, O 
while O 
treatment O 
of O 
these O 
cells O 
with O 
purified O 
Neu1 O 
restores O 
signaling O 
. O 
Genetically O 
- O 
modified O 
mice O 
with O 
∼10% O 
of O 
the O 
normal O 
Neu1 O 
activity O 
exposed O 
to O 
a O 
high O 
- O 
fat O 
diet O 
develop O 
hyperglycemia O 
and O 
insulin O 
resistance O 
twice O 
as O 
fast O 
as O 
their O 
wild O 
type O 
counterparts O 
. O 
Together O 
, O 
these O 
studies O 
identify O 
Neu1 O 
as O 
a O 
novel O 
component O 
of O 
the O 
signaling O 
pathways O 
of O 
energy O 
metabolism O 
and O 
glucose B-TRIVIAL 
uptake O 
. O 

fibrinolysis O 
inhibitor O 
discovered O 
by O 
shape O 
and O 
electrostatic O 
complementarity O 
to O 
the O 
drug O 
tranexamic B-TRIVIAL 
Acid I-TRIVIAL 
. O 

- O 
protein O 
interfaces O 
provide O 
an O 
important O 
class O 
of O 
drug O 
targets O 
currently O 
receiving O 
increased O 
attention O 
. O 
The O 
typical O 
design O 
strategy O 
to O 
inhibit O 
protein O 
- O 
protein O 
interactions O 
usually O 
involves O 
large O 
molecules O 
such O 
as O 
peptides O 
and O 
macrocycles O 
. O 
One O 
exception O 
is O 
tranexamic B-TRIVIAL 
acid I-TRIVIAL 
( O 
TXA B-ABBREVIATION 
) O 
, O 
which O 
, O 
as O 
a O 
lysine B-TRIVIAL 
mimetic O 
, O 
inhibits O 
binding O 
of O 
plasminogen O 
to O 
fibrin O 
. O 
However O 
, O 
the O 
daily O 
dose O 
of O 
TXA B-ABBREVIATION 
is O 
high O 
due O 
to O 
its O 
modest O 
potency O 
and O 
pharmacokinetic O 
properties O 
. O 
In O 
this O 
study O 
, O 
we O 
report O 
a O 
computational O 
approach O 
, O 
where O 
the O 
focus O 
was O 
on O 
finding O 
electrostatic O 
potential O 
similarities O 
to O 
TXA B-ABBREVIATION 
. O 
Coupling O 
this O 
computational O 
technique O 
with O 
a O 
high O 
- O 
quality O 
low O 
- O 
throughput O 
screen O 
identified O 
5-(4-piperidyl)-3-isoxazolol B-SYSTEMATIC 
( O 
4-PIOL B-SYSTEMATIC 
) O 
as O 
a O 
potent O 
plasminogen O 
binding O 
inhibitor O 
with O 
the O 
potential O 
for O 
the O 
treatment O 
of O 
various O 
bleeding O 
disorders O 
. O 
Remarkably O 
, O 
4-PIOL B-SYSTEMATIC 
was O 
found O 
to O 
be O 
more O 
than O 
four O 
times O 
as O 
potent O 
as O 
the O 
drug O 
TXA B-ABBREVIATION 
. O 

from O 
Scutellaria O 
baicalensis O 
Suppresses O 
Adipogenesis O 
by O 
Upregulating O 
PPARα O 
in O 
3T3-L1 O 
Cells O 
. O 

dysfunction O 
is O 
a O 
major O 
cause O 
of O 
obesity O 
, O 
which O 
is O 
associated O 
strongly O 
with O 
many O 
disorders O 
including O 
psychological O 
and O 
medical O 
morbidities O 
, O 
metabolic O 
abnormalities O 
, O 
and O 
cardiovascular O 
diseases O 
as O 
well O 
as O 
a O 
series O 
of O 
cancers O 
. O 
This O 
study O 
investigated O 
the O 
antiadipogenic O 
activity O 
of O 
scutellarin B-TRIVIAL 
( O 
1 O 
) O 
in O 
3T3-L1 O 
preadipocytes O 
as O 
well O 
as O 
the O 
underlying O 
molecular O 
mechanisms O 
. O 
It O 
was O 
observed O 
that O 
1 O 
reduced O 
adipocyte O 
differentiation O 
of O 
3T3-L1 O 
cells O 
potently O 
, O 
as O 
evidenced O 
by O 
a O 
decrease O 
in O 
cellular O 
lipid O 
accumulation O 
. O 
At O 
the O 
molecular O 
level O 
, O 
mRNA O 
expression O 
of O 
the O 
master O 
adipogenic O 
transcription O 
factors O 
, O 
PPARγ O 
and O 
C O 
/ O 
EBPα O 
, O 
was O 
decreased O 
markedly O 
. O 
However O 
, O 
mRNA O 
levels O 
of O 
C O 
/ O 
EBPβ O 
, O 
the O 
upstream O 
regulator O 
of O 
PPARγ O 
and O 
C O 
/ O 
EBPα O 
, O 
were O 
not O 
decreased O 
by O 
1 O 
. O 
Moreover O 
, O 
a O 
dose O 
- O 
dependent O 
upregulation O 
of O 
PPARα O 
was O 
observed O 
for O 
1 O 
. O 
Computational O 
modeling O 
indicated O 
that O 
1 O 
can O 
bind O 
to O 
PPARα O 
, O 
γ O 
, O 
and O 
δ O 
each O 
in O 
a O 
distinct O 
manner O 
, O 
while O 
it O 
can O 
activate O 
PPARα O 
only O 
by O 
forming O 
a O 
hydrogen B-SYSTEMATIC 
bond O 
with O 
Y464 O 
, O 
thus O 
stabilizing O 
the O 
AF-2 O 
helix O 
and O 
activating O 
PPARα O 
. O 
Therefore O 
, O 
these O 
results O 
suggest O 
that O 
1 O 
, O 
a O 
major O 
component O 
of O 
Scutellaria O 
baicalensis O 
, O 
attenuates O 
fat O 
cell O 
differentiation O 
by O 
upregulating O 
PPARα O 
as O 
well O 
as O 
downregulating O 
the O 
expression O 
of O 
PPARγ O 
and O 
C O 
/ O 
EBPα O 
, O 
thus O 
showing O 
therapeutic O 
potential O 
for O 
obesity O 
- O 
related O 
diseases O 
. O 

integration O 
of O 
a O 
tripeptide B-FAMILY 
derivative O 
, O 
which O 
is O 
a O 
versatile O 
self O 
- O 
assembly O 
motif O 
, O 
with O 
a O 
ruthenium(II)tris(bipyridine) B-SYSTEMATIC 
complex O 
affords O 
the O 
first O 
supramolecular O 
metallo-hydrogelator O 
that O 
not O 
only O 
self O 
assembles O 
in O 
water O 
to O 
form O 
a O 
hydrogel O 
but O 
also O 
exhibits O 
gel O 
- O 
sol O 
transition O 
upon O 
oxidation O 
of O 
the O 
metal O 
center O 
. O 
Surprisingly O 
, O 
the O 
incorporation O 
of O 
the O 
metal O 
complex O 
in O 
the O 
hydrogelator O 
results O 
in O 
the O 
nanofibers O 
, O 
formed O 
by O 
the O 
self O 
- O 
assembly O 
of O 
the O 
hydrogelator O 
in O 
water O 
, O 
to O 
have O 
the O 
width O 
of O 
a O 
single O 
molecule O 
of O 
the O 
hydrogelator O 
. O 
These O 
results O 
illustrate O 
that O 
metal O 
complexes O 
, O 
besides O 
being O 
able O 
to O 
impart O 
rich O 
optical O 
, O 
electronic O 
, O 
redox O 
, O 
or O 
magnetic O 
properties O 
to O 
supramolecular O 
hydrogels O 
, O 
also O 
offer O 
a O 
unique O 
geometrical O 
control O 
to O 
prearrange O 
the O 
self O 
- O 
assembly O 
motif O 
prior O 
to O 
self O 
- O 
assembling O 
. O 
The O 
use O 
of O 
metal O 
complexes O 
to O 
modulate O 
the O 
dimensionality O 
of O 
intermolecular O 
interactions O 
may O 
also O 
help O 
elucidate O 
the O 
interactions O 
of O 
the O 
molecular O 
nanofibers O 
with O 
other O 
molecules O 
, O 
thus O 
facilitating O 
the O 
development O 
of O 
supramolecular O 
hydrogel O 
materials O 
for O 
a O 
wide O 
range O 
of O 
applications O 
. O 

- O 
like O 
kinase-2 O 
( O 
Plk-2 O 
) O 
is O 
a O 
potential O 
therapeutic O 
target O 
for O 
Parkinson's O 
disease O 
and O 
this O 
Letter O 
describes O 
the O 
SAR O 
of O 
a O 
series O 
of O 
dihydropteridinone B-SYSTEMATIC 
based O 
Plk-2 O 
inhibitors O 
. O 
By O 
optimizing O 
both O 
the O 
N-8 O 
substituent O 
and O 
the O 
biaryl O 
region O 
of O 
the O 
inhibitors O 
we O 
obtained O 
single O 
digit O 
nanomolar O 
compounds O 
such O 
as O 
37 O 
with O 
excellent O 
selectivity O 
for O 
Plk-2 O 
over O 
Plk-1 O 
. O 
When O 
dosed O 
orally O 
in O 
rats O 
, O 
compound O 
37 O 
demonstrated O 
a O 
41-45% O 
reduction O 
of O 
pS129-α-synuclein O 
levels O 
in O 
the O 
cerebral O 
cortex O 
. O 

linteus O 
mushroom O 
protects O 
against O 
tacrine B-TRIVIAL 
-induced O 
mitochondrial O 
impairment O 
and O 
oxidative O 
stress O 
in O 
HepG2 O 
cells O 
. O 

( O 
THA B-ABBREVIATION 
) O 
was O 
the O 
first O 
drug O 
licensed O 
for O 
the O 
treatment O 
of O 
Alzheimer's O 
disease O 
. O 
Unfortunately O 
, O 
reversible O 
hepatotoxicity O 
is O 
evident O 
in O 
about O 
30% O 
of O 
patients O 
and O 
limits O 
its O 
clinical O 
use O 
. O 
The O 
intracellular O 
mechanisms O 
have O 
not O 
yet O 
been O 
elucidated O 
. O 
Phellinus O 
linteus O 
( O 
PL O 
) O 
is O 
a O 
mushroom O 
that O 
has O 
long O 
been O 
used O 
as O 
a O 
folk O 
medicine O 
. O 
In O 
our O 
previous O 
study O 
, O 
we O 
found O 
that O 
PL O 
could O 
decrease O 
the O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
formation O 
in O 
HepG2 O 
cells O 
. O 
Presently O 
, O 
protective O 
effects O 
of O 
PL O 
on O 
tacrine B-TRIVIAL 
-induced O 
ROS O 
formation O 
and O 
mitochondria O 
dysfunction O 
were O 
evaluated O 
. O 
The O 
results O 
showed O 
that O 
PL O 
significantly O 
reduced O 
tacrine B-TRIVIAL 
-induced O 
ROS O 
production O 
, O 
disruption O 
of O 
ΔΨm O 
, O 
8-OHdG B-SYSTEMATIC 
formation O 
in O 
mitochondrial O 
DNA O 
, O 
and O 
cytotoxicity O 
in O 
HepG2 O 
cells O 
. O 
These O 
data O 
suggest O 
that O 
PL O 
could O 
attenuate O 
the O 
cytotoxicity O 
and O 
mitochondria O 
dysfunction O 
induced O 
by O 
tacrine B-TRIVIAL 
in O 
HepG2 O 
cells O 
. O 
The O 
protection O 
is O 
probably O 
mediated O 
by O 
an O 
antioxidant O 
protective O 
mechanism O 
. O 
Consumption O 
of O 
PL O 
may O 
be O 
a O 
plausible O 
way O 
to O 
prevent O 
tacrine B-TRIVIAL 
-induced O 
hepatotoxicity O 
. O 

- I-FAMILY 
glycolide I-FAMILY 
( O 
PLGA B-ABBREVIATION 
) O 
microparticles O 
emerged O 
as O 
one O 
of O 
the O 
most O 
promising O 
strategies O 
to O 
achieve O 
site O 
- O 
specific O 
drug O 
delivery O 
. O 
Although O 
these O 
microparticles O 
have O 
been O 
demonstrated O 
to O 
be O 
effective O 
in O 
several O 
wound O 
healing O 
models O 
, O 
their O 
potential O 
in O 
cardiac O 
regeneration O 
has O 
not O 
yet O 
been O 
fully O 
assessed O 
. O 
The O 
present O 
work O 
sought O 
to O 
explore O 
PLGA B-ABBREVIATION 
microparticles O 
as O 
cardiac O 
drug O 
delivery O 
systems O 
. O 
PLGA B-ABBREVIATION 
microparticles O 
were O 
prepared O 
by O 
Total O 
Recirculation O 
One-Machine O 
System O 
( O 
TROMS O 
) O 
after O 
the O 
formation O 
of O 
a O 
multiple O 
emulsion O 
. O 
Microparticles O 
of O 
different O 
size O 
were O 
prepared O 
and O 
characterized O 
to O 
select O 
the O 
most O 
suitable O 
size O 
for O 
intramyocardial O 
administration O 
. O 
Next O 
, O 
the O 
potential O 
of O 
PLGA B-ABBREVIATION 
microparticles O 
for O 
administration O 
in O 
the O 
heart O 
was O 
assessed O 
in O 
a O 
MI O 
rat O 
model O 
. O 
Particle O 
biodegradation O 
over O 
time O 
and O 
myocardial O 
tissue O 
reaction O 
were O 
studied O 
by O 
routine O 
staining O 
and O 
confocal O 
microscopy O 
. O 
Results O 
showed O 
that O 
microparticles O 
with O 
a O 
diameter O 
of O 
5μm O 
were O 
the O 
most O 
compatible O 
with O 
intramyocardial O 
administration O 
in O 
terms O 
of O 
injectability O 
through O 
a O 
29-gauge O 
needle O 
and O 
tissue O 
response O 
. O 
Particles O 
were O 
present O 
in O 
the O 
heart O 
tissue O 
for O 
up O 
to O 
3months O 
post O 
- O 
implantation O 
and O 
no O 
particle O 
migration O 
toward O 
other O 
solid O 
organs O 
was O 
observed O 
, O 
demonstrating O 
good O 
myocardial O 
retention O 
. O 
CD68 O 
immunolabeling O 
revealed O 
31% O 
, O 
47% O 
and O 
below O 
4% O 
microparticle O 
uptake O 
by O 
macrophages O 
1week O 
, O 
1month O 
, O 
and O 
3months O 
after O 
injection O 
, O 
respectively O 
( O 
P O 
< O 
0.001 O 
) O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
support O 
the O 
feasibility O 
of O 
the O 
developed O 
PLGA B-ABBREVIATION 
microparticles O 
as O 
vehicles O 
for O 
delivering O 
growth O 
factors O 
in O 
the O 
infarcted O 
myocardium O 
. O 

, O 
a O 
novel O 
selective O 
androgen B-FAMILY 
receptor O 
modulator O 
, O 
improves O 
muscle O 
performance O 
in O 
the O 
exercised O 
- O 
mdx O 
mouse O 
model O 
of O 
muscular O 
dystrophy O 
. O 

drugs O 
may O 
counteract O 
muscle O 
wasting O 
and O 
dysfunction O 
in O 
Duchenne O 
muscular O 
dystrophy O 
( O 
DMD O 
) O 
; O 
however O 
, O 
steroids B-FAMILY 
have O 
unwanted O 
side O 
effects O 
. O 
We O 
focused O 
on O 
GLPG0492 B-IDENTIFIER 
, O 
a O 
new O 
non-steroidal O 
selective O 
androgen B-FAMILY 
receptor O 
modulator O 
that O 
is O 
currently O 
under O 
development O 
for O 
musculo O 
- O 
skeletal O 
diseases O 
such O 
as O 
sarcopenia O 
and O 
cachexia O 
. O 
GLPG0492 B-IDENTIFIER 
was O 
tested O 
in O 
the O 
exercised O 
mdx O 
mouse O 
model O 
of O 
DMD O 
in O 
a O 
4-week O 
trial O 
at O 
a O 
single O 
high O 
dose O 
( O 
30mg O 
/ O 
kg O 
, O 
6 O 
day O 
/ O 
week O 
s.c O 
. O 
) O 
, O 
and O 
the O 
results O 
were O 
compared O 
with O 
those O 
from O 
the O 
administration O 
of O 
α-methylprednisolone B-SYSTEMATIC 
( O 
PDN B-ABBREVIATION 
; O 
1mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
and O 
nandrolone B-TRIVIAL 
( O 
NAND B-ABBREVIATION 
, O 
5mg O 
/ O 
kg O 
, O 
s.c O 
. O 
) O 
. O 
This O 
assessment O 
was O 
followed O 
by O 
a O 
12-week O 
dose O 
- O 
dependence O 
study O 
( O 
0.3-30mg O 
/ O 
kg O 
s.c O 
. O 
) O 
. O 
The O 
outcomes O 
were O 
evaluated O 
in O 
vivo O 
and O 
ex O 
vivo O 
on O 
functional O 
, O 
histological O 
and O 
biochemical O 
parameters O 
. O 
Similar O 
to O 
PDN B-ABBREVIATION 
and O 
NAND B-ABBREVIATION 
, O 
GLPG0492 B-IDENTIFIER 
significantly O 
increased O 
mouse O 
strength O 
. O 
In O 
acute O 
exhaustion O 
tests O 
, O 
a O 
surrogate O 
of O 
the O 
6-min O 
walking O 
test O 
used O 
in O 
DMD O 
patients O 
, O 
GLPG0492 B-IDENTIFIER 
preserved O 
running O 
performance O 
, O 
whereas O 
vehicle- O 
or O 
comparator O 
- O 
treated O 
animals O 
showed O 
a O 
significant O 
increase O 
in O 
fatigue O 
( O 
30-50% O 
) O 
. O 
Ex O 
vivo O 
, O 
all O 
drugs O 
resulted O 
in O 
a O 
modest O 
but O 
significant O 
increase O 
of O 
diaphragm O 
force O 
. O 
In O 
parallel O 
, O 
a O 
decrease O 
in O 
the O 
non-muscle O 
area O 
and O 
markers O 
of O 
fibrosis O 
was O 
observed O 
in O 
GLPG0492 B-IDENTIFIER 
- O 
and O 
NAND B-ABBREVIATION 
-treated O 
mice O 
. O 
The O 
drugs O 
exerted O 
minor O 
effects O 
on O 
limb O 
muscles O 
; O 
however O 
, O 
electrophysiological O 
biomarkers O 
were O 
ameliorated O 
in O 
extensor O 
digitorum O 
longus O 
muscle O 
. O 
The O 
longer O 
dose O 
- O 
dependence O 
study O 
confirmed O 
the O 
effect O 
on O 
mdx O 
mouse O 
strength O 
and O 
resistance O 
to O 
fatigue O 
and O 
demonstrated O 
the O 
efficacy O 
of O 
lower O 
drug O 
doses O 
on O 
in O 
vivo O 
and O 
ex O 
vivo O 
functional O 
parameters O 
. O 
These O 
results O 
support O 
the O 
interest O 
of O 
further O 
studies O 
of O 
GLPG0492 B-IDENTIFIER 
as O 
a O 
potential O 
treatment O 
for O 
DMD O 
. O 

dibenzoylmethane B-SYSTEMATIC 
derivatives O 
protect O 
cells O 
from O 
oxidative O 
stress O 
- O 
induced O 
necrotic O 
cell O 
death O 
. O 

of O 
a O 
small O 
in O 
- O 
house O 
library O 
of O 
1863 O 
compounds O 
identified O 
29 O 
compounds O 
that O 
protected O 
Jurkat O 
cells O 
from O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
-induced O 
cytotoxicity O 
. O 
From O 
the O 
cytoprotective O 
compounds O 
eleven O 
proved O 
to O 
possess O 
antioxidant O 
activity O 
( O 
ABTS B-ABBREVIATION 
radical O 
scavenger O 
effect O 
) O 
and O 
two O 
were O 
found O 
to O 
inhibit O 
poly(ADP-ribosyl) B-FAMILY 
ation O 
( O 
PARylation O 
) O 
, O 
a O 
cytotoxic O 
pathway O 
operating O 
in O 
severely O 
injured O 
cells O 
. O 
Four O 
cytoprotective O 
dibenzoylmethane B-SYSTEMATIC 
( O 
DBM B-ABBREVIATION 
) O 
derivatives O 
were O 
investigated O 
in O 
more O 
detail O 
as O 
they O 
did O 
not O 
scavenge O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
nor O 
did O 
they O 
inhibit O 
PARylation O 
. O 
These O 
compounds O 
protected O 
cells O 
from O 
necrotic O 
cell O 
death O 
while O 
caspase O 
activation O 
, O 
a O 
parameter O 
of O 
apoptotic O 
cell O 
death O 
was O 
not O 
affected O 
. O 
Hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
activated O 
extracellular O 
signal O 
regulated O 
kinase O 
( O 
ERK1 O 
/ O 
2 O 
) O 
and O 
p38 O 
MAP O 
kinases O 
but O 
not O 
c-Jun O 
N B-FORMULA 
-terminal O 
kinase O 
( O 
JNK O 
) O 
. O 
The O 
cytoprotective O 
DBMs B-FAMILY 
suppressed O 
the O 
activation O 
of O 
Erk1 O 
/ O 
2 O 
but O 
not O 
that O 
of O 
p38 O 
. O 
Cytoprotection O 
was O 
confirmed O 
in O 
another O 
cell O 
type O 
( O 
A549 O 
lung O 
epithelial O 
cells O 
) O 
, O 
indicating O 
that O 
the O 
cytoprotective O 
effect O 
is O 
not O 
cell O 
type O 
specific O 
. O 
In O 
conclusion O 
we O 
identified O 
DBM B-ABBREVIATION 
analogs O 
as O 
a O 
novel O 
class O 
of O 
cytoprotective O 
compounds O 
inhibiting O 
ERK1 O 
/ O 
2 O 
kinase O 
and O 
protecting O 
from O 
necrotic O 
cell O 
death O 
by O 
a O 
mechanism O 
independent O 
of O 
poly(ADP-ribose) B-SYSTEMATIC 
polymerase O 
inhibition O 
. O 

induces O 
P-glycoprotein O 
expression O 
in O 
S2 O 
cells O 
via O 
the O 
calcium B-SYSTEMATIC 
/ O 
calmodulin O 
/ O 
NF-κB O 
pathway O 
. O 

( O 
AVM B-ABBREVIATION 
) O 
is O 
a O 
macrocyclic O 
lactone B-FAMILY 
agent O 
widely O 
used O 
as O 
a O 
nematicide O 
, O 
acaricide O 
and O 
insecticide O 
in O 
veterinary O 
medicine O 
and O 
plant O 
protection O 
. O 
P-glycoprotein O 
( O 
P-gp O 
) O 
is O 
an O 
ATP B-ABBREVIATION 
-dependent O 
drug O 
efflux O 
pump O 
for O 
xenobiotic O 
compounds O 
, O 
and O 
is O 
involved O 
in O 
multidrug O 
resistance O 
. O 
To O 
understand O 
the O 
development O 
of O 
AVM B-ABBREVIATION 
resistance O 
in O 
invertebrates O 
, O 
we O 
investigated O 
the O 
mechanisms O 
by O 
which O 
AVM B-ABBREVIATION 
affected O 
P-gp O 
expression O 
in O 
Drosophila O 
S2 O 
cells O 
. O 
We O 
found O 
that O 
AVM B-ABBREVIATION 
induced O 
upregulation O 
of O 
P-gp O 
protein O 
expression O 
, O 
increased O 
P-gp O 
ATPase O 
activity O 
and O 
enhanced O 
cellular O 
efflux O 
of O 
the O 
P-gp O 
substrate O 
rhodamine B-TRIVIAL 
123 I-TRIVIAL 
from O 
cells O 
. O 
Furthermore O 
, O 
we O 
observed O 
that O 
AVM B-ABBREVIATION 
-induced O 
expression O 
of O 
P-gp O 
was O 
due O 
to O 
elevation O 
of O 
intracellular O 
calcium B-SYSTEMATIC 
concentration O 
( O 
[ O 
Ca(2+) B-FORMULA 
]i O 
) O 
. O 
This O 
occurred O 
both O 
directly O 
, O 
by O 
activating O 
calcium B-SYSTEMATIC 
ion O 
channels O 
, O 
and O 
indirectly O 
, O 
by O 
activating O 
chloride B-SYSTEMATIC 
ion O 
channels O 
. O 
These O 
results O 
are O 
supported O 
by O 
our O 
observations O 
that O 
verapamil B-TRIVIAL 
, O 
a O 
Ca(2+) B-FORMULA 
channel O 
blocker O 
, O 
and O 
niflumic B-TRIVIAL 
acid I-TRIVIAL 
, O 
a O 
chloride B-SYSTEMATIC 
channel O 
antagonist O 
, O 
significantly O 
attenuated O 
AVM B-ABBREVIATION 
-induced O 
[ O 
Ca(2+) B-FORMULA 
]i O 
elevation O 
, O 
thereby O 
reducing O 
P-gp O 
expression O 
. O 
Inhibition O 
of O 
P-gp O 
with O 
anti-P-gp O 
antibody O 
or O 
cyclosporine B-TRIVIAL 
A I-TRIVIAL 
( O 
a O 
P-gp O 
inhibitor O 
) O 
reduced O 
the O 
AVM B-ABBREVIATION 
-induced O 
elevation O 
of O 
[ O 
Ca(2+) B-FORMULA 
]i O 
, O 
implying O 
that O 
P-gp O 
and O 
[ O 
Ca(2+) B-FORMULA 
]i O 
regulate O 
each O 
other O 
. O 
Finally O 
, O 
we O 
found O 
that O 
trifluoperazine B-TRIVIAL 
, O 
a O 
calmodulin O 
inhibitor O 
, O 
and O 
pyrrolidine B-SYSTEMATIC 
dithiocarbamic I-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
an O 
NF-κB O 
inhibitor O 
, O 
attenuated O 
the O 
AVM B-ABBREVIATION 
-induced O 
expression O 
of O 
P-gp O 
, O 
suggesting O 
that O 
AVM B-ABBREVIATION 
induces O 
P-gp O 
protein O 
expression O 
via O 
the O 
calmodulin O 
/ O 
Relish O 
( O 
NF-κB O 
) O 
signaling O 
pathway O 
. O 

of O 
securin O 
- O 
mediated O 
resistance O 
to O 
gefitinib B-TRIVIAL 
-induced O 
apoptosis O 
in O 
human O 
cancer O 
cells O 
. O 

, O 
a O 
tyrosine B-TRIVIAL 
kinase O 
inhibitor O 
of O 
the O 
epidermal O 
growth O 
factor O 
receptor O 
( O 
EGFR O 
) O 
, O 
has O 
been O 
used O 
to O 
treat O 
numerous O 
cancers O 
; O 
however O 
, O 
evidence O 
has O 
shown O 
that O 
cancer O 
cells O 
can O 
become O 
resistant O 
to O 
gefitinib B-TRIVIAL 
during O 
therapy O 
. O 
Here O 
, O 
we O 
report O 
a O 
human O 
proto O 
- O 
oncogene O 
, O 
securin O 
, O 
which O 
displays O 
resistance O 
to O 
death O 
in O 
cancer O 
cells O 
. O 
Gefitinib B-TRIVIAL 
treatment O 
decreases O 
securin O 
levels O 
at O 
the O 
protein O 
level O 
by O 
inducing O 
protein O 
instability O 
but O 
did O 
not O 
affect O 
on O 
the O 
securin O 
gene O 
expression O 
. O 
Treatment O 
with O 
gefitinib B-TRIVIAL 
induced O 
cytotoxicity O 
in O 
various O 
human O 
cancer O 
cell O 
types O 
, O 
including O 
RKO O 
( O 
colon O 
cancer O 
) O 
, O 
A549 O 
( O 
lung O 
cancer O 
) O 
, O 
BFTC905 O 
( O 
bladder O 
cancer O 
) O 
, O 
MCF7 O 
( O 
breast O 
cancer O 
) O 
and O 
A375 O 
( O 
skin O 
cancer O 
) O 
. O 
BFTC905 O 
and O 
A549 O 
cells O 
expressed O 
relatively O 
high O 
levels O 
of O 
the O 
phosphorylated O 
and O 
total O 
EGFR O 
proteins O 
; O 
however O 
, O 
A375 O 
, O 
MCF7 O 
and O 
RKO O 
cells O 
did O 
not O 
markedly O 
express O 
these O 
proteins O 
. O 
Moreover O 
, O 
following O 
treatment O 
with O 
gefitinib B-TRIVIAL 
, O 
the O 
securin O 
- O 
wild O 
type O 
cancer O 
cells O 
were O 
more O 
resistant O 
to O 
apoptotic O 
induction O 
than O 
the O 
securin O 
- O 
nan O 
cancer O 
cells O 
. O 
Surprisingly O 
, O 
both O 
the O 
securin O 
- O 
wild O 
type O 
and O 
securin O 
- O 
nan O 
cancer O 
cells O 
expressed O 
the O 
EGFR O 
protein O 
at O 
similar O 
levels O 
. O 
Treatment O 
with O 
gefitinib B-TRIVIAL 
induced O 
mitochondrial O 
dysfunction O 
, O 
cytochrome O 
c O 
release O 
, O 
caspase-3 O 
activation O 
and O 
poly B-SYSTEMATIC 
( I-SYSTEMATIC 
ADP-ribose I-SYSTEMATIC 
) I-SYSTEMATIC 
polymerase O 
protein O 
cleavage O 
, O 
indicating O 
that O 
apoptosis O 
occurred O 
in O 
these O 
cancer O 
cells O 
. O 
The O 
transfection O 
of O 
a O 
GPF-securin O 
expression O 
vector O 
increased O 
both O 
the O 
proliferation O 
rates O 
and O 
resistance O 
to O 
gefitinib B-TRIVIAL 
-induced O 
death O 
in O 
these O 
cancer O 
cells O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
demonstrate O 
that O 
the O 
presence O 
of O 
securin O 
promotes O 
resistance O 
to O 
gefitinib B-TRIVIAL 
-induced O 
apoptosis O 
via O 
an O 
EGFR O 
- O 
independent O 
pathway O 
in O 
human O 
cancer O 
cells O 
. O 

induces O 
apoptotic O 
cell O 
death O 
through O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
- O 
triggered O 
oxidative O 
stress O 
in O 
the O 
intertidal O 
copepod O 
Tigriopus O 
japonicus O 
. O 

copepod O 
, O 
Tigriopus O 
japonicus O 
is O 
an O 
important O 
model O 
for O 
toxicity O 
testing O 
. O 
However O 
, O 
no O 
attempt O 
has O 
been O 
made O 
in O 
analyzing O 
the O 
effect O 
of O 
toxicants O 
at O 
the O 
level O 
of O 
the O 
ROS O 
- O 
mediated O 
signal O 
transduction O 
pathway O 
. O 
To O 
understand O 
copper B-SYSTEMATIC 
-induced O 
cytotoxicity O 
at O 
the O 
molecular O 
level O 
, O 
we O 
employed O 
several O 
cellular O 
and O 
biochemical O 
assays O 
after O 
exposure O 
to O 
copper B-SYSTEMATIC 
, O 
and O 
found O 
a O 
significant O 
induction O 
of O 
enzyme O 
activities O 
of O 
antioxidant O 
proteins O 
with O 
increased O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
as O 
well O 
as O 
an O 
increase O 
of O 
TUNEL-positive O 
cells O 
, O 
but O 
a O 
decrease O 
of O 
BrdU B-ABBREVIATION 
-positive O 
cells O 
. O 
In O 
addition O 
, O 
several O 
important O 
genes O 
such O 
as O 
p38 O 
MAPK O 
, O 
antioxidant O 
- O 
related O 
genes O 
, O 
Hsps O 
, O 
and O 
apoptosis O 
- O 
related O 
genes O 
were O 
significantly O 
modulated O 
by O 
copper B-SYSTEMATIC 
exposure O 
. O 
Taken O 
together O 
, O 
we O 
suggest O 
that O 
copper B-SYSTEMATIC 
-induced O 
cytotoxicity O 
is O 
mediated O 
by O 
the O 
formation O 
of O 
intracellular O 
ROS O 
and O 
oxidative O 
stress O 
in O 
T O 
. O 
japonicus O 
. O 
Whole O 
body O 
biochemical O 
assays O 
such O 
as O 
TUNEL- O 
and O 
BrdU B-ABBREVIATION 
-assay O 
will O 
provide O 
a O 
better O 
understanding O 
of O 
cellular O 
responses O 
such O 
as O 
apoptosis O 
and O 
cell O 
death O 
upon O 
cytotoxic O 
exposure O 
of O 
copper B-SYSTEMATIC 
in O 
T O 
. O 
japonicus O 
. O 

synthesis O 
of O 
new O 
(R)-2-amino-1-butanol B-SYSTEMATIC 
derived O 
ureas B-FAMILY 
, O 
thioureas B-FAMILY 
and O 
acylthioureas B-FAMILY 
and O 
in O 
vitro O 
evaluation O 
of O 
their O 
antimycobacterial O 
activity O 
. O 

synthesis O 
of O 
22 O 
structurally O 
diverse O 
urea B-TRIVIAL 
, O 
thiourea B-SYSTEMATIC 
and O 
acylthiourea B-SYSTEMATIC 
derivatives O 
containing O 
the O 
(R)-2-amino-1-butanol B-SYSTEMATIC 
motif O 
has O 
been O 
performed O 
. O 
The O 
evaluation O 
of O 
their O 
in O 
vitro O 
activity O 
against O 
Mycobacterium O 
tuberculosis O 
( O 
H37Rv O 
and O 
strain O 
43 O 
) O 
showed O 
promising O 
results O 
in O 
the O 
case O 
of O 
the O 
acylthiourea B-SYSTEMATIC 
derivatives O 
( O 
MIC O 
range O 
0.36-7.46 O 
μM O 
for O 
H37Rv O 
strain O 
) O 
. O 

human O 
placenta O 
, O 
in O 
addition O 
to O 
its O 
roles O 
as O 
a O 
nutrient O 
transfer O 
and O 
endocrine O 
organ O 
, O 
functions O 
as O 
a O 
selective O 
barrier O 
to O 
protect O 
the O 
fetus O 
against O 
the O 
harmful O 
effects O 
of O 
exogenous O 
and O 
endogenous O 
toxins O 
. O 
Members O 
of O 
the O 
ATP O 
- O 
binding O 
cassette O 
( O 
ABC O 
) O 
family O 
of O 
transport O 
proteins O 
limit O 
the O 
entry O 
of O 
xenobiotics O 
into O 
the O 
fetal O 
circulation O 
via O 
vectorial O 
efflux O 
from O 
the O 
placenta O 
to O 
the O 
maternal O 
circulation O 
. O 
Several O 
members O 
of O 
the O 
ABC O 
family O 
, O 
including O 
proteins O 
from O 
the O 
ABCA O 
, O 
ABCB O 
, O 
ABCC O 
and O 
ABCG O 
subfamilies O 
, O 
have O 
been O 
shown O 
to O 
be O 
functional O 
in O 
the O 
placenta O 
with O 
clinically O 
significant O 
roles O 
in O 
xenobiotic O 
efflux O 
. O 
However O 
, O 
recent O 
findings O 
suggest O 
that O 
these O 
transporters O 
also O 
protect O 
placental O 
tissue O 
by O 
preventing O 
the O 
cellular O 
accumulation O 
of O 
cytotoxic O 
compounds O 
such O 
as O 
lipids O 
, O 
sterols O 
and O 
their O 
derivatives O 
. O 
Such O 
protective O 
functions O 
are O 
likely O 
to O 
be O 
particularly O 
important O 
in O 
pregnancies O 
complicated O 
by O 
inflammatory O 
or O 
oxidative O 
stress O 
, O 
where O 
the O 
generation O 
of O 
toxic O 
metabolites O 
is O 
enhanced O 
. O 
For O 
example O 
, O 
ABC O 
transporters O 
have O 
been O 
shown O 
to O 
protect O 
against O 
the O 
harmful O 
effects O 
of O 
hypoxia O 
and O 
oxidative O 
stress O 
through O 
increased O 
expression O 
and O 
efflux O 
of O 
oxysterols B-FAMILY 
and O 
glutathione B-TRIVIAL 
conjugated O 
xenobiotics O 
. O 
However O 
, O 
this O 
protective O 
capacity O 
may O 
be O 
diminished O 
in O 
response O 
to O 
the O 
same O 
stressors O 
. O 
Several O 
studies O 
in O 
primary O 
human O 
trophoblast O 
cells O 
and O 
animal O 
models O 
have O 
demonstrated O 
decreased O 
expression O 
and O 
activity O 
of O 
placental O 
ABC O 
transporters O 
with O 
inflammatory O 
, O 
oxidative O 
or O 
metabolic O 
stress O 
. O 
Several O 
clinical O 
studies O 
in O 
pregnancies O 
complicated O 
by O 
inflammatory O 
conditions O 
such O 
as O 
preeclampsia O 
and O 
gestational O 
diabetes O 
support O 
these O 
findings O 
, O 
although O 
further O 
studies O 
are O 
required O 
to O 
determine O 
the O 
clinical O 
relevance O 
of O 
the O 
relationships O 
between O 
placental O 
ABC O 
transporter O 
expression O 
and O 
activity O 
, O 
and O 
placental O 
function O 
in O 
stressed O 
pregnancies O 
. O 
Such O 
studies O 
are O 
necessary O 
to O 
fully O 
understand O 
the O 
consequences O 
of O 
pregnancy O 
disorders O 
on O 
placental O 
function O 
and O 
viability O 
in O 
order O 
to O 
optimise O 
pregnancy O 
care O 
and O 
maximise O 
fetal O 
growth O 
and O 
health O 
. O 

situ O 
forming O 
systems O 
including O 
thermoreversible O 
hydrogels O 
, O 
which O 
undergo O 
sol O 
- O 
gel O 
transition O 
upon O 
an O 
increase O 
in O 
temperature O 
have O 
been O 
used O 
for O 
various O 
biomedical O 
applications O 
. O 
Heparins O 
are O 
the O 
standard O 
of O 
anticoagulation O 
in O 
the O 
prophylaxis O 
and O 
treatment O 
of O 
deep O 
vein O 
thrombosis O 
and O 
pulmonary O 
embolism O 
. O 
Both O 
conditions O 
require O 
long O 
- O 
lasting O 
treatment O 
with O 
frequent O 
subcutaneous O 
administrations O 
of O 
heparin O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
prepare O 
and O 
evaluate O 
in O 
situ O 
forming O 
gel O 
systems O 
designed O 
by O 
combination O 
of O 
two O 
poloxamers B-MULTIPLE 
( I-MULTIPLE 
P407 I-MULTIPLE 
and I-MULTIPLE 
P188 I-MULTIPLE 
) I-MULTIPLE 
and O 
hydroxypropylmethylcellulose O 
( O 
HPMC O 
) O 
for O 
prolonged O 
release O 
of O 
heparin O 
. O 
Thermoreversible O 
hydrogels O 
were O 
prepared O 
with O 
heparin O 
solution O 
and O 
dispersion O 
of O 
heparin O 
/ O 
chitosan O 
nanocomplexes O 
. O 
Nanocomplexes O 
formed O 
by O 
self O 
- O 
assembly O 
of O 
heparin O 
with O 
chitosan O 
at O 
various O 
mass O 
ratios O 
were O 
thoroughly O 
characterized O 
. O 
A O 
heparin O 
/ O 
chitosan O 
mass O 
ratio O 
of O 
1 O 
: O 
1 O 
with O 
pH O 
5.2 O 
was O 
the O 
most O 
appropriate O 
for O 
preparation O 
of O 
small O 
, O 
homogenous O 
and O 
stable O 
nanocomplexes O 
( O 
mean O 
diameter O 
123nm O 
; O 
polydispersity O 
index O 
0.22 O 
and O 
zeta O 
potential O 
+ O 
35.5mV O 
) O 
. O 
Thermoreversible O 
hydrogels O 
were O 
evaluated O 
by O 
gelation O 
temperature O 
, O 
viscosity O 
over O 
the O 
temperature O 
range O 
20-40°C O 
, O 
rate O 
of O 
hydrogel O 
dissolution O 
, O 
and O 
heparin O 
release O 
in O 
vitro O 
. O 
The O 
addition O 
of O 
P188 B-IDENTIFIER 
to O 
P407 B-IDENTIFIER 
gel O 
formulations O 
resulted O 
in O 
an O 
increase O 
in O 
gelation O 
temperature O 
, O 
decrease O 
in O 
viscosity O 
at O 
room O 
temperature O 
and O 
faster O 
gel O 
dissolution O 
. O 
The O 
opposite O 
effects O 
were O 
observed O 
with O 
formulations O 
containing O 
HPMC O 
which O 
demonstrated O 
18-day- O 
long O 
gel O 
dissolution O 
and O 
complete O 
heparin O 
release O 
in O 
9days O 
from O 
gels O 
containing O 
heparin O 
solution O 
. O 
Considerable O 
prolongation O 
of O 
heparin O 
release O 
was O 
achieved O 
with O 
incorporation O 
of O 
heparin O 
/ O 
chitosan O 
nanocomplexes O 
into O 
the O 
gelling O 
systems O 
. O 
It O 
may O 
be O 
concluded O 
that O 
with O 
poloxamer O 
mixtures O 
at O 
specific O 
concentrations O 
, O 
addition O 
of O 
HPMC O 
and O 
use O 
of O 
heparin O 
/ O 
chitosan O 
nanocomplexes O 
dispersions O 
, O 
thermoreversible O 
formulations O 
for O 
prolonged O 
subcutaneous O 
release O 
of O 
heparin O 
are O 
feasible O 
. O 

interactions O 
between O 
pectin O 
coated O 
liposomes O 
and O 
parotid O 
saliva O 
and O 
dental O 
enamel O 
were O 
studied O 
to O 
investigate O 
their O 
potential O 
to O 
mimic O 
the O 
protective O 
biofilm O 
formed O 
naturally O 
on O 
tooth O 
surfaces O 
. O 
Different O 
pectin O 
coated O 
liposomes O 
with O 
respect O 
to O 
pectin O 
type O 
( O 
LM- O 
, O 
HM- O 
and O 
AM-pectin O 
) O 
and O 
concentration O 
( O 
0.05% O 
and O 
0.2% O 
) O 
were O 
prepared O 
. O 
Interactions O 
between O 
the O 
pectin O 
coated O 
liposomes O 
and O 
parotid O 
saliva O 
were O 
studied O 
by O 
turbidimetry O 
and O 
imaging O 
by O 
atomic O 
force O 
microscopy O 
. O 
The O 
liposomes O 
were O 
adsorbed O 
to O 
hydroxyapatite B-TRIVIAL 
( O 
HA O 
) O 
and O 
human O 
dental O 
enamel O 
using O 
phosphate B-SYSTEMATIC 
buffer O 
and O 
parotid O 
saliva O 
as O 
adsorption O 
media O 
. O 
A O 
continuous O 
flow O 
was O 
imposed O 
on O 
the O 
enamel O 
surfaces O 
for O 
various O 
time O 
intervals O 
to O 
examine O 
their O 
retention O 
on O 
the O 
dental O 
enamel O 
. O 
The O 
results O 
were O 
compared O 
to O 
uncoated O 
, O 
charged O 
liposomes O 
. O 
No O 
aggregation O 
tendencies O 
for O 
the O 
pectin O 
coated O 
liposomes O 
and O 
parotid O 
saliva O 
were O 
revealed O 
. O 
This O 
makes O 
them O 
promising O 
as O 
drug O 
delivery O 
systems O 
to O 
be O 
used O 
in O 
the O 
oral O 
cavity O 
. O 
In O 
phosphate B-SYSTEMATIC 
buffer O 
the O 
adsorption O 
to O 
HA O 
of O 
pectin O 
coated O 
liposomes O 
was O 
significantly O 
lower O 
than O 
the O 
negative O 
liposomes O 
. O 
The O 
difference O 
diminished O 
in O 
parotid O 
saliva O 
. O 
Positive O 
liposomes O 
adsorbed O 
better O 
to O 
the O 
dental O 
enamel O 
than O 
the O 
pectin O 
coated O 
liposomes O 
. O 
However O 
, O 
when O 
subjected O 
to O 
flow O 
for O 
1h O 
, O 
no O 
significant O 
differences O 
in O 
the O 
retention O 
levels O 
on O 
the O 
enamel O 
were O 
found O 
between O 
the O 
formulations O 
. O 
For O 
all O 
formulations O 
, O 
more O 
than O 
40% O 
of O 
the O 
liposomes O 
still O 
remained O 
on O 
the O 
enamel O 
surfaces O 
. O 
At O 
time O 
point O 
20min O 
the O 
retention O 
of O 
HM-pectin O 
coated O 
and O 
positive O 
liposomes O 
were O 
significantly O 
higher O 
. O 
It O 
was O 
concluded O 
that O 
pectin O 
coated O 
liposomes O 
can O 
adsorb O 
to O 
HA O 
as O 
well O 
as O 
to O 
the O 
dental O 
enamel O 
. O 
Their O 
ability O 
to O 
retain O 
on O 
the O 
enamel O 
surfaces O 
promotes O 
the O 
concept O 
of O 
using O 
them O 
as O 
protective O 
structures O 
for O 
the O 
teeth O 
. O 

of O 
quercetin B-TRIVIAL 
-rich O 
onion O 
peel O 
extracts O 
on O 
arterial O 
thrombosis O 
in O 
rats O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
examine O 
whether O 
oral O 
supplementation O 
of O 
quercetin B-TRIVIAL 
-rich O 
onion O 
peel O 
extract O 
( O 
OPE O 
) O 
influences O 
blood O 
coagulation O 
and O 
arterial O 
thrombosis O 
in O 
Sprague-Dawley O 
( O 
SD O 
) O 
rats O 
. O 
24 O 
male O 
rats O 
, O 
5weeks O 
old O 
, O 
were O 
divided O 
into O 
three O 
groups O 
with O 
different O 
diets O 
( O 
C O 
: O 
control O 
, O 
2mg O 
OPE O 
: O 
chow O 
diet O 
with O 
2mg O 
OPE O 
supplementation O 
, O 
10mg O 
OPE O 
: O 
chow O 
diet O 
with O 
10mg O 
OPE O 
supplementation O 
) O 
for O 
6weeks O 
. O 
Blood O 
coagulation O 
parameters O 
including O 
prothrombin O 
time O 
( O 
PT O 
) O 
, O 
activated O 
partial O 
thromboplastin O 
time O 
( O 
aPTT O 
) O 
and O 
platelet O 
aggregation O 
were O 
examined O 
. O 
The O 
OPE O 
did O 
not O 
affect O 
blood O 
cholesterol B-TRIVIAL 
levels O 
but O 
significantly O 
decreased O 
blood O 
triglyceride B-FAMILY 
and O 
glucose B-TRIVIAL 
levels O 
. O 
PT O 
, O 
aPTT O 
and O 
platelet O 
aggregation O 
were O 
not O 
significantly O 
different O 
among O 
all O 
tested O 
groups O 
. O 
However O 
, O 
in O 
vivo O 
arterial O 
thrombosis O 
was O 
significantly O 
delayed O 
in O 
groups O 
that O 
were O 
fed O 
2mg O 
and O 
10mg O 
OPE O 
diets O 
compared O 
to O 
the O 
control O 
group O 
. O 
In O 
addition O 
, O 
the O 
OPE O 
greatly O 
diminished O 
thrombin O 
- O 
induced O 
expression O 
of O 
tissue O 
factor O 
in O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
( O 
HUVECs O 
) O 
, O 
a O 
coagulation O 
initiator O 
. O 
In O 
addition O 
, O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
( O 
ERK O 
) O 
and O 
c-Jun O 
N B-FORMULA 
-terminal O 
kinase O 
( O 
JNK O 
) O 
signaling O 
pathways O 
activated O 
by O 
thrombin O 
treatment O 
were O 
prevented O 
by O 
the O 
OPE O 
pre O 
- O 
treatment O 
. O 
These O 
results O 
indicate O 
that O 
OPE O 
may O 
have O 
anti-thrombotic O 
effects O 
through O 
restricting O 
the O 
induced O 
expression O 
of O 
tissue O 
factor O 
via O 
down O 
- O 
regulating O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
activation O 
upon O 
coagulation O 
stimulus O 
, O 
leading O 
to O 
the O 
prolongation O 
of O 
time O 
for O 
arterial O 
thrombosis O 
. O 

: O 
To O 
investigate O 
the O 
relationship O 
of O 
fibroblast O 
growth O 
factor O 
receptor O 
4 O 
( O 
FGFR4 O 
) O 
gene O 
polymorphisms O 
with O 
the O 
response O 
of O 
Chinese O 
patients O 
with O 
non-small O 
cell O 
lung O 
cancer O 
( O 
NSCLC O 
) O 
to O 
chemotherapy.Methods O 
: O 
A O 
total O 
of O 
629 O 
patients O 
with O 
Stage O 
III O 
( O 
A O 
+ O 
B O 
) O 
or O 
IV O 
NSCLC O 
, O 
as O 
well O 
as O 
729 O 
age- O 
and O 
gender O 
- O 
matched O 
healthy O 
controls O 
were O 
recruited O 
. O 
All O 
the O 
patients O 
received O 
platinum B-SYSTEMATIC 
-based O 
chemotherapy O 
, O 
and O 
the O 
therapeutic O 
effects O 
were O 
evaluated O 
. O 
Three O 
polymorphisms O 
in O 
the O 
FGFR4 O 
gene O 
( O 
rs351855G O 
/ O 
A O 
, O 
rs145302848C O 
/ O 
G O 
, O 
and O 
rs147603016G O 
/ O 
A O 
) O 
were O 
genotyped O 
, O 
and O 
the O 
association O 
between O 
the O 
3 O 
polymorphisms O 
and O 
the O 
chemotherapy O 
effect O 
was O 
analyzed O 
using O 
SPSS O 
software O 
, O 
version O 
16.0.Results O 
: O 
The O 
genotype O 
frequencies O 
of O 
rs145302848C O 
/ O 
G O 
and O 
rs147603016G O 
/ O 
A O 
were O 
not O 
significantly O 
different O 
between O 
NSCLC O 
patients O 
and O 
healthy O 
controls O 
on O 
one O 
hand O 
, O 
and O 
between O 
the O 
responders O 
and O 
non-responders O 
to O 
the O 
chemotherapy O 
on O 
the O 
other O 
hand O 
. O 
The O 
distribution O 
of O 
AA O 
genotype O 
and O 
A-allele O 
of O 
rs351855G O 
/ O 
A O 
was O 
significantly O 
lower O 
in O 
NSCLC O 
patients O 
than O 
in O 
healthy O 
controls O 
. O 
Using O 
patients O 
with O 
the O 
GG O 
genotype O 
as O 
a O 
reference O 
, O 
the O 
AA O 
carrier O 
had O 
a O 
significantly O 
reduced O 
risk O 
for O 
the O 
development O 
of O 
NSCLC O 
after O 
normalizing O 
to O 
age O 
, O 
sex O 
and O 
smoking O 
habits O 
. O 
In O 
NSCLC O 
patients O 
, O 
this O 
genotype O 
occurred O 
more O 
frequently O 
in O 
the O 
responders O 
to O 
the O 
chemotherapy O 
than O 
in O 
non-responders O 
. O 
The O 
chance O 
of O 
being O 
a O 
responder O 
was O 
significantly O 
increased O 
with O 
the O 
AA O 
genotype O 
as O 
compared O 
to O 
G O 
genotype O 
. O 
The O 
AA O 
genotype O 
of O 
rs351855G O 
/ O 
A O 
had O 
a O 
better O 
prognosis O 
compared O 
with O 
GA O 
and O 
GG O 
genotype O 
carriers O 
: O 
the O 
overall O 
survival O 
of O 
patients O 
with O 
the O 
AA O 
genotype O 
of O 
rs351855G O 
/ O 
A O 
was O 
significantly O 
longer O 
than O 
those O 
with O 
the O 
GG O 
+ O 
GA O 
genotype O 
( O 
21.1 O 
vs O 
16.5 O 
months).Conclusion:The O 
rs351855G O 
/ O 
A O 
polymorphisms O 
of O 
FGFR4 O 
gene O 
can O 
be O 
used O 
to O 
predict O 
the O 
occurrence O 
, O 
chemotherapy O 
response O 
and O 
prognosis O 
of O 
NSCLC O 
. O 

of O 
iron B-SYSTEMATIC 
overload O 
- O 
induced O 
liver O 
toxicity O 
by O 
a O 
potent O 
antioxidant O 
and O 
iron B-SYSTEMATIC 
chelator O 
, O 
Emblica O 
officinalis O 
Gaertn O 
. O 

liver O 
, O 
the O 
major O 
site O 
of O 
iron B-SYSTEMATIC 
storage O 
, O 
iron B-SYSTEMATIC 
overload O 
is O 
associated O 
with O 
oxidative O 
damage O 
of O 
protein O 
, O 
lipid O 
, O 
and O 
DNA O 
and O 
causes O 
protein O 
oxidation O 
, O 
lipid O 
peroxidation O 
, O 
and O 
rupture O 
of O 
hepatocytes O 
, O 
leading O 
to O 
cell O 
death O 
. O 
Serum O 
ferritin O 
and O 
liver O 
iron B-SYSTEMATIC 
content O 
are O 
the O 
main O 
forecasters O 
of O 
moderate O 
to O 
severe O 
iron B-SYSTEMATIC 
overload O 
in O 
the O 
liver O 
. O 
The O 
sequels O 
of O 
excess O 
iron B-SYSTEMATIC 
deposition O 
in O 
the O 
liver O 
are O 
fibrosis O 
and O 
enhanced O 
levels O 
of O 
serum O 
enzymes O 
and O 
bilirubin B-TRIVIAL 
markers O 
. O 
Emblica O 
officinalis O 
( O 
EO O 
) O 
fruit O 
extract O 
was O 
found O 
efficient O 
in O 
lessening O 
intraperitoneally O 
injected O 
iron B-SYSTEMATIC 
dextran O 
- O 
induced O 
liver O 
toxicity O 
in O 
Swiss O 
albino O 
mice O 
. O 
Mice O 
administered O 
with O 
different O 
doses O 
of O 
70% O 
methanol B-SYSTEMATIC 
extract O 
of O 
EO O 
( O 
50 O 
, O 
100 O 
, O 
and O 
200 O 
mg O 
kg(-1) O 
body O 
weight O 
) O 
showed O 
significant O 
decrease O 
in O 
liver O 
iron B-SYSTEMATIC 
, O 
serum O 
ferritin O 
, O 
and O 
serum O 
enzyme O 
levels O 
, O 
along O 
with O 
the O 
decrease O 
in O 
lipid O 
peroxidation O 
, O 
protein O 
oxidation O 
, O 
and O 
collagen O 
content O 
. O 
The O 
activity O 
was O 
further O 
supported O 
by O 
its O 
considerable O 
iron B-SYSTEMATIC 
chelation O 
with O 
half O 
- O 
maximal O 
inhibitory O 
concentration O 
of O 
70.24 O 
± O 
2.74 O 
μg O 
ml(-1) O 
and O 
the O 
protection O 
on O 
ferrous B-SYSTEMATIC 
ion O 
- O 
mediated O 
DNA O 
breakdown O 
with O 
50% O 
protection O 
( O 
[P]50 O 
) O 
of O 
1.04 O 
± O 
0.01 O 
μg O 
ml(-1) O 
. O 
Simultaneously O 
, O 
the O 
extract O 
effectively O 
induced O 
the O 
antioxidant O 
enzyme O 
levels O 
and O 
also O 
exhibited O 
the O 
potential O 
activity O 
of O 
reductive O 
release O 
of O 
ferritin O 
iron B-SYSTEMATIC 
. O 
These O 
findings O 
suggest O 
that O 
the O 
EO O 
extract O 
may O 
be O 
used O 
as O 
a O 
potent O 
drug O 
for O 
the O 
treatment O 
of O 
pathological O 
sequences O 
arisen O 
in O 
the O 
iron B-SYSTEMATIC 
overload O 
- O 
induced O 
liver O 
damage O 
. O 

findings O 
in O 
acute O 
mercury B-SYSTEMATIC 
poisoning O 
in O 
adults O 
: O 
A O 
case O 
series O 
study O 
. O 

aim O 
of O 
this O 
study O 
is O 
to O 
report O 
ophthalmic O 
findings O 
of O 
acute O 
mercury B-SYSTEMATIC 
poisoning O 
in O 
48 O 
adults O 
referred O 
to O 
emergency O 
department O 
. O 
Full O 
ophthalmologic O 
examination O 
including O 
the O 
best O 
corrected O 
visual O 
acuity O 
, O 
external O 
eye O 
examination O 
, O 
reaction O 
to O 
light O 
, O 
a O 
slit O 
- O 
lamp O 
examination O 
, O 
funduscopy O 
, O 
intraocular O 
pressure O 
measurements O 
, O 
and O 
visual O 
field O 
( O 
VF O 
) O 
and O 
color O 
vision O 
( O 
CV O 
) O 
tests O 
were O 
performed O 
at O 
the O 
presentation O 
and O 
repeated O 
after O 
6 O 
months O 
. O 
The O 
parametric O 
values O 
of O 
VF O 
test O 
, O 
the O 
mean O 
deviation O 
( O 
MD O 
) O 
, O 
and O 
pattern O 
standard O 
deviation O 
( O 
PSD O 
) O 
were O 
recorded O 
in O 
order O 
to O 
compare O 
patients O 
and O 
the O 
30 O 
healthy O 
controls O 
. O 
The O 
mean O 
parameter O 
of O 
color O 
confusion O 
index O 
in O 
patients O 
was O 
found O 
to O 
be O 
statistically O 
different O 
than O 
controls O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
The O 
MD O 
and O 
PSD O 
in O 
patients O 
were O 
different O 
from O 
controls O 
statistically O 
significant O 
( O 
p O 
< O 
0.01 O 
and O 
p O 
< O 
0.01 O 
, O 
respectively O 
) O 
. O 
There O 
was O 
no O 
correlation O 
between O 
the O 
ocular O 
findings O 
and O 
the O 
urine O 
and O 
blood O 
mercury B-SYSTEMATIC 
levels O 
. O 
Methyl B-SYSTEMATIC 
mercury I-SYSTEMATIC 
, O 
held O 
in O 
the O 
school O 
laboratory O 
for O 
experimental O 
purpose O 
, O 
may O 
be O 
a O 
source O 
of O 
poisoning O 
. O 
In O 
this O 
case O 
series O 
, O 
we O 
showed O 
that O 
acute O 
exposure O 
to O 
mercury B-SYSTEMATIC 
had O 
hazardous O 
effect O 
on O 
the O 
visual O 
system O 
, O 
especially O 
CV O 
and O 
VF O 
. O 
We O 
propose O 
that O 
emphasizing O 
the O 
public O 
education O 
on O 
the O 
potential O 
hazards O 
of O 
mercury B-SYSTEMATIC 
is O 
crucial O 
for O 
preventive O 
community O 
health O 
. O 

-dependent O 
conformational O 
transitions O 
in O 
the O 
fingers O 
subdomain O 
of O 
Klentaq1 O 
DNA O 
polymerase O 
: O 
insights O 
into O 
the O 
role O 
of O 
the O 
" O 
nucleotide B-FAMILY 
binding O 
" O 
state O 
. O 

polymerases O 
are O 
responsible O 
for O 
the O 
accurate O 
replication O 
of O 
DNA O 
. O 
Kinetic O 
, O 
single O 
molecule O 
and O 
X-ray O 
studies O 
show O 
that O 
multiple O 
conformational O 
states O 
are O 
important O 
for O 
DNA O 
polymerase O 
fidelity O 
. O 
Using O 
high O 
- O 
precision O 
FRET O 
we O 
show O 
that O 
Klentaq1 O 
( O 
the O 
Klenow O 
fragment O 
of O 
Thermus O 
aquaticus O 
DNA O 
polymerase O 
1 O 
) O 
is O 
in O 
equilibrium O 
between O 
three O 
structurally O 
distinct O 
states O 
. O 
In O 
the O 
absence O 
of O 
nucleotide B-FAMILY 
, O 
the O 
enzyme O 
is O 
mostly O 
open O 
, O 
whereas O 
in O 
the O 
presence O 
of O 
DNA O 
and O 
a O 
correctly O 
base O 
- O 
pairing O 
dNTP B-ABBREVIATION 
it O 
re O 
- O 
equilibrates O 
to O 
a O 
closed O 
state O 
. O 
In O 
the O 
presence O 
of O 
a O 
dNTP B-ABBREVIATION 
alone O 
, O 
with O 
DNA O 
and O 
an O 
incorrect O 
dNTP B-ABBREVIATION 
, O 
or O 
in O 
elevated O 
MgCl2 B-FORMULA 
concentrations O 
, O 
an O 
intermediate O 
state O 
termed O 
″ O 
nucleotide B-FAMILY 
binding″ O 
state O 
predominates O 
. O 
Photon O 
distribution O 
and O 
hidden O 
Markov O 
analysis O 
revealed O 
fast O 
dynamic O 
and O 
slow O 
conformational O 
processes O 
occurring O 
between O 
all O 
three O 
states O 
in O 
a O 
complex O 
energy O 
landscape O 
suggesting O 
a O 
mechanism O 
in O 
which O 
dNTP B-ABBREVIATION 
delivery O 
is O 
mediated O 
by O 
the O 
″ O 
nucleotide B-FAMILY 
binding″ O 
state O 
: O 
After O 
nucleotide B-FAMILY 
binding O 
, O 
correct O 
dNTPs B-ABBREVIATION 
are O 
transported O 
to O 
the O 
closed O 
state O 
while O 
incorrect O 
dNTPs B-ABBREVIATION 
are O 
delivered O 
to O 
the O 
open O 
state O 
. O 

- O 
pot O 
formation O 
of O 
multifunctional O 
Pt B-FORMULA 
-conducting O 
polymer O 
intercalated O 
nanostructures O 
. O 

novel O 
multifunctional O 
Pt B-FORMULA 
nanoparticle@ O 
PPy B-ABBREVIATION 
nanofiber O 
intercalated O 
structure O 
( O 
Pt B-FORMULA 
NP@ O 
PPy B-ABBREVIATION 
NF O 
) O 
has O 
been O 
synthesized O 
facilely O 
in O 
one O 
- O 
pot O 
. O 
Pt B-FORMULA 
NPs O 
, O 
with O 
size O 
and O 
facet O 
control O 
, O 
were O 
nicely O 
assembled O 
and O 
embedded O 
into O 
the O 
polymer O 
nanofiber O 
network O 
. O 
Polyvinylpyrrolidone B-FAMILY 
( O 
PVP B-ABBREVIATION 
) O 
was O 
used O 
during O 
the O 
synthesis O 
process O 
which O 
would O 
assist O 
the O 
self O 
- O 
assembly O 
of O 
the O 
metal O 
nanoparticles O 
and O 
polymer O 
backbones O 
into O 
the O 
intercalated O 
structure O 
. O 
Space O 
- O 
confined O 
distribution O 
of O 
the O 
Pt B-FORMULA 
NPs O 
was O 
achieved O 
within O 
the O 
large O 
dimension O 
PPy B-ABBREVIATION 
nanofiber O 
network O 
, O 
which O 
could O 
enhance O 
the O 
interfacial O 
electron O 
transfer O 
process O 
as O 
well O 
as O 
diminish O 
the O 
catalyst O 
deformation O 
. O 
The O 
as O 
- O 
formed O 
Pt B-FORMULA 
NPs O 
have O 
a O 
cluster O 
- O 
like O 
structure O 
and O 
are O 
mainly O 
composed O 
of O 
3.5 O 
nm O 
primary O 
Pt B-FORMULA 
particles O 
with O 
( O 
100 O 
) O 
surface O 
atoms O 
. O 
Enhanced O 
electrocatalytic O 
properties O 
were O 
shown O 
by O 
the O 
Pt B-FORMULA 
NP@ O 
PPy B-ABBREVIATION 
NF O 
intercalated O 
structure O 
, O 
with O 
sufficiently O 
high O 
enzyme O 
- O 
less O 
glucose B-TRIVIAL 
biosensitivity O 
and O 
a O 
long O 
linear O 
range O 
from O 
1-30 O 
mM O 
( O 
R O 
= O 
0.9995 O 
) O 
. O 
High O 
electrochemical O 
cycling O 
stability O 
, O 
chloride B-SYSTEMATIC 
( O 
Cl(-) B-FORMULA 
) O 
tolerance O 
and O 
good O 
selectivity O 
are O 
also O 
obtained O 
for O 
the O 
Pt B-FORMULA 
NP@ O 
PPy B-ABBREVIATION 
NF O 
structure O 
, O 
as O 
the O 
electrode O 
showed O 
no O 
obvious O 
response O 
to O 
the O 
common O 
interfering O 
agents O 
, O 
such O 
as O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
( O 
AA O 
) O 
, O 
uric B-TRIVIAL 
acid I-TRIVIAL 
( O 
UA O 
) O 
, O 
and O 
4-acetamidophenol B-SYSTEMATIC 
( O 
AP O 
) O 
. O 
Furthermore O 
, O 
the O 
Pt B-FORMULA 
NP@ O 
PPy B-ABBREVIATION 
NF O 
showed O 
excellent O 
catalytic O 
activity O 
for O 
the O 
methanol B-SYSTEMATIC 
oxidation O 
reaction O 
( O 
MOR O 
) O 
and O 
oxygen B-SYSTEMATIC 
reduction O 
reaction O 
( O 
ORR O 
) O 
, O 
which O 
displayed O 
sufficient O 
CO B-FORMULA 
tolerance O 
, O 
and O 
higher O 
activity O 
compared O 
to O 
the O 
commercial O 
Pt B-FORMULA 
/ O 
C B-FORMULA 
catalyst O 
. O 
This O 
intrinsically O 
multifunctional O 
Pt B-FORMULA 
NP@ O 
PPy B-ABBREVIATION 
NF O 
with O 
well O 
- O 
controlled O 
Pt B-FORMULA 
facets O 
thus O 
could O 
serve O 
as O 
an O 
advanced O 
electrocatalyst O 
for O 
biosensing O 
and O 
fuel O 
cell O 
applications O 
, O 
surpassing O 
the O 
performance O 
of O 
many O 
existing O 
materials O 
. O 

fatty B-FAMILY 
acids I-FAMILY 
induce O 
Lhb O 
mRNA O 
but O 
suppress O 
Fshb O 
mRNA O 
in O 
pituitary O 
LβT2 O 
gonadotropes O 
and O 
diet O 
- O 
induced O 
obesity O 
reduces O 
FSH O 
levels O 
in O 
male O 
mice O 
and O 
disrupts O 
the O 
proestrus O 
LH O 
/ O 
FSH O 
surge O 
in O 
female O 
mice O 
. O 

obesity O 
is O 
associated O 
with O 
insulin O 
resistance O 
, O 
hyperandrogenemia O 
, O 
and O 
reproductive O 
dysfunction O 
. O 
We O 
hypothesized O 
that O 
elevated O 
free O 
fatty B-FAMILY 
acids I-FAMILY 
( O 
FFAs O 
) O 
might O 
directly O 
modulate O 
pituitary O 
gonadotropin O 
production O 
. O 
FFAs O 
caused O 
a O 
time O 
and O 
dose O 
- O 
dependent O 
increase O 
in O 
phosphorylation O 
of O 
the O 
MAP O 
kinases O 
p38MAPK O 
, O 
JNK1 O 
/ O 
2 O 
and O 
ERK1 O 
/ O 
2 O 
in O 
LβT2 O 
gonadotrope O 
cells O 
. O 
Furthermore O 
, O 
FFAs O 
upregulated O 
Lhb O 
mRNA O 
expression O 
acutely O 
, O 
an O 
effect O 
that O 
was O 
blocked O 
by O 
JNK O 
inhibition O 
, O 
but O 
suppressed O 
Fshb O 
mRNA O 
expression O 
, O 
an O 
effect O 
that O 
was O 
independent O 
of O 
MAPK O 
signaling O 
. O 
FFAs O 
enhanced O 
the O 
activation O 
of O 
the O 
MAPKs O 
in O 
the O 
presence O 
of O 
GnRH B-ABBREVIATION 
although O 
the O 
cotreatment O 
did O 
not O 
alter O 
Lhb O 
induction O 
, O 
but O 
did O 
eliminate O 
the O 
GnRH B-ABBREVIATION 
induction O 
of O 
Fshb O 
. O 
FFAs O 
also O 
suppressed O 
activin O 
- O 
induced O 
Fshb O 
expression O 
. O 
Knockdown O 
experiments O 
showed O 
that O 
the O 
FFA O 
effect O 
on O 
the O 
inflammatory O 
kinases O 
p38MAPK O 
and O 
JNK O 
and O 
on O 
Lhb O 
, O 
but O 
not O 
Fshb O 
, O 
mRNA O 
expression O 
is O 
mediated O 
via O 
TLR2 O 
and O 
TLR4 O 
and O 
was O 
mimicked O 
by O 
LPS O 
stimulation O 
. O 
In O 
vivo O 
, O 
male O 
C57BL O 
/ O 
6 O 
mice O 
on O 
a O 
high O 
- O 
fat O 
diet O 
( O 
HFD O 
) O 
showed O 
reduced O 
FSH O 
levels O 
consistent O 
with O 
the O 
suppression O 
of O 
Fshb O 
seen O 
in O 
vitro O 
. O 
Histological O 
analysis O 
of O 
the O 
testes O 
showed O 
an O 
increased O 
number O 
of O 
abnormal O 
seminiferous O 
tubules O 
. O 
Female O 
mice O 
on O 
HFD O 
lacked O 
the O 
expected O 
proestrus O 
LH O 
and O 
FSH O 
surge O 
, O 
exhibited O 
an O 
increase O 
in O 
the O 
number O 
of O 
days O 
at O 
estrus O 
and O 
a O 
reduced O 
number O 
of O 
days O 
at O 
proestrus O 
, O 
and O 
ovaries O 
had O 
significantly O 
fewer O 
corpora O 
lutea O 
. O 
Taken O 
together O 
, O 
our O 
findings O 
suggest O 
that O 
lipid O 
excess O 
can O 
lead O 
to O 
reproductive O 
defects O 
in O 
both O 
male O 
and O 
female O 
mice O 
. O 

dots O 
( O 
QDs O 
) O 
have O 
received O 
great O 
interest O 
for O 
diverse O 
applications O 
due O 
to O 
their O 
distinct O 
advantages O 
, O 
such O 
as O 
narrow O 
and O 
symmetric O 
emission O 
with O 
tunable O 
colors O 
, O 
broad O 
and O 
strong O 
absorption O 
, O 
reasonable O 
stability O 
, O 
and O 
solution O 
processibility O 
. O 
Doped O 
QDs O 
not O 
only O 
potentially O 
retain O 
almost O 
all O 
of O 
the O 
above O 
advantages O 
, O 
but O 
also O 
avoid O 
the O 
self O 
- O 
quenching O 
problem O 
due O 
to O 
their O 
substantial O 
ensemble O 
Stokes O 
shift O 
. O 
Two O 
obvious O 
advantages O 
of O 
doped O 
QDs O 
, O 
especially O 
doped O 
ZnS B-FORMULA 
QDs O 
, O 
over O 
typical O 
CdSe B-FORMULA 
@ O 
ZnS B-FORMULA 
and O 
CdTe B-FORMULA 
QDs O 
are O 
longer O 
dopant O 
emission O 
lifetime O 
and O 
potentially O 
lower O 
cytotoxicity O 
. O 
The O 
lifetime O 
of O 
dopant O 
emission O 
from O 
transition O 
- O 
metal O 
ion O 
or O 
lanthanide B-FAMILY 
ion O 
- O 
doped O 
QDs O 
is O 
generally O 
longer O 
than O 
that O 
of O 
the O 
bandgap O 
or O 
defect O 
- O 
related O 
emission O 
of O 
host O 
, O 
and O 
that O 
of O 
biological O 
background O 
fluorescence O 
, O 
providing O 
great O 
opportunities O 
to O 
eliminate O 
background O 
fluorescence O 
for O 
biosensing O 
and O 
bioimaging O 
. O 
For O 
bioimaging O 
applications O 
, O 
fluorescent O 
dopants O 
may O 
mitigate O 
toxicity O 
problems O 
by O 
producing O 
visible O 
or O 
infrared O 
emission O 
in O 
nanocrystals O 
made O 
from O 
less O 
- O 
harmful O 
elements O 
than O 
those O 
currently O 
used O 
. O 
In O 
this O 
review O 
, O 
recent O 
advances O 
in O 
utilizing O 
doped O 
QDs O 
for O 
chemo O 
/ O 
biosensing O 
and O 
bioimaging O 
are O 
discussed O 
, O 
and O 
the O 
synthetic O 
routes O 
and O 
optical O 
properties O 
of O 
doped O 
QDs O 
that O 
make O 
them O 
excellent O 
probes O 
for O 
various O 
strategies O 
in O 
chemo O 
/ O 
biosensing O 
and O 
bioimaging O 
are O 
highlighted O 
. O 
Moreover O 
, O 
perspectives O 
on O 
future O 
exploration O 
of O 
doped O 
QDs O 
for O 
chemo O 
/ O 
biosensing O 
and O 
bioimaging O 
are O 
also O 
given O 
. O 

the O 
surface O 
free O 
energy O 
parameters O 
of O 
polyurethane B-SYSTEMATIC 
coats O 
- O 
part O 
1 O 
. O 
Solvent O 
- O 
based O 
coats O 
obtained O 
from O 
linear O 
polyurethane B-SYSTEMATIC 
elastomers O 
. O 

elastomers O 
coating O 
were O 
synthesised O 
by O 
using O 
typical O 
diisocyanates B-FAMILY 
, O 
polyether B-SYSTEMATIC 
and O 
polyester B-FAMILY 
polyols I-FAMILY 
and O 
HO B-FORMULA 
- O 
tertiary B-FAMILY 
amines I-FAMILY 
or O 
diols B-FAMILY 
as O 
a O 
chain O 
extenders O 
. O 
Mole O 
fractions O 
of O 
structural O 
fragments O 
( O 
κ O 
exp O 
) O 
responsible O 
for O 
the O 
polar O 
interactions O 
within O 
polyurethane B-SYSTEMATIC 
chains O 
were O 
calculated O 
by O 
(1)H B-FORMULA 
NMR O 
method O 
. O 
Obtained O 
results O 
were O 
confronted O 
with O 
the O 
analogous O 
parameter O 
values O 
( O 
κ O 
theor O 
) O 
calculated O 
on O 
the O 
basis O 
of O 
process O 
stoichiometry O 
, O 
considering O 
the O 
stage O 
of O 
the O 
production O 
of O 
isocyanate B-SYSTEMATIC 
prepolymers O 
and O 
reaction O 
of O 
their O 
extension O 
for O 
polyurethanes B-FAMILY 
. O 
Trials O 
of O 
linear O 
correlation O 
between O 
the O 
κ O 
exp O 
parameters O 
and O 
surface O 
free O 
energy O 
( O 
SFE O 
) O 
values O 
of O 
investigated O 
coatings O 
were O 
presented O 
. O 
SFE O 
values O 
were O 
determined O 
by O 
Owens-Wendt O 
method O 
, O 
using O 
contact O 
angles O 
measured O 
with O 
the O 
goniometric O 
method O 
. O 
Based O 
on O 
achieved O 
results O 
, O 
another O 
empirical O 
models O 
, O 
allowing O 
for O 
prediction O 
the O 
influence O 
of O 
the O 
kind O 
of O 
polyurethane B-SYSTEMATIC 
raw O 
materials O 
on O 
SFE O 
values O 
of O 
received O 
coatings O 
were O 
determined O 
. O 
It O 
was O 
found O 
that O 
it O 
is O 
possible O 
to O 
regulate O 
the O 
SFE O 
in O 
the O 
range O 
millijoules O 
per O 
cubic O 
metre O 
by O 
the O 
selection O 
of O 
appropriate O 
substrates O 
. O 
It O 
has O 
been O 
found O 
that O 
use O 
of O 
2,2,3,3-tetrafluoro-1,4-butanediol B-SYSTEMATIC 
as O 
a O 
fluorinated O 
extender O 
of O 
prepolymer O 
chains O 
is O 
essential O 
to O 
obtain O 
coatings O 
with O 
increased O 
hydrophobicity O 
, O 
applied O 
among O 
others O 
as O 
biomaterials O 
- O 
next O 
to O 
diphenylmethane B-SYSTEMATIC 
diisocyanate I-SYSTEMATIC 
and O 
polyoxyethylene B-FAMILY 
glycol I-FAMILY 
. O 

of O 
pHEMA B-ABBREVIATION 
with O 
HA/ O 
β B-ABBREVIATION 
-TCP I-ABBREVIATION 
( O 
60 O 
/ O 
40 O 
) O 
for O 
bone O 
tissue O 
engineering O 
: O 
Swelling O 
, O 
hydrolytic O 
degradation O 
, O 
and O 
in O 
vitro O 
behavior O 
. O 

field O 
of O 
bone O 
and O 
cartilage O 
tissue O 
engineering O 
has O 
a O 
pressing O 
need O 
for O 
novel O 
, O 
biocompatible O 
, O 
biodegradable O 
biocomposites O 
comprising O 
polymers O 
with O 
bioceramics O 
or O 
bioglasses O 
to O 
meet O 
numerous O 
requirements O 
for O 
these O 
applications O 
. O 
We O 
created O 
hydrolytically O 
degradable O 
hydrogel O 
/ O 
bioceramic O 
biocomposites O 
, O 
comprising O 
poly(2-hydroxyethyl B-FAMILY 
methacrylate I-FAMILY 
) I-FAMILY 
( O 
pHEMA B-ABBREVIATION 
) O 
hydrogels O 
and O 
50 O 
wt% O 
biphasic O 
hydroxyapatite B-TRIVIAL 
/ O 
β-tricalcium B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
( O 
60 O 
/ O 
40 O 
) O 
through O 
in O 
situ O 
polymerization O 
. O 
The O 
hydrolytic O 
degradation O 
starts O 
with O 
hydrolysis O 
of O 
the O 
cross O 
- O 
linker O 
, O 
N B-SYSTEMATIC 
, I-SYSTEMATIC 
O-dimethacryloyl I-SYSTEMATIC 
hydroxylamine I-SYSTEMATIC 
, O 
which O 
was O 
synthesized O 
in O 
house O 
. O 
Swelling O 
and O 
degradation O 
were O 
examined O 
in O 
details O 
at O 
a O 
phosphate B-SYSTEMATIC 
buffered O 
saline O 
solution O 
at O 
37 O 
°C O 
over O 
a O 
12-week O 
period O 
of O 
time O 
. O 
To O 
vary O 
degradability O 
, O 
a O 
co O 
- O 
monomer O 
, O 
acrylic B-TRIVIAL 
acid I-TRIVIAL 
( O 
AA O 
) O 
or O 
2-hydroxypropyl B-SYSTEMATIC 
methacrylamide I-SYSTEMATIC 
( O 
HPMA B-ABBREVIATION 
) O 
, O 
was O 
introduced O 
, O 
coupled O 
with O 
altering O 
the O 
concentration O 
of O 
the O 
cross O 
- O 
linker O 
and O 
of O 
the O 
bioceramic O 
. O 
The O 
co O 
- O 
monomer O 
HPMA B-ABBREVIATION 
was O 
found O 
to O 
be O 
more O 
effective O 
than O 
AA O 
in O 
enhancing O 
degradation O 
, O 
though O 
AA O 
led O 
to O 
greater O 
swelling O 
ratios O 
. O 
33% O 
of O 
weight O 
loss O 
was O 
achieved O 
in O 
some O 
of O 
the O 
biocomposites O 
containing O 
HPMA B-ABBREVIATION 
. O 
Porous O 
structures O 
were O 
developed O 
during O 
swelling O 
and O 
degradation O 
in O 
biocomposites O 
with O 
AA O 
but O 
not O 
in O 
those O 
containing O 
HPMA B-ABBREVIATION 
, O 
suggesting O 
different O 
degradation O 
mechanisms O 
: O 
bulk O 
erosion O 
vs O 
. O 
bulk O 
degradation O 
. O 
Good O 
biocompatibility O 
, O 
as O 
evidenced O 
by O 
attachment O 
and O 
proliferation O 
of O 
mouse O 
- O 
derived O 
osteoblast O 
precursor O 
cells O 
from O 
the O 
MC3T3-E1 O 
lineage O 
, O 
was O 
observed O 
on O 
these O 
biomaterials O 
, O 
regardless O 
of O 
the O 
type O 
of O 
the O 
co O 
- O 
monomer O 
. O 
The O 
rationale O 
and O 
approaches O 
employed O 
here O 
open O 
up O 
new O 
opportunities O 
for O 
creating O 
novel O 
, O 
complex O 
organic O 
- O 
inorganic O 
biomaterials O 
in O 
orthopedic O 
tissue O 
engineering O 
. O 

Acid I-TRIVIAL 
and O 
Nicotinamide B-TRIVIAL 
: O 
A O 
Review O 
of O 
Their O 
Use O 
for O 
Hyperphosphatemia O 
in O 
Dialysis O 
Patients O 
. O 

binders O 
have O 
traditionally O 
been O 
used O 
to O 
treat O 
hyperphosphatemia O 
, O 
a O 
common O 
complication O 
in O 
patients O 
with O 
end O 
stage O 
renal O 
disease O 
( O 
ESRD O 
) O 
. O 
New O 
evidence O 
suggests O 
that O 
nicotinic B-TRIVIAL 
acid I-TRIVIAL 
and O 
its O 
metabolites O 
may O 
effectively O 
decrease O 
phosphorus B-SYSTEMATIC 
absorption O 
in O 
the O 
gastrointestinal O 
tract O 
, O 
thereby O 
reducing O 
serum O 
phosphorus B-SYSTEMATIC 
concentrations O 
. O 
We O 
conducted O 
a O 
literature O 
search O 
to O 
identify O 
studies O 
of O 
patients O 
with O 
ESRD O 
on O 
dialysis O 
that O 
evaluated O 
the O 
role O 
of O 
niacin B-TRIVIAL 
and O 
related O 
compounds O 
in O 
decreasing O 
serum O 
phosphorus B-SYSTEMATIC 
levels O 
. O 
We O 
searched O 
PubMed O 
using O 
the O 
search O 
terms O 
niacin B-TRIVIAL 
, O 
nicotinic B-TRIVIAL 
acid I-TRIVIAL 
, O 
niacinamide B-TRIVIAL 
, O 
nicotinamide B-TRIVIAL 
and O 
hyperphosphatemia O 
. O 
Limits O 
were O 
set O 
to O 
include O 
only O 
those O 
articles O 
published O 
since O 
2002 O 
, O 
conducted O 
in O 
human O 
subjects O 
, O 
and O 
written O 
in O 
the O 
English O 
language O 
. O 
Review O 
articles O 
captured O 
through O 
this O 
process O 
were O 
mined O 
for O 
references O 
to O 
other O 
primary O 
literature O 
that O 
may O 
not O 
have O 
been O 
returned O 
through O 
the O 
initial O 
search O 
. O 
All O 
studies O 
were O 
included O 
if O 
they O 
met O 
the O 
search O 
criteria O 
and O 
were O 
conducted O 
in O 
patients O 
with O 
ESRD O 
who O 
received O 
either O 
hemodialysis O 
or O 
peritoneal O 
dialysis O 
. O 
To O 
identify O 
current O 
, O 
ongoing O 
studies O 
, O 
another O 
search O 
was O 
conducted O 
through O 
clinicaltrials.gov O 
. O 
Among O 
the O 
seven O 
studies O 
that O 
met O 
our O 
exclusion O 
criteria O 
, O 
three O 
used O 
nicotinic B-TRIVIAL 
acid I-TRIVIAL 
as O 
the O 
therapeutic O 
intervention O 
and O 
four O 
used O 
nicotinamide B-TRIVIAL 
. O 
Both O 
nicotinic B-TRIVIAL 
acid I-TRIVIAL 
and O 
nicotinamide B-TRIVIAL 
were O 
effective O 
in O 
significantly O 
reducing O 
serum O 
phosphorus B-SYSTEMATIC 
concentrations O 
in O 
patients O 
with O 
ESRD O 
on O 
either O 
hemodialysis O 
or O 
peritoneal O 
dialysis O 
. O 
Additional O 
, O 
large O 
- O 
scale O 
studies O 
that O 
assess O 
the O 
appropriate O 
dose O 
as O 
well O 
as O 
long O 
- O 
term O 
safety O 
and O 
efficacy O 
are O 
recommended O 
before O 
clinicians O 
can O 
confirm O 
their O 
place O 
in O 
therapy O 
. O 

Phytoestrogens O 
Inhibit O 
Cell O 
Growth O 
and O 
Confer O 
Cytoprotection O 
By O 
Inducing O 
Manganese B-SYSTEMATIC 
Superoxide I-SYSTEMATIC 
Dismutase O 
Expression O 
. O 

are O 
of O 
interest O 
because O 
of O 
their O 
reported O 
beneficial O 
effects O 
on O 
many O 
human O 
maladies O 
including O 
cancer O 
, O 
neurodegeneration O 
, O 
cardiovascular O 
disease O 
and O 
diabetes O 
. O 
As O 
data O 
on O 
phytoestrogens O 
continues O 
to O 
accumulate O 
, O 
it O 
is O 
clear O 
that O 
there O 
is O 
significant O 
overlap O 
in O 
the O 
cellular O 
effects O 
elicited O 
by O 
these O 
various O 
compounds O 
. O 
Here O 
, O 
we O 
show O 
that O 
one O 
mechanism O 
by O 
which O 
a O 
number O 
of O 
phytoestrogens O 
achieve O 
their O 
growth O 
inhibitory O 
and O 
cytoprotective O 
effects O 
is O 
via O 
induction O 
of O 
the O 
mitochondrial O 
manganese B-SYSTEMATIC 
superoxide I-SYSTEMATIC 
dismutase O 
( O 
MnSOD O 
) O 
. O 
Eight O 
phytoestrogens O 
, O 
including O 
resveratrol B-TRIVIAL 
, O 
coumestrol B-TRIVIAL 
, O 
kaempferol B-TRIVIAL 
, O 
genistein B-TRIVIAL 
, O 
daidzein B-TRIVIAL 
, O 
apigenin B-TRIVIAL 
, O 
isoliquirtigenin B-TRIVIAL 
and O 
glycitin B-TRIVIAL 
, O 
were O 
tested O 
for O 
their O 
ability O 
to O 
induce O 
MnSOD O 
expression O 
in O 
mouse O 
C2C12 O 
and O 
primary O 
myoblasts O 
. O 
Five O 
of O 
these O 
, O 
resveratrol B-TRIVIAL 
, O 
coumestrol B-TRIVIAL 
, O 
kaempferol B-TRIVIAL 
, O 
genistein B-TRIVIAL 
and O 
daidzein B-TRIVIAL 
, O 
significantly O 
increased O 
MnSOD O 
expression O 
, O 
slowed O 
proliferative O 
growth O 
and O 
enhanced O 
stress O 
resistance O 
( O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
LD50 O 
) O 
. O 
When O 
siRNA O 
was O 
used O 
to O 
prevent O 
the O 
MnSOD O 
induction O 
by O 
genistein B-TRIVIAL 
, O 
coumestrol B-TRIVIAL 
or O 
daidzein B-TRIVIAL 
, O 
none O 
of O 
these O 
compounds O 
exerted O 
any O 
effect O 
on O 
proliferative O 
growth O 
, O 
and O 
only O 
the O 
effect O 
of O 
coumestrol B-TRIVIAL 
on O 
stress O 
resistance O 
persisted O 
. O 
The O 
estrogen B-FAMILY 
antagonist O 
ICI182780 B-IDENTIFIER 
prevented O 
the O 
increased O 
MnSOD O 
expression O 
and O 
also O 
the O 
changes O 
in O 
cell O 
growth O 
and O 
stress O 
resistance O 
, O 
indicating O 
that O 
these O 
effects O 
are O 
mediated O 
by O 
estrogen B-FAMILY 
receptors O 
( O 
ER O 
) O 
. O 
The O 
absence O 
of O 
effects O 
of O 
resveratrol B-TRIVIAL 
or O 
coumestrol B-TRIVIAL 
, O 
but O 
not O 
genistein B-TRIVIAL 
, O 
in O 
ERβ-null O 
cells O 
further O 
indicated O 
that O 
this O 
ER O 
in O 
particular O 
is O 
important O 
in O 
mediating O 
these O 
effects O 
. O 
Thus O 
, O 
an O 
ER O 
- O 
mediated O 
induction O 
of O 
MnSOD O 
expression O 
appears O 
to O 
underlie O 
the O 
growth O 
inhibitory O 
and O 
cytoprotective O 
activities O 
of O 
multiple O 
phytoestrogens O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

pre O 
- O 
clinical O 
absorption O 
, O 
distribution O 
, O 
metabolism O 
and O 
excretion O 
properties O 
of O 
IPI-926 B-IDENTIFIER 
, O 
an O 
orally O 
bioavailable O 
antagonist O 
of O 
the O 
hedgehog O 
signal O 
transduction O 
pathway O 
. O 

1 O 
. O 
IPI-926 B-IDENTIFIER 
is O 
a O 
novel O 
semisynthetic O 
cyclopamine B-TRIVIAL 
derivative O 
that O 
is O 
a O 
potent O 
and O 
selective O 
Smoothened O 
inhibitor O 
that O 
blocks O 
the O 
hedgehog O 
signal O 
transduction O 
pathway O 
. O 
2 O 
. O 
The O 
in O 
vivo O 
clearance O 
of O 
IPI-926 B-IDENTIFIER 
is O 
low O 
in O 
mouse O 
and O 
dog O 
and O 
moderate O 
in O 
monkey O 
. O 
The O 
volume O 
of O 
distribution O 
is O 
high O 
across O 
species O 
. O 
Oral O 
bioavailability O 
ranges O 
from O 
moderate O 
in O 
monkey O 
to O 
high O 
in O 
mouse O 
and O 
dog O 
. O 
Predicted O 
human O 
clearance O 
using O 
simple O 
allometry O 
is O 
low O 
(24 O 
L O 
h(-1)) O 
, O 
predicted O 
volume O 
of O 
distribution O 
is O 
high O 
( O 
469 O 
L O 
) O 
and O 
predicted O 
half O 
- O 
life O 
is O 
long O 
( O 
20 O 
h O 
) O 
. O 
3 O 
. O 
IPI-926 B-IDENTIFIER 
is O 
highly O 
bound O 
to O 
plasma O 
proteins O 
and O 
has O 
minimal O 
interaction O 
with O 
human O 
α-1-acid O 
glycoprotein O 
. O 
4 O 
. O 
In O 
vitro O 
metabolic O 
stability O 
ranges O 
from O 
stable O 
to O 
moderately O 
stable O 
. O 
Twelve O 
oxidative O 
metabolites O 
were O 
detected O 
in O 
mouse O 
, O 
rat O 
, O 
dog O 
, O 
monkey O 
and O 
human O 
liver O 
microsome O 
incubations O 
and O 
none O 
were O 
unique O 
to O 
human O 
. O 
5 O 
. O 
IPI-926 B-IDENTIFIER 
is O 
not O 
a O 
potent O 
reversible O 
inhibitor O 
of O 
CYP1A2 O 
, O 
2C8 O 
, O 
2C9 O 
or O 
3A4 O 
( O 
testosterone B-TRIVIAL 
) O 
. O 
IPI-926 B-IDENTIFIER 
is O 
a O 
moderate O 
inhibitor O 
of O 
CYP2C19 O 
, O 
2D6 O 
and O 
3A4 O 
( O 
midazolam B-TRIVIAL 
) O 
with O 
KI O 
values O 
of O 
19 O 
, O 
16 O 
and O 
4.5 O 
µM O 
, O 
respectively O 
. O 
IPI-926 B-IDENTIFIER 
is O 
both O 
a O 
substrate O 
and O 
inhibitor O 
( O 
IC50 O 
= O 
1.9 O 
µM O 
) O 
of O 
P-glycoprotein O 
. O 
6 O 
. O 
In O 
summary O 
, O 
IPI-926 B-IDENTIFIER 
has O 
desirable O 
pre O 
- O 
clinical O 
absorption O 
, O 
distribution O 
, O 
metabolism O 
and O 
excretion O 
properties O 
. O 

Sulfoxides I-FAMILY 
as O 
New O 
Reactive O 
Metabolites O 
Acting O 
as O 
Bis-Electrophiles O 
: O 
Implication O 
in O 
Clopidogrel B-TRIVIAL 
and O 
Prasugrel B-TRIVIAL 
Bioactivation O 
. O 

antithrombotics O 
of O 
the O 
tetrahydrothienopyridine B-SYSTEMATIC 
series O 
, O 
clopidogrel B-TRIVIAL 
and O 
prasugrel B-TRIVIAL 
, O 
are O 
prodrugs O 
that O 
must O 
be O 
metabolized O 
in O 
two O 
steps O 
to O 
become O 
pharmacologically O 
active O 
. O 
The O 
first O 
step O 
is O 
the O 
formation O 
of O 
a O 
thiolactone B-SYSTEMATIC 
metabolite O 
. O 
The O 
second O 
step O 
is O 
a O 
cytochrome O 
P450 O 
(P450)-dependent O 
oxidation O 
of O 
this O 
thiolactone B-SYSTEMATIC 
resulting O 
in O 
the O 
formation O 
of O 
a O 
sulfenic B-SYSTEMATIC 
acid I-SYSTEMATIC 
that O 
is O 
eventually O 
reduced O 
into O 
the O 
corresponding O 
active O 
thiol B-FAMILY 
. O 
It O 
has O 
been O 
postulated O 
that O 
the O 
sulfenic B-SYSTEMATIC 
acid I-SYSTEMATIC 
metabolite O 
resulted O 
from O 
a O 
nucleophilic O 
attack O 
of O 
water O 
on O 
a O 
highly O 
reactive O 
thiolactone B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
derived O 
from O 
P450-dependent O 
oxidation O 
of O 
the O 
thiolactone B-SYSTEMATIC 
primary O 
metabolite O 
. O 
The O 
data O 
described O 
in O 
the O 
present O 
article O 
are O 
in O 
complete O 
agreement O 
with O 
this O 
proposition O 
as O 
they O 
show O 
that O 
it O 
was O 
possible O 
to O 
trap O 
these O 
thiolactone B-FAMILY 
sulfoxides I-FAMILY 
by O 
a O 
series O 
of O 
nucleophiles O 
such O 
as O 
amines B-FAMILY 
, O 
thiols B-FAMILY 
, O 
or O 
cyclopentane-1,3-dione B-SYSTEMATIC 
( O 
CPDH B-ABBREVIATION 
) O 
, O 
an O 
equivalent O 
of O 
dimedone B-TRIVIAL 
that O 
is O 
used O 
as O 
a O 
sulfenic B-SYSTEMATIC 
acid I-SYSTEMATIC 
trapping O 
agent O 
. O 
HPLC-MS O 
studies O 
showed O 
that O 
various O 
bis-adducts O 
having O 
incorporated O 
two O 
nucleophile O 
molecules O 
were O 
formed O 
in O 
these O 
reactions O 
. O 
One O 
of O 
them O 
that O 
resulted O 
from O 
the O 
oxidation O 
of O 
2-oxo- B-SYSTEMATIC 
prasugrel I-SYSTEMATIC 
by O 
human O 
liver O 
microsomes O 
in O 
the O 
presence O 
of O 
ethanolamine B-SYSTEMATIC 
and O 
CPDH B-ABBREVIATION 
was O 
isolated O 
and O 
completely O 
characterized O 
by O 
(1)H B-FORMULA 
and O 
(13)C B-FORMULA 
NMR O 
spectroscopy O 
in O 
addition O 
to O 
MS O 
and O 
MS(2) O 
spectrometry O 
. O 
All O 
metabolites O 
derived O 
from O 
an O 
attack O 
of O 
H2O B-FORMULA 
or O 
an O 
amine B-SYSTEMATIC 
at O 
the O 
CO B-FORMULA 
carbon B-SYSTEMATIC 
of O 
the O 
intermediate O 
thiolactone B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
existed O 
as O 
a O 
mixture O 
of O 
two O 
diastereomers O 
having O 
a O 
cis O 
configuration O 
of O 
the O 
double O 
bond O 
, O 
whereas O 
those O 
formed O 
in O 
the O 
presence O 
of O 
thiols B-FAMILY 
appeared O 
as O 
a O 
mixture O 
of O 
four O 
diastereomers O 
with O 
a O 
cis O 
or O 
trans O 
configuration O 
of O 
the O 
double O 
bond O 
. O 
This O 
led O 
us O 
to O 
propose O 
tentative O 
mechanisms O 
for O 
the O 
previously O 
reported O 
formation O 
of O 
trans O 
isomers O 
of O 
the O 
active O 
thiol B-FAMILY 
metabolite O 
of O 
clopidogrel B-TRIVIAL 
upon O 
microsomal O 
metabolism O 
of O 
this O 
antithrombotic O 
in O 
the O 
presence O 
of O 
thiols B-FAMILY 
. O 
The O 
results O 
described O 
in O 
this O 
article O 
showed O 
that O 
thiolactone B-FAMILY 
sulfoxides I-FAMILY 
are O 
formed O 
as O 
reactive O 
metabolites O 
during O 
the O 
metabolism O 
of O 
clopidogrel B-TRIVIAL 
and O 
prasugrel B-TRIVIAL 
and O 
are O 
able O 
to O 
react O 
as O 
bis-electrophiles O 
with O 
a O 
variety O 
of O 
nucleophiles O 
. O 
The O 
possible O 
implications O 
of O 
the O 
formation O 
of O 
these O 
reactive O 
metabolites O 
in O 
the O 
pharmacological O 
and O 
/ O 
or O 
secondary O 
toxic O 
effects O 
of O 
these O 
drugs O 
remain O 
to O 
be O 
studied O 
. O 

Lattice O 
Strain O 
Accelerates O 
Oxygen B-SYSTEMATIC 
Surface O 
Exchange O 
and O 
Diffusion O 
in O 
La1-xSrxCoO3-δ O 
Thin O 
Films O 
. O 

influence O 
of O 
lattice O 
strain O 
on O 
the O 
oxygen B-SYSTEMATIC 
exchange O 
kinetics O 
and O 
diffusion O 
in O 
oxides B-FAMILY 
was O 
investigated O 
on O 
( O 
100 O 
) O 
epitaxial O 
La1-xSrxCoO3-δ B-FAMILY 
( O 
LSC B-ABBREVIATION 
) O 
thin O 
films O 
grown O 
by O 
pulsed O 
laser O 
deposition O 
. O 
Planar O 
tensile O 
and O 
compressively O 
strained O 
LSC B-ABBREVIATION 
films O 
were O 
obtained O 
on O 
single O 
- O 
crystalline O 
SrTiO3 B-FORMULA 
and O 
LaAlO3 B-FORMULA 
. O 
(18)O B-FORMULA 
isotope O 
exchange O 
depth O 
profiling O 
with O 
ToF-SIMS O 
was O 
employed O 
to O 
simultaneously O 
measure O 
the O 
tracer O 
surface O 
exchange O 
coefficient O 
k* O 
and O 
the O 
tracer O 
diffusion O 
coefficient O 
D* O 
in O 
the O 
temperature O 
range O 
280-475 O 
°C O 
. O 
In O 
accordance O 
with O 
recent O 
theoretical O 
findings O 
, O 
much O 
faster O 
surface O 
exchange O 
( O 
∼4 O 
times O 
) O 
and O 
diffusion O 
( O 
∼10 O 
times O 
) O 
were O 
observed O 
for O 
the O 
tensile O 
strained O 
films O 
compared O 
to O 
the O 
compressively O 
strained O 
films O 
in O 
the O 
entire O 
temperature O 
range O 
. O 
The O 
same O 
strain O 
effect O 
- O 
tensile O 
strain O 
leading O 
to O 
higher O 
k* O 
and O 
D*-was O 
found O 
for O 
different O 
LSC B-ABBREVIATION 
compositions O 
( O 
x O 
= O 
0.2 O 
and O 
x O 
= O 
0.4 O 
) O 
and O 
for O 
surface O 
- O 
etched O 
films O 
. O 
The O 
temperature O 
dependence O 
of O 
k* O 
and O 
D* O 
is O 
discussed O 
with O 
respect O 
to O 
the O 
contributions O 
of O 
strain O 
states O 
, O 
formation O 
enthalpy O 
of O 
oxygen B-SYSTEMATIC 
vacancies O 
, O 
and O 
vacancy O 
mobility O 
at O 
different O 
temperatures O 
. O 
Our O 
findings O 
point O 
toward O 
the O 
control O 
of O 
oxygen B-SYSTEMATIC 
surface O 
exchange O 
and O 
diffusion O 
kinetics O 
by O 
means O 
of O 
lattice O 
strain O 
in O 
existing O 
mixed O 
conducting O 
oxides B-FAMILY 
for O 
energy O 
conversion O 
applications O 
. O 

dominant O 
effect O 
in O 
exciton O 
coupling O 
is O 
usually O 
the O 
so O 
- O 
called O 
Coulomb O 
coupling O 
contribution O 
, O 
that O 
is O 
the O 
Coulomb O 
interaction O 
between O 
transition O 
densities O 
of O 
localized O 
excitations O 
. O 
At O 
short O 
distances O 
, O 
Dexter O 
- O 
type O 
exchange O 
effects O 
are O 
discussed O 
to O 
play O 
a O 
role O 
, O 
which O 
are O 
not O 
well O 
described O 
by O 
(semi)local O 
functionals O 
in O 
time O 
- O 
dependent O 
density O 
functional O 
theory O 
( O 
TDDFT O 
) O 
calculations O 
. O 
Overall O 
, O 
a O 
large O 
effect O 
of O 
the O 
percentage O 
of O 
exact O 
exchange O 
on O 
the O 
resulting O 
exciton O 
splittings O 
is O 
known O 
. O 
Subsystem O 
TDDFT O 
allows O 
one O 
to O 
analyze O 
the O 
exciton O 
coupling O 
mechanism O 
by O 
distinguishing O 
direct O 
from O 
indirect O 
effects O 
, O 
that O 
is O 
, O 
changes O 
in O 
the O 
actual O 
coupling O 
mechanism O 
from O 
modifications O 
in O 
the O 
underlying O 
local O 
excitations O 
. O 
Our O 
analysis O 
shows O 
that O 
the O 
strong O 
influence O 
of O 
exact O 
exchange O 
is O 
not O 
due O 
to O 
a O 
direct O 
Dexter O 
- O 
type O 
( O 
exchange O 
) O 
coupling O 
, O 
but O 
rather O 
to O 
an O 
increased O 
Coulomb O 
( O 
or O 
pseudo O 
- O 
exchange O 
) O 
coupling O 
triggered O 
by O 
a O 
change O 
in O 
transition O 
densities O 
. O 
This O 
is O 
demonstrated O 
in O 
calculations O 
for O 
2-pyridone B-SYSTEMATIC 
and O 
chlorophyll O 
dimers O 
. O 
We O 
finally O 
propose O 
a O 
route O 
to O 
efficient O 
calculations O 
of O 
excited O 
states O 
of O 
large O 
pigment O 
aggregates O 
with O 
hybrid O 
functionals O 
, O 
which O 
so O 
far O 
has O 
been O 
out O 
of O 
reach O 
for O 
quantum O 
chemical O 
methods O 
. O 

as O 
fatty B-FAMILY 
acid I-FAMILY 
transport O 
protein O 
1 O 
( O 
FATP1 O 
) O 
inhibitors O 
with O 
improved O 
potency O 
and O 
pharmacokinetic O 
properties O 
. O 

discovery O 
and O 
optimization O 
of O 
a O 
novel O 
series O 
of O 
FATP1 O 
inhibitors O 
are O 
described O 
. O 
Through O 
the O 
derivatization O 
process O 
, O 
arylpiperazine B-FAMILY 
derivatives O 
5k O 
and O 
12a O 
were O 
identified O 
as O 
possessing O 
potent O 
in O 
vitro O 
activity O 
against O 
human O 
and O 
mouse O 
FATP1s O 
as O 
well O 
as O 
excellent O 
pharmacokinetic O 
properties O 
. O 
In O 
vivo O 
evaluation O 
of O 
triglyceride B-FAMILY 
accumulation O 
in O 
the O 
liver O 
, O 
white O 
gastrocnemius O 
muscle O 
and O 
soleus O 
is O 
also O 
described O 
. O 

design O 
, O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
cyclic B-FAMILY 
imides I-FAMILY 
bearing O 
benzenesulfonamide B-SYSTEMATIC 
fragment O 
as O 
potential O 
COX-2 O 
inhibitors O 
. O 
Part O 
2 O 
. O 

group O 
of O 
cyclic B-FAMILY 
imides I-FAMILY 
( O 
1-10 O 
) O 
was O 
designed O 
for O 
evaluation O 
as O 
a O 
selective O 
COX-2 O 
inhibitors O 
and O 
investigated O 
in O 
vivo O 
for O 
their O 
anti-inflammatory O 
activity O 
. O 
Compounds O 
6a O 
, O 
6b O 
, O 
8a O 
, O 
8b O 
, O 
9a O 
, O 
9b O 
, O 
10a O 
and O 
10b O 
were O 
proved O 
to O 
be O 
potent O 
COX-2 O 
inhibitors O 
with O 
IC50 O 
range O 
of O 
0.1-4.0μM O 
. O 
In O 
vitro O 
COX-1 O 
/ O 
COX-2 O 
inhibition O 
structure O 
- O 
activity O 
studies O 
identified O 
compound O 
8a O 
as O 
a O 
highly O 
potent O 
( O 
IC50=0.1μM O 
) O 
, O 
and O 
an O 
extremely O 
selective O 
[ O 
COX-2 O 
( O 
SI O 
) O 
> O 
1000 O 
] O 
comparable O 
to O 
celecoxib B-TRIVIAL 
[ O 
COX-2 O 
( O 
SI O 
) O 
> O 
384 O 
] O 
, O 
COX-2 O 
inhibitor O 
that O 
showed O 
superior O 
anti-inflammatory O 
activity O 
( O 
ED50=72.4mg O 
/ O 
kg O 
) O 
relative O 
to O 
diclofenac B-TRIVIAL 
( O 
ED50=114mg O 
/ O 
kg O 
) O 
. O 
Molecular O 
modeling O 
was O 
carried O 
out O 
through O 
docking O 
the O 
designed O 
compounds O 
into O 
the O 
COX-2 O 
binding O 
site O 
to O 
predict O 
if O 
these O 
compounds O 
have O 
analogous O 
binding O 
mode O 
to O 
the O 
COX-2 O 
inhibitors O 
. O 
The O 
study O 
showed O 
that O 
the O 
homosulfonamide B-SYSTEMATIC 
fragment O 
of O 
8a O 
inserted O 
deep O 
inside O 
the O 
2°-pocket O 
of O 
the O 
COX-2 O 
active O 
site O 
, O 
where O 
the O 
SO2NH2 B-FORMULA 
group O 
underwent O 
H B-FORMULA 
-bonding O 
interaction O 
with O 
Gln B-FORMULA 
(192)(2.95Å) O 
, O 
Phe B-FORMULA 
(518)(2.82Å) O 
and O 
Arg B-FORMULA 
( O 
513)(2.63 O 
and O 
2.73Å O 
) O 
. O 
Docking O 
study O 
of O 
the O 
synthesized O 
compound O 
8a O 
into O 
the O 
active O 
site O 
of O 
COX-2 O 
revealed O 
a O 
similar O 
binding O 
mode O 
to O 
SC-558 B-IDENTIFIER 
, O 
a O 
selective O 
COX-2 O 
inhibitor O 
. O 

of O 
glycyrrhizic B-TRIVIAL 
acid I-TRIVIAL 
against O 
AGEs-induced O 
endothelial O 
dysfunction O 
through O 
inhibiting O 
RAGE O 
/ O 
NF-κB O 
pathway O 
activation O 
in O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
. O 

RELEVANCE O 
: O 
Licorice O 
( O 
Glycyrrhiza O 
uralensis O 
roots O 
) O 
is O 
used O 
as O 
a O 
traditional O 
medicine O 
for O 
the O 
treatment O 
of O 
diabetes O 
mellitus O 
and O 
its O 
vascular O 
complications O 
. O 
Glycyrrhizic B-TRIVIAL 
acid I-TRIVIAL 
( O 
GA O 
, O 
also O 
known O 
as O 
Glycyrrhizin B-TRIVIAL 
) O 
, O 
a O 
triterpenoid B-FAMILY 
saponin I-FAMILY 
glycoside I-FAMILY 
, O 
is O 
considered O 
to O 
be O 
a O 
bioactive O 
component O 
in O 
Licorice O 
and O 
is O 
beneficial O 
to O 
diabetic O 
vascular O 
complications O 
. O 
AIM O 
OF O 
STUDY O 
: O 
The O 
present O 
study O 
was O 
conducted O 
to O 
evaluate O 
the O 
potential O 
protective O 
activities O 
on O 
AGEs-induced O 
endothelial O 
dysfunction O 
, O 
including O 
anti-apoptosis O 
, O 
antioxidant O 
stress O 
and O 
anti-proinflammatory O 
responses O 
, O 
and O 
explore O 
the O 
underlying O 
mechanism O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Human O 
umbilical O 
vein O 
endothelial O 
cells O 
( O 
HUVECs O 
) O 
were O 
incubated O 
and O 
pre O 
- O 
treated O 
with O 
GA O 
( O 
10(-9)-10(-6)M O 
) O 
or O 
RAGE-Ab O 
( O 
5μg O 
/ O 
ml O 
) O 
in O 
the O 
presence O 
or O 
absence O 
of O 
200μg O 
/ O 
ml O 
AGEs O 
. O 
AO O 
/ O 
EB O 
fluorescence O 
staining O 
assay O 
was O 
performed O 
to O 
evaluate O 
anti-apoptosis O 
activity O 
. O 
The O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
activity O 
and O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
level O 
in O 
cell O 
supernatant O 
were O 
detected O 
by O 
kits O 
while O 
the O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
generation O 
was O 
determined O 
by O 
2,7-dichlorodihydrofluorescin B-SYSTEMATIC 
diacetate I-SYSTEMATIC 
( O 
DCFH-DA B-ABBREVIATION 
) O 
kit O 
. O 
Immunocytochemistry O 
analysis O 
was O 
designed O 
to O 
determine O 
transforming O 
growth O 
factor O 
beta1(TGF-β1) O 
protein O 
expression O 
while O 
immunofluorescence O 
analysis O 
for O 
RAGE O 
and O 
NF-kB O 
. O 
The O 
protein O 
expressions O 
of O 
TGF-β1 O 
, O 
RAGE O 
and O 
NF-kB O 
were O 
analyzed O 
by O 
Western O 
blot O 
analysis O 
. O 
RESULTS O 
: O 
Pretreatment O 
with O 
GA O 
at O 
a O 
concentration O 
of O 
10(-8)-10(-6)M O 
significantly O 
reduced O 
the O 
AGEs-induced O 
apoptosis O 
in O 
HUVECs O 
. O 
GA O 
significantly O 
increased O 
antioxidant O 
enzyme O 
SOD O 
activity O 
and O 
decreased O 
peroxide O 
degradation O 
product O 
MDA B-ABBREVIATION 
level O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Furthermore O 
, O 
GA O 
also O 
remarkably O 
inhibited O 
the O 
overgeneration O 
of O 
AGEs-induced O 
ROS O 
. O 
Both O 
immunocytochemistry O 
analysis O 
and O 
western O 
blot O 
analysis O 
showed O 
that O 
GA O 
significantly O 
decreased O 
the O 
protein O 
expression O 
of O 
poinflammatory O 
cytokine O 
TGF-β1 O 
in O 
a O 
similar O 
manner O 
which O 
RAGE-Ab O 
did O 
. O 
Additionally O 
, O 
AGEs-induced O 
RAGE O 
and O 
NF-kB O 
protein O 
expressions O 
were O 
down O 
- O 
regulated O 
significantly O 
by O 
the O 
pretreatment O 
with O 
GA O 
or O 
RAGE-Ab O 
. O 
CONCLUSION O 
: O 
These O 
findings O 
provide O 
evidences O 
that O 
GA O 
possesses O 
protective O 
activity O 
on O 
AGEs-induced O 
endothelial O 
dysfunction O 
, O 
including O 
anti-apoptosis O 
, O 
anti-inflammation O 
and O 
antioxidant O 
stress O 
, O 
via O 
inhibiting O 
RAGE O 
/ O 
NF-kB O 
pathway O 
. O 
GA O 
might O 
be O 
an O 
alternative O 
for O 
the O 
prevention O 
and O 
treatment O 
of O 
diabetic O 
vascular O 
complications O 
in O 
an O 
appropriate O 
dosage O 
. O 

activation O 
by O 
PEGylated O 
liposomes O 
containing O 
prednisolone B-TRIVIAL 
. O 

of O 
PEGylated O 
liposomes O 
can O 
give O 
rise O 
to O 
hypersensitivity O 
reactions O 
( O 
HSRs O 
) O 
in O 
a O 
relatively O 
large O 
number O 
of O 
patients O 
. O 
Previously O 
it O 
has O 
been O 
shown O 
that O 
these O 
reactions O 
can O 
be O 
caused O 
by O 
activation O 
of O 
the O 
complement O 
( O 
C O 
) O 
system O 
by O 
a O 
negative O 
charge O 
on O 
the O 
anchor O 
molecule O 
of O 
PEG B-ABBREVIATION 
at O 
the O 
liposomal O 
surface O 
. O 
In O 
this O 
study O 
it O 
is O 
tested O 
whether O 
the O 
activation O 
of O 
the O 
C O 
system O 
by O 
PEG B-ABBREVIATION 
-liposomes O 
could O 
be O 
significantly O 
reduced O 
to O 
values O 
comparable O 
to O 
nonreactive O 
liposomal O 
formulations O 
, O 
by O 
changing O 
the O 
PEGylation O 
- O 
profile O 
on O 
the O 
liposomal O 
surface O 
. O 
Therefore O 
, O 
the O 
formation O 
of O 
C O 
activation O 
markers O 
SC5b-9 O 
, O 
C3a O 
, O 
C4d O 
and O 
Bb O 
in O 
normal O 
human O 
serum O 
by O 
both O 
prednisolone B-TRIVIAL 
loaded O 
and O 
empty O 
liposomes O 
with O 
a O 
variation O 
of O 
PEG B-ABBREVIATION 
chain O 
length O 
, O 
PEG B-ABBREVIATION 
surface O 
concentration O 
, O 
PEG B-ABBREVIATION 
anchor O 
molecule O 
and O 
liposomal O 
size O 
was O 
determined O 
using O 
in O 
vitro O 
assays O 
. O 
The O 
tested O 
liposomes O 
caused O 
no O 
or O 
only O 
mild O 
( O 
30% O 
) O 
activation O 
of O 
C O 
except O 
for O 
one O 
formulation O 
wherein O 
the O 
PEG2000 B-TRIVIAL 
was O 
anchored O 
to O 
cholesterol B-TRIVIAL 
( O 
CHOL-PEG2000 B-TRIVIAL 
) O 
. O 
The O 
latter O 
liposomes O 
caused O 
paralleling O 
rises O 
in O 
SC5b-9 O 
and O 
Bb O 
levels O 
, O 
suggesting O 
excess O 
activation O 
of O 
the O 
alternative O 
pathway O 
. O 
While O 
the O 
relative O 
safety O 
of O 
weak O 
C O 
activator O 
liposomes O 
remains O 
to O 
be O 
confirmed O 
in O 
vivo O 
, O 
the O 
unique O 
, O 
non-charge O 
and O 
non-antibody O 
- O 
mediated O 
direct O 
conversion O 
of O 
C3 O 
by O 
CHOL-PEG2000 B-TRIVIAL 
liposomes O 
( O 
although O 
argues O 
against O 
the O 
clinical O 
development O 
of O 
these O 
vesicles O 
) O 
opens O 
new O 
opportunities O 
to O 
understand O 
liposomal O 
C O 
activation O 
at O 
the O 
molecular O 
level O 
. O 

and O 
biopharmaceutical O 
optimization O 
of O 
nystatin B-TRIVIAL 
release O 
from O 
a O 
multiparticulate O 
based O 
bioadhesive O 
drug O 
delivery O 
system O 
. O 

considerations O 
of O 
a O 
new O 
drug O 
delivery O 
system O 
include O 
controlling O 
the O 
site O 
of O 
release O 
of O 
the O 
active O 
ingredient O 
, O 
maintaining O 
drug O 
level O 
for O 
a O 
suitable O 
time O 
and O 
decreasing O 
dosage O 
frequency O 
. O 
In O 
research O 
and O 
development O 
practice O 
, O 
these O 
therapeutic O 
benefits O 
can O 
be O 
attained O 
by O 
selecting O 
suitable O 
active O 
ingredients O 
and O 
optimizing O 
procedure O 
parameters O 
, O 
determining O 
the O 
composition O 
of O 
the O 
medicine O 
, O 
and O 
dissolution O 
properties O 
. O 
The O 
aim O 
of O 
our O 
study O 
was O 
to O 
design O 
a O 
pharmaceutical O 
preparation O 
with O 
increased O 
local O 
therapeutic O 
effect O 
in O 
the O 
therapy O 
of O 
gastrointestinal O 
candidiasis O 
. O 
The O 
polyene B-SYSTEMATIC 
antibiotic O 
nystatin B-TRIVIAL 
may O 
be O 
an O 
optimal O 
choice O 
for O 
active O 
agent O 
, O 
incorporated O 
in O 
a O 
bioadhesive O 
multiparticulate O 
system O 
. O 
Choosing O 
the O 
proper O 
excipients O 
in O 
the O 
proper O 
dosage O 
form O 
and O 
ensuring O 
prolonged O 
residence O 
time O 
may O 
further O 
improve O 
the O 
optimal O 
treatment O 
. O 
Using O 
an O 
experimental O 
design O 
, O 
the O 
micropellets O 
were O 
prepared O 
with O 
5% O 
nystatin B-TRIVIAL 
content O 
, O 
taking O 
the O 
factors O 
average O 
pellet O 
size O 
( O 
∼200 O 
to O 
∼800μm O 
) O 
and O 
the O 
amount O 
of O 
applied O 
carbomer O 
and O 
hydroxyethylcellulose O 
( O 
0-5% O 
) O 
into O 
consideration O 
. O 
Dissolution O 
of O 
the O 
active O 
ingredient O 
was O 
detected O 
by O 
UV O 
spectrophotometric O 
and O 
microbiological O 
assay O 
. O 
The O 
bioadhesive O 
character O 
of O 
the O 
multiparticulate O 
dosage O 
form O 
was O 
examined O 
by O 
ex O 
vivo O 
wash O 
- O 
off O 
test O 
. O 
The O 
only O 
factor O 
which O 
significantly O 
influenced O 
the O 
examined O 
parameters O 
was O 
average O 
pellet O 
size O 
. O 
The O 
proportion O 
of O 
applied O 
bioadhesive O 
excipients O 
had O 
significance O 
mostly O 
in O 
interactions O 
with O 
average O 
pellet O 
size O 
. O 
Eventually O 
, O 
optimized O 
drug O 
release O 
( O 
5-10min O 
mean O 
dissolution O 
time O 
, O 
50-55% O 
bioadhesion O 
retention O 
) O 
could O 
be O 
achieved O 
with O 
550μm O 
pellet O 
size O 
, O 
containing O 
carbomer O 
and O 
hydroxyethylcellulose O 
in O 
85 O 
: O 
15 O 
ratio O 
. O 

in O 
Combination O 
with O 
Exemestane B-TRIVIAL 
: O 
A O 
Review O 
of O 
its O 
Use O 
in O 
the O 
Treatment O 
of O 
Patients O 
with O 
Postmenopausal O 
Hormone O 
Receptor-Positive O 
, O 
HER2-Negative O 
Advanced O 
Breast O 
Cancer O 
. O 

everolimus B-TRIVIAL 
( O 
Afinitor B-TRIVIAL 
( O 
® O 
) O 
) O 
in O 
combination O 
with O 
exemestane B-TRIVIAL 
is O 
indicated O 
for O 
the O 
treatment O 
of O 
hormone O 
receptor O 
- O 
positive O 
, O 
human O 
epidermal O 
growth O 
factor O 
receptor O 
( O 
HER O 
) O 
2-negative O 
advanced O 
breast O 
cancer O 
in O 
postmenopausal O 
women O 
after O 
failure O 
of O 
treatment O 
with O 
letrozole B-TRIVIAL 
or O 
anastrozole B-TRIVIAL 
( O 
in O 
the O 
USA O 
) O 
or O 
after O 
recurrence O 
of O 
progression O 
following O 
a O 
nonsteroidal O 
aromatase O 
inhibitor O 
( O 
AI O 
) O 
in O 
women O 
without O 
symptomatic O 
visceral O 
disease O 
( O 
in O 
the O 
EU O 
) O 
. O 
Everolimus B-TRIVIAL 
, O 
a O 
selective O 
inhibitor O 
of O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
( O 
mTOR O 
) O 
, O 
inhibits O 
the O 
downstream O 
signalling O 
events O 
of O 
the O 
mTOR O 
pathway O 
. O 
This O 
review O 
summarizes O 
the O 
pharmacology O 
of O 
everolimus B-TRIVIAL 
and O 
reviews O 
its O 
efficacy O 
and O 
tolerability O 
when O 
administered O 
in O 
combination O 
with O 
exemestane B-TRIVIAL 
in O 
postmenopausal O 
women O 
with O 
oestrogen B-FAMILY 
receptor O 
- O 
positive O 
, O 
HER2-negative O 
advanced O 
breast O 
cancer O 
refractory O 
to O 
nonsteroidal O 
AIs O 
. O 
In O 
the O 
well O 
- O 
designed O 
BOLERO-2 O 
study O 
, O 
the O 
addition O 
of O 
everolimus B-TRIVIAL 
to O 
exemestane B-TRIVIAL 
was O 
shown O 
to O 
significantly O 
prolong O 
progression O 
- O 
free O 
survival O 
in O 
this O 
patient O 
population O 
. O 
However O 
, O 
treatment-emergent O 
adverse O 
events O 
and O 
treatment O 
discontinuations O 
occurred O 
more O 
frequently O 
with O 
combination O 
therapy O 
than O 
with O 
exemestane B-TRIVIAL 
alone O 
, O 
suggesting O 
a O 
need O 
for O 
careful O 
benefit O 
/ O 
risk O 
assessment O 
prior O 
to O 
initiating O 
therapy O 
. O 
Mature O 
survival O 
data O 
from O 
this O 
study O 
are O 
awaited O 
and O 
additional O 
studies O 
would O 
help O 
to O 
further O 
demonstrate O 
the O 
benefit O 
of O 
combination O 
therapy O 
. O 
Nevertheless O 
, O 
current O 
evidence O 
suggests O 
that O 
everolimus B-TRIVIAL 
plus O 
exemestane B-TRIVIAL 
combination O 
therapy O 
may O 
be O 
a O 
useful O 
treatment O 
option O 
in O 
patients O 
with O 
postmenopausal O 
hormone O 
receptor O 
- O 
positive O 
, O 
HER2-negative O 
, O 
advanced O 
breast O 
cancer O 
refractory O 
to O 
nonsteroidal O 
AIs O 
. O 

: O 
a O 
review O 
of O 
its O 
use O 
in O 
chronic O 
weight O 
management O 
. O 

lorcaserin B-TRIVIAL 
( O 
BELVIQ B-TRIVIAL 
( O 
® O 
) O 
) O 
, O 
a O 
selective O 
serotonin B-TRIVIAL 
5-HT2C O 
receptor O 
agonist O 
, O 
is O 
indicated O 
in O 
the O 
US O 
as O 
an O 
adjunct O 
to O 
diet O 
and O 
exercise O 
in O 
the O 
chronic O 
weight O 
management O 
of O 
obese O 
adults O 
, O 
or O 
overweight O 
adults O 
with O 
at O 
least O 
one O 
weight O 
- O 
related O 
comorbidity O 
( O 
e.g O 
. O 
dyslipidaemia O 
, O 
hypertension O 
, O 
type O 
2 O 
diabetes O 
) O 
. O 
This O 
article O 
reviews O 
the O 
pharmacological O 
properties O 
, O 
therapeutic O 
efficacy O 
and O 
tolerability O 
of O 
oral O 
lorcaserin B-TRIVIAL 
in O 
this O 
patient O 
population O 
. O 
In O 
three O 
large O 
randomized O 
, O 
double O 
- O 
blind O 
, O 
multicentre O 
studies O 
, O 
oral O 
lorcaserin B-TRIVIAL 
was O 
more O 
effective O 
than O 
placebo O 
in O 
the O 
management O 
of O 
obese O 
and O 
overweight O 
adults O 
with O 
or O 
without O 
type O 
2 O 
diabetes O 
mellitus O 
. O 
Following O 
12 O 
months O 
' O 
therapy O 
, O 
significantly O 
higher O 
proportions O 
of O 
lorcaserin B-TRIVIAL 
than O 
placebo O 
recipients O 
achieved O 
a O 
≥ O 
5 O 
and O 
≥ O 
10 O 
% O 
reduction O 
from O 
baseline O 
in O 
their O 
bodyweight O 
and O 
a O 
significant O 
between O 
- O 
group O 
difference O 
favouring O 
lorcaserin B-TRIVIAL 
over O 
placebo O 
was O 
observed O 
for O 
the O 
change O 
from O 
baseline O 
in O 
bodyweight O 
. O 
Moreover O 
, O 
among O 
patients O 
who O 
had O 
achieved O 
a O 
≥ O 
5 O 
% O 
reduction O 
in O 
their O 
bodyweight O 
after O 
12 O 
months O 
' O 
therapy O 
with O 
lorcaserin B-TRIVIAL 
, O 
a O 
significantly O 
higher O 
proportion O 
who O 
received O 
lorcaserin B-TRIVIAL 
for O 
a O 
further O 
12 O 
months O 
than O 
those O 
who O 
switched O 
to O 
placebo O 
maintained O 
≥ O 
5 O 
% O 
weight O 
loss O 
at O 
24 O 
months O 
. O 
In O 
general O 
, O 
oral O 
lorcaserin B-TRIVIAL 
was O 
well O 
tolerated O 
in O 
clinical O 
studies O 
, O 
with O 
hypoglycaemia O 
and O 
headache O 
the O 
most O 
frequently O 
reported O 
adverse O 
events O 
in O 
those O 
with O 
or O 
without O 
type O 
2 O 
diabetes O 
, O 
respectively O 
. O 
According O 
to O 
a O 
pooled O 
analysis O 
, O 
the O 
risk O 
of O 
US-FDA-defined O 
valvulopathy O 
with O 
lorcaserin B-TRIVIAL 
is O 
generally O 
low O 
and O 
not O 
statistically O 
significantly O 
different O 
from O 
placebo O 
. O 
From O 
these O 
and O 
other O 
data O 
, O 
the O 
FDA O 
has O 
concluded O 
that O 
lorcaserin B-TRIVIAL 
is O 
unlikely O 
to O 
elevate O 
the O 
risk O 
of O 
valvulopathy O 
. O 

Light-Trapping O 
Enhancement O 
in O 
an O 
Ultrathin O 
Film O 
a- O 
Si B-FORMULA 
Absorber O 
Using O 
Whispering O 
Gallery O 
Modes O 
and O 
Guided O 
Wave O 
Modes O 
with O 
Dielectric O 
Surface-Textured O 
Structures O 
. O 

embedded O 
nanosphere O 
dielectric O 
structure O 
on O 
an O 
a- O 
Si B-FORMULA 
ultrathin O 
film O 
improves O 
weighted O 
absorption O 
from O 
23.8% O 
to O 
39.9% O 
. O 
The O 
PMMA B-ABBREVIATION 
embedding O 
layer O 
offers O 
a O 
guided O 
wave O 
mode O 
as O 
well O 
as O 
mechanical O 
robustness O 
, O 
in O 
addition O 
to O 
the O 
resonant O 
whispering O 
gallery O 
modes O 
coupling O 
. O 
Broadband O 
light O 
- O 
trapping O 
enhancements O 
are O 
observed O 
by O 
dielectric O 
surface O 
textured O 
structures O 
of O 
hemispheres O 
, O 
nanocones O 
, O 
nanospheres O 
, O 
or O 
embedded O 
nanospheres O 
. O 

sympathetic O 
activity O 
is O 
a O 
well O 
- O 
known O 
pathophysiological O 
mechanism O 
in O 
insulin O 
resistance O 
( O 
IR O 
) O 
and O 
hypertension O 
( O 
HT O 
) O 
. O 
The O 
carotid O 
bodies O 
( O 
CB O 
) O 
are O 
peripheral O 
chemoreceptors O 
that O 
classically O 
respond O 
to O 
hypoxia O 
by O 
increasing O 
chemosensory O 
activity O 
in O 
the O 
carotid O 
sinus O 
nerve O 
( O 
CSN O 
) O 
, O 
causing O 
hyperventilation O 
and O 
activation O 
of O 
the O 
sympathoadrenal O 
system O 
. O 
Besides O 
its O 
role O 
in O 
the O 
control O 
of O 
ventilation O 
, O 
the O 
CB O 
has O 
been O 
proposed O 
as O 
a O 
glucose B-TRIVIAL 
sensor O 
being O 
implicated O 
in O 
the O 
control O 
of O 
energy O 
homeostasis O 
. O 
However O 
, O 
to O 
date O 
no O 
studies O 
have O 
anticipated O 
its O 
role O 
in O 
the O 
development O 
of O 
IR O 
. O 
Herein O 
we O 
propose O 
that O 
CB O 
overstimulation O 
is O 
involved O 
in O 
the O 
aetiology O 
of O 
IR O 
and O 
HT O 
, O 
core O 
metabolic O 
and O 
hemodynamic O 
disturbances O 
of O 
highly O 
prevalent O 
diseases O 
like O 
the O 
metabolic O 
syndrome O 
, O 
type O 
2 O 
diabetes O 
and O 
obstructive O 
sleep O 
apnoea O 
. O 
We O 
demonstrated O 
CB O 
activity O 
is O 
increased O 
in O 
IR O 
animal O 
models O 
and O 
that O 
CSN O 
resection O 
prevents O 
CB-overactivation O 
and O 
diet O 
- O 
induced O 
IR O 
and O 
HT O 
. O 
Moreover O 
we O 
showed O 
that O 
insulin O 
triggers O 
CB O 
, O 
highlighting O 
a O 
new O 
role O 
for O 
hyperinsulinemia O 
as O 
a O 
stimulus O 
for O 
CB-overactivation O 
. O 
We O 
propose O 
that O 
CB O 
is O 
implicated O 
in O 
the O 
pathogenesis O 
of O 
metabolic O 
and O 
hemodynamic O 
disturbances O 
through O 
sympathoadrenal O 
overactivation O 
and O 
may O 
represent O 
a O 
novel O 
therapeutic O 
target O 
in O 
these O 
diseases O 
. O 

rule O 
on O 
chirality O 
- O 
dependent O 
bandgaps O 
in O 
graphene B-TRIVIAL 
antidot O 
lattices O 
. O 

with O 
periodically O 
patterned O 
antidots O 
has O 
attracted O 
intense O 
research O 
attention O 
as O 
it O 
represents O 
a O 
facile O 
route O 
to O 
open O 
a O 
bandgap O 
for O 
graphene B-TRIVIAL 
electronics O 
. O 
However O 
, O 
not O 
all O 
graphene B-TRIVIAL 
antidot O 
lattices O 
( O 
GALs O 
) O 
can O 
open O 
a O 
bandgap O 
and O 
a O 
guiding O 
rule O 
is O 
missing O 
. O 
Here O 
, O 
through O 
systematic O 
first O 
- O 
principles O 
calculations O 
, O 
it O 
is O 
found O 
that O 
bandgaps O 
in O 
triangular O 
GALs O 
are O 
surprisingly O 
well O 
defined O 
by O 
a O 
chirality O 
vector O 
R O 
= O 
n O 
a1 O 
+ O 
ma2 O 
connecting O 
two O 
neighboring O 
antidots O 
, O 
where O 
a1 O 
and O 
a2 O 
are O 
the O 
basis O 
vectors O 
of O 
graphene B-TRIVIAL 
. O 
The O 
bandgap O 
opens O 
in O 
the O 
GALs O 
with O 
(n-m)mod3 O 
= O 
0 O 
but O 
remains O 
closed O 
in O 
those O 
with O 
(n-m)mod3 O 
= O 
±1 O 
, O 
reminiscent O 
of O 
the O 
gap O 
- O 
chirality O 
rule O 
in O 
carbon B-SYSTEMATIC 
nanotubes O 
. O 
Remarkably O 
, O 
the O 
gap O 
value O 
in O 
GALs O 
allows O 
ample O 
modulation O 
by O 
adjusting O 
the O 
length O 
of O 
chirality O 
vectors O 
, O 
shape O 
and O 
size O 
of O 
the O 
antidots O 
. O 
The O 
gap O 
- O 
chirality O 
relation O 
in O 
GALs O 
stems O 
from O 
the O 
chirality O 
- O 
dependent O 
atomic O 
structures O 
of O 
GALs O 
as O 
revealed O 
by O 
a O 
super O 
- O 
atom O 
model O 
as O 
well O 
as O 
Clar O 
sextet O 
analyses O 
. O 
This O 
chirality O 
- O 
dependent O 
bandgap O 
is O 
further O 
shown O 
to O 
be O 
a O 
generic O 
behavior O 
in O 
any O 
parallelogram O 
GAL O 
and O 
thus O 
serves O 
as O 
an O 
essential O 
stepping O 
stone O 
for O 
experimenters O 
to O 
realize O 
graphene B-TRIVIAL 
devices O 
by O 
antidot O 
engineering O 
. O 

Vitamin B-FAMILY 
D I-FAMILY 
Metabolites O 
and O 
Subclinical O 
Atherosclerosis O 
in O 
Type O 
1 O 
Diabetes O 
. O 

with O 
type O 
1 O 
diabetes O 
are O 
at O 
high O 
risk O 
of O 
premature O 
atherosclerosis O 
. O 
Existing O 
evidence O 
suggests O 
that O 
impaired O 
vitamin B-FAMILY 
D I-FAMILY 
metabolism O 
may O 
contribute O 
to O 
the O 
development O 
of O 
atherosclerosis O 
. O 
We O 
tested O 
associations O 
of O 
circulating O 
vitamin B-FAMILY 
D I-FAMILY 
metabolite O 
concentrations O 
with O 
subclinical O 
atherosclerosis O 
among O 
1193 O 
participants O 
with O 
type O 
1 O 
diabetes O 
in O 
the O 
DCCT O 
/ O 
EDIC O 
study.RESEARCH O 
DESIGN O 
AND O 
METHODSWe O 
measured O 
plasma O 
concentrations O 
of O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
[ O 
25(OH)D B-SYSTEMATIC 
] O 
, O 
1,25-dihydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
, O 
and O 
24,25-dihydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
by O 
mass O 
spectrometry O 
at O 
the O 
end O 
of O 
the O 
DCCT O 
. O 
In O 
a O 
staggered O 
cross O 
- O 
sectional O 
design O 
, O 
we O 
tested O 
associations O 
with O 
coronary O 
artery O 
calcium B-SYSTEMATIC 
( O 
CAC O 
) O 
, O 
measured O 
by O 
computed O 
tomography O 
a O 
median O 
of O 
10 O 
years O 
later O 
, O 
and O 
with O 
common O 
and O 
internal O 
carotid O 
intima O 
- O 
media O 
thickness O 
( O 
IMT O 
) O 
, O 
measured O 
by O 
B-mode O 
ultrasonography O 
on O 
two O 
occasions O 
a O 
median O 
of O 
4 O 
years O 
later O 
and O 
a O 
median O 
of O 
10 O 
years O 
later O 
. O 
We O 
hypothesized O 
that O 
lower O 
concentrations O 
of O 
each O 
vitamin B-FAMILY 
D I-FAMILY 
metabolite O 
would O 
be O 
associated O 
with O 
increased O 
risk O 
of O 
CAC O 
and O 
greater O 
carotid O 
IMT.RESULTSAt O 
the O 
time O 
metabolites O 
were O 
measured O 
, O 
mean O 
age O 
was O 
32.4 O 
years O 
and O 
mean O 
duration O 
of O 
diabetes O 
was O 
7.5 O 
years O 
. O 
The O 
prevalence O 
and O 
severity O 
of O 
CAC O 
tended O 
to O 
be O 
lower O 
- O 
not O 
higher O 
- O 
with O 
lower O 
concentrations O 
of O 
each O 
vitamin B-FAMILY 
D I-FAMILY 
metabolite O 
. O 
For O 
instance O 
, O 
in O 
a O 
fully O 
adjusted O 
multinomial O 
logistic O 
model O 
, O 
a O 
25 O 
nmol O 
/ O 
L O 
lower O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
was O 
associated O 
with O 
a O 
0.8-fold O 
decrease O 
in O 
the O 
odds O 
of O 
having O 
higher O 
CAC O 
( O 
95% O 
CI O 
0.68-0.96 O 
, O 
P O 
= O 
0.01 O 
) O 
. O 
No O 
vitamin B-FAMILY 
D I-FAMILY 
metabolite O 
was O 
associated O 
with O 
either O 
common O 
or O 
internal O 
mean O 
IMT.CONCLUSIONSWe O 
did O 
not O 
find O 
evidence O 
linking O 
impaired O 
vitamin B-FAMILY 
D I-FAMILY 
metabolism O 
with O 
increased O 
subclinical O 
atherosclerosis O 
in O 
type O 
1 O 
diabetes O 
. O 

of O 
the O 
Bone O 
- O 
restricted O 
ifitm O 
- O 
like O 
( O 
Bril O 
) O 
gene O 
transcription O 
by O 
Sp O 
and O 
Gli O 
family O 
members O 
and O 
CpG B-ABBREVIATION 
methylation O 
. O 

encodes O 
a O 
small O 
membrane O 
protein O 
present O 
in O 
osteoblasts O 
. O 
In O 
humans O 
, O 
a O 
single O 
recurrent O 
mutation O 
in O 
the O 
5'UTR O 
of O 
BRIL O 
causes O 
osteogenesis O 
imperfecta O 
type O 
V O 
. O 
The O 
exact O 
function O 
of O 
BRIL O 
and O 
the O 
mechanism O 
by O 
which O 
it O 
contributes O 
to O 
disease O 
are O 
still O 
unknown O 
. O 
The O 
goal O 
of O 
the O 
current O 
study O 
was O 
to O 
characterize O 
the O 
mechanisms O 
governing O 
Bril O 
transcription O 
in O 
the O 
human O 
, O 
rat O 
and O 
mouse O 
. O 
In O 
the O 
three O 
species O 
, O 
as O 
detected O 
by O 
luciferase O 
reporter O 
assays O 
in O 
UMR106 O 
cells O 
, O 
we O 
found O 
that O 
most O 
of O 
the O 
baseline O 
regulatory O 
activity O 
was O 
localized O 
within O 
≈250bp O 
upstream O 
of O 
the O 
coding O 
ATG O 
. O 
Co-transfection O 
experiments O 
indicated O 
that O 
Sp1 O 
and O 
Sp3 O 
were O 
potent O 
inducers O 
of O 
the O 
promoter O 
activity O 
, O 
through O 
the O 
binding O 
several O 
GC-rich O 
boxes O 
. O 
Osterix O 
was O 
a O 
weak O 
activator O 
but O 
acted O 
cooperatively O 
with O 
Sp1 O 
and O 
GLI2 O 
to O 
synergistically O 
induce O 
the O 
BRIL O 
promoter O 
. O 
GLI2 O 
, O 
a O 
mediator O 
of O 
hedgehog O 
signaling O 
pathway O 
, O 
was O 
also O 
a O 
potent O 
activator O 
of O 
BRIL O 
through O 
a O 
single O 
GLI O 
binding O 
site O 
. O 
Correspondingly O 
, O 
agonists O 
of O 
the O 
Hedgehog O 
pathway O 
( O 
purmorphamine B-TRIVIAL 
and O 
Indian O 
hedgehog O 
) O 
in O 
MC3T3 O 
osteoblasts O 
led O 
to O 
increased O 
BRIL O 
levels O 
. O 
The O 
BRIL O 
promoter O 
activity O 
was O 
also O 
found O 
to O 
be O 
negatively O 
modulated O 
through O 
two O 
different O 
mechanisms O 
. O 
First O 
, O 
the O 
ZFP354C O 
zinc O 
finger O 
protein O 
repressed O 
basal O 
and O 
Sp1-induced O 
activity O 
. O 
Second O 
, O 
CpG B-ABBREVIATION 
methylation O 
of O 
the O 
promoter O 
region O 
correlated O 
with O 
an O 
inactive O 
state O 
, O 
and O 
prevented O 
Sp1 O 
activation O 
. O 
The O 
data O 
provide O 
the O 
very O 
first O 
analyses O 
of O 
the O 
cis- O 
and O 
trans-acting O 
factors O 
regulating O 
Bril O 
transcription O 
. O 
They O 
revealed O 
key O 
roles O 
for O 
the O 
Sp O 
members O 
and O 
GLI2 O 
that O 
possibly O 
cooperate O 
to O 
activate O 
Bril O 
when O 
the O 
promoter O 
becomes O 
demethylated O 
. O 

report O 
a O 
highly O 
conserved O 
motif O 
in O 
the O 
E-cadherin O 
juxtamembrane O 
domain O 
that O 
determines O 
apical O 
- O 
lateral O 
polarity O 
by O 
conferring O 
both O 
restricted O 
mobility O 
at O 
the O 
lateral O 
membrane O 
and O 
transcytosis O 
of O 
apically O 
mis O 
- O 
sorted O 
protein O 
to O 
the O 
lateral O 
membrane O 
. O 
Mutations O 
causing O 
either O 
increased O 
lateral O 
membrane O 
mobility O 
or O 
loss O 
of O 
apical O 
- O 
lateral O 
transcytosis O 
result O 
in O 
partial O 
mis O 
- O 
sorting O 
of O 
E-cadherin O 
in O 
MDCK O 
cells O 
. O 
However O 
, O 
loss O 
of O 
both O 
activities O 
results O 
in O 
complete O 
loss O 
of O 
polarity O 
. O 
We O 
present O 
evidence O 
that O 
residues O 
required O 
for O 
restricted O 
mobility O 
mediate O 
retention O 
at O 
the O 
lateral O 
membrane O 
through O 
interaction O 
with O 
ankyrin-G O 
, O 
while O 
dileucine B-TRIVIAL 
residues O 
conferring O 
apical O 
- O 
lateral O 
transcytosis O 
act O 
through O 
a O 
clathrin O 
- O 
dependent O 
process O 
and O 
function O 
in O 
an O 
editing O 
pathway O 
. O 
Ankyrin-G O 
interaction O 
with O 
E-cadherin O 
is O 
abolished O 
by O 
the O 
same O 
mutations O 
resulting O 
in O 
increased O 
E-cadherin O 
mobility O 
. O 
Clathrin O 
heavy O 
chain O 
knockdown O 
and O 
dileucine B-TRIVIAL 
mutation O 
of O 
E-cadherin O 
both O 
cause O 
the O 
same O 
partial O 
loss O 
of O 
polarity O 
of O 
E-cadherin O 
. O 
Moreover O 
, O 
clathrin O 
knockdown O 
causes O 
no O 
further O 
change O 
in O 
polarity O 
of O 
E-cadherin O 
with O 
dileucine B-TRIVIAL 
mutation O 
, O 
but O 
does O 
completely O 
randomize O 
E-cadherin O 
mutants O 
lacking O 
ankyrin O 
- O 
binding O 
. O 
Dileucine B-TRIVIAL 
mutation O 
, O 
but O 
not O 
loss O 
of O 
ankyrin O 
- O 
binding O 
, O 
prevented O 
transcytosis O 
of O 
apically O 
mis O 
- O 
sorted O 
E-cadherin O 
to O 
the O 
lateral O 
membrane O 
. O 
Finally O 
, O 
neurofascin O 
, O 
which O 
binds O 
ankyrin O 
but O 
lacks O 
dileucine B-TRIVIAL 
residues O 
, O 
exhibited O 
partial O 
apical O 
- O 
lateral O 
polarity O 
that O 
was O 
abolished O 
by O 
mutation O 
of O 
its O 
ankyrin O 
- O 
binding O 
site O 
but O 
was O 
not O 
affected O 
by O 
clathrin O 
knockdown O 
. O 
The O 
polarity O 
motif O 
thus O 
integrates O 
complementary O 
activities O 
of O 
lateral O 
membrane O 
retention O 
through O 
ankyrin-G O 
and O 
apical O 
- O 
lateral O 
transcytosis O 
of O 
mis O 
- O 
localized O 
protein O 
through O 
clathrin O 
. O 
Together O 
, O 
the O 
combination O 
of O 
retention O 
and O 
editing O 
function O 
to O 
ensure O 
a O 
high O 
fidelity O 
steady O 
state O 
localization O 
of O 
E-cadherin O 
at O 
the O 
lateral O 
membrane O 
. O 

- O 
mechanotransduction O 
, O 
the O 
way O 
by O 
which O 
mechanical O 
forces O 
are O 
transformed O 
into O 
chemical O 
signals O 
, O 
plays O 
a O 
fundamental O 
role O 
in O 
many O 
biological O 
processes O 
. O 
The O 
first O 
step O 
of O 
mechanotransduction O 
often O 
relies O 
on O 
exposure O 
, O 
under O 
stretching O 
, O 
of O 
cryptic O 
sites O 
buried O 
in O 
adhesion O 
proteins O 
. O 
Likewise O 
, O 
here O 
we O 
report O 
the O 
first O 
example O 
of O 
synthetic O 
surfaces O 
allowing O 
for O 
specific O 
and O 
fully O 
reversible O 
adhesion O 
of O 
proteins O 
or O 
cells O 
promoted O 
by O 
mechanical O 
action O 
. O 
Silicone O 
sheets O 
are O 
first O 
plasma O 
treated O 
and O 
then O 
functionalized O 
by O 
grafting O 
sequentially O 
under O 
stretching O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
chains O 
and O 
biotin B-TRIVIAL 
or O 
arginine B-TRIVIAL 
- O 
glycine B-TRIVIAL 
- O 
aspartic B-TRIVIAL 
acid I-TRIVIAL 
( O 
RGD O 
) O 
peptides O 
. O 
At O 
unstretched O 
position O 
, O 
these O 
ligands O 
are O 
not O 
accessible O 
for O 
their O 
receptors O 
. O 
Under O 
a O 
mechanical O 
deformation O 
, O 
the O 
surface O 
becomes O 
specifically O 
interactive O 
to O 
streptavidin O 
, O 
biotin B-TRIVIAL 
antibodies O 
, O 
or O 
adherent O 
for O 
cells O 
, O 
the O 
interactions O 
both O 
for O 
proteins O 
and O 
cells O 
being O 
fully O 
reversible O 
by O 
stretching O 
/ O 
unstretching O 
, O 
revealing O 
a O 
reversible O 
exposure O 
process O 
of O 
the O 
ligands O 
. O 
By O 
varying O 
the O 
degree O 
of O 
stretching O 
, O 
the O 
amount O 
of O 
interacting O 
proteins O 
can O 
be O 
varied O 
continuously O 
. O 

(II) I-SYSTEMATIC 
Dithiocarbamate I-SYSTEMATIC 
Complexes O 
Containing O 
Sulforhodamine B-TRIVIAL 
B I-TRIVIAL 
as O 
Fluorescent O 
Probes O 
for O 
Selective O 
Detection O 
of O 
Nitrogen B-SYSTEMATIC 
Dioxide I-SYSTEMATIC 
. O 

synthesized O 
complexes O 
of O 
Ni B-FORMULA 
(II) I-FORMULA 
with O 
dithiocarbamate B-SYSTEMATIC 
ligands O 
derived O 
from O 
the O 
ortho O 
and O 
para O 
isomers O 
of O 
sulforhodamine B-TRIVIAL 
B I-TRIVIAL 
fluorophores O 
and O 
demonstrated O 
they O 
are O 
highly O 
selective O 
in O 
reactions O 
with O 
nitrogen B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
NO2 B-FORMULA 
) O 
. O 
Compared O 
with O 
the O 
para O 
isomer O 
, O 
the O 
ortho O 
isomer O 
showed O 
a O 
much O 
greater O 
fluorescence O 
increase O 
upon O 
reaction O 
with O 
NO2 B-FORMULA 
, O 
which O 
led O 
to O 
oxidation O 
and O 
decomplexation O 
of O 
the O 
dithiocarbamate B-SYSTEMATIC 
ligand O 
from O 
Ni B-FORMULA 
(II) I-FORMULA 
. O 
We O 
applied O 
this O 
probe O 
for O 
visual O 
detection O 
of O 
1 O 
ppm O 
NO2 B-FORMULA 
in O 
the O 
gas O 
phase O 
and O 
fluorescence O 
imaging O 
of O 
NO2 B-FORMULA 
in O 
macrophage O 
cells O 
treated O 
with O 
a O 
nitrogen B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
donor O 
. O 

Biomineralization O 
in O 
Magnetospirillum O 
gryphiswaldense O 
: O 
Time-Resolved O 
Magnetic O 
and O 
Structural O 
Studies O 
. O 

bacteria O 
biosynthesize O 
magnetite B-TRIVIAL 
nanoparticles O 
of O 
high O 
structural O 
and O 
chemical O 
purity O 
that O 
allow O 
them O 
to O 
orientate O 
in O 
the O 
geomagnetic O 
field O 
. O 
In O 
this O 
work O 
we O 
have O 
followed O 
the O 
process O 
of O 
biomineralization O 
of O 
these O 
magnetite B-TRIVIAL 
nanoparticles O 
. O 
We O 
have O 
performed O 
a O 
time O 
- O 
resolved O 
study O 
on O 
magnetotactic O 
bacteria O 
Magnetospirillum O 
gryphiswaldense O 
strain O 
MSR-1 O 
. O 
From O 
the O 
combination O 
of O 
magnetic O 
and O 
structural O 
studies O 
by O 
means O 
of O 
Fe O 
K-edge O 
X-ray O 
absorption O 
near O 
edge O 
structure O 
( O 
XANES O 
) O 
and O 
high O 
- O 
resolution O 
transmission O 
electron O 
microscopy O 
we O 
have O 
identified O 
and O 
quantified O 
two O 
phases O 
of O 
Fe B-FORMULA 
( O 
ferrihydrite B-TRIVIAL 
and O 
magnetite B-TRIVIAL 
) O 
involved O 
in O 
the O 
biomineralization O 
process O 
, O 
confirming O 
the O 
role O 
of O 
ferrihydrite B-TRIVIAL 
as O 
the O 
source O 
of O 
Fe B-FORMULA 
ions O 
for O 
magnetite B-TRIVIAL 
biomineralization O 
in O 
M O 
. O 
gryphiswaldense O 
. O 
We O 
have O 
distinguished O 
two O 
steps O 
in O 
the O 
biomineralization O 
process O 
: O 
the O 
first O 
, O 
in O 
which O 
Fe B-FORMULA 
is O 
accumulated O 
in O 
the O 
form O 
of O 
ferrihydrite B-TRIVIAL 
, O 
and O 
the O 
second O 
, O 
in O 
which O 
the O 
magnetite B-TRIVIAL 
is O 
rapidly O 
biomineralized O 
from O 
ferrihydrite B-TRIVIAL 
. O 
Finally O 
, O 
the O 
XANES O 
analysis O 
suggests O 
that O 
the O 
origin O 
of O 
the O 
ferrihydrite B-TRIVIAL 
could O 
be O 
at O 
bacterial O 
ferritin O 
cores O 
, O 
characterized O 
by O 
a O 
poorly O 
crystalline O 
structure O 
and O 
high O 
phosphorus B-SYSTEMATIC 
content O 
. O 

the O 
Unique O 
ATP B-ABBREVIATION 
-Binding O 
Pocket O 
of O 
Toxoplasma O 
Calcium B-SYSTEMATIC 
-Dependent O 
Protein O 
Kinase O 
1 O 
To O 
Identify O 
Its O 
Substrates O 
. O 

parasites O 
rely O 
on O 
calcium B-SYSTEMATIC 
as O 
a O 
second O 
messenger O 
to O 
regulate O 
a O 
variety O 
of O 
essential O 
cellular O 
processes O 
. O 
Calcium B-SYSTEMATIC 
-dependent O 
protein O 
kinases O 
( O 
CDPK O 
) O 
, O 
which O 
transduce O 
these O 
signals O 
, O 
are O 
conserved O 
among O 
apicomplexans O 
but O 
absent O 
from O 
mammalian O 
hosts O 
, O 
making O 
them O 
attractive O 
targets O 
for O 
therapeutic O 
intervention O 
. O 
Despite O 
their O 
importance O 
, O 
the O 
signaling O 
pathways O 
CDPK O 
regulate O 
remain O 
poorly O 
characterized O 
, O 
and O 
their O 
protein O 
substrates O 
are O 
completely O 
unknown O 
. O 
In O 
Toxoplasma O 
gondii O 
, O 
CDPK1 O 
is O 
required O 
for O 
calcium B-SYSTEMATIC 
-regulated O 
secretion O 
from O 
micronemes O 
, O 
thereby O 
controlling O 
motility O 
, O 
invasion O 
, O 
and O 
egress O 
from O 
host O 
cells O 
. O 
CDPK1 O 
is O 
unique O 
among O 
parasite O 
and O 
mammalian O 
kinases O 
in O 
containing O 
glycine B-TRIVIAL 
at O 
the O 
key O 
" O 
gatekeeper O 
" O 
residue O 
, O 
which O 
results O 
in O 
an O 
expanded O 
ATP B-ABBREVIATION 
-binding O 
pocket O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
use O 
a O 
synthetic O 
ATPγS O 
analogue O 
that O 
displays O 
steric O 
complementarity O 
to O 
the O 
ATP B-ABBREVIATION 
-binding O 
pocket O 
and O 
hence O 
allows O 
identification O 
of O 
protein O 
substrates O 
based O 
on O 
selective O 
thiophosphorylation O 
. O 
The O 
specificity O 
of O 
this O 
approach O 
was O 
validated O 
by O 
the O 
concordance O 
between O 
the O 
identified O 
phosphorylation O 
sites O 
and O 
the O 
in O 
vitro O 
substrate O 
preference O 
of O 
CDPK1 O 
. O 
We O 
further O 
demonstrate O 
that O 
the O 
phosphorylation O 
of O 
predicted O 
substrates O 
is O 
dependent O 
on O 
CDPK1 O 
both O 
in O 
vivo O 
and O 
in O 
vitro O 
. O 
This O 
combined O 
strategy O 
for O 
identifying O 
the O 
targets O 
of O 
specific O 
protein O 
kinases O 
provides O 
a O 
platform O 
for O 
defining O 
the O 
roles O 
of O 
CDPKs O 
in O 
apicomplexans O 
. O 

Vivo O 
Degradation O 
and O 
Elimination O 
of O 
Injectable O 
Ricinoleic B-TRIVIAL 
Acid I-TRIVIAL 
-Based O 
Poly(ester-anhydride) B-FAMILY 
. O 

in O 
vivo O 
degradation O 
and O 
elimination O 
after O 
subcutaneous O 
implantation O 
of O 
injectable O 
p(SA-RA) B-ABBREVIATION 
3 I-ABBREVIATION 
: I-ABBREVIATION 
7 I-ABBREVIATION 
copolymer O 
in O 
rats O 
, O 
followed O 
by O 
characterization O 
of O 
the O 
polymer O 
matrix O 
composition O 
during O 
hydrolysis O 
and O 
erosion O 
, O 
is O 
reported O 
. O 
Major O 
chemical O 
changes O 
were O 
observed O 
during O 
the O 
first O 
few O 
days O 
post O 
implantation O 
, O 
the O 
anhydride O 
bonds O 
hydrolyzed O 
along O 
with O 
about O 
45% O 
weight O 
loss O 
and O 
a O 
significant O 
decrease O 
in O 
the O 
molecular O 
weight O 
. O 
(1)H B-FORMULA 
NMR O 
spectral O 
analysis O 
was O 
used O 
to O 
determine O 
the O 
structures O 
and O 
content O 
of O 
ricinoleic B-TRIVIAL 
acid I-TRIVIAL 
containing O 
oligomeric O 
chains O 
present O 
in O 
the O 
degraded O 
polymer O 
. O 
The O 
polymer O 
degrades O 
into O 
ester O 
oligomers O 
of O 
2-4 O 
ricinoleic B-TRIVIAL 
acid I-TRIVIAL 
units O 
which O 
further O 
degrade O 
to O 
ricinoleic B-TRIVIAL 
acid I-TRIVIAL 
, O 
a O 
natural O 
fatty B-FAMILY 
acid I-FAMILY 
. O 
The O 
polymer O 
hydrolytic O 
degradation O 
process O 
fit O 
the O 
in O 
vitro O 
degradation O 
process O 
. O 

Copolyelectrolyte O 
Adhesive O 
of O 
the O 
Sandcastle O 
Worm O 
, O 
Phragmatopoma O 
californica O 
( O 
Fewkes O 
) O 
: O 
Catechol B-TRIVIAL 
Oxidase O 
Catalyzed O 
Curing O 
through O 
Peptidyl- O 
DOPA B-ABBREVIATION 
. O 

- O 
building O 
sabellariid O 
polychaetes O 
have O 
major O 
impacts O 
on O 
the O 
geology O 
and O 
ecology O 
of O 
shorelines O 
worldwide O 
. O 
Sandcastle O 
worms O 
, O 
Phragmatopoma O 
californica O 
( O 
Fewkes O 
) O 
, O 
live O 
along O 
the O 
western O 
coast O 
of O 
North O 
America O 
. O 
Individual O 
sabellariid O 
worms O 
build O 
tubular O 
shells O 
by O 
gluing O 
together O 
mineral O 
particles O 
with O 
a O 
multipart O 
polyelectrolytic O 
adhesive O 
. O 
Distinct O 
sets O 
of O 
oppositely O 
charged O 
components O 
are O 
packaged O 
and O 
stored O 
in O 
concentrated O 
granules O 
in O 
separate O 
cell O 
types O 
. O 
Homogeneous O 
granules O 
contain O 
sulfated O 
macromolecules O 
as O 
counter O 
- O 
polyanion O 
to O 
polycationic O 
Pc2 O 
and O 
Pc5 O 
proteins O 
, O 
which O 
become O 
major O 
components O 
of O 
the O 
fully O 
cured O 
glue O 
. O 
Heterogeneous O 
granules O 
contain O 
polyphosphoproteins O 
, O 
Pc3A O 
/ O 
B O 
, O 
paired O 
with O 
divalent O 
cations O 
and O 
polycationic O 
Pc1 O 
and O 
Pc4 O 
proteins O 
. O 
Both O 
types O 
of O 
granules O 
contain O 
catechol B-TRIVIAL 
oxidase O 
that O 
catalyzes O 
oxidative O 
cross O 
- O 
linking O 
of O 
L-DOPA B-ABBREVIATION 
. O 
Co-secretion O 
of O 
catechol B-TRIVIAL 
oxidase O 
guarantees O 
rapid O 
and O 
spatially O 
homogeneous O 
curing O 
with O 
limited O 
mixing O 
of O 
the O 
preassembled O 
adhesive O 
packets O 
. O 
Catechol B-TRIVIAL 
oxidase O 
remains O 
active O 
long O 
after O 
the O 
glue O 
is O 
fully O 
cured O 
, O 
perhaps O 
providing O 
an O 
active O 
cue O 
for O 
conspecific O 
larval O 
settlement O 
. O 

: O 
To O 
compare O 
' O 
progression O 
to O 
insulin O 
' O 
for O 
three O 
cohorts O 
on O 
oral O 
antidiabetic O 
medication O 
combinations O 
: O 
metformin B-TRIVIAL 
/ O 
sulphonylurea B-SYSTEMATIC 
( O 
Met B-FORMULA 
/ O 
SU O 
) O 
, O 
metformin B-TRIVIAL 
/ O 
thiazolidinedione B-FAMILY 
( O 
Met B-FORMULA 
/ O 
TZD B-ABBREVIATION 
) O 
and O 
sulphonylurea B-SYSTEMATIC 
/ O 
thiazolidinedione B-FAMILY 
( O 
SU/ O 
TZD B-ABBREVIATION 
) O 
. O 
METHODS O 
: O 
Retrospective O 
cohort O 
analysis O 
design O 
was O 
used O 
. O 
The O 
subjects O 
were O 
US O 
nationwide O 
members O 
of O 
military O 
and O 
their O 
families O 
. O 
A O 
total O 
of O 
5608 O 
patients O 
who O 
were O 
on O 
antidiabetic O 
monotherapy O 
for O 
at O 
least O 
1 O 
year O 
before O 
adding O 
a O 
second O 
agent O 
to O 
their O 
medication O 
regimen O 
between O 
October O 
2001 O 
and O 
September O 
2008 O 
participated O 
in O 
this O 
study O 
. O 
Mean O 
age O 
ranged O 
from O 
64 O 
to O 
71 O 
years O 
among O 
the O 
cohorts O 
. O 
Cox O 
regression O 
compared O 
the O 
progression O 
to O 
insulin O 
, O 
adjusting O 
for O 
demographics O 
, O 
months O 
of O 
follow O 
- O 
up O 
and O 
co O 
- O 
morbidities O 
[ O 
measured O 
with O 
Chronic O 
Disease O 
Score O 
( O 
CDS O 
) O 
] O 
. O 
RESULTS O 
: O 
By O 
the O 
end O 
of O 
the O 
2- O 
to O 
6-year O 
follow O 
- O 
up O 
period O 
, O 
14.3% O 
of O 
the O 
Met B-FORMULA 
/ O 
TZD B-ABBREVIATION 
cohort O 
, O 
23.6% O 
of O 
the O 
Met B-FORMULA 
/ O 
SU O 
cohort O 
and O 
28.2% O 
of O 
the O 
SU/ O 
TZD B-ABBREVIATION 
cohort O 
had O 
insulin O 
added O 
to O 
their O 
regimen O 
. O 
Those O 
in O 
the O 
Met B-FORMULA 
/ O 
SU O 
cohort O 
had O 
a O 
1.8 O 
times O 
higher O 
probability O 
of O 
progression O 
to O 
insulin O 
than O 
those O 
in O 
the O 
Met B-FORMULA 
/ O 
TZD B-ABBREVIATION 
cohort O 
[ O 
odds O 
ratio O 
(OR) O 
= O 
1.8 O 
, O 
95% O 
confidence O 
interval O 
(CI) O 
= O 
1.51-2.14 O 
) O 
, O 
and O 
those O 
in O 
the O 
SU/ O 
TZD B-ABBREVIATION 
cohort O 
had O 
a O 
2.5 O 
times O 
higher O 
probability O 
of O 
progression O 
to O 
insulin O 
than O 
those O 
in O 
the O 
Met B-FORMULA 
/ O 
TZD B-ABBREVIATION 
cohort O 
( O 
OR O 
= O 
2.51 O 
, O 
95% O 
CI O 
= O 
2.04-3.08 O 
) O 
. O 
CONCLUSION O 
: O 
When O 
sensitizers O 
were O 
paired O 
( O 
Met B-FORMULA 
/ O 
TZD B-ABBREVIATION 
) O 
, O 
a O 
lower O 
percentage O 
of O 
patients O 
progressed O 
to O 
insulin O 
during O 
the O 
study O 
period O 
, O 
as O 
opposed O 
to O 
patients O 
who O 
used O 
a O 
combination O 
of O 
a O 
secretagogue O 
with O 
a O 
sensitizer O 
( O 
SU/ O 
TZD B-ABBREVIATION 
or O 
Met B-FORMULA 
/ O 
SU O 
) O 
. O 

Protective O 
Effects O 
of O 
α-Lipoic B-TRIVIAL 
Acid I-TRIVIAL 
on O 
Kidneys O 
in O 
Type O 
2 O 
Diabetic O 
Goto-Kakisaki O 
Rats O 
via O 
Reducing O 
Oxidative O 
Stress O 
. O 

evaluate O 
the O 
protective O 
effects O 
of O 
α-lipoic B-TRIVIAL 
acid I-TRIVIAL 
on O 
the O 
kidneys O 
of O 
Goto-Kakisaki O 
( O 
GK O 
) O 
diabetic O 
rats O 
, O 
ten O 
GK O 
diabetic O 
rats O 
were O 
randomly O 
divided O 
into O 
a O 
diabetic O 
control O 
group O 
and O 
a O 
lipoic B-TRIVIAL 
acid I-TRIVIAL 
-treated O 
diabetic O 
group O 
with O 
α-lipoic B-TRIVIAL 
acid I-TRIVIAL 
35 O 
mg·Kg-1 O 
intraperitoneal O 
injections O 
. O 
Four O 
healthy O 
Wistar O 
rats O 
served O 
as O 
normal O 
controls O 
. O 
Malonaldehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
, O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
( O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
) O 
, O 
vitamin B-FAMILY 
E I-FAMILY 
, O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
and O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
levels O 
in O 
renal O 
homogenate O 
, O 
and O 
urine O 
protein O 
excretion O 
were O 
measured O 
. O 
The O 
expression O 
of O 
mRNA O 
for O 
NF-κB O 
, O 
NADPH B-ABBREVIATION 
oxidase O 
subunits O 
p22phox O 
and O 
p47phox O 
in O 
renal O 
tissue O 
was O 
examined O 
by O 
realtime O 
PCR O 
. O 
Pathological O 
changes O 
in O 
renal O 
tissue O 
were O 
evaluated O 
by O 
light O 
and O 
electron O 
microscopy O 
. O 
There O 
were O 
significant O 
increases O 
in O 
urine O 
protein O 
excretion O 
, O 
MDA B-ABBREVIATION 
levels O 
and O 
the O 
expression O 
of O 
mRNA O 
of O 
NF-κB O 
, O 
p22phox O 
and O 
p47phox O 
, O 
and O 
significant O 
decreases O 
in O 
GSH B-ABBREVIATION 
, O 
SOD O 
, O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
and O 
vitamin B-FAMILY 
E I-FAMILY 
levels O 
in O 
the O 
diabetic O 
control O 
group O 
compared O 
with O 
the O 
normal O 
control O 
group O 
. O 
Pathological O 
changes O 
of O 
renal O 
tissue O 
were O 
more O 
progressive O 
in O 
the O 
diabetic O 
control O 
group O 
than O 
in O 
the O 
normal O 
control O 
group O 
. O 
All O 
the O 
parameters O 
above O 
were O 
improved O 
in O 
the O 
α-lipoic B-TRIVIAL 
acid I-TRIVIAL 
-treated O 
diabetic O 
group O 
. O 
Oxidative O 
stress O 
is O 
increased O 
in O 
the O 
kidney O 
of O 
type O 
2 O 
diabetic O 
GK O 
rats O 
. O 
It O 
is O 
associated O 
with O 
the O 
progression O 
of O 
diabetic O 
nephropathy O 
. O 
α-lipoic B-TRIVIAL 
acid I-TRIVIAL 
can O 
protect O 
renal O 
function O 
in O 
diabetic O 
rats O 
via O 
its O 
antioxidant O 
activity O 
. O 

of O 
oxygen B-SYSTEMATIC 
concentration O 
and O 
selected O 
protocol O 
factors O 
on O 
viability O 
and O 
gene O 
expression O 
of O 
mouse O 
liver O 
slices O 
. O 

cut O 
liver O 
slices O 
( O 
PCLSs O 
) O 
are O 
widely O 
used O 
as O 
a O 
model O 
to O 
study O 
hepatotoxicity O 
. O 
For O 
culturing O 
of O 
PCLS O 
diverse O 
protocols O 
are O 
used O 
which O 
could O 
affect O 
slices O 
viability O 
and O 
results O 
. O 
We O 
aimed O 
to O 
identify O 
the O 
most O 
optimal O 
culture O 
protocol O 
for O 
mouse O 
PCLS O 
. O 
Slices O 
were O 
cultured O 
for O 
24h O 
under O 
different O 
concentrations O 
of O 
serum O 
, O 
glucose B-TRIVIAL 
, O 
insulin O 
, O 
and O 
oxygen B-SYSTEMATIC 
. O 
Thereafter O 
, O 
slices O 
viability O 
was O 
assessed O 
by O 
biochemical O 
methods O 
. O 
Transcriptome O 
analysis O 
was O 
performed O 
to O 
identify O 
changes O 
introduced O 
by O 
culture O 
at O 
different O 
oxygen B-SYSTEMATIC 
concentrations O 
( O 
20% O 
, O 
40% O 
, O 
60% O 
, O 
and O 
80% O 
of O 
oxygen B-SYSTEMATIC 
) O 
. O 
Medium O 
composition O 
did O 
not O 
affect O 
the O 
slices O 
viability O 
. O 
Although O 
metabolic O 
competence O 
was O 
unaffected O 
by O 
oxygen B-SYSTEMATIC 
concentrations O 
, O 
culturing O 
at O 
80% O 
of O 
oxygen B-SYSTEMATIC 
yielded O 
slices O 
with O 
the O 
best O 
biochemical O 
characteristics O 
. O 
The O 
comparison O 
of O 
uncultured O 
vs O 
. O 
cultured O 
slices O 
revealed O 
2524 O 
genes O 
to O 
be O 
differentially O 
expressed O 
. O 
Genes O 
involved O 
in O 
drug O 
metabolism O 
, O 
peroxisomal O 
and O 
mitochondrial O 
functions O 
were O 
down O 
- O 
regulated O 
while O 
several O 
adaptive O 
/ O 
stress O 
response O 
processes O 
were O 
up O 
- O 
regulated O 
. O 
Moreover O 
, O 
80% O 
of O 
oxygen B-SYSTEMATIC 
was O 
the O 
most O 
favorable O 
condition O 
with O 
respect O 
to O 
maintenance O 
of O 
expression O 
of O 
genes O 
involved O 
in O 
drug O 
and O 
energy O 
metabolism O 
. O 
The O 
outcome O 
of O 
this O 
study O 
indicates O 
that O 
mouse O 
PCLS O 
are O 
a O 
valuable O 
tool O 
in O 
research O 
on O 
hepatic O 
functions O 
and O 
toxicity O 
, O 
particularly O 
if O 
they O 
are O 
cultured O 
under O 
a O 
controlled O 
oxygen B-SYSTEMATIC 
concentration O 
of O 
80% O 
. O 

noncellular O 
reduction O 
of O 
MTT B-TRIVIAL 
tetrazolium I-TRIVIAL 
salt I-TRIVIAL 
by O 
TiO2 B-FORMULA 
nanoparticles O 
and O 
its O 
implications O 
for O 
cytotoxicity O 
assays O 
. O 

report O 
results O 
of O 
noncellular O 
tests O 
, O 
revealing O 
the O 
occurrence O 
of O 
photocatalytic O 
interactions O 
between O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
TiO2 B-FORMULA 
, O 
titania B-TRIVIAL 
) O 
nanoparticles O 
and O 
the O 
MTT B-ABBREVIATION 
[ O 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium- B-SYSTEMATIC 
bromide I-SYSTEMATIC 
] O 
cytotoxicity O 
indicator O 
. O 
These O 
interactions O 
induce O 
the O 
reduction O 
of O 
MTT B-ABBREVIATION 
and O 
formation O 
of O 
purple O 
formazan O 
under O 
biologically O 
relevant O 
conditions O 
. O 
Classical O 
MTT B-ABBREVIATION 
assays O 
have O 
been O 
performed O 
to O 
evaluate O 
the O 
production O 
of O 
formazan B-FAMILY 
in O 
DMEM-F12 O 
and O 
RPMI-1640 O 
cell O 
culture O 
media O 
( O 
containing O 
10% O 
fetal O 
bovine O 
serum-FBS O 
) O 
treated O 
with O 
Degussa- O 
P25 B-FORMULA 
TiO2 I-FORMULA 
nanoparticles O 
, O 
in O 
the O 
absence O 
of O 
cells O 
. O 
The O 
colorimetric O 
determinations O 
revealed O 
the O 
noncellular O 
MTT B-ABBREVIATION 
to O 
formazan B-FAMILY 
transformation O 
induced O 
by O 
TiO2 B-FORMULA 
nanoparticles O 
, O 
under O 
conditions O 
commonly O 
used O 
for O 
in O 
vitro O 
cytotoxicity O 
testing O 
of O 
nanomaterials O 
. O 
The O 
formazan B-FAMILY 
precipitation O 
was O 
found O 
to O 
be O 
proportional O 
to O 
the O 
TiO2 B-FORMULA 
concentration O 
, O 
being O 
enhanced O 
under O 
laboratory O 
daylight O 
exposure O 
. O 
The O 
photocatalytic O 
nature O 
of O 
the O 
studied O 
effect O 
was O 
assessed O 
under O 
UV O 
irradiation O 
at O 
365nm O 
. O 
The O 
biological O 
significance O 
of O 
the O 
reported O 
reaction O 
was O 
established O 
with O 
respect O 
to O 
cellular O 
reference O 
experiments O 
performed O 
on O 
V79-4 O 
, O 
HeLa O 
and O 
B16 O 
cell O 
lines O 
. O 
The O 
results O 
show O 
false O 
viability O 
increases O 
with O 
up O 
to O 
14% O 
( O 
for O 
TiO2 B-FORMULA 
concentrations O 
generally O 
higher O 
than O 
50μg O 
/ O 
ml O 
) O 
, O 
induced O 
by O 
the O 
TiO2 B-FORMULA 
- O 
MTT B-ABBREVIATION 
reaction O 
. O 
This O 
type O 
of O 
artifacts O 
may O 
lead O 
to O 
underestimated O 
toxicity O 
or O 
false O 
proliferation O 
results O 
. O 

of O 
visible O 
- O 
light O 
- O 
active O 
Sn B-FORMULA 
(ii) I-FORMULA 
- O 
TiO2 B-FORMULA 
photocatalysts O 
. O 

influence O 
of O 
Sn B-FORMULA 
(ii) I-FORMULA 
species O 
on O 
TiO2 B-FORMULA 
is O 
investigated O 
. O 
The O 
absorption O 
spectra O 
of O 
these O 
materials O 
are O 
red O 
- O 
shifted O 
by O 
115 O 
nm O 
to O 
the O 
visible O 
region O 
of O 
the O 
solar O 
spectrum O 
compared O 
with O 
P25 B-FORMULA 
TiO2 I-FORMULA 
. O 
This O 
prominent O 
red O 
- O 
shift O 
is O 
attributed O 
to O 
the O 
interaction O 
of O 
Sn B-FORMULA 
(ii) I-FORMULA 
5s O 
orbitals O 
with O 
the O 
TiO2 B-FORMULA 
decreasing O 
the O 
band O 
gap O 
of O 
TiO2 B-FORMULA 
by O 
raising O 
its O 
valence O 
band O 
. O 
The O 
tin B-SYSTEMATIC 
oxidation O 
state O 
and O 
the O 
materials O 
electronic O 
structure O 
are O 
evaluated O 
using O 
Mössbauer O 
spectroscopy O 
and O 
valence O 
band O 
X-ray O 
photoelectron O 
spectroscopy O 
respectively O 
. O 
These O 
materials O 
are O 
active O 
for O 
sacrificial O 
photo O 
- O 
generation O 
of O 
hydrogen B-SYSTEMATIC 
in O 
visible O 
light O 
. O 

pyrrolidinium B-SYSTEMATIC 
nitrate I-SYSTEMATIC 
protic O 
ionic O 
liquid O 
- O 
based O 
electrolyte O 
for O 
very O 
low O 
- O 
temperature O 
electrical O 
double O 
- O 
layer O 
capacitors O 
. O 

study O 
describes O 
the O 
use O 
of O 
the O 
pyrrolidinium B-SYSTEMATIC 
nitrate I-SYSTEMATIC 
( O 
[Pyrr][NO3] B-FORMULA 
) O 
protic O 
ionic O 
liquid O 
( O 
PIL O 
) O 
in O 
a O 
mixture O 
with O 
gamma B-SYSTEMATIC 
butyrolactone I-SYSTEMATIC 
( O 
γ-BL B-ABBREVIATION 
) O 
as O 
an O 
electrolyte O 
for O 
carbon B-SYSTEMATIC 
-based O 
supercapacitors O 
with O 
an O 
operating O 
voltage O 
of O 
2 O 
V O 
and O 
at O 
very O 
low O 
temperature O 
. O 
Thermal O 
and O 
transport O 
properties O 
of O 
this O 
electrolyte O 
were O 
firstly O 
evaluated O 
from O 
-40 O 
°C O 
to O 
80 O 
°C O 
. O 
The O 
evolution O 
of O 
conductivity O 
with O 
the O 
addition O 
of O 
γ-BL B-ABBREVIATION 
rendered O 
it O 
possible O 
to O 
determine O 
the O 
optimal O 
composition O 
for O 
electrochemical O 
application O 
, O 
with O 
a O 
molar O 
fraction O 
of O 
γ-BL B-ABBREVIATION 
of O 
0.6 O 
. O 
This O 
mixture O 
shows O 
a O 
Newtonian O 
behavior O 
with O 
a O 
low O 
viscosity O 
value O 
of O 
5 O 
mPa O 
s O 
at O 
25 O 
°C O 
, O 
and O 
exhibits O 
high O 
conductivity O 
values O 
of O 
up O 
to O 
65 O 
mS O 
cm(-1) O 
at O 
80 O 
°C O 
. O 
At O 
the O 
same O 
time O 
, O 
exceptional O 
residual O 
conductivity O 
was O 
measured O 
for O 
this O 
composition O 
at O 
-40 O 
°C O 
( O 
9 O 
mS O 
cm(-1) O 
) O 
, O 
thanks O 
to O 
the O 
superionic O 
character O 
of O 
pyrrolidinium B-SYSTEMATIC 
nitrate I-SYSTEMATIC 
PIL O 
. O 
Electrochemical O 
characterization O 
of O 
this O 
electrolyte O 
demonstrated O 
, O 
at O 
first O 
, O 
a O 
passivation O 
on O 
the O 
aluminum B-SYSTEMATIC 
collector O 
, O 
secondly O 
good O 
cycling O 
performances O 
with O 
an O 
activated O 
carbon B-SYSTEMATIC 
electrode O 
from O 
50 O 
°C O 
to O 
-40 O 
°C O 
with O 
capacitance O 
up O 
to O 
132 O 
F O 
g(-1) O 
at O 
room O 
temperature O 
and O 
a O 
wide O 
voltage O 
window O 
( O 
2 O 
V O 
) O 
. O 
Finally O 
at O 
very O 
low O 
temperature O 
( O 
-40 O 
°C O 
) O 
, O 
this O 
system O 
demonstrates O 
an O 
unprecedented O 
combination O 
of O 
high O 
specific O 
capacitance O 
( O 
up O 
to O 
117 O 
F O 
g(-1) O 
) O 
, O 
and O 
rapid O 
charging O 
- O 
discharging O 
even O 
at O 
high O 
current O 
density O 
, O 
which O 
is O 
very O 
promising O 
for O 
the O 
progress O 
of O 
energy O 
storage O 
systems O 
with O 
environmentally O 
friendly O 
electrolytes O 
at O 
such O 
very O 
low O 
temperatures O 
. O 

/ O 
HYPOTHESIS O 
: O 
Immunosuppressive O 
drugs O 
used O 
in O 
human O 
islet O 
transplantation O 
interfere O 
with O 
the O 
balance O 
between O 
beta O 
cell O 
renewal O 
and O 
death O 
, O 
and O 
thus O 
may O 
contribute O 
to O 
progressive O 
graft O 
dysfunction O 
. O 
We O 
analysed O 
the O 
influence O 
of O 
immunosuppressants O 
on O 
the O 
proliferation O 
of O 
transplanted O 
alpha O 
and O 
beta O 
cells O 
after O 
syngeneic O 
islet O 
transplantation O 
in O 
streptozotocin B-TRIVIAL 
-induced O 
diabetic O 
mice O 
. O 
METHODS O 
: O 
C57BL O 
/ O 
6 O 
diabetic O 
mice O 
were O 
transplanted O 
with O 
syngeneic O 
islets O 
in O 
the O 
liver O 
and O 
simultaneously O 
abdominally O 
implanted O 
with O 
a O 
mini O 
- O 
osmotic O 
pump O 
delivering O 
BrdU O 
alone O 
or O 
together O 
with O 
an O 
immunosuppressant O 
( O 
tacrolimus B-TRIVIAL 
, O 
sirolimus B-TRIVIAL 
, O 
everolimus B-TRIVIAL 
or O 
mycophenolate B-TRIVIAL 
mofetil I-TRIVIAL 
[ O 
MMF B-ABBREVIATION 
] O 
) O 
. O 
Glycaemic O 
control O 
was O 
assessed O 
for O 
4 O 
weeks O 
. O 
The O 
area O 
and O 
proliferation O 
of O 
transplanted O 
alpha O 
and O 
beta O 
cells O 
were O 
subsequently O 
quantified O 
. O 
RESULTS O 
: O 
After O 
4 O 
weeks O 
, O 
glycaemia O 
was O 
significantly O 
higher O 
in O 
treated O 
mice O 
than O 
in O 
controls O 
. O 
Insulinaemia O 
was O 
significantly O 
lower O 
in O 
mice O 
treated O 
with O 
everolimus B-TRIVIAL 
, O 
tacrolimus B-TRIVIAL 
and O 
sirolimus B-TRIVIAL 
. O 
MMF B-ABBREVIATION 
was O 
the O 
only O 
immunosuppressant O 
that O 
did O 
not O 
significantly O 
reduce O 
beta O 
cell O 
area O 
or O 
proliferation O 
, O 
albeit O 
its O 
levels O 
were O 
in O 
a O 
lower O 
range O 
than O 
those O 
used O 
in O 
clinical O 
settings O 
. O 
CONCLUSIONS O 
/ O 
INTERPRETATION O 
: O 
After O 
transplantation O 
in O 
diabetic O 
mice O 
, O 
syngeneic O 
beta O 
cells O 
have O 
a O 
strong O 
capacity O 
for O 
self O 
- O 
renewal O 
. O 
In O 
contrast O 
to O 
other O 
immunosuppressants O 
, O 
MMF B-ABBREVIATION 
neither O 
impaired O 
beta O 
cell O 
proliferation O 
nor O 
adversely O 
affected O 
the O 
fractional O 
beta O 
cell O 
area O 
. O 
Although O 
human O 
beta O 
cells O 
are O 
less O 
prone O 
to O 
proliferate O 
compared O 
with O 
rodent O 
beta O 
cells O 
, O 
the O 
use O 
of O 
MMF B-ABBREVIATION 
may O 
improve O 
the O 
long O 
- O 
term O 
outcome O 
of O 
islet O 
transplantation O 
. O 

data O 
regarding O 
the O 
changes O 
in O 
adrenocortical O 
reserves O 
during O 
hyperthyroidism O 
do O 
not O 
exist O 
. O 
We O 
aimed O 
to O 
document O 
the O 
capability O 
( O 
response O 
) O 
of O 
adrenal O 
gland O 
to O 
secrete O 
cortisol B-TRIVIAL 
and O 
DHEA B-ABBREVIATION 
-S O 
during O 
hyperthyroidism O 
compared O 
to O 
euthyroidism O 
, O 
and O 
to O 
describe O 
factors O 
associated O 
with O 
these O 
responses O 
. O 
A O 
standard O 
- O 
dose O 
( O 
0.25 O 
mg O 
/ O 
i.v O 
. O 
) O 
ACTH O 
stimulation O 
test O 
was O 
performed O 
to O 
the O 
same O 
patients O 
before O 
hyperthyroidism O 
treatment O 
, O 
and O 
after O 
attainment O 
of O 
euthyroidism O 
. O 
Baseline O 
cortisol B-TRIVIAL 
( O 
Cor0 O 
) O 
, O 
DHEA B-ABBREVIATION 
-S O 
( O 
DHEA B-ABBREVIATION 
-S0 O 
) O 
, O 
cortisol B-TRIVIAL 
binding O 
globulin O 
( O 
CBG O 
) O 
, O 
ACTH O 
, O 
calculated O 
free O 
cortisol B-TRIVIAL 
( O 
by O 
Coolen's O 
equation O 
= O 
CFC O 
) O 
, O 
free O 
cortisol B-TRIVIAL 
index O 
( O 
FCI O 
) O 
, O 
60-min O 
cortisol B-TRIVIAL 
( O 
Cor60 O 
) O 
, O 
and O 
DHEA B-ABBREVIATION 
-S O 
( O 
DHEA B-ABBREVIATION 
-S60 O 
) O 
, O 
delta B-TRIVIAL 
cortisol I-TRIVIAL 
( O 
ΔCor B-ABBREVIATION 
) O 
, O 
delta B-ABBREVIATION 
DHEA I-ABBREVIATION 
-S O 
( O 
ΔDHEA B-ABBREVIATION 
-S O 
) O 
responses O 
were O 
evaluated O 
. O 
Forty O 
- O 
one O 
patients O 
[ O 
22 O 
females O 
, O 
49.5 O 
± O 
15.2 O 
years O 
old O 
, O 
32 O 
Graves O 
disease O 
, O 
nine O 
toxic O 
nodular O 
goiter O 
] O 
had O 
similar O 
Cor0 O 
, O 
DHEA B-ABBREVIATION 
-S0 O 
, O 
CFC O 
, O 
FCI O 
, O 
and O 
DHEA B-ABBREVIATION 
-S60 O 
in O 
hyperthyroid O 
and O 
euthyroid O 
states O 
. O 
Cor60 O 
, O 
ΔCor B-ABBREVIATION 
, O 
and O 
ΔDHEA B-ABBREVIATION 
-S O 
were O 
lower O 
in O 
hyperthyroidism O 
. O 
In O 
four O 
( O 
10 O 
% O 
) O 
patients O 
the O 
peak O 
ACTH-stimulated O 
cortisol B-TRIVIAL 
values O 
were O 
lower O 
than O 
18 O 
μg O 
/ O 
dL O 
. O 
When O 
the O 
test O 
repeated O 
after O 
attainment O 
of O 
euthyroidism O 
, O 
all O 
of O 
the O 
patients O 
had O 
normal O 
cortisol B-TRIVIAL 
response O 
. O 
Regression O 
analysis O 
demonstrated O 
an O 
independent O 
association O 
of O 
Cor60 O 
with O 
free O 
T3 O 
in O 
hyperthyroidism O 
. O 
However O 
, O 
the O 
predictors O 
of O 
CFC O 
, O 
FCI O 
, O 
and O 
DHEA B-ABBREVIATION 
-S O 
levels O 
were O 
serum O 
creatinine B-TRIVIAL 
levels O 
in O 
hyperthyroidism O 
, O 
and O 
both O 
creatinine B-TRIVIAL 
and O 
transaminase O 
levels O 
in O 
euthyroidism O 
. O 
ACTH-stimulated O 
peak O 
cortisol B-TRIVIAL 
, O 
delta B-TRIVIAL 
cortisol I-TRIVIAL 
, O 
and O 
delta B-ABBREVIATION 
DHEA I-ABBREVIATION 
-S O 
levels O 
are O 
decreased O 
during O 
hyperthyroidism O 
, O 
probably O 
due O 
to O 
increased O 
turnover O 
. O 
Since O 
about O 
10 O 
% O 
of O 
the O 
subjects O 
with O 
hyperthyroidism O 
are O 
at O 
risk O 
for O 
adrenal O 
insufficiency O 
, O 
clinicians O 
dealing O 
with O 
Graves' O 
disease O 
should O 
be O 
alert O 
to O 
the O 
possibility O 
of O 
adrenal O 
insufficiency O 
during O 
hyperthyroid O 
stage O 
. O 

residue O 
at O 
active O 
- O 
site O 
tunnel O 
entrance O 
of O 
Trichoderma O 
reesei O 
cellobiohydrolase O 
Cel7A O 
is O 
important O 
to O 
initiate O 
degradation O 
of O 
crystalline O 
cellulose O 
. O 

hydrolase O 
family-7 O 
cellobiohydrolase O 
from O 
Trichoderma O 
reesei O 
( O 
TrCel7A O 
) O 
is O 
one O 
of O 
the O 
best O 
- O 
studied O 
cellulases O 
with O 
the O 
ability O 
to O 
degrade O 
highly O 
crystalline O 
cellulose O 
( O 
HCC O 
) O 
. O 
The O 
catalytic O 
domain O 
( O 
cat O 
) O 
and O 
cellulose O 
- O 
binding O 
domain O 
( O 
CBD O 
) O 
are O 
both O 
necessary O 
for O 
full O 
activity O 
on O 
crystalline O 
substrates O 
. O 
Our O 
previous O 
high O 
- O 
speed O 
AFM O 
studies O 
showed O 
that O 
mutation O 
of O 
tryptophan B-TRIVIAL 
residue O 
( O 
Trp B-FORMULA 
40 O 
; O 
W40 O 
) O 
at O 
the O 
entrance O 
of O 
the O 
catalytic O 
tunnel O 
drastically O 
decreases O 
the O 
ability O 
to O 
degrade O 
crystalline O 
cellulose O 
. O 
Here O 
, O 
we O 
examined O 
the O 
activities O 
of O 
the O 
wild O 
- O 
type O 
( O 
WT O 
) O 
enzyme O 
and O 
tryptophan B-TRIVIAL 
to O 
alanine B-TRIVIAL 
mutant O 
( O 
W40A O 
) O 
enzyme O 
, O 
with O 
and O 
without O 
the O 
CBD O 
, O 
towards O 
various O 
substrates O 
. O 
Evaluation O 
and O 
comparison O 
of O 
the O 
specific O 
activities O 
of O 
the O 
enzymes O 
( O 
WT O 
, O 
WTcat O 
, O 
W40A O 
, O 
and O 
W40Acat O 
) O 
adsorbed O 
on O 
crystalline O 
cellulose O 
indicated O 
that O 
Trp B-FORMULA 
40 O 
is O 
involved O 
in O 
recruiting O 
individual O 
substrate O 
chains O 
into O 
the O 
active O 
site O 
tunnel O 
to O 
initiate O 
processive O 
hydrolysis O 
. O 
This O 
idea O 
was O 
supported O 
by O 
molecular O 
dynamics O 
simulation O 
study O 
, O 
i.e O 
. O 
, O 
the O 
reducing O 
- O 
end O 
glucose B-TRIVIAL 
unit O 
was O 
effectively O 
loaded O 
into O 
the O 
active O 
site O 
of O 
WTcat O 
, O 
but O 
not O 
into O 
that O 
of O 
W40Acat O 
. O 
when O 
the O 
simulation O 
was O 
started O 
from O 
subsite O 
-7 O 
. O 
However O 
, O 
when O 
the O 
similar O 
simulations O 
were O 
carried O 
out O 
starting O 
from O 
subsite O 
-5 O 
, O 
both O 
enzymes O 
hold O 
the O 
substrate O 
in O 
50 O 
ns O 
, O 
indicating O 
that O 
the O 
major O 
difference O 
between O 
WTcat O 
and O 
W40Acat O 
is O 
the O 
length O 
of O 
free O 
chain O 
- O 
end O 
of O 
the O 
substrate O 
required O 
to O 
allow O 
initiation O 
of O 
processive O 
movements O 
; O 
this O 
also O 
reflects O 
the O 
difference O 
between O 
crystalline O 
and O 
amorphous O 
celluloses O 
. O 
The O 
CBD O 
is O 
important O 
for O 
enhancing O 
the O 
enzyme O 
population O 
on O 
crystalline O 
substrate O 
, O 
but O 
it O 
also O 
decreases O 
the O 
specific O 
activity O 
of O 
the O 
adsorbed O 
enzyme O 
, O 
possibly O 
by O 
attaching O 
the O 
enzyme O 
to O 
non-optimal O 
places O 
on O 
cellulose O 
surface O 
and O 
/ O 
or O 
hindering O 
processive O 
hydrolysis O 
. O 

Novel O 
Automethylation O 
Reaction O 
in O 
the O 
Aspergillus O 
nidulans O 
LaeA O 
Protein O 
Generates O 
S-Methylmethionine B-SYSTEMATIC 
. O 

filamentous O 
fungi O 
in O 
the O 
genus O 
Aspergillus O 
are O 
opportunistic O 
plant O 
and O 
animal O 
pathogens O 
that O 
can O 
adapt O 
to O 
their O 
environment O 
by O 
producing O 
various O 
secondary O 
metabolites O 
including O 
lovastatin B-TRIVIAL 
, O 
penicillin B-FAMILY 
, O 
and O 
aflatoxin B-FAMILY 
. O 
The O 
synthesis O 
of O 
these O 
small O 
molecules O 
is O 
dependent O 
on O 
gene O 
clusters O 
that O 
are O 
globally O 
regulated O 
by O 
the O 
LaeA O 
protein O 
. O 
Null O 
mutants O 
of O 
LaeA O 
in O 
all O 
pathogenic O 
fungi O 
examined O 
to O 
date O 
show O 
decreased O 
virulence O 
coupled O 
with O 
reduced O 
secondary O 
metabolism O 
. O 
Although O 
the O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
of O 
LaeA O 
contains O 
the O 
motifs O 
characteristic O 
of O 
seven-beta-strand O 
methyltransferases O 
, O 
a O 
methyl B-SYSTEMATIC 
-accepting O 
substrate O 
of O 
LaeA O 
has O 
not O 
been O 
identified O 
. O 
In O 
this O 
work O 
, O 
we O 
did O 
not O 
find O 
a O 
methyl B-SYSTEMATIC 
-accepting O 
substrate O 
in O 
A O 
. O 
nidulans O 
with O 
various O 
assays O 
including O 
in O 
vivo O 
S-adenosyl-[methyl-(3)H]methionine B-SYSTEMATIC 
labeling O 
, O 
targeted O 
in O 
vitro O 
methylation O 
experiments O 
using O 
putative O 
protein O 
substrates O 
, O 
or O 
in O 
vitro O 
methylation O 
assays O 
using O 
whole O 
cell O 
extracts O 
grown O 
under O 
different O 
conditions O 
. O 
However O 
, O 
in O 
each O 
experiment O 
LaeA O 
was O 
shown O 
to O 
self O 
- O 
methylate O 
. O 
Amino B-FAMILY 
acid I-FAMILY 
hydrolysis O 
of O 
radioactively O 
- O 
labeled O 
LaeA O 
followed O 
by O 
cation O 
exchange O 
and O 
reverse O 
phase O 
chromatography O 
identified O 
methionine B-TRIVIAL 
as O 
the O 
modified O 
residue O 
. O 
Point O 
mutations O 
show O 
that O 
the O 
major O 
site O 
of O 
modification O 
of O 
LaeA O 
is O 
on O 
methionine B-TRIVIAL 
-207 O 
. O 
However O 
, O 
in O 
vivo O 
complementation O 
showed O 
that O 
methionine B-TRIVIAL 
-207 O 
is O 
not O 
required O 
for O 
the O 
biological O 
function O 
of O 
LaeA O 
. O 
LaeA O 
is O 
the O 
first O 
protein O 
to O 
exhibit O 
automethylation O 
at O 
a O 
methionine B-TRIVIAL 
residue O 
. O 
These O 
findings O 
not O 
only O 
indicate O 
LaeA O 
may O 
perform O 
novel O 
chemistry O 
with O 
S-adenosylmethionine B-TRIVIAL 
, O 
but O 
also O 
provide O 
new O 
insights O 
into O 
the O 
physiological O 
function O 
of O 
LaeA O 
. O 

and O 
in O 
Vitro O 
Characterisation O 
of O 
Ifenprodil B-TRIVIAL 
-Based O 
Fluorescein B-TRIVIAL 
Conjugates O 
as O 
GluN1 O 
/ O 
GluN2B O 
N-Methyl-D-aspartate B-SYSTEMATIC 
Receptor O 
Antagonists O 
. O 

- O 
containing O 
NMDA B-ABBREVIATION 
receptors O 
are O 
involved O 
in O 
many O 
important O 
physiological O 
functions O 
and O 
play O 
a O 
pivotal O 
role O 
in O 
mediating O 
pain O 
as O 
well O 
as O 
in O 
several O 
neurodegenerative O 
disorders O 
. O 
We O 
aimed O 
to O 
develop O 
fluorescent O 
probes O 
to O 
target O 
the O 
GluN2B O 
subunit O 
selectively O 
in O 
order O 
to O 
allow O 
better O 
understanding O 
of O 
the O 
relationships O 
between O 
receptor O 
localisation O 
and O 
physiological O 
importance O 
. O 
Ifenprodil B-TRIVIAL 
, O 
known O 
as O 
the O 
GluNR2B O 
antagonist O 
of O 
reference O 
, O 
was O 
chosen O 
as O 
the O 
template O 
for O 
the O 
elaboration O 
of O 
probes O 
. O 
We O 
had O 
previously O 
reported O 
a O 
fluorescein B-TRIVIAL 
conjugate O 
that O 
was O 
shown O 
( O 
by O 
confocal O 
microscopy O 
imaging O 
of O 
DS-red O 
- O 
labelled O 
cortical O 
neurons O 
) O 
to O 
bind O 
specifically O 
to O 
GluN2B O 
. O 
To O 
elaborate O 
this O 
probe O 
, O 
we O 
explored O 
the O 
influence O 
of O 
both O 
the O 
nature O 
and O 
the O 
attachment O 
point O 
of O 
the O 
spacer O 
between O 
the O 
fluorophore O 
and O 
the O 
parent O 
compound O 
, O 
ifenprodil B-TRIVIAL 
. O 
We O 
performed O 
chemical O 
modifications O 
of O 
ifenprodil B-TRIVIAL 
at O 
the O 
benzylic B-TRIVIAL 
position O 
and O 
on O 
the O 
phenol B-SYSTEMATIC 
ring O 
by O 
introducing O 
secondary B-MULTIPLE 
amine I-MULTIPLE 
or I-MULTIPLE 
amide I-MULTIPLE 
functions O 
and O 
evaluated O 
alkyl O 
chains O 
from O 
two O 
to O 
20 O 
bonds O 
either O 
including O 
or O 
not O 
including O 
secondary B-FAMILY 
amide I-FAMILY 
functions O 
as O 
spacers O 
. O 
The O 
previously O 
developed O 
probe O 
was O 
found O 
to O 
display O 
the O 
greatest O 
activity O 
in O 
the O 
inhibition O 
of O 
NMDA B-ABBREVIATION 
-induced O 
Ca(2+) B-FORMULA 
influx O 
by O 
calcium B-SYSTEMATIC 
imaging O 
experiments O 
on O 
HEK293 O 
cells O 
transfected O 
with O 
the O 
cDNA O 
encoding O 
for O 
GluN1-1A O 
and O 
GluN2B O 
. O 
Further O 
investigations O 
revealed O 
that O 
this O 
probe O 
had O 
a O 
neuroprotective O 
effect O 
equivalent O 
to O 
that O 
of O 
ifenprodil B-TRIVIAL 
in O 
a O 
standard O 
test O 
for O 
neurotoxicity O 
. O 
Despite O 
effects O 
of O 
lesser O 
amplitude O 
with O 
these O 
probes O 
relative O 
to O 
ifenprodil B-TRIVIAL 
, O 
we O 
demonstrated O 
that O 
they O 
displaced O 
[ B-SYSTEMATIC 
( I-SYSTEMATIC 
3 I-SYSTEMATIC 
) I-SYSTEMATIC 
H]ifenprodil I-SYSTEMATIC 
in O 
mouse O 
brain O 
slices O 
in O 
a O 
similar O 
manner O 
. O 

efficient O 
FRET O 
leads O 
to O 
important O 
enhancements O 
for O 
homogeneous O 
immunoassays O 
. O 
By O 
using O 
the O 
novel O 
phosphorescent O 
dye O 
EuLH O 
and O 
BHQ-10 B-IDENTIFIER 
as O 
a O 
donor-acceptor O 
pair O 
, O 
the O 
FRET O 
efficiency O 
increases O 
to O 
> O 
99.5 O 
% O 
, O 
leading O 
to O 
significantly O 
improved O 
signal O 
- O 
to O 
- O 
background O 
ratio O 
, O 
precision O 
and O 
linear O 
range O 
. O 
The O 
phosphorescence O 
detection O 
enabled O 
full O 
compatibility O 
to O 
serum O 
samples O 
for O 
this O 
fast O 
- O 
responding O 
immunoassay O 
. O 

hückel O 
theory O 
for O 
carbon B-SYSTEMATIC 
nanotubes O 
: O 
band O 
structure O 
and O 
transport O 
properties O 
. O 

Hückel O 
theory O 
( O 
EHT O 
) O 
is O 
a O 
well O 
established O 
method O 
for O 
the O 
description O 
of O 
the O 
electronic O 
structure O 
of O 
molecules O 
and O 
solids O 
. O 
In O 
this O 
article O 
, O 
we O 
present O 
a O 
set O 
of O 
extended O 
Hückel O 
parameters O 
for O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
CNTs O 
) O 
, O 
obtained O 
by O 
fitting O 
the O 
ab O 
initio O 
band O 
structure O 
of O 
the O 
( O 
6,0 O 
) O 
CNT O 
. O 
The O 
new O 
parameters O 
are O 
highly O 
transferable O 
to O 
different O 
types O 
of O 
CNTs O 
. O 
To O 
demonstrate O 
the O 
versatility O 
of O 
the O 
approach O 
, O 
we O 
perform O 
self O 
- O 
consistent O 
EHT O 
- O 
based O 
electron O 
transport O 
calculations O 
for O 
finite O 
length O 
CNTs O 
with O 
metal O 
electrodes O 
. O 

and O 
biological O 
evaluation O 
of O 
tricyclic B-FAMILY 
guanidine I-FAMILY 
analogues O 
of O 
batzelladine B-TRIVIAL 
K I-TRIVIAL 
for O 
antimalarial O 
, O 
antileishmanial O 
, O 
antibacterial O 
, O 
antifungal O 
, O 
and O 
anti-HIV O 
activities O 
. O 

analogues O 
of O 
batzelladine B-TRIVIAL 
K I-TRIVIAL 
were O 
synthesized O 
and O 
evaluated O 
for O 
in O 
vitro O 
antimalarial O 
( O 
Plasmodium O 
falciparum O 
) O 
, O 
antileishmanial O 
( O 
Leishmania O 
donovani O 
) O 
, O 
antimicrobial O 
( O 
panel O 
of O 
bacteria O 
and O 
fungi O 
) O 
, O 
antiviral O 
( O 
HIV-1 O 
) O 
activities O 
. O 
Analogues O 
14h O 
and O 
20l O 
exhibited O 
potential O 
antimalarial O 
activity O 
against O 
chloroquine B-TRIVIAL 
-sensitive O 
D6 O 
strain O 
with O 
IC(50) O 
1.25 O 
and O 
0.88 O 
μM O 
and O 
chloroquine B-TRIVIAL 
-resistant O 
W2 O 
strain O 
with O 
IC(50) O 
1.64 O 
and O 
1.07 O 
μM O 
, O 
respectively O 
. O 
Analogues O 
12c O 
and O 
14c O 
having O 
nonyl B-SYSTEMATIC 
substitution O 
showed O 
the O 
most O 
potent O 
antileishmanial O 
activity O 
with O 
IC(50) O 
2.39 O 
and O 
2.78 O 
μM O 
and O 
IC(90) O 
11.27 O 
and O 
12.76 O 
μM O 
, O 
respectively O 
. O 
Three O 
analogues O 
12c O 
, O 
14c O 
, O 
and O 
14i O 
were O 
the O 
most O 
active O 
against O 
various O 
pathogenic O 
bacteria O 
and O 
fungi O 
with O 
IC(50) O 
< O 
3.02 O 
μM O 
and O 
MIC O 
/ O 
MBC O 
/ O 
MFC O 
< O 
6 O 
μM O 
. O 
Analogue O 
20l O 
having O 
pentyl B-SYSTEMATIC 
and O 
methyl B-SYSTEMATIC 
substituents O 
on O 
tricycle O 
showed O 
promising O 
activities O 
against O 
all O 
pathogens O 
. O 
However O 
, O 
none O 
was O 
found O 
active O 
against O 
HIV-1 O 
. O 
Our O 
study O 
demonstrated O 
that O 
the O 
tricyclic B-FAMILY 
guanidine I-FAMILY 
compounds O 
provide O 
new O 
structural O 
class O 
for O 
broad O 
spectrum O 
activity O 
. O 

Polystyrene B-SYSTEMATIC 
/ O 
Fe2O3 B-FORMULA 
Composite O 
Particles O 
and O 
Their O 
Magnetoresponsive O 
Characteristics O 
. O 

- O 
shell O 
- O 
structured O 
magnetic O 
polystyrene B-SYSTEMATIC 
( O 
PS O 
) O 
/ O 
inorganic O 
particles O 
were O 
fabricated O 
by O 
Pickering O 
emulsion O 
polymerization O 
using O 
nanosized O 
Fe2O3 B-FORMULA 
particles O 
as O 
a O 
solid O 
stabilizer O 
. O 
Scanning O 
electron O 
microscopy O 
and O 
transmission O 
electron O 
microscopy O 
confirmed O 
the O 
synthesized O 
PS/ O 
Fe2O3 B-FORMULA 
particles O 
to O 
be O 
comprised O 
of O 
a O 
PS O 
surface O 
coated O 
with O 
Fe2O3 B-FORMULA 
nanoparticles O 
. O 
The O 
chemical O 
structure O 
of O 
the O 
composite O 
nanospheres O 
was O 
characterized O 
by O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
and O 
X-ray O 
diffraction O 
. O 
The O 
thermal O 
properties O 
of O 
composite O 
nanospheres O 
and O 
corresponding O 
pure O 
polymer O 
were O 
examined O 
by O 
thermogravimetric O 
analysis O 
. O 
The O 
rheological O 
properties O 
of O 
the O 
core O 
- O 
shell O 
- O 
structured O 
magnetic O 
PS O 
/ O 
inorganic O 
particles O 
dispersed O 
in O 
silicone O 
oil O 
were O 
investigated O 
under O 
an O 
external O 
magnetic O 
field O 
strength O 
using O 
a O 
rotational O 
rheometer O 
. O 
The O 
particles O 
with O 
extremely O 
lower O 
density O 
than O 
common O 
magnetic O 
particles O 
exhibited O 
solid O 
- O 
like O 
magnetorheological O 
phase O 
characteristics O 
, O 
and O 
the O 
flow O 
curves O 
were O 
fitted O 
to O 
the O 
Cho-Choi-Jhon O 
model O 
of O 
the O 
rheological O 
equation O 
of O 
state O 
. O 

the O 
structure O 
and O 
organization O 
of O 
electrospun O 
fibers O 
is O 
desirable O 
for O 
fabricating O 
scaffolds O 
and O 
materials O 
with O 
defined O 
microstructures O 
. O 
However O 
, O 
the O 
effects O 
of O 
microtopography O 
on O 
the O 
deposition O 
and O 
, O 
in O 
turn O 
, O 
the O 
organization O 
of O 
the O 
electrospun O 
fibers O 
are O 
not O 
well O 
understood O 
. O 
In O 
this O 
study O 
, O 
conductive O 
polydimethylsiloxane B-SYSTEMATIC 
( O 
PDMS B-ABBREVIATION 
) O 
templates O 
with O 
different O 
micropatterns O 
were O 
fabricated O 
by O 
combining O 
photolithography O 
, O 
silicon B-SYSTEMATIC 
wet O 
etching O 
, O 
and O 
PDMS B-ABBREVIATION 
molding O 
techniques O 
. O 
The O 
fiber O 
organization O 
was O 
varied O 
by O 
fine O 
- O 
tuning O 
the O 
microtopography O 
of O 
the O 
electrospinning O 
collector O 
. O 
Fiber O 
conformity O 
and O 
alignment O 
were O 
influenced O 
by O 
the O 
depth O 
and O 
the O 
slope O 
of O 
microtopography O 
features O 
, O 
resulting O 
in O 
scaffolds O 
comprising O 
either O 
an O 
array O 
of O 
microdomains O 
with O 
different O 
porosity O 
and O 
fiber O 
alignment O 
or O 
an O 
array O 
of O 
microwells O 
. O 
Microtopography O 
affected O 
the O 
fiber O 
organization O 
for O 
hundreds O 
of O 
micrometers O 
below O 
the O 
scaffold O 
surface O 
, O 
resulting O 
in O 
scaffolds O 
with O 
distinct O 
surface O 
properties O 
on O 
each O 
side O 
. O 
In O 
addition O 
, O 
the O 
fiber O 
diameter O 
was O 
also O 
affected O 
by O 
the O 
fiber O 
conformity O 
. O 
The O 
effects O 
of O 
the O 
fiber O 
arrangement O 
in O 
the O 
scaffolds O 
on O 
the O 
morphology O 
, O 
migration O 
, O 
and O 
infiltration O 
of O 
cells O 
were O 
examined O 
by O 
in O 
vitro O 
and O 
in O 
vivo O 
experiments O 
. O 
Cell O 
morphology O 
and O 
organization O 
were O 
guided O 
by O 
the O 
fibers O 
in O 
the O 
microdomains O 
, O 
and O 
cell O 
migration O 
was O 
enhanced O 
by O 
the O 
aligned O 
fibers O 
and O 
the O 
three O 
- O 
dimensional O 
scaffold O 
structure O 
. O 
Cell O 
infiltration O 
was O 
correlated O 
with O 
the O 
microdomain O 
porosity O 
. O 
Microscale O 
control O 
of O 
the O 
fiber O 
organization O 
and O 
the O 
porosity O 
at O 
the O 
surface O 
and O 
through O 
the O 
thickness O 
of O 
the O 
fibrous O 
scaffolds O 
, O 
as O 
demonstrated O 
by O 
the O 
results O 
of O 
this O 
study O 
, O 
provides O 
a O 
powerful O 
means O 
of O 
engineering O 
the O 
three O 
- O 
dimensional O 
structure O 
of O 
electrospun O 
fibrous O 
scaffolds O 
for O 
cell O 
and O 
tissue O 
engineering O 
. O 

and O 
structure O 
- O 
activity O 
relationship O 
of O 
pyripyropene B-TRIVIAL 
A I-TRIVIAL 
derivatives O 
as O 
potent O 
and O 
selective O 
acyl-CoA B-ABBREVIATION 
: O 
cholesterol B-TRIVIAL 
acyltransferase O 
2 O 
( O 
ACAT2 O 
) O 
inhibitors O 
: O 
Part O 
2 O 
. O 

and O 
structure O 
- O 
activity O 
relationships O 
of O 
7-O-p-cyanobenzoyl B-SYSTEMATIC 
pyripyropene I-SYSTEMATIC 
A I-SYSTEMATIC 
derivatives O 
with O 
modification O 
at O 
C1 O 
and O 
11 O 
are O 
described O 
. O 
Regioselective O 
mono-deprotection O 
of O 
di-tert-butylsilylene B-SYSTEMATIC 
acetal I-SYSTEMATIC 
was O 
critical O 
in O 
their O 
synthesis O 
. O 

of O 
AtWNK8 O 
Enhances O 
Tolerance O 
of O 
Arabidopsis O 
to O 
Salt O 
and O 
Osmotic O 
Stresses O 
via O 
Modulating O 
Proline B-TRIVIAL 
Content O 
and O 
Activities O 
of O 
Catalase O 
and O 
Peroxidase O 
. O 

no O 
lysine B-TRIVIAL 
kinases O 
( O 
WNKs O 
) O 
play O 
important O 
roles O 
in O 
plant O 
growth O 
and O 
development O 
. O 
However O 
, O 
its O 
role O 
in O 
salt O 
and O 
osmotic O 
stress O 
tolerance O 
is O 
unclear O 
. O 
Here O 
, O 
we O 
report O 
that O 
AtWNK8 O 
is O 
mainly O 
expressed O 
in O 
primary O 
root O 
, O 
hypocotyl O 
, O 
stamen O 
and O 
pistil O 
and O 
is O 
induced O 
by O 
NaCl B-FORMULA 
and O 
sorbitol B-TRIVIAL 
treatment O 
. O 
Compared O 
to O 
the O 
wild O 
- O 
type O 
, O 
the O 
T-DNA O 
knock O 
- O 
out O 
wnk8 O 
mutant O 
was O 
more O 
tolerant O 
to O 
severe O 
salinity O 
and O 
osmotic O 
stresses O 
, O 
as O 
indicated O 
by O 
27% O 
and O 
198% O 
more O 
fresh O 
weight O 
in O 
the O 
NaCl B-FORMULA 
and O 
sorbitol B-TRIVIAL 
treatment O 
, O 
respectively O 
. O 
The O 
wnk8 O 
mutant O 
also O 
accumulated O 
1.43-fold O 
more O 
proline B-TRIVIAL 
than O 
the O 
wild O 
- O 
type O 
in O 
the O 
sorbitol B-TRIVIAL 
treatment O 
. O 
Under O 
NaCl B-FORMULA 
and O 
sorbitol B-TRIVIAL 
stresses O 
, O 
catalase O 
( O 
CAT O 
) O 
activity O 
in O 
wnk8 O 
mutant O 
was O 
1.92- O 
and O 
3.7-times O 
of O 
that O 
in O 
Col-0 O 
, O 
respectively O 
. O 
Similarly O 
, O 
under O 
salt O 
and O 
osmotic O 
stress O 
conditions O 
, O 
peroxidase O 
( O 
POD O 
) O 
activities O 
in O 
wnk8 O 
mutant O 
were O 
1.81- O 
and O 
1.58-times O 
of O 
that O 
in O 
Col-0 O 
, O 
respectively O 
. O 
Taken O 
together O 
, O 
we O 
revealed O 
that O 
maintaining O 
higher O 
CAT O 
and O 
POD O 
activities O 
might O 
be O 
one O 
of O 
the O 
reasons O 
that O 
the O 
disruption O 
of O 
AtWNK8 O 
enhances O 
the O 
tolerance O 
to O 
salt O 
stress O 
, O 
and O 
accumulating O 
more O 
proline B-TRIVIAL 
and O 
higher O 
activities O 
of O 
CAT O 
and O 
POD O 
might O 
result O 
in O 
the O 
higher O 
tolerance O 
of O 
WNK8 O 
to O 
osmotic O 
stress O 
. O 

comparative O 
study O 
of O 
the O 
lipid O 
status O 
( O 
i.e O 
. O 
, O 
the O 
total O 
lipid O 
and O 
phospholipid O 
concentrations O 
and O 
the O 
percentage O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
of O 
the O 
total O 
lipids O 
) O 
of O 
adult O 
specimens O 
of O 
daubed O 
shanny O 
( O 
Leptoclinus O 
maculatus O 
) O 
from O 
Svalbard O 
waters O 
( O 
Isfjord O 
) O 
and O 
slender O 
eel O 
blenny O 
( O 
Lumpenus O 
fabricii O 
) O 
from O 
the O 
White O 
Sea O 
( O 
Onega O 
Bay O 
and O 
Tersky O 
shore O 
) O 
was O 
performed O 
to O 
study O 
the O 
metabolism O 
and O 
functions O 
of O 
lipids O 
of O 
these O 
fishes O 
in O 
ontogeny O 
and O 
under O 
various O 
ecological O 
conditions O 
. O 
Slender O 
eel O 
blenny O 
from O 
both O 
areas O 
of O 
the O 
White O 
Sea O 
were O 
distinguished O 
by O 
a O 
high O 
level O 
of O 
sphingomyelin B-FAMILY 
compared O 
with O 
the O 
daubed O 
shanny O 
from O 
Svalbard O 
, O 
and O 
the O 
amount O 
of O 
total O 
phospholipids O 
was O 
higher O 
in O 
slender O 
eel O 
blenny O 
from O 
Onega O 
Bay O 
than O 
in O 
slender O 
eel O 
blenny O 
from O 
the O 
Tersky O 
shore O 
. O 
The O 
extent O 
of O 
saturation O 
and O 
the O 
signature O 
of O 
polyenic B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
varied O 
according O 
to O 
the O 
specific O 
species O 
of O 
the O 
Stichaeidae O 
family O 
under O 
study O 
. O 
These O 
results O 
demonstrate O 
the O 
differences O 
in O 
the O 
trophoecological O 
and O 
hydrobiological O 
conditions O 
of O 
habitations O 
of O 
these O 
species O 
and O 
highlighted O 
the O 
importance O 
of O 
considering O 
certain O 
trends O 
in O 
the O 
lipid O 
profiles O 
of O 
these O 
fishes O 
as O 
specific O 
features O 
of O 
the O 
organization O 
of O 
the O 
ecological O 
and O 
biochemical O 
mechanisms O 
of O 
adaptation O 
. O 

evidence O 
for O 
involvement O 
of O 
the O 
dorsal O 
hippocampus O 
serotonergic O 
and O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
)ergic O 
pathways O 
in O 
the O 
expression O 
of O 
contextual O 
fear O 
conditioning O 
in O 
rats O 
. O 

- O 
dorsal O 
hippocampus O 
( O 
DH O 
) O 
injections O 
of O 
8-hydroxy-2-(di-n-propylamino) B-SYSTEMATIC 
tetralin I-SYSTEMATIC 
( O 
8-OH-DPAT B-SYSTEMATIC 
) O 
, O 
a O 
serotonin B-TRIVIAL 
-1A O 
( O 
5-hydroxytryptamine B-SYSTEMATIC 
( O 
5-HT B-SYSTEMATIC 
)-1A O 
) O 
receptor O 
agonist O 
, O 
were O 
previously O 
shown O 
to O 
inhibit O 
the O 
expression O 
of O 
contextual O 
fear O 
when O 
administered O 
six O 
hours O 
after O 
conditioning O 
. O 
However O 
, O 
further O 
understanding O 
of O 
the O 
consolidation O 
and O 
expression O 
of O 
aversive O 
memories O 
requires O 
investigations O 
of O 
these O 
and O 
other O 
mechanisms O 
at O 
distinct O 
time O 
points O 
and O 
the O 
regions O 
of O 
the O 
brain O 
to O 
which O 
they O 
are O 
transferred O 
. O 
Thus O 
, O 
the O 
purpose O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
the O 
role O 
of O 
DH O 
serotonergic O 
and O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
)ergic O 
mechanisms O 
in O 
the O 
expression O 
of O 
contextual O 
fear O 
24 O 
h O 
after O 
conditioning O 
, O 
reflected O 
by O 
fear O 
- O 
potentiated O 
startle O 
( O 
FPS O 
) O 
and O 
freezing O 
behavior O 
. O 
The O 
recruitment O 
of O 
the O 
amygdala O 
and O 
medial O 
prefrontal O 
cortex O 
( O 
mPFC O 
) O 
in O 
these O 
processes O 
was O 
also O 
evaluated O 
by O 
measuring O 
Fos O 
protein O 
immunoreactivity O 
. O 
Although O 
intra-DH O 
injections O 
of O 
8-OH-DPAT B-SYSTEMATIC 
did O 
not O 
produce O 
behavioral O 
changes O 
, O 
muscimol O 
reduced O 
both O 
FPS O 
and O 
the O 
freezing O 
response O 
. O 
Fos O 
protein O 
immunoreactivity O 
revealed O 
that O 
contextual O 
fear O 
promoted O 
wide O 
activation O 
of O 
the O 
mPFC O 
, O 
which O 
was O 
significantly O 
reduced O 
after O 
intra-DH O 
infusions O 
of O 
muscimol B-TRIVIAL 
. O 
The O 
present O 
findings O 
, O 
together O 
with O 
previous O 
data O 
, O 
indicate O 
that O 
in O 
contrast O 
to O 
5-HT B-SYSTEMATIC 
, O 
which O 
appears O 
to O 
play O 
a O 
role O 
during O 
the O 
early O 
phases O 
of O 
contextual O 
aversive O 
memory O 
consolidation O 
, O 
longer O 
- O 
lasting O 
GABA B-ABBREVIATION 
-mediated O 
mechanisms O 
are O 
recruited O 
during O 
the O 
expression O 
of O 
contextual O 
fear O 
memories O 
. O 

of O 
ischemic O 
stroke O 
with O 
the O 
use O 
of O 
risperidone B-TRIVIAL 
, O 
quetiapine B-TRIVIAL 
and O 
olanzapine B-TRIVIAL 
in O 
elderly O 
patients O 
: O 
a O 
population O 
- O 
based O 
, O 
case O 
- O 
crossover O 
study O 
. O 

conducted O 
a O 
case O 
- O 
crossover O 
study O 
to O 
evaluate O 
the O 
comparative O 
risk O 
of O 
ischemic O 
stroke O 
associated O 
with O 
the O 
use O 
of O 
risperidone B-TRIVIAL 
, O 
quetiapine B-TRIVIAL 
and O 
olanzapine B-TRIVIAL 
in O 
geriatric O 
patients O 
using O 
the O 
Korean O 
Health O 
Insurance O 
Review O 
and O 
Assessment O 
Service O 
database O 
. O 
Cases O 
included O 
elderly O 
patients O 
> O 
64 O 
years O 
old O 
who O 
had O 
experienced O 
their O 
first O 
ischemic O 
stroke O 
( O 
International O 
Classification O 
of O 
Disease O 
, O 
Tenth O 
Revision O 
( O 
ICD-10 O 
) O 
, O 
I63 O 
) O 
hospitalization O 
from O 
July O 
2005 O 
to O 
June O 
2006 O 
and O 
who O 
had O 
been O 
without O 
prior O 
cerebrovascular O 
diseases O 
( O 
ICD-10 O 
, O 
I60-I69 O 
) O 
, O 
or O 
transient O 
ischemic O 
attack O 
( O 
ICD-10 O 
, O 
G45 O 
) O 
. O 
Exposures O 
to O 
risperidone B-TRIVIAL 
, O 
quetiapine B-TRIVIAL 
and O 
olanzapine B-TRIVIAL 
were O 
assessed O 
during O 
the O 
30 O 
days O 
prior O 
to O 
the O 
stroke O 
episode O 
. O 
We O 
set O 
two O 
control O 
periods O 
with O 
lengths O 
which O 
were O 
the O 
same O 
as O 
the O 
hazard O 
periods O 
. O 
Adjusted O 
odds O 
ratios O 
( O 
aORs O 
) O 
with O 
95% O 
confidence O 
intervals O 
( O 
CIs O 
) O 
were O 
estimated O 
by O 
conditional O 
logistic O 
regression O 
. O 
A O 
total O 
of O 
1601 O 
cases O 
of O 
ischemic O 
stroke O 
with O 
a O 
mean O 
age O 
of O 
75.6 O 
( O 
±6.7 O 
) O 
years O 
were O 
identified O 
, O 
among O 
which O 
933 O 
( O 
58.3% O 
) O 
were O 
female O 
. O 
An O 
increased O 
risk O 
of O 
ischemic O 
stroke O 
was O 
associated O 
with O 
the O 
use O 
of O 
risperidone B-TRIVIAL 
( O 
aOR=3.5 O 
, O 
95% O 
CI O 
3.3-4.6 O 
) O 
and O 
quetiapine B-TRIVIAL 
( O 
aOR=2.7 O 
, O 
95% O 
CI O 
2.0-3.6 O 
) O 
during O 
the O 
30 O 
days O 
prior O 
to O 
stroke O 
: O 
however O 
, O 
no O 
significant O 
risk O 
was O 
observed O 
with O 
olanzapine B-TRIVIAL 
( O 
aOR=1.2 O 
, O 
95% O 
CI O 
0.7-2.0 O 
) O 
. O 
The O 
increased O 
stroke O 
risk O 
in O 
demented O 
patients O 
, O 
assessed O 
within O 
30 O 
days O 
after O 
exposure O 
, O 
was O 
also O 
observed O 
with O 
olanzapine B-TRIVIAL 
. O 
However O 
, O 
the O 
sample O 
of O 
olanzapine B-TRIVIAL 
users O 
was O 
small O 
and O 
underpowered O 
. O 

of O 
Perturbations O 
in O 
Serum O 
Thyroid O 
Hormones O 
During O 
Human O 
Pregnancy O 
Due O 
to O 
Dietary O 
Iodide B-SYSTEMATIC 
and O 
Perchlorate B-SYSTEMATIC 
Exposure O 
Using O 
a O 
Biologically O 
Based O 
Dose-Response O 
Model O 
. O 

biologically O 
based O 
dose O 
- O 
response O 
model O 
( O 
BBDR O 
) O 
for O 
the O 
hypothalamic O 
pituitary O 
thyroid O 
( O 
HPT O 
) O 
axis O 
was O 
developed O 
in O 
the O 
near O 
- O 
term O 
pregnant O 
mother O 
and O 
fetus O 
. O 
This O 
model O 
was O 
calibrated O 
to O 
predict O 
serum O 
levels O 
of O 
iodide B-SYSTEMATIC 
, O 
total O 
thyroxine B-TRIVIAL 
( O 
T4 O 
) O 
, O 
free O 
thyroxine B-TRIVIAL 
( O 
fT4 O 
) O 
, O 
and O 
total O 
triiodothyronine B-TRIVIAL 
( O 
T3 O 
) O 
in O 
the O 
mother O 
and O 
fetus O 
for O 
a O 
range O 
of O 
dietary O 
iodide B-SYSTEMATIC 
intake O 
. O 
The O 
model O 
was O 
extended O 
to O 
describe O 
perchlorate B-SYSTEMATIC 
, O 
an O 
environmental O 
and O 
food O 
contaminant O 
, O 
that O 
competes O 
with O 
the O 
sodium B-SYSTEMATIC 
iodide I-SYSTEMATIC 
symporter O 
protein O 
for O 
thyroidal O 
uptake O 
of O 
iodide B-SYSTEMATIC 
. O 
Using O 
this O 
mode-of O 
- O 
action O 
framework O 
, O 
simulations O 
were O 
performed O 
to O 
determine O 
the O 
daily O 
ingestion O 
rates O 
of O 
perchlorate B-SYSTEMATIC 
that O 
would O 
be O 
associated O 
with O 
hypothyroxinemia O 
or O 
onset O 
of O 
hypothyroidism O 
for O 
varying O 
iodide B-SYSTEMATIC 
intake O 
. O 
Model O 
simulations O 
suggested O 
that O 
a O 
maternal O 
iodide B-SYSTEMATIC 
intake O 
of O 
75 O 
to O 
250 O 
µg O 
/ O 
day O 
and O 
an O 
environmentally O 
relevant O 
exposure O 
of O 
perchlorate B-SYSTEMATIC 
( O 
~0.1 O 
µg O 
/ O 
kg O 
/ O 
day O 
) O 
did O 
not O 
result O 
in O 
hypothyroxinemia O 
or O 
hypothyroidism O 
. O 
For O 
a O 
daily O 
iodide B-SYSTEMATIC 
-sufficient O 
intake O 
of O 
200 O 
µg O 
/ O 
day O 
, O 
the O 
dose O 
of O 
perchlorate B-SYSTEMATIC 
required O 
to O 
reduce O 
maternal O 
fT4 O 
levels O 
to O 
a O 
hypothyroxinemic O 
state O 
was O 
estimated O 
at O 
32.2 O 
µg O 
/ O 
kg O 
/ O 
day O 
. O 
As O 
iodide B-SYSTEMATIC 
intake O 
was O 
lowered O 
to O 
75 O 
µg O 
/ O 
day O 
, O 
the O 
model O 
simulated O 
daily O 
perchlorate B-SYSTEMATIC 
dose O 
required O 
to O 
cause O 
hypothyroxinemia O 
was O 
reduced O 
by O 
eightfold O 
. O 
Similarly O 
, O 
the O 
perchlorate B-SYSTEMATIC 
intake O 
rates O 
associated O 
with O 
the O 
onset O 
of O 
subclinical O 
hypothyroidism O 
ranged O 
from O 
54.8 O 
to O 
21.5 O 
µg O 
/ O 
kg O 
/ O 
day O 
for O 
daily O 
iodide B-SYSTEMATIC 
intake O 
of O 
250-75 O 
µg O 
/ O 
day O 
. O 
This O 
BBDR-HPT O 
axis O 
model O 
for O 
pregnancy O 
provides O 
an O 
example O 
of O 
a O 
novel O 
public O 
health O 
assessment O 
tool O 
that O 
may O 
be O 
expanded O 
to O 
address O 
other O 
endocrine O 
- O 
active O 
chemicals O 
found O 
in O 
food O 
and O 
the O 
environment O 
. O 

Promoter O 
Is O 
Hypermethylated O 
in O 
Blood O 
DNA O 
from O 
Workers O 
with O 
Confirmed O 
Diisocyanate B-SYSTEMATIC 
Asthma O 
. O 

factors O 
have O 
not O 
been O 
identified O 
that O 
determine O 
susceptibility O 
for O 
development O 
of O 
diisocyanate B-SYSTEMATIC 
-induced O 
occupational O 
asthma O 
( O 
DA O 
) O 
. O 
We O 
hypothesized O 
that O 
diisocyanate B-SYSTEMATIC 
( O 
DI O 
) O 
exposure O 
could O 
modify O 
gene O 
promoter O 
regions O 
regulating O 
transcription O 
of O 
cytokine O 
mediators O 
and O 
thereby O 
influence O 
expression O 
of O 
DA O 
. O 
A O 
cross O 
- O 
sectional O 
study O 
was O 
designed O 
to O 
investigate O 
the O 
promoter O 
methylation O 
status O 
of O 
candidate O 
genes O 
in O 
DI-exposed O 
workers O 
. O 
Subjects O 
consisted O 
of O 
131 O 
workers O 
in O 
three O 
groups O 
: O 
40 O 
cases O 
with O 
DA O 
confirmed O 
by O 
a O 
positive O 
specific O 
inhalation O 
challenge O 
( O 
SIC O 
) O 
( O 
DA+ O 
) O 
, O 
41 O 
exposed O 
workers O 
with O 
lower O 
respiratory O 
symptoms O 
and O 
negative O 
SIC O 
( O 
DA- O 
) O 
, O 
and O 
50 O 
asymptomatic O 
exposed O 
workers O 
( O 
AWs O 
) O 
. O 
We O 
studied O 
four O 
candidate O 
genes O 
( O 
GSTM1 O 
, O 
DUSP22 O 
, O 
IFN-γ O 
, O 
and O 
IL-4 O 
) O 
for O 
which O 
altered O 
promoter O 
methylation O 
has O 
been O 
previously O 
investigated O 
for O 
relationships O 
with O 
a O 
variety O 
of O 
other O 
environmental O 
exposures O 
. O 
Methylation O 
status O 
was O 
determined O 
using O 
methylation O 
- O 
specific O 
quantitative O 
PCR O 
performed O 
on O 
genomic O 
DNA O 
extracted O 
from O 
whole O 
blood O 
. O 
Results O 
showed O 
that O 
relative O 
methylation O 
of O 
IFN-γ O 
promoter O 
was O 
significantly O 
increased O 
in O 
DA+ O 
in O 
comparison O 
with O 
both O 
comparator O 
groups O 
( O 
DA- O 
and O 
AW O 
) O 
, O 
and O 
it O 
exhibited O 
good O 
sensitivity O 
( O 
77.5% O 
) O 
and O 
specificity O 
( O 
80% O 
) O 
for O 
identifying O 
DA O 
workers O 
in O 
a O 
multivariate O 
predictive O 
model O 
after O 
adjusting O 
for O 
type O 
of O 
DI O 
exposure O 
, O 
smoking O 
status O 
, O 
methacholine B-TRIVIAL 
PC20 O 
, O 
and O 
gender O 
. O 
IL-4 O 
promoter O 
was O 
slightly O 
less O 
methylated O 
only O 
in O 
DA+ O 
compared O 
with O 
AW O 
among O 
nonsmoking O 
workers O 
. O 
Both O 
GSTM1 O 
and O 
DUSP22 O 
promoter O 
methylations O 
were O 
found O 
not O 
associated O 
with O 
DA O 
. O 
Our O 
finding O 
suggests O 
that O 
exposure O 
to O 
occupational O 
chemicals O 
could O 
play O 
a O 
heretofore O 
undefined O 
mechanistic O 
role O 
via O 
epigenetic O 
modification O 
of O 
specific O 
genes O 
in O 
the O 
promoter O 
region O 
. O 

Adduct O 
Formation O 
of O 
2-Amino-9H-pyrido[2,3-b]indole B-SYSTEMATIC 
and O 
2-Amino-3,4-dimethylimidazo[4,5-f]quinoline B-SYSTEMATIC 
in O 
Mouse O 
Liver O 
and O 
Extrahepatic O 
Tissues O 
During O 
a O 
Subchronic O 
Feeding O 
Study O 
. O 

smoking O 
is O 
a O 
risk O 
factor O 
for O 
cancers O 
of O 
the O 
liver O 
and O 
gastrointestinal O 
( O 
GI O 
) O 
tract O 
, O 
but O 
the O 
causal O 
agents O 
responsible O 
for O 
these O 
cancers O 
are O 
uncertain O 
. O 
2-Amino-9H-pyrido[2,3-b]indole B-SYSTEMATIC 
( O 
AαC O 
) O 
is O 
an O 
abundant O 
heterocyclic B-FAMILY 
aromatic I-FAMILY 
amine I-FAMILY 
present O 
in O 
tobacco O 
smoke O 
. O 
AαC O 
is O 
a O 
liver O 
carcinogen O 
and O 
both O 
a O 
transgene O 
mutagen O 
and O 
inducer O 
of O 
aberrant O 
crypt O 
foci O 
in O 
the O 
colon O 
of O 
mice O 
. O 
We O 
hypothesize O 
that O 
AαC O 
may O 
contribute O 
to O 
DNA O 
damage O 
and O 
tumorigenesis O 
in O 
these O 
organs O 
of O 
smokers O 
. O 
The O 
potential O 
of O 
AαC O 
to O 
induce O 
DNA O 
adduct O 
formation O 
in O 
liver O 
, O 
organs O 
of O 
the O 
GI O 
tract O 
, O 
lung O 
, O 
and O 
urinary O 
bladder O 
, O 
which O 
are O 
target O 
organs O 
of O 
cancer O 
in O 
smokers O 
, O 
was O 
examined O 
using O 
the O 
C57BL O 
/ O 
6 O 
mouse O 
as O 
an O 
animal O 
model O 
. O 
AαC O 
( O 
400 O 
or O 
800 O 
ppm O 
) O 
and O 
2-amino-3,4-dimethylimidazo[4,5-f]quinoline B-SYSTEMATIC 
( O 
MeIQ B-ABBREVIATION 
) O 
( O 
300 O 
ppm O 
) O 
, O 
a O 
liver O 
and O 
colon O 
carcinogen O 
in O 
C57BL O 
/ O 
6 O 
mice O 
, O 
were O 
given O 
in O 
the O 
diet O 
for O 
up O 
to O 
12 O 
weeks O 
. O 
Liquid O 
chromatography O 
/ O 
mass O 
spectrometry O 
was O 
employed O 
to O 
measure O 
DNA O 
adducts O 
. O 
The O 
major O 
DNA O 
adducts O 
of O 
both O 
carcinogens O 
were O 
identified O 
as O 
deoxyguanosine B-SYSTEMATIC 
-C8 O 
adducts O 
. O 
The O 
levels O 
of O 
formation O 
of O 
AαC- O 
and O 
MeIQ B-ABBREVIATION 
-DNA O 
adducts O 
were O 
similar O 
in O 
liver O 
and O 
extrahepatic O 
tissues O 
when O 
adjusted O 
for O 
dose O 
. O 
The O 
highest O 
levels O 
of O 
adducts O 
occurred O 
in O 
liver O 
, O 
followed O 
by O 
urinary O 
bladder O 
, O 
and O 
then O 
in O 
cecum O 
and O 
colon O 
; O 
lower O 
DNA O 
adduct O 
levels O 
were O 
formed O 
in O 
the O 
lung O 
and O 
pancreas O 
following O 
12 O 
weeks O 
of O 
feeding O 
. O 
The O 
high O 
levels O 
of O 
AαC O 
adduct O 
formed O 
in O 
liver O 
, O 
GI O 
tract O 
, O 
and O 
bladder O 
of O 
C57BL O 
/ O 
6 O 
mice O 
reinforce O 
the O 
notion O 
that O 
AαC O 
may O 
contribute O 
to O 
DNA O 
damage O 
and O 
cancer O 
of O 
these O 
organs O 
in O 
smokers O 
. O 

waste O 
components O 
contain O 
significant O 
levels O 
of O 
high O 
quality O 
protein O 
and O 
are O 
therefore O 
a O 
potential O 
source O 
for O 
biofunctional O 
high O 
- O 
value O 
peptides O 
. O 
The O 
feasibility O 
of O 
applying O 
a O 
pilot O 
scale O 
enzymatic O 
hydrolysis O 
process O 
to O 
whole O 
Mytilus O 
edulis O 
and O 
, O 
by O 
fractionation O 
, O 
recover O 
hydrolysates O 
presenting O 
a O 
biological O 
activity O 
of O 
interest O 
, O 
was O 
evaluated O 
. O 
Fractions O 
were O 
tested O 
on O 
four O 
immortalized O 
cancerous O 
cell O 
lines O 
: O 
A549 O 
, O 
BT549 O 
, O 
HCT15 O 
and O 
PC3 O 
. O 
The O 
50 O 
kDa O 
fraction O 
, O 
enriched O 
in O 
peptides O 
, O 
presented O 
anti-proliferative O 
activity O 
with O 
all O 
cell O 
lines O 
and O 
results O 
suggest O 
a O 
bioactive O 
molecule O 
synergy O 
within O 
the O 
fraction O 
. O 
At O 
a O 
protein O 
concentration O 
of O 
44 O 
µg O 
/ O 
mL O 
, O 
the O 
50 O 
kDa O 
fraction O 
induced O 
a O 
mortality O 
of O 
90% O 
for O 
PC3 O 
, O 
89% O 
for O 
A549 O 
, O 
85% O 
for O 
HCT15 O 
and O 
of O 
81% O 
for O 
BT549 O 
cell O 
lines O 
. O 
At O 
the O 
low O 
protein O 
concentration O 
of O 
only O 
11 O 
µg O 
/ O 
mL O 
the O 
50 O 
kDa O 
fraction O 
still O 
entails O 
a O 
cell O 
mortality O 
of O 
76% O 
for O 
A549 O 
and O 
87% O 
for O 
PC3 O 
cell O 
lines O 
. O 
The O 
50 O 
kDa O 
fraction O 
contains O 
56% O 
of O 
proteins O 
, O 
3% O 
of O 
lipids O 
and O 
6% O 
of O 
minerals O 
on O 
a O 
dry O 
weight O 
basis O 
and O 
the O 
lowest O 
levels O 
detected O 
of O 
taurine B-TRIVIAL 
and O 
methionine B-TRIVIAL 
and O 
highest O 
levels O 
of O 
threonine B-TRIVIAL 
, O 
proline B-TRIVIAL 
and O 
glycine B-TRIVIAL 
amino B-FAMILY 
acids I-FAMILY 
. O 
The O 
enzymatic O 
hydrolysis O 
process O 
suggests O 
that O 
Mytilus O 
edulis O 
by O 
- O 
products O 
should O 
be O 
viewed O 
as O 
high O 
- O 
valued O 
products O 
with O 
strong O 
potential O 
as O 
anti-proliferative O 
agent O 
and O 
promising O 
active O 
ingredients O 
in O 
functional O 
foods O 
. O 

developments O 
in O 
design O 
and O 
synthesis O 
of O 
bicyclic B-FAMILY 
azasugars I-FAMILY 
, O 
carbasugars B-FAMILY 
and O 
related O 
molecules O 
as O 
glycosidase O 
inhibitors O 
. O 

study O 
aimed O 
to O 
evaluate O 
the O 
relationship O 
between O 
blood O 
lead O 
and O 
serum O 
creatinine B-TRIVIAL 
and O 
blood O 
lead O 
and O 
serum O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
levels O 
as O 
biomarkers O 
of O 
lead O 
exposure O 
from O 
subjects O 
living O 
in O 
a O 
historic O 
polymetallic O 
mining O 
area O 
in O 
China O 
. O 
Elevated O 
levels O 
were O 
found O 
for O 
blood O 
lead O 
, O 
serum O 
creatinine B-TRIVIAL 
, O 
and O 
serum O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
in O 
the O 
mining O 
area O 
with O 
mean O 
values O 
at O 
245.65 O 
μg O 
/ O 
l O 
, O 
74.16 O 
μmol O 
/ O 
l O 
, O 
and O 
12.79 O 
mmol O 
/ O 
l O 
, O 
which O 
were O 
significantly O 
higher O 
than O 
those O 
in O 
the O 
control O 
area O 
, O 
respectively O 
. O 
Moreover O 
, O 
the O 
coefficients O 
between O 
paired O 
results O 
for O 
blood O 
lead O 
and O 
serum O 
creatinine B-TRIVIAL 
and O 
blood O 
lead O 
and O 
serum O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
were O 
positively O 
statistically O 
significant O 
( O 
serum O 
creatinine B-TRIVIAL 
vs O 
. O 
blood O 
lead O 
, O 
r O 
= O 
0.35 O 
, O 
p O 
< O 
0.05 O 
; O 
serum O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
vs O 
. O 
blood O 
lead O 
, O 
r O 
= O 
0.48 O 
, O 
p O 
< O 
0.05 O 
) O 
. O 
With O 
respect O 
to O 
the O 
effects O 
of O 
sex O 
and O 
age O 
on O 
the O 
blood O 
lead O 
, O 
serum O 
creatinine B-TRIVIAL 
, O 
and O 
serum O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
levels O 
, O 
data O 
analysis O 
revealed O 
there O 
was O 
a O 
tendency O 
for O 
higher O 
blood O 
lead O 
, O 
serum O 
creatinine B-TRIVIAL 
, O 
and O 
serum O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
levels O 
in O 
females O 
than O 
in O 
males O 
, O 
and O 
the O 
levels O 
of O 
blood O 
lead O 
, O 
serum O 
creatinine B-TRIVIAL 
, O 
and O 
serum O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
increased O 
among O 
older O 
residents O 
. O 
We O 
conclude O 
that O 
females O 
and O 
the O 
older O 
population O 
in O 
the O 
mining O 
area O 
are O 
more O 
susceptible O 
to O 
lead O 
exposure O 
. O 
Blood O 
lead O 
, O 
serum O 
creatinine B-TRIVIAL 
, O 
and O 
serum O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
can O 
be O 
useful O 
biomarkers O 
of O 
lead O 
exposure O 
among O 
populations O 
under O 
environmental O 
stress O 
. O 

Effects O 
of O 
Cilostazol B-TRIVIAL 
on O 
Retinal O 
Ganglion O 
Cell O 
damage O 
in O 
Diabetic O 
Rats O 
. O 

is O 
an O 
important O 
component O 
of O 
diabetic O 
retinopathy O 
with O 
increasing O 
evidence O 
that O 
retinal O 
ganglion O 
cell O 
( O 
RGC O 
) O 
death O 
occurs O 
early O 
in O 
diabetes O 
. O 
We O 
investigated O 
the O 
effects O 
of O 
cilostazol B-TRIVIAL 
, O 
which O 
has O 
been O 
widely O 
used O 
to O 
manage O 
diabetic O 
complications O 
, O 
on O 
retinal O 
ganglion O 
cell O 
death O 
in O 
diabetic O 
retina O 
. O 
Four O 
- O 
week O 
- O 
old O 
Otsuka O 
Long-Evans O 
Tokushima O 
Fatty O 
( O 
OLETF O 
) O 
rats O 
and O 
Long-Evans O 
Tokushima O 
Otsuka O 
( O 
LETO O 
) O 
rats O 
as O 
matched O 
nondiabetic O 
controls O 
were O 
treated O 
with O 
daily O 
oral O 
cilostazol B-TRIVIAL 
at O 
30mg O 
/ O 
kg O 
or O 
0.9 O 
% O 
saline O 
solution O 
. O 
In O 
OLETF O 
rats O 
at O 
the O 
age O 
of O 
40 O 
weeks O 
, O 
glial O 
fibrillary O 
acidic O 
protein O 
( O 
GFAP O 
) O 
immunofluorescence O 
staining O 
was O 
upregulated O 
in O 
vertical O 
sections O 
and O 
showed O 
a O 
more O 
ramified O 
pattern O 
in O 
whole O 
- O 
mount O 
retinas O 
compared O 
with O 
that O 
in O 
LETO O 
rats O 
. O 
Vascular O 
endothelial O 
growth O 
factor O 
( O 
VEGF O 
) O 
expression O 
was O 
limited O 
to O 
the O 
ganglion O 
cell O 
layer O 
in O 
LETO O 
rats O 
, O 
but O 
extended O 
into O 
the O 
outer O 
plexiform O 
layer O 
in O 
OLETF O 
rats O 
. O 
Immunofluorescence O 
staining O 
and O 
western O 
blotting O 
demonstrated O 
that O 
cilostazol B-TRIVIAL 
treatment O 
reduced O 
GFAP O 
and O 
VEGF O 
expression O 
in O 
the O 
retinas O 
of O 
OLETF O 
rats O 
. O 
Terminal O 
deoxynucleotidyl O 
transferase O 
- O 
mediated O 
dUTP B-ABBREVIATION 
nick O 
- O 
end O 
labeling O 
( O 
TUNLEL O 
) O 
staining O 
revealed O 
an O 
increase O 
in O 
the O 
RGC O 
layer O 
in O 
OLETF O 
compared O 
with O 
LETO O 
rats O 
( O 
P O 
< O 
0.05 O 
) O 
, O 
and O 
cilostazol B-TRIVIAL 
treatment O 
reduced O 
the O 
number O 
of O 
TUNEL-positive O 
cells O 
in O 
OLETF O 
rats O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Relieving O 
retinal O 
ischemia O 
by O 
systemic O 
cilostazol B-TRIVIAL 
treatment O 
had O 
a O 
noticeable O 
protective O 
effect O 
on O 
RGCs O 
in O 
diabetic O 
rats O 
. O 
Cilostazol B-TRIVIAL 
treatment O 
may O 
be O 
useful O 
for O 
the O 
management O 
of O 
diabetic O 
retinal O 
vascular O 
dysfunction O 
and O 
neuronal O 
degeneration O 
. O 

Ameliorates O 
Chemically O 
Induced O 
Colitis O 
in O 
the O 
Mouse O 
Through O 
Modulation O 
of O 
a O 
PXR O 
/ O 
NF-κB O 
Signaling O 
Pathway O 
. O 

activation O 
of O 
pregnane O 
X O 
receptor O 
( O 
PXR O 
) O 
in O 
recent O 
years O 
has O 
become O 
a O 
therapeutic O 
strategy O 
for O 
inflammatory O 
bowel O 
disease O 
( O 
IBD O 
) O 
. O 
Chrysin B-TRIVIAL 
is O 
a O 
naturally O 
occurring O 
flavonoid B-FAMILY 
with O 
anti-inflammation O 
activity O 
. O 
The O 
current O 
study O 
investigated O 
the O 
role O 
of O 
chrysin B-TRIVIAL 
as O 
a O 
putative O 
mouse O 
PXR O 
agonist O 
in O 
preventing O 
experimental O 
colitis O 
. O 
Pre O 
- O 
administration O 
of O 
chrysin B-TRIVIAL 
ameliorated O 
inflammatory O 
symptoms O 
in O 
mouse O 
models O 
of O 
colitis O 
( O 
DSS- O 
and O 
TNBS-induced O 
) O 
and O 
resulted O 
in O 
down O 
- O 
regulation O 
of O 
NF-κB O 
target O 
genes O 
( O 
iNOS O 
, O 
ICAM-1 O 
, O 
MCP-1 O 
, O 
Cox2 O 
, O 
TNF-α O 
and O 
IL-6 O 
) O 
in O 
the O 
colon O 
mucosa O 
. O 
Chrysin B-TRIVIAL 
inhibited O 
the O 
phosphorylation O 
/ O 
degradation O 
of O 
IκBα O 
, O 
which O 
correlated O 
with O 
the O 
decline O 
in O 
the O 
activity O 
of O 
myeloperoxidase O 
( O 
MPO O 
) O 
and O 
the O 
levels O 
of O 
TNF-α O 
and O 
IL-6 O 
in O 
the O 
colon O 
. O 
Consistent O 
with O 
the O 
in O 
vivo O 
results O 
, O 
chrysin B-TRIVIAL 
blocked O 
LPS-stimulated O 
nuclear O 
translocation O 
of O 
NF-κB O 
p65 O 
in O 
mouse O 
macrophage O 
RAW264.7 O 
. O 
Furthermore O 
, O 
chrysin B-TRIVIAL 
dose O 
- O 
dependently O 
activated O 
human O 
/ O 
mouse O 
PXR O 
in O 
reporter O 
gene O 
assays O 
and O 
up O 
- O 
regulated O 
xenobiotic O 
detoxification O 
genes O 
in O 
the O 
colon O 
mucosa O 
, O 
but O 
not O 
in O 
the O 
liver O 
. O 
Silencing O 
of O 
PXR O 
by O 
RNAi O 
demonstrated O 
necessity O 
of O 
PXR O 
in O 
mediating O 
chrysin B-TRIVIAL 
' O 
s O 
ability O 
to O 
induce O 
xenobiotic O 
detoxification O 
genes O 
and O 
NF-κB O 
inactivation O 
. O 
The O 
repression O 
of O 
NF-κB O 
transcription O 
activity O 
by O 
chrysin B-TRIVIAL 
was O 
confirmed O 
by O 
in O 
vitro O 
PXR O 
transduction O 
. O 
These O 
findings O 
suggest O 
the O 
effect O 
of O 
chrysin B-TRIVIAL 
in O 
preventing O 
chemically O 
induced O 
colitis O 
is O 
mediated O 
in O 
large O 
part O 
by O 
a O 
PXR O 
/ O 
NF-κB O 
pathway O 
. O 
The O 
data O 
also O 
suggest O 
that O 
chrysin B-TRIVIAL 
or O 
chrysin B-TRIVIAL 
-like O 
flavonoids B-FAMILY 
could O 
be O 
further O 
developed O 
as O 
intestine O 
- O 
specific O 
PXR O 
activators O 
. O 

protective O 
effects O 
of O 
taurine B-TRIVIAL 
on O 
experimental O 
acute O 
pancreatitis O 
in O 
a O 
rat O 
model O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
protective O 
effects O 
of O 
taurine B-TRIVIAL 
( O 
Tau B-ABBREVIATION 
) O 
on O 
experimental O 
acute O 
pancreatitis O 
( O 
AP O 
) O 
in O 
a O 
rat O 
model O 
by O 
measuring O 
cytokines O 
and O 
oxidant O 
stress O 
markers.Forty O 
rats O 
were O 
randomly O 
divided O 
into O 
four O 
groups O 
: O 
sham O 
, O 
AP O 
, O 
Tau B-ABBREVIATION 
and O 
AP O 
+ O 
Tau O 
. O 
AP O 
was O 
induced O 
with O 
sodium B-SYSTEMATIC 
taurocholate I-SYSTEMATIC 
. O 
No O 
treatment O 
was O 
given O 
to O 
the O 
AP O 
. O 
All O 
rats O 
were O 
killed O 
5 O 
days O 
later O 
. O 
Pancreatic O 
tissues O 
of O 
rats O 
and O 
blood O 
samples O 
were O 
obtained O 
. O 
Tau B-ABBREVIATION 
treatment O 
significantly O 
decreased O 
serum O 
amylase O 
activity O 
( O 
p O 
< O 
0.001 O 
) O 
, O 
total O 
injury O 
score O 
( O 
p O 
< O 
0.001 O 
) O 
, O 
malondialdehyde B-TRIVIAL 
levels O 
( O 
p O 
< O 
0.001 O 
) O 
and O 
myeloperoxidase O 
( O 
MPO O 
) O 
activity O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
There O 
was O 
no O 
significant O 
difference O 
between O 
the O 
Tau B-ABBREVIATION 
and O 
AP O 
+ O 
Tau B-ABBREVIATION 
groups O 
in O 
serum O 
and O 
pancreatic O 
tumor O 
necrosis O 
factor-α O 
, O 
interleukin O 
(IL)-1β O 
and O 
IL-6 O 
levels O 
( O 
p O 
= O 
1 O 
) O 
. O 
Histopathologic O 
scores O 
in O 
the O 
AP O 
+ O 
Tau B-ABBREVIATION 
and O 
Tau B-ABBREVIATION 
groups O 
were O 
significantly O 
lower O 
compared O 
with O 
the O 
AP O 
group O 
( O 
both O 
p O 
< O 
0.001).These O 
results O 
showed O 
that O 
Tau B-ABBREVIATION 
reduces O 
lipid O 
peroxidation O 
, O 
amylase O 
and O 
MPO O 
activities O 
and O 
the O 
concentrations O 
of O 
proinflammatory O 
cytokines O 
secondary O 
to O 
AP O 
and O 
also O 
increases O 
superoxide B-TRIVIAL 
dismutase O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
activities O 
in O 
rats O 
with O 
sodium B-SYSTEMATIC 
taurocholate I-SYSTEMATIC 
-induced O 
AP O 
. O 
It O 
also O 
has O 
a O 
marked O 
ameliorative O 
effect O 
at O 
histopathologic O 
lesions O 
. O 
With O 
these O 
effects O 
, O 
Tau O 
protects O 
the O 
cells O 
from O 
oxidative O 
damage O 
, O 
reduces O 
inflammation O 
and O 
promotes O 
regression O 
of O 
pancreatic O 
damage O 
. O 

of O 
oily O 
vehicles O 
on O 
fetal O 
testis O 
and O 
lipid O 
profile O 
of O 
rats O 
exposed O 
to O 
di B-SYSTEMATIC 
- I-SYSTEMATIC 
butyl I-SYSTEMATIC 
phthalate I-SYSTEMATIC 
. O 

has O 
been O 
hypothesized O 
that O 
oils O 
containing O 
high O 
levels O 
of O 
omega-3 B-FAMILY 
polyunsaturated I-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
, O 
such O 
as O 
canola O 
and O 
fish O 
oil O 
, O 
could O 
counteract O 
some O 
of O 
the O 
adverse O 
effects O 
induced O 
by O 
phthalates B-FAMILY 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
influence O 
of O 
different O 
oily O 
vehicles O 
on O 
di B-SYSTEMATIC 
- I-SYSTEMATIC 
butyl I-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DBP B-ABBREVIATION 
)-induced O 
testicular O 
toxicity O 
and O 
lipid O 
profile O 
was O 
investigated O 
. O 
Pregnant O 
Wistar O 
rats O 
were O 
treated O 
by O 
oral O 
gavage O 
from O 
gestation O 
days O 
13 O 
to O 
20 O 
with O 
DBP B-ABBREVIATION 
( O 
500 O 
mg O 
/ O 
kg O 
/ O 
day O 
) O 
diluted O 
in O 
three O 
different O 
vehicles O 
: O 
corn O 
, O 
canola O 
or O 
fish O 
oil O 
. O 
Male O 
fetuses O 
were O 
analyzed O 
on O 
gestation O 
day O 
20 O 
. O 
DBP B-ABBREVIATION 
exposure O 
lowered O 
intratesticular O 
testosterone B-TRIVIAL 
levels O 
and O 
anogenital O 
distance O 
, O 
regardless O 
of O 
the O 
vehicle O 
used O 
. O 
The O 
percentage O 
of O 
seminiferous O 
cords O 
containing O 
multinucleated O 
gonocytes O 
and O 
cord O 
diameter O 
was O 
increased O 
in O 
DBP B-ABBREVIATION 
-exposed O 
groups O 
, O 
compared O 
with O 
vehicle O 
controls O 
, O 
with O 
no O 
difference O 
between O 
the O 
three O 
DBP B-ABBREVIATION 
-exposed O 
groups O 
. O 
Clustering O 
of O 
Leydig O 
cells O 
was O 
seen O 
in O 
all O 
DBP B-ABBREVIATION 
groups O 
. O 
Lipid O 
profile O 
indicated O 
that O 
administration O 
of O 
canola O 
and O 
fish O 
oil O 
can O 
increase O 
the O 
content O 
of O 
omega-3 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
in O 
rat O 
testis O 
. O 
However O 
, O 
content O 
of O 
omega-3 B-FAMILY 
was O 
diminished O 
in O 
DBP B-ABBREVIATION 
-treated O 
groups O 
. O 
Overall O 
, O 
our O 
results O 
indicate O 
that O 
different O 
oily O 
vehicles O 
did O 
not O 
alter O 
fetal O 
rat O 
testicular O 
toxicity O 
induced O 
by O 
a O 
high O 
DBP B-ABBREVIATION 
dose O 
. O 

inhibits O 
proliferation O 
, O 
angiogenesis O 
and O 
induces O 
apoptosis O 
in O 
colon O 
cancer O 
cells O 
: O 
Calorie O 
restriction O 
is O 
the O 
force O 
to O 
the O 
cytotoxicity O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
antitumour O 
activity O 
of O 
resveratrol B-TRIVIAL 
in O 
human O 
colorectal O 
cancer O 
cell O 
lines O 
( O 
HCT116 O 
and O 
Caco2 O 
) O 
and O 
to O 
explore O 
its O 
mechanism O 
of O 
action O 
assuming O 
that O 
it O 
is O 
by O 
calorie O 
- O 
restriction O 
effect O 
. O 
Resveratrol B-TRIVIAL 
inhibited O 
the O 
proliferation O 
of O 
colon O 
cancer O 
cells O 
with O 
half O 
maximal O 
inhibitory O 
concentration O 
( O 
IC50 O 
) O 
equal O 
to O 
50 O 
and O 
130 O 
μM O 
for O 
HCT116 O 
and O 
Caco2 O 
, O 
respectively O 
. O 
Caco2 O 
cells O 
appeared O 
with O 
significant O 
time O 
- O 
dependent O 
increase O 
in O 
the O 
glycolytic O 
pathway O 
, O 
a O 
behaviour O 
that O 
was O 
absent O 
in O 
HCT116 O 
cells O 
. O 
Resveratrol B-TRIVIAL 
( O 
100 O 
μM O 
) O 
significantly O 
decreased O 
the O 
glycolytic O 
enzymes O 
( O 
pyruvate O 
kinase O 
and O 
lactate O 
dehydrogenase O 
) O 
in O 
Caco2 O 
cells O 
, O 
while O 
an O 
increase O 
in O 
citrate B-FAMILY 
synthase O 
activity O 
and O 
a O 
decrease O 
in O 
glucose B-TRIVIAL 
consumption O 
were O 
observed O 
in O 
both O 
cell O 
lines O 
. O 
Moreover O 
, O 
resveratrol B-TRIVIAL 
downregulated O 
the O 
expressions O 
of O 
leptin O 
and O 
c-Myc O 
, O 
and O 
decreased O 
the O 
content O 
of O 
vascular O 
endothelial O 
growth O 
factor O 
. O 
The O 
apoptotic O 
markers O 
, O 
caspases O 
3 O 
and O 
8 O 
, O 
were O 
activated O 
and O 
the O 
Bax O 
/ O 
BCl2 O 
ratio O 
was O 
increased O 
. O 
The O 
study O 
suggested O 
a O 
promising O 
anticancer O 
activity O 
of O 
resveratrol B-TRIVIAL 
, O 
calorie O 
- O 
restriction O 
pathway O 
may O 
be O 
one O 
of O 
the O 
driving O 
forces O 
for O 
this O 
activity O 
. O 

effects O 
of O 
organic O 
and O 
inorganic O 
selenium B-SYSTEMATIC 
compounds O 
on O 
adenosine B-TRIVIAL 
deaminase O 
activity O 
and O 
scavenger O 
capacity O 
in O 
cerebral O 
cortex O 
slices O 
of O 
young O 
rats O 
. O 

( O 
Se B-FORMULA 
) O 
has O 
anti-inflammatory O 
and O 
antioxidant O 
properties O 
and O 
is O 
necessary O 
for O 
the O 
development O 
and O 
normal O 
function O 
of O 
the O 
central O 
nervous O 
system O 
. O 
This O 
study O 
was O 
aimed O 
to O 
compare O 
the O 
in O 
vitro O 
effects O 
of O 
3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one B-SYSTEMATIC 
( O 
C21H2HOSe B-FORMULA 
; O 
organoselenium B-FAMILY 
) O 
and O 
sodium B-SYSTEMATIC 
selenate I-SYSTEMATIC 
( O 
inorganic O 
Se B-FORMULA 
) O 
on O 
adenosine B-TRIVIAL 
deaminase O 
( O 
ADA O 
) O 
activity O 
, O 
cell O 
viability O 
, O 
lipid O 
peroxidation O 
, O 
scavenger O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
and O 
nonprotein O 
thiols B-FAMILY 
( O 
NP- O 
SH B-FORMULA 
) O 
content O 
in O 
the O 
cerebral O 
cortex O 
slices O 
of O 
the O 
young O 
rats O 
. O 
A O 
decrease O 
in O 
ADA O 
activity O 
was O 
observed O 
when O 
the O 
slices O 
were O 
exposed O 
to O 
organoselenium B-FAMILY 
at O 
the O 
concentrations O 
of O 
1 O 
, O 
10 O 
and O 
30 O 
µM O 
. O 
The O 
same O 
compound O 
showed O 
higher O 
scavenger O 
capacity O 
of O 
NO B-FORMULA 
than O 
the O 
inorganic O 
compound O 
. O 
Inorganic O 
Se B-FORMULA 
was O 
able O 
to O 
protect O 
against O 
sodium B-SYSTEMATIC 
nitroprusside I-SYSTEMATIC 
-induced O 
oxidative O 
damage O 
and O 
increased O 
the O 
NP- O 
SH B-FORMULA 
content O 
. O 
Both O 
the O 
compounds O 
displayed O 
distinctive O 
antioxidant O 
capacities O 
and O 
were O 
not O 
cytotoxic O 
for O 
the O 
cerebral O 
cortex O 
slices O 
in O 
the O 
conditions O 
tested O 
. O 
These O 
findings O 
are O 
likely O 
to O 
be O 
related O 
to O 
immunomodulatory O 
and O 
antioxidant O 
properties O 
of O 
this O 
compound O 
. O 

of O 
the O 
Relative O 
Propensities O 
of O 
Isoamyl B-SYSTEMATIC 
Nitrite I-SYSTEMATIC 
and O 
Sodium B-SYSTEMATIC 
Nitrite I-SYSTEMATIC 
to O 
Ameliorate O 
Acute O 
Cyanide B-SYSTEMATIC 
Poisoning O 
in O 
Mice O 
and O 
a O 
Novel O 
Antidotal O 
Effect O 
Arising O 
from O 
Anesthetics O 
. O 

nitrite I-SYSTEMATIC 
has O 
previously O 
been O 
considered O 
acceptable O 
as O 
an O 
inhaled O 
cyanide B-SYSTEMATIC 
antidote O 
; O 
therefore O 
, O 
the O 
antidotal O 
utility O 
of O 
this O 
organic O 
nitrite B-SYSTEMATIC 
compared O 
with O 
sodium B-SYSTEMATIC 
nitrite I-SYSTEMATIC 
was O 
investigated O 
. O 
To O 
facilitate O 
a O 
quantitative O 
comparison O 
, O 
doses O 
of O 
both O 
sodium B-SYSTEMATIC 
nitrite I-SYSTEMATIC 
and O 
isoamyl B-SYSTEMATIC 
nitrite I-SYSTEMATIC 
were O 
given O 
intraperitoneally O 
in O 
equimolar O 
amounts O 
to O 
sublethally O 
cyanide B-SYSTEMATIC 
-challenged O 
mice O 
. O 
Righting O 
recovery O 
from O 
the O 
knockdown O 
state O 
was O 
clearly O 
compromised O 
in O 
the O 
isoamyl B-SYSTEMATIC 
nitrite I-SYSTEMATIC 
-treated O 
animals O 
, O 
the O 
effect O 
being O 
attributable O 
to O 
the O 
toxicity O 
of O 
the O 
isoamyl B-SYSTEMATIC 
alchol I-SYSTEMATIC 
produced O 
during O 
hydrolysis O 
of O 
the O 
isoamyl B-SYSTEMATIC 
nitrite I-SYSTEMATIC 
to O 
release O 
nitrite B-SYSTEMATIC 
anion O 
. O 
Subsequently O 
, O 
inhaled O 
aqueous O 
sodium B-SYSTEMATIC 
nitrite I-SYSTEMATIC 
aerosol O 
was O 
demonstrated O 
to O 
ameliorate O 
sublethal O 
cyanide B-SYSTEMATIC 
toxicity O 
, O 
when O 
provided O 
to O 
mice O 
after O 
the O 
toxic O 
dose O 
, O 
by O 
the O 
more O 
rapid O 
recovery O 
of O 
righting O 
ability O 
compared O 
to O 
that O 
of O 
the O 
control O 
animals O 
given O 
only O 
the O 
toxicant O 
. O 
Aerosolized O 
sodium B-SYSTEMATIC 
nitrite I-SYSTEMATIC 
has O 
thus O 
been O 
shown O 
by O 
these O 
experiments O 
to O 
have O 
promise O 
as O 
a O 
better O 
alternative O 
to O 
organic O 
nitrites B-FAMILY 
for O 
development O 
as O 
an O 
inhaled O 
cyanide B-SYSTEMATIC 
antidote O 
. O 
The O 
inhaled O 
sodium B-SYSTEMATIC 
nitrite I-SYSTEMATIC 
led O 
to O 
the O 
production O 
of O 
NO B-FORMULA 
in O 
the O 
bloodstream O 
as O 
determined O 
by O 
the O 
appearance O 
of O 
EPR O 
signals O 
attributable O 
to O 
nitrosylhemoglobin O 
and O 
methemoglobin O 
. O 
The O 
aerosol O 
delivery O 
was O 
performed O 
in O 
an O 
unmetered O 
inhalation O 
chamber O 
, O 
and O 
in O 
this O 
study O 
, O 
no O 
attempt O 
was O 
made O 
to O 
optimize O 
the O 
procedure O 
. O 
It O 
is O 
argued O 
that O 
administration O 
of O 
an O 
effective O 
inhaled O 
aqueous O 
sodium B-SYSTEMATIC 
nitrite I-SYSTEMATIC 
dose O 
in O 
humans O 
is O 
possible O 
, O 
though O 
just O 
beyond O 
the O 
capability O 
of O 
current O 
individual O 
metered O 
- O 
dose O 
inhaler O 
designs O 
, O 
such O 
as O 
those O 
used O 
for O 
asthma O 
. O 
Finally O 
, O 
working O 
at O 
slightly O 
greater O 
than O 
LD50 O 
NaCN B-FORMULA 
doses O 
, O 
it O 
was O 
fortuitously O 
discovered O 
that O 
(i) O 
anesthesia O 
leads O 
to O 
significantly O 
prolonged O 
survival O 
compared O 
to O 
that O 
of O 
unanesthetized O 
animals O 
and O 
that O 
(ii) O 
the O 
antidotal O 
activity O 
of O 
nitrite B-SYSTEMATIC 
anion O 
was O 
completely O 
abolished O 
under O 
anesthesia O 
. O 
Plausible O 
explanations O 
for O 
these O 
effects O 
in O 
mice O 
and O 
their O 
practical O 
consequences O 
in O 
relation O 
to O 
testing O 
putative O 
cyanide B-SYSTEMATIC 
antidotes O 
are O 
discussed O 
. O 

of O 
2,2',4,4'-Tetrabromodiphenyl B-SYSTEMATIC 
Ether I-SYSTEMATIC 
( O 
BDE-47 B-ABBREVIATION 
) O 
by O 
Human O 
Liver O 
Microsomes O 
: O 
Identification O 
of O 
Cytochrome O 
P450 O 
2B6 O 
as O 
the O 
Major O 
Enzyme O 
Involved O 
. O 

diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
were O 
widely O 
used O 
flame O 
retardants O 
that O 
have O 
become O 
persistent O 
environmental O 
pollutants O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
in O 
vitro O 
oxidative O 
metabolism O 
of O 
2,2',4,4'-tetrabromodiphenyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
BDE-47 B-ABBREVIATION 
) O 
, O 
a O 
major O 
PBDE B-ABBREVIATION 
detected O 
in O 
human O 
tissue O 
and O 
environmental O 
samples O 
. O 
Biotransformation O 
of O 
BDE-47 B-ABBREVIATION 
by O 
pooled O 
and O 
individual O 
human O 
liver O 
microsomes O 
and O 
by O 
human O 
recombinant O 
cytochrome O 
P450 O 
( O 
P450 O 
) O 
enzymes O 
was O 
assessed O 
using O 
a O 
liquid O 
chromatography O 
/ O 
tandem O 
mass O 
spectrometry O 
- O 
based O 
method O 
. O 
Of O 
the O 
nine O 
hydroxylated O 
metabolites O 
of O 
BDE-47 B-ABBREVIATION 
produced O 
by O 
human O 
liver O 
microsomes O 
, O 
seven O 
metabolites O 
were O 
identified O 
using O 
authentic O 
standards O 
. O 
A O 
monohydroxy B-SYSTEMATIC 
-tetrabrominated O 
and O 
a O 
dihydroxy B-SYSTEMATIC 
-tetrabrominated O 
metabolite O 
remain O 
unidentified O 
. O 
Kinetic O 
analysis O 
of O 
the O 
rates O 
of O 
metabolite O 
formation O 
revealed O 
that O 
the O 
major O 
metabolites O 
were O 
5-hydroxy-2,2',4,4'-tetrabromodiphenyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
5-OH-BDE-47 B-SYSTEMATIC 
) O 
, O 
6-hydroxy-2,2',4,4'-tetrabromodiphenyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
6-OH-BDE-47 B-SYSTEMATIC 
) O 
, O 
and O 
possibly O 
the O 
unidentified O 
monohydroxy B-SYSTEMATIC 
-tetrabrominated O 
metabolite O 
. O 
Among O 
the O 
human O 
recombinant O 
P450 O 
enzymes O 
tested O 
, O 
P450 O 
2B6 O 
was O 
the O 
most O 
active O 
enzyme O 
in O 
the O 
formation O 
of O 
the O 
hydroxylated O 
metabolites O 
of O 
BDE-47 B-ABBREVIATION 
. O 
Moreover O 
, O 
the O 
formation O 
of O 
all O 
metabolites O 
of O 
BDE-47 B-ABBREVIATION 
by O 
pooled O 
human O 
liver O 
microsomes O 
was O 
inhibited O 
by O 
a O 
P450 O 
2B6-specific O 
antibody O 
and O 
was O 
highly O 
correlated O 
with O 
P450 O 
2B6 O 
- O 
mediated O 
activity O 
in O 
single O 
donor O 
liver O 
microsomes O 
indicating O 
that O 
P450 O 
2B6 O 
was O 
the O 
major O 
P450 O 
responsible O 
for O 
the O 
biotransformation O 
of O 
BDE-47 B-ABBREVIATION 
. O 
Additional O 
experiments O 
involving O 
the O 
incubation O 
of O 
liver O 
microsomes O 
with O 
individual O 
monohydroxy B-SYSTEMATIC 
-tetrabrominated O 
metabolites O 
in O 
place O 
of O 
BDE-47 B-ABBREVIATION 
demonstrated O 
that O 
2,4-dibromophenol B-SYSTEMATIC 
was O 
a O 
product O 
of O 
BDE-47 B-ABBREVIATION 
and O 
several O 
primary O 
metabolites O 
, O 
but O 
the O 
dihydroxy B-SYSTEMATIC 
-tetrabrominated O 
metabolite O 
was O 
not O 
formed O 
by O 
sequential O 
hydroxylation O 
of O 
any O 
of O 
the O 
monohydroxy B-SYSTEMATIC 
-tetrabrominated O 
metabolites O 
tested O 
. O 
The O 
present O 
study O 
provides O 
a O 
comprehensive O 
characterization O 
of O 
the O 
oxidative O 
metabolism O 
of O 
BDE-47 B-ABBREVIATION 
by O 
human O 
liver O 
microsomes O 
and O 
P450 O 
2B6 O 
. O 

of O 
Dikamali O 
: O 
A O 
phytochemical O 
reinvestigation O 
. O 

known O 
flavonoids B-FAMILY 
( O 
1-11 O 
) O 
were O 
isolated O 
from O 
Dikamali O 
, O 
the O 
gum O 
resin O 
of O 
Gardenia O 
lucida O 
. O 
Three O 
of O 
them O 
, O 
desmethylnobiletin B-TRIVIAL 
, O 
pectolinarigenin B-TRIVIAL 
and O 
xanthomicrol B-TRIVIAL 
, O 
are O 
a O 
new O 
report O 
from O 
this O 
source O 
. O 
Nuclear O 
magnetic O 
resonance O 
( O 
NMR O 
) O 
data O 
are O 
being O 
given O 
for O 
all O 
the O 
isolates O 
. O 
For O 
two O 
of O 
them O 
, O 
viz O 
. O 
, O 
3',4'-dimethoxywogonin B-SYSTEMATIC 
and O 
4'-hydroxywogonin B-SYSTEMATIC 
, O 
such O 
data O 
have O 
not O 
been O 
reported O 
in O 
literature O 
. O 
Furthermore O 
, O 
correct O 
NMR O 
data O 
are O 
being O 
provided O 
for O 
gardenin B-TRIVIAL 
C I-TRIVIAL 
as O 
the O 
data O 
reported O 
in O 
literature O 
were O 
found O 
to O 
be O 
incorrect O 
. O 

triterpene B-FAMILY 
glycoside I-FAMILY 
and O 
other O 
chemical O 
constituents O 
from O 
the O 
leaves O 
of O 
Swartzia O 
apetala O 
Raddi O 
var O 
. O 
glabra O 
. O 

new O 
triterpene B-FAMILY 
saponin I-FAMILY 
( O 
1 O 
) O 
was O 
isolated O 
from O 
a O 
methanol B-SYSTEMATIC 
extract O 
of O 
Swartzia O 
apetala O 
Raddi O 
var O 
. O 
glabra O 
, O 
together O 
with O 
the O 
flavonoids B-FAMILY 
mauritianin B-TRIVIAL 
( O 
2 O 
) O 
, O 
kaempferol B-TRIVIAL 
( O 
3 O 
) O 
and O 
the O 
triterpene B-FAMILY 
saponin I-FAMILY 
β-D-glucopyranosyl B-SYSTEMATIC 
3β-hydroxy-olean-12-en-28-oate I-SYSTEMATIC 
( O 
4 O 
) O 
. O 
These O 
compounds O 
were O 
characterised O 
on O 
the O 
basis O 
of O 
their O 
spectral O 
data O 
, O 
mainly O 
one O 
- O 
dimension O 
( O 
1D O 
; O 
(1)H B-FORMULA 
, O 
(13)C B-FORMULA 
, O 
APT O 
) O 
and O 
two O 
- O 
dimension O 
( O 
2D O 
; O 
(1)H B-FORMULA 
- O 
(1)H B-FORMULA 
-COSY O 
, O 
HMQC O 
and O 
HMBC O 
) O 
nuclear O 
magnetic O 
resonance O 
( O 
NMR O 
) O 
and O 
HR-ESI-MS O 
, O 
and O 
comparison O 
with O 
values O 
in O 
the O 
literature O 
. O 
The O 
analysis O 
by O 
HR-ESI-MS O 
showed O 
a O 
mass O 
compatible O 
with O 
that O 
of O 
triterpene B-FAMILY 
saponin I-FAMILY 
1 O 
. O 
This O 
proposal O 
was O 
supported O 
by O 
molecular O 
modelling O 
. O 
LC-HR-ESI-MS O 
experiment O 
was O 
also O 
used O 
to O 
evaluate O 
the O 
purity O 
of O 
1 O 
and O 
allowed O 
to O 
speculate O 
about O 
the O 
possibility O 
of O 
the O 
presence O 
of O 
5 O 
in O 
very O 
small O 
quantity O 
. O 
The O 
extract O 
and O 
four O 
compounds O 
were O 
assayed O 
for O 
antifungal O 
activity O 
against O 
nine O 
strains O 
of O 
Candida O 
spp O 
. O 

of O 
Rate O 
Constants O 
for O 
the O 
OH B-FORMULA 
Reactions O 
with O 
Bromoform B-SYSTEMATIC 
( O 
CHBr3 B-FORMULA 
) O 
, O 
CHBr2Cl B-FORMULA 
, O 
CHBrCl2 B-FORMULA 
, O 
and O 
Epichlorohydrin B-TRIVIAL 
( O 
C3H5ClO B-FORMULA 
) O 
. O 

of O 
the O 
rate O 
constants O 
for O 
the O 
gas O 
phase O 
reactions O 
of O 
OH B-FORMULA 
radicals O 
with O 
bromoform B-SYSTEMATIC 
( O 
CHBr3 B-FORMULA 
) O 
and O 
epichlorohydrin B-TRIVIAL 
( O 
C3H5ClO B-FORMULA 
) O 
were O 
performed O 
using O 
a O 
flash O 
photolysis O 
resonance O 
- O 
fluorescence O 
technique O 
over O 
the O 
temperature O 
range O 
230-370 O 
K O 
. O 
The O 
temperature O 
dependences O 
of O 
the O 
rate O 
constants O 
can O 
be O 
represented O 
by O 
the O 
following O 
expressions O 
: O 
kBF(230-370 O 
K O 
) O 
= O 
( O 
9.94 O 
± O 
0.76 O 
) O 
× O 
10(-13) O 
exp[-(387 O 
± O 
22 O 
) O 
/ O 
T O 
] O 
cm(3) O 
molecule(-1) O 
s(-1) O 
and O 
kECH(230-370 O 
K O 
) O 
= O 
1.05 O 
× O 
10(-14)(T O 
/ O 
298)(5.16 O 
) O 
exp(+1082 O 
/ O 
T O 
) O 
cm(3) O 
molecule(-1) O 
s(-1) O 
. O 
Rate O 
constants O 
for O 
the O 
reactions O 
of O 
OH B-FORMULA 
with O 
CHCl2Br B-FORMULA 
and O 
CHClBr2 B-FORMULA 
were O 
measured O 
between O 
230 O 
and O 
330 O 
K O 
. O 
They O 
can O 
be O 
represented O 
by O 
the O 
following O 
expressions O 
: O 
kDCBM(230-330 O 
K O 
) O 
= O 
( O 
9.4 O 
± O 
1.3 O 
) O 
× O 
10(-13) O 
exp[-(513 O 
± O 
37 O 
) O 
/ O 
T O 
] O 
cm(3) O 
molecule(-1) O 
s(-1) O 
and O 
kCDBM(230-330 O 
K O 
) O 
= O 
( O 
9 O 
± O 
1.9 O 
) O 
× O 
10(-13) O 
exp[-(423 O 
± O 
61 O 
) O 
/ O 
T O 
] O 
cm(3) O 
molecule(-1) O 
s(-1) O 
. O 
The O 
atmospheric O 
lifetimes O 
due O 
to O 
reactions O 
with O 
tropospheric O 
OH B-FORMULA 
were O 
estimated O 
to O 
be O 
57 O 
, O 
39 O 
, O 
72 O 
, O 
and O 
96 O 
days O 
, O 
respectively O 
. O 
The O 
total O 
atmospheric O 
lifetimes O 
of O 
the O 
Br B-FORMULA 
-containing O 
methanes B-FAMILY 
due O 
to O 
both O 
reaction O 
with O 
OH B-FORMULA 
and O 
photolysis O 
were O 
calculated O 
to O 
be O 
22 O 
, O 
50 O 
, O 
and O 
67 O 
days O 
for O 
CHBr3 B-FORMULA 
, O 
CHClBr2 B-FORMULA 
, O 
and O 
CHCl2Br B-FORMULA 
, O 
respectively O 
. O 

biological O 
screening O 
was O 
performed O 
to O 
establish O 
the O 
total O 
exposure O 
to O 
estrogenic O 
compounds O 
of O 
red O 
mullet O 
( O 
Mullus O 
barbatus O 
) O 
collected O 
at O 
several O 
sites O 
along O 
the O 
Spanish O 
Mediterranean O 
coast O 
by O 
testing O 
male O 
fish O 
bile O 
extracts O 
using O 
the O 
in O 
vitro O 
ER-LUC O 
reporter O 
gene O 
assay O 
. O 
In O 
addition O 
, O 
major O 
metabolites O 
were O 
identified O 
and O 
measurements O 
of O 
OH-PAHs B-FORMULA 
( O 
1-naphthol B-SYSTEMATIC 
, O 
9-phenantrol B-SYSTEMATIC 
, O 
9-fluorenol B-SYSTEMATIC 
, O 
1-pyrenol B-SYSTEMATIC 
, O 
1OH-BaP B-SYSTEMATIC 
and O 
3OH-BaP B-SYSTEMATIC 
) O 
and O 
alkylphenols B-FAMILY 
( O 
4-n-nonylphenol B-SYSTEMATIC 
( O 
4-n-NP B-SYSTEMATIC 
) O 
and O 
4-tertoctylphenol B-SYSTEMATIC 
( O 
4-tert-OP B-SYSTEMATIC 
) O 
) O 
in O 
the O 
same O 
fish O 
bile O 
extracts O 
were O 
taken O 
by O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
in O 
electron O 
ionization O 
mode O 
( O 
GC-EI-MS O 
) O 
. O 
Relative O 
in O 
vitro O 
estrogenic O 
potencies O 
of O 
the O 
chemically O 
quantified O 
compounds O 
were O 
also O 
tested O 
. O 
The O 
highest O 
biliary O 
concentrations O 
of O 
1-pyrenol B-SYSTEMATIC 
, O 
9-fluorenol B-SYSTEMATIC 
and O 
4-n-NP B-SYSTEMATIC 
were O 
found O 
in O 
fish O 
from O 
Barcelona O 
and O 
from O 
the O 
Mar O 
Menor O 
coastal O 
lagoon O 
. O 
However O 
, O 
these O 
concentrations O 
can O 
be O 
considered O 
relatively O 
low O 
compared O 
to O 
values O 
reported O 
in O 
red O 
mullet O 
from O 
other O 
polluted O 
waters O 
in O 
the O 
Mediterranean O 
Sea O 
. O 
The O 
contribution O 
of O 
1-pyrenol B-SYSTEMATIC 
, O 
4-n-NP B-SYSTEMATIC 
and O 
4-tert-OP B-SYSTEMATIC 
to O 
the O 
total O 
estrogenic O 
potency O 
measured O 
in O 
male O 
fish O 
bile O 
was O 
found O 
to O 
be O 
negligible O 
, O 
indicating O 
the O 
presence O 
of O 
other O 
estrogenic O 
compounds O 
in O 
red O 
mullet O 
bile O 
. O 
Estrogenic O 
potency O 
in O 
bile O 
from O 
male O 
fish O 
was O 
markedly O 
elevated O 
in O 
Mar O 
Menor O 
lagoon O 
( O 
234.8±5.7pgE2EQ O 
/ O 
μl O 
) O 
, O 
and O 
further O 
research O 
will O 
be O 
necessary O 
to O 
explain O 
whether O 
the O 
presence O 
of O 
natural O 
and O 
synthetic O 
- O 
hormones O 
in O 
the O 
lagoon O 
contributed O 
to O 
this O 
finding O 
. O 
Values O 
of O 
approximately O 
15-16E2EQpg O 
/ O 
mg O 
bile O 
can O 
be O 
regarded O 
as O 
preliminary O 
baseline O 
levels O 
of O 
bile O 
estrogenicity O 
in O 
male O 
red O 
mullet O 
from O 
the O 
western O 
Mediterranean O 
Sea O 
. O 

nutraceutical O 
potential O 
of O 
Chenopodium O 
quinoa O 
Leaves O 
( O 
ChL O 
) O 
was O 
assessed O 
through O 
analyses O 
of O 
their O 
phenolic B-FAMILY 
content O 
, O 
elucidation O 
of O 
the O 
effect O 
of O 
ChL O 
phenolic B-FAMILY 
compounds O 
on O 
cancer O 
cell O 
properties O 
and O 
estimation O 
of O 
their O 
antioxidative O 
activity O 
, O 
bioaccessibility O 
and O 
bioavailability O 
in O 
vitro O 
. O 
Considerable O 
amounts O 
of O 
ferulic B-MULTIPLE 
, I-MULTIPLE 
sinapinic I-MULTIPLE 
and I-MULTIPLE 
gallic I-MULTIPLE 
acids I-MULTIPLE 
, O 
kaempferol B-TRIVIAL 
, O 
isorhamnetin B-TRIVIAL 
and O 
rutin B-TRIVIAL 
were O 
observed O 
in O 
the O 
chemical O 
ChL O 
extract O 
and O 
were O 
linked O 
with O 
its O 
inhibitory O 
effect O 
on O 
prostate O 
cancer O 
cell O 
proliferation O 
, O 
motility O 
and O 
cellular O 
competence O 
for O 
gap O 
junctional O 
communication O 
. O 
Both O 
extracts O 
, O 
chemical O 
and O 
obtained O 
after O 
simulated O 
digestion O 
, O 
exerted O 
an O 
inhibitory O 
effect O 
on O 
lipoxygenase O 
activity O 
, O 
paralleled O 
by O 
their O 
considerable O 
chelating O 
, O 
antioxidative O 
, O 
antiradical O 
and O 
reducing O 
power O 
. O 
These O 
observations O 
indicate O 
that O 
phenolic B-FAMILY 
ChL O 
compounds O 
may O 
exert O 
a O 
chemopreventive O 
and O 
anticarcinogenic O 
effect O 
on O 
oxidative O 
stress O 
and O 
ROS-dependent O 
intracellular O 
signaling O 
via O 
synergic O 
effects O 
. O 
The O 
relatively O 
high O 
potential O 
bioaccessibility O 
and O 
bioavailability O 
of O 
the O 
compounds O 
probably O 
responsible O 
for O 
these O 
effects O 
demonstrates O 
the O 
suitability O 
of O 
ChL O 
for O 
dietary O 
supplementation O 
. O 

ultra O 
- O 
low O 
dose O 
of O 
tetrahydrocannabinol B-SYSTEMATIC 
provides O 
cardioprotection O 
. O 

( O 
THC B-ABBREVIATION 
) O 
, O 
the O 
major O 
psychoactive O 
component O 
of O 
marijuana O 
, O 
is O 
a O 
cannabinoid O 
agonist O 
that O 
exerts O 
its O 
effects O 
by O 
activating O 
at O 
least O 
two O 
specific O 
receptors O 
( O 
CB1 O 
and O 
CB2 O 
) O 
that O 
belong O 
to O 
the O 
seven O 
transmembrane O 
G O 
- O 
protein O 
coupled O 
receptor O 
( O 
GPCR O 
) O 
family O 
. O 
Both O 
CB1 O 
and O 
CB2 O 
mRNA O 
and O 
proteins O 
are O 
present O 
in O 
the O 
heart O 
. O 
THC B-ABBREVIATION 
treatment O 
was O 
beneficial O 
against O 
hypoxia O 
in O 
neonatal O 
cardiomyocytes O 
in O 
vitro O 
. O 
We O 
also O 
observed O 
a O 
neuroprotective O 
effect O 
of O 
an O 
ultra O 
low O 
dose O 
of O 
THC B-ABBREVIATION 
when O 
applied O 
to O 
mice O 
before O 
brain O 
insults O 
. O 
The O 
present O 
study O 
was O 
aimed O 
to O 
test O 
and O 
characterize O 
the O 
cardioprotective O 
effects O 
of O 
a O 
very O 
low O 
dose O 
( O 
0.002mg O 
/ O 
kg O 
) O 
of O 
THC B-ABBREVIATION 
which O 
is O 
3-4 O 
orders O 
of O 
magnitude O 
lower O 
than O 
the O 
conventional O 
doses O 
, O 
administered O 
before O 
myocardial O 
infarction O 
in O 
mice O 
in O 
vivo O 
. O 
Three O 
regimens O 
of O 
THC B-ABBREVIATION 
administration O 
were O 
tested O 
: O 
single O 
THC B-ABBREVIATION 
application O 
2h O 
or O 
48h O 
before O 
the O 
induction O 
of O 
infarct O 
, O 
or O 
3 O 
weeks O 
continuous O 
treatment O 
before O 
MI O 
. O 
All O 
protocols O 
of O 
THC B-ABBREVIATION 
administration O 
were O 
found O 
to O 
be O 
beneficial O 
. O 
In O 
the O 
case O 
of O 
THC B-ABBREVIATION 
treatment O 
2h O 
before O 
MI O 
, O 
fractional O 
shortening O 
was O 
elevated O 
( O 
37±4% O 
vs O 
. O 
42±1% O 
, O 
p O 
< O 
0.04 O 
) O 
, O 
troponin O 
T O 
leakage O 
to O 
the O 
blood O 
was O 
reduced O 
( O 
14±3ng O 
/ O 
ml O 
vs O 
. O 
10±4ng O 
/ O 
ml O 
, O 
p O 
< O 
0.008 O 
) O 
, O 
infarct O 
size O 
decreased O 
( O 
29±4% O 
vs O 
. O 
23±4% O 
, O 
p O 
< O 
0.02 O 
) O 
, O 
and O 
the O 
accumulation O 
of O 
neutrophils O 
to O 
the O 
infarct O 
area O 
declined O 
( O 
36±10cells O 
/ O 
field O 
vs O 
. O 
19±4cells O 
/ O 
field O 
, O 
p O 
< O 
0.007 O 
) O 
in O 
THC B-ABBREVIATION 
- O 
compared O 
to O 
vehicle O 
- O 
pretreated O 
mice O 
, O 
24h O 
after O 
MI O 
. O 
ERK1 O 
/ O 
2 O 
phosphorylation O 
following O 
infarct O 
was O 
also O 
inhibited O 
by O 
pre O 
- O 
treatment O 
with O 
THC B-ABBREVIATION 
( O 
p O 
< O 
0.01 O 
) O 
. O 
CONCLUSION O 
: O 
A O 
single O 
ultra O 
low O 
dose O 
of O 
THC B-ABBREVIATION 
before O 
ischemia O 
is O 
a O 
safe O 
and O 
effective O 
treatment O 
that O 
reduces O 
myocardial O 
ischemic O 
damage O 
. O 

T O 
cells O 
( O 
Treg O 
) O 
, O 
which O 
play O 
a O 
pivotal O 
role O 
in O 
maintaining O 
immune O 
homeostasis O 
by O 
suppressing O 
the O 
proliferation O 
of O 
effector O 
T O 
cells O 
, O 
have O 
great O 
therapeutic O 
potential O 
for O 
autoimmune O 
diseases O 
and O 
transplantation O 
. O 
However O 
, O 
progress O 
on O 
their O 
clinical O 
application O 
has O 
been O 
hampered O 
by O 
the O 
lack O 
of O 
high O 
throughput O 
screening O 
( O 
HTS O 
) O 
strategies O 
for O 
the O 
systematic O 
and O 
rapid O 
evaluation O 
of O 
existing O 
drugs O 
and O 
the O 
identification O 
of O 
novel O 
drug O 
candidates O 
. O 
In O 
this O 
report O 
, O 
we O 
present O 
an O 
innovative O 
in O 
vitro O 
HTS O 
assay O 
using O 
CD4(+) O 
T O 
cells O 
from O 
Foxp3-GFP O 
transgenic O 
mice O 
that O 
specifically O 
express O 
the O 
GFP O 
signal O 
in O 
Foxp3(+) O 
Treg O 
cells O 
detectable O 
by O 
FACS O 
analysis O 
in O 
a O 
high O 
throughput O 
manner O 
. O 
Systematic O 
evaluation O 
of O 
640 O 
FDA-approved O 
drugs O 
revealed O 
that O 
70 O 
drugs O 
increased O 
the O 
number O 
of O 
Treg O 
cells O 
with O 
suppression O 
function O 
only O 
in O 
the O 
presence O 
of O 
TGFβ O 
, O 
75 O 
drugs O 
increased O 
Treg O 
numbers O 
even O 
in O 
the O 
absence O 
of O 
TGFβ O 
, O 
and O 
32 O 
drugs O 
increased O 
Treg O 
numbers O 
synergistically O 
with O 
TGFβ O 
. O 
The O 
identified O 
Treg O 
- O 
promoting O 
drugs O 
include O 
those O 
previously O 
known O 
to O 
induce O 
Treg O 
( O 
rapamycin B-TRIVIAL 
and O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
) I-TRIVIAL 
, O 
statins O 
, O 
glucocorticoids O 
and O 
drugs O 
in O 
many O 
other O 
categories O 
. O 
Furthermore O 
, O 
Treg O 
cells O 
cultured O 
with O 
the O 
identified O 
drugs O 
possess O 
surface O 
and O 
intracellular O 
markers O 
characteristic O 
of O 
natural O 
Treg O 
cells O 
and O 
possess O 
suppressive O 
function O 
. O 
These O 
results O 
suggest O 
that O 
this O 
Treg O 
HTS O 
assay O 
can O 
be O 
used O 
to O 
screen O 
compound O 
libraries O 
to O 
identify O 
novel O 
chemical O 
entities O 
for O 
Treg O 
- O 
based O 
immune O 
therapies O 
. O 

effect O 
of O 
a O 
Cimicifuga O 
racemosa O 
extracts O 
Ze B-NO_CLASS 
450 I-NO_CLASS 
in O 
the O 
treatment O 
of O 
climacteric O 
complaints O 
- O 
an O 
observational O 
study O 
. O 

: O 
Root O 
extracts O 
of O 
Cimicifuga O 
racemosa O 
( O 
L O 
. O 
) O 
Nutt O 
. O 
have O 
been O 
successfully O 
used O 
in O 
the O 
treatment O 
of O 
climacteric O 
complaints O 
. O 
METHOD O 
: O 
In O 
this O 
observational O 
study O 
, O 
Cimicifuga O 
racemosa O 
( O 
CR O 
) O 
extract O 
Ze B-NO_CLASS 
450 I-NO_CLASS 
was O 
studied O 
in O 
442 O 
unselected O 
ambulatory O 
female O 
outpatients O 
with O 
menopausal O 
complaints O 
under O 
daily O 
practice O 
conditions O 
. O 
Physicians O 
were O 
suggested O 
to O 
treat O 
patients O 
for O 
the O 
first O 
3 O 
months O 
with O 
13mg O 
/ O 
d O 
CR O 
( O 
high O 
dose O 
, O 
HD O 
) O 
and O 
to O 
continue O 
over O 
additional O 
6 O 
months O 
either O 
with O 
this O 
treatment O 
or O 
to O 
switch O 
to O 
6.5mg O 
/ O 
d O 
CR O 
( O 
low O 
dose O 
, O 
LD O 
) O 
. O 
The O 
choice O 
of O 
treatment O 
and O 
its O 
dose O 
, O 
however O 
, O 
was O 
fully O 
at O 
the O 
discretion O 
of O 
the O 
physician O 
. O 
RESULTS O 
: O 
After O 
3-months O 
treatment O 
with O 
HD O 
, O 
symptom O 
severity O 
( O 
Kupperman O 
Menopause O 
Index O 
, O 
KMI O 
) O 
decreased O 
significantly O 
( O 
p O 
< O 
0.001 O 
) O 
from O 
baseline O 
values O 
. O 
Continuation O 
of O 
treatment O 
with O 
HD O 
or O 
LD O 
decreased O 
total O 
KMI O 
and O 
its O 
sub O 
- O 
item O 
scores O 
further O 
( O 
HD O 
, O 
LD O 
: O 
p O 
< O 
0.001 O 
) O 
. O 
However O 
, O 
more O 
patients O 
( O 
84.9% O 
) O 
responded O 
to O 
HD O 
than O 
to O 
LD O 
( O 
78.4% O 
) O 
and O 
showed O 
an O 
improvement O 
of O 
symptoms O 
( O 
p=0.011 O 
) O 
. O 
CONCLUSION O 
: O 
This O 
observational O 
study O 
demonstrated O 
that O 
treatment O 
with O 
CR O 
in O 
unselected O 
patients O 
with O 
climacteric O 
complaints O 
under O 
the O 
conditions O 
of O 
daily O 
practice O 
resulted O 
in O 
a O 
significant O 
improvement O 
of O 
menopausal O 
symptoms O 
assessed O 
by O 
the O 
total O 
KMI O 
score O 
and O 
its O 
sub O 
- O 
item O 
scores O 
with O 
an O 
effect O 
size O 
similar O 
to O 
that O 
in O 
a O 
previous O 
randomized O 
, O 
controlled O 
clinical O 
trial O 
. O 

this O 
study O 
we O 
investigated O 
the O 
relationship O 
between O 
several O 
selected O 
commercially O 
available O 
essential O 
oils O 
and O 
beta-lactam B-TRIVIAL 
antibiotics O 
on O 
their O 
antibacterial O 
effect O 
against O 
multidrug O 
resistant O 
bacteria O 
. O 
The O 
antibacterial O 
activity O 
of O 
essential O 
oils O 
and O 
antibiotics O 
was O 
assessed O 
using O 
broth O 
microdilution O 
. O 
The O 
combined O 
effects O 
between O 
essential O 
oils O 
of O 
cinnamon O 
bark O 
, O 
lavender O 
, O 
marjoram O 
, O 
tea O 
tree O 
, O 
peppermint O 
and O 
ampicillin B-TRIVIAL 
, O 
piperacillin B-TRIVIAL 
, O 
cefazolin B-TRIVIAL 
, O 
cefuroxime B-TRIVIAL 
, O 
carbenicillin B-TRIVIAL 
, O 
ceftazidime B-TRIVIAL 
, O 
meropenem B-TRIVIAL 
, O 
were O 
evaluated O 
by O 
means O 
of O 
the O 
checkerboard O 
method O 
against O 
beta-lactamase O 
- O 
producing O 
Escherichia O 
coli O 
. O 
In O 
the O 
latter O 
assays O 
, O 
fractional O 
inhibitory O 
concentration O 
( O 
FIC O 
) O 
values O 
were O 
calculated O 
to O 
characterize O 
interaction O 
between O 
the O 
combinations O 
. O 
Substantial O 
susceptibility O 
of O 
the O 
bacteria O 
toward O 
natural O 
antibiotics O 
and O 
a O 
considerable O 
reduction O 
in O 
the O 
minimum O 
inhibitory O 
concentrations O 
( O 
MIC O 
) O 
of O 
the O 
antibiotics O 
were O 
noted O 
in O 
some O 
paired O 
combinations O 
of O 
antibiotics O 
and O 
essential O 
oils O 
. O 
Out O 
of O 
35 O 
antibiotic O 
- O 
essential O 
oil O 
pairs O 
tested O 
, O 
four O 
of O 
them O 
showed O 
synergistic O 
effect O 
( O 
FIC≤0.5 O 
) O 
and O 
31 O 
pairs O 
showed O 
no O 
interaction O 
( O 
FIC O 
> O 
0.5-4.0 O 
) O 
. O 
The O 
preliminary O 
results O 
obtained O 
highlighted O 
the O 
occurrence O 
of O 
a O 
pronounced O 
synergistic O 
relationship O 
between O 
piperacillin B-TRIVIAL 
/ O 
cinnamon O 
bark O 
oil O 
, O 
piperacillin B-TRIVIAL 
/ O 
lavender O 
oil O 
, O 
piperacillin B-TRIVIAL 
/ O 
peppermint O 
oil O 
as O 
well O 
as O 
meropenem B-TRIVIAL 
/ O 
peppermint O 
oil O 
against O 
two O 
of O 
the O 
three O 
bacteria O 
under O 
study O 
with O 
a O 
FIC O 
index O 
in O 
the O 
range O 
0.26-0.5 O 
. O 
The O 
finding O 
highlighted O 
the O 
potential O 
of O 
peppermint O 
, O 
cinnamon O 
bark O 
and O 
lavender O 
essential O 
oils O 
being O 
as O 
antibiotic O 
resistance O 
modifying O 
agent O 
. O 
Reduced O 
usage O 
of O 
antibiotics O 
could O 
be O 
employed O 
as O 
a O 
treatment O 
strategy O 
to O 
decrease O 
the O 
adverse O 
effects O 
and O 
possibly O 
to O 
reverse O 
the O 
beta-lactam B-TRIVIAL 
antibiotic O 
resistance O 
. O 

new O 
tryptophan B-TRIVIAL 
derivatives O 
from O 
the O 
seed O 
kernels O 
of O 
Entada O 
rheedei O 
: O 
Effects O 
on O 
cell O 
viability O 
and O 
HIV O 
infectivity O 
. O 

new O 
tryptophan B-TRIVIAL 
derivatives O 
, O 
N-sulfonyl-L-tryptophan B-SYSTEMATIC 
( O 
tryptorheedei B-TRIVIAL 
A I-TRIVIAL 
) O 
( O 
1 O 
) O 
and O 
3-(N-sulfonylindolyl)-D-lactic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
tryptorheedei B-TRIVIAL 
B I-TRIVIAL 
) O 
( O 
2 O 
) O 
together O 
with O 
the O 
known O 
5-O-β-D-glucopyranosyl-2-hydroxyphenylacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
3 O 
) O 
, O 
1-O-methylglucopyranoside B-SYSTEMATIC 
, O 
entadamide B-TRIVIAL 
A I-TRIVIAL 
, O 
homogentisic B-TRIVIAL 
acid I-TRIVIAL 
and O 
3-O-β-D-glucopyranosyl-β-sitosterol B-TRIVIAL 
, O 
were O 
isolated O 
from O 
the O 
seed O 
kernels O 
of O 
Entada O 
rheedei O 
( O 
Mimosaceae O 
) O 
. O 
Their O 
structures O 
were O 
established O 
using O 
1D O 
and O 
2D O 
NMR O 
spectroscopy O 
, O 
mass O 
spectrometry O 
and O 
by O 
comparison O 
with O 
spectroscopic O 
data O 
reported O 
in O 
the O 
literature O 
. O 
Compounds O 
1 O 
and O 
2 O 
showed O 
no O 
toxicity O 
to O 
TZM O 
and O 
Human O 
PBMC O 
cells O 
. O 
Both O 
compounds O 
1 O 
and O 
2 O 
were O 
found O 
to O 
promote O 
early O 
infection O 
events O 
in O 
HIV O 
, O 
likely O 
by O 
inhibiting O 
the O 
enzyme O 
indolamine B-TRIVIAL 
2,3-dioxygenase O 
( O 
IDO O 
) O 
and O 
preventing O 
tryptophan B-TRIVIAL 
depletion O 
. O 
Inhibition O 
of O 
IDO O 
acutely O 
in O 
HIV O 
infection O 
inhibits O 
viral O 
replication O 
, O 
but O 
chronic O 
activation O 
of O 
IDO O 
leads O 
to O 
immune O 
impairment O 
in O 
AIDS O 
. O 
IDO O 
is O 
also O 
the O 
gatekeeper O 
enzyme O 
for O 
kynurenine B-TRIVIAL 
metabolism O 
, O 
a O 
pathway O 
involved O 
in O 
serotonin B-TRIVIAL 
and O 
melatonin O 
biosynthesis O 
and O 
the O 
regulation O 
of O 
glutamate B-TRIVIAL 
and O 
dopamine B-TRIVIAL 
levels O 
in O 
the O 
brain O 
. O 
Therefore O 
inhibition O 
of O 
IDO O 
might O 
explain O 
both O 
the O 
reported O 
medicinal O 
and O 
neuropsychiatric O 
effects O 
of O 
E O 
. O 
rheedei O 
. O 

conjugation O 
of O 
microcystin-RR B-TRIVIAL 
by O 
human O 
recombinant O 
GSTs O 
and O 
hepatic O 
cytosol O 
. O 

cyanobacterial O 
species O 
can O 
produce O 
cyanotoxins O 
, O 
among O 
which O 
mycrocistins B-FAMILY 
( O 
MC O 
) O 
are O 
a O 
group O 
of O 
≈100 O 
congeners O 
of O 
hepatotoxic O 
cyclic B-FAMILY 
heptapeptides I-FAMILY 
. O 
MC-RR B-ABBREVIATION 
differs O 
from O 
MC-LR B-ABBREVIATION 
, O 
the O 
most O 
studied O 
congener O 
only O 
for O 
one O 
residue O 
( O 
arginine B-TRIVIAL 
vs O 
leucine B-TRIVIAL 
) O 
, O 
resulting O 
in O 
a O 
ten O 
- O 
fold O 
difference O 
in O 
the O 
acute O 
toxicity O 
in O 
mice O 
. O 
Although O 
humans O 
may O 
be O 
exposed O 
to O 
MC O 
through O 
several O 
routes O 
and O 
kinetics O 
appeared O 
to O 
be O 
the O 
major O 
factor O 
affecting O 
congener O 
- O 
specific O 
toxicity O 
, O 
little O 
is O 
known O 
on O 
MC O 
metabolism O 
. O 
The O 
accepted O 
pathway O 
for O 
MC O 
detoxication O 
is O 
GSH B-ABBREVIATION 
conjugation O 
: O 
here O 
the O 
MC-RR B-ABBREVIATION 
conjugation O 
with O 
GSH B-ABBREVIATION 
catalyzed O 
by O 
5 O 
recombinant O 
human O 
GSTs O 
and O 
human O 
liver O 
cytosol O 
( O 
HLC O 
) O 
has O 
been O 
characterized O 
and O 
appeared O 
to O 
be O 
more O 
efficient O 
than O 
MC-LR B-ABBREVIATION 
conjugation O 
. O 
The O 
catalytic O 
efficiency O 
score O 
is O 
T1-1 O 
> O 
A1-1≈P1-1 O 
> O 
M1-1 O 
> O 
A3-3 O 
( O 
0.161-0.056pmol O 
GSMC-RR O 
(μgproteinminμM)(-1) O 
) O 
. O 
In O 
HLC O 
the O 
spontaneous O 
reaction O 
is O 
favored O 
vs O 
the O 
enzymatic O 
one O 
( O 
ratio O 
3 O 
: O 
1 O 
) O 
at O 
physiological O 
GSH B-ABBREVIATION 
content O 
. O 
However O 
, O 
at O 
low O 
MC-RR B-ABBREVIATION 
concentrations O 
, O 
representative O 
of O 
repeated O 
oral O 
exposure O 
, O 
and O 
low O 
GSH B-ABBREVIATION 
content O 
( O 
down O 
to O 
0.05mM O 
) O 
, O 
possibly O 
associated O 
to O 
exposure O 
to O 
drugs O 
or O 
in O 
patients O 
affected O 
by O 
several O 
pathologies O 
, O 
the O 
relevance O 
of O 
the O 
enzymatic O 
reaction O 
progressively O 
increases O 
, O 
providing O 
the O 
predominant O 
contribution O 
to O 
MC-RR B-ABBREVIATION 
detoxication O 
. O 

glucocorticoid O 
receptor-ERK O 
signaling O 
pathway O 
contributes O 
to O 
ginsenoside B-TRIVIAL 
Rg1 I-TRIVIAL 
protection O 
against O 
β-amyloid O 
peptide-induced O 
human O 
endothelial O 
cells O 
apoptosis O 
. O 

deposition O 
of O 
β-amyloid O 
( O 
Aβ O 
) O 
in O 
neurons O 
and O 
vascular O 
cells O 
of O 
the O 
brain O 
has O 
been O 
characterized O 
in O 
Alzheimer's O 
disease O 
. O 
Ginsenoside B-TRIVIAL 
Rg1 I-TRIVIAL 
( O 
Rg1 B-ABBREVIATION 
) O 
is O 
an O 
active O 
components O 
in O 
Panax O 
ginseng O 
, O 
a O 
famous O 
traditional O 
Chinese O 
medicines O 
recorded O 
in O 
Compendium O 
of O 
Materia O 
Medica O 
. O 
Present O 
study O 
attempted O 
to O 
evaluate O 
the O 
potential O 
mechanisms O 
of O 
Aβ O 
- O 
mediated O 
insult O 
and O 
the O 
protective O 
effects O 
of O 
Rg1 B-ABBREVIATION 
on O 
human O 
endothelial O 
cells O 
. O 
Rg1 B-ABBREVIATION 
attenuated O 
the O 
Aβ25-35-associated O 
mitochondrial O 
apoptotic O 
events O 
, O 
accompanied O 
by O 
inhibiting O 
HIF-1α O 
expression O 
followed O 
by O 
intracellular O 
reactive O 
nitrogen B-SYSTEMATIC 
species O 
generation O 
, O 
and O 
protein O 
nitrotyrosination O 
. O 
These O 
protective O 
effects O 
were O 
abolished O 
by O 
glucocorticoid O 
receptor O 
( O 
GR O 
) O 
antagonist O 
RU486 B-IDENTIFIER 
or O 
p-ERK O 
inhibitor O 
U0126 B-IDENTIFIER 
rather O 
than O 
estrogen B-FAMILY 
receptor O 
α O 
antagonist O 
ICI B-IDENTIFIER 
82780 I-IDENTIFIER 
. O 
Taken O 
together O 
, O 
our O 
results O 
suggested O 
that O 
Rg1 B-ABBREVIATION 
protected O 
against O 
Aβ25-35-induced O 
apoptosis O 
at O 
least O 
in O 
part O 
by O 
two O 
complementary O 
GR-dependent O 
ERK O 
phosphorylation O 
pathways O 
: O 
( O 
1 O 
) O 
down O 
- O 
regulating O 
HIF-1α O 
initiated O 
protein O 
nitrotyrosination O 
, O 
and O 
( O 
2 O 
) O 
inhibiting O 
mitochondrial O 
apoptotic O 
cascades O 
. O 
These O 
data O 
provided O 
a O 
novel O 
insight O 
to O 
the O 
mechanisms O 
of O 
Rg1 B-ABBREVIATION 
protective O 
effects O 
on O 
Aβ25-35-induced O 
endothelial O 
cells O 
apoptosis O 
, O 
suggesting O 
that O 
GR-ERK O 
signaling O 
pathway O 
might O 
play O 
an O 
important O 
role O 
in O 
it O 
. O 

to O 
2,4-dichlorophenoxyacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
alters O 
glucose B-TRIVIAL 
metabolism O 
in O 
immature O 
rat O 
Sertoli O 
cells O 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
effects O 
of O 
2,4-D B-SYSTEMATIC 
, O 
an O 
herbicide O 
used O 
worldwide O 
also O 
known O 
as O 
endocrine O 
disruptor O 
, O 
in O 
Sertoli O 
cell O 
( O 
SC O 
) O 
metabolism O 
. O 
Immature O 
rat O 
SCs O 
were O 
maintained O 
50h O 
under O 
basal O 
conditions O 
or O 
exposed O 
to O 
2,4-D B-SYSTEMATIC 
( O 
100nM O 
, O 
10μM O 
and O 
1mM O 
) O 
. O 
SCs O 
exposed O 
to O 
10μM O 
and O 
1mM O 
of O 
2,4-D B-SYSTEMATIC 
presented O 
lower O 
intracellular O 
glucose B-TRIVIAL 
and O 
lactate B-FAMILY 
content O 
. O 
Exposure O 
to O 
10μM O 
of O 
2,4-D B-SYSTEMATIC 
induced O 
a O 
significant O 
decrease O 
in O 
glucose B-TRIVIAL 
transporter-3 O 
mRNA O 
levels O 
and O 
phosphofructokinase-1 O 
mRNA O 
levels O 
decreased O 
in O 
cells O 
exposed O 
to O 
100nM O 
and O 
10μM O 
of O 
2,4-D B-SYSTEMATIC 
. O 
Exposure O 
to O 
100nM O 
and O 
10μM O 
also O 
induced O 
a O 
decrease O 
in O 
lactate B-FAMILY 
dehydrogenase O 
( O 
LDH O 
) O 
mRNA O 
levels O 
while O 
the O 
LDH O 
protein O 
levels O 
were O 
only O 
decreased O 
in O 
cells O 
exposed O 
to O 
1mM O 
of O 
2,4-D B-SYSTEMATIC 
. O 
Exposure O 
to O 
2,4-D B-SYSTEMATIC 
altered O 
glucose B-TRIVIAL 
uptake O 
and O 
metabolization O 
in O 
SCs O 
, O 
as O 
well O 
as O 
lactate B-FAMILY 
metabolism O 
and O 
export O 
that O 
may O 
result O 
in O 
impaired O 
spermatogenesis O 
. O 

of O 
some O 
novel O 
thieno[3,2-d]pyrimidines B-FAMILY 
as O 
potential O 
cytotoxic O 
small O 
molecules O 
against O 
breast O 
cancer O 
. O 

variety O 
of O 
novel O 
thieno[3,2-d]pyrimidines B-FAMILY 
with O 
different O 
decorating O 
functional O 
groups O 
were O 
synthesized O 
as O 
a O 
part O 
of O 
a O 
study O 
aiming O 
to O 
enrich O 
the O 
arsenal O 
of O 
chemotherapeutic O 
agents O 
for O 
the O 
treatment O 
of O 
cancer O 
. O 
The O 
design O 
of O 
synthetic O 
molecules O 
based O 
on O 
DNA-interchelating O 
properties O 
by O 
hydrogen B-SYSTEMATIC 
bond O 
formation O 
. O 
The O 
reported O 
compounds O 
herein O 
are O 
: O 
4-aminothienopyrimidine B-SYSTEMATIC 
derivatives O 
4a,b O 
and O 
their O 
4- B-SYSTEMATIC 
substituted I-SYSTEMATIC 
phenylamino I-SYSTEMATIC 
analogues O 
8a,b O 
; O 
4-thienopyrimidin-4-ones B-FAMILY 
5a,b O 
; O 
N-alkyl B-FAMILY 
thienopyrimidin-4-ones I-FAMILY 
6a-g O 
; O 
4-chlorothienopyrimidines B-FAMILY 
7a,b O 
; O 
and O 
thienopyrimidoquinazolinones B-FAMILY 
9a,b O 
which O 
are O 
the O 
structural O 
mimics O 
of O 
8a,b O 
. O 
The O 
synthesized O 
molecules O 
were O 
evaluated O 
for O 
their O 
in O 
vitro O 
cytotoxic O 
activity O 
against O 
human O 
breast O 
cancer O 
cell O 
line O 
( O 
MCF-7 O 
) O 
. O 
Biological O 
screening O 
revealed O 
varying O 
cytotoxic O 
potencies O 
of O 
the O 
tested O 
molecules O 
compared O 
with O 
Doxorubicin B-TRIVIAL 
as O 
a O 
reference O 
drug O 
. O 
The O 
cytotoxicity O 
results O 
from O 
the O 
study O 
suggested O 
that O 
the O 
synthesized O 
molecules O 
are O 
potential O 
antitumor O 
agents O 
and O 
compound O 
4a O 
was O 
the O 
most O 
potent O 
with O 
an O 
IC O 
50 O 
2.04 O 
nM O 
. O 

Tolerance O 
and O 
Removal O 
from O 
Cunninghamella O 
elegans O 
Related O 
to O 
the O 
Polyphosphate O 
Metabolism O 
. O 

aim O 
of O 
the O 
present O 
work O 
was O 
to O 
study O 
the O 
cadmium B-SYSTEMATIC 
effects O 
on O 
growth O 
, O 
ultrastructure O 
and O 
polyphosphate O 
metabolism O 
, O 
as O 
well O 
as O 
to O 
evaluate O 
the O 
metal O 
removal O 
and O 
accumulation O 
by O 
Cunninghamella O 
elegans O 
( O 
IFM O 
46109 O 
) O 
growing O 
in O 
culture O 
medium O 
. O 
The O 
presence O 
of O 
cadmium B-SYSTEMATIC 
reduced O 
growth O 
, O 
and O 
a O 
longer O 
lag O 
phase O 
was O 
observed O 
. O 
However O 
, O 
the O 
phosphate B-SYSTEMATIC 
uptake O 
from O 
the O 
culture O 
medium O 
increased O 
15% O 
when O 
compared O 
to O 
the O 
control O 
. O 
Moreover O 
, O 
C O 
. O 
elegans O 
removed O 
70%-81% O 
of O 
the O 
cadmium B-SYSTEMATIC 
added O 
to O 
the O 
culture O 
medium O 
during O 
its O 
growth O 
. O 
The O 
C O 
. O 
elegans O 
mycelia O 
showed O 
a O 
removal O 
efficiency O 
of O 
280 O 
mg O 
/ O 
g O 
at O 
a O 
cadmium B-SYSTEMATIC 
concentration O 
of O 
22.1 O 
mg O 
/ O 
L O 
, O 
and O 
the O 
removal O 
velocity O 
of O 
cadmium B-SYSTEMATIC 
was O 
0.107 O 
mg O 
/ O 
h O 
. O 
Additionally O 
, O 
it O 
was O 
observed O 
that O 
cadmium B-SYSTEMATIC 
induced O 
vacuolization O 
, O 
the O 
presence O 
of O 
electron O 
dense O 
deposits O 
in O 
vacuoles O 
, O 
cytoplasm O 
and O 
cell O 
membranes O 
, O 
as O 
well O 
as O 
the O 
distinct O 
behavior O 
of O 
polyphosphate O 
fractions O 
. O 
The O 
results O 
obtained O 
with O 
C O 
. O 
elegans O 
suggest O 
that O 
precipitation O 
, O 
vacuolization O 
and O 
polyphosphate O 
fractions O 
were O 
associated O 
to O 
cadmium B-SYSTEMATIC 
tolerance O 
, O 
and O 
this O 
species O 
demonstrated O 
a O 
higher O 
potential O 
for O 
bioremediation O 
of O 
heavy O 
metals O 
. O 

Stability O 
of O 
the O 
Lipid O 
Phase O 
in O 
Concentrated O 
Beverage O 
Emulsions O 
Colored O 
with O 
Natural O 
β-Carotene B-TRIVIAL 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
oxidation O 
of O 
selected O 
plant O 
oils O 
in O 
concentrated O 
beverage O 
emulsions O 
colored O 
with O 
natural O 
β-carotene B-TRIVIAL 
. O 
Carotenoid O 
preparations O 
obtained O 
from O 
carrots O 
were O 
dissolved O 
in O 
cold O 
- O 
pressed O 
linseed O 
oil O 
, O 
refined O 
canola O 
oil O 
, O 
and O 
refined O 
palm O 
olein O 
. O 
Oxidative O 
stability O 
of O 
the O 
lipids O 
was O 
examined O 
with O 
and O 
without O 
addition O 
of O 
the O 
pigment O 
to O 
the O 
oil O 
/ O 
water O 
( O 
O O 
/ O 
W O 
) O 
emulsion O 
. O 
Carotenoid O 
/ O 
lipid O 
hydro B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
LOOH O 
) O 
concentration O 
was O 
evaluated O 
using O 
two O 
different O 
methods O 
: O 
LOOH O 
+ O 
Fe(2+) B-FORMULA 
reaction O 
connected O 
with O 
a O 
colored O 
complex O 
of O 
ammonium B-SYSTEMATIC 
thiocyanate I-SYSTEMATIC 
determined O 
with O 
the O 
help O 
of O 
a O 
spectrophotometer O 
, O 
and O 
LOOH O 
determined O 
with O 
the O 
help O 
of O 
a O 
chemiluminometer O 
. O 
It O 
was O 
shown O 
that O 
oxidation O 
rate O 
of O 
lipids O 
in O 
the O 
O O 
/ O 
W O 
emulsions O 
strongly O 
depended O 
on O 
chemical O 
composition O 
of O 
the O 
lipid O 
fraction O 
( O 
type O 
of O 
oil O 
used O 
) O 
. O 
Presence O 
of O 
the O 
carotenoid O 
pigment O 
increased O 
the O 
rate O 
. O 
Therefore O 
, O 
if O 
a O 
carotenoid O 
- O 
containing O 
emulsion O 
is O 
to O 
be O 
stable O 
, O 
it O 
should O 
be O 
based O 
on O 
oils O 
of O 
a O 
high O 
oxidative O 
stability O 
. O 

Relationship O 
Between O 
Serum O 
Calcium B-SYSTEMATIC 
Level O 
, O 
Blood O 
Lipids O 
, O 
and O 
Blood O 
Pressure O 
in O 
Hypertensive O 
and O 
Normotensive O 
Subjects O 
who O 
Come O 
from O 
a O 
Normal O 
University O 
in O 
East O 
of O 
China O 
. O 

studies O 
revealed O 
that O 
low O 
calcium B-SYSTEMATIC 
intake O 
is O 
related O 
to O 
high O 
prevalence O 
of O 
cardiovascular O 
diseases O 
such O 
as O 
hypertension O 
. O 
However O 
, O 
the O 
relationship O 
between O 
serum O 
calcium B-SYSTEMATIC 
and O 
blood O 
pressure O 
was O 
unclear O 
. O 
The O 
prevalence O 
of O 
hypertension O 
is O 
high O 
in O 
China O 
. O 
Thus O 
, O 
the O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
serum O 
calcium B-SYSTEMATIC 
level O 
between O 
hypertensive O 
and O 
normotensive O 
groups O 
and O 
to O 
investigate O 
the O 
correlation O 
between O 
serum O 
calcium B-SYSTEMATIC 
, O 
blood O 
pressure O 
, O 
and O 
blood O 
lipid O 
parameters O 
. O 
A O 
total O 
of O 
1135 O 
adult O 
subjects O 
participated O 
in O 
this O 
study O 
and O 
were O 
divide O 
into O 
two O 
study O 
groups O 
: O 
a O 
hypertensive O 
group O 
( O 
n O 
= O 
316 O 
) O 
who O 
had O 
140 O 
mmHg O 
or O 
higher O 
in O 
systolic O 
blood O 
pressure O 
( O 
SBP O 
) O 
or O 
90 O 
mmHg O 
or O 
higher O 
in O 
diastolic O 
blood O 
pressure O 
( O 
DBP O 
) O 
and O 
an O 
age- O 
and O 
sex O 
- O 
matched O 
normotensive O 
group O 
( O 
n O 
= O 
819 O 
, O 
120 O 
mmHg O 
or O 
less O 
SBP O 
and O 
80 O 
mmHg O 
or O 
less O 
DBP O 
) O 
. O 
Our O 
results O 
indicate O 
a O 
significant O 
trend O 
for O 
men O 
( O 
60 O 
years O 
old O 
or O 
older O 
) O 
in O 
the O 
direction O 
of O 
decreasing O 
blood O 
pressure O 
with O 
increasing O 
serum O 
calcium B-SYSTEMATIC 
level O 
, O 
but O 
no O 
trend O 
for O 
women O 
was O 
indicated O 
. O 
In O 
the O 
normotensive O 
group O 
, O 
a O 
significant O 
positive O 
correlation O 
was O 
found O 
between O 
DBP O 
and O 
total O 
cholesterol B-TRIVIAL 
( O 
P O 
< O 
0.01 O 
) O 
and O 
triglyceride B-FAMILY 
( O 
P O 
< O 
0.01 O 
) O 
, O 
Likewise O 
, O 
triglyceride B-FAMILY 
was O 
positively O 
correlated O 
with O 
SBP O 
( O 
P O 
< O 
0.01 O 
) O 
. O 
Overall O 
, O 
these O 
data O 
suggest O 
that O 
serum O 
calcium B-SYSTEMATIC 
may O 
have O 
an O 
influence O 
in O 
the O 
blood O 
pressure O 
of O 
older O 
male O 
subjects O 
with O 
hypertension O 
and O 
in O 
blood O 
lipid O 
profiles O 
of O 
normotensive O 
subjects O 
. O 

is O 
a O 
homolog O 
of O 
eukaryotic O 
tubulin O 
that O 
is O 
widely O 
conserved O 
among O 
bacteria O 
and O 
coordinates O 
the O 
assembly O 
of O 
the O 
cell O 
division O 
machinery O 
. O 
FtsZ O 
plays O 
a O 
central O 
role O 
in O 
cell O 
replication O 
and O 
is O 
a O 
target O 
of O 
interest O 
for O 
antibiotic O 
development O 
. O 
Several O 
FtsZ O 
inhibitors O 
have O 
been O 
reported O 
. O 
We O 
characterized O 
the O 
mechanism O 
of O 
these O 
compounds O 
in O 
bacteria O 
and O 
found O 
that O 
many O 
of O 
them O 
disrupt O 
the O 
localization O 
of O 
membrane O 
- O 
associated O 
proteins O 
, O 
including O 
FtsZ O 
, O 
by O 
reducing O 
the O 
transmembrane O 
potential O 
or O 
perturbing O 
membrane O 
permeability O 
. O 
We O 
tested O 
whether O 
the O 
reported O 
phenotypes O 
of O 
a O 
broad O 
collection O 
of O 
FtsZ O 
inhibitors O 
disrupt O 
the O 
transmembrane O 
potential O 
in O 
Bacillus O 
subtilis O 
strain O 
168 O 
. O 
Using O 
a O 
combination O 
of O 
flow O 
cytometry O 
and O 
microscopy O 
, O 
we O 
found O 
that O 
zantrin B-TRIVIAL 
Z1 I-TRIVIAL 
, O 
cinnamaldehyde B-TRIVIAL 
, O 
totarol B-TRIVIAL 
, O 
sanguinarine B-TRIVIAL 
, O 
and O 
viriditoxin B-TRIVIAL 
decreased O 
the O 
B O 
. O 
subtilis O 
transmembrane O 
potential O 
or O 
perturbed O 
membrane O 
permeability O 
, O 
and O 
influenced O 
the O 
localization O 
of O 
the O 
membrane O 
- O 
associated O 
, O 
division O 
protein O 
MinD O 
. O 
These O 
studies O 
demonstrate O 
that O 
small O 
molecules O 
that O 
disrupt O 
membrane O 
function O 
in O 
bacterial O 
cells O 
produce O 
phenotypes O 
that O 
are O 
similar O 
to O 
the O 
inhibition O 
of O 
proteins O 
associated O 
with O 
membranes O 
in O 
vivo O 
, O 
including O 
bacterial O 
cytoskeleton O 
homologs O 
, O 
such O 
as O 
FtsZ O 
. O 
The O 
results O 
provide O 
a O 
new O 
dimension O 
for O 
consideration O 
in O 
the O 
design O 
and O 
testing O 
of O 
inhibitors O 
of O 
bacterial O 
targets O 
that O 
are O 
membrane O 
- O 
associated O 
and O 
provide O 
additional O 
insight O 
into O 
the O 
structural O 
characteristics O 
of O 
antibiotics O 
that O 
disrupt O 
the O 
membrane O 
. O 

: O 
In O 
familial O 
hypercholesterolemia O 
( O 
FH O 
) O 
, O 
the O 
metabolism O 
and O 
anti-atherogenic O 
functions O 
of O 
HDL O 
can O 
be O 
affected O 
by O 
the O 
continuous O 
interactions O 
with O 
excess O 
LDL O 
amounts O 
. O 
Here O 
, O 
lipid O 
transfers O 
to O 
HDL O 
, O 
an O 
important O 
step O 
for O 
HDL O 
intravascular O 
metabolism O 
and O 
for O 
HDL O 
role O 
in O 
reverse O 
cholesterol B-TRIVIAL 
transport O 
( O 
RCT O 
) O 
were O 
investigated O 
in O 
FH O 
patients O 
. O 
METHODS O 
: O 
Seventy O 
- O 
one O 
FH O 
patients O 
( O 
39±15years O 
, O 
LDL- O 
cholesterol B-TRIVIAL 
= O 
274±101 O 
; O 
HDL- O 
cholesterol B-TRIVIAL 
= O 
50±14mg O 
/ O 
dl O 
) O 
and O 
66 O 
normolipidemic O 
subjects O 
( O 
NL O 
) O 
( O 
38±11years O 
, O 
LDL- O 
cholesterol B-TRIVIAL 
= O 
105±27 O 
; O 
HDL- O 
cholesterol B-TRIVIAL 
= O 
52±12mg O 
/ O 
dl O 
) O 
were O 
studied O 
. O 
In O 
vitro O 
, O 
lipid O 
transfers O 
were O 
evaluated O 
by O 
incubation O 
of O 
plasma O 
samples O 
( O 
37°C O 
, O 
1h O 
) O 
with O 
a O 
donor O 
lipid O 
nanoemulsion O 
labeled O 
with O 
3H-triglycerides B-FAMILY 
( O 
TG O 
) O 
and O 
14C B-FORMULA 
-unesterified O 
cholesterol B-TRIVIAL 
( O 
UC O 
) O 
or O 
with O 
3H-cholesteryl B-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
EC O 
) O 
and O 
14C B-FORMULA 
-phospholipids O 
( O 
PL O 
) O 
. O 
Radioactivity O 
was O 
counted O 
at O 
the O 
HDL O 
fraction O 
after O 
chemical O 
precipitation O 
of O 
apolipoprotein O 
( O 
apo O 
) O 
B O 
- O 
containing O 
lipoproteins O 
and O 
the O 
nanoemulsion O 
. O 
Data O 
are O 
% O 
of O 
total O 
radioactivity O 
measured O 
in O 
the O 
HDL O 
fraction O 
. O 
RESULTS O 
: O 
Transfer O 
of O 
UC O 
to O 
HDL O 
was O 
lower O 
in O 
FH O 
than O 
in O 
NL O 
( O 
5.6±2.1 O 
vs O 
6.7±2.0% O 
, O 
p=0.0005 O 
) O 
whereas O 
TG O 
( O 
5.5±3.1 O 
vs O 
3.7±0.9% O 
, O 
p=0.018 O 
) O 
and O 
PL O 
( O 
20.9±4.6 O 
vs O 
18.2±3.7 O 
% O 
, O 
p=0.023 O 
) O 
transfers O 
were O 
higher O 
in O 
FH O 
. O 
EC O 
transfer O 
was O 
equal O 
. O 
By O 
multivariate O 
analysis O 
, O 
transfers O 
of O 
all O 
four O 
lipids O 
correlated O 
with O 
HDL- O 
cholesterol B-TRIVIAL 
and O 
with O 
apo O 
A-I O 
. O 
CONCLUSION O 
: O 
FH O 
elicited O 
marked O 
changes O 
in O 
three O 
of O 
the O 
four O 
tested O 
lipid O 
transfers O 
to O 
HDL O 
. O 
The O 
entry O 
of O 
UC O 
into O 
HDL O 
for O 
subsequent O 
esterification O 
is O 
an O 
important O 
driving O 
force O 
for O 
RCT O 
and O 
reduction O 
of O 
UC O 
transfer O 
to O 
HDL O 
was O 
previously O 
associated O 
to O 
precocious O 
coronary O 
heart O 
disease O 
. O 
Therefore O 
, O 
in O 
FH O 
, O 
HDL O 
functions O 
can O 
be O 
lessened O 
, O 
which O 
can O 
also O 
contribute O 
to O 
atherogenesis O 
. O 

, O 
synthesis O 
and O 
biological O 
activity O 
of O 
multifunctional O 
α,β- B-FAMILY 
unsaturated I-FAMILY 
carbonyl I-FAMILY 
scaffolds O 
for O 
Alzheimer's O 
disease O 
. O 

series O 
of O 
compounds O 
containing O 
an O 
α,β- B-FAMILY 
unsaturated I-FAMILY 
carbonyl I-FAMILY 
moiety O 
, O 
such O 
as O 
chalcones B-FAMILY 
and O 
coumarins B-FAMILY 
were O 
designed O 
, O 
synthesized O 
and O 
tested O 
in O 
a O 
variety O 
of O 
assays O 
to O 
assess O 
their O 
potential O 
as O 
anti-Alzheimer's O 
disease O 
( O 
AD O 
) O 
agents O 
. O 
The O 
investigations O 
included O 
the O 
inhibition O 
of O 
cholinesterases O 
( O 
AChE O 
, O 
BuChE O 
) O 
, O 
the O 
inhibition O 
of O 
amyloid O 
beta O 
( O 
Aβ O 
) O 
self O 
- O 
assembly O 
and O 
the O 
disassembly O 
of O 
preformed O 
Aβ O 
oligomers O 
. O 
Several O 
compounds O 
showed O 
excellent O 
potential O 
as O 
multifunctional O 
compounds O 
for O 
AD O 
. O 
Docking O 
studies O 
for O 
16 O 
that O 
performed O 
well O 
in O 
all O 
the O 
assays O 
gave O 
a O 
clear O 
interpretation O 
of O 
various O 
interactions O 
in O 
the O 
gorge O 
of O 
AChE O 
. O 
Based O 
on O 
the O 
results O 
, O 
the O 
long O 
- O 
chain O 
coumarin B-TRIVIAL 
scaffold O 
appears O 
to O 
be O 
a O 
promising O 
structural O 
template O 
for O 
further O 
AD O 
drug O 
development O 
. O 

Pyridinone B-FAMILY 
Derivatives O 
As O 
Non- O 
Nucleoside B-FAMILY 
Reverse O 
Transcriptase O 
Inhibitors O 
( O 
NNRTIs O 
) O 
with O 
High O 
Potency O 
against O 
NNRTI-Resistant O 
HIV-1 O 
Strains O 
. O 

6- B-FAMILY 
substituted-4-cycloalkyloxy-pyridin-2(1H)-ones I-FAMILY 
were O 
synthesized O 
as O 
non- O 
nucleoside B-FAMILY 
reverse O 
transcriptase O 
inhibitors O 
( O 
NNRTIs O 
) O 
, O 
and O 
their O 
biological O 
activity O 
was O 
evaluated O 
. O 
Most O 
of O 
the O 
compounds O 
, O 
especially O 
26 O 
and O 
22 O 
, O 
bearing O 
a O 
3-isopropyl B-SYSTEMATIC 
and O 
3-iodine B-SYSTEMATIC 
group O 
, O 
respectively O 
, O 
exhibited O 
highly O 
potent O 
activity O 
against O 
wild O 
- O 
type O 
HIV-1 O 
strains O 
and O 
those O 
resistant O 
to O 
reverse O 
transcriptase O 
inhibitors O 
( O 
RTIs O 
) O 
. O 
The O 
diastereoisomers O 
of O 
26-trans O 
and O 
26-cis O 
were O 
synthesized O 
separately O 
and O 
confirmed O 
with O 
HPLC O 
and O 
NOESY O 
spectra O 
. O 
The O 
26-trans O 
isomers O 
had O 
an O 
activity O 
about O 
400-fold O 
more O 
potent O 
than O 
that O 
of O 
26-cis O 
. O 
The O 
pair O 
of O 
26-trans O 
enantiomers O 
, O 
one O 
of O 
the O 
most O 
potent O 
inhibitors O 
with O 
EC50 O 
of O 
4 O 
nM O 
and O 
selectivity O 
index O 
( O 
SI O 
) O 
of O 
75000 O 
, O 
was O 
highly O 
effective O 
against O 
a O 
panel O 
of O 
RTIs-resistant O 
strains O 
with O 
single O 
( O 
Y181C O 
and O 
K103N O 
) O 
or O 
double O 
( O 
A17 O 
) O 
mutations O 
in O 
reverse O 
transcriptase O 
. O 
The O 
results O 
suggest O 
that O 
these O 
novel O 
pyridinone B-FAMILY 
derivatives O 
have O 
the O 
potential O 
to O 
be O 
further O 
developed O 
as O 
new O 
antiretroviral O 
drugs O 
with O 
improved O 
antiviral O 
efficacy O 
and O 
drug O 
resistance O 
profile O 
. O 

and O 
Analgesic O 
Effects O 
of O 
Maslinic B-TRIVIAL 
Acid I-TRIVIAL 
, O 
a O 
Pentacyclic B-FAMILY 
Triterpenoid I-FAMILY 
from O 
Olea O 
europaea O 
. O 

effects O 
of O 
maslinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
1 O 
) O 
, O 
a O 
pentacyclic B-FAMILY 
triterpenoid I-FAMILY 
obtained O 
from O 
Olea O 
europaea O 
, O 
were O 
studied O 
in O 
several O 
tests O 
for O 
nociception O 
in O 
mice O 
. O 
Systemic O 
administration O 
of O 
1 O 
reduced O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-induced O 
writhing O 
, O 
the O 
inflammatory O 
phase O 
of O 
formalin B-TRIVIAL 
-induced O 
pain O 
, O 
and O 
capsaicin B-TRIVIAL 
-induced O 
mechanical O 
allodynia O 
. O 
However O 
, O 
it O 
did O 
not O 
induce O 
motor O 
incoordination O 
in O 
the O 
rotarod O 
test O 
. O 
The O 
topical O 
administration O 
of O 
1 O 
also O 
reduced O 
the O 
inflammatory O 
phase O 
of O 
the O 
formalin B-TRIVIAL 
test O 
, O 
indicating O 
that O 
at O 
least O 
some O 
of O 
its O 
effects O 
are O 
mediated O 
peripherally O 
. O 
The O 
present O 
results O 
demonstrate O 
for O 
the O 
first O 
time O 
that O 
maslinic B-TRIVIAL 
acid I-TRIVIAL 
induces O 
antinociceptive O 
and O 
antiallodynic O 
effects O 
. O 

from O 
HLA-B*57 O 
: O 
01+ O 
Human O 
Subjects O 
Are O 
Activated O 
with O 
Abacavir B-TRIVIAL 
through O 
Two O 
Independent O 
Pathways O 
and O 
Induce O 
Cell O 
Death O 
by O 
Multiple O 
Mechanisms O 
. O 

to O 
abacavir O 
hypersensitivity O 
has O 
been O 
attributed O 
to O 
possession O 
of O 
the O 
specific O 
human O 
leukocyte O 
antigen O 
allele O 
HLA-B*57 O 
: O 
1 O 
. O 
HLA-B*57 O 
: O 
01-restricted O 
activation O 
of O 
CD8+ O 
T-cells O 
provides O 
a O 
link O 
between O 
the O 
genetic O 
association O 
and O 
the O 
iatrogenic O 
disease O 
. O 
The O 
objectives O 
of O 
this O 
study O 
were O 
to O 
characterize O 
the O 
functionality O 
of O 
drug O 
- O 
responsive O 
CD8+ O 
T-cell O 
clones O 
generated O 
from O 
HLA-B*57 O 
: O 
01+ O 
drug O 
- O 
naive O 
subjects O 
and O 
to O 
explore O 
the O 
relationship O 
between O 
abacavir B-TRIVIAL 
accumulation O 
in O 
antigen O 
presenting O 
cells O 
and O 
the O 
T-cell O 
response O 
. O 
Seventy O 
- O 
four O 
CD8+ O 
clones O 
expressing O 
different O 
Vβ O 
receptors O 
were O 
shown O 
to O 
proliferate O 
and O 
kill O 
target O 
cells O 
via O 
different O 
mechanisms O 
when O 
exposed O 
to O 
abacavir B-TRIVIAL 
. O 
Certain O 
clones O 
were O 
activated O 
with O 
abacavir B-TRIVIAL 
in O 
the O 
absence O 
of O 
antigen O 
presenting O 
cells O 
. O 
Analysis O 
of O 
the O 
remaining O 
clones O 
revealed O 
two O 
pathways O 
of O 
drug O 
- O 
dependent O 
T-cell O 
activation O 
. O 
Overnight O 
incubation O 
of O 
antigen O 
presenting O 
cells O 
with O 
abacavir B-TRIVIAL 
, O 
followed O 
by O 
repeated O 
washing O 
to O 
remove O 
soluble O 
drug O 
, O 
activated O 
approximately O 
50% O 
of O 
the O 
clones O 
, O 
and O 
the O 
response O 
was O 
blocked O 
by O 
glutaraldehyde B-TRIVIAL 
fixation O 
. O 
In O 
contrast O 
, O 
a O 
1 O 
h O 
antigen O 
presenting O 
cell O 
pulse O 
did O 
not O 
activate O 
any O 
of O 
the O 
clones O 
. O 
Accumulation O 
of O 
abacavir B-TRIVIAL 
in O 
antigen O 
presenting O 
cells O 
was O 
rapid O 
( O 
less O 
than O 
1 O 
h O 
) O 
, O 
and O 
the O 
intracellular O 
concentrations O 
were O 
maintained O 
for O 
16 O 
h O 
. O 
However O 
, O 
intracellular O 
abacavir B-TRIVIAL 
was O 
not O 
detectable O 
by O 
mass O 
spectrometry O 
after O 
pulsing O 
. O 
These O 
data O 
suggest O 
that O 
T-cells O 
can O 
be O 
activated O 
by O 
abacavir B-TRIVIAL 
through O 
a O 
direct O 
interaction O 
with O 
surface O 
and O 
intracellular O 
major O 
histocompatibility O 
complex O 
( O 
MHC O 
) O 
molecules O 
. O 
With O 
the O 
former O 
, O 
abacavir B-TRIVIAL 
seemingly O 
participates O 
in O 
the O 
MHC O 
T-cell O 
receptor O 
binding O 
interaction O 
. O 
In O 
contrast O 
, O 
the O 
latter O 
pathway O 
likely O 
involves O 
MHC O 
binding O 
peptides O 
displayed O 
as O 
a O 
consequence O 
of O 
abacavir B-TRIVIAL 
exposure O 
, O 
but O 
not O 
abacavir B-TRIVIAL 
itself O 
. O 

smoke O 
, O 
diesel O 
exhaust O 
, O 
and O 
other O 
combustion O 
- O 
derived O 
particles O 
activate O 
the O 
calcium B-SYSTEMATIC 
channel O 
transient O 
receptor O 
potential O 
ankyrin-1 O 
( O 
TRPA1 O 
) O 
, O 
causing O 
irritation O 
and O 
inflammation O 
in O 
the O 
respiratory O 
tract O 
. O 
It O 
was O 
hypothesized O 
that O 
wood O 
smoke O 
particulate O 
and O 
select O 
chemical O 
constituents O 
thereof O 
would O 
also O 
activate O 
TRPA1 O 
in O 
lung O 
cells O 
, O 
potentially O 
explaining O 
the O 
adverse O 
effects O 
of O 
wood O 
and O 
other O 
forms O 
of O 
biomass O 
smoke O 
on O 
the O 
respiratory O 
system O 
. O 
TRPA1 O 
activation O 
was O 
assessed O 
using O 
calcium B-SYSTEMATIC 
imaging O 
assays O 
in O 
TRPA1-overexpressing O 
HEK-293 O 
cells O 
, O 
mouse O 
primary O 
trigeminal O 
neurons O 
, O 
and O 
human O 
adenocarcinoma O 
( O 
A549 O 
) O 
lung O 
cells O 
. O 
Particles O 
from O 
pine O 
and O 
mesquite O 
smoke O 
were O 
less O 
potent O 
agonists O 
of O 
TRPA1 O 
than O 
an O 
equivalent O 
mass O 
concentration O 
of O 
an O 
ethanol B-SYSTEMATIC 
extract O 
of O 
diesel O 
exhaust O 
particles O 
; O 
pine O 
particles O 
were O 
comparable O 
in O 
potency O 
to O 
cigarette O 
smoke O 
condensate O 
, O 
and O 
mesquite O 
particles O 
were O 
the O 
least O 
potent O 
. O 
The O 
fine O 
particulate O 
( O 
PM O 
< O 
2.5 O 
μm O 
) O 
of O 
wood O 
smoke O 
were O 
the O 
most O 
potent O 
TRPA1 O 
agonists O 
and O 
several O 
chemical O 
constituents O 
of O 
wood O 
smoke O 
particulate O 
, O 
3,5-ditert-butylphenol B-SYSTEMATIC 
, O 
coniferaldehyde B-TRIVIAL 
, O 
formaldehyde B-SYSTEMATIC 
, O 
perinaphthenone B-TRIVIAL 
, O 
agathic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
isocupressic B-TRIVIAL 
acid I-TRIVIAL 
, O 
were O 
TRPA1 O 
agonists O 
. O 
Pine O 
particulate O 
activated O 
TRPA1 O 
in O 
mouse O 
trigeminal O 
neurons O 
and O 
A549 O 
cells O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
, O 
which O 
was O 
inhibited O 
by O 
the O 
TRPA1 O 
antagonist O 
HC-030031 B-IDENTIFIER 
. O 
TRPA1 O 
activation O 
by O 
wood O 
smoke O 
particles O 
occurred O 
through O 
the O 
electrophile O 
/ O 
oxidant O 
- O 
sensing O 
domain O 
( O 
i.e O 
. O 
, O 
C621 O 
/ O 
C641 O 
/ O 
C665 O 
/ O 
K710 O 
) O 
, O 
based O 
on O 
the O 
inhibition O 
of O 
cellular O 
responses O 
when O 
the O 
particles O 
were O 
pretreated O 
with O 
glutathione B-TRIVIAL 
; O 
a O 
role O 
for O 
the O 
menthol B-TRIVIAL 
-binding O 
site O 
of O 
TRPA1 O 
( O 
S873 O 
/ O 
T874 O 
) O 
was O 
demonstrated O 
for O 
3,5-ditert-butylphenol B-SYSTEMATIC 
. O 
This O 
study O 
demonstrated O 
that O 
TRPA1 O 
is O 
a O 
molecular O 
sensor O 
for O 
wood O 
smoke O 
particulate O 
and O 
several O 
chemical O 
constituents O 
thereof O 
, O 
in O 
sensory O 
neurons O 
and O 
A549 O 
cells O 
, O 
suggesting O 
that O 
TRPA1 O 
may O 
mediate O 
some O 
of O 
the O 
adverse O 
effects O 
of O 
wood O 
smoke O 
in O 
humans O 
. O 

of O 
exposure O 
to O 
amitraz B-TRIVIAL 
on O 
noradrenaline B-TRIVIAL 
, O 
serotonin B-TRIVIAL 
and O 
dopamine B-TRIVIAL 
levels O 
in O 
brain O 
regions O 
of O 
30 O 
and O 
60 O 
days O 
old O 
male O 
rats O 
. O 

effects O 
of O 
amitraz B-TRIVIAL 
oral O 
exposure O 
( O 
20 O 
, O 
50 O 
and O 
80mg O 
/ O 
kg O 
bw O 
, O 
5 O 
days O 
) O 
on O 
brain O 
region O 
monoamine B-FAMILY 
levels O 
of O 
male O 
rats O 
at O 
30 O 
and O 
60 O 
days O 
of O 
age O 
were O 
examined O 
. O 
The O 
amitraz B-TRIVIAL 
-treated O 
rats O 
at O 
the O 
oral O 
doses O 
of O 
20 O 
and O 
50mg O 
/ O 
kg O 
bw O 
had O 
no O 
visible O 
injury O 
, O 
i.e O 
. O 
, O 
any O 
clinical O 
signs O 
of O 
dysfunction O 
observed O 
in O 
any O 
of O 
the O 
animals O 
. O 
However O 
, O 
rats O 
treated O 
with O 
amitraz B-TRIVIAL 
at O 
the O 
highest O 
dose O 
( O 
80mg O 
/ O 
kg O 
bw O 
, O 
5 O 
days O 
) O 
showed O 
a O 
slight O 
motor O 
incoordination O 
after O 
1-2h O 
of O 
treatment O 
. O 
These O 
signs O 
were O 
reversible O 
approximately O 
at O 
6h O 
after O 
dose O 
. O 
After O 
the O 
last O 
dose O 
of O 
amitraz B-TRIVIAL 
, O 
NE O 
, O 
DA O 
and O 
5-HT B-SYSTEMATIC 
and O 
its O 
metabolites O 
levels O 
were O 
determined O 
in O 
the O 
brain O 
regions O 
hypothalamus O 
, O 
midbrain O 
, O 
prefrontal O 
cortex O 
, O 
striatum O 
and O 
hippocampus O 
by O 
HPLC O 
. O 
Amitraz O 
caused O 
changes O 
in O 
the O 
NE O 
, O 
DA O 
and O 
5-HT B-SYSTEMATIC 
and O 
their O 
metabolite O 
levels O 
in O 
a O 
brain O 
regional- O 
, O 
dose- O 
and O 
age O 
- O 
related O 
manner O 
. O 
In O 
the O 
brain O 
regions O 
studied O 
, O 
amitraz O 
induced O 
a O 
statistically O 
significant O 
increase O 
in O 
5-HT B-SYSTEMATIC 
, O 
NE O 
and O 
DA O 
content O 
with O 
age O 
interaction O 
, O 
but O 
the O 
NE O 
increases O 
in O 
prefrontal O 
cortex O 
and O 
hippocampus O 
was O 
without O 
age O 
interaction O 
. O 
Moreover O 
, O 
in O 
the O 
brain O 
regions O 
studied O 
, O 
amitraz B-TRIVIAL 
induced O 
a O 
statistically O 
significant O 
decrease O 
in O 
the O 
metabolite O 
5-HIAA B-SYSTEMATIC 
, O 
MHPG B-ABBREVIATION 
, O 
DOPAC B-ABBREVIATION 
and O 
HVA B-ABBREVIATION 
levels O 
displaying O 
an O 
age O 
interaction O 
, O 
excepting O 
the O 
5-HIAA B-SYSTEMATIC 
decrease O 
in O 
midbrain O 
and O 
the O 
DOPAC B-ABBREVIATION 
decrease O 
in O 
hypothalamus O 
and O 
striatum O 
which O 
were O 
without O 
age O 
interaction O 
. O 
Furthermore O 
, O 
amitraz B-TRIVIAL 
evoked O 
a O 
statistically O 
significant O 
decrease O 
in O 
5-HT B-SYSTEMATIC 
, O 
NE O 
and O 
DA O 
turnover O 
in O 
the O 
brain O 
regions O 
studied O 
. O 
The O 
present O 
findings O 
indicate O 
that O 
amitraz B-TRIVIAL 
significantly O 
altered O 
CNS O 
monoaminergic O 
neurotransmitters O 
in O 
a O 
brain O 
regional- O 
, O 
dose- O 
and O 
age O 
- O 
related O 
manner O 
. O 

of O 
PVP B-ABBREVIATION 
/ O 
PEG B-ABBREVIATION 
mixtures O 
as O 
appropriate O 
carriers O 
for O 
the O 
preparation O 
of O 
drug O 
solid O 
dispersions O 
by O 
melt O 
mixing O 
technique O 
and O 
optimization O 
of O 
dissolution O 
using O 
artificial O 
neural O 
networks O 
. O 

effect O 
of O 
plasticizer's O 
( O 
PEG B-ABBREVIATION 
) O 
molecular O 
weight O 
( O 
MW O 
) O 
on O 
PVP B-ABBREVIATION 
based O 
solid O 
dispersions O 
( O 
SDs O 
) O 
, O 
prepared O 
by O 
melt O 
mixing O 
, O 
was O 
evaluated O 
in O 
the O 
present O 
study O 
using O 
Tibolone B-TRIVIAL 
as O 
a O 
poorly O 
water O 
soluble O 
model O 
drug O 
. O 
PEGs B-ABBREVIATION 
with O 
MW O 
of O 
400 O 
, O 
600 O 
, O 
and O 
2000g O 
/ O 
mol O 
were O 
tested O 
, O 
and O 
the O 
effect O 
of O 
drug O 
content O 
, O 
time O 
and O 
temperature O 
of O 
melt O 
mixing O 
on O 
the O 
physical O 
state O 
of O 
Tibolone B-TRIVIAL 
, O 
and O 
the O 
dissolution O 
characteristics O 
from O 
SDs O 
was O 
investigated O 
. O 
PVP B-ABBREVIATION 
blends O 
with O 
PEG400 B-TRIVIAL 
and O 
PEG600 B-TRIVIAL 
were O 
completely O 
miscible O 
, O 
while O 
blends O 
were O 
heterogeneous O 
. O 
Furthermore O 
, O 
a O 
single O 
Tg O 
recorded O 
in O 
all O 
samples O 
, O 
indicating O 
that O 
Tibolone B-TRIVIAL 
was O 
dispersed O 
in O 
a O 
molecular O 
lever O 
( O 
or O 
in O 
the O 
form O 
of O 
nanodispersions O 
) O 
, O 
varied O 
with O 
varying O 
PEG B-ABBREVIATION 
' O 
s O 
molecular O 
weight O 
, O 
melt O 
mixing O 
temperature O 
, O 
and O 
drug O 
content O 
, O 
while O 
FTIR O 
analysis O 
indicated O 
significant O 
interactions O 
between O 
Tibolone B-TRIVIAL 
and O 
PVP B-ABBREVIATION 
/ O 
PEG B-ABBREVIATION 
matrices O 
. O 
All O 
prepared O 
solid O 
dispersion O 
showed O 
long O 
- O 
term O 
physical O 
stability O 
( O 
18months O 
in O 
room O 
temperature O 
) O 
. O 
The O 
extent O 
of O 
interaction O 
between O 
mixture O 
components O 
was O 
verified O 
using O 
Fox O 
and O 
Gordon-Taylor O 
equations O 
. O 
Artificial O 
neural O 
networks O 
, O 
used O 
to O 
correlate O 
the O 
studied O 
factors O 
with O 
selected O 
dissolution O 
characteristics O 
, O 
showed O 
good O 
prediction O 
ability O 
. O 

and O 
biological O 
evaluation O 
of O 
Foscan B-TRIVIAL 
( O 
® O 
) O 
bile B-FAMILY 
acid I-FAMILY 
conjugates O 
to O 
target O 
esophageal O 
cancer O 
cells O 
. O 

and O 
chlorins B-FAMILY 
such O 
as O 
Foscan B-TRIVIAL 
® O 
have O 
a O 
natural O 
proclivity O 
to O 
accumulate O 
in O 
cancer O 
cells O 
. O 
This O 
trait O 
has O 
made O 
them O 
good O 
candidates O 
for O 
photosensitizers O 
and O 
as O 
imaging O 
agents O 
in O 
phototherapy O 
. O 
In O 
order O 
to O 
improve O 
on O 
cellular O 
selectivity O 
to O 
lower O 
post O 
- O 
treatment O 
photosensitivity O 
bile B-FAMILY 
acid I-FAMILY 
porphyrin I-FAMILY 
bioconjugates O 
have O 
been O 
prepared O 
and O 
investigated O 
in O 
esophageal O 
cancer O 
cells O 
. O 
Bile B-FAMILY 
acids I-FAMILY 
which O 
are O 
known O 
to O 
selectively O 
bind O 
to O 
, O 
or O 
be O 
readily O 
taken O 
up O 
by O 
cancer O 
cells O 
were O 
chosen O 
as O 
targeting O 
moieties O 
. O 
Synthesis O 
of O 
the O 
conjugates O 
was O 
achieved O 
via O 
selective O 
nucleophilic O 
monofunctionalization O 
of O 
5,10,15,20-tetrahydroxyphenylporphyrins B-FAMILY 
with O 
propargyl B-SYSTEMATIC 
bromide I-SYSTEMATIC 
followed O 
by O 
Cu B-FORMULA 
(I) I-FORMULA 
mediated O 
cycloaddition O 
with O 
bile B-FAMILY 
acid I-FAMILY 
azides I-FAMILY 
in O 
good O 
yields O 
. O 
The O 
compounds O 
were O 
readily O 
taken O 
up O 
by O 
esophageal O 
cancer O 
cells O 
but O 
showed O 
no O 
PDT O 
activity O 
. O 

diazen-1-ium-1,2-diolate B-SYSTEMATIC 
analog O 
of O 
7-azabenzobicyclo[2.2.1]heptane B-SYSTEMATIC 
: O 
Synthesis O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
nitroxyl B-SYSTEMATIC 
release O 
, O 
in O 
vitro O 
hemodynamic O 
, O 
and O 
anti-hypertensive O 
studies O 
. O 

( O 
16 O 
) O 
was O 
designed O 
with O 
the O 
expectation O 
that O 
it O 
would O 
act O 
as O 
a O 
dual O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
and O 
nitroxyl B-SYSTEMATIC 
( O 
HNO B-FORMULA 
) O 
donor O 
that O 
is O 
not O 
carcinogenic O 
or O 
genotoxic O 
. O 
Compound O 
16 O 
, O 
with O 
a O 
suitable O 
half O 
- O 
life O 
( O 
17.8min O 
) O 
in O 
PBS O 
at O 
pH O 
7 O 
, O 
released O 
NO B-FORMULA 
( O 
19% O 
) O 
and O 
HNO B-FORMULA 
( O 
22% O 
) O 
during O 
a O 
2h O 
incubation O 
in O 
PBS O 
at O 
pH O 
7 O 
. O 
In O 
addition O 
, O 
compound O 
16 O 
exhibited O 
a O 
significant O 
in O 
vitro O 
positive O 
inotropic O 
effect O 
, O 
increased O 
the O 
rates O 
of O 
contraction O 
and O 
relaxation O 
, O 
and O 
increased O 
coronary O 
flow O 
rate O 
, O 
but O 
did O 
not O 
induce O 
a O 
chronotropic O 
effect O 
. O 
Furthermore O 
, O 
compound O 
16 O 
( O 
13.7mgkg(-1) O 
, O 
po O 
dose O 
) O 
provided O 
a O 
significant O 
reduction O 
in O 
the O 
blood O 
pressure O 
of O 
mice O 
up O 
to O 
3h O 
post O 
- O 
drug O 
administration O 
. O 
All O 
these O 
data O 
suggest O 
that O 
compound O 
16 O 
constitutes O 
an O 
attractive O 
' O 
lead O 
- O 
compound O 
' O 
that O 
could O 
have O 
potential O 
applications O 
to O 
treat O 
cardiovascular O 
disease(s) O 
such O 
as O 
congestive O 
heart O 
failure O 
. O 

oligoureas O 
of O 
metaphenylenediamine B-SYSTEMATIC 
mimic O 
host O 
defence O 
peptides O 
in O 
their O 
antimicrobial O 
behaviour O 
. O 

ureas B-FAMILY 
of O 
m-phenylenediamine B-SYSTEMATIC 
target O 
anionic O 
DMPG B-ABBREVIATION 
( O 
dimyristoylphosphatidylglycerol B-TRIVIAL 
) O 
and O 
possess O 
promise O 
as O 
antimicrobial O 
agents O 
. O 
Their O 
similar O 
size O 
, O 
shape O 
and O 
hydrophobicity O 
to O 
helical O 
antimicrobial O 
peptides O 
( O 
AMPs O 
) O 
may O 
be O 
important O 
for O 
activity O 
to O 
exist O 
and O 
the O 
ability O 
of O 
these O 
compounds O 
to O 
insert O 
into O 
a O 
well O 
ordered O 
lipid O 
environment O 
. O 

mediated O 
synthesis O 
and O 
pharmacological O 
evaluation O 
of O 
some O 
fluoro B-FAMILY 
substituted I-FAMILY 
pyrazoline I-FAMILY 
derivatives O 
as O 
antiinflammatory O 
and O 
analgesic O 
agents O 
. O 

new O 
series O 
of O 
fluoro B-FAMILY 
substituted I-FAMILY 
pyrazoline I-FAMILY 
derivatives O 
5a-g O 
and O 
6a-g O 
were O 
synthesized O 
in O 
good O 
to O 
excellent O 
yield O 
from O 
the O 
corresponding O 
pyrazole B-FAMILY 
chalcones I-FAMILY 
, O 
4a-g O 
, O 
by O 
using O 
polyethylene B-TRIVIAL 
glycol-400 I-TRIVIAL 
( O 
PEG-400 B-TRIVIAL 
) O 
as O 
an O 
alternative O 
reaction O 
medium O 
. O 
The O 
newly O 
synthesized O 
compounds O 
were O 
characterized O 
and O 
screened O 
for O 
their O 
in O 
vivo O 
antiinflammatory O 
and O 
analgesic O 
activity O 
. O 
Compounds O 
5g O 
and O 
6g O 
were O 
found O 
to O 
be O 
more O 
potent O 
than O 
standard O 
drug O 
Diclofenac B-TRIVIAL 
and O 
six O 
other O 
compounds O 
5b O 
, O 
5c O 
, O 
5f O 
, O 
6b O 
, O 
6c O 
and O 
6f O 
showed O 
significant O 
antiinflammatory O 
activity O 
as O 
compared O 
to O 
standard O 
drug O 
. O 
Compounds O 
5c O 
, O 
5d O 
, O 
5e O 
, O 
5f O 
, O 
6c O 
, O 
6d O 
, O 
6e O 
and O 
6f O 
showed O 
significant O 
analgesic O 
activity O 
as O 
compared O 
to O 
standard O 
drug O 
Aspirin O 
. O 

of O 
metal O 
ion O 
binding O 
peptides O 
containing O 
unnatural O 
amino B-FAMILY 
acids I-FAMILY 
by O 
phage O 
display O 
. O 

bidentate O 
metal O 
binding O 
amino B-FAMILY 
acid I-FAMILY 
bipyridylalanine B-SYSTEMATIC 
( O 
BpyAla B-FORMULA 
) O 
was O 
incorporated O 
into O 
a O 
disulfide B-SYSTEMATIC 
linked O 
cyclic O 
peptide O 
phage O 
displayed O 
library O 
to O 
identify O 
metal O 
ion O 
binding O 
peptides O 
. O 
Selection O 
against O 
Ni(2+) B-FORMULA 
- O 
nitrilotriacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
NTA B-ABBREVIATION 
) O 
enriched O 
for O 
sequences O 
containing O 
histidine B-TRIVIAL 
and O 
BpyAla B-FORMULA 
. O 
BpyAla B-FORMULA 
predominated O 
when O 
selections O 
were O 
carried O 
out O 
at O 
lower O 
pH O 
, O 
consistent O 
with O 
the O 
differential O 
pKa's O 
of O 
histidine B-TRIVIAL 
and O 
BpyAla B-FORMULA 
. O 
Two O 
peptides O 
containing O 
BpyAla B-FORMULA 
were O 
synthesized O 
and O 
found O 
to O 
bind O 
Ni(2+) B-FORMULA 
with O 
low O 
micromolar O 
dissociation O 
constants O 
. O 
Incorporation O 
of O 
BpyAla B-FORMULA 
and O 
other O 
metal O 
binding O 
amino B-FAMILY 
acids I-FAMILY 
into O 
peptide O 
and O 
protein O 
libraries O 
should O 
enable O 
the O 
evolution O 
of O 
novel O 
binding O 
and O 
catalytic O 
activities O 
. O 

- O 
eluting O 
stents O 
reside O 
in O 
a O 
dynamic O 
fluid O 
environment O 
where O 
the O 
extent O 
to O 
which O 
drugs O 
are O 
distributed O 
within O 
the O 
arterial O 
wall O 
is O 
critically O 
modulated O 
by O 
the O 
blood O 
flowing O 
through O 
the O 
arterial O 
lumen O 
. O 
Yet O 
several O 
factors O 
associated O 
with O 
the O 
pulsatile O 
nature O 
of O 
blood O 
flow O 
and O 
their O 
impact O 
on O 
arterial O 
drug O 
deposition O 
have O 
not O 
been O 
fully O 
investigated O 
. O 
We O 
employed O 
an O 
integrated O 
framework O 
comprising O 
bench O 
- O 
top O 
and O 
computational O 
models O 
to O 
explore O 
the O 
factors O 
governing O 
the O 
time O 
- O 
varying O 
fluid O 
dynamic O 
environment O 
within O 
the O 
vasculature O 
and O 
their O 
effects O 
on O 
arterial O 
drug O 
distribution O 
patterns O 
. O 
A O 
custom O 
- O 
designed O 
bench O 
- O 
top O 
framework O 
comprising O 
a O 
model O 
of O 
a O 
single O 
drug O 
- O 
eluting O 
stent O 
strut O 
and O 
a O 
poly B-FAMILY 
- I-FAMILY 
vinyl I-FAMILY 
alcohol I-FAMILY 
-based O 
hydrogel O 
as O 
a O 
model O 
tissue O 
bed O 
simulated O 
fluid O 
flow O 
and O 
drug O 
transport O 
under O 
fully O 
apposed O 
strut O 
settings O 
. O 
Bench O 
- O 
top O 
experiments O 
revealed O 
a O 
relative O 
independence O 
between O 
drug O 
distribution O 
and O 
the O 
factors O 
governing O 
pulsatile O 
flow O 
and O 
these O 
findings O 
were O 
validated O 
with O 
the O 
in O 
silico O 
model O 
. O 
Interestingly O 
, O 
computational O 
models O 
simulating O 
suboptimal O 
deployment O 
settings O 
revealed O 
a O 
complex O 
interplay O 
between O 
arterial O 
drug O 
distribution O 
, O 
Womersley O 
number O 
and O 
the O 
extent O 
of O 
malapposition O 
. O 
In O 
particular O 
, O 
for O 
a O 
stent O 
strut O 
offset O 
from O 
the O 
wall O 
, O 
total O 
drug O 
deposition O 
was O 
sensitive O 
to O 
changes O 
in O 
the O 
pulsatile O 
flow O 
environment O 
, O 
with O 
this O 
dependence O 
increasing O 
with O 
greater O 
wall O 
displacement O 
. O 
Our O 
results O 
indicate O 
that O 
factors O 
governing O 
pulsatile O 
luminal O 
flow O 
on O 
arterial O 
drug O 
deposition O 
should O 
be O 
carefully O 
considered O 
in O 
conjunction O 
with O 
device O 
deployment O 
settings O 
for O 
better O 
utilization O 
of O 
drug O 
- O 
eluting O 
stent O 
therapy O 
. O 

reversibly O 
reverse O 
chemical O 
LTD O 
induced O 
by O 
group O 
I O 
, O 
group O 
II O 
and O 
group O 
III O 
metabotropic O 
glutamate B-TRIVIAL 
receptors O 
. O 

glutamate B-TRIVIAL 
( O 
mGlu O 
) O 
receptors O 
are O 
implicated O 
in O 
many O 
neurological O 
and O 
psychiatric O 
diseases O 
and O 
are O 
the O 
targets O 
of O 
therapeutic O 
agents O 
currently O 
in O 
clinical O 
development O 
. O 
Their O 
activation O 
has O 
diverse O 
effects O 
in O 
the O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
that O 
includes O 
an O 
involvement O 
in O 
synaptic O 
plasticity O 
. O 
We O 
previously O 
reported O 
that O 
the O 
brief O 
exposure O 
of O 
hippocampal O 
slices O 
to O 
dihydroxyphenylglycine B-SYSTEMATIC 
( O 
DHPG B-ABBREVIATION 
) O 
can O 
result O 
in O 
a O 
long O 
- O 
term O 
depression O 
( O 
LTD O 
) O 
of O 
excitatory O 
synaptic O 
transmission O 
. O 
Surprisingly O 
, O 
this O 
LTD O 
could O 
be O 
fully O 
reversed O 
by O 
mGlu O 
receptor O 
antagonists O 
in O 
a O 
manner O 
that O 
was O 
itself O 
fully O 
reversible O 
upon O 
washout O 
of O 
the O 
antagonist O 
. O 
Here O 
, O 
15 O 
years O 
after O 
the O 
discovery O 
of O 
DHPG B-ABBREVIATION 
-LTD O 
and O 
its O 
reversible O 
reversibility O 
, O 
we O 
summarise O 
these O 
initial O 
findings O 
. O 
We O 
then O 
present O 
new O 
data O 
on O 
DHPG B-ABBREVIATION 
-LTD O 
, O 
which O 
demonstrates O 
that O 
evoked O 
epileptiform O 
activity O 
triggered O 
by O 
activation O 
of O 
group O 
I O 
mGlu O 
receptors O 
can O 
also O 
be O 
reversibly O 
reversed O 
by O 
mGlu O 
receptor O 
antagonists O 
. O 
Furthermore O 
, O 
we O 
show O 
that O 
the O 
phenomenon O 
of O 
reversible O 
reversibility O 
is O 
not O 
specific O 
to O 
group O 
I O 
mGlu O 
receptors O 
. O 
We O 
report O 
that O 
activation O 
of O 
group O 
II O 
mGlu O 
receptors O 
in O 
the O 
temporo O 
- O 
ammonic O 
pathway O 
( O 
TAP O 
) O 
and O 
mossy O 
fibre O 
pathway O 
within O 
the O 
hippocampus O 
and O 
in O 
the O 
cortical O 
input O 
to O 
neurons O 
of O 
the O 
lateral O 
amygdala O 
induces O 
an O 
LTD O 
that O 
is O 
reversed O 
by O 
LY341495 B-IDENTIFIER 
, O 
a O 
group O 
II O 
mGlu O 
receptor O 
antagonist O 
. O 
We O 
also O 
show O 
that O 
activation O 
of O 
group O 
III O 
mGlu8 O 
receptors O 
induces O 
an O 
LTD O 
at O 
lateral O 
perforant O 
path O 
inputs O 
to O 
the O 
dentate O 
gyrus O 
and O 
that O 
this O 
LTD O 
is O 
reversed O 
by O 
MDCPG O 
, O 
an O 
mGlu8 O 
receptor O 
antagonist O 
. O 
In O 
conclusion O 
, O 
we O 
have O 
shown O 
that O 
activation O 
of O 
representative O 
members O 
of O 
each O 
of O 
the O 
three O 
groups O 
of O 
mGlu O 
receptors O 
can O 
induce O 
forms O 
of O 
LTD O 
than O 
can O 
be O 
reversed O 
by O 
antagonists O 
, O 
and O 
that O 
in O 
each O 
case O 
washout O 
of O 
the O 
antagonist O 
is O 
associated O 
with O 
the O 
re O 
- O 
establishment O 
of O 
the O 
LTD O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
GluR-dep O 
synaptic O 
plasticity O 
' O 
. O 

trioxide I-SYSTEMATIC 
depletes O 
cancer O 
stem O 
- O 
like O 
cells O 
and O 
inhibits O 
repopulation O 
of O 
neurosphere O 
derived O 
from O 
glioblastoma O 
by O 
downregulation O 
of O 
Notch O 
pathway O 
. O 

signaling O 
has O 
been O 
demonstrated O 
to O 
have O 
a O 
central O 
role O 
in O 
cancer O 
stem O 
- O 
like O 
cells O 
( O 
CSLCs O 
) O 
in O 
glioblastoma O 
multiforme O 
( O 
GBM O 
) O 
. O 
We O 
have O 
recently O 
demonstrated O 
the O 
inhibitory O 
effect O 
of O 
arsenic B-SYSTEMATIC 
trioxide I-SYSTEMATIC 
( O 
ATO B-ABBREVIATION 
) O 
on O 
CSLCs O 
in O 
glioblastoma O 
cell O 
lines O 
. O 
In O 
this O 
study O 
we O 
used O 
neurosphere O 
recovery O 
assay O 
that O 
measured O 
neurosphere O 
formation O 
at O 
three O 
time O 
points O 
to O 
assess O 
the O 
capacity O 
of O 
the O 
culture O 
to O 
repopulate O 
after O 
ATO B-ABBREVIATION 
treatment O 
. O 
Our O 
results O 
provided O 
strong O 
evidence O 
that O 
ATO B-ABBREVIATION 
depleted O 
CSLCs O 
in O 
GBM O 
, O 
and O 
inhibited O 
neurosphere O 
recovery O 
and O 
secondary O 
neurosphere O 
formation O 
. O 
ATO B-ABBREVIATION 
inhibited O 
the O 
phosphorylation O 
and O 
activation O 
of O 
AKT O 
and O 
STAT3 O 
through O 
Notch O 
signaling O 
blockade O 
. O 
These O 
data O 
show O 
that O 
the O 
ATO B-ABBREVIATION 
is O 
a O 
promising O 
new O 
approach O 
to O 
decrease O 
glioblastoma O 
proliferation O 
and O 
recurrence O 
by O 
downregulation O 
of O 
Notch O 
pathway O 
. O 

- O 
activity O 
relationship O 
of O 
5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole B-SYSTEMATIC 
analogues O 
as O 
5-HT6 O 
receptor O 
agonists O 
. O 

further O 
investigate O 
the O 
structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
of O 
the O 
5-hydroxytryptamine B-SYSTEMATIC 
type O 
6 O 
( O 
5-HT6 O 
) O 
receptor O 
agonist O 
5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole B-SYSTEMATIC 
( O 
EMD386088 B-IDENTIFIER 
, O 
6 O 
) O 
, O 
a O 
series O 
of O 
2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles B-FAMILY 
were O 
synthesized O 
, O 
and O 
in O 
vitro O 
affinity O 
to O 
, O 
and O 
functional O 
activity O 
at O 
5-HT6 O 
receptors O 
was O 
tested O 
. O 
We O 
focused O 
on O 
substituents O 
made O 
at O 
the O 
indole B-SYSTEMATIC 
N(1)- O 
, O 
2- O 
and O 
5- O 
positions O 
and O 
these O 
were O 
found O 
to O 
not O 
only O 
influence O 
the O 
affinity O 
at O 
5-HT6 O 
receptors O 
but O 
also O 
the O 
intrinsic O 
activity O 
leading O 
to O 
antagonists O 
, O 
partial O 
agonists O 
and O 
full O 
agonists O 
. O 
In O 
order O 
for O 
a O 
compound O 
to O 
demonstrate O 
potent O 
5-HT6 O 
receptor O 
agonist O 
properties O 
, O 
the O 
indole B-SYSTEMATIC 
N(1) O 
should O 
be O 
unsubstituted O 
, O 
an O 
alkyl B-FAMILY 
group O 
such O 
as O 
2-methyl B-SYSTEMATIC 
is O 
needed O 
and O 
finally O 
halogen B-FAMILY 
substituents O 
in O 
the O 
indole B-SYSTEMATIC 
5- O 
position O 
( O 
fluoro B-SYSTEMATIC 
, O 
chloro B-SYSTEMATIC 
or O 
, O 
bromo B-SYSTEMATIC 
) O 
were O 
essential O 
requirements O 
. O 
However O 
, O 
the O 
introduction O 
of O 
a O 
benzenesulfonyl B-SYSTEMATIC 
group O 
at O 
N(1) O 
- O 
position O 
switched O 
the O 
full O 
agonist O 
6 O 
to O 
be O 
a O 
5-HT6 O 
receptor O 
antagonist O 
( O 
30 O 
) O 
. O 
A O 
few O 
compounds O 
within O 
the O 
2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles B-FAMILY 
were O 
also O 
screened O 
for O 
off O 
- O 
targets O 
and O 
generally O 
they O 
displayed O 
low O 
affinity O 
for O 
other O 
5-HT B-SYSTEMATIC 
subtypes O 
and O 
serotonin B-TRIVIAL 
transporter O 
protein O 
( O 
SERT O 
) O 
. O 

of O 
G2 O 
/ O 
M O 
arrest O 
, O 
caspase O 
activation O 
and O 
apoptosis O 
by O 
α-santonin B-TRIVIAL 
derivatives O 
in O 
HL-60 O 
cells O 
. O 

lactones I-FAMILY 
( O 
SLs B-FAMILY 
) O 
are O 
natural O 
products O 
with O 
a O 
variety O 
of O 
biological O 
activities O 
. O 
Previously O 
, O 
we O 
demonstrated O 
the O 
cytotoxic O 
effects O 
of O 
three O 
new O 
α-santonin B-TRIVIAL 
derivatives O 
on O 
different O 
tumor O 
cell O 
lines O 
with O 
low O 
toxic O 
effects O 
upon O 
peripheral O 
human O 
leukocytes O 
. O 
Here O 
, O 
we O 
evaluated O 
the O 
mechanism O 
of O 
action O 
triggered O 
by O 
these O 
derivatives O 
. O 
HL-60 O 
cell O 
cycle O 
determined O 
after O 
24h O 
treatment O 
revealed O 
a O 
significant O 
inhibition O 
on O 
cell O 
- O 
cycle O 
progression O 
and O 
leading O 
to O 
an O 
increasing O 
of O 
cells O 
in O 
G2 O 
/ O 
M O 
[ O 
7.6% O 
and O 
9.0% O 
for O 
compound O 
3% O 
and O 
9.0% O 
and O 
8.6% O 
for O 
compound O 
4 O 
( O 
1 O 
and O 
2μM O 
, O 
respectively O 
) O 
] O 
. O 
However O 
, O 
after O 
48h O 
exposure O 
, O 
all O 
compounds O 
caused O 
G2 O 
/ O 
M O 
reduction O 
and O 
a O 
significant O 
DNA O 
fragmentation O 
. O 
Compounds O 
2 O 
, O 
3 O 
and O 
4 O 
were O 
able O 
to O 
induce O 
apoptosis O 
on O 
leukemia O 
cells O 
, O 
which O 
was O 
corroborated O 
by O 
phosphatidyserine O 
externalization O 
and O 
activation O 
of O 
caspases-3 O 
and O 
-7 O 
after O 
24h O 
exposure O 
. O 
None O 
of O 
the O 
derivatives O 
analyzed O 
caused O 
depolarization O 
of O 
mitochondrial O 
membrane O 
within O 
24h O 
of O 
incubation O 
, O 
suggesting O 
the O 
involvement O 
of O 
the O 
extrinsic O 
apoptotic O 
pathway O 
in O 
the O 
death O 
process O 
. O 
The O 
antiproliferative O 
action O 
of O 
these O 
compounds O 
is O 
related O 
to O 
the O 
DNA O 
synthesis O 
inhibition O 
and O 
cell O 
cycle O 
arrest O 
, O 
which O 
probably O 
lead O 
to O 
apoptosis O 
activation O 
. O 
Therefore O 
, O 
these O 
santonin B-TRIVIAL 
derivatives O 
are O 
promising O 
lead O 
candidates O 
for O 
development O 
of O 
new O 
cytotoxic O 
agents O 
. O 

many O 
as O 
15% O 
of O 
women O 
experience O 
hypertension O 
during O 
pregnancy O 
. O 
Large O 
proportions O 
of O 
them O 
are O 
receiving O 
antihypertensive O 
medications O 
. O 
This O 
review O 
investigated O 
whether O 
hypertension O 
itself O 
, O 
or O 
the O 
antihypertensive O 
medications O 
, O 
adversely O 
affect O 
long O 
term O 
child O 
neurocognitive O 
development O 
. O 
The O 
existing O 
evidence O 
suggests O 
that O 
methyldopa B-TRIVIAL 
and O 
labetalol B-TRIVIAL 
probably O 
do O 
not O 
adversely O 
affect O 
neurobehavioral O 
development O 
. O 
Although O 
an O 
increasing O 
body O 
of O 
evidence O 
suggests O 
adverse O 
neurocognitive O 
effects O 
of O 
the O 
hypertension O 
itself O 
, O 
none O 
of O 
the O 
existing O 
studies O 
examined O 
simultaneously O 
the O 
effects O 
of O 
both O 
hypertension O 
and O 
the O 
drugs O 
used O 
therapeutically O 
. O 
The O 
confounding O 
effects O 
by O 
indication O 
must O 
be O 
addressed O 
in O 
future O 
studies O 
. O 

Tip O 
Proteins O 
Related O 
to O 
Bacteriophage O 
λ O 
gpL O 
Coordinate O 
an O 
Iron-Sulfur B-SYSTEMATIC 
Cluster O 
. O 

assembly O 
of O 
long O 
non-contractile O 
phage O 
tails O 
begins O 
with O 
the O 
formation O 
of O 
the O 
tail O 
tip O 
complex O 
( O 
TTC O 
) O 
. O 
TTCs O 
are O 
multi O 
- O 
functional O 
protein O 
structures O 
that O 
mediate O 
host O 
cell O 
adsorption O 
and O 
genome O 
injection O 
. O 
The O 
TTC O 
of O 
phage O 
λ O 
is O 
assembled O 
from O 
multiple O 
copies O 
of O 
eight O 
different O 
proteins O 
, O 
including O 
gpL O 
. O 
Purified O 
preparations O 
of O 
gpL O 
and O 
several O 
homologues O 
all O 
displayed O 
a O 
distinct O 
reddish O 
color O 
, O 
suggesting O 
the O 
binding O 
of O 
iron B-SYSTEMATIC 
by O 
these O 
proteins O 
. O 
Further O 
characterization O 
of O 
the O 
gpL O 
homologue O 
from O 
phage O 
N15 O 
, O 
which O 
was O 
most O 
amenable O 
to O 
in O 
vitro O 
analyses O 
, O 
showed O 
that O 
it O 
contains O 
two O 
domains O 
. O 
The O 
C B-FORMULA 
-terminal O 
domain O 
was O 
demonstrated O 
to O 
coordinate O 
an O 
iron B-SYSTEMATIC 
- I-SYSTEMATIC 
sulfur I-SYSTEMATIC 
cluster O 
, O 
providing O 
the O 
first O 
example O 
of O 
a O 
viral O 
structural O 
protein O 
binding O 
to O 
this O 
type O 
of O 
metal O 
group O 
. O 
We O 
characterized O 
the O 
iron B-SYSTEMATIC 
- I-SYSTEMATIC 
sulfur I-SYSTEMATIC 
cluster O 
using O 
inductively O 
coupled O 
plasma O 
- O 
atomic O 
emission O 
spectroscopy O 
, O 
absorbance O 
spectroscopy O 
, O 
and O 
electron O 
paramagnetic O 
resonance O 
spectroscopy O 
and O 
found O 
that O 
it O 
is O 
an O 
oxygen B-SYSTEMATIC 
-sensitive O 
[4Fe-4S](2+) B-FORMULA 
cluster O 
. O 
Four O 
highly O 
conserved O 
cysteine B-TRIVIAL 
residues O 
were O 
shown O 
to O 
be O 
required O 
for O 
coordinating O 
the O 
iron B-SYSTEMATIC 
- I-SYSTEMATIC 
sulfur I-SYSTEMATIC 
cluster O 
, O 
and O 
substitution O 
of O 
any O 
of O 
these O 
Cys B-FORMULA 
residues O 
with O 
Ser B-FORMULA 
or O 
Ala B-FORMULA 
within O 
the O 
context O 
of O 
λ O 
gpL O 
abolished O 
biological O 
activity O 
. O 
These O 
data O 
imply O 
that O 
the O 
intact O 
iron B-SYSTEMATIC 
- I-SYSTEMATIC 
sulfur I-SYSTEMATIC 
cluster O 
is O 
required O 
for O 
function O 
. O 
The O 
presence O 
of O 
four O 
conserved O 
Cys B-FORMULA 
residues O 
in O 
the O 
C B-FORMULA 
-terminal O 
regions O 
of O 
very O 
diverse O 
gpL O 
homologues O 
suggest O 
that O 
utilization O 
of O 
an O 
iron B-SYSTEMATIC 
- I-SYSTEMATIC 
sulfur I-SYSTEMATIC 
cluster O 
is O 
a O 
widespread O 
feature O 
of O 
non-contractile O 
tailed O 
phages O 
that O 
infect O 
Gram O 
- O 
negative O 
bacteria O 
. O 
In O 
addition O 
, O 
this O 
is O 
the O 
first O 
example O 
of O 
a O 
viral O 
structural O 
protein O 
that O 
binds O 
an O 
iron B-SYSTEMATIC 
- I-SYSTEMATIC 
sulfur I-SYSTEMATIC 
cluster O 
. O 

nanosuspension O 
for O 
long O 
- O 
acting O 
intramuscular O 
delivery O 
of O 
curcumin B-SYSTEMATIC 
didecanoate I-SYSTEMATIC 
prodrug O 
: O 
Preparation O 
, O 
characterization O 
and O 
in O 
vivo O 
evaluation O 
. O 

objective O 
of O 
this O 
study O 
was O 
to O 
prepare O 
the O 
nanocrystals O 
of O 
curcumin B-SYSTEMATIC 
didecanoate I-SYSTEMATIC 
( O 
CurDD B-ABBREVIATION 
) O 
by O 
wet O 
ball O 
milling O 
and O 
to O 
investigate O 
the O 
comparative O 
pharmacokinetics O 
of O 
oily O 
nano- O 
and O 
micro O 
- O 
suspensions O 
after O 
intramuscular O 
( O 
i.m O 
. O 
) O 
administration O 
to O 
rats O 
. O 
Upon O 
optimizing O 
the O 
wet O 
ball O 
milling O 
parameters O 
, O 
CurDD B-ABBREVIATION 
nanocrystals O 
were O 
produced O 
with O 
median O 
particle O 
size O 
of O 
∼500nm O 
and O 
the O 
freeze O 
- O 
dried O 
nanocrystals O 
were O 
readily O 
dispersed O 
in O 
peanut O 
oil O 
to O 
form O 
stable O 
nanosuspensions O 
. O 
Although O 
the O 
nanosuspension O 
appeared O 
to O 
exhibit O 
slower O 
clearance O 
from O 
the O 
injection O 
site O 
after O 
i.m O 
. O 
injection O 
, O 
compared O 
to O 
microsuspension O 
( O 
∼5μm O 
) O 
, O 
a O 
significantly O 
higher O 
maximum O 
plasma O 
curcumin B-TRIVIAL 
concentration O 
( O 
69.0ng O 
/ O 
ml O 
) O 
was O 
observed O 
for O 
the O 
former O 
than O 
that O 
for O 
the O 
latter O 
( O 
18.5ng O 
/ O 
ml O 
) O 
. O 
In O 
addition O 
, O 
the O 
nanosuspension O 
provided O 
significant O 
higher O 
plasma O 
curcumin B-TRIVIAL 
concentrations O 
and O 
brain O 
CurDD B-ABBREVIATION 
contents O 
for O 
at O 
least O 
15days O 
than O 
the O 
microsuspension O 
, O 
except O 
for O 
the O 
initial O 
times O 
. O 
A O 
single O 
i.m O 
. O 
injection O 
of O 
nanosuspension O 
appeared O 
to O 
achieve O 
reversal O 
effect O 
on O 
reserpine B-TRIVIAL 
-induced O 
hypothermia O 
for O 
at O 
least O 
13days O 
. O 
This O 
study O 
demonstrates O 
that O 
CurDD B-ABBREVIATION 
nanosuspension O 
may O 
act O 
as O 
a O 
long O 
- O 
acting O 
i.m O 
. O 
injectable O 
for O 
sustained O 
delivery O 
of O 
curcumin B-TRIVIAL 
, O 
potentially O 
applicable O 
to O 
elicit O 
a O 
long O 
- O 
lasting O 
antidepressant O 
effect O 
. O 

phthalocyanine I-SYSTEMATIC 
polymeric O 
nanoparticles O 
as O 
photosensitisers O 
: O 
Photophysical O 
and O 
physicochemical O 
characterisation O 
, O 
release O 
and O 
phototoxicity O 
in O 
vitro O 
. O 

of O 
poly(d,l-lactide-co-glycolide) B-FAMILY 
, O 
poly(d,l-lactide) B-FAMILY 
and O 
polyethylene B-FAMILY 
glycol-block-poly(d,l-lactide) I-FAMILY 
were O 
developed O 
to O 
encapsulate O 
chloroaluminium B-SYSTEMATIC 
phthalocyanine I-SYSTEMATIC 
( O 
AlClPc B-FORMULA 
) O 
, O 
a O 
new O 
hydrophobic O 
photosensitiser O 
used O 
in O 
photodynamic O 
therapy O 
( O 
PDT O 
) O 
. O 
The O 
mean O 
nanoparticle O 
size O 
varied O 
from O 
115 O 
to O 
274nm O 
, O 
and O 
the O 
encapsulation O 
efficiency O 
ranged O 
from O 
57% O 
to O 
96% O 
due O 
to O 
drug O 
precipitation O 
induced O 
by O 
different O 
types O 
of O 
polymer O 
. O 
All O 
nanoparticle O 
formulations O 
presented O 
negative O 
zeta O 
potential O 
values O 
( O 
-37mV O 
to O 
-59mV O 
) O 
, O 
explaining O 
their O 
colloidal O 
stability O 
. O 
The O 
characteristic O 
photophysical O 
parameters O 
were O 
analysed O 
: O 
the O 
absorption O 
spectrum O 
profile O 
, O 
fluorescence O 
quantum O 
yield O 
and O 
transient O 
absorbance O 
decay O 
, O 
with O 
similar O 
values O 
for O 
free O 
and O 
nanoparticles O 
of O 
AlClPc B-FORMULA 
. O 
The O 
time O 
- O 
resolved O 
spectroscopy O 
measurements O 
for O 
AlClPc B-FORMULA 
triplet O 
excited O 
state O 
lifetimes O 
indicate O 
that O 
encapsulation O 
in O 
nanocapsules O 
increases O 
triplet O 
lifetime O 
, O 
which O 
is O 
advantageous O 
for O 
PDT O 
efficiency O 
. O 
A O 
sustained O 
release O 
profile O 
over O 
168h O 
was O 
obtained O 
using O 
external O 
sink O 
method O 
. O 
An O 
in O 
vitro O 
phototoxic O 
effect O 
higher O 
than O 
80% O 
was O 
observed O 
in O 
human O 
fibroblasts O 
at O 
low O 
laser O 
light O 
doses O 
( O 
3J O 
/ O 
cm(2) O 
) O 
with O 
10μM O 
of O 
AlClPc B-FORMULA 
. O 
The O 
AlClPc B-FORMULA 
loaded O 
within O 
polymeric O 
nanocapsules O 
presented O 
suitable O 
physical O 
stability O 
, O 
improved O 
photophysical O 
properties O 
, O 
sustained O 
released O 
profile O 
and O 
suitable O 
activity O 
in O 
vitro O 
to O 
be O 
considered O 
a O 
promising O 
formulation O 
for O 
PDT O 
. O 

trioxide I-SYSTEMATIC 
induces O 
cardiac O 
fibroblast O 
apoptosis O 
in O 
vitro O 
and O 
in O 
vivo O 
by O 
up O 
- O 
regulating O 
TGF-β1 O 
expression O 
. O 

trioxide I-SYSTEMATIC 
( O 
As2O3 B-FORMULA 
; O 
ATO B-ABBREVIATION 
) O 
is O 
clinically O 
effective O 
in O 
treating O 
acute O 
promyelocytic O 
leukemia O 
( O 
APL O 
) O 
; O 
however O 
, O 
it O 
frequently O 
causes O 
cardiotoxic O 
effects O 
. O 
This O 
study O 
was O 
designed O 
to O 
investigate O 
whether O 
ATO B-ABBREVIATION 
could O 
induce O 
apoptosis O 
of O 
cardiac O 
fibroblasts O 
( O 
CFs O 
) O 
that O 
play O 
very O 
important O 
roles O 
in O 
maintaining O 
the O 
structure O 
integrity O 
and O 
function O 
of O 
the O 
heart O 
. O 
Cardiac O 
fibroblasts O 
from O 
guinea O 
pigs O 
administered O 
with O 
ATO B-ABBREVIATION 
( O 
1mg O 
/ O 
kgbw O 
) O 
were O 
used O 
to O 
test O 
the O 
pro O 
- O 
apoptotic O 
role O 
of O 
ATO B-ABBREVIATION 
in O 
vivo O 
. O 
The O 
current O 
study O 
demonstrated O 
that O 
ATO B-ABBREVIATION 
induced O 
morphological O 
characteristics O 
of O 
apoptosis O 
and O 
Caspase-3 O 
activation O 
in O 
CFs O 
of O 
guinea O 
pigs O 
along O 
with O 
a O 
significant O 
up O 
- O 
regulation O 
in O 
TGF-β1 O 
protein O 
expression O 
, O 
Bax O 
/ O 
Bcl-2 O 
ratio O 
and O 
ERK1 O 
/ O 
2 O 
phosphorylation O 
. O 
In O 
vitro O 
MTT B-ABBREVIATION 
assay O 
showed O 
that O 
ATO B-ABBREVIATION 
remarkably O 
reduced O 
the O 
viability O 
of O 
cultured O 
cardiac O 
fibroblasts O 
( O 
NRCFs O 
) O 
from O 
neonatal O 
rat O 
in O 
a O 
concentration- O 
and O 
time O 
- O 
dependent O 
manner O 
. O 
Consistent O 
with O 
the O 
notions O 
in O 
vivo O 
, O 
ATO B-ABBREVIATION 
significantly O 
induced O 
the O 
apoptosis O 
in O 
NRCFs O 
, O 
dramatically O 
up O 
- O 
regulated O 
TGF-β1 O 
protein O 
level O 
and O 
Bax O 
/ O 
Bcl-2 O 
ratio O 
in O 
a O 
time O 
- O 
dependent O 
fashion O 
and O 
activated O 
Caspase-3 O 
and O 
ERK1 O 
/ O 
2 O 
. O 
Finally O 
, O 
pretreatment O 
with O 
LY364947 B-IDENTIFIER 
, O 
an O 
inhibitor O 
of O 
TGF-β O 
signaling O 
could O 
apparently O 
reverse O 
these O 
changes O 
. O 
We O 
therefore O 
conclude O 
that O 
TGF-β O 
is O 
functionally O 
linked O 
to O 
ERK1 O 
/ O 
2 O 
and O 
that O 
TGF-β O 
signaling O 
is O 
responsible O 
for O 
ATO B-ABBREVIATION 
-induced O 
CFs O 
apoptosis O 
, O 
which O 
provides O 
a O 
novel O 
mechanism O 
of O 
ATO B-ABBREVIATION 
related O 
cardiac O 
toxicology O 
. O 

utero O 
phthalate B-FAMILY 
effects O 
in O 
the O 
female O 
rat O 
: O 
A O 
model O 
for O 
MRKH O 
syndrome O 
. O 

( O 
MRKH O 
) O 
syndrome O 
is O 
characterized O 
by O 
uterine O 
and O 
vaginal O 
canal O 
aplasia O 
in O 
normal O 
karyotype O 
human O 
females O 
and O 
is O 
a O 
syndrome O 
with O 
poorly O 
defined O 
etiology O 
. O 
Reproductive O 
toxicity O 
of O 
phthalate B-FAMILY 
esters I-FAMILY 
( O 
PEs B-FAMILY 
) O 
occurs O 
in O 
rat O 
offspring O 
exposed O 
in O 
utero O 
, O 
a O 
phenomenon O 
that O 
is O 
better O 
studied O 
in O 
male O 
offspring O 
than O 
females O 
. O 
The O 
current O 
study O 
reports O 
female O 
reproductive O 
tract O 
malformations O 
in O 
the O 
Sprague-Dawley O 
rat O 
similar O 
to O 
those O 
characteristic O 
of O 
MRKH O 
syndrome O 
, O 
following O 
in O 
utero O 
exposure O 
to O 
a O 
mixture O 
of O 
5 O 
PEs B-FAMILY 
. O 
We O 
determined O 
that O 
females O 
are O 
~2-fold O 
less O 
sensitive O 
to O 
the O 
effects O 
of O 
the O 
5-PE O 
mixture O 
than O 
males O 
for O 
reproductive O 
tract O 
malformations O 
. O 
We O 
were O 
not O 
fully O 
successful O 
in O 
defining O 
the O 
critical O 
exposure O 
period O 
for O 
females O 
; O 
however O 
, O 
incidence O 
of O 
malformations O 
was O 
88% O 
following O 
dosing O 
from O 
GD8 O 
to O 
19 O 
versus O 
22% O 
and O 
0% O 
for O 
GD8-13 O 
and O 
GD14-19 O 
, O 
respectively O 
. O 
Overall O 
, O 
this O 
study O 
provides O 
valuable O 
information O 
regarding O 
female O 
vulnerability O 
to O 
in O 
utero O 
phthalate B-FAMILY 
exposure O 
and O 
further O 
characterizes O 
a O 
potential O 
model O 
for O 
the O 
human O 
MRKH O 
syndrome O 
. O 

exhaust O 
particles O 
( O 
DEPs O 
) O 
, O 
a O 
by O 
- O 
product O 
of O 
diesel O 
engine O 
exhaust O 
( O 
DEE O 
) O 
, O 
are O 
known O 
to O 
produce O 
pro O 
- O 
oxidative O 
and O 
pro O 
- O 
inflammatory O 
effects O 
, O 
thereby O 
leading O 
to O 
oxidative O 
stress O 
- O 
induced O 
damage O 
. O 
Given O 
the O 
key O 
role O 
of O 
DEPs O 
in O 
inducing O 
oxidative O 
stress O 
, O 
we O 
investigated O 
the O 
role O 
of O 
DEPs O 
in O 
disrupting O 
the O 
integrity O 
and O 
function O 
of O 
immortalized O 
human O 
brain O 
microvascular O 
endothelial O 
cells O 
( O 
HBMVEC O 
) O 
. O 
To O 
study O 
this O 
, O 
HBMVEC O 
cells O 
were O 
exposed O 
to O 
media O 
containing O 
three O 
different O 
concentrations O 
of O 
DEPs O 
or O 
plain O 
media O 
for O 
24h O 
. O 
Those O 
exposed O 
to O 
DEPs O 
showed O 
significantly O 
higher O 
oxidative O 
stress O 
than O 
the O 
untreated O 
group O 
, O 
as O 
indicated O 
by O 
the O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
and O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
levels O 
, O 
and O 
the O 
glutathione B-TRIVIAL 
peroxidase O 
and O 
glutathione B-TRIVIAL 
reductase O 
activities O 
. O 
DEPs O 
also O 
induced O 
oxidative O 
stress O 
- O 
related O 
disruption O 
of O 
the O 
HBMVEC O 
cells O 
monolayer O 
, O 
as O 
measured O 
by O 
trans-epithelial O 
electrical O 
resistance O 
. O 
Taken O 
together O 
, O 
these O 
data O 
suggest O 
that O 
DEPs O 
induce O 
cell O 
death O 
and O 
disrupt O 
the O 
function O 
and O 
integrity O 
of O 
HBMVEC O 
cells O 
, O 
indicating O 
a O 
potential O 
role O 
of O 
DEPs O 
in O 
neurotoxicities O 
. O 

ethylene B-SYSTEMATIC 
bis-dithiocarbamate I-SYSTEMATIC 
fungicide O 
Mancozeb B-FAMILY 
activates O 
voltage O 
- O 
gated O 
KCNQ2 O 
potassium B-SYSTEMATIC 
channel O 
. O 

( O 
manganese B-MULTIPLE 
/ I-MULTIPLE 
zinc I-MULTIPLE 
ethylene I-MULTIPLE 
bis-dithiocarbamate I-MULTIPLE 
) O 
is O 
an O 
organometallic O 
fungicide O 
that O 
has O 
been O 
associated O 
with O 
human O 
neurotoxicity O 
and O 
neurodegeneration O 
. O 
In O 
a O 
high O 
- O 
throughput O 
screen O 
for O 
modulators O 
of O 
KCNQ2 O 
channel O 
, O 
a O 
fundamental O 
player O 
modulating O 
neuronal O 
excitability O 
, O 
Mancozeb B-FAMILY 
, O 
was O 
found O 
to O 
significantly O 
potentiate O 
KCNQ2 O 
activity O 
. O 
Mancozeb B-FAMILY 
was O 
validated O 
electrophysiologically O 
as O 
a O 
KCNQ2 O 
activator O 
with O 
an O 
EC50 O 
value O 
of O 
0.92±0.23μM O 
. O 
Further O 
examination O 
showed O 
that O 
manganese B-SYSTEMATIC 
but O 
not O 
zinc B-SYSTEMATIC 
ethylene I-SYSTEMATIC 
bis-dithiocarbamate I-SYSTEMATIC 
is O 
the O 
active O 
component O 
for O 
the O 
positive O 
modulation O 
effects O 
. O 
In O 
addition O 
, O 
the O 
compounds O 
are O 
effective O 
when O 
the O 
metal O 
ions O 
are O 
substituted O 
by O 
iron B-SYSTEMATIC 
but O 
lack O 
potentiation O 
activity O 
when O 
the O 
metal O 
ions O 
are O 
substituted O 
by O 
sodium B-SYSTEMATIC 
, O 
signifying O 
the O 
importance O 
of O 
the O 
metal O 
ion O 
. O 
However O 
, O 
the O 
iron B-SYSTEMATIC 
( O 
Fe(3+) B-FORMULA 
) O 
alone O 
, O 
organic O 
ligands O 
alone O 
or O 
the O 
mixture O 
of O 
iron B-SYSTEMATIC 
with O 
the O 
organic O 
ligand O 
did O 
not O 
show O 
any O 
potentiation O 
effect O 
, O 
suggesting O 
as O 
the O 
active O 
ingredient O 
is O 
a O 
specific O 
complex O 
rather O 
than O 
two O 
separate O 
additive O 
or O 
synergistic O 
components O 
. O 
Our O 
study O 
suggests O 
that O 
potentiation O 
on O 
KCNQ2 O 
potassium B-SYSTEMATIC 
channels O 
might O 
be O 
the O 
possible O 
mechanism O 
of O 
Mancozeb B-FAMILY 
toxicity O 
in O 
the O 
nervous O 
system O 
. O 

and O 
MGMT O 
promoter O 
hypomethylation O 
independently O 
associated O 
with O 
genomic O 
instability O 
of O 
lymphocytes O 
in O 
subjects O 
exposed O 
to O 
high O 
- O 
dose O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbon I-FAMILY 
. O 

hypomethylation O 
, O 
gene O 
- O 
specific O 
methylation O 
, O 
and O 
genome O 
instability O 
are O 
common O 
events O 
in O 
tumorigenesis O 
. O 
To O 
date O 
, O 
few O 
studies O 
have O 
examined O 
the O 
aberrant O 
DNA O 
methylation O 
patterns O 
in O 
coke O 
oven O 
workers O 
, O 
who O 
are O 
highly O 
at O 
risk O 
of O 
lung O 
cancer O 
by O 
occupational O 
exposure O 
to O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PAHs B-ABBREVIATION 
) O 
. O 
We O 
recruited O 
82 O 
PAH B-ABBREVIATION 
-exposed O 
workers O 
and O 
62 O 
unexposed O 
controls O 
, O 
assessed O 
exposure O 
levels O 
by O 
urinary O 
1-hydroxypyrene B-SYSTEMATIC 
, O 
and O 
measured O 
genetic O 
damages O 
by O 
comet O 
assay O 
, O 
bleomycin B-FAMILY 
sensitivity O 
, O 
and O 
micronucleus O 
assay O 
. O 
The O 
PAHs B-ABBREVIATION 
in O 
coke O 
oven O 
emissions O 
( O 
COE O 
) O 
were O 
estimated O 
based O 
on O 
toxic O 
equivalency O 
factors O 
. O 
We O 
used O 
bisulfite B-SYSTEMATIC 
-PCR O 
pyrosequencing O 
to O 
quantitate O 
DNA O 
methylation O 
in O 
long O 
interspersed O 
nuclear O 
element-1 O 
( O 
LINE-1 O 
) O 
and O 
O(6)-methylguanine B-SYSTEMATIC 
-DNA O 
methyltransferase O 
( O 
MGMT O 
) O 
. O 
Further O 
, O 
the O 
methylation O 
alteration O 
was O 
also O 
investigated O 
in O 
COE O 
- O 
treated O 
human O 
bronchial O 
epithelial O 
( O 
16HBE O 
) O 
cells O 
. O 
We O 
found O 
there O 
are O 
higher O 
levels O 
of O 
PAHs B-ABBREVIATION 
in O 
COE O 
. O 
Among O 
PAH B-ABBREVIATION 
-exposed O 
workers O 
, O 
LINE-1 O 
and O 
MGMT O 
methylation O 
levels O 
( O 
with O 
CpG B-ABBREVIATION 
site O 
specificity O 
) O 
were O 
significantly O 
lowered O 
. O 
LINE-1 O 
, O 
MGMT O 
, O 
and O 
its O 
hot O 
CpG B-ABBREVIATION 
site O 
- O 
specific O 
methylation O 
were O 
negatively O 
correlated O 
with O 
urinary O 
1-hydroxypyrene B-SYSTEMATIC 
levels O 
( O 
r O 
= O 
-0.329 O 
, O 
p O 
< O 
0.001 O 
; O 
r O 
= O 
-0.164 O 
, O 
p O 
= O 
0.049 O 
and O 
r O 
= O 
-0.176 O 
, O 
p O 
= O 
0.034 O 
, O 
respectively O 
) O 
. O 
In O 
addition O 
, O 
LINE-1 O 
methylation O 
was O 
inversely O 
associated O 
with O 
comet O 
tail O 
moment O 
and O 
micronucleus O 
frequency O 
, O 
and O 
a O 
significant O 
increase O 
of O 
micronucleus O 
in O 
low O 
MGMT O 
methylation O 
group O 
. O 
In O 
vitro O 
study O 
revealed O 
that O 
treatment O 
of O 
COE O 
in O 
16HBE O 
cells O 
resulted O 
in O 
higher O 
production O 
of O 
BPDE B-ABBREVIATION 
-DNA O 
adducts O 
, O 
LINE-1 O 
hypomethylation O 
, O 
hypomethylation O 
, O 
and O 
suppression O 
of O 
MGMT O 
expression O 
. O 
These O 
findings O 
suggest O 
hypomethylation O 
of O 
LINE-1 O 
and O 
MGMT O 
promoter O 
could O 
be O 
used O 
as O 
markers O 
for O 
PAHs B-ABBREVIATION 
exposure O 
and O 
merit O 
further O 
investigation O 
. O 

differences O 
in O 
therapeutic O 
effectiveness O 
between O 
sustained O 
low O 
- O 
efficiency O 
dialysis O 
( O 
SLED O 
) O 
and O 
continuous O 
blood O 
purification O 
( O 
CBP O 
) O 
were O 
investigated O 
. O 
In O 
order O 
to O 
assess O 
the O 
different O 
treatment O 
methods O 
, O 
56 O 
critically O 
ill O 
patients O 
were O 
divided O 
into O 
two O 
groups O 
, O 
the O 
CBP O 
group O 
and O 
the O 
SLED O 
group O 
. O 
A O 
comparison O 
was O 
made O 
between O 
all O 
the O 
biochemical O 
indicators O 
, O 
in O 
- O 
hospital O 
duration O 
, O 
hemodynamic O 
parameters O 
, O 
acute O 
physiology O 
and O 
chronic O 
health O 
evaluation O 
( O 
APACHE-II O 
) O 
, O 
the O 
survival O 
, O 
and O 
the O 
mortality O 
rates O 
. O 
After O 
treatment O 
, O 
the O 
levels O 
of O 
serum O 
creatine B-TRIVIAL 
kinase O 
isozyme O 
MB O 
( O 
CK-MB O 
) O 
, O 
creatine B-TRIVIAL 
kinase O 
, O 
creatinine B-TRIVIAL 
, O 
glutamate B-TRIVIAL 
- O 
oxalacetate B-TRIVIAL 
transaminase O 
( O 
AST O 
) O 
, O 
glutamate B-TRIVIAL 
- O 
pyruvate B-TRIVIAL 
transaminase O 
( O 
ALT O 
) O 
, O 
APACHE O 
II O 
score O 
on O 
the O 
1st O 
, O 
2nd O 
, O 
and O 
7th O 
day O 
in O 
both O 
the O 
treatment O 
groups O 
were O 
lower O 
than O 
that O 
before O 
the O 
treatment O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
There O 
are O 
no O 
statistical O 
differences O 
in O 
in O 
- O 
hospital O 
duration O 
, O 
biochemical O 
indicators O 
, O 
APACHE O 
II O 
score O 
, O 
hemodynamic O 
parameters O 
, O 
the O 
survival O 
rate O 
and O 
the O 
mortality O 
rate O 
between O 
the O 
two O 
groups O 
( O 
P O 
> O 
0.05 O 
) O 
. O 
It O 
was O 
concluded O 
that O 
SLED O 
has O 
similar O 
hemodynamic O 
stability O 
with O 
CBP O 
and O 
the O 
two O 
methods O 
have O 
similar O 
treatment O 
effects O 
in O 
critically O 
ill O 
patients O 
. O 
However O 
, O 
we O 
noticed O 
that O 
SLED O 
can O 
be O 
relatively O 
economical O 
and O 
convenient O 
for O 
critically O 
ill O 
patients O 
in O 
clinical O 
practice O 
. O 

ameliorating O 
effects O 
of O 
5,7-dihydroxy-6-methoxy-2(4-phenoxyphenyl)-4H-chromene-4-one B-SYSTEMATIC 
, O 
an O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
derivative O 
, O 
against O 
memory O 
impairment O 
and O 
sensorimotor O 
gating O 
deficit O 
in O 
mice O 
. O 

previously O 
reported O 
that O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
, O 
a O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
A O 
( O 
GABAA O 
) O 
receptor O 
antagonist O 
, O 
ameliorates O 
drugs O 
- O 
induced O 
memory O 
impairments O 
. O 
We O 
synthesized O 
several O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
derivatives O 
in O 
efforts O 
to O 
find O 
a O 
substance O 
that O 
has O 
pro O 
- O 
cognitive O 
effects O 
as O 
well O 
as O 
improves O 
sensorimotor O 
gating O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
is O 
to O 
investigate O 
the O 
effect O 
of O 
a O 
novel O 
oroxylin B-TRIVIAL 
A I-TRIVIAL 
derivative O 
, O 
5,7-dihydroxy-6-methoxy-2(4-phenoxyphenyl)-4H-chromene-4-one B-SYSTEMATIC 
( O 
DMPC B-ABBREVIATION 
) O 
, O 
on O 
pharmacological O 
models O 
of O 
schizophrenia O 
, O 
which O 
exhibit O 
memory O 
impairment O 
and O 
sensorimotor O 
gating O 
deficit O 
. O 
Memory O 
impairment O 
was O 
induced O 
by O 
scopolamine B-TRIVIAL 
, O 
a O 
muscarinic O 
receptor O 
antagonist O 
, O 
or O 
MK-801 B-IDENTIFIER 
, O 
an O 
N-methyl-D-aspartate B-SYSTEMATIC 
receptor O 
antagonist O 
. O 
Sensorimotor O 
gating O 
deficits O 
were O 
induced O 
by O 
MK-801 B-IDENTIFIER 
and O 
measured O 
by O 
prepulse O 
inhibition O 
( O 
PPI O 
) O 
of O 
the O 
acoustic O 
startle O 
response O 
task O 
. O 
DMPC B-ABBREVIATION 
treatment O 
( O 
20 O 
mg O 
/ O 
kg O 
) O 
significantly O 
attenuated O 
scopolamine B-TRIVIAL 
- O 
or O 
MK-801 B-IDENTIFIER 
-induced O 
memory O 
impairment O 
and O 
it O 
even O 
enhanced O 
cognitive O 
performance O 
of O 
normal O 
animals O 
. O 
Furthermore O 
, O 
DMPC B-ABBREVIATION 
significantly O 
ameliorated O 
MK-801 B-IDENTIFIER 
-induced O 
PPI O 
deficits O 
in O 
the O 
acoustic O 
startle O 
response O 
task O 
. O 
In O 
an O 
in O 
vitro O 
study O 
, O 
DMPC B-ABBREVIATION 
( O 
20 O 
μM O 
) O 
inhibited O 
intracellular O 
Cl(-) B-FORMULA 
influx O 
induced O 
by O 
muscimol B-TRIVIAL 
, O 
a O 
selective O 
GABAA O 
receptor O 
agonist O 
. O 
These O 
results O 
suggest O 
that O 
DMPC B-ABBREVIATION 
would O 
be O 
a O 
potential O 
candidate O 
for O 
alleviating O 
cognitive O 
dysfunction O 
and O 
sensorimotor O 
gating O 
deficits O 
in O 
schizophrenia O 
, O 
and O 
that O 
its O 
effects O 
may O 
be O 
mediated O 
, O 
in O 
part O 
, O 
via O 
blockade O 
of O 
the O 
GABAergic O 
neurotransmitter O 
system O 
. O 

in O 
the O 
studies O 
on O 
tryptanthrin B-TRIVIAL 
, O 
an O 
alkaloid O 
of O 
history O 
. O 

, O 
an O 
indoloquinazoline B-FAMILY 
alkaloid I-FAMILY 
, O 
was O 
first O 
obtained O 
by O 
sublimation O 
of O 
natural O 
indigo O 
and O 
later O 
isolated O 
from O 
the O 
culture O 
of O 
fungus O 
Candida O 
lipolytica O 
and O 
a O 
variety O 
of O 
other O 
natural O 
sources O 
. O 
Tryptanthrin B-TRIVIAL 
showed O 
a O 
variety O 
of O 
intriguing O 
biological O 
properties O 
such O 
as O 
antibacterial O 
, O 
antifungal O 
, O 
antiprotozoal O 
, O 
and O 
antiparasitic O 
activities O 
, O 
inhibitory O 
activities O 
against O 
COX-2 O 
, O 
5-LOX O 
, O 
NO B-FORMULA 
synthase O 
and O 
PGE(2) B-ABBREVIATION 
expression O 
, O 
as O 
well O 
as O 
cytotoxic O 
and O 
antitumor O 
activities O 
. O 
Present O 
review O 
covers O 
recent O 
studies O 
on O 
the O 
natural O 
sources O 
, O 
biological O 
activities O 
and O 
mechanisms O 
of O 
their O 
actions O 
, O 
synthesis O 
, O 
structure O 
- O 
activity O 
relationship O 
, O 
and O 
metabolism O 
of O 
tryptanthrin B-TRIVIAL 
. O 

, O 
synthesis O 
, O 
in O 
vitro O 
cytotoxicity O 
evaluation O 
and O 
structure O 
- O 
activity O 
relationship O 
of O 
Goniothalamin B-TRIVIAL 
analogs O 
. O 

series O 
of O 
six O 
/ O 
five O 
member O 
( B-TRIVIAL 
E I-TRIVIAL 
/ I-TRIVIAL 
Z)-Goniothalamin I-TRIVIAL 
analogs O 
were O 
synthesized O 
from O 
commercially O 
available O 
(3,4-dihydro-2H-pyran-2-yl)methanol B-SYSTEMATIC 
/ O 
5-(hydroxymethyl)dihydrofuran-2(3H)-one B-SYSTEMATIC 
in O 
three O 
steps O 
with O 
good O 
to O 
moderate O 
overall O 
yields O 
and O 
their O 
cytotoxicity O 
against O 
lymphoblastic O 
leukemic O 
T O 
cell O 
line O 
( O 
Jurkat O 
E6.1 O 
) O 
have O 
been O 
evaluated O 
. O 
Among O 
the O 
synthesized O 
analogs O 
, O 
(Z)-Goniothalamin B-TRIVIAL 
appeared O 
to O 
be O 
the O 
most O 
active O 
in O 
cytotoxicity O 
( O 
IC50 O 
= O 
12 O 
μM O 
) O 
. O 
Structure O 
- O 
activity O 
relationship O 
study O 
indicates O 
that O 
introducing O 
substituent O 
in O 
phenyl O 
ring O 
or O 
replacing O 
phenyl B-SYSTEMATIC 
ring O 
by O 
pyridine B-SYSTEMATIC 
/ O 
naphthalene B-SYSTEMATIC 
, O 
or O 
decreasing O 
the O 
ring O 
size O 
of O 
lactones B-FAMILY 
( O 
from O 
six O 
to O 
five O 
member O 
) O 
do O 
not O 
increase O 
the O 
cytotoxicity O 
. O 

of O 
Calcium B-SYSTEMATIC 
/ O 
Calmodulin-Dependent O 
Protein O 
Kinase O 
II O 
Activity O 
in O 
Cortical O 
Astrocytes O 
Decreases O 
Glutamate B-TRIVIAL 
Uptake O 
and O 
Induces O 
Neurotoxic O 
Release O 
of O 
ATP B-ABBREVIATION 
. O 

extent O 
of O 
calcium B-SYSTEMATIC 
/ O 
calmodulin O 
- O 
dependent O 
protein O 
kinase O 
II O 
( O 
CaMKII O 
) O 
inactivation O 
in O 
the O 
brain O 
following O 
ischemia O 
correlates O 
with O 
the O 
extent O 
of O 
damage O 
. O 
We O 
have O 
previously O 
shown O 
that O 
a O 
loss O 
of O 
CaMKII O 
activity O 
in O 
neurons O 
is O 
detrimental O 
to O 
neuronal O 
viability O 
by O 
inducing O 
excitotoxic O 
glutamate B-TRIVIAL 
release O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
extend O 
these O 
findings O 
to O 
show O 
that O 
the O 
ability O 
of O 
astrocytes O 
to O 
buffer O 
extracellular O 
glutamate B-TRIVIAL 
is O 
reduced O 
when O 
CaMKII O 
is O 
inhibited O 
. O 
Furthermore O 
, O 
CaMKII O 
inhibition O 
in O 
astrocytes O 
is O 
associated O 
with O 
the O 
rapid O 
onset O 
of O 
intracellular O 
calcium B-SYSTEMATIC 
oscillations O 
. O 
Surprisingly O 
, O 
this O 
rapid O 
calcium B-SYSTEMATIC 
influx O 
is O 
blocked O 
by O 
the O 
N B-FORMULA 
-type O 
calcium B-SYSTEMATIC 
channel O 
antagonist O 
, O 
omega-conotoxin O 
. O 
While O 
the O 
function O 
of O 
N B-FORMULA 
-type O 
calcium B-SYSTEMATIC 
channels O 
within O 
astrocytes O 
is O 
controversial O 
, O 
these O 
voltage O 
- O 
gated O 
calcium B-SYSTEMATIC 
channels O 
have O 
been O 
linked O 
to O 
calcium B-SYSTEMATIC 
-dependent O 
vesicular O 
gliotransmitter O 
release O 
. O 
When O 
extracellular O 
glutamate B-TRIVIAL 
and O 
ATP B-ABBREVIATION 
levels O 
are O 
measured O 
following O 
CaMKII O 
inhibition O 
within O 
our O 
enriched O 
astrocyte O 
cultures O 
, O 
no O 
alterations O 
in O 
glutamate B-TRIVIAL 
levels O 
are O 
observed O 
, O 
whereas O 
ATP B-ABBREVIATION 
levels O 
in O 
the O 
extracellular O 
environment O 
significantly O 
increase O 
. O 
Extracellular O 
ATP B-ABBREVIATION 
accumulation O 
associated O 
with O 
CaMKII O 
inhibition O 
contributes O 
both O 
to O 
calcium B-SYSTEMATIC 
oscillations O 
within O 
astrocytes O 
and O 
ultimately O 
cortical O 
neuron O 
toxicity O 
. O 
Thus O 
, O 
a O 
loss O 
of O 
CaMKII O 
signaling O 
within O 
astrocytes O 
dysregulates O 
glutamate B-TRIVIAL 
uptake O 
and O 
supports O 
ATP B-ABBREVIATION 
release O 
, O 
two O 
processes O 
that O 
would O 
compromise O 
neuronal O 
survival O 
following O 
ischemic O 
/ O 
excitotoxic O 
insults O 
. O 

and O 
Ion O 
Transport O 
in O 
Ketones B-FAMILY 
and O 
Ketone B-SYSTEMATIC 
Electrolytes O 
: O 
Comparison O 
with O 
Acetate B-SYSTEMATIC 
Systems O 
. O 

- O 
diffusion O 
coefficient O 
measurements O 
were O 
performed O 
for O 
pure O 
n-alkyl B-FAMILY 
ketone I-FAMILY 
liquids O 
using O 
the O 
pulsed O 
field O 
gradient O 
NMR O 
spin O 
- O 
echo O 
technique O 
. O 
Ionic O 
conductivities O 
and O 
dielectric O 
constants O 
of O 
0.0055 O 
mol·L(-1) O 
tetrabutylammonium B-SYSTEMATIC 
trifluoromethanesulfonate I-SYSTEMATIC 
in O 
2-pentanone B-SYSTEMATIC 
, O 
2-hexanone B-SYSTEMATIC 
, O 
2-heptanone B-SYSTEMATIC 
, O 
2-octanone B-SYSTEMATIC 
, O 
2-nonanone B-SYSTEMATIC 
, O 
and O 
2-decanone B-SYSTEMATIC 
were O 
also O 
measured O 
. O 
The O 
temperature O 
- O 
dependent O 
conductivities O 
and O 
diffusion O 
coefficients O 
over O 
the O 
range O 
5-80 O 
°C O 
can O 
be O 
described O 
using O 
the O 
compensated O 
Arrhenius O 
formalism O 
. O 
Compensated O 
Arrhenius O 
equation O 
plots O 
were O 
used O 
to O 
calculate O 
the O 
average O 
activation O 
energy O 
for O 
both O 
sets O 
of O 
data O 
. O 
The O 
average O 
activation O 
energy O 
from O 
conductivity O 
data O 
is O 
approximately O 
equal O 
to O 
that O 
from O 
diffusion O 
data O 
. O 
The O 
data O 
for O 
the O 
pure O 
ketones B-FAMILY 
and O 
ketone B-SYSTEMATIC 
-based O 
electrolytes O 
are O 
compared O 
with O 
analogous O 
data O 
for O 
pure O 
n-alkyl B-FAMILY 
acetates I-FAMILY 
and O 
n-alkyl B-FAMILY 
acetate I-FAMILY 
-based O 
electrolytes O 
. O 

and O 
Pharmacological O 
Characterization O 
of O 
2-(Acylamino)thiophene B-SYSTEMATIC 
Derivatives O 
as O 
Metabolically O 
Stable O 
, O 
Orally O 
Effective O 
, O 
Positive O 
Allosteric O 
Modulators O 
of O 
the O 
GABAB O 
Receptor O 
. O 

recently O 
reported O 
hit O 
compounds O 
, O 
COR627 B-IDENTIFIER 
and O 
COR628 B-IDENTIFIER 
, O 
underpinned O 
the O 
development O 
of O 
a O 
series O 
of O 
2-(acylamino)thiophene B-SYSTEMATIC 
derivatives O 
. O 
Some O 
of O 
these O 
compounds O 
displayed O 
significant O 
activity O 
in O 
vitro O 
as O 
positive O 
allosteric O 
modulators O 
of O 
the O 
GABAB O 
receptor O 
by O 
potentiating O 
GTPγS O 
stimulation O 
induced O 
by O 
GABA B-ABBREVIATION 
at O 
2.5 O 
and O 
25 O 
μM O 
while O 
failing O 
to O 
exhibit O 
intrinsic O 
agonist O 
activity O 
. O 
Compounds O 
were O 
also O 
found O 
to O 
be O 
effective O 
in O 
vivo O 
, O 
potentiating O 
baclofen B-TRIVIAL 
-induced O 
sedation O 
/ O 
hypnosis O 
in O 
DBA O 
mice O 
when O 
administered O 
either O 
intraperitoneally O 
or O 
intragastrically O 
. O 
Although O 
displaying O 
a O 
lower O 
potency O 
in O 
vitro O 
than O 
the O 
reference O 
compound O 
GS39783 B-IDENTIFIER 
, O 
the O 
new O 
compounds O 
6 O 
, O 
10 O 
, O 
and O 
11 O 
exhibited O 
a O 
higher O 
efficacy O 
in O 
vivo O 
: O 
combination O 
of O 
these O 
compounds O 
with O 
a O 
per O 
se O 
nonsedative O 
dose O 
of O 
baclofen B-TRIVIAL 
resulted O 
in O 
shorter O 
onset O 
and O 
longer O 
duration O 
of O 
the O 
loss O 
of O 
righting O 
reflex O 
in O 
mice O 
. O 
Test O 
compounds O 
showed O 
cytotoxic O 
effects O 
at O 
concentrations O 
comparable O 
to O 
or O 
higher O 
than O 
those O 
of O 
GS39783 B-IDENTIFIER 
or O 
BHF177 B-IDENTIFIER 
. O 

Asymmetric O 
Synthesis O 
of O 
γ-Butenolides B-FAMILY 
by O 
Direct O 
Vinylogous O 
Reactions O 
. O 

γ-butenolide B-SYSTEMATIC 
structural O 
motif O 
is O 
a O 
prominent O 
feature O 
in O 
many O 
bioactive O 
natural O 
products O 
and O 
drugs O 
. O 
This O 
short O 
review O 
summarizes O 
catalytic O 
asymmetric O 
synthesis O 
of O 
γ-butenolides B-FAMILY 
through O 
direct O 
vinylogous O 
reactions O 
by O 
metal O 
complexes O 
and O 
organocatalysts O 
. O 
In O 
light O 
of O 
building O 
chiral O 
γ-tertiary B-MULTIPLE 
and I-MULTIPLE 
quaternary I-MULTIPLE 
carbon I-MULTIPLE 
centers O 
of O 
butenolides B-FAMILY 
, O 
three O 
synthetic O 
strategies O 
are O 
included O 
: O 
1 O 
) O 
the O 
reactions O 
with O 
furanone O 
derivatives O 
as O 
nucleophiles O 
, O 
2 O 
) O 
olefination O 
of O 
γ,γ- B-FAMILY 
disubstituted I-FAMILY 
butenolides I-FAMILY 
and O 
3 O 
) O 
the O 
reactions O 
by O 
using O 
γ,γ- B-FAMILY 
disubstituted I-FAMILY 
butenolides I-FAMILY 
as O 
nucleophiles O 
. O 

metal I-FAMILY 
-catalyzed O 
efficient O 
and O 
green O 
transformations O 
of O 
p(o)-h O 
compounds O 
to O 
functional O 
organophosphorus B-FAMILY 
compounds O 
. O 

compounds O 
are O 
of O 
high O 
importance O 
in O 
organic O 
synthesis O 
, O 
catalysis O 
, O 
biochemistry O 
, O 
pharmaceuticals O 
, O 
and O 
material O 
science O 
. O 
In O 
this O 
mini O 
review O 
, O 
we O 
summarize O 
our O 
recent O 
studies O 
on O 
transition B-FAMILY 
metal I-FAMILY 
-catalyzed O 
green O 
and O 
atom O 
efficient O 
transformations O 
of O 
P(O)-H B-FORMULA 
bonds O 
to O 
various O 
versatile O 
organophosphorus B-FAMILY 
compounds O 
, O 
including O 
the O 
highly O 
regio- O 
and O 
stereoselective O 
P(O)-H B-FORMULA 
additions O 
to O 
carbon B-SYSTEMATIC 
- O 
carbon B-SYSTEMATIC 
unsaturated O 
compounds O 
, O 
asymmetric O 
hydrophosphorylation O 
reactions O 
, O 
and O 
dehydrogenative O 
coupling O 
reactions O 
of O 
P(O)-H B-FORMULA 
compounds O 
with O 
carbon B-SYSTEMATIC 
- O 
H B-FORMULA 
and O 
heteroatom- O 
H B-FORMULA 
compounds O 
. O 
These O 
new O 
reactions O 
provide O 
efficient O 
, O 
general O 
and O 
practical O 
ways O 
for O 
the O 
preparation O 
of O 
a O 
variety O 
of O 
well O 
- O 
defined O 
functional O 
organophosphorus B-FAMILY 
compounds O 
. O 
Mechanistic O 
aspects O 
related O 
to O 
the O 
catalytic O 
processes O 
are O 
also O 
discussed O 
. O 

selenium B-SYSTEMATIC 
resin O 
in O 
solid O 
phase O 
synthesis O 
and O 
its O 
application O 
in O 
constructing O 
medicinally O 
relevant O 
small O 
organic O 
molecules O 
. O 

compounds O 
are O 
of O 
high O 
importance O 
in O 
constructing O 
active O 
drug O 
intermediates O 
library O 
. O 
The O 
emergence O 
of O 
solid O 
- O 
phase O 
and O 
combinatorial O 
chemistry O 
has O 
led O 
to O 
renewed O 
interest O 
in O 
using O 
organoselenium B-FAMILY 
resins O 
to O 
library O 
drug O 
- O 
like O 
production O 
. O 
In O 
this O 
mini O 
review O 
, O 
we O 
summarize O 
the O 
construction O 
of O 
heterocyclic O 
compounds O 
libraries O 
such O 
as O 
isoxazoles B-FAMILY 
, O 
oxadiazoles B-FAMILY 
, O 
triazoles B-FAMILY 
, O 
pyrimidines B-FAMILY 
, O 
pyrrolines B-FAMILY 
, O 
indolines B-FAMILY 
, O 
benzopyrans B-FAMILY 
, O 
furans B-FAMILY 
etc O 
. O 
using O 
organoselenium B-FAMILY 
resins O 
. O 
And O 
it O 
provided O 
efficient O 
and O 
practical O 
ways O 
for O 
the O 
preparation O 
of O 
a O 
variety O 
of O 
well O 
- O 
defined O 
functional O 
heterocyclic O 
compounds O 
with O 
the O 
advantages O 
of O 
good O 
yields O 
, O 
high O 
purity O 
, O 
straightforward O 
operations O 
, O 
broad O 
range O 
and O 
high O 
diversity O 
of O 
the O 
products O 
, O 
lack O 
of O 
odor O 
, O 
and O 
good O 
stability O 
of O 
the O 
resins O 
, O 
all O 
of O 
these O 
give O 
expression O 
to O 
green O 
chemistry O 
. O 

catalyzed O 
polycondensation O 
of O 
p-xylylenediamine B-SYSTEMATIC 
and O 
diethyl B-SYSTEMATIC 
sebacate I-SYSTEMATIC 
resulted O 
in O 
oligo(p-xylylene B-FAMILY 
sebacamide I-FAMILY 
) I-FAMILY 
with O 
high O 
melting O 
temperatures O 
( O 
223-230 O 
°C O 
) O 
and O 
the O 
enzymatic O 
polycondensation O 
of O 
dimethyl B-SYSTEMATIC 
terephthalate I-SYSTEMATIC 
and O 
1,8-diaminooctane B-SYSTEMATIC 
leads O 
to O 
oligo(octamethylene B-FAMILY 
terephthalamide I-FAMILY 
) I-FAMILY 
with O 
two O 
melting O 
temperatures O 
at O 
186 O 
and O 
218 O 
°C O 
. O 
No O 
oligoamides O 
, O 
but O 
products O 
1 O 
and O 
2 O 
, O 
were O 
formed O 
from O 
the O 
enzymatic O 
reaction O 
of O 
dimethyl B-SYSTEMATIC 
terephthalate I-SYSTEMATIC 
and O 
p-xylylenediamine B-SYSTEMATIC 
. O 
All O 
reactions O 
were O 
catalyzed O 
by O 
CAL-B O 
, O 
icutinase O 
, O 
or O 
CLEA O 
cutinase O 
. O 
All O 
reactions O 
catalyzed O 
by O 
CAL-B O 
show O 
higher O 
conversion O 
than O 
reactions O 
catalyzed O 
by O 
icutinase O 
or O 
CLEA O 
cutinase O 
. O 
The O 
highest O 
DPmax O 
of O 
15 O 
was O 
achieved O 
in O 
a O 
one O 
- O 
step O 
and O 
two O 
- O 
step O 
synthesis O 
of O 
oligo(p-xylylene B-FAMILY 
sebacamide I-FAMILY 
) I-FAMILY 
catalyzed O 
by O 
CLEA O 
cutinase O 
. O 

have O 
found O 
that O 
an O 
impurity O 
partitioning O 
takes O 
place O 
during O 
growth O 
of O 
colloidal O 
crystals O 
, O 
which O 
was O 
recognized O 
by O 
the O 
fact O 
that O 
the O 
impurity O 
concentration O 
in O 
the O 
solid O 
( O 
CS O 
) O 
was O 
different O 
from O 
that O 
in O 
the O 
initial O 
solution O 
( O 
C0 O 
) O 
. O 
The O 
effective O 
partition O 
coefficient O 
keff O 
( O 
= O 
CS O 
/ O 
C0 O 
) O 
was O 
investigated O 
for O 
pure O 
polystyrene B-SYSTEMATIC 
and O 
polystyrene B-SYSTEMATIC 
dyed O 
with O 
fluorescent O 
particles O 
by O 
changing O 
the O 
ratio O 
of O 
particle O 
diameters O 
dimp O 
/ O 
dcryst O 
and O 
growth O 
rate O 
V O 
. O 
At O 
each O 
size O 
ratio O 
for O 
the O 
polystyrene B-SYSTEMATIC 
impurity O 
, O 
keff O 
was O 
less O 
than O 
unity O 
and O 
increased O 
to O 
unity O 
with O 
increasing O 
V O 
, O 
whereas O 
at O 
a O 
given O 
growth O 
rate O 
, O 
keff O 
increased O 
to O 
unity O 
as O 
dimp O 
/ O 
dcryst O 
approached O 
unity O 
. O 
These O 
results O 
were O 
consistent O 
with O 
the O 
solute O 
behavior O 
analyzed O 
using O 
the O 
Burton O 
, O 
Prim O 
, O 
and O 
Slichter O 
( O 
BPS O 
) O 
model O 
. O 
The O 
obtained O 
k0 O 
, O 
equilibrium O 
partition O 
coefficient O 
, O 
from O 
a O 
BPS O 
plot O 
increased O 
as O 
dimp O 
/ O 
dcryst O 
approached O 
unity O 
. O 
In O 
contrast O 
, O 
while O 
the O 
fluorescent O 
particles O 
also O 
followed O 
the O 
BPS O 
model O 
, O 
they O 
showed O 
higher O 
k0 O 
values O 
than O 
those O 
of O 
the O 
same O 
size O 
of O 
polystyrene B-SYSTEMATIC 
particles O 
. O 
A O 
k0 O 
value O 
greater O 
than O 
unity O 
was O 
obtained O 
for O 
impurities O 
that O 
were O 
similar O 
in O 
size O 
to O 
the O 
host O 
particle O 
. O 
This O 
behavior O 
is O 
attributed O 
to O 
the O 
positive O 
free O 
energy O 
of O 
fusion O 
associated O 
with O 
the O 
incorporation O 
of O 
the O 
fluorescent O 
particles O 
into O 
the O 
host O 
matrix O 
. O 
Such O 
positive O 
free O 
energy O 
of O 
fusion O 
implies O 
the O 
presence O 
of O 
the O 
enthalpy O 
associated O 
with O 
interaction O 
between O 
particles O 
. O 

novel O 
method O 
for O 
applying O 
high O 
- O 
throughput O 
docking O 
to O 
challenging O 
metalloenzyme O 
targets O 
is O 
described O 
. O 
The O 
method O 
utilizes O 
information O 
- O 
based O 
virtual O 
transformation O 
of O 
library O 
carboxylates B-FAMILY 
to O 
hydroxamic B-FAMILY 
acids I-FAMILY 
prior O 
to O 
docking O 
, O 
followed O 
by O 
compound O 
acquisition O 
, O 
one O 
- O 
pot O 
( O 
two O 
steps O 
) O 
chemical O 
synthesis O 
and O 
in O 
vitro O 
screening O 
. O 
In O 
two O 
experiments O 
targeting O 
the O 
botulinum O 
neurotoxin O 
serotype O 
A O 
metalloprotease O 
light O 
chain O 
, O 
hit O 
rates O 
of O 
32% O 
and O 
18% O 
were O 
observed O 
. O 

RELEVANCE O 
: O 
Ethnobotanical O 
reports O 
on O 
more O 
than O 
100 O 
southern O 
African O 
medicinal O 
plants O 
with O 
dermatological O 
relevance O 
have O 
been O 
highlighted O 
, O 
yet O 
there O 
is O 
still O 
limited O 
scientific O 
data O 
to O 
support O 
claims O 
for O 
their O 
antimicrobial O 
effectiveness O 
against O 
skin O 
pathogens O 
. O 
Guided O 
by O 
ethnobotanical O 
data O 
, O 
this O 
paper O 
explores O 
the O 
antimicrobial O 
efficacies O 
of O 
southern O 
African O 
medicinal O 
plants O 
used O 
to O 
treat O 
skin O 
ailments O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
To O 
investigate O 
the O 
antimicrobial O 
properties O 
of O 
southern O 
African O 
medicinal O 
plants O 
against O 
dermatologically O 
relevant O 
pathogens O 
. O 
The O 
study O 
also O 
aimed O 
at O 
providing O 
a O 
scientific O 
rationale O 
for O 
the O 
traditional O 
use O 
of O 
plant O 
combinations O 
to O 
treat O 
skin O 
diseases O 
and O 
the O 
isolation O 
of O 
the O 
bioactive O 
compound O 
from O 
the O 
most O 
active O 
species O 
, O 
Aristea O 
ecklonii O 
( O 
Iridaceae O 
) O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Organic O 
and O 
aqueous O 
extracts O 
( O 
132 O 
) O 
were O 
prepared O 
from O 
47 O 
plant O 
species O 
and O 
screened O 
for O 
antimicrobial O 
properties O 
against O 
dermatologically O 
relevant O 
pathogens O 
using O 
the O 
micro O 
- O 
titre O 
plate O 
dilution O 
method O 
. O 
Four O 
different O 
plant O 
combinations O 
were O 
investigated O 
for O 
interactive O 
properties O 
and O 
the O 
sum O 
of O 
the O 
fractional O 
inhibitory O 
concentration O 
( O 
ƩFIC O 
) O 
calculated O 
. O 
Isobolograms O 
were O 
used O 
to O 
further O 
investigate O 
the O 
antimicrobial O 
interactive O 
properties O 
of O 
Pentanisia O 
prunelloides O 
combined O 
with O 
Elephantorrhiza O 
elephantina O 
at O 
varied O 
ratios O 
. O 
A O 
bioactivity O 
- O 
guided O 
fractionation O 
process O 
was O 
adopted O 
to O 
fractionate O 
the O 
organic O 
leaf O 
extract O 
of O 
Aristea O 
ecklonii O 
. O 
RESULTS O 
: O 
Plants O 
demonstrating O 
notable O 
broad O 
- O 
spectrum O 
activities O 
( O 
MIC O 
values O 
≤ O 
1.00mg O 
/ O 
ml O 
) O 
against O 
the O 
tested O 
pathogens O 
included O 
extracts O 
from O 
Aristea O 
ecklonii O 
, O 
Chenopodium O 
ambrosioides O 
, O 
Diospyros O 
mespiliformis O 
, O 
Elephantorrhiza O 
elephantina O 
, O 
Eucalyptus O 
camaldulensis O 
, O 
Gunnera O 
perpensa O 
, O 
Harpephyllum O 
caffrum O 
, O 
Hypericum O 
perforatum O 
, O 
Melianthus O 
comosus O 
, O 
Terminalia O 
sericea O 
and O 
Warburgia O 
salutaris O 
. O 
The O 
organic O 
extract O 
of O 
Elephantorrhiza O 
elephantina O 
, O 
a O 
plant O 
reportedly O 
used O 
to O 
treat O 
acne O 
vulgaris O 
, O 
demonstrated O 
noteworthy O 
antimicrobial O 
activity O 
( O 
MIC O 
value O 
of O 
0.05mg O 
/ O 
ml O 
) O 
against O 
Propionibacterium O 
acnes O 
. O 
Similarly O 
, O 
Diospyros O 
mespiliformis O 
reported O 
for O 
its O 
traditional O 
use O 
to O 
treat O 
ringworm O 
, O 
also O 
displayed O 
noteworthy O 
antimicrobial O 
activity O 
against O 
Trichophyton O 
mentagrophytes O 
( O 
MIC O 
0.10mg O 
/ O 
ml O 
) O 
and O 
Microsporum O 
canis O 
( O 
MIC O 
0.50mg O 
/ O 
ml O 
) O 
. O 
The O 
aqueous O 
root O 
extracts O 
of O 
Pentanisia O 
prunelloides O 
combined O 
( O 
1 O 
: O 
1 O 
) O 
with O 
Elephantorrhiza O 
elephantina O 
displayed O 
synergistic O 
interactions O 
( O 
ƩFIC O 
values O 
0.31-0.38 O 
) O 
against O 
Staphylococcus O 
aureus O 
, O 
gentamycin B-FAMILY 
- O 
methicillin B-TRIVIAL 
resistant O 
Staphylococcus O 
aureus O 
, O 
Staphylococcus O 
epidermidis O 
and O 
Candida O 
albicans O 
. O 
Fractionation O 
of O 
Aristea O 
ecklonii O 
resulted O 
in O 
the O 
isolation O 
of O 
the O 
known O 
bioactive O 
compound O 
, O 
plumbagin B-TRIVIAL 
, O 
displaying O 
noteworthy O 
antimicrobial O 
activity O 
( O 
MIC O 
range O 
between O 
2.00μg O 
/ O 
ml O 
and O 
16.00μg O 
/ O 
ml O 
) O 
. O 
CONCLUSION O 
: O 
Most O 
of O 
the O 
plant O 
extracts O 
demonstrated O 
pathogen O 
specific O 
antimicrobial O 
effects O 
with O 
a O 
few O 
exhibiting O 
broad O 
- O 
spectrum O 
activities O 
. O 
Positive O 
antimicrobial O 
effects O 
noted O 
for O 
plants O 
such O 
as O 
Elephantorrhiza O 
elephantina O 
and O 
Diospyros O 
mespiliformis O 
used O 
for O 
acne O 
vulgaris O 
and O 
ringworm O 
infections O 
, O 
respectively O 
, O 
give O 
some O 
validation O 
to O 
their O 
reported O 
traditiona O 
l O 
uses O 
. O 
Synergistic O 
interactions O 
noted O 
for O 
Pentanisia O 
prunelloides O 
combined O 
with O 
Elephantorrhiza O 
elephantina O 
validate O 
an O 
enhanced O 
antimicrobial O 
effect O 
when O 
used O 
in O 
combination O 
. O 
Noteworthy O 
antimicrobial O 
activities O 
( O 
MIC O 
range O 
between O 
2.00μg O 
/ O 
ml O 
and O 
16.00μg O 
/ O 
ml O 
) O 
were O 
observed O 
for O 
plumbagin B-TRIVIAL 
isolated O 
from O 
Aristea O 
ecklonii O 
. O 

and O 
high O 
- O 
rate O 
overcharge O 
protection O 
for O 
rechargeable O 
lithium B-SYSTEMATIC 
batteries O 
. O 

lithium B-SYSTEMATIC 
or O 
lithium B-SYSTEMATIC 
-ion O 
cells O 
can O 
be O 
overcharge O 
- O 
protected O 
by O 
an O 
electroactive O 
polymer O 
composite O 
separator O 
. O 
The O 
use O 
of O 
non-woven O 
fibrous O 
membranes O 
instead O 
of O 
conventional O 
microporous O 
membranes O 
as O 
the O 
composite O 
substrates O 
allowed O 
better O 
distribution O 
of O 
the O 
electroactive O 
polymer O 
, O 
which O 
led O 
to O 
improved O 
utilization O 
and O 
a O 
40-fold O 
increase O 
in O 
sustainable O 
current O 
density O 
. O 
For O 
the O 
first O 
time O 
, O 
stable O 
overcharge O 
protection O 
for O 
hundreds O 
of O 
cycles O 
was O 
demonstrated O 
in O 
several O 
cell O 
chemistries O 
, O 
including O 
LiNi1 B-FORMULA 
/ O 
3Co1 B-FORMULA 
/ O 
3Mn1 B-FORMULA 
/ O 
3O2 B-FORMULA 
, O 
LiFePO4 B-FORMULA 
, O 
and O 
spinel O 
Li1.05Mn1.95O4 B-FORMULA 
half O 
- O 
cells O 
. O 
Protection O 
at O 
a O 
charging O 
rate O 
as O 
high O 
as O 
5 O 
C O 
was O 
achieved O 
at O 
a O 
steady O 
state O 
cell O 
potential O 
below O 
4.85 O 
V O 
. O 

metabolic O 
profile O 
of O 
mitoxantrone B-TRIVIAL 
and O 
its O 
relation O 
with O 
mitoxantrone B-TRIVIAL 
-induced O 
cardiotoxicity O 
. O 

( O 
MTX B-ABBREVIATION 
) O 
is O 
an O 
antitumor O 
agent O 
that O 
causes O 
cardiotoxicity O 
in O 
18 O 
% O 
patients O 
. O 
The O 
metabolic O 
profile O 
of O 
MTX B-ABBREVIATION 
was O 
assessed O 
after O 
incubation O 
of O 
100 O 
μM O 
MTX B-ABBREVIATION 
with O 
hepatic O 
S9 O 
fraction O 
isolated O 
from O 
rats O 
. O 
The O 
presence O 
of O 
MTX B-ABBREVIATION 
and O 
its O 
metabolites O 
was O 
also O 
assessed O 
in O 
vivo O 
through O 
the O 
analysis O 
of O 
liver O 
and O 
heart O 
extracts O 
of O 
MTX B-ABBREVIATION 
-treated O 
rats O 
. O 
The O 
cytotoxic O 
effects O 
of O 
MTX B-ABBREVIATION 
and O 
MTX B-ABBREVIATION 
metabolites O 
were O 
evaluated O 
in O 
the O 
H9c2 O 
cells O 
after O 
24-h O 
incubation O 
with O 
MTX B-ABBREVIATION 
alone O 
and O 
MTX B-ABBREVIATION 
+ O 
metabolites O 
. O 
The O 
influence O 
of O 
CYP450- O 
and O 
CYP2E1 O 
- O 
mediated O 
metabolism O 
for O 
the O 
cytotoxicity O 
of O 
MTX B-ABBREVIATION 
was O 
assessed O 
after O 
96-h O 
incubation O 
with O 
MTX B-ABBREVIATION 
( O 
100 O 
nM O 
and O 
1 O 
μM O 
) O 
in O 
the O 
presence O 
/ O 
absence O 
of O 
CYP450 O 
or O 
CYP2E1 O 
inhibitors O 
. O 
After O 
4-h O 
incubation O 
in O 
supplemented O 
S9 O 
fraction O 
, O 
the O 
MTX B-ABBREVIATION 
content O 
was O 
35 O 
% O 
lower O 
and O 
5 O 
metabolites O 
were O 
identified O 
: O 
an O 
acetoxy O 
ester O 
derivative O 
(never O 
described O 
before O 
) O 
, O 
two O 
glutathione B-TRIVIAL 
conjugates O 
, O 
a O 
monocarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
derivative O 
, O 
and O 
the O 
naphtoquinoxaline B-SYSTEMATIC 
, O 
the O 
later O 
commonly O 
related O 
to O 
MTX B-ABBREVIATION 
pharmacological O 
effects O 
. O 
The O 
presence O 
of O 
MTX B-ABBREVIATION 
and O 
naphtoquinoxaline B-SYSTEMATIC 
metabolite O 
was O 
evidenced O 
in O 
vivo O 
in O 
liver O 
and O 
heart O 
of O 
MTX B-ABBREVIATION 
-treated O 
rats O 
. O 
The O 
cytotoxicity O 
caused O 
by O 
MTX B-ABBREVIATION 
+ O 
metabolites O 
was O 
higher O 
than O 
that O 
observed O 
in O 
the O 
H9c2 O 
cells O 
incubated O 
with O 
non-metabolized O 
MTX B-ABBREVIATION 
group O 
. O 
The O 
co O 
- O 
incubation O 
of O 
MTX B-ABBREVIATION 
with O 
CYP450 O 
and O 
CYP2E1 O 
inhibitors O 
partially O 
prevented O 
the O 
cytotoxicity O 
observed O 
in O 
the O 
MTX B-ABBREVIATION 
groups O 
incubated O 
with O 
H9c2 O 
cells O 
, O 
highlighting O 
that O 
the O 
metabolism O 
of O 
MTX B-ABBREVIATION 
is O 
relevant O 
for O 
its O 
undesirable O 
effects O 
. O 
The O 
naphtoquinoxaline B-SYSTEMATIC 
metabolite O 
is O 
described O 
in O 
heart O 
and O 
liver O 
in O 
vivo O 
, O 
highlighting O 
that O 
this O 
metabolite O 
accumulates O 
in O 
these O 
tissues O 
. O 
It O 
was O 
demonstrated O 
that O 
MTX B-ABBREVIATION 
P450 O 
- O 
mediated O 
metabolism O 
contributed O 
to O 
MTX B-ABBREVIATION 
toxicity O 
. O 

new O 
cyclic O 
peptides O 
, O 
gypsophin B-MULTIPLE 
A-F I-MULTIPLE 
( O 
1-6 O 
) O 
, O 
were O 
isolated O 
from O 
Gypsophila O 
oldhamiana O 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
extensive O 
NMR O 
and O 
chemical O 
degradation O 
. O 
Compound O 
3 O 
exhibited O 
moderate O 
activity O 
of O 
antiplatelet O 
aggregation O 
in O 
vitro O 
. O 

potential O 
of O 
Lavandula O 
coronopifolia O 
extracts O 
against O 
ethanol B-SYSTEMATIC 
induced O 
oxidative O 
stress O 
- O 
mediated O 
cytotoxicity O 
in O 
HepG2 O 
cells O 
. O 

present O 
investigations O 
were O 
carried O 
out O 
to O 
study O 
the O 
protective O 
potential O 
of O 
four O 
extracts O 
( O 
namely O 
petroleum B-TRIVIAL 
ether I-TRIVIAL 
extract O 
( O 
LCR O 
) O 
, O 
chloroform B-TRIVIAL 
extract O 
( O 
LCM O 
) O 
, O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
( O 
LCE O 
) O 
, O 
and O 
alcoholic O 
extract O 
( O 
LCL O 
) O 
) O 
of O 
Lavandula O 
coronopifolia O 
on O 
oxidative O 
stress O 
- O 
mediated O 
cell O 
death O 
induced O 
by O 
ethanol B-SYSTEMATIC 
, O 
a O 
known O 
hepatotoxin O 
in O 
human O 
hapatocellular O 
carcinoma O 
( O 
HepG2 O 
) O 
cells O 
. O 
Cells O 
were O 
pretreated O 
with O 
LCR O 
, O 
LCM O 
, O 
LCE O 
, O 
and O 
LCL O 
extracts O 
( O 
10-50 O 
μg O 
/ O 
ml O 
) O 
of O 
L O 
. O 
coronopifolia O 
for O 
24 O 
h O 
and O 
then O 
ethanol B-SYSTEMATIC 
was O 
added O 
and O 
incubated O 
further O 
for O 
24 O 
h O 
. O 
After O 
the O 
exposure O 
, O 
cell O 
viability O 
using O 
( O 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
) O 
and O 
neutral B-TRIVIAL 
red I-TRIVIAL 
uptake O 
assays O 
and O 
morphological O 
changes O 
in O 
HepG2 O 
cells O 
were O 
studied O 
. O 
Pretreatment O 
with O 
various O 
extracts O 
of O 
L O 
. O 
coronpifolia O 
was O 
found O 
to O 
be O 
significantly O 
effective O 
in O 
countering O 
the O 
cytotoxic O 
responses O 
of O 
ethanol B-SYSTEMATIC 
. O 
Antioxidant O 
properties O 
of O 
these O 
L O 
. O 
coronopifolia O 
extracts O 
against O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
generation O 
, O 
lipid O 
peroxidation O 
( O 
LPO O 
) O 
, O 
and O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
levels O 
induced O 
by O 
ethanol B-SYSTEMATIC 
were O 
investigated O 
. O 
Results O 
show O 
that O 
pretreatment O 
with O 
these O 
extracts O 
for O 
24 O 
h O 
significantly O 
inhibited O 
ROS O 
generation O 
and O 
LPO O 
induced O 
and O 
increased O 
the O 
GSH B-ABBREVIATION 
levels O 
reduced O 
by O 
ethanol B-SYSTEMATIC 
. O 
The O 
data O 
from O 
the O 
study O 
suggests O 
that O 
LCR O 
, O 
LCM O 
, O 
LCE O 
, O 
and O 
LCL O 
extracts O 
of O 
L O 
. O 
coronopifolia O 
showed O 
hepatoprotective O 
activity O 
against O 
ethanol B-SYSTEMATIC 
-induced O 
damage O 
in O 
HepG2 O 
cells O 
. O 
However O 
, O 
a O 
comparative O 
study O 
revealed O 
that O 
the O 
LCE O 
extract O 
was O 
found O 
to O 
be O 
the O 
most O 
effective O 
and O 
LCL O 
the O 
least O 
effective O 
. O 
The O 
hepatoprotective O 
effects O 
observed O 
in O 
the O 
study O 
could O 
be O 
associated O 
with O 
the O 
antioxidant O 
properties O 
of O 
these O 
extracts O 
of O 
L O 
. O 
coronopifolia O 
. O 

propensity O 
of O 
citrate B-FAMILY 
- O 
and O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
-coated O 
silver B-SYSTEMATIC 
nanoparticles O 
to O 
bovine O 
hemoglobin O 
. O 

of O 
two O 
different O 
silver B-SYSTEMATIC 
nanoparticles O 
( O 
Ag B-FORMULA 
-NPs O 
) O 
to O 
bovine O 
hemoglobin O 
( O 
BHb O 
) O 
was O 
investigated O 
by O 
means O 
of O 
spectroscopic O 
methods O 
. O 
We O 
have O 
combined O 
spectrophotometric O 
and O 
calorimetric O 
methods O 
to O 
show O 
that O 
there O 
is O 
no O 
significant O 
interaction O 
between O 
citrate B-FAMILY 
-coated O 
Ag B-FORMULA 
-NPs O 
and O 
BHb O 
at O 
physiological O 
pH O 
and O 
20°C O 
. O 
However O 
, O 
our O 
previous O 
results O 
show O 
that O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
-coated O 
Ag B-FORMULA 
-NPs O 
strongly O 
bind O 
to O 
Hb O 
and O 
effect O 
on O 
the O 
secondary O 
and O 
tertiary O 
structures O 
of O 
BHb O 
. O 
Thus O 
, O 
a O 
suitable O 
surface O 
coating O 
and O 
modification O 
of O 
surface O 
charge O 
would O 
increase O 
the O 
NPs O 
safety O 
and O 
reduce O 
adverse O 
biological O 
responses O 
. O 

androgens B-FAMILY 
in O 
utero O 
alters O 
fetal O 
testis O 
development O 
. O 

androgenization O 
induces O 
a O 
polycystic O 
ovary O 
syndrome O 
- O 
like O 
phenotype O 
in O 
adult O 
female O 
offspring O 
, O 
which O 
is O 
associated O 
with O 
alterations O 
that O 
can O 
be O 
detected O 
in O 
the O 
fetal O 
ovary O 
, O 
suggesting O 
gestational O 
origins O 
of O 
this O 
condition O 
. O 
We O 
therefore O 
investigated O 
whether O 
increased O 
prenatal O 
androgen B-FAMILY 
exposure O 
also O 
altered O 
testicular O 
development O 
using O 
ovine O 
animal O 
models O 
. O 
Biweekly O 
maternal O 
testosterone B-SYSTEMATIC 
propionate I-SYSTEMATIC 
( O 
TP O 
; O 
100 O 
mg O 
) O 
from O 
day O 
62 O 
to O 
day O 
70 O 
/ O 
day O 
90 O 
of O 
gestation O 
altered O 
male O 
developmental O 
trajectory O 
. O 
In O 
male O 
fetuses O 
serum O 
LH O 
was O 
decreased O 
( O 
P O 
< O 
0.01 O 
) O 
, O 
and O 
testicular O 
STAR O 
, O 
CYP11 O 
, O 
and O 
CYP17 O 
abundance O 
were O 
reduced O 
. O 
Coincident O 
with O 
this O 
, O 
basal O 
testicular O 
T O 
synthesis O 
was O 
decreased O 
in O 
vitro O 
( O 
P O 
< O 
0.001 O 
) O 
. O 
Leydig O 
cell O 
distribution O 
was O 
severely O 
perturbed O 
in O 
all O 
testes O 
prenatally O 
exposed O 
to O 
TP O 
( O 
P O 
< O 
0.001 O 
) O 
. O 
To O 
examine O 
the O 
contribution O 
of O 
estrogens B-FAMILY 
, O 
fetuses O 
were O 
injected O 
with O 
TP O 
( O 
20 O 
mg O 
) O 
, O 
the O 
potent O 
estrogen B-FAMILY 
agonist O 
, O 
diethylstilbestrol B-SYSTEMATIC 
( O 
DES B-ABBREVIATION 
; O 
20 O 
mg O 
) O 
, O 
or O 
vehicle O 
control O 
at O 
day O 
62 O 
and O 
day O 
82 O 
and O 
assessed O 
at O 
day O 
90 O 
. O 
The O 
effects O 
of O 
fetal O 
( O 
direct O 
) O 
TP O 
treatment O 
, O 
but O 
not O 
DES B-ABBREVIATION 
, O 
paralleled O 
maternal O 
( O 
indirect O 
) O 
TP O 
exposure O 
, O 
supporting O 
a O 
direct O 
androgen B-FAMILY 
effect O 
. O 
Cessation O 
of O 
maternal O 
androgenization O 
at O 
day O 
102 O 
returned O 
Leydig O 
cell O 
distribution O 
to O 
normal O 
but O 
increased O 
basal O 
T O 
output O 
, O 
at O 
day O 
112 O 
, O 
demonstrating O 
Leydig O 
cell O 
developmental O 
plasticity O 
. O 
Earlier O 
maternal O 
androgen B-FAMILY 
exposure O 
from O 
day O 
30 O 
similarly O 
influenced O 
Leydig O 
cell O 
development O 
at O 
day O 
90 O 
but O 
additionally O 
affected O 
the O 
expression O 
of O 
Sertoli O 
and O 
germ O 
cell O 
markers O 
. O 
We O 
show O 
in O 
this O 
study O 
that O 
increased O 
prenatal O 
androgen O 
exposure O 
alters O 
development O 
and O 
function O 
of O 
Leydig O 
cells O 
at O 
a O 
time O 
when O 
androgen B-FAMILY 
production O 
is O 
paramount O 
for O 
male O 
development O 
. O 
This O 
supports O 
the O 
concept O 
that O 
gestational O 
antecedents O 
associated O 
with O 
polycystic O 
ovary O 
syndrome O 
may O 
have O 
effects O 
on O 
the O 
male O 
fetus O 
. O 

/ O 
cyclodextrin O 
complex O 
- O 
loaded O 
lyophilized O 
microparticles O 
for O 
intranasal O 
application O 
. O 

Objective O 
: O 
Lyophilized O 
microparticles O 
composed O 
of O 
budesonide B-TRIVIAL 
( O 
BDS B-ABBREVIATION 
) O 
, O 
hydroxypropyl-β-cyclodextrin B-SYSTEMATIC 
( O 
HP-β-CD B-ABBREVIATION 
) O 
, O 
and O 
hydroxypropylmethylcellulose O 
( O 
HPMC O 
) O 
or O 
sodium B-SYSTEMATIC 
carboxymethylcellulose O 
( O 
CMC- O 
Na B-FORMULA 
) O 
were O 
developed O 
for O 
intranasal O 
delivery O 
and O 
their O 
characteristics O 
were O 
evaluated O 
. O 
Materials O 
and O 
methods O 
: O 
The O 
particle O 
size O 
and O 
morphology O 
were O 
assessed O 
by O 
mean O 
diameter O 
measurement O 
and O 
scanning O 
electron O 
microscopy O 
( O 
SEM O 
) O 
image O 
, O 
respectively O 
. O 
The O 
solid O 
- O 
state O 
of O 
products O 
was O 
tested O 
by O 
X-ray O 
powder O 
diffraction O 
( O 
XRPD O 
) O 
, O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
( O 
FT-IR O 
) O 
and O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
. O 
In O 
vitro O 
drug O 
release O 
and O 
cytotoxicity O 
to O 
the O 
primary O 
human O 
nasal O 
epithelial O 
( O 
HNE O 
) O 
cells O 
were O 
also O 
evaluated O 
. O 
Results O 
and O 
discussion O 
: O 
Lyophilized O 
microparticles O 
exhibited O 
vanishment O 
of O 
crystallinity O 
of O 
drug O 
in O 
XRPD O 
analysis O 
, O 
the O 
enfeeblement O 
of O 
carbonyl B-FAMILY 
( O 
C=O B-FORMULA 
) O 
stretching O 
bands O 
of O 
carboxyl B-SYSTEMATIC 
group O 
in O 
BDS B-ABBREVIATION 
in O 
FT-IR O 
spectra O 
and O 
the O 
disappearance O 
of O 
endothermic O 
peak O 
of O 
drug O 
in O 
the O 
results O 
of O 
DSC O 
study O 
. O 
Based O 
on O 
the O 
results O 
of O 
solid O 
- O 
state O 
studies O 
, O 
BDS B-ABBREVIATION 
was O 
existed O 
as O 
an O 
amorphous O 
form O 
in O 
the O 
lyophilized O 
microparticles O 
. O 
CD O 
complexation O 
enhanced O 
drug O 
solubility O 
and O 
release O 
rate O 
, O 
and O 
HPMC O 
or O 
CMC- O 
Na B-FORMULA 
also O 
improved O 
drug O 
dissolution O 
rates O 
. O 
Cytotoxicity O 
of O 
developed O 
microparticles O 
to O 
the O 
HNE O 
cells O 
was O 
measured O 
and O 
their O 
safety O 
to O 
HNE O 
cell O 
was O 
identified O 
. O 
Conclusion O 
: O 
Developed O 
microparticles O 
can O 
efficiently O 
deliver O 
insoluble O 
drug O 
, O 
such O 
as O 
BDS B-ABBREVIATION 
, O 
to O 
the O 
nasal O 
epithelium O 
and O 
thus O 
it O 
may O 
improve O 
therapeutic O 
efficacy O 
in O 
the O 
respiratory O 
tract O 
. O 

( O 
5-HT B-SYSTEMATIC 
) O 
in O 
the O 
Regulation O 
of O 
Depression O 
- O 
Related O 
Emotionality O 
: O 
Insight O 
from O 
5-HT B-SYSTEMATIC 
Transporter O 
and O 
Tryptophan B-TRIVIAL 
Hydroxylase-2 O 
Knockout O 
Mouse O 
Models O 
. O 

of O 
emotion O 
regulation O 
such O 
as O 
anxiety O 
disorders O 
and O 
depression O 
are O 
common O 
and O 
yet O 
debilitating O 
. O 
Accumulating O 
evidence O 
suggests O 
involvement O 
of O 
serotonin B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
) O 
in O 
the O 
regulation O 
of O 
emotion O 
. O 
Mice O 
with O 
targeted O 
deletion O 
of O 
genes O 
encoding O 
mediators O 
of O 
the O 
serotonergic O 
transmission O 
have O 
proven O 
to O 
be O 
a O 
powerful O 
tool O 
for O 
understanding O 
contributions O 
of O 
such O 
mediators O 
of O 
emotion O 
regulation O 
. O 
Over O 
the O 
last O 
decade O 
, O 
research O 
on O 
mice O 
with O 
a O 
targeted O 
inactivation O 
of O 
the O 
5-HT B-SYSTEMATIC 
transporter O 
( O 
5-Htt O 
, O 
Sert O 
, O 
Slc6a4 O 
) O 
has O 
considerably O 
advanced O 
our O 
knowledge O 
about O 
functions O 
that O 
the O 
5-HTT O 
plays O 
in O 
the O 
context O 
of O 
emotion O 
related O 
to O 
depression O 
. O 
Moreover O 
, O 
the O 
recent O 
advent O 
of O 
knockout O 
( O 
KO O 
) O 
mice O 
for O 
tryptophan B-TRIVIAL 
hydroxylase O 
2 O 
( O 
Tph2 O 
KO O 
) O 
, O 
which O 
lacks O 
the O 
rate O 
- O 
limiting O 
enzyme O 
for O 
5-HT B-SYSTEMATIC 
synthesis O 
in O 
the O 
brain O 
, O 
has O 
further O 
provided O 
insight O 
to O 
the O 
brain O 
serotonergic O 
system O 
and O 
its O 
role O 
in O 
emotion O 
dysregulation O 
. O 
Here O 
, O 
we O 
first O 
highlight O 
basic O 
characteristics O 
of O 
the O 
serotonergic O 
system O 
including O 
the O 
biosynthesis O 
of O 
5-HT B-SYSTEMATIC 
as O 
well O 
as O 
the O 
anatomy O 
and O 
firing O 
activity O 
of O 
serotonergic O 
neurons O 
. O 
Furthermore O 
, O 
characteristics O 
of O 
5-Htt O 
and O 
Tph2 O 
KO O 
mice O 
are O 
covered O 
together O 
with O 
association O 
studies O 
on O 
human O 
variants O 
of O 
5-HTT O 
and O 
TPH2 O 
in O 
emotional O 
regulation O 
. O 
Among O 
various O 
targets O 
of O 
serotonergic O 
projections O 
, O 
which O 
originate O 
from O 
the O 
raphe O 
nuclei O 
in O 
the O 
brain O 
stem O 
, O 
particular O 
focus O 
is O 
placed O 
on O 
the O 
hippocampus O 
due O 
to O 
its O 
unique O 
dual O 
role O 
in O 
memory O 
and O 
emotion O 
. O 
Finally O 
, O 
effects O 
of O 
therapeutic O 
drugs O 
and O 
psychoactive O 
drugs O 
on O 
KO O 
mouse O 
models O 
as O 
well O 
as O 
on O 
synaptic O 
plasticity O 
will O 
be O 
discussed O 
. O 

Hydrogen B-SYSTEMATIC 
Sulfide I-SYSTEMATIC 
Donors O 
and O 
Their O 
Activity O 
against O 
Myocardial O 
Ischemia-Reperfusion O 
Injury O 
. O 

sulfide I-SYSTEMATIC 
( O 
H2S B-FORMULA 
) O 
, O 
known O 
as O 
an O 
important O 
cellular O 
signaling O 
molecule O 
, O 
plays O 
critical O 
roles O 
in O 
many O 
physiological O 
and O 
/ O 
or O 
pathological O 
processes O 
. O 
Modulation O 
of O 
H2S B-FORMULA 
levels O 
could O 
have O 
tremendous O 
therapeutic O 
value O 
. O 
However O 
, O 
the O 
study O 
on O 
H2S B-FORMULA 
has O 
been O 
hindered O 
due O 
to O 
the O 
lack O 
of O 
controllable O 
H2S B-FORMULA 
releasing O 
agents O 
that O 
could O 
mimic O 
the O 
slow O 
and O 
moderate O 
H2S B-FORMULA 
release O 
in O 
vivo O 
. O 
In O 
this O 
work O 
we O 
report O 
the O 
design O 
, O 
synthesis O 
, O 
and O 
biological O 
evaluation O 
of O 
a O 
new O 
class O 
of O 
controllable O 
H2S B-FORMULA 
donors O 
. O 
Twenty O 
- O 
five O 
donors O 
were O 
prepared O 
and O 
tested O 
. O 
Their O 
structures O 
were O 
based O 
on O 
a O 
perthiol B-SYSTEMATIC 
template O 
, O 
which O 
was O 
suggested O 
to O 
be O 
involved O 
in O 
H2S B-FORMULA 
biosynthesis O 
. O 
H2S B-FORMULA 
release O 
mechanism O 
from O 
these O 
donors O 
was O 
studied O 
and O 
proved O 
to O 
be O 
thiol B-FAMILY 
-dependent O 
. O 
We O 
also O 
developed O 
a O 
series O 
of O 
cell O 
- O 
based O 
assays O 
to O 
access O 
their O 
H2S B-FORMULA 
-related O 
activities O 
. O 
H9c2 O 
cardiac O 
myocytes O 
were O 
used O 
in O 
these O 
experiments O 
. O 
We O 
tested O 
lead O 
donors O 
' O 
cytotoxicity O 
and O 
confirmed O 
their O 
H2S B-FORMULA 
production O 
in O 
cells O 
. O 
Finally O 
we O 
demonstrated O 
that O 
selected O 
donors O 
showed O 
potent O 
protective O 
effects O 
in O 
an O 
in O 
vivo O 
murine O 
model O 
of O 
myocardial O 
ischemia O 
- O 
reperfusion O 
injury O 
, O 
through O 
a O 
H2S B-FORMULA 
-related O 
mechanism O 
. O 

Hybrid O 
Isoprenoids B-FAMILY 
from O 
a O 
Reed O 
Rhizosphere O 
Soil O 
Derived O 
Streptomyces O 
sp O 
. O 
CHQ-64 O 
. O 

new O 
hybrid O 
isoprenoids B-FAMILY 
, O 
named O 
indotertine B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
and O 
drimentine B-TRIVIAL 
H I-TRIVIAL 
( O 
3 O 
) O 
, O 
along O 
with O 
the O 
known O 
analogue O 
drimentine B-TRIVIAL 
C I-TRIVIAL 
( O 
4 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
reed O 
rhizosphere O 
soil O 
derived O 
actinomycete O 
Streptomyces O 
sp O 
. O 
CHQ-64 O 
. O 
The O 
structures O 
of O 
these O 
compounds O 
, O 
including O 
absolute O 
configurations O 
, O 
were O 
elucidated O 
by O 
extensive O 
NMR O 
, O 
MS O 
, O 
and O 
CD O 
analyses O 
. O 
Indotertine B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
exists O 
as O 
a O 
pair O 
of O 
rotamers O 
about O 
the O 
N-C B-FORMULA 
(O) I-FORMULA 
bond O 
with O 
a O 
2 O 
: O 
1 O 
ratio O 
and O 
displays O 
activities O 
against O 
HCT-8 O 
and O 
A549 O 
tumor O 
cell O 
lines O 
with O 
IC50 O 
values O 
of O 
6.96 O 
and O 
4.88 O 
μM O 
, O 
respectively O 
. O 

evolution O 
of O 
orthologous O 
proteins O 
opens O 
a O 
new O 
era O 
of O 
research O 
where O 
the O 
concepts O 
of O 
orthology O 
and O 
paralogy O 
have O 
become O 
more O 
and O 
more O 
substantial O 
, O 
as O 
the O 
whole O 
- O 
genome O 
comparison O 
allows O 
their O 
identification O 
in O 
complete O 
genomes O 
. O 
Functional O 
specificity O 
of O 
proteins O 
is O 
understood O 
to O 
be O 
conserved O 
among O 
orthologs O 
but O 
it O 
shows O 
much O 
more O 
variability O 
among O 
paralogs O 
. O 
We O 
used O 
this O 
laying O 
claim O 
to O 
identify O 
inter O 
- O 
species O 
interactions O 
based O 
on O 
orthologous O 
protein O 
networks O 
which O 
are O 
crucial O 
for O 
understanding O 
the O 
evolution O 
of O 
orthologous O 
proteins O 
. O 
We O 
analyzed O 
six O 
classes O 
of O 
enzymatic O 
protein O 
sequence O 
data O 
using O 
the O 
node O 
degrees O 
of O 
orthologous O 
proteins O 
. O 
The O 
results O 
demonstrated O 
the O 
evolutionary O 
importance O 
of O 
the O 
fatty B-FAMILY 
acid I-FAMILY 
syntheses O 
and O 
the O 
photosynthetic O 
system O 
in O 
algae O 
. O 
Methods O 
which O 
have O 
successfully O 
exploited O 
network O 
structure O 
at O 
many O 
different O 
levels O 
of O 
detail O 
are O 
a O 
cornerstone O 
of O 
systems O 
biology O 
. O 

Coupling O 
of O 
Benzamides B-FAMILY 
and O 
Donor O 
/ O 
Acceptor O 
Diazo B-SYSTEMATIC 
Compounds O 
To O 
Form O 
γ-Lactams B-FAMILY 
via O 
Rh B-FORMULA 
(III) I-FORMULA 
-Catalyzed O 
C-H B-FORMULA 
Activation O 
. O 

coupling O 
of O 
O-pivaloyl B-FAMILY 
benzhydroxamic I-FAMILY 
acids I-FAMILY 
with O 
donor O 
/ O 
acceptor O 
diazo B-SYSTEMATIC 
compounds O 
provides O 
isoindolones B-FAMILY 
in O 
high O 
yield O 
. O 
The O 
reaction O 
tolerates O 
a O 
broad O 
range O 
of O 
benzhydroxamic B-FAMILY 
acids I-FAMILY 
and O 
diazo B-SYSTEMATIC 
compounds O 
, O 
including O 
substituted O 
2,2,2-trifluorodiazoethanes B-FAMILY 
. O 
Mechanistic O 
experiments O 
suggested O 
that O 
C-H B-FORMULA 
activation O 
is O 
turnover O 
- O 
limiting O 
and O 
irreversible O 
and O 
that O 
insertion O 
of O 
the O 
diazo B-SYSTEMATIC 
compound O 
favors O 
electron O 
- O 
deficient O 
substrates O 
. O 

, O 
metabolism O 
and O 
disposition O 
of O 
oral O 
pazopanib B-TRIVIAL 
in O 
patients O 
with O 
advanced O 
cancer O 
. O 

. O 
Pazopanib B-TRIVIAL 
( O 
Votrient B-TRIVIAL 
) O 
is O 
an O 
oral O 
tyrosine B-TRIVIAL 
kinase O 
inhibitor O 
that O 
was O 
recently O 
approved O 
for O 
the O 
treatment O 
of O 
renal O 
cell O 
carcinoma O 
and O 
soft O 
tissue O 
sarcoma O 
. O 
2 O 
. O 
In O 
this O 
two O 
- O 
part O 
study O 
, O 
we O 
investigated O 
the O 
metabolism O 
, O 
disposition O 
of O 
[(14)C]pazopanib B-SYSTEMATIC 
, O 
and O 
the O 
oral O 
bioavailability O 
of O 
pazopanib B-TRIVIAL 
tablets O 
in O 
patients O 
with O 
advanced O 
cancer O 
. O 
3 O 
. O 
In O 
part O 
A O 
, O 
three O 
men O 
each O 
received O 
a O 
single O 
oral O 
dose O 
of O 
[(14)C]pazopanib B-SYSTEMATIC 
in O 
suspension O 
( O 
400 O 
mg O 
, O 
70 O 
µCi O 
) O 
. O 
Pazopanib B-TRIVIAL 
was O 
the O 
predominant O 
drug O 
- O 
related O 
component O 
in O 
circulation O 
. O 
Two O 
metabolites O 
derived O 
from O 
hydroxylation O 
and O 
one O 
from O 
N B-FORMULA 
-demethylation O 
were O 
also O 
circulating O 
, O 
but O 
were O 
minor O 
, O 
each O 
accounting O 
for O 
< O 
5% O 
of O 
plasma O 
radioactivity O 
. O 
Faecal O 
elimination O 
predominated O 
, O 
accounting O 
for O 
82.2% O 
of O 
the O 
administered O 
radio O 
- O 
dose O 
, O 
with O 
negligible O 
renal O 
elimination O 
( O 
2.6% O 
of O 
dose O 
) O 
. O 
Pazopanib B-TRIVIAL 
was O 
primarily O 
excreted O 
as O 
the O 
unchanged O 
drug O 
in O 
faeces O 
( O 
67% O 
of O 
dose O 
) O 
. O 
4 O 
. O 
In O 
part O 
B O 
, O 
seven O 
additional O 
patients O 
received O 
a O 
single O 
intravenous O 
administration O 
of O 
5 O 
mg O 
pazopanib B-TRIVIAL 
( O 
day O 
1 O 
) O 
followed O 
by O 
oral O 
administration O 
of O 
800 O 
mg O 
pazopanib B-TRIVIAL 
tablet O 
once O 
daily O 
for O 
26 O 
days O 
( O 
days O 
3 O 
or O 
5-28 O 
) O 
. O 
In O 
the O 
three O 
evaluable O 
patients O 
from O 
part O 
B O 
, O 
pazopanib B-TRIVIAL 
had O 
a O 
slow O 
plasma O 
clearance O 
and O 
a O 
small O 
volume O 
of O 
distribution O 
. O 
The O 
absolute O 
oral O 
bioavailability O 
of O 
the O 
800 O 
mg O 
pazopanib B-TRIVIAL 
tablet O 
ranged O 
from O 
14% O 
to O 
39% O 
. O 

extract O 
of O 
Artemisia O 
capillaris O 
exerts O 
hepatoprotective O 
action O 
in O 
alcohol- O 
pyrazole B-SYSTEMATIC 
-fed O 
rat O 
model O 
. O 

RELEVANCE O 
: O 
Artemisia O 
capillaris O 
, O 
also O 
called O 
" O 
InJin O 
" O 
in O 
Korean O 
, O 
has O 
been O 
widely O 
used O 
to O 
treat O 
various O 
hepatic O 
disorders O 
in O 
traditional O 
Oriental O 
medicine O 
. O 
AIMS O 
: O 
The O 
purpose O 
of O 
this O 
study O 
is O 
to O 
evaluate O 
the O 
hepatoprotective O 
effect O 
of O 
Artemisia O 
capillaris O 
( O 
aqueous O 
extract O 
, O 
WAC O 
) O 
on O 
alcoholic O 
liver O 
injury O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Liver O 
injury O 
was O 
induced O 
by O 
oral O 
administration O 
of O 
30% O 
alcohol O 
( O 
10mL O 
/ O 
kg O 
, O 
twice O 
per O 
day O 
) O 
plus O 
pyrazole B-SYSTEMATIC 
( O 
PRZ B-ABBREVIATION 
, O 
30mg O 
/ O 
kg O 
) O 
with O 
/ O 
without O 
WAC O 
( O 
50 O 
, O 
100mg O 
/ O 
kg O 
, O 
orally O 
once O 
per O 
day O 
) O 
or O 
silymarin O 
( O 
50mg O 
/ O 
kg O 
) O 
for O 
10 O 
days O 
. O 
The O 
hepatoprotective O 
effects O 
were O 
assessed O 
by O 
observing O 
histopathological O 
changes O 
, O 
hepatic O 
transaminase O 
enzymes O 
, O 
hepatic O 
oxidation O 
and O 
antioxidant O 
parameters O 
, O 
inflammatory O 
cytokines O 
, O 
and O 
alcohol O 
metabolic O 
enzymes O 
in O 
serum O 
and O 
hepatic O 
gene O 
expression O 
level O 
, O 
respectively O 
. O 
RESULTS O 
: O 
Alcohol- O 
PRZ B-ABBREVIATION 
treatment O 
drastically O 
increased O 
the O 
serum O 
levels O 
of O 
aspartate B-TRIVIAL 
transaminase O 
( O 
AST O 
) O 
, O 
alanine B-TRIVIAL 
transaminase O 
( O 
ALT O 
) O 
, O 
and O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
levels O 
in O 
serum O 
and O 
liver O 
tissues O 
while O 
these O 
changes O 
were O 
significantly O 
ameliorated O 
by O 
WAC O 
administration O 
( O 
p O 
< O 
0.05 O 
or O 
0.01 O 
) O 
. O 
The O 
prominent O 
microvesicular O 
steatosis O 
and O 
mild O 
necrosis O 
in O 
hepatic O 
histopathology O 
were O 
induced O 
by O 
alcohol- O 
PRZ B-ABBREVIATION 
treatment O 
, O 
but O 
notably O 
attenuated O 
by O 
WAC O 
administration O 
. O 
Moreover O 
, O 
the O 
alcohol- O 
PRZ B-ABBREVIATION 
treatment-induced O 
depletions O 
of O 
the O 
antioxidant O 
components O 
including O 
glutathione B-TRIVIAL 
content O 
, O 
total O 
antioxidant O 
capacity O 
( O 
TAC O 
) O 
, O 
activities O 
of O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GSH-Px O 
) O 
, O 
reductase O 
( O 
GSH-Rd O 
) O 
, O 
catalase O 
, O 
and O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
were O 
significantly O 
ameliorated O 
by O 
WAC O 
administration O 
( O 
p O 
< O 
0.05 O 
, O 
except O 
GSH-Rd O 
) O 
. O 
These O 
results O 
were O 
in O 
accordance O 
with O 
the O 
modulation O 
of O 
NF-E2 O 
- O 
related O 
factor O 
( O 
Nrf2 O 
) O 
and O 
heme O 
oxygenase-1 O 
( O 
HO-1 O 
) O 
gene O 
expression O 
. O 
Alcohol- O 
PRZ B-ABBREVIATION 
treatment O 
increased O 
the O 
levels O 
of O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
( O 
TNF-α O 
) O 
and O 
transforming O 
growth O 
factor O 
- O 
beta O 
( O 
TGF-β O 
) O 
in O 
hepatic O 
tissues O 
. O 
However O 
they O 
were O 
significantly O 
normalized O 
by O 
WAC O 
administration O 
( O 
p O 
< O 
0.05 O 
or O 
0.01 O 
) O 
. O 
In O 
addition O 
, O 
WAC O 
administration O 
significantly O 
attenuated O 
the O 
alterations O 
of O 
aldehyde B-SYSTEMATIC 
dehydrogenase O 
( O 
ALDH O 
) O 
level O 
in O 
serum O 
and O 
hepatic O 
gene O 
expressions O 
of O 
ALDH O 
and O 
alcohol O 
dehydrogenase O 
( O 
ADH O 
) O 
. O 
CONCLUSIONS O 
: O 
These O 
results O 
support O 
the O 
relevance O 
in O 
clinical O 
use O 
of O 
Artemisia O 
capillaris O 
for O 
alcohol O 
- O 
associated O 
hepatic O 
disorders O 
. O 
The O 
underlying O 
mechanisms O 
may O 
involve O 
both O 
enhancement O 
of O 
antioxidant O 
activities O 
and O 
modulation O 
of O 
proinflammatory O 
cytokines O 
. O 

quinolone B-FAMILY 
substituted O 
thiazolidin-4-ones B-FAMILY 
as O 
anti-inflammatory O 
, O 
anticancer O 
agents O 
: O 
Design O 
, O 
synthesis O 
and O 
biological O 
screening O 
. O 

factor-kappaB O 
( O 
NF-κB O 
) O 
has O 
been O 
reported O 
to O 
regulate O 
various O 
genes O 
involved O 
in O 
cancer O 
and O 
inflammation O 
. O 
Accordingly O 
, O 
drugs O 
suppressing O 
or O 
inhibiting O 
NF-κB O 
may O 
possess O 
both O 
anti-inflammatory O 
and O 
anticancer O 
properties O 
. O 
A O 
library O 
of O 
quinolone B-FAMILY 
substituted O 
thiazolidin-4-ones B-FAMILY 
was O 
docked O 
into O 
the O 
active O 
site O 
of O 
NF-κB O 
and O 
the O 
top O 
- O 
ranked O 
31 O 
compounds O 
were O 
synthesized O 
and O 
evaluated O 
for O 
anti-inflammatory O 
and O 
anticancer O 
activity O 
. O 
The O 
best O 
- O 
ranked O 
compound O 
6b O 
showed O 
highest O 
anti-inflammatory O 
activity O 
in O 
carrageenan O 
- O 
induced O 
paw O 
edema O 
model O 
. O 
In O 
vitro O 
anticancer O 
studies O 
revealed O 
1a O 
and O 
16a O 
as O 
most O 
active O 
compounds O 
against O 
BT-549 O 
, O 
HeLa O 
, O 
COLO-205 O 
and O 
ACHN O 
human O 
cancer O 
cell O 
lines O 
. O 
Compounds O 
1a O 
and O 
16a O 
exhibited O 
NF-κB O 
dependent O 
anticancer O 
properties O 
and O 
apoptosis O 
mediated O 
cell O 
death O 
. O 
In O 
vivo O 
Ehrlich O 
ascites O 
carcinoma O 
study O 
further O 
confirmed O 
the O 
antitumor O 
activity O 
of O 
1a O 
and O 
16a O 
. O 

central O 
role O 
for O 
thiols B-FAMILY 
in O 
plant O 
tolerance O 
to O 
abiotic O 
stress O 
. O 

stress O 
poses O 
major O 
problems O 
to O 
agriculture O 
and O 
increasing O 
efforts O 
are O 
being O 
made O 
to O 
understand O 
plant O 
stress O 
response O 
and O 
tolerance O 
mechanisms O 
and O 
to O 
develop O 
new O 
tools O 
that O 
underpin O 
successful O 
agriculture O 
. O 
However O 
, O 
the O 
molecular O 
mechanisms O 
of O 
plant O 
stress O 
tolerance O 
are O 
not O 
fully O 
understood O 
, O 
and O 
the O 
data O 
available O 
is O 
incomplete O 
and O 
sometimes O 
contradictory O 
. O 
Here O 
, O 
we O 
review O 
the O 
significance O 
of O 
protein O 
and O 
non O 
- O 
protein O 
thiol O 
compounds O 
in O 
relation O 
to O 
plant O 
tolerance O 
of O 
abiotic O 
stress O 
. O 
First O 
, O 
the O 
roles O 
of O 
the O 
amino O 
acids O 
cysteine B-TRIVIAL 
and O 
methionine B-TRIVIAL 
, O 
are O 
discussed O 
, O 
followed O 
by O 
an O 
extensive O 
discussion O 
of O 
the O 
low O 
- O 
molecular O 
- O 
weight O 
tripeptide B-FAMILY 
, O 
thiol B-SYSTEMATIC 
glutathione I-SYSTEMATIC 
, O 
which O 
plays O 
a O 
central O 
part O 
in O 
plant O 
stress O 
response O 
and O 
oxidative O 
signalling O 
and O 
of O 
glutathione B-TRIVIAL 
-related O 
enzymes O 
, O 
including O 
those O 
involved O 
in O 
the O 
biosynthesis O 
of O 
non O 
- O 
protein O 
thiol B-FAMILY 
compounds O 
. O 
Special O 
attention O 
is O 
given O 
to O 
the O 
glutathione B-TRIVIAL 
redox O 
state O 
, O 
to O 
phytochelatins O 
and O 
to O 
the O 
role O 
of O 
glutathione B-TRIVIAL 
in O 
the O 
regulation O 
of O 
the O 
cell O 
cycle O 
. O 
The O 
protein O 
thiol B-FAMILY 
section O 
focuses O 
on O 
glutaredoxins O 
and O 
thioredoxins O 
, O 
proteins O 
with O 
oxidoreductase O 
activity O 
, O 
which O 
are O 
involved O 
in O 
protein O 
glutathionylation O 
. O 
The O 
review O 
concludes O 
with O 
a O 
brief O 
overview O 
of O 
and O 
future O 
perspectives O 
for O 
the O 
involvement O 
of O 
plant O 
thiols B-FAMILY 
in O 
abiotic O 
stress O 
tolerance O 
. O 

of O 
exogenous O 
thiocyanate B-SYSTEMATIC 
on O 
mineral O 
nutrients O 
, O 
antioxidative O 
responses O 
and O 
free O 
amino B-FAMILY 
acids I-FAMILY 
in O 
rice O 
seedlings O 
. O 

effects O 
of O 
exogenous O 
thiocyanate B-SYSTEMATIC 
( O 
SCN(-) B-FORMULA 
) O 
on O 
amino B-FAMILY 
acids I-FAMILY 
composition O 
, O 
content O 
of O 
mineral O 
nutrients O 
and O 
antioxidative O 
systems O 
in O 
plants O 
were O 
investigated O 
. O 
Young O 
rice O 
seedlings O 
( O 
Oryza O 
sativa O 
L O 
. O 
cv O 
. O 
XZX O 
45 O 
) O 
were O 
grown O 
in O 
nutrient O 
solutions O 
amended O 
with O 
potassium B-SYSTEMATIC 
thiocyanate I-SYSTEMATIC 
( O 
KSCN B-FORMULA 
) O 
. O 
Activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
peroxidase O 
( O 
POD O 
) O 
, O 
catalase O 
( O 
CAT O 
) O 
, O 
and O 
ascorbate B-TRIVIAL 
peroxidase O 
( O 
APX O 
) O 
in O 
plant O 
materials O 
were O 
analyzed O 
in O 
vivo O 
. O 
Mineral O 
nutrients O 
and O 
free O 
amino B-FAMILY 
acids I-FAMILY 
in O 
rice O 
seedlings O 
were O 
also O 
measured O 
to O 
determine O 
metabolic O 
responses O 
to O 
SCN(-) B-FORMULA 
exposure O 
. O 
A O 
significant O 
reduction O 
in O 
transpiration O 
and O 
relative O 
growth O 
was O 
recorded O 
with O 
all O 
treatments O 
( O 
p O 
< O 
0.05 O 
) O 
, O 
while O 
changes O 
of O 
total O 
chlorophyll B-FAMILY 
content O 
in O 
leaves O 
was O 
negligible O 
( O 
p O 
> O 
0.05 O 
) O 
. O 
SCN B-FORMULA 
-induced O 
toxicity O 
appeared O 
to O 
be O 
more O 
sensitive O 
to O 
activities O 
of O 
POD O 
in O 
shoots O 
and O 
APX O 
activities O 
in O 
roots O 
than O 
the O 
others O 
. O 
The O 
content O 
of O 
nutrient O 
elements O 
in O 
rice O 
seedlings O 
exposed O 
to O 
exogenous O 
SCN(-) B-FORMULA 
was O 
variable O 
, O 
while O 
the O 
effects O 
were O 
more O 
evident O 
at O 
the O 
highest O 
SCN B-FORMULA 
-treatment O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Although O 
the O 
change O 
of O 
total O 
free O 
amino B-FAMILY 
acids I-FAMILY 
in O 
shoots O 
of O 
SCN B-FORMULA 
-exposed O 
seedlings O 
was O 
negligible O 
( O 
p O 
> O 
0.05 O 
) O 
, O 
responses O 
of O 
different O 
amino B-FAMILY 
acids I-FAMILY 
to O 
SCN(-) B-FORMULA 
application O 
were O 
quite O 
different O 
. O 
Among O 
fifteen O 
free O 
amino B-FAMILY 
acids I-FAMILY 
detected O 
, O 
serine B-TRIVIAL 
( O 
Ser B-FORMULA 
) O 
, O 
proline B-TRIVIAL 
( O 
Pro B-FORMULA 
) O 
, O 
and O 
methionine B-TRIVIAL 
( O 
Met B-FORMULA 
) O 
increased O 
, O 
while O 
asparagine B-TRIVIAL 
( O 
Asp B-FORMULA 
) O 
decreased O 
with O 
an O 
increase O 
of O 
the O 
doses O 
of O 
SCN(-) B-FORMULA 
supplied O 
. O 
Phyto O 
- O 
transport O 
of O 
SCN(-) B-FORMULA 
was O 
apparent O 
and O 
the O 
removal O 
rates O 
were O 
positively O 
correlated O 
to O 
the O 
doses O 
, O 
suggesting O 
that O 
phyto O 
- O 
assimilation O 
of O 
SCN(-) B-FORMULA 
is O 
an O 
enzymatic O 
process O 
through O 
a O 
potentially O 
un O 
- O 
identified O 
degradation O 
pathway O 
. O 

from O 
Hedyotis O 
diffusa O 
Willd O 
induces O 
apoptosis O 
in O 
human O 
leukemic O 
U937 O 
cells O 
through O 
modulation O 
of O 
MAPK O 
pathways O 
. O 

herb O 
of O 
Hedyotis O 
diffusa O 
Willd O 
( O 
H O 
. O 
diffusa O 
Willd O 
) O 
, O 
an O 
annual O 
herb O 
distributed O 
in O 
northeastern O 
Asia O 
, O 
has O 
been O 
known O 
as O 
a O 
traditional O 
oriental O 
medicine O 
for O 
the O 
treatment O 
of O 
cancer O 
. O 
Recently O 
, O 
Chinese O 
researchers O 
have O 
discovered O 
that O 
two O 
anthraquinones B-FAMILY 
isolated O 
from O 
a O 
water O 
extract O 
of O 
H O 
. O 
diffusa O 
Willd O 
showed O 
apoptosis O 
- O 
inducing O 
effects O 
against O 
cancer O 
cells O 
. O 
However O 
, O 
the O 
cellular O 
and O 
molecular O 
mechanisms O 
responsible O 
for O 
this O 
phenomenon O 
are O 
poorly O 
understood O 
. O 
The O 
current O 
study O 
determines O 
the O 
role O 
of O 
mitogen O 
- O 
activated O 
protein O 
kinases O 
( O 
MAPK O 
) O 
in O 
human O 
leukemic O 
U937 O 
cells O 
apoptosis O 
induced O 
by O 
2-hydroxy-3-methylanthraquinone B-SYSTEMATIC 
from O 
H O 
. O 
diffusa O 
. O 
Our O 
results O 
showed O 
that O 
2-hydroxy-3-methylanthraquinone B-SYSTEMATIC 
decreased O 
phosphorylation-ERK1 O 
/ O 
2 O 
( O 
p-ERK1 O 
/ O 
2 O 
) O 
, O 
and O 
increased O 
p-p38MAPK O 
, O 
but O 
did O 
not O 
affect O 
expressions O 
of O 
p-JNK1 O 
/ O 
2 O 
in O 
U937 O 
cells O 
. O 
Moreover O 
, O 
treatment O 
of O 
U937 O 
cells O 
with O 
2-hydroxy-3-methylanthraquinone B-SYSTEMATIC 
resulted O 
in O 
activation O 
of O 
caspase-3 O 
. O 
Furthermore O 
, O 
PD98059 B-IDENTIFIER 
( O 
ERK1 O 
/ O 
2 O 
inhibitor O 
) O 
significantly O 
enhanced O 
2-hydroxy-3-methylanthraquinone B-SYSTEMATIC 
-induced O 
apoptosis O 
in O 
U937 O 
cells O 
, O 
whereas O 
caspase-3 O 
inhibitor O 
or O 
SB203580 B-IDENTIFIER 
( O 
p-p38MAPK O 
inhibitor O 
) O 
, O 
decreased O 
apoptosis O 
in O 
U937 O 
cells O 
. O 
Taken O 
together O 
, O 
our O 
study O 
for O 
the O 
first O 
time O 
suggests O 
that O 
2-hydroxy-3-methylanthraquinone B-SYSTEMATIC 
is O 
able O 
to O 
enhance O 
apoptosis O 
of O 
U937 O 
cells O 
, O 
at O 
least O 
in O 
part O 
, O 
through O 
activation O 
of O 
p-p38MAPK O 
and O 
downregulation O 
of O 
p-ERK1 O 
/ O 
2 O 
. O 
Moreover O 
, O 
the O 
triggering O 
of O 
caspase-3 O 
activation O 
mediated O 
apoptotic O 
induction O 
. O 

Curcumin I-SYSTEMATIC 
Analogues O 
: O 
Heterocyclic O 
Pleiotropic O 
Kinase O 
Inhibitors O 
That O 
Mediate O 
Anticancer O 
Properties O 
. O 

is O 
a O 
biologically O 
active O 
component O 
of O 
curry O 
powder O 
. O 
A O 
structurally O 
related O 
class O 
of O 
mimetics O 
possesses O 
similar O 
anti-inflammatory O 
and O 
anticancer O 
properties O 
. O 
Mechanism O 
has O 
been O 
examined O 
by O 
exploring O 
kinase O 
inhibition O 
trends O 
. O 
In O 
a O 
screen O 
of O 
50 O 
kinases O 
relevant O 
to O 
many O 
forms O 
of O 
cancer O 
, O 
one O 
member O 
of O 
the O 
series O 
( O 
4 O 
, O 
EF31 O 
) O 
showed O 
≥ O 
85% O 
inhibition O 
for O 
10 O 
of O 
the O 
enzymes O 
at O 
5 O 
μM O 
, O 
while O 
22 O 
of O 
the O 
proteins O 
were O 
blocked O 
at O 
≥ O 
40% O 
. O 
IC50 O 
values O 
for O 
an O 
expanded O 
set O 
of O 
curcumin B-TRIVIAL 
analogues O 
established O 
a O 
rank O 
order O 
of O 
potencies O 
, O 
and O 
analyses O 
of O 
IKKβ O 
and O 
AKT2 O 
enzyme O 
kinetics O 
for O 
4 O 
revealed O 
a O 
mixed O 
inhibition O 
model O 
, O 
ATP B-ABBREVIATION 
competition O 
dominating O 
. O 
Our O 
curcumin B-TRIVIAL 
mimetics O 
are O 
generally O 
selective O 
for O 
Ser B-FORMULA 
/ O 
Thr B-FORMULA 
kinases O 
. O 
Both O 
selectivity O 
and O 
potency O 
trends O 
are O 
compatible O 
with O 
protein O 
sequence O 
comparisons O 
, O 
while O 
modeled O 
kinase O 
binding O 
site O 
geometries O 
deliver O 
a O 
reasonable O 
correlation O 
with O 
mixed O 
inhibition O 
. O 
Overall O 
, O 
these O 
analogues O 
are O 
shown O 
to O 
be O 
pleiotropic O 
inhibitors O 
that O 
operate O 
at O 
multiple O 
points O 
along O 
cell O 
signaling O 
pathways O 
. O 

, O 
Antitopoisomerase O 
IIα O 
, O 
and O 
Anti-HIV-1 O 
Activities O 
of O 
Triterpenoids B-FAMILY 
Isolated O 
from O 
Leaves O 
and O 
Twigs O 
of O 
Gardenia O 
carinata O 
. O 

new O 
cycloartane B-FAMILY 
triterpenoids I-FAMILY 
( O 
1-8 O 
) O 
, O 
named O 
carinatins B-MULTIPLE 
A-H I-MULTIPLE 
, O 
and O 
the O 
known O 
compounds O 
secaubryolide B-TRIVIAL 
( O 
9 O 
) O 
and O 
dikamaliartane B-TRIVIAL 
D I-TRIVIAL 
( O 
10 O 
) O 
were O 
isolated O 
from O 
the O 
leaves O 
and O 
twigs O 
of O 
Gardenia O 
carinata O 
. O 
Their O 
structures O 
were O 
determined O 
on O 
the O 
basis O 
of O 
spectroscopic O 
methods O 
. O 
Cytotoxic O 
, O 
antitopoisomerase O 
IIα O 
, O 
and O 
anti-HIV-1 O 
activities O 
of O 
compounds O 
1-7 O 
, O 
9 O 
, O 
and O 
10 O 
were O 
investigated O 
. O 

high O 
throughput O 
assay O 
for O 
the O 
glucuronidation O 
of O 
7-hydroxy-4-trifluoromethylcoumarin B-SYSTEMATIC 
by O 
recombinant O 
human O 
UDP B-ABBREVIATION 
-glucuronosyltransferases O 
and O 
liver O 
microsomes O 
. O 

1 O 
. O 
U O 
DP- B-ABBREVIATION 
glucuronosyltransferases O 
( O 
UGTs O 
) O 
are O 
versatile O 
and O 
important O 
conjugation O 
enzymes O 
in O 
the O 
metabolism O 
of O 
drugs O 
and O 
other O 
xenobiotics O 
. O 
2 O 
. O 
We O 
have O 
developed O 
a O 
convenient O 
quantitative O 
multi O 
- O 
well O 
plate O 
assay O 
to O 
measure O 
the O 
glucuronidation O 
rate O 
of O 
7- O 
hydroxy-4-trifluoromethylcoumarin B-SYSTEMATIC 
( I-SYSTEMATIC 
HF O 
C B-ABBREVIATION 
) I-ABBREVIATION 
for O 
several O 
UGTs O 
. O 
3 O 
. O 
We O 
have O 
used O 
this O 
method O 
to O 
screen O 
11 O 
recombinant O 
human O 
UGTs O 
for O 
HFC O 
gl B-ABBREVIATION 
ucuronidation O 
activity O 
and O 
studied O 
the O 
reaction O 
kinetics O 
with O 
the O 
most O 
active O 
enzymes O 
. O 
We O 
have O 
also O 
examined O 
the O 
HFC O 
gl B-ABBREVIATION 
ucuronidation O 
activity O 
of O 
liver O 
microsomes O 
from O 
human O 
, O 
pig O 
, O 
rabbit O 
and O 
rat O 
. O 
4 O 
. O 
At O 
a O 
substrate O 
concentration O 
of O 
20 O 
µM O 
, O 
the O 
most O 
active O 
HFC O 
glu B-ABBREVIATION 
curonidation O 
catalysts O 
were O 
UGT1A10 O 
followed O 
by O 
UGT1A6 O 
> O 
UGT1A7 O 
> O 
UGT2A1 O 
, O 
whereas O 
at O 
300 O 
µM O 
UGT1A6 O 
was O 
about O 
10 O 
times O 
better O 
catalyst O 
than O 
the O 
other O 
recombinant O 
UGTs O 
. O 
The O 
activities O 
of O 
UGTs O 
1A3 O 
, O 
1A8 O 
, O 
1A9 O 
, O 
2B4 O 
and O 
2B7 O 
were O 
low O 
, O 
whereas O 
UGT1A1 O 
and O 
UGT2B17 O 
exhibited O 
no O 
HFC O 
glu B-ABBREVIATION 
curonidation O 
activity O 
. O 
UGT1A6 O 
exhibited O 
a O 
significantly O 
higher O 
Vmax O 
and O 
Km O 
values O 
toward O 
both O 
HFC O 
and B-ABBREVIATION 
UDP- O 
glu B-ABBREVIATION 
c O 
uronic B-TRIVIAL 
acid I-TRIVIAL 
tha I-TRIVIAL 
n O 
the O 
other O 
UGTs O 
. O 
5 O 
. O 
Human O 
, O 
pig O 
and O 
rabbit O 
, O 
but O 
not O 
rat O 
liver O 
microsomes O 
, O 
catalyzed O 
HFC O 
g O 
luc B-ABBREVIATION 
uronidation O 
at O 
high O 
rates O 
. O 
6 O 
. O 
This O 
new O 
method O 
is O 
particularly O 
suitable O 
for O 
fast O 
activity O 
screenings O 
of O 
UGTs O 
1A6 O 
, O 
1A7 O 
, O 
1A10 O 
and O 
2A1 O 
and O 
HFC O 
gl O 
ucu B-ABBREVIATION 
ronidation O 
activity O 
determination O 
from O 
various O 
samples O 
. O 

Distributions O 
at O 
the O 
Water/ O 
1,2-Dichloroethane B-SYSTEMATIC 
Interface O 
: O 
Potential O 
of O 
Mean O 
Force O 
Approach O 
to O 
Analyzing O 
X-ray O 
Reflectivity O 
and O 
Interfacial O 
Tension O 
Measurements O 
. O 

present O 
X-ray O 
reflectivity O 
and O 
interfacial O 
tension O 
measurements O 
of O 
the O 
electrified O 
liquid O 
/ O 
liquid O 
interface O 
between O 
two O 
immiscible O 
electrolyte O 
solutions O 
for O 
the O 
purpose O 
of O 
understanding O 
the O 
dependence O 
of O 
interfacial O 
ion O 
distributions O 
on O 
the O 
applied O 
electric O 
potential O 
difference O 
across O 
the O 
interface O 
. O 
The O 
aqueous O 
phase O 
contains O 
alkali B-FAMILY 
- I-FAMILY 
metal I-FAMILY 
chlorides I-FAMILY 
, O 
including O 
LiCl B-FORMULA 
, O 
NaCl B-FORMULA 
, O 
RbCl B-FORMULA 
, O 
or O 
CsCl B-FORMULA 
, O 
and O 
the O 
organic O 
phase O 
is O 
a O 
1,2-dichloroethane B-SYSTEMATIC 
solution O 
of O 
bis(triphenylphosphor B-SYSTEMATIC 
anylidene I-SYSTEMATIC 
) I-SYSTEMATIC 
ammonium I-SYSTEMATIC 
tetrakis(pentafluorophenyl)borate I-SYSTEMATIC 
( O 
BTPPATPFB B-ABBREVIATION 
) O 
. O 
Selected O 
data O 
for O 
a O 
subset O 
of O 
electric O 
potential O 
differences O 
are O 
analyzed O 
to O 
determine O 
the O 
potentials O 
of O 
mean O 
force O 
for O 
Li(+) B-FORMULA 
, O 
Rb(+) B-FORMULA 
, O 
Cs(+) B-FORMULA 
, O 
BTPPA(+) B-ABBREVIATION 
, O 
and O 
TPFB(-) B-ABBREVIATION 
. O 
These O 
potentials O 
of O 
mean O 
force O 
are O 
then O 
used O 
to O 
analyze O 
both O 
X-ray O 
reflectivity O 
and O 
interfacial O 
tension O 
data O 
measured O 
over O 
a O 
wide O 
range O 
of O 
electric O 
potential O 
differences O 
. O 
Comparison O 
of O 
X-ray O 
reflectivity O 
data O 
for O 
strongly O 
hydrated O 
alkali B-FAMILY 
- I-FAMILY 
metal I-FAMILY 
ions O 
( O 
Li(+) B-FORMULA 
and O 
Na(+) B-FORMULA 
) O 
, O 
for O 
which O 
ion O 
pairing O 
to O 
TPFB(-) B-ABBREVIATION 
ions O 
across O 
the O 
interface O 
is O 
not O 
expected O 
, O 
to O 
data O 
for O 
weakly O 
hydrated O 
alkali B-FAMILY 
- I-FAMILY 
metal I-FAMILY 
ions O 
( O 
Rb(+) B-FORMULA 
and O 
Cs(+) B-FORMULA 
) O 
indicates O 
that O 
the O 
Gibbs O 
energy O 
of O 
adsorption O 
due O 
to O 
ion O 
pairing O 
at O 
the O 
interface O 
must O 
be O 
small O 
( O 
< O 
1 O 
kBT O 
per O 
ion O 
pair O 
) O 
for O 
both O 
the O 
CsCl B-FORMULA 
and O 
RbCl B-FORMULA 
samples O 
. O 
This O 
paper O 
demonstrates O 
the O 
applicability O 
of O 
the O 
Poisson-Boltzmann O 
potential O 
of O 
mean O 
force O 
approach O 
to O 
the O 
analysis O 
of O 
X-ray O 
reflectivity O 
measurements O 
that O 
probe O 
the O 
nanoscale O 
ion O 
distribution O 
and O 
the O 
consequences O 
of O 
these O 
underlying O 
distributions O 
for O 
thermodynamic O 
studies O 
, O 
such O 
as O 
interfacial O 
tension O 
measurements O 
, O 
that O 
yield O 
quantities O 
related O 
to O 
the O 
integrated O 
ion O 
distribution O 
. O 

Individual O 
Atoms O 
beneath O 
a O 
Corrugated O 
Single O 
Layer O 
of O 
Boron B-SYSTEMATIC 
Nitride I-SYSTEMATIC 
. O 

atoms O 
, O 
and O 
in O 
particular O 
the O 
least O 
reactive O 
noble B-FAMILY 
gases I-FAMILY 
, O 
are O 
difficult O 
to O 
immobilize O 
at O 
room O 
temperature O 
. O 
Ion O 
implantation O 
into O 
a O 
crystal O 
lattice O 
has O 
this O 
capability O 
, O 
but O 
the O 
randomness O 
of O 
the O 
involved O 
processes O 
does O 
not O 
permit O 
much O 
control O 
over O 
their O 
distribution O 
within O 
the O 
solid O 
. O 
Here O 
we O 
demonstrate O 
that O 
the O 
boron B-SYSTEMATIC 
nitride I-SYSTEMATIC 
nanomesh O 
, O 
a O 
corrugated O 
single O 
layer O 
of O 
hexagonal O 
boron B-SYSTEMATIC 
nitride I-SYSTEMATIC 
( O 
h-BN B-ABBREVIATION 
) O 
with O 
a O 
3.2 O 
nm O 
honeycomb O 
superstructure O 
formed O 
on O 
a O 
Rh(111) B-FORMULA 
surface O 
, O 
can O 
trap O 
individual O 
argon B-SYSTEMATIC 
atoms O 
at O 
distinct O 
subsurface O 
sites O 
at O 
room O 
temperature O 
. O 
A O 
kinetic O 
energy O 
window O 
for O 
implantation O 
is O 
identified O 
where O 
the O 
argon B-SYSTEMATIC 
ions O 
can O 
penetrate O 
the O 
h-BN B-ABBREVIATION 
layer O 
but O 
not O 
enter O 
the O 
Rh B-FORMULA 
lattice O 
. O 
Scanning O 
tunneling O 
microscopy O 
and O 
photoemission O 
data O 
show O 
the O 
presence O 
of O 
argon B-SYSTEMATIC 
atoms O 
at O 
two O 
distinct O 
sites O 
within O 
the O 
nanomesh O 
unit O 
cell O 
, O 
confirmed O 
also O 
by O 
density O 
functional O 
theory O 
calculations O 
. O 
The O 
single O 
atom O 
implants O 
are O 
stable O 
in O 
air O 
. O 
Annealing O 
of O 
implanted O 
structures O 
to O 
900 O 
K O 
induces O 
the O 
formation O 
of O 
highly O 
regular O 
holes O 
of O 
2 O 
nm O 
diameter O 
in O 
the O 
h-BN B-ABBREVIATION 
layer O 
with O 
adjacent O 
flakes O 
of O 
the O 
same O 
size O 
found O 
on O 
top O 
of O 
the O 
layer O 
. O 
We O 
explain O 
this O 
" O 
can O 
- O 
opener O 
" O 
effect O 
by O 
the O 
presence O 
of O 
a O 
vacancy O 
defect O 
, O 
generated O 
during O 
the O 
penetration O 
of O 
the O 
Ar B-FORMULA 
ion O 
through O 
the O 
h-BN B-ABBREVIATION 
lattice O 
, O 
and O 
propagating O 
along O 
the O 
rim O 
of O 
a O 
nanomesh O 
pore O 
where O 
the O 
h-BN B-ABBREVIATION 
lattice O 
is O 
highly O 
bent O 
. O 
The O 
reported O 
effects O 
are O 
also O 
observed O 
in O 
graphene B-TRIVIAL 
on O 
ruthenium B-SYSTEMATIC 
and O 
for O 
neon B-SYSTEMATIC 
atoms O 
. O 

Dexamethasone B-TRIVIAL 
Treatment O 
Promotes O 
Pro-Survival O 
Signalling O 
Pathway O 
In O 
Adult O 
Rat O 
Prefrontal O 
Cortex O 
. O 

glucocorticoid O 
dexamethasone B-TRIVIAL 
( O 
DEX B-ABBREVIATION 
) O 
, O 
a O 
highly O 
potent O 
anti-inflammatory O 
and O 
immunosuppressive O 
agent O 
, O 
is O 
widely O 
used O 
in O 
treatments O 
of O 
brain O 
cancer O 
, O 
inflammatory O 
and O 
autoimmune O 
diseases O 
. O 
The O 
objective O 
of O 
the O 
current O 
study O 
was O 
to O 
determine O 
whether O 
a O 
low O 
- O 
dose O 
subchronic O 
DEX B-ABBREVIATION 
treatment O 
( O 
100 O 
μg O 
/ O 
kg O 
for O 
8 O 
consecutive O 
days O 
) O 
exerts O 
long O 
- O 
term O 
effects O 
on O 
apoptosis O 
in O 
the O 
adult O 
rat O 
prefrontal O 
cortex O 
( O 
PFC O 
) O 
by O 
examining O 
the O 
expression O 
of O 
cell O 
death O 
- O 
promoting O 
molecules O 
( O 
poly B-SYSTEMATIC 
( I-SYSTEMATIC 
ADP-ribose I-SYSTEMATIC 
) I-SYSTEMATIC 
polymerase O 
( O 
PARP O 
) O 
, O 
p53 O 
, O 
procaspase O 
3 O 
, O 
cleaved O 
caspase O 
3 O 
, O 
Bax O 
) O 
and O 
cell O 
- O 
survival O 
molecules O 
( O 
AKT O 
, O 
Bcl-2 O 
) O 
. O 
Our O 
results O 
revealed O 
that O 
body O 
, O 
thymus O 
and O 
adrenal O 
weight O 
as O 
well O 
corticosterone B-TRIVIAL 
level O 
in O 
the O 
serum O 
and O 
PFC O 
were O 
reduced O 
a O 
day O 
following O 
last O 
DEX B-ABBREVIATION 
injection O 
. O 
In O 
PFC O 
, O 
DEX B-ABBREVIATION 
caused O 
activation O 
of O 
AKT O 
, O 
augmentation O 
of O 
pro O 
- O 
survival O 
Bcl-2 O 
protein O 
and O 
enhanced O 
Bcl-2 O 
/ O 
Bax O 
protein O 
ratio O 
, O 
as O 
well O 
Bcl-2 O 
translocation O 
to O 
mitochondria O 
. O 
The O 
unaltered O 
profile O 
in O 
the O 
protein O 
expression O 
of O 
apoptotic O 
molecules O 
PARP O 
, O 
procaspase O 
3 O 
and O 
Bax O 
was O 
detected O 
, O 
while O 
the O 
p53 O 
protein O 
was O 
decreased O 
. O 
Results O 
of O 
RT-PCR O 
analysis O 
showed O 
decrease O 
of O 
p53 O 
mRNA O 
level O 
and O 
no O 
significant O 
difference O 
in O 
Bcl-2 O 
and O 
Bax O 
mRNA O 
expressions O 
in O 
DEX B-ABBREVIATION 
-treated O 
rats O 
. O 
Finally O 
, O 
the O 
DNA O 
fragmentation O 
assay O 
and O 
Fluoro-Jade O 
staining O 
demonstrated O 
no O 
considerable O 
changes O 
in O 
the O 
apoptosis O 
in O 
rat O 
PFC O 
. O 
Our O 
findings O 
support O 
the O 
concept O 
that O 
a O 
low O 
- O 
dose O 
DEX B-ABBREVIATION 
creates O 
the O 
hypocorticoid O 
state O 
in O 
the O 
brain O 
and O 
indicate O 
that O 
subchronic O 
DEX B-ABBREVIATION 
treatment O 
activates O 
pro O 
- O 
survival O 
signalling O 
pathway O 
but O 
does O 
not O 
change O 
apoptotic O 
markers O 
in O 
rat O 
PFC O 
. O 
This O 
mechanism O 
might O 
be O 
relevant O 
for O 
DEX B-ABBREVIATION 
-induced O 
apoptosis O 
resistance O 
observed O 
during O 
and O 
after O 
chemotherapy O 
of O 
patients O 
with O 
brain O 
tumours O 
. O 
© O 
2013 O 
British O 
Society O 
for O 
Neuroendocrinology O 
. O 

, O 
ultrastructural O 
and O 
immunohistochemical O 
studies O 
on O 
the O 
protective O 
effect O 
of O 
ginger O 
extract O 
against O 
cisplatin B-TRIVIAL 
-induced O 
nephrotoxicity O 
in O 
male O 
rats O 
. O 

( O 
CP O 
) O 
is O 
a O 
widely O 
used O 
anticancer O 
drug O 
; O 
however O 
, O 
it O 
has O 
several O 
side O 
effects O 
such O 
as O 
nephrotoxicity O 
. O 
Ginger O 
, O 
the O 
rhizome O 
of O 
Zingiber O 
officinale O 
, O 
consumed O 
since O 
ancient O 
times O 
has O 
numerous O 
health O 
benefits O 
. O 
The O 
objective O 
of O 
this O 
work O 
was O 
to O 
evaluate O 
the O 
protective O 
effect O 
of O 
ginger O 
extract O 
( O 
GE O 
) O 
against O 
CP-induced O 
nephrotoxicity O 
. O 
CP O 
group O 
displayed O 
a O 
marked O 
renal O 
failure O 
characterized O 
by O 
a O 
significant O 
increase O 
in O 
serum O 
creatinine B-TRIVIAL 
and O 
blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
( O 
BUN O 
) O 
levels O 
in O 
addition O 
to O 
severe O 
histopathological O 
and O 
ultrastructural O 
renal O 
alterations O 
. O 
Also O 
, O 
CP O 
group O 
showed O 
an O 
increase O 
in O 
the O 
immunohistochemical O 
expression O 
of O 
Bax O 
proapoptotic O 
protein O 
. O 
In O 
contrast O 
, O 
GE O 
+ O 
CP O 
group O 
showed O 
significant O 
decrease O 
in O 
the O 
elevated O 
serum O 
creatinine B-TRIVIAL 
and O 
BUN O 
levels O 
and O 
an O 
improvement O 
in O 
the O 
histopathological O 
and O 
ultrastructural O 
renal O 
injury O 
induced O 
by O 
CP O 
. O 
The O 
overexpression O 
of O 
Bax O 
proapoptotic O 
protein O 
was O 
significantly O 
decreased O 
in O 
the O 
GE O 
+ O 
CP O 
group O 
. O 
Hence O 
, O 
the O 
present O 
results O 
indicated O 
that O 
GE O 
has O 
a O 
protective O 
effect O 
against O 
CP-induced O 
renal O 
damage O 
in O 
rats O 
. O 
Thereby O 
, O 
such O 
findings O 
recommended O 
the O 
usage O 
of O 
GE O 
to O 
prevent O 
and O 
/ O 
or O 
decrease O 
the O 
renal O 
damage O 
induced O 
by O 
CP O 
chemotherapeutic O 
treatment O 
. O 

expression O 
of O 
lipoxygenase O 
( O 
LOX O 
) O 
and O 
urease O 
has O 
already O 
contributed O 
to O 
the O 
pathology O 
of O 
different O 
human O 
disease O 
. O 
Targeting O 
the O 
inhibition O 
of O 
these O 
enzymes O 
has O 
proved O 
great O 
clinical O 
utility O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
scrutinised O 
the O 
inhibitory O 
profile O 
of O 
the O 
aerial O 
parts O 
of O 
the O 
Polygonatum O 
verticillatum O 
enzyme O 
against O 
LOX O 
, O 
urease O 
, O 
acetylcholinesterase O 
( O 
AChE O 
) O 
and O 
butyrylcholinesterase O 
( O 
BChE O 
) O 
using O 
standard O 
experimental O 
protocols O 
. O 
When O 
checked O 
against O 
lipoxygenase O 
, O 
the O 
extracts O 
revealed O 
significant O 
attenuation O 
. O 
Of O 
the O 
tested O 
extracts O 
, O 
the O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
fraction O 
was O 
the O 
most O 
potent O 
( O 
half O 
- O 
maximal O 
inhibitory O 
concentration O 
( O 
IC50 O 
) O 
: O 
97 O 
µg O 
/ O 
mL O 
) O 
followed O 
by O 
aqueous O 
fraction O 
IC50 O 
: O 
109 O 
µg O 
/ O 
mL O 
) O 
. O 
Regarding O 
urease O 
inhibition O 
, O 
n-butanol B-SYSTEMATIC 
was O 
the O 
most O 
potent O 
fraction O 
( O 
IC50 O 
: O 
97 O 
µg O 
/ O 
mL O 
) O 
. O 
However O 
, O 
the O 
extracts O 
did O 
not O 
show O 
significant O 
inhibition O 
on O 
AChE O 
and O 
BChE O 
. O 
In O 
the O 
preliminary O 
phytochemical O 
tests O 
, O 
the O 
aerial O 
parts O 
of O 
the O 
plant O 
showed O 
the O 
presence O 
of O 
saponins B-FAMILY 
, O 
alkaloids O 
, O 
flavonoids B-FAMILY 
, O 
phenols B-FAMILY 
, O 
tannins B-FAMILY 
and O 
terpenoids B-FAMILY 
. O 
The O 
current O 
findings O 
could O 
be O 
attributed O 
to O 
these O 
groups O 
of O 
compounds O 
. O 

study O 
investigated O 
the O 
toxic O 
effects O 
of O 
diesel O 
and O 
biodiesel O 
derived O 
from O 
opium O 
poppy O 
( O 
Papaver O 
somniferum O 
L O 
. O 
) O 
oil O 
seeds O 
on O 
the O 
trace O 
and O 
major O 
elements O 
in O 
kidney O 
, O 
lung O 
, O 
liver O 
, O 
and O 
serum O 
of O 
rats O 
. O 
By O 
the O 
end O 
of O 
21 O 
days O 
, O 
trace O 
and O 
major O 
element O 
concentrations O 
in O 
kidney O 
, O 
lung O 
, O 
and O 
liver O 
tissues O 
and O 
the O 
serum O 
were O 
measured O 
using O 
inductively O 
coupled O 
plasma O 
- O 
optical O 
emission O 
spectroscopy O 
. O 
We O 
observed O 
that O 
trace O 
and O 
major O 
element O 
levels O 
in O 
kidney O 
, O 
lung O 
, O 
and O 
liver O 
tissues O 
and O 
the O 
serum O 
changed O 
. O 
Especially O 
, O 
important O 
differences O 
were O 
detected O 
in O 
trace O 
and O 
major O 
element O 
concentrations O 
in O 
kidney O 
and O 
lung O 
tissues O 
. O 
In O 
kidney O 
tissue O 
, O 
the O 
concentration O 
differences O 
of O 
calcium B-SYSTEMATIC 
, O 
sodium B-SYSTEMATIC 
, O 
and O 
zinc B-SYSTEMATIC 
( O 
Zn B-FORMULA 
) O 
were O 
found O 
between O 
diesel O 
and O 
biodiesel O 
groups O 
. O 
In O 
lung O 
tissue O 
, O 
the O 
concentration O 
differences O 
of O 
cadmium B-SYSTEMATIC 
, O 
lithium B-SYSTEMATIC 
, O 
magnesium B-SYSTEMATIC 
, O 
manganese B-SYSTEMATIC 
, O 
and O 
Zn B-FORMULA 
were O 
found O 
between O 
diesel O 
and O 
biodiesel O 
groups O 
. O 
Among O 
the O 
significant O 
findings O 
, O 
Zn B-FORMULA 
concentration O 
in O 
serum O 
and O 
liver O 
tissue O 
of O 
diesel O 
and O 
biodiesel O 
were O 
different O 
from O 
control O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
However O 
, O 
the O 
metal O 
levels O 
of O 
biodiesel O 
group O 
were O 
similar O 
to O 
control O 
group O 
. O 
Due O 
to O 
lesser O 
toxicity O 
of O 
biodiesel O 
, O 
it O 
could O 
be O 
considered O 
as O 
an O 
alternate O 
fuel O 
. O 

of O 
sugammadex B-TRIVIAL 
on O 
rocuronium B-TRIVIAL 
induced O 
changes O 
in O 
pancreatic O 
mast O 
cells O 
. O 

cells O 
play O 
a O 
vital O 
role O 
in O 
hypersensitivity O 
reactions O 
. O 
Rocuronium B-TRIVIAL 
is O 
known O 
to O 
cause O 
mast O 
cell O 
mobilization O 
, O 
hypersensitivity O 
, O 
and O 
pancreatitis O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
effects O 
of O 
sugammadex B-TRIVIAL 
on O 
pancreatic O 
changes O 
due O 
to O 
rocuronium B-TRIVIAL 
. O 
A O 
total O 
of O 
42 O 
Sprague-Dawley O 
male O 
rats O 
were O 
divided O 
into O 
six O 
equal O 
groups O 
to O 
receive O 
either O 
rocuronium B-TRIVIAL 
1 O 
mg O 
/ O 
kg O 
intravenously O 
( O 
i.v O 
. O 
, O 
R O 
group O 
) O 
, O 
rocuronium B-TRIVIAL 
1 O 
mg O 
/ O 
kg O 
+ O 
sugammadex B-TRIVIAL 
16 O 
mg O 
/ O 
kg O 
i.v O 
. O 
( O 
RS16 O 
group O 
) O 
, O 
rocuronium B-TRIVIAL 
1 O 
mg O 
/ O 
kg O 
+ O 
sugammadex B-TRIVIAL 
96 O 
mg O 
/ O 
kg O 
i.v O 
. O 
( O 
RS96 O 
group O 
) O 
, O 
sugammadex B-TRIVIAL 
16 O 
mg O 
/ O 
kg O 
( O 
S16 O 
) O 
, O 
sugammadex B-TRIVIAL 
96 O 
mg O 
/ O 
kg O 
i.v O 
. O 
( O 
S96 O 
group O 
) O 
, O 
or O 
0.9% O 
sodium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
control O 
group O 
) O 
. O 
Sugammadex B-TRIVIAL 
was O 
administered O 
5s O 
later O 
following O 
rocuronium B-TRIVIAL 
. O 
In O 
R O 
group O 
, O 
mast O 
count O 
was O 
higher O 
, O 
and O 
the O 
distribution O 
rate O 
of O 
granules O 
and O 
nuclear O 
changes O 
were O 
different O 
compared O 
with O 
other O 
groups O 
. O 
Distribution O 
rate O 
of O 
granules O 
in O 
groups O 
S16 O 
and O 
S96 O 
were O 
similar O 
to O 
the O 
control O 
group O 
and O 
lower O 
compared O 
with O 
other O 
groups O 
. O 
The O 
amount O 
of O 
mast O 
cells O 
and O 
granule O 
density O 
in O 
groups O 
RS16 O 
and O 
RS96 O 
was O 
lower O 
compared O 
with O 
R O 
group O 
. O 
The O 
amount O 
of O 
mast O 
cells O 
in O 
groups O 
RS16 O 
and O 
RS96 O 
was O 
significantly O 
lower O 
compared O 
with O 
other O 
treatment O 
groups O 
. O 
These O 
results O 
suggest O 
that O 
sugammadex B-TRIVIAL 
may O 
have O 
an O 
inhibitory O 
effect O 
on O 
mobilization O 
and O 
morphological O 
changes O 
in O 
pancreatic O 
mast O 
cells O 
induced O 
by O 
administration O 
of O 
rocuronium B-TRIVIAL 
and O 
sugammadex B-TRIVIAL 
in O 
rats O 
. O 

and O 
characterization O 
of O 
naphthalenediimide B-SYSTEMATIC 
-functionalized O 
flavin B-FAMILY 
derivatives O 
. O 

acceptor O 
- O 
acceptor O 
dyads O 
have O 
been O 
synthesized O 
featuring O 
a O 
flavin B-FAMILY 
moiety O 
and O 
a O 
naphthalenediimide B-SYSTEMATIC 
( O 
NDI B-ABBREVIATION 
) O 
unit O 
. O 
The O 
NDI B-ABBREVIATION 
unit O 
is O 
linked O 
to O 
the O 
flavin B-FAMILY 
through O 
a O 
short O 
spacer O 
group O 
via O 
either O 
the O 
N(3) O 
or O 
N(10) O 
positions O 
of O 
the O 
flavin B-FAMILY 
. O 
We O 
have O 
investigated O 
the O 
UV-Vis O 
and O 
redox O 
properties O 
of O 
these O 
multi O 
- O 
electron O 
accepting O 
systems O 
which O 
indicate O 
that O 
these O 
materials O 
display O 
the O 
collective O 
properties O 
of O 
their O 
component O 
systems O 
. O 
Fluorescence O 
spectroscopy O 
measurements O 
have O 
revealed O 
that O 
their O 
emission O 
properties O 
are O 
dominated O 
by O 
the O 
flavin B-FAMILY 
unit O 
. O 

the O 
Vibrational O 
linear O 
and O 
nonlinear O 
optical O 
properties O 
of O 
compounds O 
involving O 
noble O 
gas O 
atoms O 
: O 
HXeOXeH B-FORMULA 
, O 
HXeOXeF B-FORMULA 
, O 
and O 
FXeOXeF B-FORMULA 
. O 

vibrational O 
(hyper)polarizabilities O 
of O 
some O 
selected O 
Xe B-FORMULA 
derivatives O 
are O 
studied O 
in O 
the O 
context O 
of O 
Bishop-Kirtman O 
perturbation O 
theory O 
( O 
BKPT O 
) O 
and O 
numerical O 
finite O 
field O 
methodology O 
. O 
It O 
was O 
found O 
that O 
for O 
this O 
set O 
of O 
rare O 
gas O 
compounds O 
, O 
the O 
static O 
vibrational O 
properties O 
are O 
quite O 
large O 
, O 
in O 
comparison O 
to O 
the O 
corresponding O 
electronic O 
ones O 
, O 
especially O 
those O 
of O 
the O 
second O 
hyperpolarizability O 
. O 
This O 
also O 
holds O 
for O 
the O 
dc-Pockels O 
β(-ω;ω,0) O 
, O 
Kerr O 
γ(-ω;ω,0,0) O 
and O 
electric O 
field O 
second O 
harmonic O 
generation O 
γ O 
( O 
-2ω;ω,ω,0 O 
) O 
effects O 
, O 
although O 
the O 
computed O 
nuclear O 
relaxation O 
( O 
nr O 
) O 
vibrational O 
contributions O 
are O 
smaller O 
in O 
magnitude O 
than O 
the O 
static O 
ones O 
. O 
HXeOXeH B-FORMULA 
was O 
used O 
to O 
study O 
the O 
effects O 
of O 
electron O 
correlation O 
, O 
basis O 
set O 
, O 
and O 
geometry O 
. O 
Geometry O 
effects O 
were O 
found O 
to O 
lead O 
to O 
noticeable O 
changes O 
of O 
the O 
vibrational O 
and O 
electronic O 
second O 
hyperpolarizability O 
. O 
A O 
limited O 
study O 
of O 
the O 
effect O 
of O 
Xe B-FORMULA 
insertion O 
to O 
the O 
nr O 
vibrational O 
properties O 
is O 
also O 
reported O 
. O 
Assessment O 
of O 
the O 
results O 
revealed O 
that O 
Xe B-FORMULA 
insertion O 
has O 
a O 
remarkable O 
effect O 
on O 
the O 
nr O 
(hyper)polarizabilities O 
. O 
In O 
terms O 
of O 
the O 
BKPT O 
, O 
this O 
is O 
associated O 
with O 
a O 
remarkable O 
increase O 
of O 
the O 
electrical O 
and O 
mechanical O 
anharmonicity O 
terms O 
. O 
The O 
latter O 
is O 
consistent O 
with O 
the O 
anharmonic O 
character O 
of O 
several O 
vibrational O 
modes O 
reported O 
for O 
rare O 
gas O 
compounds O 
. O 
© O 
2013 O 
Wiley O 
Periodicals O 
, O 
Inc O 
. O 

2 O 
diabetes O 
affects O 
over O 
25 O 
million O 
people O 
in O 
the O 
United O 
States O 
. O 
There O 
are O 
many O 
treatment O 
options O 
for O 
patients O 
with O 
type O 
2 O 
diabetes O 
, O 
but O 
current O 
treatments O 
must O 
be O 
administered O 
on O 
a O 
daily O 
basis O 
. O 
Once O 
- O 
weekly O 
exenatide O 
, O 
an O 
extended O 
- O 
duration O 
glucagon O 
- O 
like O 
peptide-1 O 
( O 
GLP-1 O 
) O 
agonist O 
, O 
provides O 
an O 
option O 
for O 
patients O 
to O 
take O 
a O 
drug O 
weekly O 
, O 
with O 
pharmacotherapeutic O 
effects O 
that O 
are O 
superior O 
to O 
twice O 
- O 
daily O 
exenatide O 
and O 
sitagliptin B-TRIVIAL 
and O 
comparable O 
to O 
insulin O 
glargine O 
. O 
The O 
DURATION O 
trials O 
provide O 
evidence O 
that O 
once O 
- O 
weekly O 
exenatide O 
reduces O 
hemoglobin O 
A1c O 
, O 
and O 
may O 
result O 
in O 
weight O 
loss O 
. O 
Once O 
- O 
weekly O 
exenatide O 
is O 
marketed O 
as O 
a O 
2-mg O 
injection O 
administered O 
subcutaneously O 
once O 
every O 
7 O 
days O 
. O 
Adverse O 
effects O 
of O 
once O 
- O 
weekly O 
exenatide O 
include O 
gastrointestinal O 
effects O 
, O 
hypoglycemia O 
, O 
injection O 
- O 
site O 
reactions O 
, O 
pancreatitis O 
, O 
and O 
antibody O 
development O 
. O 
Patients O 
with O 
a O 
self O 
history O 
or O 
family O 
history O 
of O 
thyroid O 
tumors O 
should O 
avoid O 
using O 
once O 
- O 
weekly O 
exenatide O 
. O 
Delayed O 
gastric O 
absorption O 
with O 
orally O 
administered O 
drugs O 
is O 
possible O 
, O 
and O 
monitoring O 
should O 
occur O 
to O 
avoid O 
loss O 
in O 
therapeutic O 
effect O 
. O 
Once O 
- O 
weekly O 
exenatide O 
is O 
a O 
new O 
extended O 
- O 
duration O 
agent O 
with O 
efficacy O 
and O 
tolerability O 
profiles O 
comparative O 
to O 
older O 
therapies O 
. O 
Appropriate O 
patients O 
for O 
once O 
- O 
weekly O 
exenatide O 
would O 
be O 
those O 
who O 
are O 
concerned O 
about O 
weight O 
gain O 
, O 
hypoglycemia O 
, O 
or O 
those O 
who O 
do O 
not O 
wish O 
to O 
administer O 
injections O 
daily O 
. O 

bone O 
mineral O 
density O 
is O 
common O 
among O 
persons O 
with O 
human O 
immunodeficiency O 
virus O 
( O 
HIV O 
) O 
infection O 
, O 
and O 
studies O 
reporting O 
increased O 
fracture O 
rates O 
in O 
this O 
patient O 
population O 
are O 
emerging O 
. O 
The O 
causes O 
of O 
low O 
bone O 
mineral O 
density O 
, O 
osteoporosis O 
, O 
and O 
fractures O 
in O 
persons O 
with O 
HIV O 
are O 
likely O 
multifactorial O 
, O 
involving O 
traditional O 
risk O 
factors O 
, O 
HIV O 
infection O 
, O 
and O 
exposure O 
to O 
antiretroviral O 
treatment O 
. O 
Specific O 
antiretrovirals O 
such O 
as O 
tenofovir B-TRIVIAL 
may O 
cause O 
a O 
greater O 
loss O 
of O 
bone O 
mineral O 
density O 
compared O 
with O 
other O 
agents O 
and O 
have O 
recently O 
been O 
linked O 
to O 
an O 
increased O 
risk O 
for O 
fracture O 
. O 
As O 
a O 
result O 
, O 
recent O 
treatment O 
guidelines O 
suggest O 
that O 
clinicians O 
consider O 
avoiding O 
tenofovir B-TRIVIAL 
as O 
initial O 
therapy O 
in O 
postmenopausal O 
women O 
. O 
Evaluating O 
bone O 
mineral O 
density O 
and O 
vitamin B-FAMILY 
D I-FAMILY 
status O 
in O 
persons O 
with O 
HIV O 
may O 
be O 
important O 
steps O 
in O 
identifying O 
those O 
requiring O 
pharmacotherapy O 
; O 
however O 
, O 
the O 
appropriate O 
timing O 
for O 
bone O 
mineral O 
density O 
and O 
vitamin B-FAMILY 
D I-FAMILY 
screening O 
is O 
uncertain O 
, O 
as O 
is O 
the O 
appropriate O 
method O 
of O 
replacing O 
vitamin B-FAMILY 
D I-FAMILY 
in O 
HIV-positive O 
patients O 
who O 
are O 
deficient O 
. O 
Further O 
study O 
is O 
necessary O 
to O 
definitively O 
determine O 
the O 
approach O 
to O 
evaluating O 
bone O 
health O 
and O 
managing O 
low O 
bone O 
mineral O 
density O 
and O 
vitamin B-FAMILY 
D I-FAMILY 
deficiency O 
in O 
patients O 
with O 
HIV O 
infection O 
. O 

Flexible O 
Organic O 
Solar O 
Cells O 
with O 
Graphene B-TRIVIAL 
top O 
Electrodes O 
. O 

- O 
free O 
flexible O 
organic O 
solar O 
cells O 
were O 
fabricated O 
with O 
multilayer O 
graphene B-TRIVIAL 
as O 
top O 
transparent O 
electrodes O 
, O 
which O 
show O 
the O 
highest O 
power O 
conversion O 
efficiency O 
of O 
about O 
3.2% O 
and O 
excellent O 
flexibility O 
and O 
bending O 
stability O 
. O 
The O 
devices O 
also O 
show O 
good O 
air O 
stability O 
, O 
indicating O 
that O 
multilayer O 
graphene B-TRIVIAL 
is O 
a O 
promising O 
environmental O 
barrier O 
that O 
can O 
protect O 
the O 
organic O 
solar O 
cells O 
from O 
air O 
contamination O 
. O 

functionalization O 
allows O 
development O 
of O 
high O 
- O 
performance O 
soluble O 
small O 
- O 
molecule O 
organic O 
semiconductors O 
with O 
mobilities O 
greater O 
than O 
5 O 
cm(2) O 
V(-1) O 
s(-1) O 
. O 
Spray O 
- O 
deposited O 
organic O 
thin O 
- O 
film O 
transistors O 
show O 
a O 
record O 
mobility O 
of O 
2.2 O 
cm(2) O 
V(-1) O 
s(-1) O 
and O 
demonstrate O 
the O 
potential O 
for O 
incorporation O 
in O 
large O 
- O 
area O 
, O 
low O 
- O 
cost O 
electronic O 
applications O 
. O 

remodeling O 
allows O 
the O 
conservation O 
of O 
normal O 
bone O 
mass O 
despite O 
constant O 
changes O 
in O 
internal O 
and O 
external O 
environments O 
. O 
The O 
adaptation O 
of O 
the O 
skeleton O 
to O 
these O 
various O 
stimuli O 
led O 
credence O 
to O 
the O 
notion O 
that O 
bone O 
remodeling O 
is O 
a O 
true O 
homeostatic O 
function O 
, O 
and O 
as O 
such O 
is O 
under O 
the O 
control O 
of O 
specific O 
centers O 
in O 
the O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
. O 
Hypothalamic O 
and O 
brainstem O 
centers O 
, O 
as O 
well O 
as O 
the O 
sympathetic O 
nervous O 
system O 
( O 
SNS O 
) O 
, O 
have O 
been O 
identified O 
as O 
regulators O 
of O 
bone O 
remodeling O 
. O 
However O 
, O 
the O 
nature O 
of O 
the O 
afferent O 
CNS O 
stimuli O 
that O 
may O 
modulate O 
CNS O 
centers O 
involved O 
in O 
the O 
control O 
of O 
bone O 
remodeling O 
, O 
with O 
the O 
exception O 
of O 
leptin O 
, O 
remains O 
unclear O 
. O 
Based O 
on O 
the O 
partial O 
efficacy O 
of O 
exercise O 
and O 
mechanical O 
stimulation O 
regimens O 
to O 
prevent O 
microgravity O 
- O 
induced O 
bone O 
loss O 
and O 
the O 
known O 
alterations O 
in O 
vestibular O 
functions O 
associated O 
with O 
space O 
flights O 
, O 
we O 
hypothesized O 
that O 
inner O 
ear O 
vestibular O 
signals O 
may O 
contribute O 
to O 
the O 
regulation O 
of O 
bone O 
remodeling O 
. O 
Using O 
an O 
established O 
model O 
of O 
bilateral O 
vestibular O 
lesions O 
and O 
microtomographic O 
and O 
histomorphometric O 
bone O 
analyses O 
, O 
we O 
show O 
here O 
that O 
induction O 
of O 
bilateral O 
vestibular O 
lesion O 
in O 
rats O 
generates O 
significant O 
bone O 
loss O 
, O 
which O 
is O 
restricted O 
to O 
weight O 
- O 
bearing O 
bones O 
and O 
associated O 
with O 
a O 
significant O 
reduction O 
in O 
bone O 
formation O 
, O 
as O 
observed O 
in O 
rats O 
under O 
microgravity O 
conditions O 
. O 
Importantly O 
, O 
this O 
bone O 
loss O 
was O 
not O 
associated O 
with O 
reduced O 
locomotor O 
activity O 
or O 
metabolic O 
abnormalities O 
, O 
was O 
accompanied O 
with O 
molecular O 
signs O 
of O 
increased O 
sympathetic O 
outflow O 
, O 
and O 
could O 
be O 
prevented O 
by O 
the O 
β-blocker O 
propranolol B-TRIVIAL 
. O 
Collectively O 
, O 
these O 
data O 
suggest O 
that O 
the O 
homeostatic O 
process O 
of O 
bone O 
remodeling O 
has O 
a O 
vestibulo O 
- O 
sympathetic O 
regulatory O 
component O 
and O 
that O 
vestibular O 
system O 
pathologies O 
might O 
be O 
accompanied O 
by O 
bone O 
fragility O 
. O 
© O 
2013 O 
American O 
Society O 
for O 
Bone O 
and O 
Mineral O 
Research O 
. O 

Glucuronidation O 
of O 
R- B-MULTIPLE 
and I-MULTIPLE 
S- I-MULTIPLE 
Lorazepam I-MULTIPLE 
: O 
Human O 
Liver O 
Microsomal O 
Kinetics O 
, O 
UDP B-ABBREVIATION 
-Glucuronosyltransferase O 
Enzyme O 
Selectivity O 
, O 
and O 
Inhibition O 
by O 
Drugs O 
. O 

widely O 
used O 
hypnosedative O 
- O 
anxiolytic O 
agent O 
R,S-lorazepam B-MULTIPLE 
is O 
cleared O 
predominantly O 
by O 
conjugation O 
with O 
glucuronic B-TRIVIAL 
acid I-TRIVIAL 
in O 
humans O 
, O 
but O 
the O 
enantioselective O 
glucuronidation O 
of O 
lorazepam B-TRIVIAL 
has O 
received O 
little O 
attention O 
. O 
The O 
present O 
study O 
characterized O 
the O 
kinetics O 
of O 
the O 
separate O 
R- O 
and O 
S- O 
enantiomers O 
of O 
lorazepam B-TRIVIAL 
by O 
human O 
liver O 
microsomes O 
( O 
HLM O 
) O 
and O 
by O 
a O 
panel O 
of O 
recombinant O 
human O 
UDP B-ABBREVIATION 
-glucuronosyltransferase O 
( O 
UGT O 
) O 
enzymes O 
. O 
Respective O 
mean O 
Km O 
and O 
Vmax O 
values O 
for O 
R- B-MULTIPLE 
and I-MULTIPLE 
S- I-MULTIPLE 
lorazepam I-MULTIPLE 
by O 
HLM O 
were O 
29 O 
± O 
8.9 O 
and O 
36 O 
± O 
10 O 
μM O 
, O 
and O 
7.4 O 
± O 
1.9 O 
and O 
10 O 
± O 
3.8 O 
pmol O 
/ O 
min.mg O 
. O 
Microsomal O 
intrinsic O 
clearances O 
were O 
not O 
significantly O 
different O 
, O 
suggesting O 
the O 
in O 
vivo O 
clearances O 
of O 
R- B-MULTIPLE 
and I-MULTIPLE 
S- I-MULTIPLE 
lorazepam I-MULTIPLE 
are O 
likely O 
to O 
be O 
similar O 
. O 
Both O 
R- B-MULTIPLE 
and I-MULTIPLE 
S- I-MULTIPLE 
lorazepam I-MULTIPLE 
were O 
glucuronidated O 
by O 
UGT O 
2B4 O 
, O 
2B7 O 
, O 
and O 
2B15 O 
, O 
while O 
R-lorazepam B-TRIVIAL 
was O 
additionally O 
metabolized O 
by O 
the O 
extra O 
- O 
hepatic O 
enzymes O 
UGT O 
1A7 O 
and O 
1A10 O 
. O 
Based O 
on O 
in O 
vitro O 
clearances O 
and O 
consideration O 
of O 
available O 
in O 
vivo O 
and O 
in O 
vitro O 
data O 
, O 
UGT2B15 O 
is O 
likely O 
to O 
play O 
an O 
important O 
role O 
in O 
the O 
glucuronidation O 
of O 
R- B-MULTIPLE 
and I-MULTIPLE 
S-lorazepam I-MULTIPLE 
. O 
However O 
, O 
the O 
possible O 
contribution O 
of O 
other O 
enzymes O 
and O 
the O 
low O 
activities O 
observed O 
in O 
vitro O 
indicate O 
that O 
the O 
lorazepam B-TRIVIAL 
enantiomers O 
are O 
of O 
limited O 
use O 
as O 
substrate O 
probes O 
for O 
UGT2B15 O 
. O 
In O 
order O 
to O 
identify O 
potential O 
drug O 
- O 
drug O 
interactions O 
, O 
codeine B-TRIVIAL 
, O 
fluconazole B-TRIVIAL 
, O 
ketamine B-TRIVIAL 
, O 
ketoconazole B-TRIVIAL 
, O 
methadone B-TRIVIAL 
, O 
morphine B-TRIVIAL 
, O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
zidovudine B-TRIVIAL 
were O 
screened O 
as O 
inhibitors O 
of O 
R- B-MULTIPLE 
and I-MULTIPLE 
S- I-MULTIPLE 
lorazepam I-MULTIPLE 
glucuronidation O 
by O 
HLM O 
. O 
Of O 
these O 
drugs O 
, O 
in O 
vitro O 
- O 
in O 
vivo O 
extrapolation O 
suggested O 
that O 
only O 
ketoconazole B-TRIVIAL 
had O 
the O 
potential O 
to O 
inhibit O 
lorazepam B-TRIVIAL 
clearance O 
to O 
a O 
clinically O 
significant O 
extent O 
. O 

chromatography O 
- O 
mass O 
spectrometry O 
method O 
for O 
the O 
quantification O 
of O 
posaconazole B-TRIVIAL 
in O 
human O 
plasma O 
: O 
application O 
to O 
pharmacokinetics O 
following O 
single O 
- O 
dose O 
administration O 
in O 
the O 
fasted O 
state O 
and O 
with O 
a O 
high O 
- O 
fat O 
meal O 
. O 

liquid O 
chromatography O 
/ O 
tandem O 
mass O 
spectrometry O 
( O 
LC-MS O 
/ O 
MS O 
) O 
method O 
was O 
developed O 
to O 
determine O 
concentrations O 
of O 
posaconazole B-TRIVIAL 
in O 
human O 
plasma O 
precipitated O 
by O 
acetonitrile B-SYSTEMATIC 
including O 
internal O 
standard O 
. O 
Rapid O 
chromatographic O 
separation O 
was O 
achieved O 
in O 
the O 
mobile O 
phase O 
composition O 
of O 
acetonitrile B-SYSTEMATIC 
, O 
water O 
and O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
v O 
/ O 
v O 
/ O 
v O 
, O 
55 O 
: O 
45 O 
: O 
0.1 O 
) O 
with O 
a O 
flow O 
rate O 
of O 
0.25 O 
ml O 
/ O 
min O 
. O 
Posaconazole-d4 B-TRIVIAL 
was O 
used O 
as O 
internal O 
standard O 
. O 
Detection O 
was O 
undertaken O 
with O 
cation O 
electrospray O 
tandem O 
mass O 
spectrometry O 
on O 
a O 
Sciex O 
/ O 
API3000 O 
. O 
The O 
method O 
was O 
accurate O 
, O 
specific O 
and O 
sensitive O 
for O 
the O 
analysis O 
of O 
posaconazole B-TRIVIAL 
in O 
human O 
plasma O 
in O 
the O 
concentration O 
range O 
of O 
2-1000 O 
ng O 
/ O 
ml O 
. O 
The O 
inter- O 
and O 
intra O 
- O 
batch O 
accuracy O 
was O 
within O 
+ O 
/ O 
- O 
10% O 
and O 
the O 
lower O 
limit O 
of O 
quantification O 
was O 
2 O 
ng O 
/ O 
ml O 
. O 
The O 
method O 
facilitated O 
a O 
clinical O 
pharmacokinetic O 
study O 
after O 
oral O 
administration O 
of O 
a O 
single O 
- O 
dose O 
of O 
posaconazole B-TRIVIAL 
suspension O 
in O 
the O 
fasted O 
state O 
and O 
with O 
a O 
high O 
- O 
fat O 
meal O 
in O 
a O 
two O 
- O 
period O 
crossover O 
design O 
. O 
Cmax O 
( O 
maximum O 
concentration O 
) O 
and O 
AUC O 
( O 
area O 
under O 
serum O 
drug O 
concentration O 
) O 
were O 
significantly O 
increased O 
, O 
and O 
Tmax O 
( O 
time O 
to O 
maximum O 
plasma O 
concentration O 
) O 
was O 
delayed O 
under O 
fed O 
condition O 
, O 
which O 
suggested O 
that O 
simultaneous O 
administration O 
of O 
posaconazole B-TRIVIAL 
with O 
food O 
may O 
help O 
to O 
achieve O 
higher O 
plasma O 
concentrations O 
and O 
result O 
in O 
better O 
antifungal O 
efficacy O 
. O 

difference O 
of O 
luteolin B-TRIVIAL 
and O 
apigenin B-TRIVIAL 
after O 
oral O 
administration O 
of O 
Chrysanthemum O 
morifolium O 
extract O 
and O 
prediction O 
of O 
human O 
pharmacokinetics O 
. O 

aims O 
of O 
the O 
present O 
study O 
were O 
to O 
study O 
the O 
interspecies O 
difference O 
in O 
the O 
pharmacokinetics O 
of O 
luteolin B-TRIVIAL 
and O 
apigenin B-TRIVIAL 
occurring O 
in O 
Chrysanthemum O 
morifolium O 
extract O 
( O 
CME O 
) O 
among O 
rats O 
, O 
beagle O 
dogs O 
, O 
mini O 
- O 
pigs O 
, O 
and O 
humans O 
, O 
and O 
compared O 
the O 
human O 
pharmacokinetic O 
parameters O 
with O 
the O 
data O 
predicted O 
from O 
the O 
above O 
three O 
animals O 
. O 
The O 
plasma O 
concentrations O 
of O 
luteolin B-TRIVIAL 
and O 
apigenin B-TRIVIAL 
were O 
determined O 
with O 
a O 
RP-HPLC O 
method O 
. O 
An O 
interspecies O 
difference O 
of O 
pharmacokinetics O 
was O 
found O 
, O 
especially O 
between O 
rats O 
and O 
other O 
species O 
, O 
the O 
plasma O 
concentration O 
of O 
luteolin B-TRIVIAL 
was O 
much O 
lower O 
than O 
that O 
of O 
apigenin B-TRIVIAL 
in O 
rats O 
, O 
although O 
the O 
content O 
of O 
luteolin B-TRIVIAL 
in O 
CME O 
was O 
higherthan O 
that O 
of O 
apigenin B-TRIVIAL 
, O 
whereas O 
the O 
plasma O 
concentration O 
of O 
luteolin B-TRIVIAL 
was O 
much O 
higher O 
than O 
that O 
of O 
apigenin B-TRIVIAL 
in O 
dogs O 
, O 
mini O 
- O 
pigs O 
and O 
humans O 
. O 
Animal O 
scale O 
- O 
up O 
of O 
some O 
pharmacokinetic O 
parameters O 
of O 
luteolin B-TRIVIAL 
and O 
apigenin B-TRIVIAL 
were O 
also O 
performed O 
after O 
rats O 
, O 
beagle O 
dogs O 
, O 
mini O 
- O 
pigs O 
and O 
humans O 
were O 
orally O 
given O 
CME O 
at O 
dosages O 
of O 
400 O 
mg O 
/ O 
kg O 
, O 
102 O 
mg O 
/ O 
kg O 
, O 
90 O 
mg O 
/ O 
kg O 
, O 
and O 
20 O 
mg O 
/ O 
kg O 
, O 
respectively O 
. O 
Linear O 
relationships O 
were O 
obtained O 
between O 
log O 
mean O 
retention O 
time O 
( O 
MRT O 
) O 
and O 
log O 
species O 
body O 
weight O 
( O 
W O 
) O 
( O 
kg O 
) O 
, O 
and O 
log O 
elimination O 
half O 
- O 
life O 
( O 
t1 O 
/ O 
2 O 
) O 
( O 
h O 
) O 
and O 
logW O 
. O 
The O 
corresponding O 
allometric O 
equations O 
were O 
MRT=9.382W(0.1711) O 
( O 
R2 O 
= O 
0.9999 O 
) O 
and O 
t1 O 
/ O 
2 O 
= O 
4.811W(0.1093) O 
( O 
R2 O 
= O 
0.9013 O 
) O 
for O 
luteolin B-TRIVIAL 
, O 
MRT O 
= O 
12.53W(0.0356) O 
( O 
R2 O 
= O 
0.998 O 
) O 
and O 
t1 O 
/ O 
2 O 
= O 
7.940W(0.0294) O 
( O 
R2 O 
= O 
0.9258 O 
) O 
for O 
apigenin B-TRIVIAL 
, O 
respectively O 
. O 
The O 
predicted O 
human O 
pharmacokinetic O 
parameters O 
( O 
MRT O 
and O 
t1 O 
/ O 
2 O 
) O 
by O 
an O 
allometric O 
approach O 
were O 
18.6 O 
h O 
and O 
7.46 O 
h O 
for O 
luteolin B-TRIVIAL 
, O 
14.3 O 
h O 
and O 
8.95 O 
h O 
for O 
apigenin B-TRIVIAL 
, O 
respectively O 
, O 
which O 
were O 
close O 
to O 
the O 
values O 
obtained O 
from O 
humans O 
( O 
20 O 
mg O 
CME O 
/ O 
kg O 
) O 
in O 
the O 
present O 
study O 
. O 
The O 
study O 
has O 
demonstrated O 
the O 
possibility O 
to O 
extrapolate O 
the O 
pharmacokinetic O 
behavior O 
of O 
flavonoids B-FAMILY 
from O 
animals O 
to O 
humans O 
. O 

of O 
PAMAM B-ABBREVIATION 
Dendrimers O 
with O 
SDS B-ABBREVIATION 
at O 
the O 
Solid-Liquid O 
Interface O 
. O 

work O 
addresses O 
structural O 
and O 
nonequilibrium O 
effects O 
of O 
the O 
interactions O 
between O 
well O 
- O 
defined O 
cationic O 
poly(amidoamine) B-SYSTEMATIC 
PAMAM B-ABBREVIATION 
dendrimers O 
of O 
generations O 
4 O 
and O 
8 O 
and O 
the O 
anionic O 
surfactant O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
SDS B-ABBREVIATION 
) O 
at O 
the O 
hydrophilic O 
silica B-TRIVIAL 
-water O 
interface O 
. O 
Neutron O 
reflectometry O 
and O 
quartz O 
crystal O 
microbalance O 
with O 
dissipation O 
monitoring O 
were O 
used O 
to O 
reveal O 
the O 
adsorption O 
from O 
premixed O 
dendrimer O 
/ O 
surfactant O 
solutions O 
as O 
well O 
as O 
sequential O 
addition O 
of O 
the O 
surfactant O 
to O 
preadsorbed O 
layers O 
of O 
dendrimers O 
. O 
PAMAM B-ABBREVIATION 
dendrimers O 
of O 
both O 
generations O 
adsorb O 
to O 
hydrophilic O 
silica B-TRIVIAL 
as O 
a O 
compact O 
monolayer O 
, O 
and O 
the O 
adsorption O 
is O 
irreversible O 
upon O 
rinsing O 
with O 
salt O 
solution O 
. O 
SDS B-ABBREVIATION 
adsorbs O 
on O 
the O 
dendrimer O 
layer O 
and O 
at O 
low O 
bulk O 
concentrations O 
causes O 
the O 
expansion O 
of O 
the O 
dendrimer O 
layers O 
on O 
the O 
surface O 
. O 
When O 
the O 
bulk O 
concentration O 
of O 
SDS B-ABBREVIATION 
is O 
increased O 
, O 
the O 
surfactant O 
layer O 
consists O 
of O 
aggregates O 
or O 
bilayer O 
- O 
like O 
structures O 
. O 
The O 
adsorption O 
of O 
surfactant O 
is O 
reversible O 
upon O 
rinsing O 
, O 
but O 
slight O 
changes O 
of O 
the O 
structure O 
of O 
the O 
preadsorbed O 
PAMAM B-ABBREVIATION 
monolayer O 
were O 
observed O 
. O 
The O 
adsorption O 
from O 
premixed O 
solutions O 
close O 
to O 
charge O 
neutrality O 
results O 
in O 
thick O 
multilayers O 
, O 
but O 
the O 
surface O 
excess O 
is O 
lower O 
when O 
the O 
bulk O 
complexes O 
have O 
a O 
net O 
negative O 
charge O 
. O 
A O 
critical O 
examination O 
of O 
the O 
pathway O 
of O 
adsorption O 
for O 
the O 
interactions O 
of O 
SDS B-ABBREVIATION 
with O 
preadsorbed O 
PAMAM B-ABBREVIATION 
monolayers O 
and O 
premixed O 
PAMAM B-ABBREVIATION 
/ O 
SDS B-ABBREVIATION 
solutions O 
with O 
hydrophilic O 
silica B-TRIVIAL 
revealed O 
that O 
nonequilibrium O 
effects O 
are O 
important O 
only O 
in O 
the O 
latter O 
case O 
, O 
and O 
the O 
application O 
of O 
a O 
thermodynamic O 
model O 
to O 
such O 
experimental O 
data O 
would O 
be O 
inappropriate O 
. O 

drainage O 
from O 
thick O 
plane O 
vertical O 
soap O 
films O 
and O 
hemispherical O 
bubbles O 
is O 
studied O 
experimentally O 
and O 
theoretically O 
. O 
The O 
experiments O 
involve O 
microinterferometry O 
kindred O 
to O 
the O 
one O 
used O 
in O 
the O 
experiments O 
in O 
the O 
Scheludko O 
cell O 
. O 
The O 
following O 
surfactants O 
were O 
used O 
in O 
the O 
experiments O 
: O 
cationic O 
dodecyltrimethylammonium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
DTAB B-ABBREVIATION 
) O 
, O 
anionic O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
SDS B-ABBREVIATION 
) O 
, O 
anionic O 
Pantene O 
shampoo O 
which O 
primarily O 
contains O 
sodium B-SYSTEMATIC 
lauryl I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
, O 
nonionic O 
tetraethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
monooctyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
C8E4 B-FORMULA 
) O 
, O 
and O 
nonionic O 
Pluronic B-TRIVIAL 
( I-TRIVIAL 
P-123 I-TRIVIAL 
) I-TRIVIAL 
surfactants O 
at O 
different O 
concentrations O 
. O 
The O 
theoretical O 
results O 
explain O 
the O 
drainage O 
mechanism O 
and O 
are O 
used O 
to O 
develop O 
a O 
new O 
method O 
of O 
measurement O 
of O 
the O 
surface O 
elasticity O 
and O 
to O 
test O 
it O 
on O 
the O 
above O 
- O 
mentioned O 
surfactants O 
. O 

of O 
Specific O 
Binding O 
Interactions O 
at O 
l-Cystine B-TRIVIAL 
Crystal O 
Surfaces O 
with O 
Chemical O 
Force O 
Microscopy O 
. O 

pathogenesis O 
of O 
l-cystine B-TRIVIAL 
kidney O 
stones O 
involves O 
four O 
critical O 
steps O 
: O 
nucleation O 
, O 
crystal O 
growth O 
, O 
crystal O 
aggregation O 
, O 
and O 
crystal O 
adhesion O 
to O 
cells O 
. O 
Although O 
inhibition O 
of O 
crystal O 
growth O 
by O 
l-cystine B-TRIVIAL 
" O 
imposters O 
" O 
at O 
l-cystine B-TRIVIAL 
crystal O 
surfaces O 
has O 
been O 
suggested O 
as O 
a O 
plausible O 
route O 
for O 
the O 
suppression O 
of O 
stones O 
, O 
understanding O 
the O 
factors O 
that O 
govern O 
crystal O 
- O 
crystal O 
aggregation O 
and O 
adhesion O 
of O 
crystals O 
to O 
epithelial O 
cells O 
also O 
is O 
essential O 
for O 
devising O 
strategies O 
to O 
mitigate O 
l-cystine B-TRIVIAL 
stone O 
formation O 
. O 
Chemical O 
force O 
microscopy O 
performed O 
with O 
atomic O 
force O 
microscope O 
tips O 
decorated O 
with O 
functional O 
groups O 
commonly O 
found O 
in O 
urinary O 
constituents O 
that O 
likely O 
mediate O 
aggregation O 
and O 
attachment O 
( O 
e.g O 
. O 
, O 
COOH B-FORMULA 
, O 
NH2 B-FORMULA 
, O 
SH B-FORMULA 
, O 
CH3 B-FORMULA 
, O 
OH B-FORMULA 
) O 
revealed O 
signatures O 
that O 
reflect O 
differences O 
in O 
the O 
chemical O 
affinity O 
of O 
these O 
groups O 
for O 
the O 
( O 
1 O 
) O 
and O 
{ O 
100 O 
} O 
faces O 
of O 
the O 
naturally O 
occurring O 
hexagonal O 
form O 
of O 
l-cystine B-TRIVIAL 
single O 
crystals O 
and O 
the O 
{ O 
110 O 
} O 
faces O 
of O 
the O 
non-native O 
tetragonal O 
form O 
. O 
These O 
signatures O 
can O 
be O 
explained O 
by O 
the O 
different O 
chemical O 
compositions O 
of O 
the O 
crystal O 
faces O 
, O 
and O 
they O 
reveal O 
a O 
remarkable O 
binding O 
specificity O 
of O 
the O 
thiol O 
group O 
for O 
the O 
sulfur B-SYSTEMATIC 
-rich O 
{ O 
100 O 
} O 
and O 
{ O 
110 O 
} O 
faces O 
of O 
the O 
hexagonal O 
and O 
tetragonal O 
forms O 
, O 
respectively O 
. O 
Collectively O 
, O 
these O 
observations O 
suggest O 
that O 
alterations O 
of O 
the O 
crystal O 
habit O 
and O 
polymorph O 
by O 
crystal O 
growth O 
inhibitors O 
may O 
not O 
affect O 
crystal O 
aggregation O 
or O 
adhesion O 
to O 
cells O 
significantly O 
. O 

gene O 
expression O 
analysis O 
reveals O 
pathway O 
differences O 
between O 
teratogenic O 
and O 
non-teratogenic O 
exposure O 
concentrations O 
of O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
and O 
17β-estradiol B-SYSTEMATIC 
in O 
embryonic O 
zebrafish O 
. O 

developmental O 
exposure O 
to O 
0.1μM O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
results O 
in O 
larval O 
zebrafish O 
hyperactivity O 
and O 
learning O 
impairments O 
in O 
the O 
adult O 
, O 
while O 
exposure O 
to O 
80μM O 
BPA B-ABBREVIATION 
results O 
in O 
teratogenic O 
responses O 
, O 
including O 
craniofacial O 
abnormalities O 
and O 
edema O 
. O 
The O 
mode O 
of O 
action O 
underlying O 
these O 
effects O 
is O 
unclear O 
. O 
We O 
used O 
global O 
gene O 
expression O 
analysis O 
to O 
identify O 
candidate O 
genes O 
and O 
signaling O 
pathways O 
that O 
mediate O 
BPA B-ABBREVIATION 
' O 
s O 
developmental O 
toxicity O 
in O 
zebrafish O 
. O 
Exposure O 
concentrations O 
were O 
selected O 
and O 
anchored O 
to O 
the O 
positive O 
control O 
, O 
17β-estradiol B-SYSTEMATIC 
( O 
E2 O 
) O 
, O 
based O 
on O 
previously O 
determined O 
behavioral O 
or O 
teratogenic O 
phenotypes O 
. O 
Functional O 
analysis O 
of O 
differentially O 
expressed O 
genes O 
revealed O 
distinct O 
expression O 
profiles O 
at O 
24h O 
post O 
fertilization O 
for O 
0.1μM O 
versus O 
80μM O 
BPA B-ABBREVIATION 
and O 
0.1μM O 
versus O 
15μM O 
E2 O 
exposure O 
, O 
identification O 
of O 
prothrombin O 
activation O 
as O 
a O 
top O 
canonical O 
pathway O 
impacted O 
by O 
both O 
0.1μM O 
BPA B-ABBREVIATION 
and O 
0.1μM O 
E2 O 
exposure O 
, O 
and O 
suppressed O 
expression O 
of O 
several O 
genes O 
involved O 
in O 
nervous O 
system O 
development O 
and O 
function O 
following O 
0.1μM O 
BPA B-ABBREVIATION 
exposure O 
. O 

pesticide O 
exposure O 
modulates O 
cytokines O 
, O 
arginase O 
and O 
ornithine B-TRIVIAL 
decarboxylase O 
expression O 
in O 
human O 
placenta O 
. O 

evaluate O 
the O 
cytokine O 
balance O 
and O 
enzymatic O 
alterations O 
induced O 
by O 
environmental O 
pesticide O 
exposure O 
during O 
pregnancy O 
, O 
this O 
transversal O 
study O 
explored O 
placentas O 
derived O 
from O 
non-exposed O 
women O 
( O 
control O 
group-CG O 
) O 
, O 
and O 
from O 
women O 
living O 
in O 
a O 
rural O 
area O 
( O 
rural O 
group-RG O 
) O 
, O 
collected O 
during O 
intensive O 
organophosphate B-FAMILY 
( O 
OP O 
) O 
pesticide O 
spraying O 
season O 
( O 
RG-SS O 
) O 
and O 
during O 
non-spraying O 
season O 
( O 
RG-NSS O 
) O 
. O 
The O 
exposure O 
biomarkers O 
blood O 
cholinesterase O 
and O 
placental O 
carboxylesterase O 
( O 
CaE O 
) O 
were O 
significantly O 
decreased O 
in O 
RG-SS O 
. O 
Among O 
the O 
cytokines O 
studied O 
IL-8 O 
, O 
IL-6 O 
, O 
TNFα O 
, O 
IL-10 O 
, O 
TGFβ O 
and O 
IL-13 O 
, O 
the O 
expression O 
frequency O 
of O 
IL-13 O 
increased O 
in O 
RG-SS O 
. O 
Arginase O 
and O 
ornithine B-TRIVIAL 
decarboxylase O 
( O 
ODC O 
) O 
enzymes O 
were O 
induced O 
in O 
syncytiotrophoblast O 
and O 
endothelial O 
cells O 
. O 
Interestingly O 
, O 
the O 
decrease O 
in O 
CaE O 
activity O 
was O 
associated O 
with O 
arginase O 
and O 
ODC O 
activity O 
induction O 
. O 
These O 
findings O 
suggest O 
that O 
environmental O 
pesticide O 
exposure O 
impacts O 
the O 
placenta O 
by O 
increasing O 
the O 
expression O 
frequency O 
of O 
the O 
anti-inflammatory O 
cytokine O 
IL-13 O 
, O 
which O 
may O 
be O 
related O 
to O 
the O 
up O 
- O 
regulation O 
of O 
enzymes O 
implicated O 
in O 
tissue O 
repair O 
. O 

enhancement O 
of O 
Deflazacort B-TRIVIAL 
using O 
hollow O 
crystals O 
prepared O 
by O 
antisolvent O 
crystallization O 
process O 
. O 

( O 
DFZ B-ABBREVIATION 
) O 
, O 
a O 
derivate O 
of O 
prednisolone B-TRIVIAL 
, O 
is O 
a O 
poorly O 
soluble O 
drug O 
which O 
has O 
been O 
proposed O 
to O 
have O 
major O 
advantages O 
over O 
other O 
corticosteroids B-FAMILY 
. O 
Poorly O 
soluble O 
drugs O 
present O 
limited O 
bioavailability O 
due O 
to O 
their O 
low O 
solubility O 
and O 
dissolution O 
rate O 
and O 
several O 
strategies O 
have O 
been O 
developed O 
in O 
order O 
to O 
find O 
ways O 
to O 
improve O 
them O 
. O 
In O 
general O 
, O 
pharmaceutical O 
laboratories O 
use O 
a O 
micronized O 
process O 
to O 
reduce O 
the O 
particle O 
size O 
in O 
order O 
to O 
increase O 
the O 
dissolution O 
of O 
the O 
drugs O 
. O 
However O 
, O 
this O 
process O 
causes O 
changes O 
such O 
as O 
polymorphic O 
transitions O 
, O 
particle O 
agglomeration O 
and O 
a O 
reduction O 
in O 
fluidity O 
and O 
wettability O 
. O 
These O 
solid O 
- O 
state O 
properties O 
affect O 
the O 
dissolution O 
behavior O 
and O 
stability O 
performance O 
of O 
drugs O 
. O 
Crystallization O 
techniques O 
are O 
widely O 
used O 
in O 
the O 
pharmaceutical O 
industry O 
and O 
antisolvent O 
crystallization O 
has O 
been O 
used O 
to O 
obtain O 
ultrafine O 
particles O 
. O 
In O 
this O 
study O 
, O 
DFZ B-ABBREVIATION 
was O 
investigated O 
in O 
terms O 
of O 
its O 
antisolvent O 
crystallization O 
in O 
different O 
solvents O 
and O 
under O 
various O 
preparation O 
conditions O 
( O 
methanol B-SYSTEMATIC 
/ O 
water O 
ratio O 
, O 
stirring O 
and O 
evaporation O 
rate O 
, O 
etc O 
. O 
) O 
, O 
in O 
order O 
to O 
compare O 
the O 
physicochemical O 
properties O 
between O 
crystallized O 
samples O 
and O 
raw O 
materials O 
available O 
on O 
the O 
Brazilian O 
market O 
with O 
and O 
without O 
micronization O 
. O 
Crystalline O 
structure O 
, O 
morphology O 
, O 
and O 
particle O 
size O 
, O 
and O 
their O 
correlation O 
with O 
the O 
Intrinsic O 
Dissolution O 
Rate O 
( O 
IDR O 
) O 
and O 
dissolution O 
profile O 
as O 
relevant O 
biopharmaceutical O 
properties O 
were O 
studied O 
. O 
Crystallization O 
conditions O 
were O 
achieved O 
which O 
provided O 
crystalline O 
samples O 
of O 
hollow O 
- O 
shaped O 
crystals O 
with O 
internal O 
channels O 
, O 
which O 
increased O 
the O 
dissolution O 
rate O 
of O 
DF B-ABBREVIATION 
Z O 
. O 
The O 
antisolvent O 
crystallization O 
process O 
allowed O 
the O 
formation O 
of O 
hollow O 
crystals O 
, O 
which O 
demonstrated O 
a O 
better O 
dissolution O 
profile O 
than O 
the O 
raw O 
material O 
( O 
crystalline O 
and O 
micronized O 
) O 
, O 
making O 
this O 
a O 
promising O 
technique O 
as O 
a O 
crystallization O 
strategy O 
for O 
improving O 
the O 
dissolution O 
and O 
thus O 
the O 
bioavailability O 
of O 
poorly O 
soluble O 
drugs O 
. O 

A I-TRIVIAL 
protects O 
against O 
cisplatin B-TRIVIAL 
-induced O 
ototoxicity O 
by O 
regulating O 
expression O 
of O 
genes O 
related O 
to O 
apoptosis O 
and O 
synaptic O 
function O 
. O 

: O 
Although O 
inhibition O 
of O 
histone O 
deacetylases O 
( O 
HDACs O 
) O 
has O 
been O 
shown O 
to O 
protect O 
against O 
cisplatin B-TRIVIAL 
-induced O 
hearing O 
loss O 
, O 
the O 
underlying O 
mechanism O 
is O 
still O 
poorly O 
understood O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
aim O 
to O 
investigate O 
the O 
protective O 
effect O 
of O 
trichostatin B-TRIVIAL 
A I-TRIVIAL 
( O 
TSA B-ABBREVIATION 
) O 
, O 
a O 
specific O 
inhibitor O 
of O 
HDACs O 
, O 
on O 
cisplatin B-TRIVIAL 
-induced O 
ototoxicity O 
and O 
to O 
determine O 
the O 
differentially O 
expressed O 
genes O 
involved O 
in O 
this O 
process O 
. O 
METHODS O 
: O 
The O 
basilar O 
membrane O 
of O 
the O 
cochlea O 
was O 
isolated O 
from O 
3-day O 
newborn O 
Wistar O 
rats O 
. O 
Organotypic O 
cultures O 
were O 
treated O 
with O 
150μM O 
cisplatin B-TRIVIAL 
or O 
200nM O 
TSA B-ABBREVIATION 
. O 
For O 
combination O 
treatment O 
, O 
cells O 
were O 
pre O 
- O 
incubated O 
with O 
TSA B-ABBREVIATION 
for O 
1h O 
, O 
followed O 
by O 
TSA B-ABBREVIATION 
plus O 
cisplatin B-TRIVIAL 
treatment O 
. O 
Rhodamine B-FAMILY 
- O 
phalloidin B-TRIVIAL 
staining O 
was O 
used O 
to O 
label O 
hair O 
cells O 
, O 
and O 
immunocytochemistry O 
with O 
an O 
anti-neurofilament-200 O 
antibody O 
was O 
applied O 
to O 
label O 
spiral O 
ganglion O 
neurons O 
( O 
SGNs O 
) O 
. O 
Global O 
expression O 
profile O 
microarray O 
analysis O 
was O 
used O 
to O 
identify O 
differentially O 
expressed O 
genes O 
. O 
Molecular O 
function O 
and O 
signal O 
pathway O 
analysis O 
were O 
performed O 
using O 
a O 
protein O 
analysis O 
through O 
evolutionary O 
relationships O 
( O 
PANTHER O 
) O 
classification O 
system O 
. O 
Real O 
- O 
time O 
quantitative O 
PCR O 
( O 
qPCR O 
) O 
was O 
carried O 
out O 
for O 
data O 
validation O 
. O 
RESULTS O 
: O 
Severe O 
loss O 
of O 
hair O 
cells O 
and O 
SGNs O 
occurred O 
after O 
48h O 
of O 
cisplatin B-TRIVIAL 
incubation O 
, O 
while O 
TSA B-ABBREVIATION 
significantly O 
increased O 
the O 
number O 
of O 
hair O 
cells O 
and O 
SGNs O 
in O 
the O 
combination O 
treatment O 
group O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Compared O 
with O 
control O 
, O 
expression O 
of O 
71 O 
genes O 
were O 
up O 
- O 
regulated O 
and O 
383 O 
genes O 
were O 
down O 
- O 
regulated O 
upon O 
cisplatin B-TRIVIAL 
treatment O 
. O 
Addition O 
of O 
TSA B-ABBREVIATION 
induced O 
the O 
up O 
- O 
regulation O 
of O 
1387 O 
genes O 
and O 
down O 
- O 
regulation O 
of O 
1226 O 
genes O 
as O 
compared O 
with O 
cisplatin B-TRIVIAL 
administration O 
alone O 
. O 
After O 
cisplatin B-TRIVIAL 
treatment O 
, O 
we O 
observed O 
significant O 
down O 
- O 
regulation O 
of O 
mRNA O 
for O 
several O 
genes O 
related O 
to O 
synaptic O 
function O 
genes O 
, O 
including O 
Camk2a O 
, O 
Camk2b O 
, O 
Vglut1 O 
, O 
Snap25 O 
and O 
Rab3b O 
, O 
whereas O 
pretreatment O 
with O 
TSA B-ABBREVIATION 
elevated O 
mRNA O 
levels O 
of O 
these O 
genes O 
. O 
TSA B-ABBREVIATION 
greatly O 
decreased O 
expression O 
of O 
genes O 
related O 
to O 
the O 
calcium B-SYSTEMATIC 
signaling O 
pathway O 
( O 
Capn1 O 
and O 
Capn2 O 
) O 
and O 
apoptosis O 
signaling O 
pathway O 
( O 
Tnfrsf1a O 
and O 
Tp53 O 
) O 
, O 
while O 
addition O 
of O 
TSA B-ABBREVIATION 
significantly O 
reduced O 
levels O 
of O 
Tnfrsf1a O 
and O 
Tp53 O 
compared O 
with O 
cisplatin B-TRIVIAL 
alone O 
( O 
P O 
< O 
0.01 O 
) O 
. O 
CONCLUSIONS O 
: O 
Our O 
results O 
suggested O 
that O 
TSA B-ABBREVIATION 
might O 
protect O 
against O 
cisplatin B-TRIVIAL 
-induced O 
ototoxicity O 
via O 
mediating O 
expression O 
of O 
genes O 
responsible O 
for O 
regulating O 
apoptosis O 
, O 
intracellular O 
calcium B-SYSTEMATIC 
homeostasis O 
, O 
neurotransmitter O 
synthesis O 
and O 
release O 
, O 
and O 
synaptic O 
plasticity O 
. O 

novel O 
series O 
of O 
histamine B-TRIVIAL 
H4 O 
receptor O 
antagonists O 
based O 
on O 
the O 
pyrido[3,2-d]pyrimidine B-SYSTEMATIC 
scaffold O 
: O 
Comparison O 
of O 
hERG O 
binding O 
and O 
target O 
residence O 
time O 
with O 
PF-3893787 B-IDENTIFIER 
. O 

this O 
work O 
we O 
describe O 
the O 
optimization O 
of O 
a O 
lead O 
compound O 
based O 
on O 
the O 
quinazoline B-SYSTEMATIC 
template O 
to O 
give O 
a O 
new O 
series O 
of O 
potent O 
pyrido[3,2-d]pyrimidines B-FAMILY 
as O 
histamine B-TRIVIAL 
H4 O 
receptor O 
antagonists O 
. O 
The O 
pyrido[3,2-d]pyrimidine B-SYSTEMATIC 
ligands O 
have O 
significantly O 
reduced O 
hERG O 
binding O 
compared O 
to O 
clinical O 
stage O 
compound O 
PF-3893787 B-IDENTIFIER 
while O 
showing O 
good O 
affinities O 
at O 
the O 
human O 
and O 
rodent O 
histamine B-TRIVIAL 
receptors O 
. O 
The O 
receptor O 
residence O 
time O 
of O 
several O 
of O 
these O 
new O 
compounds O 
was O 
determined O 
for O 
the O 
human O 
H4R O 
and O 
compared O 
with O 
JNJ7777120 B-IDENTIFIER 
and O 
PF-3893787 B-IDENTIFIER 
. O 
The O 
pyrido[3,2-d]pyrimidines B-FAMILY 
showed O 
residence O 
times O 
lower O 
than O 
JNJ7777120 B-IDENTIFIER 
but O 
comparable O 
to O 
the O 
residence O 
time O 
of O 
PF-3893787 B-IDENTIFIER 
. O 
Overall O 
, O 
the O 
pyrido[3,2-d]pyrimidines B-FAMILY 
show O 
an O 
excellent O 
in O 
vitro O 
profile O 
that O 
warrants O 
their O 
further O 
investigation O 
in O 
relevant O 
models O 
of O 
human O 
disease O 
. O 

of O 
gap O 
- O 
junctional O 
intercellular O 
communication O 
( O 
GJIC O 
) O 
via O 
exposure O 
to O 
various O 
toxic O 
substances O 
has O 
been O 
implicated O 
in O 
tumor O 
promotion O 
. O 
In O 
the O 
present O 
study O 
, O 
cigarette O 
smoke O 
total O 
particulate O 
matter O 
( O 
TPM O 
) O 
, O 
a O 
known O 
inhibitor O 
of O 
GJIC O 
, O 
were O 
used O 
to O 
characterize O 
a O 
new O 
GJIC O 
screening O 
assay O 
in O 
three O 
independent O 
experiments O 
. O 
The O 
main O 
features O 
of O 
this O 
assay O 
were O 
automated O 
fluorescence O 
microscopy O 
combined O 
with O 
non-invasive O 
parachute O 
technique O 
. O 
Rat O 
liver O 
epithelial O 
cells O 
( O 
WB-F344 O 
) O 
were O 
stained O 
with O 
the O 
fluorescent O 
dye O 
Calcein B-TRIVIAL 
AM I-TRIVIAL 
( O 
acetoxymethyl B-SYSTEMATIC 
) O 
and O 
exposed O 
to O 
TPM O 
from O 
the O 
Kentucky O 
Reference O 
Cigarette O 
2R4F O 
( O 
a O 
blend O 
of O 
Bright O 
and O 
Burley O 
tobaccos O 
) O 
and O 
from O 
two O 
single O 
- O 
tobacco O 
cigarettes O 
( O 
Bright O 
and O 
Burley O 
) O 
for O 
3h O 
. O 
Phorbol-12-myristate-13-acetate B-SYSTEMATIC 
( O 
TPA B-ABBREVIATION 
) O 
was O 
used O 
as O 
positive O 
control O 
and O 
0.5% O 
dimethyl B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
( O 
DMSO B-ABBREVIATION 
) O 
as O 
solvent O 
control O 
. O 
The O 
transfer O 
of O 
dye O 
to O 
adjacent O 
cells O 
( O 
percentage O 
of O 
stained O 
cells O 
) O 
was O 
used O 
as O 
a O 
measure O 
of O 
cellular O 
communication O 
. O 
A O 
clear O 
and O 
reproducible O 
dose O 
- O 
response O 
of O 
GJIC O 
inhibition O 
following O 
TPM O 
exposure O 
was O 
seen O 
. O 
Reproducibility O 
and O 
repeatability O 
measurements O 
for O 
the O 
2R4F O 
cigarette O 
were O 
3.7% O 
and O 
6.9% O 
, O 
respectively O 
. O 
The O 
half O 
- O 
maximal O 
effective O 
concentration O 
values O 
were O 
0.34ng O 
/ O 
ml O 
for O 
TPA B-ABBREVIATION 
, O 
0.050mg O 
/ O 
ml O 
for O 
the O 
2R4F O 
, O 
0.044mg O 
/ O 
ml O 
for O 
the O 
Bright O 
cigarette O 
, O 
and O 
0.060mg O 
/ O 
ml O 
for O 
the O 
Burley O 
cigarette O 
. O 
The O 
assay O 
was O 
able O 
to O 
discriminate O 
between O 
the O 
two O 
single O 
- O 
tobacco O 
cigarettes O 
( O 
P O 
< O 
0.0001 O 
) O 
, O 
and O 
between O 
the O 
single O 
- O 
tobacco O 
cigarettes O 
and O 
the O 
2R4F O 
( O 
P=0.0008 O 
, O 
2R4F O 
vs O 
. O 
Burley O 
and O 
P O 
< O 
0.0001 O 
, O 
2R4F O 
vs O 
. O 
Bright O 
) O 
. O 
Thus O 
, O 
this O 
assay O 
can O 
be O 
used O 
to O 
determine O 
the O 
activity O 
of O 
complex O 
mixtures O 
such O 
as O 
cigarette O 
smoke O 
with O 
high O 
throughput O 
and O 
high O 
precision O 
. O 

: O 
A O 
case O 
study O 
on O 
the O 
identification O 
of O 
endocrine O 
active O 
substances O 
in O 
the O 
past O 
and O 
a O 
future O 
perspective O 
. O 

the O 
late O 
1980s O 
vinclozolin B-TRIVIAL 
was O 
tested O 
for O 
prenatal O 
developmental O 
toxicity O 
in O 
rats O 
for O 
registration O 
purposes O 
in O 
USA O 
. O 
At O 
1000mg O 
/ O 
kgbw O 
, O 
95% O 
of O 
all O 
fetuses O 
were O 
female O 
upon O 
visual O 
inspection O 
( O 
ano O 
- O 
genital O 
distance O 
determination O 
) O 
. O 
Anti-androgenic O 
effects O 
( O 
AA O 
) O 
were O 
also O 
noted O 
in O 
a O 
subsequent O 
2-generation O 
study O 
. O 
These O 
findings O 
triggered O 
mechanistic O 
investigations O 
at O 
BASF O 
and O 
at O 
US-EPA O 
. O 
Results O 
published O 
by O 
the O 
latter O 
were O 
the O 
starting O 
point O 
of O 
the O 
endocrine O 
disruption O 
( O 
ED O 
) O 
discussion O 
in O 
the O 
1990s O 
. O 
AA O 
effects O 
of O 
vinclozolin B-TRIVIAL 
are O 
mediated O 
by O 
two O 
metabolites O 
, O 
which O 
have O 
an O 
antagonistic O 
effect O 
on O 
the O 
androgen O 
receptor O 
. O 
Currently O 
, O 
determination O 
of O 
ED O 
has O 
become O 
a O 
major O 
end O 
- O 
point O 
in O 
toxicology O 
testing O 
and O 
the O 
US-EPA O 
has O 
set O 
up O 
an O 
elaborated O 
testing O 
paradigm O 
to O 
fulfill O 
this O 
requirement O 
. O 
Future O 
screening O 
for O 
ED O 
can O 
be O 
improved O 
making O 
use O 
of O 
new O 
technologies O 
. O 
ED O 
modes O 
of O 
action O 
can O 
be O 
determined O 
by O 
three O 
alternative O 
( O 
3R O 
) O 
methods O 
. O 
Steroid O 
synthesis O 
in O 
H295R O 
cells O 
( O 
1 O 
) O 
, O 
androgen B-FAMILY 
-receptor O 
binding O 
in O 
modified O 
yeast O 
( O 
2 O 
) O 
and O 
metabolomics O 
( O 
3 O 
) O 
. O 
Using O 
vinclozolin B-TRIVIAL 
as O 
a O 
case O 
study O 
, O 
results O 
indicate O 
: O 
( O 
1 O 
) O 
an O 
effect O 
on O 
steroid B-FAMILY 
synthesis O 
in O 
vitro O 
, O 
( O 
2 O 
) O 
an O 
antagonistic O 
effect O 
on O 
the O 
androgen B-FAMILY 
receptor O 
and O 
( O 
3 O 
) O 
that O 
the O 
metabolome O 
profile O 
of O 
vinclozolin B-TRIVIAL 
is O 
similar O 
to O 
that O 
of O 
other O 
receptor O 
mediated O 
anti- O 
androgens B-FAMILY 
( O 
e.g O 
. O 
flutamide B-TRIVIAL 
) O 
. O 

and O 
impulsivity O 
: O 
effects O 
of O 
acute O 
yohimbine B-TRIVIAL 
. O 

: O 
Rapid O 
- O 
response O 
impulsivity O 
, O 
characterized O 
by O 
inability O 
to O 
withhold O 
response O 
to O 
a O 
stimulus O 
until O 
it O 
is O 
adequately O 
appraised O 
, O 
is O 
associated O 
with O 
risky O 
behavior O 
and O 
may O 
be O 
increased O 
in O 
a O 
state O 
- O 
dependent O 
manner O 
by O 
norepinephrine B-TRIVIAL 
. O 
OBJECTIVE O 
: O 
We O 
assessed O 
effects O 
of O 
yohimbine B-TRIVIAL 
, O 
which O 
increases O 
norepinephrine B-TRIVIAL 
release O 
by O 
blocking O 
alpha-2 O 
noradrenergic O 
receptors O 
, O 
on O 
plasma O 
catecholamine B-TRIVIAL 
metabolites O 
, O 
blood O 
pressure O 
, O 
subjective O 
symptoms O 
, O 
and O 
laboratory O 
- O 
measured O 
rapid O 
- O 
response O 
impulsivity O 
. O 
METHODS O 
: O 
Subjects O 
were O 
23 O 
healthy O 
controls O 
recruited O 
from O 
the O 
community O 
, O 
with O 
normal O 
physical O 
examination O 
and O 
ECG O 
, O 
and O 
negative O 
history O 
for O 
hypertension O 
, O 
cardiovascular O 
illness O 
, O 
and O 
axis O 
I O 
or O 
II O 
disorder O 
. O 
Blood O 
pressure O 
, O 
pulse O 
, O 
and O 
behavioral O 
measures O 
were O 
obtained O 
before O 
and O 
periodically O 
after O 
0.4 O 
mg O 
/ O 
kg O 
oral O 
yohimbine B-TRIVIAL 
or O 
placebo O 
in O 
a O 
randomized O 
, O 
counterbalanced O 
design O 
. O 
Metabolites O 
of O 
norepinephrine B-TRIVIAL 
[ O 
3-methoxy-4-hydroxyphenylglycol B-SYSTEMATIC 
( O 
MHPG B-ABBREVIATION 
) O 
and O 
vanillylmandelic B-TRIVIAL 
acid I-TRIVIAL 
( O 
VMA B-ABBREVIATION 
) O 
] O 
and O 
dopamine B-TRIVIAL 
[ O 
homovanillic B-TRIVIAL 
acid I-TRIVIAL 
( O 
HVA B-ABBREVIATION 
) O 
] O 
were O 
measured O 
by O 
high O 
- O 
pressure O 
liquid O 
chromatography O 
with O 
electrochemical O 
detection O 
. O 
Rapid O 
- O 
response O 
impulsivity O 
was O 
measured O 
by O 
commission O 
errors O 
and O 
reaction O 
times O 
on O 
the O 
immediate O 
memory O 
task O 
( O 
IMT O 
) O 
, O 
a O 
continuous O 
performance O 
test O 
designed O 
to O 
measure O 
impulsivity O 
and O 
attention O 
. O 
RESULTS O 
: O 
Yohimbine B-TRIVIAL 
increased O 
plasma O 
MHPG B-ABBREVIATION 
and O 
VMA B-ABBREVIATION 
but O 
not O 
HVA B-ABBREVIATION 
. O 
Yohimbine B-TRIVIAL 
increased O 
systolic O 
and O 
diastolic O 
blood O 
pressure O 
and O 
pulse O 
rate O 
. O 
On O 
the O 
IMT O 
, O 
yohimbine B-TRIVIAL 
increased O 
impulsive O 
errors O 
and O 
impulsive O 
response O 
bias O 
and O 
accelerated O 
reaction O 
times O 
. O 
Yohimbine B-TRIVIAL 
-associated O 
increase O 
in O 
plasma O 
MHPG B-ABBREVIATION 
correlated O 
with O 
increased O 
impulsive O 
response O 
rates O 
. O 
Time O 
courses O 
varied O 
; O 
effects O 
on O 
blood O 
pressure O 
generally O 
preceded O 
those O 
on O 
metabolites O 
and O 
test O 
performance O 
. O 
CONCLUSIONS O 
: O 
These O 
effects O 
are O 
consistent O 
with O 
increased O 
rapid O 
- O 
response O 
impulsivity O 
after O 
pharmacological O 
noradrenergic O 
stimulation O 
in O 
healthy O 
controls O 
. O 
Labile O 
noradrenergic O 
responses O 
, O 
or O 
increased O 
sensitivity O 
to O 
norepinephrine B-TRIVIAL 
, O 
may O 
increase O 
risk O 
for O 
impulsive O 
behavior O 
. O 

waste O 
Li B-FORMULA 
ion O 
batteries O 
as O 
cathodes O 
in O 
rechargeable O 
Li B-FORMULA 
-liquid O 
batteries O 
. O 

rechargeable O 
Li B-FORMULA 
-liquid O 
battery O 
was O 
developed O 
using O 
waste O 
Li B-FORMULA 
ion O 
battery O 
materials O 
immersed O 
in O 
water O 
and O 
used O 
as O 
the O 
liquid O 
cathode O 
. O 
Either O 
the O 
Li B-FORMULA 
metal O 
or O 
Li B-FORMULA 
ions O 
( O 
by O 
the O 
formation O 
LixC6 B-FAMILY 
or O 
Li4 B-FAMILY 
+ I-FAMILY 
xTi5O12 I-FAMILY 
) O 
was O 
harvested O 
from O 
waste O 
Li B-FORMULA 
ion O 
source O 
materials O 
such O 
as O 
a O 
waste O 
anode O 
( O 
LixC6 B-FAMILY 
) O 
, O 
cathode O 
( O 
LixFePO4 B-FAMILY 
) O 
, O 
and O 
electrolyte O 
( O 
LiPF6 B-FORMULA 
in O 
EC O 
: O 
DEC O 
) O 
by O 
charging O 
the O 
cell O 
, O 
which O 
then O 
discharged O 
with O 
the O 
waste O 
products O 
in O 
the O 
liquid O 
cathode O 
solution O 
to O 
produce O 
electric O 
energy O 
. O 
When O 
the O 
Li4Ti5O12 B-FORMULA 
was O 
used O 
as O 
the O 
anode O 
with O 
the O 
waste O 
products O 
as O 
the O 
cathode O 
in O 
the O 
proposed O 
battery O 
system O 
, O 
a O 
good O 
cycle O 
- O 
life O 
with O 
high O 
coulombic O 
efficiency O 
was O 
observed O 
. O 

sunshine O 
, O 
reusable O 
rays O 
: O 
A O 
solar O 
rechargeable O 
redox O 
flow O 
battery O 
is O 
proposed O 
based O 
on O 
the O 
photoregeneration O 
of O 
I3 B-FORMULA 
( I-FORMULA 
- I-FORMULA 
) I-FORMULA 
/ O 
I(-) B-FORMULA 
and O 
[ B-FORMULA 
Fe(C10 I-FORMULA 
H15 I-FORMULA 
)2 I-FORMULA 
](+ I-FORMULA 
) I-FORMULA 
/ O 
Fe(C10 B-FORMULA 
H15 I-FORMULA 
)2 I-FORMULA 
soluble O 
redox O 
couples O 
, O 
which O 
can O 
be O 
regenerated O 
by O 
flowing O 
from O 
a O 
discharged O 
redox O 
flow O 
battery O 
( O 
RFB O 
) O 
into O 
a O 
dye O 
- O 
sensitized O 
solar O 
cell O 
( O 
DSSC O 
) O 
and O 
then O 
stored O 
in O 
tanks O 
for O 
subsequent O 
RFB O 
applications O 
This O 
technology O 
enables O 
effective O 
solar O 
- O 
to O 
- O 
chemical O 
energy O 
conversion O 
. O 

Emission O 
Enhancement O 
of O 
Star O 
Conjugated O 
Copolymers O 
with O 
Poly(2-(dimethylamino)ethyl B-FAMILY 
methacrylate I-FAMILY 
) I-FAMILY 
Coronas O 
for O 
Detection O 
of O 
Bacteria O 
. O 

facile O 
strategy O 
for O 
temperature O 
- O 
induced O 
emission O 
enhancement O 
of O 
star O 
conjugated O 
copolymers O 
has O 
been O 
developed O 
for O 
biodetection O 
. O 
The O 
star O 
copolymers O 
( O 
HCP-star- O 
PDMAEMAs B-FAMILY 
) O 
with O 
different O 
poly(2-(dimethylamino)ethyl B-FAMILY 
methacrylate I-FAMILY 
) I-FAMILY 
( O 
PDMAEMA B-ABBREVIATION 
) O 
chain O 
lengths O 
were O 
synthesized O 
from O 
the O 
hyperbranched O 
conjugated O 
polymer O 
( O 
HCP O 
) O 
macroinitiator O 
by O 
atom O 
transfer O 
radical O 
polymerization O 
( O 
ATRP O 
) O 
. O 
The O 
star O 
conjugated O 
copolymers O 
exhibited O 
interesting O 
thermoresponsive O 
phase O 
transitions O 
with O 
adjustable O 
lower O 
critical O 
solution O 
temperature O 
( O 
LCST O 
) O 
depending O 
on O 
the O 
pH O 
of O 
copolymer O 
solution O 
. O 
Above O 
the O 
LCST O 
, O 
the O 
emission O 
of O 
HCP-star- O 
PDMAEMAs B-FAMILY 
was O 
enhanced O 
greatly O 
through O 
restriction O 
of O 
intermolecular O 
aggregation O 
of O 
conjugated O 
polymer O 
cores O 
by O 
the O 
collapse O 
of O 
PDMAEMA B-ABBREVIATION 
arms O 
. O 
By O 
changing O 
the O 
PDMAEMA B-ABBREVIATION 
length O 
, O 
the O 
emission O 
performance O 
of O 
HCP-star- O 
PDMAEMAs B-FAMILY 
could O 
be O 
readily O 
adjusted O 
. O 
Correspondingly O 
, O 
this O 
temperature O 
- O 
dependent O 
emission O 
enhancement O 
of O 
HCP-star- O 
PDMAEMAs B-FAMILY 
was O 
successfully O 
applied O 
in O 
the O 
highly O 
sensitive O 
detection O 
of O 
bacteria O 
. O 
Due O 
to O 
the O 
existence O 
of O 
a O 
hyperbranched O 
conjugated O 
core O 
and O 
many O 
thermo O 
- O 
responsive O 
PDMAEMA B-ABBREVIATION 
arms O 
, O 
the O 
detection O 
limit O 
of O 
E O 
. O 
coli O 
could O 
reach O 
10(2) O 
cfu O 
mL(-1) O 
. O 

alcohol I-FAMILY 
) I-FAMILY 
Physical O 
Hydrogel O 
Nanoparticles O 
, O 
Not O 
Polymer O 
Solutions O 
, O 
Exert O 
Inhibition O 
of O 
Nitric B-SYSTEMATIC 
Oxide I-SYSTEMATIC 
Synthesis O 
in O 
Cultured O 
Macrophages O 
. O 

nanoparticles O 
( O 
HNP O 
) O 
are O 
an O 
emerging O 
tool O 
of O 
biomedicine O 
with O 
unique O 
materials O 
characteristics O 
, O 
scope O 
, O 
and O 
utility O 
. O 
These O 
hydrated O 
, O 
soft O 
colloidal O 
carriers O 
can O 
penetrate O 
through O 
voids O 
with O 
dimensions O 
narrower O 
than O 
the O 
size O 
of O 
the O 
particle O 
, O 
provide O 
stabilization O 
for O 
fragile O 
biological O 
cargo O 
and O 
allow O 
diffusion O 
and O 
exchange O 
of O 
solutes O 
with O 
external O 
phase O 
. O 
However O 
, O 
techniques O 
to O 
assemble O 
HNP O 
are O 
few O 
; O 
solitary O 
examples O 
exist O 
of O 
biocompatible O 
polymers O 
being O 
formulated O 
into O 
HNP O 
; O 
and O 
knowledge O 
on O 
the O 
biomedical O 
properties O 
of O 
HNP O 
remains O 
rather O 
cursory O 
. O 
In O 
this O 
work O 
, O 
we O 
investigate O 
assembly O 
of O 
HNP O 
based O 
on O 
a O 
polymer O 
with O 
decades O 
of O 
prominence O 
in O 
the O 
biomedical O 
field O 
, O 
poly(vinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
) I-SYSTEMATIC 
, O 
PVA B-ABBREVIATION 
. O 
We O 
develop O 
a O 
novel O 
method O 
for O 
production O 
of O 
PVA B-ABBREVIATION 
HNP O 
through O 
nanoprecipitation O 
- O 
based O 
assembly O 
of O 
polymer O 
nanoparticles O 
and O 
subsequent O 
physical O 
hydrogelation O 
of O 
the O 
polymer O 
. O 
Polymer O 
nanoparticles O 
and O 
HNP O 
were O 
visualized O 
using O 
scanning O 
electron O 
microscopy O 
and O 
fluorescence O 
imaging O 
, O 
and O 
characterized O 
using O 
dynamic O 
light O 
scattering O 
and O 
zeta O 
potential O 
measurements O 
. O 
Interaction O 
of O 
PVA B-ABBREVIATION 
HNP O 
with O 
mammalian O 
cells O 
was O 
investigated O 
using O 
flow O 
cytometry O 
, O 
viability O 
screening O 
, O 
and O 
measurements O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
by O 
cultured O 
macrophages O 
. O 
The O 
latter O 
analyses O 
revealed O 
that O 
PVA B-ABBREVIATION 
administered O 
as O 
a O 
polymer O 
solution O 
or O 
in O 
the O 
form O 
of O 
HNP O 
resulted O 
in O 
no O 
measurable O 
increase O 
in O 
production O 
of O 
the O 
inflammation O 
marker O 
. O 
Unexpectedly O 
, O 
PVA B-ABBREVIATION 
HNP O 
exerted O 
a O 
pronounced O 
inhibition O 
of O 
NO B-FORMULA 
synthesis O 
by O 
stimulated O 
macrophages O 
, O 
that O 
is O 
, O 
had O 
an O 
anti-inflammatory O 
activity O 
. O 
This O 
effect O 
was O 
accomplished O 
with O 
a O 
negligible O 
change O 
in O 
the O 
cell O 
viability O 
and O 
was O 
not O 
observed O 
when O 
PVA B-ABBREVIATION 
was O 
administered O 
as O 
a O 
polymer O 
solution O 
. O 
To O 
the O 
best O 
of O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
observation O 
of O 
inhibition O 
of O 
NO B-FORMULA 
synthesis O 
in O 
macrophages O 
by O 
administered O 
nanoparticles O 
and O 
specifically O 
hydrogel O 
nanoparticles O 
. O 
Taken O 
together O 
, O 
our O 
results O 
present O 
PVA B-ABBREVIATION 
HNP O 
as O 
promising O 
colloidal O 
hydrogel O 
nanocarriers O 
for O 
biomedical O 
applications O 
, O 
specifically O 
drug O 
delivery O 
and O 
assembly O 
of O 
intracellular O 
biosensors O 
. O 

Raman O 
Scattering O 
without O 
Plasmons O 
: O 
Unprecedented O 
Sensitivity O 
Achieved O 
by O 
TiO2 B-FORMULA 
Shell O 
- O 
Based O 
Resonators O 
. O 

remarkable O 
enhancement O 
of O 
Raman O 
scattering O 
is O 
achieved O 
by O 
TiO2 B-FORMULA 
shell O 
- O 
based O 
spherical O 
resonators O 
in O 
the O 
absence O 
of O 
plasmonic O 
enhancers O 
. O 
This O 
effect O 
is O 
ascribed O 
to O 
the O 
synergistic O 
combination O 
of O 
high O 
refractive O 
index O 
of O 
the O 
shell O 
layer O 
, O 
multiple O 
light O 
scattering O 
through O 
the O 
spheres O 
, O 
and O 
related O 
geometrical O 
factors O 
and O 
can O 
be O 
exploited O 
to O 
fabricate O 
a O 
new O 
generation O 
of O 
self O 
- O 
diagnostic O 
, O 
recyclable O 
SERS-active O 
substrates O 
. O 

MEMS O 
: O 
AFM O 
Probe O 
Performance O 
Improvement O 
. O 

explore O 
the O 
feasibility O 
of O 
growing O 
a O 
continuous O 
layer O 
of O 
graphene B-TRIVIAL 
in O 
prepatterned O 
substrates O 
, O 
like O 
an O 
engineered O 
silicon B-SYSTEMATIC 
wafer O 
, O 
and O 
we O 
apply O 
this O 
as O 
a O 
mold O 
for O 
the O 
fabrication O 
of O 
AFM O 
probes O 
. O 
This O 
fabrication O 
method O 
proves O 
the O 
fabrication O 
of O 
SU-8 O 
devices O 
coated O 
with O 
graphene B-TRIVIAL 
in O 
a O 
full O 
- O 
wafer O 
parallel O 
technology O 
and O 
with O 
high O 
yield O 
. O 
It O 
also O 
demonstrates O 
that O 
graphene B-TRIVIAL 
coating O 
enhances O 
the O 
functionality O 
of O 
SU-8 O 
probes O 
, O 
turning O 
them O 
conductive O 
and O 
more O 
resistant O 
to O 
wear O 
. O 
Furthermore O 
, O 
it O 
opens O 
new O 
experimental O 
possibilities O 
such O 
as O 
studying O 
graphene B-TRIVIAL 
- O 
graphene B-TRIVIAL 
interaction O 
at O 
the O 
nanoscale O 
with O 
the O 
precision O 
of O 
an O 
AFM O 
or O 
the O 
exploration O 
of O 
properties O 
in O 
nonplanar O 
graphene B-TRIVIAL 
layers O 
. O 

semiconductor O 
nanocrystals O 
, O 
called O 
quantum O 
dots O 
( O 
QD O 
) O 
, O 
electronic O 
transition O 
energies O 
, O 
phonon O 
frequencies O 
, O 
and O 
electron O 
- O 
phonon O 
coupling O 
strengths O 
are O 
all O 
reported O 
to O 
depend O 
on O 
the O 
size O 
of O 
the O 
crystals O 
. O 
The O 
size O 
dependencies O 
of O 
the O 
transition O 
energies O 
and O 
the O 
mode O 
frequencies O 
are O 
well O 
characterized O 
and O 
understood O 
. O 
At O 
the O 
same O 
time O 
, O 
the O 
electron O 
- O 
phonon O 
coupling O 
dependence O 
on O 
size O 
is O 
controversial O 
- O 
even O 
the O 
sign O 
of O 
the O 
change O 
is O 
not O 
settled O 
. O 
In O 
this O 
article O 
, O 
third O 
- O 
order O 
response O 
functions O 
of O 
a O 
model O 
QD O 
resembling O 
CdSe B-FORMULA 
are O 
calculated O 
. O 
The O 
longitudinal O 
optical O 
( O 
LO O 
) O 
mode O 
is O 
included O 
as O 
a O 
relatively O 
narrow O 
Lorentzian O 
contribution O 
to O 
the O 
spectral O 
density O 
. O 
A O 
novel O 
version O 
of O 
electronic O 
2D O 
spectroscopy O 
is O 
investigated O 
where O 
a O 
third O 
Fourier O 
transform O 
is O 
taken O 
over O 
a O 
so O 
- O 
called O 
population O 
time O 
, O 
leading O 
to O 
3D O 
spectral O 
representation O 
. O 
The O 
amplitude O 
and O 
phase O 
of O 
the O 
2D O 
cuts O 
of O 
the O 
3D O 
spectral O 
body O 
around O 
the O 
LO O 
mode O 
frequency O 
are O 
analyzed O 
. O 
The O 
analytical O 
power O 
and O 
sensitivity O 
of O 
the O 
cuts O 
in O 
determining O 
the O 
possible O 
Huang-Rhys O 
factor O 
( O 
electron O 
- O 
phonon O 
coupling O 
strength O 
) O 
and O 
the O 
LO O 
mode O 
frequency O 
dependence O 
on O 
the O 
QD O 
size O 
are O 
investigated O 
. O 
Peak O 
structures O 
in O 
the O 
cuts O 
with O 
a O 
tilt O 
relative O 
to O 
the O 
diagonal O 
are O 
identified O 
as O 
sensitive O 
signatures O 
for O 
the O 
size O 
dependencies O 
. O 
The O 
study O 
elucidates O 
the O 
3D O 
representation O 
of O 
the O 
electronic O 
2D O 
spectroscopy O 
as O 
a O 
powerful O 
tool O 
for O 
obtaining O 
insight O 
into O 
otherwise O 
hardly O 
accessible O 
characteristics O 
of O 
the O 
system O 
. O 

Preparation O 
and O 
X-ray O 
Structural O 
Study O 
of O 
Au B-FORMULA 
Nanoparticles O 
on O 
Titanium B-SYSTEMATIC 
Surfaces O 
. O 

report O 
the O 
peptide-directed O 
preparation O 
and O 
X-ray O 
structural O 
study O 
of O 
biofunctionalized O 
Au B-FORMULA 
nanoparticles O 
( O 
NPs O 
) O 
deposited O 
on O 
Ti B-FORMULA 
surfaces O 
. O 
Au B-FORMULA 
NPs O 
were O 
prepared O 
by O 
reduction O 
of O 
Au(3+) B-FORMULA 
compound O 
onto O 
HCl B-FORMULA 
-refreshed O 
Ti B-FORMULA 
in O 
the O 
presence O 
of O 
thiol B-FAMILY 
-functionalized O 
small O 
peptides O 
. O 
A O 
modified O 
extended O 
X-ray O 
absorption O 
fine O 
- O 
structure O 
( O 
EXAFS O 
) O 
technique O 
, O 
equipped O 
with O 
a O 
rotating O 
- O 
stage O 
and O 
glancing O 
- O 
angle O 
setup O 
, O 
was O 
able O 
to O 
more O 
sensitively O 
detect O 
the O 
structure O 
and O 
bonding O 
of O 
Au B-FORMULA 
NPs O 
on O 
Ti B-FORMULA 
with O 
low O 
surface O 
coverage O 
. O 
It O 
was O 
found O 
that O 
the O 
use O 
of O 
the O 
tripeptide O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
results O 
in O 
smaller O 
NP O 
size O 
when O 
compared O 
to O 
N-(2-mercapto-propionyl) B-SYSTEMATIC 
glycine I-SYSTEMATIC 
( O 
MPG B-ABBREVIATION 
) O 
, O 
a O 
pseudodipeptide O 
, O 
over O 
a O 
wide O 
range O 
of O 
Au B-FORMULA 
/ O 
peptide O 
molar O 
ratios O 
( O 
20 O 
: O 
1 O 
, O 
10 O 
: O 
1 O 
, O 
5 O 
: O 
1 O 
, O 
and O 
2 O 
: O 
1 O 
) O 
. O 
By O 
varying O 
the O 
ligand O 
concentration O 
, O 
the O 
Au B-FORMULA 
NP O 
structure O 
in O 
both O 
systems O 
can O 
be O 
controlled O 
, O 
generating O 
nanocrystals O 
, O 
nanoclusters O 
, O 
and O 
Au B-FORMULA 
- O 
thiolate B-SYSTEMATIC 
polymer O 
, O 
which O 
is O 
unique O 
for O 
substrate O 
- O 
supported O 
NP O 
synthesis O 
. O 
This O 
work O 
presents O 
a O 
facile O 
preparation O 
of O 
Au B-FORMULA 
-peptide O 
nanoparticles O 
on O 
biocompatible O 
surfaces O 
, O 
and O 
illustrates O 
the O 
high O 
sensitivity O 
of O 
this O 
modified O 
EXAFS O 
technique O 
for O 
structural O 
studies O 
of O 
substrate O 
- O 
supported O 
nanoparticles O 
with O 
low O 
coverage O 
. O 

this O 
study O 
, O 
rapeseed O 
cake O 
( O 
RSC O 
) O 
was O 
used O 
as O 
a O 
source O 
of O 
pectins O 
due O 
to O 
its O 
high O 
carbohydrate B-FAMILY 
content O 
. O 
Different O 
combinations O 
of O 
treatments O 
were O 
applied O 
to O 
investigate O 
the O 
effect O 
of O 
combination O 
processes O 
on O 
the O 
extraction O 
of O 
pectin O 
from O 
RSC O 
. O 
The O 
treatments O 
chosen O 
for O 
combination O 
were O 
a O 
fat O 
removal O 
process O 
( O 
FRP O 
) O 
( O 
solvent O 
extraction O 
using O 
an O 
alcohol B-FAMILY 
- O 
benzene B-SYSTEMATIC 
mixture O 
) O 
, O 
a O 
chemical O 
treatment O 
( O 
CT O 
) O 
( O 
hydrolysis O 
using O 
1% O 
hydrochloric B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
, O 
and O 
an O 
enzymatic O 
hydrolysis O 
( O 
EH O 
) O 
. O 
After O 
the O 
combined O 
processes O 
, O 
pectins O 
were O 
extracted O 
by O 
isopropanol B-SYSTEMATIC 
/ O 
ethanol B-SYSTEMATIC 
precipitation O 
and O 
the O 
residues O 
were O 
analysed O 
by O 
HPLC O 
or O 
an O 
elemental O 
analyser O 
. O 
The O 
pectin O 
yields O 
and O 
galacturonic B-TRIVIAL 
acid I-TRIVIAL 
contents O 
were O 
increased O 
by O 
FRP O 
because O 
72.13% O 
of O 
the O 
total O 
fat O 
was O 
removed O 
; O 
additionally O 
, O 
EH O 
had O 
a O 
similar O 
effect O 
. O 
However O 
, O 
CT O 
decreased O 
the O 
yields O 
because O 
the O 
treatment O 
was O 
too O 
harsh O 
and O 
the O 
galacturonic B-TRIVIAL 
acid I-TRIVIAL 
broke O 
down O 
. O 
Pectin O 
yields O 
and O 
galacturonic B-TRIVIAL 
acid I-TRIVIAL 
contents O 
were O 
highest O 
in O 
the O 
combination O 
process O 
FRP O 
/ O 
EH O 
( O 
6.23% O 
and O 
64.23% O 
, O 
respectively O 
) O 
. O 

of O 
aspartame B-TRIVIAL 
by O 
double O 
emulsion O 
followed O 
by O 
complex O 
coacervation O 
to O 
provide O 
protection O 
and O 
prolong O 
sweetness O 
. O 

objective O 
of O 
this O 
work O 
was O 
to O 
microencapsulate O 
aspartame B-TRIVIAL 
by O 
double O 
emulsion O 
followed O 
by O 
complex O 
coacervation O 
, O 
aiming O 
to O 
protect O 
it O 
and O 
control O 
its O 
release O 
. O 
Six O 
treatments O 
were O 
prepared O 
using O 
sunflower O 
oil O 
to O 
prepare O 
the O 
primary O 
emulsion O 
and O 
gelatin O 
and O 
gum O 
Arabic O 
as O 
the O 
wall O 
materials O 
. O 
The O 
microcapsules O 
were O 
evaluated O 
structurally O 
with O 
respect O 
to O 
their O 
sorption O 
isotherms O 
and O 
release O 
into O 
water O 
( O 
36°C O 
and O 
80°C O 
) O 
. O 
The O 
microcapsules O 
were O 
multinucleated O 
, O 
not O 
very O 
water O 
- O 
soluble O 
or O 
hygroscopic O 
and O 
showed O 
reduced O 
rates O 
of O 
equilibrium O 
moisture O 
content O 
and O 
release O 
at O 
both O 
temperatures O 
. O 
FTIR O 
confirmed O 
complexation O 
between O 
the O 
wall O 
materials O 
and O 
the O 
intact O 
nature O 
of O 
aspartame B-TRIVIAL 
. O 
The O 
results O 
indicated O 
it O 
was O 
possible O 
to O 
encapsulate O 
aspartame B-TRIVIAL 
with O 
the O 
techniques O 
employed O 
and O 
that O 
these O 
protected O 
the O 
sweetener O 
even O 
at O 
80°C O 
. O 
The O 
reduced O 
solubility O 
and O 
low O 
release O 
rates O 
indicated O 
the O 
enormous O 
potential O 
of O 
the O 
vehicle O 
developed O 
in O 
controlling O 
the O 
release O 
of O 
the O 
aspartame B-TRIVIAL 
into O 
the O 
food O 
, O 
thus O 
prolonging O 
its O 
sweetness O 
. O 

of O 
two O 
isoflavone B-FAMILY 
aglycones I-FAMILY 
in O 
black O 
soymilk O 
by O 
using O 
spent O 
coffee O 
grounds O 
as O 
an O 
immobiliser O 
for O 
β-glucosidase O 
. O 

coffee O 
grounds O 
, O 
discarded O 
as O 
environmental O 
pollutants O 
, O 
were O 
adopted O 
as O 
enzyme O 
immobilisation O 
solid O 
carriers O 
instead O 
of O 
commercialised O 
solid O 
supports O 
to O 
establish O 
an O 
economical O 
catalytic O 
system O 
. O 
β-Glucosidase O 
was O 
covalently O 
immobilised O 
onto O 
spent O 
coffee O 
grounds O 
for O 
the O 
conversion O 
of O 
isoflavone B-FAMILY 
glycosides I-FAMILY 
into O 
their O 
aglycones O 
in O 
black O 
soymilk O 
. O 
Optimum O 
conditions O 
were O 
determined O 
to O 
be O 
40°C O 
and O 
pH O 
6 O 
using O 
4-nitrophenyl B-SYSTEMATIC 
β-d-glucuronide I-SYSTEMATIC 
as O 
an O 
indicator O 
. O 
Operational O 
reusability O 
was O 
confirmed O 
for O 
more O 
than O 
30 O 
batch O 
reactions O 
and O 
the O 
storage O 
stability O 
was O 
capable O 
of O 
sustaining O 
its O 
highest O 
catalytic O 
activity O 
for O 
20days O 
. O 
The O 
kinetic O 
parameters O 
including O 
rate O 
constant O 
( O 
K O 
) O 
, O 
time O 
( O 
τ50 O 
) O 
in O 
which O 
50% O 
of O 
isoflavone B-FAMILY 
deglycosylation O 
was O 
reached O 
, O 
and O 
time O 
( O 
τcomplete O 
) O 
required O 
to O 
achieve O 
complete O 
isoflavone B-FAMILY 
deglycosylation O 
, O 
were0.16±0.02min(-1) O 
, O 
4.54±0.32min O 
, O 
60min O 
for O 
daidzin B-TRIVIAL 
and O 
0.16±0.02min(-1) O 
, O 
2.28±0.11min O 
, O 
60min O 
for O 
genistin B-TRIVIAL 
, O 
respectively O 
. O 
The O 
total O 
aglycone O 
content O 
in O 
black O 
soymilk O 
was O 
enriched O 
by O 
67.14±0.60% O 
in O 
the O 
enzymatic O 
treatment O 
of O 
60min O 
duration O 
. O 

activity O 
- O 
guided O 
separation O 
of O 
coumarins B-FAMILY 
and O 
lignan B-FAMILY 
from O 
Melicope O 
glabra O 
( O 
Rutaceae O 
) O 
. O 

ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
and O 
methanol B-SYSTEMATIC 
bark O 
extracts O 
of O 
Melicope O 
glabra O 
were O 
evaluated O 
for O 
their O 
antioxidant O 
capacities O 
by O 
1,1-diphenyl-2-picrylhydrazyl B-SYSTEMATIC 
( O 
DPPH B-ABBREVIATION 
) O 
free O 
radical O 
scavenging O 
activity O 
and O 
β-carotene B-TRIVIAL 
bleaching/ O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
system O 
. O 
Both O 
extracts O 
exhibited O 
strong O 
inhibition O 
against O 
the O 
DPPH B-ABBREVIATION 
radical O 
( O 
IC50 O 
values O 
of O 
24.81 O 
and O 
13.01 O 
μgml(-1) O 
, O 
respectively O 
) O 
and O 
strong O 
antioxidant O 
activity O 
in O 
β-carotene B-TRIVIAL 
bleaching O 
assay O 
. O 
Both O 
samples O 
were O 
found O 
to O 
have O 
high O 
phenolic O 
content O 
with O 
values O 
of O 
39 O 
and O 
44mg O 
GAE O 
/ O 
g O 
as O 
indicated O 
by O 
Follin-Ciocalteau's O 
reagent O 
. O 
Antioxidant O 
TLC O 
assay O 
- O 
guided O 
isolation O 
on O 
the O 
methanol B-SYSTEMATIC 
extract O 
led O 
to O 
the O 
isolation O 
of O 
a O 
new O 
pyranocoumarin B-TRIVIAL 
, O 
glabranin B-TRIVIAL 
( O 
1 O 
) O 
, O 
umbelliferone B-TRIVIAL 
( O 
2 O 
) O 
, O 
scopoletin B-TRIVIAL 
( O 
3 O 
) O 
and O 
sesamin B-TRIVIAL 
( O 
4 O 
) O 
, O 
and O 
their O 
structures O 
were O 
determined O 
by O 
spectroscopy O 
. O 
Compounds O 
( O 
1-3 O 
) O 
showed O 
significant O 
activities O 
on O 
DPPH B-ABBREVIATION 
free O 
radical O 
with O 
the O 
IC50 O 
of O 
240.2 O 
, O 
810.02 O 
and O 
413.19μgml(-1) O 
, O 
respectively O 
. O 
However O 
, O 
in O 
β-carotene B-TRIVIAL 
bleaching O 
assay O 
, O 
sesamin B-TRIVIAL 
( O 
4 O 
) O 
showed O 
higher O 
inhibitory O 
activity O 
( O 
1mgml(-1) O 
, O 
95% O 
) O 
than O 
glabranin B-TRIVIAL 
( O 
1 O 
) O 
( O 
1mgml(-1) O 
, O 
74% O 
) O 
, O 
whilst O 
umbelliferone B-TRIVIAL 
( O 
2 O 
) O 
and O 
scopoletin B-TRIVIAL 
( O 
3 O 
) O 
were O 
slightly O 
pro O 
- O 
oxidant O 
. O 

phenolics B-FAMILY 
and O 
polyphenol B-FAMILY 
oxidase O 
( O 
PPO O 
) O 
: O 
The O 
factors O 
affecting O 
post O 
- O 
cut O 
browning O 
in O 
eggplant O 
( O 
Solanum O 
melongena O 
) O 
. O 

oxidase O 
( O 
PPO O 
) O 
catalyses O 
oxidation O 
of O 
phenolics B-FAMILY 
, O 
which O 
results O 
in O 
instant O 
but O 
differential O 
browning O 
in O 
many O 
cut O 
fruits O 
and O 
vegetables O 
, O 
including O 
eggplant O 
. O 
Eight O 
cultivars O 
of O 
eggplant O 
were O 
characterised O 
by O 
their O 
PPO O 
specific O 
activity O 
, O 
phenolic B-FAMILY 
content O 
, O 
browning O 
index O 
, O 
and O 
PPO O 
polymorphism O 
. O 
In O 
fresh O 
eggplant O 
, O 
browning O 
was O 
found O 
to O 
be O 
dependent O 
on O 
both O 
the O 
phenolic B-FAMILY 
content O 
and O 
PPO O 
specific O 
activity O 
, O 
whereas O 
, O 
total O 
phenolic B-FAMILY 
content O 
played O 
a O 
major O 
role O 
in O 
browning O 
of O 
stored O 
fruits O 
. O 
Interestingly O 
, O 
although O 
browning O 
index O 
increased O 
in O 
stored O 
eggplant O 
fruits O 
, O 
PPO O 
activity O 
reduced O 
in O 
four O 
out O 
of O 
eight O 
cultivars O 
studied O 
. O 
Phenolic B-FAMILY 
level O 
was O 
found O 
to O 
increase O 
in O 
all O 
these O 
cultivars O 
during O 
storage O 
. O 
Although O 
a O 
significant O 
level O 
of O 
homology O 
was O 
observed O 
in O 
PPO O 
nucleotide B-FAMILY 
and O 
conceptually O 
translated O 
protein O 
sequence O 
, O 
two O 
cultivars O 
, O 
which O 
displayed O 
highest O 
PPO O 
specific O 
activity O 
, O 
differed O 
in O 
the O 
38 O 
amino B-FAMILY 
acid I-FAMILY 
stretch O 
in O 
the O 
peptide O 
region O 
301-338 O 
. O 

objective O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
antioxidant O 
properties O 
, O 
and O 
provide O 
characteristics O 
, O 
of O 
the O 
oil O 
obtained O 
from O 
the O 
seeds O 
of O 
12 O 
pumpkin O 
varieties O 
belonging O 
to O 
the O 
species O 
Cucurbita O 
maxima O 
Duch O 
. O 
and O 
Cucurbita O 
pepo O 
L O 
. O 
Another O 
objective O 
was O 
to O 
establish O 
which O 
of O 
the O 
two O 
extracting O 
agents O 
, O 
ethanol B-SYSTEMATIC 
or O 
methanol B-SYSTEMATIC 
, O 
is O 
more O 
effective O 
. O 
The O 
seeds O 
of O 
the O 
pumpkin O 
varieties O 
examined O 
differ O 
in O 
chemical O 
composition O 
and O 
antioxidant O 
activity O 
. O 
The O 
seeds O 
of O 
the O 
cultivars O 
belonging O 
to O 
the O 
species O 
C O 
. O 
maxima O 
are O 
characterised O 
by O 
a O 
higher O 
content O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
than O 
are O 
the O 
cultivars O 
of O 
the O 
species O 
C O 
. O 
pepo O 
. O 
In O 
the O 
seed O 
oil O 
, O 
unsaturated O 
acids O 
are O 
dominant O 
( O 
oleic B-TRIVIAL 
and O 
linoleic B-TRIVIAL 
) O 
, O 
and O 
their O 
proportion O 
depends O 
on O 
the O 
pumpkin O 
variety O 
. O 
The O 
highest O 
content O 
of O 
unsaturated O 
acids O 
has O 
been O 
measured O 
in O 
the O 
oil O 
extracted O 
from O 
the O 
seeds O 
of O 
the O 
cultivar O 
, O 
Jet O 
F1 O 
( O 
C O 
. O 
pepo O 
) O 
. O 
Antioxidant O 
activity O 
analysis O 
has O 
produced O 
the O 
following O 
findings O 
. O 
The O 
seeds O 
of O 
the O 
pumpkin O 
varieties O 
that O 
belong O 
to O 
the O 
species O 
C O 
. O 
pepo O 
exhibit O 
better O 
antioxidant O 
properties O 
, O 
regardless O 
of O 
the O 
extraction O 
solvent O 
used O 
. O 
50% O 
ethanol B-SYSTEMATIC 
is O 
more O 
efficient O 
than O 
80% O 
methanol B-SYSTEMATIC 
when O 
used O 
as O 
an O 
extracting O 
agent O 
. O 
The O 
antioxidant O 
activity O 
values O 
obtained O 
with O 
50% O 
ethanol B-SYSTEMATIC 
are O 
higher O 
than O 
those O 
achieved O 
with O 
80% O 
methanol B-SYSTEMATIC 
. O 
Owing O 
to O 
the O 
considerable O 
differences O 
in O 
composition O 
among O 
the O 
fatty B-FAMILY 
acids I-FAMILY 
examined O 
, O 
it O 
is O 
possible O 
to O 
choose O 
the O 
desired O 
pumpkin O 
variety O 
for O 
the O 
intended O 
use O 
. O 

of O 
isothermal O 
crystallisation O 
kinetics O 
of O 
sunflower O 
hard O 
stearin B-TRIVIAL 
-based O 
confectionery O 
fats O 
. O 

crystallisation O 
and O 
polymorphic O 
properties O 
of O 
three O 
sunflower O 
hard O 
stearins B-FAMILY 
( O 
SHSs O 
) O 
and O 
cocoa O 
butter O 
equivalents O 
( O 
CBEs O 
) O 
formulated O 
by O 
blending O 
SHSs O 
and O 
palm O 
mid O 
fraction O 
( O 
PMF O 
) O 
were O 
studied O 
and O 
compared O 
with O 
those O 
from O 
cocoa O 
butter O 
( O 
CB O 
) O 
, O 
to O 
explore O 
their O 
possibilities O 
as O 
confectionery O 
fats O 
. O 
The O 
isothermal O 
crystallisation O 
kinetics O 
of O 
these O 
fats O 
were O 
examined O 
by O 
pNMR O 
and O 
DSC O 
at O 
three O 
different O 
temperatures O 
. O 
All O 
samples O 
studied O 
displayed O 
a O 
two O 
- O 
step O 
crystallisation O 
profile O 
that O 
could O 
be O 
fitted O 
to O 
an O 
exponential-Gompertz O 
equation O 
. O 
Stop O 
- O 
and O 
- O 
return O 
DSC O 
studies O 
showed O 
that O 
SHSs O 
and O 
CBEs O 
exhibited O 
different O 
crystallisation O 
mechanisms O 
according O 
to O 
their O 
triacylglycerol B-FAMILY 
composition O 
, O 
with O 
a O 
quick O 
formation O 
of O 
metastable O 
crystals O 
, O 
followed O 
by O 
a O 
polymorphic O 
transition O 
to O 
the O 
more O 
stable O 
β O 
or O 
β O 
' O 
forms O 
. O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
was O 
used O 
to O 
investigate O 
the O 
polymorphic O 
forms O 
of O 
tempered O 
SHSs O 
and O 
CBEs O 
in O 
the O 
long O 
term O 
. O 
In O 
all O 
cases O 
the O 
resulting O 
fats O 
displayed O 
short O 
spacing O 
patterns O 
associated O 
with O 
β O 
polymorphism O 
. O 
These O 
formulations O 
based O 
on O 
SHSs O 
and O 
PMF O 
met O 
all O 
the O 
requirements O 
to O 
be O 
considered O 
as O 
CBEs O 
; O 
therefore O 
they O 
could O 
be O 
used O 
as O 
an O 
alternative O 
to O 
traditional O 
confectionery O 
fats O 
. O 

digestion O 
of O 
proanthocyanidins B-FAMILY 
in O 
grape O 
skin O 
and O 
seed O 
extracts O 
and O 
the O 
effects O 
of O 
digestion O 
on O 
the O 
angiotensin O 
I-converting O 
enzyme O 
( O 
ACE O 
) O 
inhibitory O 
activity O 
. O 

study O 
investigated O 
the O 
effect O 
of O 
in O 
vitro O 
gastrointestinal O 
digestion O 
on O 
the O 
stability O 
and O 
composition O 
of O 
flavan-3-ols B-FAMILY 
from O 
red O 
grape O 
skin O 
and O 
seed O 
extracts O 
( O 
raw O 
and O 
purified O 
, O 
which O 
are O 
high O 
in O 
proanthocyanidins B-FAMILY 
( O 
PAs B-FAMILY 
) O 
) O 
. O 
In O 
addition O 
, O 
the O 
effects O 
of O 
digestion O 
on O 
the O 
angiotensin O 
I-converting O 
enzyme O 
( O 
ACE O 
) O 
inhibitory O 
activities O 
of O 
these O 
extracts O 
were O 
evaluated O 
. O 
The O 
extracts O 
were O 
digested O 
with O 
a O 
mixture O 
of O 
pepsin- O 
HCl B-FORMULA 
for O 
2h O 
, O 
followed O 
by O 
a O 
2h O 
incubation O 
with O 
pancreatin O 
and O 
bile B-FAMILY 
salts I-FAMILY 
including O 
a O 
cellulose O 
dialysis O 
tubing O 
( O 
molecular O 
weight O 
cut O 
- O 
off O 
12kDa O 
) O 
at O 
37°C O 
with O 
shaking O 
in O 
the O 
dark O 
and O 
under O 
N2 O 
. O 
Under O 
gastric O 
conditions O 
, O 
the O 
mean O 
degree O 
of O 
polymerisation O 
( O 
mDP O 
) O 
of O 
seed O 
extracts O 
, O 
raw O 
( O 
mDP≈6 O 
, O 
p O 
< O 
0.05 O 
) O 
, O 
and O 
purified O 
( O 
mDP≈10 O 
, O 
p O 
< O 
0.05 O 
) O 
was O 
stable O 
. O 
The O 
mDP O 
of O 
the O 
raw O 
skin O 
extracts O 
increased O 
from O 
19 O 
to O 
25 O 
towards O 
the O 
end O 
of O 
the O 
digestion O 
. O 
The O 
PAs B-FAMILY 
were O 
significantly O 
degraded O 
( O 
up O 
to O 
80% O 
) O 
during O 
the O 
pancreatic O 
digestion O 
, O 
yielding O 
low O 
- O 
molecular O 
- O 
weight O 
compounds O 
that O 
diffused O 
into O 
the O 
serum O 
- O 
available O 
fraction O 
( O 
mDP≈2 O 
) O 
. O 
The O 
overall O 
mass O 
transfer O 
coefficient O 
( O 
K O 
) O 
of O 
the O 
seed O 
extracts O 
was O 
10(-7)m(2) O 
/ O 
s O 
. O 
After O 
simulated O 
gastrointestinal O 
digestion O 
, O 
over O 
80% O 
of O 
ACE O 
inhibition O 
by O 
raw O 
seed O 
and O 
skin O 
extracts O 
was O 
preserved O 
. O 
However O 
, O 
the O 
purified O 
seed O 
and O 
skin O 
extracts O 
lost O 
their O 
ability O 
to O 
inhibit O 
ACE O 
after O 
intestinal O 
digestion O 
. O 

and O 
characterisation O 
of O 
sarcoplasmic O 
calcium B-SYSTEMATIC 
-binding O 
protein O 
, O 
a O 
novel O 
allergen O 
of O 
red O 
swamp O 
crayfish O 
( O 
Procambarus O 
clarkii O 
) O 
. O 

sarcoplasmic O 
calcium B-SYSTEMATIC 
-binding O 
protein O 
( O 
SCP O 
) O 
was O 
purified O 
. O 
The O 
physicochemical O 
and O 
polymorphic O 
characterisations O 
were O 
also O 
analysed O 
. O 
SCP O 
was O 
purified O 
by O 
column O 
chromatography O 
to O 
reveal O 
a O 
single O 
band O 
with O 
molecular O 
mass O 
of O 
22kDa O 
and O 
further O 
confirmed O 
by O 
mass O 
spectrometry O 
. O 
The O 
results O 
of O 
physicochemical O 
characterisation O 
showed O 
that O 
SCP O 
was O 
stable O 
in O 
the O 
processes O 
of O 
thermal O 
or O 
acid O 
/ O 
alkali O 
treatment O 
, O 
and O 
could O 
be O 
digested O 
by O 
simulate O 
gastrointestinal O 
fluid O 
. O 
Importantly O 
, O 
the O 
comparison O 
of O 
SCP O 
polymorphism O 
using O 
sera O 
from O 
crustacean O 
- O 
allergic O 
patients O 
demonstrated O 
SCP-II O 
had O 
a O 
weaker O 
IgE O 
- O 
binding O 
activity O 
. O 
The O 
isoelectric O 
points O 
of O 
SCP O 
subunits O 
a O 
, O 
b O 
and O 
c O 
were O 
4.6 O 
, O 
4.7 O 
, O 
and O 
4.8 O 
, O 
respectively O 
, O 
as O 
determined O 
by O 
two O 
- O 
dimensional O 
electrophoresis O 
and O 
IgE O 
immunoblotting O 
analysis O 
showed O 
that O 
patients O 
' O 
sera O 
reacted O 
to O 
three O 
subunits O 
of O 
SCP O 
. O 
Finally O 
, O 
it O 
can O 
be O 
concluded O 
that O 
SCP O 
is O 
a O 
stable O 
polymorphic O 
allergen O 
in O 
crayfish O 
, O 
and O 
all O 
of O 
its O 
isotypes O 
and O 
subunits O 
have O 
allergenicity O 
. O 

modification O 
enhances O 
the O 
protective O 
activity O 
of O 
citrus O 
flavonoids B-FAMILY 
against O 
alcohol B-FAMILY 
-induced O 
liver O 
disease O 
. O 

liver O 
disease O 
( O 
ALD O 
) O 
can O 
be O 
developed O 
by O 
a O 
prolonged O 
or O 
large O 
intake O 
of O 
alcohol B-FAMILY 
in O 
a O 
short O 
period O 
of O 
time O 
. O 
ALD O 
is O 
considered O 
as O 
a O 
leading O 
cause O 
for O 
a O 
liver O 
injury O 
in O 
modern O 
dietary O 
life O 
. O 
This O 
study O 
was O 
aimed O 
to O 
investigate O 
the O 
effects O 
of O 
orally O 
administrated O 
citrus O 
flavonoids B-FAMILY 
( O 
CFs O 
) O 
and O 
their O 
enzymatically O 
modified O 
ones O 
( O 
EM-CFs O 
) O 
to O 
prevent O 
ALD O 
. O 
Hesperidin B-TRIVIAL 
and O 
narirutin B-TRIVIAL 
were O 
extracted O 
from O 
peels O 
of O 
Citrus O 
unshiu O 
by O 
ultra O 
- O 
sonication O 
and O 
purified O 
further O 
. O 
These O 
CFs O 
were O 
modified O 
enzymatically O 
through O 
glycosylation O 
and O 
de-rhamnosylation O 
by O 
the O 
actions O 
of O 
cyclodextrin O 
glucanotransferase O 
( O 
CGTase O 
) O 
and O 
hesperidinase O 
, O 
respectively O 
. O 
CFs O 
and O 
EM-CFs O 
were O 
fed O 
to O 
ICR O 
mouse O 
along O 
with O 
ethanol B-SYSTEMATIC 
for O 
8weeks O 
, O 
and O 
changes O 
in O 
lipid O 
contents O 
, O 
lipid O 
peroxidation O 
, O 
GSH B-ABBREVIATION 
, O 
antioxidant O 
enzymes O 
activity O 
and O 
proinflammatory O 
cytokines O 
in O 
hepatic O 
tissues O 
were O 
observed O 
. O 
Administration O 
of O 
CFs O 
and O 
EM-CFs O 
along O 
with O 
alcohol B-FAMILY 
significantly O 
suppressed O 
increases O 
in O 
prognostic O 
parameters O 
of O 
a O 
hepatocellular O 
injury O 
. O 
Especially O 
, O 
EM-CFs O 
fed O 
groups O 
maintained O 
malondialdehyde B-TRIVIAL 
, O 
GSH B-ABBREVIATION 
levels O 
and O 
catalase O 
activity O 
in O 
hepatic O 
tissues O 
close O 
to O 
those O 
of O 
the O 
normal O 
diet O 
fed O 
group O 
. O 
Abrupt O 
increases O 
in O 
proinflammatory O 
cytokines O 
such O 
as O 
IκB-α O 
, O 
TNF-α O 
, O 
IL-1β O 
and O 
IL-6 O 
in O 
hepatocytes O 
due O 
to O 
a O 
chronic O 
alcohol B-FAMILY 
uptake O 
were O 
significantly O 
suppressed O 
by O 
co O 
- O 
administration O 
of O 
EM-CFs O 
. O 
These O 
results O 
indicate O 
that O 
although O 
the O 
administration O 
of O 
CFs O 
can O 
alleviate O 
ALD O 
through O 
preventing O 
excessive O 
lipid O 
formation O 
, O 
protecting O 
the O 
antioxidant O 
system O 
and O 
suppressing O 
induction O 
of O 
inflammation O 
in O 
hepatocytes O 
, O 
their O 
effectiveness O 
can O 
be O 
further O 
improved O 
by O 
glycosylation O 
and O 
de-rhamnosylation O 
. O 

nanotubes O 
- O 
reinforced O 
hollow O 
fibre O 
solid O 
- O 
phase O 
microextraction O 
coupled O 
with O 
high O 
performance O 
liquid O 
chromatography O 
for O 
the O 
determination O 
of O 
carbamate B-FAMILY 
pesticides O 
in O 
apples O 
. O 

effective O 
and O 
sensitive O 
method O 
to O 
determinate O 
five O 
carbamate B-FAMILY 
pesticides O 
in O 
apples O 
was O 
developed O 
by O 
using O 
carbon B-SYSTEMATIC 
nanotubes O 
- O 
reinforced O 
hollow O 
fibre O 
solid O 
- O 
phase O 
microextraction O 
( O 
CNTs-HF-SPME O 
) O 
combined O 
with O 
high O 
performance O 
liquid O 
chromatography O 
- O 
photodiode O 
array O 
detection O 
( O 
HPLC-DAD O 
) O 
. O 
The O 
CNTs O 
were O 
dispersed O 
in O 
water O 
via O 
adding O 
surfactant O 
, O 
and O 
then O 
were O 
held O 
in O 
the O 
pores O 
of O 
HF O 
supported O 
by O 
capillary O 
forces O 
and O 
sonification O 
. O 
The O 
SPME O 
device O 
, O 
which O 
was O 
wetted O 
with O 
1-octanol B-SYSTEMATIC 
, O 
was O 
placed O 
in O 
a O 
stirred O 
apple O 
samples O 
to O 
extract O 
target O 
analytes O 
. O 
After O 
extraction O 
, O 
analytes O 
were O 
desorbed O 
and O 
analyzed O 
using O 
HPLC-DAD O 
. O 
Under O 
the O 
optimized O 
extraction O 
conditions O 
, O 
the O 
enrichment O 
factors O 
were O 
achieved O 
in O 
the O 
range O 
from O 
49 O 
to O 
308 O 
with O 
good O 
inter O 
- O 
fibre O 
repeatability O 
and O 
batch O 
- O 
to O 
- O 
batch O 
reproducibility O 
, O 
while O 
good O 
linearity O 
ranges O 
and O 
recoveries O 
were O 
obtained O 
. O 
The O 
limits O 
of O 
detection O 
ranged O 
from O 
0.09 O 
to O 
6.00ng O 
/ O 
g O 
. O 
Therefore O 
, O 
the O 
results O 
demonstrated O 
that O 
this O 
novel O 
method O 
was O 
an O 
efficient O 
pretreatment O 
and O 
enrichment O 
procedure O 
for O 
the O 
determination O 
of O 
trace O 
carbamate B-FAMILY 
pesticides O 
in O 
apples O 
. O 

sensitive O 
and O 
selective O 
imprinted O 
solid O 
phase O 
extraction O 
coupled O 
to O 
HPLC O 
for O 
simultaneous O 
detection O 
of O 
trace O 
quinoxaline-2-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
methyl-3-quinoxaline-2-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
animal O 
muscles O 
. O 

new O 
molecularly O 
imprinted O 
polymer O 
( O 
MIP O 
) O 
, O 
selective O 
for O 
major O 
metabolites O 
of O 
quinoxaline-1,4-dioxides B-FAMILY 
, O 
was O 
prepared O 
through O 
bulk O 
polymerisation O 
using O 
quinoxaline-2-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
QCA B-ABBREVIATION 
) O 
as O 
template O 
, O 
diethylaminoethylmethacrylate B-SYSTEMATIC 
as O 
functional O 
monomer O 
and O 
ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
dimethacrylate I-SYSTEMATIC 
as O 
cross O 
- O 
linker O 
in O 
tetrahydrofuran B-SYSTEMATIC 
. O 
The O 
synthesised O 
MIP O 
was O 
characterised O 
by O 
Fourier O 
transform O 
infrared O 
and O 
adsorption O 
experiments O 
. O 
MIP O 
exhibited O 
high O 
affinity O 
, O 
fast O 
kinetics O 
for O 
QCA B-ABBREVIATION 
and O 
good O 
selectivity O 
for O 
QCA B-ABBREVIATION 
and O 
methyl-3-quinoxaline-2-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
MQCA B-ABBREVIATION 
) O 
. O 
MIP O 
obtained O 
was O 
used O 
as O 
a O 
selective O 
sorbent O 
for O 
molecularly O 
imprinted O 
solid O 
phase O 
extraction O 
( O 
MISPE O 
) O 
coupled O 
with O 
HPLC O 
to O 
detect O 
QCA B-ABBREVIATION 
and O 
MQCA B-ABBREVIATION 
. O 
Under O 
the O 
optimal O 
conditions O 
, O 
the O 
limits O 
of O 
detection O 
( O 
S O 
/ O 
N=3 O 
) O 
of O 
porcine O 
, O 
chicken O 
and O 
fish O 
muscles O 
were O 
0.1 O 
, O 
0.3 O 
, O 
0.1μg O 
/ O 
kg O 
for O 
QCA B-ABBREVIATION 
and O 
0.2 O 
, O 
0.3 O 
, O 
0.1μg O 
/ O 
kg O 
for O 
MQCA B-ABBREVIATION 
, O 
respectively O 
and O 
good O 
recoveries O 
were O 
obtained O 
in O 
the O 
range O 
from O 
60 O 
to O 
119.4% O 
. O 
These O 
results O 
indicated O 
the O 
MISPE-HPLC O 
procedure O 
could O 
be O 
successfully O 
used O 
for O 
the O 
determination O 
QCA B-ABBREVIATION 
and O 
MQCA B-ABBREVIATION 
in O 
animal O 
muscles O 
. O 

of O 
amino B-FAMILY 
acid I-FAMILY 
conjugates O 
of O 
tetrahydrocurcumin B-SYSTEMATIC 
and O 
evaluation O 
of O 
their O 
antibacterial O 
and O 
anti-mutagenic O 
properties O 
. O 

( O 
THC B-ABBREVIATION 
) O 
, O 
the O 
hydrogenated O 
and O 
stable O 
form O 
of O 
curcumin B-TRIVIAL 
, O 
exhibits O 
physiological O 
and O 
pharmacological O 
activities O 
similar O 
to O 
curcumin B-TRIVIAL 
. O 
A O 
protocol O 
has O 
been O 
developed O 
for O 
the O 
synthesis O 
of O 
novel O 
conjugates O 
of O 
THC B-ABBREVIATION 
with O 
alanine B-TRIVIAL 
( O 
2a O 
) O 
, O 
isoleucine B-TRIVIAL 
( O 
2b O 
) O 
, O 
proline B-TRIVIAL 
( O 
2c O 
) O 
, O 
valine B-TRIVIAL 
( O 
2d O 
) O 
, O 
phenylalanine B-TRIVIAL 
( O 
2e O 
) O 
, O 
glycine B-TRIVIAL 
( O 
2f O 
) O 
and O 
leucine B-TRIVIAL 
( O 
2g O 
) O 
in O 
high O 
yields O 
( O 
43-82% O 
) O 
. O 
All O 
the O 
derivatives O 
of O 
THC B-ABBREVIATION 
exhibited O 
more O 
potent O 
anti-microbial O 
activity O 
than O 
THC B-ABBREVIATION 
against O 
Bacillus O 
cereus O 
, O 
Staphylococcus O 
aureus O 
, O 
Escherichia O 
coli O 
and O 
Yersinia O 
enterocolitica O 
. O 
The O 
MIC O 
values O 
of O 
the O 
derivatives O 
were O 
24-37% O 
of O 
those O 
for O 
THC B-ABBREVIATION 
in O 
case O 
of O 
both O 
Gram O 
- O 
positive O 
and O 
Gram O 
- O 
negative O 
bacteria O 
. O 
Derivatives O 
2g O 
and O 
2d O 
exhibited O 
maximum O 
anti-mutagenicity O 
against O 
Salmonella O 
typhimurium O 
TA O 
98 O 
and O 
TA O 
1538 O 
, O 
respectively O 
at O 
a O 
low O 
concentration O 
of O 
313μg O 
/ O 
plate O 
, O 
with O 
comparable O 
activity O 
for O 
THC B-ABBREVIATION 
evident O 
only O 
at O 
3750μg O 
/ O 
plate O 
. O 
These O 
results O 
clearly O 
demonstrated O 
that O 
the O 
conjugation O 
of O 
THC B-ABBREVIATION 
at O 
the O 
phenolic B-FAMILY 
position O 
with O 
amino B-FAMILY 
acids I-FAMILY 
led O 
to O 
significant O 
improvement O 
of O 
its O 
in O 
vitro O 
biological O 
attributes O 
. O 

of O 
triterpenoids B-FAMILY 
present O 
in O 
apple O 
peel O 
on O 
inflammatory O 
gene O 
expression O 
associated O 
with O 
inflammatory O 
bowel O 
disease O 
( O 
IBD O 
) O 
. O 

ursanic B-MULTIPLE 
, I-MULTIPLE 
oleanic I-MULTIPLE 
and I-MULTIPLE 
lupanic I-MULTIPLE 
pentacyclic I-MULTIPLE 
triterpenoids I-MULTIPLE 
found O 
in O 
apple O 
peel O 
were O 
studied O 
for O 
anti-inflammatory O 
effects O 
in O 
vitro O 
using O 
T84 O 
colon O 
carcinoma O 
cells O 
. O 
After O 
pretreatment O 
with O 
single O 
triterpenoids B-FAMILY 
, O 
cells O 
were O 
stimulated O 
with O 
pro O 
- O 
inflammatory O 
cytokines O 
( O 
TNF-α O 
, O 
INF-γ O 
, O 
IL-1β O 
) O 
. O 
Regulation O 
of O 
mRNA O 
expression O 
was O 
analysed O 
for O 
three O 
specific O 
inflammation O 
- O 
associated O 
marker O 
genes O 
( O 
TNF-α O 
, O 
IL-8 O 
, O 
IP-10 O 
) O 
using O 
qRT-PCR O 
. O 
Furthermore O 
, O 
the O 
effects O 
of O 
ursolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
UA O 
) O 
and O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
OA O 
) O 
on O 
the O 
synthesis O 
of O 
certain O 
pro O 
- O 
inflammatory O 
proteins O 
were O 
examined O 
. O 
IP-10 O 
expression O 
was O 
inhibited O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
by O 
all O 
the O 
tested O 
compounds O 
at O 
concentrations O 
⩾25μM O 
. O 
The O 
mRNA O 
expression O 
of O 
TNF-α O 
was O 
slightly O 
affected O 
and O 
the O 
IL-8 O 
level O 
was O 
increased O 
. O 
At O 
the O 
protein O 
level O 
, O 
UA O 
and O 
OA O 
( O 
25μM O 
) O 
reduced O 
the O 
synthesis O 
of O 
IP-10 O 
; O 
sICAM-1 O 
, O 
IL-23 O 
and O 
GROα O 
were O 
slightly O 
repressed O 
. O 
The O 
TNF-α O 
level O 
was O 
not O 
modulated O 
, O 
whereas O 
induction O 
of O 
IL-8 O 
was O 
increased O 
. O 
UA O 
also O 
enhanced O 
the O 
synthesis O 
of O 
IL-1ra O 
, O 
while O 
OA O 
suppressed O 
the O 
level O 
of O 
I-TAC O 
. O 
The O 
present O 
study O 
confirms O 
that O 
triterpenoids B-FAMILY 
present O 
in O 
apple O 
peel O 
and O 
β-damascone B-TRIVIAL 
may O 
be O 
implicated O 
in O 
the O 
anti-inflammatory O 
properties O 
of O 
apple O 
constituents O 
, O 
suggesting O 
that O 
these O 
substances O 
might O 
be O 
helpful O 
in O 
the O 
treatment O 
of O 
IBD O 
as O 
nutrient O 
supplements O 
. O 

objective O 
of O 
this O 
study O 
was O 
to O 
determine O 
antioxidant O 
activities O 
of O 
water O 
- O 
soluble O 
MRPs O 
( O 
Maillard O 
reaction O 
products O 
) O 
from O 
the O 
reactions O 
between O 
whey O 
protein O 
isolate O 
( O 
WPI O 
) O 
and O 
xylose B-TRIVIAL 
(X) O 
, O 
glucose B-TRIVIAL 
( O 
G O 
) O 
, O 
fructose B-TRIVIAL 
( O 
F O 
) O 
, O 
lactose B-TRIVIAL 
( O 
L O 
) O 
, O 
maltose B-TRIVIAL 
( O 
M O 
) O 
and O 
sucrose B-TRIVIAL 
( O 
S O 
) O 
at O 
different O 
initial O 
pH O 
values O 
( O 
3 O 
, O 
4 O 
, O 
5 O 
, O 
6 O 
, O 
7 O 
, O 
8 O 
and O 
9 O 
) O 
. O 
MRPs O 
derived O 
from O 
the O 
WPI-X O 
system O 
with O 
increasing O 
of O 
pH O 
rendered O 
the O 
highest O 
browning O 
, O 
reducing O 
power O 
and O 
DPPH B-ABBREVIATION 
radical O 
- O 
scavenging O 
activity O 
. O 
SDS B-ABBREVIATION 
-PAGE O 
analyses O 
indicated O 
formation O 
of O 
cross O 
- O 
linked O 
proteins O 
of O 
large O 
molecular O 
mass O 
produced O 
from O 
WPI-X O 
systems O 
. O 
Results O 
of O 
FT-IR O 
analysis O 
indicated O 
that O 
the O 
amide B-FAMILY 
I O 
, O 
II O 
and O 
III O 
bands O 
of O 
WPI O 
from O 
the O 
WPI-X O 
and O 
WPI-G O 
systems O 
were O 
changed O 
by O 
the O 
Maillard O 
reaction O 
. O 
CD O 
spectroscopy O 
showed O 
that O 
β-sheet O 
, O 
β-turns O 
and O 
random O 
coil O 
were O 
increased O 
while O 
the O 
α-helix O 
was O 
decreased O 
after O 
the O 
WPI-G O 
and O 
WPI-X O 
system O 
aqueous O 
solutions O 
were O 
heated O 
. O 
In O 
conclusion O 
, O 
MRPs O 
obtained O 
from O 
the O 
WPI-X O 
system O 
had O 
high O 
antioxidant O 
activity O 
. O 

antioxidant O 
and O 
antiglucotoxic O 
effects O 
of O 
Alternanthera O 
paronychioides O 
on O 
pancreatic O 
β-cell O 
were O 
investigated O 
. O 
Antioxidant O 
assays O 
demonstrated O 
that O 
ethanol B-SYSTEMATIC 
extracts O 
of O 
A O 
. O 
paronychioides O 
( O 
EEAP O 
) O 
exhibited O 
the O 
highest O 
antioxidant O 
activity O 
, O 
which O 
also O 
had O 
the O 
highest O 
phenolic B-FAMILY 
and O 
flavonoid B-FAMILY 
contents O 
. O 
Two O 
major O 
polyphenolics B-FAMILY 
, O 
ferulic B-TRIVIAL 
acid I-TRIVIAL 
and O 
quercetin B-TRIVIAL 
, O 
were O 
identified O 
from O 
EEAP O 
by O 
HPLC-DAD O 
. O 
Effects O 
of O 
EEAP O 
, O 
ferulic B-TRIVIAL 
acid I-TRIVIAL 
and O 
quercetin B-TRIVIAL 
on O 
high O 
glucose O 
( O 
25mmol O 
/ O 
L)-induced O 
pancreatic O 
β-cell O 
apoptosis O 
and O 
dysfunction O 
were O 
further O 
evaluated O 
. O 
Results O 
showed O 
that O 
EEAP O 
and O 
quercetin B-TRIVIAL 
but O 
not O 
ferulic B-TRIVIAL 
acid I-TRIVIAL 
protected O 
β-cells O 
from O 
glucotoxicity O 
through O 
several O 
mechanisms O 
, O 
including O 
: O 
( O 
1 O 
) O 
maintaining O 
β-cell O 
viability O 
; O 
( O 
2 O 
) O 
suppressing O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
production O 
; O 
( O 
3 O 
) O 
reducing O 
characteristic O 
features O 
of O 
apoptosis O 
; O 
( O 
4 O 
) O 
inhibiting O 
the O 
activation O 
of O 
caspase-9 O 
and O 
caspase-3 O 
and O 
the O 
cleavage O 
of O 
poly B-SYSTEMATIC 
( I-SYSTEMATIC 
ADP-ribose I-SYSTEMATIC 
) I-SYSTEMATIC 
polymerase O 
; O 
( O 
5 O 
) O 
upregulating O 
pancreatic O 
and O 
duodenal O 
homeobox O 
1 O 
gene O 
expression O 
and O 
the O 
insulin O 
secretagogue O 
action O 
of O 
pancreatic O 
β-cells O 
. O 
These O 
findings O 
may O 
shed O 
light O 
on O 
the O 
preventive O 
actions O 
of O 
A O 
. O 
paronychioides O 
on O 
diabetic O 
glucotoxicity O 
. O 

( O 
Prunus O 
persica O 
) O 
extract O 
inhibits O 
angiotensin B-TRIVIAL 
II I-TRIVIAL 
-induced O 
signal O 
transduction O 
in O 
vascular O 
smooth O 
muscle O 
cells O 
. O 

II I-TRIVIAL 
( O 
Ang B-ABBREVIATION 
II I-ABBREVIATION 
) O 
is O 
a O 
vasoactive O 
hormone O 
that O 
has O 
been O 
implicated O 
in O 
cardiovascular O 
diseases O 
. O 
Here O 
, O 
the O 
effect O 
of O 
peach O 
, O 
Prunus O 
persica O 
L O 
. O 
Batsch O 
, O 
pulp O 
extract O 
on O 
Ang B-ABBREVIATION 
II I-ABBREVIATION 
-induced O 
intracellular O 
Ca(2+) B-FORMULA 
mobilization O 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
production O 
and O 
signal O 
transduction O 
events O 
in O 
cultured O 
vascular O 
smooth O 
muscle O 
cells O 
( O 
VSMCs O 
) O 
was O 
investigated O 
. O 
Pretreatment O 
of O 
peach O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
inhibited O 
Ang B-ABBREVIATION 
II I-ABBREVIATION 
-induced O 
intracellular O 
Ca(2+) B-FORMULA 
elevation O 
in O 
VSMCs O 
. O 
Furthermore O 
, O 
Ang B-ABBREVIATION 
II I-ABBREVIATION 
-induced O 
ROS O 
generation O 
, O 
essential O 
for O 
signal O 
transduction O 
events O 
, O 
was O 
diminished O 
by O 
the O 
peach O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
. O 
The O 
peach O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
also O 
attenuated O 
the O 
Ang B-ABBREVIATION 
II I-ABBREVIATION 
-induced O 
phosphorylation O 
of O 
epidermal O 
growth O 
factor O 
receptor O 
and O 
myosin O 
phosphatase O 
target O 
subunit O 
1 O 
, O 
both O 
of O 
which O 
are O 
associated O 
with O 
atherosclerosis O 
and O 
hypertension O 
. O 
These O 
results O 
suggest O 
that O 
peach O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
may O 
have O 
clinical O 
potential O 
for O 
preventing O 
cardiovascular O 
diseases O 
by O 
interfering O 
with O 
Ang B-ABBREVIATION 
II I-ABBREVIATION 
-induced O 
intracellular O 
Ca(2+) B-FORMULA 
elevation O 
, O 
the O 
generation O 
of O 
ROS O 
, O 
and O 
then O 
blocking O 
signal O 
transduction O 
events O 
. O 

fatty B-FAMILY 
acid I-FAMILY 
profiles O 
of O 
emulsified O 
lipids O 
during O 
in O 
vitro O 
digestion O 
with O 
pancreatic O 
lipase O 
. O 

free O 
fatty B-FAMILY 
acids I-FAMILY 
released O 
from O 
milk O 
protein O 
- O 
stabilized O 
emulsions O 
prepared O 
with O 
milk O 
fat O 
, O 
soya O 
bean O 
oil O 
or O 
tuna O 
fish O 
oil O 
during O 
in O 
vitro O 
digestion O 
with O 
pancreatic O 
lipase O 
were O 
monitored O 
using O 
gas O 
chromatography O 
. O 
The O 
results O 
showed O 
that O 
saturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
C16 B-FORMULA 
: I-FORMULA 
0 I-FORMULA 
and O 
C18 B-FORMULA 
: I-FORMULA 
0 I-FORMULA 
) O 
were O 
released O 
faster O 
than O 
unsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
C18 B-FAMILY 
: I-FAMILY 
1n9 I-FAMILY 
, O 
C18 B-FAMILY 
: I-FAMILY 
2n6 I-FAMILY 
and O 
C18 B-FAMILY 
: I-FAMILY 
3n3 I-FAMILY 
) O 
from O 
soya O 
bean O 
oil O 
emulsions O 
; O 
short O 
chain O 
fatty B-FAMILY 
acids I-FAMILY 
were O 
released O 
faster O 
than O 
long O 
chain O 
fatty B-FAMILY 
acids I-FAMILY 
from O 
milk O 
fat O 
emulsions O 
; O 
long O 
chain O 
polyunsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
, O 
such O 
as O 
eicosapentaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
were O 
released O 
more O 
slowly O 
than O 
other O 
fatty B-FAMILY 
acids I-FAMILY 
from O 
fish O 
oil O 
emulsions O 
. O 
The O 
results O 
confirm O 
that O 
the O 
release O 
behaviour O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
from O 
emulsions O 
during O 
digestion O 
is O 
related O 
not O 
only O 
to O 
the O 
position O 
of O 
the O 
fatty B-FAMILY 
acids I-FAMILY 
in O 
the O 
triglycerides B-FAMILY 
in O 
the O 
fat O 
/ O 
oil O 
, O 
but O 
also O 
to O 
the O 
length O 
of O 
the O 
carbon B-SYSTEMATIC 
chain O 
of O 
the O 
fatty B-FAMILY 
acid I-FAMILY 
. O 
The O 
rates O 
and O 
the O 
extents O 
of O 
the O 
digestion O 
of O 
lipids O 
consisting O 
of O 
short O 
chain O 
fatty B-FAMILY 
acids I-FAMILY 
are O 
higher O 
than O 
those O 
of O 
lipids O 
consisting O 
of O 
long O 
chain O 
fatty B-FAMILY 
acids I-FAMILY 
. O 

mackerel O 
( O 
Auxis O 
thazard O 
) O 
and O 
catfish O 
( O 
Clarias O 
macrocephalus O 
) O 
can O 
be O 
used O 
as O 
alternative O 
sources O 
for O 
surimi O 
production O 
. O 
However O 
, O 
the O 
functionality O 
of O 
surimi O 
is O 
species O 
- O 
dependent O 
. O 
This O 
study O 
aimed O 
to O 
characterise O 
certain O 
chemical O 
and O 
physical O 
compositions O 
of O 
dark O 
and O 
ordinary O 
muscles O 
from O 
these O 
species O 
. O 
Catfish O 
, O 
particularly O 
ordinary O 
muscle O 
, O 
was O 
composed O 
of O 
higher O 
contents O 
of O 
lipid O 
and O 
carotenoid O 
than O 
Frigate O 
mackerel O 
muscle O 
( O 
p O 
< O 
0.05 O 
) O 
but O 
ordinary O 
muscle O 
from O 
Frigate O 
mackerel O 
had O 
the O 
highest O 
phospholipid O 
content O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Both O 
dark O 
and O 
ordinary O 
muscles O 
of O 
Frigate O 
mackerel O 
had O 
greater O 
contents O 
of O 
myofibrillar O 
proteins O 
than O 
had O 
catfish O 
muscle O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Myosin O 
heavy O 
chain O 
and O 
actin O 
were O 
predominant O 
proteins O 
found O 
in O 
both O 
muscle O 
types O 
of O 
both O 
species O 
. O 
Dark O 
muscle O 
from O 
Frigate O 
mackerel O 
had O 
the O 
highest O 
sarcoplasmic O 
protein O 
content O 
, O 
especially O 
extractable O 
myoglobin O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Muscles O 
from O 
Frigate O 
mackerel O 
had O 
greater O 
content O 
of O 
sodium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
than O 
had O 
catfish O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
highest O 
contents O 
of O 
iron B-SYSTEMATIC 
, O 
copper B-SYSTEMATIC 
and O 
selenium B-SYSTEMATIC 
were O 
found O 
in O 
Frigate O 
mackerel O 
dark O 
muscle O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
pH O 
of O 
ordinary O 
muscle O 
from O 
both O 
species O 
was O 
higher O 
than O 
that O 
of O 
dark O 
muscle O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Frigate O 
mackerel O 
, O 
especilly O 
dark O 
muscle O 
, O 
exhibited O 
the O 
most O 
dark O 
- O 
red O 
colour O 
, O 
as O 
shown O 
by O 
the O 
lowest O 
L(*) O 
and O 
b(*) O 
values O 
with O 
the O 
highest O 
a(*) O 
value O 
and O 
redness O 
index O 
( O 
a(*) O 
/ O 
b(*) O 
) O 
( O 
p O 
< O 
0.05 O 
) O 
. O 

are O 
gaining O 
increasing O 
scientific O 
and O 
public O 
interest O 
for O 
their O 
purported O 
antioxidant O 
- O 
associated O 
health O 
benefits O 
. O 
Most O 
reported O 
studies O 
focused O 
on O 
specific O 
oat O 
extracts O 
or O 
particular O 
oat O 
components O 
, O 
such O 
as O 
β-glucans O 
, O 
tocols B-FAMILY 
( O 
vitamin B-FAMILY 
E I-FAMILY 
) O 
, O 
or O 
avenanthramides B-FAMILY 
. O 
Studies O 
on O 
whole O 
oats O 
with O 
respect O 
to O 
antioxidant O 
and O 
anti-inflammatory O 
activities O 
are O 
still O 
lacking O 
. O 
Here O 
the O 
antioxidant O 
and O 
anti-inflammatory O 
activities O 
from O 
whole O 
oat O 
groats O 
of O 
seven O 
common O 
varieties O 
were O 
evaluated O 
. O 
All O 
oat O 
varieties O 
had O 
very O 
similar O 
oxygen B-SYSTEMATIC 
radical O 
absorption O 
capacity O 
compared O 
with O 
other O 
whole O 
grains O 
. O 
In O 
an O 
anti-inflammatory O 
assay O 
, O 
oat O 
variety O 
CDC O 
Dancer O 
inhibited O 
tumor O 
necrosis O 
factor-α O 
induced O 
nuclear O 
factor O 
- O 
kappa O 
B O 
activation O 
by O 
27.5% O 
at O 
2mg O 
/ O 
ml O 
, O 
whereas O 
variety O 
Deiter O 
showed O 
13.7% O 
inhibition O 
at O 
a O 
comparable O 
dose O 
. O 
Avenanthramide B-FAMILY 
levels O 
did O 
not O 
correlate O 
with O 
the O 
observed O 
antioxidant O 
and O 
anti-inflammatory O 
activities O 
. O 
Further O 
investigations O 
are O 
needed O 
to O 
pinpoint O 
the O 
specific O 
antioxidant O 
and O 
anti-inflammatory O 
compounds O 
, O 
and O 
potential O 
synergistic O 
and O 
/ O 
or O 
matrix O 
effects O 
that O 
may O 
help O 
explain O 
the O 
mechanisms O 
of O 
oat's O 
anti-inflammatory O 
actions O 
. O 

of O 
phenolic B-FAMILY 
compounds O 
from O 
four O 
species O 
of O 
ber O 
( O 
Ziziphus O 
mauritiana O 
L O 
. O 
) O 
fruits O 
: O 
Comparison O 
of O 
three O 
base O 
hydrolysis O 
procedure O 
for O 
quantification O 
of O 
total O 
phenolic B-FAMILY 
acids I-FAMILY 
. O 

present O 
study O 
was O 
undertaken O 
to O 
investigate O 
the O 
flavonoid B-FAMILY 
profile O 
in O 
four O 
species O 
of O 
ber O 
( O 
Ziziphus O 
mauritiana O 
Lamk O 
. O 
) O 
fruit O 
. O 
The O 
12 O 
flavonoids B-FAMILY 
identified O 
were O 
quercetin B-SYSTEMATIC 
3-O-robinobioside I-SYSTEMATIC 
, O 
quercetin B-SYSTEMATIC 
3-O-rutinoside I-SYSTEMATIC 
, O 
quercetin B-SYSTEMATIC 
3'-O-galactoside I-SYSTEMATIC 
, O 
quercetin B-SYSTEMATIC 
3'-O-glucoside I-SYSTEMATIC 
, O 
quercetin B-SYSTEMATIC 
3'-O-rhamnoside I-SYSTEMATIC 
, O 
quercetin B-SYSTEMATIC 
3'-O-pentosylhexoside I-SYSTEMATIC 
, O 
quercetin B-SYSTEMATIC 
3-O-6'malonylglucoside I-SYSTEMATIC 
, O 
quercetin B-SYSTEMATIC 
3'-O-malonylglucoside I-SYSTEMATIC 
, O 
luteolin B-SYSTEMATIC 
7-O-6'malonylglucoside I-SYSTEMATIC 
, O 
luteolin B-SYSTEMATIC 
7-O-malonylglucoside I-SYSTEMATIC 
, O 
myricetin B-SYSTEMATIC 
3-O-galactoside I-SYSTEMATIC 
, O 
and O 
naringenin B-FAMILY 
tri I-FAMILY 
glycoside I-FAMILY 
. O 
This O 
is O 
the O 
first O 
report O 
on O 
extraction O 
of O 
nine O 
additional O 
flavonoids B-FAMILY 
from O 
the O 
ber O 
fruits O 
. O 
In O 
addition O 
, O 
we O 
also O 
compared O 
the O 
impact O 
of O 
three O 
different O 
base O 
hydrolysis O 
techniques O 
namely O 
ultrasonic O 
assisted O 
base O 
hydrolysis O 
( O 
UABH O 
) O 
, O 
microwave O 
assisted O 
base O 
hydrolysis O 
( O 
MWABH O 
) O 
, O 
and O 
pressurised O 
liquid O 
assisted O 
base O 
hydrolysis O 
( O 
PLABH O 
) O 
for O 
the O 
quantification O 
of O 
total O 
phenolic B-FAMILY 
acids I-FAMILY 
. O 
Nine O 
phenolic B-FAMILY 
acids I-FAMILY 
, O 
protocatechuic B-TRIVIAL 
acid I-TRIVIAL 
, O 
p-hydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
ferulic B-TRIVIAL 
acid I-TRIVIAL 
, O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
, O 
vanillic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
, O 
vanillin B-TRIVIAL 
, O 
ortho- B-MULTIPLE 
and I-MULTIPLE 
para-coumaric I-MULTIPLE 
acids I-MULTIPLE 
, O 
were O 
identified O 
and O 
quantified O 
. O 
The O 
three O 
major O 
phenolic B-FAMILY 
acids I-FAMILY 
identified O 
in O 
all O 
four O 
ber O 
species O 
were O 
p-coumaric B-TRIVIAL 
acid I-TRIVIAL 
, O 
vanillin B-TRIVIAL 
and O 
ferulic B-FAMILY 
acids I-FAMILY 
. O 
Higher O 
amounts O 
( O 
p O 
< O 
0.05 O 
) O 
of O 
total O 
phenolic B-FAMILY 
acids I-FAMILY 
in O 
all O 
cultivars O 
were O 
obtained O 
with O 
the O 
PLABH O 
technique O 
as O 
compared O 
to O 
other O 
two O 
procedures O 
( O 
UABH O 
and O 
MWABH O 
) O 
. O 

physico O 
- O 
chemical O 
and O 
sensorial O 
properties O 
of O 
the O 
control O 
( O 
BCtr O 
) O 
, O 
commercial O 
wheat O 
flour O 
( O 
CWF O 
) O 
bread O 
substituted O 
with O 
10% O 
BPF O 
( O 
banana O 
pseudo O 
- O 
stem O 
flour O 
) O 
( O 
B10BPF O 
) O 
and O 
B10BPF O 
with O 
added O 
0.8% O 
w O 
/ O 
w O 
( O 
flour O 
weight O 
basis O 
) O 
xanthan O 
gum O 
( O 
XG O 
) O 
or O 
sodium B-SYSTEMATIC 
carboxymethylcellulose O 
( O 
CMC O 
) O 
( O 
B10BPFXG O 
and O 
B10BPFCMC O 
, O 
respectively O 
) O 
were O 
examined O 
. O 
The O 
proximate O 
analyses O 
revealed O 
that O 
the O 
composite O 
bread O 
had O 
significantly O 
higher O 
moisture O 
, O 
ash O 
, O 
crude O 
fibre O 
, O 
soluble O 
, O 
insoluble O 
and O 
total O 
dietary O 
fibre O 
contents O 
but O 
lower O 
protein O 
, O 
fat O 
and O 
carbohydrate B-FAMILY 
contents O 
than O 
the O 
BCtr O 
. O 
Bread O 
incorporated O 
with O 
BPF O 
resulted O 
in O 
a O 
lower O 
volume O 
, O 
darker O 
crumb O 
and O 
lighter O 
crust O 
colour O 
than O 
the O 
BCtr O 
. O 
The O 
addition O 
of O 
CMC O 
improved O 
the O 
bread O 
volume O 
. O 
All O 
breads O 
containing O 
BPF O 
had O 
greater O 
total O 
phenolics B-FAMILY 
, O 
and O 
antioxidant O 
properties O 
than O 
the O 
control O 
bread O 
. O 
Sensory O 
evaluation O 
indicated O 
that O 
the O 
B10BPFCMC O 
bread O 
had O 
the O 
highest O 
acceptability O 
. O 

study O 
investigates O 
the O 
quality O 
of O 
retail O 
milk O 
labelled O 
as O 
Jersey O 
& O 
Guernsey O 
( O 
JG O 
) O 
when O 
compared O 
with O 
milk O 
without O 
breed O 
specifications O 
( O 
NS O 
) O 
and O 
repeatability O 
of O 
differences O 
over O 
seasons O 
and O 
years O 
. O 
16 O 
different O 
brands O 
of O 
milk O 
( O 
4 O 
Jersey O 
& O 
Guernsey O 
, O 
12 O 
non O 
specified O 
breed O 
) O 
were O 
sampled O 
over O 
2years O 
on O 
4 O 
occasions O 
. O 
JG O 
milk O 
was O 
associated O 
with O 
both O 
favourable O 
traits O 
for O 
human O 
health O 
, O 
such O 
as O 
the O 
higher O 
total O 
protein O 
, O 
total O 
casein O 
, O 
α-casein O 
, O 
β-casein O 
, O 
κ-casein O 
and O 
α-tocopherol B-TRIVIAL 
contents O 
, O 
and O 
unfavourable O 
traits O 
, O 
such O 
as O 
the O 
higher O 
concentrations O 
of O 
saturated O 
fat O 
, O 
C12 O 
: O 
0 O 
, O 
C14 O 
: O 
0 O 
and O 
lower O 
concentrations O 
of O 
monounsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
. O 
In O 
summer O 
, O 
JG O 
milk O 
had O 
a O 
higher O 
omega-3 O 
: O 
omega-6 O 
ratio O 
than O 
had O 
NS O 
milk O 
. O 
Also O 
, O 
the O 
relative O 
increase O 
in O 
omega-3 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
and O 
α-tocopherol B-TRIVIAL 
, O 
from O 
winter O 
to O 
summer O 
, O 
was O 
greater O 
in O 
JG O 
milk O 
. O 
The O 
latter O 
characteristic O 
could O 
be O 
of O 
use O 
in O 
breeding O 
schemes O 
and O 
farming O 
systems O 
producing O 
niche O 
dairy O 
products O 
. O 
Seasonality O 
had O 
a O 
more O 
marked O 
impact O 
on O 
the O 
fatty B-FAMILY 
acid I-FAMILY 
composition O 
of O 
JG O 
milk O 
than O 
had O 
NS O 
milk O 
, O 
while O 
the O 
opposite O 
was O 
found O 
for O 
protein O 
composition O 
. O 
Potential O 
implication O 
for O 
the O 
findings O 
in O 
human O 
health O 
, O 
producers O 
, O 
industry O 
and O 
consumers O 
are O 
considered O 
. O 

isolation O 
and O 
purification O 
of O 
seven O 
main O 
antioxidants O 
from O 
Eucommia O 
ulmoides O 
Oliv O 
. O 
( O 
Du-zhong O 
) O 
leaves O 
using O 
HSCCC O 
guided O 
by O 
DPPH B-ABBREVIATION 
-HPLC O 
experiment O 
. O 

antioxidants O 
were O 
purified O 
from O 
Eucommia O 
ulmoides O 
Oliv O 
. O 
leaves O 
using O 
HSCCC O 
guided O 
by O 
DPPH B-ABBREVIATION 
-HPLC O 
experiment O 
. O 
HSCCC O 
was O 
successfully O 
used O 
to O 
separate O 
target O 
antioxidants O 
by O 
three O 
runs O 
with O 
different O 
solvent O 
systems O 
after O 
D101 O 
column O 
chromatography O 
fractionation O 
. O 
Ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
- O 
n-butanol B-SYSTEMATIC 
-water O 
( O 
1 O 
: O 
2 O 
: O 
3 O 
, O 
v O 
/ O 
v O 
/ O 
v O 
) O 
was O 
selected O 
as O 
the O 
optimum O 
solvent O 
system O 
to O 
purify O 
geniposidic B-TRIVIAL 
acid I-TRIVIAL 
. O 
Ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
- O 
ethanol B-SYSTEMATIC 
-water O 
( O 
4 O 
: O 
1 O 
: O 
5 O 
, O 
v O 
/ O 
v O 
/ O 
v O 
) O 
was O 
used O 
to O 
isolate O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
, O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
and O 
ferulic B-TRIVIAL 
acid I-TRIVIAL 
. O 
While O 
three O 
flavonoids B-FAMILY 
, O 
quercetin-3-O-sambubioside B-SYSTEMATIC 
, O 
rutin B-TRIVIAL 
and O 
isoquercitrin B-TRIVIAL 
were O 
purified O 
by O 
petroleum B-TRIVIAL 
ether I-TRIVIAL 
- O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
- O 
methanol B-SYSTEMATIC 
-water O 
( O 
1 O 
: O 
5 O 
: O 
1 O 
: O 
5 O 
, O 
v O 
/ O 
v O 
/ O 
v O 
/ O 
v O 
) O 
. O 
The O 
structures O 
were O 
identified O 
by O 
MS O 
and O 
NMR O 
. O 
Antioxidant O 
activities O 
were O 
assessed O 
, O 
and O 
compounds O 
2-7 O 
showed O 
strong O 
antioxidant O 
activities O 
. O 
This O 
is O 
the O 
first O 
report O 
about O 
separation O 
of O 
antioxidants O 
from O 
E O 
. O 
ulmoides O 
leaves O 
by O 
HSCCC O 
. O 
The O 
results O 
indicated O 
that O 
the O 
combinative O 
methods O 
using O 
DPPH B-ABBREVIATION 
-HPLC O 
and O 
HSCCC O 
could O 
be O 
widely O 
applied O 
for O 
screening O 
and O 
isolation O 
of O 
antioxidants O 
from O 
complex O 
extracts O 
. O 

acid I-TRIVIAL 
derivatives O 
, O 
ellagitannins O 
, O 
proanthocyanidins B-FAMILY 
and O 
other O 
phenolics B-FAMILY 
, O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
and O 
antioxidant O 
capacity O 
of O 
two O 
powder O 
products O 
from O 
camu-camu O 
fruit O 
( O 
Myrciaria O 
dubia O 
) O 
. O 

aims O 
of O 
this O 
study O 
were O 
the O 
evaluation O 
of O 
polyphenols B-FAMILY 
and O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
content O 
, O 
and O 
antioxidant O 
capacity O 
of O 
dehydrated O 
pulp O 
powder O 
and O 
the O 
dried O 
flour O 
obtained O 
from O 
the O 
skin O 
and O 
seeds O 
residue O 
remaining O 
after O 
pulp O 
preparation O 
from O 
camu-camu O 
( O 
Myrciaria O 
dudia O 
) O 
. O 
Fifty O 
- O 
three O 
different O 
phenolics B-FAMILY 
were O 
characterised O 
by O 
HPLC-DAD-ESI-MS-MS O 
and O 
UPLC-HR-QTOF-MS-MS O 
. O 
The O 
phenolic O 
content O 
of O 
camu-camu O 
flour O 
was O 
higher O 
than O 
that O 
of O 
the O 
pulp O 
powder O 
( O 
4007.95mg O 
/ O 
100g O 
vs O 
. O 
48.54mg O 
/ O 
100g O 
) O 
. O 
In O 
both O 
products O 
the O 
flavonol B-TRIVIAL 
myricetin B-TRIVIAL 
and O 
conjugates O 
, O 
ellagic B-TRIVIAL 
acid I-TRIVIAL 
and O 
conjugates O 
and O 
ellagitannins O 
were O 
detected O 
. O 
Cyanidin B-SYSTEMATIC 
3-glucoside I-SYSTEMATIC 
, O 
and O 
quercetin B-TRIVIAL 
and O 
its O 
glycosides O 
were O 
only O 
found O 
in O 
the O 
pulp O 
powder O 
, O 
while O 
proanthocyanidins B-FAMILY 
were O 
only O 
present O 
in O 
the O 
flour O 
( O 
3.5g O 
/ O 
100g O 
, O 
mean O 
degree O 
of O 
polymerisation O 
3 O 
) O 
. O 
The O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
content O 
was O 
lower O 
in O 
pulp O 
powder O 
( O 
3.5% O 
) O 
than O 
in O 
the O 
flour O 
( O 
9.1% O 
) O 
. O 
The O 
radical O 
- O 
scavenging O 
capacity O 
of O 
both O 
powders O 
was O 
determined O 
by O 
the O 
DPPH B-ABBREVIATION 
, O 
ABTS B-ABBREVIATION 
and O 
ORAC O 
assays O 
, O 
and O 
was O 
higher O 
for O 
camu-camu O 
flour O 
as O 
could O 
be O 
expected O 
for O 
its O 
higher O 
phenolics B-FAMILY 
and O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
content O 
. O 
Comparative O 
analyses O 
with O 
fresh O 
camu-camu O 
berries O 
indicate O 
that O 
some O 
transformations O 
occur O 
during O 
processing O 
. O 
Analysis O 
of O 
fresh O 
berries O 
showed O 
that O 
ellagic B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
and O 
ellagitannins O 
were O 
mainly O 
present O 
in O 
the O 
seeds O 
, O 
while O 
proanthocyanidins B-FAMILY 
were O 
present O 
both O 
in O 
the O 
seeds O 
and O 
skin O 
. O 

study O 
was O 
conducted O 
to O 
evaluate O 
the O 
tenderization O 
effect O 
of O 
soy O 
sauce O 
on O 
beef O 
M O 
. O 
biceps O 
femoris O 
( O 
BF O 
) O 
. O 
Five O 
marinades O 
were O 
prepared O 
with O 
4% O 
( O 
w O 
/ O 
v O 
) O 
sodium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
and O 
25% O 
( O 
w O 
/ O 
v O 
) O 
soy O 
sauce O 
solutions O 
( O 
4% O 
salt O 
concentration O 
) O 
and O 
mixed O 
with O 
the O 
ratios O 
of O 
100 O 
: O 
0 O 
( O 
S0 O 
, O 
pH O 
6.52 O 
) O 
, O 
75 O 
: O 
25 O 
( O 
S25 O 
, O 
5.4 O 
) O 
50 O 
: O 
50 O 
( O 
S50 O 
, O 
5.24 O 
) O 
, O 
25 O 
: O 
75 O 
( O 
S75 O 
, O 
5.05 O 
) O 
, O 
and O 
0 O 
: O 
100 O 
( O 
S100 O 
, O 
4.85 O 
) O 
, O 
respectively O 
. O 
The O 
BF O 
samples O 
which O 
were O 
obtained O 
from O 
Hanwoo O 
cows O 
at O 
48h O 
postmortem O 
( O 
n=24 O 
) O 
were O 
marinated O 
with O 
five O 
marinades O 
for O 
72h O 
at O 
4°C O 
( O 
1 O 
: O 
4 O 
w O 
/ O 
w O 
) O 
, O 
and O 
the O 
effects O 
of O 
soy O 
sauce O 
on O 
tenderness O 
were O 
evaluated O 
. O 
Soy O 
sauce O 
marination O 
resulted O 
in O 
a O 
decrease O 
in O 
the O 
pH O 
value O 
of O 
the O 
BF O 
sample O 
. O 
However O 
, O 
there O 
were O 
no O 
significant O 
differences O 
in O 
the O 
water O 
holding O 
capacity O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
The O 
S100 O 
treatment O 
showed O 
the O 
significant O 
( O 
P O 
< O 
0.05 O 
) O 
increase O 
in O 
collagen O 
solubility O 
and O 
myofibrillar O 
fragmentation O 
index O 
, O 
contributing O 
to O 
decreased O 
shear O 
force O 
compared O 
to O 
S0 O 
( O 
control O 
) O 
. O 
Reduction O 
in O 
intensity O 
of O 
few O 
myofibrillar O 
protein O 
bands O 
were O 
observed O 
for O 
S100 O 
treatment O 
compared O 
to O 
control O 
using O 
SDS B-ABBREVIATION 
-PAGE O 
. O 
Scanning O 
electron O 
microscopy O 
revealed O 
breakdown O 
of O 
connective O 
tissue O 
surrounding O 
muscle O 
fibers O 
of O 
the O 
S100 O 
treatment O 
. O 
The O 
tenderization O 
effect O 
of O 
soy O 
sauce O 
may O 
attribute O 
various O 
mechanisms O 
such O 
as O 
increased O 
collagen O 
solubility O 
or O 
proteolysis O 
which O 
depend O 
on O 
soy O 
sauce O 
level O 
in O 
marinade O 
. O 

of O 
NaCl B-FORMULA 
and O 
pH O 
on O 
the O 
structural O 
conformations O 
of O 
kidney O 
bean O 
vicilin O 
. O 

changes O 
as O 
a O 
result O 
of O 
variations O 
in O 
pH O 
value O 
and O 
salt O 
concentration O 
were O 
determined O 
for O 
purified O 
vicilin O 
, O 
the O 
major O 
globular O 
protein O 
in O 
kidney O 
beans O 
using O 
intrinsic O 
fluorescence O 
and O 
circular O 
dichroism O 
( O 
CD O 
) O 
. O 
The O 
vicilin O 
consisted O 
of O 
two O 
polypeptide O 
chains O 
of O 
about O 
43 O 
and O 
45kDa O 
in O 
size O 
when O 
analysed O 
under O 
reducing O 
SDS B-ABBREVIATION 
-PAGE O 
. O 
Amino B-FAMILY 
acid I-FAMILY 
analysis O 
showed O 
that O 
the O 
vicilin O 
had O 
high O 
contents O 
of O 
acidic B-FAMILY 
amino I-FAMILY 
acids I-FAMILY 
and O 
a O 
low O 
lysine B-TRIVIAL 
/ O 
arginine B-TRIVIAL 
ratio O 
. O 
Intrinsic O 
fluorescence O 
measurements O 
were O 
performed O 
to O 
measure O 
exposure O 
of O 
tyrosine B-TRIVIAL 
and O 
tryptophan B-TRIVIAL 
as O 
a O 
means O 
of O 
estimating O 
protein O 
conformational O 
changes O 
. O 
Generally O 
, O 
the O 
vicilin O 
showed O 
an O 
unfolded O 
structure O 
at O 
pH O 
3 O 
, O 
5 O 
, O 
7 O 
, O 
and O 
9 O 
as O 
evident O 
by O 
the O 
extensive O 
red O 
shift O 
( O 
> O 
350nm O 
) O 
of O 
the O 
wavelength O 
of O 
maximum O 
tryptophan B-TRIVIAL 
fluorescence O 
intensity O 
. O 
At O 
pH O 
3 O 
and O 
5 O 
, O 
the O 
fluorescence O 
intensity O 
( O 
FI O 
) O 
was O 
greater O 
than O 
values O 
obtained O 
at O 
pH O 
7 O 
and O 
9 O 
, O 
which O 
suggests O 
that O 
the O 
microenvironment O 
of O 
tryptophan B-TRIVIAL 
was O 
less O 
hydrophilic O 
at O 
acidic O 
pH O 
. O 
Addition O 
of O 
NaCl B-FORMULA 
also O 
led O 
to O 
increased O 
FI O 
, O 
an O 
indication O 
of O 
structural O 
changes O 
of O 
tryptophan B-TRIVIAL 
in O 
response O 
to O 
the O 
hydrophilic O 
environment O 
. O 
These O 
changes O 
in O 
FI O 
were O 
due O 
mostly O 
to O 
tryptophan B-TRIVIAL 
emission O 
because O 
tyrosine B-TRIVIAL 
emission O 
( O 
at O 
303nm O 
) O 
was O 
suppressed O 
. O 
The O 
far-UV O 
CD O 
spectra O 
showed O 
that O 
vicilin O 
had O 
minimal O 
measurable O 
secondary O 
structures O 
at O 
pH O 
3 O 
and O 
5 O 
when O 
compared O 
to O 
pH O 
7 O 
and O 
9 O 
. O 
Addition O 
of O 
NaCl B-FORMULA 
led O 
to O 
an O 
increase O 
in O 
the O 
tertiary O 
structure O 
conformation O 
of O 
vicilin O 
as O 
determined O 
from O 
the O 
near-UV O 
CD O 
spectra O 
. O 

of O 
highly O 
enriched O 
(13)C-lycopene B-SYSTEMATIC 
for O 
human O 
metabolic O 
studies O 
using O 
repeated O 
batch O 
tomato O 
cell O 
culturing O 
with O 
(13)C-glucose B-SYSTEMATIC 
. O 

putative O 
disease O 
- O 
preventing O 
lycopene B-TRIVIAL 
metabolites O 
are O 
found O 
in O 
both O 
tomato O 
( O 
Solanum O 
lycopersicum O 
) O 
products O 
and O 
in O 
their O 
consumers O 
, O 
mammalian O 
lycopene B-TRIVIAL 
metabolism O 
is O 
poorly O 
understood O 
. O 
Advances O 
in O 
tomato O 
cell O 
culturing O 
techniques O 
offer O 
an O 
economical O 
tool O 
for O 
generation O 
of O 
highly O 
- O 
enriched O 
(13)C-lycopene B-SYSTEMATIC 
for O 
human O 
bioavailability O 
and O 
metabolism O 
studies O 
. O 
To O 
enhance O 
the O 
(13)C B-FORMULA 
-enrichment O 
and O 
yields O 
of O 
labelled O 
lycopene B-TRIVIAL 
from O 
the O 
hp-1 O 
tomato O 
cell O 
line O 
, O 
cultures O 
were O 
first O 
grown O 
in O 
(13)C-glucose B-SYSTEMATIC 
media O 
for O 
three O 
serial O 
batches O 
and O 
produced O 
increasing O 
proportions O 
of O 
uniformly O 
labelled O 
lycopene B-TRIVIAL 
( O 
14.3±1.2% O 
, O 
39.6±0.5% O 
, O 
and O 
48.9±1.5% O 
) O 
with O 
consistent O 
yields O 
( O 
from O 
5.8 O 
to O 
9mg O 
/ O 
L O 
) O 
. O 
An O 
optimised O 
9-day- O 
long O 
(13)C B-FORMULA 
-loading O 
and O 
18-day- O 
long O 
labelling O 
strategy O 
developed O 
based O 
on O 
glucose B-TRIVIAL 
utilisation O 
and O 
lycopene B-TRIVIAL 
yields O 
, O 
yielded O 
(13)C-lycopene B-SYSTEMATIC 
with O 
93% O 
(13)C B-FORMULA 
isotopic O 
purity O 
, O 
and O 
55% O 
of O 
isotopomers O 
were O 
uniformly O 
labelled O 
. O 
Furthermore O 
, O 
an O 
optimised O 
acetone B-SYSTEMATIC 
and O 
hexane B-SYSTEMATIC 
extraction O 
led O 
to O 
a O 
fourfold O 
increase O 
in O 
lycopene B-TRIVIAL 
recovery O 
from O 
cultures O 
compared O 
to O 
a O 
standard O 
extraction O 
. O 

natural O 
oil O 
body O 
emulsions O 
of O 
a O 
similar O 
fat O 
content O 
( O 
∼5% O 
) O 
, O 
but O 
differing O 
in O 
their O 
protein O 
composition O 
were O 
obtained O 
from O 
an O 
aqueous O 
maize O 
germ O 
extract O 
. O 
The O 
first O 
was O 
prepared O 
by O 
concentrating O 
the O 
aqueous O 
oil O 
body O 
extract O 
with O 
ultrafiltration O 
to O 
a O 
fat O 
content O 
of O 
∼5% O 
. O 
The O 
other O 
two O 
were O 
prepared O 
by O 
initially O 
recovering O 
the O 
oil O 
bodies O 
from O 
the O 
extract O 
by O 
centrifugation O 
, O 
either O 
in O 
the O 
presence O 
of O 
sucrose B-TRIVIAL 
or O 
by O 
applying O 
isoelectric O 
precipitation O 
at O 
pH O 
5 O 
and O 
then O 
diluting O 
the O 
resulting O 
oil O 
body O 
creams O 
with O 
deionized O 
water O 
. O 
The O 
oxidative O 
and O 
physical O 
stability O 
of O 
the O 
three O 
emulsions O 
, O 
either O 
as O 
they O 
were O 
or O 
after O 
submission O 
to O 
thermal O 
treatment O 
( O 
100°C O 
for O 
15min O 
) O 
, O 
were O 
studied O 
following O 
storage O 
at O 
45°C O 
. O 
The O 
emulsions O 
differed O 
both O 
in O 
their O 
oxidative O 
and O 
physical O 
stability O 
, O 
depending O 
on O 
the O 
recovery O 
method O 
that O 
in O 
turn O 
influenced O 
their O 
continuous O 
phase O 
and O 
/ O 
or O 
interfacial O 
membrane O 
protein O 
and O 
/ O 
or O 
polar O 
antioxidant O 
composition O 
. O 
Ultrafiltration O 
resulted O 
in O 
the O 
most O 
stable O 
emulsion O 
. O 
Mixtures O 
of O 
the O 
natural O 
oil O 
body O 
emulsions O 
with O 
green O 
tea O 
extracts O 
, O 
aiming O 
to O 
serve O 
as O 
a O 
base O 
for O 
functional O 
beverages O 
, O 
were O 
then O 
prepared O 
and O 
studied O 
for O 
their O 
creaming O 
behaviour O 
. O 
The O 
green O 
tea O 
polyphenols B-FAMILY 
seem O 
to O 
interact O 
with O 
the O 
oil O 
bodies O 
leading O 
to O 
intensive O 
dispersion O 
destabilisation O 
which O 
, O 
however O 
, O 
was O 
halted O 
following O 
carrageenan O 
addition O 
at O 
a O 
relatively O 
very O 
low O 
level O 
. O 

of O 
temperature O 
on O 
the O 
release O 
of O 
intentionally O 
and O 
non-intentionally O 
added O 
substances O 
from O 
polyethylene B-SYSTEMATIC 
terephthalate I-SYSTEMATIC 
( O 
PET B-ABBREVIATION 
) O 
bottles O 
into O 
water O 
: O 
Chemical O 
analysis O 
and O 
potential O 
toxicity O 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
impact O 
of O 
temperature O 
on O 
the O 
release O 
of O 
PET B-ABBREVIATION 
-bottle O 
constituents O 
into O 
water O 
and O 
to O 
assess O 
the O 
potential O 
health O 
hazard O 
using O 
in O 
vitro O 
bioassays O 
with O 
bacteria O 
and O 
human O 
cell O 
lines O 
. O 
Aldehydes B-FAMILY 
, O 
trace O 
metals O 
and O 
other O 
compounds O 
found O 
in O 
plastic O 
packaging O 
were O 
analysed O 
in O 
PET B-ABBREVIATION 
-bottled O 
water O 
stored O 
at O 
different O 
temperatures O 
: O 
40 O 
, O 
50 O 
, O 
and O 
60°C O 
. O 
In O 
this O 
study O 
, O 
temperature O 
and O 
the O 
presence O 
of O 
CO2 B-FORMULA 
increased O 
the O 
release O 
of O 
formaldehyde B-SYSTEMATIC 
, O 
acetaldehyde B-SYSTEMATIC 
and O 
antimony B-SYSTEMATIC 
( O 
Sb B-FORMULA 
) O 
. O 
In O 
parallel O 
, O 
genotoxicity O 
assays O 
( O 
Ames O 
and O 
micronucleus O 
assays O 
) O 
and O 
transcriptional O 
- O 
reporter O 
gene O 
assays O 
for O 
estrogenic O 
and O 
anti-androgenic O 
activity O 
were O 
performed O 
on O 
bottled O 
water O 
extracts O 
at O 
relevant O 
consumer O 
exposure O 
levels O 
. O 
As O 
expected O 
, O 
and O 
in O 
accordance O 
with O 
the O 
chemical O 
formulations O 
specified O 
for O 
PET B-ABBREVIATION 
bottles O 
, O 
neither O 
phthalates B-FAMILY 
nor O 
UV O 
stabilisers O 
were O 
present O 
in O 
the O 
water O 
extracts O 
. O 
However O 
, O 
2,4-di-tert-butylphenol B-SYSTEMATIC 
, O 
a O 
degradation O 
compound O 
of O 
phenolic B-FAMILY 
antioxidants O 
, O 
was O 
detected O 
. O 
In O 
addition O 
, O 
an O 
intermediary O 
monomer O 
, O 
bis(2-hydroxyethyl)terephthalate B-SYSTEMATIC 
, O 
was O 
found O 
but O 
only O 
in O 
PET B-ABBREVIATION 
-bottled O 
waters O 
. O 
None O 
of O 
the O 
compounds O 
are O 
on O 
the O 
positive O 
list O 
of O 
EU O 
Regulation O 
No O 
. O 
10 O 
/ O 
2011 O 
. O 
However O 
, O 
the O 
PET B-ABBREVIATION 
-bottled O 
water O 
extracts O 
did O 
not O 
induce O 
any O 
cytotoxic O 
, O 
genotoxic O 
or O 
endocrine O 
- O 
disruption O 
activity O 
in O 
the O 
bioassays O 
after O 
exposure O 
. O 

in O 
sugar B-FAMILY 
cane O 
spirits O 
aged O 
in O 
casks O 
of O 
different O 
woods O 
. O 

profile O 
of O 
volatile O 
compounds O 
and O 
aging O 
markers O 
in O 
sugar B-FAMILY 
cane O 
spirits O 
aged O 
for O 
36months O 
in O 
casks O 
made O 
of O 
10 O 
types O 
of O 
wood O 
were O 
studied O 
. O 
The O 
ethanol B-SYSTEMATIC 
content O 
, O 
volatile O 
acidity O 
, O 
aldehydes B-FAMILY 
, O 
esters B-FAMILY 
, O 
higher O 
alcohols B-FAMILY 
, O 
and O 
methanol B-SYSTEMATIC 
were O 
determined O 
. O 
In O 
addition O 
, O 
gallic B-MULTIPLE 
, I-MULTIPLE 
vanilic I-MULTIPLE 
and I-MULTIPLE 
syringic I-MULTIPLE 
acids I-MULTIPLE 
, O 
siringaldehyde B-TRIVIAL 
, O 
coniferaldehyde B-TRIVIAL 
, O 
sinapaldehyde B-TRIVIAL 
, O 
vanillin B-TRIVIAL 
, O 
5-hydroxymethylfurfural B-SYSTEMATIC 
and O 
furfural B-TRIVIAL 
were O 
identified O 
and O 
quantified O 
. O 
The O 
profile O 
of O 
volatile O 
compounds O 
characterised O 
aging O 
in O 
each O 
type O 
of O 
wood O 
. O 
The O 
beverage O 
aged O 
in O 
oak O 
cask O 
achieved O 
the O 
highest O 
contents O 
of O 
maturation O 
- O 
related O 
congeners O 
. O 
The O 
Brazilian O 
woods O 
, O 
similar O 
to O 
oak O 
, O 
were O 
jequitibá O 
rosa O 
and O 
cerejeira O 
, O 
which O 
presented O 
the O 
highest O 
contents O 
of O 
some O 
maturation O 
- O 
related O 
compounds O 
, O 
such O 
as O 
vanillin B-TRIVIAL 
, O 
vanilic B-TRIVIAL 
acid I-TRIVIAL 
, O 
syringaldehyde B-TRIVIAL 
and O 
sinapaldehyde B-TRIVIAL 
. O 
Although O 
oak O 
wood O 
conferred O 
more O 
chemical O 
complexity O 
to O 
the O 
beverage O 
, O 
Brazilian O 
woods O 
, O 
singly O 
or O 
complementarily O 
, O 
present O 
potential O 
for O 
spirit O 
characterisation O 
and O 
for O 
improving O 
the O 
quality O 
of O 
sugar B-FAMILY 
cane O 
spirits O 
. O 

of O 
fisetin B-TRIVIAL 
supplementation O 
on O 
hepatic O 
lipogenesis O 
and O 
glucose B-TRIVIAL 
metabolism O 
in O 
Sprague-Dawley O 
rats O 
fed O 
on O 
a O 
high O 
fat O 
diet O 
. O 

modulatory O 
effects O 
of O 
daily O 
fisetin B-TRIVIAL 
supplementation O 
for O 
8weeks O 
on O 
genes O 
involved O 
in O 
hepatic O 
lipogenesis O 
and O 
gluconeogenesis O 
and O 
hyperglycemia O 
in O 
rats O 
fed O 
a O 
high O 
fat O 
( O 
HF O 
) O 
diet O 
were O 
evaluated O 
. O 
Elevated O 
levels O 
of O 
triglyceride B-FAMILY 
( O 
TG O 
) O 
, O 
along O 
with O 
hepatic O 
TG O 
content O 
and O 
glucose B-TRIVIAL 
concentrations O 
in O 
a O 
high O 
fat O 
diet O 
group O 
were O 
found O 
to O 
be O 
reduced O 
by O 
fisetin B-TRIVIAL 
supplementation O 
. O 
The O 
high O 
fat O 
diet O 
significantly O 
increased O 
hepatic O 
mRNA O 
expressions O 
of O 
PPARγ O 
, O 
SREBP1C O 
and O 
SCD-1 O 
genes O 
in O 
comparison O 
to O 
the O 
control O 
diet O 
, O 
which O 
was O 
subsequently O 
reversed O 
by O 
supplementation O 
with O 
fisetin B-TRIVIAL 
. O 
In O 
addition O 
, O 
fisetin B-TRIVIAL 
supplementation O 
significantly O 
reduced O 
hepatic O 
mRNA O 
abundance O 
of O 
FAS O 
, O 
ATPCL O 
and O 
G6Pase O 
compared O 
to O 
the O 
control O 
group O 
. O 
Finally O 
, O 
epididymal O 
mRNA O 
abundance O 
of O 
GLUT4 O 
was O 
significantly O 
increased O 
by O 
fisetin B-TRIVIAL 
supplementation O 
, O 
compared O 
to O 
levels O 
in O 
the O 
control O 
and O 
HF O 
groups O 
. O 
Enhancement O 
of O 
GLUT4 O 
expression O 
by O 
fisetin B-TRIVIAL 
was O 
further O 
confirmed O 
in O 
differentiated O 
3T3-L1 O 
adipocytes O 
. O 
Fisetin B-TRIVIAL 
supplementation O 
decreases O 
cardiovascular O 
risks O 
by O 
ameliorating O 
hepatic O 
steatosis O 
and O 
lowering O 
circulating O 
glucose B-TRIVIAL 
concentrations O 
. O 

of O 
polyphenol B-FAMILY 
contents O 
and O 
antioxidant O 
activities O 
of O 
Irish O 
brown O 
macroalgae O 
using O 
food O 
- O 
friendly O 
techniques O 
based O 
on O 
polarity O 
and O 
molecular O 
size O 
. O 

efficient O 
, O 
food O 
- O 
friendly O 
process O 
for O 
the O 
enrichment O 
of O 
macroalgal O 
phlorotannins O 
from O 
solid O 
- O 
liquid O 
extracts O 
( O 
SLE O 
) O 
of O 
three O 
brown O 
macroalgae O 
, O 
namely O 
Fucus O 
spiralis O 
Linnaeus O 
, O 
Pelvetia O 
canaliculata O 
( O 
Linnaeus O 
) O 
Decaisne O 
& O 
Thuret O 
and O 
Ascophyllum O 
nodosum O 
( O 
Linnaeus O 
) O 
Le O 
Jolis O 
, O 
has O 
been O 
demonstrated O 
. O 
The O 
initial O 
utilisation O 
of O 
molecular O 
weight O 
cut O 
- O 
off O 
( O 
MWCO O 
) O 
dialysis O 
generated O 
fractions O 
of O 
low O 
molecular O 
weight O 
( O 
LMW O 
) O 
( O 
< O 
3.5kDa O 
) O 
and O 
of O 
high O 
molecular O 
weight O 
( O 
HMW O 
) O 
( O 
3.5-100kDa O 
and O 
> O 
100kDa O 
) O 
from O 
cold O 
water O 
, O 
hot O 
water O 
and O 
aqueous O 
ethanolic O 
SLE O 
extracts O 
. O 
An O 
enhancement O 
of O 
the O 
total O 
phenolic O 
content O 
( O 
TPC O 
) O 
, O 
radical O 
scavenging O 
abilities O 
( O 
RSA O 
) O 
and O 
ferric B-SYSTEMATIC 
reducing O 
antioxidant O 
power O 
( O 
FRAP O 
) O 
in O 
the O 
HMW O 
fractions O 
of O 
3.5-100kDa O 
and O 
/ O 
or O 
> O 
100kDa O 
from O 
the O 
cold O 
water O 
and O 
aqueous O 
ethanolic O 
extracts O 
was O 
observed O 
. O 
The O 
initial O 
weak O 
TPC O 
, O 
RSA O 
and O 
FRAP O 
observed O 
in O 
the O 
LMW O 
fractions O 
relative O 
to O 
the O 
HMW O 
fractions O 
were O 
substantially O 
enhanced O 
following O 
a O 
reverse O 
- O 
phase O 
flash O 
chromatography O 
fractionation O 
method O 
. O 
Quadrupole O 
time O 
- O 
of O 
- O 
flight O 
mass O 
spectrometry O 
( O 
Q-Tof-MS O 
) O 
suggests O 
that O 
phlorotannins O 
of O 
varying O 
degrees O 
of O 
phloroglucinol B-TRIVIAL 
polymerisation O 
are O 
present O 
in O 
LMW O 
fractions O 
of O 
the O 
three O 
brown O 
macroalgal O 
species O 
. O 
The O 
development O 
of O 
a O 
food O 
- O 
friendly O 
process O 
for O 
the O 
extraction O 
and O 
enrichment O 
of O 
phlorotannins O 
from O 
Irish O 
macroalgae O 
is O 
vital O 
to O 
facilitate O 
the O 
use O 
of O 
this O 
valuable O 
resource O 
in O 
future O 
developments O 
of O 
macroalgal O 
- O 
based O 
functional O 
foods O 
. O 

volatile O 
compounds O 
of O 
wines O 
made O 
from O 
three O 
grape O 
varieties O 
( O 
Monastrell O 
, O 
Cabernet O 
Sauvignon O 
and O 
Syrah O 
) O 
using O 
three O 
pre O 
- O 
fermentation O 
techniques O 
( O 
grape O 
freezing O 
, O 
dry B-TRIVIAL 
- I-TRIVIAL 
ice I-TRIVIAL 
and O 
cold O 
maceration O 
) O 
and O 
a O 
control O 
treatment O 
were O 
measured O 
. O 
The O 
different O 
winemaking O 
practices O 
, O 
which O 
are O 
intended O 
to O 
increase O 
the O 
aromatic O 
properties O 
of O 
wines O 
, O 
produced O 
results O 
that O 
depended O 
on O 
the O 
variety O 
concerned O 
. O 
For O 
example O 
, O 
freezing O 
the O 
Cabernet O 
Sauvignon O 
and O 
Syrah O 
grapes O 
produced O 
different O 
results O 
compared O 
with O 
the O 
respective O 
controls O 
, O 
whereas O 
few O 
changes O 
were O 
found O 
on O 
freezing O 
the O 
Monastrell O 
wine O 
. O 
Differences O 
were O 
significant O 
in O 
the O 
case O 
of O 
some O 
volatile O 
compounds O 
. O 
Linear O 
discriminant O 
analysis O 
allowed O 
some O 
grouping O 
of O 
the O 
varieties O 
at O 
sampling O 
but O 
not O 
of O 
the O 
pre O 
- O 
fermentation O 
techniques O 
used O 
. O 

of O 
chlorophyll B-FAMILY 
oxidation O 
mediated O 
by O 
peroxidative O 
activity O 
in O 
olives O 
( O 
Olea O 
europaea O 
L O 
. O 
) O 
cv O 
. O 
Hojiblanca O 
. O 

oxidation O 
of O 
chlorophyll B-TRIVIAL 
a I-TRIVIAL 
( O 
chl B-ABBREVIATION 
a I-ABBREVIATION 
) O 
catalysed O 
by O 
peroxidase O 
( O 
POD O 
) O 
from O 
mesocarp O 
of O 
the O 
olive O 
fruit O 
( O 
Olea O 
europaea O 
L O 
. O 
, O 
cv O 
Hojiblanca O 
) O 
in O 
the O 
presence O 
of O 
H2O2 B-FORMULA 
and O 
2,4-dichlorophenol B-SYSTEMATIC 
( O 
2,4-DCP B-SYSTEMATIC 
) O 
, O 
is O 
characterised O 
via O 
the O 
individualised O 
quantification O 
of O 
the O 
products O 
of O 
the O 
enzymatic O 
reaction O 
using O 
a O 
new O 
methodology O 
of O 
HPLC-UV O 
spectrometry O 
. O 
This O 
innovation O 
has O 
allowed O 
the O 
discovery O 
that O 
, O 
in O 
addition O 
to O 
13(2) B-SYSTEMATIC 
OH I-SYSTEMATIC 
chl I-SYSTEMATIC 
a I-SYSTEMATIC 
and O 
15(1) B-SYSTEMATIC 
OH I-SYSTEMATIC 
lactone I-SYSTEMATIC 
chl I-SYSTEMATIC 
a I-SYSTEMATIC 
, O 
which O 
are O 
the O 
first O 
products O 
of O 
POD O 
on O 
chl B-ABBREVIATION 
a I-ABBREVIATION 
, O 
the O 
reaction O 
process O 
sequentially O 
creates O 
another O 
series O 
of O 
oxidised O 
chlorophyll B-FAMILY 
derivatives O 
which O 
have O 
not O 
been O 
previously O 
described O 
. O 
Their O 
origins O 
have O 
been O 
linked O 
to O 
POD O 
activity O 
in O 
the O 
presence O 
of O 
2,4-DCP B-SYSTEMATIC 
. O 
Likewise O 
, O 
a O 
study O 
of O 
the O 
effect O 
of O 
the O 
concentration O 
of O 
the O 
various O 
cosubstrates O 
on O 
the O 
POD O 
reaction O 
rate O 
demonstrated O 
that O 
the O 
correct O 
establishment O 
of O 
the O 
relative O 
concentrations O 
of O 
the O 
same O 
( O 
[ O 
H2O2 B-FORMULA 
] O 
/ O 
[ O 
2,4-DCP B-SYSTEMATIC 
] O 
/ O 
[ O 
Chl B-ABBREVIATION 
]=1:3:0.02 O 
) O 
is O 
crucial O 
to O 
explaining O 
inhibition O 
effects O 
by O 
substrates O 
and O 
carrying O 
out O 
optimum O 
measurements O 
. O 
Therefore O 
, O 
new O 
essential O 
parameters O 
for O 
the O 
determination O 
of O 
POD O 
activity O 
on O 
a O 
chlorophyll B-FAMILY 
substrate O 
are O 
established O 
. O 

composition O 
and O 
characterisation O 
of O 
phenolic B-FAMILY 
compounds O 
of O 
Opuntia O 
ficus O 
- O 
indica O 
seeds O 
. O 

seed O 
composition O 
of O 
four O 
varieties O 
of O 
Opuntia O 
ficus O 
- O 
indica O 
growing O 
in O 
Algeria O 
was O 
investigated O 
. O 
Seeds O 
ground O 
into O 
a O 
fine O 
powder O 
were O 
first O 
, O 
subjected O 
to O 
oil O 
extraction O 
and O 
fatty B-FAMILY 
acids I-FAMILY 
analysis O 
. O 
The O 
phenolic B-FAMILY 
compounds O 
were O 
then O 
extracted O 
from O 
the O 
defatted O 
powder O 
of O 
seeds O 
in O 
order O 
to O 
be O 
quantified O 
and O 
characterised O 
by O 
liquid O 
chromatography O 
coupled O 
to O 
mass O 
spectrometry O 
(LC-MS(n)) O 
and O 
to O 
nuclear O 
magnetic O 
resonance O 
( O 
LC-NMR O 
) O 
approaches O 
. O 
In O 
addition O 
, O 
an O 
evaluation O 
of O 
the O 
antioxidant O 
activity O 
of O 
the O 
phenolic O 
extracts O 
was O 
investigated O 
. O 
Gas O 
chromatography O 
analysis O 
of O 
the O 
seed O 
oil O 
showed O 
high O 
percentages O 
of O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
in O 
the O 
four O 
varieties O 
ranging O 
from O 
58% O 
to O 
63% O 
. O 
The O 
phenolic O 
profile O 
of O 
the O 
Opuntia O 
ficus O 
- O 
indica O 
seeds O 
displayed O 
a O 
high O 
complexity O 
, O 
with O 
more O 
than O 
20 O 
compounds O 
detected O 
at O 
330nm O 
after O 
the O 
LC O 
separation O 
. O 
Among O 
them O 
, O 
three O 
isomers O 
of O 
feruloyl-sucrose B-TRIVIAL 
were O 
firmly O 
identified O 
and O 
another O 
was O 
strongly O 
supposed O 
to O 
be O 
a O 
sinapoyl-diglycoside B-FAMILY 
. O 
High O 
correlations O 
were O 
found O 
between O 
phenolic O 
content O 
in O 
the O 
defatted O 
seed O 
extracts O 
and O 
their O 
antioxidant O 
activity O 
. O 
The O 
data O 
indicate O 
that O 
the O 
defatted O 
cactus O 
seed O 
wastes O 
still O 
contain O 
various O 
components O 
that O 
constitute O 
a O 
source O 
for O 
natural O 
foods O 
. O 

by O 
using O 
Aspergillus O 
oryzae O 
has O 
been O 
reported O 
to O 
increase O 
antioxidant O 
activity O 
of O 
soybeans O 
significantly O 
. O 
The O 
effectiveness O 
of O 
the O 
extract O 
from O 
fermented O 
soybeans O 
was O 
studied O 
in O 
3 O 
model O 
foods O 
with O 
different O 
complexities O 
, O 
i.e O 
. O 
, O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
emulsion O 
, O 
sunflower O 
oil O 
emulsions O 
and O 
bulk O 
sunflower O 
oil O 
. O 
For O 
the O 
emulsion O 
systems O 
, O 
oxidation O 
at O 
two O 
different O 
pH O 
values O 
( O 
4.5 O 
and O 
7 O 
) O 
was O 
also O 
compared O 
. O 
A O 
reparameterised O 
logistic O 
equation O 
was O 
used O 
to O 
describe O 
and O 
to O 
predict O 
the O 
experimental O 
data O 
. O 
In O 
general O 
, O 
a O 
good O 
agreement O 
between O 
experimental O 
trends O 
and O 
simulated O 
data O 
from O 
the O 
model O 
was O 
found O 
. O 
A O 
crude O 
antioxidant O 
extract O 
( O 
5mg O 
/ O 
g O 
) O 
showed O 
a O 
comparable O 
antioxidant O 
activity O 
to O 
0.26mg O 
/ O 
g O 
of O 
butylated B-SYSTEMATIC 
hydroxytoluene I-SYSTEMATIC 
( O 
BHT B-ABBREVIATION 
) O 
in O 
the O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
emulsions O 
. O 
The O 
extract O 
exhibited O 
a O 
better O 
capability O 
to O 
retard O 
primary O 
products O 
in O 
the O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
systems O 
than O 
the O 
secondary O 
products O 
. O 
The O 
opposite O 
effect O 
was O 
observed O 
in O 
the O 
bulk O 
sunflower O 
oil O 
and O 
its O 
emulsion O 
systems O 
. O 

dipeptide B-FAMILY 
and O 
an O 
amino B-FAMILY 
acid I-FAMILY 
present O 
in O 
whey O 
protein O 
hydrolysate O 
increase O 
translocation O 
of O 
GLUT-4 O 
to O 
the O 
plasma O 
membrane O 
in O 
Wistar O 
rats O 
. O 

protein O 
hydrolysate O 
( O 
WPH O 
) O 
is O 
capable O 
of O 
increasing O 
muscle O 
glycogen O 
reserves O 
and O 
of O 
concentrating O 
the O 
glucose B-TRIVIAL 
transporter O 
in O 
the O 
plasma O 
membrane O 
( O 
PM O 
) O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
determine O 
which O 
WPH O 
components O 
could O 
modulate O 
translocation O 
of O 
the O 
glucose B-TRIVIAL 
transporter O 
GLUT-4 O 
to O 
the O 
PM O 
of O 
animal O 
skeletal O 
muscle O 
. O 
Forty O 
- O 
nine O 
animals O 
were O 
divided O 
into O 
7 O 
groups O 
( O 
n=7 O 
) O 
and O 
received O 
by O 
oral O 
gavage O 
30% O 
glucose B-TRIVIAL 
plus O 
0.55g O 
/ O 
kg O 
body O 
mass O 
of O 
the O 
following O 
WPH O 
components O 
: O 
( O 
a O 
) O 
control O 
; O 
( O 
b O 
) O 
WPH O 
; O 
( O 
c O 
) O 
l-isoleucine B-TRIVIAL 
; O 
( O 
d O 
) O 
l-leucine B-TRIVIAL 
; O 
( O 
e O 
) O 
l-leucine B-TRIVIAL 
plus O 
l-isoleucine B-TRIVIAL 
; O 
( O 
f O 
) O 
l-isoleucyl-l-leucine B-TRIVIAL 
dipeptide I-TRIVIAL 
; O 
( O 
g O 
) O 
l-leucyl-l-isoleucine B-TRIVIAL 
dipeptide I-TRIVIAL 
. O 
After O 
receiving O 
these O 
solutions O 
, O 
the O 
animals O 
were O 
sacrificed O 
and O 
the O 
GLUT-4 O 
analysed O 
by O 
western O 
blot O 
. O 
Additionally O 
, O 
glycogen O 
, O 
glycaemia O 
, O 
insulin O 
and O 
free O 
amino B-FAMILY 
acids I-FAMILY 
were O 
also O 
determined O 
by O 
standard O 
methods O 
. O 
Of O 
the O 
WPH O 
components O 
tested O 
, O 
the O 
amino O 
acid O 
l-isoleucine B-TRIVIAL 
and O 
the O 
peptide O 
l-leucyl-l-isoleucine B-TRIVIAL 
showed O 
greater O 
efficiency O 
in O 
translocating O 
GLUT-4 O 
to O 
the O 
PM O 
and O 
of O 
increasing O 
glucose B-TRIVIAL 
capture O 
by O 
skeletal O 
muscle O 
. O 

, O 
free O 
radical O 
scavenging O 
and O 
liver O 
protective O 
effects O 
of O 
friedelin B-TRIVIAL 
isolated O 
from O 
Azima O 
tetracantha O 
Lam O 
. O 
leaves O 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
the O 
antioxidant O 
, O 
free O 
radical O 
scavenging O 
and O 
liver O 
protective O 
effects O 
of O 
friedelin B-TRIVIAL 
isolated O 
from O 
Azima O 
tetracantha O 
Lam O 
. O 
leaves O 
. O 
In O 
in O 
vitro O 
antioxidant O 
study O 
, O 
the O 
free O 
radical O 
scavenging O 
effect O 
of O 
friedelin B-TRIVIAL 
on O 
2,2-diphenyl-picrylhydrazyl B-SYSTEMATIC 
( O 
DPPH B-ABBREVIATION 
) O 
, O 
hydroxyl B-SYSTEMATIC 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
superoxide B-TRIVIAL 
radicals O 
were O 
evaluated O 
. O 
Friedelin B-TRIVIAL 
showed O 
very O 
good O 
scavenging O 
effect O 
on O 
DPPH B-ABBREVIATION 
( O 
IC50 O 
21.1mM O 
) O 
, O 
hydroxyl B-SYSTEMATIC 
( O 
IC50 O 
19.8mM O 
) O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
IC50 O 
22.1mM O 
) O 
and O 
superoxide B-TRIVIAL 
( O 
IC50 O 
21.9mM O 
) O 
radicals O 
. O 
Friedelin B-TRIVIAL 
also O 
showed O 
strong O 
suppressive O 
effect O 
on O 
lipid O 
peroxidation O 
. O 
In O 
in O 
vivo O 
antioxidant O 
study O 
, O 
CCl4 B-FORMULA 
induced O 
oxidative O 
stress O 
on O 
rats O 
produced O 
significant O 
increase O 
in O 
serum O 
glutamate B-TRIVIAL 
oxaloacetate B-SYSTEMATIC 
transaminase O 
( O 
SGOT O 
) O 
, O 
serum O 
glutamate B-TRIVIAL 
pyruvate B-TRIVIAL 
transaminase O 
( O 
SGPT O 
) O 
and O 
lactate B-FAMILY 
dehydrogenase O 
( O 
LDH O 
) O 
levels O 
along O 
with O 
reduction O 
in O 
liver O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
catalase O 
( O 
CAT O 
) O 
, O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
levels O 
. O 
Pre O 
- O 
treatment O 
of O 
rats O 
with O 
friedelin B-TRIVIAL 
at O 
40mg O 
/ O 
kg O 
for O 
7days O 
restored O 
these O 
levels O 
to O 
normality O 
and O 
showed O 
liver O 
protection O 
, O 
comparable O 
to O 
the O 
standard O 
, O 
silymarin O 
( O 
25mg O 
/ O 
kg O 
) O 
. O 
These O 
results O 
clearly O 
demonstrated O 
that O 
friedelin B-TRIVIAL 
possessed O 
marked O 
antioxidant O 
and O 
liver O 
protective O 
effects O 
. O 

vitro O 
bioavailability O 
of O 
total O 
selenium B-SYSTEMATIC 
and O 
selenium B-SYSTEMATIC 
species O 
from O 
seafood O 
. O 

vitro O 
bioavailability O 
of O 
total O 
selenium B-SYSTEMATIC 
and O 
selenium B-SYSTEMATIC 
species O 
from O 
different O 
raw O 
seafood O 
has O 
been O 
assessed O 
by O 
using O 
a O 
simulated O 
gastric O 
and O 
intestinal O 
digestion O 
/ O 
dialysis O 
method O 
. O 
Inductively O 
coupled O 
plasma O 
- O 
mass O 
spectrometry O 
( O 
ICP-MS O 
) O 
was O 
used O 
to O 
assess O 
total O 
selenium B-SYSTEMATIC 
contents O 
after O 
a O 
microwave O 
assisted O 
acid O 
digestion O 
, O 
and O 
also O 
to O 
quantify O 
total O 
selenium B-SYSTEMATIC 
in O 
the O 
dialyzable O 
and O 
non-dialyzable O 
fractions O 
. O 
Selenium B-SYSTEMATIC 
speciation O 
in O 
the O 
dialyzates O 
was O 
assessed O 
by O 
high O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
coupled O 
with O 
ICP-MS O 
detection O 
. O 
Major O 
Se B-FORMULA 
species O 
( O 
selenium B-SYSTEMATIC 
methionine I-SYSTEMATIC 
and O 
oxidized B-SYSTEMATIC 
selenium I-SYSTEMATIC 
methionine I-SYSTEMATIC 
) O 
from O 
dialyzate O 
were O 
identified O 
and O 
characterized O 
by O 
HPLC O 
coupled O 
to O 
mass O 
spectrometry O 
( O 
HPLC-MS O 
) O 
. O 
Selenocystine B-SYSTEMATIC 
was O 
detected O 
at O 
low O 
concentrations O 
while O 
Se B-FORMULA 
- O 
(Methyl)selenocysteine B-SYSTEMATIC 
and O 
inorganic O 
selenium B-SYSTEMATIC 
species O 
( O 
selenite B-TRIVIAL 
and O 
selenate B-SYSTEMATIC 
) O 
were O 
not O 
detected O 
in O 
the O 
dialyzate O 
. O 
Low O 
bioavailability O 
percentages O 
for O 
total O 
selenium B-SYSTEMATIC 
( O 
6.69±3.39 O 
and O 
5.45±2.44% O 
for O 
fish O 
and O 
mollusk O 
samples O 
, O 
respectively O 
) O 
were O 
obtained O 
. O 
Similar O 
bioavailability O 
percentages O 
was O 
achieved O 
for O 
total O 
selenium B-SYSTEMATIC 
as O 
a O 
sum O 
of O 
selenium B-SYSTEMATIC 
species O 
( O 
selenocystine B-SYSTEMATIC 
plus O 
oxidized B-SYSTEMATIC 
selenium I-SYSTEMATIC 
methionine I-SYSTEMATIC 
and O 
selenium B-SYSTEMATIC 
methionine I-SYSTEMATIC 
, O 
mainly O 
) O 
. O 
HPLC-MS O 
data O 
confirmed O 
SeMet B-FORMULA 
oxidation O 
during O 
the O 
in O 
vitro O 
procedure O 
. O 

' O 
Pinot O 
noir O 
' O 
grape O 
anthocyanin B-FAMILY 
enhancement O 
by O 
early O 
leaf O 
removal O 
. O 

cluster O 
zone O 
leaf O 
removal O 
of O 
' O 
Pinot O 
noir O 
' O 
was O 
initiated O 
at O 
three O 
separate O 
pre-véraison O 
growth O 
stages O 
( O 
bloom O 
, O 
grain O 
- O 
pea O 
size O 
, O 
and O 
bunch O 
closure O 
) O 
and O 
maintained O 
leaf O 
free O 
until O 
harvest O 
, O 
for O 
four O 
growing O 
seasons O 
( O 
2008-2011 O 
) O 
. O 
Fruit O 
anthocyanin B-FAMILY 
composition O 
was O 
examined O 
at O 
harvest O 
for O 
the O 
last O 
two O 
vintages O 
( O 
2010 O 
and O 
2011 O 
) O 
and O 
compared O 
to O 
a O 
control O 
- O 
no O 
cluster O 
zone O 
leaf O 
removal O 
. O 
Experiments O 
were O 
conducted O 
at O 
two O 
commercially O 
operating O 
Oregon O 
vineyards O 
( O 
site O 
A=420 O 
rootstock O 
/ O 
' O 
Pinot O 
noir O 
' O 
115 O 
scion O 
and O 
site O 
B=3309C O 
rootstock O 
/ O 
' O 
Pinot O 
noir O 
' O 
777 O 
scion O 
) O 
. O 
All O 
clusters O 
contained O 
the O 
five O 
anthocyanins B-FAMILY 
typically O 
found O 
in O 
' O 
Pinot O 
noir O 
' O 
. O 
Leaf O 
removal O 
at O 
bloom O 
and O 
maintained O 
until O 
harvest O 
produced O 
maximum O 
anthocyanin B-FAMILY 
accumulation O 
in O 
' O 
Pinot O 
noir O 
' O 
grapes O 
( O 
site O 
A=85.24mg O 
/ O 
100g O 
and O 
site O 
B=125.06mg O 
/ O 
100g O 
) O 
, O 
compared O 
to O 
no O 
leaf O 
removal O 
( O 
control O 
; O 
site O 
A=57.91mg O 
/ O 
100g O 
and O 
site O 
B=97.56mg O 
/ O 
100g O 
) O 
. O 
Even O 
leaf O 
removal O 
at O 
bunch O 
closure O 
( O 
last O 
leaf O 
removal O 
initiation O 
period O 
) O 
increased O 
grape O 
anthocyanin B-FAMILY 
( O 
site O 
A=73.22mg O 
/ O 
100g O 
and O 
site O 
B=118.93mg O 
/ O 
100g O 
) O 
compared O 
to O 
control O 
, O 
but O 
total O 
anthocyanins B-FAMILY 
were O 
lower O 
than O 
grapes O 
from O 
bloom O 
leaf O 
removal O 
( O 
first O 
time O 
period O 
) O 
. O 
Results O 
differed O 
slightly O 
by O 
vineyard O 
site O 
and O 
rootstock O 
/ O 
scion O 
combination O 
. O 

effects O 
of O 
myricetin B-TRIVIAL 
on O 
mammalian O 
DNA O 
polymerase O 
, O 
topoisomerase O 
and O 
human O 
cancer O 
cell O 
proliferation O 
. O 

this O 
study O 
, O 
the O 
inhibitory O 
activities O 
against O 
mammalian O 
DNA O 
polymerases O 
( O 
pols O 
) O 
of O 
16 O 
major O 
bioflavonoids B-FAMILY 
were O 
investigated O 
. O 
Myricetin B-TRIVIAL 
( O 
3,3',4',5,5',7-hexahydroxyflavone B-SYSTEMATIC 
) O 
was O 
the O 
most O 
potent O 
inhibitor O 
of O 
pols O 
amongst O 
the O 
compounds O 
tested O 
, O 
with O 
IC50 O 
values O 
of O 
21.3-40.9μM O 
. O 
This O 
compound O 
did O 
not O 
affect O 
the O 
activities O 
of O 
plant O 
( O 
cauliflower O 
) O 
pol O 
α O 
or O 
prokaryotic O 
pols O 
. O 
Myricetin B-TRIVIAL 
also O 
inhibited O 
human O 
DNA O 
topoisomerase O 
II O 
( O 
topo O 
II O 
) O 
activity O 
with O 
an O 
IC50 O 
value O 
of O 
27.5μM O 
, O 
but O 
did O 
not O 
inhibit O 
the O 
activities O 
of O 
other O 
DNA O 
metabolic O 
enzymes O 
tested O 
. O 
Myricetin B-TRIVIAL 
also O 
did O 
not O 
influence O 
the O 
direct O 
binding O 
to O 
double O 
stranded O 
DNA O 
as O 
determined O 
by O 
thermal O 
transition O 
analysis O 
. O 
It O 
was O 
found O 
to O 
prevent O 
the O 
proliferation O 
of O 
human O 
colon O 
HCT116 O 
carcinoma O 
cells O 
with O 
an O 
LD50 O 
of O 
28.2μM O 
, O 
halt O 
the O 
cell O 
cycle O 
in O 
G2 O 
/ O 
M O 
phase O 
, O 
and O 
induce O 
apoptosis O 
. O 
These O 
results O 
suggest O 
that O 
the O 
decrease O 
of O 
proliferation O 
may O 
be O 
a O 
result O 
of O 
the O 
inhibition O 
of O 
cellular O 
topoisomerase O 
( O 
topo O 
) O 
II O 
rather O 
than O 
pols O 
. O 

experimental O 
investigation O 
was O 
performed O 
on O 
blend O 
extra O 
virgin O 
olive O 
oils O 
( O 
EVOOs O 
) O 
from O 
different O 
cultivars O 
and O 
EVOO O 
from O 
different O 
olive O 
monovarieties O 
( O 
Coratina O 
, O 
Leccino O 
, O 
Maiatica O 
, O 
Ogliarola O 
) O 
with O 
the O 
aim O 
to O 
evaluate O 
the O 
possibility O 
of O 
estimating O 
the O 
perceived O 
bitterness O 
intensity O 
by O 
using O 
chemical O 
indices O 
, O 
such O 
as O 
the O 
total O 
phenol B-SYSTEMATIC 
content O 
and O 
the O 
compounds O 
responsible O 
for O 
oil O 
bitterness O 
measured O 
spectrophotometrically O 
at O 
225nm O 
( O 
K225 O 
value O 
) O 
, O 
as O 
bitterness O 
predictors O 
in O 
different O 
EVOO O 
. O 
Therefore O 
, O 
a O 
bitterness O 
predictive O 
model O 
, O 
based O 
on O 
the O 
relationship O 
between O 
the O 
perceived O 
bitterness O 
intensity O 
of O 
the O 
selected O 
stimuli O 
and O 
the O 
chosen O 
chemicals O 
parameters O 
has O 
been O 
built O 
and O 
validated O 
. O 
The O 
results O 
indicated O 
that O 
the O 
oil O 
bitterness O 
intensity O 
could O 
be O 
satisfactorily O 
predicted O 
by O 
using O 
the O 
K225 O 
values O 
of O 
oil O 
samples O 
. O 

aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PAH B-ABBREVIATION 
) O 
and O 
phenolic B-FAMILY 
substances O 
in O 
meat O 
products O 
smoked O 
with O 
different O 
types O 
of O 
wood O 
and O 
smoking O 
spices O 
. O 

contents O 
of O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
15 O 
+ O 
1 O 
EU O 
PAH B-ABBREVIATION 
) O 
and O 
phenolic B-FAMILY 
substances O 
( O 
guaiacol B-TRIVIAL 
, O 
4-methylguaiacol B-SYSTEMATIC 
, O 
syringol B-TRIVIAL 
, O 
eugenol B-TRIVIAL 
, O 
and O 
trans-isoeugenol B-TRIVIAL 
) O 
were O 
investigated O 
in O 
smouldering O 
- O 
smoked O 
Frankfurters O 
and O 
mini O 
- O 
salamis O 
. O 
For O 
the O 
51 O 
smoking O 
experiments O 
wood O 
chips O 
of O 
oak O 
, O 
poplar O 
, O 
hickory O 
, O 
spruce O 
, O 
fir O 
, O 
alder O 
, O 
beech O 
, O 
and O 
beech O 
with O 
an O 
apple O 
- O 
smoking O 
spice O 
mix O 
, O 
cherry O 
- O 
smoking O 
spice O 
mix O 
, O 
and O 
a O 
mix O 
of O 
juniper O 
berries O 
and O 
bay O 
leaves O 
were O 
tested O 
. O 
The O 
use O 
of O 
poplar O 
and O 
hickory O 
led O 
to O 
a O 
decrease O 
in O 
the O 
PAH B-ABBREVIATION 
contents O 
in O 
the O 
range O 
of O 
35-55% O 
compared O 
to O 
the O 
commonly O 
used O 
beech O 
wood O 
. O 
Higher O 
PAH B-ABBREVIATION 
contents O 
by O 
using O 
softwood O 
were O 
not O 
observed O 
. O 
The O 
use O 
of O 
the O 
rapidly O 
growing O 
poplar O 
seems O 
to O 
be O 
a O 
reasonable O 
approach O 
for O 
reducing O 
the O 
PAH B-ABBREVIATION 
contents O 
in O 
smoked O 
meat O 
products O 
. O 
Furthermore O 
, O 
the O 
sum O 
contents O 
of O 
the O 
five O 
phenolic B-FAMILY 
substances O 
in O 
sausages O 
smoked O 
with O 
poplar O 
were O 
higher O 
, O 
or O 
only O 
slightly O 
lower O 
, O 
when O 
compared O 
to O 
the O 
use O 
of O 
beech O 
. O 

this O 
study O 
, O 
the O 
effects O 
of O 
a O 
water O 
extract O 
of O 
Flos O 
Inulae O 
( O 
WFI O 
) O 
on O 
antioxidant O 
, O 
antimutation O 
and O 
antityrosinase O 
were O 
investigated O 
. O 
The O 
results O 
showed O 
that O 
WFI O 
inhibited O 
the O 
mutagenicity O 
of O 
2-aminoanthracene B-SYSTEMATIC 
( O 
2-AA B-SYSTEMATIC 
) O 
, O 
an O 
indirect O 
mutagen O 
; O 
and O 
4-nitroquinoline-N-oxide B-SYSTEMATIC 
( O 
4-NQO B-SYSTEMATIC 
) O 
, O 
a O 
direct O 
mutagen O 
toward O 
Salmonella O 
typhimurium O 
TA O 
98 O 
and O 
TA O 
100 O 
. O 
In O 
addition O 
, O 
WFI O 
, O 
in O 
the O 
range O 
of O 
0.2-0.6mg O 
/ O 
ml O 
, O 
showed O 
radical O 
scavenging O 
, O 
reducing O 
activities O 
and O 
chelating O 
activity O 
as O 
well O 
as O 
decreased O 
lipid O 
oxidative O 
damage O 
. O 
Meanwhile O 
, O 
WFI O 
also O 
inhibited O 
tyrosinase O 
activity O 
and O 
NO B-FORMULA 
generation O 
in O 
lipopolysaccharide O 
( O 
LPS O 
) O 
stimulated O 
macrophages O 
. O 
High O 
performance O 
liquid O 
chromatography O 
analysis O 
suggests O 
that O 
the O 
major O 
phenolic B-FAMILY 
constituents O 
in O 
WFI O 
are O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
, O 
rutin B-TRIVIAL 
, O 
quercetin B-TRIVIAL 
, O 
luteolin B-TRIVIAL 
and O 
kaempferol B-TRIVIAL 
. O 
These O 
bioactive O 
components O 
may O 
contribute O 
to O 
the O 
protective O 
effects O 
of O 
WFI O 
. O 
The O 
obtained O 
data O 
suggests O 
that O 
Flos O 
Inulae O 
can O 
be O 
applied O 
to O 
antimutation O 
, O 
antityrosinase O 
and O 
anti-inflammation O 
. O 

postharvest O 
dehydration O 
is O 
one O 
of O 
the O 
most O 
important O 
steps O 
in O 
obtaining O 
a O 
high O 
quality O 
naturally O 
sweet O 
wine O 
and O 
it O 
can O 
play O 
an O 
important O 
role O 
in O 
modulating O 
the O 
production O 
and O 
the O 
release O 
of O 
volatile O 
compounds O 
. O 
However O 
, O 
only O 
a O 
few O 
studies O 
have O 
analysed O 
the O 
changes O 
in O 
the O 
free O 
and O 
bound O 
volatile O 
compounds O 
of O 
grapes O 
throughout O 
the O 
process O 
. O 
In O 
this O 
work O 
, O 
GC-MS O 
was O 
applied O 
to O 
determine O 
the O 
aromatic O 
composition O 
of O 
Garnacha O 
Tintorera O 
grapes O 
subjected O 
to O 
off O 
- O 
vine O 
dehydration O 
or O 
raisining O 
at O 
several O 
points O 
during O 
the O 
process O 
. O 
The O 
total O 
water O 
loss O 
in O 
83days O 
was O 
about O 
62% O 
and O 
the O 
sugar B-FAMILY 
concentration O 
rose O 
from O 
225 O 
to O 
464g O 
/ O 
L O 
. O 
Within O 
the O 
free O 
volatile O 
compounds O 
, O 
isoamyl B-FAMILY 
alcohols I-FAMILY 
, O 
benzaldehyde B-SYSTEMATIC 
and O 
guaiacol B-TRIVIAL 
registered O 
the O 
largest O 
increase O 
above O 
the O 
concentration O 
effect O 
due O 
to O 
water O 
loss O 
; O 
while O 
within O 
the O 
bound O 
volatile O 
compounds O 
were O 
isoamyl B-FAMILY 
alcohols I-FAMILY 
, O 
ethyl B-SYSTEMATIC 
vanillate I-SYSTEMATIC 
and O 
benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
The O 
aromatic O 
profile O 
of O 
the O 
raisins O 
obtained O 
were O 
mainly O 
caramelised O 
, O 
floral O 
, O 
phenolic B-FAMILY 
and O 
burned O 
. O 

this O 
work O 
, O 
liquid O 
chromatography O 
coupled O 
to O 
electrospray O 
time O 
- O 
of O 
- O 
flight O 
mass O 
spectrometry O 
( O 
LC-ESI-TOF-MS O 
) O 
has O 
been O 
applied O 
to O 
screen O 
bioactive O 
metabolites O 
in O 
shoot O 
extract O 
of O 
the O 
medicinal O 
halophyte O 
Zygophyllum O 
album O 
. O 
Among O 
10 O 
compounds O 
identified O 
( O 
saponins B-FAMILY 
, O 
flavonoids B-FAMILY 
and O 
sterols B-FAMILY 
) O 
five O 
were O 
reported O 
for O 
the O 
first O 
time O 
in O 
Z O 
. O 
album O 
. O 
Furthermore O 
, O 
novel O 
biological O 
activities O 
of O 
hexane B-SYSTEMATIC 
, O 
dichloromethane B-SYSTEMATIC 
and O 
methanolic O 
extracts O 
were O 
assessed O 
. O 
Results O 
showed O 
that O 
methanolic O 
extract O 
exhibit O 
the O 
highest O 
antioxidant O 
activity O 
using O 
in O 
vitro O 
ORAC O 
test O 
and O 
anti-inflammatory O 
activity O 
, O 
inhibiting O 
by O 
84.8% O 
NO B-FORMULA 
release O 
in O 
RAW264.7 O 
macrophages O 
. O 
However O 
, O 
dichloromethane B-SYSTEMATIC 
extract O 
proved O 
the O 
utmost O 
antioxidant O 
activity O 
in O 
cell O 
( O 
WS1 O 
) O 
based O 
- O 
assay O 
( O 
IC50=57μg O 
/ O 
ml O 
) O 
and O 
interesting O 
anticancer O 
capacity O 
against O 
human O 
lung O 
carcinoma O 
( O 
A-549 O 
) O 
and O 
colon O 
adenocarcinoma O 
( O 
DLD-1 O 
) O 
cells O 
( O 
IC50=37 O 
and O 
48μg O 
/ O 
ml O 
, O 
respectively O 
) O 
. O 
These O 
findings O 
can O 
be O 
attributed O 
to O 
the O 
presence O 
of O 
triterpenes B-FAMILY 
, O 
flavonoids B-FAMILY 
and O 
sterols B-FAMILY 
in O 
Z O 
. O 
album O 
, O 
which O 
are O 
widely O 
known O 
as O 
powerful O 
antioxidants O 
and O 
used O 
in O 
various O 
industrial O 
fields O 
. O 

of O 
complex O 
carbohydrate B-FAMILY 
: O 
Immobilization O 
of O 
pectinase O 
from O 
Bacillus O 
licheniformis O 
KIBGE-IB21 O 
using O 
calcium B-SYSTEMATIC 
alginate O 
as O 
a O 
support O 
. O 

are O 
heterogeneous O 
group O 
of O 
enzymes O 
that O 
catalyse O 
the O 
hydrolysis O 
of O 
pectin O 
substances O 
which O 
is O 
responsible O 
for O 
the O 
turbidity O 
and O 
undesirable O 
cloudiness O 
in O 
fruits O 
juices O 
. O 
In O 
current O 
study O 
, O 
partially O 
purified O 
pectinase O 
from O 
Bacillus O 
licheniformis O 
KIBGE-IB21 O 
was O 
immobilized O 
in O 
calcium B-SYSTEMATIC 
alginate O 
beads O 
. O 
The O 
effect O 
of O 
sodium B-SYSTEMATIC 
alginate O 
and O 
calcium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
concentration O 
on O 
immobilization O 
was O 
studied O 
and O 
it O 
was O 
found O 
that O 
the O 
optimal O 
sodium B-SYSTEMATIC 
alginate O 
and O 
calcium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
concentration O 
was O 
3.0% O 
and O 
0.2M O 
, O 
respectively O 
. O 
It O 
was O 
found O 
that O 
immobilization O 
increases O 
the O 
optimal O 
reaction O 
time O 
for O 
pectin O 
degradation O 
from O 
5 O 
to O 
10min O 
and O 
temperature O 
from O 
45 O 
to O 
55°C O 
, O 
whereas O 
, O 
the O 
optimal O 
pH O 
remained O 
same O 
with O 
reference O 
to O 
free O 
enzyme O 
. O 
Thermal O 
stability O 
of O 
enzyme O 
increased O 
after O 
immobilization O 
and O 
immobilized O 
pectinase O 
retained O 
more O 
than O 
80% O 
of O 
its O 
initial O 
activity O 
after O 
5days O 
at O 
30°C O 
as O 
compared O 
with O 
free O 
enzyme O 
which O 
showed O 
only O 
30% O 
of O 
residual O 
activity O 
. O 
The O 
immobilized O 
enzyme O 
also O 
exhibited O 
good O 
operational O 
stability O 
and O 
65% O 
of O 
its O 
initial O 
activity O 
was O 
observed O 
during O 
third O 
cycle O 
. O 
In O 
term O 
of O 
pectinase O 
immobilization O 
efficiency O 
and O 
stability O 
, O 
this O 
calcium B-SYSTEMATIC 
alginate O 
beads O 
approach O 
seemed O 
to O 
permit O 
good O 
results O 
and O 
can O 
be O 
used O 
to O 
make O 
a O 
bioreactor O 
for O 
various O 
applications O 
in O 
food O 
industries O 
. O 

of O 
pH O 
, O 
metal O 
chelator O 
, O 
free O 
radical O 
scavenger O 
and O 
interfacial O 
characteristics O 
on O 
the O 
oxidative O 
stability O 
of O 
β-carotene B-TRIVIAL 
in O 
conjugated O 
whey O 
protein O 
- O 
pectin O 
stabilised O 
emulsion O 
. O 

influence O 
of O 
whey O 
protein O 
isolate O 
(WPI)-beet O 
pectin O 
conjugates O 
formed O 
by O 
dry O 
- O 
heating O 
on O 
the O 
oxidative O 
stability O 
of O 
β-carotene B-TRIVIAL 
in O 
O O 
/ O 
W O 
emulsions O 
was O 
studied O 
. O 
It O 
was O 
mainly O 
focused O 
on O 
the O 
influence O 
of O 
pH O 
, O 
metal O 
chelator O 
, O 
free O 
radical O 
scavenger O 
and O 
interfacial O 
characteristics O 
on O 
the O 
degradation O 
of O 
β-carotene B-TRIVIAL 
in O 
the O 
emulsion O 
stabilised O 
by O 
conjugate O 
. O 
The O 
conjugate O 
increased O 
the O 
oxidative O 
stability O 
of O 
β-carotene B-TRIVIAL 
in O 
the O 
emulsion O 
as O 
compared O 
to O 
their O 
unconjugated O 
mixture O 
at O 
pH O 
7 O 
. O 
The O 
desferoxamine B-TRIVIAL 
retarded O 
β-carotene B-TRIVIAL 
degradation O 
at O 
pH O 
4 O 
more O 
effectively O 
than O 
pH O 
7 O 
and O 
more O 
effectively O 
in O 
the O 
emulsion O 
with O 
the O 
conjugate O 
than O 
the O 
unconjugated O 
mixture O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
addition O 
of O 
200mg O 
/ O 
kg O 
α-tocopherol B-TRIVIAL 
significantly O 
improved O 
the O 
stability O 
of O 
β-carotene B-TRIVIAL 
in O 
the O 
conjugate O 
stabilised O 
emulsion O 
. O 
The O 
emulsions O 
were O 
washed O 
to O 
remove O 
conjugate O 
not O 
absorbed O 
to O 
the O 
emulsion O 
droplet O 
interface O 
, O 
indicating O 
that O 
unabsorbed O 
emulsifiers O 
could O 
protect O 
β-carotene B-TRIVIAL 
. O 
It O 
suggested O 
that O 
WPI-pectin O 
conjugate O 
could O 
be O 
used O 
to O 
protect O 
bioactive O 
lipids O 
in O 
emulsions O 
. O 

( O 
PLs O 
) O 
are O 
a O 
major O 
class O 
of O 
lipid O 
in O 
rice O 
grain O 
. O 
Although O 
PLs O 
are O 
only O 
a O 
minor O 
nutrient O 
compared O 
to O 
starch O 
and O 
protein O 
, O 
they O 
may O 
have O 
both O 
nutritional O 
and O 
functional O 
significance O 
. O 
We O 
have O 
systemically O 
reviewed O 
the O 
literature O 
on O 
the O 
class O 
, O 
distribution O 
and O 
variation O 
of O 
PLs O 
in O 
rice O 
, O 
their O 
relation O 
to O 
rice O 
end O 
- O 
use O 
quality O 
and O 
human O 
health O 
, O 
as O 
well O 
as O 
available O 
methods O 
for O 
analytical O 
profiling O 
. O 
Phosphatidylcholine B-FAMILY 
( O 
PC O 
) O 
, O 
phosphatidylethanolamine B-SYSTEMATIC 
( O 
PE O 
) O 
, O 
phosphatidylinositol B-TRIVIAL 
( O 
PI O 
) O 
and O 
their O 
lyso O 
forms O 
are O 
the O 
major O 
PLs O 
in O 
rice O 
. O 
The O 
deterioration O 
of O 
PC O 
in O 
rice O 
bran O 
during O 
storage O 
was O 
considered O 
as O 
a O 
trigger O 
for O 
the O 
degradation O 
of O 
rice O 
lipids O 
with O 
associated O 
rancid O 
flavour O 
in O 
paddy O 
and O 
brown O 
rice O 
. O 
The O 
lyso O 
forms O 
in O 
rice O 
endosperm O 
represent O 
the O 
major O 
starch O 
lipid O 
, O 
and O 
may O 
form O 
inclusion O 
complexes O 
with O 
amylose O 
, O 
affecting O 
the O 
physicochemical O 
properties O 
and O 
digestibility O 
of O 
starch O 
, O 
and O 
hence O 
its O 
cooking O 
and O 
eating O 
quality O 
. O 
Dietary O 
PLs O 
have O 
a O 
positive O 
impact O 
on O 
several O 
human O 
diseases O 
and O 
reduce O 
the O 
side-effects O 
of O 
some O 
drugs O 
. O 
As O 
rice O 
has O 
long O 
been O 
consumed O 
as O 
a O 
staple O 
food O 
in O 
many O 
Asian O 
countries O 
, O 
rice O 
PLs O 
may O 
have O 
significant O 
health O 
benefits O 
for O 
those O 
populations O 
. O 
Rice O 
PLs O 
may O 
be O 
influenced O 
both O 
by O 
genetic O 
( O 
G O 
) O 
and O 
environmental O 
( O 
E O 
) O 
factors O 
, O 
and O 
resolving O 
G×E O 
interactions O 
may O 
allow O 
future O 
exploitation O 
of O 
PL O 
composition O 
and O 
content O 
, O 
thus O 
boosting O 
rice O 
eating O 
quality O 
and O 
health O 
benefits O 
for O 
consumers O 
. O 
We O 
have O 
identified O 
and O 
summarised O 
the O 
different O 
methods O 
used O 
for O 
rice O 
PL O 
analysis O 
, O 
and O 
discussed O 
the O 
consequences O 
of O 
variation O 
in O 
reported O 
PL O 
values O 
due O 
to O 
inconsistencies O 
between O 
methods O 
. O 
This O 
review O 
enhances O 
the O 
understanding O 
of O 
the O 
nature O 
and O 
importance O 
of O 
PLs O 
in O 
rice O 
and O 
outlines O 
potential O 
approaches O 
for O 
manipulating O 
PLs O 
to O 
improve O 
the O 
quality O 
of O 
rice O 
grain O 
and O 
other O 
cereals O 
. O 

series O 
of O 
xanthans O 
containing O 
different O 
levels O 
of O 
the O 
charged O 
group O 
pyruvate B-TRIVIAL 
has O 
been O 
examined O 
. O 
The O 
X-ray O 
diffraction O 
patterns O 
of O 
the O 
powders O 
of O 
these O 
materials O 
had O 
different O 
levels O 
of O 
a O 
sharp O 
pattern O 
superimposed O 
on O 
an O 
amorphous O 
background O 
. O 
As O 
the O 
moisture O 
content O 
increased O 
so O 
the O 
intensity O 
of O 
the O 
sharp O 
pattern O 
increased O 
up O 
to O 
a O 
level O 
between O 
20% O 
and O 
40% O 
moisture O 
content O 
where O 
the O 
sharp O 
pattern O 
disappeared O 
. O 
X-ray O 
diffraction O 
pattern O 
identification O 
software O 
and O 
an O 
inorganic O 
X-ray O 
diffraction O 
database O 
showed O 
the O 
origin O 
of O 
the O 
sharp O 
peaks O 
to O 
be O 
due O 
to O 
sodium B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
polymorphs O 
. O 
The O 
behaviour O 
of O 
the O 
xanthans O 
was O 
thought O 
to O 
be O 
due O 
to O 
the O 
differences O 
in O 
charge O 
on O 
the O 
molecule O 
; O 
however O 
, O 
the O 
increase O 
in O 
the O 
crystalline O 
component O 
observed O 
with O 
increased O 
amounts O 
of O 
water O 
was O 
unexpected O 
. O 
The O 
possibility O 
of O 
the O 
drying O 
of O 
samples O 
was O 
considered O 
but O 
the O 
interplay O 
between O 
ions O 
, O 
the O 
charged O 
polymer O 
and O 
the O 
water O 
present O 
was O 
considered O 
necessary O 
to O 
more O 
closely O 
describe O 
the O 
results O 
. O 

of O 
pectin O 
type O 
on O 
the O 
storage O 
stability O 
of O 
black O 
currant O 
( O 
Ribes O 
nigrum O 
L O 
. O 
) O 
anthocyanins B-FAMILY 
in O 
pectic O 
model O 
solutions O 
. O 

effects O 
of O 
different O 
pectins O 
on O 
the O 
stabilisation O 
of O 
black O 
currant O 
anthocyanins B-FAMILY 
in O 
viscous O 
model O 
solutions O 
at O 
pH O 
3 O 
were O 
investigated O 
. O 
For O 
this O 
purpose O 
, O 
low O 
esterified O 
amidated O 
( O 
AM O 
) O 
, O 
low O 
( O 
LM O 
) O 
and O 
high O 
( O 
HM O 
) O 
methoxylated O 
citrus O 
and O 
apple O 
pectins O 
and O 
a O 
sugar O 
beet O 
pectin O 
were O 
added O 
to O 
a O 
purified O 
anthocyanin B-FAMILY 
extract O 
( O 
ACN B-ABBREVIATION 
-E O 
) O 
and O 
to O 
an O 
extract O 
containing O 
anthocyanins B-FAMILY 
and O 
non- O 
anthocyanin B-FAMILY 
phenolics I-FAMILY 
( O 
PP-E O 
) O 
. O 
Model O 
systems O 
were O 
stored O 
at O 
20±0.5°C O 
in O 
the O 
dark O 
. O 
Anthocyanin B-FAMILY 
contents O 
were O 
monitored O 
by O 
HPLC O 
analysis O 
over O 
a O 
period O 
of O 
18weeks O 
, O 
and O 
half O 
- O 
life O 
and O 
destruction O 
values O 
were O 
calculated O 
. O 
In O 
all O 
pectic O 
model O 
solutions O 
anthocyanin B-FAMILY 
stability O 
was O 
significantly O 
improved O 
compared O 
to O 
stability O 
of O 
the O 
extracts O 
without O 
added O 
pectins O 
( O 
blank O 
) O 
. O 
Best O 
stabilisation O 
was O 
obtained O 
with O 
AM O 
pectin O 
, O 
followed O 
by O 
LM O 
and O 
HM O 
pectins O 
. O 
In O 
model O 
systems O 
containing O 
citrus O 
pectins O 
, O 
anthocyanin B-FAMILY 
stabilisation O 
was O 
better O 
compared O 
to O 
that O 
of O 
apple O 
pectins O 
having O 
similar O 
degrees O 
of O 
esterification O 
and O 
amidation O 
, O 
respectively O 
. O 
This O 
was O 
primarily O 
due O 
to O 
the O 
strong O 
interaction O 
of O 
delphinidin B-FAMILY 
glycosides I-FAMILY 
with O 
the O 
citrus O 
pectins O 
, O 
whereas O 
stabilisation O 
of O 
cyanidin B-TRIVIAL 
derivatives O 
was O 
less O 
important O 
. O 
Sugar O 
beet O 
pectin O 
improved O 
anthocyanin B-FAMILY 
stability O 
only O 
to O 
a O 
limited O 
extent O 
. O 
In O 
the O 
presence O 
of O 
non- O 
anthocyanin B-FAMILY 
phenolics I-FAMILY 
( O 
PP-E O 
) O 
the O 
impact O 
of O 
the O 
pectin O 
source O 
was O 
even O 
more O 
pronounced O 
than O 
the O 
effect O 
of O 
the O 
pectin O 
type O 
. O 
Addition O 
of O 
citrate O 
to O 
pectic O 
systems O 
accelerated O 
anthocyanin B-FAMILY 
decay O 
. O 
Stabilising O 
effects O 
of O 
pectins O 
were O 
hardly O 
noticeable O 
when O 
evaluating O 
total O 
phenolic B-FAMILY 
content O 
( O 
TPC O 
, O 
Folin-Ciocalteu O 
) O 
and O 
antioxidant O 
capacity O 
during O 
storage O 
. O 
Highest O 
TPC O 
, O 
TEAC- O 
and O 
FRAP O 
values O 
were O 
observed O 
in O 
systems O 
containing O 
citrus O 
pectin O 
, O 
which O 
was O 
in O 
contrast O 
to O 
sugar O 
beet O 
pectin O 
, O 
where O 
values O 
fell O 
below O 
those O 
of O 
the O 
blank O 
after O 
storage O 
. O 

restriction O 
approach O 
to O 
BACE1 O 
inhibitors O 
II O 
: O 
SAR O 
study O 
of O 
the O 
isocytosine B-TRIVIAL 
derivatives O 
fixed O 
with O 
a O 
cis-cyclopropane B-SYSTEMATIC 
ring O 
. O 

improve O 
the O 
efficacy O 
of O 
the O 
conformationally O 
restricted O 
BACE1 O 
inhibitors O 
, O 
structural O 
modifications O 
were O 
investigated O 
using O 
two O 
strategies O 
: O 
( O 
a O 
) O 
modification O 
of O 
the O 
terminal O 
aromatic O 
ring O 
and O 
( O 
b O 
) O 
insertion O 
of O 
a O 
spacer O 
between O 
the O 
aromatic O 
rings O 
. O 
In O 
the O 
latter O 
approach O 
, O 
another O 
type O 
of O 
inhibitor O 
17 O 
bearing O 
an O 
ethylene B-SYSTEMATIC 
spacer O 
between O 
two O 
aromatic O 
rings O 
was O 
found O 
to O 
exhibit O 
good O 
BACE1 O 
inhibitory O 
activity O 
, O 
while O 
the O 
corresponding O 
conformationally O 
unrestricted O 
compound O 
25 O 
showed O 
no O 
activity O 
. O 
This O 
result O 
revealed O 
an O 
interesting O 
effect O 
of O 
a O 
conformational O 
restriction O 
with O 
a O 
cyclopropane B-SYSTEMATIC 
ring O 
. O 

of O 
ML326 B-IDENTIFIER 
: O 
The O 
first O 
sub O 
- O 
micromolar O 
, O 
selective O 
M5 O 
PAM O 
. O 

Letter O 
describes O 
the O 
further O 
chemical O 
optimization O 
of O 
the O 
M5 O 
PAM O 
MLPCN O 
probes O 
ML129 B-IDENTIFIER 
and O 
ML172 B-IDENTIFIER 
. O 
A O 
multi O 
- O 
dimensional O 
iterative O 
parallel O 
synthesis O 
effort O 
quickly O 
explored O 
isatin B-TRIVIAL 
replacements O 
and O 
a O 
number O 
of O 
southern O 
heterobiaryl O 
variations O 
with O 
no O 
improvement O 
over O 
ML129 B-IDENTIFIER 
and O 
ML172 B-IDENTIFIER 
. O 
An O 
HTS O 
campaign O 
identified O 
several O 
weak O 
M5 O 
PAMs O 
( O 
M5 O 
EC50 O 
> O 
10μM O 
) O 
with O 
a O 
structurally O 
related O 
isatin B-TRIVIAL 
core O 
that O 
possessed O 
a O 
southern O 
phenethyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
linkage O 
. O 
While O 
SAR O 
within O 
the O 
HTS O 
series O 
was O 
very O 
shallow O 
and O 
unable O 
to O 
be O 
optimized O 
, O 
grafting O 
the O 
phenethyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
linkage O 
onto O 
the O 
ML129 B-IDENTIFIER 
/ O 
ML172 B-IDENTIFIER 
cores O 
led O 
to O 
the O 
first O 
sub O 
- O 
micromolar O 
M5 O 
PAM O 
, O 
ML326 B-IDENTIFIER 
( O 
VU0467903 B-IDENTIFIER 
) O 
, O 
( O 
human O 
and O 
rat O 
M5 O 
EC50s O 
of O 
409nM O 
and O 
500nM O 
, O 
respectively O 
) O 
with O 
excellent O 
mAChR O 
selectivity O 
( O 
M1-M4 O 
EC50s O 
> O 
30μM O 
) O 
and O 
a O 
robust O 
20-fold O 
leftward O 
shift O 
of O 
the O 
ACh B-ABBREVIATION 
CRC O 
. O 

novel O 
and O 
potent O 
small O 
molecule O 
glucagon O 
receptor O 
antagonist O 
for O 
the O 
treatment O 
of O 
diabetes O 
mellitus O 
is O 
reported O 
. O 
This O 
candidate O 
, O 
(S)-3-[4-(1-{3,5-dimethyl-4-[4-(trifluoromethyl)-1H-pyrazol-1-yl]phenoxy}butyl)benzamido]propanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
has O 
lower O 
molecular O 
weight O 
and O 
lipophilicity O 
than O 
historical O 
glucagon O 
receptor O 
antagonists O 
, O 
resulting O 
in O 
excellent O 
selectivity O 
in O 
broad O 
- O 
panel O 
screening O 
, O 
lower O 
cytotoxicity O 
, O 
and O 
excellent O 
overall O 
in O 
vivo O 
safety O 
in O 
early O 
pre O 
- O 
clinical O 
testing O 
. O 
Additionally O 
, O 
it O 
displays O 
low O 
in O 
vivo O 
clearance O 
and O 
excellent O 
oral O 
bioavailability O 
in O 
both O 
rats O 
and O 
dogs O 
. O 
In O 
a O 
rat O 
glucagon O 
challenge O 
model O 
, O 
it O 
was O 
shown O 
to O 
reduce O 
the O 
glucagon O 
- O 
elicited O 
glucose B-TRIVIAL 
excursion O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
and O 
at O 
a O 
concentration O 
consistent O 
with O 
its O 
rat O 
in O 
vitro O 
potency O 
. O 
Its O 
properties O 
make O 
it O 
an O 
excellent O 
candidate O 
for O 
further O 
investigation O 
. O 

cholesterol B-TRIVIAL 
homeostasis O 
in O 
aged O 
macrophages O 
linked O 
to O 
neovascular O 
macular O 
degeneration O 
. O 

lipid O 
metabolism O 
has O 
been O 
linked O 
to O 
age O 
- O 
related O 
macular O 
degeneration O 
( O 
AMD O 
) O 
; O 
choroidal O 
neovascularization O 
in O 
late O 
AMD O 
commonly O 
causes O 
blindness O 
. O 
Sene O 
et O 
al O 
. O 
( O 
2013 O 
) O 
now O 
demonstrate O 
that O 
in O 
aged O 
macrophages O 
decreased O 
ABCA1 O 
expression O 
, O 
regulated O 
by O 
liver O 
X O 
receptor O 
and O 
miR-33 O 
, O 
impairs O 
export O 
of O 
intracellular O 
cholesterol B-TRIVIAL 
, O 
which O 
promotes O 
neovascular O 
AMD O 
. O 

extracted O 
from O 
Vitex O 
negundo O 
possess O 
cytotoxic O 
activity O 
by O 
G2 O 
/ O 
M O 
phase O 
cell O 
cycle O 
arrest O 
and O 
apoptosis O 
induction O 
. O 

is O 
a O 
lignan B-FAMILY 
compounds O 
mixture O 
extracted O 
from O 
Vitex O 
negundo O 
, O 
a O 
widely O 
used O 
herb O 
in O 
traditional O 
Chinese O 
medicine O 
. O 
This O 
study O 
is O 
aimed O 
to O 
define O 
the O 
spectrum O 
of O 
cytotoxic O 
activity O 
of O 
EVn-50 B-NO_CLASS 
, O 
and O 
also O 
to O 
investigate O 
mechanisms O 
underlying O 
the O 
anticancer O 
actions O 
via O 
assessing O 
the O 
influence O 
on O 
cell O 
cycle O 
using O 
EVn-50 B-NO_CLASS 
, O 
and O 
the O 
lignan B-FAMILY 
compound O 
VB1 B-IDENTIFIER 
purified O 
from O 
EVn-50 B-NO_CLASS 
. O 
The O 
cytotoxic O 
effect O 
of O 
EVn-50 B-NO_CLASS 
and O 
VB1 B-IDENTIFIER 
was O 
determined O 
with O 
SRB O 
assay O 
using O 
a O 
panel O 
of O 
cancer O 
cell O 
lines O 
. O 
Breast O 
cancer O 
cell O 
line O 
MDA-MB-435 O 
and O 
liver O 
cancer O 
cell O 
line O 
SMMC-7721 O 
were O 
selected O 
for O 
further O 
evaluating O 
the O 
effect O 
of O 
EVn-50 B-NO_CLASS 
or O 
VB1 B-IDENTIFIER 
on O 
cell O 
cycle O 
by O 
flow O 
cytometric O 
analysis O 
. O 
Apoptosis O 
exerted O 
by O 
EVn-50 B-NO_CLASS 
or O 
VB1 B-IDENTIFIER 
was O 
measured O 
by O 
TUNEL O 
assay O 
and O 
DAPI O 
staining O 
, O 
and O 
Western O 
blot O 
analysis O 
was O 
utilized O 
to O 
assess O 
the O 
influence O 
on O 
expression O 
and O 
phosphorylation O 
of O 
proteins O 
which O 
are O 
closely O 
related O 
to O 
cell O 
cycle O 
and O 
apoptosis O 
. O 
EVn-50 B-NO_CLASS 
possessed O 
a O 
broad O 
spectrum O 
of O 
in O 
vitro O 
anticancer O 
activity O 
for O 
those O 
tested O 
cancer O 
cells O 
, O 
especially O 
sensitive O 
to O 
MDA-MB-435 O 
, O 
SKOV-3 O 
, O 
BXPC-3 O 
, O 
SMMC-7721 O 
, O 
MCF-7 O 
, O 
HO-8910 O 
, O 
SGC-7901 O 
, O 
BEL-7402 O 
, O 
HCT-116 O 
, O 
and O 
786-O O 
, O 
with O 
the O 
respective O 
IC50 O 
below O 
10μg O 
/ O 
ml O 
. O 
Treatment O 
with O 
EVn-50 B-NO_CLASS 
or O 
VB1 B-IDENTIFIER 
resulted O 
in O 
arresting O 
the O 
MDA-MB-435 O 
and O 
SMMC-7721 O 
cells O 
at O 
G2 O 
/ O 
M O 
phase O 
, O 
which O 
was O 
further O 
supported O 
by O 
observations O 
of O 
increased O 
phosphorylation O 
of O 
Histone O 
3 O 
at O 
Ser B-FORMULA 
10 O 
, O 
phosphorylation O 
of O 
Cdk1 O 
at O 
Tyr B-FORMULA 
15 O 
, O 
expression O 
of O 
cyclin O 
B1 O 
, O 
and O 
decreased O 
expression O 
of O 
Cdc25c O 
. O 
Moreover O 
, O 
we O 
found O 
that O 
exposure O 
of O 
MDA-MB-435 O 
cells O 
to O 
EVn-50 B-NO_CLASS 
or O 
VB1 B-IDENTIFIER 
caused O 
obvious O 
apoptosis O 
of O 
MDA-MB-435 O 
cells O 
. O 
Our O 
data O 
show O 
that O 
EVn-50 B-NO_CLASS 
, O 
lignan B-FAMILY 
compounds O 
extracted O 
from O 
Vitex O 
negundo O 
, O 
possesses O 
a O 
broad O 
spectrum O 
cytotoxic O 
effect O 
via O 
arresting O 
cancer O 
cells O 
at O 
G2 O 
/ O 
M O 
phase O 
cell O 
cycle O 
and O 
subsequently O 
inducing O 
apoptosis O 
. O 

of O 
metformin B-TRIVIAL 
across O 
the O 
rat O 
placenta O 
is O 
mediated O 
by O 
organic O 
cation O 
transporter O 
3 O 
( O 
OCT3 O 
/ O 
SLC22A3 O 
) O 
and O 
multidrug O 
and O 
toxin O 
extrusion O 
1 O 
( O 
MATE1 O 
/ O 
SLC47A1 O 
) O 
protein O 
. O 

our O 
previous O 
studies O 
we O 
described O 
functional O 
expression O 
of O 
organic O 
cation O 
transporter O 
3 O 
( O 
OCT3 O 
) O 
and O 
multidrug O 
and O 
toxin O 
extrusion O 
1 O 
( O 
MATE1 O 
) O 
protein O 
in O 
the O 
rat O 
placenta O 
. O 
Since O 
metformin B-TRIVIAL 
is O 
a O 
substrate O 
of O 
both O 
OCT3 O 
and O 
MATE1 O 
, O 
in O 
this O 
study O 
we O 
used O 
the O 
model O 
of O 
dually O 
perfused O 
rat O 
placenta O 
to O 
investigate O 
the O 
role O 
of O 
these O 
transporters O 
in O 
metformin B-TRIVIAL 
passage O 
across O 
the O 
placenta O 
. O 
We O 
observed O 
concentration O 
- O 
dependent O 
transplacental O 
clearance O 
of O 
metformin B-TRIVIAL 
in O 
both O 
maternal O 
- O 
to O 
- O 
fetal O 
and O 
fetal O 
- O 
to O 
- O 
maternal O 
directions O 
; O 
in O 
addition O 
metformin B-TRIVIAL 
crossed O 
the O 
placenta O 
from O 
the O 
fetal O 
to O 
maternal O 
compartment O 
even O 
against O 
its O 
concentration O 
gradient O 
. O 
This O 
transport O 
was O 
completely O 
inhibited O 
by O 
MPP(+) B-ABBREVIATION 
, O 
a O 
common O 
OCT3 O 
and O 
MATE1 O 
inhibitor O 
. O 
Furthermore O 
, O 
we O 
observed O 
that O 
the O 
oppositely O 
directed O 
H(+) B-FORMULA 
-gradient O 
can O 
drive O 
the O 
secretion O 
of O 
metformin B-TRIVIAL 
from O 
placenta O 
to O 
maternal O 
circulation O 
, O 
confirming O 
apical O 
efflux O 
of O 
metformin B-TRIVIAL 
from O 
trophoblast O 
by O 
MATE1 O 
. O 
In O 
conclusion O 
, O 
we O 
suggest O 
an O 
important O 
role O 
of O 
OCT3 O 
and O 
MATE1 O 
in O 
the O 
transplacental O 
transfer O 
of O 
metformin B-TRIVIAL 
. O 

and O 
xanthohumol B-TRIVIAL 
inhibit O 
invasion O 
of O 
triple O 
negative O 
breast O 
cancer O 
cells O 
. O 

cancer O 
is O 
estimated O 
as O 
one O 
of O 
the O 
most O 
common O 
causes O 
of O 
cancer O 
death O 
among O 
women O 
. O 
In O 
particular O 
, O 
triple O 
negative O 
breast O 
cancers O 
( O 
TNBCs O 
) O 
, O 
which O 
do O 
not O 
express O 
the O 
genes O 
for O 
estrogen B-FAMILY 
/ O 
progesterone B-TRIVIAL 
receptors O 
( O 
ER O 
/ O 
PR O 
) O 
and O 
human O 
epidermal O 
growth O 
factor O 
receptor O 
2 O 
( O 
HER2 O 
) O 
, O 
have O 
been O 
associated O 
with O 
poor O 
prognosis O 
and O 
metastasis O 
. O 
Chalcones B-FAMILY 
, O 
the O 
biosynthetic O 
precursors O 
of O 
flavonoids B-FAMILY 
present O 
in O 
edible O 
plants O 
, O 
exert O 
cytotoxic O 
and O 
chemopreventive O 
activities O 
. O 
Although O 
mounting O 
evidence O 
suggests O 
the O 
anticancer O 
properties O 
of O 
chalcones B-FAMILY 
, O 
limited O 
information O 
is O 
available O 
regarding O 
the O 
inhibitory O 
effects O 
of O 
chalcones B-FAMILY 
on O 
the O 
aggressiveness O 
of O 
breast O 
cancer O 
cells O 
. O 
The O 
present O 
study O 
aimed O 
to O 
investigate O 
the O 
effects O 
of O 
chalcone B-FAMILY 
and O 
its O 
derivatives O 
on O 
the O 
growth O 
and O 
the O 
invasiveness O 
of O 
TNBC O 
cells O 
. O 
Here O 
, O 
we O 
showed O 
that O 
treatment O 
with O 
chalcone B-FAMILY 
, O 
2-hydroxychalcone B-SYSTEMATIC 
, O 
and O 
xanthohumol B-TRIVIAL 
for O 
24h O 
inhibited O 
the O 
growth O 
of O 
MDA-MB-231cells O 
with O 
IC50 O 
values O 
of O 
18.1 O 
, O 
4.6 O 
, O 
and O 
6.7μM O 
, O 
respectively O 
. O 
Similarly O 
, O 
Chalcone B-TRIVIAL 
, O 
2-hydroxychalcone B-SYSTEMATIC 
, O 
and O 
xanthohumol B-TRIVIAL 
also O 
exerted O 
cytotoxicity O 
in O 
another O 
TNBC O 
cell O 
line O 
, O 
Hs578T O 
. O 
Neohesperidin B-SYSTEMATIC 
dihydrochalcone I-SYSTEMATIC 
, O 
4-methoxychalcone B-SYSTEMATIC 
, O 
and O 
hesperidin B-TRIVIAL 
methylchalcone I-TRIVIAL 
did O 
not O 
show O 
the O 
cytotoxicity O 
on O 
the O 
MDA-MB-231cells O 
. O 
Xanthohumol B-TRIVIAL 
and O 
2-hydroxychalcone B-SYSTEMATIC 
induced O 
apoptosis O 
by O 
Bcl-2 O 
downregulation O 
. O 
Importantly O 
, O 
2-hydroxychalcone B-SYSTEMATIC 
and O 
xanthohumol B-TRIVIAL 
exerted O 
more O 
potent O 
inhibitory O 
effects O 
on O 
the O 
proliferation O 
, O 
MMP-9 O 
expression O 
and O 
invasive O 
phenotype O 
of O 
MDA-MB-231 O 
than O 
chalcone B-FAMILY 
. O 
These O 
results O 
suggest O 
a O 
potential O 
application O 
of O 
these O 
chalcones B-FAMILY 
as O 
anticancer O 
agents O 
that O 
can O 
alleviate O 
malignant O 
progression O 
of O 
TNBC O 
. O 

dissolution O 
and O 
oral O 
absorption O 
of O 
itraconazole B-TRIVIAL 
/ O 
Soluplus B-TRIVIAL 
extrudate O 
compared O 
with O 
itraconazole B-TRIVIAL 
nanosuspension O 
. O 

purpose O 
of O 
this O 
article O 
was O 
to O 
compare O 
the O 
in O 
vitro O 
and O 
in O 
vivo O 
profiles O 
of O 
itraconazole B-TRIVIAL 
( O 
ITZ B-ABBREVIATION 
) O 
extrudates O 
and O 
nanosuspension O 
separately O 
prepared O 
by O 
two O 
different O 
methods O 
. O 
And O 
it O 
was O 
proved O 
truly O 
to O 
form O 
nanocrystalline O 
and O 
amorphous O 
ITZ B-ABBREVIATION 
characterized O 
by O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
, O 
X-ray O 
powder O 
diffraction O 
( O 
XRD O 
) O 
analysis O 
, O 
Fourier O 
transform O 
infrared O 
spectrum O 
( O 
FTIR O 
) O 
, O 
transmission O 
electron O 
microscope O 
( O 
TEM O 
) O 
, O 
and O 
scanning O 
electron O 
microscope O 
( O 
SEM O 
) O 
. O 
The O 
release O 
of O 
ITZ B-ABBREVIATION 
/ O 
Soluplus B-TRIVIAL 
solid O 
dispersions O 
with O 
amorphous O 
ITZ B-ABBREVIATION 
was O 
almost O 
complete O 
while O 
only O 
40% O 
release O 
was O 
obtained O 
with O 
ITZ B-ABBREVIATION 
nanocrystals O 
. O 
The O 
amorphous O 
state O 
need O 
not O 
to O 
cross O 
over O 
the O 
crystal O 
lattice O 
energy O 
upon O 
dissolution O 
while O 
the O 
crystalline O 
need O 
to O 
overcome O 
it O 
. O 
In O 
the O 
in O 
vivo O 
assay O 
, O 
the O 
AUC(0-t) O 
and O 
Cmax O 
of O 
ITZ B-ABBREVIATION 
/ O 
Soluplus B-TRIVIAL 
were O 
6.9- O 
and O 
11.6-time O 
higher O 
than O 
those O 
of O 
pure O 
ITZ B-ABBREVIATION 
. O 
The O 
formulation O 
of O 
the O 
extrudate O 
had O 
an O 
AUC(0-t) O 
and O 
Cmax O 
similar O 
to O 
those O 
of O 
ITZ B-ABBREVIATION 
and O 
also O 
OH B-FORMULA 
OH-ITZ B-FORMULA 
ITZ B-ABBREVIATION 
compared O 
with O 
the O 
commercial O 
capsule O 
( O 
Sporanox B-TRIVIAL 
® O 
) O 
. O 
The O 
relative O 
bioavailability O 
values O 
with O 
their O 
95% O 
confidence O 
limit O 
were O 
calculated O 
to O 
be O 
98.3% O 
( O 
92.5-104.1% O 
) O 
and O 
101.3% O 
( O 
97.9-104.1% O 
) O 
, O 
respectively O 
. O 
The O 
results O 
of O 
this O 
study O 
showed O 
increased O 
dissolution O 
and O 
bioavailability O 
of O 
the O 
solid O 
dispersion O 
of O 
Soluplus B-TRIVIAL 
-based O 
carrier O 
loading O 
ITZ B-ABBREVIATION 
prepared O 
by O 
HME O 
compared O 
with O 
the O 
ITZ B-ABBREVIATION 
nanosuspension O 
prepared O 
by O 
wet O 
milling O 
. O 

effects O 
of O 
asiaticoside B-TRIVIAL 
on O 
cognitive O 
deficits O 
in O 
senescence O 
- O 
accelerated O 
mice O 
. O 

effect O 
of O 
asiaticoside B-TRIVIAL 
isolated O 
from O 
Hydrocotyle O 
sibthorpioides O 
( O 
AHS O 
) O 
on O 
the O 
promotion O 
of O 
cognition O 
in O 
senescence O 
- O 
accelerated O 
mice O 
( O 
SAMP O 
) O 
was O 
evaluated O 
. O 
Six O 
- O 
month O 
old O 
male O 
SAMP8 O 
mice O 
were O 
orally O 
administered O 
20 O 
, O 
40 O 
or O 
80mg O 
/ O 
kg O 
AHS O 
daily O 
for O 
three O 
months O 
. O 
SAMR1 O 
mice O 
were O 
used O 
as O 
a O 
" O 
normal O 
aging O 
" O 
control O 
. O 
The O 
results O 
showed O 
that O 
treatment O 
with O 
AHS O 
significantly O 
improved O 
learning O 
and O 
memory O 
abilities O 
in O 
behavioral O 
tests O 
. O 
AHS O 
- O 
treated O 
mice O 
showed O 
higher O 
antioxidant O 
enzyme O 
activity O 
and O 
lower O 
lipid O 
oxidation O 
in O 
serum O 
compared O 
with O 
untreated O 
SAMP8 O 
mice O 
. O 
Mechanistically O 
, O 
studies O 
showed O 
that O 
AHS O 
markedly O 
reduced O 
the O 
content O 
and O 
deposition O 
of O 
β-amyloid O 
peptide O 
( O 
Aβ O 
) O 
by O 
inhibiting O 
the O 
expression O 
of O 
mRNA O 
for O 
amyloid O 
protein O 
precursor O 
, O 
β-site O 
amyloid O 
cleaving O 
enzyme-1 O 
and O 
cathepsin O 
B O 
and O 
promoting O 
the O 
expression O 
of O 
mRNA O 
for O 
neprilysin O 
and O 
insulin O 
degrading O 
enzyme O 
. O 
In O 
addition O 
, O 
AHS O 
significantly O 
increased O 
the O 
expression O 
of O 
plasticity O 
- O 
related O 
proteins O 
including O 
postsynaptic O 
density-95 O 
, O 
phosphor- O 
N-methyl-d-aspartate B-SYSTEMATIC 
receptor O 
1 O 
, O 
phospho B-SYSTEMATIC 
- O 
calcium B-SYSTEMATIC 
-calmodulin O 
dependent O 
kinase O 
II O 
, O 
phospho B-SYSTEMATIC 
-protein O 
kinase O 
A O 
Catalyticβ O 
subunit O 
, O 
protein O 
kinase O 
Cγ O 
subunit O 
, O 
phospho B-SYSTEMATIC 
-CREB O 
and O 
brain O 
derived O 
neurotrophic O 
factor O 
. O 
Furthermore O 
, O 
AHS O 
increased O 
the O 
levels O 
of O 
acetylcholine B-SYSTEMATIC 
( O 
Ach B-ABBREVIATION 
) O 
, O 
but O 
decreased O 
cholinesterase O 
( O 
AchE O 
) O 
activity O 
. O 
These O 
results O 
demonstrated O 
that O 
AHS O 
administration O 
may O 
prevent O 
spatial O 
learning O 
and O 
memory O 
decline O 
by O 
scavenging O 
free O 
radicals O 
, O 
up O 
- O 
regulating O 
the O 
activity O 
of O 
antioxidant O 
enzymes O 
, O 
decreasing O 
the O 
level O 
of O 
Aβ O 
, O 
ameliorating O 
dysfunction O 
in O 
synaptic O 
plasticity O 
, O 
and O 
reversing O 
abnormal O 
changes O 
in O 
Ach B-ABBREVIATION 
level O 
and O 
AchE O 
activity O 
. O 
Thus O 
, O 
AHS O 
should O 
be O 
developed O 
as O 
a O 
new O 
drug O 
to O 
prevent O 
age O 
- O 
related O 
cognitive O 
deficits O 
. O 

alginate- O 
poly(ethylenimine) B-FAMILY 
nanogels O 
as O 
an O 
antigen O 
- O 
delivery O 
system O 
robustly O 
enhance O 
vaccine O 
- O 
elicited O 
humoral O 
and O 
cellular O 
immune O 
responses O 
. O 

polysaccharide O 
nanogels O 
have O 
emerged O 
as O 
a O 
novel O 
antigen O 
delivery O 
system O 
for O 
vaccine O 
development O 
, O 
whether O 
modulating O 
the O 
redox O 
sensitivity O 
of O 
nanogels O 
could O 
improve O 
vaccine O 
efficacy O 
remains O 
unclear O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
generated O 
bioreducible O 
cationic O 
alginate- O 
polyethylenimine B-SYSTEMATIC 
( O 
PEI B-ABBREVIATION 
) O 
nanogels O 
as O 
a O 
novel O 
vaccine O 
delivery O 
system O 
. O 
Briefly O 
, O 
nanogels O 
were O 
prepared O 
by O 
the O 
electrostatic O 
interaction O 
of O 
negatively O 
charged O 
alginate O 
sodium B-SYSTEMATIC 
with O 
branched O 
PEI2k O 
, O 
followed O 
by O 
disulfide B-SYSTEMATIC 
cross O 
- O 
linking O 
to O 
generate O 
bioreducible O 
nanogels O 
( O 
AP-SS O 
) O 
. O 
The O 
AP-SS O 
nanogels O 
demonstrated O 
great O 
antigen O 
- O 
loading O 
capacity O 
and O 
minimal O 
cytotoxicity O 
. O 
The O 
in O 
vitro O 
study O 
showed O 
that O 
reducible O 
AP-SS O 
nanogels O 
not O 
only O 
facilitated O 
antigen O 
uptake O 
by O 
mouse O 
bone O 
marrow O 
dendritic O 
cells O 
( O 
BMDCs O 
) O 
, O 
but O 
also O 
promoted O 
intracellular O 
antigen O 
degradation O 
and O 
cytosolic O 
release O 
. O 
Moreover O 
, O 
AP-SS O 
nanogels O 
significantly O 
enhanced O 
both O 
MHC O 
class O 
I O 
and O 
II O 
antigen O 
presentation O 
by O 
BMDCs O 
. O 
Compared O 
with O 
the O 
non-reducible O 
nanogels O 
, O 
AP-SS O 
nanogels O 
more O 
potently O 
enhanced O 
vaccine O 
- O 
induced O 
antibody O 
production O 
and O 
CD8(+) O 
T O 
cell O 
- O 
mediated O 
tumor O 
cell O 
lysis O 
. O 
Hence O 
, O 
the O 
bioreducible O 
alginate-PEI O 
nanogels O 
could O 
serve O 
as O 
a O 
potent O 
adjuvant O 
to O 
improve O 
vaccine O 
- O 
elicited O 
humoral O 
and O 
cellular O 
immune O 
responses O 
. O 

transport O 
of O 
aconitine B-TRIVIAL 
across O 
human O 
intestinal O 
Caco-2 O 
cells O 
. O 

( O 
AC O 
) O 
is O 
a O 
highly O 
toxic O 
compound O 
present O 
in O 
plants O 
of O 
the O 
genus O 
Aconitum O 
. O 
The O 
transcellular O 
transport O 
mechanism O 
of O 
AC O 
was O 
investigated O 
using O 
Caco-2 O 
cells O 
. O 
The O 
flux O 
of O 
AC O 
was O 
time- O 
and O 
concentration O 
- O 
dependent O 
in O 
both O 
apical O 
- O 
to O 
- O 
basolateral O 
and O 
the O 
reverse O 
direction O 
. O 
The O 
efflux O 
of O 
AC O 
was O 
more O 
than O 
two O 
- O 
fold O 
that O 
in O 
the O 
opposite O 
direction O 
. O 
The O 
influx O 
of O 
AC O 
was O 
temperature- O 
, O 
pH- O 
and O 
Na(+) B-FORMULA 
-dependent O 
. O 
Glucose B-TRIVIAL 
markedly O 
decreased O 
the O 
absorption O 
of O 
AC O 
. O 
However O 
, O 
the O 
efflux O 
of O 
AC O 
was O 
temperature- O 
and O 
pH-dependent O 
, O 
but O 
Na(+) B-FORMULA 
-independent O 
. O 
Cyclosporin B-TRIVIAL 
A I-TRIVIAL 
and O 
verapamil B-TRIVIAL 
, O 
both O 
inhibitors O 
of O 
P-glycoprotein O 
( O 
P-gp O 
) O 
, O 
significantly O 
decreased O 
the O 
efflux O 
of O 
AC O 
. O 
In O 
addition O 
, O 
MK-571 B-IDENTIFIER 
, O 
an O 
inhibitor O 
of O 
multidrug O 
resistance O 
- O 
associated O 
protein O 
2 O 
( O 
MRP2 O 
) O 
, O 
exhibited O 
the O 
same O 
trend O 
but O 
to O 
a O 
lesser O 
extent O 
. O 
These O 
results O 
indicate O 
that O 
both O 
the O 
influx O 
and O 
efflux O 
of O 
AC O 
across O 
Caco-2 O 
monolayers O 
were O 
through O 
an O 
active O 
process O 
. O 
A O 
pH-dependent O 
carrier O 
- O 
mediated O 
transport O 
system O 
was O 
the O 
major O 
absorption O 
mechanism O 
and O 
a O 
sodium B-SYSTEMATIC 
-dependent O 
glucose B-TRIVIAL 
transporter O 
may O 
be O 
involved O 
. O 
The O 
active O 
efflux O 
of O 
AC O 
across O 
Caco-2 O 
cells O 
was O 
mediated O 
mainly O 
by O 
ABC-transporter O 
P-gp O 
. O 
It O 
is O 
involved O 
in O 
reducing O 
the O 
toxicity O 
of O 
AC O 
to O 
organisms O 
and O 
is O 
the O 
major O 
reasons O 
for O 
the O 
poor O 
absorption O 
of O 
AC O 
in O 
vivo O 
. O 

this O 
study O 
, O 
a O 
structured O 
protocol O 
for O 
the O 
classification O 
of O 
wet O 
mass O 
in O 
extrusion O 
- O 
spheronization O 
was O 
developed O 
to O 
predict O 
formation O 
and O 
pellet O 
quality O 
. O 
The O 
wet O 
masses O 
of O 
120 O 
formulae O 
were O 
prepared O 
taking O 
microcrystalline O 
celluloses O 
as O 
pelletization O 
aid O 
and O 
lactose B-TRIVIAL 
, O 
hydroxypropyl B-SYSTEMATIC 
methylcellulose O 
grades O 
, O 
herbal O 
medicines O 
as O 
model O 
drugs O 
. O 
Physical O 
properties O 
of O 
the O 
wet O 
masses O 
such O 
as O 
hardness O 
, O 
adhesiveness O 
, O 
springiness O 
, O 
cohesiveness O 
, O 
chewiness O 
, O 
and O 
resilience O 
were O 
tested O 
, O 
respectively O 
, O 
using O 
a O 
texture O 
analyzer O 
. O 
Particles O 
were O 
produced O 
by O 
spheronization O 
process O 
, O 
and O 
the O 
quality O 
of O 
spherical O 
pellets O 
was O 
also O 
evaluated O 
. O 
Data O 
were O 
analyzed O 
by O 
principal O 
component O 
analysis O 
, O 
factor O 
analysis O 
, O 
and O 
classification O 
analysis O 
. O 
The O 
wet O 
masses O 
could O 
be O 
classified O 
into O 
five O 
groups O 
taking O 
the O 
ratio O 
of O 
hardness O 
to O 
springiness O 
( O 
Ha O 
/ O 
Sp O 
) O 
as O 
the O 
first O 
classification O 
index O 
and O 
chewiness O 
, O 
resilience O 
as O 
the O 
second O 
and O 
the O 
third O 
classification O 
index O 
. O 
The O 
wet O 
masses O 
of O 
different O 
classification O 
could O 
correspondingly O 
form O 
the O 
different O 
shapes O 
. O 
So O 
, O 
a O 
new O 
protocol O 
could O 
be O 
devised O 
, O 
for O 
example O 
, O 
if O 
the O 
range O 
of O 
Ha O 
/ O 
Sp O 
of O 
the O 
wet O 
masses O 
was O 
30,992-47,689g O 
, O 
at O 
the O 
same O 
time O 
, O 
the O 
value O 
of O 
chewiness O 
was O 
less O 
than O 
4842 O 
, O 
and O 
the O 
value O 
of O 
resilience O 
was O 
no O 
more O 
than O 
0.139 O 
; O 
it O 
would O 
form O 
spherical O 
pellets O 
under O 
the O 
experimental O 
condition O 
. O 
These O 
results O 
demonstrate O 
that O 
the O 
proposed O 
protocol O 
could O 
be O 
a O 
valuable O 
asset O 
in O 
a O 
formulation O 
development O 
project O 
to O 
assess O 
the O 
physical O 
properties O 
of O 
wet O 
masses O 
and O 
to O 
predict O 
formation O 
and O 
pellet O 
quality O 
. O 
So O 
, O 
the O 
tedious O 
and O 
expensive O 
pre O 
- O 
production O 
( O 
pre O 
- O 
formulation O 
and O 
optimization O 
) O 
work O 
could O 
be O 
considerably O 
reduced O 
. O 

: O 
GPR7 O 
, O 
the O 
endogenous O 
coupled O 
receptor O 
for O 
neuropeptide O 
B O 
and O 
neuropeptide O 
W O 
, O 
is O 
expressed O 
in O 
several O 
regions O 
of O 
the O 
Central O 
Nervous O 
System O 
( O 
CNS O 
) O 
, O 
which O 
are O 
involved O 
in O 
the O 
regulation O 
of O 
feeding O 
behaviour O 
. O 
GPR7 O 
affects O 
the O 
regulation O 
of O 
energy O 
balance O 
through O 
a O 
mechanism O 
independent O 
of O 
leptin O 
and O 
melanocortin O 
pathways O 
. O 
Aim O 
: O 
Aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
whether O 
GPR7 O 
gene O 
mutations O 
can O 
be O 
detected O 
in O 
human O 
subjects O 
and O 
, O 
in O 
that O 
event O 
, O 
if O 
they O 
are O 
differently O 
distributed O 
among O 
lean O 
and O 
obese O 
subjects O 
. O 
Subjects O 
and O 
Methods O 
: O 
The O 
coding O 
region O 
of O 
GPR7 O 
were O 
sequenced O 
in O 
150 O 
obese O 
patients O 
and O 
100 O 
normal O 
- O 
weight O 
unrelated O 
controls O 
. O 
Functional O 
studies O 
of O 
the O 
allelic O 
variants O 
were O 
performed O 
. O 
Results O 
: O 
One O 
genetic O 
GPR7 O 
variant O 
was O 
found O 
( O 
Tyr135Phe O 
- O 
rs33977775 O 
) O 
in O 
obese O 
subjects O 
( O 
13,3% O 
) O 
and O 
lean O 
control O 
( O 
25% O 
) O 
. O 
Functional O 
studies O 
did O 
not O 
reveal O 
significant O 
differences O 
between O 
the O 
wild O 
type O 
and O 
the O 
Tyr135Phe O 
allelic O 
variants O 
in O 
their O 
NPW O 
mediated O 
capacity O 
to O 
inhibit O 
forskolin B-TRIVIAL 
-induced O 
cAMP B-ABBREVIATION 
production O 
. O 
Conclusions O 
: O 
Screening O 
of O 
GPR7 O 
gene O 
mutations O 
among O 
lean O 
and O 
obese O 
subjects O 
revealed O 
a O 
Tyr135Phe O 
allelic O 
variant O 
that O 
was O 
fairly O 
common O 
in O 
the O 
study O 
population O 
. O 
As O 
indicated O 
by O 
in O 
vitro O 
and O 
in O 
silico O 
studies O 
, O 
this O 
variant O 
is O 
unlikely O 
to O 
cause O 
a O 
functional O 
derangement O 
of O 
the O 
receptor O 
. O 

ranges O 
for O 
serum O 
thyroid O 
hormones O 
free O 
triiodothyronine B-TRIVIAL 
( O 
FT3 O 
) O 
, O 
free O 
thyroxine B-TRIVIAL 
( O 
FT4 O 
) O 
and O 
thyroid O 
stimulating O 
hormone O 
( O 
TSH O 
) O 
in O 
children O 
were O 
set O 
using O 
the O 
assay O 
kits O 
currently O 
used O 
in O 
clinical O 
settings O 
. O 
A O 
total O 
of O 
342 O 
children O 
( O 
111 O 
males O 
and O 
231 O 
females O 
) O 
who O 
were O 
negative O 
for O 
antithyroid O 
antibodies O 
( O 
TgAb O 
, O 
TPOAb O 
) O 
and O 
were O 
found O 
to O 
have O 
no O 
abnormalities O 
on O 
ultrasonographic O 
examination O 
of O 
the O 
thyroid O 
gland O 
were O 
divided O 
into O 
6 O 
age O 
groups O 
: O 
4-6 O 
years O 
( O 
45 O 
children O 
) O 
, O 
7-8 O 
years O 
( O 
40 O 
) O 
, O 
9-10 O 
years O 
( O 
53 O 
) O 
, O 
11-12 O 
years O 
( O 
65 O 
) O 
, O 
13-14 O 
years O 
( O 
83 O 
) O 
, O 
and O 
15 O 
years O 
( O 
56 O 
) O 
for O 
the O 
study O 
. O 
FT3 O 
, O 
FT4 O 
and O 
TSH O 
levels O 
were O 
determined O 
by O 
electrochemiluminescence O 
immunoassay O 
( O 
ECLIA O 
) O 
( O 
ECLusys O 
FT3 O 
, O 
FT4 O 
and O 
TSH).The O 
reference O 
range O 
for O 
FT3 O 
( O 
pg O 
/ O 
mL O 
) O 
was O 
2.91-4.70 O 
for O 
the O 
age O 
group O 
of O 
4-6 O 
years O 
, O 
3.10-5.10 O 
for O 
the O 
age O 
group O 
of O 
7-8 O 
years O 
, O 
3.10-4.87 O 
for O 
the O 
age O 
group O 
of O 
9-10 O 
years O 
, O 
2.78-4.90 O 
for O 
the O 
age O 
group O 
of O 
11-12 O 
years O 
, O 
2.77-4.59 O 
for O 
the O 
age O 
group O 
of O 
13-14 O 
years O 
, O 
and O 
2.50-4.64 O 
for O 
the O 
age O 
group O 
of O 
15 O 
years O 
. O 
The O 
reference O 
range O 
for O 
FT4 O 
( O 
ng O 
/ O 
dL O 
) O 
was O 
1.12-1.67 O 
, O 
1.07-1.61 O 
, O 
0.96-1.60 O 
, O 
1.02-1.52 O 
, O 
0.96-1.52 O 
, O 
0.95-1.53 O 
. O 
The O 
reference O 
range O 
for O 
TSH O 
( O 
μU O 
/ O 
mL O 
) O 
was O 
0.62-4.90 O 
, O 
0.53-5.16 O 
, O 
0.67-4.52 O 
, O 
0.62-3.36 O 
, O 
0.54-2.78 O 
, O 
0.32-3.00 O 
. O 
Serum O 
FT3 O 
, O 
FT4 O 
and O 
TSH O 
levels O 
in O 
children O 
differ O 
from O 
those O 
in O 
adults O 
. O 
It O 
is O 
, O 
therefore O 
, O 
of O 
importance O 
to O 
perform O 
evaluation O 
of O 
thyroid O 
function O 
in O 
children O 
using O 
reference O 
values O 
appropriate O 
for O 
the O 
chronological O 
ages O 
, O 
because O 
misdiagnosis O 
of O 
hypothyroidism O 
or O 
inappropriate O 
secretion O 
of O 
TSH O 
( O 
SITSH O 
) O 
and O 
oversight O 
of O 
mild O 
subclinical O 
hypothyroidism O 
could O 
occur O 
if O 
the O 
diagnosis O 
is O 
made O 
using O 
reference O 
values O 
for O 
adults O 
. O 

modification O 
of O 
PDMS B-ABBREVIATION 
microfluidic O 
devices O 
to O 
resist O 
thrombus O 
formation O 
in O 
whole O 
blood O 
. O 

polydimethylsiloxane B-SYSTEMATIC 
microfluidic O 
devices O 
were O 
modified O 
with O 
a O 
sulfobetaine B-SYSTEMATIC 
polymer O 
through O 
continuous O 
" O 
tip O 
- O 
to O 
- O 
tip O 
" O 
modification O 
, O 
significantly O 
reducing O 
blood O 
clotting O 
and O 
extending O 
device O 
patency O 
under O 
blood O 
flow O 
. O 
This O 
technology O 
can O 
be O 
designed O 
to O 
enable O 
the O 
development O 
of O 
devices O 
that O 
can O 
continuously O 
work O 
in O 
whole O 
blood O 
, O 
especially O 
in O 
an O 
extracorporeal O 
or O 
in O 
vivo O 
environment O 
. O 

triclosan B-TRIVIAL 
-induced O 
ecological O 
and O 
trans-generational O 
effects O 
in O 
natural O 
phytoplankton O 
communities O 
: O 
a O 
trait O 
- O 
based O 
field O 
method O 
. O 

exposed O 
replicated O 
phytoplankton O 
communities O 
confined O 
in O 
semi-permeable O 
membrane O 
- O 
based O 
mesocosms O 
to O 
0 O 
, O 
0.1 O 
, O 
1 O 
and O 
10 O 
μg O 
L(-1) O 
triclosan B-TRIVIAL 
( O 
TCS B-ABBREVIATION 
) O 
and O 
placed O 
them O 
back O 
in O 
their O 
original O 
environment O 
to O 
investigate O 
the O 
occurrence O 
of O 
trans-generational O 
responses O 
at O 
individual O 
, O 
population O 
and O 
community O 
levels O 
. O 
TCS B-ABBREVIATION 
diffused O 
out O 
of O 
mesocosms O 
with O 
a O 
half O 
- O 
life O 
of O 
less O 
than O 
8 O 
h O 
, O 
so O 
that O 
only O 
the O 
parental O 
generation O 
was O 
directly O 
stressed O 
. O 
At O 
the O 
beginning O 
of O 
the O 
experiment O 
and O 
after O 
7 O 
days O 
( O 
approximately O 
2 O 
generations O 
) O 
we O 
analysed O 
responses O 
in O 
the O 
phytoplankton O 
using O 
scanning O 
flow O 
- O 
cytometry O 
. O 
We O 
acquired O 
information O 
on O 
several O 
individually O 
expressed O 
phenotypic O 
traits O 
, O 
such O 
as O 
size O 
, O 
biovolume O 
, O 
pigment O 
fluorescence O 
and O 
packaging O 
, O 
for O 
thousands O 
of O 
individuals O 
per O 
replicated O 
population O 
and O 
derived O 
population O 
and O 
community O 
aggregated O 
traits O 
. O 
We O 
found O 
significant O 
changes O 
in O 
community O 
functioning O 
( O 
increased O 
productivity O 
in O 
terms O 
of O 
biovolume O 
and O 
total O 
fluorescence O 
) O 
, O 
with O 
maximal O 
effects O 
at O 
1 O 
μg O 
L(-1) O 
TCS B-ABBREVIATION 
. O 
We O 
detected O 
significant O 
and O 
dose O 
- O 
dependent O 
responses O 
on O 
population O 
traits O 
, O 
such O 
as O 
changes O 
in O 
abundance O 
for O 
several O 
populations O 
, O 
increased O 
average O 
size O 
and O 
fluorescence O 
of O 
cells O 
, O 
and O 
strong O 
changes O 
in O 
within O 
- O 
population O 
trait O 
mean O 
and O 
variance O 
( O 
suggesting O 
micro O 
- O 
evolutionary O 
effects O 
) O 
. O 
We O 
applied O 
the O 
Price O 
equation O 
approach O 
to O 
partition O 
community O 
effects O 
( O 
changes O 
in O 
biovolume O 
or O 
fluorescence O 
) O 
in O 
their O 
physiological O 
and O 
ecological O 
components O 
, O 
and O 
quantified O 
the O 
residual O 
component O 
( O 
including O 
also O 
evolutionary O 
responses O 
) O 
. O 
Our O 
results O 
suggested O 
that O 
evolutionary O 
or O 
inheritable O 
phenotypic O 
plasticity O 
responses O 
may O 
represent O 
a O 
significant O 
component O 
of O 
the O 
total O 
observed O 
change O 
following O 
exposure O 
and O 
over O 
relatively O 
small O 
temporal O 
scales O 
. O 

response O 
demonstrated O 
by O 
18F-FDG B-SYSTEMATIC 
-PET O 
/ O 
CT O 
in O 
metastatic O 
medullary O 
thyroid O 
carcinoma O 
under O 
sorafenib B-TRIVIAL 
therapy O 
. O 

51-year- O 
old O 
woman O 
with O 
a O 
medullary O 
thyroid O 
carcinoma O 
( O 
MTC O 
) O 
presented O 
with O 
a O 
palpable O 
nodule O 
in O 
the O 
right O 
breast O 
. O 
Serum O 
calcitonin O 
was O 
1453 O 
pg O 
/ O 
ml O 
and O 
carcinoembryonic O 
antigen O 
was O 
201 O 
ng O 
/ O 
ml O 
. O 
Cervical O 
ultrasound O 
and O 
bone O 
scintigraphy O 
were O 
normal O 
. O 
Computed O 
tomography O 
( O 
CT O 
) O 
showed O 
nodules O 
in O 
the O 
right O 
breast O 
and O 
anterior O 
thoracic O 
wall O 
and O 
a O 
hypodense O 
lesion O 
in O 
the O 
right O 
hepatic O 
lobe O 
. O 
Histology O 
of O 
the O 
breast O 
nodule O 
confirmed O 
metastasis O 
from O 
MTC O 
. O 
To O 
evaluate O 
the O 
metabolic O 
activity O 
of O 
these O 
lesions O 
, O 
18F-fluorodeoxiglucose B-SYSTEMATIC 
positron O 
emission O 
tomography-CT O 
( O 
FDG B-ABBREVIATION 
-PET O 
/ O 
CT O 
) O 
scan O 
was O 
requested O 
. O 
Axial O 
fused O 
images O 
revealed O 
high O 
FDG B-ABBREVIATION 
uptake O 
by O 
the O 
breast O 
and O 
thoracic O 
wall O 
nodules O 
and O 
the O 
right O 
hepatic O 
lobe O 
. O 
FDG B-ABBREVIATION 
-PET O 
/ O 
CT O 
also O 
showed O 
uptake O 
in O 
sacrum O 
and O 
right O 
iliac O 
bone O 
, O 
undetected O 
by O 
CT O 
and O 
bone O 
scintigraphy O 
. O 
After O 
seven O 
cycles O 
of O 
sorafenib B-TRIVIAL 
PET O 
/ O 
CT O 
became O 
negative O 
. O 
Calcitonin O 
decreased O 
to O 
82.5 O 
. O 
A O 
PET O 
/ O 
CT O 
performed O 
6 O 
months O 
later O 
remained O 
negative O 
. O 
This O 
is O 
the O 
first O 
published O 
image O 
of O 
the O 
complete O 
metabolic O 
response O 
of O 
MTC O 
to O 
sorafenib B-TRIVIAL 
therapy O 
using O 
FDG B-ABBREVIATION 
-PET O 
/ O 
CT O 
. O 

of O 
a O 
compound O 
is O 
determined O 
by O 
the O 
intracellular O 
concentration O 
mediated O 
both O 
by O 
passive O 
permeability O 
and O 
active O 
uptake O 
through O 
drug O 
transporters O 
. O 
However O 
, O 
the O 
major O 
liver O 
uptake O 
transporters O 
were O 
either O 
absent O 
or O 
expressed O 
at O 
significantly O 
lower O 
levels O 
in O 
human O 
liver O 
cell O 
lines O 
than O 
in O 
human O 
liver O 
. O 
When O 
comparing O 
cytotoxicity O 
of O 
five O 
statins O 
, O 
the O 
organic O 
anion O 
transporting O 
polypeptide O 
1B1 O 
( O 
OATP1B1 O 
) O 
expressing O 
HEK O 
cells O 
showed O 
a O 
significantly O 
higher O 
sensitivity O 
than O 
the O 
wild O 
- O 
type O 
HEK O 
cells O 
. O 
The O 
IC50 O 
shifts O 
ranged O 
from O 
9- O 
to O 
> O 
100-fold O 
, O 
and O 
the O 
potency O 
shifts O 
collapsed O 
in O 
the O 
presence O 
of O 
rifampicin B-TRIVIAL 
, O 
the O 
inhibitor O 
for O 
OATPs O 
. O 
The O 
extent O 
of O 
the O 
IC50 O 
shift O 
correlated O 
with O 
the O 
permeability O 
of O 
the O 
statins O 
with O 
high O 
permeable O 
compounds O 
having O 
smaller O 
shifts O 
and O 
low O 
permeable O 
compounds O 
having O 
larger O 
shifts O 
. O 
The O 
changes O 
in O 
statin O 
potency O 
in O 
transporter O 
transfected O 
cells O 
reflect O 
the O 
active O 
uptake O 
of O 
statins O 
into O 
the O 
cells O 
and O 
the O 
increased O 
intracellular O 
drug O 
concentration O 
lead O 
to O 
increased O 
toxicity O 
. O 
The O 
data O 
suggested O 
that O 
uptake O 
transporters O 
have O 
a O 
significant O 
impact O 
on O 
the O 
outcomes O 
of O 
a O 
cell O 
- O 
based O 
assay O 
and O 
should O 
be O 
considered O 
during O 
the O 
early O 
stages O 
of O 
compound O 
toxicity O 
screening O 
in O 
drug O 
discovery O 
. O 
For O 
compounds O 
with O 
low O 
permeability O 
which O 
are O 
likely O 
to O 
undergo O 
transporter O 
- O 
mediated O 
uptake O 
, O 
it O 
is O 
important O 
to O 
test O 
them O 
in O 
transporter O 
- O 
competent O 
cell O 
models O 
. O 

of O 
a O 
novel O 
mRNA O 
transcript O 
for O 
human O 
microsomal O 
epoxide B-SYSTEMATIC 
hydrolase O 
( O 
EPHX1 O 
) O 
is O 
regulated O 
by O 
short O 
open O 
reading O 
frames O 
within O 
its O 
5'-untranslated O 
region O 
. O 

epoxide B-SYSTEMATIC 
hydrolase O 
( O 
mEH O 
, O 
EPHX1 O 
) O 
is O 
a O 
critical O 
xenobiotic O 
- O 
metabolizing O 
enzyme O 
, O 
catalyzing O 
both O 
detoxification O 
and O 
bioactivation O 
reactions O 
that O 
direct O 
the O 
disposition O 
of O 
chemical O 
epoxides B-FAMILY 
, O 
including O 
the O 
carcinogenic O 
metabolites O 
of O 
several O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
. O 
Recently O 
, O 
we O 
discovered O 
that O 
a O 
previously O 
unrecognized O 
and O 
primate O 
- O 
specific O 
EPHX1 O 
transcript O 
, O 
termed O 
E1-b O 
, O 
was O 
actually O 
the O 
predominant O 
driver O 
of O 
EPHX1 O 
expression O 
in O 
all O 
human O 
tissues O 
. O 
In O 
this O 
study O 
, O 
we O 
identify O 
another O 
human O 
EPHX1 O 
transcript O 
, O 
designated O 
as O 
E1-b O 
' O 
. O 
Unusually O 
, O 
both O 
the O 
E1-b O 
and O 
E1-b O 
' O 
mRNA O 
transcripts O 
are O 
generated O 
from O 
the O 
use O 
of O 
a O 
far O 
upstream O 
gene O 
promoter O 
, O 
localized O 
∼18.5 O 
kb O 
5'-upstream O 
of O 
the O 
EPHX1 O 
protein O 
- O 
coding O 
region O 
. O 
Although O 
expressed O 
at O 
comparatively O 
lower O 
levels O 
than O 
E1-b O 
, O 
the O 
novel O 
E1-b O 
' O 
transcript O 
is O 
readily O 
detected O 
in O 
all O 
tissues O 
examined O 
, O 
with O 
highest O 
levels O 
maintained O 
in O 
human O 
ovary O 
. O 
The O 
E1-b O 
' O 
mRNA O 
possesses O 
unusual O 
functional O 
features O 
in O 
its O 
5'-untranslated O 
region O 
, O 
including O 
a O 
GC-rich O 
leader O 
sequence O 
and O 
two O 
upstream O 
AUGs O 
that O 
encode O 
for O 
short O 
peptides O 
of O 
26 O 
and O 
17 O 
amino O 
acids O 
in O 
length O 
, O 
respectively O 
. O 
Results O 
from O 
in O 
vitro O 
transcription O 
/ O 
translation O 
assays O 
and O 
direct O 
transfection O 
in O 
mammalian O 
cells O 
of O 
either O 
the O 
E1-b O 
' O 
transcript O 
or O 
the O 
encoded O 
peptides O 
demonstrated O 
that O 
the O 
E1-b O 
' O 
upstream O 
open O 
reading O 
frames O 
( O 
uORFs O 
) O 
are O 
functional O 
, O 
with O 
their O 
presence O 
markedly O 
inhibiting O 
the O 
translation O 
of O 
EPHX1 O 
protein O 
, O 
both O 
in O 
cis O 
and O 
in O 
trans O 
configurations O 
. O 
These O 
unique O 
uORF O 
peptides O 
exhibit O 
no O 
homology O 
to O 
any O 
other O 
known O 
uORF O 
sequences O 
but O 
likely O 
function O 
to O 
mediate O 
post O 
- O 
transcription O 
regulation O 
of O 
EPHX1 O 
and O 
perhaps O 
more O 
broadly O 
as O 
translational O 
regulators O 
in O 
human O 
cells O 
. O 

of O 
Intraduodenal O 
Glutamine B-TRIVIAL 
on O 
Incretin O 
Hormone O 
and O 
Insulin O 
Release O 
, O 
the O 
Glycemic O 
Response O 
to O 
an O 
Intraduodenal O 
Glucose B-TRIVIAL 
Infusion O 
, O 
and O 
Antropyloroduodenal O 
Motility O 
in O 
Health O 
and O 
Type O 
2 O 
Diabetes O 
. O 

Glutamine B-TRIVIAL 
reduces O 
postprandial O 
glycemia O 
when O 
given O 
before O 
oral O 
glucose B-TRIVIAL 
. O 
We O 
evaluated O 
whether O 
this O 
is O 
mediated O 
by O 
stimulation O 
of O 
insulin O 
and O 
/ O 
or O 
slowing O 
of O 
gastric O 
emptying.RESEARCH O 
DESIGN O 
AND O 
METHODSTen O 
healthy O 
subjects O 
were O 
studied O 
during O 
intraduodenal O 
( O 
ID O 
) O 
infusion O 
of O 
glutamine B-TRIVIAL 
( O 
7.5 O 
or O 
15 O 
g O 
) O 
or O 
saline O 
over O 
30 O 
min O 
, O 
followed O 
by O 
glucose B-TRIVIAL 
( O 
75 O 
g O 
over O 
100 O 
min O 
) O 
, O 
while O 
recording O 
antropyloroduodenal O 
pressures O 
. O 
Ten O 
patients O 
with O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
were O 
also O 
studied O 
with O 
15 O 
g O 
glutamine B-TRIVIAL 
or O 
saline.RESULTSID O 
glutamine B-TRIVIAL 
stimulated O 
glucagon O 
- O 
like O 
peptide O 
1 O 
( O 
GLP-1 O 
; O 
healthy O 
: O 
P O 
< O 
0.05 O 
; O 
T2DM O 
: O 
P O 
< O 
0.05 O 
) O 
, O 
glucose B-TRIVIAL 
-dependent O 
insulinotropic O 
polypeptide O 
( O 
GIP O 
; O 
P O 
= O 
0.098 O 
; O 
P O 
< O 
0.05 O 
) O 
, O 
glucagon O 
( O 
P O 
< O 
0.01 O 
; O 
P O 
< O 
0.001 O 
) O 
, O 
insulin O 
( O 
P O 
= O 
0.05 O 
; O 
P O 
< O 
0.01 O 
) O 
, O 
and O 
phasic O 
pyloric O 
pressures O 
( O 
P O 
< O 
0.05 O 
; O 
P O 
< O 
0.05 O 
) O 
, O 
but O 
did O 
not O 
lower O 
blood O 
glucose B-TRIVIAL 
( O 
P O 
= O 
0.077 O 
; O 
P O 
= O 
0.5).CONCLUSIONS O 
Glutamine B-TRIVIAL 
does O 
not O 
lower O 
glycemia O 
after O 
ID O 
glucose B-TRIVIAL 
, O 
despite O 
stimulating O 
GLP-1 O 
, O 
GIP O 
, O 
and O 
insulin O 
, O 
probably O 
due O 
to O 
increased O 
glucagon O 
. O 
Its O 
capacity O 
for O 
pyloric O 
stimulation O 
suggests O 
that O 
delayed O 
gastric O 
emptying O 
is O 
a O 
major O 
mechanism O 
for O 
lowering O 
glycemia O 
when O 
glutamine B-TRIVIAL 
is O 
given O 
before O 
oral O 
glucose B-TRIVIAL 
. O 

Carbohydrate B-FAMILY 
Diet O 
for O 
the O 
Treatment O 
of O 
Gestational O 
Diabetes O 
: O 
A O 
randomized O 
controlled O 
trial O 
. O 

nutrition O 
therapy O 
based O 
on O 
the O 
control O 
of O 
the O 
amount O 
and O 
distribution O 
of O 
carbohydrates B-FAMILY 
( O 
CHO B-FORMULA 
) O 
is O 
the O 
initial O 
treatment O 
for O 
gestational O 
diabetes O 
mellitus O 
( O 
GDM O 
) O 
, O 
but O 
there O 
is O 
a O 
need O 
for O 
randomized O 
controlled O 
trials O 
comparing O 
different O 
dietary O 
strategies O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
test O 
the O 
hypothesis O 
that O 
a O 
low- O 
CHO B-FORMULA 
diet O 
for O 
the O 
treatment O 
of O 
GDM O 
would O 
lead O 
to O 
a O 
lower O 
rate O 
of O 
insulin O 
treatment O 
with O 
similar O 
pregnancy O 
outcomes O 
compared O 
with O 
a O 
control O 
diet.RESEARCH O 
DESIGN O 
AND O 
METHODSA O 
total O 
of O 
152 O 
women O 
with O 
GDM O 
were O 
included O 
in O 
this O 
open O 
, O 
randomized O 
controlled O 
trial O 
and O 
assigned O 
to O 
follow O 
either O 
a O 
diet O 
with O 
low- O 
CHO B-FORMULA 
content O 
( O 
40% O 
of O 
the O 
total O 
diet O 
energy O 
content O 
as O 
CHO B-FORMULA 
) O 
or O 
a O 
control O 
diet O 
( O 
55% O 
of O 
the O 
total O 
diet O 
energy O 
content O 
as O 
CHO B-FORMULA 
) O 
. O 
CHO B-FORMULA 
intake O 
was O 
assessed O 
by O 
3-day O 
food O 
records O 
. O 
The O 
main O 
pregnancy O 
outcomes O 
were O 
also O 
assessed.RESULTSThe O 
rate O 
of O 
women O 
requiring O 
insulin O 
was O 
not O 
significantly O 
different O 
between O 
the O 
treatment O 
groups O 
( O 
low O 
CHO B-FORMULA 
54.7% O 
vs O 
. O 
control O 
54.7% O 
; O 
P O 
= O 
1 O 
) O 
. O 
Daily O 
food O 
records O 
confirmed O 
a O 
difference O 
in O 
the O 
amount O 
of O 
CHO B-FORMULA 
consumed O 
between O 
the O 
groups O 
( O 
P O 
= O 
0.0001 O 
) O 
. O 
No O 
differences O 
were O 
found O 
in O 
the O 
obstetric O 
and O 
perinatal O 
outcomes O 
between O 
the O 
treatment O 
groups.CONCLUSIONSTreatment O 
of O 
women O 
with O 
GDM O 
using O 
a O 
low- O 
CHO B-FORMULA 
diet O 
did O 
not O 
reduce O 
the O 
number O 
of O 
women O 
needing O 
insulin O 
and O 
produced O 
similar O 
pregnancy O 
outcomes O 
. O 
In O 
GDM O 
, O 
CHO B-FORMULA 
amount O 
( O 
40 O 
vs O 
. O 
55% O 
of O 
calories O 
) O 
did O 
not O 
influence O 
insulin O 
need O 
or O 
pregnancy O 
outcomes O 
. O 

describe O 
and O 
make O 
available O 
an O 
interactive O 
, O 
24-variable O 
homeostasis O 
model O 
assessment O 
( O 
iHOMA2 O 
) O 
that O 
extends O 
the O 
HOMA2 O 
model O 
, O 
enabling O 
the O 
modeling O 
of O 
physiology O 
and O 
treatment O 
effects O 
, O 
to O 
present O 
equations O 
of O 
the O 
HOMA2 O 
and O 
iHOMA2 O 
models O 
, O 
and O 
to O 
exemplify O 
iHOMA2 O 
in O 
two O 
widely O 
differing O 
scenarios O 
: O 
changes O 
in O 
insulin O 
sensitivity O 
with O 
thiazolidinediones B-FAMILY 
and O 
changes O 
in O 
renal O 
threshold O 
with O 
sodium B-SYSTEMATIC 
glucose B-TRIVIAL 
transporter O 
( O 
SGLT2 O 
) O 
inhibition.RESEARCH O 
DESIGN O 
AND O 
METHODSiHOMA2 O 
enables O 
a O 
user O 
of O 
the O 
available O 
software O 
to O 
examine O 
and O 
modify O 
the O 
mathematical O 
functions O 
describing O 
the O 
organs O 
and O 
tissues O 
involved O 
in O 
the O 
glucose B-TRIVIAL 
and O 
hormonal O 
compartments O 
. O 
We O 
exemplify O 
this O 
with O 
SGLT2 O 
inhibition O 
modeling O 
( O 
by O 
changing O 
the O 
renal O 
threshold O 
parameters O 
) O 
using O 
published O 
data O 
of O 
renal O 
effect O 
, O 
showing O 
that O 
the O 
modeled O 
effect O 
is O 
concordant O 
with O 
the O 
effects O 
on O 
fasting O 
glucose B-TRIVIAL 
from O 
independent O 
data.RESULTSiHOMA2 O 
modeling O 
of O 
thiazolidinediones B-FAMILY 
effect O 
suggested O 
that O 
changes O 
in O 
insulin O 
sensitivity O 
in O 
the O 
fasting O 
state O 
are O 
predominantly O 
hepatic O 
. O 
SGLT2 O 
inhibition O 
modeled O 
by O 
iHOMA2 O 
resulted O 
in O 
a O 
decrease O 
in O 
mean O 
glucose B-TRIVIAL 
of O 
1.1 O 
mmol O 
/ O 
L O 
. O 
Observed O 
data O 
showed O 
a O 
decrease O 
in O 
glucose B-TRIVIAL 
of O 
0.9 O 
mmol O 
/ O 
L O 
. O 
There O 
was O 
no O 
significant O 
difference O 
between O 
the O 
model O 
and O 
the O 
independent O 
data O 
. O 
Manipulation O 
of O 
iHOMA2s O 
renal O 
excretion O 
threshold O 
variable O 
suggested O 
that O 
a O 
decrease O 
of O 
17% O 
was O 
required O 
to O 
obtain O 
a O 
0.9 O 
mmol O 
/ O 
L O 
decrease O 
in O 
mean O 
glucose B-TRIVIAL 
.CONCLUSIONSiHOMA2 O 
is O 
an O 
extended O 
mathematical O 
model O 
for O 
the O 
assessment O 
of O 
insulin O 
resistance O 
and O 
β-cell O 
function O 
. O 
The O 
model O 
can O 
be O 
used O 
to O 
evaluate O 
therapeutic O 
agents O 
and O 
predict O 
effects O 
on O 
fasting O 
glucose B-TRIVIAL 
and O 
insulin O 
and O 
on O 
β-cell O 
function O 
and O 
insulin O 
sensitivity O 
. O 

neurotoxins O 
( O 
BoNTs O 
) O 
are O 
among O 
the O 
most O 
deadly O 
poisons O 
known O 
though O 
ironically O 
, O 
they O 
also O 
are O 
of O 
great O 
therapeutic O 
utility O 
. O 
A O 
number O 
of O 
research O 
programs O 
have O 
been O 
initiated O 
to O 
discover O 
small O 
molecule O 
inhibitors O 
of O 
BoNTs O 
metalloprotease O 
activity O 
. O 
Many O 
, O 
though O 
not O 
all O 
of O 
these O 
programs O 
have O 
screened O 
against O 
a O 
truncated O 
and O 
more O 
stable O 
form O 
of O 
the O 
enzyme O 
, O 
that O 
possess O 
comparable O 
catalytic O 
properties O 
to O 
the O 
full O 
length O 
enzyme O 
. O 
Interestingly O 
, O 
several O 
classes O 
of O 
inhibitors O 
notably O 
the O 
hydroxamates B-FAMILY 
, O 
display O 
a O 
large O 
shift O 
in O 
potency O 
between O 
the O 
two O 
enzyme O 
forms O 
. O 
In O 
this O 
report O 
we O 
compare O 
the O 
kinetics O 
of O 
active O 
- O 
site O 
, O 
alpha-exosite O 
and O 
beta-exosite O 
inhibitors O 
versus O 
truncated O 
and O 
full O 
length O 
enzyme O 
. O 
Molecular O 
dynamics O 
simulations O 
conducted O 
with O 
the O 
truncated O 
and O 
homology O 
models O 
of O 
the O 
fully O 
length O 
BoNT O 
LC O 
/ O 
A O 
indicate O 
the O 
flexibility O 
of O 
the O 
C-terminus O 
of O 
the O 
full O 
length O 
enzyme O 
is O 
responsible O 
for O 
the O 
potency O 
shifts O 
of O 
active O 
- O 
site O 
proximally O 
binding O 
inhibitors O 
while O 
distal O 
binding O 
( O 
alpha-exosite O 
) O 
inhibitors O 
remain O 
equipotent O 
. O 

drug O 
- O 
induced O 
liver O 
injury O 
( O 
IDILI O 
) O 
is O 
a O 
major O 
problem O 
during O 
drug O 
development O 
and O 
has O 
caused O 
drug O 
withdrawal O 
and O 
black O 
- O 
box O 
warnings O 
. O 
Because O 
of O 
the O 
low O 
concordance O 
of O 
the O 
hepatotoxicity O 
of O 
drugs O 
in O 
animals O 
and O 
humans O 
, O 
robust O 
screening O 
methods O 
using O 
human O 
tissue O 
are O 
needed O 
to O 
predict O 
IDILI O 
in O 
humans O 
. O 
According O 
to O 
the O 
inflammatory O 
stress O 
hypothesis O 
, O 
the O 
effects O 
of O 
inflammation O 
interact O 
with O 
the O 
effects O 
of O 
a O 
drug O 
or O 
its O 
reactive O 
metabolite O 
, O 
precipitating O 
toxic O 
reactions O 
in O 
the O 
liver O 
. O 
As O 
a O 
follow O 
- O 
up O 
to O 
our O 
recently O 
published O 
mouse O 
precision O 
- O 
cut O 
liver O 
slices O 
model O 
, O 
an O 
ex O 
vivo O 
model O 
involving O 
human O 
precision O 
- O 
cut O 
liver O 
slices O 
( O 
hPCLS O 
) O 
, O 
co O 
- O 
incubated O 
for O 
24 O 
h O 
with O 
IDILI O 
- O 
related O 
drugs O 
and O 
lipopolysaccharide O 
( O 
LPS O 
) O 
, O 
was O 
developed O 
to O 
study O 
IDILI O 
mechanisms O 
related O 
to O 
inflammatory O 
stress O 
in O 
humans O 
and O 
to O 
detect O 
potential O 
biomarkers O 
. O 
LPS O 
exacerbated O 
the O 
effects O 
of O 
ketoconazole B-TRIVIAL 
and O 
clozapine B-TRIVIAL 
toxicity O 
but O 
not O 
those O 
of O 
their O 
non-IDILI O 
- O 
related O 
comparators O 
, O 
voriconazole B-TRIVIAL 
and O 
olanzapine B-TRIVIAL 
. O 
However O 
, O 
the O 
IDILI O 
- O 
related O 
drugs O 
diclofenac B-TRIVIAL 
, O 
carbamazepine B-TRIVIAL 
, O 
and O 
troglitazone B-TRIVIAL 
did O 
not O 
show O 
synergistic O 
toxicity O 
with O 
LPS O 
after O 
incubation O 
for O 
24 O 
h O 
. O 
Co-incubation O 
of O 
ketoconazole B-TRIVIAL 
and O 
clozapine B-TRIVIAL 
with O 
LPS O 
decreased O 
the O 
levels O 
of O 
glutathione B-TRIVIAL 
in O 
hPCLS O 
, O 
but O 
this O 
was O 
not O 
seen O 
for O 
the O 
other O 
drugs O 
. O 
All O 
drugs O 
affected O 
LPS-induced O 
cytokine O 
release O 
, O 
but O 
interestingly O 
, O 
only O 
ketoconazole B-TRIVIAL 
and O 
clozapine B-TRIVIAL 
increased O 
the O 
level O 
of O 
LPS-induced O 
TNF O 
release O 
. O 
Decreased O 
levels O 
of O 
glutathione B-TRIVIAL 
and O 
cysteine B-TRIVIAL 
conjugates O 
of O 
clozapine B-TRIVIAL 
were O 
detected O 
in O 
IDILI-responding O 
livers O 
following O 
cotreatment O 
with O 
LPS O 
. O 
In O 
conclusion O 
, O 
we O 
identified O 
ketoconazole B-TRIVIAL 
and O 
clozapine B-TRIVIAL 
as O 
drugs O 
that O 
exhibited O 
synergistic O 
toxicity O 
with O 
LPS O 
, O 
while O 
glutathione B-TRIVIAL 
and O 
TNF O 
were O 
found O 
to O 
be O 
potential O 
biomarkers O 
for O 
IDILI-inducing O 
drugs O 
mediated O 
by O 
inflammatory O 
stress O 
. O 
hPCLS O 
appear O 
to O 
be O 
suitable O 
for O 
further O 
unraveling O 
the O 
mechanisms O 
of O 
inflammatory O 
stress O 
- O 
associated O 
IDILI O 
. O 

the O 
Effective O 
Surface O 
Area O 
and O 
Pore O 
Size O 
Distribution O 
of O 
sp(2) O 
Carbon B-SYSTEMATIC 
Materials O 
and O 
Their O 
Impact O 
on O 
the O 
Capacitance O 
Performance O 
of O 
These O 
Materials O 
. O 

series O 
of O 
sp(2) O 
carbon B-SYSTEMATIC 
materials O 
with O 
different O 
specific O 
surface O 
area O 
( O 
SSA O 
) O 
and O 
controlled O 
pore O 
size O 
distribution O 
( O 
PSD O 
) O 
were O 
synthesized O 
at O 
large O 
scale O 
through O 
a O 
facile O 
and O 
low O 
- O 
cost O 
method O 
. O 
The O 
SSA O 
and O 
PSD O 
of O 
these O 
carbon B-SYSTEMATIC 
materials O 
were O 
controlled O 
by O 
using O 
different O 
carbon B-SYSTEMATIC 
sources O 
and O 
preparation O 
methods O 
. O 
With O 
different O 
total O 
and O 
effective O 
SSA O 
( O 
E-SSA O 
) O 
and O 
PSD O 
, O 
the O 
impacts O 
on O 
their O 
capacitance O 
performance O 
were O 
investigated O 
thoroughly O 
, O 
which O 
demonstrated O 
that O 
both O 
E-SSA O 
and O 
PSD O 
played O 
the O 
most O 
important O 
roles O 
in O 
their O 
capacitance O 
performance O 
. O 
Furthermore O 
, O 
theoretical O 
modeling O 
was O 
performed O 
, O 
and O 
the O 
results O 
are O 
in O 
agreement O 
with O 
the O 
experimental O 
results O 
for O 
the O 
influence O 
of O 
E-SSA O 
and O 
PSD O 
on O 
their O 
capacitance O 
performance O 
. O 
Based O 
on O 
these O 
, O 
a O 
general O 
model O 
using O 
the O 
slit O 
/ O 
cylindrical O 
NL-DFT O 
approach O 
is O 
proposed O 
for O 
the O 
estimation O 
of O 
the O 
specific O 
capacitance O 
of O 
sp(2) O 
carbon B-SYSTEMATIC 
materials O 
, O 
which O 
offers O 
a O 
simple O 
but O 
reliable O 
method O 
to O 
predict O 
the O 
capacitance O 
performance O 
of O 
these O 
materials O 
, O 
thus O 
speeding O 
up O 
the O 
design O 
and O 
screening O 
of O 
the O 
materials O 
for O 
high O 
- O 
performance O 
supercapacitor O 
and O 
other O 
surface O 
area O 
related O 
devices O 
. O 

to O 
dark O 
spin O 
cooling O 
in O 
a O 
diamond B-TRIVIAL 
nanocrystal O 
. O 

a O 
Hartman-Hahn O 
protocol O 
, O 
we O 
demonstrate O 
spin O 
polarization O 
transfer O 
from O 
a O 
single O 
, O 
optically O 
polarized O 
nitrogen B-SYSTEMATIC 
-vacancy O 
( O 
NV O 
) O 
center O 
to O 
the O 
ensemble O 
of O 
paramagnetic O 
defects O 
hosted O 
by O 
an O 
individual O 
diamond B-TRIVIAL 
nanocrystal O 
. O 
Owing O 
to O 
the O 
strong O 
NV-bath O 
coupling O 
, O 
the O 
transfer O 
takes O 
place O 
on O 
a O 
short O 
, O 
microsecond O 
time O 
scale O 
. O 
Upon O 
fast O 
repetition O 
of O 
the O 
pulse O 
sequence O 
, O 
we O 
observe O 
strong O 
polarization O 
transfer O 
blockade O 
, O 
which O 
we O 
interpret O 
as O 
an O 
indication O 
of O 
spin O 
bath O 
cooling O 
. O 
Numerical O 
simulations O 
indicate O 
that O 
the O 
spin O 
bath O 
polarization O 
is O 
nonuniform O 
throughout O 
the O 
nanoparticle O 
, O 
averaging O 
approximately O 
5% O 
over O 
the O 
crystal O 
volume O 
, O 
but O 
reaching O 
up O 
to O 
25% O 
in O 
the O 
immediate O 
vicinity O 
of O 
the O 
NV O 
. O 
These O 
observations O 
may O 
prove O 
relevant O 
to O 
the O 
planning O 
of O 
future O 
bath O 
- O 
assisted O 
magnetometry O 
tests O 
. O 

role O 
of O 
intracrine O 
androgen B-FAMILY 
metabolism O 
, O 
androgen B-FAMILY 
receptor O 
and O 
apoptosis O 
in O 
the O 
survival O 
and O 
recurrence O 
of O 
prostate O 
cancer O 
during O 
androgen B-FAMILY 
deprivation O 
therapy O 
. O 

cancer O 
( O 
CaP O 
) O 
is O 
the O 
most O 
frequently O 
diagnosed O 
cancer O 
and O 
leading O 
cause O 
of O 
cancer O 
death O 
in O 
American O 
men O 
. O 
Almost O 
all O 
men O 
present O 
with O 
advanced O 
CaP O 
and O 
some O 
men O 
who O 
fail O 
potentially O 
curative O 
therapy O 
are O 
treated O 
with O 
androgen B-FAMILY 
deprivation O 
therapy O 
( O 
ADT O 
) O 
. O 
ADT O 
is O 
not O 
curative O 
and O 
CaP O 
recurs O 
as O 
the O 
lethal O 
phenotype O 
. O 
The O 
goal O 
of O 
this O 
review O 
is O 
to O 
apply O 
our O 
current O 
understanding O 
of O 
CaP O 
and O 
castration O 
- O 
recurrent O 
CaP O 
( O 
CR-CaP O 
) O 
to O 
earlier O 
studies O 
that O 
characterized O 
ADT O 
and O 
the O 
molecular O 
mechanisms O 
that O 
facilitate O 
the O 
transition O 
from O 
androgen B-FAMILY 
-stimulated O 
CaP O 
to O 
CR-CaP O 
. O 
Reexamination O 
of O 
earlier O 
studies O 
also O 
may O 
provide O 
a O 
better O 
understanding O 
of O 
how O 
more O 
newly O 
recognized O 
mechanisms O 
, O 
such O 
as O 
intracrine O 
metabolism O 
, O 
may O 
be O 
involved O 
with O 
the O 
early O 
events O 
that O 
allow O 
CaP O 
survival O 
after O 
initiation O 
of O 
ADT O 
and O 
subsequent O 
development O 
of O 
CR-CaP O 
. O 

is O 
a O 
key O 
, O 
ubiquitous O 
phenomenon O 
in O 
nature O 
characterized O 
by O 
a O 
complex O 
combination O 
of O 
binding O 
mechanisms O 
, O 
with O 
special O 
relevance O 
in O 
carbohydrate B-FAMILY 
-lectin O 
recognition O 
. O 
Herein O 
we O 
introduce O 
an O 
original O 
surface O 
plasmon O 
resonance O 
kinetic O 
approach O 
to O 
analyze O 
multivalent O 
interactions O 
that O 
has O 
been O 
validated O 
with O 
dendrimers O 
as O 
monodisperse O 
multivalent O 
analytes O 
binding O 
to O 
lectin O 
clusters O 
. O 
The O 
method O 
, O 
based O 
on O 
the O 
analysis O 
of O 
early O 
association O 
and O 
late O 
dissociation O 
phases O 
of O 
the O 
sensorgrams O 
provides O 
robust O 
information O 
of O 
the O 
glycoconjugate O 
binding O 
efficiency O 
and O 
real O 
- O 
time O 
structural O 
data O 
of O 
the O 
binding O 
events O 
under O 
the O 
complex O 
scenario O 
of O 
the O 
glyco O 
- O 
cluster O 
effect O 
. O 
Notably O 
, O 
it O 
reveals O 
the O 
dynamic O 
nature O 
of O 
the O 
interaction O 
and O 
offers O 
experimental O 
evidence O 
on O 
the O 
contribution O 
of O 
binding O 
mechanisms O 
. O 

Catalytic O 
Performance O 
of O 
Palladium B-SYSTEMATIC 
in O 
Gold O 
and O 
Palladium B-SYSTEMATIC 
Alloy O 
Nanoparticles O 
for O 
Organic O 
Synthesis O 
Reactions O 
through O 
Visible O 
Light O 
Irradiation O 
at O 
Ambient O 
Temperatures O 
. O 

intrinsic O 
catalytic O 
activity O 
of O 
palladium B-SYSTEMATIC 
( O 
Pd B-FORMULA 
) O 
is O 
significantly O 
enhanced O 
in O 
gold O 
( O 
Au B-FORMULA 
)- O 
Pd B-FORMULA 
alloy O 
nanoparticles O 
( O 
NPs O 
) O 
under O 
visible O 
light O 
irradiation O 
at O 
ambient O 
temperatures O 
. O 
The O 
alloy O 
NPs O 
strongly O 
absorb O 
light O 
and O 
efficiently O 
enhance O 
the O 
conversion O 
of O 
several O 
reactions O 
, O 
including O 
Suzuki-Miyaura O 
cross O 
coupling O 
, O 
oxidative O 
addition O 
of O 
benzylamine B-SYSTEMATIC 
, O 
selective O 
oxidation O 
of O 
aromatic B-FAMILY 
alcohols I-FAMILY 
to O 
corresponding O 
aldehydes B-FAMILY 
and O 
ketones B-FAMILY 
, O 
and O 
phenol B-SYSTEMATIC 
oxidation O 
. O 
The O 
Au B-FORMULA 
/ O 
Pd B-FORMULA 
molar O 
ratio O 
of O 
the O 
alloy O 
NPs O 
has O 
an O 
important O 
impact O 
on O 
performance O 
of O 
the O 
catalysts O 
since O 
it O 
determines O 
both O 
the O 
electronic O 
heterogeneity O 
and O 
the O 
distribution O 
of O 
Pd B-FORMULA 
sites O 
at O 
the O 
NP O 
surface O 
, O 
with O 
these O 
two O 
factors O 
playing O 
key O 
roles O 
in O 
the O 
catalytic O 
activity O 
. O 
Irradiating O 
with O 
light O 
produces O 
an O 
even O 
more O 
profound O 
enhancement O 
in O 
the O 
catalytic O 
performance O 
of O 
the O 
NPs O 
. O 
For O 
example O 
, O 
the O 
best O 
conversion O 
rate O 
achieved O 
thermally O 
at O 
30 O 
°C O 
for O 
Suzuki-Miyaura O 
cross O 
coupling O 
was O 
37% O 
at O 
a O 
Au B-FORMULA 
/ O 
Pd B-FORMULA 
ratio O 
of O 
1 O 
: O 
1.86 O 
, O 
while O 
under O 
light O 
illumination O 
the O 
yield O 
increased O 
to O 
96% O 
under O 
the O 
same O 
conditions O 
. O 
The O 
catalytic O 
activity O 
of O 
the O 
alloy O 
NPs O 
depends O 
on O 
the O 
intensity O 
and O 
wavelength O 
of O 
incident O 
light O 
. O 
Light O 
absorption O 
due O 
to O 
the O 
Localized O 
Surface O 
Plasmon O 
Resonance O 
of O 
gold O 
nanocrystals O 
plays O 
an O 
important O 
role O 
in O 
enhancing O 
catalyst O 
performance O 
. O 
We O 
believe O 
that O 
the O 
conduction O 
electrons O 
of O 
the O 
NPs O 
gain O 
the O 
light O 
absorbed O 
energy O 
producing O 
energetic O 
electrons O 
at O 
the O 
surface O 
Pd B-FORMULA 
sites O 
, O 
which O 
enhances O 
the O 
sites O 
' O 
intrinsic O 
catalytic O 
ability O 
. O 
These O 
findings O 
provide O 
useful O 
guidelines O 
for O 
designing O 
efficient O 
catalysts O 
composed O 
of O 
alloys O 
of O 
a O 
plasmonic O 
metal O 
and O 
a O 
catalytically O 
active O 
transition B-FAMILY 
metal I-FAMILY 
for O 
various O 
organic O 
syntheses O 
driven O 
by O 
sunlight O 
. O 

of O 
Curcumin B-TRIVIAL 
on O 
Apoptosis O 
and O 
Oxidoinflammatory O 
Regulation O 
in O 
a O 
Rat O 
Model O 
of O 
Acetic B-SYSTEMATIC 
Acid I-SYSTEMATIC 
-Induced O 
Colitis O 
: O 
The O 
Roles O 
of O 
c-Jun O 
N B-FORMULA 
-Terminal O 
Kinase O 
and O 
p38 O 
Mitogen-Activated O 
Protein O 
Kinase O 
. O 

The O 
present O 
study O 
evaluated O 
the O 
effects O 
of O 
curcumin B-TRIVIAL 
on O 
epithelial O 
cell O 
apoptosis O 
, O 
the O 
immunoreactivity O 
of O 
the O 
phospho-c-Jun O 
N B-FORMULA 
-terminal O 
kinase O 
( O 
JNK O 
) O 
and O 
phospho-p38 O 
mitogen O 
- O 
activated O 
protein O 
kinases O 
( O 
MAPKs O 
) O 
in O 
inflamed O 
colon O 
mucosa O 
, O 
and O 
oxidative O 
stress O 
in O 
a O 
rat O 
model O 
of O 
ulcerative O 
colitis O 
induced O 
by O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
Rats O 
were O 
randomly O 
divided O 
into O 
three O 
groups O 
: O 
control O 
, O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
and O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
+ O 
curcumin B-TRIVIAL 
. O 
Curcumin B-TRIVIAL 
( O 
100 O 
mg O 
/ O 
kg O 
per O 
day O 
, O 
intragastrically O 
) O 
was O 
administered O 
10 O 
days O 
before O 
the O 
induction O 
of O 
colitis O 
and O 
was O 
continued O 
for O 
two O 
additional O 
days O 
. O 
Acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-induced O 
colitis O 
caused O 
a O 
significant O 
increase O 
in O 
the O 
macroscopic O 
and O 
microscopic O 
tissue O 
ranking O 
scores O 
as O 
well O 
as O 
an O 
elevation O 
in O 
colonic O 
myeloperoxidase O 
( O 
MPO O 
) O 
activity O 
, O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
levels O 
, O 
and O 
the O 
number O 
of O 
apoptotic O 
epithelial O 
cells O 
in O 
colon O 
tissue O 
compared O 
to O 
controls O 
. O 
In O 
the O 
rat O 
colon O 
, O 
immunoreactivity O 
of O 
phospho-p38 O 
MAPK O 
was O 
increased O 
, O 
whereas O 
the O 
phospho-JNK O 
activity O 
was O 
decreased O 
following O 
the O 
induction O 
of O 
colitis O 
. O 
Curcumin B-TRIVIAL 
treatment O 
was O 
associated O 
with O 
amelioration O 
of O 
macroscopic O 
and O 
microscopic O 
colitis O 
sores O 
, O 
decreased O 
MPO O 
activity O 
, O 
and O 
decreased O 
MDA B-ABBREVIATION 
levels O 
in O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-induced O 
colitis O 
. O 
Furthermore O 
, O 
oral O 
curcumin B-TRIVIAL 
supplementation O 
clearly O 
prevented O 
programmed O 
cell O 
death O 
and O 
restored O 
immunreactivity O 
of O 
MAPKs O 
in O 
the O 
colons O 
of O 
colitic O 
rats O 
. O 
The O 
results O 
of O 
this O 
study O 
suggest O 
that O 
oral O 
curcumin B-TRIVIAL 
treatment O 
decreases O 
colon O 
injury O 
and O 
is O 
associated O 
with O 
decreased O 
inflammatory O 
reactions O 
, O 
lipid O 
peroxidation O 
, O 
apoptotic O 
cell O 
death O 
, O 
and O 
modulating O 
p38- O 
and O 
JNK-MAPK O 
pathways O 
. O 

supplementation O 
attenuates O 
body O 
temperature O 
and O 
the O 
circulating O 
levels O 
of O 
prostaglandin B-TRIVIAL 
e2 I-TRIVIAL 
and O 
cyclooxygenase-2 O 
after O 
heat O 
stress O 
in O 
humans O 
. O 

Oligonol O 
, O 
a O 
phenolic B-FAMILY 
production O 
from O 
lychee O 
, O 
has O 
been O 
reported O 
to O 
exhibit O 
anti-oxidative O 
and O 
anti-inflammatory O 
effects O 
. O 
This O 
study O 
investigated O 
the O 
effect O 
of O 
Oligonol O 
supplementation O 
on O 
circulating O 
levels O 
of O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
( O 
PGE2 B-ABBREVIATION 
) O 
and O 
cyclooxygenase O 
(COX)-2 O 
, O 
as O 
well O 
as O 
body O 
temperature O 
, O 
after O 
heat O 
stress O 
in O 
17 O 
healthy O 
human O 
male O 
volunteers O 
( O 
age O 
, O 
21.6±2.1 O 
years O 
) O 
. O 
All O 
experiments O 
were O 
performed O 
in O 
an O 
automated O 
climate O 
chamber O 
( O 
26.0°C±0.5°C O 
, O 
relative O 
humidity O 
60%±3.0% O 
, O 
air O 
velocity O 
less O 
than O 
1 O 
m O 
/ O 
sec O 
) O 
between O 
2 O 
and O 
5 O 
p.m O 
. O 
Subjects O 
ingested O 
an O 
Oligonol O 
( O 
100 O 
mg O 
) O 
- O 
containing O 
beverage O 
or O 
placebo O 
beverage O 
before O 
half O 
- O 
body O 
immersion O 
into O 
hot O 
water O 
( O 
42°C±0.5°C O 
for O 
30 O 
min O 
) O 
. O 
Tympanic O 
and O 
skin O 
temperatures O 
were O 
measured O 
and O 
mean O 
body O 
temperatures O 
were O 
calculated O 
. O 
Serum O 
concentrations O 
of O 
PGE2 B-ABBREVIATION 
and O 
COX-2 O 
were O 
analyzed O 
before O 
, O 
immediately O 
after O 
, O 
and O 
60 O 
min O 
after O 
immersion O 
. O 
Oligonol O 
intake O 
significantly O 
prevented O 
elevation O 
of O 
tympanic O 
( O 
temperature O 
difference O 
: O 
0.17°C O 
at O 
Post O 
, O 
P O 
< O 
0.05 O 
; O 
0.17°C O 
at O 
Re-60 O 
, O 
P O 
< O 
0.05 O 
) O 
and O 
mean O 
body O 
temperatures O 
( O 
temperature O 
difference O 
: O 
0.18°C O 
at O 
Post O 
, O 
P O 
< O 
0.05 O 
; O 
0.15°C O 
at O 
Re-60 O 
, O 
P O 
< O 
0.05 O 
) O 
, O 
and O 
lowered O 
concentrations O 
of O 
serum O 
PGE2 B-ABBREVIATION 
( O 
increased O 
by O 
13.3% O 
vs O 
. O 
29.6% O 
at O 
Post O 
, O 
P O 
< O 
0.05 O 
) O 
and O 
COX-2 O 
( O 
increased O 
by O 
15.6% O 
vs O 
. O 
21.8% O 
at O 
Post O 
, O 
P O 
< O 
0.05 O 
) O 
, O 
compared O 
to O 
placebo O 
beverage O 
. O 
Our O 
result O 
suggests O 
that O 
Oligonol O 
has O 
the O 
potential O 
to O 
suppress O 
increases O 
in O 
body O 
temperature O 
under O 
heat O 
stress O 
, O 
and O 
this O 
is O 
associated O 
with O 
decreases O 
in O 
serum O 
levels O 
of O 
PGE2 B-ABBREVIATION 
and O 
COX-2 O 
. O 

- O 
derived O 
enterolactone B-TRIVIAL 
is O 
inversely O 
associated O 
with O 
tumor O 
cell O 
proliferation O 
in O 
men O 
with O 
localized O 
prostate O 
cancer O 
. O 

Enterolactone B-TRIVIAL 
and O 
enterodiol B-TRIVIAL 
, O 
mammalian O 
lignans B-FAMILY 
derived O 
from O 
dietary O 
sources O 
such O 
as O 
flaxseed O 
, O 
sesame O 
seeds O 
, O 
kale O 
, O 
broccoli O 
, O 
and O 
apricots O 
, O 
may O 
impede O 
tumor O 
proliferation O 
by O 
inhibiting O 
activation O 
of O 
nuclear O 
factor O 
kappa O 
B O 
( O 
NFκB O 
) O 
and O 
vascular O 
endothelial O 
growth O 
factor O 
( O 
VEGF O 
) O 
. O 
We O 
examined O 
the O 
associations O 
between O 
urinary O 
enterolactone B-TRIVIAL 
and O 
enterodiol B-TRIVIAL 
with O 
prostatic O 
tumor O 
expression O 
of O 
NFκB O 
, O 
VEGF O 
, O 
and O 
Ki67 O 
among O 
147 O 
patients O 
with O 
prostate O 
cancer O 
who O 
participated O 
in O 
a O 
presurgical O 
trial O 
of O 
flaxseed O 
supplementation O 
( O 
30 O 
g O 
/ O 
day O 
) O 
for O 
∼30 O 
days O 
. O 
Urinary O 
enterolignans B-FAMILY 
and O 
tissue O 
biomarkers O 
were O 
determined O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
and O 
immunohistochemistry O 
, O 
respectively O 
. O 
After O 
supplementation O 
, O 
we O 
observed O 
significant O 
correlations O 
between O 
intakes O 
of O 
plant O 
lignan B-FAMILY 
and O 
urinary O 
concentrations O 
of O 
total O 
enterolignans B-FAMILY 
( O 
ρ=0.677 O 
, O 
P O 
< O 
0.0001 O 
) O 
, O 
enterolactone B-TRIVIAL 
( O 
ρ=0.676 O 
, O 
P O 
< O 
0.0001 O 
) O 
, O 
and O 
enterodiol B-TRIVIAL 
( O 
ρ=0.628 O 
, O 
P O 
< O 
0.0001 O 
) O 
. O 
Importantly O 
, O 
we O 
observed O 
that O 
total O 
urinary O 
enterolignans B-FAMILY 
and O 
enterolactone B-TRIVIAL 
were O 
significantly O 
and O 
inversely O 
correlated O 
with O 
Ki67 O 
in O 
the O 
tumor O 
tissue O 
( O 
ρ=-0.217 O 
, O 
P=.011 O 
, O 
and O 
ρ=-0.230 O 
, O 
P=.007 O 
, O 
respectively O 
) O 
, O 
and O 
a O 
near O 
- O 
significant O 
inverse O 
association O 
was O 
observed O 
for O 
enterodiol B-TRIVIAL 
( O 
ρ=-0.159 O 
, O 
P=.064 O 
) O 
. O 
An O 
inverse O 
association O 
was O 
observed O 
between O 
enterolactone B-TRIVIAL 
and O 
VEGF O 
( O 
ρ=-0.143 O 
, O 
P=.141 O 
) O 
, O 
although O 
this O 
did O 
not O 
reach O 
statistical O 
significance O 
. O 
We O 
did O 
not O 
observe O 
an O 
association O 
between O 
enterolignans B-FAMILY 
and O 
NFκB O 
. O 
In O 
conclusion O 
, O 
flaxseed O 
- O 
derived O 
enterolignans B-FAMILY 
may O 
hinder O 
cancer O 
cell O 
proliferation O 
via O 
VEGF-associated O 
pathways O 
. O 

and O 
structure O 
- O 
activity O 
relationships O 
of O 
2-amino-3-carboxy-4-phenylthiophenes B-FAMILY 
as O 
novel O 
atypical O 
protein O 
kinase O 
C O 
inhibitors O 
. O 

evidence O 
suggests O 
atypical O 
protein O 
kinase O 
C O 
( O 
aPKC O 
) O 
isoforms O 
are O 
required O 
for O 
both O 
TNF- O 
and O 
VEGF-induced O 
breakdown O 
of O 
the O 
blood- O 
retinal B-TRIVIAL 
barrier O 
( O 
BRB O 
) O 
and O 
endothelial O 
permeability O 
to O 
70kDa O 
dextran O 
or O 
albumin O 
. O 
A O 
chemical O 
library O 
screen O 
revealed O 
a O 
series O 
of O 
novel O 
small O 
molecule O 
phenylthiophene B-SYSTEMATIC 
based O 
inhibitors O 
of O 
aPKC O 
isoforms O 
that O 
effectively O 
block O 
permeability O 
in O 
cell O 
culture O 
and O 
in O 
vivo O 
. O 
In O 
an O 
effort O 
to O 
further O 
elucidate O 
the O 
structural O 
requirements O 
of O 
this O 
series O 
of O 
inhibitors O 
, O 
we O 
detail O 
in O 
this O 
study O 
a O 
structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
built O 
on O 
screening O 
hit O 
1 O 
, O 
which O 
expands O 
on O 
our O 
initial O 
pharmacophore O 
model O 
. O 
The O 
biological O 
activity O 
of O 
our O 
analogues O 
was O 
evaluated O 
in O 
models O 
of O 
bona O 
fide O 
aPKC-dependent O 
signaling O 
including O 
NFκB O 
driven O 
- O 
gene O 
transcription O 
as O 
a O 
marker O 
for O 
an O 
inflammatory O 
response O 
and O 
VEGF O 
/ O 
TNF-induced O 
vascular O 
endothelial O 
permeability O 
. O 
The O 
EC50 O 
for O 
the O 
most O 
efficacious O 
inhibitors O 
( O 
6 O 
, O 
32 O 
) O 
was O 
in O 
the O 
low O 
nanomolar O 
range O 
in O 
these O 
two O 
cellular O 
assays O 
. O 
Our O 
study O 
demonstrates O 
the O 
key O 
structural O 
elements O 
that O 
confer O 
inhibitory O 
activity O 
and O 
highlights O 
the O 
requirement O 
for O 
electron O 
- O 
donating O 
moieties O 
off O 
the O 
C-4 O 
aryl O 
moiety O 
of O 
the O 
2-amino-3-carboxy-4-phenylthiophene B-SYSTEMATIC 
backbone O 
. O 
These O 
studies O 
suggest O 
that O 
this O 
class O 
has O 
potential O 
for O 
further O 
development O 
into O 
small O 
molecule O 
aPKC O 
inhibitors O 
with O 
therapeutic O 
efficacy O 
in O 
a O 
host O 
of O 
diseases O 
involving O 
increased O 
vascular O 
permeability O 
and O 
inflammation O 
. O 

, O 
cytotoxicity O 
and O 
topoisomerase O 
II O 
inhibitory O 
activity O 
of O 
lomefloxacin B-TRIVIAL 
derivatives O 
. O 

novel O 
series O 
of O 
amide B-FAMILY 
derivatives O 
of O 
lomefloxacin B-TRIVIAL 
were O 
synthesized O 
and O 
evaluated O 
for O 
their O 
topoisomerase O 
I O 
and O 
II O 
inhibitory O 
activity O 
as O 
well O 
as O 
cytotoxicity O 
against O 
a O 
panel O 
of O 
five O 
human O 
cancer O 
cell O 
lines O 
. O 
Of O 
the O 
compounds O 
prepared O 
compounds O 
9d O 
and O 
9g O 
exhibited O 
strong O 
inhibition O 
against O 
topoisomerase O 
II O 
at O 
100μM O 
. O 
In O 
addition O 
, O 
docking O 
studies O 
were O 
performed O 
to O 
predict O 
the O 
inhibition O 
mode O 
. O 

inhibits O 
invasion O 
of O 
human O 
lung O 
adenocarcinoma O 
cell O 
A549 O 
by O 
reducing O 
matrix O 
metalloproteinases O 
expression O 
. O 

is O 
an O 
aglycone O 
of O 
glycoalkaloid O 
tomatine B-TRIVIAL 
in O 
tomato O 
. O 
Tomatidine B-TRIVIAL 
is O 
found O 
to O 
possess O 
anti-inflammatory O 
properties O 
and O 
may O 
serve O 
as O 
a O 
chemosensitizer O 
in O 
multidrug O 
- O 
resistant O 
tumor O 
cells O 
. O 
However O 
, O 
the O 
effect O 
of O 
tomatidine B-TRIVIAL 
on O 
cancer O 
cell O 
metastasis O 
remains O 
unclear O 
. O 
This O 
study O 
examines O 
the O 
effect O 
of O 
tomatidine B-TRIVIAL 
on O 
the O 
migration O 
and O 
invasion O 
of O 
human O 
lung O 
adenocarcinoma O 
A549 O 
cell O 
in O 
vitro O 
. O 
The O 
data O 
demonstrates O 
that O 
tomatidine B-TRIVIAL 
does O 
not O 
effectively O 
inhibit O 
the O 
viability O 
of O 
A549 O 
cells O 
. O 
When O 
treated O 
with O 
non-toxic O 
doses O 
of O 
tomatidine B-TRIVIAL 
, O 
cell O 
invasion O 
is O 
markedly O 
suppressed O 
by O 
Boyden O 
chamber O 
invasion O 
assay O 
, O 
while O 
cell O 
migration O 
is O 
not O 
affected O 
. O 
Tomatidine B-TRIVIAL 
reduces O 
the O 
mRNA O 
level O 
of O 
matrix O 
metalloproteinase-2 O 
( O 
MMP-2 O 
) O 
, O 
MMP-9 O 
and O 
increases O 
the O 
expression O 
of O 
reversion O 
- O 
inducing O 
cysteine B-TRIVIAL 
-rich O 
protein O 
with O 
kazal O 
motifs O 
( O 
RECK O 
) O 
, O 
as O 
well O 
as O 
tissue O 
inhibitor O 
of O 
metalloproteinase-1 O 
( O 
TIMP-1 O 
) O 
. O 
The O 
immunoblotting O 
assays O 
indicate O 
that O 
tomatidine B-TRIVIAL 
is O 
very O 
effective O 
in O 
suppressing O 
the O 
phosphorylation O 
of O 
Akt O 
and O 
extracellular O 
signal O 
regulating O 
kinase O 
( O 
ERK O 
) O 
. O 
In O 
addition O 
, O 
tomatidine B-TRIVIAL 
significantly O 
decreases O 
the O 
nuclear O 
level O 
of O 
nuclear O 
factor O 
kappa O 
B O 
( O 
NF-κB O 
) O 
, O 
which O 
suggests O 
that O 
tomatidine B-TRIVIAL 
inhibits O 
NF-κB O 
activity O 
. O 
Furthermore O 
, O 
the O 
treatment O 
of O 
inhibitors O 
specific O 
for O 
PI3K O 
/ O 
Akt O 
( O 
LY294002 B-IDENTIFIER 
) O 
, O 
ERK O 
( O 
U0126 B-IDENTIFIER 
) O 
, O 
or O 
NF-κB O 
( O 
pyrrolidine B-SYSTEMATIC 
dithiocarbamate I-SYSTEMATIC 
) O 
to O 
A549 O 
cells O 
reduced O 
cell O 
invasion O 
and O 
MMP-2 O 
/ O 
9 O 
expression O 
. O 
The O 
results O 
suggest O 
that O 
tomatidine B-TRIVIAL 
inhibits O 
the O 
invasion O 
of O 
A549 O 
cells O 
by O 
reducing O 
the O 
expression O 
of O 
MMPs O 
. O 
It O 
also O 
inhibits O 
ERK O 
and O 
Akt O 
signaling O 
pathways O 
and O 
NF-κB O 
activity O 
. O 
These O 
findings O 
demonstrate O 
a O 
new O 
therapeutic O 
potential O 
for O 
tomatidine B-TRIVIAL 
in O 
anti-metastatic O 
therapy O 
. O 

influence O 
of O 
Bauhinia O 
forficata O 
Link O 
subsp O 
. O 
pruinosa O 
tea O 
on O 
lipid O 
peroxidation O 
and O 
non O 
- O 
protein O 
SH B-FORMULA 
groups O 
in O 
human O 
erythrocytes O 
exposed O 
to O 
high O 
glucose B-TRIVIAL 
concentrations O 
. O 

RELEVANCE O 
: O 
Bauhinia O 
forficata O 
( O 
BF O 
) O 
has O 
been O 
traditionally O 
used O 
as O 
tea O 
in O 
folk O 
medicine O 
of O 
Brazil O 
for O 
treatment O 
of O 
Diabetes O 
mellitus O 
( O 
DM O 
) O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
To O 
evaluate O 
the O 
effects O 
of O 
BF O 
leaf O 
tea O 
on O 
markers O 
of O 
oxidative O 
damage O 
and O 
antioxidant O 
levels O 
in O 
an O 
experimental O 
model O 
of O 
hyperglycemia O 
in O 
human O 
erythrocytes O 
in O 
vitro O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Human O 
erythrocytes O 
were O 
incubated O 
with O 
high O 
glucose B-TRIVIAL 
concentrations O 
or O 
glucose B-TRIVIAL 
and O 
BF O 
tea O 
for O 
24h O 
and O 
48h O 
. O 
After O 
incubation O 
lipid O 
peroxidation O 
and O 
non O 
- O 
protein O 
SH B-FORMULA 
levels O 
were O 
analyzed O 
. O 
Moreover O 
, O 
quantification O 
of O 
polyphenols B-FAMILY 
and O 
flavonoids B-FAMILY 
, O 
iron B-SYSTEMATIC 
chelating O 
property O 
, O 
scavenging O 
of O 
DPPH B-ABBREVIATION 
, O 
and O 
prevention O 
of O 
lipid O 
peroxidation O 
in O 
isolated O 
lipids O 
were O 
also O 
assessed O 
. O 
RESULTS O 
: O 
A O 
significant O 
amount O 
of O 
polyphenols B-FAMILY 
and O 
flavonoids B-FAMILY 
was O 
observed O 
. O 
The O 
main O 
components O 
found O 
by O 
LC-MS O 
analysis O 
were O 
quercetin-3-O-(2-rhamnosyl) B-SYSTEMATIC 
rutinoside I-SYSTEMATIC 
, O 
kaempferol-3-O-(2-rhamnosyl) B-SYSTEMATIC 
rutinoside I-SYSTEMATIC 
, O 
quercetin-3-O-rutinoside B-SYSTEMATIC 
and O 
kaempferol-3-O-rutinoside B-SYSTEMATIC 
. O 
BF O 
tea O 
presents O 
important O 
antioxidant O 
and O 
chelating O 
properties O 
. O 
Moreover O 
, O 
BF O 
tea O 
was O 
effective O 
to O 
increase O 
non O 
- O 
protein O 
SH B-FORMULA 
levels O 
and O 
reduce O 
lipid O 
peroxidation O 
induced O 
by O 
high O 
glucose B-TRIVIAL 
concentrations O 
in O 
human O 
erythrocytes O 
. O 
CONCLUSION O 
: O 
The O 
antioxidant O 
effects O 
of O 
BF O 
tea O 
could O 
be O 
related O 
to O 
the O 
presence O 
of O 
different O 
phenolic B-FAMILY 
and O 
flavonoids B-FAMILY 
components O 
. O 
We O 
believe O 
that O 
these O 
components O 
can O 
be O 
responsible O 
to O 
protect O 
human O 
erythrocytes O 
exposed O 
to O 
high O 
glucose B-TRIVIAL 
concentrations O 
against O 
oxidative O 
damage O 
. O 

RELEVANCE O 
: O 
Swertia O 
kouitchensis O 
has O 
long O 
been O 
used O 
as O 
a O 
folk O 
medicine O 
to O 
treat O 
hepatitis O 
and O 
diabetes O 
in O 
central O 
- O 
western O 
China O 
. O 
Therefore O 
, O 
this O 
study O 
was O 
aimed O 
to O 
evaluate O 
the O 
anti-diabetic O 
activity O 
of O 
the O 
plant O 
ethanol B-SYSTEMATIC 
extract O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Firstly O 
, O 
the O 
extract O 
was O 
tested O 
for O 
its O 
inhibitory O 
activity O 
on O 
α-amylase O 
and O 
α-glucosidase O 
in O 
vitro O 
. O 
Following O 
that O 
, O 
insulin O 
secretion O 
test O 
in O 
NIT-1cell O 
was O 
performed O 
. O 
Then O 
, O 
oral O 
sucrose O 
or O 
starch O 
tolerance O 
test O 
of O 
the O 
extract O 
were O 
carried O 
out O 
in O 
normal O 
mice O 
. O 
After O 
that O 
, O 
acute O 
effect O 
of O 
the O 
extract O 
was O 
executed O 
in O 
normal O 
and O 
streptozotocin B-TRIVIAL 
-induced O 
( O 
60mg O 
/ O 
kg O 
) O 
diabetic O 
mice O 
. O 
Eventually O 
, O 
long O 
term O 
effect O 
of O 
the O 
extract O 
was O 
performed O 
in O 
diabetic O 
mice O 
for O 
4 O 
weeks O 
. O 
Oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
and O 
biochemical O 
parameters O 
were O 
estimated O 
at O 
the O 
end O 
of O 
the O 
study O 
. O 
RESULTS O 
: O 
Swertia O 
kouitchensis O 
extract O 
could O 
remarkably O 
inhibit O 
the O 
activity O 
of O 
α-amylase O 
and O 
α-glucosidase O 
and O 
stimulate O 
insulin O 
secretion O 
in O 
vitro O 
. O 
And O 
also O 
the O 
extract O 
displayed O 
anti-hyperglycemic O 
activity O 
, O 
improved O 
antioxidant O 
capacity O 
, O 
ameliorated O 
the O 
hyperlipidemia O 
and O 
carbohydrate B-FAMILY 
metabolism O 
in O 
diabetic O 
mice O 
. O 
CONCLUSIONS O 
: O 
Swertia O 
kouitchensis O 
exhibits O 
considerable O 
anti-diabetic O 
activity O 
and O 
metabolic O 
alterations O 
in O 
diabetic O 
mice O 
. O 
These O 
results O 
provide O 
a O 
rationale O 
for O 
the O 
use O 
of O 
Swertia O 
kouitchensis O 
to O 
treat O 
diabetes O 
mellitus O 
. O 

RELEVANCE O 
: O 
Preparations O 
of O 
Carissa O 
edulis O 
( O 
Vahl O 
) O 
have O 
been O 
used O 
in O 
the O 
Nigerian O 
traditional O 
medicine O 
for O 
the O 
management O 
of O 
fever O 
, O 
sickle O 
cell O 
disease O 
, O 
epilepsy O 
, O 
pain O 
and O 
inflammation O 
for O 
many O 
years O 
and O 
their O 
efficacy O 
is O 
widely O 
acclaimed O 
among O 
the O 
Hausa O 
communities O 
of O 
northern O 
Nigeria O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
The O 
present O 
studies O 
aimed O 
at O 
evaluating O 
the O 
toxicological O 
properties O 
of O 
the O 
standardized O 
ethanol B-SYSTEMATIC 
extract O 
of O 
C O 
. O 
edulis O 
root O 
bark O 
in O 
rats O 
, O 
in O 
order O 
to O 
determine O 
its O 
safety O 
and O 
to O 
complement O 
earlier O 
efficacy O 
studies O 
on O 
this O 
widely O 
used O 
medicinal O 
plant O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
High O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
and O 
preliminary O 
phytochemical O 
analysis O 
of O 
the O 
extract O 
were O 
conducted O 
and O 
its O 
oral O 
median O 
lethal O 
dose O 
( O 
LD50 O 
) O 
determined O 
. O 
Signs O 
of O 
toxicity O 
, O 
body O 
weight O 
changes O 
, O 
relative O 
organs O 
weight O 
, O 
feed O 
and O 
water O 
consumption O 
were O 
monitored O 
following O 
28 O 
days O 
of O 
daily O 
oral O 
administration O 
of O 
graded O 
doses O 
of O 
the O 
extract O 
in O 
rats O 
. O 
Effects O 
of O 
the O 
extract O 
on O 
sex O 
hormones O 
, O 
low- O 
and O 
high O 
- O 
density O 
lipids O 
, O 
hematological O 
and O 
biochemical O 
parameters O 
were O 
examined O 
and O 
pathological O 
changes O 
of O 
the O 
vital O 
organs O 
after O 
treatment O 
with O 
the O 
extract O 
were O 
also O 
investigated O 
. O 
RESULTS O 
: O 
The O 
oral O 
LD50 O 
of O 
the O 
extract O 
was O 
estimated O 
to O 
be O 
> O 
5000mg O 
/ O 
kg O 
. O 
The O 
body O 
weights O 
of O 
treated O 
rats O 
increased O 
progressively O 
, O 
but O 
the O 
changes O 
were O 
not O 
significantly O 
different O 
from O 
the O 
control O 
groups O 
. O 
The O 
extract O 
neither O 
produces O 
significant O 
changes O 
in O 
feed O 
and O 
water O 
consumption O 
nor O 
affected O 
the O 
relative O 
organs O 
weight O 
. O 
Although O 
some O 
variations O 
were O 
observed O 
in O 
hormonal O 
and O 
lipid O 
profiles O 
hematological O 
and O 
biochemical O 
indices O 
, O 
these O 
important O 
parameters O 
were O 
normal O 
and O 
within O 
acceptable O 
limits O 
. O 
No O 
lesions O 
or O 
pathological O 
changes O 
of O 
the O 
organs O 
attributable O 
to O 
treatment O 
with O 
the O 
extract O 
were O 
observed O 
from O 
the O 
pathological O 
examinations O 
. O 
The O 
HPLC O 
fingerprint O 
of O 
the O 
extract O 
shows O 
a O 
spectrum O 
profile O 
characteristic O 
of O 
C O 
. O 
edulis O 
, O 
while O 
the O 
preliminary O 
phytochemical O 
screening O 
revealed O 
the O 
presence O 
of O 
saponins B-FAMILY 
, O 
flavonoids B-FAMILY 
, O 
tannins B-FAMILY 
, O 
anthraquinones B-FAMILY 
and O 
cardiac O 
glycosides O 
. O 
CONCLUSION O 
: O 
Our O 
results O 
provided O 
evidence O 
that O 
short O 
- O 
term O 
administration O 
of O 
the O 
standardized O 
ethanol B-SYSTEMATIC 
extract O 
of O 
C O 
. O 
edulis O 
root O 
bark O 
at O 
doses O 
lower O 
than O 
1000mg O 
/ O 
kg O 
is O 
safe O 
in O 
rats O 
and O 
may O 
not O 
exert O 
severe O 
toxic O 
effects O 
. O 

of O 
microcystins B-FAMILY 
in O 
a O 
Lake O 
Victoria O 
cyanobacterial O 
bloom O 
using O 
LC-MS O 
with O 
thiol B-FAMILY 
derivatization O 
. O 

are O 
cyclic B-FAMILY 
heptapeptides I-FAMILY 
from O 
cyanobacteria O 
which O 
are O 
responsible O 
for O 
poisonings O 
of O 
livestock O 
and O 
humans O 
. O 
Cyanobacteria O 
also O 
produce O 
a O 
range O 
of O 
peptides O 
and O 
other O 
compounds O 
that O 
can O 
result O 
in O 
complex O 
chromatograms O 
when O 
samples O 
are O 
analysed O 
by O 
LC-MS O 
. O 
Thiol B-SYSTEMATIC 
derivatization O 
of O 
the O 
α,β- B-SYSTEMATIC 
unsaturated I-SYSTEMATIC 
amide I-SYSTEMATIC 
present O 
in O 
most O 
microcystins B-FAMILY 
was O 
recently O 
shown O 
to O 
simplify O 
analysis O 
of O 
LC-MS O 
chromatograms O 
of O 
a O 
Microcystis O 
culture O 
, O 
making O 
it O 
easier O 
to O 
identify O 
peaks O 
corresponding O 
to O 
microcystins B-FAMILY 
in O 
complex O 
mixtures O 
. O 
This O 
method O 
was O 
applied O 
to O 
analysis O 
of O 
extracts O 
taken O 
from O 
a O 
natural O 
cyanobacteria O 
bloom O 
in O 
Mwanza O 
Gulf O 
, O 
Lake O 
Victoria O 
, O 
Tanzania O 
, O 
in O 
2010 O 
, O 
revealing O 
the O 
presence O 
of O 
numerous O 
putative O 
microcystin B-FAMILY 
analogues O 
in O 
the O 
sample O 
. O 
Results O 
were O 
verified O 
using O 
LC-MS(2) O 
, O 
LC-MS O 
/ O 
MS O 
with O 
precursor O 
- O 
ion O 
scanning O 
, O 
and O 
LC-HRMS O 
, O 
leading O 
to O 
identification O 
of O 
8 O 
major O 
and O 
17 O 
minor O 
microcystins B-FAMILY 
in O 
the O 
sample O 
, O 
including O 
analogues O 
of O 
microcystin-RY B-MULTIPLE 
, I-MULTIPLE 
-RL I-MULTIPLE 
and I-MULTIPLE 
-RA I-MULTIPLE 
. O 
Microcystin-YR B-MULTIPLE 
( I-MULTIPLE 
2 I-MULTIPLE 
) I-MULTIPLE 
, I-MULTIPLE 
-RR I-MULTIPLE 
( I-MULTIPLE 
3 I-MULTIPLE 
) I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
-RY I-MULTIPLE 
( I-MULTIPLE 
9 I-MULTIPLE 
) I-MULTIPLE 
were O 
isolated O 
from O 
bloom O 
material O 
from O 
Lake O 
Victoria O 
, O 
and O 
the O 
structure O 
of O 
9 O 
was O 
confirmed O 
by O 
NMR O 
spectroscopic O 
analysis O 
and O 
NMR O 
spectral O 
comparison O 
with O 
2 O 
and O 
3 O 
. O 
Confirmation O 
of O 
the O 
structure O 
of O 
MC-RY B-ABBREVIATION 
( O 
9 O 
) O 
facilitated O 
detailed O 
analysis O 
of O 
its O 
MS(2) O 
spectrum O 
, O 
thereby O 
supporting O 
the O 
structures O 
of O 
related O 
analogues O 
tentatively O 
established O 
on O 
the O 
basis O 
of O 
MS O 
analyses O 
. O 

- O 
articular O 
drug O 
delivery O 
from O 
an O 
optimized O 
topical O 
patch O 
containing O 
teriflunomide B-TRIVIAL 
and O 
lornoxicam B-TRIVIAL 
for O 
rheumatoid O 
arthritis O 
treatment O 
: O 
Does O 
the O 
topical O 
patch O 
really O 
enhance O 
a O 
local O 
treatment O 
? O 

with O 
rheumatoid O 
arthritis O 
( O 
RA O 
) O 
often O 
bear O 
joint O 
destruction O 
and O 
symptomatic O 
pain O 
. O 
The O 
aim O 
of O 
this O 
work O 
is O 
to O 
develop O 
a O 
compound O 
transdermal O 
patch O 
containing O 
teriflunomide B-TRIVIAL 
( O 
TEF B-ABBREVIATION 
) O 
and O 
lornoxicam B-TRIVIAL 
( O 
LOX B-ABBREVIATION 
) O 
to O 
transport O 
these O 
drugs O 
across O 
the O 
skin O 
with O 
the O 
isochronous O 
permeation O 
rates O 
for O 
RA O 
therapy O 
and O 
investigate O 
intra O 
- O 
articular O 
delivery O 
of O 
TEF B-ABBREVIATION 
and O 
LOX B-ABBREVIATION 
following O 
transdermal O 
patches O 
applied O 
topically O 
. O 
The O 
salts O 
of O 
TEF B-ABBREVIATION 
and O 
LOX B-ABBREVIATION 
with O 
organic B-FAMILY 
amines I-FAMILY 
amines B-FAMILY 
diethylamine B-SYSTEMATIC 
( O 
DEtA B-ABBREVIATION 
) O 
, O 
triethylamine B-SYSTEMATIC 
( O 
TEtA B-ABBREVIATION 
) O 
, O 
diethanolamine B-SYSTEMATIC 
( O 
DEA B-ABBREVIATION 
) O 
, O 
triethanolamine B-SYSTEMATIC 
( O 
TEA B-ABBREVIATION 
) O 
and O 
N-(2'-hydroxy-ethanol)-piperdine B-SYSTEMATIC 
( O 
NP O 
) O 
were O 
prepared O 
to O 
improve O 
the O 
skin O 
permeation O 
of O 
the O 
parent O 
drug O 
. O 
The O 
optimized O 
patch O 
formulation O 
is O 
obtained O 
from O 
a O 
3-factor O 
, O 
2-level O 
central O 
composite O 
design O 
. O 
After O 
topical O 
application O 
of O 
the O 
optimized O 
compound O 
patch O 
to O 
only O 
one O 
knee O 
joint O 
in O 
rabbit O 
, O 
intra O 
- O 
articular O 
delivery O 
of O 
TEF B-ABBREVIATION 
and O 
LOX B-ABBREVIATION 
on O 
the O 
application O 
site O 
was O 
compared O 
with O 
that O 
on O 
the O 
non-application O 
site O 
. O 
Anti-inflammatory O 
and O 
analgesic O 
effects O 
of O 
the O 
optimized O 
compound O 
patch O 
were O 
evaluated O 
using O 
the O 
adjuvant O 
arthritis O 
model O 
and O 
the O 
pain O 
model O 
induced O 
by O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
respectively O 
. O 
The O 
in O 
vitro O 
experiment O 
results O 
showed O 
that O 
the O 
amine B-FAMILY 
salts I-FAMILY 
of O 
TEF B-ABBREVIATION 
and O 
LOX B-ABBREVIATION 
, O 
especially O 
TEF-TEtA B-ABBREVIATION 
and O 
LOX-TEtA B-ABBREVIATION 
, O 
enhanced O 
the O 
skin O 
permeation O 
of O 
TEF B-ABBREVIATION 
and O 
LOX B-ABBREVIATION 
from O 
the O 
transdermal O 
patch O 
system O 
. O 
The O 
optimal O 
formulation O 
successfully O 
displayed O 
isochronous O 
permeation O 
rates O 
for O 
TEF B-ABBREVIATION 
and O 
LOX B-ABBREVIATION 
across O 
rabbit O 
skin O 
, O 
and O 
was O 
defined O 
with O 
5% O 
of O 
TEF-TEtA B-ABBREVIATION 
, O 
10% O 
of O 
LOX-TEtA B-ABBREVIATION 
and O 
15% O 
of O 
azone O 
. O 
The O 
in O 
vivo O 
study O 
showed O 
that O 
TEF B-ABBREVIATION 
and O 
LOX B-ABBREVIATION 
from O 
transdermal O 
patches O 
were O 
transferred O 
into O 
skin O 
, O 
ligament O 
and O 
fat O 
pad O 
on O 
the O 
application O 
site O 
by O 
direct O 
diffusion O 
and O 
on O 
the O 
non-application O 
site O 
by O 
the O 
redistribution O 
of O 
systemic O 
blood O 
supply O 
, O 
while O 
local O 
absorption O 
of O 
TEF B-ABBREVIATION 
and O 
LOX B-ABBREVIATION 
in O 
synovial O 
fluid O 
originated O 
from O 
the O 
systemic O 
blood O 
supply O 
rather O 
than O 
direct O 
diffusion O 
. O 
In O 
the O 
RA O 
rat O 
model O 
, O 
the O 
results O 
of O 
swelling O 
inhibition O 
on O 
primary O 
arthritis O 
of O 
bilateral O 
hind O 
paws O 
further O 
confirmed O 
the O 
above O 
- O 
mentioned O 
point O 
. O 
The O 
optimal O 
formulation O 
displayed O 
a O 
double O 
response O 
on O 
joint O 
inflammation O 
and O 
symptomatic O 
pain O 
. O 
In O 
conclusion O 
, O 
although O 
transdermal O 
administration O 
applied O 
topically O 
can O 
provide O 
a O 
local O 
enhanced O 
drug O 
delivery O 
for O 
the O 
superficial O 
joint O 
tissues O 
by O 
direct O 
diffusion O 
, O 
it O 
seemed O 
unlikely O 
to O 
do O 
that O 
for O 
the O 
deeper O 
tissue O 
synovial O 
fluid O 
. O 

mechanisms O 
concerning O 
the O 
modulation O 
of O 
nitrosative O 
stress O 
, O 
signal O 
transduction O 
and O 
proliferation O 
/ O 
apoptosis O 
by O 
a O 
grape O 
seed O 
extract O 
, O 
Burgund O 
Mare O 
variety O 
( O 
BM O 
) O 
, O 
in O 
SKH-1 O 
mice O 
exposed O 
to O 
UVB O 
, O 
were O 
investigated O 
. O 
The O 
animals O 
were O 
irradiated O 
with O 
single O 
and O 
multiple O 
doses O 
of O 
UVB O 
in O 
10 O 
consecutive O 
days O 
. O 
In O 
each O 
experiment O 
were O 
used O 
five O 
groups O 
of O 
animals O 
: O 
control O 
, O 
vehicle O 
, O 
UVB O 
irradiated O 
, O 
vehicle O 
+ O 
UVB O 
, O 
BM O 
+ O 
UVB O 
. O 
The O 
extract O 
was O 
applied O 
topically O 
, O 
30min O 
before O 
each O 
UVB O 
exposure O 
, O 
in O 
a O 
dose O 
of O 
4mg O 
total O 
polyphenols B-FAMILY 
/ O 
cm(2) O 
. O 
BM O 
remarkably O 
inhibited O 
UVB-induced O 
activation O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
and O 
therefore O 
generation O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
and O 
nitrotyrosine B-SYSTEMATIC 
, O 
in O 
a O 
UVB O 
single O 
dose O 
regimen O 
. O 
BM O 
also O 
suppressed O 
NF-kB O 
activation O 
by O 
UVB O 
but O 
did O 
not O 
affect O 
the O 
activity O 
of O 
total O 
ERK O 
1 O 
/ O 
2 O 
. O 
In O 
multiple O 
UVB O 
irradiations O 
, O 
BM O 
increased O 
NO B-FORMULA 
formation O 
and O 
total O 
ERK O 
1 O 
/ O 
2 O 
activity O 
and O 
reduced O 
iNOS O 
activity O 
and O 
nitrotyrosine B-SYSTEMATIC 
levels O 
, O 
inhibited O 
cell O 
proliferation O 
, O 
diminished O 
p53 O 
and O 
caspase-3 O 
immunoreactivities O 
and O 
increased O 
the O 
percentage O 
of O 
Bcl-2 O 
positive O 
cells O 
. O 
We O 
concluded O 
that O 
BM O 
modulates O 
the O 
apoptotic O 
response O 
of O 
SKH-1 O 
mice O 
skin O 
in O 
UVB O 
irradiation O 
by O 
the O 
inhibition O 
of O 
p53 O 
, O 
caspase-3 O 
, O 
Bax O 
/ O 
Bcl-2 O 
and O 
proliferating O 
cell O 
nuclear O 
antigen O 
expressions O 
, O 
as O 
well O 
as O 
by O 
reducing O 
the O 
activation O 
of O 
iNOS O 
and O 
NF-kB O 
. O 

exposure O 
to O 
lipopolysaccharide O 
enhances O 
accumulation O 
of O 
α-synuclein O 
aggregation O 
and O 
dopamine B-TRIVIAL 
transporter O 
protein O 
expression O 
in O 
the O 
substantia O 
nigra O 
in O 
responses O 
to O 
rotenone B-TRIVIAL 
challenge O 
in O 
later O 
life O 
. O 

inflammation O 
in O 
early O 
life O 
may O 
enhance O 
adult O 
susceptibility O 
to O 
develop O 
neurodegenerative O 
disorders O 
triggered O 
by O 
environmental O 
toxins O 
. O 
Our O 
previous O 
studies O 
show O 
that O 
perinatal O 
lipopolysaccharide O 
( O 
LPS O 
) O 
exposure O 
enhances O 
adult O 
susceptibility O 
to O 
rotenone B-TRIVIAL 
-induced O 
injury O 
to O 
the O 
dopaminergic O 
system O 
in O 
the O 
substantia O 
nigra O 
( O 
SN O 
) O 
of O 
the O 
adult O 
rat O 
brain O 
. O 
To O 
further O 
investigate O 
the O 
enhanced O 
adult O 
susceptibility O 
by O 
neonatal O 
LPS O 
exposure O 
to O 
rotenone B-TRIVIAL 
neurotoxicity O 
, O 
we O 
used O 
our O 
neonatal O 
rat O 
model O 
of O 
LPS O 
exposure O 
( O 
1mg O 
/ O 
kg O 
, O 
intracerebral O 
injection O 
in O 
postnatal O 
day O 
5 O 
, O 
P5 O 
, O 
neonatal O 
rats O 
) O 
to O 
examine O 
the O 
protein O 
levels O 
of O 
α-synuclein O 
and O 
dopamine B-TRIVIAL 
transporters O 
( O 
DAT O 
) O 
in O 
the O 
adult O 
rat O 
. O 
By O 
P70 O 
, O 
rats O 
from O 
the O 
saline- O 
or O 
LPS-exposed O 
group O 
were O 
challenged O 
with O 
rotenone B-TRIVIAL 
, O 
a O 
commonly O 
used O 
pesticide O 
, O 
through O 
subcutaneous O 
mini O 
- O 
pump O 
infusion O 
at O 
a O 
dose O 
of O 
1.25mg O 
/ O 
kg O 
/ O 
day O 
for O 
14 O 
days O 
. O 
The O 
accumulation O 
of O 
α-synuclein O 
aggregation O 
and O 
increment O 
of O 
DAT O 
protein O 
content O 
were O 
found O 
in O 
the O 
SN O 
of O 
LPS-exposed O 
rats O 
. O 
Neonatal O 
LPS O 
exposure O 
enhanced O 
rotenone B-TRIVIAL 
-stimulated O 
accumulation O 
of O 
α-synuclein O 
aggregation O 
and O 
increment O 
in O 
DAT O 
protein O 
expression O 
in O 
the O 
cytoplasmic O 
compartment O 
of O 
the O 
SN O 
, O 
and O 
in O 
the O 
synaptosomal O 
compartment O 
of O 
the O 
striatum O 
of O 
adult O 
rats O 
. O 
Rotenone B-TRIVIAL 
treatment O 
also O 
resulted O 
in O 
reduction O 
of O 
[(3)H]dopamine B-SYSTEMATIC 
uptake O 
and O 
mitochondrial O 
complex O 
I O 
activity O 
in O 
the O 
striatum O 
of O 
rats O 
with O 
neonatal O 
LPS O 
exposure O 
, O 
but O 
not O 
in O 
those O 
without O 
this O 
exposure O 
. O 
The O 
current O 
study O 
suggests O 
possible O 
roles O 
of O 
α-synuclein O 
aggregate O 
and O 
DAT O 
distribution O 
in O 
the O 
cytoplasm O 
and O 
synaptosome O 
triggered O 
by O 
environmental O 
toxins O 
in O 
later O 
life O 
in O 
the O 
development O 
of O 
neurodegenerative O 
disorders O 
. O 
Our O 
model O 
may O 
be O 
useful O 
in O 
studying O 
mechanisms O 
involved O 
in O 
the O 
pathogenesis O 
of O 
nonfamilial O 
Parkinson's O 
disease O 
and O 
for O 
developing O 
potential O 
therapeutic O 
treatments O 
for O 
this O 
disease O 
. O 

liquid O 
liposomal O 
formulations O 
are O 
prone O 
to O 
chemical O 
degradation O 
and O 
aggregation O 
, O 
these O 
formulations O 
often O 
require O 
freeze O 
drying O 
( O 
e.g O 
. O 
, O 
lyophilization O 
) O 
to O 
achieve O 
sufficient O 
shelf O 
- O 
life O 
. O 
However O 
, O 
liposomal O 
formulations O 
may O 
undergo O 
oxidation O 
during O 
lyophilization O 
and O 
/ O 
or O 
during O 
prolonged O 
storage O 
. O 
The O 
goal O 
of O 
the O 
current O 
study O 
was O 
to O 
characterize O 
the O 
degradation O 
of O 
1,2-dilinolenoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
( O 
DLPC B-ABBREVIATION 
) O 
during O 
lyophilization O 
and O 
to O 
also O 
probe O 
the O 
influence O 
of O 
metal O 
contaminants O 
in O 
promoting O 
the O 
observed O 
degradation O 
. O 
Aqueous O 
sugar B-FAMILY 
formulations O 
containing O 
DLPC B-ABBREVIATION 
( O 
0.01mg O 
/ O 
ml O 
) O 
were O 
lyophilized O 
, O 
and O 
DLPC B-ABBREVIATION 
degradation O 
was O 
monitored O 
using O 
HPLC O 
/ O 
UV O 
and O 
GC O 
/ O 
MS O 
methods O 
. O 
The O 
effect O 
of O 
ferrous B-SYSTEMATIC 
ion O 
and O 
sucrose B-TRIVIAL 
concentration O 
, O 
as O 
well O 
as O 
lyophilization O 
stage O 
promoting O 
lipid O 
degradation O 
, O 
was O 
investigated O 
. O 
DLPC B-ABBREVIATION 
degradation O 
increased O 
with O 
higher O 
levels O 
of O 
ferrous B-SYSTEMATIC 
ion O 
. O 
After O 
lyophilization O 
, O 
103.1±1.1% O 
, O 
66.9±0.8% O 
, O 
and O 
28.7±0.7% O 
DLPC B-ABBREVIATION 
remained O 
in O 
the O 
sucrose B-TRIVIAL 
samples O 
spiked O 
with O 
0.0ppm O 
, O 
0.2ppm O 
, O 
and O 
1.0ppm O 
ferrous B-SYSTEMATIC 
ion O 
, O 
respectively O 
. O 
Lipid O 
degradation O 
predominantly O 
occurs O 
during O 
the O 
freezing O 
stage O 
of O 
lyophilization O 
. O 
Sugar B-FAMILY 
concentration O 
and O 
buffer O 
ionic O 
strength O 
also O 
influence O 
the O 
extent O 
of O 
lipid O 
degradation O 
, O 
and O 
DLPC B-ABBREVIATION 
loss O 
correlated O 
with O 
degradation O 
product O 
formation O 
. O 
We O 
conclude O 
that O 
DLPC B-ABBREVIATION 
oxidation O 
during O 
the O 
freezing O 
stage O 
of O 
lyophilization O 
dramatically O 
compromises O 
the O 
stability O 
of O 
lipid O 
- O 
based O 
formulations O 
. O 
In O 
addition O 
, O 
we O 
demonstrate O 
that O 
metal O 
contaminants O 
in O 
sugars B-FAMILY 
can O 
become O 
highly O 
active O 
when O 
lyophilized O 
in O 
the O 
presence O 
of O 
a O 
reducing O 
agent O 
. O 

cyclin O 
D1 O 
( O 
CCND1 O 
) O 
rs9344 O 
G O 
> O 
A O 
polymorphism O 
predicts O 
clinical O 
outcome O 
in O 
colon O 
cancer O 
patients O 
treated O 
with O 
adjuvant O 
5-FU B-SYSTEMATIC 
-based O 
chemotherapy O 
. O 

evidence O 
indicates O 
a O 
potential O 
prognostic O 
and O 
predictive O 
value O 
for O 
germline O 
polymorphisms O 
in O 
genes O 
involved O 
in O 
cell O 
cycle O 
control O 
. O 
We O 
investigated O 
the O 
effect O 
of O 
cyclin O 
D1 O 
( O 
CCND1 O 
) O 
rs9344 O 
G O 
> O 
A O 
in O 
stage O 
II O 
/ O 
III O 
colon O 
cancer O 
patients O 
and O 
validated O 
the O 
findings O 
in O 
an O 
independent O 
study O 
cohort O 
. O 
For O 
evaluation O 
and O 
validation O 
set O 
, O 
a O 
total O 
of O 
264 O 
and O 
234 O 
patients O 
were O 
included O 
. O 
Patients O 
treated O 
with O 
5-fluorouracil B-SYSTEMATIC 
-based O 
chemotherapy O 
, O 
carrying O 
the O 
CCND1 O 
rs9344 O 
A O 
/ O 
A O 
genotype O 
had O 
significantly O 
decreased O 
time O 
- O 
to O 
- O 
tumor O 
recurrence O 
( O 
TTR O 
) O 
in O 
univariate O 
analysis O 
and O 
multivariate O 
analysis O 
( O 
hazard O 
ratio O 
( O 
HR O 
) O 
2.47 O 
; O 
95% O 
confidence O 
interval O 
( O 
CI O 
) O 
1.16-5.29 O 
; O 
P=0.019 O 
) O 
. O 
There O 
was O 
no O 
significant O 
association O 
between O 
CCND1 O 
rs9344 O 
G O 
> O 
A O 
and O 
TTR O 
in O 
patients O 
with O 
curative O 
surgery O 
alone O 
. O 
In O 
the O 
validation O 
set O 
, O 
the O 
A O 
allele O 
of O 
CCND1 O 
rs9344 O 
G O 
> O 
A O 
remained O 
significantly O 
associated O 
with O 
decreased O 
TTR O 
in O 
univariate O 
and O 
multivariate O 
analyses O 
( O 
HR O 
1.94 O 
; O 
95% O 
CI O 
1.05-3.58 O 
; O 
P=0.035 O 
) O 
. O 
CCND1 O 
rs9344 O 
G O 
> O 
A O 
may O 
be O 
a O 
predictive O 
and O 
/ O 
or O 
prognostic O 
biomarker O 
in O 
stage O 
II O 
/ O 
III O 
colon O 
cancer O 
patients O 
, O 
however O 
, O 
prospective O 
trials O 
are O 
warranted O 
to O 
confirm O 
our O 
findings.The O 
Pharmacogenomics O 
Journal O 
advance O 
online O 
publication O 
, O 
9 O 
April O 
2013 O 
; O 
doi O 
: O 
10.1038 O 
/ O 
tpj.2013.15 O 
. O 

- O 
binding O 
, O 
photocleavage O 
, O 
cytotoxicity O 
in O 
vitro O 
, O 
apoptosis O 
and O 
cell O 
cycle O 
arrest O 
studies O 
of O 
symmetric O 
ruthenium B-SYSTEMATIC 
(II) I-SYSTEMATIC 
complexes O 
. O 

novel O 
ruthenium B-SYSTEMATIC 
(II) I-SYSTEMATIC 
complexes O 
[Ru(dmb)2(addppn)](ClO4)2 B-FORMULA 
( O 
1 O 
) O 
and O 
[Ru(bpy)2(addppn)](ClO4)2 B-FORMULA 
( O 
2 O 
) O 
were O 
synthesized O 
. O 
The O 
DNA O 
- O 
binding O 
constants O 
of O 
complexes O 
1 O 
and O 
2 O 
were O 
determined O 
to O 
be O 
4.78 O 
(±0.49) O 
× O 
10(5) O 
and O 
7.42 O 
(±0.53) O 
× O 
10(5) O 
M(-1) O 
. O 
The O 
results O 
indicate O 
that O 
complexes O 
1 O 
and O 
2 O 
interact O 
with O 
CT O 
DNA O 
through O 
intercalative O 
mode O 
. O 
The O 
cytotoxicity O 
in O 
vitro O 
of O 
the O 
complexes O 
toward O 
BEL-7402 O 
, O 
HeLa O 
, O 
MG-63 O 
and O 
SKBR-3 O 
cells O 
was O 
assessed O 
by O 
MTT B-ABBREVIATION 
assay O 
. O 
The O 
apoptosis O 
was O 
carried O 
out O 
with O 
Hoechst B-TRIVIAL 
33258 I-TRIVIAL 
staining O 
method O 
and O 
flow O 
cytometry O 
. O 
The O 
cellular O 
uptake O 
was O 
observed O 
under O 
fluorescence O 
microscope O 
. O 
The O 
cell O 
cycle O 
arrest O 
shows O 
that O 
the O 
antiproliferative O 
mechanism O 
induced O 
by O 
complexes O 
1 O 
and O 
2 O 
on O 
BEL-7402 O 
cells O 
is O 
G0 O 
/ O 
G1 O 
phase O 
arrest O 
. O 

of O 
novel O 
1,3,4- B-FAMILY 
trisubstituted I-FAMILY 
pyrazoles I-FAMILY 
as O 
anti-inflammatory O 
and O 
analgesic O 
agents O 
. O 

novel O 
1,3,4- B-FAMILY 
trisubstituted I-FAMILY 
pyrazoles I-FAMILY 
were O 
synthesized O 
and O 
screened O 
for O 
their O 
anti-inflammatory O 
and O 
analgesic O 
activities O 
as O 
well O 
as O 
their O 
ulcerogenic O 
liability O 
. O 
They O 
showed O 
anti-inflammatory O 
and O 
analgesic O 
activities O 
with O 
better O 
GIT O 
tolerance O 
than O 
the O 
standard O 
drug O 
phenylbutazone B-TRIVIAL 
. O 
In O 
addition O 
, O 
IC50 O 
values O 
for O 
5e O 
and O 
8e O 
were O 
recorded O 
. O 
Compound O 
5e O 
was O 
found O 
to O 
be O 
the O 
most O 
active O 
one O 
as O 
anti-inflammatory O 
and O 
analgesic O 
agent O 
. O 
On O 
the O 
other O 
hand O 
, O 
COX-1 O 
/ O 
COX-2 O 
isozyme O 
selectivity O 
was O 
also O 
done O 
which O 
showed O 
equal O 
inhibition O 
to O 
both O 
isoforms O 
. O 

of O 
the O 
antioxidant O 
properties O 
of O 
differently O 
substituted O 
2- B-MULTIPLE 
and I-MULTIPLE 
3-indolyl I-MULTIPLE 
carbohydrazides I-MULTIPLE 
and O 
related O 
derivatives O 
. O 

, O 
we O 
report O 
the O 
antioxidant O 
properties O 
of O 
some O 
selected O 
substituted O 
2-indolyl B-FAMILY 
carbohydrazides I-FAMILY 
( O 
JL34 B-IDENTIFIER 
, O 
JL40 B-IDENTIFIER 
, O 
JL71 B-IDENTIFIER 
, O 
JL87 B-IDENTIFIER 
, O 
JL317 B-IDENTIFIER 
, O 
JL432 B-IDENTIFIER 
, O 
JL436 B-IDENTIFIER 
) O 
, O 
the O 
substituted O 
3-indolyl B-SYSTEMATIC 
carbohydrazide I-SYSTEMATIC 
JL344 B-IDENTIFIER 
, O 
3-(3-hydrazinylpropyl)-1H-indole B-SYSTEMATIC 
( O 
JL72 B-IDENTIFIER 
) O 
and O 
3-(1H-indol-3-yl)propanehydrazide B-SYSTEMATIC 
( O 
JL418 B-IDENTIFIER 
) O 
, O 
throughout O 
the O 
assessment O 
of O 
their O 
antioxidative O 
potential O 
using O 
different O 
antioxidant O 
assays O 
such O 
as O 
DPPH B-ABBREVIATION 
, O 
lipid O 
peroxidation O 
in O 
the O 
APPH O 
, O 
or O 
the O 
DMSO B-ABBREVIATION 
method O 
. O 
We O 
conclude O 
that O 
these O 
compounds O 
are O 
convenient O 
templates O 
for O 
the O 
design O 
of O 
useful O 
drugs O 
in O 
to O 
treat O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
, O 
a O 
pathology O 
characterized O 
by O 
extensive O 
oxidative O 
stress O 
and O 
inflammation O 
, O 
thus O 
essentially O 
affected O 
by O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
. O 
Most O 
of O 
them O 
are O 
potent O 
hydroxyl B-SYSTEMATIC 
radical O 
scavengers O 
and O 
inhibit O 
in O 
vitro O 
lipid O 
peroxidation O 
. O 
Compounds O 
JL40 B-IDENTIFIER 
and O 
JL432 B-IDENTIFIER 
presenting O 
higher O 
lipoxygenase O 
inhibitory O 
activity O 
among O 
the O 
tested O 
derivatives O 
, O 
were O 
found O 
to O 
present O 
a O 
promising O 
anti-inflammatory O 
in O 
vivo O 
result O 
, O 
as O 
well O 
as O 
antioxidant O 
and O 
LOX O 
inhibitory O 
profile O 
. O 
These O 
results O 
in O 
combination O 
to O 
their O 
known O 
AChE O 
/ O 
BuChE O 
inhibitory O 
activities O 
led O 
us O 
to O 
propose O 
these O 
indolyl B-FAMILY 
carbohydrazides I-FAMILY 
as O 
new O 
multifunctional O 
compounds O 
against O 
AD O 
. O 

evaluation O 
of O 
bisbenzaldehydes B-FAMILY 
against O 
four O 
Mycobacterium O 
species O 
. O 

series O 
of O 
bisbenzaldehydes B-FAMILY 
and O 
structurally O 
related O 
analogs O 
, O 
conveniently O 
synthesized O 
via O 
microwave O 
- O 
assisted O 
reactions O 
, O 
were O 
evaluated O 
in O 
vitro O 
against O 
drug O 
susceptible O 
and O 
multi O 
- O 
drug O 
resistant O 
Mycobacterium O 
tuberculosis O 
, O 
against O 
virulent O 
Mycobacterium O 
bovis O 
, O 
against O 
Mycobacterium O 
ulcerans O 
and O 
against O 
two O 
Mycobacterium O 
avium O 
subspecies O 
. O 
Among O 
the O 
33 O 
substances O 
that O 
were O 
tested O 
, O 
compound O 
12 O 
, O 
i.e O 
. O 
4,4'-[1,12-dodecanediyl(oxy)]bisbenzaldehyde B-SYSTEMATIC 
, O 
emerged O 
as O 
the O 
most O 
promising O 
hit O 
. O 
Its O 
activity O 
was O 
further O 
confirmed O 
in O 
an O 
intracellular O 
growth O 
inhibition O 
assay O 
of O 
M. O 
tb O 
in O 
murine O 
J774 O 
A.1 O 
macrophages O 
. O 
None O 
of O 
the O 
compounds O 
showed O 
significant O 
cytotoxicity O 
on O 
human O 
C3A O 
hepatocytes O 
in O 
a O 
neutral B-TRIVIAL 
red I-TRIVIAL 
dye O 
uptake O 
assay O 
and O 
no O 
genotoxicity O 
or O 
mutagenicity O 
was O 
observed O 
as O 
demonstrated O 
by O 
a O 
VITOTOX O 
™ O 
test O 
and O 
confirmed O 
with O 
a O 
comet O 
assay O 
. O 

films O 
: O 
organic O 
vapor O 
passivation O 
of O 
silicon B-SYSTEMATIC 
at O 
room O 
temperature O 
( O 
adv O 
. O 
Mater O 
. O 
14 O 
/ O 
2013 O 
) O 
. O 

chemical O 
vapor O 
deposition O 
is O 
used O 
to O 
achieve O 
air O 
- O 
stable O 
organic O 
passivation O 
of O 
silicon B-SYSTEMATIC 
, O 
as O 
reported O 
by O 
Karen O 
K O 
. O 
Gleason O 
and O 
co O 
- O 
workers O 
on O 
page O 
2078 O 
. O 
This O 
layer O 
also O 
functions O 
as O 
an O 
anti-reflection O 
coating O 
. O 
Resistively O 
heated O 
wires O 
produce O 
reactive O 
gas O 
phase O 
species O 
, O 
including O 
methyl B-SYSTEMATIC 
radicals O 
, O 
while O 
the O 
silicon B-SYSTEMATIC 
surface O 
below O 
remains O 
near O 
room O 
temperature O 
. O 
Photoshop O 
enhanced O 
image O 
by O 
Felice O 
C O 
. O 
Frankel O 
. O 

AMP I-TRIVIAL 
responsive O 
element O 
binding O 
protein- O 
a O 
vital O 
link O 
in O 
embryonic O 
hormonal O 
adaptation O 
. O 

transcription O 
factor O 
cyclic B-TRIVIAL 
AMP I-TRIVIAL 
responsive O 
element O 
binding O 
protein O 
( O 
CREB O 
) O 
and O 
activating O 
transcription O 
factors O 
( O 
ATFs O 
) O 
are O 
downstream O 
components O 
of O 
the O 
insulin O 
/ O 
IGF O 
cascade O 
, O 
playing O 
crucial O 
roles O 
in O 
maintaining O 
cell O 
viability O 
and O 
embryo O 
survival O 
. O 
One O 
of O 
the O 
CREB O 
target O 
genes O 
is O 
adiponectin O 
which O 
acts O 
synergistically O 
with O 
insulin O 
. O 
We O 
have O 
studied O 
the O 
CREB-ATF-adiponectin O 
network O 
in O 
rabbit O 
preimplantation O 
development O 
in O 
vivo O 
and O 
in O 
vitro.From O 
the O 
blastocyst O 
stage O 
onwards O 
CREB O 
and O 
ATF1 O 
, O 
3 O 
and O 
4 O 
are O 
present O 
with O 
increasing O 
expression O 
for O 
CREB O 
, O 
ATF1 O 
and O 
3 O 
during O 
gastrulation O 
and O 
with O 
a O 
dominant O 
expression O 
in O 
the O 
embryoblast O 
( O 
EB O 
) O 
. O 
In O 
vitro O 
stimulation O 
with O 
insulin O 
and O 
IGF1 O 
reduced O 
CREB O 
and O 
ATF1 O 
transcripts O 
by O 
approx O 
. O 
50% O 
, O 
while O 
CREB O 
phosphorylation O 
was O 
increased O 
. O 
Activation O 
of O 
CREB O 
was O 
accompanied O 
by O 
subsequent O 
reduction O 
in O 
adiponectin O 
and O 
adiponectin O 
receptor O 
1 O 
( O 
adipoR1 O 
) O 
expression.Under O 
in O 
vivo O 
conditions O 
of O 
diabetes O 
type O 
1 O 
, O 
maternal O 
adiponectin O 
levels O 
were O 
up O 
- O 
regulated O 
in O 
serum O 
and O 
endometrium O 
. O 
Embryonic O 
CREB O 
expression O 
was O 
altered O 
in O 
a O 
cell O 
lineage O 
- O 
specific O 
pattern O 
. O 
While O 
in O 
EB O 
cells O 
CREB O 
localization O 
did O 
not O 
change O 
, O 
it O 
was O 
translocated O 
from O 
the O 
nucleus O 
into O 
the O 
cytosol O 
in O 
trophoblast O 
( O 
TB O 
) O 
cells O 
. O 
In O 
TB O 
adiponectin O 
expression O 
was O 
increased O 
[ O 
diabetic O 
427.8±59.3 O 
pg O 
/ O 
ml O 
versus O 
normoinsulinaemic O 
143.9±26.5 O 
pg O 
/ O 
ml O 
] O 
, O 
while O 
it O 
was O 
no O 
longer O 
measureable O 
in O 
the O 
EB O 
. O 
Analysis O 
of O 
embryonic O 
adiponectin O 
receptors O 
showed O 
an O 
increased O 
expression O 
of O 
adipoR1 O 
and O 
no O 
changes O 
in O 
adipoR2 O 
transcription.We O 
conclude O 
that O 
the O 
transcription O 
factors O 
CREB O 
and O 
ATFs O 
vitally O 
participate O 
in O 
embryo O 
- O 
maternal O 
crosstalk O 
prior O 
to O 
implantation O 
in O 
a O 
cell O 
lineage O 
- O 
specific O 
manner O 
. O 
Embryonic O 
CREB O 
/ O 
ATFs O 
act O 
as O 
insulin O 
/ O 
IGF O 
sensors O 
. O 
Lack O 
of O 
insulin O 
is O 
compensated O 
by O 
a O 
CREB O 
- O 
mediated O 
adiponectin O 
expression O 
which O 
may O 
maintain O 
glucose B-TRIVIAL 
uptake O 
in O 
blastocysts O 
grown O 
in O 
diabetic O 
mothers O 
. O 

Stretchable O 
Patterned O 
Gold O 
Electrodes O 
Made O 
of O 
Au B-FORMULA 
Nanosheets O 
. O 

Au B-FORMULA 
nanosheets O 
are O 
suggested O 
as O 
a O 
novel O 
class O 
of O 
material O 
for O 
fabricating O 
stretchable O 
electrodes O 
suitable O 
for O 
organic O 
- O 
based O 
electronic O 
devices O 
. O 
The O 
electrodes O 
show O 
no O 
difference O 
in O 
resistivity O 
during O 
repeated O 
stretching O 
cycles O 
up O 
to O 
ϵ O 
= O 
40% O 
. O 

of O 
Topical O 
Application O 
of O 
Chlorogenic B-TRIVIAL 
Acid I-TRIVIAL 
on O 
Excision O 
Wound O 
Healing O 
in O 
Rats O 
. O 

study O 
was O 
undertaken O 
to O 
evaluate O 
the O 
therapeutic O 
effects O 
of O 
topical O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
on O 
excision O 
wounds O 
in O 
Wistar O 
rats O 
. O 
A O 
1 O 
% O 
( O 
w O 
/ O 
w O 
) O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
or O 
silver B-SYSTEMATIC 
sulfadiazine I-SYSTEMATIC 
ointment O 
was O 
applied O 
topically O 
once O 
a O 
day O 
for O 
15 O 
days O 
on O 
full O 
- O 
thickness O 
excision O 
wounds O 
created O 
on O 
rats O 
. O 
The O 
1 O 
% O 
( O 
w O 
/ O 
w O 
) O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
ointment O 
had O 
potent O 
wound O 
healing O 
capacity O 
as O 
evident O 
from O 
the O 
wound O 
contraction O 
on O 
the O 
15th O 
post O 
- O 
surgery O 
day O 
, O 
which O 
was O 
similar O 
to O 
that O 
produced O 
by O 
1 O 
% O 
( O 
w O 
/ O 
w O 
) O 
silver B-SYSTEMATIC 
sulfadiazine I-SYSTEMATIC 
ointment O 
. O 
Increased O 
rates O 
of O 
epithelialization O 
were O 
observed O 
in O 
the O 
treated O 
rats O 
. O 
It O 
also O 
improved O 
cellular O 
proliferation O 
, O 
increased O 
tumor O 
necrosis O 
factor-α O 
levels O 
during O 
the O 
inflammatory O 
phase O 
( O 
12 O 
h O 
, O 
24 O 
h O 
, O 
48 O 
h O 
, O 
and O 
72 O 
h O 
post O 
- O 
wounding O 
) O 
of O 
wound O 
healing O 
, O 
upregulated O 
transforming O 
growth O 
factor-β1 O 
and O 
elevated O 
collagen O 
IV O 
synthesis O 
in O 
the O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
-treated O 
group O 
. O 
The O 
results O 
also O 
indicated O 
that O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
possesses O 
potent O 
antioxidant O 
activity O 
by O 
increasing O 
superoxide B-TRIVIAL 
dismutase O 
, O 
catalase O 
, O 
and O 
glutathione B-TRIVIAL 
, O 
and O 
decreasing O 
lipid O 
peroxidation O 
. O 
In O 
conclusion O 
, O 
these O 
results O 
demonstrate O 
that O 
topical O 
application O 
of O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
can O 
accelerate O 
the O 
process O 
of O 
excision O 
wound O 
healing O 
by O 
its O 
ability O 
to O 
increase O 
collagen O 
synthesis O 
through O 
upregulation O 
of O 
key O 
players O 
such O 
as O 
tumor O 
necrosis O 
factor-α O 
and O 
transforming O 
growth O 
factor-β1 O 
in O 
different O 
phases O 
of O 
wound O 
healing O 
as O 
well O 
as O 
by O 
its O 
antioxidant O 
potential O 
. O 

N B-FORMULA 
-end O 
rule O 
pathway O 
contributes O 
significantly O 
to O 
accelerated O 
muscle O 
proteolysis O 
mediated O 
by O 
the O 
ubiquitin O 
- O 
proteasome O 
pathway O 
in O 
various O 
catabolic O 
conditions O 
. O 
UBR2 O 
( O 
aka O 
E3α-II O 
) O 
is O 
the O 
only O 
known O 
E3 O 
ubiquitin O 
ligase O 
of O 
the O 
N B-FORMULA 
-end O 
rule O 
pathway O 
that O 
is O 
up O 
- O 
regulated O 
by O 
cachectic O 
stimuli O 
including O 
proinflammatory O 
cytokines O 
and O 
tumors O 
. O 
However O 
, O 
the O 
signaling O 
mechanism O 
through O 
which O 
UBR2 O 
is O 
up O 
- O 
regulated O 
remains O 
undetermined O 
. O 
Here O 
we O 
identify O 
a O 
signaling O 
pathway O 
that O 
mediates O 
tumor O 
cell O 
- O 
induced O 
up O 
- O 
regulation O 
of O 
UBR2 O 
. O 
UBR2 O 
expression O 
in O 
C2C12 O 
myotubes O 
was O 
up O 
- O 
regulated O 
by O 
conditioned O 
medium O 
from O 
Lewis O 
lung O 
carcinoma O 
cells O 
or O 
C26 O 
colon O 
adenocarcinoma O 
cells O 
, O 
which O 
was O 
blocked O 
by O 
a O 
pharmacological O 
inhibitor O 
of O 
p38α O 
/ O 
β O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
, O 
SB202190 B-IDENTIFIER 
. O 
Similarly O 
, O 
SB202190 B-IDENTIFIER 
administration O 
( O 
i.p O 
. O 
) O 
abolished O 
UBR2 O 
up O 
- O 
regulation O 
in O 
the O 
tibialis O 
anterior O 
of O 
LLC O 
tumor O 
- O 
bearing O 
mice O 
. O 
Genetic O 
gain O 
and O 
loss O 
of O 
function O 
assays O 
in O 
C2C12 O 
myotubes O 
indicated O 
that O 
tumor O 
- O 
induced O 
activation O 
of O 
the O 
p38β O 
isoform O 
is O 
sufficient O 
and O 
necessary O 
for O 
UBR2 O 
up O 
- O 
regulation O 
. O 
In O 
addition O 
, O 
UBR2 O 
up O 
- O 
regulation O 
required O 
p38β O 
- O 
mediated O 
phosphorylation O 
of O 
CCAAT O 
/ O 
enhancer O 
binding O 
protein O 
( O 
C O 
/ O 
EBP)-β O 
Thr B-FORMULA 
-188 O 
, O 
which O 
was O 
critical O 
to O 
C O 
/ O 
EBPβ O 
binding O 
to O 
the O 
UBR2 O 
promoter O 
. O 
Furthermore O 
, O 
luciferase O 
reporter O 
assay O 
revealed O 
that O 
the O 
C O 
/ O 
EBPβ O 
binding O 
motif O 
in O 
the O 
UBR2 O 
promoter O 
is O 
a O 
functional O 
C O 
/ O 
EBPβ-responsive O 
cis-element O 
that O 
enhances O 
the O 
promoter O 
activity O 
on O 
activation O 
by O 
p38β O 
. O 
Finally O 
, O 
genetic O 
ablation O 
of O 
C O 
/ O 
EBPβ O 
blocked O 
UBR2 O 
up O 
- O 
regulation O 
in O 
LLC O 
tumor O 
- O 
bearing O 
mice O 
. O 
These O 
results O 
suggest O 
that O 
UBR2 O 
up O 
- O 
regulation O 
in O 
cachectic O 
muscle O 
is O 
mediated O 
by O 
the O 
p38β-C O 
/ O 
EBPβ O 
signaling O 
pathway O 
responsible O 
for O 
the O 
bulk O 
of O 
tumor O 
- O 
induced O 
muscle O 
proteolysis.-Zhang O 
, O 
G O 
. O 
, O 
Lin O 
, O 
R.-K O 
. O 
, O 
Kwon O 
, O 
Y O 
. O 
T O 
. O 
, O 
Li O 
, O 
Y.-P O 
. O 
Signaling O 
mechanism O 
of O 
tumor O 
cell O 
- O 
induced O 
up O 
- O 
regulation O 
of O 
E3 O 
ubiquitin O 
ligase O 
UBR2 O 
. O 

, O 
Bcrp- O 
, O 
and O 
Mrp2-knockout O 
rats O 
are O 
a O 
more O 
practical O 
species O 
for O 
ADME O 
studies O 
than O 
murine O 
models O 
and O 
previously O 
demonstrated O 
expected O 
alterations O 
in O 
pharmacokinetics O 
of O 
various O 
probe O 
substrates O 
. O 
At O 
present O 
, O 
gene O 
expression O 
and O 
pathology O 
changes O 
were O 
systematically O 
studied O 
in O 
small O 
intestine O 
, O 
liver O 
, O 
kidney O 
, O 
and O 
brain O 
tissue O 
from O 
male O 
SAGE O 
Mdr1a- O 
, O 
Bcrp- O 
, O 
and O 
Mrp2-knockout O 
rats O 
versus O 
wild O 
- O 
type O 
Sprague O 
Dawley O 
controls O 
. O 
Gene O 
expression O 
data O 
supported O 
the O 
relevant O 
knockout O 
genotype O 
. O 
As O 
expected O 
, O 
Mrp2-knockout O 
rats O 
were O 
hyperbilirubinemic O 
and O 
exhibited O 
upregulation O 
of O 
hepatic O 
Mrp3 O 
. O 
Overall O 
, O 
few O 
alterations O 
were O 
observed O 
within O 
112 O 
ADME-relevant O 
genes O 
. O 
The O 
two O 
potentially O 
most O 
consequential O 
changes O 
were O 
upregulation O 
of O 
intestinal O 
carboxylesterase O 
in O 
Mdr1a-knockouts O 
and O 
catechol B-TRIVIAL 
- O 
O B-FORMULA 
-methyltransferase O 
in O 
all O 
tissues O 
of O 
Bcrp O 
- O 
knockout O 
rats O 
. O 
Previously O 
reported O 
upregulation O 
of O 
hepatic O 
Mdr1b O 
P-glycoprotein O 
in O 
proprietary O 
Wistar O 
Mdr1a-knockout O 
rats O 
was O 
not O 
observed O 
in O 
the O 
SAGE O 
counterpart O 
investigated O 
herein O 
. O 
Relative O 
liver O 
and O 
kidney O 
weights O 
were O 
22-53% O 
higher O 
in O 
all O 
three O 
knockouts O 
, O 
with O 
microscopic O 
increases O 
in O 
hepatocyte O 
size O 
in O 
Mdr1a- O 
and O 
Mrp2-knockout O 
rats O 
, O 
and O 
glomerular O 
size O 
in O 
Bcrp- O 
and O 
Mrp2-knockouts O 
. O 
Increased O 
relative O 
weight O 
of O 
clearing O 
organs O 
is O 
quantitatively O 
consistent O 
with O 
reported O 
increases O 
in O 
clearance O 
of O 
drugs O 
that O 
are O 
not O 
substrates O 
of O 
the O 
knocked O 
- O 
out O 
transporter O 
. O 
Overall O 
, O 
SAGE O 
knockout O 
rats O 
demonstrated O 
modest O 
compensatory O 
changes O 
, O 
which O 
do O 
not O 
preclude O 
their O 
general O 
application O 
to O 
study O 
transporter O 
- O 
mediated O 
pharmacokinetics O 
. O 
However O 
, O 
until O 
future O 
studies O 
elucidate O 
the O 
magnitude O 
of O 
functional O 
change O 
, O 
caution O 
is O 
warranted O 
in O 
rare O 
instances O 
of O 
extensive O 
metabolism O 
by O 
catechol B-TRIVIAL 
- O 
O B-FORMULA 
-methyltransferase O 
in O 
Bcrp O 
- O 
knockouts O 
and O 
intestinal O 
carboxylesterase O 
in O 
Mdr1a-knockout O 
rats O 
, O 
specifically O 
for O 
molecules O 
with O 
free O 
catechol B-TRIVIAL 
groups O 
and O 
esters O 
subject O 
to O 
gut O 
wall O 
hydrolysis O 
. O 

cerevisiae O 
τ55 O 
, O 
a O 
subunit O 
of O 
the O 
RNA O 
polymerase O 
III-specific O 
general O 
transcription O 
factor O 
TFIIIC O 
, O 
comprises O 
an O 
N B-FORMULA 
-terminal O 
histidine B-TRIVIAL 
phosphatase O 
domain O 
( O 
τ55-HPD O 
) O 
whose O 
catalytic O 
activity O 
and O 
cellular O 
function O 
is O 
poorly O 
understood O 
. O 
We O 
solved O 
the O 
crystal O 
structures O 
of O 
τ55-HPD O 
and O 
its O 
closely O 
related O 
paralogue O 
Huf O 
and O 
used O 
in O 
silico O 
docking O 
methods O 
to O 
identify O 
phospho B-SYSTEMATIC 
- I-SYSTEMATIC 
serine I-SYSTEMATIC 
and O 
phospho B-SYSTEMATIC 
- I-SYSTEMATIC 
tyrosine I-SYSTEMATIC 
containing O 
peptides O 
as O 
possible O 
substrates O 
that O 
were O 
subsequently O 
validated O 
using O 
in O 
vitro O 
phosphatase O 
assays O 
. O 
A O 
comparative O 
phospho B-SYSTEMATIC 
-proteomic O 
study O 
identified O 
additional O 
phosphopeptides O 
as O 
possible O 
targets O 
, O 
which O 
show O 
the O 
involvement O 
of O 
these O 
two O 
phosphatases O 
in O 
the O 
regulation O 
of O 
a O 
variety O 
of O 
cellular O 
functions O 
. O 
Our O 
results O 
identify O 
τ55-HPD O 
and O 
Huf O 
as O 
bona O 
fide O 
protein O 
phosphatases O 
, O 
characterize O 
their O 
substrate O 
specificities O 
and O 
provide O 
a O 
small O 
set O 
of O 
regulated O 
phosphosite O 
targets O 
in O 
vivo O 
. O 

-DNA O 
Adducts O 
Derived O 
from O 
the O 
Highly O 
Tumorigenic O 
Dibenzo[a,l]pyrene B-SYSTEMATIC 
Are O 
Resistant O 
to O 
Nucleotide B-FAMILY 
Excision O 
Repair O 
while O 
Guanine B-TRIVIAL 
Adducts O 
Are O 
Not O 
. O 

structural O 
origins O 
of O 
differences O 
in O 
susceptibilities O 
of O 
various O 
DNA O 
lesions O 
to O 
nucleotide B-FAMILY 
excision O 
repair O 
( O 
NER O 
) O 
are O 
poorly O 
understood O 
. O 
Here O 
we O 
compared O 
, O 
in O 
the O 
same O 
sequence O 
context O 
, O 
the O 
relative O 
NER O 
dual O 
incision O 
efficiencies O 
elicited O 
by O 
two O 
stereochemically O 
distinct O 
pairs O 
of O 
guanine B-TRIVIAL 
( O 
N(2)-dG O 
) O 
and O 
adenine B-TRIVIAL 
( O 
N(6)-dA O 
) O 
DNA O 
lesions O 
, O 
derived O 
from O 
enantiomeric O 
genotoxic O 
diol B-FAMILY 
epoxides I-FAMILY 
of O 
the O 
highly O 
tumorigenic O 
fjord O 
region O 
polycyclic O 
aromatic O 
hydrocarbon O 
dibenzo[a,l]pyrene B-SYSTEMATIC 
( O 
DB[a,l]P B-ABBREVIATION 
) O 
. O 
Remarkably O 
, O 
in O 
cell O 
- O 
free O 
HeLa O 
cell O 
extracts O 
, O 
the O 
guanine B-TRIVIAL 
adduct O 
with O 
R O 
absolute O 
chemistry O 
at O 
the O 
N(2)-dG O 
linkage O 
site O 
is O 
∼35 O 
times O 
more O 
susceptible O 
to O 
NER O 
dual O 
incisions O 
than O 
the O 
stereochemically O 
identical O 
N(6)-dA O 
adduct O 
. O 
For O 
the O 
guanine B-TRIVIAL 
and O 
adenine B-TRIVIAL 
adducts O 
with O 
S O 
stereochemistry O 
, O 
a O 
similar O 
but O 
somewhat O 
smaller O 
effect O 
( O 
factor O 
of O 
∼15 O 
) O 
is O 
observed O 
. O 
The O 
striking O 
resistance O 
of O 
the O 
bulky O 
N(6)-dA O 
in O 
contrast O 
to O 
the O 
modest O 
to O 
good O 
susceptibilities O 
of O 
the O 
N(2)-dG O 
adducts O 
to O 
NER O 
is O 
interpreted O 
in O 
terms O 
of O 
the O 
balance O 
between O 
lesion O 
- O 
induced O 
DNA O 
distorting O 
and O 
DNA O 
stabilizing O 
van O 
der O 
Waals O 
interactions O 
in O 
their O 
structures O 
, O 
that O 
are O 
partly O 
reflected O 
in O 
the O 
overall O 
thermal O 
stabilities O 
of O 
the O 
modified O 
duplexes O 
. O 
Our O 
results O 
are O 
consistent O 
with O 
the O 
hypothesis O 
that O 
the O 
high O 
genotoxic O 
activity O 
of O 
DB[a,l]P B-ABBREVIATION 
is O 
related O 
to O 
the O 
formation O 
of O 
NER-resistant O 
and O 
persistent O 
DB[a,l]P B-ABBREVIATION 
-derived O 
adenine B-TRIVIAL 
adducts O 
in O 
cellular O 
DNA O 
. O 

of O 
Hydrocarbon B-MULTIPLE 
Radicals I-MULTIPLE 
and I-MULTIPLE 
Biradicals I-MULTIPLE 
. O 

measurements O 
of O 
the O 
rate O 
coefficients O 
for O 
several O 
types O 
of O 
gas O 
phase O 
radical O 
reactions O 
are O 
reviewed O 
. O 
They O 
include O 
radical O 
isomerization O 
and O 
dissociation O 
, O 
radical O 
+ O 
radical O 
association O 
, O 
and O 
unimolecular O 
reactions O 
of O 
peroxy B-FAMILY 
radicals O 
. O 
Some O 
reactions O 
of O 
methylene B-SYSTEMATIC 
in O 
its O 
lowest O 
singlet O 
state O 
are O 
also O 
considered O 
. O 
The O 
links O 
to O 
theories O 
of O 
chemical O 
reaction O 
rates O 
and O 
especially O 
of O 
capture O 
rates O 
for O 
radical O 
+ O 
radical O 
reactions O 
are O 
examined O 
. O 
Many O 
of O 
the O 
reactions O 
involve O 
formation O 
of O 
adducts O 
, O 
which O 
can O 
isomerize O 
and O 
dissociate O 
. O 
Such O 
reactions O 
frequently O 
involve O 
energy O 
distributions O 
of O 
the O 
adducts O 
that O 
are O 
far O 
from O 
Boltzmann O 
, O 
and O 
the O 
interpretation O 
of O 
measurements O 
requires O 
the O 
use O 
of O 
master O 
equation O 
techniques O 
. O 
The O 
basis O 
of O 
these O 
methods O 
and O 
the O 
use O 
of O 
matrix O 
diagonalization O 
and O 
eigenvector O 
/ O 
eigenvalue O 
analysis O 
to O 
extract O 
phenomenological O 
rate O 
coefficients O 
are O 
discussed O 
. O 
The O 
relevance O 
of O 
the O 
measurements O 
to O 
applications O 
in O 
atmospheric O 
chemistry O 
and O 
, O 
especially O 
, O 
in O 
combustion O 
is O 
briefly O 
considered O 
. O 

impacts O 
on O 
graphene B-TRIVIAL 
/ O 
ir(111) B-FORMULA 
: O 
interface O 
channeling O 
, O 
vacancy O 
funnels O 
, O 
and O 
a O 
nanomesh O 
. O 

combining O 
ion O 
beam O 
experiments O 
and O 
atomistic O 
simulations O 
we O 
study O 
the O 
production O 
of O 
defects O 
in O 
graphene B-TRIVIAL 
on O 
Ir(111) B-FORMULA 
under O 
grazing O 
incidence O 
of O 
low O 
energy O 
Xe B-FORMULA 
ions O 
. O 
We O 
demonstrate O 
that O 
the O 
ions O 
are O 
channeled O 
in O 
between O 
graphene B-TRIVIAL 
and O 
the O 
substrate O 
, O 
giving O 
rise O 
to O 
chains O 
of O 
vacancy O 
clusters O 
with O 
their O 
edges O 
bending O 
down O 
toward O 
the O 
substrate O 
. O 
These O 
clusters O 
self O 
- O 
organize O 
to O 
a O 
graphene B-TRIVIAL 
nanomesh O 
via O 
thermally O 
activated O 
diffusion O 
as O 
their O 
formation O 
energy O 
varies O 
within O 
the O 
graphene B-TRIVIAL 
moiré O 
supercell O 
. O 

facile O 
strategy O 
to O 
design O 
zeolite B-TRIVIAL 
L I-TRIVIAL 
crystals O 
with O 
tunable O 
morphology O 
and O 
surface O 
architecture O 
. O 

the O 
anisotropic O 
growth O 
rates O 
of O 
materials O 
to O 
achieve O 
desired O 
structural O 
outcomes O 
is O 
a O 
pervasive O 
challenge O 
in O 
synthetic O 
crystallization O 
. O 
Here O 
we O 
discuss O 
a O 
method O 
to O 
selectively O 
control O 
the O 
growth O 
of O 
zeolite B-TRIVIAL 
crystals O 
, O 
which O 
are O 
used O 
extensively O 
in O 
a O 
wide O 
range O 
of O 
industrial O 
applications O 
. O 
This O 
facile O 
method O 
cooperatively O 
tunes O 
crystal O 
properties O 
, O 
such O 
as O 
morphology O 
and O 
surface O 
architecture O 
, O 
through O 
the O 
use O 
of O 
inexpensive O 
, O 
commercially O 
available O 
chemicals O 
with O 
specificity O 
for O 
binding O 
to O 
crystallographic O 
surfaces O 
and O 
mediating O 
anisotropic O 
growth O 
. O 
We O 
examined O 
over O 
30 O 
molecules O 
as O 
potential O 
zeolite B-TRIVIAL 
growth O 
modifiers O 
( O 
ZGMs O 
) O 
of O 
zeolite B-TRIVIAL 
L I-TRIVIAL 
( O 
LTL O 
type O 
) O 
crystallization O 
. O 
ZGM O 
efficacy O 
was O 
quantified O 
through O 
a O 
combination O 
of O 
macroscopic O 
( O 
bulk O 
) O 
and O 
microscopic O 
( O 
surface O 
) O 
investigations O 
that O 
identified O 
modifiers O 
capable O 
of O 
dramatically O 
altering O 
the O 
cylindrical O 
morphology O 
of O 
LTL O 
crystals O 
. O 
We O 
demonstrate O 
an O 
ability O 
to O 
tailor O 
properties O 
critical O 
to O 
zeolite B-TRIVIAL 
performance O 
, O 
such O 
as O 
external O 
porous O 
surface O 
area O 
, O 
crystal O 
shape O 
, O 
and O 
pore O 
length O 
, O 
which O 
can O 
enhance O 
sorbate B-TRIVIAL 
accessibility O 
to O 
LTL O 
pores O 
, O 
tune O 
the O 
supramolecular O 
organization O 
of O 
guest O 
- O 
host O 
composites O 
, O 
and O 
minimize O 
the O 
diffusion O 
path O 
length O 
, O 
respectively O 
. O 
We O 
report O 
that O 
a O 
synergistic O 
combination O 
of O 
ZGMs O 
and O 
the O 
judicious O 
adjustment O 
of O 
synthesis O 
parameters O 
produce O 
LTL O 
crystals O 
with O 
unique O 
surface O 
features O 
, O 
and O 
a O 
range O 
of O 
length O 
- O 
to O 
- O 
diameter O 
aspect O 
ratios O 
spanning O 
3 O 
orders O 
of O 
magnitude O 
. O 
A O 
systematic O 
examination O 
of O 
different O 
ZGM O 
structures O 
and O 
molecular O 
compositions O 
( O 
i.e O 
. O 
, O 
hydrophobicity O 
and O 
binding O 
moieties O 
) O 
reveal O 
interesting O 
physicochemical O 
properties O 
governing O 
their O 
efficacy O 
and O 
specificity O 
. O 
Results O 
of O 
this O 
study O 
suggest O 
this O 
versatile O 
strategy O 
may O 
prove O 
applicable O 
for O 
a O 
host O 
of O 
framework O 
types O 
to O 
produce O 
unrivaled O 
materials O 
that O 
have O 
eluded O 
more O 
conventional O 
techniques O 
. O 

Nanoparticles O 
Induced O 
RNA O 
Polymerase- O 
Silver B-SYSTEMATIC 
Binding O 
and O 
RNA O 
Transcription O 
Inhibition O 
in O 
Erythroid O 
Progenitor O 
Cells O 
. O 

to O 
its O 
antimicrobial O 
activity O 
, O 
nanosilver O 
( O 
nAg O 
) O 
has O 
become O 
the O 
most O 
widely O 
used O 
nanomaterial O 
. O 
Thus O 
far O 
, O 
the O 
mechanisms O 
responsible O 
for O 
nAg-induced O 
antimicrobial O 
properties O 
and O 
nAg O 
- O 
mediated O 
toxicity O 
to O 
organisms O 
have O 
not O 
been O 
clearly O 
recognized O 
. O 
Silver B-SYSTEMATIC 
( O 
Ag B-FORMULA 
) O 
ions O 
certainly O 
play O 
a O 
crucial O 
role O 
, O 
and O 
the O 
form O 
of O 
nanoparticles O 
can O 
change O 
the O 
dissolution O 
rate O 
, O 
bioavailability O 
, O 
biodistribution O 
, O 
and O 
cellular O 
uptake O 
of O 
Ag B-FORMULA 
. O 
However O 
, O 
whether O 
nAg O 
exerts O 
direct O 
" O 
particle O 
- O 
specific O 
" O 
effects O 
has O 
been O 
under O 
debate O 
. O 
Here O 
we O 
demonstrated O 
that O 
nAg O 
exhibited O 
a O 
robust O 
inhibition O 
on O 
RNA O 
polymerase O 
activity O 
and O 
overall O 
RNA O 
transcription O 
through O 
direct O 
Ag B-FORMULA 
binding O 
to O 
RNA O 
polymerase O 
, O 
which O 
is O 
separated O 
from O 
the O 
cytotoxicity O 
pathway O 
induced O 
by O 
Ag B-FORMULA 
ions O 
. O 
nAg O 
treatment O 
in O 
vitro O 
resulted O 
in O 
reduced O 
hemoglobin O 
concentration O 
in O 
erythroid O 
cells O 
; O 
in O 
vivo O 
administration O 
of O 
nAg O 
in O 
mice O 
caused O 
profound O 
reduction O 
of O 
hemoglobin O 
content O 
in O 
embryonic O 
erythrocytes O 
, O 
associated O 
with O 
anemia O 
in O 
the O 
embryos O 
. O 
Embryonic O 
anemia O 
and O 
general O 
proliferation O 
deficit O 
due O 
to O 
the O 
significant O 
inhibition O 
on O 
RNA O 
synthesis O 
, O 
at O 
least O 
partially O 
, O 
accounted O 
for O 
embryonic O 
developmental O 
retardation O 
upon O 
nAg O 
administration O 
. O 
To O 
date O 
, O 
there O 
is O 
no O 
conclusive O 
answer O 
to O 
the O 
sources O 
of O 
nAg O 
- O 
mediated O 
toxicity O 
: O 
Ag B-FORMULA 
ions O 
or O 
" O 
particle O 
- O 
specific O 
" O 
effects O 
, O 
or O 
both O 
. O 
We O 
here O 
demonstrated O 
that O 
both O 
Ag B-FORMULA 
ions O 
and O 
nAg O 
particles O 
simultaneously O 
existed O 
inside O 
cells O 
, O 
demonstrating O 
the O 
" O 
Trojan O 
horse O 
" O 
effects O 
of O 
nAg O 
particles O 
in O 
posing O 
biological O 
impacts O 
on O 
erythroid O 
cells O 
. O 
Moreover O 
, O 
our O 
results O 
suggested O 
that O 
" O 
particle O 
- O 
specific O 
" O 
effects O 
could O 
be O 
the O 
predominant O 
mediator O 
in O 
eliciting O 
biological O 
influences O 
on O 
erythroid O 
cells O 
under O 
relatively O 
low O 
concentrations O 
of O 
nAg O 
exposure O 
. O 
The O 
combined O 
data O 
highlighted O 
the O 
inhibitory O 
effect O 
of O 
nAg O 
on O 
RNA O 
polymerase O 
activity O 
through O 
a O 
direct O 
reciprocal O 
interaction O 
. O 

genetic O 
associations O 
in O 
thiopurine B-TRIVIAL 
-related O 
bone O 
marrow O 
toxicity O 
among O 
inflammatory O 
bowel O 
disease O 
patients O 
. O 

: O 
The O 
toxicity O 
related O 
to O 
thiopurine B-TRIVIAL 
drug O 
therapy O 
for O 
inflammatory O 
bowel O 
disease O 
( O 
IBD O 
) O 
varies O 
widely O 
among O 
patients O 
. O 
Almost O 
15-30% O 
of O 
patients O 
with O 
IBD O 
develop O 
side O 
effects O 
during O 
treatment O 
, O 
often O 
bone O 
marrow O 
suppression O 
. O 
Several O 
factors O 
have O 
been O 
implicated O 
in O 
determining O 
this O 
toxicity O 
, O 
mainly O 
individual O 
genetic O 
variation O 
related O 
to O 
formation O 
of O 
active O 
thiopurine B-TRIVIAL 
metabolites O 
. O 
The O 
aim O 
was O 
to O 
identify O 
genes O 
involved O 
in O 
thiopurine B-TRIVIAL 
-related O 
myelosuppression O 
. O 
Materials O 
& O 
methods O 
: O 
A O 
two O 
- O 
stage O 
investigation O 
of O 
19217 O 
coding O 
SNPs O 
( O 
cSNPs O 
) O 
was O 
performed O 
in O 
a O 
Spanish O 
( O 
Inflammatory O 
Bowel O 
Disease O 
Group O 
of O 
Galicia O 
[ O 
EIGA O 
] O 
) O 
cohort O 
of O 
173 O 
IBD O 
patients O 
, O 
15 O 
with O 
bone O 
marrow O 
suppression O 
. O 
The O 
top O 
20 O 
cSNPs O 
identified O 
in O 
the O 
first O 
stage O 
with O 
p O 
< O 
10(-3) O 
for O 
allelic O 
test O 
association O 
and O 
SNPs O 
that O 
define O 
the O 
common O 
TPMT O 
alleles O 
were O 
replicated O 
in O 
a O 
different O 
Spanish O 
( O 
ENEIDA O 
) O 
cohort O 
( O 
87 O 
patients O 
, O 
29 O 
with O 
bone O 
marrow O 
suppression O 
) O 
. O 
Results O 
: O 
Several O 
cSNPs O 
showed O 
a O 
significant O 
p-value O 
in O 
the O 
allelic O 
joint O 
analysis O 
( O 
p-Cochran-Mantel-Haenszel O 
test O 
≤ O 
2.55 O 
× O 
10(-3) O 
) O 
despite O 
no O 
cSNP O 
passing O 
correction O 
for O 
multiple O 
testing O 
in O 
the O 
first O 
cohort O 
. O 
Of O 
note O 
is O 
rs3729961 O 
in O 
the O 
gene O 
IL6ST O 
, O 
a O 
transducer O 
signal O 
chain O 
shared O 
by O 
many O 
cytokines O 
including O 
IL6 O 
( O 
p-value O 
combined O 
= O 
2.36 O 
× O 
10(-4) O 
, O 
odds O 
ratio O 
[ O 
95% O 
CI O 
] O 
: O 
3.41 O 
[ O 
1.71-6.78 O 
] O 
) O 
. O 
In O 
addition O 
, O 
we O 
detected O 
association O 
with O 
rs3749598 O 
in O 
the O 
FSTL5 O 
gene O 
that O 
appears O 
to O 
interact O 
with O 
metalloproteases O 
at O 
the O 
extracellular O 
matrix O 
level O 
( O 
p-value O 
combined O 
= O 
4.89 O 
× O 
10(-4) O 
) O 
, O 
odds O 
ratio O 
( O 
95% O 
CI O 
) O 
: O 
3.67 O 
( O 
1.68-8.01 O 
) O 
. O 
Conclusion O 
: O 
We O 
have O 
identified O 
IL6ST O 
and O 
FSLT5 O 
as O 
new O 
bone O 
marrow O 
suppression O 
susceptibility O 
candidate O 
genes O 
after O 
thiopurine B-TRIVIAL 
treatment O 
in O 
IBD O 
patients O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
variants O 
associated O 
with O 
thiopurine B-TRIVIAL 
-related O 
myelosuppression O 
that O 
was O 
identified O 
by O 
a O 
genome O 
- O 
wide O 
association O 
study O 
. O 
Its O 
validation O 
awaits O 
functional O 
analyses O 
and O 
replication O 
in O 
additional O 
studies O 
. O 
Original O 
submitted O 
14 O 
September O 
2012 O 
; O 
Revision O 
submitted O 
13 O 
February O 
2013 O 
. O 

disorder O 
( O 
BD O 
) O 
is O 
a O 
lifelong O 
severe O 
psychiatric O 
condition O 
with O 
high O 
morbidity O 
, O 
disability O 
and O 
excess O 
mortality O 
. O 
The O 
longitudinal O 
clinical O 
trajectory O 
of O 
BD O 
is O 
significantly O 
modified O 
by O 
pharmacological O 
treatment(s) O 
, O 
both O 
in O 
acute O 
and O 
in O 
long O 
- O 
term O 
stages O 
. O 
However O 
, O 
a O 
large O 
proportion O 
of O 
BD O 
patients O 
have O 
inadequate O 
response O 
to O 
pharmacological O 
treatments O 
. O 
Pharmacogenomic O 
research O 
may O 
lead O 
to O 
the O 
identification O 
of O 
molecular O 
predictors O 
of O 
treatment O 
response O 
. O 
When O 
integrated O 
with O 
clinical O 
information O 
, O 
pharmacogenomic O 
findings O 
may O 
be O 
used O 
in O 
the O 
future O 
to O 
determine O 
the O 
probability O 
of O 
response O 
/ O 
nonresponse O 
to O 
treatment O 
on O 
an O 
individual O 
basis O 
. O 
Here O 
we O 
present O 
a O 
selective O 
review O 
of O 
pharmacogenomic O 
findings O 
in O 
BD O 
. O 
In O 
light O 
of O 
the O 
evidence O 
suggesting O 
a O 
genetic O 
effect O 
of O 
lithium B-SYSTEMATIC 
reponse O 
in O 
BD O 
, O 
we O 
focused O 
particularly O 
on O 
the O 
pharmacogenomic O 
literature O 
relevant O 
to O 
this O 
trait O 
. O 
The O 
article O 
contributes O 
a O 
detailed O 
overview O 
of O 
the O 
current O 
status O 
of O 
pharmacogenomics O 
in O 
BD O 
and O 
offers O 
a O 
perspective O 
on O 
the O 
challenges O 
that O 
can O 
hinder O 
its O 
transition O 
to O 
personalized O 
healthcare O 
. O 

of O 
small O 
organic O 
molecules O 
on O 
graphene B-TRIVIAL 
. O 

present O 
a O 
combined O 
experimental O 
and O 
theoretical O 
quantification O 
of O 
the O 
adsorption O 
enthalpies O 
of O 
seven O 
organic O 
molecules O 
( O 
acetone B-SYSTEMATIC 
, O 
acetonitrile B-SYSTEMATIC 
, O 
dichloromethane B-SYSTEMATIC 
, O 
ethanol B-SYSTEMATIC 
, O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
hexane B-SYSTEMATIC 
, O 
and O 
toluene B-TRIVIAL 
) O 
on O 
graphene B-TRIVIAL 
. O 
Adsorption O 
enthalpies O 
were O 
measured O 
by O 
inverse O 
gas O 
chromatography O 
and O 
ranged O 
from O 
-5.9 O 
kcal O 
/ O 
mol O 
for O 
dichloromethane B-SYSTEMATIC 
to O 
-13.5 O 
kcal O 
/ O 
mol O 
for O 
toluene B-TRIVIAL 
. O 
The O 
strength O 
of O 
interaction O 
between O 
graphene B-TRIVIAL 
and O 
the O 
organic O 
molecules O 
was O 
estimated O 
by O 
density O 
functional O 
theory O 
( O 
PBE O 
, O 
B97D O 
, O 
M06-2X O 
, O 
and O 
optB88-vdW O 
) O 
, O 
wave O 
function O 
theory O 
( O 
MP2 O 
, O 
SCS(MI)-MP2 O 
, O 
MP2.5 O 
, O 
MP2.X O 
, O 
and O 
CCSD(T) O 
) O 
, O 
and O 
empirical O 
calculations O 
( O 
OPLS-AA O 
) O 
using O 
two O 
graphene B-TRIVIAL 
models O 
: O 
coronene B-TRIVIAL 
and O 
infinite O 
graphene B-TRIVIAL 
. O 
Symmetry O 
- O 
adapted O 
perturbation O 
theory O 
calculations O 
indicated O 
that O 
the O 
interactions O 
were O 
governed O 
by O 
London O 
dispersive O 
forces O 
( O 
amounting O 
to O 
∼60% O 
of O 
attractive O 
interactions O 
) O 
, O 
even O 
for O 
the O 
polar O 
molecules O 
. O 
The O 
results O 
also O 
showed O 
that O 
the O 
adsorption O 
enthalpies O 
were O 
largely O 
controlled O 
by O 
the O 
interaction O 
energy O 
. O 
Adsorption O 
enthalpies O 
obtained O 
from O 
ab O 
initio O 
molecular O 
dynamics O 
employing O 
non-local O 
optB88-vdW O 
functional O 
were O 
in O 
excellent O 
agreement O 
with O 
the O 
experimental O 
data O 
, O 
indicating O 
that O 
the O 
functional O 
can O 
cover O 
physical O 
phenomena O 
behind O 
adsorption O 
of O 
organic O 
molecules O 
on O 
graphene B-TRIVIAL 
sufficiently O 
well O 
. O 

three O 
- O 
quarters O 
of O 
the O 
143 O 
genetic O 
signals O 
associated O 
with O 
platelet O 
and O 
erythrocyte O 
phenotypes O 
identified O 
by O 
meta-analyses O 
of O 
genome O 
- O 
wide O 
association O 
( O 
GWA O 
) O 
studies O 
are O 
located O 
at O 
non O 
- O 
protein O 
coding O 
regions O 
. O 
Here O 
, O 
we O 
assessed O 
the O 
role O 
of O 
candidate O 
regulatory O 
variants O 
associated O 
with O 
cell O 
type O 
- O 
restricted O 
, O 
closely O 
related O 
hematological O 
quantitative O 
traits O 
in O 
biologically O 
relevant O 
hematopoietic O 
cell O 
types O 
. O 
We O 
used O 
formaldehyde B-SYSTEMATIC 
-assisted O 
isolation O 
of O 
regulatory O 
elements O 
followed O 
by O 
next O 
- O 
generation O 
sequencing O 
( O 
FAIRE-seq O 
) O 
to O 
map O 
regions O 
of O 
open O 
chromatin O 
in O 
three O 
primary O 
human O 
blood O 
cells O 
of O 
the O 
myeloid O 
lineage O 
. O 
In O 
the O 
precursors O 
of O 
platelets O 
and O 
erythrocytes O 
, O 
as O 
well O 
as O 
in O 
monocytes O 
, O 
we O 
found O 
that O 
open O 
chromatin O 
signatures O 
reflect O 
the O 
corresponding O 
hematopoietic O 
lineages O 
of O 
the O 
studied O 
cell O 
types O 
, O 
and O 
associate O 
with O 
the O 
cell O 
type O 
- O 
specific O 
gene O 
expression O 
patterns O 
. O 
Dependent O 
on O 
their O 
signal O 
strength O 
, O 
open O 
chromatin O 
regions O 
showed O 
correlation O 
with O 
promoter O 
and O 
enhancer O 
histone O 
marks O 
, O 
distance O 
to O 
the O 
transcription O 
start O 
site O 
and O 
ontology O 
classes O 
of O 
nearby O 
genes O 
. O 
Cell O 
type O 
- O 
restricted O 
regions O 
of O 
open O 
chromatin O 
were O 
enriched O 
in O 
sequence O 
variants O 
associated O 
with O 
hematological O 
indices O 
. O 
The O 
majority O 
( O 
63.6% O 
) O 
of O 
such O 
candidate O 
functional O 
variants O 
at O 
platelet O 
quantitative O 
trait O 
loci O 
( O 
QTLs O 
) O 
coincided O 
with O 
binding O 
sites O 
of O 
five O 
transcription O 
factors O 
key O 
in O 
regulating O 
megakaryopoiesis O 
. O 
We O 
experimentally O 
tested O 
13 O 
candidate O 
regulatory O 
variants O 
at O 
10 O 
platelet O 
QTLs O 
, O 
and O 
found O 
that O 
10 O 
( O 
76.9% O 
) O 
affected O 
protein O 
binding O 
, O 
suggesting O 
that O 
this O 
is O 
a O 
frequent O 
mechanism O 
by O 
which O 
regulatory O 
variants O 
influence O 
quantitative O 
trait O 
levels O 
. O 
Our O 
findings O 
demonstrate O 
that O 
combining O 
large O 
- O 
scale O 
GWA O 
data O 
with O 
open O 
chromatin O 
profiles O 
of O 
relevant O 
cell O 
types O 
can O 
be O 
a O 
powerful O 
means O 
of O 
dissecting O 
the O 
genetic O 
architecture O 
of O 
closely O 
related O 
quantitative O 
traits O 
. O 

- O 
activity O 
relationship O 
of O 
potent O 
antimicrobial O 
peptide O 
analogs O 
of O 
Ixosin-B O 
amide B-FAMILY 
. O 

is O 
a O 
great O 
urgency O 
in O 
developing O 
a O 
new O 
generation O 
of O 
antibiotics O 
and O 
antimicrobial O 
agents O 
since O 
the O 
bacterial O 
resistance O 
to O 
antibiotics O 
have O 
increased O 
dramatically O 
. O 
A O 
series O 
of O 
overlapped O 
peptide O 
fragments O 
of O 
Ixosin-B O 
, O 
an O 
antimicrobial O 
peptide O 
with O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
of O 
QLKVDLWGTRSGIQPEQHSSGKSDVRRWRSRY O 
, O 
was O 
designed O 
, O 
synthesized O 
and O 
examined O 
for O 
their O 
antimicrobial O 
activities O 
against O 
Escherichia O 
coli O 
, O 
Staphylococcus O 
aureus O 
, O 
and O 
Pseudomonas O 
aeruginosa O 
. O 
A O 
potent O 
11-mer O 
peptide O 
TSG-8-1 B-TRIVIAL 
, O 
WWSYVRRWRSR- O 
amide B-FAMILY 
, O 
was O 
developed O 
, O 
which O 
exhibited O 
antimicrobial O 
activity O 
against O 
E O 
. O 
coli O 
and O 
S O 
. O 
aureus O 
while O 
very O 
little O 
hemolytic O 
activity O 
in O 
human O 
erythrocytes O 
was O 
observed O 
at O 
high O 
dose O 
level O 
. O 
This O 
peptide O 
could O 
be O 
further O 
modified O 
for O 
the O 
development O 
of O 
a O 
potent O 
antimicrobial O 
agent O 
in O 
the O 
future O 
. O 

A I-TRIVIAL 
, O 
a O 
novel O 
gastroprotective O 
compound O 
from O 
Artocarpus O 
obtusus O 
Jarret O 
, O 
against O 
ethanol B-SYSTEMATIC 
-induced O 
acute O 
gastric O 
ulcer O 
in O 
vivo O 
. O 

A I-TRIVIAL 
( O 
PA O 
) O 
, O 
a O 
xanthone B-TRIVIAL 
derived O 
from O 
the O 
Artocarpus O 
obtusus O 
Jarret O 
, O 
belongs O 
to O 
the O 
Moraceae O 
family O 
which O 
is O 
native O 
to O 
the O 
tropical O 
forest O 
of O 
Malaysia O 
. O 
In O 
this O 
study O 
, O 
the O 
efficacy O 
of O 
PA O 
as O 
a O 
gastroprotective O 
compound O 
was O 
examined O 
against O 
ethanol B-SYSTEMATIC 
-induced O 
ulcer O 
model O 
in O 
rats O 
. O 
The O 
rats O 
were O 
pretreated O 
with O 
PA O 
and O 
subsequently O 
exposed O 
to O 
acute O 
gastric O 
lesions O 
induced O 
by O 
absolute O 
ethanol B-SYSTEMATIC 
. O 
The O 
ulcer O 
index O 
, O 
gastric O 
juice O 
acidity O 
, O 
mucus O 
content O 
, O 
histological O 
analysis O 
, O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
levels O 
, O 
malondialdehyde B-TRIVIAL 
level O 
( O 
MDA B-ABBREVIATION 
) O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
and O 
non O 
- O 
protein O 
sulfhydryl B-FAMILY 
group O 
( O 
NP- O 
SH B-FORMULA 
) O 
contents O 
were O 
evaluated O 
in O 
vivo O 
. O 
The O 
activities O 
of O 
PA O 
as O 
anti-Helicobacter O 
pylori O 
, O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
inhibitor O 
and O 
free O 
radical O 
scavenger O 
were O 
also O 
investigated O 
in O 
vitro O 
. O 
The O 
results O 
showed O 
that O 
the O 
oral O 
administration O 
of O 
PA O 
protects O 
gastric O 
mucosa O 
from O 
ethanol B-SYSTEMATIC 
-induced O 
gastric O 
lesions O 
. O 
PA O 
pretreatment O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
restored O 
the O 
depleted O 
GSH B-ABBREVIATION 
, O 
NP- O 
SH B-FORMULA 
and O 
NO B-FORMULA 
levels O 
in O 
the O 
gastric O 
homogenate O 
. O 
Moreover O 
, O 
PA O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
reduced O 
the O 
elevated O 
MDA B-ABBREVIATION 
level O 
due O 
to O 
ethanol B-SYSTEMATIC 
administration O 
. O 
The O 
gastroprotective O 
effect O 
of O 
PA O 
was O 
associated O 
with O 
an O 
over O 
expression O 
of O 
HSP70 O 
and O 
suppression O 
of O 
Bax O 
proteins O 
in O 
the O 
ulcerated O 
tissue O 
. O 
In O 
addition O 
, O 
PA O 
exhibited O 
a O 
potent O 
FRAP O 
value O 
and O 
significant O 
COX-2 O 
inhibition O 
. O 
It O 
also O 
showed O 
a O 
significant O 
minimum O 
inhibitory O 
concentration O 
( O 
MIC O 
) O 
against O 
H O 
. O 
pylori O 
bacterium O 
. O 
The O 
efficacy O 
of O 
PA O 
was O 
accomplished O 
safely O 
without O 
the O 
presence O 
of O 
any O 
toxicological O 
parameters O 
. O 
The O 
results O 
of O 
the O 
present O 
study O 
indicate O 
that O 
the O 
gastroprotective O 
effect O 
of O 
PA O 
might O 
contribute O 
to O 
the O 
antioxidant O 
and O 
anti-inflammatory O 
properties O 
as O 
well O 
as O 
the O 
anti-apoptotic O 
mechanism O 
and O 
antibacterial O 
action O 
against O 
Helicobacter O 
pylori O 
. O 

High-Affinity O 
Potassium B-SYSTEMATIC 
( O 
HKT O 
) O 
Transporters O 
Involved O 
in O 
Salinity O 
Tolerance O 
: O 
Structural O 
Insights O 
to O 
Probe O 
Differences O 
in O 
Ion O 
Selectivity O 
. O 

- O 
affinity O 
Potassium B-SYSTEMATIC 
Transporters O 
( O 
HKTs O 
) O 
belong O 
to O 
an O 
important O 
class O 
of O 
integral O 
membrane O 
proteins O 
( O 
IMPs O 
) O 
that O 
facilitate O 
cation O 
transport O 
across O 
the O 
plasma O 
membranes O 
of O 
plant O 
cells O 
. O 
Some O 
members O 
of O 
the O 
HKT O 
protein O 
family O 
have O 
been O 
shown O 
to O 
be O 
critical O 
for O 
salinity O 
tolerance O 
in O 
commercially O 
important O 
crop O 
species O 
, O 
particularly O 
in O 
grains O 
, O 
through O 
exclusion O 
of O 
Na+ B-FORMULA 
ions O 
from O 
sensitive O 
shoot O 
tissues O 
in O 
plants O 
. O 
However O 
, O 
given O 
the O 
number O 
of O 
different O 
HKT O 
proteins O 
expressed O 
in O 
plants O 
, O 
it O 
is O 
likely O 
that O 
different O 
members O 
of O 
this O 
protein O 
family O 
perform O 
in O 
a O 
range O 
of O 
functions O 
. O 
Plant O 
breeders O 
and O 
biotechnologists O 
have O 
attempted O 
to O 
manipulate O 
HKT O 
gene O 
expression O 
through O 
genetic O 
engineering O 
and O 
more O 
conventional O 
plant O 
breeding O 
methods O 
to O 
improve O 
the O 
salinity O 
tolerance O 
of O 
commercially O 
important O 
crop O 
plants O 
. O 
Successful O 
manipulation O 
of O 
a O 
biological O 
trait O 
is O 
more O 
likely O 
to O 
be O 
effective O 
after O 
a O 
thorough O 
understanding O 
of O 
how O 
the O 
trait O 
, O 
genes O 
and O 
proteins O 
are O 
interconnected O 
at O 
the O 
whole O 
plant O 
level O 
. O 
This O 
article O 
examines O 
the O 
current O 
structural O 
and O 
functional O 
knowledge O 
relating O 
to O 
plant O 
HKTs O 
and O 
how O 
their O 
structural O 
features O 
may O 
explain O 
their O 
transport O 
selectivity O 
. O 
We O 
also O 
highlight O 
specific O 
areas O 
where O 
new O 
knowledge O 
of O 
plant O 
HKT O 
transporters O 
is O 
needed O 
. O 
Our O 
goal O 
is O 
to O 
present O 
how O 
knowledge O 
of O 
the O 
structure O 
of O 
HKT O 
proteins O 
is O 
helpful O 
in O 
understanding O 
their O 
function O 
and O 
how O 
this O 
understanding O 
can O 
be O 
an O 
invaluable O 
experimental O 
tool O 
. O 
As O 
such O 
, O 
we O 
assert O 
that O 
accurate O 
structural O 
information O 
of O 
plant O 
IMPs O 
will O 
greatly O 
inform O 
functional O 
studies O 
and O 
will O 
lead O 
to O 
a O 
deeper O 
understanding O 
of O 
plant O 
nutrition O 
, O 
signalling O 
and O 
stress O 
tolerance O 
, O 
all O 
of O 
which O 
represent O 
factors O 
that O 
can O 
be O 
manipulated O 
to O 
improve O 
agricultural O 
productivity O 
. O 

in O 
high O 
- O 
density O 
lipoproteins O 
: O 
structural O 
role O 
and O 
biological O 
function O 
. O 

- O 
density O 
lipoprotein O 
( O 
HDL O 
) O 
levels O 
are O 
an O 
inverse O 
risk O 
factor O 
for O 
cardiovascular O 
diseases O 
, O 
and O 
sphingomyelin B-FAMILY 
( O 
SM O 
) O 
is O 
the O 
second O 
most O 
abundant O 
phospholipid O 
component O 
and O 
the O 
major O 
sphingolipid B-FAMILY 
in O 
HDL O 
. O 
Considering O 
the O 
marked O 
presence O 
of O 
SM O 
, O 
the O 
present O 
review O 
has O 
focused O 
on O 
the O 
current O 
knowledge O 
about O 
this O 
phospholipid O 
by O 
addressing O 
its O 
variable O 
distribution O 
among O 
HDL O 
lipoparticles O 
, O 
how O 
they O 
acquire O 
this O 
phospholipid O 
, O 
and O 
the O 
important O 
role O 
that O 
SM O 
plays O 
in O 
regulating O 
their O 
fluidity O 
and O 
cholesterol B-TRIVIAL 
efflux O 
from O 
different O 
cells O 
. O 
In O 
addition O 
, O 
plasma O 
enzymes O 
involved O 
in O 
HDL O 
metabolism O 
such O 
as O 
lecithin- O 
cholesterol B-TRIVIAL 
acyltransferase O 
or O 
phospholipid O 
transfer O 
protein O 
are O 
inhibited O 
by O 
HDL O 
SM O 
content O 
. O 
Likewise O 
, O 
HDL O 
SM O 
levels O 
are O 
influenced O 
by O 
dietary O 
maneuvers O 
( O 
source O 
of O 
protein O 
or O 
fat O 
) O 
, O 
drugs O 
( O 
statins O 
or O 
diuretics O 
) O 
and O 
modified O 
in O 
diseases O 
such O 
as O 
diabetes O 
, O 
renal O 
failure O 
or O 
Niemann-Pick O 
disease O 
. O 
Furthermore O 
, O 
increased O 
levels O 
of O 
HDL O 
SM O 
have O 
been O 
shown O 
to O 
be O 
an O 
inverse O 
risk O 
factor O 
for O 
coronary O 
heart O 
disease O 
. O 
The O 
complexity O 
of O 
SM O 
species O 
, O 
described O 
using O 
new O 
lipidomic O 
methodologies O 
, O 
and O 
their O 
distribution O 
in O 
different O 
HDL O 
particles O 
under O 
many O 
experimental O 
conditions O 
are O 
promising O 
avenues O 
for O 
further O 
research O 
in O 
the O 
future O 
. O 

design O 
and O 
macroscopic O 
assembly O 
of O 
poly(vinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
) I-SYSTEMATIC 
-coated O 
graphene B-TRIVIAL 
into O 
kilometers O 
- O 
long O 
fibers O 
. O 

is O 
characterized O 
by O 
its O 
excellent O 
mechanical O 
performance O 
due O 
to O 
the O 
well O 
- O 
recognized O 
" O 
brick O 
and O 
mortar O 
" O 
structure O 
. O 
Many O 
efforts O 
have O 
been O 
applied O 
to O 
make O 
nacre O 
- O 
mimicking O 
materials O 
, O 
but O 
it O 
is O 
still O 
a O 
big O 
challenge O 
to O 
realize O 
their O 
continuous O 
production O 
. O 
Here O 
, O 
we O 
prepared O 
sandwich O 
- O 
like O 
building O 
blocks O 
of O 
poly(vinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PVA B-ABBREVIATION 
) O 
- O 
coated O 
graphene B-TRIVIAL 
, O 
and O 
achieved O 
high O 
- O 
nanofiller O 
- O 
content O 
kilometers O 
- O 
long O 
fibers O 
by O 
continuous O 
wet O 
- O 
spinning O 
assembly O 
technology O 
. O 
The O 
fibers O 
have O 
a O 
strict O 
" O 
brick O 
and O 
mortar O 
" O 
layered O 
structure O 
, O 
with O 
graphene B-TRIVIAL 
sheet O 
as O 
rigid O 
brick O 
and O 
PVA B-ABBREVIATION 
as O 
soft O 
mortar O 
. O 
The O 
mortar O 
thickness O 
can O 
be O 
precisely O 
tuned O 
from O 
2.01 O 
to O 
3.31 O 
nm O 
by O 
the O 
weight O 
feed O 
ratio O 
of O 
PVA O 
to O 
graphene B-TRIVIAL 
, O 
as O 
demonstrated O 
by O 
both O 
atomic O 
force O 
microscopy O 
and O 
X-ray O 
diffraction O 
measurements O 
. O 
The O 
mechanical O 
strength O 
of O 
the O 
nacre O 
- O 
mimicking O 
fibers O 
increases O 
with O 
increasing O 
the O 
content O 
of O 
PVA B-ABBREVIATION 
, O 
and O 
it O 
rises O 
gradually O 
from O 
81 O 
MPa O 
for O 
the O 
fiber O 
with O 
53.1 O 
wt% O 
PVA B-ABBREVIATION 
to O 
161 O 
MPa O 
for O 
the O 
fiber O 
with O 
65.8 O 
wt% O 
PVA B-ABBREVIATION 
. O 
The O 
mechanical O 
performance O 
of O 
our O 
fibers O 
was O 
independent O 
of O 
the O 
molecular O 
weight O 
( O 
MW O 
) O 
of O 
PVA B-ABBREVIATION 
in O 
the O 
wide O 
range O 
of O 
2-100 O 
kDa O 
, O 
indicating O 
that O 
low O 
MW O 
polymers O 
can O 
also O 
be O 
used O 
to O 
make O 
strong O 
nanocomposites O 
. O 
The O 
tensile O 
stress O 
of O 
fibers O 
immersed O 
in O 
PVA B-ABBREVIATION 
5 O 
wt% O 
solution O 
reached O 
ca O 
. O 
200 O 
MPa O 
, O 
surpassing O 
the O 
values O 
of O 
nacre O 
and O 
most O 
of O 
other O 
nacre O 
- O 
mimicking O 
materials O 
. O 
The O 
nacre O 
- O 
mimicking O 
fibers O 
are O 
highly O 
electrically O 
conductive O 
( O 
∼350 O 
S O 
m(-1) O 
) O 
after O 
immersing O 
in O 
hydroiodic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
enabling O 
them O 
to O 
connect O 
a O 
circuit O 
to O 
illuminate O 
an O 
LED O 
lamp O 
. O 

that O 
recognize O 
and O 
bind O 
specific O 
sites O 
in O 
DNA O 
are O 
essential O 
for O 
regulation O 
of O 
numerous O 
biological O 
functions O 
. O 
Such O 
proteins O 
often O 
require O 
a O 
negative O 
supercoiled O 
DNA O 
topology O 
to O 
function O 
correctly O 
. O 
In O 
current O 
research O 
, O 
short O 
linear O 
DNA O 
is O 
often O 
used O 
to O 
study O 
DNA O 
- O 
protein O 
interactions O 
. O 
Although O 
linear O 
DNA O 
can O 
easily O 
be O 
modified O 
, O 
for O 
capture O 
on O 
a O 
surface O 
, O 
its O 
relaxed O 
topology O 
does O 
not O 
accurately O 
resemble O 
the O 
natural O 
situation O 
in O 
which O 
DNA O 
is O 
generally O 
negatively O 
supercoiled O 
. O 
Moreover O 
, O 
specific O 
binding O 
sequences O 
are O 
flanked O 
by O 
large O 
stretches O 
of O 
non-target O 
sequence O 
in O 
vivo O 
. O 
Here O 
, O 
we O 
present O 
a O 
straightforward O 
method O 
for O 
capturing O 
negatively O 
supercoiled O 
plasmid O 
DNA O 
on O 
a O 
streptavidin O 
surface O 
. O 
It O 
relies O 
on O 
the O 
formation O 
of O 
a O 
temporary O 
parallel O 
triplex O 
, O 
using O 
a O 
triple O 
helix O 
forming O 
oligonucleotide O 
containing O 
locked O 
nucleic O 
acid O 
nucleotides B-FAMILY 
. O 
All O 
materials O 
required O 
for O 
this O 
method O 
are O 
commercially O 
available O 
. O 
Lac O 
repressor O 
binding O 
to O 
its O 
operator O 
was O 
used O 
as O 
model O 
system O 
. O 
Although O 
the O 
dissociation O 
constants O 
for O 
both O 
the O 
linear O 
and O 
plasmid O 
- O 
based O 
operator O 
are O 
in O 
the O 
range O 
of O 
4 O 
nM O 
, O 
the O 
association O 
and O 
dissociation O 
rates O 
of O 
Lac O 
repressor O 
binding O 
to O 
the O 
plasmid O 
- O 
based O 
operator O 
are O 
∼18 O 
times O 
slower O 
than O 
on O 
a O 
linear O 
fragment O 
. O 
This O 
difference O 
underscores O 
the O 
importance O 
of O 
using O 
a O 
physiologically O 
relevant O 
DNA O 
topology O 
for O 
studying O 
DNA O 
- O 
protein O 
interactions O 
. O 

p16 O 
and O 
p15 O 
proteins O 
are O 
inhibitors O 
of O 
cyclin O 
- O 
dependent O 
kinases O 
that O 
prevent O 
the O 
cell O 
going O 
through O 
the O 
G1 O 
/ O 
S O 
phase O 
transaction O 
. O 
E-cadherin O 
is O 
a O 
transmembrane O 
glycoprotein O 
that O 
mediates O 
calcium B-SYSTEMATIC 
-dependent O 
interactions O 
between O 
adjacent O 
epithelial O 
cells O 
. O 
Two O 
groups O 
of O 
patients O 
were O 
selected O 
: O 
the O 
first O 
group O 
suffered O 
from O 
epithelial O 
serous O 
ovarian O 
tumors O 
and O 
the O 
second O 
group O 
suffered O 
from O 
benign O 
ovarian O 
lesions O 
; O 
ovarian O 
tissue O 
samples O 
from O 
all O 
the O 
subjects O 
( O 
benign O 
and O 
malignant O 
) O 
were O 
subjected O 
to O 
methylation O 
- O 
specific O 
polymerase O 
chain O 
reaction O 
for O 
methylated O 
and O 
unmethylated O 
alleles O 
of O 
the O 
genes O 
( O 
E-cadherin O 
, O 
p15 O 
, O 
and O 
p16 O 
) O 
. O 
Results O 
obtained O 
showed O 
that O 
aberrant O 
methylation O 
of O 
p15 O 
and O 
p16 O 
genes O 
were O 
detected O 
in O 
64.29 O 
and O 
50% O 
of O 
ovarian O 
cancer O 
patients O 
, O 
while O 
E-cadherin O 
hypermethylation O 
was O 
detected O 
in O 
78.57% O 
of O 
ovarian O 
cancer O 
patients O 
. O 
Methylation O 
of O 
E-cadherin O 
was O 
significantly O 
correlated O 
with O 
different O 
stage O 
of O 
disease O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
It O 
was O 
found O 
that O 
the O 
risk O 
of O 
E-cadherin O 
hypermethylation O 
was O 
1.347-fold O 
, O 
while O 
risk O 
of O 
p15 O 
hypermethylation O 
was O 
1.543-fold O 
and O 
p16 O 
was O 
1.2-fold O 
among O 
patients O 
with O 
ovarian O 
cancer O 
than O 
that O 
among O 
patients O 
with O 
benign O 
ovarian O 
lesions O 
. O 
In O 
conclusion O 
, O 
Dysfunction O 
of O 
the O 
cell O 
cycle O 
and O 
/ O 
or O 
the O 
cell O 
- O 
cell O 
adhesion O 
molecule O 
plays O 
a O 
role O 
in O 
the O 
pathogenesis O 
of O 
ovarian O 
cancer O 
and O 
that O 
the O 
analysis O 
of O 
the O 
methylation O 
of O 
p15 O 
and O 
E-cadherin O 
genes O 
can O 
provide O 
clinically O 
important O 
evidence O 
on O 
which O 
to O 
base O 
the O 
treatment O 
. O 

allelopathy O 
, O 
one O 
plant O 
suppresses O 
the O 
growth O 
and O 
development O 
of O 
other O 
plant O 
/ O 
plants O 
by O 
negatively O 
affecting O 
a O 
variety O 
of O 
physiological O 
and O 
biochemical O 
reactions O 
. O 
We O 
checked O 
the O 
effects O 
of O 
methanolic O 
extracts O 
( O 
allelochemical O 
extracts O 
) O 
of O 
Phytolacca O 
latbenia O 
( O 
Moq O 
. O 
) O 
H O 
. O 
Walter O 
on O 
antioxidant O 
enzyme O 
activities O 
such O 
as O 
peroxidases O 
( O 
PODs O 
) O 
, O 
super B-TRIVIAL 
oxide I-TRIVIAL 
dismutases O 
( O 
SODs O 
) O 
and O 
catalase O 
( O 
CAT O 
) O 
and O 
on O 
total O 
protein O 
contents O 
( O 
TPC O 
) O 
, O 
cellular O 
injury O 
( O 
CI O 
) O 
, O 
and O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
in O 
the O 
germinating O 
seeds O 
of O 
Brassica O 
napus O 
L O 
. O 
( O 
dicot O 
) O 
and O 
Triticum O 
aestivum O 
L O 
. O 
( O 
monocot O 
) O 
. O 
Both O 
the O 
crude O 
methanolic O 
extract O 
root O 
( O 
CMER O 
) O 
and O 
crude O 
methanolic O 
extract O 
aerial O 
( O 
CMEA O 
) O 
of O 
P O 
. O 
latbenia O 
at O 
10000 O 
ppm O 
significantly O 
reduced O 
the O 
POD O 
activity O 
in O 
both O 
the O 
test O 
seeds O 
. O 
The O 
activity O 
of O 
SODs O 
was O 
significantly O 
decreased O 
by O 
both O 
CMER O 
and O 
CMEA O 
in O 
B O 
. O 
napus O 
germinating O 
seeds O 
. O 
A O 
linear O 
increase O 
in O 
the O 
activity O 
of O 
CAT O 
, O 
CI O 
, O 
and O 
MDA B-ABBREVIATION 
contents O 
was O 
found O 
in O 
both O 
the O 
test O 
seeds O 
with O 
the O 
increasing O 
concentrations O 
of O 
CMEA O 
and O 
CMER O 
, O 
while O 
TPC O 
of O 
the O 
germinating O 
seeds O 
was O 
found O 
decreased O 
. O 
It O 
is O 
inferred O 
that O 
both O 
the O 
CMEA O 
and O 
CMER O 
inhibited O 
/ O 
delayed O 
the O 
seed O 
germination O 
, O 
reduced O 
the O 
seedling O 
growth O 
by O 
affecting O 
a O 
variety O 
of O 
biochemical O 
and O 
physiological O 
attributes O 
, O 
and O 
also O 
caused O 
cellular O 
membrane O 
injury O 
in O 
the O 
germinating O 
seeds O 
of O 
both O 
the O 
monocot O 
and O 
dicot O 
seeds O 
. O 

synthesis O 
, O 
characterization O 
of O 
β-aminoketone B-FAMILY 
s O 
by O 
bismuth B-SYSTEMATIC 
(III) I-SYSTEMATIC 
triflate I-SYSTEMATIC 
and O 
determination O 
of O 
antigenotoxic O 
properties O 
. O 

- O 
type O 
catalytic O 
Mannich O 
reaction O 
for O 
the O 
synthesis O 
of O 
β-aminoketones B-FAMILY 
from O 
cyclohexanone B-SYSTEMATIC 
, O 
substituted O 
aromatic B-MULTIPLE 
amines I-MULTIPLE 
and I-MULTIPLE 
aromatic I-MULTIPLE 
or I-MULTIPLE 
hetero I-MULTIPLE 
- I-MULTIPLE 
aromatic I-MULTIPLE 
aldehydes I-MULTIPLE 
has O 
been O 
applied O 
in O 
water O 
with O 
bismuth B-SYSTEMATIC 
triflate I-SYSTEMATIC 
under O 
ultrasound O 
. O 
Good O 
yields O 
of O 
the O 
expected O 
β-aminoketones B-FAMILY 
were O 
obtained O 
from O 
available O 
substrates O 
, O 
at O 
room O 
temperature O 
in O 
1-2 O 
hours O 
. O 
This O 
study O 
was O 
designed O 
to O 
evaluate O 
the O 
mutagenic O 
and O 
antimutagenic O 
potential O 
of O 
synthesized O 
β-aminoketones B-FAMILY 
compounds O 
using O 
Ames O 
/ O 
Salmonella O 
and O 
Escherichia O 
coli O 
WP2 O 
bacterial O 
reverse O 
mutation O 
assay O 
systems O 
. O 

effect O 
of O 
lycopene B-TRIVIAL 
against O 
2,3,7,8-tetrachlorodibenzo- B-SYSTEMATIC 
pdioxin I-SYSTEMATIC 
- O 
induced O 
rat O 
liver O 
microsomal O 
toxicity O 
: O 
An O 
in O 
vitro O 
study O 
. O 

objective O 
of O 
the O 
current O 
study O 
was O 
to O 
investigate O 
the O 
potential O 
oxidative O 
damage O 
of O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
in O 
hepatic O 
microsomal O 
fractions O 
in O 
vitro O 
and O 
to O 
further O 
elucidate O 
the O 
potential O 
modulatory O 
effect O 
of O 
lycopene B-TRIVIAL 
. O 
Rat O 
liver O 
microsomes O 
were O 
divided O 
into O 
four O 
groups O 
. O 
Group O 
I O 
served O 
as O 
a O 
control O 
and O 
is O 
incubated O 
with O 
vehicle O 
( O 
toluene B-TRIVIAL 
) O 
. O 
Groups O 
II O 
and O 
IV O 
were O 
incubated O 
with O 
20 O 
µM O 
lycopene B-TRIVIAL 
for O 
1 O 
h O 
before O 
further O 
incubating O 
; O 
groups O 
III O 
and O 
IV O 
with O 
15 O 
nM O 
of O 
TCDD B-ABBREVIATION 
for O 
further O 
1 O 
h O 
. O 
Hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
H2O2 B-FORMULA 
) O 
production O 
, O 
lipid O 
peroxidation O 
( O 
LPO O 
) O 
, O 
protein O 
carbonyl B-FAMILY 
content O 
and O 
activities O 
of O 
uridine B-SYSTEMATIC 
5'-diphospho I-SYSTEMATIC 
-glucuronyltransferase O 
( O 
UDPGT O 
) O 
and O 
P450 O 
were O 
significantly O 
increased O 
. O 
Moreover O 
, O 
the O 
activity O 
of O 
antioxidant O 
enzymes O 
superoxide O 
dismutase O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
, O 
catalse O 
, O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
and O 
glutathione B-TRIVIAL 
reductase O 
as O 
well O 
as O 
the O 
microsomal O 
thiol O 
content O 
were O 
significantly O 
decreased O 
. O 
Incubation O 
with O 
lycopene B-TRIVIAL 
( O 
group O 
IV O 
) O 
maintained O 
near O 
normal O 
activities O 
of O 
the O 
enzymes O 
, O 
normalized O 
thiol B-FAMILY 
and O 
carbonyl B-FAMILY 
content O 
and O 
significantly O 
reduced O 
LPO O 
and O 
H2O2 B-FORMULA 
production O 
. O 
In O 
conclusion O 
, O 
the O 
findings O 
of O 
the O 
study O 
indicate O 
that O 
TCDD B-ABBREVIATION 
induces O 
a O 
significant O 
oxidative O 
stress O 
in O 
liver O 
microsomes O 
as O 
manifested O 
by O 
increased O 
LPO O 
, O 
H2O2 B-FORMULA 
production O 
, O 
protein O 
carbonyl B-FAMILY 
content O 
and O 
activities O 
of O 
UDPGT O 
and O 
P450 O 
and O 
decreased O 
antioxidant O 
enzymes O 
activities O 
and O 
thiol B-FAMILY 
content O 
. O 
By O 
the O 
reversal O 
of O 
biochemical O 
and O 
oxidative O 
markers O 
toward O 
normalcy O 
, O 
the O 
protective O 
role O 
of O 
lycopene B-TRIVIAL 
is O 
illuminated O 
in O 
rat O 
liver O 
microsomal O 
toxicity O 
. O 

to O 
stimulated O 
overall O 
metabolism O 
, O 
a O 
state O 
of O 
nutritional O 
inadequacy O 
often O 
ensues O 
, O 
during O 
thyrotoxicosis O 
. O 
We O 
aimed O 
to O 
investigate O 
circulating O 
levels O 
of O 
some O 
major O 
components O 
of O 
the O 
system O 
that O 
regulates O 
energy O 
stores O 
, O 
glucose B-TRIVIAL 
, O 
and O 
fat O 
metabolism O 
, O 
during O 
thyrotoxicosis O 
compared O 
to O 
euthyroidism O 
. O 
Fasting O 
serum O 
ghrelin O 
, O 
leptin O 
, O 
adiponectin O 
, O 
insulin O 
, O 
glucagon O 
, O 
glucose B-TRIVIAL 
, O 
as O 
well O 
as O 
body O 
fat O 
composition O 
were O 
analyzed O 
during O 
thyrotoxicosis O 
in O 
40 O 
hyperthyroid O 
patients O 
( O 
50.5 O 
± O 
15.2 O 
years O 
old O 
, O 
22 O 
females O 
, O 
31 O 
with O 
Graves O 
disease O 
, O 
and O 
9 O 
with O 
toxic O 
nodular O 
goiter O 
) O 
. O 
The O 
same O 
measurements O 
were O 
repeated O 
an O 
average O 
3 O 
months O 
later O 
, O 
when O 
all O 
patients O 
achieved O 
euthyroidism O 
. O 
Compared O 
to O 
euthyroidism O 
, O 
in O 
thyrotoxicosis O 
, O 
patients O 
had O 
lower O 
ghrelin O 
and O 
fat O 
mass O 
; O 
had O 
comparable O 
insulin O 
, O 
HOMA-IR O 
, O 
glucagon O 
, O 
and O 
leptin O 
levels O 
; O 
higher O 
levels O 
of O 
circulating O 
adiponectin O 
. O 
Fasting O 
serum O 
glucose B-TRIVIAL 
tended O 
to O 
be O 
higher O 
during O 
thyrotoxicosis O 
. O 
The O 
unique O 
correlation O 
of O 
HOMA-IR O 
was O 
with O 
the O 
- O 
glucagon O 
to O 
ghrelin O 
ratio-(r O 
= O 
0.801 O 
, O 
p O 
< O 
0.001 O 
) O 
in O 
hyperthyrodism O 
, O 
and O 
with O 
glucagon O 
itself O 
in O 
euthyroidism O 
( O 
r O 
= O 
-0.844 O 
, O 
p O 
< O 
0.001 O 
) O 
. O 
Circulating O 
levels O 
of O 
ghrelin O 
are O 
decreased O 
; O 
leptin O 
, O 
insulin O 
, O 
glucagon O 
are O 
unchanged O 
; O 
adiponectin O 
are O 
increased O 
during O 
hyperthyroidism O 
. O 
The O 
fasting O 
HOMA-IR O 
tends O 
to O 
be O 
higher O 
, O 
despite O 
the O 
decreased O 
adiposity O 
in O 
hyperthyroidism O 
. O 
The O 
- O 
glucagon O 
to O 
ghrelin O 
ratio O 
- O 
strongly O 
correlates O 
with O 
fasting O 
HOMA-IR O 
in O 
hyperthyroidism O 
. O 

strategies O 
to O 
enhance O 
the O 
efficacy O 
of O 
nicotine B-TRIVIAL 
replacement O 
therapy O 
for O 
smoking O 
cessation O 
: O 
a O 
review O 
of O 
the O 
literature O 
. O 

number O 
of O 
smoking O 
cessation O 
pharmacotherapies O 
have O 
led O 
to O 
increases O 
in O 
quitting O 
and O 
thus O 
to O 
significant O 
benefits O 
to O 
public O 
health O 
. O 
Among O 
existing O 
medications O 
, O 
nicotine B-TRIVIAL 
replacement O 
therapy O 
( O 
NRT O 
) O 
has O 
been O 
available O 
the O 
longest O 
, O 
has O 
the O 
largest O 
literature O 
base O 
in O 
support O 
, O 
and O 
is O 
the O 
only O 
option O 
for O 
over O 
- O 
the O 
- O 
counter O 
access O 
. O 
While O 
the O 
short O 
- O 
term O 
efficacy O 
of O 
NRT O 
is O 
well O 
documented O 
in O 
clinical O 
trials O 
, O 
long O 
- O 
term O 
abstinence O 
rates O 
associated O 
with O 
using O 
NRT O 
are O 
modest O 
, O 
as O 
most O 
smokers O 
will O 
relapse O 
. O 
This O 
literature O 
review O 
examines O 
emerging O 
clinical O 
strategies O 
to O 
improve O 
NRT O 
efficacy O 
. O 
After O 
an O 
initial O 
overview O 
of O 
NRT O 
and O 
its O 
FDA-approved O 
indications O 
for O 
use O 
, O 
we O 
review O 
randomized O 
trials O 
in O 
which O 
clinical O 
delivery O 
of O 
NRT O 
was O 
manipulated O 
and O 
tested O 
, O 
in O 
an O 
attempt O 
to O 
enhance O 
efficacy O 
, O 
through O 
( O 
1 O 
) O 
duration O 
of O 
use O 
( O 
pre O 
- O 
quit O 
and O 
extended O 
use O 
) O 
, O 
( O 
2 O 
) O 
amount O 
of O 
use O 
( O 
high O 
- O 
dose O 
and O 
combination O 
NRT O 
) O 
, O 
( O 
3 O 
) O 
tailoring O 
to O 
specific O 
smoker O 
groups O 
( O 
genotype O 
and O 
phenotype O 
) O 
, O 
or O 
( O 
4 O 
) O 
use O 
of O 
NRT O 
for O 
novel O 
purposes O 
( O 
relapse O 
prevention O 
, O 
temporary O 
abstinence O 
, O 
cessation O 
induction O 
) O 
. O 
Outcomes O 
vary O 
within O 
and O 
across O 
topic O 
area O 
, O 
and O 
we O 
highlight O 
areas O 
that O 
offer O 
stronger O 
promise O 
. O 
Combination O 
NRT O 
likely O 
represents O 
the O 
most O 
promising O 
strategy O 
moving O 
forward O 
; O 
other O 
clinical O 
strategies O 
offer O 
conflicting O 
evidence O 
but O 
deserve O 
further O 
testing O 
( O 
pre O 
- O 
quit O 
NRT O 
or O 
tailored O 
treatment O 
) O 
or O 
offer O 
potential O 
utility O 
but O 
are O 
in O 
need O 
of O 
further O 
, O 
direct O 
tests O 
. O 
Some O 
areas O 
, O 
though O 
based O 
on O 
a O 
limited O 
set O 
of O 
studies O 
, O 
do O 
not O 
offer O 
great O 
promise O 
( O 
high O 
- O 
dose O 
and O 
extended O 
treatment O 
NRT O 
) O 
. O 
We O 
conclude O 
with O 
a O 
brief O 
discussion O 
of O 
emergent O 
NRT O 
products O 
( O 
e.g O 
. O 
, O 
oral O 
nicotine B-TRIVIAL 
spray O 
, O 
among O 
others O 
) O 
, O 
which O 
may O 
ultimately O 
offer O 
greater O 
efficacy O 
than O 
current O 
formulations O 
. O 
In O 
order O 
to O 
further O 
lower O 
the O 
prevalence O 
of O 
smoking O 
, O 
novel O 
strategies O 
designed O 
to O 
optimize O 
NRT O 
efficacy O 
are O 
needed O 
. O 

armamentarium O 
for O 
the O 
systemic O 
therapy O 
of O 
advanced O 
renal O 
cell O 
carcinoma O 
( O 
RCC O 
) O 
has O 
undergone O 
dramatic O 
changes O 
over O 
the O 
past O 
6 O 
years O 
. O 
While O 
high O 
- O 
dose O 
interleukin O 
(IL)-2 O 
remains O 
an O 
option O 
for O 
highly O 
selected O 
good O 
and O 
intermediate O 
risk O 
patients O 
with O 
clear O 
- O 
cell O 
histology O 
because O 
of O 
durable O 
complete O 
responses O 
in O 
a O 
small O 
fraction O 
of O 
patients O 
, O 
cytokine O 
- O 
based O 
therapy O 
including O 
interferon O 
( O 
IFN O 
) O 
has O 
been O 
supplanted O 
by O 
vascular O 
- O 
endothelial O 
growth O 
factor O 
( O 
VEGF O 
) O 
and O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
( O 
mTOR O 
) O 
inhibitors O 
. O 
Treatment O 
decision O 
is O 
initially O 
based O 
on O 
prognostication O 
of O 
the O 
disease O 
. O 
As O 
metastatic O 
RCC O 
( O 
mRCC O 
) O 
is O 
commonly O 
an O 
indolent O 
disease O 
, O 
a O 
period O 
of O 
observation O 
should O 
always O 
been O 
considered O 
. O 
For O 
good O 
and O 
intermediate O 
risk O 
disease O 
, O 
pazopanib B-TRIVIAL 
, O 
sunitinib B-TRIVIAL 
or O 
the O 
combination O 
of O 
bevacizumab O 
plus O 
IFN O 
are O 
considered O 
. O 
Notably O 
, O 
recent O 
data O 
suggest O 
non-inferiority O 
for O 
the O 
efficacy O 
of O 
pazopanib B-TRIVIAL 
compared O 
to O 
sunitinib B-TRIVIAL 
coupled O 
with O 
a O 
better O 
toxicity O 
profile O 
. O 
A O 
novel O 
VEGF O 
receptor O 
inhibitor O 
, O 
tivozanib B-TRIVIAL 
, O 
is O 
expected O 
to O 
be O 
approved O 
based O 
on O 
improvement O 
in O 
PFS O 
when O 
compared O 
to O 
sorafenib B-TRIVIAL 
in O 
the O 
first O 
- O 
line O 
setting O 
. O 
The O 
use O 
of O 
temsirolimus B-TRIVIAL 
for O 
poor O 
risk O 
disease O 
is O 
supported O 
by O 
a O 
phase O 
III O 
trial O 
dedicated O 
to O 
this O 
group O 
of O 
patients O 
. O 
The O 
role O 
of O 
cytoreductive O 
nephrectomy O 
in O 
the O 
context O 
of O 
VEGF O 
and O 
mTOR O 
inhibitors O 
is O 
being O 
studied O 
in O 
randomized O 
trials O 
. O 
Selected O 
patients O 
with O 
solitary O 
or O 
oligometastatic O 
disease O 
may O 
be O 
eligible O 
for O 
metastatectomy O 
. O 
Following O 
first O 
- O 
line O 
VEGF O 
inhibitors O 
, O 
second O 
- O 
line O 
therapy O 
with O 
everolimus B-TRIVIAL 
and O 
axitinib B-TRIVIAL 
have O 
demonstrated O 
benefits O 
in O 
progression O 
- O 
free O 
survival O 
( O 
PFS O 
) O 
. O 
One O 
phase O 
III O 
trial O 
comparing O 
sorafenib B-TRIVIAL 
and O 
temsirolimus B-TRIVIAL 
in O 
the O 
post- O 
sunitinib B-TRIVIAL 
setting O 
showed O 
no O 
difference O 
in O 
PFS O 
, O 
the O 
primary O 
endpoint O 
, O 
but O 
did O 
show O 
a O 
superior O 
overall O 
survival O 
for O 
sorafenib B-TRIVIAL 
. O 
Sorafenib B-TRIVIAL 
, O 
pazopanib B-TRIVIAL 
and O 
axitinib B-TRIVIAL 
have O 
all O 
demonstrated O 
clinical O 
benefit O 
following O 
cytokines O 
. O 
Therapy O 
following O 
first O 
- O 
line O 
mTOR O 
inhibitors O 
remains O 
undefined O 
, O 
although O 
VEGF O 
inhibitors O 
have O 
demonstrated O 
activity O 
in O 
this O 
setting O 
. O 
Optimal O 
sequencing O 
of O 
agents O 
and O 
individualized O 
therapy O 
based O 
on O 
biomarkers O 
is O 
undergoing O 
investigation O 
. O 
Today O 
, O 
the O 
choice O 
of O 
therapy O 
is O 
based O 
on O 
patient O 
and O 
physician O 
decision O 
, O 
which O 
is O 
a O 
function O 
of O 
comorbidities O 
, O 
toxicity O 
profiles O 
and O 
costs O 
. O 
Clinical O 
trials O 
evaluating O 
novel O 
agents O 
and O 
combinations O 
should O 
be O 
preferred O 
when O 
available O 
since O 
agents O 
in O 
the O 
current O 
therapeutic O 
arsenal O 
have O 
not O 
yielded O 
cures O 
despite O 
extending O 
median O 
survival O 
to O 
greater O 
than O 
2 O 
years O 
. O 
One O 
noteworthy O 
new O 
class O 
of O 
agents O 
that O 
has O 
yielded O 
durable O 
responses O 
is O 
programmed O 
death O 
(PD)-1 O 
inhibitors O 
, O 
which O 
target O 
a O 
T-lymphocyte O 
checkpoint O 
and O 
are O 
heralding O 
a O 
resurgence O 
of O 
immunotherapy O 
. O 
Finally O 
, O 
optimal O 
therapy O 
for O 
non-clear O 
cell O 
RCC O 
remains O 
to O 
be O 
delineated O 
, O 
although O 
sunitinib B-TRIVIAL 
, O 
everolimus B-TRIVIAL 
and O 
other O 
VEGFR-TKI O 
or O 
mTOR O 
inhibitors O 
have O 
all O 
demonstrated O 
modest O 
benefit O 
. O 

: O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
develop O 
and O 
evaluate O 
a O 
more O 
effective O 
mucoadhesive O 
thiomer O 
for O 
buccal O 
drug O 
- O 
delivery O 
systems O 
. O 
Methods O 
: O 
2-iminothiolane B-SYSTEMATIC 
was O 
covalently O 
attached O 
to O 
a O 
chitosan O 
backbone O 
. O 
A O 
preactivation O 
step O 
followed O 
, O 
mediated O 
by O 
6,6´dithionicotinamide B-SYSTEMATIC 
, O 
thiol B-FAMILY 
groups O 
were O 
modified O 
by O 
disulfide B-SYSTEMATIC 
bonds O 
formation O 
. O 
Mucoadhesion O 
studies O 
were O 
performed O 
on O 
buccal O 
mucosa O 
. O 
In O 
addition O 
, O 
water O 
- O 
uptake O 
capacity O 
, O 
disintegration O 
, O 
release O 
and O 
cytotoxicity O 
studies O 
were O 
completed O 
. O 
Results O 
: O 
The O 
obtained O 
chitosan- O 
thiobutylamidine B-SYSTEMATIC 
conjugate O 
displayed O 
647.4 O 
± O 
85.23 O 
µmol O 
/ O 
g O 
immobilized O 
thiol O 
groups O 
. O 
Due O 
to O 
the O 
preactivation O 
, O 
approximately O 
60% O 
of O 
thiol O 
groups O 
were O 
modified O 
by O 
formation O 
of O 
disulfide B-SYSTEMATIC 
bonds O 
. O 
Chitosan- O 
thiobutylamidine B-SYSTEMATIC 
- O 
mercaptonicotinamide B-SYSTEMATIC 
displayed O 
1.8-fold O 
higher O 
stability O 
and O 
1.6-fold O 
higher O 
mucoadhesive O 
properties O 
, O 
respectively O 
. O 
The O 
release O 
study O 
demonstrated O 
a O 
1.4-fold O 
more O 
prolonged O 
drug O 
release O 
compared O 
with O 
corresponding O 
thiomers O 
. O 
Conclusion O 
: O 
According O 
to O 
these O 
results O 
, O 
preactivated O 
thiomers O 
demonstrate O 
an O 
improved O 
stability O 
and O 
increased O 
mucoadhesive O 
properties O 
. O 
Therefore O 
, O 
they O 
seem O 
to O 
be O 
advantageous O 
for O 
buccal O 
administration O 
over O 
corresponding O 
thiomers O 
and O 
chitosan O 
. O 

Solvent O 
- O 
Based O 
Graphene B-SYSTEMATIC 
Oxide I-SYSTEMATIC 
Liquid O 
Crystals O 
: O 
A O 
Facile O 
Route O 
toward O 
the O 
Next O 
Generation O 
of O 
Self-Assembled O 
Layer O 
- O 
by O 
- O 
Layer O 
Multifunctional O 
3D O 
Architectures O 
. O 

introduce O 
soft O 
self O 
- O 
assembly O 
of O 
ultralarge O 
liquid O 
crystalline O 
( O 
LC O 
) O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
GO O 
) O 
sheets O 
in O 
a O 
wide O 
range O 
of O 
organic O 
solvents O 
overcoming O 
the O 
practical O 
limitations O 
imposed O 
on O 
LC O 
GO O 
processing O 
in O 
water O 
. O 
This O 
expands O 
the O 
number O 
of O 
known O 
solvents O 
which O 
can O 
support O 
amphiphilic O 
self O 
- O 
assembly O 
to O 
ethanol B-SYSTEMATIC 
, O 
acetone B-SYSTEMATIC 
, O 
tetrahydrofuran B-SYSTEMATIC 
, O 
N-dimethylformamide B-SYSTEMATIC 
, O 
N-cyclohexyl-2-pyrrolidone B-SYSTEMATIC 
, O 
and O 
a O 
number O 
of O 
other O 
organic O 
solvents O 
, O 
many O 
of O 
which O 
were O 
not O 
known O 
to O 
afford O 
solvophobic O 
self O 
- O 
assembly O 
prior O 
to O 
this O 
report O 
. O 
The O 
LC O 
behavior O 
of O 
the O 
as-prepared O 
GO O 
sheets O 
in O 
organic O 
solvents O 
has O 
enabled O 
us O 
to O 
disperse O 
and O 
organize O 
substantial O 
amounts O 
of O 
aggregate O 
- O 
free O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWNTs O 
, O 
up O 
to O 
10 O 
wt O 
% O 
) O 
without O 
compromise O 
in O 
LC O 
properties O 
. O 
The O 
as-prepared O 
LC O 
GO-SWNT O 
dispersions O 
were O 
employed O 
to O 
achieve O 
self O 
- O 
assembled O 
layer O 
- O 
by O 
- O 
layer O 
multifunctional O 
3D O 
hybrid O 
architectures O 
comprising O 
SWNTs O 
and O 
GO O 
with O 
unrivalled O 
superior O 
mechanical O 
properties O 
( O 
Young's O 
modulus O 
in O 
excess O 
of O 
50 O 
GPa O 
and O 
tensile O 
strength O 
of O 
more O 
than O 
500 O 
MPa O 
) O 
. O 

as O 
a O 
Steric O 
Force O 
: O 
Stabilization O 
and O 
Helicity-Dependent O 
Reversion O 
of O 
Colored O 
o-Quinonoid B-FAMILY 
Intermediates O 
of O 
Helical O 
Chromenes O 
. O 

of O 
regioisomeric O 
helical O 
chromenes O 
1 O 
and O 
2 O 
leads O 
to O 
colored O 
reactive O 
intermediates O 
. O 
While O 
the O 
latter O 
generally O 
decay O 
quite O 
rapidly O 
, O 
they O 
are O 
found O 
to O 
be O 
longer O 
lived O 
in O 
1 O 
and O 
highly O 
persistent O 
in O 
2 O 
. O 
The O 
remarkable O 
stability O 
of O 
the O 
otherwise O 
fleeting O 
transient O 
in O 
2 O 
allowed O 
isolation O 
and O 
structural O 
characterization O 
by O 
X-ray O 
crystallography O 
. O 
The O 
structural O 
analyses O 
revealed O 
that O 
steric O 
force O 
inherent O 
to O 
the O 
helical O 
scaffold O 
is O 
the O 
origin O 
of O 
stability O 
as O 
well O 
as O 
differentiation O 
in O 
the O 
persistence O 
of O 
the O 
intermediates O 
of O 
1 O 
and O 
2 O 
( O 
1Q O 
and O 
2Q O 
) O 
. O 
The O 
structure O 
further O 
shows O 
that O 
diphenylvinyl B-SYSTEMATIC 
moiety O 
in O 
the O 
TT O 
isomer O 
of O 
2Q O 
gets O 
splayed O 
over O 
the O 
helical O 
scaffold O 
such O 
that O 
it O 
is O 
fraught O 
with O 
a O 
huge O 
steric O 
strain O 
to O 
undergo O 
required O 
bond O 
rotations O 
to O 
regenerate O 
the O 
precursor O 
chromene O 
. O 
Otherwise O 
, O 
reversion O 
of O 
2Q O 
was O 
found O 
to O 
occur O 
at O 
higher O 
temperatures O 
. O 
Aazahelical O 
chromenes O 
3 O 
and O 
4 O 
with O 
varying O 
magnitudes O 
of O 
helicity O 
were O 
designed O 
in O 
pursuit O 
of O 
o-quinonoid B-FAMILY 
intermediates O 
with O 
graded O 
activation O 
barriers O 
. O 
Their O 
photogenerated O 
intermediates O 
3Q O 
and O 
4Q O 
were O 
also O 
isolated O 
and O 
structurally O 
characterized O 
. O 
The O 
activation O 
barriers O 
for O 
thermal O 
reversion O 
of O 
2Q-4Q O 
, O 
as O 
determined O 
from O 
Arrhenius O 
and O 
Eyring O 
plots O 
, O 
are O 
found O 
to O 
correlate O 
nicely O 
with O 
the O 
helical O 
turn O 
, O 
which O 
decisively O 
determines O 
the O 
steric O 
force O 
. O 
The O 
exploitation O 
of O 
helicity O 
is O 
thus O 
demonstrated O 
to O 
develop O 
a O 
novel O 
set O 
of O 
photoresponsive O 
helicenes O 
2-4 O 
that O 
lead O 
to O 
colored O 
intermediates O 
exhibiting O 
graded O 
stability O 
. O 
It O 
is O 
further O 
shown O 
that O 
the O 
photochromism O 
of O 
2-4 O 
in O 
conjunction O 
with O 
response O 
of O 
2Q-4Q O 
to O 
external O 
stimuli O 
( O 
acid O 
, O 
heat O 
, O 
and O 
visible O 
radiation O 
) O 
permits O 
development O 
of O 
molecular O 
logic O 
gates O 
with O 
INHIBIT O 
function O 
. O 

and O 
Structural O 
Analysis O 
of O 
Flavones B-FAMILY 
Inhibiting O 
Tankyrases O 
. O 

are O 
known O 
for O 
their O 
beneficial O 
effects O 
on O 
human O 
health O 
, O 
and O 
therefore O 
the O 
therapeutic O 
potential O 
of O 
these O 
compounds O 
have O 
been O 
extensively O 
studied O 
. O 
Flavone B-TRIVIAL 
has O 
been O 
previously O 
identified O 
as O 
a O 
tankyrase O 
inhibitor O 
, O 
and O 
to O 
further O 
elucidate O 
whether O 
tankyrases O 
would O 
be O 
inhibited O 
by O 
other O 
flavonoids B-FAMILY 
, O 
we O 
performed O 
a O 
systematic O 
screening O 
of O 
tankyrase O 
2 O 
inhibitory O 
activity O 
using O 
500 O 
natural O 
and O 
naturally O 
derived O 
flavonoids B-FAMILY 
covering O 
nine O 
different O 
flavonoid B-FAMILY 
classes O 
. O 
All O 
identified O 
tankyrase O 
inhibitors O 
were O 
flavones B-FAMILY 
. O 
We O 
report O 
crystal O 
structures O 
of O 
all O 
the O 
hit O 
compounds O 
in O 
complex O 
with O 
the O 
catalytic O 
domain O 
of O 
human O 
tankyrase O 
2 O 
. O 
Flavone B-TRIVIAL 
derivatives O 
in O 
all O 
10 O 
crystal O 
structures O 
bind O 
to O 
the O 
nicotinamide B-TRIVIAL 
binding O 
site O 
of O 
tankyrase O 
2 O 
. O 
Potencies O 
of O 
the O 
active O 
flavones B-FAMILY 
toward O 
tankyrases O 
vary O 
between O 
50 O 
nM O 
and O 
1.1 O 
μM O 
, O 
and O 
flavones B-FAMILY 
show O 
up O 
to O 
200-fold O 
selectivity O 
for O 
tankyrases O 
over O 
ARTD1 O 
. O 
The O 
molecular O 
details O 
of O 
the O 
interactions O 
revealed O 
by O 
cocrystal O 
structures O 
efficiently O 
describe O 
the O 
properties O 
of O 
potent O 
flavone B-TRIVIAL 
derivatives O 
inhibiting O 
tankyrases O 
. O 

- O 
Mediated O 
Interactions O 
Influence O 
the O 
Binding O 
of O 
Thapsigargin B-TRIVIAL 
to O 
Sarco O 
/ O 
Endoplasmic O 
Reticulum O 
Calcium B-SYSTEMATIC 
Adenosinetriphosphatase O 
. O 

crystal O 
structure O 
suggests O 
four O 
water O 
molecules O 
are O 
present O 
in O 
the O 
binding O 
cavity O 
of O 
thapsigargin B-TRIVIAL 
in O 
sarco O 
/ O 
endoplasmic O 
reticulum O 
calcium B-SYSTEMATIC 
ATPase O 
( O 
SERCA O 
) O 
. O 
Computational O 
chemistry O 
indicates O 
that O 
three O 
of O 
these O 
water O 
molecules O 
mediate O 
an O 
extensive O 
hydrogen B-SYSTEMATIC 
-bonding O 
network O 
between O 
thapsigargin B-TRIVIAL 
and O 
the O 
backbone O 
of O 
SERCA O 
. O 
The O 
orientation O 
of O 
the O 
thapsigargin B-TRIVIAL 
molecule O 
in O 
SERCA O 
is O 
crucially O 
dependent O 
on O 
these O 
interactions O 
. O 
The O 
hypothesis O 
has O 
been O 
verified O 
by O 
measuring O 
the O 
affinity O 
of O 
newly O 
synthesized O 
model O 
compounds O 
, O 
which O 
are O 
prevented O 
from O 
participating O 
in O 
such O 
water O 
- O 
mediated O 
interactions O 
as O 
hydrogen B-SYSTEMATIC 
-bond O 
donors O 
. O 

- O 
Soluble O 
Polymer O 
Exfoliated O 
Graphene B-TRIVIAL 
: O 
As O 
Catalyst O 
Support O 
and O 
Sensor O 
. O 

this O 
paper O 
, O 
we O 
obtained O 
various O 
water O 
- O 
soluble O 
polymer O 
functionalized O 
graphene B-TRIVIAL 
in O 
dimethyl B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
under O 
ultrasonication O 
. O 
The O 
atomic O 
force O 
microscope O 
analysis O 
and O 
control O 
experiment O 
shows O 
the O 
water O 
- O 
soluble O 
polymer O 
is O 
the O 
crucial O 
part O 
to O 
help O 
solvent O 
molecules O 
separate O 
interlayer O 
. O 
Such O 
polymer/ O 
graphene B-TRIVIAL 
exhibits O 
high O 
conductivity O 
and O 
tunable O 
surface O 
property O 
, O 
as O 
confirmed O 
by O 
the O 
selected O 
area O 
electron O 
diffraction O 
and O 
Raman O 
and O 
electrochemical O 
impedance O 
spectroscopy O 
. O 
As O 
a O 
result O 
, O 
a O 
catalyst O 
based O 
on O 
polyvinyl B-SYSTEMATIC 
pyrrolidone I-SYSTEMATIC 
( O 
PVP B-ABBREVIATION 
)/ O 
graphene B-TRIVIAL 
shows O 
better O 
methanol B-SYSTEMATIC 
oxidation O 
performance O 
than O 
that O 
based O 
on O 
PVP B-ABBREVIATION 
/ O 
reduced O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
. O 
By O 
changing O 
to O 
another O 
polymer O 
, O 
poly(4-vinylpyridine) B-FAMILY 
/ O 
graphene B-TRIVIAL 
shows O 
a O 
stable O 
and O 
reversible O 
response O 
to O 
pH O 
, O 
and O 
demonstrates O 
its O 
potential O 
for O 
sensor O 
application O 
. O 

of O 
Nitrogen B-SYSTEMATIC 
- O 
Protonated B-SYSTEMATIC 
Nitrous I-SYSTEMATIC 
Oxide I-SYSTEMATIC 
( O 
HNNO(+) B-FORMULA 
) O 
by O 
Rotational O 
Spectroscopy O 
. O 

rotational O 
spectrum O 
of O 
nitrogen B-SYSTEMATIC 
- O 
protonated B-SYSTEMATIC 
nitrous I-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
HNNO(+) B-FORMULA 
) O 
, O 
an O 
isomer O 
whose O 
existence O 
was O 
first O 
inferred O 
from O 
kinetic O 
studies O 
more O 
than O 
30 O 
years O 
ago O 
, O 
has O 
now O 
been O 
detected O 
by O 
Fourier O 
transform O 
microwave O 
spectroscopy O 
, O 
guided O 
by O 
new O 
high O 
- O 
level O 
coupled O 
- O 
cluster O 
calculations O 
of O 
its O 
molecular O 
structure O 
. O 
From O 
high O 
- O 
resolution O 
measurements O 
of O 
the O 
hyperfine O 
splitting O 
in O 
its O 
fundamental O 
rotational O 
transition O 
, O 
the O 
rotational O 
constant O 
( O 
B O 
+ O 
C O 
) O 
/ O 
2 O 
and O 
the O 
quadrupole O 
tensor O 
element O 
χaa( O 
N B-FORMULA 
) O 
for O 
both O 
nitrogen B-SYSTEMATIC 
atoms O 
have O 
been O 
precisely O 
determined O 
. O 
The O 
derived O 
constants O 
agree O 
well O 
with O 
quantum O 
- O 
chemical O 
calculations O 
here O 
and O 
others O 
in O 
the O 
literature O 
. O 
The O 
χaa( O 
N B-FORMULA 
) O 
values O 
for O 
the O 
two O 
isomers O 
of O 
protonated B-SYSTEMATIC 
nitrous I-SYSTEMATIC 
oxide I-SYSTEMATIC 
are O 
qualitatively O 
consistent O 
with O 
the O 
valence O 
bond O 
description O 
of O 
H-N═N(+)═O B-FORMULA 
for O 
the O 
electronic O 
structure O 
of O 
the O 
nitrogen B-SYSTEMATIC 
-protonated O 
form O 
and O 
N≡N(+)-O-H B-FORMULA 
for O 
the O 
oxygen B-SYSTEMATIC 
-protonated O 
form O 
. O 
HNNO(+) B-FORMULA 
is O 
found O 
to O 
be O 
2-4 O 
times O 
less O 
abundant O 
than O 
NNOH(+) B-FORMULA 
under O 
a O 
range O 
of O 
experimental O 
conditions O 
, O 
as O 
might O 
be O 
expected O 
because O 
this O 
metastable O 
isomer O 
is O 
known O 
to O 
be O 
only O 
∼6 O 
kcal O 
mol(-1) O 
less O 
stable O 
than O 
ground O 
- O 
state O 
NNOH(+) B-FORMULA 
from O 
kinetic O 
measurements O 
by O 
Ferguson O 
and O 
co O 
- O 
workers O 
. O 

evaluation O 
of O 
desloratadine B-TRIVIAL 
in O 
allergic O 
rhinitis O 
. O 

: O 
Desloratadine B-TRIVIAL 
is O 
a O 
biologically O 
active O 
metabolite O 
of O 
second O 
- O 
generation O 
antihistamine O 
loratadine B-TRIVIAL 
. O 
It O 
is O 
also O 
indicated O 
for O 
the O 
treatment O 
of O 
allergic O 
diseases O 
, O 
including O 
allergic O 
rhinitis O 
. O 
Areas O 
covered O 
: O 
A O 
Medline O 
search O 
was O 
conducted O 
to O 
identify O 
preclinical O 
and O 
clinical O 
studies O 
of O 
desloratadine B-TRIVIAL 
. O 
This O 
was O 
supplemented O 
with O 
additional O 
articles O 
obtained O 
from O 
online O 
sources O 
. O 
The O 
focus O 
of O 
this O 
review O 
is O 
on O 
the O 
safety O 
profile O 
of O 
desloratadine B-TRIVIAL 
. O 
Expert O 
opinion O 
: O 
The O 
review O 
of O 
these O 
data O 
indicates O 
that O 
the O 
safety O 
profile O 
of O 
desloratadine B-TRIVIAL 
is O 
similar O 
to O 
other O 
second O 
- O 
generation O 
antihistamines O 
. O 
Desloratadine B-TRIVIAL 
is O 
highly O 
selective O 
for O 
histamine B-TRIVIAL 
H1-receptors O 
, O 
does O 
not O 
cross O 
the O 
blood O 
- O 
brain O 
barrier O 
( O 
BBB O 
) O 
, O 
and O 
has O 
minimal O 
adverse O 
events O 
( O 
very O 
low O 
sedation O 
rate O 
) O 
, O 
with O 
a O 
better O 
safety O 
and O 
tolerability O 
than O 
first O 
- O 
generation O 
antihistamines O 
. O 
Desloratadine B-TRIVIAL 
is O 
safe O 
and O 
well O 
tolerated O 
without O 
having O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
or O 
cardiovascular O 
effects O 
and O 
with O 
low O 
drug O 
interaction O 
. O 

Cushing's O 
syndrome O 
( O 
SCS O 
) O 
associated O 
with O 
adrenal O 
incidentaloma O 
is O 
usually O 
characterized O 
by O 
autonomous O 
cortisol B-TRIVIAL 
secretion O 
without O 
overt O 
symptoms O 
of O 
Cushing's O 
syndrome O 
( O 
CS O 
) O 
. O 
Although O 
the O 
diagnostic O 
criteria O 
for O 
SCS O 
differ O 
among O 
countries O 
, O 
the O 
1 O 
mg O 
dexamethasone B-TRIVIAL 
suppression O 
test O 
( O 
DST O 
) O 
is O 
essential O 
to O 
confirm O 
the O 
presence O 
and O 
the O 
extent O 
of O 
cortisol B-TRIVIAL 
overproduction O 
. O 
Since O 
1995 O 
, O 
SCS O 
has O 
been O 
diagnosed O 
in O 
Japan O 
based O 
on O 
serum O 
cortisol B-TRIVIAL 
levels O 
≥ O 
3 O 
μg O 
/ O 
dl O 
( O 
measured O 
by O 
radioimmunoassay O 
[ O 
RIA O 
] O 
) O 
after O 
a O 
1 O 
mg O 
DST O 
. O 
However O 
, O 
the O 
increasing O 
use O 
of O 
enzyme O 
immunoassays O 
( O 
EIA O 
) O 
instead O 
of O 
RIA O 
has O 
hindered O 
the O 
diagnosis O 
of O 
SCS O 
because O 
of O 
the O 
differing O 
sensitivities O 
of O 
commercially O 
available O 
assays O 
, O 
particularly O 
for O 
serum O 
cortisol B-TRIVIAL 
levels O 
of O 
around O 
3 O 
μg O 
/ O 
dl O 
. O 
One O 
way O 
to O 
overcome O 
this O 
problem O 
is O 
to O 
lower O 
the O 
cortisol B-TRIVIAL 
threshold O 
level O 
after O 
a O 
1 O 
mg O 
DST O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
examined O 
the O 
clinical O 
applicability O 
of O 
lowering O 
the O 
cortisol B-TRIVIAL 
threshold O 
to O 
1.8 O 
μg O 
/ O 
dl O 
, O 
similar O 
to O 
the O 
American O 
Endocrine O 
Society's O 
guidelines O 
for O 
CS O 
, O 
by O 
reanalyzing O 
119 O 
patients O 
with O 
adrenal O 
incidentaloma O 
. O 
Our O 
findings O 
indicate O 
that O 
serum O 
cortisol B-TRIVIAL 
levels O 
≥ O 
1.8 O 
μg O 
/ O 
dl O 
after O 
1 O 
mg O 
DST O 
are O 
useful O 
to O 
confirm O 
the O 
diagnosis O 
of O 
SCS O 
if O 
both O 
of O 
the O 
following O 
criteria O 
are O 
met O 
: O 
( O 
1 O 
) O 
basal O 
ACTH O 
level O 
< O 
10 O 
pg O 
/ O 
ml O 
( O 
or O 
poor O 
plasma O 
ACTH O 
response O 
to O 
corticotrophin O 
- O 
releasing O 
hormone O 
) O 
and O 
( O 
2 O 
) O 
serum O 
cortisol B-TRIVIAL 
≥ O 
5 O 
μg O 
/ O 
dl O 
at O 
21 O 
: O 
0 O 
to O 
23 O 
: O 
0 O 
h O 
. O 
If O 
only O 
one O 
of O 
( O 
1 O 
) O 
and O 
( O 
2 O 
) O 
are O 
met O 
, O 
we O 
recommend O 
that O 
other O 
clinical O 
features O 
are O 
considered O 
in O 
the O 
diagnosis O 
of O 
SCS O 
, O 
including O 
serum O 
dehydroepiandrosterone B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
levels O 
, O 
urine O 
free O 
cortisol B-TRIVIAL 
levels O 
, O 
adrenal O 
scintigraphy O 
, O 
and O 
clinical O 
manifestation O 
. O 

, O 
Antidepressant O 
Evaluation O 
and O 
Docking O 
Studies O 
of O 
Long-Chain O 
Alkylnitroquipazines B-FAMILY 
as O 
Serotonin B-TRIVIAL 
Transporter O 
Inhibitors O 
. O 

alkyl B-FAMILY 
analogues O 
( O 
1-12 O 
) O 
of O 
the O 
high O 
- O 
affinity O 
serotonin B-TRIVIAL 
transporter O 
( O 
SERT O 
) O 
inhibitor O 
6-nitroquipazine B-SYSTEMATIC 
( O 
6-NQ B-SYSTEMATIC 
) O 
were O 
synthesized O 
and O 
studied O 
using O 
in O 
vitro O 
radioligand O 
competition O 
binding O 
assays O 
to O 
determine O 
their O 
binding O 
affinity O 
( O 
Ki O 
) O 
. O 
The O 
putative O 
antidepressant O 
activity O 
of O 
five O 
of O 
the O 
binders O 
with O 
the O 
highest O 
SERT O 
binding O 
affinities O 
was O 
studied O 
by O 
the O 
forced O 
swim O 
and O 
locomotor O 
activity O 
mouse O 
tests O 
. O 
The O 
three O 
- O 
dimensional O 
( O 
3D O 
) O 
structures O 
of O 
8 O 
and O 
9 O 
were O 
determined O 
using O 
NOE O 
NMR O 
technique O 
. O 
Flexible O 
docking O 
of O 
the O 
compounds O 
was O 
undertaken O 
to O 
illustrate O 
the O 
binding O 
of O 
the O 
compounds O 
in O 
the O 
SERT O 
model O 
. O 
Our O 
results O 
showed O 
that O 
several O 
of O 
the O 
6-NQ B-SYSTEMATIC 
analogues O 
are O 
high O 
- O 
affinity O 
SERT O 
inhibitors O 
and O 
indicated O 
that O 
the O 
octyl B-SYSTEMATIC 
( O 
8 O 
) O 
, O 
decyl B-SYSTEMATIC 
( O 
10 O 
) O 
and O 
dodecyl B-SYSTEMATIC 
( O 
12 O 
) O 
6-NQ B-SYSTEMATIC 
analogues O 
exhibit O 
moderate O 
antidepressant O 
activity O 
. O 

field O 
simulations O 
were O 
conducted O 
to O 
investigate O 
the O 
effect O 
of O 
misfit O 
strain O 
on O 
the O 
vortex O 
domain O 
structure O 
( O 
VDS O 
) O 
in O 
a O 
BaTiO3 B-FORMULA 
nanodot O 
. O 
Taking O 
into O 
account O 
the O 
effect O 
of O 
inhomogeneous O 
eletromechanical O 
fields O 
, O 
ambient O 
temperature O 
and O 
surface O 
effects O 
, O 
our O 
calculations O 
demonstrate O 
a O 
strong O 
effect O 
of O 
misfit O 
strain O 
on O 
the O 
orientation O 
and O 
magnitude O 
of O 
the O 
polarization O 
dipoles O 
. O 
As O 
a O 
consequence O 
, O 
fruitful O 
equilibrium O 
vortex O 
domain O 
patterns O 
can O 
be O 
obtained O 
by O 
adjusting O 
the O 
epitaxial O 
misfit O 
strain O 
between O 
the O 
substrate O 
and O 
the O 
nanodot O 
. O 
While O 
the O 
nanodot O 
exhibits O 
a O 
single O 
transition O 
from O 
a O 
paraelectric O 
to O 
a O 
near O 
- O 
rhombohedral O 
vortex O 
state O 
at O 
zero O 
misfit O 
strain O 
with O 
the O 
decrease O 
of O 
temperature O 
, O 
complicated O 
transformations O 
of O 
vortex O 
domain O 
patterns O 
are O 
found O 
under O 
nonzero O 
misfit O 
strain O 
. O 
Typically O 
, O 
orthorhombic O 
, O 
tetragonal O 
and O 
several O 
unreported O 
vortex O 
domain O 
patterns O 
( O 
e.g O 
. O 
, O 
with O 
zero O 
toroidal O 
moment O 
) O 
are O 
found O 
. O 
Moreover O 
, O 
misfit O 
strain O 
- O 
induced O 
transformations O 
into O 
these O 
domain O 
patterns O 
are O 
also O 
predicted O 
for O 
a O 
ferroelectric O 
nanodot O 
with O 
initial O 
near O 
- O 
rhombohedral O 
vortex O 
state O 
. O 
Combining O 
effects O 
of O 
the O 
ambient O 
temperature O 
and O 
misfit O 
strain O 
, O 
a O 
" O 
temperature O 
- O 
misfit O 
strain O 
" O 
phase O 
- O 
diagram O 
depicting O 
the O 
fruitful O 
vortex O 
domain O 
patterns O 
of O 
the O 
nanodot O 
was O 
obtained O 
. O 
Our O 
simulations O 
indicate O 
promising O 
application O 
of O 
strain O 
engineering O 
in O 
controlling O 
the O 
VDS O 
in O 
ferroelectric O 
nanostructures O 
. O 

reveals O 
trichloroacetate B-SYSTEMATIC 
as O 
a O 
major O 
contributor O 
to O 
trichloroethylene B-SYSTEMATIC 
-induced O 
metabolic O 
alterations O 
in O 
mouse O 
urine O 
and O 
serum O 
. O 

( O 
TCE B-ABBREVIATION 
)-induced O 
liver O 
toxicity O 
and O 
carcinogenesis O 
is O 
believed O 
to O 
be O 
mediated O 
in O 
part O 
by O 
activation O 
of O 
the O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
α O 
( O 
PPARα O 
) O 
. O 
However O 
, O 
the O 
contribution O 
of O 
the O 
two O 
TCE B-ABBREVIATION 
metabolites O 
, O 
dichloroacetate B-SYSTEMATIC 
( O 
DCA B-ABBREVIATION 
) O 
and O 
trichloroacetate B-SYSTEMATIC 
( O 
TCA B-ABBREVIATION 
) O 
to O 
the O 
toxicity O 
of O 
TCE B-ABBREVIATION 
, O 
remains O 
unclear O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
determine O 
the O 
metabolite O 
profiles O 
in O 
serum O 
and O 
urine O 
upon O 
exposure O 
of O 
mice O 
to O 
TCE B-ABBREVIATION 
, O 
to O 
aid O 
in O 
determining O 
the O 
metabolic O 
response O 
to O 
TCE B-ABBREVIATION 
exposure O 
and O 
the O 
contribution O 
of O 
DCA B-ABBREVIATION 
and O 
TCA B-ABBREVIATION 
to O 
TCE B-ABBREVIATION 
toxicity O 
. O 
C57BL O 
/ O 
6 O 
mice O 
were O 
administered O 
TCE B-ABBREVIATION 
, O 
TCA B-ABBREVIATION 
, O 
or O 
DCA B-ABBREVIATION 
, O 
and O 
urine O 
and O 
serum O 
subjected O 
to O 
ultra O 
- O 
performance O 
liquid O 
chromatography O 
coupled O 
with O 
electrospray O 
ionization O 
quadrupole O 
time O 
- O 
of O 
- O 
flight O 
mass O 
spectrometry O 
( O 
UPLC-ESI-QTOFMS O 
) O 
- O 
based O 
global O 
metabolomics O 
analysis O 
. O 
The O 
ions O 
were O 
identified O 
through O 
searching O 
metabolomics O 
databases O 
and O 
by O 
comparison O 
with O 
authentic O 
standards O 
, O 
and O 
quantitated O 
using O 
multiple O 
reactions O 
monitoring O 
. O 
Quantitative O 
polymerase O 
chain O 
reaction O 
of O 
mRNA O 
, O 
biochemical O 
analysis O 
, O 
and O 
liver O 
histology O 
were O 
also O 
performed O 
. O 
TCE B-ABBREVIATION 
exposure O 
resulted O 
in O 
a O 
decrease O 
in O 
urine O 
of O 
metabolites O 
involved O 
in O 
fatty B-FAMILY 
acid I-FAMILY 
metabolism O 
, O 
resulting O 
from O 
altered O 
expression O 
of O 
PPARα O 
target O 
genes O 
. O 
TCE B-ABBREVIATION 
treatment O 
also O 
induced O 
altered O 
phospholipid O 
homeostasis O 
in O 
serum O 
, O 
as O 
revealed O 
by O 
increased O 
serum O 
lysophosphatidylcholine B-MULTIPLE 
18 I-MULTIPLE 
: I-MULTIPLE 
0 I-MULTIPLE 
and I-MULTIPLE 
18 I-MULTIPLE 
: I-MULTIPLE 
1 I-MULTIPLE 
, O 
and O 
phosphatidylcholine B-FAMILY 
metabolites O 
. O 
TCA B-ABBREVIATION 
administration O 
revealed O 
similar O 
metabolite O 
profiles O 
in O 
urine O 
and O 
serum O 
upon O 
TCE B-ABBREVIATION 
exposure O 
, O 
which O 
correlated O 
with O 
a O 
more O 
robust O 
induction O 
of O 
PPARα O 
target O 
gene O 
expression O 
associated O 
with O 
TCA B-ABBREVIATION 
than O 
DCA B-ABBREVIATION 
treatment O 
. O 
These O 
data O 
show O 
the O 
metabolic O 
response O 
to O 
TCE B-ABBREVIATION 
exposure O 
and O 
demonstrate O 
that O 
TCA B-ABBREVIATION 
is O 
the O 
major O 
contributor O 
to O 
TCE B-ABBREVIATION 
-induced O 
metabolite O 
alterations O 
observed O 
in O 
urine O 
and O 
serum O 
. O 

Enhances O 
Odontogenic O 
and O 
Osteogenic O 
Differentiation O 
of O 
Human O 
Tooth O 
Germ O 
Stem O 
Cells O 
( O 
hTGSCs O 
) O 
In O 
Vitro O 
. O 

cell O 
technology O 
has O 
been O 
a O 
great O 
hope O 
for O 
the O 
treatment O 
of O 
many O 
common O 
problems O 
such O 
as O 
Parkinson's O 
disease O 
, O 
Alzheimer's O 
disease O 
, O 
diabetes O 
, O 
cancer O 
, O 
and O 
tissue O 
regeneration O 
. O 
Therefore O 
, O 
the O 
main O 
challenge O 
in O 
hard O 
tissue O 
engineering O 
is O 
to O 
make O 
a O 
successful O 
combination O 
of O 
stem O 
cells O 
and O 
efficient O 
inductors O 
in O 
the O 
concept O 
of O 
stem O 
cell O 
differentiation O 
into O 
odontogenic O 
and O 
osteogenic O 
cell O 
types O 
. O 
Although O 
some O 
boron B-SYSTEMATIC 
derivatives O 
have O 
been O 
reported O 
to O 
promote O 
bone O 
and O 
teeth O 
growth O 
in O 
vivo O 
, O 
the O 
molecular O 
mechanism O 
of O 
bone O 
formation O 
has O 
not O 
been O 
elucidated O 
yet O 
. O 
Different O 
concentrations O 
of O 
sodium B-SYSTEMATIC 
pentaborate I-SYSTEMATIC 
pentahydrate I-SYSTEMATIC 
( O 
NaB B-FORMULA 
) O 
were O 
prepared O 
for O 
the O 
analysis O 
of O 
cell O 
toxicity O 
and O 
differentiation O 
evaluations O 
. O 
The O 
odontogenic O 
, O 
osteogenic O 
differentiation O 
and O 
biomineralization O 
of O 
human O 
tooth O 
germ O 
stem O 
cells O 
( O 
hTGSCs O 
) O 
were O 
evaluated O 
by O 
analyzing O 
the O 
mRNA O 
expression O 
levels O 
, O 
odontogenic O 
and O 
osteogenic O 
protein O 
expressions O 
, O 
alkaline O 
phosphatase O 
( O 
ALP O 
) O 
activity O 
, O 
mineralization O 
, O 
and O 
calcium B-SYSTEMATIC 
deposits O 
. O 
The O 
NaB B-FORMULA 
-treated O 
group O 
displayed O 
the O 
highest O 
ALP O 
activity O 
and O 
expression O 
of O 
osteo- O 
and O 
odontogenic O 
- O 
related O 
genes O 
and O 
proteins O 
compared O 
to O 
the O 
other O 
groups O 
and O 
baseline O 
. O 
In O 
the O 
current O 
study O 
, O 
increased O 
in O 
vitro O 
odontogenic O 
and O 
osteogenic O 
differentiation O 
capacity O 
of O 
hTGSCs O 
by O 
NaB B-FORMULA 
application O 
has O 
been O 
shown O 
for O 
the O 
first O 
time O 
. O 
The O 
study O 
offers O 
considerable O 
promise O 
for O 
the O 
development O 
of O 
new O 
scaffold O 
systems O 
combined O 
with O 
NaB B-FORMULA 
in O 
both O 
functional O 
bone O 
and O 
tooth O 
tissue O 
engineering O 
. O 

the O 
incidence O 
of O 
HIV-associated O 
cryptococcosis O 
has O 
decreased O 
in O 
developed O 
countries O 
since O 
the O 
introduction O 
of O 
antiretroviral O 
therapy O 
, O 
this O 
disease O 
continues O 
to O 
cause O 
significant O 
morbidity O 
and O 
mortality O 
in O 
sub-Saharan O 
Africa O 
among O 
patients O 
with O 
AIDS O 
. O 
Important O 
strides O 
have O 
been O 
made O 
in O 
an O 
attempt O 
to O 
decrease O 
the O 
burden O 
of O 
disease O 
, O 
particularly O 
the O 
development O 
of O 
the O 
lateral O 
flow O 
assay O 
cryptococcal O 
antigen O 
( O 
LFA O 
CrAg O 
) O 
as O 
a O 
diagnostic O 
tool O 
in O 
resource O 
- O 
limited O 
settings O 
, O 
coupled O 
with O 
the O 
introduction O 
of O 
pre O 
- O 
emptive O 
treatment O 
with O 
fluconazole B-TRIVIAL 
for O 
HIV-positive O 
patients O 
at O 
risk O 
for O 
cryptococcosis O 
with O 
a O 
positive O 
LFA O 
CrAg O 
. O 
Among O 
solid O 
organ O 
transplant O 
recipients O 
, O 
recent O 
prospective O 
studies O 
have O 
identified O 
cryptococcosis O 
as O 
the O 
third O 
most O 
common O 
invasive O 
fungal O 
infection O 
, O 
and O 
progress O 
is O 
being O 
made O 
toward O 
earlier O 
diagnosis O 
and O 
more O 
effective O 
therapy O 
. O 
Finally O 
, O 
the O 
Cryptococcus O 
gattii O 
outbreak O 
in O 
British O 
Columbia O 
, O 
Canada O 
and O 
the O 
US O 
Pacific O 
Northwest O 
is O 
providing O 
important O 
new O 
insights O 
into O 
the O 
emergence O 
of O 
this O 
pathogen O 
in O 
geographic O 
areas O 
previously O 
considered O 
low O 
risk O 
for O 
acquisition O 
of O 
infection O 
. O 
Understanding O 
the O 
similarities O 
and O 
differences O 
among O 
C O 
. O 
gattii O 
and O 
C O 
. O 
neoformans O 
infections O 
will O 
provide O 
critical O 
insights O 
into O 
the O 
behavior O 
of O 
these O 
organisms O 
in O 
the O 
human O 
host O 
. O 
Both O 
pathogens O 
affect O 
immunocompetent O 
and O 
immunosuppressed O 
hosts O 
, O 
causing O 
pulmonary O 
, O 
central O 
nervous O 
system O 
and O 
widely O 
disseminated O 
infections O 
. O 
Treatment O 
recommendations O 
in O 
the O 
future O 
will O 
necessarily O 
take O 
into O 
account O 
the O 
site O 
of O 
infection O 
, O 
clinical O 
severity O 
of O 
the O 
infection O 
, O 
Cryptococcus O 
species O 
, O 
host O 
immune O 
status O 
and O 
economic O 
resources O 
. O 

materials O 
are O 
environmental O 
contaminants O 
, O 
are O 
extensively O 
used O 
in O 
laboratories O 
, O 
and O 
may O 
cause O 
various O 
forms O 
of O 
health O 
hazards O 
in O 
laboratory O 
workers O 
. O 
Therefore O 
, O 
this O 
toxicity O 
most O 
likely O 
is O 
a O 
result O 
of O 
the O 
oxidative O 
metabolism O 
of O 
chemical O 
to O 
reactive O 
products O 
. O 
As O 
green O 
tea O 
( O 
GT O 
) O 
possesses O 
antioxidant O 
effects O 
, O 
the O 
objective O 
of O 
this O 
study O 
was O 
to O 
examine O 
any O 
amelioration O 
oxidative O 
stress O 
in O 
chemical O 
laboratory O 
workers O 
drinking O 
one O 
cup O 
( O 
3 O 
g O 
/ O 
300 O 
ml O 
water O 
) O 
of O 
freshly O 
prepared O 
tea O 
once O 
daily O 
. O 
Baseline O 
characteristics O 
including O 
age O 
, O 
sex O 
, O 
smoking O 
, O 
fruit O 
consumption O 
, O 
and O 
duration O 
of O 
exposure O 
were O 
recorded O 
via O 
questionnaire O 
to O 
the O 
subjects O 
. O 
Saliva O 
level O 
oxidative O 
stress O 
parameters O 
such O 
as O 
total O 
antioxidant O 
capacity O 
( O 
TAC O 
) O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
, O 
catalase O 
( O 
CAT O 
) O 
, O 
and O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
were O 
estimated O 
before O 
and O 
after O 
consumption O 
of O 
GT O 
in O 
these O 
workers O 
. O 
Treatment O 
of O 
subjects O 
with O 
GT O 
induced O 
a O 
significant O 
reduction O 
in O 
saliva O 
GPx O 
activity O 
( O 
406.61 O 
± O 
22.07 O 
vs O 
. O 
238.96 O 
± O 
16.26 O 
U O 
/ O 
l O 
p O 
= O 
0.001 O 
) O 
and O 
induction O 
in O 
TAC O 
( O 
0.46 O 
± O 
0.029 O 
μmol O 
/ O 
ml O 
vs O 
. O 
0.56 O 
± O 
0.031 O 
, O 
p O 
= O 
0.016 O 
) O 
. O 
No O 
statistically O 
significant O 
alteration O 
was O 
found O 
for O 
saliva O 
SOD O 
( O 
0.08 O 
± O 
0.0019 O 
vs O 
. O 
0.079 O 
± O 
0.0014 O 
, O 
p O 
> O 
0.05 O 
) O 
and O 
CAT O 
( O 
20.36 O 
± O 
0.69 O 
vs O 
. O 
19.78 O 
± O 
0.71 O 
, O 
p O 
> O 
0.05 O 
) O 
after O 
28 O 
days O 
treatment O 
by O 
GT O 
. O 
These O 
results O 
demonstrate O 
that O 
drinking O 
GT O 
during O 
chemical O 
exposure O 
can O 
reduce O 
several O 
parameters O 
indicative O 
of O 
oxidative O 
stress O 
. O 
In O 
conclusion O 
, O 
using O 
GT O 
as O 
a O 
dietary O 
supplement O 
can O 
be O 
a O 
rational O 
protocol O 
to O 
control O 
source O 
of O 
hazards O 
in O 
chemical O 
laboratory O 
workers O 
. O 

of O 
Gouty O 
Arthritis O 
by O 
Emodinol B-TRIVIAL 
in O 
Monosodium B-SYSTEMATIC 
Urate I-SYSTEMATIC 
Crystal O 
- O 
Treated O 
Mice O 
. O 

series O 
of O 
studies O 
have O 
recently O 
demonstrated O 
that O 
the O 
release O 
of O 
interleukin O 
1β O 
induced O 
by O 
monosodium B-SYSTEMATIC 
urate I-SYSTEMATIC 
crystals O 
is O 
central O 
to O 
the O 
experimental O 
gouty O 
arthritis O 
. O 
Elaeagnus O 
pungens O 
has O 
been O 
traditionally O 
used O 
for O 
the O 
treatment O 
of O 
gouty O 
arthritis O 
in O 
China O 
for O 
more O 
than O 
thousands O 
years O 
. O 
However O 
, O 
there O 
is O 
still O 
little O 
known O 
about O 
the O 
active O 
ingredients O 
and O 
mechanisms O 
of O 
E O 
. O 
pungens O 
against O 
gouty O 
arthritis O 
. O 
Emodinol B-TRIVIAL 
, O 
as O 
a O 
major O 
triterpene B-FAMILY 
compound O 
in O 
E O 
. O 
pungens O 
, O 
has O 
been O 
seldom O 
reported O 
to O 
have O 
an O 
effect O 
on O 
gouty O 
arthritis O 
. O 
Therefore O 
, O 
the O 
potential O 
beneficial O 
effects O 
and O 
mechanisms O 
of O 
emodinol B-TRIVIAL 
on O 
gouty O 
arthritis O 
were O 
investigated O 
in O 
this O 
study O 
. O 
Results O 
showed O 
that O 
it O 
significantly O 
ameliorated O 
the O 
hyperalgesia O 
, O 
inflammation O 
, O 
and O 
levels O 
of O 
multiple O 
proinflammatory O 
cytokines O 
in O 
monosodium B-SYSTEMATIC 
urate I-SYSTEMATIC 
crystals O 
- O 
treated O 
mice O 
. O 
These O 
findings O 
elucidate O 
that O 
emodinol B-TRIVIAL 
exhibits O 
a O 
prominent O 
effect O 
on O 
improving O 
symptoms O 
of O 
acute O 
gouty O 
arthritis O 
induced O 
by O 
monosodium B-SYSTEMATIC 
urate I-SYSTEMATIC 
crystals O 
through O 
inhibiting O 
the O 
generation O 
of O 
proinflammatory O 
cytokines O 
. O 

, O 
" O 
metallomics O 
, O 
" O 
in O 
addition O 
to O 
genomics O 
and O 
proteomics O 
, O 
has O 
become O 
a O 
focus O 
as O 
a O 
novel O 
approach O 
to O 
identify O 
sensitive O 
fluctuations O 
in O 
homeostasis O 
that O 
accompany O 
metabolic O 
processes O 
, O 
such O 
as O 
stress O 
responses O 
, O 
differentiation O 
, O 
and O 
proliferation O 
. O 
Cellular O 
elements O 
and O 
associated O 
protein O 
behavior O 
provide O 
important O 
clues O 
for O 
understanding O 
cellular O 
and O 
disease O 
mechanism(s) O 
. O 
It O 
is O 
important O 
to O 
develop O 
a O 
system O 
for O 
measuring O 
the O 
native O 
status O 
of O 
the O 
protein O 
. O 
In O 
this O 
study O 
, O 
we O 
developed O 
an O 
original O 
freeze O 
- O 
dried O 
electrofocusing O 
native O 
gel O 
over O 
polyimide B-FAMILY 
film O 
( O 
native O 
- O 
gel O 
film O 
) O 
for O 
scanning O 
protein O 
analysis O 
using O 
synchrotron O 
radiation O 
excited O 
X-ray O 
fluorescence O 
( O 
SPAX O 
) O 
. O 
To O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
report O 
detailing O 
the O 
successful O 
mapping O 
of O 
metal O 
- O 
associated O 
proteins O 
of O 
electrofocusing O 
gels O 
using O 
X-ray O 
fluorescence O 
. O 
SPAX O 
can O 
provide O 
detection O 
sensitivity O 
equivalent O 
to O 
that O 
of O 
LA-ICP-MS O 
. O 
In O 
addition O 
to O 
this O 
increased O 
sensitivity O 
, O 
SPAX O 
has O 
the O 
potential O 
to O 
be O 
combined O 
with O 
other O 
X-ray O 
spectroscopies O 
. O 
Our O 
system O 
is O 
useful O 
for O 
further O 
applications O 
in O 
proteomics O 
investigating O 
cellular O 
element-associated O 
protein O 
behaviors O 
and O 
disease O 
mechanisms O 
. O 

two O 
and O 
three O 
photon O 
resonant O 
enhancement O 
of O 
third O 
- O 
order O 
NLO O 
susceptibility O 
in O 
an O 
azo B-SYSTEMATIC 
-dye O 
functionalized O 
polymer O 
film O 
. O 

report O 
the O 
observation O 
of O 
simultaneous O 
two O 
and O 
three O 
photon O 
resonances O 
, O 
enhancing O 
the O 
third O 
- O 
order O 
NLO O 
susceptibility O 
in O 
a O 
thin O 
film O 
of O 
an O 
azo B-SYSTEMATIC 
-dye O 
polymer O 
. O 
The O 
possibility O 
of O 
2-3 O 
orders O 
of O 
magnitude O 
increase O 
in O 
χ((3)) O 
susceptibility O 
is O 
sustained O 
by O 
quantum O 
mechanical O 
calculations O 
. O 
This O 
improves O 
the O 
applications O 
of O 
azo B-SYSTEMATIC 
-polymers O 
in O 
all O 
optical O 
signal O 
processing O 
as O 
well O 
as O 
in O 
nonlinear O 
optical O 
imaging O 
. O 

lifetime O 
and O 
efficiency O 
of O 
triplet O 
- O 
triplet O 
fluorescence O 
from O 
the O 
excited O 
state O 
of O 
a O 
TMM B-ABBREVIATION 
biradical O 
determined O 
using O 
transient O 
emission O 
spectroscopy O 
by O 
two O 
- O 
color O 
two O 
- O 
laser O 
flash O 
photolysis O 
. O 

single O 
laser O 
flash O 
photolysis O 
( O 
FP O 
) O 
of O 
2-(4-benzoylphenyl)-2-phenyl-1-methylenecyclopropane B-SYSTEMATIC 
gave O 
rise O 
to O 
a O 
ground O 
state O 
trimethylenemethane B-SYSTEMATIC 
( O 
TMM B-ABBREVIATION 
) O 
biradical O 
with O 
absorption O 
bands O 
at O 
362 O 
and O 
545 O 
nm O 
and O 
an O 
excited O 
state O 
of O 
this O 
biradical O 
that O 
displays O 
triplet O 
- O 
triplet O 
fluorescence O 
at O 
580 O 
nm O 
. O 
The O 
excited O 
biradical O 
is O 
likely O 
formed O 
via O 
an O 
expected O 
two O 
- O 
photon O 
process O 
as O 
well O 
as O 
an O 
unexpected O 
one O 
- O 
photon O 
process O 
. O 
The O 
fluorescence O 
quantum O 
yield O 
of O 
the O 
excited O 
biradical O 
, O 
0.021 O 
, O 
was O 
successfully O 
determined O 
by O 
employing O 
a O 
two O 
- O 
color O 
two O 
- O 
laser O 
FP O 
technique O 
. O 

PIM O 
Family O 
of O 
Serine B-TRIVIAL 
/ O 
Threonine B-TRIVIAL 
Kinases O 
in O 
Cancer O 
. O 

proviral O 
insertion O 
site O 
in O 
Moloney O 
murine O 
leukemia O 
virus O 
, O 
or O 
PIM O 
proteins O 
, O 
are O 
a O 
family O 
of O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
kinases O 
composed O 
of O 
three O 
different O 
isoforms O 
( O 
PIM1 O 
, O 
PIM2 O 
, O 
and O 
PIM3 O 
) O 
that O 
are O 
highly O 
evolutionarily O 
conserved O 
. O 
These O 
proteins O 
are O 
regulated O 
primarily O 
by O 
transcription O 
and O 
stability O 
through O 
pathways O 
that O 
are O 
controlled O 
by O 
Janus O 
kinase O 
/ O 
Signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
, O 
JAK O 
/ O 
STAT O 
, O 
transcription O 
factors O 
. O 
The O 
PIM O 
family O 
proteins O 
have O 
been O 
found O 
to O 
be O 
overexpressed O 
in O 
hematological O 
malignancies O 
and O 
solid O 
tumors O 
, O 
and O 
their O 
roles O 
in O 
these O 
tumors O 
were O 
confirmed O 
in O 
mouse O 
tumor O 
models O 
. O 
Furthermore O 
, O 
the O 
PIM O 
family O 
proteins O 
have O 
been O 
implicated O 
in O 
the O 
regulation O 
of O 
apoptosis O 
, O 
metabolism O 
, O 
cell O 
cycle O 
, O 
and O 
homing O 
and O 
migration O 
, O 
which O 
has O 
led O 
to O 
the O 
postulation O 
of O 
these O 
proteins O 
as O 
interesting O 
targets O 
for O 
anticancer O 
drug O 
discovery O 
. O 
In O 
the O 
present O 
work O 
, O 
we O 
review O 
the O 
importance O 
of O 
PIM O 
kinases O 
in O 
tumor O 
growth O 
and O 
as O 
drug O 
targets O 
. O 

Assignment O 
of O 
Secondary O 
Hydroxyl B-SYSTEMATIC 
Groups O 
and O 
Methyl B-SYSTEMATIC 
Branches O 
in O 
Polyketide O 
Natural O 
Products O 
through O 
Bioinformatic O 
Analysis O 
of O 
the O 
Ketoreductase O 
Domain O 
. O 

hidden O 
Markov O 
models O 
( O 
HMMs O 
) O 
were O 
used O 
to O 
predict O 
the O 
configuration O 
of O 
secondary B-FAMILY 
alcohols I-FAMILY 
and O 
α-methyl B-SYSTEMATIC 
branches O 
of O 
modular O 
polyketides O 
. O 
Based O 
on O 
the O 
configurations O 
of O 
two O 
chiral O 
centers O 
in O 
these O 
polyketides O 
, O 
78 O 
ketoreductases O 
were O 
classified O 
into O 
four O 
different O 
types O 
of O 
polyketide O 
producers O 
. O 
The O 
identification O 
of O 
positions O 
that O 
discriminate O 
between O 
these O 
protein O 
families O 
was O 
followed O 
by O 
fitting O 
six O 
profile O 
HMMs O 
to O 
the O 
data O 
set O 
and O 
the O 
corresponding O 
subsets O 
, O 
to O 
model O 
the O 
conserved O 
regions O 
of O 
the O 
protein O 
types O 
. O 
Ultimately O 
, O 
the O 
profile O 
HMMs O 
described O 
herein O 
predict O 
protein O 
subtypes O 
based O 
on O 
the O 
complete O 
information O 
- O 
rich O 
region O 
; O 
consequently O 
, O 
slight O 
changes O 
in O 
a O 
multiple O 
sequence O 
alignment O 
do O 
not O 
significantly O 
alter O 
the O 
outcome O 
of O 
this O 
classification O 
method O 
. O 
Additionally O 
, O 
Viterbi O 
scores O 
can O 
be O 
used O 
to O 
assess O 
the O 
reliability O 
of O 
the O 
classification O 
. O 

and O 
Characterization O 
of O 
a O 
Cellulose O 
Binding O 
Heptapeptide B-FAMILY 
Revealed O 
by O 
Phage O 
Display O 
. O 

nanowhiskers O 
( O 
CNWs O 
) O 
were O 
used O 
in O 
conjunction O 
with O 
phage O 
display O 
technology O 
to O 
identify O 
polypeptides O 
which O 
bind O 
the O 
crystalline O 
region O 
of O 
cellulose O 
. O 
A O 
consensus O 
peptide O 
WHWTYYW O 
was O 
identified O 
to O 
efficiently O 
bind O 
the O 
CNWs O 
. O 
The O 
binding O 
affinities O 
of O 
specific O 
phage O 
particles O 
were O 
assessed O 
using O 
biopanning O 
assays O 
and O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
( O 
ELISA O 
) O 
. O 
The O 
WHWTYYW O 
peptide O 
was O 
synthesized O 
and O 
isothermal O 
titration O 
calorimetry O 
( O 
ITC O 
) O 
analysis O 
showed O 
that O 
the O 
peptide O 
exhibited O 
a O 
binding O 
constant O 
of O 
~10(5) O 
M(-1) O 
toward O 
the O 
crystalline O 
CNWs O 
. O 
In O 
order O 
to O 
understand O 
how O 
the O 
affinity O 
of O 
this O 
peptide O 
differs O 
for O 
non-crystalline O 
cellulose O 
, O 
binding O 
properties O 
were O 
characterized O 
using O 
cello O 
- O 
oligosaccharides O 
as O 
substrates O 
. O 
Binding O 
analysis O 
was O 
performed O 
using O 
UV O 
spectroscopy O 
and O 
fluorescence O 
quenching O 
experiments O 
. O 
The O 
specific O 
molecular O 
interactions O 
of O 
the O 
WHWTYYW O 
peptide O 
with O 
cellohexaose B-TRIVIAL 
were O 
examined O 
using O 
nuclear O 
magnetic O 
resonance O 
( O 
NMR O 
) O 
. O 
Interactions O 
of O 
this O 
peptide O 
with O 
crystalline O 
cellulose O 
were O 
also O 
investigated O 
using O 
computational O 
molecular O 
modeling O 
( O 
MM O 
) O 
studies O 
. O 
The O 
MM O 
and O 
NMR O 
experiments O 
indicate O 
that O 
the O 
WHWTYYW O 
peptide O 
exhibits O 
a O 
bent O 
structure O 
when O 
bound O 
, O 
allowing O 
the O 
Y5 O 
amino B-FAMILY 
acid I-FAMILY 
to O 
form O 
a O 
CH B-FORMULA 
/π O 
stacking O 
interaction O 
and O 
H B-FORMULA 
-bond O 
with O 
the O 
glucose B-TRIVIAL 
ring O 
of O 
cellulose O 
. O 

the O 
Mechanism O 
of O 
TBAF B-ABBREVIATION 
-Catalyzed O 
Deacylation O 
of O 
Cellulose O 
Esters B-FAMILY 
. O 

mechanism O 
of O 
the O 
recently O 
discovered O 
, O 
unusual O 
tetrabutylammonium B-SYSTEMATIC 
fluoride I-SYSTEMATIC 
( O 
TBAF B-ABBREVIATION 
) O 
deacylation O 
of O 
cellulose O 
esters O 
has O 
been O 
investigated O 
by O 
methods O 
including O 
kinetic O 
isotope O 
effect O 
( O 
KIE O 
) O 
studies O 
. O 
The O 
secondary O 
KIE O 
( O 
kH O 
/ O 
kD O 
= O 
1.26 O 
± O 
0.04 O 
) O 
measured O 
for O 
deacylation O 
at O 
C-2 O 
/ O 
3 O 
suggests O 
a O 
mechanism O 
involving O 
a O 
ketene O 
intermediate O 
for O 
those O 
positions O 
. O 
An O 
inverse O 
KIE O 
( O 
kH O 
/ O 
kD O 
= O 
0.87 O 
± O 
0.03 O 
) O 
for O 
the O 
deacylation O 
at O 
C-6 O 
indicates O 
the O 
involvement O 
of O 
a O 
tetrahedral O 
intermediate O 
in O 
the O 
mechanism O 
. O 
Additional O 
studies O 
suggest O 
the O 
possibility O 
that O 
TBAF B-ABBREVIATION 
chelation O 
by O 
neighboring O 
acyl B-FAMILY 
groups O 
may O 
account O 
for O 
the O 
unexpected O 
regioselectivity O 
at O 
the O 
secondary B-FAMILY 
alcohol I-FAMILY 
esters I-FAMILY 
that O 
is O 
observed O 
in O 
the O 
TBAF B-ABBREVIATION 
deacylation O 
of O 
cellulose O 
esters B-FAMILY 
. O 

thermodynamic O 
behavior O 
of O 
the O 
system O 
H2O B-FORMULA 
/ O 
BSA O 
was O 
studied O 
at O 
25 O 
°C O 
within O 
the O 
entire O 
composition O 
range O 
: O 
vapor O 
pressure O 
measurements O 
via O 
head O 
space O 
sampling O 
gas O 
chromatography O 
demonstrate O 
that O 
the O 
attainment O 
of O 
equilibria O 
takes O 
more O 
than O 
one O 
week O 
. O 
A O 
miscibility O 
gap O 
was O 
detected O 
via O 
turbidity O 
and O 
the O 
coexisting O 
phases O 
were O 
analyzed O 
. O 
At O 
6 O 
°C O 
the O 
two O 
phase O 
region O 
extends O 
from O 
ca O 
. O 
34 O 
to O 
40 O 
wt O 
% O 
BSA O 
; O 
it O 
shrinks O 
upon O 
heating O 
. O 
The O 
polymer O 
rich O 
phase O 
is O 
locally O 
ordered O 
, O 
as O 
can O 
be O 
seen O 
under O 
the O 
optical O 
microscope O 
using O 
crossed O 
polarizers O 
. O 
The O 
Flory-Huggins O 
theory O 
turns O 
out O 
to O 
be O 
inappropriate O 
for O 
the O 
modeling O 
of O 
experimental O 
results O 
. O 
A O 
phenomenological O 
expression O 
is O 
employed O 
which O 
uses O 
three O 
adjustable O 
parameters O 
and O 
describes O 
the O 
vapor O 
pressures O 
quantitatively O 
; O 
it O 
also O 
forecasts O 
the O 
existence O 
of O 
a O 
miscibility O 
gap O 
. O 

Products O 
Containing O 
a O 
Nitrogen B-SYSTEMATIC 
- O 
Nitrogen B-SYSTEMATIC 
Bond O 
. O 

of O 
early O 
2013 O 
, O 
over O 
200 O 
natural O 
products O 
are O 
known O 
to O 
contain O 
a O 
nitrogen B-SYSTEMATIC 
- O 
nitrogen B-SYSTEMATIC 
( O 
N-N B-FORMULA 
) O 
bond O 
. O 
This O 
report O 
categorizes O 
these O 
compounds O 
by O 
structural O 
class O 
and O 
details O 
their O 
isolation O 
and O 
biological O 
activity O 
. O 

synthesis O 
of O 
the O 
amphiphilic O 
homoglycopolypeptide O 
was O 
carried O 
out O 
by O 
a O 
combination O 
of O 
NCA O 
polymerization O 
and O 
click O 
chemistry O 
to O 
yield O 
a O 
well O 
- O 
defined O 
polypeptide O 
having O 
an O 
amphiphilic O 
carbohydrate B-FAMILY 
on O 
its O 
side O 
chain O 
. O 
The O 
amphiphilicity O 
of O 
the O 
carbohydrate B-FAMILY 
was O 
achieved O 
by O 
incorporation O 
of O 
an O 
alkyl B-FAMILY 
chain O 
at O 
the O 
C-6 O 
position O 
of O 
the O 
carbohydrate B-FAMILY 
thus O 
also O 
rendering O 
the O 
homoglycopolypeptide O 
amphiphilic O 
. O 
The O 
homoglycopolypeptide O 
formed O 
multimicellar O 
aggregates O 
in O 
water O 
above O 
a O 
critical O 
concentration O 
of O 
0.9 O 
μM O 
due O 
to O 
phase O 
separation O 
. O 
The O 
multimicellar O 
aggregates O 
were O 
characterized O 
by O 
DLS O 
, O 
TEM O 
, O 
and O 
AFM O 
. O 
It O 
is O 
proposed O 
that O 
hydrophobic O 
interactions O 
of O 
the O 
aliphatic O 
chains O 
at O 
the O 
6- O 
position O 
of O 
the O 
sugar B-FAMILY 
moieties O 
drives O 
the O 
assembly O 
of O 
these O 
rod O 
- O 
like O 
homoglycopolypeptide O 
into O 
large O 
spherical O 
aggregates O 
. O 
These O 
multimicellar O 
aggregates O 
encapsulate O 
both O 
hydrophilic O 
as O 
well O 
as O 
hydrophobic O 
dye O 
as O 
was O 
confirmed O 
by O 
confocal O 
microscopy O 
. O 
Finally O 
, O 
amphiphilic O 
random O 
polypeptides O 
containing O 
10% O 
and O 
20% O 
α-d-mannose B-TRIVIAL 
in O 
addition O 
to O 
glucose B-TRIVIAL 
containing O 
a O 
hydrophobic O 
alkyl B-FAMILY 
chain O 
at O 
its O 
6 O 
position O 
were O 
synthesized O 
by O 
our O 
methodology O 
, O 
and O 
these O 
polymers O 
were O 
also O 
found O 
to O 
assemble O 
into O 
spherical O 
nanostructures O 
. O 
The O 
spherical O 
assemblies O 
of O 
amphiphilic O 
random O 
glycopolypeptides O 
containing O 
10% O 
and O 
20% O 
mannose B-TRIVIAL 
were O 
found O 
to O 
be O 
surface O 
bioactive O 
and O 
were O 
found O 
to O 
interact O 
with O 
the O 
lectin O 
Con-A O 
. O 

time O 
point O 
of O 
β-catenin O 
knockout O 
in O 
hepatocytes O 
determines O 
their O 
response O 
to O 
xenobiotic O 
activation O 
of O 
the O 
constitutive O 
androstane B-TRIVIAL 
receptor O 
. O 

constitutive O 
androstane B-TRIVIAL 
receptor O 
( O 
CAR O 
) O 
controls O 
the O 
expression O 
of O 
drug O 
- O 
metabolizing O 
enzymes O 
and O 
regulates O 
hepatocyte O 
proliferation O 
. O 
Studies O 
with O 
transgenic O 
mice O 
with O 
an O 
early O 
postnatal O 
conditional O 
hepatocyte O 
- O 
specific O 
knockout O 
of O 
the O 
β-catenin O 
gene O 
Ctnnb1 O 
revealed O 
that O 
β-catenin O 
deficiency O 
decreases O 
the O 
magnitude O 
of O 
induction O 
of O 
drug O 
- O 
metabolizing O 
enzymes O 
by O 
CAR O 
activators O 
, O 
abrogates O 
zonal O 
differences O 
in O 
the O 
hepatocytes O 
' O 
susceptibility O 
to O 
these O 
compounds O 
, O 
and O 
impacts O 
on O 
hepatocyte O 
proliferation O 
. O 
These O 
data O 
, O 
however O 
, O 
do O 
not O 
allow O 
distinguishing O 
between O 
effects O 
caused O 
by O 
β-catenin O 
deficiency O 
during O 
postnatal O 
liver O 
development O 
and O 
acute O 
effects O 
of O 
β-catenin O 
deficiency O 
in O 
the O 
adult O 
animal O 
at O 
the O 
time O 
point O 
of O 
CAR O 
activation O 
. O 
Therefore O 
, O 
CAR O 
activation O 
was O 
now O 
studied O 
in O 
a O 
different O 
mouse O 
model O 
allowing O 
for O 
the O 
hepatocyte O 
- O 
specific O 
knockout O 
of O 
β-catenin O 
in O 
adult O 
mice O 
. O 
Treatment O 
of O 
these O 
mice O 
with O 
3mg O 
/ O 
kg O 
body O 
weight O 
of O 
the O 
model O 
CAR O 
activator O 
1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene B-SYSTEMATIC 
( O 
TCPOBOP B-TRIVIAL 
) O 
confirmed O 
previous O 
findings O 
related O 
to O 
the O 
coordinate O 
regulation O 
of O 
drug O 
metabolism O 
by O 
β-catenin O 
and O 
CAR O 
. O 
More O 
importantly O 
, O 
the O 
present O 
study O 
clarified O 
that O 
the O 
impact O 
of O 
β-catenin O 
signaling O 
on O 
CAR O 
- O 
mediated O 
enzyme O 
induction O 
in O 
the O 
liver O 
is O 
not O 
merely O 
due O 
to O 
developmental O 
defects O 
caused O 
by O 
a O 
postnatal O 
lack O 
of O 
β-catenin O 
, O 
but O 
depends O 
on O 
the O 
presence O 
of O 
β-catenin O 
at O 
the O 
time O 
point O 
of O 
xenobiotic O 
treatment O 
. O 
The O 
study O 
also O 
revealed O 
interesting O 
differences O 
between O 
the O 
two O 
mouse O 
models O 
: O 
hepatic O 
zonation O 
of O 
TCPOBOP B-TRIVIAL 
-dependent O 
induction O 
of O 
drug O 
- O 
metabolizing O 
enzymes O 
was O 
restored O 
in O 
mice O 
with O 
late O 
knockout O 
of O 
β-catenin O 
, O 
and O 
the O 
strong O 
proliferative O 
response O 
of O 
female O 
mice O 
was O 
exclusively O 
abolished O 
when O 
using O 
animals O 
with O 
a O 
late O 
β-catenin O 
knockout O 
. O 
This O 
suggests O 
a O 
β-catenin- O 
dependent O 
postnatal O 
priming O 
of O 
hepatocytes O 
during O 
postnatal O 
liver O 
development O 
, O 
later O 
affecting O 
the O 
proliferative O 
response O 
of O 
adult O 
animals O 
to O 
CAR-activating O 
xenobiotics O 
. O 

conjugation O 
attenuates O 
biological O 
activities O 
of O 
6-dehydroshogaol B-SYSTEMATIC 
from O 
ginger O 
. O 

( O 
6-DHSG B-SYSTEMATIC 
) O 
is O 
a O 
bioactive O 
α,β- B-FAMILY 
unsaturated I-FAMILY 
carbonyl I-FAMILY 
compound O 
isolated O 
from O 
fresh O 
ginger O 
with O 
anti-inflammatory O 
and O 
phase O 
II O 
enzyme O 
inducing O 
activities O 
. O 
Here O 
we O 
describe O 
the O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
)-dependent O 
metabolism O 
and O 
the O 
effect O 
of O 
this O 
metabolic O 
transformation O 
on O 
the O 
biological O 
activities O 
of O 
6-DHSG B-SYSTEMATIC 
. O 
Compared O 
with O 
other O 
ginger O 
compounds O 
, O 
such O 
as O 
6-gingerol B-SYSTEMATIC 
and O 
6-shogaol B-SYSTEMATIC 
, O 
6-DHSG B-SYSTEMATIC 
showed O 
the O 
most O 
potent O 
anti-inflammatory O 
effect O 
in O 
lipopolysaccharide O 
(LPS)-stimulated O 
RAW O 
264.7 O 
cells O 
. O 
The O 
biological O 
activities O 
of O 
6-DHSG B-SYSTEMATIC 
were O 
attenuated O 
by O 
sulfhydryl B-FAMILY 
antioxidants O 
such O 
as O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
or O 
N-acetyl B-SYSTEMATIC 
cysteine I-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
, O 
but O 
not O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
( O 
ASC B-ABBREVIATION 
) O 
. O 
6-DHSG B-SYSTEMATIC 
was O 
metabolised O 
by O 
GSH B-ABBREVIATION 
to O 
form O 
a O 
GSH B-ABBREVIATION 
conjugate O 
( O 
GS-6-DHSG B-SYSTEMATIC 
) O 
in O 
RAW O 
264.7 O 
cells O 
, O 
via O 
a O 
potential O 
mechanism O 
involving O 
the O 
catalytic O 
activity O 
of O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
( O 
GST O 
) O 
. O 
GS-6-DHSG B-SYSTEMATIC 
showed O 
reduced O 
biological O 
activities O 
compared O 
with O 
6-DHSG B-SYSTEMATIC 
in O 
multiple O 
biological O 
assays O 
. O 
Together O 
, O 
these O 
results O 
indicate O 
that O 
GSH B-ABBREVIATION 
conjugation O 
attenuates O 
the O 
biological O 
activities O 
of O 
6-DHSG B-SYSTEMATIC 
and O 
other O 
α,β- B-FAMILY 
unsaturated I-FAMILY 
carbonyl I-FAMILY 
compounds O 
. O 

in O 
noni O 
juice O 
( O 
NJ O 
) O 
are O 
mainly O 
composed O 
of O 
phenolic B-FAMILY 
acids I-FAMILY 
, O 
mainly O 
gentisic B-MULTIPLE 
, I-MULTIPLE 
p-hydroxybenoic I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
chlorogenic I-MULTIPLE 
acids I-MULTIPLE 
. O 
To O 
investigate O 
the O 
beneficial O 
effects O 
of O 
NJ O 
on O 
the O 
liver O 
, O 
hamsters O 
were O 
fed O 
with O 
two O 
diets O 
, O 
normal O 
- O 
fat O 
and O 
high O 
- O 
fat O 
diets O 
. O 
Furthermore O 
, O 
high O 
- O 
fat O 
dietary O 
hamsters O 
were O 
received O 
distilled O 
water O 
, O 
and O 
3 O 
, O 
6 O 
, O 
and O 
9mL O 
NJ O 
/ O 
kg O 
BW O 
, O 
respectively O 
. O 
After O 
a O 
6-week O 
feeding O 
period O 
, O 
the O 
increased O 
( O 
p O 
< O 
0.05 O 
) O 
sizes O 
of O 
liver O 
and O 
visceral O 
fat O 
in O 
high O 
- O 
fat O 
dietary O 
hamsters O 
compared O 
to O 
the O 
control O 
hamsters O 
were O 
ameliorated O 
( O 
p O 
< O 
0.05 O 
) O 
by O 
NJ O 
supplementation O 
. O 
NJ O 
also O 
decreased O 
( O 
p O 
< O 
0.05 O 
) O 
serum O 
/ O 
liver O 
lipids O 
but O 
enhanced O 
( O 
p O 
< O 
0.05 O 
) O 
daily O 
faecal O 
lipid/ O 
bile B-FAMILY 
acid I-FAMILY 
outputs O 
in O 
the O 
high O 
- O 
fat O 
dietary O 
hamsters O 
. O 
High O 
- O 
fat O 
dietary O 
hamsters O 
supplemented O 
with O 
NJ O 
had O 
higher O 
( O 
p O 
< O 
0.05 O 
) O 
liver O 
antioxidant O 
capacities O 
but O 
lowered O 
( O 
p O 
< O 
0.05 O 
) O 
liver O 
iNOS O 
, O 
COX-2 O 
, O 
TNF-α O 
, O 
and O 
IL-1β O 
expressions O 
, O 
gelatinolytic O 
levels O 
of O 
MMP9 O 
, O 
and O 
serum O 
ALT O 
values O 
compared O 
to O 
those O 
without O 
NJ O 
. O 
Hence O 
, O 
NJ O 
protects O 
liver O 
against O 
a O 
high O 
- O 
fat O 
dietary O 
habit O 
via O 
regulations O 
of O 
antioxidative O 
and O 
anti-inflammatory O 
responses O 
. O 

mechanism O 
underlying O 
the O 
freeze O 
- O 
thaw O 
fractionation O 
of O 
7S O 
and O 
11S O 
globulins O 
in O 
soymilk O 
was O 
investigated O 
. O 
Freeze O 
- O 
thawed O 
soymilk O 
demonstrated O 
an O 
increased O 
particle O 
size O 
compared O 
with O 
raw O 
soymilk O 
. O 
Further O 
, O 
when O 
defatted O 
raw O 
soymilk O 
was O 
freeze O 
- O 
thawed O 
, O 
it O 
was O 
fractionated O 
into O 
7S O 
( O 
supernatant O 
) O 
and O 
11S O 
( O 
precipitate O 
) O 
globulins O 
, O 
similar O 
to O 
what O 
is O 
found O 
with O 
freeze O 
- O 
thaw O 
of O 
raw O 
soymilk O 
. O 
When O 
raw O 
soymilk O 
samples O 
with O 
different O 
ratios O 
of O 
11S O 
/ O 
7S O 
were O 
freeze O 
- O 
thawed O 
, O 
the O 
11S-deficient O 
variety O 
showed O 
no O 
precipitate O 
. O 
The O 
addition O 
of O 
sodium B-SYSTEMATIC 
sulphite I-SYSTEMATIC 
or O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulphate I-SYSTEMATIC 
also O 
inhibited O 
precipitate O 
formation O 
after O 
freeze O 
- O 
thawing O 
, O 
resulting O 
in O 
no O 
fractionation O 
. O 
These O 
results O 
suggest O 
that O 
the O 
fractionation O 
is O 
due O 
to O 
selective O 
precipitation O 
of O 
aggregates O 
of O 
11S O 
globulins O 
and O 
/ O 
or O 
11S O 
globulins O 
and O 
lipid O 
complexes O 
, O 
in O 
which O 
the O 
protein O 
molecules O 
interact O 
through O 
disulphide B-SYSTEMATIC 
bonds O 
and O 
/ O 
or O 
hydrophobic O 
interactions O 
. O 

water O 
- O 
resistant O 
UV-activated O 
oxygen B-SYSTEMATIC 
indicator O 
for O 
intelligent O 
food O 
packaging O 
. O 

the O 
first O 
time O 
, O 
alginate O 
polymer O 
has O 
been O 
applied O 
to O 
prevent O 
dyes O 
from O 
leaching O 
out O 
of O 
colorimetric O 
oxygen B-SYSTEMATIC 
indicator O 
films O 
, O 
which O 
enable O 
people O 
to O 
notice O 
the O 
presence O 
of O 
oxygen B-SYSTEMATIC 
in O 
the O 
package O 
in O 
an O 
economic O 
and O 
simple O 
manner O 
. O 
The O 
dye O 
- O 
based O 
oxygen B-SYSTEMATIC 
indicator O 
film O 
suffers O 
from O 
dye O 
leaching O 
upon O 
contact O 
with O 
water O 
. O 
In O 
this O 
work O 
, O 
UV-activated O 
visual O 
oxygen B-SYSTEMATIC 
indicator O 
films O 
were O 
fabricated O 
using O 
thionine B-TRIVIAL 
, O 
glycerol B-TRIVIAL 
, O 
P25 B-FORMULA 
TiO2 I-FORMULA 
, O 
and O 
zein O 
as O 
a O 
redox O 
dye O 
, O 
a O 
sacrificial O 
electron O 
donor O 
, O 
UV-absorbing O 
semiconducting O 
photocatalyst O 
, O 
and O 
an O 
encapsulation O 
polymer O 
, O 
respectively O 
. O 
When O 
this O 
zein O 
- O 
coated O 
film O 
was O 
immersed O 
in O 
water O 
for O 
24h O 
, O 
the O 
dye O 
leakage O 
was O 
as O 
high O 
as O 
80.80±0.45% O 
. O 
However O 
, O 
introduction O 
of O 
alginate O 
( O 
1.25% O 
) O 
as O 
the O 
coating O 
polymer O 
considerably O 
diminished O 
the O 
dye O 
leaching O 
to O 
only O 
5.80±0.06% O 
. O 
This O 
is O 
because O 
the O 
ion O 
- O 
binding O 
ability O 
of O 
alginate O 
could O 
prevent O 
the O 
cation O 
dye O 
from O 
leaching O 
into O 
water O 
. O 
This O 
novel O 
water O 
- O 
resistant O 
UV-activated O 
oxygen B-SYSTEMATIC 
indicator O 
was O 
also O 
successfully O 
photo O 
- O 
bleached O 
and O 
regained O 
colour O 
fast O 
in O 
the O 
presence O 
of O 
oxygen B-SYSTEMATIC 
. O 

of O 
phenolic B-FAMILY 
compounds O 
on O 
the O 
sensorial O 
perception O 
and O 
volatility O 
of O 
red O 
wine O 
esters B-FAMILY 
in O 
model O 
solution O 
: O 
An O 
insight O 
at O 
the O 
molecular O 
level O 
. O 

of O 
(+)-catechin B-TRIVIAL 
and O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
on O 
sensory O 
perception O 
and O 
volatility O 
of O 
isoamyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
ethyl B-SYSTEMATIC 
isobutyrate I-SYSTEMATIC 
, O 
ethyl B-SYSTEMATIC 
butyrate I-SYSTEMATIC 
and O 
ethyl B-SYSTEMATIC 
octanoate I-SYSTEMATIC 
was O 
investigated O 
in O 
model O 
solutions O 
, O 
by O 
means O 
of O 
triangle O 
tests O 
, O 
detection O 
threshold O 
determination O 
and O 
HS-GC-MS O 
analyses O 
. O 
Catechin B-TRIVIAL 
significantly O 
altered O 
the O 
sensory O 
perception O 
of O 
most O 
esters B-FAMILY 
( O 
ethyl B-SYSTEMATIC 
isobutyrate I-SYSTEMATIC 
, O 
ethyl B-SYSTEMATIC 
butyrate I-SYSTEMATIC 
and O 
ethyl B-SYSTEMATIC 
octanoate I-SYSTEMATIC 
) O 
while O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
displayed O 
no O 
impact O 
. O 
Ethyl B-SYSTEMATIC 
butyrate I-SYSTEMATIC 
and O 
ethyl B-SYSTEMATIC 
octanoate I-SYSTEMATIC 
odour O 
thresholds O 
doubled O 
or O 
tripled O 
in O 
the O 
presence O 
of O 
catechin B-TRIVIAL 
, O 
underlining O 
a O 
retention O 
impact O 
of O 
phenolic B-FAMILY 
compounds O 
in O 
liquid O 
matrix O 
. O 
The O 
headspace O 
analyses O 
displayed O 
a O 
decrease O 
only O 
in O 
ethyl B-SYSTEMATIC 
octanoate I-SYSTEMATIC 
volatility O 
in O 
presence O 
of O 
catechin B-TRIVIAL 
, O 
whereas O 
no O 
significant O 
difference O 
in O 
other O 
esters B-FAMILY 
concentrations O 
was O 
observed O 
. O 
This O 
study O 
indicated O 
that O 
phenolic B-FAMILY 
compounds O 
have O 
a O 
variable O 
impact O 
on O 
aroma O 
compounds O 
' O 
volatility O 
and O 
their O 
sensory O 
perception O 
. O 
The O 
polarity O 
of O 
phenolic B-FAMILY 
and O 
volatile O 
compounds O 
as O 
well O 
as O 
their O 
spatial O 
conformation O 
also O 
appeared O 
to O 
influence O 
the O 
interaction O 
strength O 
. O 

determination O 
of O 
sulfonamides B-FAMILY 
from O 
egg O 
samples O 
using O 
magnetic O 
multiwalled O 
carbon B-SYSTEMATIC 
nanotubes O 
as O 
adsorbents O 
followed O 
by O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
. O 

simple O 
and O 
effective O 
method O 
based O 
on O 
magnetic O 
separation O 
has O 
been O 
developed O 
for O 
the O 
extraction O 
of O 
sulfonamides B-FAMILY 
( O 
SAs B-FAMILY 
) O 
from O 
egg O 
samples O 
using O 
magnetic O 
multiwalled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
MMWCNTs O 
) O 
as O 
an O 
adsorbent O 
. O 
The O 
MMWCNTs O 
were O 
simply O 
prepared O 
by O 
depositing O 
Fe3O4 B-FORMULA 
onto O 
MWCNTs O 
that O 
had O 
been O 
previously O 
oxidised O 
. O 
The O 
extraction O 
procedure O 
was O 
carried O 
out O 
in O 
a O 
single O 
step O 
by O 
blending O 
and O 
subsequently O 
stirring O 
the O 
mixture O 
of O 
MMWCNTs O 
and O 
aqueous O 
egg O 
samples O 
. O 
The O 
SAs B-FAMILY 
were O 
first O 
extracted O 
as O 
described O 
above O 
, O 
adsorbed O 
onto O 
the O 
MMWCNTs O 
directly O 
and O 
finally O 
analysed O 
by O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
. O 
The O 
limits O 
of O 
detection O 
obtained O 
are O 
in O 
the O 
range O 
of O 
1.4-2.8ngg(-1) O 
. O 
The O 
proposed O 
method O 
was O 
successfully O 
applied O 
in O 
determining O 
SAs B-FAMILY 
in O 
the O 
eggs O 
obtained O 
from O 
laying O 
hens O 
fed O 
with O 
SA O 
standards O 
, O 
and O 
compared O 
to O 
eggs O 
purchased O 
from O 
local O 
markets O 
. O 
The O 
results O 
demonstrate O 
that O 
SAs B-FAMILY 
were O 
detectable O 
in O 
the O 
incurred O 
egg O 
samples O 
. O 

of O 
tocotrienol B-FAMILY 
biosynthesis O 
in O 
rice O 
( O 
Oryza O 
sativa O 
L O 
. O 
) O 
. O 

tocotrienol B-FAMILY 
( O 
T3 O 
) O 
has O 
gained O 
attention O 
due O 
to O 
its O 
physiological O 
activities O 
( O 
e.g O 
. O 
, O 
antiangiogenesis O 
) O 
. O 
However O 
, O 
the O 
biosynthetic O 
pathway O 
for O 
T3 O 
production O 
in O 
rice O 
grain O 
has O 
not O 
been O 
well O 
studied O 
. O 
We O 
hypothesized O 
that O 
T3 O 
biosynthesis O 
enzymes O 
and O 
/ O 
or O 
precursors O 
play O 
an O 
important O 
role O 
in O 
T3 O 
production O 
in O 
whole O 
grain O 
. O 
This O 
proposal O 
was O 
evaluated O 
in O 
rice O 
( O 
Oryza O 
sativa O 
L O 
. O 
) O 
by O 
PCR O 
and O 
HPLC O 
techniques O 
. O 
Grain O 
tocopherol B-FAMILY 
as O 
well O 
as O 
flag O 
leaf O 
vitamin B-FAMILY 
E I-FAMILY 
levels O 
were O 
also O 
investigated O 
for O 
comparison O 
. O 
For O 
rice O 
samples O 
14days O 
after O 
flowering O 
, O 
grain O 
was O 
abundant O 
in O 
T3 O 
, O 
but O 
not O 
in O 
flag O 
leaf O 
. O 
Expression O 
of O 
a O 
gene O 
encoding O 
homogentisate O 
geranylgeranyltransferase O 
( O 
HGGT O 
, O 
which O 
has O 
long O 
been O 
believed O 
to O 
be O 
important O 
for O 
T3 O 
production O 
) O 
differed O 
significantly O 
between O 
grain O 
and O 
flag O 
leaf O 
. O 
We O 
then O 
investigated O 
rice O 
samples O 
during O 
the O 
grain O 
maturation O 
period O 
, O 
and O 
found O 
that O 
grain O 
T3 O 
and O 
HGGT O 
levels O 
increased O 
in O 
the O 
early O 
stage O 
and O 
then O 
reached O 
a O 
plateau O 
. O 
T3 O 
precursors O 
such O 
as O 
homogentisate O 
and O 
geranylgeranyl B-SYSTEMATIC 
pyrophosphate I-SYSTEMATIC 
decreased O 
during O 
maturation O 
. O 
No O 
increase O 
in O 
grain O 
T3 O 
from O 
the O 
middle O 
to O 
late O 
stages O 
of O 
maturation O 
and O 
a O 
decrease O 
in O 
T3 O 
precursors O 
during O 
maturation O 
suggest O 
that O 
HGGT O 
would O 
be O 
an O 
essential O 
, O 
but O 
not O 
limiting O 
factor O 
for O 
T3 O 
biosynthesis O 
, O 
and O 
T3 O 
precursors O 
could O 
regulate O 
the O 
T3 O 
level O 
in O 
grain O 
. O 
The O 
results O 
of O 
this O 
study O 
would O 
be O 
useful O 
for O 
nutraceutical O 
purposes O 
( O 
e.g O 
. O 
, O 
development O 
of O 
T3-overproducing O 
rice O 
for O 
the O 
prevention O 
of O 
angiogenic O 
disorders O 
) O 
. O 

of O 
α-keto B-FAMILY 
acids I-FAMILY 
in O 
pork O 
meat O 
and O 
Iberian O 
ham O 
via O 
tandem O 
mass O 
spectrometry O 
. O 

analytical O 
method O 
which O 
offers O 
accurate O 
determination O 
and O 
identification O 
of O 
eight O 
α-keto B-FAMILY 
acids I-FAMILY 
( O 
α-ketoglutaric B-TRIVIAL 
acid I-TRIVIAL 
, O 
pyruvic B-TRIVIAL 
acid I-TRIVIAL 
, O 
4-hydroxyphenylpyruvic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
3-methyl-2-oxobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
α-keto-γ-methylthiobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
4-methyl-2-oxovaleric B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
3-methyl-2-oxovaleric B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
and O 
phenylpyruvic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
in O 
pork O 
meat O 
and O 
Iberian O 
ham O 
samples O 
is O 
reported O 
. O 
The O 
method O 
utilises O 
a O 
highly O 
selective O 
and O 
sensitive O 
method O 
of O 
multiple O 
reaction O 
monitoring O 
( O 
MRM O 
) O 
by O 
mass O 
spectrometry O 
. O 
The O 
analytical O 
method O 
is O 
simple O 
( O 
although O 
the O 
chemical O 
derivatisation O 
of O 
the O 
α-keto B-FAMILY 
acids I-FAMILY 
with O 
dansylhydrazine B-TRIVIAL 
is O 
required O 
) O 
, O 
precise O 
( O 
< O 
18% O 
RSD O 
) O 
, O 
accurate O 
( O 
90-110% O 
) O 
, O 
sensitive O 
( O 
0.01-0.34mg O 
/ O 
kg O 
of O 
defatted O 
and O 
freeze O 
- O 
dried O 
meat O 
depending O 
on O 
the O 
α-keto B-FAMILY 
acid I-FAMILY 
) O 
and O 
linear O 
( O 
R O 
> O 
0.99 O 
) O 
over O 
several O 
orders O 
of O 
magnitude O 
( O 
until O 
0.01-146.1mg O 
/ O 
kg O 
of O 
defatted O 
and O 
freeze O 
- O 
dried O 
meat O 
depending O 
on O 
the O 
α-keto B-FAMILY 
acid I-FAMILY 
) O 
. O 
Using O 
this O 
methodology O 
, O 
α-keto B-FAMILY 
acids I-FAMILY 
were O 
found O 
to O 
be O 
present O 
in O 
pork O 
meat O 
to O 
a O 
low O 
extent O 
, O 
and O 
their O 
concentration O 
increased O 
when O 
they O 
were O 
determined O 
in O 
Iberian O 
ham O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
the O 
presence O 
of O 
α-keto B-FAMILY 
acids I-FAMILY 
in O 
both O 
pork O 
meats O 
and O 
Iberian O 
hams O 
. O 

acid I-FAMILY 
profiles O 
and O 
quantitative O 
structure O 
- O 
property O 
relationship O 
models O 
as O 
markers O 
for O 
Merlot O 
and O 
Torrontés O 
wines O 
. O 

structure O 
- O 
property O 
relationships O 
( O 
QSPRs O 
) O 
were O 
applied O 
to O 
the O 
aminograms O 
obtained O 
by O 
HPLC O 
in O 
our O 
laboratories O 
for O 
Torrontés O 
and O 
Merlot O 
wines O 
. O 
Dragon O 
theoretical O 
descriptors O 
were O 
derived O 
for O 
a O 
set O 
of O 
optimized O 
amino B-FAMILY 
acid I-FAMILY 
structures O 
with O 
the O 
purpose O 
of O 
establishing O 
QSPR O 
models O 
. O 
The O 
statistical O 
Replacement O 
Method O 
was O 
used O 
for O 
designing O 
the O 
best O 
multi O 
- O 
parametric O 
linear O 
regression O 
models O 
, O 
which O 
included O 
structural O 
features O 
selected O 
from O 
a O 
pool O 
containing O 
1497 O 
constitutional O 
, O 
topological O 
, O 
geometrical O 
or O 
electronic O 
molecular O 
descriptors O 
. O 
Predicted O 
QSPR O 
results O 
were O 
in O 
good O 
agreement O 
with O 
experimental O 
amino B-FAMILY 
acid I-FAMILY 
profiles O 
. O 
The O 
developed O 
QSPR O 
approach O 
showed O 
to O 
be O 
of O 
practical O 
value O 
for O 
distinguishing O 
each O 
wine O 
varietal O 
, O 
and O 
for O 
calculating O 
experimentally O 
non-available O 
amino B-FAMILY 
acid I-FAMILY 
concentrations O 
of O 
Torrontés O 
and O 
Merlot O 
wines O 
. O 
It O 
was O 
also O 
useful O 
for O 
assessing O 
wine O 
authenticity O 
; O 
the O 
models O 
were O 
especially O 
suitable O 
for O 
Merlot O 
and O 
Torrontés O 
wines O 
. O 

and O 
antioxidative O 
properties O 
of O 
β-carotene B-TRIVIAL 
in O 
chlorophyll B-FAMILY 
and O 
riboflavin B-TRIVIAL 
photosensitized O 
oil O 
- O 
in O 
- O 
water O 
emulsions O 
. O 

of O 
β-carotene B-TRIVIAL 
on O 
the O 
oxidative O 
stability O 
of O 
chlorophyll B-FAMILY 
or O 
riboflavin B-TRIVIAL 
photosensitized O 
oil O 
- O 
in O 
- O 
water O 
( O 
O O 
/ O 
W O 
) O 
emulsions O 
were O 
determined O 
by O 
analysing O 
the O 
depleted O 
headspace O 
oxygen B-SYSTEMATIC 
content O 
, O 
lipid O 
hydroperoxides B-FAMILY 
, O 
fluorescence O 
intensity O 
, O 
and O 
headspace O 
volatiles O 
. O 
As O 
the O 
concentration O 
of O 
β-carotene B-TRIVIAL 
increased O 
from O 
0 O 
to O 
10 O 
, O 
100 O 
, O 
and O 
1000μM O 
, O 
the O 
oxidative O 
stability O 
of O 
samples O 
containing O 
chlorophylls B-FAMILY 
decreased O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
under O 
light O 
, O 
indicating O 
that O 
β-carotene B-TRIVIAL 
acted O 
as O 
a O 
prooxidant O 
. O 
However O 
, O 
in O 
riboflavin B-TRIVIAL 
photosensitized O 
O O 
/ O 
W O 
emulsions O 
, O 
100 O 
and O 
1000μM O 
β-carotene B-TRIVIAL 
inhibited O 
lipid O 
oxidation O 
. O 
Although O 
β-carotene B-TRIVIAL 
protected O 
both O 
photosensitisers O 
in O 
O O 
/ O 
W O 
emulsions O 
, O 
β-carotene B-TRIVIAL 
displayed O 
antioxidative O 
or O 
prooxidative O 
properties O 
, O 
which O 
depended O 
on O 
the O 
polarity O 
of O 
the O 
photosensitisers O 
. O 
The O 
development O 
of O 
t-2-heptenal B-SYSTEMATIC 
and O 
1-octen-3-ol B-SYSTEMATIC 
increased O 
greatly O 
in O 
chlorophyll B-FAMILY 
sensitised O 
O O 
/ O 
W O 
emulsions O 
with O 
an O 
increase O 
in O 
β-carotene B-TRIVIAL 
concentration O 
, O 
implying O 
that O 
more O 
singlet O 
oxygen B-SYSTEMATIC 
oxidation O 
occurred O 
due O 
to O 
the O 
higher O 
levels O 
of O 
remaining O 
chlorophylls B-FAMILY 
. O 
However O 
, O 
the O 
content O 
of O 
t-2-heptenal B-SYSTEMATIC 
and O 
1-octen-3-ol B-SYSTEMATIC 
in O 
the O 
riboflavin B-TRIVIAL 
sensitised O 
O O 
/ O 
W O 
emulsions O 
was O 
not O 
significantly O 
correlated O 
with O 
the O 
β-carotene B-TRIVIAL 
concentration O 
, O 
which O 
indicates O 
that O 
β-carotene B-TRIVIAL 
in O 
the O 
lipid O 
particles O 
effectively O 
quenched O 
singlet O 
oxygen B-SYSTEMATIC 
. O 

linoleic B-TRIVIAL 
acid I-TRIVIAL 
and O 
calcium B-SYSTEMATIC 
co O 
- O 
supplementation O 
improves O 
bone O 
health O 
in O 
ovariectomised O 
mice O 
. O 

is O 
a O 
significant O 
health O 
concern O 
for O 
the O 
elderly O 
; O 
conjugated O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
( O 
CLA O 
) O 
has O 
been O 
shown O 
to O 
improve O 
overall O 
bone O 
mass O 
when O 
calcium B-SYSTEMATIC 
is O 
included O 
as O 
a O 
co O 
- O 
supplement O 
. O 
However O 
, O 
potential O 
effects O 
of O 
CLA O 
and O 
calcium B-SYSTEMATIC 
on O 
bone O 
mass O 
during O 
a O 
period O 
of O 
bone O 
loss O 
have O 
not O 
been O 
reported O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
determine O 
how O 
dietary O 
calcium B-SYSTEMATIC 
modulates O 
the O 
effects O 
of O 
conjugated O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
( O 
CLA O 
) O 
in O 
preventing O 
bone O 
loss O 
, O 
using O 
an O 
ovariectomised O 
mouse O 
model O 
. O 
CLA O 
supplementation O 
significantly O 
prevented O 
ovariectomy O 
- O 
associated O 
weight O 
and O 
fat O 
mass O 
gain O 
, O 
compared O 
to O 
non-supplemented O 
controls O 
. O 
CLA O 
significantly O 
increased O 
bone O 
markers O 
without O 
major O 
changes O 
in O 
bone O 
mineral O 
composition O 
in O 
the O 
femur O 
compared O 
to O 
respective O 
controls O 
. O 
CLA O 
treatment O 
increased O 
serum O 
parathyroid O 
hormone O 
( O 
PTH O 
) O 
significantly O 
( O 
p=0.0172 O 
) O 
, O 
while O 
serum O 
1,25-dihydroxyvitamin B-SYSTEMATIC 
D3 I-SYSTEMATIC 
concentration O 
was O 
not O 
changed O 
by O 
CLA O 
. O 
Meanwhile O 
, O 
CLA O 
significantly O 
reduced O 
femur O 
tartrate O 
resistant O 
acid O 
phosphatase O 
( O 
TRAP O 
) O 
activity O 
, O 
suggesting O 
potential O 
reduction O 
of O 
osteoclastogenesis O 
. O 
The O 
data O 
suggest O 
that O 
CLA O 
, O 
along O 
with O 
dietary O 
calcium B-SYSTEMATIC 
, O 
has O 
great O 
potential O 
to O 
be O 
used O 
to O 
prevent O 
bone O 
loss O 
and O 
weight O 
gain O 
associated O 
with O 
menopause O 
. O 

oestrogenic O 
and O 
anti-platelet O 
activities O 
of O 
dihydrobenzofuroisocoumarins B-FAMILY 
and O 
homoisoflavonoids B-FAMILY 
from O 
Liriope O 
platyphylla O 
roots O 
. O 

ethanolic O 
extract O 
of O 
Liriope O 
platyphylla O 
( O 
Liliaceae O 
) O 
roots O 
showed O 
potential O 
oestrogenic O 
and O 
anti-platelet O 
activities O 
. O 
Twenty O 
- O 
six O 
compounds O 
were O 
isolated O 
and O 
classified O 
as O 
10 O 
skeletons O 
, O 
including O 
two O 
unusual O 
new O 
dihydrobenzofuroisocoumarins B-FAMILY 
, O 
(+)-platyphyllarin B-MULTIPLE 
A I-MULTIPLE 
( I-MULTIPLE 
1 I-MULTIPLE 
) I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
( O 
2 O 
) O 
, O 
one O 
new O 
butanoate B-SYSTEMATIC 
, O 
ethyltributanoate B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
and O 
two O 
new O 
homoisoflavanones B-FAMILY 
, O 
(-)-liriopein B-MULTIPLE 
A I-MULTIPLE 
( I-MULTIPLE 
4 I-MULTIPLE 
) I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
( O 
5 O 
) O 
, O 
along O 
with O 
21 O 
known O 
compounds O 
, O 
including O 
six O 
homoisoflavonoids B-FAMILY 
, O 
one O 
chalcone B-FAMILY 
, O 
six O 
amides B-FAMILY 
, O 
one O 
lignan B-FAMILY 
, O 
one O 
fatty B-FAMILY 
acid I-FAMILY 
derivative O 
, O 
one O 
alkaloid O 
, O 
three O 
benzenoids B-FAMILY 
, O 
and O 
two O 
steroids B-FAMILY 
. O 
The O 
biosynthetic O 
pathway O 
of O 
compounds O 
1 O 
and O 
2 O 
was O 
proposed O 
in O 
the O 
current O 
investigation O 
. O 
The O 
oestrogenic O 
activity O 
of O 
the O 
isolates O 
was O 
evaluated O 
utilising O 
the O 
pER8 O 
: O 
GUS O 
reporter O 
assay O 
system O 
in O 
transgenic O 
Arabidopsis O 
plant O 
as O 
well O 
as O 
the O 
SEAP O 
reporter O 
assay O 
system O 
in O 
MCF-7 O 
breast O 
cancer O 
cell O 
- O 
line O 
; O 
the O 
anti-platelet O 
activity O 
was O 
evaluated O 
using O 
the O 
anti-platelet O 
aggregation O 
assay O 
. O 
Several O 
components O 
exhibited O 
significant O 
oestrogenic O 
and O 
anti-platelet O 
activities O 
; O 
demonstrating O 
for O 
the O 
first O 
time O 
the O 
potential O 
use O 
of O 
L O 
. O 
platyphylla O 
as O 
a O 
nutritional O 
supplement O 
for O 
cardiovascular O 
and O 
endocrine O 
diseases O 
. O 

study O 
investigated O 
the O 
role O 
of O 
Spirulina O 
platensis O 
in O 
reversing O 
sodium B-SYSTEMATIC 
fluoride I-SYSTEMATIC 
-induced O 
thyroid O 
, O 
neurodevelopment O 
and O 
oxidative O 
alterations O 
in O 
offspring O 
of O 
pregnant O 
rats O 
. O 
The O 
total O 
antioxidant O 
activity O 
, O 
phycocyanins O 
, O 
and O 
β B-TRIVIAL 
carotene I-TRIVIAL 
content O 
were O 
quantified O 
in O 
Spirulina O 
. O 
Thirty O 
female O 
pregnant O 
rats O 
were O 
allocated O 
to O 
six O 
groups O 
and O 
treatment O 
initiated O 
orally O 
from O 
embryonic O 
day O 
( O 
ED O 
) O 
6 O 
to O 
postnatal O 
day O 
( O 
PND O 
) O 
15 O 
. O 
Treatment O 
groups O 
included O 
control O 
, O 
Spirulina O 
alone O 
, O 
sodium B-SYSTEMATIC 
fluoride I-SYSTEMATIC 
( O 
20mg O 
/ O 
kg O 
) O 
alone O 
, O 
and O 
sodium B-SYSTEMATIC 
fluoride I-SYSTEMATIC 
along O 
with O 
Spirulina O 
( O 
250 O 
and O 
500mg O 
/ O 
kg O 
) O 
. O 
Serum O 
fluoride B-SYSTEMATIC 
levels O 
were O 
determined O 
on O 
ED O 
20 O 
and O 
PND O 
11 O 
. O 
Offspring O 
were O 
subjected O 
to O 
behavioural O 
testing O 
, O 
estimation O 
of O 
thyroid O 
levels O 
, O 
oxidative O 
measurements O 
in O 
brain O 
mitochondrial O 
fraction O 
and O 
histological O 
evaluation O 
of O 
the O 
cerebellum O 
. O 
Fluoride B-SYSTEMATIC 
-induced O 
alterations O 
in O 
thyroid O 
hormones O 
, O 
behaviour O 
and O 
increased O 
oxidative O 
stress O 
. O 
Spirulina O 
augmented O 
the O 
displacement O 
of O 
fluoride B-SYSTEMATIC 
, O 
facilitated O 
antioxidant O 
formation O 
, O 
improved O 
behaviour O 
and O 
protected O 
Purkinje O 
cells O 
. O 
Supplementing O 
Spirulina O 
during O 
pregnancy O 
could O 
reduce O 
the O 
risk O 
of O 
fluoride B-SYSTEMATIC 
toxicity O 
in O 
offspring O 
. O 

of O 
blanching O 
on O 
polyphenol B-FAMILY 
stability O 
and O 
antioxidant O 
capacity O 
of O 
innovative O 
coriander O 
( O 
Coriandrum O 
sativum O 
L O 
. O 
) O 
pastes O 
. O 

coriander O 
leaves O 
were O 
steam- O 
and O 
water O 
- O 
blanched O 
at O 
100°C O 
and O 
at O 
90 O 
and O 
100°C O 
, O 
respectively O 
, O 
for O 
1-10min O 
, O 
and O 
subsequently O 
comminuted O 
to O 
form O 
a O 
paste O 
. O 
Pasty O 
products O 
obtained O 
from O 
coriander O 
fruits O 
were O 
processed O 
after O 
water O 
- O 
blanching O 
applying O 
the O 
same O 
time O 
- O 
temperature O 
regimes O 
. O 
Among O 
the O 
11 O 
phenolics B-FAMILY 
characterised O 
in O 
leaves O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
coupled O 
to O 
mass O 
spectrometric O 
detection O 
, O 
several O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
, O 
5-feruloylquinic B-MULTIPLE 
and I-MULTIPLE 
5-p-coumaroylquinic I-MULTIPLE 
acids I-MULTIPLE 
were O 
tentatively O 
identified O 
for O 
the O 
first O 
time O 
. O 
In O 
fruits O 
, O 
10 O 
phenolics B-FAMILY 
were O 
detected O 
, O 
whereas O 
rutin B-TRIVIAL 
, O 
a O 
dicaffeic B-TRIVIAL 
acid I-TRIVIAL 
derivative O 
and O 
two O 
feruloylquinic B-MULTIPLE 
and I-MULTIPLE 
caffeoylquinic I-MULTIPLE 
acid I-MULTIPLE 
isomers O 
were O 
newly O 
detected O 
. O 
Upon O 
steam O 
- O 
blanching O 
for O 
1min O 
, O 
phenolic B-FAMILY 
contents O 
and O 
antioxidant O 
capacities O 
remained O 
virtually O 
unchanged O 
. O 
In O 
contrast O 
, O 
water O 
- O 
blanching O 
and O 
extended O 
steam O 
- O 
blanching O 
even O 
yielded O 
increased O 
levels O 
compared O 
to O 
the O 
unheated O 
control O 
, O 
whereas O 
short O 
- O 
time O 
water O 
- O 
blanching O 
resulted O 
in O 
higher O 
values O 
than O 
prolonged O 
heat O 
treatment O 
. O 
Thus O 
, O 
short O 
- O 
time O 
water O 
- O 
blanching O 
is O 
recommended O 
as O 
the O 
initial O 
unit O 
in O 
the O 
processing O 
of O 
coriander O 
leaves O 
and O 
fruits O 
into O 
novel O 
pasty O 
products O 
. O 

and O 
evaluation O 
of O 
carbamoylmethylene B-SYSTEMATIC 
linked O 
prodrugs O 
of O 
BMS-582949 B-IDENTIFIER 
, O 
a O 
clinical O 
p38α O 
inhibitor O 
. O 

series O 
of O 
carbamoylmethylene B-SYSTEMATIC 
linked O 
prodrugs O 
of O 
1 O 
( O 
BMS-582949 B-IDENTIFIER 
) O 
, O 
a O 
clinical O 
p38α O 
inhibitor O 
, O 
were O 
synthesized O 
and O 
evaluated O 
. O 
Though O 
the O 
phosphoryloxymethylene B-FAMILY 
carbamates I-FAMILY 
( O 
3 O 
, O 
4 O 
, O 
and O 
5 O 
) O 
and O 
α-aminoacyloxymethylene B-FAMILY 
carbamates I-FAMILY 
( O 
22 O 
, O 
23 O 
, O 
and O 
26 O 
) O 
were O 
found O 
unstable O 
at O 
neutral O 
pH O 
values O 
, O 
fumaric B-TRIVIAL 
acid I-TRIVIAL 
derived O 
acyloxymethylene B-FAMILY 
carbamates I-FAMILY 
( O 
2 O 
, O 
28 O 
, O 
and O 
31 O 
) O 
were O 
highly O 
stable O 
under O 
both O 
acidic O 
and O 
neutral O 
conditions O 
. O 
Prodrugs O 
2 O 
and O 
31 O 
were O 
also O 
highly O 
soluble O 
at O 
both O 
acidic O 
and O 
neutral O 
pH O 
values O 
. O 
At O 
a O 
solution O 
dose O 
of O 
14.2mpk O 
( O 
equivalent O 
to O 
10mpk O 
of O 
1 O 
) O 
, O 
2 O 
gave O 
essentially O 
the O 
same O 
exposure O 
of O 
1 O 
compared O 
to O 
dosing O 
10mpk O 
of O 
1 O 
itself O 
. O 
At O 
a O 
suspension O 
dose O 
of O 
142mpk O 
( O 
equivalent O 
to O 
100mpk O 
of O 
1 O 
) O 
, O 
2 O 
demonstrated O 
that O 
it O 
could O 
overcome O 
the O 
solubility O 
issue O 
associated O 
with O 
1 O 
and O 
provide O 
a O 
much O 
higher O 
exposure O 
of O 
1 O 
. O 
To O 
our O 
knowledge O 
, O 
the O 
unique O 
type O 
of O 
prodrugs O 
like O 
2 O 
, O 
28 O 
, O 
and O 
31 O 
was O 
not O 
reported O 
in O 
the O 
past O 
and O 
could O 
represent O 
a O 
novel O 
prodrug O 
approach O 
for O 
secondary B-FAMILY 
amides I-FAMILY 
, O 
a O 
class O 
of O 
molecules O 
frequently O 
identified O 
as O 
drug O 
candidates O 
. O 

restricted O 
homotryptamines B-FAMILY 
. O 
Part O 
6 O 
: O 
Indole-5-cycloalkyl B-FAMILY 
methylamines I-FAMILY 
as O 
selective O 
serotonin B-TRIVIAL 
reuptake O 
inhibitors O 
. O 

5-(trans-2-aminomethylcyclopropyl)indoles I-FAMILY 
, O 
5-(trans-2-aminomethylcyclopentyl) B-FAMILY 
indoles I-FAMILY 
, O 
and O 
5-(cis-2-aminomethylcyclopentyl)indoles B-FAMILY 
were O 
synthesized O 
and O 
evaluated O 
as O 
selective O 
serotonin B-TRIVIAL 
reuptake O 
inhibitors O 
. O 
These O 
analogs O 
followed O 
SAR O 
trends O 
similar O 
to O 
those O 
previously O 
reported O 
for O 
3-cycloalkyl B-FAMILY 
substituted I-FAMILY 
indoles I-FAMILY 
. O 
The O 
most O 
potent O 
analogs O 
exhibited O 
single O 
digit O 
nanomolar O 
inhibition O 
at O 
the O 
human O 
serotonin O 
transporter O 
but O 
were O 
10-fold O 
less O 
active O 
than O 
the O 
previously O 
reported O 
compounds O 
. O 

lot O 
of O 
research O 
has O 
been O 
carried O 
out O 
in O 
the O 
last O 
decade O 
to O 
find O 
a O 
cure O 
for O 
neurodegenerative O 
diseases O 
especially O 
Parkinson's O 
disease O 
but O 
to O 
little O 
avail O 
. O 
In O 
this O 
study O 
we O 
have O 
demonstrated O 
the O 
use O 
of O 
poly B-FAMILY 
( I-FAMILY 
lactic I-FAMILY 
acid I-FAMILY 
- I-FAMILY 
co I-FAMILY 
- I-FAMILY 
glycolic I-FAMILY 
acid I-FAMILY 
) I-FAMILY 
( O 
PLGA B-ABBREVIATION 
) O 
/ O 
collagen O 
biodegradable O 
microparticles O 
formed O 
using O 
water O 
- O 
in O 
- O 
oil O 
- O 
in O 
- O 
water O 
( O 
W O 
/ O 
O O 
/ O 
W O 
) O 
double O 
emulsion O 
method O 
, O 
as O 
a O 
neurotrophic O 
factor O 
delivery O 
vehicle O 
. O 
The O 
microparticles O 
were O 
encapsulated O 
with O 
glial O 
cell O 
- O 
derived O 
neurotrophic O 
factor O 
( O 
GDNF O 
) O 
fused O 
with O 
collagen O 
binding O 
peptide O 
( O 
CBP O 
) O 
immobilized O 
to O 
the O 
inner O 
collagen O 
phase O 
. O 
The O 
novelty O 
lies O 
in O 
the O 
strict O 
regulation O 
of O 
release O 
of O 
GDNF-CBP O 
from O 
the O 
microparticles O 
as O 
compared O 
to O 
a O 
burst O 
release O 
from O 
standard O 
microparticles O 
. O 
The O 
microparticles O 
were O 
demonstrated O 
to O 
be O 
non-cytotoxic O 
till O 
300μg O 
/ O 
2×10(5) O 
cells O 
and O 
revealed O 
a O 
maximum O 
release O 
of O 
250ng O 
GDNF-CBP O 
/ O 
mg O 
microparticles O 
in O 
0.3% O 
collagenase O 
. O 
Differentiation O 
of O 
neural O 
progenitor O 
cells O 
( O 
NPCs O 
) O 
into O 
mature O 
neurons O 
was O 
demonstrated O 
by O 
co O 
- O 
culturing O 
microparticles O 
with O 
cells O 
in O 
a O 
medium O 
containing O 
collagenase O 
which O 
enabled O 
the O 
release O 
of O 
encapsulated O 
GDNF-CBP O 
, O 
signaling O 
the O 
differentiation O 
of O 
NPCs O 
into O 
microtubule O 
- O 
associated O 
protein O 
2 O 
(MAP2)-expressing O 
neurons O 
. O 
The O 
successful O 
ability O 
of O 
these O 
microparticles O 
to O 
deliver O 
neurotrophic O 
factors O 
and O 
allow O 
differentiation O 
of O 
NPCs O 
into O 
mature O 
neurons O 
provides O 
some O 
scope O 
in O 
its O 
use O 
for O 
the O 
treatment O 
of O 
Parkinson's O 
disease O 
and O 
other O 
neurodegenerative O 
diseases O 
. O 

lipase O 
inhibition O 
- O 
induced O 
changes O 
in O 
plasma O 
corticosterone B-TRIVIAL 
levels O 
, O 
anxiety O 
and O 
locomotor O 
activity O 
in O 
male O 
CD1 O 
mice O 
. O 

hypothalamus O 
- O 
pituitary O 
- O 
adrenal O 
- O 
axis O 
is O 
strongly O 
controlled O 
by O 
the O 
endocannabinoid O 
system O 
. O 
The O 
specific O 
impact O 
of O 
enhanced O 
2-arachidonoylglycerol B-SYSTEMATIC 
signaling O 
on O 
corticosterone B-TRIVIAL 
plasma O 
levels O 
, O 
however O 
, O 
was O 
not O 
investigated O 
so O 
far O 
. O 
Here O 
we O 
studied O 
the O 
effects O 
of O 
the O 
recently O 
developed O 
monoacylglycerol B-SYSTEMATIC 
lipase O 
inhibitor O 
JZL184 B-IDENTIFIER 
on O 
basal O 
and O 
stress O 
- O 
induced O 
corticosterone B-TRIVIAL 
levels O 
in O 
male O 
CD1 O 
mice O 
, O 
and O 
found O 
that O 
this O 
compound O 
dramatically O 
increased O 
basal O 
levels O 
without O 
affecting O 
stress O 
responses O 
. O 
Since O 
acute O 
changes O 
in O 
corticosterone B-TRIVIAL 
levels O 
can O 
affect O 
behavior O 
, O 
JZL184 B-IDENTIFIER 
was O 
administered O 
concurrently O 
with O 
the O 
corticosterone B-TRIVIAL 
synthesis O 
inhibitor O 
metyrapone B-TRIVIAL 
, O 
to O 
investigate O 
whether O 
the O 
previously O 
shown O 
behavioral O 
effects O 
of O 
JZL184 B-IDENTIFIER 
are O 
dependent O 
on O 
corticosterone B-TRIVIAL 
. O 
We O 
found O 
that O 
in O 
the O 
elevated O 
plus O 
- O 
maze O 
, O 
the O 
effects O 
of O 
JZL184 B-IDENTIFIER 
on O 
" O 
classical O 
" O 
anxiety O 
- O 
related O 
measures O 
were O 
abolished O 
by O 
corticosterone B-TRIVIAL 
synthesis O 
blockade O 
. O 
By O 
contrast O 
, O 
effects O 
on O 
the O 
" O 
ethological O 
" O 
measures O 
of O 
anxiety O 
( O 
i.e O 
. O 
risk O 
assessment O 
) O 
were O 
not O 
affected O 
by O 
metyrapone B-TRIVIAL 
. O 
In O 
the O 
open O 
- O 
field O 
, O 
the O 
locomotion O 
- O 
enhancing O 
effects O 
of O 
the O 
compound O 
were O 
not O 
changed O 
either O 
. O 
These O 
findings O 
show O 
that O 
monoacylglycerol B-SYSTEMATIC 
lipase O 
inhibition O 
dramatically O 
increases O 
basal O 
levels O 
of O 
corticosterone B-TRIVIAL 
. O 
This O 
endocrine O 
effect O 
partly O 
affects O 
the O 
anxiolytic O 
, O 
but O 
not O 
the O 
locomotion O 
- O 
enhancing O 
effects O 
of O 
monoacylglycerol B-SYSTEMATIC 
lipase O 
blockade O 
. O 

of O 
N-acetyl B-SYSTEMATIC 
cysteine I-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
, O 
an O 
organosulfur B-FAMILY 
compound O 
from O 
Allium O 
plants O 
, O 
on O 
experimentally O 
induced O 
hepatic O 
prefibrogenic O 
events O 
in O 
wistar O 
rat O 
. O 

of O 
present O 
study O 
was O 
to O 
investigate O 
the O 
effect O 
of O 
NAC B-ABBREVIATION 
on O 
experimental O 
chronic O 
hepatotoxicity O 
models O 
induced O 
by O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
( O 
CCl4 B-FORMULA 
) O 
and O 
thioacetamide B-SYSTEMATIC 
( O 
TAA B-ABBREVIATION 
) O 
. O 
CCl4 O 
toxicity O 
was O 
induced O 
by O 
administering O 
200μl O 
CCl4 B-FORMULA 
( O 
diluted O 
2 O 
: O 
3 O 
in O 
coconut O 
oil O 
) O 
/ O 
100g O 
body O 
weight O 
, O 
p.o O 
. O 
, O 
twice O 
weekly O 
for O 
8 O 
weeks O 
. O 
TAA B-ABBREVIATION 
toxicity O 
was O 
induced O 
by O 
administering O 
150mg O 
/ O 
kg O 
b O 
. O 
wt O 
. O 
of O 
TAA B-ABBREVIATION 
i.p O 
. O 
, O 
twice O 
weekly O 
for O 
8 O 
weeks O 
. O 
NAC B-ABBREVIATION 
treatment O 
was O 
started O 
along O 
with O 
toxicants O 
( O 
CCl4 B-FORMULA 
and O 
TAA B-ABBREVIATION 
) O 
for O 
8 O 
weeks O 
and O 
continued O 
for O 
further O 
4 O 
weeks O 
. O 
Self O 
reversal O 
group O 
was O 
kept O 
without O 
any O 
treatment O 
for O 
4 O 
weeks O 
after O 
completion O 
of O 
toxicant O 
treatments O 
. O 
Alanine B-TRIVIAL 
aminotransferase O 
( O 
ALT O 
) O 
, O 
Aspartate B-TRIVIAL 
aminotransferase O 
( O 
AST O 
) O 
, O 
Alkaline O 
phosphatase O 
( O 
ALP O 
) O 
, O 
Bilirubin B-TRIVIAL 
were O 
measured O 
in O 
serum O 
. O 
Hydroxyproline B-SYSTEMATIC 
( O 
HP O 
) O 
, O 
lipid O 
peroxidation O 
( O 
LPO O 
) O 
, O 
catalase O 
( O 
CAT O 
) O 
, O 
Glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
and O 
Glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
were O 
determined O 
in O 
liver O 
samples O 
by O 
colorimetric O 
methods O 
. O 
Cytochrome O 
P450 O 
20 O 
( O 
CYP O 
450 O 
20 O 
) O 
, O 
activity O 
was O 
determined O 
as O 
hydroxylation O 
of O 
aniline B-SYSTEMATIC 
in O 
liver O 
microsomes O 
. O 
General O 
examination O 
and O 
histological O 
analysis O 
were O 
also O 
performed O 
. O 
Serum O 
markers O 
of O 
liver O 
damage O 
( O 
AST O 
, O 
ALT O 
, O 
ALP O 
and O 
Bilirubin B-TRIVIAL 
) O 
were O 
increased O 
by O 
CCl4 B-FORMULA 
and O 
TAA B-ABBREVIATION 
intoxication O 
( O 
p O 
< O 
0.001 O 
) O 
, O 
whereas O 
co O 
- O 
treatment O 
with O 
NAC B-ABBREVIATION 
reversed O 
such O 
changes O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
HP O 
was O 
enhanced O 
in O 
toxicant O 
groups O 
( O 
p O 
< O 
0.001 O 
in O 
CCl4 B-FORMULA 
and O 
TAA B-ABBREVIATION 
) O 
, O 
but O 
inhibited O 
by O 
NAC B-ABBREVIATION 
( O 
p O 
< O 
0.001 O 
) O 
. O 
LPO O 
was O 
increased O 
while O 
as O 
GSH B-ABBREVIATION 
, O 
CAT O 
and O 
GPx O 
decreased O 
by O 
the O 
administration O 
of O 
CCl4 O 
and O 
TAA O 
( O 
p O 
< O 
0.001 O 
) O 
; O 
co O 
- O 
administration O 
of O 
NAC B-ABBREVIATION 
restored O 
these O 
liver O 
markers O 
to O 
normal O 
levels O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
Biochemical O 
determinations O 
were O 
corroborated O 
by O 
general O 
and O 
histological O 
findings O 
. O 
Keeping O 
in O 
view O 
the O 
biochemical O 
and O 
histopathological O 
studies O 
, O 
it O 
was O 
concluded O 
that O 
CCl4 B-FORMULA 
and O 
TAA B-ABBREVIATION 
are O 
strong O 
hepatotoxic O 
agents O 
that O 
produce O 
liver O 
fibrosis O 
with O 
close O 
proximity O 
to O 
human O 
etiology O 
( O 
micronodular O 
cirrhosis O 
) O 
and O 
NAC B-ABBREVIATION 
has O 
a O 
significant O 
protective O 
activity O 
against O 
CCl4 B-FORMULA 
and O 
TAA B-ABBREVIATION 
. O 
NAC B-ABBREVIATION 
has O 
also O 
been O 
validated O 
as O 
a O 
model O 
against O 
oxidative O 
burden O 
in O 
chronic O 
liver O 
pathology O 
. O 

hormone O 
action O 
on O 
ß-cells O 
stimulates O 
in O 
parallel O 
two O 
different O 
intracellular O 
cyclic B-TRIVIAL 
AMP I-TRIVIAL 
-dependent O 
signaling O 
branches O 
mediated O 
by O 
PKA O 
and O 
EPAC2A O 
. O 
Both O 
pathways O 
contribute O 
towards O 
potentiation O 
of O 
glucose B-TRIVIAL 
-stimulated O 
insulin O 
secretion O 
( O 
GSIS O 
) O 
. O 
However O 
, O 
the O 
overall O 
functional O 
role O 
of O 
EPAC2A O 
in O 
ß-cells O 
as O 
it O 
relates O 
to O 
in O 
vivo O 
glucose B-TRIVIAL 
homeostasis O 
remains O 
incompletely O 
understood O 
. O 
Therefore O 
, O 
we O 
have O 
examined O 
in O 
vivo O 
GSIS O 
in O 
global O 
EPAC2A O 
knockout O 
mice O 
. O 
Additionally O 
, O 
we O 
have O 
conducted O 
in O 
vitro O 
studies O 
of O 
GSIS O 
and O 
calcium B-SYSTEMATIC 
dynamics O 
in O 
isolated O 
EPAC2A-deficient O 
islets O 
. O 
EPAC2A O 
deficiency O 
does O 
not O 
impact O 
glucose B-TRIVIAL 
-stimulated O 
insulin O 
secretion O 
in O 
mice O 
under O 
basal O 
conditions O 
. O 
However O 
, O 
when O 
mice O 
are O 
exposed O 
to O 
diet O 
- O 
induced O 
insulin O 
resistance O 
, O 
pharmacologic O 
secretagogue O 
stimulation O 
of O 
ß-cells O 
with O 
an O 
incretin O 
hormone O 
glucagon O 
- O 
like O 
peptide-1 O 
analogue O 
or O 
with O 
a O 
Fatty B-FAMILY 
Acid I-FAMILY 
Receptor O 
1 O 
/ O 
GPR40 O 
selective O 
activator O 
, O 
EPAC2A O 
is O 
required O 
for O 
the O 
increased O 
ß-cell O 
response O 
to O 
secretory O 
demand O 
. O 
Under O 
these O 
circumstances O 
, O 
EPAC2A O 
is O 
required O 
for O 
potentiating O 
the O 
early O 
dynamic O 
increase O 
in O 
islet O 
calcium B-SYSTEMATIC 
levels O 
after O 
glucose B-TRIVIAL 
stimulation O 
, O 
which O 
is O 
reflected O 
in O 
potentiated O 
first O 
phase O 
insulin O 
secretion O 
. O 
These O 
studies O 
broaden O 
our O 
understanding O 
of O 
EPAC2A O 
function O 
and O 
highlight O 
its O 
significance O 
during O 
increased O 
secretory O 
demand O 
or O 
drive O 
on O 
ß-cells O 
. O 
Our O 
findings O 
advance O 
the O 
rationale O 
for O 
developing O 
EPAC2A O 
selective O 
pharmacologic O 
activators O 
for O 
ß-cell O 
targeted O 
pharmacotherapy O 
in O 
type O 
2 O 
diabetes O 
mellitus O 
. O 

acid I-TRIVIAL 
alleviates O 
copper B-SYSTEMATIC 
toxicity O 
in O 
rice O 
( O 
Oryza O 
sativa O 
L O 
. O 
) O 
seedlings O 
by O 
up O 
- O 
regulating O 
antioxidative O 
and O 
glyoxalase O 
systems O 
. O 

present O 
study O 
investigated O 
the O 
effect O 
of O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
( O 
SA O 
) O 
on O 
toxic O 
symptoms O 
, O 
lipid O 
peroxidation O 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
generation O 
and O 
responses O 
of O 
antioxidative O 
and O 
glyoxalase O 
systems O 
in O 
rice O 
seedlings O 
grown O 
hydroponically O 
under O 
copper B-SYSTEMATIC 
( O 
Cu B-FORMULA 
) O 
stress O 
for O 
48 O 
h O 
. O 
Exposures O 
of O 
75 O 
and O 
150 O 
μM O 
Cu(2+) B-FORMULA 
caused O 
toxicity O 
symptoms O 
( O 
chlorosis O 
, O 
necrosis O 
and O 
rolling O 
in O 
leaves O 
) O 
, O 
sharp O 
increases O 
in O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
, O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
H2O2 B-FORMULA 
) O 
contents O 
and O 
lipoxygenase O 
( O 
LOX O 
) O 
activity O 
with O 
concomitant O 
reductions O 
of O 
chlorophyll O 
( O 
Chl O 
) O 
and O 
relative O 
water O 
content O 
( O 
RWC O 
) O 
. O 
Both O 
levels O 
of O 
Cu B-FORMULA 
decreased O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
( O 
AsA B-ABBREVIATION 
) O 
, O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
, O 
non O 
- O 
protein O 
thiol B-FAMILY 
( O 
NPT O 
) O 
and O 
proline B-TRIVIAL 
contents O 
in O 
roots O 
but O 
rather O 
increased O 
in O 
leaves O 
except O 
that O 
AsA B-ABBREVIATION 
decreased O 
in O 
leaves O 
too O 
. O 
These O 
results O 
together O 
with O 
overaccumulation O 
of O 
superoxide B-TRIVIAL 
( O 
O B-FORMULA 
2 I-FORMULA 
( I-FORMULA 
•- I-FORMULA 
) I-FORMULA 
) O 
and O 
H2O2 B-FORMULA 
in O 
leaves O 
revealed O 
that O 
Cu B-FORMULA 
exposures O 
induced O 
oxidative O 
stress O 
. O 
Contrary O 
, O 
SA O 
- O 
pretreatment O 
( O 
100 O 
μM O 
for O 
24 O 
h O 
) O 
reduced O 
toxicity O 
symptoms O 
and O 
diminished O 
Cu B-FORMULA 
-induced O 
increases O 
in O 
LOX O 
activity O 
, O 
H2O2 B-FORMULA 
, O 
MDA B-ABBREVIATION 
and O 
proline B-TRIVIAL 
contents O 
while O 
the O 
levels O 
of O 
RWC O 
, O 
Chl O 
, O 
AsA B-ABBREVIATION 
and O 
redox O 
ratios O 
were O 
elevated O 
. O 
Higher O 
levels O 
of O 
GSH B-ABBREVIATION 
and O 
NPT O 
were O 
also O 
observed O 
in O 
roots O 
of O 
SA O 
- O 
pretreated O 
Cu B-FORMULA 
-exposed O 
seedlings O 
. O 
SA O 
- O 
pretreatment O 
also O 
exerted O 
its O 
beneficial O 
role O 
by O 
inhibiting O 
the O 
Cu B-FORMULA 
upward O 
process O 
. O 
Studies O 
on O 
antioxidant O 
enzymes O 
showed O 
that O 
SA O 
further O 
enhanced O 
the O 
activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
, O 
ascorbate B-TRIVIAL 
peroxidase O 
, O 
glutathione B-TRIVIAL 
reductase O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
, O 
and O 
also O 
elevated O 
the O 
depressed O 
activities O 
of O 
catalase O 
, O 
dehydroascorbate B-SYSTEMATIC 
reductase O 
and O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
particularly O 
at O 
150 O 
μM O 
Cu(2+) B-FORMULA 
stress O 
. O 
In O 
addition O 
, O 
the O 
activity O 
of O 
glyoxalase O 
system O 
( O 
glyoxalase O 
I O 
and O 
II O 
) O 
was O 
further O 
elevated O 
by O 
SA O 
pretreatment O 
in O 
the O 
Cu B-FORMULA 
-exposed O 
seedlings O 
. O 
These O 
results O 
concluded O 
that O 
SA O 
- O 
mediated O 
retention O 
of O 
Cu B-FORMULA 
in O 
roots O 
and O 
enhanced O 
capacity O 
of O 
both O 
antioxidative O 
and O 
glyoxalase O 
systems O 
might O 
be O 
associated O 
with O 
the O 
alleviation O 
of O 
Cu B-FORMULA 
-toxicity O 
in O 
rice O 
seedlings O 
. O 

carbon B-SYSTEMATIC 
nanotubes O 
with O 
superparamagnetic O 
properties O 
: O 
applications O 
for O 
cell O 
labeling O 
, O 
MRI O 
cell O 
tracking O 
and O 
magnetic O 
manipulations O 
. O 

of O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
CNTs O 
) O 
with O 
magnetic O 
nanoparticles O 
( O 
NPs O 
) O 
imparts O 
novel O 
magnetic O 
, O 
optical O 
, O 
and O 
thermal O 
properties O 
with O 
potential O 
applications O 
in O 
the O 
biomedical O 
domain O 
. O 
Multi O 
- O 
walled O 
CNTs O 
have O 
been O 
decorated O 
with O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
superparamagnetic O 
NPs O 
. O 
Two O 
different O 
approaches O 
have O 
been O 
investigated O 
based O 
on O 
ligand O 
exchange O 
or O 
" O 
click O 
chemistry O 
" O 
. O 
The O 
presence O 
of O 
the O 
NPs O 
on O 
the O 
nanotube O 
surface O 
allows O 
conferring O 
magnetic O 
properties O 
to O 
CNTs O 
. O 
We O 
have O 
evaluated O 
the O 
potential O 
of O 
the O 
NP O 
/ O 
CNT O 
hybrids O 
as O 
a O 
contrast O 
agent O 
for O 
magnetic O 
resonance O 
imaging O 
( O 
MRI O 
) O 
and O 
their O 
interactions O 
with O 
cells O 
. O 
The O 
capacity O 
of O 
the O 
hybrids O 
to O 
magnetically O 
monitor O 
and O 
manipulate O 
cells O 
has O 
also O 
been O 
investigated O 
. O 
The O 
NP O 
/ O 
CNTs O 
can O 
be O 
manipulated O 
by O 
a O 
remote O 
magnetic O 
field O 
with O 
enhanced O 
contrast O 
in O 
MRI O 
. O 
They O 
are O 
internalized O 
into O 
tumor O 
cells O 
without O 
showing O 
cytotoxicity O 
. O 
The O 
labeled O 
cells O 
can O 
be O 
magnetically O 
manipulated O 
as O 
they O 
display O 
magnetic O 
mobility O 
and O 
are O 
detected O 
at O 
a O 
single O 
cell O 
level O 
through O 
high O 
resolution O 
MRI O 
. O 

: O 
Although O 
a O 
number O 
of O 
studies O 
investigated O 
the O 
link O 
between O 
major O 
depressive O 
disorder O 
( O 
MDD O 
) O 
and O 
metabolic O 
syndrome O 
( O 
MetS O 
) O 
, O 
the O 
association O 
between O 
MetS O 
and O 
treatment-resistant O 
depression O 
( O 
TRD O 
) O 
is O 
still O 
not O 
clear O 
. O 
OBJECTIVES O 
: O 
The O 
aim O 
of O 
the O 
study O 
was O 
to O 
investigate O 
the O 
relationship O 
between O 
TRD O 
and O 
MetS O 
and O 
/ O 
or O 
components O 
of O 
MetS O 
and O 
cardiovascular O 
risk O 
factors O 
. O 
Given O 
the O 
high O 
prevalence O 
of O 
both O 
conditions O 
, O 
the O 
hypothesis O 
was O 
that O 
TRD O 
would O 
be O 
significantly O 
associated O 
with O 
MetS O 
. O 
METHODS O 
: O 
This O 
cross O 
- O 
sectional O 
study O 
included O 
203 O 
inpatients O 
with O 
MDD O 
, O 
assessed O 
for O 
the O 
treatment O 
resistance O 
, O 
MetS O 
and O 
its O 
components O 
, O 
and O 
severity O 
of O 
MDD O 
. O 
Diagnoses O 
and O 
evaluations O 
were O 
made O 
with O 
SCID O 
based O 
on O 
DSM-IV O 
, O 
National O 
Cholesterol B-TRIVIAL 
Education O 
Program O 
Adult O 
Treatment O 
Panel O 
III O 
criteria O 
, O 
and O 
the O 
Hamilton O 
Depression O 
Rating O 
Scale O 
. O 
RESULTS O 
: O 
TRD O 
prior O 
to O 
study O 
entry O 
was O 
found O 
in O 
26.1 O 
% O 
of O 
patients O 
, O 
while O 
MetS O 
was O 
observed O 
in O 
33.5 O 
% O 
of O 
patients O 
. O 
The O 
prevalence O 
of O 
MetS O 
did O 
not O 
differ O 
significantly O 
between O 
TRD O 
and O 
non-TRD O 
patients O 
. O 
In O 
addition O 
, O 
the O 
frequency O 
of O 
the O 
altered O 
values O 
of O 
particular O 
components O 
of O 
the O 
MetS O 
or O 
cardiovascular O 
risk O 
factors O 
was O 
not O 
associated O 
with O 
treatment O 
resistance O 
in O 
depressed O 
patients O 
. O 
Patients O 
with O 
TRD O 
were O 
older O 
, O 
had O 
a O 
higher O 
number O 
of O 
lifetime O 
episodes O 
of O 
depression O 
and O 
suicide O 
attempts O 
, O 
and O 
longer O 
duration O 
of O 
MDD O 
compared O 
to O 
non-TRD O 
patients O 
. O 
CONCLUSIONS O 
: O 
The O 
occurrence O 
of O 
either O 
MetS O 
or O 
the O 
particular O 
components O 
of O 
the O 
MetS O 
and O 
other O 
cardiovascular O 
risk O 
factors O 
was O 
similar O 
between O 
TRD O 
and O 
non-TRD O 
patients O 
. O 
Although O 
there O 
is O 
a O 
bidirectional O 
relationship O 
between O 
depression O 
and O 
MetS O 
, O 
neither O 
MetS O 
nor O 
its O 
components O 
appear O 
to O 
influence O 
treatment O 
resistance O 
to O 
antidepressants O 
. O 

efficacy O 
of O 
metformin B-TRIVIAL 
in O 
pregnant O 
women O 
with O 
polycystic O 
ovary O 
syndrome O 
: O 
a O 
meta-analysis O 
of O 
clinical O 
trials O 
. O 

: O 
The O 
role O 
of O 
metformin B-TRIVIAL 
in O 
the O 
treatment O 
of O 
pregnant O 
women O 
with O 
polycystic O 
ovary O 
syndrome O 
is O 
controversial O 
. O 
Therefore O 
, O 
we O 
evaluated O 
whether O 
the O 
use O 
of O 
metformin B-TRIVIAL 
during O 
pregnancy O 
in O 
women O 
with O 
polycystic O 
ovary O 
syndrome O 
could O 
reduce O 
pregnancy O 
- O 
related O 
complications O 
. O 
Research O 
design O 
and O 
methods O 
: O 
MEDLINE O 
was O 
searched O 
to O 
retrieve O 
relevant O 
trials O 
. O 
In O 
addition O 
, O 
reviews O 
and O 
reference O 
lists O 
of O 
the O 
retrieved O 
articles O 
were O 
scanned O 
for O 
further O 
appropriate O 
studies O 
. O 
The O 
primary O 
outcome O 
measure O 
was O 
the O 
incidence O 
of O 
complications O 
of O 
pregnancy O 
, O 
which O 
included O 
early O 
pregnancy O 
loss O 
, O 
gestational O 
diabetes O 
, O 
preeclampsia O 
and O 
preterm O 
delivery O 
. O 
Results O 
: O 
In O 
total O 
, O 
eight O 
studies O 
with O 
1106 O 
patients O 
were O 
included O 
. O 
The O 
pooled O 
ORs O 
( O 
95% O 
CIs O 
) O 
of O 
outcome O 
for O 
pregnant O 
women O 
with O 
polycystic O 
ovary O 
syndrome O 
prescribed O 
metformin B-TRIVIAL 
were O 
0.32 O 
( O 
0.19-0.55 O 
) O 
for O 
early O 
pregnancy O 
loss O 
, O 
0.37 O 
( O 
0.25-0.56 O 
) O 
for O 
gestational O 
diabetes O 
, O 
0.53 O 
( O 
0.30-0.95 O 
) O 
for O 
preeclampsia O 
and O 
0.3 O 
( O 
0.13-0.68 O 
) O 
for O 
preterm O 
delivery O 
. O 
Conclusions O 
: O 
Metformin B-TRIVIAL 
therapy O 
throughout O 
pregnancy O 
decreased O 
the O 
ORs O 
of O 
early O 
pregnancy O 
loss O 
, O 
gestational O 
diabetes O 
, O 
preeclampsia O 
and O 
preterm O 
delivery O 
in O 
pregnant O 
PCOS O 
women O 
with O 
no O 
serious O 
detrimental O 
sideeffects O 
. O 

of O 
Ultra-Performance O 
Liquid O 
Chromatography O 
/ O 
Mass O 
Spectrometry O 
- O 
Based O 
Metabonomic O 
Techniques O 
to O 
Analyze O 
the O 
Joint O 
Toxic O 
Action O 
of O 
Long-Term O 
Low-Level O 
Exposure O 
to O 
a O 
Mixture O 
of O 
Organophosphate B-FAMILY 
Pesticides O 
on O 
Rat O 
Urine O 
Profile O 
. O 

previously O 
published O 
articles O 
, O 
we O 
evaluated O 
the O 
toxicity O 
of O 
four O 
organophosphate B-FAMILY 
( O 
OP O 
) O 
pesticides O 
( O 
dichlorvos B-TRIVIAL 
, O 
dimethoate B-TRIVIAL 
, O 
acephate B-TRIVIAL 
and O 
phorate B-TRIVIAL 
) O 
to O 
rats O 
using O 
metabonomic O 
technology O 
at O 
their O 
corresponding O 
no O 
observed O 
adverse O 
effect O 
level O 
( O 
NOAEL O 
) O 
. O 
Results O 
show O 
that O 
a O 
single O 
pesticide O 
elicits O 
no O 
toxic O 
response O 
. O 
The O 
present O 
study O 
aimed O 
to O 
determine O 
whether O 
chronic O 
exposure O 
to O 
a O 
mixture O 
of O 
the O 
above O 
four O 
pesticides O 
( O 
at O 
their O 
corresponding O 
NOAEL O 
) O 
can O 
lead O 
to O 
joint O 
toxic O 
action O 
in O 
rats O 
using O 
the O 
same O 
technology O 
. O 
Pesticides O 
were O 
administered O 
daily O 
to O 
rats O 
through O 
drinking O 
water O 
for O 
24 O 
weeks O 
. O 
The O 
above O 
mixture O 
of O 
the O 
four O 
pesticides O 
showed O 
joint O 
toxic O 
action O 
at O 
the O 
NOAEL O 
of O 
each O 
pesticide O 
. O 
The O 
metabonomic O 
profiles O 
of O 
rats O 
urine O 
were O 
analyzed O 
by O 
ultra O 
- O 
performance O 
liquid O 
chromatography O 
/ O 
mass O 
spectrometry O 
. O 
The O 
16 O 
metabolites O 
statistically O 
significantly O 
changed O 
in O 
all O 
treated O 
groups O 
compared O 
with O 
the O 
control O 
group O 
. O 
Dimethylphosphate B-SYSTEMATIC 
and O 
dimethyldithiophosphate B-SYSTEMATIC 
exclusively O 
detected O 
in O 
all O 
treated O 
groups O 
can O 
be O 
used O 
as O 
early O 
, O 
sensitive O 
biomarkers O 
for O 
exposure O 
to O 
a O 
mixture O 
of O 
the O 
OP O 
pesticides O 
. O 
Moreover O 
, O 
exposure O 
to O 
the O 
OP O 
pesticides O 
resulted O 
in O 
increased O 
7-methylguanine B-SYSTEMATIC 
, O 
ribothymidine B-TRIVIAL 
, O 
cholic B-TRIVIAL 
acid I-TRIVIAL 
, O 
4-pyridoxic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
kynurenine B-TRIVIAL 
and O 
indoxyl B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
levels O 
, O 
as O 
well O 
as O 
decreased O 
hippuric B-TRIVIAL 
acid I-TRIVIAL 
, O 
creatinine B-TRIVIAL 
, O 
uric B-TRIVIAL 
acid I-TRIVIAL 
, O 
gentisic B-TRIVIAL 
acid I-TRIVIAL 
, O 
C18-dihydrosphingosine B-SYSTEMATIC 
, O 
phytosphingosine B-TRIVIAL 
, O 
suberic B-TRIVIAL 
acid I-TRIVIAL 
and O 
citric B-TRIVIAL 
acid I-TRIVIAL 
. O 
The O 
results O 
indicated O 
that O 
a O 
mixture O 
of O 
OP O 
pesticides O 
induced O 
DNA O 
damage O 
, O 
oxidative O 
stress O 
, O 
disturbed O 
the O 
metabolism O 
of O 
lipids O 
as O 
well O 
as O 
interfered O 
with O 
the O 
tricarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
cycle O 
. O 
Ensuring O 
food O 
safety O 
requires O 
not O 
only O 
the O 
toxicology O 
test O 
data O 
of O 
each O 
pesticide O 
for O 
the O 
calculation O 
of O 
the O 
acceptable O 
daily O 
intake O 
, O 
but O 
also O 
the O 
joint O 
toxic O 
action O 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
the O 
anti-ulcerative O 
colitis O 
( O 
UC O 
) O 
activity O 
of O 
the O 
total O 
alcohol B-FAMILY 
extracts O 
of O 
Euphorbia O 
granuleta O 
Forssk O 
. O 
( O 
Euphorpiaceae O 
) O 
, O 
isolate O 
and O 
identify O 
the O 
active O 
compounds O 
that O 
could O 
be O 
responsible O 
for O 
the O 
activity O 
, O 
in O 
addition O 
to O 
determination O 
of O 
the O 
possible O 
mechanism O 
of O 
action O 
. O 
Six O 
compounds O 
were O 
isolated O 
and O 
identified O 
from O 
this O 
plant O 
: O 
three O 
phenolic B-FAMILY 
compounds O 
( O 
kampferol B-TRIVIAL 
, O 
kampferol-3-glucoside B-SYSTEMATIC 
and O 
kampferol-3-galactoside B-SYSTEMATIC 
) O 
in O 
addition O 
to O 
three O 
steroidal O 
compounds O 
( O 
1-ethoxypentacosane B-SYSTEMATIC 
, O 
heptacosan-1-ol B-SYSTEMATIC 
and O 
β-sitosterol B-TRIVIAL 
) O 
. O 
Three O 
compounds O 
( O 
heptacosan-1-ol B-SYSTEMATIC 
, O 
β-sitosterol B-TRIVIAL 
and O 
kampferol-3-galactoside B-SYSTEMATIC 
) O 
were O 
found O 
to O 
be O 
responsible O 
for O 
the O 
anti-UC O 
activity O 
of O 
E O 
. O 
granuleta O 
extract O 
. O 
The O 
anti-UC O 
activity O 
of O 
these O 
compounds O 
may O 
be O 
explained O 
by O 
reducing O 
the O 
pro O 
- O 
inflammatory O 
cytokine O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
( O 
TNF-α O 
) O 
, O 
in O 
addition O 
to O 
reduction O 
of O 
colonic O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
contents O 
. O 
No O 
side O 
effects O 
were O 
reported O 
on O 
liver O 
and O 
kidney O 
functions O 
. O 
The O 
active O 
compounds O 
reduced O 
both O 
serum O 
TNF-α O 
and O 
mucosal O 
MDA B-ABBREVIATION 
levels O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

Exerts O 
Anti-cancer O 
Activity O 
in O 
MDA-MB-231 O 
Breast O 
Cancer O 
Cells O 
Via O 
Inhibition O 
of O 
the O 
Pin1 O 
Activity O 
and O 
Enhancement O 
of O 
the O 
Pin1 O 
/ O 
p53 O 
Association O 
. O 

peptidyl- O 
prolyl B-TRIVIAL 
cis O 
/ O 
trans O 
isomerase O 
Pin1 O 
is O 
overexpressed O 
in O 
a O 
wide O 
variety O 
of O 
cancer O 
cells O 
and O 
thus O 
considered O 
as O 
an O 
important O 
target O 
molecule O 
for O 
cancer O 
therapy O 
. O 
This O 
study O 
demonstrates O 
that O 
decursin B-TRIVIAL 
, O 
a O 
bioactive O 
compound O 
from O 
Angelica O 
gigas O 
, O 
exert O 
the O 
anti-cancer O 
effect O 
against O 
breast O 
cancer O 
cells O 
via O 
regulation O 
of O 
Pin1 O 
and O 
its O 
related O 
signaling O 
molecules O 
. O 
We O 
observed O 
that O 
decursin B-TRIVIAL 
induced O 
G1 O 
arrest O 
with O 
decrease O 
in O 
cyclin O 
D1 O 
level O 
in O 
Pin1-expressing O 
breast O 
cancer O 
cells O 
MDA-MB-231 O 
, O 
but O 
not O 
Pin1-non-expressing O 
breast O 
cancer O 
cells O 
MDA-MB-157 O 
. O 
In O 
addition O 
, O 
decursin B-TRIVIAL 
significantly O 
reduced O 
protein O 
expression O 
and O 
enzymatic O 
activity O 
of O 
Pin1 O 
in O 
MDA-MB-231 O 
cells O 
. O 
Further O 
, O 
we O 
found O 
that O 
decursin B-TRIVIAL 
treatment O 
enhanced O 
the O 
p53 O 
expression O 
level O 
and O 
failed O 
to O 
down O 
- O 
regulate O 
Pin1 O 
in O 
the O 
cells O 
transfected O 
with O 
p53 O 
siRNA O 
, O 
indicating O 
the O 
importance O 
of O 
p53 O 
in O 
the O 
decursin B-TRIVIAL 
-mediated O 
Pin1 O 
inhibition O 
in O 
MDA-MB-231 O 
cells O 
. O 
Decursin B-TRIVIAL 
stimulated O 
association O 
between O 
Pin1 O 
to O 
p53 O 
. O 
Moreover O 
, O 
decursin B-TRIVIAL 
facilitated O 
p53 O 
transcription O 
in O 
MDA-MB-231 O 
cells O 
. O 
Overall O 
, O 
our O 
current O 
study O 
suggests O 
the O 
potential O 
of O 
decursin B-TRIVIAL 
as O 
an O 
attractive O 
cancer O 
therapeutic O 
agent O 
for O 
breast O 
cancer O 
by O 
targeting O 
Pin1 O 
protein O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

- O 
derived O 
prostanoids B-FAMILY 
can O 
influence O 
several O 
processes O 
that O 
are O 
linked O 
to O 
carcinogenesis O 
. O 
We O 
aimed O 
to O 
address O 
the O 
hypothesis O 
that O 
platelets O 
contribute O 
to O 
aberrant O 
COX-2 O 
expression O 
in O 
HT29 O 
colon O 
carcinoma O 
cells O 
and O 
to O 
reveal O 
the O 
role O 
of O 
platelet O 
- O 
induced O 
COX-2 O 
on O 
the O 
expression O 
of O 
proteins O 
involved O 
in O 
malignancy O 
and O 
marker O 
genes O 
of O 
epithelial O 
- O 
mesenchymal O 
transition(EMT) O 
. O 
Human O 
platelets O 
co O 
- O 
cultured O 
with O 
HT29 O 
cells O 
rapidly O 
adhered O 
to O 
cancer O 
cells O 
and O 
induced O 
COX-2 O 
mRNA O 
expression O 
, O 
but O 
not O 
protein O 
synthesis O 
which O 
required O 
the O 
late O 
release O 
of O 
platelet O 
PDGF O 
and O 
COX-2 O 
mRNA O 
stabilization O 
. O 
Platelet O 
- O 
induced O 
COX-2-dependent O 
PGE2 B-ABBREVIATION 
synthesis O 
in O 
HT29 O 
cells O 
was O 
involved O 
in O 
downregulation O 
of O 
p21(WAF1 O 
/ O 
CIP1 O 
) O 
and O 
upregulation O 
of O 
cyclinB1 O 
, O 
since O 
these O 
effects O 
were O 
prevented O 
by O 
rofecoxib B-TRIVIAL 
( O 
a O 
selective O 
COX-2 O 
inhibitor O 
) O 
and O 
rescued O 
by O 
exogenous O 
PGE2 B-ABBREVIATION 
. O 
Galectin-3 O 
, O 
highly O 
expressed O 
in O 
HT29 O 
cells O 
, O 
is O 
unique O 
among O 
galectins O 
because O 
it O 
contains O 
a O 
collagen O 
- O 
like O 
domain O 
. O 
Thus O 
, O 
we O 
studied O 
the O 
role O 
of O 
galectin-3 O 
and O 
platelet O 
collagen O 
receptors O 
in O 
platelet O 
- O 
induced O 
COX-2 O 
overexpression O 
. O 
Inhibitors O 
of O 
galectin-3 O 
function( O 
β-lactose B-TRIVIAL 
, O 
a O 
dominant O 
- O 
negative O 
form O 
of O 
galectin-3,Gal-3C O 
, O 
and O 
anti-galectin-3 O 
antibody O 
M3 O 
/ O 
38 O 
) O 
or O 
collagen O 
receptor O 
- O 
mediated O 
platelet O 
adhesion(revacept O 
, O 
a O 
dimeric O 
collagen O 
receptor O 
GPVI-Fc O 
) O 
prevented O 
aberrant O 
COX-2 O 
expression O 
. O 
Inhibition O 
of O 
platelet O 
- O 
cancer O 
cell O 
interaction O 
by O 
revacept O 
was O 
more O 
effective O 
than O 
rofecoxib B-TRIVIAL 
in O 
preventing O 
platelet O 
- O 
induced O 
mRNA O 
changes O 
of O 
EMT O 
markers O 
suggesting O 
that O 
direct O 
cell O 
- O 
cell O 
contact O 
and O 
aberrant O 
COX-2 O 
expression O 
synergistically O 
induced O 
gene O 
expression O 
modifications O 
associated O 
with O 
EMT O 
. O 
In O 
conclusion O 
, O 
our O 
findings O 
provide O 
the O 
rationale O 
for O 
testing O 
blockers O 
of O 
collagen O 
binding O 
sites O 
, O 
such O 
as O 
revacept O 
, O 
and O 
galectin-3 O 
inhibitors O 
in O 
the O 
prevention O 
of O 
colon O 
cancer O 
metastasis O 
in O 
animal O 
models O 
followed O 
by O 
studies O 
in O 
patients O 
. O 

the O 
spatial O 
and O 
temporal O 
expression O 
of O 
genes O 
involved O 
in O 
the O 
ovulatory O 
pathway O 
is O 
critical O 
for O 
the O 
understanding O 
of O 
the O 
role O 
of O 
each O 
estrogen B-FAMILY 
receptor O 
in O 
the O 
modulation O 
of O 
folliculogenesis O 
and O 
ovulation O 
. O 
Estrogen B-FAMILY 
receptor O 
( O 
ER O 
) O 
β O 
is O 
highly O 
expressed O 
in O 
ovarian O 
granulosa O 
cells O 
and O 
mice O 
lacking O 
ERβ O 
( O 
βERKO O 
) O 
are O 
subfertile O 
due O 
to O 
inefficient O 
ovulation O 
. O 
Previous O 
work O 
has O 
focused O 
on O 
isolated O 
granulosa O 
cells O 
or O 
cultured O 
follicles O 
and O 
while O 
informative O 
, O 
provides O 
confounding O 
results O 
due O 
to O 
the O 
heterogeneous O 
cell O 
types O 
present O 
including O 
granulosa O 
, O 
theca O 
and O 
oocytes O 
and O 
exposure O 
to O 
in O 
vitro O 
conditions O 
. O 
Herein O 
, O 
we O 
isolated O 
preovulatory O 
granulosa O 
cells O 
from O 
WT O 
and O 
ERβ-null O 
mice O 
using O 
laser O 
capture O 
microdissection O 
to O 
examine O 
the O 
genomic O 
transcriptional O 
response O 
downstream O 
of O 
PMSG O 
( O 
mimicking O 
FSH O 
) O 
and O 
PMSG O 
/ O 
hCG O 
( O 
mimicking O 
LH O 
) O 
stimulation O 
. O 
This O 
allows O 
for O 
a O 
direct O 
comparison O 
of O 
in O 
vivo O 
granulosa O 
cells O 
at O 
the O 
same O 
stage O 
of O 
development O 
from O 
both O 
WT O 
and O 
ERβ-null O 
ovaries O 
. O 
ERβ-null O 
granulosa O 
cells O 
showed O 
altered O 
expression O 
of O 
genes O 
known O 
to O 
be O 
regulated O 
by O 
FSH O 
( O 
Akap12 O 
and O 
Runx2 O 
) O 
as O 
well O 
as O 
not O 
previously O 
reported O 
( O 
Arnt2 O 
and O 
Pou5f1 O 
) O 
in O 
WT O 
granulosa O 
cells O 
. O 
Our O 
analysis O 
also O 
identified O 
304 O 
genes O 
not O 
previously O 
associated O 
with O 
ERβ O 
in O 
granulosa O 
cells O 
. O 
LH O 
responsive O 
genes O 
including O 
Abcb1b O 
and O 
Fam110c O 
show O 
reduced O 
expression O 
in O 
ERβ-null O 
granulosa O 
cells O 
; O 
however O 
novel O 
genes O 
including O 
Rassf2 O 
and O 
Megf10 O 
were O 
also O 
identified O 
as O 
being O 
downstream O 
of O 
LH O 
signaling O 
in O 
granulosa O 
cells O 
. O 
Collectively O 
, O 
our O 
data O 
suggests O 
that O 
granulosa O 
cells O 
from O 
ERβ-null O 
ovaries O 
may O 
not O 
be O 
appropriately O 
differentiated O 
and O 
are O 
unable O 
to O 
respond O 
properly O 
to O 
gonadotropin O 
stimulation O 
. O 

cell O 
missing O 
1 O 
( O 
GCM1 O 
) O 
transcription O 
factor O 
regulates O 
placental O 
cell O 
fusion O 
into O 
the O 
syncytiotrophoblast O 
. O 
Caspase-14 O 
is O 
proteolytically O 
activated O 
to O 
mediate O 
filaggrin O 
processing O 
during O 
keratinocyte O 
differentiation O 
. O 
Interestingly O 
, O 
altered O 
expression O 
of O 
nonactivated O 
caspase-14 O 
proenzyme O 
is O 
associated O 
with O 
tumorigenesis O 
and O 
diabetic O 
retinopathy O 
, O 
suggesting O 
that O 
caspase-14 O 
may O 
perform O 
physiological O 
functions O 
independently O 
of O 
its O 
protease O 
activity O 
. O 
Here O 
, O 
we O 
performed O 
tandem O 
affinity O 
purification O 
coupled O 
with O 
mass O 
spectrometry O 
analysis O 
to O 
identify O 
caspase-14 O 
proenzyme O 
as O 
a O 
GCM1-interacting O 
protein O 
that O 
suppresses O 
GCM1 O 
activity O 
and O 
syncytiotrophoblast O 
differentiation O 
. O 
Immunohistochemistry O 
revealed O 
that O 
caspase-14 O 
and O 
GCM1 O 
colocalize O 
to O 
placental O 
cytotrophoblast O 
cells O 
at O 
8 O 
wk O 
of O 
gestation O 
and O 
syncytiotrophoblast O 
layer O 
at O 
term O 
. O 
Further O 
, O 
we O 
demonstrated O 
that O 
caspase-14 O 
mRNA O 
level O 
is O 
decreased O 
by O 
40% O 
in O 
placental O 
BeWo O 
cells O 
treated O 
with O 
forskolin B-TRIVIAL 
( O 
FSK B-ABBREVIATION 
) O 
. O 
To O 
the O 
contrary O 
, O 
stimulation O 
of O 
GCM1-regulated O 
placental O 
cell O 
fusion O 
and O 
human O 
chorionic O 
gonadotropin O 
β O 
( O 
hCGβ O 
) O 
expression O 
by O 
FSK O 
is O 
enhanced O 
by O 
caspase-14 O 
knockdown O 
. O 
Indeed O 
, O 
GCM1 O 
protein O 
level O 
is O 
increased O 
by O 
40% O 
in O 
the O 
caspase-14-knockdown O 
BeWo O 
cells O 
. O 
Because O 
GCM1 O 
is O 
stabilized O 
by O 
acetylation O 
, O 
we O 
subsequently O 
showed O 
that O 
caspase-14 O 
impedes O 
the O 
interaction O 
between O 
GCM1 O 
and O 
cAMP B-ABBREVIATION 
response O 
element O 
- O 
binding O 
protein O 
( O 
CREB O 
) O 
- O 
binding O 
protein O 
( O 
CBP O 
) O 
to O 
suppress O 
CBP O 
- O 
mediated O 
acetylation O 
and O 
transcriptional O 
coactivation O 
of O 
GCM1 O 
. O 
Therefore O 
, O 
caspase-14 O 
can O 
suppress O 
placental O 
cell O 
differentiation O 
through O 
down O 
- O 
regulation O 
of O 
GCM1 O 
activity.-Wu O 
, O 
Y.-H O 
. O 
, O 
Lo O 
, O 
H.-F O 
. O 
, O 
Chen O 
, O 
S.-H O 
. O 
, O 
Chen O 
, O 
H O 
. O 
Caspase-14 O 
suppresses O 
GCM1 O 
acetylation O 
and O 
inhibits O 
placental O 
cell O 
differentiation O 
. O 

surfaces O 
stabilize O 
dextran- O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
aqueous O 
two O 
- O 
phase O 
system O 
liquid O 
patterns O 
. O 

paper O 
analyzes O 
surface O 
chemistry O 
effects O 
to O 
stably O 
pattern O 
aqueous O 
two O 
- O 
phase O 
system O 
( O 
ATPS O 
) O 
droplets O 
on O 
chemically O 
modified O 
poly(dimethylsiloxane) B-SYSTEMATIC 
( O 
PDMS B-ABBREVIATION 
) O 
. O 
Polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
and O 
dextran O 
( O 
DEX O 
) O 
are O 
used O 
as O 
phase O 
- O 
forming O 
polymers O 
for O 
the O 
ATPS O 
. O 
PDMS B-ABBREVIATION 
surface O 
modifications O 
studied O 
include O 
primary B-FAMILY 
amine I-FAMILY 
groups O 
, O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
groups O 
, O 
and O 
neutral O 
polymer O 
surfaces O 
. O 
The O 
PDMS B-ABBREVIATION 
surfaces O 
were O 
characterized O 
by O 
fluorescent O 
measurement O 
, O 
water O 
and O 
DEX O 
contact O 
angle O 
measurements O 
, O 
and O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
analysis O 
to O 
confirm O 
surface O 
properties O 
. O 
While O 
homogeneous O 
surfaces O 
of O 
different O 
functional O 
groups O 
affect O 
DEX O 
droplet O 
pinning O 
somewhat O 
, O 
the O 
most O 
stable O 
patterns O 
were O 
realized O 
using O 
surfaces O 
with O 
chemical O 
heterogeneity O 
. O 
Arbitrary O 
DEX O 
solution O 
patterning O 
was O 
achieved O 
on O 
a O 
chemically O 
patchy O 
surface O 
. O 

Butterfly O 
- O 
Shaped O 
Pyrene B-SYSTEMATIC 
Derivative O 
of O 
Cholesterol B-TRIVIAL 
and O 
Its O 
Uses O 
as O 
a O 
Fluorescent O 
Probe O 
. O 

butterfly O 
- O 
shaped O 
pyrene O 
derivative O 
of O 
cholesterol B-TRIVIAL 
, O 
namely O 
, O 
N,N'-(ethane-1,2-diyl)-bis(N-(2-(chol-amino)ethyl)pyrene-1-sulfonamide) B-SYSTEMATIC 
( O 
ECPS B-ABBREVIATION 
) O 
, O 
has O 
been O 
designed O 
and O 
synthesized O 
. O 
Solvent O 
effect O 
studies O 
revealed O 
that O 
in O 
good O 
solvents O 
such O 
as O 
n-hexane B-SYSTEMATIC 
, O 
benzene B-SYSTEMATIC 
, O 
and O 
1,4-dioxane B-SYSTEMATIC 
, O 
the O 
profile O 
of O 
the O 
fluorescence O 
emission O 
of O 
the O 
compound O 
is O 
characterized O 
by O 
pyrene B-SYSTEMATIC 
monomer O 
emission O 
, O 
but O 
in O 
poor O 
solvent O 
such O 
as O 
water O 
, O 
the O 
emission O 
is O 
dominated O 
by O 
pyrene O 
excimer O 
emission O 
. O 
Quantitatively O 
speaking O 
, O 
the O 
ratio O 
of O 
the O 
excimer O 
emission O 
to O 
monomer O 
emission O 
changes O 
from O 
50 O 
to O 
0 O 
when O 
ECPS O 
is O 
dissolved O 
in O 
water O 
and O 
n-hexane B-SYSTEMATIC 
, O 
respectively O 
. O 
In O 
contrast O 
, O 
for O 
a O 
commonly O 
used O 
polarity O 
probe O 
pyrene B-SYSTEMATIC 
, O 
the O 
ratio O 
of O 
I3 O 
/ O 
I1 O 
varies O 
only O 
from O 
∼0.6 O 
to O 
∼1.7 O 
, O 
where O 
I3 O 
and O 
I1 O 
stand O 
for O 
the O 
intensities O 
of O 
the O 
fluorescence O 
emission O 
at O 
peak O 
3 O 
and O 
peak O 
1 O 
, O 
respectively O 
. O 
This O 
value O 
suggests O 
that O 
a O 
more O 
powerful O 
discriminating O 
ability O 
of O 
the O 
new O 
compound O 
in O 
polarity O 
sensing O 
. O 
Furthermore O 
, O 
unlike O 
the O 
main O 
components O 
of O 
the O 
compound O 
, O 
pyrene B-SYSTEMATIC 
and O 
cholesterol B-TRIVIAL 
, O 
its O 
main O 
chain O 
is O 
composed O 
of O 
multiple O 
hydrophilic O 
structures O 
, O 
and O 
it O 
is O 
this O 
structure O 
that O 
makes O 
the O 
emission O 
of O 
the O 
compound O 
in O 
organic O 
solvents O 
sensitive O 
to O 
the O 
presence O 
of O 
water O 
. O 
Accordingly O 
, O 
the O 
applicability O 
of O 
the O 
compound O 
in O 
determination O 
of O 
the O 
trace O 
amount O 
of O 
water O 
in O 
some O 
organic O 
solvents O 
was O 
evaluated O 
. O 
As O 
expected O 
, O 
the O 
detection O 
limit O 
of O 
the O 
compound O 
toward O 
water O 
in O 
acetonitrile B-SYSTEMATIC 
reaches O 
7 O 
ppm O 
, O 
a O 
result O 
never O 
reached O 
before O 
. O 
Furthermore O 
, O 
the O 
fluorescence O 
emission O 
of O 
the O 
compound O 
is O 
also O 
sensitive O 
to O 
viscosity O 
variation O 
. O 
Therefore O 
, O 
it O 
is O 
assumed O 
that O 
ECPS B-ABBREVIATION 
may O 
be O 
used O 
both O 
as O 
a O 
polarity O 
probe O 
and O 
a O 
viscosity O 
probe O 
. O 
On O 
the O 
bases O 
of O 
a O 
series O 
of O 
steady O 
- O 
state O 
and O 
time O 
- O 
resolved O 
fluorescence O 
, O 
as O 
well O 
as O 
dynamic O 
light O 
scattering O 
studies O 
, O 
a O 
structural O 
model O 
was O 
proposed O 
to O 
rationalize O 
the O 
fluorescence O 
behavior O 
of O 
the O 
compound O 
in O 
different O 
solvents O 
and O 
its O 
polarity O 
and O 
viscosity O 
probing O 
performances O 
. O 

Optical O 
Second-Harmonic O 
Generation O 
from O 
the O 
Current-Biased O 
Graphene B-TRIVIAL 
/ O 
SiO2 B-FORMULA 
/ O 
Si B-FORMULA 
( O 
1 O 
) O 
Structure O 
. O 

find O 
that O 
optical O 
second O 
- O 
harmonic O 
generation O 
( O 
SHG O 
) O 
in O 
reflection O 
from O 
a O 
chemical O 
- O 
vapor O 
- O 
deposition O 
graphene B-TRIVIAL 
monolayer O 
transferred O 
onto O 
a O 
SiO2 B-FORMULA 
/ O 
Si B-FORMULA 
( O 
1 O 
) O 
substrate O 
is O 
enhanced O 
about O 
3 O 
times O 
by O 
the O 
flow O 
of O 
direct O 
current O 
electric O 
current O 
in O 
graphene B-TRIVIAL 
. O 
Measurements O 
of O 
rotational O 
- O 
anisotropy O 
SHG O 
revealed O 
that O 
the O 
current-induced O 
SHG O 
from O 
the O 
current-biased O 
graphene B-TRIVIAL 
/ O 
SiO2 B-FORMULA 
/ O 
Si B-FORMULA 
( O 
1 O 
) O 
structure O 
undergoes O 
a O 
phase O 
inversion O 
as O 
the O 
measurement O 
location O 
on O 
graphene B-TRIVIAL 
is O 
shifted O 
laterally O 
along O 
the O 
current O 
flow O 
direction O 
. O 
The O 
enhancement O 
is O 
due O 
to O 
current-associated O 
charge O 
trapping O 
at O 
the O 
graphene B-TRIVIAL 
/ O 
SiO2 B-FORMULA 
interface O 
, O 
which O 
introduces O 
a O 
vertical O 
electric O 
field O 
across O 
the O 
SiO2 B-FORMULA 
/ O 
Si B-FORMULA 
interface O 
that O 
produces O 
electric O 
field O 
- O 
induced O 
SHG O 
. O 
The O 
phase O 
inversion O 
is O 
due O 
to O 
the O 
positive O 
- O 
to O 
- O 
negative O 
polarity O 
switch O 
in O 
the O 
current O 
direction O 
of O 
the O 
trapped O 
charges O 
at O 
the O 
current-biased O 
graphene B-TRIVIAL 
/ O 
SiO2 B-FORMULA 
interface O 
. O 

Formation O 
in O 
Blended O 
Spin-Cast O 
Films O 
of O 
Fluorene B-TRIVIAL 
-Linked O 
Dyes O 
and O 
Bisphthalimide B-SYSTEMATIC 
Quenchers O 
. O 

- O 
cast O 
films O 
of O 
dyes O 
( O 
donor-π O 
- O 
donor O 
, O 
donor-π-acceptor O 
, O 
and O 
acceptor-π-acceptor O 
type O 
, O 
where O 
the O 
donor O 
is O 
Ph2N B-FORMULA 
- O 
, O 
the O 
acceptor O 
is O 
2-benzothiazoyl B-SYSTEMATIC 
, O 
and O 
the O 
π-linker O 
is O 
9,9-diethylfluorene B-SYSTEMATIC 
) O 
blended O 
with O 
nonconjugated O 
bisphthalimides B-FAMILY 
were O 
prepared O 
. O 
Upon O 
visible O 
- O 
light O 
excitation O 
of O 
the O 
dyes O 
, O 
quenching O 
of O 
the O 
excited O 
state O 
occurs O 
by O 
exciplex O 
formation O 
between O 
dye O 
and O 
bisphthalimide B-SYSTEMATIC 
molecules O 
or O 
, O 
in O 
some O 
cases O 
, O 
by O 
excimer O 
formation O 
or O 
aggregation O 
- O 
induced O 
emission O 
between O 
two O 
dye O 
molecules O 
. O 
The O 
extent O 
of O 
exciplex O 
formation O 
is O 
dependent O 
on O 
the O 
driving O 
force O 
, O 
which O 
can O 
be O 
calculated O 
using O 
the O 
energy O 
difference O 
between O 
the O 
lowest O 
unoccupied O 
molecular O 
orbitals O 
( O 
LUMOs O 
) O 
of O 
the O 
dyes O 
and O 
bisphthalimides B-FAMILY 
. O 
The O 
results O 
show O 
that O 
complete O 
exciplex O 
formation O 
occurs O 
when O 
this O 
driving O 
force O 
is O 
greater O 
than O 
0.57 O 
eV O 
whereas O 
partial O 
exciplex O 
formation O 
occurs O 
when O 
the O 
driving O 
force O 
is O 
between O 
0.28 O 
and O 
0.57 O 
eV O 
. O 
The O 
exciplex O 
emission O 
energies O 
can O 
also O 
be O 
predicted O 
by O 
calculating O 
the O 
difference O 
between O 
the O 
LUMO O 
level O 
of O 
the O 
bisphthalimide B-SYSTEMATIC 
and O 
the O 
highest O 
occupied O 
molecular O 
orbital O 
( O 
HOMO O 
) O 
of O 
the O 
dye O 
. O 
These O 
calculated O 
values O 
, O 
which O 
were O 
obtained O 
from O 
the O 
electrochemically O 
determined O 
energy O 
levels O 
, O 
showed O 
good O 
agreement O 
with O 
the O 
observed O 
emission O 
energies O 
. O 
The O 
exciplex O 
lifetimes O 
were O 
found O 
to O 
be O 
significantly O 
longer O 
than O 
the O 
lifetimes O 
of O 
the O 
lone O 
dyes O 
. O 
These O 
exciplexes O 
formed O 
from O 
nonlinked O 
donors O 
and O 
acceptors O 
in O 
the O 
solid O 
state O 
might O 
have O 
potential O 
uses O 
in O 
nonlinear O 
photonics O 
. O 

DNA O 
damages O 
are O 
defined O 
as O 
two O 
or O 
more O 
closely O 
located O 
DNA O 
damage O 
lesions O 
that O 
may O 
be O 
present O 
within O 
a O 
few O 
helical O 
turns O 
of O 
the O 
DNA O 
double O 
strand O 
. O 
These O 
damages O 
are O 
potential O 
signatures O 
of O 
ionizing O 
radiation O 
and O 
are O 
often O 
found O 
to O 
be O 
repair O 
resistant O 
. O 
Types O 
of O 
damaged O 
lesions O 
frequently O 
found O 
inside O 
clustered O 
DNA O 
damage O 
sites O 
include O 
oxidized O 
bases O 
, O 
abasic O 
sites O 
, O 
nucleotide B-FAMILY 
dimers I-FAMILY 
, O 
strand O 
breaks O 
or O 
their O 
complex O 
combinations O 
. O 
In O 
this O 
study O 
, O 
we O 
used O 
a O 
bistranded O 
two O 
- O 
lesion O 
abasic O 
cluster O 
DNA O 
damage O 
model O 
to O 
access O 
the O 
repair O 
process O 
of O 
DNA O 
in O 
condensate O 
form O 
. O 
Oligomer O 
DNA O 
duplexes O 
( O 
47bp O 
) O 
were O 
designed O 
to O 
have O 
two O 
deoxyuridine B-TRIVIAL 
in O 
the O 
middle O 
of O 
the O 
sequences O 
, O 
three O 
bases O 
apart O 
in O 
opposite O 
strands O 
. O 
The O 
deoxyuridine B-TRIVIAL 
residues O 
were O 
converted O 
into O 
abasic O 
sites O 
by O 
treatment O 
with O 
UDG O 
enzyme O 
creating O 
an O 
abasic O 
clustered O 
damage O 
site O 
in O 
a O 
precise O 
position O 
in O 
each O 
of O 
the O 
single O 
strand O 
of O 
the O 
DNA O 
duplex O 
. O 
This O 
oligomer O 
duplex O 
having O 
compatible O 
cohesive O 
ends O 
was O 
ligated O 
to O 
pUC19 O 
plasmid O 
, O 
linearized O 
with O 
HindIII O 
restriction O 
endonuclease O 
. O 
The O 
plasmid O 
- O 
oligomer O 
conjugate O 
was O 
transformed O 
into O 
condensates O 
by O 
treating O 
them O 
with O 
spermidine B-TRIVIAL 
. O 
The O 
efficiency O 
of O 
strand O 
cleavage O 
action O 
of O 
ApeI O 
enzyme O 
on O 
the O 
abasic O 
sites O 
was O 
determined O 
by O 
denaturing O 
PAGE O 
after O 
timed O 
incubation O 
of O 
the O 
oligomer O 
duplex O 
and O 
the O 
oligomer O 
- O 
plasmid O 
conjugate O 
in O 
presence O 
and O 
absence O 
of O 
spermidine B-TRIVIAL 
. O 
The O 
efficiency O 
of O 
double O 
strand O 
breaks O 
was O 
determined O 
similarly O 
by O 
native O 
PAGE O 
. O 
Quantitative O 
gel O 
analysis O 
revealed O 
that O 
rate O 
of O 
abasic O 
site O 
cleavage O 
is O 
reduced O 
in O 
the O 
DNA O 
condensates O 
as O 
compared O 
to O 
the O 
oligomer O 
DNA O 
duplex O 
or O 
the O 
linear O 
ligated O 
oligomer O 
- O 
plasmid O 
conjugates O 
. O 
Generation O 
of O 
double O 
strand O 
break O 
is O 
significantly O 
reduced O 
also O 
, O 
suggesting O 
that O 
their O 
creation O 
is O 
not O 
proportionate O 
to O 
the O 
number O 
of O 
abasic O 
sites O 
cleaved O 
in O 
the O 
condensate O 
model O 
. O 
All O 
these O 
suggest O 
that O 
the O 
ApeI O 
enzyme O 
have O 
difficulty O 
to O 
access O 
the O 
abasic O 
sites O 
located O 
deep O 
into O 
the O 
condensates O 
leading O 
to O 
repair O 
refractivity O 
of O 
the O 
damages O 
. O 
In O 
addition O 
, O 
we O 
found O 
that O 
presence O 
of O 
a O 
polyamine B-FAMILY 
such O 
as O 
spermidine B-TRIVIAL 
has O 
no O 
notable O 
effect O 
in O 
the O 
incision O 
activity O 
of O 
ApeI O 
enzyme O 
in O 
linear O 
oligomer O 
DNA O 
duplexes O 
in O 
our O 
experimental O 
concentration O 
. O 

and O 
antitumor O 
activity O 
of O 
1,3,4-oxadiazole B-SYSTEMATIC 
possessing O 
1,4-benzodioxan B-SYSTEMATIC 
moiety O 
as O 
a O 
novel O 
class O 
of O 
potent O 
methionine B-TRIVIAL 
aminopeptidase O 
type O 
II O 
inhibitors O 
. O 

series O 
of O 
1,3,4-oxadiazole B-SYSTEMATIC 
derivatives O 
containing O 
1,4-benzodioxan B-SYSTEMATIC 
moiety O 
( O 
7a-7q O 
) O 
have O 
been O 
designed O 
, O 
synthesized O 
and O 
evaluated O 
for O 
their O 
antitumor O 
activity O 
. O 
Most O 
of O 
the O 
synthesized O 
compounds O 
were O 
proved O 
to O 
have O 
potent O 
antitumor O 
activity O 
and O 
low O 
toxicity O 
. O 
Among O 
them O 
, O 
compound O 
7a O 
showed O 
the O 
most O 
potent O 
biological O 
activity O 
against O 
Human O 
Umbilical O 
Vein O 
Endothelial O 
cells O 
, O 
which O 
was O 
comparable O 
to O 
the O 
positive O 
control O 
. O 
The O 
results O 
of O 
apoptosis O 
and O 
flow O 
cytometry O 
( O 
FCM O 
) O 
demonstrated O 
that O 
compound O 
7a O 
induce O 
cell O 
apoptosis O 
by O 
the O 
inhibition O 
of O 
Met B-FORMULA 
AP2 O 
pathway O 
. O 
Molecular O 
docking O 
was O 
performed O 
to O 
position O 
compound O 
7a O 
into O 
Met B-FORMULA 
AP2 O 
binding O 
site O 
in O 
order O 
to O 
explore O 
the O 
potential O 
target O 
. O 

anti-diabetic O 
effects O 
and O 
pharmacokinetic O 
profiles O 
of O 
berberine B-TRIVIAL 
in O 
mice O 
treated O 
with O 
Jiao-Tai-Wan O 
and O 
its O 
compatibility O 
. O 

( O 
JTW O 
) O 
, O 
a O 
classical O 
Chinese O 
prescription O 
, O 
has O 
been O 
clinically O 
employed O 
to O 
treat O 
diabetes O 
mellitus O 
in O 
recent O 
years O 
. O 
To O 
investigate O 
the O 
comparative O 
evaluations O 
on O 
anti-diabetic O 
effects O 
and O 
pharmacokinetics O 
of O 
the O 
active O 
ingredient O 
berberine B-TRIVIAL 
in O 
mice O 
treated O 
with O 
JTW O 
in O 
various O 
combinations O 
of O 
its O 
constituent O 
herbs O 
. O 
In O 
our O 
study O 
, O 
the O 
anti-diabetic O 
study O 
was O 
carried O 
out O 
in O 
diabetic O 
mice O 
induced O 
by O 
intraperitoneal O 
injection O 
of O 
streptozotocin B-TRIVIAL 
. O 
The O 
diabetic O 
mice O 
were O 
randomly O 
assigned O 
to O 
three O 
therapy O 
groups O 
and O 
orally O 
administered O 
with O 
different O 
prescription O 
proportions O 
of O 
Rhizoma O 
Coptidis O 
and O 
Cinnamomum O 
cassia O 
respectively O 
. O 
The O 
level O 
of O 
plasma O 
glucose B-TRIVIAL 
, O 
lipid O 
profile O 
and O 
parameters O 
related O 
to O 
oxidative O 
stress O 
were O 
determined O 
. O 
The O 
concentrations O 
of O 
berberine B-TRIVIAL 
in O 
non-diabetic O 
mice O 
plasma O 
were O 
determined O 
using O 
HPLC O 
, O 
and O 
main O 
pharmacokinetic O 
parameters O 
were O 
investigated O 
. O 
The O 
results O 
indicated O 
that O 
the O 
compatibility O 
effects O 
of O 
ingredients O 
present O 
in O 
Cinnamomum O 
cassia O 
could O 
affect O 
the O 
anti-diabetic O 
ability O 
and O 
pharmacokinetics O 
of O 
berberine B-TRIVIAL 
in O 
JTW O 
. O 

suppressed O 
CYP2E1-dependent O 
ethanol B-SYSTEMATIC 
hepatotoxicity O 
via O 
depleting O 
heme O 
pool O 
and O 
releasing O 
CO B-FORMULA 
. O 

occuring O 
quercetin B-TRIVIAL 
protects O 
hepatocytes O 
from O 
ethanol B-SYSTEMATIC 
-induced O 
oxidative O 
stress O 
, O 
and O 
heme B-FAMILY 
oxygenase-1 O 
( O 
HO-1 O 
) O 
induction O 
and O 
carbon B-SYSTEMATIC 
monoxide I-SYSTEMATIC 
( O 
CO B-FORMULA 
) O 
metabolite O 
may O 
be O 
implicated O 
in O 
the O 
beneficial O 
effect O 
. O 
However O 
, O 
the O 
precise O 
mechanism O 
by O 
which O 
quercetin B-TRIVIAL 
counteracts O 
CYP2E1 O 
- O 
mediated O 
ethanol B-SYSTEMATIC 
hepatotoxicity O 
through O 
HO-1 O 
system O 
is O 
still O 
remained O 
unclear O 
. O 
To O 
explore O 
the O 
potential O 
mechanism O 
, O 
herein O 
, O 
ethanol B-SYSTEMATIC 
( O 
4.0g O 
/ O 
kg.bw O 
. O 
) O 
was O 
administrated O 
to O 
rats O 
for O 
90 O 
days O 
. O 
Our O 
data O 
showed O 
that O 
chronic O 
ethanol B-SYSTEMATIC 
over O 
- O 
activated O 
CYP2E1 O 
but O 
suppressed O 
HO-1 O 
with O 
concurrent O 
hepatic O 
oxidative O 
damage O 
, O 
which O 
was O 
partially O 
normalized O 
by O 
quercetin B-TRIVIAL 
( O 
100mg O 
/ O 
kg.bw O 
. O 
) O 
. O 
Quercetin B-TRIVIAL 
( O 
100μM O 
) O 
induced O 
HO-1 O 
and O 
depleted O 
heme O 
pool O 
when O 
incubated O 
to O 
human O 
hepatocytes O 
. O 
Ethanol B-SYSTEMATIC 
-stimulated O 
( O 
100mM O 
) O 
CYP2E1 O 
upregulation O 
was O 
suppressed O 
by O 
quercetin B-TRIVIAL 
but O 
further O 
enhanced O 
by O 
HO-1 O 
inhibition O 
with O 
resultant O 
heme B-FAMILY 
accumulation O 
. O 
CO B-FORMULA 
scavenging O 
blocked O 
the O 
suppression O 
of O 
quercetin B-TRIVIAL 
only O 
on O 
CYP2E1 O 
activity O 
. O 
CO B-FORMULA 
donor O 
dose O 
- O 
dependently O 
inactivated O 
CYP2E1 O 
of O 
ethanol B-SYSTEMATIC 
-incubated O 
microsome O 
, O 
which O 
was O 
mimicked O 
by O 
HO-1 O 
substrate O 
but O 
abolished O 
by O 
CO B-FORMULA 
scavenger O 
. O 
Thus O 
, O 
CYP2E1 O 
- O 
mediated O 
ethanol B-SYSTEMATIC 
hepatotoxicity O 
was O 
alleviated O 
by O 
quercetin B-TRIVIAL 
through O 
HO-1 O 
induction O 
. O 
Depleted O 
heme O 
pool O 
and O 
CO B-FORMULA 
releasing O 
limited O 
protein O 
synthesis O 
and O 
inhibited O 
enzymatic O 
activity O 
of O 
CYP2E1 O 
, O 
respectively O 
. O 

compounds O 
regulate O 
the O 
level O 
of O 
ROS O 
production O 
by O 
the O 
NADPH B-ABBREVIATION 
oxidase O 
Nox4 O 
. O 

oxidase O 
Nox4 O 
is O 
expressed O 
in O 
a O 
wide O 
range O 
of O 
tissues O 
and O 
plays O 
a O 
role O 
in O 
cellular O 
signaling O 
by O 
providing O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
as O 
intracellular O 
messengers O 
. O 
Nox4 O 
oxidase O 
activity O 
is O 
thought O 
to O 
be O 
constitutive O 
and O 
regulated O 
at O 
the O 
transcriptional O 
level O 
; O 
however O 
, O 
we O 
challenge O 
this O 
point O 
of O 
view O 
and O 
suggest O 
that O 
specific O 
quinone B-FAMILY 
derivatives O 
could O 
modulate O 
this O 
activity O 
. O 
In O 
fact O 
, O 
we O 
demonstrated O 
a O 
significant O 
stimulation O 
of O 
Nox4 O 
activity O 
by O 
4 O 
quinone B-FAMILY 
derivatives O 
( O 
AA-861 B-TRIVIAL 
, O 
tBuBHQ B-ABBREVIATION 
, O 
tBuBQ B-ABBREVIATION 
, O 
and O 
duroquinone B-TRIVIAL 
) O 
observed O 
in O 
3 O 
different O 
cellular O 
models O 
, O 
HEK293E O 
, O 
T-REx O 
™ O 
, O 
and O 
chondrocyte O 
cell O 
lines O 
. O 
Our O 
results O 
indicate O 
that O 
the O 
effect O 
is O 
specific O 
toward O 
Nox4 O 
versus O 
Nox2 O 
. O 
Furthermore O 
, O 
we O 
showed O 
that O 
NAD(P)H B-ABBREVIATION 
: O 
quinone B-FAMILY 
oxidoreductase O 
( O 
NQO1 O 
) O 
may O 
participate O 
in O 
this O 
stimulation O 
. O 
Interestingly O 
, O 
Nox4 O 
activity O 
is O 
also O 
stimulated O 
by O 
reducing O 
agents O 
that O 
possibly O 
act O 
by O 
reducing O 
the O 
disulfide B-SYSTEMATIC 
bridge O 
( O 
Cys B-FORMULA 
226 O 
, O 
Cys B-FORMULA 
270 O 
) O 
located O 
in O 
the O 
extracellular O 
E-loop O 
of O 
Nox4 O 
. O 
Such O 
model O 
of O 
Nox4 O 
activity O 
regulation O 
could O 
provide O 
new O 
insight O 
into O 
the O 
understanding O 
of O 
the O 
molecular O 
mechanism O 
of O 
the O 
electron O 
transfer O 
through O 
the O 
enzyme O 
, O 
i.e O 
. O 
, O 
its O 
potential O 
redox O 
regulation O 
, O 
and O 
could O 
also O 
define O 
new O 
therapeutic O 
targets O 
in O 
diseases O 
in O 
which O 
quinones B-FAMILY 
and O 
Nox4 O 
are O 
implicated O 
. O 

compounds O 
present O 
in O 
Sardinian O 
wine O 
extracts O 
protect O 
against O 
the O 
production O 
of O 
inflammatory O 
cytokines O 
induced O 
by O 
oxysterols B-FAMILY 
in O 
CaCo-2 O 
human O 
enterocyte O 
- O 
like O 
cells O 
. O 

auto O 
- O 
oxidation O 
products O 
, O 
namely O 
oxysterols B-FAMILY 
, O 
are O 
widely O 
present O 
in O 
cholesterol B-TRIVIAL 
-rich O 
foods O 
. O 
They O 
are O 
thought O 
to O 
potentially O 
interfere O 
with O 
homeostasis O 
of O 
the O 
human O 
digestive O 
tract O 
, O 
playing O 
a O 
role O 
in O 
intestinal O 
mucosal O 
damage O 
. O 
This O 
report O 
concerns O 
the O 
marked O 
up O 
- O 
regulation O 
in O 
differentiated O 
CaCo-2 O 
colonic O 
epithelial O 
cells O 
of O 
two O 
key O 
inflammatory O 
interleukins O 
, O 
IL-6 O 
and O 
IL-8 O 
, O 
caused O 
by O 
a O 
mixture O 
of O 
oxysterols B-FAMILY 
representative O 
of O 
a O 
high O 
cholesterol B-TRIVIAL 
diet O 
. O 
This O 
strong O 
pro O 
- O 
inflammatory O 
effect O 
appeared O 
to O 
be O 
dependent O 
on O 
the O 
net O 
imbalance O 
of O 
red O 
- O 
ox O 
equilibrium O 
with O 
the O 
production O 
of O 
excessive O 
levels O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
through O 
the O 
colonic O 
NADPH B-ABBREVIATION 
-oxidase O 
NOX1 O 
activation O 
. O 
Induction O 
of O 
NOX1 O 
was O 
markedly O 
while O 
not O 
fully O 
inhibited O 
by O 
CaCo-2 O 
cell O 
pre O 
- O 
incubation O 
with O 
phenolic O 
extracts O 
obtained O 
from O 
well O 
- O 
selected O 
wines O 
from O 
typical O 
grape O 
varieties O 
grown O 
in O 
Sardinia O 
. O 
Oxysterol B-FAMILY 
-dependent O 
NOX1 O 
activation O 
, O 
as O 
well O 
as O 
interleukin O 
synthesis O 
, O 
were O 
completely O 
prevented O 
by O 
Cannonau O 
red O 
wine O 
extract O 
that O 
contains O 
an O 
abundant O 
phenolic O 
fraction O 
, O 
in O 
particular O 
phenolic B-FAMILY 
acids I-FAMILY 
and O 
flavonoids B-FAMILY 
. O 
Conversely O 
, O 
cell O 
pre O 
- O 
treatment O 
with O 
Vermentino O 
white O 
wine O 
extract O 
with O 
smaller O 
phenolic O 
fraction O 
showed O 
only O 
a O 
partial O 
NOX1 O 
down O 
- O 
regulation O 
and O 
was O 
ineffective O 
in O 
interleukin O 
synthesis O 
induced O 
by O 
dietary O 
oxysterols B-FAMILY 
. O 
It O 
is O 
thus O 
likely O 
that O 
the O 
effects O 
of O 
Sardinian O 
wine O 
extracts O 
against O 
intestinal O 
inflammation O 
induced O 
by O 
dietary O 
oxysterols B-FAMILY 
are O 
mainly O 
due O 
to O 
their O 
high O 
phenolic O 
content O 
: O 
low O 
doses O 
of O 
phenolics B-FAMILY 
would O 
be O 
responsible O 
only O 
for O 
direct O 
scavenging O 
oxysterol B-FAMILY 
-dependent O 
ROS O 
production O 
. O 
Besides O 
this O 
direct O 
activity O 
, O 
an O 
excess O 
of O 
phenolic B-FAMILY 
compounds O 
detectable O 
in O 
red O 
wine O 
, O 
may O 
exert O 
an O 
additional O 
indirect O 
action O 
by O 
blocking O 
oxysterol B-FAMILY 
-related O 
NOX1 O 
induction O 
, O 
thus O 
totally O 
preventing O 
the O 
pro O 
- O 
oxidant O 
and O 
pro O 
- O 
inflammatory O 
events O 
triggered O 
by O 
dietary O 
oxysterols B-FAMILY 
. O 

A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
, O 
two O 
novel O 
sesqui B-FAMILY 
- I-FAMILY 
neolignans I-FAMILY 
from O 
the O 
fruits O 
of O 
Illicium O 
simonsii O 
. O 

new O 
sesqui B-FAMILY 
- I-FAMILY 
neolignans I-FAMILY 
with O 
novel O 
conjugation O 
way O 
, O 
simonol B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
, O 
featuring O 
a O 
unique O 
motif O 
of O 
a O 
5,5-dihydro-pyran B-SYSTEMATIC 
with O 
a O 
hemiketal B-SYSTEMATIC 
carbon I-SYSTEMATIC 
, O 
while O 
simonol B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
possessing O 
two O 
dihydronfuran B-SYSTEMATIC 
rings O 
in O 
the O 
same O 
direction O 
, O 
were O 
isolated O 
from O 
the O 
ethanol B-SYSTEMATIC 
extract O 
of O 
the O 
fruits O 
of O 
Illicium O 
simonii O 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
spectroscopic O 
methods O 
including O 
1D O 
and O 
2D O 
NMR O 
, O 
HRESIMS O 
, O 
and O 
calculation O 
of O 
electronic O 
circular O 
dichroism O 
( O 
ECD O 
) O 
using O 
density O 
functional O 
theory O 
( O 
DFT O 
) O 
. O 
The O 
two O 
isolates O 
were O 
evaluated O 
for O 
their O 
inhibitory O 
activities O 
against O 
the O 
growth O 
of O 
four O 
lines O 
of O 
human O 
cancer O 
cells O 
( O 
NCI-H460 O 
, O 
SMMC-7721 O 
, O 
MCF-7 O 
, O 
BGC-823 O 
) O 
: O 
1 O 
showed O 
strong O 
activities O 
comparable O 
to O 
5-Fluorouracil B-SYSTEMATIC 
, O 
and O 
2 O 
to O 
a O 
less O 
content O 
. O 
In O 
addition O 
, O 
plausible O 
biosynthetic O 
routes O 
for O 
the O 
two O 
compounds O 
were O 
also O 
proposed O 
. O 

comprehensive O 
machine O 
- O 
readable O 
view O 
of O 
the O 
mammalian O 
cholesterol B-TRIVIAL 
biosynthesis O 
pathway O 
. O 

biosynthesis O 
serves O 
as O 
a O 
central O 
metabolic O 
hub O 
for O 
numerous O 
biological O 
processes O 
in O 
health O 
and O 
disease O 
. O 
A O 
detailed O 
, O 
integrative O 
single O 
- O 
view O 
description O 
of O 
how O 
the O 
cholesterol B-TRIVIAL 
pathway O 
is O 
structured O 
and O 
how O 
it O 
interacts O 
with O 
other O 
pathway O 
systems O 
is O 
lacking O 
in O 
the O 
existing O 
literature O 
. O 
Here O 
we O 
provide O 
a O 
systematic O 
review O 
of O 
the O 
existing O 
literature O 
and O 
present O 
a O 
detailed O 
pathway O 
diagram O 
that O 
describes O 
the O 
cholesterol B-TRIVIAL 
biosynthesis O 
pathway O 
( O 
the O 
mevalonate B-TRIVIAL 
, O 
the O 
Kandutch-Russell O 
and O 
the O 
Bloch O 
pathway O 
) O 
and O 
shunt O 
pathway O 
that O 
leads O 
to O 
24(S),25-epoxycholesterol B-SYSTEMATIC 
synthesis O 
. O 
The O 
diagram O 
has O 
been O 
produced O 
using O 
the O 
Systems O 
Biology O 
Graphical O 
Notation O 
( O 
SBGN O 
) O 
and O 
is O 
available O 
in O 
the O 
SBGN-ML O 
format O 
, O 
a O 
human O 
readable O 
and O 
machine O 
semantically O 
parsable O 
open O 
community O 
file O 
format O 
. O 

mechanisms O 
for O 
the O 
anti-cancer O 
effects O 
of O 
diallyl B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
. O 

evidence O 
in O 
recent O 
years O 
suggests O 
that O 
garlic O 
has O 
anti-proliferative O 
effects O 
against O 
various O 
types O 
of O 
cancer O 
. O 
Garlic O 
contains O 
water O 
- O 
soluble O 
and O 
oil O 
- O 
soluble O 
sulfur O 
compounds O 
. O 
Oil O 
- O 
soluble O 
compounds O 
such O 
as O 
diallyl B-SYSTEMATIC 
sulfide I-SYSTEMATIC 
( O 
DAS B-ABBREVIATION 
) O 
, O 
diallyl B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
( O 
DADS B-ABBREVIATION 
) O 
, O 
diallyl B-SYSTEMATIC 
trisulfide I-SYSTEMATIC 
( O 
DATS B-ABBREVIATION 
) O 
and O 
ajoene B-TRIVIAL 
are O 
more O 
effective O 
than O 
water O 
- O 
soluble O 
compounds O 
in O 
protection O 
against O 
cancer O 
. O 
DADS B-ABBREVIATION 
, O 
a O 
major O 
organosulfur B-FAMILY 
compound O 
derived O 
from O 
garlic O 
, O 
can O 
decrease O 
carcinogen O 
- O 
induced O 
cancers O 
in O 
experimental O 
animals O 
and O 
inhibit O 
the O 
proliferation O 
of O 
various O 
types O 
of O 
cancer O 
cells O 
. O 
Its O 
mechanisms O 
of O 
action O 
include O 
: O 
the O 
activation O 
of O 
metabolizing O 
enzymes O 
that O 
detoxify O 
carcinogens O 
; O 
suppression O 
of O 
the O 
formation O 
of O 
DNA O 
adducts O 
; O 
antioxidant O 
effects O 
; O 
regulation O 
of O 
cell O 
- O 
cycle O 
arrest O 
; O 
induction O 
of O 
apoptosis O 
and O 
differentiation O 
; O 
histone O 
modification O 
; O 
and O 
inhibition O 
of O 
angiogenesis O 
and O 
invasion O 
. O 
These O 
topics O 
are O 
discussed O 
in O 
depth O 
in O 
this O 
review O 
. O 

of O 
protein O 
- O 
release O 
completeness O 
and O 
polymer O 
degradation O 
in O 
PLGA B-ABBREVIATION 
-based O 
implants O 
. O 

of O 
BSA O 
( O 
model O 
protein O 
) O 
from O 
hot O 
- O 
melt O 
extruded O 
poly(lactide-co-glycolide) B-SYSTEMATIC 
( O 
PLGA B-ABBREVIATION 
) O 
- O 
based O 
implants O 
was O 
incomplete O 
. O 
A O 
residual O 
mass O 
of O 
covalent O 
BSA- O 
PLGA B-ABBREVIATION 
adducts O 
was O 
still O 
present O 
after O 
6months O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
increase O 
the O 
completeness O 
of O 
BSA O 
release O 
. O 
BSA O 
reduced O 
the O 
PLGA B-ABBREVIATION 
degradation O 
and O 
erosion O 
rate O 
as O 
well O 
as O 
the O 
extent O 
of O 
erosion O 
. O 
An O 
increased O 
uptake O 
of O 
release O 
medium O 
in O 
the O 
presence O 
of O 
BSA O 
in O 
addition O 
to O 
the O 
early O 
outflux O 
of O 
PLGA B-ABBREVIATION 
oligomers O 
resulted O 
in O 
a O 
reduction O 
of O 
the O 
matrix O 
acidity O 
and O 
thus O 
reduction O 
of O 
autocatalysis O 
effects O 
. O 
PLGA B-ABBREVIATION 
mass O 
loss O 
was O 
incomplete O 
at O 
60% O 
and O 
80% O 
for O 
10% O 
and O 
25% O 
BSA O 
- O 
containing O 
implants O 
. O 
The O 
extent O 
of O 
PLGA B-ABBREVIATION 
mass O 
loss O 
was O 
correlated O 
with O 
the O 
total O 
releasable O 
protein O 
. O 
The O 
same O 
release O 
was O 
obtained O 
from O 
implants O 
prepared O 
with O 
pre O 
- O 
degraded O 
PLGA B-ABBREVIATION 
suggesting O 
that O 
the O 
induction O 
phase O 
did O 
not O 
affect O 
the O 
release O 
completeness O 
. O 
Thus O 
, O 
the O 
focus O 
was O 
on O 
the O 
erosion O 
phase O 
to O 
enhance O 
outflux O 
of O 
soluble O 
oligomers O 
. O 
BSA O 
release O 
completeness O 
increased O 
by O 
increasing O 
the O 
porosity O 
of O 
the O 
implants O 
at O 
the O 
onset O 
of O 
erosion O 
phase O 
. O 
This O 
could O 
be O 
obtained O 
with O 
a O 
higher O 
initial O 
porosity O 
, O 
formation O 
of O 
porosity O 
upon O 
higher O 
diffusional O 
release O 
and O 
/ O 
or O 
incorporation O 
of O 
pore O 
- O 
formers O 
/ O 
plasticizers O 
. O 
Accordingly O 
, O 
the O 
BSA O 
release O 
completeness O 
could O 
be O 
improved O 
by O 
enhancing O 
the O 
outflux O 
of O 
soluble O 
PLGA B-ABBREVIATION 
degradation O 
products O 
. O 

stability O 
of O 
oligodeoxynucleotide O 
duplexes O 
containing O 
l-deoxynucleotide B-FAMILY 
at O 
termini O 
. O 

effects O 
of O 
substituting O 
l-deoxynucleotide B-FAMILY 
for O 
d-deoxynucleotide B-FAMILY 
at O 
duplex O 
termini O 
were O 
evaluated O 
and O 
the O 
terminal O 
substitutions O 
were O 
found O 
to O 
show O 
much O 
less O 
effects O 
on O 
duplex O 
destabilization O 
and O 
to O 
show O 
a O 
similar O 
tendency O 
in O 
base O 
pairing O 
selectivity O 
, O 
compared O 
with O 
internal O 
chiral O 
substitutions O 
. O 

activity O 
of O 
ICI B-IDENTIFIER 
182 I-IDENTIFIER 
780 I-IDENTIFIER 
on O 
activation O 
of O 
GSK O 
3β O 
/ O 
AKT O 
pathway O 
in O 
the O 
rat O 
uterus O 
during O 
the O 
estrous O 
cycle O 
. O 

examined O 
the O 
ability O 
of O 
ICI B-IDENTIFIER 
182780 I-IDENTIFIER 
( O 
ICI B-ABBREVIATION 
) O 
to O 
block O 
uterine O 
cell O 
proliferation O 
via O 
protein O 
kinase O 
b O 
/ O 
AKT O 
pathway O 
in O 
the O 
uterus O 
of O 
the O 
rat O 
during O 
the O 
estrous O 
cycle O 
. O 
Intact O 
rats O 
, O 
with O 
regular O 
estrous O 
cycles O 
, O 
received O 
a O 
subcutaneous O 
( O 
s.c O 
. O 
) O 
injection O 
of O 
either O 
vehicle O 
or O 
ICI B-ABBREVIATION 
at O 
8 O 
: O 
00h O 
on O 
the O 
day O 
of O 
proestrus O 
or O 
at O 
0 O 
: O 
00h O 
on O 
the O 
day O 
of O 
estrus O 
and O 
sacrificed O 
at O 
13 O 
: O 
00h O 
of O 
metaestrus O 
. O 
Estradiol B-TRIVIAL 
( O 
E2 O 
) O 
and O 
progesterone B-TRIVIAL 
( O 
P4 O 
) O 
plasma O 
levels O 
were O 
measured O 
by O 
radioimmunoassay O 
. O 
Both O 
ICI B-ABBREVIATION 
treatments O 
, O 
induced O 
a O 
significant O 
decrease O 
( O 
p O 
< O 
0.01 O 
) O 
in O 
uterine O 
estrogen B-FAMILY 
receptor O 
alpha O 
( O 
ERα O 
) O 
content O 
, O 
had O 
no O 
effect O 
on O 
uterine O 
progesterone B-TRIVIAL 
receptor O 
( O 
PR O 
) O 
protein O 
expression O 
and O 
caused O 
marked O 
nuclear O 
localization O 
of O 
cyclin O 
D1 O 
, O 
in O 
both O 
luminal O 
and O 
glandular O 
uterine O 
epithelium O 
, O 
as O 
compared O 
to O 
vehicle O 
- O 
treated O 
animals O 
. O 
Furthermore O 
, O 
we O 
detected O 
that O 
ICI B-ABBREVIATION 
treatment O 
induced O 
glycogen O 
synthase O 
kinase O 
( O 
Gsk3-β O 
) O 
Ser O 
9 O 
phosphorylation O 
, O 
which O 
correlates O 
with O 
cyclin O 
D1 O 
nuclear O 
localization O 
. O 
However O 
, O 
some O 
differences O 
were O 
observed O 
between O 
the O 
two O 
different O 
time O 
schedules O 
of O 
administration O 
. O 
We O 
observed O 
that O 
the O 
administration O 
of O 
ICI B-ABBREVIATION 
at O 
8 O 
: O 
00h O 
on O 
proestrus O 
day O 
produced O 
a O 
15% O 
inhibition O 
of O 
luminal O 
epithelial O 
cell O 
proliferation O 
, O 
reduced O 
uterine O 
wet O 
weight O 
by O 
21% O 
and O 
caused O 
reduction O 
of O 
Akt O 
phosphorylation O 
at O 
Ser B-FORMULA 
473 O 
as O 
compared O 
to O 
vehicle O 
- O 
treated O 
animals O 
, O 
whereas O 
ICI B-ABBREVIATION 
treatment O 
at O 
0 O 
: O 
00h O 
on O 
estrus O 
day O 
had O 
no O 
effect O 
on O 
these O 
parameters O 
. O 
The O 
overall O 
results O 
indicate O 
that O 
ICI B-ABBREVIATION 
may O 
exert O 
agonistic O 
and O 
antagonistic O 
effects O 
on O 
uterine O 
cell O 
proliferation O 
through O 
differential O 
activation O 
of O 
the O 
Akt O 
pathway O 
depending O 
on O 
the O 
administration O 
period O 
during O 
the O 
estrous O 
cycle O 
, O 
and O 
indicates O 
that O 
the O 
mechanism O 
of O 
cell O 
proliferation O 
during O 
the O 
physiological O 
conditions O 
of O 
the O 
estrous O 
cycle O 
, O 
is O 
under O 
a O 
different O 
and O 
more O 
complex O 
regulation O 
than O 
in O 
the O 
ovariectomized O 
+ O 
E2 O 
animal O 
model O 
. O 

penetration O 
enhancing O 
properties O 
of O 
the O 
plant O 
N-alkylamide B-FAMILY 
spilanthol I-FAMILY 
. O 

RELEVANCE O 
: O 
Plants O 
are O 
often O 
used O 
for O 
skin O 
diseases O 
in O 
different O 
ethnopharmacological O 
systems O 
. O 
Local O 
and O 
systemic O 
effects O 
of O 
topically O 
applied O 
compounds O 
can O 
be O 
significantly O 
increased O 
by O 
plant O 
constituents O 
having O 
skin O 
penetration O 
enhancers O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
In O 
this O 
study O 
, O 
we O 
examined O 
the O 
proposed O 
penetration O 
enhancing O 
properties O 
of O 
spilanthol B-TRIVIAL 
, O 
an O 
N-alkylamide B-FAMILY 
abundantly O 
present O 
in O 
several O 
Asteraceae O 
plants O 
like O 
Spilanthes O 
acmella O 
L O 
. O 
, O 
on O 
three O 
model O 
drugs O 
( O 
caffeine B-TRIVIAL 
, O 
testosterone B-TRIVIAL 
and O 
ibuprofen B-TRIVIAL 
) O 
. O 
Moreover O 
, O 
as O 
plants O 
are O 
frequently O 
contaminated O 
with O 
toxic O 
environmental O 
substances O 
, O 
the O 
mutual O 
influence O 
on O 
the O 
transdermal O 
behavior O 
between O 
spilanthol B-TRIVIAL 
and O 
six O 
model O 
mycotoxins O 
( O 
aflatoxin B-TRIVIAL 
B1 I-TRIVIAL 
, O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
, O 
fumonisin B-TRIVIAL 
B1 I-TRIVIAL 
, O 
citrinin B-TRIVIAL 
, O 
zearalenone B-TRIVIAL 
, O 
T-2 B-TRIVIAL 
toxin I-TRIVIAL 
) O 
was O 
investigated O 
. O 
RESULTS O 
: O 
Spilanthol B-TRIVIAL 
exhibits O 
component O 
and O 
concentration O 
dependent O 
penetration O 
enhancing O 
effects O 
. O 
No O 
significant O 
penetration O 
enhancing O 
effect O 
for O 
ibuprofen B-TRIVIAL 
has O 
been O 
observed O 
, O 
but O 
with O 
increasing O 
spilanthol B-TRIVIAL 
concentration O 
( O 
from O 
0 O 
up O 
to O 
1w O 
/ O 
V% O 
) O 
, O 
the O 
permeability O 
of O 
caffeine B-TRIVIAL 
increased O 
, O 
resulting O 
in O 
an O 
enhancing O 
ratio O 
( O 
ER O 
) O 
of O 
4.6 O 
. O 
For O 
testosterone B-TRIVIAL 
, O 
a O 
maximal O 
penetration O 
enhancing O 
concentration O 
of O 
0.5% O 
spilanthol B-TRIVIAL 
was O 
found O 
( O 
ER=4.13 O 
) O 
. O 
Next O 
to O 
its O 
beneficial O 
applicability O 
to O 
increase O 
local O 
as O 
well O 
as O 
systemic O 
pharmacological O 
effects O 
of O 
dermally O 
co O 
- O 
administrated O 
drug O 
, O 
this O 
N-alkylamide B-FAMILY 
negatively O 
influences O 
human O 
health O 
risk O 
if O 
spilanthol B-TRIVIAL 
containing O 
formulations O 
are O 
polluted O 
with O 
mycotoxins O 
: O 
the O 
presence O 
of O 
spilanthol B-TRIVIAL 
( O 
0.3w O 
/ O 
V% O 
) O 
induced O 
a O 
significant O 
increase O 
of O 
permeability O 
coefficient O 
Kp O 
of O 
five O 
investigated O 
mycotoxins O 
, O 
with O 
ER O 
values O 
ranging O 
between O 
1.57 O 
and O 
6.37 O 
. O 
On O 
the O 
other O 
hand O 
, O 
mycotoxins O 
themselves O 
do O 
not O 
significantly O 
influence O 
the O 
transdermal O 
behavior O 
of O 
spilanthol B-TRIVIAL 
. O 
CONCLUSIONS O 
: O 
The O 
existence O 
of O 
a O 
significant O 
mutual O 
influence O 
of O 
compounds O 
towards O 
skin O 
penetration O 
should O 
always O 
be O 
considered O 
during O 
the O 
development O 
or O 
as O 
part O 
of O 
the O 
functional O 
quality O 
evaluation O 
of O 
topical O 
products O 
. O 

nimodipine B-TRIVIAL 
delays O 
the O 
onset O 
of O 
methylmercury B-SYSTEMATIC 
neurotoxicity O 
in O 
mice O 
. O 

- O 
onset O 
exposure O 
is O 
thought O 
to O 
result O 
primarily O 
in O 
sensory O 
and O 
motor O 
deficits O 
but O 
effects O 
on O 
learning O 
are O 
poorly O 
understood O 
. O 
One O 
mechanism O 
by O 
which O 
chronic O 
MeHg B-FORMULA 
may O 
exert O 
its O 
neurotoxicity O 
is O 
via O 
sustained O 
disruption O 
of O 
intracellular O 
calcium B-SYSTEMATIC 
homeostasis O 
, O 
with O 
a O 
consequent O 
increase O 
of O 
intracellular O 
Ca(2+) B-FORMULA 
ions O 
in O 
vulnerable O 
neurons O 
. O 
A O 
biochemically O 
heterogeneous O 
group O 
of O 
compounds O 
, O 
calcium B-SYSTEMATIC 
channel O 
blockers O 
, O 
have O 
been O 
shown O 
in O 
vitro O 
to O 
attenuate O 
MeHg B-FORMULA 
' O 
s O 
toxicity O 
. O 
To O 
evaluate O 
the O 
role O 
of O 
calcium B-SYSTEMATIC 
antagonism O 
in O 
MeHg B-FORMULA 
toxicity O 
in O 
vivo O 
, O 
adult O 
BALB O 
/ O 
c O 
mice O 
were O 
exposed O 
chronically O 
to O 
0 O 
or O 
15ppm O 
of O 
Hg B-FORMULA 
( O 
as O 
MeHg B-FORMULA 
) O 
via O 
drinking O 
water O 
and O 
to O 
nimodipine B-TRIVIAL 
, O 
a O 
dihydropryidine B-SYSTEMATIC 
, O 
L- O 
type O 
Ca(2+) B-FORMULA 
channel O 
blocker O 
with O 
action O 
in O 
the O 
CNS O 
. O 
Nimodipine B-TRIVIAL 
was O 
administered O 
orally O 
in O 
diets O 
( O 
0 O 
, O 
20 O 
, O 
or O 
200ppm O 
, O 
producing O 
approximately O 
0 O 
, O 
2 O 
, O 
or O 
20mg O 
/ O 
kg O 
/ O 
day O 
of O 
nimodipine B-TRIVIAL 
) O 
. O 
An O 
incremental O 
repeated O 
acquisition O 
( O 
IRA O 
) O 
of O 
response O 
chains O 
procedure O 
was O 
used O 
to O 
detect O 
MeHg B-FORMULA 
-induced O 
deficits O 
in O 
learning O 
or O 
motoric O 
function O 
and O 
to O 
evaluate O 
possible O 
neuroprotection O 
by O 
nimodipine B-TRIVIAL 
. O 
MeHg B-FORMULA 
impaired O 
performance O 
on O 
the O 
IRA O 
task O 
, O 
and O 
this O 
was O 
partially O 
or O 
completely O 
blocked O 
by O 
dietary O 
nimodipine B-TRIVIAL 
, O 
depending O 
on O 
dose O 
. O 
Measures O 
of O 
learning O 
co O 
- O 
varied O 
with O 
measures O 
of O 
motoric O 
function O 
as O 
indicated O 
by O 
overall O 
response O 
rate O 
. O 
Nimodipine B-TRIVIAL 
delayed O 
or O 
prevented O 
the O 
behavioral O 
toxicity O 
of O 
MeHg B-FORMULA 
exposure O 
as O 
evidenced O 
by O 
IRA O 
performance O 
; O 
effects O 
on O 
learning O 
seemed O 
secondary O 
to O 
response O 
rate O 
decreases O 
. O 

and O 
subacute O 
toxicity O 
studies O 
on O 
triptolide B-TRIVIAL 
and O 
triptolide B-TRIVIAL 
-loaded O 
polymeric O 
micelles O 
following O 
intravenous O 
administration O 
in O 
rodents O 
. O 

its O 
anti-tumour O 
effects O 
, O 
triptolide B-TRIVIAL 
( O 
TP O 
) O 
also O 
shows O 
multiple O 
pharmacological O 
side O 
activities O 
, O 
such O 
as O 
immune O 
- O 
suppressive O 
and O 
male O 
anti-fertility O 
. O 
To O 
increase O 
the O 
therapeutic O 
index O 
of O 
TP O 
, O 
a O 
novel O 
polymeric O 
micelle O 
system O 
containing O 
TP O 
( O 
TP-PM O 
) O 
has O 
been O 
developed O 
to O 
treat O 
tumour O 
. O 
Our O 
previous O 
studies O 
have O 
demonstrated O 
the O 
good O 
anti-tumour O 
efficacy O 
of O 
TP-PM O 
. O 
This O 
paper O 
investigated O 
the O 
acute O 
toxicity O 
in O 
mice O 
and O 
subacute O 
toxicity O 
in O 
rats O 
of O 
TP-PM O 
and O 
TP O 
. O 
Results O 
demonstrated O 
that O 
the O 
LD50 O 
for O 
TP-PM O 
and O 
TP O 
administered O 
intravenously O 
were O 
1.06mg O 
/ O 
kg O 
and O 
0.83mg O 
/ O 
kg O 
in O 
mice O 
, O 
respectively O 
. O 
In O 
subacute O 
toxicity O 
study O 
, O 
TP-PM O 
and O 
TP O 
were O 
administered O 
intravenously O 
at O 
the O 
dose O 
levels O 
of O 
0.1mg O 
/ O 
kg O 
and O 
0.3mg O 
/ O 
kg O 
for O 
14d O 
. O 
Compared O 
to O 
the O 
control O 
, O 
there O 
was O 
significant O 
decrease O 
in O 
the O 
serum O 
AST O 
activities O 
, O 
the O 
testis O 
ACP O 
activities O 
, O 
thymus O 
index O 
, O 
testis O 
index O 
, O 
and O 
significant O 
increase O 
in O 
spleen O 
index O 
, O 
and O 
obvious O 
histopathological O 
changes O 
in O 
rats O 
treated O 
with O 
TP O 
, O 
however O 
, O 
the O 
toxicities O 
of O 
TP-PM O 
on O 
liver O 
, O 
kidney O 
, O 
testis O 
and O 
spleen O 
are O 
slighter O 
than O 
TP O 
. O 
Compared O 
to O 
TP O 
, O 
TP-PM O 
significantly O 
increased O 
the O 
ACP O 
activity O 
of O 
the O 
testis O 
and O 
decreased O 
the O 
MDA B-ABBREVIATION 
level O 
in O 
serum O 
. O 
So O 
, O 
the O 
polymeric O 
micelles O 
may O 
be O 
a O 
novel O 
drug O 
delivery O 
carrier O 
of O 
TP O 
for O 
reducing O 
the O 
toxicities O 
of O 
TP O 
. O 

activity O 
of O 
Cymbopogon O 
citratus O 
leaves O 
infusion O 
via O 
proteasome O 
and O 
nuclear O 
factor-κB O 
pathway O 
inhibition O 
: O 
Contribution O 
of O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
. O 

RELEVANCE O 
: O 
Cymbopogon O 
citratus O 
( O 
DC O 
) O 
Stapf O 
leaves O 
infusion O 
is O 
used O 
in O 
traditional O 
medicine O 
for O 
the O 
treatment O 
of O 
inflammatory O 
conditions O 
, O 
however O 
little O 
is O 
known O 
about O 
their O 
bio O 
- O 
active O 
compounds O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
Investigate O 
the O 
compounds O 
responsible O 
for O 
anti-inflammatory O 
potential O 
of O 
Cymbopogon O 
citratus O 
( O 
Cy O 
) O 
on O 
cytokines O 
production O 
induced O 
by O 
lipopolysaccharide O 
in O 
human O 
and O 
mouse O 
macrophages O 
, O 
and O 
the O 
action O 
mechanisms O 
involved O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
An O 
essential O 
oil O 
- O 
free O 
infusion O 
of O 
Cy O 
was O 
prepared O 
and O 
polyphenol B-FAMILY 
-rich O 
fractions O 
( O 
PFs O 
) O 
were O 
obtained O 
from O 
it O 
by O 
column O 
chromatography O 
. O 
Chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
was O 
identified O 
, O 
by O 
HPLC O 
/ O 
PDA O 
/ O 
ESI-MS(n) O 
. O 
The O 
expression O 
of O 
cytokines O 
, O 
namely O 
TNF-α O 
and O 
CCL5 O 
, O 
was O 
analyzed O 
by O 
real O 
- O 
time O 
RT-PCR O 
, O 
on O 
lipopolysaccharide-stimulated O 
human O 
macrophages O 
. O 
Activation O 
of O 
nuclear O 
factor-κB O 
, O 
a O 
master O 
regulator O 
of O 
inflammation O 
, O 
was O 
investigated O 
by O 
western O 
blot O 
and O 
gene O 
reporter O 
assay O 
. O 
Proteasome O 
activity O 
was O 
assessed O 
using O 
a O 
fluorogenic O 
peptide O 
. O 
RESULTS O 
: O 
Cymbopogon O 
citratus O 
extract O 
and O 
its O 
polyphenols B-FAMILY 
inhibited O 
the O 
cytokine O 
production O 
on O 
human O 
macrophages O 
. O 
This O 
supports O 
the O 
anti-inflammatory O 
activity O 
of O 
Cy O 
polyphenols B-FAMILY 
in O 
physiologically O 
relevant O 
cells O 
. O 
Concerning O 
the O 
effect O 
on O 
the O 
activation O 
of O 
nuclear O 
factor O 
(NF)-κB O 
pathway O 
, O 
the O 
results O 
pointed O 
to O 
an O 
inhibition O 
of O 
LPS-induced O 
NF-κB O 
activation O 
by O 
Cy O 
and O 
PFs O 
. O 
Chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
was O 
identified O 
, O 
by O 
HPLC O 
/ O 
PDA O 
/ O 
ESI-MS(n) O 
, O 
as O 
the O 
main O 
phenolic B-FAMILY 
acid I-FAMILY 
of O 
the O 
Cy O 
infusion O 
, O 
and O 
it O 
demonstrated O 
to O 
be O 
, O 
at O 
least O 
in O 
part O 
, O 
responsible O 
by O 
that O 
effect O 
. O 
Additionally O 
, O 
it O 
was O 
verified O 
for O 
the O 
first O 
time O 
that O 
Cy O 
and O 
PFs O 
inhibited O 
the O 
proteasome O 
activity O 
, O 
a O 
complex O 
that O 
controls O 
NF-κB O 
activation O 
, O 
having O 
CGA O 
a O 
strong O 
contribution O 
. O 
CONCLUSIONS O 
: O 
The O 
results O 
evidenced O 
, O 
for O 
the O 
first O 
time O 
, O 
the O 
anti-inflammatory O 
properties O 
of O 
Cymbopogon O 
citratus O 
through O 
proteasome O 
inhibition O 
and O 
, O 
consequently O 
NF-κB O 
pathway O 
and O 
cytokine O 
expression O 
. O 
Additionally O 
, O 
Cy O 
polyphenols B-FAMILY 
, O 
in O 
particular O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
, O 
were O 
highlighted O 
as O 
bio O 
- O 
active O 
compounds O 
. O 

RELEVANCE O 
: O 
In O 
traditional O 
Chinese O 
medicines O 
for O 
hepatic O 
fibrosis O 
therapy O 
, O 
Carapax O 
Trionycis O 
is O 
used O 
usually O 
as O 
an O 
indispensable O 
component O 
and O 
has O 
a O 
long O 
history O 
of O 
medical O 
use O 
in O 
China O 
. O 
Previous O 
studies O 
have O 
demonstrated O 
that O 
extracts O 
of O 
Carapax O 
Trionycis O 
were O 
able O 
to O 
protect O 
liver O 
against O 
fibrosis O 
in O 
CCl4 O 
animal O 
models O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
The O 
purpose O 
of O 
this O 
study O 
is O 
to O 
verify O 
the O 
inhibitory O 
effect O 
and O 
the O 
underlying O 
mechanisms O 
of O 
Carapax O 
Trionycis O 
extract O 
peptide O 
( O 
CTEP O 
) O 
on O 
activated O 
hepatic O 
stellate O 
cells O 
which O 
play O 
a O 
central O 
role O 
in O 
liver O 
fibrogenesis O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Hepatic O 
stellate O 
cells O 
induced O 
by O 
TGF-β1 O 
were O 
applied O 
to O 
evaluate O 
the O 
anti-fibrotic O 
effect O 
of O 
CTEP O 
in O 
vitro O 
. O 
MTS B-ABBREVIATION 
assay O 
, O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
and O 
western O 
blotting O 
were O 
then O 
used O 
to O 
further O 
investigate O 
the O 
molecular O 
mechanisms O 
. O 
RESULTS O 
: O 
The O 
results O 
show O 
that O 
the O 
contents O 
of O 
collagen O 
I O 
, O 
collagen O 
III O 
and O 
TIMP-1 O 
were O 
significantly O 
inhibited O 
and O 
the O 
level O 
of O 
collagen O 
I O 
, O 
collagen O 
III O 
, O 
p-Smad O 
3 O 
, O 
TIMP-1 O 
and O 
α-SMA O 
proteins O 
decreased O 
significantly O 
in O 
a O 
concentration O 
- O 
dependence O 
manner O 
after O 
treatment O 
with O 
CTEP O 
. O 
Interestingly O 
, O 
the O 
level O 
of O 
Smad O 
3 O 
protein O 
was O 
not O 
different O 
significantly O 
. O 
CONCLUSIONS O 
: O 
Our O 
data O 
indicate O 
that O 
CTEP O 
efficiently O 
inhibits O 
cultured O 
HSC-T6 O 
cell O 
activation O 
and O 
proliferation O 
via O 
the O 
TGF-β1 O 
/ O 
Smad O 
pathway O 
as O 
well O 
as O 
by O 
the O 
elimination O 
of O 
the O 
extracellular O 
matrix O 
. O 

, O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
new O 
classes O 
of O 
thieno[3,2-d]pyrimidinone B-SYSTEMATIC 
and O 
thieno[1,2,3]triazine B-SYSTEMATIC 
as O 
inhibitor O 
of O 
vascular O 
endothelial O 
growth O 
factor O 
receptor-2 O 
( O 
VEGFR-2 O 
) O 
. O 

by O 
a O 
multidisciplinary O 
approach O 
combination O 
( O 
Structure O 
- O 
Based O 
( O 
SB O 
) O 
Three-Dimensional O 
Quantitative O 
Structure-Activity O 
Relationships O 
( O 
3-D O 
QSAR O 
) O 
, O 
molecular O 
modeling O 
, O 
organic O 
chemistry O 
and O 
various O 
biological O 
evaluations O 
) O 
here O 
is O 
reported O 
the O 
disclosure O 
of O 
new O 
thienopyrimidines B-FAMILY 
1-3 O 
as O 
inhibitors O 
of O 
KDR O 
activity O 
and O 
human O 
umbilical O 
vein O 
endothelial O 
cell O 
( O 
HUVEC O 
) O 
proliferation O 
. O 
More O 
specifically O 
, O 
compound O 
2f O 
represents O 
a O 
new O 
lead O 
compound O 
that O 
inhibits O 
VEGFR-2 O 
and O 
HUVEC O 
at O 
μM O 
concentration O 
. O 
Moreover O 
by O 
the O 
mean O 
of O 
an O 
endothelial O 
cell O 
tube O 
formation O 
in O 
vitro O 
model O 
2f O 
tartaric B-TRIVIAL 
acid I-TRIVIAL 
salt O 
proved O 
to O 
block O 
angiogenesis O 
of O 
HUVEC O 
at O 
μM O 
level O 
. O 

acid I-TRIVIAL 
blocks O 
the O 
gap O 
junction O 
communication O 
between O 
the O 
retinal O 
pigment O 
epithelial O 
cells O 
. O 

: O 
Nonsteroidal O 
anti-inflammatory O 
drugs O 
( O 
NSAIDs O 
) O 
are O 
commonly O 
used O 
to O 
manage O 
the O 
pain O 
and O 
inflammation O 
. O 
NSAIDs O 
can O 
cause O 
serious O 
side O 
effects O 
, O 
including O 
vision O 
problems O 
. O 
However O 
, O 
the O 
underlying O 
mechanisms O 
are O 
still O 
unclear O 
. O 
Therefore O 
, O 
we O 
aimed O 
to O 
investigate O 
the O 
effect O 
of O 
meclofenamic B-TRIVIAL 
acid I-TRIVIAL 
( O 
MFA B-ABBREVIATION 
) O 
on O 
retinal O 
pigment O 
epithelium O 
( O 
RPE O 
) O 
. O 
Materials O 
and O 
methods O 
: O 
In O 
our O 
study O 
, O 
we O 
applied O 
image O 
analysis O 
and O 
whole O 
- O 
cell O 
patch O 
clamp O 
recording O 
to O 
directly O 
measure O 
the O 
effect O 
of O 
MFA B-ABBREVIATION 
on O 
the O 
gap O 
junctional O 
coupling O 
between O 
RPE O 
cells O 
. O 
Results O 
: O 
Analysis O 
of O 
Lucifer B-TRIVIAL 
yellow I-TRIVIAL 
( O 
LY O 
) O 
transfer O 
revealed O 
that O 
the O 
gap O 
junction O 
communication O 
existed O 
between O 
RPE O 
cells O 
. O 
Functional O 
experiments O 
using O 
the O 
whole O 
- O 
cell O 
configuration O 
of O 
the O 
patch O 
clamp O 
technique O 
showed O 
that O 
a O 
gap O 
junction O 
conductance O 
also O 
existed O 
between O 
this O 
kind O 
of O 
cells O 
. O 
Importantly O 
, O 
MFA B-ABBREVIATION 
largely O 
inhibited O 
the O 
gap O 
junction O 
conductance O 
and O 
induced O 
the O 
uncoupling O 
of O 
RPE O 
cells.Other O 
NSAIDs O 
, O 
like O 
aspirin B-TRIVIAL 
and O 
flufenamic B-TRIVIAL 
acid I-TRIVIAL 
( O 
FFA B-ABBREVIATION 
) O 
, O 
had O 
the O 
same O 
effect O 
. O 
Conclusion O 
: O 
The O 
gap O 
junction O 
functionally O 
existed O 
in O 
RPE O 
cells O 
, O 
which O 
can O 
be O 
blocked O 
by O 
MFA B-ABBREVIATION 
. O 
These O 
findings O 
may O 
explain O 
, O 
at O 
least O 
partially O 
, O 
the O 
vision O 
problems O 
with O 
certain O 
clinically O 
used O 
NSAIDs O 
. O 

rate O 
( O 
HR O 
) O 
predicts O 
cardiovascular O 
morbidity O 
and O 
mortality O 
in O 
individuals O 
either O 
with O 
or O 
without O 
diabetes O 
. O 
In O 
type O 
2 O 
diabetic O 
patients O 
, O 
cardiac O 
autonomic O 
neuropathy O 
is O 
a O 
risk O 
marker O 
for O 
cardiac O 
morbidity O 
and O 
mortality O 
. O 
A O 
major O 
pathogenic O 
potential O 
may O 
be O 
attributed O 
to O 
vagal O 
depression O 
and O 
sympathetic O 
predominance O 
. O 
In O 
this O 
issue O 
of O 
Diabetologia O 
, O 
Berkelaar O 
et O 
al O 
( O 
DOI O 
: O 
10.1007 O 
/ O 
s00125-013-2848-6 O 
) O 
examined O 
the O 
effects O 
of O 
euglycaemic O 
, O 
and O 
hyperglycaemic O 
clamp O 
with O 
the O 
addition O 
of O 
glucagon O 
- O 
like O 
- O 
peptide-1 O 
( O 
GLP-1 O 
) O 
and O 
arginine B-TRIVIAL 
, O 
on O 
cardiac O 
vagal O 
control O 
in O 
a O 
large O 
number O 
of O 
healthy O 
subjects O 
. O 
After O 
adjustments O 
for O 
age O 
, O 
BMI O 
and O 
insulin O 
sensitivity O 
, O 
insulin O 
associations O 
with O 
HR O 
remained O 
partially O 
intact O 
while O 
those O 
with O 
vagal O 
control O 
disappeared O 
. O 
This O 
suggested O 
that O 
BMI O 
and O 
insulin O 
sensitivity O 
, O 
but O 
not O 
insulin O 
levels O 
, O 
were O 
the O 
main O 
drivers O 
of O 
cardiac O 
vagal O 
control O 
. O 
GLP-1 O 
infusion O 
during O 
hyperglycaemia O 
increased O 
HR O 
and O 
BP O 
and O 
produced O 
a O 
statistically O 
non-significant O 
decrease O 
in O 
measures O 
of O 
cardiac O 
vagal O 
control O 
compared O 
with O 
values O 
before O 
any O 
manipulation O 
of O 
insulin O 
levels O 
. O 
This O 
commentary O 
summarises O 
how O 
, O 
and O 
to O 
what O 
extent O 
, O 
insulin O 
and O 
GLP-1 O 
affect O 
autonomic O 
nervous O 
system O 
activity O 
, O 
HR O 
and O 
BP O 
. O 
More O 
information O 
is O 
needed O 
on O 
the O 
mechanisms O 
through O 
which O 
acute O 
administration O 
of O 
, O 
and O 
long O 
- O 
term O 
treatment O 
with O 
, O 
GLP-1 O 
may O 
affect O 
haemodynamics O 
and O 
autonomic O 
activity O 
in O 
diabetic O 
and O 
obese O 
patients O 
, O 
since O 
this O 
may O 
influence O 
cardiovascular O 
outcomes O 
. O 

of O 
copper B-SYSTEMATIC 
(II) I-SYSTEMATIC 
complexes O 
of O 
curcumin B-TRIVIAL 
and O 
N-ferrocenylmethyl-l-amino B-FAMILY 
acids I-FAMILY 
. O 

(II) I-SYSTEMATIC 
complexes O 
[Cu(Fc-aa)(cur)] B-FORMULA 
( O 
1-3 O 
) O 
of O 
curcumin B-TRIVIAL 
( O 
Hcur B-ABBREVIATION 
) O 
and O 
N-ferrocenylmethyl-l-amino B-FAMILY 
acids I-FAMILY 
( O 
Fc-aa B-ABBREVIATION 
) O 
, O 
viz O 
. O 
, O 
ferrocenylmethyl-l-tyrosine B-SYSTEMATIC 
( O 
Fc-TyrH B-ABBREVIATION 
) O 
, O 
ferrocenylmethyl-l-tryptophan B-SYSTEMATIC 
( O 
Fc-TrpH B-ABBREVIATION 
) O 
and O 
ferrocenylmethyl-l-methionine B-SYSTEMATIC 
( O 
Fc-MetH B-ABBREVIATION 
) O 
, O 
were O 
prepared O 
and O 
characterized O 
. O 
The O 
DNA O 
photocleavage O 
activity O 
, O 
photocytotoxicity O 
and O 
cellular O 
localization O 
in O 
HeLa O 
and O 
MCF-7 O 
cancer O 
cells O 
of O 
these O 
complexes O 
were O 
studied O 
. O 
Acetylacetonate B-SYSTEMATIC 
( O 
acac B-ABBREVIATION 
) O 
complexes O 
[Cu(Fc-aa)(acac)] B-FORMULA 
( O 
4-6 O 
) O 
were O 
prepared O 
and O 
used O 
as O 
controls O 
. O 
The O 
chemical O 
nuclease O 
inactive O 
complexes O 
showed O 
efficient O 
pUC19 O 
DNA O 
cleavage O 
activity O 
in O 
visible O 
light O 
. O 
Complexes O 
1-3 O 
showed O 
high O 
photocytotoxicity O 
with O 
low O 
dark O 
toxicity O 
thus O 
giving O 
remarkable O 
photodynamic O 
effect O 
. O 
FACScan O 
analysis O 
showed O 
apoptosis O 
of O 
the O 
cancer O 
cells O 
. O 
Fluorescence O 
microscopic O 
studies O 
revealed O 
primarily O 
cytosolic O 
localization O 
of O 
the O 
complexes O 
. O 

-Lipid O 
Hybrids O 
Enhance O 
Chemotherapeutic O 
Tolerance O 
and O 
Mediate O 
Tumor O 
Regression O 
. O 

- O 
assembled O 
nanodiamond O 
- O 
lipid O 
hybrid O 
particles O 
( O 
NDLPs O 
) O 
harness O 
the O 
potent O 
interaction O 
between O 
the O 
nanodiamond O 
(ND)-surface O 
and O 
small O 
molecules O 
, O 
while O 
providing O 
a O 
mechanism O 
for O 
cell O 
- O 
targeted O 
imaging O 
and O 
therapy O 
of O 
triple O 
negative O 
breast O 
cancers O 
. O 
Epidermal O 
growth O 
factor O 
receptor O 
- O 
targeted O 
NDLPs O 
are O 
highly O 
biocompatible O 
particles O 
that O 
provide O 
cell O 
- O 
specific O 
imaging O 
, O 
promote O 
tumor O 
retention O 
of O 
ND O 
- O 
complexes O 
, O 
prevent O 
epirubicin B-TRIVIAL 
toxicities O 
and O 
mediate O 
regression O 
of O 
triple O 
negative O 
breast O 
cancers O 
. O 

Oxidation O 
by O 
an O 
Immobilized O 
Nickel B-SYSTEMATIC 
Complex O 
Catalyst O 
: O 
Structural O 
and O 
Reactivity O 
Differences O 
Induced O 
by O 
Surface O 
- O 
Ligand O 
Density O 
on O 
Mesoporous O 
Silica B-TRIVIAL 
. O 

nickel B-SYSTEMATIC 
catalysts O 
SBA*-L-x/ O 
Ni B-FORMULA 
( O 
L= O 
bis(2-pyridylmethyl)(1H-1,2,3-triazol-4-ylmethyl)amine B-SYSTEMATIC 
) O 
with O 
various O 
ligand O 
densities O 
( O 
L O 
content O 
(x)=0.5 O 
, O 
1 O 
, O 
2 O 
, O 
4 O 
mol O 
% O 
Si B-FORMULA 
) O 
have O 
been O 
prepared O 
from O 
azidopropyl B-SYSTEMATIC 
-functionalized O 
mesoporous O 
silicas B-TRIVIAL 
SBA-N3 O 
-x O 
. O 
Related O 
homogeneous O 
ligand O 
L(t) B-FORMULA 
( I-FORMULA 
Bu I-FORMULA 
) I-FORMULA 
and O 
its O 
Ni B-FORMULA 
(II) I-FORMULA 
complexes O 
, O 
[ B-FORMULA 
Ni(L(t) I-FORMULA 
( I-FORMULA 
Bu I-FORMULA 
) I-FORMULA 
)(OAc)2 I-FORMULA 
( I-FORMULA 
H2 I-FORMULA 
O I-FORMULA 
) I-FORMULA 
] I-FORMULA 
( I-FORMULA 
L(t) I-FORMULA 
( I-FORMULA 
Bu I-FORMULA 
) I-FORMULA 
/ I-FORMULA 
Ni I-FORMULA 
) I-FORMULA 
and O 
[ B-FORMULA 
Ni(L(t) I-FORMULA 
( I-FORMULA 
Bu I-FORMULA 
) I-FORMULA 
)2 I-FORMULA 
]BF4 I-FORMULA 
( I-FORMULA 
2 I-FORMULA 
L(t) I-FORMULA 
( I-FORMULA 
Bu I-FORMULA 
) I-FORMULA 
/ I-FORMULA 
Ni I-FORMULA 
) I-FORMULA 
, O 
have O 
been O 
synthesized O 
. O 
The O 
L/ O 
Ni B-FORMULA 
ratio O 
( O 
0.9-1.7 O 
: O 
1 O 
) O 
in O 
SBA*-L-x/ O 
Ni B-FORMULA 
suggests O 
the O 
formation O 
of O 
an O 
inert O 
[ O 
NiL2 B-FAMILY 
] O 
site O 
on O 
the O 
surface O 
at O 
higher O 
ligand O 
loadings O 
. O 
SBA*-L-x/ O 
Ni B-FORMULA 
has O 
been O 
applied O 
to O 
the O 
catalytic O 
oxidation O 
of O 
cyclohexane B-SYSTEMATIC 
with O 
m-chloroperbenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
mCPBA B-ABBREVIATION 
) O 
. O 
The O 
catalyst O 
with O 
the O 
lowest O 
loading O 
shows O 
high O 
activity O 
in O 
its O 
initial O 
use O 
as O 
the O 
homogeneous O 
L(t) B-FORMULA 
( I-FORMULA 
Bu I-FORMULA 
) I-FORMULA 
/ O 
Ni B-FORMULA 
catalyst O 
, O 
with O 
some O 
metal O 
leaching O 
. O 
As O 
the O 
ligand O 
loading O 
increases O 
, O 
the O 
activity O 
and O 
Ni B-FORMULA 
leaching O 
are O 
suppressed O 
. O 
The O 
importance O 
of O 
site O 
- O 
density O 
control O 
for O 
the O 
development O 
of O 
immobilized O 
catalysts O 
has O 
been O 
demonstrated O 
. O 

: O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
develop O 
a O 
discrete O 
- O 
time O 
simulation O 
model O 
for O 
people O 
with O 
type O 
1 O 
diabetes O 
mellitus O 
, O 
to O 
estimate O 
and O 
compare O 
mean O 
life O 
expectancy O 
and O 
quality O 
- O 
adjusted O 
life O 
- O 
years O 
( O 
QALYs O 
) O 
over O 
a O 
lifetime O 
between O 
intensive O 
and O 
conventional O 
blood O 
glucose B-TRIVIAL 
treatment O 
groups O 
. O 
METHODS O 
: O 
We O 
synthesized O 
evidence O 
on O 
type O 
1 O 
diabetes O 
patients O 
using O 
several O 
published O 
sources O 
. O 
The O 
simulation O 
model O 
was O 
based O 
on O 
13 O 
equations O 
to O 
estimate O 
risks O 
of O 
events O 
and O 
mortality O 
. O 
Cardiovascular O 
disease O 
( O 
CVD O 
) O 
risk O 
was O 
obtained O 
from O 
results O 
of O 
the O 
DCCT O 
( O 
diabetes O 
control O 
and O 
complications O 
trial O 
) O 
. O 
Mortality O 
post-CVD O 
event O 
was O 
based O 
on O 
a O 
study O 
using O 
linked O 
administrative O 
data O 
on O 
people O 
with O 
diabetes O 
from O 
Western O 
Australia O 
. O 
Information O 
on O 
incidence O 
of O 
renal O 
disease O 
and O 
the O 
progression O 
to O 
CVD O 
was O 
obtained O 
from O 
studies O 
in O 
Finland O 
and O 
Italy O 
. O 
Lower O 
- O 
extremity O 
amputation O 
( O 
LEA O 
) O 
risk O 
was O 
based O 
on O 
the O 
type O 
1 O 
diabetes O 
Swedish O 
inpatient O 
registry O 
, O 
and O 
the O 
risk O 
of O 
blindness O 
was O 
obtained O 
from O 
results O 
of O 
a O 
German O 
- O 
based O 
study O 
. O 
Where O 
diabetes O 
- O 
specific O 
data O 
were O 
unavailable O 
, O 
information O 
from O 
other O 
populations O 
was O 
used O 
. O 
We O 
examine O 
the O 
degree O 
and O 
source O 
of O 
parameter O 
uncertainty O 
and O 
illustrate O 
an O 
application O 
of O 
the O 
model O 
in O 
estimating O 
lifetime O 
outcomes O 
of O 
using O 
intensive O 
and O 
conventional O 
treatments O 
for O 
blood O 
glucose B-TRIVIAL 
control O 
. O 
RESULTS O 
: O 
From O 
15 O 
years O 
of O 
age O 
, O 
male O 
and O 
female O 
patients O 
had O 
an O 
estimated O 
life O 
expectancy O 
of O 
47.2 O 
( O 
95 O 
% O 
CI O 
35.2-59.2 O 
) O 
and O 
52.7 O 
( O 
95 O 
% O 
CI O 
41.7-63.6) O 
years O 
in O 
the O 
intensive O 
treatment O 
group O 
. O 
The O 
model O 
produced O 
estimates O 
of O 
the O 
lifetime O 
benefits O 
of O 
intensive O 
treatment O 
for O 
blood O 
glucose B-TRIVIAL 
from O 
the O 
DCCT O 
of O 
4 O 
( O 
95 O 
% O 
CI O 
1.2-6.8 O 
) O 
QALYs O 
for O 
women O 
and O 
4.6 O 
( O 
95 O 
% O 
CI O 
2.7-6.9 O 
) O 
QALYs O 
for O 
men O 
. O 
Absolute O 
risk O 
per O 
1000 O 
person O 
- O 
years O 
for O 
fatal O 
CVD O 
events O 
was O 
simulated O 
to O 
be O 
1.37 O 
and O 
2.51 O 
in O 
intensive O 
and O 
conventional O 
treatment O 
groups O 
, O 
respectively O 
. O 
CONCLUSIONS O 
: O 
The O 
model O 
incorporates O 
diabetic O 
complications O 
risk O 
data O 
from O 
a O 
type O 
1 O 
diabetes O 
population O 
and O 
synthesizes O 
other O 
type O 
1-specific O 
data O 
to O 
estimate O 
long O 
- O 
term O 
outcomes O 
of O 
CVD O 
, O 
end O 
- O 
stage O 
renal O 
disease O 
, O 
LEA O 
and O 
risk O 
of O 
blindness O 
, O 
along O 
with O 
life O 
expectancy O 
and O 
QALYs O 
. O 
External O 
validation O 
was O 
carried O 
out O 
using O 
life O 
expectancy O 
and O 
absolute O 
risk O 
for O 
fatal O 
CVD O 
events O 
. O 
Because O 
of O 
the O 
flexible O 
and O 
transparent O 
nature O 
of O 
the O 
model O 
, O 
it O 
has O 
many O 
potential O 
future O 
applications O 
. O 

reduces O 
lipid O 
accumulation O 
in O 
C57BL O 
/ O 
6 O 
mice O 
with O 
lower O 
body O 
weight O 
gain O 
. O 

( O 
tBHQ B-ABBREVIATION 
) O 
is O 
a O 
commonly O 
used O 
antioxidant O 
additive O 
that O 
is O 
approved O 
for O 
human O 
use O 
by O 
both O 
the O 
Food O 
and O 
Agriculture O 
Organization O 
and O 
the O 
World O 
Health O 
Organization O 
( O 
FAO O 
/ O 
WHO O 
) O 
. O 
In O 
this O 
study O 
, O 
we O 
examined O 
the O 
effect O 
of O 
tBHQ B-ABBREVIATION 
on O 
body O 
weight O 
gain O 
and O 
found O 
that O 
food O 
supplementation O 
with O 
0.001 O 
% O 
( O 
w O 
/ O 
w O 
) O 
tBHQ B-ABBREVIATION 
inhibited O 
61.4 O 
% O 
( O 
P O 
< O 
0.01 O 
) O 
of O 
body O 
weight O 
gain O 
in O 
high O 
- O 
fat O 
diet O 
(HFD)-induced O 
C57BL O 
/ O 
6 O 
mice O 
, O 
and O 
the O 
oral O 
administration O 
of O 
tBHQ B-ABBREVIATION 
( O 
1.5 O 
mg O 
/ O 
kg O 
) O 
reduced O 
47.5 O 
% O 
( O 
P O 
< O 
0.05 O 
) O 
of O 
body O 
weight O 
gain O 
in O 
normal O 
diet O 
fed O 
db O 
/ O 
db O 
mice O 
. O 
The O 
HFD O 
increased O 
lipid O 
deposit O 
in O 
adipocytes O 
, O 
but O 
these O 
were O 
reduced O 
significantly O 
by O 
tBHQ B-ABBREVIATION 
treatment O 
in O 
C57BL O 
/ O 
6 O 
mice O 
. O 
tBHQ B-ABBREVIATION 
supplementation O 
significantly O 
lowered O 
the O 
plasma O 
triglyceride B-FAMILY 
and O 
total O 
cholesterol B-TRIVIAL 
, O 
with O 
reduced O 
size O 
of O 
accumulated O 
fat O 
mass O 
. O 
The O 
rate O 
limiting O 
enzyme O 
of O 
beta-oxidation O 
( O 
ACOX1 O 
) O 
was O 
significantly O 
over O 
- O 
expressed O 
in O 
the O 
liver O 
with O 
tBHQ B-ABBREVIATION 
treatment O 
. O 
These O 
results O 
indicate O 
that O 
tBHQ B-ABBREVIATION 
suppresses O 
body O 
weight O 
gain O 
in O 
mice O 
, O 
possibly O 
at O 
least O 
related O 
to O 
the O 
up O 
- O 
regulation O 
of O 
ACOX1 O 
gene O 
expression O 
. O 

Assays O 
of O 
Protein O 
and O 
Glucose B-TRIVIAL 
with O 
Functionalized O 
Core O 
/ O 
Shell O 
Particles O 
Based O 
on O 
Magnetic O 
Separation O 
and O 
Surface-Enhanced O 
Raman O 
Scattering O 
. O 

assays O 
of O 
protein O 
and O 
glucose B-TRIVIAL 
in O 
combination O 
with O 
mannose B-TRIVIAL 
-functionalized O 
Fe3 B-FORMULA 
O4 I-FORMULA 
@ O 
SiO2 B-FORMULA 
and O 
Ag B-FORMULA 
@ O 
SiO2 B-FORMULA 
tag O 
particles O 
have O 
promising O 
potential O 
in O 
effective O 
magnetic O 
separation O 
and O 
highly O 
sensitive O 
and O 
selective O 
SERS O 
assays O 
of O 
biomaterials O 
. O 
It O 
is O 
for O 
the O 
first O 
time O 
that O 
tandem O 
assay O 
of O 
glucose B-TRIVIAL 
is O 
developed O 
using O 
SERS O 
based O 
on O 
the O 
Con O 
A-sandwiched O 
microstructures O 
between O 
the O 
functionalized O 
magnetic O 
and O 
tag O 
particles O 
. O 

have O 
employed O 
in O 
situ O 
X-ray O 
reflectivity O 
( O 
IXRR O 
) O 
to O 
study O 
the O 
adsorption O 
of O 
a O 
variety O 
of O 
proteins O 
( O 
lysozyme O 
, O 
cytochrome O 
c O 
, O 
myoglobin O 
, O 
hemoglobin O 
, O 
serum O 
albumin O 
, O 
and O 
immunoglobulin O 
G O 
) O 
on O 
model O 
hydrophilic O 
( O 
silicon B-SYSTEMATIC 
oxide I-SYSTEMATIC 
) O 
and O 
hydrophobic O 
surfaces O 
( O 
octadecyltrichlorosilane B-SYSTEMATIC 
self O 
- O 
assembled O 
monolayers O 
) O 
, O 
evaluating O 
this O 
recently O 
developed O 
technique O 
for O 
its O 
applicability O 
in O 
the O 
area O 
of O 
biomolecular O 
studies O 
. O 
We O 
report O 
herein O 
the O 
highest O 
resolution O 
depiction O 
of O 
adsorbed O 
protein O 
films O 
, O 
greatly O 
improving O 
on O 
the O 
precision O 
of O 
previous O 
neutron O 
reflectivity O 
( O 
NR O 
) O 
results O 
and O 
previous O 
IXRR O 
studies O 
. O 
We O 
were O 
able O 
to O 
perform O 
complete O 
scans O 
in O 
5 O 
min O 
or O 
less O 
with O 
the O 
maximum O 
momentum O 
transfer O 
of O 
at O 
least O 
0.52 O 
Å(-1) O 
, O 
allowing O 
for O 
some O 
time O 
- O 
resolved O 
information O 
about O 
the O 
evolution O 
of O 
the O 
protein O 
film O 
structure O 
. O 
The O 
three O 
smallest O 
proteins O 
( O 
lysozyme O 
, O 
cytochrome O 
c O 
, O 
and O 
myoglobin O 
) O 
were O 
seen O 
to O 
deposit O 
as O 
fully O 
hydrated O 
, O 
nondenatured O 
molecules O 
onto O 
hydrophilic O 
surfaces O 
, O 
with O 
indications O 
of O 
particular O 
preferential O 
orientations O 
. O 
Time O 
evolution O 
was O 
observed O 
for O 
both O 
lysozyme O 
and O 
myoglobin O 
films O 
. O 
The O 
larger O 
proteins O 
were O 
not O 
observed O 
to O 
deposit O 
on O 
the O 
hydrophilic O 
substrates O 
, O 
perhaps O 
because O 
of O 
contrast O 
limitations O 
. O 
On O 
hydrophobic O 
surfaces O 
, O 
all O 
proteins O 
were O 
seen O 
to O 
denature O 
extensively O 
in O 
a O 
qualitatively O 
similar O 
way O 
but O 
with O 
a O 
rough O 
trend O 
that O 
the O 
larger O 
proteins O 
resulted O 
in O 
lower O 
coverage O 
. O 
We O 
have O 
generated O 
high O 
- O 
resolution O 
electron O 
density O 
profiles O 
of O 
these O 
denatured O 
films O 
, O 
including O 
capturing O 
the O 
growth O 
of O 
a O 
lysozyme O 
film O 
. O 
Because O 
the O 
solution O 
interface O 
of O 
these O 
denatured O 
films O 
is O 
diffuse O 
, O 
IXRR O 
cannot O 
unambiguously O 
determine O 
the O 
film O 
extent O 
and O 
coverage O 
, O 
a O 
drawback O 
compared O 
to O 
NR O 
. O 
X-ray O 
radiation O 
damage O 
was O 
systematically O 
evaluated O 
, O 
including O 
the O 
controlled O 
exposure O 
of O 
protein O 
films O 
to O 
high O 
- O 
intensity O 
X-rays O 
and O 
exposure O 
of O 
the O 
hydrophobic O 
surface O 
to O 
X-rays O 
before O 
adsorption O 
. O 
Our O 
analysis O 
showed O 
that O 
standard O 
measuring O 
procedures O 
used O 
for O 
XRR O 
studies O 
may O 
lead O 
to O 
altered O 
protein O 
films O 
; O 
therefore O 
, O 
we O 
used O 
modified O 
procedures O 
to O 
limit O 
the O 
influence O 
of O 
X-ray O 
damage O 
. O 

Determination O 
of O 
Lateral O 
Concentration O 
and O 
Depth O 
Profile O 
of O 
Histidine B-TRIVIAL 
-Tagged O 
Recombinant O 
Proteins O 
Probed O 
by O 
Grazing O 
Incidence O 
X-ray O 
Fluorescence O 
. O 

have O 
demonstrated O 
that O 
the O 
complementary O 
combination O 
of O 
grazing O 
incidence O 
X-ray O 
fluorescence O 
( O 
GIXF O 
) O 
with O 
specular O 
X-ray O 
reflectivity O 
( O 
XRR O 
) O 
can O 
be O 
used O 
to O 
quantitatively O 
determine O 
the O 
density O 
profiles O 
of O 
Ni(2)(+) B-FORMULA 
ions O 
complexed O 
with O 
chelator O 
headgroups O 
as O 
well O 
as O 
S B-FORMULA 
atoms O 
in O 
recombinant O 
proteins O 
anchored O 
to O 
lipid O 
monolayers O 
at O 
the O 
air O 
/ O 
water O 
interface O 
. O 
First O 
, O 
we O 
prepared O 
phospholipid O 
monolayers O 
incorporating O 
chelator O 
lipid O 
anchors O 
at O 
different O 
molar O 
fractions O 
at O 
the O 
air O 
/ O 
water O 
interface O 
. O 
The O 
fine O 
- O 
structures O 
perpendicular O 
to O 
the O 
global O 
plane O 
of O 
monolayers O 
were O 
characterized O 
by O 
XRR O 
in O 
the O 
presence O 
of O 
Ni(2)(+) B-FORMULA 
ions O 
, O 
yielding O 
the O 
thickness O 
, O 
roughness O 
, O 
and O 
electron O 
density O 
of O 
the O 
stratified O 
lipid O 
monolayers O 
. O 
X-ray O 
fluorescence O 
intensities O 
from O 
Ni B-FORMULA 
Kα O 
core O 
levels O 
recorded O 
at O 
the O 
incidence O 
angles O 
below O 
and O 
above O 
the O 
critical O 
angle O 
of O 
total O 
reflection O 
allow O 
for O 
the O 
determination O 
of O 
the O 
position O 
and O 
lateral O 
density O 
of O 
Ni(2)(+) B-FORMULA 
ions O 
associated O 
with O 
chelator O 
headgroups O 
with O 
a O 
high O 
spatial O 
accuracy O 
( O 
±5 O 
Å O 
) O 
. O 
The O 
coupling O 
of O 
histidine B-TRIVIAL 
-tagged O 
Xenopus O 
cadherin O 
11 O 
( O 
Xcad-11 O 
) O 
can O 
also O 
be O 
identified O 
by O 
changes O 
in O 
the O 
fines O 
- O 
structures O 
using O 
XRR O 
. O 
Although O 
fluorescence O 
intensities O 
from O 
S B-FORMULA 
Kα O 
level O 
were O 
much O 
weaker O 
than O 
Ni B-FORMULA 
Kα O 
signals O 
, O 
we O 
could O 
detect O 
the O 
location O 
of O 
S B-FORMULA 
atoms O 
in O 
recombinant O 
Xcad-11 O 
proteins O 
. O 

Based O 
Approach O 
to O 
L- O 
Type O 
Calcium B-SYSTEMATIC 
Channel O 
by O 
Imidazo[2,1-b]thiazole-1,4-Dihydropyridines B-FAMILY 
: O 
from O 
Heart O 
Activity O 
to O 
Brain O 
Affinity O 
. O 

synthesis O 
, O 
characterization O 
, O 
and O 
functional O 
in O 
vitro O 
assay O 
in O 
cardiac O 
and O 
smooth O 
muscle O 
( O 
vascular O 
and O 
nonvascular O 
) O 
of O 
a O 
series O 
of O 
4-imidazo[2,1-b]thiazole-1,4-dihydropyridines B-FAMILY 
are O 
reported O 
. O 
To O 
define O 
the O 
calcium B-SYSTEMATIC 
blocker O 
nature O 
of O 
the O 
imidazo[2,1-b]thiazole-1,4-DHPs B-FAMILY 
and O 
their O 
selectivity O 
on O 
Cav1.2 O 
and O 
Cav1.3 O 
isoforms O 
we O 
performed O 
binding O 
studies O 
on O 
guinea O 
pig O 
atrial O 
and O 
ventricular O 
membranes O 
, O 
on O 
intact O 
cells O 
expressing O 
the O 
cloned O 
Cav1.2a O 
subunit O 
and O 
on O 
rat O 
brain O 
cortex O 
. O 
To O 
get O 
major O 
insights O 
into O 
the O 
reasons O 
for O 
the O 
affinity O 
for O 
Cav1.2 O 
and O 
/ O 
or O 
Cav1.3 O 
molecular O 
modelling O 
studies O 
were O 
also O 
undertaken O 
. O 
Some O 
physicochemical O 
and O 
pharmacokinetic O 
properties O 
of O 
selected O 
compounds O 
were O 
calculated O 
and O 
compared O 
. O 
All O 
the O 
biological O 
data O 
collected O 
and O 
reported O 
herein O 
allowed O 
us O 
to O 
rationalize O 
the O 
structure O 
- O 
activity O 
relationship O 
of O 
the O 
4-imidazo[2,1-b]thiazole-1,4-DHPs B-FAMILY 
and O 
to O 
identify O 
which O 
of O 
these O 
enhanced O 
the O 
activity O 
at O 
the O 
central O 
level O 
. O 

and O 
cost O 
- O 
effective O 
conversion O 
of O 
solar O 
energy O 
to O 
useful O 
chemicals O 
and O 
fuels O 
could O 
lead O 
to O 
a O 
significant O 
reduction O 
in O 
fossil O 
hydrocarbon B-FAMILY 
use O 
. O 
Artificial O 
systems O 
that O 
use O 
solar O 
energy O 
to O 
produce O 
chemicals O 
have O 
been O 
reported O 
for O 
more O 
than O 
a O 
century O 
. O 
However O 
the O 
most O 
efficient O 
devices O 
demonstrated O 
, O 
based O 
on O 
traditionally O 
fabricated O 
compound O 
semiconductors O 
, O 
have O 
extremely O 
short O 
working O 
lifetimes O 
due O 
to O 
photocorrosion O 
by O 
the O 
electrolyte O 
. O 
Here O 
we O 
report O 
a O 
stable O 
, O 
scalable O 
design O 
and O 
molecular O 
level O 
fabrication O 
strategy O 
to O 
create O 
photoelectrochemically O 
active O 
heterostructure O 
( O 
PAH O 
) O 
units O 
consisting O 
of O 
an O 
efficient O 
semiconductor O 
light O 
absorber O 
in O 
contact O 
with O 
oxidation O 
and O 
reduction O 
electrocatalysts O 
and O 
otherwise O 
protected O 
by O 
alumina B-TRIVIAL 
. O 
The O 
functional O 
heterostructures O 
are O 
fabricated O 
by O 
layer O 
- O 
by O 
- O 
layer O 
, O 
template O 
- O 
directed O 
, O 
electrochemical O 
synthesis O 
in O 
porous O 
anodic O 
aluminum B-SYSTEMATIC 
oxide I-SYSTEMATIC 
membranes O 
to O 
produce O 
high O 
density O 
arrays O 
of O 
electronically O 
autonomous O 
, O 
nanostructured O 
, O 
corrosion O 
resistant O 
, O 
photoactive O 
units O 
( O 
∼10(9)-10(10) O 
PAHs O 
per O 
cm(2) O 
) O 
. O 
Each O 
PAH O 
unit O 
is O 
isolated O 
from O 
its O 
neighbor O 
by O 
the O 
transparent O 
electrically O 
insulating O 
oxide B-SYSTEMATIC 
cellular O 
enclosure O 
that O 
makes O 
the O 
overall O 
assembly O 
fault O 
tolerant O 
. O 
When O 
illuminated O 
with O 
visible O 
light O 
, O 
the O 
free O 
floating O 
devices O 
have O 
been O 
demonstrated O 
to O 
produce O 
hydrogen B-SYSTEMATIC 
at O 
a O 
stable O 
rate O 
for O 
over O 
24 O 
h O 
in O 
corrosive O 
hydroiodic B-SYSTEMATIC 
acid I-SYSTEMATIC 
electrolyte O 
with O 
light O 
as O 
the O 
only O 
input O 
. O 
The O 
quantum O 
efficiency O 
( O 
averaged O 
over O 
the O 
solar O 
spectrum O 
) O 
for O 
absorbed O 
photons-to- O 
hydrogen B-SYSTEMATIC 
conversion O 
was O 
7.4% O 
and O 
solar-to- O 
hydrogen B-SYSTEMATIC 
energy O 
efficiency O 
of O 
incident O 
light O 
was O 
0.9% O 
. O 
The O 
fabrication O 
approach O 
is O 
scalable O 
for O 
commercial O 
manufacturing O 
and O 
readily O 
adaptable O 
to O 
a O 
variety O 
of O 
earth O 
abundant O 
semiconductors O 
which O 
might O 
otherwise O 
be O 
unstable O 
as O 
photoelectrocatalysts O 
. O 

role O 
of O 
external O 
defects O 
in O 
chemical O 
sensing O 
of O 
graphene B-TRIVIAL 
field O 
- O 
effect O 
transistors O 
. O 

fundamental O 
understanding O 
of O 
chemical O 
sensing O 
mechanisms O 
in O 
graphene B-TRIVIAL 
-based O 
chemical O 
field O 
- O 
effect O 
transistors O 
( O 
chemFETs O 
) O 
is O 
essential O 
for O 
the O 
development O 
of O 
next O 
generation O 
chemical O 
sensors O 
. O 
Here O 
we O 
explore O 
the O 
hidden O 
sensing O 
modalities O 
responsible O 
for O 
tailoring O 
the O 
gas O 
detection O 
ability O 
of O 
pristine B-TRIVIAL 
graphene I-TRIVIAL 
sensors O 
by O 
exposing O 
graphene B-TRIVIAL 
chemFETs O 
to O 
electron O 
donor O 
and O 
acceptor O 
trace O 
gas O 
vapors O 
. O 
We O 
uncover O 
that O 
the O 
sensitivity O 
( O 
in O 
terms O 
of O 
modulation O 
in O 
electrical O 
conductivity O 
) O 
of O 
pristine B-TRIVIAL 
graphene I-TRIVIAL 
chemFETs O 
is O 
not O 
necessarily O 
intrinsic O 
to O 
graphene B-TRIVIAL 
, O 
but O 
rather O 
it O 
is O 
facilitated O 
by O 
external O 
defects O 
in O 
the O 
insulating O 
substrate O 
, O 
which O 
can O 
modulate O 
the O 
electronic O 
properties O 
of O 
graphene B-TRIVIAL 
. O 
We O 
disclose O 
a O 
mixing O 
effect O 
caused O 
by O 
partial O 
overlap O 
of O 
the O 
highest O 
occupied O 
molecular O 
orbital O 
( O 
HOMO O 
) O 
and O 
lowest O 
unoccupied O 
molecular O 
orbital O 
( O 
LUMO O 
) O 
of O 
adsorbed O 
gas O 
molecules O 
to O 
explain O 
graphene B-TRIVIAL 
' O 
s O 
ability O 
to O 
detect O 
adsorbed O 
molecules O 
. O 
Our O 
results O 
open O 
a O 
new O 
design O 
space O 
, O 
suggesting O 
that O 
control O 
of O 
external O 
defects O 
in O 
supporting O 
substrates O 
can O 
lead O 
to O 
tunable O 
graphene O 
chemical O 
sensors O 
, O 
which O 
could O 
be O 
developed O 
without O 
compromising O 
the O 
intrinsic O 
electrical O 
and O 
structural O 
properties O 
of O 
graphene B-TRIVIAL 
. O 

of O 
the O 
microcharacter O 
of O 
ultrastable O 
aqueous O 
foam O 
stabilized O 
by O 
a O 
kind O 
of O 
flexible O 
connecting O 
bipolar O 
- O 
headed O 
surfactant O 
with O 
existence O 
of O 
magnesium B-SYSTEMATIC 
ion O 
. O 

this O 
paper O 
, O 
ultrastable O 
aqueous O 
foam O 
stabilized O 
by O 
a O 
kind O 
of O 
flexible O 
connecting O 
bipolar O 
- O 
headed O 
surfactant O 
alkyl B-FAMILY 
polyoxyethylene I-FAMILY 
sulfate I-FAMILY 
( O 
AE3S B-ABBREVIATION 
) O 
with O 
coexisting O 
Mg(2+) B-FORMULA 
was O 
reported O 
. O 
Detailed O 
molecular O 
behaviors O 
of O 
AE3S B-ABBREVIATION 
in O 
foam O 
film O 
with O 
coexisting O 
divalent O 
cationic O 
Ca(2+) B-FORMULA 
or O 
Mg(2+) B-FORMULA 
were O 
investigated O 
by O 
molecular O 
dynamic O 
simulation O 
, O 
comparing O 
with O 
the O 
traditional O 
surfactant O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
SDS B-ABBREVIATION 
) O 
, O 
to O 
find O 
out O 
how O 
the O 
microcharacter O 
and O 
array O 
behavior O 
of O 
molecules O 
in O 
the O 
foam O 
film O 
determined O 
by O 
molecular O 
interaction O 
effect O 
the O 
foam O 
stability O 
. O 
It O 
was O 
found O 
that O 
the O 
ultrastable O 
foam O 
film O 
obtained O 
by O 
the O 
cooperation O 
of O 
magnesium B-SYSTEMATIC 
ions O 
and O 
AE3S B-ABBREVIATION 
was O 
driven O 
from O 
two O 
aspects O 
: O 
one O 
is O 
the O 
favorable O 
arrangement O 
of O 
surfactant O 
molecules O 
, O 
and O 
the O 
other O 
is O 
the O 
increase O 
of O 
capacity O 
of O 
foam O 
films O 
for O 
resolutely O 
holding O 
water O 
molecules O 
deduced O 
by O 
a O 
dipolar O 
pair O 
formed O 
by O 
the O 
flexible O 
connecting O 
head O 
groups O 
of O 
AE3S B-ABBREVIATION 
and O 
hydrated B-FORMULA 
Mg(2+) I-FORMULA 
via O 
intermolecular O 
coactions O 
, O 
both O 
related O 
to O 
the O 
presence O 
of O 
magnesium B-SYSTEMATIC 
ions O 
. O 
Foam O 
lamella O 
stability O 
measurement O 
and O 
foam O 
decay O 
method O 
were O 
both O 
used O 
to O 
evaluate O 
the O 
stability O 
of O 
foam O 
. O 
Fourier O 
transform O 
infrared O 
( O 
FT-IR O 
) O 
was O 
used O 
to O 
detect O 
the O 
composition O 
variation O 
of O 
foam O 
film O 
in O 
the O 
drainage O 
process O 
; O 
the O 
vibration O 
peak O 
of O 
OH B-FORMULA 
for O 
water O 
molecule O 
shifted O 
from O 
the O 
3390 O 
cm(-1) O 
( O 
being O 
assigned O 
to O 
the O 
bulk O 
water O 
integrated O 
by O 
hydrogen B-SYSTEMATIC 
bonds O 
) O 
to O 
3685 O 
cm(-1) O 
( O 
being O 
assigned O 
to O 
the O 
vibration O 
of O 
isolated O 
water O 
molecules O 
) O 
for O 
the O 
ultrastable O 
foam O 
film O 
after O 
complete O 
drainage O 
, O 
which O 
agreed O 
very O 
well O 
with O 
the O 
molecular O 
simulation O 
results O 
. O 

Drug- O 
Heme B-FAMILY 
Interactions O 
and O 
Implications O 
for O 
Antimalarial O 
Cytostatic O 
versus O 
Cytocidal O 
Activities O 
. O 

, O 
the O 
most O 
successful O 
molecular O 
target O 
for O 
antimalarial O 
drugs O 
has O 
been O 
heme O 
biomineralization O 
within O 
the O 
malarial O 
parasite O 
digestive O 
vacuole O 
. O 
Heme B-FAMILY 
released O 
from O 
catabolized O 
host O 
red O 
blood O 
cell O 
hemoglobin O 
is O 
toxic O 
, O 
so O 
malarial O 
parasites O 
crystallize O 
heme B-FAMILY 
to O 
nontoxic O 
hemozoin O 
. O 
For O 
years O 
it O 
has O 
been O 
accepted O 
that O 
a O 
number O 
of O 
effective O 
quinoline B-SYSTEMATIC 
antimalarial O 
drugs O 
( O 
e.g O 
. O 
, O 
chloroquine B-TRIVIAL 
, O 
quinine B-TRIVIAL 
, O 
amodiaquine B-TRIVIAL 
) O 
function O 
by O 
preventing O 
hemozoin O 
crystallization O 
. O 
However O 
, O 
recent O 
studies O 
over O 
the O 
past O 
decade O 
have O 
revealed O 
a O 
surprising O 
molecular O 
diversity O 
in O 
quinoline B-SYSTEMATIC 
- O 
heme B-FAMILY 
molecular O 
interactions O 
. O 
This O 
diversity O 
shows O 
that O 
even O 
closely O 
related O 
quinoline B-SYSTEMATIC 
drugs O 
may O 
have O 
quite O 
different O 
molecular O 
pharmacology O 
. O 
This O 
paper O 
reviews O 
the O 
molecular O 
diversity O 
and O 
highlights O 
important O 
implications O 
for O 
understanding O 
quinoline B-SYSTEMATIC 
antimalarial O 
drug O 
resistance O 
and O 
for O 
future O 
drug O 
design O 
. O 

and O 
Absolute O 
Configuration O 
of O 
Fumiquinazoline B-TRIVIAL 
L I-TRIVIAL 
, O 
an O 
Alkaloid O 
from O 
a O 
Gorgonian O 
- O 
Derived O 
Scopulariopsis O 
sp O 
. O 
Fungus O 
. O 

L I-TRIVIAL 
( O 
1 O 
) O 
, O 
an O 
alkaloid O 
with O 
a O 
heptacyclic O 
skeleton O 
formed O 
via O 
a O 
bridging O 
hemiaminal O 
linkage O 
, O 
was O 
isolated O 
from O 
a O 
gorgonian O 
- O 
derived O 
Scopulariopsis O 
sp O 
. O 
fungus O 
. O 
The O 
structure O 
and O 
absolute O 
configuration O 
of O 
the O 
new O 
compound O 
were O 
identified O 
by O 
comprehensive O 
spectroscopic O 
data O 
and O 
X-ray O 
diffraction O 
analysis O 
. O 
During O 
acid O 
hydrolysis O 
of O 
1 O 
, O 
the O 
isomerization O 
of O 
the O 
valine B-TRIVIAL 
residue O 
was O 
observed O 
and O 
also O 
studied O 
in O 
different O 
conditions O 
. O 
Fumiquinazoline B-TRIVIAL 
L I-TRIVIAL 
( O 
1 O 
) O 
showed O 
no O 
cytotoxic O 
or O 
antibacterial O 
activities O 
. O 

of O 
the O 
Post-Polyketide O 
Synthase O 
Modification O 
Enzymes O 
for O 
Fostriecin B-TRIVIAL 
Biosynthesis O 
in O 
Streptomyces O 
pulveraceus O 
. O 

( O 
FST B-ABBREVIATION 
, O 
1 O 
) O 
is O 
a O 
natural O 
product O 
with O 
promising O 
antitumor O 
activity O 
produced O 
by O 
Streptomyces O 
pulveraceus O 
. O 
Its O 
antitumor O 
activity O 
is O 
associated O 
with O 
the O 
selective O 
inhibition O 
of O 
protein O 
phosphatase O 
activities O 
. O 
The O 
biosynthetic O 
gene O 
cluster O 
for O 
FST O 
has O 
recently O 
been O 
cloned O 
and O 
sequenced O 
. O 
To O 
better O 
understand O 
the O 
post O 
- O 
polyketide O 
synthase O 
( O 
PKS O 
) O 
modification O 
steps O 
in O 
the O 
biosynthetic O 
pathway O 
of O 
FST O 
, O 
we O 
constructed O 
and O 
characterized O 
three O 
post-PKS O 
modification O 
gene O 
mutants O 
of O 
fosG O 
, O 
fosK O 
, O 
and O 
fosM O 
by O 
knockout O 
inactivation O 
in O 
S O 
. O 
pulveraceus O 
. O 
As O 
a O 
result O 
, O 
we O 
determined O 
that O 
a O 
fosK-encoded O 
cytochrome O 
P450 O 
monooxygenase O 
is O 
responsible O 
for O 
C-18 O 
hydroxylation O 
, O 
formation O 
of O 
an O 
unsaturated B-SYSTEMATIC 
lactone I-SYSTEMATIC 
is O 
dependent O 
upon O 
FosM O 
, O 
and O 
the O 
fosG O 
gene O 
product O 
is O 
involved O 
in O 
hydroxylation O 
at O 
C-4 O 
after O 
the O 
action O 
of O 
FosM O 
to O 
yield O 
PD B-IDENTIFIER 
113271 I-IDENTIFIER 
from O 
FST B-ABBREVIATION 
. O 
The O 
accumulated O 
analogues O 
from O 
the O 
ΔfosK O 
and O 
ΔfosM O 
mutant O 
strains O 
possessed O 
a O 
malonyl B-TRIVIAL 
ester I-TRIVIAL 
moiety O 
that O 
suggested O 
that O 
all O 
the O 
post-PKS O 
modification O 
steps O 
in O 
FST O 
biosynthesis O 
occur O 
with O 
the O 
polyketide O 
chain O 
bearing O 
a O 
malonyl B-TRIVIAL 
ester I-TRIVIAL 
at O 
the O 
C-3 O 
position O 
, O 
with O 
formation O 
of O 
the O 
unsaturated O 
six O 
- O 
membered O 
lactone B-FAMILY 
as O 
the O 
last O 
step O 
in O 
FST B-ABBREVIATION 
biosynthesis O 
. O 

- O 
water O 
interfaces O 
interact O 
strongly O 
with O 
colloidal O 
particles O 
by O 
capillary O 
forces O 
. O 
The O 
magnitude O 
of O 
the O 
interaction O 
force O 
depends O 
on O 
, O 
among O 
other O 
things O 
, O 
the O 
particle O 
shape O 
. O 
Here O 
, O 
we O 
investigate O 
the O 
effects O 
of O 
particle O 
shape O 
on O 
colloid O 
detachment O 
by O 
a O 
moving O 
air O 
- O 
water O 
interface O 
. O 
We O 
used O 
hydrophilic O 
polystyrene B-SYSTEMATIC 
colloids O 
with O 
four O 
different O 
shapes O 
( O 
spheres O 
, O 
barrels O 
, O 
rods O 
, O 
and O 
oblong O 
disks O 
) O 
, O 
but O 
otherwise O 
identical O 
surface O 
properties O 
. O 
The O 
nonspherical O 
shapes O 
were O 
created O 
by O 
stretching O 
spherical O 
microspheres O 
on O 
a O 
film O 
of O 
polyvinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
( O 
PVA B-ABBREVIATION 
) O 
. O 
The O 
colloids O 
were O 
then O 
deposited O 
onto O 
the O 
inner O 
surface O 
of O 
a O 
glass O 
channel O 
. O 
An O 
air O 
bubble O 
was O 
introduced O 
into O 
the O 
channel O 
and O 
passed O 
through O 
, O 
thereby O 
generating O 
a O 
receding O 
followed O 
by O 
an O 
advancing O 
air O 
- O 
water O 
interface O 
. O 
The O 
detachment O 
of O 
colloids O 
by O 
the O 
air O 
- O 
water O 
interfaces O 
was O 
visualized O 
with O 
a O 
confocal O 
microscope O 
, O 
quantified O 
by O 
image O 
analysis O 
, O 
and O 
analyzed O 
statistically O 
to O 
determine O 
significant O 
differences O 
. O 
For O 
all O 
colloid O 
shapes O 
, O 
the O 
advancing O 
air O 
- O 
water O 
interface O 
caused O 
pronounced O 
colloid O 
detachment O 
( O 
> O 
63% O 
) O 
, O 
whereas O 
the O 
receding O 
interface O 
was O 
ineffective O 
in O 
colloid O 
detachment O 
( O 
< O 
1.5% O 
) O 
. O 
Among O 
the O 
different O 
colloid O 
shapes O 
, O 
the O 
barrels O 
were O 
most O 
readily O 
removed O 
( O 
94% O 
) O 
by O 
the O 
advancing O 
interface O 
, O 
followed O 
by O 
the O 
spheres O 
and O 
oblong O 
disks O 
( O 
80% O 
) O 
and O 
the O 
rods O 
( O 
63% O 
) O 
. O 
Colloid O 
detachment O 
was O 
significantly O 
affected O 
by O 
colloid O 
shape O 
. O 
The O 
presence O 
of O 
an O 
edge O 
, O 
as O 
it O 
occurs O 
in O 
a O 
barrel O 
- O 
shaped O 
colloid O 
, O 
promoted O 
colloid O 
detachment O 
because O 
the O 
air O 
- O 
water O 
interface O 
is O 
being O 
pinned O 
at O 
the O 
edge O 
of O 
the O 
colloid O 
. O 
This O 
suggests O 
that O 
the O 
magnitude O 
of O 
colloid O 
mobilization O 
and O 
transport O 
in O 
porous O 
media O 
is O 
underestimated O 
for O 
edged O 
particles O 
and O 
overestimated O 
for O 
rodlike O 
particles O 
when O 
a O 
sphere O 
is O 
used O 
as O 
a O 
model O 
colloid O 
. O 

man O 
- O 
made O 
composite O 
materials O 
, O 
natural O 
biominerals O 
containing O 
composites O 
usually O 
demonstrate O 
different O 
levels O 
of O 
sophisticated O 
hierarchical O 
structures O 
which O 
are O 
responsible O 
for O 
their O 
mechanical O 
properties O 
and O 
other O 
metabolic O 
functions O 
. O 
However O 
, O 
the O 
complex O 
spatial O 
organizations O 
of O 
the O 
organic O 
- O 
inorganic O 
phases O 
are O 
far O 
beyond O 
what O 
they O 
achieved O 
by O 
contemporary O 
engineering O 
techniques O 
. O 
Here O 
, O 
we O 
demonstrate O 
that O 
carbonated O 
apatite O 
present O 
in O 
collagen O 
matrices O 
derived O 
from O 
fish O 
scale O 
and O 
bovine O 
bone O 
may O 
be O 
replaced O 
by O 
amorphous O 
silica B-TRIVIAL 
, O 
using O 
an O 
approach O 
that O 
simulates O 
what O 
is O 
utilized O 
by O 
phylogenetically O 
ancient O 
glass O 
sponges O 
. O 
The O 
structural O 
hierarchy O 
of O 
these O 
collagen O 
- O 
based O 
biomaterials O 
is O 
replicated O 
by O 
the O 
infiltration O 
and O 
condensation O 
of O 
fluidic O 
polymer O 
- O 
stabilized O 
silicic B-TRIVIAL 
acid I-TRIVIAL 
precursors O 
within O 
the O 
intrafibrillar O 
milieu O 
of O 
type O 
I O 
collagen O 
fibrils O 
. O 
This O 
facile O 
biomimetic O 
silicification O 
strategy O 
may O 
be O 
used O 
for O 
fabricating O 
silica B-TRIVIAL 
-based O 
, O 
three O 
- O 
dimensional O 
functional O 
materials O 
with O 
specific O 
morphological O 
and O 
hierarchical O 
requirements O 
. O 

A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
, O 
Two O 
Cyclohexapeptides B-FAMILY 
from O 
the O 
Marine O 
- O 
Derived O 
Actinomycete O 
Nocardiopsis O 
sp O 
. O 
CNX037 O 
. O 

new O 
cyclic B-FAMILY 
hexapeptides I-FAMILY 
, O 
nocardiamides B-FAMILY 
A O 
( O 
1 O 
) O 
and O 
B O 
( O 
2 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
culture O 
broth O 
of O 
marine O 
- O 
derived O 
actinomycete O 
CNX037 O 
strain O 
that O 
was O 
identified O 
as O 
a O 
Nocardiopsis O 
species O 
. O 
The O 
planar O 
structures O 
of O 
nocardiamides B-FAMILY 
A O 
( O 
1 O 
) O 
and O 
B O 
( O 
2 O 
) O 
were O 
assigned O 
on O 
the O 
basis O 
of O 
1D O 
and O 
2D O 
NMR O 
and O 
HRESIMS O 
spectroscopic O 
analyses O 
. O 
Their O 
absolute O 
configurations O 
were O 
deduced O 
by O 
the O 
advanced O 
Marfey's O 
method O 
and O 
chiral O 
- O 
phase O 
HPLC O 
analysis O 
. O 
The O 
challenge O 
of O 
locating O 
two O 
d- B-MULTIPLE 
and I-MULTIPLE 
one I-MULTIPLE 
l-valine I-MULTIPLE 
residue O 
in O 
1 O 
and O 
2 O 
was O 
accomplished O 
by O 
total O 
synthesis O 
using O 
solid O 
- O 
phase O 
peptide O 
synthetic O 
methods O 
. O 
Both O 
1 O 
and O 
2 O 
showed O 
negligible O 
antimicrobial O 
activities O 
against O 
seven O 
indicator O 
strains O 
and O 
exhibited O 
no O 
cytotoxicity O 
against O 
HCT-116 O 
. O 

switch O 
between O 
CHK1 O 
and O 
MK2 O 
: O 
Discovery O 
of O 
imidazo[1,2-a]pyrazine B-SYSTEMATIC 
- O 
and O 
imidazo[1,2-c]pyrimidine B-SYSTEMATIC 
-based O 
kinase O 
inhibitors O 
. O 

has O 
been O 
developed O 
to O 
access O 
both O 
imidazo[1,2-a]pyrazines B-FAMILY 
and O 
imidazo[1,2-c]pyrimidines B-FAMILY 
. O 
Small O 
structural O 
modifications O 
in O 
both O 
series O 
led O 
to O 
a O 
switch O 
of O 
potency O 
between O 
two O 
kinases O 
involved O 
in O 
mediating O 
cell O 
cycle O 
checkpoint O 
control O 
, O 
CHK1 O 
and O 
MK2 O 
. O 

in O 
vitro O 
effect O 
of O 
duroquinone B-TRIVIAL 
on O 
functional O 
competence O 
, O 
genomic O 
integrity O 
, O 
and O 
oxidative O 
stress O 
indices O 
of O 
sterlet O 
( O 
Acipenser O 
ruthenus O 
) O 
spermatozoa O 
. O 

sturgeon O 
is O 
a O 
highly O 
endangered O 
fish O 
species O 
mostly O 
due O 
to O 
over O 
- O 
fishing O 
, O 
habitat O 
destruction O 
, O 
and O 
water O 
pollution O 
. O 
Duroquinone B-TRIVIAL 
( O 
derivative O 
of O 
1,4-benzoquinone B-SYSTEMATIC 
) O 
is O 
a O 
xenobiotic O 
compound O 
widespread O 
in O 
the O 
environment O 
. O 
The O 
effect O 
of O 
duroquinone B-TRIVIAL 
on O 
motility O 
, O 
DNA O 
integrity O 
, O 
and O 
oxidative O 
stress O 
indices O 
in O 
sterlet O 
, O 
Acispenser O 
ruthenus O 
, O 
spermatozoa O 
was O 
investigated O 
. O 
Sterlet O 
sperm O 
was O 
exposed O 
for O 
2h O 
to O 
duroquinone B-TRIVIAL 
at O 
concentrations O 
of O 
25 O 
, O 
50 O 
, O 
100 O 
, O 
and O 
150μM O 
. O 
Spermatozoa O 
motility O 
, O 
velocity O 
, O 
and O 
ATP B-ABBREVIATION 
content O 
were O 
significantly O 
decreased O 
with O 
exposure O 
to O 
duroquinone B-TRIVIAL 
. O 
The O 
level O 
of O 
DNA O 
damage O 
significantly O 
increased O 
at O 
concentrations O 
of O 
50μM O 
and O 
above O 
. O 
Oxidative O 
stress O 
indices O 
( O 
lipid O 
peroxidation O 
and O 
content O 
of O 
carbonyl B-FAMILY 
proteins O 
) O 
and O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
activity O 
increased O 
significantly O 
with O 
increasing O 
concentrations O 
of O 
duroquinone B-TRIVIAL 
. O 
Oxidative O 
stress O 
in O 
sterlet O 
spermatozoa O 
induced O 
by O 
duroquinone B-TRIVIAL 
was O 
shown O 
to O 
impair O 
spermatozoa O 
DNA O 
integrity O 
, O 
motility O 
parameters O 
, O 
and O 
the O 
antioxidant O 
defense O 
system O 
. O 
Spermatozoa O 
motility O 
, O 
content O 
of O 
carbonyl B-FAMILY 
proteins O 
, O 
and O 
SOD O 
activity O 
were O 
shown O 
to O 
be O 
sensitive O 
biomarkers O 
, O 
exhibiting O 
strong O 
responses O 
to O 
low O 
concentrations O 
of O 
the O 
xenobiotic O 
. O 
Results O 
also O 
suggested O 
that O 
fish O 
spermatozoa O 
in O 
vitro O 
assays O 
may O 
provide O 
a O 
simple O 
and O 
efficient O 
means O 
of O 
monitoring O 
residual O 
pollutants O 
in O 
the O 
aquatic O 
environment O 
. O 

opioid O 
receptors O 
in O 
the O 
central O 
amygdala O 
regulate O 
ethanol B-SYSTEMATIC 
actions O 
at O 
presynaptic O 
GABAergic O 
sites O 
. O 

and O 
animal O 
studies O 
indicate O 
that O 
kappa O 
opioid O 
receptor O 
( O 
KOR O 
) O 
systems O 
are O 
involved O 
in O 
ethanol B-SYSTEMATIC 
drinking O 
and O 
dependence O 
( O 
Xuei O 
et O 
al O 
. O 
, O 
2006 O 
; O 
Walker O 
and O 
Koob O 
, O 
2008 O 
; O 
Walker O 
et O 
al O 
. O 
, O 
2011 O 
) O 
. O 
The O 
central O 
amygdala O 
( O 
CeA O 
) O 
is O 
a O 
critical O 
brain O 
region O 
mediating O 
anxiety O 
- O 
related O 
behavior O 
and O 
drug O 
reward O 
and O 
is O 
a O 
likely O 
site O 
for O 
the O 
interaction O 
of O 
the O 
KOR O 
system O 
and O 
ethanol B-SYSTEMATIC 
, O 
although O 
few O 
studies O 
have O 
explored O 
this O 
interaction O 
. O 
Using O 
in O 
vitro O 
single O 
- O 
cell O 
recording O 
techniques O 
in O 
mouse O 
brain O 
slices O 
, O 
we O 
examined O 
the O 
physiological O 
effects O 
of O 
KOR O 
activation O 
in O 
CeA O 
on O 
GABAergic O 
neurotransmission O 
and O 
its O 
interaction O 
with O 
acute O 
ethanol B-SYSTEMATIC 
. O 
A O 
selective O 
KOR O 
agonist O 
( O 
U69593 B-IDENTIFIER 
, O 
1 O 
μM O 
) O 
diminished O 
evoked O 
GABAergic O 
inhibitory O 
postsynaptic O 
currents O 
( O 
IPSCs O 
) O 
by O 
18% O 
( O 
n O 
= O 
10 O 
) O 
in O 
the O 
CeA O 
, O 
whereas O 
blockade O 
of O 
KORs O 
with O 
a O 
selective O 
antagonist O 
( O 
nor-binaltorphimine B-TRIVIAL 
, O 
1 O 
μM O 
) O 
augmented O 
the O 
baseline O 
evoked O 
GABAergic O 
IPSCs O 
by O 
14% O 
( O 
p O 
< O 
0.01 O 
; O 
n O 
= O 
34 O 
) O 
, O 
suggesting O 
that O 
the O 
KOR O 
system O 
contributes O 
to O 
tonic O 
inhibition O 
of O 
GABAergic O 
neurotransmission O 
in O 
the O 
CeA O 
. O 
In O 
addition O 
, O 
the O 
enhancement O 
by O 
acute O 
ethanol B-SYSTEMATIC 
of O 
GABAergic O 
IPSC O 
amplitudes O 
in O 
the O 
CeA O 
was O 
further O 
augmented O 
by O 
pharmacological O 
blockade O 
of O 
KORs O 
, O 
from O 
14 O 
% O 
( O 
n O 
= O 
36 O 
) O 
to O 
27% O 
( O 
n O 
= O 
26 O 
; O 
p O 
< O 
0.01 O 
) O 
, O 
or O 
by O 
genetic O 
deletion O 
of O 
KORs O 
, O 
from O 
14 O 
% O 
in O 
WT O 
mice O 
( O 
n O 
= O 
19 O 
) O 
to O 
34 O 
% O 
in O 
KOR O 
knockout O 
( O 
KO O 
) O 
mice O 
( O 
n O 
= O 
13 O 
, O 
p O 
< O 
0.01 O 
) O 
, O 
suggesting O 
that O 
the O 
KOR O 
system O 
regulates O 
acute O 
ethanol B-SYSTEMATIC 
actions O 
in O 
the O 
CeA O 
. O 
Subsequent O 
experiments O 
using O 
tetrodotoxin O 
to O 
block O 
activity O 
- O 
dependent O 
neurotransmission O 
suggest O 
that O 
KORs O 
regulate O 
GABA B-ABBREVIATION 
release O 
at O 
presynaptic O 
sites O 
. O 
Thus O 
, O 
KOR O 
activation O 
modulates O 
GABAergic O 
neurotransmission O 
and O 
ethanol B-SYSTEMATIC 
effects O 
in O 
CeA O 
in O 
a O 
manner O 
similar O 
to O 
other O 
subtypes O 
of O 
opioid O 
receptors O 
, O 
i.e O 
. O 
, O 
mu O 
and O 
delta O 
opioid O 
receptors O 
( O 
Kang-Park O 
et O 
al O 
. O 
, O 
2007 O 
; O 
Kang-Park O 
et O 
al O 
. O 
, O 
2009 O 
) O 
. O 
Our O 
data O 
support O 
the O 
idea O 
that O 
KORs O 
modulate O 
GABAergic O 
synaptic O 
responses O 
and O 
ethanol B-SYSTEMATIC 
effects O 
as O 
one O 
of O 
multiple O 
opioid O 
system O 
- O 
dependent O 
actions O 
of O 
ethanol B-SYSTEMATIC 
in O 
the O 
CeA O 
, O 
possibly O 
in O 
a O 
circuit O 
- O 
specific O 
manner O 
. O 

of O 
the O 
combinative O 
particle O 
size O 
reduction O 
technology O 
H O 
42 O 
to O 
produce O 
fast O 
dissolving O 
glibenclamide B-TRIVIAL 
tablets O 
. O 

particle O 
size O 
reduction O 
techniques O 
such O 
as O 
high O 
pressure O 
homogenization O 
or O 
wet O 
bead O 
milling O 
are O 
frequently O 
used O 
in O 
the O 
production O 
of O 
nanosuspensions O 
. O 
The O 
need O 
for O 
micronized O 
starting O 
material O 
and O 
long O 
process O 
times O 
are O 
their O 
evident O 
disadvantages O 
. O 
Combinative O 
particle O 
size O 
reduction O 
technologies O 
have O 
been O 
developed O 
to O 
overcome O 
the O 
drawbacks O 
of O 
the O 
standard O 
techniques O 
. O 
The O 
H O 
42 O 
combinative O 
technology O 
consists O 
of O 
a O 
drug O 
pre O 
- O 
treatment O 
by O 
means O 
of O 
spray O 
- O 
drying O 
followed O 
by O 
standard O 
high O 
pressure O 
homogenization O 
. O 
In O 
the O 
present O 
paper O 
, O 
spray O 
- O 
drying O 
process O 
parameters O 
influencing O 
the O 
diminution O 
effectiveness O 
, O 
such O 
as O 
drug O 
and O 
surfactant O 
concentration O 
, O 
were O 
systematically O 
analyzed O 
. O 
Subsequently O 
, O 
the O 
untreated O 
and O 
pre O 
- O 
treated O 
drug O 
powders O 
were O 
homogenized O 
for O 
20 O 
cycles O 
at O 
1500bar O 
. O 
For O 
untreated O 
, O 
micronized O 
glibenclamide B-TRIVIAL 
, O 
the O 
particle O 
size O 
analysis O 
revealed O 
a O 
mean O 
particle O 
size O 
of O 
772nm O 
and O 
volume O 
- O 
based O 
size O 
distribution O 
values O 
of O 
2.686μm O 
( O 
d50% O 
) O 
and O 
14.423μm O 
( O 
d90% O 
) O 
. O 
The O 
use O 
of O 
pre O 
- O 
treated O 
material O 
( O 
10 O 
: O 
1 O 
glibenclamide B-TRIVIAL 
/ O 
docusate B-SYSTEMATIC 
sodium I-SYSTEMATIC 
salt O 
ratio O 
spray O 
- O 
dried O 
as O 
ethanolic O 
solution O 
) O 
resulted O 
in O 
a O 
mean O 
particle O 
size O 
of O 
236nm O 
and O 
volume O 
- O 
based O 
size O 
distribution O 
values O 
of O 
0.131μm O 
( O 
d50% O 
) O 
and O 
0.285μm O 
( O 
d90% O 
) O 
. O 
These O 
results O 
were O 
markedly O 
improved O 
compared O 
to O 
the O 
standard O 
process O 
. O 
The O 
nanosuspensions O 
were O 
further O 
transferred O 
into O 
tablet O 
formulations O 
. O 
Wet O 
granulation O 
, O 
freeze O 
- O 
drying O 
and O 
spray O 
- O 
drying O 
were O 
investigated O 
as O 
downstream O 
methods O 
to O 
produce O 
dry O 
intermediates O 
. O 
Regarding O 
the O 
dissolution O 
rate O 
, O 
the O 
rank O 
order O 
of O 
the O 
downstream O 
processes O 
was O 
as O 
follows O 
: O 
Spray O 
- O 
drying O 
> O 
freeze O 
- O 
drying O 
> O 
wet O 
granulation O 
. O 
The O 
best O 
drug O 
release O 
( O 
90% O 
within O 
10min O 
) O 
was O 
obtained O 
for O 
tablets O 
produced O 
with O 
spray O 
- O 
dried O 
nanosuspension O 
containing O 
2% O 
mannitol B-TRIVIAL 
as O 
matrix O 
former O 
. O 
In O 
comparison O 
, O 
the O 
tablets O 
processed O 
with O 
micronized O 
glibenclamide B-TRIVIAL 
showed O 
a O 
drug O 
release O 
of O 
only O 
26% O 
after O 
10min O 
. O 
The O 
H O 
42 O 
combinative O 
technology O 
could O 
be O 
successfully O 
applied O 
in O 
the O 
production O 
of O 
small O 
drug O 
nanocrystals O 
. O 
A O 
nanosuspension O 
transfer O 
to O 
tablets O 
that O 
maintained O 
the O 
fast O 
dissolution O 
properties O 
of O 
the O 
drug O 
nanocrystals O 
was O 
successfully O 
achieved O 
. O 

of O 
connexin O 
hemichannel O 
activity O 
by O 
membrane O 
potential O 
and O 
the O 
extracellular O 
calcium B-SYSTEMATIC 
in O 
health O 
and O 
disease O 
. O 

are O 
thought O 
to O 
solely O 
mediate O 
cell O 
- O 
to O 
- O 
cell O 
communication O 
by O 
forming O 
gap O 
junction O 
channels O 
composed O 
of O 
two O 
membrane O 
- O 
spanning O 
hemichannels O 
positioned O 
end O 
- O 
to O 
- O 
end O 
. O 
However O 
, O 
many O 
if O 
not O 
all O 
connexin O 
isoforms O 
also O 
form O 
functional O 
hemichannels O 
( O 
i.e O 
. O 
, O 
the O 
precursors O 
of O 
complete O 
channels O 
) O 
that O 
mediate O 
the O 
rapid O 
exchange O 
of O 
ions O 
, O 
second O 
messengers O 
and O 
metabolites O 
between O 
the O 
cell O 
interior O 
and O 
the O 
interstitial O 
space O 
. O 
Electrical O 
and O 
molecular O 
signaling O 
via O 
connexin O 
hemichannels O 
is O 
now O 
widely O 
recognized O 
to O 
be O 
important O 
in O 
many O 
physiological O 
scenarios O 
and O 
pathological O 
conditions O 
. O 
Indeed O 
, O 
mutations O 
in O 
connexins O 
that O 
alter O 
hemichannel O 
function O 
have O 
been O 
implicated O 
in O 
several O 
diseases O 
. O 
Here O 
, O 
we O 
present O 
a O 
comprehensive O 
overview O 
of O 
how O 
hemichannel O 
activity O 
is O 
tightly O 
regulated O 
by O 
membrane O 
potential O 
and O 
the O 
external O 
calcium B-SYSTEMATIC 
concentration O 
. O 
In O 
addition O 
, O 
we O 
discuss O 
the O 
genetic O 
mutations O 
known O 
to O 
alter O 
hemichannel O 
function O 
and O 
their O 
deleterious O 
effects O 
, O 
of O 
which O 
a O 
better O 
understanding O 
is O 
necessary O 
to O 
develop O 
novel O 
therapeutic O 
approaches O 
for O 
diseases O 
caused O 
by O 
hemichannel O 
dysfunction O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Connexin O 
based O 
channels O 
' O 
. O 

reporter O 
zebrafish O 
reveals O 
target O 
tissues O 
for O 
dioxin B-FAMILY 
. O 

( O 
TCDD B-ABBREVIATION 
) O 
is O 
the O 
unintentional O 
byproduct O 
of O 
various O 
industrial O 
processes O 
, O 
is O 
classified O 
as O 
human O 
carcinogen O 
and O 
could O 
disrupt O 
reproductive O 
, O 
developmental O 
and O 
endocrine O 
systems O 
. O 
Induction O 
of O 
cyp1a1 O 
is O 
used O 
as O 
an O 
indicator O 
of O 
TCDD B-ABBREVIATION 
exposure O 
. O 
We O 
sought O 
to O 
determine O 
tissues O 
that O 
are O 
vulnerable O 
to O 
TCDD B-ABBREVIATION 
toxicity O 
using O 
a O 
transgenic O 
zebrafish O 
( O 
Danio O 
rerio O 
) O 
model O 
. O 
We O 
inserted O 
a O 
nuclear O 
enhanced O 
green O 
fluorescent O 
protein O 
gene O 
( O 
EGFP O 
) O 
into O 
the O 
start O 
codon O 
of O 
a O 
zebrafish O 
cyp1a O 
gene O 
in O 
a O 
fosmid O 
clone O 
using O 
DNA O 
recombineering O 
. O 
The O 
resulting O 
recombineered O 
fosmid O 
was O 
then O 
used O 
to O 
generate O 
cyp1a O 
reporter O 
zebrafish O 
, O 
embryos O 
of O 
which O 
were O 
exposed O 
to O 
TCDD B-ABBREVIATION 
. O 
Expression O 
pattern O 
of O 
EGFP O 
in O 
the O 
reporter O 
zebrafish O 
mirrored O 
that O 
of O 
endogenous O 
cyp1a O 
mRNA O 
. O 
In O 
addition O 
, O 
exposure O 
of O 
the O 
embryos O 
to O 
TCDD B-ABBREVIATION 
at O 
as O 
low O 
as O 
10pM O 
for O 
72h O 
, O 
which O 
does O 
not O 
elicit O 
morphological O 
abnormalities O 
of O 
embryos O 
, O 
markedly O 
increased O 
GFP O 
expression O 
. O 
Furthermore O 
, O 
the O 
reporter O 
embryos O 
responded O 
to O 
other O 
AhR O 
ligands O 
as O 
well O 
. O 
Exposure O 
of O 
the O 
embryos O 
to O 
TCDD B-ABBREVIATION 
revealed O 
previously O 
reported O 
( O 
the O 
cardiovascular O 
system O 
, O 
liver O 
, O 
pancreas O 
, O 
kidney O 
, O 
swim O 
bladder O 
and O 
skin O 
) O 
and O 
unreported O 
target O 
tissues O 
( O 
retinal O 
bipolar O 
cells O 
, O 
otic O 
vesicle O 
, O 
lateral O 
line O 
, O 
cloaca O 
and O 
pectoral O 
fin O 
bud O 
) O 
for O 
TCDD B-ABBREVIATION 
. O 
Transgenic O 
cyp1a O 
reporter O 
zebrafish O 
we O 
have O 
developed O 
can O 
further O 
understanding O 
of O 
ecotoxicological O 
relevance O 
and O 
human O 
health O 
risks O 
by O 
TCDD B-ABBREVIATION 
. O 
In O 
addition O 
, O 
they O 
could O 
be O 
used O 
to O 
identify O 
agonists O 
of O 
AhR O 
and O 
antidotes O 
to O 
TCDD B-ABBREVIATION 
toxicity O 
. O 

of O 
the O 
enniatins B-MULTIPLE 
A I-MULTIPLE 
, I-MULTIPLE 
A1 I-MULTIPLE 
, I-MULTIPLE 
B I-MULTIPLE 
, I-MULTIPLE 
B1 I-MULTIPLE 
by O 
an O 
in O 
vitro O 
degradation O 
employing O 
different O 
strains O 
of O 
probiotic O 
bacteria O 
: O 
Identification O 
of O 
degradation O 
products O 
by O 
LC-MS-LIT O 
. O 

degradation O 
of O 
the O 
Fusarium O 
mycotoxins O 
ENs B-FAMILY 
by O 
9 O 
bacterial O 
strains O 
characteristic O 
of O 
the O 
gastrointestinal O 
tract O 
like O 
Bb O 
. O 
longum O 
, O 
Bb O 
. O 
bifidum O 
, O 
Bb O 
. O 
breve O 
, O 
Bb O 
. O 
adolescentes O 
, O 
Lb O 
. O 
rhamnosus O 
, O 
Lb O 
. O 
casei O 
- O 
casei O 
, O 
S O 
. O 
termofilus O 
, O 
Lb O 
. O 
ruminis O 
, O 
Lb O 
. O 
casei O 
and O 
twenty O 
two O 
strains O 
of O 
Saccharomyces O 
cerevisiae O 
was O 
studied O 
. O 
The O 
fermentations O 
were O 
carried O 
out O 
in O 
the O 
liquid O 
medium O 
of O 
De O 
Man O 
Rogosa O 
Sharpe O 
( O 
MRS O 
) O 
under O 
anaerobic O 
conditions O 
for O 
Bifidobacteria O 
Streptococcus O 
and O 
Lactobacillus O 
, O 
and O 
in O 
Potato O 
Dextrose B-TRIVIAL 
Broth O 
( O 
PDB O 
) O 
for O 
Saccharomyces O 
strains O 
, O 
during O 
48 O 
h O 
. O 
The O 
degradation O 
of O 
the O 
bioactive O 
compounds O 
ENs B-FAMILY 
was O 
also O 
studied O 
in O 
a O 
food O 
system O 
composed O 
by O 
wheat O 
flour O 
naturally O 
contaminated O 
by O 
ENs B-FAMILY 
through O 
fermentation O 
by O 
a O 
strain O 
of O 
Fusarium O 
tricinctum O 
. O 
The O 
determination O 
of O 
the O 
ENs B-FAMILY 
in O 
the O 
fermentation O 
mediums O 
was O 
performed O 
using O 
the O 
technique O 
of O 
the O 
liquid O 
chromatography O 
coupled O 
to O 
the O 
mass O 
spectrometry O 
detector O 
in O 
tandem O 
( O 
LC-MS O 
/ O 
MS O 
) O 
, O 
whereas O 
the O 
identification O 
of O 
the O 
degradation O 
products O 
produced O 
by O 
microbial O 
fermentation O 
was O 
carried O 
out O 
using O 
the O 
technique O 
of O 
the O 
LC O 
coupled O 
to O 
the O 
linear O 
ion O 
trap O 
( O 
LIT O 
) O 
. O 
All O 
the O 
bacteria O 
analyzed O 
in O 
this O 
study O 
showed O 
a O 
significant O 
ENs B-FAMILY 
reduction O 
in O 
vitro O 
during O 
the O 
fermentation O 
processes O 
, O 
with O 
degradation O 
data O 
ranging O 
from O 
5 O 
to O 
the O 
99% O 
. O 
In O 
the O 
food O 
system O 
, O 
the O 
ENs B-FAMILY 
degradation O 
data O 
evidenced O 
ranged O 
from O 
1.3 O 
to O 
49.2% O 
. O 
Also O 
three O 
ENs B-FAMILY 
degradation O 
products O 
were O 
identified O 
. O 

RELEVANCE O 
: O 
Plants O 
are O 
often O 
combined O 
in O 
traditional O 
herbal O 
remedies O 
to O 
increase O 
medicinal O 
efficacy O 
, O 
thus O 
this O 
investigation O 
provides O 
some O 
insight O 
into O 
the O 
antimicrobial O 
efficacies O 
of O 
selected O 
combinations O 
. O 
AIMS O 
OF O 
THE O 
STUDY O 
: O 
The O 
first O 
aim O 
was O 
to O 
scientifically O 
validate O 
antibacterial O 
efficacy O 
of O 
plant O 
mixtures O 
that O 
are O 
traded O 
within O 
peri O 
- O 
urban O 
centres O 
of O 
Cape O 
Town O 
( O 
Western O 
Cape O 
, O 
South O 
Africa O 
) O 
. O 
This O 
was O 
followed O 
by O 
an O 
in O 
- O 
depth O 
evaluation O 
of O 
the O 
most O 
antimicrobially O 
active O 
mixture O 
; O 
Agathosma O 
crenulata O 
, O 
Dodonaea O 
viscosa O 
with O 
Eucalyptus O 
globulus O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Methanol B-SYSTEMATIC 
and O 
aqueous O 
extracts O 
of O 
six O 
plant O 
mixtures O 
were O 
screened O 
for O 
antibacterial O 
properties O 
against O 
two O 
Gram O 
- O 
negative O 
and O 
two O 
Gram O 
- O 
positive O 
bacteria O 
using O 
the O 
minimum O 
inhibitory O 
microdilution O 
method O 
. O 
Thereafter O 
, O 
chloroform B-TRIVIAL 
: O 
methanol B-SYSTEMATIC 
( O 
1 O 
: O 
1 O 
; O 
v O 
/ O 
v O 
) O 
extracts O 
, O 
essential O 
oils O 
and O 
aqueous O 
extracts O 
of O 
Agathosma O 
crenulata O 
, O 
Dodonaea O 
viscosa O 
and O 
Eucalyptus O 
globulus O 
were O 
assayed O 
for O 
antimicrobial O 
activity O 
independently O 
and O 
in O 
various O 
combinations O 
. O 
The O 
fractional O 
inhibitory O 
concentration O 
indices O 
( O 
ƩFIC O 
) O 
were O 
determined O 
for O 
double O 
and O 
triple O 
plant O 
combinations O 
to O 
establish O 
antimicrobial O 
interactions O 
. O 
RESULTS O 
: O 
From O 
the O 
six O 
plant O 
mixtures O 
prepared O 
by O 
herbalists O 
, O 
a O 
methanol B-SYSTEMATIC 
extract O 
derived O 
from O 
combining O 
Agathosma O 
crenulata O 
, O 
Dodonaea O 
viscosa O 
and O 
Eucalyptus O 
globulus O 
showed O 
the O 
best O 
antibacterial O 
activity O 
. O 
The O 
MIC O 
values O 
of O 
49μg O 
/ O 
ml O 
for O 
Staphylococcus O 
aureus O 
and O 
Bacillus O 
subtilis O 
, O 
and O 
98μg O 
/ O 
ml O 
for O 
Klebsiella O 
pneumoniae O 
and O 
Escherichia O 
coli O 
were O 
recorded O 
. O 
When O 
Agathosma O 
crenulata O 
, O 
Dodonaea O 
viscosa O 
and O 
Eucalyptus O 
globulus O 
were O 
mixed O 
in O 
various O 
1 O 
: O 
1 O 
combinations O 
, O 
mostly O 
additive O 
and O 
synergistic O 
interactions O 
were O 
noted O 
. O 
The O 
most O 
noteworthy O 
synergistic O 
( O 
ΣFIC O 
value O 
0.07 O 
) O 
1 O 
: O 
1 O 
combinations O 
were O 
observed O 
for O 
the O 
chloroform B-TRIVIAL 
: O 
methanol B-SYSTEMATIC 
extracts O 
of O 
Agathosma O 
crenulata O 
mixed O 
with O 
Eucalyptus O 
globulus O 
against O 
Klebsiella O 
pneumoniae O 
, O 
Staphylococcus O 
aureus O 
and O 
Bacillus O 
subtilis O 
. O 
When O 
combined O 
in O 
a O 
mixture O 
of O 
three O 
plants O 
( O 
1 O 
: O 
1 O 
: O 
1 O 
) O 
, O 
enhanced O 
efficacy O 
was O 
evident O 
against O 
most O 
of O 
the O 
pathogens O 
, O 
for O 
both O 
organic O 
and O 
aqueous O 
extracts O 
. O 
The O 
triple O 
combination O 
against O 
Bacillus O 
subtilis O 
demonstrated O 
the O 
greatest O 
synergy O 
( O 
ΣFIC O 
values O 
of O 
0.03 O 
) O 
. O 
CONCLUSIONS O 
: O 
The O 
enhanced O 
antimicrobial O 
efficacy O 
and O 
synergistic O 
interactions O 
noted O 
for O 
some O 
of O 
the O 
mixtures O 
, O 
particularly O 
the O 
combination O 
of O 
Agathosma O 
crenulata O 
, O 
Dodonaea O 
viscosa O 
and O 
Eucalyptus O 
globulus O 
support O 
the O 
Western O 
Cape O 
Khoi-San O 
traditional O 
medicinal O 
practices O 
of O 
combining O 
plants O 
for O 
enhanced O 
efficacy O 
. O 

in O 
mRNA O 
and O 
protein O 
expression O 
in O 
the O 
renal O 
cortex O 
of O 
male O 
and O 
female O 
F344 O 
rats O 
treated O 
with O 
bromate B-SYSTEMATIC 
. O 

( O 
BrO3 B-FORMULA 
( I-FORMULA 
- I-FORMULA 
) I-FORMULA 
) O 
, O 
a O 
by O 
- O 
product O 
of O 
ozonation O 
of O 
drinking O 
water O 
, O 
induces O 
nephrotoxicity O 
in O 
male O 
rats O 
at O 
much O 
lower O 
doses O 
than O 
in O 
female O 
rats O 
. O 
This O 
difference O 
appears O 
to O 
be O 
related O 
to O 
the O 
development O 
of O 
α-2u-globulin O 
nephropathy O 
in O 
males O 
. O 
To O 
determine O 
sex O 
- O 
dependent O 
changes O 
in O 
mRNA O 
and O 
protein O 
expression O 
in O 
the O 
renal O 
cortex O 
attributable O 
to O 
α-2u-globulin O 
nephropathy O 
, O 
we O 
performed O 
microarray O 
and O 
immunohistochemical O 
analyses O 
in O 
proximal O 
renal O 
tubules O 
of O 
male O 
and O 
female O 
F344 O 
rats O 
treated O 
with O 
KBrO3 B-FORMULA 
for O 
28 O 
days O 
. O 
Particular O 
attention O 
was O 
paid O 
to O 
molecular O 
biomarkers O 
of O 
renal O 
tubular O 
injury O 
. O 
Microarray O 
analysis O 
of O 
male O 
and O 
female O 
rats O 
treated O 
with O 
BrO3 B-FORMULA 
( I-FORMULA 
- I-FORMULA 
) I-FORMULA 
at O 
low O 
doses O 
( O 
125 O 
mg O 
/ O 
L O 
KBrO3 B-FORMULA 
) O 
displayed O 
marked O 
sex O 
- O 
dependent O 
changes O 
in O 
renal O 
gene O 
expression O 
. O 
The O 
greatest O 
differences O 
were O 
seen O 
in O 
genes O 
encoding O 
for O 
cellular O 
differentiation O 
, O 
apoptosis O 
, O 
ion O 
transport O 
, O 
and O 
cell O 
proliferation O 
. O 
Differences O 
by O 
sex O 
were O 
especially O 
prominent O 
for O 
the O 
cell O 
cycle O 
checkpoint O 
gene O 
p21 O 
, O 
the O 
renal O 
injury O 
protein O 
Kim-1 O 
, O 
and O 
the O 
kidney O 
injury O 
and O 
cancer O 
biomarker O 
protein O 
osteopontin O 
. O 
Dose O 
- O 
related O 
nephrotoxicity O 
, O 
assessed O 
by O 
hematoxylin B-TRIVIAL 
and O 
eosin B-FAMILY 
staining O 
, O 
was O 
greater O 
in O 
males O 
compared O 
to O 
female O 
rats O 
, O 
as O 
was O 
cellular O 
proliferation O 
, O 
assessed O 
by O 
bromodeoxyuridine B-TRIVIAL 
staining O 
. O 
The O 
fraction O 
of O 
proximal O 
renal O 
cells O 
with O 
elevated O 
8-oxodeoxyguanosine B-SYSTEMATIC 
( O 
8-OH-dG B-SYSTEMATIC 
) O 
was O 
only O 
increased O 
at O 
the O 
high O 
dose O 
and O 
did O 
not O 
differ O 
by O 
sex O 
. O 
Dose O 
- O 
dependent O 
increases O 
in O 
the O 
expression O 
of O 
osteopontin O 
were O 
detected O 
immunohistochemically O 
only O 
in O 
male O 
rats O 
and O 
were O 
localized O 
in O 
proximal O 
tubule O 
cells O 
. O 
Similarly O 
, O 
BrO3 B-FORMULA 
( I-FORMULA 
- I-FORMULA 
) I-FORMULA 
treatment O 
increased O 
clusterin O 
and O 
Kim-1 O 
staining O 
in O 
the O 
proximal O 
tubules O 
; O 
however O 
, O 
staining O 
for O 
these O 
proteins O 
did O 
not O 
differ O 
appreciably O 
between O 
males O 
and O 
females O 
. O 
These O 
data O 
demonstrate O 
both O 
qualitative O 
and O 
quantitative O 
differences O 
in O 
the O 
response O 
of O 
male O 
versus O 
female O 
kidneys O 
to O 
BrO3 B-FORMULA 
( I-FORMULA 
- I-FORMULA 
) I-FORMULA 
-treatment O 
. O 
These O 
sex O 
- O 
dependent O 
effects O 
likely O 
contribute O 
to O 
renal O 
carcinogenesis O 
of O 
BrO3 B-FORMULA 
( I-FORMULA 
- I-FORMULA 
) I-FORMULA 
in O 
the O 
male O 
rat O 
. O 

cytokine O 
levels O 
can O 
down O 
- O 
regulate O 
expression O 
of O 
cytochrome O 
P450 O 
enzymes O 
( O 
CYPs O 
) O 
and O 
suppress O 
their O 
activity O 
. O 
Treatment O 
of O 
inflammation O 
or O 
infection O 
with O 
cytokine O 
- O 
modulating O 
therapeutic O 
proteins O 
( O 
TP O 
) O 
could O 
reverse O 
suppression O 
manifesting O 
as O 
therapeutic O 
protein O 
- O 
drug O 
drug O 
interactions O 
( O 
TP-DDI O 
) O 
. O 
A O 
physiologically O 
- O 
based O 
pharmacokinetic O 
model O 
was O 
used O 
to O 
quantitatively O 
predict O 
the O 
impact O 
of O 
IL-6 O 
on O 
sensitive O 
CYP3A4 O 
substrates O 
. O 
Elevated O 
simvastatin B-TRIVIAL 
AUC O 
in O 
virtual O 
rheumatoid O 
arthritis O 
patients O 
, O 
following O 
100 O 
pg O 
/ O 
mL O 
of O 
IL-6 O 
was O 
comparable O 
to O 
observed O 
clinical O 
data O 
( O 
59% O 
versus O 
58% O 
) O 
. O 
In O 
virtual O 
bone O 
marrow O 
transplant O 
( O 
BMT O 
) O 
patients O 
, O 
500 O 
pg O 
/ O 
ml O 
of O 
IL-6 O 
resulted O 
in O 
increase O 
in O 
cyclosporine B-TRIVIAL 
AUC O 
that O 
was O 
in O 
good O 
agreement O 
with O 
the O 
observed O 
data O 
( O 
45% O 
versus O 
39% O 
) O 
. O 
In O 
a O 
different O 
group O 
of O 
BMT O 
patients O 
treated O 
with O 
cyclosporine B-TRIVIAL 
, O 
the O 
magnitude O 
of O 
interaction O 
with O 
IL-6 O 
was O 
under O 
predicted O 
~3-fold O 
. O 
The O 
complexity O 
of O 
TP-DDI O 
highlights O 
underlying O 
pathophysiological O 
factors O 
to O 
be O 
considered O 
but O 
these O 
simulations O 
provide O 
valuable O 
first O 
steps O 
towards O 
predictions O 
of O 
TP-DDI O 
risk.Clinical O 
Pharmacology O 
& O 
Therapeutics O 
( O 
2013 O 
) O 
; O 
accepted O 
article O 
preview O 
online O 
10 O 
April O 
2013 O 
doi O 
: O 
10.1038 O 
/ O 
clpt.2013.79 O 
. O 

Mechanisms O 
of O 
Silibinin B-TRIVIAL 
-Mediated O 
Cancer O 
Chemoprevention O 
with O 
Major O 
Emphasis O 
on O 
Prostate O 
Cancer O 
. O 

advances O 
in O 
early O 
detection O 
, O 
prostate O 
cancer O 
remains O 
the O 
second O 
highest O 
cancer O 
mortality O 
in O 
American O 
men O 
, O 
and O 
even O 
successful O 
interventions O 
are O 
associated O 
with O 
enormous O 
health O 
care O 
costs O 
as O 
well O 
as O 
prolonged O 
deleterious O 
effects O 
on O 
quality O 
of O 
patient O 
life O 
. O 
Prostate O 
cancer O 
chemoprevention O 
is O 
one O 
potential O 
avenue O 
to O 
alleviate O 
these O 
burdens O 
. O 
It O 
is O 
a O 
regime O 
whereby O 
long O 
- O 
term O 
treatments O 
are O 
intended O 
to O 
prevent O 
or O 
arrest O 
cancer O 
development O 
, O 
in O 
contrast O 
to O 
more O 
direct O 
intervention O 
upon O 
disease O 
diagnosis O 
. O 
Based O 
on O 
this O 
intention O 
, O 
cancer O 
chemoprevention O 
generally O 
focuses O 
on O 
the O 
use O 
of O 
nontoxic O 
chemical O 
agents O 
which O 
are O 
well O 
- O 
tolerated O 
for O 
prolonged O 
usage O 
that O 
is O 
necessary O 
to O 
address O 
prostate O 
cancer's O 
multistage O 
and O 
lengthy O 
period O 
of O 
progression O 
. O 
One O 
such O 
nontoxic O 
natural O 
agent O 
is O 
the O 
flavonoid O 
silibinin B-TRIVIAL 
, O 
derived O 
from O 
the O 
milk O 
thistle O 
plant O 
( O 
Silybum O 
marianum O 
) O 
, O 
which O 
has O 
ancient O 
medicinal O 
usage O 
and O 
potent O 
antioxidant O 
activity O 
. O 
Based O 
on O 
these O 
properties O 
, O 
silibinin B-TRIVIAL 
has O 
been O 
investigated O 
in O 
a O 
host O 
of O 
cancer O 
models O 
where O 
it O 
exhibits O 
broad O 
- O 
spectrum O 
efficacy O 
against O 
cancer O 
progression O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
without O 
noticeable O 
toxicity O 
. O 
Specifically O 
in O 
prostate O 
cancer O 
models O 
, O 
silibinin B-TRIVIAL 
has O 
shown O 
the O 
ability O 
to O 
modulate O 
cell O 
signaling O 
, O 
proliferation O 
, O 
apoptosis O 
, O 
epithelial O 
to O 
mesenchymal O 
transition O 
, O 
invasion O 
, O 
metastasis O 
, O 
and O 
angiogenesis O 
, O 
which O 
taken O 
together O 
provides O 
strong O 
support O 
for O 
silibinin B-TRIVIAL 
as O 
a O 
candidate O 
prostate O 
cancer O 
chemopreventive O 
agent O 
. O 

Fer O 
tyrosine B-TRIVIAL 
kinase O 
is O 
important O 
for O 
platelet O 
- O 
derived O 
growth O 
factor-BB-induced O 
Stat3 O 
phosphorylation O 
, O 
colony O 
formation O 
in O 
soft O 
agar O 
and O 
tumor O 
growth O 
in O 
vivo O 
. O 

is O 
a O 
cytoplasmic O 
tyrosine B-TRIVIAL 
kinase O 
that O 
is O 
activated O 
in O 
response O 
to O 
platelet O 
- O 
derived O 
growth O 
factor O 
( O 
PDGF O 
) O 
stimulation O 
. O 
In O 
the O 
present O 
report O 
, O 
we O 
show O 
that O 
Fer O 
associates O 
with O 
the O 
activated O 
PDGFbeta O 
receptor O 
( O 
PDGFRbeta O 
) O 
through O 
multiple O 
autophosphorylation O 
sites O 
, O 
i.e O 
. O 
Tyr B-FORMULA 
579 O 
, O 
Tyr B-FORMULA 
581 O 
, O 
Tyr B-FORMULA 
740 O 
and O 
Tyr B-FORMULA 
1021 O 
. O 
Using O 
low O 
molecular O 
weight O 
inhibitors O 
, O 
we O 
found O 
that O 
PDGF-BB-induced O 
Fer O 
activation O 
is O 
dependent O 
on O 
PDGFRbeta O 
kinase O 
activity O 
, O 
but O 
not O 
on O 
the O 
enzymatic O 
activity O 
of O 
Src O 
or O 
Jak O 
kinases O 
. O 
In O 
cells O 
in O 
which O 
Fer O 
was O 
downregulated O 
using O 
siRNA O 
, O 
PDGF-BB O 
was O 
unable O 
to O 
induce O 
phosphorylation O 
of O 
Stat3 O 
, O 
whereas O 
phosphorylations O 
of O 
Stat5 O 
, O 
Erk1 O 
/ O 
2 O 
and O 
Akt O 
were O 
unaffected O 
. O 
PDGF-BB-induced O 
activation O 
of O 
Stat3 O 
occurred O 
also O 
in O 
cells O 
expressing O 
kinase O 
- O 
dead O 
Fer O 
, O 
suggesting O 
a O 
kinase O 
- O 
independent O 
adaptor O 
role O 
of O 
Fer O 
. O 
Expression O 
of O 
Fer O 
was O 
dispensable O 
for O 
PDGF-BB-induced O 
proliferation O 
and O 
migration O 
, O 
but O 
essential O 
for O 
colony O 
formation O 
in O 
soft O 
agar O 
. O 
Tumor O 
growth O 
in O 
vivo O 
was O 
delayed O 
in O 
cells O 
depleted O 
of O 
Fer O 
expression O 
. O 
Our O 
data O 
suggests O 
a O 
critical O 
role O 
of O 
Fer O 
in O 
PDGF-BB-induced O 
Stat3 O 
activation O 
and O 
cell O 
transformation O 
. O 

to O 
mercury B-SYSTEMATIC 
among O 
dental O 
health O 
workers O 
in O 
Turkey O 
: O 
Correlation O 
with O 
amalgam B-TRIVIAL 
work O 
and O 
own O 
fillings O 
. O 

: O 
To O 
investigate O 
the O 
current O 
status O 
of O 
exposure O 
to O 
mercury B-SYSTEMATIC 
( O 
Hg B-FORMULA 
) O 
among O 
dental O 
health O 
workers O 
in O 
Turkey O 
. O 
METHODS O 
: O 
A O 
total O 
of O 
115 O 
persons O 
working O 
in O 
the O 
same O 
hospital O 
were O 
included O 
in O 
the O 
study O 
and O 
were O 
divided O 
into O 
three O 
groups O 
. O 
Group O 
1 O 
consisted O 
of O 
67 O 
dentists O 
; O 
group O 
2 O 
consisted O 
of O 
21 O 
dental O 
personnel O 
who O 
work O 
with O 
amalgam B-TRIVIAL 
, O 
and O 
group O 
3 O 
consisted O 
of O 
27 O 
control O 
subjects O 
who O 
work O 
in O 
the O 
same O 
hospital O 
but O 
are O 
non-dental O 
personnel O 
. O 
The O 
number O 
of O 
amalgam B-TRIVIAL 
fillings O 
that O 
have O 
been O 
made O 
by O 
the O 
dentists O 
and O 
the O 
number O 
of O 
own O 
fillings O 
of O 
the O 
subjects O 
were O 
recorded O 
. O 
RESULTS O 
: O 
Plasma O 
Hg B-FORMULA 
levels O 
were O 
found O 
to O 
be O 
3.76 O 
± O 
1.84 O 
, O 
3.54 O 
± O 
1.83 O 
, O 
and O 
2.69 O 
± O 
0.97 O 
µg O 
/ O 
L O 
in O 
groups O 
1 O 
, O 
2 O 
, O 
and O 
3 O 
, O 
respectively O 
. O 
Hg B-FORMULA 
concentrations O 
in O 
group O 
1 O 
were O 
significantly O 
higher O 
than O 
the O 
control O 
group O 
. O 
There O 
was O 
no O 
significant O 
difference O 
between O 
groups O 
1 O 
and O 
2 O 
. O 
The O 
number O 
of O 
amalgam B-TRIVIAL 
fillings O 
made O 
by O 
the O 
dentists O 
in O 
the O 
previous O 
year O 
correlated O 
significantly O 
with O 
plasma O 
Hg B-FORMULA 
levels O 
( O 
r O 
= O 
0.378 O 
, O 
p O 
< O 
0.01 O 
) O 
. O 
There O 
was O 
no O 
significant O 
correlation O 
between O 
the O 
own O 
amalgam B-TRIVIAL 
fillings O 
in O 
the O 
teeth O 
of O 
the O 
subjects O 
and O 
Hg B-FORMULA 
levels O 
. O 
CONCLUSION O 
: O 
Preventive O 
measures O 
for O 
protection O 
from O 
exposure O 
to O 
Hg B-FORMULA 
are O 
necessary O 
for O 
occupational O 
health O 
in O 
dentistry O 
and O 
proper O 
industrial O 
hygiene O 
rules O 
should O 
be O 
emphasized O 
to O 
avoid O 
contamination O 
during O 
work O 
. O 

of O 
hepatotoxicity O 
induced O 
by O 
aflatoxin B-FAMILY 
using O 
citrus O 
fruit O 
oil O 
in O 
broilers O 
( O 
Gallus O 
domesticus O 
) O 
. O 

study O 
was O 
conducted O 
to O 
evaluate O 
the O 
efficacy O 
of O 
citrus O 
fruit O 
oil O 
( O 
CFO O 
; O 
2.5 O 
g O 
kg(-)(1) O 
) O 
on O 
the O 
clinicopathological O 
changes O 
in O 
broilers O 
fed O 
with O 
diets O 
containing O 
1 O 
ppm O 
of O 
aflatoxin B-FAMILY 
( O 
AF O 
) O 
. O 
A O 
total O 
of O 
160 O 
Ross O 
308 O 
broiler O 
chicks O 
of O 
1-day- O 
old O 
were O 
procured O 
from O 
a O 
commercial O 
hatchery O 
, O 
divided O 
randomly O 
on O 
7th O 
day O 
of O 
age O 
into O 
four O 
groups O 
with O 
two O 
replicates O 
of O 
20 O 
birds O 
each O 
and O 
fed O 
with O 
basal O 
diet O 
( O 
group O 
A O 
) O 
, O 
basal O 
diet O 
+ O 
CFO O 
( O 
group O 
B O 
) O 
, O 
basal O 
diet O 
+ O 
AF O 
( O 
group O 
C O 
) O 
and O 
CFO O 
+ O 
basal O 
diet O 
+ O 
AF O 
( O 
group O 
D O 
) O 
. O 
The O 
gross O 
and O 
histopathological O 
changes O 
in O 
the O 
liver O 
, O 
kidney O 
, O 
spleen O 
, O 
thymus O 
and O 
bursa O 
of O 
Fabricius O 
were O 
investigated O 
and O 
relative O 
organ O 
weights O 
were O 
calculated O 
. O 
Slight O 
to O 
moderate O 
hydropic O 
degeneration O 
, O 
fatty O 
change O 
with O 
the O 
formation O 
of O 
cyst O 
in O 
some O 
cases O 
, O 
periportal O 
necrosis O 
, O 
infiltration O 
of O 
heterophils O 
and O 
mononuclear O 
cells O 
and O 
bile O 
duct O 
hyperplasia O 
were O 
observed O 
in O 
chicks O 
fed O 
with O 
1 O 
ppm O 
AF O 
- O 
containing O 
diet O 
. O 
The O 
addition O 
of O 
CFO O 
to O 
AF O 
- O 
containing O 
diet O 
moderately O 
decreased O 
the O 
magnitude O 
and O 
severity O 
of O 
lesions O 
( O 
hydropic O 
degeneration O 
and O 
bile O 
duct O 
hyperplasia O 
) O 
in O 
the O 
liver O 
. O 
The O 
supplementation O 
of O 
CFO O 
to O 
the O 
basal O 
diet O 
did O 
not O 
produce O 
any O 
adverse O 
effects O 
in O 
birds O 
. O 

Inhibitory O 
Activity O 
of O 
2-Arylbenzofurans B-FAMILY 
versus O 
3-Arylcoumarins B-FAMILY 
: O 
Synthesis O 
, O 
in O 
vitro O 
Study O 
, O 
and O 
Docking O 
Calculations O 
. O 

oxidase O 
( O 
MAO O 
) O 
is O 
an O 
important O 
drug O 
target O 
for O 
the O 
treatment O 
of O 
neurological O 
disorders O 
. O 
Several O 
3-arylcoumarin B-FAMILY 
derivatives O 
were O 
previously O 
described O 
as O 
interesting O 
selective O 
MAO-B O 
inhibitors O 
. O 
Preserving O 
the O 
trans-stilbene B-TRIVIAL 
structure O 
, O 
a O 
series O 
of O 
2-arylbenzofuran B-FAMILY 
and O 
corresponding O 
3-arylcoumarin B-FAMILY 
derivatives O 
were O 
synthesized O 
and O 
evaluated O 
as O 
inhibitors O 
of O 
both O 
MAO O 
isoforms O 
, O 
MAO-A O 
and O 
MAO-B O 
. O 
In O 
general O 
, O 
both O 
types O 
of O 
derivatives O 
were O 
found O 
to O 
be O 
selective O 
MAO-B O 
inhibitors O 
, O 
with O 
IC50 O 
values O 
in O 
the O 
nano- O 
to O 
micromolar O 
range O 
. O 
5-Nitro-2-(4-methoxyphenyl)benzofuran B-SYSTEMATIC 
( O 
8 O 
) O 
is O 
the O 
most O 
active O 
compound O 
of O 
the O 
benzofuran B-SYSTEMATIC 
series O 
, O 
presenting O 
MAO-B O 
selectivity O 
and O 
reversible O 
inhibition O 
( O 
IC50 O 
= O 
140 O 
nM O 
) O 
. O 
3-(4'-Methoxyphenyl)-6-nitrocoumarin B-SYSTEMATIC 
( O 
15 O 
) O 
, O 
with O 
the O 
same O 
substitution O 
pattern O 
as O 
that O 
of O 
compound O 
8 O 
, O 
was O 
found O 
to O 
be O 
the O 
most O 
active O 
MAO-B O 
inhibitor O 
of O 
the O 
coumarin B-TRIVIAL 
series O 
( O 
IC50 O 
= O 
3 O 
nM O 
) O 
. O 
However O 
, O 
3-phenylcoumarin B-SYSTEMATIC 
14 O 
showed O 
activity O 
in O 
the O 
same O 
range O 
( O 
IC50 O 
= O 
6 O 
nM O 
) O 
, O 
is O 
reversible O 
, O 
and O 
also O 
severalfold O 
more O 
selective O 
than O 
compound O 
15 O 
. O 
Docking O 
experiments O 
for O 
the O 
most O 
active O 
compounds O 
into O 
the O 
MAO-B O 
and O 
MAO-A O 
binding O 
pockets O 
highlighted O 
different O 
interactions O 
between O 
the O 
derivative O 
classes O 
( O 
2-arylbenzofurans B-FAMILY 
and O 
3-arylcoumarins B-FAMILY 
) O 
, O 
and O 
provided O 
new O 
information O 
about O 
the O 
enzyme O 
- O 
inhibitor O 
interaction O 
and O 
the O 
potential O 
therapeutic O 
application O 
of O 
these O 
scaffolds O 
. O 

Laser-Patterned O 
Micro-Supercapacitors O 
from O 
Paintable O 
MoS2 B-FORMULA 
Films O 
. O 

- O 
sized O 
electrochemical O 
capacitors O 
have O 
recently O 
attracted O 
attention O 
due O 
to O 
their O 
possible O 
applications O 
in O 
micro O 
- O 
electronic O 
devices O 
. O 
Here O 
, O 
a O 
new O 
approach O 
to O 
large O 
- O 
scale O 
fabrication O 
of O 
high O 
- O 
capacitance O 
, O 
two O 
- O 
dimensional O 
MoS2 B-FORMULA 
film O 
- O 
based O 
micro O 
- O 
supercapacitors O 
is O 
demonstrated O 
via O 
simple O 
and O 
low O 
- O 
cost O 
spray O 
painting O 
of O 
MoS2 B-FORMULA 
nanosheets O 
on O 
Si B-FORMULA 
/ O 
SiO2 B-FORMULA 
chip O 
and O 
subsequent O 
laser O 
patterning O 
. O 
The O 
obtained O 
micro O 
- O 
supercapacitors O 
are O 
well O 
defined O 
by O 
ten O 
interdigitated O 
electrodes O 
( O 
five O 
electrodes O 
per O 
polarity O 
) O 
with O 
4.5 O 
mm O 
length O 
, O 
820 O 
μm O 
wide O 
for O 
each O 
electrode O 
, O 
200 O 
μm O 
spacing O 
between O 
two O 
electrodes O 
and O 
the O 
thickness O 
of O 
electrode O 
is O 
∼0.45 O 
μm O 
. O 
The O 
optimum O 
MoS2 B-FORMULA 
-based O 
micro O 
- O 
supercapacitor O 
exhibits O 
excellent O 
electrochemical O 
performance O 
for O 
energy O 
storage O 
with O 
aqueous O 
electrolytes O 
, O 
with O 
a O 
high O 
area O 
capacitance O 
of O 
8 O 
mF O 
cm(-2) O 
( O 
volumetric O 
capacitance O 
of O 
178 O 
F O 
cm(-3) O 
) O 
and O 
excellent O 
cyclic O 
performance O 
, O 
superior O 
to O 
reported O 
graphene B-TRIVIAL 
-based O 
micro O 
- O 
supercapacitors O 
. O 
This O 
strategy O 
could O 
provide O 
a O 
good O 
opportunity O 
to O 
develop O 
various O 
micro- O 
/ O 
nanosized O 
energy O 
storage O 
devices O 
to O 
satisfy O 
the O 
requirements O 
of O 
portable O 
, O 
flexible O 
, O 
and O 
transparent O 
micro O 
- O 
electronic O 
devices O 
. O 

is O 
an O 
amyloid O 
- O 
forming O 
polypeptide O 
built O 
of O 
two O 
disulfide B-SYSTEMATIC 
-linked O 
chains O 
( O 
A O 
and O 
B O 
) O 
, O 
both O 
themselves O 
amyloidogenic O 
. O 
An O 
interesting O 
property O 
of O 
insulin O 
is O 
that O 
agitation O 
strongly O 
influences O 
the O 
course O 
of O 
its O 
aggregation O 
, O 
resulting O 
in O 
characteristic O 
chiral O 
superstructures O 
of O 
amyloid O 
fibrils O 
. O 
Here O 
, O 
we O 
investigate O 
the O 
self O 
- O 
assembly O 
of O 
these O 
superstructures O 
by O 
comparing O 
the O 
quiescent O 
and O 
vortex O 
- O 
assisted O 
aggregation O 
of O 
insulin O 
and O 
its O 
individual O 
A O 
and O 
B O 
chains O 
in O 
the O 
presence O 
or O 
absence O 
of O 
reducing O 
agent O 
tris(2-carboxyethyl)phosphine B-SYSTEMATIC 
( O 
TCEP B-ABBREVIATION 
) O 
. O 
Our O 
study O 
shows O 
that O 
only O 
the O 
B O 
chain O 
in O 
the O 
presence O 
of O 
TCEP B-ABBREVIATION 
is O 
converted O 
into O 
aggregates O 
with O 
morphology O 
( O 
according O 
to O 
atomic O 
force O 
microscopy O 
) O 
and O 
optical O 
activity O 
( O 
manifested O 
as O 
an O 
extrinsic O 
Cotton O 
effect O 
induced O 
in O 
bound O 
thioflavin B-TRIVIAL 
T I-TRIVIAL 
) O 
characteristic O 
of O 
amyloid O 
superstructures O 
that O 
are O 
normally O 
formed O 
by O 
insulin O 
in O 
the O 
absence O 
of O 
TCEP B-ABBREVIATION 
. O 
In O 
contrast O 
to O 
more O 
rigid O 
B O 
- O 
peptide O 
fibrils O 
, O 
elongated O 
aggregates O 
of O 
the O 
A O 
peptide O 
become O 
amorphous O 
upon O 
agitation O 
. O 
Moreover O 
, O 
the O 
aggregation O 
of O 
equimolar O 
mixture O 
of O 
both O 
peptides O 
does O 
not O 
produce O 
highly O 
ordered O 
entities O 
. O 
Our O 
results O 
suggest O 
that O 
the O 
dynamics O 
of O 
the O 
B O 
chain O 
are O 
the O 
driving O 
force O 
for O 
the O 
assembly O 
of O 
superstructures O 
, O 
with O 
the O 
A O 
chain O 
being O 
complicit O 
as O 
long O 
as O 
its O 
own O 
dynamics O 
are O 
controlled O 
by O 
the O 
firm O 
attachment O 
to O 
the O 
B O 
chain O 
provided O 
by O 
the O 
intact O 
covalent O 
structure O 
of O 
insulin O 
. O 

of O 
urinary O 
6-mercaptopurine B-TRIVIAL 
and O 
three O 
of O 
its O 
metabolites O 
by O 
HPLC-UV O 
coupled O 
with O 
the O 
iodine B-SYSTEMATIC 
- O 
azide B-SYSTEMATIC 
reaction O 
. O 

: O 
The O 
presented O 
method O 
is O 
able O 
to O 
determine O 
6-mercaptopurine B-TRIVIAL 
( O 
6-MP B-SYSTEMATIC 
) O 
, O 
6-thioguanine B-SYSTEMATIC 
, O 
6-mercaptopurine B-SYSTEMATIC 
riboside I-SYSTEMATIC 
and O 
6-thioguanine B-SYSTEMATIC 
riboside I-SYSTEMATIC 
in O 
urine O 
, O 
and O 
is O 
thereby O 
dedicated O 
to O 
control O 
of O 
thiopurine B-TRIVIAL 
therapy O 
of O 
children O 
with O 
acute O 
lymphoblastic O 
leukemia O 
. O 
Good O 
separation O 
of O 
the O 
mentioned O 
compounds O 
was O 
achieved O 
on O 
a O 
C18 O 
stationary O 
phase O 
with O 
a O 
sodium B-SYSTEMATIC 
azide I-SYSTEMATIC 
and O 
sodium B-SYSTEMATIC 
heptane I-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
solution O 
, O 
acetonitrile B-SYSTEMATIC 
and O 
water O 
at O 
ratio O 
of O 
50 O 
: O 
1 O 
: O 
49 O 
( O 
v O 
/ O 
v O 
/ O 
v O 
) O 
. O 
Results O 
: O 
Coefficient O 
of O 
regression O 
is O 
> O 
0.99 O 
for O 
all O 
linearity O 
ranges O 
. O 
LOD O 
and O 
LOQ O 
are O 
0.3 O 
, O 
0.4 O 
, O 
0.3 O 
, O 
0.8 O 
and O 
0.4 O 
, O 
0.6 O 
, O 
0.5 O 
and O 
0.9 O 
nmol O 
/ O 
ml O 
of O 
urine O 
for O 
6-MP B-SYSTEMATIC 
, O 
6-thioguanine B-SYSTEMATIC 
, O 
6-mercaptopurine B-SYSTEMATIC 
riboside I-SYSTEMATIC 
and O 
6-thioguanine B-SYSTEMATIC 
riboside I-SYSTEMATIC 
, O 
respectively O 
. O 
Intra- O 
and O 
inter O 
- O 
day O 
recovery O 
and O 
RSD O 
are O 
close O 
to O 
100% O 
and O 
less O 
than O 
10% O 
, O 
respectively O 
, O 
for O 
all O 
investigated O 
thiopurines B-FAMILY 
. O 
Conclusion O 
: O 
The O 
elaborated O 
method O 
was O 
successfully O 
applied O 
for O 
detection O 
and O 
quantitation O 
of O 
6-MP B-SYSTEMATIC 
and O 
its O 
selected O 
metabolites O 
in O 
patients O 
' O 
urine O 
samples O 
. O 

Complexes O 
of O 
Poly[3,5-bis(dimethylaminomethyl)-4-hydroxystyrene]-block-poly(ethylene B-FAMILY 
oxide I-FAMILY 
) I-FAMILY 
and O 
Sodium B-SYSTEMATIC 
Dodecyl I-SYSTEMATIC 
Sulfate I-SYSTEMATIC 
: O 
Anomalous O 
Self-Assembly O 
Behavior O 
. O 

- O 
surfactant O 
complexes O 
( O 
PE-S O 
) O 
formed O 
by O 
double O 
hydrophilic O 
cationic O 
polyelectrolyte O 
poly[3,5-bis(dimethylaminomethyl)-4-hydroxystyrene]-block-poly(ethylene B-FAMILY 
oxide I-FAMILY 
) I-FAMILY 
( O 
NPHOS-PEO B-ABBREVIATION 
) O 
and O 
anionic O 
surfactant O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
SDS B-ABBREVIATION 
) O 
in O 
acidic O 
aqueous O 
solutions O 
were O 
studied O 
by O 
light O 
scattering O 
, O 
SAXS O 
, O 
and O 
scanning O 
transmission O 
electron O 
microcopy O 
in O 
the O 
environmental O 
mode O 
( O 
wet-STEM O 
) O 
for O 
various O 
stoichiometric O 
ratios O 
between O 
the O 
numbers O 
of O 
SDS O 
anions O 
and O 
dimethylaminomethyl B-SYSTEMATIC 
groups O 
of O 
NPHOS B-ABBREVIATION 
in O 
the O 
complex O 
. O 
The O 
obtained O 
results O 
show O 
that O 
the O 
NPHOS-PEO B-ABBREVIATION 
/ O 
SDS B-ABBREVIATION 
system O 
behaves O 
differently O 
from O 
other O 
systems O 
of O 
double O 
hydrophilic O 
block O 
polyelectrolyte O 
and O 
oppositely O 
charged O 
ionic O 
surfactant O 
because O 
it O 
forms O 
water O 
- O 
insoluble O 
PE-S O 
for O 
compositions O 
close O 
to O 
the O 
zero O 
net O 
charge O 
of O 
the O 
complex O 
. O 
This O 
phase O 
separation O 
occurs O 
, O 
instead O 
of O 
the O 
PE-S O 
rearrangement O 
to O 
core O 
- O 
shell O 
particles O 
, O 
which O 
is O 
hindered O 
due O 
to O 
conformational O 
rigidity O 
of O 
the O 
NPHOS B-ABBREVIATION 
blocks O 
. O 
For O 
the O 
surfactant O 
amounts O 
below O 
and O 
above O 
the O 
precipitation O 
region O 
, O 
large O 
spherical O 
aggregates O 
and O 
their O 
clusters O 
are O 
present O 
in O 
the O 
solution O 
. O 
SAXS O 
measurements O 
indicate O 
that O 
although O 
the O 
NPHOS-PEO B-ABBREVIATION 
/ O 
SDS B-ABBREVIATION 
system O 
does O 
not O 
form O 
the O 
core O 
- O 
shell O 
particles O 
with O 
the O 
NPHOS B-ABBREVIATION 
/ O 
SDS B-ABBREVIATION 
core O 
and O 
the O 
PEO B-ABBREVIATION 
shell O 
as O 
other O 
PE-S O 
of O 
double O 
hydrophilic O 
polyelectrolytes O 
, O 
the O 
aggregates O 
contain O 
domains O 
of O 
closely O 
packed O 
surfactant O 
micelles O 
which O 
bind O 
to O 
both O 
NPHOS B-ABBREVIATION 
polyelectrolyte O 
blocks O 
and O 
PEO B-ABBREVIATION 
blocks O 
. O 

in O 
the O 
Visible O 
Absorption O 
Bands O 
of O 
Jet-Cooled O 
Phenylperoxy B-FAMILY 
Radicals O 
. O 

visible O 
absorption O 
bands O 
of O 
the O 
phenylperoxy B-SYSTEMATIC 
radical O 
in O 
the O 
gas O 
phase O 
have O 
been O 
investigated O 
using O 
cavity O 
ring O 
- O 
down O 
spectroscopy O 
. O 
Jet O 
- O 
cooling O 
was O 
used O 
to O 
reduce O 
the O 
spectral O 
congestion O 
. O 
Structured O 
spectra O 
spanning O 
the O 
range O 
from O 
17 O 
500 O 
to O 
19 O 
0 O 
cm(-1) O 
are O 
reported O 
for O 
the O 
first O 
time O 
. O 
Analyses O 
of O 
these O 
data O 
have O 
been O 
guided O 
by O 
the O 
results O 
from O 
time O 
- O 
dependent O 
density O 
functional O 
calculations O 
. O 
The O 
observed O 
spectrum O 
was O 
found O 
to O 
be O 
dominated O 
by O 
the O 
bands O 
of O 
the O 
B̃(2)A″-X̃(2)A″ O 
transition O 
. O 
An O 
analysis O 
of O 
the O 
rotational O 
contour O 
for O 
the O 
origin O 
band O 
yielded O 
a O 
homogeneous O 
line O 
width O 
of O 
2.2 O 
cm(-1) O 
, O 
corresponding O 
to O 
a O 
decay O 
rate O 
of O 
4.1 O 
× O 
10(11) O 
s(-1) O 
. O 
The O 
results O 
provide O 
a O 
rationale O 
for O 
the O 
lack O 
of O 
structure O 
in O 
room O 
temperature O 
spectra O 
that O 
have O 
been O 
previously O 
attributed O 
to O 
phenylperoxy B-SYSTEMATIC 
. O 
They O 
also O 
indicate O 
that O 
the O 
lower O 
energy O 
region O 
of O 
the O 
spectrum O 
may O 
show O 
resolvable O 
structure O 
at O 
room O 
temperature O 
. O 
If O 
so O 
, O 
this O 
would O 
provide O 
a O 
more O 
definitive O 
signature O 
for O 
monitoring O 
phenylperoxy B-SYSTEMATIC 
in O 
kinetic O 
measurements O 
. O 

subunit O 
vaccines O 
offer O 
important O 
potential O 
advantages O 
over O 
live O 
vaccine O 
vectors O 
but O 
generally O 
elicit O 
weaker O 
and O 
shorter O 
- O 
lived O 
cellular O 
immune O 
responses O 
. O 
Here O 
we O 
investigate O 
the O 
use O 
of O 
pH-responsive O 
, O 
endosomolytic O 
polymer O 
nanoparticles O 
that O 
were O 
originally O 
developed O 
for O 
RNA O 
delivery O 
as O 
vaccine O 
delivery O 
vehicles O 
for O 
enhancing O 
cellular O 
and O 
humoral O 
immune O 
responses O 
. O 
Micellar O 
nanoparticles O 
were O 
assembled O 
from O 
amphiphilic O 
diblock O 
copolymers O 
composed O 
of O 
an O 
ampholytic O 
core O 
- O 
forming O 
block O 
and O 
a O 
redesigned O 
polycationic O 
corona O 
block O 
doped O 
with O 
thiol B-FAMILY 
-reactive O 
pyridyl B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
groups O 
to O 
enable O 
dual O 
- O 
delivery O 
of O 
antigens O 
and O 
immunostimulatory O 
CpG B-ABBREVIATION 
oligodeoxynucleotide O 
( O 
CpG B-ABBREVIATION 
ODN O 
) O 
adjuvants O 
. O 
Polymers O 
assembled O 
into O 
23 O 
nm O 
particles O 
with O 
simultaneous O 
packaging O 
of O 
CpG B-ABBREVIATION 
ODN O 
and O 
a O 
thiolated O 
protein O 
antigen O 
, O 
ovalbumin O 
( O 
ova O 
) O 
. O 
Conjugation O 
of O 
ova O 
to O 
nanoparticles O 
significantly O 
enhanced O 
antigen O 
cross O 
- O 
presentation O 
in O 
vitro O 
relative O 
to O 
free O 
ova O 
or O 
an O 
unconjugated O 
, O 
physical O 
mixture O 
of O 
the O 
parent O 
compounds O 
. O 
Subcutaneous O 
vaccination O 
of O 
mice O 
with O 
ova O 
- O 
nanoparticle O 
conjugates O 
elicited O 
a O 
significantly O 
higher O 
CD8(+) O 
T O 
cell O 
response O 
( O 
0.5% O 
IFN-γ(+) O 
of O 
CD8(+) O 
) O 
compared O 
to O 
mice O 
vaccinated O 
with O 
free O 
ova O 
or O 
a O 
physical O 
mixture O 
of O 
the O 
two O 
components O 
. O 
Significantly O 
, O 
immunization O 
with O 
ova O 
- O 
nanoparticle O 
conjugates O 
electrostatically O 
complexed O 
with O 
CpG B-ABBREVIATION 
ODN O 
( O 
dual O 
- O 
delivery O 
) O 
enhanced O 
CD8(+) O 
T O 
cell O 
responses O 
( O 
3.4% O 
IFN-γ(+) O 
of O 
CD8(+) O 
) O 
7- O 
, O 
18- O 
, O 
and O 
8-fold O 
relative O 
to O 
immunization O 
with O 
conjugates O 
, O 
ova O 
administered O 
with O 
free O 
CpG B-ABBREVIATION 
, O 
or O 
a O 
formulation O 
containing O 
free O 
ova O 
and O 
CpG B-ABBREVIATION 
complexed O 
to O 
micelles O 
, O 
respectively O 
. O 
Similarly O 
, O 
dual O 
- O 
delivery O 
carriers O 
significantly O 
increased O 
CD4(+)IFN-γ(+) O 
( O 
Th1 O 
) O 
responses O 
and O 
elicited O 
a O 
balanced O 
IgG1 O 
/ O 
IgG2c O 
antibody O 
response O 
. O 
Intradermal O 
administration O 
further O 
augmented O 
cellular O 
immune O 
responses O 
, O 
with O 
dual O 
- O 
delivery O 
carriers O 
inducing O 
∼7% O 
antigen O 
- O 
specific O 
CD8(+) O 
T O 
cells O 
. O 
This O 
work O 
demonstrates O 
the O 
ability O 
of O 
pH-responsive O 
, O 
endosomolytic O 
nanoparticles O 
to O 
actively O 
promote O 
antigen O 
cross O 
- O 
presentation O 
and O 
augment O 
cellular O 
and O 
humoral O 
immune O 
responses O 
via O 
dual O 
- O 
delivery O 
of O 
protein O 
antigens O 
and O 
CpG B-ABBREVIATION 
ODN O 
. O 
Hence O 
, O 
pH-responsive O 
polymeric O 
nanoparticles O 
offer O 
promise O 
as O 
a O 
delivery O 
platform O 
for O 
protein O 
subunit O 
vaccines O 
. O 

Carrier O 
Mobility O 
in O 
Few O 
- O 
Layer O 
MoS2 B-FORMULA 
Field-Effect O 
Transistors O 
with O 
Ionic-Liquid O 
Gating O 
. O 

report O 
the O 
fabrication O 
of O 
ionic O 
liquid O 
(IL)-gated O 
field O 
- O 
effect O 
transistors O 
( O 
FETs O 
) O 
consisting O 
of O 
bilayer O 
and O 
few O 
- O 
layer O 
MoS2 B-FORMULA 
. O 
Our O 
transport O 
measurements O 
indicate O 
that O 
the O 
electron O 
mobility O 
μ O 
≈ O 
60 O 
cm(2) O 
V(-1) O 
s(-1) O 
at O 
250 O 
K O 
in O 
IL-gated O 
devices O 
exceeds O 
significantly O 
that O 
of O 
comparable O 
back O 
- O 
gated O 
devices O 
. O 
IL-FETs O 
display O 
a O 
mobility O 
increase O 
from O 
≈100 O 
cm(2) O 
V(-1) O 
s(-1) O 
at O 
180 O 
K O 
to O 
≈220 O 
cm(2) O 
V(-1) O 
s(-1) O 
at O 
77 O 
K O 
in O 
good O 
agreement O 
with O 
the O 
true O 
channel O 
mobility O 
determined O 
from O 
four O 
- O 
terminal O 
measurements O 
, O 
ambipolar O 
behavior O 
with O 
a O 
high O 
ON O 
/ O 
OFF O 
ratio O 
> O 
10(7) O 
(10(4)) O 
for O 
electrons O 
( O 
holes O 
) O 
, O 
and O 
a O 
near O 
ideal O 
subthreshold O 
swing O 
of O 
≈50 O 
mV O 
/ O 
dec O 
at O 
250 O 
K O 
. O 
We O 
attribute O 
the O 
observed O 
performance O 
enhancement O 
, O 
specifically O 
the O 
increased O 
carrier O 
mobility O 
that O 
is O 
limited O 
by O 
phonons O 
, O 
to O 
the O 
reduction O 
of O 
the O 
Schottky O 
barrier O 
at O 
the O 
source O 
and O 
drain O 
electrode O 
by O 
band O 
bending O 
caused O 
by O 
the O 
ultrathin O 
IL O 
dielectric O 
layer O 
. O 

Aggregation O 
States O 
of O 
Chiral O 
Polymerizable O 
Amphiphiles O 
from O 
l-Tyrosine B-TRIVIAL 
and O 
l-Phenyl B-TRIVIAL 
Alanine I-TRIVIAL 
in O 
Water O 
. O 

salts O 
of O 
maleamic B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
of O 
lauryl B-TRIVIAL 
ester I-TRIVIAL 
of O 
tyrosine B-TRIVIAL 
( O 
MTNa O 
) O 
and O 
phenyl B-TRIVIAL 
alanine I-TRIVIAL 
( O 
MPNa O 
) O 
in O 
water O 
exhibited O 
strong O 
pH-responsive O 
behaviors O 
of O 
viscosity O 
and O 
specific O 
conductivity O 
that O 
originate O 
from O 
the O 
concentration O 
and O 
pH O 
dependence O 
of O 
their O 
aggregation O 
states O 
. O 
The O 
aggregates O 
were O 
characterized O 
by O 
a O 
novel O 
spin O 
- O 
probe O 
- O 
partitioning O 
electron O 
paramagnetic O 
resonance O 
( O 
SPPEPR O 
) O 
method O 
and O 
dynamic O 
light O 
scattering O 
( O 
DLS O 
) O 
. O 
Results O 
of O 
high O 
- O 
precision O 
fitting O 
of O 
the O 
second O 
- O 
harmonic O 
EPR O 
spectra O 
of O 
the O 
small O 
spin O 
probe O 
di-tert-butyl B-SYSTEMATIC 
nitroxide I-SYSTEMATIC 
( O 
DTBN B-ABBREVIATION 
) O 
in O 
these O 
aggregates O 
together O 
with O 
viscosity O 
, O 
conductivity O 
, O 
and O 
DLS O 
showed O 
that O 
, O 
at O 
pH O 
∼ O 
7.54 O 
, O 
MTNa O 
formed O 
micelles O 
and O 
MPNa O 
vesicles O 
and O 
MTNa O 
exhibited O 
a O 
pH-induced O 
micelle O 
to O 
vesicle O 
transition O 
as O 
pH O 
was O 
lowered O 
toward O 
6 O 
. O 
MTNa O 
, O 
at O 
pH O 
∼ O 
7.54 O 
, O 
formed O 
small O 
micelles O 
at O 
low O 
concentrations O 
that O 
transformed O 
to O 
long O 
worm O 
- O 
like O 
micelles O 
for O 
concentrations O 
≥ O 
0.05 O 
M O 
, O 
accompanied O 
by O 
a O 
30-fold O 
increase O 
in O 
solution O 
viscosity O 
. O 
The O 
hydrodynamic O 
radii O 
from O 
DLS O 
confirmed O 
the O 
presence O 
of O 
small O 
micellar O 
aggregates O 
of O 
radius O 
∼ O 
2 O 
nm O 
in O 
MTNa O 
at O 
pH O 
∼ O 
7.54 O 
at O 
the O 
lower O 
concentrations O 
, O 
with O 
coexisting O 
micelles O 
( O 
∼2 O 
nm O 
) O 
and O 
vesicles O 
( O 
∼50 O 
nm O 
) O 
at O 
pH O 
near O 
6.5 O 
, O 
vesicles O 
( O 
radii O 
∼ O 
70 O 
nm O 
) O 
at O 
pH O 
near O 
6 O 
, O 
and O 
large O 
vesicles O 
( O 
85 O 
nm O 
) O 
in O 
MPNa O 
at O 
pH O 
∼ O 
7.6 O 
. O 
Both O 
MTNa O 
and O 
MPNa O 
precipitated O 
upon O 
reduction O 
of O 
pH O 
below O 
6 O 
and O 
below O 
7 O 
, O 
respectively O 
. O 
The O 
rate O 
of O 
transfer O 
of O 
DTBN B-ABBREVIATION 
between O 
the O 
aqueous O 
phase O 
and O 
the O 
aggregate O 
was O 
calculated O 
from O 
the O 
high O 
- O 
field O 
Lorentzian O 
linewidths O 
of O 
the O 
electron O 
paramagnetic O 
resonance O 
( O 
EPR O 
) O 
spectra O 
. O 
The O 
activation O 
energy O 
for O 
the O 
transfer O 
determined O 
from O 
the O 
temperature O 
dependence O 
of O 
the O 
rate O 
of O 
transfer O 
is O 
12.7 O 
kJ O 
/ O 
mol O 
for O 
MTNa O 
vesicles O 
( O 
pH O 
∼ O 
6 O 
) O 
and O 
20.6 O 
± O 
1.3 O 
kJ O 
/ O 
mol O 
for O 
MPNa O 
( O 
pH O 
∼ O 
7.6 O 
) O 
. O 
The O 
pH-induced O 
transformations O 
were O 
reversible O 
. O 

of O 
aryl B-FAMILY 
ureas I-FAMILY 
and O 
aryl B-FAMILY 
amides I-FAMILY 
as O 
potent O 
and O 
selective O 
histamine B-TRIVIAL 
H3 O 
receptor O 
antagonists O 
for O 
the O 
treatment O 
of O 
obesity O 
( O 
Part O 
I O 
) O 
. O 

series O 
of O 
structurally O 
novel O 
aryl B-FAMILY 
ureas I-FAMILY 
was O 
derived O 
from O 
optimization O 
of O 
the O 
HTS O 
lead O 
as O 
selective O 
histamine B-TRIVIAL 
H3 O 
receptor O 
( O 
H3R O 
) O 
antagonists O 
. O 
The O 
SAR O 
was O 
explored O 
and O 
the O 
data O 
obtained O 
set O 
up O 
the O 
starting O 
point O 
and O 
foundation O 
for O 
further O 
optimization O 
. O 
The O 
most O 
potent O 
tool O 
compounds O 
, O 
as O 
exemplified O 
by O 
compounds O 
2l O 
, O 
5b O 
, O 
5d O 
, O 
and O 
5e O 
, O 
displayed O 
antagonism O 
potencies O 
in O 
the O 
subnanomolar O 
range O 
in O 
in O 
vitro O 
human-H3R O 
FLIPR O 
assays O 
and O 
rhesus O 
monkey O 
H3R O 
binding O 
assays O 
. O 

-based O 
thiobenzamide B-SYSTEMATIC 
as O 
an O 
effective O 
sensor O 
for O 
highly O 
selective O 
detection O 
of O 
mercury B-SYSTEMATIC 
(II) I-SYSTEMATIC 
. O 

on O 
highly O 
selective O 
and O 
irreversible O 
Hg(2+) B-FORMULA 
-promoted O 
desulfurization O 
reaction O 
, O 
a O 
new O 
and O 
simple O 
phenanthroimidazole B-FAMILY 
-type O 
sensor O 
was O 
prepared O 
and O 
exhibited O 
high O 
selectivity O 
towards O 
Hg(2+) B-FORMULA 
ion O 
over O 
other O 
metal O 
ions O 
, O 
accompanied O 
by O 
transformation O 
of O 
a O 
weakly O 
fluorescent O 
thioamide B-SYSTEMATIC 
moiety O 
( O 
colorless O 
) O 
to O 
a O 
highly O 
fluorescent O 
amide B-FAMILY 
one O 
( O 
blue O 
) O 
, O 
with O 
a O 
136-fold O 
increase O 
in O 
fluorescent O 
intensity O 
in O 
aqueous O 
solution O 
with O 
a O 
pH O 
span O 
2.57-9.12 O 
. O 

' O 
vascular O 
depression O 
' O 
hypothesis O 
has O 
recently O 
attracted O 
significant O 
research O 
attention O 
, O 
although O 
the O 
causal O 
relationship O 
between O 
vascular O 
- O 
related O 
injuries O 
and O 
depression O 
has O 
not O 
been O 
established O 
. O 
Here O 
, O 
we O 
show O 
that O 
one O 
episode O 
of O 
cerebral O 
ischemia O 
was O 
sufficient O 
to O 
greatly O 
increase O 
the O 
sensitivity O 
of O 
rats O 
to O 
potentially O 
depressogenic O 
events O 
, O 
evaluated O 
at O 
below O 
- O 
threshold O 
intensities O 
in O 
the O 
open O 
space O 
swim O 
test O 
. O 
The O 
induced O 
' O 
ischemic O 
depression O 
' O 
was O 
lasting O 
and O 
sensitive O 
to O 
an O 
acute O 
administration O 
of O 
brain O 
- O 
derived O 
neurotrophic O 
factor O 
or O 
bryostatin-1 B-TRIVIAL 
, O 
a O 
relatively O 
selective O 
activator O 
of O 
protein O 
kinase O 
Cε O 
, O 
during O 
the O 
induction O 
phase O 
. O 
Chronic O 
treatment O 
with O 
bryostatin-1 B-TRIVIAL 
( O 
5 O 
weeks O 
) O 
after O 
the O 
induction O 
of O 
depressive O 
behavior O 
reversed O 
the O 
depressive O 
immobility O 
and O 
produced O 
a O 
lasting O 
therapeutic O 
effect O 
, O 
which O 
remained O 
effective O 
3 O 
weeks O 
after O 
discontinuation O 
of O 
the O 
treatment O 
. O 
Similar O 
treatment O 
with O 
alaproclate B-TRIVIAL 
, O 
a O 
selective O 
serotonin B-TRIVIAL 
reuptake O 
inhibitor O 
, O 
in O 
contrast O 
, O 
produced O 
temporary O 
relief O 
from O 
the O 
depressive O 
symptoms O 
, O 
with O 
the O 
therapeutic O 
effect O 
disappearing O 
soon O 
after O 
the O 
end O 
of O 
the O 
treatment O 
. O 
The O 
results O 
strongly O 
suggest O 
that O 
cerebral O 
ischemia O 
has O 
a O 
direct O 
role O 
in O 
shaping O 
the O 
sensitivity O 
of O 
an O 
individual O 
to O 
depressogenic O 
events O 
and O 
that O 
bryostatin-1 B-TRIVIAL 
-like O 
agents O 
may O 
be O 
developed O 
as O 
therapeutics O 
for O 
treating O 
ischemic O 
depression O 
in O 
humans O 
. O 

status O 
of O 
liposomal O 
porphyrinoid B-FAMILY 
photosensitizers O 
. O 

complete O 
eradication O 
of O 
various O 
targets O 
, O 
such O 
as O 
infectious O 
agents O 
or O 
cancer O 
cells O 
, O 
while O 
leaving O 
healthy O 
host O 
cells O 
untouched O 
, O 
is O 
still O 
a O 
great O 
challenge O 
faced O 
in O 
the O 
field O 
of O 
medicine O 
. O 
Photodynamic O 
therapy O 
( O 
PDT O 
) O 
seems O 
to O 
be O 
a O 
promising O 
approach O 
for O 
anticancer O 
treatment O 
, O 
as O 
well O 
as O 
to O 
combat O 
various O 
dermatologic O 
and O 
ophthalmic O 
diseases O 
and O 
microbial O 
infections O 
. O 
The O 
application O 
of O 
liposomes O 
as O 
delivery O 
systems O 
for O 
porphyrinoids B-FAMILY 
has O 
helped O 
overcome O 
many O 
drawbacks O 
of O 
conventional O 
photosensitizers O 
and O 
facilitated O 
the O 
development O 
of O 
novel O 
effective O 
photosensitizers O 
that O 
can O 
be O 
encapsulated O 
in O 
liposomes O 
. O 
The O 
development O 
, O 
preclinical O 
studies O 
and O 
future O 
directions O 
for O 
liposomal O 
delivery O 
of O 
conventional O 
and O 
novel O 
photosensitizers O 
are O 
reviewed O 
. O 

and O 
energetics O 
of O 
gas O 
phase O 
halogen B-FAMILY 
-bonding O 
in O 
mono- O 
, O 
bi- O 
, O 
and O 
tri O 
- O 
dentate O 
anion O 
receptors O 
as O 
studied O 
by O 
BIRD O 
. O 

of O 
mono- O 
, O 
bi- O 
( O 
RB O 
) O 
, O 
and O 
tridentate O 
( O 
RT O 
) O 
receptors O 
with O 
a O 
range O 
of O 
anions O 
( O 
Cl(-) B-FORMULA 
, O 
Br(-) B-FORMULA 
, O 
I(-) B-FORMULA 
, O 
NO3(-) B-FORMULA 
, O 
H2PO4(-) B-FORMULA 
, O 
HSO4(-) B-FORMULA 
, O 
and O 
tosylate B-TRIVIAL 
( O 
TsO(-) B-FORMULA 
) O 
) O 
have O 
been O 
studied O 
in O 
the O 
gas O 
phase O 
by O 
both O 
experimental O 
and O 
theoretical O 
methods O 
. O 
Temperature O 
dependent O 
blackbody O 
infrared O 
radiative O 
dissociation O 
( O 
BIRD O 
) O 
experiments O 
were O 
performed O 
on O 
complexes O 
of O 
C8F17I B-FORMULA 
with O 
Br(-) B-FORMULA 
and O 
I(-) B-FORMULA 
, O 
RB O 
with O 
I(-) B-FORMULA 
, O 
NO3(-) B-FORMULA 
, O 
HSO4(-) B-FORMULA 
, O 
H2PO4(-) B-FORMULA 
, O 
and O 
TsO(-) B-FORMULA 
, O 
and O 
RT O 
with O 
I(-) B-FORMULA 
, O 
HSO4(-) B-FORMULA 
and O 
TsO(-) B-FORMULA 
and O 
the O 
observed O 
Arrhenius O 
parameters O 
are O 
reported O 
here O 
. O 
Master O 
equation O 
modeling O 
of O 
the O 
BIRD O 
kinetics O 
data O 
was O 
carried O 
out O 
to O 
determine O 
threshold O 
dissociation O 
energies O 
. O 
Geometry O 
optimizations O 
and O 
thermochemistry O 
calculations O 
were O 
performed O 
using O 
the O 
B3LYP O 
/ O 
6-31 O 
+ O 
G(d,p) O 
level O 
of O 
theory O 
. O 
Additional O 
single O 
point O 
energies O 
were O 
calculated O 
using O 
MP2 O 
/ O 
6-311 O 
+ O 
+ O 
G(2d,p) O 
. O 
Results O 
were O 
examined O 
in O 
terms O 
of O 
the O 
binding O 
order O 
of O 
various O 
anions O 
as O 
well O 
as O 
the O 
added O 
binding O 
strength O 
from O 
additional O 
halogen B-FAMILY 
bonding O 
( O 
XB O 
) O 
interactions O 
. O 
The O 
relative O 
binding O 
energies O 
of O 
ions O 
were O 
generally O 
consistent O 
with O 
the O 
ordering O 
previously O 
reported O 
from O 
solution O 
phase O 
experiments O 
; O 
however O 
, O 
the O 
relatively O 
strong O 
binding O 
of O 
H2PO4(-) B-FORMULA 
to O 
the O 
bidentate O 
receptor O 
contrasted O 
the O 
solution O 
phase O 
observation O 
of O 
oxo B-SYSTEMATIC 
anions O 
having O 
weaker O 
interactions O 
when O 
compared O 
to O 
halides B-FAMILY 
. O 
An O 
increase O 
in O 
the O 
energy O 
required O 
to O 
remove O 
the O 
same O 
anion O 
from O 
the O 
tridentate O 
receptor O 
when O 
compared O 
to O 
the O 
bidentate O 
and O 
monodentate O 
receptors O 
is O 
explained O 
as O 
being O 
due O 
to O 
the O 
increase O 
in O 
halogen B-FAMILY 
bonding O 
interactions O 
. O 
The O 
possibility O 
of O 
mixed O 
halogen B-FAMILY 
and O 
hydrogen B-SYSTEMATIC 
bonded O 
complexes O 
were O 
considered O 
. O 

new O 
potential O 
nano O 
- O 
oncological O 
therapy O 
based O 
on O 
polyamino B-FAMILY 
acid I-FAMILY 
nanocapsules O 
. O 

critical O 
objective O 
in O 
cancer O 
therapy O 
is O 
to O 
reduce O 
the O 
systemic O 
toxicity O 
through O 
the O 
modification O 
of O 
the O 
biodistribution O 
of O 
anticancer O 
drugs O 
. O 
Herein O 
, O 
we O 
disclose O 
a O 
new O 
biodegradable O 
nanocarrier O 
, O 
polyglutamic B-FAMILY 
acid I-FAMILY 
( O 
PGA B-ABBREVIATION 
) O 
nanocapsules O 
, O 
and O 
present O 
the O 
in O 
vivo O 
pharmacokinetics O 
/ O 
toxicity O 
proof O 
- O 
of O 
- O 
concept O 
for O 
the O 
anticancer O 
drug O 
plitidepsin B-TRIVIAL 
. O 
These O 
novel O 
nanocapsules O 
were O 
prepared O 
using O 
a O 
modified O 
solvent O 
displacement O 
technique O 
where O 
the O 
polyamino B-FAMILY 
acid I-FAMILY 
was O 
electrostatically O 
deposited O 
onto O 
the O 
lipid O 
core O 
. O 
The O 
nanocapsules O 
exhibited O 
an O 
average O 
size O 
of O 
200nm O 
, O 
a O 
negative O 
zeta O 
potential O 
and O 
a O 
great O 
capacity O 
for O 
the O 
encapsulation O 
of O 
plitidepsin B-TRIVIAL 
( O 
encapsulation O 
efficiency O 
above O 
90% O 
) O 
. O 
In O 
addition O 
, O 
the O 
nanocapsules O 
could O 
be O 
freeze O 
- O 
dried O 
and O 
showed O 
an O 
adequate O 
stability O 
profile O 
upon O 
storage O 
. O 
Finally O 
, O 
the O 
in O 
vivo O 
proof O 
- O 
of O 
- O 
concept O 
studies O 
performed O 
in O 
mice O 
indicated O 
that O 
the O 
encapsulation O 
provided O 
the O 
drug O 
with O 
a O 
prolonged O 
blood O 
circulation O 
and O 
a O 
significantly O 
reduced O 
toxicity O 
. O 
In O 
fact O 
, O 
the O 
maximum O 
tolerated O 
dose O 
of O 
the O 
nanoencapsulated O 
drug O 
was O 
more O 
than O 
3 O 
times O 
that O 
of O 
the O 
reference O 
formulation O 
( O 
Cremophor B-TRIVIAL 
® O 
EL O 
plitidepsin B-TRIVIAL 
solution O 
) O 
. O 
Overall O 
, O 
beyond O 
the O 
value O 
of O 
this O 
specific O 
formulation O 
, O 
the O 
work O 
reported O 
here O 
represents O 
the O 
evidence O 
of O 
the O 
potential O 
of O 
polyamino B-FAMILY 
acid I-FAMILY 
nanocapsules O 
in O 
nano O 
- O 
oncological O 
therapy O 
. O 

of O 
Selenium B-SYSTEMATIC 
Intervention O 
on O 
Chronic O 
Fluorosis-Induced O 
Renal O 
Cell O 
Apoptosis O 
in O 
Rats O 
. O 

study O 
aims O 
to O 
explore O 
the O 
effect O 
of O 
selenium B-SYSTEMATIC 
in O 
fluoride B-SYSTEMATIC 
-induced O 
renal O 
cell O 
apoptosis O 
in O 
rats O 
and O 
determine O 
the O 
optimal O 
level O 
of O 
selenium B-SYSTEMATIC 
in O 
drinking O 
water O 
to O 
prevent O 
fluorosis O 
. O 
Experimental O 
animals O 
were O 
divided O 
into O 
a O 
control O 
group O 
, O 
a O 
sodium B-SYSTEMATIC 
fluoride I-SYSTEMATIC 
-treated O 
group O 
( O 
NaF B-FORMULA 
, O 
50 O 
mg O 
/ O 
L O 
) O 
, O 
three O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
-treated O 
groups O 
( O 
Na2SeO3 B-FORMULA 
, O 
0.375 O 
, O 
0.75 O 
, O 
and O 
1.5 O 
mg O 
/ O 
L O 
) O 
, O 
and O 
three O 
selenium B-SYSTEMATIC 
+ O 
NaF B-FORMULA 
-treated O 
groups O 
( O 
Na2SeO3 B-FORMULA 
, O 
0.375 O 
, O 
0.75 O 
, O 
and O 
1.5 O 
mg O 
/ O 
L O 
; O 
NaF B-FORMULA 
, O 
50 O 
mg O 
/ O 
L O 
) O 
. O 
Ultrastructural O 
changes O 
in O 
the O 
kidney O 
tissues O 
of O 
each O 
group O 
were O 
observed O 
by O 
transmission O 
electron O 
microscopy O 
. O 
Apoptosis O 
was O 
detected O 
by O 
terminal O 
deoxynucleotidyl O 
transferase O 
- O 
mediated O 
dUTP B-ABBREVIATION 
nick O 
- O 
end O 
labeling O 
assay O 
and O 
the O 
expressions O 
of O 
Bcl-2 O 
and O 
Bax O 
proteins O 
were O 
detected O 
by O 
immunohistochemical O 
methods O 
. O 
The O 
expressions O 
of O 
Bcl-2 O 
and O 
Bax O 
mRNA O 
were O 
detected O 
by O 
reverse O 
transcription O 
- O 
polymerase O 
chain O 
reaction O 
. O 
The O 
results O 
showed O 
that O 
Bcl-2 O 
, O 
Bax O 
, O 
and O 
Bax O 
/ O 
Bcl-2 O 
protein O 
expressions O 
in O 
the O 
fluoride B-SYSTEMATIC 
and O 
high O 
selenium B-SYSTEMATIC 
groups O 
were O 
highly O 
elevated O 
compared O 
with O 
the O 
control O 
group O 
( O 
P O 
< O 
0.01 O 
) O 
. O 
Bax O 
expression O 
in O 
the O 
low O 
selenium B-SYSTEMATIC 
group O 
and O 
Bcl-2 O 
, O 
Bax O 
, O 
and O 
Bax O 
/ O 
Bcl-2 O 
protein O 
expressions O 
in O 
the O 
moderate O 
selenium B-SYSTEMATIC 
groups O 
were O 
observably O 
elevated O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Bax O 
and O 
Bax O 
/ O 
Bcl-2 O 
expressions O 
in O 
the O 
fluoride B-SYSTEMATIC 
group O 
and O 
Bax O 
mRNA O 
expression O 
in O 
the O 
high O 
selenium B-SYSTEMATIC 
group O 
were O 
highly O 
elevated O 
( O 
P O 
< O 
0.01 O 
) O 
. O 
Bax O 
/ O 
Bcl-2 O 
mRNA O 
expression O 
in O 
the O 
high O 
selenium B-SYSTEMATIC 
group O 
was O 
also O 
highly O 
elevated O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Compared O 
with O 
the O 
fluoride B-SYSTEMATIC 
group O 
, O 
the O 
group O 
treated O 
with O 
low O 
selenium B-SYSTEMATIC 
has O 
Bax O 
protein O 
expression O 
that O 
was O 
observably O 
reduced O 
( O 
P O 
< O 
0.05 O 
) O 
; O 
the O 
group O 
treated O 
with O 
moderate O 
selenium B-SYSTEMATIC 
has O 
Bcl-2 O 
protein O 
expression O 
that O 
was O 
observably O 
elevated O 
( O 
P O 
< O 
0.05 O 
) O 
, O 
Bax O 
protein O 
expression O 
that O 
was O 
highly O 
reduced O 
( O 
P O 
< O 
0.01 O 
) O 
, O 
and O 
Bax O 
/ O 
Bcl-2 O 
protein O 
expression O 
that O 
was O 
observably O 
reduced O 
( O 
P O 
< O 
0.05 O 
) O 
; O 
the O 
group O 
treated O 
with O 
high O 
selenium B-SYSTEMATIC 
has O 
Bcl-2 O 
protein O 
expression O 
that O 
was O 
highly O 
elevated O 
( O 
P O 
< O 
0.01 O 
) O 
, O 
Bax O 
protein O 
expression O 
that O 
was O 
highly O 
elevated O 
( O 
P O 
< O 
0.01 O 
) O 
, O 
and O 
Bax O 
/ O 
Bcl-2 O 
protein O 
expression O 
that O 
was O 
highly O 
reduced O 
( O 
P O 
< O 
0.01 O 
) O 
; O 
the O 
groups O 
treated O 
with O 
moderate O 
selenium B-SYSTEMATIC 
and O 
high O 
selenium B-SYSTEMATIC 
have O 
Bax O 
mRNA O 
expression O 
that O 
was O 
highly O 
reduced O 
( O 
P O 
< O 
0.01 O 
) O 
, O 
and O 
the O 
groups O 
treated O 
with O 
high O 
selenium B-SYSTEMATIC 
have O 
Bax O 
/ O 
Bcl-2 O 
mRNA O 
expression O 
that O 
was O 
observably O 
reduced O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Selenium B-SYSTEMATIC 
may O 
inhibit O 
the O 
apoptosis O 
of O 
renal O 
cells O 
in O 
fluorosis O 
rats O 
by O 
regulating O 
the O 
expressions O 
of O 
Bcl-2 O 
and O 
Bax O 
. O 
The O 
optimal O 
dose O 
of O 
Na2SeO3 B-FORMULA 
to O 
protect O 
against O 
fluoride B-SYSTEMATIC 
-induced O 
renal O 
cell O 
apoptosis O 
was O 
determined O 
to O 
be O 
1.5 O 
mg O 
/ O 
L O 
. O 

and O 
its O 
analogue O 
5-MCA-NAT B-SYSTEMATIC 
potentiate O 
adrenergic O 
receptor O 
- O 
mediated O 
ocular O 
hypotensive O 
effects O 
in O 
rabbits O 
: O 
Significance O 
for O 
combination O 
therapy O 
in O 
glaucoma O 
. O 

is O 
currently O 
considered O 
as O 
a O 
promising O 
drug O 
for O 
glaucoma O 
treatment O 
due O 
to O 
its O 
ocular O 
hypotensive O 
and O 
neuroprotective O 
effects O 
. O 
We O 
have O 
investigated O 
the O 
effect O 
of O 
melatonin B-TRIVIAL 
and O 
its O 
analogue O 
5-methoxycarbonylamino-N-acetyltryptamine B-SYSTEMATIC 
, O 
5-MCA-NAT B-SYSTEMATIC 
, O 
on O 
β2 O 
/ O 
α2A-adrenergic O 
receptor O 
mRNA O 
as O 
well O 
as O 
protein O 
expression O 
in O 
cultured O 
rabbit O 
non-pigmented O 
ciliary O 
epithelial O 
cells O 
. O 
Quantitative O 
PCR O 
and O 
immunocytochemical O 
assays O 
revealed O 
a O 
significant O 
β2-adrenergic O 
receptor O 
down O 
- O 
regulation O 
as O 
well O 
as O 
α2A-adrenergic O 
receptor O 
up O 
- O 
regulation O 
of O 
treated O 
cells O 
( O 
p O 
< O 
0.001 O 
, O 
maximal O 
significant O 
effect O 
) O 
. O 
In O 
addition O 
, O 
we O 
have O 
studied O 
the O 
effect O 
of O 
these O 
drugs O 
upon O 
the O 
ocular O 
hypotensive O 
action O 
of O 
a O 
non-selective O 
β-adrenergic O 
receptor O 
( O 
timolol B-TRIVIAL 
) O 
and O 
a O 
selective O 
α2-adrenergic O 
receptor O 
agonist O 
( O 
brimonidine B-TRIVIAL 
) O 
in O 
normotensive O 
rabbits O 
. O 
IOP O 
experiments O 
showed O 
that O 
the O 
administration O 
of O 
timolol B-TRIVIAL 
in O 
rabbits O 
pre O 
- O 
treated O 
with O 
melatonin B-TRIVIAL 
or O 
5-MCA-NAT B-SYSTEMATIC 
evoked O 
an O 
additional O 
IOP O 
reduction O 
of O 
14.02 O 
± O 
5.8 O 
% O 
or O 
16.75 O 
± O 
5.48 O 
% O 
( O 
p O 
< O 
0.01 O 
) O 
in O 
comparison O 
with O 
rabbits O 
treated O 
with O 
timolol B-TRIVIAL 
alone O 
for O 
24 O 
hours O 
. O 
Concerning O 
brimonidine B-TRIVIAL 
hypotensive O 
action O 
, O 
an O 
additional O 
IOP O 
reduction O 
of O 
29.26 O 
± O 
5.21 O 
% O 
or O 
39.07 O 
± O 
5.81 O 
% O 
( O 
p O 
< O 
0.001 O 
) O 
was O 
observed O 
in O 
rabbits O 
pretreated O 
with O 
melatonin B-TRIVIAL 
or O 
5-MCA-NAT B-SYSTEMATIC 
when O 
compared O 
with O 
animals O 
treated O 
with O 
brimonidine B-TRIVIAL 
alone O 
for O 
24 O 
hours O 
. O 
Additionally O 
, O 
a O 
sustained O 
potentiating O 
effect O 
of O 
a O 
single O 
dose O 
of O 
5-MCA-NAT B-SYSTEMATIC 
was O 
seen O 
in O 
rabbits O 
treated O 
with O 
brimonidine B-TRIVIAL 
once O 
daily O 
for O 
up O 
four O 
days O 
( O 
extra O 
IOP O 
decrease O 
of O 
15.57 O 
± O 
5.15% O 
, O 
p O 
< O 
0.05 O 
, O 
compared O 
to O 
brimonidine B-TRIVIAL 
alone O 
) O 
. O 
These O 
data O 
confirm O 
the O 
indirect O 
action O 
of O 
melatoninergic O 
compounds O 
on O 
adrenergic O 
receptors O 
and O 
their O 
remarkable O 
effect O 
upon O 
the O 
ocular O 
hypotensive O 
action O 
mainly O 
of O 
α2-adrenergic O 
receptor O 
agonists O 
but O 
also O 
of O 
β-adrenergic O 
antagonists O 
. O 

extracellular O 
matrix O 
( O 
ECM O 
) O 
deposition O 
and O 
airway O 
smooth O 
muscle O 
( O 
ASM O 
) O 
mass O 
are O 
major O 
contributors O 
to O 
airway O 
remodeling O 
in O 
asthma O 
. O 
Recently O 
, O 
we O 
have O 
demonstrated O 
that O 
the O 
ECM O 
protein O 
collagen O 
I O 
, O 
which O 
is O 
increased O 
surrounding O 
asthmatic O 
ASM O 
, O 
induces O 
a O 
proliferative O 
, O 
hypocontractile O 
ASM O 
phenotype O 
. O 
Little O 
is O 
known O 
, O 
however O 
, O 
on O 
the O 
signaling O 
pathways O 
involved O 
. O 
Using O 
bovine O 
tracheal O 
smooth O 
muscle O 
, O 
we O 
investigated O 
the O 
role O 
of O 
focal O 
adhesion O 
kinase O 
( O 
FAK O 
) O 
and O 
downstream O 
signaling O 
pathways O 
in O 
collagen O 
I-induced O 
ASM O 
phenotype O 
modulation O 
. O 
Phosphorylation O 
of O 
FAK O 
was O 
increased O 
during O 
adhesion O 
to O 
both O 
uncoated O 
and O 
collagen O 
I O 
- O 
coated O 
culture O 
dishes O 
, O 
without O 
differences O 
between O 
these O 
matrices O 
. O 
No O 
differences O 
in O 
cellular O 
adhesion O 
were O 
found O 
either O 
. O 
Inhibition O 
of O 
FAK O 
activity O 
by O 
overexpression O 
of O 
the O 
FAK O 
deletion O 
mutants O 
FAT O 
( O 
focal O 
adhesion O 
targeting O 
domain O 
) O 
and O 
FRNK O 
( O 
FAK O 
- O 
related O 
non-kinase O 
) O 
attenuated O 
adhesion O 
. O 
After O 
attachment O 
, O 
FAK O 
phosphorylation O 
was O 
time O 
- O 
dependently O 
increased O 
in O 
cells O 
cultured O 
on O 
collagen O 
I O 
, O 
whereas O 
no O 
activation O 
was O 
found O 
on O 
an O 
uncoated O 
plastic O 
matrix O 
. O 
In O 
addition O 
, O 
collagen O 
I O 
time- O 
and O 
concentration O 
- O 
dependently O 
increased O 
cell O 
proliferation O 
, O 
which O 
was O 
fully O 
inhibited O 
by O 
FAT O 
and O 
FRNK O 
. O 
Similarly O 
, O 
the O 
specific O 
pharmacological O 
FAK O 
inhibitor O 
PF-573,228 B-IDENTIFIER 
as O 
well O 
as O 
specific O 
inhibitors O 
of O 
p38 O 
MAPK O 
and O 
Src O 
also O 
fully O 
inhibited O 
collagen O 
I-induced O 
proliferation O 
, O 
whereas O 
partial O 
inhibition O 
was O 
observed O 
by O 
inhibition O 
of O 
PI3-kinase O 
and O 
MEK O 
. O 
The O 
inhibition O 
of O 
cell O 
proliferation O 
by O 
these O 
inhibitors O 
was O 
associated O 
with O 
attenuation O 
of O 
the O 
collagen O 
I-induced O 
hypocontractility O 
. O 
Collectively O 
, O 
the O 
results O 
indicate O 
that O 
induction O 
of O 
a O 
proliferative O 
, O 
hypocontractile O 
ASM O 
phenotype O 
by O 
collagen O 
I O 
is O 
mediated O 
by O 
FAK O 
and O 
downstream O 
signaling O 
pathways O 
. O 

TGF-β O 
signaling O 
pathway O 
is O 
involved O 
with O 
multiple O 
processes O 
in O 
the O 
mammalian O 
ovary O 
, O 
including O 
primordial O 
follicle O 
formation O 
, O 
granulosa O 
cell O 
( O 
GC O 
) O 
proliferation O 
, O 
follicle O 
atresia O 
, O 
ovulation O 
, O 
and O 
feedback O 
regulation O 
between O 
the O 
pituitary O 
and O 
ovary O 
. O 
The O 
transcriptional O 
factor O 
SMAD4 O 
is O 
the O 
central O 
component O 
of O 
the O 
canonical O 
TGF-β O 
signaling O 
pathway O 
. O 
Smad4 O 
knockout O 
using O 
Amhr2-Cre O 
, O 
which O 
is O 
expressed O 
in O 
GCs O 
of O 
immature O 
developing O 
follicles O 
, O 
causes O 
premature O 
luteinization O 
. O 
In O 
this O 
study O 
, O 
we O 
specifically O 
depleted O 
Smad4 O 
in O 
GCs O 
of O 
preovulatory O 
follicles O 
using O 
Cyp19-Cre O 
mice O 
. O 
As O 
different O 
from O 
results O 
with O 
Smad4(fl O 
/ O 
fl);Amhr2-Cre O 
mice O 
, O 
Smad4 O 
depletion O 
in O 
preovulatory O 
follicles O 
did O 
not O 
cause O 
premature O 
luteinization O 
or O 
suppress O 
GC O 
proliferation O 
; O 
rather O 
, O 
it O 
increased O 
follicle O 
atresia O 
. O 
In O 
addition O 
, O 
Nppc O 
and O 
Npr2 O 
expressions O 
were O 
reduced O 
by O 
Smad4 O 
depletion O 
; O 
thus O 
, O 
their O 
effect O 
of O 
maintaining O 
oocyte O 
meiotic O 
arrest O 
was O 
weakened O 
in O 
Smad4 O 
conditional O 
knockout O 
mice O 
. O 
Smad4(fl O 
/ O 
fl);Cyp19-Cre O 
female O 
mice O 
were O 
subfertile O 
and O 
had O 
irregular O 
estrous O 
cycles O 
and O 
ovulation O 
defects O 
. O 
Smad4 O 
knockout O 
also O 
blocked O 
luteinizing O 
hormone O 
(LH)-induced O 
cumulus O 
expansion O 
and O 
follicle O 
rupture O 
, O 
but O 
not O 
oocyte O 
meiotic O 
resumption O 
. O 
Our O 
results O 
also O 
indicated O 
that O 
SMAD4 O 
was O 
required O 
for O 
LH-stimulated O 
activation O 
of O 
ERK1 O 
/ O 
2 O 
and O 
the O 
expressions O 
of O 
ovulation O 
- O 
related O 
genes O 
. O 
The O 
defects O 
arising O 
from O 
SMAD4 O 
depletion O 
could O 
not O 
be O 
rescued O 
by O 
intra O 
- O 
ovarian O 
mediators O 
of O 
LH O 
actions O 
, O 
such O 
as O 
EGF O 
- O 
like O 
factors O 
and O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
. O 
Furthermore O 
, O 
corpus O 
lutea O 
did O 
not O 
form O 
in O 
Smad4(fl O 
/ O 
fl);Cyp19-Cre O 
female O 
mice O 
, O 
indicating O 
that O 
SMAD4 O 
was O 
crucial O 
for O 
GCs O 
terminal O 
differentiation O 
. O 
Thus O 
, O 
by O 
characterizing O 
the O 
ovarian O 
phenotypes O 
of O 
preovulatory O 
follicle O 
- O 
specific O 
Smad4 O 
knockout O 
mice O 
, O 
we O 
identified O 
the O 
developmental O 
stage O 
- O 
specific O 
functions O 
of O 
the O 
canonical O 
TGF-β O 
signaling O 
pathway O 
in O 
ovulation O 
and O 
luteinization O 
. O 

Interaction O 
between O 
Few O 
- O 
Layer O 
MoS2 B-FORMULA 
and O 
Tetrathiafulvalene B-SYSTEMATIC 
. O 

look O 
- O 
alike O 
: O 
MoS2 B-FORMULA 
has O 
a O 
layered O 
structure O 
similar O 
to O 
graphene B-TRIVIAL 
. O 
Tetrathiafulvalene B-SYSTEMATIC 
( O 
TTF B-ABBREVIATION 
) O 
interacts O 
with O 
thin O 
, O 
few O 
- O 
layer O 
MoS2 B-FORMULA 
material O 
by O 
donating O 
an O 
electron O 
, O 
resulting O 
in O 
the O 
formation O 
of O 
TTF B-ABBREVIATION 
radical O 
cation O 
and O 
n O 
- O 
type O 
doping O 
of O 
MoS2 B-FORMULA 
. O 
Electron O 
- O 
withdrawing O 
tetracyanoethylene B-SYSTEMATIC 
, O 
in O 
contrast O 
, O 
does O 
not O 
cause O 
p- O 
type O 
doping O 
in O 
MoS2 B-FORMULA 
. O 

effect O 
of O 
wogonin B-TRIVIAL 
on O 
proinflammatory O 
cytokine O 
generation O 
via O 
Jak1 O 
/ O 
3-STAT1 O 
/ O 
3 O 
pathway O 
in O 
lipopolysaccharide O 
stimulated O 
BV2 O 
microglial O 
cells O 
. O 

is O 
a O 
flavonoid B-FAMILY 
compound O 
which O 
exhibits O 
antioxidation O 
, O 
anti-inflammation O 
, O 
neuroprotection O 
, O 
and O 
antitumorgenesis O 
functions O 
. O 
However O 
, O 
the O 
mechanism O 
of O 
how O 
wogonin B-TRIVIAL 
reduces O 
proinflammatory O 
cytokine O 
generation O 
in O 
activated O 
microglia O 
is O 
unclear O 
. O 
At O 
present O 
, O 
we O 
found O 
wogonin B-TRIVIAL 
inhibited O 
lipopolysaccharide O 
(LPS)- O 
/ O 
interferon-γ O 
(INF-γ)-induced O 
generation O 
of O 
interleukin-6 O 
( O 
IL-6 O 
) O 
and O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
. O 
Wogonin B-TRIVIAL 
exhibited O 
parallel O 
inhibition O 
on O 
LPS- O 
/ O 
INF-γ-induced O 
expression O 
of O 
IL-6 O 
and O 
TNF-α O 
messenger O 
RNA O 
at O 
the O 
same O 
concentration O 
range O 
. O 
LPS- O 
/ O 
INF-γ-induced O 
phosphorylation O 
of O 
signal O 
transduction O 
and O 
transcription O 
1 O 
and O 
3 O 
( O 
STAT1 O 
/ O 
3 O 
) O 
were O 
also O 
inhibited O 
by O 
wogonin B-TRIVIAL 
. O 
Although O 
wogonin B-TRIVIAL 
expressed O 
only O 
weak O 
inhibitory O 
effect O 
on O 
LPS- O 
/ O 
INF-γ-induced O 
phosphorylation O 
of O 
Janus O 
kinase-2 O 
( O 
Jak-2 O 
) O 
and O 
tyrosine B-TRIVIAL 
kinase O 
(Tyk)-2 O 
, O 
it O 
significantly O 
attenuated O 
the O 
phosphorylation O 
of O 
Jak-1 O 
and O 
Jak-3 O 
. O 
These O 
results O 
indicated O 
that O 
the O 
blockade O 
of O 
IL-6 O 
and O 
TNF-α O 
production O 
by O 
wogonin B-TRIVIAL 
in O 
LPS- O 
/ O 
INF-γ-stimulated O 
BV2 O 
microglial O 
cells O 
was O 
attributed O 
mainly O 
to O 
the O 
interference O 
in O 
Jak-1 O 
/ O 
-3-STAT1 O 
/ O 
3 O 
signaling O 
pathway O 
. O 

mechanism O 
of O 
ring O 
opening O 
reaction O 
of O 
glucose B-TRIVIAL 
by O 
human O 
serum O 
albumin O 
. O 

reacts O 
with O 
proteins O 
non-enzymatically O 
under O 
physiological O 
conditions O 
. O 
Such O 
glycation O 
is O 
exacerbated O 
in O 
diabetic O 
patients O 
with O 
high O 
level O 
of O 
blood O 
sugar B-FAMILY 
, O 
and O 
induces O 
various O 
complications O 
. O 
Human O 
albumin O 
serum O 
( O 
HSA O 
) O 
is O 
the O 
most O 
abundant O 
protein O 
in O 
plasma O 
and O 
is O 
glycated O 
by O 
glucose B-TRIVIAL 
. O 
The O 
glycation O 
sites O 
on O 
HSA O 
remain O 
controversial O 
among O 
different O 
studies O 
. O 
Here O 
, O 
we O 
report O 
two O 
protein O 
crystal O 
structures O 
of O 
HSA O 
in O 
complex O 
with O 
either O 
glucose B-TRIVIAL 
or O 
fructose B-TRIVIAL 
. O 
These O 
crystal O 
structures O 
reveal O 
that O 
the O 
presence O 
of O 
linear O 
forms O 
of O 
sugar B-FAMILY 
for O 
both O 
monosaccharides B-FAMILY 
. O 
The O 
linear O 
form O 
of O 
glucose B-TRIVIAL 
forms O 
a O 
covalent O 
bond O 
to O 
Lys B-FORMULA 
195 O 
of O 
HSA O 
, O 
but O 
not O 
the O 
case O 
for O 
fructose B-TRIVIAL 
. O 
Based O 
on O 
these O 
structures O 
, O 
we O 
propose O 
a O 
mechanism O 
for O 
glucose B-TRIVIAL 
ring O 
opening O 
involving O 
both O 
residues O 
Lys B-FORMULA 
195 O 
and O 
Lys B-FORMULA 
199 O 
. O 
These O 
results O 
provide O 
mechanistic O 
insights O 
to O 
understand O 
the O 
glucose B-TRIVIAL 
ring O 
opening O 
reaction O 
and O 
the O 
glycation O 
of O 
proteins O 
by O 
monosaccharides B-FAMILY 
. O 

discovery O 
that O 
rapamycin B-TRIVIAL 
extends O 
the O 
life O 
span O 
of O 
diverse O 
organisms O 
has O 
triggered O 
many O 
studies O 
aimed O 
at O 
identifying O 
the O 
underlying O 
molecular O 
mechanisms O 
. O 
Mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
complex O 
1 O 
( O 
mTORC1 O 
) O 
regulates O 
cell O 
growth O 
and O 
may O 
regulate O 
organismal O 
aging O 
by O 
controlling O 
mRNA O 
translation O 
. O 
However O 
, O 
how O 
inhibiting O 
mTORC1 O 
and O 
decreasing O 
protein O 
synthesis O 
can O 
extend O 
life O 
span O 
remains O 
an O 
unresolved O 
issue O 
. O 
We O 
showed O 
that O 
constitutively O 
active O 
mTORC1 O 
signaling O 
increased O 
general O 
protein O 
synthesis O 
but O 
unexpectedly O 
reduced O 
the O 
quality O 
of O 
newly O 
synthesized O 
polypeptides O 
. O 
We O 
demonstrated O 
that O 
constitutively O 
active O 
mTORC1 O 
decreased O 
translation O 
fidelity O 
by O 
increasing O 
the O 
speed O 
of O 
ribosomal O 
elongation O 
. O 
Conversely O 
, O 
rapamycin B-TRIVIAL 
treatment O 
restored O 
the O 
quality O 
of O 
newly O 
synthesized O 
polypeptides O 
mainly O 
by O 
slowing O 
the O 
rate O 
of O 
ribosomal O 
elongation O 
. O 
We O 
also O 
found O 
distinct O 
roles O 
for O 
mTORC1 O 
downstream O 
targets O 
in O 
maintaining O 
protein O 
homeostasis O 
. O 
Loss O 
of O 
S6 O 
kinases O 
, O 
but O 
not O 
4E-BP O 
family O 
proteins O 
, O 
which O 
are O 
both O 
involved O 
in O 
regulation O 
of O 
translation O 
, O 
attenuated O 
the O 
effects O 
of O 
rapamycin B-TRIVIAL 
on O 
the O 
quality O 
of O 
newly O 
translated O 
proteins O 
. O 
Our O 
results O 
reveal O 
a O 
mechanistic O 
connection O 
between O 
mTORC1 O 
and O 
protein O 
quality O 
, O 
highlighting O 
the O 
central O 
role O 
of O 
nutrient O 
signaling O 
in O 
growth O 
and O 
aging O 
. O 

reactivity O 
of O 
bioglasses O 
, O 
which O 
is O 
related O 
to O 
the O 
dissolution O 
of O 
cations O 
and O 
orthosilicate B-TRIVIAL 
groups O 
in O 
the O 
physiological O 
fluid O 
, O 
strongly O 
depends O 
on O 
the O 
key O 
structural O 
features O 
present O 
at O 
the O 
glass O 
surfaces O 
. O 
On O 
the O 
basis O 
of O 
the O 
composition O 
and O 
the O 
synthetic O 
routes O 
employed O 
to O 
make O 
the O 
glass O 
, O 
surfaces O 
with O 
very O 
different O 
characteristics O 
and O 
thus O 
presenting O 
different O 
mechanisms O 
of O 
dissolution O 
can O 
be O 
observed O 
. O 
In O 
this O 
paper O 
, O 
the O 
surface O 
structures O 
of O 
two O 
very O 
different O 
bioglass O 
compositions O 
, O 
namely O 
45S5 O 
( O 
46.1 O 
SiO2 B-FORMULA 
, O 
24.4 O 
Na2O B-FORMULA 
, O 
26.9 O 
CaO B-FORMULA 
, O 
and O 
2.6 O 
P2O5 B-FORMULA 
mol O 
% O 
) O 
and O 
77S O 
( O 
80 O 
SiO2 B-FORMULA 
, O 
16 O 
CaO B-FORMULA 
, O 
and O 
4 O 
P2O5 B-FORMULA 
mol O 
% O 
) O 
, O 
have O 
been O 
investigated O 
by O 
means O 
of O 
periodic O 
DFT O 
calculations O 
based O 
on O 
a O 
PBE O 
functional O 
and O 
localized O 
Gaussian O 
basis O 
set O 
as O 
encoded O 
in O 
the O 
CRYSTAL O 
code O 
. O 
Our O 
calculations O 
show O 
that O 
the O 
two O 
glass O 
surfaces O 
differ O 
by O 
the O 
relative O 
amount O 
of O 
key O 
structural O 
sites O 
such O 
as O 
NBOs O 
, O 
exposed O 
ions O 
, O 
orthosilicate B-TRIVIAL 
units O 
, O 
and O 
small O 
rings O 
. O 
We O 
have O 
demonstrated O 
how O 
the O 
number O 
of O 
these O 
sites O 
affects O 
the O 
surface O 
stability O 
and O 
reactivity O 
( O 
bioactivity O 
) O 
. O 

Mechanism O 
of O 
TiO B-FORMULA 
2 I-FORMULA 
Nanotubes O 
and O 
Their O 
Applications O 
in O 
Photoelectrochemical O 
Water O 
Splitting O 
and O 
Supercapacitors O 
. O 

observations O 
of O 
the O 
transition O 
of O 
TiO B-FORMULA 
2 I-FORMULA 
nanopores O 
into O 
nanotubes O 
by O 
increasing O 
the O 
OH B-FORMULA 
( I-FORMULA 
- I-FORMULA 
) I-FORMULA 
concentration O 
in O 
the O 
electrolyte O 
challenge O 
the O 
validity O 
of O 
existing O 
formation O 
mechanisms O 
of O 
anodic O 
TiO B-FORMULA 
2 I-FORMULA 
nanotubes O 
. O 
In O 
this O 
study O 
, O 
dehydration O 
of O 
titanium B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
in O 
the O 
cell O 
wall O 
is O 
proposed O 
as O 
the O 
mechanism O 
that O 
leads O 
to O 
the O 
separation O 
of O 
neighboring O 
nanotubes O 
. O 
Based O 
on O 
this O 
understanding O 
, O 
bamboo O 
- O 
type O 
TiO B-FORMULA 
2 I-FORMULA 
nanotubes O 
with O 
large O 
surface O 
area O 
and O 
excellent O 
interconnectivity O 
are O 
achieved O 
by O 
cycling O 
high O 
and O 
low O 
applied O 
potentials O 
. O 
After O 
thermal O 
treatment O 
in O 
a O 
H B-FORMULA 
2 I-FORMULA 
atmosphere O 
, O 
the O 
bamboo O 
- O 
type O 
TiO B-FORMULA 
2 I-FORMULA 
nanotubes O 
show O 
large O 
photoelectrochemical O 
water O 
splitting O 
efficiency O 
and O 
supercapacitors O 
performace O 
. O 

interfaces O 
impede O 
phonon O 
transport O 
of O 
thermal O 
energy O 
, O 
nanostructuring O 
can O 
transform O 
fully O 
dense O 
solids O 
into O 
ultralow O 
thermal O 
conductivity O 
materials O 
. O 
Here O 
we O 
report O 
a O 
simple O 
self O 
- O 
assembly O 
approach O 
to O 
synthesizing O 
organoclay O 
nanolaminates O 
with O 
cross O 
- O 
planar O 
thermal O 
conductivities O 
below O 
0.1 O 
W O 
m(-1) O 
K(-1)-a O 
5-fold O 
decrease O 
compared O 
to O 
unmodified O 
clay O 
. O 
These O 
organoclays O 
are O 
produced O 
via O 
alkylammonium B-FAMILY 
cation O 
exchange O 
with O 
colloidally O 
dispersed O 
montmorillonite B-TRIVIAL 
clay O 
sheets O 
followed O 
by O 
solvent O 
casting O 
. O 
Time O 
- O 
domain O 
thermoreflectance O 
( O 
TDTR O 
) O 
is O 
used O 
to O 
evaluate O 
the O 
thermal O 
conductivity O 
of O 
the O 
organoclay O 
nanolaminates O 
. O 
Variations O 
in O 
both O 
organic O 
layer O 
thickness O 
and O 
cation O 
chemistry O 
are O 
investigated O 
. O 
At O 
these O 
interface O 
densities O 
( O 
1.0-1.5 O 
interfaces O 
/ O 
nm O 
) O 
, O 
we O 
demonstrate O 
that O 
thermal O 
conductivity O 
is O 
relatively O 
independent O 
of O 
nanolaminate O 
spacing O 
. O 
A O 
simple O 
series O 
resistance O 
model O 
describes O 
the O 
behavior O 
and O 
gives O 
an O 
interfacial O 
thermal O 
conductance O 
value O 
of O 
≈150 O 
MW O 
m(-2) O 
K(-1) O 
for O 
the O 
organic O 
/ O 
clay O 
interface O 
, O 
consistent O 
with O 
similar O 
organic O 
- O 
inorganic O 
interfaces O 
. O 
The O 
wide O 
range O 
of O 
compositional O 
substitutions O 
and O 
structural O 
variations O 
possible O 
in O 
these O 
materials O 
, O 
make O 
organoclays O 
a O 
versatile O 
new O 
platform O 
for O 
investigating O 
the O 
underlying O 
physics O 
of O 
nanolaminate O 
structures O 
. O 

Isolation O 
Spectroscopy O 
and O 
Nuclear O 
Spin O 
Conversion O 
of O 
NH3 B-FORMULA 
and O 
ND3 B-FORMULA 
in O 
Solid O 
Parahydrogen B-SYSTEMATIC 
. O 

present O 
matrix O 
isolation O 
infrared O 
absorption O 
spectra O 
of O 
NH3 B-FORMULA 
and O 
ND3 B-FORMULA 
trapped O 
in O 
solid O 
parahydrogen B-SYSTEMATIC 
( O 
pH2 B-FORMULA 
) O 
at O 
temperatures O 
around O 
1.8 O 
K O 
. O 
We O 
used O 
the O 
relatively O 
slow O 
nuclear O 
spin O 
conversion O 
( O 
NSC O 
) O 
of O 
NH3 B-FORMULA 
and O 
ND3 B-FORMULA 
in O 
freshly O 
deposited O 
pH2 B-FORMULA 
samples O 
as O 
a O 
tool O 
to O 
assign O 
the O 
sparse O 
vibration O 
- O 
inversion O 
- O 
rotation O 
( O 
VIR O 
) O 
spectra O 
of O 
NH3 B-FORMULA 
in O 
the O 
regions O 
of O 
the O 
ν2 O 
, O 
ν4 O 
, O 
2ν4 O 
, O 
ν1 O 
, O 
and O 
ν3 O 
bands O 
and O 
ND3 B-FORMULA 
in O 
the O 
regions O 
of O 
the O 
ν2 O 
, O 
ν4 O 
, O 
ν1 O 
, O 
and O 
ν3 O 
fundamentals O 
. O 
Partial O 
assignments O 
are O 
also O 
presented O 
for O 
various O 
combination O 
bands O 
of O 
NH3 B-FORMULA 
. O 
Detailed O 
analysis O 
of O 
the O 
ν2 O 
bands O 
of O 
NH3 B-FORMULA 
and O 
ND3 B-FORMULA 
indicates O 
that O 
both O 
isotopomers O 
are O 
nearly O 
free O 
rotors O 
; O 
that O 
the O 
vibrational O 
energy O 
is O 
blue O 
- O 
shifted O 
by O 
1-2% O 
; O 
and O 
that O 
the O 
rotational O 
constants O 
and O 
inversion O 
tunneling O 
splitting O 
are O 
91-94% O 
and O 
67-75% O 
, O 
respectively O 
, O 
of O 
the O 
gas-phase O 
values O 
. O 
The O 
line O 
shapes O 
of O 
the O 
VIR O 
absorptions O 
are O 
narrow O 
( O 
0.2-0.4 O 
cm(-1) O 
) O 
for O 
upper O 
states O 
that O 
cannot O 
rotationally O 
relax O 
and O 
broad O 
( O 
> O 
1 O 
cm(-1) O 
) O 
for O 
upper O 
states O 
that O 
can O 
rotationally O 
relax O 
. O 
We O 
report O 
and O 
assign O 
a O 
number O 
of O 
NH3 B-FORMULA 
-induced O 
infrared O 
absorption O 
features O 
of O 
the O 
pH2 B-FORMULA 
host O 
near O 
4150 O 
cm(-1) O 
, O 
along O 
with O 
a O 
cooperative O 
transition O 
that O 
involves O 
simultaneous O 
vibrational O 
excitation O 
of O 
a O 
pH2 B-FORMULA 
molecule O 
and O 
rotation O 
- O 
inversion O 
excitation O 
of O 
NH3 B-FORMULA 
. O 
The O 
NSCs O 
of O 
NH3 B-FORMULA 
and O 
ND3 B-FORMULA 
were O 
found O 
to O 
follow O 
first O 
- O 
order O 
kinetics O 
with O 
rate O 
constants O 
at O 
1.8 O 
K O 
of O 
k O 
= O 
1.88(16) O 
× O 
10(-3) O 
s(-1) O 
and O 
k O 
= O 
1.08(8) O 
× O 
10(-3) O 
s(-1) O 
, O 
respectively O 
. O 
These O 
measured O 
rate O 
constants O 
are O 
compared O 
to O 
previous O 
measurements O 
for O 
NH3 B-FORMULA 
in O 
an O 
Ar O 
matrix O 
and O 
with O 
the O 
rate O 
constants O 
measured O 
for O 
other O 
dopant O 
molecules O 
isolated O 
in O 
solid O 
pH2 B-FORMULA 
. O 

and O 
validation O 
of O 
NIR-chemometric O 
methods O 
for O 
chemical O 
and O 
pharmaceutical O 
characterization O 
of O 
meloxicam B-TRIVIAL 
tablets O 
. O 

Context O 
: O 
Near-Infrared O 
( O 
NIR O 
) O 
spectroscopy O 
is O 
an O 
important O 
component O 
of O 
a O 
Process O 
Analytical O 
Technology O 
( O 
PAT O 
) O 
toolbox O 
and O 
is O 
a O 
key O 
technology O 
for O 
enabling O 
the O 
rapid O 
analysis O 
of O 
pharmaceutical O 
tablets O 
. O 
Objective O 
: O 
The O 
aim O 
of O 
this O 
research O 
work O 
was O 
to O 
develop O 
and O 
validate O 
NIR-chemometric O 
methods O 
not O 
only O 
for O 
the O 
determination O 
of O 
active O 
pharmaceutical O 
ingredients O 
content O 
but O 
also O 
pharmaceutical O 
properties O 
( O 
crushing O 
strength O 
, O 
disintegration O 
time O 
) O 
of O 
meloxicam B-TRIVIAL 
tablets O 
. O 
Materials O 
and O 
methods O 
: O 
The O 
development O 
of O 
the O 
method O 
for O 
active O 
content O 
assay O 
was O 
performed O 
on O 
samples O 
corresponding O 
to O 
80% O 
, O 
90% O 
, O 
100% O 
, O 
110% O 
and O 
120% O 
of O 
meloxicam B-TRIVIAL 
content O 
and O 
the O 
development O 
of O 
the O 
methods O 
for O 
pharmaceutical O 
characterization O 
was O 
performed O 
on O 
samples O 
prepared O 
at O 
seven O 
different O 
compression O 
forces O 
( O 
ranging O 
from O 
7 O 
to O 
45 O 
kN O 
) O 
using O 
NIR O 
transmission O 
spectra O 
of O 
intact O 
tablets O 
and O 
PLS O 
as O 
a O 
regression O 
method O 
. O 
Results O 
: O 
The O 
results O 
show O 
that O 
the O 
developed O 
methods O 
have O 
good O 
trueness O 
, O 
precision O 
and O 
accuracy O 
and O 
are O 
appropriate O 
for O 
direct O 
active O 
content O 
assay O 
in O 
tablets O 
( O 
ranging O 
from O 
12 O 
to O 
18 O 
mg O 
/ O 
tablet O 
) O 
and O 
also O 
for O 
predicting O 
crushing O 
strength O 
and O 
disintegration O 
time O 
of O 
intact O 
meloxicam B-TRIVIAL 
tablets O 
. O 
Discussion O 
: O 
The O 
comparative O 
data O 
show O 
that O 
the O 
proposed O 
methods O 
are O 
in O 
good O 
agreement O 
with O 
the O 
reference O 
methods O 
currently O 
used O 
for O 
the O 
characterization O 
of O 
meloxicam B-TRIVIAL 
tablets O 
( O 
HPLC-UV O 
methods O 
for O 
the O 
assay O 
and O 
European O 
Pharmacopeia O 
methods O 
for O 
determining O 
the O 
crushing O 
strength O 
and O 
disintegration O 
time O 
) O 
. O 
Conclusion O 
: O 
The O 
results O 
show O 
the O 
possibility O 
to O 
predict O 
both O 
chemical O 
properties O 
( O 
active O 
content O 
) O 
and O 
physical O 
/ O 
pharmaceutical O 
properties O 
( O 
crushing O 
strength O 
and O 
disintegration O 
time O 
) O 
directly O 
, O 
without O 
any O 
sample O 
preparation O 
, O 
from O 
the O 
same O 
NIR O 
transmission O 
spectrum O 
of O 
meloxicam B-TRIVIAL 
tablets O 
. O 

characterization O 
of O 
phyllanthin B-TRIVIAL 
from O 
Phyllanthus O 
amarus O 
Schum O 
. O 
et O 
Thonn O 
. O 

Phyllanthin B-TRIVIAL 
is O 
a O 
major O 
bioactive O 
lignan B-FAMILY 
component O 
of O 
Phyllanthus O 
amarus O 
, O 
with O 
several O 
known O 
biological O 
activities O 
. O 
This O 
study O 
dealt O 
with O 
the O 
isolation O 
and O 
physicochemical O 
characterization O 
of O 
phyllanthin B-TRIVIAL 
. O 
Phyllanthin B-TRIVIAL 
was O 
isolated O 
from O 
P O 
. O 
amarus O 
leaves O 
by O 
column O 
chromatography O 
and O 
purified O 
by O 
recrystallization O 
to O 
obtain O 
phyllanthin B-TRIVIAL 
crystals O 
with O 
a O 
purity O 
of O 
more O 
than O 
98% O 
. O 
UV O 
, O 
IR O 
, O 
MS O 
, O 
(1)H B-FORMULA 
NMR O 
and O 
(13)C B-FORMULA 
NMR O 
spectra O 
were O 
employed O 
to O 
identify O 
phyllanthin B-TRIVIAL 
. O 
The O 
physicochemical O 
properties O 
of O 
phyllanthin B-TRIVIAL 
were O 
characterized O 
using O 
differential O 
scanning O 
calorimetry O 
, O 
thermogravimetric O 
analysis O 
, O 
X-ray O 
diffraction O 
, O 
pH-solubility O 
, O 
ionization O 
property O 
and O 
lipophilicity O 
. O 
The O 
results O 
indicated O 
that O 
phyllanthin B-TRIVIAL 
crystals O 
had O 
the O 
melting O 
point O 
and O 
melting O 
enthalpy O 
range O 
of O 
96.67-97.03 O 
°C O 
and O 
109.61-116.34 O 
J O 
/ O 
g O 
, O 
respectively O 
. O 
Three O 
kinds O 
of O 
phyllanthin B-TRIVIAL 
crystals O 
, O 
recrystallized O 
by O 
petroleum B-TRIVIAL 
ether I-TRIVIAL 
, O 
absolute O 
ethanol B-SYSTEMATIC 
and O 
25% O 
ethanol B-SYSTEMATIC 
solution O 
, O 
showed O 
only O 
one O 
polymorph O 
and O 
no O 
polymorphic O 
impurity O 
. O 
Phyllanthin B-TRIVIAL 
in O 
a O 
solid O 
state O 
was O 
found O 
to O 
undergo O 
significant O 
thermal O 
decomposition O 
above O 
200 O 
°C O 
. O 
The O 
compound O 
demonstrated O 
good O 
stability O 
in O 
aqueous O 
solution O 
over O 
a O 
pH O 
range O 
of O 
1.07-10.02 O 
for O 
at O 
least O 
4 O 
h O 
. O 
The O 
solubility O 
of O 
phyllanthin B-TRIVIAL 
appeared O 
to O 
be O 
pH O 
- O 
independent O 
of O 
pH O 
range O 
from O 
1.07 O 
to O 
10.26 O 
. O 
Ionization O 
property O 
studied O 
by O 
absorbance O 
spectroscopy O 
method O 
was O 
in O 
agreement O 
with O 
the O 
result O 
of O 
pH-solubility O 
study O 
, O 
showing O 
that O 
phyllanthin B-TRIVIAL 
has O 
no O 
pKa O 
over O 
a O 
pH O 
range O 
of O 
1.12-10.02 O 
. O 
The O 
log O 
Pow O 
value O 
of O 
phyllanthin B-TRIVIAL 
was O 
found O 
to O 
be O 
3.3 O 
± O 
0.05 O 
at O 
pH O 
7.48 O 
, O 
suggesting O 
that O 
phyllanthin B-TRIVIAL 
may O 
have O 
good O 
permeability O 
through O 
biological O 
membranes O 
. O 
The O 
findings O 
could O 
be O 
useful O 
tools O 
for O 
the O 
development O 
of O 
stable O 
and O 
bioavailable O 
oral O 
dosage O 
forms O 
of O 
phyllanthin B-TRIVIAL 
. O 

- O 
Modified O 
Poly(ethylene B-FAMILY 
oxide I-FAMILY 
) I-FAMILY 
/ O 
Poly(d,l-lactic B-FAMILY 
acid I-FAMILY 
) I-FAMILY 
Electrospun O 
Mats O 
with O 
Improved O 
Antioxidant O 
and O 
Anti-inflammatory O 
Properties O 
. O 

is O 
a O 
phytochemical O 
with O 
a O 
broad O 
range O 
of O 
desirable O 
biological O 
activity O 
for O 
wound O 
healing O 
. O 
However O 
, O 
its O 
poor O 
bioavailability O 
requires O 
developing O 
a O 
new O 
method O 
for O 
fabricating O 
an O 
appropriate O 
carrier O 
vehicle O 
to O 
deliver O 
genistein B-TRIVIAL 
in O 
a O 
sustained O 
manner O 
. O 
Based O 
on O 
the O 
guidance O 
afforded O 
by O 
the O 
ternary O 
phase O 
diagram O 
of O 
poly(d,l-lactic B-FAMILY 
acid I-FAMILY 
) I-FAMILY 
( O 
PDLLA B-ABBREVIATION 
) O 
, O 
poly(ethylene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEO B-ABBREVIATION 
) O 
, O 
and O 
genistein B-TRIVIAL 
blends O 
, O 
certain O 
selective O 
compositions O 
were O 
electrospun O 
. O 
We O 
obtained O 
a O 
uniformly O 
smooth O 
surface O 
morphology O 
in O 
unmodified O 
and O 
genistein B-TRIVIAL 
-modified O 
PEO B-ABBREVIATION 
/ O 
PDLLA B-ABBREVIATION 
fibers O 
, O 
documented O 
by O 
scanning O 
electron O 
microscopy O 
. O 
Moreover O 
, O 
wide-angle O 
X-ray O 
diffraction O 
and O 
(1)H B-FORMULA 
NMR O 
studies O 
revealed O 
that O 
the O 
genistein B-TRIVIAL 
molecules O 
, O 
successfully O 
incorporated O 
in O 
the O 
blends O 
, O 
remained O 
chemically O 
stable O 
after O 
electrospinning O 
. O 
Besides O 
surface O 
wettability O 
and O 
dimensional O 
stability O 
of O 
the O 
electrospun O 
mats O 
, O 
the O 
released O 
genistein B-TRIVIAL 
amount O 
has O 
been O 
evaluated O 
as O 
a O 
function O 
of O 
PEO B-ABBREVIATION 
concentration O 
. O 
Our O 
biocompatibility O 
investigations O 
suggest O 
that O 
genistein B-TRIVIAL 
-modified O 
PEO B-ABBREVIATION 
/ O 
PDLLA B-ABBREVIATION 
electrospun O 
mats O 
exhibit O 
strong O 
antioxidant O 
and O 
anti-inflammatory O 
activities O 
which O 
indicate O 
they O 
have O 
potential O 
applications O 
for O 
wound O 
dressings O 
. O 

Permeation O 
of O 
Hydrogen B-SYSTEMATIC 
Gas O 
Using O 
Cellulose O 
Nanofibril O 
Film O 
. O 

membranes O 
that O 
can O 
selectively O 
permeate O 
hydrogen B-SYSTEMATIC 
gas O 
have O 
been O 
developed O 
from O 
aqueous O 
dispersions O 
of O 
2,2,6,6-tetramethylpiperidine-1-oxyl B-SYSTEMATIC 
( O 
TEMPO B-ABBREVIATION 
)-oxidized O 
cellulose O 
nanofibrils O 
( O 
TOCN O 
) O 
prepared O 
from O 
wood O 
cellulose O 
: O 
TOCN O 
- O 
coated O 
plastic O 
films O 
and O 
self O 
- O 
standing O 
TOCN O 
films O 
. O 
Compared O 
with O 
TOCNs O 
with O 
sodium B-SYSTEMATIC 
, O 
lithium B-SYSTEMATIC 
, O 
potassium B-SYSTEMATIC 
, O 
and O 
cesium B-SYSTEMATIC 
carboxylate B-SYSTEMATIC 
groups O 
, O 
TOCN O 
with O 
free O 
carboxyl B-SYSTEMATIC 
groups O 
( O 
TOCN- O 
COOH B-FORMULA 
) O 
had O 
much O 
high O 
and O 
selective O 
H2 B-FORMULA 
gas O 
permeation O 
performance O 
. O 
Because O 
permeabilities O 
of O 
H2 B-FORMULA 
, O 
N2 B-FORMULA 
, O 
O2 B-FORMULA 
, O 
and O 
CO2 B-FORMULA 
gases O 
through O 
the O 
membranes O 
primarily O 
depended O 
on O 
their O 
kinetic O 
diameters O 
, O 
the O 
gas O 
permeation O 
behavior O 
of O 
the O 
various O 
TOCNs O 
can O 
be O 
explained O 
in O 
terms O 
of O 
a O 
diffusion O 
mechanism O 
. O 
Thus O 
, O 
the O 
selective O 
H2 B-FORMULA 
gas O 
permeability O 
for O 
TOCN- O 
COOH B-FORMULA 
was O 
probably O 
due O 
to O 
a O 
larger O 
average O 
size O 
in O 
free O 
volume O 
holes O 
present O 
between O 
nanofibrils O 
in O 
the O 
layer O 
and O 
film O 
than O 
those O 
of O 
other O 
TOCNs O 
with O 
metal B-FAMILY 
carboxylate I-FAMILY 
groups O 
. O 
The O 
obtained O 
results O 
indicate O 
that O 
TOCN- O 
COOH B-FORMULA 
membranes O 
are O 
applicable O 
as O 
biobased O 
H2 B-FORMULA 
gas O 
separation O 
membranes O 
in O 
fuel O 
cell O 
electric O 
power O 
generation O 
systems O 
. O 

Activity O 
of O 
Axidjiferosides B-FAMILY 
, O 
New O 
β-Galactosylceramides B-FAMILY 
from O 
the O 
African O 
Sponge O 
Axinyssa O 
djiferi O 
. O 

marine O 
sponge O 
, O 
Axinyssa O 
djiferi O 
, O 
collected O 
on O 
mangrove O 
tree O 
roots O 
in O 
Senegal O 
, O 
was O 
investigated O 
for O 
glycolipids O 
. O 
A O 
mixture O 
containing O 
new O 
glycosphingolipids B-FAMILY 
, O 
named O 
axidjiferoside-A B-MULTIPLE 
, I-MULTIPLE 
-B I-MULTIPLE 
and I-MULTIPLE 
-C I-MULTIPLE 
, O 
accounted O 
for O 
0.07% O 
of O 
sponge O 
biomass O 
( O 
dry O 
weight O 
) O 
and O 
for O 
2.16% O 
of O 
total O 
lipids O 
. O 
It O 
showed O 
a O 
significant O 
antimalarial O 
activity O 
, O 
with O 
a O 
50% O 
inhibitory O 
concentration O 
( O 
IC50 O 
) O 
of O 
0.53 O 
± O 
0.2 O 
μM O 
against O 
a O 
chloroquine B-TRIVIAL 
-resistant O 
strain O 
of O 
Plasmodium O 
falciparum O 
. O 
They O 
were O 
identified O 
as O 
homologous O 
β-galactopyranosylceramides B-FAMILY 
composed O 
of O 
2-amino-(6E)-octadec-6-en-1,3,4-triol B-SYSTEMATIC 
, O 
and O 
the O 
major O 
one O 
, O 
axidjiferoside-A B-TRIVIAL 
( O 
around O 
60% O 
) O 
, O 
contained O 
2-hydroxytetracosanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
Cytotoxicity O 
was O 
studied O 
in O 
vitro O 
on O 
human O 
cancer O 
cell O 
lines O 
( O 
multiple O 
myeloma O 
, O 
colorectal O 
adenocarcinoma O 
, O 
glioblastoma O 
and O 
two O 
lung O 
cancer O 
NSCLC-N6 O 
and O 
A549 O 
) O 
. O 
Results O 
of O 
this O 
investigation O 
showed O 
that O 
axidjiferosides B-FAMILY 
are O 
of O 
interest O 
, O 
because O 
they O 
proved O 
a O 
good O 
antiplasmodial O 
activity O 
, O 
with O 
only O 
a O 
low O 
cytotoxicity O 
against O 
various O 
human O 
cell O 
lines O 
and O 
no O 
significant O 
antitrypanosomal O 
and O 
antileishmanial O 
activity O 
. O 
Thus O 
, O 
it O 
seems O 
that O 
galactosylceramides B-FAMILY 
with O 
a O 
β O 
anomeric O 
configuration O 
may O 
be O 
suitable O 
in O 
searching O 
for O 
new O 
antimalarial O 
drugs O 
. O 

the O 
Reaction O 
Mechanisms O 
Governing O 
Methanol B-SYSTEMATIC 
-to- O 
Olefins B-FAMILY 
Catalysis O 
by O 
Theory O 
and O 
Experiment O 
. O 

conversion O 
of O 
methanol B-SYSTEMATIC 
to O 
olefins B-FAMILY 
( O 
MTO O 
) O 
over O 
a O 
heterogeneous O 
nanoporous O 
catalyst O 
material O 
is O 
a O 
highly O 
complex O 
process O 
involving O 
a O 
cascade O 
of O 
elementary O 
reactions O 
. O 
The O 
elucidation O 
of O 
the O 
reaction O 
mechanisms O 
leading O 
to O 
either O 
the O 
desired O 
production O 
of O 
ethene B-SYSTEMATIC 
and O 
/ O 
or O 
propene B-SYSTEMATIC 
or O 
undesired O 
deactivation O 
has O 
challenged O 
researchers O 
for O 
many O 
decades O 
. O 
Clearly O 
, O 
catalyst O 
choice O 
, O 
in O 
particular O 
topology O 
and O 
acidity O 
, O 
as O 
well O 
as O 
the O 
specific O 
process O 
conditions O 
determine O 
the O 
overall O 
MTO O 
activity O 
and O 
selectivity O 
; O 
however O 
, O 
the O 
subtle O 
balances O 
between O 
these O 
factors O 
remain O 
not O 
fully O 
understood O 
. O 
In O 
this O 
review O 
, O 
an O 
overview O 
of O 
proposed O 
reaction O 
mechanisms O 
for O 
the O 
MTO O 
process O 
is O 
given O 
, O 
focusing O 
on O 
the O 
archetypal O 
MTO O 
catalysts O 
, O 
H-ZSM-5 B-FAMILY 
and O 
H-SAPO-34 B-TRIVIAL 
. O 
The O 
presence O 
of O 
organic O 
species O 
, O 
that O 
is O 
, O 
the O 
so O 
- O 
called O 
hydrocarbon O 
pool O 
, O 
in O 
the O 
inorganic O 
framework O 
forms O 
the O 
starting O 
point O 
for O 
the O 
majority O 
of O 
the O 
mechanistic O 
routes O 
. O 
The O 
combination O 
of O 
theory O 
and O 
experiment O 
enables O 
a O 
detailed O 
description O 
of O 
reaction O 
mechanisms O 
and O 
corresponding O 
reaction O 
intermediates O 
. O 
The O 
identification O 
of O 
such O 
intermediates O 
occurs O 
by O 
different O 
spectroscopic O 
techniques O 
, O 
for O 
which O 
theory O 
and O 
experiment O 
also O 
complement O 
each O 
other O 
. O 
Depending O 
on O 
the O 
catalyst O 
topology O 
, O 
reaction O 
mechanisms O 
proposed O 
thus O 
far O 
involve O 
aromatic O 
or O 
aliphatic O 
intermediates O 
. O 
Ab O 
initio O 
simulations O 
taking O 
into O 
account O 
the O 
zeolitic O 
environment O 
can O 
nowadays O 
be O 
used O 
to O 
obtain O 
reliable O 
reaction O 
barriers O 
and O 
chemical O 
kinetics O 
of O 
individual O 
reactions O 
. O 
As O 
a O 
result O 
, O 
computational O 
chemistry O 
and O 
by O 
extension O 
computational O 
spectroscopy O 
have O 
matured O 
to O 
the O 
level O 
at O 
which O 
reliable O 
theoretical O 
data O 
can O 
be O 
obtained O 
, O 
supplying O 
information O 
that O 
is O 
very O 
hard O 
to O 
acquire O 
experimentally O 
. O 
Special O 
emphasis O 
is O 
given O 
to O 
theoretical O 
developments O 
that O 
open O 
new O 
perspectives O 
and O 
possibilities O 
that O 
aid O 
to O 
unravel O 
a O 
process O 
as O 
complex O 
as O 
methanol B-SYSTEMATIC 
conversion O 
over O 
an O 
acidic O 
porous O 
material O 
. O 

and O 
pathways O 
for O 
denitration O 
of O 
organic O 
nitrates B-FAMILY 
in O 
the O 
human O 
liver O 
. O 

first O 
- O 
pass O 
metabolism O 
differs O 
considerably O 
among O 
organic O 
nitrates B-FAMILY 
but O 
little O 
information O 
exists O 
on O 
the O 
mechanism O 
of O 
denitration O 
of O 
these O 
compounds O 
in O 
hepatic O 
tissue O 
. O 
The O 
metabolism O 
of O 
nitrooxybutyl-esters B-FAMILY 
of O 
flurbiprofen B-TRIVIAL 
and O 
ferulic B-TRIVIAL 
- I-TRIVIAL 
acid I-TRIVIAL 
, O 
a O 
class O 
of O 
organic O 
nitrates B-FAMILY 
with O 
potential O 
therapeutic O 
implication O 
in O 
variety O 
of O 
different O 
conditions O 
, O 
was O 
investigated O 
in O 
comparison O 
with O 
glyceryl B-SYSTEMATIC 
trinitrate I-SYSTEMATIC 
( O 
GTN B-ABBREVIATION 
) O 
in O 
human O 
liver O 
by O 
a O 
multiple O 
approach O 
, O 
using O 
a O 
spontaneous O 
metabolism O 
- O 
independent O 
NO B-FORMULA 
donor O 
( O 
NOC-5 B-TRIVIAL 
) O 
as O 
a O 
reference O 
tool O 
. O 
Nitrooxybutyl-esters B-FAMILY 
were O 
rapidly O 
and O 
quantitatively O 
metabolized O 
to O 
their O 
respective O 
parent O 
compounds O 
and O 
the O 
organic O 
nitrate B-SYSTEMATIC 
moiety O 
nitrooxybutyl-alcohol B-SYSTEMATIC 
( O 
NOBA B-ABBREVIATION 
) O 
. O 
Differently O 
from O 
GTN B-ABBREVIATION 
which O 
was O 
rapidly O 
and O 
completely O 
metabolized O 
to O 
nitrite B-SYSTEMATIC 
, O 
NOBA B-ABBREVIATION 
was O 
slowly O 
metabolized O 
to O 
nitrate B-SYSTEMATIC 
. O 
In O 
contrast O 
to O 
the O 
spontaneous O 
NO B-FORMULA 
donor O 
NOC-5 B-TRIVIAL 
, O 
NOBA B-ABBREVIATION 
and O 
GTN B-ABBREVIATION 
did O 
not O 
generate O 
detectable O 
NO B-FORMULA 
and O 
failed O 
to O 
suppress O 
the O 
activity O 
of O 
cytochromeP450 O 
; O 
an O 
enzyme O 
known O 
to O 
be O 
inhibited O 
by O 
NO B-FORMULA 
. O 
The O 
direct O 
identification O 
of O 
NOBA B-ABBREVIATION 
following O 
liver O 
metabolism O 
targets O 
this O 
compound O 
as O 
the O 
functional O 
organic O 
nitrate B-SYSTEMATIC 
metabolite O 
of O 
nitrooxybutyl-esters B-FAMILY 
. O 
Moreover O 
the O 
investigation O 
of O 
the O 
pathways O 
for O 
denitration O 
of O 
NOBA B-ABBREVIATION 
and O 
GTN B-ABBREVIATION 
suggests O 
that O 
organic O 
nitrates B-FAMILY 
are O 
not O 
primarily O 
metabolized O 
to O 
NO B-FORMULA 
in O 
the O 
liver O 
but O 
to O 
different O 
extents O 
of O 
nitrite B-SYSTEMATIC 
or O 
nitrate B-SYSTEMATIC 
depending O 
from O 
their O 
different O 
chemical O 
structure O 
. O 
It O 
follows O 
that O 
cytochromeP450-dependent O 
metabolism O 
of O 
concomitant O 
drugs O 
is O 
not O 
likely O 
to O 
be O 
affected O 
by O 
oral O 
co O 
- O 
administration O 
of O 
organic O 
nitrates B-FAMILY 
. O 
However O 
the O 
first O 
- O 
pass O 
may O 
differently O 
affect O 
the O 
pharmacological O 
profile O 
of O 
organic O 
nitrates B-FAMILY 
in O 
connection O 
with O 
the O 
different O 
extent O 
of O 
denitration O 
and O 
the O 
distinct O 
bioactive O 
species O 
generated O 
and O 
exported O 
from O 
the O 
liver O 
( O 
nitrate B-SYSTEMATIC 
or O 
nitrite B-SYSTEMATIC 
) O 
. O 

a O 
Multipotent O 
Stilbene B-TRIVIAL 
to O 
Soluble O 
Epoxide B-SYSTEMATIC 
Hydrolase O 
Inhibitors O 
with O 
Antiproliferative O 
Properties O 
. O 

by O 
nature O 
: O 
Natural O 
product O 
isopropylstilbene B-SYSTEMATIC 
was O 
identified O 
as O 
an O 
inhibitor O 
of O 
soluble O 
epoxide B-SYSTEMATIC 
hydrolase O 
exhibiting O 
antiproliferative O 
properties O 
. O 
Following O 
the O 
natural O 
product O 
inspired O 
design O 
approach O 
, O 
a O 
library O 
of O 
(E)-styryl-1H-benzo[d]imidazoles B-FAMILY 
was O 
synthesized O 
and O 
evaluated O 
with O 
recombinant O 
enzyme O 
and O 
on O 
several O 
cancer O 
cell O 
lines O 
. O 

exposure O 
during O 
the O 
early O 
postnatal O 
period O 
of O 
mice O 
: O 
Immediate O 
and O 
late O 
- O 
emergent O 
effects O 
on O 
the O 
cholinergic O 
and O 
serotonergic O 
systems O 
and O 
on O 
behavior O 
. O 

( O 
OPs B-FAMILY 
) O 
are O 
among O 
the O 
most O 
used O 
pesticides O 
. O 
While O 
some O 
OPs B-FAMILY 
have O 
had O 
their O 
use O 
progressively O 
more O 
restricted O 
, O 
other O 
OPs B-FAMILY 
are O 
being O 
used O 
without O 
sufficient O 
investigation O 
of O 
their O 
effects O 
. O 
Here O 
, O 
we O 
investigated O 
the O 
immediate O 
neurochemical O 
and O 
delayed O 
neurochemical O 
and O 
behavioral O 
actions O 
of O 
the O 
OP O 
methamidophos B-TRIVIAL 
to O 
verify O 
whether O 
there O 
are O 
concerns O 
regarding O 
exposure O 
during O 
early O 
postnatal O 
development O 
. O 
From O 
the O 
3(rd) O 
to O 
the O 
9(th) O 
postnatal O 
day O 
( O 
PN O 
) O 
, O 
Swiss O 
mice O 
were O 
subcutaneously O 
injected O 
with O 
methamidophos B-TRIVIAL 
( O 
1 O 
mg O 
/ O 
kg O 
) O 
. O 
At O 
PN10 O 
, O 
we O 
assessed O 
cholinergic O 
and O 
serotonergic O 
biomarkers O 
in O 
the O 
cerebral O 
cortex O 
and O 
brainstem O 
. O 
From O 
PN60 O 
to O 
PN63 O 
, O 
mice O 
were O 
submitted O 
to O 
a O 
battery O 
of O 
behavioral O 
tests O 
and O 
subsequently O 
to O 
biochemical O 
analyses O 
. O 
At O 
PN10 O 
, O 
the O 
effects O 
were O 
restricted O 
to O 
females O 
and O 
to O 
the O 
cholinergic O 
system O 
: O 
Methamidophos B-TRIVIAL 
promoted O 
increased O 
choline B-FAMILY 
transporter O 
binding O 
in O 
the O 
brainstem O 
. O 
At O 
PN63 O 
, O 
in O 
the O 
brainstem O 
, O 
there O 
was O 
a O 
decrease O 
in O 
choline B-FAMILY 
transporter O 
, O 
a O 
female O 
- O 
only O 
decrease O 
in O 
5HT1A O 
and O 
a O 
male O 
- O 
only O 
increase O 
in O 
5HT2 O 
receptor O 
binding O 
. O 
In O 
the O 
cortex O 
, O 
choline B-FAMILY 
acetyltransferase O 
activity O 
was O 
decreased O 
and O 
5HT2 O 
receptor O 
binding O 
was O 
increased O 
both O 
in O 
males O 
and O 
females O 
. O 
Methamidophos B-TRIVIAL 
elicited O 
behavioral O 
alterations O 
suggestive O 
of O 
increased O 
depressive O 
- O 
like O 
behavior O 
and O 
impaired O 
decision O 
- O 
making O 
. O 
There O 
were O 
no O 
significant O 
alterations O 
on O 
anxiety O 
- O 
related O 
measures O 
and O 
on O 
memory O 
/ O 
learning O 
. O 
Methamidophos B-TRIVIAL 
elicited O 
cholinergic O 
and O 
serotonergic O 
alterations O 
that O 
depended O 
on O 
brain O 
region O 
, O 
sex O 
and O 
age O 
of O 
the O 
animals O 
. O 
These O 
outcomes O 
, O 
together O 
with O 
the O 
behavioral O 
effects O 
, O 
indicate O 
that O 
this O 
OP O 
is O 
deleterious O 
to O 
the O 
developing O 
brain O 
and O 
that O 
alterations O 
are O 
indeed O 
identified O 
long O 
after O 
the O 
end O 
of O 
exposure O 
. O 

Triboelectric O 
Nanogenerators O 
and O 
Triboelectric O 
Nanosensor O 
Using O 
Chemically O 
Modified O 
TiO2 B-FORMULA 
Nanomaterials O 
. O 

energy O 
harvesting O 
based O 
on O 
triboelectric O 
effect O 
has O 
been O 
proven O 
to O 
be O 
a O 
simple O 
, O 
cost O 
- O 
effective O 
, O 
and O 
robust O 
method O 
for O 
electricity O 
generation O 
. O 
In O 
this O 
study O 
, O 
we O 
developed O 
a O 
rationally O 
designed O 
triboelectric O 
nanogenerator O 
( O 
TENG O 
) O 
by O 
utilizing O 
the O 
contact O 
electrification O 
between O 
a O 
polytetrafluoroethylene B-TRIVIAL 
( O 
PTFE B-ABBREVIATION 
) O 
thin O 
film O 
and O 
a O 
layer O 
of O 
TiO2 B-FORMULA 
nanomaterial O 
( O 
nanowire O 
and O 
nanosheet O 
) O 
array O 
. O 
The O 
as-developed O 
TENG O 
was O 
systematically O 
studied O 
and O 
demonstrated O 
as O 
a O 
self O 
- O 
powered O 
nanosensor O 
toward O 
catechin B-TRIVIAL 
detection O 
. O 
The O 
high O 
sensitivity O 
( O 
detection O 
limit O 
of O 
5 O 
μM O 
) O 
and O 
selectivity O 
are O 
achieved O 
through O 
a O 
strong O 
interaction O 
between O 
Ti B-FORMULA 
atoms O 
of O 
TiO2 B-FORMULA 
nanomaterial O 
and O 
enediol O 
group O 
of O 
catechin B-TRIVIAL 
. O 
The O 
output O 
voltage O 
and O 
current O 
density O 
were O 
increased O 
by O 
a O 
factor O 
of O 
5 O 
and O 
2.9 O 
, O 
respectively O 
, O 
when O 
adsorbed O 
with O 
catechin B-TRIVIAL 
of O 
a O 
saturated O 
concentration O 
, O 
because O 
of O 
the O 
charge O 
transfer O 
from O 
catechin B-TRIVIAL 
to O 
TiO2 B-FORMULA 
. O 
This O 
study O 
demonstrates O 
the O 
possibility O 
of O 
improving O 
the O 
electrical O 
output O 
of O 
TENG O 
through O 
chemical O 
modification O 
. O 

Polypyrrole B-FAMILY 
Microvessels O 
: O 
Toward O 
Encapsulation O 
of O 
mRNA O 
Cap O 
Analogues O 
. O 

phosphorylated O 
nucleoside B-FAMILY 
derivatives O 
have O 
therapeutic O 
potential O 
, O 
but O 
their O 
application O 
is O 
limited O 
by O 
problems O 
with O 
membrane O 
permeability O 
and O 
with O 
intracellular O 
delivery O 
. O 
Here O 
, O 
we O 
prepared O 
polypyrrole B-FAMILY 
microvessel O 
structures O 
modified O 
with O 
superparamagnetic O 
nanoparticles O 
for O 
use O 
as O 
potential O 
carriers O 
of O 
nucleotides B-FAMILY 
. O 
The O 
microvessels O 
were O 
prepared O 
via O 
the O 
photochemical O 
polymerization O 
of O 
the O 
monomer O 
onto O 
the O 
surface O 
of O 
aqueous O 
ferrofluidic O 
droplets O 
. O 
A O 
complementary O 
physicochemical O 
analysis O 
revealed O 
that O 
a O 
fraction O 
of O 
the O 
nanoparticles O 
was O 
embedded O 
in O 
the O 
microvessel O 
walls O 
, O 
while O 
the O 
other O 
nanoparticles O 
were O 
in O 
the O 
core O 
of O 
the O 
vessel O 
. O 
SQUID O 
( O 
superconducting O 
quantum O 
interference O 
device O 
) O 
measurements O 
indicated O 
that O 
the O 
incorporated O 
nanoparticles O 
retained O 
their O 
superparamagnetic O 
properties O 
; O 
thus O 
, O 
the O 
resulting O 
nanoparticle O 
- O 
modified O 
microvessels O 
can O 
be O 
directed O 
by O 
an O 
external O 
magnetic O 
field O 
. O 
As O 
a O 
result O 
of O 
these O 
features O 
, O 
these O 
microvessels O 
may O 
be O 
useful O 
as O 
drug O 
carriers O 
in O 
biomedical O 
applications O 
. O 
To O 
demonstrate O 
the O 
encapsulation O 
of O 
drug O 
molecules O 
, O 
two O 
labeled O 
mRNA O 
cap O 
analogues O 
, O 
nucleotide B-FAMILY 
-derived O 
potential O 
anticancer O 
agents O 
, O 
were O 
used O 
. O 
It O 
was O 
shown O 
that O 
the O 
cap O 
analogues O 
are O 
located O 
in O 
the O 
aqueous O 
core O 
of O 
the O 
microvessels O 
and O 
can O 
be O 
released O 
to O 
the O 
external O 
solution O 
by O 
spontaneous O 
permeation O 
through O 
the O 
polymer O 
walls O 
. O 
Mass O 
spectrometry O 
analysis O 
confirmed O 
that O 
the O 
cap O 
analogues O 
were O 
preserved O 
during O 
encapsulation O 
, O 
storage O 
, O 
and O 
release O 
. O 
This O 
finding O 
provides O 
a O 
foundation O 
for O 
the O 
future O 
development O 
of O 
anticancer O 
therapies O 
and O 
for O 
the O 
delivery O 
of O 
nucleotide B-FAMILY 
-based O 
therapeutics O 
. O 

thiourea B-SYSTEMATIC 
-catalyzed O 
intramolecular O 
cope O 
- O 
type O 
hydroamination O 
. O 

of O 
Cope O 
- O 
type O 
rearrangements O 
of O 
bis-homoallylic B-FAMILY 
hydroxylamines I-FAMILY 
is O 
demonstrated O 
using O 
chiral O 
thiourea O 
derivatives O 
. O 
This O 
formal O 
intramolecular O 
hydroamination O 
reaction O 
provides O 
access O 
to O 
highly O 
enantioenriched O 
α- O 
substituted O 
pyrrolidine B-SYSTEMATIC 
products O 
and O 
represents O 
a O 
complementary O 
approach O 
to O 
metal O 
- O 
catalyzed O 
methods O 
. O 

study O 
on O 
effects O 
of O 
two O 
different O 
types O 
of O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
nanoparticles O 
on O 
human O 
neuronal O 
cells O 
. O 

dioxide I-SYSTEMATIC 
( O 
TiO2 B-FORMULA 
) O 
are O 
among O 
most O 
frequently O 
used O 
nanoparticles O 
( O 
NPs O 
) O 
. O 
They O 
are O 
present O 
in O 
a O 
variety O 
of O 
consumer O 
products O 
, O 
including O 
food O 
industry O 
in O 
which O 
they O 
are O 
employed O 
as O 
an O 
additive O 
. O 
The O 
potential O 
toxic O 
effects O 
of O 
these O 
NPs O 
on O 
mammal O 
cells O 
have O 
been O 
extensively O 
studied O 
. O 
However O 
, O 
studies O 
regarding O 
neurotoxicity O 
and O 
specific O 
effects O 
on O 
neuronal O 
systems O 
are O 
very O 
scarce O 
and O 
, O 
to O 
our O 
knowledge O 
, O 
no O 
studies O 
on O 
human O 
neuronal O 
cells O 
have O 
been O 
reported O 
so O 
far O 
. O 
Therefore O 
, O 
the O 
main O 
objective O 
of O 
this O 
work O 
was O 
to O 
investigate O 
the O 
effects O 
of O 
two O 
types O 
of O 
TiO2 B-FORMULA 
NPs O 
, O 
with O 
different O 
crystalline O 
structure O 
, O 
on O 
human O 
SHSY5Y O 
neuronal O 
cells O 
. O 
After O 
NPs O 
characterization O 
, O 
a O 
battery O 
of O 
assays O 
was O 
performed O 
to O 
evaluate O 
the O 
viability O 
, O 
cytotoxicity O 
, O 
genotoxicity O 
and O 
oxidative O 
damage O 
in O 
TiO2 B-FORMULA 
NP-exposed O 
SHSY5Y O 
cells O 
. O 
Results O 
obtained O 
showed O 
that O 
the O 
behaviour O 
of O 
both O 
types O 
of O 
NPs O 
resulted O 
quite O 
comparable O 
. O 
They O 
did O 
not O 
reduce O 
the O 
viability O 
of O 
neuronal O 
cells O 
but O 
were O 
effectively O 
internalized O 
by O 
the O 
cells O 
and O 
induced O 
dose O 
- O 
dependent O 
cell O 
cycle O 
alterations O 
, O 
apoptosis O 
by O 
intrinsic O 
pathway O 
, O 
and O 
genotoxicity O 
not O 
related O 
with O 
double O 
strand O 
break O 
production O 
. O 
Furthermore O 
, O 
all O 
these O 
effects O 
were O 
not O 
associated O 
with O 
oxidative O 
damage O 
production O 
and O 
, O 
consequently O 
, O 
further O 
investigations O 
on O 
the O 
specific O 
mechanisms O 
underlying O 
the O 
effects O 
observed O 
in O 
this O 
study O 
are O 
required O 
. O 

deficiency O 
and O 
heightened O 
neuropathic O 
pain O 
in O 
aged O 
mice O 
. O 

of O 
peripheral O 
nerves O 
may O 
result O 
in O 
chronic O 
neuropathic O 
pain O 
for O 
which O 
the O 
likelihood O 
is O 
increased O 
in O 
the O 
elderly O 
. O 
We O 
assessed O 
in O 
mice O 
if O 
age O 
- O 
dependent O 
alterations O 
of O 
endocannabinoids O 
contributed O 
to O 
the O 
heightened O 
vulnerability O 
to O 
neuropathic O 
pain O 
at O 
old O 
age O 
. O 
We O 
assessed O 
nociception O 
, O 
endocannabinoids O 
and O 
the O 
therapeutic O 
efficacy O 
of O 
R-flurbiprofen B-TRIVIAL 
in O 
young O 
and O 
aged O 
mice O 
in O 
the O 
spared O 
nerve O 
injury O 
model O 
of O 
neuropathic O 
pain O 
. O 
R-flurbiprofen B-TRIVIAL 
was O 
used O 
because O 
it O 
is O 
able O 
to O 
reduce O 
neuropathic O 
pain O 
in O 
young O 
mice O 
in O 
part O 
by O 
increasing O 
anandamide B-TRIVIAL 
. O 
Aged O 
mice O 
developed O 
stronger O 
nociceptive O 
hypersensitivity O 
after O 
sciatic O 
nerve O 
injury O 
than O 
young O 
mice O 
. O 
This O 
was O 
associated O 
with O 
low O 
anandamide B-TRIVIAL 
levels O 
in O 
the O 
dorsal O 
root O 
ganglia O 
, O 
spinal O 
cord O 
, O 
thalamus O 
and O 
cortex O 
, O 
which O 
further O 
decreased O 
after O 
nerve O 
injury O 
. O 
In O 
aged O 
mice O 
, O 
R-flurbiprofen B-TRIVIAL 
had O 
only O 
weak O 
antinociceptive O 
efficacy O 
and O 
it O 
failed O 
to O 
restore O 
normal O 
anandamide B-TRIVIAL 
levels O 
after O 
nerve O 
injury O 
. O 
In O 
terms O 
of O 
the O 
mechanisms O 
, O 
we O 
found O 
that O 
fatty B-FAMILY 
acid I-FAMILY 
amide B-FAMILY 
hydrolase O 
( O 
FAAH O 
) O 
which O 
degrades O 
anandamide B-TRIVIAL 
, O 
was O 
upregulated O 
after O 
nerve O 
injury O 
at O 
both O 
ages O 
, O 
so O 
that O 
this O 
upregulation O 
likely O 
did O 
not O 
account O 
for O 
the O 
age O 
- O 
dependent O 
differences O 
. O 
However O 
, O 
enzymes O 
contributing O 
to O 
oxidative O 
metabolism O 
of O 
anandamide B-TRIVIAL 
, O 
namely O 
cyclooxygenase-1 O 
and O 
Cyp2D6 O 
, O 
were O 
increased O 
in O 
the O 
brain O 
of O 
aged O 
mice O 
, O 
possibly O 
enhancing O 
the O 
oxidative O 
breakdown O 
of O 
anandamide B-TRIVIAL 
. O 
This O 
may O 
overwhelm O 
the O 
capacity O 
of O 
R-flurbiprofen B-TRIVIAL 
to O 
restore O 
anandamide B-TRIVIAL 
homeostasis O 
and O 
may O 
contribute O 
to O 
the O 
heightened O 
risk O 
for O 
neuropathic O 
pain O 
at O 
old O 
age O 
. O 

novel O 
recreational O 
drug O 
3,4-methylenedioxypyrovalerone B-SYSTEMATIC 
( O 
MDPV B-ABBREVIATION 
) O 
is O 
a O 
potent O 
psychomotor O 
stimulant O 
: O 
Self O 
- O 
administration O 
and O 
locomotor O 
activity O 
in O 
rats O 
. O 

use O 
of O 
the O 
cathinone O 
derivative O 
3,4-methylenedioxypyrovalerone B-SYSTEMATIC 
( O 
MDPV B-ABBREVIATION 
; O 
" O 
bath O 
salts O 
" O 
) O 
has O 
increased O 
worldwide O 
in O 
past O 
years O 
, O 
accompanied O 
by O 
accounts O 
of O 
health O 
and O 
legal O 
problems O 
in O 
the O 
popular O 
media O 
and O 
efforts O 
to O 
criminalize O 
possession O 
in O 
numerous O 
jurisdictions O 
. O 
Minimal O 
information O 
exists O 
on O 
the O 
effects O 
of O 
MDPV B-ABBREVIATION 
in O 
laboratory O 
models O 
. O 
This O 
study O 
determined O 
the O 
effects O 
of O 
MDPV B-ABBREVIATION 
, O 
alongside O 
those O 
of O 
the O 
better O 
studied O 
stimulant O 
d-methamphetamine B-TRIVIAL 
( O 
METH B-ABBREVIATION 
) O 
, O 
using O 
rodent O 
models O 
of O 
intravenous O 
self O 
- O 
administration O 
( O 
IVSA O 
) O 
, O 
thermoregulation O 
and O 
locomotor O 
activity O 
. O 
Male O 
Wistar O 
rats O 
were O 
trained O 
to O 
self O 
- O 
administer O 
MDPV B-ABBREVIATION 
or O 
METH B-ABBREVIATION 
( O 
0.05 O 
mg O 
/ O 
kg O 
/ O 
infusion O 
, O 
i.v O 
. O 
) O 
or O 
were O 
prepared O 
with O 
radiotelemetry O 
implants O 
for O 
the O 
assessment O 
of O 
body O 
temperature O 
and O 
activity O 
responses O 
to O 
MDPV B-ABBREVIATION 
or O 
METH B-ABBREVIATION 
( O 
0-5.6 O 
mg O 
/ O 
kg O 
s.c O 
. O 
) O 
. O 
METH B-ABBREVIATION 
and O 
MDPV B-ABBREVIATION 
were O 
consistently O 
self O 
- O 
administered O 
within O 
10 O 
training O 
sessions O 
( O 
mg O 
/ O 
kg O 
/ O 
h O 
; O 
METH B-ABBREVIATION 
Mean O 
= O 
0.4 O 
and O 
Max O 
= O 
1.15 O 
; O 
MDPV B-ABBREVIATION 
Mean O 
= O 
0.9 O 
and O 
Max O 
= O 
5.8 O 
) O 
. O 
Dose O 
- O 
substitution O 
studies O 
demonstrated O 
that O 
behavior O 
was O 
sensitive O 
to O 
dose O 
for O 
both O 
drugs O 
, O 
but O 
MDPV B-ABBREVIATION 
( O 
0.01-0.50 O 
mg O 
/ O 
kg O 
/ O 
inf O 
) O 
showed O 
greater O 
potency O 
and O 
efficacy O 
than O 
METH B-ABBREVIATION 
( O 
0.1-0.25 O 
mg O 
/ O 
kg O 
/ O 
inf O 
) O 
. O 
In O 
addition O 
, O 
both O 
MDPV B-ABBREVIATION 
and O 
METH B-ABBREVIATION 
increased O 
locomotor O 
activity O 
at O 
lower O 
doses O 
( O 
0.5-1.0 O 
mg O 
/ O 
kg O 
, O 
s.c O 
. O 
) O 
and O 
transiently O 
decreased O 
activity O 
at O 
the O 
highest O 
dose O 
( O 
5.6 O 
mg O 
/ O 
kg O 
, O 
s.c O 
. O 
) O 
. O 
Body O 
temperature O 
increased O 
monotonically O 
with O 
increasing O 
doses O 
of O 
METH B-ABBREVIATION 
but O 
MDPV B-ABBREVIATION 
had O 
a O 
negligible O 
effect O 
on O 
temperature O 
. O 
Stereotypy O 
was O 
associated O 
with O 
relatively O 
high O 
self O 
- O 
administered O 
cumulative O 
doses O 
of O 
MDPV B-ABBREVIATION 
( O 
∼1.5 O 
mg O 
/ O 
kg O 
/ O 
h O 
) O 
as O 
well O 
as O 
with O 
non-contingent O 
MDPV B-ABBREVIATION 
administration O 
wherein O 
the O 
intensity O 
and O 
duration O 
of O 
stereotypy O 
increased O 
as O 
MDPV B-ABBREVIATION 
dose O 
increased O 
. O 
Thus O 
, O 
MDPV B-ABBREVIATION 
poses O 
a O 
substantial O 
threat O 
for O 
compulsive O 
use O 
that O 
is O 
potentially O 
greater O 
than O 
that O 
for O 
METH B-ABBREVIATION 
. O 

phosphodiesterase O 
2 O 
( O 
PDE2 O 
) O 
inhibitors O 
are O 
shown O 
to O 
have O 
efficacy O 
in O 
a O 
rat O 
model O 
of O 
osteoarthritis O 
( O 
OA O 
) O 
pain O 
. O 
We O 
identified O 
potent O 
, O 
selective O 
PDE2 O 
inhibitors O 
by O 
optimizing O 
residual O 
PDE2 O 
activity O 
in O 
a O 
series O 
of O 
phosphodiesterase O 
4 O 
( O 
PDE4 O 
) O 
inhibitors O 
, O 
while O 
minimizing O 
PDE4 O 
inhibitory O 
activity O 
. O 
These O 
newly O 
designed O 
PDE2 O 
inhibitors O 
bind O 
to O 
the O 
PDE2 O 
enzyme O 
in O 
a O 
cGMP B-ABBREVIATION 
-like O 
binding O 
mode O 
orthogonal O 
to O 
the O 
cAMP B-ABBREVIATION 
-like O 
binding O 
mode O 
found O 
in O 
PDE4 O 
. O 
Extensive O 
structure O 
activity O 
relationship O 
studies O 
ultimately O 
led O 
to O 
identification O 
of O 
pyrazolodiazepinone B-SYSTEMATIC 
, O 
22 O 
, O 
which O 
was O 
> O 
1000-fold O 
selective O 
for O 
PDE2 O 
over O 
recombinant O 
, O 
full O 
length O 
PDEs O 
1B O 
, O 
3A O 
, O 
3B O 
, O 
4A O 
, O 
4B O 
, O 
4C O 
, O 
7A O 
, O 
7B O 
, O 
8A O 
, O 
8B O 
, O 
9 O 
, O 
10 O 
and O 
11 O 
. O 
Compound O 
22 O 
also O 
retained O 
excellent O 
PDE2 O 
selectivity O 
( O 
241-fold O 
to O 
419-fold O 
) O 
over O 
the O 
remaining O 
recombinant O 
, O 
full O 
length O 
PDEs O 
, O 
1A O 
, O 
4D O 
, O 
5 O 
, O 
and O 
6 O 
. O 
Compound O 
22 O 
exhibited O 
good O 
pharmacokinetic O 
properties O 
and O 
excellent O 
oral O 
bioavailability O 
( O 
F=78% O 
, O 
rat O 
) O 
. O 
In O 
an O 
in O 
vivo O 
rat O 
model O 
of O 
OA O 
pain O 
, O 
compound O 
22 O 
had O 
significant O 
analgesic O 
activity O 
1 O 
and O 
3h O 
after O 
a O 
single O 
, O 
10mg O 
/ O 
kg O 
, O 
subcutaneous O 
dose O 
. O 

mechanisms O 
by O 
which O 
early O 
chronic O 
lead O 
( O 
Pb B-FORMULA 
) O 
exposure O 
alter O 
brain O 
development O 
have O 
not O 
been O 
identified O 
. O 
We O 
examined O 
neuroimmune O 
system O 
effects O 
in O 
C57BL O 
/ O 
6J O 
mice O 
with O 
Pb B-FORMULA 
exposure O 
, O 
including O 
levels O 
that O 
may O 
be O 
common O 
among O 
children O 
in O 
lower O 
socioeconomic O 
income O 
environments O 
. O 
Pups O 
were O 
exposed O 
via O 
dams O 
' O 
drinking O 
water O 
from O 
birth O 
to O 
post O 
- O 
natal O 
day O 
28 O 
to O 
low O 
, O 
high O 
or O 
no O 
Pb B-FORMULA 
conditions O 
. O 
We O 
compared O 
gene O 
expression O 
of O 
neuroinflammatory O 
markers O 
( O 
study O 
1 O 
) O 
; O 
and O 
microglial O 
mean O 
cell O 
body O 
volume O 
and O 
mean O 
cell O 
body O 
number O 
in O 
dentate O 
gyrus O 
, O 
and O 
dentate O 
gyrus O 
volume O 
( O 
study O 
2 O 
) O 
. O 
Blood O 
Pb B-FORMULA 
levels O 
in O 
exposed O 
animals O 
at O 
sacrifice O 
( O 
post O 
- O 
natal O 
day O 
28 O 
) O 
ranged O 
from O 
2.66 O 
to O 
20.31μg O 
/ O 
dL O 
. O 
Only O 
interleukin-6 O 
( O 
IL6 O 
) O 
differed O 
between O 
groups O 
and O 
reductions O 
were O 
dose O 
- O 
dependent O 
. O 
Microglia O 
cell O 
body O 
number O 
also O 
differed O 
between O 
groups O 
and O 
reductions O 
were O 
dose O 
- O 
dependent O 
. O 
As O 
compared O 
with O 
controls O 
, O 
microglia O 
cell O 
body O 
volume O 
was O 
greater O 
but O 
highly O 
variable O 
in O 
only O 
low O 
- O 
dose O 
animals O 
; O 
dentate O 
gyri O 
volumes O 
in O 
low- O 
and O 
high O 
- O 
dose O 
animals O 
were O 
reduced O 
. O 
The O 
results O 
did O 
not O 
support O 
a O 
model O 
of O 
increased O 
neuroinflammation O 
. O 
Instead O 
, O 
early O 
chronic O 
exposure O 
to O 
Pb B-FORMULA 
disrupted O 
microglia O 
via O 
damage O 
to O 
, O 
loss O 
of O 
, O 
or O 
lack O 
of O 
proliferation O 
of O 
microglia O 
in O 
the O 
developing O 
brains O 
of O 
Pb B-FORMULA 
-exposed O 
animals O 
. O 

of O 
platinum B-SYSTEMATIC 
-damaged O 
oocytes O 
from O 
programmed O 
cell O 
death O 
through O 
inactivation O 
of O 
the O 
p53 O 
family O 
signaling O 
network O 
. O 

oocytes O 
within O 
avascular O 
regions O 
of O 
the O 
ovary O 
are O 
exquisitely O 
susceptible O 
to O 
chemotherapy O 
. O 
Early O 
menopause O 
and O 
sterility O 
are O 
unintended O 
consequences O 
of O 
chemotherapy O 
, O 
and O 
efforts O 
to O 
understand O 
the O 
oocyte O 
apoptotic O 
pathway O 
may O 
provide O 
new O 
targets O 
for O 
mitigating O 
this O 
outcome O 
. O 
Recently O 
, O 
the O 
c-Abl O 
kinase O 
inhibitor O 
imatinib B-TRIVIAL 
mesylate I-TRIVIAL 
( O 
imatinib B-TRIVIAL 
) O 
has O 
become O 
the O 
focus O 
of O 
research O 
as O 
a O 
fertoprotective O 
drug O 
against O 
cisplatin B-TRIVIAL 
. O 
However O 
, O 
the O 
mechanism O 
by O 
which O 
imatinib B-TRIVIAL 
protects O 
oocytes O 
is O 
not O 
fully O 
understood O 
, O 
and O 
reports O 
of O 
the O 
drug's O 
efficacy O 
have O 
been O 
contradictory O 
. O 
Using O 
in O 
vitro O 
culture O 
and O 
subrenal O 
grafting O 
of O 
mouse O 
ovaries O 
, O 
we O 
demonstrated O 
that O 
imatinib B-TRIVIAL 
inhibits O 
the O 
cisplatin B-TRIVIAL 
-induced O 
apoptosis O 
of O 
oocytes O 
within O 
primordial O 
follicles O 
. O 
We O 
found O 
that O 
, O 
before O 
apoptosis O 
, O 
cisplatin B-TRIVIAL 
induces O 
c-Abl O 
and O 
TAp73 O 
expression O 
in O 
the O 
oocyte O 
. O 
Oocytes O 
undergoing O 
apoptosis O 
showed O 
downregulation O 
of O 
TAp63 O 
and O 
upregulation O 
of O 
Bax O 
. O 
While O 
imatinib B-TRIVIAL 
was O 
unable O 
to O 
block O 
cisplatin B-TRIVIAL 
-induced O 
DNA O 
damage O 
and O 
damage O 
response O 
, O 
such O 
as O 
the O 
upregulation O 
of O 
p53 O 
, O 
imatinib B-TRIVIAL 
inhibited O 
the O 
cisplatin B-TRIVIAL 
-induced O 
nuclear O 
accumulation O 
of O 
c-Abl O 
/ O 
TAp73 O 
and O 
the O 
subsequent O 
downregulation O 
of O 
TAp63 O 
and O 
upregulation O 
of O 
Bax O 
, O 
thereby O 
abrogating O 
oocyte O 
cell O 
death O 
. O 
Surprisingly O 
, O 
the O 
conditional O 
deletion O 
of O 
Trp B-FORMULA 
63 O 
, O 
but O 
not O 
ΔNp63 O 
, O 
in O 
oocytes O 
inhibited O 
apoptosis O 
, O 
as O 
well O 
as O 
the O 
accumulation O 
of O 
c-Abl O 
and O 
TAp73 O 
caused O 
by O 
cisplatin B-TRIVIAL 
. O 
These O 
data O 
suggest O 
that O 
TAp63 O 
is O 
the O 
master O 
regulator O 
of O 
cisplatin B-TRIVIAL 
-induced O 
oocyte O 
death O 
. O 
The O 
expression O 
kinetics O 
of O 
TAp63 O 
, O 
c-Abl O 
and O 
TAp73 O 
suggest O 
that O 
cisplatin B-TRIVIAL 
activates O 
TAp63-dependent O 
expression O 
of O 
c-Abl O 
and O 
TAp73 O 
and O 
, O 
in O 
turn O 
, O 
the O 
activation O 
of O 
TAp73 O 
by O 
c-Abl O 
- O 
induced O 
BAX O 
expression O 
. O 
Our O 
findings O 
indicate O 
that O 
imatinib B-TRIVIAL 
protects O 
oocytes O 
from O 
cisplatin B-TRIVIAL 
-induced O 
cell O 
death O 
by O 
inhibiting O 
c-Abl O 
kinase O 
, O 
which O 
would O 
otherwise O 
activate O 
TAp73-BAX O 
- O 
mediated O 
apoptosis O 
. O 
Thus O 
, O 
imatinib B-TRIVIAL 
and O 
other O 
c-Abl O 
kinase O 
inhibitors O 
provide O 
an O 
intriguing O 
new O 
way O 
to O 
halt O 
cisplatin B-TRIVIAL 
-induced O 
oocyte O 
death O 
in O 
early O 
follicles O 
and O 
perhaps O 
conserve O 
the O 
endocrine O 
function O 
of O 
the O 
ovary O 
against O 
chemotherapy.Cell O 
Death O 
and O 
Differentiation O 
advance O 
online O 
publication O 
, O 
19 O 
April O 
2013 O 
; O 
doi O 
: O 
10.1038 O 
/ O 
cdd.2013.31 O 
. O 

of O 
' O 
split O 
waves O 
' O 
for O 
the O 
measurement O 
of O 
electrocatalytic O 
kinetics O 
: O 
methyl B-SYSTEMATIC 
viologen I-SYSTEMATIC 
mediated O 
oxygen B-SYSTEMATIC 
reduction O 
on O 
a O 
boron B-SYSTEMATIC 
-doped O 
diamond B-TRIVIAL 
electrode O 
. O 

mediated O 
reduction O 
of O 
oxygen B-SYSTEMATIC 
via O 
the O 
reduced O 
form O 
of O 
methyl B-SYSTEMATIC 
viologen I-SYSTEMATIC 
is O 
studied O 
voltammetrically O 
. O 
The O 
investigation O 
is O 
facilitated O 
through O 
the O 
use O 
of O 
a O 
boron B-SYSTEMATIC 
-doped O 
diamond B-TRIVIAL 
electrode O 
, O 
allowing O 
the O 
catalytic O 
response O 
to O 
be O 
clearly O 
delineated O 
from O 
that O 
of O 
the O 
direct O 
oxygen B-SYSTEMATIC 
reduction O 
process O 
at O 
the O 
electrode O 
surface O 
. O 
From O 
simulation O 
a O 
high O 
homogeneous O 
electron O 
transfer O 
rate O 
( O 
6 O 
× O 
10(9) O 
M(-1) O 
s(-1) O 
) O 
is O 
found O 
for O 
the O 
one O 
- O 
electron O 
reduction O 
of O 
oxygen B-SYSTEMATIC 
to O 
superoxide B-TRIVIAL 
. O 
This O 
value O 
is O 
in O 
close O 
agreement O 
with O 
that O 
found O 
using O 
non-electrochemical O 
methods O 
and O 
is O 
significantly O 
higher O 
than O 
the O 
values O 
previously O 
reported O 
in O 
electrochemical O 
studies O 
. O 
In O 
the O 
latter O 
case O 
it O 
is O 
demonstrated O 
that O 
the O 
underestimation O 
of O 
the O 
electron O 
transfer O 
rate O 
arises O 
due O 
to O 
oversimplification O 
of O 
the O 
reaction O 
mechanism O 
. O 

kinetics O 
of O 
CO2 B-FORMULA 
absorption O 
in O 
to O 
phosphonium B-SYSTEMATIC 
based O 
anion O 
- O 
functionalized O 
ionic O 
liquids O 
. O 

reaction O 
kinetics O 
between O 
CO2 B-FORMULA 
and O 
trihexyl(tetradecyl)phosphonium B-SYSTEMATIC 
( O 
[ B-IDENTIFIER 
P66614 I-IDENTIFIER 
] I-IDENTIFIER 
) O 
- O 
based O 
ionic O 
liquids O 
( O 
ILs O 
) O 
with O 
prolinate B-TRIVIAL 
( O 
[ B-FORMULA 
Pro I-FORMULA 
] I-FORMULA 
) O 
, O 
2-cyanopyrrolide B-SYSTEMATIC 
( O 
[ B-SYSTEMATIC 
2-CNpyr I-SYSTEMATIC 
] I-SYSTEMATIC 
) O 
, O 
and O 
3-(trifluoromethyl)pyrazolide B-SYSTEMATIC 
( O 
[ B-SYSTEMATIC 
3-CF3pyra I-SYSTEMATIC 
] I-SYSTEMATIC 
) O 
anions O 
are O 
studied O 
at O 
temperatures O 
from O 
22-60 O 
°C O 
. O 
The O 
absorption O 
of O 
CO2 B-FORMULA 
is O 
carried O 
out O 
in O 
a O 
stirred O 
reactor O 
under O 
pseudo O 
first O 
order O 
conditions O 
. O 
ILs O 
are O 
diluted O 
to O 
concentrations O 
of O 
0.05 O 
, O 
0.1 O 
and O 
0.15 O 
M O 
with O 
tetraglyme B-TRIVIAL 
- O 
a O 
nonreactive O 
, O 
low O 
volatility O 
solvent O 
with O 
much O 
lower O 
viscosity O 
than O 
the O 
ILs O 
. O 
Physical O 
solubility O 
of O 
CO2 B-FORMULA 
in O 
the O 
mixtures O 
is O 
calculated O 
using O 
correlations O 
developed O 
from O 
CO2 B-FORMULA 
solubility O 
measurements O 
in O 
tetraglyme B-TRIVIAL 
and O 
the O 
N2O B-FORMULA 
-analogy O 
for O 
ILs O 
and O 
dilute O 
IL O 
solutions O 
. O 
The O 
diffusivity O 
of O 
CO2 B-FORMULA 
is O 
estimated O 
from O 
viscosity O 
- O 
dependent O 
correlations O 
chosen O 
after O 
a O 
thorough O 
literature O 
review O 
. O 
The O 
results O 
indicate O 
partial O 
first O 
order O 
reaction O 
kinetics O 
with O 
respect O 
to O 
IL O 
with O 
values O 
ranging O 
from O 
19 O 
500 O 
L O 
mol(-1) O 
s(-1) O 
( O 
[P66614][Pro] B-IDENTIFIER 
) O 
to O 
3200 O 
L O 
mol(-1) O 
s(-1) O 
( O 
[P66614][3-CF3pyra] B-SYSTEMATIC 
) O 
at O 
22 O 
°C O 
. O 
The O 
second O 
order O 
reaction O 
rate O 
constants O 
follow O 
Arrhenius O 
behavior O 
with O 
the O 
highest O 
activation O 
energy O 
of O 
43 O 
kJ O 
mol(-1) O 
measured O 
for O 
[P66614][Pro] B-IDENTIFIER 
. O 
ILs O 
with O 
aprotic O 
heterocylic O 
anions O 
( O 
AHA O 
) O 
, O 
on O 
the O 
other O 
hand O 
, O 
show O 
small O 
activation O 
energies O 
of O 
18 O 
and O 
11 O 
kJ O 
mol(-1) O 
for O 
[P66614][3-CF3pyra] B-SYSTEMATIC 
and O 
[P66614][2-CNpyr] B-SYSTEMATIC 
, O 
respectively O 
. O 
The O 
ILs O 
studied O 
in O 
this O 
work O 
exhibit O 
reactivity O 
comparable O 
to O 
or O 
higher O 
than O 
common O 
aqueous O 
amines O 
. O 
High O 
reaction O 
rates O 
and O 
tunable O 
capacity O 
make O 
ILs O 
, O 
and O 
AHA O 
ILs O 
in O 
particular O 
, O 
attractive O 
solvents O 
for O 
CO2 B-FORMULA 
separations O 
. O 

during O 
response O 
inhibition O 
is O 
associated O 
with O 
ad O 
- O 
lib O 
alcohol B-FAMILY 
consumption O 
in O 
social O 
drinkers O 
. O 

amplitude O 
of O 
the O 
cortical O 
P300 O 
event O 
- O 
related O 
potential O 
( O 
ERP O 
) O 
component O 
during O 
response O 
inhibition O 
is O 
associated O 
with O 
vulnerability O 
to O 
alcohol B-FAMILY 
use O 
disorders O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
investigated O 
the O 
effect O 
of O 
an O 
experimental O 
manipulation O 
of O 
response O 
conflict O 
on O 
the O 
amplitude O 
of O 
the O 
P300 O 
component O 
during O 
response O 
inhibition O 
, O 
and O 
examined O 
whether O 
individual O 
differences O 
in O 
the O 
amplitude O 
of O 
this O 
P300 O 
component O 
would O 
predict O 
voluntary O 
ad O 
- O 
lib O 
alcohol B-FAMILY 
consumption O 
, O 
in O 
social O 
drinkers O 
. O 
Using O 
a O 
repeated O 
measures O 
design O 
, O 
16 O 
participants O 
performed O 
a O 
stop O 
- O 
signal O 
task O 
after O 
receiving O 
instructions O 
that O 
either O 
emphasised O 
or O 
de-emphasised O 
response O 
conflict O 
while O 
their O 
electroencephalogram O 
( O 
EEG O 
) O 
was O 
concurrently O 
recorded O 
, O 
before O 
their O 
ad O 
- O 
lib O 
drinking O 
was O 
assessed O 
. O 
Results O 
revealed O 
that O 
task O 
instructions O 
had O 
the O 
predicted O 
effects O 
on O 
behavioural O 
indices O 
of O 
response O 
inhibition O 
and O 
the O 
associated O 
P300 O 
components O 
. O 
Most O 
importantly O 
, O 
individual O 
differences O 
in O 
the O 
amplitude O 
of O 
P300 O 
subcomponents O 
during O 
response O 
inhibition O 
were O 
negatively O 
correlated O 
with O 
ad O 
- O 
lib O 
alcohol B-FAMILY 
consumption O 
. O 
Results O 
provide O 
the O 
first O 
experimental O 
support O 
for O 
theoretical O 
models O 
that O 
posit O 
that O 
reduced O 
amplitude O 
of O 
the O 
P300 O 
during O 
response O 
inhibition O 
is O 
associated O 
with O 
alcohol B-FAMILY 
-seeking O 
behaviour O 
in O 
humans O 
. O 

is O 
activated O 
by O 
melatonin B-TRIVIAL 
, O 
and O 
drives O 
the O 
clock O 
gene O 
Cry1 O 
in O 
the O 
ovine O 
pars O 
tuberalis O 
. O 

mammals O 
integrate O 
changes O 
in O 
the O 
duration O 
of O 
nocturnal O 
melatonin B-TRIVIAL 
secretion O 
to O 
drive O 
annual O 
physiological O 
cycles O 
. O 
Melatonin B-TRIVIAL 
receptors O 
within O 
the O 
proximal O 
pituitary O 
region O 
, O 
the O 
pars O 
tuberalis O 
( O 
PT O 
) O 
, O 
are O 
essential O 
in O 
regulating O 
seasonal O 
neuroendocrine O 
responses O 
. O 
In O 
the O 
ovine O 
PT O 
, O 
melatonin B-TRIVIAL 
is O 
known O 
to O 
influence O 
acute O 
changes O 
in O 
transcriptional O 
dynamics O 
coupled O 
to O 
the O 
onset O 
( O 
dusk O 
) O 
and O 
offset O 
( O 
dawn O 
) O 
of O 
melatonin B-TRIVIAL 
secretion O 
, O 
leading O 
to O 
a O 
potential O 
interval O 
- O 
timing O 
mechanism O 
capable O 
of O 
decoding O 
changes O 
in O 
day O 
- O 
length O 
( O 
photoperiod O 
) O 
. O 
Melatonin B-TRIVIAL 
offset O 
at O 
dawn O 
is O 
linked O 
to O 
cAMP B-ABBREVIATION 
accumulation O 
, O 
which O 
directly O 
induces O 
transcription O 
of O 
the O 
clock O 
gene O 
Per1 O 
. O 
The O 
rise O 
of O 
melatonin B-TRIVIAL 
at O 
dusk O 
induces O 
a O 
separate O 
and O 
distinct O 
cohort O 
, O 
including O 
the O 
clock O 
- O 
regulated O 
genes O 
Cry1 O 
and O 
Nampt O 
, O 
but O 
little O 
is O 
known O 
of O 
the O 
up O 
- O 
stream O 
mechanisms O 
involved O 
. O 
Here O 
, O 
we O 
used O 
next O 
generation O 
sequencing O 
of O 
the O 
ovine O 
PT O 
transcriptome O 
at O 
melatonin B-TRIVIAL 
onset O 
, O 
and O 
identified O 
Npas4 O 
as O 
a O 
rapidly O 
induced O 
bHLH-PAS O 
domain O 
transcription O 
factor O 
. O 
In O 
vivo O 
we O 
show O 
nuclear O 
localisation O 
of O 
NPAS4 O 
protein O 
in O 
presumptive O 
melatonin B-TRIVIAL 
target O 
cells O 
of O 
the O 
PT O 
( O 
αGSU-expressing O 
cells O 
) O 
, O 
while O 
in O 
situ O 
hybridisation O 
studies O 
identified O 
acute O 
and O 
transient O 
expression O 
in O 
the O 
PT O 
of O 
Npas4 O 
in O 
response O 
to O 
melatonin B-TRIVIAL 
. O 
In O 
vitro O 
, O 
NPAS4 O 
forms O 
functional O 
dimers O 
with O 
bHLH-PAS O 
domain O 
co O 
- O 
factors O 
ARNT O 
, O 
ARNT2 O 
and O 
ARNTL O 
, O 
transactivating O 
both O 
Cry1 O 
and O 
Nampt O 
ovine O 
promoter O 
reporters O 
. O 
Using O 
a O 
combination O 
of O 
5` O 
deletions O 
and O 
site O 
- O 
directed O 
mutagenesis O 
we O 
show O 
NPAS4 O 
: O 
ARNT O 
transactivation O 
to O 
be O 
co O 
- O 
dependent O 
upon O 
two O 
conserved O 
central O 
midline O 
elements O 
( O 
CMEs O 
) O 
within O 
the O 
Cry1 O 
promoter O 
. O 
Our O 
data O 
thus O 
reveal O 
NPAS4 O 
as O 
a O 
candidate O 
immediate O 
early O 
- O 
response O 
gene O 
in O 
the O 
ovine O 
PT O 
, O 
driving O 
molecular O 
responses O 
to O 
melatonin B-TRIVIAL 
. O 

C-glycosides I-FAMILY 
from O 
the O 
flowers O 
of O 
Trollius O 
chinensis O 
and O 
their O 
anti-complementary O 
activity O 
. O 

investigation O 
of O 
ethanol B-SYSTEMATIC 
extract O 
from O 
the O 
flowers O 
of O 
Trollius O 
chinensis O 
Bunge O 
resulted O 
in O 
the O 
isolation O 
of O 
two O 
new O 
flavone B-FAMILY 
C-glycosides I-FAMILY 
( O 
1-2 O 
) O 
, O 
along O 
with O 
10 O 
known O 
compounds O 
( O 
3-12 O 
) O 
. O 
The O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
established O 
as O 
6‴-(3-hydroxy-3-methylglutaroyl)-2″-O-β-d-galactopyranosyl B-SYSTEMATIC 
orientin I-SYSTEMATIC 
( O 
1 O 
) O 
and O 
6‴-(3-hydroxy-3-methylglutaroyl)-2″-O-β-d-galactopyranosyl B-SYSTEMATIC 
vitexin I-SYSTEMATIC 
( O 
2 O 
) O 
on O 
the O 
basis O 
of O 
various O 
spectroscopic O 
analysis O 
( O 
including O 
different O 
1D O 
and O 
2D O 
NMR O 
spectroscopies O 
, O 
high O 
- O 
resolution O 
electrospray O 
ionization O 
mass O 
spectrometry O 
) O 
and O 
chemical O 
evidences O 
. O 
Bioassay O 
showed O 
that O 
eight O 
flavonoids B-FAMILY 
inhibited O 
complement O 
activation O 
on O 
the O 
classic O 
pathway O 
in O 
vitro O 
, O 
with O 
their O 
IC50 O 
values O 
ranging O 
from O 
0.88 O 
to O 
4.02 O 
mM O 
, O 
which O 
may O 
contribute O 
to O 
the O 
applications O 
of O 
the O 
herb O 
in O 
treatment O 
of O 
acute O 
respiratory O 
distress O 
syndrome O 
, O 
etc O 
. O 

The O 
alpha-fetoprotein O 
( O 
AFP O 
) O 
binding O 
protein O 
, O 
a O 
putative O 
AFP O 
receptor O 
, O 
is O 
a O 
tumour O 
marker O 
that O 
is O 
present O 
on O 
the O 
surfaces O 
of O 
malignant O 
cells O 
. O 
AFP O 
enters O 
cells O 
through O 
receptor O 
- O 
mediated O 
endocytosis O 
. O 
The O 
recombinant O 
C B-FORMULA 
-terminal O 
fragment O 
of O 
AFP O 
( O 
AFP-3BC O 
, O 
which O 
consists O 
of O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
473-596 O 
) O 
was O 
obtained O 
by O 
the O 
expression O 
in O 
Escherichia O 
coli O 
. O 
AFP-3BC O 
was O 
shown O 
to O 
be O 
bound O 
specifically O 
to O 
the O 
AFP O 
putative O 
receptor O 
on O 
tumour O 
cells O 
and O 
accumulated O 
by O 
endocytosis O 
in O 
these O 
cells O 
in O 
a O 
similar O 
manner O 
to O 
that O 
of O 
full O 
- O 
length O 
human O 
AFP O 
. O 
In O 
lymphocytes O 
, O 
the O 
binding O 
and O 
endocytosis O 
of O 
AFP-3BC O 
were O 
absent O 
. O 
Thus O 
, O 
the O 
AFP O 
receptor O 
binding O 
site O 
was O 
shown O 
experimentally O 
to O 
be O 
located O 
within O 
the O 
AFP-3BC O 
sequence O 
. O 
A O 
conjugate O 
of O 
synthesised O 
AFP-3BC O 
with O 
the O 
antitumour O 
antibiotic O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
-AFP-3BC O 
) O 
demonstrated O 
high O 
antitumour O 
activity O 
in O 
vitro O 
. O 
Thus O 
, O 
AFP-3BC O 
can O 
be O 
used O 
successfully O 
as O 
a O 
vector O 
for O 
the O 
targeted O 
selective O 
delivery O 
of O 
drugs O 
into O 
tumour O 
cells O 
. O 

: O 
A O 
Group O 
of O 
Small-Molecule O 
Probes O 
for O 
Exploring O 
the O 
Active O 
Site O 
Cavities O 
of O 
Cytochrome O 
P450 O 
Enzymes O 
1A1 O 
, O 
1A2 O 
, O 
and O 
1B1 O 
. O 

inhibition O 
of O 
P450 O 
enzymes O 
is O 
the O 
key O 
to O 
block O 
the O 
conversion O 
of O 
environmental O 
procarcinogens O 
to O 
their O 
carcinogenic O 
metabolites O 
in O 
both O 
animals O 
and O 
humans O 
. O 
To O 
discover O 
highly O 
potent O 
and O 
selective O 
inhibitors O 
of O 
P450s O 
1A1 O 
, O 
1A2 O 
, O 
and O 
1B1 O 
, O 
as O 
well O 
as O 
to O 
investigate O 
active O 
site O 
cavities O 
of O 
these O 
enzymes O 
, O 
14 O 
novel O 
flavone B-TRIVIAL 
derivatives O 
were O 
prepared O 
as O 
chemical O 
probes O 
. O 
Fluorimetric O 
enzyme O 
inhibition O 
assays O 
were O 
used O 
to O 
determine O 
the O 
inhibitory O 
activities O 
of O 
these O 
probes O 
toward O 
P450s O 
1A1 O 
, O 
1A2 O 
, O 
1B1 O 
, O 
2A6 O 
, O 
and O 
2B1 O 
. O 
A O 
highly O 
selective O 
P450 O 
1B1 O 
inhibitor O 
5-hydroxy-4'-propargyloxyflavone B-SYSTEMATIC 
( O 
5H4'FPE B-SYSTEMATIC 
) O 
was O 
discovered O 
. O 
Some O 
tested O 
compounds O 
also O 
showed O 
selectivity O 
between O 
P450s O 
1A1 O 
and O 
1A2 O 
. O 
α-Naphthoflavone B-TRIVIAL 
-like O 
and O 
5-hydroxyflavone B-SYSTEMATIC 
derivatives O 
preferentially O 
inhibited O 
P450 O 
1A2 O 
, O 
while O 
β-naphthoflavone B-TRIVIAL 
-like O 
flavone B-TRIVIAL 
derivatives O 
showed O 
selective O 
inhibition O 
of O 
P450 O 
1A1 O 
. O 
On O 
the O 
basis O 
of O 
structural O 
analysis O 
, O 
the O 
active O 
site O 
cavity O 
models O 
of O 
P450 O 
enzymes O 
1A1 O 
and O 
1A2 O 
were O 
generated O 
, O 
demonstrating O 
a O 
planar O 
long O 
strip O 
cavity O 
and O 
a O 
planar O 
triangular O 
cavity O 
, O 
respectively O 
. O 

fatty I-FAMILY 
acids I-FAMILY 
in O 
a O 
range O 
of O 
UK O 
processed O 
foods O 
. O 

survey O 
to O 
determine O 
the O 
trans B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
content O 
of O 
a O 
range O 
of O 
processed O 
foods O 
was O 
carried O 
out O 
in O 
response O 
to O 
recent O 
reformulation O 
work O 
by O 
the O 
food O 
industry O 
to O 
lower O 
the O 
artificial O 
trans B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
content O 
of O 
processed O 
products O 
. O 
Sixty O 
two O 
composite O 
samples O 
, O 
made O 
up O 
of O 
between O 
5 O 
and O 
12 O 
sub O 
- O 
samples O 
, O 
were O 
collected O 
in O 
2010 O 
and O 
were O 
analysed O 
for O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
and O 
a O 
range O 
of O 
nutrients O 
. O 
The O 
foods O 
analysed O 
included O 
pizza O 
, O 
garlic O 
bread O 
, O 
breakfast O 
cereals O 
, O 
quiche O 
, O 
fat O 
spreads O 
, O 
a O 
range O 
of O 
fish O 
and O 
meat O 
products O 
, O 
chips O 
, O 
savoury O 
snacks O 
, O 
confectionery O 
and O 
ice O 
cream O 
. O 
Levels O 
of O 
trans B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
were O 
reduced O 
considerably O 
compared O 
with O 
previous O 
UK O 
analyses O 
of O 
similar O 
foods O 
where O 
comparisons O 
are O 
possible O 
. O 
Concentrations O 
of O 
trans B-TRIVIAL 
elaidic I-TRIVIAL 
acid I-TRIVIAL 
( O 
t9-C18 B-FORMULA 
: I-FORMULA 
1 I-FORMULA 
) O 
from O 
hydrogenated O 
oils O 
in O 
all O 
samples O 
were O 
< O 
0.2g O 
/ O 
100g O 
food O 
. O 
These O 
results O 
confirm O 
information O 
provided O 
by O 
the O 
food O 
industry O 
in O 
2007 O 
on O 
the O 
levels O 
of O 
trans O 
fats O 
in O 
key O 
processed O 
food O 
sectors O 
. O 

of O 
food O 
composition O 
data O 
, O 
recipe O 
information O 
and O 
portion O 
sizes O 
for O 
ethnic O 
foods O 
are O 
commonly O 
reported O 
problems O 
for O 
dietary O 
assessment O 
of O 
ethnic O 
minority O 
groups O 
. O 
One O 
of O 
the O 
main O 
aims O 
of O 
this O 
study O 
was O 
to O 
use O 
food O 
composition O 
data O 
to O 
validate O 
portion O 
sizes O 
, O 
identify O 
important O 
sources O 
of O 
nutrients O 
and O 
describe O 
the O 
characteristics O 
of O 
the O 
South O 
Asian O 
diet O 
. O 
The O 
top O 
five O 
ethnic O 
foods O 
containing O 
highest O 
levels O 
of O 
selected O 
nutrients O 
were O 
lamb O 
balti O 
( O 
3mg O 
/ O 
100g O 
iron B-SYSTEMATIC 
) O 
, O 
lamb O 
kebab O 
( O 
3.2mg O 
/ O 
100g O 
zinc B-SYSTEMATIC 
) O 
, O 
mixed O 
dhal O 
( O 
62μg O 
/ O 
100g O 
folate B-TRIVIAL 
) O 
, O 
fish O 
curry O 
( O 
1.4μg O 
/ O 
100g O 
vitamin B-FAMILY 
D I-FAMILY 
) O 
, O 
ghee O 
( O 
968μg O 
/ O 
100g O 
retinol B-TRIVIAL 
) O 
and O 
toor O 
dhal O 
( O 
9.1g O 
/ O 
100g O 
dietary O 
fibre O 
) O 
. O 
Typical O 
adult O 
South O 
Asian O 
diets O 
included O 
traditional O 
cereals O 
( O 
chapatti O 
, O 
rice O 
and O 
paratha O 
) O 
and O 
low O 
consumption O 
of O 
meat O 
dishes O 
; O 
with O 
vegetable O 
curries O 
contributing O 
most O 
towards O 
energy O 
intake O 
. O 
A O 
higher O 
consumption O 
of O 
full O 
fat O 
milk O 
and O 
fruit O 
juices O 
by O 
toddlers O 
and O 
school O 
children O 
were O 
observed O 
when O 
compared O 
with O 
the O 
National O 
Diet O 
and O 
Nutrition O 
Survey O 
of O 
the O 
UK O 
. O 

shoulder O 
, O 
loin O 
and O 
leg O 
from O 
P-class O 
pork O 
carcasses O 
were O 
used O 
to O 
determine O 
the O 
nutrient O 
composition O 
of O 
both O 
raw O 
and O 
cooked O 
cuts O 
. O 
Significantly O 
lower O 
fat O 
content O 
were O 
observed O 
in O 
the O 
current O 
study O 
for O 
the O 
leg O 
( O 
5.21g O 
/ O 
100g O 
) O 
and O 
loin O 
( O 
6.99g O 
/ O 
100g O 
) O 
compared O 
to O 
the O 
shoulder O 
cut O 
( O 
10.32g O 
/ O 
100g O 
) O 
. O 
The O 
overall O 
percentage O 
fat O 
for O 
all O 
three O 
cuts O 
was O 
less O 
than O 
10% O 
which O 
is O 
recommended O 
by O 
the O 
South O 
African O 
Heart O 
Mark O 
. O 
The O 
cooked O 
loin O 
cut O 
contained O 
the O 
most O 
protein O 
( O 
27.50g O 
/ O 
100g O 
) O 
of O 
the O 
three O 
cooked O 
cuts O 
. O 
When O 
compared O 
to O 
other O 
meat O 
products O 
( O 
beef O 
, O 
mutton O 
and O 
chicken O 
) O 
it O 
is O 
clear O 
that O 
pork O 
is O 
a O 
good O 
source O 
of O 
B B-FAMILY 
vitamins I-FAMILY 
, O 
especially O 
vitamin B-TRIVIAL 
B3 I-TRIVIAL 
. O 
The O 
cooked O 
loin O 
cut O 
contained O 
the O 
least O 
vitamin B-TRIVIAL 
B1 I-TRIVIAL 
( O 
0.22mg O 
/ O 
100g O 
) O 
, O 
B2 O 
( O 
0.02mg O 
/ O 
100g O 
) O 
but O 
the O 
most O 
vitamin B-TRIVIAL 
B3 I-TRIVIAL 
( O 
7.09mg O 
/ O 
100g O 
) O 
, O 
of O 
the O 
three O 
cooked O 
cuts O 
. O 
The O 
100g O 
cooked O 
shoulder O 
, O 
loin O 
and O 
leg O 
cuts O 
provide O 
on O 
average O 
40.11% O 
protein O 
, O 
5.19% O 
magnesium B-SYSTEMATIC 
, O 
3.37% O 
calcium B-SYSTEMATIC 
, O 
24.29% O 
phosphorus B-SYSTEMATIC 
, O 
18.22% O 
zinc B-SYSTEMATIC 
, O 
22.33% O 
iron B-SYSTEMATIC 
and O 
22.50% O 
vitamin B-TRIVIAL 
B1 I-TRIVIAL 
, O 
2.57% O 
vitamin B-TRIVIAL 
B2 I-TRIVIAL 
and O 
42.6% O 
vitamin B-TRIVIAL 
B3 I-TRIVIAL 
of O 
Recommended O 
Daily O 
Allowances O 
for O 
males O 
, O 
age O 
25-50 O 
. O 
Energy O 
from O 
a O 
100g O 
portion O 
provides O 
5.81% O 
of O 
the O 
Recommended O 
Daily O 
Allowances O 
. O 
To O 
conclude O 
, O 
the O 
pork O 
cuts O 
are O 
undoubtedly O 
a O 
good O 
source O 
of O 
nutrients O 
that O 
is O 
required O 
for O 
good O 
health O 
because O 
it O 
is O 
high O 
in O 
protein O 
, O 
have O 
a O 
low O 
fat O 
content O 
and O 
are O 
a O 
nutrient-packed O 
choice O 
for O 
the O 
family O 
and O 
compares O 
favourably O 
with O 
the O 
fat O 
, O 
energy O 
, O 
and O 
cholesterol B-TRIVIAL 
content O 
of O 
many O 
other O 
meats O 
and O 
poultry O 
. O 

meat O 
is O 
generally O 
recognised O 
as O 
a O 
food O 
with O 
relevant O 
nutritional O 
properties O 
because O 
of O 
its O 
content O 
in O 
high O 
biological O 
value O 
proteins O 
, O 
group O 
B O 
vitamins O 
, O 
minerals O 
especially O 
heme B-FAMILY 
iron B-SYSTEMATIC 
, O 
trace O 
elements O 
and O 
other O 
bioactive O 
compounds O 
. O 
But O 
pork O 
meat O 
also O 
contributes O 
to O 
the O 
intake O 
of O 
fat O 
, O 
saturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
, O 
cholesterol B-TRIVIAL 
, O 
and O 
other O 
substances O 
that O 
, O 
in O 
inappropriate O 
amounts O 
, O 
may O 
result O 
in O 
negative O 
physiologically O 
effects O 
. O 
However O 
, O 
there O 
are O 
relevant O 
factors O 
affecting O 
the O 
content O 
of O 
many O 
of O 
these O 
substances O 
and O 
somehow O 
such O 
variability O 
should O 
be O 
taken O 
into O 
consideration O 
. O 
So O 
, O 
genetics O 
, O 
age O 
and O 
even O 
type O 
of O 
muscle O 
have O 
a O 
relevant O 
influence O 
on O 
the O 
amount O 
of O 
fat O 
and O 
the O 
contents O 
in O 
heme B-FAMILY 
iron B-SYSTEMATIC 
. O 
Also O 
the O 
composition O 
in O 
fatty B-FAMILY 
acids I-FAMILY 
of O 
triacylglycerols B-FAMILY 
is O 
very O 
sensitive O 
to O 
the O 
contents O 
of O 
cereals O 
in O 
the O 
feed O 
; O 
for O 
instance O 
, O 
polyunsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
may O 
range O 
from O 
10% O 
to O 
22% O 
in O 
pork O 
meat O 
. O 
The O 
content O 
of O 
other O 
nutrients O 
, O 
like O 
vitamins B-MULTIPLE 
E I-MULTIPLE 
and I-MULTIPLE 
A I-MULTIPLE 
, O 
are O 
also O 
depending O 
on O 
the O 
type O 
of O 
feed O 
. O 
Some O 
bioactive O 
substances O 
like O 
coenzyme B-TRIVIAL 
Q10 I-TRIVIAL 
, O 
taurine B-TRIVIAL 
, O 
glutamine B-TRIVIAL 
, O 
creatine B-TRIVIAL 
, O 
creatinine B-TRIVIAL 
, O 
carnosine B-TRIVIAL 
and O 
anserine B-TRIVIAL 
show O 
a O 
large O 
dependence O 
on O 
the O 
type O 
of O 
muscle O 
. O 
This O 
manuscript O 
describes O 
the O 
main O 
factors O 
affecting O 
the O 
composition O 
of O 
pork O 
meat O 
nutrients O 
and O 
how O 
these O 
changes O 
may O 
affect O 
the O 
general O 
food O 
composition O 
databases O 
. O 

dietary O 
fibre O 
definition O 
- O 
Justification O 
for O 
inclusion O 
of O 
carbohydrates B-FAMILY 
from O 
3 O 
to O 
9 O 
degrees O 
of O 
polymerisation O 
. O 

main O 
controversy O 
about O 
the O 
DF O 
definition O 
, O 
adopted O 
by O 
the O 
commission O 
of O 
Codex O 
Alimentarius O 
, O 
refers O 
to O 
the O 
inclusion O 
of O 
carbohydrates B-FAMILY 
of O 
3-9 O 
degrees O 
of O 
polymerisation O 
( O 
DP O 
) O 
, O 
decision O 
which O 
may O 
be O 
made O 
individually O 
by O 
the O 
authorities O 
of O 
each O 
country O 
. O 
Due O 
to O 
the O 
possibility O 
of O 
having O 
two O 
definitions O 
and O 
the O 
negative O 
impact O 
it O 
would O 
cause O 
over O 
the O 
harmonisation O 
of O 
nutritional O 
information O 
, O 
a O 
bibliographic O 
review O 
was O 
carried O 
, O 
from O 
2009 O 
to O 
2011 O 
, O 
aiming O 
to O 
gather O 
justifications O 
for O 
the O 
inclusion O 
of O 
carbohydrates B-FAMILY 
of O 
3-9 O 
DP O 
in O 
the O 
definition O 
. O 
The O 
current O 
review O 
presents O 
scientific O 
bases O 
that O 
are O 
directed O 
to O 
three O 
topics O 
: O 
physiological O 
aspects O 
; O 
repercussion O 
over O 
the O 
analytical O 
method O 
; O 
and O 
impact O 
on O 
consumers O 
and O 
other O 
users O 
. O 
The O 
decision O 
of O 
including O 
unavailable O 
carbohydrates B-FAMILY 
of O 
3-9 O 
DP O 
in O 
the O 
definition O 
of O 
DF O 
may O 
cause O 
effective O 
global O 
harmonisation O 
in O 
the O 
nutritional O 
labelling O 
, O 
considering O 
that O 
the O 
main O 
goal O 
is O 
to O 
help O 
consumers O 
choose O 
healthy O 
foods O 
. O 

amines B-FAMILY 
content O 
as O 
a O 
measure O 
of O 
the O 
quality O 
of O 
wines O 
of O 
Abruzzo O 
( O 
Italy O 
) O 
. O 

of O 
this O 
research O 
was O 
to O 
study O 
the O 
effect O 
of O 
some O 
agronomic O 
and O 
oenological O 
factors O 
on O 
the O 
content O 
of O 
biogenic O 
amines B-FAMILY 
as O 
quality O 
index O 
of O 
sixty O 
- O 
five O 
Abruzzo O 
wines O 
. O 
Sum O 
of O 
amines B-FAMILY 
was O 
found O 
to O 
be O 
decreasing O 
in O 
the O 
order O 
: O 
red O 
(19.3±12.8mgL(-1)) O 
, O 
rosé O 
(9.20±6.34mgL(-1)) O 
, O 
white O 
(7.67±3.84mgL(-1)) O 
wine O 
. O 
Significant O 
differences O 
in O 
relationship O 
among O 
amines B-FAMILY 
levels O 
and O 
chemical O 
and O 
chemico O 
- O 
physical O 
characteristics O 
of O 
red O 
, O 
white O 
and O 
rosé O 
wine O 
are O 
due O 
to O 
their O 
different O 
biotechnological O 
process O 
and O 
winemaking O 
. O 
Besides O 
the O 
aging O 
treatment O 
, O 
influential O 
seems O 
to O 
be O 
the O 
effect O 
of O 
the O 
winery O 
, O 
regardless O 
of O 
the O 
area O 
in O 
which O 
it O 
is O 
situated O 
. O 
The O 
single O 
amines B-FAMILY 
significantly O 
correlated O 
with O 
their O 
sum O 
were O 
putrescine B-TRIVIAL 
, O 
histamine B-TRIVIAL 
and O 
tyramine B-TRIVIAL 
, O 
even O 
if O 
reached O 
levels O 
were O 
below O 
toxicity O 
threshold O 
, O 
demonstrating O 
a O 
good O 
quality O 
of O 
the O 
wines O 
of O 
Abruzzo O 
whose O 
consumption O 
is O 
no O 
risk O 
to O 
the O 
health O 
of O 
the O 
consumer O 
following O 
the O 
rules O 
of O 
proper O 
nutrition O 
. O 

study O 
assessed O 
the O 
performance O 
of O 
17 O 
laboratories O 
in O 
Thailand O 
in O 
analysing O 
mandatory O 
nutrients O 
in O 
salted O 
, O 
fried O 
broad O 
bean O 
and O 
in O 
using O 
data O 
to O 
prepare O 
nutrition O 
labels O 
. O 
Nutrient O 
levels O 
in O 
the O 
test O 
material O 
, O 
as O 
robust O 
mean O 
(x(∗)) O 
and O 
robust O 
standard O 
deviation O 
(s(∗)) O 
, O 
were O 
assigned O 
in O 
line O 
with O 
ISO O 
13528 O 
. O 
Data O 
obtained O 
from O 
the O 
laboratories O 
were O 
statistically O 
evaluated O 
against O 
these O 
values O 
. O 
Laboratories O 
with O 
satisfactory O 
, O 
questionable O 
and O 
unsatisfactory O 
results O 
for O 
each O 
nutrient O 
were O 
identified O 
based O 
on O 
robust O 
z-score O 
. O 
Laboratories O 
achieving O 
satisfactory O 
analytical O 
results O 
( O 
z-score⩽2 O 
) O 
were O 
for O 
lipid O 
, O 
82% O 
; O 
protein O 
, O 
85% O 
; O 
Na B-FORMULA 
, O 
82% O 
; O 
Ca B-FORMULA 
, O 
62% O 
; O 
Fe B-FORMULA 
, O 
81% O 
; O 
ash O 
, O 
70% O 
; O 
and O 
moisture O 
, O 
62% O 
. O 
Reference O 
values O 
for O 
some O 
nutrients O 
in O 
broad O 
bean O 
powder O 
were O 
developed O 
using O 
data O 
from O 
satisfactorily O 
performing O 
laboratories O 
. O 
Less O 
than O 
20% O 
of O 
the O 
laboratories O 
demonstrated O 
good O 
performance O 
in O 
preparing O 
nutrition O 
labels O 
. O 
Common O 
mistakes O 
were O 
the O 
nutrition O 
information O 
format O 
, O 
estimation O 
of O 
serving O 
size O 
and O 
serving(s) O 
per O 
package O 
. O 

dynamic O 
, O 
posttranslational O 
modification O 
of O 
proteins O 
with O 
a O 
small O 
ubiquitin O 
- O 
like O 
modifier O 
( O 
SUMO O 
) O 
tag O 
has O 
been O 
recognized O 
as O 
an O 
important O 
cellular O 
regulatory O 
mechanism O 
relevant O 
to O 
a O 
number O 
of O 
cancers O 
as O 
well O 
as O 
normal O 
embryonic O 
development O 
. O 
As O 
part O 
of O 
a O 
program O 
aimed O 
toward O 
the O 
identification O 
of O 
inhibitors O 
of O 
SUMO-conjugating O 
enzymes O 
, O 
we O 
developed O 
a O 
microfluidic O 
electrophoretic O 
mobility O 
shift O 
assay O 
to O 
monitor O 
sumoylation O 
events O 
in O 
real O 
time O 
. O 
We O 
disclose O 
herein O 
the O 
use O 
of O 
this O 
assay O 
to O 
identify O 
a O 
cell O 
- O 
permeable O 
compound O 
capable O 
of O 
blocking O 
the O 
transfer O 
of O 
SUMO-1 O 
from O 
the O 
E2 O 
enzyme O 
Ubc9 O 
to O 
the O 
substrate O 
. O 
We O 
screened O 
a O 
small O 
collection O 
of O 
compounds O 
and O 
identified O 
an O 
oxygenated B-FAMILY 
flavonoid I-FAMILY 
derivative O 
that O 
inhibits O 
sumoylation O 
in O 
vitro O 
. O 
Next O 
, O 
we O 
carried O 
out O 
an O 
in O 
- O 
depth O 
mechanistic O 
analysis O 
that O 
ruled O 
out O 
many O 
common O 
false O 
- O 
positive O 
mechanisms O 
such O 
as O 
aggregation O 
or O 
alkylation O 
. O 
Furthermore O 
, O 
we O 
report O 
that O 
this O 
flavonoid B-FAMILY 
inhibits O 
a O 
single O 
step O 
in O 
the O 
sumoylation O 
cascade O 
: O 
the O 
transfer O 
of O 
SUMO O 
from O 
the O 
E2 O 
enzyme O 
( O 
Ubc9 O 
) O 
thioester O 
conjugate O 
to O 
the O 
substrate O 
. O 
In O 
addition O 
to O 
having O 
a O 
unique O 
mechanism O 
of O 
action O 
, O 
this O 
inhibitor O 
has O 
a O 
discrete O 
structure O 
- O 
activity O 
relationship O 
uncharacteristic O 
of O 
a O 
promiscuous O 
inhibitor O 
. O 
Cell O 
- O 
based O 
studies O 
showed O 
that O 
the O 
flavonoid O 
inhibits O 
the O 
sumoylation O 
of O 
topoisomerase-I O 
in O 
response O 
to O 
camptothecin B-TRIVIAL 
treatment O 
in O 
two O 
different O 
breast O 
cancer O 
cell O 
lines O 
, O 
while O 
isomeric O 
analogs O 
are O 
inactive O 
. O 
Importantly O 
, O 
this O 
compound O 
blocks O 
sumoylation O 
while O 
not O 
affecting O 
ubiquitylation O 
in O 
cells O 
. O 
This O 
work O 
identifies O 
a O 
point O 
of O 
entry O 
for O 
pharmacologic O 
inhibition O 
of O 
the O 
sumoylation O 
cascade O 
and O 
may O 
serve O 
as O 
the O 
basis O 
for O 
continued O 
study O 
of O 
additional O 
pharmacophores O 
that O 
modulate O 
SUMO-conjugating O 
enzymes O 
such O 
as O 
Ubc9 O 
. O 

we O 
have O 
shown O 
that O 
a O 
fraction O 
of O 
the O 
matrix O 
metalloproteinase-9 O 
( O 
MMP-9 O 
) O 
synthesized O 
by O 
the O 
macrophage O 
cell O 
line O 
THP-1 O 
was O 
bound O 
to O 
a O 
chondroitin O 
sulphate O 
proteoglycan O 
( O 
CSPG O 
) O 
core O 
protein O 
as O 
a O 
reduction O 
sensitive O 
heteromer O 
. O 
It O 
was O 
also O 
shown O 
that O 
the O 
hemopexin O 
- O 
like O 
( O 
PEX O 
) O 
domain O 
and O 
the O 
fibronectin O 
- O 
like O 
( O 
FnII O 
) O 
module O 
in O 
the O 
enzyme O 
are O 
involved O 
in O 
the O 
heteromer O 
formation O 
. O 
In O 
the O 
present O 
work O 
we O 
show O 
that O 
reduction O 
sensitive O 
and O 
SDS B-ABBREVIATION 
-stable O 
heteromers O 
can O 
be O 
reconstituted O 
in O 
vitro O 
by O 
mixing O 
proMMP-9 O 
with O 
either O 
serglycin O 
, O 
versican O 
or O 
CSPGs O 
isolated O 
from O 
various O 
monocytic O 
cell O 
lines O 
. O 
In O 
addition O 
, O 
a O 
strong O 
but O 
SDS B-ABBREVIATION 
-soluble O 
proMMP-9·CSPG O 
heteromer O 
was O 
formed O 
. O 
The O 
two O 
macromolecules O 
in O 
the O 
SDS B-ABBREVIATION 
-stable O 
reduction O 
sensitive O 
heteromers O 
were O 
not O 
linked O 
together O 
by O 
disulphide B-SYSTEMATIC 
bonds O 
. O 
As O 
for O 
the O 
heteromer O 
isolated O 
from O 
THP-1 O 
cells O 
, O 
the O 
in O 
vitro O 
reconstituted O 
SDS B-ABBREVIATION 
-stable O 
and O 
SDS B-ABBREVIATION 
-soluble O 
heteromers O 
had O 
a O 
weaker O 
binding O 
to O 
gelatin O 
than O 
the O 
proMMP-9 O 
monomer O 
. O 
Furthermore O 
, O 
gelatin O 
inhibited O 
the O 
in O 
vitro O 
reconstitution O 
of O 
the O 
heteromers O 
, O 
showing O 
that O 
the O 
FnII O 
module O 
is O 
involved O 
in O 
the O 
complex O 
formation O 
. O 
TIMP-1 O 
could O 
not O 
be O 
detected O 
in O 
the O 
formed O 
proMMP-9·CSPG O 
complexes O 
. O 
However O 
, O 
the O 
presence O 
of O 
TIMP-1 O 
inhibited O 
the O 
formation O 
of O 
the O 
SDS B-ABBREVIATION 
-soluble O 
heteromer O 
, O 
but O 
not O 
the O 
SDS B-ABBREVIATION 
-stable O 
reduction O 
sensitive O 
heteromer O 
. O 
This O 
indicates O 
that O 
different O 
regions O 
in O 
the O 
PEX O 
domain O 
are O 
involved O 
the O 
formation O 
of O 
these O 
heteromers O 
. O 
This O 
article O 
is O 
protected O 
by O 
copyright O 
. O 
All O 
rights O 
reserved O 
. O 

in O 
human O 
cationic O 
trypsinogen O 
cause O 
hereditary O 
pancreatitis O 
by O 
altering O 
its O 
proteolytic O 
regulation O 
of O 
activation O 
and O 
degradation O 
by O 
chymotrypsin O 
C O 
( O 
CTRC O 
) O 
. O 
CTRC O 
stimulates O 
trypsinogen O 
autoactivation O 
by O 
processing O 
the O 
activation O 
peptide O 
to O 
a O 
shorter O 
form O 
but O 
also O 
promotes O 
degradation O 
by O 
cleaving O 
the O 
calcium B-SYSTEMATIC 
binding O 
loop O 
in O 
trypsinogen O 
. O 
Mutations O 
render O 
trypsinogen O 
resistant O 
to O 
CTRC O 
- O 
mediated O 
degradation O 
and O 
/ O 
or O 
increase O 
processing O 
of O 
the O 
activation O 
peptide O 
by O 
CTRC O 
. O 
Here O 
we O 
demonstrate O 
that O 
activation O 
peptide O 
mutations O 
D19A O 
, O 
D22G O 
, O 
K23R O 
and O 
K23_I24insIDK O 
robustly O 
increased O 
the O 
rate O 
of O 
trypsinogen O 
autoactivation O 
, O 
both O 
in O 
the O 
presence O 
and O 
absence O 
of O 
CTRC O 
. O 
Degradation O 
of O 
the O 
mutants O 
by O 
CTRC O 
was O 
unchanged O 
and O 
processing O 
of O 
the O 
activation O 
peptide O 
was O 
increased O 
only O 
in O 
the O 
D19A O 
mutant O 
by O 
4-fold O 
. O 
Surprisingly O 
, O 
however O 
, O 
this O 
increased O 
processing O 
had O 
only O 
a O 
minimal O 
effect O 
on O 
autoactivation O 
. O 
The O 
tetra- O 
aspartate B-TRIVIAL 
motif O 
in O 
the O 
trypsinogen O 
activation O 
peptide O 
binds O 
calcium B-SYSTEMATIC 
( O 
KD O 
~1.6 O 
mM O 
) O 
, O 
which O 
stimulates O 
autoactivation O 
. O 
Unexpectedly O 
, O 
calcium B-SYSTEMATIC 
binding O 
was O 
not O 
compromised O 
by O 
any O 
of O 
the O 
activation O 
peptide O 
mutations O 
. O 
Despite O 
normal O 
binding O 
, O 
autoactivation O 
of O 
mutants O 
D22G O 
and O 
K23_I24insIDK O 
was O 
not O 
stimulated O 
by O 
calcium B-SYSTEMATIC 
. O 
Finally O 
, O 
the O 
activation O 
peptide O 
mutants O 
exhibited O 
reduced O 
secretion O 
from O 
transfected O 
cells O 
, O 
and O 
secreted O 
trypsinogen O 
levels O 
were O 
inversely O 
proportional O 
with O 
autoactivation O 
rates O 
. O 
We O 
conclude O 
that O 
D19A O 
, O 
D22G O 
, O 
K23R O 
and O 
K23_I24insIDK O 
form O 
a O 
mechanistically O 
distinct O 
subset O 
of O 
hereditary O 
pancreatitis O 
associated O 
mutations O 
, O 
which O 
exert O 
their O 
effect O 
primarily O 
through O 
direct O 
stimulation O 
of O 
autoactivation O 
, O 
independently O 
of O 
CTRC O 
. O 
The O 
potentially O 
severe O 
clinical O 
impact O 
of O 
the O 
markedly O 
increased O 
autoactivation O 
is O 
offset O 
by O 
diminished O 
secretion O 
, O 
resulting O 
in O 
a O 
clinical O 
phenotype O 
indistinguishable O 
from O 
typical O 
hereditary O 
pancreatitis O 
. O 
This O 
article O 
is O 
protected O 
by O 
copyright O 
. O 
All O 
rights O 
reserved O 
. O 

and O 
biological O 
evaluation O 
of O 
phosphorylated B-FAMILY 
flavonoids I-FAMILY 
as O 
potent O 
and O 
selective O 
inhibitors O 
of O 
cholesterol B-TRIVIAL 
esterase O 
. O 

series O 
of O 
phosphorylated B-FAMILY 
flavonoids I-FAMILY 
were O 
synthesized O 
and O 
investigated O 
in O 
vitro O 
as O 
inhibitors O 
of O 
pancreatic O 
cholesterol B-TRIVIAL 
esterase O 
( O 
CEase O 
) O 
and O 
acetylcholinesterase O 
( O 
AChE O 
) O 
. O 
The O 
results O 
showed O 
that O 
most O 
of O 
the O 
synthesized O 
compounds O 
exhibited O 
nanomolar O 
potency O 
against O 
CEase O 
, O 
much O 
better O 
than O 
the O 
parent O 
flavonoids B-FAMILY 
. O 
Furthermore O 
, O 
these O 
phosphorylated B-FAMILY 
flavonoids I-FAMILY 
demonstrated O 
good O 
to O 
high O 
selectivity O 
for O 
CEase O 
over O 
AChE O 
, O 
which O 
only O 
showed O 
micromolar O 
potency O 
inhibition O 
of O 
AChE O 
. O 
The O 
most O 
selective O 
and O 
potent O 
inhibitor O 
of O 
CEase O 
( O 
3e O 
) O 
had O 
IC50 O 
value O 
of O 
0.72 O 
nM O 
and O 
11800-fold O 
selectivity O 
for O 
CEase O 
over O 
AChE O 
. O 
The O 
structure O 
- O 
activity O 
relationships O 
revealed O 
that O 
the O 
free O 
hydroxyl B-SYSTEMATIC 
group O 
at O 
position O 
5 O 
and O 
phosphate B-SYSTEMATIC 
group O 
at O 
position O 
7 O 
of O 
the O 
phosphorylated B-FAMILY 
flavonoids I-FAMILY 
are O 
favorable O 
to O 
the O 
inhibition O 
of O 
CEase O 
. O 
The O 
inhibition O 
mechanism O 
and O 
kinetic O 
characterization O 
studies O 
indicated O 
that O 
they O 
are O 
irreversible O 
competitive O 
inhibitors O 
of O 
CEase O 
. O 

a O 
wide O 
range O 
of O 
animals O 
, O 
uncontrollable O 
stressful O 
events O 
can O 
induce O 
a O 
condition O 
called O 
" O 
learned O 
helplessness O 
. O 
" O 
In O 
mammals O 
it O 
is O 
associated O 
with O 
low O 
general O 
activity O 
, O 
poor O 
learning O 
, O 
disorders O 
of O 
sleep O 
and O 
feeding O 
, O 
ulcers O 
, O 
and O 
reduced O 
immune O 
status O 
, O 
as O 
well O 
as O 
with O 
increased O 
serotonin B-TRIVIAL 
in O 
parts O 
of O 
the O 
brain O 
. O 
It O 
is O 
considered O 
an O 
animal O 
model O 
of O 
depression O 
in O 
humans O 
[ O 
1-4 O 
] O 
. O 
Here O 
we O 
investigate O 
learned O 
helplessness O 
in O 
Drosophila O 
, O 
showing O 
that O 
this O 
behavioral O 
state O 
consists O 
of O 
a O 
cognitive O 
and O 
a O 
modulatory O 
, O 
possibly O 
mood O 
- O 
like O 
, O 
component O 
. O 
A O 
fly O 
, O 
getting O 
heated O 
as O 
soon O 
as O 
it O 
stops O 
walking O 
, O 
reliably O 
resumes O 
walking O 
to O 
escape O 
the O 
heat O 
. O 
If O 
, O 
in O 
contrast O 
, O 
the O 
fly O 
is O 
not O 
in O 
control O 
of O 
the O 
heat O 
, O 
it O 
learns O 
that O 
its O 
behavior O 
has O 
no O 
effect O 
and O 
quits O 
responding O 
. O 
In O 
this O 
state O 
, O 
the O 
fly O 
walks O 
slowly O 
and O 
takes O 
longer O 
and O 
more O 
frequent O 
rests O 
, O 
as O 
if O 
it O 
were O 
" O 
depressed O 
. O 
" O 
This O 
downregulation O 
of O 
walking O 
behavior O 
is O 
more O 
pronounced O 
in O 
females O 
than O 
in O 
males O 
. O 
Learned O 
helplessness O 
in O 
Drosophila O 
is O 
an O 
example O 
of O 
how O 
, O 
in O 
a O 
certain O 
situation O 
, O 
behavior O 
is O 
organized O 
according O 
to O 
its O 
expected O 
consequences O 
. O 

Metnase O 
and O 
Artemis O 
possess O 
endonuclease O 
activities O 
that O 
trim O 
3 O 
' O 
overhangs O 
of O 
duplex O 
DNA O 
. O 
To O 
assess O 
the O 
potential O 
of O 
these O 
enzymes O 
for O 
facilitating O 
resolution O 
of O 
damaged O 
ends O 
during O 
double O 
- O 
strand O 
break O 
rejoining O 
, O 
substrates O 
bearing O 
a O 
variety O 
of O 
normal O 
and O 
structurally O 
modified O 
3 O 
' O 
overhangs O 
were O 
constructed O 
, O 
and O 
treated O 
either O 
with O 
Metnase O 
or O 
with O 
Artemis O 
plus O 
DNA-dependent O 
protein O 
kinase O 
( O 
DNA-PK O 
) O 
. O 
Unlike O 
Artemis O 
, O 
which O 
trims O 
long O 
overhangs O 
to O 
4-5 O 
bases O 
, O 
cleavage O 
by O 
Metnase O 
was O 
more O 
evenly O 
distributed O 
over O 
the O 
length O 
of O 
the O 
overhang O 
, O 
but O 
with O 
significant O 
sequence O 
dependence O 
. O 
In O 
many O 
substrates O 
, O 
Metnase O 
also O 
induced O 
marked O 
cleavage O 
in O 
the O 
double O 
- O 
stranded O 
region O 
within O 
a O 
few O 
bases O 
of O 
the O 
overhang O 
. O 
Like O 
Artemis O 
, O 
Metnase O 
efficiently O 
trimmed O 
overhangs O 
terminated O 
in O 
3'-phosphoglycolates B-FAMILY 
( O 
PGs B-FAMILY 
) O 
, O 
and O 
in O 
some O 
cases O 
the O 
presence O 
of O 
3'-PG B-SYSTEMATIC 
stimulated O 
cleavage O 
and O 
altered O 
its O 
specificity O 
. O 
The O 
nonplanar O 
base O 
thymine B-TRIVIAL 
glycol I-TRIVIAL 
in O 
a O 
3 O 
' O 
overhang O 
severely O 
inhibited O 
cleavage O 
by O 
Metnase O 
in O 
the O 
vicinity O 
of O 
the O 
modified O 
base O 
, O 
while O 
Artemis O 
was O 
less O 
affected O 
. O 
Nevertheless O 
, O 
thymine B-TRIVIAL 
glycol I-TRIVIAL 
moieties O 
could O 
be O 
removed O 
by O 
Metnase- O 
or O 
Artemis O 
- O 
mediated O 
cleavage O 
at O 
sites O 
farther O 
from O 
the O 
terminus O 
than O 
the O 
lesion O 
itself O 
. O 
In O 
in O 
vitro O 
end O 
- O 
joining O 
systems O 
based O 
on O 
human O 
cell O 
extracts O 
, O 
addition O 
of O 
Artemis O 
, O 
but O 
not O 
Metnase O 
, O 
effected O 
robust O 
trimming O 
of O 
an O 
unligatable O 
3'-PG B-SYSTEMATIC 
overhang O 
, O 
resulting O 
in O 
a O 
dramatic O 
stimulation O 
of O 
ligase O 
IV- O 
and O 
XLF-dependent O 
end O 
joining O 
. O 
Thus O 
, O 
while O 
both O 
Metnase O 
and O 
Artemis O 
are O 
biochemically O 
capable O 
of O 
resolving O 
a O 
variety O 
of O 
damaged O 
DNA O 
ends O 
for O 
the O 
repair O 
of O 
complex O 
double O 
- O 
strand O 
breaks O 
, O 
Artemis O 
appears O 
to O 
act O 
more O 
efficiently O 
in O 
the O 
context O 
of O 
other O 
nonhomologous O 
end O 
joining O 
proteins O 
. O 

enhancement O 
of O 
cancer O 
therapy O 
using O 
a O 
combination O 
of O 
heat O 
shock O 
protein O 
targeted O 
HPMA B-ABBREVIATION 
copolymer O 
- O 
drug O 
conjugates O 
and O 
gold O 
nanorod O 
induced O 
hyperthermia O 
. O 

the O 
field O 
of O 
nanomedicine O 
, O 
selective O 
delivery O 
to O 
cancer O 
cells O 
is O 
a O 
common O 
goal O 
, O 
where O 
active O 
targeting O 
strategies O 
are O 
often O 
employed O 
to O 
increase O 
tumor O 
accumulation O 
. O 
In O 
this O 
study O 
, O 
tumor O 
hyperthermia O 
was O 
utilized O 
as O 
a O 
means O 
to O 
increase O 
the O 
active O 
delivery O 
of O 
heat O 
shock O 
protein O 
( O 
HSP O 
) O 
targeted O 
N-(2-hydroxypropyl)methacrylamide B-SYSTEMATIC 
( O 
HPMA B-ABBREVIATION 
) O 
copolymer O 
- O 
drug O 
conjugates O 
. O 
Following O 
hyperthermia O 
, O 
induced O 
expression O 
of O 
cell O 
surface O 
heat O 
shock O 
protein O 
( O 
HSP O 
) O 
glucose B-TRIVIAL 
regulated O 
protein O 
78kDa O 
( O 
GRP78 O 
) O 
was O 
utilized O 
for O 
targeted O 
drug O 
therapy O 
. O 
Conjugates O 
bearing O 
the O 
anticancer O 
agents O 
aminohexylgeldanamycin B-SYSTEMATIC 
( O 
AHGDM B-ABBREVIATION 
) O 
, O 
docetaxel B-TRIVIAL 
( O 
DOC B-ABBREVIATION 
) O 
, O 
or O 
cisplatin B-TRIVIAL 
and O 
the O 
GRP78 O 
targeting O 
peptide O 
WDLAWMFRLPVG O 
were O 
synthesized O 
and O 
characterized O 
. O 
Binding O 
to O 
cell O 
surface O 
expressed O 
heat O 
shock O 
protein O 
GRP78 O 
on O 
the O 
surface O 
of O 
human O 
prostate O 
cancer O 
DU145 O 
cells O 
was O 
evaluated O 
. O 
HSP O 
targeted O 
AHGDM B-ABBREVIATION 
and O 
DOC B-ABBREVIATION 
conjugates O 
demonstrated O 
active O 
binding O 
comparable O 
to O 
native O 
targeting O 
peptide O 
. O 
They O 
were O 
then O 
assessed O 
in O 
vitro O 
for O 
the O 
ability O 
to O 
synergistically O 
induce O 
cytotoxicity O 
in O 
combination O 
with O 
moderate O 
hyperthermia O 
( O 
43°C O 
, O 
30min O 
) O 
. O 
HSP O 
targeted O 
DOC B-ABBREVIATION 
conjugates O 
exhibited O 
high O 
potency O 
against O 
DU145 O 
cells O 
with O 
an O 
IC50 O 
of O 
2.4nM O 
. O 
HSP O 
targeted O 
AHGDM B-ABBREVIATION 
and O 
DOC B-ABBREVIATION 
conjugates O 
demonstrated O 
synergistic O 
effects O 
in O 
combination O 
with O 
hyperthermia O 
with O 
combination O 
index O 
values O 
of O 
0.65 O 
and O 
0.45 O 
respectively O 
. O 
Based O 
on O 
these O 
results O 
, O 
HSP O 
targeted O 
DOC B-ABBREVIATION 
conjugates O 
were O 
selected O 
for O 
in O 
vivo O 
evaluation O 
. O 
In O 
DU145 O 
tumor O 
bearing O 
mice O 
, O 
a O 
single O 
treatment O 
of O 
tumor O 
hyperthermia O 
, O 
induced O 
via O 
gold O 
nanorod O 
mediated O 
plasmonic O 
photothermal O 
therapy O 
, O 
and O 
intravenous O 
administration O 
of O 
HSP O 
targeted O 
HPMA B-ABBREVIATION 
copolymer- O 
docetaxel B-TRIVIAL 
at O 
10mg O 
/ O 
kg O 
resulted O 
in O 
maintained O 
tumor O 
regression O 
for O 
a O 
period O 
of O 
30days O 
. O 
These O 
results O 
demonstrate O 
the O 
potential O 
for O 
tumor O 
hyperthermia O 
to O 
increase O 
the O 
delivery O 
of O 
HSP O 
targeted O 
macromolecular O 
chemotherapeutics O 
. O 

type O 
1 O 
cannabinoid O 
receptor O 
( O 
CB1 O 
) O 
is O 
a O 
G O 
protein O 
- O 
coupled O 
receptor O 
that O 
is O 
expressed O 
at O 
high O 
levels O 
in O 
the O 
striatum O 
. O 
Activation O 
of O 
CB1 O 
increases O 
expression O 
of O 
neuronal O 
trophic O 
factors O 
and O 
inhibits O 
neurotransmitter O 
release O 
from O 
GABA B-ABBREVIATION 
-ergic O 
striatal O 
neurons O 
. O 
CB1 O 
mRNA O 
levels O 
can O 
be O 
elevated O 
by O 
treatment O 
with O 
cannabinoids O 
in O 
non-neuronal O 
cells O 
. O 
We O 
wanted O 
to O 
determine O 
whether O 
cannabinoid O 
treatment O 
could O 
induce O 
CB1 O 
expression O 
in O 
a O 
cell O 
culture O 
model O 
of O 
striatal O 
neurons O 
and O 
, O 
if O 
possible O 
, O 
determine O 
the O 
molecular O 
mechanism O 
by O 
which O 
this O 
occurred O 
. O 
We O 
found O 
that O 
treatment O 
of O 
STHdh(7 O 
/ O 
7 O 
) O 
cells O 
with O 
the O 
cannabinoids O 
ACEA O 
, O 
mAEA O 
, O 
and O 
AEA O 
produced O 
a O 
CB1 O 
receptor O 
- O 
dependent O 
increase O 
in O 
CB1 O 
promoter O 
activity O 
, O 
mRNA O 
, O 
and O 
protein O 
expression O 
. O 
This O 
response O 
was O 
Akt- O 
and O 
NF-κB-dependent O 
. O 
Because O 
decreased O 
CB1 O 
expression O 
is O 
thought O 
to O 
contribute O 
to O 
the O 
pathogenesis O 
of O 
Huntington's O 
disease O 
( O 
HD O 
) O 
, O 
we O 
wanted O 
to O 
determine O 
whether O 
cannabinoids O 
could O 
increase O 
CB1 O 
expression O 
in O 
STHdh(7 O 
/ O 
111 O 
) O 
and O 
( O 
111 O 
/ O 
111 O 
) O 
cells O 
expressing O 
the O 
mutant O 
huntingtin O 
protein O 
. O 
We O 
observed O 
that O 
cannabinoid O 
treatment O 
increased O 
CB1 O 
mRNA O 
levels O 
approximately O 
10-fold O 
in O 
STHdh(7 O 
/ O 
111 O 
) O 
and O 
( O 
111 O 
/ O 
111 O 
) O 
cells O 
, O 
compared O 
to O 
vehicle O 
treatment O 
. O 
Importantly O 
, O 
cannabinoid O 
treatment O 
improved O 
ATP B-ABBREVIATION 
production O 
, O 
increased O 
the O 
expression O 
of O 
the O 
trophic O 
factor O 
BDNF-2 O 
, O 
and O 
the O 
mitochondrial O 
regulator O 
PGC1α O 
, O 
and O 
reduced O 
spontaneous O 
GABA B-ABBREVIATION 
release O 
, O 
in O 
HD O 
cells O 
. O 
Therefore O 
, O 
cannabinoid O 
- O 
mediated O 
increases O 
in O 
CB1 O 
levels O 
could O 
reduce O 
the O 
severity O 
of O 
some O 
molecular O 
pathologies O 
observed O 
in O 
HD O 
. O 

social O 
stress O 
during O 
adolescence O 
: O 
Interplay O 
of O 
paroxetine B-TRIVIAL 
treatment O 
and O 
ageing O 
. O 

to O 
chronic O 
stress O 
during O 
developmental O 
periods O 
is O 
a O 
risk O 
factor O 
for O 
a O 
number O 
of O 
psychiatric O 
disorders O 
. O 
While O 
the O 
direct O 
effects O 
of O 
stress O 
exposure O 
have O 
been O 
studied O 
extensively O 
, O 
little O 
is O 
known O 
about O 
the O 
long O 
- O 
lasting O 
effects O 
and O 
the O 
interaction O 
with O 
ageing O 
. O 
The O 
same O 
holds O 
true O 
for O 
the O 
treatment O 
with O 
selective O 
serotonin B-TRIVIAL 
reuptake O 
inhibitors O 
( O 
SSRIs O 
) O 
, O 
which O 
have O 
been O 
shown O 
to O 
prevent O 
or O 
reverse O 
some O 
stress O 
- O 
induced O 
effects O 
. O 
Here O 
, O 
we O 
studied O 
the O 
direct O 
and O 
long O 
- O 
lasting O 
impact O 
of O 
chronic O 
social O 
stress O 
during O 
adolescence O 
and O 
the O 
impact O 
of O 
chronic O 
treatment O 
with O 
the O 
SSRI O 
paroxetine B-TRIVIAL 
in O 
adulthood O 
and O 
aged O 
animals O 
. O 
Therefore O 
, O 
male O 
CD1 O 
mice O 
at O 
the O 
age O 
of O 
28 O 
days O 
were O 
subjected O 
to O 
7 O 
weeks O 
of O 
chronic O 
social O 
stress O 
. O 
Treatment O 
with O 
paroxetine B-TRIVIAL 
was O 
performed O 
per O 
os O 
with O 
a O 
dosage O 
of O 
20 O 
mg O 
/ O 
g O 
BW O 
. O 
We O 
were O 
able O 
to O 
reverse O 
most O 
of O 
the O 
effects O 
of O 
chronic O 
social O 
stress O 
in O 
adult O 
mice O 
( O 
4 O 
months O 
old O 
) O 
and O 
to O 
some O 
extend O 
in O 
aged O 
animals O 
( O 
15 O 
months O 
old O 
) O 
with O 
the O 
SSRI O 
treatment O 
. O 
Especially O 
the O 
regulation O 
of O 
the O 
HPA O 
axis O 
seems O 
to O 
be O 
affected O 
in O 
aged O 
mice O 
with O 
a O 
shift O 
to O 
the O 
use O 
of O 
vasopressin B-FAMILY 
. O 
Our O 
results O 
demonstrate O 
that O 
chronic O 
stress O 
exposure O 
and O 
antidepressant O 
treatment O 
at O 
the O 
end O 
of O 
the O 
developmental O 
period O 
can O 
have O 
a O 
significant O 
and O 
long O 
- O 
lasting O 
impact O 
, O 
highly O 
relevant O 
for O 
healthy O 
ageing O 
. O 

chromatographic O 
systems O 
( O 
three O 
systems O 
of O 
high O 
- O 
performance O 
liquid O 
chromatography O 
and O 
two O 
micellar O 
electrokinetic O 
chromatography O 
systems O 
) O 
besides O 
the O 
reference O 
octanol B-SYSTEMATIC 
-water O 
partition O 
system O 
are O 
evaluated O 
by O 
a O 
systematic O 
procedure O 
previously O 
proposed O 
in O 
order O 
to O 
know O 
their O 
ability O 
to O 
model O 
human O 
skin O 
permeation O 
. O 
The O 
precision O 
achieved O 
when O 
skin O 
- O 
water O 
permeability O 
coefficients O 
are O 
correlated O 
against O 
chromatographic O 
retention O 
factors O 
is O 
predicted O 
within O 
the O 
framework O 
of O 
the O 
solvation O 
parameter O 
model O 
. O 
It O 
consists O 
in O 
estimating O 
the O 
contribution O 
of O 
error O 
due O 
to O 
the O 
biological O 
and O 
chromatographic O 
data O 
, O 
as O 
well O 
as O 
the O 
error O 
coming O 
from O 
the O 
dissimilarity O 
between O 
the O 
human O 
skin O 
permeation O 
and O 
the O 
chromatographic O 
systems O 
. O 
Both O 
predictions O 
and O 
experimental O 
tests O 
show O 
that O 
all O 
correlations O 
are O 
greatly O 
affected O 
by O 
the O 
considerable O 
uncertainty O 
of O 
the O 
skin O 
permeability O 
data O 
and O 
the O 
error O 
associated O 
to O 
the O 
dissimilarity O 
between O 
the O 
systems O 
. O 
Correlations O 
with O 
much O 
better O 
predictive O 
abilities O 
are O 
achieved O 
when O 
the O 
volume O 
of O 
the O 
solute O 
is O 
used O 
as O 
additional O 
variable O 
, O 
which O 
illustrates O 
the O 
main O 
roles O 
of O 
both O 
lipophilicity O 
and O 
size O 
of O 
the O 
solute O 
to O 
penetrate O 
through O 
the O 
skin O 
. O 
In O 
this O 
way O 
, O 
the O 
considered O 
systems O 
are O 
able O 
to O 
give O 
precise O 
estimations O 
of O 
human O 
skin O 
permeability O 
coefficients O 
. O 
In O 
particular O 
, O 
the O 
HPLC O 
systems O 
with O 
common O 
C18 O 
columns O 
provide O 
the O 
best O 
performances O 
in O 
emulating O 
the O 
permeation O 
of O 
neutral O 
compounds O 
from O 
aqueous O 
solution O 
through O 
the O 
human O 
skin O 
. O 
As O 
a O 
result O 
, O 
a O 
methodology O 
based O 
on O 
easy O 
, O 
fast O 
, O 
and O 
economical O 
HPLC O 
measurements O 
in O 
a O 
common O 
C18 O 
column O 
has O 
been O 
developed O 
. O 
After O 
a O 
validation O 
based O 
on O 
training O 
and O 
test O 
sets O 
, O 
the O 
method O 
has O 
been O 
applied O 
with O 
good O 
results O 
to O 
the O 
estimation O 
of O 
skin O 
permeation O 
of O 
several O 
hormones O 
and O 
pesticides O 
. O 

iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
( O 
SPIONs O 
) O 
show O 
a O 
great O 
promise O 
for O 
a O 
wide O 
specter O 
of O 
bioapplications O 
, O 
due O 
to O 
their O 
characteristic O 
magnetic O 
properties O 
exhibited O 
only O 
in O 
the O 
presence O 
of O 
magnetic O 
field O 
. O 
Their O 
advantages O 
in O 
the O 
fields O 
of O 
magnetic O 
drug O 
targeting O 
and O 
imaging O 
are O 
well O 
established O 
and O 
their O 
safety O 
is O 
assumed O 
, O 
since O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
have O 
already O 
been O 
approved O 
for O 
in O 
vivo O 
application O 
, O 
however O 
, O 
according O 
to O 
many O 
literature O 
reports O 
the O 
bare O 
metal O 
oxide O 
nanoparticles O 
may O 
cause O 
toxic O 
effects O 
on O 
treated O 
cells O 
. O 
Therefore O 
, O 
it O 
is O 
reasonable O 
to O 
prevent O 
the O 
direct O 
interactions O 
between O 
metal O 
oxide O 
core O 
and O 
surrounding O 
environment O 
. O 
In O 
the O 
current O 
research O 
ricinoleic B-TRIVIAL 
acid I-TRIVIAL 
coated O 
maghemite B-TRIVIAL 
nanoparticles O 
were O 
successfully O 
synthesized O 
, O 
characterized O 
and O 
incorporated O 
in O 
the O 
polymeric O 
matrix O 
, O 
resulting O 
in O 
nanosized O 
magnetic O 
polymeric O 
particles O 
. O 
The O 
carrier O 
system O 
was O 
shown O 
to O 
exhibit O 
superparamagnetic O 
properties O 
and O 
was O 
therefore O 
responsive O 
towards O 
external O 
magnetic O 
field O 
. O 
Bioevaluation O 
using O 
T47-D O 
breast O 
cancer O 
cells O 
confirmed O 
internalization O 
of O 
magnetic O 
polymeric O 
nanoparticles O 
( O 
MNPs O 
) O 
and O 
their O 
intracellular O 
localization O 
in O 
various O 
subcellular O 
compartments O 
, O 
depending O 
on O 
presence O 
/ O 
absence O 
of O 
external O 
magnetic O 
field O 
. O 
However O 
, O 
the O 
number O 
of O 
internalized O 
MNPs O 
observed O 
by O 
fluorescent O 
and O 
transmission O 
electron O 
microscopy O 
was O 
relatively O 
low O 
, O 
making O 
such O 
way O 
of O 
targeting O 
effective O 
only O 
for O 
delivery O 
of O 
highly O 
potent O 
drugs O 
. O 
The O 
scanning O 
electron O 
microscopy O 
of O 
treated O 
cells O 
revealed O 
that O 
MNPs O 
influenced O 
the O 
cell O 
adhesion O 
, O 
when O 
external O 
magnetic O 
field O 
was O 
applied O 
, O 
and O 
that O 
treatment O 
resulted O 
in O 
damaged O 
apical O 
plasma O 
membrane O 
right O 
after O 
exposure O 
to O 
the O 
magnetic O 
carrier O 
. O 
On O 
the O 
other O 
hand O 
, O 
MNPs O 
showed O 
only O 
reversibly O 
reduced O 
cellular O 
metabolic O 
activity O 
in O 
concentrations O 
up O 
to O 
200μg O 
/ O 
ml O 
and O 
, O 
in O 
the O 
tested O 
concentration O 
the O 
cell O 
cycle O 
distribution O 
was O 
within O 
the O 
normal O 
range O 
, O 
indicating O 
safety O 
of O 
the O 
established O 
magnetic O 
carrier O 
system O 
for O 
the O 
treated O 
cells O 
. O 

order O 
to O 
develop O 
new O 
iodinated O 
and O 
fluorinated O 
matched O 
- O 
pair O 
radiotracers O 
for O 
Single-Photon O 
Emission O 
Computed O 
Tomography O 
( O 
SPECT O 
) O 
/ O 
Positron O 
Emission O 
Tomography O 
( O 
PET O 
) O 
imaging O 
and O 
targeted O 
radionuclide O 
therapy O 
of O 
melanoma O 
, O 
we O 
successfully O 
synthesized O 
and O 
radiolabelled O 
with O 
iodine-125 B-SYSTEMATIC 
seven O 
new O 
derivatives O 
, O 
starting O 
from O 
our O 
previously O 
described O 
lead O 
structure O 
3 O 
. O 
The O 
relevance O 
of O 
these O 
radiotracers O 
for O 
gamma O 
scintigraphic O 
imaging O 
of O 
melanoma O 
in O 
rodent O 
was O 
assessed O 
. O 
The O 
tumoural O 
radioactivity O 
uptake O 
was O 
most O 
often O 
high O 
and O 
specific O 
even O 
at O 
early O 
time O 
points O 
( O 
12.1-18.3% O 
ID O 
/ O 
g O 
at O 
3 O 
h O 
p.i O 
. O 
for O 
[ O 
(125)I B-FORMULA 
]39-42 O 
) O 
and O 
a O 
fast O 
clearance O 
from O 
the O 
non-target O 
organs O 
was O 
observed O 
. O 
Also O 
, O 
calculated O 
effective O 
doses O 
that O 
could O 
be O 
delivered O 
to O 
tumours O 
when O 
using O 
corresponding O 
[ O 
(131)I B-FORMULA 
] O 
- O 
labelled O 
analogues O 
were O 
generally O 
higher O 
than O 
100 O 
cGy O 
/ O 
MBq O 
injected O 
( O 
98.9-150.5 O 
cGy O 
/ O 
MBq O 
for O 
[ O 
(131)I B-FORMULA 
]39-42 O 
) O 
. O 
These O 
results O 
make O 
compounds O 
39-42 O 
suitable O 
candidates O 
for O 
(i) O 
PET O 
imaging O 
of O 
melanoma O 
after O 
labelling O 
with O 
fluorine-18 B-SYSTEMATIC 
and O 
(ii) O 
targeted O 
radionuclide O 
therapy O 
of O 
disseminated O 
melanoma O 
after O 
labelling O 
with O 
iodine-131 B-SYSTEMATIC 
. O 

and O 
triazolothiadiazines B-FAMILY 
- O 
Biologically O 
attractive O 
scaffolds O 
. O 

medicinal O 
chemistry O 
faces O 
diverse O 
challenges O 
from O 
several O 
directions O 
, O 
including O 
the O 
need O 
for O 
both O 
potency O 
and O 
specificity O 
of O 
any O 
therapeutic O 
agent O 
. O 
Therefore O 
, O 
in O 
the O 
present O 
perspective O 
, O 
the O 
triazolothiadiazoles B-FAMILY 
and O 
triazolothiadiazines B-FAMILY 
with O 
broad O 
spectrum O 
biological O 
profile O 
have O 
matured O 
into O 
indispensable O 
heterocyclic O 
scaffolds O 
. O 
This O 
review O 
article O 
is O 
an O 
effort O 
to O 
summarize O 
medicinal O 
chemistry O 
investigations O 
over O 
the O 
last O 
decade O 
, O 
in O 
search O 
for O 
new O 
N B-FORMULA 
-bridged O 
heterocycles O 
which O 
can O 
be O 
a O 
rich O 
source O 
of O 
promising O 
biological O 
activities O 
. O 

Fusarium O 
toxin O 
deoxynivalenol B-TRIVIAL 
( O 
DON B-ABBREVIATION 
) O 
modulates O 
the O 
LPS O 
induced O 
acute O 
phase O 
reaction O 
in O 
pigs O 
. O 

systemic O 
effects O 
of O 
the O 
Fusarium O 
toxin O 
deoxynivalenol B-TRIVIAL 
( O 
DON B-ABBREVIATION 
) O 
and O 
of O 
bacterial O 
lipopolysaccharides O 
( O 
LPS O 
) O 
were O 
studied O 
in O 
male O 
castrated O 
pigs O 
( O 
40.4±3.7kg O 
) O 
infused O 
intravenously O 
with O 
either O 
DON B-ABBREVIATION 
or O 
LPS O 
alone O 
( O 
100μg O 
DON B-ABBREVIATION 
/ O 
kg O 
/ O 
h O 
, O 
7.5μg O 
/ O 
LPS O 
/ O 
kg O 
/ O 
h O 
) O 
, O 
or O 
together O 
( O 
100μg O 
DON B-ABBREVIATION 
plus O 
7.5μg O 
/ O 
LPS O 
/ O 
kg O 
/ O 
h O 
) O 
. O 
The O 
Control O 
group O 
received O 
a O 
saline O 
infusion O 
( O 
n=6 O 
/ O 
treatment O 
, O 
24h O 
observation O 
period O 
) O 
. O 
An O 
additional O 
DON B-ABBREVIATION 
infusion O 
did O 
not O 
exacerbate O 
the O 
clinical O 
signs O 
observed O 
in O 
LPS-infused O 
pigs O 
. O 
For O 
example O 
, O 
rectal O 
temperature O 
climaxed O 
after O 
4h O 
( O 
40.4±0.2°C O 
) O 
and O 
5h O 
( O 
40.1±0.3°C O 
) O 
, O 
in O 
the O 
LPS O 
and O 
LPS+ O 
DON B-ABBREVIATION 
groups O 
, O 
respectively O 
. O 
Saline O 
and O 
DON B-ABBREVIATION 
alone O 
did O 
not O 
induce O 
an O 
acute O 
phase O 
reaction O 
as O 
indicated O 
by O 
unaltered O 
plasma O 
levels O 
of O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
( O 
TNF-alpha O 
) O 
and O 
interleukin-6 O 
( O 
IL-6 O 
) O 
while O 
LPS O 
caused O 
a O 
significant O 
rise O 
of O 
both O 
cytokines O 
. O 
TNF-alpha O 
plasma O 
peak O 
concentrations O 
were O 
significantly O 
higher O 
in O 
the O 
LPS O 
compared O 
to O 
the O 
DON B-ABBREVIATION 
+ O 
LPS O 
group O 
( O 
94.3±17.2ng O 
/ O 
mL O 
vs O 
. O 
79.2±15.7ng O 
/ O 
mL O 
) O 
while O 
IL-6 O 
climaxed O 
earlier O 
in O 
the O 
latter O 
group O 
( O 
3h O 
p.i O 
. O 
vs O 
. O 
2h O 
p.i O 
. O 
) O 
. O 
From O 
the O 
tested O 
clinical O 
- O 
chemical O 
plasma O 
characteristics O 
the O 
total O 
bilirubin B-TRIVIAL 
concentration O 
and O 
the O 
ASAT O 
activity O 
were O 
strongly O 
elevated O 
by O 
the O 
LPS O 
infusion O 
and O 
additionally O 
increased O 
and O 
decreased O 
by O 
DON B-ABBREVIATION 
, O 
respectively O 
. O 
In O 
conclusion O 
, O 
the O 
LPS-induced O 
effects O 
were O 
only O 
marginally O 
modified O 
by O 
DON B-ABBREVIATION 
. O 

inactivation O 
reaction O 
rates O 
for O 
ricin O 
are O 
influenced O 
by O 
pH O 
and O 
carbohydrates B-FAMILY 
. O 

is O 
a O 
lethal O 
protein O 
toxin O 
produced O 
by O 
the O 
castor O 
bean O 
plant O 
. O 
Ricin O 
is O 
known O 
to O 
possess O 
significant O 
heat O 
resistance O 
. O 
Therefore O 
, O 
we O 
placed O 
it O 
in O 
a O 
variety O 
of O 
foods O 
to O 
study O 
the O 
influence O 
of O 
the O 
food O 
matrix O 
on O 
behavior O 
of O 
a O 
thermally O 
stable O 
protein O 
toxin O 
. O 
First O 
order O 
rate O 
constants O 
for O 
the O 
thermal O 
inactivation O 
of O 
ricin O 
in O 
foods O 
and O 
simple O 
buffers O 
were O 
measured O 
using O 
cytotoxicity O 
assays O 
. O 
We O 
observed O 
greater O 
thermal O 
stability O 
at O 
75°C O 
for O 
the O 
cytotoxic O 
activity O 
of O 
ricin O 
when O 
it O 
was O 
placed O 
in O 
a O 
yogurt O 
- O 
containing O 
fruit O 
drink O 
compared O 
to O 
its O 
stability O 
when O 
placed O 
in O 
the O 
other O 
foods O 
tested O 
. O 
We O 
found O 
that O 
galactose B-TRIVIAL 
and O 
high O 
molecular O 
weight O 
exopolysaccharides O 
present O 
in O 
various O 
dairy O 
products O 
contributed O 
to O 
the O 
thermal O 
stability O 
of O 
ricin O 
. O 
Differential O 
scanning O 
calorimetry O 
also O 
showed O 
enhanced O 
thermal O 
stability O 
for O 
ricin O 
at O 
pH O 
4.5 O 
. O 
Our O 
results O 
demonstrate O 
the O 
importance O 
of O 
considering O 
pH O 
and O 
the O 
presence O 
of O 
stabilizing O 
ligands O 
in O 
the O 
thermal O 
inactivation O 
of O 
protein O 
toxins O 
in O 
foods O 
. O 

- O 
term O 
toxicity O 
of O 
hexavalent-chromium B-SYSTEMATIC 
to O 
epipsammic O 
diatoms O 
of O 
a O 
microtidal O 
estuary O 
( O 
Río O 
de O 
la O 
Plata O 
) O 
: O 
Responses O 
from O 
the O 
individual O 
cell O 
to O 
the O 
community O 
structure O 
. O 

are O 
an O 
integral O 
and O 
often O 
dominant O 
component O 
of O 
the O 
benthic O 
microalgal O 
assemblage O 
in O 
estuarine O 
and O 
shallow O 
coastal O 
environments O 
. O 
Different O 
toxic O 
substances O 
discharged O 
into O 
these O 
ecosystems O 
persist O 
in O 
the O 
water O 
, O 
sediments O 
, O 
and O 
biota O 
for O 
long O 
periods O 
. O 
Among O 
these O 
pernicious O 
agents O 
, O 
the O 
toxicity O 
in O 
diatoms O 
by O 
metal O 
is O 
linked O 
to O 
different O 
steps O 
in O 
the O 
transmembrane O 
and O 
internal O 
movements O 
of O 
the O 
toxicant O 
, O 
causing O 
perturbations O 
in O 
the O 
normal O 
structural O 
and O 
functional O 
cellular O 
components O 
. O 
These O 
changes O 
constitute O 
an O 
early O 
, O 
nontaxonomic O 
warning O 
signal O 
that O 
could O 
potentially O 
serve O 
as O 
an O 
indicator O 
of O 
this O 
type O 
of O 
pollution O 
. O 
The O 
aim O 
of O 
this O 
work O 
was O 
to O 
study O 
the O 
environment-reflecting O 
short O 
- O 
term O 
responses O 
at O 
different O 
levels O 
of O 
organization O 
of O 
epipsammic O 
diatoms O 
from O 
the O 
Río O 
de O 
la O 
Plata O 
estuary O 
, O 
Argentina O 
that O 
had O 
been O 
exposed O 
to O 
hexavalent B-SYSTEMATIC 
chromium I-SYSTEMATIC 
within O 
experimental O 
microcosms O 
. O 
To O 
this O 
end O 
we O 
monitored O 
: O 
(i) O 
changes O 
in O 
the O 
proportion O 
of O 
the O 
diatoms O 
in O 
relation O 
to O 
other O 
algal O 
groups O 
at O 
the O 
biofilm O 
community O 
level O 
; O 
(ii) O 
shifts O 
in O 
species O 
composition O 
at O 
the O 
diatom O 
- O 
assemblage O 
level O 
; O 
(iii) O 
projected O 
changes O 
in O 
the O 
densities O 
of O 
the O 
most O 
representative O 
species O 
at O 
the O 
population O 
level O 
through O 
comparison O 
of O 
relative O 
growth O 
rates O 
and O 
generation O 
times O 
; O 
and O 
(iv) O 
the O 
cytological O 
changes O 
at O 
the O 
cellular O 
and O 
subcellular O 
levels O 
as O 
indicated O 
by O 
the O 
appearance O 
of O 
teratological O 
effects O 
on O 
individuals O 
and O 
nuclear O 
alterations O 
. O 
The O 
epipsammic O 
biofilms O 
were O 
exposed O 
for O 
96h O 
to O 
chromium B-SYSTEMATIC 
at O 
a O 
concentration O 
similar O 
to O 
that O 
measured O 
in O 
highly O 
impacted O 
sites O 
along O 
the O 
coast O 
(80μgL(-1)) O 
. O 
Chromium B-SYSTEMATIC 
pollution O 
, O 
at O 
this O 
concentration O 
and O 
short O 
exposure O 
time O 
did O 
not O 
affect O 
the O 
algal O 
biomass O 
and O 
density O 
of O 
these O 
mature O 
biofilms O 
. O 
The O 
biofilm O 
composition O 
, O 
however O 
, O 
did O 
change O 
, O 
as O 
reflected O 
in O 
a O 
decline O 
in O 
cyanophytes O 
and O 
an O 
increment O 
in O 
the O 
proportions O 
of O 
diatoms O 
and O 
chlorophytes O 
; O 
with O 
Hippodonta O 
hungarica O 
, O 
Navicula O 
novaesiberica O 
, O 
Nitzschia O 
palea O 
, O 
and O 
Sellaphora O 
pupula O 
being O 
the O 
most O 
frequent O 
and O 
abundant O 
species O 
. O 
The O 
most O 
notable O 
shifts O 
related O 
to O 
chromium B-SYSTEMATIC 
exposure O 
were O 
a O 
decrease O 
in O 
the O 
relative O 
abundance O 
of O 
H O 
. O 
hungarica O 
and O 
a O 
significant O 
increase O 
in O 
the O 
proportion O 
of O 
N O 
. O 
palea O 
. O 
Moreover O 
, O 
the O 
species O 
analyzed O 
in O 
the O 
treatment O 
microcosms O 
showed O 
higher O 
growth O 
rates O 
than O 
in O 
the O 
controls O 
- O 
N O 
. O 
palea O 
grew O 
faster O 
, O 
while O 
H O 
. O 
hungarica O 
replicated O 
more O 
slowly O 
. O 
The O 
total O 
nuclear O 
abnormalities O 
- O 
as O 
recorded O 
in O 
Fallacia O 
pygmaea O 
and O 
N O 
. O 
novaesiberica O 
- O 
were O 
significantly O 
higher O 
in O 
the O 
treatment O 
microcosms O 
; O 
whereas O 
in O 
N O 
. O 
palea O 
, O 
the O 
dominant O 
species O 
in O 
treatment O 
microcosms O 
, O 
neither O 
nuclear O 
alterations O 
nor O 
abnormal O 
frustules O 
were O 
observed O 
. O 

RELEVANCE O 
: O 
Garcinia O 
gardneriana O 
( O 
Planchon O 
and O 
Triana O 
) O 
Zappi O 
( O 
Clusiaceae O 
) O 
is O 
popularly O 
called O 
" O 
bacopari O 
" O 
in O 
southern O 
Brazil O 
. O 
The O 
leaves O 
of O 
this O 
plant O 
are O 
traditionally O 
used O 
to O 
treat O 
skin O 
disorders O 
. O 
AIM O 
OF O 
STUDY O 
: O 
This O 
study O 
evaluated O 
the O 
effects O 
of O 
a O 
hydroalcoholic O 
extract O 
of O 
Garcinia O 
gardneriana O 
leaves O 
( O 
HEGG O 
) O 
on O 
B16F10 O 
murine O 
melanoma O 
cells O 
in O 
order O 
to O 
search O 
for O 
new O 
depigmenting O 
agents O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
The O 
effects O 
of O 
HEGG O 
were O 
assessed O 
in O 
melanin O 
content O 
assays O 
in O 
B16F10 O 
melanoma O 
cells O 
compared O 
with O 
the O 
reference O 
drug O 
kojic B-TRIVIAL 
acid I-TRIVIAL 
( O 
500mM O 
) O 
. O 
Melanin O 
content O 
was O 
measured O 
after O 
spontaneous O 
melanogenesis O 
, O 
UVB-induced O 
melanogenesis O 
and O 
melanogenesis O 
induced O 
by O 
α-MSH O 
. O 
At O 
the O 
same O 
time O 
, O 
cell O 
viability O 
assays O 
were O 
conducted O 
. O 
Intracellular O 
and O 
mushroom O 
tyrosinase O 
activity O 
assays O 
were O 
employed O 
to O 
evaluate O 
the O 
effect O 
of O 
HEGG O 
on O 
tyrosinase O 
activity O 
. O 
RESULTS O 
: O 
HEGG O 
decreased O 
the O 
level O 
of O 
melanin O 
under O 
all O 
three O 
experimental O 
conditions O 
of O 
melanin O 
content O 
evaluation O 
without O 
reducing O 
cell O 
viability O 
. O 
In O 
intracellular O 
tyrosinase O 
assays O 
, O 
the O 
enzyme's O 
activity O 
was O 
reduced O 
about O 
19% O 
with O 
extract O 
concentrations O 
ranging O 
0.1-10µg O 
/ O 
mL O 
. O 
In O 
the O 
mushroom O 
tyrosinase O 
activity O 
assay O 
a O 
maximal O 
inhibition O 
of O 
35% O 
( O 
1000µg O 
/ O 
mL O 
) O 
was O 
observed O 
. O 
CONCLUSION O 
: O 
These O 
results O 
suggest O 
that O 
HEGG O 
inhibition O 
relates O 
to O 
its O 
tyrosinase O 
activity O 
. O 
Therefore O 
, O 
the O 
hydroalcoholic O 
extract O 
of O 
Garcinia O 
gardneriana O 
shows O 
great O 
potential O 
for O 
use O 
as O 
a O 
depigmenting O 
agent O 
in O 
hyperpigmentation O 
disorders O 
. O 

ventromedial O 
nucleus O 
of O 
the O 
hypothalamus O 
( O 
VMH O 
) O 
plays O 
an O 
important O 
role O 
in O 
feeding O 
and O 
energy O 
homeostasis O 
. O 
Electroconvulsive O 
seizure O 
( O 
ECS O 
) O 
therapy O 
is O 
highly O 
effective O 
in O 
the O 
treatment O 
of O 
several O 
psychiatric O 
diseases O 
, O 
including O 
depression O 
, O 
but O 
may O 
also O 
have O 
beneficial O 
effects O 
in O 
other O 
neurological O 
diseases O 
. O 
Although O 
it O 
has O 
been O 
reported O 
that O 
the O 
neurons O 
of O 
the O 
VMH O 
are O 
strongly O 
activated O 
by O 
ECS O 
stimulation O 
, O 
the O 
specific O 
effects O 
of O 
ECS O 
in O 
this O 
hypothalamic O 
subnucleus O 
remain O 
unknown O 
. O 
To O 
address O 
this O 
issue O 
, O 
we O 
investigated O 
the O 
changes O 
in O 
gene O 
expression O 
in O 
microdissected-VMH O 
samples O 
in O 
response O 
to O 
ECS O 
in O 
mice O 
, O 
and O 
examined O 
the O 
behavioral O 
effects O 
of O 
ECS O 
on O 
feeding O 
behavior O 
. O 
ECS O 
significantly O 
induced O 
the O 
expression O 
of O 
immediate O 
- O 
early O 
genes O 
such O 
as O 
Fos O 
, O 
Fosb O 
, O 
and O 
Jun O 
, O 
as O 
well O 
as O 
Bdnf O 
, O 
Adcyap1 O 
, O 
Hrh1 O 
, O 
and O 
Crhr2 O 
in O 
the O 
VMH O 
. O 
Given O 
that O 
signals O 
of O 
these O 
gene O 
products O 
are O 
suggested O 
to O 
have O 
anorexigenic O 
roles O 
in O 
the O 
VMH O 
, O 
we O 
also O 
examined O 
the O 
effect O 
of O 
ECS O 
on O 
food O 
intake O 
and O 
body O 
weight O 
. O 
Repeated O 
ECS O 
had O 
a O 
suppressive O 
effect O 
on O 
food O 
intake O 
and O 
body O 
weight O 
gain O 
under O 
both O 
regular O 
and O 
high O 
- O 
fat O 
diet O 
conditions O 
. O 
Furthermore O 
, O 
gold B-SYSTEMATIC 
- I-SYSTEMATIC 
thioglucose I-SYSTEMATIC 
-induced O 
hypothalamic O 
lesions O 
, O 
including O 
the O 
VMH O 
and O 
the O 
arcuate O 
nucleus O 
, O 
abolished O 
the O 
anorexigenic O 
effects O 
of O 
ECS O 
, O 
indicating O 
the O 
requirement O 
for O 
the O 
activation O 
of O 
the O 
hypothalamus O 
. O 
Our O 
data O 
show O 
an O 
effect O 
of O 
ECS O 
on O 
increased O 
expression O 
of O 
anorexigenic O 
factors O 
in O 
the O 
VMH O 
, O 
and O 
suggest O 
a O 
role O 
in O 
the O 
regulation O 
of O 
energy O 
homeostasis O 
by O 
ECS O 
. O 

venom O 
contains O 
various O 
toxins O 
and O 
can O 
cause O 
itching O 
, O 
edema O 
, O 
muscle O 
aches O 
, O 
shortness O 
of O 
breath O 
, O 
blood O 
pressure O 
depression O 
, O 
shock O 
or O 
even O 
death O 
after O 
being O 
stung O 
. O 
Hemolytic O 
protein O 
is O 
one O 
of O 
the O 
most O 
hazardous O 
components O 
in O 
the O 
venom O 
. O 
The O 
present O 
study O 
investigated O 
the O 
hemolytic O 
activity O 
of O 
the O 
nematocyst O 
venom O 
from O 
jellyfish O 
Stomolophus O 
meleagris O 
. O 
Anion O 
exchange O 
chromatography O 
, O 
DEAE B-ABBREVIATION 
Sepharose O 
Fast O 
Flow O 
, O 
and O 
gel O 
filtration O 
chromatography O 
, O 
Superdex200 O 
had O 
been O 
employed O 
to O 
isolate O 
hemolytic O 
proteins O 
from O 
the O 
nematocyst O 
venom O 
of O 
jellyfish O 
S O 
. O 
meleagris O 
. O 
Hemolysis O 
of O 
chicken O 
red O 
blood O 
cells O 
was O 
used O 
to O 
quantify O 
hemolytic O 
potency O 
of O 
crude O 
nematocyst O 
venom O 
and O 
chromatography O 
fractions O 
during O 
the O 
purification O 
process O 
. O 
Native-PAGE O 
profile O 
displayed O 
one O 
protein O 
band O 
in O 
the O 
purified O 
hemolytic O 
protein O 
( O 
SmTX O 
) O 
; O 
however O 
, O 
two O 
protein O 
bands O 
with O 
apparent O 
molecular O 
weights O 
of O 
∼45kDa O 
and O 
52kDa O 
were O 
observed O 
in O 
the O 
reducing O 
SDS B-ABBREVIATION 
-PAGE O 
analysis O 
. O 
Approximately O 
70μg O 
/ O 
mL O 
of O 
SmTX O 
caused O 
50% O 
hemolysis O 
( O 
HU50 O 
) O 
of O 
the O 
erythrocyte O 
suspension O 
. O 
The O 
hemolytic O 
activity O 
of O 
SmTX O 
was O 
shown O 
to O 
be O 
temperature O 
and O 
pH O 
dependent O 
, O 
with O 
the O 
optimum O 
temperature O 
and O 
pH O 
being O 
37°C O 
and O 
pH O 
5 O 
. O 
The O 
present O 
study O 
is O 
the O 
first O 
report O 
of O 
isolation O 
and O 
partial O 
characterization O 
of O 
hemolytic O 
proteins O 
from O 
the O 
nematocyst O 
venom O 
of O 
the O 
jellyfish O 
S O 
. O 
meleagris O 
. O 
The O 
mechanism O 
of O 
the O 
hemolytic O 
activity O 
of O 
SmTX O 
is O 
not O 
clear O 
and O 
deserves O 
further O 
investigation O 
. O 

studies O 
suggest O 
that O 
endocrine O 
disrupting O 
chemicals O 
( O 
EDCs O 
) O 
may O 
form O 
a O 
risk O 
factor O 
for O 
obesity O 
by O 
altering O 
energy O 
metabolism O 
through O 
epigenetic O 
gene O 
regulation O 
. O 
The O 
goal O 
of O 
this O 
study O 
is O 
to O 
investigate O 
the O 
effects O 
of O 
a O 
range O 
of O 
EDCs O 
with O 
putative O 
obesogenic O 
properties O 
on O 
global O 
DNA O 
methylation O 
and O 
adipocyte O 
differentiation O 
in O 
vitro O 
. O 
Murine O 
N2A O 
and O 
human O 
SK-N-AS O 
neuroblastoma O 
cells O 
and O 
murine O 
preadipocyte O 
fibroblasts O 
( O 
3T3-L1 O 
) O 
were O 
exposed O 
to O 
tributyltin B-SYSTEMATIC 
( O 
TBT B-ABBREVIATION 
) O 
, O 
diethylstilbestrol B-SYSTEMATIC 
( O 
DES B-ABBREVIATION 
) O 
, O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
, O 
2,3,7,8-tetrachlorodibenzo-[p]-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
, O 
2,2',4,4',5,5'-hexachlorobiphenyl B-SYSTEMATIC 
( O 
PCB-153 B-ABBREVIATION 
) O 
, O 
hexachlorobenzene B-SYSTEMATIC 
( O 
HCB B-ABBREVIATION 
) O 
, O 
hexabromocyclododecane B-SYSTEMATIC 
( O 
HBCD B-ABBREVIATION 
) O 
, O 
2,2',4,4'-tetrabrominated B-SYSTEMATIC 
diphenyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
BDE-47 B-ABBREVIATION 
) O 
, O 
perfluorinated B-SYSTEMATIC 
octyl I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
PFOA B-ABBREVIATION 
) O 
and O 
perfluorinated B-SYSTEMATIC 
octyl I-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
( O 
PFOS B-ABBREVIATION 
) O 
. O 
A O 
modest O 
decrease O 
in O 
global O 
DNA O 
methylation O 
was O 
observed O 
in O 
N2A O 
cells O 
exposed O 
to O 
10μM O 
DES B-ABBREVIATION 
, O 
BPA B-ABBREVIATION 
, O 
TCDD B-ABBREVIATION 
, O 
BDE-47 B-ABBREVIATION 
, O 
PCB-153 B-ABBREVIATION 
and O 
1μM O 
HCB B-ABBREVIATION 
, O 
but O 
no O 
changes O 
were O 
found O 
in O 
the O 
human O 
SK-N-AS O 
cells O 
. O 
We O 
reveal O 
for O 
the O 
first O 
time O 
that O 
BDE-47 B-ABBREVIATION 
increases O 
adipocyte O 
differentiation O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
( O 
2.5-25μM O 
) O 
. O 
Adipocyte O 
differentiation O 
was O 
also O 
enhanced O 
by O 
TBT B-ABBREVIATION 
( O 
⩾10nM O 
) O 
and O 
BPA B-ABBREVIATION 
( O 
> O 
10μM O 
) O 
and O 
inhibited O 
by O 
TCDD B-ABBREVIATION 
( O 
⩾0.1nM O 
) O 
. O 
The O 
other O 
chemicals O 
showed O 
either O 
modest O 
or O 
no O 
effects O 
on O 
adipocyte O 
differentiation O 
at O 
the O 
concentrations O 
tested O 
( O 
PFOA B-ABBREVIATION 
, O 
PFOS B-ABBREVIATION 
and O 
HBCD B-ABBREVIATION 
at O 
10μM O 
; O 
PCB-153 B-ABBREVIATION 
, O 
3.4μM O 
and O 
HCB B-ABBREVIATION 
, O 
1μM O 
) O 
. O 
This O 
study O 
demonstrates O 
that O 
, O 
selected O 
EDCs O 
can O 
induce O 
functional O 
changes O 
in O 
murine O 
adipocyte O 
differentiation O 
in O 
vitro O 
which O 
are O 
accompanied O 
by O 
decreased O 
global O 
DNA O 
methylation O 
. O 

RELEVANCE O 
: O 
There O 
are O 
a O 
number O 
of O 
reports O 
from O 
traditional O 
medical O 
practice O 
in O 
Zimbabwe O 
and O 
neighboring O 
countries O 
and O 
few O 
in O 
vitro O 
studies O 
suggesting O 
an O 
effect O 
with O 
extracts O 
of O 
Boophone O 
disticha O 
in O 
some O 
forms O 
of O 
anxiety O 
disorders O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
In O 
order O 
to O 
validate O 
the O 
use O 
of O 
Boophone O 
disticha O 
in O 
treatment O 
of O 
anxiety O 
, O 
this O 
study O 
was O 
set O 
to O 
determine O 
the O 
effects O 
of O 
the O 
plant O 
extracts O 
on O 
blood O 
pressure O 
( O 
BP O 
) O 
and O 
heart O 
rate O 
( O 
HR O 
) O 
in O 
adult O 
BALB O 
/ O 
c O 
mice O 
subjected O 
to O 
repeated O 
early O 
maternal O 
separation O 
( O 
MS O 
) O 
stress O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
To O 
test O 
whether O 
early O 
life O 
stress O 
increases O 
anxiety O 
in O 
mice O 
, O 
non-invasive O 
tail O 
cuff O 
method O 
was O 
used O 
to O 
examine O 
the O 
autonomic O 
nervous O 
system O 
activity O 
by O 
assessing O 
cardiovascular O 
reactivity O 
and O 
response O 
to O 
acute O 
mixing O 
stress O 
( O 
AMS O 
) O 
and O 
restraint O 
stress O 
( O 
RS O 
) O 
in O 
adult O 
mice O 
subjected O 
to O 
early O 
postnatal O 
stress O 
as O 
compared O 
to O 
control O 
. O 
AMS-induced O 
cardiovascular O 
response O 
was O 
then O 
evaluated O 
in O 
adult O 
MS O 
mice O 
treated O 
with O 
Boophone O 
disticha O 
as O 
compared O 
to O 
vehicle O 
and O 
diazepam B-TRIVIAL 
. O 
RESULTS O 
: O 
Comparisons O 
of O 
the O 
BP O 
and O 
HR O 
measurements O 
indicated O 
that O 
MS O 
significantly O 
reduced O 
AMS-induced O 
HR O 
responses O 
in O 
BALB O 
/ O 
c O 
mice O 
when O 
compared O 
with O 
control O 
. O 
Boophone O 
disticha O 
treatment O 
significantly O 
reduced O 
AMS-induced O 
BP O 
response O 
in O 
BALB O 
/ O 
c O 
MS O 
as O 
compared O 
to O 
vehicle O 
and O 
diazepam B-TRIVIAL 
treatments O 
. O 
CONCLUSIONS O 
: O 
Our O 
findings O 
demonstrate O 
for O 
the O 
first O 
time O 
that O 
postnatal O 
stress O 
can O 
induce O 
short O 
- O 
term O 
changes O 
in O 
the O 
sensitivity O 
of O 
the O 
cardiovascular O 
system O 
to O 
subsequent O 
stress O 
which O 
can O 
be O 
reduced O 
by O 
treatment O 
with O 
a O 
freeze O 
dried O 
aqueous O 
ethanolic O 
extract O 
of O 
Boophone O 
disticha O 
. O 

treatments O 
with O 
liposomal O 
doxorubicin B-TRIVIAL 
and O 
ultrasound O 
- O 
induced O 
disruption O 
of O 
blood O 
- O 
tumor O 
and O 
blood O 
- O 
brain O 
barriers O 
improve O 
outcomes O 
in O 
a O 
rat O 
glioma O 
model O 
. O 

blood O 
- O 
brain O 
- O 
barrier O 
( O 
BBB O 
) O 
prevents O 
the O 
transport O 
of O 
most O 
anticancer O 
agents O 
to O 
the O 
central O 
nervous O 
system O 
and O 
restricts O 
delivery O 
to O 
infiltrating O 
brain O 
tumors O 
. O 
The O 
heterogeneous O 
vascular O 
permeability O 
in O 
tumor O 
vessels O 
, O 
along O 
with O 
several O 
other O 
factors O 
, O 
creates O 
additional O 
barriers O 
for O 
drug O 
treatment O 
of O 
brain O 
tumors O 
. O 
Focused O 
ultrasound O 
( O 
FUS O 
) O 
, O 
when O 
combined O 
with O 
circulating O 
microbubbles O 
, O 
is O 
an O 
emerging O 
noninvasive O 
method O 
to O 
temporarily O 
permeabilize O 
the O 
BBB O 
and O 
the O 
" O 
blood O 
- O 
tumor O 
barrier O 
" O 
. O 
Here O 
, O 
we O 
tested O 
the O 
impact O 
of O 
three O 
weekly O 
sessions O 
of O 
FUS O 
and O 
liposomal O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
in O 
9L O 
rat O 
glioma O 
tumors O 
. O 
Animals O 
that O 
received O 
FUS+ O 
DOX B-ABBREVIATION 
( O 
N=8 O 
) O 
had O 
a O 
median O 
survival O 
time O 
that O 
was O 
increased O 
significantly O 
( O 
P O 
< O 
0.001 O 
) O 
compared O 
to O 
animals O 
who O 
received O 
DOX B-ABBREVIATION 
only O 
( O 
N=6 O 
) O 
, O 
FUS O 
only O 
( O 
N=8 O 
) O 
, O 
or O 
no O 
treatment O 
( O 
N=7 O 
) O 
. O 
Median O 
survival O 
for O 
animals O 
that O 
received O 
FUS+ O 
DOX B-ABBREVIATION 
was O 
increased O 
by O 
100% O 
relative O 
to O 
untreated O 
controls O 
, O 
whereas O 
animals O 
who O 
received O 
DOX B-ABBREVIATION 
alone O 
had O 
only O 
a O 
16% O 
improvement O 
. O 
Animals O 
who O 
received O 
only O 
FUS O 
showed O 
no O 
improvement O 
. O 
No O 
tumor O 
cells O 
were O 
found O 
in O 
histology O 
in O 
4 O 
/ O 
8 O 
animals O 
in O 
the O 
FUS+ O 
DOX B-ABBREVIATION 
group O 
, O 
and O 
in O 
two O 
animals O 
, O 
only O 
a O 
few O 
tumor O 
cells O 
were O 
detected O 
. O 
Adverse O 
events O 
in O 
the O 
treatment O 
group O 
included O 
skin O 
toxicity O 
, O 
impaired O 
activity O 
, O 
damage O 
to O 
surrounding O 
brain O 
tissue O 
, O 
and O 
tissue O 
loss O 
at O 
the O 
tumor O 
site O 
. O 
In O 
one O 
animal O 
, O 
intratumoral O 
hemorrhage O 
was O 
observed O 
. O 
These O 
events O 
are O 
largely O 
consistent O 
with O 
known O 
side O 
effects O 
of O 
doxorubicin B-TRIVIAL 
and O 
with O 
an O 
extensive O 
tumor O 
burden O 
. O 
Overall O 
this O 
work O 
demonstrates O 
that O 
multiple O 
sessions O 
using O 
this O 
FUS O 
technique O 
to O 
enhance O 
the O 
delivery O 
of O 
liposomal O 
doxorubicin B-TRIVIAL 
have O 
a O 
pronounced O 
therapeutic O 
effect O 
in O 
this O 
rat O 
glioma O 
model O 
. O 

Changes O 
in O 
U.S O 
. O 
Prediabetes O 
Prevalence O 
Defined O 
by O 
Hemoglobin O 
A1c O 
and O 
Fasting O 
Plasma O 
Glucose B-TRIVIAL 
: O 
National O 
Health O 
and O 
Nutrition O 
Examination O 
Surveys O 
, O 
1999-2010 O 
. O 

a O 
nationally O 
representative O 
sample O 
of O 
the O 
civilian O 
noninstitutionalized O 
U.S O 
. O 
population O 
, O 
we O 
estimated O 
prediabetes O 
prevalence O 
and O 
its O 
changes O 
during O 
1999-2010.RESEARCH O 
DESIGN O 
AND O 
METHODSData O 
were O 
from O 
19182 O 
nonpregnant O 
individuals O 
aged O 
≥ O 
12 O 
years O 
who O 
participated O 
in O 
the O 
1999-2010 O 
National O 
Health O 
and O 
Nutrition O 
Examination O 
Surveys O 
. O 
We O 
defined O 
prediabetes O 
as O 
hemoglobin O 
A1c O 
5.7 O 
to O 
< O 
6.5% O 
( O 
39 O 
to O 
< O 
48 O 
mmol O 
/ O 
mol O 
, O 
A1C5.7 O 
) O 
or O 
fasting O 
plasma O 
glucose B-TRIVIAL 
( O 
FPG O 
) O 
100 O 
to O 
< O 
126 O 
mg O 
/ O 
dL O 
( O 
impaired O 
fasting O 
glucose B-TRIVIAL 
[ O 
IFG O 
] O 
) O 
. O 
We O 
estimated O 
the O 
prevalence O 
of O 
prediabetes O 
, O 
A1C5.7 O 
, O 
and O 
IFG O 
for O 
1999-2002 O 
, O 
2003-2006 O 
, O 
and O 
2007-2010 O 
. O 
We O 
calculated O 
estimates O 
age O 
- O 
standardized O 
to O 
the O 
2000 O 
U.S O 
. O 
census O 
population O 
and O 
used O 
logistic O 
regression O 
to O 
compute O 
estimates O 
adjusted O 
for O 
age O 
, O 
sex O 
, O 
race O 
/ O 
ethnicity O 
, O 
poverty O 
- O 
to O 
- O 
income O 
ratio O 
, O 
and O 
BMI O 
. O 
Participants O 
with O 
self O 
- O 
reported O 
diabetes O 
, O 
A1C O 
≥ O 
6.5% O 
( O 
≥ O 
48 O 
mmol O 
/ O 
mol O 
) O 
, O 
or O 
FPG O 
≥ O 
126 O 
mg O 
/ O 
dL O 
were O 
included.RESULTSAmong O 
those O 
aged O 
≥ O 
12 O 
years O 
, O 
age O 
- O 
adjusted O 
prediabetes O 
prevalence O 
increased O 
from O 
27.4% O 
( O 
95% O 
CI O 
25.1-29.7 O 
) O 
in O 
1999-2002 O 
to O 
34.1% O 
( O 
32.5-35.8 O 
) O 
in O 
2007-2010 O 
. O 
Among O 
adults O 
aged O 
≥ O 
18 O 
years O 
, O 
the O 
prevalence O 
increased O 
from O 
29.2% O 
( O 
26.8-31.8 O 
) O 
to O 
36.2% O 
( O 
34.5-38.0 O 
) O 
. O 
As O 
single O 
measures O 
among O 
individuals O 
aged O 
≥ O 
12 O 
years O 
, O 
A1C5.7 O 
prevalence O 
increased O 
from O 
9.5% O 
( O 
8.4-10.8 O 
) O 
to O 
17.8% O 
( O 
16.6-19.0 O 
) O 
, O 
a O 
relative O 
increase O 
of O 
87% O 
, O 
whereas O 
IFG O 
remained O 
stable O 
. O 
These O 
prevalence O 
changes O 
were O 
similar O 
among O 
the O 
total O 
population O 
, O 
across O 
subgroups O 
, O 
and O 
after O 
controlling O 
for O 
covariates.CONCLUSIONSDuring O 
1999-2010 O 
, O 
U.S O 
. O 
prediabetes O 
prevalence O 
increased O 
because O 
of O 
increases O 
in O 
A1C5.7 O 
. O 
Continuous O 
monitoring O 
of O 
prediabetes O 
is O 
needed O 
to O 
identify O 
, O 
quantify O 
, O 
and O 
characterize O 
the O 
population O 
of O 
high O 
- O 
risk O 
individuals O 
targeted O 
for O 
ongoing O 
diabetes O 
primary O 
prevention O 
efforts O 
. O 

sub-10 O 
nm O 
thin O 
metallic O 
films O 
, O 
very O 
little O 
knowledge O 
is O 
available O 
so O 
far O 
on O 
how O 
electron O 
scattering O 
at O 
surface O 
and O 
grain O 
boundaries O 
reduces O 
the O 
thermal O 
transport O 
. O 
This O 
work O 
reports O 
on O 
the O 
first O 
time O 
characterization O 
of O 
the O 
thermal O 
and O 
electrical O 
conductivities O 
of O 
gold O 
films O 
of O 
6.4 O 
nm O 
average O 
thickness O 
. O 
The O 
electrical O 
( O 
σ O 
) O 
and O 
thermal O 
( O 
k O 
) O 
conductivities O 
of O 
the O 
Au B-FORMULA 
film O 
are O 
found O 
to O 
be O 
reduced O 
dramatically O 
from O 
their O 
bulk O 
counterparts O 
by O 
93.7% O 
( O 
σ O 
) O 
and O 
80.5% O 
( O 
k O 
) O 
. O 
Its O 
Lorenz O 
number O 
is O 
measured O 
as O 
7.44 O 
× O 
10(-8) O 
W O 
Ω O 
K(-2) O 
, O 
almost O 
a O 
twofold O 
increase O 
from O 
the O 
bulk O 
value O 
. O 
The O 
Mayadas-Shatzkes O 
model O 
is O 
used O 
to O 
interpret O 
the O 
experimental O 
results O 
and O 
reveals O 
very O 
strong O 
electron O 
reflection O 
( O 
77% O 
) O 
at O 
grain O 
boundaries O 
. O 

relationship O 
between O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
and O 
actigraphy O 
- O 
based O 
measures O 
of O 
sleep O 
in O 
adult O 
rhesus O 
monkeys O 
. O 

: O 
Clinical O 
trials O 
show O 
that O 
chronic O 
cocaine B-TRIVIAL 
users O 
suffer O 
from O 
sleep O 
disturbances O 
and O 
preclinical O 
research O 
has O 
shown O 
that O 
acute O 
sleep O 
deprivation O 
increases O 
the O 
rate O 
of O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
in O 
rats O 
. O 
OBJECTIVE O 
: O 
This O 
study O 
examined O 
the O 
effect O 
of O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
on O 
behavioral O 
indices O 
of O 
sleep O 
and O 
alternatively O 
the O 
effect O 
of O 
sleep O 
disruption O 
on O 
cocaine B-TRIVIAL 
-maintained O 
responding O 
by O 
rhesus O 
monkeys O 
. O 
METHODS O 
: O 
Seven O 
adult O 
rhesus O 
monkeys O 
, O 
fitted O 
with O 
Actical O 
® O 
activity O 
monitors O 
, O 
were O 
trained O 
to O 
respond O 
under O 
a O 
concurrent O 
choice O 
paradigm O 
with O 
food O 
( O 
three O 
1.0-g O 
pellets O 
) O 
and O 
cocaine B-TRIVIAL 
( O 
0.003-0.3 O 
mg O 
/ O 
kg O 
) O 
or O 
saline O 
presentation O 
. O 
For O 
each O 
monkey O 
, O 
the O 
lowest O 
preferred O 
dose O 
of O 
cocaine B-TRIVIAL 
( O 
> O 
80 O 
% O 
cocaine B-TRIVIAL 
choice O 
) O 
was O 
determined O 
. O 
Activity O 
data O 
were O 
analyzed O 
during O 
lights O 
out O 
( O 
2000-0600 O 
) O 
to O 
determine O 
sleep O 
efficiency O 
, O 
sleep O 
latency O 
, O 
and O 
total O 
activity O 
counts O 
. O 
Subsequently O 
, O 
the O 
monkeys O 
' O 
sleep O 
was O 
disrupted O 
( O 
every O 
hour O 
during O 
lights O 
- O 
out O 
period O 
) O 
the O 
night O 
prior O 
to O 
food- O 
cocaine B-TRIVIAL 
choice O 
sessions O 
. O 
RESULTS O 
: O 
Self O 
- O 
administration O 
of O 
the O 
preferred O 
dose O 
of O 
cocaine B-TRIVIAL 
resulted O 
in O 
a O 
significant O 
decrease O 
in O 
sleep O 
efficiency O 
, O 
with O 
a O 
significant O 
increase O 
in O 
total O 
lights O 
- O 
out O 
activity O 
. O 
Sleep O 
disruption O 
significantly O 
altered O 
behavioral O 
indices O 
of O 
sleep O 
, O 
similar O 
to O 
those O 
seen O 
following O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
. O 
However O 
, O 
sleep O 
disruption O 
did O 
not O 
affect O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
under O 
concurrent O 
choice O 
conditions O 
. O 
CONCLUSIONS O 
: O 
Based O 
on O 
these O 
findings O 
, O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
does O 
appear O 
to O 
disrupt O 
behavioral O 
indices O 
of O 
sleep O 
, O 
although O 
it O 
remains O 
to O 
be O 
determined O 
if O 
treatments O 
that O 
improve O 
sleep O 
measures O 
can O 
affect O 
future O 
cocaine B-TRIVIAL 
taking O 
. O 

action O 
of O 
salicylideneamino-2-thiophenol B-SYSTEMATIC 
on O 
NF-κB O 
signaling O 
cascade O 
and O 
cyclooxygenase-2 O 
in O 
HNE B-ABBREVIATION 
-treated O 
endothelial O 
cells O 
. O 

the O 
present O 
study O 
, O 
the O 
anti-inflammatory O 
effect O 
of O 
salicylideneamino-2-thiophenol B-SYSTEMATIC 
( O 
SAL-2 B-SYSTEMATIC 
) O 
, O 
a O 
derivative O 
of O 
salicylate B-SYSTEMATIC 
, O 
on O 
a O 
potent O 
oxidant O 
4-hydroxynonenal B-SYSTEMATIC 
( O 
HNE B-ABBREVIATION 
)-induced O 
oxidative O 
stress O 
was O 
investigated O 
using O 
rat O 
prostate O 
endothelial O 
( O 
YPEN-1 O 
) O 
cells O 
. O 
We O 
focused O 
on O 
anti-inflammatory O 
activity O 
of O 
SAL-2 B-SYSTEMATIC 
which O 
was O 
determined O 
by O 
its O 
ability O 
to O 
suppress O 
COX-2 O 
and O 
iNOS O 
gene O 
expression O 
through O 
suppression O 
of O 
NF-κB O 
and O 
redox O 
regulation O 
. O 
We O 
found O 
that O 
SAL-2 B-SYSTEMATIC 
effectively O 
inhibited O 
HNE B-ABBREVIATION 
-induced O 
reactive O 
species O 
generation O 
, O 
while O 
upregulated O 
GSH B-ABBREVIATION 
/ O 
GSSG B-ABBREVIATION 
ratio O 
. O 
Prostagrandin O 
( B-ABBREVIATION 
PG I-ABBREVIATION 
) I-ABBREVIATION 
E2 I-ABBREVIATION 
production O 
stimulated O 
by O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
was O 
suppressed O 
by O 
SAL-2 B-SYSTEMATIC 
. O 
SAL-2 B-SYSTEMATIC 
also O 
downregulated O 
COX-2 O 
and O 
iNOS O 
expression O 
induced O 
by O 
HNE B-ABBREVIATION 
, O 
but O 
salicylate B-SYSTEMATIC 
did O 
not O 
. O 
We O 
found O 
that O 
SAL-2 B-SYSTEMATIC 
inhibited O 
HNE B-ABBREVIATION 
-mediated O 
IKK O 
phosphorylation O 
, O 
IκBα O 
degradation O 
and O 
nuclear O 
translocation O 
of O 
p65 O 
which O 
are O 
linked O 
to O 
NF-κB O 
activation O 
. O 
Furthermore O 
, O 
SAL-2 B-SYSTEMATIC 
inhibited O 
HNE B-ABBREVIATION 
-induced O 
activation O 
of O 
mitogen O 
- O 
activated O 
protein O 
kinases O 
. O 
Collectively O 
, O 
SAL-2 B-SYSTEMATIC 
inhibited O 
COX-2 O 
and O 
iNOS O 
gene O 
expression O 
through O 
suppression O 
of O 
NF-κB O 
leading O 
to O 
the O 
inhibition O 
of O 
PGE2 B-ABBREVIATION 
synthesis O 
. O 
Based O 
on O 
these O 
data O 
, O 
we O 
propose O 
that O 
with O 
its O 
combined O 
effect O 
on O 
strong O 
anti-oxidant O 
and O 
anti-inflammatory O 
action O 
, O 
SAL-2 B-SYSTEMATIC 
can O 
be O 
a O 
potent O 
anti-inflammatory O 
agent O 
for O 
treatment O 
of O 
inflammatory O 
- O 
related O 
diseases O 
. O 

part O 
of O 
our O 
ongoing O 
search O 
for O 
natural O 
sources O 
of O 
therapeutic O 
and O 
preventive O 
agents O 
for O 
diabetic O 
complications O 
, O 
we O 
evaluated O 
the O 
inhibitory O 
effects O 
of O 
components O 
of O 
the O 
fruit O 
of O 
Xanthium O 
strumarium O 
( O 
X O 
. O 
strumarium O 
) O 
on O 
aldose B-FAMILY 
reductase O 
( O 
AR O 
) O 
and O 
galactitol B-TRIVIAL 
formation O 
in O 
rat O 
lenses O 
with O 
high O 
levels O 
of O 
glucose B-TRIVIAL 
. O 
To O 
identify O 
the O 
bioactive O 
components O 
of O 
X O 
. O 
strumarium O 
, O 
7 O 
caffeoylquinic B-FAMILY 
acids I-FAMILY 
and O 
3 O 
phenolic B-FAMILY 
compounds O 
were O 
isolated O 
and O 
their O 
chemical O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
spectroscopic O 
evidence O 
and O 
comparison O 
with O 
published O 
data O 
. O 
The O 
abilities O 
of O 
10 O 
X O 
. O 
strumarium O 
- O 
derived O 
components O 
to O 
counteract O 
diabetic O 
complications O 
were O 
investigated O 
by O 
means O 
of O 
inhibitory O 
assays O 
with O 
rat O 
lens O 
AR O 
( O 
rAR O 
) O 
and O 
recombinant O 
human O 
AR O 
( O 
rhAR O 
) O 
. O 
From O 
the O 
10 O 
isolated O 
compounds O 
, O 
methyl-3,5-di-O-caffeoylquinate B-SYSTEMATIC 
showed O 
the O 
most O 
potent O 
inhibition O 
, O 
with O 
IC50 O 
values O 
of O 
0.3 O 
and O 
0.67 O 
μM O 
for O 
rAR O 
and O 
rhAR O 
, O 
respectively O 
. O 
In O 
the O 
kinetic O 
analyses O 
using O 
Lineweaver-Burk O 
plots O 
of O 
1 O 
/ O 
velocity O 
and O 
1 O 
/ O 
substrate O 
, O 
methyl-3,5-di-O-caffeoylquinate B-SYSTEMATIC 
showed O 
competitive O 
inhibition O 
of O 
rhAR O 
. O 
Furthermore O 
, O 
methyl-3,5-di-O-caffeoylquinate B-SYSTEMATIC 
inhibited O 
galactitol B-TRIVIAL 
formation O 
in O 
the O 
rat O 
lens O 
and O 
in O 
erythrocytes O 
incubated O 
with O 
a O 
high O 
concentration O 
of O 
glucose B-TRIVIAL 
, O 
indicating O 
that O 
this O 
compound O 
may O 
be O 
effective O 
in O 
preventing O 
diabetic O 
complications O 
. O 

ameliorates O 
lipopolysaccharide-induced O 
dysfunction O 
of O 
blood O 
- O 
brain O 
barrier O 
. O 

( O 
FBP B-ABBREVIATION 
) O 
, O 
a O 
glycolytic O 
intermediate O 
, O 
has O 
neuroprotective O 
effects O 
in O 
various O 
brain O 
injury O 
models O 
. O 
However O 
, O 
its O 
effects O 
on O 
blood O 
- O 
brain O 
barrier O 
( O 
BBB O 
) O 
are O 
largely O 
unknown O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
FBP B-ABBREVIATION 
on O 
lipopolysaccharide O 
(LPS)-induced O 
BBB O 
dysfunction O 
in O 
in O 
vitro O 
BBB O 
model O 
comprising O 
co O 
- O 
culture O 
of O 
mouse O 
brain O 
endothelial O 
cell O 
line O 
, O 
bEnd.3 O 
and O 
mouse O 
primary O 
astrocyte O 
and O 
explored O 
its O 
action O 
mechanism O 
therein O 
involved O 
. O 
LPS O 
induced O 
the O 
impairment O 
of O 
endothelial O 
permeability O 
and O 
transendothelial O 
electrical O 
resistance O 
( O 
TEER O 
) O 
. O 
The O 
functional O 
changes O 
were O 
confirmed O 
by O 
alterations O 
in O 
immunostaining O 
for O 
junctional O 
proteins O 
occludin O 
, O 
ZO-1 O 
and O 
VE-cadherin O 
, O 
such O 
as O 
the O 
loss O 
of O 
cortical O 
staining O 
pattern O 
and O 
appearance O 
of O 
intercellular O 
gaps O 
in O 
endothelial O 
cells O 
. O 
Co-administration O 
of O 
FBP B-ABBREVIATION 
alleviated O 
the O 
deleterious O 
effects O 
of O 
LPS O 
on O 
BBB O 
permeability O 
and O 
TEER O 
in O 
a O 
dose O 
dependent O 
manner O 
. O 
And O 
also O 
FBP B-ABBREVIATION 
inhibited O 
the O 
LPS-induced O 
changes O 
in O 
the O 
distribution O 
of O 
endothelial O 
junctional O 
proteins O 
, O 
resulting O 
in O 
the O 
better O 
preservation O 
of O 
monolayer O 
integrity O 
. O 
FBP B-ABBREVIATION 
suppressed O 
the O 
production O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
but O 
did O 
not O 
affect O 
cyclooxygenase-2 O 
expression O 
and O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
production O 
in O 
endothelial O 
cells O 
stimulated O 
with O 
LPS O 
. O 
Taken O 
together O 
, O 
these O 
data O 
suggest O 
that O 
FBP B-ABBREVIATION 
could O 
ameliorate O 
LPS-induced O 
BBB O 
dysfunction O 
through O 
the O 
maintenance O 
of O 
junctional O 
integrity O 
, O 
which O 
might O 
be O 
mediated O 
by O 
downregulation O 
of O 
ROS O 
production O 
. O 

regulation O 
of O 
epidermal O 
melanogenesis O 
via O 
cAMP B-ABBREVIATION 
and O 
/ O 
or O 
PKC O 
signaling O 
pathways O 
: O 
insights O 
for O 
the O 
development O 
of O 
hypopigmenting O 
agents O 
. O 

pigmentation O 
, O 
particularly O 
hyperpigmentation O 
, O 
is O 
major O 
issue O 
of O 
concern O 
for O 
people O 
with O 
colored O 
skin O 
. O 
Several O 
hypopigmenting O 
agents O 
, O 
which O 
exert O 
their O 
action O 
by O 
inhibiting O 
tyrosinase O 
activity O 
and O 
/ O 
or O 
transcription O 
, O 
have O 
been O 
used O 
for O 
treatment O 
. O 
However O 
, O 
results O 
have O 
been O 
discouraging O 
. O 
To O 
manage O 
abnormal O 
pigmentation O 
properly O 
, O 
the O 
mechanisms O 
of O 
melanogenesis O 
should O 
be O 
understood O 
. O 
Endogenous O 
and O 
exogenous O 
factors O 
affect O 
melanogenesis O 
via O 
intracellular O 
machineries O 
. O 
cAMP B-ABBREVIATION 
and O 
PKC O 
are O 
critical O 
factors O 
of O 
important O 
transduction O 
pathways O 
and O 
cross O 
- O 
talk O 
between O 
them O 
could O 
amplify O 
the O 
melanogenic O 
effect O 
. O 
Here O 
, O 
factors O 
involved O 
in O 
melanogenesis O 
regulation O 
via O 
cAMP B-ABBREVIATION 
and O 
/ O 
or O 
PKC O 
pathways O 
are O 
reviewed O 
with O 
their O 
action O 
mechanisms O 
. O 

biloba O 
extract O 
EGb761 O 
is O 
widely O 
used O 
to O 
treat O 
patients O 
with O 
learning O 
and O 
memory O 
impairment O 
in O 
Alzheimer's O 
disease O 
and O 
Parkinson's O 
disease O 
in O 
China O 
. O 
However O 
, O 
it O 
is O 
not O 
yet O 
clear O 
whether O 
the O 
analog O 
of O 
EGb761 O 
( O 
EGb O 
) O 
has O 
a O 
protective O 
effect O 
on O 
the O 
learning O 
and O 
memory O 
damage O 
induced O 
by O 
chronic O 
fluorosis O 
. O 
In O 
this O 
study O 
, O 
30 O 
Wistar O 
rats O 
were O 
randomly O 
divided O 
into O 
three O 
groups O 
: O 
a O 
control O 
group O 
, O 
a O 
sodium B-SYSTEMATIC 
fluoride I-SYSTEMATIC 
( O 
NaF B-FORMULA 
) O 
+ O 
EGb O 
group O 
, O 
and O 
a O 
NaF B-FORMULA 
group O 
. O 
The O 
rats O 
were O 
administered O 
0.5 O 
ml O 
water O 
containing O 
NaF B-FORMULA 
( O 
100 O 
mg O 
/ O 
l O 
) O 
and O 
EGb O 
( O 
120 O 
mg O 
/ O 
kg O 
) O 
per O 
day O 
via O 
gavage O 
. O 
After O 
3 O 
months O 
, O 
the O 
rats O 
' O 
capacity O 
for O 
learning O 
and O 
memory O 
was O 
tested O 
using O 
a O 
Y-maze O 
. O 
Damage O 
to O 
hippocampal O 
neurons O 
was O 
evaluated O 
by O 
histological O 
examination O 
of O 
the O 
CA3 O 
area O 
. O 
Superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
activity O 
and O 
the O 
levels O 
of O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GSH B-ABBREVIATION 
-Px O 
) O 
and O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
were O 
measured O 
. O 
Furthermore O 
, O 
the O 
expression O 
levels O 
of O 
Bcl-2 O 
and O 
Bax O 
and O 
the O 
levels O 
of O 
cleaved O 
Caspase3 O 
in O 
the O 
hippocampus O 
were O 
evaluated O 
by O 
RT-PCR O 
and O 
Western O 
blotting O 
. O 
The O 
results O 
showed O 
that O 
EGb O 
could O 
improve O 
learning O 
and O 
memory O 
abilities O 
, O 
enhance O 
the O 
activities O 
of O 
SOD O 
and O 
GSH B-ABBREVIATION 
-Px O 
, O 
attenuate O 
the O 
level O 
of O 
MDA O 
, O 
upregulate O 
the O 
ratio O 
of O 
Bcl-2 O 
/ O 
Bax O 
, O 
and O 
downregulate O 
the O 
level O 
of O 
cleaved O 
Caspase3 O 
. O 

of O 
High O 
Iron B-SYSTEMATIC 
and O 
Glucose B-TRIVIAL 
Concentrations O 
over O 
the O 
Relative O 
Expression O 
of O 
Bcl2 O 
, O 
Bax O 
, O 
and O 
Mfn2 O 
in O 
MIN6 O 
Cells O 
. O 

2 O 
diabetes O 
is O 
characterized O 
by O 
hyperglycemia O 
and O 
oxidative O 
stress O 
. O 
Hyperglycemia O 
is O 
linked O 
to O 
mitochondrial O 
dysfunction O 
and O 
reduced O 
β-cell O 
mass O 
due O 
to O 
the O 
reduced O 
expression O 
of O 
genes O 
such O 
as O 
Mfn2 O 
as O 
well O 
as O 
the O 
participation O 
of O 
the O 
Bcl2 O 
gene O 
family O 
, O 
responsible O 
for O 
increased O 
apoptosis O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
describe O 
the O 
effect O 
of O 
different O 
iron B-SYSTEMATIC 
and O 
/ O 
or O 
glucose B-TRIVIAL 
concentrations O 
over O 
Mfn2 O 
, O 
Bax O 
, O 
and O 
Bcl2 O 
expressions O 
in O 
a O 
β-pancreatic O 
cell O 
line O 
( O 
MIN6 O 
cells O 
) O 
. O 
MIN6 O 
cells O 
were O 
pre O 
- O 
incubated O 
with O 
different O 
iron B-SYSTEMATIC 
and O 
/ O 
or O 
glucose B-TRIVIAL 
concentrations O 
, O 
and O 
the O 
relative O 
mRNA O 
abundance O 
of O 
the O 
Bcl2 O 
/ O 
Bax O 
ratio O 
and O 
of O 
Mfn2 O 
genes O 
was O 
measured O 
by O 
qRT-PCR O 
. O 
Heme O 
oxygenase O 
( O 
HO O 
) O 
activity O 
, O 
iron B-SYSTEMATIC 
uptake O 
, O 
superoxide B-TRIVIAL 
dismutase O 
activity O 
, O 
and O 
glutathione B-TRIVIAL 
content O 
were O 
also O 
determined O 
. O 
The O 
Bcl2 O 
/ O 
Bax O 
ratio O 
increased O 
and O 
Mfn2 O 
expression O 
decreased O 
in O 
MIN6 O 
cells O 
after O 
glucose B-TRIVIAL 
stimulation O 
. O 
These O 
effects O 
were O 
higher O 
when O 
glucose B-TRIVIAL 
and O 
iron B-SYSTEMATIC 
were O 
incubated O 
together O 
. O 
Additionally O 
, O 
treatment O 
with O 
glucose B-TRIVIAL 
/ O 
iron B-SYSTEMATIC 
showed O 
a O 
higher O 
HO O 
activity O 
. O 
Our O 
study O 
revealed O 
that O 
high O 
glucose B-TRIVIAL 
/ O 
Fe B-FORMULA 
concentrations O 
in O 
MIN6 O 
cells O 
induced O 
an O 
increase O 
of O 
the O 
Bcl2 O 
/ O 
Bax O 
ratio O 
, O 
an O 
indicator O 
of O 
increased O 
cell O 
apoptosis O 
. O 

: O 
first O 
global O 
approval O 
. O 

( O 
Osphena B-TRIVIAL 
™ O 
) O 
is O 
an O 
oral O 
selective O 
estrogen B-FAMILY 
receptor O 
modulator O 
( O 
SERM O 
) O 
, O 
with O 
tissue O 
- O 
specific O 
estrogenic O 
agonist O 
/ O 
antagonist O 
effects O 
. O 
QuatRx O 
Pharmaceuticals O 
conducted O 
the O 
global O 
development O 
of O 
the O 
agent O 
before O 
licensing O 
it O 
to O 
Shionogi O 
for O 
regulatory O 
filing O 
and O 
commercialization O 
worldwide O 
. O 
Ospemifene B-TRIVIAL 
is O 
the O 
first O 
non- O 
estrogen B-FAMILY 
treatment O 
approved O 
for O 
moderate O 
to O 
severe O 
dyspareunia O 
in O 
women O 
with O 
menopause O 
- O 
related O 
vulvar O 
and O 
vaginal O 
atrophy O 
. O 
The O 
drug O 
is O 
approved O 
in O 
the O 
USA O 
, O 
and O 
application O 
for O 
EU O 
regulatory O 
approval O 
is O 
underway O 
. O 
This O 
article O 
summarizes O 
the O 
milestones O 
in O 
the O 
development O 
of O 
ospemifene B-TRIVIAL 
leading O 
to O 
this O 
first O 
approval O 
for O 
moderate O 
to O 
severe O 
dyspareunia O 
, O 
a O 
symptom O 
of O 
postmenopausal O 
vulvar O 
and O 
vaginal O 
atrophy O 
. O 

: O 
A O 
Review O 
of O 
Its O 
Use O 
in O 
Cushing's O 
Disease O 
. O 

( O 
Signifor B-TRIVIAL 
( O 
® O 
) O 
) O 
is O 
a O 
new O 
subcutaneous O 
somatostatin B-TRIVIAL 
analogue O 
that O 
acts O 
via O 
somatostatin B-TRIVIAL 
receptors O 
to O 
inhibit O 
the O 
secretion O 
of O 
corticotropin O 
from O 
the O 
pituitary O 
adenoma O 
in O 
patients O 
with O 
Cushing's O 
disease O 
. O 
Pasireotide B-TRIVIAL 
has O 
a O 
receptor O 
binding O 
profile O 
that O 
is O 
distinct O 
from O 
that O 
of O 
other O 
somatostatin B-TRIVIAL 
analogues O 
, O 
binding O 
with O 
high O 
affinity O 
to O 
somatostatin B-TRIVIAL 
receptor O 
subtype O 
5 O 
, O 
which O 
is O 
strongly O 
over O 
expressed O 
in O 
corticotroph O 
adenoma O 
cells O 
. O 
Pasireotide B-TRIVIAL 
is O 
the O 
first O 
pituitary O 
- O 
directed O 
agent O 
to O 
be O 
approved O 
for O 
use O 
in O 
Cushing's O 
disease O 
. O 
In O 
a O 
phase O 
III O 
clinical O 
trial O 
in O 
patients O 
with O 
Cushing's O 
disease O 
, O 
twice O 
- O 
daily O 
pasireotide B-TRIVIAL 
600 O 
or O 
900 O 
μg O 
for O 
6 O 
months O 
led O 
to O 
normalization O 
of O 
urinary O 
free O 
cortisol B-TRIVIAL 
( O 
UFC O 
) O 
levels O 
in O 
up O 
to O 
a O 
quarter O 
of O 
all O 
patients O 
( O 
primary O 
endpoint O 
) O 
and O 
significantly O 
reduced O 
mean O 
UFC O 
levels O 
. O 
The O 
reduction O 
in O 
UFC O 
levels O 
is O 
rapid O 
( O 
within O 
one O 
to O 
two O 
months O 
) O 
and O 
sustained O 
( O 
up O 
to O 
24 O 
months O 
) O 
. O 
Most O 
patients O 
who O 
do O 
not O 
have O 
an O 
early O 
response O 
to O 
pasireotide B-TRIVIAL 
do O 
not O 
respond O 
at O 
a O 
later O 
time O 
point O 
. O 
Decreases O 
in O 
UFC O 
levels O 
achieved O 
during O 
pasireotide B-TRIVIAL 
treatment O 
are O 
accompanied O 
by O 
decreases O 
in O 
serum O 
and O 
salivary O 
cortisol B-TRIVIAL 
levels O 
, O 
as O 
well O 
as O 
improvements O 
in O 
clinical O 
signs O 
and O 
symptoms O 
, O 
including O 
body O 
weight O 
, O 
blood O 
pressure O 
and O 
health O 
- O 
related O 
quality O 
- O 
of O 
- O 
life O 
. O 
Pasireotide B-TRIVIAL 
has O 
a O 
generally O 
similar O 
tolerability O 
profile O 
to O 
that O 
of O 
other O 
somatostatin B-TRIVIAL 
analogues O 
, O 
but O 
is O 
associated O 
with O 
a O 
relatively O 
high O 
incidence O 
of O 
hyperglycaemia O 
, O 
requiring O 
the O 
addition O 
or O 
intensification O 
of O 
glucose B-TRIVIAL 
-lowering O 
medication O 
in O 
a O 
substantial O 
proportion O 
of O 
patients O 
. O 
Thus O 
, O 
pasireotide B-TRIVIAL 
, O 
together O 
with O 
on O 
- O 
going O 
patient O 
monitoring O 
, O 
provides O 
a O 
promising O 
new O 
option O 
for O 
the O 
medical O 
management O 
of O 
Cushing's O 
disease O 
. O 

Derivatives O 
of O 
L-Idonojirimycin B-TRIVIAL 
as O 
Pharmacological O 
Chaperones O 
for O 
Neuronopathic O 
Forms O 
of O 
Gaucher O 
Disease O 
. O 

human O 
β-glucocerebrosidase O 
( O 
GCase O 
) O 
ligands O 
with O 
rigid O 
1,6-anhydro-β-L-idonojirimycin B-SYSTEMATIC 
cores O 
have O 
been O 
designed O 
with O 
the O 
aid O 
of O 
molecular O 
modeling O 
. O 
Efficient O 
pharmacological O 
chaperones O 
for O 
the O 
L444P O 
( O 
trafficking O 
- O 
incompetent O 
) O 
mutant O 
GCase O 
enzyme O 
associated O 
with O 
type O 
2 O 
and O 
3 O 
Gaucher O 
disease O 
( O 
GD O 
) O 
were O 
identified O 
. O 

identification O 
of O 
the O 
candidate O 
target O 
proteins O 
of O 
15-deoxy-delta(12,14) B-SYSTEMATIC 
-prostaglandin I-SYSTEMATIC 
J2 I-SYSTEMATIC 
. O 

J2 I-SYSTEMATIC 
( O 
15d-PGJ2 B-SYSTEMATIC 
) O 
is O 
an O 
endogenous O 
anti-inflammatory O 
lipid O 
derived O 
from O 
PGD2 B-ABBREVIATION 
. O 
One O 
potential O 
mechanism O 
for O 
its O 
activity O 
is O 
the O 
covalent O 
modification O 
of O 
cellular O 
proteins O 
, O 
via O 
a O 
reactive O 
α,β- B-FAMILY 
unsaturated I-FAMILY 
carbonyl I-FAMILY 
group O 
in O 
its O 
cyclopentenone B-SYSTEMATIC 
ring O 
, O 
which O 
in O 
turn O 
alters O 
protein O 
function O 
. O 
In O 
order O 
to O 
identify O 
the O 
candidate O 
target O 
proteins O 
covalently O 
modified O 
by O 
15d-PGJ2 B-SYSTEMATIC 
in O 
human O 
aortic O 
endothelial O 
cell O 
( O 
EC O 
) O 
, O 
EC O 
were O 
treated O 
with O 
biotinylated-15d-PGJ2 B-SYSTEMATIC 
, O 
the O 
modified O 
proteins O 
extracted O 
by O 
Neutravidin O 
affinity O 
- O 
purification O 
and O 
the O 
proteins O 
identified O 
by O 
LTQ O 
Orbitrap O 
mass O 
spectrometer O 
. O 
Classification O 
of O 
the O 
358 O 
identified O 
proteins O 
was O 
performed O 
using O 
PANTHER O 
classification O 
system O 
( O 
www.pantherdb.org O 
) O 
, O 
showing O 
that O 
the O 
proteins O 
mapped O 
to O 
metabolic O 
process O 
, O 
cellular O 
process O 
and O 
transport O 
activity O 
. O 
This O 
protein O 
data O 
set O 
highlights O 
the O 
potential O 
for O 
15d-PGJ2 B-SYSTEMATIC 
to O 
covalently O 
modify O 
cellular O 
proteins O 
and O 
provides O 
a O 
source O 
of O 
data O 
that O 
will O 
aid O 
further O 
studies O 
on O 
the O 
mechanism O 
of O 
action O 
of O 
this O 
endogenous O 
regulator O 
of O 
inflammation O 
. O 
This O 
article O 
is O 
protected O 
by O 
copyright O 
. O 
All O 
rights O 
reserved O 
. O 

Renal O 
Dysfunction O 
with O 
Colistin B-FAMILY 
Pharmacotherapy O 
. O 

OBJECTIVE O 
: O 
To O 
evaluate O 
the O 
association O 
between O 
the O 
administration O 
of O 
intravenous O 
(IV) O 
colistin B-FAMILY 
and O 
the O 
emergence O 
of O 
renal O 
dysfunction O 
. O 
DESIGN O 
: O 
A O 
retrospective O 
medical O 
record O 
review O 
. O 
SETTING O 
: O 
A O 
tertiary O 
care O 
academic O 
medical O 
center O 
. O 
PATIENTS O 
: O 
A O 
total O 
of O 
174 O 
critically O 
ill O 
patients O 
who O 
received O 
at O 
least O 
one O 
dose O 
of O 
IV O 
colistin B-FAMILY 
between O 
2004 O 
and O 
2007 O 
. O 
MEASUREMENTS O 
AND O 
MAIN O 
RESULTS O 
: O 
The O 
primary O 
outcome O 
was O 
development O 
of O 
renal O 
dysfunction O 
, O 
defined O 
as O 
an O 
increase O 
in O 
serum O 
creatinine B-TRIVIAL 
of O 
50% O 
or O 
more O 
during O 
therapy O 
or O 
the O 
initiation O 
of O 
renal O 
replacement O 
therapy O 
( O 
RRT O 
) O 
, O 
in O 
patients O 
who O 
received O 
at O 
least O 
one O 
dose O 
of O 
colistin B-FAMILY 
and O 
were O 
not O 
already O 
on O 
RRT O 
. O 
The O 
severity O 
of O 
renal O 
dysfunction O 
was O 
further O 
categorized O 
by O 
the O 
RIFLE O 
criteria O 
. O 
Demographic O 
and O 
clinical O 
characteristics O 
were O 
analyzed O 
by O 
logistic O 
regression O 
for O 
association O 
with O 
new O 
renal O 
dysfunction O 
. O 
A O 
total O 
of O 
174 O 
patients O 
were O 
evaluated O 
for O 
renal O 
dysfunction O 
. O 
Of O 
these O 
patients O 
, O 
84 O 
( O 
48% O 
) O 
experienced O 
renal O 
dysfunction O 
on O 
colistin B-FAMILY 
. O 
On O 
multivariate O 
analysis O 
, O 
age O 
in O 
years O 
( O 
odds O 
ratio O 
[ O 
OR O 
] O 
1.03 O 
, O 
95% O 
confidence O 
interval O 
[ O 
CI O 
] O 
1.01-1.05 O 
) O 
and O 
receipt O 
of O 
concurrent O 
nephrotoxin(s) O 
( O 
OR O 
3.35 O 
, O 
95% O 
CI O 
1.34-8.36 O 
) O 
significantly O 
increased O 
the O 
risk O 
of O 
developing O 
renal O 
dysfunction O 
. O 
CONCLUSION O 
: O 
In O 
this O 
critically O 
ill O 
population O 
, O 
renal O 
dysfunction O 
occurred O 
frequently O 
and O 
was O 
associated O 
with O 
older O 
age O 
and O 
receipt O 
of O 
nephrotoxins O 
. O 

play O 
a O 
fundamental O 
role O 
in O 
thrombus O 
formation O 
and O 
in O 
the O 
pathogenesis O 
of O 
arterial O 
thrombosis O 
. O 
Patterning O 
surfaces O 
for O 
controlled O 
platelet O 
adhesion O 
paves O 
the O 
way O 
for O 
adhesion O 
and O 
activation O 
mechanisms O 
in O 
platelets O 
and O 
detection O 
of O 
platelet O 
functional O 
defects O 
. O 
Here O 
, O 
a O 
new O 
and O 
simple O 
method O 
based O 
on O 
controlled O 
polymerization O 
of O 
2-methacryloyloxyethyl B-SYSTEMATIC 
phosphorylcholine I-SYSTEMATIC 
( O 
MPC B-ABBREVIATION 
) O 
on O 
the O 
surface O 
of O 
styrene-block-(ethylene-co-butylene)-block B-FAMILY 
- I-FAMILY 
styrene I-FAMILY 
( O 
SEBS B-ABBREVIATION 
) O 
is O 
shown O 
. O 
The O 
competition O 
between O 
polymerization O 
and O 
degradation O 
enables O 
platelet O 
adhesion O 
on O 
SEBS B-ABBREVIATION 
to O 
be O 
switched O 
on O 
and O 
off O 
. O 
The O 
adhesive O 
sites O 
of O 
the O 
platelets O 
can O 
be O 
down O 
to O 
single O 
cell O 
level O 
, O 
and O 
the O 
dysfunctional O 
platelets O 
can O 
be O 
quantitatively O 
detected O 
. O 

and O 
Electrical O 
Transport O 
in O 
Ultralow O 
Density O 
Single-Walled O 
Carbon B-SYSTEMATIC 
Nanotube O 
Networks O 
. O 

thermal O 
, O 
electrical O 
, O 
and O 
thermoelectric O 
properties O 
of O 
aerogels O 
of O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
are O 
characterized O 
. O 
Their O 
ultralow O 
density O 
enables O 
the O 
transport O 
properties O 
of O 
the O 
junctions O 
to O 
be O 
distinguished O 
from O 
those O 
of O 
the O 
nanotubes O 
themselves O 
. O 
Junction O 
thermal O 
and O 
electrical O 
conductances O 
are O 
found O 
to O 
be O 
orders O 
of O 
magnitude O 
larger O 
than O 
those O 
found O 
in O 
typical O 
dense O 
SWCNT O 
networks O 
. O 
In O 
particular O 
, O 
the O 
average O 
junction O 
thermal O 
conductance O 
is O 
close O 
to O 
the O 
theoretical O 
maximum O 
for O 
a O 
van O 
der O 
Waals O 
bonded O 
SWCNT O 
junction O 
. O 

Dual O 
Enzyme O 
Microgel O 
with O 
High O 
Antioxidant O 
Ability O 
Based O 
on O 
Engineered O 
Seleno-Ferritin O 
and O 
Artificial O 
Superoxide B-TRIVIAL 
Dismutase O 
. O 

antioxidant O 
microgel O 
with O 
both O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
and O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
activities O 
is O 
reported O 
. O 
Using O 
computational O 
design O 
and O 
genetic O 
engineering O 
methods O 
, O 
the O 
main O 
catalytic O 
components O 
of O 
GPx O 
are O 
fabricated O 
onto O 
the O 
surface O 
of O 
ferritin O 
. O 
The O 
resulting O 
seleno O 
- O 
ferritin O 
( O 
Se B-FORMULA 
-Fn O 
) O 
monomers O 
can O 
self O 
- O 
assemble O 
into O 
nanocomposites O 
that O 
exhibit O 
remarkable O 
GPx O 
activity O 
due O 
to O 
the O 
well O 
organized O 
multi-GPx O 
catalytic O 
centers O 
. O 
Subsequently O 
, O 
a O 
porphyrin B-FAMILY 
derivative O 
is O 
synthesized O 
as O 
an O 
SOD O 
mimic O 
, O 
and O 
is O 
employed O 
to O 
construct O 
a O 
synergistic O 
dual O 
enzyme O 
system O 
by O 
crosslinking O 
Se B-FORMULA 
-Fn O 
nanocomposites O 
into O 
a O 
microgel O 
. O 
Significantly O 
, O 
this O 
dual O 
enzyme O 
microgel O 
is O 
demonstrated O 
to O 
display O 
better O 
antioxidant O 
ability O 
than O 
single O 
GPx O 
or O 
SOD O 
mimics O 
in O 
protecting O 
cells O 
from O 
oxidative O 
damage O 
. O 

Model O 
- O 
Based O 
Approach O 
to O 
Predict O 
Longitudinal O 
HbA1c O 
, O 
Using O 
Early O 
Phase O 
Glucose B-TRIVIAL 
Data O 
From O 
Type O 
2 O 
Diabetes O 
Mellitus O 
Patients O 
After O 
Anti-Diabetic O 
Treatment O 
. O 

late O 
phase O 
outcomes O 
from O 
early O 
- O 
phase O 
findings O 
can O 
help O 
inform O 
decisions O 
in O 
drug O 
development O 
. O 
If O 
the O 
measurements O 
in O 
early O 
- O 
phase O 
differ O 
from O 
those O 
in O 
late O 
phase O 
, O 
forecasting O 
is O 
more O 
challenging O 
. O 
In O 
this O 
paper O 
, O 
we O 
present O 
a O 
model O 
- O 
based O 
approach O 
for O 
predicting O 
glycosylated O 
hemoglobin O 
( O 
HbA1c O 
) O 
in O 
late O 
phase O 
using O 
glucose B-TRIVIAL 
and O 
insulin O 
concentrations O 
from O 
an O 
early O 
- O 
phase O 
study O 
, O 
investigating O 
an O 
anti-diabetic O 
treatment O 
. O 
Two O 
previously O 
published O 
models O 
were O 
used O 
; O 
an O 
integrated O 
glucose B-TRIVIAL 
and O 
insulin O 
( O 
IGI O 
) O 
model O 
for O 
meal O 
tolerance O 
tests O 
and O 
an O 
integrated O 
glucose B-TRIVIAL 
-red O 
blood O 
cell-HbA1c O 
( O 
IGRH O 
) O 
model O 
predicting O 
the O 
formation O 
of O 
HbA1c O 
from O 
the O 
average O 
glucose B-TRIVIAL 
concentration O 
( O 
Cg,av O 
) O 
. O 
Output O 
from O 
the O 
IGI O 
model O 
was O 
used O 
as O 
input O 
to O 
the O 
IGRH O 
model O 
. O 
Parameters O 
of O 
the O 
IGI O 
model O 
and O 
drug O 
effects O 
were O 
estimated O 
using O 
data O 
from O 
a O 
phase1 O 
study O 
in O 
59 O 
diabetic O 
patients O 
receiving O 
various O 
doses O 
of O 
a O 
glucokinase O 
activator O 
. O 
Cg,av O 
values O 
were O 
simulated O 
according O 
to O 
a O 
Phase O 
2 O 
study O 
design O 
and O 
used O 
in O 
the O 
IGRH O 
model O 
for O 
predictions O 
of O 
HbA1c O 
. O 
The O 
performance O 
of O 
the O 
model O 
- O 
based O 
approach O 
was O 
assessed O 
by O 
comparing O 
the O 
predicted O 
to O 
the O 
actual O 
outcome O 
of O 
the O 
Phase O 
2 O 
study O 
. O 
We O 
have O 
shown O 
that O 
this O 
approach O 
well O 
predicts O 
the O 
longitudinal O 
HbA1c O 
response O 
in O 
a O 
12-week O 
study O 
using O 
only O 
information O 
from O 
a O 
1-week O 
study O 
where O 
glucose B-TRIVIAL 
and O 
insulin O 
concentrations O 
were O 
measured O 
. O 

, O 
Biocompatible O 
Electronics O 
and O 
Energy O 
Harvesters O 
Based O 
on O 
ZnO B-FORMULA 
. O 

combined O 
use O 
of O 
ZnO B-FORMULA 
, O 
Mg B-FORMULA 
, O 
MgO B-FORMULA 
, O 
and O 
silk O 
provides O 
routes O 
to O 
classes O 
of O 
thin O 
- O 
film O 
transistors O 
and O 
mechanical O 
energy O 
harvesters O 
that O 
are O 
soluble O 
in O 
water O 
and O 
biofluids O 
. O 
Experimental O 
and O 
theoretical O 
studies O 
of O 
the O 
operational O 
aspects O 
and O 
dissolution O 
properties O 
of O 
this O 
type O 
of O 
transient O 
electronics O 
technology O 
illustrate O 
its O 
various O 
capabilities O 
. O 
Application O 
opportunities O 
range O 
from O 
resorbable O 
biomedical O 
implants O 
, O 
to O 
environmentally O 
dissolvable O 
sensors O 
, O 
and O 
degradable O 
consumer O 
electronics O 
. O 

Surface O 
Receptor O 
Targeted O 
Biomimetic O 
Apatite B-FAMILY 
Nanocrystals O 
for O 
Cancer O 
Therapy O 
. O 

drug O 
carriers O 
functionalized O 
with O 
moieties O 
specifically O 
targeting O 
tumor O 
cells O 
are O 
promising O 
tools O 
in O 
cancer O 
therapy O 
, O 
due O 
to O 
their O 
ability O 
to O 
circulate O 
in O 
the O 
bloodstream O 
for O 
longer O 
periods O 
and O 
their O 
selectivity O 
for O 
tumor O 
cells O 
, O 
enabling O 
the O 
sparing O 
of O 
healthy O 
tissues O 
. O 
Because O 
of O 
its O 
biocompatibility O 
, O 
high O 
bioresorbability O 
, O 
and O 
responsiveness O 
to O 
pH O 
changes O 
, O 
synthetic O 
biomimetic O 
nanocrystalline O 
apatites B-FAMILY 
are O 
used O 
as O 
nanocarriers O 
to O 
produce O 
multifunctional O 
nanoparticles O 
, O 
by O 
coupling O 
them O 
with O 
the O 
chemotherapeutic O 
drug O 
doxorubicin B-TRIVIAL 
( O 
DOXO B-ABBREVIATION 
) O 
and O 
the O 
DO-24 O 
monoclonal O 
antibody O 
( O 
mAb O 
) O 
directed O 
against O 
the O 
Met O 
/ O 
Hepatocyte O 
Growth O 
Factor O 
receptor O 
( O 
Met O 
/ O 
HGFR O 
) O 
, O 
which O 
is O 
over O 
- O 
expressed O 
on O 
different O 
types O 
of O 
carcinomas O 
and O 
thus O 
represents O 
a O 
useful O 
tumor O 
target O 
. O 
The O 
chemical O 
- O 
physical O 
features O 
of O 
the O 
nanoparticles O 
are O 
fully O 
investigated O 
and O 
their O 
interaction O 
with O 
cells O 
expressing O 
( O 
GTL-16 O 
gastric O 
carcinoma O 
line O 
) O 
or O 
not O 
expressing O 
( O 
NIH-3T3 O 
fibroblasts O 
) O 
the O 
Met O 
/ O 
HGFR O 
is O 
analyzed O 
. O 
Functionalized O 
nanoparticles O 
specifically O 
bind O 
to O 
and O 
are O 
internalized O 
in O 
cells O 
expressing O 
the O 
receptor O 
( O 
GTL-16 O 
) O 
but O 
not O 
in O 
the O 
ones O 
that O 
do O 
not O 
express O 
it O 
( O 
NIH-3T3 O 
) O 
. O 
Moreover O 
they O 
discharge O 
DOXO B-ABBREVIATION 
in O 
the O 
targeted O 
GTL-16 O 
cells O 
that O 
reach O 
the O 
nucleus O 
and O 
display O 
cytotoxicity O 
as O 
assessed O 
in O 
an O 
MTT B-ABBREVIATION 
assay O 
. O 
Two O 
different O 
types O 
of O 
ternary O 
nanoparticles O 
are O 
prepared O 
, O 
differing O 
for O 
the O 
sequence O 
of O 
the O 
functionalization O 
steps O 
( O 
adsorption O 
of O 
DOXO B-ABBREVIATION 
first O 
and O 
then O 
mAb O 
or O 
vice O 
versa O 
) O 
, O 
and O 
it O 
is O 
found O 
that O 
the O 
ones O 
in O 
which O 
mAb O 
is O 
adsorbed O 
first O 
are O 
more O 
efficient O 
under O 
all O 
the O 
examined O 
aspects O 
( O 
binding O 
, O 
internalization O 
, O 
cytotoxicity O 
) O 
, O 
possibly O 
because O 
of O 
a O 
better O 
mAb O 
orientation O 
on O 
the O 
nanoparticle O 
surface O 
. O 
These O 
multifunctional O 
nanoparticles O 
could O 
thus O 
be O 
useful O 
instruments O 
for O 
targeted O 
local O 
or O 
systemic O 
drug O 
delivery O 
, O 
allowing O 
a O 
reduction O 
in O 
the O 
therapeutic O 
dose O 
of O 
the O 
drug O 
and O 
thus O 
adverse O 
side O 
effects O 
. O 
Moreover O 
, O 
this O 
work O 
opens O 
new O 
perspectives O 
in O 
the O 
use O 
of O 
nanocrystalline O 
apatites B-FAMILY 
as O 
a O 
new O 
platform O 
for O 
theranostic O 
applications O 
in O 
nanomedicine O 
. O 

Preparation O 
of O 
Ordered O 
Porous O 
Graphene B-TRIVIAL 
- O 
Metal B-FAMILY 
Oxide I-FAMILY 
@C O 
Binder-Free O 
Electrodes O 
with O 
High O 
Li B-FORMULA 
Storage O 
Performance O 
. O 

facile O 
and O 
general O 
method O 
is O 
reported O 
to O 
prepare O 
ordered O 
porous O 
graphene B-TRIVIAL 
-based O 
binder O 
- O 
free O 
electrodes O 
on O 
a O 
large O 
scale O 
. O 
This O 
preparation O 
process O 
allows O 
the O 
easy O 
adjustment O 
of O 
the O 
selected O 
components O 
, O 
weight O 
ratio O 
of O 
componets O 
, O 
and O 
the O 
thickness O 
of O 
the O 
electrodes O 
. O 
Such O 
ordered O 
porous O 
electrodes O 
demonstrate O 
superior O 
Li B-FORMULA 
storage O 
properties O 
; O 
for O 
example O 
, O 
graphene B-TRIVIAL 
- O 
Fe3 B-FORMULA 
O4 I-FORMULA 
@C O 
depicts O 
high O 
capacities O 
of O 
1123.8 O 
and O 
505 O 
mAh O 
g(-1) O 
at O 
current O 
densities O 
of O 
0.5 O 
and O 
10 O 
A O 
g(-1) O 
, O 
respectively O 
. O 

report O 
on O 
a O 
novel O 
experimental O 
study O 
of O 
a O 
pH-responsive O 
polyelectrolyte O 
brush O 
at O 
the O 
silicon B-SYSTEMATIC 
/ O 
D2O B-FORMULA 
interface O 
. O 
A O 
poly[2-(diethylamino)ethyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
] I-SYSTEMATIC 
brush O 
was O 
grown O 
on O 
a O 
large O 
silicon B-SYSTEMATIC 
crystal O 
which O 
acted O 
as O 
both O 
a O 
substrate O 
for O 
a O 
neutron O 
reflectivity O 
solid O 
/ O 
liquid O 
experiment O 
but O 
also O 
as O 
an O 
FTIR-ATR O 
spectroscopy O 
crystal O 
. O 
This O 
arrangement O 
has O 
allowed O 
for O 
both O 
neutron O 
reflectivities O 
and O 
FTIR O 
spectroscopic O 
information O 
to O 
be O 
measured O 
in O 
parallel O 
. O 
The O 
chosen O 
polybase O 
brush O 
shows O 
strong O 
IR O 
bands O 
which O 
can O 
be O 
assigned O 
to O 
the O 
N-D(+) O 
stretch O 
, O 
D2O B-FORMULA 
, O 
and O 
a O 
carbonyl B-FAMILY 
group O 
. O 
From O 
such O 
FTIR O 
data O 
, O 
we O 
are O 
able O 
to O 
closely O 
monitor O 
the O 
degree O 
of O 
protonation O 
along O 
the O 
polymer O 
chain O 
as O 
well O 
as O 
revealing O 
information O 
concerning O 
the O 
D2O B-FORMULA 
concentration O 
at O 
the O 
interface O 
. O 
The O 
neutron O 
reflectivity O 
data O 
allows O 
us O 
to O 
determine O 
the O 
physical O 
brush O 
profile O 
normal O 
to O 
the O 
solid O 
/ O 
liquid O 
interface O 
along O 
with O 
the O 
corresponding O 
degree O 
of O 
hydration O 
. O 
This O 
combined O 
approach O 
makes O 
it O 
possible O 
to O 
quantify O 
the O 
charge O 
on O 
a O 
polymer O 
brush O 
alongside O 
the O 
morphology O 
adopted O 
by O 
the O 
polymer O 
chains O 
. O 

Synthesis O 
of O 
the O 
Marine O 
Cyclic O 
Depsipeptide O 
Viequeamide B-TRIVIAL 
A I-TRIVIAL 
. O 

first O 
total O 
synthesis O 
of O 
viequeamide B-TRIVIAL 
A I-TRIVIAL 
, O 
a O 
natural O 
cyclic O 
depsipeptide O 
isolated O 
from O 
a O 
marine O 
button O 
cyanobacterium O 
, O 
was O 
achieved O 
with O 
the O 
N-Me-Val-Thr B-FORMULA 
peptide O 
bond O 
as O 
the O 
final O 
macrocyclization O 
site O 
. O 
The O 
synthetic O 
product O 
gave O 
nearly O 
identical O 
spectroscopic O 
data O 
to O 
that O 
reported O 
for O 
the O 
natural O 
product O 
. O 

coenzyme I-SYSTEMATIC 
A I-SYSTEMATIC 
reductase O 
inhibitors O 
( O 
statins O 
) O 
exert O 
pleiotropic O 
effects O 
on O 
the O 
cardiovascular O 
system O 
, O 
in O 
part O 
through O 
a O 
decrease O 
in O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
formation O 
and O 
reduction O 
of O 
vascular O 
inflammation O 
. O 
To O 
elucidate O 
the O 
molecular O 
mechanisms O 
involved O 
in O 
these O 
effects O 
, O 
we O 
investigated O 
the O 
effect O 
of O 
statins O 
on O 
TNF-α-induced O 
ROS O 
production O 
, O 
vascular O 
cell O 
adhesion O 
molecule-1 O 
( O 
VCAM-1 O 
) O 
and O 
intercellular O 
adhesion O 
molecule-1 O 
( O 
ICAM-1 O 
) O 
expression O 
in O 
human O 
aortic O 
endothelial O 
cells O 
( O 
HAECs O 
) O 
. O 
Exposure O 
of O 
HAECs O 
to O 
TNF-α O 
caused O 
production O 
of O 
ROS O 
via O 
Rac-1 O 
membrane O 
translocation O 
and O 
activation O 
. O 
The O 
Rac-1 O 
activation O 
and O 
ROS O 
liberation O 
mediated O 
TNF-stimulated O 
NF-κB O 
activation O 
and O 
the O 
subsequent O 
VCAM-1 O 
and O 
ICAM-1 O 
expression O 
. O 
Extracellular O 
- O 
signal O 
- O 
regulated O 
kinase O 
5 O 
( O 
ERK5 O 
) O 
plays O 
a O 
central O 
role O 
in O 
inhibiting O 
endothelial O 
inflammation O 
. O 
Immune O 
complex O 
kinase O 
assay O 
of O 
protein O 
extracts O 
from O 
HAECs O 
treated O 
with O 
atorvastatin B-TRIVIAL 
revealed O 
increased O 
ERK5 O 
activity O 
in O 
a O 
time- O 
and O 
dose O 
- O 
dependent O 
manner O 
. O 
In O 
addition O 
, O 
pretreatment O 
with O 
atorvastatin B-TRIVIAL 
inhibited O 
TNF-α-induced O 
ROS O 
production O 
and O 
VCAM-1 O 
and O 
ICAM-1 O 
expression O 
. O 
Chemical O 
or O 
genetic O 
inhibition O 
of O 
ERK5 O 
ablated O 
the O 
statins O 
inhibition O 
of O 
Rac-1 O 
activation O 
, O 
ROS O 
formation O 
, O 
NF-κB O 
, O 
VCAM-1 O 
and O 
ICAM-1 O 
expression O 
induced O 
by O 
TNF-α O 
. O 
Taken O 
together O 
, O 
statins O 
, O 
via O 
ERK5 O 
activation O 
, O 
suppress O 
TNF-stimulated O 
Rac-1 O 
activation O 
, O 
ROS O 
generation O 
, O 
NF-κB O 
activation O 
and O 
VCAM-1 O 
and O 
ICAM-1 O 
expression O 
in O 
human O 
ECs O 
, O 
which O 
provides O 
a O 
novel O 
explanation O 
for O 
the O 
pleiotropic O 
effects O 
of O 
statins O 
that O 
benefit O 
the O 
cardiovascular O 
system O 
. O 

effect O 
of O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
fraction O 
of O 
Acacia O 
ferruginea O 
DC O 
. O 
against O 
ethanol B-SYSTEMATIC 
-induced O 
gastric O 
ulcer O 
in O 
rats O 
. O 

RELEVANCE O 
: O 
In O 
traditional O 
systems O 
of O 
medicine O 
, O 
stem O 
bark O 
of O 
Acacia O 
ferruginea O 
DC O 
. O 
is O 
used O 
for O 
the O 
treatment O 
of O 
itching O 
, O 
leucoderma O 
, O 
ulcers O 
, O 
stomatitis O 
and O 
diseases O 
of O 
the O 
blood O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
determined O 
antioxidant O 
and O 
anti-ulcerogenic O 
activities O 
of O 
Acacia O 
ferruginea O 
stem O 
bark O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Acetone B-SYSTEMATIC 
extract O 
and O 
its O 
sub O 
- O 
fractions O 
of O 
Acacia O 
ferruginea O 
stem O 
bark O 
were O 
subjected O 
to O 
assess O 
their O 
antioxidant O 
potential O 
using O 
various O 
in O 
vitro O 
systems O 
such O 
as O 
DPPH(•) B-ABBREVIATION 
, O 
ABTS(•+) B-ABBREVIATION 
scavenging O 
, O 
FRAP O 
and O 
phosphomolybdenum B-SYSTEMATIC 
reduction O 
activities O 
. O 
Based O 
on O 
the O 
antioxidant O 
potential O 
, O 
the O 
ethyl O 
acetate O 
fraction O 
was O 
used O 
to O 
evaluate O 
the O 
protective O 
effect O 
of O 
ethanol B-SYSTEMATIC 
-induced O 
gastric O 
damage O 
in O 
rat O 
model O 
. O 
Enzyme O 
activities O 
such O 
as O 
superoxide B-TRIVIAL 
dismutase O 
, O 
glutathione B-TRIVIAL 
, O 
catalase O 
and O 
lipid O 
peroxidation O 
were O 
also O 
determined O 
in O 
the O 
stomach O 
tissues O 
. O 
RESULTS O 
: O 
Ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
fraction O 
( O 
AFE O 
) O 
of O 
Acacia O 
ferruginea O 
stem O 
bark O 
registered O 
higher O 
antioxidant O 
and O 
free O 
radical O 
scavenging O 
activities O 
than O 
the O 
crude O 
acetone B-SYSTEMATIC 
extract O 
and O 
other O 
fractions O 
. O 
In O 
addition O 
, O 
AFE O 
exhibited O 
that O 
the O 
IC50 O 
values O 
of O 
DPPH B-ABBREVIATION 
( O 
2.5µg O 
/ O 
ml O 
) O 
and O 
ABTS B-ABBREVIATION 
( O 
1.8µg O 
/ O 
ml O 
) O 
were O 
lower O 
when O 
compared O 
to O 
the O 
standard O 
quercetin B-TRIVIAL 
( O 
12.4µg O 
/ O 
ml O 
and O 
4.7µg O 
/ O 
ml O 
, O 
respectively O 
) O 
. O 
In O 
ethanol B-SYSTEMATIC 
induced O 
gastric O 
ulcer O 
, O 
administration O 
of O 
AFE O 
at O 
doses O 
of O 
10mg O 
/ O 
kg O 
, O 
50mg O 
/ O 
kg O 
and O 
100mg O 
/ O 
kg O 
body O 
weight O 
prior O 
to O 
ethanol B-SYSTEMATIC 
ingestion O 
significantly O 
protected O 
the O 
stomach O 
ulceration O 
. O 
Consequently O 
significant O 
changes O 
were O 
observed O 
in O 
enzyme O 
activities O 
such O 
as O 
SOD O 
, O 
CAT O 
, O 
GSH B-ABBREVIATION 
and O 
LPO O 
in O 
the O 
stomach O 
tissues O 
when O 
compared O 
with O 
ethanol B-SYSTEMATIC 
control O 
group O 
. O 
CONCLUSION O 
: O 
It O 
is O 
concluded O 
that O 
the O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
fraction O 
of O 
Acacia O 
ferruginea O 
stem O 
bark O 
possessed O 
higher O 
antioxidant O 
and O 
anti-ulcerogenic O 
activities O 
. O 
Based O 
on O 
the O 
results O 
we O 
suggest O 
that O 
Acacia O 
ferruginea O 
stem O 
bark O 
has O 
potential O 
to O 
provide O 
a O 
therapeutic O 
approach O 
to O 
ethanol B-SYSTEMATIC 
mediated O 
ulcer O 
as O 
an O 
effective O 
anti-ulcer O 
agent O 
. O 

RELEVANCE O 
: O 
Waltheria O 
indica O 
L O 
. O 
( O 
syn O 
. O 
Waltheria O 
americana O 
) O 
is O 
commonly O 
used O 
in O 
traditional O 
medicine O 
in O 
Africa O 
, O 
South O 
America O 
and O 
Hawaii O 
, O 
mainly O 
against O 
pain O 
, O 
inflammation O 
, O 
conditions O 
of O 
inflammation O 
, O 
diarrhea O 
, O 
dysentery O 
, O 
conjunctivitis O 
, O 
wounds O 
, O 
abscess O 
, O 
epilepsy O 
, O 
convulsions O 
, O 
anemia O 
, O 
erectile O 
dysfunctions O 
, O 
bladder O 
ailments O 
and O 
asthma O 
. O 
AIM O 
OF O 
THE O 
REVIEW O 
: O 
To O 
provide O 
an O 
up O 
- O 
to O 
- O 
date O 
overview O 
of O 
the O 
botany O 
, O 
phytochemistry O 
, O 
traditional O 
uses O 
, O 
pharmacological O 
activities O 
and O 
toxicity O 
data O 
of O 
Waltheria O 
indica O 
. O 
Additionally O 
, O 
studies O 
providing O 
an O 
evidence O 
for O 
local O 
and O 
traditional O 
uses O 
of O 
Waltheria O 
indica O 
are O 
discussed O 
. O 
Further O 
phytochemical O 
and O 
pharmacological O 
potential O 
of O 
this O 
species O 
are O 
suggested O 
for O 
future O 
investigations O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
The O 
information O 
was O 
collected O 
from O 
scientific O 
journals O 
, O 
books O 
, O 
theses O 
and O 
reports O 
via O 
academic O 
libraries O 
and O 
electronic O 
search O 
. O 
These O 
sources O 
include O 
Pubmed O 
, O 
Web O 
of O 
Science O 
, O 
Portal O 
de O 
Portales-Latindex O 
, O 
Science O 
Research.com O 
and O 
Google O 
scholar O 
. O 
These O 
studies O 
about O 
the O 
medical O 
botanical O 
, O 
traditional O 
uses O 
, O 
chemical O 
, O 
pharmacological O 
and O 
toxicological O 
data O 
on O 
Waltheria O 
indica O 
were O 
published O 
in O 
English O 
, O 
Portuguese O 
, O 
Spanish O 
, O 
German O 
and O 
French O 
. O 
RESULTS O 
: O 
Crude O 
extracts O 
and O 
isolated O 
compounds O 
from O 
Waltheria O 
indica O 
were O 
investigated O 
and O 
showed O 
analgesic O 
, O 
anti-inflammatory O 
, O 
antibacterial O 
, O 
antifungal O 
, O 
antimalarial O 
, O 
anti-anemic O 
, O 
anti-oxidant O 
, O 
sedative O 
and O 
anticonvulsant O 
activities O 
. O 
The O 
phytochemical O 
investigations O 
showed O 
the O 
presence O 
of O 
cyclopeptid B-FAMILY 
alkaloids I-FAMILY 
, O 
flavonoids B-FAMILY 
( O 
e.g O 
. O 
, O 
(-)-epicatechin B-SYSTEMATIC 
, O 
quercetin B-TRIVIAL 
, O 
kaempferol B-TRIVIAL 
, O 
kaempferol-3-O-β-d-(6″-E-p-coumaryl)-glucopyranoside B-SYSTEMATIC 
) I-SYSTEMATIC 
, O 
tannins B-FAMILY 
, O 
sterols B-FAMILY 
, O 
terpenes B-FAMILY 
, O 
saponins B-FAMILY 
, O 
anthraquinones B-FAMILY 
. O 
Studies O 
of O 
acute O 
toxicity O 
in O 
animal O 
indicated O 
that O 
Waltheria O 
indica O 
can O 
be O 
toxic O 
. O 
CONCLUSION O 
: O 
Waltheria O 
indica O 
possess O 
therapeutic O 
potential O 
in O 
the O 
treatment O 
of O 
inflammation O 
, O 
malaria O 
, O 
infectious O 
diseases O 
( O 
e.g O 
. O 
, O 
lungs O 
infection O 
due O 
to O 
Klebsiella O 
pneumoniae O 
, O 
diarrhea O 
due O 
to O 
Candida O 
albicans O 
or O 
Escherichia O 
coli O 
) O 
and O 
prevention O 
of O 
oxidative O 
stress O 
. O 
Further O 
studies O 
are O 
necessary O 
to O 
explore O 
pure O 
compounds O 
responsible O 
for O 
the O 
pharmacological O 
effects O 
and O 
the O 
mechanisms O 
of O 
action O 
. O 
Further O 
investigations O 
are O 
also O 
needed O 
to O 
provide O 
an O 
evidence O 
base O 
for O 
traditional O 
uses O 
of O 
this O 
species O 
against O 
pain O 
, O 
anemia O 
, O 
convulsions O 
and O 
epilepsy O 
. O 
In O 
addition O 
, O 
there O 
is O 
a O 
pressing O 
need O 
to O 
investigate O 
the O 
other O 
traditional O 
uses O 
such O 
as O 
dysentery O 
, O 
syphilis O 
, O 
erectile O 
dysfunctions O 
and O 
asthma O 
. O 

17-valerate I-SYSTEMATIC 
affects O 
embryonic O 
development O 
and O 
sexual O 
differentiation O 
in O 
Japanese O 
medaka O 
( O 
Oryzias O 
latipes O 
) O 
. O 

17-valerate I-SYSTEMATIC 
( O 
EV O 
) O 
is O 
a O 
synthetic O 
estrogen B-FAMILY 
widely O 
used O 
in O 
combination O 
with O 
other O 
steroid B-FAMILY 
hormones I-FAMILY 
in O 
hormone O 
replacement O 
therapy O 
drugs O 
and O 
is O 
detected O 
in O 
natural O 
waters O 
. O 
Although O 
EV O 
is O 
known O 
as O 
an O 
estrogenic O 
chemical O 
, O 
there O 
is O 
still O 
a O 
lack O 
of O 
data O 
on O 
its O 
developmental O 
and O 
reproductive O 
toxicities O 
in O 
fish O 
following O 
exposure O 
to O 
EV O 
during O 
embryo-larval- O 
, O 
juvenile- O 
and O 
adult O 
- O 
life O 
stages O 
in O 
Japanese O 
medaka O 
( O 
Oryzias O 
latipes O 
) O 
. O 
At O 
the O 
early O 
life O 
stage O 
, O 
the O 
fertilized O 
eggs O 
of O 
medaka O 
were O 
exposed O 
to O 
1 O 
, O 
10 O 
, O 
100 O 
and O 
1000ng O 
/ O 
L O 
EV O 
for O 
15 O 
days O 
, O 
and O 
hatched O 
larval O 
fish O 
were O 
continually O 
exposed O 
to O 
the O 
same O 
concentration O 
range O 
for O 
an O 
additional O 
15 O 
days O 
. O 
The O 
results O 
showed O 
that O 
exposure O 
to O 
10ng O 
/ O 
L O 
or O 
above O 
resulted O 
in O 
adverse O 
effects O 
on O 
hatchability O 
and O 
time O 
to O 
hatching O 
, O 
and O 
the O 
number O 
of O 
hatched O 
females O 
was O 
twice O 
that O 
of O 
males O 
at O 
10ng O 
/ O 
L O 
or O 
above O 
. O 
When O 
the O 
hatched O 
fish O 
were O 
continually O 
exposed O 
to O 
1 O 
, O 
10 O 
and O 
100ng O 
/ O 
L O 
of O 
EV O 
for O 
another O 
40 O 
days O 
, O 
the O 
hepatosomatic O 
index O 
( O 
HSI O 
) O 
was O 
increased O 
in O 
both O 
males O 
and O 
females O 
, O 
and O 
the O 
gonadosomatic O 
index O 
( O 
GSI O 
) O 
was O 
decreased O 
in O 
females O 
, O 
and O 
increased O 
in O 
males O 
. O 
Sex O 
reversal O 
was O 
found O 
in O 
fish O 
exposed O 
to O 
1ng O 
/ O 
L O 
and O 
above O 
. O 
Quantitative O 
real O 
- O 
time O 
RT-PCR O 
showed O 
that O 
mRNA O 
levels O 
of O 
estrogen B-FAMILY 
receptor O 
α O 
( O 
ER-α O 
) O 
and O 
vitellogenin-I O 
( O 
VTG-I O 
) O 
in O 
the O 
liver O 
of O 
females O 
were O 
significantly O 
down O 
- O 
regulated O 
, O 
while O 
those O 
of O 
vitellogenin-I O 
( O 
VTG-I O 
) O 
in O 
the O 
liver O 
of O 
males O 
were O 
significantly O 
up O 
- O 
regulated O 
at O 
all O 
concentrations O 
. O 
These O 
findings O 
suggest O 
that O 
EV O 
is O 
a O 
reproductive O 
toxicant O 
and O 
estrogenic O 
chemical O 
in O 
both O 
male O 
and O 
female O 
fish O 
. O 

replacement O 
enhances O 
cocaine B-TRIVIAL 
-stimulated O 
locomotion O 
in O 
female O 
C57BL O 
/ O 
6 O 
mice O 
through O 
estrogen B-FAMILY 
receptor O 
alpha O 
. O 

effects O 
are O 
enhanced O 
by O 
ovarian O 
hormones O 
in O 
women O 
and O 
female O 
rodents O 
. O 
Estradiol B-TRIVIAL 
increases O 
behavioral O 
responses O 
to O 
psychostimulants O 
in O 
women O 
and O 
female O 
rats O 
, O 
although O 
the O 
underlying O 
mechanism O 
is O 
unknown O 
. O 
This O 
study O 
utilized O 
mice O 
to O 
investigate O 
the O 
time O 
frame O 
and O 
receptor O 
mediation O 
of O 
estradiol B-TRIVIAL 
' O 
s O 
enhancement O 
of O 
cocaine B-TRIVIAL 
-induced O 
behavior O 
as O 
mice O 
enable O 
parallel O 
use O 
of O 
genetic O 
, O 
surgical O 
and O 
pharmacological O 
methods O 
. O 
The O 
spontaneous O 
behavior O 
of O 
Sham O 
and O 
Ovariectomized O 
( O 
Ovx O 
) O 
female O 
wildtype O 
( O 
WT O 
) O 
mice O 
was O 
determined O 
during O 
habituation O 
to O 
a O 
novel O 
environment O 
and O 
after O 
cocaine B-TRIVIAL 
administration O 
. O 
Ovx O 
mice O 
were O 
replaced O 
with O 
vehicle O 
( O 
sesame O 
oil O 
) O 
or O 
17β-estradiol B-SYSTEMATIC 
( O 
E2 O 
) O 
for O 
2 O 
days O 
or O 
30 O 
min O 
prior O 
to O 
a O 
cocaine B-TRIVIAL 
challenge O 
to O 
investigate O 
the O 
time O 
course O 
of O 
E2's O 
effects O 
. O 
To O 
examine O 
receptor O 
mediation O 
of O 
estradiol B-TRIVIAL 
effects O 
, O 
Ovx O 
mice O 
replaced O 
for O 
2 O 
days O 
with O 
either O 
the O 
ERα-selective O 
agonist O 
PPT B-ABBREVIATION 
or O 
the O 
ERβ-selective O 
agonist O 
DPN B-ABBREVIATION 
were O 
compared O 
to O 
Sham O 
mice O 
, O 
and O 
mice O 
lacking O 
either O 
ERα O 
( O 
αERKO O 
) O 
or O 
ERβ O 
( O 
βERKO O 
) O 
were O 
compared O 
to O 
WT O 
littermates O 
. O 
Ovx O 
mice O 
exhibited O 
fewer O 
ambulations O 
during O 
habituation O 
than O 
Sham O 
females O 
. O 
Cocaine B-TRIVIAL 
-induced O 
increases O 
in O 
behavioral O 
ratings O 
were O 
greater O 
in O 
Sham O 
than O 
in O 
Ovx O 
mice O 
. O 
Two O 
days O 
but O 
not O 
30 O 
min O 
of O 
E2 O 
replacement O 
in O 
Ovx O 
mice O 
increased O 
cocaine B-TRIVIAL 
responses O 
to O 
Sham O 
levels O 
. O 
PPT B-ABBREVIATION 
replacement O 
also O 
increased O 
the O 
cocaine B-TRIVIAL 
response O 
relative O 
to O 
vehicle- O 
or O 
DPN B-ABBREVIATION 
- O 
treated O 
Ovx O 
mice O 
. O 
αERKO O 
mice O 
displayed O 
modestly O 
attenuated O 
behavioral O 
responses O 
to O 
novelty O 
and O 
cocaine B-TRIVIAL 
compared O 
to O 
αWT O 
littermates O 
, O 
but O 
no O 
behavioral O 
differences O 
were O 
found O 
between O 
βERKO O 
and O 
βWT O 
mice O 
. O 
These O 
results O 
suggest O 
that O 
E2 O 
enhances O 
cocaine B-TRIVIAL 
-stimulated O 
locomotion O 
in O 
mice O 
predominantly O 
through O 
ERα O 
. O 

of O 
natural O 
estrogen B-FAMILY 
receptor O 
modulators O 
with O 
structure O 
- O 
based O 
virtual O 
screening O 
. O 

compounds O 
were O 
identified O 
as O 
estrogen B-FAMILY 
receptor O 
modulators O 
from O 
an O 
in O 
- O 
house O 
natural O 
product O 
database O 
( O 
NPD O 
) O 
by O 
structure O 
- O 
based O 
virtual O 
screening O 
for O 
ERα O 
and O 
ERβ O 
. O 
Among O 
them O 
, O 
3 O 
compounds O 
were O 
confirmed O 
as O 
ER O 
agonists O 
and O 
8 O 
compounds O 
were O 
confirmed O 
as O 
ER O 
antagonists O 
by O 
yeast O 
two O 
- O 
hybrid O 
( O 
Y2H O 
) O 
assay O 
, O 
with O 
EC50 O 
values O 
ranging O 
from O 
several O 
micromolar O 
to O 
100 O 
micromolar O 
. O 
In O 
this O 
study O 
, O 
a O 
novel O 
series O 
of O 
cycloartane B-FAMILY 
triterpenoids I-FAMILY 
isolated O 
from O 
Schisandra O 
glaucescens O 
Diels O 
was O 
found O 
to O 
have O 
ER O 
antagonistic O 
effect O 
, O 
the O 
most O 
potent O 
antagonist O 
of O 
which O 
exhibited O 
activity O 
with O 
EC50 O 
value O 
of O 
2.55 O 
and O 
4.68μM O 
for O 
ERα O 
and O 
ERβ O 
, O 
respectively O 
. O 
Moreover O 
, O 
the O 
types O 
of O 
modulation O 
and O 
subtype O 
selectivity O 
were O 
also O 
investigated O 
through O 
molecular O 
docking O 
simulation O 
. O 

Potential O 
of O 
Cyclopia O 
Extracts O 
and O 
Polyphenols B-FAMILY 
. O 

Vent O 
. O 
species O 
, O 
commonly O 
known O 
as O 
honeybush O 
, O 
are O 
endemic O 
to O 
Southern O 
Africa O 
. O 
The O 
plant O 
is O 
traditionally O 
used O 
as O 
an O 
herbal O 
tea O 
but O 
several O 
health O 
benefits O 
have O 
recently O 
been O 
recorded O 
. O 
This O 
minireview O 
presents O 
an O 
overview O 
of O 
polyphenols B-FAMILY 
found O 
in O 
Cyclopia O 
and O 
focusses O 
on O 
the O 
phytoestrogenic O 
potential O 
of O 
selected O 
polyphenols B-FAMILY 
and O 
of O 
extracts O 
prepared O 
from O 
the O 
plant O 
. O 

of O 
menstruation O 
and O 
pituitary O 
response O 
to O 
gonadotropin B-TRIVIAL 
- I-TRIVIAL 
releasing I-TRIVIAL 
hormone I-TRIVIAL 
in O 
functional O 
hypothalamic O 
amenorrhea O 
undertaking O 
estrogen B-FAMILY 
replacement O 
therapy O 
. O 

: O 
Functional O 
hypothalamic O 
amenorrhea O 
( O 
FHA O 
) O 
refers O 
to O 
a O 
functional O 
menstrual O 
disorder O 
with O 
various O 
causes O 
and O 
presentations O 
. O 
Recovery O 
of O 
menstrual O 
cyclicity O 
is O 
common O 
in O 
long O 
- O 
term O 
follow O 
- O 
up O 
but O 
the O 
affecting O 
factors O 
remain O 
unknown O 
. O 
Aim O 
: O 
To O 
explore O 
factors O 
affecting O 
the O 
menstrual O 
resumption O 
and O 
to O 
evaluate O 
the O 
pituitary O 
response O 
to O 
gonadotropin B-TRIVIAL 
- I-TRIVIAL 
releasing I-TRIVIAL 
hormone I-TRIVIAL 
( O 
GnRH B-ABBREVIATION 
) O 
in O 
FHA O 
. O 
Materials O 
and O 
Methods O 
: O 
Thirty O 
cases O 
with O 
FHA O 
were O 
recruited O 
. O 
All O 
subjects O 
were O 
put O 
on O 
continuous O 
1mg O 
/ O 
day O 
estradiol B-TRIVIAL 
valerate I-TRIVIAL 
orally O 
and O 
followed O 
up O 
monthly O 
. O 
Recovery O 
was O 
defined O 
as O 
the O 
occurrence O 
of O 
at O 
least O 
three O 
consecutive O 
regular O 
cycles O 
. O 
Responder O 
referred O 
to O 
those O 
who O 
recovered O 
within O 
two O 
years O 
of O 
therapy O 
. O 
Gonadotropin O 
response O 
to O 
the O 
50 O 
microgram O 
GnRH B-ABBREVIATION 
challenge O 
was O 
tested O 
every O 
three O 
months O 
. O 
Results O 
: O 
Nineteen O 
( O 
63.3% O 
) O 
subjects O 
recovered O 
with O 
a O 
mean O 
time O 
to O 
recovery O 
of O 
26.8 O 
months O 
. O 
Time O 
to O 
recovery O 
was O 
negatively O 
correlated O 
with O 
body O 
mass O 
index O 
( O 
BMI O 
) O 
before O 
and O 
by O 
amenorrhea O 
. O 
Twenty O 
- O 
one O 
cases O 
had O 
undertaken O 
therapy O 
for O 
more O 
than O 
two O 
years O 
and O 
ten O 
of O 
them O 
recovered O 
. O 
BMI O 
before O 
and O 
by O 
amenorrhea O 
were O 
negatively O 
correlated O 
with O 
the O 
recovery O 
. O 
Significant O 
increase O 
of O 
serum O 
luteinizing O 
hormone O 
( O 
LH O 
) O 
and O 
LH O 
response O 
to O 
GnRH B-ABBREVIATION 
were O 
noted O 
after O 
recovery O 
. O 
Conclusions O 
: O 
Menstrual O 
resumption O 
was O 
common O 
in O 
FHA O 
undertaking O 
ERT O 
. O 
The O 
likelihood O 
of O 
recovery O 
was O 
affected O 
by O 
their O 
BMI O 
before O 
and O 
by O 
amenorrhea O 
but O 
not O 
by O 
the O 
weight O 
gain O 
during O 
therapy O 
. O 
Low O 
serum O 
LH O 
and O 
attenuated O 
LH O 
response O 
to O 
GnRH B-ABBREVIATION 
were O 
the O 
main O 
features O 
of O 
pituitary O 
deficiency O 
in O 
FHA O 
. O 
The O 
menstrual O 
resumption O 
in O 
FHA O 
was O 
accompanied O 
by O 
the O 
recovery O 
of O 
serum O 
LH O 
and O 
the O 
LH O 
response O 
to O 
GnRH B-ABBREVIATION 
. O 

Polypeptides O 
as O 
a O 
Bifunctional O 
Template O 
in O 
the O 
Mineralization O 
of O 
Calcium B-SYSTEMATIC 
Carbonate I-SYSTEMATIC 
at O 
the O 
Air O 
/ O 
Water O 
Interface O 
. O 

well O 
- O 
defined O 
amphiphilic O 
polypeptide O 
, O 
poly(glutamic B-FAMILY 
acid)22 I-FAMILY 
-block-poly(alanine)8 I-FAMILY 
( O 
PGlu22 B-ABBREVIATION 
-b-PAla8 I-ABBREVIATION 
) O 
, O 
which O 
plays O 
the O 
roles O 
of O 
both O 
soluble O 
( O 
functional O 
) O 
additive O 
and O 
insoluble O 
( O 
structural O 
) O 
matrix O 
, O 
is O 
employed O 
to O 
mediate O 
the O 
mineralization O 
of O 
CaCO3 B-FORMULA 
at O 
the O 
air O 
/ O 
water O 
interface O 
. O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
and O 
Raman O 
spectroscopy O 
, O 
for O 
example O 
, O 
show O 
that O 
the O 
polymorph O 
of O 
CaCO3 B-FORMULA 
particles O 
obtained O 
is O 
calcite B-TRIVIAL 
. O 
The O 
observations O 
from O 
SEM O 
and O 
TEM O 
suggest O 
that O 
PGlu22 B-ABBREVIATION 
-b-PAla8 I-ABBREVIATION 
initiates O 
the O 
amorphous O 
precursor O 
phase O 
and O 
heterogeneous O 
nucleation O 
of O 
CaCO3 B-FORMULA 
at O 
the O 
air O 
/ O 
water O 
interface O 
, O 
while O 
temporarily O 
stabilizes O 
the O 
gelatinous O 
precursors O 
as O 
a O 
process O 
- O 
directing O 
agent O 
; O 
nevertheless O 
, O 
the O 
initial O 
concentration O 
of O 
Ca(2+) B-FORMULA 
controls O 
the O 
procedure O 
of O 
crystallization O 
and O 
the O 
final O 
morphology O 
of O 
CaCO3 B-FORMULA 
particles O 
. O 
Such O 
" O 
bifunctional O 
" O 
amphiphilic-polypeptide-regulated O 
mineralization O 
at O 
the O 
air O 
/ O 
water O 
interface O 
may O 
be O 
applied O 
to O 
the O 
synthesis O 
of O 
many O 
kinds O 
of O 
symmetrical O 
inorganic O 
/ O 
organic O 
hybrids O 
. O 

improvement O 
in O 
glycemic O 
control O 
occurs O 
in O 
patients O 
with O 
type O 
2 O 
diabetes O 
( O 
T2DM O 
) O 
shortly O 
after O 
Roux-en-Y O 
gastric O 
bypass O 
surgery O 
( O 
RYGB O 
) O 
and O 
before O 
there O 
is O 
major O 
weight O 
loss O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
determine O 
if O 
the O 
magnitude O 
of O 
this O 
change O 
is O 
primarily O 
due O 
to O 
caloric O 
restriction O 
or O 
is O 
unique O 
to O 
the O 
surgical O 
procedure O 
. O 
We O 
studied O 
eleven O 
subjects O 
who O 
underwent O 
RYGB O 
and O 
fourteen O 
subjects O 
mean O 
- O 
matched O 
for O 
BMI O 
, O 
HbA1c O 
and O 
diabetes O 
duration O 
who O 
were O 
admitted O 
to O 
our O 
inpatient O 
research O 
unit O 
and O 
given O 
a O 
very O 
low O 
calorie O 
diet O 
( O 
VLCD O 
) O 
of O 
500 O 
kcal O 
/ O 
day O 
with O 
a O 
macronutrient O 
content O 
similar O 
to O 
that O 
consumed O 
by O 
patients O 
after O 
RYGB O 
. O 
Frequently O 
sampled O 
intravenous O 
glucose B-TRIVIAL 
tolerance O 
tests O 
were O 
performed O 
before O 
and O 
after O 
interventions O 
. O 
Both O 
groups O 
lost O 
an O 
equivalent O 
amount O 
of O 
weight O 
over O 
a O 
mean O 
study O 
period O 
of O 
21 O 
days O 
. O 
Insulin O 
sensitivity O 
, O 
acute O 
insulin O 
secretion O 
after O 
intravenous O 
glucose B-TRIVIAL 
administration O 
and O 
beta-cell O 
function O 
as O 
determined O 
by O 
disposition O 
index O 
improved O 
to O 
a O 
similar O 
extent O 
in O 
both O 
groups O 
. O 
Likewise O 
, O 
changes O 
in O 
fasting O 
glucose B-TRIVIAL 
and O 
fructosamine B-SYSTEMATIC 
levels O 
were O 
similar O 
. O 
Based O 
on O 
these O 
data O 
, O 
VLCD O 
improves O 
insulin O 
sensitivity O 
and O 
beta-cell O 
function O 
just O 
as O 
well O 
as O 
RYGB O 
in O 
the O 
short O 
term O 
. O 
This O 
study O 
was O 
registered O 
in O 
ClinicalTrials.gov O 
NCT00627484 O 
. O 

Pulse O 
Pressure O 
and O 
Its O 
Hemodynamic O 
Determinants O 
in O 
Middle-Aged O 
Adults O 
With O 
Impaired O 
Fasting O 
Glucose B-TRIVIAL 
and O 
Diabetes O 
: O 
The O 
Asklepios O 
study O 
. O 

pressure O 
( O 
PP O 
) O 
, O 
a O 
strong O 
predictor O 
of O 
cardiovascular O 
events O 
in O 
type O 
2 O 
diabetes O 
, O 
is O 
a O 
composite O 
measure O 
affected O 
by O 
several O 
hemodynamic O 
factors O 
. O 
Little O 
is O 
known O 
about O 
the O 
hemodynamic O 
determinants O 
of O 
central O 
PP O 
in O 
type O 
2 O 
diabetes O 
or O 
whether O 
abnormalities O 
in O 
central O 
pulsatile O 
hemodynamics O 
are O 
already O 
present O 
in O 
individuals O 
with O 
impaired O 
fasting O 
glucose B-TRIVIAL 
( O 
IFG O 
) O 
. O 
In O 
a O 
population O 
- O 
based O 
study O 
, O 
we O 
aimed O 
to O 
compare O 
central O 
PP O 
and O 
its O 
hemodynamic O 
determinants O 
among O 
adults O 
with O 
normal O 
fasting O 
glucose B-TRIVIAL 
( O 
n O 
= O 
1654 O 
) O 
, O 
IFG O 
( O 
n O 
= O 
240 O 
) O 
, O 
and O 
type O 
2 O 
diabetes O 
( O 
n O 
= O 
33).RESEARCH O 
DESIGN O 
AND O 
METHODSWe O 
measured O 
carotid O 
pressure O 
, O 
left O 
ventricular O 
outflow O 
, O 
aortic O 
root O 
diameter O 
, O 
carotid O 
artery O 
flow O 
, O 
and O 
distension O 
in O 
order O 
to O 
measure O 
various O 
structural O 
and O 
hemodynamic O 
arterial O 
parameters.RESULTSIFG O 
was O 
associated O 
with O 
a O 
greater O 
mean O 
arterial O 
pressure O 
( O 
MAP O 
) O 
but O 
was O 
not O 
associated O 
with O 
intrinsic O 
aortic O 
stiffening O 
or O 
abnormal O 
aortic O 
pulsatile O 
indices O 
after O 
adjustment O 
for O 
MAP O 
. O 
After O 
adjustment O 
for O 
age O 
, O 
sex O 
, O 
and O 
MAP O 
, O 
type O 
2 O 
diabetes O 
was O 
associated O 
with O 
a O 
higher O 
aortic O 
root O 
characteristic O 
impedance O 
( O 
Zc O 
) O 
, O 
aortic O 
root O 
elastance O 
- O 
thickness O 
product O 
( O 
Eh O 
) O 
, O 
and O 
aortic O 
root O 
pulse O 
wave O 
velocity O 
( O 
but O 
not O 
aortic O 
root O 
diameter O 
) O 
, O 
a O 
greater O 
carotid O 
- O 
femoral O 
pulse O 
wave O 
velocity O 
, O 
and O 
lower O 
total O 
arterial O 
compliance O 
and O 
wave O 
reflection O 
magnitude O 
. O 
Carotid O 
size O 
, O 
Zc O 
, O 
distensibility O 
, O 
or O 
Eh O 
did O 
not O 
significantly O 
differ O 
between O 
the O 
groups.CONCLUSIONSType O 
2 O 
diabetes O 
, O 
but O 
not O 
IFG O 
, O 
is O 
associated O 
with O 
greater O 
large O 
artery O 
stiffness O 
, O 
without O 
abnormalities O 
in O 
aortic O 
root O 
diameter O 
or O 
carotid O 
stiffness O 
. O 
Subjects O 
with O 
type O 
2 O 
diabetes O 
demonstrate O 
a O 
decreased O 
reflection O 
magnitude O 
, O 
which O 
may O 
indicate O 
an O 
increased O 
penetration O 
of O 
pulsatile O 
energy O 
to O 
distal O 
vascular O 
beds O 
. O 

plays O 
a O 
major O 
role O 
in O 
regulating O 
sodium B-SYSTEMATIC 
and O 
potassium B-SYSTEMATIC 
homeostasis O 
, O 
and O 
blood O 
pressure O 
. O 
More O 
recently O 
aldosterone B-TRIVIAL 
has O 
emerged O 
as O 
a O 
key O 
hormone O 
in O 
mediating O 
end O 
organ O 
damage O 
. O 
In O 
extreme O 
cases O 
, O 
dysregulated O 
aldosterone B-TRIVIAL 
production O 
leads O 
to O 
primary O 
aldosteronism O 
, O 
the O 
most O 
common O 
form O 
of O 
secondary O 
hypertension O 
. O 
However O 
, O 
even O 
within O 
the O 
physiological O 
range O 
, O 
high O 
levels O 
of O 
aldosterone B-TRIVIAL 
are O 
associated O 
with O 
an O 
increased O 
risk O 
of O 
developing O 
hypertension O 
over O 
time O 
. O 
Primary O 
aldosteronism O 
represents O 
the O 
most O 
common O 
and O 
curable O 
form O 
of O 
hypertension O 
, O 
with O 
a O 
prevalence O 
that O 
increases O 
with O 
the O 
severity O 
of O 
hypertension O 
. O 
Although O 
genetic O 
causes O 
underlying O 
glucocorticoid O 
remediable O 
aldosteronism O 
, O 
one O 
of O 
the O 
three O 
Mendelian O 
forms O 
of O 
primary O 
aldosteronism O 
, O 
were O 
established O 
some O 
time O 
ago O 
, O 
somatic O 
and O 
inherited O 
mutations O 
in O 
the O 
potassium B-SYSTEMATIC 
channel O 
GIRK4 O 
have O 
only O 
recently O 
been O 
implicated O 
in O 
the O 
formation O 
of O 
aldosterone B-TRIVIAL 
producing O 
adenoma O 
and O 
in O 
familial O 
hyperaldosteronism O 
type O 
3 O 
. O 
Moreover O 
, O 
recent O 
findings O 
have O 
identified O 
somatic O 
mutations O 
in O 
two O 
additional O 
genes O 
, O 
involved O 
in O 
maintaining O 
intracellular O 
ionic O 
homeostasis O 
and O 
cell O 
membrane O 
potential O 
, O 
in O 
a O 
subset O 
of O 
aldosterone B-TRIVIAL 
producing O 
adenoma.This O 
review O 
summarizes O 
our O 
current O 
knowledge O 
on O 
the O 
genetic O 
determinants O 
that O 
contribute O 
to O 
variations O 
in O 
plasma O 
aldosterone B-TRIVIAL 
and O 
renin O 
levels O 
in O 
the O 
general O 
population O 
, O 
and O 
the O 
genetics O 
of O 
familial O 
and O 
sporadic O 
primary O 
aldosteronism O 
. O 
Various O 
animal O 
models O 
that O 
have O 
significantly O 
improved O 
our O 
understanding O 
of O 
the O 
pathophysiology O 
of O 
excess O 
aldosterone B-TRIVIAL 
production O 
will O 
also O 
be O 
discussed O 
. O 
Finally O 
, O 
we O 
will O 
outline O 
the O 
cardiovascular O 
, O 
renal O 
and O 
metabolic O 
consequences O 
of O 
mineralocorticoid O 
excess O 
beyond O 
blood O 
pressure O 
regulation O 
. O 

of O 
Atactic O 
and O 
Isotactic O 
Poly(1,2-glycerol B-FAMILY 
carbonate)s I-FAMILY 
: O 
Degradable O 
Polymers O 
for O 
Biomedical O 
and O 
Pharmaceutical O 
Applications O 
. O 

synthesis O 
and O 
characterization O 
of O 
atactic O 
and O 
isotactic O 
linear O 
poly(benzyl B-FAMILY 
1,2-glycerol I-FAMILY 
carbonate)s I-FAMILY 
are O 
reported O 
. O 
The O 
poly(benzyl B-FAMILY 
1,2-glycerol I-FAMILY 
carbonate)s I-FAMILY 
were O 
obtained O 
via O 
the O 
ring O 
- O 
opening O 
copolymerization O 
of O 
rac- B-MULTIPLE 
/ I-MULTIPLE 
(R)-benzyl I-MULTIPLE 
glycidyl I-MULTIPLE 
ether I-MULTIPLE 
with O 
CO2 B-FORMULA 
using O 
[ B-FAMILY 
SalcyCo(III)X I-FAMILY 
] I-FAMILY 
complexes O 
with O 
high O 
carbonate B-FAMILY 
linkage O 
selectivity O 
and O 
polymer O 
/ O 
cyclic O 
carbonate B-FAMILY 
selectivity O 
( O 
> O 
99% O 
) O 
. O 
Deprotection O 
of O 
the O 
resultant O 
polymers O 
afforded O 
poly(1,2-glycerol B-FAMILY 
carbonate)s I-FAMILY 
with O 
a O 
functionalizable O 
pendant O 
primary B-FAMILY 
hydroxyl I-FAMILY 
group O 
. O 
Poly(1,2-glycerol B-FAMILY 
carbonate I-FAMILY 
) I-FAMILY 
showed O 
a O 
remarkable O 
increase O 
in O 
degradation O 
rate O 
compared O 
to O 
poly(1,3-glycerol B-FAMILY 
carbonate I-FAMILY 
) I-FAMILY 
with O 
a O 
t1 O 
/ O 
2 O 
≈ O 
2-3 O 
days O 
. O 
These O 
polymers O 
fulfill O 
an O 
unmet O 
need O 
for O 
a O 
readily O 
degradable O 
biocompatible O 
polycarbonate B-FAMILY 
. O 

New O 
Face O 
for O 
Old O 
Antibiotics O 
: O 
Tetracyclines B-FAMILY 
in O 
Treatment O 
of O 
Amyloidoses O 
. O 

use O 
of O 
tetracyclines B-FAMILY 
has O 
declined O 
because O 
of O 
the O 
appearance O 
of O 
resistant O 
bacterial O 
strains O 
. O 
However O 
, O 
the O 
indications O 
of O 
nonantimicrobial O 
activities O 
of O 
these O 
drugs O 
have O 
considerably O 
raised O 
interest O 
and O 
triggered O 
clinical O 
trials O 
for O 
a O 
number O 
of O 
different O 
pathologies O 
. O 
About O 
10 O 
years O 
ago O 
we O 
first O 
reported O 
that O 
tetracyclines B-FAMILY 
inhibited O 
the O 
aggregation O 
of O 
prion O 
protein O 
fragments O 
and O 
Alzheimer's O 
β O 
peptides O 
, O 
destabilizing O 
their O 
aggregates O 
and O 
promoting O 
their O 
degradation O 
by O 
proteases O 
. O 
On O 
the O 
basis O 
of O 
these O 
observations O 
, O 
the O 
antiamyloidogenic O 
effects O 
of O 
tetracyclines B-FAMILY 
on O 
a O 
variety O 
of O 
amyloidogenic O 
proteins O 
were O 
studied O 
and O 
confirmed O 
by O 
independent O 
research O 
groups O 
. O 
In O 
this O 
review O 
we O 
comment O 
on O 
the O 
data O 
available O 
on O 
their O 
antiamyloidogenic O 
activity O 
in O 
preclinical O 
and O 
clinical O 
studies O 
. O 
We O 
also O 
put O 
forward O 
that O 
the O 
beneficial O 
effects O 
of O 
these O 
drugs O 
are O 
a O 
result O 
of O 
a O 
peculiar O 
pleiotropic O 
action O 
, O 
comprising O 
their O 
interaction O 
with O 
oligomers O 
and O 
disruption O 
of O 
fibrils O 
, O 
as O 
well O 
as O 
their O 
antioxidant O 
, O 
anti-inflammatory O 
, O 
antiapoptotic O 
, O 
and O 
matrix O 
metalloproteinase O 
inhibitory O 
activities O 
. O 

characterization O 
of O 
nimodipine B-TRIVIAL 
- O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
solid O 
dispersion O 
systems O 
. O 

This O 
study O 
investigates O 
the O 
solid O 
- O 
solid O 
interactions O 
between O 
nimodipine B-TRIVIAL 
( O 
NIM B-ABBREVIATION 
) O 
and O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
of O 
different O 
mean O 
molecular O 
weights O 
( O 
PEG B-MULTIPLE 
2000 I-MULTIPLE 
, I-MULTIPLE 
4000 I-MULTIPLE 
and I-MULTIPLE 
6000 I-MULTIPLE 
) O 
, O 
in O 
solid O 
dispersion O 
systems O 
, O 
applying O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
, O 
Fourier-Transform O 
infrared O 
spectroscopy O 
, O 
powder O 
X-ray O 
diffraction O 
( O 
PXRD O 
) O 
, O 
hot O 
stage O 
microscopy O 
( O 
HSM O 
) O 
and O 
theoretical O 
modeling O 
by O 
the O 
Flory-Huggins O 
( O 
FH O 
) O 
solution O 
theory O 
. O 
Phase O 
diagrams O 
constructed O 
with O 
the O 
aid O 
of O 
DSC O 
and O 
FH O 
solution O 
theory O 
showed O 
sensitivity O 
on O 
the O 
estimated O 
values O 
of O 
the O 
FH O 
interaction O 
parameter O 
( O 
χ O 
) O 
. O 
When O 
χ O 
is O 
considered O 
a O 
constant O 
number O 
( O 
χ O 
= O 
α O 
, O 
α O 
≠ O 
0 O 
) O 
, O 
formation O 
of O 
a O 
eutectic O 
mixture O 
is O 
predicted O 
in O 
the O 
70-80% O 
w O 
/ O 
w O 
PEG B-ABBREVIATION 
concentration O 
region O 
, O 
while O 
when O 
χ O 
was O 
considered O 
as O 
a O 
function O 
of O 
concentration O 
and O 
temperature O 
(χ O 
= O 
f(φ,Τ)) O 
, O 
the O 
model O 
predicts O 
the O 
formation O 
of O 
monotectic O 
systems O 
. O 
Construction O 
of O 
more O 
precise O 
phase O 
diagrams O 
by O 
HSM O 
to O 
the O 
aid O 
of O 
Kofler's O 
" O 
contact O 
preparation O 
" O 
method O 
confirmed O 
the O 
monotectic O 
nature O 
of O 
the O 
examined O 
systems O 
. O 
Studies O 
on O 
NIM B-ABBREVIATION 
' O 
s O 
re O 
- O 
crystallization O 
process O 
in O 
the O 
solid O 
dispersions O 
revealed O 
a O 
strong O 
dependence O 
of O 
the O 
crystallization O 
rate O 
, O 
as O 
well O 
as O 
the O 
resulting O 
crystal O 
form O 
, O 
on O 
the O 
mean O 
molecular O 
weight O 
and O 
concentration O 
of O 
PEG B-ABBREVIATION 
: O 
NIM B-ABBREVIATION 
crystallization O 
rates O 
decrease O 
as O 
PEG B-ABBREVIATION 
' O 
s O 
MW O 
increases O 
, O 
while O 
NIM B-ABBREVIATION 
mod O 
II O 
crystals O 
predominate O 
in O 
dispersions O 
prepared O 
at O 
temperatures O 
above O 
NIM B-ABBREVIATION 
' O 
s O 
liquidus O 
and O 
growth O 
of O 
NIM B-ABBREVIATION 
mod O 
I O 
prevailing O 
in O 
PEG B-ABBREVIATION 
-rich O 
samples O 
. O 

of O 
a O 
New O 
Class O 
of O 
Natural O 
Product-Inspired O 
Quinazolinone B-SYSTEMATIC 
Hybrid O 
as O 
Potent O 
Antileishmanial O 
agents O 
. O 

high O 
potential O 
of O 
quinazolinone B-SYSTEMATIC 
containing O 
natural O 
products O 
and O 
their O 
derivatives O 
in O 
medicinal O 
chemistry O 
led O 
us O 
to O 
discover O 
four O 
novel O 
series O 
of O 
53 O 
compounds O 
of O 
quinazolinone B-SYSTEMATIC 
based O 
on O 
the O 
concept O 
of O 
molecular O 
hybridization O 
. O 
Most O 
of O 
the O 
synthesized O 
analogues O 
exhibited O 
potent O 
leishmanicidal O 
activity O 
against O 
intracellular O 
amastigotes O 
( O 
IC50 O 
from O 
0.65 O 
± O 
0.2 O 
to O 
7.76 O 
± O 
2.1 O 
μM O 
) O 
as O 
compared O 
to O 
miltefosine B-TRIVIAL 
( O 
IC50 O 
= O 
8.4 O 
± O 
2.1 O 
μM O 
) O 
and O 
nontoxic O 
toward O 
the O 
J-774A.1 O 
cell O 
line O 
and O 
Vero O 
cells O 
. O 
Moreover O 
, O 
activation O 
of O 
Th1 O 
type O 
and O 
suppression O 
of O 
Th2 O 
type O 
immune O 
responses O 
and O 
induction O 
in O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
generation O 
proved O 
that O 
8a O 
and O 
8g O 
induce O 
murine O 
macrophages O 
to O 
prevent O 
survival O 
of O 
parasites O 
. O 
Compounds O 
8a O 
and O 
8g O 
exhibited O 
significant O 
in O 
vivo O 
inhibition O 
of O 
parasite O 
73.15 O 
± O 
12.69% O 
and O 
80.93 O 
± O 
10.50% O 
against O 
Leishmania O 
donovani O 
/ O 
hamster O 
model O 
. O 
Our O 
results O 
indicate O 
that O 
compounds O 
8a O 
, O 
8g O 
, O 
and O 
9f O 
represent O 
a O 
new O 
structural O 
lead O 
for O 
this O 
serious O 
and O 
neglected O 
disease O 
. O 

trifluoromethyl B-SYSTEMATIC 
quinolone I-SYSTEMATIC 
derivatives O 
: O 
Synthesis O 
and O 
investigation O 
of O 
antimicrobial O 
properties O 
. O 

series O 
of O 
quinolone B-FAMILY 
derivatives O 
, O 
containing O 
different O 
heterocyclic B-FAMILY 
amines I-FAMILY 
were O 
prepared O 
. O 
Synthesized O 
compounds O 
were O 
evaluated O 
for O 
their O 
in O 
vitro O 
antimicrobial O 
activities O 
against O 
two O 
Gram O 
- O 
positive O 
bacteria O 
, O 
three O 
Gram O 
- O 
negative O 
bacteria O 
as O 
well O 
as O 
four O 
fungi O 
. O 
All O 
the O 
derivatives O 
showed O 
good O 
activity O 
towards O 
Gram O 
- O 
positive O 
bacteria O 
and O 
less O 
activity O 
towards O 
Gram O 
- O 
negative O 
bacteria O 
. O 
They O 
also O 
showed O 
moderate O 
to O 
comparable O 
activity O 
against O 
Aspergillus O 
niger O 
and O 
Candida O 
albicans O 
and O 
low O 
to O 
moderate O 
antifungal O 
activity O 
against O 
Aspergillus O 
fumigatus O 
and O 
Aspergillus O 
flavus O 
. O 

is O 
associated O 
with O 
a O 
major O 
prevalence O 
of O 
cardiovascular O 
risk O 
factors O 
and O 
high O 
risk O 
of O 
cardiovascular O 
events O 
and O 
contributes O 
to O 
the O 
increase O 
in O 
cardiovascular O 
morbidity O 
and O 
mortality O 
worldwide O 
. O 
Beyond O 
the O 
fat O 
mass O 
per O 
se O 
, O 
the O 
pattern O 
of O 
fat O 
distribution O 
has O 
a O 
profound O 
influence O 
on O 
cardiometabolic O 
risk O 
. O 
The O 
increase O 
in O 
abdominal O 
adipose O 
tissue O 
confers O 
an O 
independent O 
risk O 
, O 
while O 
the O 
amount O 
of O 
gluteofemoral O 
body O 
fat O 
is O 
thought O 
to O 
be O 
protective O 
. O 
Changes O 
in O 
the O 
capacity O 
of O 
different O 
depots O 
to O 
store O 
and O 
release O 
fatty B-FAMILY 
acids I-FAMILY 
and O 
to O 
produce O 
adipocytokines O 
are O 
important O 
determinants O 
of O 
fat O 
distribution O 
and O 
its O 
metabolic O 
consequences O 
. O 
Because O 
of O 
the O 
complexity O 
of O 
the O 
assessment O 
of O 
body O 
fat O 
with O 
imaging O 
techniques O 
, O 
great O 
attention O 
has O 
been O 
paid O 
to O 
other O 
measures O 
of O 
adiposity O 
, O 
such O 
as O 
waist O 
circumference O 
( O 
WC O 
) O 
, O 
waist O 
- O 
to O 
- O 
hip O 
ratio O 
( O 
WHR O 
) O 
and O 
waist O 
- O 
to O 
- O 
height O 
ratio O 
( O 
WHtR O 
) O 
, O 
which O 
provide O 
information O 
on O 
body O 
fat O 
distribution O 
, O 
although O 
BMI O 
is O 
the O 
established O 
clinical O 
measure O 
to O 
estimate O 
the O 
cardiovascular O 
risk O 
disease O 
associated O 
with O 
excessive O 
body O 
weight O 
. O 
Abdominal O 
obesity O 
is O 
a O 
main O 
predictive O 
factor O 
of O 
the O 
Metabolic O 
Syndrome O 
, O 
so O 
it O 
is O 
certain O 
that O 
it O 
represents O 
a O 
better O 
marker O 
of O 
cardiovascular O 
risk O 
than O 
BMI O 
. O 
Visceral O 
adiposity O 
index O 
( O 
VAI O 
) O 
has O 
recently O 
proven O 
to O 
be O 
a O 
marker O 
of O 
visceral O 
adipose O 
distribution O 
and O 
function O 
, O 
associated O 
with O 
insulin O 
sensitivity O 
in O 
patients O 
at O 
metabolic O 
risk O 
; O 
however O 
, O 
the O 
evidence O 
needs O 
to O 
be O 
further O 
confirmed O 
. O 
In O 
summary O 
, O 
BMI O 
, O 
WC O 
, O 
WHR O 
, O 
WHtR O 
and O 
VAI O 
are O 
all O 
useful O 
tools O 
for O 
assessing O 
adiposity O 
/ O 
obesity O 
in O 
clinical O 
practice O 
, O 
and O 
should O 
be O 
evaluated O 
along O 
with O 
other O 
cardiometabolic O 
risk O 
factors O 
to O 
define O 
cardiovascular O 
risk O 
stratification O 
. O 

produced O 
by O 
marine O 
organisms O 
can O 
offer O 
useful O 
tools O 
for O 
regenerative O 
medicine O 
. O 
Particularly O 
, O 
HE800 O 
exopolysaccharide O 
( O 
HE800 O 
EPS O 
) O 
secreted O 
by O 
a O 
deep O 
- O 
sea O 
hydrothermal O 
bacterium O 
displays O 
an O 
interesting O 
glycosaminoglycan O 
- O 
like O 
feature O 
resembling O 
hyaluronan O 
. O 
Previous O 
studies O 
demonstrated O 
its O 
effectiveness O 
to O 
enhance O 
in O 
vivo O 
bone O 
regeneration O 
and O 
to O 
support O 
osteoblastic O 
cell O 
metabolism O 
in O 
culture O 
. O 
Thus O 
, O 
in O 
order O 
to O 
assess O 
the O 
usefulness O 
of O 
this O 
high O 
- O 
molecular O 
weight O 
polymer O 
in O 
tissue O 
engineering O 
and O 
tissue O 
repair O 
, O 
in O 
vitro O 
reconstructed O 
connective O 
tissues O 
containing O 
HE800 O 
EPS O 
were O 
performed O 
. O 
We O 
showed O 
that O 
this O 
polysaccharide O 
promotes O 
both O 
collagen O 
structuring O 
and O 
extracellular O 
matrix O 
settle O 
by O 
dermal O 
fibroblasts O 
. O 
Furthermore O 
, O 
from O 
the O 
native O 
HE800 O 
EPS O 
, O 
a O 
low O 
- O 
molecular O 
weight O 
sulfated O 
derivative O 
( O 
HE800 O 
DROS O 
) O 
displaying O 
chemical O 
analogy O 
with O 
heparan- O 
sulfate B-SYSTEMATIC 
, O 
was O 
designed O 
. O 
Thus O 
, O 
it O 
was O 
demonstrated O 
that O 
HE800 O 
DROS O 
mimics O 
some O 
properties O 
of O 
heparan- O 
sulfate B-SYSTEMATIC 
, O 
such O 
as O 
promotion O 
of O 
fibroblast O 
proliferation O 
and O 
inhibition O 
of O 
matrix O 
metalloproteinase O 
( O 
MMP O 
) O 
secretion O 
. O 
Therefore O 
, O 
we O 
suggest O 
that O 
the O 
HE800EPS O 
family O 
can O 
be O 
considered O 
as O 
an O 
innovative O 
biotechnological O 
source O 
of O 
glycosaminoglycan O 
- O 
like O 
compounds O 
useful O 
to O 
design O 
biomaterials O 
and O 
drugs O 
for O 
tissue O 
engineering O 
and O 
repair O 
. O 

RELEVANCE O 
: O 
To O 
evaluate O 
the O 
antiprotozoal O 
activity O 
and O 
cytotoxicity O 
of O 
extracts O 
and O 
fractions O 
from O 
the O 
leaves O 
, O 
root O 
bark O 
and O 
stem O 
bark O 
of O 
Alstonia O 
congensis O 
( O 
Apocynaceae O 
) O 
, O 
used O 
in O 
traditional O 
medicine O 
against O 
parasitic O 
diseases O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
The O 
aqueous O 
and O 
80% O 
MeOH B-FORMULA 
extracts O 
, O 
and O 
a O 
series O 
of O 
fractions O 
and O 
subfractions O 
from O 
the O 
leaves O 
, O 
stem O 
and O 
root O 
bark O 
of O 
Alstonia O 
congensis O 
were O 
tested O 
in O 
vitro O 
for O 
their O 
antiprotozoal O 
activity O 
against O 
Trypanosoma O 
brucei O 
brucei O 
, O 
Trypanosoma O 
cruzi O 
, O 
Lesihamania O 
infantum O 
and O 
the O 
chloroquine B-TRIVIAL 
and O 
pyrimethamine B-TRIVIAL 
-resitant O 
K1 O 
strain O 
of O 
Plasmodium O 
falciparum O 
. O 
Their O 
cytotoxicity O 
on O 
MRC-5 O 
cells O 
( O 
human O 
lung O 
fibroblasts O 
) O 
was O 
evaluated O 
as O 
well O 
. O 
RESULTS O 
: O 
The O 
aqueous O 
and O 
80% O 
MeOH B-FORMULA 
extracts O 
and O 
a O 
series O 
of O 
subfractions O 
of O 
each O 
plant O 
part O 
exhibited O 
pronounced O 
antiprotozoal O 
activity O 
against O 
the O 
K1 O 
strain O 
of O 
Plasmodium O 
falciparum O 
with O 
IC50 O 
values O 
ranging O 
from O 
2 O 
to O 
5µg O 
/ O 
ml O 
, O 
and O 
good O 
activity O 
against O 
Trypanosoma O 
brucei O 
brucei O 
and O 
Trypanosoma O 
cruzi O 
with O 
IC50 O 
values O 
ranging O 
between O 
5 O 
and O 
10µg O 
/ O 
ml O 
. O 
The O 
residual O 
80% O 
MeOH B-FORMULA 
extract O 
from O 
the O 
leaves O 
, O 
and O 
the O 
total O 
alkaloid O 
extract O 
from O 
stem O 
and O 
root O 
bark O 
were O 
the O 
only O 
subfractions O 
active O 
against O 
Leishmania O 
infantum O 
with O 
IC50 O 
values O 
< O 
10µg O 
/ O 
ml O 
. O 
None O 
of O 
the O 
samples O 
from O 
the O 
root O 
bark O 
was O 
cytotoxic O 
against O 
MRC-cell O 
lines O 
( O 
CC50 O 
> O 
64µg O 
/ O 
ml O 
) O 
. O 
In O 
general O 
, O 
the O 
aqueous O 
extracts O 
( O 
traditional O 
decoctions O 
) O 
showed O 
the O 
highest O 
selectivity O 
, O 
especially O 
against O 
Plasmodium O 
falciparum O 
. O 
CONCLUSION O 
: O 
These O 
results O 
can O 
partly O 
support O 
and O 
justify O 
the O 
traditional O 
use O 
of O 
these O 
plant O 
parts O 
of O 
Alstonina O 
congensis O 
as O 
raw O 
materials O 
for O 
the O 
preparation O 
of O 
traditional O 
remedies O 
to O 
treat O 
parasitic O 
diseases O 
such O 
as O 
malaria O 
and O 
trypanosomiasis O 
. O 

of O 
hydrated O 
cobalt B-SYSTEMATIC 
ions O 
confined O 
in O 
the O 
nanospace O 
of O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
. O 

structure O 
of O 
hydrated O 
Co B-FORMULA 
ions O 
confined O 
in O 
the O 
nanospace O 
of O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWNTs O 
) O 
has O 
been O 
studied O 
using O 
the O 
X-ray O 
absorption O 
fine O 
structure O 
( O 
XAFS O 
) O 
technique O 
. O 
Water O 
adsorption O 
isotherms O 
on O 
Co B-FORMULA 
-impregnated O 
SWNTs O 
indicate O 
a O 
high O 
affinity O 
of O 
Co B-FORMULA 
ions O 
to O 
water O 
molecules O 
. O 
The O 
results O 
of O 
XAFS O 
analysis O 
provided O 
the O 
information O 
on O 
the O 
proportion O 
of O 
dissolved O 
species O 
in O 
nanospaces O 
against O 
the O 
total O 
amount O 
of O 
cobalt B-SYSTEMATIC 
ions O 
adsorbed O 
on O 
the O 
open O 
- O 
pored O 
SWNT O 
. O 
The O 
structural O 
information O 
of O 
the O 
first O 
shell O 
around O 
a O 
Co B-FORMULA 
ion O 
was O 
expressed O 
in O 
terms O 
of O 
the O 
hydration O 
number O 
, O 
Co-O B-FORMULA 
distance O 
and O 
Debye-Waller O 
factor O 
. O 
The O 
actual O 
coordination O 
number O 
and O 
the O 
interatomic O 
distance O 
of O 
Co-O B-FORMULA 
for O 
the O 
dissolved O 
species O 
were O 
remarkably O 
reduced O 
compared O 
to O 
the O 
bulk O 
aqueous O 
solution O 
indicating O 
the O 
dehydration O 
of O 
water O 
molecules O 
from O 
Co B-FORMULA 
ions O 
and O 
a O 
compact O 
hydrated O 
structure O 
in O 
the O 
micropore O 
of O 
SWNTs O 
. O 

cells O 
recover O 
from O 
a O 
DNA O 
damage O 
- O 
induced O 
arrest O 
is O 
currently O 
poorly O 
understood O 
. O 
We O 
performed O 
large O 
- O 
scale O 
quantitative O 
phosphoproteomics O 
to O 
identify O 
changes O 
in O 
protein O 
phosphorylation O 
that O 
occurred O 
during O 
recovery O 
from O 
arrest O 
in O 
the O 
G2 O 
phase O 
of O 
the O 
cell O 
cycle O 
caused O 
by O 
DNA O 
damage O 
. O 
We O 
identified O 
154 O 
proteins O 
that O 
were O 
differentially O 
phosphorylated O 
, O 
and O 
systematic O 
depletion O 
of O 
each O 
of O 
these O 
differentially O 
phosphorylated O 
proteins O 
by O 
small O 
interfering O 
RNA O 
( O 
siRNA O 
) O 
identified O 
at O 
least O 
10 O 
potential O 
regulators O 
of O 
recovery O 
. O 
Astrin B-NO_CLASS 
, O 
a O 
protein O 
associated O 
with O 
the O 
mitotic O 
spindle O 
, O 
was O 
among O 
the O 
potential O 
regulators O 
of O 
recovery O 
. O 
We O 
found O 
that O 
astrin O 
controlled O 
the O 
abundance O 
of O 
the O 
cell O 
cycle O 
regulator O 
p53 O 
during O 
DNA O 
damage O 
- O 
induced O 
arrest O 
. O 
Cells O 
in O 
which O 
astrin B-NO_CLASS 
was O 
depleted O 
had O 
decreased O 
murine O 
double O 
minute O 
2 O 
( O 
MDM2 O 
) O 
abundance O 
and O 
increased O 
p53 O 
at O 
the O 
later O 
stages O 
of O 
the O 
DNA O 
damage O 
response O 
. O 
Astrin B-NO_CLASS 
was O 
required O 
for O 
continued O 
expression O 
of O 
genes O 
encoding O 
proteins O 
that O 
promote O 
cell O 
cycle O 
progression O 
in O 
arrested O 
cells O 
. O 
Thus O 
, O 
by O 
controlling O 
p53 O 
abundance O 
in O 
cells O 
recovering O 
from O 
DNA O 
damage O 
, O 
astrin O 
maintains O 
the O 
cells O 
in O 
a O 
state O 
competent O 
to O 
resume O 
the O 
cell O 
cycle O 
. O 

molecular O 
mechanism O 
for O 
therapeutic O 
effects O 
of O 
cGMP B-ABBREVIATION 
-elevating O 
agents O 
in O 
pulmonary O 
arterial O 
hypertension O 
. O 

arterial O 
hypertension O 
(PAH)5 O 
is O 
a O 
progressive O 
, O 
usually O 
fatal O 
disease O 
with O 
abnormal O 
vascular O 
remodeling O 
. O 
Pulmonary O 
artery O 
smooth O 
muscle O 
cells O 
( O 
PASMCs O 
) O 
from O 
PAH O 
patients O 
are O 
hyper O 
- O 
proliferative O 
and O 
apoptosis O 
- O 
resistant O 
, O 
and O 
demonstrate O 
decreased O 
signaling O 
in O 
response O 
to O 
bone O 
morphogenetic O 
proteins O 
( O 
BMPs O 
) O 
. O 
Cyclic B-TRIVIAL 
GMP I-TRIVIAL 
-elevating O 
agents O 
are O 
beneficial O 
in O 
PAH O 
, O 
but O 
their O 
mechanism(s) O 
of O 
action O 
are O 
incompletely O 
understood O 
. O 
Here O 
we O 
show O 
that O 
BMP O 
signaling O 
via O 
Smad1 O 
/ O 
5 O 
/ O 
8 O 
requires O 
cGMP B-ABBREVIATION 
-dependent O 
protein O 
kinase O 
isotype O 
I O 
( O 
PKGI O 
) O 
to O 
maintain O 
PASMCs O 
in O 
a O 
differentiated O 
, O 
low O 
- O 
proliferative O 
state O 
. O 
BMP O 
cooperation O 
with O 
cGMP B-ABBREVIATION 
/ O 
PKGI O 
was O 
crucial O 
for O 
transcription O 
of O 
contractile O 
genes O 
, O 
and O 
suppression O 
of O 
pro O 
- O 
proliferative O 
and O 
anti-apoptotic O 
genes O 
. O 
Lungs O 
from O 
mice O 
with O 
low O 
or O 
absent O 
PKGI O 
( O 
Prkg1+ O 
/ O 
- O 
and O 
Prkg1- O 
/ O 
- O 
mice O 
) O 
exhibited O 
impaired O 
BMP O 
signaling O 
, O 
decreased O 
contractile O 
gene O 
expression O 
, O 
and O 
abnormal O 
vascular O 
remodeling O 
. O 
Conversely O 
, O 
cGMP B-ABBREVIATION 
stimulation O 
of O 
PKGI O 
restored O 
defective O 
BMP O 
signaling O 
in O 
rats O 
with O 
hypoxia O 
- O 
induced O 
PAH O 
, O 
consistent O 
with O 
cGMP B-ABBREVIATION 
-elevating O 
agents O 
reversing O 
vascular O 
remodeling O 
in O 
this O 
PAH O 
model O 
. O 
Our O 
results O 
provide O 
a O 
mechanism O 
for O 
the O 
therapeutic O 
effects O 
of O 
cGMP B-ABBREVIATION 
-elevating O 
agents O 
in O 
PAH O 
, O 
and O 
suggest O 
that O 
combining O 
them O 
with O 
BMP O 
mimetics O 
may O 
provide O 
a O 
novel O 
, O 
disease O 
- O 
modifying O 
approach O 
to O 
PAH O 
therapy O 
. O 

in O 
vivo O 
TRPV6 O 
protein O 
starts O 
at O 
a O 
non-AUG O 
triplet O 
decoded O 
as O 
methionine B-TRIVIAL 
upstream O 
the O 
canonical O 
initiation O 
at O 
AUG O 
. O 

channels O 
function O 
as O 
epithelial O 
Ca2+ B-FORMULA 
entry O 
pathways O 
in O 
the O 
epididymis O 
, O 
prostate O 
and O 
placenta O 
. O 
However O 
, O 
like O 
of O 
most O 
proteins O 
the O 
identity O 
of O 
the O 
endogenous O 
TRPV6 O 
protein O 
relies O 
on O 
predicted O 
gene O 
coding O 
regions O 
and O 
is O 
only O 
known O 
to O 
a O 
certain O 
level O 
of O 
approximation O 
. O 
We O 
show O 
that O 
in O 
vivo O 
the O 
TRPV6 O 
protein O 
has O 
an O 
extended O 
N B-FORMULA 
-terminus O 
. O 
Translation O 
initiates O 
at O 
a O 
non-AUG O 
codon O 
, O 
at O 
ACG O 
, O 
which O 
is O 
decoded O 
by O 
methionine B-TRIVIAL 
and O 
which O 
is O 
upstream O 
of O 
the O 
annotated O 
AUG O 
which O 
is O 
not O 
used O 
for O 
initiation O 
. O 
The O 
in O 
vitro O 
properties O 
of O 
channels O 
formed O 
by O 
the O 
extended O 
full O 
length O 
TRPV6 O 
proteins O 
and O 
the O 
so O 
far O 
annotated O 
and O 
shorter O 
TRPV6 O 
are O 
similar O 
, O 
but O 
the O 
extended O 
N B-FORMULA 
-terminus O 
increases O 
trafficking O 
to O 
the O 
plasma O 
membrane O 
and O 
represents O 
an O 
additional O 
scaffold O 
for O 
channel O 
assembly O 
. O 
The O 
increased O 
translation O 
of O 
the O 
shorter O 
TRPV6 O 
cDNA O 
version O 
may O 
overestimate O 
the O 
in O 
vivo O 
situation O 
where O 
translation O 
efficiency O 
may O 
represent O 
an O 
additional O 
mechanism O 
to O 
tightly O 
control O 
the O 
TRPV6 O 
- O 
mediated O 
Ca2+ B-FORMULA 
entry O 
in O 
order O 
to O 
prevent O 
deleterious O 
Ca2+ B-FORMULA 
overload O 
. O 

in O 
Situ O 
Mixed O 
Film O 
Formation O 
by O 
Azo B-SYSTEMATIC 
Coupling O 
and O 
Diazonium B-SYSTEMATIC 
Salt I-SYSTEMATIC 
Electrografting O 
. O 

simple O 
: O 
The O 
in O 
situ O 
synthesis O 
of O 
an O 
aryldiazonium B-FAMILY 
salt I-FAMILY 
and O 
an O 
azo B-FAMILY 
- I-FAMILY 
aryldiazonium I-FAMILY 
salt I-FAMILY 
by O 
azo B-SYSTEMATIC 
coupling O 
from O 
sulfanilic B-TRIVIAL 
acid I-TRIVIAL 
and O 
aniline B-SYSTEMATIC 
is O 
reported O 
. O 
Formation O 
of O 
a O 
mixed O 
organic O 
layer O 
is O 
monitored O 
by O 
cyclic O 
voltammetry O 
and O 
atomic O 
force O 
microscopy O 
. O 
A O 
compact O 
mixed O 
layer O 
is O 
obtained O 
with O 
a O 
global O 
roughness O 
of O 
0.4 O 
nm O 
and O 
10-15 O 
% O 
vertical O 
extension O 
in O 
the O 
range O 
1.5-6 O 
nm O 
. O 

cibarius O 
Fr O 
. O 
( O 
chanterelle O 
) O 
and O 
Boletus O 
badius O 
Pers O 
. O 
( O 
bay O 
bolete O 
) O 
harvested O 
from O 
natural O 
sites O 
in O 
Poland O 
were O 
used O 
to O 
derive O 
in O 
vitro O 
cultures O 
. O 
The O 
optimal O 
medium O 
composition O 
for O 
cultures O 
was O 
developed O 
. O 
Concentrations O 
of O 
the O 
chosen O 
elements O 
( O 
Zn B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Fe B-FORMULA 
, O 
Mg B-FORMULA 
, O 
Ni B-FORMULA 
, O 
and O 
Cd B-FORMULA 
) O 
in O 
mycelium O 
samples O 
were O 
measured O 
by O 
means O 
of O 
atomic O 
absorption O 
spectrometry O 
. O 
Fe B-FORMULA 
concentration O 
in O 
the O 
analyzed O 
mushroom O 
materials O 
was O 
in O 
the O 
range O 
215.4-680.3 O 
μg O 
/ O 
g O 
dry O 
weight O 
. O 
Mean O 
values O 
of O 
Mg B-FORMULA 
were O 
respectively O 
( O 
in O 
micrograms O 
per O 
gram O 
dry O 
weight O 
) O 
541.8 O 
for O 
mycelium O 
of O 
C O 
. O 
cibarius O 
cultured O 
in O 
vitro O 
and O 
1004.1 O 
for O 
C O 
. O 
cibarius O 
fruiting O 
bodies O 
and O 
928.9 O 
for O 
the O 
mycelium O 
of O 
B O 
. O 
badius O 
cultured O 
in O 
vitro O 
and O 
906.4 O 
for O 
B O 
. O 
badius O 
fruiting O 
bodies O 
. O 
The O 
mean O 
concentrations O 
of O 
Zn B-FORMULA 
were O 
442.7 O 
μg O 
/ O 
g O 
dry O 
weight O 
in O 
mycelium O 
from O 
in O 
vitro O 
cultures O 
of O 
B O 
. O 
badius O 
and O 
172.1 O 
in O 
B O 
. O 
badius O 
fruiting O 
bodies O 
and O 
131.9 O 
in O 
the O 
case O 
of O 
C O 
. O 
cibarius O 
in O 
mycelium O 
from O 
in O 
vitro O 
cultures O 
and O 
95.5 O 
for O 
the O 
C O 
. O 
cibarius O 
fruiting O 
bodies O 
. O 
Cu B-FORMULA 
exhibited O 
a O 
reversal O 
tendency O 
, O 
i.e O 
. O 
, O 
the O 
element O 
concentrations O 
in O 
naturally O 
grown O 
mushrooms O 
were O 
significantly O 
higher O 
( O 
43.57 O 
μg O 
/ O 
g O 
dry O 
weight O 
for O 
C O 
. O 
cibarius O 
and O 
43.54 O 
μg O 
/ O 
g O 
for O 
B O 
. O 
badius O 
) O 
than O 
in O 
cultured O 
in O 
vitro O 
mycelium O 
( O 
12.47 O 
μg O 
/ O 
g O 
for O 
C O 
. O 
cibarius O 
and O 
4.17 O 
μg O 
/ O 
g O 
for O 
B O 
. O 
badius O 
) O 
. O 
Ni B-FORMULA 
was O 
found O 
in O 
lowest O 
concentrations O 
ranging O 
from O 
0.33 O 
to O 
1.88 O 
μg O 
/ O 
g O 
dry O 
weight O 
. O 
Toxic O 
metal O 
Cd B-FORMULA 
was O 
found O 
in O 
relatively O 
high O 
concentrations O 
in O 
naturally O 
grown O 
species O 
( O 
0.79 O 
μg O 
/ O 
g O 
dry O 
weight-1.02 O 
) O 
. O 
The O 
lowest O 
was O 
the O 
concentration O 
of O 
Cd B-FORMULA 
in O 
C O 
. O 
cibarius O 
mycelium O 
from O 
in O 
vitro O 
culture-0.06 O 
μg O 
/ O 
g O 
dry O 
weight-a O 
bit O 
higher O 
than O 
it O 
was O 
in O 
the O 
B O 
. O 
badius O 
mycelium O 
( O 
0.21 O 
μg O 
/ O 
g O 
) O 
. O 

Polysilsesquioxane B-FAMILY 
Nanoparticles O 
as O 
Efficient O 
Contrast O 
Agents O 
for O 
Magnetic O 
Resonance O 
Imaging O 
. O 

( O 
PSQ B-ABBREVIATION 
) O 
nanoparticles O 
are O 
crosslinked O 
homopolymers O 
formed O 
by O 
condensation O 
of O 
functionalized O 
trialkoxysilanes B-FAMILY 
, O 
and O 
provide O 
an O 
interesting O 
platform O 
for O 
developing O 
biologically O 
and O 
biomedically O 
relevant O 
nanomaterials O 
. O 
In O 
this O 
work O 
, O 
the O 
design O 
and O 
synthesis O 
of O 
biodegradable O 
PSQ B-ABBREVIATION 
particles O 
with O 
extremely O 
high O 
payloads O 
of O 
paramagnetic O 
Gd B-FORMULA 
(III) I-FORMULA 
centers O 
is O 
explored O 
, O 
for O 
use O 
as O 
efficient O 
contrast O 
agents O 
for O 
magnetic O 
resonance O 
imaging O 
( O 
MRI O 
) O 
. O 
Two O 
new O 
bis(trialkoxysilyl) B-FAMILY 
derivatives O 
of O 
Gd B-SYSTEMATIC 
(III) I-SYSTEMATIC 
diethylenetriamine I-SYSTEMATIC 
pentaacetate I-SYSTEMATIC 
( O 
Gd-DTPA B-FORMULA 
) O 
containing O 
disulfide B-SYSTEMATIC 
linkages O 
are O 
synthesized O 
and O 
used O 
to O 
form O 
biodegradable O 
Gd-PSQ B-FORMULA 
particles O 
by O 
base O 
- O 
catalyzed O 
condensation O 
reactions O 
in O 
reverse O 
microemulsions O 
. O 
The O 
Gd-PSQ B-FORMULA 
particles O 
, O 
PSQ-1 O 
and O 
PSQ-2 O 
, O 
carry O 
53.8 O 
wt% O 
and O 
49.3 O 
wt% O 
of O 
Gd-DTPA B-FORMULA 
derivatives O 
, O 
respectively O 
. O 
In O 
addition O 
, O 
the O 
surface O 
carboxy O 
groups O 
on O 
the O 
PSQ-2 O 
particles O 
can O 
be O 
modified O 
with O 
polyethylene O 
glycol O 
( O 
PEG O 
) O 
and O 
the O 
anisamide O 
( O 
AA O 
) O 
ligand O 
to O 
enhance O 
biocompatibility O 
and O 
cell O 
uptake O 
, O 
respectively O 
. O 
The O 
Gd-PSQ B-FORMULA 
particles O 
are O 
readily O 
degradable O 
to O 
release O 
the O 
constituent O 
Gd B-FORMULA 
(III) I-FORMULA 
chelates O 
in O 
the O 
presence O 
of O 
endogenous O 
reducing O 
agents O 
such O 
as O 
cysteine B-TRIVIAL 
and O 
glutathione B-TRIVIAL 
. O 
The O 
MR O 
relaxivities O 
of O 
the O 
Gd-PSQ B-FORMULA 
particles O 
are O 
determined O 
using O 
a O 
3T O 
MR O 
scanner O 
, O 
with O 
r1 O 
values O 
ranging O 
from O 
5.9 O 
to O 
17.8 O 
mMs(-1) O 
on O 
a O 
per- O 
Gd B-FORMULA 
basis O 
. O 
Finally O 
, O 
the O 
high O 
sensitivity O 
of O 
the O 
Gd-PSQ B-FORMULA 
particles O 
as O 
T1 O 
-weighted O 
MR O 
contrast O 
agents O 
is O 
demonstrated O 
with O 
in O 
vitro O 
MR O 
imaging O 
of O 
human O 
lung O 
and O 
pancreatic O 
cancer O 
cells O 
. O 
The O 
enhanced O 
efficiency O 
of O 
the O 
anisamide B-TRIVIAL 
-functionalized O 
PSQ-2 O 
particles O 
as O 
a O 
contrast O 
agent O 
is O 
corroborated O 
by O 
both O 
confocal O 
laser O 
scanning O 
microscopy O 
imaging O 
and O 
ICP-MS O 
analysis O 
of O 
Gd B-FORMULA 
content O 
in O 
vitro O 
. O 

HP-2MG O 
modified O 
with O 
2-(2,6-dichlorobenzylideneamino) B-SYSTEMATIC 
benzenethiol I-SYSTEMATIC 
as O 
new O 
adsorbent O 
for O 
solid O 
phase O 
extraction O 
and O 
flame O 
atomic O 
absorption O 
spectrometric O 
determination O 
of O 
metal O 
ions O 
. O 

solid O 
phase O 
extraction O 
method O 
for O 
enrichment-separation O 
and O 
the O 
determination O 
of O 
cobalt B-SYSTEMATIC 
( O 
Co(2+) B-FORMULA 
) O 
, O 
copper B-SYSTEMATIC 
( O 
Cu(2+) B-FORMULA 
) O 
, O 
nickel B-SYSTEMATIC 
( O 
Ni(2+) B-FORMULA 
) O 
, O 
zinc B-SYSTEMATIC 
( O 
Zn(2+) B-FORMULA 
) O 
and O 
lead O 
( O 
Pb(2+) B-FORMULA 
) O 
ions O 
in O 
real O 
samples O 
has O 
been O 
proposed O 
. O 
The O 
influences O 
of O 
some O 
analytical O 
parameters O 
like O 
pH O 
, O 
flow O 
rate O 
, O 
eluent O 
type O 
and O 
interference O 
of O 
matrix O 
ions O 
on O 
recoveries O 
of O 
analytes O 
were O 
optimized O 
. O 
The O 
limits O 
of O 
detection O 
were O 
found O 
in O 
the O 
range O 
of O 
1.6-3.9 O 
µg O 
L(-1) O 
, O 
while O 
preconcentration O 
factor O 
for O 
all O 
understudy O 
metal O 
ions O 
were O 
found O 
to O 
be O 
166 O 
with O 
loading O 
half O 
time O 
( O 
t O 
1 O 
/ O 
2 O 
) O 
less O 
than O 
10 O 
min O 
. O 
The O 
procedure O 
was O 
applied O 
for O 
the O 
enrichment-separation O 
of O 
analyte O 
ions O 
in O 
environmental O 
samples O 
with O 
recoveries O 
higher O 
than O 
94.8% O 
and O 
relative O 
SD O 
< O 
4.9% O 
( O 
N O 
= O 
5 O 
) O 
. O 

factor O 
receptor O 
- O 
bound O 
protein O 
10(Grb10)is O 
a O 
Src O 
homology O 
2 O 
( O 
SH2 O 
) O 
domain O 
- O 
containing O 
protein O 
and O 
one O 
of O 
the O 
binding O 
partners O 
for O 
several O 
trans-membrane O 
tyrosine B-TRIVIAL 
-kinase O 
receptors O 
, O 
including O 
insulin O 
receptor O 
( O 
IR O 
) O 
and O 
insulin O 
- O 
like O 
growth O 
factor-1 O 
receptor O 
( O 
IGF1-R O 
) O 
. O 
The O 
hippocampus O 
, O 
which O 
is O 
critical O 
for O 
cognitive O 
functions O 
, O 
is O 
one O 
of O 
the O 
main O 
distribution O 
areas O 
of O 
Grb10 O 
in O 
the O 
central O 
nervous O 
system O 
. O 
In O 
recent O 
years O 
, O 
diabetic O 
encephalopathy O 
has O 
been O 
defined O 
as O 
a O 
third O 
type O 
of O 
diabetes O 
and O 
the O 
IGF1-IR O 
pathway O 
has O 
been O 
shown O 
to O 
be O 
critical O 
for O 
the O 
neuropathogenic O 
process O 
of O 
cognitive O 
disorder O 
in O 
diabetes O 
. O 
However O 
, O 
the O 
role O 
of O 
endogenous O 
Grb10 O 
in O 
regulating O 
the O 
IGF1-IR O 
pathway O 
and O 
neurobehavioral O 
changes O 
is O 
not O 
explicit O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
in O 
vivo O 
function O 
of O 
endogenous O 
Grb10 O 
in O 
diabetic O 
encephalopathy O 
and O 
the O 
underlying O 
mechanisms O 
. O 
Using O 
stereotaxic O 
surgical O 
techniques O 
and O 
lentiviral O 
vectors O 
expressing O 
specific O 
short O 
hairpin O 
RNA O 
( O 
shRNA O 
) O 
, O 
we O 
could O 
steadily O 
knock O 
down O 
Grb10 O 
expression O 
in O 
the O 
hippocampus O 
. O 
More O 
importantly O 
, O 
we O 
demonstrated O 
that O 
hippocampus O 
- O 
specific O 
modulation O 
of O 
Grb10 O 
protein O 
levels O 
led O 
to O 
a O 
prominent O 
remission O 
of O 
cognitive O 
disorder O 
, O 
including O 
improvements O 
in O 
both O 
ultrastructural O 
pathology O 
and O 
abnormal O 
neurobehavioural O 
changes O 
. O 
Our O 
findings O 
indicate O 
that O 
endogenous O 
overexpression O 
of O 
Grb10 O 
functions O 
as O 
a O 
suppressor O 
of O 
the O 
IGF1-IR O 
pathway O 
, O 
which O 
may O 
represent O 
an O 
important O 
mechanism O 
that O 
regulates O 
cognitive O 
disorder O 
in O 
diabetes O 
. O 
This O 
article O 
is O 
protected O 
by O 
copyright O 
. O 
All O 
rights O 
reserved O 
. O 

new O 
ent-kaurane B-TRIVIAL 
diterpenoid B-FAMILY 
glycoside I-FAMILY 
from O 
Isodon O 
japonica O 
var O 
. O 
glaucocalyx O 
. O 

new O 
ent-kaurane B-TRIVIAL 
diterpenoid B-FAMILY 
glycoside I-FAMILY 
( O 
1 O 
) O 
, O 
named O 
glaucocalyxin B-TRIVIAL 
G I-TRIVIAL 
, O 
has O 
been O 
isolated O 
from O 
the O 
n-butanol B-SYSTEMATIC 
-soluble O 
fraction O 
of O 
the O 
dried O 
whole O 
plants O 
of O 
Isodon O 
japonica O 
var O 
. O 
glaucocalyx O 
along O 
with O 
two O 
known O 
compounds O 
, O 
namely O 
arjunglucoside B-TRIVIAL 
( O 
2 O 
) O 
and O 
kaempferol-3-O-rutinoside B-SYSTEMATIC 
( O 
3 O 
) O 
. O 
The O 
structures O 
of O 
the O 
isolated O 
compounds O 
were O 
assigned O 
on O 
the O 
basis O 
of O 
their O 
(1)H B-FORMULA 
and O 
(13)C B-FORMULA 
NMR O 
spectra O 
including O 
two O 
- O 
dimensional O 
NMR O 
techniques O 
such O 
as O 
HMQC O 
, O 
HMBC O 
, O 
and O 
NOESY O 
experiments O 
and O 
comparison O 
with O 
the O 
literature O 
data O 
. O 

1 O 
. O 
Cytochrome O 
P450 O 
2D6 O 
( O 
CYP2D6 O 
) O 
is O 
a O 
pivotal O 
enzyme O 
responsible O 
for O 
a O 
major O 
drug O 
oxidation O 
polymorphism O 
in O 
human O 
populations O 
. O 
Distribution O 
of O 
CYP2D6 O 
in O 
brain O 
and O 
its O 
role O 
in O 
serotonin B-TRIVIAL 
metabolism O 
suggest O 
that O 
CYP2D6 O 
may O 
have O 
a O 
function O 
in O 
the O 
central O 
nervous O 
system O 
. O 
2 O 
. O 
To O 
establish O 
an O 
efficient O 
and O 
accurate O 
platform O 
for O 
the O 
study O 
of O 
CYP2D6 O 
in O 
vivo O 
, O 
a O 
human O 
CYP2D6 O 
( O 
Tg-2D6 O 
) O 
model O 
was O 
generated O 
by O 
transgenesis O 
in O 
wild O 
- O 
type O 
( O 
WT O 
) O 
C57BL O 
/ O 
6 O 
mice O 
using O 
a O 
P1 O 
phage O 
artificial O 
chromosome O 
clone O 
containing O 
the O 
complete O 
human O 
CYP2D O 
locus O 
, O 
including O 
the O 
CYP2D6 O 
gene O 
and O 
5'- O 
and O 
3'-flanking O 
sequences O 
. O 
3 O 
. O 
Human O 
CYP2D6 O 
was O 
expressed O 
not O 
only O 
in O 
the O 
liver O 
but O 
also O 
in O 
the O 
brain O 
. O 
The O 
abundance O 
of O 
serotonin B-TRIVIAL 
and O 
5-hydroxyindoleacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
brain O 
of O 
Tg-2D6 O 
is O 
higher O 
than O 
in O 
WT O 
mice O 
, O 
either O 
basal O 
levels O 
or O 
after O 
harmaline B-TRIVIAL 
induction O 
. O 
Metabolomics O 
of O 
brain O 
homogenate O 
and O 
cerebrospinal O 
fluid O 
revealed O 
a O 
significant O 
up O 
- O 
regulation O 
of O 
L-carnitine B-TRIVIAL 
, O 
acetyl-L-carnitine B-SYSTEMATIC 
, O 
pantothenic B-TRIVIAL 
acid I-TRIVIAL 
, O 
2'-deoxycytidine B-SYSTEMATIC 
diphosphate I-SYSTEMATIC 
( O 
dCDP B-ABBREVIATION 
) O 
, O 
anandamide B-TRIVIAL 
, O 
N-acetylglucosaminylamine B-SYSTEMATIC 
and O 
a O 
down O 
- O 
regulation O 
of O 
stearoyl-L-carnitine B-TRIVIAL 
in O 
Tg-2D6 O 
mice O 
compared O 
with O 
WT O 
mice O 
. O 
Anxiety O 
tests O 
indicate O 
Tg-2D6 O 
mice O 
have O 
a O 
higher O 
capability O 
to O 
adapt O 
to O 
anxiety O 
. O 
4 O 
. O 
Overall O 
, O 
these O 
findings O 
indicate O 
that O 
the O 
Tg-2D6 O 
mouse O 
model O 
may O 
serve O 
as O 
a O 
valuable O 
in O 
vivo O 
tool O 
to O 
determine O 
CYP2D6-involved O 
neurophysiological O 
metabolism O 
and O 
function O 
. O 

Substrate-Confined O 
Sol-Gel O 
Coassembled O 
Ordered O 
Macroporous O 
Silica B-TRIVIAL 
Structures O 
with O 
an O 
Open O 
Surface O 
. O 

sol O 
- O 
gel O 
cooperative O 
assembly O 
method O 
was O 
demonstrated O 
for O 
the O 
fabrication O 
of O 
inverse O 
opal O 
films O 
with O 
an O 
open O 
surface O 
. O 
In O 
this O 
method O 
, O 
a O 
sol O 
- O 
gel O 
silicate B-FAMILY 
precursor O 
was O 
cooperatively O 
assembled O 
into O 
the O 
interstitial O 
spaces O 
of O 
microspheres O 
at O 
the O 
same O 
time O 
when O 
polystyrene O 
templates O 
formed O 
in O 
between O 
two O 
desired O 
substrates O 
. O 
Silica B-TRIVIAL 
inverse O 
opals O 
with O 
a O 
three O 
- O 
dimensional O 
ordered O 
macroporous O 
( O 
3DOM O 
) O 
structure O 
were O 
obtained O 
after O 
selective O 
removing O 
the O 
colloidal O 
templates O 
by O 
calcination O 
. O 
The O 
open O 
surfaces O 
with O 
a O 
high O 
degree O 
of O 
interconnected O 
porosity O 
and O 
extremely O 
uniform O 
pore O 
size O 
were O 
characterized O 
by O 
scanning O 
electron O 
microscope O 
( O 
SEM O 
) O 
. O 
Optical O 
transmission O 
spectra O 
reveals O 
the O 
existence O 
of O 
considerable O 
deep O 
band O 
gaps O 
of O 
up O 
to O 
70% O 
and O 
steep O 
band O 
edges O 
of O 
up O 
to O 
6% O 
/ O 
nm O 
in O 
the O 
[ O 
111 O 
] O 
directions O 
of O 
the O 
3DOM O 
silica B-TRIVIAL 
samples O 
. O 
A O 
little O 
shrinkage O 
confirmed O 
by O 
transmission O 
spectra O 
is O 
not O 
larger O 
than O 
3% O 
, O 
in O 
consistent O 
with O 
the O 
results O 
measured O 
by O 
SEM O 
, O 
which O 
revealing O 
the O 
sufficient O 
and O 
compact O 
infiltration O 
into O 
the O 
interstitial O 
spaces O 
by O 
our O 
confined O 
sol O 
- O 
gel O 
coassembly O 
method O 
. O 
With O 
different O 
incidence O 
angles O 
, O 
the O 
positions O 
of O 
pseudogaps O 
can O 
be O 
easily O 
tuned O 
in O 
the O 
wide O 
range O 
from O 
720 O 
nm O 
to O 
887 O 
nm O 
, O 
agreed O 
well O 
with O 
the O 
calculated O 
values O 
by O 
the O 
Bragg O 
law O 
. O 
All O 
the O 
results O 
prove O 
that O 
the O 
sol O 
- O 
gel O 
coassembly O 
method O 
with O 
two O 
substrates O 
confinement O 
is O 
a O 
simple O 
, O 
low O 
cost O 
, O 
convenient O 
and O 
versatile O 
method O 
for O 
the O 
fabrication O 
of O 
silica B-TRIVIAL 
inverse O 
opals O 
without O 
overlayers O 
in O 
large O 
domains O 
. O 

Context O 
: O 
High O 
malaria O 
burden O 
has O 
led O 
to O 
the O 
increased O 
use O 
of O 
insecticides O 
in O 
the O 
tropics O 
and O 
subtropics O 
. O 
This O 
study O 
thus O 
aimed O 
at O 
assessing O 
the O 
hematological O 
effects O 
alteration O 
of O 
pyrethroid B-FAMILY 
insecticide O 
exposure O 
using O 
the O 
experimental O 
animal O 
model O 
. O 
Objective O 
: O 
A O 
commonly O 
available O 
Electric O 
Mosquito-Repellent O 
Liquid O 
pyrethroid B-FAMILY 
insecticide O 
containing O 
prallethrin B-TRIVIAL 
1.6% O 
w O 
/ O 
w O 
is O 
widely O 
used O 
for O 
mosquito O 
control O 
in O 
Saudi O 
Arabia O 
. O 
The O 
immunotoxic O 
effects O 
after O 
inhalation O 
exposures O 
to O 
the O 
preparation O 
for O 
a O 
continuous O 
period O 
of O 
24 O 
, O 
48 O 
, O 
and O 
72 O 
h O 
were O 
investigated O 
in O 
rats O 
. O 
Methods O 
and O 
materials O 
: O 
Rats O 
were O 
exposed O 
to O 
prallethrin B-TRIVIAL 
1.6% O 
w O 
/ O 
w O 
by O 
inhalation O 
for O 
72 O 
consecutive O 
hours O 
. O 
Total O 
blood O 
count O 
, O 
blood O 
indices O 
of O 
creatine B-TRIVIAL 
kinase O 
( O 
CK O 
) O 
, O 
gamma-glutamyltranspeptidase O 
( O 
γ-GT O 
) O 
, O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
, O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
, O 
interleukin O 
(IL)-2 O 
, O 
tumor O 
necrosis O 
factors O 
(TNF)α O 
, O 
alpha-fetoprotein O 
( O 
AFP O 
) O 
, O 
carbohydrate B-FAMILY 
antigen O 
( O 
CA O 
) O 
19.9 O 
and O 
carcinoembrionic O 
antigen O 
( O 
CEA O 
) O 
were O 
assayed O 
. O 
Results O 
: O 
The O 
administration O 
of O 
prallethrin B-TRIVIAL 
1.6% O 
w O 
/ O 
w O 
created O 
significant O 
increased O 
changes O 
in O 
the O 
levels O 
of O 
total O 
WBC O 
, O 
lymphocytes O 
, O 
RBC O 
, O 
hemoglobin O 
, O 
packed O 
cell O 
volume O 
, O 
platelets O 
, O 
mean O 
corpuscular O 
volume O 
, O 
and O 
mean O 
corpuscular O 
hemoglobin O 
in O 
rats O 
after O 
24 O 
, O 
48 O 
, O 
and O 
72 O 
h O 
of O 
continuous O 
inhalation O 
; O 
however O 
, O 
there O 
was O 
a O 
significant O 
reduction O 
in O 
neutrophils O 
at O 
transient O 
reduction O 
in O 
the O 
monocytes O 
after O 
24 O 
and O 
48 O 
h O 
to O 
return O 
to O 
normal O 
after O 
72 O 
h O 
. O 
Significant O 
increases O 
in O 
the O 
levels O 
of O 
CK O 
, O 
γ-GT O 
, O 
SOD O 
, O 
NO B-FORMULA 
, O 
MDA B-ABBREVIATION 
, O 
AFP O 
, O 
IL-2 O 
, O 
and O 
TNFα O 
were O 
recorded O 
. O 
CA O 
and O 
CEA O 
did O 
not O 
exhibit O 
any O 
change O 
. O 
Conclusions O 
: O 
Continuous O 
inhalation O 
to O 
prallethrin B-TRIVIAL 
1.6% O 
insecticides O 
poses O 
toxicity O 
on O 
hematological O 
variables O 
. O 
It O 
is O 
also O 
concluded O 
that O 
pyrethroid B-FAMILY 
group O 
of O 
insecticide O 
may O 
cause O 
hematological O 
, O 
biochemical O 
, O 
cytokine O 
disturbances O 
and O 
possible O 
mutagenic O 
damage O 
to O 
the O 
tissues O 
. O 

an O 
integrated O 
computational O 
approach O 
involving O 
homology O 
modeling O 
, O 
Pharmacophore O 
/ O 
Structure O 
- O 
Based O 
virtual O 
screening O 
, O 
molecular O 
dynamics O 
simulations O 
and O 
per O 
- O 
residue O 
energy O 
contribution O 
, O 
ten O 
compounds O 
were O 
proposed O 
as O 
potential O 
TB O 
inhibitors O 
. O 
Via O 
validated O 
docking O 
calculations O 
, O 
binding O 
free O 
energy O 
calculations O 
showed O 
that O 
the O 
proposed O 
compounds O 
presented O 
better O 
binding O 
affinity O 
with O 
DNA O 
Gyrase O 
B O 
when O 
compared O 
to O 
Novobiocin B-TRIVIAL 
. O 
The O 
compiled O 
in O 
- O 
silico O 
approach O 
employed O 
in O 
this O 
study O 
may O 
serve O 
as O 
a O 
useful O 
tool O 
in O 
the O 
process O 
of O 
the O 
design O 
and O 
development O 
of O 
drugs O 
, O 
not O 
only O 
against O 
TB O 
, O 
but O 
also O 
for O 
a O 
wide O 
range O 
of O 
biological O 
systems O 
. O 
This O 
article O 
is O 
protected O 
by O 
copyright O 
. O 
All O 
rights O 
reserved O 
. O 

C I-TRIVIAL 
forestalls O 
cigarette O 
smoke O 
induced O 
NF-κB O 
activation O 
in O 
alveolar O 
epithelial O 
cells O 
. O 

smoking O 
causes O 
cellular O 
oxidative O 
stress O 
resulting O 
in O 
inflammatory O 
diseases O 
of O 
lung O 
wherein O 
transcription O 
factor O 
NF-κB O 
plays O 
an O 
important O 
role O 
. O 
It O 
is O 
possible O 
that O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
, O 
an O 
antioxidant O 
, O 
may O 
prevent O 
cigarette O 
smoke O 
(CS)-induced O 
NF-κB O 
activation O 
that O 
involves O 
degradation O 
of O 
I-κBε O 
and O 
nuclear O 
translocation O 
of O 
c-Rel O 
/ O 
p50 O 
in O 
alveolar O 
epithelial O 
cells O 
. O 
Therefore O 
, O 
to O 
examine O 
the O 
hypothesis O 
, O 
we O 
verified O 
the O 
effect O 
of O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
on O 
CS-induced O 
expression O 
of O 
NF-κB O 
driven O 
luciferase O 
reporter O 
and O 
NF-κB O 
binding O 
at O 
its O 
target O 
DNA O 
by O 
EMSA O 
in O 
alveolar O 
epithelial O 
A549 O 
cells O 
. O 
We O 
also O 
examined O 
the O 
level O 
of O 
I-κBε O 
and O 
sub O 
- O 
cellular O 
distribution O 
of O 
c-Rel O 
by O 
western O 
blotting O 
and O 
immunofluorescence O 
respectively O 
in O 
CSE O 
- O 
treated O 
A549 O 
cells O 
with O 
or O 
without O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
pretreatment O 
. O 
We O 
observed O 
a O 
significant O 
reduction O 
in O 
CSE O 
induced O 
luciferase O 
expression O 
, O 
NF-κB O 
DNA O 
binding O 
, O 
I-κBε O 
degradation O 
and O 
c-Rel O 
nuclear O 
translocation O 
in O 
cells O 
pretreated O 
with O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
. O 
To O 
further O 
validate O 
the O 
result O 
, O 
we O 
examined O 
sub O 
- O 
cellular O 
distribution O 
of O 
c-Rel O 
in O 
lungs O 
of O 
CS-exposed O 
guinea O 
pigs O 
treated O 
or O 
untreated O 
with O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
. O 
Result O 
showed O 
that O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
treatment O 
resulted O 
in O 
markedly O 
reduced O 
c-Rel O 
nuclear O 
translocation O 
. O 
All O 
these O 
results O 
demonstrate O 
that O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
prevents O 
CS(E)-induced O 
NF-κB O 
activation O 
and O 
thus O 
it O 
could O 
be O 
used O 
for O 
the O 
prevention O 
of O 
CS-induced O 
inflammatory O 
diseases O 
. O 

for O 
polyphenols B-FAMILY 
, O 
antioxidant O 
and O 
antimicrobial O 
activitiesof O 
extracts O 
from O 
eleven O 
Helianthemum O 
taxa O 
( O 
Cistaceae O 
) O 
used O 
in O 
folk O 
medicine O 
in O 
south O 
- O 
eastern O 
Spain O 
. O 

RELEVANCE O 
: O 
The O 
Helianthemum O 
genus O 
contains O 
approximately O 
one O 
hundred O 
taxa O 
. O 
Some O 
of O 
them O 
are O 
important O 
medicinal O 
plants O 
used O 
in O 
several O 
countries O 
for O 
many O 
different O 
purposes O 
. O 
However O 
, O 
studies O 
addressing O 
the O 
phytochemistry O 
of O 
many O 
of O 
these O 
species O 
or O 
their O 
biological O 
activities O 
are O 
currently O 
nonexistent O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
To O 
perform O 
a O 
comparative O 
analysis O 
of O 
the O 
qualitative O 
composition O 
of O 
secondary O 
metabolites O 
and O 
biological O 
activities O 
of O 
the O 
leaves O 
of O 
the O 
most O 
commonly O 
distributed O 
and O 
used O 
Spanish O 
Helianthemum O 
taxa O 
in O 
order O 
to O 
find O 
a O 
relationship O 
between O 
chemotype O 
, O 
biological O 
activity O 
and O 
uses O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
water O 
and O 
80% O 
methanolic O 
extracts O 
derived O 
from O 
11 O 
different O 
Helianthemum O 
taxa O 
were O 
analyzed O 
for O 
their O 
phytochemical O 
composition O 
using O 
standard O 
methods O 
. O 
Furthermore O 
, O 
HPLC O 
analysis O 
was O 
performed O 
for O 
the O 
estimation O 
of O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
, O 
ellagic B-TRIVIAL 
acid I-TRIVIAL 
, O 
tannins B-FAMILY 
and O 
flavonols B-FAMILY 
as O 
marker O 
compounds O 
. O 
The O 
antioxidant O 
activity O 
was O 
measured O 
by O 
employing O 
the O 
scavenging O 
activity O 
on O 
DPPH B-ABBREVIATION 
( O 
2,2-diphenyl-1-picrylhydrazyl B-SYSTEMATIC 
) O 
and O 
ABTS B-ABBREVIATION 
( O 
2,2'-azinobis-3-ethylbenzothiazoline-6-sulfonate B-SYSTEMATIC 
) O 
radicals O 
. O 
The O 
80% O 
methanolic O 
extracts O 
were O 
evaluated O 
for O 
antibacterial O 
( O 
Gram O 
- O 
positive O 
Staphylococcus O 
aureus O 
, O 
Enterococcus O 
faecalis O 
and O 
Listeria O 
monocytogenes O 
and O 
Gram O 
- O 
negative O 
Escherichia O 
coli O 
and O 
Salmonella O 
enterica O 
) O 
activity O 
using O 
the O 
micro O 
dilution O 
technique O 
. O 
RESULTS O 
: O 
The O 
total O 
polyphenolic O 
content O 
and O 
antioxidant O 
capabilities O 
differed O 
significantly O 
among O 
the O 
Helianthemum O 
leaf O 
extracts O 
. O 
A O 
strong O 
correlation O 
between O 
total O 
phenolic O 
content O 
, O 
antioxidant O 
properties O 
and O 
antimicrobial O 
activity O 
was O 
found O 
. O 
The O 
polyphenolic O 
profile O 
was O 
specific O 
for O 
each O 
taxon O 
. O 
Whereas O 
Helianthemum O 
alypoides O 
, O 
Helianthemum O 
cinereum O 
subsp O 
. O 
rotundifolium O 
, O 
Helianthemum O 
hirtum O 
, O 
Helianthemum O 
asperum O 
, O 
and O 
Helianthemum O 
marifolium O 
subsp O 
. O 
marifolium O 
were O 
characterized O 
by O 
the O 
presence O 
of O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
, O 
egallic B-FAMILY 
derivatives O 
and O 
ellagitannins O 
; O 
the O 
polyphenolic O 
profile O 
of O 
Helianthemum O 
apenninum O 
subsp O 
. O 
cavanillesianum O 
, O 
Helianthemum O 
syriacum O 
and O 
Helianthemum O 
polygonoides O 
was O 
mostly O 
based O 
on O 
flavonoids B-FAMILY 
. O 
Helianthemum O 
cinereum O 
, O 
Helianthemum O 
alypoides O 
and O 
Helianthemum O 
marifolium O 
consistently O 
presented O 
the O 
strongest O 
radical O 
scavenging O 
activity O 
( O 
in O 
water O 
extracts O 
EC50 O 
ranges O 
from O 
29.88 O 
to O 
38.1 O 
against O 
DPPH B-ABBREVIATION 
and O 
from O 
8.11 O 
to O 
20.8 O 
against O 
ABTS B-ABBREVIATION 
, O 
and O 
in O 
80% O 
MeOH B-FORMULA 
extracts O 
from O 
25.3 O 
to O 
31.8 O 
against O 
DPPH B-ABBREVIATION 
and O 
from O 
6.15 O 
to O 
8.6 O 
against O 
ABTS B-ABBREVIATION 
) O 
, O 
total O 
phenol O 
content O 
( O 
> O 
117mg O 
GAE O 
/ O 
l O 
) O 
and O 
antimicrobial O 
activities O 
. O 
CONCLUSION O 
: O 
The O 
Helianthemum O 
taxa O 
used O 
in O 
folk O 
medicine O 
did O 
not O 
cluster O 
in O 
a O 
unique O 
section O 
, O 
being O 
equally O 
distributed O 
in O 
two O 
out O 
of O 
the O 
four O 
sections O 
analysed O 
. O 
There O 
was O 
not O 
a O 
clear O 
relationship O 
between O 
the O 
chemotype O 
, O 
based O 
on O 
the O 
polyphenolic O 
composition O 
of O 
the O 
taxa O 
, O 
and O 
their O 
taxonomical O 
classification O 
. O 
However O 
, O 
the O 
composition O 
of O 
the O 
methanolic O 
and O 
water O 
extracts O 
from O 
the O 
leaves O 
of O 
plants O 
belonging O 
to O 
the O 
Helianthemum O 
genus O 
was O 
strongly O 
related O 
to O 
their O 
medicinal O 
uses O 
. O 

Acid I-SYSTEMATIC 
Phenethyl I-SYSTEMATIC 
Ester I-SYSTEMATIC 
Suppresses O 
Proliferation O 
and O 
Survival O 
of O 
TW2.6 O 
Human O 
Oral O 
Cancer O 
Cells O 
via O 
Inhibition O 
of O 
Akt O 
Signaling O 
. O 

acid I-SYSTEMATIC 
phenethyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
CAPE B-ABBREVIATION 
) O 
is O 
a O 
bioactive O 
component O 
extracted O 
from O 
honeybee O 
hive O 
propolis O 
. O 
Our O 
observations O 
indicated O 
that O 
CAPE B-ABBREVIATION 
treatment O 
suppressed O 
cell O 
proliferation O 
and O 
colony O 
formation O 
of O 
TW2.6 O 
human O 
oral O 
squamous O 
cell O 
carcinoma O 
( O 
OSCC O 
) O 
cells O 
dose O 
- O 
dependently O 
. O 
CAPE B-ABBREVIATION 
treatment O 
decreased O 
G1 O 
phase O 
cell O 
population O 
, O 
increased O 
G2 O 
/ O 
M O 
phase O 
cell O 
population O 
, O 
and O 
induced O 
apoptosis O 
in O 
TW2.6 O 
cells O 
. O 
Treatment O 
with O 
CAPE B-ABBREVIATION 
decreased O 
protein O 
abundance O 
of O 
Akt O 
, O 
Akt1 O 
, O 
Akt2 O 
, O 
Akt3 O 
, O 
phospho B-SYSTEMATIC 
-Akt O 
Ser B-FORMULA 
473 O 
, O 
phospho B-SYSTEMATIC 
-Akt O 
Thr O 
308 O 
, O 
GSK3β O 
, O 
FOXO1 O 
, O 
FOXO3a O 
, O 
phospho B-SYSTEMATIC 
-FOXO1 O 
Thr24 O 
, O 
phospho B-SYSTEMATIC 
-FoxO3a O 
Thr32 O 
, O 
NF-κB O 
, O 
phospho B-SYSTEMATIC 
-NF-κB O 
Ser536 O 
, O 
Rb O 
, O 
phospho B-SYSTEMATIC 
-Rb O 
Ser B-FORMULA 
807 O 
/ O 
811 O 
, O 
Skp2 O 
, O 
and O 
cyclin O 
D1 O 
, O 
but O 
increased O 
cell O 
cycle O 
inhibitor O 
p27Kip O 
. O 
Overexpression O 
of O 
Akt1 O 
or O 
Akt2 O 
in O 
TW2.6 O 
cells O 
rescued O 
growth O 
inhibition O 
caused O 
by O 
CAPE B-ABBREVIATION 
treatment O 
. O 
Co-treating O 
TW2.6 O 
cells O 
with O 
CAPE B-ABBREVIATION 
and O 
5-fluorouracil B-SYSTEMATIC 
, O 
a O 
commonly O 
used O 
chemotherapeutic O 
drug O 
for O 
oral O 
cancers O 
, O 
exhibited O 
additive O 
cell O 
proliferation O 
inhibition O 
. O 
Our O 
study O 
suggested O 
that O 
administration O 
of O 
CAPE B-ABBREVIATION 
is O 
a O 
potential O 
adjuvant O 
therapy O 
for O 
patients O 
with O 
OSCC O 
oral O 
cancer O 
. O 

of O 
genotoxic O 
effects O 
of O 
flumorph B-TRIVIAL 
by O 
the O 
comet O 
assay O 
in O 
mice O 
organs O 
. O 

present O 
study O 
investigated O 
the O 
genotoxic O 
effects O 
of O 
flumorph B-TRIVIAL 
in O 
various O 
organs O 
( O 
brain O 
, O 
liver O 
, O 
spleen O 
, O 
kidney O 
and O 
sperm O 
) O 
of O 
mice O 
. O 
The O 
DNA O 
damage O 
, O 
measured O 
as O 
comet O 
tail O 
length O 
( O 
µm O 
) O 
, O 
was O 
determined O 
using O 
the O 
alkaline O 
comet O 
assay O 
. O 
The O 
comet O 
assay O 
is O 
a O 
sensitive O 
assay O 
for O 
the O 
detection O 
of O 
genotoxicity O 
caused O 
by O 
flumorph B-TRIVIAL 
using O 
mice O 
as O 
a O 
model O 
. O 
Statistically O 
significant O 
increases O 
in O 
comet O 
assay O 
for O 
both O 
dose O 
- O 
dependent O 
and O 
duration O 
- O 
dependent O 
DNA O 
damage O 
were O 
observed O 
in O 
all O 
the O 
organs O 
assessed O 
. O 
The O 
organs O 
exhibited O 
the O 
maximum O 
DNA O 
damage O 
in O 
96 O 
h O 
at O 
54 O 
mg O 
/ O 
kg O 
body O 
weight O 
. O 
Brain O 
showed O 
maximum O 
DNA O 
damage O 
followed O 
by O 
spleen O 
> O 
kidney O 
> O 
liver O 
> O 
sperm O 
. O 
Our O 
data O 
demonstrated O 
that O 
flumorph B-TRIVIAL 
had O 
induced O 
systemic O 
genotoxicity O 
in O 
mammals O 
as O 
it O 
caused O 
DNA O 
damage O 
in O 
all O 
tested O 
vital O 
organs O 
, O 
especially O 
in O 
brain O 
and O 
spleen O 
. O 

osmoadaptation O 
involves O 
the O 
cytoplasmic O 
accumulation O 
of O 
compatible O 
solutes O 
in O 
order O 
to O 
counteract O 
extracellular O 
osmolarity O 
. O 
The O 
halophilic O 
and O 
highly O 
halotolerant O 
bacterium O 
Chromohalobacter O 
salexigens O 
is O 
able O 
to O 
grow O 
up O 
to O 
3 O 
M O 
NaCl B-FORMULA 
in O 
a O 
minimal O 
medium O 
due O 
to O 
the O 
de O 
novo O 
synthesis O 
of O 
ectoines B-FAMILY 
. O 
This O 
is O 
an O 
osmoregulated O 
pathway O 
that O 
burdens O 
central O 
metabolic O 
routes O 
by O 
quantitatively O 
drawing O 
off O 
TCA B-ABBREVIATION 
cycle O 
intermediaries O 
. O 
Consequently O 
, O 
metabolism O 
in O 
C O 
. O 
salexigens O 
has O 
adapted O 
to O 
support O 
this O 
biosynthetic O 
route O 
. O 
Metabolism O 
of O 
C O 
. O 
salexigens O 
is O 
more O 
efficient O 
at O 
high O 
salinity O 
than O 
at O 
low O 
salinity O 
, O 
as O 
reflected O 
by O 
lower O 
glucose B-TRIVIAL 
consumption O 
, O 
lower O 
metabolite O 
overflow O 
and O 
higher O 
biomass O 
yield O 
. O 
At O 
low O 
salinity O 
, O 
by O 
- O 
products O 
( O 
mainly O 
gluconate B-TRIVIAL 
, O 
pyruvate B-TRIVIAL 
and O 
acetate B-SYSTEMATIC 
) O 
accumulate O 
extracellularly O 
. O 
Using O 
[1-13C]- B-MULTIPLE 
, I-MULTIPLE 
[2-13C]- I-MULTIPLE 
, I-MULTIPLE 
[6-13C]- I-MULTIPLE 
and I-MULTIPLE 
[U-13C6]-glucose I-MULTIPLE 
as O 
carbon B-SYSTEMATIC 
sources O 
, O 
we O 
were O 
able O 
to O 
determine O 
the O 
main O 
central O 
metabolic O 
pathways O 
involved O 
in O 
ectoines B-FAMILY 
biosynthesis O 
from O 
glucose B-TRIVIAL 
. O 
C O 
. O 
salexigens O 
uses O 
the O 
Entner-Doudoroff O 
pathway O 
rather O 
than O 
the O 
standard O 
glycolytic O 
pathway O 
for O 
glucose B-TRIVIAL 
catabolism O 
, O 
and O 
anaplerotic O 
activity O 
is O 
high O 
to O 
replenish O 
the O 
TCA B-ABBREVIATION 
cycle O 
with O 
the O 
intermediaries O 
withdrawn O 
for O 
ectoines B-FAMILY 
biosynthesis O 
. O 
Metabolic O 
flux O 
ratios O 
at O 
low O 
and O 
high O 
salinity O 
were O 
similar O 
, O 
revealing O 
a O 
certain O 
metabolic O 
rigidity O 
, O 
probably O 
due O 
to O 
its O 
specialization O 
to O 
support O 
high O 
biosynthetic O 
fluxes O 
and O 
partially O 
explaining O 
why O 
metabolic O 
yields O 
are O 
so O 
highly O 
affected O 
by O 
salinity O 
. O 
This O 
work O 
represents O 
an O 
im O 
- O 
portant O 
contribution O 
to O 
the O 
elucidation O 
of O 
specific O 
metabolic O 
adaptations O 
in O 
compatible O 
solute O 
accumulating O 
halophilic O 
bacteria O 
. O 

and O 
selective O 
: O 
The O 
unique O 
nature O 
of O 
the O 
ATP B-ABBREVIATION 
binding O 
pocket O 
structure O 
of O 
Pim O 
family O 
protein O 
kinases O 
( O 
PKs O 
) O 
was O 
used O 
for O 
the O 
development O 
of O 
bisubstrate O 
inhibitors O 
and O 
a O 
fluorescent O 
probe O 
with O 
sub O 
- O 
nanomolar O 
affinity O 
. O 
Conjugates O 
of O 
arginine B-TRIVIAL 
-rich O 
peptides O 
with O 
two O 
ATP B-ABBREVIATION 
mimetic O 
scaffolds O 
were O 
synthesized O 
and O 
tested O 
as O 
inhibitors O 
of O 
Pim-1 O 
. O 
Against O 
a O 
panel O 
of O 
124 O 
protein O 
kinases O 
, O 
a O 
novel O 
ARC-PIM O 
conjugate O 
selectively O 
inhibited O 
PKs O 
of O 
the O 
Pim O 
family O 
. O 

Vitro O 
Activity O 
of O 
Paclitaxel B-TRIVIAL 
-Loaded O 
Polymeric O 
Expansile O 
Nanoparticles O 
in O 
Breast O 
Cancer O 
Cells O 
. O 

a O 
series O 
of O 
in O 
vitro O 
studies O 
, O 
the O 
essential O 
steps O 
for O 
intracellular O 
drug O 
delivery O 
of O 
paclitaxel B-TRIVIAL 
using O 
a O 
pH-responsive O 
nanoparticle O 
system O 
have O 
been O 
investigated O 
in O 
breast O 
cancer O 
cells O 
. O 
We O 
successfully O 
encapsulated O 
paclitaxel B-TRIVIAL 
within O 
polymeric O 
expansile O 
nanoparticles O 
( O 
Pax B-ABBREVIATION 
-eNPs O 
) O 
at O 
5% O 
loading O 
via O 
a O 
miniemulsion O 
polymerization O 
procedure O 
. O 
Fluorescently O 
tagged O 
eNPs O 
were O 
readily O 
taken O 
up O 
by O 
MDA-MB-231 O 
breast O 
cancer O 
cells O 
grown O 
in O 
culture O 
as O 
confirmed O 
by O 
confocal O 
microscopy O 
and O 
flow O 
cytometry O 
. O 
The O 
ability O 
of O 
the O 
encapsulated O 
paclitaxel B-TRIVIAL 
to O 
reach O 
the O 
cytoplasm O 
was O 
also O 
observed O 
using O 
confocal O 
microscopy O 
and O 
fluorescently O 
labeled O 
paclitaxel B-TRIVIAL 
. O 
Pax B-ABBREVIATION 
-eNPs O 
were O 
shown O 
to O 
be O 
efficacious O 
against O 
three O 
in O 
vitro O 
human O 
breast O 
adenocarcinoma O 
cell O 
lines O 
( O 
MDA-MB-231 O 
, O 
MCF-7 O 
and O 
SK-BR-3 O 
) O 
as O 
well O 
as O 
cells O 
isolated O 
from O 
the O 
pleural O 
effusions O 
of O 
two O 
different O 
breast O 
cancer O 
patients O 
. O 
Lastly O 
, O 
macropinocytosis O 
was O 
identified O 
as O 
the O 
major O 
cellular O 
pathway O 
responsible O 
for O 
eNP O 
uptake O 
, O 
as O 
confirmed O 
using O 
temperature O 
- O 
sensitive O 
metabolic O 
reduction O 
, O 
pharmacologic O 
inhibitors O 
, O 
and O 
fluid O 
- O 
phase O 
marker O 
co O 
- O 
localization O 
. O 

nucleic O 
acid O 
( O 
LNA O 
) O 
is O 
a O 
chemical O 
modification O 
which O 
introduces O 
a O 
- O 
O-CH2 B-FORMULA 
- O 
linkage O 
in O 
the O 
furanose B-FAMILY 
sugar I-FAMILY 
of O 
nucleic O 
acids O 
and O 
blocks O 
its O 
conformation O 
in O 
a O 
particular O 
state O 
. O 
Two O 
types O 
of O 
modifications O 
, O 
namely O 
, O 
2'-O,4'-C-methylene-β-d-ribofuranose B-SYSTEMATIC 
( O 
β-d-LNA O 
) O 
and O 
2'-O,4'-C-methylene-α-l-ribofuranose B-SYSTEMATIC 
( O 
α-l-LNA O 
) O 
, O 
have O 
been O 
shown O 
to O 
yield O 
RNA O 
and O 
DNA O 
duplex O 
- O 
like O 
structures O 
, O 
respectively O 
. O 
LNA O 
modifications O 
lead O 
to O 
increased O 
melting O 
temperatures O 
of O 
DNA O 
and O 
RNA O 
duplexes O 
, O 
and O 
have O 
been O 
suggested O 
as O 
potential O 
therapeutic O 
agents O 
in O 
antisense O 
therapy O 
. O 
In O 
this O 
study O 
, O 
molecular O 
dynamics O 
( O 
MD O 
) O 
simulations O 
were O 
performed O 
on O 
fully O 
modified O 
LNA O 
duplexes O 
and O 
pure O 
DNA O 
and O 
RNA O 
duplexes O 
sharing O 
a O 
similar O 
sequence O 
to O 
investigate O 
their O 
structure O 
, O 
stabilities O 
, O 
and O 
solvation O 
properties O 
. O 
Both O 
LNA O 
duplexes O 
undergo O 
unwinding O 
of O 
the O 
helical O 
structure O 
compared O 
to O 
the O 
pure O 
DNA O 
and O 
RNA O 
duplexes O 
. O 
Though O 
the O 
α-LNA O 
substituent O 
has O 
been O 
proposed O 
to O 
mimic O 
deoxyribose B-SYSTEMATIC 
sugar B-FAMILY 
in O 
its O 
conformational O 
properties O 
, O 
the O 
fully O 
modified O 
duplex O 
was O 
found O 
to O 
exhibit O 
unique O 
structural O 
and O 
dynamic O 
properties O 
with O 
respect O 
to O 
the O 
other O 
three O 
nucleic O 
acid O 
structures O 
. O 
Free O 
energy O 
calculations O 
accurately O 
capture O 
the O 
enhanced O 
stabilization O 
of O 
the O 
LNA O 
duplex O 
structures O 
compared O 
to O 
DNA O 
and O 
RNA O 
molecules O 
as O 
observed O 
in O 
experiments O 
. O 
π-stacking O 
interaction O 
between O 
bases O 
from O 
complementary O 
strands O 
is O 
shown O 
to O 
be O 
one O 
of O 
the O 
contributors O 
to O 
enhanced O 
stabilization O 
upon O 
LNA O 
substitution O 
. O 
A O 
combination O 
of O 
two O 
factors O 
, O 
namely O 
, O 
nature O 
of O 
the O 
- O 
O-CH2 B-FORMULA 
- O 
linkage O 
in O 
the O 
LNAs O 
vs O 
their O 
absence O 
in O 
the O 
pure O 
duplexes O 
and O 
similar O 
conformations O 
of O 
the O 
sugar O 
rings O 
in O 
DNA O 
and O 
α-LNA O 
vs O 
the O 
other O 
two O 
, O 
is O 
suggested O 
to O 
contribute O 
to O 
the O 
stark O 
differences O 
among O 
the O 
four O 
duplexes O 
studied O 
here O 
in O 
terms O 
of O 
their O 
structural O 
, O 
dynamic O 
, O 
and O 
energetic O 
properties O 
. O 

Frederick O 
Hawthorne O 
is O 
a O 
world O 
- O 
renowned O 
scientist O 
in O 
the O 
field O 
of O 
molecular O 
medicine O 
and O 
a O 
pioneer O 
in O 
boron B-SYSTEMATIC 
chemistry O 
. O 
He O 
currently O 
serves O 
as O 
the O 
founding O 
Director O 
of O 
the O 
University O 
of O 
Missouri O 
International O 
Institute O 
of O 
Nano O 
and O 
Molecular O 
Medicine O 
( O 
MO O 
, O 
USA O 
) O 
. O 
Prof O 
. O 
Hawthorne O 
is O 
a O 
University O 
of O 
Missouri O 
Curators' O 
Distinguished O 
Professor O 
and O 
University O 
Professor O 
of O 
Chemistry O 
Emeritus O 
of O 
the O 
University O 
of O 
California O 
, O 
Los O 
Angeles O 
( O 
CA O 
, O 
USA O 
) O 
. O 
He O 
is O 
a O 
member O 
of O 
the O 
US O 
National O 
Academy O 
of O 
Sciences O 
and O 
the O 
recipient O 
of O 
many O 
national O 
and O 
international O 
honors O 
, O 
including O 
the O 
2003 O 
King O 
Faisal O 
Prize O 
in O 
Science O 
, O 
the O 
American O 
Chemical O 
Society's O 
2009 O 
Priestley O 
Medal O 
and O 
the O 
2011 O 
National O 
Medal O 
of O 
Science O 
. O 
Prof O 
. O 
Hawthorne O 
has O 
authored O 
or O 
co O 
- O 
authored O 
more O 
than O 
540 O 
research O 
articles O 
, O 
30 O 
patents O 
, O 
ten O 
book O 
chapters O 
and O 
two O 
books O 
. O 
Prof O 
. O 
Hawthorne O 
spoke O 
to O 
Future O 
Medicinal O 
Chemistry O 
on O 
how O 
he O 
became O 
involved O 
in O 
the O 
field O 
, O 
the O 
future O 
of O 
boron B-SYSTEMATIC 
neutron O 
capture O 
therapy O 
, O 
and O 
provides O 
his O 
advice O 
for O 
the O 
next O 
generation O 
of O 
boron B-SYSTEMATIC 
scientists O 
. O 
Interview O 
conducted O 
by O 
Isaac O 
Bruce O 
, O 
Managing O 
Commissioning O 
Editor O 
. O 

chemicals O 
in O 
diagnosis O 
and O 
therapeutics O 
. O 

in O 
the O 
field O 
of O 
boron B-SYSTEMATIC 
chemistry O 
have O 
expanded O 
the O 
application O 
of O 
boron B-SYSTEMATIC 
from O 
material O 
use O 
to O 
medicine O 
. O 
Boron B-SYSTEMATIC 
-based O 
drugs O 
represent O 
a O 
new O 
class O 
of O 
molecules O 
that O 
possess O 
several O 
biomedical O 
applications O 
including O 
use O 
as O 
imaging O 
agents O 
for O 
both O 
optical O 
and O 
nuclear O 
imaging O 
as O 
well O 
as O 
therapeutic O 
agents O 
with O 
anticancer O 
, O 
antiviral O 
, O 
antibacterial O 
, O 
antifungal O 
and O 
other O 
disease O 
- O 
specific O 
activities O 
. O 
For O 
example O 
, O 
bortezomib B-TRIVIAL 
( O 
Velcade B-TRIVIAL 
( O 
® O 
) O 
) O 
, O 
the O 
only O 
drug O 
in O 
clinical O 
use O 
with O 
boron B-SYSTEMATIC 
as O 
an O 
active O 
element O 
, O 
was O 
approved O 
in O 
2003 O 
as O 
a O 
proteasome O 
inhibitor O 
for O 
the O 
treatment O 
of O 
multiple O 
myeloma O 
and O 
non-Hodgkin's O 
lymphoma O 
. O 
Several O 
other O 
boron B-SYSTEMATIC 
-based O 
compounds O 
are O 
in O 
various O 
phases O 
of O 
clinical O 
trials O 
, O 
which O 
illustrates O 
the O 
promise O 
of O 
this O 
approach O 
for O 
medicinal O 
chemists O 
working O 
in O 
the O 
area O 
of O 
boron B-SYSTEMATIC 
chemistry O 
. O 
It O 
is O 
expected O 
that O 
in O 
the O 
near O 
future O 
, O 
several O 
boron B-SYSTEMATIC 
-containing O 
drugs O 
should O 
become O 
available O 
in O 
the O 
market O 
with O 
better O 
efficacy O 
and O 
potency O 
than O 
existing O 
drugs O 
. O 
This O 
article O 
discusses O 
the O 
current O 
status O 
of O 
the O 
development O 
of O 
boron B-SYSTEMATIC 
-based O 
compounds O 
as O 
diagnostic O 
and O 
therapeutic O 
agents O 
in O 
humans O 
. O 

carbohydrate I-FAMILY 
derivatives O 
as O 
potential O 
boron B-SYSTEMATIC 
neutron O 
capture O 
therapy O 
reagents O 
. O 

treatment O 
of O 
cancer O 
remains O 
one O 
of O 
the O 
most O 
challenging O 
problems O 
for O 
humanity O 
. O 
Boron B-SYSTEMATIC 
neutron O 
capture O 
therapy O 
is O 
a O 
binary O 
approach O 
for O 
cancer O 
treatment O 
that O 
is O 
particularly O 
attractive O 
in O 
treating O 
high O 
- O 
grade O 
gliomas O 
and O 
metastatic O 
brain O 
tumors O 
. O 
Among O 
the O 
types O 
of O 
boron B-SYSTEMATIC 
-containing O 
molecules O 
used O 
as O 
boron B-SYSTEMATIC 
neutron O 
capture O 
therapy O 
agents O 
, O 
boronated B-FAMILY 
carbohydrate I-FAMILY 
derivatives O 
have O 
received O 
significant O 
attention O 
because O 
of O 
their O 
preferential O 
uptake O 
by O 
growing O 
tumor O 
cells O 
. O 
This O 
review O 
provides O 
a O 
summary O 
of O 
the O 
recent O 
developments O 
in O 
the O 
chemistry O 
of O 
carborane B-SYSTEMATIC 
-containing O 
carbohydrates B-FAMILY 
. O 

ideal O 
colloidal O 
system O 
should O 
be O 
highly O 
stable O 
in O 
a O 
diverse O 
range O 
of O 
buffer O 
conditions O 
while O 
still O 
retaining O 
its O 
surface O 
accessibility O 
. O 
We O 
recently O 
reported O 
that O 
dispersing O 
citrate B-FAMILY 
-capped O 
gold O 
nanoparticles O 
( O 
Au B-FORMULA 
NPs O 
) O 
in O 
polymers O 
such O 
as O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
can O 
achieve O 
such O 
a O 
goal O 
due O 
to O 
contributions O 
from O 
depletion O 
stabilization O 
. O 
Since O 
AuNPs O 
can O 
weakly O 
adsorb O 
PEG B-ABBREVIATION 
to O 
exert O 
steric O 
stabilization O 
and O 
the O 
remaining O 
citrate B-FAMILY 
can O 
impart O 
charge O 
stabilization O 
, O 
the O 
extent O 
of O 
the O 
contribution O 
of O 
depletion O 
stabilization O 
is O 
unclear O 
. O 
In O 
this O 
work O 
, O 
we O 
aim O 
to O 
dissect O 
the O 
contribution O 
of O 
each O 
stabilizing O 
factor O 
. O 
This O 
is O 
achieved O 
by O 
coating O 
Au B-FORMULA 
NPs O 
with O 
a O 
layer O 
of O 
thiolated O 
compound O 
, O 
which O 
inhibits O 
the O 
adsorption O 
of O 
PEG B-ABBREVIATION 
and O 
also O 
allows O 
the O 
control O 
of O 
surface O 
charge O 
. O 
We O 
found O 
that O 
depletion O 
stabilization O 
alone O 
was O 
insufficient O 
to O 
stabilize O 
Au B-FORMULA 
NPs O 
at O 
room O 
temperature O 
. O 
However O 
, O 
when O 
working O 
together O 
with O 
other O 
stabilization O 
mechanisms O 
, O 
ultrahigh O 
stability O 
can O 
be O 
achieved O 
. O 
The O 
size O 
of O 
both O 
Au B-FORMULA 
NPs O 
and O 
PEG B-ABBREVIATION 
was O 
systematically O 
varied O 
and O 
the O 
trend O 
was O 
compared O 
with O 
theoretical O 
calculations O 
. O 
Finally O 
, O 
we O 
report O 
the O 
importance O 
of O 
the O 
surface O 
chemistry O 
of O 
commercial O 
AuNPs O 
. O 

( O 
LPS O 
) O 
make O 
up O 
approximately O 
75% O 
of O 
the O 
Gram O 
- O 
negative O 
bacterial O 
outer O 
membrane O 
( O 
OM O 
) O 
surface O 
, O 
however O 
, O 
due O 
to O 
the O 
complexity O 
of O 
the O 
molecule O 
, O 
there O 
are O 
very O 
few O 
model O 
OMs O 
that O 
include O 
LPS O 
. O 
The O 
LPS O 
molecule O 
consists O 
of O 
lipid B-TRIVIAL 
A I-TRIVIAL 
, O 
which O 
anchors O 
the O 
LPS O 
within O 
the O 
OM O 
, O 
a O 
core O 
polysaccharide O 
region O 
and O 
a O 
variable O 
O-antigen O 
polysaccharide O 
chain O 
. O 
In O 
this O 
work O 
we O 
used O 
RcLPS O 
( O 
consisting O 
of O 
lipid B-TRIVIAL 
A I-TRIVIAL 
plus O 
the O 
first O 
seven O 
sugars B-FAMILY 
of O 
the O 
core O 
polysaccharide O 
) O 
from O 
a O 
rough O 
strain O 
of O 
E O 
. O 
coli O 
to O 
form O 
stable O 
monolayers O 
of O 
LPS O 
at O 
the O 
air O 
- O 
liquid O 
interface O 
. O 
The O 
vertical O 
structure O 
RcLPS O 
monolayers O 
were O 
characterized O 
using O 
neutron O 
and O 
X-ray O 
reflectometry O 
whilst O 
the O 
lateral O 
structure O 
was O 
investigated O 
using O 
grazing O 
incidence O 
X-ray O 
diffraction O 
and O 
Brewster O 
Angle O 
Microscopy O 
. O 
It O 
was O 
found O 
that O 
RcLPS O 
monolayers O 
at O 
surface O 
pressures O 
of O 
20 O 
mN O 
m(-1) O 
and O 
above O 
are O 
resolved O 
as O 
hydrocarbon B-FAMILY 
tails O 
, O 
an O 
inner O 
headgroup O 
and O 
an O 
outer O 
headgroup O 
of O 
polysaccharide O 
with O 
increasing O 
solvation O 
from O 
tails O 
to O 
outer O 
headgroups O 
. O 
The O 
lateral O 
organization O 
of O 
the O 
hydrocarbon B-FAMILY 
lipid O 
chains O 
displays O 
an O 
oblique O 
hexagonal O 
unit O 
cell O 
at O 
all O 
surface O 
pressures O 
, O 
with O 
only O 
the O 
chain O 
tilt O 
angle O 
changing O 
with O 
surface O 
pressure O 
. O 
This O 
is O 
in O 
contrast O 
to O 
lipid B-TRIVIAL 
A I-TRIVIAL 
which O 
displays O 
hexagonal O 
or O 
, O 
above O 
20 O 
mN O 
m(-1) O 
, O 
distorted O 
hexagonal O 
packing O 
. O 
This O 
work O 
provides O 
the O 
first O 
complete O 
structural O 
analysis O 
of O 
a O 
realistic O 
E O 
. O 
coli O 
OM O 
surface O 
model O 
. O 

the O 
Role O 
of O 
the O 
Vancomycin B-TRIVIAL 
E-Ring O 
Aryl B-FAMILY 
Chloride I-FAMILY 
: O 
Selective O 
Divergent O 
Synthesis O 
and O 
Evaluation O 
of O 
Alternatively O 
Substituted O 
E-Ring O 
Analogues O 
. O 

selective O 
functionalization O 
of O 
a O 
vancomycin B-TRIVIAL 
aglycon O 
derivative O 
through O 
direct O 
conversion O 
of O 
the O 
E-ring O 
aryl B-FAMILY 
chloride I-FAMILY 
to O 
a O 
reactive O 
boronic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
and O 
its O 
use O 
in O 
the O 
synthesis O 
of O 
a O 
systematic O 
series O 
of O 
vancomycin B-TRIVIAL 
E-ring O 
analogues O 
are O 
described O 
. O 
The O 
series O 
of O 
analogues O 
was O 
used O 
to O 
examine O 
the O 
impact O 
of O 
the O 
E-ring O 
chloride O 
in O 
binding O 
D-Ala-D-Ala B-FORMULA 
and O 
on O 
antimicrobial O 
activity O 
. O 
In O 
contrast O 
to O 
the O 
reduced O 
activity O 
of O 
the O 
unsubstituted O 
E-ring O 
derivatives O 
, O 
hydrophobic O 
and O 
relatively O 
non-polar O 
substituents O 
approach O 
or O 
match O 
the O 
chloro B-FAMILY 
substituted I-FAMILY 
vancomycin I-FAMILY 
and O 
was O 
insensitive O 
to O 
the O 
electronic O 
character O 
of O 
the O 
substituent O 
( O 
e.g O 
. O 
Cl B-FORMULA 
vs O 
CN B-FORMULA 
or O 
OMe B-FORMULA 
) O 
, O 
whereas O 
highly O 
polar O 
substituents O 
fail O 
to O 
provide O 
the O 
enhancements O 
. O 
Moreover O 
, O 
the O 
active O 
permethylated O 
vancomycin B-TRIVIAL 
aglycon O 
derivatives O 
examined O 
exhibit O 
VanB B-ABBREVIATION 
VRE O 
antimicrobial O 
activity O 
at O 
levels O 
that O 
approach O 
( O 
typically O 
within O 
2-fold O 
) O 
their O 
activity O 
against O 
sensitive O 
bacteria O 
. O 
The O 
robust O 
borylation O 
reaction O 
also O 
enabled O 
the O 
selective O 
functionalization O 
of O 
a O 
minimally O 
protected O 
vancomycin B-TRIVIAL 
aglycon O 
( O 
N-Boc B-FORMULA 
vancomycin B-TRIVIAL 
aglycon O 
) O 
, O 
and O 
provides O 
a O 
direct O 
method O 
for O 
the O 
preparation O 
of O 
previously O 
inaccessible O 
analogues O 
. O 

of O 
WWOX O 
and O 
FHIT O 
is O 
downregulated O 
by O 
exposure O 
to O 
arsenite B-SYSTEMATIC 
in O 
human O 
uroepithelial O 
cells O 
. O 

studies O 
in O 
Taiwan O 
, O 
Chile O 
, O 
Argentina O 
, O 
Bangladesh O 
, O 
and O 
Mexico O 
have O 
confirmed O 
significant O 
dose O 
- O 
dependent O 
associations O 
between O 
ingestion O 
of O 
arsenic B-SYSTEMATIC 
-contaminated O 
drinking O 
water O 
and O 
the O 
risk O 
of O 
various O 
human O 
malignancies O 
. O 
The O 
FHIT O 
and O 
WWOX O 
genes O 
are O 
active O 
in O 
common O 
fragile O 
sites O 
FRA3B O 
and O 
FRA16D O 
, O 
respectively O 
. O 
Reduced O 
expression O 
of O 
FHIT O 
or O 
WWOX O 
is O 
known O 
to O 
be O 
an O 
early O 
indicator O 
of O 
carcinogen O 
- O 
induced O 
cancers O 
. O 
However O 
, O 
the O 
effect O 
of O 
arsenite B-SYSTEMATIC 
on O 
the O 
expressions O 
and O 
molecular O 
mechanisms O 
of O 
these O 
markers O 
is O 
still O 
unclear O 
. O 
The O 
aims O 
of O 
this O 
study O 
were O 
(i) O 
to O 
observe O 
the O 
expression O 
of O 
ATR O 
, O 
WWOX O 
and O 
FHIT O 
proteins O 
in O 
urothelial O 
carcinoma O 
( O 
UC O 
) O 
between O 
endemic O 
and O 
non-endemic O 
areas O 
of O 
blackfoot O 
disease O 
( O 
BFD O 
) O 
by O 
immunohistochemical O 
analyses O 
; O 
(ii) O 
to O 
compare O 
expression O 
of O 
these O 
genes O 
between O 
arsenite B-SYSTEMATIC 
-treated O 
SV-HUC-1 O 
human O 
epithelial O 
cells O 
and O 
rat O 
uroepithelial O 
cells O 
; O 
and O 
(iii) O 
to O 
determine O 
the O 
role O 
of O 
DNMT O 
and O 
MEK O 
inhibitors O 
on O 
expressions O 
of O 
WWOX O 
and O 
FHIT O 
in O 
response O 
to O 
arsenite B-SYSTEMATIC 
in O 
SV-HUC-1 O 
. O 
The O 
experiments O 
revealed O 
that O 
expressions O 
of O 
ATR O 
, O 
WWOX O 
and O 
FHIT O 
in O 
UC O 
significantly O 
differed O 
between O 
BFD O 
areas O 
and O 
non-BFD O 
areas O 
( O 
p=0.003 O 
, O 
0.009 O 
and O 
0.021 O 
, O 
respectively O 
) O 
. O 
In O 
fact O 
, O 
the O 
results O 
for O 
the O 
arsenite B-SYSTEMATIC 
-treated O 
groups O 
showed O 
that O 
ATR O 
, O 
WWOX O 
and O 
FHIT O 
are O 
downregulated O 
by O 
arsenite B-SYSTEMATIC 
in O 
SV-HUC-1 O 
. O 
However O 
, O 
the O 
inhibitors O 
suppressed O 
the O 
effects O 
of O 
arsenite B-SYSTEMATIC 
on O 
WWOX O 
and O 
FHIT O 
proteins O 
and O 
mRNA O 
expression O 
. O 
In O 
conclusion O 
, O 
arsenite O 
decreased O 
expressions O 
of O 
ATR O 
, O 
WWOX O 
and O 
FHIT O 
via O 
ERK1 O 
/ O 
2 O 
activation O 
in O 
SV-HUC-1 O 
cells O 
. O 
These O 
findings O 
confirm O 
that O 
dysregulations O 
of O 
these O 
markers O 
may O 
contribute O 
to O 
arsenite B-SYSTEMATIC 
-induced O 
carcinogenesis O 
. O 

smoke O 
is O 
the O 
major O 
cause O 
of O 
chronic O 
obstructive O 
pulmonary O 
disease O 
( O 
COPD O 
) O 
, O 
yet O 
pathogenic O 
mechanisms O 
are O 
not O 
fully O 
understood O 
. O 
Vascular O 
endothelial O 
growth O 
factor O 
( O 
VEGF O 
) O 
is O 
one O 
of O 
the O 
major O 
regulators O 
of O 
endothelial O 
cell O 
survival O 
and O 
is O 
believed O 
to O 
play O 
a O 
role O 
in O 
the O 
pathogenesis O 
of O 
COPD O 
. O 
Fibroblasts O 
are O 
a O 
significant O 
source O 
of O 
VEGF O 
in O 
the O 
lungs O 
; O 
however O 
the O 
effect O 
of O 
cigarette O 
smoke O 
exposure O 
on O 
VEGF O 
release O 
by O 
fibroblasts O 
is O 
not O 
fully O 
understood O 
. O 
We O 
hypothesized O 
that O 
cigarette O 
smoke O 
- O 
induced O 
disturbed O 
VEGF O 
release O 
by O 
human O 
lung O 
fibroblasts O 
is O 
a O 
potential O 
pathogenic O 
mechanism O 
that O 
could O 
contribute O 
to O 
COPD O 
. O 
Cigarette O 
smoke O 
extract O 
( O 
CSE O 
) O 
was O 
prepared O 
by O 
modification O 
of O 
the O 
methods O 
of O 
Carp O 
and O 
Janoff O 
( O 
American O 
Review O 
of O 
Respiratory O 
Disease O 
, O 
1978 O 
) O 
. O 
Human O 
fetal O 
lung O 
fibroblasts O 
( O 
HFL-1 O 
) O 
were O 
exposed O 
to O 
different O 
concentrations O 
of O 
CSE O 
and O 
for O 
different O 
durations O 
. O 
VEGF O 
release O 
into O 
the O 
media O 
was O 
measured O 
using O 
ELISA O 
. O 
TGF-β1 O 
receptor O 
( O 
TβR1 O 
) O 
/ O 
Smad3 O 
as O 
a O 
potential O 
pathway O 
for O 
CSE O 
modulated O 
VEGF O 
release O 
was O 
also O 
investigated O 
using O 
biochemical O 
analyses O 
and O 
siRNA O 
inhibition O 
of O 
Smad3 O 
and O 
siRNA O 
and O 
pharmacologic O 
inhibition O 
of O 
TβR1 O 
. O 
CSE O 
induced O 
VEGF O 
release O 
by O 
HFL-1 O 
in O 
concentration O 
and O 
time O 
dependent O 
manner O 
. O 
This O 
was O 
confirmed O 
in O 
two O 
additional O 
types O 
of O 
primary O 
human O 
fetal O 
lung O 
fibroblasts O 
. O 
CSE O 
induced O 
Smad3 O 
phosphorylation O 
and O 
nuclear O 
translocation O 
in O 
HFL-1 O 
cells O 
. O 
Silencing O 
of O 
Smad3 O 
by O 
siRNA O 
not O 
only O 
eliminated O 
the O 
stimulatory O 
effect O 
of O 
CSE O 
on O 
VEGF O 
release O 
but O 
also O 
inhibited O 
baseline O 
VEGF O 
production O 
. O 
Suppression O 
of O 
TβR1 O 
by O 
the O 
pharmacological O 
inhibitor O 
( O 
SB431542 B-IDENTIFIER 
) O 
markedly O 
reduced O 
VEGF O 
release O 
by O 
HFL-1 O 
in O 
response O 
to O 
CSE O 
and O 
this O 
effect O 
was O 
confirmed O 
by O 
TβR1 O 
siRNA O 
. O 
In O 
contrast O 
, O 
nicotine O 
inhibited O 
VEGF O 
release O 
by O 
HFL-1 O 
in O 
a O 
dose O 
and O 
time O 
dependent O 
manner O 
. O 
Our O 
findings O 
indicate O 
that O 
CSE O 
stimulates O 
Smad3 O 
- O 
mediated O 
VEGF O 
release O 
by O 
lung O 
fibroblasts O 
. O 
Nicotine B-TRIVIAL 
does O 
not O 
account O 
for O 
the O 
CSE O 
stimulation O 
of O 
VEGF O 
in O 
HFL-1 O 
. O 
The O 
ability O 
of O 
lung O 
fibroblasts O 
to O 
produce O 
VEGF O 
may O 
play O 
a O 
role O 
in O 
pathogenesis O 
of O 
cigarette O 
smoke O 
induced O 
lung O 
disease O 
. O 

induces O 
neurotoxicity O 
and O 
neuronal O 
apoptosis O 
in O 
the O 
rat O 
brain O 
cortex O 
and O 
PC12 O 
cell O 
line O 
through O 
the O 
down O 
- O 
regulation O 
of O 
the O 
Wnt O 
/ O 
β-catenin O 
signaling O 
pathway O 
. O 

exposure O 
has O 
various O 
toxic O 
effects O 
on O 
in O 
the O 
human O 
nervous O 
system O 
resulting O 
in O 
various O 
developmental O 
and O 
behavioral O 
deficits O 
. O 
However O 
the O 
underlying O 
molecular O 
mechanism O 
of O 
TCDD B-ABBREVIATION 
-induced O 
adverse O 
effects O 
on O 
the O 
CNS O 
and O 
associated O 
signaling O 
pathways O 
remains O 
largely O 
unknown O 
. O 
Herein O 
we O 
analyzed O 
acute O 
TCDD B-ABBREVIATION 
exposure O 
in O 
the O 
rat O 
brain O 
cortex O 
to O 
investigate O 
whether O 
misregulation O 
of O 
the O 
Wnt O 
/ O 
β-catenin O 
signaling O 
pathway O 
plays O 
a O 
role O 
in O 
neurotoxicity O 
. O 
Western O 
blot O 
and O 
immunohistochemical O 
experiments O 
revealed O 
a O 
significant O 
down O 
- O 
regulation O 
of O 
β-catenin O 
and O 
phospho O 
- O 
glycogen O 
synthase O 
kinase-3β O 
( O 
pSer9-GSK-3β O 
) O 
after O 
TCDD B-ABBREVIATION 
exposure O 
. O 
TUNEL O 
assay O 
results O 
showed O 
apoptosis O 
occurs O 
mainly O 
at O 
day O 
7 O 
after O 
TCDD B-ABBREVIATION 
treatment O 
. O 
Immunofluorescent O 
labeling O 
indicated O 
that O 
β-catenin O 
was O 
localized O 
mainly O 
in O 
the O 
neurons O 
; O 
co O 
- O 
localization O 
of O 
β-catenin O 
and O 
active O 
caspase-3 O 
was O 
found O 
following O 
TCDD B-ABBREVIATION 
exposure O 
. O 
Further O 
, O 
TCDD B-ABBREVIATION 
exposure O 
decreased O 
the O 
level O 
of O 
pSer9-GSK-3β O 
and O 
β-catenin O 
, O 
and O 
increased O 
apoptosis O 
in O 
the O 
PC12 O 
neuronal O 
cell O 
line O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Interestingly O 
the O 
application O 
of O 
lithium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
, O 
a O 
GSK-3β O 
inhibitor O 
, O 
reversed O 
the O 
suppressive O 
effect O 
of O 
TCDD B-ABBREVIATION 
on O 
β-catenin O 
in O 
PC12 O 
cells O 
and O 
primary O 
cortical O 
neurons O 
restoring O 
cell O 
viability O 
and O 
protecting O 
cells O 
from O 
apoptosis O 
as O 
compared O 
to O 
untreated O 
controls O 
. O 
Taken O 
together O 
, O 
these O 
results O 
indicate O 
that O 
the O 
canonical O 
Wnt O 
/ O 
β-catenin O 
signaling O 
pathway O 
may O 
play O 
an O 
important O 
role O 
in O 
TCDD B-ABBREVIATION 
-induced O 
neurotoxicity O 
and O 
neuronal O 
apoptosis O 
. O 

RELEVANCE O 
: O 
Xie O 
- O 
xin O 
decoction O 
( O 
XXD O 
) O 
has O 
been O 
used O 
as O 
a O 
classic O 
formula O 
in O 
China O 
for O 
the O 
treatment O 
of O 
gastrointestinal O 
dysfunction O 
such O 
as O 
ulcerative O 
colitis O 
( O 
UC O 
) O 
. O 
However O 
, O 
no O 
potential O 
action O 
mechanisms O 
and O 
active O 
compounds O 
had O 
been O 
systematically O 
investigated O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
To O 
explore O 
the O 
effectiveness O 
and O 
the O 
material O 
basis O 
of O 
XXD O 
in O 
trinitrobenzene B-SYSTEMATIC 
sulfonic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
TNBS B-ABBREVIATION 
)-induced O 
UC O 
rats O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
XXD O 
was O 
administered O 
orally O 
for O 
8 O 
days O 
at O 
a O 
dosage O 
of O 
2 O 
or O 
4g O 
/ O 
kg O 
/ O 
day O 
. O 
Plasma O 
pharmacokinetic O 
properties O 
and O 
colon O 
tissue O 
concentrations O 
of O 
multiple O 
compounds O 
from O 
XXD O 
were O 
detected O 
. O 
Tissue O 
damage O 
scores O 
, O 
production O 
of O 
interleukin O 
(IL)-10 O 
and O 
myeloperoxidase O 
( O 
MPO O 
) O 
, O 
expression O 
of O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
( O 
TNF-α O 
) O 
and O 
nuclear O 
factor O 
- O 
kappa O 
Bp65 O 
( O 
NF-κBp65 O 
) O 
in O 
colon O 
tissues O 
were O 
examined O 
. O 
Canonical O 
correlation O 
analysis O 
was O 
performed O 
to O 
evaluate O 
the O 
relationships O 
between O 
pharmacokinetics O 
and O 
efficacy O 
to O 
elucidate O 
significantly O 
active O 
compounds O 
of O 
XXD O 
. O 
RESULTS O 
: O 
XXD O 
promoted O 
the O 
recovery O 
of O 
colitis O 
and O 
inhibited O 
the O 
colonic O 
inflammation O 
damage O 
in O 
UC O 
rats O 
by O 
reducing O 
the O 
level O 
of O 
MPO O 
and O 
the O 
expression O 
of O 
TNF-α O 
and O 
NF-κBp65 O 
, O 
and O 
increasing O 
the O 
production O 
of O 
IL-10 O 
in O 
colon O 
tissues O 
. O 
Efficacy O 
of O 
XXD O 
was O 
positively O 
related O 
with O 
AUC O 
of O 
five O 
plasma O 
compounds O 
( O 
baicalin B-TRIVIAL 
, O 
berberine B-TRIVIAL 
, O 
wogonoside B-TRIVIAL 
, O 
wogonin B-TRIVIAL 
, O 
and O 
rhein B-TRIVIAL 
) O 
and O 
concentrations O 
of O 
six O 
colon O 
tissue O 
compounds O 
( O 
coptisine B-TRIVIAL 
, O 
jatrorrhizine B-TRIVIAL 
, O 
palmatine B-TRIVIAL 
, O 
berberine B-TRIVIAL 
, O 
baicalein B-TRIVIAL 
and O 
emodin B-TRIVIAL 
) O 
, O 
respectively O 
. O 
CONCLUSIONS O 
: O 
The O 
multiple O 
compounds O 
in O 
plasma O 
and O 
colon O 
tissues O 
from O 
XXD O 
might O 
be O 
the O 
main O 
material O 
basis O 
for O 
therapeutic O 
potentials O 
in O 
UC O 
rats O 
. O 

RELEVANCE O 
: O 
Antrodia O 
camphorata O 
( O 
AC O 
) O 
is O 
well O 
known O 
in O 
Taiwan O 
as O 
a O 
traditional O 
Chinese O 
medicinal O 
fungus O 
. O 
However O 
, O 
the O 
anticancer O 
activity O 
of O 
AC O 
against O 
human O 
HER-2 O 
/ O 
neu O 
- O 
overexpressing O 
ovarian O 
cancers O 
is O 
poorly O 
understood O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
The O 
aim O 
of O 
this O 
study O 
is O 
to O 
investigate O 
whether O 
a O 
submerged O 
fermentation O 
culture O 
of O 
AC O 
can O 
inhibit O 
human O 
ovarian O 
carcinoma O 
cell O 
( O 
SKOV-3 O 
) O 
proliferation O 
by O 
suppressing O 
the O 
HER-2 O 
/ O 
neu O 
signaling O 
pathway O 
. O 
Cell O 
viability O 
, O 
colony O 
formation O 
, O 
DCFH-DA O 
fluorescence O 
microscopy O 
, O 
western O 
blotting O 
, O 
HER-2 O 
/ O 
neu O 
immunofluorescence O 
imaging O 
, O 
flow O 
cytometry O 
, O 
and O 
TUNEL O 
assays O 
were O 
carried O 
out O 
to O 
determine O 
the O 
anti-cancer O 
effects O 
of O 
AC O 
. O 
RESULTS O 
: O 
MTT B-ABBREVIATION 
and O 
colony O 
formation O 
assays O 
showed O 
that O 
AC O 
induced O 
a O 
dose O 
- O 
dependent O 
reduction O 
in O 
SKOV-3 O 
cell O 
growth O 
. O 
Immunoblot O 
analysis O 
demonstrated O 
that O 
HER-2 O 
/ O 
neu O 
activity O 
and O 
tyrosine B-TRIVIAL 
phosphorylation O 
were O 
significantly O 
inhibited O 
by O 
AC O 
. O 
Furthermore O 
, O 
AC O 
treatment O 
significantly O 
inhibited O 
the O 
activation O 
of O 
PI3K O 
/ O 
Akt O 
and O 
their O 
downstream O 
effector O 
β-catenin O 
. O 
We O 
also O 
observed O 
that O 
AC O 
caused O 
G2 O 
/ O 
M O 
arrest O 
mediated O 
by O 
down O 
- O 
regulation O 
of O 
cyclin O 
D1 O 
, O 
cyclin O 
A O 
, O 
cyclin O 
B1 O 
, O 
and O 
Cdk1 O 
and O 
increased O 
p27 O 
expression O 
. O 
Notably O 
, O 
AC O 
induced O 
apoptosis O 
, O 
which O 
was O 
associated O 
with O 
DNA O 
fragmentation O 
, O 
cytochrome O 
c O 
release O 
, O 
caspase-9 O 
/ O 
-3 O 
activation O 
, O 
PARP O 
degradation O 
, O 
and O 
Bcl-2 O 
/ O 
Bax O 
dysregulation O 
. O 
An O 
increase O 
in O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
was O 
observed O 
in O 
AC O 
- O 
treated O 
cells O 
, O 
whereas O 
the O 
antioxidant O 
N-acetylcysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
prevented O 
AC-induced O 
cell O 
death O 
, O 
HER-2 O 
/ O 
neu O 
depletion O 
, O 
PI3K O 
/ O 
Akt O 
inactivation O 
, O 
and O 
Bcl-2 O 
/ O 
Bax O 
dysregulation O 
, O 
indicating O 
that O 
AC-induced O 
cell O 
death O 
was O 
mediated O 
by O 
ROS O 
generation O 
. O 
CONCLUSIONS O 
: O 
These O 
results O 
suggest O 
that O 
AC O 
may O 
exert O 
anti-tumor O 
activity O 
against O 
human O 
ovarian O 
carcinoma O 
by O 
suppressing O 
HER-2 O 
/ O 
neu O 
signaling O 
pathways O 
. O 

effectiveness O 
of O 
dabigatran B-TRIVIAL 
, O 
rivaroxaban B-TRIVIAL 
, O 
apixaban B-TRIVIAL 
and O 
warfarin B-TRIVIAL 
in O 
the O 
management O 
of O 
patients O 
with O 
non-valvular O 
atrial O 
fibrillation O 
. O 

anticoagulants O 
to O 
warfarin B-TRIVIAL 
( O 
dabigatran B-TRIVIAL 
, O 
rivaroxaban B-TRIVIAL 
and O 
apixaban B-TRIVIAL 
) O 
are O 
becoming O 
available O 
for O 
the O 
prevention O 
of O 
thromboembolic O 
stroke O 
in O 
atrial O 
fibrillation O 
, O 
but O 
there O 
is O 
a O 
lack O 
of O 
information O 
on O 
their O 
comparative O 
effectiveness O 
. O 
We O 
evaluated O 
this O 
using O 
a O 
discrete O 
event O 
simulation O 
with O 
a O 
lifetime O 
horizon O 
of O 
analysis O 
, O 
based O 
on O 
an O 
indirect O 
comparison O 
of O 
the O 
RE-LY O 
, O 
ROCKET-AF O 
and O 
ARISTOTLE O 
trial O 
results O 
for O 
patients O 
with O 
the O 
characteristics O 
of O 
the O 
US O 
atrial O 
fibrillation O 
population O 
. O 
Over O 
a O 
lifetime O 
, O 
apixaban B-TRIVIAL 
, O 
dabigatran B-TRIVIAL 
and O 
rivaroxaban B-TRIVIAL 
accrued O 
0.13 O 
( O 
95% O 
central O 
range O 
[ O 
CR O 
] O 
-0.03 O 
to O 
0.264 O 
) O 
, O 
0.106 O 
( O 
95% O 
CR O 
-0.048 O 
to O 
0.248 O 
) O 
and O 
0.095 O 
( O 
95% O 
CR O 
-0.052 O 
to O 
0.242 O 
) O 
more O 
quality O 
- O 
adjusted O 
life O 
- O 
years O 
than O 
warfarin B-TRIVIAL 
, O 
respectively O 
, O 
with O 
apixaban B-TRIVIAL 
having O 
a O 
55% O 
probability O 
of O 
accruing O 
the O 
highest O 
total O 
lifetime O 
QALYs O 
. O 
In O 
the O 
absence O 
of O 
a O 
definitive O 
trial O 
, O 
and O 
acknowledging O 
the O 
limitations O 
of O 
an O 
indirect O 
comparison O 
, O 
the O 
available O 
evidence O 
suggests O 
apixaban B-TRIVIAL 
to O 
be O 
the O 
more O 
effective O 
anticoagulant.Clinical O 
Pharmacology O 
& O 
Therapeutics O 
( O 
2013 O 
) O 
; O 
accepted O 
article O 
preview O 
online O 
25 O 
April O 
2013 O 
; O 
doi O 
: O 
10.1038 O 
/ O 
clpt.2013.83 O 
. O 

( O 
MLN518 B-IDENTIFIER 
/ O 
CT53518 B-IDENTIFIER 
) O 
targeted O 
to O 
stem O 
- O 
like O 
cells O 
by O 
inhibiting O 
the O 
function O 
of O 
ATP B-ABBREVIATION 
-binding O 
cassette O 
subfamily O 
G O 
member O 
2 O 
. O 

is O 
a O 
novel O 
inhibitor O 
of O 
tyrosine B-TRIVIAL 
kinases O 
FLT3 O 
, O 
PDGFR O 
and O 
KIT O 
. O 
Our O 
study O 
was O 
to O 
explore O 
the O 
capability O 
of O 
tandutinib B-TRIVIAL 
to O 
reverse O 
ABC O 
transporter O 
- O 
mediated O 
multidrug O 
resistance O 
. O 
Tandutinib B-TRIVIAL 
reversed O 
ABCG2 O 
- O 
mediated O 
drug O 
resistance O 
in O 
ABCG2-482-R2 O 
, O 
ABCG2-482-G2 O 
, O 
ABCG2-482-T7 O 
and O 
S1-M1-80 O 
cells O 
and O 
increased O 
the O 
accumulation O 
of O 
doxorubicin B-TRIVIAL 
, O 
rhodamine B-TRIVIAL 
123 I-TRIVIAL 
and O 
[H(3)] B-SYSTEMATIC 
mitoxantrone I-SYSTEMATIC 
in O 
ABCG2-overexpressing O 
cells O 
. O 
Importantly O 
, O 
tandutinib B-TRIVIAL 
selectively O 
sensitized O 
side O 
population O 
cells O 
to O 
mitoxantrone B-TRIVIAL 
. O 
Taken O 
together O 
, O 
our O 
results O 
advocate O 
the O 
potency O 
of O 
tandutinib B-TRIVIAL 
as O 
an O 
ABCG2 O 
modulator O 
and O 
stem O 
- O 
like O 
cells O 
targeted O 
agent O 
to O 
increase O 
efficiency O 
of O 
anticancer O 
drugs O 
. O 

allosterically O 
inhibits O 
the O 
proteasome O 
. O 

is O 
a O 
canonical O 
allosteric O 
inhibitor O 
of O 
the O 
mTOR O 
kinase O 
with O 
immunosuppressive O 
and O 
pro O 
- O 
apoptotic O 
activities O 
. O 
We O 
found O 
that O 
in O 
vitro O 
rapamycin B-TRIVIAL 
also O 
regulates O 
the O 
proteasome O 
, O 
an O 
essential O 
intracellular O 
protease O 
of O 
the O 
ubiquitin O 
- O 
proteasome O 
pathway O 
. O 
Rapamycin B-TRIVIAL 
inhibits O 
proteinase O 
and O 
selected O 
peptidase O 
activities O 
of O 
the O 
catalytic O 
core O 
proteasome O 
at O 
low O 
micromolar O 
concentrations O 
. O 
Moreover O 
, O 
the O 
drug O 
interferes O 
with O 
binding O 
of O 
the O 
19S O 
cap O 
essential O 
for O 
processing O 
of O 
polyubiquitinylated O 
substrates O 
, O 
and O 
the O 
PA200 O 
activator O 
to O 
the O 
20S O 
catalytic O 
core O 
proteasome O 
. O 
These O 
protein O 
complexes O 
are O 
known O 
to O 
bind O 
to O 
specific O 
grooves O 
on O 
the O 
α O 
face O 
region O 
of O 
the O 
20S O 
core O 
. O 
A O 
treatment O 
with O 
rapamycin B-TRIVIAL 
affects O 
conformational O 
dynamics O 
of O 
the O 
proteasomal O 
gate O 
, O 
a O 
centrally O 
positioned O 
within O 
the O 
α O 
face O 
and O 
allosterically O 
regulated O 
element O 
responsible O 
for O 
the O 
intake O 
of O 
substrates O 
. O 
Interestingly O 
, O 
we O 
showed O 
that O 
rapamycin B-TRIVIAL 
shares O 
all O 
the O 
proteasome O 
targeting O 
properties O 
not O 
only O 
with O 
other O 
two O 
- O 
domain O 
, O 
closed O 
- O 
ring O 
analogs O 
( O 
rapalogs O 
) O 
, O 
but O 
also O 
with O 
its O 
single O 
domain O 
mimics O 
, O 
and O 
with O 
seco B-TRIVIAL 
- I-TRIVIAL 
rapamycin I-TRIVIAL 
. O 
The O 
latter O 
is O 
the O 
first O 
in O 
vivo O 
open O 
- O 
ring O 
metabolite O 
of O 
rapamycin B-TRIVIAL 
that O 
does O 
not O 
affect O 
mTOR O 
. O 
We O 
hypothesize O 
that O 
the O 
rapamycin B-TRIVIAL 
and O 
related O 
compounds O 
bind O 
to O 
the O 
α O 
face O 
and O 
allosterically O 
impact O 
the O 
proteasome O 
function O 
. O 
The O 
implications O 
of O 
our O 
finding O 
for O 
mechanism O 
of O 
in O 
vivo O 
actions O 
of O 
rapamycin B-TRIVIAL 
and O 
for O 
design O 
of O 
novel O 
allosteric O 
drugs O 
targeting O 
the O 
proteasome O 
are O 
discussed O 
. O 

- O 
like O 
growth O 
factor O 
1 O 
( O 
IGF-1 O 
) O 
expression O 
is O 
up O 
- O 
regulated O 
in O 
lymphoblastoid O 
cell O 
lines O 
of O 
lithium B-SYSTEMATIC 
responsive O 
bipolar O 
disorder O 
patients O 
. O 

disorder O 
( O 
BD O 
) O 
is O 
a O 
debilitating O 
psychiatric O 
disease O 
characterized O 
by O 
alternating O 
episodes O 
of O 
mania O 
and O 
depression O 
. O 
Among O 
mood O 
stabilizers O 
, O 
lithium B-SYSTEMATIC 
is O 
the O 
mainstay O 
for O 
the O 
treatment O 
of O 
BD O 
, O 
with O 
approximately O 
one O 
- O 
third O 
of O 
patients O 
showing O 
remission O 
from O 
episode O 
recurrence O 
. O 
While O 
there O 
is O 
evidence O 
suggesting O 
genetic O 
load O 
for O 
lithium B-SYSTEMATIC 
response O 
in O 
BD O 
, O 
its O 
molecular O 
underpinnings O 
are O 
still O 
not O 
completely O 
understood O 
. O 
To O 
identify O 
genes O 
potentially O 
involved O 
in O 
( O 
or O 
correlated O 
with O 
) O 
lithium B-SYSTEMATIC 
response O 
, O 
we O 
carried O 
out O 
a O 
genome O 
- O 
wide O 
expression O 
analysis O 
on O 
lymphoblastoid O 
cell O 
lines O 
( O 
LCLs O 
) O 
from O 
10 O 
BD O 
patients O 
responders O 
( O 
R O 
) O 
and O 
10 O 
non-responders O 
( O 
NR O 
) O 
to O 
lithium B-SYSTEMATIC 
. O 
We O 
compared O 
expression O 
levels O 
of O 
the O 
two O 
groups O 
and O 
tested O 
whether O 
in O 
vitro O 
lithium B-SYSTEMATIC 
treatment O 
had O 
different O 
effects O 
in O 
LCLs O 
of O 
R O 
compared O 
to O 
NR O 
. O 
At O 
basal O 
, O 
2060 O 
genes O 
were O 
differentially O 
expressed O 
between O 
R O 
and O 
NR O 
while O 
no O 
genes O 
were O 
differentially O 
regulated O 
by O 
lithium B-SYSTEMATIC 
in O 
the O 
two O 
groups O 
. O 
After O 
pathway O 
analysis O 
based O 
on O 
the O 
2060 O 
genes O 
, O 
9 O 
genes O 
were O 
selected O 
for O 
validation O 
with O 
qRT-PCR O 
. O 
Eight O 
genes O 
were O 
validated O 
in O 
the O 
same O 
sample O 
of O 
LCLs O 
while O 
only O 
insulin O 
- O 
like O 
growth O 
factor O 
1 O 
( O 
IGF-1 O 
) O 
was O 
significantly O 
over O 
- O 
expressed O 
in O 
R O 
compared O 
to O 
NR O 
in O 
the O 
same O 
sample O 
as O 
well O 
as O 
in O 
an O 
independent O 
sample O 
comprised O 
of O 
6 O 
R O 
and O 
6 O 
NR O 
( O 
sample O 
1 O 
, O 
fold O 
change=1.94 O 
; O 
p=0.005 O 
; O 
sample O 
2 O 
, O 
fold O 
change=2.21 O 
; O 
p=0.005 O 
) O 
. O 
IGF-1 O 
was O 
also O 
significantly O 
over O 
- O 
expressed O 
in O 
R O 
but O 
not O 
in O 
NR O 
when O 
compared O 
to O 
a O 
sample O 
of O 
non-psychiatric O 
controls O 
. O 
Our O 
findings O 
suggest O 
that O 
IGF-1 O 
may O 
be O 
involved O 
in O 
lithium B-SYSTEMATIC 
response O 
, O 
supporting O 
further O 
investigation O 
on O 
its O 
potential O 
as O 
a O 
biomarker O 
. O 

in O 
porphyrin B-FAMILY 
monolayers O 
: O 
the O 
relation O 
between O 
adsorption O 
configuration O 
and O 
molecular O 
conformation O 
. O 

- O 
assembled O 
monolayers O 
of O 
meso-5,10,15,20-tetrakis(undecyl)porphyrin B-SYSTEMATIC 
copper I-SYSTEMATIC 
(ii) I-SYSTEMATIC 
on O 
a O 
graphite B-TRIVIAL 
/ O 
1-octanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
interface O 
have O 
been O 
studied O 
by O 
Scanning O 
Tunnelling O 
Microscopy O 
. O 
Four O 
distinct O 
polymorphs O 
were O 
observed O 
, O 
varying O 
in O 
their O 
unit O 
cell O 
size O 
. O 
Arrays O 
of O 
unit O 
cells O 
of O 
the O 
various O 
polymorphs O 
seamlessly O 
connect O 
to O 
each O 
other O 
via O 
shared O 
unit O 
cell O 
vectors O 
. O 
The O 
monolayers O 
are O 
not O 
commensurate O 
, O 
but O 
coincident O 
with O 
the O 
underlying O 
graphite B-TRIVIAL 
substrate O 
. O 
The O 
seamless O 
transition O 
between O 
the O 
polymorphs O 
is O 
proposed O 
to O 
be O 
the O 
result O 
of O 
an O 
adaptation O 
of O 
the O 
molecular O 
conformations O 
in O 
the O 
polymorphs O 
and O 
at O 
the O 
boundaries O 
, O 
which O 
is O 
enabled O 
by O 
the O 
conformational O 
freedom O 
of O 
the O 
alkyl B-FAMILY 
tails O 
of O 
these O 
molecules O 
. O 

- O 
scale O 
Mid-Infrared O 
chemical O 
sensors O 
using O 
air O 
- O 
clad O 
pedestal O 
silicon B-SYSTEMATIC 
waveguides O 
. O 

a O 
future O 
lab-on-a-chip O 
spectrometer O 
, O 
we O 
demonstrate O 
a O 
compact O 
chip O 
- O 
scale O 
air O 
- O 
clad O 
silicon O 
pedestal O 
waveguide O 
as O 
a O 
Mid-Infrared O 
( O 
Mid-IR O 
) O 
sensor O 
capable O 
of O 
in O 
situ O 
monitoring O 
of O 
organic O 
solvents O 
. O 
The O 
sensor O 
is O 
a O 
planar O 
crystalline O 
silicon B-SYSTEMATIC 
waveguide O 
, O 
which O 
is O 
highly O 
transparent O 
, O 
between O 
λ O 
= O 
1.3 O 
and O 
6.5 O 
μm O 
, O 
so O 
that O 
its O 
operational O 
spectral O 
range O 
covers O 
most O 
characteristic O 
chemical O 
absorption O 
bands O 
due O 
to O 
bonds O 
such O 
as O 
C-H B-FORMULA 
, O 
N-H B-FORMULA 
, O 
O-H B-FORMULA 
, O 
C-C B-FORMULA 
, O 
N-O B-FORMULA 
, O 
C B-FORMULA 
[ O 
double O 
bond O 
, O 
length O 
as O 
m-dash O 
] O 
O B-FORMULA 
, O 
and O 
C B-FORMULA 
[ O 
triple O 
bond O 
, O 
length O 
as O 
m-dash O 
] O 
N B-FORMULA 
, O 
as O 
opposed O 
to O 
conventional O 
UV O 
, O 
Vis O 
, O 
Near-IR O 
sensors O 
, O 
which O 
use O 
weaker O 
overtones O 
of O 
these O 
fundamental O 
bands O 
. O 
To O 
extend O 
light O 
transmission O 
beyond O 
λ O 
= O 
3.7 O 
μm O 
, O 
a O 
spectral O 
region O 
where O 
a O 
typical O 
silicon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
under O 
- O 
clad O 
is O 
absorbing O 
, O 
we O 
fabricate O 
a O 
unique O 
air O 
- O 
clad O 
silicon B-SYSTEMATIC 
pedestal O 
waveguide O 
. O 
The O 
sensing O 
mechanism O 
of O 
our O 
Mid-IR O 
waveguide O 
sensor O 
is O 
based O 
on O 
evanescent O 
wave O 
absorption O 
by O 
functional O 
groups O 
of O 
the O 
surrounding O 
chemical O 
molecules O 
, O 
which O 
selectively O 
absorb O 
specific O 
wavelengths O 
in O 
the O 
mid-IR O 
, O 
depending O 
on O 
the O 
nature O 
of O 
their O 
chemical O 
bonds O 
. O 
From O 
a O 
measurement O 
of O 
the O 
waveguide O 
mode O 
intensities O 
, O 
we O 
demonstrate O 
in O 
situ O 
identification O 
of O 
chemical O 
compositions O 
and O 
concentrations O 
of O 
organic O 
solvents O 
. O 
For O 
instance O 
, O 
we O 
show O 
that O 
when O 
testing O 
at O 
λ O 
= O 
3.55 O 
μm O 
, O 
the O 
Mid-IR O 
sensor O 
can O 
distinguish O 
hexane B-SYSTEMATIC 
from O 
the O 
rest O 
of O 
the O 
tested O 
analytes O 
( O 
methanol B-SYSTEMATIC 
, O 
toluene B-TRIVIAL 
, O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
, O 
ethanol B-SYSTEMATIC 
and O 
acetone B-SYSTEMATIC 
) O 
, O 
since O 
hexane B-SYSTEMATIC 
has O 
a O 
strong O 
absorption O 
from O 
the O 
aliphatic O 
C-H B-FORMULA 
stretch O 
at O 
λ O 
= O 
3.55 O 
μm O 
. O 
Analogously O 
, O 
applying O 
the O 
same O 
technique O 
at O 
λ O 
= O 
3.3 O 
μm O 
, O 
the O 
Mid-IR O 
sensor O 
is O 
able O 
to O 
determine O 
the O 
concentration O 
of O 
toluene B-TRIVIAL 
dissolved O 
in O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
, O 
because O 
toluene B-TRIVIAL 
has O 
a O 
strong O 
absorption O 
at O 
λ O 
= O 
3.3 O 
μm O 
from O 
the O 
aromatic O 
C-H B-FORMULA 
stretch O 
. O 
With O 
our O 
demonstration O 
of O 
an O 
air O 
- O 
clad O 
silicon B-SYSTEMATIC 
pedestal O 
waveguide O 
sensor O 
, O 
we O 
move O 
closer O 
towards O 
the O 
ultimate O 
goal O 
of O 
an O 
ultra O 
- O 
compact O 
portable O 
spectrometer-on-a-chip O 
. O 

: O 
Characterization O 
of O 
novel O 
rodent O 
models O 
for O 
prostate O 
cancer O 
studies O 
requires O 
evaluation O 
of O 
either O 
spontaneous O 
and O 
carcinogen O 
- O 
induced O 
tumors O 
as O 
well O 
as O 
tumor O 
incidence O 
in O 
different O 
prostatic O 
lobes O 
. O 
We O 
propose O 
a O 
new O 
short O 
- O 
term O 
rodent O 
model O 
of O 
chemically O 
induced O 
prostate O 
carcinogenesis O 
in O 
which O 
prostate O 
cancer O 
progression O 
occurs O 
differentially O 
in O 
the O 
dorsolateral O 
and O 
ventral O 
lobes O 
. O 
METHODS O 
: O 
Adult O 
gerbils O 
were O 
treated O 
with O 
MNU B-ABBREVIATION 
alone O 
or O 
associated O 
with O 
testosterone B-TRIVIAL 
for O 
3 O 
or O 
6 O 
months O 
of O 
treatment O 
. O 
Tumor O 
incidence O 
, O 
latency O 
, O 
localization O 
, O 
and O 
immunohistochemistry O 
( O 
AR O 
, O 
PCNA O 
, O 
smooth O 
muscle O 
α-actin O 
, O 
p63 O 
, O 
MGMT O 
, O 
and O 
E-cadherin O 
) O 
were O 
studied O 
in O 
both O 
lobes O 
. O 
RESULTS O 
: O 
Comparisons O 
between O 
both O 
lobes O 
revealed O 
that O 
lesions O 
developed O 
first O 
in O 
the O 
DL O 
while O 
the O 
VL O 
presented O 
longer O 
tumor O 
latency O 
. O 
However O 
, O 
after O 
6 O 
months O 
, O 
there O 
was O 
a O 
dramatic O 
increase O 
in O 
tumor O 
multiplicity O 
in O 
the O 
VL O 
, O 
mainly O 
in O 
MNU B-ABBREVIATION 
-treated O 
groups O 
. O 
Lesions O 
clearly O 
progressed O 
from O 
a O 
premalignant O 
to O 
a O 
malignant O 
phenotype O 
over O 
time O 
and O 
tumor O 
latency O 
was O 
decreased O 
by O 
MNU B-ABBREVIATION 
+ O 
testosterone B-TRIVIAL 
administration O 
. O 
Three O 
- O 
dimensional O 
reconstruction O 
of O 
the O 
prostatic O 
complex O 
showed O 
that O 
the O 
DL O 
developed O 
tumors O 
exclusively O 
in O 
the O 
periurethral O 
area O 
and O 
showed O 
intense O 
AR O 
, O 
PCNA O 
, O 
and O 
MGMT O 
immunostaining O 
. O 
Moreover O 
, O 
VL O 
lesions O 
emerged O 
throughout O 
the O 
entire O 
lobe O 
. O 
MNU B-ABBREVIATION 
-induced O 
lesions O 
presented O 
markers O 
indicative O 
of O 
an O 
aggressive O 
phenotype O 
: O 
lack O 
of O 
basal O 
cells O 
, O 
rupture O 
of O 
the O 
smooth O 
muscle O 
cell O 
layer O 
, O 
loss O 
of O 
E-cadherin O 
, O 
and O 
high O 
MGMT O 
staining O 
. O 
CONCLUSIONS O 
: O 
There O 
are O 
distinct O 
pathways O 
involved O 
in O 
tumor O 
progression O 
in O 
gerbil O 
prostate O 
lobes O 
. O 
This O 
animal O 
provides O 
a O 
good O 
model O 
for O 
prostate O 
cancer O 
since O 
it O 
allows O 
the O 
investigation O 
of O 
advanced O 
steps O 
of O 
carcinogenesis O 
with O 
shorter O 
latency O 
periods O 
in O 
both O 
lobes O 
. O 
Prostate O 
© O 
2013 O 
Wiley O 
Periodicals O 
, O 
Inc O 
. O 

Effect O 
of O 
BCRP O 
, O 
MDR1 O 
and O 
OATP1B3 O 
on O 
the O 
Antitumor O 
Efficacy O 
of O 
the O 
Lipophilic O 
Camptothecin B-TRIVIAL 
AR-67 B-IDENTIFIER 
In O 
Vitro O 
. O 

is O 
a O 
lipophilic O 
camptothecin B-TRIVIAL 
analogue O 
, O 
currently O 
under O 
early O 
stage O 
clinical O 
trials O 
. O 
Transporters O 
are O 
known O 
to O 
have O 
an O 
impact O 
on O 
the O 
disposition O 
of O 
camptothecins B-FAMILY 
and O 
on O 
the O 
response O 
to O 
chemotherapeutics O 
in O 
general O 
due O 
to O 
their O 
expression O 
in O 
tumor O 
tissues O 
. O 
Therefore O 
, O 
the O 
interplay O 
between O 
the O 
BCRP O 
, O 
MDR1 O 
and O 
OATP1B1 O 
/ O 
OATP1B3 O 
transporters O 
and O 
AR-67 B-IDENTIFIER 
and O 
their O 
impact O 
on O 
the O 
toxicity O 
profile O 
of O 
AR-67 B-IDENTIFIER 
was O 
investigated O 
. O 
Using O 
cell O 
lines O 
expressing O 
the O 
aforementioned O 
transporters O 
, O 
we O 
showed O 
that O 
the O 
lipophilic O 
AR-67 B-IDENTIFIER 
lactone B-FAMILY 
form O 
is O 
a O 
substrate O 
for O 
efflux O 
transporters O 
BCRP O 
and O 
MDR1 O 
. O 
Additionally O 
, O 
OATP1B1 O 
and O 
OATP1B3 O 
facilitated O 
the O 
uptake O 
of O 
AR-67 B-IDENTIFIER 
carboxylate B-SYSTEMATIC 
in O 
SLCO1B1 O 
and O 
SLCO1B3-transfected O 
cell O 
systems O 
compared O 
to O 
the O 
mock O 
- O 
transfected O 
ones O 
. O 
Notably O 
, O 
both O 
BCRPand O 
MDR1 O 
, O 
conferred O 
resistance O 
to O 
AR-67 B-IDENTIFIER 
lactone B-FAMILY 
. O 
Prompted O 
by O 
recent O 
studies O 
showing O 
increased O 
OATP1B3 O 
expression O 
in O 
certain O 
cancer O 
types O 
, O 
we O 
investigated O 
the O 
effect O 
of O 
OATP1B3 O 
expression O 
on O 
cell O 
viability O 
after O 
exposure O 
to O 
AR-67 B-IDENTIFIER 
carboxylate B-SYSTEMATIC 
. O 
OATP1B3 O 
expressing O 
cells O 
had O 
increased O 
carboxylate B-SYSTEMATIC 
uptake O 
as O 
compared O 
to O 
mock O 
transfected O 
cells O 
, O 
but O 
were O 
not O 
sensitized O 
because O 
the O 
intracellular O 
amount O 
of O 
lactone B-FAMILY 
was O 
fifty O 
- O 
fold O 
higher O 
than O 
that O 
of O 
carboxylate B-SYSTEMATIC 
and O 
comparable O 
between O 
OATP1B3 O 
expressing O 
and O 
non-expressing O 
cells O 
. O 
In O 
conclusion O 
, O 
BCRP- O 
and O 
MDR1 O 
- O 
mediated O 
efflux O 
of O 
AR-67 B-IDENTIFIER 
lactone B-FAMILY 
confers O 
resistance O 
to O 
AR-67 B-IDENTIFIER 
, O 
but O 
OATP1B3 O 
- O 
mediated O 
uptake O 
of O 
the O 
AR-67 B-IDENTIFIER 
carboxylate B-SYSTEMATIC 
does O 
not O 
sensitize O 
OATP1B3 O 
expressing O 
tumor O 
cells O 
. O 

environments O 
are O 
linked O 
to O 
fetal O 
renal O 
development O 
and O 
postnatal O 
health O 
. O 
Influence O 
of O 
salt O 
diets O 
during O 
pregnancy O 
on O 
renal O 
functions O 
and O 
renin O 
- O 
angiotensin O 
system O 
( O 
RAS O 
) O 
were O 
determined O 
in O 
the O 
ovine O 
fetus O 
and O 
offspring O 
. O 
Pregnant O 
ewes O 
were O 
fed O 
high O 
- O 
salt O 
diet O 
( O 
HSD O 
) O 
or O 
normal O 
- O 
salt O 
diet O 
( O 
NSD O 
) O 
for O 
two O 
months O 
during O 
middle O 
- O 
later O 
gestation O 
. O 
Fetal O 
renal O 
functions O 
, O 
plasma O 
hormones O 
, O 
mRNA O 
and O 
protein O 
expressions O 
of O 
the O 
key O 
elements O 
of O 
renal O 
RAS O 
were O 
measured O 
in O 
the O 
fetus O 
and O 
offspring O 
. O 
Fetal O 
renal O 
excretion O 
of O 
sodium B-SYSTEMATIC 
was O 
increased O 
while O 
urine O 
volume O 
decreased O 
in O 
HSD O 
group O 
. O 
Fetal O 
blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
was O 
increased O 
, O 
while O 
kidney O 
/ O 
body O 
weight O 
ratio O 
decreased O 
in O 
HSD O 
group O 
. O 
The O 
altered O 
ratio O 
also O 
was O 
observed O 
in O 
the O 
offspring O 
at O 
15-day- O 
old O 
and O 
90-day- O 
old O 
. O 
Maternal O 
and O 
fetal O 
plasma O 
antidiuretic O 
hormone O 
was O 
elevated O 
without O 
change O 
in O 
plasma O 
renin O 
activity O 
and O 
Ang O 
I O 
levels O 
, O 
while O 
plasma O 
Ang O 
II O 
was O 
decreased O 
. O 
The O 
key O 
elements O 
of O 
local O 
renal O 
RAS O 
, O 
including O 
angiotensinogen O 
, O 
ACE O 
, O 
ACE2 O 
, O 
AT1 O 
and O 
AT2 O 
receptor O 
expression O 
in O 
both O 
mRNA O 
and O 
protein O 
, O 
except O 
renin O 
, O 
were O 
altered O 
following O 
maternal O 
high O 
salt O 
intake O 
. O 
The O 
results O 
suggest O 
that O 
High O 
intake O 
of O 
salt O 
during O 
pregnancy O 
affected O 
fetal O 
renal O 
development O 
associated O 
with O 
an O 
altered O 
expression O 
of O 
the O 
renal O 
key O 
elements O 
of O 
RAS O 
, O 
some O 
alterations O 
of O 
fetal O 
origins O 
remained O 
after O 
birth O 
as O 
possible O 
risks O 
in O 
developing O 
renal O 
or O 
cardiovascular O 
diseases O 
. O 

Porous O 
Sugar B-FAMILY 
-Functionalized O 
PEG B-ABBREVIATION 
Microgels O 
for O 
Efficient O 
Isolation O 
and O 
Removal O 
of O 
Bacteria O 
from O 
Solution O 
. O 

we O 
present O 
a O 
new O 
microparticle O 
system O 
for O 
the O 
selective O 
detection O 
and O 
magnetic O 
removal O 
of O 
bacteria O 
from O 
contaminated O 
solutions O 
. O 
The O 
novelty O 
of O 
this O 
system O 
lies O 
in O 
the O 
combination O 
of O 
a O 
biocompatible O 
scaffold O 
reducing O 
unspecific O 
interactions O 
with O 
high O 
capacity O 
for O 
bacteria O 
binding O 
. O 
We O 
apply O 
highly O 
porous O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
microparticles O 
and O 
functionalize O 
them O 
introducing O 
both O 
sugar B-FAMILY 
ligands O 
for O 
specific O 
bacteria O 
targeting O 
and O 
cationic O 
moieties O 
for O 
electrostatic O 
loading O 
of O 
superparamagnetic O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
. O 
The O 
resulting O 
magnetic O 
, O 
porous O 
, O 
sugar O 
- O 
functionalized O 
( O 
MaPoS O 
) O 
PEG B-ABBREVIATION 
microgels O 
are O 
able O 
to O 
selectively O 
bind O 
and O 
discriminate O 
between O 
different O 
strains O 
of O 
bacteria O 
Escherichia O 
coli O 
. O 
Furthermore O 
, O 
they O 
allow O 
for O 
a O 
highly O 
efficient O 
removal O 
of O 
bacteria O 
from O 
solution O 
as O 
their O 
increased O 
surface O 
area O 
can O 
bind O 
three O 
times O 
more O 
bacteria O 
than O 
non-porous O 
particles O 
. O 
All O 
in O 
all O 
, O 
MaPoS O 
particles O 
represent O 
a O 
novel O 
generation O 
of O 
magnetic O 
beads O 
introducing O 
for O 
the O 
first O 
time O 
a O 
porous O 
, O 
biocompatible O 
and O 
easy O 
to O 
functionalize O 
scaffold O 
and O 
show O 
great O 
potential O 
for O 
various O 
biotechnological O 
applications O 
. O 

: O 
Dipeptidyl O 
peptidase-4 O 
( O 
DPP-4 O 
) O 
inhibitors O 
( O 
gliptins O 
) O 
play O 
an O 
increasing O 
role O 
in O 
the O 
management O 
of O 
type O 
2 O 
diabetes O 
. O 
Such O 
incretin O 
- O 
based O 
therapies O 
offer O 
some O 
advantages O 
over O 
other O 
glucose B-TRIVIAL 
-lowering O 
agents O 
, O 
but O 
might O 
be O 
associated O 
with O 
an O 
increased O 
risk O 
of O 
acute O 
pancreatitis O 
. O 
Areas O 
covered O 
: O 
An O 
extensive O 
literature O 
search O 
was O 
performed O 
to O 
analyze O 
clinical O 
cases O 
of O 
acute O 
pancreatitis O 
reported O 
in O 
the O 
literature O 
or O 
to O 
the O 
Food O 
and O 
Drug O 
Administration O 
( O 
FDA O 
) O 
, O 
in O 
randomized O 
clinical O 
trials O 
, O 
and O 
in O 
observational O 
studies O 
with O 
five O 
DPP-4 O 
inhibitors O 
: O 
sitagliptin B-TRIVIAL 
, O 
vildagliptin B-TRIVIAL 
, O 
saxagliptin B-TRIVIAL 
, O 
alogliptin B-TRIVIAL 
, O 
and O 
linagliptin B-TRIVIAL 
. O 
Expert O 
opinion O 
: O 
An O 
increased O 
risk O 
of O 
pancreatitis O 
has O 
been O 
reported O 
in O 
diabetic O 
versus O 
nondiabetic O 
patients O 
. O 
Several O 
anecdotal O 
clinical O 
cases O 
of O 
pancreatitis O 
have O 
been O 
reported O 
with O 
sitagliptin B-TRIVIAL 
and O 
vildagliptin B-TRIVIAL 
and O 
an O 
increased O 
relative O 
risk O 
reported O 
to O 
the O 
FDA O 
with O 
sitagliptin B-TRIVIAL 
versus O 
other O 
comparators O 
, O 
but O 
reporting O 
bias O 
cannot O 
be O 
excluded O 
. O 
In O 
rather O 
short O 
- O 
term O 
clinical O 
trials O 
with O 
well O 
- O 
selected O 
diabetic O 
patients O 
, O 
no O 
increased O 
risk O 
of O 
acute O 
pancreatitis O 
has O 
been O 
observed O 
with O 
any O 
of O 
the O 
five O 
commercialized O 
DPP-4 O 
inhibitors O 
: O 
sitagliptin B-TRIVIAL 
, O 
vildagliptin B-TRIVIAL 
, O 
saxagliptin B-TRIVIAL 
, O 
alogliptin B-TRIVIAL 
, O 
and O 
linagliptin B-TRIVIAL 
. O 
Similarly O 
, O 
real O 
- O 
life O 
cohort O 
studies O 
showed O 
no O 
increased O 
incidence O 
of O 
pancreatitis O 
with O 
gliptins O 
compared O 
with O 
other O 
glucose B-TRIVIAL 
-lowering O 
agents O 
, O 
a O 
finding O 
recently O 
challenged O 
by O 
a O 
case- O 
control O 
study O 
. O 
These O 
results O 
must O 
be O 
confirmed O 
in O 
postmarketing O 
surveillance O 
programs O 
and O 
in O 
ongoing O 
large O 
prospective O 
trials O 
with O 
cardiovascular O 
outcomes O 
. O 

degradation O 
of O 
microcystins B-FAMILY 
. O 

microcystins B-FAMILY 
that O 
are O 
produced O 
by O 
freshwater O 
cyanobacteria O 
pose O 
a O 
risk O 
to O 
public O 
health O 
. O 
These O 
compounds O 
may O 
be O 
eliminated O 
by O 
enzymatic O 
degradation O 
. O 
Here O 
, O 
we O 
review O 
the O 
enzymatic O 
pathways O 
for O 
the O 
degradation O 
of O 
these O 
hepatotoxins O 
, O 
some O 
of O 
which O 
are O 
newly O 
discovered O 
processes O 
. O 
The O 
efficiencies O 
of O 
microcystin B-FAMILY 
biodegradation O 
pathways O 
are O 
documented O 
in O 
several O 
papers O 
and O 
are O 
compared O 
here O 
. O 
Additionally O 
, O 
a O 
comprehensive O 
description O 
of O 
the O 
microcystin B-FAMILY 
enzymatic O 
degradation O 
scheme O 
has O 
been O 
supplemented O 
with O 
a O 
proposal O 
for O 
a O 
new O 
biodegradation O 
pathway O 
. O 
Critical O 
comments O 
on O 
less O 
documented O 
hypotheses O 
are O 
also O 
included O 
in O 
this O 
review O 
. O 
The O 
genetic O 
aspects O 
of O 
biodegradation O 
activity O 
are O 
discussed O 
in O 
detail O 
. O 
We O 
also O 
describe O 
some O 
methods O 
that O 
are O 
useful O 
for O 
studying O 
the O 
biological O 
decomposition O 
of O 
microcystins B-FAMILY 
, O 
including O 
screening O 
for O 
microcystin B-FAMILY 
degraders O 
and O 
detecting O 
microcystin B-FAMILY 
degradation O 
products O 
, O 
with O 
an O 
emphasis O 
on O 
mass O 
spectrometric O 
methodology O 
. O 

of O 
CO2 B-FORMULA 
and O 
COS B-FORMULA 
into O 
Bi-C B-FORMULA 
Bonds O 
: O 
Reactivity O 
of O 
a O 
Bismuth B-SYSTEMATIC 
NCN I-SYSTEMATIC 
Pincer O 
Complex O 
of O 
an O 
Oxyaryl B-FAMILY 
Dianionic O 
Ligand O 
, O 
[2,6-(Me2NCH2)2C6H3]Bi(C6H2tBu2O) B-FORMULA 
. O 

reactivity O 
of O 
the O 
unusual O 
oxyaryl B-FAMILY 
dianionic O 
ligand O 
, O 
(C6H2tBu2-3,5-O-4)2 B-SYSTEMATIC 
- O 
, O 
in O 
the O 
Bi3+ B-FORMULA 
NCN I-FORMULA 
pincer O 
complex O 
Ar'Bi(C6H2tBu2-3,5-O-4) B-FAMILY 
, O 
1 O 
, O 
[ O 
Ar O 
' O 
= O 
2,6-(Me2NCH2)2C6H3 B-SYSTEMATIC 
] O 
has O 
been O 
explored O 
with O 
small O 
molecule O 
substrates O 
and O 
electrophiles O 
. O 
The O 
first O 
insertion O 
reactions O 
of O 
CO2 B-FORMULA 
and O 
COS B-FORMULA 
into O 
Bi-C B-FORMULA 
bonds O 
are O 
observed O 
with O 
this O 
oxyaryl B-FAMILY 
dianionic O 
ligand O 
complex O 
. O 
These O 
reactions O 
generate O 
new O 
dianions O 
that O 
have O 
quinoidal O 
character O 
similar O 
to O 
the O 
oxyaryl B-FAMILY 
dianionic O 
ligand O 
in O 
1 O 
. O 
The O 
oxyarylcarboxy B-FAMILY 
and O 
oxyarylthiocarboxy B-FAMILY 
dianionic O 
ligands O 
were O 
identified O 
by O 
X-ray O 
crystallography O 
in O 
Ar'Bi[O2C(C6H2tBu2-3-5-O-4)-κ2O,O'] B-FAMILY 
, O 
2 O 
and O 
Ar'Bi[OSC(C6H2tBu2-3-5-O-4)-κ2O,S] B-FAMILY 
, O 
3 O 
, O 
respectively O 
. O 
Silyl B-FAMILY 
halides I-FAMILY 
and O 
pseudohalides B-FAMILY 
, O 
R3SiX B-FAMILY 
( O 
X O 
= O 
Cl B-FORMULA 
, O 
CN B-FORMULA 
, O 
N3 B-FORMULA 
; O 
R O 
= O 
Me B-FORMULA 
, O 
Ph B-FORMULA 
) O 
, O 
react O 
with O 
1 O 
by O 
attaching O 
X O 
to O 
bismuth B-SYSTEMATIC 
and O 
R3Si B-FAMILY 
to O 
the O 
oxyaryl B-FAMILY 
oxygen B-SYSTEMATIC 
to O 
form O 
Ar'Bi(X)(C6H2tBu2-3,5-OSiR3-4) B-FAMILY 
complexes O 
, O 
a O 
formal O 
addition O 
across O 
five O 
bonds O 
. O 
These O 
react O 
with O 
additional O 
R3SiX B-FAMILY 
to O 
generate O 
Ar'BiX2 B-FAMILY 
complexes O 
and O 
R3SiOC6H3tBu2-2,6 B-FAMILY 
. O 
The O 
reaction O 
of O 
1 O 
with O 
I2 B-FORMULA 
forms O 
Ar'BiI2 B-FAMILY 
and O 
the O 
coupled O 
quinone B-FAMILY 
, O 
3,3',5,5'-tetra-tert-butyl-4,4'-diphenoquinone B-SYSTEMATIC 
, O 
by O 
oxidative O 
coupling O 
. O 

Estimates O 
for O 
the O 
Vinylidene B-SYSTEMATIC 
- O 
Acetylene B-SYSTEMATIC 
Isomerization O 
Energy O 
and O 
the O 
Ground O 
State O 
Rotational O 
Constants O 
of O 
: B-FORMULA 
C=CH2 I-FORMULA 
. O 

accurate O 
calculations O 
are O 
reported O 
for O 
properties O 
of O 
vinylidene B-SYSTEMATIC 
( O 
H2C=C B-FORMULA 
: I-FORMULA 
) O 
, O 
specically O 
the O 
position O 
of O 
its O 
zero O 
- O 
point O 
vibrational O 
level O 
relative O 
to O 
that O 
of O 
acetylene B-SYSTEMATIC 
and O 
its O 
equilibrium O 
structure O 
and O 
ground O 
state O 
rotational O 
constants O 
. O 
The O 
isomerization O 
energy O 
of O 
vinylidene B-SYSTEMATIC 
calculated O 
at O 
the O 
HEAT-456QP O 
level O 
of O 
theory O 
is O 
45.530.15 O 
kcal O 
mol1 O 
, O 
in O 
agreement O 
with O 
the O 
previous O 
best O 
estimate O 
, O 
but O 
associated O 
with O 
a O 
much O 
smaller O 
uncertainty O 
. O 
In O 
addition O 
, O 
the O 
thermochemical O 
calculations O 
presented O 
here O 
also O 
allow O 
a O 
determination O 
of O 
the O 
: B-FORMULA 
C=CH2 I-FORMULA 
bond O 
energy O 
of O 
the O 
vinyl B-FAMILY 
radical O 
at O 
the O 
HEAT-345(Q) O 
level O 
of O 
theory O 
, O 
which O 
is O 
77.70.3 O 
kcal O 
mol1 O 
. O 
The O 
equilibrium O 
structure O 
of O 
vinylidene B-SYSTEMATIC 
, O 
estimated O 
with O 
an O 
additivity O 
scheme O 
that O 
includes O 
treatment O 
of O 
correlation O 
eects O 
beyond O 
CCSD(T) O 
as O 
well O 
as O 
relativistic O 
and O 
adiabatic O 
( O 
diagonal O 
Born-Oppenheimer O 
correction O 
) O 
contributions O 
is O 
rCC=1.29820.0003 O 
A O 
; O 
rCH=1.08440.0003 O 
A O 
; O 
and O 
CCH B-FORMULA 
= O 
120.050.05o O 
, O 
with O 
zero O 
- O 
point O 
rotational O 
constants O 
( O 
including O 
vibrational O 
contributions O 
and O 
electronic O 
contributions O 
to O 
the O 
moment O 
of O 
inertia O 
) O 
estimated O 
to O 
be O 
A0 O 
= O 
9.49250.0150 O 
cm1 O 
; O 
B0 O 
= O 
1.32170.0017 O 
cm1 O 
and O 
C0 O 
= O 
1.16020.0016 O 
cm1 O 
. O 
INTRODUCTION O 
. O 

Interfacial O 
Band O 
Mapping O 
across O 
Vertically O 
Phased-Separated O 
Polymer/ O 
Fullerene B-TRIVIAL 
Hybrid O 
Solar O 
Cells O 
. O 

cross O 
- O 
sectional O 
scanning O 
tunneling O 
microscope O 
( O 
XSTM O 
) O 
with O 
samples O 
cleaved O 
in O 
situ O 
in O 
an O 
ultrahigh O 
vacuum O 
( O 
UHV O 
) O 
chamber O 
, O 
this O 
study O 
demonstrates O 
the O 
direct O 
visualization O 
of O 
high O 
- O 
resolution O 
interfacial O 
band O 
mapping O 
images O 
across O 
the O 
film O 
thickness O 
in O 
an O 
optimized O 
bulk O 
heterojunction O 
polymer O 
solar O 
cell O 
consisting O 
of O 
nanoscale O 
phase O 
segregated O 
blends O 
of O 
poly(3-hexylthiophene) B-SYSTEMATIC 
( O 
P3HT B-ABBREVIATION 
) O 
and O 
[6,6]-phenyl B-SYSTEMATIC 
C61 I-SYSTEMATIC 
butyric I-SYSTEMATIC 
acid I-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
PCBM B-ABBREVIATION 
) O 
. O 
We O 
were O 
able O 
to O 
achieve O 
the O 
direct O 
observation O 
of O 
the O 
interfacial O 
band O 
alignments O 
at O 
the O 
donor O 
( O 
P3HT B-ABBREVIATION 
)-acceptor O 
( O 
PCBM B-ABBREVIATION 
) O 
interfaces O 
and O 
at O 
the O 
interfaces O 
between O 
the O 
photoactive O 
P3HT B-ABBREVIATION 
: O 
PCBM B-ABBREVIATION 
blends O 
and O 
the O 
poly(3,4-ethylenedioxythiophene) B-SYSTEMATIC 
poly(styrenesulfonate) B-FAMILY 
( O 
PEDOT B-ABBREVIATION 
: O 
PSS B-ABBREVIATION 
) O 
anode O 
modification O 
layer O 
with O 
an O 
atomic O 
- O 
scale O 
spatial O 
resolution O 
. O 
The O 
unique O 
advantage O 
of O 
using O 
XSTM O 
to O 
characterize O 
polymer O 
: O 
fullerene B-TRIVIAL 
bulk O 
heterojunction O 
solar O 
cells O 
allows O 
us O 
to O 
explore O 
simultaneously O 
the O 
quantitative O 
link O 
between O 
the O 
vertical O 
morphologies O 
and O 
their O 
corresponding O 
local O 
electronic O 
properties O 
. O 
This O 
provides O 
an O 
atomic O 
insight O 
of O 
interfacial O 
band O 
alignments O 
between O 
the O 
two O 
opposite O 
electrodes O 
, O 
which O 
will O 
be O 
crucial O 
for O 
improving O 
the O 
efficiencies O 
of O 
the O 
charge O 
generation O 
, O 
transport O 
, O 
and O 
collection O 
and O 
the O 
corresponding O 
device O 
performance O 
of O 
polymer O 
solar O 
cells O 
. O 

/ O 
Hydrazones B-FAMILY 
as O 
antimicrobial O 
and O 
anticancer O 
agents O 
in O 
the O 
new O 
millennium O 
. O 

/ O 
hydrazone B-FAMILY 
derivatives O 
are O 
of O 
quite O 
interest O 
for O 
medicinal O 
chemists O 
because O 
of O 
their O 
vast O 
spectrum O 
of O 
biological O 
activity O 
. O 
Literature O 
reports O 
reveal O 
that O 
the O 
hydrazide B-SYSTEMATIC 
derivatives O 
have O 
been O 
extensively O 
studied O 
for O 
their O 
biological O 
profile O 
during O 
the O 
past O 
decade O 
. O 
The O 
aim O 
of O 
the O 
present O 
work O 
is O 
to O 
collect O 
literature O 
reports O 
focusing O 
the O 
antimicrobial O 
and O 
anticancer O 
study O 
of O 
different O 
hydrazide B-SYSTEMATIC 
/ O 
hydrazone B-FAMILY 
derivatives O 
carried O 
out O 
during O 
the O 
past O 
decade O 
which O 
will O 
serve O 
as O 
a O 
valuable O 
source O 
of O 
information O 
for O 
the O 
researchers O 
working O 
in O 
the O 
field O 
of O 
antimicrobial O 
and O 
anticancer O 
research O 
. O 

of O 
Chlorpheniramine B-TRIVIAL 
Maleate I-TRIVIAL 
microparticles O 
in O 
orally O 
disintegrating O 
film O 
and O 
orally O 
disintegrating O 
tablet O 
for O 
pediatrics O 
. O 

Objective O 
: O 
To O 
mask O 
the O 
bitterness O 
of O 
Chlorpheniramine B-TRIVIAL 
Maleate I-TRIVIAL 
via O 
encapsulating O 
drug O 
into O 
Eudragit B-TRIVIAL 
EPO I-TRIVIAL 
microparticles O 
, O 
and O 
then O 
incorporate O 
these O 
microparticles O 
into O 
orally O 
disintegrating O 
films O 
( O 
ODF O 
) O 
and O 
orally O 
disintegrating O 
tablets O 
( O 
ODT O 
) O 
for O 
pediatric O 
uses O 
. O 
Methods O 
: O 
Spray O 
drying O 
of O 
water O 
- O 
in O 
- O 
oil O 
emulsion O 
was O 
utilized O 
to O 
encapsulate O 
Chlorpheniramine B-TRIVIAL 
Maleate I-TRIVIAL 
into O 
Eudragit B-TRIVIAL 
EPO I-TRIVIAL 
microparticles O 
. O 
Based O 
on O 
an O 
orthogonal O 
experimental O 
design O 
L9 O 
(3(3)) O 
, O 
polynomial O 
regression O 
models O 
were O 
developed O 
to O 
evaluate O 
correlation O 
between O 
microparticle O 
properties O 
( O 
encapsulation O 
efficiency O 
and O 
drug O 
release O 
) O 
and O 
variables O 
( O 
X1 O 
: O 
weight O 
ratio O 
of O 
polymer O 
to O 
drug O 
, O 
X2 O 
: O 
volume O 
ratio O 
of O 
oil O 
to O 
water O 
and O 
X3 O 
: O 
Q-flow O 
of O 
spray O 
dryer O 
) O 
. O 
ODF O 
and O 
ODT O 
formulations O 
were O 
evaluated O 
including O 
weight O 
variation O 
, O 
content O 
uniformity O 
, O 
tensile O 
strength O 
, O 
disintegration O 
time O 
, O 
friability O 
and O 
dissolution O 
profiles O 
. O 
The O 
bitterness O 
taste O 
test O 
was O 
evaluated O 
in O 
10 O 
adult O 
volunteers O 
. O 
Results O 
and O 
discussion O 
: O 
From O 
polynomial O 
regression O 
analysis O 
, O 
the O 
best O 
values O 
of O 
variables O 
leading O 
to O 
the O 
optimized O 
microparticles O 
were O 
X1 O 
= O 
10 O 
, O 
X2 O 
= O 
3 O 
and O 
X3 O 
= O 
45 O 
. O 
The O 
optimized O 
microparticles O 
were O 
incorporated O 
into O 
ODF O 
and O 
ODT O 
with O 
satisfactory O 
weight O 
and O 
drug O 
content O 
uniformity O 
, O 
and O 
acceptable O 
physical O 
strength O 
. O 
Both O 
dosage O 
forms O 
disintegrated O 
immediately O 
( O 
less O 
than O 
40 O 
s O 
) O 
in O 
simulated O 
saliva O 
solutions O 
. O 
The O 
outcome O 
of O 
taste O 
- O 
masking O 
test O 
indicated O 
that O 
microparticles O 
alleviated O 
drug O 
bitterness O 
significantly O 
; O 
bitterness O 
was O 
not O 
discernible O 
with O 
microparticles O 
incorporated O 
in O 
ODT O 
, O 
whereas O 
only O 
slight O 
bitterness O 
was O 
detected O 
from O 
microparticles O 
incorporated O 
into O 
ODF O 
. O 
Conclusion O 
: O 
Both O 
ODF O 
and O 
ODT O 
are O 
shown O 
to O 
be O 
suitable O 
vehicles O 
for O 
taste O 
masked O 
Chlorpheniramine B-TRIVIAL 
Maleate I-TRIVIAL 
microparticles O 
with O 
potential O 
for O 
pediatric O 
uses O 
. O 

The O 
conservative O 
single O 
- O 
layered O 
wound O 
dressing O 
system O 
is O 
decomposed O 
when O 
mixed O 
in O 
polyvinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
( O 
PVA B-ABBREVIATION 
) O 
solution O 
, O 
which O 
means O 
it O 
cannot O 
be O 
used O 
with O 
a O 
temperature O 
- O 
sensitive O 
drug O 
. O 
The O 
goal O 
of O 
this O 
investigation O 
was O 
to O 
make O 
an O 
amniotic O 
membrane O 
extract O 
(AME)-loaded O 
double O 
- O 
layered O 
wound O 
dressing O 
with O 
an O 
improved O 
healing O 
result O 
compared O 
to O 
the O 
conservative O 
single O 
- O 
layered O 
wound O 
dressing O 
systems O 
. O 
The O 
double O 
- O 
layered O 
wound O 
dressing O 
was O 
developed O 
with O 
PVA B-ABBREVIATION 
/ O 
sodium B-SYSTEMATIC 
alginate I-SYSTEMATIC 
using O 
a O 
freeze O 
- O 
melting O 
technique O 
; O 
one O 
layer O 
was O 
PVA B-ABBREVIATION 
layer O 
and O 
the O 
other O 
was O 
the O 
drug O 
- O 
loaded O 
sodium B-SYSTEMATIC 
alginate I-SYSTEMATIC 
layer O 
. O 
Its O 
gel O 
properties O 
were O 
assessed O 
compared O 
to O 
single O 
- O 
layered O 
wound O 
dressings O 
. O 
Moreover O 
, O 
in O 
vivo O 
wound O 
- O 
healing O 
effects O 
and O 
histopathology O 
were O 
calculated O 
compared O 
to O 
commercial O 
products O 
. O 
The O 
double O 
- O 
layered O 
wound O 
dressing O 
gave O 
a O 
similar O 
gel O 
fraction O 
and O 
Young's O 
module O 
as O 
single O 
- O 
layered O 
wound O 
bandages O 
developed O 
with O 
only O 
PVA B-ABBREVIATION 
, O 
and O 
a O 
similar O 
inflammation O 
ability O 
and O 
WVTR O 
as O 
single O 
- O 
layered O 
wound O 
dressings O 
developed O 
with O 
PVA B-ABBREVIATION 
and O 
sodium B-SYSTEMATIC 
alginate I-SYSTEMATIC 
. O 
Our O 
data O 
indicate O 
that O 
these O 
double O 
- O 
layered O 
wound O 
bandages O 
were O 
just O 
as O 
swellable O 
, O 
but O 
more O 
elastic O 
and O 
stronger O 
than O 
single O 
- O 
layered O 
wound O 
dressings O 
comprised O 
of O 
the O 
same O 
polymers O 
and O 
quantities O 
, O 
possibly O 
giving O 
an O 
acceptable O 
level O 
of O 
moisture O 
and O 
accumulation O 
of O 
exudates O 
in O 
the O 
wound O 
zone O 
. O 
Compared O 
to O 
the O 
commercial O 
product O 
, O 
the O 
double O 
- O 
layered O 
wound O 
dressing O 
comprising O 
6.7% O 
PVA B-ABBREVIATION 
, O 
0.5% O 
sodium B-SYSTEMATIC 
alginate I-SYSTEMATIC 
and O 
0.01% O 
AME O 
significantly O 
enhanced O 
the O 
wound O 
- O 
healing O 
effect O 
in O 
the O 
wound O 
- O 
healing O 
test O 
. O 
Histological O 
investigations O 
showed O 
that O 
superior O 
full O 
- O 
thickness O 
wound O 
- O 
healing O 
effects O 
compared O 
to O 
the O 
commercial O 
product O 
. O 
Therefore O 
, O 
the O 
double O 
- O 
layered O 
wound O 
dressing O 
would O 
be O 
an O 
outstanding O 
wound O 
- O 
dressing O 
system O 
with O 
improved O 
wound O 
healing O 
and O 
good O 
gel O 
property O 
. O 

from O 
the O 
Aerial O 
Parts O 
of O 
Cimicifuga O 
yunnanensis O 
and O 
Their O 
Antiproliferative O 
Effects O 
on O 
p53(N236S) O 
Mouse O 
Embryonic O 
Fibroblasts O 
. O 

new O 
triterpene B-FAMILY 
derivatives O 
, O 
yunnanterpenes B-MULTIPLE 
A-F I-MULTIPLE 
( O 
1-6 O 
) O 
, O 
15,16-seco- B-MULTIPLE 
cimiterpenes I-MULTIPLE 
A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
( O 
7 O 
, O 
8 O 
) O 
, O 
and O 
cimilactone B-TRIVIAL 
C I-TRIVIAL 
( O 
9 O 
) O 
, O 
and O 
15 O 
known O 
analogues O 
( O 
10-24 O 
) O 
were O 
isolated O 
from O 
the O 
aerial O 
parts O 
of O 
Cimicifuga O 
yunnanensis O 
. O 
The O 
new O 
structures O 
were O 
established O 
using O 
a O 
combination O 
of O 
MS O 
, O 
NMR O 
, O 
and O 
single O 
- O 
crystal O 
X-ray O 
diffraction O 
techniques O 
. O 
WT O 
MEFs O 
( O 
wild O 
- O 
type O 
mouse O 
embryonic O 
fibroblasts O 
) O 
and O 
tumorigenic O 
cell O 
lines O 
p53(- O 
/ O 
-)+H-RasV12 O 
and O 
p53(- O 
/ O 
-)+p53(N236S)+H-RasV12 O 
were O 
used O 
for O 
evaluating O 
active O 
structures O 
, O 
targeting O 
p53(N236S) O 
( O 
corresponding O 
to O 
p53(N239S) O 
in O 
humans O 
) O 
mutation O 
. O 
Compound O 
5 O 
showed O 
nonselective O 
activities O 
against O 
these O 
cell O 
lines O 
, O 
with O 
IC50 O 
values O 
of O 
5.8 O 
, O 
8.6 O 
, O 
and O 
6 O 
μM O 
, O 
respectively O 
. O 
Compound O 
4 O 
exhibited O 
greater O 
selectivity O 
against O 
the O 
p53(- O 
/ O 
-)+p53(N236S)+H-RasV12 O 
cells O 
( O 
IC50 O 
5.5 O 
μM O 
) O 
than O 
against O 
the O 
WT O 
MEFs O 
cells O 
( O 
IC50 O 
14.3 O 
μM O 
) O 
. O 

Bisbenzylisoquinoline B-FAMILY 
Alkaloids I-FAMILY 
from O 
Stephania O 
epigaea O 
. O 

new O 
bisbenzylisoquinoline B-FAMILY 
alkaloids I-FAMILY 
( O 
1-6 O 
) O 
and O 
seven O 
known O 
compounds O 
( O 
8-14 O 
) O 
were O 
isolated O 
from O 
the O 
tubers O 
of O 
Stephania O 
epigaea O 
, O 
in O 
addition O 
to O 
the O 
major O 
alkaloid O 
, O 
cepharanthine B-TRIVIAL 
( O 
7 O 
) O 
. O 
The O 
structures O 
of O 
1-6 O 
were O 
elucidated O 
by O 
combined O 
spectroscopic O 
data O 
analysis O 
and O 
chemical O 
methods O 
, O 
with O 
their O 
configurations O 
determined O 
from O 
their O 
optical O 
rotation O 
values O 
and O 
confirmed O 
using O 
circular O 
dichroism O 
. O 
Compounds O 
1-6 O 
belong O 
to O 
the O 
oxyacanthine B-TRIVIAL 
type O 
of O 
bisbenzylisoquinoline B-FAMILY 
alkaloids I-FAMILY 
and O 
have O 
a O 
rare O 
methylenedioxy B-SYSTEMATIC 
substituent O 
. O 
Compound O 
1 O 
, O 
a O 
dimer O 
composed O 
of O 
benzylisoquinoline B-SYSTEMATIC 
and O 
seco B-TRIVIAL 
- I-TRIVIAL 
aristolactam I-TRIVIAL 
units O 
, O 
represents O 
a O 
new O 
type O 
of O 
bisbenzylisoquinoline B-FAMILY 
alkaloid I-FAMILY 
, O 
while O 
compounds O 
3-6 O 
are O 
bisbenzylisoquinoline B-FAMILY 
N-oxides I-FAMILY 
. O 
These O 
compounds O 
were O 
evaluated O 
for O 
their O 
in O 
vitro O 
cytotoxicities O 
against O 
six O 
human O 
cancer O 
cell O 
lines O 
( O 
A-549 O 
, O 
ECA109 O 
, O 
HL-60 O 
, O 
MCF-7 O 
, O 
SMMC-7721 O 
, O 
and O 
SW480 O 
) O 
. O 
Cepharanthine B-TRIVIAL 
( O 
7 O 
) O 
, O 
the O 
major O 
component O 
of O 
S O 
. O 
epigaea O 
, O 
exhibited O 
cytotoxicity O 
against O 
all O 
of O 
these O 
cancer O 
cell O 
lines O 
except O 
ECA109 O 
, O 
while O 
its O 
known O 
analogue O 
, O 
10 O 
, O 
displayed O 
cytotoxicity O 
against O 
all O 
six O 
cancer O 
cell O 
lines O 
. O 

inhibitory O 
daphnane B-FAMILY 
diterpenoids I-FAMILY 
from O 
the O 
flower O 
buds O 
of O 
Daphne O 
genkwa O 
. O 

new O 
daphnane O 
- O 
type O 
diterpene O 
esters O 
, O 
daphneresiniferins B-MULTIPLE 
A I-MULTIPLE 
( I-MULTIPLE 
1 I-MULTIPLE 
) I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
( O 
2 O 
) O 
, O 
along O 
with O 
seven O 
known O 
diterpenes B-FAMILY 
, O 
yuanhuacine B-TRIVIAL 
( O 
3 O 
) O 
, O 
yuanhuadine B-TRIVIAL 
( O 
4 O 
) O 
, O 
yuanhuahine B-TRIVIAL 
( O 
5 O 
) O 
, O 
genkwadaphnin B-TRIVIAL 
( O 
6 O 
) O 
, O 
genkwanine B-TRIVIAL 
A I-TRIVIAL 
( O 
7 O 
) O 
, O 
genkwanine B-TRIVIAL 
F I-TRIVIAL 
( O 
8 O 
) O 
, O 
and O 
genkwanine B-TRIVIAL 
H I-TRIVIAL 
( O 
9 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
methanol B-SYSTEMATIC 
extract O 
of O 
the O 
flower O 
buds O 
of O 
Daphne O 
genkwa O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
spectroscopic O 
methods O 
, O 
especially O 
2D O 
NMR O 
spectra O 
such O 
as O 
HMQC O 
, O 
HMBC O 
, O 
and O 
NOESY O 
. O 
All O 
the O 
isolates O 
were O 
evaluated O 
for O 
their O 
inhibitory O 
effects O 
of O 
the O 
melanogenesis O 
against O 
α-melanocyte O 
stimulating O 
hormone O 
(α-MSH)-activated O 
B16 O 
melanoma O 
cells O 
. O 

of O 
pyrazolo[1,5-a]pyrimidine B-SYSTEMATIC 
linked O 
aminobenzothiazole B-SYSTEMATIC 
conjugates O 
as O 
potential O 
anticancer O 
agents O 
. O 

series O 
of O 
pyrazolo[1,5-a]pyrimidine B-SYSTEMATIC 
linked O 
2-aminobenzothizole B-SYSTEMATIC 
conjugates O 
( O 
6a-t O 
) O 
were O 
synthesized O 
and O 
evaluated O 
for O 
their O 
anticancer O 
activity O 
against O 
five O 
human O 
cancer O 
cell O 
lines O 
. O 
Among O 
them O 
two O 
compounds O 
6p O 
and O 
6m O 
showed O 
significant O 
anticancer O 
activity O 
with O 
IC50 O 
values O 
ranging O 
from O 
2.01 O 
to O 
7.07 O 
and O 
1.94-3.46μM O 
, O 
respectively O 
. O 
Moreover O 
, O 
cell O 
cycle O 
arrest O 
in O 
G2 O 
/ O 
M O 
and O 
reduction O 
in O 
Cdk1 O 
expression O 
level O 
were O 
observed O 
upon O 
treatment O 
of O 
these O 
compounds O 
and O 
they O 
also O 
induced O 
caspase-3 O 
dependent O 
apoptosis O 
. O 
This O 
was O 
further O 
confirmed O 
by O 
staining O 
as O 
well O 
as O 
DNA O 
fragmentation O 
analysis O 
. O 

and O 
functional O 
characterization O 
of O 
flavin B-FAMILY 
-containing O 
monooxygenases O 
in O 
cynomolgus O 
macaque O 
. O 

-containing O 
monooxygenases O 
( O 
FMOs O 
) O 
, O 
drug O 
- O 
metabolizing O 
enzymes O 
essential O 
for O 
the O 
metabolism O 
of O 
endogenous O 
biochemicals O 
and O 
foreign O 
compounds O 
, O 
have O 
been O 
characterized O 
in O 
human O 
( O 
including O 
FMO1-5 O 
and O 
FMO6P O 
) O 
, O 
but O 
remain O 
to O 
be O 
investigated O 
in O 
cynomolgus O 
macaque O 
. O 
In O 
this O 
study O 
, O 
cDNAs O 
of O 
cynomolgus O 
FMO1-5 O 
and O 
FMO6 O 
were O 
isolated O 
and O 
characterized O 
. O 
Amino B-FAMILY 
acid I-FAMILY 
sequences O 
of O 
cynomolgus O 
FMO1-5 O 
, O 
respectively O 
, O 
shared O 
high O 
sequence O 
identities O 
( O 
94-98% O 
) O 
and O 
were O 
closely O 
clustered O 
in O 
a O 
phylogenetic O 
tree O 
, O 
with O 
human O 
FMO1-5 O 
. O 
Eight O 
different O 
transcripts O 
, O 
due O 
to O 
alternative O 
splicing O 
, O 
were O 
isolated O 
for O 
cynomolgus O 
FMO6 O 
, O 
which O 
is O 
highly O 
identical O 
( O 
∼96% O 
) O 
to O 
human O 
FMO6P O 
. O 
Among O 
the O 
10 O 
tissue O 
types O 
analyzed O 
, O 
cynomolgus O 
FMO1 O 
, O 
FMO2 O 
, O 
FMO4 O 
, O 
and O 
FMO6 O 
were O 
most O 
abundantly O 
expressed O 
in O 
kidney O 
, O 
while O 
cynomolgus O 
FMO3 O 
and O 
FMO5 O 
were O 
most O 
abundantly O 
expressed O 
in O 
liver O 
. O 
In O 
kidney O 
and O 
liver O 
, O 
the O 
most O 
abundantly O 
expressed O 
cynomolgus O 
FMO O 
genes O 
were O 
FMO1 O 
and O 
FMO3 O 
respectively O 
. O 
Cynomolgus O 
FMO1 O 
, O 
FMO2 O 
, O 
FMO3 O 
, O 
and O 
FMO5 O 
metabolized O 
benzydamine B-TRIVIAL 
, O 
and O 
FMO1 O 
/ O 
FMO3 O 
and O 
FMO3 O 
also O 
metabolized O 
methimazole B-TRIVIAL 
and O 
trimethylamine B-SYSTEMATIC 
, O 
respectively O 
. O 
Rates O 
of O 
benzydamine B-TRIVIAL 
N B-FORMULA 
-oxygenation O 
( O 
catalyzed O 
by O 
FMO3 O 
) O 
varied O 
( O 
approximately O 
20-fold O 
) O 
among O 
the O 
28 O 
cynomolgus O 
livers O 
and O 
were O 
significantly O 
correlated O 
with O 
FMO3 O 
protein O 
expression O 
, O 
indicating O 
that O 
the O 
inter O 
- O 
animal O 
variations O 
in O 
benzydamine B-TRIVIAL 
N B-FORMULA 
-oxygenation O 
might O 
be O 
partly O 
accounted O 
for O 
by O 
the O 
variable O 
FMO3 O 
expression O 
. O 
Cynomolgus O 
FMO6 O 
metabolized O 
benzydamine B-TRIVIAL 
only O 
slightly O 
, O 
but O 
minimal O 
expression O 
of O 
FMO6 O 
in O 
all O 
tissue O 
precludes O 
the O 
importance O 
of O 
FMO6 O 
in O 
drug O 
metabolism O 
, O 
unlike O 
cynomolgus O 
FMO1 O 
, O 
FMO2 O 
, O 
FMO3 O 
, O 
and O 
FMO5 O 
which O 
were O 
all O 
functional O 
. O 
Abundant O 
expression O 
of O 
FMO1 O 
and O 
FMO3 O 
in O 
kidney O 
and O 
liver O 
, O 
respectively O 
, O 
suggest O 
their O 
importance O 
in O 
drug O 
metabolism O 
in O 
cynomolgus O 
macaque O 
, O 
similar O 
to O 
human O 
. O 

receptor O 
modulation O 
by O 
piperine B-TRIVIAL 
and O 
a O 
non-TRPV1 O 
activating O 
derivative O 
. O 

action O 
of O 
piperine B-TRIVIAL 
( O 
the O 
pungent O 
component O 
of O 
pepper O 
) O 
and O 
its O 
derivative O 
SCT-66 B-IDENTIFIER 
((2E,4E)-5-(1,3-benzodioxol-5-yl))-N,N-diisobutyl-2,4-pentadienamide B-SYSTEMATIC 
) I-SYSTEMATIC 
on O 
different O 
gamma-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
) O 
type O 
A O 
( O 
GABAA O 
) O 
receptors O 
, O 
transient-receptor-potential-vanilloid-1 O 
( O 
TRPV1 O 
) O 
receptors O 
and O 
behavioral O 
effects O 
were O 
investigated O 
. O 
GABAA O 
receptor O 
subtypes O 
and O 
TRPV1 O 
receptors O 
were O 
expressed O 
in O 
Xenopus O 
laevis O 
oocytes O 
. O 
Modulation O 
of O 
GABA B-ABBREVIATION 
-induced O 
chloride B-SYSTEMATIC 
currents O 
( O 
IGABA O 
) O 
by O 
piperine B-TRIVIAL 
and O 
SCT-66 B-IDENTIFIER 
and O 
activation O 
of O 
TRPV1 O 
was O 
studied O 
using O 
the O 
two-microelectrode-voltage O 
- O 
clamp O 
technique O 
and O 
fast O 
perfusion O 
. O 
Their O 
effects O 
on O 
explorative O 
behavior O 
, O 
thermoregulation O 
and O 
seizure O 
threshold O 
were O 
analyzed O 
in O 
mice O 
. O 
Piperine B-TRIVIAL 
acted O 
with O 
similar O 
potency O 
on O 
all O 
GABAA O 
receptor O 
subtypes O 
( O 
EC50 O 
range O 
: O 
42.8±7.6μM O 
(α2β2)-59.6±12.3μM O 
( O 
α3β2 O 
) O 
) O 
. O 
IGABA O 
modulation O 
by O 
piperine B-TRIVIAL 
did O 
not O 
require O 
the O 
presence O 
of O 
a O 
γ2S-subunit O 
, O 
suggesting O 
a O 
binding O 
site O 
involving O 
only O 
α O 
and O 
β O 
subunits O 
. O 
IGABA O 
activation O 
was O 
slightly O 
more O 
efficacious O 
on O 
receptors O 
formed O 
from O 
β2 O 
/ O 
3 O 
subunits O 
( O 
maximal O 
IGABA O 
stimulation O 
through O 
α1β3 O 
receptors O 
: O 
332±64% O 
and O 
α1β2 O 
: O 
271±36% O 
vs O 
. O 
α1β1 O 
: O 
171±22% O 
, O 
p O 
< O 
0.05 O 
) O 
and O 
α3-subunits O 
( O 
α3β2 O 
: O 
375±51% O 
vs O 
. O 
α5β2 O 
: O 
136±22% O 
, O 
p O 
< O 
0.05 O 
) O 
. O 
Replacing O 
the O 
piperidine B-SYSTEMATIC 
ring O 
by O 
a O 
N-di- B-SYSTEMATIC 
isobutyl I-SYSTEMATIC 
residue O 
( O 
SCT-66 B-IDENTIFIER 
) O 
prevents O 
interactions O 
with O 
TRPV1 O 
and O 
simultaneously O 
increases O 
the O 
potency O 
and O 
efficiency O 
of O 
GABAA O 
receptor O 
modulation O 
. O 
SCT-66 B-IDENTIFIER 
displayed O 
greater O 
efficacy O 
on O 
GABAA O 
receptors O 
than O 
piperine B-TRIVIAL 
, O 
with O 
different O 
subunit O 
- O 
dependence O 
. O 
Both O 
compounds O 
induced O 
anxiolytic O 
, O 
anticonvulsant O 
effects O 
and O 
reduced O 
locomotor O 
activity O 
; O 
however O 
, O 
SCT-66 B-IDENTIFIER 
induced O 
stronger O 
anxiolysis O 
without O 
decreasing O 
body O 
temperature O 
and O 
without O 
the O 
proconvulsive O 
effects O 
of O 
TRPV1 O 
activation O 
and O 
thus O 
may O 
serve O 
as O 
a O 
scaffold O 
for O 
the O 
development O 
of O 
novel O 
GABAA O 
receptor O 
modulators O 
. O 

field O 
of O 
proteomics O 
is O 
undergoing O 
rapid O 
development O 
in O 
a O 
number O 
of O 
different O 
areas O 
including O 
improvements O 
in O 
mass O 
spectrometric O 
platforms O 
, O 
peptide O 
identification O 
algorithms O 
and O 
bioinformatics O 
. O 
In O 
particular O 
, O 
new O 
and O 
/ O 
or O 
improved O 
approaches O 
have O 
established O 
robust O 
methods O 
that O 
not O 
only O 
allow O 
for O 
in O 
- O 
depth O 
and O 
accurate O 
peptide O 
and O 
protein O 
identification O 
and O 
modification O 
, O 
but O 
also O 
allow O 
for O 
sensitive O 
measurement O 
of O 
relative O 
or O 
absolute O 
quantitation O 
. O 
These O 
methods O 
are O 
beginning O 
to O 
be O 
applied O 
to O 
the O 
area O 
of O 
neuroproteomics O 
, O 
but O 
the O 
central O 
nervous O 
system O 
poses O 
many O 
specific O 
challenges O 
in O 
terms O 
of O 
quantitative O 
proteomics O 
, O 
given O 
the O 
large O 
number O 
of O 
different O 
neuronal O 
cell O 
types O 
that O 
are O 
intermixed O 
and O 
that O 
exhibit O 
distinct O 
patterns O 
of O 
gene O 
and O 
protein O 
expression O 
. O 
This O 
review O 
highlights O 
the O 
recent O 
advances O 
that O 
have O 
been O 
made O 
in O 
quantitative O 
neuroproteomics O 
, O 
with O 
a O 
focus O 
on O 
work O 
published O 
over O 
the O 
last O 
five O 
years O 
that O 
applies O 
emerging O 
methods O 
to O 
normal O 
brain O 
function O 
as O 
well O 
as O 
to O 
various O 
neuropsychiatric O 
disorders O 
including O 
schizophrenia O 
and O 
drug O 
addiction O 
as O 
well O 
as O 
of O 
neurodegenerative O 
diseases O 
including O 
Parkinson's O 
disease O 
and O 
Alzheimer's O 
disease O 
. O 
While O 
older O 
methods O 
such O 
as O 
two O 
- O 
dimensional O 
polyacrylamide B-SYSTEMATIC 
electrophoresis O 
continued O 
to O 
be O 
used O 
, O 
a O 
variety O 
of O 
more O 
in O 
- O 
depth O 
MS O 
- O 
based O 
approaches O 
including O 
both O 
label O 
( O 
ICAT O 
, O 
iTRAQ O 
, O 
TMT O 
, O 
SILAC O 
, O 
SILAM O 
) O 
, O 
label O 
- O 
free O 
( O 
label O 
- O 
free O 
, O 
MRM O 
, O 
SWATH O 
) O 
and O 
absolute O 
quantification O 
methods O 
, O 
are O 
rapidly O 
being O 
applied O 
to O 
neurobiological O 
investigations O 
of O 
normal O 
and O 
diseased O 
brain O 
tissue O 
as O 
well O 
as O 
of O 
cerebrospinal O 
fluid O 
( O 
CSF O 
) O 
. O 
While O 
the O 
biological O 
implications O 
of O 
many O 
of O 
these O 
studies O 
remain O 
to O 
be O 
clearly O 
established O 
, O 
that O 
there O 
is O 
a O 
clear O 
need O 
for O 
standardization O 
of O 
experimental O 
design O 
and O 
data O 
analysis O 
, O 
and O 
that O 
the O 
analysis O 
of O 
protein O 
changes O 
in O 
specific O 
neuronal O 
cell O 
types O 
in O 
the O 
central O 
nervous O 
system O 
remains O 
a O 
serious O 
challenge O 
, O 
it O 
appears O 
that O 
the O 
quality O 
and O 
depth O 
of O 
the O 
more O 
recent O 
quantitative O 
proteomics O 
studies O 
is O 
beginning O 
to O 
shed O 
light O 
on O 
a O 
number O 
of O 
aspects O 
of O 
neuroscience O 
that O 
relates O 
to O 
normal O 
brain O 
function O 
as O 
well O 
as O 
of O 
the O 
changes O 
in O 
protein O 
expression O 
and O 
regulation O 
that O 
occurs O 
in O 
neuropsychiatric O 
and O 
neurodegenerative O 
disorders O 
. O 

nicotine B-TRIVIAL 
exposure O 
during O 
lactation O 
alters O 
hypothalamic O 
neuropeptides O 
expression O 
in O 
the O 
adult O 
rat O 
progeny O 
. O 

exposure O 
to O 
nicotine O 
during O 
lactation O 
causes O 
hyperleptinemia O 
in O 
the O 
pups O 
and O 
, O 
at O 
adulthood O 
, O 
these O 
animals O 
are O 
overweight O 
and O 
hyperleptinemic O 
, O 
while O 
, O 
in O 
their O 
hypothalamus O 
, O 
the O 
leptin O 
signaling O 
pathway O 
is O 
reduced O 
, O 
evidencing O 
a O 
central O 
leptin O 
resistance O 
. O 
Then O 
, O 
we O 
evaluated O 
the O 
expression O 
of O 
pro O 
- O 
opiomelanocortin O 
( O 
POMC O 
) O 
, O 
alpha-melanocyte O 
stimulating O 
hormone O 
( O 
α-MSH O 
) O 
, O 
cocaine B-TRIVIAL 
and O 
amphetamine B-TRIVIAL 
-regulated O 
transcript O 
( O 
CART O 
) O 
, O 
neuropeptide O 
Y O 
( O 
NPY O 
) O 
, O 
agouti O 
- O 
related O 
peptide O 
( O 
AgRP O 
) O 
and O 
others O 
in O 
different O 
hypothalamic O 
nuclei O 
in O 
order O 
to O 
better O 
understand O 
the O 
mechanisms O 
underlying O 
the O 
obese O 
phenotype O 
observed O 
in O 
these O 
animals O 
at O 
adulthood O 
. O 
On O 
the O 
2nd O 
postnatal O 
day O 
( O 
P2 O 
) O 
, O 
dams O 
were O 
subcutaneously O 
implanted O 
with O 
osmotic O 
minipumps O 
releasing O 
nicotine B-TRIVIAL 
( O 
NIC B-ABBREVIATION 
-6mg O 
/ O 
kg O 
/ O 
day O 
) O 
or O 
saline O 
for O 
14days O 
. O 
Offspring O 
were O 
killed O 
in O 
P180 O 
and O 
immunohistochemistry O 
and O 
Western O 
blot O 
analysis O 
were O 
carried O 
out O 
. O 
Significance O 
data O 
had O 
p O 
< O 
0.05 O 
. O 
Adult O 
NIC B-ABBREVIATION 
offspring O 
showed O 
more O 
intense O 
NPY O 
staining O 
in O 
the O 
paraventricular O 
nucleus O 
( O 
PVN O 
) O 
( O 
+ O 
21% O 
) O 
and O 
increased O 
number O 
of O 
POMC-positive O 
cells O 
in O 
the O 
: O 
arcuate O 
nucleus O 
( O 
+ O 
33% O 
) O 
, O 
as O 
an O 
increase O 
in O 
fiber O 
density O 
of O 
α-MSH O 
in O 
PVN O 
( O 
+ O 
85% O 
) O 
. O 
However O 
, O 
the O 
number O 
of O 
CART-positive O 
cells O 
was O 
reduced O 
in O 
the O 
PVN O 
( O 
-25% O 
) O 
. O 
CRH O 
staining O 
was O 
more O 
intense O 
in O 
NIC B-ABBREVIATION 
offspring O 
( O 
+ O 
136% O 
) O 
. O 
Orexins O 
and O 
AgRP O 
were O 
not O 
altered O 
. O 
Thus O 
, O 
maternal O 
nicotine B-TRIVIAL 
exposure O 
changes O 
hypothalamic O 
neuropeptides O 
in O 
the O 
adult O 
progeny O 
that O 
is O 
partially O 
compatible O 
with O 
leptin O 
resistance O 
. O 

immunotoxicity O 
in O 
male O 
rats O 
after O 
juvenile O 
exposure O 
to O 
ethanol B-SYSTEMATIC 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
determine O 
the O 
sensitivity O 
of O 
the O 
developing O 
immune O 
system O 
to O 
ethanol B-SYSTEMATIC 
( O 
EtOH B-FORMULA 
) O 
after O 
exposure O 
from O 
postnatal O 
day O 
( O 
PND O 
) O 
10 O 
onward O 
. O 
Adult O 
Wistar O 
dams O 
and O 
litters O 
were O 
exposed O 
to O 
EtOH B-FORMULA 
via O 
drinking O 
water O 
( O 
0 O 
, O 
0.25 O 
, O 
1.5 O 
, O 
2.75 O 
, O 
4 O 
, O 
5.25 O 
, O 
or O 
6.5% O 
( O 
w O 
/ O 
v O 
) O 
EtOH B-FORMULA 
ad O 
libitum O 
) O 
and O 
drinking O 
water O 
exposure O 
of O 
the O 
F1 O 
was O 
continued O 
from O 
weaning O 
until O 
sacrifice O 
. O 
Immune O 
assessments O 
were O 
performed O 
at O 
postnatal O 
days O 
( O 
PNDs O 
) O 
21 O 
, O 
42 O 
, O 
and O 
70 O 
. O 
Furthermore O 
, O 
Keyhole O 
Limpet O 
Hemocyanin O 
( O 
KLH O 
) O 
specific O 
immune O 
responses O 
were O 
evaluated O 
following O 
subcutaneous O 
immunizations O 
on O 
PNDs O 
21 O 
and O 
35 O 
. O 
EtOH B-FORMULA 
exposure O 
affected O 
innate O 
immune O 
responses O 
, O 
such O 
as O 
LPS-induced O 
NO B-FORMULA 
-production O 
by O 
adherent O 
splenocytes O 
, O 
as O 
well O 
as O 
adaptive O 
immune O 
responses O 
as O 
represented O 
by O 
KLH-specific O 
parameters O 
. O 
The O 
most O 
sensitive O 
developmental O 
parameters O 
included O 
effects O 
on O 
maternal O 
and O 
pup O 
bodyweight O 
with O 
calculated O 
BMDs O 
of O 
4.0% O 
and O 
4.3% O 
EtOH B-FORMULA 
, O 
respectively O 
. O 
The O 
most O 
sensitive O 
immune O 
parameters O 
were O 
affected O 
at O 
dose O 
levels O 
lower O 
than O 
those O 
affecting O 
developmental O 
parameters O 
and O 
included O 
KLH-specific O 
immune O 
responses O 
, O 
LPS-induced O 
NO B-FORMULA 
production O 
by O 
adherent O 
splenocytes O 
, O 
and O 
IL-10 O 
production O 
by O 
ConA O 
stimulated O 
splenocytes O 
. O 
Calculated O 
BMDs O 
for O 
these O 
parameters O 
were O 
between O 
0.01% O 
and O 
0.1% O 
EtOH B-FORMULA 
. O 
A O 
comparison O 
of O 
the O 
results O 
of O 
this O 
juvenile O 
study O 
with O 
an O 
extended O 
one O 
- O 
generation O 
reproductive O 
toxicity O 
study O 
revealed O 
that O 
the O 
juvenile O 
study O 
design O 
may O 
result O 
in O 
a O 
higher O 
sensitivity O 
related O 
to O 
differences O 
in O 
the O 
exposure O 
design O 
. O 
These O 
findings O 
demonstrate O 
the O 
relative O 
sensitivity O 
of O 
the O 
developing O 
immune O 
system O 
for O 
EtOH B-FORMULA 
exposure O 
, O 
the O 
additional O 
value O 
of O 
assessing O 
functional O 
immune O 
parameters O 
, O 
and O 
the O 
importance O 
of O 
the O 
juvenile O 
window O 
in O 
developmental O 
immunotoxicity O 
testing O 
. O 

requirements O 
within O 
protoporphyrin B-TRIVIAL 
IX I-TRIVIAL 
in O 
the O 
inhibition O 
of O 
heat O 
shock O 
protein O 
90 O 
. O 

are O 
used O 
for O 
photodynamic O 
therapy O 
for O 
their O 
light O 
- O 
absorbing O 
properties O 
, O 
and O 
some O 
of O 
them O 
were O 
approved O 
for O 
the O 
treatment O 
of O 
certain O 
types O 
of O 
cancers O 
. O 
Porphyrins B-FAMILY 
prevent O 
activation O 
of O 
hypoxia O 
inducible O 
factor-1α O 
( O 
HIF-1α O 
) O 
by O 
inhibiting O 
heat O 
shock O 
protein O 
90 O 
( O 
HSP90 O 
) O 
. O 
This O 
study O 
investigated O 
the O 
structural O 
requirements O 
within O 
protoporphyrin B-TRIVIAL 
IX I-TRIVIAL 
( O 
PPIX B-ABBREVIATION 
) O 
for O 
the O 
inhibition O 
of O 
HSP90 O 
activity O 
. O 
In O 
HCT116 O 
, O 
HT29 O 
and O 
DLD-1 O 
cells O 
, O 
PPIX B-ABBREVIATION 
treatment O 
directly O 
hindered O 
the O 
binding O 
between O 
HSP90 O 
and O 
HIF-1α O 
; O 
PPIX B-ABBREVIATION 
treatment O 
inhibited O 
the O 
chaperone O 
activity O 
of O 
HSP90 O 
, O 
accelerating O 
protein O 
degradation O 
of O 
HIF-1α O 
. O 
In O 
addition O 
, O 
PPIX B-ABBREVIATION 
treatment O 
suppressed O 
cancer O 
cell O 
migration O 
, O 
endothelial O 
cell O 
tube O 
formation O 
, O 
and O 
aortic O 
ring O 
sprouting O 
, O 
being O 
consistent O 
with O 
its O 
anti-tumor O 
and O 
anti-angiogenic O 
activities O 
. O 
In O 
silico O 
analysis O 
, O 
molecular O 
docking O 
model O 
indicated O 
that O 
a O 
tetrapyrrole B-FAMILY 
macrocycle I-FAMILY 
and O 
two O 
propionate B-SYSTEMATIC 
chains O 
within O 
PPIX B-ABBREVIATION 
are O 
necessary O 
for O 
the O 
binding O 
to O 
the O 
adenosine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
( O 
ATP B-ABBREVIATION 
) O 
- O 
binding O 
pocket O 
of O 
HSP90 O 
. O 
The O 
predicted O 
structural O 
requirement O 
was O 
verified O 
by O 
the O 
differential O 
inhibitory O 
effects O 
of O 
PPIX B-ABBREVIATION 
analogs O 
, O 
or O 
the O 
precursor O 
of O 
PPIX B-ABBREVIATION 
, O 
on O 
HIF-1α O 
; O 
compounds O 
lacking O 
either O 
the O 
tetrapyrrole B-FAMILY 
macrocycle I-FAMILY 
or O 
the O 
propionate B-SYSTEMATIC 
chains O 
were O 
inactive O 
. O 
Our O 
results O 
show O 
that O 
a O 
tetrapyrrole B-FAMILY 
macrocycle I-FAMILY 
and O 
two O 
attached O 
propionate B-SYSTEMATIC 
chains O 
in O 
PPIX B-ABBREVIATION 
coordinately O 
interact O 
with O 
the O 
ATP B-ABBREVIATION 
-binding O 
pocket O 
of O 
HSP90 O 
, O 
offering O 
structural O 
information O 
on O 
the O 
inhibitory O 
effect O 
of O 
porphyrins O 
on O 
angiogenesis O 
. O 

purpose O 
of O 
this O 
work O 
was O 
to O 
explore O 
the O 
relation O 
between O 
protein O 
- O 
protein O 
interactions O 
( O 
PPIs O 
) O 
and O 
solution O 
viscosity O 
at O 
high O 
protein O 
concentration O 
using O 
three O 
monoclonal O 
antibodies O 
( O 
mAbs O 
) O 
, O 
two O 
of O 
the O 
IgG4 O 
subclass O 
and O 
one O 
of O 
the O 
IgG1 O 
subclass O 
. O 
A O 
range O 
of O 
methods O 
was O 
used O 
to O 
quantify O 
the O 
PPI O 
either O 
at O 
low O 
concentration O 
( O 
interaction O 
parameter O 
( O 
kD O 
) O 
obtained O 
from O 
dynamic O 
light O 
scattering O 
, O 
DLS O 
) O 
or O 
at O 
high O 
concentration O 
( O 
solution O 
storage O 
modulus O 
( O 
G O 
' O 
) O 
from O 
ultrasonic O 
shear O 
rheology O 
) O 
. O 
We O 
also O 
developed O 
a O 
novel O 
method O 
for O 
the O 
determination O 
of O 
PPI O 
using O 
the O 
apparent O 
radius O 
of O 
the O 
protein O 
at O 
either O 
low O 
or O 
high O 
protein O 
concentration O 
determined O 
using O 
DLS O 
. O 
The O 
PPI O 
measurements O 
were O 
correlated O 
with O 
solution O 
viscosity O 
( O 
measured O 
by O 
DLS O 
using O 
polystyrene B-SYSTEMATIC 
nanospheres O 
and O 
ultrasonic O 
shear O 
rheology O 
) O 
as O 
a O 
function O 
of O 
pH O 
( O 
4-9 O 
) O 
and O 
ionic O 
strength O 
( O 
10 O 
, O 
50 O 
and O 
150mM O 
) O 
. O 
Our O 
measurements O 
showed O 
that O 
the O 
highest O 
solution O 
viscosity O 
was O 
observed O 
under O 
conditions O 
with O 
the O 
most O 
negative O 
kD O 
, O 
the O 
highest O 
apparent O 
radius O 
and O 
the O 
lowest O 
net O 
charge O 
. O 
An O 
increase O 
in O 
ionic O 
strength O 
resulted O 
in O 
a O 
change O 
in O 
the O 
nature O 
of O 
the O 
PPI O 
at O 
low O 
pH O 
from O 
repulsive O 
to O 
attractive O 
. O 
In O 
the O 
neutral O 
to O 
alkaline O 
pH O 
region O 
the O 
mAbs O 
behaved O 
differently O 
with O 
respect O 
to O 
increase O 
in O 
ionic O 
strength O 
. O 
Two O 
mAbs O 
( O 
A O 
and O 
B O 
) O 
showed O 
little O 
or O 
no O 
effect O 
of O 
increasing O 
ionic O 
strength O 
, O 
whereas O 
mAb-C O 
showed O 
a O 
remarkable O 
decrease O 
in O 
attractive O 
PPI O 
and O 
viscosity O 
. O 
Previous O 
studies O 
have O 
mainly O 
investigated O 
mAbs O 
of O 
the O 
IgG1 O 
and O 
IgG2 O 
subclass O 
. O 
We O 
show O 
here O 
, O 
for O 
the O 
first O 
time O 
, O 
that O 
mAbs O 
of O 
the O 
IgG4 O 
subclass O 
behave O 
similar O 
as O 
the O 
other O 
subclasses O 
. O 
By O 
comparison O 
of O 
the O 
three O 
tested O 
mAbs O 
with O 
mAbs O 
investigated O 
in O 
other O 
studies O 
a O 
clear O 
linear O 
trend O 
emerges O 
between O 
the O 
pH O 
of O 
strongest O 
attractive O 
PPI O 
and O 
highest O 
solution O 
viscosity O 
. O 
The O 
determination O 
of O 
PPI O 
using O 
either O 
kD O 
or O 
apparent O 
radius O 
is O 
thus O 
a O 
useful O 
prediction O 
tool O 
in O 
the O 
determination O 
of O 
solution O 
conditions O 
that O 
favors O 
low O 
solution O 
viscosity O 
at O 
high O 
protein O 
concentration O 
of O 
therapeutically O 
used O 
mAb O 
molecules O 
. O 
The O 
novel O 
methodology O 
using O 
apparent O 
radius O 
is O 
a O 
simple O 
and O 
rapid O 
alternative O 
to O 
determine O 
relative O 
PPI O 
directly O 
under O 
formulation O 
conditions O 
. O 
The O 
method O 
can O 
potentially O 
serve O 
as O 
a O 
high O 
- O 
throughput O 
screening O 
tool O 
in O 
formulation O 
development O 
. O 

nanoparticles O 
have O 
revealed O 
very O 
effective O 
in O 
transmucosal O 
delivery O 
of O 
proteins O 
. O 
Polysaccharides O 
are O 
among O 
the O 
most O 
used O 
materials O 
for O 
the O 
production O 
of O 
these O 
carriers O 
, O 
owing O 
to O 
their O 
structural O 
flexibility O 
and O 
propensity O 
to O 
evidence O 
biocompatibility O 
and O 
biodegradability O 
. O 
In O 
parallel O 
, O 
there O 
is O 
a O 
preference O 
for O 
the O 
use O 
of O 
mild O 
methods O 
for O 
their O 
production O 
, O 
in O 
order O 
to O 
prevent O 
protein O 
degradation O 
, O 
ensure O 
lower O 
costs O 
and O 
easier O 
procedures O 
that O 
enable O 
scaling O 
up O 
. O 
In O 
this O 
work O 
we O 
propose O 
the O 
production O 
of O 
pullulan O 
- O 
based O 
nanoparticles O 
by O 
a O 
mild O 
method O 
of O 
polyelectrolyte O 
complexation O 
. O 
As O 
pullulan O 
is O 
a O 
neutral O 
polysaccharide O 
, O 
sulfated O 
and O 
aminated O 
derivatives O 
of O 
the O 
polymer O 
were O 
synthesized O 
to O 
provide O 
pullulan O 
with O 
a O 
charge O 
. O 
These O 
derivatives O 
were O 
then O 
complexed O 
with O 
chitosan O 
and O 
carrageenan O 
, O 
respectively O 
, O 
to O 
produce O 
the O 
nanocarriers O 
. O 
Positively O 
charged O 
nanoparticles O 
of O 
180-270nm O 
were O 
obtained O 
, O 
evidencing O 
ability O 
to O 
associate O 
bovine O 
serum O 
albumin O 
, O 
which O 
was O 
selected O 
as O 
model O 
protein O 
. O 
In O 
PBS O 
pH O 
7.4 O 
, O 
pullulan O 
- O 
based O 
nanoparticles O 
were O 
found O 
to O 
have O 
a O 
burst O 
release O 
of O 
30% O 
of O 
the O 
protein O 
, O 
which O 
maintained O 
up O 
to O 
24h O 
. O 
Nanoparticle O 
size O 
and O 
zeta O 
potential O 
were O 
preserved O 
upon O 
freeze O 
- O 
drying O 
in O 
the O 
presence O 
of O 
appropriate O 
cryoprotectants O 
. O 
A O 
factorial O 
design O 
was O 
approached O 
to O 
assess O 
the O 
cytotoxicity O 
of O 
raw O 
materials O 
and O 
nanoparticles O 
by O 
the O 
metabolic O 
test O 
MTT B-ABBREVIATION 
. O 
Nanoparticles O 
demonstrated O 
to O 
not O 
cause O 
overt O 
toxicity O 
in O 
a O 
respiratory O 
cell O 
model O 
( O 
Calu-3 O 
) O 
. O 
Pullulan O 
has O 
, O 
thus O 
, O 
demonstrated O 
to O 
hold O 
potential O 
for O 
the O 
production O 
of O 
nanoparticles O 
with O 
an O 
application O 
in O 
protein O 
delivery O 
. O 

of O 
drugs O 
from O 
multi O 
- O 
wall O 
carbon B-SYSTEMATIC 
nanotube O 
carriers O 
. O 

in O 
the O 
' O 
nanotube O 
- O 
drug O 
' O 
hybrids O 
can O 
play O 
a O 
role O 
of O 
carriers O 
or O 
additives O 
( O 
enhancers O 
) O 
in O 
the O 
more O 
complex O 
formulations O 
. O 
This O 
work O 
reviews O 
qualitative O 
and O 
quantitative O 
analyses O 
of O 
Drug O 
Delivery O 
Systems O 
( O 
DDSs O 
) O 
based O 
on O 
multi O 
- O 
wall O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
MWCNTs O 
) O 
and O 
their O 
chemically O 
modified O 
analogues O 
( O 
mainly O 
oxidised O 
MWCNTs O 
) O 
. O 
A O 
special O 
emphasis O 
was O 
placed O 
on O 
the O 
chemical O 
interactions O 
between O 
drug O 
molecules O 
and O 
the O 
nanotube O 
carrier O 
critical O 
both O 
in O 
the O 
stage O 
of O 
preparation O 
/ O 
synthesis O 
of O 
the O 
hybrids O 
and O 
liberation O 
of O 
the O 
drug O 
. O 

damage O 
induced O 
by O 
chlorpyrifos B-TRIVIAL 
in O 
the O 
hepatic O 
and O 
renal O 
tissue O 
of O 
Kunming O 
mice O 
and O 
the O 
antioxidant O 
role O 
of O 
vitamin B-FAMILY 
E I-FAMILY 
. O 

is O 
a O 
broad O 
- O 
spectrum O 
, O 
chlorinated B-FAMILY 
organophosphate I-FAMILY 
pesticide O 
employed O 
for O 
pest O 
control O 
in O 
various O 
agricultural O 
and O 
animal O 
husbandries O 
. O 
Acute O 
and O 
chronic O 
exposure O 
to O 
CPF B-ABBREVIATION 
can O 
elicit O 
several O 
adverse O 
effects O 
, O 
including O 
oxidative O 
stress O 
. O 
We O 
investigated O 
neurotoxicity O 
of O 
CPF B-ABBREVIATION 
-treated O 
mice O 
, O 
and O 
evaluated O 
the O 
antioxidant O 
effect O 
of O 
vitamin B-FAMILY 
E I-FAMILY 
against O 
oxidative O 
stress O 
and O 
histological O 
changes O 
in O 
the O 
livers O 
and O 
kidneys O 
of O 
CPF B-ABBREVIATION 
-treated O 
mice O 
. O 
Kunming O 
mice O 
were O 
divided O 
randomly O 
into O 
five O 
exposure O 
groups O 
of O 
six O 
: O 
( O 
A O 
) O 
peanut O 
oil O 
; O 
( O 
B O 
) O 
3mg O 
/ O 
kg O 
CPF B-ABBREVIATION 
; O 
( O 
C O 
) O 
6mg O 
/ O 
kg O 
CPF B-ABBREVIATION 
; O 
( O 
D O 
) O 
12mg O 
/ O 
kg O 
CPF B-ABBREVIATION 
; O 
( O 
E O 
) O 
vitamin B-FAMILY 
E I-FAMILY 
( O 
100mg O 
/ O 
kg O 
) O 
, O 
3h O 
after O 
administration O 
of O 
CPF B-ABBREVIATION 
( O 
12mg O 
/ O 
kg O 
) O 
and O 
used O 
as O 
a O 
post O 
- O 
treatment O 
group O 
. O 
Oral O 
administration O 
of O 
high O 
- O 
dose O 
groups O 
( O 
12mg O 
/ O 
kg O 
) O 
CPF B-ABBREVIATION 
led O 
to O 
a O 
significant O 
increase O 
in O 
levels O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
DNA O 
- O 
protein O 
crosslinks O 
, O 
8-hydroxy-2-deoxyguanosine B-SYSTEMATIC 
and O 
malondialdehyde B-TRIVIAL 
, O 
decreases O 
in O 
acetylcholinesterase O 
activity O 
and O 
glutathione B-TRIVIAL 
level O 
, O 
as O 
well O 
as O 
causing O 
hepatic O 
and O 
renal O 
histopathological O 
change O 
. O 
Except O 
for O 
AChE O 
activity O 
levels O 
, O 
administration O 
of O 
vitamin B-FAMILY 
E I-FAMILY 
to O 
CPF B-ABBREVIATION 
-treated O 
mice O 
restored O 
these O 
biochemical O 
parameters O 
to O 
within O 
normal O 
levels O 
, O 
and O 
resulted O 
in O 
overall O 
improvement O 
in O 
damage O 
to O 
livers O 
and O 
kidneys O 
. O 
These O 
data O 
suggest O 
that O 
oxidative O 
stress O 
is O 
involved O 
in O 
CPF B-ABBREVIATION 
-induced O 
toxicity O 
and O 
that O 
vitamin B-FAMILY 
E I-FAMILY 
can O 
protect O 
against O 
the O 
tissue O 
damage O 
induced O 
by O 
CPF B-ABBREVIATION 
. O 

is O 
a O 
critical O 
need O 
for O 
more O 
accurate O 
, O 
highly O 
sensitive O 
and O 
specific O 
assay O 
for O 
disease O 
diagnosis O 
and O 
management O 
. O 
A O 
novel O 
, O 
multiplexed O 
, O 
single O 
sensor O 
using O 
rapid O 
and O 
label O 
free O 
electrochemical O 
impedance O 
spectroscopy O 
tuning O 
method O 
has O 
been O 
developed O 
. O 
The O 
key O 
challenges O 
while O 
monitoring O 
multiple O 
targets O 
is O 
frequency O 
overlap O 
. O 
Here O 
we O 
describe O 
the O 
methods O 
to O 
circumvent O 
the O 
overlap O 
, O 
tune O 
by O 
use O 
of O 
nanoparticle O 
( O 
NP O 
) O 
and O 
discuss O 
the O 
various O 
fabrication O 
and O 
characterization O 
methods O 
to O 
develop O 
this O 
technique O 
. O 
First O 
sensors O 
were O 
fabricated O 
using O 
printed O 
circuit O 
board O 
( O 
PCB O 
) O 
technology O 
and O 
nickel B-SYSTEMATIC 
and O 
gold O 
layers O 
were O 
electrodeposited O 
onto O 
the O 
PCB O 
sensors O 
. O 
An O 
off O 
- O 
chip O 
conjugation O 
of O 
gold O 
NP's O 
to O 
molecular O 
recognition O 
elements O 
( O 
with O 
verification O 
technique O 
) O 
is O 
described O 
as O 
well O 
. O 
A O 
standard O 
covalent O 
immobilization O 
of O 
the O 
molecular O 
recognition O 
elements O 
is O 
also O 
discussed O 
with O 
quality O 
control O 
techniques O 
. O 
Finally O 
use O 
and O 
verification O 
of O 
sensitivity O 
and O 
specificity O 
is O 
also O 
presented O 
. O 
By O 
use O 
of O 
gold O 
NP's O 
of O 
various O 
sizes O 
, O 
we O 
have O 
demonstrated O 
the O 
possibility O 
and O 
shown O 
little O 
loss O 
of O 
sensitivity O 
and O 
specificity O 
in O 
the O 
molecular O 
recognition O 
of O 
inflammatory O 
markers O 
as O 
" O 
model O 
" O 
targets O 
for O 
our O 
tuning O 
system O 
. O 
By O 
selection O 
of O 
other O 
sized O 
NP's O 
or O 
NP's O 
of O 
various O 
materials O 
, O 
the O 
tuning O 
effect O 
can O 
be O 
further O 
exploited O 
. O 
The O 
novel O 
platform O 
technology O 
developed O 
could O 
be O 
utilized O 
in O 
critical O 
care O 
, O 
clinical O 
management O 
and O 
at O 
home O 
health O 
and O 
disease O 
management O 
. O 

and O 
potential O 
damage O 
of O 
human O 
bone O 
- O 
derived O 
cells O 
on O 
fresh O 
and O 
aged O 
fullerene B-TRIVIAL 
c60 B-TRIVIAL 
films O 
. O 

are O 
nanoparticles O 
composed O 
of O 
carbon B-SYSTEMATIC 
atoms O 
arranged O 
in O 
a O 
spherical O 
hollow O 
cage O 
- O 
like O 
structure O 
. O 
Numerous O 
studies O 
have O 
evaluated O 
the O 
therapeutic O 
potential O 
of O 
fullerene B-TRIVIAL 
derivates O 
against O 
oxidative O 
stress O 
- O 
associated O 
conditions O 
, O 
including O 
the O 
prevention O 
or O 
treatment O 
of O 
arthritis O 
. O 
On O 
the O 
other O 
hand O 
, O 
fullerenes B-FAMILY 
are O 
not O 
only O 
able O 
to O 
quench O 
, O 
but O 
also O 
to O 
generate O 
harmful O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
. O 
The O 
reactivity O 
of O 
fullerenes B-FAMILY 
may O 
change O 
in O 
time O 
due O 
to O 
the O 
oxidation O 
and O 
polymerization O 
of O 
fullerenes B-FAMILY 
in O 
an O 
air O 
atmosphere O 
. O 
In O 
this O 
study O 
, O 
we O 
therefore O 
tested O 
the O 
dependence O 
between O 
the O 
age O 
of O 
fullerene B-TRIVIAL 
films O 
( O 
from O 
one O 
week O 
to O 
one O 
year O 
) O 
and O 
the O 
proliferation O 
, O 
viability O 
and O 
metabolic O 
activity O 
of O 
human O 
osteosarcoma O 
cells O 
( O 
lines O 
MG-63 O 
and O 
U-2 O 
OS O 
) O 
. O 
We O 
also O 
monitored O 
potential O 
membrane O 
and O 
DNA O 
damage O 
and O 
morphological O 
changes O 
of O 
the O 
cells O 
. O 
After O 
seven O 
days O 
of O 
cultivation O 
, O 
we O 
did O 
not O 
observe O 
any O 
cytotoxic O 
morphological O 
changes O 
, O 
such O 
as O 
enlarged O 
cells O 
or O 
cytosolic O 
vacuole O 
formation O 
. O 
Furthermore O 
, O 
there O 
was O 
no O 
increased O 
level O 
of O 
DNA O 
damage O 
. O 
The O 
increasing O 
age O 
of O 
the O 
fullerene B-TRIVIAL 
films O 
did O 
not O 
cause O 
enhancement O 
of O 
cytotoxicity O 
. O 
On O 
the O 
contrary O 
, O 
it O 
resulted O 
in O 
an O 
improvement O 
in O 
the O 
properties O 
of O 
these O 
materials O 
, O 
which O 
are O 
more O 
suitable O 
for O 
cell O 
cultivation O 
. O 
Therefore O 
, O 
fullerene B-TRIVIAL 
films O 
could O 
be O 
considered O 
as O 
a O 
promising O 
material O 
with O 
potential O 
use O 
as O 
a O 
bioactive O 
coating O 
of O 
cell O 
carriers O 
for O 
bone O 
tissue O 
engineering O 
. O 

- O 
affinity O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
expression O 
and O 
trafficking O 
abnormalities O 
in O 
psychiatric O 
illness O 
. O 

: O 
Nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
nAChRs O 
) O 
are O 
a O 
critical O 
component O 
of O 
the O 
cholinergic O 
system O 
of O 
neurotransmission O 
in O 
the O 
brain O 
that O 
modulates O 
important O 
physiological O 
processes O 
such O 
as O 
reward O 
, O 
cognition O 
, O 
and O 
mood O 
. O 
Abnormalities O 
in O 
this O 
system O 
are O 
accordingly O 
implicated O 
in O 
multiple O 
psychiatric O 
illnesses O 
, O 
including O 
addiction O 
, O 
schizophrenia O 
, O 
and O 
mood O 
disorders O 
. O 
There O 
is O 
significantly O 
increased O 
tobacco O 
use O 
, O 
and O 
therefore O 
nicotine B-TRIVIAL 
intake O 
, O 
in O 
patient O 
populations O 
, O 
and O 
pharmacological O 
agents O 
that O 
act O 
on O 
various O 
nicotinic O 
receptor O 
subtypes O 
ameliorate O 
clinical O 
features O 
of O 
these O 
disorders O 
. O 
Better O 
understanding O 
of O 
the O 
molecular O 
mechanisms O 
underlying O 
cholinergic O 
dysfunction O 
in O 
psychiatric O 
disease O 
will O 
permit O 
more O 
targeted O 
design O 
of O 
novel O 
therapeutic O 
agents O 
. O 
RESULTS O 
: O 
The O 
objective O 
of O 
this O 
review O 
is O 
to O 
describe O 
the O 
multiple O 
cellular O 
pathways O 
through O 
which O 
chronic O 
nicotine B-TRIVIAL 
exposure O 
regulates O 
nAChR O 
expression O 
, O 
and O 
to O 
juxtapose O 
these O 
mechanisms O 
with O 
evidence O 
for O 
altered O 
expression O 
of O 
high O 
- O 
affinity O 
nAChRs O 
in O 
human O 
psychiatric O 
illness O 
. O 
Here O 
, O 
we O 
summarize O 
multiple O 
studies O 
from O 
pre O 
- O 
clinical O 
animal O 
models O 
to O 
human O 
in O 
vivo O 
imaging O 
and O 
post O 
- O 
mortem O 
experiments O 
demonstrating O 
changes O 
in O 
nAChR O 
regulation O 
and O 
expression O 
in O 
psychiatric O 
illness O 
. O 
CONCLUSIONS O 
: O 
We O 
conclude O 
that O 
a O 
mechanistic O 
explanation O 
of O 
nAChR O 
abnormalities O 
in O 
psychiatric O 
illness O 
will O 
arise O 
from O 
a O 
fuller O 
understanding O 
of O 
normal O 
nAChR O 
trafficking O 
, O 
along O 
with O 
the O 
detailed O 
study O 
of O 
human O 
tissue O 
, O 
perhaps O 
using O 
novel O 
biotechnological O 
advances O 
, O 
such O 
as O 
induced O 
pluripotent O 
stem O 
cells O 
. O 

can O 
be O 
induced O 
by O 
three O 
main O 
conditions O 
: O 
a O 
massive O 
acute O 
phosphate B-SYSTEMATIC 
load O 
, O 
a O 
primary O 
increase O 
in O 
renal O 
phosphate B-SYSTEMATIC 
reabsorption O 
, O 
and O 
an O 
impaired O 
renal O 
phosphate B-SYSTEMATIC 
excretion O 
due O 
to O 
acute O 
or O 
chronic O 
renal O 
insufficiency O 
. O 
Renal O 
excretion O 
is O 
so O 
efficient O 
in O 
normal O 
subjects O 
that O 
balance O 
can O 
be O 
maintained O 
with O 
only O 
a O 
minimal O 
rise O 
in O 
serum O 
phosphorus B-SYSTEMATIC 
concentration O 
even O 
for O 
a O 
large O 
phosphorus B-SYSTEMATIC 
load O 
. O 
Therefore O 
, O 
acute O 
hyperphosphataemia O 
usually O 
resolves O 
within O 
few O 
hours O 
if O 
renal O 
function O 
is O 
intact O 
. O 
The O 
most O 
frequent O 
cause O 
of O 
chronic O 
hyperphosphataemia O 
is O 
chronic O 
renal O 
failure O 
. O 
Hyperphosphataemia O 
in O 
chronic O 
kidney O 
disease O 
( O 
CKD O 
) O 
is O 
associated O 
with O 
increased O 
cardiovascular O 
morbidity O 
and O 
mortality O 
. O 
Lowering O 
the O 
phosphate B-SYSTEMATIC 
load O 
and O 
maintaining O 
serum O 
phosphorus B-SYSTEMATIC 
levels O 
within O 
the O 
normal O 
range O 
are O 
considered O 
important O 
therapeutic O 
goals O 
to O 
improve O 
clinical O 
outcomes O 
in O 
CKD O 
patients O 
. O 
Treatment O 
consists O 
of O 
diminishing O 
intestinal O 
phosphate B-SYSTEMATIC 
absorption O 
by O 
a O 
low O 
phosphate B-SYSTEMATIC 
diet O 
and O 
phosphate B-SYSTEMATIC 
binders O 
. O 
In O 
CKD O 
patients O 
on O 
dialysis O 
an O 
efficient O 
dialysis O 
removal O 
of O 
phosphate B-SYSTEMATIC 
should O 
be O 
ensured O 
. O 
Dietary O 
restriction O 
of O 
phosphorus B-SYSTEMATIC 
while O 
maintaining O 
adequate O 
protein O 
intake O 
is O 
not O 
sufficient O 
to O 
control O 
serum O 
phosphate B-SYSTEMATIC 
levels O 
in O 
most O 
CKD O 
patients O 
; O 
therefore O 
, O 
the O 
prescription O 
of O 
a O 
phosphate B-SYSTEMATIC 
binder O 
is O 
required O 
. O 
Aluminium B-SYSTEMATIC 
-containing O 
agents O 
are O 
efficient O 
but O 
no O 
longer O 
widely O 
used O 
because O 
of O 
their O 
toxicity O 
. O 
Calcium B-SYSTEMATIC 
-based O 
salts O 
are O 
inexpensive O 
, O 
effective O 
and O 
most O 
widely O 
used O 
, O 
but O 
there O 
is O 
now O 
concern O 
about O 
their O 
association O 
with O 
hypercalcaemia O 
, O 
parathyroid O 
gland O 
suppression O 
, O 
adynamic O 
bone O 
disease O 
, O 
and O 
vascular O 
and O 
extraosseous O 
calcification O 
. O 
The O 
average O 
daily O 
dose O 
of O 
calcium B-MULTIPLE 
acetate I-MULTIPLE 
or I-MULTIPLE 
carbonate I-MULTIPLE 
prescribed O 
in O 
the O 
randomised O 
controlled O 
trials O 
to O 
control O 
hyperphosphataemia O 
in O 
dialysis O 
patients O 
ranges O 
between O 
1.2 O 
and O 
2.3 O 
g O 
of O 
elemental O 
calcium B-SYSTEMATIC 
. O 
Such O 
doses O 
are O 
greater O 
than O 
the O 
recommended O 
dietary O 
calcium B-SYSTEMATIC 
intake O 
and O 
can O 
lead O 
to O 
a O 
positive O 
calcium B-SYSTEMATIC 
balance O 
. O 
Although O 
large O 
amounts O 
of O 
calcium B-SYSTEMATIC 
salts O 
should O 
probably O 
be O 
avoided O 
, O 
modest O 
doses O 
( O 
< O 
1 O 
g O 
of O 
elemental O 
calcium B-SYSTEMATIC 
) O 
may O 
represent O 
a O 
reasonable O 
initial O 
approach O 
to O 
reduced O 
serum O 
phosphorus O 
levels O 
. O 
A O 
non- O 
calcium B-SYSTEMATIC 
-based O 
binder O 
can O 
then O 
be O 
added O 
when O 
large O 
doses O 
of O 
binder O 
are O 
required O 
. O 
At O 
present O 
, O 
there O 
are O 
three O 
types O 
of O 
non- O 
calcium B-SYSTEMATIC 
-based O 
phosphate O 
binders O 
available O 
: O 
sevelamer B-FAMILY 
, O 
lanthanum B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
and O 
magnesium B-SYSTEMATIC 
salts O 
. O 
Each O 
of O 
these O 
compounds O 
is O 
as O 
effective O 
as O 
calcium B-SYSTEMATIC 
salts O 
in O 
lowering O 
serum O 
phosphorus B-SYSTEMATIC 
levels O 
depending O 
on O 
an O 
adequate O 
prescribed O 
dose O 
and O 
adherence O 
of O 
the O 
patient O 
to O 
treatment O 
. O 
Sevelamer B-FAMILY 
is O 
the O 
only O 
non- O 
calcium B-SYSTEMATIC 
-containing O 
phosphate B-SYSTEMATIC 
binder O 
that O 
does O 
not O 
have O 
potential O 
for O 
systemic O 
accumulation O 
and O 
presents O 
pleiotropic O 
effects O 
that O 
may O 
impact O 
on O 
cardiovascular O 
disease O 
. O 
In O 
contrast O 
, O 
lanthanum B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
and O 
magnesium B-SYSTEMATIC 
salts O 
are O 
absorbed O 
in O 
the O 
gut O 
and O 
their O 
route O 
of O 
excretion O 
is O 
biliary O 
for O 
lanthanum B-SYSTEMATIC 
and O 
urinary O 
for O 
magnesium B-SYSTEMATIC 
. O 
There O 
are O 
insufficient O 
data O 
to O 
establish O 
the O 
comparative O 
superiority O 
of O 
non- O 
calcium B-SYSTEMATIC 
binding O 
agents O 
over O 
calcium B-SYSTEMATIC 
salts O 
for O 
such O 
important O 
patient-level O 
outcomes O 
as O 
all O 
- O 
cause O 
mortality O 
and O 
cardiovascular O 
end O 
points O 
. O 
Moreover O 
, O 
full O 
adoption O 
of O 
sevelamer B-FAMILY 
and O 
lanthanum B-SYSTEMATIC 
by O 
government O 
drug O 
reimbursement O 
agencies O 
in O 
place O 
of O 
calcium B-SYSTEMATIC 
salts O 
would O 
lead O 
to O 
a O 
large O 
increase O 
in O 
health O 
- O 
care O 
expenditure O 
. O 
Therefore O 
, O 
the O 
choice O 
of O 
phosphate B-SYSTEMATIC 
binder O 
should O 
be O 
individualised O 
, O 
considering O 
the O 
clinical O 
context O 
, O 
the O 
costs O 
, O 
and O 
the O 
individual O 
tolerability O 
the O 
concomitant O 
effects O 
on O 
other O 
parameters O 
of O 
mineral O 
metabolism O 
, O 
such O 
as O 
serum O 
calcium B-SYSTEMATIC 
and O 
parathyroid O 
hormone O 
, O 
besides O 
those O 
on O 
serum O 
phosphorus B-SYSTEMATIC 
. O 

water O 
molecules O 
play O 
an O 
important O 
role O 
in O 
many O 
aspects O 
of O 
protein-DNA O 
specificity O 
and O 
recognition O 
. O 
Yet O 
they O 
have O 
been O 
mostly O 
neglected O 
in O 
the O 
computational O 
modeling O 
of O 
these O 
complexes O 
. O 
We O 
present O 
here O 
a O 
solvated O 
docking O 
protocol O 
that O 
allows O 
explicit O 
inclusion O 
of O 
water O 
molecules O 
in O 
the O 
docking O 
of O 
protein-DNA O 
complexes O 
and O 
demonstrate O 
its O 
feasibility O 
on O 
a O 
benchmark O 
of O 
30 O 
high O 
- O 
resolution O 
protein-DNA O 
complexes O 
containing O 
crystallographically O 
- O 
determined O 
water O 
molecules O 
at O 
their O 
interfaces O 
. O 
Our O 
protocol O 
is O 
capable O 
of O 
reproducing O 
the O 
solvation O 
pattern O 
at O 
the O 
interface O 
and O 
recovers O 
hydrogen B-SYSTEMATIC 
-bonded O 
water O 
- O 
mediated O 
contacts O 
in O 
many O 
of O 
the O 
benchmark O 
cases O 
. O 
Solvated O 
docking O 
leads O 
to O 
an O 
overall O 
improvement O 
in O 
the O 
quality O 
of O 
the O 
generated O 
protein-DNA O 
models O 
for O 
cases O 
with O 
limited O 
conformational O 
change O 
of O 
the O 
partners O 
upon O 
complex O 
formation O 
. O 
The O 
applicability O 
of O 
this O 
approach O 
is O 
demonstrated O 
on O 
real O 
cases O 
by O 
docking O 
a O 
representative O 
set O 
of O 
6 O 
complexes O 
using O 
unbound O 
protein O 
coordinates O 
, O 
model O 
- O 
built O 
DNA O 
and O 
knowledge O 
- O 
based O 
restraints O 
. O 
As O 
HADDOCK O 
supports O 
the O 
inclusion O 
of O 
a O 
variety O 
of O 
NMR O 
restraints O 
, O 
solvated O 
docking O 
is O 
also O 
applicable O 
for O 
NMR O 
- O 
based O 
structure O 
calculations O 
of O 
protein-DNA O 
complexes O 
. O 

: O 
Major O 
orthopedic O 
surgery O 
is O 
associated O 
with O 
a O 
high O 
risk O 
of O 
venous O 
thromboembolism O 
( O 
VTE O 
) O 
. O 
Anticoagulants O 
are O 
recommended O 
to O 
prevent O 
VTE O 
, O 
and O 
recently O 
an O 
oral O 
direct O 
factor O 
Xa O 
inhibitor O 
( O 
FXaI O 
) O 
was O 
approved O 
for O 
this O 
indication O 
. O 
We O 
compared O 
the O 
cost O 
- O 
effectiveness O 
of O 
FXaIs O 
with O 
low O 
- O 
molecular O 
- O 
weight O 
heparin O 
( O 
LMWH O 
) O 
in O 
patients O 
undergoing O 
total O 
hip O 
replacement O 
( O 
THR O 
) O 
or O 
total O 
knee O 
replacement O 
( O 
TKR O 
) O 
surgery O 
. O 
DESIGN O 
: O 
A O 
decision O 
- O 
tree O 
model O 
was O 
developed O 
to O 
compare O 
the O 
cost O 
- O 
effectiveness O 
of O 
oral O 
direct O 
FXaIs O 
( O 
rivaroxaban B-TRIVIAL 
, O 
apixaban B-TRIVIAL 
, O 
and O 
edoxaban B-TRIVIAL 
) O 
to O 
subcutaneous O 
LMWHs O 
( O 
enoxaparin O 
and O 
dalteparin O 
) O 
, O 
with O 
separate O 
models O 
for O 
THR O 
and O 
TKR O 
. O 
The O 
analysis O 
was O 
conducted O 
over O 
a O 
180-day O 
postoperative O 
time O 
horizon O 
from O 
the O 
U.S O 
. O 
Medicare O 
perspective O 
. O 
The O 
model O 
was O 
developed O 
using O 
TreeAge O 
Pro O 
2011 O 
( O 
TreeAge O 
Software O 
Inc O 
. O 
, O 
Williamstown O 
, O 
MA O 
, O 
USA O 
) O 
. O 
METHODS O 
: O 
Efficacy O 
and O 
safety O 
data O 
( O 
probabilities O 
of O 
distal O 
and O 
proximal O 
deep O 
vein O 
thrombosis O 
, O 
symptomatic O 
pulmonary O 
embolism O 
, O 
and O 
major O 
bleeding O 
) O 
were O 
derived O 
from O 
a O 
systematic O 
review O 
and O 
meta-analysis O 
of O 
phase O 
II O 
and O 
III O 
clinical O 
trials O 
. O 
Costs O 
and O 
quality O 
- O 
adjusted O 
life O 
- O 
years O 
( O 
QALYs O 
) O 
are O 
reported O 
. O 
One O 
- O 
way O 
and O 
probabilistic O 
sensitivity O 
analyses O 
were O 
performed O 
to O 
evaluate O 
parameter O 
uncertainty O 
. O 
RESULTS O 
: O 
In O 
the O 
THR O 
model O 
, O 
the O 
average O 
costs O 
per O 
patient O 
for O 
FXaIs O 
and O 
LMWHs O 
were O 
$18,762 O 
and O 
$18,897, O 
respectively O 
, O 
and O 
the O 
QALYs O 
were O 
0.938 O 
and O 
0.932 O 
. O 
In O 
the O 
TKR O 
model O 
, O 
the O 
average O 
cost O 
per O 
patient O 
for O 
FXaIs O 
and O 
LMWHs O 
were O 
$18,804 O 
and O 
$18,991, O 
respectively O 
, O 
and O 
the O 
QALYs O 
were O 
0.935 O 
and O 
0.931 O 
. O 
In O 
both O 
models O 
, O 
FXaIs O 
dominated O 
LMWH O 
( O 
less O 
costly O 
and O 
more O 
efficacious O 
) O 
. O 
Neither O 
model O 
was O 
sensitive O 
to O 
changes O 
in O 
any O 
of O 
the O 
variables O 
in O 
the O 
one O 
- O 
way O 
sensitivity O 
analyses O 
. O 
Probabilistic O 
sensitivity O 
analysis O 
indicated O 
that O 
FXaIs O 
were O 
cost O 
- O 
effective O 
in O 
more O 
than O 
99% O 
of O 
iterations O 
in O 
the O 
THR O 
population O 
and O 
in O 
98% O 
of O 
iterations O 
in O 
the O 
TKR O 
population O 
assuming O 
a O 
willingness O 
- O 
to O 
- O 
pay O 
threshold O 
of O 
$50,000/QALY. O 
CONCLUSION O 
: O 
Oral O 
direct O 
FXaIs O 
may O 
be O 
an O 
economically O 
dominant O 
strategy O 
compared O 
with O 
LMWHs O 
for O 
VTE O 
prophylaxis O 
in O 
patients O 
undergoing O 
either O 
THR O 
or O 
TKR O 
surgery O 
. O 

Aspects O 
of O 
hSOD1 O 
Maturation O 
from O 
the O 
Solution O 
Structure O 
of O 
Cu B-FORMULA 
(I) I-FORMULA 
-Loaded O 
hCCS O 
Domain O 
1 O 
and O 
Analysis O 
of O 
Disulfide B-SYSTEMATIC 
-Free O 
hSOD1 O 
Mutants O 
. O 

dismutase O 
1 O 
( O 
SOD1 O 
) O 
maturation O 
within O 
the O 
cell O 
is O 
mainly O 
accomplished O 
with O 
the O 
SOD1-specific O 
chaperone O 
, O 
CCS O 
, O 
a O 
dimeric O 
protein O 
with O 
three O 
distinct O 
domains O 
in O 
each O 
monomer O 
. O 
We O 
recently O 
showed O 
that O 
the O 
first O 
domain O 
of O 
human O 
CCS O 
( O 
hCCSD1 O 
) O 
is O 
responsible O 
for O 
copper B-SYSTEMATIC 
transfer O 
to O 
its O 
protein O 
partner O 
, O 
human O 
SOD1 O 
( O 
hSOD1 O 
) O 
. O 
The O 
NMR O 
solution O 
structure O 
of O 
the O 
copper B-SYSTEMATIC 
(I) I-SYSTEMATIC 
-loaded O 
form O 
of O 
hCCSD1 O 
reported O 
here O 
contributes O 
further O 
to O 
characterization O 
of O 
the O 
copper O 
- O 
transfer O 
mechanism O 
to O 
hSOD1 O 
. O 
NMR O 
spectroscopy O 
was O 
also O 
used O 
to O 
examine O 
the O 
hSOD1 O 
mutants O 
C57A O 
, O 
C146A O 
, O 
and O 
C57A O 
/ O 
C146A O 
, O 
which O 
are O 
unable O 
to O 
form O 
the O 
structurally O 
conserved O 
disulfide B-SYSTEMATIC 
bond O 
in O 
SOD1 O 
, O 
in O 
order O 
to O 
investigate O 
the O 
role O 
of O 
these O 
cysteines B-FAMILY 
during O 
hSOD1 O 
copper O 
acquisition O 
. O 
Together O 
, O 
the O 
information O 
on O 
both O 
hCCS O 
and O 
hSOD1 O 
, O 
along O 
with O 
a O 
sequence O 
analysis O 
of O 
eukaryotic O 
CCSD1 O 
, O 
allows O 
us O 
to O 
propose O 
important O 
mechanistic O 
aspects O 
regarding O 
the O 
copper B-SYSTEMATIC 
-transfer O 
process O 
from O 
hCCS O 
to O 
hSOD1 O 
. O 

and O 
diltiazem B-TRIVIAL 
ameliorate O 
ziprasidone B-TRIVIAL 
-induced O 
prolonged O 
corrected O 
QT O 
interval O 
in O 
rats O 
. O 

, O 
an O 
atypical O 
antipsychotic O 
agent O 
, O 
has O 
been O 
shown O 
to O 
increase O 
the O 
corrected O 
QT O 
( O 
QTc O 
) O 
interval O 
in O 
some O 
patients O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
reveal O 
the O 
effects O 
of O 
metoprolol B-TRIVIAL 
and O 
diltiazem B-TRIVIAL 
on O 
ziprasidone B-TRIVIAL 
drug O 
- O 
induced O 
prolonged O 
QTc O 
interval O 
. O 
A O 
total O 
of O 
24 O 
rats O 
were O 
equally O 
divided O 
into O 
the O 
following O 
four O 
groups O 
: O 
the O 
first O 
group O 
was O 
used O 
as O 
the O 
control O 
and O 
received O 
1 O 
mL O 
/ O 
kg O 
saline O 
; O 
3 O 
mg O 
/ O 
kg O 
ziprasidone B-TRIVIAL 
and O 
saline O 
were O 
administered O 
to O 
the O 
second O 
group O 
; O 
3 O 
mg O 
/ O 
kg O 
ziprasidone B-TRIVIAL 
and O 
1 O 
mg O 
/ O 
kg O 
metoprolol B-TRIVIAL 
were O 
administered O 
to O 
the O 
third O 
group O 
and O 
3 O 
mg O 
/ O 
kg O 
ziprasidone B-TRIVIAL 
and O 
2 O 
mg O 
/ O 
kg O 
diltiazem B-TRIVIAL 
were O 
administered O 
to O 
the O 
fourth O 
group O 
. O 
Two O 
hours O 
following O 
application O 
of O 
the O 
drugs O 
, O 
the O 
QTc O 
was O 
calculated O 
by O 
performing O 
electrocardiography O 
in O 
derivation O 
(D)I O 
. O 
The O 
duration O 
of O 
QTc O 
interval O 
was O 
compared O 
among O 
the O 
four O 
groups O 
. O 
The O 
mean O 
QTc O 
intervals O 
were O 
significantly O 
increased O 
in O 
the O 
third O 
and O 
fourth O 
groups O 
compared O 
with O 
the O 
second O 
group O 
( O 
p O 
< O 
0.0005 O 
and O 
p O 
< O 
0.0001 O 
, O 
respectively O 
) O 
. O 
The O 
study O 
demonstrated O 
the O 
effectiveness O 
of O 
metoprolol B-TRIVIAL 
and O 
diltiazem B-TRIVIAL 
in O 
the O 
prevention O 
of O 
ziprasidone B-TRIVIAL 
-induced O 
elongation O 
in O 
the O 
QTc O 
interval O 
. O 
Both O 
metoprolol B-TRIVIAL 
and O 
diltiazem B-TRIVIAL 
may O 
be O 
considered O 
in O 
the O 
prophylactic O 
therapy O 
of O 
high O 
- O 
risk O 
patients O 
who O 
are O 
using O 
ziprasidone B-TRIVIAL 
. O 

- O 
operated O 
Ca2+ B-FORMULA 
Entry O 
( O 
SOCE O 
) O 
Induced O 
by O 
Protease O 
- O 
activated O 
Receptor-1 O 
mediates O 
STIM1 O 
Phosphorylation O 
to O 
inhibit O 
SOCE O 
in O 
Endothelial O 
Cells O 
through O 
AMP B-ABBREVIATION 
-activated O 
Protein O 
Kinase O 
and O 
p38beta O 
Mitogen O 
- O 
activated O 
Protein O 
Kinase O 
. O 

Ca2+ B-FORMULA 
sensor O 
STIM1 O 
is O 
crucial O 
for O 
activation O 
of O 
store O 
- O 
operated O 
Ca2+ B-FORMULA 
entry O 
( O 
SOCE O 
) O 
through O 
TRPC O 
and O 
Orai O 
channels O 
. O 
STIM1 O 
phosphorylation O 
serves O 
as O 
an O 
off O 
- O 
switch O 
for O 
SOCE O 
. O 
However O 
, O 
the O 
signaling O 
pathway O 
for O 
STIM1 O 
phosphorylation O 
is O 
unknown O 
. O 
Here O 
we O 
show O 
that O 
SOCE O 
activates O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
; O 
its O 
effector O 
p38β O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
p38β O 
MAPK O 
) O 
phosphorylates O 
STIM1 O 
, O 
thus O 
inhibiting O 
SOCE O 
in O 
human O 
lung O 
microvascular O 
endothelial O 
cells O 
( O 
ECs O 
) O 
. O 
Activation O 
of O 
AMPK O 
using O 
AICAR B-ABBREVIATION 
resulted O 
in O 
STIM1 O 
phosphorylation O 
on O 
serine B-TRIVIAL 
residues O 
and O 
prevented O 
PAR-1-induced O 
Ca2+ B-FORMULA 
entry O 
. O 
Further O 
, O 
AICAR B-ABBREVIATION 
pretreatment O 
blocked O 
PAR-1-induced O 
increase O 
in O 
permeability O 
of O 
mouse O 
- O 
lung O 
microvessels O 
. O 
Activation O 
of O 
SOCE O 
with O 
thrombin O 
caused O 
phosphorylation O 
of O 
isoform O 
α1 O 
, O 
but O 
not O 
α2 O 
of O 
the O 
AMPK O 
catalytic O 
subunit O 
. O 
Moreover O 
, O 
knockdown O 
of O 
AMPKα1 O 
augmented O 
SOCE O 
induced O 
by O 
thrombin O 
. O 
Interestingly O 
, O 
SB203580 B-IDENTIFIER 
, O 
a O 
selective O 
inhibitor O 
of O 
p38 O 
MAPK O 
, O 
blocked O 
STIM1 O 
phosphorylation O 
and O 
led O 
to O 
sustained O 
STIM1-puncta O 
formation O 
and O 
Ca2+ B-FORMULA 
entry O 
. O 
Of O 
the O 
three O 
p38 O 
MAPK O 
isoforms O 
expressed O 
in O 
ECs O 
, O 
p38β O 
knockdown O 
prevented O 
PAR-1 O 
- O 
mediated O 
STIM1 O 
phosphorylation O 
and O 
potentiated O 
SOCE O 
. O 
In O 
addition O 
, O 
inhibition O 
of O 
the O 
SOCE O 
downstream O 
target O 
CaMKKβ O 
or O 
knockdown O 
of O 
AMPKα1 O 
suppressed O 
PAR-1 O 
- O 
mediated O 
phosphorylation O 
of O 
p38β O 
and O 
hence O 
STIM1 O 
. O 
Thus O 
, O 
our O 
findings O 
demonstrate O 
that O 
SOCE O 
activates O 
CaMKKβ-AMPKα1-p38β O 
MAPK O 
signaling O 
to O 
phosphorylate O 
STIM1 O 
, O 
thereby O 
suppressing O 
endothelial O 
SOCE O 
and O 
permeability O 
responses O 
. O 

pentablock O 
copolymer O 
( O 
PLA B-ABBREVIATION 
- O 
PCL B-ABBREVIATION 
- O 
PEG B-ABBREVIATION 
- O 
PCL B-ABBREVIATION 
- O 
PLA B-ABBREVIATION 
) O 
based O 
nanoparticles O 
for O 
controlled O 
drug O 
delivery O 
: O 
Effect O 
of O 
copolymer O 
compositions O 
on O 
the O 
crystallinity O 
of O 
copolymers O 
and O 
in O 
vitro O 
drug O 
release O 
profile O 
from O 
nanoparticles O 
. O 

purpose O 
of O 
this O 
investigation O 
was O 
to O 
design O 
novel O 
pentablock O 
copolymers O 
( O 
polylatide B-FAMILY 
- O 
polycaprolactone B-SYSTEMATIC 
- O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
- O 
polycaprolactone B-SYSTEMATIC 
- O 
polylatide B-FAMILY 
) O 
( O 
PLA B-ABBREVIATION 
- O 
PCL B-ABBREVIATION 
- O 
PEG B-ABBREVIATION 
- O 
PCL B-ABBREVIATION 
- O 
PLA B-ABBREVIATION 
) O 
to O 
prepare O 
nanoparticle O 
formulations O 
which O 
provide O 
continuous O 
delivery O 
of O 
steroids B-FAMILY 
over O 
a O 
longer O 
duration O 
with O 
minimal O 
burst O 
effect O 
. O 
Another O 
purpose O 
was O 
to O 
evaluate O 
the O 
effect O 
of O 
poly B-FAMILY 
( I-FAMILY 
L-lactide I-FAMILY 
) I-FAMILY 
( O 
PLLA B-ABBREVIATION 
) O 
or O 
poly B-FAMILY 
( I-FAMILY 
D I-FAMILY 
, I-FAMILY 
L-lactide I-FAMILY 
) I-FAMILY 
( O 
PDLLA B-ABBREVIATION 
) O 
incorporation O 
on O 
crystallinity O 
of O 
pentablock O 
copolymers O 
and O 
in O 
vitro O 
release O 
profile O 
of O 
triamcinolone B-TRIVIAL 
acetonide I-TRIVIAL 
( O 
selected O 
as O 
model O 
drug O 
) O 
from O 
nanoparticles O 
. O 
PLA B-ABBREVIATION 
- O 
PCL B-ABBREVIATION 
- O 
PEG B-ABBREVIATION 
- O 
PCL B-ABBREVIATION 
- O 
PLA B-ABBREVIATION 
copolymers O 
with O 
different O 
block O 
ratio O 
of O 
PCL B-ABBREVIATION 
/ O 
PLA B-ABBREVIATION 
segment O 
were O 
synthesized O 
. O 
Release O 
of O 
triamcinolone B-TRIVIAL 
acetonide I-TRIVIAL 
from O 
nanoparticles O 
was O 
significantly O 
affected O 
by O 
crystallinity O 
of O 
the O 
copolymers O 
. O 
Burst O 
release O 
of O 
triamcinolone B-TRIVIAL 
acetonide I-TRIVIAL 
from O 
nanoparticles O 
was O 
significantly O 
minimized O 
with O 
incorporation O 
of O 
proper O 
ratio O 
of O 
PDLLA B-ABBREVIATION 
in O 
the O 
existing O 
triblock O 
( O 
PCL B-ABBREVIATION 
- O 
PEG B-ABBREVIATION 
- O 
PCL B-ABBREVIATION 
) O 
copolymer O 
. O 
Moreover O 
, O 
pentablock O 
copolymer O 
based O 
nanoparticles O 
exhibited O 
continuous O 
release O 
of O 
triamcinolone B-TRIVIAL 
acetonide I-TRIVIAL 
. O 
Pentablock O 
copolymer O 
based O 
nanoparticles O 
can O 
be O 
utilized O 
to O 
achieve O 
continuous O 
near O 
zero O 
- O 
order O 
delivery O 
of O 
corticosteroids O 
from O 
nanoparticles O 
without O 
any O 
burst O 
effect O 
. O 

and O 
Structure O 
Activity O 
Relationship O 
of O 
Tetrahydroisoquinoline B-SYSTEMATIC 
-based O 
Potentiators O 
of O 
GluN2C O 
and O 
GluN2D O 
Containing O 
N-Methyl-D-Aspartate B-SYSTEMATIC 
Receptors O 
. O 

describe O 
here O 
the O 
synthesis O 
and O 
evaluation O 
of O 
a O 
series O 
of O 
tetrahydroisoquinolines B-FAMILY 
that O 
show O 
subunit O 
- O 
selective O 
potentiation O 
of O 
NMDA B-ABBREVIATION 
receptors O 
containing O 
the O 
GluN2C O 
or O 
GluN2D O 
subunits O 
. O 
Bischler-Napieralski O 
conditions O 
were O 
employed O 
in O 
the O 
key O 
step O 
for O 
the O 
conversion O 
of O 
acyclic B-FAMILY 
amides I-FAMILY 
to O 
the O 
corresponding O 
tetrahydroisoquinoline B-SYSTEMATIC 
containing O 
analogs O 
. O 
Compounds O 
were O 
evaluated O 
using O 
both O 
two O 
electrode O 
voltage O 
clamp O 
recordings O 
from O 
Xenopus O 
laevis O 
oocytes O 
and O 
imaging O 
of O 
mammalian O 
BHK O 
cells O 
loaded O 
with O 
Ca(2+) B-FORMULA 
-sensitive O 
dyes O 
. O 
The O 
most O 
potent O 
analogues O 
had O 
EC50 O 
values O 
of O 
300 O 
nM O 
and O 
showed O 
over O 
2-fold O 
potentiation O 
of O 
the O 
response O 
to O 
maximally O 
effective O 
concentrations O 
of O 
glutamate B-TRIVIAL 
and O 
glycine B-TRIVIAL 
, O 
but O 
had O 
no O 
effect O 
on O 
responses O 
from O 
NMDA B-ABBREVIATION 
receptors O 
containing O 
the O 
GluN2A O 
or O 
GluN2B O 
subunits O 
, O 
AMPA B-ABBREVIATION 
, O 
kainate B-TRIVIAL 
, O 
GABA B-ABBREVIATION 
, O 
or O 
glycine B-TRIVIAL 
receptors O 
or O 
a O 
variety O 
of O 
other O 
potential O 
targets O 
. O 
These O 
compounds O 
represent O 
a O 
potent O 
class O 
of O 
small O 
molecule O 
subunit O 
- O 
selective O 
potentiators O 
of O 
NMDA B-ABBREVIATION 
receptors O 
. O 

, O 
synthesis O 
and O 
molecular O 
modeling O 
of O 
novel O 
pyrido[2,3-d]pyrimidine B-SYSTEMATIC 
analogs O 
as O 
antifolates O 
: O 
Application O 
of O 
Buchwald-Hartwig O 
aminations O 
of O 
heterocycles O 
. O 

infections O 
caused O 
by O 
Pneumocystis O 
jirovecii O 
( O 
P O 
. O 
jirovecii O 
, O 
pj O 
) O 
, O 
Toxoplasma O 
gondii O 
( O 
T O 
. O 
gondii O 
, O 
tg O 
) O 
and O 
Mycobacterium O 
avium O 
( O 
M O 
. O 
avium O 
, O 
ma O 
) O 
are O 
the O 
principal O 
causes O 
of O 
morbidity O 
and O 
mortality O 
in O 
patients O 
with O 
acquired O 
immunodeficiency O 
syndrome O 
( O 
AIDS O 
) O 
. O 
The O 
absence O 
of O 
any O 
animal O 
models O 
for O 
human O 
Pneumocystis O 
jirovecii O 
pneumonia O 
and O 
the O 
lack O 
of O 
crystal O 
structures O 
of O 
pjDHFR O 
and O 
tgDHFR O 
make O 
the O 
design O 
of O 
inhibitors O 
challenging O 
. O 
A O 
novel O 
series O 
of O 
pyrido[2,3-d]pyrimidines B-FAMILY 
as O 
selective O 
and O 
potent O 
DHFR O 
inhibitors O 
against O 
these O 
opportunistic O 
infections O 
are O 
presented O 
. O 
Buchwald-Hartwig O 
coupling O 
reaction O 
of O 
substituted O 
anilines O 
with O 
pivaloyl B-SYSTEMATIC 
protected O 
2,4-diamino-6-bromo-pyrido[2,3-d]pyrimidine B-SYSTEMATIC 
was O 
successfully O 
explored O 
to O 
synthesize O 
these O 
analogs O 
. O 
Compound O 
26 O 
was O 
the O 
most O 
selective O 
inhibitor O 
with O 
excellent O 
potency O 
against O 
pjDHFR O 
. O 
Molecular O 
modeling O 
studies O 
with O 
a O 
pjDHFR O 
homology O 
model O 
explained O 
the O 
potency O 
and O 
selectivity O 
of O 
26 O 
. O 
Structural O 
data O 
are O 
also O 
reported O 
for O 
26 O 
with O 
pcDHFR O 
and O 
16 O 
and O 
22 O 
with O 
variants O 
of O 
pcDHFR O 
. O 

present O 
CCSD(T) O 
interaction O 
energies O 
and O 
the O 
bonding O 
analysis O 
for O 
complexes O 
of O 
Cu B-FORMULA 
, O 
Ag B-FORMULA 
, O 
and O 
Au B-FORMULA 
with O 
the O 
lone O 
- O 
pair O 
ligands O 
, O 
H2O B-FORMULA 
, O 
OF2 B-FORMULA 
, O 
OMe2 B-FORMULA 
, O 
NH3 B-FORMULA 
, O 
NF3 B-FORMULA 
, O 
NMe3 B-FORMULA 
, O 
H2S B-FORMULA 
, O 
SF2 B-FORMULA 
, O 
SMe2 B-FORMULA 
, O 
PH3 B-FORMULA 
, O 
PF3 B-FORMULA 
, O 
PCl3 B-FORMULA 
, O 
PMe3 B-FORMULA 
( O 
ML O 
complexes O 
) O 
. O 
Both O 
, O 
electron O 
correlation O 
and O 
relativistic O 
effects O 
, O 
are O 
crucial O 
in O 
the O 
bonding O 
of O 
all O 
complexes O 
. O 
AuPH3 B-FORMULA 
, O 
AuPF3 B-FORMULA 
and O 
AuPCl3 B-FORMULA 
( O 
MPX3 O 
) O 
complexes O 
exhibit O 
particularly O 
large O 
relativistic O 
effects O 
, O 
30 O 
- O 
46 O 
kJ O 
/ O 
mol O 
. O 
Upon O 
neglecting O 
relativistic O 
effects O 
the O 
Au B-FORMULA 
- O 
P B-FORMULA 
bonds O 
almost O 
vanish O 
aside O 
from O 
weak O 
long O 
- O 
range O 
van O 
der O 
Waals O 
interactions O 
. O 
Highest O 
binding O 
energies O 
are O 
computed O 
for O 
complexes O 
with O 
Au B-FORMULA 
, O 
followed O 
by O 
Cu B-FORMULA 
and O 
Ag B-FORMULA 
. O 
For O 
all O 
coinage O 
metals O 
the O 
strongest O 
interactions O 
are O 
computed O 
for O 
PX3 B-FAMILY 
ligands O 
followed O 
by O 
SX2 B-FAMILY 
and O 
NX3 B-FAMILY 
OX2 B-FAMILY 
ligands O 
. O 
Upon O 
methylation O 
the O 
interaction O 
energy O 
rises O 
significantly O 
. O 
Metal B-FAMILY 
- I-FAMILY 
thiol I-FAMILY 
complexes O 
, O 
particularly O 
AuSCH3 B-FORMULA 
, O 
form O 
a O 
separate O 
class O 
. O 
Exceptional O 
stability O 
of O 
gold O 
complexes O 
is O 
due O 
to O 
large O 
relativistic O 
enhancement O 
of O 
the O 
electron O 
affinity O 
of O 
Au B-FORMULA 
. O 
Along O 
with O 
the O 
electron O 
affinity O 
of O 
a O 
metal O 
we O 
link O 
the O 
pattern O 
of O 
interaction O 
energies O 
in O 
ML O 
complexes O 
with O 
ionization O 
potentials O 
( O 
IPs O 
) O 
of O 
ligands O 
. O 
Strong O 
interaction O 
with O 
P B-FORMULA 
containing O 
ligands O 
is O 
attributed O 
to O 
their O 
lower O 
IP O 
and O 
the O 
lone O 
pair O 
→ O 
metal O 
electron O 
donation O 
accompanied O 
with O 
the O 
back O 
- O 
donation O 
characteristic O 
for O 
P B-FORMULA 
containing O 
ligand O 
. O 
Energy O 
data O 
are O 
accompanied O 
with O 
the O 
Natural O 
Bond O 
Orbital O 
( O 
NBO O 
) O 
analysis O 
. O 
Computationally O 
less O 
demanding O 
DFT O 
computations O 
with O 
the O 
PBE0 O 
functional O 
provide O 
correct O 
pattern O 
of O 
interaction O 
energies O 
when O 
compared O 
with O 
benchmark O 
CCSD(T) O 
results O 
. O 

the O 
monolayer O 
limit O 
, O 
transition B-FAMILY 
metal I-FAMILY 
dichalcogenides I-FAMILY 
become O 
direct O 
- O 
bandgap O 
, O 
light O 
- O 
emitting O 
semiconductors O 
. O 
The O 
quantum O 
yield O 
of O 
light O 
emission O 
is O 
low O 
and O 
extremely O 
sensitive O 
to O 
the O 
substrate O 
used O 
, O 
while O 
the O 
underlying O 
physics O 
remains O 
elusive O 
. O 
In O 
this O 
work O 
, O 
we O 
report O 
over O 
100 O 
times O 
modulation O 
of O 
light O 
emission O 
efficiency O 
of O 
these O 
two O 
- O 
dimensional O 
semiconductors O 
by O 
physical O 
adsorption O 
of O 
O2 B-FORMULA 
and O 
/ O 
or O 
H2O B-FORMULA 
molecules O 
, O 
while O 
inert O 
gases O 
do O 
not O 
cause O 
such O 
effect O 
. O 
The O 
O2 B-FORMULA 
and O 
/ O 
or O 
H2O B-FORMULA 
pressure O 
acts O 
quantitatively O 
as O 
an O 
instantaneously O 
reversible O 
" O 
molecular O 
gating O 
" O 
force O 
, O 
providing O 
orders O 
of O 
magnitude O 
broader O 
control O 
of O 
carrier O 
density O 
and O 
light O 
emission O 
than O 
conventional O 
electric O 
field O 
gating O 
. O 
Physi O 
- O 
sorbed O 
O2 B-FORMULA 
and O 
/ O 
or O 
H2O B-FORMULA 
molecules O 
electronically O 
deplete O 
n O 
- O 
type O 
materials O 
such O 
as O 
MoS2 B-FORMULA 
and O 
MoSe2 B-FORMULA 
, O 
which O 
weakens O 
electrostatic O 
screening O 
that O 
would O 
otherwise O 
destabilize O 
excitons O 
, O 
leading O 
to O 
the O 
drastic O 
enhancement O 
in O 
photoluminescence O 
. O 
In O 
p- O 
type O 
materials O 
such O 
as O 
WSe2 B-FORMULA 
, O 
the O 
molecular O 
physisorption O 
results O 
in O 
the O 
opposite O 
effect O 
. O 
Unique O 
and O 
universal O 
in O 
two O 
- O 
dimensional O 
semiconductors O 
, O 
the O 
effect O 
offers O 
a O 
new O 
mechanism O 
for O 
modulating O 
electronic O 
interactions O 
and O 
implementing O 
optical O 
devices O 
. O 

- O 
assembled O 
vertical O 
epitaxial O 
nanostructures O 
form O 
a O 
new O 
class O 
of O 
heterostructured O 
materials O 
that O 
has O 
emerged O 
in O 
recent O 
years O 
. O 
Interestingly O 
, O 
such O 
kind O 
of O 
architectures O 
can O 
be O 
grown O 
using O 
combinatorial O 
processes O 
, O 
implying O 
sequential O 
deposition O 
of O 
distinct O 
materials O 
. O 
Although O 
opening O 
many O 
perspectives O 
, O 
this O 
combinatorial O 
nature O 
has O 
not O 
been O 
fully O 
exploited O 
yet O 
. O 
This O 
work O 
demonstrates O 
that O 
the O 
combinatorial O 
character O 
of O 
the O 
growth O 
can O 
be O 
further O 
exploited O 
in O 
order O 
to O 
obtain O 
alloy O 
nanowires O 
coherently O 
embedded O 
in O 
a O 
matrix O 
. O 
This O 
issue O 
is O 
illustrated O 
in O 
the O 
case O 
of O 
a O 
fully O 
epitaxial O 
system O 
: O 
CoxNi1-x B-FAMILY 
nanowires O 
in O 
CeO2 B-FORMULA 
/ O 
SrTiO3 B-FORMULA 
( O 
1 O 
) O 
. O 
The O 
advantage O 
brought O 
by O 
the O 
ability O 
to O 
grow O 
alloys O 
is O 
illustrated O 
by O 
the O 
control O 
of O 
the O 
magnetic O 
anisotropy O 
of O 
the O 
nanowires O 
when O 
passing O 
from O 
pure O 
Ni B-FORMULA 
wires O 
to O 
CoxNi1-x B-FAMILY 
alloys O 
. O 
Further O 
exploitation O 
of O 
this O 
combinatorial O 
approach O 
may O 
pave O 
the O 
way O 
toward O 
full O 
three O 
- O 
dimensional O 
heteroepitaxial O 
architectures O 
through O 
axial O 
structuring O 
of O 
the O 
wires O 
. O 

antiproliferative O 
factor O 
( O 
APF O 
) O 
involved O 
in O 
interstitial O 
cystitis O 
is O 
a O 
glycosylated O 
nonapeptide B-FAMILY 
( O 
TVPAAVVVA O 
) O 
containing O 
a O 
sialylated O 
core O 
α-O-disaccharide B-FAMILY 
linked O 
to O 
the O 
N B-FORMULA 
-terminal O 
threonine B-TRIVIAL 
. O 
The O 
chemical O 
structure O 
of O 
APF O 
was O 
deduced O 
using O 
spectroscopic O 
techniques O 
and O 
confirmed O 
using O 
total O 
syn- O 
thesis O 
. O 
The O 
synthetic O 
APF O 
provided O 
a O 
platform O 
to O 
study O 
amino B-FAMILY 
acid I-FAMILY 
modifications O 
and O 
their O 
effect O 
on O 
APF O 
activity O 
, O 
based O 
on O 
which O 
a O 
structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
for O 
APF O 
activity O 
was O 
previously O 
proposed O 
. O 
However O 
, O 
this O 
SAR O 
model O 
could O 
not O 
explain O 
the O 
change O 
in O 
activity O 
associated O 
with O 
minor O 
al O 
- O 
terations O 
in O 
the O 
peptide O 
sequence O 
. O 
Presented O 
is O 
computational O 
analysis O 
of O 
14 O 
APF O 
derivatives O 
to O 
identify O 
structural O 
trends O 
from O 
which O 
a O 
more O 
detailed O 
SAR O 
is O 
obtained O 
. O 
The O 
APF O 
activity O 
is O 
found O 
to O 
be O 
dictated O 
by O 
the O 
close O 
interplay O 
between O 
carbohydrate B-FAMILY 
-peptide O 
and O 
peptide O 
- O 
peptide O 
interactions O 
. O 
The O 
former O 
in O 
- O 
volves O 
hydrogen B-SYSTEMATIC 
bond O 
and O 
hydrophobic O 
interactions O 
and O 
the O 
latter O 
is O 
dominated O 
by O 
hydrophobic O 
interac O 
- O 
tions O 
. O 
The O 
highly O 
flexible O 
hydrophobic O 
peptide O 
adopts O 
collapsed O 
conformations O 
separated O 
by O 
low O 
energy O 
barriers O 
. O 
APF O 
activity O 
correlates O 
with O 
hydrophobic O 
clustering O 
associated O 
with O 
amino B-FAMILY 
acids I-FAMILY 
4A O 
, O 
6V O 
and O 
8V O 
. O 
Peptide O 
conformations O 
are O 
highly O 
sensitive O 
to O 
single O 
point O 
mutations O 
, O 
which O 
explain O 
the O 
experi O 
- O 
mental O 
trends O 
. O 
The O 
presented O 
SAR O 
will O 
act O 
as O 
a O 
guide O 
for O 
lead O 
optimization O 
of O 
more O 
potent O 
APF O 
ana O 
- O 
logues O 
of O 
potential O 
therapeutic O 
utility O 
. O 

Layer-Incorporated O 
, O 
Spectrally-Tuned O 
Au B-FORMULA 
/ O 
SiO2 B-FORMULA 
Core O 
/ O 
Shell O 
Nanorod O 
- O 
Based O 
Light O 
Trapping O 
for O 
Organic O 
Photovoltaics O 
. O 

demonstrated O 
that O 
incorporation O 
of O 
octadecyltrimethoxysilane B-SYSTEMATIC 
( O 
OTMS B-ABBREVIATION 
) O 
functionalized O 
, O 
spectrally O 
tuned O 
, O 
gold/ O 
silica B-TRIVIAL 
( O 
Au B-FORMULA 
/ O 
SiO2 B-FORMULA 
) O 
core O 
/ O 
shell O 
nanospheres O 
and O 
nanorods O 
into O 
the O 
active O 
layer O 
of O 
an O 
organic O 
photovoltaic O 
( O 
OPV O 
) O 
device O 
led O 
to O 
an O 
in O 
increase O 
photo O 
conversion O 
efficiency O 
( O 
PCE O 
) O 
. O 
A O 
silica B-TRIVIAL 
shell O 
layer O 
was O 
added O 
onto O 
Au B-FORMULA 
core O 
nanospheres O 
and O 
nanorods O 
in O 
order O 
to O 
provide O 
an O 
electrically O 
insulating O 
surface O 
that O 
does O 
not O 
interfere O 
with O 
carrier O 
generation O 
and O 
transport O 
inside O 
the O 
active O 
layer O 
. O 
Functionalization O 
of O 
the O 
Au B-FORMULA 
/ O 
SiO2 B-FORMULA 
core O 
/ O 
shell O 
nanoparticles O 
with O 
the O 
OTMS B-ABBREVIATION 
organic O 
ligand O 
was O 
then O 
necessary O 
in O 
order O 
to O 
transfer O 
the O 
Au B-FORMULA 
/ O 
SiO2 B-FORMULA 
core O 
/ O 
shell O 
nanoparticles O 
from O 
an O 
ethanol B-SYSTEMATIC 
solution O 
into O 
an O 
OPV O 
polymer O 
- O 
compatible O 
solvent O 
, O 
such O 
as O 
dichlorobenzene B-SYSTEMATIC 
( O 
DCB B-ABBREVIATION 
) O 
. O 
The O 
OTMS B-ABBREVIATION 
-functionalized O 
Au B-FORMULA 
/ O 
SiO2 B-FORMULA 
core O 
/ O 
shell O 
nanorods O 
and O 
nanospheres O 
were O 
then O 
incorporated O 
into O 
the O 
active O 
layers O 
of O 
two O 
OPV O 
polymer O 
systems O 
: O 
a O 
poly(3-hexylthiophene) B-SYSTEMATIC 
: O 
[6,6]-phenyl-C61-butyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
P3HT B-ABBREVIATION 
: O 
PCB60M B-SYSTEMATIC 
) O 
OPV O 
device O 
and O 
a O 
poly[2,6-4,8-di(5-ethylhexylthienyl)benzo[1,2-b;3,4-b]dithiophene-alt-5-dibutyloctyl-3,6-bis(5-bromothiophen-2-yl) B-FAMILY 
pyrrolo[3,4-c]pyrrole-1,4-dione I-FAMILY 
] I-FAMILY 
( O 
PBDTT-DPP B-ABBREVIATION 
: O 
PC60BM B-TRIVIAL 
) O 
OPV O 
device O 
. O 
For O 
the O 
P3HT B-ABBREVIATION 
: O 
PC60BM B-TRIVIAL 
polymer O 
with O 
a O 
band O 
edge O 
of O 
~700 O 
nm O 
, O 
the O 
addition O 
of O 
the O 
core O 
/ O 
shell O 
nanorods O 
with O 
an O 
aspect O 
ratio O 
( O 
AR O 
) O 
of O 
~2.5 O 
( O 
extinction O 
peak O 
~670 O 
nm O 
) O 
resulted O 
in O 
a O 
7.1% O 
improvement O 
in O 
PCE O 
, O 
while O 
for O 
the O 
PBDTT-DPP B-ABBREVIATION 
: O 
PC60BM B-TRIVIAL 
polymer O 
with O 
a O 
band O 
edge O 
~860 O 
nm O 
, O 
the O 
addition O 
of O 
core O 
/ O 
shell O 
nanorods O 
with O 
an O 
AR O 
of O 
~4 O 
( O 
extinction O 
peak O 
~830 O 
nm O 
) O 
resulted O 
in O 
a O 
14.4% O 
improvement O 
in O 
PCE O 
. O 
The O 
addition O 
of O 
Au B-FORMULA 
/ O 
SiO2 B-FORMULA 
core O 
/ O 
shell O 
nanospheres O 
to O 
the O 
P3HT B-ABBREVIATION 
: O 
PC60BM B-TRIVIAL 
-polymer O 
resulted O 
in O 
a O 
2.7% O 
improvement O 
in O 
PCE O 
, O 
while O 
their O 
addition O 
to O 
a O 
PBDTT-DPP B-ABBREVIATION 
: O 
PC60BM B-TRIVIAL 
polymer O 
resulted O 
in O 
a O 
9.1% O 
improvement O 
. O 
The O 
PCE O 
and O 
Jsc O 
enhancements O 
were O 
consistent O 
with O 
external O 
quantum O 
efficiency O 
( O 
EQE O 
) O 
measurements O 
and O 
the O 
EQE O 
enhancements O 
spectrally O 
matched O 
the O 
extinction O 
spectra O 
of O 
Au B-FORMULA 
/ O 
SiO2 B-FORMULA 
nanospheres O 
and O 
nanorods O 
in O 
both O 
OPV O 
polymer O 
systems O 
. O 

between O 
solid O 
surfaces O 
with O 
pre O 
- O 
adsorbed O 
poly(ethylenimine) B-FAMILY 
( O 
PEI B-ABBREVIATION 
) O 
layers O 
: O 
effect O 
of O 
unadsorbed O 
free O 
PEI B-ABBREVIATION 
chains O 
. O 

( O 
PEI B-ABBREVIATION 
) O 
polyelectrolytes O 
have O 
been O 
widely O 
used O 
to O 
tune O 
the O 
stability O 
, O 
rheology O 
, O 
or O 
adhesion O 
properties O 
of O 
colloidal O 
suspensions O 
due O 
to O 
their O 
strong O 
tendency O 
to O 
adsorb O 
to O 
solid O 
surfaces O 
. O 
They O 
have O 
also O 
gained O 
importance O 
as O 
gene O 
carriers O 
in O 
biomedical O 
applications O 
, O 
in O 
which O 
the O 
anionic O 
DNA O 
chains O 
are O 
complexed O 
and O 
condensed O 
to O 
form O 
PEI B-ABBREVIATION 
/ O 
DNA O 
polyplexes O 
. O 
Some O 
reported O 
literatures O 
have O 
recently O 
shown O 
that O 
the O 
overdosed O 
PEI B-ABBREVIATION 
chains O 
, O 
which O 
are O 
free O 
in O 
the O 
solution O 
mixture O 
, O 
also O 
play O 
a O 
vital O 
role O 
in O 
promoting O 
the O 
gene O 
transfection O 
, O 
but O 
the O 
reason O 
is O 
unclear O 
. O 
In O 
this O 
work O 
, O 
we O 
present O 
the O 
results O 
of O 
using O 
total O 
internal O 
reflection O 
microscopy O 
( O 
TIRM O 
) O 
to O 
measure O 
the O 
interaction O 
forces O 
between O 
a O 
Brownian O 
colloidal O 
sphere O 
and O 
a O 
flat O 
glass O 
plate O 
in O 
the O 
presence O 
of O 
overdosed O 
free O 
PEI B-ABBREVIATION 
cationic O 
chains O 
, O 
when O 
both O 
surfaces O 
were O 
saturated O 
adsorbed O 
with O 
the O 
PEI B-ABBREVIATION 
chains O 
. O 
The O 
colloidal O 
sphere O 
pre O 
- O 
adsorbed O 
with O 
PEI B-ABBREVIATION 
chains O 
was O 
chosen O 
to O 
mimic O 
the O 
PEI B-ABBREVIATION 
/ O 
DNA O 
polyplex O 
. O 
Results O 
for O 
the O 
potential O 
energy O 
of O 
interaction O 
measured O 
for O 
model O 
polyplex O 
( O 
e.g O 
. O 
, O 
PEI B-ABBREVIATION 
-coated O 
sphere O 
) O 
interacting O 
with O 
a O 
PEI B-ABBREVIATION 
-coated O 
glass O 
surface O 
in O 
the O 
presence O 
of O 
overdosed O 
free O 
PEI B-ABBREVIATION 
chains O 
at O 
various O 
pH O 
values O 
and O 
salt O 
concentrations O 
were O 
presented O 
. O 
As O 
can O 
be O 
shown O 
by O 
direct O 
force O 
measurements O 
, O 
the O 
interaction O 
potentials O 
in O 
NaCl B-FORMULA 
salt O 
solution O 
are O 
dominated O 
by O 
repulsive O 
forces O 
originating O 
from O 
diffuse O 
layer O 
overlap O 
and O 
gravitational O 
attraction O 
. O 
However O 
, O 
the O 
presence O 
of O 
free O 
PEI B-ABBREVIATION 
chains O 
in O 
the O 
solution O 
mixture O 
produces O 
a O 
long O 
- O 
ranged O 
( O 
> O 
60 O 
nm O 
) O 
attractive O 
force O 
between O 
two O 
PEI B-ABBREVIATION 
-coated O 
surfaces O 
with O 
the O 
range O 
and O 
magnitude O 
tunable O 
by O 
pH O 
value O 
, O 
PEI B-ABBREVIATION 
and O 
salt O 
concentrations O 
. O 
The O 
possible O 
mechanisms O 
of O 
this O 
long O 
- O 
ranged O 
attractive O 
force O 
are O 
discussed O 
. O 
A O 
better O 
understanding O 
of O 
this O 
free O 
PEI B-ABBREVIATION 
-induced O 
attractive O 
force O 
will O 
be O 
useful O 
in O 
the O 
development O 
of O 
improved O 
PEI B-ABBREVIATION 
/ O 
DNA O 
polyplexes O 
systems O 
for O 
biomedical O 
applications O 
. O 

study O 
evaluated O 
the O 
in O 
vitro O 
cytotoxicity O 
of O 
poly(propylene B-FAMILY 
fumarate I-FAMILY 
) I-FAMILY 
( O 
PPF B-ABBREVIATION 
) O 
. O 
PPF B-ABBREVIATION 
is O 
an O 
aliphatic O 
biodegradable O 
polymer O 
that O 
has O 
been O 
well O 
characterized O 
for O 
use O 
in O 
bone O 
tissue O 
engineering O 
scaffolds O 
. O 
Four O 
different O 
cell O 
types O 
, O 
human O 
mesenchymal O 
stem O 
cells O 
( O 
hMSC O 
) O 
, O 
fibroblasts O 
( O 
L929 O 
) O 
, O 
preosteoblasts O 
( O 
MC3T3 O 
) O 
, O 
and O 
canine O 
mesenchymal O 
stem O 
cells O 
( O 
cMSC O 
) O 
, O 
were O 
used O 
to O 
evaluate O 
the O 
cytotoxicity O 
of O 
PPF B-ABBREVIATION 
. O 
These O 
cell O 
types O 
represent O 
the O 
tissues O 
that O 
PPF B-ABBREVIATION 
would O 
interact O 
with O 
in O 
vivo O 
as O 
a O 
bone O 
tissue O 
scaffold O 
. O 
The O 
sol O 
fraction O 
of O 
the O 
PPF B-ABBREVIATION 
films O 
was O 
measured O 
and O 
then O 
utilized O 
to O 
estimate O 
cross O 
- O 
linking O 
density O 
. O 
Cytotoxicity O 
was O 
evaluated O 
using O 
XTT B-ABBREVIATION 
assay O 
and O 
fluorescence O 
imaging O 
. O 
Results O 
showed O 
that O 
PPF B-ABBREVIATION 
supported O 
similar O 
cell O 
metabolic O 
activities O 
of O 
hMSC O 
, O 
L929 O 
, O 
MC3T3 O 
, O 
and O 
cMSC O 
compared O 
to O 
the O 
noncytotoxic O 
control O 
, O 
high O 
- O 
density O 
polyethylene B-SYSTEMATIC 
( O 
HDPE O 
) O 
and O 
were O 
statistically O 
different O 
than O 
those O 
cultured O 
with O 
the O 
cytotoxic O 
control O 
, O 
a O 
polyurethane B-SYSTEMATIC 
film O 
containing O 
0.1% O 
zinc B-SYSTEMATIC 
diethyldithiocarbamate I-SYSTEMATIC 
( O 
ZCF B-ABBREVIATION 
) O 
. O 
Results O 
showed O 
differing O 
cellular O 
responses O 
to O 
ZCF B-ABBREVIATION 
, O 
the O 
cytotoxic O 
control O 
. O 
The O 
L929 O 
cells O 
had O 
the O 
lowest O 
cell O 
metabolic O 
activity O 
levels O 
after O 
exposure O 
to O 
ZCF B-ABBREVIATION 
compared O 
to O 
the O 
cell O 
metabolic O 
activity O 
levels O 
of O 
the O 
MC3T3 O 
, O 
hMSC O 
, O 
or O 
cMSC O 
cells O 
. O 
Qualitative O 
verification O 
of O 
the O 
results O 
using O 
fluorescence O 
imaging O 
demonstrated O 
no O 
change O 
in O 
cell O 
morphology O 
, O 
vacuolization O 
, O 
or O 
detachment O 
when O 
cultured O 
with O 
PPF B-ABBREVIATION 
compared O 
to O 
HDPE O 
or O 
blank O 
media O 
cultures O 
. O 
Overall O 
, O 
the O 
cytotoxicity O 
response O 
of O 
the O 
cells O 
to O 
PPF B-ABBREVIATION 
was O 
demonstrated O 
to O 
be O 
similar O 
to O 
the O 
cytotoxic O 
response O 
of O 
cells O 
to O 
known O 
noncytotoxic O 
materials O 
( O 
HDPE O 
) O 
. O 

receptor O 
- O 
deficient O 
lpr O 
mice O 
are O 
protected O 
against O 
acetaminophen B-TRIVIAL 
hepatotoxicity O 
due O 
to O 
higher O 
glutathione B-TRIVIAL 
synthesis O 
and O 
enhanced O 
detoxification O 
of O 
oxidant O 
stress O 
. O 

( O 
APAP B-ABBREVIATION 
) O 
overdose O 
is O 
a O 
classical O 
model O 
of O 
hepatocellular O 
necrosis O 
; O 
however O 
, O 
the O 
involvement O 
of O 
the O 
Fas O 
receptor O 
in O 
the O 
pathophysiology O 
remains O 
controversial O 
. O 
Fas O 
receptor O 
- O 
deficient O 
( O 
lpr O 
) O 
and O 
C57BL O 
/ O 
6 O 
mice O 
were O 
treated O 
with O 
APAP B-ABBREVIATION 
to O 
compare O 
the O 
mechanisms O 
of O 
hepatotoxicity O 
. O 
Lpr O 
mice O 
were O 
partially O 
protected O 
against O 
APAP B-ABBREVIATION 
hepatotoxicity O 
as O 
indicated O 
by O 
reduced O 
plasma O 
ALT O 
and O 
GDH O 
levels O 
and O 
liver O 
necrosis O 
. O 
Hepatic O 
Cyp2e1 O 
protein O 
, O 
adduct O 
formation O 
and O 
hepatic O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
depletion O 
were O 
similar O 
, O 
demonstrating O 
equivalent O 
reactive O 
metabolite O 
generation O 
. O 
There O 
was O 
no O 
difference O 
in O 
cytokine O 
formation O 
or O 
hepatic O 
neutrophil O 
recruitment O 
. O 
Interestingly O 
, O 
hepatic O 
GSH B-ABBREVIATION 
recovered O 
faster O 
in O 
lpr O 
mice O 
than O 
in O 
wild O 
type O 
animals O 
resulting O 
in O 
enhanced O 
detoxification O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
. O 
Driving O 
the O 
increased O 
GSH B-ABBREVIATION 
levels O 
, O 
mRNA O 
induction O 
and O 
protein O 
expression O 
of O 
glutamate B-TRIVIAL 
- O 
cysteine B-TRIVIAL 
ligase O 
( O 
gclc O 
) O 
were O 
higher O 
in O 
lpr O 
mice O 
. O 
Inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
mRNA O 
and O 
protein O 
levels O 
at O 
6h O 
were O 
significantly O 
lower O 
in O 
lpr O 
mice O 
, O 
which O 
correlated O 
with O 
reduced O 
nitrotyrosine B-SYSTEMATIC 
staining O 
. O 
Heat O 
shock O 
protein O 
70 O 
( O 
Hsp70 O 
) O 
mRNA O 
levels O 
were O 
substantially O 
higher O 
in O 
lpr O 
mice O 
after O 
APAP B-ABBREVIATION 
. O 
Conclusion O 
: O 
Our O 
data O 
suggest O 
that O 
the O 
faster O 
recovery O 
of O 
hepatic O 
GSH B-ABBREVIATION 
levels O 
during O 
oxidant O 
stress O 
and O 
peroxynitrite B-SYSTEMATIC 
formation O 
, O 
reduced O 
iNOS O 
expression O 
and O 
enhanced O 
induction O 
of O 
Hsp70 O 
attenuated O 
the O 
susceptibility O 
to O 
APAP B-ABBREVIATION 
-induced O 
cell O 
death O 
in O 
lpr O 
mice O 
. O 

and O 
peroxisomes O 
can O 
be O 
fragmented O 
by O 
the O 
process O 
of O 
fission O 
. O 
The O 
fission O 
machineries O 
of O 
both O 
organelles O 
share O 
a O 
set O 
of O 
proteins O 
. O 
GDAP1 O 
is O 
a O 
tail O 
- O 
anchored O 
protein O 
of O 
mitochondria O 
and O 
induces O 
mitochondrial O 
fragmentation O 
. O 
Mutations O 
in O 
GDAP1 O 
lead O 
to O 
Charcot-Marie-Tooth O 
disease O 
( O 
CMT O 
) O 
, O 
an O 
inherited O 
peripheral O 
neuropathy O 
, O 
and O 
affect O 
mitochondrial O 
dynamics O 
. O 
Here O 
, O 
we O 
show O 
that O 
GDAP1 O 
is O 
also O 
targeted O 
to O 
peroxisomes O 
mediated O 
by O 
the O 
import O 
receptor O 
Pex19 O 
. O 
Knockdown O 
of O 
GDAP1 O 
leads O 
to O 
peroxisomal O 
elongation O 
that O 
can O 
be O 
rescued O 
by O 
re O 
- O 
expressing O 
GDAP1 O 
and O 
by O 
missense O 
mutated O 
forms O 
found O 
in O 
CMT O 
patients O 
. O 
GDAP1-induced O 
peroxisomal O 
fission O 
is O 
dependent O 
on O 
the O 
integrity O 
of O 
its O 
hydrophobic O 
domain O 
1 O 
, O 
and O 
on O 
Drp1 O 
and O 
Mff O 
, O 
as O 
is O 
mitochondrial O 
fission O 
. O 
Thus O 
, O 
GDAP1 O 
regulates O 
mitochondrial O 
and O 
peroxisomal O 
fission O 
by O 
a O 
similar O 
mechanism O 
. O 
However O 
, O 
our O 
results O 
reveal O 
also O 
a O 
more O 
critical O 
role O 
of O 
the O 
amino B-FAMILY 
-terminal O 
GDAP1 O 
domains O 
, O 
carrying O 
most O 
CMT-causing O 
mutations O 
, O 
in O 
the O 
regulation O 
of O 
mitochondrial O 
compared O 
to O 
peroxisomal O 
fission O 
. O 

- O 
regulation O 
of O 
LRRK2 O 
in O 
control O 
and O 
DAT O 
transfected O 
HEK O 
cells O 
increases O 
manganese B-SYSTEMATIC 
-induced O 
oxidative O 
stress O 
and O 
cell O 
toxicity O 
. O 

extra O 
- O 
pyramidal O 
symptoms O 
associated O 
with O 
manganism B-SYSTEMATIC 
often O 
overlap O 
with O 
that O 
seen O 
in O 
Parkinsonism O 
suggesting O 
a O 
common O 
link O 
between O 
the O 
two O 
disorders O 
. O 
Since O 
wide O 
deviations O 
are O 
observed O 
in O 
susceptibility O 
and O 
characteristics O 
of O 
the O 
symptoms O 
observed O 
in O 
manganism B-SYSTEMATIC 
, O 
these O 
differences O 
may O 
be O 
due O 
to O 
underlying O 
genetic O 
variability O 
. O 
Genes O 
linked O 
to O 
early O 
onset O 
of O 
Parkinsonism O 
which O 
includes O 
ATP13A2 O 
and O 
parkin O 
have O 
already O 
been O 
suggested O 
to O 
promote O 
development O 
of O 
Mn B-FORMULA 
toxicity O 
. O 
Of O 
the O 
other O 
Parkinson O 
- O 
linked O 
genes O 
, O 
mutations O 
in O 
LRRK2 O 
, O 
an O 
autosomal O 
dominant O 
gene O 
, O 
represent O 
another O 
likely O 
candidate O 
involved O 
in O 
the O 
development O 
of O 
manganism B-SYSTEMATIC 
. O 
In O 
this O 
paper O 
the O 
effect O 
of O 
shRNA O 
LRRK2 O 
knock O 
- O 
down O 
on O 
Mn B-FORMULA 
toxicity O 
was O 
examined O 
in O 
control O 
and O 
DAT O 
transfected O 
HEK293 O 
cells O 
. O 
Results O 
demonstrate O 
that O 
LRRK2 O 
down O 
- O 
regulation O 
potentiates O 
Mn B-FORMULA 
toxicity O 
in O 
both O 
control O 
and O 
DAT-transfected O 
cell O 
as O 
well O 
as O 
potentiates O 
DA O 
toxicity O 
. O 
Combined O 
treatment O 
of O 
Mn B-FORMULA 
and O 
DA O 
further O 
augments O 
cell O 
toxicity O 
, O 
ROS O 
production O 
and O 
JNK O 
phosphorylation O 
in O 
LRRK2 O 
deficient O 
cells O 
compared O 
to O 
controls O 
. O 
Consistent O 
with O 
studies O 
demonstrating O 
that O 
LRRK2 O 
plays O 
a O 
role O 
in O 
the O 
phosphorylation O 
of O 
p38 O 
, O 
our O 
results O 
similarly O 
demonstrate O 
a O 
decrease O 
in O 
p38 O 
activation O 
in O 
LRRK2 O 
knock O 
- O 
down O 
cells O 
. O 
Our O 
findings O 
suggest O 
that O 
nan O 
mutations O 
in O 
LRRK2 O 
which O 
cause O 
Parkinsonism O 
potentiate O 
Mn B-FORMULA 
toxicity O 
and O 
increase O 
susceptibility O 
to O 
develop O 
manganism B-SYSTEMATIC 
. O 

architectures O 
based O 
on O 
bis-MPA B-SYSTEMATIC 
: O 
functional O 
polymeric O 
scaffolds O 
for O 
application O 
- O 
driven O 
research O 
. O 

polymers O 
are O 
highly O 
branched O 
, O 
globular O 
architectures O 
with O 
multiple O 
representations O 
of O 
functional O 
groups O 
. O 
These O 
nanoscale O 
organic O 
frameworks O 
continue O 
to O 
fascinate O 
researchers O 
worldwide O 
and O 
are O 
today O 
under O 
intensive O 
investigation O 
in O 
application O 
- O 
driven O 
research O 
. O 
A O 
large O 
number O 
of O 
potential O 
application O 
areas O 
have O 
been O 
suggested O 
for O 
dendritic O 
polymers O 
, O 
including O 
theranostics O 
, O 
biosensors O 
, O 
optics O 
, O 
adhesives O 
and O 
coatings O 
. O 
The O 
transition O 
from O 
potential O 
to O 
real O 
applications O 
is O 
strongly O 
dictated O 
by O 
their O 
commercial O 
accessibility O 
, O 
scaffolding O 
ability O 
as O 
well O 
as O 
biocompatibility O 
. O 
A O 
dendritic O 
family O 
that O 
fulfills O 
these O 
requirements O 
is O 
based O 
on O 
the O 
2,2-bismethylolpropionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
bis-MPA B-SYSTEMATIC 
) O 
monomer O 
. O 
This O 
critical O 
review O 
is O 
the O 
first O 
of O 
its O 
kind O 
to O 
cover O 
most O 
of O 
the O 
research O 
activities O 
generated O 
on O 
aliphatic O 
polyester O 
dendritic O 
architectures O 
based O 
on O 
bis-MPA B-SYSTEMATIC 
. O 
It O 
is O 
apparent O 
that O 
these O 
scaffolds O 
will O 
continue O 
to O 
be O 
in O 
the O 
forefront O 
of O 
cutting O 
- O 
edge O 
research O 
as O 
their O 
structural O 
variations O 
are O 
endless O 
including O 
dendrons O 
, O 
dendrimers O 
, O 
hyperbranched O 
polymers O 
, O 
dendritic O 
- O 
linear O 
hybrids O 
and O 
their O 
hybridization O 
with O 
inorganic O 
surfaces O 
. O 

species O 
can O 
be O 
used O 
as O 
a O 
highly O 
convenient O 
model O 
system O 
to O 
reveal O 
key O 
ionic O 
and O 
molecular O 
mechanisms O 
that O 
confer O 
salinity O 
tolerance O 
in O 
plants O 
. O 
Earlier O 
, O 
we O 
reported O 
that O 
quinoa O 
( O 
Chenopodium O 
quinoa O 
Willd O 
. O 
) O 
, O 
a O 
facultative O 
C3 O 
halophyte O 
species O 
, O 
can O 
efficiently O 
control O 
the O 
activity O 
of O 
slow O 
( O 
SV O 
) O 
and O 
fast O 
( O 
FV O 
) O 
tonoplast O 
channels O 
to O 
match O 
specific O 
growth O 
conditions O 
by O 
ensuring O 
that O 
most O 
of O 
accumulated O 
Na B-FORMULA 
+ O 
is O 
safely O 
locked O 
in O 
the O 
vacuole O 
( O 
Bonales-Alatorre O 
et O 
al O 
. O 
( O 
2013 O 
) O 
Plant O 
Physiology O 
) O 
. O 
This O 
work O 
extends O 
these O 
finding O 
by O 
comparing O 
the O 
properties O 
of O 
tonoplast O 
FV O 
and O 
SV O 
channels O 
in O 
two O 
quinoa O 
genotypes O 
contrasting O 
in O 
their O 
salinity O 
tolerance O 
. O 
The O 
work O 
is O 
complemented O 
by O 
studies O 
of O 
the O 
kinetics O 
of O 
net O 
ion O 
fluxes O 
across O 
the O 
plasma O 
membrane O 
of O 
quinoa O 
leaf O 
mesophyll O 
tissue O 
. O 
Our O 
results O 
suggest O 
that O 
multiple O 
mechanisms O 
contribute O 
towards O 
genotypic O 
differences O 
in O 
salinity O 
tolerance O 
in O 
quinoa O 
. O 
These O 
include O 
: O 
(i) O 
a O 
higher O 
rate O 
of O 
Na B-FORMULA 
+ O 
exclusion O 
from O 
leaf O 
mesophyll O 
; O 
(ii) O 
maintenance O 
of O 
low O 
cytosolic O 
Na B-FORMULA 
+ O 
levels O 
; O 
(iii) O 
better O 
K B-FORMULA 
+ O 
retention O 
in O 
the O 
leaf O 
mesophyll O 
; O 
(iv) O 
a O 
high O 
rate O 
of O 
H B-FORMULA 
+ O 
pumping O 
, O 
which O 
increases O 
the O 
ability O 
of O 
mesophyll O 
cells O 
to O 
restore O 
their O 
membrane O 
potential O 
; O 
and O 
(v) O 
the O 
ability O 
to O 
reduce O 
the O 
activity O 
of O 
SV O 
and O 
FV O 
channels O 
under O 
saline O 
conditions O 
. O 
These O 
mechanisms O 
appear O 
to O 
be O 
highly O 
orchestrated O 
, O 
thus O 
enabling O 
the O 
remarkable O 
overall O 
salinity O 
tolerance O 
of O 
quinoa O 
species O 
. O 

evidence O 
for O 
epidermal O 
H2O2 B-FORMULA 
/ O 
ONOO B-FORMULA 
-- O 
mediated O 
oxidation O 
/ O 
nitration O 
in O 
segmental O 
vitiligo O 
is O 
supported O 
by O 
repigmentation O 
of O 
skin O 
and O 
eyelashes O 
after O 
reduction O 
of O 
epidermal O 
H2O2 B-FORMULA 
with O 
topical O 
NB-UVB-activated O 
pseudocatalase O 
PC-KUS O 
. O 

vitiligo O 
( O 
NSV O 
) O 
is O 
characterized O 
by O 
loss O 
of O 
inherited O 
skin O 
color O 
. O 
The O 
cause O 
of O 
the O 
disease O 
is O 
still O 
unknown O 
despite O 
accumulating O 
in O 
vivo O 
and O 
in O 
vitro O 
evidence O 
of O 
massive O 
epidermal O 
oxidative O 
stress O 
via O 
H2O2 B-FORMULA 
and O 
peroxynitrite B-SYSTEMATIC 
( O 
ONOO(-) B-FORMULA 
) O 
in O 
affected O 
individuals O 
. O 
The O 
most O 
favored O 
hypothesis O 
is O 
based O 
on O 
autoimmune O 
mechanisms O 
. O 
Strictly O 
segmental O 
vitiligo O 
( O 
SSV O 
) O 
with O 
dermatomal O 
distribution O 
is O 
a O 
rare O 
entity O 
, O 
often O 
associated O 
with O 
stable O 
outcome O 
. O 
Recently O 
, O 
it O 
was O 
documented O 
that O 
this O 
form O 
can O 
be O 
associated O 
with O 
NSV O 
( O 
mixed O 
vitiligo O 
) O 
. O 
We O 
here O 
asked O 
the O 
question O 
whether O 
ROS O 
and O 
possibly O 
ONOO(-) B-FORMULA 
could O 
be O 
players O 
in O 
the O 
pathogenesis O 
of O 
SSV O 
. O 
Our O 
in O 
situ O 
results O 
demonstrate O 
for O 
the O 
first O 
time O 
epidermal O 
biopterin O 
accumulation O 
together O 
with O 
significantly O 
decreased O 
epidermal O 
catalase O 
, O 
thioredoxin O 
/ O 
thioreoxin O 
reductase O 
, O 
and O 
MSRA O 
/ O 
MSRB O 
expression O 
. O 
Moreover O 
, O 
we O 
show O 
epidermal O 
ONOO(-) B-FORMULA 
accumulation O 
. O 
In O 
vivo O 
FT-Raman O 
spectroscopy O 
reveals O 
the O 
presence O 
of O 
H2O2 B-FORMULA 
, O 
methionine B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
, O 
and O 
tryptophan B-TRIVIAL 
metabolites O 
; O 
i.e O 
. O 
, O 
N- B-SYSTEMATIC 
formylkynurenine I-SYSTEMATIC 
and O 
kynurenine B-TRIVIAL 
, O 
implying O 
Fenton O 
chemistry O 
in O 
the O 
cascade O 
( O 
n=10 O 
) O 
. O 
Validation O 
of O 
the O 
basic O 
data O 
stems O 
from O 
successful O 
repigmentation O 
of O 
skin O 
and O 
eyelashes O 
in O 
affected O 
individuals O 
, O 
regardless O 
of O 
SSV O 
or O 
segmental O 
vitiligo O 
in O 
association O 
with O 
NSV O 
after O 
reduction O 
of O 
epidermal O 
H2O2 B-FORMULA 
( O 
n=5 O 
) O 
. O 
Taken O 
together O 
, O 
our O 
contribution O 
strongly O 
supports O 
H2O2 B-FORMULA 
/ O 
ONOO- B-FORMULA 
mediated O 
stress O 
in O 
the O 
pathogenesis O 
of O 
SSV O 
. O 
Our O 
findings O 
offer O 
new O 
treatment O 
intervention O 
for O 
lost O 
skin O 
and O 
hair O 
color.-Schallreuter O 
, O 
K O 
. O 
U O 
. O 
, O 
Salem O 
, O 
M O 
. O 
A O 
. O 
E O 
. O 
L O 
. O 
, O 
Holtz O 
, O 
S O 
. O 
, O 
Panske O 
, O 
A O 
. O 
Basic O 
evidence O 
for O 
epidermal O 
H2O2 B-FORMULA 
/ O 
ONOO(-) B-FORMULA 
-mediated O 
oxidation O 
/ O 
nitration O 
in O 
segmental O 
vitiligo O 
is O 
supported O 
by O 
repigmentation O 
of O 
skin O 
and O 
eyelashes O 
after O 
reduction O 
of O 
epidermal O 
H2O2 B-FORMULA 
with O 
topical O 
NB-UVB-activated O 
pseudocatalase O 
PC-KUS O 
. O 

the O 
cellular O 
entry O 
pathways O 
of O 
synthetic O 
biomaterials O 
is O 
highly O 
important O 
to O 
improve O 
overall O 
labeling O 
and O 
delivery O 
efficiency O 
. O 
Herein O 
, O 
cellular O 
entry O 
mechanisms O 
of O 
conjugated O 
polymer O 
nanoparticles O 
( O 
CPNs O 
) O 
are O 
presented O 
. O 
CPNs O 
are O 
intrinsic O 
fluorescent O 
materials O 
used O 
for O 
various O 
biological O 
applications O 
. O 
While O 
CPNs O 
cause O 
no O 
toxicity O 
, O 
decreased O 
CPN O 
uptake O 
is O 
observed O 
from O 
cancer O 
cells O 
pretreated O 
with O 
genistein B-TRIVIAL 
, O 
which O 
is O 
an O 
inhibitor O 
of O 
caveolae O 
- O 
mediated O 
endocytosis O 
( O 
CvME O 
) O 
. O 
CvME O 
is O 
further O 
confirmed O 
by O 
high O 
co O 
- O 
localization O 
with O 
caveolin-1 O 
proteins O 
found O 
in O 
the O 
caveolae O 
and O 
caveosomes O 
. O 
Excellent O 
photophysical O 
properties O 
, O 
non-toxicity O 
, O 
and O 
non-destructive O 
delivery O 
pathways O 
support O 
that O 
CPNs O 
are O 
promising O 
multifunctional O 
carriers O 
minimizing O 
degradation O 
of O 
contents O 
during O 
delivery O 
. O 

of O 
an O 
Inhibitory O 
Mechanism O 
of O 
Luteolin B-TRIVIAL 
on O 
the O 
Insulin O 
- O 
Like O 
Growth O 
Factor-1 O 
Ligand-Receptor O 
Interaction O 
. O 

single O 
- O 
molecule O 
force O 
measurement O 
and O 
fluorescence O 
imaging O 
, O 
we O 
have O 
demonstrated O 
that O 
luteolin B-TRIVIAL 
has O 
an O 
inhibitory O 
effect O 
on O 
IGF-1 O 
ligand O 
- O 
receptor O 
binding O 
, O 
the O 
initial O 
step O 
in O 
IGF-1 O 
signaling O 
. O 
This O 
inhibition O 
mechanism O 
, O 
which O 
was O 
confirmed O 
by O 
flow O 
cytometry O 
and O 
molecular O 
docking O 
, O 
could O 
play O 
a O 
role O 
in O 
cancer O 
therapy O 
. O 

- O 
origin O 
effects O 
were O 
observed O 
in O 
an O 
Icelandic O 
population O 
for O 
several O 
genetic O 
variants O 
associated O 
with O 
type O 
2 O 
diabetes O 
, O 
including O 
those O 
in O 
KLF14 O 
( O 
rs4731702 O 
) O 
, O 
MOB2 O 
( O 
rs2334499 O 
) O 
and O 
KCNQ1 O 
( O 
rs2237892 O 
, O 
rs231362 O 
) O 
. O 
We O 
analyzed O 
parent-of O 
- O 
origin O 
effects O 
for O 
these O 
variants O 
, O 
along O 
with O 
two O 
others O 
in O 
KCNQ1 O 
identified O 
in O 
previous O 
genome O 
- O 
wide O 
association O 
studies O 
( O 
rs2237895 O 
, O 
rs2299620 O 
) O 
, O 
in O 
7351 O 
Pima O 
Indians O 
from O 
4549 O 
nuclear O 
families O 
; O 
34% O 
of O 
participants O 
had O 
diabetes O 
. O 
In O 
a O 
subset O 
of O 
287 O 
normoglycemic O 
individuals O 
, O 
acute O 
insulin O 
secretion O 
was O 
measured O 
by O 
an O 
intravenous O 
glucose B-TRIVIAL 
tolerance O 
test O 
. O 
Statistically O 
significant O 
( O 
P O 
< O 
0.05 O 
) O 
parent-of O 
- O 
origin O 
effects O 
were O 
seen O 
for O 
association O 
with O 
type O 
2 O 
diabetes O 
for O 
all O 
variants O 
. O 
The O 
strongest O 
effect O 
was O 
seen O 
at O 
rs2299620 O 
in O 
KCNQ1 O 
: O 
the O 
C O 
allele O 
was O 
associated O 
with O 
increased O 
diabetes O 
when O 
maternally O 
- O 
derived O 
( O 
odds O 
ratio=1.92 O 
, O 
P=4.1x10(-12) O 
) O 
, O 
but O 
not O 
when O 
paternally O 
- O 
derived O 
( O 
odds O 
ratio=0.93 O 
, O 
P=0.47 O 
; O 
P=9.9x10(-6) O 
for O 
difference O 
in O 
maternal O 
and O 
paternal O 
effects O 
) O 
. O 
A O 
maternally O 
- O 
derived O 
C O 
allele O 
was O 
also O 
associated O 
with O 
a O 
28% O 
decrease O 
in O 
insulin O 
secretion O 
( O 
P=0.002 O 
) O 
. O 
This O 
study O 
confirms O 
parent-of O 
- O 
origin O 
effects O 
in O 
the O 
association O 
with O 
type O 
2 O 
diabetes O 
for O 
variants O 
in O 
KLF14 O 
, O 
MOB2 O 
and O 
KCNQ1 O 
. O 
In O 
Pima O 
Indians O 
the O 
effect O 
of O 
maternally O 
- O 
derived O 
KCNQ1 O 
variants O 
appears O 
to O 
be O 
mediated O 
through O 
decreased O 
insulin O 
secretion O 
, O 
and O 
is O 
particularly O 
strong O 
, O 
accounting O 
for O 
4% O 
of O 
the O 
variance O 
in O 
liability O 
to O 
diabetes O 
. O 

Metalloproteinase O 
Inhibitors O 
Based O 
on O 
the O 
3-Mercaptopyrrolidine B-SYSTEMATIC 
Core O 
. O 

series O 
of O 
pyrrolidine B-SYSTEMATIC 
mercaptosulfide I-SYSTEMATIC 
, O 
2-mercaptocyclopentane B-FAMILY 
arylsulfonamide I-FAMILY 
, O 
and O 
3-mercapto-4-arylsulfonamido B-FAMILY 
pyrrolidine I-FAMILY 
matrix O 
metalloproteinase O 
inhibitors O 
( O 
MMPIs O 
) O 
were O 
designed O 
, O 
synthesized O 
, O 
and O 
evaluated O 
. O 
Exhibiting O 
unique O 
properties O 
over O 
other O 
MMPIs O 
( O 
e.g O 
. O 
, O 
hydroxamates B-FAMILY 
) O 
, O 
these O 
newly O 
reported O 
compounds O 
are O 
capable O 
of O 
modulating O 
activities O 
of O 
several O 
MMPs O 
in O 
the O 
low O 
nanomolar O 
range O 
, O 
including O 
MMP-2 O 
( O 
~2 O 
to O 
50 O 
nM O 
) O 
, O 
MMP-13 O 
( O 
~2 O 
to O 
50 O 
nM O 
) O 
, O 
and O 
MMP-14 O 
( O 
~4 O 
to O 
60 O 
nM O 
) O 
. O 
Additionally O 
these O 
compounds O 
are O 
selective O 
to O 
intermediate- O 
and O 
deep O 
- O 
pocket O 
MMPs O 
but O 
not O 
shallow O 
- O 
pocketed O 
MMPs O 
( O 
e.g O 
. O 
, O 
MMP-1 O 
, O 
~850 O 
to O 
> O 
50000 O 
nM O 
; O 
MMP-7 O 
, O 
~4,000 O 
to O 
> O 
25000 O 
nM O 
) O 
. O 
Our O 
previous O 
work O 
with O 
the O 
mercaptosulfide B-SYSTEMATIC 
functionality O 
attached O 
to O 
both O 
cyclopentane B-SYSTEMATIC 
and O 
pyrrolidine B-SYSTEMATIC 
frameworks O 
demonstrated O 
that O 
the O 
cis-(3S,4R)- O 
stereochemistry O 
was O 
optimal O 
for O 
all O 
of O 
the O 
MMPs O 
tested O 
. O 
However O 
, O 
in O 
our O 
newest O 
compounds O 
an O 
interesting O 
shift O 
of O 
preference O 
to O 
the O 
trans- O 
form O 
of O 
the O 
mercaptosulfonamides B-FAMILY 
was O 
observed O 
with O 
increased O 
oxidative O 
stability O 
and O 
biological O 
compatibility O 
. O 
We O 
also O 
report O 
several O 
kinetic O 
and O 
biological O 
characteristics O 
showing O 
that O 
these O 
compounds O 
may O 
be O 
used O 
to O 
probe O 
the O 
mechanistic O 
activities O 
of O 
MMPs O 
in O 
disease O 
. O 

, O 
Synthesis O 
and O 
Biological O 
Evaluation O 
of O 
Aminoalkylindole B-FAMILY 
Derivatives O 
as O 
Cannabinoid O 
Receptor O 
Ligands O 
with O 
Potential O 
for O 
Treatment O 
of O 
Alcohol B-SYSTEMATIC 
Abuse O 
. O 

of O 
increased O 
endocannabinoid O 
signaling O 
with O 
a O 
CB1R O 
neutral O 
antagonist O 
might O 
offer O 
a O 
new O 
therapeutic O 
direction O 
for O 
treatment O 
of O 
alcohol B-FAMILY 
abuse O 
. O 
We O 
have O 
recently O 
reported O 
that O 
a O 
mono-hydroxylated O 
metabolite O 
of O 
the O 
synthetic O 
aminoalkylindole B-FAMILY 
cannabinoid O 
JHW-073 B-IDENTIFIER 
( O 
3 O 
) O 
exhibits O 
neutral O 
antagonist O 
activity O 
at O 
CB1Rs O 
and O 
thus O 
may O 
serve O 
as O 
a O 
promising O 
lead O 
for O 
the O 
development O 
of O 
novel O 
alcohol B-FAMILY 
abuse O 
therapies O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
show O 
that O 
systematic O 
modification O 
of O 
an O 
aminoalkylindole B-FAMILY 
scaffold O 
identifies O 
two O 
new O 
compounds O 
with O 
dual O 
CB1R O 
antagonist O 
/ O 
CB2R O 
agonist O 
activity O 
. O 
Similar O 
to O 
the O 
CB1R O 
antagonist O 
/ O 
inverse O 
agonist O 
rimonabant O 
, O 
analogues O 
27 O 
and O 
30 O 
decrease O 
oral O 
alcohol B-FAMILY 
self O 
- O 
administration O 
, O 
without O 
affecting O 
total O 
fluid O 
intake O 
and O 
block O 
the O 
development O 
of O 
alcohol B-FAMILY 
-conditioned O 
place O 
preference O 
. O 
Collectively O 
, O 
these O 
initial O 
findings O 
suggest O 
that O 
design O 
and O 
systematic O 
modification O 
of O 
aminoalkylindoles B-FAMILY 
such O 
as O 
3 O 
may O 
lead O 
to O 
development O 
of O 
novel O 
cannabinoid O 
ligands O 
with O 
dual O 
CB1R O 
antagonist O 
/ O 
CB2R O 
agonist O 
activity O 
with O 
potential O 
for O 
use O 
as O 
treatments O 
of O 
alcohol B-FAMILY 
abuse O 
. O 

- O 
Derived O 
Peptides O 
, O 
Val-Pro-Pro B-FORMULA 
and O 
Ile-Pro-Pro B-FORMULA 
, O 
Attenuate O 
Atherosclerosis O 
Development O 
in O 
Apolipoprotein O 
E-Deficient O 
Mice O 
: O 
A O 
Preliminary O 
Study O 
. O 

Milk O 
- O 
derived O 
peptides O 
, O 
Val-Pro-Pro B-FORMULA 
( O 
VPP O 
) O 
and O 
Ile-Pro-Pro B-FORMULA 
( O 
IPP O 
) O 
, O 
have O 
angiotensin O 
I-converting O 
enzyme O 
inhibitory O 
activities O 
and O 
blood O 
pressure O 
- O 
lowering O 
effects O 
. O 
We O 
examined O 
the O 
effects O 
of O 
these O 
peptides O 
on O 
the O 
development O 
of O 
atherosclerosis O 
in O 
apolipoprotein O 
E-deficient O 
[ O 
apoE(- O 
/ O 
- O 
) O 
] O 
mice O 
. O 
For O 
31 O 
weeks O 
, O 
six O 
- O 
week O 
- O 
old O 
male O 
apoE(- O 
/ O 
- O 
) O 
mice O 
received O 
a O 
diet O 
that O 
included O 
one O 
of O 
the O 
following O 
: O 
fermented O 
milk O 
containing O 
both O 
VPP O 
and O 
IPP O 
; O 
casein O 
hydrolysate O 
containing O 
both O 
of O 
these O 
peptides O 
; O 
synthesized O 
VPP O 
; O 
synthesized O 
IPP O 
; O 
enalapril B-TRIVIAL 
; O 
captopril B-TRIVIAL 
; O 
or O 
control O 
diet O 
. O 
At O 
the O 
end O 
of O 
feeding O 
, O 
blood O 
biochemistry O 
, O 
aortic O 
atherogenesis O 
, O 
and O 
gene O 
expression O 
by O 
DNA O 
microarray O 
analysis O 
were O 
evaluated O 
. O 
There O 
were O 
no O 
significant O 
changes O 
in O 
the O 
plasma O 
lipid O 
levels O 
and O 
8-isoprostane B-SYSTEMATIC 
, O 
a O 
marker O 
of O 
oxidative O 
stress O 
. O 
The O 
area O 
ratio O 
of O 
intima O 
to O 
media O 
in O 
the O 
aortic O 
arch O 
was O 
significantly O 
lower O 
in O 
the O 
fermented O 
milk O 
, O 
casein O 
hydrolysate O 
, O 
synthesized O 
VPP O 
, O 
enalapril B-TRIVIAL 
, O 
and O 
captopril B-TRIVIAL 
groups O 
than O 
in O 
the O 
control O 
group O 
. O 
As O 
is O 
common O 
with O 
diets O 
containing O 
VPP O 
and O 
/ O 
or O 
IPP O 
, O 
we O 
observed O 
reductions O 
in O 
mRNA O 
expression O 
of O 
inflammatory O 
cytokines O 
, O 
such O 
as O 
interleukin O 
(IL)-6 O 
and O 
IL-1β O 
, O 
oxidized O 
low O 
- O 
density O 
lipoprotein O 
receptor O 
, O 
and O 
transcription O 
regulators O 
. O 
These O 
results O 
suggest O 
that O 
a O 
continuous O 
intake O 
of O 
VPP O 
and O 
IPP O 
might O 
be O 
beneficial O 
for O 
preventing O 
atherosclerosis O 
caused O 
by O 
hypercholesterolemia O 
. O 

Pomegranates O 
have O 
health O 
- O 
promoting O 
benefits O 
because O 
of O 
their O 
polyphenol B-FAMILY 
constituents O 
. O 
Previous O 
studies O 
have O 
demonstrated O 
the O 
antimicrobial O 
activity O 
of O 
aqueous O 
and O 
organic O 
extracts O 
of O 
pomegranate O 
components O 
and O 
by O 
- O 
products O 
. O 
We O 
sought O 
to O 
determine O 
the O 
antimicrobial O 
activity O 
against O 
40 O 
foodborne O 
pathogens O 
representing O 
eight O 
bacterial O 
species O 
using O 
juice O 
itself O 
. O 
In O 
addition O 
, O 
we O 
sought O 
to O 
determine O 
the O 
synergistic O 
antimicrobial O 
activity O 
between O 
pomegranate O 
juice O 
and O 
other O 
plant O 
products O 
displaying O 
antimicrobial O 
activity O 
. O 
The O 
antimicrobial O 
activity O 
of O 
pomegranate O 
juice O 
was O 
dependent O 
on O 
the O 
test O 
organism O 
, O 
which O 
varied O 
to O 
highly O 
susceptible O 
( O 
four O 
Gram O 
- O 
positive O 
species O 
) O 
to O 
unaffected O 
( O 
Salmonella O 
and O 
Escherichia O 
coli O 
O157 O 
: O 
H7 O 
) O 
. O 
Two O 
Gram O 
- O 
negative O 
species O 
, O 
which O 
were O 
inhibited O 
were O 
Helicobacter O 
pylori O 
and O 
Vibrio O 
parahemolyticus O 
. O 
No O 
synergistic O 
antimicrobial O 
activity O 
was O 
seen O 
between O 
pomegranate O 
and O 
either O 
barberry O 
, O 
oregano O 
, O 
or O 
cranberry O 
. O 
The O 
antimicrobial O 
activity O 
of O 
pomegranate O 
juice O 
is O 
dependent O 
on O 
the O 
test O 
organism O 
and O 
extraction O 
method O 
. O 
The O 
sensitivity O 
of O 
H O 
. O 
pylori O 
suggests O 
that O 
pomegranate O 
juice O 
may O 
be O 
an O 
alternative O 
or O 
supplemental O 
treatment O 
for O 
gastric O 
ulcers O 
caused O 
by O 
this O 
organism O 
. O 

amphiphilic O 
β-sheet O 
peptides O 
as O 
templates O 
for O 
paraoxon B-TRIVIAL 
adsorption O 
and O 
detection O 
. O 

peptides O 
were O 
designed O 
to O 
fold O 
into O 
a O 
β-sheet O 
monolayer O 
structure O 
while O 
presenting O 
the O 
catalytic O 
triad O 
residues O 
of O 
the O 
enzyme O 
, O 
acetylcholinesterase O 
( O 
Glu B-FORMULA 
, O 
His B-FORMULA 
and O 
Ser B-FORMULA 
) O 
, O 
to O 
a O 
solution O 
containing O 
the O 
organophosphate B-FAMILY 
, O 
paraoxon B-TRIVIAL 
. O 
Three O 
peptides O 
, O 
in O 
which O 
the O 
catalytic O 
triad O 
residues O 
were O 
arranged O 
in O 
different O 
orders O 
along O 
the O 
strand O 
, O 
were O 
generated O 
to O 
reveal O 
potential O 
differences O 
in O 
interactions O 
with O 
paraoxon B-TRIVIAL 
as O 
a O 
function O 
of O 
the O 
order O 
of O 
these O 
amino B-FAMILY 
acids I-FAMILY 
. O 
One O 
additional O 
peptide O 
with O 
amino B-FAMILY 
acids I-FAMILY 
introduced O 
in O 
random O 
order O 
was O 
studied O 
to O 
highlight O 
the O 
contribution O 
of O 
the O 
β-sheet O 
secondary O 
structure O 
to O 
any O 
interactions O 
with O 
paraoxon B-TRIVIAL 
. O 
Langmuir O 
isotherms O 
, O 
Brewster O 
angle O 
microscope O 
at O 
interfaces O 
and O 
circular O 
dichroism O 
measurements O 
in O 
bulk O 
showed O 
that O 
both O 
the O 
β-sheet O 
conformation O 
and O 
the O 
order O 
of O 
the O 
amino B-FAMILY 
acids I-FAMILY 
along O 
the O 
strand O 
influenced O 
the O 
interactions O 
of O 
paraoxon B-TRIVIAL 
with O 
the O 
peptides O 
. O 
Compression O 
isotherm O 
curves O 
, O 
as O 
well O 
as O 
Brewster O 
- O 
angle O 
microscopy O 
images O 
, O 
provided O 
evidence O 
for O 
enhanced O 
adsorption O 
of O 
the O 
paraoxon B-TRIVIAL 
to O 
the O 
monolayers O 
of O 
peptides O 
which O 
present O 
neighboring O 
Glu B-FORMULA 
and O 
Ser B-FORMULA 
residues O 
along O 
the O 
hydrophilic O 
face O 
of O 
the O 
β-strand O 
. O 
Circular O 
dichroism O 
revealed O 
that O 
the O 
peptide O 
most O 
sensitive O 
to O 
interactions O 
with O 
paraoxon B-TRIVIAL 
was O 
that O 
with O 
the O 
triad O 
residues O 
in O 
the O 
order O 
Glu B-FORMULA 
, O 
Ser B-FORMULA 
and O 
His B-FORMULA 
, O 
which O 
appears O 
to O 
be O 
appropriate O 
for O 
supporting O 
a O 
catalytic O 
mechanism O 
similar O 
to O 
that O 
in O 
acetylcholinesterase O 
enzyme O 
. O 
These O 
rationally O 
designed O 
peptides O 
may O 
be O 
further O 
utilized O 
for O 
the O 
development O 
of O 
technologies O 
for O 
organophosphate B-FAMILY 
adsorption O 
and O 
detection O 
. O 

A O 
convenient O 
and O 
efficient O 
in O 
vitro O 
diffusion O 
cell O 
method O 
to O 
evaluate O 
formulations O 
for O 
inner O 
ear O 
delivery O 
via O 
the O 
intratympanic O 
route O 
is O 
currently O 
not O 
available O 
. O 
The O 
existing O 
in O 
vitro O 
diffusion O 
cell O 
systems O 
commonly O 
used O 
to O 
evaluate O 
drug O 
formulations O 
do O 
not O 
resemble O 
the O 
physical O 
dimensions O 
of O 
the O 
middle O 
ear O 
and O 
round O 
window O 
membrane O 
. O 
The O 
objectives O 
of O 
this O 
study O 
were O 
to O 
examine O 
a O 
modified O 
in O 
vitro O 
diffusion O 
cell O 
system O 
of O 
a O 
small O 
diffusion O 
area O 
for O 
studying O 
sustained O 
release O 
formulations O 
in O 
inner O 
ear O 
drug O 
delivery O 
and O 
to O 
identify O 
a O 
formulation O 
for O 
sustained O 
drug O 
delivery O 
to O 
the O 
inner O 
ear O 
. O 
Four O 
formulations O 
and O 
a O 
control O 
were O 
examined O 
in O 
this O 
study O 
using O 
cidofovir B-TRIVIAL 
as O 
the O 
model O 
drug O 
. O 
Drug O 
release O 
from O 
the O 
formulations O 
in O 
the O 
modified O 
diffusion O 
cell O 
system O 
was O 
slower O 
than O 
that O 
in O 
the O 
conventional O 
diffusion O 
cell O 
system O 
due O 
to O 
the O 
decrease O 
in O 
the O 
diffusion O 
surface O 
area O 
of O 
the O 
modified O 
diffusion O 
cell O 
system O 
. O 
The O 
modified O 
diffusion O 
cell O 
system O 
was O 
able O 
to O 
show O 
different O 
drug O 
release O 
behaviors O 
among O 
the O 
formulations O 
and O 
allowed O 
formulation O 
evaluation O 
better O 
than O 
the O 
conventional O 
diffusion O 
cell O 
system O 
. O 
Among O 
the O 
formulations O 
investigated O 
, O 
poly(lactic B-FAMILY 
- I-FAMILY 
co I-FAMILY 
- I-FAMILY 
glycolic I-FAMILY 
acid I-FAMILY 
) I-FAMILY 
- O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
- O 
poly(lactic B-FAMILY 
- I-FAMILY 
co I-FAMILY 
- I-FAMILY 
glycolic I-FAMILY 
acid I-FAMILY 
) I-FAMILY 
triblock O 
copolymer O 
systems O 
provided O 
the O 
longest O 
sustained O 
drug O 
delivery O 
, O 
probably O 
due O 
to O 
their O 
rigid O 
gel O 
structures O 
and O 
/ O 
or O 
polymer-to- O 
cidofovir B-TRIVIAL 
interactions O 
. O 

of O 
Amylose- O 
Polystyrene B-SYSTEMATIC 
Inclusion O 
Complexes O 
by O 
a O 
Facile O 
Preparation O 
Route O 
. O 

formation O 
of O 
amylose- O 
polystyrene B-SYSTEMATIC 
inclusion O 
complexes O 
via O 
a O 
novel O 
two O 
- O 
step O 
approach O 
is O 
described O 
. O 
In O 
the O 
first O 
- O 
step O 
, O 
styrene O 
was O 
inserted O 
inside O 
the O 
amylose O 
helical O 
cavity O 
, O 
followed O 
by O 
free O 
radical O 
polymerization O 
in O 
the O 
second O 
step O 
. O 
The O 
inclusion O 
complexes O 
were O 
characterized O 
by O 
Attenuated O 
Total O 
Reflection O 
Fourier O 
Transform O 
Infrared O 
Spectroscopy O 
( O 
ATR-FTIR O 
) O 
, O 
Ultraviolet O 
Spectroscopy O 
( O 
UV O 
) O 
, O 
X-ray O 
Diffraction O 
( O 
XRD O 
) O 
, O 
Atomic O 
Force O 
Microscopy O 
( O 
AFM O 
) O 
, O 
and O 
Differential O 
Scanning O 
Calorimetry O 
( O 
DSC O 
) O 
. O 
The O 
formation O 
of O 
polystyrene B-SYSTEMATIC 
was O 
confirmed O 
by O 
gel O 
Permeation O 
Chromatography O 
( O 
GPC O 
) O 
. O 
The O 
molecular O 
weight O 
of O 
polystyrene B-SYSTEMATIC 
can O 
be O 
varied O 
by O 
using O 
amylose O 
bearing O 
different O 
molar O 
masses O 
. O 
The O 
approach O 
described O 
here O 
is O 
general O 
and O 
could O 
be O 
used O 
to O 
synthesis O 
other O 
host O 
- O 
polymer O 
inclusion O 
complexes O 
for O 
which O 
long O 
chains O 
of O 
polymeric O 
guests O 
are O 
difficult O 
to O 
insert O 
into O 
the O 
host O 
cavity O 
. O 

of O 
Silver B-SYSTEMATIC 
Octahedra O 
with O 
Controlled O 
Sizes O 
and O 
Optical O 
Properties O 
via O 
Seed O 
- O 
Mediated O 
Growth O 
. O 

octahedra O 
with O 
edge O 
lengths O 
controlled O 
in O 
the O 
range O 
of O 
20-72 O 
nm O 
were O 
synthesized O 
via O 
seed O 
- O 
mediated O 
growth O 
. O 
The O 
key O 
to O 
the O 
success O 
of O 
this O 
synthesis O 
is O 
the O 
use O 
of O 
single O 
- O 
crystal O 
Ag B-FORMULA 
seeds O 
with O 
uniform O 
and O 
precisely O 
controlled O 
sizes O 
to O 
direct O 
the O 
growth O 
and O 
the O 
use O 
of O 
citrate B-FAMILY 
as O 
a O 
selective O 
capping O 
agent O 
for O 
the O 
{ O 
111 O 
} O 
facets O 
. O 
Our O 
mechanistic O 
studies O 
demonstrated O 
that O 
Ag B-FORMULA 
seeds O 
with O 
both O 
cubic O 
and O 
quasi O 
- O 
spherical O 
shapes O 
could O 
evolve O 
into O 
octahedra O 
. O 
For O 
the O 
first O 
time O 
, O 
we O 
were O 
able O 
to O 
precisely O 
control O 
the O 
edge O 
lengths O 
of O 
Ag B-FORMULA 
octahedra O 
below O 
100 O 
nm O 
, O 
and O 
the O 
lower O 
limit O 
of O 
size O 
could O 
even O 
be O 
pushed O 
down O 
to O 
20 O 
nm O 
. O 
Using O 
the O 
as-obtained O 
Ag B-FORMULA 
octahedra O 
as O 
sacrificial O 
templates O 
, O 
Au B-FORMULA 
nanocages O 
with O 
an O 
octahedral O 
shape O 
and O 
precisely O 
tunable O 
optical O 
properties O 
were O 
synthesized O 
through O 
a O 
galvanic O 
replacement O 
reaction O 
. O 
Such O 
hollow O 
nanostructures O 
are O 
promising O 
candidates O 
for O 
a O 
broad O 
range O 
of O 
applications O 
related O 
to O 
optics O 
, O 
catalysis O 
, O 
and O 
biomedicine O 
. O 

Enantioselective O 
Zirconium B-SYSTEMATIC 
-Catalyzed O 
Cyclization O 
of O 
Aminoalkenes B-FAMILY 
. O 

are O 
catalytically O 
cyclized O 
in O 
the O 
presence O 
of O 
cyclopentadienylbis(oxazolinyl)borato B-SYSTEMATIC 
group O 
4 O 
complexes O 
{PhB(C5H4)(Ox(R))2}M(NMe2)2 B-FAMILY 
( O 
M O 
= O 
Ti B-FORMULA 
, O 
Zr B-FORMULA 
, O 
Hf B-FORMULA 
; O 
Ox B-ABBREVIATION 
( I-ABBREVIATION 
R I-ABBREVIATION 
) I-ABBREVIATION 
= O 
4,4-dimethyl-2-oxazoline B-SYSTEMATIC 
, O 
4S-isopropyl-5,5-dimethyl-2-oxazoline B-SYSTEMATIC 
, O 
4S-tert-butyl-2-oxazoline B-SYSTEMATIC 
) O 
at O 
room O 
temperature O 
and O 
below O 
, O 
affording O 
five- O 
, O 
six- O 
, O 
and O 
seven O 
- O 
membered O 
N-heterocyclic B-FAMILY 
amines I-FAMILY 
with O 
enantiomeric O 
excesses O 
of O 
> O 
90% O 
in O 
many O 
cases O 
and O 
up O 
to O 
99% O 
. O 
Mechanistic O 
investigations O 
of O 
this O 
highly O 
selective O 
system O 
employed O 
synthetic O 
tests O 
, O 
kinetics O 
, O 
and O 
stereochemistry O 
. O 
Secondary B-SYSTEMATIC 
aminopentene I-SYSTEMATIC 
cyclizations O 
require O 
a O 
primary B-FAMILY 
amine I-FAMILY 
( O 
1-2 O 
equiv O 
vs O 
catalyst O 
) O 
. O 
Aminoalkenes B-FAMILY 
are O 
unchanged O 
in O 
the O 
presence O 
of O 
a O 
zirconium B-SYSTEMATIC 
monoamido I-SYSTEMATIC 
complex O 
{PhB(C5H4)(Ox(4S-iPr,Me2))2}Zr(NMe2)Cl B-FORMULA 
or O 
a O 
cyclopentadienylmono(oxazolinyl)borato B-SYSTEMATIC 
zirconium I-SYSTEMATIC 
diamide I-SYSTEMATIC 
{Ph2B(C5H4)(Ox(4S-iPr,Me2))}Zr(NMe2)2 B-FORMULA 
. O 
Plots O 
of O 
initial O 
rate O 
versus O 
[ O 
substrate O 
] O 
show O 
a O 
rate O 
dependence O 
that O 
evolves O 
from O 
first O 
- O 
order O 
at O 
low O 
concentration O 
to O 
zero O 
- O 
order O 
at O 
high O 
concentration O 
, O 
and O 
this O 
is O 
consistent O 
with O 
a O 
reversible O 
substrate O 
- O 
catalyst O 
interaction O 
preceding O 
an O 
irreversible O 
step O 
. O 
Primary O 
kinetic O 
isotope O 
effects O 
from O 
substrate O 
conversion O 
measurements O 
( O 
k'obs((H)) O 
/ O 
k'obs((D)) O 
= O 
3.3 O 
± O 
0.3 O 
) O 
and O 
from O 
initial O 
rate O 
analysis O 
( O 
k2((H)) O 
/ O 
k2((D)) O 
= O 
2.3 O 
± O 
0.4 O 
) O 
indicate O 
that O 
a O 
N-H B-FORMULA 
bond O 
is O 
broken O 
in O 
the O 
turnover O 
- O 
limiting O 
and O 
irreversible O 
step O 
of O 
the O 
catalytic O 
cycle O 
. O 
Asymmetric O 
hydroamination O 
/ O 
cyclization O 
of O 
N-deutero- B-FAMILY 
aminoalkenes I-FAMILY 
provides O 
products O 
with O 
higher O 
optical O 
purities O 
than O 
obtained O 
with O 
N-proteo- B-FAMILY 
aminoalkenes I-FAMILY 
. O 
Transition O 
state O 
theory O 
, O 
applied O 
to O 
the O 
rate O 
constant O 
k2 O 
that O 
characterizes O 
the O 
irreversible O 
step O 
, O 
provides O 
activation O 
parameters O 
consistent O 
with O 
a O 
highly O 
organized O 
transition O 
state O 
( O 
ΔS(⧧) O 
= O 
-43(7) O 
cal·mol(-1) O 
K(-1) O 
) O 
and O 
a O 
remarkably O 
low O 
enthalpic O 
barrier O 
( O 
ΔH(⧧) O 
= O 
6.7(2) O 
kcal·mol(-1) O 
) O 
. O 
A O 
six O 
- O 
centered O 
, O 
concerted O 
transition O 
state O 
for O 
C-N B-FORMULA 
and O 
C-H B-FORMULA 
bond O 
formation O 
and O 
N-H B-FORMULA 
bond O 
cleavage O 
involving O 
two O 
amidoalkene B-FAMILY 
ligands O 
is O 
proposed O 
as O 
most O 
consistent O 
with O 
the O 
current O 
data O 
. O 

of O 
the O 
biochemical O 
basis O 
for O 
a O 
clinical O 
drug O 
- O 
drug O 
interaction O 
between O 
atorvastatin B-TRIVIAL 
and O 
5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl B-SYSTEMATIC 
benzoic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
CP-778 B-IDENTIFIER 
875 I-IDENTIFIER 
) O 
, O 
a O 
subtype O 
selective O 
agonist O 
of O 
the O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
alpha O 
. O 

1 O 
. O 
5 O 
-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl B-SYSTEMATIC 
benzoic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
C O 
P-778 B-IDENTIFIER 
875 I-IDENTIFIER 
) I-IDENTIFIER 
, O 
an O 
agonist O 
of O 
the O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
alpha O 
, O 
has O 
been O 
evaluated O 
in O 
the O 
clinic O 
to O 
treat O 
dyslipidemia O 
and O 
type O 
2 O 
diabetes O 
mellitus O 
. O 
Herein O 
, O 
we O 
investigate O 
the O 
effect O 
of O 
C O 
P-778 B-IDENTIFIER 
875 I-IDENTIFIER 
on O 
the O 
pharmacokinetics O 
of O 
a O 
torvastatin B-TRIVIAL 
acid I-TRIVIAL 
and O 
its O 
metabolites O 
in O 
humans O 
. O 
2 O 
. O 
The O 
study O 
incorporated O 
a O 
fixed O 
- O 
sequence O 
design O 
conducted O 
in O 
two O 
groups O 
. O 
Group O 
A O 
was O 
designed O 
to O 
estimate O 
the O 
effects O 
of O 
multiple O 
doses O 
of O 
CP O 
-778 B-IDENTIFIER 
875 I-IDENTIFIER 
o I-IDENTIFIER 
n O 
the O 
single O 
dose O 
pharmacokinetics O 
of O 
atorvastatin O 
. O 
Subjects O 
in O 
group O 
A O 
( O 
n O 
= O 
26 O 
) O 
received O 
at O 
orvastatin B-TRIVIAL 
( I-TRIVIAL 
40 O 
mg O 
) O 
on O 
days O 
1 O 
and O 
9 O 
and O 
CP O 
-778 B-IDENTIFIER 
875 I-IDENTIFIER 
( I-IDENTIFIER 
1 O 
mg O 
QD O 
) O 
on O 
days O 
5-12 O 
. O 
Group O 
B O 
was O 
designed O 
to O 
examine O 
the O 
effects O 
of O 
multiple O 
doses O 
of O 
at O 
orvastatin B-TRIVIAL 
o I-TRIVIAL 
n O 
the O 
single O 
dose O 
pharmacokinetics O 
of O 
CP-778 O 
875 O 
. O 
Subjects O 
in O 
group O 
B O 
( O 
n O 
= O 
29 O 
) O 
received O 
CP O 
-778 B-IDENTIFIER 
875 I-IDENTIFIER 
( I-IDENTIFIER 
0.3 O 
mg O 
) O 
on O 
days O 
1 O 
and O 
9 O 
and O 
at O 
orvastatin B-TRIVIAL 
( I-TRIVIAL 
40 O 
mg O 
QD O 
) O 
on O 
days O 
5-12 O 
. O 
3 O 
. O 
Mean O 
maximum O 
serum O 
concentration O 
( O 
Cmax O 
) O 
and O 
area O 
under O 
the O 
curve O 
of O 
ato O 
rvastatin B-TRIVIAL 
we I-TRIVIAL 
re O 
increased O 
by O 
45% O 
and O 
20% O 
, O 
respectively O 
, O 
upon O 
co O 
- O 
administration O 
with O 
CP-778 O 
875 O 
. O 
Statistically O 
significant O 
increases O 
in O 
the O 
systemic O 
exposure O 
of O 
ort O 
ho- B-MULTIPLE 
and I-MULTIPLE 
para-hydroxyatorvastatin I-MULTIPLE 
we I-MULTIPLE 
re O 
also O 
observed O 
upon O 
concomitant O 
dosing O 
with O 
CP-778 O 
875 O 
. O 
CP- O 
778 B-IDENTIFIER 
875 I-IDENTIFIER 
ph I-IDENTIFIER 
armacokinetics O 
, O 
however O 
, O 
were O 
not O 
impacted O 
upon O 
concomitant O 
dosing O 
with O 
atorvastatin O 
. O 
4 O 
. O 
Inhibition O 
of O 
organic O 
anion O 
transporting O 
polypeptide O 
1B1 O 
by O 
CP-7 O 
78 B-IDENTIFIER 
875 I-IDENTIFIER 
( I-IDENTIFIER 
IC I-IDENTIFIER 
50 O 
= O 
2.14 O 
±0.40 O 
μM O 
) O 
could O 
be O 
the O 
dominant O 
cause O 
of O 
the O 
pharmacokinetic O 
interaction O 
as O 
CP-7 O 
78 B-IDENTIFIER 
875 I-IDENTIFIER 
did I-IDENTIFIER 
not O 
exhibit O 
significant O 
inhibition O 
of O 
cytochrome O 
P450 O 
3A4 O 
/ O 
3A5 O 
, O 
multidrug O 
resistant O 
protein O 
1 O 
or O 
breast O 
cancer O 
resistant O 
protein O 
, O 
which O 
are O 
also O 
involved O 
in O 
the O 
hepatobiliary O 
disposition O 
of O 
atorvastatin O 
. O 

determination O 
by O 
LC-MS O 
/ O 
MS O 
of O 
25-methoxydammarane-3β,12β,20-triol B-SYSTEMATIC 
epimers O 
and O 
active O 
metabolites O 
in O 
rat O 
plasma O 
after O 
intravenous O 
administration O 
. O 

1 O 
. O 
The O 
pharmacokinetics O 
of O 
the O 
25-OCH3-PPD B-SYSTEMATIC 
epimers O 
and O 
active O 
metabolites O 
in O 
rat O 
plasma O 
after O 
a O 
single O 
intravenous O 
( O 
i.v O 
. O 
) O 
administration O 
were O 
studied O 
by O 
a O 
rapid O 
, O 
selective O 
and O 
sensitive O 
UPLC-MS O 
/ O 
MS O 
method O 
. O 
2 O 
. O 
Chromatographic O 
separation O 
was O 
performed O 
on O 
an O 
Acquity O 
UPLC O 
with O 
Agela O 
C18 O 
column O 
, O 
and O 
the O 
solvents O 
of O 
5 O 
mM O 
ammonium B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
pH O 
7.8 O 
) O 
- O 
acetonitrile B-SYSTEMATIC 
( O 
65 O 
: O 
35 O 
, O 
v O 
/ O 
v O 
) O 
were O 
used O 
as O 
mobile O 
phase O 
for O 
elution O 
. O 
The O 
quantification O 
was O 
performed O 
with O 
the O 
transitions O 
of O 
m O 
/ O 
z O 
493.5 O 
→ O 
475.5 O 
for O 
20(R,S)-25-OCH3-PPD B-SYSTEMATIC 
, O 
m O 
/ O 
z O 
479.5 O 
→ O 
461.5 O 
for O 
20(R,S)-25-OH-PPD B-SYSTEMATIC 
. O 
The O 
Lower O 
Limit O 
Of O 
Quantitation O 
( O 
LLOQ O 
) O 
was O 
20 O 
ng O 
mL(-1) O 
for O 
20(R,S)-25-OCH3-PPD B-SYSTEMATIC 
, O 
2 O 
ng O 
mL(-1) O 
for O 
20(R,S)-25-OH-PPD B-SYSTEMATIC 
in O 
the O 
plasma O 
samples O 
assay O 
. O 
3 O 
. O 
The O 
pharmacokinetic O 
parameters O 
of O 
AUC O 
, O 
t1 O 
/ O 
2 O 
and O 
MRT O 
had O 
no O 
difference O 
between O 
20(R)- B-MULTIPLE 
and I-MULTIPLE 
(S)-25-OCH3-PPD I-MULTIPLE 
, O 
but O 
S-epimer O 
has O 
a O 
lower O 
plasma O 
clearance O 
compared O 
to O 
the O 
R- O 
isomer O 
. O 
The O 
active O 
metabolite O 
20(S)-25-OH-PPD B-SYSTEMATIC 
showed O 
significantly O 
higher O 
AUC O 
, O 
MRT O 
and O 
a O 
longer O 
half O 
- O 
life O 
than O 
that O 
of O 
20(R)-25-OH-PPD B-SYSTEMATIC 
. O 
These O 
assay O 
results O 
are O 
necessary O 
for O 
the O 
evaluation O 
of O 
the O 
pharmacokinetic O 
behavior O 
of O 
25-methoxydammarane-3β,12β,20-triol B-SYSTEMATIC 
in O 
vivo O 
. O 

memory O 
deficits O 
in O 
maternal O 
iron B-SYSTEMATIC 
deficiency O 
paradigms O 
are O 
associated O 
with O 
altered O 
glucocorticoid O 
levels O 
. O 

The O 
goal O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
effect O 
of O 
maternal O 
iron B-SYSTEMATIC 
deficiency O 
on O 
the O 
developing O 
hippocampus O 
in O 
order O 
to O 
define O 
a O 
developmental O 
window O 
for O 
this O 
effect O 
, O 
and O 
to O 
see O 
whether O 
iron B-SYSTEMATIC 
deficiency O 
causes O 
changes O 
in O 
glucocorticoid O 
levels O 
. O 
The O 
study O 
was O 
carried O 
out O 
using O 
pre O 
- O 
natal O 
, O 
post O 
- O 
natal O 
, O 
and O 
pre O 
+ O 
post O 
- O 
natal O 
iron B-SYSTEMATIC 
deficiency O 
paradigm O 
. O 
Iron B-SYSTEMATIC 
deficient O 
pregnant O 
dams O 
and O 
their O 
pups O 
displayed O 
elevated O 
corticosterone B-TRIVIAL 
which O 
, O 
in O 
turn O 
, O 
differentially O 
affected O 
glucocorticoid O 
receptor O 
( O 
GR O 
) O 
expression O 
in O 
the O 
CA1 O 
and O 
the O 
dentate O 
gyrus O 
. O 
Brain O 
Derived O 
Neurotrophic O 
Factor O 
( O 
BDNF O 
) O 
was O 
reduced O 
in O 
the O 
hippocampi O 
of O 
pups O 
following O 
elevated O 
corticosterone B-TRIVIAL 
levels O 
. O 
Reduced O 
neurogenesis O 
at O 
P7 O 
was O 
seen O 
in O 
pups O 
born O 
to O 
iron B-SYSTEMATIC 
deficient O 
mothers O 
, O 
and O 
these O 
pups O 
had O 
reduced O 
numbers O 
of O 
hippocampal O 
pyramidal O 
and O 
granule O 
cells O 
as O 
adults O 
. O 
Hippocampal O 
subdivision O 
volumes O 
also O 
were O 
altered O 
. O 
The O 
structural O 
and O 
molecular O 
defects O 
in O 
the O 
pups O 
were O 
correlated O 
with O 
radial O 
arm O 
maze O 
performance O 
; O 
reference O 
memory O 
function O 
was O 
especially O 
affected O 
. O 
Pups O 
from O 
dams O 
that O 
were O 
iron B-SYSTEMATIC 
deficient O 
throughout O 
pregnancy O 
and O 
lactation O 
displayed O 
the O 
complete O 
spectrum O 
of O 
defects O 
, O 
while O 
pups O 
from O 
dams O 
that O 
were O 
iron B-SYSTEMATIC 
deficient O 
only O 
during O 
pregnancy O 
or O 
during O 
lactation O 
displayed O 
subsets O 
of O 
defects O 
. O 
These O 
findings O 
show O 
that O 
maternal O 
iron B-SYSTEMATIC 
deficiency O 
is O 
associated O 
with O 
altered O 
levels O 
of O 
corticosterone B-TRIVIAL 
and O 
GR O 
expression O 
, O 
and O 
with O 
spatial O 
memory O 
deficits O 
in O 
their O 
pups O 
. O 
" O 

investigation O 
of O 
the O 
effect O 
of O 
thiamine B-SYSTEMATIC 
pyrophosphate I-SYSTEMATIC 
on O 
cisplatin B-TRIVIAL 
-induced O 
oxidative O 
stress O 
and O 
DNA O 
damage O 
in O 
rat O 
brain O 
tissue O 
compared O 
with O 
thiamine B-TRIVIAL 
: O 
Thiamine B-TRIVIAL 
and O 
thiamine B-SYSTEMATIC 
pyrophosphate I-SYSTEMATIC 
effects O 
on O 
cisplatin B-TRIVIAL 
neurotoxicity O 
. O 

study O 
investigated O 
the O 
effects O 
of O 
thiamine B-SYSTEMATIC 
pyrophosphate I-SYSTEMATIC 
( O 
TPP B-ABBREVIATION 
) O 
at O 
dosages O 
of O 
10 O 
and O 
20 O 
mg O 
/ O 
kg O 
on O 
oxidative O 
stress O 
induced O 
in O 
rat O 
brain O 
tissue O 
with O 
cisplatin B-TRIVIAL 
and O 
compared O 
this O 
with O 
thiamine B-TRIVIAL 
. O 
Cisplatin B-TRIVIAL 
neurotoxicity O 
represents O 
one O 
of O 
the O 
main O 
restrictions O 
on O 
the O 
drug O 
being O 
given O 
in O 
effective O 
doses O 
. O 
Oxidative O 
stress O 
is O 
considered O 
responsible O 
for O 
cisplatin B-TRIVIAL 
toxicity O 
. O 
Our O 
results O 
showed O 
that O 
cisplatin B-TRIVIAL 
increased O 
the O 
levels O 
of O 
oxidant O 
parameters O 
such O 
as O 
lipid O 
peroxidation O 
( O 
thio B-SYSTEMATIC 
barbituric I-SYSTEMATIC 
acid I-SYSTEMATIC 
reactive O 
substance O 
( O 
TBARS O 
) O 
) O 
and O 
myeloperoxidase O 
( O 
MPO O 
) O 
in O 
brain O 
tissue O 
and O 
suppressed O 
the O 
effects O 
of O 
antioxidants O 
such O 
as O 
total O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
and O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
. O 
TPP B-ABBREVIATION 
, O 
especially O 
at O 
a O 
dosage O 
of O 
20 O 
mg O 
/ O 
kg O 
, O 
significantly O 
reduced O 
TBARS O 
and O 
MPO O 
levels O 
that O 
increase O 
with O 
cisplatin B-TRIVIAL 
administration O 
compared O 
with O 
the O 
thiamine B-TRIVIAL 
group O 
, O 
while O 
TPP B-ABBREVIATION 
significantly O 
increases O 
GSH B-ABBREVIATION 
and O 
SOD O 
levels O 
. O 
In O 
addition O 
, O 
the O 
level O 
of O 
8-Gua B-SYSTEMATIC 
( O 
guanine B-TRIVIAL 
) O 
, O 
a O 
product O 
of O 
DNA O 
damage O 
, O 
was O 
1.7 O 
± O 
0.12 O 
8-hydroxyl B-SYSTEMATIC 
guanine I-SYSTEMATIC 
( O 
8-OH B-SYSTEMATIC 
Gua I-SYSTEMATIC 
) O 
/ O 
105 O 
Gua B-ABBREVIATION 
in O 
brain O 
tissue O 
in O 
the O 
control O 
group O 
receiving O 
cisplatin B-TRIVIAL 
, O 
compared O 
with O 
0.97 O 
± O 
0.03 O 
8-OH O 
Gua B-ABBREVIATION 
/ O 
105 O 
Gua B-ABBREVIATION 
in O 
the O 
thiamine B-SYSTEMATIC 
pyrophosphate I-SYSTEMATIC 
( O 
20 O 
mg O 
/ O 
kg O 
) O 
group O 
and O 
1.55 O 
± O 
0.11 O 
8-OH B-SYSTEMATIC 
Gua I-SYSTEMATIC 
/ O 
105 O 
Gua B-ABBREVIATION 
in O 
the O 
thiamine B-TRIVIAL 
( O 
20 O 
mg O 
/ O 
kg O 
) O 
group O 
. O 
These O 
results O 
show O 
that O 
thiamine B-SYSTEMATIC 
pyrophosphate I-SYSTEMATIC 
significantly O 
prevents O 
oxidative O 
damage O 
induced O 
by O 
cisplatin B-TRIVIAL 
in O 
brain O 
tissue O 
, O 
while O 
the O 
protective O 
effect O 
of O 
thiamine B-TRIVIAL 
is O 
insignificant O 
. O 

of O 
subacute O 
exposure O 
to O 
silver B-SYSTEMATIC 
nanoparticle O 
on O 
some O 
hematological O 
and O 
plasma O 
biochemical O 
indices O 
in O 
silver B-SYSTEMATIC 
carp O 
( O 
Hypophthalmichthys O 
molitrix O 
) O 
. O 

use O 
of O 
silver B-SYSTEMATIC 
nanoparticles O 
( O 
Ag B-FORMULA 
-NPs O 
) O 
is O 
rapidly O 
increasing O 
, O 
but O 
there O 
are O 
limited O 
data O 
on O 
their O 
effects O 
on O 
the O 
aquatic O 
environment O 
. O 
The O 
present O 
study O 
aimed O 
to O 
determine O 
the O 
acute O 
toxicity O 
and O 
evaluate O 
the O 
effect O 
of O 
subacute O 
concentrations O 
of O 
Ag B-FORMULA 
-NPs O 
( O 
Nanocid B-TRIVIAL 
® O 
: O 
average O 
particle O 
size O 
of O 
61 O 
nm O 
) O 
on O 
hematological O 
and O 
plasma O 
biochemical O 
indices O 
of O 
silver B-SYSTEMATIC 
carp O 
, O 
Hypophthalmichthys O 
molitrix O 
, O 
after O 
3 O 
, O 
7 O 
and O 
14 O 
days O 
. O 
The O 
24- O 
, O 
48- O 
, O 
72- O 
and O 
96-h O 
median O 
lethal O 
concentration O 
( O 
LC50 O 
) O 
values O 
of O 
Nanocid B-TRIVIAL 
for O 
silver B-SYSTEMATIC 
carp O 
were O 
estimated O 
at O 
0.81 O 
, O 
0.648 O 
, O 
0.383 O 
and O 
0.202 O 
mg O 
/ O 
L O 
, O 
respectively O 
; O 
20% O 
and O 
10% O 
of O 
the O 
96-h O 
LC50 O 
values O 
( O 
0.04 O 
and O 
0.02 O 
mg O 
/ O 
L O 
) O 
were O 
selected O 
for O 
subacute O 
study O 
. O 
Red O 
blood O 
cell O 
( O 
RBC O 
) O 
count O 
, O 
hemoglobin O 
( O 
Hb O 
) O 
count O 
and O 
hematocrit O 
( O 
Hct O 
) O 
level O 
were O 
significantly O 
reduced O 
at O 
both O 
concentrations O 
tested O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
White O 
blood O 
cell O 
( O 
WBC O 
) O 
, O 
mean O 
corpuscular O 
hemoglobin O 
( O 
MCH O 
) O 
, O 
mean O 
corpuscular O 
hemoglobin O 
concentration O 
( O 
MCHC O 
) O 
, O 
cortisol B-TRIVIAL 
and O 
glucose B-TRIVIAL 
levels O 
in O 
Nanocid B-TRIVIAL 
-treated O 
groups O 
were O 
significantly O 
higher O 
than O 
the O 
controlled O 
group O 
at O 
experimental O 
periods O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
In O 
conclusion O 
, O 
Ag B-FORMULA 
-NPs O 
intoxication O 
resulted O 
in O 
erythrocyte O 
reduction O 
, O 
hematological O 
disturbances O 
, O 
leucocytosis O 
and O 
stress O 
response O 
in O 
silver B-SYSTEMATIC 
carp O 
and O 
offered O 
a O 
simple O 
tool O 
to O 
evaluate O 
toxicity O 
- O 
derived O 
alterations O 
. O 

or O 
late O 
- O 
onset O 
congenital O 
adrenal O 
hyperplasia O 
( O 
NCAH O 
) O 
due O 
to O 
21-hydroxylase O 
deficiency O 
is O 
one O 
of O 
the O 
most O 
common O 
autosomal O 
recessive O 
disorders O 
. O 
Reported O 
prevalence O 
is O 
approximately O 
1 O 
in O 
1000 O 
. O 
Affected O 
individuals O 
typically O 
present O 
due O 
to O 
signs O 
and O 
symptoms O 
of O 
androgen B-FAMILY 
excess O 
. O 
The O 
purpose O 
of O 
this O 
review O 
is O 
to O 
provide O 
current O 
information O 
regarding O 
the O 
pathophysiology O 
, O 
molecular O 
genetics O 
, O 
and O 
management O 
of O 
this O 
common O 
disorder O 
. O 
The O 
treatment O 
of O 
NCAH O 
needs O 
to O 
be O 
directed O 
towards O 
the O 
symptoms O 
. O 
For O 
affected O 
children O 
, O 
goals O 
of O 
treatment O 
include O 
normal O 
linear O 
growth O 
velocity O 
, O 
normal O 
rate O 
of O 
skeletal O 
maturation O 
, O 
" O 
on O 
- O 
time O 
" O 
puberty O 
. O 
For O 
affected O 
adolescent O 
and O 
adult O 
women O 
, O 
goals O 
of O 
treatment O 
include O 
regular O 
menstrual O 
cycles O 
, O 
prevention O 
or O 
progression O 
of O 
hirsutism O 
and O 
acne O 
, O 
and O 
fertility O 
. O 
Treatment O 
needs O 
to O 
be O 
individualized O 
and O 
should O 
not O 
be O 
initiated O 
merely O 
to O 
decrease O 
abnormally O 
elevated O 
hormone O 
concentrations O 
. O 

pathways O 
such O 
as O 
cAMP B-ABBREVIATION 
modulate O 
clothianidin B-TRIVIAL 
action O 
through O 
activation O 
of O 
alpha-bungarotoxin O 
- O 
sensitive O 
and O 
-insensitive O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
. O 

is O 
a O 
neonicotinoid O 
insecticide O 
developed O 
in O 
the O 
early O 
2000s O 
. O 
We O 
have O 
recently O 
demonstrated O 
that O 
it O 
was O 
a O 
full O 
agonist O 
of O 
α-bungarotoxin- O 
sensitive O 
and O 
-insensitive O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
expressed O 
in O 
the O 
cockroach O 
dorsal O 
unpaired O 
median O 
neurons O 
. O 
Clothianidin B-TRIVIAL 
was O 
able O 
to O 
act O 
as O 
an O 
agonist O 
of O 
imidacloprid B-TRIVIAL 
-insensitive O 
nAChR2 O 
receptor O 
and O 
internal O 
regulation O 
of O 
cAMP B-ABBREVIATION 
concentration O 
modulated O 
nAChR2 O 
sensitivity O 
to O 
clothianidin B-TRIVIAL 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
demonstrated O 
that O 
cAMP B-ABBREVIATION 
modulated O 
the O 
agonist O 
action O 
of O 
clothianidin B-TRIVIAL 
via O 
α-bungarotoxin- O 
sensitive O 
and O 
insensitive O 
receptors O 
. O 
Clothianidin B-TRIVIAL 
-induced O 
current-voltage O 
curves O 
were O 
dependent O 
to O 
clothianidin B-TRIVIAL 
concentrations O 
. O 
At O 
10μM O 
clothianidin B-TRIVIAL 
, O 
increasing O 
cAMP B-ABBREVIATION 
concentration O 
induced O 
a O 
linear O 
current-voltage O 
curve O 
. O 
Clothianidin B-TRIVIAL 
effects O 
were O 
blocked O 
by O 
0.5μM O 
α-bungarotoxin O 
suggesting O 
that O 
cAMP B-ABBREVIATION 
modulation O 
occurred O 
through O 
α-bungarotoxin- O 
sensitive O 
receptors O 
. O 
At O 
1mM O 
clothianidin B-TRIVIAL 
, O 
cAMP B-ABBREVIATION 
effects O 
were O 
associated O 
to O 
α-bungarotoxin- O 
insensitive O 
receptors O 
because O 
clothianidin B-TRIVIAL 
-induced O 
currents O 
were O 
blocked O 
by O 
5μM O 
mecamylamine B-TRIVIAL 
and O 
20μM O 
d-tubocurarine B-TRIVIAL 
. O 
In O 
addition O 
, O 
we O 
found O 
that O 
application O 
of O 
1mM O 
clothianidin B-TRIVIAL 
induced O 
a O 
strong O 
increase O 
of O 
intracellular O 
calcium B-SYSTEMATIC 
concentration O 
. O 
These O 
data O 
reinforced O 
the O 
finding O 
that O 
calcium B-SYSTEMATIC 
pathways O 
including O 
cAMP B-ABBREVIATION 
modulated O 
clothianidin B-TRIVIAL 
action O 
on O 
insect O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
. O 
We O 
proposed O 
that O 
intracellular O 
calcium B-SYSTEMATIC 
pathways O 
such O 
as O 
cAMP B-ABBREVIATION 
could O 
be O 
a O 
target O 
to O 
modulate O 
the O 
mode O 
of O 
action O 
of O 
neonicotinoid O 
insecticides O 
. O 

effects O 
of O 
Glycyrrhizic B-TRIVIAL 
acid I-TRIVIAL 
exerts O 
anti-asthmatic O 
effects O 
via O 
modulation O 
of O 
Th1 O 
/ O 
Th2 O 
cytokines O 
and O 
enhancement O 
of O 
CD4(+)CD25(+)Foxp3(+) O 
regulatory O 
T O 
cells O 
in O 
ovalbumin O 
- O 
sensitized O 
mice O 
. O 

RELEVANCE O 
: O 
Glycyrrhizic B-TRIVIAL 
acid I-TRIVIAL 
( O 
GA O 
) O 
is O 
the O 
main O 
bioactive O 
ingredient O 
of O 
licorice O 
( O 
Glycyrrhiza O 
glabra O 
) O 
, O 
and O 
has O 
been O 
found O 
to O 
be O 
associated O 
with O 
multiple O 
therapeutic O 
properties O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
In O 
this O 
study O 
, O 
we O 
investigated O 
immunoregulatory O 
effects O 
of O 
glycyrrhizic B-TRIVIAL 
acid I-TRIVIAL 
on O 
anti-asthmatic O 
effects O 
and O 
underlying O 
mechanisms O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Asthma O 
model O 
was O 
established O 
by O 
ovalbumin O 
- O 
induced O 
. O 
A O 
total O 
of O 
60 O 
mice O 
were O 
randomly O 
assigned O 
to O 
six O 
experimental O 
groups O 
: O 
control O 
, O 
model O 
, O 
dexamethasone B-TRIVIAL 
( O 
2mg O 
/ O 
kg O 
) O 
and O 
GA O 
( O 
10mg O 
/ O 
kg O 
, O 
20mg O 
/ O 
kg O 
, O 
40mg O 
/ O 
kg O 
) O 
. O 
Airway O 
resistance O 
( O 
Raw O 
) O 
were O 
measured O 
by O 
the O 
forced O 
oscillation O 
technique O 
, O 
histological O 
studies O 
were O 
evaluated O 
by O 
The O 
hematoxylin B-TRIVIAL 
and O 
eosin B-FAMILY 
( O 
HE O 
) O 
staining O 
, O 
Th1 O 
/ O 
Th2 O 
and O 
Th17 O 
cytokines O 
were O 
evaluated O 
by O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
( O 
ELISA O 
) O 
, O 
and O 
CD4(+)CD25(+)Foxp3(+) O 
regulatory O 
T O 
cells O 
( O 
Tregs O 
) O 
was O 
evaluated O 
by O 
Flow O 
Cytometry O 
( O 
FCM O 
) O 
, O 
the O 
forkhead O 
/ O 
winged O 
helix O 
transcription O 
factor O 
( O 
Foxp3 O 
) O 
was O 
evaluated O 
by O 
western O 
blotting O 
. O 
RESULTS O 
: O 
Our O 
study O 
demonstrated O 
that O 
, O 
compared O 
with O 
model O 
group O 
, O 
GA O 
inhibited O 
OVA-induced O 
increases O 
in O 
Raw O 
and O 
eosinophil O 
count O 
; O 
interleukin O 
(IL)-4 O 
, O 
IL-5 O 
, O 
IL-13 O 
levels O 
were O 
recovered O 
in O 
bronchoalveolar O 
lavage O 
fluid O 
compared O 
; O 
increased O 
IFN-γlevel O 
in O 
bronchoalveolar O 
lavage O 
fluid O 
; O 
histological O 
studies O 
demonstrated O 
that O 
GA O 
substantially O 
inhibited O 
OVA-induced O 
eosinophilia O 
in O 
lung O 
tissue O 
and O 
airway O 
tissue O 
compared O 
with O 
model O 
group O 
. O 
Flow O 
cytometry O 
studies O 
demonstrated O 
that O 
GA O 
substantially O 
enhanced O 
Tregs O 
compared O 
with O 
model O 
group O 
. O 
CONCLUSION O 
: O 
These O 
findings O 
suggest O 
that O 
GA O 
may O 
effectively O 
ameliorate O 
the O 
progression O 
of O 
asthma O 
and O 
could O 
be O 
used O 
as O 
a O 
therapy O 
for O 
patients O 
with O 
allergic O 
asthma O 
. O 

structure O 
analysis O 
of O 
multistate O 
reactivity O 
in O 
transition O 
metal O 
catalyzed O 
reactions O 
: O 
the O 
case O 
of O 
C-H B-FORMULA 
bond O 
activation O 
by O 
non-heme O 
iron(iv)-oxo O 
cores O 
. O 

perspective O 
discusses O 
the O 
principles O 
of O 
the O 
multistate O 
scenario O 
often O 
encountered O 
in O 
transition O 
metal O 
catalyzed O 
reactions O 
, O 
and O 
is O 
organized O 
as O 
follows O 
. O 
First O 
, O 
several O 
important O 
theoretical O 
concepts O 
( O 
physical O 
versus O 
formal O 
oxidation O 
states O 
, O 
orbital O 
interactions O 
, O 
use O 
of O 
( O 
spin O 
) O 
natural O 
and O 
corresponding O 
orbitals O 
, O 
exchange O 
enhanced O 
reactivity O 
and O 
the O 
connection O 
between O 
valence O 
bond O 
and O 
molecular O 
orbital O 
based O 
electronic O 
structure O 
analysis O 
) O 
are O 
presented O 
. O 
These O 
concepts O 
are O 
then O 
used O 
to O 
analyze O 
the O 
electronic O 
structure O 
changes O 
occurring O 
in O 
the O 
reaction O 
of O 
C-H B-FORMULA 
bond O 
oxidation O 
by O 
Fe(IV)oxo B-SYSTEMATIC 
species O 
. O 
The O 
analysis O 
reveals O 
that O 
the O 
energy O 
separation O 
and O 
the O 
overlap O 
between O 
the O 
electron O 
donating O 
orbitals O 
and O 
electron O 
accepting O 
orbitals O 
of O 
the O 
Fe(IV)oxo B-SYSTEMATIC 
complexes O 
dictate O 
the O 
reaction O 
stereochemistry O 
, O 
and O 
that O 
the O 
manner O 
in O 
which O 
the O 
exchange O 
interaction O 
changes O 
depends O 
on O 
the O 
identity O 
of O 
these O 
orbitals O 
. O 
The O 
electronic O 
reorganization O 
of O 
the O 
Fe(IV)oxo B-SYSTEMATIC 
species O 
during O 
the O 
reaction O 
is O 
thoroughly O 
analyzed O 
and O 
it O 
is O 
shown O 
that O 
the O 
Fe(IV)oxo B-SYSTEMATIC 
reactant O 
develops O 
oxyl B-SYSTEMATIC 
radical O 
character O 
, O 
which O 
interacts O 
effectively O 
with O 
the O 
σ O 
CH B-FORMULA 
orbital O 
of O 
the O 
alkane B-FAMILY 
. O 
The O 
factors O 
that O 
determine O 
the O 
energy O 
barrier O 
for O 
the O 
reaction O 
are O 
discussed O 
in O 
terms O 
of O 
molecular O 
orbital O 
and O 
valence O 
bond O 
concepts O 
. O 

principles O 
intensity O 
calculations O 
of O 
the O 
methane B-SYSTEMATIC 
rovibrational O 
spectra O 
in O 
the O 
infrared O 
up O 
to O 
9300 O 
cm(-1.) O 

report O 
global O 
calculations O 
of O 
rovibrational O 
spectra O 
and O 
dipole O 
transition O 
intensities O 
of O 
methane B-SYSTEMATIC 
using O 
our O 
recent O 
ab O 
initio O 
dipole O 
moment O 
and O 
potential O 
surfaces O 
[ O 
Nikitin O 
et O 
al O 
. O 
, O 
Chem O 
. O 
Phys O 
. O 
Lett O 
. O 
, O 
2011 O 
, O 
501 O 
, O 
179 O 
; O 
2013 O 
, O 
565 O 
, O 
5 O 
] O 
. O 
For O 
the O 
full O 
symmetry O 
account O 
, O 
a O 
recently O 
published O 
variational O 
tensor O 
formalism O 
in O 
normal O 
modes O 
[ O 
Rey O 
et O 
al O 
. O 
, O 
J O 
. O 
Chem O 
. O 
Phys O 
. O 
, O 
2012 O 
, O 
136 O 
, O 
244106 O 
] O 
is O 
applied O 
, O 
the O 
convergence O 
of O 
high-J O 
calculations O 
being O 
improved O 
by O 
the O 
use O 
of O 
vibrational O 
eigenfunctions O 
to O 
make O 
a O 
compressed O 
basis O 
set O 
for O 
solving O 
the O 
rovibrational O 
problem O 
. O 
Comparisons O 
of O 
theoretical O 
predictions O 
up O 
to O 
J O 
= O 
25 O 
for O 
various O 
complex O 
polyads O 
of O 
methane B-SYSTEMATIC 
involving O 
strongly O 
coupled O 
vibration O 
- O 
rotation O 
bands O 
support O 
the O 
validity O 
of O 
this O 
new O 
approach O 
. O 
For O 
the O 
first O 
time O 
, O 
positions O 
and O 
line O 
intensities O 
at O 
80 O 
K O 
and O 
296 O 
K O 
are O 
shown O 
to O 
be O 
in O 
excellent O 
agreement O 
with O 
raw O 
experimental O 
data O 
, O 
even O 
for O 
high O 
energy O 
ranges O 
. O 
The O 
theoretical O 
predictions O 
also O 
correctly O 
describe O 
the O 
isotopic O 
effects O 
in O 
line O 
positions O 
and O 
intensities O 
due O 
to O 
the O 
CH4 B-FORMULA 
→ O 
CD4 B-FORMULA 
substitution O 
which O 
is O 
considered O 
as O 
the O 
test O 
for O 
the O 
method O 
. O 
This O 
work O 
is O 
a O 
first O 
step O 
toward O 
the O 
theoretical O 
interpretation O 
of O 
numerous O 
methane B-SYSTEMATIC 
bands O 
which O 
remain O 
still O 
unassigned O 
and O 
detailed O 
line O 
- O 
by O 
- O 
line O 
absorption O 
/ O 
emission O 
spectra O 
analyses O 
for O 
atmospheric O 
and O 
planetological O 
applications O 
. O 

Structural O 
Snapshot O 
of O 
Cytochrome O 
P450 O 
2B4 O 
in O 
Complex O 
with O 
Paroxetine B-TRIVIAL 
Provides O 
Insights O 
into O 
Ligand O 
Binding O 
and O 
Clusters O 
of O 
Conformational O 
States O 
. O 

X-ray O 
crystal O 
structure O 
of O 
cytochrome O 
P450 O 
2B4 O 
in O 
complex O 
with O 
the O 
drug O 
paroxetine B-TRIVIAL 
was O 
solved O 
at O 
2.14 O 
Å O 
resolution O 
. O 
The O 
structure O 
revealed O 
a O 
conformation O 
intermediate O 
to O 
that O 
of O 
the O 
recently O 
solved O 
complex O 
with O 
amlodipine B-TRIVIAL 
and O 
of O 
the O 
more O 
compact O 
complex O 
with O 
4-(4-chlorophenyl)imidazole B-SYSTEMATIC 
in O 
terms O 
of O 
the O 
placement O 
of O 
the O 
F-G O 
cassette O 
. O 
Moreover O 
, O 
the O 
comparison O 
of O 
the O 
new O 
structure O 
with O 
15 O 
previously O 
solved O 
structures O 
of O 
P450 O 
2B4 O 
revealed O 
some O 
new O 
insights O 
into O 
determinants O 
of O 
active O 
site O 
size O 
and O 
shape O 
. O 
The O 
2B4- O 
paroxetine B-TRIVIAL 
structure O 
is O 
nearly O 
superimposable O 
on O 
a O 
previously O 
solved O 
closed O 
structure O 
in O 
a O 
ligand O 
free O 
state O 
. O 
Despite O 
the O 
overall O 
conformational O 
similarity O 
among O 
multiple O 
closed O 
structures O 
, O 
the O 
active O 
site O 
cavity O 
volume O 
of O 
the O 
paroxetine B-TRIVIAL 
complex O 
is O 
enlarged O 
. O 
Further O 
analysis O 
of O 
the O 
accessible O 
space O 
and O 
binding O 
pocket O 
near O 
the O 
heme O 
reveals O 
a O 
new O 
sub O 
- O 
chamber O 
that O 
resulted O 
from O 
the O 
movement O 
of O 
secondary O 
structural O 
elements O 
and O 
rearrangements O 
of O 
active O 
site O 
side O 
chains O 
. O 
Overall O 
, O 
the O 
results O 
from O 
the O 
comparison O 
of O 
all O 
the O 
16 O 
structures O 
of O 
P450 O 
2B4 O 
demonstrate O 
a O 
cluster O 
of O 
protein O 
conformations O 
that O 
were O 
observed O 
in O 
the O 
presence O 
or O 
absence O 
of O 
various O 
ligands O 
. O 

Selectively O 
Inhibit O 
Human O 
Methionine B-TRIVIAL 
Aminopeptidase-1 O 
in O 
Cells O 
. O 

aminopeptidases O 
( O 
MetAPs O 
) O 
, O 
which O 
remove O 
the O 
initiator O 
methionine B-TRIVIAL 
from O 
nascent O 
peptides O 
, O 
are O 
essential O 
in O 
all O 
organisms O 
. O 
While O 
MetAP2 O 
has O 
been O 
demonstrated O 
to O 
be O 
a O 
therapeutic O 
target O 
for O 
inhibiting O 
angiogenesis O 
in O 
mammals O 
, O 
MetAP1 O 
seems O 
to O 
be O 
vital O 
for O 
cell O 
proliferation O 
. O 
Our O 
earlier O 
efforts O 
identified O 
two O 
structural O 
classes O 
of O 
human O 
MetAP1 O 
(HsMetAP1)-selective O 
inhibitors O 
( O 
1-4 O 
) O 
, O 
but O 
all O 
of O 
them O 
failed O 
to O 
inhibit O 
cellular O 
HsMetAP1 O 
. O 
Using O 
Mn B-FORMULA 
(II) I-FORMULA 
or O 
Zn B-FORMULA 
(II) I-FORMULA 
to O 
activate O 
HsMetAP1 O 
, O 
we O 
found O 
that O 
1-4 O 
could O 
only O 
effectively O 
inhibit O 
purified O 
HsMetAP1 O 
in O 
the O 
presence O 
of O 
physiologically O 
unachievable O 
concentrations O 
of O 
Co B-FORMULA 
(II) I-FORMULA 
. O 
In O 
an O 
effort O 
to O 
seek O 
Co B-FORMULA 
(II) I-FORMULA 
-independent O 
inhibitors O 
, O 
a O 
novel O 
structural O 
class O 
containing O 
a O 
2-(pyridin-2-yl)quinazoline B-SYSTEMATIC 
core O 
has O 
been O 
discovered O 
. O 
Many O 
compounds O 
in O 
this O 
class O 
potently O 
and O 
selectively O 
inhibited O 
HsMetAP1 O 
without O 
Co B-FORMULA 
(II) I-FORMULA 
. O 
Subsequently O 
, O 
we O 
demonstrated O 
that O 
11j O 
, O 
an O 
auxiliary O 
metal O 
- O 
dependent O 
inhibitor O 
, O 
effectively O 
inhibited O 
HsMetAP1 O 
in O 
primary O 
cells O 
. O 
This O 
is O 
the O 
first O 
report O 
that O 
an O 
HsMetAP1-selective O 
inhibitor O 
is O 
effective O 
against O 
its O 
target O 
in O 
cells O 
. O 

present O 
single O 
- O 
ion O 
- O 
channel O 
recordings O 
performed O 
with O 
biomimetic O 
lipid O 
membranes O 
which O 
are O 
directly O 
attached O 
to O 
the O 
surface O 
of O 
a O 
complementary O 
metal B-FAMILY 
- I-FAMILY 
oxide I-FAMILY 
-semiconductor O 
( O 
CMOS O 
) O 
preamplifier O 
chip O 
. O 
With O 
this O 
system O 
we O 
resolve O 
single O 
- O 
channel O 
currents O 
from O 
several O 
types O 
of O 
bacterial O 
ion O 
channels O 
, O 
including O 
fluctuations O 
of O 
a O 
single O 
alamethicin O 
channel O 
at O 
a O 
bandwidth O 
of O 
1 O 
MHz O 
which O 
represent O 
the O 
fastest O 
single O 
- O 
ion O 
- O 
channel O 
recordings O 
reported O 
to O 
date O 
. O 
The O 
platform O 
is O 
also O 
used O 
for O 
high O 
- O 
resolution O 
α-hemolysin O 
nanopore O 
recordings O 
. O 
These O 
results O 
illustrate O 
the O 
high O 
signal O 
fidelity O 
, O 
fine O 
temporal O 
resolution O 
, O 
small O 
geometry O 
, O 
and O 
multiplexed O 
integration O 
which O 
can O 
be O 
achieved O 
by O 
leveraging O 
integrated O 
semiconductor O 
platforms O 
for O 
advanced O 
ion O 
channel O 
interfaces O 
. O 

-based O 
Potent O 
and O 
Cell-Active O 
Mps1 O 
Kinase O 
Inhibitors O 
: O 
Rational O 
Design O 
from O 
Pan-Kinase O 
Inhibitor O 
Anthrapyrazolone B-TRIVIAL 
( O 
SP600125 B-IDENTIFIER 
) O 
. O 

spindle O 
1 O 
( O 
Mps1 O 
) O 
is O 
essential O 
for O 
centrosome O 
duplication O 
, O 
the O 
spindle O 
assembly O 
check O 
point O 
, O 
and O 
the O 
maintenance O 
of O 
chromosomal O 
instability O 
. O 
Mps1 O 
is O 
highly O 
expressed O 
in O 
cancer O 
cells O 
, O 
and O 
its O 
expression O 
levels O 
correlate O 
with O 
the O 
histological O 
grades O 
of O 
cancers O 
. O 
Thus O 
, O 
selective O 
Mps1 O 
inhibitors O 
offer O 
an O 
attractive O 
opportunity O 
for O 
the O 
development O 
of O 
novel O 
cancer O 
therapies O 
. O 
To O 
design O 
novel O 
Mps1 O 
inhibitors O 
, O 
we O 
utilized O 
the O 
pan O 
- O 
kinase O 
inhibitor O 
anthrapyrazolone B-TRIVIAL 
( O 
4 O 
, O 
SP600125 B-IDENTIFIER 
) O 
and O 
its O 
crystal O 
structure O 
bound O 
to O 
JNK1 O 
. O 
Our O 
design O 
efforts O 
led O 
to O 
the O 
identification O 
of O 
indazole B-SYSTEMATIC 
-based O 
lead O 
6 O 
with O 
an O 
Mps1 O 
IC50 O 
value O 
of O 
498 O 
nM O 
. O 
Optimization O 
of O 
the O 
3- O 
and O 
6- O 
positions O 
on O 
the O 
indazole B-SYSTEMATIC 
core O 
of O 
6 O 
resulted O 
in O 
23c O 
with O 
improved O 
Mps1 O 
activity O 
( O 
IC50 O 
= O 
3.06 O 
nM O 
) O 
. O 
Finally O 
, O 
application O 
of O 
structure O 
- O 
based O 
design O 
using O 
the O 
X-ray O 
structure O 
of O 
23d O 
bound O 
to O 
Mps1 O 
culminated O 
in O 
the O 
discovery O 
of O 
32a O 
and O 
32b O 
with O 
improved O 
potency O 
for O 
cellular O 
Mps1 O 
and O 
A549 O 
lung O 
cancer O 
cells O 
. O 
Moreover O 
, O 
32a O 
and O 
32b O 
exhibited O 
reasonable O 
selectivities O 
over O 
120 O 
and O 
166 O 
kinases O 
, O 
respectively O 
. O 

ability O 
to O 
three O 
- O 
dimensionally O 
interweave O 
biological O 
tissue O 
with O 
functional O 
electronics O 
could O 
enable O 
the O 
creation O 
of O 
bionic O 
organs O 
possessing O 
enhanced O 
functionalities O 
over O 
their O 
human O 
counterparts O 
. O 
Conventional O 
electronic O 
devices O 
are O 
inherently O 
two O 
- O 
dimensional O 
, O 
preventing O 
seamless O 
multidimensional O 
integration O 
with O 
synthetic O 
biology O 
, O 
as O 
the O 
processes O 
and O 
materials O 
are O 
very O 
different O 
. O 
Here O 
, O 
we O 
present O 
a O 
novel O 
strategy O 
for O 
overcoming O 
these O 
difficulties O 
via O 
additive O 
manufacturing O 
of O 
biological O 
cells O 
with O 
structural O 
and O 
nanoparticle O 
derived O 
electronic O 
elements O 
. O 
As O 
a O 
proof O 
of O 
concept O 
, O 
we O 
generated O 
a O 
bionic O 
ear O 
via O 
3D O 
printing O 
of O 
a O 
cell O 
- O 
seeded O 
hydrogel O 
matrix O 
in O 
the O 
anatomic O 
geometry O 
of O 
a O 
human O 
ear O 
, O 
along O 
with O 
an O 
intertwined O 
conducting O 
polymer O 
consisting O 
of O 
infused O 
silver B-SYSTEMATIC 
nanoparticles O 
. O 
This O 
allowed O 
for O 
in O 
vitro O 
culturing O 
of O 
cartilage O 
tissue O 
around O 
an O 
inductive O 
coil O 
antenna O 
in O 
the O 
ear O 
, O 
which O 
subsequently O 
enables O 
readout O 
of O 
inductively O 
- O 
coupled O 
signals O 
from O 
cochlea O 
- O 
shaped O 
electrodes O 
. O 
The O 
printed O 
ear O 
exhibits O 
enhanced O 
auditory O 
sensing O 
for O 
radio O 
frequency O 
reception O 
, O 
and O 
complementary O 
left O 
and O 
right O 
ears O 
can O 
listen O 
to O 
stereo O 
audio O 
music O 
. O 
Overall O 
, O 
our O 
approach O 
suggests O 
a O 
means O 
to O 
intricately O 
merge O 
biologic O 
and O 
nanoelectronic O 
functionalities O 
via O 
3D O 
printing O 
. O 

and O 
biological O 
evaluation O 
of O 
(68)Ga B-SYSTEMATIC 
labeled I-SYSTEMATIC 
bis-DOTA I-SYSTEMATIC 
- O 
3,3'-(benzylidene)-bis-(1H-indole-2-carbohydrazide) B-SYSTEMATIC 
as O 
a O 
PET O 
tracer O 
for O 
in O 
vivo O 
visualization O 
of O 
necrosis O 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
develop O 
a O 
(68)Ga B-SYSTEMATIC 
labeled I-SYSTEMATIC 
bis-DOTA I-SYSTEMATIC 
derivative O 
of O 
benzylidene-bis-indole B-SYSTEMATIC 
and O 
compare O 
the O 
in O 
vivo O 
stability O 
and O 
biodistribution O 
with O 
that O 
of O 
the O 
previously O 
reported O 
bis-DTPA B-ABBREVIATION 
derivate O 
for O 
in O 
vivo O 
imaging O 
of O 
necrosis O 
using O 
PET O 
. O 
Uptake O 
of O 
the O 
tracer O 
was O 
evaluated O 
in O 
a O 
mouse O 
model O 
of O 
Fas O 
- O 
mediated O 
hepatic O 
apoptosis O 
in O 
correlation O 
with O 
histochemical O 
stainings O 
. O 
The O 
novel O 
(68)Ga B-FORMULA 
labeled O 
tracer O 
showed O 
an O 
improved O 
in O 
vivo O 
stability O 
and O 
could O 
therefore O 
be O 
used O 
for O 
selective O 
non-invasive O 
imaging O 
of O 
necrotic O 
cell O 
death O 
using O 
PET O 
. O 

craving O 
and O 
withdrawal O 
symptoms O 
during O 
temporary O 
abstinence O 
and O 
the O 
effect O 
of O 
nicotine B-TRIVIAL 
gum O 
. O 

: O 
It O 
is O 
widely O 
believed O 
that O 
nicotine B-TRIVIAL 
withdrawal O 
symptoms O 
appear O 
within O 
a O 
few O 
hours O 
of O 
stopping O 
smoking O 
, O 
but O 
few O 
data O 
exist O 
documenting O 
their O 
emergence O 
in O 
naturalistic O 
settings O 
. O 
In O 
several O 
countries O 
, O 
nicotine B-TRIVIAL 
replacement O 
products O 
are O 
licensed O 
for O 
relief O 
of O 
withdrawal O 
symptoms O 
during O 
temporary O 
abstinence O 
, O 
but O 
again O 
, O 
there O 
are O 
no O 
data O 
supporting O 
this O 
from O 
naturalistic O 
settings O 
. O 
OBJECTIVES O 
: O 
To O 
examine O 
the O 
emergence O 
of O 
cigarette O 
craving O 
and O 
withdrawal O 
symptoms O 
during O 
temporary O 
abstinence O 
in O 
a O 
naturalistic O 
setting O 
while O 
using O 
either O 
nicotine B-TRIVIAL 
or O 
placebo O 
gum O 
. O 
METHODS O 
: O 
Double O 
- O 
blind O 
, O 
randomised O 
, O 
placebo O 
- O 
controlled O 
study O 
in O 
which O 
132 O 
dependent O 
smokers O 
abstained O 
for O 
6 O 
h O 
with O 
the O 
assistance O 
of O 
either O 
nicotine B-TRIVIAL 
( O 
2 O 
mg O 
, O 
n O 
= O 
42 O 
or O 
4 O 
mg O 
, O 
n O 
= O 
24 O 
) O 
or O 
placebo O 
( O 
n O 
= O 
66 O 
) O 
gum O 
while O 
travelling O 
on O 
a O 
non-smoking O 
train O 
. O 
Outcome O 
measures O 
were O 
ratings O 
of O 
craving O 
and O 
mood O 
withdrawal O 
symptoms O 
prior O 
to O 
treatment O 
and O 
at O 
regular O 
intervals O 
during O 
abstinence O 
. O 
RESULTS O 
: O 
In O 
a O 
multivariate O 
analysis O 
of O 
all O 
symptoms O 
, O 
there O 
was O 
no O 
interaction O 
between O 
treatment O 
and O 
time O 
[ O 
F(21,110) O 
= O 
1.28 O 
, O 
p O 
= O 
0.2 O 
, O 
[ O 
Formula O 
: O 
see O 
text] O 
= O 
0.2 O 
] O 
nor O 
an O 
effect O 
of O 
treatment O 
[ O 
F(7,124) O 
= O 
0.45 O 
, O 
p O 
= O 
0.87 O 
, O 
[ O 
Formula O 
: O 
see O 
text] O 
= O 
0.03 O 
] O 
. O 
There O 
was O 
an O 
effect O 
of O 
time O 
[ O 
F(21,110) O 
= O 
11.59 O 
, O 
p O 
< O 
0.001 O 
, O 
[ O 
Formula O 
: O 
see O 
text] O 
= O 
0.69 O 
) O 
and O 
univariate O 
analyses O 
revealed O 
that O 
the O 
majority O 
of O 
symptoms O 
increased O 
linearly O 
throughout O 
the O 
period O 
of O 
abstinence O 
with O 
detectable O 
onsets O 
typically O 
between O 
the O 
first O 
60 O 
and O 
180 O 
min O 
of O 
abstinence O 
. O 
CONCLUSIONS O 
: O 
Smokers O 
who O 
temporarily O 
abstain O 
in O 
naturalistic O 
settings O 
experience O 
craving O 
and O 
withdrawal O 
symptoms O 
that O 
emerge O 
linearly O 
over O 
the O 
first O 
6 O 
h O 
of O 
abstinence O 
. O 
Changes O 
in O 
craving O 
and O 
several O 
mood O 
withdrawal O 
symptoms O 
can O 
be O 
detected O 
within O 
the O 
first O 
3 O 
h O 
. O 
Nicotine B-TRIVIAL 
gum O 
may O 
not O 
have O 
an O 
acute O 
effect O 
on O 
the O 
development O 
of O 
these O 
symptoms O 
. O 

beta O 
cell O 
function O 
and O 
anti-inflammatory O 
effect O 
after O 
chronic O 
treatment O 
with O 
the O 
dipeptidyl O 
peptidase-4 O 
inhibitor O 
vildagliptin B-TRIVIAL 
in O 
an O 
advanced O 
- O 
aged O 
diet O 
- O 
induced O 
obesity O 
mouse O 
model O 
. O 

/ O 
HYPOTHESIS O 
: O 
Studies O 
have O 
shown O 
that O 
dipeptidyl O 
peptidase-4 O 
( O 
DPP4 O 
) O 
inhibitors O 
stimulate O 
insulin O 
secretion O 
and O 
increase O 
beta O 
cell O 
mass O 
in O 
rodents O 
. O 
However O 
, O 
in O 
these O 
models O 
hyperglycaemia O 
has O 
been O 
induced O 
early O 
on O 
in O 
life O 
and O 
the O 
treatment O 
periods O 
have O 
been O 
short O 
. O 
To O 
explore O 
the O 
long O 
- O 
term O 
effects O 
of O 
DPP4 O 
inhibition O 
on O 
insulin O 
secretion O 
and O 
beta O 
cell O 
mass O 
, O 
we O 
have O 
generated O 
a O 
high O 
- O 
fat O 
diet O 
(HFD)-induced O 
- O 
obesity O 
model O 
in O 
mice O 
of O 
advanced O 
age O 
( O 
10 O 
months O 
old O 
) O 
. O 
METHODS O 
: O 
After O 
1 O 
month O 
of O 
HFD O 
alone O 
, O 
the O 
mice O 
were O 
given O 
the O 
DPP4 O 
inhibitor O 
vildagliptin B-TRIVIAL 
for O 
a O 
further O 
11 O 
months O 
. O 
At O 
multiple O 
time O 
points O 
throughout O 
the O 
study O 
, O 
OGTTs O 
were O 
performed O 
and O 
beta O 
cell O 
area O 
and O 
long O 
- O 
term O 
survival O 
were O 
evaluated O 
. O 
RESULTS O 
: O 
Beta O 
cell O 
function O 
and O 
glucose B-TRIVIAL 
tolerance O 
were O 
significantly O 
improved O 
by O 
vildagliptin B-TRIVIAL 
with O 
both O 
diets O 
. O 
In O 
contrast O 
, O 
in O 
spite O 
of O 
the O 
long O 
treatment O 
period O 
, O 
beta O 
cell O 
area O 
was O 
not O 
significantly O 
different O 
between O 
vildagliptin B-TRIVIAL 
-treated O 
mice O 
and O 
controls O 
. O 
Mice O 
of O 
advanced O 
age O 
chronically O 
fed O 
an O 
HFD O 
displayed O 
clear O 
and O 
extensive O 
pancreatic O 
inflammation O 
and O 
peri O 
- O 
insulitis O 
, O 
mainly O 
formed O 
by O 
CD3-positive O 
T O 
cells O 
, O 
which O 
were O 
completely O 
prevented O 
by O 
vildagliptin B-TRIVIAL 
treatment O 
. O 
Chronic O 
vildagliptin B-TRIVIAL 
treatment O 
also O 
improved O 
survival O 
rates O 
for O 
HFD-fed O 
mice O 
. O 
CONCLUSIONS O 
/ O 
INTERPRETATION O 
: O 
In O 
a O 
unique O 
advanced O 
- O 
aged O 
HFD-induced O 
- O 
obesity O 
mouse O 
model O 
, O 
insulin O 
secretion O 
was O 
improved O 
and O 
the O 
extensive O 
peri O 
- O 
insulitis O 
prevented O 
by O 
chronic O 
DPP4 O 
inhibition O 
. O 
The O 
improved O 
survival O 
rates O 
for O 
obese O 
mice O 
chronically O 
treated O 
with O 
vildagliptin B-TRIVIAL 
suggest O 
that O 
chronic O 
DPP4 O 
inhibition O 
potentially O 
results O 
in O 
additional O 
quality O 
- O 
adjusted O 
life O 
- O 
years O 
for O 
individuals O 
with O 
type O 
2 O 
diabetes O 
, O 
which O 
is O 
the O 
primary O 
goal O 
of O 
any O 
diabetes O 
therapy O 
. O 

, O 
A O 
Platinum B-SYSTEMATIC 
- O 
Acridine B-TRIVIAL 
Anticancer O 
Agent O 
, O 
Lengthens O 
and O 
Aggregates O 
, O 
but O 
does O 
not O 
Stiffen O 
or O 
Soften O 
DNA O 
. O 

used O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
to O 
study O 
the O 
dose O 
- O 
dependent O 
change O 
in O 
conformational O 
and O 
mechanical O 
properties O 
of O 
DNA O 
treated O 
with O 
PT-ACRAMTU B-ABBREVIATION 
( B-FORMULA 
[PtCl(en)(ACRAMTU-S)](NO3)2 I-FORMULA 
, O 
( O 
en O 
= O 
ethane-1,2-diamine B-SYSTEMATIC 
, O 
ACRAMTU B-ABBREVIATION 
= O 
1-[2-(acridin-9-ylamino)ethyl]-1,3-dimethylthiourea B-SYSTEMATIC 
. O 
PT-ACRAMTU B-ABBREVIATION 
is O 
the O 
parent O 
drug O 
of O 
a O 
family O 
of O 
non-classical O 
platinum B-SYSTEMATIC 
-based O 
agents O 
that O 
show O 
potent O 
activity O 
in O 
non-small O 
cell O 
lung O 
cancer O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Its O 
acridine B-TRIVIAL 
moiety O 
intercalates O 
between O 
DNA O 
bases O 
, O 
while O 
the O 
platinum B-SYSTEMATIC 
group O 
forms O 
mono-adducts O 
with O 
DNA O 
bases O 
. O 
AFM O 
images O 
show O 
that O 
PT-ACRAMTU B-ABBREVIATION 
causes O 
some O 
DNA O 
looping O 
and O 
aggregation O 
at O 
drug O 
- O 
to O 
- O 
base O 
pair O 
ratio O 
( O 
r O 
b O 
) O 
of O 
0.1 O 
and O 
higher O 
. O 
Very O 
significant O 
lengthening O 
of O 
the O 
DNA O 
was O 
observed O 
with O 
increasing O 
doses O 
of O 
PT-ACRAMTU B-ABBREVIATION 
, O 
and O 
reached O 
saturation O 
at O 
an O 
r O 
b O 
of O 
0.15 O 
. O 
At O 
r O 
b O 
of O 
0.1 O 
, O 
lengthening O 
was O 
0.6 O 
nm O 
per O 
drug O 
molecule O 
, O 
which O 
is O 
more O 
than O 
one O 
fully O 
stretched O 
base O 
pair O 
stack O 
can O 
accommodate O 
, O 
indicating O 
that O 
ACRAMTU B-ABBREVIATION 
also O 
disturbs O 
the O 
stacking O 
of O 
neighboring O 
base O 
pair O 
stacks O 
. O 
Analysis O 
of O 
the O 
AFM O 
images O 
based O 
on O 
the O 
worm O 
- O 
like O 
chain O 
( O 
WLC O 
) O 
model O 
showed O 
that O 
PT-ACRAMTU B-ABBREVIATION 
did O 
not O 
change O 
the O 
flexibility O 
of O 
( O 
non-aggregated O 
) O 
DNA O 
, O 
despite O 
the O 
extreme O 
lengthening O 
. O 
The O 
persistence O 
length O 
of O 
untreated O 
DNA O 
and O 
DNA O 
treated O 
with O 
PT-ACRAMTU B-ABBREVIATION 
was O 
in O 
the O 
range O 
of O 
49-65 O 
nm O 
. O 
Potential O 
consequences O 
of O 
the O 
perturbations O 
caused O 
by O 
this O 
agent O 
for O 
the O 
recognition O 
and O 
processing O 
of O 
the O 
DNA O 
adducts O 
it O 
forms O 
are O 
discussed O 
. O 

hypothesized O 
that O 
the O 
minor O 
allele O 
of O 
the O 
atrial O 
natriuretic O 
peptide O 
( O 
ANP O 
) O 
genetic O 
variant O 
rs5068 O 
is O 
associated O 
with O 
a O 
favorable O 
cardiometabolic O 
phenotype O 
in O 
a O 
general O 
Mediterranean O 
population.RESEARCH O 
DESIGN O 
AND O 
METHODSWe O 
genotyped O 
a O 
random O 
sample O 
of O 
the O 
residents O 
of O 
Ventimiglia O 
di O 
Sicilia O 
, O 
Sicily O 
, O 
for O 
rs5068.RESULTSGenotype O 
frequencies O 
of O 
rs5068 O 
are O 
AA O 
, O 
93.5% O 
; O 
AG O 
, O 
6.4% O 
; O 
and O 
GG O 
, O 
0.1% O 
. O 
All O 
subsequent O 
analyses O 
are O 
AA O 
versus O 
AG O 
+ O 
GG O 
. O 
After O 
adjusting O 
for O 
age O 
and O 
sex O 
, O 
the O 
minor O 
G O 
allele O 
is O 
associated O 
with O 
lower O 
BMI O 
( O 
estimate O 
[ O 
SE O 
] O 
: O 
-1.7 O 
kg O 
/ O 
m(2) O 
[ O 
0.8 O 
] O 
, O 
P O 
= O 
0.04 O 
) O 
. O 
In O 
the O 
AG O 
+ O 
GG O 
group O 
, O 
males O 
with O 
HDL O 
cholesterol B-TRIVIAL 
levels O 
< O 
40 O 
mg O 
/ O 
dL O 
are O 
less O 
frequent O 
( O 
P O 
= O 
0.05 O 
) O 
and O 
obesity O 
tends O 
to O 
be O 
less O 
prevalent O 
( O 
P O 
= O 
0.07 O 
) O 
. O 
Importantly O 
, O 
the O 
G O 
allele O 
is O 
associated O 
with O 
a O 
lower O 
prevalence O 
of O 
metabolic O 
syndrome O 
( O 
P O 
= O 
0.02 O 
) O 
. O 
After O 
adjusting O 
for O 
BMI O 
, O 
the O 
above O 
associations O 
were O 
attenuated O 
. O 
Independently O 
of O 
age O 
, O 
sex O 
, O 
and O 
BMI O 
, O 
the O 
minor O 
allele O 
is O 
also O 
associated O 
with O 
lower O 
systolic O 
blood O 
pressure O 
( O 
-6 O 
mmHg O 
[ O 
2.5 O 
] O 
, O 
P O 
= O 
0.02 O 
) O 
and O 
lower O 
prevalence O 
of O 
hypertension O 
( O 
odds O 
ratio O 
0.41 O 
[ O 
95% O 
CI O 
0.20-0.83 O 
] O 
, O 
P O 
= O 
0.01).CONCLUSIONSThe O 
association O 
between O 
the O 
minor O 
allele O 
of O 
rs5068 O 
and O 
a O 
favorable O 
cardiometabolic O 
phenotype O 
that O 
we O 
previously O 
reported O 
in O 
a O 
U.S O 
. O 
population O 
is O 
now O 
replicated O 
in O 
a O 
Mediterranean O 
population O 
in O 
which O 
the O 
G O 
allele O 
of O 
rs5068 O 
is O 
associated O 
with O 
lower O 
blood O 
pressure O 
, O 
BMI O 
, O 
and O 
prevalence O 
of O 
hypertension O 
and O 
metabolic O 
syndrome O 
. O 
These O 
findings O 
may O 
lead O 
to O 
a O 
diagnostic O 
strategy O 
to O 
assess O 
cardiometabolic O 
risk O 
and O 
lay O 
the O 
foundation O 
for O 
the O 
future O 
development O 
of O 
an O 
ANP O 
or O 
ANP O 
- O 
like O 
therapy O 
for O 
metabolic O 
syndrome O 
. O 

transfer O 
and O 
Penning O 
ionization O 
of O 
dopants O 
in O 
or O 
on O 
helium B-SYSTEMATIC 
nanodroplets O 
exposed O 
to O 
EUV O 
radiation O 
. O 

nanodroplets O 
are O 
widely O 
used O 
as O 
a O 
cold O 
, O 
weakly O 
interacting O 
matrix O 
for O 
spectroscopy O 
of O 
embedded O 
species O 
. O 
In O 
this O 
work O 
we O 
excite O 
or O 
ionize O 
doped O 
He B-FORMULA 
droplets O 
using O 
synchrotron O 
radiation O 
and O 
study O 
the O 
effect O 
onto O 
the O 
dopant O 
atoms O 
depending O 
on O 
their O 
location O 
inside O 
the O 
droplets O 
( O 
rare O 
gases O 
) O 
or O 
outside O 
at O 
the O 
droplet O 
surface O 
( O 
alkali B-FAMILY 
metals I-FAMILY 
) O 
. O 
Using O 
photoelectron O 
- O 
photoion O 
coincidence O 
imaging O 
spectroscopy O 
at O 
variable O 
photon O 
energies O 
( O 
20-25eV O 
) O 
, O 
we O 
compare O 
the O 
rates O 
of O 
charge O 
- O 
transfer O 
to O 
Penning O 
ionization O 
of O 
the O 
dopants O 
in O 
the O 
two O 
cases O 
. O 
The O 
surprising O 
finding O 
is O 
that O 
alkali B-FAMILY 
metals I-FAMILY 
, O 
in O 
contrast O 
to O 
the O 
rare O 
gases O 
, O 
are O 
efficiently O 
Penning O 
ionized O 
upon O 
excitation O 
of O 
the O 
(n=2)-bands O 
of O 
the O 
host O 
droplets O 
. O 
This O 
indicates O 
rapid O 
migration O 
of O 
the O 
excitation O 
to O 
the O 
droplet O 
surface O 
, O 
followed O 
by O 
relaxation O 
, O 
and O 
eventually O 
energy O 
transfer O 
to O 
the O 
alkali O 
dopants O 
. O 

revision O 
of O 
methyl B-SYSTEMATIC 
tortuoate I-SYSTEMATIC 
D I-SYSTEMATIC 
, O 
a O 
bis-cembranoid B-FAMILY 
from O 
Hainan O 
Sarcophyton O 
tortuosum O 
and O 
its O 
absolute O 
stereochemistry O 
. O 

tortuoate I-SYSTEMATIC 
D I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
together O 
with O 
five O 
other O 
known O 
related O 
bis-cembranoids B-FAMILY 
, O 
was O 
isolated O 
from O 
Hainan O 
soft O 
coral O 
Sarcophyton O 
tortuosum O 
. O 
The O 
structure O 
of O 
methyl B-SYSTEMATIC 
tortuoate I-SYSTEMATIC 
D I-SYSTEMATIC 
( O 
1a O 
) O 
, O 
firstly O 
isolated O 
and O 
reported O 
by O 
Li O 
et O 
al O 
. O 
from O 
the O 
title O 
organism O 
, O 
was O 
corrected O 
as O 
1 O 
by O 
an O 
extensive O 
analysis O 
of O 
its O 
one O 
- O 
dimensional O 
and O 
two O 
- O 
dimensional O 
nuclear O 
magnetic O 
resonance O 
data O 
and O 
by O 
comparison O 
with O 
those O 
reported O 
in O 
the O 
literature O 
. O 
In O 
addition O 
, O 
lobophytone B-TRIVIAL 
K I-TRIVIAL 
( O 
1b O 
) O 
, O 
recently O 
isolated O 
from O 
Hainan O 
soft O 
coral O 
Lobophytum O 
pauciflorum O 
by O 
Lin O 
et O 
al O 
. O 
, O 
was O 
proved O 
to O 
be O 
the O 
same O 
compound O 
as O 
1 O 
and O 
1a O 
. O 
The O 
absolute O 
configuration O 
of O 
1 O 
was O 
determined O 
by O 
comparing O 
its O 
electronic O 
circular O 
dichroism O 
curve O 
with O 
that O 
of O 
co O 
- O 
occurring O 
ximaolide B-TRIVIAL 
A I-TRIVIAL 
( O 
2 O 
) O 
. O 

of O 
p-CREB O 
and O 
phase O 
II O 
detoxifying O 
enzyme O 
system O 
in O 
neuroprotection O 
mediated O 
by O 
the O 
flavonoid O 
calycopterin B-TRIVIAL 
isolated O 
from O 
Dracocephalum O 
kotschyi O 
. O 

: O 
There O 
is O 
an O 
increasing O 
amount O 
of O 
experimental O 
evidence O 
that O 
oxidative O 
stress O 
has O 
a O 
central O 
role O 
in O 
the O 
neuropathology O 
of O 
neurodegenerative O 
diseases O 
. O 
It O 
has O 
been O 
suggested O 
that O 
the O 
loss O 
of O 
cell O 
function O 
results O 
from O 
the O 
increased O 
oxidative O 
damage O 
to O 
proteins O 
and O 
DNA O 
. O 
Herein O 
, O 
we O 
investigated O 
the O 
effect O 
of O 
a O 
natural O 
neuroprotective O 
flavonoid O 
, O 
calycopterin B-TRIVIAL 
, O 
on O 
H2O2 B-FORMULA 
-induced O 
disruption O 
of O 
phase O 
II O 
detoxifying O 
enzyme O 
system O 
and O 
cAMP B-ABBREVIATION 
response O 
element O 
binding O 
protein O 
( O 
CREB O 
) O 
phosphorylation O 
. O 
METHODS O 
: O 
PC12 O 
cells O 
were O 
treated O 
with O 
25 O 
, O 
50 O 
and O 
100μM O 
of O 
calycopterin B-TRIVIAL 
for O 
3h O 
, O 
followed O 
by O 
adding O 
H2O2 B-FORMULA 
( O 
150μM O 
) O 
for O 
24h O 
. O 
The O 
extent O 
of O 
apoptosis O 
was O 
assessed O 
by O 
comet O 
assay O 
. O 
The O 
level O 
of O 
phosphorylated O 
CREB O 
, O 
nuclear O 
factor O 
erythroid O 
2- O 
related O 
factor O 
2 O 
( O 
Nrf2 O 
) O 
, O 
glutamylcysteine B-TRIVIAL 
synthetase O 
( O 
γ-GCS O 
) O 
and O 
heme O 
oxygenase O 
1 O 
( O 
HO-1 O 
) O 
were O 
measured O 
by O 
western O 
blot O 
method O 
. O 
The O 
concentration O 
of O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
was O 
determined O 
in O 
whole O 
cell O 
lysate O 
using O 
dithionitrobenzoic O 
acid O 
method O 
. O 
Superoxide O 
dismutase O 
( O 
SOD O 
) O 
activity O 
was O 
measured O 
by O 
colorimetric O 
assay O 
. O 
RESULT O 
: O 
Morphological O 
analysis O 
of O 
protection O 
induced O 
by O 
calycopterin B-TRIVIAL 
, O 
determined O 
by O 
comet O 
assay O 
, O 
showed O 
that O 
calycopterin B-TRIVIAL 
reduced O 
DNA O 
in O 
tail O 
. O 
We O 
found O 
that O 
H2O2 B-FORMULA 
decreased O 
mitochondrial O 
membrane O 
potential O 
( O 
MMP O 
) O 
, O 
while O 
, O 
calycopterin B-TRIVIAL 
prevented O 
this O 
decrease O 
in O 
MMP O 
in O 
presence O 
of O 
H2O2 B-FORMULA 
. O 
In O 
H2O2 B-FORMULA 
-treated O 
cells O 
, O 
calycopterin B-TRIVIAL 
also O 
suppressed O 
cytochrome O 
C O 
release O 
to O 
cytosol O 
that O 
is O 
necessary O 
for O 
maintaining O 
mitochondrial O 
homeostasis O 
in O 
survived O 
cells O 
. O 
Moreover O 
, O 
calycopterin B-TRIVIAL 
, O 
in O 
presence O 
of O 
H2O2 B-FORMULA 
inhibited O 
the O 
decrease O 
caused O 
by O 
oxidative O 
stress O 
in O 
stress O 
- O 
sensing O 
transcription O 
factors O 
, O 
CREB O 
and O 
Nrf2 O 
, O 
which O 
play O 
an O 
important O 
role O 
in O 
antioxidant O 
capacity O 
of O 
the O 
cell O 
. O 
There O 
was O 
also O 
an O 
increase O 
in O 
γ-GCS O 
and O 
HO-1 O 
levels O 
in O 
calycopterin B-TRIVIAL 
pretreated O 
cells O 
. O 
In O 
the O 
presence O 
of O 
H2O2 B-FORMULA 
, O 
calycopterin B-TRIVIAL 
inhibited O 
decrease O 
in O 
GSH B-ABBREVIATION 
level O 
and O 
SOD O 
activity O 
. O 
CONCLUSION O 
: O 
We O 
provided O 
documentation O 
of O 
neuroprotective O 
effect O 
of O 
a O 
natural O 
flavone O 
, O 
calycopterin B-TRIVIAL 
, O 
against O 
H2O2 B-FORMULA 
-induced O 
oxidative O 
stress O 
in O 
differentiated O 
PC12 O 
cells O 
by O 
modulating O 
the O 
level O 
of O 
CREB O 
phosphorylation O 
and O 
Nrf2 O 
pathway O 
. O 

Conformational O 
Changes O 
in O 
Peroxisome O 
Proliferator-Activated O 
Receptor O 
alpha O 
by O 
a O 
Genetically O 
Encoded O 
Photo- O 
Amino B-FAMILY 
Acid I-FAMILY 
, O 
Cross-Linking O 
, O 
and O 
Mass O 
Spectrometry O 
. O 

cross O 
- O 
linking O 
combined O 
with O 
an O 
enzymatic O 
digestion O 
and O 
mass O 
spectrometric O 
analysis O 
of O 
the O 
reaction O 
products O 
has O 
evolved O 
into O 
an O 
alternative O 
strategy O 
to O 
structurally O 
resolve O 
protein O 
complexes O 
. O 
We O 
investigated O 
conformational O 
changes O 
in O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
α O 
( O 
PPARα O 
) O 
upon O 
ligand O 
binding O 
. O 
Using O 
E O 
. O 
coli O 
cells O 
with O 
a O 
special O 
tRNA O 
/ O 
aminoacyl-tRNA O 
synthetase O 
pair O 
, O 
two O 
PPARα O 
variants O 
were O 
prepared O 
, O 
in O 
which O 
Leu B-FORMULA 
-258 O 
or O 
Phe B-FORMULA 
-273 O 
were O 
site O 
- O 
specifically O 
replaced O 
by O 
the O 
genetically O 
encoded O 
photo O 
- O 
reactive O 
amino B-FAMILY 
acid I-FAMILY 
para-benzoylphenylalanine B-SYSTEMATIC 
( O 
Bpa B-ABBREVIATION 
) O 
. O 
PPARα O 
variants O 
were O 
subjected O 
to O 
UV-induced O 
cross O 
- O 
linking O 
, O 
both O 
in O 
the O 
absence O 
and O 
presence O 
of O 
ligands O 
. O 
After O 
the O 
photo O 
- O 
cross O 
- O 
linking O 
reaction O 
, O 
reaction O 
mixtures O 
were O 
enzymatically O 
digested O 
and O 
peptides O 
were O 
analyzed O 
by O 
mass O 
spectrometry O 
. O 
The O 
inter O 
- O 
residue O 
distances O 
disclosed O 
by O 
the O 
photo O 
- O 
chemical O 
cross O 
- O 
links O 
served O 
to O 
monitor O 
conformational O 
changes O 
in O 
PPARα O 
upon O 
agonist O 
and O 
antagonist O 
binding O 
. O 
The O 
data O 
obtained O 
with O 
our O 
strategy O 
underline O 
the O 
potential O 
of O 
genetically O 
encoded O 
internal O 
photo O 
- O 
cross O 
- O 
linkers O 
in O 
combination O 
with O 
mass O 
spectrometry O 
as O 
an O 
alternative O 
method O 
to O 
monitor O 
in O 
- O 
solution O 
3D- O 
protein O 
structures O 
. O 

Induction O 
of O 
Cytochrome O 
P450 O 
Isoforms O 
and O 
Peroxisomal O 
Proliferation O 
by O 
Cyfluthrin B-TRIVIAL 
in O 
Male O 
Wistar O 
Rats O 
. O 

effects O 
on O 
in O 
vivo O 
drug O 
metabolizing O 
enzymes O 
were O 
evaluated O 
using O 
the O 
oxidative O 
substrate O 
antipyrine B-TRIVIAL 
. O 
Antipyrine B-TRIVIAL 
pharmacokinetics O 
in O 
plasma O 
and O 
urinary O 
excretion O 
of O 
its O 
major O 
metabolites O 
with O 
and O 
without O 
cyfluthrin B-TRIVIAL 
oral O 
treatment O 
( O 
20mg O 
/ O 
kg O 
/ O 
day O 
for O 
6 O 
days O 
) O 
were O 
investigated O 
in O 
rats O 
. O 
Cyfluthrin B-TRIVIAL 
increased O 
the O 
apparent O 
intrinsic O 
clearance O 
and O 
decreased O 
the O 
antipyrine B-TRIVIAL 
half O 
- O 
life O 
at O 
β O 
phase O 
. O 
Cyfluthrin B-TRIVIAL 
also O 
increased O 
the O 
clearance O 
of O 
the O 
antipyrine B-TRIVIAL 
metabolites O 
, O 
norantipyrine B-TRIVIAL 
, O 
4-hydroxyantipyrine B-SYSTEMATIC 
and O 
3-hydroxymethylantipyrine B-SYSTEMATIC 
and O 
the O 
formation O 
rate O 
constants O 
for O 
each O 
of O 
the O 
three O 
metabolites O 
measured O 
in O 
urine O 
. O 
These O 
results O 
suggest O 
that O 
cyfluthrin B-TRIVIAL 
affects O 
hepatic O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
system O 
. O 
In O 
order O 
to O 
confirm O 
, O 
a O 
second O 
experiment O 
was O 
carried O 
out O 
. O 
We O 
evaluated O 
the O 
effects O 
of O 
repeated O 
exposure O 
to O 
cyfluthrin B-TRIVIAL 
on O 
hepatic O 
and O 
renal O 
CYP2E O 
, O 
CYP1A O 
and O 
CYP4A O 
subfamilies O 
and O 
peroxisomal O 
proliferation O 
in O 
rats O 
following O 
oral O 
administration O 
( O 
10 O 
and O 
20mg O 
/ O 
kg O 
/ O 
day O 
for O 
6 O 
days O 
) O 
. O 
At O 
the O 
highest O 
dose O 
, O 
cyfluthrin B-TRIVIAL 
increased O 
renal O 
and O 
hepatic O 
O B-FORMULA 
-deethylation O 
of O 
ethoxyresorufin B-SYSTEMATIC 
and O 
O B-FORMULA 
-demethylation O 
of O 
methoxyresorufin B-SYSTEMATIC 
, O 
metabolism O 
mediated O 
by O 
the O 
CYP1A O 
subfamily O 
. O 
Liver O 
and O 
kidney O 
were O 
susceptible O 
to O 
cyfluthrin B-TRIVIAL 
-dependent O 
induction O 
of O 
12- O 
and O 
11-hydroxylation O 
of O 
lauric B-TRIVIAL 
acid I-TRIVIAL 
, O 
suggesting O 
CYP4A O 
subfamily O 
induction O 
. O 
Also O 
cyfluthrin B-TRIVIAL 
increased O 
the O 
β-oxidation O 
of O 
palmitoyl B-TRIVIAL 
-coenzyme O 
A O 
and O 
carnitine B-TRIVIAL 
acetyltransferase O 
activity O 
, O 
supporting O 
cyfluthrin B-TRIVIAL 
as O 
a O 
peroxisome O 
proliferator O 
. O 
In O 
conclusion O 
, O 
the O 
demonstration O 
that O 
cyfluthrin B-TRIVIAL 
induced O 
hepatic O 
CYP1A O 
, O 
CYP4A O 
subfamilies O 
and O 
peroxisomal O 
proliferation O 
raises O 
the O 
possibility O 
of O 
cyfluthrin B-TRIVIAL 
could O 
produce O 
changes O 
in O 
oxidative O 
stress O 
. O 

3-sulfate I-SYSTEMATIC 
stimulates O 
Th17 O 
differentiation O 
enhancing O 
phosphorylation O 
of O 
c-Src O 
and O 
STAT3 O 
to O 
worsen O 
experimental O 
autoimmune O 
encephalomyelitis O 
. O 

AhR O 
activation O 
regulates O 
CD4T O 
cell O 
differentiation O 
, O 
how O 
it O 
works O 
has O 
yet O 
to O 
be O 
elucidated O 
. O 
In O 
the O 
present O 
study O 
, O 
using O 
in O 
vitro O 
Th17 O 
differentiation O 
model O 
, O 
we O 
examined O 
effects O 
of O 
AhR O 
activation O 
by O 
indoxyl B-SYSTEMATIC 
3-sulfate I-SYSTEMATIC 
( O 
I3S B-SYSTEMATIC 
) O 
, O 
a O 
uremic O 
toxin O 
, O 
on O 
Th17 O 
differentiation O 
and O 
investigated O 
underlying O 
mechanisms O 
. O 
I3S B-SYSTEMATIC 
increased O 
expression O 
of O 
RORγt O 
, O 
the O 
master O 
transcription O 
factor O 
for O 
Th17 O 
differentiation O 
, O 
and O 
stimulated O 
Th17 O 
differentiation O 
, O 
in O 
a O 
comparative O 
manner O 
as O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
, O 
a O 
prototypical O 
AhR O 
ligand O 
. O 
Activation O 
of O 
STAT3 O 
, O 
which O 
is O 
phosphorylated O 
by O 
the O 
IL-6 O 
signaling O 
pathways O 
and O 
thus O 
is O 
necessary O 
for O 
Th17 O 
differentiation O 
, O 
was O 
strongly O 
stimulated O 
by O 
I3S B-SYSTEMATIC 
and O 
TCDD B-ABBREVIATION 
. O 
Phosphorylation O 
of O 
c-Src O 
, O 
which O 
was O 
shown O 
to O 
be O 
activated O 
by O 
AhR O 
ligands O 
, O 
was O 
also O 
increased O 
by O 
I3S B-SYSTEMATIC 
and O 
TCDD B-ABBREVIATION 
, O 
and O 
blocking O 
of O 
c-Src O 
activity O 
by O 
4-amino-5-(4-chlorophenyl)-7-(t-butyl) B-SYSTEMATIC 
pyrazolo[3,4-d]pyrimidine I-SYSTEMATIC 
( O 
PP2 O 
) O 
inhibited O 
phosphorylation O 
of O 
both O 
c-Src O 
and O 
STAT3 O 
, O 
raising O 
a O 
possibility O 
that O 
stimulatory O 
activities O 
of O 
I3S B-SYSTEMATIC 
and O 
TCDD B-ABBREVIATION 
on O 
Th17 O 
differentiation O 
could O 
be O 
exerted O 
via O 
increased O 
phosphorylation O 
of O 
c-Src O 
, O 
which O 
in O 
turn O 
stimulates O 
STAT3 O 
activation O 
. O 
Finally O 
, O 
we O 
found O 
that O 
I3S B-SYSTEMATIC 
worsened O 
experimental O 
autoimmune O 
encephalomyelitis O 
( O 
EAE O 
) O 
, O 
which O 
is O 
primarily O 
mediated O 
by O 
Th17 O 
cells O 
, O 
enhancing O 
the O 
frequency O 
of O 
IL-17-producing O 
cells O 
in O 
draining O 
lymph O 
nodes O 
. O 

indica O 
L O 
. O 
attenuates O 
high- O 
glucose B-TRIVIAL 
- O 
and O 
lipopolysaccharide-induced O 
inflammatory O 
mediators O 
in O 
monocyte O 
/ O 
macrophage O 
. O 

RELEVANCE O 
: O 
Canna O 
indica O 
L O 
. O 
( O 
CI O 
) O 
has O 
been O 
widely O 
used O 
as O 
a O 
folklore O 
medicine O 
in O 
tropical O 
and O 
subtropical O 
areas O 
with O 
beneficial O 
effects O 
in O 
numerous O 
diseases O 
, O 
including O 
infection O 
, O 
rheumatism O 
, O 
hepatitis O 
, O 
and O 
it O 
has O 
also O 
been O 
identified O 
as O 
an O 
antioxidant O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
The O 
present O 
study O 
aimed O 
to O 
investigate O 
the O 
effect O 
of O 
CI O 
ethanolic O 
extract O 
( O 
CIE O 
) O 
on O 
productions O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
, O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
( O 
PGE2 B-ABBREVIATION 
) O 
, O 
and O 
interleukin-1β O 
( O 
IL-1β O 
) O 
in O 
lipopolysaccharide O 
(LPS)-induced O 
RAW264.7 O 
macrophages O 
. O 
In O 
addition O 
, O 
the O 
effects O 
of O 
CIE O 
in O 
high O 
glucose B-TRIVIAL 
(HG)-induced O 
U937 O 
monocytes O 
on O 
mRNA O 
expressions O 
of O 
IL-8 O 
and O 
monocyte O 
chemoattractant O 
protein-1 O 
( O 
MCP-1 O 
) O 
, O 
and O 
regulation O 
of O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
pathways O 
were O 
also O 
identified O 
. O 
RESULTS O 
: O 
CIE O 
was O 
found O 
to O 
inhibit O 
the O 
production O 
of O 
inflammatory O 
mediators O 
including O 
NO B-FORMULA 
, O 
IL-1β O 
, O 
and O 
PGE2 B-ABBREVIATION 
from O 
LPS-induced O 
RAW O 
264.7 O 
macrophages O 
. O 
The O 
increases O 
in O 
HG-induced O 
mRNA O 
expressions O 
of O 
IL-8 O 
and O 
MCP-1 O 
were O 
also O 
significantly O 
inhibited O 
by O 
CIE O 
. O 
Stimulation O 
of O 
HG O 
in O 
U937 O 
monocytes O 
resulted O 
in O 
activation O 
of O 
p38 O 
MAPK O 
, O 
ERK1 O 
/ O 
2 O 
, O 
and O 
JNK O 
. O 
However O 
, O 
CIE O 
treatment O 
significantly O 
decreased O 
phosphorylation O 
of O 
p38 O 
MAPK O 
, O 
ERK1 O 
/ O 
2 O 
, O 
and O 
JNK O 
. O 
CONCLUSION O 
: O 
The O 
present O 
study O 
demonstrated O 
that O 
CIE O 
suppressed O 
the O 
LPS-induced O 
inflammatory O 
mediator O 
production O 
and O 
also O 
inhibited O 
HG-induced O 
inflammatory O 
mediator O 
expression O 
by O 
the O 
regulation O 
of O 
MAPK O 
pathway O 
. O 

is O 
a O 
specific O 
E3 O 
ubiquitin O 
ligase O 
for O 
the O 
NMDA B-ABBREVIATION 
receptor O 
subunit O 
GluN2D O 
. O 

receptors O 
are O 
a O 
family O 
of O 
glutamate B-TRIVIAL 
-gated O 
ion O 
channels O 
that O 
regulate O 
various O 
CNS O 
functions O 
such O 
as O 
synaptic O 
plasticity O 
and O 
learning O 
. O 
However O 
hypo O 
- O 
or O 
hyper O 
- O 
activation O 
of O 
NMDA B-ABBREVIATION 
receptors O 
is O 
critically O 
involved O 
in O 
many O 
neurological O 
and O 
psychiatric O 
conditions O 
such O 
as O 
pain O 
, O 
stroke O 
, O 
epilepsy O 
, O 
neurodegeneration O 
, O 
schizophrenia O 
, O 
and O 
depression O 
. O 
Thus O 
, O 
it O 
is O 
important O 
to O 
identify O 
mechanisms O 
( O 
such O 
as O 
by O 
targeted O 
ubiquitination O 
) O 
that O 
regulate O 
the O 
levels O 
of O 
individual O 
subtypes O 
of O 
NMDA B-ABBREVIATION 
receptors O 
. O 
In O 
this O 
study O 
, O 
we O 
used O 
a O 
series O 
of O 
tagged O 
, O 
carboxy B-SYSTEMATIC 
terminal O 
constructs O 
of O 
GluN2D O 
to O 
identify O 
associating O 
proteins O 
from O 
rat O 
brain O 
. O 
Of O 
seven O 
different O 
GluN2D O 
C B-FORMULA 
-terminal O 
fragments O 
used O 
as O 
bait O 
, O 
only O 
the O 
construct O 
containing O 
amino B-FAMILY 
acids I-FAMILY 
983-1097 O 
associated O 
with O 
an O 
E3 O 
ligase O 
, O 
Nedd4 O 
. O 
A O 
direct O 
interaction O 
between O 
GluN2D O 
and O 
Nedd4 O 
was O 
confirmed O 
both O 
in O 
vivo O 
and O 
in O 
vitro O 
. O 
This O 
association O 
is O 
mediated O 
by O 
an O 
interaction O 
between O 
GluN2D's O 
C B-FORMULA 
-terminal O 
PPXY O 
motif O 
and O 
the O 
2nd O 
and O 
3rd O 
WW O 
domains O 
of O 
Nedd4 O 
. O 
Of O 
the O 
four O 
GluN2 O 
subunits O 
, O 
Nedd4 O 
directly O 
interacted O 
with O 
GluN2D O 
and O 
also O 
weakly O 
with O 
GluN2A O 
. O 
Nedd4 O 
coexpression O 
with O 
GluN2D O 
enhances O 
GluN2D O 
ubiquitination O 
and O 
reduces O 
GluN1 O 
/ O 
GluN2D O 
NMDA B-ABBREVIATION 
receptor O 
responses O 
. O 
These O 
results O 
identify O 
Nedd4 O 
as O 
a O 
novel O 
binding O 
partner O 
for O 
GluN2D O 
and O 
suggest O 
a O 
mechanism O 
for O 
the O 
regulation O 
of O 
NMDA B-ABBREVIATION 
receptors O 
that O 
contains O 
GluN2D O 
subunit O 
through O 
ubiquitination O 
- O 
dependent O 
downregulation O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
GluR-dep O 
synaptic O 
plasticity O 
' O 
. O 

its O 
considerable O 
interest O 
in O 
human O 
therapy O 
, O 
in O 
vivo O 
siRNA O 
delivery O 
is O 
still O 
suffering O 
from O 
hurdles O 
of O 
vectorization O 
. O 
We O 
have O 
shown O 
recently O 
efficient O 
gene O 
silencing O 
by O 
non-vectorized O 
cationic O 
siRNA O 
. O 
Here O 
, O 
we O 
describe O 
the O 
synthesis O 
and O 
in O 
vitro O 
evaluation O 
of O 
new O 
amphiphilic O 
cationic O 
siRNA O 
. O 
C12 B-FORMULA 
- O 
, O 
(C12)2 B-FORMULA 
- O 
and O 
cholesteryl-spermine B-TRIVIAL 
x-siRNA O 
were O 
capable O 
of O 
luciferase O 
knockdown O 
at O 
nanomolar O 
concentrations O 
without O 
vectorization O 
( O 
i.e O 
. O 
one O 
to O 
two O 
orders O 
of O 
magnitude O 
more O 
potent O 
than O 
commercially O 
available O 
cholesteryl B-TRIVIAL 
siRNA O 
) O 
. O 
Moreover O 
, O 
incubation O 
in O 
the O 
presence O 
of O 
serum O 
did O 
not O 
impair O 
their O 
efficiency O 
. O 
Finally O 
, O 
amphiphilic O 
cationic O 
siRNA O 
was O 
pre O 
- O 
loaded O 
on O 
albumin O 
. O 
In O 
A549Luc O 
cells O 
in O 
the O 
presence O 
of O 
serum O 
, O 
these O 
siRNA O 
conjugates O 
were O 
highly O 
effective O 
and O 
had O 
low O 
toxicity O 
. O 

dihydrochalcone B-SYSTEMATIC 
and O 
several O 
homoisoflavonoids B-FAMILY 
from O 
Polygonatum O 
odoratum O 
are O 
activators O 
of O 
adenosine B-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
-activated O 
protein O 
kinase O 
. O 

monophosphate I-SYSTEMATIC 
( O 
AMP B-ABBREVIATION 
)-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
is O 
a O 
major O 
cellular O 
energy O 
sensor O 
and O 
master O 
regulator O 
of O 
metabolic O 
homeostasis O 
; O 
thus O 
, O 
AMPK O 
plays O 
a O 
central O 
role O 
in O 
studies O 
on O 
diabetes O 
and O 
related O 
metabolic O 
diseases O 
. O 
From O 
the O 
rhizomes O 
of O 
Polygonatum O 
odoratum O 
( O 
Mill O 
. O 
) O 
Druce O 
, O 
six O 
homoisoflavonoids B-FAMILY 
( O 
1-6 O 
) O 
and O 
one O 
dihydrochalcone B-SYSTEMATIC 
( O 
7 O 
) O 
were O 
isolated O 
, O 
and O 
the O 
structures O 
of O 
polygonatones B-MULTIPLE 
A-D I-MULTIPLE 
( O 
4-7 O 
) O 
were O 
elucidated O 
by O 
various O 
spectroscopic O 
analyses O 
. O 
Compounds O 
1-7 O 
were O 
evaluated O 
for O 
their O 
effect O 
on O 
AMPK O 
activation O 
. O 
The O 
amount O 
of O 
active O 
phosphorylated O 
AMPK O 
and O 
acetyl-CoA B-SYSTEMATIC 
carboxylase O 
in O 
rat O 
liver O 
epithelial O 
IAR-20 O 
cells O 
increased O 
when O 
the O 
cells O 
were O 
incubated O 
with O 
the O 
aforementioned O 
compounds O 
. O 
Specifically O 
, O 
(3R)-5,7-dihydroxyl-6-methyl-8-methoxyl-3-(4'-hydroxylbenzyl)-chroman-4-one B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
(3R)-5,7-dihydroxyl-6,8-dimethyl-3-(4'-hydroxylbenzyl)-chroman-4-one B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
(3R)-5,7-dihydroxyl-6-methyl-3-(4'-hydroxylbenzyl)-chroman-4-one B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
and O 
polygonatone B-TRIVIAL 
D I-TRIVIAL 
( O 
7 O 
) O 
exhibited O 
significant O 
activation O 
effects O 
. O 

and O 
structure O 
- O 
activity O 
relationships O 
of O 
a O 
novel O 
and O 
selective O 
bone O 
morphogenetic O 
protein O 
receptor O 
( O 
BMP O 
) O 
inhibitor O 
derived O 
from O 
the O 
pyrazolo[1.5-a]pyrimidine B-SYSTEMATIC 
scaffold O 
of O 
Dorsomorphin O 
: O 
The O 
discovery O 
of O 
ML347 B-IDENTIFIER 
as O 
an O 
ALK2 O 
versus O 
ALK3 O 
selective O 
MLPCN O 
probe O 
. O 

structure O 
- O 
activity O 
relationship O 
of O 
the O 
3- O 
and O 
6- O 
positions O 
of O 
the O 
pyrazolo[1,5-a]pyrimidine B-SYSTEMATIC 
scaffold O 
of O 
the O 
known O 
BMP O 
inhibitors O 
dorsomorphin B-TRIVIAL 
, O 
1 O 
, O 
LDN-193189 B-IDENTIFIER 
, O 
2 O 
, O 
and O 
DMH1 B-TRIVIAL 
, O 
3 O 
, O 
led O 
to O 
the O 
identification O 
of O 
a O 
potent O 
and O 
selective O 
compound O 
for O 
ALK2 O 
versus O 
ALK3 O 
. O 
The O 
potency O 
contributions O 
of O 
several O 
3- O 
position O 
substituents O 
were O 
evaluated O 
with O 
subtle O 
structural O 
changes O 
leading O 
to O 
significant O 
changes O 
in O 
potency O 
. O 
From O 
these O 
studies O 
, O 
a O 
novel O 
5-quinoline B-SYSTEMATIC 
molecule O 
was O 
identified O 
and O 
designated O 
an O 
MLPCN O 
probe O 
molecule O 
, O 
ML347 B-IDENTIFIER 
, O 
which O 
shows O 
> O 
300-fold O 
selectivity O 
for O 
ALK2 O 
and O 
presents O 
the O 
community O 
with O 
a O 
selective O 
molecular O 
probe O 
for O 
further O 
biological O 
evaluation O 
. O 

new O 
photosensitizers O 
based O 
on O 
the O 
BODIPY B-ABBREVIATION 
scaffold O 
have O 
been O 
synthesized O 
, O 
of O 
which O 
one O 
bears O 
an O 
NLS O 
peptide O 
, O 
which O 
is O 
linked O 
to O 
the O 
BODIPY's O 
core O 
using O 
the O 
copper B-SYSTEMATIC 
catalysed O 
azide B-SYSTEMATIC 
- O 
alkyne B-FAMILY 
click O 
reaction O 
. O 
The O 
phototoxicities O 
of O 
these O 
BODIPY B-ABBREVIATION 
based O 
photosensitizers O 
have O 
been O 
determined O 
, O 
as O 
well O 
as O 
their O 
dark O 
toxicities O 
. O 
Although O 
the O 
conjugation O 
of O 
a O 
single O 
NLS O 
peptide O 
to O 
the O 
BODIPY B-ABBREVIATION 
did O 
not O 
lead O 
to O 
any O 
observable O 
nuclear O 
localization O 
, O 
the O 
photosensitizer O 
did O 
exhibit O 
a O 
superior O 
photoxicity O 
. O 
Cellular O 
co O 
- O 
localization O 
experiments O 
revealed O 
a O 
localization O 
of O 
both O 
dyes O 
in O 
the O 
lysosomes O 
, O 
as O 
well O 
as O 
a O 
partial O 
localization O 
within O 
the O 
ER O 
( O 
for O 
the O 
peptide-bearing O 
BODIPY B-ABBREVIATION 
) O 
. O 

officinalis O 
attenuates O 
the O 
rotenone B-TRIVIAL 
-induced O 
toxicity O 
in O 
Drosophila O 
melanogaster O 
. O 

this O 
study O 
, O 
we O 
investigated O 
the O 
potential O 
protective O 
effects O 
of O 
Valeriana O 
officinalis O 
( O 
V O 
. O 
officinalis O 
) O 
against O 
the O 
toxicity O 
induced O 
by O 
rotenone B-TRIVIAL 
in O 
Drosophila O 
melanogaster O 
( O 
D O 
. O 
melanogaster O 
) O 
. O 
Adult O 
wild O 
- O 
type O 
flies O 
were O 
concomitantly O 
exposed O 
to O 
rotenone B-TRIVIAL 
( O 
500μM O 
) O 
and O 
V O 
. O 
officinalis O 
aqueous O 
extract O 
( O 
10mg O 
/ O 
mL O 
) O 
in O 
the O 
food O 
during O 
7 O 
days O 
. O 
Rotenone B-TRIVIAL 
-fed O 
flies O 
had O 
a O 
worse O 
performance O 
in O 
the O 
negative O 
geotaxis O 
assay O 
( O 
i.e O 
. O 
climbing O 
capability O 
) O 
and O 
open O 
- O 
field O 
test O 
( O 
i.e O 
. O 
mobility O 
time O 
) O 
as O 
well O 
as O 
a O 
higher O 
incidence O 
of O 
mortality O 
when O 
compared O 
to O 
control O 
group O 
. O 
V O 
. O 
officinalis O 
treatment O 
offered O 
protection O 
against O 
these O 
detrimental O 
effects O 
of O 
rotenone B-TRIVIAL 
. O 
In O 
contrast O 
, O 
the O 
decreased O 
number O 
of O 
crossings O 
observed O 
in O 
the O 
flies O 
exposed O 
to O 
rotenone B-TRIVIAL 
was O 
not O 
modified O 
by O 
V O 
. O 
officinalis O 
. O 
Rotenone B-TRIVIAL 
toxicity O 
was O 
also O 
associated O 
with O 
a O 
marked O 
decrease O 
on O 
the O 
total- O 
thiol B-FAMILY 
content O 
in O 
the O 
homogenates O 
and O 
cell O 
viability O 
of O 
flies O 
, O 
which O 
were O 
reduced O 
by O 
V O 
. O 
officinalis O 
treatment O 
. O 
Indeed O 
, O 
rotenone B-TRIVIAL 
exposure O 
caused O 
a O 
significant O 
increase O 
in O 
the O 
mRNA O 
expression O 
of O 
antioxidant O 
enzymes O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
and O 
catalase O 
( O 
CAT O 
) O 
and O 
also O 
in O 
the O 
tyrosine B-TRIVIAL 
hydroxylase O 
gene O 
( O 
TH O 
) O 
. O 
The O 
expression O 
of O 
SOD O 
and O 
CAT O 
mRNAs O 
were O 
normalized O 
by O 
V O 
. O 
officinalis O 
treatment O 
. O 
Our O 
results O 
suggest O 
that O 
V O 
. O 
officinalis O 
extract O 
was O 
effective O 
in O 
reducing O 
the O 
toxicity O 
induced O 
by O 
rotenone B-TRIVIAL 
in O 
D O 
. O 
melonogaster O 
as O 
well O 
as O 
confirm O 
the O 
utility O 
of O 
this O 
model O 
to O 
investigate O 
potential O 
therapeutic O 
strategies O 
on O 
movement O 
disorders O 
, O 
including O 
Parkinson O 
disease O 
( O 
PD O 
) O 
. O 

methods O 
for O 
detection O 
of O 
protein O 
S B-FORMULA 
-nitrosylation O 
. O 

-nitrosylation O 
of O 
protein O 
cysteine B-TRIVIAL 
residues O 
is O 
known O 
to O 
be O 
an O 
important O 
mechanism O 
for O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
signaling O 
. O 
However O 
, O 
the O 
detection O 
of O 
protein O 
S B-FORMULA 
-nitrosylation O 
is O 
still O 
challenging O 
due O 
to O 
technical O 
limitations O 
of O 
current O 
methods O 
. O 
This O 
chapter O 
provides O 
a O 
brief O 
review O 
on O 
recent O 
developments O 
of O 
methods O 
, O 
which O 
directly O 
target O 
S B-FORMULA 
- O 
nitroso B-SYSTEMATIC 
moieties O 
for O 
detection O 
. O 
We O 
also O 
describe O 
in O 
detail O 
the O 
protocol O 
of O 
an O 
organophosphine B-FAMILY 
-based O 
biotin B-TRIVIAL 
labeling O 
of O 
protein O 
S B-FORMULA 
- O 
nitroso B-SYSTEMATIC 
moieties O 
. O 

of O 
BDE209 B-TRIVIAL 
-induced O 
impaired O 
glucose B-TRIVIAL 
homeostasis O 
based O 
on O 
gene O 
microarray O 
analysis O 
of O 
adult O 
rat O 
liver O 
. O 

persistent O 
organic O 
pollutants O 
are O 
reported O 
to O 
be O 
potentially O 
associated O 
with O 
the O 
risk O 
of O 
human O 
diabetes O 
that O 
has O 
become O 
rapidly O 
epidemic O 
in O 
China O 
currently O 
. O 
2,2',3,3',4,4',5,5',6,6'-decabromodiphenyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
BDE209 B-TRIVIAL 
) O 
is O 
commercially O 
most O 
important O 
both O 
in O 
the O 
production O 
and O 
in O 
the O 
use O 
of O 
polybrominated B-FAMILY 
diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
. O 
It O 
might O 
bioaccumulate O 
in O 
wildlife O 
and O 
human O 
and O 
is O 
the O 
only O 
PBDEs B-ABBREVIATION 
mixture O 
still O 
used O 
today O 
. O 
In O 
the O 
present O 
study O 
, O 
male O 
adult O 
rats O 
treated O 
with O 
BDE209 B-TRIVIAL 
( O 
0 O 
, O 
0.05 O 
, O 
1 O 
, O 
and O 
20 O 
mg O 
/ O 
kg O 
) O 
for O 
8 O 
weeks O 
were O 
used O 
to O 
explore O 
the O 
effects O 
of O 
BDE209 B-TRIVIAL 
on O 
glucose B-TRIVIAL 
homeostasis O 
and O 
possible O 
mechanisms O 
; O 
0.05 O 
mg O 
/ O 
kg O 
of O 
BDE209 B-TRIVIAL 
induced O 
dose O 
- O 
related O 
hyperglycemia O 
. O 
Then O 
, O 
we O 
performed O 
the O 
full O 
- O 
genome O 
gene O 
expression O 
microarrays O 
, O 
gene O 
ontology O 
analysis O 
, O 
and O 
pathway O 
analysis O 
in O 
this O 
group O 
and O 
control O 
. O 
BDE209 B-TRIVIAL 
induced O 
1257 O 
liver O 
gene O 
transcript O 
changes O 
, O 
and O 
18 O 
canonical O 
pathways O 
were O 
significantly O 
enriched O 
. O 
Four O 
of O 
them O 
were O 
involved O 
in O 
immune O 
diseases O 
, O 
including O 
autoimmune O 
thyroid O 
disease O 
, O 
graft O 
- O 
versus O 
- O 
host O 
disease O 
, O 
allograft O 
rejection O 
, O 
and O 
type O 
I O 
diabetes O 
mellitus O 
( O 
T1MD O 
) O 
, O 
which O 
was O 
confirmed O 
by O 
the O 
decrease O 
in O 
serum O 
insulin O 
. O 
Subsequently O 
, O 
gene O 
act O 
network O 
and O 
gene O 
co O 
- O 
expression O 
network O 
found O 
that O 
some O 
MHC O 
molecules O 
and O 
TNF-α O 
were O 
involved O 
in O 
T1DM O 
pathway O 
, O 
which O 
was O 
then O 
confirmed O 
by O 
the O 
increase O 
in O 
serum O 
TNF-α O 
. O 
Additionally O 
, O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
and O 
superoxide B-TRIVIAL 
dismutase O 
in O 
plasma O 
indicated O 
that O 
oxidative O 
damage O 
might O 
partly O 
contribute O 
to O 
BDE209 B-TRIVIAL 
-induced O 
hyperglycemia O 
. O 
The O 
results O 
of O 
this O 
study O 
provide O 
some O 
new O 
experimental O 
evidence O 
that O 
the O 
exposure O 
to O 
high O 
levels O 
of O 
BDE209 B-TRIVIAL 
may O 
contribute O 
to O 
the O 
onset O 
of O 
diabetes O 
in O 
human O 
populations O 
. O 
Further O 
work O 
needs O 
to O 
be O 
done O 
to O 
confirm O 
this O 
link O 
. O 

work O 
demonstrates O 
a O 
novel O 
multifunctional O 
nanofibrous O 
mat O 
for O 
photocatalytic O 
applications O 
based O 
on O 
TiO2 B-FORMULA 
nanocables O 
functionalized O 
by O 
Ag B-FORMULA 
nanoparticles O 
and O 
coated O 
with O 
a O 
thin O 
( O 
∼2 O 
nm O 
) O 
graphitic B-TRIVIAL 
shell O 
. O 
In O 
this O 
mat O 
, O 
which O 
was O 
realized O 
by O 
an O 
electrospinning O 
technique O 
, O 
each O 
component O 
serves O 
a O 
unique O 
function O 
: O 
the O 
carbon B-SYSTEMATIC 
coating O 
acts O 
as O 
both O 
an O 
adsorption O 
material O 
for O 
capturing O 
pollutants O 
and O 
as O 
a O 
charge O 
- O 
transfer O 
material O 
, O 
the O 
Ag B-FORMULA 
nanoparticles O 
act O 
as O 
a O 
visible O 
- O 
light O 
sensitizing O 
agent O 
and O 
also O 
as O 
a O 
charge O 
- O 
transfer O 
material O 
, O 
finally O 
the O 
TiO2 B-FORMULA 
nanocable O 
mat O 
acts O 
as O 
a O 
UV O 
sensitive O 
photocatalytic O 
matrix O 
and O 
as O 
the O 
flexible O 
substrate O 
for O 
the O 
other O 
functional O 
components O 
. O 
This O 
multicomponent O 
nanocable O 
mat O 
exhibits O 
excellent O 
photocatalytic O 
activity O 
under O 
simulated O 
solar O 
irradiation O 
for O 
the O 
degradation O 
of O 
model O 
pollutants O 
including O 
RhB B-ABBREVIATION 
and O 
phenol B-SYSTEMATIC 
. O 
The O 
significant O 
photocatalytic O 
properties O 
are O 
attributed O 
to O 
the O 
synergetic O 
effect O 
of O 
the O 
three O 
functional O 
components O 
and O 
the O 
unique O 
charge O 
transport O 
" O 
freeway O 
" O 
property O 
of O 
the O 
nanofibrous O 
mat O 
. O 
In O 
addition O 
, O 
the O 
porous O 
carbon B-SYSTEMATIC 
coating O 
infiltrated O 
into O 
the O 
nanocable O 
matrix O 
endows O 
the O 
mat O 
with O 
excellent O 
flexibility O 
and O 
enables O 
robust O 
, O 
large O 
- O 
area O 
( O 
10 O 
× O 
10 O 
cm O 
) O 
fabrication O 
, O 
representing O 
a O 
significant O 
advantage O 
over O 
previous O 
brittle O 
ceramic O 
nanofibrous O 
mat O 
photocatalyst O 
substrates O 
. O 
This O 
study O 
provides O 
new O 
insight O 
into O 
the O 
design O 
and O 
preparation O 
of O 
an O 
advanced O 
, O 
yet O 
commercially O 
practical O 
and O 
scaleable O 
photocatalytic O 
composite O 
membrane O 
material O 
. O 
The O 
as-prepared O 
photocatalytic O 
mat O 
might O 
also O 
be O 
of O 
interest O 
in O 
solar O 
cell O 
, O 
catalysis O 
, O 
separation O 
technology O 
, O 
biomedical O 
engineering O 
, O 
and O 
nanotechnology O 
. O 

role O 
of O 
PYK2 O 
in O 
mediating O 
thromboxane B-FAMILY 
generation O 
downstream O 
of O 
both O 
G12 O 
/ O 
13 O 
and O 
integrin O 
αiibβ O 
in O 
platelets O 
. O 

-rich O 
tyrosine B-TRIVIAL 
kinase O 
2 O 
( O 
Pyk2 O 
) O 
is O 
activated O 
by O 
various O 
agonists O 
in O 
platelets O 
. O 
We O 
evaluated O 
the O 
signaling O 
mechanism O 
and O 
the O 
functional O 
role O 
of O 
Pyk2 O 
in O 
platelets O 
by O 
using O 
pharmacological O 
inhibitors O 
and O 
Pyk2-deficient O 
platelets O 
. O 
We O 
found O 
that O 
platelet O 
aggregation O 
and O 
secretion O 
in O 
response O 
to O 
2-MeSADP B-SYSTEMATIC 
and O 
AYPGKF O 
were O 
diminished O 
in O 
the O 
presence O 
of O 
Pyk2 O 
inhibitors O 
or O 
in O 
Pyk2-deficient O 
platelets O 
, O 
suggesting O 
that O 
Pyk2 O 
plays O 
a O 
positive O 
regulatory O 
role O 
in O 
platelet O 
functional O 
responses O 
. O 
It O 
has O 
been O 
shown O 
that O 
ADP B-ABBREVIATION 
- O 
, O 
but O 
not O 
thrombin- O 
, O 
induced O 
thromboxane B-FAMILY 
( O 
TxA2 B-ABBREVIATION 
) O 
generation O 
depends O 
on O 
integrin O 
signaling O 
. O 
Unlike O 
ADP B-ABBREVIATION 
, O 
thrombin O 
activates O 
G12 O 
/ O 
13 O 
pathways O 
, O 
and O 
G12 O 
/ O 
13 O 
pathways O 
can O 
substitute O 
for O 
integrin O 
signaling O 
for O 
TxA2 B-ABBREVIATION 
generation O 
. O 
We O 
found O 
that O 
Pyk2 O 
was O 
activated O 
downstream O 
of O 
both O 
G12 O 
/ O 
13 O 
and O 
integrin O 
- O 
mediated O 
pathways O 
, O 
and O 
both O 
2-MeSADP B-SYSTEMATIC 
- O 
and O 
AYPGKF-induced O 
TxA2 B-ABBREVIATION 
generation O 
was O 
significantly O 
diminished O 
in O 
Pyk2-deficient O 
platelets O 
. O 
In O 
addition O 
, O 
TxA2 B-ABBREVIATION 
generation O 
induced O 
by O 
co O 
- O 
stimulation O 
of O 
Gi O 
and O 
Gz O 
pathways O 
, O 
which O 
is O 
dependent O 
on O 
integrin O 
signaling O 
, O 
was O 
inhibited O 
by O 
blocking O 
Pyk2 O 
. O 
Furthermore O 
, O 
inhibition O 
of O 
2-MeSADP B-SYSTEMATIC 
-induced O 
TxA2 B-ABBREVIATION 
generation O 
by O 
fibrinogen O 
receptor O 
antagonist O 
was O 
not O 
rescued O 
by O 
co O 
- O 
stimulation O 
of O 
G12 O 
/ O 
13 O 
pathways O 
in O 
the O 
presence O 
of O 
Pyk2 O 
inhibitor O 
. O 
We O 
conclude O 
that O 
Pyk2 O 
is O 
a O 
common O 
signaling O 
effector O 
downstream O 
of O 
both O 
G12 O 
/ O 
13 O 
and O 
integrin O 
αIIbβ3 O 
signaling O 
which O 
contributes O 
to O 
thromboxane B-FAMILY 
generation O 
. O 

: O 
Antibody O 
- O 
drug O 
conjugates O 
( O 
ADCs O 
) O 
such O 
as O 
Kadcyla O 
™ O 
( O 
ado O 
- O 
trastuzumab O 
emtansine O 
[ O 
T- O 
DM1 B-ABBREVIATION 
] O 
) O 
present O 
covalently O 
bound O 
cytotoxic O 
drugs O 
, O 
which O 
may O 
influence O 
their O 
immunogenicity O 
potential O 
compared O 
with O 
antibody O 
therapies O 
. O 
Therefore O 
, O 
ADCs O 
require O 
assay O 
strategies O 
that O 
allow O 
measurement O 
of O 
responses O 
to O 
all O 
the O 
molecular O 
components O 
. O 
Results O 
: O 
The O 
immunogenicity O 
strategy O 
for O 
T- O 
DM1 B-ABBREVIATION 
used O 
a O 
risk O 
- O 
based O 
, O 
tiered O 
approach O 
that O 
included O 
screening O 
and O 
titration O 
to O 
detect O 
antitherapeutic O 
antibodies O 
; O 
confirmation O 
of O 
positive O 
responses O 
; O 
and O 
characterization O 
to O 
assess O 
whether O 
the O 
immune O 
response O 
is O 
primarily O 
to O 
the O 
antibody O 
or O 
to O 
the O 
linker O 
- O 
drug O 
and O 
/ O 
or O 
new O 
epitopes O 
in O 
trastuzumab O 
resulting O 
from O 
conjugation O 
. O 
Conclusion O 
: O 
The O 
tiered O 
immunogenicity O 
assay O 
strategy O 
for O 
T- O 
DM1 B-ABBREVIATION 
allowed O 
detection O 
of O 
antitherapeutic O 
antibodies O 
to O 
all O 
components O 
of O 
the O 
ADC O 
in O 
multiple O 
nonclinical O 
and O 
clinical O 
studies O 
. O 
Characterization O 
strategies O 
implemented O 
in O 
clinical O 
studies O 
provided O 
additional O 
insights O 
into O 
the O 
specificity O 
of O 
the O 
immune O 
response O 
. O 

: O 
A O 
novel O 
device O 
and O 
procedure O 
for O 
the O 
collection O 
and O 
isolation O 
of O 
microvolumes O 
of O 
plasma O 
have O 
been O 
developed O 
and O 
two O 
pilot O 
rodent O 
PK O 
studies O 
have O 
been O 
completed O 
. O 
Results O 
: O 
This O 
method O 
involves O 
collection O 
of O 
blood O 
into O 
a O 
plastic O 
- O 
wrapped O 
, O 
EDTA B-ABBREVIATION 
-coated O 
capillary O 
tube O 
, O 
containing O 
a O 
small O 
amount O 
of O 
a O 
thixotropic O 
gel O 
and O 
a O 
porous O 
plug O 
. O 
Following O 
blood O 
collection O 
, O 
the O 
capillary O 
is O 
placed O 
into O 
a O 
secondary O 
labeled O 
container O 
suitable O 
for O 
centrifugation O 
and O 
plasma O 
is O 
generated O 
. O 
During O 
centrifugation O 
, O 
the O 
thixotropic O 
gel O 
isolates O 
the O 
plasma O 
from O 
the O 
red O 
blood O 
cells O 
and O 
creates O 
a O 
physical O 
barrier O 
between O 
the O 
two O 
matrices O 
. O 
The O 
plasma O 
is O 
then O 
dispensed O 
from O 
the O 
capillary O 
tube O 
into O 
a O 
separate O 
container O 
for O 
storage O 
or O 
processing O 
. O 
Conclusion O 
: O 
A O 
simple O 
and O 
robust O 
novel O 
approach O 
for O 
the O 
collection O 
of O 
small O 
plasma O 
volumes O 
from O 
rodent O 
TK O 
studies O 
has O 
been O 
demonstrated O 
. O 

pH O 
and O 
Oligoamine O 
Molecular O 
Weight O 
Dependence O 
of O 
the O 
Transition O 
from O 
Monolayer O 
to O 
Multilayer O 
Adsorption O 
at O 
the O 
Air-Water O 
Interface O 
from O 
Sodium B-SYSTEMATIC 
Dodecyl I-SYSTEMATIC 
Sulfate I-SYSTEMATIC 
/ O 
Oligoamine O 
Mixtures O 
. O 

reflectivity O 
and O 
surface O 
tension O 
have O 
been O 
used O 
to O 
investigate O 
the O 
solution O 
pH O 
and O 
oligoamine O 
molecular O 
weight O 
dependence O 
of O 
the O 
adsorption O 
of O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
SDS B-ABBREVIATION 
) O 
/ O 
oligoamine O 
mixtures O 
at O 
the O 
air O 
- O 
water O 
interface O 
. O 
For O 
diethylenetriamine B-SYSTEMATIC 
, O 
triamine B-SYSTEMATIC 
, O 
or O 
triethylenetetramine B-SYSTEMATIC 
, O 
tetramine B-SYSTEMATIC 
mixed O 
with O 
SDS B-ABBREVIATION 
, O 
there O 
is O 
monolayer O 
adsorption O 
at O 
pH O 
7 O 
and O 
10 O 
, O 
and O 
multilayer O 
adsorption O 
at O 
pH O 
3 O 
. O 
For O 
the O 
slightly O 
higher O 
molecular O 
weight O 
tetraethylenepentamine B-SYSTEMATIC 
, O 
pentamine B-SYSTEMATIC 
, O 
and O 
pentaethylenehexamine B-SYSTEMATIC 
, O 
hexamine B-SYSTEMATIC 
, O 
the O 
adsorption O 
is O 
in O 
the O 
form O 
of O 
a O 
monolayer O 
at O 
pH O 
3 O 
and O 
multilayers O 
at O 
pH O 
7 O 
and O 
10 O 
. O 
Hence O 
, O 
there O 
is O 
a O 
pH O 
driven O 
transition O 
from O 
monolayer O 
to O 
multilayer O 
adsorption O 
, O 
which O 
shifts O 
from O 
low O 
pH O 
to O 
higher O 
pH O 
as O 
the O 
oligoamine O 
molecular O 
weight O 
increases O 
from O 
tetramine B-SYSTEMATIC 
to O 
pentamine B-SYSTEMATIC 
. O 
This O 
results O 
from O 
the O 
relative O 
balance O 
between O 
the O 
electrostatic O 
attraction O 
between O 
the O 
SDS B-ABBREVIATION 
and O 
amine B-SYSTEMATIC 
nitrogen I-SYSTEMATIC 
group O 
which O 
decreases O 
as O 
the O 
charge O 
density O 
decreases O 
with O 
increasing O 
pH O 
, O 
the O 
ion O 
- O 
dipole O 
interaction O 
between O 
the O 
amine B-SYSTEMATIC 
nitrogen I-SYSTEMATIC 
and O 
SDS B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
group O 
which O 
is O 
dominant O 
at O 
higher O 
pH O 
, O 
and O 
the O 
hydrophobic O 
interalkyl O 
chain O 
interaction O 
between O 
bound O 
SDS B-ABBREVIATION 
molecules O 
which O 
changes O 
with O 
oligoamine O 
molecular O 
weight O 
. O 

cement O 
( O 
BC O 
) O 
was O 
utilized O 
' O 
beneficially O 
' O 
as O 
a O 
surface O 
anchor O 
on O 
stainless O 
steel O 
( O 
SS O 
) O 
for O 
coupling O 
of O 
functional O 
polymer O 
brushes O 
via O 
' O 
click O 
' O 
reactions O 
in O 
both O 
" O 
grafting O 
- O 
to O 
" O 
and O 
" O 
grafting O 
- O 
from O 
" O 
processes O 
. O 
Ethylene B-SYSTEMATIC 
sulfide I-SYSTEMATIC 
( O 
ES O 
) O 
, O 
propargyl B-SYSTEMATIC 
carbonylimidazole I-SYSTEMATIC 
( O 
PPC B-ABBREVIATION 
) O 
and O 
azidoethyl B-SYSTEMATIC 
carbonylimidazole I-SYSTEMATIC 
( O 
AEC B-ABBREVIATION 
) O 
reacted O 
with O 
amine B-SYSTEMATIC 
and O 
/ O 
or O 
hydroxyl B-SYSTEMATIC 
groups O 
in O 
BC O 
to O 
introduce O 
the O 
corresponding O 
thiol B-FAMILY 
, O 
alkyne B-FAMILY 
and O 
azide B-SYSTEMATIC 
groups O 
on O 
SS O 
surfaces O 
( O 
SS- O 
thiol B-FAMILY 
, O 
SS- O 
alkyne B-FAMILY 
and O 
SS- O 
azide B-SYSTEMATIC 
, O 
respectively O 
) O 
. O 
Antifouling O 
zwitterionic O 
SS-PMPC O 
surface O 
was O 
prepared O 
by O 
thiol B-FAMILY 
-ene O 
photopolymerization O 
of O 
2-methacryloyloxyethyl B-SYSTEMATIC 
phosphorylcholine I-SYSTEMATIC 
( O 
MPC B-ABBREVIATION 
) O 
from O 
the O 
SS- O 
thiol B-FAMILY 
surface O 
. O 
Protein O 
- O 
resistant O 
SS- O 
PPEGMA B-ABBREVIATION 
and O 
protein O 
- O 
adsorbing O 
SS- O 
PPFS B-ABBREVIATION 
surfaces O 
were O 
prepared O 
by O 
coupling O 
of O 
the O 
respective O 
azide B-SYSTEMATIC 
-functionalized O 
poly(poly(ethylene B-FAMILY 
glycol)methyl I-FAMILY 
ether I-FAMILY 
methacrylate I-FAMILY 
) I-FAMILY 
( O 
azido-PPEGMA B-SYSTEMATIC 
) O 
and O 
poly(2,3,4,5,6-pentafluorostyrene) B-FAMILY 
( O 
azido-PPFS B-SYSTEMATIC 
) O 
polymer O 
brushes O 
in O 
azide B-SYSTEMATIC 
- O 
alkyne B-FAMILY 
' O 
click O 
' O 
reaction O 
. O 
Antifouling O 
alkyne B-FAMILY 
-functionalized O 
poly(N-hydroxyethyl B-FAMILY 
acrylamide I-FAMILY 
) I-FAMILY 
( O 
alkynyl-PHEAA B-FAMILY 
) O 
and O 
antibacterial O 
alkyne B-FAMILY 
-functionalized O 
poly(2-(methacryloyloxy)ethyl B-FAMILY 
trimethylammonium I-FAMILY 
chloride I-FAMILY 
) I-FAMILY 
( O 
alkynyl-PMETA B-FAMILY 
) O 
polymer O 
brushes O 
were O 
clicked O 
on O 
the O 
SS- O 
azide B-SYSTEMATIC 
surface O 
. O 
Adsorption O 
of O 
bovine O 
serum O 
albumin O 
and O 
bacteria O 
fouling O 
of O 
Gram O 
- O 
negative O 
Escherichia O 
coli O 
( O 
E O 
. O 
coli O 
) O 
and O 
Gram O 
- O 
positive O 
Staphylococcus O 
epidermidis O 
( O 
S O 
. O 
epidermidis O 
) O 
were O 
investigated O 
on O 
the O 
polymer O 
- O 
functionalized O 
SS O 
surfaces O 
. O 
The O 
versatile O 
bio O 
- O 
anchor O 
and O 
functional O 
polymer O 
brush O 
coatings O 
are O 
stable O 
in O 
abiotic O 
aqueous O 
environment O 
for O 
over O 
a O 
month O 
. O 

the O 
Mechanism O 
of O 
Neutral O 
Hydrolysis O 
of O 
Esters B-FAMILY 
: O 
Water O 
Autoionization O 
Mechanisms O 
with O 
Acid O 
or O 
Base O 
Initiation O 
Pathways O 
. O 

mechanism O 
of O 
neutral O 
hydrolysis O 
of O 
ester B-FAMILY 
has O 
long O 
been O 
explored O 
by O 
theoretical O 
studies O 
. O 
However O 
, O 
reliable O 
theoretical O 
calculations O 
show O 
that O 
the O 
usual O 
bifunctional O 
catalysis O 
mechanism O 
reported O 
by O 
different O 
authors O 
cannot O 
explain O 
the O 
experimental O 
kinetics O 
. O 
An O 
important O 
advance O 
was O 
recently O 
reported O 
by O 
Gunaydin O 
and O 
Houk O 
, O 
suggesting O 
that O 
ions O 
are O 
involved O 
in O 
the O 
mechanism O 
and O 
the O 
process O 
initiates O 
by O 
water O 
autoionization O 
followed O 
by O 
protonation O 
of O 
the O 
ester B-FAMILY 
( O 
WAIA O 
mechanism O 
) O 
. O 
However O 
, O 
this O 
mechanism O 
does O 
not O 
explain O 
the O 
hydrolysis O 
of O 
activated O 
esters B-FAMILY 
. O 
In O 
this O 
work O 
, O 
we O 
have O 
used O 
ab O 
initio O 
calculations O 
, O 
continuum O 
solvation O 
models O 
and O 
ab O 
initio O 
classical O 
trajectory O 
to O 
support O 
the O 
WAIA O 
mechanism O 
for O 
normal O 
ester B-FAMILY 
. O 
In O 
the O 
case O 
of O 
activated O 
esters O 
, O 
the O 
process O 
can O 
also O 
be O 
viewed O 
as O 
water O 
autoionization O 
with O 
formation O 
of O 
hydroxide B-SYSTEMATIC 
ion O 
aided O 
by O 
a O 
second O 
water O 
moleculeacting O 
as O 
a O 
general O 
base O 
( O 
WAIB O 
mechanism O 
) O 
. O 
This O 
is O 
the O 
mechanism O 
proposed O 
by O 
Jencks O 
and O 
Carriuolo O 
fifty O 
years O 
ago O 
. O 
Our O 
analysis O 
point O 
out O 
that O 
the O 
usual O 
method O 
for O 
exploring O 
mechanisms O 
, O 
searching O 
for O 
saddle O 
points O 
, O 
may O 
not O 
work O 
for O 
problems O 
like O 
the O 
present O 
one O 
, O 
since O 
there O 
are O 
no O 
saddle O 
points O 
on O 
the O 
reaction O 
pathway O 
. O 
Rather O 
, O 
the O 
formation O 
of O 
a O 
pair O 
of O 
ions O 
from O 
a O 
neutral O 
species O 
may O 
have O 
an O 
asymptotic O 
barrier O 
. O 
The O 
approach O 
used O 
in O 
this O 
paper O 
allows O 
the O 
calculation O 
of O 
the O 
free O 
energy O 
profile O 
and O 
enable O 
us O 
to O 
explain O 
the O 
mechanism O 
and O 
kinetics O 
of O 
the O 
neutral O 
hydrolysis O 
of O 
normal O 
( O 
methyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
) O 
and O 
activated O 
( O 
methyl B-SYSTEMATIC 
trifluoroacetate I-SYSTEMATIC 
) O 
esters B-FAMILY 
. O 
In O 
addition O 
, O 
the O 
present O 
study O 
suggests O 
that O 
formation O 
of O 
a O 
pair O 
of O 
ions O 
should O 
be O 
always O 
considered O 
in O 
reactions O 
in O 
aqueous O 
solution O 
. O 

work O 
describes O 
a O 
technique O 
for O 
forming O 
high O 
- O 
density O 
arrays O 
and O 
patterns O 
of O 
membrane O 
- O 
bound O 
proteins O 
through O 
binding O 
to O 
a O 
curvature O 
- O 
organized O 
compositional O 
pattern O 
of O 
metal O 
- O 
chelating O 
lipids O 
( O 
Cu(2+) B-FORMULA 
-DOIDA O 
or O 
Cu(2+) B-FORMULA 
-DSIDA O 
) O 
. O 
In O 
this O 
bottom O 
- O 
up O 
approach O 
, O 
the O 
underlying O 
support O 
is O 
an O 
e-beam O 
formed O 
, O 
square O 
lattice O 
pattern O 
of O 
hemispheres O 
. O 
This O 
curvature O 
pattern O 
sorts O 
Cu(2+) B-FORMULA 
-DOIDA O 
to O 
the O 
200 O 
nm O 
hemispherical O 
lattice O 
sites O 
of O 
a O 
600 O 
nm O 
X O 
600 O 
nm O 
unit O 
cell O 
in O 
Ld O 
- O 
Lo O 
phase O 
separated O 
lipid O 
multibilayers O 
. O 
Binding O 
of O 
histidine O 
- O 
tagged O 
green O 
fluorescent O 
protein O 
( O 
His-GFP O 
) O 
creates O 
a O 
high O 
density O 
array O 
of O 
His-GFP O 
- O 
bound O 
pixels O 
localized O 
to O 
the O 
square O 
lattice O 
sites O 
. O 
In O 
comparison O 
, O 
the O 
negative O 
pixel O 
pattern O 
is O 
created O 
by O 
sorting O 
Cu(2+) B-FORMULA 
-DSIDA O 
in O 
Ld O 
- O 
Lβ O 
' O 
phase O 
separated O 
lipid O 
multibilayers O 
to O 
the O 
flat O 
grid O 
between O 
the O 
lattice O 
sites O 
followed O 
by O 
binding O 
to O 
His-GFP O 
. O 
Lattice O 
defects O 
in O 
the O 
His-GFP O 
pattern O 
lead O 
to O 
interesting O 
features O 
such O 
as O 
pattern O 
circularity O 
. O 
We O 
also O 
observe O 
defect O 
- O 
free O 
arrays O 
of O 
His-GFP O 
that O 
demonstrate O 
perfect O 
arrays O 
can O 
be O 
formed O 
by O 
this O 
method O 
suggesting O 
the O 
possibility O 
of O 
using O 
this O 
approach O 
for O 
the O 
localization O 
of O 
various O 
active O 
molecules O 
to O 
form O 
protein O 
, O 
DNA O 
, O 
or O 
optically O 
active O 
molecular O 
arrays O 
. O 

of O 
Hollow O 
Ag-Au B-FORMULA 
Bimetallic O 
Nanoparticles O 
in O 
Polyelectrolyte O 
Multilayers O 
. O 

nanoparticles O 
of O 
~20 O 
nm O 
size O 
and O 
rather O 
uniform O 
size O 
distribution O 
were O 
synthesized O 
in O 
polyelectrolyte O 
multilayers O 
( O 
PEMs O 
) O 
via O 
an O 
ion O 
- O 
exchange O 
/ O 
reduction O 
process O 
in O 
two O 
stages O 
( O 
seeding O 
and O 
growth O 
) O 
, O 
which O 
were O 
used O 
as O 
sacrificial O 
templates O 
to O 
fabricate O 
Ag-Au B-FORMULA 
bimetallic O 
hollow O 
nanoparticles O 
via O 
galvanic O 
replacement O 
reaction O 
. O 
The O 
reaction O 
process O 
was O 
monitored O 
by O 
UV-vis O 
spectroscopy O 
. O 
The O 
morphology O 
and O 
structure O 
of O 
the O 
nanoparticles O 
were O 
characterized O 
by O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
and O 
energy O 
dispersive O 
X-ray O 
spectroscopy O 
, O 
which O 
confirmed O 
the O 
formation O 
of O 
hollow O 
Ag-Au B-FORMULA 
bimetallic O 
nanoparticles O 
. O 
UV-vis O 
absorbance O 
spectroscopy O 
and O 
TEM O 
results O 
indicated O 
that O 
both O 
size O 
and O 
optical O 
properties O 
of O 
the O 
Ag B-FORMULA 
nanoparticles O 
in O 
the O 
PEM O 
can O 
be O 
controlled O 
by O 
manipulating O 
ion O 
content O 
in O 
the O 
PEM O 
and O 
the O 
number O 
of O 
the O 
ion O 
- O 
exchange O 
/ O 
reduction O 
cycle O 
, O 
whereas O 
that O 
of O 
Ag-Au B-FORMULA 
bimetallic O 
nanoparticles O 
were O 
dependent O 
on O 
size O 
of O 
the O 
Ag B-FORMULA 
templates O 
and O 
the O 
replacement O 
reaction O 
kinetics O 
. O 
The O 
hollow O 
Ag-Au B-FORMULA 
bimetallic O 
nanoparticles O 
exhibited O 
a O 
significant O 
red O 
shift O 
in O 
the O 
surface O 
plasmon O 
resonance O 
to O 
the O 
near O 
- O 
infrared O 
region O 
. O 
The O 
strategy O 
enables O 
facile O 
preparation O 
of O 
hollow O 
bimetallic O 
nanoparticles O 
in O 
situ O 
in O 
polymer O 
matrices O 
. O 

Perturbations O 
of O 
W(CO)6 B-FORMULA 
Trapped O 
in O 
a O 
Molecular O 
Lattice O 
Probed O 
by O 
Linear O 
and O 
Non O 
Linear O 
Spectroscopy O 
. O 

dynamics O 
of O 
the O 
T1u O 
CO B-FORMULA 
stretching O 
mode O 
of O 
tungsten B-SYSTEMATIC 
hexacarbonyl I-SYSTEMATIC 
is O 
explored O 
when O 
the O 
molecule O 
is O 
embedded O 
in O 
a O 
nitrogen B-SYSTEMATIC 
matrix O 
at O 
low O 
temperature O 
. O 
Experiments O 
combined O 
IR O 
absorption O 
spectroscopy O 
and O 
IR O 
stimulated O 
photon O 
echoes O 
at O 
the O 
femtosecond O 
timescale O 
. O 
W(CO)6 B-FORMULA 
is O 
found O 
to O 
be O 
trapped O 
in O 
two O 
main O 
families O 
of O 
sites O 
differing O 
by O 
their O 
symmetries O 
( O 
called O 
hereafter O 
Oh O 
and O 
D2h O 
) O 
. O 
In O 
Oh O 
sites O 
, O 
the O 
vibrational O 
coherence O 
is O 
strongly O 
temperature O 
dependent O 
, O 
exhibiting O 
a O 
coupling O 
with O 
librational O 
phonons O 
of O 
the O 
nitrogen B-SYSTEMATIC 
lattice O 
. O 
Perturbation O 
in O 
D2h O 
sites O 
results O 
in O 
the O 
splitting O 
of O 
the O 
T1u O 
band O 
in O 
three O 
components O 
. O 
Each O 
component O 
is O 
inhomogeneously O 
broadened O 
, O 
with O 
dephasing O 
times O 
in O 
the O 
tens O 
of O 
picoseconds O 
, O 
weakly O 
coupled O 
to O 
the O 
lattice O 
phonons O 
. O 
Experiments O 
in O 
solid O 
krypton B-SYSTEMATIC 
are O 
performed O 
to O 
compare O 
the O 
effect O 
of O 
atomic O 
and O 
diatomic O 
host O 
lattices O 
. O 
Dephasing O 
time O 
in O 
Kr B-FORMULA 
does O 
not O 
depend O 
on O 
temperature O 
and O 
remains O 
in O 
the O 
hundreds O 
of O 
picosecond O 
, O 
highlighting O 
the O 
molecular O 
origin O 
of O 
dephasing O 
process O 
in O 
N2 B-FORMULA 
. O 
Additionally O 
, O 
non O 
linear O 
signals O 
show O 
oscillations O 
due O 
to O 
quantum O 
beats O 
and O 
polarization O 
interferences O 
between O 
different O 
frequency O 
components O 
of O 
the O 
induced O 
third O 
order O 
polarization O 
, O 
giving O 
information O 
, O 
in O 
particular O 
, O 
on O 
the O 
overtone O 
vibrational O 
transition O 
. O 

Ionization O 
of O 
Deprotonated O 
Nucleotides B-FAMILY 
by O 
Resonance O 
Enhanced O 
Two-Photon O 
Detachment O 
. O 

intrinsic O 
ionization O 
energy O 
of O 
a O 
base O 
in O 
DNA O 
plays O 
a O 
critical O 
role O 
in O 
determining O 
the O 
energies O 
at O 
which O 
damage O 
mechanisms O 
may O 
emerge O 
. O 
Here O 
, O 
a O 
two O 
- O 
photon O 
resonance O 
- O 
enhanced O 
ionization O 
scheme O 
is O 
presented O 
that O 
utilizes O 
the O 
1ππ* O 
transition O 
, O 
localized O 
on O 
the O 
DNA O 
base O 
, O 
to O 
elucidate O 
the O 
base O 
- O 
specific O 
ionization O 
in O 
a O 
deprotonated O 
nucleotide B-FAMILY 
. O 
In O 
contrast O 
to O 
previous O 
reports O 
, O 
the O 
scheme O 
is O 
insensitive O 
to O 
competing O 
ionization O 
channels O 
arising O 
from O 
the O 
sugar B-FAMILY 
- O 
phosphate B-SYSTEMATIC 
backbone O 
. O 
Using O 
this O 
approach O 
, O 
we O 
demonstrate O 
that O 
for O 
all O 
bases O 
except O 
guanine B-TRIVIAL 
, O 
the O 
lowest O 
electron O 
detachment O 
energy O 
corresponds O 
to O 
detachment O 
from O 
the O 
sugar B-FAMILY 
- O 
phosphate B-SYSTEMATIC 
backbone O 
and O 
allows O 
us O 
to O 
determine O 
the O 
lowest O 
adiabatic O 
ionization O 
energy O 
for O 
the O 
other O 
three O 
bases O 
for O 
the O 
first O 
time O 
in O 
an O 
isolated O 
nucleotide B-FAMILY 
. O 

Pyrimidyn B-FAMILY 
compounds O 
: O 
dual O 
- O 
action O 
small O 
molecule O 
pyrimidine B-SYSTEMATIC 
-based O 
dynamin O 
inhibitors O 
. O 

is O 
required O 
for O 
clathrin O 
- O 
mediated O 
endocytosis O 
( O 
CME O 
) O 
. O 
Its O 
GTPase O 
activity O 
stimulated O 
by O 
phospholipid O 
binding O 
to O 
its O 
PH O 
domain O 
which O 
induces O 
helical O 
oligomerization O 
. O 
We O 
have O 
designed O 
a O 
series O 
of O 
novel O 
pyrimidine B-SYSTEMATIC 
-based O 
' O 
PyrimidynTM O 
' O 
compounds O 
which O 
inhibit O 
the O 
lipid O 
stimulated O 
GTPase O 
activity O 
of O 
full O 
length O 
dynamin O 
I O 
and O 
II O 
with O 
similar O 
potency O 
. O 
The O 
most O 
potent O 
analogue O 
, O 
Pyrimidyn B-FAMILY 
7 O 
, O 
has O 
an O 
IC50 O 
of O 
1.1 O 
μM O 
for O 
dynamin O 
I O 
and O 
1.8 O 
μM O 
for O 
dynamin O 
II O 
, O 
making O 
it O 
among O 
the O 
most O 
potent O 
dynamin O 
inhibitors O 
identified O 
to O 
date O 
. O 
We O 
investigated O 
the O 
mechanism O 
of O 
action O 
of O 
the O 
Pyrimidyn B-FAMILY 
compounds O 
in O 
detail O 
by O 
examining O 
the O 
kinetics O 
of O 
Pyrimidyn B-FAMILY 
7 O 
inhibition O 
of O 
dynamin O 
. O 
The O 
compound O 
competitively O 
inhibits O 
both O 
GTP B-ABBREVIATION 
and O 
phospholipid O 
interactions O 
with O 
dynamin O 
I O 
. O 
While O 
both O 
mechanisms O 
of O 
action O 
have O 
been O 
previously O 
observed O 
separately O 
, O 
this O 
is O 
the O 
first O 
inhibitor O 
series O 
to O 
incorporate O 
both O 
and O 
thereby O 
targets O 
two O 
distinct O 
domains O 
of O 
dynamin O 
. O 
Pyrimidyn B-FAMILY 
6 O 
and O 
7 O 
reversibly O 
inhibit O 
CME O 
of O 
both O 
transferrin O 
and O 
EGF O 
in O 
a O 
number O 
of O 
non-neuronal O 
cell O 
lines O 
as O 
well O 
as O 
inhibiting O 
synaptic O 
vesicle O 
endocytosis O 
( O 
SVE O 
) O 
in O 
nerve O 
terminals O 
. O 
Therefore O 
, O 
Pyrimidyn B-FAMILY 
compounds O 
block O 
endocytosis O 
by O 
directly O 
competing O 
with O 
GTP B-ABBREVIATION 
and O 
lipid O 
binding O 
to O 
dynamin O 
, O 
limiting O 
both O 
the O 
recruitment O 
of O 
dynamin O 
to O 
membranes O 
and O 
its O 
activation O 
. O 
This O 
dual O 
mode O 
of O 
action O 
provides O 
an O 
important O 
new O 
tool O 
for O 
molecular O 
dissection O 
of O 
dynamin's O 
role O 
in O 
endocytosis O 
. O 

effects O 
of O 
smoking O 
and O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
polymorphisms O 
on O 
the O 
development O 
of O 
non-alcoholic O 
fatty O 
liver O 
disease O 
. O 

S B-FORMULA 
-transferases O 
( O 
GSTs O 
) O 
protect O 
cells O 
against O 
exogenous O 
and O 
endogenous O 
oxidative O 
stress O 
. O 
GST O 
polymorphisms O 
are O 
associated O 
with O 
the O 
development O 
of O 
cardiovascular O 
disease O 
( O 
CVD O 
) O 
and O 
diabetes O 
mellitus O 
( O 
DM O 
) O 
, O 
especially O 
in O 
current-smokers O 
. O 
Non-alcoholic O 
fatty O 
liver O 
disease O 
( O 
NAFLD O 
) O 
is O 
a O 
predictor O 
of O 
future O 
CVD O 
or O 
DM O 
, O 
because O 
oxidative O 
stress O 
contributes O 
to O 
their O 
pathogenesis O 
. O 
This O 
study O 
investigated O 
whether O 
the O 
combination O 
of O 
smoking O 
status O 
and O 
GST O 
genotypes O 
could O 
affect O 
the O 
risk O 
for O 
NAFLD O 
. O 
A O 
cross O 
- O 
sectional O 
analysis O 
was O 
conducted O 
among O 
713 O 
Japanese O 
participants O 
( O 
458 O 
males O 
and O 
255 O 
females O 
) O 
during O 
a O 
health O 
screening O 
program O 
. O 
The O 
GSTM1 O 
nan O 
, O 
GSTT1 O 
nan O 
, O 
GSTP1 O 
*A O 
/ O 
*B O 
or O 
*B O 
/ O 
*B O 
and O 
GSTA1 O 
*A O 
/ O 
*B O 
or O 
*B O 
/ O 
*B O 
genotypes O 
were O 
determined O 
and O 
deemed O 
to O 
be O 
high O 
- O 
risk O 
genotypes O 
. O 
The O 
prevalence O 
of O 
NAFLD O 
was O 
18.7% O 
. O 
Among O 
never O 
- O 
smokers O 
, O 
carriers O 
of O 
one O 
, O 
and O 
those O 
of O 
two O 
or O 
more O 
high O 
- O 
risk O 
GSTM1 O 
, O 
GSTP1 O 
or O 
GSTA1 O 
genotypes O 
were O 
at O 
a O 
higher O 
risk O 
for O 
NAFLD O 
than O 
those O 
who O 
were O 
not O 
carriers O 
[ O 
odds O 
ratio O 
( O 
95% O 
confidence O 
interval O 
) O 
: O 
2.6 O 
( O 
1.1-5.9 O 
) O 
and O 
3.3 O 
( O 
1.3-8.1 O 
) O 
, O 
respectively O 
] O 
, O 
and O 
the O 
risk O 
was O 
further O 
increased O 
among O 
current-smokers O 
[ O 
4.6 O 
( O 
1.6-13.0 O 
) O 
and O 
5.4 O 
( O 
1.2-23.7 O 
) O 
, O 
respectively O 
] O 
. O 
This O 
is O 
the O 
first O 
report O 
to O 
show O 
that O 
the O 
combination O 
of O 
current-smoking O 
and O 
harboring O 
high O 
- O 
risk O 
GSTM1 O 
, O 
GSTP1 O 
and O 
/ O 
or O 
GSTA1 O 
genotypes O 
is O 
interactively O 
associated O 
with O 
the O 
risk O 
of O 
NAFLD O 
. O 

activates O 
NFκB O 
/ O 
COX-2 O 
/ O 
PGE2 O 
pathway O 
and O 
increases O 
NADPH B-ABBREVIATION 
oxidase O 
- O 
dependent O 
ROS O 
production O 
in O 
macrophages O 
and O 
human O 
embryonic O 
kidney O 
cells O 
. O 

is O 
a O 
wildly O 
used O 
compound O 
in O 
manufactures O 
of O 
plastics O 
and O 
resins O 
. O 
A O 
variety O 
of O 
toxic O 
effects O 
from O 
melamine B-TRIVIAL 
, O 
including O 
nephrolithiasis O 
, O 
chronic O 
kidney O 
inflammation O 
, O 
and O 
bladder O 
carcinoma O 
, O 
have O 
been O 
mentioned O 
. O 
Oxidative O 
stress O 
is O 
considered O 
to O 
be O 
an O 
important O 
pathogenic O 
mechanism O 
of O 
kidney O 
disease O 
which O 
may O 
develop O 
from O 
an O 
increasing O 
free O 
radical O 
production O 
through O 
inflammation O 
. O 
The O 
aim O 
of O 
this O 
study O 
is O 
to O 
investigate O 
melamine B-TRIVIAL 
-induced O 
oxidative O 
stress O 
and O 
inflammation O 
in O 
macrophage O 
- O 
like O 
cell O 
line O 
RAW O 
264.7 O 
and O 
human O 
embryonic O 
kidney O 
cell O 
line O 
HEK293 O 
. O 
Results O 
indicated O 
melamine B-TRIVIAL 
activated O 
nuclear O 
factor O 
(NF)-κB O 
through O 
increasing O 
IκB-α O 
degradation O 
and O 
NF-κB O 
p65 O 
/ O 
p50 O 
DNA O 
- O 
binding O 
activity O 
. O 
In O 
addition O 
, O 
melamine B-TRIVIAL 
significantly O 
increased O 
COX-2 O 
expression O 
and O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
( O 
PGE2 B-ABBREVIATION 
) O 
production O 
. O 
Moreover O 
, O 
melamine B-TRIVIAL 
activated O 
NADPH B-ABBREVIATION 
oxidase O 
( O 
NOX O 
) O 
, O 
including O 
NOX1 O 
, O 
2 O 
and O 
4 O 
, O 
accompanied O 
with O 
an O 
increase O 
in O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
production O 
. O 
Furthermore O 
, O 
melamine B-TRIVIAL 
-induced O 
ROS O 
production O 
could O 
be O 
attenuated O 
by O 
apocynin B-TRIVIAL 
, O 
a O 
NOX O 
inhibitor O 
. O 
In O 
conclusion O 
, O 
our O 
findings O 
suggest O 
melamine B-TRIVIAL 
increased O 
inflammation O 
and O 
oxidative O 
stress O 
via O 
activation O 
of O 
NF-κB O 
/ O 
COX-2 O 
and O 
NOX O 
/ O 
ROS O 
pathway O 
, O 
and O 
first O 
revealed O 
the O 
critical O 
role O 
of O 
NOX O 
in O 
melamine B-TRIVIAL 
-induced O 
ROS O 
production O 
, O 
suggesting O 
the O 
potential O 
of O 
NOX O 
inhibitor O 
against O 
melamine B-TRIVIAL 
toxicity O 
. O 

Polymorphism O 
at O 
Val B-ABBREVIATION 
( O 
80 O 
) O 
( O 
rs700518 O 
) O 
of O 
the O 
CYP19A1 O 
Gene O 
is O 
Associated O 
with O 
Aromatase O 
Inhibitor O 
Associated O 
Bone O 
Loss O 
in O 
Women O 
with O 
ER O 
( O 
+ O 
) O 
Breast O 
Cancer O 
. O 

: O 
Polymorphisms O 
in O 
the O 
CYP19A1 O 
( O 
aromatase O 
) O 
gene O 
have O 
been O 
reported O 
to O 
influence O 
disease O 
- O 
free O 
survival O 
and O 
the O 
incidence O 
of O 
musculoskeletal O 
complaints O 
in O 
patients O 
taking O 
aromatase O 
inhibitors O 
( O 
AIs O 
) O 
for O 
estrogen B-FAMILY 
receptor O 
positive O 
( O 
ER+ O 
) O 
breast O 
cancer O 
. O 
Bone O 
loss O 
and O 
fractures O 
are O 
well O 
- O 
recognized O 
complications O 
from O 
AI O 
therapy O 
. O 
The O 
objective O 
of O 
this O 
study O 
is O 
to O 
determine O 
the O 
influence O 
of O 
polymorphisms O 
in O 
the O 
CYP19A1 O 
gene O 
on O 
bone O 
loss O 
among O 
patients O 
taking O 
aromatase O 
inhibitors O 
for O 
ER+ O 
breast O 
cancer O 
. O 
PATIENTS O 
AND O 
METHODS O 
: O 
The O 
subjects O 
consisted O 
of O 
97 O 
postmenopausal O 
women O 
with O 
ER+ O 
breast O 
cancer O 
who O 
were O 
initiated O 
on O 
third O 
- O 
generation O 
AIs O 
. O 
Bone O 
mineral O 
density O 
( O 
BMD O 
) O 
was O 
measured O 
by O 
dual O 
energy O 
x-ray O 
absorptiometry O 
at O 
baseline O 
and O 
at O 
6 O 
and O 
12 O 
months O 
. O 
Twenty O 
- O 
four O 
hour O 
urine O 
N B-FORMULA 
-telopeptide O 
( O 
NTX O 
) O 
was O 
measured O 
by O 
Elisa O 
and O 
serum O 
estradiol B-TRIVIAL 
was O 
measured O 
by O 
ultrasensitive O 
radioimmunoassay O 
at O 
baseline O 
, O 
and O 
at O 
6 O 
months O 
. O 
Genotyping O 
was O 
done O 
by O 
Taqman O 
SNP O 
allelic O 
discrimination O 
assay O 
. O 
RESULTS O 
: O 
Women O 
with O 
the O 
AA O 
genotype O 
for O 
the O 
rs700518 O 
( O 
G O 
/ O 
A O 
at O 
Val B-ABBREVIATION 
( O 
80 O 
) O 
) O 
developed O 
significant O 
bone O 
loss O 
at O 
the O 
lumbar O 
spine O 
and O 
the O 
total O 
hip O 
at O 
12 O 
months O 
relative O 
to O 
patients O 
carrying O 
the O 
G O 
allele O 
( O 
GA O 
/ O 
GG O 
) O 
; O 
both O 
p=0.03 O 
. O 
There O 
was O 
a O 
borderline O 
greater O 
increase O 
in O 
urinary O 
NTX O 
in O 
those O 
with O 
the O 
AA O 
genotype O 
compared O 
to O 
patients O 
with O 
the O 
G O 
allele O 
, O 
p=0.05 O 
; O 
but O 
no O 
significant O 
difference O 
in O 
changes O 
in O 
estradiol B-TRIVIAL 
levels O 
among O 
the O 
genotypes O 
. O 
CONCLUSION O 
: O 
Patients O 
with O 
the O 
AA O 
genotype O 
for O 
the O 
rs700518 O 
polymorphism O 
in O 
the O 
CYP19A1 O 
gene O 
are O 
at O 
risk O 
for O 
AI-associated O 
bone O 
loss O 
and O 
deserve O 
close O 
follow O 
- O 
up O 
during O 
long O 
- O 
term O 
AI O 
therapy O 
. O 

has O 
traditionally O 
only O 
been O 
regarded O 
as O 
a O 
neurotransmitter O 
of O 
the O 
parasympathetic O 
nervous O 
system O 
, O 
causing O 
bronchoconstriction O 
and O 
mucus O 
secretion O 
in O 
asthma O 
and O 
COPD O 
by O 
muscarinic O 
receptor O 
activation O 
on O 
airway O 
smooth O 
muscle O 
and O 
mucus O 
- O 
producing O 
cells O 
. O 
Recent O 
studies O 
in O 
experimental O 
models O 
indicate O 
that O 
muscarinic O 
receptor O 
stimulation O 
in O 
the O 
airways O 
also O 
induces O 
pro O 
- O 
inflammatory O 
, O 
pro O 
- O 
proliferative O 
and O 
pro O 
- O 
fibrotic O 
effects O 
, O 
which O 
may O 
involve O 
activation O 
of O 
airway O 
structural O 
and O 
inflammatory O 
cells O 
by O 
neuronal O 
as O 
well O 
as O 
non-neuronal O 
acetylcholine B-SYSTEMATIC 
. O 
In O 
addition O 
, O 
mechanical O 
changes O 
caused O 
by O 
muscarinic O 
agonist O 
- O 
induced O 
bronchoconstriction O 
may O 
be O 
involved O 
in O 
airway O 
remodeling O 
. O 
Crosstalk O 
between O 
muscarinic O 
receptors O 
and O 
β2-adrenoceptors O 
on O 
airway O 
smooth O 
muscle O 
causes O 
a O 
reduced O 
bronchodilator O 
response O 
to O 
β2-agonists O 
, O 
and O 
a O 
similar O 
mechanism O 
could O 
possibly O 
apply O 
to O 
the O 
poor O 
inhibition O 
of O 
inflammatory O 
and O 
remodeling O 
processes O 
by O 
these O 
drugs O 
. O 
Collectively O 
, O 
these O 
findings O 
provide O 
novel O 
perspectives O 
for O 
muscarinic O 
receptor O 
antagonists O 
in O 
asthma O 
and O 
COPD O 
, O 
since O 
these O 
drugs O 
may O 
not O 
only O 
acutely O 
affect O 
cholinergic O 
airways O 
obstruction O 
, O 
but O 
also O 
have O 
important O 
beneficial O 
effects O 
on O 
β2-agonist O 
responsiveness O 
, O 
airway O 
inflammation O 
and O 
remodeling O 
. O 
The O 
clinical O 
relevance O 
of O 
these O 
findings O 
is O 
presently O 
under O 
investigation O 
and O 
starting O 
to O 
emerge O 
. O 

medial O 
prefrontal O 
cortex O 
( O 
mPFC O 
) O 
has O 
been O 
implicated O 
in O 
modulating O 
anxiety O 
. O 
However O 
, O 
it O 
is O 
unknown O 
whether O 
excitatory O 
or O 
inhibitory O 
neurotransmission O 
in O 
the O 
infralimbic O 
( O 
IL O 
) O 
subregion O 
of O 
the O 
mPFC O 
underlies O 
the O 
pathology O 
of O 
anxiety O 
- O 
related O 
behavior O 
. O 
To O 
address O 
this O 
issue O 
, O 
we O 
infused O 
the O 
GABAA O 
receptor O 
( O 
GABAAR O 
) O 
antagonist O 
bicuculline B-TRIVIAL 
to O 
temporarily O 
activate O 
the O 
IL O 
cortex O 
. O 
IL O 
cortex O 
activation O 
decreased O 
the O 
time O 
spent O 
in O 
the O 
center O 
area O 
in O 
the O 
open O 
field O 
test O 
, O 
decreased O 
exploration O 
of O 
the O 
open O 
- O 
arms O 
in O 
the O 
elevated O 
plus O 
maze O 
test O 
, O 
and O 
increased O 
the O 
latency O 
to O 
bite O 
food O 
in O 
the O 
novelty O 
- O 
suppressed O 
feeding O 
test O 
. O 
These O 
findings O 
substantiate O 
the O 
GABA B-ABBREVIATION 
ergic O 
system's O 
role O 
in O 
anxiety O 
- O 
related O 
behaviors O 
. O 
IL O 
cortex O 
inactivation O 
with O 
the O 
AMPA B-ABBREVIATION 
receptor O 
( O 
AMPAR O 
) O 
antagonist O 
CNQX O 
produced O 
opposite O 
, O 
anxiolytic O 
effects O 
. O 
However O 
, O 
infusion O 
of O 
the O 
NMDA B-ABBREVIATION 
receptor O 
( O 
NMDAR O 
) O 
antagonist O 
AP5 O 
into O 
the O 
IL O 
cortex O 
had O 
no O 
significant O 
effect O 
. O 
Additionally O 
, O 
we O 
did O 
not O 
observe O 
motor O 
activity O 
deficits O 
or O 
appetite O 
deficits O 
following O 
inhibition O 
of O 
GABA B-ABBREVIATION 
ergic O 
or O 
glutamatergic O 
neurotransmission O 
. O 
Interestingly O 
, O 
we O 
found O 
parallel O 
and O 
corresponding O 
electrophysiological O 
changes O 
in O 
anxious O 
mice O 
; O 
compared O 
to O 
mice O 
with O 
relatively O 
low O 
anxiety O 
, O 
the O 
relatively O 
high O 
anxiety O 
mice O 
exhibited O 
smaller O 
evoked O 
inhibitory O 
postsynaptic O 
currents O 
( O 
eIPSCs O 
) O 
and O 
larger O 
AMPA B-ABBREVIATION 
-mediated O 
evoked O 
excitatory O 
postsynaptic O 
currents O 
( O 
eEPSCs O 
) O 
in O 
pyramidal O 
neurons O 
in O 
the O 
IL O 
cortex O 
. O 
The O 
changes O 
of O 
eIPSCs O 
and O 
eEPSCs O 
were O 
due O 
to O 
presynaptic O 
mechanisms O 
. O 
Our O 
results O 
suggest O 
that O 
imbalances O 
of O 
neurotransmission O 
in O 
the O 
IL O 
cortex O 
may O 
cause O 
a O 
net O 
increase O 
in O 
excitatory O 
inputs O 
onto O 
pyramidal O 
neurons O 
, O 
which O 
may O 
underlie O 
the O 
pathogenic O 
mechanism O 
of O 
anxiety O 
disorders O 
. O 

promotes O 
mTORC1-dependent O 
phosphorylation O 
of O 
ribosomal O 
protein O 
S6 O 
via O 
dopamine B-TRIVIAL 
- O 
and O 
cAMP B-ABBREVIATION 
-regulated O 
phosphoprotein O 
of O 
32 O 
kDa O 
and O 
inhibition O 
of O 
protein O 
phosphatase-1 O 
. O 

ribosomal O 
protein O 
S6 O 
( O 
rpS6 O 
) O 
is O 
a O 
component O 
of O 
the O 
small O 
40S O 
ribosomal O 
subunit O 
, O 
involved O 
in O 
multiple O 
physiological O 
functions O 
. O 
Here O 
, O 
we O 
examined O 
the O 
effects O 
produced O 
by O 
haloperidol B-TRIVIAL 
, O 
a O 
typical O 
antipsychotic O 
drug O 
, O 
on O 
the O 
phosphorylation O 
of O 
rpS6 O 
at O 
Ser B-FORMULA 
240 O 
/ O 
244 O 
in O 
the O 
striatum O 
, O 
a O 
brain O 
region O 
involved O 
in O 
neurodegenerative O 
and O 
neuropsychiatric O 
disorders O 
. O 
Administration O 
of O 
haloperidol B-TRIVIAL 
increased O 
Ser B-FORMULA 
240 O 
/ O 
244 O 
phosphorylation O 
in O 
a O 
subpopulation O 
of O 
GABA B-ABBREVIATION 
-ergic O 
medium O 
spiny O 
neurons O 
( O 
MSNs O 
) O 
, O 
which O 
express O 
dopamine B-TRIVIAL 
D2 O 
receptors O 
( O 
D2Rs O 
) O 
. O 
This O 
effect O 
was O 
prevented O 
by O 
rapamycin B-TRIVIAL 
, O 
an O 
inhibitor O 
of O 
the O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
complex O 
1 O 
( O 
mTORC1 O 
) O 
, O 
or O 
by O 
PF470867 B-IDENTIFIER 
, O 
a O 
selective O 
inhibitor O 
of O 
the O 
p70 O 
ribosomal O 
S6 O 
kinase O 
1 O 
( O 
S6K1 O 
) O 
. O 
We O 
also O 
found O 
that O 
the O 
effect O 
of O 
haloperidol B-TRIVIAL 
on O 
Ser B-FORMULA 
240 O 
/ O 
244 O 
phosphorylation O 
was O 
prevented O 
by O 
functional O 
inactivation O 
of O 
dopamine B-TRIVIAL 
- O 
and O 
cAMP B-ABBREVIATION 
-regulated O 
phosphoprotein O 
of O 
32 O 
kDa O 
( O 
DARPP-32 O 
) O 
, O 
an O 
endogenous O 
inhibitor O 
of O 
protein O 
phosphatase-1 O 
( O 
PP-1 O 
) O 
. O 
In O 
line O 
with O 
this O 
observation O 
, O 
incubation O 
of O 
striatal O 
slices O 
with O 
okadaic B-TRIVIAL 
acid I-TRIVIAL 
and O 
calyculin B-TRIVIAL 
A I-TRIVIAL 
, O 
two O 
inhibitors O 
of O 
PP-1 O 
, O 
increased O 
Ser B-FORMULA 
240 O 
/ O 
244 O 
phosphorylation O 
. O 
These O 
results O 
show O 
that O 
haloperidol B-TRIVIAL 
promotes O 
mTORC1- O 
and O 
S6K1-dependent O 
phosphorylation O 
of O 
rpS6 O 
at O 
Ser B-FORMULA 
240 O 
/ O 
244 O 
, O 
in O 
a O 
subpopulation O 
of O 
striatal O 
MSNs O 
expressing O 
D2Rs O 
. O 
They O 
also O 
indicate O 
that O 
this O 
effect O 
is O 
exerted O 
by O 
suppressing O 
dephosphorylation O 
at O 
Ser B-FORMULA 
240 O 
/ O 
244 O 
, O 
through O 
PKA-dependent O 
activation O 
of O 
DARPP-32 O 
and O 
inhibition O 
of O 
PP-1 O 
. O 

-mediated O 
activation O 
of O 
Akt O 
protects O 
SH-SY5Y O 
neuroblastoma O 
cells O 
from O 
6-hydroxydopamine B-SYSTEMATIC 
-induced O 
apoptotic O 
and O 
autophagic O 
death O 
. O 

investigated O 
the O 
ability O 
of O 
19 O 
recently O 
synthesized O 
arylpiperazine B-FAMILY 
compounds O 
to O 
protect O 
human O 
SH-SY5Y O 
neuroblastoma O 
cells O 
from O 
the O 
neurotoxin O 
6-hydroxydopamine B-SYSTEMATIC 
( O 
6-OHDA B-SYSTEMATIC 
) O 
. O 
The O 
compound O 
with O 
the O 
most O 
potent O 
neuroprotective O 
action O 
was O 
N-{3-[2-(4-phenyl-piperazin-1-yl)-ethyl]-phenyl}-picolinamide B-SYSTEMATIC 
( O 
6b O 
) O 
, O 
which O 
reduced O 
6-OHDA B-SYSTEMATIC 
-induced O 
apoptotic O 
death O 
through O 
stabilization O 
of O 
mitochondrial O 
membrane O 
and O 
subsequent O 
prevention O 
of O 
superoxide B-TRIVIAL 
production O 
, O 
caspase O 
activation O 
and O 
DNA O 
fragmentation O 
. O 
6-OHDA B-SYSTEMATIC 
-triggered O 
autophagic O 
response O 
was O 
also O 
reduced O 
by O 
6b O 
, O 
which O 
prevented O 
inactivation O 
of O 
the O 
main O 
autophagy O 
repressor O 
mTOR O 
, O 
upregulation O 
of O 
pro O 
- O 
autophagic O 
beclin-1 O 
, O 
conversion O 
of O 
microtubule O 
- O 
associated O 
protein O 
1 O 
light O 
chain O 
3 O 
(LC3)-I O 
to O 
autophagosome O 
- O 
associated O 
LC3-II O 
, O 
as O 
well O 
as O 
intracytoplasmic O 
acidification O 
induced O 
by O 
6-OHDA B-SYSTEMATIC 
. O 
The O 
inhibition O 
of O 
autophagy O 
using O 
LC3β O 
gene O 
silencing O 
or O 
pharmacological O 
autophagy O 
blockers O 
3-methyladenine B-SYSTEMATIC 
or O 
bafilomycin B-TRIVIAL 
A1 I-TRIVIAL 
, O 
mimicked O 
the O 
cytoprotective O 
effect O 
of O 
6b O 
. O 
While O 
the O 
treatment O 
with O 
6b O 
had O 
no O 
effect O 
on O 
the O 
phosphorylation O 
of O 
proapoptotic O 
MAP O 
kinases O 
ERK O 
and O 
JNK O 
, O 
it O 
markedly O 
increased O 
the O 
phosphorylation O 
of O 
the O 
prosurvival O 
kinase O 
Akt O 
in O 
6-OHDA B-SYSTEMATIC 
-treated O 
cells O 
. O 
Akt O 
inhibitor O 
DEBC O 
or O 
RNA O 
interference O 
- O 
mediated O 
Akt O 
silencing O 
reduced O 
the O 
ability O 
of O 
6b O 
to O 
block O 
6-OHDA B-SYSTEMATIC 
-triggered O 
apoptotic O 
and O 
autophagic O 
responses O 
, O 
thus O 
confirming O 
their O 
dependency O 
on O 
Akt O 
activation O 
. O 
The O 
cytoprotective O 
effect O 
of O 
6b O 
was O 
also O 
observed O 
in O 
6-OHDA B-SYSTEMATIC 
-treated O 
neuronal O 
PC12 O 
cells O 
, O 
but O 
not O 
in O 
SH-SY5Y O 
or O 
PC12 O 
cells O 
exposed O 
to O 
1-methyl-4-phenylpyridinium B-SYSTEMATIC 
, O 
indicating O 
that O 
the O 
observed O 
neuroprotection O 
was O 
dependent O 
on O 
the O 
cytotoxic O 
stimulus O 
. O 
Because O 
of O 
the O 
ability O 
to O 
prevent O 
6-OHDA B-SYSTEMATIC 
induced O 
apoptotic O 
/ O 
autophagic O 
cell O 
death O 
through O 
activation O 
of O 
Akt O 
, O 
the O 
investigated O 
arylpiperazines B-FAMILY 
could O 
be O 
potential O 
candidates O 
for O 
treatment O 
of O 
neurodegenerative O 
diseases O 
. O 

fatty B-FAMILY 
acid I-FAMILY 
amide I-FAMILY 
hydrolase O 
inhibitor O 
, O 
URB597 B-IDENTIFIER 
, O 
promotes O 
retinal B-TRIVIAL 
ganglion O 
cell O 
neuroprotection O 
in O 
a O 
rat O 
model O 
of O 
optic O 
nerve O 
axotomy O 
. O 

endocannabinoid O 
, O 
N-arachidonoylethanolamine B-SYSTEMATIC 
( O 
AEA B-ABBREVIATION 
) O 
, O 
is O 
degraded O 
by O 
the O 
enzyme O 
fatty B-FAMILY 
acid I-FAMILY 
amide I-FAMILY 
hydrolase O 
( O 
FAAH O 
) O 
. O 
This O 
study O 
examined O 
whether O 
the O 
FAAH O 
inhibitor O 
, O 
URB597 O 
, O 
increases O 
retinal B-TRIVIAL 
ganglion O 
cell O 
( O 
RGC O 
) O 
survival O 
following O 
optic O 
nerve O 
axotomy O 
in O 
young O 
and O 
aged O 
animals O 
. O 
URB597 B-IDENTIFIER 
alone O 
, O 
or O 
together O 
with O 
either O 
a O 
CB1 O 
or O 
CB2 O 
receptor O 
antagonist O 
, O 
was O 
administered O 
daily O 
for O 
1 O 
or O 
2 O 
weeks O 
post O 
- O 
axotomy O 
. O 
Histological O 
assessment O 
of O 
retinas O 
indicated O 
that O 
URB597 B-IDENTIFIER 
increased O 
RGC O 
survival O 
in O 
young O 
retina O 
at O 
1 O 
and O 
2 O 
weeks O 
post O 
- O 
axotomy O 
. O 
The O 
increase O 
in O 
RGC O 
survival O 
at O 
2 O 
weeks O 
was O 
accompanied O 
by O 
a O 
reduction O 
in O 
phagocytic O 
microglia O 
. O 
The O 
CB1 O 
antagonist O 
, O 
AM281 B-IDENTIFIER 
, O 
but O 
not O 
the O 
CB2 O 
antagonist O 
, O 
AM630 B-IDENTIFIER 
, O 
ablated O 
URB597 B-IDENTIFIER 
-mediated O 
RGC O 
neuroprotection O 
. O 
CB1 O 
or O 
CB2 O 
antagonism O 
increased O 
phagocytic O 
microglia O 
in O 
URB597 B-IDENTIFIER 
and O 
vehicle O 
- O 
treated O 
animals O 
. O 
In O 
aged O 
animals O 
, O 
URB597 B-IDENTIFIER 
increased O 
RGC O 
survival O 
at O 
1 O 
week O 
, O 
but O 
not O 
at O 
2 O 
weeks O 
post O 
- O 
axotomy O 
and O 
had O 
no O 
effect O 
on O 
microglia O 
. O 
Retinal B-TRIVIAL 
Iba-1 O 
positive O 
microglia O 
were O 
also O 
decreased O 
in O 
URB597 B-IDENTIFIER 
-treated O 
axotomized O 
young O 
animals O 
and O 
this O 
decrease O 
was O 
mitigated O 
by O 
CB1 O 
but O 
not O 
CB2 O 
antagonism O 
. O 
As O 
seen O 
with O 
phagocytotic O 
microglia O 
, O 
the O 
CB2 O 
antagonist O 
, O 
AM630 B-IDENTIFIER 
, O 
increased O 
Iba-1 O 
positive O 
microglia O 
in O 
the O 
absence O 
of O 
URB597 B-IDENTIFIER 
treatment O 
. O 
Measurement O 
of O 
retinal B-TRIVIAL 
endocannabinoid O 
levels O 
in O 
URB597 B-IDENTIFIER 
-treated O 
animals O 
at O 
2 O 
weeks O 
post O 
- O 
axotomy O 
revealed O 
a O 
significant O 
increase O 
in O 
AEA B-ABBREVIATION 
levels O 
, O 
accompanied O 
by O 
a O 
decrease O 
by O 
a O 
decrease O 
in O 
the O 
AEA B-ABBREVIATION 
metabolite O 
, O 
N-arachidonoylglycine B-SYSTEMATIC 
, O 
in O 
young O 
animals O 
but O 
not O 
aged O 
animals O 
. O 
2-arachidonoylglycerol B-SYSTEMATIC 
levels O 
were O 
similar O 
across O 
all O 
experimental O 
groups O 
. O 
These O 
data O 
demonstrate O 
that O 
URB597 B-IDENTIFIER 
-mediated O 
retinal B-TRIVIAL 
neuroprotective O 
effects O 
are O 
mediated O 
primarily O 
through O 
CB1 O 
receptors O 
and O 
that O 
URB597 B-IDENTIFIER 
neuroprotective O 
efficacy O 
declines O 
with O 
age O 
. O 

and O 
noradrenergic O 
neuromodulation O 
play O 
a O 
key O 
role O 
in O 
determining O 
overall O 
behavioral O 
state O 
by O 
shaping O 
the O 
underlying O 
cortical O 
network O 
dynamics O 
. O 
The O 
effects O 
of O 
these O 
systems O 
on O 
synaptic O 
and O 
intrinsic O 
cellular O 
targets O 
are O 
quite O 
diverse O 
and O 
a O 
comprehensive O 
understanding O 
of O 
how O 
these O 
neuromodulators O 
regulate O 
( O 
spontaneous O 
) O 
cortical O 
network O 
activity O 
has O 
remained O 
elusive O 
. O 
Here O 
, O 
we O 
used O 
multielectrode O 
electrophysiology O 
in O 
vitro O 
to O 
investigate O 
the O 
effect O 
of O 
these O 
neuromodulators O 
on O 
spontaneous O 
network O 
dynamics O 
in O 
acute O 
slices O 
of O 
mouse O 
visual O 
cortex O 
. O 
We O 
found O 
that O 
application O 
of O 
Carbachol B-TRIVIAL 
( O 
CCh B-ABBREVIATION 
) O 
and O 
Norepinephrine B-TRIVIAL 
( O 
NE O 
) O 
both O 
enhanced O 
the O 
spontaneous O 
network O 
dynamics O 
by O 
increasing O 
( O 
1 O 
) O 
the O 
activity O 
levels O 
, O 
( O 
2 O 
) O 
the O 
temporal O 
complexity O 
of O 
the O 
network O 
activity O 
, O 
and O 
( O 
3 O 
) O 
the O 
spatial O 
complexity O 
by O 
decorrelating O 
the O 
network O 
activity O 
over O 
a O 
wide O 
range O 
of O 
neuromodulator O 
concentrations O 
( O 
1μM O 
, O 
10μM O 
, O 
50μM O 
, O 
and O 
100μM O 
) O 
. O 
Interestingly O 
, O 
we O 
found O 
that O 
cholinergic O 
neuromodulation O 
was O 
limited O 
to O 
the O 
presence O 
of O 
CCh B-ABBREVIATION 
in O 
the O 
bath O 
whereas O 
the O 
effects O 
of O 
NE O 
, O 
in O 
particular O 
for O 
higher O 
concentrations O 
, O 
induced O 
plasticity O 
that O 
caused O 
outlasting O 
effects O 
most O 
prominently O 
in O 
the O 
deep O 
cortical O 
layers O 
. O 
Together O 
, O 
these O 
results O 
provide O 
a O 
comprehensive O 
network O 
- O 
level O 
understanding O 
of O 
the O 
similarities O 
and O 
differences O 
of O 
cholinergic O 
and O 
noradrenergic O 
modulation O 
of O 
spontaneous O 
network O 
dynamics O 
. O 

the O 
Physical O 
form O 
of O 
Mannitol B-TRIVIAL 
in O 
Freeze-Dried O 
Systems O 
. O 

potential O 
drawback O 
with O 
the O 
use O 
of O 
mannitol B-TRIVIAL 
as O 
a O 
bulking O 
agent O 
is O 
its O 
existence O 
as O 
mannitol B-TRIVIAL 
hemihydrate I-TRIVIAL 
( O 
MHH B-ABBREVIATION 
; O 
C6H14O6( O 
. O 
)0.5H2O O 
) O 
in O 
the O 
lyophile O 
. O 
Once O 
formed O 
during O 
freeze O 
- O 
drying O 
, O 
MH B-ABBREVIATION 
H O 
dehydration O 
may O 
require O 
secondary O 
drying O 
under O 
aggressive O 
conditions O 
which O 
can O 
be O 
detrimental O 
to O 
the O 
stability O 
of O 
thermolabile O 
components O 
. O 
If O 
MH B-ABBREVIATION 
H O 
is O 
retained O 
in O 
the O 
lyophile O 
, O 
the O 
water O 
released O 
by O 
MH B-ABBREVIATION 
H O 
dehydration O 
during O 
storage O 
has O 
the O 
potential O 
to O 
cause O 
product O 
instability O 
. O 
We O 
systematically O 
identified O 
the O 
conditions O 
under O 
which O 
anhydrous O 
mannito B-TRIVIAL 
l O 
and O 
MH B-ABBREVIATION 
H O 
crystallized O 
in O 
frozen O 
systems O 
with O 
the O 
goal O 
of O 
preventing O 
MH B-ABBREVIATION 
H O 
formation O 
during O 
freeze O 
- O 
drying O 
. O 
When O 
mannito B-TRIVIAL 
l O 
solutions O 
were O 
cooled O 
, O 
the O 
temperature O 
of O 
solute O 
crystallization O 
was O 
the O 
determinant O 
of O 
the O 
physical O 
form O 
of O 
mannito B-TRIVIAL 
l O 
. O 
Based O 
on O 
low O 
temperature O 
X-ray O 
diffractometry O 
( O 
using O 
both O 
laboratory O 
and O 
synchrotron O 
sources O 
) O 
, O 
MH B-ABBREVIATION 
H O 
formation O 
was O 
observed O 
when O 
solute O 
crystallization O 
occurred O 
at O 
temperatures O 
⩽ O 
-20 O 
°C O 
while O 
anhydrous O 
mannito B-TRIVIAL 
l O 
crystallized O 
at O 
temperatures O 
⩾ O 
-10 O 
°C O 
. O 
The O 
transition O 
temperature O 
( O 
anhydrate O 
- O 
MH B-ABBREVIATION 
H O 
) O 
appears O 
to O 
be O 
∼ O 
-15 O 
°C O 
. O 
The O 
use O 
of O 
a O 
freeze O 
- O 
dryer O 
with O 
controlled O 
ice O 
nucleation O 
technology O 
enabled O 
anhydrous O 
mannito B-TRIVIAL 
l O 
crystallization O 
at O 
∼ O 
-5 O 
°C O 
. O 
Thus O 
, O 
ice O 
crystallization O 
followed O 
by O 
annealing O 
at O 
temperatures O 
⩾ O 
-10 O 
°C O 
can O 
be O 
an O 
effective O 
strategy O 
to O 
prevent O 
MH B-ABBREVIATION 
H O 
formation O 
. O 

on O 
the O 
interaction O 
of O 
the O 
toxicant O 
, O 
gentian B-TRIVIAL 
violet I-TRIVIAL 
, O 
with O 
bovine O 
hemoglobin O 
. O 

violet I-TRIVIAL 
( O 
GV O 
) O 
is O 
a O 
well O 
- O 
known O 
triarylmethane B-FAMILY 
dye O 
that O 
is O 
used O 
in O 
aquacultural O 
, O 
industrial O 
and O 
medicinal O 
fields O 
. O 
But O 
concerns O 
in O 
growing O 
number O 
have O 
been O 
paid O 
to O 
its O 
potential O 
health O 
problems O 
to O 
human O 
beings O 
and O 
its O 
hazardous O 
effects O 
to O 
environment O 
. O 
Herein O 
, O 
the O 
toxic O 
interaction O 
of O 
GV O 
with O 
bovine O 
hemoglobin O 
( O 
BHb O 
) O 
was O 
investigated O 
by O 
a O 
series O 
of O 
spectroscopic O 
methods O 
and O 
molecular O 
modeling O 
method O 
. O 
The O 
fluorescence O 
emission O 
profile O 
exhibited O 
a O 
remarkable O 
quenching O 
upon O 
addition O 
of O 
GV O 
to O 
the O 
buffered O 
aqueous O 
solution O 
of O 
BHb O 
and O 
the O 
analysis O 
of O 
results O 
revealed O 
the O 
dominant O 
role O 
of O 
static O 
quenching O 
mechanism O 
in O 
GV-BHb O 
interaction O 
. O 
The O 
negative O 
ΔH O 
and O 
positive O 
ΔS O 
values O 
demonstrated O 
that O 
the O 
electrostatic O 
interactions O 
mainly O 
stabilized O 
this O 
toxicant O 
- O 
protein O 
complex O 
. O 
Synchronous O 
fluorescence O 
, O 
UV-vis O 
absorption O 
and O 
CD O 
spectroscopic O 
studies O 
proved O 
that O 
the O 
conformational O 
change O 
of O 
BHb O 
was O 
induced O 
by O 
GV's O 
combination O 
. O 
Molecular O 
modeling O 
studies O 
exhibited O 
the O 
binding O 
mode O 
of O 
GV-BHb O 
complex O 
and O 
the O 
detailed O 
information O 
of O 
related O 
driving O 
forces O 
. O 
During O 
the O 
1H B-FORMULA 
nuclear O 
magnetic O 
resonance O 
spectra O 
( O 
1H B-FORMULA 
NMR O 
) O 
study O 
, O 
the O 
chemical O 
shift O 
perturbation O 
and O 
spin O 
- O 
lattice O 
relaxation O 
times O 
of O 
different O 
protons O 
were O 
further O 
used O 
to O 
investigate O 
the O 
interaction O 
of O 
GV O 
with O 
BHb O 
and O 
the O 
results O 
indicated O 
that O 
GV O 
bound O 
orientationally O 
to O 
BHb O 
. O 

of O 
prolyl B-TRIVIAL 
oligopeptidase O 
and O 
activated O 
alpha-2-macroglobulin O 
in O 
multiple O 
sclerosis O 
subtypes O 
and O 
in O 
the O 
clinically O 
isolated O 
syndrome O 
. O 

oligopeptidase O 
( O 
PREP O 
) O 
has O 
been O 
considered O 
as O 
a O 
drug O 
target O 
for O 
the O 
treatment O 
of O 
neurodegenerative O 
diseases O 
. O 
In O 
plasma O 
, O 
PREP O 
has O 
been O 
found O 
altered O 
in O 
several O 
disorders O 
of O 
the O 
central O 
nervous O 
system O 
including O 
multiple O 
sclerosis O 
( O 
MS O 
) O 
. O 
Oxidative O 
stress O 
and O 
the O 
levels O 
of O 
an O 
endogenous O 
plasma O 
PREP O 
inhibitor O 
have O 
been O 
proposed O 
to O 
decrease O 
PREP O 
activity O 
in O 
MS O 
. O 
In O 
this O 
work O 
, O 
we O 
measured O 
the O 
circulating O 
levels O 
of O 
PREP O 
in O 
patients O 
suffering O 
of O 
relapsing O 
remitting O 
( O 
RR O 
) O 
, O 
secondary O 
progressive O 
( O 
SP O 
) O 
, O 
primary O 
progressive O 
( O 
PP O 
) O 
MS O 
, O 
and O 
in O 
subjects O 
with O 
clinically O 
isolated O 
syndrome O 
( O 
CIS O 
) O 
. O 
We O 
found O 
a O 
significantly O 
lower O 
PREP O 
activity O 
in O 
plasma O 
of O 
RRMS O 
as O 
well O 
as O 
in O 
PPMS O 
patients O 
and O 
a O 
trend O 
to O 
reduced O 
activity O 
in O 
subjects O 
diagnosed O 
with O 
CIS O 
, O 
compared O 
to O 
controls O 
. O 
No O 
signs O 
of O 
oxidative O 
inactivation O 
of O 
PREP O 
, O 
and O 
no O 
correlation O 
with O 
the O 
endogenous O 
PREP O 
inhibitor O 
, O 
identified O 
as O 
activated O 
α-2-macroglobulin O 
( O 
α2M* O 
) O 
, O 
were O 
observed O 
in O 
any O 
of O 
the O 
patients O 
studied O 
. O 
However O 
, O 
a O 
significant O 
decrease O 
of O 
α2M* O 
was O 
recorded O 
in O 
MS O 
. O 
In O 
cell O 
cultures O 
, O 
we O 
found O 
that O 
PREP O 
specifically O 
stimulates O 
immune O 
active O 
cells O 
possibly O 
by O 
modifying O 
the O 
levels O 
of O 
fibrinogen O 
β O 
, O 
thymosin O 
β4 O 
, O 
and O 
collagen O 
. O 
Our O 
results O 
open O 
new O 
lines O 
of O 
research O 
on O 
the O 
role O 
of O 
PREP O 
and O 
α2M* O 
in O 
MS O 
, O 
aiming O 
to O 
relate O 
them O 
to O 
the O 
diagnosis O 
and O 
prognosis O 
of O 
this O 
devastating O 
disease O 
. O 

C1 O 
domain O 
- O 
targeted O 
isophthalate B-SYSTEMATIC 
derivative O 
HMI-1b11 O 
promotes O 
neurite O 
outgrowth O 
and O 
GAP-43 O 
expression O 
through O 
PKCα O 
activation O 
in O 
SH-SY5Y O 
cells O 
. O 

kinase O 
C O 
( O 
PKC O 
) O 
is O 
a O 
family O 
of O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
phosphotransferases O 
ubiquitously O 
expressed O 
and O 
involved O 
in O 
multiple O 
cellular O 
functions O 
, O 
such O 
as O 
proliferation O 
, O 
apoptosis O 
and O 
differentiation O 
. O 
The O 
C1 O 
domain O 
of O 
PKC O 
represents O 
an O 
attractive O 
drug O 
target O 
, O 
especially O 
for O 
developing O 
PKC O 
activators O 
. O 
Dialkyl B-FAMILY 
5-(hydroxymethyl)isophthalates I-FAMILY 
are O 
a O 
novel O 
group O 
of O 
synthetic O 
C1 O 
domain O 
ligands O 
that O 
exhibit O 
antiproliferative O 
effect O 
in O 
HeLa O 
cervical O 
carcinoma O 
cells O 
. O 
Here O 
we O 
selected O 
two O 
isophthalates B-FAMILY 
, O 
HMI-1a3 O 
and O 
HMI-1b11 O 
, O 
and O 
characterized O 
their O 
effects O 
in O 
the O 
human O 
neuroblastoma O 
cell O 
line O 
SH-SY5Y O 
. O 
Both O 
of O 
the O 
active O 
isophthalates B-FAMILY 
exhibited O 
significant O 
antiproliferative O 
and O 
differentiation O 
- O 
inducing O 
effects O 
. O 
Since O 
HMI-1b11 O 
did O 
not O 
impair O 
cell O 
survival O 
even O 
at O 
the O 
highest O 
concentration O 
tested O 
( O 
20μM O 
) O 
, O 
and O 
supported O 
neurite O 
growth O 
and O 
differentiation O 
of O 
SH-SY5Y O 
cells O 
, O 
we O 
focused O 
on O 
studying O 
its O 
downstream O 
signaling O 
cascades O 
and O 
effects O 
on O 
gene O 
expression O 
. O 
Consistently O 
, O 
genome O 
- O 
wide O 
gene O 
expression O 
microarray O 
and O 
gene O 
set O 
enrichment O 
analysis O 
indicated O 
that O 
HMI-1b11 O 
( O 
10μM O 
) O 
induced O 
changes O 
in O 
genes O 
mainly O 
related O 
to O 
cell O 
differentiation O 
. O 
In O 
particular O 
, O 
further O 
studies O 
revealed O 
that O 
HMI-1b11 O 
exposure O 
induced O 
up O 
- O 
regulation O 
of O 
GAP-43 O 
, O 
a O 
marker O 
for O 
neurite O 
sprouting O 
and O 
neuronal O 
differentiation O 
. O 
These O 
effects O 
were O 
induced O 
by O 
a O 
7-minute O 
HMI-1b11 O 
treatment O 
and O 
specifically O 
depended O 
on O 
PKCα O 
activation O 
, O 
since O 
pretreatment O 
with O 
the O 
selective O 
inhibitor O 
Gö6976 B-IDENTIFIER 
abolished O 
the O 
up O 
- O 
regulation O 
of O 
GAP-43 O 
protein O 
observed O 
at O 
12hours O 
In O 
parallel O 
, O 
we O 
found O 
that O 
a O 
7-minute O 
exposure O 
to O 
HMI-1b11 O 
induced O 
PKCα O 
accumulation O 
to O 
the O 
cytoskeleton O 
, O 
an O 
effect O 
that O 
was O 
again O 
prevented O 
by O 
pretreatment O 
with O 
Gö6976 B-IDENTIFIER 
. O 
Despite O 
similar O 
binding O 
affinities O 
to O 
PKC O 
, O 
the O 
isophthalates O 
had O 
different O 
effects O 
on O 
PKC-dependent O 
ERK1 O 
/ O 
2 O 
signaling O 
: O 
HMI-1a3-induced O 
ERK1 O 
/ O 
2 O 
phosphorylation O 
was O 
transient O 
, O 
while O 
HMI-1b11 O 
induced O 
a O 
rapid O 
but O 
prolonged O 
ERK1 O 
/ O 
2 O 
phosphorylation O 
. O 
Overall O 
our O 
data O 
are O 
in O 
accordance O 
with O 
previous O 
studies O 
showing O 
that O 
activation O 
of O 
the O 
PKCα O 
and O 
ERK1 O 
/ O 
2 O 
pathways O 
participate O 
in O 
regulating O 
neuronal O 
differentiation O 
. O 
Furthermore O 
, O 
since O 
PKC O 
has O 
been O 
classified O 
as O 
one O 
of O 
the O 
cognitive O 
kinases O 
, O 
and O 
activation O 
of O 
PKC O 
is O 
considered O 
a O 
potential O 
therapeutic O 
strategy O 
for O 
the O 
treatment O 
of O 
cognitive O 
disorders O 
, O 
our O 
findings O 
suggest O 
that O 
HMI-1b11 O 
represents O 
a O 
promising O 
lead O 
compound O 
in O 
research O 
aimed O 
to O 
prevent O 
or O 
counteract O 
memory O 
impairment O 
. O 

of O 
highly O 
potent O 
triazole B-FAMILY 
antifungal O 
derivatives O 
by O 
heterocycle- O 
benzene B-SYSTEMATIC 
bioisosteric O 
replacement O 
. O 

the O 
basis O 
of O 
our O 
previously O 
discovered O 
triazole B-FAMILY 
antifungal O 
lead O 
compounds O 
, O 
heterocycle- O 
benzene B-SYSTEMATIC 
bioisosteric O 
replacement O 
was O 
used O 
to O 
improve O 
their O 
pharmacokinetic O 
profile O 
. O 
The O 
designed O 
new O 
triazole B-FAMILY 
derivatives O 
have O 
good O 
antifungal O 
activity O 
toward O 
a O 
wide O 
range O 
of O 
pathogenic O 
fungi O 
. O 
Their O 
binding O 
mode O 
with O 
the O 
target O 
enzyme O 
was O 
clarified O 
by O 
molecular O 
docking O 
. O 
The O 
MIC O 
value O 
of O 
the O 
highly O 
potent O 
compound O 
8f O 
against O 
Candida O 
albicans O 
, O 
Candida O 
tropicalis O 
, O 
and O 
Cryptococcus O 
neoformans O 
is O 
0.016 O 
μg O 
/ O 
mL O 
, O 
0.004 O 
μg O 
/ O 
mL O 
, O 
and O 
0.016 O 
μg O 
/ O 
mL O 
, O 
respectively O 
. O 
Moreover O 
, O 
preliminary O 
pharmacokinetic O 
studies O 
revealed O 
that O 
it O 
showed O 
improved O 
oral O 
absorption O 
as O 
compared O 
to O 
the O 
lead O 
compound O 
iodiconazole B-TRIVIAL 
and O 
deserved O 
for O 
further O 
evaluations O 
. O 

of O 
energy O 
sources O 
depends O 
upon O 
the O 
ability O 
to O 
form O 
associations O 
between O 
food O 
cues O 
and O 
nutritional O 
value O 
. O 
As O 
such O 
, O 
cues O 
previously O 
paired O 
with O 
calories O 
elicit O 
neuronal O 
activation O 
in O 
the O 
nucleus O 
accumbens O 
( O 
NAcc O 
) O 
, O 
which O 
reflects O 
the O 
reinforcing O 
value O 
of O 
food O 
[ O 
1-4 O 
] O 
. O 
The O 
identity O 
of O 
the O 
physiological O 
signals O 
regulating O 
this O 
response O 
remains O 
elusive O 
. O 
Using O 
fMRI O 
, O 
we O 
examined O 
brain O 
response O 
to O 
noncaloric O 
versions O 
of O 
flavors O 
that O 
had O 
been O 
consumed O 
in O 
previous O 
days O 
with O 
either O 
0 O 
or O 
112.5 O 
calories O 
from O 
undetected O 
maltodextrin O 
. O 
We O 
report O 
a O 
small O 
but O 
perceptually O 
meaningful O 
increase O 
in O 
liking O 
for O 
the O 
flavor O 
that O 
had O 
been O 
paired O 
with O 
calories O 
and O 
find O 
that O 
change O 
in O 
liking O 
was O 
associated O 
with O 
changes O 
in O 
insular O 
responses O 
to O 
this O 
beverage O 
. O 
In O 
contrast O 
, O 
NAcc O 
and O 
hypothalamic O 
response O 
to O 
the O 
calorie O 
- O 
paired O 
flavor O 
was O 
unrelated O 
to O 
liking O 
but O 
was O 
strongly O 
associated O 
with O 
the O 
changes O 
in O 
plasma O 
glucose B-TRIVIAL 
levels O 
produced O 
by O 
ingestion O 
of O 
the O 
beverage O 
when O 
consumed O 
previously O 
with O 
calories O 
. O 
Importantly O 
, O 
because O 
each O 
participant O 
ingested O 
the O 
same O 
caloric O 
dose O 
, O 
the O 
change O 
in O 
plasma O 
glucose B-TRIVIAL 
depended O 
upon O 
individual O 
differences O 
in O 
glucose B-TRIVIAL 
metabolism O 
. O 
We O 
conclude O 
that O 
glucose B-TRIVIAL 
metabolism O 
is O 
a O 
critical O 
signal O 
regulating O 
NAcc O 
and O 
hypothalamic O 
response O 
to O 
food O 
cues O 
, O 
and O 
that O 
this O 
process O 
operates O 
independently O 
from O 
the O 
ability O 
of O 
calories O 
to O 
condition O 
liking O 
. O 

pneumoniae O 
causes O 
the O 
most O 
severe O 
form O 
of O 
the O 
bacterial O 
meningitis O 
which O 
is O 
the O 
major O 
cause O 
of O 
bacterial O 
meningitis O 
. O 
Virulence O 
factors O 
produced O 
by O 
S O 
. O 
pneumoniae O 
have O 
been O 
known O 
to O 
contribute O 
significantly O 
to O 
the O 
disease O 
process O 
. O 
ClpP O 
protease O 
( O 
ClpP O 
) O 
which O 
is O 
essential O 
for O 
virulence O 
and O 
survival O 
under O 
stress O 
conditions O 
in O 
S O 
. O 
pneumonia O 
was O 
examined O 
for O 
the O 
ability O 
to O 
induce O 
apoptosis O 
and O 
the O 
mechanism O 
of O 
the O 
induction O 
of O 
apoptosis O 
in O 
human O 
neuron O 
- O 
like O 
cells O 
, O 
SK-N-SH O 
neuroblastoma O 
cells O 
. O 
ClpP O 
inhibited O 
cell O 
growth O 
and O 
induced O 
apoptosis O 
in O 
SK-N-SH O 
cells O 
. O 
Treatment O 
with O 
ClpP O 
resulted O 
in O 
hypodiploid O 
DNA O 
contents O 
, O 
increased O 
Bax/ O 
Bcl-2 O 
ratio O 
and O 
induction O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
production O 
. O 
The O 
release O 
of O 
cytochrome O 
c O 
from O 
mitochondria O 
into O 
the O 
cytosol O 
, O 
which O 
is O 
an O 
initiator O 
of O 
the O 
activation O 
of O 
caspase O 
cascades O 
, O 
was O 
not O 
observed O 
in O 
ClpP O 
- O 
treated O 
cells O 
. O 
In O 
addition O 
, O 
pretreatment O 
with O 
Z-Val-Ala-Asp- B-SYSTEMATIC 
fluoromethylketone I-SYSTEMATIC 
( O 
Z-VAD-fmk B-ABBREVIATION 
) O 
, O 
a O 
broad O 
spectrum O 
of O 
caspase O 
inhibitor O 
, O 
could O 
not O 
rescue O 
apoptotic O 
cells O 
from O 
ClpP O 
toxicity O 
. O 
Coincidently O 
, O 
caspase-3 O 
and O 
-8 O 
activation O 
and O 
cleavage O 
of O 
PARP O 
were O 
not O 
detected O 
. O 
Moreover O 
, O 
caspase O 
independent O 
apoptosis O 
- O 
inducing O 
factor O 
( O 
AIF O 
) O 
was O 
released O 
from O 
mitochondria O 
and O 
translocated O 
to O 
the O 
nucleus O 
in O 
response O 
to O 
ClpP O 
. O 
We O 
also O 
found O 
that O 
ClpP O 
treatment O 
resulted O 
in O 
the O 
increase O 
of O 
p53 O 
activity O 
and O 
cytoplasmic O 
p53 O 
levels O 
were O 
increased O 
by O 
ClpP O 
, O 
suggesting O 
that O 
functional O 
activation O 
of O 
p53 O 
is O 
intact O 
despite O 
increased O 
cytoplasmic O 
accumulation O 
. O 
Taken O 
together O 
, O 
these O 
data O 
suggest O 
that O 
ClpP O 
contributes O 
to O 
neuronal O 
damage O 
in O 
meningitis O 
and O 
provide O 
further O 
insight O 
into O 
the O 
mechanisms O 
underlying O 
action O 
of O 
pneumococcal O 
virulence O 
factors O 
during O 
bacterial O 
pathogenesis O 
. O 

expressed O 
formyl B-SYSTEMATIC 
peptide O 
receptor O 
2 O 
( O 
FPR2 O 
/ O 
ALX O 
) O 
does O 
not O 
respond O 
to O 
lipoxin B-TRIVIAL 
A4 I-TRIVIAL 
. O 

A4 I-TRIVIAL 
( O 
LXA4 B-ABBREVIATION 
) O 
has O 
been O 
described O 
as O 
an O 
anti-inflammatory O 
mediator O 
, O 
which O 
exerts O 
its O 
effects O 
through O 
the O 
formyl O 
peptide O 
receptor O 
FPR2 O 
, O 
also O 
known O 
as O 
ALX O 
. O 
However O 
, O 
there O 
has O 
been O 
a O 
controversy O 
whether O 
or O 
not O 
cells O 
expressing O 
FPR2 O 
/ O 
ALX O 
, O 
such O 
as O 
neutrophils O 
, O 
respond O 
to O 
LXA4 B-ABBREVIATION 
. O 
We O 
, O 
therefore O 
, O 
systematically O 
examined O 
the O 
ability O 
of O 
the O 
human O 
and O 
murine O 
forms O 
of O 
the O 
receptor O 
to O 
respond O 
to O 
LXA4 B-ABBREVIATION 
. O 
We O 
show O 
that O 
both O 
receptor O 
orthologues O 
responded O 
to O 
the O 
FPR2 O 
/ O 
ALX O 
peptide O 
agonist O 
WKYMVM O 
when O 
expressed O 
heterologously O 
. O 
In O 
contrast O 
, O 
LXA4 B-ABBREVIATION 
from O 
different O 
sources O 
neither O 
increased O 
[ O 
Ca(2+) B-FORMULA 
]i O 
and O 
extracellular O 
- O 
signal O 
- O 
regulated O 
kinase O 
( O 
ERK O 
) O 
phosphorylation O 
, O 
nor O 
did O 
it O 
induce O 
a O 
decrease O 
in O 
cAMP B-ABBREVIATION 
levels O 
or O 
a O 
translocation O 
of O 
β-arrestin O 
. O 
Also O 
, O 
several O 
LXA4 B-ABBREVIATION 
analogues O 
were O 
found O 
to O 
be O 
unable O 
to O 
signal O 
through O 
FPR2 O 
/ O 
ALX O 
. O 
We O 
conclude O 
that O 
FPR2 O 
/ O 
ALX O 
is O 
not O 
activated O 
by O 
LXA4 B-ABBREVIATION 
and O 
that O 
the O 
molecular O 
mechanism O 
by O 
which O 
LXA4 B-ABBREVIATION 
functions O 
still O 
needs O 
to O 
be O 
identified O 
. O 

, O 
synthesis O 
and O 
antiproliferative O 
activity O 
studies O 
of O 
novel O 
1,2,3-triazole-dithiocarbamate- B-SYSTEMATIC 
urea I-SYSTEMATIC 
hybrids O 
. O 

series O 
of O 
novel O 
1,2,3-triazole-dithiocarbamate- B-SYSTEMATIC 
urea I-SYSTEMATIC 
hybrids O 
were O 
designed O 
, O 
synthesized O 
and O 
their O 
antiproliferative O 
activities O 
against O 
four O 
selected O 
human O 
cancer O 
cell O 
lines O 
were O 
evaluated O 
. O 
The O 
results O 
showed O 
that O 
a O 
number O 
of O 
the O 
hybrids O 
exhibited O 
potent O 
activity O 
in O 
selected O 
human O 
cancer O 
cell O 
lines O 
. O 
Among O 
them O 
, O 
compounds O 
27 O 
and O 
34 O 
showed O 
broad O 
spectrum O 
anticancer O 
activity O 
with O 
IC50 O 
values O 
ranging O 
from O 
1.62 O 
to O 
20.84 O 
μM O 
and O 
0.76 O 
to O 
13.55 O 
μM O 
, O 
respectively O 
. O 
Interestingly O 
, O 
compounds O 
27 O 
and O 
34 O 
, O 
being O 
very O 
potent O 
against O 
MGC-803 O 
cells O 
, O 
exhibited O 
no O 
significant O 
cytotoxicity O 
against O 
normal O 
human O 
embryonic O 
kidney O 
cells O 
at O 
up O 
to O 
55 O 
μM O 
and O 
70 O 
μM O 
, O 
respectively O 
. O 
Evidences O 
of O 
cell O 
cycle O 
arrest O 
and O 
apoptosis O 
induction O 
were O 
obtained O 
for O 
the O 
most O 
effective O 
compounds O 
27 O 
and O 
34 O 
by O 
means O 
of O 
flow O 
cytometry O 
and O 
microscopic O 
techniques O 
. O 

of O 
the O 
pharmacophore O 
of O 
echinocystic B-TRIVIAL 
acid I-TRIVIAL 
, O 
a O 
new O 
lead O 
for O 
blocking O 
HCV O 
entry O 
. O 

elucidate O 
the O 
pharmacophore O 
of O 
echinocystic B-TRIVIAL 
acid I-TRIVIAL 
( O 
EA O 
) O 
, O 
an O 
oleanane B-TRIVIAL 
-type O 
triterpene B-FAMILY 
displaying O 
substantial O 
inhibitory O 
activity O 
on O 
HCV O 
entry O 
, O 
two O 
microbial O 
strains O 
, O 
Rhizopus O 
chinensis O 
CICC O 
3043 O 
and O 
Alternaria O 
alternata O 
AS O 
3.4578 O 
, O 
were O 
utilized O 
to O 
modify O 
the O 
chemical O 
structure O 
of O 
EA O 
. O 
Eight O 
new O 
metabolites O 
with O 
regio- O 
and O 
stereo O 
- O 
selective O 
introduction O 
of O 
hydroxyl B-SYSTEMATIC 
and O 
lactone B-FAMILY 
groups O 
at O 
various O 
inert O 
carbon B-SYSTEMATIC 
positions O 
were O 
obtained O 
. O 
The O 
anti-HCV O 
entry O 
activity O 
of O 
the O 
metabolites O 
2-13 O 
, O 
along O 
with O 
their O 
parental O 
compound O 
EA O 
and O 
other O 
analogs O 
14- O 
15 O 
, O 
were O 
evaluated O 
. O 
Most O 
of O 
the O 
metabolites O 
showed O 
no O 
improvement O 
but O 
detrimental O 
effect O 
on O 
potency O 
except O 
compound O 
5 O 
and O 
6 O 
, O 
which O 
showed O 
similar O 
and O 
even O 
a O 
litter O 
higher O 
anti-HCV O 
entry O 
activity O 
than O 
that O 
of O 
EA O 
. O 
The O 
results O 
demonstrated O 
that O 
ring O 
A O 
, O 
B O 
, O 
C O 
and O 
the O 
left O 
side O 
of O 
ring O 
E O 
of O 
EA O 
are O 
highly O 
conserved O 
, O 
while O 
ring O 
D O 
and O 
the O 
right O 
side O 
of O 
ring O 
E O 
of O 
EA O 
are O 
flexible O 
. O 
Introduction O 
of O 
a O 
hydroxyl B-SYSTEMATIC 
group O 
at O 
C-16 O 
enhanced O 
the O 
triterpene B-FAMILY 
potency O 
. O 
Further O 
analysis O 
indicated O 
that O 
the O 
hemolytic O 
effect O 
of O 
EA O 
disappeared O 
upon O 
such O 
modifications O 
. O 

- O 
based O 
design O 
, O 
synthesis O 
, O 
and O 
experimental O 
evaluation O 
of O 
novel O 
benzofuroxan B-TRIVIAL 
derivatives O 
as O 
anti-Trypanosoma O 
cruzi O 
agents O 
. O 

set O 
of O 
substituted-[ O 
N'-(benzofuroxan-5-yl)methylene]benzohydrazides B-FAMILY 
( O 
4a-t O 
) O 
, O 
previously O 
designed O 
and O 
synthesized O 
, O 
was O 
experimentally O 
assayed O 
against O 
Trypanosoma O 
cruzi O 
, O 
the O 
etiological O 
agent O 
of O 
Chagas' O 
disease O 
, O 
one O 
of O 
the O 
most O 
neglected O 
tropical O 
diseases O 
. O 
Exploratory O 
data O 
analysis O 
, O 
Hansch O 
approach O 
and O 
VolSurf O 
formalism O 
were O 
applied O 
to O 
aid O 
the O 
ligand O 
- O 
based O 
design O 
of O 
novel O 
anti-T. O 
cruzi O 
agents O 
. O 
The O 
best O 
2D-QSAR O 
model O 
showed O 
suitable O 
statistical O 
measures O 
[ O 
n O 
= O 
18 O 
; O 
s O 
= O 
0.11 O 
; O 
F O 
= O 
42.19 O 
; O 
R(2) O 
= O 
0.9 O 
and O 
Q(2) O 
= O 
0.77 O 
( O 
SDEP O 
= O 
0.15 O 
) O 
] O 
, O 
and O 
according O 
to O 
the O 
optimum O 
3D-QSAR O 
model O 
[ O 
R(2) O 
= O 
0.98 O 
, O 
Q(2) O 
= O 
0.93 O 
( O 
SDEP O 
= O 
0.08 O 
) O 
] O 
, O 
three O 
latent O 
variables O 
explained O 
62% O 
of O 
the O 
total O 
variance O 
from O 
original O 
data O 
. O 
Steric O 
and O 
hydrophobic O 
properties O 
were O 
pointed O 
out O 
as O 
the O 
key O 
for O 
biological O 
activity O 
. O 
Based O 
upon O 
the O 
findings O 
, O 
six O 
novel O 
benzofuroxan B-TRIVIAL 
derivatives O 
( O 
4u-z O 
) O 
were O 
designed O 
, O 
synthesized O 
, O 
and O 
in O 
vitro O 
assayed O 
to O 
perform O 
the O 
QSAR O 
external O 
prediction O 
. O 
Then O 
, O 
the O 
predictability O 
for O 
the O 
both O 
models O 
, O 
2D-QSAR O 
( O 
Rpred(2) O 
= O 
0.91 O 
) O 
and O 
3D-QSAR O 
( O 
Rpred(2) O 
= O 
0.77 O 
) O 
, O 
was O 
experimentally O 
validated O 
, O 
and O 
compound O 
4u O 
was O 
identified O 
as O 
the O 
most O 
active O 
anti-T. O 
cruzi O 
hit O 
( O 
IC50 O 
= O 
3.04 O 
μM O 
) O 
. O 

2,3,3-trimethylindolenines I-FAMILY 
and O 
2-methylbenzothiazoles B-FAMILY 
. O 
Potential O 
lead O 
compounds O 
in O 
the O 
fight O 
against O 
Saccharomyces O 
cerevisiae O 
infections O 
. O 

synthesis O 
of O 
a O 
variety O 
of O 
N-alkylated B-FAMILY 
2,3,3-trimethylindolenines I-FAMILY 
and O 
2-methylbenzothiazoles B-FAMILY 
is O 
reported O 
herein O 
. O 
Their O 
potential O 
as O 
antifungal O 
agents O 
is O 
evaluated O 
by O 
preliminary O 
screening O 
against O 
Saccharomyces O 
cerevisiae O 
( O 
S. O 
cerevisiae O 
) O 
, O 
Schizosaccharomyces O 
pombe O 
( O 
S. O 
pombe O 
) O 
, O 
and O 
Candida O 
albicans O 
( O 
C. O 
albicans O 
) O 
. O 
Statistical O 
analyses O 
illustrate O 
a O 
strong O 
relationship O 
between O 
chain O 
length O 
and O 
growth O 
inhibition O 
for O 
S. O 
cerevisiae O 
and O 
S. O 
pombe O 
( O 
p O 
< O 
0.0001 O 
in O 
every O 
case O 
) O 
. O 
Of O 
particular O 
interest O 
is O 
the O 
activity O 
of O 
both O 
sets O 
of O 
compounds O 
against O 
S. O 
cerevisiae O 
, O 
as O 
this O 
is O 
emerging O 
as O 
an O 
opportunistic O 
pathogen O 
, O 
especially O 
in O 
immunosuppressed O 
and O 
immunocompromised O 
patients O 
. O 
Bioassays O 
were O 
set O 
up O 
to O 
compare O 
the O 
efficacy O 
of O 
our O 
range O 
of O 
N B-FORMULA 
-alkylated O 
compounds O 
against O 
classic O 
antifungal O 
agents O 
; O 
Amphotericin B-TRIVIAL 
B I-TRIVIAL 
and O 
Thiabendazole B-TRIVIAL 
. O 

and O 
biological O 
characterization O 
of O 
spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] B-SYSTEMATIC 
based O 
histone O 
deacetylase O 
inhibitors O 
. O 

Deacetylases O 
( O 
HDACs O 
) O 
have O 
become O 
important O 
targets O 
for O 
the O 
treatment O 
of O 
cancer O 
and O 
other O 
diseases O 
. O 
In O 
previous O 
studies O 
we O 
described O 
the O 
development O 
of O 
novel O 
spirocyclic O 
HDAC O 
inhibitors O 
based O 
on O 
the O 
combination O 
of O 
privileged O 
structures O 
with O 
hydroxamic B-SYSTEMATIC 
acid I-SYSTEMATIC 
moieties O 
as O 
zinc B-SYSTEMATIC 
binding O 
group O 
. O 
Herein O 
, O 
we O 
report O 
further O 
explorations O 
, O 
which O 
resulted O 
in O 
the O 
discovery O 
of O 
a O 
new O 
class O 
of O 
spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] B-SYSTEMATIC 
derivatives O 
. O 
Several O 
compounds O 
showed O 
good O 
potency O 
of O 
around O 
100 O 
nM O 
and O 
less O 
in O 
the O 
HDAC O 
inhibition O 
assays O 
, O 
submicromolar O 
IC50 O 
values O 
when O 
tested O 
against O 
tumour O 
cell O 
lines O 
and O 
a O 
remarkable O 
stability O 
in O 
human O 
and O 
mouse O 
microsomes O 
. O 
Two O 
representative O 
examples O 
exhibited O 
a O 
good O 
pharmacokinetic O 
profile O 
with O 
an O 
oral O 
bioavailability O 
equal O 
or O 
higher O 
than O 
35% O 
and O 
one O 
of O 
them O 
studied O 
in O 
an O 
HCT116 O 
murine O 
xenograft O 
model O 
showing O 
a O 
robust O 
tumour O 
growth O 
inhibition O 
. O 
In O 
addition O 
, O 
the O 
two O 
benzoxazines B-FAMILY 
were O 
found O 
to O 
have O 
a O 
minor O 
affinity O 
for O 
the O 
hERG O 
potassium B-SYSTEMATIC 
channel O 
compared O 
to O 
their O 
corresponding O 
ketone B-SYSTEMATIC 
analogues O 
. O 

and O 
in O 
vitro O 
anticancer O 
studies O 
of O 
novel O 
C-2 O 
arylidene O 
congeners O 
of O 
lantadenes B-FAMILY 
. O 

antitumor O 
pentacyclic O 
triterpenoids O 
, O 
Lantadene B-MULTIPLE 
A I-MULTIPLE 
( I-MULTIPLE 
1 I-MULTIPLE 
) I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
( O 
2 O 
) O 
were O 
isolated O 
from O 
the O 
leaves O 
of O 
weed O 
Lantana O 
camara O 
L O 
. O 
( O 
Verbenaceae O 
) O 
and O 
were O 
structurally O 
transformed O 
to O 
bioactive O 
intermediates O 
3-6 O 
. O 
The O 
Claisen-Schmidt O 
reaction O 
of O 
22β-hydroxy-3-oxoolean-12-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
5 O 
) O 
with O 
requisite O 
aldehydes B-FAMILY 
afforded O 
2-arylidene-22β-hydroxy-3-oxoolean-12-en-28-oic B-FAMILY 
acids I-FAMILY 
( O 
7-16 O 
) O 
. O 
The O 
compounds O 
were O 
evaluated O 
for O 
their O 
in O 
- O 
vitro O 
anticancer O 
activity O 
by O 
National O 
Cancer O 
Institute O 
( O 
NCI O 
) O 
, O 
USA O 
and O 
some O 
of O 
these O 
compounds O 
showed O 
marked O 
cytotoxicity O 
in O 
micromolar O 
range O 
. O 
The O 
mean O 
graph O 
midpoint O 
( O 
MG_MID O 
) O 
value O 
of O 
compound O 
3 O 
( O 
MG_MID O 
-5.69 O 
) O 
was O 
higher O 
than O 
standard O 
drug O 
cisplatin B-TRIVIAL 
( O 
MG_MID O 
-5.66 O 
) O 
while O 
comparable O 
in O 
case O 
of O 
compound O 
12 O 
( O 
MG_MID O 
-5.52 O 
) O 
. O 
The O 
NCI's O 
COMPARE O 
molecular O 
mechanistic O 
analysis O 
showed O 
that O 
these O 
compounds O 
were O 
in O 
significant O 
correlations O 
with O 
activity O 
patterns O 
of O 
mechanistic O 
set O 
of O 
compounds O 
( O 
PCC O 
≥ O 
0.6 O 
) O 
. O 

antithrombotic O 
agents O 
acting O 
as O 
anticoagulants O 
and O 
aggregation O 
inhibitors O 
could O 
have O 
substantial O 
advantages O 
over O 
currently O 
prescribed O 
combinations O 
of O 
antithrombotic O 
drugs O 
. O 
Herein O 
, O 
we O 
report O 
compounds O 
with O 
moderate O 
inhibitory O 
activity O 
for O 
factor O 
Xa O 
and O 
fibrinogen O 
GPIIb O 
/ O 
IIIa O 
binding O 
( O 
both O 
in O 
the O 
micromolar O 
range O 
) O 
. O 
These O 
compounds O 
resulted O 
from O 
our O 
efforts O 
to O 
merge O 
the O 
pharmacophores O 
of O 
selective O 
factor O 
Xa O 
inhibitor O 
rivaroxaban B-TRIVIAL 
with O 
a O 
mimic O 
of O 
the O 
Arg-Gly-Asp B-FORMULA 
( O 
RGD O 
) O 
sequence O 
of O 
fibrinogen O 
to O 
obtain O 
designed O 
multiple O 
ligands O 
with O 
potential O 
antithrombotic O 
activity O 
. O 
Resulting O 
from O 
this O 
study O 
, O 
a O 
structurally O 
novel O 
class O 
of O 
submicromolar O 
fibrinogen O 
GPIIb O 
/ O 
IIIa O 
binding O 
inhibitor O 
bearing O 
1,2,4-oxadiazol-5(4H)-one B-SYSTEMATIC 
moiety O 
is O 
also O 
described O 
. O 

and O 
biological O 
evaluation O 
of O 
N-(4-hydroxy-3-mercaptonaphthalen-1-yl)amides B-FAMILY 
as O 
inhibitors O 
of O 
angiogenesis O 
and O 
tumor O 
growth O 
. O 

series O 
of O 
N-(4-hydroxy-3-mercaptonaphthalen-1-yl)amides B-FAMILY 
were O 
synthesized O 
and O 
investigated O 
for O 
their O 
in O 
vitro O 
antiangiogenic O 
activity O 
. O 
Among O 
these O 
compounds O 
, O 
6d O 
, O 
which O 
possesses O 
an O 
ortho-nitro B-SYSTEMATIC 
group O 
at O 
the O 
benzene B-SYSTEMATIC 
ring O 
, O 
exhibited O 
potent O 
inhibitory O 
effect O 
on O 
the O 
proliferation O 
of O 
HUVECs O 
, O 
A549 O 
, O 
K562 O 
, O 
PC-3 O 
, O 
HCT116 O 
, O 
MDA-MB-231 O 
and O 
MCF-7 O 
cells O 
( O 
IC50 O 
= O 
5.34 O 
, O 
40.53 O 
, O 
10.81 O 
, O 
52.52 O 
, O 
10.19 O 
, O 
21.37 O 
and O 
2.81 O 
μM O 
, O 
respectively O 
) O 
. O 
Meanwhile O 
, O 
compound O 
6d O 
inhibited O 
in O 
vitro O 
angiogenesis O 
markedly O 
in O 
both O 
HUVECs O 
tube O 
formation O 
assay O 
and O 
the O 
rat O 
thoracic O 
aorta O 
rings O 
test O 
. O 
Further O 
kinase O 
assay O 
study O 
showed O 
that O 
compound O 
6d O 
had O 
good O 
VEGFR2 O 
, O 
ALK O 
, O 
AKT1 O 
and O 
ABL O 
inhibitory O 
activities O 
and O 
moderate O 
EGFR O 
and O 
PDGFR-β O 
inhibitory O 
activities O 
. O 
The O 
data O 
supports O 
the O 
further O 
investigation O 
of O 
this O 
class O 
of O 
compounds O 
as O 
potential O 
antiangiogenic O 
and O 
anticancer O 
agents O 
. O 

glycosides I-FAMILY 
from O 
the O 
bulbs O 
of O 
Easter O 
lily O 
( O 
Lilium O 
longiflorum O 
Thunb O 
. O 
) O 
promote O 
dermal O 
fibroblast O 
migration O 
in O 
vitro O 
. O 

RELEVANCE O 
: O 
Preparations O 
derived O 
from O 
bulbs O 
of O 
various O 
Lilium O 
species O 
have O 
been O 
used O 
to O 
promote O 
the O 
healing O 
of O 
skin O 
abrasions O 
, O 
sores O 
and O 
burns O 
and O 
to O 
aid O 
in O 
healing O 
wounds O 
in O 
Traditional O 
Chinese O 
and O 
Greco-Roman O 
Medicine O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
To O 
evaluate O 
fractionated O 
Easter O 
lily O 
bulb O 
extracts O 
and O 
their O 
steroidal B-FAMILY 
glycosides I-FAMILY 
( O 
1-5 O 
) O 
for O 
the O 
promotion O 
of O 
dermal O 
fibroblast O 
migration O 
in O 
vitro O 
, O 
as O 
a O 
model O 
for O 
the O 
early O 
events O 
in O 
wound O 
healing O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
An O 
activity O 
- O 
guided O 
screening O 
approach O 
was O 
used O 
by O 
coupling O 
sequential O 
solvent O 
extraction O 
, O 
gel O 
permeation O 
chromatography O 
( O 
GPC O 
) O 
, O 
and O 
semi-preparative O 
reverse O 
- O 
phase O 
high O 
performance O 
liquid O 
chromatography O 
( O 
RP-HPLC O 
) O 
with O 
an O 
in O 
vitro O 
dermal O 
fibroblast O 
migration O 
assay O 
. O 
Cytotoxicity O 
was O 
evaluated O 
with O 
methyl B-SYSTEMATIC 
thiazole I-SYSTEMATIC 
tetrazolium I-SYSTEMATIC 
( O 
MTT B-ABBREVIATION 
) O 
. O 
To O 
gain O 
insight O 
into O 
the O 
mode O 
of O 
action O 
of O 
the O 
steroidal B-FAMILY 
glycosides I-FAMILY 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
production O 
, O 
and O 
expression O 
of O 
genes O 
for O 
transforming O 
growth O 
factor O 
beta-1 O 
( O 
TGF-β O 
) O 
and O 
its O 
receptors O 
were O 
evaluated O 
. O 
RESULTS O 
: O 
Fractionated O 
bulb O 
extracts O 
and O 
the O 
two O 
isolated O 
steroidal B-FAMILY 
glycoalkaloids I-FAMILY 
( O 
1 O 
) O 
and O 
( O 
2 O 
) O 
induced O 
NO B-FORMULA 
production O 
and O 
TGF-β O 
receptor O 
I O 
mRNA O 
expression O 
in O 
fibroblast O 
cell O 
culture O 
. O 
In O 
a O 
cytotoxicity O 
assay O 
, O 
steroidal B-FAMILY 
glycosides I-FAMILY 
( O 
1 O 
) O 
and O 
( O 
3 O 
) O 
had O 
IC50 O 
values O 
of O 
8.2 O 
and O 
8.7µM O 
, O 
but O 
the O 
natural O 
acetylation O 
of O 
the O 
C-6″ O 
' O 
hydroxy B-SYSTEMATIC 
of O 
the O 
terminal O 
glucose B-TRIVIAL 
unit O 
in O 
( O 
2 O 
) O 
resulted O 
in O 
a O 
3-fold O 
decrease O 
in O 
cell O 
cytotoxicity O 
when O 
compared O 
with O 
( O 
1 O 
) O 
. O 
Results O 
from O 
the O 
dermal O 
fibroblast O 
migration O 
assay O 
revealed O 
that O 
the O 
steroidal B-FAMILY 
glycoalkaloids I-FAMILY 
( O 
1 O 
) O 
and O 
( O 
2 O 
) O 
, O 
and O 
the O 
furostanol B-FAMILY 
saponin I-FAMILY 
( O 
3 O 
) O 
promoted O 
fibroblast O 
migration O 
from O 
the O 
range O 
of O 
23.7±5.7 O 
to O 
37.7±5.1% O 
, O 
as O 
compared O 
with O 
the O 
control O 
. O 
CONCLUSION O 
: O 
Collectively O 
, O 
our O 
data O 
demonstrate O 
that O 
the O 
steroidal B-FAMILY 
glycosides I-FAMILY 
present O 
in O 
Easter O 
lily O 
bulbs O 
induce O 
, O 
at O 
least O 
in O 
part O 
, O 
the O 
observed O 
dermal O 
fibroblast O 
migration O 
activity O 
of O 
the O 
bulb O 
extracts O 
. O 
This O 
is O 
the O 
first O 
evidence O 
that O 
steroidal B-FAMILY 
glycosides I-FAMILY 
from O 
L O 
. O 
longiflorum O 
may O 
potentially O 
play O 
a O 
role O 
in O 
the O 
wound O 
healing O 
process O 
and O 
may O 
provide O 
a O 
scientific O 
basis O 
for O 
the O 
historical O 
use O 
of O 
lily O 
bulbs O 
for O 
this O 
purpose O 
. O 

excitability O 
in O 
smoking O 
and O 
not O 
smoking O 
individuals O 
with O 
and O 
without O 
nicotine B-TRIVIAL 
. O 

: O 
Activation O 
of O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
has O 
a O 
major O 
neuromodulatory O 
impact O 
on O 
central O 
nervous O 
system O 
function O 
. O 
Beyond O 
acute O 
activation O 
, O 
chronic O 
nicotine B-TRIVIAL 
intake O 
has O 
long O 
- O 
lasting O 
effects O 
on O 
cortical O 
excitability O 
in O 
animal O 
experiments O 
, O 
caused O 
by O 
receptor O 
up- O 
or O 
down O 
- O 
regulation O 
. O 
Knowledge O 
about O 
the O 
impact O 
of O 
nicotine B-TRIVIAL 
on O 
cortical O 
excitability O 
in O 
humans O 
, O 
however O 
, O 
is O 
limited O 
. O 
OBJECTIVES O 
: O 
We O 
therefore O 
aimed O 
to O 
explore O 
the O 
effect O 
of O 
nicotine B-TRIVIAL 
intake O 
on O 
cortical O 
excitability O 
in O 
healthy O 
human O 
smokers O 
and O 
non-smokers O 
. O 
METHODS O 
: O 
The O 
primary O 
motor O 
cortex O 
served O 
as O 
model O 
, O 
and O 
cortical O 
excitability O 
was O 
monitored O 
via O 
transcranial O 
magnetic O 
stimulation O 
( O 
TMS O 
) O 
. O 
Corticospinal O 
excitability O 
and O 
intracortical O 
excitability O 
were O 
recorded O 
before O 
and O 
after O 
application O 
of O 
nicotine B-TRIVIAL 
patch O 
in O 
both O 
groups O 
. O 
Corticospinal O 
excitability O 
was O 
explored O 
by O 
motor O 
threshold O 
and O 
input O 
/ O 
output O 
curve O 
( O 
I O 
/ O 
O O 
curve O 
) O 
, O 
and O 
intracortical O 
excitability O 
was O 
explored O 
by O 
means O 
of O 
paired O 
- O 
pulse O 
TMS O 
techniques O 
( O 
intracortical O 
facilitation O 
( O 
ICF O 
) O 
, O 
short O 
- O 
latency O 
intracortical O 
inhibition O 
( O 
SICI O 
) O 
, O 
I-wave O 
facilitation O 
and O 
short O 
- O 
latency O 
afferent O 
inhibition O 
( O 
SAI O 
) O 
) O 
. O 
RESULTS O 
: O 
The O 
results O 
show O 
that O 
smokers O 
during O 
nicotine B-TRIVIAL 
withdrawal O 
display O 
increased O 
corticospinal O 
excitability O 
with O 
regard O 
to O 
the O 
I O 
/ O 
O O 
curve O 
( O 
TMS O 
intensity O 
150 O 
% O 
of O 
resting O 
motor O 
threshold O 
) O 
compared O 
to O 
non-smokers O 
and O 
furthermore O 
enhanced O 
SAI O 
and O 
diminished O 
ICF O 
at O 
the O 
intracortical O 
circuit O 
level O 
. O 
After O 
administration O 
of O 
nicotine B-TRIVIAL 
, O 
intracortical O 
facilitation O 
in O 
smokers O 
increased O 
, O 
while O 
in O 
non-smokers O 
, O 
inhibition O 
( O 
SICI O 
, O 
SAI O 
) O 
was O 
enhanced O 
. O 
CONCLUSION O 
: O 
Our O 
results O 
show O 
that O 
chronic O 
nicotine B-TRIVIAL 
consumption O 
in O 
smokers O 
alters O 
cortical O 
excitability O 
independent O 
from O 
acute O 
nicotine B-TRIVIAL 
consumption O 
and O 
that O 
acute O 
nicotine B-TRIVIAL 
has O 
different O 
effects O 
on O 
motor O 
cortical O 
excitability O 
in O 
both O 
groups O 
. O 

and O 
Neuroprotective O 
Effects O 
of O 
Polar O 
Steroids B-FAMILY 
from O 
the O 
Far O 
East O 
Starfishes O 
Patiria O 
pectinifera O 
and O 
Distolasterias O 
nipon O 
. O 

neuritogenic O 
and O 
neuroprotective O 
activities O 
of O 
six O 
starfish O 
polar O 
steroids B-FAMILY 
, O 
asterosaponin B-TRIVIAL 
Р1 I-TRIVIAL 
, O 
(25S)-5α-cholestane-3β,4β,6α,7α,8,15α,16β,26-octaol B-SYSTEMATIC 
, O 
and O 
(25S)-5α-cholestane-3β,6α,7α,8,15α,16β,26-heptaol B-SYSTEMATIC 
( O 
1-3 O 
) O 
from O 
the O 
starfish O 
Patiria O 
pectinifera O 
and O 
distolasterosides B-MULTIPLE 
D1-D3 I-MULTIPLE 
( O 
4-6 O 
) O 
from O 
the O 
starfish O 
Distolasterias O 
nipon O 
were O 
analyzed O 
using O 
the O 
mouse O 
neuroblastoma O 
( O 
NB O 
) O 
C-1300 O 
cell O 
line O 
and O 
an O 
organotypic O 
rat O 
hippocampal O 
slice O 
culture O 
( O 
OHSC O 
) O 
. O 
All O 
of O 
these O 
compounds O 
enhanced O 
neurite O 
outgrowth O 
in O 
NB O 
cells O 
. O 
Dose O 
- O 
dependent O 
responses O 
to O 
compounds O 
1-3 O 
were O 
observed O 
within O 
the O 
concentration O 
range O 
of O 
10-100 O 
nM O 
, O 
and O 
dose O 
- O 
dependent O 
responses O 
to O 
glycosides O 
4-6 O 
were O 
observed O 
at O 
concentrations O 
of O 
1-50 O 
nM O 
. O 
All O 
the O 
tested O 
substances O 
exhibited O 
notable O 
synergistic O 
effects O 
with O 
trace O 
amounts O 
of O 
nerve O 
growth O 
factor O 
( O 
NGF O 
, O 
1 O 
ng O 
/ O 
mL O 
) O 
or O 
brain O 
- O 
derived O 
neurotrophic O 
factor O 
( O 
BDNF O 
, O 
0.1 O 
ng O 
/ O 
mL O 
) O 
. O 
Using O 
NB O 
cells O 
and O 
OHSCs O 
, O 
it O 
was O 
shown O 
for O 
the O 
first O 
time O 
that O 
starfish O 
steroids B-FAMILY 
1-6 O 
act O 
as O 
neuroprotectors O 
against O 
oxygen B-SYSTEMATIC 
- O 
glucose B-TRIVIAL 
deprivation O 
( O 
OGD O 
) O 
by O 
increasing O 
the O 
number O 
of O 
surviving O 
cells O 
. O 
Altogether O 
, O 
these O 
results O 
suggest O 
that O 
neurotrophin O 
- O 
like O 
neuritogenic O 
and O 
neuroprotective O 
activities O 
are O 
most O 
likely O 
common O 
properties O 
of O 
starfish O 
polyhydroxysteroids B-FAMILY 
and O 
the O 
related O 
glycosides O 
, O 
although O 
the O 
magnitude O 
of O 
the O 
effect O 
depended O 
on O 
the O 
particular O 
compound O 
structure O 
. O 

Basic O 
Helix-Loop-Helix O 
/ O 
bZIP O 
Transcription O 
Factors O 
Form O 
Transcriptional O 
Modules O 
That O 
Integrate O 
Light O 
and O 
Reactive O 
Oxygen B-SYSTEMATIC 
Species O 
Signaling O 
in O 
Arabidopsis O 
. O 

critical O 
developmental O 
switch O 
from O 
heterotrophic O 
to O 
autotrophic O 
growth O 
of O 
plants O 
involves O 
light O 
signaling O 
transduction O 
and O 
the O 
production O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
. O 
ROS O 
function O 
as O 
signaling O 
molecules O 
that O 
regulate O 
multiple O 
developmental O 
processes O 
, O 
including O 
cell O 
death O 
. O 
However O 
, O 
the O 
relationship O 
between O 
light O 
and O 
ROS O 
signaling O 
remains O 
unclear O 
. O 
Here O 
, O 
we O 
identify O 
transcriptional O 
modules O 
composed O 
of O 
the O 
basic O 
helix O 
- O 
loop O 
- O 
helix O 
and O 
bZIP O 
transcription O 
factors O 
PHYTOCHROME-INTERACTING O 
FACTOR1 O 
( O 
PIF1 O 
) O 
, O 
PIF3 O 
, O 
ELONGATED O 
HYPOCOTYL5 O 
( O 
HY5 O 
) O 
, O 
and O 
HY5 O 
HOMOLOGY O 
( O 
HYH O 
) O 
that O 
bridge O 
light O 
and O 
ROS O 
signaling O 
to O 
regulate O 
cell O 
death O 
and O 
photooxidative O 
response O 
. O 
We O 
show O 
that O 
pif O 
mutants O 
release O 
more O 
singlet O 
oxygen B-SYSTEMATIC 
and O 
exhibit O 
more O 
extensive O 
cell O 
death O 
than O 
the O 
wild O 
type O 
during O 
Arabidopsis O 
thaliana O 
deetiolation O 
. O 
Genome O 
- O 
wide O 
expression O 
profiling O 
indicates O 
that O 
PIF1 O 
represses O 
numerous O 
ROS O 
and O 
stress O 
- O 
related O 
genes O 
. O 
Molecular O 
and O 
biochemical O 
analyses O 
reveal O 
that O 
PIF1 O 
/ O 
PIF3 O 
and O 
HY5 O 
/ O 
HYH O 
physically O 
interact O 
and O 
coordinately O 
regulate O 
the O 
expression O 
of O 
five O 
ROS-responsive O 
genes O 
by O 
directly O 
binding O 
to O 
their O 
promoters O 
. O 
Furthermore O 
, O 
PIF1 O 
/ O 
PIF3 O 
and O 
HY5 O 
/ O 
HYH O 
function O 
antagonistically O 
during O 
the O 
seedling O 
greening O 
process O 
. O 
In O 
addition O 
, O 
phytochromes O 
, O 
cryptochromes O 
, O 
and O 
CONSTITUTIVE O 
PHOTOMORPHOGENIC1 O 
act O 
upstream O 
to O 
regulate O 
ROS O 
signaling O 
. O 
Together O 
, O 
this O 
study O 
reveals O 
that O 
the O 
PIF1 O 
/ O 
PIF3-HY5 O 
/ O 
HYH O 
transcriptional O 
modules O 
mediate O 
crosstalk O 
between O 
light O 
and O 
ROS O 
signaling O 
and O 
sheds O 
light O 
on O 
a O 
new O 
mechanism O 
by O 
which O 
plants O 
adapt O 
to O 
the O 
light O 
environments O 
. O 

- O 
assembling O 
doxorubicin B-TRIVIAL 
silk O 
hydrogels O 
for O 
the O 
focal O 
treatment O 
of O 
primary O 
breast O 
cancer O 
. O 

care O 
for O 
early O 
stage O 
breast O 
cancer O 
includes O 
tumor O 
resection O 
and O 
local O 
radiotherapy O 
to O 
achieve O 
long O 
- O 
term O 
remission O 
. O 
Systemic O 
chemotherapy O 
provides O 
only O 
low O 
locoregional O 
control O 
of O 
the O 
disease O 
; O 
therefore O 
, O 
we O 
describe O 
self O 
- O 
assembling O 
silk O 
hydrogels O 
that O 
can O 
retain O 
and O 
then O 
deliver O 
doxorubicin B-TRIVIAL 
locally O 
. O 
Self O 
- O 
assembling O 
silk O 
hydrogels O 
show O 
no O 
swelling O 
, O 
are O 
readily O 
loaded O 
with O 
doxorubicin B-TRIVIAL 
under O 
aqueous O 
conditions O 
and O 
release O 
drug O 
over O 
4 O 
weeks O 
in O 
amounts O 
that O 
can O 
be O 
fine O 
- O 
tuned O 
by O 
varying O 
the O 
silk O 
content O 
. O 
Following O 
successful O 
in O 
vitro O 
studies O 
, O 
locally O 
injected O 
silk O 
hydrogels O 
loaded O 
with O 
doxorubicin B-TRIVIAL 
show O 
excellent O 
antitumor O 
response O 
in O 
mice O 
, O 
outperforming O 
the O 
equivalent O 
amount O 
of O 
doxorubicin B-TRIVIAL 
delivered O 
intravenously O 
. O 
In O 
addition O 
to O 
reducing O 
primary O 
tumor O 
growth O 
, O 
doxorubicin B-TRIVIAL 
-loaded O 
silk O 
hydrogels O 
reduce O 
metastatic O 
spread O 
and O 
are O 
well O 
tolerated O 
in O 
vivo O 
. O 
Thus O 
, O 
silk O 
hydrogels O 
are O 
well O 
suited O 
for O 
the O 
local O 
delivery O 
of O 
chemotherapy O 
and O 
provide O 
a O 
promising O 
approach O 
to O 
improve O 
locoregional O 
control O 
of O 
breast O 
cancer O 
. O 

efficiency O 
and O 
insight O 
of O 
global O 
, O 
polyad O 
- O 
based O 
modeling O 
in O 
overtone O 
spectroscopy O 
and O 
dynamics O 
is O 
demonstrated O 
. O 
Both O 
vibration O 
and O 
vibration O 
- O 
rotation O 
polyads O 
are O 
considered O 
. O 
The O 
spectroscopic O 
implications O 
of O 
polyad O 
Hamiltonians O 
derive O 
from O 
their O 
ability O 
to O 
account O 
for O 
the O 
detailed O 
line O 
positions O 
and O 
intensities O 
of O 
spectral O 
features O 
and O 
their O 
unique O 
predictive O 
power O 
. O 
The O 
dynamical O 
implications O 
of O 
polyad O 
Hamiltonians O 
include O 
classical O 
bifurcations O 
that O 
lead O 
to O 
the O 
birth O 
of O 
new O 
vibrational O 
modes O 
and O 
intramolecular O 
vibrational O 
- O 
rotational O 
energy O 
redistribution O 
over O 
multiple O 
timescales O 
. O 
The O 
literature O 
is O 
reviewed O 
, O 
with O 
emphasis O 
on O 
acetylene B-SYSTEMATIC 
results O 
. O 

attachment O 
of O 
low O 
- O 
energy O 
electrons O 
to O 
xenobiotic O 
molecules O 
, O 
2,4-dichlorophenoxyacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
() O 
, O 
dichlorodiphenyltrichloroethane B-SYSTEMATIC 
() O 
and O 
dichlorodiphenyldichloroethylene B-SYSTEMATIC 
() O 
, O 
was O 
investigated O 
under O 
gas-phase O 
conditions O 
by O 
means O 
of O 
complementary O 
experimental O 
techniques O 
. O 
Electron O 
transmission O 
spectroscopy O 
( O 
